<SEC-DOCUMENT>0001370368-23-000006.txt : 20230201
<SEC-HEADER>0001370368-23-000006.hdr.sgml : 20230201
<ACCEPTANCE-DATETIME>20230201074624
ACCESSION NUMBER:		0001370368-23-000006
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		258
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230201
DATE AS OF CHANGE:		20230201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVARTIS AG
		CENTRAL INDEX KEY:			0001114448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15024
		FILM NUMBER:		23574750

	BUSINESS ADDRESS:	
		STREET 1:		LICHTSTRASSE 35
		CITY:			BASEL
		STATE:			V8
		ZIP:			CH 4056
		BUSINESS PHONE:		01141613241111

	MAIL ADDRESS:	
		STREET 1:		LICHTSTRASSE 35
		CITY:			BASEL
		STATE:			V8
		ZIP:			CH 4056
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>nvs-20221231.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2022" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:nvs="http://novartis.com/20221231" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ns0="http://www.novartis.com/custom-units">
  <head>
    <title>20-F</title>
    <meta http-equiv="Content-Type" content="text/html" />
  </head>
  <body>
    <div style="display:none">
      <ix:header>
        <ix:hidden>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:OptionsExcludedFromTheCalculation" decimals="0" scale="0">0</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:OptionsExcludedFromTheCalculation" decimals="0" scale="0">0</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">0.60</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.9996</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.7068</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.9923</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.9923</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.9999</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.9923</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.9923</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.9999</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.9923</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.9923</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.9923</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">0.20</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="4" scale="0">0.9923</ix:nonFraction>
          <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfVotingPowerHeldInSubsidiary" decimals="2" scale="0">1.00</ix:nonFraction>
          <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityCentralIndexKey">0001114448</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:AmendmentFlag">false</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">France</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">France</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">United Kingdom</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Italy</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Malaysia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Russian Federation</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">United Kingdom</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">South Africa</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Spain</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">France</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Germany</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityIncorporationStateCountryCode">V8</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember" name="dei:EntityAddressAddressLine1">Lichtstrasse 35</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Algeria</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Argentina</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Australia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Australia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Australia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Austria</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Austria</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Austria</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Austria</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Bangladesh</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Belgium</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Belgium</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Belgium</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Bermuda</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Bermuda</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Bermuda</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Bermuda</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Bermuda</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Brazil</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Brazil</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Canada</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Canada</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Chile</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">China</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">China</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">China</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">China</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">China</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">China</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Colombia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Croatia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Czech Republic</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Czech Republic</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Denmark</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Denmark</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Ecuador</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Egypt</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Egypt</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Finland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">France</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">France</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">France</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">France</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Germany</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Germany</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Germany</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Germany</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Germany</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Germany</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Germany</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Germany</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Greece</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Hungary</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Hungary</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">India</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">India</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">India</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Indonesia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Ireland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Ireland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Ireland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Israel</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Italy</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Italy</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Japan</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Japan</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Japan</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Latvia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Luxembourg</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Luxembourg</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Mexico</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Mexico</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Morocco</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Netherlands</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Netherlands</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Netherlands</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Netherlands</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">New Zealand</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Norway</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Pakistan</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Panama</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Philippines</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Philippines</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Poland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Poland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Poland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Portugal</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Portugal</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Portugal</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Romania</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Romania</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Russian Federation</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Russian Federation</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Saudi Arabia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Singapore</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Singapore</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Singapore</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Slovakia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Slovenia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Slovenia</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">South Africa</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">South Korea</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Spain</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Spain</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Spain</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Spain</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Sweden</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisForschungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Switzerland</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Taiwan</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Thailand</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Turkey</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Turkey</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Turkey</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Turkey</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Ukraine</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">United Arab Emirates</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">United Kingdom</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">United Kingdom</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">United Kingdom</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">United Kingdom</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">United Kingdom</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">USA</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Venezuela</ix:nonNumeric>
          <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary">Vietnam</ix:nonNumeric>
        </ix:hidden>
        <ix:references>
          <link:schemaRef d5p1:type="simple" d5p1:href="nvs-20221231.xsd" xmlns:d5p1="http://www.w3.org/1999/xlink" />
        </ix:references>
        <ix:resources>
          <xbrli:context id="AR_I-CurrentYearEnd">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-December-22-2021_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GyroscopeTherapeuticsHoldingsPlcMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-12-22</xbrli:startDate>
              <xbrli:endDate>2021-12-22</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GyroscopeTherapeuticsHoldingsPlcMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-02-17</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GyroscopeTherapeuticsHoldingsPlcMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-02-17</xbrli:startDate>
              <xbrli:endDate>2022-02-17</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-February-10-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GlaxoSmithKlinePlcGSKMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-02-10</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GlaxoSmithKlinePlcGSKMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-10-08</xbrli:startDate>
              <xbrli:endDate>2021-10-08</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GlaxoSmithKlinePlcGSKMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-10-08</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-Transaction-TheMedicinesCompany_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-11-23</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-Transaction-TheMedicinesCompany_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2019-11-23</xbrli:startDate>
              <xbrli:endDate>2019-11-23</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-01-06</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-06</xbrli:startDate>
              <xbrli:endDate>2020-01-06</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenGlobalIncorporatedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-31</xbrli:startDate>
              <xbrli:endDate>2020-01-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenGlobalIncorporatedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-01-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-Transaction-Sandoz-Divestment_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2018-09-06</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-03-01</xbrli:startDate>
              <xbrli:endDate>2020-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022FR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022FR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022FR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022DE">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022DE">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022DE">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022CN">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022CN">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022CN">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022JP">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022JP">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022JP">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022JP">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022JP">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:LargestCustomerMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:SecondLargestCustomerMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:ThirdLargestCustomerMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:LargestCustomerMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:SecondLargestCustomerMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:ThirdLargestCustomerMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:LargestCustomerMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:SecondLargestCustomerMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:ThirdLargestCustomerMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:MayzentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:MayzentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:MayzentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PiqrayMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PiqrayMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PiqrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PluvictoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PluvictoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PluvictoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PluvictoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TabrectaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TabrectaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TabrectaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AdakveoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AdakveoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AdakveoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ScemblixMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ScemblixMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ScemblixMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ScemblixMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XiidraMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XiidraMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XiidraMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:BeovuMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:BeovuMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:BeovuMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherRespiratoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherRespiratoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherRespiratoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ContractManufacturingMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ContractManufacturingMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ContractManufacturingMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ContractManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:TotalAntiinfectivesNetSalesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:TotalAntiinfectivesNetSalesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:TotalAntiinfectivesNetSalesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:AntiInfectivesSoldUnderSandozNameMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:AntiInfectivesSoldUnderSandozNameMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:AntiInfectivesSoldUnderSandozNameMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4NetInvestmentHedgeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:NetInvestmentHedgeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesSoldMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesSoldMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4NetInvestmentHedgeMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:NetInvestmentHedgeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesSoldMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesSoldMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ValueAdjustmentsRelatedToDivestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ValueAdjustmentsRelatedToDivestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nvs:SaleAndLeaseBackMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nvs:SaleAndLeaseBackMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryRawMaterialsGrossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryRawMaterialsGrossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryRawMaterialsGrossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryRawMaterialsGrossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryWorkInProgressGrossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryWorkInProgressGrossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryWorkInProgressGrossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryWorkInProgressGrossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryFinishedGoodsGrossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryFinishedGoodsGrossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryFinishedGoodsGrossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryFinishedGoodsGrossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022CurrentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:CurrentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022CurrentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:CurrentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022NotLaterThanOneMonthMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022NotLaterThanOneMonthMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanThreeMonthsAndNotLaterThanSixMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanThreeMonthsAndNotLaterThanSixMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanSixMonthsAndNotLaterThanOneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanSixMonthsAndNotLaterThanOneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneYearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022USD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022USD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022EUR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022EUR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022RUB">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:RUB</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022RUB">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:RUB</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022JPY">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022JPY">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022GBP">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022GBP">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CNY">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CNY">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CAD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CAD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022BRL">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:BRL</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022BRL">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:BRL</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022AUD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022AUD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CHF">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CHF">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanFiveYearsAndNotLaterThanSixYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanFiveYearsAndNotLaterThanSixYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanSixYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanSixYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022USD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022USD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022EUR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022EUR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022JPY">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022JPY">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022CHF">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022CHF">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:FairValueDisclosureItemAmountsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:FairValueDisclosureItemAmountsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022IT_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NAGAndNovartisPharmaSpAMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NAGAndNovartisPharmaSpAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022IT_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022GeographicalAreasAxis_country-2022FR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4FHoffmanLaRocheAGAndRocheSpAMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:FHoffmanLaRocheAGAndRocheSpAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022GR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022GR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GR</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ReclastAclastaMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NPCAndOthersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NPCAndOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ReclastAclastaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TaxotereMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TaxotereMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AmiodaroneMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AmiodaroneMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NPCAndOthersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NPCAndOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:FinancialAssetsImpairedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:FinancialAssetsImpairedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:FinancialAssetsImpairedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022DiscontinuedOperationsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4LifeExpectancyMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Increase1YearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">nvs:LifeExpectancyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Increase1YearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4LifeExpectancyMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Increase1YearMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">nvs:LifeExpectancyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Increase1YearMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:EquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:EquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:EquityInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:RealEstateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:RealEstateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:RealEstateMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AlternativeInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AlternativeInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AlternativeInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:CashAndOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:CashAndOtherInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:CashAndOtherInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentiveRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentiveRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentiveRestrictedSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentiveRestrictedSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationShareSavingsPlansRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationShareSavingsPlansRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationShareSavingsPlansSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationShareSavingsPlansSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeSharePurchasePlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermPerformancePSUPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermPerformancePSUPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsRSUMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRestrictedSharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsRestrictedSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SparkTherapeuticsInc.Member">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SparkTherapeuticsInc.Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-4_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisPensionFundMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NovartisPensionFundMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2018-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:NonExecutiveDirectorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:NonExecutiveDirectorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:NonExecutiveDirectorMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4DrAlexKrauerMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:DrAlexKrauerMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4DrAlexKrauerMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:DrAlexKrauerMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2020-01-01</xbrli:startDate>
              <xbrli:endDate>2020-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:TimeDepositsWithOriginalMaturityMoreThan90DaysMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4OtherCurrentAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:OtherCurrentAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableForSaleMarketableSecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableForSaleMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4FundInvestmentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4BankAndOtherFinancialDebtMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:BankAndOtherFinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4CommercialPaperMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:CommercialPaperMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4StraightBondsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:StraightBondsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LiabilitiesToBanksAndOtherFinancialInstitutionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TradePayablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TradePayablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationAndOtherFinancialLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2022LeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:TimeDepositsWithOriginalMaturityMoreThan90DaysMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022TradeReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4OtherCurrentAssetsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:OtherCurrentAssetsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableForSaleMarketableSecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableForSaleMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4FundInvestmentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4InterestBearningAccountsOfAssociatesPayableOnDemandMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:InterestBearningAccountsOfAssociatesPayableOnDemandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4BankAndOtherFinancialDebtMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:BankAndOtherFinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4CommercialPaperMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:CommercialPaperMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4StraightBondsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:StraightBondsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LiabilitiesToBanksAndOtherFinancialInstitutionsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TradePayablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TradePayablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommitmentForRepurchaseOfOwnSharesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommitmentForRepurchaseOfOwnSharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationAndOtherFinancialLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2022LeaseLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4NoncurrentContingentConsiderationLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:NoncurrentContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4NoncurrentContingentConsiderationLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:NoncurrentContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2020-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:NonlistedEquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:NonlistedEquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:ListedEquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:ListedEquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:ListedEquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:ListedEquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:NonlistedEquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:NonlistedEquitySecuritiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4LargestFinancialInstitutionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:LargestFinancialInstitutionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4SecondLargestFinancialInstitutionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:SecondLargestFinancialInstitutionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4ThirdLargestFinancialInstitutionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:ThirdLargestFinancialInstitutionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4LargestFinancialInstitutionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:LargestFinancialInstitutionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4SecondLargestFinancialInstitutionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:SecondLargestFinancialInstitutionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4ThirdLargestFinancialInstitutionMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:ThirdLargestFinancialInstitutionMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4USCommercialPaperProgramsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:USCommercialPaperProgramsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4JPCommercialPaperProgramsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:JPCommercialPaperProgramsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2021-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical5IncreaseMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical5IncreaseMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical5DecreaseMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical5DecreaseMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical15IncreaseMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical15IncreaseMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical15DecreaseMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical15DecreaseMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-01-01</xbrli:startDate>
              <xbrli:endDate>2021-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_nvs-2022Q4SubsequentEventTypAxis_nvs-2022Q4SubsequentEventMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="nvs:SubsequentEventTypAxis">nvs:SubsequentEventMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SocieteParActionsSANDOZAlgiersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SocieteParActionsSANDOZAlgiersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisArgentinaS.A.BuenosAiresMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisArgentinaS.A.BuenosAiresMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustriaGmbHViennaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustriaGmbHViennaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHViennaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHViennaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGmbHViennaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGmbHViennaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EBEWEPharmaGes.m.b.HNfg.KGViennaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EBEWEPharmaGes.m.b.HNfg.KGViennaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBangladeshLimitedGazipurMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBangladeshLimitedGazipurMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaNVVilvoordeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaNVVilvoordeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozNVVilvoordeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozNVVilvoordeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AlconCouvreurNVPuursMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AlconCouvreurNVPuursMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSecuritiesInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSecuritiesInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceServicesLtd.HamiltonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceServicesLtd.HamiltonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TriangleInternationalReinsuranceLimitedHamiltonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TriangleInternationalReinsuranceLimitedHamiltonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TrinityRiverInsuranceCoLtd.HamiltonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TrinityRiverInsuranceCoLtd.HamiltonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBiocienciasS.A.SaoPauloMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBiocienciasS.A.SaoPauloMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozCanadaInc.BouchervilleQuebecMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozCanadaInc.BouchervilleQuebecMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisChileS.A.SantiagoDeChileMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisChileS.A.SantiagoDeChileMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:BeijingNovartisPharmaCo.Ltd.BeijingMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:BeijingNovartisPharmaCo.Ltd.BeijingMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsHKLimitedHongKongMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsHKLimitedHongKongMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ShanghaiNovartisTradingLtd.ShanghaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ShanghaiNovartisTradingLtd.ShanghaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeColombiaS.A.SantafeDeBobotaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeColombiaS.A.SantafeDeBobotaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozD.o.o.FarmaceutskaIndustrijaZagrebMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozD.o.o.FarmaceutskaIndustrijaZagrebMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisS.r.o.PragueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisS.r.o.PragueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.r.o.PragueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.r.o.PragueMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcareASCopenhagenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcareASCopenhagenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozASCopenhagenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozASCopenhagenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisEcuadorS.A.QuitoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisEcuadorS.A.QuitoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.E.CairoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.E.CairoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozEgyptPharmaS.A.E.NewCairoCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozEgyptPharmaS.A.E.NewCairoCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinlandOyEspooMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinlandOyEspooMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGroupeFranceS.A.RueilMalmaisonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGroupeFranceS.A.RueilMalmaisonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.S.RueilMalmaisonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.S.RueilMalmaisonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CELLforCURELesUlisMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CELLforCURELesUlisMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.S.LevalloisPerretMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.S.LevalloisPerretMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeutschlandGmbHNurembergMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeutschlandGmbHNurembergMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBusinessServicesGmbHWehrMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBusinessServicesGmbHWehrMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHNurembergMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHNurembergMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaProduktionsGmbHWehrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaProduktionsGmbHWehrMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInternationalGmbHHolzkirchenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInternationalGmbHHolzkirchenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:A1APharmaGmbHHolzkirchenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:A1APharmaGmbHHolzkirchenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:HEXALAGHolzkirchenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:HEXALAGHolzkirchenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SalutasPharmaGmbHBarlebenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SalutasPharmaGmbHBarlebenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AeropharmGmbHRudolstadtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AeropharmGmbHRudolstadtMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozHungaryLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozHungaryLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIndiaLimitedMumbaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIndiaLimitedMumbaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePrivateLimitedMumbaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePrivateLimitedMumbaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPrivateLimitedMumbaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPrivateLimitedMumbaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:PT.NovartisIndonesiaJakartaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:PT.NovartisIndonesiaJakartaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIrelandLimitedDublinMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIrelandLimitedDublinMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesEULimitedDublinMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesEULimitedDublinMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIsraelLtd.TelAvivMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIsraelLtd.TelAvivMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaS.p.A.MilanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaS.p.A.MilanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.p.A.OriggioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.p.A.OriggioMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaK.K.TokyoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaK.K.TokyoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CibaGeigyJapanLimitedTokyoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CibaGeigyJapanLimitedTokyoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozK.K.TokyoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozK.K.TokyoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBalticsSIARigaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBalticsSIARigaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentsS.aR.l.LuxembourgCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentsS.aR.l.LuxembourgCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceS.A.LuxembourgCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceS.A.LuxembourgCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaMarocSACasablancaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaMarocSACasablancaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNetherlandsB.V.AmsterdamMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNetherlandsB.V.AmsterdamMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaB.V.AmsterdamMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaB.V.AmsterdamMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:IDBHollandBVBaarleNassauMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:IDBHollandBVBaarleNassauMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozB.V.AlmereMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozB.V.AlmereMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNewZealandLtdAucklandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNewZealandLtdAucklandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNorgeASOsloMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNorgeASOsloMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaPakistanLimitedKarachiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaPakistanLimitedKarachiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLogisticsInc.PanamaCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLogisticsInc.PanamaCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePhilippinesInc.MakatiCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePhilippinesInc.MakatiCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPhilippinesCorporationMakatiCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPhilippinesCorporationMakatiCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPolandSp.ZO.o.WarsawMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPolandSp.ZO.o.WarsawMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPolskaSp.ZO.o.WarsawMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPolskaSp.ZO.o.WarsawMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekS.A.StrykowMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekS.A.StrykowMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPortugalSGPSLda.PortoSalvoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPortugalSGPSLda.PortoSalvoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaLda.PortoSalvoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaLda.PortoSalvoMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesRomaniaS.R.L.BucharestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesRomaniaS.R.L.BucharestMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.R.L.TarguMuresMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.R.L.TarguMuresMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLLCMoscowMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLLCMoscowMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNevaLLCSt.PetersburgMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNevaLLCSt.PetersburgMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:JSCSandozMoscowMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:JSCSandozMoscowMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaudiLtd.RiyadhMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaudiLtd.RiyadhMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePteLtd.SingaporeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePteLtd.SingaporeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSlovakiaS.r.o.BratislavaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSlovakiaS.r.o.BratislavaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSouthAfricaPtyLtdMidrandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSouthAfricaPtyLtdMidrandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozSouthAfricaPtyLtdMidrandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozSouthAfricaPtyLtdMidrandMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisKoreaLtd.SeoulMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisKoreaLtd.SeoulMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.BarcelonaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.BarcelonaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaS.A.MadridMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaS.A.MadridMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AbadiaRetuertaS.A.SardonDeDueroValladolidMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AbadiaRetuertaS.A.SardonDeDueroValladolidMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSverigeABStockholmMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSverigeABStockholmMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHoldingAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHoldingAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalPharmaceuticalInvestmentAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalPharmaceuticalInvestmentAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBioventuresAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBioventuresAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisOverseasInvestmentsAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisOverseasInvestmentsAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:JapatAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:JapatAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizerhalleAGMuttenzMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizerhalleAGMuttenzMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSteinAGSteinMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSteinAGSteinMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizAGRischMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizAGRischMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CellerysAGSchlierenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CellerysAGSchlierenMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ArctosMedicalAGBernMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ArctosMedicalAGBernMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInnovativeTherapiesAGRischMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInnovativeTherapiesAGRischMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsInternationalSAGeneveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsInternationalSAGeneveMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozAGBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsAGRischMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsAGRischMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisTaiwanCo.Ltd.TaipeiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisTaiwanCo.Ltd.TaipeiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisThailandLimitedBangkokMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisThailandLimitedBangkokMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIlacSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIlacSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozUkraineLLCKievMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozUkraineLLCKievMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisMiddleEastFZEDubaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisMiddleEastFZEDubaiMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisUKLimitedLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisUKLimitedLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsUKLimitedLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsUKLimitedLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGrimsbyLimitedLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGrimsbyLimitedLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUKIrelandLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUKIrelandLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NeutecPharmaLimitedLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NeutecPharmaLimitedLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GyroscopeTherapeuticsLimitedLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GyroscopeTherapeuticsLimitedLondonMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozLimitedFrimleyCamberleyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozLimitedFrimleyCamberleyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationEastHanoverNYMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationEastHanoverNYMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceCorporationEastHanoverNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceCorporationEastHanoverNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCapitalCorporationEastHanoverNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCapitalCorporationEastHanoverNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisServicesInc.EastHanoverNYMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisServicesInc.EastHanoverNYMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCorporationEastHanoverNYMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCorporationEastHanoverNYMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesInc.BannockburnILMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesInc.BannockburnILMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CadentTherapeuticsCambridgeMAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CadentTherapeuticsCambridgeMAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EndocyteInc.EastHanoverNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EndocyteInc.EastHanoverNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NavigateBioPharmaServicesInc.CarlsbadCAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NavigateBioPharmaServicesInc.CarlsbadCAMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInc.PrincetonNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInc.PrincetonNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:OrielTherapeuticsInc.DurhamNCMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:OrielTherapeuticsInc.DurhamNCMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FougeraPharmaceuticalsInc.MelvilleNYMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FougeraPharmaceuticalsInc.MelvilleNYMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EonLabsInc.PrincetonNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EonLabsInc.PrincetonNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeVenezuelaS.A.CaracasMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeVenezuelaS.A.CaracasMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisVietnamCompanyLimitedHoChiMinhCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisVietnamCompanyLimitedHoChiMinhCityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4AmericanDepositarySharesEachRepresenting1ShareMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nvs:AmericanDepositarySharesEachRepresenting1ShareMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4OrdinarySharesNominalValueCHF0.50PerShareMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nvs:OrdinarySharesNominalValueCHF0.50PerShareMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisForschungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisForschungsstiftungBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisStiftungFuerKaderausbildungBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisMitarbeiterbeteiligungsstiftungBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisStiftungFuerMenschUndUmweltBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisUSFoundationEastHanoverNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisTechnologyLLCInc.EastHanoverNJMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentivePlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentivePlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeShareOwnershipPlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationEmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePlanMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermPerformancePlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationSpecialShareAwardsMember">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001114448</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationSpecialShareAwardsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2022-01-01</xbrli:startDate>
              <xbrli:endDate>2022-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:unit id="Shares">
            <xbrli:measure>xbrli:shares</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="USD">
            <xbrli:measure>iso4217:USD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="USDPerShares">
            <xbrli:divide>
              <xbrli:unitNumerator>
                <xbrli:measure>iso4217:USD</xbrli:measure>
              </xbrli:unitNumerator>
              <xbrli:unitDenominator>
                <xbrli:measure>xbrli:shares</xbrli:measure>
              </xbrli:unitDenominator>
            </xbrli:divide>
          </xbrli:unit>
          <xbrli:unit id="CHFPerShares">
            <xbrli:divide>
              <xbrli:unitNumerator>
                <xbrli:measure>iso4217:CHF</xbrli:measure>
              </xbrli:unitNumerator>
              <xbrli:unitDenominator>
                <xbrli:measure>xbrli:shares</xbrli:measure>
              </xbrli:unitDenominator>
            </xbrli:divide>
          </xbrli:unit>
          <xbrli:unit id="Pure">
            <xbrli:measure>xbrli:pure</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="EUR">
            <xbrli:measure>iso4217:EUR</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="Year">
            <xbrli:measure>ns0:year</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="CHF">
            <xbrli:measure>iso4217:CHF</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="JPY">
            <xbrli:measure>iso4217:JPY</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="DZD">
            <xbrli:measure>iso4217:DZD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="ARS">
            <xbrli:measure>iso4217:ARS</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="AUD">
            <xbrli:measure>iso4217:AUD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="BDT">
            <xbrli:measure>iso4217:BDT</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="BRL">
            <xbrli:measure>iso4217:BRL</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="CAD">
            <xbrli:measure>iso4217:CAD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="CLP">
            <xbrli:measure>iso4217:CLP</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="HKD">
            <xbrli:measure>iso4217:HKD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="COP">
            <xbrli:measure>iso4217:COP</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="HRK">
            <xbrli:measure>iso4217:HRK</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="CZK">
            <xbrli:measure>iso4217:CZK</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="DKK">
            <xbrli:measure>iso4217:DKK</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="EGP">
            <xbrli:measure>iso4217:EGP</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="HUF">
            <xbrli:measure>iso4217:HUF</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="INR">
            <xbrli:measure>iso4217:INR</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="IDR">
            <xbrli:measure>iso4217:IDR</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="ILS">
            <xbrli:measure>iso4217:ILS</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="MYR">
            <xbrli:measure>iso4217:MYR</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="MXN">
            <xbrli:measure>iso4217:MXN</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="MAD">
            <xbrli:measure>iso4217:MAD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="NZD">
            <xbrli:measure>iso4217:NZD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="NOK">
            <xbrli:measure>iso4217:NOK</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="PKR">
            <xbrli:measure>iso4217:PKR</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="PHP">
            <xbrli:measure>iso4217:PHP</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="PLN">
            <xbrli:measure>iso4217:PLN</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="RON">
            <xbrli:measure>iso4217:RON</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="RUB">
            <xbrli:measure>iso4217:RUB</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="SAR">
            <xbrli:measure>iso4217:SAR</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="SGD">
            <xbrli:measure>iso4217:SGD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="ZAR">
            <xbrli:measure>iso4217:ZAR</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="KRW">
            <xbrli:measure>iso4217:KRW</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="SEK">
            <xbrli:measure>iso4217:SEK</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="TWD">
            <xbrli:measure>iso4217:TWD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="THB">
            <xbrli:measure>iso4217:THB</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="TRY">
            <xbrli:measure>iso4217:TRY</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="UAH">
            <xbrli:measure>iso4217:UAH</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="AED">
            <xbrli:measure>iso4217:AED</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="GBP">
            <xbrli:measure>iso4217:GBP</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="VEF">
            <xbrli:measure>iso4217:VEF</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="VND">
            <xbrli:measure>iso4217:VND</xbrli:measure>
          </xbrli:unit>
        </ix:resources>
      </ix:header>
    </div>
    <div>
      <br />
      <img src="x_coverfront.jpg" alt="picture" />
      <br />
      <br />
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"></span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <b>As filed with the Securities and Exchange Commission on February 1, 2023</b>
              </span>
            </div>
          </div>
          <div style="width:100%;padding-bottom:20px;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <div style="border:none;border-bottom:solid .25em;padding:0in 0in 1.0pt 0in"></div>
              <div style="border:none;border-bottom:solid .05em;padding:0in 0in 1.0pt 0in"></div>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:16pt; font-weight: bold; color:#000000;">UNITED STATES <br />SECURITIES AND EXCHANGE COMMISSION</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <b>Washington D.C. 20549</b>
              </span>
            </div>
          </div>
          <div style="Margin: 0 auto; WIDTH: 120px;padding-top:10px;">
            <div style="border-top: solid #000000 3px;"></div>
            <div style="TEXT-ALIGN: center; font-family:arial,helvetica,sans-serif; font-size:16pt; font-weight: bold; color:#000000;">
              <span>Form <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:DocumentType">20-F</ix:nonNumeric></span>
            </div>
            <div style="border-top: solid #000000 3px;padding-bottom:20px;"></div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:DocumentRegistrationStatement" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>    REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">OR</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric>    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen">December 31, 2022</ix:nonNumeric></span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">OR</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">OR</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:DocumentShellCompanyReport" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>    SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Date of event requiring this shell company report&#x2026;&#x2026;&#x2026;&#x2026;&#x2026;</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">For the transition period from _____ to _____</span>
            </div>
          </div>
          <div style="padding-bottom:20px;"></div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <b>Commission file number </b>
                <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityFileNumber">1-15024</ix:nonNumeric>
              </span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:16pt; font-weight: bold; color:#000000;">
                <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityRegistrantName">Novartis AG</ix:nonNumeric>
              </span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">(Exact name of Registrant as specified in its charter)</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:16pt; font-weight: bold; color:#000000;">NOVARTIS Inc.</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">(Translation of Registrant&#x2019;s name into English)</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:16pt; font-weight: bold; color:#000000;">Switzerland</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">(Jurisdiction of incorporation or organization)</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityAddressAddressLine1">Lichtstrasse 35</ix:nonNumeric>
              </span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityAddressPostalZipCode">4056</ix:nonNumeric>
                <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityAddressCityOrTown">Basel</ix:nonNumeric>, <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen">Switzerland</ix:nonNumeric></span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">(Address of principal executive offices)</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember" name="dei:ContactPersonnelName">Karen L. Hale</ix:nonNumeric>
              </span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Chief Legal Officer</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Novartis AG</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">CH <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember" name="dei:EntityAddressPostalZipCode">4056</ix:nonNumeric><span>&#xA0;</span><ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember" name="dei:EntityAddressCityOrTown">Basel</ix:nonNumeric></span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen">Switzerland</ix:nonNumeric>
              </span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Tel.: +<ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember" name="dei:CountryRegion">41</ix:nonNumeric>-<ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember" name="dei:CityAreaCode">61</ix:nonNumeric>-<ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember" name="dei:LocalPhoneNumber">324-1111</ix:nonNumeric></span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Fax: +<ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember" name="dei:CountryRegion">41</ix:nonNumeric>-<ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember" name="dei:CityAreaCode">61</ix:nonNumeric>-<ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember" name="dei:ContactPersonnelFaxNumber">324-7826</ix:nonNumeric></span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Securities registered or to be registered pursuant to Section 12(b) of the Act:</span>
            </div>
          </div>
          <div>
            <div style="padding-top:10px;"></div>
            <div style="width:100%;">
              <div style="TEXT-ALIGN: center; WIDTH: 33%; float:left; ">
                <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-decoration:underline;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;">Title of each class</span>
              </div>
              <div style="TEXT-ALIGN: center; WIDTH: 33%; float:left;">
                <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-decoration:underline;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;">Trading Symbol(s)</span>
              </div>
              <div style="TEXT-ALIGN: center; WIDTH: 33%; float:left;">
                <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-decoration:underline;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;">Name of each exchange on which registered</span>
              </div>
            </div>
            <div style="width:100%;">
              <div style="TEXT-ALIGN: center; WIDTH: 33%; float:left; ">
                <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                  <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4AmericanDepositarySharesEachRepresenting1ShareMember" name="dei:Security12bTitle">American Depositary Shares each representing 1 share</ix:nonNumeric>
                  <br />
                </span>
              </div>
              <div style="TEXT-ALIGN: center; WIDTH: 33%; float:left;">
                <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                  <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4AmericanDepositarySharesEachRepresenting1ShareMember" name="dei:TradingSymbol">NVS</ix:nonNumeric>
                  <br /> &#xA0;</span>
              </div>
              <div style="TEXT-ALIGN: center; WIDTH: 33%; float:left;">
                <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                  <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4AmericanDepositarySharesEachRepresenting1ShareMember" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric>
                  <br /> &#xA0;</span>
              </div>
            </div>
            <div style="width:100%;">
              <div style="TEXT-ALIGN: center; WIDTH: 33%; float:left; ">
                <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                  <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4OrdinarySharesNominalValueCHF0.50PerShareMember" name="dei:Security12bTitle">Ordinary shares, nominal value CHF 0.50 per share</ix:nonNumeric>*</span>
              </div>
              <div style="TEXT-ALIGN: center; WIDTH: 33%; float:left;">
                <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                  <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4OrdinarySharesNominalValueCHF0.50PerShareMember" name="dei:TradingSymbol">NOVN</ix:nonNumeric>
                </span>
              </div>
              <div style="TEXT-ALIGN: center; WIDTH: 33%; float:left;">
                <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                  <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4OrdinarySharesNominalValueCHF0.50PerShareMember" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric>*</span>
              </div>
            </div>
          </div>
          <div style="TEXT-ALIGN: center; WIDTH: 33%; clear: both">
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">&#xA0;</span>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Securities registered or to be registered pursuant to Section 12(g) of the Act:</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <b>None</b>
              </span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <b>None</b>
              </span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate the number of outstanding shares of each of the issuer&#x2019;s classes of capital or common stock as of the close of the period covered by the annual report:</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; font-weight: bold; color:#000000;">
                <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd" name="dei:EntityCommonStockSharesOutstanding" decimals="0" scale="0" format="ixt:numdotdecimal">2 119 609 057</ix:nonFraction> ordinary shares</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="padding-top:10px;padding-bottom:10px;TEXT-ALIGN: center; WIDTH: 99%;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <b>&#xA0;&#xA0;&#xA0;</b>
                <b>
                  <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityWellKnownSeasonedIssuer">Yes</ix:nonNumeric>
                </b>&#xA0;&#xA0;&#xA0; &#x2612;&#xA0;&#xA0;&#xA0;<b>No</b>&#xA0;&#xA0;&#xA0; &#x2610;</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="padding-top:10px;padding-bottom:10px;TEXT-ALIGN: center; WIDTH: 99%;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <b>&#xA0;&#xA0;&#xA0; Yes</b>&#xA0;&#xA0;&#xA0; &#x2610; &#xA0;&#xA0;&#xA0;<b><ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></b>&#xA0;&#xA0;&#xA0; &#x2612;</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Note&#x2014;Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"> &#xA0;</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="padding-top:10px;padding-bottom:10px;TEXT-ALIGN: center; WIDTH: 99%;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <b>&#xA0;&#xA0;&#xA0;</b>
                <b>
                  <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric>
                </b>&#xA0;&#xA0;&#xA0; &#x2612;&#xA0;&#xA0;&#xA0;<b>No</b>&#xA0;&#xA0;&#xA0; &#x2610;</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#xA7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="padding-top:10px;padding-bottom:10px;TEXT-ALIGN: center; WIDTH: 99%;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <b>&#xA0;&#xA0;&#xA0;</b>
                <b>
                  <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric>
                </b>&#xA0;&#xA0;&#xA0; &#x2612;&#xA0;&#xA0;&#xA0;<b>No</b>&#xA0;&#xA0;&#xA0; &#x2610;</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See&#xA0;definition of &#x201C;large accelerated filer,&#x201D; &#x201C;accelerated filer,&#x201D; and &#x201C;emerging growth company&#x201D; in Rule 12b-2 of the Exchange Act.</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric>&#xA0;&#x2612; &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; Accelerated filer&#xA0;&#x2610; &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; Non-accelerated filer&#xA0;&#x2610; &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; Emerging growth company&#xA0;&#x2610;</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#x2020; provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">&#x2020; The term &#x201C;new or revised financial accounting standard&#x201D; refers to any update issued by the Financial&#xA0;Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#x2610;</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive officers during the relevant recovery period pursuant to &#xA7;240.10D-1(b). &#x2610;</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">U.S. GAAP&#xA0;&#x2610; &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;<ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:DocumentAccountingStandard">International Financial Reporting Standards</ix:nonNumeric> as issued by the International Accounting Standards Board&#xA0;&#x2612; &#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; Other&#xA0;&#x2610;</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">If &#x201C;Other&#x201D; has been checked in response to the previous question, indicate by check mark which financial&#xA0;statement item the registrant has elected to follow.</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="padding-top:10px;padding-bottom:10px;TEXT-ALIGN: center; WIDTH: 99%;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <b>&#xA0;&#xA0;&#xA0;Item 17</b>&#xA0;&#xA0;&#xA0; &#x2610; &#xA0;&#xA0;&#xA0;<b>Item 18</b>&#xA0;&#xA0;&#xA0; &#x2610; </span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="padding-top:10px;padding-bottom:10px;TEXT-ALIGN: center; WIDTH: 99%;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">
                <b>&#xA0;&#xA0;&#xA0;Yes</b>&#xA0;&#xA0;&#xA0;<ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#xA0;&#xA0;&#xA0;<b>No</b>&#xA0;&#xA0;&#xA0; &#x2612; </span>
            </div>
          </div>
          <div style="width:100%;">
            <div style="TEXT-ALIGN: left; WIDTH: 99%">
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">*  Not for trading but only in connection with the registration of American Depositary Shares representing such ordinary shares.</span>
            </div>
          </div>
          <div style="width:100%;padding-top:30px;padding-bottom:20px;">
            <div style="TEXT-ALIGN: center; WIDTH: 99%">
              <div style="border:none;border-bottom:solid .05em;padding:0in 0in 1.0pt 0in"></div>
              <div style="border:none;border-bottom:solid .25em;padding:0in 0in 1.0pt 0in"></div>
            </div>
          </div>
        </div>
      </div>
      <div>
        <div>
          <div id="anchorId001111362"></div>
          <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Table of contents</p>
        </div>
      </div>
      <br />
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00210918">Introduction and use of certain terms</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00210937">Forward-looking statements</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;text-transform:uppercase;font-weight:bold;">
        <a style="text-decoration: none;" href="#anchorId00310941">Part I</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00310943">Item 1.  Identity of Directors, Senior&#xA0;Management and Advisers</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00310950">Item 2.  Offer Statistics and Expected Timetable</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00310956">Item 3.  Key Information</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00310958">3.A [Reserved]</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00310960">3.B Capitalization and indebtedness</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00310964">3.C Reasons for the offer and use of proceeds</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00310968">3.D Risk factors </a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00311500">Item&#xA0;4.  Information on the Company</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00311503">4.A History and development of Novartis</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00311534">4.B Business overview</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 54px;">
        <a style="text-decoration: none;" href="#anchorId00311598">Innovative Medicines</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 54px;">
        <a style="text-decoration: none;" href="#anchorId00315155">Sandoz</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00316061">4.C Organizational structure</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00316079">4.D Property, plants and equipment</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00316292">Item&#xA0;4A.  Unresolved Staff Comments</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId0010010984">Item 5. Operating and Financial Review and&#xA0;Prospects</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId0010010987">5.A Operating results</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId0010024751">5.B Liquidity and capital resources</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId0010028559">5.C Research and development, patents and licenses</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId0010028577">5.D Trend information</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId0010028584">5.E Critical accounting estimates </a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00410918">Item 6.  Directors, Senior Management and Employees</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00410920">6.A Directors and senior management</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00911069">6.B Compensation</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001010938">6.C Board practices </a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00510930">6.D Employees</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00511785">6.E Share ownership</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00511806">Item&#xA0;7.  Major Shareholders and Related Party Transactions</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00511809">7.A Major shareholders</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512258">7.B Related party transactions</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512264">7.C Interests of experts and counsel</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00512270">Item&#xA0;8.  Financial Information</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512273">8.A Consolidated statements and other financial information</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512314">8.B Significant changes</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00512321">Item&#xA0;9.  The Offer and Listing</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512324">9.A Offer and listing details</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512332">9.B Plan of distribution</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512336">9.C Markets</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512342">9.D Selling shareholders</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512346">9.E Dilution</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512350">9.F Expenses of the issue</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00512356">Item&#xA0;10.  Additional Information</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512359">10.A Share capital</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512363">10.B Memorandum and articles of association</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512619">10.C Material contracts</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512634">10.D Exchange controls</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512641">10.E Taxation</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512953">10.F Dividends and paying agents</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512957">10.G Statement by experts</a>
      </div>
      <div style="padding-bottom:50px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">2</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512963">10.H Documents on display</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00512977">10.I Subsidiary information</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00512983">Item&#xA0;11.  Quantitative and Qualitative Disclosures About Market Risk</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00513002">Item&#xA0;12.  Description of Securities Other Than Equity Securities</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00513005">12.A Debt securities</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00513009">12.B Warrants and rights</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00513013">12.C Other securities</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId00513017">12.D American Depositary Shares</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;text-transform:uppercase;font-weight:bold;">
        <a style="text-decoration: none;" href="#anchorId00513211">PART II</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00513213">Item&#xA0;13.  Defaults, Dividend Arrearages and Delinquencies</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00513220">Item&#xA0;14.  Material Modifications to the Rights of Security Holders and Use of Proceeds</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00610918">Item&#xA0;15.  Controls and Procedures</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00710921">Item&#xA0;16A.  Audit Committee Financial Expert</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00710930">Item&#xA0;16B.  Code of Ethics</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00710939">Item&#xA0;16C.  Principal Accountant Fees and Services</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00710950">Item&#xA0;16D.  Exemptions from the Listing Standards for Audit Committees</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00710957">Item&#xA0;16E.  Purchases of Equity Securities by the Issuer and Affiliated Purchasers</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00711642">Item&#xA0;16F.  Change in Registrant&#x2019;s Certifying Accountant</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00711650">Item&#xA0;16G.  Corporate Governance</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00711683">Item&#xA0;16H.  Mine Safety Disclosure</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00711691">Item&#xA0;16I.  Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;text-transform:uppercase;font-weight:bold;">
        <a style="text-decoration: none;" href="#anchorId00711699">PART III</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00711701">Item&#xA0;17.  Financial Statements</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId00711709">Item&#xA0;18.  Financial Statements</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId001810920">Item&#xA0;19.  Exhibits</a>
      </div>
      <div style="padding-bottom:30px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">3</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00210918"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Introduction and use of certain terms</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG and its consolidated affiliates publish consolidated financial statements expressed in US dollars. Our consolidated financial statements responsive to Item 18 of this Annual Report on Form&#xA0;20-F (Annual Report) are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). &#x201C;Item 5. Operating and Financial Review and Prospects,&#x201D; together with the sections on products in development and key development projects of our businesses (see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B. Business overview&#x201D;), constitute the Operating and Financial Review (&#x201C;Lagebericht&#x201D;), as defined by the Swiss Code of Obligations.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Unless the context requires otherwise, the words &#x201C;we,&#x201D; &#x201C;our,&#x201D; &#x201C;us,&#x201D; &#x201C;Novartis,&#x201D; &#x201C;Group,&#x201D; &#x201C;Company,&#x201D; and similar words or phrases in this Annual Report refer to Novartis AG and its consolidated affiliates. However, each Group company is legally separate from all other Group companies and manages its business independently through its respective board of directors or similar supervisory body or other top local management body, if applicable. Each executive identified in this Annual Report reports directly to other executives of the Group company that employs the executive, or to that Group company&#x2019;s board of directors.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In this Annual Report, references to &#x201C;US dollars,&#x201D; &#x201C;USD&#x201D; or &#x201C;$&#x201D; are to the lawful currency of the United States of America, references to &#x201C;CHF&#x201D; are to Swiss francs, and references to &#x201C;euro&#x201D; or &#x201C;EUR&#x201D; are to the lawful currency of 27 member states participating in the European Union; references to the &#x201C;United States&#x201D; or to &#x201C;US&#x201D; are to the United States of America, references to the &#x201C;European Union&#x201D; or to &#x201C;EU&#x201D; are to the European Union and its 27 member states, references to &#x201C;Latin America&#x201D; are to Central and South America, including the Caribbean, and references to &#x201C;Australasia&#x201D; are to Australia, New Zealand, Melanesia, Micronesia and Polynesia, unless the context otherwise requires; references to the &#x201C;EC&#x201D; are to the European Commission; references to &#x201C;associates&#x201D; are to employees of our affiliates; references to the &#x201C;SEC&#x201D; are to the US Securities and Exchange Commission; references to the &#x201C;FDA&#x201D; are to the US Food and Drug Administration; references to the &#x201C;EMA&#x201D; are to the European Medicines Agency, an agency of the EU, and references to the &#x201C;CHMP&#x201D; are to the Committee for Medicinal Products for Human Use of the EMA; references to &#x201C;ADR&#x201D; or &#x201C;ADRs&#x201D; are to Novartis American Depositary Receipts, and references to &#x201C;ADS&#x201D; or &#x201C;ADSs&#x201D; are to Novartis American Depositary Shares; references to the &#x201C;NYSE&#x201D; are to the New York Stock Exchange, and references to &#x201C;SIX&#x201D; are to the SIX Swiss Exchange; references to &#x201C;ECN&#x201D; are to the Executive Committee of Novartis; references to &#x201C;GSK&#x201D; are to GlaxoSmithKline plc; references to &#x201C;Roche&#x201D; are to Roche Holding AG; references to &#x201C;Gyroscope Therapeutics&#x201D; are to Gyroscope Therapeutics Holdings plc; references to &#x201C;AAA&#x201D; are to Advanced Accelerator Applications S.A., references to &#x201C;Novartis Gene Therapies&#x201D; are to Novartis Gene Therapies, Inc., and references to &#x201C;Endocyte&#x201D; are to Endocyte, Inc.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">All product names appearing in italics are trademarks owned by or licensed to Group companies. Product names identified by a &#x201C;&#xAE;&#x201D; or a &#x201C;&#x2122;&#x201D; are trademarks that are not owned by or licensed to Group companies and are the property of their respective owners.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">4</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00210937"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Forward-looking statements</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">This Annual Report contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended (the &#x201C;Exchange Act&#x201D;), and the United States Private Securities Litigation Reform Act of 1995, as amended. Other written materials filed with or furnished to the SEC by Novartis, as well as other written and oral statements made to the public, may also contain forward-looking statements. Forward-looking statements can be identified by words such as &#x201C;potential,&#x201D; &#x201C;expected,&#x201D; &#x201C;will,&#x201D; &#x201C;planned,&#x201D; &#x201C;pipeline,&#x201D; &#x201C;outlook,&#x201D; &#x201C;may,&#x201D; &#x201C;could,&#x201D; &#x201C;would,&#x201D; &#x201C;anticipate,&#x201D; &#x201C;seek,&#x201D; or similar terms, or by express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products; or regarding the potential outcome, or financial or other impact on Novartis, of any of the transactions described; or regarding the potential impact of share buybacks; or regarding potential future sales or earnings of the Group or any of its divisions or potential shareholder returns; or regarding potential future credit ratings of the Group; or by discussions of strategy, plans, expectations or intentions. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements.</div>
      <div style="padding-top:15px;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In particular, our expectations could be affected by, among other things:</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Uncertainties regarding the success of key products and commercial priorities;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Uncertainties in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Global trends toward healthcare cost-containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The potential that the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities, our intention to separate our Sandoz Division into a new publicly traded standalone company by way of a 100% spin-off, or the implementation of our new organizational structure and operating model, may not be realized or may take longer to realize than expected;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"> &#x2022;  Our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products that commenced in prior years and is expected to continue this year;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Our performance on environmental, social and governance matters;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Uncertainties in the development or adoption of potentially transformational digital technologies and business models;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Uncertainties regarding potential significant breaches of information security or disruptions of our information technology systems;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Uncertainties surrounding the implementation of our new Enterprise Resource Planning system and other IT projects;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Our reliance on outsourcing key business functions to third parties;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Uncertainties regarding actual or potential legal proceedings, including, among others, litigation and other legal disputes with respect to our recent transactions, product liability litigation, litigation and investigations regarding sales and marketing practices, intellectual property disputes and government investigations generally;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Safety, quality, data integrity or manufacturing issues;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Our ability to attract, integrate and retain key personnel and qualified individuals;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Regulatory actions or delays or government regulation generally, including potential regulatory actions or delays with respect to the development of the products described in this Annual Report;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">5</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Our ability to comply with data privacy laws and regulations, and uncertainties regarding potential significant breaches of data privacy;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Our ability  to adapt to major geopolitical and macroeconomic developments, including the effects of and efforts to mitigate pandemic diseases such as COVID-19, and the impact of the war in Ukraine;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Uncertainties involved in predicting shareholder returns;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Uncertainties regarding the effects of recent and anticipated future changes in tax laws and their application to us;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Uncertainties regarding future global exchange rates; and</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Uncertainties regarding future demand for our products.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Some of these factors are discussed in more detail in this Annual Report, including under &#x201C;Item 3. Key Information&#x2014;Item 3.D. Risk factors,&#x201D; &#x201C;Item 4. Information on the Company,&#x201D; and &#x201C;Item 5. Operating and Financial Review and Prospects.&#x201D; Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this Annual Report as anticipated, believed, estimated or expected. We provide the information in this Annual Report as of the date of its filing. We do not intend, and do not assume any obligation, to update any information or forward-looking statements set out in this Annual Report as a result of new information, future events or otherwise.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">6</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00310941"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000;">Part I</p>
      <div id="anchorId00310943"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item 1.  Identity of Directors, Senior&#xA0;Management and Advisers</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">7</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00310950"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item 2.  Offer Statistics and Expected Timetable</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">8</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00310956"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item 3.  Key Information</p>
      <div id="anchorId00310958"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">3.A [Reserved]</p>
      <div id="anchorId00310960"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">3.B Capitalization and indebtedness</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div id="anchorId00310964"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">3.C Reasons for the offer and use of proceeds</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div id="anchorId00310968"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">3.D Risk factors </p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our businesses face significant risks and uncertainties. You should carefully consider all of the information set forth in this Annual Report and in other documents we file with or furnish to the SEC, including the following risk factors, before deciding to invest in or to maintain an investment in any Novartis securities. Our business, as well as our reputation, financial condition, results of operations, and share price, could be materially adversely affected by any of these risks, as well as other risks and uncertainties not currently known to us or not currently considered material.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Strategic risks</span>
      </div>
      <div style="padding-bottom:15px; ">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Key products and commercial priorities</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Failure to deliver key commercial priorities and successfully launch new products</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our ability to maintain and grow our business and to replace revenue and income lost to generic, biosimilar and other competition depends heavily on the commercial success of our new or existing key products. The commercial success of these products could be impacted at any time by a number of factors, including pressure from new or existing competitive products, changes in the prescribing habits of healthcare professionals, unexpected side effects or safety signals, supply chain issues or other product shortages, pricing pressure, regulatory proceedings, changes in labeling, loss of intellectual property protection, and global pandemics. In addition, our revenue and margins could be significantly impacted by the timing and rate of commercial acceptance of new products. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Healthcare professionals, patients and payers may choose competitor products instead of ours for various reasons, including if they perceive them to be better in terms of efficacy, safety, cost, convenience or other reasons. The commercial success of our key products and launches in the face of increasing competition requires significant attention and management focus. Such competition could significantly affect the revenue from our products and our results of operations. This impact could also be compounded to the extent that such competition results in us making significant additional investments in research and development, marketing or sales.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Research and development</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Failure to successfully prioritize, integrate and execute our research and development programs for new products or new indications for existing products, given our focus on innovative medicines</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We engage in extensive and costly research and development activities, both through our own internal resources and through collaborations with third parties, in an effort to identify and develop new products and new indications for existing products that address unmet and changing medical needs, and that are commercially successful. Our ability to grow our business and our product pipeline; to replace sales lost due to branded competition, entry of generics, or other reasons; and to bring to market products that take advantage of new and potentially disruptive technologies, including cell, gene and radioligand therapies, depends in significant part on the success of these efforts. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Failure to successfully develop our pipeline products is typically the result of the inherent uncertainty of science, suboptimal internal execution, or both. Key elements of internal execution include our ability to prioritize our investments on our highest potential value assets, optimize the transition of assets from research to </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">9</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">development, integrate externally acquired assets in an efficient way, and execute the steps in our drug development process that enable our assets to be approved and reimbursed in a timely manner to positively impact clinical practice. See also &#x201C;Item 4. Information on the Company&#x2014; Item 4.B Business overview&#x2014;Innovative Medicines&#x2014;Research and development&#x201D; with regards to the research and development efforts of our Innovative Medicines Division.   </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our new products must undergo intensive preclinical and clinical testing and are approved by means of a highly complex, lengthy, and expensive approval process that varies substantially from country to country and may have very specific requirements for the recruitment of patients for clinical trials. We face increasing and evolving regulatory approval and reimbursement requirements. If we fail to successfully progress late-stage assets and the core elements of drug development for key programs, this could have a negative impact on the development of our product pipeline, and ultimately on the success of our business and our financial results.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, in the US it is becoming increasingly challenging to adequately recruit a sufficient number of US patients in clinical trials due to new and changing requirements for recruitment of patients into such trials. As a result, we may be unable to develop the necessary clinical evidence to support the desired indications and product profile for a particular disease that is needed to drive clinical adoption of our new products, and thereby achieve the full potential of our assets (also known as the &#x201C;target product profile&#x201D;). Similarly, the post&#x2011;approval regulatory burden has also increased. These requirements make the maintenance of regulatory approvals for our products increasingly expensive, and further heighten the risk of recalls, product withdrawals, change to product specifications, loss of market share, and loss of revenue and profitability.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The clinical testing, regulatory processes and post-approval activities described above become more difficult during pandemics, such as the COVID-19 pandemic, as well as during periods of geopolitical and economic uncertainty. This is due to challenges related to recruiting, enrolling and treating patients in clinical trials, as well as ensuring the supply of trial materials. For a further description of the research and development of, and approval processes for, the products of our Innovative Medicines Division, see the sections headed &#x201C;Research and development&#x201D; and &#x201C;Regulation&#x201D; included in the description of our Innovative Medicines Division under &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview&#x2014;Innovative Medicines.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our Sandoz Division has made, and expects to continue to make, significant investments in the development of biotechnology&#x2011;based, &#x201C;biologic&#x201D; medicines that are intended for sale as bioequivalent or &#x201C;biosimilar&#x201D; versions of currently marketed biotechnology products. While the development of such products is typically significantly less costly and complex than the development of the equivalent originator medicines, it is nonetheless significantly more costly and complex than that for typical small-molecule generic products. For&#xA0;more information about the research and development efforts of our Sandoz Division, see &#x201C;Item 4.  Information on the Company&#x2014;Item 4.B Business overview&#x2014; Sandoz&#x2014;Development and registration.&#x201D; In addition, many countries do not yet have fully developed legislative or regulatory pathways to facilitate the development of biosimilars, and to permit their sale in such a way that they are readily substitutable alternatives to the originator product. Further delays or difficulties in the development or marketing of biosimilars could put at risk the significant investments that Sandoz has made, and will continue to make, in its Biopharmaceuticals business. Failure to successfully develop and market biosimilars could have a material adverse effect on the success of the Sandoz Division and the Group as a whole. For more information about the approval processes that must be followed to market Sandoz Division products, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview&#x2014;Sandoz&#x2014;Regulation.&#x201D;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Furthermore, our research and development activities must be conducted in an ethical and compliant manner. Among other things, we are concerned with patient safety (both pre- and post-product approval), data privacy, current Good Clinical Practices (cGCP) requirements, data integrity, the fair treatment of patients, diversity and inclusion in the recruitment of patients to clinical trials, and animal welfare. Should we fail to properly manage such issues, we risk injury to third parties, damage to our reputation, negative financial consequences as a result of potential claims for damages, sanctions and fines, and the potential that investments in research and development activities may not bring the expected benefits to the Group.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Pricing, reimbursement and access</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Pricing and reimbursement pressure, including pricing transparency and access to healthcare</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our business has continuously experienced significant pressures on the pricing of our products and on our ability to obtain and maintain satisfactory rates of reimbursement for our products by governments, insurers and other payers. These pressures have many sources, including growth of healthcare costs as a percentage of gross domestic product; funding restrictions and policy changes; and public controversies, political debate, investigations and legal proceedings regarding pharmaceutical pricing. Pressures on pricing may negatively impact both our product pricing and the availability of our products. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, we face numerous cost&#x2011;containment measures imposed by governments and other payers. These include government&#x2011;imposed industrywide price reductions, mandatory pricing systems, reference pricing systems, payers limiting access to treatments based on cost&#x2011;benefit analyses, the importation of drugs from lower&#x2011;cost countries to higher&#x2011;cost countries, the shifting of the payment burden to patients through higher co&#x2011;payments and co-pay accumulator programs, the limiting of physicians&#x2019; ability to choose among competing medicines, the mandatory substitution of generic drugs for the patented equivalent, pressure on physicians to reduce the prescribing of patented prescription medicines, increasing pressure on intellectual property </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">10</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">protections, and growing requirements for increased transparency on pricing. For more information on price controls, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview&#x2014;Innovative Medicines&#x2014;Price controls.&#x201D; </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Recent trends in the external environment may have an impact on the likelihood of these pricing and reimbursement pressures occurring. A worldwide slowdown in economic growth following the COVID-19 pandemic and the war in Ukraine (contributing to challenges such as high energy costs and inflation) has led to increased strain on fiscal budgets in many major economies. In addition, legislative developments such as those in the US (e.g., the Inflation Reduction Act) and in Europe (e.g., the EU Joint Health Technology Assessment) pose potential further pressures on pricing and timelines for reimbursement in these countries.  These external factors may materially affect our ability to achieve value-based prices; to achieve and maintain an acceptable return on our investments in the research and development of our products; and may impact our ability to research and develop new products. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, our Sandoz Division has faced and may continue to face intense competition from other generic and biosimilar pharmaceutical companies that aggressively compete for market share, including through significant price competition. Such competitive actions may increase the costs and risks associated with our efforts to introduce and market generic and biosimilar products, may delay the introduction or marketing of such products, and may further limit the prices at which we are able to sell these products. In particular, in the US in past years, industrywide price competition among generic pharmaceutical companies and consolidation of buyers caused significant declines in sales and profits of Sandoz.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Alliances, acquisitions and divestments</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Failure to identify, execute, and/or realize the expected benefits from our external business opportunities</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As part of our strategy, from time to time we acquire and divest products or entire businesses and enter into strategic alliances and collaborations. For example, in February 2022, we closed the acquisition of Gyroscope Therapeutics. This strategy is partly dependent on our ability to identify strategic external business opportunities and to close transactions with third parties on acceptable terms.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Once the terms of a strategic transaction have been agreed with a third party, we may not be able to complete the transaction in a timely manner or at all, nor can we be sure that pre-transaction due diligence will identify all possible issues that might arise during and after the transaction. Our efforts on such transactions can also divert management&#x2019;s attention from our existing businesses.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">After a transaction is closed, efforts to develop and market acquired or licensed products, to integrate the acquired business or to achieve expected synergies may fail or may not fully meet expectations. This may occur due to difficulties in retaining key personnel, customers and suppliers; failure to obtain marketing approval or reimbursement within expected time frames or at all; differences in corporate culture, standards, controls, processes and policies; or other factors. Transactions can also result in liabilities being incurred that were not known at the time of acquisition, or the creation of tax or accounting issues. Acquired businesses are not always in full compliance with legal, regulatory or Novartis standards, including, for example, Current Good Manufacturing Practices (cGMP) or cGCP standards, which can be costly and time-consuming to remediate. Furthermore, our strategic alliances and collaborations with third parties may not achieve their intended goals and objectives within expected time frames, or at all.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Similarly, we cannot ensure that we will be able to successfully divest or spin off businesses or other assets that we have identified for this purpose, or that any completed divestment or spin-off will achieve the expected strategic benefits, operational efficiencies or opportunities, or that the divestment or spin-off will ultimately maximize shareholder value.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Intellectual property</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Expiry, assertion or loss of intellectual property protection </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Many products of our Innovative Medicines Division are protected by intellectual property rights, which may provide us with exclusive rights to market those products for a limited time, and to enable our purpose of reimagining medicine by sustainably financing our research and development. However, the strength and duration of those rights can vary significantly from product to product and from country to country, and they may be successfully challenged by third parties or governmental authorities. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Loss of intellectual property protection and the introduction of generic or biosimilar competition for a patented branded medicine in a country typically result in a significant and rapid reduction in net sales and operating income for the branded product. Such competition can occur after successful challenges to intellectual property rights or the regular expiration of the patent term or other intellectual property rights. Such competition can also result from the entry of generic or biosimilar versions of another medicine in the same therapeutic class as one of our drugs or in a competing therapeutic class, from a Declaration of Public Interest or the compulsory licensing of our intellectual property by governmental authorities, or as a result of a general weakening of intellectual property and governing laws in certain countries around the world. In addition, generic or biosimilar manufacturers may sometimes conduct so-called &#x201C;launches at risk&#x201D; of products that are still under legal challenge for infringement, or whose patents are still under legal challenge for validity, before final resolution of legal proceedings.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We also rely in all aspects of our businesses on unpatented proprietary technology, know-how, trade secrets, </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">11</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">and other confidential information, which we seek to protect through various measures, including confidentiality agreements with licensees, employees, third-party collaborators and consultants who may have had access to such information. If these agreements are breached or our other protective measures should fail, then our contractual or other remedies may not be adequate to cover our losses.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We may also be subject to assertions of intellectual property rights against our innovative medicines by third parties. If successful, these actions may involve payment of future royalties or damages, for example for patent infringement, and may also involve injunctive relief requiring the removal of one or more dosage strengths of a product from the market (or removal of a therapeutic indication from the product&#x2019;s approved labeling) for some period of time or throughout the life of the asserted intellectual property right. Such damages or such an injunction may have a material impact on our operating income and net sales.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In any given year, we may experience a potentially significant impact on our net sales from products that have already lost intellectual property protections, as well as products that may lose protection during the year. Because we may have substantially reduced marketing and research and development expenses related to products that are in their final years of exclusivity, the initial loss of protection for a product during a given year could also have an impact on our operating income for that year in an amount corresponding to a significant portion of the product&#x2019;s lost sales. The magnitude of the impact of generic or biosimilar competition on our income could depend on a number of factors. These include, with respect to income in a given year, the time of year at which the generic or biosimilar competitor is launched; the ease or difficulty of manufacturing a competitor product and obtaining regulatory approval to market it; the number of generic or biosimilar competitor products approved, including whether, in the US, a single competitor is granted an exclusive marketing period; whether an authorized generic is launched; the geographies in which generic or biosimilar competitor products are approved, including the strength of the market for generic or biosimilar pharmaceutical products in such geographies, and the comparative profitability of branded pharmaceutical products in such geographies; and our ability to successfully develop and launch new products for patients that may also offset the income lost to generic or biosimilar competition. For more information on the patent and generic competition status of our Innovative Medicines Division products, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview&#x2014;Innovative Medicines&#x2014;Intellectual property.&#x201D; </div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Strategic transformations</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Failure to meet organizational transformation programs objectives and/or unintended adverse impacts on our business  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">From time to time, we reassess our business organization to ensure we have the optimal structure with which to execute our strategy. In April 2022, we announced a new organizational structure and operating model designed to support our innovation, growth, and productivity ambitions as a focused medicines company. See &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Overview.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, in October 2021 we announced the commencement of a strategic review of our Sandoz Division. After exploring all options, ranging from retaining the business to separation, on August 25, 2022, we announced our intention to separate our Sandoz Division into a new publicly traded standalone company, by way of a 100% spin-off in order to maximize shareholder value. See &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Sandoz.&#x201D;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our inability to successfully implement our new organizational structure and operating model or to successfully complete the spin-off of our Sandoz Division could have a material adverse effect on the success of the Group as a whole, and could have a material adverse effect on our results of operations and financial condition. The overall extent and pace of these organizational changes, and the additional workload and complexity for our employees in some areas, could trigger uncertainty, stress and fatigue among employees, potentially resulting in instability within the organization that could lead to failure of these organizational changes to succeed or to achieve the desired benefits. As a result, the expected benefits of these organizational changes may never be fully realized or may take longer to realize than expected.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Environmental, social and governance matters</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Failure to meet environmental, social and governance expectations</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Increasingly, in addition to financial results, companies are being judged by performance on a variety of environmental, social and governance (ESG) matters, which can contribute to the long-term sustainability of our company&#x2019;s performance. An inability to successfully perform on ESG matters and to meet societal expectations can result in negative impacts on our recruitment, retention, operations, financial results, reputation, and share price.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Topics related to large societal changes such as social inequity, access to medicines and climate change are increasingly important to a wide range of our stakeholders. For example, a variety of organizations measure the performance of companies on ESG topics, and the results of these assessments are widely publicized. In addition, investments in funds that specialize in companies that perform well in such assessments are increasingly popular, and major institutional investors have publicly emphasized the importance of such ESG measures in making their investment decisions. Our actions related </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">12</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">to ESG topics may in the long-term therefore impact our operations and ability to achieve our strategic goals, and ultimately could have a potential negative impact on the value of Novartis. For this reason, the role of our Board of Directors and executive officers in supervising various sustainability issues is becoming increasingly important.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We actively manage a broad range of ESG matters, taking into consideration their expected impact on the sustainability of our business over time, and the potential impact of our business on society and the environment. We have created a Sustainability &amp; ESG Office, which, in coordination with the ESG Committee of the Executive Committee of Novartis, is tasked with developing our ESG strategy and tracking our performance against our ESG targets. However, considering investors&#x2019; increasing focus on ESG matters, the fast pace of change of external expectations, and a range of upcoming regulations, there can be no certainty that we will manage such issues successfully, that the ESG standards we currently use to measure our performance against will remain the same, or that we will successfully meet society or investors&#x2019; expectations.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Operational risks</span>
      </div>
      <div style="padding-bottom:15px; ">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Cybersecurity and IT systems</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cybersecurity breaches, data loss and catastrophic loss of IT systems</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We are heavily dependent on critical, complex and interdependent information technology (IT) systems, including internet&#x2011;based systems to support our business processes. We have also outsourced significant parts of our IT infrastructure to third-party providers, and we currently use these providers to perform business-critical IT services for us. We are therefore vulnerable to cybersecurity attacks and incidents on such networks and systems, whether our own or those of the third-party providers we contract, and we have experienced and may in the future experience such cybersecurity threats and attacks. Cybersecurity threats and attacks take many forms, and the size, age and complexity of our IT systems make them potentially vulnerable to external and internal security threats; outages; malicious intrusions and attacks; cybercrimes, including state-sponsored cybercrimes; malware; misplaced data, lost data or data errors; programming or human errors; or other similar events. In the context of the COVID-19 pandemic, the risk of such threats and attacks has increased, as virtual and remote working has become more widely used, and sensitive data is accessed by employees working in less secure, home-based environments. In addition, due to our reliance on third-party providers, we have experienced and may in the future experience interruptions, delays or outages in IT service availability due to a variety of factors outside of our control, including technical failures, natural disasters, fraud, or security attacks experienced by or caused by third-party providers. Interruptions in the service provided by these third parties could affect our ability to perform critical tasks.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A significant information security or other event, such as a disruption or loss of availability of one or more of our IT systems, whether managed by us or a third-party service provider, has previously and could in the future negatively impact important business processes, such as the conduct of scientific research and clinical trials, the submission of data and information to health authorities, our manufacturing and supply chain processes, our shipments to customers, our compliance with legal obligations, and communication between employees and with third parties. IT issues have previously led to, and could in the future lead to, the compromise of trade secrets or other intellectual property that could be sold and used by competitors to accelerate the development or manufacturing of competing products; to the compromise of personal financial and health information; and to the compromise of IT security data such as usernames, passwords and encryption keys, as well as security strategies and information about network infrastructure, which could allow unauthorized parties to gain access to additional systems or data. In addition, malfunctions in software or medical devices that make significant use of IT could lead to a risk of direct harm to patients.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Although we have experienced some of the events described above, to date they have not had a material impact on our operations. Nonetheless, the occurrence of any of the events described above in the future could disrupt our business operations and result in enforcement actions or liability, including potential government fines and penalties, claims for damages, and shareholder litigation or allegations that the public health, or the health of individuals, has been harmed.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Any significant events of this type could require us to expend significant resources beyond those we already invest to remediate any damage, to further modify or enhance our protective measures, and to enable the continuity of our business.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Fragmented IT landscape and strategic technology programs implementation</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Failure to address fragmented business processes, unclear data ownership, and IT applications and infrastructure nearing their end-of-life, may disrupt our core business processes</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact   </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We rely on various IT systems to operate our complex global business. Historically, while highly overlapping data strategy and architectural needs exist across our businesses, in the past we built distinct solutions across both prior business units and our various geographies, which have led to a fragmented and complex landscape of IT systems.  Additionally, several of our current IT systems are reaching the end of their useful life, which, together with our fragmented IT landscape, may cause disruptions to our operational stability. As a result, we started to implement several companywide IT programs with a view toward replacing and consolidating outdated IT systems. For example, we have completed the conceptual design phase and started to build a new global Enterprise Resource Planning (ERP) system that seeks to simplify, standardize and digitize processes in our </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">13</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">commercial, finance and operations functions, thereby helping to ensure efficient and compliant business operations across our businesses and geographies, as well as the availability of high-quality data necessary to aid our decision-making. We expect the first implementation of our new ERP system to begin in the first quarter of 2024, with full implementation by 2028. In addition, we are also implementing other IT projects, seeking to simplify and standardize our processes, systems and tools, and create a unified data marketplace. Implementation and operation of the new ERP system and other IT projects involves certain risks, including a failure of the new ERP system and other IT projects to operate as expected, a failure to properly integrate with other systems we use, potential loss of data or information, compliance issues, or cost overruns and delays. Any disruptions or malfunctions of the new ERP system and other IT projects could cause critical information to be delayed, lost, defective, corrupted, or rendered inadequate or inaccessible, which could negatively impact our operations and the effectiveness of our internal controls.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Talent management</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description    </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inability to attract, retain and motivate qualified individuals in key roles and markets</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We rely on attracting and retaining a diverse, highly skilled workforce across our businesses and functions to achieve our business objectives. If we are unable to sustain our supply of key personnel &#x2013; including senior members of our scientific and management teams, high&#x2011;quality researchers and development specialists and skilled employees in key markets &#x2013; our ability to achieve our major business objectives may be adversely affected. In addition, our brand and reputation could be negatively impacted, and the diversity of our workforce may decline.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The market for skilled talent has become increasingly competitive, and we anticipate this trend will persist long-term. We face a challenge to attract and retain top talent in several areas, including biology, chemistry, clinical development, drug manufacturing, IT, oncology, and advanced therapy platforms (i.e., gene and cell therapy, radioligand therapy and &#x201C;xRNA&#x201D;). In addition, many biotechnology companies have received significant inflows of capital and are not only competing with us to attract the same skilled talent but are also aggressively pursuing our experienced talent. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In recent years, we have adopted new ways of working that include location flexibility and increasingly recruiting from a global pool of talent. However, the success of our business continues to depend on having employees who possess local knowledge of, and experience in, our key markets. The external talent supply is especially limited in many of the geographies that are expected to be sources of growth for Novartis. In the United States, China and several other markets, the geographic mobility of talent is decreasing, as they find ample career opportunities available closer to home.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, in April 2022 we announced a new, integrated organizational structure and operating model. The corporate reorganization undertaken to implement this new organizational structure has resulted in significant redundancies and senior leadership changes that may reduce morale, increase employee distraction and prompt higher voluntary turnover, any of which could negatively impact our competitiveness and ability to achieve strategic objectives. For more information on this new organizational structure see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Overview.&#x201D;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The risks associated with the challenging external talent market and the implementation of our new organizational structure will be exacerbated if we are unable to retain and effectively develop employees and maintain an internal pipeline with critical skills, experiences, and leadership to deliver our business priorities. As a result, development, engagement, motivation, succession planning and performance rewards for our critical talent are essential to achieve our business priorities.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Third-party management </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Failure to maintain adequate governance and oversight over third-party relationships, and failure of third parties to meet their contractual, regulatory or other obligations</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We outsource the performance of certain key business functions and services to third parties. Such activities include research and development collaborations, manufacturing operations, warehousing and distribution, certain finance functions, sales and marketing activities, data management and others. Some third parties, particularly those in developing countries, do not have internal compliance systems or resources comparable to those of Novartis. As a result, our investment and efforts in relation to third party management include focusing on risk management and the oversight of such third parties.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our reliance on third parties poses certain risks, including the misappropriation of our intellectual property, the failure of the third party to comply with regulatory and quality assurance requirements, the failure of the third party to comply with environmental, anti-bribery and human rights standards and regulations, unexpected supply disruptions, breach of our agreement by the third party, and the unexpected termination or nonrenewal of our agreement by the third party.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, governments require, and the public expects, Novartis to take responsibility for and report on compliance with various human rights, responsible sourcing and environmental practices, as well as other actions of our third-party contractors around the world. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Ultimately, if third parties fail to meet their obligations to us, we may lose our investment in the relationship with the third parties or fail to receive the expected benefits of our agreements with such third parties. In addition, should any of these third parties fail to comply with the law or our standards, or should they otherwise act inappropriately while performing services for us, there is a risk that we could be held responsible for their acts, that our reputation may suffer, and that penalties may be imposed on us.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">14</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Legal, ethics and compliance</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Challenges posed by evolving legal and regulatory requirements and societal expectations regarding ethical behavior</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We must comply with the laws of all countries in which we operate, and we sell products with respect to a wide and growing range of activities. Such legal requirements are extensive and complex. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The laws and regulations relevant to the healthcare industry and applicable to us are broad in scope, are subject to change, and have evolving interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our business practices. For example, we have been, are currently, and may in the future be, subject to various significant legal proceedings, such as private party litigation, government investigations and law enforcement actions worldwide. These types of matters may take various forms based on evolving government enforcement and private party litigation priorities, and could include, for example, matters pertaining to pricing; bribery and corruption; trade regulation and embargo legislation; product liability; commercial disputes; employment and wrongful discharge; antitrust and competition; securities; government benefit programs; reimbursement; rebates; healthcare fraud; sales and marketing practices; insider trading; occupational health and safety; environmental regulations; tax; cybersecurity; data privacy; regulatory interactions; and intellectual property. Such matters can involve civil and/or criminal proceedings and can retroactively challenge practices previously considered to be legal.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There is also a risk that governance for our medical and patient support activities, and our interactions with governments, public officials/institutions, healthcare professionals, healthcare organizations and patient organizations may be inadequate or fail, or that we may undertake activities based on improper or inadequate scientific justification.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our Sandoz Division may from time to time seek approval to market a generic version of a product before the expiration of patents claimed by the marketer of the patented product. We do this in cases in which we believe the relevant patents are invalid or unenforceable, or would not be infringed by our generic product. As a result, affiliates of our Sandoz Division frequently face patent litigation, and in certain circumstances we may make the business decision to market a generic product even though patent infringement actions are still pending. Should we elect to do so and conduct a so-called &#x201C;launch at risk,&#x201D; we could face substantial damages if the final court decision is adverse to us.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Legal proceedings and investigations are inherently unpredictable, and large judgments sometimes occur. Consequently, we may in the future incur judgments that could involve large payments, including the potential repayment of amounts allegedly obtained improperly, and other penalties, including treble damages. In addition, such legal proceedings and investigations, even if meritless, may affect our reputation, may create a risk of potential exclusion from government reimbursement programs in the US and other countries, and may lead to civil litigation and/or criminal exposure. As a result, having considered all relevant factors, we have in the past and may again in the future enter into major settlements of such claims without bringing them to final legal adjudication by courts or other such bodies, despite having potentially significant defenses against them, to limit the risks they pose to our business and reputation. Such settlements may require us to pay significant sums of money and to enter into corporate integrity or similar agreements, which are intended to regulate company behavior for extended periods. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For information on significant legal matters pending against us, see &#x201C;Item 18. Financial Statements&#x2014;Note 20. Provisions and other non&#x2011;current liabilities&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 28. Commitments and contingent liabilities.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">New requirements may also be imposed on us due to changing government and societal expectations regarding the healthcare industry, and acceptable corporate behavior generally. For example, we are faced with laws and regulations requiring changes in how we do business, including with respect to disclosures concerning our interactions with healthcare professionals, healthcare organizations and patient organizations. These laws and regulations include requirements that we disclose payments or other transfers of value made to healthcare professionals and organizations, as well as information relating to the costs and prices for our products, which represent evolving standards of acceptable corporate behavior. These requirements may incur significant costs, including substantial time and additional resources, that are necessary to bring our interactions with healthcare professionals and organizations into compliance with these evolving standards.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition to legal and regulatory requirements, we aim to meet the evolving societal expectations of the public and our investors regarding ethical behavior and the increasing importance placed on ESG matters.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To support our efforts to comply with the many requirements that impact us, we have a significant global ethics and compliance program in place, and we devote substantial time and resources to efforts to ensure that we conduct business in a lawful manner, and in line with society&#x2019;s expectations. Despite our efforts, an actual or alleged failure to comply with the law or with heightened public expectations could lead to substantial liabilities that may not be covered by insurance, or to other significant losses.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Manufacturing and product quality</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inability to ensure proper controls in product development and product manufacturing, and failure to comply with applicable regulations and standards</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The development and manufacture of our products is complex and heavily regulated by governmental health authorities around the world. Whether or not our products and the related raw materials are developed and manufactured at our own manufacturing sites or by third </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">15</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">parties, we must ensure that all development and manufacturing processes comply with regulatory requirements, as well as our own quality standards in order to deliver novel therapies to patients with unmet needs while ensuring patient safety. Failure to comply with regulatory requirements has resulted in, and may in the future result in, warning letters, suspension of manufacturing, seizure of products, injunctions, product recalls, failure to secure product approvals, or debarment. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In recent years, global health authorities have substantially intensified their scrutiny of manufacturers&#x2019; compliance with regulatory requirements. Any significant failure by us or our third-party suppliers to comply with regulatory requirements, or with health authorities&#x2019; expectations, may create the need to suspend clinical trials, shut down production facilities or production lines, and recall commercial products. A failure to fully comply with regulatory requirements could also lead to a delay in the approval of new products, an inability to ship or import our products, and significant penalties and reputational harm.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, the technically complex manufacturing processes required to manufacture many of our products increase the risk of both production failures and product recalls and can increase the cost of producing our goods. Some of our products require a supply of highly specialized raw materials, such as cell lines, tissue samples, bacteria, viral strains and radioisotopes. In addition, we manufacture and sell a number of sterile products, biologic products and products that involve advanced therapy platforms, such as CAR-T therapies, gene therapies and radioligand therapy products, all of which are particularly complex and involve highly specialized manufacturing technologies. As a result, even slight deviations at any point in their production processes or in material used have led to, and may in the future lead to, production failures or recalls. See &#x201C;Item 4. Information on the Company&#x2014;Item 4.B. Business overview&#x2014;Sandoz&#x2014;Production.&#x201D; </div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Supply chain</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inability to maintain continuity of product supply</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Many of our products are produced using technically complex manufacturing processes and require a supply of highly specialized raw materials. For some of our products and raw materials, we may rely on a single source of supply. In addition, we manufacture and sell a number of sterile products, biologic products, and products that involve advanced therapy platforms, such as gene and cell therapy, radioligand therapy, and &#x201C;xRNA&#x201D;, all of which are particularly complex and involve highly specialized manufacturing technologies. Due to this complexity, there is a risk of production and supply of critical raw materials failures, which may result in supply interruptions or product recalls due to manufactured products not meeting required specifications.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, due to the inherent complexities of our manufacturing processes and the supply chains for advanced therapy platforms, we are required to plan our production activities and purchase of materials well in advance. If we suffer from third-party raw material shortages, underestimate market demand for a product, or fail to accurately predict when a new product will be approved for sale, then we may not be able to produce sufficient product to meet demand. These issues could be made worse during a pandemic, such as the COVID-19 pandemic, or geopolitical events, such as  the war in Ukraine, and could lead to (i) a sudden increase in demand for selected medicinal products, resulting in the short-term unavailability of critical materials; (ii) logistical and supply challenges that may lead to our inability to ship products from one place to another due to restrictions imposed as a result of a pandemic or geopolitical events and any related sanctions, which can also impact transportation and warehousing costs; or (iii) our inability to properly operate a manufacturing site due to restrictions imposed as the result of a pandemic or any issues arising from geopolitical events.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our or our third-party suppliers&#x2019; inability to manage such issues could lead to shutdowns, product shortages, or to us being entirely unable to supply products to patients for an extended period of time. Furthermore, as our products are intended to promote the health of patients, such shortages or shutdowns could endanger our reputation and have led to, and could continue to lead to, significant losses of sales revenue, potential litigation or allegations that the public health, or the health of individuals, has been harmed.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Data privacy</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Noncompliance with personal data protection laws and regulations</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We operate in an environment that relies on the collection, processing, analysis and interpretation of large sets of patients and other individuals&#x2019; personal information, including via social media and mobile technologies. In addition, the operation of our business requires data to flow across the borders of numerous countries in which there are different, potentially conflicting, and frequently changing, data privacy laws in effect. Examples of such laws include: the EU General Data Protection Regulation (GDPR), which took effect in May 2018; the California Consumer Privacy Act, which took effect in January 2020; Brazil&#x2019;s General Personal Data Protection Law, which entered into force in September 2020; and the Personal Information Protection Law in China, which took effect in November 2021. Such laws impose stringent requirements on how we and third parties with whom we contract collect, share, export or otherwise process personal information, and provide for significant penalties for noncompliance. Breaches of our systems or those of our third-party contractors, or other failures to protect the data we collect from misuse or breach by third parties, could expose such personal information to unauthorized persons.  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Events involving the substantial loss of personal information, use of personal information without a legal basis, or other privacy violations could give rise to significant liability, reputational harm, damaged relationships with business partners, and potentially substantial monetary </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">16</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">penalties and other sanctions under laws enacted or being enacted around the world. Such events could also lead to restrictions on our ability to use personal information and/or transfer personal information across country borders. In addition, there is a trend of increasing divergence of data privacy legal frameworks, not only across these frameworks but also within individual legal frameworks themselves. This divergence may constrain the implementation of global business processes and may lead to different approaches on the use of health data for scientific research, which may have a negative impact on our business and operations.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Falsified medicines</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Impact of falsified medicines on patient safety, and reputational and financial harm to Novartis and our products</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact   </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We continue to be challenged by the vulnerability of distribution channels to falsified medicines, which include counterfeit, stolen, tampered and illegally diverted medicines as defined by the World Health Organization. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Falsified medicines pose patient safety risks and can be seriously harmful or life-threatening. Reports of adverse events related to falsified medicines and increased levels of falsified medicines in the healthcare system affect patient confidence in genuine medicines and in healthcare systems in general. These events could also cause us substantial reputational and financial harm, and potentially lead to litigation if the adverse event from the falsified medicine is mistakenly attributed to the genuine one. Stolen or illegally diverted medicines that are not properly stored and later sold through unauthorized channels, could adversely impact patient safety, our reputation and our business. Furthermore, there is a direct financial loss when, for example, falsified medicines replace sales of genuine medicines, or genuine medicines are recalled following the discovery of falsified products.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Emerging risks</span>
      </div>
      <div style="padding-bottom:15px; ">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Geopolitical developments</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Impact of geo- and socio-political threats</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Challenging political conditions currently exist in various parts of the world, including an economic downturn; risk of direct conflicts between nations, such as the war in Ukraine; a global pandemic; resistance in certain areas against free trade; anti-corporate sentiment; and social unrest.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The imposition of tariffs, including those imposed by the US and China, and the possibility of additional tariffs or other trade restrictions relating to trade could have a material negative impact on our business. Given that the outcome of ongoing trade negotiations remains uncertain, we cannot yet determine the nature or extent of the potential impact on our business. For example, if tariffs on pharmaceutical products or active pharmaceutical ingredients (APIs) were increased, this could impact the profitability of our products and disrupt our supply chain. Increasing opposition to free trade may increase the risks we face in our efforts to improve and harmonize standards in regulation and intellectual property.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Furthermore, significant conflicts continue in certain parts of the world. Collectively, such unstable conditions could, among other things, disturb the international flow of goods and increase the costs and difficulties of international transactions, which could in turn significantly impact time to market and our ability to supply our products to patients in an undisrupted fashion, and further erode reimbursement levels for innovative therapies.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Macroeconomic developments</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Impact of macroeconomic developments</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our business may be impacted by deteriorating macroeconomic and financial conditions directly affecting consumers. Given that patients, in many countries, directly pay a sizable portion of their own healthcare costs, there is a risk that consumers may cut back on prescription drugs due to financial constraints. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Negative macroeconomic developments may also adversely affect the ability of payers, as well as our distributors, customers, suppliers, and service providers, to pay for our products, or otherwise to buy necessary inventory or raw materials, and to perform their obligations under agreements with us. Although we make efforts to monitor the financial condition and liquidity of these third parties, our ability to do so is limited, and some of them may become unable to pay their bills in a timely manner or may even become insolvent. These risks may be elevated with respect to our interactions with fiscally challenged government payers, or with third parties with substantial exposure to such payers.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">At the same time, significant changes, and potential future volatility in financial markets, the consumer and business environment, the competitive landscape, and the global political and security landscape make it increasingly difficult for us to predict our revenues and earnings. As a result, any revenue or earnings guidance or outlook that we have given or might give may be overtaken by events or may otherwise prove to be inaccurate. Although we endeavor to give reasonable estimates of future revenues and earnings at the time at which we give such guidance, based on then&#x2011;current knowledge and conditions, there is a risk that such guidance or outlook will prove to be incorrect. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Asset price corrections in financial markets may also result in lower returns on our financial investments. In addition, pricing pressures in developed markets resulting from efforts to reduce the cost of healthcare (e.g., the Inflation Reduction Act in the US, which targets drug prices) may have a negative impact on our revenue and our net sales. In addition, inflation has an impact on our operating costs due to the increased cost of supplies. Higher costs for energy, raw materials, wages, and capital will increase our operating costs, potentially reducing our net sales.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">17</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Uncertainties around future central bank and other economic policies in the US and EU, as well as high debt levels in some countries could also impact world trade. Sudden increases in economic, currency or financial market volatility in different countries, such as the recent appreciation of the US dollar, have also impacted, and may continue to have an unpredictable impact on our business, or results of operations, including the conversion of our operating results into our reporting currency, the US dollar, as well as the value of our investments in our pension plans. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For a discussion on the effect of price controls on our business, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B&#x2014;Business overview&#x2014;Innovative Medicines&#x2014;Price controls.&#x201D; See also &#x201C;Item 5. Operating and Financial Review and Prospects&#x2014;Item 5.B Liquidity and capital resources&#x2014;Effects of currency fluctuations,&#x201D; &#x201C;Item 5. Operating and Financial Review and Prospects&#x2014;Item 5.B Liquidity and capital resources&#x2014;Condensed consolidated balance sheets,&#x201D; &#x201C;Item 18. Financial Statements&#x2014;Note 15. Trade receivables&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 29. Financial instruments &#x2013; additional disclosures.&#x201D;</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Climate change</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Impact of climate change and increased risk of major natural disasters</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis is exposed to a broad range of climate risks such as transition risks (e.g., regulatory frameworks, carbon pricing, and the cost of and access to capital) and physical risks (e.g., heat, water scarcity, sea level rise, and flooding from severe weather events), which could vary in magnitude and impact across different countries. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Climate change has triggered, and may continue to trigger, the adoption of new regulatory requirements across the globe. To comply with such legislation, we may be required to increase our investment in technology to reduce our energy use, water use and greenhouse gas emissions. In addition, legislative and regulatory action, both current and in the future, includes or could include carbon pricing, climate risk related disclosures, and changes in zoning or building codes to increase climate resilience. As a result, the combined impact of these transition risks could increase our direct operating costs and impact our supply chain. We have also committed to incorporating the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD) framework into our business, which includes providing qualitative and quantitative disclosures on climate-related topics on a recurring basis. As a result of these transition risks, we are committed to becoming carbon neutral in our own operations by 2025, and carbon neutral across our value chain by 2030. In addition, we are committed to achieving net zero across our value chain by 2040. Any failure to achieve these commitments in the expected time frame, or at all, could result in negative impacts on our reputation, our operations, and the price of our shares.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Climate change has created, and will continue to create, physical risks to our business. Some of our production facilities that depend on the availability of significant water supplies are located in areas where water is increasingly scarce. Other facilities are located in areas that, due to increasingly violent weather events, rising sea levels, or both, are increasingly at risk of substantial flooding. In regions where such a risk is present, this has an impact not only on our own operations but also our distributed supply chain. Such events may result in the loss of life, increased costs, business interruptions, destruction of facilities, and disruption to healthcare systems that patients use to access our medicines.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Furthermore, our corporate headquarters, the headquarters of our Innovative Medicines and Sandoz Divisions, and a number of major Innovative Medicines Division production and research facilities are located near earthquake fault lines in Basel, Switzerland. Other major facilities are located near major earthquake fault lines in various locations around the world. A major earthquake could result in loss of life, business interruptions and the destruction of our facilities.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Tax laws and developments</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Changes in tax laws or their application</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our multinational operations are taxed under the laws of the countries and other jurisdictions in which we operate. Changes in tax laws or in their application could lead to an increased risk of international tax disputes and an increase in our effective tax rate, which could adversely affect our financial results. The integrated nature of our worldwide operations can produce conflicting claims from revenue authorities in different countries as to the profits to be taxed in the individual countries, including potential disputes relating to the prices our subsidiaries charge one another for intercompany transactions, known as transfer pricing. Most of the jurisdictions in which we operate have double tax treaties with other foreign jurisdictions, which provide a framework for mitigating the impact of double taxation on our revenues and capital gains. However, mechanisms developed to resolve such conflicting claims are largely untried and can be expected to be very lengthy. Accruals for tax contingencies are made based on experience, interpretations of tax law, and judgments about potential actions by tax authorities. However, due to the complexity of tax contingencies, the ultimate resolution of any tax matter may result in payments materially different from the amounts accrued. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2019, the Organization for Economic Co-operation and Development (OECD) launched a new initiative on behalf of the G20 to minimize profit shifting by working toward a global tax framework that ensures that corporate income taxes are paid where consumption takes place, in addition to introducing a global standard on minimum taxation combined with new tax dispute resolution processes. This project achieved OECD political consensus in October 2021, and the detailed principles are still under discussion by the OECD and political leaders. The OECD expects that the implementation of these new principles will begin globally in 2024. Once changes to the tax laws in any jurisdiction in which the Group </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">18</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">operates are enacted or substantially enacted, the Group may be subject to the OECD top-up tax, the aim of which is to bring the total amount of taxes paid on our profit in a jurisdiction up to a minimum rate of 15%. In 2020, the EU announced that it would introduce new centralized taxation powers (which have not yet been introduced) to address the financial impact of the COVID-19 pandemic. In addition, the European Commission continues to extend the application of its policies seeking to limit fiscal aid by member states to particular companies, together with the related investigation into member states&#x2019; practices regarding the issuance of rulings on tax matters relating to individual companies. Although we have taken steps to comply with evolving initiatives such as these of the OECD and the EU, and we will continue to do so, significant uncertainties remain as to the outcome of our efforts. For more information, see &#x201C;Item 18. Financial Statements&#x2014;Note 6. Income taxes&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 12. Deferred tax assets and liabilities.&#x201D; </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">General risks</span>
      </div>
      <div style="padding-bottom:15px; ">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Indebtedness</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our indebtedness could adversely affect our operations</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As of December 31, 2022, we had USD 20.2 billion of non&#x2011;current financial debt, and USD 5.9 billion of current financial debt. Our current and long&#x2011;term debt requires us to dedicate a portion of our cash flow to service interest and principal payments and, if interest rates rise, this amount may increase. As a result, our existing debt may limit our ability to use our cash flow to fund capital expenditures, to engage in transactions, or to meet other capital needs, or otherwise may place us at a competitive disadvantage relative to competitors that have less debt. Our debt could also limit our flexibility to plan for and react to changes in our business or industry, and increase our vulnerability to general adverse economic and industry conditions, including changes in interest rates or a downturn in our business or the economy. We may also have difficulty refinancing our existing debt or incurring new debt on terms that we would consider to be commercially reasonable, if at all.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Goodwill and intangible assets</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Goodwill and intangible assets resulting in significant impairment charges</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We carry a significant amount of goodwill and other intangible assets on our consolidated balance sheet, including, in particular, substantial goodwill and other intangible assets obtained through acquisitions, including most recently through our acquisitions of Gyroscope Therapeutics, The Medicines Company, <i>Xiidra</i>, Endocyte, Novartis Gene Therapies, and AAA. As a result, we may incur significant impairment charges in the future if the fair value of the intangible assets and the groupings of cash-generating units containing goodwill would be less than their carrying value on the Group&#x2019;s consolidated balance sheet at any point in time.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We regularly review our intangible and tangible assets for impairment, including identifiable intangible assets and goodwill. Any significant impairment charges could have a material adverse effect on our results of operations and financial condition. In 2022, for example, we recorded intangible asset impairment charges of USD 1.3 billion. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For a detailed discussion of how we determine whether an impairment has occurred, what factors could result in an impairment, and the impact of impairment charges on our results of operations, see Item 18. Financial Statements&#x2014;Note 1. Significant accounting policies&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 11. Goodwill and intangible assets.&#x201D;</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Foreign currency exchange rates</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Negative effect on financial results due to foreign currency exchange rate fluctuations</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Changes in exchange rates between the US dollar, our reporting currency, and other currencies can result in significant increases or decreases in our reported sales, costs and earnings as expressed in US dollars, and in the reported value of our assets, liabilities and cash flows.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition to ordinary market risk, there is a risk that countries could take affirmative steps that could significantly impact the value of their currencies. Such steps could include &#x201C;quantitative easing&#x201D; measures and potential withdrawals by countries from common currencies. In addition, countries facing local financial difficulties, including countries experiencing high inflation rates, and highly indebted countries facing large capital outflows, may impose controls on the exchange of foreign currency. Currency exchange controls and sanctions could limit our ability to distribute retained earnings from our local affiliates, or to pay intercompany payables due from those countries. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Despite measures undertaken to reduce or hedge against foreign currency exchange risks, as a significant portion of our earnings and expenditures are in currencies other than the US dollar, including expenditures in Swiss francs that are significantly higher than our revenue in Swiss francs, any such exchange rate volatility may negatively and materially impact our results of operations and financial condition, and may impact the reported value of our net sales, earnings, assets and liabilities. In addition, the timing and extent of such volatility can be difficult to predict. Furthermore, depending on the movements of particular foreign exchange rates, we may be materially adversely affected at a time when the same currency movements are benefiting some of our competitors.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For more information on the effects of currency fluctuations on our consolidated financial statements and on how we manage currency risk, see &#x201C;Item 5. Operating and Financial Review and Prospects&#x2014;Item 5.B Liquidity and capital resources&#x2014;Effects of currency </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">19</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">fluctuations&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 29. Financial instruments &#x2013; additional disclosures.&#x201D;</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Key customers</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Ongoing consolidation among our distributors and retailers, and the concentration of credit risk</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">A significant portion of our global sales is made to a relatively small number of drug wholesalers, retail chains and other purchasing organizations. For example, our three most important customers globally accounted for approximately 16%, 11% and 7%, respectively, of net sales in 2022. The largest trade receivables outstanding were for these three customers, amounting to 16%, 14% and 7%, respectively, of the Group&#x2019;s trade receivables at December 31, 2022. The trend has been toward further consolidation among some distributors and retailers. As a result, we may be affected by fluctuations in the buying patterns of such customers. Furthermore, these customers are gaining additional purchasing leverage, increasing the pricing pressures facing our businesses. These pressures can impact our Sandoz Division in particular, the generic products of which can often be obtained from numerous competitors. Moreover, we are exposed to a concentration of credit risk as a result of this concentration among our customers. If one or more of our major customers experienced financial difficulties, the effect on us would be substantial, and could include a substantial loss of sales and an inability to collect amounts owed to us.</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Environmental matters</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Impact of environmental liabilities</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The environmental laws of various jurisdictions impose actual and potential obligations on us to investigate and remediate contaminated sites, including in connection with activities in the past by businesses that are no longer part of Novartis. In some cases, these remediation efforts may take many years. While we have set aside provisions for known worldwide environmental liabilities that are probable and estimable, there is no guarantee that additional costs will not be incurred beyond the amounts for which we have provided in the Group consolidated financial statements. If environmental contamination resulting from our facility operations, business activities or products adversely impacts third parties or if we fail to properly manage the safety of our facilities, including the safety of our employees and contractors, and the environmental risks, we may face substantial one-time and recurring costs and other penalties, and be required to increase our provisions for environmental liabilities. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">See also &#x201C;Item 4. Information on the Company&#x2014;Item 4.D Property, plants and equipment&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 20. Provisions and other non&#x2011;current liabilities.&#x201D;</div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:15px; padding-top:15px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Pension plans   </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Risk description</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inaccuracies in the assumptions and estimates used to calculate our pension plan and other post-employment obligations</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Context and potential impact</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We sponsor pension and other post-employment benefit plans in various forms that cover a significant portion of our current and former employees. For post-employment plans with defined benefit obligations, we are required to make significant assumptions and estimates about future events in calculating the expense and the present value of the liability related to these plans. These include assumptions about the discount rates we apply to estimate future defined benefit obligations and net periodic pension expense, as well as rates of future pension increases. In addition, our actuarial consultants provide our management with historical statistical information, such as withdrawal and mortality rates in connection with these estimates. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Assumptions and estimates that we use may differ materially from the actual results we experience due to changing market and economic conditions, higher or lower withdrawal rates, and longer or shorter life spans of participants, among other factors. Depending on events, such differences could have a material effect on our total equity, and may require us to make additional contributions to our pension funds.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For more information on obligations under retirement and other post-employment benefit plans and underlying actuarial assumptions, see &#x201C;Item 18. Financial Statements&#x2014;Note 25. Post-employment benefits for employees.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">20</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00311500"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;4.  Information on the Company</p>
      <div id="anchorId00311503"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">4.A History and development of Novartis</p>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis AG</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG was incorporated on February&#xA0;29, 1996, under the laws of Switzerland as a stock corporation (&#x201C;Aktiengesellschaft&#x201D;) with an indefinite duration. On December&#xA0;20, 1996, our predecessor companies, Ciba&#x2011;Geigy AG and Sandoz AG, merged into this new entity, creating Novartis. We are domiciled in and governed by the laws of Switzerland. Our registered office is located at the following address:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Novartis AG</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Lichtstrasse 35</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">CH&#x2011;4056 Basel, Switzerland</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Telephone: +41&#x2011;61&#x2011;324&#x2011;1111</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Web: www.novartis.com</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Novartis is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of innovative pharmaceuticals and cost-saving generic medicines. Novartis AG, our Swiss holding company, owns, directly or indirectly, all of our significant operating companies. For a list of our significant operating subsidiaries, see &#x201C;Item 18. Financial Statements&#x2014;Note 31. Principal Group subsidiaries and associated companies.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">For a description of important corporate developments since January 1, 2020, see &#x201C;Item 18. Financial Statements&#x2014;Note 2. Significant transactions.&#x201D; For information regarding the Company&#x2019;s material commitments for capital expenditures, see &#x201C;Item 5. Operating and Financial Review and Prospects&#x2014;Liquidity and Capital Resources&#x2014;Material short- and long-term cash requirements.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The SEC maintains an internet site at http://www.sec.gov that contains reports, information statements, and other information regarding issuers that file electronically with the SEC.</div>
      <div id="anchorId00311534"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">4.B Business overview</p>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Overview</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our purpose is to reimagine medicine to improve and extend people&#x2019;s lives. We use innovative science and technology to address some of society&#x2019;s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our Company. Our vision is to become the most valued and trusted medicines company in the world. Our strategy is to deliver high-value medicines that alleviate society&#x2019;s greatest disease burdens through technology leadership in research and development (R&amp;D) and novel access approaches. To support this strategy, we have clear focus areas and priorities, ensuring we deliver on our purpose and continue to create value for both stakeholders and society. See, &#x201C;Item 5. Operating and Financial Review and Prospects&#x2014;Item 5.A Operating Results&#x2014;Overview&#x2014;Our strategy.&#x201D; </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2022, Novartis achieved net sales from continuing operations of USD 50.5&#xA0;billion, and total net income amounted to USD 7.0 billion. Headquartered in Basel, Switzerland, our Group companies employed approximately 102 000 full&#x2011;time equivalent employees as of December&#xA0;31, 2022. Our products are sold in approximately 140 countries around the world.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group comprises two global operating divisions:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"> &#xA0;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Innovative Medicines: innovative patent&#x2011;protected prescription medicines</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">For a description of our Innovative Medicines Division, see &#x201C;&#x2014;Innovative Medicines&#x2014;Overview&#x201D; below.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Sandoz: generic pharmaceuticals and biosimilars</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">For a description of our Sandoz Division, see &#x201C;&#x2014;Sandoz&#x201D; below.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In April 2022, we announced a new, integrated organizational structure and operating model designed to support our innovation, growth, and productivity ambitions as a focused medicines company. As part of this new organizational structure, we have integrated our former Pharmaceuticals and Oncology business units and created two separate commercial organizations&#x2014;Innovative Medicines US and Innovative Medicines International. The Innovative Medicines Division focuses on five core therapeutic areas&#x2014;cardiovascular, immunology, neuroscience, solid tumor, and hematology&#x2014;as well as other promoted brands (in the therapeutic areas of ophthalmology and respiratory) and established brands. For more information, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Innovative Medicines.&#x201D; We have also created a new Strategy and Growth function that combines corporate strategy, R&amp;D portfolio strategy and business development. The purpose of our Strategy and Growth function is to help drive the company&#x2019;s growth strategy </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">21</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">end-to-end and look across internal and external opportunities to strengthen the Novartis pipeline with medicines that are both transformational and can make significant contributions to growth. Finally, we have combined our former Novartis Technical Operations and Customer &amp; Technology Solutions units to create a new operations unit called Operations. This new unit seeks to provide a stronger and simpler operational backbone that can accelerate multiple technology transformation initiatives more efficiently, create novel digital solutions at scale, and increase productivity, while maintaining industry-leading quality and service levels.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Under this new organizational structure, our divisions are supported by the following organizational units: the Novartis Institutes for BioMedical Research (NIBR), Global Drug Development (GDD), and Operations. The financial results of these organizational units are included in the results of the divisions for which their work is performed. For more information about NIBR, see &#x201C;&#x2014;Innovative Medicines&#x2014;Research and development&#x2014;Research program&#x201D; below. For more information about GDD, see &#x201C;&#x2014;Innovative Medicines&#x2014;Research and development&#x2014;Development program&#x201D; below. For more information about Operations, see &#x201C;&#x2014;Item 4.D Property, plants and equipment&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 3. Segmentation of key figures 2022, 2021 and 2020.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Corporate activities</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We separately report the results of Corporate activities. The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries. In addition, Corporate includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights and certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships.</div>
      <div id="anchorId00311598"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Innovative Medicines</p>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Overview</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Innovative Medicines Division is a world leader in offering patent-protected medicines to patients and physicians. The Innovative Medicines Division researches, develops, manufactures, distributes and sells patented pharmaceuticals. The Innovative Medicines Division is organized into two commercial organizational units&#x2014;Innovative Medicines US and Innovative Medicines International. These units were created in April 2022 as part of our new, integrated organizational structure. Prior to April 2022, the Innovative Medicines Division was organized into two global business units: Novartis Oncology and Novartis Pharmaceuticals. See &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Overview.&#x201D; </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Innovative Medicines Division focuses on core therapeutic areas&#x2014;cardiovascular, immunology, neuroscience, solid tumor, and hematology&#x2014;as well as other promoted brands (in the therapeutic areas of ophthalmology and respiratory) and established brands. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Innovative Medicines Division is the larger of our two divisions in terms of consolidated net sales. It reported consolidated net sales of USD 41.3 billion in 2022, which represented 81.7% of the Group&#x2019;s net sales. The product portfolio of the Innovative Medicines Division includes a significant number of key marketed products, many of which are among the leaders in their respective therapeutic areas.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Innovative Medicines Division products</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following summaries describe certain key marketed products in our Innovative Medicines Division, listed according to year-end net sales within each therapeutic area or reporting category. Some of the products described below have lost patent protection or are otherwise subject to generic competition. Others are subject to patent challenges by potential generic competitors. Please see &#x201C;&#x2014;Intellectual property&#x201D; for general information on intellectual property and regulatory data protection, and for more information on the status of patents and exclusivity for Innovative Medicines Division products.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">While we typically seek to sell our marketed products throughout the world, not all products and indications are available in every country. The indications described in these summaries may therefore vary by country. In addition, a product may be available under different brand names depending on country and indication.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key marketed products</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Cardiovascular </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <i>&#x2022;</i>
        <i>  Entresto </i>(sacubitril/valsartan) is an oral, first&#x2011;in&#x2011;class angiotensin receptor neprilysin inhibitor. <i>Entresto</i> enhances the protective effects of a hormone system called the natriuretic peptide system, and simultaneously suppresses the harmful effects of a hormone system called the renin&#x2011;angiotensin&#x2011;aldosterone system. It is approved:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In the US, the EU and other countries to treat adults who have symptomatic heart failure with reduced ejection fraction (HFrEF). HFrEF is a disease in which the heart cannot pump enough blood. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In the US and other countries to treat most heart failure patients with preserved ejection fraction (HFpEF). HFpEF is another disease in which the heart cannot pump enough blood.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In the US and other countries to treat children aged 1 year and older who have symptomatic heart failure with systemic left ventricular systolic dysfunction</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">22</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In China and Japan to treat patients with essential hypertension (a type of high blood pressure)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"> &#x2022;   <i>Leqvio</i> (inclisiran) is the first and only small-interfering RNA therapy to reduce LDL cholesterol, a risk factor for atherosclerotic cardiovascular disease (ASCVD), which is caused by plaque buildup in the arteries. <i>Leqvio</i> is administered by a healthcare professional twice a year as an injection, following an initial dose and a dose at three months. It is approved:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In the EU and other countries to treat adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia. In patients unable to reach LDL cholesterol goals, <i>Leqvio</i> is used in combination with the maximum tolerated dose of a statin, or alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant or for whom a statin is contraindicated. Primary hypercholesterolemia and mixed dyslipidemia are disorders characterized by high levels of fats in the blood.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In the US to treat adults with clinical ASCVD or heterozygous familial hypercholesterolemia (HeFH), as an adjunct to diet and maximally tolerated statin therapy, who require additional lowering of LDL cholesterol. HeFH is an inherited disorder that causes dangerously high levels of LDL cholesterol. (The effect of <i>Leqvio</i> on cardiovascular morbidity and mortality has not yet been determined).</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Novartis obtained global rights to develop, manufacture and commercialize <i>Leqvio</i> under a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Immunology</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <i>&#x2022;</i>
        <i>  Cosentyx</i> (secukinumab) is an injectable, fully human monoclonal antibody that selectively inhibits interleukin-17A (IL&#x2011;17A), a cytokine involved in several immunological diseases. It is approved in the US, the EU and other countries to treat:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults and children aged 6 years and older with moderate&#x2011;to&#x2011;severe plaque psoriasis. Psoriasis is a debilitating systemic inflammatory disease that is characterized by the appearance of raised, red patches on the skin.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with active ankylosing spondylitis (AS). AS is a progressive inflammatory disease that is characterized by chronic back pain, is generally visible on X-rays, and can cause structural damage to the bones and joints.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with active non-radiographic axial spondyloarthritis (nr-axSpA). This is a long-term inflammatory disease that is characterized by chronic back pain and is not visible on X-rays.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults and children (aged 2 years and older in the US and 6 years and older in the EU) with active psoriatic arthritis (PsA). PsA is a type of progressive inflammatory arthritis that results in swollen and painful joints and tendons, which can cause structural damage to the bones and joints.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Children (aged 4 years and older in the US and 6 years and older in the EU) with enthesitis-related arthritis (ERA) and children (aged 2 years and older in the US and 6 years and older in the EU) with juvenile psoriatic arthritis (JPsA). ERA and JPsA are subtypes of juvenile idiopathic arthritis. If left untreated, they can lead to high levels of pain and disability.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <i>&#x2022;</i>
        <i>  Xolair </i>(omalizumab) is an injectable prescription medicine and the only approved antibody designed to target and block immunoglobulin E (IgE). It is approved in the US, the EU and other countries to treat:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults and children aged 6 years and older with moderate&#x2011;to&#x2011;severe, or severe, persistent allergic asthma </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults and children aged 12 years and older with chronic spontaneous urticaria/chronic idiopathic urticaria (hives)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with nasal polyps or severe chronic rhinosinusitis with nasal polyps (CRSwNP). CRSwNP is a chronic inflammation of the nose and the sinuses with the presence of benign lesions (nasal polyps) on the lining of the nasal sinuses or nasal cavity.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Approved indications vary by country. <i>Xolair</i> is provided as lyophilized powder for reconstitution, and as liquid formulation in a pre&#x2011;filled syringe. Novartis co-promotes <i>Xolair</i> with Genentech in the US and shares a portion of operating income, but Novartis does not record any US sales. Novartis records all sales of <i>Xolair</i> outside the US. For more information, see &#x201C;Item 18. Financial Statements&#x2014;Note 27. Transactions with related parties&#x2014;Roche Holding AG.&#x201D; </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Ilaris</i> (canakinumab) is an injectable, selective, high-affinity, fully human monoclonal antibody that inhibits interleukin-1 beta (IL-1 beta), a key cytokine in the inflammatory pathway. It is approved in the US, the EU and other countries to treat patients with certain debilitating autoinflammatory disorders, including:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults and children with periodic fever syndromes. Periodic fever syndromes are a set of rare disorders characterized by recurrent episodes of illness, with fever as the main symptom.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Patients with Still&#x2019;s disease, including systemic juvenile idiopathic arthritis and adult-onset Still&#x2019;s disease. Still&#x2019;s disease is a disorder that causes fevers, rash and joint pain.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with acute gouty arthritis. Gouty arthritis is a type of arthritis characterized by pain, redness, tenderness and swelling in one or more joints.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Approved indications vary by country.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Neuroscience</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <i>&#x2022;</i>
        <i>  Gilenya</i>  (fingolimod) is an oral sphingosine-1-phosphate (S1P) receptor modulator that inhibits the movement of lymphocytes (a type of white blood cell) out of the lymph nodes into the central nervous system, thereby preventing nerve inflammation and nervous tissue damage. It is approved:  </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In the US to treat adults and children aged 10 years and older with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS). Multiple </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">23</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#xA0;&#xA0;sclerosis is a disease in which the immune system attacks the protective covering of nerves (known as myelin).</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In the EU to treat adults and children aged 10 years and older who have highly active RRMS despite treatment with at least one disease-modifying agent, or who have rapidly evolving severe RRMS </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">
        <i>Gilenya</i> is licensed from Mitsubishi Tanabe Pharma Corporation.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Zolgensma</i> (onasemnogene abeparvovec) is a one-time intravenous gene therapy designed to address the genetic root cause of spinal muscular atrophy (SMA) by replacing the function of the missing or nonworking SMN1 gene. <i>Zolgensma</i> delivers a new working copy of the SMN1 gene into a patient&#x2019;s cells. It is approved in the US, the EU and other countries to treat:</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Babies and young children who have SMA with biallelic mutations in the SMN1 gene. SMA is a rare, genetic neuromuscular disease resulting in the progressive and irreversible loss of motor neurons, which causes muscle weakness and atrophy.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Kesimpta</i> (ofatumumab) is an anti-CD20 monoclonal antibody that enables the targeted depletion of B-cells, specifically in lymph nodes. <i>Kesimpta</i> is self-administered as a once-monthly injection via the <i>Sensoready</i> autoinjector pen. It is approved:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In the US to treat adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS). Multiple sclerosis is a disease in which the immune system attacks the protective covering of nerves (known as myelin).</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In the EU to treat adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features (i.e., relapse, disability, or lesions detected by MRI scans)  </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Approved indications vary across other countries. Ofatumumab was originally developed by Genmab and licensed to GlaxoSmithKline (GSK). Novartis obtained the rights to ofatumumab from GSK across all indications.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Solid Tumor</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Tafinlar</i> + <i>Mekinist</i> (dabrafenib + trametinib) is an oral combination therapy. <i>Tafinlar</i> and <i>Mekinist</i> are kinase inhibitors of the BRAF and MEK1/2 proteins, respectively, approved in combination in the US, the EU and other countries to treat patients who have certain types of cancer with a change in the BRAF gene (called a BRAF V600 mutation), including: </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with unresectable or metastatic melanoma with a BRAF V600 mutation. Melanoma is a form of skin cancer; unresectable melanoma cannot be removed with surgery and metastatic melanoma has spread to other parts of the body. <i>Tafinlar</i> and <i>Mekinist</i> are also approved as single agents for this indication.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with stage III melanoma with a BRAF V600 mutation as an adjuvant treatment (following surgery)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation. NSCLC is the most common type of lung cancer. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with locally advanced or metastatic anaplastic thyroid cancer (ATC) with a BRAF V600 mutation whose cancer has progressed following treatment, and who have no satisfactory alternative treatment options (US). ATC is a rare and aggressive form of thyroid cancer. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Approved indications vary by country. Novartis has worldwide exclusive rights to develop, manufacture and commercialize trametinib granted by Japan Tobacco Inc.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Kisqali</i> (ribociclib) is a selective oral cyclin&#x2011;dependent inhibitor of kinases 4 and 6 (CDK4/6) with somewhat greater inhibitory activity against CDK4 vs CDK6 &#x2013; the two enzymes involved in the control of cell cycle progression. <i>Kisqali</i> is approved in the US, the EU and other countries to treat: </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Pre-, peri- and postmenopausal women, and men (US), with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer, in combination with an aromatase inhibitor as initial endocrine&#x2011;based therapy. HR+/HER2- breast cancer is the most common subtype of breast cancer.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Pre-, peri- (EU) and postmenopausal women, and men (US), with HR+/HER2- locally advanced or metastatic breast cancer, in combination with fulvestrant, as first- or second-line therapy</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">
        <i>Kisqali</i> was developed by the Novartis Institutes for BioMedical Research under a research collaboration with Astex Pharmaceuticals. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Piqray</i> (alpelisib) is an oral kinase inhibitor that specifically targets the PIK3CA gene. This is the most commonly mutated gene in HR+/HER2- breast cancer, the most common subtype of breast cancer. <i>Piqray</i> is approved in the US, the EU and other countries to treat:</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Postmenopausal women, and men, with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer with a PIK3CA mutation. It is used in combination with fulvestrant after disease progression while on or following an endocrine-based regimen (US), or after disease progression following endocrine therapy as monotherapy (EU).</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Pluvicto</i> (lutetium (<sup>177</sup>Lu) vipivotide tetraxetan) is an intravenous radioligand therapy combining a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177). <i>Pluvicto</i> delivers radiation selectively to PSMA-positive cells and the surrounding cells. It is approved in the US, the EU and other countries to treat:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with a type of advanced cancer that has spread to other parts of the body (metastatic) called prostate-specific membrane antigen&#x2013;positive </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">24</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#xA0;&#xA0;metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) who have already been treated with other anticancer treatments (androgen receptor pathway inhibition and taxane-based chemotherapy)</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Hematology</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Promacta</i>/<i>Revolade</i> (eltrombopag) is a once&#x2011;daily oral thrombopoietin receptor agonist that works by stimulating bone marrow cells to produce platelets. It is approved in the US, the EU and other countries to treat:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Immune thrombocytopenia (ITP) in patients who have had an insufficient response to or have failed previous therapies. ITP is a bleeding disorder caused by an unusually low number of platelets. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Thrombocytopenia in patients with chronic hepatitis C to allow them to initiate and maintain interferon&#x2011;based therapy</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Patients with severe aplastic anemia (SAA). SAA is a condition in which the body does not produce enough blood cells</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">
        <i>Promacta</i>/<i>Revolade</i> is marketed under a research, development and license agreement between Novartis and RPI Finance Trust (dba Royalty Pharma), as assignee of Ligand Pharmaceuticals.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Tasigna</i> (nilotinib) is a twice-daily oral tyrosine kinase inhibitor that acts by blocking the BCR-ABL protein. It is approved in the US, the EU and other countries to treat:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic and/or accelerated phase who are resistant or intolerant to existing treatment. Ph+ CML is a cancer that starts in the blood-forming cells of bone marrow.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Newly diagnosed adults and children with Ph+ CML in the chronic phase </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Jakavi</i> (ruxolitinib) is an oral inhibitor of the JAK1 and JAK2 tyrosine kinases. It is the first therapy approved in the EU and other countries to treat: </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with myelofibrosis (MF), including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. MF is a rare blood cancer characterized by abnormal blood cell production and scarring in the bone marrow, which can lead to an enlarged spleen.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with polycythemia vera (PV) who are resistant or intolerant to a medication called hydroxyurea. PV is a rare blood cancer in which the bone marrow produces too many red blood cells, resulting in serious problems like clots.   </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Patients aged 12 years and older with acute or chronic graft-versus-host disease (GvHD) and who have had an inadequate response to corticosteroids or other systemic therapies. GvHD occurs in stem-cell transplant patients when donor cells see the recipient&#x2019;s healthy cells as foreign and attack them.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Novartis licensed ruxolitinib from Incyte Corporation for development and commercialization in the indications of oncology, hematology and graft-versus-host disease outside the US. Incyte Corporation markets ruxolitinib as Jakafi<sup>&#xAE;</sup> in the US. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Scemblix</i> (asciminib) is an oral kinase inhibitor that works by binding to the ABL myristoyl pocket. It is approved: </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In the US, the EU and other countries to treat adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase who have previously been treated with two or more tyrosine kinase inhibitors (TKIs). CML is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. There are three phases of CML: chronic phase, accelerated phase and blast phase. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In the US and other countries to treat adults with Ph+ CML in chronic phase with the T315I mutation. Some patients with CML develop mutations that cause resistance to TKI therapy, including the T315I mutation, which confers resistance to most available TKIs. As a result, patients with this mutation have limited treatment options.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Other Promoted Brands</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <i>&#x2022;</i>
        <i>Lucentis</i> (ranibizumab) is a humanized, high-affinity antibody fragment that binds to vascular endothelial growth factor A (VEGF&#x2011;A), a protein that can cause the growth of blood vessels in the eye, potentially leading to vision loss. <i>Lucentis</i> is an anti-VEGF therapy that is injected into the eye. It is approved in the EU and other countries to treat patients with certain eye conditions, including:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with neovascular (wet) age&#x2011;related macular degeneration (AMD). Wet AMD develops when abnormal blood vessels grow under the macula and leak blood and other fluids in the back of the eye, which damages the macula.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with proliferative diabetic retinopathy, moderately severe to severe non-proliferative diabetic retinopathy, and/or diabetic macular edema. These conditions are complications of diabetes.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Adults with visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO). Retinal vein occlusion&#xA0;is a blockage of the branch or central retinal veins, which carry blood away from the retina.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Approved indications vary by country. <i>Lucentis</i> is licensed from Genentech, and Novartis holds the rights to commercialize the product outside the US. Genentech holds the rights to commercialize <i>Lucentis</i> in the US. For more information, see &#x201C;Item 18. Financial Statements&#x2014;Note 27. Transactions with related parties&#x2014;Roche Holding AG.&#x201D;</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Xiidra</i> (lifitegrast 0.5%), an LFA-1 antagonist, is a prescription eye drop designed to block the interaction of two key proteins called ICAM-1 and LFA-1, thereby reducing inflammation. It is approved in the US and other countries to treat:</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The signs and symptoms of dry eye disease in adults</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">25</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Established Brands</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Sandostatin</i> SC (octreotide acetate for injection) and <i>Sandostatin</i> LAR (octreotide acetate for injectable suspension) are somatostatin analogs approved in the US, the EU and other countries to treat:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Adults with acromegaly that is inadequately controlled by surgery or radiotherapy. Acromegaly is a chronic disease caused by the oversecretion of growth hormone.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:18px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Patients with certain symptoms associated with carcinoid tumors and other types of functional gastrointestinal and pancreatic neuroendocrine tumors</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">
        <i>Sandostatin</i> LAR is also approved in the EU and other countries to treat patients with advanced neuroendocrine tumors of the midgut or of unknown primary tumor origin. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Compounds in development</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides an overview of the key Innovative Medicines Division projects currently in the Confirmatory Development stage and may also describe certain projects in the Exploratory Development stage. Projects typically enter Confirmatory Development and become the responsibility of our Global Drug Development organization during Phase II testing. (For more information about our drug development program, see &#x201C;&#x2014;Research and development&#x2014;Development program.&#x201D;) Projects are listed in alphabetical order by compound code, or by product name where applicable. Projects include those seeking to develop potential uses of new molecular entities as well as potential additional indications or new formulations for already marketed products. The table below, entitled &#x201C;Projects removed from the development table since 2021,&#x201D; highlights changes to the table entitled &#x201C;Selected development projects&#x201D; from the previous year.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The year that each project entered the current phase of development refers to the year of the first patient&#x2019;s first visit in the first clinical trial of that phase. For projects in Phase II, the year refers to the first patient&#x2019;s first visit in the first Phase II trial, which can occur before the Confirmatory Development stage. Prior to 2020, we reported the current phase based on the year in which the decision to enter the phase was made. To maintain continuity, we have included certain previously disclosed projects, noted below, that have not yet achieved &#x201C;first patient, first visit&#x201D; in any Phase I-III study for the reported indication and route of administration. We have disclosed these projects using our previous reporting criteria.  </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"> A reference to a project being in registration means that an application has been submitted to a health authority for marketing approval. Compounds and new indications in development are subject to required regulatory approvals and, in certain instances, contractual limitations. These compounds and indications are in various stages of development throughout the world. It may not be possible to obtain regulatory approval for any or all of the new compounds and new indications referred to in this Form&#xA0;20&#x2011;F in any country or in every country. See &#x201C;&#x2014;Regulation&#x201D; for more information on the approval process.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">26</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Selected development projects </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />Compound/<br />product</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Common <br /> name</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Mechanism <br /> of action</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br />
                <br /> Potential indication</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br />
                <br /> Category</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Formulation/<br /> route of<br /> administration</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Year project<br /> entered<br /> current<br /> development<br /> phase</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Planned filing<br /> dates/current<br /> phase</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">AVXS-101<br />(OAV101)</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> onasemno-<br /> gene abepar-<br /> vovec</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Survival motor neuron <br /> (SMN) gene therapy<br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy <br /> (IT formulation)<br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience<br /><br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intrathecal injection<br /><br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021<br /><br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025/III<br /><br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Beovu</i>
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> brolucizumab</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VEGF inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Diabetic retinopathy</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravitreal injection</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CFZ533</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> iscalimab</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CD40 inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Sj&#xF6;gren's syndrome</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Coartem</i>
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> artemether + <br /> lumefantrine<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PGH-1 (artemisinin <br /> combination therapy)<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Malaria, <br /> uncomplicated <br /> (&lt;5 kg patients)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Global Health<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/III<br /><br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Cosentyx</i>
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> secukinumab<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IL&#x2011;17A inhibitor<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hidradenitis suppurativa<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> US/EU <br /> registration</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Giant cell arteritis</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Lupus nephritis</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriatic arthritis (IV formulation)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> US registration</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ankylosing spondylitis (IV formulation)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> US registration</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">JDQ443</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBD</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> KRAS inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Non-small cell lung cancer, 2/3L<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">KAE609</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> cipargamin</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PfATP4 inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Malaria, uncomplicated</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Global Health</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Malaria, severe</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Global Health</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">KAF156</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ganaplacide<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Non-artemisinin<br /> plasmodium<br /> falciparum inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Malaria, uncomplicated<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Global Health<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II<br /><br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Kisqali</i>
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ribociclib<br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CDK4 inhibitor<br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hormone receptor-positive <br /> (HR+)/human epidermal growth <br /> factor receptor 2-negative (HER2-)<br /> early breast cancer (adjuvant)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor<br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018<br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III<br /><br /><br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Leqvio</i>
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> inclisiran<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> siRNA <br /> (regulation of LDL-C)<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Secondary prevention of cardiovascular <br /> events in patients with elevated levels <br /> of LDL-C</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/III<br /><br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">LNA043</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBD</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ANGPTL3 agonist</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Knee osteoarthritis</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intra-articular</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">LNP023</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> iptacopan</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CFB inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IgA nephropathy</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> C3 glomerulopathy</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Paroxysmal nocturnal hemoglobinuria</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Atypical hemolytic uremic syndrome</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">LOU064</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> remibrutinib</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BTK inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic spontaneous urticaria</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Sj&#xF6;gren's syndrome</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Multiple sclerosis</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Lutathera</i>
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> lutetium <br /> Lu 177 <br /> dotatate/<br /> lutetium <br /> (<sup>177</sup>Lu)<br /> oxodotreotide</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Radioligand therapy <br /> targeting SSTR<br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Gastroenteropancreatic <br /> neuroendocrine tumors, <br /> 1st line in G2/3 tumors<br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor<br /><br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br /><br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020<br /><br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III<br /><br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">LXE408</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBD</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Proteasome inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Visceral leishmaniasis</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Global Health</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">MBG453</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> sabatolimab</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TIM-3 antagonist</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelodysplastic syndrome</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Unfit acute myeloid leukemia</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">MIJ821</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> onfasprodil<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NR2B negative <br /> allosteric modulator</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Major depressive disorder<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II<br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">NIS793</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBD</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TGF-beta 1 inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Pancreatic cancer, 1st line</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Piqray</i>
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> alpelisib</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PI3K&#x2011;alpha inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ovarian cancer</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Pluvicto</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> lutetium<br /> Lu 177 <br /> vipivotide <br /> tetraxetan/<br /> lutetium <br /> (<sup>177</sup>Lu) <br /> vipivotide <br /> tetraxetan</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Radioligand therapy <br /> targeting PSMA<br /><br /><br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Metastatic castration-resistant <br /> prostate cancer, pre-taxane<br /><br /><br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor<br /><br /><br /><br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br /><br /><br /><br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021<br /><br /><br /><br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III<br /><br /><br /><br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <br />
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <br />
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Metastatic hormone-sensitive <br /> prostate cancer</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/III<br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td colspan="16" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="16">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Project added to selected development projects table in 2022 &#x2013; entered Confirmatory Development</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">27</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />Compound/<br />product</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Common <br /> name</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Mechanism <br /> of action</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br />
                <br /> Potential indication</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br />
                <br /> Category</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Formulation/<br /> route of<br /> administration</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Year project<br /> entered<br /> current<br /> development<br /> phase</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Planned filing<br /> dates/current<br /> phase</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">PPY988<sup style="white-space: nowrap">&#xA0;2</sup></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBD<br /><br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Gene therapy -<br /> complement<br /> factor I modulation</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Geographic atrophy<br /><br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology<br /><br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subretinal injection<br /><br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022<br /><br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II<br /><br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">QGE031</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ligelizumab</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IgE inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Food allergy</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">SAF312</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> libvatrep</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRPV1 antagonist</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic ocular surface pain</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Topical</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2016</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Scemblix</i>
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> asciminib<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BCR&#x2011;ABL inhibitor<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid <br /> leukemia, 1st line</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oral<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025/III<br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">SKO136<sup style="white-space: nowrap">&#xA0;3</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ensovibep<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Multispecific DARPin<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Coronavirus infection<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Global Health<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Not applicable<br /> (N/A)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBD<sup>4</sup>/II<br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">TQJ230</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> pelacarsen<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ASO targeting<br /> lipoprotein(a)<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Secondary prevention of cardiovascular <br /> events in patients with elevated levels <br /> of lipoprotein(a)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025/III<br /><br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">VAY736</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ianalumab</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BAFF-R inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Autoimmune hepatitis</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2018</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Lupus nephritis<sup style="white-space: nowrap">&#xA0;5</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Sj&#xF6;gren&#x2019;s syndrome</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <br />
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <br />
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Warm autoimmune hemolytic anemia<br /> (wAIHA)<sup style="white-space: nowrap">&#xA0;5</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/III<br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">VDT482</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> tislelizumab<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti-PD-1 monoclonal <br /> antibody</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Esophageal cancer, 2nd line<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> N/A<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> US/EU <br /> registration</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Non&#x2011;small cell lung cancer</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> N/A</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EU registration</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Nasopharyngeal carcinoma, 1st line</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> N/A</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Gastric cancer, 1st line</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> N/A</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Esophageal cancer, 1st line</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> N/A</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Localized esophageal cancer</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> N/A</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hepatocellular carcinoma, 1st line</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> N/A</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Small cell lung cancer, 1st line</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> N/A</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Urothelial cell carcinoma, 1st line<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> N/A</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">VPM087</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> gevokizumab</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IL-1 beta antagonist</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Colorectal cancer, 1st line</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous infusion</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/I</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Xolair</i>
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> omalizumab</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IgE inhibitor</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Food allergy</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023/III</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">XXB750<sup style="white-space: nowrap">&#xA0;5</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TBD</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NPR1 agonist</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous injection</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2265;2026/II</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td colspan="16" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="16">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Entered confirmatory development following the acquisition of Gyroscope Thereapeutics.</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="16">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> In-licensed from Molecular Partners in 2021 (option deal)</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="16">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> No definite submission date can be provided at this time</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="16">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> Project added to selected development projects table in 2022 &#x2013; entered Confirmatory Development</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="16">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;6&#xA0;</sup> Formerly &#x201C;bladder urothelial cell carcinoma&#x201D;. Indication language updated in 2022 to reflect latest development plan</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="16">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="16">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">28</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Projects removed from the development table since 2021</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="top">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">Compound/product</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Potential indication</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Change</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Reason</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">ACZ885 (canakinumab)</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Non&#x2011;small cell lung cancer, adjuvant</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                <i>Beovu</i>
              </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Diabetic macular edema</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CFZ533 (iscalimab)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Liver transplantation</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ankylosing spondylitis head&#x2011;to&#x2011;head study versus   Sandoz biosimilar Hyrimoz (adalimumab)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed  </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued  </div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Lichen Planus</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CSJ117</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Asthma</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Acute graft&#x2011;versus&#x2011;host disease</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic graft&#x2011;versus&#x2011;host disease</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsed/refractory follicular lymphoma</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">LJN452</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Nonalcoholic steatohepatitis</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">LMI070</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Huntington's disease</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">LNP023</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Membranous nephropathy</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Vijoice<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PIK3CA-related overgrowth spectrum</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Triple negative breast cancer</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Human epidermal growth factor   receptor 2-positive (HER2+)   advanced breast cancer</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed    </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued    </div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Pluvicto</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Metastatic castration-resistant prostate cancer, post-taxane</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">QBW251 (icenticaftor)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic obstructive pulmonary disease</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">QGE031 (ligelizumab)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic spontaneous urticaria</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">QGE031 (ligelizumab)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic inducible urticaria</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Scemblix</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia, 3rd line</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Commercialized</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">UNR844</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Presbyopia</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Removed</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Development discontinued</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td colspan="8" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Formerly listed as BYL719</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">29</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Principal markets</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Innovative Medicines Division sells products in approximately 130 countries worldwide. Net sales are primarily concentrated in the US and Europe. The following table sets forth the aggregate 2022 net sales of the Innovative Medicines Division by region:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022 net sales  to third parties</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD millions</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United States</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&#xA0;899</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&#xA0;554</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia, Africa, Australasia</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&#xA0;929</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;914</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 41&#xA0;296</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Of which in Established Markets<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30&#xA0;548</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 74</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Of which in Emerging Growth Markets<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;748</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Many of our Innovative Medicines Division products are used for chronic conditions that require patients to consume the product over long periods of time, ranging from months to years. However, certain of our marketed products and development projects, such as cell and gene therapies, are administered only once. Net sales of the vast majority of our products are not subject to material changes in seasonal demand.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Production</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our primary goal is to ensure the uninterrupted and timely supply of medicines that meet all product specifications and quality standards, and that are produced in the most cost-effective and sustainable manner. The manufacturing of our products is highly regulated by governmental health authorities around the world, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). In addition to regulatory requirements, many of our products involve technically complex manufacturing processes or require highly specialized raw materials.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2022, we began to integrate Advanced Accelerator Applications (AAA), a Novartis company that focuses on radioligand therapies, into our existing manufacturing and supply structure. We manufacture our products across the following technologies at facilities worldwide: large molecules, small molecules, cell and gene therapy, RNA therapy and radioligand therapy (see also &#x201C;&#x2014;Item 4.D Property, plants and equipment&#x201D;). In our manufacturing network, we maintain state&#x2011;of&#x2011;the&#x2011;art processes, with quality as a priority, and require our suppliers to adhere to the same high standards we expect from our own people and processes. These processes include: chemical and biological syntheses; radioisotope handling, which relates to our radioligand therapies; sterile processing, including CAR-T cell processing; and formulation and packaging. We are constantly working to improve our existing manufacturing processes, develop new and innovative technologies, and review and adapt our manufacturing network to meet our needs and those of our patients and customers.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We produce raw materials for manufacturing in&#x2011;house or purchase them from a number of third-party suppliers. Where possible, we maintain multiple supply sources so that the business is not dependent on a single or limited number of suppliers. However, our ability to do so may at times be limited by regulatory or other requirements. We monitor market developments that could have an adverse effect on the supply of essential materials. Our suppliers of raw materials are required to comply with applicable regulations and Novartis quality standards.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Because the manufacturing of our products is complex and highly regulated by governmental health authorities, supply is never guaranteed. If we or our third-party suppliers fail to comply with applicable regulations, then there could be a product recall or other disruption to our production activities. We have experienced supply interruptions for our products in the past, and there can be no assurance that supply will not be interrupted again in the future. However, we have implemented a global manufacturing strategy to maximize business continuity in case of such events.  </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Marketing and sales</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Innovative Medicines Division serves customers with 21 564 field force representatives, as of December 31, 2022, including supervisors and administrative personnel. These trained representatives present the therapeutic benefits and risks of our products to physicians, pharmacists, hospitals, insurance groups, managed care organizations and other healthcare professionals. In the US, Novartis advertises certain products via digital and traditional media channels, including the internet, television, newspapers and magazines. Novartis also pursues co&#x2011;promotion or co&#x2011;marketing opportunities as well as licensing and distribution agreements with other companies in various markets. </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">30</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The marketplace for healthcare is evolving. Customer groups beyond prescribers have increasing influence on treatment decisions and guidelines, while patients continue to become more informed stakeholders in their healthcare decisions and look for solutions to meet their changing needs. Novartis is responding by adapting our business practices to engage appropriately with patients, customer groups and other stakeholders, including by delivering innovative solutions to drive education, access and improved patient care. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The COVID-19 pandemic has accelerated additional changes related to marketing and sales techniques in the healthcare industry. For example, many healthcare professionals have increased their use of virtual platforms when interacting with pharmaceutical companies, and prefer to receive information in a more convenient and personalized way. In response, Novartis is working to implement a new customer engagement model that combines traditional face-to-face visits with digital and other methods of engaging healthcare professionals to improve the efficiency and effectiveness of every interaction. We are similarly changing our approach to engaging healthcare systems, payers and other healthcare providers.  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Although specific distribution patterns vary by country, Novartis generally sells its prescription drugs primarily to wholesale and retail drug distributors, hospitals, clinics, government agencies and managed healthcare providers. The growing number of so&#x2011;called &#x201C;specialty&#x201D; drugs in our portfolio has resulted in increased engagement with specialty pharmacies.  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the US, the US Centers for Medicare &amp; Medicaid Services (CMS) is the largest single payer for healthcare services as a result of continuing changes in healthcare economics and an aging population. In addition, both commercial and government-sponsored managed care organizations continue to be among the largest groups of payers for healthcare services in the US. In other countries, national health services are often the only significant payer for healthcare services. In an effort to control prescription drug costs, almost all managed care organizations and national health services use formularies that list specific drugs that may be reimbursed and/or the level of reimbursement for each drug. Managed care organizations and national health services also increasingly use cost&#x2011;benefit analyses to determine whether or not newly approved drugs will be added to a formulary and/or the level of reimbursement for that drug, and to determine whether or not to continue to reimburse existing drugs. We have dedicated teams that actively seek to optimize patient access, including formulary positions, for our products.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The trend toward consolidation among distributors and retailers of Innovative Medicines Division products continues in the US and internationally, both within and across countries. This has increased our customers&#x2019; purchasing leverage and resulted in increased pricing pressure on our products. Moreover, we are exposed to increased concentration of credit risk as a result of the consolidation among our customers. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Drug pricing is an increasingly prominent issue in many countries as healthcare spending continues to rise. This issue has received significant attention in the US, especially with the recent passage of the Inflation Reduction Act (please see &#x201C;&#x2014;Price controls&#x201D; for more information). At Novartis, we are increasing our efforts to enable patient access through innovative pricing and access initiatives in the US, Europe and other markets. These include contract structures such as pay-over-time and outcome-based agreements.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2021, Novartis reached an agreement with the National Health Service (NHS) in England to implement a first-of-its-kind population health management approach designed to provide faster and broader access to <i>Leqvio</i> for certain high-risk patients with atherosclerotic cardiovascular disease.  Novartis is engaging in similar collaborations with other countries. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Additionally, following conditional approval of <i>Zolgensma</i> in Europe in 2020, Novartis Gene Therapies established &#x201C;Day One&#x201D; early access agreements in multiple European countries. These agreements support early patient access by allowing a variety of customizable options, including retroactive rebates, deferred payments, installment options, outcome-based rebates, and collaborations with healthcare systems to optimize disease management. These efforts have expanded globally, and we now have multiple early access agreements and pay-for-performance agreements (i.e., outcome-based arrangements) in place in various markets around the world. <i>Zolgensma</i> is approved in 45 countries.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Competition</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The global pharmaceutical market is highly competitive. We compete against other major international corporations that have substantial financial and other resources, as well as against smaller companies that operate regionally or nationally. Competition within the industry is intense and extends across a wide range of activities, including pricing, product characteristics, customer service, sales and marketing, and research and development.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Like other companies selling patented pharmaceuticals, Novartis faces challenges from companies selling competing patented products. Generic forms of our products may follow the expiry of intellectual property protection or regulatory exclusivities, and generic companies may also gain entry to the market through successfully challenging our intellectual property rights and exclusivities. We use appropriate, legally permissible measures to defend those rights and exclusivities. (See also &#x201C;&#x2014;Intellectual property&#x201D; below). We also may face competition from over-the-counter (OTC) products that do not require a prescription from a physician.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"> There is ongoing consolidation in the pharmaceutical industry. At the same time, new entrants are looking to use their expertise to establish or expand their presence in healthcare, including technology companies seeking to benefit from the increasing importance of data and data management in our industry.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Research and development</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The discovery and development of a new drug usually requires approximately 10 to 15&#xA0;years from the initial research to bringing a drug to market. This includes </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">31</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">approximately six to eight years from Phase&#xA0;I clinical trials to market entry. At each of these steps, there is a substantial risk that a compound (i.e., drug or biologic) or other therapeutic candidate will not meet the requirements to progress further. In such an event, we may be required to abandon the development of a potential therapy in which we have made a substantial investment.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We manage our research and development expenditures across our entire portfolio in accordance with our strategic priorities. We make decisions about whether or not to proceed with development projects on a project&#x2011;by&#x2011;project basis. These decisions are based on the project&#x2019;s potential to meet a significant unmet medical need or to improve patient outcomes, the strength of the science underlying the project, and the potential of the project (subject to the risks inherent in pharmaceutical development) to generate significant positive financial results for the Company. Once a management decision has been made to proceed with the development of a particular molecule, the level of research and development investment required will be driven by many factors. These include the medical indications for which it is being developed, the number of indications being pursued, whether the molecule is of a chemical or biological nature, the stage of development, and the level of evidence necessary to demonstrate clinical efficacy and safety. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Research program</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our research program is conducted by the Novartis Institutes for BioMedical Research (NIBR), which is the research and early development innovation engine of Novartis. NIBR is responsible for the discovery of new medicines for diseases with unmet medical need. We focus our work in areas where we believe we can have the most impact for patients. This requires the hiring and retention of highly talented employees, a focus on fundamental disease mechanisms that are relevant across different disease areas, continuous improvement in technologies for drug discovery and potential therapies, working with patients to understand their diseases and the potential benefits of therapies, close alliances with clinical and commercial colleagues, and the establishment of strategic external alliances.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">  Approximately 5 500 full&#x2011;time-equivalent scientists, physicians and business professionals work at NIBR sites in Basel, Switzerland; Cambridge, Massachusetts; East Hanover, New Jersey; San Diego, California; and Emeryville, California. They contribute to research into disease areas such as cardiovascular, renal and metabolic diseases; neuroscience; oncology; hematology; muscle disorders; ophthalmology; autoimmune diseases; and respiratory and allergic diseases. Research at the Friedrich Miescher Institute focuses on basic genetic and genomic research, and the Novartis Institute for Tropical Diseases (NITD), in Emeryville, California, focuses on discovering new medicines to fight tropical diseases, including malaria and cryptosporidiosis.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">  All drug candidates go through proof&#x2011;of&#x2011;concept trials to enable an early assessment of the safety and efficacy of the drug while collecting basic information on pharmacokinetics and tolerability, and adhering to the guidance for early clinical testing set forth by health authorities. Following proof of concept, our Global Drug Development unit conducts confirmatory trials on the drug candidates.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">  In 2022, we integrated the Genomics Institute of the Novartis Research Foundation (GNF), which is based in San Diego, US, into NIBR. This enables closer collaboration with colleagues across NIBR and gives greater access to biological, therapeutic, and translational platforms to researchers across Novartis. The NIBR San Diego site is focused on developing novel technology to drive drug discovery research, including regenerative medicine, small interfering RNA therapy and covalent drug discovery. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Development program</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Global Drug Development (GDD) organization oversees and executes drug development activities, working collaboratively with NIBR, our commercial organization and other parts of the Company on our overall pipeline strategy. The GDD organization includes centralized global functions such as Regulatory Affairs and Global Development Operations, and global Development Units, and has approximately 12 800 full&#x2011;time equivalent employees worldwide.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The traditional model of clinical development consists of three phases:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <b>Phase&#xA0;I:</b>  The first clinical trials of a new compound &#x2013; generally performed in a small number of healthy human volunteers &#x2013; to assess the drug&#x2019;s safety profile, including the safe dosage range. These trials also determine how a drug is absorbed, distributed, metabolized and excreted, and the duration of its action.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <b>Phase&#xA0;II:</b>  Clinical studies performed with patients who have the target disease, with the aim of continuing the Phase&#xA0;I safety assessment in a larger group, assessing the efficacy of the drug in the patient population, and determining the appropriate doses for further evaluation.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <b>Phase&#xA0;III:</b>  Large&#x2011;scale clinical studies with several hundred to several thousand patients, which are conducted to establish the safety and efficacy of the drug in specific indications for regulatory approval. Phase&#xA0;III trials may also be used to compare a new drug against a current standard of care to evaluate the overall benefit&#x2011;risk relationship of the new medicine.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">In each of these phases, physicians monitor volunteer patients closely to assess the safety and efficacy of a potential new drug or indication.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Although we use this traditional model, we have tailored the development process to be simpler, more flexible and more efficient. We divide the development process into two stages: Exploratory Development to establish proof of concept, followed by Confirmatory Development to confirm the concept in large numbers of patients. Exploratory Development consists of clinical proof-of-concept (PoC) studies, which are small clinical trials (typically involving between five and 15 patients) that combine elements of traditional Phase&#xA0;I/II testing. NIBR conducts these customized trials, which are designed to give early insights into issues such as safety, efficacy and toxicity for a drug in a given indication. Once a positive proof of concept has been established, the </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">32</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">drug moves to the Confirmatory Development stage and becomes the responsibility of GDD. Confirmatory Development has elements of traditional Phase&#xA0;II/III testing and includes trials aimed at confirming the safety and efficacy of the drug in the given indication, leading up to submission of a dossier to health authorities for approval. This stage can also include trials that compare the drug to the current standard of care for the disease in order to evaluate the drug&#x2019;s overall benefit-risk profile. Further, with new treatment approaches such as gene therapy for rare diseases, elements of Exploratory and Confirmatory Development may be combined and suffice for registration under certain conditions such as high unmet medical need and clinical data showing highly favorable benefit-risk. In these cases, additional post-approval studies may be required by the regulatory authorities to continue to gather important data to further support approval.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The vast amount of data that must be collected and evaluated makes clinical testing the most time&#x2011;consuming and expensive part of new drug development. The next stage in the drug development process is to seek registration for the new drug. For more information, see &#x201C;&#x2014;Regulation.&#x201D;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our Innovation Management Board (IMB) is responsible for all strategic aspects of our development portfolio and oversees our drug development budget as well as major project phase transitions and milestones following a positive proof-of-concept outcome, including transitions to Confirmatory Development and the decision to submit a regulatory application to the health authorities. The IMB is also responsible for the endorsement of overall development strategy, the endorsement of development project priorities, and decisions on project discontinuations. Our Chief Executive Officer chairs the IMB, and other representatives from Novartis senior management, with expertise spanning multiple fields, are among its core and extended membership. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Alliances and acquisitions</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Innovative Medicines Division enters into business development agreements with other pharmaceutical and biotechnology companies and with academic and other institutions to develop new products and access new markets. We license products that complement our current product line and are appropriate to our business strategy. We focus on strategic alliances and acquisition activities for key disease areas and indications that we expect to be growth drivers in the future. We review products and compounds we are considering licensing, using the same criteria that we use for our own internally discovered drugs. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In February 2022, Novartis completed the acquisition of Gyroscope Therapeutics Holdings Plc. Through the acquisition, Novartis added PPY988 (GT005), an investigational one-time gene therapy for geographic atrophy, to its portfolio.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">For more information about recent business acquisitions, see &#x201C;Item 18. Financial Statements&#x2014;Note 2. Significant transactions.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Regulation</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The international pharmaceutical industry is highly regulated. Regulatory authorities around the world administer numerous laws and regulations regarding the testing, approval, manufacturing, importing, labeling and marketing of drugs, and review the safety and efficacy of pharmaceutical products. Extensive controls exist on the non&#x2011;clinical and clinical development of pharmaceutical products. These regulatory requirements, and the implementation of them by local health authorities around the globe, are a major factor in determining whether a substance can be developed into a marketable product, and the amount of time and expense associated with that development.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Health authorities, including those in the US and the EU, have high standards of technical evaluation. The introduction of new pharmaceutical products generally entails a lengthy approval process. Products must be authorized or registered prior to marketing, and such authorization or registration must subsequently be maintained. In recent years, the registration process has required increased testing and documentation for the approval of new drugs, with a corresponding increase in the expense of product introduction.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To register a pharmaceutical product, a registration dossier containing evidence establishing the safety, efficacy and quality of the product must be submitted to regulatory authorities. Generally, a therapeutic product must be registered in each country in which it will be sold. In every country, the submission of an application to a regulatory authority does not guarantee that approval to market the product will be granted. Although the criteria for the registration of therapeutic drugs are similar in most countries, the formal structure of the necessary registration documents and the specific requirements, including risk tolerance, of the local health authorities can vary significantly from country to country. Even if a drug is registered and marketed in one country, the registration authority in another country may request additional information from the pharmaceutical company prior to registration or even reject the product. A drug may be approved for different indications in different countries.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The registration process generally takes between six months and several years, depending on the country, the quality of the data submitted, the efficiency of the registration authority&#x2019;s procedures, and the nature of the product. Many countries provide for accelerated processing of registration applications for innovative products of particular therapeutic interest. In recent years, the US and the EU have made efforts to harmonize registration requirements in order to achieve shorter development and registration times for medical products. However, the requirement in many countries to negotiate selling prices or reimbursement levels with government regulators and other payers can substantially extend the time until a product may finally be available to patients.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following provides a summary of the regulatory processes in the principal markets served by Innovative Medicines Division affiliates:</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">33</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">United States</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In the US, applications for drug registration are submitted to and reviewed by the FDA. The FDA regulates the testing, manufacturing, labeling and approval for marketing of pharmaceutical products intended for commercialization in the US. The FDA continues to monitor the safety of pharmaceutical products after they have been approved for sale in the US market. The pharmaceutical development and registration process is typically intensive, lengthy and rigorous. When a pharmaceutical company has gathered data that it believes sufficiently demonstrates a drug&#x2019;s safety, efficacy and quality, the company may file&#xA0;a New Drug Application (NDA) or Biologics License Application (BLA), as applicable, for the compound. The NDA or BLA must contain all the scientific information that has been gathered about the compound. This typically includes information regarding the clinical experiences of patients tested in the drug&#x2019;s clinical trials. A Supplemental New Drug Application (sNDA) or Supplemental Biologics License Application (sBLA) must be filed for new indications and dosage forms for a previously approved drug.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Once an application is submitted, the FDA assigns reviewers from its staff, including experts in biopharmaceutics, chemistry, clinical microbiology, pharmacology/toxicology, and statistics. After a complete review, these content experts provide written evaluations of the NDA or BLA. These recommendations are consolidated and are used by senior FDA staff in its final evaluation of the NDA or BLA. Based on that final evaluation, the FDA then provides to the NDA or BLA&#x2019;s sponsor an approval, or a &#x201C;complete response&#x201D; letter if the NDA or BLA application is not approved. If not approved, the letter will state the specific deficiencies in the NDA or BLA that need to be addressed. The sponsor must then submit an adequate response to the deficiencies in order to restart the review procedure.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Once the FDA has approved an NDA, BLA, sNDA or sBLA, the company can make the new drug available for physicians and other healthcare providers to prescribe. The drug owner must submit periodic reports to the FDA, including any cases of adverse reactions. For some medications, the FDA requires additional post&#x2011;approval studies (Phase&#xA0;IV) to evaluate long&#x2011;term effects or to gather information on the use of the product under specified conditions.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Throughout the life cycle of a product, the FDA requires compliance with standards relating to good laboratory, clinical and manufacturing practices. The FDA also requires compliance with rules pertaining to the manner in which we may promote our products.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">European Union</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In the EU, there are three main procedures for application for authorization to market pharmaceutical products in more than one EU member state at the same time: the centralized procedure, the mutual recognition procedure and the decentralized procedure. It is also possible to obtain a national authorization for products intended for commercialization in a single EU member state only. The procedure used for first authorization must continue to be followed for subsequent changes, e.g., to add an indication for a licensed product.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Under the centralized procedure, applications are made to the EMA for an authorization that is valid for the European Union (all member states). The centralized procedure is mandatory for all biotechnology products; new chemical entities in cancer, neurodegenerative disorders, diabetes, AIDS, autoimmune diseases and other immune dysfunctions; advanced therapy medicines, such as gene therapy, somatic cell therapy and tissue-engineered medicines; and orphan medicines (medicines for rare diseases). It is optional for other new chemical entities, innovative medicinal products, and medicines for which authorization would be in the interest of public health. When a pharmaceutical company has gathered data that it believes sufficiently demonstrates a drug&#x2019;s safety, efficacy and quality, the company may submit an application to the EMA. The EMA then receives and validates the application, and the specialized committee for human medicines, the CHMP, appoints a rapporteur and co&#x2011;rapporteur to review it. They use experts from their countries to carry out the assessment but can also draw on expertise from other member states (&#x201C;multinational teams&#x201D;). The entire review cycle must be completed within 210&#xA0;days, although there are &#x201C;clock stops&#x201D; to allow the company to respond to questions set forth in the rapporteur and co&#x2011;rapporteur&#x2019;s assessment report and agreed with the CHMP. The first clock stop is at Day 120 and the clock restarts on Day 121, when the company&#x2019;s complete response is received by the EMA. If there are further aspects of the dossier requiring clarification, the CHMP will issue further questions at Day 180, and may also request an oral explanation, in which case the sponsor must not only respond to the further questions but also appear before the committee to justify its responses. On Day 210, the CHMP will take a vote to recommend the approval or non&#x2011;approval of the application, and their opinion is transferred to the EC. The final EC decision under this centralized procedure is a single decision that is applicable to all member states. This decision occurs 60&#xA0;days, on average, after a positive CHMP recommendation.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Under both the mutual recognition procedure (MRP) and the decentralized procedure (DCP), the assessment is led by one member state, called the reference member state (RMS) which then liaises with other member states, known as the concerned member states. In the MRP, the company first obtains a marketing authorization in the RMS, which is then recognized by the concerned member states in 90 days. In the DCP, the application is done simultaneously in the RMS and all concerned member states. During the DCP, the RMS drafts an assessment report within 120&#xA0;days. Within an additional 90&#xA0;days, the concerned member states review the application and can issue objections or requests for additional information. On Day 90, each concerned member state must be assured that the product is safe and effective, and that it will cause no undue risks to the public health. Once an agreement has been reached, each member state grants national marketing authorizations for the product.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">After receiving the marketing authorizations, the company must submit periodic safety reports to the relevant health authority (EMA for the centralized procedure, national health authorities for DCP or MRP). In addition, pharmacovigilance measures must be implemented </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">34</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">and monitored, including the collection, evaluation and expedited reporting of adverse events, and updates to risk management plans. For some medications, post-approval studies (Phase&#xA0;IV) may be imposed to complement available data with additional data to evaluate long-term effects (called a Post-Approval Safety Study, or PASS) or to gather additional efficacy data (called a Post-Approval Efficacy Study, or PAES).</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">European marketing authorizations have an initial duration of five years. The holder of the marketing authorization must actively apply for its renewal after this first five-year period. As part of the renewal procedure, the competent authority performs a full benefit&#x2011;risk review of the product. Should the authority conclude that the benefit&#x2011;risk balance is no longer positive, the marketing authorization can be suspended or revoked. Once renewed, the marketing authorization is valid for an unlimited period, unless it is determined that the product must be further monitored for safety reasons. In this case, the authority may require another renewal at 10 years. If the holder does not apply for renewal, the marketing authorization automatically lapses. Any marketing authorization that is not followed within three years of its granting by the actual placing on the market of the corresponding medicinal product ceases to be valid. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Price controls</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In most of the markets where we operate, the prices of pharmaceutical products are subject to both direct and indirect price controls and to drug reimbursement programs with varying price control mechanisms. Due to increasing political pressure and governmental budget constraints, we expect these mechanisms to remain robust &#x2013; and potentially even strengthened &#x2013; and to have a continued negative influence on the prices we are able to charge for our products.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Direct governmental efforts to control prices</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">United States:  The Inflation Reduction Act of 2022 (the &#x201C;Act&#x201D;) was signed into law, which mandates the negotiation of eligible Medicare Part B and Part D drugs; redesigns the Medicare Part D benefit, including a USD 2 000 out-of-pocket cap for Medicare beneficiaries; and imposes penalties for Medicare drugs that increase in price faster than the rate of inflation. Under the Act, the US government is required to negotiate the Medicare prices of single-sourced small molecule drugs that have been on the market for seven years following FDA approval as well as single-sourced biologics that have been on the market for 11 years after FDA approval. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Medicare drugs with the highest total cost to the US government will be selected for negotiation once they become eligible. Exemptions include orphan drugs with an indication for one rare disease or condition, drugs with a total cost to the US government of less than USD&#xA0;200 million, and plasma-derived drugs.   </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The negotiated price will be publicly available and will become effective for selected drugs nine years after FDA approval for eligible small molecules and 13 years after approval for eligible biologics. The negotiated price will be implemented as follows:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  10 eligible Medicare Part D drugs in 2026;  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  an additional 15 eligible Medicare Part D drugs in 2027;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   an additional 15 eligible combined Medicare Part&#xA0;B and Part D drugs in 2028;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   an additional 20 eligible combined Medicare Part&#xA0;B and Part D drugs in 2029; and </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  an additional 20 eligible combined Medicare Part&#xA0;B and Part D drugs each year after 2029 </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Novartis will participate in the Medicare negotiation process if Novartis drugs are selected. Pharmaceutical manufacturers that choose not to participate in the negotiation process will be subject to an excise tax of up to 95% of sales.  Novartis may also be affected by other provisions of the Act, such as price increase penalties for Medicare Part D drugs starting in 2022 and for Medicare Part B drugs in 2023, and rebates on eligible Medicare Part D sales starting in 2025.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, by December 31, 2022, 20 US states had passed legislation intended to impact pricing or requiring manufacturer price transparency reporting, with eight of these states also allowing for drug affordability (i.e., price control) review boards. The disclosure requirements vary by state. Many states require multiple types of reporting, including for new drug applications, new drug launches, prior notice of price increases, and quarterly or annual reporting. It is expected that state legislatures will continue to focus on drug pricing in 2023 and that similar bills will be passed in more states.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Europe: In Europe, our operations are subject to significant price and marketing regulations. Many governments are introducing healthcare reforms in a further attempt to curb increasing healthcare costs. In some member states, these include reforms to permit the reimbursed use of off-label medicines, despite the presence of licensed alternatives on the market. In the EU, governments influence the price of pharmaceutical products through their control of national healthcare systems that fund a large part of the cost of such products to patients. The downward pressure on healthcare costs in general in the EU, particularly with regard to prescription drugs, is intense. Increasingly strict analyses are applied when evaluating the entry of new products, and as a result, access to innovative medicines is limited based on strict cost&#x2011;benefit assessments. In addition, prices for marketed products are referenced within member states and across international borders, further impacting individual EU member state pricing. Member states also collaborate to enhance pricing transparency and have started conducting joint health technology assessments, joint pricing negotiations and/or joint purchasing. As an additional control for healthcare budgets, some EU countries have passed legislation to impose further mandatory rebates for pharmaceutical products and/or financial claw&#x2011;backs on the pharmaceutical industry. The calculation of these rebates and claw&#x2011;backs may lack transparency in some cases and can be difficult to predict.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Regulations favoring generics and biosimilars</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In response to rising healthcare costs, most governments and private medical care providers have established reimbursement schemes that favor the substitution of generic pharmaceuticals for more expensive </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">35</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">brand&#x2011;name pharmaceuticals. All US states have generic substitution statutes. These statutes permit or require the dispensing pharmacist to substitute a less expensive generic drug instead of an original drug. Other countries, including many European countries, have similar laws. We expect that the pressure for generic substitution will continue to increase. In addition, the US, the EU and other jurisdictions are increasingly introducing laws and regulations encouraging the development of biosimilar versions of biologic drugs, which can also be expected to have an impact on pricing.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Cross&#x2011;border sales</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Price controls in one country can have an impact in other countries as a result of cross&#x2011;border sales. In the EU, products that we have sold to customers in countries with stringent price controls can be legally resold to customers in other EU countries at a lower price than the price at which the product is otherwise available in the importing country (known as parallel trade). In North America, products that we have sold to customers in Canada &#x2013; which has relatively stringent price controls &#x2013; are sometimes resold into the US, again at a lower price than the price at which the product is otherwise sold in the US. Such imports from Canada and other countries into the US are currently illegal in most states. However, six US states (Colorado, Florida, Minnesota, New Hampshire, New Mexico, and Vermont) have enacted laws allowing the import of pharmaceutical drugs from select foreign countries. The Secretary of the US Department of Health and Human Services (HHS) must certify that each state&#x2019;s importation plan is safe and cost-effective before it can be implemented. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We expect that pressures on pricing will continue worldwide and will likely increase. Because of these pressures, there can be no certainty that in every instance we will be able to charge prices for a product that, in a particular country or in the aggregate, would enable us to earn an adequate return on our investment in that product. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Intellectual property</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We attach great importance to intellectual property (IP) rights &#x2013; including patents, trademarks, copyrights, know&#x2011;how, trade secrets and regulatory data protection &#x2013; as essential to our purpose of reimagining medicine to improve and extend people&#x2019;s lives, and to protect our investment in research and development, manufacturing and marketing. The IP system provides a means to attract the investments needed to conduct and sustainably finance innovative R&amp;D, and to manage the risks inherent in our work. For example, we seek IP protection under applicable laws for significant product developments in major markets. Among other things, patents may cover the products themselves, including the product&#x2019;s active ingredient or ingredients and its formulation. Patents may cover processes for manufacturing a product, including processes for manufacturing intermediate substances used in the manufacture of the product. Patents may also cover particular uses of a product, such as its use to treat a particular disease, or its dosage regimen. In addition, patents may cover tests for certain diseases or biomarkers &#x2013; which can improve patient outcomes when administered with certain drugs &#x2013; as well as assays, research tools and other techniques used to identify new drugs. The protection afforded, which may vary from country to country, depends upon the type of patent, its duration and its scope of coverage.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the US and other countries, the law recognizes that product development and review by the FDA and other health authorities can take an extended period, and provides an extension of patent term for a period related to the time taken for the conduct of clinical trials and for the health authority&#x2019;s review. However, the length of this extension and the patents to which it applies cannot be known in advance and can only be determined after the product is approved. In practice, it is not uncommon for patent term extensions (PTEs) or supplementary protection certificates (SPCs) to not fully account for the time it took to develop the product and receive marketing authorization. As a result, it is rarely the case, for example, that a `product&#x2019;s active ingredient(s) will have a full patent term at the time the product is approved by the FDA and other health authorities.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition to patent protection, various countries provide regulatory-based protection, including regulatory data protection (RDP) and/or other market exclusivities, for a prescribed period of time. RDP is a distinct type of IP right providing exclusivity that precludes a potential competitor from filing a regulatory application that relies on the sponsor&#x2019;s clinical trial data, or that precludes the regulatory authority from approving the application for a set period of time. The RDP period can vary depending on the type of data included in the sponsor&#x2019;s application. When it is available, market exclusivity, unlike RDP, may preclude a competitor from obtaining marketing approval for a product even if a competitor&#x2019;s application relies on its own data. RDP and market exclusivity periods generally run from the date a product is approved, and so their expiration dates cannot be known with certainty until the product approval date is known and exclusivity has been granted by the relevant authorities.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">United States</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Patents</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In the US, a patent issued from an application filed today will receive a term of 20&#xA0;years from the earliest application filing date, subject to potential patent term adjustments for delays in patent issuance based upon certain delays in prosecution by the United States Patent and Trademark Office (USPTO). A US pharmaceutical patent that claims a product, method of treatment using a product, or method of manufacturing a product may also be eligible for a PTE. This type of extension may only extend the patent term for a maximum of five&#xA0;years, and may not extend the patent term beyond 14&#xA0;years from regulatory approval. Only one patent may be extended for a product based on FDA review.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">RDP and market exclusivity</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Separate from patent exclusivities, the FDA may provide regulatory-based protection, which runs in parallel to any patent protection. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   A new small&#x2011;molecule active pharmaceutical ingredient receives five years of RDP, during which time a competitor generally may not obtain final approval of an </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">36</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">application to the FDA based on a sponsor&#x2019;s clinical data.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   A new biologic active pharmaceutical ingredient receives 12 years of regulatory-based market exclusivity, during which time a competitor generally may not market the same or similar drug. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   The FDA may also request that a sponsor conduct pediatric studies and, in exchange, it will grant an additional six&#x2011;month period of pediatric market exclusivity if the sponsor makes a timely submission of the reports of the pediatric studies in response to the FDA&#x2019;s Written Request. The sponsor must also have a patent&#x2011;based and/or regulatory&#x2011;based exclusivity period for the product to which the pediatric market exclusivity is appended.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Orphan drug exclusivity provides seven years of market exclusivity for drugs designated by the FDA as orphan drugs, meaning drugs that treat rare diseases. During this period, a potential competitor generally may not market the same or similar drug for the same indication even if the competitor&#x2019;s application does not rely on data from the sponsor. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">European Union</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Patents</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Patent applications in Europe may be filed in the European Patent Office (EPO) or in a particular country or countries. The EPO system permits a single application to be granted for the EU plus other non&#x2011;EU countries such as Switzerland, Turkey and the UK. When the EPO grants a patent, it is then validated in the countries that the patent owner designates. The term of a patent granted by the EPO or a European country office is 20&#xA0;years from the earliest application filing date. Pharmaceutical patents can be granted a further period of exclusivity under the SPC system. SPCs are designed, in part, to account for the time taken to receive marketing authorization of a product by the European health authorities. An SPC may be granted to provide, in combination with the patent, up to 15&#xA0;years of exclusivity from the date of the first European marketing authorization. However, an SPC cannot last longer than five&#xA0;years. The SPC duration may be extended by a further six&#xA0;months if the product is the subject of an agreed and successfully completed pediatric investigation plan. The post&#x2011;grant phase of patents, including the SPC system, is currently administered on a country&#x2011;by&#x2011;country basis under national laws that, while differing, are intended to (but do not always) have the same effect.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">RDP and market exclusivity</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Separate from patent exclusivities, the EU provides a system of regulatory data protection for authorized human medicines that runs in parallel to any patent protection. The system for new drugs being approved today is usually referred to as &#x201C;8+2+1&#x201D; because it provides an initial period of eight&#xA0;years of data protection, during which a competitor cannot rely on the relevant data; a further period of two&#xA0;years of market exclusivity, during which the data can be used to support applications for marketing authorization but a competitive product cannot be launched; and a possible one&#x2011;year extension of the market exclusivity period if, during the initial eight&#x2011;year data exclusivity period, the sponsor registered a new therapeutic indication with &#x201C;significant clinical benefit.&#x201D; This system generally applies both to national and centralized authorizations in the EU plus other non-EU countries such as the UK. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The EU also has an orphan drug exclusivity system for medicines. If a medicine is designated as an orphan drug, then it benefits from 10&#xA0;years of market exclusivity after it is authorized, during which time an application for the same or similar medicine for the same indication will not generally be accepted or granted. Under certain circumstances, this exclusivity can be extended with a two&#x2011;year pediatric extension.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Third-party patents and challenges to intellectual property</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Third parties can challenge our IP, including patents, patent term extensions, RDP and marketing exclusivities (such as pediatric extensions and orphan drug exclusivity), through various proceedings. For example, patents in the US can be challenged in the United States Patent and Trademark Office (USPTO) through various proceedings, including Inter Partes Review (IPR) and Post-Grant Review (PGR) proceedings. They may also be challenged through patent infringement litigation under the Abbreviated New Drug Application (ANDA) provisions of the Hatch&#x2011;Waxman Act or under the Biologics Price Competition and Innovation Act (BPCIA). In the EU, patents may be challenged through oppositions in the EPO, or national patents may be challenged in national courts or national patent offices. The outcomes of such challenges can be difficult to predict.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition to directly challenging our IP rights, in some circumstances a competitor may be able to market a generic version of one of our products by, for example, designing around our patents or marketing the generic product for non&#x2011;patent-protected indications, or filing a separate New Drug Application (NDA) under the Hatch-Waxman Act (typically referred to as a 505(b)(2) application). Despite RDP, a competitor could opt to incur the costs of conducting its own clinical trials and preparing its own regulatory application, and avoid our RDP altogether. There is a risk that some countries may seek to impose limitations on or seek not to recognize the availability of IP rights for pharmaceutical products, or limit the extent to which such rights may be enforced. Also, even though we may own, co&#x2011;own or in&#x2011;license patents protecting our products, and conduct freedom&#x2011;to&#x2011;operate analyses, a third party may nevertheless assert that one of our products infringes a third-party patent for which we do not have a license, seeking remedies such as monetary damages or an injunction against our continued marketing of the product.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As a result, there can be no assurance that our IP rights will protect our products or that we will be able to avoid adverse effects from the loss of IP protection or from third-party patents in the future.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intellectual property protection for certain key marketed products and compounds in development</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We present additional details below regarding certain IP protection for the listed Innovative Medicines Division products. For each, we identify issued, unexpired </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">37</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">patents by their general subject matter and, in parentheses, years of expiry, if relevant, in the US and the EU. The identified patents are owned, co&#x2011;owned or exclusively in&#x2011;licensed by Novartis and relate to at least one dosage strength of the product or to the method of treatment or its use as it is currently approved and marketed or, in the case of a compound in development, as it is currently submitted to the FDA and/or the EMA for approval. Identification of an EU patent refers to national patents in EU countries and/or to the national patents that have been derived from a patent granted by the EPO. Novartis may own, co-own, control or have rights to additional patents, for example, relating to compound forms, methods of treatment or use, formulations, devices, processes, product-by-process, synthesis, purification and detection.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We identify unexpired RDP periods and, in parentheses, years of expiry if the relevant marketing authorizations have been authorized or granted. We identify certain unexpired patent term extensions and marketing exclusivities and, in parentheses, years of expiry if they are granted; their subject matter scope may be limited and is not specified. Marketing exclusivities and patent term extensions include orphan drug exclusivity (ODE), pediatric exclusivity (PE), patent term extension (PTE) and supplementary protection certificate (SPC). We designate these as &#x201C;pending&#x201D; if they have been applied for but not granted and include years of expiry if estimable. Such pending applications ultimately may or may not be granted. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the case of the EU, identification of a patent, supplementary protection certificate, marketing exclusivity or regulatory data protection means grant, authorization and maintenance in at least one EU country or the UK. However, it could be pending, not granted, expired or found invalid in others. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For each product below, we indicate whether there is current generic or biosimilar competition for one or more product versions in one or more approved indications in either the US or one or more EU countries, if IP is otherwise disclosed. We identify certain enforcement actions, or ongoing challenges to the disclosed IP, including IPRs or PGRs if instituted by the USPTO, that have not been finally resolved (including appeals) unless noted. Challenges identified as being in administrative entities, such as national patent offices, include judicial appeals from decisions of those entities. Resolution of challenges to the disclosed IP, which in the EU may involve IP in one or more EU countries, may include settlement agreements under which Novartis permits or does not permit future launch of generic versions of our products before expiration of that IP. We identify certain material terms of such settlement agreements where they could have a material adverse effect on our business. In other cases, such settlement agreements may contain confidentiality obligations restricting what may be disclosed.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the event that a product listed below does not have identified patents as described above, we provide information only on generic competition.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">For additional information regarding commercial arrangements with respect to these products, see &#x201C;&#x2014;Key marketed products.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Cardiovascular</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Entresto</i>.  US: Four patents on combination (2023 (4)), PTE (2025), four PEs (2023, 2023, 2024, 2025); two patents on complex (2026, 2027), two PEs (2027, 2027); three patents on methods of treatment (2033 (3)); patent on dosage regimen (2036); RDP for new pediatric patient population (2022), PE (2023); RDP for labeling changes related to new clinical investigation (2024). EU: Patent on combination (2023), SPC (2028); two patents on complex (2026, 2026), two SPCs (2030, 2030); patent on formulation (2028); patent on method of use (2034); RDP (2025). There is no generic competition in the US or the EU. In the US, two combination patents, the two complex patents, and the dosage regimen patent are being challenged in ANDA proceedings against generic manufacturers. In the EU, one complex patent and the use patent are being opposed in the EPO. In some EU countries, the combination patent or its associated SPC is being challenged by generic manufacturers.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Leqvio</i>. US: Two patents on composition of matter (2027, 2034), PTE pending (2035); two patents on method of treatment and dosing regimen (2027, 2036); RDP (2026). EU: One patent on composition of matter (2033), SPC (2035); RDP (2030). There is no generic competition in the US or the EU. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Immunology</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Cosentyx</i>. US: Five patents on composition of matter (2025 (4), 2026), PTE (2029); patent on psoriatic arthritis use (2031); patent on psoriasis use (2032); two patents on ankylosing spondylitis use (2032, 2033); RDP (2027). EU: Four patents on composition of matter (2025 (4)), SPC (2030), PE (2030); patent on psoriasis use (2031); patent on ankylosing spondylitis use (2031); RDP (2026). There is no generic competition in the US or the EU. In the EU, the patent on ankylosing spondylitis use is being opposed in the EPO.  </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <i>&#x2022;</i>
        <i>  Xolair</i>. US: Two patents on syringe formulation (2024, 2025). EU: Three patents on syringe formulation (2024, 2024, 2025). There is no generic competition in the US or the EU. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Ilaris</i>. US: Patent on composition of matter (2024); patent on cryopyrin&#x2011;associated periodic syndromes use (2026); patent on familial Mediterranean fever (FMF) use (2026); patent on systemic onset juvenile idiopathic arthritis (SJIA) use (2028); patent on hyperimmunoglobulin D syndrome and tumor necrosis factor receptor-associated periodic syndrome use (2029); patent on formulation (2029). EU: Patent on composition of matter (2021), SPC (2024), PE (2025); patent on SJIA use (2026); patent on FMF use (2026); two patents on formulation (2029, 2029). There is no generic competition in the US or the EU.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Neuroscience</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <i>&#x2022;</i>
        <i>  Gilenya.</i> US: Patent on dosage regimen (2027), PE (2027); patent on 0.25&#xA0;mg formulation (2032), PE (2032); patent on method of treatment (2027). EU: Patent on formulation (2024), SPC (2026); patent on </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">38</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">0.25&#xA0;mg formulation (2032); patent on dosing regimen (2027). There is generic competition in the US and in most EU countries. In the US, the dosage regimen patent was challenged in ANDA proceedings against a generic manufacturer and was found invalid by the US Court of Appeals for the Federal Circuit in June 2022.  Novartis has filed a petition seeking further review with the US Supreme Court. Novartis is also enforcing the method of treatment patent against a generic manufacturer. In the EU, Novartis is enforcing the dosing regimen patent against generic manufacturers. The dosing regimen patent is being opposed in the EPO.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <i>&#x2022;</i>
        <i>  Zolgensma</i>. US: Four patents on composition of matter (2024, 2024, 2026, 2033), PTE pending (2029); three patents on methods of treatment (2028, 2028, 2029); ODE for spinal muscular atrophy (SMA) in patients less than 2 years old with biallelic mutations in the SMN1 gene (2026); RDP (2031). EU: Three patents on composition of matter (2024, 2024, 2028), SPC (2029); two patents on methods of use (2028, 2028), SPC (2033), SPC pending (2033); ODE for SMA in patients with a biallelic mutation in the SMN1 gene and a clinical diagnosis of SMA type 1, or patients with a biallelic mutation in the SMN1 gene and up to three copies of the SMN2 gene (2030); RDP (2030). There is no generic competition in the US or the EU.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Kesimpta</i>. US: Patent on compound (2031); patent on dosing regimen (2037). EU: Patent on compound (2023); patent on use (2023), SPC (2028); patent on formulation (2028), patent on formulation and use (2028), SPC (2033); patent on dosing regimen (2037). There is no generic competition in the US or the EU.  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Solid Tumor</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Tafinlar</i> and <i>Mekinist</i>.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">
        <i>Tafinlar.</i> US: Two patents on compound (2030, 2030); patent on method of treatment (2029). EU: Patent on compound (2029); RDP (2024). There is no generic competition in the US or the EU. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">
        <i>Mekinist</i>. US: Patent on compound (2025), PTE (2027); patent on method of treatment (2025); four patents on formulation (2032 (4)). EU: Patent on compound (2025), SPC (2029); patent on formulation (2031); RDP (2025). There is no generic competition in the US or the EU. In the EU, the formulation patent is being opposed in the EPO.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">Use of <i>Mekinist</i> with <i>Tafinlar</i> or <i>Tafinlar</i> with <i>Mekinist</i>. US: Patent on combination (2030); four patents on method of use of combination (2025, 2030, 2030, 2033); ODE on non&#x2011;small cell lung cancer (2024); ODE on adjuvant treatment of melanoma (2025); ODE on anaplastic thyroid cancer (2025); ODE on metastatic solid tumors (2025). EU: Patent on combination (2030); patent on adjuvant for melanoma use (2033). There is no generic competition in the US or the EU. In the EU, the adjuvant use patent is being opposed in the EPO.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <i>&#x2022;</i>
        <i>  Kisqali.</i> US: Three patents on compound (2028, 2030, 2031), PTE (2031); three patents on methods of treatment (2029, 2029, 2031); patent on salt form (2031); patent for tablet formulation (2036). EU: Patent on compound (2027); patent on compound (2029), SPC (2032); patent on salt form (2031); patent on methods of use with letrozole (2034); patent on formulation (2036); RDP (2027). There is no generic competition in the US or the EU. In the US, the three compound patents, the three method of treatment patents, the salt patent and the formulation patent are being challenged in ANDA proceedings against generic manufacturers. In the EU, the method of use patent is being opposed in the EPO.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;    <i>Piqray</i>. US: Patent on compound (2029); patent on compound and use (2029), PTE pending (2033); RDP (2024). EU: Patent on compound and use (2029), SPC (2034); RDP (2030). There is no generic competition in the US or the EU.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;    <i>Pluvicto</i>. US: Three patents on composition of matter (2028, 2028, 2034); RDP (2027). PTE pending. EU: RDP (2032). There is no generic competition in the US or the EU.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Hematology</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Promacta</i>/<i>Revolade</i>. US: Patent on compound (2021), PTE (2022), PE (2023); patent on method of enhancing platelet production using salt (2023), PE (2023); patent on salt form and thrombocytopenia use (2025), PE (2026); five patents on tablet formulations of different dose strengths (2027 (5)), five PEs (2028 (5)); ODE on severe aplastic anemia patients in combination with standard immunosuppressive therapy (2025). EU: Patent on compound (2021), SPC (2025), PE (2025); patent on salt form (2023); patent on severe aplastic anemia use (2028). There is no generic competition in the US or the EU. In the US, generic manufacturers have filed ANDAs challenging certain patents other than the compound patent. In the EU, the severe aplastic anemia use patent is being opposed in the EPO.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; <i>Tasigna.</i> US: Patent on compound (2023), PE (2024); two patents on salt forms (2026, 2028), two PEs (2027, 2029); patent on polymorph compound form (2026), PE (2027); two patents on capsule form (2026, 2027), two PEs (2027, 2028); patent on method of treatment (2032), PE (2032). EU: Patent on compound (2023); patent on salt form (2026); patent on polymorph compound form (2026); patent on capsule form (2027); patent on method of treatment (2030). There is no generic competition in the US or the EU. In the US, generic manufacturers have filed ANDAs challenging certain patents other than the compound patent. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <i>&#x2022;</i>
        <i>  Jakavi</i>. EU: Patent on compound (2026), SPC (2027); two patents on salt form (2028, 2028); patent on compound for polycythemia vera (PV) use (2026); patent on salt form for graft-versus-host disease (GvHD) use (2028). There is no generic competition in the EU<i>.</i></div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">39</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;    <i>Scemblix</i>. US: Patent on compound (2033), PTE pending (2035); Patent on polymorph compound form (2040); RDP (2026); ODE (2028). EU: Patent on compound (2033), SPC pending (2037); RDP (2032); ODE&#xA0;(2032). There is no generic competition in the US or the EU.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Other Promoted Brands</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Lucentis.</i> EU:  There is generic competition in some EU markets.  </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Xiidra</i>. US: Four patents on compound (2024, 2024, 2025, 2026); two patents on formulation (2024, 2033); five patents on method of treatment (2024, 2024, 2026, 2029, 2029); one patent on polymorph compound form (2029). PTE pending. There is no generic competition in the US. <i>Xiidra</i> is not marketed in the EU. In the US, the compound, compound and use, formulation, method of treatment, and polymorph compound form patents are being challenged in ANDA proceedings against generic manufacturers. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Established Brands</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Sandostatin</i> SC and <i>Sandostatin</i> LAR: </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">
        <i>Sandostatin</i> SC: There is generic competition in the US and the EU.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">
        <i>Sandostatin</i> LAR: There is generic competition in most EU countries but no generic competition in the US.    </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Compounds in development </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We provide certain patent information for non&#x2011;marketed compounds in development that have been submitted to the FDA and/or the EMA for registration but have not yet been approved by either agency. For these products, Novartis will seek all appropriate RDP, will continue to seek additional intellectual property protection for significant product developments, and will apply for PTEs and SPCs in keeping with the great importance we attach to intellectual property.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  VDT482 (tislelizumab). US: Patent on composition of matter (2033). EU: Patent on composition of matter (2033).</div>
      <div id="anchorId00315155"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Sandoz</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Sandoz Division is a global leader in generic pharmaceuticals and biosimilars, and sells products in well over 100 countries. In 2022, the Sandoz Division achieved consolidated net sales of USD 9.2&#xA0;billion, representing 18.3% of the Group&#x2019;s total net sales. Sandoz develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sandoz is organized globally into three franchises: Retail Generics, Anti&#x2011;Infectives and Biopharmaceuticals. In Retail Generics, Sandoz develops, manufactures and markets finished dosage forms of small-molecule pharmaceuticals for sale to third parties across a broad range of therapeutic areas, including finished dosage form anti-infectives sold to third parties. In Anti&#x2011;Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates &#x2013; mainly antibiotics &#x2013; for internal use by Retail Generics and for sale to third&#x2011;party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein&#x2011; and other biotechnology&#x2011;based products, including biosimilars.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Sandoz strategic ambition is to be the world&#x2019;s leading and most valued generics and biosimilars company . Our divisional strategy focuses on three areas: developing a broad and consistent pipeline of generic and biosimilar launches across key geographies and across a broad range of therapeutic areas; positioning Sandoz to be &#x201C;first in&#x201D; by having a strong pipeline with a focus on being first to market and &#x201C;last out&#x201D; by way of competitive costs and stable supply; and instilling a true &#x201C;generic mindset,&#x201D; with a focus on priorities, simple and rapid decision-making, and focused resource allocation.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sandoz is a global market leader in biosimilars, with a total of eight approved and marketed products, and a pipeline of over 15 molecules. In addition to internally developed projects, our biosimilar portfolio comprises publicly announced commercialization agreements with BioCon, Gan &amp; Lee, EirGenix, Polpharma Biologics and Bio-Thera Solutions Ltd. Availability of our biosimilars varies by country.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sandoz is also the global market leader in generic antibiotics. Its Kundl, Austria, manufacturing site is the hub of the last fully vertically integrated penicillin production chain in Europe, which offers certain competitive advantages including added supply chain resilience. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In January 2020, we closed the previously announced acquisition of the Japanese business of Aspen Global Incorporated, consisting of off-patent branded medicines with a focus on anesthetics and specialty brands.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In July 2020, Sandoz and the Austrian government announced a planned combined investment of more than EUR 150 million to enhance the long-term competitiveness and supply resilience of European production for key antibiotics. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In May 2021, Sandoz confirmed details of a previously announced investment of EUR 100 million in antibiotic manufacturing technology for its Kundl, Austria, manufacturing site, and announced an additional EUR 50 million investment in a new sterile production line in Palafolls, Spain. In November 2022, Sandoz announced an additional EUR 50 million investment to support increased manufacturing capacity for finished dosage form penicillin at its Kundl, Austria, manufacturing site.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In October 2021, Sandoz announced that its planned acquisition of GSK&#x2019;s global cephalosporin antibiotics business, first announced in February 2021, had been successfully closed.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">On October 1, 2021, Sandoz Inc., the US subsidiary of Sandoz, entered into a settlement agreement with the Civil Division of the US Department of Justice (DOJ) concerning the department&#x2019;s years-long pricing investigation into the US generic drug industry. This settlement </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">40</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">was an expected outcome of the resolution the company reached in March 2020 with the DOJ Antitrust Division regarding the same investigation and underlying conduct. As part of the settlement, Sandoz agreed to certain corporate integrity obligations as part of a corporate integrity agreement with the Office of Inspector General of the US Department of Health and Human Services, which have now been implemented. The settlement contains no new factual allegations against Sandoz and, in 2020, the Group fully provisioned for this settlement and disclosed the agreement in principle as part of the March 2020 resolution. For more information, see &#x201C;Item 18. Financial Statements&#x2014;Note 20. Provisions and other non-current liabilities.&#x201D;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In August 2022, Novartis announced its intention to separate the Sandoz business to create a standalone company by way of a 100% spin-off, concluding the Strategic Review announced in October 2021. The Strategic Review determined that a 100% spin-off would be in the best interests of shareholders as it would create two standalone companies focused on their respective growth strategies. The new company is planned to be incorporated in Switzerland and to be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in the US. Completion of the transaction is subject to certain conditions, including consultation with works councils and employee representatives (as required), general market conditions, tax rulings and opinions, final Board of Directors endorsement and shareholder approval in line with Swiss corporate law. The transaction is expected to be generally tax neutral to Novartis, with completion expected in the second half of 2023.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Key marketed products</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Sandoz global portfolio covers a wide range of therapeutic areas. The following are some of the Sandoz key marketed products in each of its franchises (availability varies by market):</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Retail Generics</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="top">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">Product</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Originator drug</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Description</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amoxicillin/clavulanic acid</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Augmentin<sup style="white-space: nowrap">&#xA0;&#xAE;</sup></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Antibiotic</div>
            </td>
            <td align="left" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Zoledronic acid</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> Aclasta</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Osteoporosis treatment</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acetylcysteine</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Various</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Mucolytic agent</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tacrolimus</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Various</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunosuppressive agent</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Anti&#x2011;Infectives</span>
      </div>
      <div style="padding-top:10px; padding-bottom:10px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="top">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">Active ingredients</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Description</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;width:48%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oral and sterile penicillins</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left" style=";width:48%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti&#x2011;infectives</div>
            </td>
            <td align="left" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oral and sterile cephalosporins</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti&#x2011;infectives</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Clavulanic acid and mixtures with clavulanic acid</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Beta&#x2011;lactam inhibitors</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Classical and semisynthetic macrolides</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti&#x2011;infectives</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="top">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">Intermediates</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Description</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;width:48%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Various cephalosporin intermediates</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left" style=";width:48%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti&#x2011;infectives</div>
            </td>
            <td align="left" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Macrolide base intermediates</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti&#x2011;infectives</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Various crude compounds produced by fermentation</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cyclosporine, ascomycin, rapamycin, mycophenolic acid, etc.</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">41</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Biopharmaceuticals</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="top">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">Product</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Originator drug</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Description</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Omnitrope</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Genotropin  <sup style="white-space: nowrap">&#xA0;&#xAE;</sup></div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Recombinant human growth hormone to treat growth   disorders and growth hormone deficiency</div>
            </td>
            <td align="left" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Binocrit</i> and Epoetin alfa <i>Hexal</i></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Eprex<sup>&#xAE;</sup>/Erypo  <sup style="white-space: nowrap">&#xA0;&#xAE;</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Recombinant protein (erythropoiesis-stimulating) agent  to treat anemia</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Zarzio</i>, <i>Zarxio</i> and Filgrastim <i>Hexal</i></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neupogen  <sup style="white-space: nowrap">&#xA0;&#xAE;</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Recombinant protein (granulocyte colony-stimulating   factor, short-acting) used in oncology</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Glatopa</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Copaxone<sup style="white-space: nowrap">&#xA0;&#xAE;</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Treatment for relapsing forms of multiple sclerosis</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Erelzi<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Enbrel  <sup style="white-space: nowrap">&#xA0;&#xAE;</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Fusion protein (TNF-alpha receptor) to treat multiple   immune-mediated inflammatory diseases</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Rixathon</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MabThera    <sup style="white-space: nowrap">&#xA0;&#xAE;</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chimeric monoclonal antibody (directed against   CD20 protein on B-cells) to treat blood cancers   and immunological diseases</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Hyrimoz</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Humira  <sup style="white-space: nowrap">&#xA0;&#xAE;</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Monoclonal antibody (TNF-alpha antibody) to treat multiple   immune-mediated inflammatory diseases</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zessly</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Remicade  <sup style="white-space: nowrap">&#xA0;&#xAE;</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Monoclonal antibody (TNF-alpha antibody) to treat multiple   immune-mediated  inflammatory diseases</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ziextenzo</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neulasta        <sup style="white-space: nowrap">&#xA0;&#xAE;</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PEGylated form of a recombinant human granulocyte   colony-stimulating factor (long-acting) to   reduce duration of chemotherapy-induced neutropenia   and incidence of chemotherapy-induced febrile   neutropenia</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Approved in the US in 2016. In patent litigation with Amgen, which markets Enbrel&#xAE;, the US District Court of New Jersey ruled against Sandoz in August 2019, which was upheld on appeal. The decision is final and Sandoz cannot launch its <i>Erelzi</i> product in the US until 2029.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Selected development projects &#x2013; biosimilars in Phase&#xA0;III development and registration</span>
      </div>
      <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table describes Sandoz biosimilar projects that are in registration trial or in registration with a regulatory agency (including filing preparation):</div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="top">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">Project/<br />product</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Common <br /> name (INN)</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Mechanism of action</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Potential indication/indications</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Therapeutic areas</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Route of<br /> administration</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Current phase</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">GP2411</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> denosumab  </div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti-RANKL   monoclonal antibody</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Osteoporosis (same as originator)  </div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Endocrinology,   Neurology</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous  </div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Phase III  </div>
            </td>
            <td align="left" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">SOK583</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> aflibercept  </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Recombinant fusion protein   that blocks VEGF-A</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology indication (same as originator)  </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Ophthalmology  </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravitreal  </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Phase III  </div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">EGI014A1<sup>1</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> trastuzumab    </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti-HER2 recombinant   IgG1, humanized   monoclonal antibody</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HER2+ cancer tumors    </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology    </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous    </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Registration    </div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">DST356A1<sup>2</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> natalizumab  </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Anti-alpha4 integrin   monoclonal antibody</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Multiple sclerosis and Crohn&#x2019;s disease  </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neurology,   Immunology (US only)</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous  </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Registration  </div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">HFT896,  SMQ969,  PYB106<sup>3</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> insulin glargine,   lispro, aspart  </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Long-acting (HFT896)/   rapid-acting insulin  </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Diabetes    </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Endocrinology,   Diabetology  </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Subcutaneous    </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Phase III/  Phase I  </div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">VVF379<sup>4</sup></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bevacizumab    </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Recombinant humanized   monoclonal antibody that   blocks VEGF</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid tumors    </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Oncology    </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Intravenous    </div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Registration    </div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Development in collaboration with EirGenix, Inc.</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Development in collaboration with Polpharma Biologics</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Development in collaboration with Gan &amp; Lee</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> Development in collaboration with Bio-Thera Solutions</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">42</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Principal markets</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The two largest generics markets in the world &#x2013; the US and Europe &#x2013; are the principal markets for Sandoz. The following table sets forth the aggregate 2022 net sales of Sandoz by region:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022 net sales  to third parties</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> USD millions</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;913</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 53</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United States</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;754</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia, Africa, Australasia</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;613</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 969</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&#xA0;249</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Of which in Established Markets<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&#xA0;460</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Of which in Emerging Growth Markets<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;789</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Many Sandoz products are used for chronic conditions that require patients to consume the product over long periods of time, from months to years. Sales of our anti&#x2011;infective products and over-the-counter cough and cold products are subject to material changes in seasonal demand, while sales of the vast majority of our other products are not. The COVID-19 pandemic has substantially impacted seasonal variation in recent years. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Production</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For information on the production of our products, see &#x201C;&#x2014;Item 4.B Business overview&#x2014;Innovative Medicines&#x2014;Production.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In September 2020, as part of a broader reorganization of Novartis Technical Operations (NTO), we established the Sandoz Technical Operations (STO) platform within NTO. STO focuses on producing generic medicines for Sandoz, as well as related external supply operations and supply chain. In October 2021, Sandoz created a new position, Global Head, Sandoz Operations. This new, broader role, includes full operational and financial accountability for manufacturing and supply as of January 1, 2023, and was established in anticipation of the intended Sandoz 100% spin-off. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Due to impurities found in the active ingredient batches sourced from third-party manufacturers, we recalled Sandoz valsartan, losartan and irbesartan products in the second half of 2018 and the first quarter of 2019, and ranitidine film-coated tablets in the second half of 2019, from several markets, in line with our quality standards for all of our marketed products. The discovery of nitrosamines in some types of drug products led several health regulators (e.g., EMA, FDA and others) to conduct a detailed analysis of these impurities in affected medicinal products. Novartis works with health authorities around the world to continuously review all chemical and biological human medicines for the possible presence of nitrosamines. The EMA, FDA and other health authorities have provided guidance to the pharmaceutical industry to prevent unacceptable levels of nitrosamines in medicines. The EMA review concluded in March 2021 for chemical human medicines and in July 2021 for biological human medicines. Based on guidance from health authorities, any chemical and/or biological human medicines products identified with a potential risk for nitrosamines will undergo further testing. For these products, we have provided initial testing and potential control strategy updates to the EMA and other health authorities. Due to constant and rapidly evolving health authority requirements, the risk assessment and related testing that we may be required to perform may increase.  We will submit and communicate the final outcome of any risk assessment and related testing to the relevant health authorities within their expected time frame, and make changes to the control strategy update, if necessary.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Beginning in September 2021, we initiated a voluntary recall of all finished product batches of losartan and losartan HCT products exceeding or potentially exceeding acceptable regulatory limits of the losartan azide impurity in the losartan drug substance. This impurity, which is viewed as an industrywide issue, was initially considered a mutagen that may increase the risk of cancer over time if allowed to rise above certain levels. This recall was unrelated to the nitrosamine-related recalls described above, and supply was re-established in March 2022. Since the voluntary recall, further information has been provided to the EMA by Novartis and other companies in the industry, and the EMA has concluded that the losartan azide impurity is to be classified as a non-mutagenic impurity.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Marketing and sales</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sandoz sells a broad portfolio of products, including the products of our Retail Generics franchise and biosimilars, to wholesalers, pharmacies, hospitals and other healthcare outlets. Sandoz adapts its marketing and sales approach to local decision-making processes, depending on the structure of the market in each country.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In response to rising healthcare costs, many governments and private medical care providers, such as health </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">43</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">maintenance organizations, have instituted reimbursement schemes that favor the substitution of bioequivalent generic versions of originator pharmaceutical products, such as those sold by our Retail Generics franchise. In the US, statutes have been enacted by all states that permit or require pharmacists to substitute a less expensive generic product for the brand&#x2011;name version of a drug that has been prescribed to a patient. Generic use is growing in Europe, but penetration rates in many EU countries (as a percentage of volume) remain well below those in the US.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Recent trends have been toward continued consolidation among distributors and retailers of Sandoz products, both in the US and internationally, which has increased our customers&#x2019; purchasing leverage.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Legislative or regulatory changes can have a significant impact on our business in a country. For more information on such changes, see &#x201C;&#x2014;Item 4.B Business overview&#x2014;Innovative Medicines&#x2014;Price controls.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our Anti&#x2011;Infectives franchise supplies active pharmaceutical ingredients and intermediates &#x2013; mainly antibiotics &#x2013; for internal use by Retail Generics and for sale to the pharmaceutical industry worldwide.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our Biopharmaceuticals franchise operates in an already mature market framework in Europe and some other markets, while the business environment is rapidly evolving in the US and many international markets. Regulatory pathways for approving biosimilar products are at various stages of maturity by market, but in some cases are still relatively new or still in development. Policies have not yet been fully defined or implemented regarding the substitution and reimbursement of biosimilars in many markets, including the US. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Competition</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The market for generic products is characterized by increasing demand for high&#x2011;quality pharmaceuticals that can be marketed at lower costs due to comparatively minimal initial research and development investments. Increasing pressure on healthcare expenditure and numerous patent and data exclusivity period expirations have encouraged more generic product launches, resulting in increased competition among the companies selling generic pharmaceutical products, leading to ongoing price pressure. In particular, Sandoz faces increased industrywide pressure on prices for generic products, particularly in the US, driven by factors including customer consolidation and growing competition from other manufacturers of generic medicines. These factors contributed to a decline in industrywide US sales that began in 2017 and continued through 2022. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Development and registration</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Development of Sandoz Biopharmaceuticals is jointly overseen by Sandoz and GDD, and is governed by the IMB. Development and registration activities for Retail Generics products, and registration activities for Biopharmaceuticals products, are also overseen by Sandoz.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Before a generic pharmaceutical may be marketed, intensive technical and clinical development work must be performed to demonstrate, in bioavailability studies, the bioequivalence of the generic product to the reference product. Nevertheless, research and development costs associated with generic pharmaceuticals are generally much lower than those of the originator pharmaceuticals, as no original drug discovery, preclinical studies or clinical trials on dose finding, safety and efficacy are typically performed by the generics company. As a result, the different focus and lower costs of the generic pharmaceutical model ultimately allow generic pharmaceutical products to be offered at lower prices, which support and contribute to the cost containment goals of healthcare systems.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">While generic pharmaceuticals are follow&#x2011;on versions of chemically synthesized molecules, biosimilar products contain a version of the active substance of an already approved biological reference medicine. Due to the inherent variability and complexity of biologic products, including batch&#x2011;to&#x2011;batch differences and variations following manufacturing changes, the development and the regulatory pathway of biosimilars differ significantly from that of generics.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The development of a biosimilar product is much more technically challenging than the development of a typical generic small-molecule pharmaceutical. While generic pharmaceuticals normally do not require clinical studies in patients, regulators worldwide do still require such targeted studies for biosimilar products. International regulators are nonetheless increasingly discussing the potential for &#x201C;tailored development&#x201D; (which refers to proposals that seek to implement a more efficient and expedited biosimilar development process that eliminates the current need for comparative clinical efficacy and safety studies of biosimilars, without any resulting compromise on quality, safety or efficacy) for certain molecules. Biosimilars are engineered to match the reference medicine in quality, safety and efficacy. This is achieved by systematically defining the target range of the reference medicine and then comparing the biosimilar to the reference medicine at various development stages to confirm biosimilarity and to establish that there are no clinically meaningful differences between the proposed biosimilar and the reference biologic. Because the purpose of a biosimilar clinical development program is to confirm biosimilarity and not to establish efficacy and safety de novo, the clinical studies required are less than those required for a reference biologic. Therefore, the cost of development for a biosimilar is usually less than that of a reference biologic.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The development and registration staff employed by affiliates of the Sandoz Division are based worldwide, including at facilities in Holzkirchen, Germany; Hyderabad, India; Kundl, Austria; Ljubljana, Slovenia; and Rudolstadt, Germany. In November 2020, Sandoz completed (i) the previously announced closure of the Holzkirchen, Germany, development and registration site, with the exception of patch development and the project management group, and (ii) the closure of the product development and registration site as well as the maintenance and development regulatory centers in Unterach, Austria. We conduct an ongoing review of our global development and regulatory network to consolidate and streamline operations and optimize our network structure to enable Sandoz to compete sustainably in an increasingly challenging generics environment. In 2021, Sandoz completed the previously announced closures of its maintenance regulatory center in Barleben, Germany, its Fougera development center located in </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">44</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Melville, New York, as well as its product development center in Boucherville, Canada.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Regulation</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Generics</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Hatch&#x2011;Waxman Act in the US (and similar legislation in the EU and in other countries) eliminated the requirement that manufacturers of generic pharmaceuticals repeat the extensive clinical trials required for reference products, so long as the generic version could be shown to be therapeutically equivalent to the reference product.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the US, the decision on whether a generic pharmaceutical is therapeutically equivalent to the original product is made by the FDA based on an Abbreviated New Drug Application (ANDA) filed by the generic product&#x2019;s manufacturer. An ANDA is generally permitted to be filed four years after the initial approval of the reference product and generally cannot be fully approved by the FDA until any regulatory exclusivity of the reference product has expired. The process typically takes nearly two years from the filing of the ANDA until FDA approval. However, delays can occur if issues arise, for example, regarding the interpretation of bioequivalence study data, labeling requirements for the generic product, or qualifying the supply of active ingredients. In addition, the Hatch&#x2011;Waxman Act requires a generic manufacturer to certify in certain situations that the generic product does not infringe on any current applicable patents on the product held by the holder of the marketing authorization for the reference product, or to certify that such patents are invalid. This certification often results in a patent infringement lawsuit being brought against the generics company. In the event of such a lawsuit, the Hatch&#x2011;Waxman Act imposes an automatic 30-month stay in the approval of the ANDA to allow the parties to resolve the intellectual property issues. For generic applicants who are the first to file their ANDA containing a certification claiming non&#x2011;infringement or patent invalidity, the Hatch&#x2011;Waxman Act generally provides those applicants with 180&#xA0;days of marketing exclusivity, enabling such generic applicants to exclusively market their product alongside the reference product at a certain point in time, which is generally after any intellectual property issues have been resolved. However, after such point in time, the generic applicants must launch their products within certain time frames or risk losing the marketing exclusivity that they had gained by being a first-to-file applicant.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the EU, decisions on the granting of a marketing authorization are made either by the European Commission based on a positive recommendation by the EMA under the centralized procedure, or by a single member state under the national or decentralized procedure. See &#x201C;&#x2014;Innovative Medicines&#x2014;Regulation&#x2014;European Union.&#x201D; Companies may submit abridged applications for approval of a generic medicinal product based upon its &#x201C;essential similarity&#x201D; to a medicinal product authorized and marketed in the EU following the expiration of the product&#x2019;s data exclusivity period. In such cases, the generics company is able to submit its abridged application based on the data submitted by the innovator company for the reference product, without the need to conduct extensive Phase&#xA0;III clinical trials of its own. For all products that received a marketing authorization in the EU after late 2005, the abridged application can be submitted throughout the EU. However, the data submitted by the innovator company in support of its application for a marketing authorization for the reference product is generally protected for 10 years after the first grant of marketing authorization in all member states, and can be extended for an additional year if, during the initial eight&#x2011;year data exclusivity period, the innovator company registers a new therapeutic indication with &#x201C;significant clinical benefit.&#x201D; In the case of orphan drugs, it may be extended with a two&#x2011;year pediatric extension. See &#x201C;&#x2014;Item 4.B Business overview&#x2014;Innovative Medicines&#x2014;Intellectual property.&#x201D; </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Biosimilars</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The regulatory pathways for approval of biosimilar medicines are still being developed and established in many countries of the world. A regulatory framework for the approval of biosimilars has been established in the EU, Japan, Canada and the US, while the World Health Organization (WHO) has issued guidance. Sandoz has successfully registered and launched the first biosimilar (or biosimilar-type) medicine in Europe, the US, Canada, Japan, Taiwan, Australia, and many countries in Latin America and Asia. Sandoz was the first company to secure approval for and launch a biosimilar under the US biosimilar pathway that was established as part of the Biologics Price Competition and Innovation Act (BPCIA). The approval of biosimilars in Europe follows a process similar to that followed for small molecules. However, biosimilars usually have to be approved through the centralized procedure because they are manufactured using recombinant DNA technology. As part of the approval process in the EU, biosimilars have to demonstrate comparability to the reference medicine in terms of safety, efficacy and quality through an extensive comparability exercise, based on strict guidelines set by the authorities. Regulators will only approve a biosimilar based on data that allows the regulators to conclude that there are no clinically meaningful differences between the reference medicine and the biosimilar.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the US, under the BPCIA, a biosimilar must be highly similar with no clinically meaningful differences compared to the reference medicine. Approval of a biosimilar in the US requires the submission of a BLA to the FDA, including an assessment of immunogenicity and pharmacokinetics; an efficacy study; and possibly a pharmacodynamics study. The BLA for a biosimilar can be submitted as soon as four years after the initial approval of the reference biologic, but can only be approved 12&#xA0;years after the initial approval of the reference biologic. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Intellectual property</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We take all reasonable steps to ensure that our products do not infringe valid intellectual property rights held by others, including taking steps to proactively challenge intellectual property rights that we believe should not have been granted. Nevertheless, competing companies </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">45</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">commonly assert patent and other intellectual property rights. As a result, we can become involved in significant litigation regarding our products. If we are unsuccessful in defending these suits, we could be subject to injunctions preventing us from selling our products and to potentially substantial damages.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Wherever possible, our products are protected by our own patents. Among other things, patents may cover the products themselves, including the product&#x2019;s formulation, or the processes for manufacturing a product. However, there can be no assurance that our intellectual property will protect our products or that we will be able to avoid adverse effects from the loss of intellectual property protection in the future.</div>
      <div id="anchorId00316061"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">4.C Organizational structure</p>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Organizational structure</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">See &#x201C;Item&#xA0;4. Information on the Company&#x2014;Item&#xA0;4.A History and development of Novartis&#x201D; and &#x201C;Item&#xA0;4. Information on the Company&#x2014;Item&#xA0;4.B Business overview&#x2014;Overview.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant subsidiaries</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">See &#x201C;Item 18. Financial Statements&#x2014;Note 31. Principal Group subsidiaries and associated companies.&#x201D;</div>
      <div id="anchorId00316079"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">4.D Property, plants and equipment</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our principal executive offices are located in Basel, Switzerland. Our divisions operate through a number of affiliates that have offices, research and development facilities, and production sites throughout the world.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We generally own our facilities or have entered into long-term lease arrangements for them. Some of our principal facilities are subject to mortgages and other security interests granted to secure certain debts. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis Operations manages the production, supply chains and quality of our Innovative Medicines and Sandoz Division products through a network of 55 manufacturing sites, as well as through external suppliers, and warehouse and distribution centers. In addition, Novartis Operations also manages non-production real estate owned or leased by Novartis around the world.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table sets forth our major headquarters and most significant production, research and development, and administrative facilities. See also &#x201C;&#x2014;Item 4.B Business overview&#x2014;Innovative Medicines&#x2014;Production&#x201D; and &#x201C;&#x2014;Item 4.B Business overview&#x2014;Sandoz&#x2014;Production&#x201D; for a discussion of our manufacturing processes.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Major facilities</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="top">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />Location</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Size of site <br /> (in square meters)</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Major activity</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel, Switzerland &#x2013; St.&#xA0;Johann</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 589&#xA0;000    </div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Global Group headquarters; global Innovative Medicines Division headquarters;   global Sandoz Division headquarters; research and development;   production of drug substances and drug intermediates</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kundl and Schaftenau, Austria</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 480&#xA0;000  </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Production of biotechnological products, drug products and finished products,   anti&#x2011;infectives, active drug substances and nucleic acids; product development</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, New Jersey</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 391&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Innovative Medicines Division US headquarters; research and development</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Barleben, Germany</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 340&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Production of broad range of generics finished dosage forms</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cambridge, Massachusetts</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 201&#xA0;800</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Research and development</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Menges, Slovenia</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 133&#xA0;763</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Production of drug substances and drug intermediates</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shanghai, China</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 106&#xA0;500</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Research and development</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Stein, Switzerland</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64&#xA0;700  </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Production of sterile vials, pre&#x2011;filled syringes and ampoules; inhalation capsules,   tablets and transdermals; active pharmaceutical ingredients; and cell and gene therapies</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Holzkirchen, Germany</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64&#xA0;200  </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Sandoz Division production of transdermal delivery systems and certain international   and global service functions.</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Huningue, France</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Production of drug substances for clinical and commercial supply</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Durham, North Carolina</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&#xA0;794  </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Manufacture, package and release commercial Zolgensma product   and certain clinical development activities</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Princeton, New Jersey</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&#xA0;300</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Sandoz Division US headquarters</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Schweizerhalle, Switzerland</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&#xA0;880</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Manufacture of small-interfering RNA (siRNA) drug substance for Leqvio</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">46</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As our product portfolio evolves, Novartis Operations is adapting our manufacturing capacity and capabilities to meet our changing needs, shifting from high-volume products toward lower-volume, customized and personalized medicines. As of December 31, 2022, we have closed, exited or sold 19 manufacturing sites since 2019 and have announced the closure, exit or sale of seven additional manufacturing sites. We have continued to invest in new technologies implemented at our sites, such as the new targeted radioligand therapy production facility in Indianapolis, Indiana, which is currently under construction (with an expected size of approximately 67 thousand square meters), the FDA-approved <i>Zolgensma</i> production site in Durham, North Carolina, and the small-interfering RNA (siRNA) oligonucleotide manufacturing facility in Schweizerhalle, Switzerland. We are leveraging innovation to increase the reliability and productivity of our manufacturing network, including using data and digital technologies. We continue to seek opportunities to manage our production facilities as efficiently as possible, optimize external spend, and simplify and standardize across our manufacturing network to help us increase our cost competitiveness and optimize the value of our products. At the same time, we are working to improve our environmental sustainability, for example by reducing energy, waste disposal and water consumption at our sites by making our manufacturing processes more efficient, introducing new technologies, and switching to clean and renewable energy solutions. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For a description of the impact of environmental matters, see &#x201C;Item&#xA0;3. Key Information&#x2014;Item&#xA0;3.D Risk factors&#x2014;Environmental, social and governance matters&#x2014;Failure to meet increasingly challenging environmental, social and governance expectations,&#x201D; &#x201C;Item 3. Key Information&#x2014;Item 3.D Risk factors&#x2014;Environmental matters&#x2014;Impact of environmental liabilities,&#x201D; and &#x201C;Item 3. Key Information&#x2014;Item 3.D Risk factors&#x2014;Climate change&#x2014;Climate change and increased risk of major natural disasters.&#x201D; See also &#x201C;Item 18. Financial Statements&#x2014;Note&#xA0;20. Provisions and other non&#x2011;current liabilities.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">47</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00316292"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;4A.  Unresolved Staff Comments</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">48</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId0010010984"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item 5. Operating and Financial Review and&#xA0;Prospects</p>
      <div id="anchorId0010010987"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">5.A Operating results</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">This operating and financial review should be read with the Group&#x2019;s consolidated financial statements in this Annual Report, which have been prepared in accordance with International Financial Reporting Standards (IFRS) as published by the International Accounting Standards Board (see &#x201C;Item 18. Financial Statements&#x201D;). &#x201C;Item 5. Operating and Financial Review and Prospects&#x201D; with the sections on compounds in development and selected development projects of our divisions (see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview&#x201D;) constitute the Operating and Financial Review (Lagebericht), as defined by the Swiss Code of Obligations. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The discussion and analysis of the financial condition and results of operations of certain items from fiscal year ended December 31, 2020, and year-to-year comparison between fiscal year ended December 31, 2021, and December 31, 2020, that are not included in this Form 20-F can be found in &#x201C;Item 5. Operating and Financial Review and Prospects&#x201D; of our Form 20-F for the fiscal year ended December 31, 2021, which is incorporated by reference herein.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Overview</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our purpose is to reimagine medicine to improve and extend people&#x2019;s lives. We use innovative science and technology to address some of society&#x2019;s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our Company. Our vision is to become the most valued and trusted medicines company in the world.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The businesses of Novartis are divided operationally on a worldwide basis into two identified reporting segments:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Innovative Medicines: innovative patent-protected prescription medicines</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Sandoz: generic pharmaceuticals and biosimilars</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition, we separately report the results of Corporate activities. The financial results of our Corporate activities include the costs of the Group headquarters and those of corporate coordination functions in major countries. Corporate also includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights and certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In April 2022, we announced a new, integrated organizational structure and operating model designed to support our innovation, growth, and productivity ambitions as a focused medicines company. For information about this new organizational structure, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Overview.&#x201D; Under this new organizational structure, our divisions are supported by the following organizational units: the Novartis Institutes for BioMedical Research, Global Drug Development, and Novartis Operations. The financial results of these organizational units are included in the results of the divisions for which their work is performed. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Significant transactions are discussed in &#x201C;Item 18. Financial Statements&#x2014;Note 2. Significant transactions,&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 3. Segmentation of key figures 2022, 2021 and 2020.&#x201D; </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Our business environment</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Medical technology continues to accelerate, with new advanced treatments emerging to meet the growing need for high-quality healthcare. At the same time, aging populations are putting pressure on healthcare resources, while access to healthcare remains a challenge around the world. As a result, we see challenges and opportunities in our business environment: the need for continuous innovation in healthcare, increasing access to medicines, the adoption of new working practices and the growing use of data science and technology. The following are some major trends currently shaping our business environment.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Spending on healthcare continues to grow.</i> The need for high-quality healthcare is more critical than ever. Over the next five years, global spending on medicines is forecast to rise faster than GDP in many developed countries. The price of medicines remains a key issue as increased healthcare spending and a more uncertain economic outlook weigh on government budgets.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Aging populations are fueling a rise in chronic illness</i>. Aging and lifestyle changes are triggering an increase in noncommunicable diseases, such as cancer, heart disease and diabetes, causing millions of preventable deaths and putting further pressure on healthcare resources. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Medical science continues to accelerate. </i>Scientific innovation is advancing at an unprecedented pace. In recent years, new types of treatments have been approved, including RNA therapies, gene and cell therapies, and radioligand therapies, which offer targeted approaches to treating serious diseases. Because these medicines are complex, they require focused investment and expertise to bring them to reality for patients.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Access to healthcare remains a formidable challenge. </i>Worldwide, millions of patients struggle to access the medicines they need. This may be because of cost, inequity, or structural issues in healthcare systems. While access to medicines remains an acute issue in lower-income countries, it is a problem in developed </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">49</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">countries too, where the COVID-19 pandemic highlighted that deep health inequities remain entrenched.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Patients are moving to the center of healthcare. </i>Patients are demanding more say over their treatment through patient representative groups and other means. In response, healthcare systems and pharmaceutical companies are adapting, moving toward a more integrated, end-to-end approach, with an increased focus on patient engagement in drug development and other areas. At the same time, patients are becoming more important as data owners &#x2013; as personal data allows more targeted treatments and supports development of new medicines.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"> &#x2022;   <i>Economic uncertainty is growing, post-COVID-19 pandemic</i>. The global economy is facing considerable uncertainty, driven by concerns over rising energy prices and geopolitical instability. Forecasts suggest the current economic slowdown is likely to continue in 2023. In our own industry, the COVID-19 pandemic put strain on supply chains and highlighted the importance of resilient supplies of active pharmaceutical ingredients &#x2013; the raw materials used to make finished medicines. See &#x201C;Item 3. Key Information&#x2014;Item 3.D Risk factors&#x2014;Pricing, reimbursement and access&#x2014;Pricing and reimbursement pressure, including pricing transparency and access to healthcare,&#x201D; and &#x201C;Item 3. Key Information&#x2014;Item 3.D Risk factors&#x2014;Macroeconomic developments&#x2014;Impact of macroeconomic developments.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Biopharma searches for more efficiency. </i>At a time of growing economic uncertainty, investors are looking for sustainable growth in margins and earnings. To remain competitive, pharmaceutical companies are moving to more agile, cost-efficient business models, particularly as they invest to build specialized capabilities in research and development (R&amp;D) and manufacturing. Meanwhile, rates of return on R&amp;D are increasing for the first time in several years, largely because of emergency approvals during the COVID-19 pandemic and faster innovation cycles.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>New technologies are reshaping our industry</i>. The use of data science and technology is increasing across the industry in everything from R&amp;D to manufacturing and marketing. This has brought greater efficiency, but it also requires new investment and skills. Importantly, new technologies are helping close gaps between companies, healthcare systems and patients &#x2013; for example, by providing insights into the social determinants of heart health enabling the development of new prevention measures.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <i>Working practices are changing</i>. Working practices are changing in many countries. Demand for new skills is increasing, especially in areas such as data science. Workforces are becoming more flexible and more diverse, allowing companies to tap into new talent pools &#x2013; important at a time of skills shortages in many parts of the economy.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"> &#x2022;   <i>Climate change is increasingly affecting human health.</i> Climate change could undermine decades of progress in improving human health at a time when antimicrobial resistance is also rising. At the same time, more governments are looking to decarbonize their economies over the long-term, while companies also face increased scrutiny over the sustainability of their operations and supply chains. See &#x201C;Item 3. Key Information&#x2014;Item 3.D Risk factors&#x2014;Climate change&#x2014;Impact of climate change and increased risk of major natural disasters.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Our strategy</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our strategy as a focused medicines company is to deliver high-value medicines that alleviate society&#x2019;s greatest disease burdens through technology leadership in R&amp;D and novel access approaches.  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We have made significant progress in transforming Novartis from a diversified healthcare conglomerate into a focused medicines company. In doing so, we have divested or spun off non-core businesses and made targeted acquisitions to focus on our core business: discovering and developing new medicines and finding new ways to deliver them to as many people as possible.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2022, we continued to execute on our strategy by putting in place a new organizational structure to support innovation, growth and productivity. We also updated our strategic priorities and announced our intention to spin-off our Sandoz business, which paves the way for Novartis to advance as a company focused fully on innovative medicines. See &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Overview&#x201D; and &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Sandoz.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our strategy has clear focus areas and priorities to meet the challenges and opportunities we see in our business environment, and ensure we continue to create value for our stakeholders and society. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our focus areas determine where we invest most of our time, energy and resources and include: </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <b>Core therapeutic areas </b>with high unmet patient needs: cardiovascular; immunology; neuroscience; solid tumors; and hematology.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <b>Technology platforms </b>where we have the depth and scale to discover, develop and commercialize new therapies: Chemistry; biotherapeutics; xRNA; radioligand therapy; and gene and cell therapy.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <b>Priority geographies </b>which, taken together, account for the majority of the forecast growth in global healthcare spending: US, China, Germany and Japan. While these are our priority countries, we will continue to invest in other markets worldwide.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our focus areas are supported by three strategic priorities, which determine how we implement our strategy. These three strategic priorities are:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <b><i>Deliver high-value medicines to accelerate growth</i></b>. Delivering new medicines for major diseases is at the core of our purpose and value creation as a company. We focus on high-value innovative medicines with the potential to transform the treatment of diseases across our five core therapeutic areas.  To do this, we seek to maximize the potential of our key in-market and launch medicines, while finding new ways to deliver them to as many people as possible and investing in R&amp;D to deliver the next generation of high-value therapies for patients over the longer term. As part of our efforts, we continue our longstanding commitment to reduce the burden of infectious and tropical diseases that predominantly affect underserved populations in low- and middle-income countries.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">50</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <b><i>Embed operational excellence to deliver returns</i></b>. We aim to drive efficiency and free up resources to invest in innovation for patients. This also underpins our financial performance and makes us more agile; better able to take quick decisions and scale the use of new technologies, with effective cooperation across our business. In everything we do, we maintain high standards of product quality and patient safety, while also working to reduce our environmental footprint.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   <b><i>Strengthen our foundations by</i></b>:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">
        <span style="text-decoration:underline;">
          <i>Unleashing the power of our people.</i>
        </span>  We continue to focus on culture as a key enabler of our strategy to drive innovation and long-term performance. For us, this is about building an agile, diverse workforce and making sure we attract and retain the right talent for the future.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">
        <span style="text-decoration:underline;">
          <i>Scaling data science and technology.</i>
        </span>  We are investing in data science and technology to increase efficiency, support innovation, better respond to the needs of patients and healthcare professionals, and ultimately improve the way we develop and deliver our medicines.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;">
        <span style="text-decoration:underline;">
          <i>Building trust with society.</i>
        </span>  We aim to increase access to our medicines for underserved populations around the world and follow high standards of ethical behavior wherever we operate.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">51</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Results of operations </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Financial year 2022 compared with 2021</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key figures<sup>1</sup></span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions unless indicated otherwise)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Year ended<br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Year ended<br /> Dec 31, 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Change<br /> in USD<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br /> constant<br /> currencies<br /> %<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 50&#xA0;545</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 51&#xA0;626</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;283</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;251</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -15&#xA0;486</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -15&#xA0;867</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 36&#xA0;342</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&#xA0;010</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -14&#xA0;253</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14&#xA0;886</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9&#xA0;996</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -9&#xA0;540</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 805</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;852</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -57</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -54</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3&#xA0;701</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;747</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -35</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -43</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&#xA0;197</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -21</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -13</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">% of net sales to third parties</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22.6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Loss)/income from associated companies</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&#xA0;339</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -837</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -811</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -80</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&#xA0;371</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&#xA0;137</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -68</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -64</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&#xA0;416</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;119</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&#xA0;955</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24&#xA0;018</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -71</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -67</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Shareholders of Novartis AG</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 6&#xA0;955</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 24&#xA0;021</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> -71</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> -67</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Non-controlling interests</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> -3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.19</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10.71</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -70</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -66</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&#xA0;236</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&#xA0;071</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Free cash flow<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&#xA0;945</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&#xA0;282</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> For an explanation of non-IFRS measures and reconciliation tables, see "&#x2014;Non-IFRS measures as defined by Novartis."</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">52</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Group overview</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Net sales to third parties for Novartis were USD 50.5 billion, down 2% in USD reported terms and up 4% measured in constant currencies (cc) to remove the impact of exchange rate movements. Sales growth was driven by volume growth of 11 percentage points, mainly driven by continued strong growth from <i>Entresto</i>, <i>Kesimpta</i>, <i>Kisqali, Pluvicto</i> and <i>Cosentyx</i>. Generic competition had a negative impact of 3 percentage points, mainly due to <i>Gilenya, Afinitor/Votubia</i>, <i>and Gleevec/Glivec</i>. Pricing had a negative impact of 4 percentage points. Sales in the US were USD 17.7 billion (+5%) and in the rest of the world USD 32.8 billion (-6%, +4% cc).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">By division, Innovative Medicines delivered net sales of USD&#xA0;41.3 billion (-2%, +4% cc) and Sandoz net sales were USD&#xA0;9.2 billion (-4%, +4% cc).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In Emerging Growth Markets, which comprise all markets excluding the US, Canada, Western Europe, Japan, Australia and New Zealand, sales to third parties were USD&#xA0;13.5 billion (+2%, +9% cc) driven by China (USD&#xA0;3.1 billion) growing 2% (+6% cc).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Operating income was USD 9.2 billion (-21%, -13% cc), mainly due to higher restructuring costs (USD 1.2 billion) primarily related to the implementation of the previously announced streamlined organizational model, higher impairments (USD 1.0 billion), and lower divestment gains (USD 0.6 billion). Operating income margin was 18.2% of net sales, decreasing by 4.4 percentage points (-3.8 percentage points cc).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net income was USD 7.0 billion compared with USD 24.0 billion in the prior year, impacted by Roche income in the prior year. Excluding the impact of Roche income, net income declined -9% (cc). Earnings per share were USD 3.19 compared with USD 10.71 in the prior year. Excluding the impact of Roche income, EPS declined -7% (cc).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net cash flows from operating activities amounted to USD 14.2 billion, compared with USD 15.1 billion in 2021. This decrease was mainly due to unfavorable changes in working capital and lower dividends from associated companies (2021 included the USD 0.5 billion dividends received from our investment in Roche, which was divested in the fourth quarter of 2021), partly offset by lower income taxes paid and favorable hedging results.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Free cash flow amounted to USD 11.9 billion (&#x2013;10% USD), compared with USD 13.3 billion in 2021, mainly due to a decrease in net cash flows from operating activities and lower divestment proceeds, partly offset by lower purchases of property, plant and equipment.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We also present our core results<sup>1</sup>, which exclude the impact of amortization, impairments, disposals, acquisitions, restructurings and other significant items, to help investors understand our underlying performance.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core operating income was USD 16.7 billion (0%, +8% cc), benefiting from higher sales, partly offset by higher research and development (R&amp;D) investments. Core operating income margin was 33.0% of net sales, increasing by 0.9 percentage points (+1.3 percentage points cc).  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core net income was USD 13.4 billion (-5%, +3% cc) as growth in core operating income was partly offset by the loss of Roche core income. Excluding the impact of Roche core income, core net income grew +11% (cc). </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"></div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>1</sup> For an explanation of non-IFRS measures and reconciliation tables, see &#x201C;&#x2014;Non-IFRS measures as defined by Novartis.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">53</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Net sales to third parties by segment</span>
      </div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides an overview of net sales to third parties by segment:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Year ended<br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Year ended<br /> Dec 31, 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Change<br /> in USD<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br /> constant<br />  currencies<br /> %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 41&#xA0;296</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 41&#xA0;995</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&#xA0;249</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&#xA0;631</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 50&#xA0;545</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 51&#xA0;626</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
        </table>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Innovative Medicines</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Innovative Medicines Division delivered net sales of USD 41.3 billion (-2%, +4% cc) with volume contributing 12 percentage points to growth. Generic competition had a negative impact of 4 percentage points. Pricing had a negative impact of 4 percentage points. Sales in the US were USD 15.9 billion (+6%) and in the rest of the world USD 25.4 billion (-6%, +3% cc).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sales growth was mainly driven by continued strong growth from <i>Entresto</i> (USD 4.6 billion, +31%, +37% cc), <i>Kesimpta</i> (USD 1.1 billion, +194%, +200% cc), <i>Kisqali</i> (USD 1.2 billion, +31%, +38% cc), <i>Pluvicto</i> (USD 271 million) and <i>Cosentyx</i> (USD 4.8 billion, +1%, +5% cc), partly offset by generic competition mainly for <i>Gilenya</i>, <i>Afinitor</i>/<i>Votubia</i> and <i>Gleevec</i>/<i>Glivec</i>.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the US (USD 15.9 billion +6%), sales growth was mainly driven by <i>Entresto</i>, <i>Kesimpta</i> and <i>Pluvicto</i>, partly offset by the impact of generic competition on <i>Afinitor</i>/<i>Votubia</i> and <i>Gilenya</i>. In Europe (USD 13.6 billion, -9%, +1% cc) sales growth was driven by <i>Entresto</i>, <i>Kisqali</i> and <i>Kesimpta</i>, partly offset by increased generic competition for <i>Gilenya</i>. Emerging Growth Markets grew +2% (+9% cc), with China sales USD 2.9 billion (+3%, +7% cc) driven by <i>Cosentyx</i>.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table provides an overview of net sales to third parties by core therapeutic area; other promoted brands; and established brands in the Innovative Medicines Division:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Year ended<br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Year ended<br /> Dec 31, 2021<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Change<br /> in USD<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br /> constant<br />  currencies<br /> %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Cardiovascular</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;756</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Immunology</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&#xA0;287</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&#xA0;205</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Neuroscience</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;051</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&#xA0;007</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Solid Tumors</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;723</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;101</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Hematology</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&#xA0;452</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&#xA0;430</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Other Promoted Brands</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;127</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;451</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Promoted Brands</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 31&#xA0;396</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 29&#xA0;754</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Established Brands</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&#xA0;900</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&#xA0;241</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -19</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> - 13</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Innovative Medicines</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 41&#xA0;296</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 41&#xA0;995</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Reclassified to reflect the new Innovative Medicines divisional structures announced on April 4, 2022</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">54</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides the top 20 Innovative Medicines Division product net sales to third parties in 2022 as well as the change compared with 2021:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> US</div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of world</div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />Brands</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by<br /> therapeutic area, other<br /> promoted brands or<br /> established brands</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Key indications</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> USD m</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> % <br /> change<br /> USD/cc<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> USD m</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> % <br /> change<br /> USD</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> % <br /> change<br /> cc<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> USD m</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> % <br /> change<br /> USD</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> % <br /> change<br /> cc<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;width:12%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td style=";width:12%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology          </div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td style=";width:12%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO),   ankylosing spondylitis  (AS), psoriatic arthritis   (PsA), non-radiographic   axial spondyloarthritis   (nr-axSPA)</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;770          </div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4          </div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;018          </div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10          </div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20          </div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;788          </div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1          </div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5          </div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular  </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure,  hypertension</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;354  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;290  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;644  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37  </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology    </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune   thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;083    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;005    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;088    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9    </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis  (RMS)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;153  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -19  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 860  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -37  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -29  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;013  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -28  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -24  </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia  (CML)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 877  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;046  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;923  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1  </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands    </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related   macular degeneration (AMD),   diabetic macular edema (DME),  retinal vein occlusion (RVO)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;874      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -13      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;874      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -13      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4      </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Tafinlar</i> + <i>Mekinist</i></div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors          </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic   adjuvant melanoma,  advanced non-small cell   lung cancer (NSCLC),   tumor agnostic with   BRAF mutation indication</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 678          </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12          </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;092          </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0          </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10          </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;770          </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5          </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11          </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology      </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycytomia vera (PV),   graft-versus-host disease  (GvHD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;561      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;561      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9      </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy  (SMA)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 434  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 936  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;370  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5  </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA),   chronic spontaneous urticaria   (CSU), nasal polyps</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;365    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;365    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6    </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors,  acromegaly</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 800  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 438  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -23  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -16  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;238  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -10  </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors  </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2-   metastatic breast cancer</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 472  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 759  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;231  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38  </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,  TRAPS, HIDS/MKD, FMF,  SJIA, AOSD, gout)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 570    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 563    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;133    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15    </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing-remitting   multiple sclerosis (RRMS)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 921  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 165  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 171  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;092  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 194  </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 200  </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Galvus</i> Group</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 859</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -21</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 859</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -21</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands      </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid  leukemia (CML),   gastrointestinal stromal  tumors (GIST)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 205      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -22      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 540      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -29      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -23      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 745      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -27      </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -22      </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Exforge</i> Group</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 729</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -18</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 743</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -18</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -12</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <i>Diovan</i> Group</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 55</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 597</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -17</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 652</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -16</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology        </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> r/r pediatric and young   adults acute lymphoblastic   leukemia (ALL), diffuse large   B-cell lymphoma (DLBCL),   follicular lymphoma (FL)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 196        </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -15        </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 340        </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5        </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7        </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 536        </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9        </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2        </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands    </div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/  tuberous sclerosis complex   (TSC)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 171    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -67    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 341    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -18    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 512    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -45    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -41    </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 brands total</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12&#xA0;753</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 19&#xA0;384</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 32&#xA0;137</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;146</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&#xA0;013</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&#xA0;159</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   15&#xA0;899</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   25&#xA0;397</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   -6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   41&#xA0;296</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="22" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="top">
            <td colspan="22" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="22">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="22">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> For an explanation of non-IFRS measures and reconciliation tables, see "&#x2014;Non-IFRS measures as defined by Novartis."</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="22" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="22" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">55</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For the table providing the top 20 Innovative Medicines Division product net sales to third parties in 2021, see &#x201C;Item 18. Financial statements&#x2014;Note 3. Segmentation of key figures 2022, 2021 and 2020.&#x201D;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For information about the approved indications for certain products described, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview&#x2014;Innovative Medicines&#x2014; Innovative Medicines Division products.&#x201D;</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold; text-transform:uppercase;">Cardiovascular</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sales in the Cardiovascular therapeutic area were USD 4.8 billion (+34%, +40% cc), sales growth mainly driven by <i>Entresto.</i></div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Entresto</i> (USD 4.6 billion, +31%, +37% cc) sustained robust demand-led growth, with increased patient share across all geographies. Guidelines position <i>Entresto</i> as the first choice RASi versus ACEi/ARB in patients with HFrEF. <i>Entresto</i> benefits from the adoption of guideline directed medical therapy for these patients in all geographies. In the US, <i>Entresto</i> benefits from being added to guidelines for patients with HFpEF (with LVEF below normal). In China, <i>Entresto</i> has been listed in the National Reimbursement Drug List (NRDL) for both HFrEF and hypertension, effective January 2022. In China and Japan, <i>Entresto</i> volume growth is fueled by increased penetration in hypertension in addition to growth in heart failure. It is estimated that around 10 million patients are on treatment with <i>Entresto</i>. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Leqvio</i> (USD 0.1 billion) launch in the US and other markets is ongoing, with focus on patient on-boarding, removing access hurdles and enhancing medical education. <i>Leqvio</i> is the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol approved in the US and was launched in January 2022. In the US, <i>Leqvio</i> is covered at or near label for 76% of patients eleven months after launch. <i>Leqvio</i> in the US has been assigned a unique Healthcare Common Procedure Coding System code (J-code) and average sales price. <i>Leqvio</i> is now approved in 70 countries. Novartis obtained global rights to develop, manufacture and commercialize <i>Leqvio</i> under a license and collaboration agreement with Alnylam Pharmaceuticals.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold; text-transform:uppercase;">Immunology</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sales in the Immunology therapeutic area reached USD 7.3 billion (+1%, +7% cc), sales growth was mainly driven by <i>Cosentyx</i> and <i>Ilaris</i>.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Cosentyx</i> (USD 4.8 billion, +1%, +5% cc) sales grew in Emerging Growth Markets, Europe and Japan, partly offset by decline in the US due to higher revenue deductions. In China, <i>Cosentyx</i> growth was fueled by increased biologic uptake and inclusion in approximately 1,900 hospital listings. Since initial approval in 2015, <i>Cosentyx</i> has proven its sustained efficacy and consistent safety profile across five systemic inflammatory conditions and has treated more than 960,000 patients worldwide.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Xolair</i> (USD 1.4 billion, -4%, +6% cc) sales grew (cc) in Emerging Growth Markets, Europe and Japan. Novartis co-promotes <i>Xolair</i> with Genentech in the US and shares a portion of revenue as operating income but does not record any US sales.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Ilaris</i> (USD 1.1 billion, +7%, +15% cc) showed continued growth across all geographies. Contributors to growth include the adult-onset Still&#x2019;s disease indication, together with the other adult rheumatology indications in the US and Europe, as well as strong performance for the Periodic Fevers Syndrome indications in Japan.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold; text-transform:uppercase;">Neuroscience</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sales in the Neuroscience therapeutic area were USD 5.1 billion (+1%, +5% cc), sales growth (cc) mainly driven by <i>Kesimpta</i>, which was partly offset by sales decline of <i>Gilenya</i>. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Gilenya</i> (USD 2.0 billion, -28%, -24% cc) sales declined mainly in Europe and in the US due to generic pressure. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Zolgensma</i> (USD 1.4 billion, +1%, +5% cc) has been approved in 47 countries to date. As this represents most major markets, sales growth is now mainly driven by the Incident patient population where we&#x2019;ve seen double digit growth in 2022. Access pathways are now in place in 35 countries with negotiations ongoing in additional markets.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Kesimpta</i> (USD 1.1 billion, +194%, +200% cc) showed strong sales growth driven by launch momentum across all geographies. <i>Kesimpta</i> is a targeted B-cell therapy that can deliver powerful and sustained high efficacy, with a favorable safety and tolerability profile and the flexibility of an at home self-administration for a broad population of RMS patients. <i>Kesimpta</i> is now approved in 80 countries with more than 36,000 patients treated.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Mayzent</i> (USD 0.4 billion, +27%, +32% cc) sales grew across all geographies in MS patients showing signs of progression despite being on other treatments. <i>Mayzent</i> is the first and only oral disease-modifying therapy studied and proven to delay disease progression in a broad SPMS patient population.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Aimovig</i> (USD 0.2 billion, +1%, +11% cc) sales grew in Europe and Emerging Growth Markets. <i>Aimovig</i> is reimbursed in 32 markets and has been prescribed to over 759,000 patients worldwide. Earlier this year, <i>Aimovig</i> was submitted for approval in China. In October 2022, Novartis reached an agreement in Germany by which <i>Aimovig</i> is reimbursed as a 1st line prophylactic migraine treatment based on the HER-MES trial.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold; text-transform:uppercase;">Solid Tumors</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sales in the Solid Tumors therapeutic area were USD 4.7 billion (+15%, +21% cc), sales growth mainly driven by <i>Kisqali</i>, <i>Pluvicto</i> and <i>Tafinlar</i> + <i>Mekinist</i>.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Tafinlar</i> + <i>Mekinist</i> (USD 1.8 billion, +5%, +11% cc) sales grew across all geographies, driven by demand in BRAF+ adjuvant melanoma and NSCLC indications, while maintaining demand in the highly competitive BRAF+ metastatic melanoma market. <i>Tafinlar</i> + <i>Mekinist</i> remains the worldwide targeted therapy leader in BRAF+ melanoma. Following FDA approval in late June, <i>Tafinlar</i> + <i>Mekinist</i> is the first and only therapy with a tumor-agnostic indication for adult and pediatric patients with solid tumors that have a BRAF V600E mutation, which drives tumor growth in more than 20 different tumor types.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Kisqali</i> (USD 1.2 billion, +31%, +38% cc) sales grew strongly across all geographies, based on increasing recognition of its overall survival and quality of life benefits in HR+/HER2- advanced breast cancer. It is a CDK4/6 </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">56</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">inhibitor with proven overall survival benefit across all three Phase III trials of the MONALEESA program regardless of menopausal status, line of therapy, site and number of metastases, endocrine resistance, or endocrine partner. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Votrient</i> (USD 0.5 billion, -18%, -13% cc) declined due to increased competition, especially from immuno-oncology agents in metastatic renal cell carcinoma.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Lutathera</i> (USD 0.5 billion, -1%, +3% cc) sales grew (cc) in Europe and Japan, partly offset by decline in the US. There are approximately 500 centers actively treating patients globally. In the second quarter of 2022, there was a temporary suspension in manufacturing during the quarter; production and deliveries of patient doses resumed in early June.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Piqray</i> (USD 0.4 billion, +13%, +14% cc) sales grew mainly in the US, benefiting from indication expansion into PIK3CA-related overgrowth spectrum (PROS). <i>Piqray</i> is the first and only therapy specifically developed for the approximately 40% of HR+/HER2- advanced breast cancer patients who have a PIK3CA mutation, which is associated with a worse prognosis.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Pluvicto</i> (USD 0.3 billion) launch is progressing well, with more than 160 active centers ordering. <i>Pluvicto</i> is the first and only radioligand therapy approved by the FDA for the treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer, who have already been treated with other anticancer treatments (ARPI and taxane-based chemotherapy).</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Tabrecta</i> (USD 0.1 billion, +48%, +48% cc) sales grew across all geographies, as the first therapy approved by the FDA to specifically target metastatic NSCLC with a mutation that leads to MET exon 14 skipping (METex14).</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold; text-transform:uppercase;">Hematology</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sales in the Hematology therapeutic area were USD 6.5 billion (0%, +7% cc), sales growth (cc) mainly driven by <i>Promacta</i>/<i>Revolade</i>, <i>Jakavi</i> and <i>Scemblix</i>.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Promacta</i>/<i>Revolade</i> (USD 2.1 billion, +4%, +9% cc) growth was driven by the US, Europe and Emerging Growth Markets, partly offset by decline in Japan. Sales growth was driven by increased use in second-line persistent and chronic immune thrombocytopenia and as first-line and/or second-line treatment for severe aplastic anemia.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Tasigna</i> (USD 1.9 billion, -7%, -1% cc) sales declined in Europe, Japan and the US, partly offset by growth in Emerging Growth Markets.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Jakavi</i> (USD 1.6 billion, -2%, +9% cc) sales grew (cc) in Europe, Emerging Growth Markets, Japan, driven by strong demand in both the myelofibrosis and polycythemia vera indications. In May, EC approved <i>Jakavi</i> for the treatment of patients aged 12 years and older with acute or chronic GvHD who have inadequate response to corticosteroids or other systemic therapies.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Kymriah</i> (USD 0.5 billion, -9%, -2% cc) sales declined in the US and Europe due to lower DLBCL demand in both geographies and was partly offset by growth in Emerging Growth Markets and Japan. In May, EC and FDA approved <i>Kymriah</i> for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Adakveo</i> (USD 0.2 billion, +18%, +19% cc) continued to grow worldwide, reaching more than 11,800 patients with vaso-occlusive crises caused by sickle cell disease to date.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Scemblix</i> (USD 0.1 billion) continued its strong launch uptake in the US, with launches underway in EU and Japan, demonstrating the high unmet need in CML, particularly patients previously treated with 2 or more tyrosine kinase inhibitors, or with the T315I mutation. In October 2022, US FDA converted the accelerated approval of <i>Scemblix</i> to a full approval, confirming the clinical benefit after longer exposure.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold; text-transform:uppercase;">Other Promoted Brands</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sales for Other Promoted Brands were USD 3.1 billion (-9%, -1% cc).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Lucentis</i> (USD 1.9 billion, -13%, -4% cc) sales declined in Japan and Europe mainly due to competition, which was partly offset by growth in Emerging Growth Markets.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Xiidra</i> (USD 0.5 billion, +4%, +4% cc) sales grew mainly in the US. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Ultibro</i> Group (USD 0.5 billion, -18%, -9% cc) sales declined in Europe and Emerging Growth Markets due to competition and was partly offset by growth in Japan. <i>Ultibro</i> Group consists of <i>Ultibro Breezhaler</i>, <i>Seebri Breezhaler</i> and <i>Onbrez Breezhaler</i>.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Beovu</i> (USD 0.2 billion, +9%, +18% cc) sales grew in Europe, Emerging Growth Markets and Japan, partly offset by decline in the US. <i>Beovu</i> received approval for diabetic macular edema (DME) in the EU in the first quarter of 2022, and in the US in the second quarter of 2022.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold; text-transform:uppercase;">Established Brands</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Established Brands had sales of USD 9.9 billion (-19%, -13% cc).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Sandostatin</i> (USD 1.2 billion, -12%, -10% cc) declined across all geographies due to ongoing competitive pressure, including generic competition ex-US.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Galvus</i> Group (USD 0.9 billion, -21%, -12% cc) declined in Japan, Europe and Emerging Growth Markets.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Gleevec</i>/<i>Glivec</i> (USD 0.7 billion, -27%, -22% cc) declined due to increased generic competition.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Exforge</i> Group (USD 0.7 billion, -18%, -12% cc) declined across all geographies.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Diovan</i> Group (USD 0.7 billion, -16%, -9% cc) declined in Emerging Growth Markets, Japan and Europe.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Afinitor</i>/<i>Votubia</i> (USD 0.5 billion, -45%, -41% cc) declined in the US and Europe driven by generic competition.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Voltaren</i>/<i>Cataflam</i> (USD 0.3 billion, -10%, 0% cc) sales were stable (cc).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Zortress</i>/<i>Certican</i> (USD 0.3 billion, -24%, -14% cc) declined in the US and Japan.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Exjade</i>/<i>Jadenu</i> (USD 0.3 billion, -43%, -38% cc) declined due to pressure from generic competition.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
        <i>Neoral</i>/<i>Sandimmun(e)</i> (USD 0.3 billion, -16%, -8% cc) declined across all geographies.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">57</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Sandoz</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sandoz net sales were USD 9.2 billion (&#x2013;4%, +4% cc) with volume contributing 10 percentage points to growth. Pricing had a negative impact of 6 percentage points.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sales in Europe were USD 4.9 billion (&#x2013;7%, +4% cc), in the US USD 1.8 billion (&#x2013;4%) in Asia/Africa/Australasia USD 1.6 billion (&#x2013;3%, +6% cc) and in Canada and Latin America USD 969 million (+11%, +15% cc) driven by volume increases and tender wins.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table provides an overview of net sales to third parties by business franchise in the Sandoz Division:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Year ended<br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Year ended<br /> Dec 31, 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Change<br /> in USD<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br /> constant<br />  currencies<br /> %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Retail Generics<sup>1</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&#xA0;776</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&#xA0;092</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Biopharmaceuticals</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;093</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;116</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Anti-Infectives  (partner label/API)<sup>1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   380</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   423</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   -10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   -5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Sandoz</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&#xA0;249</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&#xA0;631</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Sandoz total anti-infectives net sales to third parties amounted to USD 1.2 billion (2021: USD 1.1 billion; 2020: USD 1.2 billion), of which USD 777 million (2021: USD 707 million; 2020: USD 694 million) is sold through the Retail Generics business franchise and USD 380 million (2021: USD 423 million; 2020: USD 474 million) is sold to other third-party companies through the Anti-Infectives business franchise.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Retail Generics </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In Retail Generics, Sandoz develops, manufactures and markets finished dosage forms of small molecule pharmaceuticals for sale to third parties across a broad range of therapeutic areas, including finished dosage form of anti-infectives sold to third parties. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Retail sales were USD 6.8 billion (&#x2013;4%, +4% cc), growing across all regions ex-US.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Biopharmaceuticals</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- and other biotechnology-based products, including biosimilars, and provides biotechnology manufacturing services to other companies. The Biopharmaceuticals business also includes <i>Glatopa</i>, a generic version of Copaxone&#xAE;, which treats relapsing forms of multiple sclerosis and is marketed in the US. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Global sales of Biopharmaceuticals (biosimilars, biopharmaceutical contract manufacturing and <i>Glatopa</i>) grew to USD 2.1 billion (&#x2013;1%, +9% cc), growing across all regions.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Anti-Infectives</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In Anti-Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by Retail Generics and for sale to third-party customers. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total Anti-Infectives sales were USD 1.2 billion (+2%, +10% cc) of which USD 777 million were sold through the Retail Generics business franchise and USD 380 million were sold to other third-party companies through the Anti-Infectives business franchise. The sales of the Anti-Infectives business franchise declined mainly due to product discontinuations and supply challenges.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">58</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Operating income</span>
      </div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides an overview of operating income by segment:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Year ended<br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % of<br /> net sales<br /> to third<br /> parties</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Year ended<br /> Dec 31, 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> % of<br /> net sales<br /> to third<br /> parties</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Change<br /> in USD<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br /> constant<br /> currencies<br /> %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&#xA0;786</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 21.3</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&#xA0;688</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25.5</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -18</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -9</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;448</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15.7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&#xA0;600</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16.6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&#xA0;037</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -599</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -73</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -84</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&#xA0;197</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18.2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22.6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -21</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -13</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Operating income was USD 9.2 billion (&#x2013;21%, &#x2013;13% cc), mainly due to higher restructuring (USD 1.2 billion) primarily related to the implementation of the previously announced streamlined organizational model, higher impairments (USD 1.0 billion) and lower divestment gains (USD 0.6 billion). Operating income margin was 18.2% of net sales, decreasing by 4.4 percentage points (-3.8 percentage points cc).</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Core operating income key figures</span>
        <span style="font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000; font-weight:bold; vertical-align:super;">1</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions unless indicated otherwise)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Year ended<br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Year ended<br /> Dec 31, 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Change<br /> in USD<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br /> constant<br /> currencies<br /> %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core gross profit</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 40&#xA0;392</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 41&#xA0;097</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -14&#xA0;190</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14&#xA0;815</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9&#xA0;088</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -9&#xA0;041</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 384</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 421</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -833</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&#xA0;074</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&#xA0;665</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;588</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">As % of net sales to third parties</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33.0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32.1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> For an explanation of non-IFRS measures and reconciliation tables, see "&#x2014;Non-IFRS measures as defined by Novartis."</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The adjustments made to operating income to arrive at core operating income amounted to USD&#xA0;7.5 billion (compared with USD&#xA0;4.9 billion in the prior year). For details, please see &#x201C;&#x2014;Non-IFRS measures as defined by Novartis&#x2014;2022 and 2021 reconciliation from IFRS results to core results.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core operating income was USD 16.7 billion (0%, +8% cc) benefiting from higher sales, partly offset by higher R&amp;D investments. Core operating income margin was 33.0% of net sales, increasing by 0.9 percentage points (+1.3 percentage points cc).</div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides an overview of core operating income by segment:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Year ended<br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % of<br /> net sales<br /> to third<br /> parties</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Year ended<br /> Dec 31, 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> % of<br /> net sales<br /> to third<br /> parties</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Change<br /> in USD<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br /> constant<br /> currencies<br /> %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&#xA0;237</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 36.9</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&#xA0;215</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 36.2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;903</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20.6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;064</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 21.4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -475</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -691</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&#xA0;665</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33.0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;588</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 32.1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Operating income was USD 8.8 billion (&#x2013;18%, &#x2013;9% cc), driven by higher impairments, restructuring, lower divestment gains and higher R&amp;D expenses, partly offset by higher gross margin. Operating income margin was 21.3% of net sales, decreasing 4.2 percentage points (-3.4 percentage points in cc).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core adjustments were USD 6.5 billion, mainly due to amortization, impairments and restructuring, compared to USD 4.5 billion in prior year. Core adjustments increased compared to prior year, mainly due to higher impairments and restructuring.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core operating income was USD 15.2 billion (0%, +8% cc), mainly driven by higher gross margin, partly offset </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">59</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">by higher R&amp;D investments. Core operating income margin was 36.9% of net sales, increasing 0.7 percentage points (+1.3 percentage points cc). Revenues as a percentage of sales increased by 0.1 percentage points (cc). Core cost of goods sold as a percentage of sales was in line with the prior year. Core R&amp;D expenses as a percentage of net sales increased by 0.2 percentage points (cc). Core selling, general and administration (SG&amp;A) expenses as a percentage of net sales decreased by 1.4 percentage points (cc). Core other income and expense as a percentage of net sales was in line with the prior year.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Operating income was USD 1.4 billion (&#x2013;10%, &#x2013;2% cc), with the decline mainly due to higher SG&amp;A investments to drive higher sales and inflationary pressures on input costs, which were partly offset by higher sales. Operating income margin was 15.7% of net sales, decreasing by 0.9 percentage points (-1.0 percentage points in cc).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core adjustments were USD 455 million, including USD 221 million of amortization. Prior year core adjustments were USD 464 million, including USD 236 million of amortization.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core operating income was USD 1.9 billion (&#x2013;8%, &#x2013;1% cc), with the decline mainly due to higher SG&amp;A, partly offset by higher sales. Core operating margin was 20.6% of net sales, decreasing by 0.8 percentage points (-1.1 percentage points cc). Core gross margin as a percentage of sales decreased by 0.3 percentage points (cc), due to higher inflation and input costs. Core R&amp;D expenses as a percentage of net sales decreased by 0.5 percentage points (cc). Core SG&amp;A expenses increased by 0.9 percentage points (cc). Core other income and expense decreased the margin by 0.4 percentage points (cc).</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Corporate income and expense, net</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Corporate income and expense, which includes the cost of Group headquarter and coordination functions, amounted to an expense of USD 1.0 billion, compared to an expense of USD 599 million in 2021, mainly driven by higher restructuring costs, lower contributions from the Novartis Venture Fund and prior year income from a fair value adjustment on contingent receivables related to intellectual property rights, partly offset by prior year adjustments to provisions on M&amp;A transactions.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Innovative Medicines Division research and development</span>
      </div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides an overview of the reported and core research and development expense of the Innovative Medicines Division:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions unless indicated otherwise)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Year ended<br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Year ended<br /> Dec 31, 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Change<br /> in USD<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br /> constant<br /> currencies<br /> %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and exploratory development</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&#xA0;938</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -3&#xA0;209</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Confirmatory development</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6&#xA0;234</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -5&#xA0;432</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -15</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -20</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Innovative Medicines Division research and development expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -9&#xA0;172</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -8&#xA0;641</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -10</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;As % of Innovative Medicines net sales to third parties</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22.2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20.6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core research and exploratory development<sup>1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&#xA0;784</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;809</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core confirmatory development<sup>1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5&#xA0;483</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -5&#xA0;341</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total core Innovative Medicines Division research and development expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -8&#xA0;267</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -8&#xA0;150</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;As % of Innovative Medicines net sales to third parties</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19.4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Core results exclude impairments, amortization and certain other items. For an explanation of non-IFRS measures and reconciliation tables, see "&#x2014;Non-IFRS measures as defined by Novartis."&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Innovative Medicine Division research and exploratory development expense decreased by 8% (+6% cc) to USD 2.9 billion. Confirmatory development expense amounted to USD 6.2 billion, increasing by 15% (-20% cc) versus prior year mainly due to higher impairment charges and higher investments in development to support recently acquired assets.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total core research and development expense in the Innovative Medicine Division as a percentage of sales increased by 0.6 percentage points (+0.2 percentage points cc) to 20.0% of net sales, mainly driven by higher investments in recently acquired assets.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">60</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Non-operating income and expense </span>
      </div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The term &#x201C;non-operating income and expense&#x201D; includes all income and expense items outside operating income. The following table provides an overview of non-operating income and expense:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions unless indicated otherwise)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Year ended<br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Year ended<br /> Dec 31, 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Change<br /> in USD<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br /> constant<br /> currencies<br /> %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&#xA0;197</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -21</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -13</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Loss)/income from associated companies</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&#xA0;339</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -837</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -811</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -80</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&#xA0;371</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&#xA0;137</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -68</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -64</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&#xA0;416</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;119</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&#xA0;955</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24&#xA0;018</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -71</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -67</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Shareholders of Novartis AG</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 6&#xA0;955</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 24&#xA0;021</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> -71</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> -67</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Non-controlling interests</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> -3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.19</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10.71</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -70</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -66</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful     </div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Income from associated companies</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Income from associated companies was a loss of USD 9 million compared to an income of USD 15.3 billion in prior year. This decrease was due to the divestment of our investment in Roche that closed in the fourth quarter of 2021 where a gain of USD 14.6 billion was recognized.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest expense and other financial income and expense</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Interest expense amounted to USD 837 million, broadly in line with prior year. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Other financial income and expense amounted to an income of USD 20 million compared to an expense of USD 80 million in the prior year, as higher interest income was partly offset by financial expenses and currency losses.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Income taxes</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The tax rate was 16.9% compared to 8.1% in the prior year period. In the prior year, the tax rate was impacted by the Roche income from associated companies (including the divestment gain recognized on the sale of our investment in Roche in December 2021), the impact of increases in uncertain tax positions and prior-year items.  </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For comparability, excluding these impacts, the prior year tax rate would have been 16.8%, broadly in line with 16.9% in the current year.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net income </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Net income was USD 7.0 billion (&#x2013;71%, &#x2013;67% cc), impacted by Roche income in the prior year. Excluding the impact of Roche income, net income declined &#x2013;9% (cc). </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Earnings per share</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Basic earnings per share were USD 3.19 compared with USD 10.71 in the prior year, mainly due to prior year Roche income. Excluding the impact of Roche income, EPS declined &#x2013;7% (cc).</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">61</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Core non-operating income and expense</span>
        <span style="font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000; font-weight:bold; vertical-align:super;">1</span>
      </div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides an overview of core non-operating income and expense:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions unless indicated otherwise)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Year ended<br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Year ended<br /> Dec 31, 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Change<br /> in USD<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br /> constant<br /> currencies<br /> %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core operating income</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&#xA0;665</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;588</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core (loss)/income from associated companies</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 993</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core interest expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -837</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -811</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core other financial income and expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 141</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -41</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core income before taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&#xA0;960</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;729</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core income taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&#xA0;608</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;635</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&#xA0;352</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&#xA0;094</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core basic earnings per share (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6.12</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6.29</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Core income from associated companies</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Core income from associated companies was a loss of USD 9 million compared with an income of USD 993 million in prior year. This decrease was due to the divestment of our investment in Roche that closed in the fourth quarter of 2021. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Core interest expense and other financial income and expense</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Core interest expense amounted to USD 837 million, broadly in line with prior year. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Core other financial income and expense amounted to an income of USD 141 million compared to an expense of USD 41 million in the prior year as higher interest income was only partly offset by currency losses.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Core income taxes</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The core tax rate (core taxes as a percentage of core income before tax) was 16.3% compared to 15.8% in the prior year. For comparability, excluding Roche Income from associated companies (divested in December 2021), the prior year core tax rate would have been 16.7% compared to 16.3% in the current year, decreasing mainly as a result of a change in core profit mix.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Core net income </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Core net income was USD 13.4 billion (&#x2013;5%, +3% cc) as growth in core operating income was partly offset by the loss of Roche core income. Excluding the impact of Roche core income, core net income grew +11% (cc). </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Core earnings per share</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Core EPS was USD 6.12 (&#x2013;3%, +6% cc), benefiting from lower weighted average number of shares outstanding. Excluding the impact of Roche core income, core EPS grew +14% (cc). </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>1</sup> For an explanation of non-IFRS measures and reconciliation tables, see &#x201C;&#x2014;Non-IFRS measures as defined by Novartis.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">62</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Results of operations excluding Roche investment impacts</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">To enhance investors&#x2019; understanding of the Group&#x2019;s performance in comparison with the prior year, the following table provides a comparison of our 2022 published IFRS results and non-IFRS measures core results and free cash flow with the 2021 results, excluding the impacts related to our Roche investment, due to its divestment.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Excluding Roche investment impacts<sup>2</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Year ended<br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Year ended<br /> Dec 31, 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change<br /> USD</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % change<br /> cc<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&#xA0;197</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -21</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -13</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Loss from associated companies</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -837</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -811</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -96</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&#xA0;416</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;119</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&#xA0;955</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&#xA0;661</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -20</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.19</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3.86</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -17</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -7</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&#xA0;236</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&#xA0;549</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Free cash flow<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&#xA0;945</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&#xA0;760</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&#xA0;665</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;588</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&#xA0;352</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&#xA0;099</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core basic earnings per share (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6.12</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.84</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> For an explanation of non-IFRS measures and reconciliation tables, see "&#x2014;Non-IFRS measures as defined by Novartis."</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> For a reconciliation of 2021 IFRS results and non-IFRS measures core results and free cash flow to exclude the impacts of the 2021 divestment of our Roche investment, see "&#x2014;Non-IFRS measures as defined by Novartis."</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">63</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Factors affecting comparability of year-on-year results of operations</span>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions </span>
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"></span>
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">in 2022 and 2021</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The comparability of the year-on-year results of our operations for the total Group can be significantly affected by acquisitions and divestments. As part of our long-term strategy to focus Novartis as a leading medicines company, we announced and/or completed several acquisitions and divestments during 2022 and 2021.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A detailed description of significant transactions in 2022 and 2021, can be found in &#x201C;Item 18. Financial Statements&#x2014;Note 2. Significant transactions.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Internal control over financial reporting</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s management has assessed the effectiveness of internal control over financial reporting. The Group&#x2019;s independent statutory auditor also issued an opinion on the effectiveness of internal control over financial reporting. Both the Group&#x2019;s management and its external auditors concluded that the Group maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022. For more details, see &#x201C;Item 15. Controls and Procedures.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Approach to risk management</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">See &#x201C;Item 6. Directors, Senior Management and Employees&#x2014;Item 6.C Board practices&#x2014;Corporate governance&#x2014;Information and control systems&#x2014;Risk management&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 29. Financial instruments &#x2013; additional disclosures.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Non-IFRS measures as defined by Novartis</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis uses certain non-IFRS metrics when measuring performance, especially when measuring current-year results against prior periods, including core results, constant currencies and free cash flow.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Despite the use of these measures by management in setting goals and measuring the Group&#x2019;s performance, these are non-IFRS measures that have no standardized meaning prescribed by IFRS. As a result, such measures have limits in their usefulness to investors.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Because of their non-standardized definitions, the non-IFRS measures (unlike IFRS measures) may not be comparable to the calculation of similar measures of other companies. These non-IFRS measures are presented solely to permit investors to more fully understand how the Group&#x2019;s management assesses underlying performance. These non-IFRS measures are not, and should not be viewed as, a substitute for IFRS measures, and should be viewed in conjunction with IFRS financials.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As an internal measure of Group performance, these non-IFRS measures have limitations, and the Group&#x2019;s performance management process is not solely restricted to these metrics.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">64</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Core results</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s core results &#x2013; including core operating income, core net income and core earnings per share &#x2013; exclude fully the amortization and impairment charges of intangible assets, excluding software, net gains and losses on fund investments and equity securities valued at fair value through profit and loss, and certain acquisition- and divestment-related items. The following items that exceed a threshold of USD&#xA0;25 million are also excluded: integration- and divestment-related income and expenses; divestment gains and losses; restructuring charges/releases and related items; legal-related items; impairments of property, plant and equipment, software, and financial assets, and income and expense items that management deems exceptional and that are or are expected to accumulate within the year to be over a USD&#xA0;25 million threshold. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis believes that investor understanding of the Group&#x2019;s performance is enhanced by disclosing core measures of performance, since core measures exclude items that can vary significantly from year to year, they enable better comparison of business performance across years. For this same reason, Novartis uses these core measures in addition to IFRS and other measures as important factors in assessing the Group&#x2019;s performance.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following are examples of how these core measures are utilized:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In addition to monthly reports containing financial information prepared under International Financial Reporting Standards (IFRS), senior management receives a monthly analysis incorporating these core measures.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Annual budgets are prepared for both IFRS and core measures. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As an internal measure of Group performance, the core results measures have limitations, and the Group&#x2019;s performance management process is not solely restricted to these metrics. A limitation of the core results measures is that they provide a view of the Group&#x2019;s operations without including all events during a period, such as the effects of an acquisition, divestment, or amortization/impairments of purchased intangible assets, impairments to property, plant and equipment and restructurings and related items.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Constant currencies</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Changes in the relative values of non-US currencies to the US dollar can affect the Group&#x2019;s financial results and financial position. To provide additional information that may be useful to investors, including changes in sales volume, we present information about our net sales and various values relating to operating and net income that are adjusted for such foreign currency effects.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Constant currency calculations have the goal of eliminating two exchange rate effects so that an estimate can be made of underlying changes in the consolidated income statement excluding the impact of fluctuations in exchanges rates:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The impact of translating the income statements of consolidated entities from their non-USD functional currencies to USD</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The impact of exchange rate movements on the major transactions of consolidated entities performed in currencies other than their functional currency.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We calculate constant currency measures by translating the current year&#x2019;s foreign currency values for sales and other income statement items into USD (excluding the IAS 29 &#x201C;Financial Reporting in Hyperinflationary Economies&#x201D; adjustments to the local currency income statements of subsidiaries operating in hyperinflationary economies), using the average exchange rates from the prior year and comparing them to the prior year values in USD.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We use these constant currency measures in evaluating the Group&#x2019;s performance, since they may assist us in evaluating our ongoing performance from year to year. However, in performing our evaluation, we also consider equivalent measures of performance that are not affected by changes in the relative value of currencies.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Growth rate calculation</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For ease of understanding, Novartis uses a sign convention for its growth rates such that a reduction in operating expenses or losses compared with the prior year is shown as a positive growth.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Free cash flow</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis defines free cash flow as net cash flows from operating activities and cash flows from investing activities associated with purchases and sales of property, plant and equipment, of intangible assets, of financial assets and of other non-current assets. Excluded from free cash flow are cash flows from investing activities associated with acquisitions and divestments of businesses and of interests in associated companies, purchases and sales of marketable securities, commodities, time deposits and net cash flows from financing activities.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Free cash flow is a non-IFRS measure and is not intended to be a substitute measure for net cash flows from operating activities as determined under IFRS. Free cash flow is presented as additional information because management believes it is a useful supplemental indicator of the Group&#x2019;s ability to operate without reliance on additional borrowing or use of existing cash. Free cash flow is a measure of the net cash generated that is available for investment in strategic opportunities, returning to shareholders and for debt repayment. Free cash flow is a non-IFRS measure, which means it should not be interpreted as a measure determined under IFRS. </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">65</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Additional information</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold; text-transform:uppercase;">NET DEBT</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis calculates net debt as current financial debts and derivative financial instruments plus non-current financial debt less cash and cash equivalents and marketable securities, commodities, time deposits and derivative financial instruments.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net debt is presented as additional information because it sets forth how management monitors net debt or liquidity and management believes it is a useful supplemental indicator of the Group&#x2019;s ability to pay dividends, to meet financial commitments, and to invest in new strategic opportunities, including strengthening its balance sheet. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For the table that shows the Group&#x2019;s net debt, see &#x201C;&#x2014; Item 5.B Liquidity and capital resources &#x2014; Group liquidity, financial debts and net debt.&#x201D;</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold; text-transform:uppercase;">EBITDA</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis defines earnings before interest, tax, depreciation and amortization (EBITDA) as operating income, excluding depreciation of property, plant and equipment, depreciation of right-of-use assets, amortization of intangible assets, and impairments of property, plant and equipment, right-of-use assets and of intangible assets.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&#xA0;197</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of property,  plant and equipment</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   1&#xA0;163</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   1&#xA0;208</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of    right-of-use assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   300</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   318</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of intangible  assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   3&#xA0;982</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   3&#xA0;903</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairments of property,  plant and equipment, right-of-use assets and  intangible assets<sup style="white-space: nowrap"> &#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     1&#xA0;736</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     684</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">EBITDA</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&#xA0;378</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&#xA0;802</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> There were no impairments of right-of-use assets in 2021.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold; text-transform:uppercase;">Enterprise value </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Enterprise value represents the total amount that shareholders and debt holders have invested in Novartis, less the Group&#x2019;s liquidity.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Market capitalization</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 191&#xA0;530</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 196&#xA0;107</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-controlling interests</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 81</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 167</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current financial debts</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20&#xA0;244</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22&#xA0;902</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current financial debts and  derivative financial instruments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   5&#xA0;931</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   6&#xA0;295</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities,  commodities, time deposits  and derivative financial  instruments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       -11&#xA0;413</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">       -15&#xA0;922</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7&#xA0;517</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -12&#xA0;407</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Enterprise value</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 198&#xA0;856</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 197&#xA0;142</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">66</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Reconciliation from IFRS results to core results </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables provide an overview of the reconciliation from IFRS results to core results:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 and 2021 reconciliation from IFRS results to core results</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines</div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz</div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate</div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions unless indicated otherwise)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">IFRS operating income</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&#xA0;786</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&#xA0;688</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;448</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&#xA0;600</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -1&#xA0;037</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -599</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&#xA0;197</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Amortization of intangible assets</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&#xA0;585</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&#xA0;528</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 221</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 236</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&#xA0;806</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&#xA0;764</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairments</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Intangible assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;291</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 360</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;318</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 387</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Property, plant and equipment related to the Group-wide rationalization of manufacturing sites</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   286</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   219</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   284</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   226</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Other property, plant and equipment</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 85</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 40</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 85</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 40</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total impairment charges</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;662</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 619</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;687</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 653</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquisition or divestment of businesses and related items</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;- Income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -64</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -66</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;- Expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 106</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 107</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total acquisition or divestment of  businesses and related items, net</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   42</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   41</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other items</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Divestment gains</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -161</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -649</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -75</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -166</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -728</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Financial assets - fair value adjustments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 134</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -43</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 126</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 260</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -38</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Restructuring and related items</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;- Income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -33</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -32</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -14</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -36</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -48</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -74</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;- Expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;572</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 833</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 167</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 193</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 449</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;188</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;058</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Legal-related items</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;- Income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -51</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -11</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -51</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -11</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;- Expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 364</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 170</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 56</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 420</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 223</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Additional income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -692</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -139</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -138</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -704</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -278</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Additional expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 63</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 241</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 48</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 72</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 289</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other items</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;196</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 381</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 211</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 194</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 564</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -134</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;971</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 441</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total adjustments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&#xA0;451</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&#xA0;527</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 455</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 464</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 562</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -92</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&#xA0;468</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&#xA0;899</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&#xA0;237</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&#xA0;215</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;903</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;064</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -475</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -691</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&#xA0;665</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;588</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">as % of net sales</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 36.9%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 36.2%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 20.6%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 21.4%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 33.0%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 32.1%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Loss)/income from associated companies</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&#xA0;332</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&#xA0;339</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core adjustments to income from associated companies, net of tax</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14&#xA0;346</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14&#xA0;346</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -837</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -811</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -80</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core adjustments to other financial income and expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 121</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes, adjusted for above items (core income taxes)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&#xA0;608</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;635</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&#xA0;352</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&#xA0;094</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core net income attributable to shareholders of Novartis AG</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&#xA0;352</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&#xA0;097</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core basic EPS  (USD)<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6.12</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6.29</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="18" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">67</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 and 2021 reconciliation from IFRS results to core results &#x2013; Group</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />2022 (USD millions unless indicated otherwise)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> IFRS results</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Amortization <br /> of intangible <br /> assets<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> Impairments<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Acquisition or <br /> divestment of <br /> businesses and<br /> related items<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br /> Other <br /> items<sup style="white-space: nowrap">4</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> Core results</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 36&#xA0;342</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&#xA0;648</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 338</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 64</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 40&#xA0;392</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&#xA0;197</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&#xA0;806</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;687</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;971</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&#xA0;665</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&#xA0;371</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&#xA0;806</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;687</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&#xA0;092</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&#xA0;960</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes<sup style="white-space: nowrap">&#xA0;5</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&#xA0;416</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&#xA0;608</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&#xA0;955</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&#xA0;352</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic EPS (USD)<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.19</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6.12</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;283</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -86</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;197</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -15&#xA0;486</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;648</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 338</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 150</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11&#xA0;350</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -14&#xA0;253</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 63</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -14&#xA0;190</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9&#xA0;996</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 158</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 954</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -204</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9&#xA0;088</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 805</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -414</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 384</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3&#xA0;701</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 398</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;462</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -833</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core income before taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 121</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 141</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to currently marketed products and other production-related intangible assets; research and development includes the amortization of acquired rights for technologies</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Impairments: cost of goods sold, research and development and other expense include impairment charges related to intangible assets; other income and other expense include net impairment charges related to property, plant and equipment</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: other income and other expense include transitional service fee income and charges related to divestments; other income also includes adjustments to provisions; other expense includes stamp duties related to an acquisition</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> Other items: other revenues includes a net income from an outlicensing agreement; cost of goods sold, selling, general and administration, research and development, other income and other expense include restructuring income and charges related to the restructuring initiative to implement a new streamlined organizational model, the Sandoz strategic review, the Group-wide rationalization of manufacturing sites and other net restructuring charges and related items; cost of goods sold, selling, general and administration, research and development and other expense include adjustments to provisions and related items; cost of goods sold and research and development also include contingent consideration adjustments; other income and other expense include fair value adjustments and divestment gains and losses on financial assets and legal-related items; other income also includes gains from the divestment of products and property, curtailment gains and an adjustment to an environmental provision; other expense includes a reversal of an accrual and other costs and items; other financial income and expense includes the monetary loss on the restatement of non-monetary items for subsidiaries in hyperinflationary economies and a revaluation impact of a financial liability incurred through the Alcon distribution</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> Taxes on the adjustments between IFRS and core results take into account, for each individual item included in the adjustment, the tax rate that will finally be applicable to the item based on the jurisdiction where the adjustment will finally have a tax impact. Generally, this results in amortization and impairment of intangible assets and acquisition-related restructuring and integration items having a full tax impact. There is usually a tax impact on other items, although this is not always the case for items arising from legal settlements in certain jurisdictions. Adjustments related to income from associated companies are recorded net of any related tax effect. Due to these factors and the differing effective tax rates in the various jurisdictions, the tax on the total adjustments of USD 7.6 billion to arrive at the core results before tax amounts to USD 1.2 billion. The average tax rate on the adjustments is 15.7% since the full year core tax charge of 16.3% has been applied to the pre-tax income of the period.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;6&#xA0;</sup> Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">68</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />2021 (USD millions unless indicated otherwise)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> IFRS results</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br /> Amortization<br /> of intangible<br /> assets<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> Impairments<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Acquisition or <br /> divestment of <br /> businesses and<br /> related items<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Other <br /> items<sup style="white-space: nowrap">4</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> Core results</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&#xA0;010</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&#xA0;655</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 414</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 41&#xA0;097</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&#xA0;764</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 653</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 41</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 441</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;588</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&#xA0;137</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&#xA0;974</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 653</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -14&#xA0;531</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 496</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;729</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes<sup style="white-space: nowrap">&#xA0;5</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;119</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;635</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24&#xA0;018</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&#xA0;094</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic EPS (USD)<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10.71</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6.29</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -15&#xA0;867</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;655</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 414</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -11&#xA0;780</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14&#xA0;886</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 71</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14&#xA0;815</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -9&#xA0;540</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 109</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 369</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -9&#xA0;041</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;852</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -100</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -66</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&#xA0;265</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 421</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;747</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 366</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 107</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;200</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&#xA0;074</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core income before taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&#xA0;339</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 210</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14&#xA0;556</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 993</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -80</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -16</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 55</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -41</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to currently marketed products and other production-related intangible assets; research and development includes the amortization of acquired rights for technologies; income from associated companies includes USD 210 million for the Novartis share of the estimated Roche core items</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Impairments: cost of goods sold and research and development include impairment charges related to intangible assets; other income and other expense include reversals of impairment charges and impairment charges related to property, plant and equipment</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: other income includes adjustments to portfolio transformation and Alcon spin-off accruals; other income and other expense include transitional service-fee income and expenses related to the Alcon distribution; other expense also includes adjustments to provisions; income from associated companies includes the gain related to the divestment of our investment in Roche; other financial income and expense includes other financial gains related to the divestment of our investment in Roche</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> Other items: cost of goods sold, research and development, other income and other expense include net restructuring and other charges related to the Group-wide rationalization of manufacturing sites; cost of goods sold, selling, general and administration, other income and other expense include other restructuring income and charges and related items; cost of goods sold, research and development, other income and other expense also include adjustments to contingent consideration; selling, general and administration, research and development, other income and other expense include adjustments to provisions; other income and other expense also include gains and losses from the divestment of products and financial assets and fair value adjustments on financial assets, adjustments to environmental provisions and legal-related items; other financial income and expense includes a charge related to the monetary loss due to hyperinflation in Argentina and Venezuela and a revaluation impact of a financial liability incurred through the Alcon distribution</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> Taxes on the adjustments between IFRS and core results take into account, for each individual item included in the adjustment, the tax rate that will finally be applicable to the item based on the jurisdiction where the adjustment will finally have a tax impact. Generally, this results in amortization and impairment of intangible assets and acquisition-related restructuring and integration items having a full tax impact. There is usually a tax impact on other items, although this is not always the case for items arising from legal settlements in certain jurisdictions. Adjustments related to income from associated companies are recorded net of any related tax effect. Due to these factors and the differing effective tax rates in the various jurisdictions, the tax on the total adjustments of USD 9.4 billion to arrive at the core results before tax amounts to USD 516 million. Excluding the gain on the divestment of our investment in Roche, the tax on the total adjustments of USD 5.2 billion to arrive at the core results before tax amounts to USD 516 million and the average tax rate on the adjustments was 10.0%.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;6&#xA0;</sup> Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">69</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 and 2021 reconciliation from IFRS results to core results &#x2013; Innovative Medicines</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />2022<br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> IFRS results</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Amortization<br /> of intangible<br /> assets<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> Impairments<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Acquisition or <br /> divestment of <br /> businesses and<br /> related items<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br /> Other <br /> items<sup style="white-space: nowrap">4</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> Core results</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 31&#xA0;801</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&#xA0;427</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 314</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -29</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 35&#xA0;513</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&#xA0;786</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&#xA0;585</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;662</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;196</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&#xA0;237</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;249</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -86</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;163</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11&#xA0;569</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;427</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 314</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7&#xA0;771</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11&#xA0;679</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11&#xA0;629</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9&#xA0;172</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 158</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 953</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -206</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8&#xA0;267</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 531</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -311</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 219</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&#xA0;695</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 396</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;692</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -599</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to currently marketed products and other production-related intangible assets; research and development includes the amortization of acquired rights for technologies</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Impairments: cost of goods sold, research and development and other expense include impairment charges related to intangible assets; other income and other expense include net impairment charges related to property, plant and equipment</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: other expense includes stamp duties related to an acquisition and transitional service fee charges related to divestments</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> Other items: other revenues includes a net income from an outlicensing agreement; cost of goods sold, selling, general and administration, research and development, other income and other expense include restructuring income and charges related to the initiative to implement a new streamlined organizational model, the Group-wide rationalization of manufacturing sites and other net restructuring charges and related items; cost of goods sold and research and development also include contingent consideration adjustments and adjustments to provisions and related items; other income and other expense include fair value adjustments and divestment gains and losses on financial assets and legal-related items; other income also includes gains from the divestment of products and property, curtailment gains and an adjustment to an environmental provision; other expense includes a reversal of an accrual and other costs and items</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />2021 <br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> IFRS results</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br /> Amortization<br /> of intangible<br /> assets<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> Impairments<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Acquisition or <br /> divestment of <br /> businesses and<br /> related items<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Other <br /> items<sup style="white-space: nowrap">4</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> Core results</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 32&#xA0;218</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&#xA0;419</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 344</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 35&#xA0;981</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&#xA0;688</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&#xA0;528</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 619</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 381</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&#xA0;215</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -11&#xA0;751</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;419</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 344</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -7&#xA0;988</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -12&#xA0;306</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 71</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -12&#xA0;235</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -8&#xA0;641</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 109</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 360</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -8&#xA0;150</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;149</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -45</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -837</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 265</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&#xA0;732</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 304</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 781</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -646</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to currently marketed products and other production-related intangible assets; research and development includes the amortization of acquired rights for technologies</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Impairments: research and development includes impairment charges related to intangible assets; other income and other expense include reversals of impairment charges and impairment charges related to property, plant and equipment</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: other income and other expense include transitional service fee income and expenses related to the Alcon distribution</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> Other items: cost of goods sold, research and development, other income and other expense include net restructuring and other charges related to the Group-wide rationalization of manufacturing sites; cost of goods sold, selling, general and administration, other income and other expense include other restructuring income and charges and related items; cost of goods sold, research and development and other expense include adjustments to contingent consideration; selling, general and administration, research and development and other expense include adjustments to provisions; other income and other expense include gains and losses from the divestment of products and financial assets and fair value adjustments on financial assets; other expense also includes legal-related items and adjustments to environmental provisions</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">70</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 and 2021 reconciliation from IFRS to core results &#x2013; Sandoz</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />2022<br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> IFRS results</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Amortization <br /> of intangible<br /> assets<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> Impairments<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Acquisition or <br /> divestment of <br /> businesses and<br /> related items</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br /> Other <br /> items<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> Core results</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&#xA0;504</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 221</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 24</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 93</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&#xA0;842</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;448</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 221</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 211</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;903</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4&#xA0;978</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 221</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 93</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4&#xA0;640</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&#xA0;062</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2&#xA0;053</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -824</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -821</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 103</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -14</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 87</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -273</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 121</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -152</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to currently marketed products and other production-related intangible assets</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Impairments: cost of goods sold and research and development include impairment charges related to intangible assets; other income includes a reversal of an impairment charge related to property, plant and equipment</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Other items: cost of goods sold, selling, general and administration, research and development, other income and other expense include charges related to the Sandoz strategic review, the Group-wide rationalization of manufacturing sites and other net restructuring charges and related items; other expense also includes legal-related items; cost of goods sold and selling, general and administration include adjustments to provisions and related items</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />2021<br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> IFRS results</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br /> Amortization <br /> of intangible<br /> assets<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> Impairments<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Acquisition or <br /> divestment of <br /> businesses and<br /> related items</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Other <br /> items<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> Core results</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&#xA0;725</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 236</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 70</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&#xA0;049</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&#xA0;600</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 236</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 34</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 194</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;064</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core gross profit</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -5&#xA0;147</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 236</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 70</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -4&#xA0;823</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -899</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -891</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 233</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -55</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -51</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 127</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -397</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 62</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 176</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -159</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Amortization of intangible assets: cost of goods sold includes the amortization of acquired rights to currently marketed products and other production-related intangible assets</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Impairments: cost of goods sold and research and development include impairment charges related to intangible assets; other income and other expense include reversals of impairment charges and impairment charges related to property, plant and equipment</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Other items: cost of goods sold, other income and other expense include net restructuring and other charges related to the Group-wide rationalization of manufacturing sites and other restructuring income and charges and related items; research and development includes adjustments to provisions; other income includes net gains from the divestment of a product; other income and other expense include legal-related items</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">71</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 and 2021 reconciliation from IFRS results to core results &#x2013; Corporate</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />2022<br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> IFRS results</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Amortization <br /> of intangible<br /> assets</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> Impairments<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Acquisition or <br /> divestment of <br /> businesses and<br /> related items<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br /> Other <br /> items<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> Core results</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 37</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 37</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating loss</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -1&#xA0;037</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 564</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -475</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating loss</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -512</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -508</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 171</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -89</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 78</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -733</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 649</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -82</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Impairments: other expense includes impairment charges related to intangible assets</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: other income includes adjustments to provisions and transitional service fee income related to divestments</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Other items: selling, general and administration, other income and other expense include restructuring income and charges related to the initiative to implement a new streamlined organizational model, the Sandoz strategic review and other net restructuring charges and related items; other income and other expense also include fair value adjustments and divestment gains and losses on financial assets; other income also includes a curtailment gain</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />2021<br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> IFRS results</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br /> Amortization <br /> of intangible<br /> assets</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> Impairments</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Acquisition or <br /> divestment of <br /> businesses and<br /> related items<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Other <br /> items<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br /> Core results</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 67</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 67</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating loss</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -599</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 42</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -134</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -691</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:16px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">The following are adjustments to arrive at core operating loss</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 470</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -64</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -377</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 29</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -618</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 106</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 243</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -269</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Acquisition or divestment of businesses and related items, including restructuring and integration charges: other income includes adjustments to portfolio transformation and Alcon spin-off accruals; other income and other expense include transitional service fee income and expenses related to the Alcon distribution; other expense also includes adjustments to provisions</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Other items: other income includes an adjustment to a contingent consideration receivable; other income and other expense include fair value adjustments and divestment gains and losses on financial assets, adjustments to environmental provisions and restructuring income and charges and related items</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">72</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Reconciliation of 2021 IFRS results and non-IFRS measures core results and free cash flow to exclude the impacts of the 2021 divestment of our Roche investment</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">To enhance investor understanding of the Group&#x2019;s performance in comparison with the prior year, we presented the 2021 IFRS results and non-IFRS measures core results and free cash flow excluding the impacts related to our Roche investment, due to its divestment in the fourth quarter of 2021. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following tables provide a reconciliation of our 2021 published IFRS results and non-IFRS measures core results and free cash flow to the 2021 results, excluding the impacts related to our Roche investment, due to its divestment.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="7" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="7" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="7" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions unless indicated otherwise)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br />
                <br />
                <br /> Results as <br /> published</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br /> Our Roche <br /> investment <br /> impacts<br /> excluding<br /> the divestment<br /> gain</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Gain on<br /> divestment<br /> of our<br /> investment<br /> in Roche</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Results <br /> excluding <br /> impacts <br /> from the <br /> divestment <br /> of our Roche<br /> investment</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&#xA0;339</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -785</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14&#xA0;556</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense and other financial  income and expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   -891</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   -16</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   -907</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before tax</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&#xA0;137</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -785</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -14&#xA0;572</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&#xA0;780</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;119</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;119</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24&#xA0;018</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -785</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -14&#xA0;572</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&#xA0;661</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10.71</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -0.35</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -6.50</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3.86</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Effective tax rate<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 8.1%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 19.7%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;588</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;588</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core income from associated companies</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 993</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -995</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core interest expense and core other  financial income and expense</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   -852</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   -852</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core income before tax</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;729</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -995</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&#xA0;734</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core income taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;635</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;635</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&#xA0;094</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -995</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&#xA0;099</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Core basic earnings per share (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6.29</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -0.45</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5.84</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Core effective tax rate<sup style="white-space: nowrap">&#xA0;2</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 15.8%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 16.7%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Free cash flow<sup style="white-space: nowrap">&#xA0;3</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&#xA0;282</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -522</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&#xA0;760</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Effective tax rate is calculated as Income taxes divided by Income before tax.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Core effective tax rate is calculated as Core income taxes divided by Core income before tax.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> The free cash flow impact represents the dividend received  in Q1 2021 from Roche in relation to the distribution of its 2020 net income.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">73</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"></div>
            </td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td colspan="5" style=";height:3;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td colspan="5" style=";height:3;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br />
                <br />
                <br />
                <br /> Free cash flow <br /> as published</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dividends <br /> received from <br /> Roche in <br /> relation to <br /> the distribution<br /> of its 2020 <br /> net income<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Free cash <br /> flow excluding<br /> dividends <br /> received <br /> from Roche</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustments for non-cash items</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&#xA0;030</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&#xA0;030</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income adjusted for non-cash items</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&#xA0;719</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&#xA0;719</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends received from associated companies and others</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 525</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -522</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest and other financial payments, net</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -953</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -953</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes paid</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;342</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;342</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other operating cash flow items, net</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -878</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -878</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&#xA0;071</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -522</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&#xA0;549</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net purchases of property, plant and equipment, intangible assets, financial assets and  other non-current assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   -1&#xA0;789</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   -1&#xA0;789</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Free cash flow</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&#xA0;282</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -522</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&#xA0;760</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> In 2021, the dividend received from Roche in relation to the distribution of its 2020 net income was received in Q1 2021.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides a summary of the percentage point impact from excluding the effect of the divestment of our investment in Roche (in the fourth quarter of 2021) on the USD and constant currencies % change on key Group figures.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> In USD</div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> In constant currencies</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br />
                <br />
                <br /> % change<br /> as published<br /> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change<br /> excluding <br /> impacts <br /> from the <br /> divestment <br /> of our Roche<br /> investment<br /> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br />
                <br /> Percentage<br /> point <br /> impact<br /> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br />
                <br />
                <br /> % change<br /> as published<br /> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % change<br /> excluding <br /> impacts <br /> from the <br /> divestment <br /> of our Roche<br /> investment<br /> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br />
                <br /> Percentage<br /> point <br /> impact<br /> 2022</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -71</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -20</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -51</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -67</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -58</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basic earnings per share (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -70</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -17</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -53</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -66</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -59</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Free cash flow</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core basic earnings per share (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
        </table>
      </div>
      <div id="anchorId0010024751"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">5.B Liquidity and capital resources</p>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables summarize the Group&#x2019;s cash flows and net debt:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows from operating activities</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&#xA0;236</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&#xA0;071</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows from investing activities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;468</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;208</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows used in financing activities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -20&#xA0;562</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -16&#xA0;264</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of exchange rate changes on cash and cash equivalents</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -32</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -266</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net change in cash and cash equivalents</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -4&#xA0;890</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;749</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in marketable securities, commodities, time deposits and derivative financial instruments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4&#xA0;509</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14&#xA0;017</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current and non-current financial debts and derivative financial instruments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;022</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&#xA0;847</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Change in net debt</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -6&#xA0;377</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&#xA0;613</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net debt at January 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -868</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -24&#xA0;481</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt at December 31</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -7&#xA0;245</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -868</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">74</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Cash flow</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Financial year 2022 compared with 2021 </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Net cash flows from operating activities amounted to USD 14.2 billion, compared with USD 15.1 billion in 2021. This decrease was mainly due to unfavorable changes in working capital and lower dividends from associated companies (2021 included the USD 0.5 billion dividends received from our investment in Roche, which was divested in the fourth quarter of 2021), partly offset by lower income taxes paid and favorable hedging results.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net cash inflows from investing activities amounted to USD 1.5 billion, compared with USD 4.2 billion in 2021.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The current year cash inflows were driven by net proceeds of USD 4.7 billion from the sale of marketable securities, commodities and time deposits; USD 0.5 billion from the sale of intangible assets, financial assets and property, plant and equipment. These cash inflows were partly offset by cash outflows of USD 1.5 billion for purchases of intangible assets; USD 1.2 billion for purchases of property, plant and equipment; USD 0.1 billion for purchases of financial assets; and USD 0.9 billion for acquisitions and divestments of businesses, net (primarily the acquisition of Gyroscope Therapeutics Holdings plc for USD 0.8 billion). </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2021, net cash inflows from investing activities of USD 4.2 billion were driven by proceeds of USD 20.7 billion from the divestment of our investment in Roche; USD 2.3 billion from the sale of marketable securities, commodities and time deposits; and USD 1.4 billion from the sale of intangible assets, financial assets and property, plant and equipment. These cash inflows were partly offset by USD 16.4 billion cash outflows for purchases of marketable securities and time deposits, mainly due to the investment of a portion of the proceeds from the divestment of our investment in Roche; USD 1.6 billion for purchases of intangible assets (including the upfront payment to in-license tislelizumab from an affiliate of BeiGene, Ltd); USD 1.4 billion for purchases of property, plant and equipment; USD 0.6 billion for acquisitions and divestments of businesses, net (including the acquisition of GSK&#x2019;s cephalosporin antibiotics business for USD 351 million); and USD 0.2 billion for purchases of financial assets.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net cash outflows used in financing activities amounted to USD 20.6 billion, compared with USD 16.3 billion in 2021.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The current year cash outflows were mainly driven by USD 10.6 billion for net treasury share transactions; USD 7.5 billion for the dividend payment; USD 2.5 billion in aggregate for the repayment of two US dollar bonds; and USD 0.3 billion payments of lease liabilities. These cash outflows were partly offset by cash inflows of USD 0.3 billion from the net increase in current financial debts. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2021, net cash outflows used in financing activities of USD 16.3 billion were driven by USD 7.4 billion for the dividend payment; USD 3.0 billion for net treasury share transactions; USD 3.5 billion net decrease in current financial debts; and USD 2.2 billion for the repayment of two bonds denominated in euro (notional amount of EUR 1.25 billion and of EUR 0.6 billion) at maturity. Payments of lease liabilities and other financing cash flows resulted in a net cash outflow of USD 0.2 billion.</div>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Free cash flow</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Free cash flow is a non-IFRS measure, see &#x201C;&#x2014;Item 5.A Operating results&#x2014;Non-IFRS measures as defined by Novartis&#x2014;Free cash flow&#x201D; for further information. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following table is a reconciliation of the three major categories of the IFRS consolidated statements of cash flows to free cash flow:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> IFRS <br /> cash flow</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Adjustments</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Free <br /> cash flow</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> IFRS <br /> cash flow</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;">
                <br /> Adjustments</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> Free <br /> cash flow</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&#xA0;236</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&#xA0;236</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&#xA0;071</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&#xA0;071</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from/(used in) investing activities<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;468</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -3&#xA0;759</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -2&#xA0;291</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&#xA0;208</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -5&#xA0;997</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -1&#xA0;789</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows used in financing activities<sup style="white-space: nowrap">&#xA0;2</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -20&#xA0;562</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20&#xA0;562</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -16&#xA0;264</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&#xA0;264</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Free cash flow</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&#xA0;945</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&#xA0;282</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Excluded from the free cash flow are cash flows from investing activities associated with acquisitions and divestments of businesses and of interest in associated companies, purchases and sales of marketable securities, commodities and time deposits.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Net cash flows used in financing activities are excluded from the free cash flow.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">75</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following table is a summary of the free cash flow:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&#xA0;197</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;689</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustments for non-cash items</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Depreciation, amortization and impairments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&#xA0;441</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&#xA0;075</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Change in provisions and other non-current liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;403</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 896</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Other</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 460</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 59</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income adjusted for non-cash items</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&#xA0;501</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&#xA0;719</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends received from associated companies and others</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 525</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest and other financial receipts</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 325</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest and other financial payments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -728</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -966</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes paid</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&#xA0;975</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;342</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments out of provisions and other net cash movements in non-current liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -885</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&#xA0;119</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in inventories and trade receivables less trade payables</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&#xA0;467</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -329</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other net current assets and other operating cash flow items</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 464</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 570</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&#xA0;236</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&#xA0;071</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of property, plant and equipment</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&#xA0;198</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&#xA0;378</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of property, plant and equipment</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 167</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 240</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of intangible assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1&#xA0;473</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1&#xA0;593</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of intangible assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 202</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 748</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of financial assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -121</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -191</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of financial assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 133</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 442</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of other non-current assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -61</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of other non-current assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Free cash flow</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&#xA0;945</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&#xA0;282</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Financial year 2022 compared with 2021</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Free cash flow amounted to USD 11.9 billion (&#x2013;10% USD), compared with USD 13.3 billion in 2021, mainly due to a decrease in net cash flows from operating activities and lower divestment proceeds, partly offset by lower purchases of property, plant and equipment.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">76</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Condensed consolidated balance sheets </span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Dec 31, 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Assets</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;764</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&#xA0;545</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;431</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;561</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29&#xA0;301</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 29&#xA0;595</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets other than goodwill</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31&#xA0;644</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 34&#xA0;182</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investments in associated companies</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 143</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 205</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;739</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;743</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial assets and other non-current assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;521</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&#xA0;246</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 80&#xA0;543</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 86&#xA0;077</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&#xA0;175</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&#xA0;666</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&#xA0;066</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&#xA0;005</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current assets and income tax receivables</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;739</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;718</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, commodities, time deposits and derivative financial instruments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;413</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&#xA0;922</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&#xA0;517</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&#xA0;407</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 36&#xA0;910</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 45&#xA0;718</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total assets</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 117&#xA0;453</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 131&#xA0;795</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Equity and liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 59&#xA0;423</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 67&#xA0;822</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debts</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20&#xA0;244</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22&#xA0;902</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;538</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;621</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;686</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;070</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other non-current liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;906</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&#xA0;172</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&#xA0;374</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 33&#xA0;765</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;146</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&#xA0;553</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debts and derivative financial instruments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;931</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&#xA0;295</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 251</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 275</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other current liabilities and current income tax liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17&#xA0;328</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&#xA0;085</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&#xA0;656</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 30&#xA0;208</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 58&#xA0;030</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 63&#xA0;973</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity and liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 117&#xA0;453</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 131&#xA0;795</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Assets</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Total non-current assets of USD 80.5 billion at December 31, 2022, decreased by USD 5.5 billion compared to December 31, 2021. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Intangible assets other than goodwill decreased by USD 2.5 billion as additions (including the acquisition of Gyroscope Therapeutics Holdings plc) were more than offset by amortization, impairments and unfavorable currency translation adjustments.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Goodwill decreased by USD 0.3 billion, mainly due to unfavorable currency translation adjustments. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Property, plant and equipment decreased by USD 0.8 billion, as net additions were more than offset by depreciation, unfavorable currency translation adjustments and impairments. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Financial and other non-current assets decreased by USD 1.7 billion, driven by the decrease of the prepaid post-employment benefit plans of USD 0.9 billion, resulting mainly from the pension accounting effects from increases in actuarial discount rates and of USD 0.6 billion from fair value losses on listed equity and fund investments.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets, investments in associated companies and deferred tax assets were broadly in line with December 31, 2021. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total current assets of USD 36.9 billion at December 31, 2022, decreased by USD 8.8 billion compared to December 31, 2021.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Cash and cash equivalents decreased by USD 4.9 billion, mainly due to the dividend payment, the purchase of treasury shares and net repayments of financial debt, partly offset by the cash generated from operating activities and from investing activities, which includes the net proceeds from the sales of marketable securities, commodities and time deposits. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities, commodities, time deposits and derivative financial instruments decreased by USD 4.5 billion mainly driven by the net sales of marketable securities, commodities and time deposits.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Inventories increased by USD 0.5 billion and trade receivables and other current assets and income tax receivables were broadly in line with December 31, 2021.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We consider our provisions for doubtful trade receivables to be adequate. We particularly monitor the level of trade receivables in countries deemed to have an </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">77</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">elevated credit risk. We consider macroeconomic environment, historical experience, country and political risk, in addition to other relevant information when assessing risk. These risk factors are monitored regularly to determine any adjustments in risk classification. The majority of the past due trade receivables from elevated credit risk countries are due from local governments or from government-funded entities. Deteriorating credit and economic conditions as well as other factors in these elevated credit risk countries have resulted in, and may continue to result in, an increase in the average length of time that it takes to collect these trade receivables and may require the Group to re-evaluate the expected credit loss amount of these trade receivables in future periods. At December 31, 2022, amounts past due for more than one year were not significant in elevated credit risk countries.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For a table showing an overview of the aging analysis of total trade receivables and the total amount of the provision for doubtful trade receivables as of December 31, 2022, and 2021, see &#x201C;Item 18. Financial Statements&#x2014;Note 15. Trade receivables.&#x201D;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There is also a risk that certain countries could devalue their currency. Currency exposures are described in more detail in &#x201C;&#x2014;Effects of currency fluctuations.&#x201D;</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Liabilities</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Total non-current liabilities of USD 29.4 billion decreased by USD 4.4 billion compared to December 31, 2021.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Non-current financial debts decreased by USD 2.7 billion, mainly due to the reclassification of USD 2.3 billion from non-current to current financial debts of two EUR denominated bonds with notional amounts of EUR 750 million and EUR 1.25 billion maturing in 2023 and favorable currency translation adjustments of USD 0.4 billion.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions and other non-current liabilities decreased by USD 1.3 billion, mainly driven by decreases in accrued liabilities for employee benefits of USD 1.2 billion (primarily due to a decrease in accrued liabilities for defined benefit pension plans of USD 0.9 billion, resulting from the pension accounting effects from increases in actuarial discount rates), and in contingent consideration of USD 0.3 billion, a reclassification of non-current legal matters provisions to current portion of USD 0.2 billion, partly offset by the increase in other non-current liabilities of USD 0.4 billion.  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Deferred tax liabilities decreased by USD 0.4 billion and non-current lease liabilities were broadly in line with December 31, 2021.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total current liabilities of USD 28.7 billion decreased by USD 1.6 billion compared to December 31, 2021.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions and other current liabilities and current income tax liabilities decreased by USD 0.8 billion, mainly driven by the decrease in the commitment for repurchase of own shares liability of USD 2.8 billion, partly offset by increases in restructuring provisions of USD 0.8 billion (primarily due to the initiative announced in April 2022, to implement a new streamlined organizational model), in provisions for legal matters of USD 0.5 billion, including a USD 0.2 billion reclassification from non-current provisions for legal matters, and in provisions for revenue deductions of USD 0.3 billion.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Current financial debts and derivative financial instruments decreased by USD 0.4 billion, mainly due to the repayment of two US dollar bonds of USD 1.0 billion and USD 1.5 billion, the closure during the third quarter of 2022 of the interest-bearing accounts of employees payable on demand, which amounted to USD 1.8 billion at December 31, 2021, and favorable currency translation adjustments, partly offset by the reclassification from non-current to current financial debts of USD 2.3 billion and an increase of USD 1.9 billion in commercial paper.  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Trade payables decreased by USD 0.4 billion and current lease liabilities were broadly in line with December 31, 2021.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In our key countries, Switzerland and the United States, assessments have been agreed by the tax authorities up to 2017 in Switzerland and up to 2014 in the United States, with the exception of one open United States position related to the 2007 tax filing. Uncertainties also exist on the application of a taxing right based on a German non-resident tax regulation for specific revenues derived from German registered intellectual property rights.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis believes that its total provisions are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities in this area, Novartis may incur additional costs beyond the amounts provided. Management believes that such additional amounts, if any, would not be material to the Group&#x2019;s financial condition but could be material to the results of operations or cash flows in a given period.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Equity</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group`s equity decreased by USD 8.4 billion to USD 59.4 billion at December 31, 2022, compared to December 31, 2021. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">This decrease was mainly due to the cash-dividend payment of USD 7.5 billion, purchase of treasury shares of USD 10.9 billion, unfavorable currency translation differences of USD 0.5 billion and fair value adjustments on equity securities of USD 0.4 billion. This was partially offset by the net income of USD 7.0 billion, decrease of the treasury share repurchase obligation of USD 2.8 billion, and equity-based compensation of USD 0.9 billion.  </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">78</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Summary of equity movements attributable to Novartis AG shareholders</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Number of outstanding shares  (in millions)</div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity attributable to   Novartis AG shareholders</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br /> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022<br /> USD millions</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021<br /> USD millions</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at beginning of year</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&#xA0;234.9</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;256.8</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 67&#xA0;655</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 56&#xA0;598</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be canceled</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -126.2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -30.7</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -10&#xA0;787</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;775</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1.4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -1.5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -123</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -145</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 88</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10.4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 854</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 745</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees as a result of the Alcon spin-off</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes on treasury share transactions</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Decrease/(increase) of treasury share repurchase  obligation under a share buyback trading plan</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   2&#xA0;809</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   -1&#xA0;040</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transaction costs, net of taxes</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7&#xA0;506</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -7&#xA0;368</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income of the year attributable to shareholders of Novartis AG</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&#xA0;955</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24&#xA0;021</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other comprehensive income attributable to shareholders of Novartis AG</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -839</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2&#xA0;493</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 217</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 48</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at end of year</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&#xA0;119.6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;234.9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 59&#xA0;342</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 67&#xA0;655</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Impact of hyperinflationary economies (see &#x201C;Item 18. Financial Statements&#x2014;Note 1. Significant accounting policies").</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, Novartis repurchased a total of 126.2 million shares for USD 10.8 billion on the SIX Swiss Exchange second trading line, including 115.3 million shares (USD 9.9 billion) under the up-to USD 15 billion share buyback announced in December 2021 and 10.9 million shares (USD 0.9 billion) to mitigate dilution related to participation plans of associates. In addition, 1.4 million shares (USD 0.1 billion) were repurchased from associates. In the same period, 12.3 million shares (for an equity value of USD 0.9 billion) were delivered as a result of option exercises and share deliveries related to participation plans of associates. Consequently, the total number of shares outstanding decreased by 115.3 million versus December 31, 2021. These treasury share transactions resulted in a decrease in equity of USD 10.0 billion and a net cash outflow of USD 10.6 billion.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2021, Novartis repurchased a total of 30.7 million shares for USD 2.8 billion on the SIX Swiss Exchange second trading line, including 19.6 million shares (USD 1.8 billion) under the up-to USD 2.5 billion share buyback announced in November 2020, 8.6 million shares (USD 0.8 billion) to mitigate dilution related to participation plans of associates and 2.5 million shares (USD 0.2 billion) under the up-to USD 15 billion share buyback announced in December 2021. In addition, 1.5 million shares (USD 0.1 billion) were repurchased from associates. In the same period, 10.3 million shares (for an equity value of USD 0.8 billion) were delivered as a result of options exercised and share deliveries related to participation plans of associates. Consequently, the total number of shares outstanding decreased by 21.9 million versus December 31, 2020. These treasury share transactions resulted in a decrease in equity of USD 2.1 billion and a net cash outflow of USD 3.0 billion. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Treasury shares</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At December 31, 2022, our holding of treasury shares amounted to 284.1 million shares, or approximately 12% of the total number of issued shares. Approximately 99.0 million treasury shares were held in entities that restrict their availability for use.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">At December 31, 2021, our holding of treasury shares amounted to 199.5 million shares, or approximately 8% of the total number of issued shares. Approximately 102.5 million treasury shares were held in entities that restrict their availability for use.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">79</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Effects of currency fluctuations</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We transact our business in many currencies other than the US dollar, our reporting currency.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following table provides an overview of net sales and operating expenses based on IFRS values for 2022 and 2021, for currencies most important to the Group:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />Currency</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Net sales<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Operating<br /> expenses<br /> %<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br /> Net sales<br /> %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Operating<br /> expenses<br /> %<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 29</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chinese yuan (CNY)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canadian dollar (CAD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">British pound (GBP)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Russian ruble (RUB)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Brazilian real (BRL)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Australian dollar (AUD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other currencies</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Operating expenses include cost of goods sold; selling, general and administration; research and development; other income and other expense.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We prepare our consolidated financial statements in US dollars. As a result, fluctuations in the exchange rates between the US dollar and other currencies can have a significant effect on both the Group&#x2019;s results of operations as well as the reported value of our assets, liabilities and cash flows. This in turn may significantly affect reported earnings (both positively and negatively) and the comparability of period-to-period results of operations.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For purposes of our consolidated balance sheets, we translate assets and liabilities denominated in other currencies into US dollars at the prevailing market exchange rates as of the relevant balance sheet date. For purposes of the Group&#x2019;s consolidated income and cash flow statements, revenue, expense and cash flow items in local currencies are translated into US dollars at average exchange rates prevailing during the relevant period. As a result, even if the amounts or values of these items remain unchanged in the respective local currency, changes in exchange rates have an impact on the amounts or values of these items in our consolidated financial statements.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Because our expenditure in Swiss francs is significantly higher than our revenue in Swiss francs, volatility in the value of the Swiss franc can have a significant impact on the reported value of our earnings, assets and liabilities, and the timing and extent of such volatility can be difficult to predict. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group manages its global currency exposure by engaging in hedging transactions where management deems appropriate, after taking into account the natural hedging afforded by our global business activity. In 2022 and 2021, we entered into various contracts that change in value with movements in foreign exchange rates, to preserve the value of assets, commitments and expected transactions. We use forward contracts and foreign currency options to hedge. For more information on how these transactions affect our consolidated financial statements and on how foreign exchange rate exposure is managed, see &#x201C;Item 18. Financial Statements&#x2014;Note 1. Significant accounting policies,&#x201D; &#x201C;Item 18. Financial Statements&#x2014;Note 5. Interest expense and other financial income and expense,&#x201D; &#x201C;Item 18. Financial Statements&#x2014;Note 15. Trade receivables,&#x201D; &#x201C;Item 18. Financial Statements&#x2014;Note 28. Commitments and contingent liabilities&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 29. Financial instruments &#x2013; additional disclosures.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">80</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table sets forth the foreign exchange rates of the US dollar against key currencies used for foreign currency translation when preparing the Group&#x2019;s consolidated financial statements:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Average for year</div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Year-end</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">USD per unit</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Australian dollar (AUD)</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.695</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.752</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.678</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.726</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Brazilian real (BRL)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.194</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.186</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.189</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.180</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canadian dollar (CAD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.769</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.798</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.738</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.785</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.048</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.094</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.081</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.093</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chinese yuan (CNY)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.149</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.155</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.144</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.157</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.054</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.183</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.065</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.131</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">British pound (GBP)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.237</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.376</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.207</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.351</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -11</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY (100))</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.766</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.912</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -16</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.757</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.868</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -13</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Russian ruble (RUB (100))</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.481</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.357</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.380</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.336</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides a summary of the currency impact on key Group figures due to their conversion into US dollars, the Group&#x2019;s reporting currency. For additional information on the constant currency calculation (&#x201C;cc&#x201D;), see &#x201C;&#x2014;Item 5.A Operating results&#x2014;Non-IFRS measures as defined by Novartis&#x2014;Constant currencies&#x201D;.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Currency impact on key figures</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Change in<br /> USD %<br /> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in<br />  constant<br />  currencies %<br /> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Percentage<br /> point currency<br />  impact<br /> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br /> Change in<br /> USD %<br /> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change in<br />  constant<br />  currencies %<br /> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Percentage<br /> point currency<br />  impact<br /> 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Group</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net sales to third parties</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -21</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -13</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -71</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -67</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 198</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 195</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basic earnings per share (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -70</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -66</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 202</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 200</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core net income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core basic earnings per share (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net sales to third parties</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -18</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net sales to third parties</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 48</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating income</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -12</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -14</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Corporate</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Operating loss</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -73</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -84</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating loss</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -23</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -20</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For additional information on the effects of currency fluctuations, see &#x201C;Item 18. Financial Statements&#x2014;Note 29. Financial instruments &#x2013; additional disclosures.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">81</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Group liquidity, financial debts and net debt</span>
      </div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows Group liquidity, financial debts and net debt:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current financial debts</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -20&#xA0;244</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -22&#xA0;902</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current financial debts and derivative financial instruments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -5&#xA0;931</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -6&#xA0;295</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial debts</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -26&#xA0;175</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -29&#xA0;197</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less liquidity</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Cash and cash equivalents</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&#xA0;517</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&#xA0;407</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Marketable securities, commodities, time deposits and derivative financial instruments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   11&#xA0;413</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   15&#xA0;922</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liquidity</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&#xA0;930</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28&#xA0;329</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt at December 31<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> -7&#xA0;245</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -868</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> For further information about the net debt measure, which is a non-IFRS measure, see &#x201C;&#x2014;Item 5.A Operating results&#x2014;Non-IFRS measures as defined by Novartis&#x2014;Net debt.&#x201D;</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Financial year 2022 </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Group net debt at December 31, 2022, increased to USD&#xA0;7.2 billion, compared with USD&#xA0;0.9 billion at December 31, 2021.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total financial debts amounted to USD 26.2 billion at December 31, 2022, compared with USD 29.2 billion at December 31, 2021. Non-current financial debts decreased by USD 2.7 billion, mainly due to the reclassification of USD 2.3 billion from non-current to current financial debts of two EUR denominated bonds with notional amounts of EUR 750 million and EUR 1.25 billion maturing in 2023 and favorable foreign currency translation adjustments of USD 0.4 billion.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Current financial debts and derivative financial instruments decreased by USD 0.4 billion, mainly due to the repayment of two US dollar bonds of USD 1.0 billion and USD 1.5 billion, the closure during the third quarter of 2022 of the interest-bearing accounts of employees payable on demand, which amounted to USD 1.8 billion at December 31, 2021, and favorable currency translation adjustments, partly offset by the reclassification from non-current to current financial debts of USD 2.3 billion and an increase of USD 1.9 billion in commercial paper.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis has two US commercial paper programs under which it can issue up to USD 9.0 billion in the aggregate of unsecured commercial paper notes. Novartis also has a Japanese commercial paper program under which it can issue up to JPY 150 billion (approximately USD 1.1 billion) of unsecured commercial paper notes. Commercial paper notes totaling USD 2.8 billion under these three programs were outstanding as per December 31, 2022 (2021: USD 0.9 billion).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis also has a committed credit facility of USD&#xA0;6.0 billion, which was extended in 2022. This credit facility is provided by a syndicate of banks and is intended to be used as a backstop for the US commercial paper programs. The extended facility matures in September 2025 and was undrawn as per December 31, 2022, and December 31, 2021.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total liquidity decreased to USD 18.9 billion compared with USD 28.3 billion at December 31, 2021. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of year-end 2022, Moody&#x2019;s Investors Service rated the Company A1 for long-term maturities and P-1 for short-term maturities and S&amp;P Global Ratings rated the company AA- for long-term maturities and A-1+ for short-term maturities.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For the tables showing the maturity schedule of our current financial assets, current and non-current financial debts and net debt at December 31, 2022 and December 31, 2021, see &#x201C;Item 18. Financial Statements&#x2014;Note 29. Financial instruments - Additional disclosures&#x2014;Nature and extent of risks arising from financial instruments&#x2014;Liquidity risk.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For a description of risks and restrictions on the ability of subsidiaries to transfer funds to the Company via cash dividends, loan or advances, please see &#x201C;&#x2014;Liquidity/short-term funding&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 29. Financial instruments - Additional disclosures&#x2014;Nature and extent of risks arising from financial instruments.&#x201D; </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Information regarding the Company&#x2019;s material commitments for capital expenditures as of the end of 2022 and 2021 and an indication of the general purpose of such commitments and the anticipated sources of funds needed to fulfill such commitments are provided in &#x201C;&#x2014;Material short- and long-term cash requirements.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">82</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Liquidity and financial debt by currency </span>
      </div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides a breakdown of liquidity and financial debt by currency as of December 31:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Liquidity<br /> in % 2022<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br /> Liquidity<br /> in % 2021<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Financial<br /> debt in %<br /> 2022<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Financial<br /> debt in %<br /> 2021<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USD</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 85</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 92</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 62</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 57</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">EUR</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">JPY</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Liquidity includes cash and cash equivalents and marketable securities, including debt securities, commodities and time deposits.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="10">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Financial debt includes non-current and current financial debt.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Bonds </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In April 2022, a 5-year USD denominated bond of USD 1.0 billion with a coupon of 2.40% was repaid, in advance of its maturity date at no additional cost. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In September 2022, a 10-year USD denominated bond of USD 1.5 billion with a coupon of 2.40% was repaid at maturity.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In March 2021, a 4-year EUR denominated bond of EUR 1.25 billion with a coupon of 0.00% was repaid at maturity.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In November 2021, a 7-year EUR denominated bond of EUR 0.6 billion with a coupon of 0.75% was repaid at maturity.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Liquidity/short-term funding</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s liquidity amounted to USD 18.9 billion at December 31, 2022, compared with USD 28.3 billion at December 31, 2021. Total non-current and current &#xFB01;nancial debts, including derivatives, amounted to USD 26.2 billion at December 31, 2022, compared with USD 29.2 billion at December 31, 2021.  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The debt/equity ratio increased to 0.44:1 at December 31, 2022, compared with 0.43:1 at December 31, 2021. The net debt increased to USD 7.2 billion at December 31, 2022, compared with USD 0.9 billion at December 31, 2021.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We continuously track our liquidity position and asset/liability profile. This involves modeling cash flow maturity profiles based on both historical experiences and contractual expectations to project our liquidity requirements. We seek to preserve prudent liquidity and funding capabilities. We are confident that we have sufficient liquidity to support our normal business activities for the foreseeable future.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain countries have legal or economic restrictions on the ability of subsidiaries to transfer funds to the Group in the form of cash dividends, loans or advances, but these restrictions do not have an impact on the ability of the Group to meet its cash obligations. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We are not aware of any significant demands to change the level of liquidity needed to support our normal business activities. We make use of various borrowing facilities provided by several financial institutions. We also successfully issued various bonds in previous years and raised funds through our commercial paper programs.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The maturity schedule of our net debt can be found in &#x201C;Item 18. Financial Statements&#x2014;Note 29. Financial instruments - Additional disclosures&#x2014;Nature and extent of risks arising from financial instruments&#x2014;Liquidity risk.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">83</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Material short- and long-term cash requirements</span>
      </div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the Group&#x2019;s material short- and long-term cash requirements:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="9" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Payments due by period</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="9" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="9" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />(USD millions)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Total</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Less than<br /> 1 year</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> 2&#x2013;3 years</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> 4&#x2013;5 years</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> After<br /> 5 years</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current financial debt, including current portion</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22&#xA0;485</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;241</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;428</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;547</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;269</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest on non-current financial debt, including current portion</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&#xA0;532</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 476</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 821</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 611</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;624</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities, non-current and current portion</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;789</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 251</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 357</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 259</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 922</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest on lease liabilities, non-current and current portion</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;416</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 46</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;227</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitments for leases not yet commenced</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 83</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Unfunded pensions and other post-employment benefit plans</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;281</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 115</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 215</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 204</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 747</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development potential milestone commitments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&#xA0;814</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 420</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;256</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 969</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;169</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 835</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 131</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 339</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 267</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment purchase commitments</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 549</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 441</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 93</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total contractual cash obligations</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 39&#xA0;784</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&#xA0;131</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&#xA0;599</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&#xA0;785</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 21&#xA0;269</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="12" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group intends to fund the research and development; property, plant and equipment; intangible asset purchase commitments with internally generated resources, and the acquisition of business commitment through available cash and short- and long-term borrowings. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For other contingent liabilities, see &#x201C;Item 8. Financial Information&#x2014;Item 8.A Consolidated statements and other financial information,&#x201D; &#x201C;Item 18. Financial Statements&#x2014;Note 10. Right-of-use assets and lease liabilities,&#x201D; &#x201C;Item 18. Financial Statements&#x2014;Note 20. Provisions and other non-current liabilities,&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 28. Commitments and contingent liabilities.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">84</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"></div>
      <div id="anchorId0010028559"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">5.C Research and development, patents and licenses</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our research and development spending totaled USD&#xA0;10.0 billion and USD&#xA0;9.5 billion (Core research and development USD&#xA0;9.1 billion and USD&#xA0;9.0 billion) for the years 2022 and 2021, respectively. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Each of our divisions has its own research and development and patents. Our divisions have numerous products in various stages of development. For further information on these policies and these products in development, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview.&#x201D;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As described in the risk factors section and elsewhere in this Annual Report, our drug development efforts are subject to the risks and uncertainties inherent in any new drug development program. Due to the risks and uncertainties involved in progressing through preclinical development and clinical trials, and the time and cost involved in obtaining regulatory approvals, among other factors, we cannot reasonably estimate the timing, completion dates and costs, or range of costs, of our drug development programs, or of the development of any particular development compound (see &#x201C;Item 3. Key Information&#x2014;Item 3.D Risk factors&#x201D;). In addition, for a description of the research and development process for the development of new drugs and our other products, and the regulatory process for their approval, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview.&#x201D;</div>
      <div id="anchorId0010028577"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">5.D Trend information</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Please see &#x201C;&#x2014;Item 5.A Operating results&#x201D;, &#x201C;&#x2014;Item 5.B Liquidity and capital resources&#x201D; and &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Business overview&#x201D; for trend information.</div>
      <div id="anchorId0010028584"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">5.E Critical accounting estimates </p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our consolidated financial statements are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). The preparation of financial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the year, which affect the reported amounts of revenues, expenses, assets, liabilities and contingent amounts. Our significant accounting policies that are set out in &#x201C;Item 18. Financial Statements&#x2014;Note 1. Significant accounting policies&#x201D; include a description of the estimates, assumptions and judgments applied in the preparation of the consolidated financial statements of the Group.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Given the uncertainties inherent in our business activities, we must make certain estimates and assumptions that require difficult, subjective and complex judgments. Because of uncertainties inherent in such judgments, actual outcomes and results may differ from our assumptions and estimates, which could materially affect the Group&#x2019;s consolidated financial statements. Application of the following accounting policies requires certain assumptions and estimates that have the potential for the most significant impact on our consolidated financial statements.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Management believes that the estimation uncertainties described below did not have or are not reasonably likely to have a material impact on the Group&#x2019;s financial condition but could be material to the results of operations or cash flows in a given period.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Deductions from revenues</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As is typical in the pharmaceutical industry, the consideration we receive in exchange for goods and services maybe fixed or variable. The most common elements of variable consideration are primarily composed of rebates and discounts granted to wholesalers, retailers, government agencies, government supported healthcare systems, private health systems, pharmacy benefit managers, managed healthcare organizations and other customers. Variable consideration is recognized when it is highly probable that a significant reversal will not occur. These elements of variable consideration represent estimates of the related obligations, requiring the use of judgment when estimating the effect of these considerations for a reporting period.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following summarizes the nature of some of these deductions and how the deduction is estimated. After recording these, net sales represent our best estimate of the cash that we expect to ultimately collect. The US market has the most complex arrangements related to revenue deductions.</div>
      <div>
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">United States-specific healthcare plans and program rebates</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The United States Medicaid Drug Rebate Program is administered by state governments, using state and federal funds to provide assistance to certain vulnerable and needy individuals and families. Calculating the rebates to be paid related to this program involves use of estimates and interpreting relevant regulations, which are subject to challenge or change in interpretative </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">85</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">guidance by government authorities. Provisions for estimated Medicaid rebates are calculated using a combination of historical experience, product and population growth, product pricing, and the mix of contracts and specific terms in the individual state agreements.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The United States Federal Medicare Program, which funds healthcare benefits to individuals aged 65 and older, and to people with certain disabilities, provides prescription drug benefits under the Part D section of the program. This benefit is provided and administered through private prescription drug plans. Calculating the rebates to be paid related to this program involves use of estimates and interpreting relevant regulations, which are subject to challenge or change in interpretative guidance by government authorities. Provisions for estimated Medicare Part D rebates are calculated based on the terms of individual plan agreements, product sales and population growth, product pricing, including inflation impacts, and the mix of contracts.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We offer rebates to key managed healthcare and private plans in an effort to ensure patient access to our products and to sustain and increase the market share of our products. These programs provide a rebate after the plans have demonstrated they have met all terms and conditions set forth in their contract with us. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">These rebates and discounts, applied using provision rates, are estimated based on the specific terms in the individual states and plans agreements, historical experience, product pricing and projected product growth rates, as appropriate to the individual rebate and discount arrangements, and are recorded as a deduction from revenue at the time the related revenues are recorded. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">These provisions are adjusted based on established processes and experiences from filing data with individual states and plans. There is often a time lag between recording of revenue deductions and the final accounting for them.</div>
      <div>
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Non-United States-specific healthcare plans and program rebates</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In certain countries other than the US, we provide rebates to governments and other entities. These rebates are often mandated by laws or government regulations. These rebates, applied using provision rates, are estimated based on government regulations, laws and terms of individual rebate arrangements, historical experience and other relevant factors, and are recorded as a deduction from revenue at the time the related revenue is recorded. These estimates are adjusted periodically to reflect actual experience. There is often a time lag between the recording of revenue deductions and the final accounting for them.</div>
      <div>
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative pay-for-performance arrangements</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We enter into innovative pay-for-performance arrangements (i.e. outcome based arrangements) with certain healthcare providers and governments. Under these agreements, we may be required to make refunds, defer a portion of the sales price until anticipated treatment outcomes meet predefined targets, or to provide additional medicines free of charge if anticipated treatment outcomes do not meet predefined targets. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The impact of potential refunds or a deferral of a portion of the sales price are estimated and recorded as a deduction from revenue at the time the related sales are recorded. The impact of the future delivery of additional medicines at no cost is estimated and recorded as a contract liability at the time the related revenues are recorded. Estimates are based on historical experience and clinical data available for the product, as well as specific terms of the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until the uncertainty is resolved, until such history is available or the period of the refund right has expired.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">These provisions for revenue deductions are adjusted periodically based on established processes and actual experience, including the products&#x2019; actual outcomes achieved compared with the anticipated predefined targets. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There is often a time lag between recording of the revenue deductions and the final accounting for them.</div>
      <div>
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Non-healthcare plans and program rebates, returns and other deductions</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We offer rebates to purchasing organizations and other direct and indirect customers to sustain and increase market share and to ensure patient access to our products. Since rebates are contractually agreed upon, the related provisions are estimated based on the terms of the individual agreements, historical experience and projected product sales growth rates. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Chargebacks occur where our subsidiaries have arrangements with indirect customers to sell products at prices that are lower than the price charged to wholesalers. A chargeback represents the difference between the invoice price to the wholesaler and the indirect customer&#x2019;s contract price. We account for chargebacks by reducing revenue by the estimate of chargebacks attributable to a sales transaction. Provisions for estimated chargebacks are calculated using a combination of factors, such as historical experience, product growth rates, product pricing, level of inventory in the distribution channel, and the terms of individual agreements.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">When we sell a product providing a customer the right to return it, we record a provision for estimated sales returns based on our sales return policy and historical return rates. Other factors considered include actual product recalls, expected marketplace changes, the remaining shelf life of the product, and the expected entry of generic products. In 2021, sales returns amounted to approximately 1% of gross product sales. If sufficient experience is not available, sales are only recorded based on evidence of product consumption or when the right of return has expired.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We enter into distribution service agreements with major wholesalers, which provide a financial disincentive for the wholesalers to purchase product quantities in excess of current customer demand. Where possible, we adjust shipping patterns for our products to maintain wholesalers&#x2019; inventory levels consistent with underlying patient demand.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We offer cash discounts to customers to encourage prompt payment. Cash discounts are estimated and </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">86</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">provisioned at the time of revenue recognition and are deducted from revenue.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Following a decrease in the price of a product, we generally grant customers a &#x201C;shelf stock adjustment&#x201D; for their existing inventory for the relevant product. Shelf stock adjustments are generally granted to customers, primarily of the Sandoz Division, to cover the inventory held by them at the time a price decline becomes effective. Revenue deduction provisions for shelf stock adjustments are recorded when the price decline is anticipated, based on the impact of the price decline on the customer&#x2019;s estimated inventory levels.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Other sales discounts, such as consumer coupons, vouchers and copay discount cards, are offered in some markets. The estimated amounts of these discounts are recorded at the time of sale or when the coupons are issued, and are estimated utilizing historical experience and the specific terms for each program. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, we offer global patient assistance programs.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We adjust provisions for revenue deductions periodically to reflect actual experience. To evaluate the adequacy of provision balances, we use internal and external estimates of the inventory in transit, the level of inventory in the distribution and retail channels, actual claims data received, and the time lag for processing rebate claims. External data sources include reports from wholesalers and third-party market data purchased by Novartis.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">For the table showing the worldwide extent of our revenue deductions provisions and related payment experiences for the Group see &#x201C;Item 18. Financial Statements&#x2014;Note 22. Provisions and other current liabilities.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impairment of goodwill, intangible assets and property, plant and equipment</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We review intangible assets and property, plant and equipment for impairment whenever events or changes in circumstance indicate that the asset&#x2019;s balance sheet carrying amount may not be recoverable. Goodwill and other intangible assets that are not yet amortized, are reviewed for impairment at least annually.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">An asset is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value in use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or cash generating units (CGUs), and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group&#x2019;s activities as indicated in &#x201C;Item 18. Financial Statements&#x2014;Note 1. Significant accounting policies.&#x201D; Due to these factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The recoverable amount of the grouping of cash-generating units to which goodwill is allocated is based on fair value less costs of disposal. The valuations are derived from applying discounted future cash flows based on key assumptions, including the terminal growth rate and discount rate. For additional information on impairment charges recognized and reversed by divisions, see &#x201C;Item 18. Financial Statements&#x2014;Note 1. Significant accounting policies&#x2014;Impairment of goodwill and intangible assets&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 11. Goodwill and intangible assets.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Goodwill and other intangible assets represent a significant part of our consolidated balance sheet, primarily due to acquisitions. Although no significant additional impairments are currently anticipated based on our impairment assessment and review of reasonable possible changes in key assumptions to the respective impairment assessment, future impairment evaluation could lead to material impairment charges in the future. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For more information, see &#x201C;Item 18. Financial Statements&#x2014;Note 11. Goodwill and intangible assets.&#x201D;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For net impairment charges for property, plant and equipment see &#x201C;Item 18. Financial Statements&#x2014;Note 9. Property, plant and equipment.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Retirement and other post-employment benefit plans</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We sponsor pension and other post-employment benefit plans in various forms that cover a significant portion of our current and former employees. For post-employment plans with defined benefit obligations, we are required to make significant assumptions and estimates about future events in calculating the expense and the present value of the liability related to these plans. These include assumptions about the interest rates we apply to estimate future defined benefit obligations and net periodic pension expense, as well as rates of future pension increases. In addition, our actuarial consultants provide our management with historical statistical information, such as withdrawal and mortality rates in connection with these estimates.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Assumptions and estimates used by the Group may differ materially from the actual results we experience due to changing market and economic conditions, higher or lower withdrawal rates, and longer or shorter life spans of participants, among other factors. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Depending on events, such differences could have a material effect on our total equity. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For more information on obligations under retirement and other post-employment benefit plans and underlying actuarial assumptions, see &#x201C;Item 18. Financial </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">87</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Statements&#x2014;Note 25. Post-employment benefits for employees.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Income taxes</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We prepare and file our tax returns based on an interpretation of tax laws and regulations, and we record estimates based on these judgments and interpretations. Our tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made, requiring payments of additional tax, interest or penalties. Since Novartis uses its intellectual property globally to deliver goods and services, the transfer prices within the Group as well as arrangements between subsidiaries to finance research and development and other activities may be challenged by the national tax authorities in any of the jurisdictions in which Novartis operates. Therefore, inherent uncertainties exist in our estimates of our tax positions, but we believe that our estimated amounts for current and deferred tax assets or liabilities, including any amounts related to any uncertain tax positions, are appropriate based on currently known facts and circumstances. Uncertain (income) tax positions are periodically (re)assessed by the Company based on management&#x2019;s best judgment given any changes in the facts, circumstances and information available and applicable tax laws. When it is probable that the tax authorities will not accept the position taken, the Group recognizes income tax liabilities based on the most likely amount of the liability (recovery) or weighted average of various possible outcomes to reflect the effect of the uncertainty in determining the related taxable profit (tax loss), tax bases, unused tax losses, unused tax credits or tax rates, to the extent that a reliable estimate can be made.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For more information, see &#x201C;Item 18. Financial Statements&#x2014;Note 6. Income taxes&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 12. Deferred tax assets and liabilities.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Provisions and contingent liabilities</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">A number of Group companies are involved in various government investigations and legal proceedings (intellectual property, sales and marketing practices, product liability, commercial, employment and wrongful discharge, environmental claims, etc.) arising out of the normal conduct of their businesses. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We record provisions for legal proceedings when it is probable that a liability has been incurred and the amount can be reliably estimated. These provisions are adjusted periodically as assessments change or additional information becomes available. For signi&#xFB01;cant product liability cases, the provision is actuarially determined based on factors such as past experience, amount and number of claims reported, and estimates of claims incurred but not yet reported.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions are recorded for environmental remediation costs when expenditure on remedial work is probable and the cost can be reliably estimated. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis believes that its total provisions are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities in this area, Novartis may incur additional costs beyond the amounts provided. Management believes that such additional amounts, if any, would not be material to the Group&#x2019;s financial condition but could be material to the results of operations or cash flows in a given period. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For more information, see &#x201C;Item 18. Financial Statements&#x2014;Note 20. Provisions and other non-current liabilities&#x201D; and &#x201C;Item 18. Financial Statements&#x2014;Note 28. Commitments and contingent liabilities.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">88</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00410918"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item 6.  Directors, Senior Management and Employees</p>
      <div id="anchorId00410920"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">6.A Directors and senior management</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The information set forth under &#x201C;Item 6. Directors, Senior Management and Employees&#x2014;Item 6.C Board practices&#x2014;Corporate governance&#x2014;Board of Directors&#x201D; and &#x201C;Item 6. Directors, Senior Management and Employees&#x2014;Item 6.C Board practices&#x2014;Corporate governance&#x2014;Executive Committee&#x201D; is incorporated by reference. </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">89</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00911069"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">6.B Compensation</p>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Dear shareholder, </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">I am pleased to share with you the Novartis Compensation Report for 2022. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We believe that our compensation system supports our strategy and motivates our executives to deliver sustainable growth, successful outcomes on our financial and strategic targets, and value creation for our shareholders. Over the course of 2022, we engaged with shareholders and proxy advisors to share how our compensation system is aligned with short and long-term performance, and to secure their continued support for our compensation system design.  Based on the feedback from these interactions and the positive response to our 2021 Compensation Report, which received a 90.7% vote in favor, we will retain the current design of our executive compensation system, with small enhancements as explained later in this letter.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 performance highlights</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">2022 was a year of solid financial performance, with growth in constant currencies (cc) across sales, core profits and core margins. Sales growth drivers were <i>Entresto</i> (USD 4.6 billion), <i>Kesimpta</i> (USD 1.1 billion), <i>Kisqali</i> (USD 1.2 billion), <i>Cosentyx</i> (USD 4.8 billion), along with the <i>Pluvicto</i> launch. Our six in-market growth drivers with multi-billion sales potential (<i>Cosentyx</i>, <i>Entresto</i>, <i>Zolgensma</i>, <i>Kisqali</i>, <i>Kesimpta</i> and <i>Leqvio</i>) grew 26% (cc) in 2022, and now represent 32% of total Innovative Medicines sales, up from 26% in 2021. Overall sales were broadly in line with target.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In April 2022, we announced the introduction of a new organizational model designed to support the company&#x2019;s innovation, growth, and productivity ambitions as a focused medicines company. The restructuring will simplify the organization and our processes, and is expected to deliver USD 1.5 billion in savings by 2024 with a proportion of these savings already delivered in 2022, enabling us to raise our long-term core operating income margin guidance. These savings are expected to help us progress towards our aspiration of achieving ~40%+ core margin beyond 2027 and further invest in our pipeline, as a pure-play medicines company (after the planned Sandoz spin-off which is subject to approval of the Novartis AG Board of Directors and shareholders). Nonetheless, there was an immediate impact on Operating Income as we incorporated related costs in the latter part of the year, that, along with higher legal settlements and unfavorable fair market value adjustments on financial assets, impacted operating income growth. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2022, we continued to deliver high value medicines to patients. We received 23 approvals in our key focus markets US, EU, China and Japan, including US and EU approvals for <i>Pluvicto</i>, a novel radioligand therapy for advanced prostate cancer. We advanced our focused pipeline of investigational medicines, with several important clinical data readouts paving the way for further launches in 2023 and beyond, a significant one being iptacopan, our investigational monotherapy in the treatment of paroxysmal nocturnal hemoglobinuria (PNH). However, we also had disappointments as some clinical trials of experimental compounds did not meet their primary endpoints, including ACZ885 (canakinumab) in lung cancer, and UNR844 in presbyopia.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We are proud that Novartis also continued to deliver on its commitments to broaden access to medicines and tackle major global health challenges. We pledged further investment in research into malaria and neglected tropical diseases, increased access to our innovative medicines for low- and middle-income countries and formed new collaborations with governments and other partners to strengthen healthcare systems. More details on our ESG efforts can be found in our Novartis in Society Integrated Report 2022.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 CEO compensation</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As a result of the above performance, the CEO was awarded a 2022 Annual Incentive of 100%, having overall met the financial targets and strategic objectives set at the beginning of the cycle. When determining performance against the operating income metric, the Board of Directors approved adjustments to exclude restructuring costs arising from the implementation of the new organizational model and costs related to the planned Sandoz spin-off, which are investments in the future of the company in terms of both sales and margin growth. These adjustments ensured that the performance assessment was consistent with the basis on which the original targets were set.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The 2020-2022 Long-Term Performance Plan (LTPP) vested at 57% of target. The LTPP outcome was heavily affected by the relative Total Shareholder Return (rTSR) performance over the period, as well as reduced sales growth during 2020 and 2021, which was substantially impacted by the COVID-19 pandemic. No adjustments were made for the COVID-19 impact, or for any other factors. (For more information, please see &#x201C;&#x2014;LTPP performance outcomes&#x201D;).</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Despite a solid 2022 performance, as outlined above, the CEO&#x2019;s 2022 total realized compensation was CHF 8&#xA0;452&#xA0;176, a decrease of 24.7% compared with prior year, driven mainly by the 2020-2022 LTPP outcome.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Changes to Executive Committee compensation system and disclosures</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During the year, we reviewed our Executive Committee compensation system, with the aim of simplification and increased transparency of our performance assessment measures and strengthening our focus on key strategic priorities, while also considering developments in compensation best practices. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Effective the 2022-2024 cycle of the LTPP, we strengthened the assessment of research and early development performance under the Innovation metrics, </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">90</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">to ensure that targets are focused more directly on activities that create long-term value, and are measurable over a three-year performance period. For the innovation performance measure, the Science &amp; Technology Committee sets targets that take into account the expected Net Present Value (eNPV) of programs transitioning to late-stage clinical development rather than the previous approach to set targets related to early-stage milestones. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Effective from performance year 2023, we will remove &#x201C;Share of Peers&#x201D; as a financial performance measure for the Annual Incentive plan, to simplify the metrics and focus on targets that provide greater transparency. The weighting of the three remaining financial measures, Group Net Sales, Group Operating Income and Group Free Cash Flow, will be 40%, 30% and 30%, respectively. In addition, we will fold division specific financial targets, where applicable, into individual strategic objectives (40% weighting) of the related Executive Committee member. All Executive Committee members will be evaluated, with a 60% weighting, against the performance of Group financial measures mentioned above.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">During the year, we announced our intention to separate our Sandoz generics and biosimilars Division into a new publicly traded standalone company, by way of a 100% spin-off, subject to approval of the Novartis AG Board of Directors and shareholders.  Based on the planned completion of the spin-off in 2023, the Compensation Committee made some initial decisions on the 2023 compensation elements related to the spin-off. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Finally, the 2023 Compensation Report will also include additional disclosures following the reform of Swiss corporate law that came into effect on January 1, 2023. For more information, please see &#x201C;&#x2014;2023 Executive Compensation Changes&#x201D;.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Inflation and cost-of-living impact on broader employee group</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board and the Executive Committee are mindful of the cost-of-living challenges that are impacting many of our associates in different markets.  The Executive Committee has considered these as part of its pay decisions and outcomes, and where appropriate, it has initiated local level initiatives to support associates. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In most countries, our 2023 salary budgets are higher than in previous years, reflecting the overall higher market forecasts driven by inflation. In some of our larger markets we are making a one-time payment to certain employee populations.  Where legally possible, we have tried to target these one-time payments to our lower paid employees, who are most impacted. We will continue to monitor our compensation against the Living Wage, and regularly monitor and adjust wages in hyperinflation markets to support our local associates. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">These actions reflect our commitment to pay market-competitive and sustainable salaries, rather than to fully match the current volatile inflation environment. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">2023 base salary increases for ECN members, including the CEO, are made in line with policy, and no ECN member will receive any inflation related one-time payments. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2023 Annual General Meeting (AGM)</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At the 2023 AGM, shareholders will be asked to vote on both the maximum aggregate amount of compensation for the Board of Directors from the 2023 AGM to the 2024 AGM, and the maximum aggregate amount of compensation for the Executive Committee for the financial year 2024. Furthermore, we will request an advisory vote on this Compensation Report.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We welcome your feedback, which is invaluable in driving improvements in our compensation system and practices. On behalf of the Compensation Committee, I would like to thank you for your continued support and trust. </div>
      <div style="padding-top:15px">
        <img src="comp_0028.gif" alt="WSGE_DP_Sign_CompChair"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <b>Simon Moroney, D.Phil.</b>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Chair of the Compensation Committee</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">91</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00911166"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Compensation&#xA0;at&#xA0;a&#xA0;glance</p>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">2022 outcomes</span>
      </div>
      <div style="border-top: 1px solid black; margin: 10px 0; line-height: 20px; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">CEO pay for performance</span>
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"></span>
      </div>
      <div style="padding-top:15px">
        <img src="comp_0029.gif" alt="WSGE_DP_Graph_ataglance_ceopfp"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">2022 Annual Incentive% of target200%150%100%50%0%MaximumPayout: 100% of targetLong-Term Performance Plan (2020&#x2013;2022 performance)% of target200%150%100%50%0%MaximumTargetPayout: 57% of targetNet sales CAGR (43% of target)Core operating income CAGR (93% of target)Innovation (92% of target)Relative TSR (0% of target)</div>
      </div>
      <div style="border-top: 1px solid black; margin: 10px 0; line-height: 20px; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">CEO total realized compensation</span>
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"></span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The 2022 total realized compensation for the CEO was CHF 8 452 176. It includes payouts of the Annual Incentive and LTPP based on actual performance assessed for the cycles concluding in 2022. More information on the assessment of the CEO by the Board of Directors can be found in &#x201C;&#x2014;2022 CEO balanced scorecard&#x201D; and &#x201C;  &#x2014;LTPP performance outcomes&#x201D;.</div>
      <div style="padding-top:15px">
        <img src="comp_0030.gif" alt="WSGE_DP_Graph_ataglance_ceototal"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style="border-top: 1px solid black; margin: 10px 0; line-height: 20px; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Board compensation </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The total actual compensation earned by Board members in the 2022 financial year is shown in the table below.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />CHF 000s</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022<br /> total compensation<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Board Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 804</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other members of the Board</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4 703</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8 506</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="4" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="4">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Includes an amount of CHF 29&#xA0;250 for mandatory employer contributions for all Board members paid by Novartis to Swiss governmental social security systems. This amount is out of total employer contributions of CHF 453&#xA0;083 and provides a right to the maximum future insured government pension benefit for the Board members.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="4">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">92</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">2023 compensation systems</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">An overview of the 2023 compensation systems for the Executive Committee and the Board of Directors is provided below. </div>
      <div style="border-top: 1px solid black; margin: 10px 0; line-height: 20px; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Executive Committee compensation system</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Effective 2023, financial measures of the Annual Incentive plan comprise Group Net Sales (40%), Group Operating Income (30%) and Group Free Cash Flow (30%) for all Executive Committee members. Additionally, &#x201C;Share of Peers&#x201D; will be removed from the financial measures. </div>
      <div style="padding-top:15px">
        <img src="comp_0003.gif" alt="WSGE_DP_Graph_ataglance_ecsystem"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">2023 fixed pay and benefitsAnnual base salaryPension and other benefitsPerformance-related variable pay2023 Annual IncentiveLong-Term Incentive awards cycle 2023-2025LTPP1PurposeReflects responsibilities, experience and skill setsProvide retirement and risk insurances (tailored to local market practices/regulations)Rewards performance against short-term financial and strategic objectives, and Values and BehaviorsRewards long-term shareholder value creation and innovation in line with our strategyForm of paymentCashCountry/individual-specific and aligned with other employees50% cash50% equity2 deferredfor three years3Equity, vesting following a three-year performance periodPerformance measuresBalanced scorecard comprising:&#x2022;Financial measures4 (60%)&#x2022;Strategic objectives5 (40%)&#x2022;Net sales  CAGR (25%)&#x2022;Core operating income CAGR (25%)&#x2022;Innovation (25%)&#x2022;Relative TSR (25%)1LTPP = Long-Term Performance Plan 2Executive Committee members may elect to receive more of their Annual Incentive in equity instead of cash3The Annual Incentive deferred in equity is granted under the Deferred Share Bonus Plan (DSBP)4Financial Measures are Group Net Sales (40%), Group Operating Income (30%) and Group Free Cash Flow (30%)5  Strategic objectives are aligned with our transformation to become a pure-play Innovative Medicines company: Strategy, Growth / Launches, Innovation, Operational excellence, Build trust with society</div>
      </div>
      <div style="border-top: 1px solid black; margin: 10px 0; line-height: 20px; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Board compensation system </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There are no changes to the Board compensation system for 2023.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; font-style:italic; color:#000000;">
                <br />CHF 000s</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> AGM 2023-2024<br /> annual fee</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Board Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;800</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Board membership</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 280</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vice-Chair</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lead Independent Director</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chair of the Audit and Compliance Committee</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 130</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chair of the Compensation Committee</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 90</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chair of the following committees:<br />&#x2022; Governance, Sustainability and Nomination Committee<br />&#x2022; Science &amp; Technology Committee<br />&#x2022; Risk Committee</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <br />
                <br />
                <br /> 70</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Membership of the Audit and Compliance Committee</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Membership of the following committees:<br />&#x2022; Compensation Committee<br />&#x2022; Governance, Sustainability and Nomination Committee<br />&#x2022; Science &amp; Technology Committee<br />&#x2022; Risk Committee</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <br />
                <br />
                <br />
                <br /> 40</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="4" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="4">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">93</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00911400"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Executive Committee compensation&#xA0;philosophy and principles</p>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis compensation philosophy</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our compensation philosophy aims to ensure that we attract and retain outstanding Executive Committee members and reward them according to their success in implementing the Company strategy, and their contribution to Company performance and long-term value creation.  The main elements of our compensation philosophy are set out in the table below.</div>
      <div style="padding-top:15px">
        <img src="comp_0006.gif" alt="WSGE_DP_Graph_ecncompensation_philosophy"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Pay for performance&#x2022;Variable compensation is tied directly to the achievement of strategic Company targetsShareholderalignment&#x2022;Our incentives are significantly weighted toward long-term equity-based plans&#x2022;Measures under the Long-Term Incentive plans are calibrated to promote the creation of shareholder value&#x2022;Executive Committee members are expected to build and maintain substantial shareholdingsBalanced rewards&#x2022;Balanced set of measures to create sustainable value&#x2022;Mix of targets based on financial metrics, strategic objectives, and performance versus our competitorsBusiness ethics&#x2022;The Novartis Values and Behaviors are an integral part of our compensation system&#x2022;They underpin the assessment of overall performance for the Annual IncentiveCompetitive compensation&#x2022;Total compensation must be sufficient to attract and retain key global talent&#x2022;Overarching emphasis on pay for performance</div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Alignment with Company strategy</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Executive compensation is strongly connected to business strategy. In 2022, we refocused our strategy to deliver high-value medicines that alleviate society&#x2019;s greatest disease burdens through technology leadership in research and development, and novel access approaches. Our strategy focuses on five core therapeutic areas with high unmet patient needs, two core and three emerging technology platforms, and four priority geographies, which together account for the majority of expected growth in global healthcare spending. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In line with this refocused strategy, we updated our strategic priorities to target innovation power, sales growth, delivering both margin and total shareholder returns, and sector leadership in material ESG factors. The Long-Term Incentive Plan was adapted, with greater emphasis now on the delivery of high value programs in our research and early development targets. The Annual Incentive plan has been simplified effective 2023, with three key financial metrics: Net Sales, weighted 40%; Operating Income, weighted 30%; and Free Cash Flow, weighted 30%.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Approach to market benchmarking</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There continues to be significant competition for top executive talent with deep expertise, the requisite competencies and proven performance within the pharmaceutical and biotechnology industries. As such, external peer compensation data is one of a number of key reference points considered by the Board of Directors and the Compensation Committee when making decisions on executive pay, so as to help ensure that the compensation system and compensation levels at Novartis remain competitive. Novartis is committed to confirming benchmarking practices, including the peer group, to shareholders on an annual basis. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Compensation Committee believes in a rigorous approach to peer group construction and maintenance. Furthermore, it believes that using a consistent set of peers that is similar in size and scope enables shareholders to evaluate the compensation year on year and make pay-for-performance comparisons. In 2022, the Compensation Committee decided to maintain the same primary peer group of <b>14 global healthcare companies</b>, as presented in the table below.</div>
      <div style="padding-top:15px">
        <img src="comp_0005.gif" alt="WSGE_DP_Graph_ecncompensation_peergroup"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Global healthcare peer groupAbbVieBiogen GlaxoSmithKlineNovo NordiskRocheAmgenBristol-Myers SquibbGilead SciencesMerck &amp; Co.SanofiAstraZenecaEli Lilly &amp; Co.Johnson &amp; JohnsonPfizer</div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The companies in this peer group reflect our industry and are similar to Novartis in terms of both size and scope of operations. Although Novartis is headquartered in Switzerland, more than a third of its sales come from the US market, and the US remains a significant talent pool for the recruitment of executives by the Company. It is therefore critical that Novartis is able to attract and retain key talent globally, especially from the US. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To ensure European and local practices were fully taken into account, in 2022 the Compensation Committee also reviewed a cross-industry peer group of Europe-headquartered multinational companies, selected based on comparability to Novartis in terms of industry, size, global scope of operations, and economic influence. Based on this review, the Committee retained the same group of <b>European peers</b> as in 2021: Anheuser-Busch InBev, AstraZeneca, Bayer, BMW, GlaxoSmithKline, L&#x2019;Or&#xE9;al, Merck KGaA, Nestl&#xE9;, Novo Nordisk, Reckitt Benckiser, Roche, Siemens, Sanofi, and Unilever.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">94</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Executive Committee appointments compensation policy</span>
      </div>
      <div style="padding-top:15px">
        <img src="comp_0007.gif" alt="WSGE_DP_Graph_ecncytotalcompensation_ecnappointmentspolicy"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Element of compensationPolicyLevelThe overall package should be market-competitive to enable the recruitment of global executive talent with deep expertise and competencies.Annual base salaryThe Compensation Committee may appoint individuals who are new to a role on an annual base salary that is below the market level, with a view to increase this toward market level over a period of three to four years as an individual develops in the role.If the scope of an existing Executive Committee member&#x2019;s role changes significantly during the year, the Compensation Committee may make adjustments to the individual&#x2019;s base salary (and/or incentives) in consideration of the benchmark of the new role and the Executive Committee appointments compensation policy.This prudent approach ensures pay levels are merit-based, with increases dependent on strong performance and proven ability in the role over a sustained period.IncentivesThe compensation package will normally include the key compensation elements and incentive opportunities in line with those offered to current Executive Committee members.In exceptional circumstances, higher incentive opportunities than those offered to current Executive Committee members may be provided at the Compensation Committee&#x2019;s discretion.Performance measures may include business-specific measures tailored to the specific role.Pension and other benefitsNewly appointed Executive Committee members are eligible for the local country pension plan and other benefits in line with the wider employee group.BuyoutsThe Compensation Committee seeks to balance the need to offer competitive compensation opportunities to acquire the talent required by the business with the principle of maintaining a strong focus on pay for performance.As such, when an individual forfeits variable compensation as a result of an appointment at Novartis, the Compensation Committee may offer replacement awards to compensate the commercial equivalent value or fair value of payments and awards forfeited by the individual, in such form as the Compensation Committee considers appropriate, taking into account relevant factors.Relevant factors include the expected value of the forfeited award, the replacement vehicle (i.e., cash, restricted share units, restricted shares or performance share units), whether the award is contingent on meeting performance conditions or not, the timing of forfeiture (i.e., Novartis mirrors the blocking or vesting period of the forfeited award) and the leaver conditions, in case the recruited individual leaves Novartis prior to the end of the blocking or vesting period.International mobility If individuals are required to relocate or be assigned away from their home location to take up their position, relocation support may be provided in line with our global mobility policies (e.g., relocation support, tax equalization). This includes ongoing US state income tax liabilities on behalf of US citizens locally employed outside the US who have US workdays and therefore, US state taxable compensation that generates a US state tax liability.</div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">95</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Treatment of variable compensation for Executive Committee leavers</span>
      </div>
      <div style="padding-top:15px">
        <img src="comp_0008.gif" alt="WSGE_DP_Graph_ecncytotalcompensation_ecnleaverspolicy"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Element of compensationPolicyAnnual Incentive &#x2013; cash elementRetirement, termination by the Company (for reasons other than performance or conduct), change of control, disability, death, i.e., &#x201C;good leavers&#x201D;Pro-rata Annual Incentive is paid to reflect the portion of the year the individual was employed.Voluntary resignation or termination by the Company for misconduct or poor performanceAnnual Incentive is fully forfeited.Annual Incentive &#x2013; mandatory deferral into restricted shares/ restricted share units (RSUs)Retirement, termination by the Company for reasons other than performance or conduct, and change of controlAwards are released on the original blocking end date. There is no accelerated vesting. All awards are subject to forfeiture in the event that a leaver joins a competitor company as defined in the applicable plan rules, before the end of the three-year blocking date, starting from the date of grant.Death or long-term disabilityAccelerated vesting is applied.Voluntary resignation or termination by the Company for misconduct or poor performanceUnvested restricted shares and restricted share units (RSUs) are forfeited.Annual Incentive &#x2013; voluntary restricted shares/RSUs/AmericanDepository Receipts (ADRs) (ADRs applicable for US employees only)Awards are not subject to forfeiture during the deferral period.  Long-Term Incentive &#x2013; mandatory performance share units (PSUs)Retirement, termination by the Company for reasons other than performance or conduct, and change of control Awards vest on the regular vesting date, subject to performance, on a pro-rata basis for time spent with the Company during the performance cycle. There is no accelerated vesting. All awards are subject to forfeiture in the event that a leaver joins a competitor company as defined in the applicable plan rules, until the vesting date.Death or long-term disabilityAccelerated vesting at target is applied.Voluntary resignation or termination by the Company for misconduct or poor performanceAll of the award is forfeited.</div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Malus and clawback</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Any incentive compensation paid to Executive Committee members is subject to malus and clawback rules. This means that the Board of Directors for the CEO, and the Compensation Committee for the other Executive Committee members, may decide &#x2013; subject to applicable law &#x2013; to retain any unpaid or unvested incentive compensation (malus), or to recover incentive compensation that has been paid or vested in the past (clawback). This applies in cases where the payout has resulted from a violation of laws or conflicts with internal management standards, including Company and accounting policies. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">This principle applies to both the short-term Annual Incentive and Long-Term Incentive (LTI) plans.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Compensation Committee is assessing the impact of the final clawback rule in the Federal Register published by the US Securities and Exchange Commission in 2022, and any required changes to the policy will be disclosed in the 2023 Compensation Report.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">96</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Executive Committee performance&#xA0;management process</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">To foster a high-performance culture, the Company applies a performance management process based on quantitative and qualitative criteria. The CEO and the other Executive Committee members are subject to a formal three-step process: objective setting, performance evaluation and compensation determination. This process is explained in the chart below.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Performance targets are generally set before the start of the relevant performance cycle. A rigorous framework is in place for establishing targets to ensure they are suitably robust and challenging, and align with the strategic priorities of the Group.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The key factors taken into account when setting targets include:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Internal and external market expectations </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Novartis strategic priorities</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Regulatory factors (e.g., new launches, patent expiries)</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Investment in capital expenditure</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Values and Behaviors</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The targets are challenged at multiple stages before they are ultimately approved by the Board of Directors. In line with good governance practices, the Compensation Committee works to set targets that are ambitious and challenging but do not encourage undue risk-taking. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Following the end of the performance cycle, the Board of Directors and the Compensation Committee consider performance against the targets originally set. The CEO and Executive Committee members are not present while the Board of Directors and the Compensation Committee discuss their individual performance evaluations and determine their individual compensation. Prior to determining the final outcome, related factors such as performance relative to peers, wider market conditions, general industry trends and good practice are used to inform the overall performance assessment. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="padding-top:15px">
        <img src="comp_0009.gif" alt="WSGE_DP_Graph_ecnperformancemgtprocess_process"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Objective setting&#x2022;The CEO proposes their targets to the Board Chair; they are then reviewed and approved by the Board of Directors, based on input from the Compensation Committee.&#x2022;For other Executive Committee members, targets for their division or unit are initially discussed with the CEO and subsequently approved by the Board of Directors and the Compensation Committee.Performance evaluation&#x2022;The CEO&#x2019;s performance against the individual balanced scorecard is assessed by the Board of Directors.&#x2022;For Executive Committee members, the CEO discusses each member&#x2019;s performance (assessed against his or her individual balanced scorecard) with the Board Chair before making recommendations to the Board of Directors for final determination.&#x2022;Periodic assessments, including at the mid-year stage, ensure progress is suitably tracked.Compensation determination &#x2022;A recommendation for the CEO&#x2019;s variable pay is made by the Compensation Committee to the Board of Directors for final determination.&#x2022;For the Long-Term Incentive financial measures&#x2019; payout schedules, a formulaic approach applies, and the Compensation Committee can also exercise judgment to ensure there is appropriate alignment between payout levels and overall performance achieved. The same principle of discretion applies to the relative TSR and innovation performance measures.&#x2022;The CEO&#x2019;s recommendations for other Executive Committee members are considered and approved by the Compensation Committee, after which the Board of Directors is notified of the outcomes.</div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">97</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00911510"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">2022 Executive Committee compensation </p>
      <div style=" padding-bottom: 10px;"></div>
      <div style="padding-top:15px">
        <img src="comp_0010.gif" alt="WSGE_DP_Graph_ecncycompensationsystem_fixedcompensation"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Annual base salaryOverview&#x2022;The annual base salary is reviewed each year, taking into account: the individual&#x2019;s role, performance and experience; business performance and the external environment; increases across the Group; and market movements.2022 annual base salariesThe 2022 annual base salaries were as follows:&#x2022;CEO (effective March 1, 2022): CHF 1 789 500.     &#x2022;OTHER EXECUTIVE COMMITTEE MEMBERS (effective March 1, 2022): All other members of the Executive Committee were awarded increases in line with the average of all Novartis employees, with the exception of five individuals as disclosed in Item 6.B of the 2021 Annual Report.Pension and other benefitsOverview&#x2022;Pension and other benefits do not constitute a significant proportion of total compensation and are provided to the Executive Committee on the same terms as all other employees based on local country practices and regulations. &#x2022;The CEO and all other Swiss-based members of the Executive Committee are members of the Novartis Swiss pension funds, which provide Company contributions on the base salary and Annual Incentive up to the legal cap on the insured salary of CHF 860 400. No supplementary pension plans or savings plans are provided. The CEO&#x2019;s employer pension contributions represent 9.77% of his base salary.&#x2022;Globally the Company operates both defined benefit and defined contribution pension plans (see also Note 25 to the Group&#x2019;s consolidated financial statements). &#x2022;Novartis may provide other benefits according to local market practice. These include Company car provision, tax and financial planning, and insurance benefits.&#x2022;Executive Committee members who are required to relocate internationally may also receive additional benefits (including tax equalization), in line with the Company&#x2019;s global mobility policies. </div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">98</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">2022 Annual Incentive</span>
      </div>
      <div style="padding-top:15px">
        <img src="comp_0012.gif" alt="WSGE_DP_Graph_ecncycompensationsystem_variablecompensation"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">PLAN OVERVIEWTarget Annual Incentive On-target opportunities&#x2022;CEO: 150% of annual base salary&#x2022;Other Executive Committee members: 80% to 120% of annual base salaryPerformance measures&#x2022;An Annual Incentive balanced scorecard containing:&#x2022;Financial performance measures (60% weighting) related to Group, division or business unit, where relevant &#x2022;Strategic objectives (40% weighting) are aligned with our transformation to become a pure-play Innovative Medicines company: Strategy, Growth / Launches, Innovation, Operational excellence, Build trust with society &#x2022;The balanced scorecard targets and achievements of the CEO are detailed on the next page.&#x2022;The balanced scorecards for other Executive Committee members include Group financial targets as well as financial or other quantitative targets that relate to their division or business unit, if applicable.&#x2022;Values and Behaviors are a key component of the Annual Incentive and are embedded in our culture. As such, members of the Executive Committee are expected to demonstrate these to the highest standards.Target setting&#x2022;Financial targets are set at the beginning of each financial year and align with the strategic plan proposed by management to the Board of Directors for approval.&#x2022;The strategic objectives are aligned with the most important priorities in any performance year.Payout ranges&#x2022;The payout schedule for the Annual Incentive incorporates performance against financial and strategic objectives. The payout range is 0% to 200% of on-target opportunity based on performance, as shown below:PERFORMANCEPAYOUT (% of on-target)Outstanding170%  200%Exceeds expectations130%  160%Meets expectations80%  120%Partially meets expectations40%  70%Below expectations0%Payout formulaPayout vehicle&#x2022;At the end of the performance period, 50% is paid in cash, and the remaining 50% is delivered in Novartis restricted shares or RSUs, deferred for three years (see &#x201C;Executive Committee compensation system&#x201D;).&#x2022;Executives may choose to receive all or part of the cash portion of their Annual Incentive in Novartis shares or American Depositary Receipts (ADRs; US only) that will not be subject to forfeiture conditions. In the US, awards may also be delivered in cash under the US-deferred compensation plan.Dividend rights, voting rights and settlement&#x2022;Novartis restricted shares and ADRs carry voting rights and dividends during the vesting period. RSUs are of equivalent value but do not carry voting rights and dividends during the vesting period.&#x2022;Following the vesting period, settlement of RSUs is made in unrestricted Novartis shares or ADRs. Annual base salaryxTarget incentive (% of base salary)=Target Annual IncentiveAnnual base salaryxTarget incentive (% of base salary)xPayout factor (% of target: 0%200%)=Realized Annual Incentive</div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">99</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px">
        <img src="comp_0014.gif" alt="WSGE_DP_Graph_ecncycompensationsystem_ceoscorecard"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">2022 CEO BALANCED SCORECARD This section presents the balanced scorecard for the CEO. Balanced scorecard performance is measured in constant currencies (cc) to reflect operational performance that can be influenced. The Board of Directors uses a stringent process to set ambitious financial targets to incentivize superior performance. In addition to the financial targets, the CEO also has ambitious strategic objectives across key priority areas, including targets related to ESG matters. Achievement versusCEO achievements  2022TargettargetFinancial measures  60% of total Annual Incentive, comprising: Group net sales (cc) (30%) 54360 millionMetGroup operating income (cc) (30%)| 11630 million|Met*Group free cash flow as a % of sales (cc) (20%)| 24.8%|BelowShare of peers for Novartis Group  (20%) 7.3%MetOverall assessment of Group financial targets in constant currencies Met*The Board concluded that the achievement for Group operating income versus target was &#x201C;Met&#x201D; after approving adjustments mainly to exclude restructuring costs arising from the implementation of the new organizational model announced to investors on April 4, 2022 (and were not available at the time of target setting in January 2022), and costs related to the planned Sandoz spin-off, to transform Novartis into a focused medicines company. Strategic objectives  40% of total Annual Incentive, comprising:Strategy (15%)|MetIn 2022, the CEO launched a new strategy and laid the foundation to improve our growth profile via a strong focus on our five core therapeutic areas (cardiovascular, immunology, neuroscience, solid tumors, and hematology), two established (chemistry and biotherapeutics) and three emerging (gene &amp; cell therapy, radioligand therapy, and xRNA) technology platforms, and four key geographies (China, Germany and Japan, and a particular priority in the US market). This strategy will transform Novartis into a pure-play Innovative Medicines business, with multiple in-market brands of multi-billion dollar peak sales potential, and prioritize our pipeline to focus on high-value assets that address high disease burden and have substantial growth potential. Sandoz separation analysis was completed with spin-off being the preferred separation path given potential future value upside for shareholders. Substantial progress was also made on the preparation for the planned spin-off, which is expected to take place in the second half of 2023.Growth/Launches (15%)| MetRecent launch products Pluvicto (USD 271 million), Kesimpta (USD 1.1 billion), and Scemblix (USD 149 million) achieved higher than target sales. However, lower uptake for Leqvio resulted in sales behind target.In-market growth drivers (including Cosentyx, Entresto, Zolgesma, Kisqali, Kesimpta, and Leqvio) delivered combined sales of USD 13.2 billion, which was slightly behind target. This was largely due to the below target performance of Cosentyx (total sales of USD 4.8 billion, impacted by US payer pressures, China business and Inflation Reduction Act headwinds). This was partly offset by strong performance of Entresto (USD 4.6 billion) and Kisqali (USD 1.2 billion). Innovation (15%)|MetIn 2022, we received 23 approvals in our top four markets (US, EU, China and Japan). Major approvals included Pluvicto (US, EU), Scemblix (EU), and further indication expansions for Kymriah and Cosentyx. 24 submissions were made across the top four markets. We advanced our focused pipeline of investigational medicines, with several important clinical data readouts including Iptacopan for patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare and deadly blood disorder, and Pluvicto in earlier lines of prostate cancer. Cosentyx was submitted to the US FDA for an additional indication, ahead of planned timelines.Among our early-stage development activities, we secured ten proofs of concept (POCs) / proofs of mechanisms (POMs). Additionally, we achieved First Patient First Visit in six pivotal trial-enabling studies against our Research and Development target of five.The year also experienced some disappointments, with important trials not meeting primary goals (such as canakinumab for lung cancer and UNR844 in presbyopia).</div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">100</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px">
        <img src="comp_0026.gif" alt="WSGE_DP_Graph_ecncycompensationsystem_ceoscorecard_2"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">2022 CEO BALANCED SCORECARD &#x2212; CONTINUEDOperational excellence (15%)|MetIn April 2022, we introduced a new operating model to make our organization more agile and efficient in support of our strategy. This simplified and leaner organization is expected to deliver identified cost savings of approximately USD 1.5 billion by 2024, and help drive mid-term Innovative Medicines margin to the low 40s. Financial performance for 2022 improved from prior year in constant currencies on core operating income and core margin to USD 16.7 billion and 33.0% respectively.The Operations unit, comprising our legacy Technical Operations unit and the legacy Customer and Technology Solutions unit, achieved savings of USD 998 million against a combined target of USD 785 million. However, these savings were partially offset by external headwinds, driven mainly by inflation, of approximately USD 350 million. Build trust with society (40%) | AboveINNOVATION AND ACCESS In 2022, we achieved a 26% increase in patient reach with our strategic innovative therapies, reaching 1.2 million patients, compared with the previous year (0.95 million).  All our product launches in 2022 included a tiered pricing strategy based on national income level and value-based pricing, in line with target.With our commitment to diversity in clinical trials, 100% of our US Phase 3 studies evaluated Diversity &amp; Inclusion principles in feasibility planning, in line with our target.  Through our Novartis Global Health flagship programs, we reached 31 million patients in 2022, beating our Sustainability-linked Bond target of 22.6 million patients by 2025. In 2022, we renewed our commitment to the research and development of new medicines for malaria and neglected tropical diseases, pledging to invest USD 250mn over five years (2021-2025), and we advanced the clinical development of next-generation malaria medicines. PEOPLE AND CULTUREWe progressed towards a &#x201C;Performance Culture&#x201D; mindset with the implementation of a new &#x201C;high support / high challenge&#x201D; approach.We remain committed in our efforts to increase workforce diversity. The percentage of women in management increased to 47%, slightly behind our target of 48%. ENVIRONMENTAL SUSTAINABILITYIn 2022, we reduced our Scope 1 and 2 carbon emissions by 49%, our water consumption by 42%, and our waste sent for disposal by 59%, compared with our 2016 baseline. This was broadly in line or ahead of our 50%, 41% and 50% targets, respectively.  To advance on our Scope 3 emissions target, environmental sustainability criteria have been integrated into supply contracts covering more than a third of our Scope 3 supplier emissions.ETHICAL BUSINESS PRACTICESWe assessed 100% of our applicable policies &amp; controls in the areas of Access to Medicine &amp; Artificial Intelligence and categorized them as either &#x201C;aligned with Human Right standards&#x201D; or &#x201C;needs update with defined scope to meet Human Rights standards&#x201D;, in line with our target. Overall assessment of strategic objectives Met Overall assessment of CEO balanced scorecardMetANNUAL INCENTIVE PAYOUTPayoutThe 2022 CEO performance showed solid financial results, including sales and operating income performance at target and most strategic objectives were achieved or exceeded. The launch of a new focused strategy transforming Novartis into a pure-play medicines company, performance of launch products and preparation for planned Sandoz spin-off were key highlights. However, Free Cash Flow performance was impacted by decrease in net cash flows from operating activities and lower divestment proceeds. On balance, based on the overall assessment, the Board of Directors decided on an Annual Incentive payout for the CEO amounting to CHF 2 684 321, which is 100% of target, within the range of 0200%.</div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">101</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Long-Term Performance Plan, 2020-2022 cycle</span>
      </div>
      <div style="padding-top:15px">
        <img src="comp_0016.gif" alt="WSGE_DP_Graph_planstructure_LTPP"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">OVERVIEW OF LONG-TERM PERFORMANCE PLANAward vehiclePerformance share units (PSUs) are granted at the beginning of the three-year performance cycle and vest at the end of the cycle to the extent that performance conditions have been met. At the time of vesting, they are converted into Novartis shares.PSUs carry dividend equivalents that are paid in shares at the end of the cycle.Grant formula At the start of the performance cycle, PSUs are granted under the Long-Term Incentive plan, as follows:Target opportunity &#x2022;CEO: 325% of annual base salary&#x2022;Other Executive Committee members: between 180% and 260% of annual base salaryPerformance measures&#x2022;Net sales CAGR (25%)&#x2022;Core operating income CAGR (25%)&#x2022;Innovation (25%)&#x2022;Relative TSR (25%)Target settingFinancial targets: Targets for net sales CAGR and core operating income CAGR are set based on the strategic plan of the Company. Innovation: Global Drug Development (GDD) targets are based on targeted filings communicated at the start of each performance cycle, weighted 70%. The Science &amp; Technology Committee determines the most important Novartis Institutes for BioMedical Research (NIBR) milestones, weighted 30%. Effective the 2022-2024 LTPP cycle, NIBR targets set by the Science &amp; Technology Committee take into account the expected Net Present Value (eNPV) of programs transitioning to late-stage clinical development. Payout rangeFinancial targets: When assessing performance, achievements for threshold, target and maximum payout are defined for each metric, and a payout curve is applied to determine the corresponding payout between 0-200% against target.Innovation: At the end of the cycle, the Compensation Committee determines the payout factor in the range of 0150% based on the performance assessment made by the Science &amp; Technology Committee. A payout between 150-200% of target is only delivered for truly exceptional performance.Relative TSR: Performance on TSR is assessed relative to a global healthcare peer group, as outlined below. A three-month averaging method is used for both the start and the end of the performance cycle. Companies are then ranked in order of highest to lowest TSR in USD. The Compensation Committee may use its discretion on each metric, including deciding on the payout within the ranges where appropriate. In doing so, it takes into consideration factors such as the underlying assumptions of the targets set at the beginning of the cycle, overall economic conditions, currency fluctuations and other unforeseeable situations.Payout formulaStep 1Annual base salaryxTarget incentive %=Grant valueStep 2Grant value/Share price=Target number of PSUsGlobal healthcare peer groupAbbvieBiogenGlaxoSmithKlineNovo NordiskRocheAmgen Bristol-Myers SquibbGilead SciencesMerck &amp; Co.SanofiAstraZenecaEli Lilly &amp; Co Johnson &amp; JohnsonPfizerNovartis position Payout rangein the peer group(% of target)Position 1  2Position 3  5Position 6  8Position 9  15170%  200% 130%  160%80%  120%0%Target number of PSUsxPerformance factor+Dividend equivalents=Realized PSUs</div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">102</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">LTPP performance outcomes </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The charts below illustrate the performance of the 2020-2022 LTPP against target. </div>
      <div style="padding-top:15px">
        <img src="comp_0031.gif" alt="WSGE_DP_Graph_LTPP_outcome"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Net sales CAGR (25% weighting)Vesting range 0200% of target8%6%4%2%0%Maximum (200%): 8.7% (CAGR)Actual: 3.8% (CAGR)Target: 5.7% (CAGR)Net sales growth payout43% of targetNotes: A minimum achievement of 3.7% CAGR was required to receive a payout under this performance measureNovartis achieved a net sales CAGR of 3.8% (in constant currencies  cc) against the 5.7% target set at the beginning of the performance cycle. The lower than target performance was mainly due to the negative and unexpected impact of COVID-19 in 2020 and 2021, the Beovu safety update, and the slower uptake of Zolgensma. Following the application of the payout curve, the net sales CAGR (cc) achievement generates a payout factor of 43% (maximum 200%) for this metric.Core operating income (COI) CAGR(25% weighting)Vesting range 0200% of target16%12%8%4%0%Maximum (200%): 16.6% (CAGR)Actual: 9.9% (CAGR)Target: 10.6% (CAGR)COI growth payout93% of targetNotes: A minimum achievement of 6.6% CAGR was required to receive a payout under this performance measureActual performance was adjusted for mergers and acquisitions as well as business development and licensing projects not included in the targetNovartis achieved a COI CAGR of 9.9% (cc) against the 10.6% target set at the beginning of the performance cycle. This was mainly due to lower than target Innovative Medicines sales over the three-year cycle, which was partly offset by lower spend in selling, general and administrative expenses (SG&amp;A). In 2022, the Company took organizational transformative measures, delivering savings reflected in COI improvement for the year.Following the application of the payout curve, the COI CAGR (cc) achievement generates a payout factor of 93% (maximum 200%) for this metric.Relative Total Shareholder Return (TSR) (25% weighting)Novartis position Payout rangein the peer group(% of target)Position 1  2Position 3  5Position 6  8Position 9  15170%  200% 130%  160%80%  120%0%Actual ranking 12th = 0% of targetTSR for the 2020-2022 cycle was 5.5%. As a result, Novartis ranked No. 12 out of 15 healthcare companies (including Novartis). Considering that the relative TSR rank is below median, there was a zero payout for this metric.Innovation (25% weighting)The following developments were considered in our 2020-2022 LTPP innovation performance:&#x2022;US and EU approvals for Pluvicto&#x2022;EU approval for Scemblix for adult patients with chronic myeloid leukemia&#x2022;US approval for Kymriah in the treatment of adult patients with relapsed or refractory follicular lymphoma&#x2022;Filing of Cosentyx for Hidradenitis suppurativa with both the US FDA and the European Medicines Agency(EMA)&#x2022;Submission of Cosentyx for an additional indication ahead of planned timelines&#x2022;Tislelizumab&#x2019;s acceptance by the EMA for regulatory review in esophageal and lung cancers&#x2022;CANOPY trials, Ligelizumab PEARL studies in chronic spontaneous urticaria (CSU), and Sabatolimab STIMULUS MDS-1 where important trial milestones were delayed/not submitted&#x2022;In NIBR, advancement of multiple development candidates including two novel radioligand therapiesBased on input from the Science &amp; Technology Committee, the Board of Directors approved an innovation performance factor of 92% of target.2020-2022 LTPP PayoutOverall, the Board of Directors approved a 2020-2022 LTPP payout at 57% of target, within the range of 0200%. No adjustments, pandemic-related or otherwise, were made in the evaluation of performance, despite the substantial shortfall in sales growth caused by Covid-19. This resulted in an LTPP payout of CHF 3 307 422 for the CEO, including dividend equivalents of CHF 317 316.Net sales CAGR43% x 25%+COI CAGR93% x 25%+Innovation92% x 25%+Relative TSR0% x 25%Final vesting57% of target</div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">103</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Compensation for joining and departing Executive Committee members in&#xA0;2022</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 Executive Committee member appointments </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, four new appointments were made to the Executive Committee, which comprise an internal promotion and three external appointments. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Victor Bulto was promoted internally as President, Innovative Medicines US, and joined the Executive Committee on May 1, 2022.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In line with our compensation policy, externally appointed Executive Committee members were granted buyout awards to compensate for entitlements forfeited by them as a result of joining Novartis, as described in the table below (see &#x201C;&#x2014;Executive Committee appointments compensation policy&#x201D;). Further details on the vesting of the awards below will be provided in relevant future compensation reports.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"> &#xA0;</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">Name</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Date of appointment</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currency</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Cash payments</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity awards</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total value at grant</div>
            </td>
            <td></td>
            <td></td>
          </tr>
          <tr>
            <td colspan="9" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shreeram Aradhye, President, Global Drug  Development and  Chief Medical Officer</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:10%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> May 16, 2022      </div>
            </td>
            <td align="right" style=";width:10%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF      </div>
            </td>
            <td align="right" style=";width:10%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> No cash buyout      </div>
            </td>
            <td align="right" style=";width:10%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;708 RSUs,   vesting over the period 2023-2026    </div>
            </td>
            <td align="right" style=";width:10%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 491 915      </div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="9" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aharon Gal, Chief Strategy &amp; Growth Officer</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> July 18, 2022  </div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF  </div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 818&#xA0;202  </div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43&#xA0;253 RSUs,   vesting over the period 2022-2023</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4 353 702  </div>
            </td>
            <td align="right"></td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="9" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fiona Marshall, President, Novartis Institutes  for BioMedical Research</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> November 1, 2022    </div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD    </div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 522 000 to be paid   out in March 2023  </div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31&#xA0;861 RSUs and 9&#xA0;649 PSUs,   vesting over the period 2023-2026  </div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 886 801    </div>
            </td>
            <td align="right"></td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="9" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 Executive Committee member departures</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In determining the compensation arrangements for departing Executive Committee members, the Compensation Committee ensures that contractual entitlements are respected, and all payments are in line with our plan rules and the Swiss Ordinance against Excessive Compensation in Listed Companies. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">All Executive Committee members have a 12-month notice period during which they are entitled to their contractual base salary, pension, Annual Incentive and other benefits. No new LTPP grants are made during the notice period. In line with the new regulations arising from the reform of Swiss corporate law, any compensation payments toward non-competition agreements from 2023 onwards, will not exceed the average annual compensation of the previous three financial years.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Equity plan rules state that malus and clawback as well as non-compete restrictions will continue to apply. No severance payments are made to departing Executive Committee members. Further details on the policy treatment of variable compensation for departing Executive Committee members can be found in &#x201C;&#x2014;Treatment of variable compensation for Executive Committee leavers.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Former President of Novartis Oncology, Susanne Schaffert, stepped down from her role following the Company&#x2019;s decision to integrate the Pharmaceuticals and Oncology business units and create separate US and International commercial organizations under the Innovative Medicines (IM) Division, and started her notice period on May 1, 2022. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Former Head of Customer &amp; Technology Solutions (CTS), Robert Weltevreden, stepped down from his role following the Company&#x2019;s decision to combine Novartis Technical Operations (NTO) and CTS into a new Operations unit, and started his notice period on May 1, 2022.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Former Head of Global Drug Development and Chief Medical Officer, John Tsai, stepped down from his role effective May 15, 2022, and started his notice period on the same day.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Former President of the Novartis Institutes for BioMedical Research (NIBR), James Bradner, stepped down from his role effective October 31, 2022, and started his notice period on November 1, 2022.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">All four executives departed under good leaver conditions. Outstanding LTI grants will vest at the end of the relevant performance cycles on a pro-rata basis, as per their contractual agreements and in line with the said plan rules.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">To avoid a conflict of interest, Richard Saynor, Chief Executive Officer of Sandoz, stepped down from the Executive Committee with effect from October 25, 2022, following his appointment as CEO designate of the Sandoz standalone company that is planned to be created in the second half of 2023. He will continue to report directly to the CEO and to lead the Sandoz division.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">104</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Realized compensation</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">To aid shareholders&#x2019; understanding of the link between pay and performance, the Compensation Committee discloses the realized compensation for the CEO individually, and for the other members of the Executive Committee on an aggregated basis. Disclosing realized compensation means that the Annual Incentive and the LTI are disclosed at the end of their respective performance cycles, reflecting actual payouts based on performance.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The total actual payout may vary year on year depending on multiple factors, including the composition of the Executive Committee and the tenure of its members (as new members may not have a vested LTI), compensation increases, payout of variable compensation based on actual performance, share price fluctuations of the LTI, and dividend equivalents.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 realized compensation for the CEO and other Executive Committee members</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The table below shows fixed and other compensation for the year, including the Annual Incentive for the 2022 performance year, the realized LTI for the 2020-2022 performance cycle, and any buyouts vesting in 2022. The portion of the Annual Incentive paid in shares for the year 2022 is disclosed using the underlying value of Novartis shares at the date of grant, while the realized values of any other equity awards (including dividend equivalents) are calculated using the share price on the date of vesting.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To determine the appropriateness of the 2022 CEO and executive compensation payouts under the Annual Incentive and LTI plans, the Board of Directors and the Compensation Committee reviewed management&#x2019;s performance and contribution, taking the following into consideration:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Operational and financial performance against targets</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Progress toward strengthening our global product portfolio</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Accomplishments across all strategic pillars, with careful attention given to ESG performance</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The incentive performance outcomes, combined with base salary and other benefits, pension, and dividend equivalents, resulted in 2022 total realized compensation for the CEO of <b>CHF&#xA0;8 452 176</b>.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 realized compensation for the CEO and other Executive Committee members</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022 annual base  salary    </div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022  pension  benefits<sup>1</sup></div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022 Annual Incentive      </div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-Term  Incentives  LTPP 2020 - 2022  cycle</div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other 2022   compensation    </div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Currency</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Cash (amount)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Amount</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Cash</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Equity<sup>2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Equity (value <br /> at vesting date)<sup>3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Amount<sup>4,5</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total realized <br /> compensation <br /> (incl. share<br /> price movement)<sup>6</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan (CEO)</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;786&#xA0;500</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 174&#xA0;488</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;342&#xA0;125</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;342&#xA0;196</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;307&#xA0;422</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 499&#xA0;445</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&#xA0;452&#xA0;176</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aggregate realized compensation of the  other 15 Executive Committee members,  including the members who stepped down  during the financial year 2022<sup style="white-space: nowrap"> &#xA0;7,8</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       9&#xA0;122&#xA0;792</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       1&#xA0;978&#xA0;304</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       4&#xA0;211&#xA0;841</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       5&#xA0;918&#xA0;318</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       10&#xA0;025&#xA0;047</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       9&#xA0;716&#xA0;294</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       40&#xA0;972&#xA0;595</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&#xA0;909&#xA0;292</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&#xA0;152&#xA0;792</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&#xA0;553&#xA0;966</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&#xA0;260&#xA0;514</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&#xA0;332&#xA0;469</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&#xA0;215&#xA0;739</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 49&#xA0;424&#xA0;771</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">See 2021 realized compensation for the CEO and other Executive Committee members for 2021 comparative figures.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Includes mandatory employer contributions of CHF 4&#xA0;560 for the CEO and CHF 67&#xA0;148 for the other current Executive Committee members paid by Novartis to governmental social security systems. This amount is out of total employer contributions of CHF 3&#xA0;937&#xA0;537 paid in 2022 for all Executive Committee members, and provides a right to the maximum future insured government pension benefit.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> The portion of the Annual Incentive delivered in equity is rounded up to the nearest share, based on the closing share price on the grant date (January 25, 2023) of CHF 85.30 per Novartis share and USD 92.81 per ADR.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> The amounts represent the underlying share value of the 97&#xA0;361 LTPP PSUs vesting on January 25, 2023, to the CEO and other Executive Committee members for the 2020-2022 performance cycle and dividend equivalents for the three-year cycle (for details, see ''&#x2014;LTPP performance outcomes''). The taxable value is determined using the closing share price on the day the Novartis Board of Directors approved the final LTPP performance factor (i.e., January 25, 2023) of CHF 85.30 per Novartis share and USD 92.81 per ADR. Robert Kowalski was promoted to the Executive Committee during the course of the 2021 performance period and Victor Bulto during the course of the 2022 performance period, and as such, the information disclosed reflects their pro-rata LTPP 2020-2022 payout attributable to the period in which they were members of the Executive Committee. Shreeram Aradhye rejoined Novartis and Karen Hale, Aharon Gal and Fiona Marshall joined Novartis after the 2020 LTI awards were made and hence did not receive an LTPP award for the 2020-2022 performance period.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> Includes any other perquisites, benefits in kind, and international assignment benefits as per the global mobility policy (e.g., housing, international health insurance, children's school fees, tax equalization). The 2022 tax payments were CHF &#xA0;221&#xA0;633 for Richard Saynor, as well as CHF &#xA0;533&#xA0;927 for Victor Bulto, CHF &#xA0;127&#xA0;980 for Robert Kowalski, CHF &#xA0;109&#xA0;966 for Aharon Gal, and CHF &#xA0;417&#xA0;826 for Vas Narasimhan.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> Includes 696 vested RSUs and 2&#xA0;765 PSUs (for a total value of CHF 268&#xA0;158), which vested on March 13, 2022, to John Tsai in lieu of the LTI that he forfeited when leaving his previous employer. Also includes 2&#xA0;348 vested RSUs and 1&#xA0;586 vested PSUs (for a total value of CHF 313&#xA0;815), which vested on February 13, 2022, to Richard Saynor in lieu of the LTI that he forfeited when leaving his previous employer, and 3&#xA0;675 vested PSUs (CHF 287&#xA0;238) on January 18, 2022, to Klaus Moosmayer in lieu of the LTI he forfeited when leaving his previous employer as well as 15 448 RSUs (CHF 1&#xA0;292&#xA0;225), which vested on December 1, 2022, to Aharon Gal in lieu of the LTI that he forfeited when leaving his previous employer.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;6&#xA0;</sup> All amounts are before deduction of the social security contribution and income tax due from the Executive Committee member.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;7&#xA0;</sup> Includes compensation of the following members who stepped down from the ECN: Richard Saynor, Sandoz CEO designate, James Bradner, former President NIBR, Susanne Schaffert, former CEO Oncology, John Tsai, former Global Head of Drug Development and Chiel Medical Officer and Robert Weltevreden, former Head of Customer and Technology Solutions, including the vesting of their Long-Term Incentives for 2020-2022 performance cycle, as per the plan rules. The compensation and benefits elements related to the period after the step-down dates are reported under the 'other 2022 compensation' column. See &#x201C;&#x2014;2022 Executive Committee member departures" for details.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;8&#xA0;</sup> Amounts for Executive Committee members paid in USD were converted at a rate of USD 1.00 = CHF 0.9548, which is the same average exchange rate used in the Group's 2022 consolidated financial statements (a similar rule applies to payments made in other currencies during the year).</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">105</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The table and information below provide additional details on awards granted as part of the 2020-2022 LTPP performance cycle, including the number of shares awarded and delivered, following the application of the payout factor and the addition of dividend equivalent shares.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2020-2022 LTPP performance cycle </span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> PSUs at grant</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="9" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Shares delivered at vesting</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="9" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="9" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> PSUs<br /> (target number)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> PSUs<br /> (target value<br /> at grant date)<br /> (CHF)<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br /> Payout factor <br /> for ECN LTPP <br /> (% of target)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br /> Performance shares <br /> delivered at vesting<br /> (number)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Performance shares <br /> delivered at vesting<br /> (value at vesting date)<br /> (CHF)<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Dividend <br /> equivalent shares <br /> delivered at vesting<br /> (number)<sup style="white-space: nowrap">4</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Dividend <br /> equivalent shares <br /> delivered at vesting<br /> (value at vesting date)<br /> (CHF)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total shares<br /> delivered at vesting<br /> (value at <br /> vesting date)<br /> (CHF)</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 61&#xA0;498</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;712&#xA0;549</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57%</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35&#xA0;054</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;990&#xA0;106</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;720</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 317&#xA0;316</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;307&#xA0;422</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other 15 Executive Committee members,  including the members who stepped  down during the financial year 2022<sup style="white-space: nowrap"> &#xA0;5</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     183&#xA0;733</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     17&#xA0;005&#xA0;806</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     57%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     105&#xA0;530</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     9&#xA0;058&#xA0;150</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     11&#xA0;156</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     966&#xA0;897</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">     10&#xA0;025&#xA0;047</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 245&#xA0;231</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22&#xA0;718&#xA0;356</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 140&#xA0;584</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12&#xA0;048&#xA0;256</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&#xA0;876</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;284&#xA0;213</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&#xA0;332&#xA0;469</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="18" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Robert Kowalski and Victor Bulto joined the Executive Committee during the course of the 2020-2022 performance period. As such, the information disclosed reflects their pro-rata LTPP 2020-2022 attributable to the period in which they were members of the Executive Committee.  Karen Hale, Aharon Gal, Fiona Marshall and Shreeram Aradhye joined Novartis after the 2020-2022 LTPP awards were made and hence did not receive an LTPP award for this performance period.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> The shown amounts represent the underlying share value of the target number of PSUs granted to each Executive Committee member for the  2020-2022 performance period, based on the closing share price on the grant date (January 21, 2020) of CHF 92.89 per Novartis share and USD 95.19 per ADR.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> The shown amounts represent the underlying share value of the number of PSUs vested for the 2020-2022 performance period, based on the closing share price on the day the Novartis Board of Directors approved the final LTPP performance payout factor (i.e., January 25, 2023) of CHF 85.30 per Novartis share and USD 92.81 per ADR.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> Dividend equivalent shares are calculated on the dividend each member of the Executive Committee would have received, based on the actual number of shares delivered at the end of the 2020-2022 performance period. At vesting, the dividend equivalents are credited in shares or ADRs.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> Includes the LTPP vesting for Richard Saynor, Sandoz CEO Designate, James Bradner, former President NIBR, Susanne Schaffert, former CEO Oncology, John Tsai, former Global Head of Drug Development and Chiel Medical Officer and Robert Weltevreden, former Head of Customer and Technology Solutions for the 2020-2022 performance cycle, as per the plan rules.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">106</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The table and information below provide details on the 2021 realized compensation for the CEO and other Executive Committee members, for comparative purposes. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2021 realized compensation for the CEO and other Executive Committee members</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2021 annual base  salary</div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2021  pension  benefits<sup>1</sup></div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2021 Annual Incentive  </div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-Term Incentives  </div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other 2021   compensation</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> LTPP 2019-2021   cycle</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Currency</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Cash (amount)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Amount</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Cash</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Equity<sup>2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Equity (value <br /> at vesting date)<sup>3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br /> Amount<sup>2,4,5</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total realized <br /> compensation <br /> (incl. share<br /> price movement)<sup>6</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan (CEO)</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;769&#xA0;200</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 176&#xA0;731</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;328&#xA0;625</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;328&#xA0;642</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&#xA0;356&#xA0;128</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 265&#xA0;401</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11&#xA0;224&#xA0;727</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aggregate realized compensation of the  other 14 Executive Committee members,  including the members who stepped down  during the financial year 2021<sup style="white-space: nowrap"> &#xA0;7,8</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">       CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">       8&#xA0;983&#xA0;841</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">       2&#xA0;065&#xA0;561</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">       4&#xA0;174&#xA0;006</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">       5&#xA0;400&#xA0;015</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">       18&#xA0;770&#xA0;029</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">       6&#xA0;021&#xA0;712</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">       45&#xA0;415&#xA0;164</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&#xA0;753&#xA0;041</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;242&#xA0;292</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&#xA0;502&#xA0;631</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&#xA0;728&#xA0;657</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25&#xA0;126&#xA0;157</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&#xA0;287&#xA0;113</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 56&#xA0;639&#xA0;891</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Includes mandatory employer contributions of CHF 5&#xA0;498 for the CEO and CHF 53&#xA0;693 for the other Executive Committee members paid by Novartis to governmental social security systems. This amount is out of total employer contributions of CHF 4&#xA0;966&#xA0;397 paid in 2021 for all Executive Committee members, and provides a right to the maximum future insured government pension benefit.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> The portion of the Annual Incentive delivered in equity is rounded up to the nearest share, based on the closing share price on the grant date (January 26, 2022) of CHF 78.16 per Novartis share and USD 84.24 per ADR.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> The amounts represent the underlying share value of the 296 741 LTPP PSUs vested on January 22, 2022, to the CEO and other Executive Committee members for the 2019-2021 performance cycle, inclusive of earned Alcon Keep Whole awards and dividend equivalents for the three-year cycle (for details, see ''&#x2014;LTPP performance outcomes''). The taxable value is determined using the closing share price on the day the Novartis Board of Directors approved the final LTPP performance factor (i.e., January 26, 2022) of CHF 78.16 per Novartis share and USD 84.24 per ADR. Marie-France Tschudin and Robert Kowalski were promoted to the Executive Committee during the course of the 2019-2021 performance period, and as such, the information disclosed reflects their pro-rata LTPP 2019-2021 payout attributable to the period in which they were members of the Executive Committee. Richard Saynor and Karen Hale joined Novartis after the 2019 LTI awards were made and hence did not receive an LTPP award for the 2019-2021 performance period.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> Includes any other perquisites, benefits in kind, and international assignment benefits as per the global mobility policy (e.g., housing, international health insurance, children's school fees, tax equalization). The 2021 tax payments were CHF  127&#xA0;009 for Mr. Saynor, as well as CHF  822&#xA0;808 for Susanne Schaffert, and CHF  156&#xA0;788 for Vas Narasimhan.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> Includes 6&#xA0;128 vested RSUs and 3&#xA0;546 PSUs (for a total value of CHF 782&#xA0;649), which vested partially on March 13, 2021, and partially on July 28, 2021, to John Tsai in lieu of the LTI that he forfeited when leaving his previous employer. Also includes 2&#xA0;584 vested RSUs and 2&#xA0;043 vested PSUs (for a total value of CHF 379&#xA0;414), which vested on February 14, 2021, to Mr. Saynor in lieu of the LTI that he forfeited when leaving his previous employer, and 4&#xA0;313 vested PSUs (CHF 370&#xA0;961) on January 18, 2021, to Klaus Moosmayer in lieu of the LTI he forfeited when leaving his previous employer.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;6&#xA0;</sup> All amounts are before deduction of the social security contribution and income tax due from the Executive Committee member.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;7&#xA0;</sup> Includes the first six weeks of Karen Hale's compensation, before her appointment to the Executive Committee, under other compensation. Comprises the compensation of Bertrand Bodson, former Chief Data Officer and Steven Baert, former Chief People &amp; Organization Officer, including the vesting of their Long-Term Incentives for 2019-2021 performance cycle, as per the plan rules. The compensation and benefits elements related to the period after the step-down dates are reported under the other compensation column. Unvested shares for Shannon Klinger were forfeited upon her departure from the Company. See &#x201C;&#x2014;2021 Executive Committee member departures" for details.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;8&#xA0;</sup> Amounts for Executive Committee members paid in USD were converted at a rate of USD 1.00 = CHF 0.9139, which is the same average exchange rate used in the Group's 2021 consolidated financial statements (a similar rule applies to payments made in other currencies during the year).</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Realized compensation for the CEO and other Executive Committee members for 2022 compared with&#xA0;2021</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The 2022 total realized compensation for the CEO was CHF 8&#xA0;452&#xA0;176. This is a reduction of 24.7% compared with the prior year, mainly due to the lower performance payout of the 2020-2022 LTPP (57% compared with the 107% payout for the 2019-2021 LTPP). At the end of the 2020-2022 LTPP performance cycle, the rTSR ranking for Novartis, which is weighted 25% of the overall LTPP opportunity, was below median, which resulted in zero payout for this measure. Payout for Net Sales CAGR performance, also weighted 25%, was significantly lower (43% compared with 119% in 2019-2021), mainly driven by the impact of Covid-19 on Sales growth during 2020 and 2021.  Furthermore, the Alcon &#x201C;keep-whole&#x201D; awards, granted at the time of Alcon spin-off in 2019, ended with the 2019-2021 LTPP payout. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The 2022 total realized compensation for the Executive Committee members, including the CEO, was CHF&#xA0;49&#xA0;424&#xA0;771. This decrease of 12.7% compared with the prior year can be attributed to the same reasons mentioned above. For more detail, please refer to &#x201C;&#x2014;LTPP performance outcomes&#x201D;.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">107</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Compensation at grant value</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In accordance with the Swiss Ordinance against Excessive Compensation in Listed Companies, Novartis continues to disclose total compensation at grant value for the CEO and other Executive Committee members. The tables below disclose the following information for the CEO and other Executive Committee members:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Fixed 2022 compensation (base salary and benefits)</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Actual cash portion and the deferred portion granted in equity of the 2022 Annual Incentive</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   2022-2024 LTPP performance cycle awards, which are reported at target grant date value, based on the assumption that the awards will vest at 100% achievement, excluding any share price movement and dividend equivalents that may be accrued over the performance cycle. The future payout will be determined only after the performance cycle concludes in three years (i.e., at the end of 2024), with a payout range of 0% to 200% of the target value</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Other compensation for 2022, which includes other benefits, either paid in cash or granted in equity during the year</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The compensation paid, promised or granted to the members of the Executive Committee during financial year 2022 was within the amount approved by shareholders at the 2021 AGM.</div>
      <div style="border:solid #eeeeee 3px; background-color:#eeeeee;padding-bottom:0px;">
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">To assess CEO actual pay for performance in 2022, including the Annual Incentive payout for the 2022 performance year and the LTI payouts for the 2020-2022 performance cycle, shareholders should refer to the 2022 realized  compensation table in &#x201C;&#x2014;2022 realized compensation for the CEO and other Executive Committee members.&#x201D;</div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022 compensation at grant value for the CEO and other Executive Committee members</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Fixed compensation and  pension benefits</div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Variable compensation  </div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="7" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Actual compensation paid or granted for 2022    </div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-Term Incentive   2022-2024 cycle  grants at target</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="7" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="7" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022 annual base  salary    </div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022 pension  benefits    </div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022 Annual Incentive   (performance achieved)    </div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> LTPP 2022-2024 cycle      </div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other 2022  compensation    </div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total   compensation   paid, promised  or granted 2022</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style="border-bottom: solid #000000 1px;height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style="border-bottom: solid #000000 1px;height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style="border-bottom: solid #000000 1px;height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style="border-bottom: solid #000000 1px;height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style="border-bottom: solid #000000 1px;height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Currency</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Cash<br /> (amount)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Amount<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Cash<br /> (amount)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Equity<br /> (value at<br /> grant date)<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> PSUs<br /> (target value<br /> at grant date)<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Amount<sup style="white-space: nowrap">4</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Amount<sup style="white-space: nowrap">5</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members active on December 31, 2022</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;786&#xA0;500</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 174&#xA0;488</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;342&#xA0;125</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;342&#xA0;196</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;815&#xA0;886</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 499&#xA0;445</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;960&#xA0;639</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shreeram Aradhye (from May 16, 2022)<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 538&#xA0;656</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 110&#xA0;041</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 270&#xA0;959</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 270&#xA0;998</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;629&#xA0;233</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 581&#xA0;328</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;401&#xA0;215</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Victor Bulto (from May 1, 2022)<sup style="white-space: nowrap">&#xA0;7, 8</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 622&#xA0;596</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49&#xA0;434</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 310&#xA0;445</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 310&#xA0;449</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 873&#xA0;500</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 782&#xA0;443</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;948&#xA0;867</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aharon Gal (from July 18, 2022)<sup style="white-space: nowrap">&#xA0;9</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 363&#xA0;441</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 78&#xA0;083</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 150&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 150&#xA0;043</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;576&#xA0;719</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;318&#xA0;285</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Karen Hale</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 845&#xA0;834</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 215&#xA0;842</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 935&#xA0;059</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;700&#xA0;058</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 146&#xA0;154</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;842&#xA0;946</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Harry Kirsch</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;082&#xA0;250</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 177&#xA0;526</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 655&#xA0;820</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 655&#xA0;872</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;818&#xA0;450</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36&#xA0;456</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;426&#xA0;373</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Kowalski</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 705&#xA0;833</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 207&#xA0;628</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 349&#xA0;965</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 349&#xA0;986</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;272&#xA0;601</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 307&#xA0;969</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;193&#xA0;982</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steffen Lang</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 840&#xA0;833</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 180&#xA0;675</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 165&#xA0;136</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 935&#xA0;826</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;722&#xA0;021</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&#xA0;431</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;858&#xA0;923</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fiona Marshall (from November 1, 2022)<sup style="white-space: nowrap">&#xA0;8, 9</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 186&#xA0;154</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&#xA0;222</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 101&#xA0;085</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 101&#xA0;163</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;961&#xA0;064</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;365&#xA0;688</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Klaus Moosmayer</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 580&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 181&#xA0;112</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 313&#xA0;740</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 313&#xA0;819</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;045&#xA0;859</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32&#xA0;026</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;466&#xA0;555</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marie-France Tschudin</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 951&#xA0;250</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 164&#xA0;480</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 527&#xA0;209</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 527&#xA0;239</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;220&#xA0;057</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&#xA0;804</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;399&#xA0;040</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&#xA0;466&#xA0;817</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;552&#xA0;567</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&#xA0;167&#xA0;896</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&#xA0;874&#xA0;057</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 19&#xA0;058&#xA0;209</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&#xA0;732&#xA0;583</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 49&#xA0;852&#xA0;130</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members who stepped down during 2022</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">James Bradner (until October 31, 2022)<sup style="white-space: nowrap">&#xA0;8, 10</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;006&#xA0;294</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 280&#xA0;763</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 605&#xA0;668</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 605&#xA0;771</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;030&#xA0;029</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 651&#xA0;499</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&#xA0;180&#xA0;024</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Richard Saynor (until October 25, 2022)<sup style="white-space: nowrap">&#xA0;11</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 641&#xA0;721</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 150&#xA0;920</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 383&#xA0;977</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 384&#xA0;021</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;493&#xA0;403</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 706&#xA0;394</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;760&#xA0;436</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Susanne Schaffert (until April 4, 2022)<sup style="white-space: nowrap">&#xA0;12</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 292&#xA0;466</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 59&#xA0;180</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 161&#xA0;112</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 161&#xA0;217</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;138&#xA0;458</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;306&#xA0;257</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;118&#xA0;690</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">John Tsai (until May 15, 2022)<sup style="white-space: nowrap">&#xA0;13</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 321&#xA0;967</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67&#xA0;322</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 161&#xA0;031</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 161&#xA0;132</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;192&#xA0;544</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;396&#xA0;407</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;300&#xA0;403</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Weltevreden (until April 4, 2022)<sup style="white-space: nowrap">&#xA0;14</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 225&#xA0;479</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 54&#xA0;721</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 101&#xA0;638</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 101&#xA0;678</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;374&#xA0;053</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;029&#xA0;246</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;886&#xA0;815</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&#xA0;442&#xA0;475</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 600&#xA0;225</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;386&#xA0;070</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;386&#xA0;456</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&#xA0;091&#xA0;626</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&#xA0;060&#xA0;376</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20&#xA0;967&#xA0;229</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&#xA0;909&#xA0;292</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&#xA0;152&#xA0;792</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&#xA0;553&#xA0;966</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&#xA0;260&#xA0;514</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&#xA0;149&#xA0;836</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&#xA0;792&#xA0;959</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 70&#xA0;819&#xA0;358</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="left" colspan="3">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;background-color:#eeeeee;">&#xA0;Based on assumption of &#xA0;100% payout at target. &#xA0;Actual payout (0-200% of &#xA0;target) will be known at  &#xA0;the end of the three-year &#xA0;cycle in January 2025</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">See next page for 2021 comparative figures.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Includes mandatory employer contributions of CHF 4&#xA0;560 for the CEO and CHF 67&#xA0;148 for the other current Executive Committee members paid by Novartis to governmental social security systems. This amount is out of total employer contributions of CHF 3&#xA0;937&#xA0;537 paid in 2022 for all Executive Committee members, and provides a right to the maximum future insured government pension benefit.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> The portion of the Annual Incentive delivered in equity is rounded up to the nearest share, based on the closing share price on the grant date (January 25, 2023) of CHF 85.30 per Novartis share and USD 92.81 per ADR.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> The amounts represent the underlying share value of the target number of PSUs granted to Executive Committee members for the 2022-2024 performance cycle, based on the closing share price on the grant date (January 26, 2022) of CHF 78.16 per Novartis share and USD 84.24 per ADR for all members.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> Includes any other perquisites, benefits in kind, and international assignment benefits as per the global mobility policy (e.g., housing, international health insurance, children's school fees, tax equalization). The compensation and benefits elements related to the period after the step-down dates are also reported under &#x2018;other 2022 compensation&#x2019;.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> All amounts are before deduction of the social security contribution and income tax due by the Executive Committee member.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;6&#xA0;</sup> Shreeram Aradhye received a pro-rata LTPP award of 18 905 PSUs on June 1, 2022 (at CHF 86.18 closing share price on grant date) upon joining the organization, as per contractual entitlement.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;7&#xA0;</sup> Victor Bulto received his 2022 LTPP grant before his appointment to Executive Committee, therefore the reported LTPP amount is pro-rated to reflect his time as Executive Committee member over the full performance cycle.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;8&#xA0;</sup> Amounts in USD for Victor Bulto, Fiona Marshall and James Bradner were converted at a rate of CHF 1.00 = USD 1.0473, which is the average rate used in the Group&#x2019;s 2022 consolidated financial statements.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;9&#xA0;</sup> Aharon Gal and Fiona Marshall did not receive a pro-rata LTPP award upon joining the organization, as they received buyout grants for their forfeited awards upon joining.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>10&#xA0;</sup> James Bradner stepped down from the Executive Committee on October 31, 2022 and will end his notice period on October 31, 2023, in line with his contractual notice period (for more details, see &#x201C;&#x2014;2022 Executive Committee member departures&#x201D;). The LTPP grant for the 2022-2024 performance cycle, included in the table above, will vest at the end of the performance cycle on a pro-rata basis subject to the plan rules.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>11&#xA0;</sup> Richard Saynor left the Executive Committee on October 25, 2022. The LTPP grant for the 2022-2024 performance cycle, included in the table above, will vest at the end of the performance cycle, subject to the plan rules.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>12&#xA0;</sup> Susanne Schaffert stepped down from the Executive Committee on April 4, 2022 and will end her notice period on April 30, 2023, in line with her contractual notice period (for more details, see &#x201C;&#x2014;2022 Executive Committee member departures&#x201D;). The LTPP grant for the 2022-2024 performance cycle, included in the table above, will vest at the end of the performance cycle on a pro-rata basis subject to the plan rules.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>13&#xA0;</sup> John Tsai stepped down from the Executive Committee on May 15, 2022 and will end his notice period on May 15, 2023, in line with his contractual notice period (for more details, see &#x201C;&#x2014;2022 Executive Committee member departures&#x201D;). The LTPP grant for the 2022-2024 performance cycle, included in the table above, will vest at the end of the performance cycle on a pro-rata basis subject to the plan rules.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>14&#xA0;</sup> Robert Weltevreden stepped down from the Executive Committee on April 4, 2022 and will end his notice period on April 30, 2023, in line with his contractual notice period (for more details, see &#x201C;&#x2014;2022 Executive Committee member departures&#x201D;). The LTPP grant for the 2022-2024 performance cycle, included in the table above, will vest at the end of the performance cycle on a pro-rata basis subject to the plan rules.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">108</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2021 compensation at grant value for the CEO and other Executive Committee members</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For comparative purposes, the table below provides the compensation at grant value for 2021. </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td></td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="margin-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:11pt; font-weight:bold; color:#000000;">Executive Committee member compensation at grant for financial year 2021</div>
            </td>
            <td></td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Fixed compensation and  pension benefits</div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Variable compensation  </div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="7" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Actual compensation paid or granted for 2021    </div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-Term Incentive  2021-2023 cycle  grants at target</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="7" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="7" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2021 annual base  salary    </div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2021 pension  benefits    </div>
            </td>
            <td></td>
            <td align="center" colspan="3" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2021 Annual Incentive   (performance achieved)    </div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> LTPP   2021-2023 cycle    </div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other 2021  compensation    </div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total   compensation   paid, promised  or granted 2021</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style="border-bottom: solid #000000 1px;height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style="border-bottom: solid #000000 1px;height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style="border-bottom: solid #000000 1px;height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style="border-bottom: solid #000000 1px;height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td style="border-bottom: solid #000000 1px;height:1;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="3" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Currency</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Cash<br /> (amount)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Amount<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Cash<br /> (amount)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Equity<br /> (value at<br /> grant date)<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> PSUs<br /> (target value<br /> at grant date)<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Amount<sup style="white-space: nowrap">4</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Amount<sup style="white-space: nowrap">5</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members active on December 31, 2021</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;769&#xA0;200</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 176&#xA0;731</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;328&#xA0;625</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;328&#xA0;642</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&#xA0;757&#xA0;423</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 265&#xA0;401</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:5%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&#xA0;626&#xA0;023</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">James Bradner<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;184&#xA0;462</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 367&#xA0;246</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 712&#xA0;802</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 712&#xA0;839</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;970&#xA0;016</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 92&#xA0;286</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&#xA0;039&#xA0;652</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Karen Hale (from May 15, 2021)<sup style="white-space: nowrap">&#xA0;7</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 519&#xA0;750</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 85&#xA0;987</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 261&#xA0;062</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 261&#xA0;133</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;442&#xA0;371</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 542&#xA0;689</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;112&#xA0;992</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Harry Kirsch</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;072&#xA0;084</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 177&#xA0;174</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 354&#xA0;255</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;062&#xA0;820</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;791&#xA0;111</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43&#xA0;617</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&#xA0;501&#xA0;060</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Kowalski (from September 1, 2021)<sup style="white-space: nowrap">&#xA0;8</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 233&#xA0;333</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 49&#xA0;692</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 105&#xA0;288</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 105&#xA0;360</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 448&#xA0;824</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180&#xA0;428</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;122&#xA0;925</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steffen Lang</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 780&#xA0;833</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180&#xA0;413</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 508&#xA0;680</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 763&#xA0;076</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;570&#xA0;027</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14&#xA0;430</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;817&#xA0;459</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Klaus Moosmayer</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 566&#xA0;667</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 198&#xA0;992</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 253&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 253&#xA0;004</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;035&#xA0;044</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 49&#xA0;850</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;356&#xA0;557</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Richard Saynor</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 785&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 190&#xA0;263</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 196&#xA0;500</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 196&#xA0;572</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;493&#xA0;478</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 416&#xA0;693</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;278&#xA0;506</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Susanne Schaffert</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 881&#xA0;333</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180&#xA0;837</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 88&#xA0;250</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 794&#xA0;262</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;118&#xA0;082</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 856&#xA0;650</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;919&#xA0;415</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">John Tsai</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 875&#xA0;834</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 186&#xA0;807</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 306&#xA0;950</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 307&#xA0;012</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;192&#xA0;567</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 201&#xA0;307</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;070&#xA0;477</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marie-France Tschudin</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 881&#xA0;333</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 164&#xA0;980</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 706&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 706&#xA0;019</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;029&#xA0;750</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;488&#xA0;083</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Weltevreden</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 673&#xA0;333</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 171&#xA0;352</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 299&#xA0;200</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 299&#xA0;275</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;292&#xA0;042</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;735&#xA0;202</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&#xA0;121&#xA0;211</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;098&#xA0;866</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&#xA0;059&#xA0;259</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&#xA0;728&#xA0;657</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24&#xA0;885&#xA0;096</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;655&#xA0;408</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 51&#xA0;548&#xA0;498</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members who stepped down during 2021</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steven Baert (until June 30, 2021)<sup style="white-space: nowrap">&#xA0;9</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 400&#xA0;277</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 87&#xA0;753</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399&#xA0;887</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 422&#xA0;223</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;831&#xA0;302</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;141&#xA0;442</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bertrand Bodson (until January 31, 2021)<sup style="white-space: nowrap">&#xA0;10</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 54&#xA0;451</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&#xA0;240</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43&#xA0;485</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;339&#xA0;471</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;452&#xA0;647</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shannon Thyme Klinger (until March 15, 2021)<sup style="white-space: nowrap">&#xA0;11</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 177&#xA0;102</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 40&#xA0;434</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 279&#xA0;791</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;018&#xA0;161</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;515&#xA0;487</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 631&#xA0;830</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 143&#xA0;427</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 443&#xA0;372</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 702&#xA0;014</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&#xA0;188&#xA0;934</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&#xA0;109&#xA0;576</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&#xA0;753&#xA0;041</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;242&#xA0;292</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&#xA0;502&#xA0;631</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&#xA0;728&#xA0;657</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25&#xA0;587&#xA0;110</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&#xA0;844&#xA0;343</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 58&#xA0;658&#xA0;074</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="left" colspan="3">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;background-color:#eeeeee;">&#xA0;Based on assumption of &#xA0;100% payout at target. &#xA0;Actual payout (0-200% of &#xA0;target) will be known at  &#xA0;the end of the three-year &#xA0;cycle in January 2024</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0; &#xA0; &#xA0;</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Includes mandatory employer contributions of CHF 5&#xA0;498 for the CEO and CHF 53&#xA0;693 for the other Executive Committee members paid by Novartis to governmental social security systems. This amount is out of total employer contributions of CHF 4&#xA0;966 397 paid in 2021 for all Executive Committee members, and provides a right to the maximum future insured government pension benefit.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> The portion of the Annual Incentive delivered in equity is rounded up to the nearest share, based on the closing share price on the grant date (January 26, 2022) of CHF 78.16 per Novartis share and USD 84.24 per ADR.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> The amounts represent the underlying share value of the target number of PSUs granted to Executive Committee members for the 2021-2023 performance cycle, based on the closing share price on the grant date (January 20, 2021) of CHF 86.01 per Novartis share and USD 96.92 per ADR for all members.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> Includes any other perquisites, benefits in kind, and international assignment benefits as per the global mobility policy (e.g., housing, international health insurance, children's school fees, tax equalization). The compensation and benefits elements related to the period after the step-down dates are also reported under &#x2018;other 2021 compensation&#x2019;.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> All amounts are before deduction of the social security contribution and income tax due by the Executive Committee member.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;6&#xA0;</sup> Amounts in USD for James Bradner were converted at a rate of CHF 1.00 = USD 1.0942, which is the average rate used in the Group&#x2019;s 2021 consolidated financial statements.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;7&#xA0;</sup> Karen Hale received a pro-rata LTPP award of 18&#xA0;639 PSUs on Apr-2, 2021 (at CHF 81.15 share price at grant) upon joining the organization, as per contractual entitlement. The other compensation amount includes the first six weeks of compensation before her appointment to the Executive Committee.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;8&#xA0;</sup> Robert Kowalski received his 2021 LTPP grant before his appointment to Executive Committee, therefore the reported LTPP amount is pro-rated to reflect his time as Executive Committee member over the full performance cycle.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;9&#xA0;</sup> Steven Baert left the Executive Committee on June 30, 2021 and ended his notice period on September 30, 2021, in line with his reduced contractual notice period (for more details, see &#x201C;&#x2014;2021 Executive Committee member departures&#x201D;). He received his 2021 Annual Incentive 100% in cash on a pro-rata basis, and the LTPP grant for the 2021-2023 performance cycle, included in the table above, will vest at the end of the performance cycle on a pro-rata basis subject to the plan rules.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>10&#xA0;</sup> Bertrand Bodson left the Executive Committee on January 31, 2021 and ended his notice period on November 30, 2021, in line with his reduced contractual notice period (for more details, see &#x201C;&#x2014;2021 Executive Committee member departures&#x201D;). He received his 2021 Annual Incentive 100% in cash on a pro-rata basis, and no LTPP was granted for the 2021-2023 performance cycle.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="18">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>11&#xA0;</sup> Shannon Klinger resigned as Chief Legal Officer as of March 15, 2021, and left the Company on May 31, 2021, in line with her reduced contractual notice period (for more details, see &#x201C;&#x2014;2021 Executive Committee member departures&#x201D;). The 2021 Annual Incentive and LTPP 2021-2023 cycle grant (23 586 PSUs), displayed at pro-rata value for the time she was in her role in 2021, were forfeited in full upon her departure.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Compensation at grant value for the CEO and other Executive Committee members for 2022 compared with 2021</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Compensation at grant delivered in 2022 to the CEO and the other Executive Committee members, including those who stepped down, was CHF 70&#xA0;819&#xA0;358, which was an increase of 20.7% compared with the prior year. This increase was driven mainly by the change in composition of the Executive Committee during 2022. Compensation at grant for the active Executive Committee members on December 31, 2022 (11 active members versus 12 in prior year) was CHF 49&#xA0;852&#xA0;130, which is a reduction of 3.3% from December 31, 2021.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">109</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Additional disclosures for the CEO and other Executive Committee members</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">This section provides additional disclosures, including information about the shareholdings of the CEO and the other Executive Committee members.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Malus and clawback</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Consistent with our &#x201C;&#x2014;Executive Committee compensation philosophy and principles,&#x201D; in 2022 there was no legal or factual basis on which to exercise malus or clawback for current or former Executive Committee members. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Number of equity instruments granted to the CEO and other Executive Committee members for the financial year 2022</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Variable compensation<sup>1</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022 Annual Incentive  (performance achieved)</div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> LTPP  2022-2024 cycle</div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other  </div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity<br /> (number)<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> PSUs<br /> (target number)<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity/PSUs<br /> (number)</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members active on December 31, 2022</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&#xA0;735</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 74&#xA0;410</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shreeram Aradhye (from May 16, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;177</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18&#xA0;905</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;708</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Victor Bulto (from May 1, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;345</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;671</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aharon Gal (from July 18, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;759</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43&#xA0;253</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Karen Hale</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;962</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21&#xA0;751</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Harry Kirsch</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&#xA0;689</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36&#xA0;060</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Kowalski</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;103</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&#xA0;282</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steffen Lang</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;971</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22&#xA0;032</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fiona Marshall (from November 1, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;090</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 41&#xA0;510</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Klaus Moosmayer</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;679</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&#xA0;381</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marie-France Tschudin</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&#xA0;181</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&#xA0;404</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 68&#xA0;691</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 241&#xA0;896</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 90&#xA0;471</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members who stepped down during  2022</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">James Bradner (until October 31, 2022)<sup style="white-space: nowrap">&#xA0;4</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&#xA0;527</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35&#xA0;969</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Richard Saynor (until October 25, 2022)<sup style="white-space: nowrap">&#xA0;5</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;502</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19&#xA0;107</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Susanne Schaffert (until April 4, 2022)<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;890</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27&#xA0;360</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">John Tsai (until May 15, 2022)<sup style="white-space: nowrap">&#xA0;7</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;889</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&#xA0;052</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Weltevreden (until April 4, 2022)<sup style="white-space: nowrap">&#xA0;8</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;192</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17&#xA0;580</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 128&#xA0;068</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 84&#xA0;691</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 369&#xA0;964</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 90&#xA0;471</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">See next page for 2021 comparative figures.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> The values of the awards are reported in the table "2022 compensation at grant value for the CEO and other Executive Committee members."</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Vested shares, restricted shares and/or RSUs granted under the Annual Incentive for the 2022 performance period.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Target number of PSUs granted under the LTPP as applicable for the 2022-2024 performance cycle.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> James Bradner stepped down from the Executive Committee on October 31, 2022 and will end his notice period on October 31, 2023, in line with his contractual notice period (for more details, see &#x201C;&#x2014;2022 Executive Committee member departures&#x201D;). The LTPP grant for the 2022-2024 performance cycle, included in the table above, will vest at the end of the performance cycle on a pro-rata basis subject to the plan rules.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> Richard Saynor left the Executive Committee on October 25, 2022. The LTPP grant for the 2022-2024 performance cycle, included in the table above, will vest at the end of the performance cycle, subject to the plan rules.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;6&#xA0;</sup> Susanne Schaffert stepped down from the Executive Committee on April 4, 2022 and will end her notice period on April 30, 2023, in line with her contractual notice period (for more details, see &#x201C;&#x2014;2022 Executive Committee member departures&#x201D;). The LTPP grant for the 2022-2024 performance cycle, included in the table above, will vest at the end of the performance cycle on a pro-rata basis subject to the plan rules.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;7&#xA0;</sup> John Tsai stepped down from the Executive Committee on May 15, 2022 and will end his notice period on May 15, 2023, in line with his contractual notice period (for more details, see &#x201C;&#x2014;2022 Executive Committee member departures&#x201D;). The LTPP grant for the 2022-2024 performance cycle, included in the table above, will vest at the end of the performance cycle on a pro-rata basis subject to the plan rules.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;8&#xA0;</sup> Robert Weltevreden stepped down from the Executive Committee on April 4, 2022 and will end his notice period on April 30, 2023, in line with his contractual notice period (for more details, see &#x201C;&#x2014;2022 Executive Committee member departures&#x201D;). The LTPP grant for the 2022-2024 performance cycle, included in the table above, will vest at the end of the performance cycle on a pro-rata basis subject to the plan rules.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">110</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Number of equity instruments granted to the CEO and other Executive Committee members for the financial year 2021 (comparative information)</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Variable compensation<sup>1</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2021 Annual Incentive  (performance achieved)</div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> LTPP  2021-2023 cycle</div>
            </td>
            <td></td>
            <td align="center" colspan="1" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other  </div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
            <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
            <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td colspan="1" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity<br /> (number)<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> PSUs<br /> (target number)<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity/PSUs<br /> (number)</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members active on December 31, 2021</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16&#xA0;999</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 66&#xA0;939</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">James Bradner</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&#xA0;462</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 30&#xA0;644</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Karen Hale (from May 15, 2021)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;341</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&#xA0;823</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Harry Kirsch</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13&#xA0;598</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32&#xA0;451</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Kowalski (from September 1, 2021)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;348</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&#xA0;067</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steffen Lang</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&#xA0;763</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&#xA0;254</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Klaus Moosmayer</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;237</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&#xA0;034</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Richard Saynor</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;515</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&#xA0;364</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Susanne Schaffert</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&#xA0;162</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24&#xA0;626</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">John Tsai</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;928</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25&#xA0;492</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marie-France Tschudin</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&#xA0;033</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23&#xA0;599</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Weltevreden</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;829</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&#xA0;022</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 86&#xA0;215</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 289&#xA0;315</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members who stepped down during  2021</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steven Baert (until June 30, 2021)<sup style="white-space: nowrap">&#xA0;4</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;909</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bertrand Bodson (until January 31, 2021)<sup style="white-space: nowrap">&#xA0;5</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shannon Thyme Klinger (until March 15, 2021)<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;253</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div>
            </td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&#xA0;162</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0</div>
            </td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 86&#xA0;215</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 297&#xA0;477</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0</div>
            </td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> The values of the awards are reported in the table "2021 compensation at grant value for the CEO and other Executive Committee members."</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Vested shares, restricted shares and/or RSUs granted under the Annual Incentive for the 2021 performance period.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Target number of PSUs granted under the LTPP as applicable for the 2021-2023 performance cycle.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> Steven Baert left the Executive Committee on June 30, 2021 and ended his notice period on September 30, 2021, in line with his reduced contractual notice period (for more details, see &#x201C;&#x2014;2021 Executive Committee member departures&#x201D;). The LTPP grant for the 2021-2023 performance cycle, included in the table above, will vest at the end of the performance cycle on a pro-rata basis subject to the plan rules.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> Bertrand Bodson left the Executive Committee on January 31, 2021 and ended his notice period on November 30, 2021, in line with his reduced contractual notice period (for more details, see &#x201C;&#x2014;2021 Executive Committee member departures&#x201D;). No LTPP was granted for the 2021-2023 performance cycle.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;6&#xA0;</sup> Shannon Klinger resigned as Chief Legal Officer as of March 15, 2021, and left the Company on May 31, 2021, in line with her reduced contractual notice period (for more details, see &#x201C;&#x2014;2021 Executive Committee member departures&#x201D;). The LTPP 2021-2023 cycle grant (23 586 PSUs), displayed at pro-rata value for the time she was in her role in 2021, was forfeited in full upon her departure.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">111</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Share ownership requirements for the CEO and other Executive Committee members</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Executive Committee members are required to own at least a minimum multiple of their annual base salary in Novartis shares or RSUs within five years of hire or promotion, as set out in the table here. In addition, the CEO and CFO are required to hold the equity vesting under the LTPP plan (granted since 2022) for a minimum of two years after the vesting date. In the event of a substantial rise or drop in the share price, the Board of Directors may, at its discretion, amend that time period accordingly.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> &#xA0;</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;">Function</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;"> Ownership level</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CEO</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 x base compensation</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other Executive Committee members</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 x base compensation</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The determination of equity amounts against the share ownership requirements is defined to include vested and unvested Novartis shares or American Depositary Receipts (ADRs), together with RSUs acquired under the Company&#x2019;s compensation plans. Unvested PSUs are, however, excluded. The determination also includes other shares and vested options of Novartis shares or ADRs that are owned directly or indirectly by &#x201C;persons closely linked&#x201D; to an Executive Committee member. The Compensation Committee reviews compliance with the share ownership guideline on an annual basis.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Shares, ADRs and other equity rights owned by Executive Committee members as at December 31, 2022<sup>1</sup></span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows, in alphabetical order after the CEO, the total number of shares, ADRs and other equity rights owned by the CEO and the other Executive Committee members and &#x201C;persons closely linked&#x201D; to them as at December 31, 2022. As at December 31, 2022, no members of the Executive Committee, either individually or together with &#x201C;persons closely linked&#x201D; to them, owned 1% or more of the outstanding shares or ADRs of Novartis. As at December 31, 2022, all members who have served at least five years on the Executive Committee have met or exceeded their personal Novartis share ownership requirements.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Vested shares <br /> and ADRs<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Unvested shares <br /> and other equity rights<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity ownership level <br /> as a multiple of <br /> annual base salary<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Unvested target PSUs <br /> (e.g., LTPP)<sup style="white-space: nowrap">4</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Total as at<br /> December 31, <br /> 2022</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 228&#xA0;614</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 69&#xA0;687</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13x</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 108&#xA0;201</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 406&#xA0;502</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shreeram Aradhye (from May 16, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;241</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&#xA0;885</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;268</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&#xA0;394</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Victor Bulto (from May 1, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21&#xA0;292</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&#xA0;094</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36&#xA0;386</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aharon Gal (from July 18, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17&#xA0;948</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 45&#xA0;012</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 62&#xA0;960</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Karen Hale</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&#xA0;458</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19&#xA0;110</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&#xA0;568</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Harry Kirsch</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 312&#xA0;682</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34&#xA0;816</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 52&#xA0;450</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 399&#xA0;948</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Kowalski</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17&#xA0;398</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&#xA0;097</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32&#xA0;495</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steffen Lang</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 118&#xA0;057</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27&#xA0;383</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&#xA0;797</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 174&#xA0;237</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fiona Marshall (from November 1, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32&#xA0;951</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;029</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34&#xA0;980</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Klaus Moosmayer</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&#xA0;713</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&#xA0;524</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18&#xA0;184</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 47&#xA0;421</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marie-France Tschudin</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 52&#xA0;818</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&#xA0;447</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 46&#xA0;699</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 127&#xA0;964</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 748&#xA0;073</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 307&#xA0;853</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 309&#xA0;929</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;365&#xA0;855</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="12">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Executive Committee members who stepped down during  2022</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">James Bradner (until October 31, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34&#xA0;231</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70&#xA0;171</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 104&#xA0;402</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Richard Saynor (until October 25, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&#xA0;843</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 48&#xA0;117</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64&#xA0;960</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Susanne Schaffert (until April 4, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 142&#xA0;844</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&#xA0;245</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44&#xA0;981</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 214&#xA0;070</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">John Tsai (until May 15, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&#xA0;550</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21&#xA0;812</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49&#xA0;826</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 85&#xA0;188</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Weltevreden (until April 4, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&#xA0;755</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&#xA0;436</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5x</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27&#xA0;317</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 70&#xA0;508</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 185&#xA0;149</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 113&#xA0;567</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 240&#xA0;412</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 539&#xA0;128</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 933&#xA0;222</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 421&#xA0;420</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 550&#xA0;341</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&#xA0;904&#xA0;983</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="12" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="12">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Includes holdings of "persons closely linked" to Executive Committee members (see the &#x2018;persons closely linked&#x2019; definition).</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="12">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Includes unvested shares and ADRs as well as other equity rights applicable for the determination of equity amounts for the share ownership requirements, as per the definition above.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="12">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> The multiple is calculated based on the full-year annual base salary and the closing share price as at the end of the 2022 financial year. The share price on the final trading day of 2022 was CHF 83.59 / USD 90.72 as at December 31, 2022.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="12">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> The target number of PSUs is disclosed pro-rata to December 31, 2022, unless the award qualified for full vesting under the relevant plan rules.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">112</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Fixed and variable compensation</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the annual base salary and variable compensation mix at grant value for the financial year 2022 for the CEO and other Executive Committee members.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Annual <br /> base salary<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Variable<br /> compensation<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vasant Narasimhan</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16.6%</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 83.4%</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shreeram Aradhye (from May 16, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16.4%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 83.6%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Victor Bulto (from May 1, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21.5%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 78.5%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aharon Gal (from July 18, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.9%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 93.1%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Karen Hale</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.3%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76.7%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Harry Kirsch</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.6%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 79.4%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Robert Kowalski</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.6%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76.4%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Steffen Lang</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22.9%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 77.1%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fiona Marshall (from November 1, 2022)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.3%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 95.7%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Klaus Moosmayer</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.4%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 74.6%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marie-France Tschudin</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22.5%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 77.5%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total<sup style="white-space: nowrap">&#xA0;3</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 17.5%</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 82.5%</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Excludes pension and other benefits and is pro-rated for ECN time.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> See the table &#x201C;2022 compensation at grant value for the CEO and other Executive Committee members&#x201D; with regard to the disclosure principles of variable compensation.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Excludes members, who stepped down during the year.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other payments to Executive Committee members </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022, no other payments or waivers of claims other than those set out in the tables (including the footnotes) contained in this Compensation Report were made to Executive Committee members or to &#x201C;persons closely linked&#x201D; to them.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Payments to former Executive Committee members</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Under the former Executive Committee members&#x2019;  contracts and in line with the Company&#x2019;s LTI plan rules, payments were made to 8 former members. Of this, CHF&#xA0;993 574 relates to the vesting of LTI awards. In addition, contractual amounts totaling CHF&#xA0;167 106 were made (comprising the base salary, the Annual Incentive and other benefits), and tax equalization on variable compensation granted during international assignments amounted to a total of CHF&#xA0;296 627.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">No other payments (or waivers of claims) were made to former Executive Committee members or to &#x201C;persons closely linked&#x201D; to them during 2022.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Persons closely linked</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">&#x201C;Persons closely linked&#x201D; are (i) their spouse, (ii) their children (under 18 years of age), (iii) any legal entities that they own or otherwise control, and (iv) any legal or natural person who is acting as their fiduciary.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Note 27 to the Group&#x2019;s audited consolidated financial statements</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The total expense for the year for compensation awarded to Executive Committee and Board members, using International Financial Reporting Standards (IFRS) measurement rules, is presented in Note 27 to the Group&#x2019;s audited consolidated financial statements.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Award and delivery of equity to Novartis employees </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022, 12.7 million unvested restricted shares (or ADRs), RSUs and target PSUs were granted, and 10.4 million Novartis vested shares (or ADRs) were delivered to Novartis employees under various equity-based participation plans. Current unvested equity instruments (restricted shares, RSUs and target PSUs) and outstanding equity options held by employees represent 1.05% of issued shares. Novartis delivers treasury shares to employees to fulfill these obligations and aims to offset the dilutive impact from its equity-based participation plans.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">113</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Interim update regarding ongoing LTI performance cycles </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Below we report how performance is tracking against our stretch targets for our ongoing LTI performance cycles. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2021-2023 LTPP </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">After the first two years of the three-year LTPP performance cycle, both net sales CAGR and core operating income CAGR are tracking behind target, driven mainly by the impact of the safety update on Beovu. Innovation is on track. At the end of 2022, the relative TSR for Novartis was below median among our global healthcare peer group.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;">Performance measures</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;"> Tracking</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net sales CAGR (25%)</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <span>
                <img src="sign-half.jpg" alt="sign"></img>
              </span>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating income CAGR (25%)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <span>
                <img src="sign-half.jpg" alt="sign"></img>
              </span>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovation (25%)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <span>
                <img src="sign-full.jpg" alt="sign"></img>
              </span>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Relative TSR (25%)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <span>
                <img src="sign-half.jpg" alt="sign"></img>
              </span>
            </td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="4" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="4" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">CAGR = compound annual growth rate</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">2022-2024 LTPP </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">After the first year of the three-year LTPP performance cycle, net sales CAGR is on target and core operating income CAGR is ahead of target, while innovation performance is on target. At the end of 2022, the relative TSR for Novartis was below the median among our global healthcare peer group.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;">Performance measures</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;"> Tracking</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net sales CAGR (25%)</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <span>
                <img src="sign-full.jpg" alt="sign"></img>
              </span>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Core operating income CAGR (25%)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <span>
                <img src="sign-full.jpg" alt="sign"></img>
              </span>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovation (25%)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <span>
                <img src="sign-full.jpg" alt="sign"></img>
              </span>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Relative TSR (25%)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <span>
                <img src="sign-half.jpg" alt="sign"></img>
              </span>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="4" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="4" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">CAGR = compound annual growth rate</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <span style="vertical-align: middle;">
          <img src="sign-full.jpg" alt="sign"></img>
        </span> On or ahead of target    <span style="vertical-align: middle;"><img src="sign-half.jpg" alt="sign"></img></span> Slightly behind or behind target    </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">114</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div id="anchorId00919593"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">2023 Executive Committee compensation</p>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">2023 Executive Committee compensation changes</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Compensation Committee believes that the compensation system supports the company&#x2019;s strategy and ensures a strong link between pay and performance. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Following a positive vote of 90.6% in favor of our 2021 Compensation Report at the 2022 AGM, the Board and Compensation Committee decided to make evolutionary changes to the compensation system. The aim of these changes is to simplify and increase the transparency of our performance assessment measures, in addition to strengthening our focus on key strategic priorities, while also considering developments in compensation best practices.  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There are also changes as a result of the Swiss Corporate Law reform, which came into effect on January 1, 2023. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Assuming that the Sandoz spin-off will occur in 2023, some impact is expected on 2023 Executive Compensation. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Annual Incentive </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Following a review, the Compensation Committee decided to adapt the financial performance in the Annual Incentive Plan effective as of performance year 2023 as below: </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Remove &#x201C;Share of Peers&#x201D; from the financial performance measures in the Annual Incentive plan. As a result, the Annual Incentive financial performance measures are Group Net Sales (40%), Group Operating Income (30%) and Group Free Cash Flow<sup>1</sup> (30%), thereby retaining a strong link to our key priorities</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Group financial measures will be weighted at 60% for all Executive Committee members. Financial targets that relate to a division or business unit, where applicable, will be part of the individual strategic objectives (40% weight)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Swiss Corporate Law reform  </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Following the reform of Swiss corporate law, which came into effect on January 1, 2023, the following changes will be made to compensation design and disclosure in the 2023 Compensation Report:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Contracts of Executive Committee members will be adapted so that any non-compete compensation will not exceed the average annual compensation of the previous three financial years</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  In previous years, the Swiss regulations permitted companies to award compensation of up to 40% above the shareholder approved budget for newly appointed members of the Executive Committee, whether that be through internal promotions or external hires. From 2023, this additional budget of 40% will only be made available for external appointments of Executive Committee members</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">These changes will require adjustments to the Articles of Incorporation of Novartis, which will be submitted to Novartis shareholders for their approval at the 2023 AGM. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz spin-off</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In August 2022, we announced our intention to separate Sandoz, our generics and biosimilars division, into a new publicly traded standalone company, by way of a 100% spin-off, subject to approval of the Novartis AG Board of Directors and shareholders. In view of the planned spin-off, the Compensation Committee made the following decisions.</div>
      <div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;font-style:italic;">Sandoz CEO 2023 Annual Incentive</div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Based on the assumption that the spin-off will be implemented in the second half of 2023, the 2023 Balanced Scorecard for Richard Saynor, CEO designate of Sandoz, will be adapted so that his 2023 Annual Incentive will be based exclusively on the financial and strategic performance of Sandoz. </div>
      <div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;font-style:italic;">Equity Restoration principles</div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">If and when the planned spin-off occurs, holders of vested and unvested awards in the form of Novartis shares or ADRs will receive a dividend in kind resulting from the spin-off in the same way as other Novartis shareholders. Holders of unvested RSUs and PSUs will not receive the dividend in kind resulting from the spin-off. To compensate for the expected reduction in shareholder value after the issue of dividend in kind, Novartis will grant equity awards (called &#x201C;Keep Whole awards&#x201D;) to its employees, including the Executive Committee members, following the spin-off. This will be undertaken in accordance with the Sandoz equity restoration plan, as follows:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The Keep Whole awards will have a value similar to the value of the dividend in kind resulting from the spin-off that each RSU or PSU would have received had it been a Novartis share or ADR</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The aim of the Keep Whole awards is to ensure that Novartis employees who have been granted RSUs or PSUs, including Executive Committee members, are not disadvantaged by the spin-off relative to Novartis shareholders</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">More details will be shared at the time of the spin-off.</div>
      <div style="padding-top:15px; padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>1</sup>  For the purposes of the 2023 annual incentives, free cash flow is defined as net cash flows from operating activities less purchases of property, plant and equipment.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">115</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">2023 Executive Committee member compensation increases</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Each year, we collaborate with our external advisors to benchmark the compensation levels of the members of the Executive Committee and assess the competitiveness of their total target compensation. 2023 salary increases have been made in line with their demonstrated performance and ability in their respective roles, and commensurate to changes in responsibilities, if any, as outlined in our &#x201C;&#x2014;Executive Committee appointments compensation policy&#x201D;.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In general, Executive Committee members (including the CEO) will receive compensation changes applicable to associates in Switzerland or where applicable, the US. The members who will receive an additional increase based on the principles outlined above are mentioned below. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Karen Hale, Chief Legal Officer </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Ms. Hale, who has joined the Executive Committee in May 2021, delivered many highlights in 2022, including effectively managing ongoing cases with the SEC/DOJ, creating a new, focused and efficient global legal function, preparing for the Sandoz spin-off effectively, and continuing to improve the governance of the company. Effective March 1, 2023, Ms. Hale will receive a 6% increase in annual base salary increase and a 10% increase LTI target, as a percentage of annual base salary. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Klaus Moosmayer, Chief Ethics, Risk &amp; Compliance Officer </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Following the implementation of the new organization structure in 2022, Mr. Moosmayer took over additional management responsibilities in the areas of HSE governance, Data Privacy, and Digital &amp; Artificial Intelligence Compliance. He demonstrated strong leadership across all responsibilities of compliance, risk, ethics, and managing emerging issues including the company&#x2019;s continuing response to the global pandemic, the lockdown in China and crisis management related to the war in Ukraine. Effective March 1, 2023, Mr. Moosmayer will receive a 12% increase in annual base salary increase and a 10% increase LTI target, as a percentage of annual base salary, to recognize these additional responsibilities. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Marie-France Tschudin, President, Innovative Medicines International &amp; Chief Commercial Officer </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Following her appointment in April 2022 as the President, Innovative Medicines International &amp; Chief Commercial Officer, Ms. Tschudin effectively executed the creation of our new Innovative Medicines International organization and Chief Commercial Office. During the year, she designed the new organization structure, implementing a large restructuring program and creating new therapeutic areas with clear portfolio focus, while delivering strong commercial performance in Region International and ensuring growth above target for many key brands. Effective March 1, 2022, Ms. Tschudin will receive a 5% increase in annual base salary, and a 10% increase in both her Annual Incentive target and LTI target, as a percentage of annual base salary, to recognize her increased responsibilities as the Chief Commercial Officer. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Following an assessment of their compensation competitiveness and performance, recently appointed Executive Committee members Victor Bulto, Aharon (Ronny) Gal, and Robert Kowalski will receive a 10-20% increase in their Annual Incentive target and/or LTI target, in line with the &#x201C;&#x2014;Executive Committee appointments compensation policy&#x201D;. Steffen Lang will also receive a 10% increase in LTI target as a result of his enhanced responsibilities in Operations.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">116</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00919692"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">2022 Board compensation</p>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Philosophy and benchmarking</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Aligned with market practice in Switzerland, the Board of Directors sets compensation for its members at a level that allows for the attraction of high-caliber individuals, including both Swiss and international members, who have global experience.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Given their focus on corporate strategy, supervision and governance, Board members do not receive variable compensation. Each year at the AGM, shareholders are requested to approve, in a binding vote, the total compensation of the Board of Directors until the following AGM.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Board of Directors sets the level of compensation for its Chair and the other members to be in line with relevant benchmark companies, including other large Switzerland-based multinational companies such as ABB, Credit Suisse, Holcim, Nestl&#xE9;, Roche and UBS. This peer group was chosen for Board compensation due to the comparability of Swiss legal requirements, including broad personal and individual liabilities under Swiss law (and criminal liability under Swiss rules regarding board and executive committee compensation related to the Ordinance against Excessive Compensation in Listed Companies), and under US law (due to the Company&#x2019;s secondary listing on the New York Stock Exchange). The Board of Directors reviews the compensation of its members, including the Board Chair, each year based on a proposal by the Compensation Committee and advice from its independent advisor, including relevant benchmarking information. To ensure independence of decision-making, the peer group used for the Board of Directors is different to that used for the Executive Committee.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Board Chair&#x2019;s contract and the Board of Directors compensation policy do not provide for any termination-related payments.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Board Chair</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As Board Chair, Joerg Reinhardt receives total annual compensation valued at CHF 3.8 million. The total compensation is comprised equally of cash and shares, as follows:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Cash compensation: CHF 1.9 million per year</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Share compensation: annual value equal to CHF 1.9 million of unrestricted Novartis shares</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For 2022, the Board Chair voluntarily waived the increase in compensation to which he is contractually entitled. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Other Board&#xA0;members</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The annual fee rates for Board membership and additional functions are included in the table below. These were approved by the Board of Directors with effect from the 2022 AGM. Aggregate Board compensation is aligned with other large Swiss companies.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />CHF 000s</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022-2023 AGM <br /> annual fee</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Board Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;800</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Board membership</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 280</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vice-Chair</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lead Independent Director</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chair of the Audit and Compliance Committee</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 130</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chair of the Compensation Committee</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 90</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chair of the following committees:<br />&#x2022; Governance, Nomination and <br /> Corporate Responsibilities Committee<br />&#x2022; Science &amp; Technology Committee<br />&#x2022; Risk Committee</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <br />
                <br />
                <br />
                <br /> 70</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Membership of the Audit <br />and Compliance Committee</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <br /> 70</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Membership of the following committees:<br />&#x2022; Compensation Committee<br />&#x2022; Governance, Nomination and <br /> Corporate Responsibilities Committee<br />&#x2022; Science &amp; Technology Committee<br />&#x2022; Risk Committee</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                <br />
                <br />
                <br />
                <br />
                <br /> 40</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition, the following policies apply regarding Board compensation:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  50% of compensation is delivered in cash, paid on a quarterly basis in arrears. Board members may choose to receive more of their compensation in shares instead of cash</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  At least 50% of compensation is delivered in shares in two installments: one six months after the AGM; and one 12 months after the AGM</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Board members bear the full cost of their employee social security contributions, if any, and do not receive share options or pension benefits. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">2023 Board compensation</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, the Compensation Committee reviewed, together with its independent advisor, the Board of Directors&#x2019; compensation system against the Swiss Market Index. They found that the Board Chair fees and retainer fees of the other Board members are well positioned and competitive among the benchmarked companies in relation to the Company&#x2019;s size, operational complexity and corporate headquarter&#x2019;s location. Additional information on our Board benchmarking practices is provided in &#x201C;&#x2014;2022 Board compensation.&#x201D; The compensation system and fee levels for the Board of Directors will therefore remain unchanged in 2023.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">117</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Board member total compensation earned for the financial year 2022</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     Board   membership</div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   Audit and  Compliance  Committee</div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     Compensation   Committee</div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Governance,  Sustainability  and Nomination  Committee</div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   Science &amp;   Technology  Committee</div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     Risk  Committee</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">     Shares   (number)<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   Cash   (CHF)  (A)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   Shares   (CHF)  (B)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   Other  (CHF)  (C)<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">   Total  (CHF)  (A)+(B)+(C)<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #ffffff 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Board members active on December 31, 2022</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Joerg Reinhardt<sup style="white-space: nowrap">&#xA0;4</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Board Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23&#xA0;574</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;900&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;900&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;803&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Simon Moroney</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Vice-Chair<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;695</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 225&#xA0;834</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 225&#xA0;834</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 456&#xA0;228</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Patrice Bula</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Lead Independent   Director<sup style="white-space: nowrap"> &#xA0;6</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   Chair<sup style="white-space: nowrap"> &#xA0;6</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   2&#xA0;259</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   197&#xA0;500</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   197&#xA0;500</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   3&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   398&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nancy C. Andrews</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;233</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 180&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 180&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 360&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ton Buechner</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;605</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 210&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 210&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 424&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Elizabeth Doherty</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;791</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 225&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 225&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 450&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bridgette Heller</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;541</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 211&#xA0;667</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 211&#xA0;667</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 423&#xA0;334</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Daniel Hochstrasser</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 856</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 116&#xA0;667</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 116&#xA0;667</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 237&#xA0;894</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frans van Houten</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;838</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 390&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 390&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ana de Pro Gonzalo</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;192</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 162&#xA0;500</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 162&#xA0;500</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 329&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Andreas von Planta</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;327</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 182&#xA0;500</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 182&#xA0;500</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 368&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charles L. Sawyers</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;233</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 180&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 180&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 360&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">William T. Winters</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;466</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 360&#xA0;000</div>
            </td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 360&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #ffffff 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 54&#xA0;610</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&#xA0;791&#xA0;668</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&#xA0;541&#xA0;668</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&#xA0;250</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&#xA0;362&#xA0;586</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #ffffff 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Board members who stepped down at the 2022 AGM</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ann Fudge<sup style="white-space: nowrap">&#xA0;5</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;132</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Enrico Vanni<sup style="white-space: nowrap">&#xA0;5</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;509</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 83&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #ffffff 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&#xA0;641</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 70&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 70&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 143&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #ffffff 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 57&#xA0;251</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&#xA0;861&#xA0;668</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&#xA0;611&#xA0;668</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 32&#xA0;919</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&#xA0;506&#xA0;255</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #ffffff 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="24" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">See next page for 2021 comparative figures.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> The shown amounts represent the gross number of shares delivered to each Board member in 2022 for the respective Board member&#x2019;s service period. The number of shares reported in this column represent: (i) the second and final equity installment delivered in February 2022 for the services from the 2021 AGM to the 2022 AGM, and (ii) the first of two equity installments delivered in August 2022 for the services from the 2022 AGM to the 2023 AGM. The second and final equity installment for the services from the 2022 AGM to the 2023 AGM will take place in February 2023.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Includes an amount of CHF 29&#xA0;250 for mandatory employer contributions for all Board members paid by Novartis to Swiss governmental social security systems. This amount is out of total employer contributions of CHF 453&#xA0;083 and provides a right to the maximum future insured government pension benefit for the Board members.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> All amounts are before deduction of the social security contribution and income tax due by the Board member.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> No additional committee fees for chairing the Science &amp; Technology Committee were delivered to Joerg Reinhardt.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> Until March 4, 2022.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;6&#xA0;</sup> From March 4, 2022.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">118</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Board member total compensation earned for the financial year 2021</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">     Board   membership</div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">   Audit and  Compliance  Committee</div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">     Compensation   Committee</div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Governance,  Sustainability  and Nomination  Committee</div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">   Science &amp;   Technology  Committee</div>
            </td>
            <td></td>
            <td align="center">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">     Risk  Committee</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">     Shares   (number)<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">   Cash   (CHF)  (A)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">   Shares   (CHF)  (B)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">   Other  (CHF)  (C)<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">   Total  (CHF)  (A)+(B)+(C)<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #ffffff 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Board members active on December 31, 2021</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Joerg Reinhardt<sup style="white-space: nowrap">&#xA0;4</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> Chairman</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22&#xA0;830</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;900&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;900&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;804&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Enrico Vanni</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> Vice Chairman /   Lead Independent   Director<sup>7</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     3&#xA0;035</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     244&#xA0;167</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     244&#xA0;167</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     3&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">     492&#xA0;004</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nancy C. Andrews</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;162</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 360&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ton Buechner</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> Chair<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;625</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 175&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 240&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 419&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Patrice Bula</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;922</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 160&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 160&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 324&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Elizabeth Doherty</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;391</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 206&#xA0;250</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 243&#xA0;750</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 450&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ann Fudge</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;162</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 360&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bridgette Heller</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;128</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 189&#xA0;167</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 189&#xA0;167</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 378&#xA0;334</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frans van Houten</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;257</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 378&#xA0;333</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 378&#xA0;333</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Simon Moroney</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> Chair<sup style="white-space: nowrap">&#xA0;6</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;187</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 197&#xA0;500</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 197&#xA0;500</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399&#xA0;560</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Andreas von Planta</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;556</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 200&#xA0;833</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 200&#xA0;833</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;670</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 405&#xA0;336</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charles L. Sawyers</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;162</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 180&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 360&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #ffffff 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
            <td style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">William T. Winters</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &#x2022;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;325</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 360&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 360&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #ffffff 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 56&#xA0;742</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&#xA0;812&#xA0;917</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&#xA0;653&#xA0;750</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25&#xA0;580</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&#xA0;492&#xA0;247</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #ffffff 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Board members who stepped down at the 2021 AGM</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Srikant Datar<sup style="white-space: nowrap">&#xA0;5</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;970</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23&#xA0;000</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53&#xA0;667</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 76&#xA0;667</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #ffffff 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> -</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #ffffff 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
            <td style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="center" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 58&#xA0;712</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&#xA0;835&#xA0;917</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&#xA0;707&#xA0;417</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25&#xA0;580</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:4%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&#xA0;568&#xA0;914</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #ffffff 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
            <td style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="24" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> The shown amounts represent the gross number of shares delivered to each Board member in 2021 for the respective Board member&#x2019;s service period. The number of shares reported in this column represent: (i) the second and final equity installment delivered in February 2021 for the services from the 2020 AGM to the 2021 AGM, and (ii) the first of two equity installments delivered in August 2021 for the services from the 2021 AGM to the 2022 AGM. The second and final equity installment for the services from the 2021 AGM to the 2022 AGM will take place in February 2022.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Includes an amount of CHF 25&#xA0;580 for mandatory employer contributions for all Board members paid by Novartis to governmental social security systems. This amount is out of total employer contributions of CHF 435&#xA0;204 and provides a right to the maximum future insured government pension benefit for the Board member.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> All amounts are before deduction of the social security contribution and income tax due by the Board member.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;4&#xA0;</sup> No additional committee fees for chairing the Science &amp; Technology Committee were delivered to Joerg Reinhardt.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;5&#xA0;</sup> Until March 2, 2021.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;6&#xA0;</sup> From March 2, 2021.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="24">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;7&#xA0;</sup> No additonal compensation was paid for the Lead Independent Director role.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">119</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Additional disclosures</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Share ownership requirements for Board members  </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board Chair is required to own a minimum of 30000 Novartis shares, and other members of the Board of Directors are required to own at least 5000 Novartis shares within five years after joining the Board of Directors, to ensure their interests are aligned with those of shareholders. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Board members are prohibited from hedging or pledging their ownership positions in Novartis shares that are part of their guideline share ownership requirement and are required to hold these shares for 12 months after retiring from the Board of Directors. As at December 31, 2022, all current and former members of the Board of Directors who were required to meet the minimum share ownership requirements did so. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Shares, ADRs and share options owned by Board members</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The total number of vested Novartis shares and ADRs owned by members of the Board of Directors and &#x201C;persons closely linked&#x201D; to them as at December 31, 2022, is shown in the table below. As at December 31, 2022, no members of the Board, either individually or together with &#x201C;persons closely linked&#x201D; to them, owned 1% or more of the outstanding shares (or ADRs) of Novartis. As of the same date, no members of the Board of Directors held any share options to purchase Novartis shares.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Number of shares <br /> at December 31, 2022<sup style="white-space: nowrap">1,2</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Joerg Reinhardt</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 632&#xA0;730</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Simon Moroney</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;102</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Patrice Bula</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&#xA0;802</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nancy C. Andrews</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&#xA0;931</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ton Buechner</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20&#xA0;461</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Elizabeth Doherty</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&#xA0;836</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bridgette Heller</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;296</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Daniel Hochstrasser</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 804</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frans van Houten</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&#xA0;442</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ana de Pro Gonzalo</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 823</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Andreas von Planta</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 168&#xA0;717</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charles L. Sawyers</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&#xA0;888</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">William T. Winters</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27&#xA0;659</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sub-Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 920&#xA0;491</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="4">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Board members who stepped down at the 2022 AGM</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Enrico Vanni</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32&#xA0;078</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ann Fudge</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&#xA0;751</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sub-Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44&#xA0;829</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 965&#xA0;320</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="4" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="4">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Includes holdings of "persons closely linked" to Board members (see definition &#x201C;Persons closely linked").</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="4">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Each share provides entitlement to one vote.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other payments to Board members</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022, no payments (or waivers of claims) other than those set out in the Board member compensation table titled &#x201C;&#x2014;Board member total compensation earned for the financial year 2022&#x201D; (including in the table footnotes) were made to current members of the Board or to &#x201C;persons closely linked&#x201D; to them.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Payments to former Board members</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022, no payments (or waivers of claims) were made to former Board members or to &#x201C;persons closely linked&#x201D; to them.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Board member compensation approved by shareholders</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The total compensation earned by Board members from the 2021 AGM to the 2022 AGM was within the amount approved by shareholders at the 2021 AGM. </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">120</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div id="anchorId00922740"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Compensation governance </p>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Legal framework</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Swiss Code of Obligations and the corporate governance guidelines of the SIX Swiss Exchange require listed companies to disclose certain information about the compensation of board and executive committee members, their equity participation, and loans made to them. This Annual Report fulfills that requirement in addition to being in line with the principles of the Swiss Code of Best Practice for Corporate Governance of the Swiss Business Federation (economiesuisse). For more details, please refer to &#x201C;&#x2014;Corporate Governance&#x201D; in Section 6C of this Report.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Risk management principles</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Compensation Committee, with support from its independent advisor, reviews market trends in compensation, and changes in corporate governance rules and best practices. Together with the Risk Committee, it also reviews the Novartis compensation systems to ensure that they do not encourage inappropriate or excessive risk-taking, and instead encourage behaviors that support sustainable value creation. A summary of the risk management principles is outlined below.</div>
      <div style="padding-top:15px">
        <img src="comp_0023.gif" alt="WSGE_DP_Graph_ecncytotalcompensation_riskmanagementprinciples"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">RISK MANAGEMENT PRINCIPLES&#x2022;Rigorous performance management process, with approval of targets and evaluation of performance for the CEO by the Board of Directors&#x2022;Balanced mix of short-term and long-term variable compensation elements&#x2022;Values and Behaviors are a key component of the Annual Incentive and are embedded in our culture&#x2022;Clawback and malus principles apply to all elements of the variable compensation&#x2022;Performance-vesting Long-Term Incentives only, with three-year cycles &#x2022;All variable compensation is capped at 200% of target&#x2022;Contractual notice period of 12months&#x2022;Post-contractual non-compete period is limited to a maximum of 12 months from the end of employment. Resulting compensation, if applicable, will not exceed the average annual compensation (annual base salary plus Annual Incentive) of the previous three financial years&#x2022;Good and bad leaver provisions apply to variable compensation of leavers&#x2022;No severance payments or change-of-control clauses&#x2022;Share ownership requirements; no hedging or pledging of Novartis share ownership&#x2022;No loans granted to current or former members of the Executive Committee and the Board of Directors or to &#x201C;persons closely linked&#x201D; to them</div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Compensation decision-making authorities</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Authority for decisions related to compensation is governed by the Articles of Incorporation, Board Regulations and the Compensation Committee Charter, which are all published on the Company website: www.novartis.com/investors/company-overview/corporate-governance. The Compensation Committee serves as the supervisory and governing body for compensation policies and plans within Novartis, and has overall responsibility for determining, reviewing and proposing compensation policies and plans for approval by the Board of Directors in line with the Compensation Committee Charter. The discussions and conclusions of each committee meeting are delivered to the full Board of Directors. A summary of the compensation decision-making authorities is set out below.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Compensation authorization levels within the parameters set by the shareholders&#x2019; meeting</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;">Decision on</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#0070f7; font-weight:bold; text-transform:uppercase;"> Decision-making authority</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Compensation of Board Chair and  other Board members</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Board of Directors  </div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Compensation of CEO</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Board of Directors</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Compensation of other Executive  Committee members</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Compensation Committee  </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div>
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Committee member independence</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Compensation Committee is composed exclusively of members of the Board of Directors who meet the independence criteria set forth in the Board Regulations. From the 2022 AGM, the Compensation Committee consisted of the following four members: Simon Moroney (as Chair), Patrice Bula, Bridgette Heller, and William Winters.</div>
      <div>
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Role of the Compensation Committee&#x2019;s independent advisor</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The independent external compensation advisor supports the committee in determining the design and implementation of compensation and benefits. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Compensation Committee retained Mercer Limited, which was appointed in July 2017, as its independent external advisor until June 2022. As part of its normal governance practices, and with a view to ensuring the independence of the advisor, the Compensation Committee considered a change in the Committee advisor. To inform this decision, it conducted a market review of compensation advisors, with a focus on companies with extensive experience in European and US markets. Following a tendering process and an analysis to ensure that there were no conflicts of interest, the Compensation Committee appointed Mitul Shah of Deloitte AG as its independent compensation advisor with effect from July 2022. The independent advisors from Mercer Limited and Deloitte AG and their respective teams that advised and supported the committee are not responsible or rewarded for work beyond support provided to the Compensation Committee and the People &amp; Organization function on senior compensation.</div>
      <div>
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Meetings held in 2022 and self-evaluation</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, the Compensation Committee held seven formal meetings. In line with prior years, it collaborated with the Science &amp; Technology Committee to review and endorse, for approval by the Board of Directors, the innovation targets and achievements of the Annual Incentive and LTPP. The Compensation Committee conducted a self-evaluation in 2022.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">(This page has been left blank intentionally.)</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">122</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div id="anchorId001010938"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">6.C Board practices </p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:28pt; color:#000000; font-weight:bold;">Corporate governance </div>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Framework </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis is committed to effective corporate governance, and our corporate governance framework is intended to support sustainable financial performance and long-term value creation for our shareholders, patients, employees and other stakeholders based on our Values and Behaviors.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The Novartis corporate governance principles are further described in key governance documents, in  particular in our Articles of Incorporation and the Regulations of the&#xA0;Board, the Board Committees and the Executive Committee (&#x201C;Board Regulations&#x201D;) (www.novartis.com/investors/company-overview/corporate-governance). </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Governance, Sustainability and Nomination Committee regularly reviews both the corporate governance principles and the key governance documents against evolving best practice standards and new developments in line with our commitment to maintaining the highest standards. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To better reflect its evolving role and responsibilities in sustainability and environmental, social and governance (ESG) matters, the Board of Directors (&#x201C;Board&#x201D;) amended, effective as of March 1, 2022, the Board Regulations and renamed the Governance, Nomination and Corporate Responsibilities Committee to the Governance, Sustainability and Nomination Committee (GSNC).</div>
      <div style="padding-top:15px">
        <img src="cogo_0002.gif" alt="WSGE_DP_Graph_GovernanceBodies_2"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Our leadership structureGovernance bodies General Meeting of ShareholdersApproves operating and financial review, Novartis Group consolidated financial statements, and financial statements of Novartis AG; decides appropriation of available earnings and dividend; approves compensation of Board and Executive Committee; elects Board members, Board Chair, Compensation Committee members, Independent Proxy and external auditor; adopts and modifies Articles of IncorporationExternal auditorProvides opinion on compliance of Novartis Group consolidated financial statements and the financial statements of NovartisAG with applicable standards and Swiss law, on compliance of the Compensation Report with applicable law, on effectiveness of internal controls over financial reporting, and limited assurance on selected performance indicators in the Novartis in Society Integrated ReportBoard of DirectorsAudit and Compliance CommitteeCompensation CommitteeGovernance, Sustainability and Nomination CommitteeRISK CommitteeSCIENCE &amp;TECHNOLOGYCommitteeSets strategic direction of Novartis, appoints and oversees key executives, approves major transactions andinvestments, adopts and modifies Board RegulationsExecutive CommitteeResponsible for operational management of Novartis</div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">123</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Group structure and shareholders</span>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Group structure</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Novartis AG and Group companies</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG, the Group&#x2019;s holding company, is a corporation organized under Swiss law with issued registered shares and registered office at Lichtstrasse 35, CH-4056 Basel, Switzerland. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The principal subsidiaries and associated companies of the Novartis Group are shown in &#x201C;Item 18. Financial Statements&#x2014;Note 31. Principal Group subsidiaries and associated companies.&#x201D;</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Divisions and business units</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has two operating divisions: Innovative Medicines (IM), which specializes in patent-protected medicines, and Sandoz<sup>1</sup>, which sells generics and biosimilars. In 2022, Novartis integrated the Pharmaceuticals and Oncology business units under the IM Division and created two separate commercial organizations with a stronger geographic focus &#x2013; Innovative Medicines International and Innovative Medicines US. IM is supported by the Novartis Institutes for BioMedical Research (NIBR) and Global Drug Development (GDD). Both operating divisions are supported by Novartis Operations (which combines the former Novartis Technical Operations (NTO) and Customer &amp; Technology Solutions (CTS) units), and corporate functions. The latter includes the newly created Strategy &amp; Growth function, which combines corporate strategy, R&amp;D portfolio strategy and business development. A&#xA0;detailed review of 2022 business results can be found in &#x201C;Item 18. Financial Statements&#x2014;Note 3. Segmentation of key figures 2022, 2021 and 2020.&#x201D;</div>
      <div style="padding-top:15px">
        <img src="cogo_0026.gif" alt="WSGE_DP_Graph_CompanyStructure"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Shareholdings</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Majority holdings in publicly traded Group companies</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Novartis Group owns 70.68% of Novartis India Ltd., with registered office in Mumbai, India, and a listing on the BSE (formerly known as the Bombay Stock Exchange) (ISIN INE234A01025, symbol: HCBA). The total market value of the 29.32% free float of Novartis India Ltd. was USD&#xA0;59.0 million on December 31, 2022, using the quoted market share price at year-end. Applying this share price to all the shares of the company, the market capitalization of the whole company was USD&#xA0;201.2 million, and that of the shares owned by Novartis was USD&#xA0;142.2 million.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Shareholders</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Significant shareholders</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to the Share Register, as of December&#xA0;31, 2022, the following registered shareholders, including nominees and the American Depositary Share (ADS) depositary, held more than 2% of the total share capital, with the right to vote all their shares based on exemptions granted by the Board (see &#x201C;&#x2014;Item 6.C Board practices&#x2014;Shareholder participation&#x2014;Voting rights, restrictions and representation&#x2014;Registration restrictions&#x201D;):<sup>2</sup></div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % holding of<br /> share capital<br /> Dec 31, 2022</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Shareholders registered for their own account:</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Emasan AG, Basel</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.7</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">UBS Fund Management (Switzerland) AG, Basel</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credit Suisse Funds AG, Zurich</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> % holding of<br /> share capital<br /> Dec 31, 2022</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Shareholders registered as nominees:</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chase Nominees Ltd., London</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nortrust Nominees Ltd., London</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.8</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">The Bank of New York Mellon, New York</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.9</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Through The Bank of New York Mellon, Everett</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 1.6</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Through The Bank of New York Mellon, New York</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 0.9</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Through The Bank of New York Mellon, SA/NV, Brussels</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 0.4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Shareholder acting as American Depositary Share (ADS) depositary:</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">JPMorgan Chase Bank, N.A., New York</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9.4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">1  On August 25, 2022, Novartis announced its intention to separate the Sandoz business to create a standalone company by way of a 100% spin-off, with completion expected in the second half of 2023.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>2</sup>  Excluding 7.7% of the share capital held as treasury shares by Novartis AG or its fully owned subsidiaries. As of the entry into force of the revised Swiss Code of Obligations on January 1, 2023, Novartis ordinary shares held by certain Swiss foundations controlled by Novartis also no longer carry the right to vote and therefore will be treated for this calculation as treasury shares going forward.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">124</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">According to a disclosure notification filed with Novartis&#xA0;AG, Norges Bank (Central Bank of Norway), Oslo, held 2.3% of the share capital but was not registered in the Share Register as of December&#xA0;31, 2022. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">According to a disclosure notification filed with Novartis&#xA0;AG and the SIX Swiss Exchange Regulation AG, BlackRock,&#xA0;Inc., New&#xA0;York, held between 5% and 10% but was registered with less than 2% of the share capital as of December&#xA0;31,&#xA0;2022.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Disclosure notifications pertaining to shareholdings filed with Novartis AG and the SIX Swiss Exchange are published on the latter&#x2019;s electronic publication platform: </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">www.ser-ag.com/en/resources/notifications-market-participants/significant-shareholders.html.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Duty to make an offer</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to the Swiss Federal Act on Financial Infrastructures, anyone who &#x2013; directly, indirectly or acting in concert with third parties &#x2013; acquires equity securities exceeding 33 1/3% of the voting rights of a company (whether or not such rights are exercisable) is required to make an offer to acquire all listed equity securities of that company. A company may raise this threshold up to 49% of the voting rights (&#x201C;opting up&#x201D;) or may, under certain circumstances, waive the threshold (&#x201C;opting out&#x201D;). Novartis AG has not adopted any such measures.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Cross shareholdings</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG has no cross shareholdings in excess of 5% of capital, or voting rights with any other company.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Overview on shareholder structure</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables relate only to registered shareholders and cannot be assumed to represent the entire investor base because nominees and JPMorgan Chase Bank, N.A., as ADS depositary, are registered as shareholders for a large number of beneficial owners.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of December 31, 2022, Novartis AG had approximately 186 000 registered shareholders. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Number of registered shareholders/shares</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />As of December 31, 2022<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Number of<br /> registered <br /> shareholders</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> % of <br /> share capital</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1&#x2013;100</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34&#xA0;085</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.08</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">101&#x2013;1&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 110&#xA0;467</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.86</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1&#xA0;001&#x2013;10&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37&#xA0;732</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.32</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">10&#xA0;001&#x2013;100&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;212</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.39</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">100&#xA0;001&#x2013;1&#xA0;000&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 475</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.85</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1&#xA0;000&#xA0;001&#x2013;5&#xA0;000&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 68</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.39</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5&#xA0;000&#xA0;001 or more<sup style="white-space: nowrap">&#xA0;2</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 46.14</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total registered shareholders/shares</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 186&#xA0;068</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67.03</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Unregistered shares</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32.97</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100.00</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> At the record date of the 2022 Annual General Meeting of Shareholders (AGM), unregistered shares amounted to 17.0%.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Including significant registered shareholders as listed above</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Registered shareholders by type</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">As of December 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Shareholders in %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Shares in %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Individual shareholders</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 96.71</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15.61</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Legal entities<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.25</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37.69</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nominees, fiduciaries  and ADS depositary</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   0.04</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   46.70</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100.00</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100.00</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Excluding 7.7% of the share capital held as treasury shares by Novartis AG or its fully owned subsidiaries. As of the entry into force of the revised Swiss Code of Obligations on January 1, 2023, Novartis ordinary shares held by certain Swiss foundations controlled by Novartis also no longer carry the right to vote and therefore will be treated for this calculation as treasury shares going forward.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Registered shareholders by country<sup>1</sup></span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">As of December 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Shareholders in %</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Shares in %</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Belgium</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.11</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.77</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">France</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.97</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.36</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Germany</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.72</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.82</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japan</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.17</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.45</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Luxembourg</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.06</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.79</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland<sup style="white-space: nowrap">&#xA0;2</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 87.14</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 48.39</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United Kingdom</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.63</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.68</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United States</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.25</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21.29</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other countries</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.95</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.45</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100.00</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100.00</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Registered shares held by nominees are shown in the country where the company/affiliate entered in the Share Register as shareholder has its registered seat.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Excluding 7.7% of the share capital held as treasury shares by Novartis AG or its fully owned subsidiaries. As of the entry into force of the revised Swiss Code of Obligations on January 1, 2023, Novartis ordinary shares held by certain Swiss foundations controlled by Novartis also no longer carry the right to vote and therefore will be treated for this calculation as treasury shares going forward.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">125</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Capital structure</span>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Share capital</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As of December 31, 2022, the share capital amounted to CHF&#xA0;1201860626 fully paid-in and divided into 2403721252 registered shares with a nominal value of CHF&#xA0;0.50 each. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Shares are listed on the SIX Swiss Exchange (ISIN CH0012005267, symbol: NOVN) and on the New York Stock Exchange (NYSE) in the form of American Depositary Receipts (ADRs) representing American Depositary Shares (ADSs) (ISIN US66987V1098, symbol: NVS).</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">No authorized and conditional capital exists as of December 31, 2022.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Shares, participation certificates, non-voting equity securities, profit-sharing certificates</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Shares are issued as uncertificated securities (in the sense of the Swiss Code of Obligations) and as book entry securities (in terms of the Swiss Act on Intermediated Securities). All shares have equal voting rights and carry equal entitlements to dividends. No participation certificates, non-voting equity securities (Genussscheine) or profit-sharing certificates have been issued.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Convertible securities and options</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG has not issued convertible or exchangeable bonds, warrants, options or other securities granting rights to shares, other than options (or similar instruments such as stock appreciation rights) granted under or in connection with equity-based participation plans of employees. Novartis AG does not grant any new stock options under these plans. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Limitation on transferability </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">No transferability restrictions are imposed on shares (for registration restrictions, see &#x201C;&#x2014;Item 6.C Board practices&#x2014;Shareholder participation&#x2014;Voting rights, restrictions and representation&#x2014;Registration restrictions&#x201D;). The registration of shareholders in the Share Register or in the ADR register kept by JPMorgan Chase Bank, N.A., does not affect the tradability of shares or ADRs. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Changes to share capital</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="top">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />AGM</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Shareholder decision</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Shares canceled</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Average repurchase <br /> share price (CHF)<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2020</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022; Capital reduction by CHF 30.16 million (from CHF&#xA0;1&#x2005;263&#x2005;687&#x2005;410 to CHF&#xA0;1&#x2005;233&#x2005;530&#x2005;460)</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60&#xA0;313&#xA0;900</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 88.18</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022; Capital reduction by CHF 16.32 million (from CHF 1&#x2005;233&#x2005;530 460 to CHF 1&#x2005;217&#x2005;210&#x2005;460)  <br />&#x2022; Authorization of the Board to repurchase shares up to a maximum of CHF 10 billion     between the 2021 AGM and the 2024 AGM</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32&#xA0;640&#xA0;000    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80.57    </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022; Capital reduction by CHF 15.35 million (from CHF 1&#x2005;217&#x2005;210&#x2005;460 to CHF 1 201 860 626)  <br />&#x2022; Authorization of the Board to repurchase shares up to a maximum of CHF 10 billion     between the 2022 AGM and the 2025 AGM<sup>2</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30&#xA0;699&#xA0;668    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 81.82    </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="top">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />AGM</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Proposal to the shareholders</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Shares to be canceled</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Average repurchase <br /> share price (CHF)<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
            </td>
            <td align="right"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &#x2022; Capital reduction by CHF 63.12 million (from CHF&#xA0;1 201 860 626 to CHF 1 138 738 876)  <br />&#x2022; Authorization of the Board to repurchase shares up to a maximum of CHF 10 billion     between the 2023 AGM and the 2026 AGM<sup>3</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 126&#xA0;243&#xA0;500    </div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 81.56    </div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td colspan="8" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> All shares were repurchased on the SIX Swiss Exchange second trading line.</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> In addition to the remaining authorization from the 2021 AGM</div>
            </td>
          </tr>
          <tr valign="top">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> In addition to the remaining authorization from the 2022 AGM</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key Novartis share data</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Issued shares</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&#xA0;403&#xA0;721&#xA0;252</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;434&#xA0;420&#xA0;920</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;467&#xA0;060&#xA0;920</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Treasury shares<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 284&#xA0;112&#xA0;195</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 199&#xA0;480&#xA0;972</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 210&#xA0;238&#xA0;872</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding shares at December 31</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&#xA0;119&#xA0;609&#xA0;057</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;234&#xA0;939&#xA0;948</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;256&#xA0;822&#xA0;048</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average number of shares outstanding</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&#xA0;181&#xA0;180&#xA0;341</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;242&#xA0;601&#xA0;173</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&#xA0;277&#xA0;041&#xA0;940</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Approximately 99 million treasury shares (2021: 102 million, 2020: 103 million) are held in Novartis entities that restrict their availability for use.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">126</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Per-share information<sup>1</sup></span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basic earnings per share from continuing operations (USD)</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.19</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10.71</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.55</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Diluted earnings per share from continuing operations (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.17</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10.63</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.52</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows from operating activities from continuing operations (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.53</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6.72</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.99</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Year-end equity for Novartis AG shareholders (USD)</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28.00</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 30.31</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25.07</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend (CHF)<sup style="white-space: nowrap">&#xA0;2</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.20</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.00</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend (USD)<sup style="white-space: nowrap">&#xA0;3</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.46</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.33</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.20</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Calculated on the weighted average number of shares outstanding, except year-end equity</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> 2022: proposal to shareholders for approval at the AGM on March 7, 2023.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Translated into US dollars at the December 31, 2022, rate of USD 1.081 to the Swiss franc. This translation is an example only, and should not be construed as a representation that the Swiss franc amount represents, or has been or could be converted into US dollars at that or any other rate. 2021 and 2020, dividends are translated into US dollars at the Bloomberg Market System Rate on the payment date.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key ratios &#x2013; December 31</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Price/earnings ratio<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28.3</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8.2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26.7</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend yield (%)<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.9</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.6</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Based on the Novartis share price at December 31 of each year</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key data on ADRs issued in the US</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Year-end ADR price (USD)</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 90.72</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 87.47</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 94.43</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">High<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 93.75</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 98.47</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 99.01</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Low<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 74.61</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 79.70</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 70.67</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Number of  ADRs outstanding<sup style="white-space: nowrap"> &#xA0;2</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   225&#xA0;435&#xA0;680</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   269&#xA0;891&#xA0;321</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">   288&#xA0;755&#xA0;853</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Based on daily closing prices</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> The depositary, JPMorgan Chase Bank, N.A., holds one Novartis AG share for every ADR issued.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Share price (CHF)</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Year-end share price</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 83.59</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 80.28</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:11%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 83.65</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">High<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 87.82</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 86.75</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 95.82</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Low<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 73.98</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 73.44</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 69.96</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Year-end market capitalization  (USD billions)<sup style="white-space: nowrap"> &#xA0;2</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   191.5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   196.1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   214.3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Year-end market capitalization  (CHF billions)<sup style="white-space: nowrap"> &#xA0;2</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">   177.2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   179.4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">   188.8</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="8" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Based on daily closing prices</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="8">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Market capitalization is calculated based on the number of shares outstanding (excluding treasury shares). Market capitalization in USD is based on the market capitalization in CHF converted at the year-end CHF/USD exchange rate.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">127</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId001012552"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Shareholder participation </p>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Shareholder engagement</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Shareholder engagement is fundamental to our commitment to governance and transparency, and the feedback we receive during these engagements helps us create long-term and sustainable value.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We concentrate our outreach efforts on our largest 100 shareholders &#x2013; portfolio managers, buy-side professionals, stewardship teams and ESG analysts &#x2013; who represent 60% of our ownership. While the Board Chair, CEO and CFO, together with Investor Relations, are accountable for ensuring effective shareholder engagement, other senior managers from within and outside the Executive Committee also participate in the meetings. We conduct regular outreach to investors throughout the year. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt; font-weight:bold; color:#0070f7; text-transform:uppercase;">Types of engagements (select examples):<div style="border:none;border-bottom:solid 2px;"></div></div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  AGM and quarterly results teleconferences (TCs)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bank conferences and management roadshows</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  &#x201C;Meet Novartis Management&#x201D; capital markets event </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Governance roadshow and TCs</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board Chair&#x2019;s TCs for US and UK investors</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  ESG roadshows</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Investor Update on Access &amp; Sustainability  (formerly known as ESG Investor Day)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Update on the new organizational model</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Update on the Sandoz business</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt; font-weight:bold; color:#0070f7; text-transform:uppercase;">Topics discussed with shareholders during 2022:<div style="border:none;border-bottom:solid 2px;"></div></div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Growth:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Replacement power</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Growth drivers (<i>Cosentyx, Entresto, Zolgensma, Kisqali, Kesimpta,</i><i> Leqvio</i>)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Policy and pricing environment</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Life cycle management</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">INNOVATION:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Progress and milestones</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Data of pipeline projects </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Return on R&amp;D investments</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">PRODUCTIVITY:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Progress on financial, strategic and operational performance</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Long-term sustainability of financial performance</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Capital allocation strategy</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  New organization model</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Intention to separate Sandoz business</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">BUILDING TRUST WITH SOCIETY AND CULTURE:</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board accountability on ESG, and integration of ESG and compensation</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Strong governance, enhanced process and focus on material ESG factors, leading to improved rating agency scores</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Patient access to innovative medicines</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Learning from <i>Novartis Access</i> programs implemented over the decades, including integrated sustainable business models and access principles to help address access and inequities</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  ESG targets: full carbon neutrality, patient access targets for strategic innovative therapies, and global health flagship programs</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Progress on culture and other human capital metrics</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Compensation AND Governance: </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Diversity of the Board, the Executive Committee and the Company</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board renewal, succession planning and evaluation</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Link of compensation system to key strategic priorities</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Risk oversight</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Stakeholder expectations from the Board on ESG matters</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We appreciate the value that shareholders attach to ESG matters. We will continue to integrate ESG into our strategy and to promote transparency through our comprehensive ESG engagement program. We have more than doubled the number of investor engagements on ESG matters in recent years, and in 2022, our CEO led our Investor Update on Access &amp; Sustainability (formerly known as ESG Investor Day) for the fourth time (marking our ninth dedicated ESG event for investors since 2014). We also held virtual roadshows in 2022 as part of our engagement with North American, European and Asian investors.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Voting rights, restrictions and representation</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Registration</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Shareholders have the right to vote and to execute all other rights as granted under Swiss law and the Articles of Incorporation (see, in particular, articles 17 and 18 of the Articles of Incorporation).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Each share registered with the right to vote by the third business day before the General Meeting entitles the holder to one vote at General Meetings. Article 5, paragraph 2 of the Articles of Incorporation provides that to be registered with voting rights, a shareholder must declare that he or she acquired the shares in his or her own name and for his or her own account. According to article 5, paragraph 3 of the Articles of Incorporation, the Board may register nominees with the right to vote. The Share Register is an internal, non-public register subject to statutory confidentiality and data privacy. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Articles of Incorporation are available at www.novartis.com/investors/company-overview/corporate-governance.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Registration restrictions</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Article 5, paragraph 2 of the Articles of Incorporation provides that no shareholder shall be registered with the right to vote for more than 2% of the share capital. Given that shareholder representation at General Meetings has traditionally been comparatively low in Switzerland, Novartis AG considers registration restrictions necessary to prevent a minority shareholder from dominating a General Meeting. The Board may, upon request, grant an exemption. Considerations include whether the shareholder supports our goal of creating sustainable value and has a long-term investment horizon. Exemptions are in force for the registered shareholders listed in &#x201C;&#x2014;Item 6.C Board practices&#x2014;Group structure and shareholders&#x2014;Shareholders&#x2014;Significant shareholders.&#x201D; Exemptions also apply to the Novartis Foundation for Employee Participation, Basel, which as of December 31, 2022, was registered in the Share Register with less than 2% of the share capital, and to Norges Bank (Central Bank of Norway), Oslo, which as of December 31, 2022, was not registered but held 2.3% according to a disclosure notification filed with Novartis AG. No further exemptions were requested in 2022. The same restrictions indirectly apply to ADR holders. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Article 5, paragraph 3 of the Articles of Incorporation provides that no nominee shall be registered with the right to vote for more than 0.5% of the registered share capital. The Board may, upon request, grant an exemption from this restriction if the nominee discloses the names, addresses </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">128</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">and number of shares of the persons for whose account it holds 0.5% or more of the registered share capital. Exemptions are in force for the nominees listed in &#x201C;&#x2014;Item 6.C Board practices&#x2014;Group structure and shareholders&#x2014;Shareholders&#x2014;Significant shareholders,&#x201D; and for the nominee Citibank, London, which in 2015 requested an exemption, but as of December 31, 2022, was not registered in the Share Register. The same restrictions indirectly apply to ADR holders.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">According to article 5, paragraph 4 of the Articles of Incorporation, shareholders, ADR holders, or nominees who are linked to each other or who act in concert to circumvent registration restrictions are treated as one person or nominee for the purposes of the restrictions on registration.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The registration restrictions may be changed by resolution of the General Meeting, with approval of at least two-thirds of the votes represented at the meeting.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Articles of Incorporation are available at www.novartis.com/investors/company-overview/corporate-governance.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Attendance, Representation and online Platform</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Registered shareholders will receive personal invitations to the General Meetings along with a registration/proxy form as well as a personal one-time password and a QR code to log in to our online platform. By returning the registration/proxy form or using the online platform, shareholders are able to order an admission card for the General Meeting or appoint another shareholder or the Independent Proxy to vote their shares on their behalf.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If the Independent Proxy is appointed, shareholders can also give voting instructions on alternative or additional motions related to the agenda items either (i) following the recommendations of the Board for such alternative or additional motions, or (ii) opposing such alternative or additional motions. They can also abstain from voting.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Shareholders choosing not to receive the comprehensive invitation materials will be informed of upcoming General Meetings through a letter containing the login credentials to access the online platform as well as a reference to www.novartis.com/investors/shareholder-information/general-meetings, where all relevant information is available.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In accordance with Swiss legislation passed in response to the COVID-19 pandemic, and as in the previous year, physical attendance at the 2022 Annual General Meeting (AGM) was not possible, and shareholders could exercise their voting rights exclusively through the Independent Proxy. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">ADR holders</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">ADR holders have the rights enumerated in the deposit agreement (such as the right to give voting instructions and to receive dividends). The ADS depositary of Novartis&#xA0;AG &#x2013; JPMorgan Chase Bank, N.A., New York &#x2013; holds the shares underlying the ADRs and is registered as a shareholder in the Share Register. An ADR is not a share, and an ADR holder is not a Novartis AG shareholder. Each ADR represents one share. ADR holders exercise their voting rights by instructing the depositary to exercise their voting rights. The ADS depositary exercises the voting rights for registered shares underlying ADRs for which no voting instructions have been given by providing a discretionary proxy to an uninstructed independent designee. Such designee has to be a shareholder.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">General Meeting</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Convening </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The AGM must be held within six months after the end of our financial year (December 31), and normally takes place in late February/early March. Extraordinary General Meetings may be requested by the Board, the external auditor, or shareholders representing at least 10% of the share capital.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Agenda</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Shareholders representing shares with an aggregate nominal value of at least CHF&#xA0;1 million may request that an item be included in a General Meeting agenda. Such requests must be made in writing at least 45 days before the meeting, specifying the requested item and proposal.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Powers</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to article 17 of the Articles of Incorporation (www.novartis.com/investors/company-overview/corporate-governance), the following powers are vested exclusively in the General Meeting:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Adoption and amendment of the Articles of Incorporation</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Election and removal of the Board Chair, the Board and Compensation Committee members, the Independent Proxy and the external auditor</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Approval of the management report and the consolidated financial statements</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Approval of the financial statements of Novartis AG, and the decision on the appropriation of available earnings shown on the balance sheet, including dividends</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Approval of the maximum aggregate compensation of the Board (from an AGM until the next AGM) and of the Executive Committee (for the financial year following the AGM). If the maximum aggregate amount of compensation already approved by the AGM is not sufficient to cover the compensation of newly appointed or promoted Executive Committee members, Novartis may use up to 40% of the amount last approved for the newly appointed or promoted Executive Committee members.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Discharge of Board and Executive Committee members</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Decision on other matters that are reserved by law or by the Articles of Incorporation (e.g., advisory vote on the Compensation Report) to the General Meeting </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Statutory Quorums</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The General Meeting passes resolutions and elections with the absolute majority of the votes represented at the meeting. However, under article 18 of the Articles of Incorporation (www.novartis.com/investors/company-overview/corporate-governance), the approval of two-thirds of the votes represented at the meeting is required for: </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Alteration of the purpose of Novartis AG</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Creation of shares with increased voting powers</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Implementation of restrictions on the transfer of registered shares, and the removal of such restrictions</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Authorized or conditional increase of the share capital</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Increase of the share capital out of equity, by contribution in kind, for the purpose of an acquisition of property or the grant of special rights</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Restriction or cancellation of subscription rights</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Change of the registered office of Novartis&#xA0;AG</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Dissolution of Novartis AG</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition, the law provides for a qualified majority for other resolutions, such as a merger or demerger.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">129</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">Board of Directors</span>
      </div>
      <div style="padding-top:15px">
        <img src="cogo_0005.gif" alt="WSGE_DP_Graph_BoardOfDirectors"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Composition (as per December 31, 2022)1BOARD Chair: J. ReinhardtVice-Chair:S. Moroneylead independent Director: P. BulaN. AndrewsT. BuechnerE. DohertyB. HellerD. Hochstrasser1F. van HoutenA. von Planta2A. de Pro GonzaloC. SawyersW. WintersAudit and Compliance CommitteeE. Doherty (Chair)T. BuechnerB. HellerF. van HoutenA. de Pro GonzaloCompensation CommitteeS. Moroney (Chair)P. BulaB. HellerW. WintersGovernance, Sustainability and Nomination CommitteeP. Bula (Chair)B. HellerA. von PlantaC. SawyersW. WintersRisk CommitteeT. Buechner (Chair)N. AndrewsE. DohertyA. von PlantaA. de Pro GonzaloScience &amp; Technology CommitteeJ. Reinhardt (Chair)N. AndrewsF. van HoutenS. MoroneyC. Sawyers1 Effective January 1, 2023, Mr. Hochstrasser became a member of the Audit and Compliance Committee and of the Governance, Sustainability and Nomination Committee.2 Mr. von Planta will not stand for re-election at the 2023 AGM.</div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Changes to the Board of Directors</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Ana de Pro Gonzalo and Daniel Hochstrasser were elected as new Board members at the 2022 AGM. Ann Fudge, Board member since 2008, and Enrico Vanni, Board member and Vice-Chair since 2011 and Lead Independent Director since 2021, did not stand for re-election at the 2022 AGM. The biographies of Ms. Fudge and Mr. Vanni can be found in the 2021 Annual Report (pages 130 and 133), available at www.novartis.com/news/media-library/novartis-annual-report-2021.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Election and term of office</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Board members (including the Board Chair) and Compensation Committee members are elected individually by shareholders at the General Meeting for a one-year term of office. The term of office expires at the end of the next AGM.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">According to article 20, paragraph 3 of the Articles of Incorporation, a member shall not serve on the Board for more than 12 years. Under special circumstances and if deemed to be in the best interest of the Company, the Board may recommend exceptions to the shareholders (www.novartis.com/investors/company-overview/corporate-governance).</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The term limit supports our commitment to renew the Board on an ongoing basis and also follows international best practice. We believe age is still a  relevant factor in Board composition, and the GSNC will consider this and other factors &#x2013; including gender, nationality and ethnicity &#x2013; when evaluating candidates and exploring ways to increase Board diversity.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Succession planning</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board Chair, supported by the GSNC, ensures effective succession plans for the Board, the CEO and the Executive Committee. These plans are discussed by the Board in private meetings. A search for a new Board member is launched &#x2013; normally with the support of a professional executive search company &#x2013; with individual selection criteria defined based on the evolving needs of the Company and a continuing focus on diversity. The set of competencies (further explained in &#x201C;&#x2014;Item 6.C Board practices&#x2014;Board of Directors&#x2014;Board skills&#x201D;) and a balance between continuity of experience and fresh perspectives are also important criteria for the GSNC when evaluating new candidates. Candidates are interviewed by the Board Chair, members of the GSNC, other Board members, and members of the Executive Committee. The GSNC then makes a recommendation to the full Board, and the Board ultimately decides who should be proposed for election at the upcoming AGM. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Board will propose to the shareholders a new candidate for election at the 2023 AGM. Andreas von Planta already announced in 2021 that he will not stand for re-election at the 2023 AGM. </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">130</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Independence</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All Board members &#x2013; including the Board Chair &#x2013; are non-executive and independent, pursuant to applicable corporate governance rules and Novartis independence criteria, which are outlined in Appendix II to the Board Regulations (www.novartis.com/investors/company-overview/corporate-governance). In particular, no Board member is or was a member of the management of Novartis AG or of any other Novartis Group company in the last three financial years up to December 31, 2022, or has or had, except for Daniel Hochstrasser, a significant business relationship with Novartis AG or with any other Novartis Group company. Mr. Hochstrasser fulfilled the independence criteria following his resignation from B&#xE4;r &amp; Karrer, a Swiss law firm that has a business relationship with Novartis, as of December 31, 2022. During 2022, Mr. Hochstrasser did not belong to any Board committee. No separate meetings of independent Board members were held in 2022. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The independence of Board members is assessed annually. Each Board member completes an independence questionnaire that is subject to review by the GSNC. The GSNC then submits a proposal to the full Board, and the Board determines the independence status of each Board member.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Diversity</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Diversity of gender, age, nationality, ethnicity, viewpoints, professional backgrounds and expertise is a key factor to success and Board effectiveness in a constantly evolving environment. A diverse Board ensures that the appropriate balance of skills, expertise, experience and cultural background is represented to discharge its responsibilities and to support long-term value creation for shareholders, patients, employees and other stakeholders. Diversity remains a critical area of focus for the Board, and the GSNC is continuously looking for opportunities to further increase the Board&#x2019;s diversity when identifying new Board member candidates.</div>
      <div style="padding-top:15px">
        <img src="cogo_0027.gif" alt="WSGE_DP_Graph_Diversity"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Diversity profileNationality1pSwiss31%pAmerican23%pDutch11%pGerman11%pBritish8%pSpanish8%pIrish4%pNew Zealander4%GenderpMale69%pFemale31%Agep556015%p616562%p&gt;6523%Tenurep&lt;3y31%p36y31%p79y31%p&gt;9y7%1Please note that five Board members have dual nationalities. Each of these nationalities is counted as a half in the above chart.</div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Board skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Upon proposal by the GSNC, the Board has determined a diverse set of competencies for its members that aligns with our status as a listed company, as well as our business portfolio, geographic reach and culture. Based on this set of competencies, our Board members were asked to identify their most relevant skills highlighted by their educational background, professional experience and personal achievements. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The GSNC assesses the set of competencies as well as the individual skills annually to ensure that an appropriate balance of skills, expertise, experience and diversity is represented on the Board.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To learn more about our Board members and their individual skills, see &#x201C;&#x2014;Item 6.C Board practices&#x2014;Board of Directors&#x2014;Members of the Board of Directors.&#x201D;</div>
      <div style="padding-top:15px">
        <img src="cogo_0059.gif" alt="WSGE_DP_Graph_DiversityBackground"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Board skill distributionMedicine/healthcare/R&amp;D46%6/13Leadership/management 92%12/13Finance/accounting46%6/13Law/regulatory/risk management69%9/13Data/digital23%3/13Environmental, social 38%5/13and governance (ESG)</div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">131</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId001012958"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Members of the Board of Directors</p>
      <div style="padding-top:15px">
        <img src="cogo_0030.jpg" alt="WSGE_DP_Pic_Reinhardt"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Joerg Reinhardt, Ph.D.</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Chair since 2013 | Nationality: German | Year of birth: 1956</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Joerg Reinhardt is a healthcare industry veteran whose career spans nearly 40 years. After receiving his doctorate in pharmaceutical sciences, Mr. Reinhardt joined Sandoz Pharma Ltd., a predecessor to Novartis, in 1982. He held a number of senior leadership positions at Novartis, including Chief Operating Officer and Head of the Vaccines and Diagnostics Division. Additionally, he led Bayer HealthCare AG as chair of the board of management and the executive committee from 2010 to 2013.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chair of the board of management and the executive committee, Bayer HealthCare AG, Germany (2010&#x2013;2013)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chief Operating Officer, Novartis AG, Switzerland (2008&#x2013;2010)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Head of the Vaccines and Diagnostics Division, Novartis AG, Switzerland (2006&#x2013;2008)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Various managerial positions at Sandoz Pharma Ltd. and Novartis AG, Switzerland (1982&#x2013;2006) </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Senate member, Helmholtz Association of German Research Centres, Germany</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chair of the board of trustees, Institute of Molecular and Clinical Ophthalmology Basel (IOB), Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chair of the board of trustees, Novartis Foundation, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Swiss Re AG, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Member of the European Advisory Panel, Temasek Holdings Private Ltd., Singapore</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Board member, Lonza Group AG, Switzerland (2012&#x2013;2013)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Chair, Genomics Institute of the Novartis Research Foundation, US (2000&#x2013;2010)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Doctorate in pharmaceutical sciences, Saarland University, Germany</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-x.jpg" alt="sign"></img>
        </span>&#xA0;Medicine/healthcare/R&amp;D &#xA0;<span style="vertical-align: middle;"><img src="skill-g.jpg" alt="sign"></img></span>&#xA0;Leadership/management &#xA0;<span style="vertical-align: middle;"><img src="skill-l.jpg" alt="sign"></img></span>&#xA0;Law/regulatory/risk management &#xA0;</div>
      <div style="padding-top:15px">
        <img src="cogo_0061.gif" alt="WSGE_DP_Pic_Moroney"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Simon Moroney, D.Phil.</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2020 | Vice-Chair since March 4, 2022 | Nationality: German/New Zealander |  <br />Year of birth: 1959</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">As co-founder and CEO of MorphoSys AG, Simon Moroney played a central role in establishing the company as a force in the field of therapeutic antibodies, with one of the broadest pipelines of drug candidates in the industry. Mr. Moroney holds both a doctorate and a Master of Science in chemistry.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Co-founder and CEO, MorphoSys AG, Germany (1992&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Research associate, Department of Pharmacology, University of Cambridge, UK (1991&#x2013;1992)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Assistant professor, Department of Chemistry, University of British Columbia, Canada (1989&#x2013;1990)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair of the board of directors and the Remuneration and Nomination Committee, Biotalys NV, Belgium</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Doctorate in chemistry, University of Oxford, UK</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master of Science in chemistry, University of Waikato, New Zealand</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-g.jpg" alt="sign"></img>
        </span>&#xA0;Leadership/management &#xA0;<span style="vertical-align: middle;"><img src="skill-x.jpg" alt="sign"></img></span>&#xA0;Medicine/healthcare/R&amp;D &#xA0;<span style="vertical-align: middle;"><img src="skill-l.jpg" alt="sign"></img></span>&#xA0;Law/regulatory/risk management</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">132</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px">
        <img src="cogo_0028.jpg" alt="WSGE_DP_Pic_Andrews"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Nancy C. Andrews, M.D., Ph.D.</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2015 | Nationality: American/Swiss | Year of birth: 1958</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Nancy C. Andrews has extensive experience as a physician, scientist, professor and senior administrator at leading academic institutions and hospitals. Her distinguished career spans more than 30 years, with leadership roles at both Harvard Medical School and the Duke University School of Medicine. Dr. Andrews currently chairs the board of the American Academy of Arts and Sciences, and is credited with conducting research that led to advances in understanding iron biology and iron diseases.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Executive vice president and chief scientific officer, Boston Children&#x2019;s Hospital, US (2021&#x2013;present)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Dean emerita, Duke University School of Medicine, and vice chancellor emerita for academic affairs, Duke University, US (2017&#x2013;2021)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Dean, Duke University School of Medicine, and vice chancellor for academic affairs,   Duke University, US (2007&#x2013;2017)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Professor of pediatrics, pharmacology and cancer biology, Duke University, US (2007&#x2013;2021)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Dean for basic sciences and graduate studies, Harvard Medical School, US (2003&#x2013;2007)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Director, Harvard/MIT M.D.-Ph.D. Program, US (1999&#x2013;2003)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Biomedical research investigator, Howard Hughes Medical Institute, US (1993&#x2013;2006)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Maze Therapeutics Inc., US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member and chair of the Science and Technology Committee, Charles River Laboratories International Inc., US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Council member, National Academy of Sciences, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Former council member (2013&#x2013;2019) and member, National Academy of Medicine, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair of the board, American Academy of Arts and Sciences, US </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the Scientific Advisory Board, Dyne Therapeutics Inc., US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the executive committee of the Corporation, Massachusetts Institute of Technology, US (2019-2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Member of the Scientific Management Review Board, National Institutes of Health, US (2014&#x2013;2019)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member and former chair, Burroughs Wellcome Fund, US (2011&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Doctor of medicine, Harvard Medical School, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Doctorate in biology, Massachusetts Institute of Technology, US</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Master of Science and Bachelor of Science in molecular biophysics and biochemistry, Yale University, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-x.jpg" alt="sign"></img>
        </span>&#xA0;Medicine/healthcare/R&amp;D &#xA0;<span style="vertical-align: middle;"><img src="skill-g.jpg" alt="sign"></img></span>&#xA0;Leadership/management  </div>
      <div style="padding-top:15px">
        <img src="cogo_0032.jpg" alt="WSGE_DP_Pic_Buechner"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Ton Buechner</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2016 | Nationality: Dutch/Swiss | Year of birth: 1965</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Ton Buechner is an engineer by training who started his career in the oil and gas construction industry. Before becoming the CEO of Sulzer AG, he held several divisional leadership roles at the company and worked in markets including Asia. Mr. Buechner most recently served as CEO and chair of the executive board of AkzoNobel NV, where he introduced industry-leading ESG policies.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   CEO and chair of the executive board, AkzoNobel NV, Netherlands (2012&#x2013;2017)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   CEO, Sulzer AG, Switzerland (2007&#x2013;2011)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   President, Sulzer Pumps, Switzerland (2003&#x2013;2006)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   President, Sulzer Turbomachinery Services, Switzerland (2000&#x2013;2002)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Various managerial positions at Sulzer AG, China and Switzerland (1994&#x2013;2000)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair of the board of directors and the sustainability board, Swiss Prime Site AG, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair of the board of directors and the Strategy and Sustainability Committee, Burckhardt Compression AG, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Advisor, Ammega, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the presidential and shareholder committees, Voith GmbH &amp; Co. KGaA, Germany  (2014&#x2013;2020)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Member of the supervisory board, Voith GmbH &amp; Co. KGaA, Germany (2014&#x2013;2018)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master of Business Administration, IMD business school, Switzerland</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master of Science in civil engineering, Delft University of Technology, Netherlands</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-m.jpg" alt="sign"></img>
        </span>&#xA0;Finance/accounting &#xA0;<span style="vertical-align: middle;"><img src="skill-g.jpg" alt="sign"></img></span>&#xA0;Leadership/management &#xA0;<span style="vertical-align: middle;"><img src="skill-l.jpg" alt="sign"></img></span>&#xA0;Law/regulatory/risk management &#xA0;  <span style="vertical-align: middle;"><img src="skill-z.jpg" alt="sign"></img></span>&#xA0;Environmental, social and governance (ESG)</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">133</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px">
        <img src="cogo_0025.jpg" alt="WSGE_DP_Pic_Bula"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Patrice Bula</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2019 | Lead Independent Director since March 4, 2022 | Nationality: Swiss | Year of birth: 1956</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Patrice Bula has 40 years of global management experience and is a leader in the consumer goods industry across established and emerging markets. He has served in various senior roles at Nestl&#xE9; SA, including as general manager of its businesses in China, Germany and South Africa. Most recently, he successfully led the Nestl&#xE9; Group&#x2019;s brand strategies, digital marketing transformation and Nespresso business.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Executive vice president and head of strategic business units, marketing, sales and Nespresso, Nestl&#xE9; SA, Switzerland (2011&#x2013;2021)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Market head of the Greater China region, Nestl&#xE9; SA, Switzerland (2007&#x2013;2011)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Market head of Germany, Nestl&#xE9; SA, Switzerland (2003&#x2013;2007)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Head of the confectionery and biscuits strategic business unit, Nestl&#xE9; SA, Switzerland (2000&#x2013;2003)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Various managerial positions at Nestl&#xE9; SA, Switzerland (1980&#x2013;2000) </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair, Froneri Lux Topco Sarl, Luxembourg </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Schindler AG, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member and chair of the ESG Committee, New Tiger LLC, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Co-chair (2020&#x2013;2021) and board member (2015&#x2013;2021), Cereal Partners Worldwide SA, Switzerland (Nestl&#xE9; representative)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Froneri Lux Topco Sarl, Luxembourg (Nestl&#xE9; representative) (2016&#x2013;2020)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Bobst Group SA, Switzerland (2017&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chair, Blue Bottle Coffee Inc., US (Nestl&#xE9; representative) (2017&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chair, Nestl&#xE9; Nespresso SA, Switzerland (Nestl&#xE9; representative) (2011&#x2013;2019)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Hsu Fu Chi Food Companies, China (Nestl&#xE9; representative) (2011&#x2013;2019) </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Program for Executive Development, IMD business school, Switzerland</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master&#x2019;s degree in economic sciences, HEC Lausanne, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-m.jpg" alt="sign"></img>
        </span>&#xA0;Finance/accounting &#xA0;<span style="vertical-align: middle;"><img src="skill-g.jpg" alt="sign"></img></span>&#xA0;Leadership/management &#xA0;<span style="vertical-align: middle;"><img src="skill-y.jpg" alt="sign"></img></span>&#xA0;Data/digital</div>
      <div style="padding-top:15px">
        <img src="cogo_0035.jpg" alt="WSGE_DP_Pic_Doherty"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Elizabeth (Liz) Doherty</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2016 | Nationality: British/Irish | Year of birth: 1957 | Audit Committee Financial Expert</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Elizabeth (Liz) Doherty is an expert in finance and accounting who has broad operational experience in international consumer and retail businesses. She began her career in internal audit at Unilever&#xA0;PLC and has held senior finance and accounting roles there and at other companies including Tesco PLC and Reckitt Benckiser Group PLC.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   CFO (interim), Cognita Schools Ltd., UK (2014&#x2013;2015) </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   CFO and board member, Reckitt Benckiser Group PLC, UK (2011&#x2013;2013)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  CFO (interim), City Inn, UK (2010)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   CFO, Brambles Ltd., Australia (2007&#x2013;2009)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Group international finance director, Tesco PLC, UK (2001&#x2013;2007)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Various managerial positions at Unilever PLC, UK (1981&#x2013;2001)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member and chair of the Audit Committee, Corbion NV, Netherlands</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the supervisory board and chair of the Audit Committee, Royal Philips NV, Netherlands</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Advisor, Affinity Petcare SA and GB Foods SA, Spain</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Dunelm Group PLC, UK (2013&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, HM Courts &amp; Tribunals Service, UK (2015&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Ministry of Justice, UK (2015&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Delhaize Group, Belgium (2013&#x2013;2016)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Nokia Corp., Finland (2013&#x2013;2016)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Fellow, Chartered Institute of Management Accountants, UK</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor&#x2019;s degree in liberal studies in science (physics), University of Manchester, UK</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-g.jpg" alt="sign"></img>
        </span>&#xA0;Leadership/management &#xA0;<span style="vertical-align: middle;"><img src="skill-m.jpg" alt="sign"></img></span>&#xA0;Finance/accounting &#xA0;<span style="vertical-align: middle;"><img src="skill-l.jpg" alt="sign"></img></span>&#xA0;Law/regulatory/risk management</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">134</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px">
        <img src="cogo_0060.gif" alt="WSGE_DP_Pic_Heller"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Bridgette Heller</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2020 | Nationality: American | Year of birth: 1961</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Bridgette Heller has proven experience in the standalone divisions of companies such as Johnson &amp; Johnson, Merck &amp; Co. Inc. and Danone SA, and has served on the audit committees of ADT Corp. and Tech Data Corp. During her career, she has overseen the performance of CFOs and made decisions on strategic R&amp;D priorities. Ms.&#xA0;Heller is an advocate for diversity, equity and inclusion, and traveled globally to reinforce Danone&#x2019;s commitment to infant and maternal health, inclusive diversity, an equitable workforce for women, and sustainable communities. She is co-founder and CEO of the Shirley Proctor Puller Foundation, an education and youth empowerment nonprofit, and devotes much of her time to strengthening education and sustainability in an underserved community in the US.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Co-founder and CEO, Shirley Proctor Puller Foundation, US (2019&#x2013;present)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   EVP and president of specialized nutrition, Danone SA, Netherlands (2017&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   EVP of early life nutrition, Danone SA, Netherlands (2016&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   EVP and president of consumer care, Merck &amp; Co. Inc., US (2010&#x2013;2015)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Global president of the baby global business unit, Johnson &amp; Johnson, US (2007&#x2013;2009)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  President of the US baby, kids and wound care business and of global innovation development,  Johnson &amp; Johnson, US (2005&#x2013;2007)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Managing partner, Heller Associates: Ideas for Growth Inc., US (2004&#x2013;2005)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   CEO, Chung&#x2019;s Gourmet Foods, US (2003&#x2013;2004)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Various managerial positions at Kraft Foods Inc., US (1985&#x2013;2003)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Integral Ad Science Inc., US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Aramark, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Dexcom Inc., US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Newman&#x2019;s Own Inc., US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the board of trustees, Northwestern University, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the advisory board, Kellogg School of Management at Northwestern University, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Shirley Proctor Puller Foundation, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Newman&#x2019;s Own Foundation, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Tech Data Corp., US (2016&#x2013;2020)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, ADT Corp., US (2012&#x2013;2016)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Girls Inc., US (2002&#x2013;2014)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master&#x2019;s degree in marketing and management policy, Kellogg School of Management at Northwestern University, US</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor&#x2019;s degree in economics and computer studies, Northwestern University, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-z.jpg" alt="sign"></img>
        </span>&#xA0;Environmental, social and governance (ESG) &#xA0;<span style="vertical-align: middle;"><img src="skill-g.jpg" alt="sign"></img></span>&#xA0;Leadership/management &#xA0;<span style="vertical-align: middle;"><img src="skill-x.jpg" alt="sign"></img></span>&#xA0;Medicine/healthcare/R&amp;D &#xA0;  <span style="vertical-align: middle;"><img src="skill-m.jpg" alt="sign"></img></span>&#xA0;Finance/accounting</div>
      <div style="padding-top:15px">
        <img src="cogo_0066.gif" alt="WSGE_DP_Pic_Hochstrasser"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Daniel Hochstrasser</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since March 4, 2022 | Nationality: Swiss | Year of birth: 1960</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Daniel Hochstrasser is an independent dispute resolution specialist practicing in Zurich, Switzerland. Until the end of 2022, he has been leading B&#xE4;r &amp; Karrer&#x2019;s arbitration practice for 15 years. He frequently represented parties in complex disputes arising from matters such as M&amp;A transactions, industrial and infrastructure projects, and license, distribution and development agreements, particularly in the pharmaceutical industry. In addition, he led the firm as senior partner from 2011 until 2021. He has published extensively on arbitration and litigation, and lectures at the University of Zurich and the University of St. Gallen in Switzerland.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Attorney-at-law, Daniel Hochstrasser AG, Switzerland (since January 2023)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Attorney-at-law and partner, B&#xE4;r &amp; Karrer AG, Switzerland (1993&#x2013;December 2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Senior partner and chair of the board of directors, B&#xE4;r &amp; Karrer AG, Switzerland (2011-2021)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Lawyer, District Court of Affoltern, Court of Appeals/Court of Cassation of Zurich, Switzerland  (1987&#x2013;1992)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   In-house lawyer, Staubli SA, France (1986&#x2013;1987)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Member (2015&#x2013;2021) and Vice President (since 2021), ICC Court of Arbitration, France</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the Ethics Court, Zurich Bar Association, Switzerland (since 2004)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Finland Arbitration Institute, Finland (since 2020)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair of the board of directors, B&#xE4;r &amp; Karrer AG, Switzerland (2011-2021)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Member of the Court, Swiss Arbitration Chambers, Switzerland (2004&#x2013;2014)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master of Laws (LL.M.), Cornell Law School, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bar examination, Switzerland</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Licentiatus iuris, University of Zurich, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-g.jpg" alt="sign"></img>
        </span>&#xA0;Leadership/management &#xA0;<span style="vertical-align: middle;"><img src="skill-l.jpg" alt="sign"></img></span>&#xA0;Law/regulatory/risk management</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">135</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px">
        <img src="cogo_0033.jpg" alt="WSGE_DP_Pic_vanHouten"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Frans van Houten</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2017 | Nationality: Dutch | Year of birth: 1960</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Frans van Houten is passionate about purpose-driven innovation, entrepreneurship and business transformation to drive customer value and competitiveness. Under his leadership as CEO of Royal Philips, the company transformed into a leading health technology solutions company, leveraging data and informatics to improve healthcare provider results, and became a forerunner across ESG dimensions, having become carbon neutral in its operations since 2020 and recycling over 90% of its waste. Mr. van Houten was an initiator of the World Economic Forum Compact for Responsive and Responsible Leadership as well as founder and co-chair of the Platform to Accelerate the Circular Economy.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Advisor, Royal Philips NV, Netherlands (October 2022&#x2013;April 2023)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   CEO and chair of the executive committee and the board of management, Royal Philips NV, Netherlands (2011&#x2013;October 2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Interim management, ING Group NV, Netherlands (2009&#x2013;2010)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   CEO and chair of the management board, NXP Semiconductors NV (formerly Philips Semiconductors NV), Netherlands (2004&#x2013;2009)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Various managerial positions at Royal Philips Electronics NV, Netherlands (1986&#x2013;2004) </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chair of the supervisory board, Erasmus Trust Foundation, Netherlands (2014&#x2013;February 2023)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Founder and co-chair of the WEF Platform to Accelerate the Circular Economy (PACE),  Netherlands (2016-December 2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the steering committee, European Round Table for Industry (ERT), Belgium  (2014-November 2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair, Graduate Entrepreneur Foundation, Netherlands</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair, NL2025 Foundation, Netherlands</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Vice chair and member of the supervisory board, Philips Lighting, Netherlands (2016&#x2013;2017)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master of Science in economics and business management, Erasmus University Rotterdam, Netherlands</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor of Science in economics, Erasmus University Rotterdam, Netherlands</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-z.jpg" alt="sign"></img>
        </span>&#xA0;Environmental, social and governance (ESG) &#xA0;<span style="vertical-align: middle;"><img src="skill-g.jpg" alt="sign"></img></span>&#xA0;Leadership/management &#xA0;<span style="vertical-align: middle;"><img src="skill-x.jpg" alt="sign"></img></span>&#xA0;Medicine/healthcare/R&amp;D &#xA0;  <span style="vertical-align: middle;"><img src="skill-y.jpg" alt="sign"></img></span>&#xA0;Data/digital &#xA0;<span style="vertical-align: middle;"><img src="skill-l.jpg" alt="sign"></img></span>&#xA0;Law/regulatory/risk management</div>
      <div style="padding-top:15px">
        <img src="cogo_0038.jpg" alt="WSGE_DP_Pic_vonPlanta"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Andreas von Planta, Ph.D.</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2006 | Nationality: Swiss | Year of birth: 1955</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Andreas von Planta is a leading expert in corporate governance, corporate law and stock exchange regulation. He advises boards of public companies on corporate governance matters and is a sought-after speaker and writer on these topics. He has co-authored the Switzerland chapter of the International Comparative Legal Guide to Corporate Governance for many years.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Senior counsel, Lenz &amp; Staehelin, Switzerland (2017&#x2013;present)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Partner, Lenz &amp; Staehelin, Switzerland (1988&#x2013;2017)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Helvetia Holding AG, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the board of trustees, Novartis Foundation, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Helvetia Schweizerische Lebensversicherungsgesellschaft AG, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Helvetia Schweizerische Versicherungsgesellschaft AG, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair, HSBC Private Bank (Suisse) SA, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair, HSBC Private Banking Holdings (Suisse) SA, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Socotab Frana SA, Switzerland </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair of the regulatory board, SIX Swiss Exchange AG, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair of the Audit Committee, International Road Transport Union, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Soci&#xE9;t&#xE9; Immobili&#xE8;re Quai Gustave Ador 50 SA, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Burberry (Suisse) SA, Switzerland (2001-2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Vice chair of the board of directors, A.P. Moller Finance SA, Switzerland (1997-2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Raymond Weil SA, Switzerland (2007&#x2013;2018)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member and former chair, Clinique G&#xE9;n&#xE9;rale-Beaulieu SA, Switzerland (2008&#x2013;2016)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member and former chair, Schweizerische National Versicherungs AG, Switzerland (1997&#x2013;2015)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Holcim AG, Switzerland (2003&#x2013;2014)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master of Laws, Columbia Law School, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bar examination, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Doctorate in law, University of Basel, Switzerland</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Licentiatus iuris, University of Basel, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-z.jpg" alt="sign"></img>
        </span>&#xA0;Environmental, social and governance (ESG) &#xA0;<span style="vertical-align: middle;"><img src="skill-l.jpg" alt="sign"></img></span>&#xA0;Law/regulatory/risk management &#xA0;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">136</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px">
        <img src="cogo_0067.gif" alt="WSGE_DP_Pic_Gonzalo"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Ana de Pro Gonzalo</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since March 4, 2022 | Nationality: Spanish | Year of birth: 1967 | Audit Committee Financial Expert</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Since starting her career at Arthur Andersen, Ana de Pro Gonzalo has worked across a variety of industries, ranging from construction and real estate to engineering and telecommunications. With deep expertise in finance, capital markets and technology, she has held executive positions at several multinational companies. Most recently, she spent 10 years as chief financial officer of Amadeus IT Group, a leading software provider for the global travel and tourism industry. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chief financial officer, Amadeus IT Group SA, Spain (2010&#x2013;2020)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Corporate general manager, Sacyr Vallehermoso SA, Spain (2002&#x2013;2010)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Deputy general manager and finance director, Metrovacesa SA, Spain (1994&#x2013;2002)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Senior auditor, Arthur Andersen SA, Spain (1990&#x2013;1994)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the supervisory board and chair of the Audit Committee, STMicroelectronics NV, Netherlands</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, National Express Group PLC, UK</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Indra Sistemas SA, Spain (2020-2022)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board member, Merlin Properties Socimi SA, Spain (2015&#x2013;2017)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  General Management Program (PDG), IESE Business School, Spain</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor of Science in business studies, Complutense University of Madrid, Spain</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-g.jpg" alt="sign"></img>
        </span>&#xA0;Leadership/management &#xA0;<span style="vertical-align: middle;"><img src="skill-m.jpg" alt="sign"></img></span>&#xA0;Finance/accounting &#xA0;<span style="vertical-align: middle;"><img src="skill-l.jpg" alt="sign"></img></span>&#xA0;Law/regulatory/risk management</div>
      <div style="padding-top:15px">
        <img src="cogo_0037.jpg" alt="WSGE_DP_Pic_Sawyers"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Charles L. Sawyers, M.D.</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2013 | Nationality: American | Year of birth: 1959</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Charles L. Sawyers is a highly accomplished expert and leader in cancer research. As a physician and  prominent scientist, he has a deep understanding of the benefits of drugs for patients and society at large, and the importance of access to medicines. Dr.&#xA0;Sawyers co-developed the Novartis cancer drug <i>Gleevec</i>/<i>Glivec</i> and has received numerous honors and awards, including the Lasker-DeBakey Clinical Medical Research Award.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chair of the Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, US (2006&#x2013;present)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Professor of medicine (2008&#x2013;present), and professor of cell and developmental biology (2011&#x2013;present), Weill Cornell Graduate School of Medical Sciences, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Investigator, Howard Hughes Medical Institute, US (2002&#x2013;2006 and 2008&#x2013;present)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Associate chief, Division of Hematology-Oncology, University of California, Los Angeles, US (1996&#x2013;2006)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member, National Academy of Medicine, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member, National Academy of Sciences, US </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Investigator, Howard Hughes Medical Institute, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Science advisor for the following US companies: Arsenal Capital Partners; BeiGene Ltd.; Blueprint Medicines Corp.; Foghorn Therapeutics Inc.; Housey Pharmaceutical Research Laboratories; KSQ Therapeutics Inc.; Nextech Invest Ltd.; ORIC Pharmaceuticals Inc.; PMV Pharmaceuticals Inc.; The Column Group </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member, National Cancer Advisory Board, US (2012&#x2013;2020)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  President, American Association for Cancer Research, US (2013&#x2013;2014)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Doctor of medicine, Johns Hopkins University School of Medicine, US</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor of Arts, Princeton University, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-x.jpg" alt="sign"></img>
        </span>&#xA0;Medicine/healthcare/R&amp;D &#xA0;<span style="vertical-align: middle;"><img src="skill-g.jpg" alt="sign"></img></span>&#xA0;Leadership/management &#xA0;<span style="vertical-align: middle;"><img src="skill-z.jpg" alt="sign"></img></span>&#xA0;Environmental, social and governance (ESG)</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">137</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px">
        <img src="cogo_0036.jpg" alt="WSGE_DP_Pic_Winters"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">William T. Winters</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Board member since 2013 | Nationality: British/American | Year of birth: 1961</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">William T. Winters has extensive leadership experience in the financial sector. He began his career at JPMorgan Chase &amp; Co. in 1983 and has held management roles across several market areas and in corporate finance. Mr. Winters founded Renshaw Bay LLP, an alternative asset management firm, and now serves as CEO of Standard Chartered PLC, where he is leading a digital transformation of the global bank.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   CEO, Standard Chartered PLC, UK (2015&#x2013;present)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chair and CEO, Renshaw Bay LLP, UK (2011&#x2013;2015)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Co-CEO of the Investment Bank, JPMorgan Chase &amp; Co., UK (2004&#x2013;2010)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Various managerial positions at JPMorgan Chase &amp; Co., UK and US (1983&#x2013;2004)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Standard Chartered Bank PLC, UK</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the board of overseers, International Rescue Committee, UK</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chair of the board of trustees, The Coronet Theatre, UK</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Commissioner, Independent Commission on Banking, UK (2010&#x2013;2011) </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master of Business Administration, Wharton School of the University of Pennsylvania, US</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor&#x2019;s degree in international relations, Colgate University, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Key skills</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">
        <span style="vertical-align: middle;">
          <img src="skill-y.jpg" alt="sign"></img>
        </span>&#xA0;Data/digital &#xA0;<span style="vertical-align: middle;"><img src="skill-g.jpg" alt="sign"></img></span>&#xA0;Leadership/management &#xA0;<span style="vertical-align: middle;"><img src="skill-l.jpg" alt="sign"></img></span>&#xA0;Law/regulatory/risk management &#xA0;<span style="vertical-align: middle;"><img src="skill-m.jpg" alt="sign"></img></span>&#xA0;Finance/accounting</div>
      <div style="padding-top: 30px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"></span>
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Corporate Secretary</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;font-weight:bold;padding-top:5px;padding-bottom:5px;">Charlotte Pamer-Wieser, Ph.D.</div>
      <div style="padding-top: 30px;font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Self-assessment</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board and its committees conduct a self-assessment once a year, covering topics including Board composition, purpose, scope and responsibilities; succession planning; Board processes and governance; interaction between the Board and the Executive Committee; Board meetings and pre-reading material; team effectiveness; and Board Chair and peer evaluation.  Every third year, this process is conducted by an independent external consultant. This last occurred in 2020 with the consulting firm Egon Zehnder. </div>
      <div style="padding-top:15px">
        <img src="cogo_0063.gif" alt="WSGE_DP_Graph_BoardSelfAssessment"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Anonymous survey&#x2022;Each Board member fills out an anonymous survey.&#x2022;A report identifying key strengths and challenges is produced for the Board and its committees. Qualitative review&#x2022;Based on the results, the Board Chair and the committee chairs each lead a qualitative review with their colleagues and then with the entire Board. &#x2022;In addition, the Vice-Chair leads a qualitative review of the Board Chair&#x2019;s performance, without the Chair being present, and then provides the Board Chair with the Board&#x2019;s feedback. Outcome&#x2022;The last self-assessment of October 2022 determined that the Board and its committees are functioning effectively and efficiently. &#x2022;The feedback confirmed that the Board has an open culture, fostering a broad range of viewpoints.&#x2022;The results also identified key areas on which to focus, such as further development of Novartis strategy, oversight of a range of challenging technology and reorganizational projects, and the impact of the current geopolitical situation in Europe, the US and China, including pricing.</div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">138</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Trainings</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Board receives regular briefings and trainings on ethics, risks and compliance, ESG and other relevant topics. In 2022, each Board member completed the following trainings: </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Health, Safety and Environment Policy</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  &#x2018;Fit to Commit&#x2019;, which focused on anti-bribery, insider trading and procurement</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  An ESG educational session conducted by an external expert on holistic value creation</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Third Party Risk Management</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Chief Legal Officer also provides regular updates to our Board members on developments related to insider trading laws and regulations and briefs the members of the Board and the Executive Committee on an annual basis on their respective duties. In addition, the Company offers a broad range of external trainings to its Board members. </div>
      <div style="padding-top:10px;  padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Role of the Board and its committees</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board is responsible for the overall direction and oversight of management, and holds the ultimate decision-making authority, with the exception of decisions reserved for shareholders.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Board has delegated certain of its duties and responsibilities to its five committees led by a Board-elected committee chair, as set out in the Board Regulations (www.novartis.com/investors/company-overview/corporate-governance). In some cases, these responsibilities are of an advisory or preparatory nature. In other cases, the committee has decision-making power that is subject to final Board approval, or the responsibilities have been fully delegated to the committee. All committees have the authority to retain external consultants.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Any Board member may request a Board or committee meeting and the inclusion of an agenda item. Before meetings, Board members receive materials to help them prepare for the discussions and to inform decision-making. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Attendance at Board and Board Committee Meetings in 2022</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />Name</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> Position</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br />
                <br /> Board</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Audit and <br /> Compliance <br /> Committee</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br /> Compensation <br /> Committee</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Governance, <br /> Sustainability <br /> and Nomination <br /> Committee</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br />
                <br /> Risk <br /> Committee</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                <br /> Science &amp; <br /> Technology <br /> Committee</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">J. Reinhardt</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:6%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Board Chair</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:6%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10/10</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:6%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:6%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:6%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:6%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:6%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4/4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">S. Moroney</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Vice-Chair</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10/10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7/7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4/4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">P. Bula</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Lead Independent Director</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10/10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7/7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3/3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">N. Andrews</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Member</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9/10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5/5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4/4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">T. Buechner</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Member</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10/10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7/7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5/5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">E. Doherty</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Member</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10/10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7/7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5/5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">B. Heller</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Member</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10/10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7/7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7/7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3/3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">F. van Houten</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Member</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10/10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7/7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3/4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">D. Hochstrasser<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Member</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8/8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">A. von Planta</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Member</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10/10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3/3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5/5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">A. de Pro Gonzalo<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Member</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8/8</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5/5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5/5</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">C. Sawyers</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Member</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10/10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3/3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4/4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">W. Winters</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Member</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9/10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6/7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3/3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="16" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="16">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Ms. de Pro Gonzalo and Mr. Hochstrasser were elected at the 2022 AGM.</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="16">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="16" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">Further details can be found on pages 140 &#x2013; 145.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">139</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Board of Directors</span>
      </div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Primary responsibilities</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Strategy: decides on the ultimate direction of the Group&#x2019;s business (including portfolio, markets, acquisitions and divestments), considering also key ESG aspects</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Structure and organization: determines major changes in the Group&#x2019;s structure and organization  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Culture: oversees the strategy and implementation of the corporate culture </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ethics and compliance: oversees the Group&#x2019;s ethics and compliance framework, including the approval of fundamental corporate policies such as the Novartis Code of Ethics</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Risk management: oversees the Group&#x2019;s risk management system, the most significant risks, and how these risks are managed</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Finance: determines the Group&#x2019;s accounting system, financial controls and financial planning;    reviews&#xA0;and approves the Annual Report (including the Compensation Report)</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Non-financial reporting: reviews and approves the Group&#x2019;s annual reporting on non-financial matters</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  People and organization: nominates or appoints, removes, and determines responsibilities of key executives,   and succession planning</div>
      <div style="border-bottom: 1px ; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Key activities in 2022</span>
        <div style="border:none; border-bottom:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Oversaw the Company&#x2019;s strategy to become a fully focused medicines company with leading technology in key therapeutic and geographic areas </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed the set-up and functioning of the Executive Committee in the context of the Company&#x2019;s new organizational structure</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed the geopolitical situation in Europe, with a special focus on the impact on the Russian and Ukrainian markets</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed and closely monitored the Transformation for Growth project to ensure a smooth transition and the successful implementation of its objectives</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received an update on the US market and our priorities to accelerate growth in Innovative Medicines and become a top player in the market</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received an update on the German market and the Company&#x2019;s strategic ambition to become the market leader in Germany</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received updates from Global Drug Development and Operations</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed and discussed strategic considerations around mergers and acquisitions, and the Company&#x2019;s larger strategic moves to drive sustainable growth</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Conducted detailed discussions about the strategic review of Sandoz, deciding that a separation through a 100% spin-off would offer the best value proposition to investors (subject to shareholders approval)</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed the Company&#x2019;s ESG strategy, plans and developments, and attended an ESG education session on holistic value creation</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed the upcoming non-financial disclosure regulations and Novartis non-financial reporting governance</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed longer-term Board succession planning and required profiles, proposing a new Board member candidate to be elected at the 2023 AGM</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed the amendment of the Articles of Incorporation of Novartis AG as part of the reform of Swiss corporate law</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed and reviewed the annual Board self-evaluation</div>
      <div style="padding-bottom: 10px;">
        <div style="border:none; border-top:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Meetings</span>
      </div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of meetings held </div>
        <div style="text-align: right; float:right; width: 100px;">10</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of members </div>
        <div style="text-align: right; float:right; width: 100px;">13</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Approximate average duration (hours) </div>
        <div style="text-align: right; float:right; width: 100px;">6:30</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Meeting attendance </div>
        <div style="text-align: right; float:right; width: 100px;">98.5%</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board met ten times in 2022. This includes regular meetings in January, April, June, August, October and December, and additional special meetings to deal with ad hoc matters. Board committees typically meet the day before the meetings of the full Board. The Board held virtual, hybrid and physical meetings, with participants joining in person when possible. </div>
      <div style="height: 20px;"></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">J. Reinhardt (Board Chair) </div>
        <div style="text-align: right; float:right; width: 100px;">10</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">S. Moroney (Vice-Chair) </div>
        <div style="text-align: right; float:right; width: 100px;">10</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">P. Bula (Lead Independent Director) </div>
        <div style="text-align: right; float:right; width: 100px;">10</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">N. Andrews </div>
        <div style="text-align: right; float:right; width: 100px;">9</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">T. Buechner </div>
        <div style="text-align: right; float:right; width: 100px;">10</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">E. Doherty </div>
        <div style="text-align: right; float:right; width: 100px;">10</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">B. Heller </div>
        <div style="text-align: right; float:right; width: 100px;">10</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">D. Hochstrasser<sup>1 </sup></div>
        <div style="text-align: right; float:right; width: 100px;">8</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">F. van Houten </div>
        <div style="text-align: right; float:right; width: 100px;">10</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">A. von Planta </div>
        <div style="text-align: right; float:right; width: 100px;">10</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">A. de Pro Gonzalo<sup>1 </sup></div>
        <div style="text-align: right; float:right; width: 100px;">8</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">C. Sawyers </div>
        <div style="text-align: right; float:right; width: 100px;">10</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">W. Winters </div>
        <div style="text-align: right; float:right; width: 100px;">9</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Documents</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Articles of Incorporation of Novartis AG </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board Regulations </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">www.novartis.com/investors/company-overview/corporate-governance</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>1</sup>  Ms. de Pro Gonzalo and Mr. Hochstrasser were elected at the 2022 AGM and have attended all Board meetings since their election.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">140</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Audit and Compliance Committee</span>
      </div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Primary responsibilities</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Supervises the external auditor, and selects and nominates the external auditor for election by the shareholders (FD)**</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Oversees Internal Audit (FD)**</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Oversees accounting policies, financial controls, and compliance with accounting and internal control standards (FD)**</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Approves financial statements for the first three quarters of each calendar year and the corresponding financial results releases (FD)**, and reviews the annual financial statements and the corresponding financial results releases (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews the non-financial data contained in the Group&#x2019;s annual reporting (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Oversees compliance with laws, regulations and internal policies related to its subject matter expertise (FD)**</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews updates with regards to Quality Assurance and patient safety twice a year and Health Safety &amp; Environment once a year (FD)**</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews updates from the SpeakUp Office twice a year (FD)**</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews the Group&#x2019;s tax policy every two years (FD)**</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews updates in closed sessions with the Chief Financial Officer, Chief Audit Officer, and external auditor</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"></div>
      <div style="border-bottom: 1px ; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Key activities in 2022</span>
        <div style="border:none; border-bottom:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Evaluated the performance of the external auditor KPMG during 2022</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed the accounting and financial reporting, focusing on those areas involving significant risk or judgment</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Monitored the geopolitical situation and reviewed the treasury aspects and cash collection in Russia</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed and discussed the Company&#x2019;s approach to non-financial reporting and assurance</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed the timelines and milestones of the intended Sandoz spin-off</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received an update on data privacy and its mechanisms of classifications and control</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received a presentation on foreign exchange risk management at Novartis</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Liaised with the Risk Committee to ensure adequate oversight of the Company&#x2019;s key transformation projects (Enterprise Data Governance and Management and Lean Digital Core (LDC) program)</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Received reports and updates from Internal Audit; Quality; Ethics, Risk &amp; Compliance; the SpeakUp Office; Health, Safety &amp; Environment; and Legal, and discussed&#xA0;progress on identifying and remedying the root causes of issues</div>
      <div style="padding-bottom: 10px;">
        <div style="border:none; border-top:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Meetings</span>
      </div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of meetings held </div>
        <div style="text-align: right; float:right; width: 100px;">7</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of members </div>
        <div style="text-align: right; float:right; width: 100px;">5</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Approximate average duration (hours) </div>
        <div style="text-align: right; float:right; width: 100px;">2:35</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Meeting attendance </div>
        <div style="text-align: right; float:right; width: 100px;">100%</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">E. Doherty (Chair, Audit Committee Financial Expert) </div>
        <div style="text-align: right; float:right; width: 100px;">7</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">T. Buechner </div>
        <div style="text-align: right; float:right; width: 100px;">7</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">B. Heller </div>
        <div style="text-align: right; float:right; width: 100px;">7</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">F. van Houten </div>
        <div style="text-align: right; float:right; width: 100px;">7</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">A. de Pro Gonzalo<sup>1 </sup> (Audit Committee Financial Expert)</div>
        <div style="text-align: right; float:right; width: 100px;">5</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Documents</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board Committees Charter, Appendix I to the Board Regulations</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">www.novartis.com/investors/company-overview/corporate-governance</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>*</sup>   A/P = advisory or preparatory task</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>**</sup>  FD = fully delegated task</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>***</sup>  FBA = task subject to final Board approval</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>1</sup>  Ms. de Pro Gonzalo became a member of the Audit and Compliance Committee after the 2022 AGM and has attended all Audit and Compliance Committee meetings since that time.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">141</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Compensation Committee</span>
      </div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Primary responsibilities</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Designs, reviews and recommends to the Board the compensation policies and programs (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Advises the Board on the compensation of Board members and the CEO (A/P)*</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Decides on the compensation of Executive Committee members (FD)**</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Prepares the Compensation Report and the Say-on-Pay brochure, and submits them to the Board for approval (FBA)***</div>
      <div style="border-bottom: 1px ; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Key activities in 2022</span>
        <div style="border:none; border-bottom:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Made decisions relating to Executive Committee and wider employee compensation during the year</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Established compensation to be paid for the future Sandoz board and executive committee members</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Determined the critical performance measures (including financial, strategic, operational, innovation and ESG) to be considered in the 2022 and 2023 incentive plan targets</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed the achievement of incentive plan targets for the Executive Committee members</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed shareholder and proxy advisor feedback related to Novartis compensation practices and disclosures and to those of peer companies</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed disclosures in the Novartis Compensation Report</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Proposed appropriate peer companies for comparisons of board and executive committee compensation, and assessed the Company&#x2019;s level of compensation against the peer group</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed incentive plan rules to secure pay-for-performance alignment while preserving market competitiveness</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Appointed a new independent advisor to the Compensation Committee</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reflected on effectiveness of the Company&#x2019;s compensation programs in view of its strategy to become a fully focused medicines company, following announcements of the introduction of a new organizational structure and the intention to separate the Sandoz business by way of a 100% spin-off</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed the Compensation Committee charter</div>
      <div style="padding-bottom: 10px;">
        <div style="border:none; border-top:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Meetings</span>
      </div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of meetings held </div>
        <div style="text-align: right; float:right; width: 100px;">7</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of members </div>
        <div style="text-align: right; float:right; width: 100px;">4</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Approximate average duration (hours) </div>
        <div style="text-align: right; float:right; width: 100px;">1:40</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Meeting attendance </div>
        <div style="text-align: right; float:right; width: 100px;">96.5%</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">S. Moroney (Chair) </div>
        <div style="text-align: right; float:right; width: 100px;">7</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">P. Bula </div>
        <div style="text-align: right; float:right; width: 100px;">7</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">B. Heller </div>
        <div style="text-align: right; float:right; width: 100px;">7</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">W. Winters </div>
        <div style="text-align: right; float:right; width: 100px;">6</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Documents</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board Committees Charter, Appendix I to the Board Regulations</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">www.novartis.com/investors/company-overview/corporate-governance</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>*</sup>   A/P = advisory or preparatory task</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>**</sup>  FD = fully delegated task</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>***</sup>  FBA = task subject to final Board approval</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">142</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Governance, Sustainability and Nomination Committee</span>
      </div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Primary responsibilities</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Oversees the Company&#x2019;s strategy, governance and progress on sustainability, including access to medicine and healthcare, global health, environmental sustainability, human capital management and other material ESG aspects (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Recommends corporate governance best practices to the Board (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews the Articles of Incorporation and Board Regulations on a periodic basis (FD)**</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews the composition and size of the Board and its committees as well as the skills matrix on a regular basis (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Identifies new Board member candidates and recommends to the Board whether existing Board members   should stand for re-election (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Prepares and reviews succession plans for the Board Chair, the Vice-Chair, the Lead Independent Director, Board&#xA0;members, committee members and chairs, and the CEO (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews the independence of each Board member on an annual basis (FBA)***</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Reviews directorships and agreements of Board members for conflicts of interest, and deals with conflicts of interest (FBA)***</div>
      <div style="border-bottom: 1px ; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Key activities in 2022</span>
        <div style="border:none; border-bottom:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Evaluated progress on sustainability at Novartis, focusing on material ESG factors, together with targets and metrics</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received updates on ESG and Global Health covering the Company&#x2019;s ESG priorities and 5-year roadmap</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received an update on environmental sustainability covering governance, strategy and progress against near- and longer-term targets for carbon emissions, waste reduction and water consumption</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received an update on human capital management covering the Company&#x2019;s People &amp; Organization strategy, key people metrics and progress in its culture journey</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Evaluated the results of the 2022 AGM as well as investor and analyst feedback from ESG / Governance roadshows held in 2022</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed and recommended to the Board amendments to the Articles of Incorporation of Novartis AG in connection with the reform of Swiss corporate law</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed candidates for the Sandoz board chair elect and the nomination process for the entire Sandoz board</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed the composition of, and the succession for, the (Novartis) Board and its committees on a regular basis</div>
      <div style="padding-bottom: 10px;">
        <div style="border:none; border-top:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Meetings </span>
      </div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of meetings held </div>
        <div style="text-align: right; float:right; width: 100px;">3</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of members </div>
        <div style="text-align: right; float:right; width: 100px;">5</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Approximate average duration (hours) </div>
        <div style="text-align: right; float:right; width: 100px;">2:00</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Meeting attendance </div>
        <div style="text-align: right; float:right; width: 100px;">100%</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">P. Bula (Chair) </div>
        <div style="text-align: right; float:right; width: 100px;">3</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">B. Heller </div>
        <div style="text-align: right; float:right; width: 100px;">3</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">A. von Planta </div>
        <div style="text-align: right; float:right; width: 100px;">3</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">C. Sawyers </div>
        <div style="text-align: right; float:right; width: 100px;">3</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">W. Winters </div>
        <div style="text-align: right; float:right; width: 100px;">3</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Documents</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Board Committees Charter, Appendix I to the Board Regulations</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">www.novartis.com/investors/company-overview/corporate-governance</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>*</sup>   A/P = advisory or preparatory task</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>**</sup>  FD = fully delegated task</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>***</sup>  FBA = task subject to final Board approval</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">143</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Risk Committee</span>
      </div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Primary responsibilities</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Oversees the risk management system and processes (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews, together with management, the prioritization and handling of risks, the risk portfolio,   and actions implemented by management (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Performs deep dives into key risk areas and fosters a culture of smart risk-taking (FBA)***</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews updates on cyber security on an annual basis (FD)**</div>
      <div style="border-bottom: 1px ; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Key activities in 2022</span>
        <div style="border:none; border-bottom:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received updates on Enterprise Risk Management mitigation measures and results</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Evaluated the emerging risks associated with the current geopolitical crisis in Russia and Ukraine, and mitigation actions</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received a presentation on launch excellence in Japan, evaluating opportunities and risks for Innovative Medicines</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed and discussed the current opportunities and risks at Global Drug Development</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed the performance, risk management and transformation of Novartis Technical Operations associated supply chain</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received updates and closely monitored the Enterprise Data Governance and Management and the risk assessment and mitigation of the Lean Digital Core (LDC) program</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received a presentation on falsified medicines covering the various types of falsification and indirect import</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Evaluated the enterprise risks for Innovative Medicines in the US for 2022 related to the Transforming for Growth program, pipeline portfolio growth and diversity in clinical trials</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed the Third-Party Risk Management (TPRM) program</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed the key risks associated with Intellectual Property (IP protection, IP enforcement, third-party assertion and trade secrets)</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Analyzed the opportunities and risks around talent management in key areas and geographies</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Received a deep-dive update on cyber security, including on data loss protection, from the Chief Security Officer</div>
      <div style="padding-bottom: 10px;">
        <div style="border:none; border-top:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Meetings</span>
      </div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of meetings held </div>
        <div style="text-align: right; float:right; width: 100px;">5</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of members </div>
        <div style="text-align: right; float:right; width: 100px;">5</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Approximate average duration (hours) </div>
        <div style="text-align: right; float:right; width: 100px;">1:50</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Meeting attendance </div>
        <div style="text-align: right; float:right; width: 100px;">100%</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">T. Buechner (Chair) </div>
        <div style="text-align: right; float:right; width: 100px;">5</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">N. Andrews </div>
        <div style="text-align: right; float:right; width: 100px;">5</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">E. Doherty </div>
        <div style="text-align: right; float:right; width: 100px;">5</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">A. von Planta </div>
        <div style="text-align: right; float:right; width: 100px;">5</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">A. de Pro Gonzalo </div>
        <div style="text-align: right; float:right; width: 100px;">5</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Documents</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board Committees Charter, Appendix I to the Board Regulations</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">www.novartis.com/investors/company-overview/corporate-governance</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>*</sup>   A/P = advisory or preparatory task</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>**</sup>  FD = fully delegated task</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>***</sup>  FBA = task subject to final Board approval</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">144</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Science &amp; Technology Committee</span>
      </div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Primary responsibilities</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Monitors emerging scientific, data-related, technological and research trends and issues,   and brings recommendations to the Board (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Informs the Board on a periodic basis about critical developments for the success of the portfolio and for scientific, technological&#xA0;and research activities as well as benchmarking (A/P)*</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Assists the Board with setting the Company&#x2019;s strategy for science, data, technology and research (A/P)*</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Assists the Board with oversight and evaluation of the performance of the Company&#x2019;s scientific, technological  and&#xA0;R&amp;D activities (FBA)***</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews performance and proposed targets in the area of science, technology and research (FD)**</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews other matters in relation to science, data, technology and research that the committee may,   in its own discretion, deem desirable in connection with its responsibilities (A/P)*</div>
      <div style="border-bottom: 1px ; padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Key activities in 2022</span>
        <div style="border:none; border-bottom:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed and provided guidance on the technology strategy for the Novartis Institutes of BioMedical Research (NIBR)</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviewed the Company&#x2019;s early clinical pipeline</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Discussed the performance of Global Drug Development and its future strategy</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#0070f7;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Provided guidance on the build-up of the Strategy &amp; Growth function, and discussed the Company&#x2019;s innovation strategy with the Strategy &amp; Growth leadership</div>
      <div style="padding-bottom: 10px;">
        <div style="border:none; border-top:solid 1px #0070f7; height: 5px"></div>
      </div>
      <div style="padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Meetings</span>
      </div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of meetings held </div>
        <div style="text-align: right; float:right; width: 100px;">4</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Number of members </div>
        <div style="text-align: right; float:right; width: 100px;">5</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Approximate average duration (hours) </div>
        <div style="text-align: right; float:right; width: 100px;">6:00</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">Meeting attendance </div>
        <div style="text-align: right; float:right; width: 100px;">95%</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">J. Reinhardt (Chair) </div>
        <div style="text-align: right; float:right; width: 100px;">4</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">N. Andrews </div>
        <div style="text-align: right; float:right; width: 100px;">4</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">F. van Houten </div>
        <div style="text-align: right; float:right; width: 100px;">3</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">S. Moroney </div>
        <div style="text-align: right; float:right; width: 100px;">4</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px; width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <div style="float:left; width: 400px;">C. Sawyers </div>
        <div style="text-align: right; float:right; width: 100px;">4</div>
      </div>
      <div style="height: 5px; width: 510px; border-top: 1px solid black;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="height: 20px;"></div>
      <div style="width: 510px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;padding-bottom:5px; padding-top:0px;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;&#xA;&#x9;&#x9;&#x9;&#x9;&#x9;&#x9;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#0070f7; font-weight:bold;">Documents</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board Committees Charter, Appendix I to the Board Regulations</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">www.novartis.com/investors/company-overview/corporate-governance</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>*</sup>   A/P = advisory or preparatory task</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>**</sup>  FD = fully delegated task</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">
        <sup>***</sup>  FBA = task subject to final Board approval</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">145</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Board Chair</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board Chair leads the Board to represent the interests of all stakeholders and ensures an appropriate balance of power between the Board and the Executive Committee. In this role, the Board Chair:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Provides leadership to the Board</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Supports and mentors the CEO</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ensures that the Board and its committees work effectively</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Sets the agenda, style and tone of Board discussions, promoting constructive dialogue and effective decision-making</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ensures onboarding programs for new Board members, and continuing education for and specialization of all Board members</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ensures the Board&#x2019;s annual performance evaluation</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Promotes effective relationships and communication between Board and Executive Committee members</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ensures effective communication with the Company&#x2019;s shareholders, other stakeholders and the public</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Vice-Chair and Lead&#xA0;Independent&#xA0;Director</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Vice-Chair</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Vice-Chair has the following responsibilities:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Leads the Board in case and as long as the Board Chair is incapacitated</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Leads the yearly session of the Board members to evaluate the performance of the Board Chair, during which the Board Chair is not present</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Vice-Chair also provides advice and support to the Board Chair.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Lead Independent Director</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">To support adequate control mechanisms, the Board Regulations outline the role of the Lead Independent Director. The Lead Independent Director has the following responsibilities: </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chairs the sessions of the independent Board members</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Leads the independent Board members in the event of a crisis or matter requiring their separate consideration or decision</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The roles of the Vice-Chair and the Lead Independent Director can be held by two Board members or by one Board member (combined role). </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Board appointed Simon Moroney as Vice-Chair and Patrice Bula as Lead Independent Director, both roles effective as of March 4, 2022. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Honorary Chairmen</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Alex Krauer and Daniel Vasella were appointed Honorary Chairmen in recognition of their significant achievements on behalf of Novartis.  In December 2021, Mr. Krauer passed away at the age of 90. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Mr. Vasella is not provided with Board documents and does not attend Board meetings.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Mandates outside the Novartis Group</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to article 34, paragraph 1 of the Articles of Incorporation (www.novartis.com/investors/company- overview/corporate-governance), the following limitations on mandates apply: </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Maximum number <br /> of mandates</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other listed companies<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="4" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="4">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Holding a chair position of the board of directors in other listed companies counts as two mandates.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to article 34, paragraph 3 of the Articles of Incorporation (www.novartis.com/investors/company- overview/corporate-governance), the following mandates are not subject to the above-mentioned limitations: </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Maximum number <br /> of mandates</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates in companies that are controlled by Novartis AG</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> No limit</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates held at the request of Novartis AG  or companies controlled by it</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates in associations, charitable organizations,  foundations, trusts and employee welfare foundations</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   10</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">&#x201C;Mandates&#x201D; means those in the supreme governing body of a legal entity that is required to be registered in the commercial register or a comparable foreign register. Mandates in different legal entities that are under joint control are deemed to be one mandate.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">146</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId001015987"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Executive Committee</p>
      <div style="padding-top:15px">
        <img src="cogo_0021.gif" alt="WSGE_DP_Graph_Management"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Composition (as per December 31, 2022)Vasant (Vas) NarasimhanChief Executive OfficerShreeram AradhyePresident, Global Drug Development&amp; Chief Medical OfficerVictor BultoPresident, InnovativeMedicines USAharon (Ronny) GalChief Strategy &amp; Growth OfficerKaren L. HaleChief Legal OfficerHarry KirschChief Financial OfficerRobert (Rob) KowalskiChief People &amp; Organization OfficerSteffen LangPresident, OperationsFiona H. MarshallPresident, Novartis Institutesfor BioMedical Research (NIBR)Klaus MoosmayerChief Ethics, Risk &amp; Compliance OfficerMarie-France TschudinPresident, Innovative Medicines International &amp; Chief Commercial Officer</div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Changes to the Executive Committee</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Susanne Schaffert, President of Novartis Oncology since 2019, stepped down from her role following the Company&#x2019;s decision to integrate the Pharmaceuticals and Oncology business units and create separate US and International commercial organizations under the Innovative Medicines (IM) Division, effective April 4, 2022. Marie-France Tschudin, President of Novartis Pharmaceuticals since 2019, was appointed President, Innovative Medicines International &amp; Chief Commercial Officer, effective April 4, 2022. Victor Bulto, President, Novartis Pharmaceuticals Corporation, US, since 2019, was appointed President, Innovative Medicines US, effective April 4, 2022. He has been a member of the Executive Committee since May 1, 2022. Robert Weltevreden, Head of Customer &amp; Technology Solutions (CTS) since February 1, 2021, stepped down from his role following the Company&#x2019;s decision to combine Novartis Technical Operations (NTO) and CTS into a new Operations unit, effective April 4, 2022. Steffen Lang, Global Head of Novartis Technical Operations since 2017, was appointed President, Operations, effective April 4, 2022. John Tsai, Head of Global Drug Development and Chief Medical Officer, stepped down from his role effective May 15, 2022. Shreeram Aradhye was appointed President, Global Drug Development &amp; Chief Medical Officer, effective May 16, 2022. Aharon (Ronny) Gal was appointed Chief Strategy &amp; Growth Officer, effective July 18, 2022. From April 4, 2022, until July 17, 2022, Lutz Hegemann, President Global Health &amp; Sustainability, served as ad interim Chief Strategy &amp; Growth Officer but was not a member of the Executive Committee. Richard Saynor, Chief Executive Officer, Sandoz, stepped down from the Executive Committee effective October 25, 2022, following his appointment as CEO designate of the Sandoz standalone company expected to be created in the second half of 2023. James (Jay) Bradner, President of the Novartis Institutes for BioMedical Research (NIBR), stepped down from his role effective October 31, 2022. Fiona H. Marshall was appointed President of the Novartis Institutes for BioMedical Research (NIBR), effective November 1, 2022.&#xA0;The biographies of the former members of the Executive Committee can be found in the 2021 Annual Report (pages 147 - 149), available at www.novartis.com/news/media-library/novartis-annual-report-2021. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Role of the Executive Committee</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board has appointed the Executive Committee members and delegated the overall responsibility for and oversight of the operational management of Novartis to them, including:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Recruiting, appointing and promoting senior management</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ensuring the efficient operation of the Group and the achievement of optimal results</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Promoting an active internal and external communications policy </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Developing policies and strategic plans for Board approval, and implementing those approved</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Submitting the following to the Board for approval: investments, divestments, transactions, contracts and litigations with a value exceeding USD 500 million, and capital market and other important financing transactions, as well as all other matters of fundamental significance to the Novartis Group</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Preparing and submitting quarterly and annual reports to the Board and its committees</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Informing the Board of all matters of fundamental significance to the businesses</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Dealing with any other matters delegated by the Board</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There are no contracts between Novartis and third parties whereby Novartis would delegate any business management tasks to such third parties.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">147</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">CEO</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">With the support of the Executive Committee, the CEO is responsible for the operational management of Novartis. This includes effectively implementing the Company strategy, delivering financial results, and shaping a corporate culture of empowerment and responsibility to help drive innovation, performance and reputation. &#xA0;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition to other Board-assigned duties, the CEO leads the Executive Committee, and is responsible for building and maintaining an effective executive team. With the support of the Executive Committee, the CEO is responsible for:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ensuring Novartis has the capabilities to achieve its long-term strategic objectives</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Developing robust management succession and development plans for presentation to the Board</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Promoting effective communication with shareholders and other stakeholders</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ensuring Novartis conducts its business in a legal and ethical manner</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Developing an effective risk control framework for all business activities </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Ensuring the flow of information to the Board is accurate, timely and clear</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Diversity</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The composition as of December 31, 2022, in terms of nationality, gender, age and length of tenure, is shown in the following charts: </div>
      <div style="padding-top:15px">
        <img src="cogo_0039.gif" alt="WSGE_DP_Graph_Diversity_ECN"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">Diversity profileNationality1pAmerican41%pGerman18%pSwiss18%pBritish9%pSpanish9%pIsraeli5%GenderpMale73%pFemale27%Agep&lt;459%p45509%p&gt;5082%Tenurep&lt;2y55%p24y27%p&gt;4y18%1Please note that three Executive Committee members have dual nationalities. Each of these nationalities is counted as a half in the above chart.</div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Mandates outside the Novartis Group</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to article 34, paragraph 2 of the Articles of Incorporation (www.novartis.com/investors/company-overview/corporate-governance), the following limitations on mandates apply:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Maximum number <br /> of mandates</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other listed companies<sup style="white-space: nowrap">&#xA0;1</sup></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="4" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="4">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Holding a chair position of the board of directors in other listed companies is not allowed.</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to article 34, paragraph 3 of the Articles of Incorporation (www.novartis.com/investors/company-overview/corporate-governance), the following mandates are not subject to the above-mentioned limitations: </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Maximum number <br /> of mandates</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates in companies that are controlled by Novartis AG</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:20%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> No limit</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates held at the request of Novartis AG  or companies controlled by it</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mandates in associations, charitable organizations,  foundations, trusts and employee welfare foundations</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   10</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">&#x201C;Mandates&#x201D; means those in the supreme governing body of a legal entity that is required to be registered in the commercial register or a comparable foreign register. Mandates in different legal entities that are under joint control are deemed to be one mandate.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">148</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId001016190"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Members of the Executive Committee </p>
      <div style="padding-top:15px">
        <img src="cogo_0043.jpg" alt="WSGE_DP_Pic_Narasimhan"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Vasant (Vas) Narasimhan, M.D.</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Chief Executive Officer of Novartis since 2018 | Nationality: American | Year of birth: 1976</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Global Head of Drug Development and Chief Medical Officer, Novartis AG, Switzerland (2016&#x2013;2018)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Global Head of Development, Novartis Pharmaceuticals, Switzerland (2014&#x2013;2016)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Global Head of Biopharmaceuticals and Oncology Injectables, Sandoz International, Germany (2014)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Global Head of Development, Novartis Vaccines, US (2012&#x2013;2014)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   North America Region Head, Novartis Vaccines, and US Country President, Novartis Vaccines and Diagnostics, US (2008&#x2013;2012)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Joined Novartis in 2005 </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member, National Academy of Medicine, US </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chair (since December 2022) and board member (2020&#x2013;2022), African Parks Network, South Africa</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Committee member, Biopharmaceutical CEOs Roundtable (BCR), International Federation of Pharmaceutical Manufacturers &amp; Associations (IFPMA), Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the board of fellows, Harvard Medical School, US</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member and treasurer, Pharmaceutical Research and Manufacturers of America (PhRMA), US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Doctor of medicine, Harvard Medical School, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master&#x2019;s degree in public policy, John F. Kennedy School of Government, Harvard University, US</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor&#x2019;s degree in biological sciences, University of Chicago, US</div>
      <div style="padding-top:15px">
        <img src="cogo_0069.gif" alt="WSGE_DP_Pic_Aradhye"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Shreeram Aradhye, M.D.</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">President, Global Drug Development &amp; Chief Medical Officer since May 16, 2022 | Nationality: American |  <br />Year of birth: 1962</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Executive Vice President &amp; Chief Medical Officer, Dicerna Pharmaceuticals, US (2020&#x2013;March 2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Executive Vice President &amp; Chief Development Officer, Axcella Health, US (2019&#x2013;2020)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Global Head, Medical Affairs and Chief Medical Officer, Pharmaceuticals, Novartis, US &amp; Switzerland (2017&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Global Head, Development Franchise, Neuroscience, and US Head, Development, Novartis, US&#xA0;&amp;&#xA0;Switzerland (2013&#x2013;2017)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Executive Global Program Head, Multiple Sclerosis, Novartis, Switzerland (2012&#x2013;2013)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Head, Global Development India, Novartis, India (2011&#x2013;2012)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Head, Global Clinical Development &amp; Medical Affairs, Biosimilars, Sandoz, Germany (2009&#x2013;2011)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Joined Novartis in 1999 holding positions of increasing responsibility</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Chief Resident and Teaching Fellow in Internal Medicine, Newton Wellesley Hospital, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Resident in Internal Medicine, Newton Wellesley Hospital, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Fellow in Nephrology, St Luke&#x2019;s Roosevelt Medical Center, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Resident in Internal Medicine (M.D.), All India Institute of Medical Sciences, India</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor of Medicine and Bachelor of Surgery, All India Institute of Medical Sciences, India</div>
      <div style="padding-top:15px">
        <img src="cogo_0068.gif" alt="WSGE_DP_Pic_Bulto"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Victor Bulto</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">President, Innovative Medicines US since April 4, 2022 | Member of the Executive Committee as of May 1, 2022 | Nationality: Spanish | Year of birth: 1978</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   President, Novartis Pharmaceuticals Corporation, US (2019&#x2013;April 2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Vice President &amp; Head US Immunology &amp; Dermatology Franchise, US (2017&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Vice President &amp; Head US Alcon Pharmaceuticals, US (2016&#x2013;2017)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Head Neuroscience Franchise, Region Europe, Novartis, Switzerland (2013&#x2013;2016)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Business Franchise Head Neuroscience, Novartis, Spain (2012&#x2013;2013)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Business Franchise Head Neuroscience/MS, Respiratory, Osteoarticular, Spain, Novartis (2010&#x2013;2012)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Marketing Head Respiratory, Osteoarticular, Novartis, Spain (2009&#x2013;2010)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Biotechnology Innovation Organization (BIO), US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master of business administration, ESADE Business School, Spain</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master&#x2019;s degree in health economics and pharmacoeconomics, Pompeu Fabra University Spain</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master&#x2019;s degree in chemical engineering, Ramon Llull University, Spain</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor&#x2019;s of science degree in chemistry, Ramon Llull University, Spain</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">149</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px">
        <img src="cogo_0070.gif" alt="WSGE_DP_Pic_Gal"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Aharon (Ronny) Gal, Ph.D.</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Chief Strategy &amp; Growth Officer since July 18, 2022 | Nationality: Israeli/American | Year of birth: 1966</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Senior analyst, US biopharmaceutical, Sanford Bernstein, US (2020&#x2013;June 2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Senior analyst, US specialty pharmaceuticals and Biotech, Sanford Bernstein, US (2016&#x2013;2020)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Senior analyst, US specialty pharmaceuticals and EU mid-cap pharmaceuticals, Sanford Bernstein,  US, UK (2013&#x2013;2016)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Senior analyst, US specialty pharmaceuticals, Sanford Bernstein, US (2004&#x2013;2013)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Vice president, Canon US Life Sciences, US (2003&#x2013;2004)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Consultant, team leader, manager, The Boston Consulting Group, Inc., US, Singapore, China  (1996&#x2013;2002)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Scientific advisor, Pure Honey Technologies, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ph.D. in Biochemistry, Massachusetts Institute of Technology, US </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  B.Sc. in Chemistry, Emory University, US</div>
      <div style="padding-top:15px">
        <img src="cogo_0064.gif" alt="WSGE_DP_Pic_Hale"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Karen L. Hale</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Chief Legal Officer of Novartis since May 15, 2021 | Nationality: American | Year of birth: 1968</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Vice president, deputy general counsel, AbbVie Inc., US (2019&#x2013;2021)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Vice president, chief ethics and compliance officer, AbbVie Inc., US (2013&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Vice president, litigation and legal specialty operations, AbbVie Inc., US (2013)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Divisional vice president, commercial litigation, Abbott Laboratories, US (2006&#x2013;2012)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Began practicing law in 1994 and joined Abbott in 1997</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bar memberships: Illinois and Virginia, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Juris doctor, William &amp; Mary Law School, US</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor&#x2019;s degree in economics, Duke University, US</div>
      <div style="padding-top:15px">
        <img src="cogo_0047.jpg" alt="WSGE_DP_Pic_Kirsch"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Harry Kirsch</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Chief Financial Officer of Novartis since 2013 | Nationality: German/Swiss | Year of birth: 1965</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chief Financial Officer of the Pharmaceuticals Division (now known as the Innovative Medicines Division), Novartis Pharmaceuticals, Switzerland (2010&#x2013;2013)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chief Financial Officer of Pharma Europe, Novartis Pharmaceuticals, Switzerland (2008&#x2013;2010)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Head of Business Planning &amp; Analysis for the Pharmaceuticals Division, Novartis Pharmaceuticals, Switzerland (2005&#x2013;2008) </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Joined Novartis in 2003 as Head Finance Global Primary Care, and over the years held positions of increasing responsibility within Finance </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Represented Novartis on the board of GlaxoSmithKline Consumer Healthcare Holdings Ltd. (2015&#x2013;2018)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Diploma degree in industrial engineering and economics, University of Karlsruhe, Germany</div>
      <div style="padding-top:15px">
        <img src="cogo_0065.gif" alt="WSGE_DP_Pic_Kowalski"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Robert (Rob) Kowalski</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Chief People &amp; Organization Officer of Novartis since September 1, 2021 | Nationality: American | Year of birth: 1968</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Executive Vice President and Global Head of Regulatory Affairs (2018&#x2013;2021), and US Head of Global Drug Development (2009&#x2013;2015 and 2017&#x2013;2021), Novartis Pharmaceuticals Corporation, US </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ad interim President, Novartis Corporation, US (2021) </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ad interim Head of Global Drug Development and Chief Medical Officer, Novartis AG,   Switzerland (2018) </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Senior Vice President and Head of Regulatory Affairs, Novartis Pharmaceuticals Corporation, US   (2009&#x2013;2015 and 2017&#x2013;2018)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Senior Vice President and Head of Regulatory Affairs, Novartis Pharma AG, Switzerland (2015&#x2013;2017)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Global Head of Country Medical Development, Novartis Pharmaceuticals Corporation, US (2010&#x2013;2011)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Previously held regulatory leadership roles at Schering-Plough Corporation (now Merck) and Pharmacia Corporation (now Pfizer) </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the advisory board, Industry Pharmacists Organization, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Doctor of pharmacy, University of Wisconsin-Madison, US</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor of Science in pharmaceutical sciences, University of Wisconsin-Madison, US</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">150</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-top:15px">
        <img src="cogo_0045.jpg" alt="WSGE_DP_Pic_Lang"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Steffen Lang, Ph.D.</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">President, Operations since April 4, 2022 | Nationality: German/Swiss | Year of birth: 1967</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Global Head of Novartis Technical Operations (NTO), Switzerland (2017&#x2013;April 2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Global Head of Biologics Technical Development and Manufacturing, Novartis Technical Operations, Switzerland (2015&#x2013;2017)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Global Head of Technical Research and Development, Novartis Pharmaceuticals, Switzerland (2009&#x2013;2015)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Joined Novartis in 1994 as Head of Laboratory in Research, and over the years held positions of increasing responsibility within Pharmaceuticals Development</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, Bachem Holding AG, Switzerland </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Doctorate in pharmaceutical technology, Swiss Federal Institute of Technology, Switzerland </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master&#x2019;s degree in pharmaceutical sciences, University of Heidelberg, Germany</div>
      <div style="padding-top:15px">
        <img src="cogo_0071.gif" alt="WSGE_DP_Pic_Marshall"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Fiona H. Marshall, Ph.D.</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">President, Novartis Institutes for BioMedical Research (NIBR) since November 1, 2022 | Nationality: British |  <br />Year of birth: 1964</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Senior vice president, head of discovery, preclinical and translational medicine, Merck &amp; Co., US, (2021&#x2013;September 2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Vice president, global head of neuroscience, Merck &amp; Co., US (2019&#x2013;2021)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Vice president, head of UK discovery research, Merck &amp; Co., UK (2018&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Executive vice president and chief scientific officer, Sosei Heptares, UK (2015&#x2013;2018)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chief scientific officer and founder, Heptares Therapeutics, UK (2006&#x2013;2018)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the Scientific Advisory Board, SciLifeLab, Sweden</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Fellow, Royal Society, UK</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Honorary Fellow, Royal Society of Chemistry, UK</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Honorary Fellow, British Pharmacological Society, UK</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Fellow, UK Academy of Medical Sciences, UK</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Fellow, Royal Society of Biology, UK</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  PhD in Neuroscience, University of Cambridge, UK</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  BSc in Biochemistry, University of Bath, UK</div>
      <div style="padding-top:15px">
        <img src="cogo_0044.jpg" alt="WSGE_DP_Pic_Moosmayer"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Klaus Moosmayer, Ph.D.</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">Chief Ethics, Risk &amp; Compliance Officer of Novartis since 2018 | Nationality: German | Year of birth: 1968</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chief compliance officer, Siemens AG, Germany (2014&#x2013;2018)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chief counsel compliance, Siemens AG, Germany (2009&#x2013;2013)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Compliance operating officer, Siemens AG, Germany (2007&#x2013;2009)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, SwissHoldings, the Swiss federation representing Swiss-based multinational companies, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the executive board, Business at OECD (BIAC), Paris </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Co-chair, B20 Integrity &amp; Compliance Task Force under the G20 presidencies of Indonesia (2022), Italy (2021), Saudi Arabia (2020), Argentina (2018), and Chair of the Task Force under the G20 presidency of Germany (2017)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Member of the advisory panel, Pharmaceutical Supply Chain Initiative, US</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Co-founder and board member, European Chief Compliance and Integrity Officers&#x2019; Forum</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Chair of the Anti-Corruption Committee of the Business and Industry Advisory Committee (BIAC), Organization for Economic Co-operation and Development (OECD), Paris (2013&#x2013;2020)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  First and second state examination in law, Germany</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Doctor of jurisprudence, University of Freiburg, Germany</div>
      <div style="padding-top:15px">
        <img src="cogo_0049.jpg" alt="WSGE_DP_Pic_France"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Marie-France Tschudin</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000;padding-bottom:10px;">President, Innovative Medicines International &amp; Chief Commercial Officer since April 4, 2022 | Nationality: Swiss |  <br />Year of birth: 1971</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Professional experience </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   President, Novartis Pharmaceuticals, Switzerland (2019&#x2013;April 2022)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  President, Advanced Accelerator Applications, France (2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Europe Region Head, Novartis Pharmaceuticals, Switzerland (2017&#x2013;2019)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Corporate vice president of hematology and oncology for Europe, the Middle East and Africa, Celgene International, Switzerland (2014&#x2013;2016)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Regional vice president of northern Europe, Celgene International, Switzerland (2012&#x2013;2014)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   General manager of Austria, Switzerland, the Czech Republic, Poland, Slovenia and Slovakia, Celgene International, Switzerland (2009&#x2013;2011)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Country manager of Switzerland, Celgene International, Switzerland (2008&#x2013;2009)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Mandates </span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, IMD Foundation, Switzerland</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, AXA, France</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Board member, European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Education</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Master of Business Administration, IMD business school, Switzerland</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Bachelor of Science, Georgetown University, US </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">151</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId001016934"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Information and control systems </p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board&#x2019;s information and control systems vis-&#xE0;-vis management include a steady flow of information from senior management; monthly financial reports; a comprehensive and integrated risk management framework; and the independent evaluation of our risk management and internal control framework by the Internal Audit function (see &#x201C;Item 15. Controls and Procedures&#x201D;).</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Information from senior management</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Board ensures that it receives sufficient information from the Executive Committee through:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Monthly CEO reporting (including detailed written updates from each division and business unit head), frequent communications from the CEO on current developments, and a yearly presentation</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Executive Committee meeting minutes</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Regular meetings and teleconferences by the Board and/or Board committees with the CEO and/or other members of the Executive Committee (e.g., the CFO, the Chief Legal Officer, the Chief Ethics, Risk &amp; Compliance Officer), and regular meetings and teleconferences with senior management (e.g., the Chief Audit Officer)</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Information from Executive Committee members or other Novartis employees, and visits to Novartis sites</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">To get an outside view, the Board and/or Board committees occasionally invite external advisors (e.g., the independent advisor of the Compensation Committee, the external auditor) to attend a meeting and/or share their observations about a specific topic.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Monthly financial reports</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis produces comprehensive, consolidated (unaudited) financial statements on a monthly basis for the Group and its operating divisions. These are typically available within 10 days after the end of the month, and include the following:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Consolidated income statement of the month and year to date, in accordance with International Financial Reporting Standards (IFRS), as well as adjustments to arrive at core results, as defined by Novartis (see &#x201C;Item 5. Operating and Financial Review and Prospects&#x2014;Item 5.A Operating results&#x2014;Non-IFRS measures as defined by Novartis&#x201D;). The IFRS and core figures are compared with the prior-year period and targets in both USD and on a constant currency basis.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Supplementary data on a monthly and year-to-date basis, such as free cash flow and earnings per share on a USD basis </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Management information related to the consolidated income statements and free cash flow is made available to Board members through the monthly CEO Report, which includes an analysis of key deviations from the prior year or target.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Prior to the release of each quarter&#x2019;s results, the Board receives the actual consolidated financial statement information and an outlook of the full-year results in accordance with IFRS and core results (as defined by Novartis), together with related commentary.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Annually, in the middle of the year, the Board approves the Company&#x2019;s strategic plan for the next three years. In the fourth quarter of the year, the Board approves the operating targets for the following year as well as the financial targets for the following three-year period, including a projected consolidated income statement in USD prepared in accordance with IFRS and non-IFRS measures as defined by Novartis (core results).</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Board does not have direct access to the Novartis financial and management reporting systems but can, at any time, request more detailed information.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">152</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Risk management</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Overview</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At Novartis, our continued success depends on our ability to manage risk. Our Board has ultimate oversight of the Enterprise Risk Management (ERM) system and regularly reviews the most significant risks and how these risks are managed. As explained further below, the Board is supported by its committees. Furthermore, our Internal Audit function provides an independent evaluation of risk management (see &#x201C;&#x2014;Item 6.C Board practices&#x2014;Information and control systems&#x2014;Internal Audit&#x201D;). </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt; font-weight:bold; color:#0070f7; text-transform:uppercase;">Board committees<div style="border:none;border-bottom:solid 2px;"></div></div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Risk committee</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Oversees the risk management system and processes</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Reviews, together with management, the prioritization and handling of risks, the risk portfolio, and actions implemented by management</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Performs deep dives into key risk areas and fosters a culture of smart risk-taking</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Receives updates on cyber security on an annual basis</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Receives regular updates from designated risk owners as well as the Chief Ethics, Risk &amp; Compliance Officer and/or the Head of Risk &amp; Resilience</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Audit and compliance committee</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Ensures that Internal Audit plans are aligned with key risks, and that the function provides independent assurance and insights around these risks</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Works closely with the Risk Committee to minimize gaps in risk&#xA0;coverage</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Receives a semiannual presentation from the Chief Ethics, Risk &amp; Compliance Officer</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Receives a quarterly presentation from the Chief Audit Officer on progress achieved in implementing the risk-based audit plan, and key insights about audit and advisory activities</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Pays particular attention to financial risk</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Has closed sessions with the Chief Audit Officer and, upon request, with the Chief Ethics, Risk &amp; Compliance Officer</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt;color:#000000; font-weight:bold;text-transform:uppercase;">Compensation committee</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Works closely with the Risk Committee to ensure that the compensation system does not lead to excessive risk-taking (see&#xA0;&#x201C;&#x2014;Item 6.B Compensation&#x2014;Compensation governance&#x2014;Risk&#xA0;management principles&#x201D;)  </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt; font-weight:bold; color:#0070f7; text-transform:uppercase;">Executive committee of NOVARTIS<div style="border:none;border-bottom:solid 2px;"></div></div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Regularly assesses risks and fosters a culture of risk awareness, in line with the Novartis Values and Behaviors and the Novartis Code&#xA0;of Ethics</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt; font-weight:bold; color:#0070f7; text-transform:uppercase;">Ethics, risk &amp; compliance<div style="border:none;border-bottom:solid 2px;"></div></div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Governs the Novartis Code of Ethics</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Provides an integrated ERM framework (further described in the following section)</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Governs the global compliance program within Novartis</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Administers the Enterprise Policy Management and global Internal Controls framework</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:9pt; font-weight:bold; color:#0070f7; text-transform:uppercase;">SENIOR LEADERS OF DIVISIONS, ORGANIZATIONAL UNITS AND&#xA0;GROUP FUNCTIONS, AT ALL LEVELS<div style="border:none;border-bottom:solid 2px;"></div></div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Provide appropriate risk management within their area of responsibility</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Establish adequate risk prevention and mitigation strategies when risk exposure is identified, including tracking progress and providing resources for possible actions</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Assess emerging risks, trends and overall exposure as part of the ERM process</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Enterprise Risk Management framework</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Ethics, Risk &amp; Compliance (ERC) function provides an integrated ERM framework to obtain a holistic view of Company risks and drive a culture of smart risk-taking. Under the leadership of the Chief Ethics, Risk &amp; Compliance Officer, the Risk &amp; Resilience team is responsible for the overall ERM process. This process covers, but is not limited to, risks associated with: </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The research, development, manufacturing, marketing and sales of products</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;   Finance, taxes, intellectual property, compliance with law and regulations, security, product safety, human resources, and health, safety and environmental protection</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Business objectives and strategies, including mergers and acquisitions</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  External factors such as the social, political and economic environment</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The ERM process continued to evolve in 2022. The Risk &amp; Resilience team conducted risk workshops and collaborated with all risk assurance and monitoring functions to identify key risks across the Company. Each Novartis unit organized a focused risk workshop at the leadership team level. In parallel, risk workshops were held in the top 11 countries (by revenue) and in certain focus markets. Once key risks were identified, mitigation action plans were created to address them in an effective way. The findings from these workshops were consolidated into the Novartis Risk Compass, which enables senior management, the Executive Committee and the Board to focus discussions on key risks and more closely align our corporate strategy with our risk exposure and ways of working.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2022, we further matured our ERM framework within the Novartis Risk &amp; Resilience organization, developed additional risk management trainings, and integrated other critical risk management functions (like Third-Party Risk Management and Health, Safety and Environment) into the Risk &amp; Resilience department. Furthermore, the Enterprise Policy &amp; Internal Control team is progressing as planned to create a holistic framework, and the Central Monitoring Coordination team is expanding its scope to ensure a harmonized and coordinated monitoring process across the Company.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">SpeakUp Office</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our SpeakUp Office provides a safe place for employees to report potential misconduct, including the option to do so anonymously. </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Global Security</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Global Security proactively collects and shares threat intelligence to protect Novartis from situations that may compromise the safety of people, products and assets, and/or the reputation of our organization. Global Security protects patients from counterfeit products and, as part of the SpeakUp process, performs fair and timely investigations into high-risk cases of alleged internal misconduct. It also provides personal security advice and support for Novartis executives and other employees with the utmost discretion. </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">153</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Internal Audit</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The purpose of Internal Audit is to assist the Board and the Executive Committee in discharging their governance responsibilities by providing independent assurance and advice on the effectiveness, efficiency and adequacy of processes and controls that support Novartis in achieving its objectives, managing its major risks, and ensuring compliance with applicable policies, laws and regulations. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Chief Audit Officer reports administratively to the CEO, and functionally to the chair of the Audit and Compliance Committee (ACC). The Chief Audit Officer meets with the ACC at least once a quarter and confirms the organizational independence of the Internal Audit function to the ACC on an annual basis.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2022, our Internal Audit function executed a risk-based audit plan and reported the results to the audited units, the Executive Committee and the ACC. Audit findings and action plans are stored and monitored in a single location to enable efficient and effective follow-up. The following outlines the number of audits, internal reviews and advisories performed in 2022, and key methodology steps when managing the Internal Audit cycle.</div>
      <div style="padding-top:15px">
        <img src="cogo_0062.gif" alt="WSGE_DP_Graph_InternalAuditActivities"></img>
      </div>
      <div style="padding-bottom:16px;">
        <div style="font-family:arial,helvetica,sans-serif;font-size:1pt;line-height:1pt;color:#ffffff;">2022 Internal Audit Activitiesaudits 41internal reviews 14advisories8Internal Audit cycle methodology includes:Planning: Monitoring and information gathering via continuous risk assessment based on data analytics, business interviews and quarterly calibration of the audit planExecution and Reporting: 63 engagements delivered in 2022, all linked to group risks, emerging topics and company-wide initiativesFollow Up: Management is responsible for resolving issues, supported by Internal Audit to ensure timely closure of observations </div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Internal Audit performed 85% of planned activities (equating to 63 of 74 engagements) in 2022, conducted under a hybrid model of engagement delivery, choosing between remote and in-person auditing based on the engagement scope and COVID-19 situation within the audited entity.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">154</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId001017164"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Auditors</p>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Duration of the mandate and&#xA0;terms&#xA0;of&#xA0;office</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On behalf of the Board, the ACC selects and nominates an independent auditor for election at the AGM. KPMG commenced its auditing mandate for Novartis in 2022. Richard Broadbelt, Auditor in charge, and Sara Burke, Global Audit Partner, began serving in their roles in 2022. The ACC together with KPMG will ensure that these partners are rotated at least every five years. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Auditing fees and additional fees</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The ACC monitors and preapproves the fees paid to the external auditor for all audit and non-audit services. It has developed and approved a policy with clear guidelines on the engagement of the independent auditor firm. This policy is designed to help ensure that the independence of the external auditor is maintained. It limits the scope of services that the external auditor may provide to the Group, stipulating certain permissible types of audit-related and non-audit services, including tax services and other services that have been preapproved by the ACC. The ACC preapproves all other services on a case-by-case basis. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The external auditor is required to report periodically to the ACC about the scope of the services it has provided to the Group and the fees for the services it has performed to date. KPMG fees for professional services related to the 12-month period ended December 31, 2022, and PwC fees for professional services related to the 12-month period ended December 31, 2021, are as follows: </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022<br /> USD million</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021<br /> USD million</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Audit services</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22.5</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:14%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22.2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Audit-related services</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.7</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.5</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tax services</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.2</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.1</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other services</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.0</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.4</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 24.4</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25.2</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="6" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="6">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
              </div>
            </td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Audit services include work performed to issue opinions on consolidated financial statements and parent company financial statements of Novartis AG, to issue opinions related to the effectiveness of the Group&#x2019;s internal control over financial reporting, and to issue reports on local statutory financial statements. Also included are audit services that generally can only be provided by the statutory auditor, such as the audit of the Compensation Report, audits of the adoption of new accounting policies, audits of information systems and the related control environment, as well as reviews of quarterly financial results.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Audit-related services include other assurance services provided by the independent auditor but not restricted to those that can only be provided by the statutory auditor. They include services such as: audits of pension and other employee benefit plans; audits in connection with non-recurring transactions; contract audits of third-party arrangements; corporate responsibility assurance; and other audit-related services.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Tax services include tax compliance, assistance with historical tax matters, and other tax-related services.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Other services in 2021 included procedures related to corporate integrity agreements, benchmarking studies, and license fees for use of accounting and other reporting guidance databases.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Information to the Board and the ACC</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The ACC, acting on behalf of the Board, is responsible for overseeing the activities of the external auditor. In 2022, this committee held seven meetings. KPMG was invited to all of these meetings to attend the discussions on auditing matters and any other matters relevant to its audit.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The ACC recommended to the Board to approve the audited consolidated financial statements and the separate parent company financial statements of Novartis&#xA0;AG for the year ended December 31, 2022. The Board proposed the acceptance of these financial statements for approval by the shareholders at the next AGM.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The ACC regularly evaluates the performance of the external auditor and, based on this, once a year determines whether the external auditor should be proposed to the shareholders for re-election. To assess the performance of the external auditor, the ACC  requests input from management and holds private meetings with the CFO and the Chief Audit Officer and, if necessary, obtains an independent external assessment. Criteria applied for the performance assessment of the external auditor include an evaluation of: its technical and operational competence; its independence and objectivity; the sufficiency of the resources it has employed; its focus on areas of significant risk to Novartis; its willingness to probe and challenge; its ability to provide effective, practical recommendations; and the openness and effectiveness of its communications and coordination with the ACC, the Internal Audit function and management. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Once a year, the Auditor in charge and the Global Audit Partner report to the Board on the external auditor&#x2019;s activities during the current year, and on the audit plan for the coming year. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">On an annual basis, the external auditor provides the ACC with written disclosures required by the US Public Company Accounting Oversight Board, and the committee and the external auditor discuss the external auditor&#x2019;s independence from Novartis. </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">155</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId001017303"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Information policy</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis is committed to open and transparent communication with shareholders, investors, financial analysts, customers, suppliers and other stakeholders. Novartis disseminates information about material developments in its businesses in a broad and timely manner that complies with the rules of the SIX Swiss Exchange and&#xA0;the NYSE.  </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Communications</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis publishes this Annual Report to provide information on the Group&#x2019;s results and operations. Novartis discloses financial results in accordance with IFRS on a quarterly basis, and issues press releases from time to time regarding business developments.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis publishes press releases related to financial results and material events to the US Securities and Exchange Commission (SEC) via Form 6-K. An archive containing annual reports, US SEC Form 20-F, quarterly results releases and all related materials &#x2013; including presentations and conference call webcasts &#x2013; is available at www.novartis.com/investors.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis also publishes a Novartis in Society Integrated Report, available at www.reporting.novartis.com, which highlights progress on the Company&#x2019;s strategic priorities and describes how Novartis creates value for diverse stakeholders. The Novartis in Society Integrated Report has been prepared in alignment with the Integrated Reporting Framework (part of the IFRS Foundation), the Task Force on Climate-related Financial Disclosures (TCFD), the Sustainability Accounting Standards Board (SASB) and the latest non-financial standards issued by the Global Reporting Initiative (GRI). It also contains our main disclosures against the Company&#x2019;s reporting requirement as a signatory of the United Nations Global Compact.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The information on Board and Executive Committee compensation is outlined in the Compensation Report (see &#x201C;&#x2014;Item 6.B Compensation&#x201D; in general, and for certain compensation information with respect to our Board that is responsive to Item 6.C.2 of Form 20-F, see &#x201C;&#x2014;Item 6.B Compensation&#x2014;2022 Board compensation&#x2014;Philosophy and benchmarking&#x201D;). Please also refer to articles 29-35 of the Articles of Incorporation (www.novartis.com/investors/company-overview/corporate-governance). There are no change-of-control or &#x2018;golden parachute&#x2019; clauses benefiting Board members, Executive Committee members, or other members of senior management. Employment contracts with Executive Committee members are either for a fixed term not exceeding one year or for an  indefinite period with a notice period not exceeding 12&#xA0;months, and do not contain commissions for the acquisition or transfer of enterprises or severance payments. No loans or credits are granted to Board and Executive Committee members.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Information contained in reports and releases issued by Novartis is only correct and accurate at the time of release. Novartis does not update past releases to reflect subsequent events, and advises against relying on them for current information. </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Investor Relations </span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Investor Relations manages the Group&#x2019;s interactions with the international financial community. Several events are held each year to provide institutional investors and analysts with various opportunities to learn more about Novartis.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Investor Relations is based at the Group&#x2019;s headquarters in Basel. Part of the team is located in the US to coordinate interaction with US investors. More information is available at www.novartis.com/investors.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Website information</span>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="top">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">Topic</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Information</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Share capital</div>
            </td>
            <td style=";width:1%;"></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Articles of Incorporation of Novartis AG <br /> www.novartis.com/investors/company-overview/corporate-governance<br /> Novartis key share data<br /> www.novartis.com/investors/share-data-analysis</div>
            </td>
            <td style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Shareholder rights</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Articles of Incorporation of Novartis AG <br /> www.novartis.com/investors/company-overview/corporate-governance</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Annual General Meeting of Shareholders</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Annual General Meeting of Shareholders<br /> www.novartis.com/investors/shareholder-information/annual-general-meeting</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Board Regulations</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Board Regulations<br /> www.novartis.com/investors/company-overview/corporate-governance</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis code for senior financial officers</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Code of Ethical Conduct for CEO and Senior Financial Officers<br /> www.novartis.com/investors/company-overview/corporate-governance</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis in Society Integrated Report</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis in Society Integrated Report<br /> www.reporting.novartis.com</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis financial data</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis financial data<br /> www.novartis.com/investors/financial-data</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Press releases</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Press releases<br /> www.novartis.com/news/news-archive?type=media_release<br /> Email service<br /> www.novartis.com/news/stay-up-to-date</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Additional information <br />(including Novartis investor event calendar, registered office, <br />contact and email addresses, phone numbers, etc.)</div>
            </td>
            <td></td>
            <td>
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Investor Relations <br /> www.novartis.com/investors<br /></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">156</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId001017445"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Quiet periods</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to our Global Insider Policy, employees who have access to material non-public information on a regular basis are designated as Continuing Insiders and are banned from trading in Novartis securities during quiet periods. Limited exemptions for the expiry of options or warrants within a quiet period apply. Until June 14, 2022, our quarterly quiet periods commenced at the beginning of the last trading day of each calendar quarter and ended at the beginning of the first trading day after the subsequent release of the quarterly and/or annual results. Effective June 15, 2022, our quarterly quiet periods commence on the first trading day of each calendar quarter and end at the beginning of the first trading day after the subsequent release of the quarterly and/or annual results.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, the following quiet periods applied:</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  December 30, 2021, until (and including) February 2, 2022</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  March 31, 2022, until (and including) April 26, 2022</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  July 1, 2022, until (and including) July 19, 2022</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  October 1, 2022, until (and including) October 25, 2022</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">157</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00510930"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">6.D Employees</p>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The table below sets forth the breakdown of the total year-end number of our full-time equivalent employees by main category of activity and geographic area for the past three years.</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">For the year ended<br />December 31, 2022<br />(full-time equivalents)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Marketing and<br /> sales</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Production and<br /> supply</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Research and<br />  development</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Operations<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> General and <br /> administration</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Total</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USA</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6&#xA0;003</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;740</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;358</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 825</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 599</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:7%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&#xA0;525</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;678</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 809</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 514</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&#xA0;071</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 270</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&#xA0;342</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&#xA0;078</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18&#xA0;781</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;483</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;028</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&#xA0;483</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 50&#xA0;853</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&#xA0;856</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&#xA0;841</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&#xA0;841</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&#xA0;513</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 932</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 30&#xA0;983</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 38&#xA0;615</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 25&#xA0;171</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 21&#xA0;196</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12&#xA0;437</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&#xA0;284</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 101&#xA0;703</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">For the year ended<br />December 31, 2021<br />(full-time equivalents)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Marketing and<br /> sales</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Production and<br /> supply</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Research and<br />  development</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Operations<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> General and <br /> administration</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Total</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USA</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&#xA0;074</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;938</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&#xA0;324</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 879</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 654</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&#xA0;869</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;116</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;426</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 510</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;116</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 370</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&#xA0;538</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&#xA0;163</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&#xA0;630</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&#xA0;307</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&#xA0;108</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;613</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 50&#xA0;821</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16&#xA0;927</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;570</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;812</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&#xA0;696</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;090</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 32&#xA0;095</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 41&#xA0;280</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24&#xA0;564</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&#xA0;953</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&#xA0;799</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&#xA0;727</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 104&#xA0;323</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">For the year ended<br />December 31, 2020<br />(full-time equivalents)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Marketing and<br /> sales</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Production and<br /> supply</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> Research and<br />  development</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Operations<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br /> General and <br /> administration</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Total</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">USA</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&#xA0;978</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;954</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&#xA0;554</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 636</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 820</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&#xA0;942</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;405</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;286</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 504</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 928</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 401</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&#xA0;524</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16&#xA0;066</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&#xA0;628</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&#xA0;043</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;506</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&#xA0;852</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 52&#xA0;095</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&#xA0;240</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&#xA0;346</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;537</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&#xA0;991</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&#xA0;119</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31&#xA0;233</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 42&#xA0;689</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 26&#xA0;214</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&#xA0;638</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 11&#xA0;061</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&#xA0;192</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 105&#xA0;794</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="14" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="14">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> relates to full time equivalent employees (FTEs) from our Operations unit, excluding the Operations units&#x2019; production and supply FTEs</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As of December 31, 2022, the total number of our full-time equivalent employees decreased by 2 620 compared with December 31, 2021, mainly driven by the initiative announced in April 2022 to implement a new, streamlined organizational model. For more information about this new organizational structure, see &#x201C;Item 4. Information on the Company&#x2014;Item 4.B Overview.&#x201D; </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A significant number of our employees are represented by unions or works councils. We have not experienced any material work stoppages in recent years, and we consider our employee relations to be good.</div>
      <div id="anchorId00511785"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">6.E Share ownership</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The information set forth under &#x201C;Item 6. Directors, Senior Management and Employees&#x2014;Item 6.B Compensation&#x2014;2021 Executive Committee compensation&#x2014;Additional disclosures for the CEO and other Executive Committee members&#x2014;Shares, ADRs and other equity rights owned by Executive Committee members at December&#xA0;31, 2021&#x201D; and under &#x201C;Item 6. Directors, Senior Management and Employees&#x2014;Item 6.B Compensation&#x2014;2021 Board compensation&#x2014;Additional disclosures&#x2014;Shares, ADRs and share options owned by Board members&#x201D; is incorporated by reference. For more information on our equity-based participation plans, see the information set forth under &#x201C;Item 18. Financial Statements&#x2014;Note&#xA0;26. Equity&#x2011;based participation plans for employees,&#x201D; which is incorporated by reference.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">158</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00511806"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;7.  Major Shareholders and Related Party Transactions</p>
      <div id="anchorId00511809"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">7.A Major shareholders</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis shares are widely held. As of December&#xA0;31, 2022, Novartis had approximately 186 000 shareholders listed in the Share Register of Novartis, representing approximately 67.0% of issued shares. Based on the Novartis Share Register and excluding treasury shares, approximately 48.4% of the shares registered by name were held in Switzerland, and approximately 21.3% were held in the US. Approximately 15.6% of the shares registered in the Share Register were held by individual investors, while approximately 37.7% were held by legal entities (excluding 7.7% of our share capital held as treasury shares by Novartis AG or its fully owned subsidiaries), and 46.7% were held by nominees, fiduciaries and the ADS depositary. Due to a change in Swiss corporate law, as of January 1, 2023, Novartis ordinary shares held by certain Swiss foundations controlled by Novartis (Foundation Shares) no longer carry the right to vote. As a result, in the future these Foundation Shares will be excluded from the calculation of the shares registered in the Share Register in the same way, as described above, that our treasury shares are excluded. This will impact some of the percentage holdings reported in this Item 7.A in future Form 20-F filings by Novartis.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Based on the Share Register, we believe that we are not directly or indirectly owned or controlled by another corporation or government, or by any other natural or legal persons. There are no arrangements that may result in a change of control.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The tables below set forth information with respect to our major shareholders according to the Share Register as of December 31, 2022, excluding 7.7% of our share capital held as treasury shares by Novartis AG or its fully owned subsidiaries. The following registered shareholders (including nominees and the ADS depositary) held more than 2% of the total share capital of Novartis with the right to vote all their Novartis shares based on an exemption granted by the Board of Directors:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % of respective share capital beneficially owned   as of:</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Ordinary shares<br /> beneficially owned as of <br /> Dec 31, 2022</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
              </div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Dec 31, 2022</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;">
                <br />
                <br />
              </div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Dec 31, 2021</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;">
                <br />
                <br />
              </div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Dec 31, 2020</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Shareholders registered for their own account:</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Emasan AG, Basel, Switzerland</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 89&#xA0;135&#xA0;960</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.7</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.7</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.6</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">UBS Fund Management (Switzerland) AG, Basel, Switzerland</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 55&#xA0;906&#xA0;821</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.3</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.3</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credit Suisse Funds AG, Zurich, Switzerland</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49&#xA0;335&#xA0;879</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.1</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.0</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="10" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:10px;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
            <td></td>
            <td align="center" colspan="5" style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> % of respective share capital held as of:</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr>
            <td style=";height:3;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td style=";height:1;"></td>
            <td colspan="5" style=";height:3;"></td>
            <td style=";height:1;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Ordinary shares<br /> held as of <br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Dec 31, 2022</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Dec 31, 2021</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                <br />
                <br /> Dec 31, 2020</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Shareholders registered as nominees:</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chase Nominees Ltd., London, England</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 201&#xA0;853&#xA0;725</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8.8</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.6</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nortrust Nominees Ltd., London, England</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 90&#xA0;962&#xA0;072</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.8</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">The Bank of New York Mellon, New York, NY</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 68&#xA0;638&#xA0;910</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.9</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.0</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Through The Bank of New York Mellon, Everett, MA</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 37&#xA0;227&#xA0;478</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 1.6</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 1.6</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 1.7</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Through The Bank of New York Mellon, New York, NY</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 22&#xA0;583&#xA0;699</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 0.9</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 1.1</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 1.2</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Through The Bank of New York Mellon, SA/NV, Brussels, Belgium</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 8&#xA0;827&#xA0;733</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 0.4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 0.3</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 0.5</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Shareholder acting as American Depositary Share (ADS) depositary:</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">JPMorgan Chase Bank, N.A., New York, NY</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 225&#xA0;529&#xA0;101</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9.4</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11.1</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:9%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11.7</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to a disclosure notification filed with Novartis AG, Norges Bank (Central Bank of Norway), Oslo, Norway, held 2.3% of the share capital of Novartis AG, or  54 667 792 shares, as of December&#xA0;31, 2022, but was not registered in the Share Register as of December&#xA0;31, 2022. Provided that these shares are registered in the Share Register on the record date of the Annual General Meeting, Norges Bank will have full voting rights for all of these shares. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">According to a disclosure notification filed with Novartis AG and the SIX Swiss Exchange, BlackRock,&#xA0;Inc., New&#xA0;York, NY, held between 5% and 10%, but was registered with less than 2% of the share capital of </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">159</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG in the Share Register as of December&#xA0;31, 2022.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of December&#xA0;31, 2022, no other shareholder was registered as owner of more than 2% of the registered share capital.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Articles of Incorporation provide that no shareholder shall be registered with the right to vote shares comprising more than 2% of the registered share capital. The Board of Directors may, upon request, grant an exemption from this restriction. Considerations include whether the shareholder supports the Novartis goal of creating sustainable value and has a long-term investment horizon. Exemptions are in force for the registered major shareholders as described above. Novartis has not entered into any agreement with any shareholder regarding the voting or holding of Novartis shares.</div>
      <div id="anchorId00512258"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">7.B Related party transactions</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The information set forth under &#x201C;Item 18. Financial Statements&#x2014;Note&#xA0;27. Transactions with related parties&#x201D; is incorporated by reference. </div>
      <div id="anchorId00512264"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">7.C Interests of experts and counsel</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">160</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00512270"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;8.  Financial Information</p>
      <div id="anchorId00512273"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">8.A Consolidated statements and other financial information</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">See &#x201C;Item&#xA0;18. Financial Statements.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Dividend policy</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Subject to the dividend policy described below, our Board of Directors expects to recommend the payment of a dividend in respect of each financial year. If approved by our shareholders at the relevant annual shareholders&#x2019; meeting, the dividends will be payable shortly following such approval. Any shareholder who purchases our shares before the ex&#x2011;dividend date and holds the shares until that date shall be deemed to be entitled to receive the dividends approved at that meeting. Dividends are reflected in our financial statements in the year in which they are approved by our shareholders.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our dividend policy is to pay a growing annual dividend in Swiss francs per share. This policy is subject to our financial conditions and outlook at the time, the results of our operations, and other factors.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Board will propose a dividend of CHF 3.20 per share to the shareholders for approval at the Annual General Meeting to be held on March 7, 2023. Because we pay dividends in Swiss francs, exchange rate fluctuations will affect the US dollar amounts received by holders of ADRs. For the amount of dividends we paid in the past three years, see &#x201C;Item 18. Financial Statements&#x2014;Note 18&#x2014;Equity.&#x201D; </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Disclosure pursuant to Section&#xA0;219 of the Iran Threat Reduction&#xA0;and Syria Human Rights Act (ITRA)</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At Novartis, our purpose is to reimagine medicine to improve and extend people&#x2019;s lives, regardless of where they live. This includes the compliant sale of medicines and other healthcare products worldwide. To help us fulfill this mission, we have for many years maintained two representative offices located in Iran.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of October&#xA0;18, 2010, a non&#x2011;US affiliate within our Innovative Medicines Division entered into a non&#x2011;binding Memorandum of Understanding (MoU) with the Ministry of Health and Medical Education of the Islamic Republic of Iran. Pursuant to the MoU, the Iranian Ministry of Health acknowledges certain benefits that may apply to sales of certain Innovative Medicines Division medicines by third&#x2011;party distributors in Iran. These include fast&#x2011;track registration, market exclusivity, end&#x2011;user subsidies, and exemptions from customs tariffs. Novartis receives no payments from the Iranian Ministry of Health under the MoU, and the MoU creates no obligations on the part of either Novartis or the Iranian Ministry of Health.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">From time to time, including in 2022, non&#x2011;US affiliates in our Innovative Medicines and Sandoz Divisions made payments to government entities in Iran related to patents, trademarks, exit fees and other transactions ordinarily incident to travel by doctors and other medical professionals resident in Iran to attend conferences or other events outside Iran. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">From time to time, including in 2022, non&#x2011;US affiliates in our Innovative Medicines and Sandoz Divisions enter into agreements with hospitals, research institutes, medical associations and universities in Iran to provide grants and sponsor congresses, seminars and symposia, and with doctors and other healthcare professionals for consulting services, including participation in advisory boards and investigator services for observational (non&#x2011;interventional) studies. Some hospitals and research institutes are owned or controlled by the government of Iran, and some doctors and healthcare professionals are employed by hospitals that may be public or government&#x2011;owned.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Because our Innovative Medicines and Sandoz Divisions have operations in Iran, including employees, they obtain services and have other dealings incidental to their activities in that country, including paying taxes and salaries either directly or indirectly through a service provider, and obtaining office rentals, insurance, electricity, water and telecommunications services, office and similar supplies, and customs&#x2011;related services from Iranian companies that may be owned or controlled by the government of Iran. In addition, from time to time, representatives of our non-US affiliates participate in meetings with Iranian officials to discuss issues relevant to our business and the pharmaceutical industry.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Non-US affiliates in our Innovative Medicines and Sandoz Divisions maintain local accounts at banks that are, as of November 5, 2018, on the Specially Designated Nationals and Blocked Persons List (SDN List). These non-US affiliates make local transactions for employee payroll and local vendor payment purposes. These transactions are conducted for the purpose of facilitating the provision of medicine to Iran, in line with the humanitarian exceptions contained in Section 11 of Executive Order 13902 and other applicable sanctions legal authorities. No transactions are made with an Iranian financial institution designated on the SDN List in connection with Iran&#x2019;s support for international terrorism or proliferation of weapons of mass destruction. </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">161</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"></div>
      <div id="anchorId00512314"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">8.B Significant changes</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">None.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">162</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div id="anchorId00512321"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;9.  The Offer and Listing</p>
      <div id="anchorId00512324"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">9.A Offer and listing details</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our shares are listed in Switzerland on the SIX Swiss Exchange (SIX).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">ADSs, each representing one share, have been available in the US through an ADR program since December 1996. This program was established pursuant to a deposit agreement that we entered into with JPMorgan Chase Bank, N.A., as depositary (&#x201C;Deposit Agreement&#x201D;). Our ADRs have been listed on the NYSE since May 2000 and are traded under the symbol NVS.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The depositary has informed us that as of January 25, 2023, there were 220 million ADRs outstanding, each representing one Novartis share (approximately 9% of total Novartis shares issued). On January 25, 2023, the closing price was CHF 85.30 per share on the SIX, and USD 92.81 per ADR on the NYSE.</div>
      <div id="anchorId00512332"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">9.B Plan of distribution</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div id="anchorId00512336"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">9.C Markets</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">See &#x201C;&#x2014;Item&#xA0;9.A Offer and listing details.&#x201D;</div>
      <div id="anchorId00512342"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">9.D Selling shareholders</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div id="anchorId00512346"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">9.E Dilution</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div id="anchorId00512350"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">9.F Expenses of the issue</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">163</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00512356"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;10.  Additional Information</p>
      <div id="anchorId00512359"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.A Share capital</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div id="anchorId00512363"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.B Memorandum and articles of association</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following is a non-exhaustive summary of certain provisions of our Articles of Incorporation (&#x201C;Articles&#x201D;); our Regulations of the Board, the Board Committees and the Executive Committee (&#x201C;Board Regulations&#x201D;); and Swiss law, particularly the Swiss Code of Obligations (&#x201C;Swiss CO&#x201D;), and is qualified in its entirety by reference to the Articles and the Board Regulations, which are an exhibit to this Form&#xA0;20&#x2011;F, and to Swiss law.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.1 Company purpose</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG is registered in the commercial register of the canton of Basel&#x2011;Stadt, Switzerland, under number CHE&#x2011;103.867.266. Our business purpose, as stated in Article&#xA0;2 of the Articles, is to hold interests in enterprises in the area of healthcare or nutrition. We may also hold interests in enterprises in the areas of biology, chemistry, physics, information technology or related areas. We may acquire, mortgage, liquidate or sell real estate and intellectual property rights in Switzerland or abroad. In pursuing our business purpose, we strive to create sustainable value.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.2 Directors</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to our Articles, the Board of Directors (&#x201C;Board&#x201D;) consists of a minimum of eight and a maximum of 16 members. The members of the Board (including the Board Chair) are elected individually by the General Meeting of Shareholders (&#x201C;General Meeting&#x201D;) for a one-year term of office lasting until completion of the next Annual General Meeting of Shareholders (&#x201C;AGM&#x201D;).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(a)   A Board resolution requires the affirmative majority of the votes cast. According to our Board Regulations, a member of our Board (&#x201C;Director&#x201D;) may not participate in decisions and resolutions on matters that affect, or reasonably might affect, the Director&#x2019;s interests or the interests of a person close to the Director. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(b)  Compensation of the Directors is subject to the approval of the aggregate amounts of such compensation by a shareholders&#x2019; resolution under the Ordinance against Excessive Compensation in Public Companies of the Swiss Federal Council.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(c)  The Articles prohibit the granting of loans or credits to Directors.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(d)  The Articles provide that a Director shall not serve on the Board for more than 12 years. The Board may, under certain circumstances and if deemed in the best interests of the Company, recommend exceptions to this rule to the General Meeting.  </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(e)  Our Directors are not required to be shareholders at the time of the election by the General Meeting. However, according to our share ownership guidelines, the Board Chair is required to own a minimum of 30 000 Novartis AG shares, and other Directors are required to own at least 5 000 Novartis AG shares within five years after joining the Board, to ensure their interests are aligned with those of our shareholders.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.3 Shareholder rights</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Because Novartis AG has only one class of registered shares, the following information applies to all shareholders.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(a)  Under the Swiss CO, we may only pay dividends out of balance sheet profits or out of distributable reserves. In any event, under the Swiss CO, while the Board may propose that a dividend be paid, we may only pay dividends upon shareholders&#x2019; approval at a General Meeting. Furthermore, the Swiss CO requires us to accrue general legal reserves under certain circumstances so long as these reserves amount to less than 20% of our registered share capital, and Swiss law and the Articles permit us to accrue additional reserves beyond the statutory reserves. Our auditors must confirm that the dividend proposal of our Board conforms with the Swiss CO and the Articles. Our Board expects to recommend the payment of a dividend in respect of each financial year. See &#x201C;Item 6. Directors, Senior Management and Employees&#x2014;Item 6.C Board Practices&#x2014;Capital Structure&#x2014;Limitation on transferability&#x2014;Per-share information&#x201D; and &#x201C;Item&#xA0;8.&#xA0;Financial Information&#x2014;Item&#xA0;8.A. Consolidated statements and other financial information&#x2014;Dividend policy.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">Dividends are usually due and payable shortly after the shareholders have passed a resolution approving the payment. Dividends that have not been claimed within five years after the due date revert to us and are allocated to our general reserves. For information about deduction of the withholding tax or other duties from dividend payments, see &#x201C;&#x2014;Item&#xA0;10.E Taxation.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">164</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(b)  Each share is entitled to one vote at a General Meeting. Voting rights may only be exercised for shares registered with the right to vote on the record date for the applicable General Meeting. In order to do so, the shareholder must file&#xA0;a share registration form with us, setting forth the shareholder&#x2019;s name, address and citizenship (or, in the case of a legal entity, its registered office). If the shareholder has not timely registered its shares, then the shareholder may not vote at, or participate in, a General Meeting.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">To vote its shares, the shareholder must also explicitly declare that it has acquired the shares in its own name and for its own account. If the shareholder refuses to make such a declaration, the shares may not be voted unless the Board recognizes such shareholder as a nominee.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">The Articles provide that no shareholder shall be registered with the right to vote shares comprising more than 2% of the registered share capital. The Board may, upon request, grant an exemption from this restriction. Considerations include whether the shareholder supports our goal of creating sustainable value and has a long&#x2011;term investment horizon. Furthermore, the Articles provide that no nominee shall be registered with the right to vote shares comprising more than 0.5% of the registered share capital. The Board may, upon request, grant an exemption from this restriction if the nominee discloses the names, addresses, and number of shares of the persons for whose account it holds 0.5% or more of the registered share capital. The same restrictions indirectly apply to ADR holders. We have in the past granted exemptions from the 2% rule for shareholders and the 0.5% rule for nominees. </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">For purposes of the 2% rule for shareholders and the 0.5% rule for nominees, groups of companies and groups of shareholders acting in concert are considered to be one shareholder. These rules also apply to shares acquired or subscribed by the exercise of subscription, option or conversion rights.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">After hearing the registered shareholder or nominee, the Board may cancel, with retroactive effect as of the date of registration, the registration of the shareholders if the registration was effected based on false information.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">Registration restrictions in the Articles may only be removed upon a resolution carrying a two&#x2011;thirds majority of the votes represented at a General Meeting.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">Except as noted below, shareholders&#x2019; resolutions require the approval of an absolute majority of the votes present at a General Meeting. As a result, abstentions have the effect of votes against such resolutions. Some examples of shareholders&#x2019; resolutions requiring a vote by such &#x201C;absolute majority of the votes&#x201D; are: </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Adoption and amendment of the Articles </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Election and removal of the Board Chair, the Board and Compensation Committee members, the Independent Proxy and the external auditor</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Approval of the management report and of the consolidated financial statements</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Approval of the financial statements of Novartis AG, and decision on the appropriation of available earnings shown on the balance sheet, including dividends, if any</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Approval of the maximum aggregate compensation of the Board (from an AGM until the next AGM) and of the Executive Committee (for the financial year following the AGM)</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Discharge of Board and Executive Committee members from liability for matters disclosed to the General Meeting</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Decision on other matters that are reserved by law or by the Articles (e.g., advisory vote on the Compensation Report) to the General Meeting</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">According to the Articles and Swiss law, the following matters require the approval of a &#x201C;supermajority&#x201D; of at least two&#x2011;thirds of the votes present at a General Meeting: </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Alteration of the purpose of Novartis AG</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Creation of shares with increased voting powers</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Implementation of restrictions on the transfer of registered shares, and the removal of such restrictions</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Authorized or conditional increase of the share capital</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Increase of the share capital out of equity, by contribution in kind, for the purpose of an acquisition of property or the grant of special rights</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Restriction or cancellation of subscription rights</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;   Change of the registered office of Novartis&#xA0;AG</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:40px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">&#x2022;  Dissolution of Novartis AG</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">In addition, the law provides for a qualified majority for other resolutions, such as a merger or demerger.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">Our shareholders are required to annually elect all Directors (including the Board Chair), the Compensation Committee members, the external auditor and the Independent Proxy. The Articles do not provide for cumulative voting of shares.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">At a General Meeting, shareholders can be represented by a proxy, which must either be the shareholder&#x2019;s legal representative, another shareholder with the right to vote, or the Independent Proxy. Votes are taken either by a show of hands or by electronic voting, unless the General Meeting resolves to have a ballot or where a ballot is ordered by the chair of the meeting. ADSs, each representing one Novartis AG share and evidenced by ADRs, are issued by our depositary JPMorgan Chase Bank, N.A., New York, and not by us. The ADR is vested with rights defined and enumerated in the Deposit Agreement (such as the rights to vote, to receive a dividend and to receive a share of Novartis AG in exchange for a certain number of </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">165</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;">ADRs). The enumeration of rights, including any limitations on those rights in the Deposit Agreement, is final. There are no other rights given to the ADR holders. Only the ADS depositary, holding our shares underlying the ADRs, is registered as shareholder in our share register. An ADR is not a Novartis AG share and an ADR holder is not a Novartis AG shareholder.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">The Deposit Agreement between our depositary, the ADR holder and us has granted certain indirect rights to vote to the ADR holders. ADR holders may not attend a General Meeting in person. ADR holders exercise their voting rights by instructing JPMorgan Chase Bank, N.A., our depositary, to exercise the voting rights attached to the registered shares underlying the ADRs. Each ADR represents one Novartis AG share. JPMorgan Chase Bank, N.A., exercises the voting rights for registered shares underlying ADRs for which no voting instructions have been given by providing a discretionary proxy to an uninstructed independent designee. Such designee has to be a shareholder of Novartis AG. The same voting restrictions apply to ADR holders as to those holding Novartis AG shares (i.e., the right to vote up to 2% of the Novartis AG registered share capital &#x2013; unless otherwise granted an exemption by the Board &#x2013; and the disclosure requirement for nominees).</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(c)  Shareholders have the right to allocate the profit shown on our balance sheet and to distribute dividends by vote taken at the General Meeting, subject to the legal requirements described in &#x201C;Item&#xA0;10.B.3(a) Shareholder rights.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(d)  Under the Swiss CO, any surplus arising out of a liquidation of Novartis AG (i.e., after the settlement of all claims of all creditors) would be distributed to the shareholders in proportion to the paid&#x2011;in nominal value of their shares.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(e)  The Swiss CO limits a corporation&#x2019;s ability to hold or repurchase its own shares. We and our subsidiaries may only repurchase shares if we have sufficient freely disposable equity in the amount of the purchase price of the acquired shares. The aggregate nominal value of all Novartis AG shares held by us and our subsidiaries may not exceed 10% of our registered share capital. However, it is accepted that a Swiss corporation may repurchase its own shares beyond the statutory limit of 10% if the repurchased shares are clearly earmarked for cancellation. In addition, we are required to recognize a negative position, or if our subsidiaries acquire our shares, to create a special reserve on our balance sheet in the amount of the purchase price of the acquired shares. Repurchased shares held by us or our subsidiaries do not carry any rights to vote at a General Meeting, but are entitled to the economic benefits generally connected with the shares. The definition of subsidiaries, and therefore, treasury shares, for purposes of the above-described reserves requirement and voting restrictions, differs from the definition of subsidiaries for purposes of consolidation in our consolidated financial statements. The definition in the consolidated financial statements requires consolidation for financial reporting purposes of special purpose entities in instances where we have the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities. Therefore, our consolidated financial statements include special purpose entities, mainly foundations, which do not qualify as subsidiaries subject to the reserve requirements and voting restrictions of the Swiss CO because we do not hold a majority participation in these special purpose entities. Accordingly, no reserve requirements apply to shares held by such special purpose entities, and such entities are not restricted from independently voting their shares.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">Under the Swiss CO, we may not cancel treasury shares without the approval of a capital reduction by our shareholders.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(f)  Not applicable.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(g)  Since all of our issued and outstanding shares have been fully paid in, our shareholders are not obliged to make further contributions with respect to their shares. </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(h)   See &#x201C;&#x2014;Item&#xA0;10.B.3(b) Shareholder rights&#x201D; and &#x201C;&#x2014;Item&#xA0;10.B.7 Change in control.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.4 Changes to shareholder rights</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Under the Swiss CO, we may not issue new shares without the prior approval of a capital increase by our shareholders. If a capital increase is approved, then our shareholders would generally have certain pre-emptive rights to obtain newly issued shares in an amount proportional to the nominal value of the shares they already hold. These pre-emptive rights could be excluded in certain limited circumstances with the approval of a resolution adopted at a General Meeting by a supermajority of two&#x2011;thirds of the votes. In addition, we may not create shares with increased voting powers or place restrictions on the transfer of registered shares without the approval of a resolution adopted at a General Meeting by a supermajority of votes. In addition, see &#x201C;&#x2014;Item&#xA0;10.B.3(b) Shareholder rights&#x201D; with regard to the Board&#x2019;s ability to cancel the registration of shares under limited circumstances.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.5 Shareholder meetings</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Under the Swiss CO and the Articles, we must hold an AGM within six months after the end of our financial year. A General Meeting may be convened by the Board or, if necessary, by the external auditor. The Board is further required to convene an extraordinary General Meeting if so resolved by a General Meeting, or if so requested by shareholders representing at least 10% of the share capital, specifying the items for the agenda and their proposals. Shareholders representing shares with an aggregate nominal value of at least CHF&#xA0;1&#xA0;000&#xA0;000 may request that an item be included in a General Meeting agenda. A General Meeting is convened by publishing a notice in the Swiss Official Gazette of Commerce  (Schweizerisches Handelsamtsblatt) at least 20&#xA0;days prior to such meeting. Shareholders may also be informed by mail. Neither the Swiss CO nor the Articles require a quorum for a General Meeting. In addition, see &#x201C;&#x2014;Item&#xA0;10.B.3(b) Shareholder rights&#x201D; regarding conditions for exercising a shareholder&#x2019;s right to vote at a General Meeting.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">166</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.6 Limitations</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There are no limitations under the Swiss CO or our Articles on the right of non&#x2011;Swiss residents or nationals to own or vote shares other than the restrictions applicable to all shareholders. But see &#x201C;&#x2014;Item&#xA0;10.B.3(b) Shareholder rights&#x201D; regarding conditions for exercising an ADR holder&#x2019;s right to vote at a shareholder meeting.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.7 Change in control</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Articles and the Board Regulations contain no provision that would have an effect of delaying, deferring or preventing a change in control of Novartis AG and that would operate only with respect to a merger, acquisition or corporate restructuring involving us or any of our subsidiaries.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">According to the Swiss Merger Act, shareholders may pass a resolution to merge with another corporation at any time. Such a resolution would require the consent of at least two&#x2011;thirds of all votes present at the necessary General Meeting.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Under the Swiss Financial Market Infrastructure Act, shareholders and groups of shareholders acting in concert who acquire more than 33 1/3% of our shares would be under an obligation to make an offer to acquire all remaining Novartis AG shares. Novartis AG has neither opted out from the mandatory takeover offer obligation nor opted to increase the threshold for mandatory takeover offers in its Articles.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.8 Disclosure of shareholdings</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Under the Swiss Financial Market Infrastructure Act, persons who directly, indirectly or in concert with other parties acquire or dispose of our shares or purchase or sale rights relating to our shares are required to notify us and the SIX of the level of their holdings whenever such holdings reach, exceed or fall below certain thresholds &#x2013; 3%, 5%, 10%, 15%, 20%, 25%, 33 1/3%, 50% and 66 2/3% &#x2013; of the voting rights represented by our share capital (whether exercisable or not). This also applies to anyone who has discretionary power to exercise voting rights associated with our shares. Following receipt of such notification, we are required to inform the public by publishing the information via the electronic publication platform operated by the SIX.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">An additional disclosure obligation exists under the Swiss CO that requires us to disclose, once a year in the notes to the financial statements published in our Annual Report, the identity of all of our shareholders (or related groups of shareholders) who have been granted exemption entitling them to vote more than 2% of our registered share capital, as described in &#x201C;&#x2014;Item&#xA0;10.B.3(b) Shareholder rights.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.9 Differences in the law</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">See the references to Swiss law throughout this &#x201C;&#x2014;Item&#xA0;10.B Memorandum and articles of association.&#x201D;</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">10.B.10 Changes in capital</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The requirements of the Articles regarding changes in capital are not more stringent than the requirements of Swiss law.</div>
      <div id="anchorId00512619"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.C Material contracts</p>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Acquisition of The Medicines Company</span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 23, 2019, we entered into an Agreement and Plan of Merger (the &#x201C;Merger Agreement&#x201D;) with US-based pharmaceutical company The Medicines Company. Pursuant to the Merger Agreement, on December 5, 2019, Novartis, through a subsidiary, commenced a tender offer to acquire all outstanding shares of The Medicines Company for USD 85 per share, or a total consideration of approximately USD 9.6 billion in cash on a fully diluted basis. The tender offer expired on January 3, 2020, and on January 6, 2020, the acquiring subsidiary merged with and into The Medicines Company, resulting in The Medicines Company becoming an indirect wholly owned subsidiary of Novartis. This merger broadens our cardiovascular portfolio by adding inclisiran, an investigational cholesterol-lowering therapy.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Divestment of Roche shares </span>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 3, 2021, we entered into a Share Repurchase Agreement with Roche under which we agreed to sell 53.3 million (approximately 33%) of Roche bearer shares in a bilateral transaction to Roche for a total consideration of USD 20.7 billion. The transaction was approved by the shareholders of Roche on November&#xA0;26,&#xA0;2021, and closed on December 6, 2021.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">167</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00512634"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.D Exchange controls</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There are no Swiss governmental laws, decrees or regulations that affect &#x2013; in a manner material to Novartis AG &#x2013; the export or import of capital, including the availability of cash and cash equivalents for use by Novartis or any foreign exchange controls that affect the remittance of dividends, interest or other payments to non&#x2011;residents or non&#x2011;citizens of Switzerland who hold Novartis AG securities. </div>
      <div id="anchorId00512641"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.E Taxation</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The taxation discussion set forth below is intended only as a descriptive summary and does not purport to be a complete analysis or listing of all potential tax effects relevant to the ownership or disposition of our shares or ADRs. The statements of US and Swiss tax laws set forth below are based on the laws and regulations in force as of the date of this 20&#x2011;F &#x2013; including the current Convention Between the US and the Swiss Confederation for the Avoidance of Double Taxation with Respect to Taxes on Income, entered into force on December&#xA0;19, 1997 (&#x201C;the Treaty&#x201D;); the US Internal Revenue Code of 1986, as amended (&#x201C;the Code&#x201D;); Treasury regulations; rulings; judicial decisions; and administrative pronouncements &#x2013; and may be subject to any changes in US and Swiss law, and in any double taxation convention or treaty between the US and Switzerland occurring after that date, which changes may have retroactive effect.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Swiss taxation</span>
      </div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Swiss residents</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
        <i>Withholding Tax on dividends and distributions.</i>  Dividends that we pay and similar cash or in&#x2011;kind distributions that we may make to a holder of shares or ADRs (including distributions of liquidation proceeds in excess of the nominal value, stock dividends and, under certain circumstances, proceeds from repurchases of shares by us in excess of the nominal value) are generally subject to a Swiss federal withholding tax (&#x201C;the Withholding Tax&#x201D;) at a current rate of 35%. Under certain circumstances, distributions out of capital contribution reserves made by shareholders after December&#xA0;31, 1996, are exempt from the Withholding Tax. We are required to withhold Withholding Tax due from the gross distribution and to pay the Withholding Tax to the Swiss Federal Tax Administration. The Withholding Tax is refundable in full to Swiss tax residents who are the beneficial owners of the taxable distribution at the time it is resolved and duly report the gross distribution received on their personal tax return or in their financial statements for tax purposes, as the case may be.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">
        <i>Income tax on dividends.</i>  A Swiss tax resident who receives dividends and similar distributions (including stock dividends and liquidation surplus) on shares or ADRs is required to include such amounts in the shareholder&#x2019;s personal income tax return. However, distributions out of qualified capital contribution reserves are not subject to income tax. A corporate shareholder may claim substantial relief from taxation of dividends and similar distributions received if the shares held represent a fair market value of at least CHF&#xA0;1&#xA0;million.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">
        <i>Capital gains tax upon disposal of shares.</i>  Under current Swiss tax law, the gain realized on shares held by a Swiss resident who holds shares or ADRs as part of his private property is generally not subject to any federal, cantonal or municipal income taxation on gains realized on the sale or other disposal of shares or ADRs. However, gains realized upon a repurchase of shares by us may be characterized as taxable dividend income if certain conditions are met. Book gains realized on shares or ADRs held by a Swiss corporate entity or by a Swiss resident individual as part of the shareholder&#x2019;s business property are, in general, included in the taxable income of such person. However, the Federal Law on the Direct Federal Tax of December&#xA0;14, 1990, and several cantonal laws on direct cantonal taxes provide for exceptions for Swiss corporate entities holding more than 10% of our voting stock for more than one year.</div>
      <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Residents of other countries</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Recipients of dividends and similar distributions on our shares who are neither residents of Switzerland for tax purposes nor holding shares as part of a business conducted through a permanent establishment situated in Switzerland (&#x201C;Non&#x2011;Resident Holders&#x201D;) are not subject to Swiss income taxes in respect of such distributions. Moreover, gains realized by such recipients upon the disposal of shares are not subject to Swiss income taxes.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Non&#x2011;Resident Holders of shares are, however, subject to the Withholding Tax on dividends and similar distributions mentioned above and, under certain circumstances, to the Stamp Duty described below. Such Non&#x2011;Resident Holders may be entitled to a partial refund of the Withholding Tax if the country in which they reside has entered into a bilateral treaty for the avoidance of double taxation with Switzerland. Non&#x2011;Resident Holders should be aware that the procedures for claiming treaty refunds (and the time frame required for obtaining a refund) may differ from country to country. Non&#x2011;Resident Holders should consult their own tax advisors regarding receipt, ownership, purchase, sale or other dispositions of shares or ADRs, and the procedures for claiming a refund of the Withholding Tax.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">168</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of January&#xA0;1, 2023, Switzerland has entered into bilateral treaties for the avoidance of double taxation with respect to income taxes with the following countries, whereby a part of the above&#x2011;mentioned Withholding Tax may be refunded (subject to the limitations set forth in such treaties):</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="column-count: 4;column-gap: 10px;padding-top:10px;">
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Albania</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Algeria</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Argentina</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Armenia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Australia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Austria</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Azerbaijan</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Bahrain</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Bangladesh</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Belarus</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Belgium</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Brazil</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Bulgaria</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Canada</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Chile</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">China</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Colombia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Croatia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cyprus</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Czech Republic</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Denmark</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Ecuador</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Egypt</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Estonia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Finland</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">France</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Georgia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Germany</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Ghana</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Greece</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Hong Kong</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Hungary</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Iceland</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">India</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Indonesia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Iran</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Republic of Ireland</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Israel</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Italy</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Ivory Coast</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Jamaica</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Japan</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Kazakhstan</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Republic of Korea</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">(South Korea)</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Kosovo</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Kuwait</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Kyrgyzstan</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Latvia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Liechtenstein</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Lithuania</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Luxembourg</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Malaysia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Malta</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Mexico</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Moldova</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Mongolia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Montenegro</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Morocco</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Netherlands</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">New Zealand</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">North Macedonia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Norway</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Oman</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Pakistan</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Peru</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Philippines</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Poland</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Portugal</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Qatar</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Romania</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Russia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Saudi Arabia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Serbia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Singapore</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Slovak Republic</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Slovenia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">South Africa</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Spain</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sri Lanka</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sweden</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Taiwan</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Tajikistan</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Thailand</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Trinidad and Tobago</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Tunisia</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Turkey</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Turkmenistan</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Ukraine</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">United Arab Emirates</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">United Kingdom</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">United States of America</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Uruguay</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Uzbekistan</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Venezuela</div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Vietnam </div>
        <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Zambia</div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Tax treaty negotiations are underway, or have been conducted, with Angola, Bosnia and Herzegovina, Cameroon, Costa Rica, Ethiopia, Jordan, Kenya, Libya, Nigeria, Rwanda, Senegal, Syria and Zimbabwe. Tax treaty negotiations between Switzerland and some of the countries listed in the immediately preceding sentence have been ongoing for an extended period of time, and we are not certain when or if such negotiations will be completed, and when or if the corresponding treaties will come into effect.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">A Non&#x2011;Resident Holder of shares or ADRs will not be liable for any Swiss taxes other than the Withholding Tax described above and, if the transfer occurs through or with a Swiss bank or other Swiss securities dealer, the Stamp Duty described below. If, however, the shares or ADRs of Non&#x2011;Resident Holders can be attributed to a permanent establishment or a fixed place of business maintained by such person within Switzerland during the relevant tax year, the shares or ADRs may be subject to Swiss income taxes in respect of income and gains realized on the shares or ADRs, and such person may qualify for a full refund of the Withholding Tax based on Swiss tax law.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">
        <i>Residents of the US.</i>  A Non&#x2011;Resident Holder who is a resident of the US for purposes of the Treaty is eligible for a reduced rate of tax on dividends equal to 15% of the dividend, provided that such holder (i)&#xA0;qualifies for benefits under the Treaty, (ii)&#xA0;is not a company (or, if it is a company, such company directly holds less than 10% of our voting stock), and (iii)&#xA0;does not conduct business through a permanent establishment or fixed base in Switzerland to which the shares or ADRs are attributable. Such an eligible holder must apply for a refund of the amount of the Withholding Tax in excess of the 15% Treaty rate. A Non&#x2011;Resident Holder who is a resident of the US for purposes of the Treaty is eligible for a reduced rate of tax on dividends equal to 5% of the dividend, provided that such holder (i)&#xA0;is a company, (ii)&#xA0;qualifies for benefits under the Treaty, (iii)&#xA0;holds directly at least 10% of our voting stock, and (iv)&#xA0;does not conduct business through a permanent establishment or fixed place of business in Switzerland to which the shares or ADRs are attributable. Such an eligible holder must apply for a refund of the amount of the Withholding Tax in excess of the 5% Treaty rate. Claims for refunds must be filed on Swiss Tax Form&#xA0;82 (82C for corporations; 82I for individuals; 82E for other entities), which may be obtained from any Swiss Consulate General in the US or from the Federal Tax Administration of Switzerland at the address below, together with an instruction form. Four copies of the form must be duly completed, signed before a notary public of the US, and sent to the Federal Tax Administration of Switzerland, Eigerstrasse 65, CH&#x2011;3003 Bern, Switzerland. The form must be accompanied by suitable evidence of deduction of Swiss tax withheld at source, such as certificates of deduction, signed bank vouchers or credit slips. The form may be filed on or after July&#xA0;1 or January&#xA0;1 following the date the dividend was payable, but no later than December&#xA0;31 of the third year following the calendar year in which the dividend became payable. For US resident holders of ADRs, JPMorgan Chase Bank, N.A., as depositary, will comply with these Swiss </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">169</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">procedures on behalf of the holders, and will remit the net amount to the holders.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">
        <i>Stamp Duty upon transfer of securities.</i>  The sale of shares, whether by Swiss residents or Non&#x2011;Resident Holders, may be subject to federal securities transfer Stamp Duty of 0.15%, calculated on the sale proceeds, if the sale occurs through or with a Swiss bank or other Swiss securities dealer, as defined in the Swiss Federal Stamp Duty Act. The Stamp Duty has to be paid by the securities dealer and may be charged to the parties in a taxable transaction who are not securities dealers. Stamp Duty may also be due if a sale of shares occurs with or through a non&#x2011;Swiss bank or securities dealer, provided that (i)&#xA0;such bank or dealer is a member of the SIX, and (ii)&#xA0;the sale takes place on the SIX. In addition to this Stamp Duty, the sale of shares by or through a member of the SIX may be subject to a minor stock exchange levy.</div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">US federal income taxation</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following is a general discussion of the material US federal income tax consequences of the ownership and disposition of our shares or ADRs that may be relevant to you if you are a US Holder (as defined below). Because this discussion does not consider any specific circumstances of any particular holder of our shares or ADRs, persons who are subject to US taxation are strongly urged to consult their own tax advisors as to the overall US federal, state and local tax consequences, as well as to the overall Swiss and other foreign tax consequences, of the ownership and disposition of our shares or ADRs. In particular, additional or different rules may apply to US expatriates; banks and other financial institutions; regulated investment companies; traders in securities who elect to apply a mark&#x2011;to&#x2011;market method of accounting; dealers in securities or currencies; tax&#x2011;exempt entities; insurance companies; broker&#x2011;dealers; investors liable for alternative minimum tax; investors that hold shares or ADRs as part of a straddle, hedging or conversion transaction; holders whose functional currency is not the US dollar; partnerships or other pass-through entities; persons who acquired our shares pursuant to the exercise of employee stock options or otherwise as compensation; and persons who hold, directly, indirectly or by attribution, 10% or more of our outstanding shares. This discussion generally applies only to US Holders who hold the shares or ADRs as a capital asset (generally, for investment purposes), and whose functional currency is the US dollar. Investors are urged to consult their own tax advisors concerning whether they are eligible for benefits under the Treaty.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For purposes of this discussion, a US Holder is a beneficial owner of our shares or ADRs who is (i)&#xA0;an individual who is a citizen or resident of the US for US federal income tax purposes; (ii)&#xA0;a corporation (or other entity taxable as a corporation for US federal income tax purposes) created or organized in or under the laws of the US or a state thereof or the District of Columbia; (iii)&#xA0;an estate the income of which is subject to US federal income taxation regardless of its source; or (iv)&#xA0;a trust (i)&#xA0;subject to the primary supervision of a US court and the control of one or more US persons, or (ii)&#xA0;that has a valid election in place to be treated as a US person. If a partnership (or other entity treated as a partnership for US federal income tax purposes) holds shares or ADRs, the tax treatment of a partner generally will depend upon the status of the partner and the activities of the partnership. Partners in a partnership that holds shares or ADRs are urged to consult their own tax advisor regarding the specific tax consequences of the owning and disposing of such shares or ADRs by the partnership.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For US federal income tax purposes, a US Holder of ADRs generally will be treated as the beneficial owner of our shares represented by the ADRs. However, see the discussion below under &#x201C;&#x2014;Dividends&#x201D; regarding certain statements made by the US Treasury concerning depositary arrangements.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">This discussion assumes that each obligation in the Deposit Agreement and any related agreement will be performed in accordance with its terms.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">
        <i>Dividends.</i>  US Holders will be required to include in gross income, as an item of ordinary income, the full amount (without reduction for any Withholding Tax) of the dividend paid with respect to our shares or ADRs at the time that such dividend is received by the US Holder, in the case of shares, or by the depositary, in the case of ADRs. For this purpose, a &#x201C;dividend&#x201D; will include any distribution paid by us with respect to our shares or ADRs (other than certain pro rata distributions of our capital stock) paid out of our current or accumulated earnings and profits, as determined under US federal income tax principles. To the extent the amount of a distribution by us exceeds our current and accumulated earnings and profits, such excess will first be treated as a tax&#x2011;free return of capital to the extent of a US Holder&#x2019;s tax basis in the shares or ADRs (with a corresponding reduction in such tax basis), and thereafter will be treated as capital gain, which will be long&#x2011;term capital gain if the US Holder held our shares or ADRs for more than one year. Under the Code, dividend payments by us on the shares or ADRs are not eligible for the dividends received deduction generally allowed to corporate shareholders.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Dividend income in respect of our shares or ADRs will constitute income from sources outside the US for US foreign tax credit purposes. Subject to the limitations and conditions provided in the Code, US Holders generally may claim as a credit against their US federal income tax liability, any Withholding Tax withheld from a dividend. The rules governing the foreign tax credit are complex. Each US Holder is urged to consult its own tax advisor concerning whether, and to what extent, a foreign tax credit will be available with respect to dividends received from us. Alternatively, a US Holder may claim the Withholding Tax as a deduction for the taxable year within which the Withholding Tax is paid or accrued, provided a deduction is claimed for all of the foreign income taxes the US Holder pays or accrues in the particular year. A deduction does not reduce US tax on a dollar&#x2011;for&#x2011;dollar basis like a tax credit. The deduction, however, is not subject to the limitations applicable to foreign tax credits, but may be subject to other limitations, and each US Holder is urged to consult its own tax advisor.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The US Treasury has expressed concern that parties to whom ADRs are released may be taking actions </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">170</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">inconsistent with the claiming of foreign tax credits for US Holders of ADRs. Accordingly, the summary above of the creditability of the Withholding Tax could be affected by future actions that may be taken by the US Treasury.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In general, a US Holder will be required to determine the amount of any dividend paid in Swiss francs, including the amount of any Withholding Tax imposed thereon, by translating the Swiss francs into US dollars at the spot rate on the date the dividend is actually or constructively received by a US Holder, in the case of shares, or by the depositary, in the case of ADRs, regardless of whether the Swiss francs are in fact converted into US dollars. If a US Holder converts the Swiss francs so received into US dollars on the date of receipt, the US Holder generally should not recognize foreign currency gain or loss on such conversion. If a US Holder does not convert the Swiss francs so received into US dollars on the date of receipt, the US Holder will have a tax basis in the Swiss francs equal to the US dollar value on such date. Any foreign currency gain or loss that a US Holder recognizes on a subsequent conversion or other disposition of the Swiss francs generally will be treated as US source ordinary income or loss.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For a non&#x2011;corporate US Holder, the US dollar amount of any dividends paid that constitute qualified dividend income generally will be taxable at a maximum rate of 15% (or 20% in the case of taxpayers with annual income that exceeds certain thresholds), provided that the US Holder meets certain holding period and other requirements. In addition, the dividends could be subject to a 3.8% net investment income tax. This tax is applied against the lesser of the US Holder&#x2019;s net investment income or the amount by which modified adjusted gross income exceeds a statutory threshold amount based on filing status. We currently believe that dividends paid with respect to our shares and ADRs will constitute qualified dividend income for US federal income tax purposes, provided that the US Holder meets certain holding period and other requirements. US Holders of shares or ADRs are urged to consult their own tax advisors regarding the availability to them of the reduced dividend rate in light of their own particular situation and the computations of their foreign tax credit limitation with respect to any qualified dividends paid to them, as applicable.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">
        <i>Sale or other taxable disposition.</i>  Upon a sale or other taxable disposition of shares or ADRs, US Holders generally will recognize capital gain or loss in an amount equal to the difference between the US dollar value of the amount realized on the disposition and the US Holder&#x2019;s tax basis (determined in US dollars) in the shares or ADRs. This capital gain or loss generally will be US source gain or loss and will be treated as long&#x2011;term capital gain or loss if the holding period in the shares or ADRs exceeds one year. In the case of a non&#x2011;corporate US Holder, any long-term capital gain generally will be subject to US federal income tax at preferential rates, with a maximum rate of 15% (or 20% in the case of taxpayers with annual income that exceeds certain thresholds). In addition, the gains could be subject to a 3.8% investment income tax. This tax is applied against the lesser of the US Holder&#x2019;s net investment income or the amount by which modified adjusted gross income exceeds a statutory threshold amount based on filing status. The deductibility of capital losses is subject to significant limitations under the Code. Deposits or withdrawals of our shares by US Holders in exchanges for ADRs will not result in the realization of gain or loss for US federal income tax purposes.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">
        <i>US information reporting and backup withholding.</i>  Dividend payments with respect to shares or ADRs and proceeds from the sale, exchange or other disposition of shares or ADRs received in the United States or through US&#x2011;related financial intermediaries may be subject to information reporting to the US Internal Revenue Service (IRS) and possible US backup withholding. Certain exempt recipients (such as corporations) are not subject to these information reporting and backup withholding requirements. Backup withholding will not apply to a US Holder who furnishes a correct taxpayer identification number and makes any other required certification or who is otherwise exempt from backup withholding. Any US Holders required to establish their exempt status generally must provide a properly executed IRS Form&#xA0;W&#x2011;9 (Request for Taxpayer Identification Number and Certification). Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against a US Holder&#x2019;s US federal income tax liability, and a US Holder may obtain a refund of any excess amounts withheld under the backup withholding rules by timely filing the appropriate claim for refund with the IRS and furnishing any required information.</div>
      <div id="anchorId00512953"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.F Dividends and paying agents</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div id="anchorId00512957"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.G Statement by experts</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">171</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00512963"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.H Documents on display</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Any statement in this Form&#xA0;20&#x2011;F about any of our contracts or other documents is not necessarily complete. If the contract or document is filed as an exhibit to the Form&#xA0;20&#x2011;F, the contract or document is deemed to modify the description contained in this Form&#xA0;20&#x2011;F. You must review the exhibits themselves for a complete description of the contract or document.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The SEC maintains an internet site at http://www.sec.gov that contains reports and other information regarding issuers that file electronically with the SEC. These SEC filings are also available to the public from commercial document retrieval services.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">We are required to file or furnish reports and other information with the SEC under the Exchange Act and regulations under that act. As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the form and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&#xA0;16 of the Exchange Act.</div>
      <div id="anchorId00512977"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">10.I Subsidiary information</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">172</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00512983"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;11.  Quantitative and Qualitative Disclosures About Market Risk</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The major financial risks facing the Group are managed centrally by Group Treasury, which has established processes and procedures to identify, aggregate and manage our financial risk exposure. The Group Treasury function is included in management&#x2019;s internal control assessment.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For information about the effects of currency fluctuations and how we manage currency risk, see &#x201C;Item&#xA0;5. Operating and Financial Review and Prospects&#x2014;Item&#xA0;5.B Liquidity and capital resources.&#x201D;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The information set forth under &#x201C;Item 18. Financial Statements&#x2014;Note&#xA0;29. Financial instruments&#x2014;additional disclosures&#x201D; is incorporated by reference.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">173</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00513002"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;12.  Description of Securities Other Than Equity Securities</p>
      <div id="anchorId00513005"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">12.A Debt securities</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div id="anchorId00513009"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">12.B Warrants and rights</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div id="anchorId00513013"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">12.C Other securities</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div id="anchorId00513017"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight:bold;">12.D American Depositary Shares</p>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Fees payable by ADR holders</span>
      </div>
      <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">According to our Deposit Agreement with the ADS depositary, JPMorgan Chase Bank, N.A. (JPMorgan), holders of our ADRs may have to pay to JPMorgan, either directly or indirectly, fees or charges up to the amounts set forth below:</div>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="top">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">Category</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Depositary actions</div>
            </td>
            <td></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Associated fee</div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depositing or substituting <br />underlying shares</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Acceptance of shares surrendered, and issuance of ADRs in exchange, <br /> including surrenders and issuances in respect of:<br /> &#x2014; Share distributions<br /> &#x2014; Stock split<br /> &#x2014; Rights<br /> &#x2014; Merger<br /> &#x2014; Exchange of shares or any other transaction or event or other distribution <br /> affecting the ADSs or the deposited shares</div>
            </td>
            <td align="left" style=";width:1%;"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD 5.00 for each 100 ADSs <br /> (or portion thereof) <br /> evidenced by the new <br /> ADRs delivered<br /><br /><br /><br /></div>
            </td>
            <td align="left" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Withdrawing <br />underlying shares</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Acceptance of ADRs surrendered for withdrawal of deposited shares<br /><br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD 5.00 for each 100 ADSs <br /> (or portion thereof) <br /> evidenced by the ADRs <br /> surrendered</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling or <br />exercising rights</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Distribution or sale of shares, the fee being in an amount equal to the fee <br /> for the execution and delivery of ADRs that would have been charged <br /> as a result of the deposit of such shares</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD 5.00 for each 100 ADSs <br /> (or portion thereof)<br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transferring, <br />splitting or <br />grouping receipts</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Transfers, combining or grouping of depositary receipts<br /><br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD 1.50 per ADR<br /><br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expenses of the <br />depositary</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Expenses incurred on behalf of holders in connection with:<br /> &#x2014; Compliance with foreign exchange control regulations or any law or <br /> regulation relating to foreign investment<br /> &#x2014; The depositary&#x2019;s or its custodian&#x2019;s compliance with applicable law, <br /> rule or regulation<br /> &#x2014; Stock transfer or other taxes and other governmental charges<br /> &#x2014; Cable, telex and facsimile transmission and delivery<br /> &#x2014; Expenses of the depositary in connection with the conversion of foreign <br /> currency into US dollars (which are paid out of such foreign currency)<br /> &#x2014; Any other charge payable by any of the depositary or its agents</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Expenses payable at the sole <br /> discretion of the depositary <br /> by billing holders or by <br /> deducting charges from one <br /> or more cash dividends or <br /> other cash distributions<br /><br /><br /><br /></div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="top">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Advance tax relief</div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Tax relief/reclamation process for qualified holders<br /></div>
            </td>
            <td align="left"></td>
            <td align="left">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> A depositary service charge <br /> of USD 0.008 per ADS</div>
            </td>
            <td align="left"></td>
          </tr>
          <tr>
            <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">174</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style=" padding-bottom: 10px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Fees payable by the depositary to the issuer</span>
      </div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Pursuant to an agreement effective as of May&#xA0;11, 2017 (&#x201C;the Agreement&#x201D;), JPMorgan, as our ADS depositary, has agreed to make an annual contribution payment to Novartis at the end of each 12-month period beginning on the effective date of the Agreement and on each subsequent anniversary of the effective date of the Agreement (each such 12-month period is a &#x201C;Contract Year&#x201D;). This annual contribution payment will equal: (a)(1) USD 1.7&#xA0;million less (a)(2) the custody costs, fees and expenses (including, without limitation, any central securities depository fees, charges and expenses) incurred during the applicable Contract Year (the items in (a)(2) collectively are the &#x201C;Custody Costs&#x201D;) plus (b)&#xA0;70% of the gross issuance and cancellation fees collected by JPMorgan under the Deposit Agreement during such Contract Year minus (c)&#xA0;that portion (if any) of JPMorgan&#x2019;s legal fees, charges and out-of-pocket expenses in excess of USD 50000 for such Contract Year. To the extent that the Custody Costs for a Contract Year exceed USD 1.7&#xA0;million, these costs would be capped at USD 1.7&#xA0;million.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">JPMorgan has further agreed to waive the USD 0.05 per ADS issuance fees that would normally be owed by Novartis in connection with our deposits of shares as part of our employee stock ownership and employee participation plans. Novartis is responsible for reimbursing JPMorgan for all taxes and governmental charges required to have been withheld and/or paid, and not so withheld and/or paid, arising from such waived fees.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">175</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00513211"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000;">PART II</p>
      <div id="anchorId00513213"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;13.  Defaults, Dividend Arrearages and Delinquencies</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">None.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">176</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00513220"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;14.  Material Modifications to the Rights of Security Holders and Use of Proceeds</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">None.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">177</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00610918"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;15.  Controls and Procedures</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(a)   Novartis AG&#x2019;s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rule&#xA0;13a-15(e)) as of the end of the period covered by this Annual Report, have concluded that, as of such date, our disclosure controls and procedures were effective.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(b)  Report of Novartis Management on Internal Control Over Financial Reporting: The Board of Directors and management of the Group are responsible for establishing and maintaining adequate internal control over financial reporting. The Group&#x2019;s internal control over financial reporting was designed to provide reasonable assurance to the Group&#x2019;s management and Board of Directors regarding the reliability of financial reporting and the preparation and fair presentation of its published consolidated financial statements.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">Internal controls over financial reporting, no matter how well designed, have inherent limitations. Therefore, even those internal controls over financial reporting determined to be effective may not prevent or detect misstatements and can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">Group management assessed the effectiveness of the Group&#x2019;s internal control over financial reporting as of December&#xA0;31, 2022. In making this assessment, it used the criteria established in <i>Internal Control&#x2014;Integrated Framework (2013)</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on our assessment, management concluded that, as of December&#xA0;31, 2022, the Group&#x2019;s internal control over financial reporting is effective based on those criteria.</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:15px;">KPMG AG, Switzerland, an independent registered public accounting firm, has issued an unqualified opinion on the effectiveness of the Group&#x2019;s internal control over financial reporting, which is included in this Annual Report under &#x201C;Item&#xA0;18. Financial Statements&#x2014;Report of independent registered public accounting firm.&#x201D;</div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(c)  See the report of KPMG AG, an independent registered public accounting firm, included under &#x201C;Item&#xA0;18. Financial Statements&#x2014;Report of independent registered public accounting firm.&#x201D;</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:20px;margin-right:0mm;margin-top:0mm;text-indent:-20px;">(d)  There were no changes to our internal control over financial reporting that occurred during the period covered by this Annual Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">178</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00710921"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;16A.  Audit Committee Financial Expert</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our Audit and Compliance Committee has determined that Elizabeth Doherty and Ana de Pro Gonzalo possess specific accounting and financial management expertise, and that they are Audit Committee Financial Experts as defined by the SEC. The Board of Directors has also determined that Elizabeth Doherty and Ana de Pro Gonzalo are &#x201C;independent&#x201D; in accordance with the applicable requirements of Rule&#xA0;10A&#x2011;3 of the Exchange Act, and that other members of the Audit and Compliance Committee have sufficient experience and ability in finance and compliance matters to enable them to adequately discharge their responsibilities.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">179</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00710930"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;16B.  Code of Ethics</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition to our Code of Ethics and Professional Practices Policy, which are applicable to all of our employees, we have adopted Ethical Conduct Requirements that impose additional obligations on our principal executive officer, principal financial officer, principal accounting officer, and persons performing similar functions. This document is accessible on our internet website at:</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">https://www.novartis.com/investors/company-overview/corporate-governance</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">180</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00710939"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;16C.  Principal Accountant Fees and Services</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The information set forth under &#x201C;Item 6. Directors, Senior Management and Employees&#x2014;Item 6.C Board practices&#x2014;Corporate governance&#x2014;Auditors&#x201D; is incorporated by reference. </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">181</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00710950"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;16D.  Exemptions from the Listing Standards for Audit Committees</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">182</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00710957"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;16E.  Purchases of Equity Securities by the Issuer and Affiliated Purchasers</p>
      <div style="padding-top:10px; padding-bottom:30px;">
        <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
          <tr valign="bottom">
            <td style=";height:12;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />2022</div>
            </td>
            <td>
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br />
                <br />
                <br />
                <br />
                <br />
                <br /> Total number of <br /> shares purchased<br /> (a)<sup style="white-space: nowrap">1</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br />
                <br />
                <br />
                <br />
                <br />
                <br /> Average price <br /> paid per share <br /> in USD<br /> (b)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                <br />
                <br /> Total number <br /> of shares<br /> purchased <br /> as part of <br /> publicly <br /> announced <br /> plans or <br /> programs<br /> (c)<sup style="white-space: nowrap">2</sup></div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Maximum <br /> approximate <br /> value of <br /> shares that <br /> may yet be <br /> purchased <br /> under the <br /> plans or <br /> programs <br /> (CHF millions)<br /> (d)</div>
            </td>
            <td></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Maximum <br /> approximate <br /> value of <br /> shares that <br /> may yet be <br /> purchased <br /> under the <br /> plans or <br /> programs <br /> (USD millions)<br /> (e)<sup style="white-space: nowrap">3</sup></div>
            </td>
            <td></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Jan. 1-31</div>
            </td>
            <td align="right" style=";width:8%;">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;746&#xA0;816</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 87.76</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&#xA0;773&#xA0;500</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&#xA0;831</div>
            </td>
            <td align="right" style=";width:1%;"></td>
            <td align="right" style=";width:8%;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&#xA0;405</div>
            </td>
            <td align="right" style=";width:1%;"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Feb. 1-28</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;160&#xA0;538</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 86.73</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;000&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&#xA0;030</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&#xA0;594</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mar. 1-31</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;494&#xA0;338</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 85.43</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;470&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&#xA0;119</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17&#xA0;451</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Apr. 1-30</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&#xA0;534&#xA0;769</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 90.61</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&#xA0;500&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&#xA0;305</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&#xA0;756</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">May 1-31</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;521&#xA0;350</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 88.04</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;500&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&#xA0;399</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&#xA0;996</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Jun. 1-30</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;524&#xA0;101</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 84.79</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;500&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&#xA0;535</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14&#xA0;164</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Jul. 1-31</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;525&#xA0;453</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 85.10</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;500&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&#xA0;670</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&#xA0;329</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aug. 1-31</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;045&#xA0;776</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 84.91</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;000&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;775</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&#xA0;098</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sep. 1-30</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;035&#xA0;057</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 79.65</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;000&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;922</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;172</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oct. 1-31</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;524&#xA0;526</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 77.45</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;500&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;113</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;118</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nov. 1-30</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;021&#xA0;724</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 84.64</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&#xA0;000&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&#xA0;216</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&#xA0;675</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dec. 1-31</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;520&#xA0;012</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 91.17</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&#xA0;500&#xA0;000</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&#xA0;324</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&#xA0;999</div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
            </td>
            <td align="right"></td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
          </tr>
          <tr valign="bottom">
            <td style=";height:16;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
            </td>
            <td align="right">
              <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 127&#xA0;654&#xA0;460</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 85.45</div>
            </td>
            <td align="right"></td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 126&#xA0;243&#xA0;500</div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
            <td align="right">
              <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
            </td>
          </tr>
          <tr>
            <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
          </tr>
          <tr valign="bottom">
            <td colspan="12" style=";height:10px;">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="12">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;1&#xA0;</sup> Column (a) shows shares repurchased on the SIX Swiss Exchange second trading line plus shares we purchased from employees who had obtained the shares through a Novartis Employee Ownership Plan. See "Item 18. Financial Statements - Note 26 Equity-based participation plans for employees."</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="12">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;2&#xA0;</sup> Column (c) shows shares repurchased on the SIX Swiss Exchange second trading line under the CHF 10 billion share buyback authority approved at the 2021 AGM and under the additional CHF 10 billion share buyback authority approved at the 2022 AGM for transactions in 2022. See "Item 6. Directors, Senior Management and Employees - Item 6C. Board Practices - Our capital structure - Changes in capital."</div>
            </td>
          </tr>
          <tr valign="bottom">
            <td colspan="12">
              <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                <sup>&#xA0;3&#xA0;</sup> Column (e) shows the Swiss franc amount from column (d) converted into US dollars as of the month-end, using the Swiss franc/US dollar  exchange rate at the applicable month-end</div>
            </td>
          </tr>
        </table>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">183</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00711642"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;16F.  Change in Registrant&#x2019;s Certifying Accountant</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">184</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"></div>
      <div id="anchorId00711650"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;16G.  Corporate Governance</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis AG is subject to and compliant with the laws and regulations of Switzerland (in particular, Swiss company and securities laws, SIX Swiss Exchange rules and the Swiss Code of Best Practice for Corporate Governance) and the securities laws of the United States, including New York Stock Exchange (NYSE) rules, as applicable to foreign private issuers of securities. The following summarizes some significant ways in which our corporate governance practices differ from those followed by domestic listed US companies under the listing standards of the NYSE:</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Novartis AG shareholders do not receive written reports directly from Board committees.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  External auditors are appointed by shareholders at the Annual General Meeting of Shareholders (AGM), as opposed to being appointed by the Audit and Compliance Committee.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  While shareholders cannot vote on all equity compensation plans, they are entitled to hold separate, yearly binding votes on Board and Executive Committee compensation.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The Board has set up a separate Risk Committee that oversees the risk management system and processes, as opposed to delegating this responsibility to the Audit and Compliance Committee.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The full Board is responsible for overseeing the performance evaluation of the Board and Executive Committee.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The full Board is responsible for setting objectives relevant to the CEO&#x2019;s compensation and for evaluating his performance.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">185</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00711683"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;16H.  Mine Safety Disclosure</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">186</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div id="anchorId00711691"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;16I.  Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Not applicable.</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">187</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div id="anchorId00711699"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000;">PART III</p>
      <div id="anchorId00711701"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;17.  Financial Statements</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">See response to &#x201C;Item&#xA0;18. Financial Statements.&#x201D;</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">188</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00711709"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;18.  Financial Statements</p>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following financial statements are filed as part of this Annual Report.</div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId001511092">Consolidated income statements</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId001511661">Consolidated statements of comprehensive income</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId001512117">Consolidated balance sheets</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId001512966">Consolidated statements of changes in equity</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId001515595">Consolidated statements of cash flows</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 0px;">
        <a style="text-decoration: none;" href="#anchorId001516726">Notes to the Novartis Group&#xA0;consolidated&#xA0;financial statements</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001516732">1. Significant accounting policies</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001517396">2. Significant transactions</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001517643">3. Segmentation of key figures 2022, 2021 and 2020</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001530097">4. Associated companies</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001530570">5. Interest expense and&#xA0;other&#xA0;financial&#xA0;income&#xA0;and&#xA0;expense</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001530822">6. Income taxes</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001531519">7. Earnings per share</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001531738">8. Changes in consolidated statements of&#xA0;comprehensive income</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001533390">9. Property, plant and equipment</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001534918">10. Right-of-use assets and lease liabilities</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001535868">11. Goodwill and intangible assets</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001538357">12. Deferred tax assets and liabilities </a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001540616">13. Financial and other non-current assets</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001540869">14. Inventories</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001541050">15. Trade receivables</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001541600">16. Marketable securities, commodities, time&#xA0;deposits, derivative financial instruments, and&#xA0;cash and cash equivalents</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001541756">17. Other current assets</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001541870">18. Equity</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001543765">19. Non-current financial debt</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001545467">20. Provisions and other non-current liabilities</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001546335">21. Current financial debt and&#xA0;derivative&#xA0;financial&#xA0;instruments</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001546511">22. Provisions and other current liabilities</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001547161">23. Details to the consolidated statements of cash flows</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001549265">24. Acquisitions of businesses</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001549649">25. Post-employment benefits for employees</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001552812">26. Equity-based participation plans for employees</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001553909">27. Transactions with related parties</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001554354">28. Commitments and contingent liabilities</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001554504">29. Financial instruments&#xA0;&#x2013;&#xA0;additional disclosures</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001561678">30. Events subsequent to the December 31, 2022, consolidated balance sheet date</a>
      </div>
      <div style="font-family: arial, helvetica, sans-serif; font-size: 10pt; padding-left: 30px;">
        <a style="text-decoration: none;" href="#anchorId001561713">31. Principal Group subsidiaries and&#xA0;associated&#xA0;companies </a>
      </div>
      <div>
        <div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
            <a style="text-decoration: none;" href="#anchorAudit">Report of Independent Registered Public Accounting Firm &#x2013; KPMG AG </a>(PCAOB ID <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:AuditorFirmId">3240</ix:nonNumeric>)   </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">
            <a style="text-decoration: none;" href="#anchorAudit2">Report of Independent Registered Public Accounting Firm &#x2013; PricewaterhouseCoopers AG </a>  (PCAOB ID <ix:nonNumeric contextRef="AR_D-CurrentYear-1" name="dei:AuditorFirmId">1358</ix:nonNumeric>)   </div>
        </div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">191</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId001810920"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Item&#xA0;19.  Exhibits</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The SEC maintains an internet site at http://www.sec.gov that contains reports and other information regarding issuers that file electronically with the SEC. These SEC filings are also available to the public from commercial document retrieval services.</div>
      <div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"></span>
      </div>
      <div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 1.1   <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/0001114448/000110465921094707/tm2122611d1_ex4-1.htm">Articles of Incorporation of Novartis AG, as amended March 2, 2021 (English translation) (incorporated by reference to Exhibit&#xA0;4.1 to Novartis AG&#x2019;s registration statement on Form&#xA0;S-8 (File No.&#xA0;333-258081) as filed with the SEC on July 22, 2021).</a></span>
      </div>
      <div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 1.2   <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1114448/000137036821000006/a21012620f-ex1_2.htm">Regulations of the Board of Directors, the Board Committees and the Executive Committee of Novartis AG, effective January 1, 2021 (incorporated by reference to Exhibit 1.2 to Novartis AG&#x2019;s Annual Report on Form 20-F (File No. 001-15024) as filed with the SEC on January 26, 2021).</a></span>
      </div>
      <div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 2.1   <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1114448/000110465922127792/tm2227652d1_ex99-a.htm">Form of Second Amended and Restated Deposit Agreement among Novartis AG, JPMorgan Chase Bank, N.A., as depositary, and all Holders and Beneficial Owners from time to time of American Depositary Receipts issued thereunder (incor</a><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1114448/000110465922127792/tm2227652d1_ex99-a.htm">porated by reference to Exhibit&#xA0;99.A to the Registration Statement on Form&#xA0;F-6 (File No.&#xA0;333-198623) as filed with the SEC on December 16, 2022).</a></span>
      </div>
      <div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 2.2   <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1114448/000110465922127792/tm2227652d1_ex99-a.htm">Form of American Depositary Receipt (incorporated by reference to Exhibit&#xA0;99.A to the Registration State</a><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1114448/000110465922127792/tm2227652d1_ex99-a.htm">ment on Form&#xA0;F-6 (File No.&#xA0;333-198623) as filed with the SEC on December 16, 2022).</a></span>
      </div>
      <div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 2.3   The total amount of long-term debt securities authorized under any instrument does not exceed 10% of the total assets of the Company and its subsidiaries on a consolidated basis. We hereby agree to furnish to the SEC, upon its request, a copy of any instrument defining the rights of holders of long-term debt of the Company or of its subsidiaries for which consolidated or unconsolidated financial statements are required to be filed.</span>
      </div>
      <div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 2.4   <a style="-sec-extract:exhibit" href="a23020120f-ex2_4.htm">Description of Securities registered under Section 12 of the Exchange Act. </a></span>
      </div>
      <div style="margin-bottom:20px;margin-left:22px;text-indent:-22px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 8.1   <a style="-sec-extract:exhibit" href="#anchorNote31">For a list of all of our principal Group subsidiaries and associated companies, see &#x201C;Item 18. Financial Statements&#x2014;Note&#xA0;31. Principal Group subsidiaries and associated companies.&#x201D;</a></span>
      </div>
      <div style="margin-bottom:20px;margin-left:31px;text-indent:-31px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 12.1   <a style="-sec-extract:exhibit" href="a23020120f-ex12_1.htm">Certification of Vasant Narasimhan, Chief Executive Officer of Novartis AG, pursuant to Section&#xA0;302 of the Sarbanes-Oxley Act of 2002.</a></span>
      </div>
      <div style="margin-bottom:20px;margin-left:31px;text-indent:-31px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 12.2   <a style="-sec-extract:exhibit" href="a23020120f-ex12_2.htm">Certification of Harry Kirsch, Chief Financial Officer of Novartis AG, pursuant to Section&#xA0;302 of the Sarbanes-Oxley Act of 2002.</a></span>
      </div>
      <div style="margin-bottom:20px;margin-left:31px;text-indent:-31px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 13.1   <a style="-sec-extract:exhibit" href="a23020120f-ex13_1.htm">Certification of Vasant Narasimhan, Chief Executive Officer of Novartis AG, pursuant to Section&#xA0;18 U.S.C. Section&#xA0;1350, as adopted pursuant to Section&#xA0;906 of the Sarbanes-Oxley Act of 2002.</a></span>
      </div>
      <div style="margin-bottom:20px;margin-left:31px;text-indent:-31px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 13.2   <a style="-sec-extract:exhibit" href="a23020120f-ex13_2.htm">Certification of Harry Kirsch, Chief Fi</a><a style="-sec-extract:exhibit" href="a23020120f-ex13_2.htm">nancial Officer of Novartis AG, pursuant to Section&#xA0;18 U.S.C. Section&#xA0;1350, as adopted pursuant to Section&#xA0;906 of the Sarbanes-Oxley Act of 2002.</a></span>
      </div>
      <div style="margin-bottom:20px;margin-left:31px;text-indent:-31px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 15.1   <a style="-sec-extract:exhibit" href="a23020120f-ex15_1.htm">Consent of KPMG AG.</a></span>
      </div>
      <div style="margin-bottom:20px;margin-left:31px;text-indent:-31px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 15.2   <a style="-sec-extract:exhibit" href="a23020120f-ex15_2.htm">Consent of PricewaterhouseCoopers AG.</a></span>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">190</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="margin-bottom:20px;margin-left:50px;text-indent:-50px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 101.INS   XBRL Instance Document </span>
      </div>
      <div style="margin-bottom:20px;margin-left:50px;text-indent:-50px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 101.SCH   XBRL Taxonomy Extension Schema Document </span>
      </div>
      <div style="margin-bottom:20px;margin-left:50px;text-indent:-50px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document </span>
      </div>
      <div style="margin-bottom:20px;margin-left:50px;text-indent:-50px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 101.DEF   XBRL Taxonomy Extension Definition Linkbase Document</span>
      </div>
      <div style="margin-bottom:20px;margin-left:50px;text-indent:-50px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 101.LAB   XBRL Taxonomy Extension Label Linkbase Document </span>
      </div>
      <div style="margin-bottom:20px;margin-left:50px;text-indent:-50px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document</span>
      </div>
      <div style="margin-bottom:20px;margin-left:50px;text-indent:-50px;">
        <span style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;"> 104   Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit&#xA0;101).</span>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">191</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div id="anchorId00810918"></div>
      <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">SIGNATURES</p>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The registrant hereby certifies that it meets all of the requirements for filing on Form&#xA0;20-F and that it has duly caused and authorized the undersigned to sign this Annual Report on its behalf.</div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="margin-left:380px;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Novartis AG</div>
      <div style="margin-left:400px;padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"></div>
      <div style="margin-left:400px;text-indent:-20px;padding-top:20px;text-decoration:underline;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">By:  /s/ Harry Kirsch</div>
      <div style="margin-left:400px;padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Name: Harry Kirsch</div>
      <div style="margin-left:400px;padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Title: <i>Chief Financial Officer of Novartis</i></div>
      <div style="margin-left:400px;padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"></div>
      <div style="margin-left:400px;text-indent:-20px;padding-top:20px;text-decoration:underline;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">By:  /s/ Karen Hale</div>
      <div style="margin-left:400px;padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Name: Karen Hale</div>
      <div style="margin-left:400px;padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Title: <i>Chief Legal Officer of Novartis</i></div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Date: February&#xA0;1, 2023</div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">192</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "></div>
      <div>
        <div>
          <div id="anchorId001511088"></div>
          <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Novartis Group consolidated&#xA0;financial&#xA0;statements</p>
          <div id="anchorId001511092"></div>
          <div>
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated income statements</span>
          </div>
          <div style="padding-top:0px;font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000;text-align:justify; ">(For the years ended December 31, 2022, 2021 and 2020) </div>
          <div style="padding-top:10px; padding-bottom:30px;">
            <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
              <tr valign="bottom">
                <td style=";height:12;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions unless indicated otherwise)</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                </td>
                <td></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">50 545</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">51 626</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">48 659</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 283</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 251</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 239</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">15 486</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">15 867</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">15 121</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">36 342</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">37 010</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">34 777</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">14 253</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">14 886</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">14 197</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">9 996</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">9 540</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">8 980</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">805</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 852</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 742</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">3 701</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">2 747</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">3 190</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">9 197</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">11 689</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">10 152</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Loss)/income from associated companies</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">15 339</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">673</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:InterestExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">837</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:InterestExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">811</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:InterestExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">869</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">80</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">78</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">8 371</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">26 137</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">9 878</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">1 416</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">2 119</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">1 807</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">6 955</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">24 018</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">8 071</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Shareholders of Novartis AG</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">6 955</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">24 021</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">8 072</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Non-controlling interests</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share (USD)</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear" name="ifrs-full:BasicEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.19</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1" name="ifrs-full:BasicEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.71</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-2" name="ifrs-full:BasicEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.55</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Diluted earnings per share (USD)</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear" name="ifrs-full:DilutedEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.17</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DilutedEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.63</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-2" name="ifrs-full:DilutedEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.52</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td colspan="10" style=";height:10px;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                </td>
              </tr>
              <tr valign="bottom">
                <td colspan="10" style=";height:10px;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">The accompanying Notes form an integral part of the consolidated financial statements.</div>
                </td>
              </tr>
            </table>
          </div>
        </div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-1</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <div></div>
      </div>
      <div>
        <div>
          <div id="anchorId001511661"></div>
          <div>
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated statements of comprehensive income</span>
          </div>
          <div style="padding-top:0px;font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000;text-align:justify; ">(For the years ended December 31, 2022, 2021 and 2020) </div>
          <div style="padding-top:10px; padding-bottom:30px;">
            <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
              <tr valign="bottom">
                <td style=";height:12;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                </td>
                <td></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">6 955</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">24 018</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">8 071</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Other comprehensive income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Items that are or may be recycled into the consolidated income statement</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Novartis share of other comprehensive income recognized by associated companies, net of taxes</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   4</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">56</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Net investment hedge, net of taxes</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">216</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">201</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Currency translation effects, net of taxes</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">450</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 762</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal">3 194</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of items that are or may be recycled</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">359</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 500</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal">2 937</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Items that will never be recycled into the consolidated income statement</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Actuarial (losses)/gains from defined benefit plans, net of taxes</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">103</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">1 809</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">143</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Fair value adjustments on equity securities, net of taxes</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">382</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">194</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of items that will never be recycled</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">485</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal">2 003</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal">393</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total comprehensive income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">6 111</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">21 521</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">11 401</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Shareholders of Novartis AG</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">6 116</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">21 528</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">11 403</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Non-controlling interests</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td colspan="10" style=";height:10px;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                </td>
              </tr>
              <tr valign="bottom">
                <td colspan="10" style=";height:10px;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">The accompanying Notes form an integral part of the consolidated financial statements.</div>
                </td>
              </tr>
            </table>
          </div>
        </div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-2</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <div>
          <div id="anchorId001512117"></div>
          <div>
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated balance sheets</span>
          </div>
          <div style="padding-top:0px;font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000;text-align:justify; ">(At December 31, 2022 and 2021) </div>
          <div style="padding-top:10px; padding-bottom:30px;">
            <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
              <tr valign="bottom">
                <td style=";height:12;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                </td>
                <td></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Assets</div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:11%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:11%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:11%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current assets</div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:11%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:11%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:11%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:11%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:11%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">10 764</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:11%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">11 545</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 431</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 561</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Goodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 301</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Goodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 595</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets other than goodwill</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">31 644</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">34 182</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investments in associated companies</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">143</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">205</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3 739</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction id="fact_188392" unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3 743</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NoncurrentFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 411</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NoncurrentFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3 036</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 110</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 210</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">80 543</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">86 077</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Inventories" decimals="-6" scale="6" format="ixt:numdotdecimal">7 175</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Inventories" decimals="-6" scale="6" format="ixt:numdotdecimal">6 666</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">8 066</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">8 005</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income tax receivables</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentTaxAssetsCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">268</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentTaxAssetsCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">278</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, commodities, time deposits and derivative financial instruments</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherCurrentFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">11 413</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherCurrentFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">15 922</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">7 517</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">12 407</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other current assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherCurrentNonfinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 471</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherCurrentNonfinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 440</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">36 910</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">45 718</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Assets" decimals="-6" scale="6" format="ixt:numdotdecimal">117 453</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Assets" decimals="-6" scale="6" format="ixt:numdotdecimal">131 795</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Equity and liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Equity</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Share capital</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:IssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">890</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:IssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">901</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Treasury shares</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:TreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">92</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:TreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reserves</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherReserves" decimals="-6" scale="6" format="ixt:numdotdecimal">58 544</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherReserves" decimals="-6" scale="6" format="ixt:numdotdecimal">66 802</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Equity attributable to Novartis AG shareholders</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:EquityAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">59 342</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:EquityAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">67 655</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-controlling interests</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NoncontrollingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal">81</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NoncontrollingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal">167</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">59 423</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">67 822</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debts</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">20 244</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">22 902</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NoncurrentLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 538</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NoncurrentLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 621</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 686</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction id="fact_188393" unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">3 070</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other non-current liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherNoncurrentNonfinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">4 906</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherNoncurrentNonfinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">6 172</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">29 374</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">33 765</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" decimals="-6" scale="6" format="ixt:numdotdecimal">5 146</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" decimals="-6" scale="6" format="ixt:numdotdecimal">5 553</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debts and derivative financial instruments</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 931</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">6 295</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">251</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">275</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current income tax liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentTaxLiabilitiesCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">2 533</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentTaxLiabilitiesCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">2 415</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions and other current liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherCurrentNonfinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">14 795</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherCurrentNonfinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">15 670</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">28 656</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">30 208</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Liabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">58 030</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Liabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">63 973</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity and liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:EquityAndLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">117 453</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:EquityAndLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">131 795</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
              </tr>
              <tr valign="bottom">
                <td colspan="8" style=";height:10px;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                </td>
              </tr>
              <tr valign="bottom">
                <td colspan="8" style=";height:10px;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">The accompanying Notes form an integral part of the consolidated financial statements.</div>
                </td>
              </tr>
            </table>
          </div>
        </div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-3</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <div>
          <div id="anchorId001512966"></div>
          <div>
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated statements of changes in equity</span>
          </div>
          <div style="padding-top:0px;font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000;text-align:justify; ">(For the years ended December 31, 2022, 2021 and 2020) </div>
          <div style="padding-top:10px; padding-bottom:30px;">
            <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
              <tr valign="bottom">
                <td style=";height:10px;">
                  <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                </td>
                <td></td>
                <td align="center" colspan="3" style=";height:12;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Reserves</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                </td>
                <td></td>
              </tr>
              <tr>
                <td style=";height:3;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td colspan="3" style=";height:3;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
              </tr>
              <tr>
                <td style=";height:1;"></td>
                <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                <td style=";height:1;"></td>
                <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                <td style=";height:1;"></td>
                <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                <td style=";height:1;"></td>
                <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                <td style=";height:1;"></td>
                <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                <td style=";height:1;"></td>
                <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                <td style=";height:1;"></td>
                <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
              </tr>
              <tr>
                <td style=";height:3;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td colspan="3" style=";height:3;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
                <td style=";height:1;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:12;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                    <br />(USD millions)</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                    <br />
                    <br />
                    <br /> Note</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                    <br />
                    <br /> Share<br /> capital</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                    <br />
                    <br /> Treasury<br /> shares</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                    <br />
                    <br /> Retained<br /> earnings</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                    <br />
                    <br /> Total value<br /> adjustments</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity<br /> attributable <br /> to Novartis <br /> shareholders</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                    <br /> Non-<br /> controlling<br /> interests</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                    <br />
                    <br /> Total<br /> equity</div>
                </td>
                <td></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity at January 1, 2020</div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">936</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">80</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">59 275</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 657</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">55 474</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">77</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">55 551</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income</div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">8 072</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">8 072</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:5%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">8 071</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other comprehensive income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">56</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">3 387</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">3 331</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">3 330</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total comprehensive income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">8 016</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">3 387</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">11 403</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">11 401</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.1</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:DividendsPaid" decimals="-6" scale="6" format="ixt:numdotdecimal">6 987</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:DividendsPaid" decimals="-6" scale="6" format="ixt:numdotdecimal">6 987</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:DividendsPaid" decimals="-6" scale="6" format="ixt:numdotdecimal">6 987</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">3 038</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">3 056</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">3 056</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reduction of share capital</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember" name="ifrs-full:ReductionOfIssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:ReductionOfIssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">31</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ReductionOfIssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">798</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">806</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">806</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repurchase of options</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.4</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:RepurchaseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">89</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="nvs:RepurchaseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">89</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:RepurchaseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">89</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">724</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">730</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">730</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees as a result of the Alcon spin-off</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes on treasury share transactions</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:TaxesOnTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">32</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="nvs:TaxesOnTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">32</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:TaxesOnTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">32</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase of treasury share repurchase  obligation under a share buyback trading plan</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.3</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 769</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 769</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 769</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on financial assets sold</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">150</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.5</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.7</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total of other equity movements</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">23</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10 134</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">149</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10 279</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10 286</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity at December 31, 2020</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">913</ix:nonFraction>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">53</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">57 157</ix:nonFraction>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 419</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">56 598</ix:nonFraction>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">56 666</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">24 021</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">24 021</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">24 018</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other comprehensive income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 539</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 493</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 497</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total comprehensive income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">24 067</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 539</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">21 528</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">21 521</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.1</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:DividendsPaid" decimals="-6" scale="6" format="ixt:numdotdecimal">7 368</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:DividendsPaid" decimals="-6" scale="6" format="ixt:numdotdecimal">7 368</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DividendsPaid" decimals="-6" scale="6" format="ixt:numdotdecimal">7 368</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 902</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 920</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 920</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reduction of share capital</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember" name="ifrs-full:ReductionOfIssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:ReductionOfIssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">18</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ReductionOfIssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">740</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">745</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">745</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees as a result of the Alcon spin-off</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes on treasury share transactions</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:TaxesOnTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="nvs:TaxesOnTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:TaxesOnTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase of treasury share repurchase  obligation under a share buyback trading plan</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.3</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 040</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 040</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 040</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transaction costs, net of taxes</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:TransactionCostsRecordedInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">12</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="nvs:TransactionCostsRecordedInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">12</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:TransactionCostsRecordedInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">12</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in non-controlling interests</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.6</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="nvs:IncreaseDecreaseInNoncontrolingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:IncreaseDecreaseInNoncontrolingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on financial assets sold</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal">164</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">164</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal">65</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">65</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.5</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal">107</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal">102</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.7</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total of other equity movements</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">12</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10 235</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">229</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10 471</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">106</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10 365</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity at December 31, 2021</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">901</ix:nonFraction>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">48</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">70 989</ix:nonFraction>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 187</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">67 655</ix:nonFraction>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">167</ix:nonFraction>
                  </div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">67 822</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">6 955</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">6 955</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:ProfitLoss" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">6 955</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other comprehensive income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">839</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">839</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">844</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total comprehensive income</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">6 955</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">839</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">6 116</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">6 111</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.1</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:DividendsPaid" decimals="-6" scale="6" format="ixt:numdotdecimal">7 506</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:DividendsPaid" decimals="-6" scale="6" format="ixt:numdotdecimal">7 506</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DividendsPaid" decimals="-6" scale="6" format="ixt:numdotdecimal">7 506</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">66</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">10 844</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">10 910</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">10 910</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reduction of share capital</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember" name="ifrs-full:ReductionOfIssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:ReductionOfIssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">15</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ReductionOfIssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">87</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">88</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">88</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">848</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">854</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">854</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees as a result of the Alcon spin-off</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes on treasury share transactions</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:TaxesOnTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">14</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="nvs:TaxesOnTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">14</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:TaxesOnTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">14</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Decrease of treasury share repurchase  obligation under a share buyback trading plan</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.3</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" decimals="-6" scale="6" format="ixt:numdotdecimal">2 809</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" decimals="-6" scale="6" format="ixt:numdotdecimal">2 809</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" decimals="-6" scale="6" format="ixt:numdotdecimal">2 809</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in non-controlling interests</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.6</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="nvs:IncreaseDecreaseInNoncontrolingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">81</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:IncreaseDecreaseInNoncontrolingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">81</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on financial assets sold</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">34</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.7</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">217</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">217</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">217</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total of other equity movements</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">11</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">44</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">14 404</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">14 429</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">81</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ChangesInEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">14 510</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity at December 31, 2022</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">890</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">92</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">63 540</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 996</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">59 342</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">81</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">59 423</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
              </tr>
              <tr valign="bottom">
                <td colspan="18" style=";height:10px;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                </td>
              </tr>
              <tr valign="bottom">
                <td colspan="18" style=";height:10px;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">The accompanying Notes form an integral part of the consolidated financial statements.</div>
                </td>
              </tr>
            </table>
          </div>
        </div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-4</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <div>
          <div id="anchorId001515595"></div>
          <div>
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Consolidated statements of cash flows</span>
          </div>
          <div style="padding-top:0px;font-family:arial,helvetica,sans-serif; font-size:8pt; color:#000000;text-align:justify; ">(For the years ended December 31, 2022, 2021 and 2020) </div>
          <div style="padding-top:10px; padding-bottom:30px;">
            <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
              <tr valign="bottom">
                <td style=";height:12;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                </td>
                <td></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                </td>
                <td></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">6 955</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">24 018</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
                <td align="right" style=";width:9%;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">8 071</ix:nonFraction>
                  </div>
                </td>
                <td align="right" style=";width:1%;"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Adjustments to reconcile net income to net cash flows from operating activities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of non-cash items and other adjustments</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.1</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdjustmentsForReconcileProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">11 546</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdjustmentsForReconcileProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5 299</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AdjustmentsForReconcileProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">9 881</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends received from associated companies and others</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DividendsReceivedClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DividendsReceivedClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">525</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:DividendsReceivedClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">490</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest received</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">254</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest paid</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">696</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">664</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">703</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial receipts</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">464</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial payments</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">302</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes paid</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.2</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 975</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 342</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 833</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities before working capital and  provision changes</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges" decimals="-6" scale="6" format="ixt:numdotdecimal">16 124</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges" decimals="-6" scale="6" format="ixt:numdotdecimal">15 949</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges" decimals="-6" scale="6" format="ixt:numdotdecimal">16 378</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments out of provisions and other net cash movements in non-current liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">885</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 119</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 437</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in net current assets and other operating cash flow items</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.3</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 003</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" decimals="-6" scale="6" format="ixt:numdotdecimal">241</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">291</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from operating activities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">14 236</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">15 071</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">13 650</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of property, plant and equipment</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 198</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 378</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 275</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of property, plant and equipment</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">167</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">240</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">88</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of intangible assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 473</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 593</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 310</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of intangible assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">202</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">748</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">380</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of financial assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">121</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">191</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">230</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of financial assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">133</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">442</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">723</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of other non-current assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">61</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">61</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of other non-current assets</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquisitions and divestments of interests in associated companies, net</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.4</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">24</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies" decimals="-6" scale="6" format="ixt:numdotdecimal">20 669</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquisitions and divestments of businesses, net</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.5</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">879</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">567</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9 957</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases of marketable securities, commodities and time deposits</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">34 695</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">16 403</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 900</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sale of marketable securities, commodities and time deposits</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">39 357</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 298</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">492</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from/(used in) investing activities from continuing operations</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">1 468</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">4 208</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">13 055</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows used in investing activities from discontinued operations</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.7</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">127</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows from/(used in) investing activities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 468</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">4 208</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">13 182</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividends paid to shareholders of Novartis AG</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">7 506</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">7 368</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">6 987</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquisitions of treasury shares</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" decimals="-6" scale="6" format="ixt:numdotdecimal">10 652</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" decimals="-6" scale="6" format="ixt:numdotdecimal">3 057</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 842</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from exercised options and other treasury share transactions, net</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">748</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.6</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProceedsFromNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProceedsFromNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProceedsFromNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">7 126</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of the current portion of non-current financial debts</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.6</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 575</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 162</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 003</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.6</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">295</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3 524</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 261</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.6</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">295</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">316</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">312</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financing cash flows, net</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">147</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows used in financing activities from continuing operations</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">20 562</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">16 264</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 158</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows used in financing activities from discontinued operations</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.7</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">50</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows used in financing activities</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">20 562</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">16 264</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 208</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net change in cash and cash equivalents before effect of exchange  rate changes</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 858</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" decimals="-6" scale="6" format="ixt:numdotdecimal">3 015</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 740</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of exchange rate changes on cash and cash equivalents</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">32</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">266</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">286</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net change in cash and cash equivalents</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 890</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">2 749</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 454</ix:nonFraction></span>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents at January 1</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">12 407</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:CashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">9 658</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3" name="ifrs-full:CashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">11 112</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
              </tr>
              <tr valign="bottom">
                <td style=";height:16;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash and cash equivalents at December 31</div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">7 517</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">12 407</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
                <td align="right">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                    <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:CashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">9 658</ix:nonFraction>
                  </div>
                </td>
                <td align="right"></td>
              </tr>
              <tr>
                <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
              </tr>
              <tr valign="bottom">
                <td colspan="10" style=";height:10px;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                </td>
              </tr>
              <tr valign="bottom">
                <td colspan="10" style=";height:10px;">
                  <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">The accompanying Notes form an integral part of the consolidated financial statements.</div>
                </td>
              </tr>
            </table>
          </div>
        </div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-5</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <div>
          <div id="anchorId001516726"></div>
          <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Notes to the Novartis Group&#xA0;consolidated&#xA0;financial statements</p>
        </div>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" id="SectionBlock_cca394f9-d866-4256-84df-c075ace106fa_0" escape="true" continuedAt="SectionBlock_cca394f9-d866-4256-84df-c075ace106fa_1">
          <div>
            <div id="anchorId001516732"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">1. Significant accounting policies</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Novartis Group (Novartis or Group) is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of innovative pharmaceuticals and cost-saving generic medicines. The Group is headquartered in Basel, Switzerland.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consolidated financial statements of the Group are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). They are prepared in accordance with the historical cost convention, except for items that are required to be accounted for at fair value.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s financial year-end is December 31, which is also the annual closing date of the individual entities&#x2019; financial statements incorporated into the Group&#x2019;s consolidated financial statements.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The preparation of financial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the year, which affect the reported amounts of revenues, expenses, assets, liabilities and contingent amounts.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Estimates are based on historical experience and other assumptions that are considered reasonable under the given circumstances and are regularly monitored. Actual outcomes and results could differ from those estimates and assumptions. Revisions to estimates are recognized in the period in which the estimate is revised.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Listed below are accounting policies of significance to Novartis or, in cases where IFRS provides alternatives, the option adopted by Novartis.</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForSubsidiariesExplanatory" id="SectionBlock_6dcd87da-4dde-4680-9ad2-2cc8d27330db_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Scope of consolidation </span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated financial statements include all entities, including structured entities, over which Novartis AG, Basel, Switzerland, directly or indirectly has control (generally as a result of owning more than 50% of the entity&#x2019;s voting interest). Consolidated entities are also referred to as &#x201C;subsidiaries.&#x201D; </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In cases where Novartis does not fully own a subsidiary, it has elected to value any remaining outstanding non-controlling interest at the time of acquiring control of the subsidiary at its proportionate share of the fair value of the net identified assets.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Investments in associated companies (generally defined as investments in entities in which Novartis holds between 20% and 50% of voting shares or over which it otherwise has significant influence) and joint ventures are accounted for using the equity method, except for selected venture fund investments for which the Group has elected to apply the method of fair value through the consolidated income statement.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="SectionBlock_3770ca29-199e-4a05-8636-4e47bcdaf8ea_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Foreign currencies</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated financial statements of Novartis are presented in US dollars (USD). The functional currency of a subsidiary is generally the local currency of that respective entity. The functional currency used for the reporting of certain Swiss and foreign finance entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in this currency.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For subsidiaries not operating in hyperinflationary economies, the subsidiary&#x2019;s results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates:</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Income, expense and cash flows for each month using the average exchange rate, with the US dollar values for each month being aggregated during the year</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Balance sheet using year-end exchange rates</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Resulting exchange rate differences are recognized in other comprehensive income</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For subsidiaries operating in hyperinflationary economies, the impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period is recorded in retained earnings in equity. The subsequent gains or losses resulting from the restatement of non-monetary assets are recorded in &#x201C;Other financial income and expense&#x201D; in the consolidated income statement. </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" id="SectionBlock_cb4e7fd9-b54b-43ec-b1eb-9daf52a97f20_0" escape="true" continuedAt="SectionBlock_cb4e7fd9-b54b-43ec-b1eb-9daf52a97f20_1">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Non-current assets held for sale or held for distribution to owners</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Non-current assets are accounted for as assets held for sale or as related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell and any resulting impairment is recognized. Assets related to discontinued operations and assets of a disposal group held for sale are not depreciated or amortized. The prior year consolidated balance sheet is not restated.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If in a subsequent period, the criteria for classification as held for sale are no longer met, the recoverable amount of assets and liabilities are reclassified out of assets held for sale into the respective balance sheet lines and the prior year consolidated balance sheet is not restated. The cumulative amount of depreciation and amortization not recorded since the date of their classification as assets held for sale, and any required </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-6</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_cca394f9-d866-4256-84df-c075ace106fa_1" continuedAt="SectionBlock_cca394f9-d866-4256-84df-c075ace106fa_2">
          <div>
            <div>
              <ix:continuation id="SectionBlock_cb4e7fd9-b54b-43ec-b1eb-9daf52a97f20_1">
                <div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">adjustments to the recoverable amounts of assets are recognized in the consolidated income statement.</div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" id="SectionBlock_74be47e5-6c1d-4bea-97e1-e2335b8d53b6_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Acquisition of assets and businesses</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Assets separately acquired are recorded at cost, which includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment and restore the site when it is no longer used are included in their cost.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Acquired businesses are accounted for by applying the acquisition method, unless the optional concentration test is applied. The optional concentration test allows for an election on a transaction-by-transaction basis to account for the acquired business as an asset separately acquired when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The acquisition method requires that the assets acquired and liabilities assumed be recorded at their respective fair values on the date the Group obtains control. The excess of the fair value of the total purchase consideration transferred over the fair value of the acquired assets and assumed liabilities is recognized as goodwill. The valuations are based on information available at the acquisition date. Acquisition related costs are expensed as incurred.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The application of the acquisition method requires certain estimates and assumptions to be made, especially concerning the fair values of the acquired intangible assets, inventories, property, plant and equipment and the liabilities assumed at the acquisition date, and the useful lives of the intangible assets and property, plant and equipment. Estimates of fair value require the use of valuation techniques. These valuations require the use of management assumptions and estimates, including the value of comparable assets in the market, amount and timing of future cash flows, outcomes and costs of research and development activities, probability of obtaining regulatory approval, long-term sales forecasts, actions of competitors, discount rates and terminal growth rates. The section &#x201C;&#x2014;Impairment of goodwill and intangible assets&#x201D; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="SectionBlock_672c4e86-5604-47fe-95df-c7d502808904_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Property, plant and equipment</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Property, plant and equipment is depreciated on a straight-line basis in the consolidated income statement over the estimated useful life of the individual asset. Freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Property, plant and equipment is assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections over the useful life.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the estimated useful life by major categories for property, plant and equipment:</div>
                  <div>
                    <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" id="SectionBlock_a9318f85-a40c-4431-8b4c-6eed14a4f1ea_0" escape="true">
                      <div>
                        <div style="padding-top:10px; padding-bottom:30px;">
                          <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                            <tr valign="bottom">
                              <td style=";height:12;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                              </td>
                              <td></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Useful life</div>
                              </td>
                              <td></td>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div>
                              </td>
                              <td align="right" style=";width:1%;"></td>
                              <td align="right" style=";width:20%;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20 to 40 years</div>
                              </td>
                              <td align="right" style=";width:1%;"></td>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and other equipment</div>
                              </td>
                              <td align="right"></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                              </td>
                              <td align="right"></td>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Machinery and equipment</div>
                              </td>
                              <td align="right"></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7 to 20 years</div>
                              </td>
                              <td align="right"></td>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Furniture and vehicles</div>
                              </td>
                              <td align="right"></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 10 years</div>
                              </td>
                              <td align="right"></td>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Computer hardware</div>
                              </td>
                              <td align="right"></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years</div>
                              </td>
                              <td align="right"></td>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                            </tr>
                          </table>
                        </div>
                      </div>
                    </ix:nonNumeric>
                  </div>
                  <div>
                    <div>
                      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Government grants obtained for construction activities, including any related equipment, are deducted from the gross acquisition cost to arrive at the balance sheet carrying value of the related assets.</div>
                    </div>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="SectionBlock_f6eb3138-3723-4a27-a629-e69937de64c5_0" escape="true" continuedAt="SectionBlock_f6eb3138-3723-4a27-a629-e69937de64c5_1">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Leases and right-of-use assets</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As lessee, at inception and upon the modification of a contract, the Group assesses whether the contract contains a lease. The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative standalone price of each component. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases. For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease to the end of the lease term. The lease term includes the period of any lease extension that management assess as reasonably certain to be exercised by the Group. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the Novartis incremental borrowing rate for the asset subject to the lease in the relevant market.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The portion of the lease payments attributable to the repayment of lease liabilities is recognized in cash flows used in financing activities, and the portion attributable to the payment of interest is included in cash flows from operating activities.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease incentive received, and any initial direct costs incurred by Novartis, and expected costs for obligations to dismantle and remove right-of-use assets when they are no longer used.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-7</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_cca394f9-d866-4256-84df-c075ace106fa_2" continuedAt="SectionBlock_cca394f9-d866-4256-84df-c075ace106fa_3">
          <div>
            <div>
              <ix:continuation id="SectionBlock_f6eb3138-3723-4a27-a629-e69937de64c5_1">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">the shorter of the useful life of the right-of-use asset or the end of the lease term. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In arrangements where the Group is the lessor, it determines at lease inception whether the lease is a finance lease or an operating lease. Leases that transfer substantially all of the risk and rewards incidental to ownership of the underlying asset to the counterparty (the lessee) are accounted for as finance leases. Leases that do not transfer substantially all of the risks and rewards of ownership are accounted for as operating leases. Operating lease payments received are recognized on a straight-line basis over the lease term in the consolidated income statement in &#x201C;Other income.&#x201D; </div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory" id="SectionBlock_32ac2f12-f284-4cf4-9292-a621b9d9cb3e_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Goodwill and intangible assets</span>
                  </div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Goodwill</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Goodwill arises on applying the acquisition method on the acquisition of a business and is the excess of the fair value of the consideration transferred to acquire the business over the underlying fair value of the net identified assets acquired. It is allocated to groups of cash-generating units (CGUs), that are expected to benefit from the synergies of the combination, and which are usually represented by the reported segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under &#x201C;Other expense&#x201D; in the consolidated income statement.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" id="SectionBlock_b22ee7ac-1b62-4d32-8247-7e01baf52145_0" escape="true">
                <div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intangible assets available for use</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has the following classes of available for use intangible assets: currently marketed products; technologies and other intangible assets (including software).</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Currently marketed products represent the composite value of acquired intellectual property (IP), patents, distribution rights and product trade names.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Technologies represent identified and separable acquired know-how used in the research, development and production processes.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Significant investments in internally developed and acquired computer software are capitalized and included in the &#x201C;Other&#x201D; category, and amortized once available for use.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Intangible assets available for use with a definite useful life are amortized over their estimated useful lives on a straight-line basis and are evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the estimated useful life by major categories for intangible assets available for use and the line in the consolidated income statement in which the amortization and any potential impairment charge is recognized:</div>
                  <div>
                    <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" id="SectionBlock_fa2cd3f0-cdac-4210-a9ca-d6cdf24c2fba_0" escape="true">
                      <div>
                        <div style="padding-top:10px; padding-bottom:30px;">
                          <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                            <tr valign="bottom">
                              <td style=";height:12;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                              </td>
                              <td></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                                  <br />
                                  <br /> Useful life</div>
                              </td>
                              <td></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement line<br /> for amortization and<br /> impairment charges</div>
                              </td>
                              <td></td>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div>
                              </td>
                              <td align="right" style=";width:1%;"></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 20 years</div>
                              </td>
                              <td align="right" style=";width:1%;"></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div>
                              </td>
                              <td align="right" style=";width:1%;"></td>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Technologies</div>
                              </td>
                              <td align="right"></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10 to 20 years    </div>
                              </td>
                              <td align="right"></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"   or "Research   and development"</div>
                              </td>
                              <td align="right"></td>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other (including software)</div>
                              </td>
                              <td align="right"></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 12 years  </div>
                              </td>
                              <td align="right"></td>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> In the relevant   functional expense</div>
                              </td>
                              <td align="right"></td>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                            </tr>
                          </table>
                        </div>
                      </div>
                    </ix:nonNumeric>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" id="SectionBlock_c90aef21-1ee7-44f3-b187-84a18c91c751_0" escape="true">
                <div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intangible assets not yet available for use</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Acquired research and development intangible assets that have not yet obtained marketing approval are recognized as in-process research and development (IPR&amp;D).</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">IPR&amp;D is not amortized, but is evaluated for potential impairment on an annual basis or when facts and circumstances warrant. Any impairment charge is recorded in the consolidated income statement under &#x201C;Research and development.&#x201D; Once a project included in IPR&amp;D has received marketing approval from a regulatory authority, it is transferred to the &#x201C;Currently marketed products&#x201D; category.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" id="SectionBlock_9f835e18-b383-405c-9e1a-bfd7b0533326_0" escape="true" continuedAt="SectionBlock_9f835e18-b383-405c-9e1a-bfd7b0533326_1">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impairment of goodwill and intangible assets</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">An asset, a CGU or a grouping of CGUs is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value-in-use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGU, and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset. These valuations are classified as &#x201C;Level 3&#x201D; in the fair value hierarchy.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group&#x2019;s activities with regard to:</div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-8</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_cca394f9-d866-4256-84df-c075ace106fa_3" continuedAt="SectionBlock_cca394f9-d866-4256-84df-c075ace106fa_4">
          <div>
            <div>
              <ix:continuation id="SectionBlock_9f835e18-b383-405c-9e1a-bfd7b0533326_1">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Amount and timing of projected future cash flows</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Sales forecasts </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Actions of competitors (launch of competing products, marketing initiatives, etc.)</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Sales erosion rates after the end of patent or other intellectual property rights protection, and timing of the entry of generic competition</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Outcome of research and development activities (compound efficacy, results of clinical trials, etc.)</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Amount and timing of projected costs to develop IPR&amp;D into commercially viable products</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Profit margins</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Probability of obtaining regulatory approval</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Future tax rate</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Appropriate terminal growth rate</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Appropriate discount rate</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Generally, for intangible assets with a definite useful life, Novartis uses cash flow projections for the whole useful life of these assets. For goodwill, Novartis generally utilizes cash flow projections for a three-year period based on management forecasts, with a terminal value based on cash flow projections usually in line with inflation rates for later periods. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Probability-weighted scenarios are typically used.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Discount rates used consider the Group&#x2019;s estimated weighted average cost of capital, adjusted for specific asset, country and currency risks associated with cash flow projections, to approximate the discount rate that market participants would use to value the asset.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Due to the above factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques. </div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" id="SectionBlock_bc16bacf-a29d-46d3-84bc-304adf1fc279_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Cash and cash equivalents</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash and cash equivalents include highly liquid investments with original maturities of three months or less, which are readily convertible to known amounts of cash. Bank overdrafts are presented within current financial debts on the consolidated balance sheet.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" id="SectionBlock_87bf163b-b6e9-4add-98c9-7d767794532f_0" escape="true" continuedAt="SectionBlock_87bf163b-b6e9-4add-98c9-7d767794532f_1">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Marketable securities, commodities and non-current financial assets </span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Commodities, which include gold bullion or coins, are valued at the lower of cost or fair value using current market prices. The changes in fair value below cost are immediately recorded in &#x201C;Other financial income and expense.&#x201D;</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities are financial assets held for short-term purposes which are principally traded in liquid markets and are classified within current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#x201C;Other financial income and expense&#x201D; in the consolidated income statement. Non-current financial assets held for long-term strategic purposes are classified within non-current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#x201C;Other income&#x201D; and &#x201C;Other expense&#x201D; in the consolidated income statement.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities and non-current financial assets are initially recorded at fair value on their trade date, which is different from the settlement date when the transaction is ultimately effected. Quoted securities are remeasured at each reporting date to fair value based on current market prices. If the market for a financial asset is not active or no market is available, fair values are established using valuation techniques. The majority of non-quoted investments are initially valued at fair value through the purchase price established between a willing buyer and seller. Non-quoted investments are subsequently adjusted based on values derived from discounted cash flow analysis or other pricing models. These investment values are classified as &#x201C;Level 3&#x201D; in the fair value hierarchy.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group classifies and accounts for its marketable securities and non-current financial assets in the following categories:</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Debt securities are valued at fair value through other comprehensive income with subsequent recycling into the consolidated income statement, as they meet both the &#x201C;solely payment of principal and interest&#x201D; and the business model criteria. Unrealized gains and losses, except exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are recognized in the consolidated income statement when the debt instrument is sold, at which time the gain is transferred to &#x201C;Other financial income and expense.&#x201D; Exchange gains and losses related to debt instruments are immediately recognized in the consolidated income statement in &#x201C;Other financial income and expense.&#x201D;</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Fund investments and equity securities of the Novartis Venture Fund are valued at fair value through profit and loss (FVPL). Unrealized gains and losses, including exchange gains and losses, are recognized in the consolidated income statement in &#x201C;Other income&#x201D; for gains and &#x201C;Other expense&#x201D; for losses.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Equity securities held as strategic investments, typically held outside of the Novartis Venture Fund, are generally designated at the date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. Unrealized gains and losses, including exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are reclassified to retained earnings when the equity security is sold. If these equity securities are not designated at the date of acquisition as financial assets valued at fair value through other comprehensive income, they are valued at FVPL, as described above.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Other non-current financial assets, such as loans and long-term receivables from customers, advances and other deposits, are valued at amortized cost, which reflects the time value of money less any allowances for expected credit losses.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group assesses on a forward-looking basis the expected credit losses associated with its debt securities valued at fair value through other comprehensive </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-9</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_cca394f9-d866-4256-84df-c075ace106fa_4" continuedAt="SectionBlock_cca394f9-d866-4256-84df-c075ace106fa_5">
          <div>
            <div>
              <ix:continuation id="SectionBlock_87bf163b-b6e9-4add-98c9-7d767794532f_1">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">income. Impairments on debt securities are recorded in &#x201C;Other financial income and expense.&#x201D;</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For other financial assets valued at amortized cost, impairments, which are based on their expected credit losses, and exchange rate losses are included in &#x201C;Other expense&#x201D; in the consolidated income statement. Exchange rate gains and interest income, using the effective interest rate method, are included in &#x201C;Other income&#x201D; or &#x201C;Other financial income&#x201D; in the consolidated income statement, depending on the nature of the item.</div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" id="SectionBlock_3987dd88-a459-48a0-b2cf-ee01026a1dfe_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Derivative financial instruments</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Derivative financial instruments are initially recognized in the balance sheet at fair value and are remeasured to their current fair value at the end of each subsequent reporting period. The valuation of a forward exchange rate contract is based on the discounted cash flow model, using interest rate curves and forward rates at the reporting date as observable inputs.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Options are valued based on a modified Black-Scholes model using volatility and exercise prices as major observable inputs.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group enters into certain derivative financial instruments for the purpose of hedging to reduce the volatility in the Group&#x2019;s performance due to the exposure to various business-related risks. The risk mitigation is obtained because the derivative&#x2019;s value or cash flows are expected, wholly or partly, to offset changes in the value or cash flows of the recognized assets or liabilities. The overall strategy is aiming to mitigate the currency and interest rate risk of positions that are contractually agreed, and to partially mitigate the exposure risk of selected anticipated transactions.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain derivative financial instruments meet the criteria for hedge accounting treatment. A prerequisite for obtaining this accounting-hedge relationship is extensive documentation on inception and proving on a regular basis that the economic hedge is effective for accounting purposes. Other derivative financial instruments do not meet the criteria to qualify for hedge accounting or are not designated in a hedge relationship. Changes in the fair value of these derivative instruments are recognized immediately in &#x201C;Other financial income and expense&#x201D; in the consolidated income statement.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, the Group has designated certain long-term debt components as hedges of the translation risk arising on certain net investments in foreign operations. On consolidation, foreign currency differences arising on long-term debt designated as net investment hedges of a foreign operation are recognized in other comprehensive income and accumulated in currency translation effects, to the extent that the hedge is effective. The foreign currency differences arising from hedge ineffectiveness are recognized in the income statement in &#x201C;Other financial income and expense.&#x201D;</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">When a hedged net investment is disposed of, the proportionate portion of the cumulative amount recognized in equity in relation to the hedged net investment is transferred to the consolidated income statement as an adjustment to the gain or loss on disposal.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories" id="SectionBlock_543e782b-168c-4cf3-a290-332e32fd8c02_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Inventories</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inventory is valued at the lower of acquisition or production cost determined on a first-in, first-out basis and net realizable value. This value is used for the &#x201C;Cost of goods sold&#x201D; in the consolidated income statement. Unsaleable inventory is fully written off in the consolidated income statement under &#x201C;Cost of goods sold.&#x201D;</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" id="SectionBlock_a58653db-a25b-4885-bc0c-b319786c0d35_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Trade receivables</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as rebates, chargebacks and cash discounts.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions for doubtful trade receivables are established using a forward-looking expected credit loss model (ECL), which includes possible default events on the trade receivables over the entire holding period of the trade receivable. These provisions represent the difference between the trade receivable&#x2019;s carrying amount in the consolidated balance sheet and the estimated collectible amount. Charges for doubtful trade receivables are recorded as marketing and selling costs recognized in the consolidated income statement within &#x201C;Selling, general and administration&#x201D; expenses.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory" id="SectionBlock_d4e7128d-a9cf-4198-a8f1-7b0eec3ca7e0_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Legal and environmental liabilities</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis and its subsidiaries are subject to contingencies arising in the ordinary course of business, such as patent litigation, environmental remediation liabilities and other product-related and commercial litigation, and governmental investigations and proceedings. A provision is recorded when there is a probable outflow of resources for which a reliable estimate can be made of the outcome of the legal or other disputes against the subsidiary.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" id="SectionBlock_c150c585-9975-4cd9-8bb9-2d48c8a9a348_0" escape="true" continuedAt="SectionBlock_c150c585-9975-4cd9-8bb9-2d48c8a9a348_1">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Contingent consideration</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In the acquisition or divestment of a business, it is necessary to recognize contingent future amounts due to previous owners, representing contractually defined potential amounts as a liability or an asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at fair value, which is then remeasured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance, and are adjusted for the probability of their likelihood of payment, and are appropriately discounted to reflect the impact of time.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in &#x201C;Cost of goods sold&#x201D; for currently marketed products and in &#x201C;Research and development&#x201D; for IPR&amp;D. Changes in contingent consideration assets are recognized in &#x201C;Other income&#x201D; or &#x201C;Other expense,&#x201D; depending on their nature. </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-10</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_cca394f9-d866-4256-84df-c075ace106fa_5" continuedAt="SectionBlock_cca394f9-d866-4256-84df-c075ace106fa_6">
          <div>
            <div>
              <ix:continuation id="SectionBlock_c150c585-9975-4cd9-8bb9-2d48c8a9a348_1">
                <div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The effect of unwinding the discount over time is recognized for contingent consideration liabilities in &#x201C;Interest expense&#x201D; and for contingent consideration assets as interest income recognized in the consolidated income statement within &#x201C;Other financial income and expense.&#x201D;</div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" id="SectionBlock_68f9a85b-acce-4131-b8a1-cb6998552239_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined benefit pension plans and&#xA0;other&#xA0;post-employment benefits</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The liability in respect of defined benefit pension plans and other post-employment benefits is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions in which employees are employed, while the net interest on the net defined benefit liability or asset is recognized as &#x201C;Other expense&#x201D; or &#x201C;Other income.&#x201D;</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory" id="SectionBlock_4c994d9a-4d13-4ea2-b0af-3259a4010d8b_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Treasury shares</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Treasury shares are initially recorded at fair value on their trade date, which is different from the settlement date, when the transaction is ultimately effected. Treasury shares are deducted from consolidated equity at their nominal value of CHF&#xA0;<ix:nonFraction unitRef="CHFPerShares" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:ParValuePerShare" decimals="2" scale="0">0.50</ix:nonFraction> per share. Differences between the nominal amount and the transaction price on purchases or sales of treasury shares with third parties, or the value of services received for the shares allocated to employees as part of share-based compensation arrangements, are recorded in &#x201C;Retained earnings&#x201D; in the consolidated statement of changes in equity.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" id="SectionBlock_a26c3984-c8d7-4c60-a0d5-3f48808c4ccc_0" escape="true" continuedAt="SectionBlock_a26c3984-c8d7-4c60-a0d5-3f48808c4ccc_1">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Revenue recognition</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Revenue on the sale of Novartis Group products and services, which is recorded as &#x201C;Net sales to third parties&#x201D; in the consolidated income statement, is recognized when a contractual promise to a customer (performance obligation) has been fulfilled by transferring control over the promised goods and services to the customer, substantially all of which is at the point in time of shipment to or receipt of the products by the customer or when the services are performed. If contracts contain customer acceptance provisions, revenue is recognized upon the satisfaction of the acceptance criteria. If a contract contains more than one performance obligation, the consideration is allocated based on the standalone selling price of each performance obligation. The amount of revenue recognized is based on the consideration Novartis expects to receive in exchange for its goods and services, when it is highly probable that a significant reversal will not occur.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consideration Novartis receives in exchange for its goods or services may be fixed or variable. Variable consideration is recognized when it is highly probable that a significant reversal will not occur. The most common elements of variable consideration are listed below.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Rebates and discounts granted to wholesalers, retailers, government agencies (including US Medicaid and US Federal Medicare programs), government supported healthcare systems, private health systems, pharmacy benefit managers, managed healthcare organizations, purchasing organizations and other direct and indirect customers, as well as chargebacks are provisioned and recorded as revenue deductions at the time the related revenues are recorded, or when the incentives are offered. These rebates and discounts, applied using provision rates, are estimated based on the terms and conditions in the individual states, plans and customer agreements, historical experience, product sales and growth rate, population growth, product pricing including inflation impacts, the mix of contracts and products, the level of inventory in the distribution channel, regulations, contracts, channels and payers, as appropriate to the individual rebate and discount arrangements.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Refunds granted to healthcare providers under innovative pay-for-performance agreements (i.e. outcome based arrangements) are provisioned and recorded as a revenue deduction at the time the related sales are recorded. They are calculated on the basis of historical experience and clinical data available for the product, as well as specific terms of the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until the uncertainty is resolved, until such history is available or the period when the refund right has expired. The provisions for revenue deductions under the innovative pay-for-performance agreements are adjusted periodically based on established processes and actual experience, including the products actual outcomes achieved compared with the anticipated predefined targets.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Cash discounts are offered to customers to encourage prompt payment and are provisioned and recorded as revenue deductions at the time the related sales are recorded.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Shelf stock adjustments are generally granted to customers, primarily of the Sandoz Division, to cover the inventory held by them at the time a price decline becomes effective. Revenue deduction provisions for shelf stock adjustments are recorded when the price decline is anticipated, based on the impact of the price decline on the customer&#x2019;s estimated inventory levels. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Sales returns provisions are recognized and recorded as revenue deductions when there is historical experience of Novartis agreeing to customer returns and Novartis can reasonably estimate expected future returns. In doing so, the estimated rate of return is applied, determined on the basis of historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a resale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Net sales to third parties and provisions for revenue deductions are adjusted periodically to reflect experience and to reflect actual amounts as rebates, refunds, </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-11</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_cca394f9-d866-4256-84df-c075ace106fa_6" continuedAt="SectionBlock_cca394f9-d866-4256-84df-c075ace106fa_7">
          <div>
            <div>
              <ix:continuation id="SectionBlock_a26c3984-c8d7-4c60-a0d5-3f48808c4ccc_1">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">discounts and returns are processed. There is often a time lag between recording of revenue deductions and the final accounting for them. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these revenue deductions.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">&#x201C;Other revenue&#x201D; includes income from profit-sharing arrangements with our collaboration partners, and royalty and milestone income from the out-licensing of intellectual property when Novartis retains an interest in the intellectual property through a license. Royalty income earned from a license is recognized when the underlying sales have occurred. Milestone income is recognized at the point in time when it is highly probable that the relevant milestone event criteria are met, and the risk of reversal of revenue recognition is remote. &#x201C;Other revenue&#x201D; also includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties, and is recognized when control transfers to the third party and our performance obligations are satisfied. </div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" id="SectionBlock_f078b42e-edbb-4178-95f6-5b5f36ae1db7_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Research and development</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Internal research and development (R&amp;D) costs are fully charged to &#x201C;Research and development&#x201D; in the consolidated income statement in the period in which they are incurred. The Group considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland or Japan.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&amp;D, that are deemed not to transfer intellectual property to Novartis are expensed as internal R&amp;D expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been received from a regulatory authority in a major market.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are capitalized, as are payments for other assets, such as technologies to be used in R&amp;D activities. If additional payments are made to the originator company to continue performing R&amp;D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&amp;D services not resulting in an additional transfer of intellectual property rights to Novartis. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Novartis of additional intellectual property developed at the risk of the originator company. Subsequent internal R&amp;D costs in relation to IPR&amp;D and other assets are expensed, since the technical feasibility of the internal R&amp;D activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval in a major market are capitalized and recognized as currently marketed products.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Inventory produced ahead of regulatory approval is fully provisioned, and the charge is included in &#x201C;Other expense&#x201D; in the consolidated income statement, as its ultimate use cannot be assured. If this inventory can subsequently be sold, the provision is released to &#x201C;Other income&#x201D; in the consolidated income statement, either on approval by the appropriate regulatory authority or, exceptionally in Europe, on recommendation by the Committee for Medicinal Products for Human Use (CHMP), if approval is virtually certain.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="SectionBlock_0b2f7514-a089-4fec-bd00-da1c9263a0d8_0" escape="true" continuedAt="SectionBlock_0b2f7514-a089-4fec-bd00-da1c9263a0d8_1">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Share-based compensation</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Vested Novartis shares and American Depositary Receipts (ADRs) that are granted as compensation are valued at their market value on the grant date and are immediately expensed in the consolidated income statement.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair values of unvested restricted shares (RSs), restricted share units (RSUs) and performance share units (PSUs) in Novartis shares and ADRs granted to employees as compensation are recognized as an expense over the related vesting period. The expense recorded in the consolidated income statement is included in the personnel expenses of the various functions in which the employees are employed.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Unvested restricted shares, restricted ADRs and RSUs are only conditional on the provision of services by the plan participant during the vesting period. They are valued at fair value on the grant date. As RSUs do not entitle the holder to dividends, the fair value is based on the Novartis share price at the grant date adjusted for the net present value of the dividends expected to be paid during the holding period. The fair value of these grants, after making adjustments for assumptions related to forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">PSUs are subject to the achievement of certain performance criteria during the vesting period and require plan participants to provide services during this period. The following paragraphs provide an overview of the accounting policies for the share-based compensation plan that grant PSUs. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs that are subject to performance criteria based on Novartis internal performance metrics and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on assumptions concerning the expected performance against the internal performance metrics throughout the vesting period. The assumptions are based on the Group&#x2019;s targets for those performance metrics, and the expected forfeitures due to plan participants not meeting their service conditions. The </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-12</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_cca394f9-d866-4256-84df-c075ace106fa_7" continuedAt="SectionBlock_cca394f9-d866-4256-84df-c075ace106fa_8">
          <div>
            <div>
              <ix:continuation id="SectionBlock_0b2f7514-a089-4fec-bd00-da1c9263a0d8_1">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">assumptions are periodically adjusted over the vesting period. Any change in estimates for past services is recorded immediately as an expense or income in the consolidated income statement, and amounts for the remaining vesting period are expensed on a straight-line basis. As a result, at the end of the vesting period, the charge during the entire vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs that are subject to performance criteria based on variables that can be observed in the market, which for Novartis plans is the Novartis total shareholder return (TSR) relative to a specific peer group of companies over the vesting period, and that are conditional on the provision of services by the plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on the total fair value of the grant over the vesting period. IFRS requires that these variables that can be observed in the market are taken into account in determining the fair value of the PSUs at the grant date. Novartis determined the fair value of these PSUs at the date of grant using a Monte Carlo simulation model. Adjustments to the number of equity instruments granted are only made if a plan participant does not fulfill the service conditions.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs granted under plans that are subject to both performance criteria based on Novartis internal performance metrics and Novartis TSR relative to a specific  peer group of companies over the vesting period and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on a bifurcation into the components based on the performance criteria related to Novartis internal performance metrics and TSR, as described in the paragraphs above.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Measuring the fair values of PSUs granted that include TSR performance criteria requires use of estimates. The Monte Carlo simulation used to determine the fair value of the PSUs TSR performance criteria requires the probability of factors related to uncertain future events; the term of the award; the grant price of underlying shares or ADRs; expected volatilities; the expected correlation matrix of the underlying equity instruments with those of the peer group of companies; and the risk-free interest rate as input parameters.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If a plan participant leaves Novartis for reasons other than retirement, disability or death, then unvested restricted shares, restricted ADRs, RSUs and PSUs are forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Novartis Board of Directors, for example, in connection with a reorganization or divestment.</div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants" id="SectionBlock_036bff7f-aa1e-4f43-9b4b-d7f18b81e8de_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Government grants</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Grants from governments or similar organizations are recognized at their fair value when there is reasonable assurance that the grant will be received and the Group will comply with all attached conditions.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Government grants received to compensate costs are deferred and recognized in the consolidated income statement over the period necessary to match them against the related costs that they are intended to compensate.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The accounting policy for property, plant and equipment describes the treatment of any related grants.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" id="SectionBlock_ff13d9b8-5e85-42fd-a343-29f17cbf1847_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Restructuring charges</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Restructuring provisions are recognized for the direct expenditure arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Charges to increase restructuring provisions are included in &#x201C;Other expense&#x201D; in the consolidated income statements. </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" id="SectionBlock_96a1979d-3a9c-48e6-b9a7-71bea5b7405b_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Healthcare contributions</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Healthcare cost contribution levies and fees under governmental programs that require the Group to contribute to a country&#x2019;s healthcare costs, other than programs described in &#x201C;Revenue recognition&#x201D; in this Note 1, are recognized in &#x201C;Other expense&#x201D; in the consolidated income statement. Provisions for healthcare cost contributions are adjusted to the actual amounts levied. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these healthcare cost contributions. </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory" id="SectionBlock_055b6e76-eb92-4c11-bb03-41901fca69be_0" escape="true" continuedAt="SectionBlock_055b6e76-eb92-4c11-bb03-41901fca69be_1">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Income taxes</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Income taxes comprise current income taxes and deferred income taxes and are recognized in the same periods as the revenues and expenses to which they relate. Income taxes include interest and penalties incurred during the period, insofar as they are considered an income tax. Income taxes related to items recognized directly to other comprehensive income or to equity are recognized together with the corresponding item, to which the income tax is attributable, directly in other comprehensive income or in equity.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Deferred income taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax base of an asset or liability and its carrying value for financial reporting purposes, except for those temporary differences related to investments in subsidiaries and associated companies, where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary&#x2019;s retained earnings are only recognized when a dividend is declared or has been planned. Furthermore, deferred income taxes are recognized for the net tax effects of net operating loss carryforwards and tax credits. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The carrying amount of deferred tax assets is reduced to the extent that it is not probable that sufficient taxable profits will be available to enable all or part of the asset to be recovered. In evaluating our ability to recover our deferred tax assets in the jurisdiction from </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-13</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_cca394f9-d866-4256-84df-c075ace106fa_8" continuedAt="SectionBlock_cca394f9-d866-4256-84df-c075ace106fa_9">
          <div>
            <div>
              <ix:continuation id="SectionBlock_055b6e76-eb92-4c11-bb03-41901fca69be_1">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimated amounts for current and deferred tax assets or liabilities, including amounts related to any uncertain tax positions, are based on applicable tax law and regulations in the various tax jurisdictions, in which the Group operates, which are subject to interpretations based on currently known facts and circumstances.  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Tax returns are based on an interpretation of tax laws and regulations, and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made requiring payments of additional tax, interest or penalties. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The calculation of income tax assets and liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions across our global operations. As a result, inherent uncertainties exist in the estimates of the tax positions. Tax liabilities for uncertain tax provisions are recognized on the consolidated balance sheets within current income tax liabilities.</div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" id="SectionBlock_3b79c294-3afb-418a-98ac-18fbd95eb241_0" escape="true" continuedAt="SectionBlock_3b79c294-3afb-418a-98ac-18fbd95eb241_1">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of new IFRS standards, amendments and interpretations in 2022</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There were no new IFRS standards adopted by the Group in 2022. In addition, new IFRS amendments or interpretations that became effective in 2022 did not have a material impact to the Group&#x2019;s consolidated financial statements. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Based on the Group&#x2019;s assessment, there are no IFRS standards, amendments or interpretations not yet effective in 2022 that would be expected to have a material impact on the Group&#x2019;s consolidated financial statements.</div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of adopting significant new IFRS standard in 2021</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following new IFRS standard has been adopted by Novartis from January 1, 2021:</div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest Rate Benchmark Reform &#x2013; Phase 2, Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 (Interest Benchmark Reform Amendments)</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Interest Benchmark Reform Amendments became effective from January 1, 2021. These amendments address issues that might affect financial reporting when an existing interest rate benchmark (i.e. Interbank offered rate &#x2013; IBOR) is replaced with an alternative benchmark interest rate. The effects of interest rate benchmark reform on the Group&#x2019;s financial instruments and risk management strategies did not have a material impact on the Group&#x2019;s consolidated financial statements.</div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of adopting significant new IFRS standard in 2020</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following new IFRS standard has been adopted by Novartis from January 1, 2020:</div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">IFRS 3 Business Combinations amendments</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The IASB issued amendments to IFRS 3 Business Combinations that revised the definition of a business, which assist entities with the evaluation of when an asset or group of assets acquired should be considered a business. This amended standard has been applied to transactions entered into on or after January 1, 2020. The amended standard allows an entity to apply an optional concentration test, on a transaction-by-transaction basis, to evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this optional concentration test is met, the set of activities and assets is determined not to be a business. The adoption of this amended standard on January 1, 2020, did not have a significant impact on our consolidated financial statements and is not expected to have a significant impact in future periods. However, this will depend on the facts and circumstances of future transactions and if the Group decides to apply the optional concentration test in the assessment of whether an acquired set of activities and assets is or is not a business.</div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-14</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_cca394f9-d866-4256-84df-c075ace106fa_9">
          <div>
            <div>
              <ix:continuation id="SectionBlock_3b79c294-3afb-418a-98ac-18fbd95eb241_1">
                <div></div>
              </ix:continuation>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfSignificantTransactionsTextBlock" id="SectionBlock_ebe58e15-af12-421e-b9f5-a20b8d01a03f_0" escape="true" continuedAt="SectionBlock_ebe58e15-af12-421e-b9f5-a20b8d01a03f_1">
          <div>
            <div id="anchorId001517396"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">2. Significant transactions</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group applied the acquisition method of accounting for businesses acquired, and did not elect to apply the optional concentration test to account for acquired business as an asset separately acquired.</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2022</span>
            </div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &#x2013; acquisition of Gyroscope Therapeutics Holdings plc</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On December 22, 2021, Novartis entered into an agreement to acquire all outstanding shares of Gyroscope Therapeutics Holdings plc (Gyroscope), a UK-based ocular gene therapy company. Gyroscope focuses on the discovery and development of gene therapy treatments for retinal indications. The purchase price consisted of a cash payment of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-December-22-2021_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" decimals="-8" scale="9">0.8</ix:nonFraction> billion, subject to certain customary purchase price adjustments, and potential additional milestone payments of up to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-December-22-2021_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:PotentialMilestoneMaximumPayments" decimals="-8" scale="9">0.7</ix:nonFraction> billion, which Gyroscope shareholders are eligible to receive upon achievement of specified milestones. The acquisition closed on February 17, 2022. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD <ix:nonFraction unitRef="USD" contextRef="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" decimals="-8" scale="9">1.0</ix:nonFraction> billion. The amount consisted of an upfront cash payment of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" decimals="-8" scale="9">0.8</ix:nonFraction> billion (including customary purchase price adjustments) and the fair value of contingent consideration of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" decimals="-8" scale="9">0.2</ix:nonFraction> billion, which Gyroscope shareholders are eligible to receive upon achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" decimals="-8" scale="9">0.9</ix:nonFraction> billion, consisting primarily of intangible assets of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" decimals="-8" scale="9">1.1</ix:nonFraction> billion and net deferred tax liabilities of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-8" scale="9">0.2</ix:nonFraction> billion. Goodwill amounted to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionalRecognitionGoodwill" decimals="-8" scale="9">0.1</ix:nonFraction> billion.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The results of operations since the date of acquisition are not material.</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2021</span>
            </div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz &#x2013; acquisition of GSK&#x2019;s cephalosporin antibiotics business</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On February 10, 2021, Sandoz entered into an agreement with certain subsidiaries of GlaxoSmithKline plc (GSK) for the acquisition of the GSK&#x2019;s cephalosporin antibiotics business. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Under the agreement, Sandoz acquired the global rights to <ix:nonFraction unitRef="Pure" contextRef="AR_I-February-10-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:NumberOfBrandsInPortfolioToAcquire" decimals="0" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> established brands (Zinnat&#xAE;, Zinacef&#xAE; and Fortum&#xAE;) in more than <ix:nonFraction unitRef="Pure" contextRef="AR_I-February-10-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:NumberOfMarketsForTheAcquiredBrands" decimals="0" scale="0" format="ixt:numdotdecimal">100</ix:nonFraction> markets. It excluded the rights in the US, Australia and Germany to certain of those brands, which were previously divested by GSK, and the rights in India, Pakistan, Egypt, Japan (to certain of the brands) and China, which will be retained by GSK. The transaction closed on October 8, 2021.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The purchase price consisted of a USD <ix:nonFraction unitRef="USD" contextRef="AR_D-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">350</ix:nonFraction> million upfront payment paid at closing and potential milestone payments up to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:PotentialMilestoneMaximumPayments" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction> million, which GSK will be eligible to receive upon the achievement of certain annual sales milestones for the portfolio.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD <ix:nonFraction unitRef="USD" contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" decimals="-6" scale="6" format="ixt:numdotdecimal">415</ix:nonFraction> million. The amount consisted of a payment of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:CashTransferred" decimals="-6" scale="6" format="ixt:numdotdecimal">351</ix:nonFraction> million, including purchase price adjustments, and the fair value of contingent consideration of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonFraction> million, which GSK is eligible to receive upon the achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" decimals="-6" scale="6" format="ixt:numdotdecimal">308</ix:nonFraction> million, consisting of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">292</ix:nonFraction> million intangible assets and USD <ix:nonFraction unitRef="USD" contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction> million deferred tax assets. Goodwill amounted to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionalRecognitionGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">107</ix:nonFraction> million. </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The 2021 results of operations since the date of acquisition were not material.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Corporate &#x2013; divestment of the investment in Roche Holding AG </span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 3, 2021, Novartis entered into a Share Repurchase Agreement with Roche Holding AG under which Novartis agreed to sell <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:NumberOfBearerShares" decimals="-5" scale="6">53.3</ix:nonFraction> million (approximately <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ProportionOfVotingPowerHeldInAssociate" decimals="3" scale="-2">33.3</ix:nonFraction>%</span>) bearer shares of Roche Holding AG voting shares in a bilateral transaction to Roche Holding AG for a total consideration of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" decimals="-8" scale="9">20.7</ix:nonFraction> billion. As a result, Novartis discontinued the use of equity method accounting starting from November 3, 2021.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The transaction closed on December 6, 2021. Novartis realized a gain of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:GainOnDivestmentOfInterestsInAssociatedCompanies" decimals="-8" scale="9">14.6</ix:nonFraction> billion, recorded in income from associated companies.</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2020</span>
            </div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &#x2013; acquisition of The&#xA0;Medicines Company</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 23, 2019, Novartis entered into an agreement and plan of merger (&#x201C;the Merger Agreement&#x201D;) with The Medicines Company, a US-based pharmaceutical company headquartered in Parsippany, New Jersey, USA. Pursuant to the Merger Agreement, on December 5, 2019, Novartis, through a subsidiary, commenced a tender offer to acquire all outstanding shares of The Medicines Company for USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-TheMedicinesCompany_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:CashOfferPerOrdinaryShare" decimals="1" scale="0" format="ixt:numdotdecimal">85</ix:nonFraction> per share, or a total consideration of approximately USD <ix:nonFraction unitRef="USD" contextRef="AR_D-Transaction-TheMedicinesCompany_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" decimals="-8" scale="9">9.6</ix:nonFraction> billion in cash on a fully diluted basis, including the equivalent share value related to The Medicines Company&#x2019;s convertible notes, in accordance with their terms. The tender offer expired on January 3, 2020, and on January 6, 2020, the acquiring subsidiary merged with and into The Medicines Company, resulting in The Medicines Company becoming an indirect wholly owned subsidiary of Novartis. Novartis financed the transaction through available cash, and short- and long-term borrowings. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Medicines Company is focused on the development of inclisiran, a potentially first-in-class, twice yearly therapy that allows administration during patients&#x2019; routine visits to their healthcare professionals and will potentially contribute to improved patient adherence and sustained lower LDL-C levels.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" decimals="-8" scale="9">9.6</ix:nonFraction> billion. The purchase price allocation resulted in net identifiable assets of approximately USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" decimals="-8" scale="9">7.1</ix:nonFraction> billion, consisting of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" decimals="-8" scale="9">8.5</ix:nonFraction> billion intangible assets, USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-8" scale="9">1.4</ix:nonFraction></div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-15</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_ebe58e15-af12-421e-b9f5-a20b8d01a03f_1" continuedAt="SectionBlock_ebe58e15-af12-421e-b9f5-a20b8d01a03f_2">
          <div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> billion net deferred tax liabilities and goodwill of approximately USD <ix:nonFraction unitRef="USD" contextRef="AR_D-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionalRecognitionGoodwill" decimals="-8" scale="9">2.5</ix:nonFraction> billion. </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The 2020 results of operations since the date of acquisition were not material.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz &#x2013; acquisition of the Japanese business of Aspen Global Incorporated </span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 11, 2019, Sandoz entered into an agreement for the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Under the agreement, Sandoz acquired the shares in Aspen Japan K.K. and associated assets held by AGI. The transaction closed on January 31, 2020.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Aspen&#x2019;s portfolio in Japan consisted of off-patent medicines with a focus on anesthetics and specialty brands. The acquisition will enable Sandoz to expand its presence in the third-largest worldwide generics marketplace.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The purchase price consisted of EUR <ix:nonFraction unitRef="EUR" contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" decimals="-5" scale="6" format="ixt:numdotdecimal">274</ix:nonFraction> million (USD <ix:nonFraction unitRef="USD" contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" decimals="-5" scale="6" format="ixt:numdotdecimal">303</ix:nonFraction> million) upfront payment, less customary purchase price adjustment of EUR <ix:nonFraction unitRef="EUR" contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:CustomaryPurchasePriceAdjustment" decimals="-5" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction> million (USD <ix:nonFraction unitRef="USD" contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:CustomaryPurchasePriceAdjustment" decimals="-5" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction> million), plus potential milestone payments of up to EUR <ix:nonFraction unitRef="EUR" contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:PotentialMilestoneMaximumPayments" decimals="-5" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction> million (USD <ix:nonFraction unitRef="USD" contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:PotentialMilestoneMaximumPayments" decimals="-5" scale="6" format="ixt:numdotdecimal">77</ix:nonFraction> million), which AGI is eligible to receive upon the achievement of specified milestones.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was EUR <ix:nonFraction unitRef="EUR" contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" decimals="-5" scale="6" format="ixt:numdotdecimal">294</ix:nonFraction> million (USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" decimals="-5" scale="6" format="ixt:numdotdecimal">324</ix:nonFraction> million). The amount consisted of a cash payment of EUR <ix:nonFraction unitRef="EUR" contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:CashTransferred" decimals="-5" scale="6" format="ixt:numdotdecimal">247</ix:nonFraction> million (USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:CashTransferred" decimals="-5" scale="6" format="ixt:numdotdecimal">273</ix:nonFraction> million) and the fair value of contingent consideration of EUR <ix:nonFraction unitRef="EUR" contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" decimals="-5" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction> million (USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate" decimals="-5" scale="6" format="ixt:numdotdecimal">51</ix:nonFraction> million), which AGI is eligible to receive upon the achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" decimals="-5" scale="6" format="ixt:numdotdecimal">238</ix:nonFraction> million, consisting of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" decimals="-5" scale="6" format="ixt:numdotdecimal">196</ix:nonFraction> million intangible assets, USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:OtherNetAssets" decimals="-5" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction> million other net assets and USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-5" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction> million net deferred tax assets. Goodwill amounted to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionalRecognitionGoodwill" decimals="-5" scale="6" format="ixt:numdotdecimal">86</ix:nonFraction> million. </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The 2020 results of operations since the date of acquisition were not material.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz &#x2013; retention of US dermatology business and generic US oral solids portfolio, previously planned to be divested</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On September 6, 2018, Novartis announced that it entered into a stock and asset purchase agreement (SAPA) with Aurobindo Pharma USA Inc. (Aurobindo) for the sale of selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, for USD <ix:nonFraction unitRef="USD" contextRef="AR_I-Transaction-Sandoz-Divestment_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember" name="nvs:DivestmentDateFairValueOfTotalConsiderationTransferred" decimals="-8" scale="9">0.8</ix:nonFraction> billion in cash and potential earnouts. The closing was conditional on obtaining regulatory approval.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In March 2020, Novartis took the decision to retain the Sandoz US generic oral solids and dermatology businesses and on April 2, 2020 entered into a mutual agreement with Aurobindo to terminate the transaction. The decision was taken as approval from the US Federal Trade Commission for the transaction was not obtained within the agreed timelines.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The cumulative amount of the depreciation on property, plant and equipment (USD <ix:nonFraction unitRef="USD" contextRef="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationPropertyPlantAndEquipment" decimals="-5" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction> million) and amortization on intangible assets (USD <ix:nonFraction unitRef="USD" contextRef="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" decimals="-5" scale="6" format="ixt:numdotdecimal">102</ix:nonFraction> million) not recorded in the consolidated income statement since the date of classification as held for sale was recognized in the consolidated income statement in the first quarter of 2020. In addition, an impairment of currently marketed products of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-5" scale="6" format="ixt:numdotdecimal">42</ix:nonFraction> million was recognized in the first quarter of 2020 consolidated income statement.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As at March 31, 2020, the assets and liabilities of the Sandoz US generic oral solids and dermatology businesses were reclassified out of assets and liabilities of disposal group held for sale. The prior year balance sheet was not required to be restated.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There were no cumulative income or expenses included in the other comprehensive income relating to the disposal group.</div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-16</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_ebe58e15-af12-421e-b9f5-a20b8d01a03f_2">
          <div></div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" id="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_0" escape="true" continuedAt="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_1">
          <div>
            <div id="anchorId001517643"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">3. Segmentation of key figures 2022, 2021 and 2020</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The businesses of Novartis are divided operationally on a worldwide basis into <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:NumberOfReportableSegments" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> identified reporting segments: Innovative Medicines and Sandoz. In addition, we separately report Corporate activities.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Reporting segments are presented in a manner consistent with the internal reporting to the chief operating decision-maker, which is the Executive Committee of Novartis. The reporting segments are managed separately because they each research, develop, manufacture, distribute and sell distinct products that require differing marketing strategies. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Executive Committee of Novartis is responsible for allocating resources and assessing the performance of the reporting segments.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The reporting segments are as follows:</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Innovative Medicines researches, develops, manufactures, distributes and sells patented pharmaceuticals. Effective as of April 4, 2022, the Innovative Medicines Division is organized in <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:NumberOfCommercialOrganizationalUnits" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> commercial organizational units: Innovative Medicines International and Innovative Medicines US, and is focused on the core therapeutic areas: cardiovascular; immunology; neuroscience; solid tumors and hematology; as well as other promoted brands (in the therapeutic areas of ophthalmology and respiratory) and established brands. Prior to the announcement on April 4, 2022, the Innovative Medicines Division was organized into <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:NumberOfBusinessUnits" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> global business units: Novartis Oncology and Novartis Pharmaceuticals.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sandoz develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. Sandoz is organized globally into <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:NumberOfFranchises" decimals="0" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> franchises: Retail Generics, Anti-Infectives and Biopharmaceuticals. In Retail Generics, Sandoz develops, manufactures and markets finished dosage forms of small molecule pharmaceuticals for sale to third parties across a broad range of therapeutic areas, including finished dosage form of anti-infectives sold to third parties. In Anti-Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by Retail Generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products, including biosimilars, and provides biotechnology manufacturing services to other companies.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Income and expenses relating to Corporate include the costs of the Group headquarters and those of corporate coordination functions in major countries. In addition, Corporate includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights, certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships. Usually, no allocation of Corporate items is made to the segments. As a result, Corporate assets and liabilities principally consist of net debt (cash and cash equivalents, marketable securities less financial debts), investments in associated companies, and current and deferred taxes and non-segment-specific environmental remediation and post-employment benefit liabilities. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our divisions are supported by Novartis Institutes for BioMedical Research, Global Drug Development, and the Operations unit. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The Novartis Institutes for BioMedical Research (NIBR) conducts research activities for the Innovative Medicines Division and also collaborates with Sandoz. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The Global Drug Development organization oversees all drug development activities for our Innovative Medicines Division and collaborates with our Sandoz Division on the development of its biosimilars portfolio.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The Operations unit, combines the Novartis Technical Operations (NTO) and Customer &amp; Technology Solutions (CTS), following the internal reorganization announced on April 4, 2022. The Operations unit manages our manufacturing operations across our Innovative Medicines and Sandoz Divisions, and delivers business support services across the Group, such as information technology, real estate and facility services and procurement.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The accounting policies mentioned in Note 1 are used in the reporting of segment results. Inter-segmental sales are made at amounts that are considered to approximate arm&#x2019;s length transactions. The Executive Committee of Novartis evaluates segmental performance and allocates resources among the segments based on a number of measures, including net sales to third parties, operating income and net operating assets. Segment net operating assets consist primarily of property, plant and equipment; right-of-use assets; intangible assets; goodwill; inventories; and trade and other operating receivables less operating liabilities.</div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-17</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_1" continuedAt="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_2">
          <div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory" id="SectionBlock_224e37ff-36d4-4efc-a4cb-a6ae43da48c3_0" escape="true" continuedAt="SectionBlock_224e37ff-36d4-4efc-a4cb-a6ae43da48c3_1">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#x2013; consolidated income statements</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate  (including eliminations)<sup>1</sup></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group  </div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">41 296</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">41 995</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 249</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 631</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">50 545</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">51 626</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to other segments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal">825</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal">795</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal">205</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 030</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">975</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">42 121</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">42 790</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">9 454</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">9 811</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 030</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">975</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">50 545</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">51 626</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 249</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 179</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">61</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 283</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 251</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">11 569</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">11 751</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">4 978</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">5 147</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 061</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 031</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">15 486</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">15 867</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">31 801</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">32 218</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">4 504</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">4 725</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">36 342</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">37 010</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">11 679</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">12 306</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">2 062</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">2 062</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">512</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">518</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">14 253</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">14 886</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">9 172</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">8 641</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">824</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">899</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">9 996</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">9 540</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">531</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 149</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">103</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">233</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">171</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">470</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">805</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 852</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">2 695</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">1 732</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">273</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">397</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">733</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">618</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">3 701</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">2 747</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">8 786</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">10 688</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 448</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 600</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 037</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">599</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">9 197</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">11 689</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Loss)/income from associated companies</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">15 332</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">15 339</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:InterestExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">837</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:InterestExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">811</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">80</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">8 371</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">26 137</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">1 416</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">2 119</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">6 955</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">24 018</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Shareholders of Novartis AG</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">6 955</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">24 021</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Non-controlling interests</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net income are:</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Interest income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:RevenueFromInterest" decimals="-6" scale="6" format="ixt:numdotdecimal">379</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:RevenueFromInterest" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Depreciation of property, plant and equipment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">837</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">859</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">210</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">122</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">139</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">1 163</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">1 208</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Depreciation of right-of-use assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">252</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">265</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">300</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">318</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Amortization of intangible assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">3 728</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">3 638</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">222</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">238</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">3 982</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">3 903</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Impairment charges on property, plant and equipment, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">407</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">271</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">407</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">281</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Impairment of right-of-use assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Impairment charges on intangible assets, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">1 299</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">367</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">1 326</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">403</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Impairment charges and fair value changes on financial assets, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">134</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">126</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">260</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Additions to restructuring provisions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">1 069</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">240</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">259</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">1 368</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">328</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Equity-based compensation of Novartis equity plans</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">706</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">721</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">65</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">280</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">193</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">1 048</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">979</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-18</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_2" continuedAt="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_3">
          <div>
            <div>
              <ix:continuation id="SectionBlock_224e37ff-36d4-4efc-a4cb-a6ae43da48c3_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate  (including eliminations)<sup>1</sup></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group  </div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">41 995</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">39 013</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 631</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 646</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">51 626</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">48 659</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to other segments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal">795</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal">792</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal">189</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">975</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:RevenueFromSaleOfGoodsSalesToOtherSegments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">981</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">42 790</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">39 805</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">9 811</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">9 835</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">975</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">981</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">51 626</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:RevenueFromSaleOfGoods" decimals="-6" scale="6" format="ixt:numdotdecimal">48 659</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 179</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 018</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">61</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">168</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 251</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 239</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">11 751</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">10 927</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">5 147</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">5 252</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 031</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 058</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">15 867</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CostOfSales" decimals="-6" scale="6" format="ixt:numdotdecimal">15 121</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">32 218</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">29 896</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">4 725</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">4 636</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">245</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">37 010</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:GrossProfit" decimals="-6" scale="6" format="ixt:numdotdecimal">34 777</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">12 306</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">11 657</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">2 062</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">2 076</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">518</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">464</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">14 886</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:SellingGeneralAndAdministrativeExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">14 197</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">8 641</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">8 118</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">899</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">862</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">9 540</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ResearchAndDevelopmentExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">8 980</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 149</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">922</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">233</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">176</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">470</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">644</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 852</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 742</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">1 732</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">1 871</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">397</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">831</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">618</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">488</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">2 747</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherExpenseByFunction" decimals="-6" scale="6" format="ixt:numdotdecimal">3 190</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">10 688</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">9 172</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 600</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 043</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">599</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">63</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">11 689</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLossFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">10 152</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">15 332</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">670</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">15 339</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">673</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:InterestExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">811</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:InterestExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">869</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">80</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">78</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">26 137</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">9 878</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">2 119</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">1 807</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">24 018</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">8 071</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Shareholders of Novartis AG</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">24 021</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">8 072</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Non-controlling interests</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net income are:</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Interest income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:RevenueFromInterest" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:RevenueFromInterest" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Depreciation of property, plant and equipment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">859</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">912</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">210</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">282</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">139</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">124</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">1 208</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">1 318</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Depreciation of right-of-use assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">265</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">273</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">318</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">330</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Amortization of intangible assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">3 638</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">3 080</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">238</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">370</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">3 903</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DepreciationAndAmortisationExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">3 462</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Impairment charges on property, plant and equipment, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">271</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">324</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">116</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">281</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">440</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Impairment charges on intangible assets, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">367</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">768</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">141</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">403</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">914</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Impairment charges and fair value changes on financial assets, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal">153</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal">182</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" decimals="-6" scale="6" format="ixt:numdotdecimal">335</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Additions to restructuring provisions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">240</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">217</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">98</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">328</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">354</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Equity-based compensation of Novartis equity plans</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">721</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">714</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">65</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">193</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">979</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">958</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:continuation>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-19</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_3" continuedAt="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_4">
          <div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" id="SectionBlock_23793b69-49b6-423e-86b6-1a8b9caa3ae5_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#x2013; consolidated balance sheets</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate  (including eliminations)<sup>1</sup></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group  </div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total assets</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:Assets" decimals="-6" scale="6" format="ixt:numdotdecimal">75 510</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:Assets" decimals="-6" scale="6" format="ixt:numdotdecimal">79 220</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:Assets" decimals="-6" scale="6" format="ixt:numdotdecimal">16 078</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:Assets" decimals="-6" scale="6" format="ixt:numdotdecimal">16 192</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:Assets" decimals="-6" scale="6" format="ixt:numdotdecimal">25 865</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:Assets" decimals="-6" scale="6" format="ixt:numdotdecimal">36 383</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Assets" decimals="-6" scale="6" format="ixt:numdotdecimal">117 453</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Assets" decimals="-6" scale="6" format="ixt:numdotdecimal">131 795</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:Liabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">16 966</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:Liabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">15 929</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:Liabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">3 710</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:Liabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">3 632</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:Liabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">37 354</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:Liabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">44 412</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Liabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">58 030</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Liabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">63 973</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">59 423</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Equity" decimals="-6" scale="6" format="ixt:numdotdecimal">67 822</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net debt<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">7 245</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">868</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">7 245</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">868</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net operating assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:NetOperatingAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">58 544</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:NetOperatingAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">63 291</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:NetOperatingAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">12 368</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:NetOperatingAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">12 560</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:NetOperatingAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 244</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:NetOperatingAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7 161</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:NetOperatingAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">66 668</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:NetOperatingAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">68 690</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in assets and liabilities are:</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Total property, plant and equipment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">8 488</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">9 168</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 861</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 901</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">415</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">476</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">10 764</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">11 545</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Additions to property, plant and equipment<sup style="white-space: nowrap"> &#xA0;3</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">842</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">991</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">292</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">349</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">85</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 219</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 430</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Total right-of-use assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 233</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 349</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">104</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">108</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">108</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 431</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 561</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Additions to right-of-use assets<sup style="white-space: nowrap">&#xA0;3</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionsToRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">196</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionsToRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">222</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionsToRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionsToRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:AdditionsToRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:AdditionsToRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdditionsToRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">247</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdditionsToRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">321</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Total goodwill and intangible assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">51 357</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">53 919</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">9 230</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">9 603</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">358</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">255</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">60 945</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">63 777</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Additions to goodwill and intangible assets<sup style="white-space: nowrap"> &#xA0;3</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 791</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 491</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">163</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">102</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">139</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">143</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">2 093</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 736</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Total investment in associated companies</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">107</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">170</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">143</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">205</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Additions to investment in associated companies</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:AdditionsToInvestmentInAssociatedCompanies" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">25</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:AdditionsToInvestmentInAssociatedCompanies" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">24</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:AdditionsToInvestmentInAssociatedCompanies" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:AdditionsToInvestmentInAssociatedCompanies" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">19</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:AdditionsToInvestmentInAssociatedCompanies" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">38</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:AdditionsToInvestmentInAssociatedCompanies" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">43</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">18 930</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">28 329</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">18 930</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">28 329</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Financial debts and derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">26 175</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">29 197</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">26 175</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">29 197</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Current income tax liabilities and deferred tax liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:CurrentIncomeTaxAndDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 219</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="nvs:CurrentIncomeTaxAndDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:CurrentIncomeTaxAndDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 219</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:CurrentIncomeTaxAndDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Eliminations mainly relate to the elimination of intercompany receivables and payables to other segments and inventories</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Note 29 provides additional disclosures related to net debt</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;3&#xA0;</sup> Excluding the impact of business acquisitions</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows countries that accounted for more than 5% of at least one of the respective Group totals, as well as regional information for net sales to third parties for the years ended December 31, 2022, 2021 and 2020, and for selected non-current assets for the years ended December 31, 2022 and 2021:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" id="SectionBlock_96977b05-dd26-4cf8-a1e2-38aff63aab2f_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net sales to third parties<sup>1</sup></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total of selected non-current assets<sup>2</sup></div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Country</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">970</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">873</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">800</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">23 708</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">32</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">25 770</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">33</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United States</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">17 653</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">35</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">16 818</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">33</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">16 484</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">34</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">35 353</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">48</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">37 054</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">48</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">France</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022FR" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 257</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022FR" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 522</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022FR" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 442</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022FR" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022FR" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3 188</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022FR" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3 615</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Germany</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022DE" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 278</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022DE" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 870</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022DE" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 518</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022DE" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022DE" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 229</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022DE" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 378</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">China</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022CN" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 128</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022CN" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 052</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022CN" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 573</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022CN" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022CN" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">599</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022CN" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">703</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japan</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022JP" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 205</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022JP" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022JP" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 683</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022JP" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022JP" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 804</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022JP" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022JP" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">165</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022JP" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">217</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">20 054</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">41</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">20 808</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">19 038</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">39</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">8 241</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">7 351</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">50 545</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">51 626</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">48 659</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">73 483</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">77 088</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Region</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">18 467</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">37</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">20 197</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">39</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">18 715</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">38</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">35 896</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">49</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">37 525</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">49</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Americas</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">21 536</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">42</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">20 463</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">19 725</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">41</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">35 806</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">49</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">37 522</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">49</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">10 542</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">10 966</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">10 219</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 781</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 041</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">50 545</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">51 626</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">48 659</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">73 483</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:SelectedNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">77 088</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1" name="nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Net sales to third parties by location of customer</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Total of property, plant and equipment; right-of-use assets; goodwill; intangible assets; investment in associated companies and other non-current assets excluding post-employment benefit assets</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-20</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_4" continuedAt="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_5">
          <div>
            <div>
              <div></div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:continuation id="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_5" continuedAt="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_6">
          <div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:CustomersWithNetSalesOverFivePercent" id="SectionBlock_23ebcf1b-3f34-49bc-b005-fb2ee017161e_0" escape="false">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s largest, second-largest and third-largest customers account for approximately <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">16</ix:nonFraction>%</span>, <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">11</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">7</ix:nonFraction>%</span> of net sales to third parties, respectively (2021: <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">17</ix:nonFraction>%</span>, <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">11</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">6</ix:nonFraction>%</span>, respectively; 2020: <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">17</ix:nonFraction>%</span>, <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">11</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">6</ix:nonFraction>%</span>, respectively). All segments had sales to these customers in 2022, 2021 and 2020.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The highest amounts of trade receivables outstanding were for these same three customers and amounted to approximately <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">16</ix:nonFraction>%</span>, <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">14</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">7</ix:nonFraction>%</span>, respectively, of the trade receivables at December 31, 2022 (2021: <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">16</ix:nonFraction>%</span>, <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">12</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">7</ix:nonFraction>%</span>, respectively).</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" id="SectionBlock_3f761a23-e3d9-40f5-8297-fe0a94e23b83_0" escape="true" continuedAt="SectionBlock_3f761a23-e3d9-40f5-8297-fe0a94e23b83_1">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#x2013; net sales to third parties</span>
                  </div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties by region<sup>1</sup></span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />
                            <br /> 2022<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> 2021<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br /> (2021<br /> to 2022)<br /> USD %</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> 2020<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br /> (2020<br /> to 2021)<br /> USD %</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">13 554</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">14 919</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">13 484</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">15 899</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">14 999</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">14 342</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">8 929</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 304</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">8 718</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 914</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 773</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 469</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">41 296</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">41 995</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">39 013</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Of which in Established Markets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">30 548</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">31 459</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">29 643</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Of which in Emerging Growth Markets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">10 748</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">10 536</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 370</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 913</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">5 278</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">5 231</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 754</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 819</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 142</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">15</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 613</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 662</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 501</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">969</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">872</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">772</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 249</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 631</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 646</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Of which in Established Markets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">6 460</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">6 855</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">7 089</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Of which in Emerging Growth Markets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 789</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 776</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 557</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">18 467</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">20 197</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">18 715</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">17 653</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">16 818</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">16 484</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">10 542</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">10 966</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">10 219</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 883</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 645</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 241</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">50 545</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">51 626</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">48 659</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Of which in Established Markets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">37 008</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">38 314</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">36 732</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Of which in Emerging Growth Markets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">13 537</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">13 312</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">11 927</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Net sales to third parties by location of customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-21</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_6" continuedAt="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_7">
          <div>
            <div>
              <ix:continuation id="SectionBlock_3f761a23-e3d9-40f5-8297-fe0a94e23b83_1">
                <div></div>
              </ix:continuation>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:continuation id="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_7" continuedAt="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_8">
          <div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:DisclosureOfOperatingSegmentsNetSalesTableTextBlock" id="SectionBlock_b9e69e43-43ee-4011-a29b-3703ba2e2dea_0" escape="true">
                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines Division net sales to third parties by core therapeutic area; other promoted brands; and established brands</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />
                            <br /> 2022<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> 2021<br /> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br /> (2021 to<br /> 2022)<br /> USD %</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> 2020<br /> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br /> (2020 to<br /> 2021)<br /> USD %</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cardiovascular</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 644</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 548</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">31</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 497</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">42</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Leqvio</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">112</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Cardiovascular</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 756</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 560</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">34</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 497</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">43</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Immunology</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 788</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 718</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 995</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 365</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 428</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 251</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">14</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 133</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 059</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">873</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Immunology</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">7 287</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">7 205</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">6 119</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Neuroscience</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 013</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 787</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">28</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 003</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 370</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 351</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">920</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">47</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 092</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">372</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">194</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Mayzent</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">357</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">281</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">27</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">170</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">65</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Aimovig</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">218</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">215</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">164</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">31</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Neuroscience</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">5 051</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">5 007</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 272</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">17</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Solid Tumors</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 770</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 693</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 542</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 231</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">937</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">31</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">687</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">36</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">474</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">577</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">18</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">635</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">471</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">475</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">445</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">373</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">329</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">320</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Pluvicto</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PluvictoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">271</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PluvictoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tabrecta</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">133</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">48</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">157</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Solid Tumors</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 723</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 101</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 666</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Hematology</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 088</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 016</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 738</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">16</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 923</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 060</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 958</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 561</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 595</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 339</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">19</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">536</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">587</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">474</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">24</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Adakveo</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">194</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">164</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">56</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Scemblix</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ScemblixMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">149</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ScemblixMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">67</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Hematology</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">6 452</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">6 430</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">5 617</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">14</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />
                            <br /> 2022<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> 2021<br /> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br /> (2021 to<br /> 2022)<br /> USD %</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> 2020<br /> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br /> (2020 to<br /> 2021)<br /> USD %</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Other Promoted Brands</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 874</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 160</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">13</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 933</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xiidra</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">487</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">468</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">376</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">24</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Ultibro</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">479</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">584</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">18</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">623</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Beovu</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">203</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">186</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">190</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other respiratory</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">84</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">58</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">104</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Other Promoted  Brands</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 127</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 451</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 148</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Promoted  Brands</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">31 396</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">29 754</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">25 319</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 238</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 413</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">12</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 439</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">859</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 092</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">21</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 199</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">745</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 024</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">27</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 188</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">14</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">743</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">901</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">18</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">980</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">8</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">652</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">773</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">16</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 003</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">23</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">512</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">938</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">45</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 083</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">13</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <i>Voltaren/Cataflam</i>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">334</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">373</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">10</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">360</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">329</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">431</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">24</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">452</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">323</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">563</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">43</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">653</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">14</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Neoral/Sandimmun(e)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">310</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">368</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">16</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">393</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contract manufacturing</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ContractManufacturingMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">214</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ContractManufacturingMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">108</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ContractManufacturingMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">98</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 641</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 257</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">14</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 944</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">14</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Established  Brands</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 900</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">12 241</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">19</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">13 694</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">11</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">41 296</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">41 995</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">39 013</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Reclassified to reflect the new Innovative Medicines divisional structures announced on April 4, 2022</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-22</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_8" continuedAt="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_9">
          <div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" id="SectionBlock_a17653c9-3732-4d05-ad56-80349f74a7a9_0" escape="true" continuedAt="SectionBlock_a17653c9-3732-4d05-ad56-80349f74a7a9_1">
                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties of the top 20 Innovative Medicines Division brands in 2022</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />Brands</div>
                        </td>
                        <td></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by<br /> therapeutic area, other<br /> promoted brands or<br /> established brands</div>
                        </td>
                        <td></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />
                            <br />
                            <br /> Key indications</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> US<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Rest of <br /> world<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />
                            <br /> Total<br /> USD m</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO),   ankylosing spondylitis  (AS), psoriatic arthritis   (PsA), non-radiographic   axial spondyloarthritis   (nr-axSPA)</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 770</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 018</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 788</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure,  hypertension</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 354</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 290</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 644</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology    </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune   thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 083</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 005</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 088</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis  (RMS)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 153</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">860</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 013</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia  (CML)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">877</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 046</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 923</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands    </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related   macular degeneration (AMD),   diabetic macular edema (DME),  retinal vein occlusion (RVO)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 874</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 874</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic   adjuvant melanoma,  advanced non-small cell   lung cancer (NSCLC),   tumor agnostic with   BRAF mutation indication</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">678</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 092</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 770</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology      </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycytomia vera (PV),   graft-versus-host disease  (GvHD)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 561</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 561</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy  (SMA)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">434</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">936</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 370</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA),   chronic spontaneous urticaria   (CSU), nasal polyps</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 365</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 365</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors,  acromegaly</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">800</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">438</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 238</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2-   metastatic breast cancer</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">472</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">759</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 231</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,  TRAPS, HIDS/MKD, FMF,  SJIA, AOSD, gout)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">570</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">563</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 133</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing-remitting   multiple sclerosis (RRMS)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">921</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">171</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 092</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">859</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">859</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands      </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid  leukemia (CML),   gastrointestinal stromal  tumors (GIST)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">205</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">540</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">745</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">729</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">743</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">597</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">652</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology        </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> r/r pediatric and young   adults acute lymphoblastic   leukemia (ALL), diffuse large   B-cell lymphoma (DLBCL),   follicular lymphoma (FL)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">196</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">340</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">536</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands    </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/  tuberous sclerosis complex   (TSC)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">171</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">341</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">512</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 brands total</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">12 753</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">19 384</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">32 137</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 146</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">6 013</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 159</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">15 899</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">25 397</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">41 296</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-23</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_9" continuedAt="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_10">
          <div>
            <div>
              <ix:continuation id="SectionBlock_a17653c9-3732-4d05-ad56-80349f74a7a9_1" continuedAt="SectionBlock_a17653c9-3732-4d05-ad56-80349f74a7a9_2">
                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties of the top 20 Innovative Medicines Division brands in 2021</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />Brands</div>
                        </td>
                        <td></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by<br /> therapeutic area, other<br /> promoted brands or<br /> established brands<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />
                            <br />
                            <br /> Key indications</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> US<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Rest of <br /> world<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;">
                            <br />
                            <br /> Total<br /> USD m</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology        </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO), ankylosing   spondylitis (AS),   psoriatic arthritis (PsA),  non-radiographic axial   spondyloarthritis (nr-axSPA)</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 883</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 835</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">4 718</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 712</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 836</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 548</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis (RMS)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 427</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 360</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 787</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular   degeneration (AMD)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 160</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 160</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia (CML)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">882</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 178</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 060</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">947</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 069</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 016</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors      </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic   adjuvant melanoma,  advanced non-small cell   lung cancer (NSCLC)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">606</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 087</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 693</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycythemia vera (PV)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 595</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 595</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA),   chronic spontaneous urticaria   (CSU), nasal polyps</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 428</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 428</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors, acromegaly</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">843</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">570</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 413</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy (SMA)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">469</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">882</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 351</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 092</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 092</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF,   SJIA, AOSD, gout)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">501</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">558</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 059</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands    </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia   (CML), gastrointestinal   stromal tumors (GIST)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">263</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">761</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 024</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/  tuberous sclerosis complex (TSC)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">521</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">417</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">938</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2-   metastatic breast cancer</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">339</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">598</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">937</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">887</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">901</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">51</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">722</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">773</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology      </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> r/r pediatric and young   adults acute lymphoblastic   leukemia (ALL), diffuse large   B-cell lymphoma (DLBCL)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">230</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">357</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">587</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Ultibro</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cronic obstructive  pulmonary disease  (COPD)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">584</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">584</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">11 688</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">20 976</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">32 664</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 311</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">6 020</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 331</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">14 999</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">26 996</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">41 995</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.</div>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:continuation>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-24</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_10" continuedAt="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_11">
          <div>
            <div>
              <ix:continuation id="SectionBlock_a17653c9-3732-4d05-ad56-80349f74a7a9_2">
                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties of the top 20 Innovative Medicines Division brands in 2020</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />Brands</div>
                        </td>
                        <td></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by<br /> therapeutic area, other<br /> promoted brands or<br /> established brands<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />
                            <br />
                            <br /> Key indications</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> US<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Rest of <br /> world<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;">
                            <br />
                            <br /> Total<br /> USD m</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology  </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO), ankylosing   spondylitis (AS), psoriatic arthritis (PsA)</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 516</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 479</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 995</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis (RMS)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 562</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 441</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 003</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 277</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 220</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 497</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia (CML)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">859</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 099</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 958</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular   degeneration (AMD)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 933</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 933</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology    </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune   thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">833</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">905</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 738</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors      </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic  adjuvant melanoma,   advanced non-small cell   lung cancer (NSCLC)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">569</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">973</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 542</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors,  acromegaly</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">837</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">602</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 439</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycythemia vera (PV)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 339</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 339</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA),  chronic spontaneous urticaria   (CSU)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 251</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 251</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 199</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 199</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia (CML),  gastrointestinal stromal tumors (GIST)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">315</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">873</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 188</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/  tuberous sclerosis complex (TSC)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">644</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">439</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 083</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">124</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">879</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 003</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">964</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">980</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy  (SMA)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">459</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">461</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">920</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF,   SJIA, AOSD gout)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">400</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">473</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">873</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors  </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2-   metastatic breast cancer</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">318</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">369</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">687</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic iron overload</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">138</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">515</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">653</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma (RCC)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">259</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">376</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">635</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">11 126</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">18 790</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">29 916</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">3 216</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">5 881</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 097</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">14 342</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">24 671</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">39 013</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.</div>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:DisclosureOfOperatingSegmentsNetSalesTableTextBlock" id="SectionBlock_5bd63dcf-303e-47d1-bc15-2a943b7c6f18_0" escape="true">
                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz Division net sales to third parties by business franchise</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />
                            <br /> 2022<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> 2021<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br /> (2021 to<br /> 2022)<br /> USD %</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> 2020<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br /> (2020 to<br /> 2021)<br /> USD %</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Retail Generics<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">6 776</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">7 092</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">7 244</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Biopharmaceuticals</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 093</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">2 116</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">1 928</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Anti-Infectives<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">380</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">423</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">10</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">474</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">11</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales to third parties</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 249</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 631</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="-2" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">9 646</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" decimals="2" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> Sandoz total anti-infectives net sales to third parties amounted to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-8" scale="9" format="ixt:numdotdecimal">1.2</ix:nonFraction> billion (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-8" scale="9" format="ixt:numdotdecimal">1.1</ix:nonFraction> billion; 2020: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-8" scale="9" format="ixt:numdotdecimal">1.2</ix:nonFraction> billion), of which USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">777</ix:nonFraction> million (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">707</ix:nonFraction> million; 2020: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">694</ix:nonFraction> million) is sold through the Retail Generics business franchise and USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">380</ix:nonFraction> million (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">423</ix:nonFraction> million; 2020: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">474</ix:nonFraction> million) is sold to other third-party companies through the Anti-Infectives business franchise.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The product portfolio of Sandoz is widely spread in 2022, 2021 and 2020.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-25</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_11">
          <div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" id="SectionBlock_0e5efc5d-a44e-40ad-8e18-33f25c057ecb_0" escape="true">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#x2013; other revenue</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate   (including eliminations)</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group  </div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Profit-sharing income</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:ProfitSharingIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">921</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:ProfitSharingIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">873</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:ProfitSharingIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">835</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ProfitSharingIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">921</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ProfitSharingIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">873</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ProfitSharingIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">835</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Royalty income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">107</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">168</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">52</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">109</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:RevenueFromRoyalties" decimals="-6" scale="6" format="ixt:numdotdecimal">300</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Milestone income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:MilestoneIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:MilestoneIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:MilestoneIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:MilestoneIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:MilestoneIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:MilestoneIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:MilestoneIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">148</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:MilestoneIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">155</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:MilestoneIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:OtherRevenueOther" decimals="-6" scale="6" format="ixt:numdotdecimal">155</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:OtherRevenueOther" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="nvs:OtherRevenueOther" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:OtherRevenueOther" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:OtherRevenueOther" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="nvs:OtherRevenueOther" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:OtherRevenueOther" decimals="-6" scale="6" format="ixt:numdotdecimal">162</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:OtherRevenueOther" decimals="-6" scale="6" format="ixt:numdotdecimal">114</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:OtherRevenueOther" decimals="-6" scale="6" format="ixt:numdotdecimal">54</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other revenues</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 249</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 179</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 018</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">61</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">168</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 283</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 251</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherRevenue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 239</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="26" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="26">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" id="SectionBlock_3a3abd27-8c36-475e-b9b5-b53fb3aa8b68_0" escape="true">
          <div>
            <div id="anchorId001530097"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">4. Associated companies</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory" id="SectionBlock_55a5dac0-0c58-44e0-ba76-245074a558f8_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net income statement effect</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other comprehensive income effect<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total comprehensive income effect</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Roche Holding AG, Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">15 341</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">677</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">56</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">15 387</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">621</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember" name="ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember" name="ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember" name="ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">15 339</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">673</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">56</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">15 385</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">617</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="20" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="20">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> In 2021, Novartis share of other comprehensive income recognized by associated companies, net of taxes of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction> million was recycled into the consolidated income statement as a result of the divestment of the investment in Roche Holding AG. <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" decimals="-6" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> Novartis share of other comprehensive income recognized by associated companies was recycled to the consolidated income statement in 2022 and 2020.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has certain non-significant investments and had a significant investment in Roche Holding AG, Basel (Roche), which was divested to Roche on December 6, 2021, that are accounted for as associated companies. </div>
              </div>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Roche Holding AG </span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 3, 2021, Novartis entered into an agreement with Roche Holding AG to divest its <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ProportionOfVotingPowerHeldInAssociate" decimals="3" scale="-2">33.3</ix:nonFraction>%</span> of Roche Holding AG (Roche) voting shares, representing approximately <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" decimals="3" scale="-2">6.2</ix:nonFraction>%</span> of Roche&#x2019;s total outstanding voting and non-voting equity instruments, to Roche for USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" decimals="-8" scale="9">20.7</ix:nonFraction> billion in cash. As a result, Novartis discontinued the use of equity method accounting starting from November 3, 2021.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The divestment transaction closed on December 6, 2021, and Novartis realized a gain of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:GainOnDivestmentOfInterestsInAssociatedCompanies" decimals="-8" scale="9">14.6</ix:nonFraction> billion, recorded in income from associated companies. See Note 2.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s holding in Roche voting shares was <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ProportionOfVotingPowerHeldInAssociate" decimals="3" scale="-2">33.3</ix:nonFraction>%</span> at December 31, 2020. This investment represented approximately <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" decimals="3" scale="-2">6.2</ix:nonFraction>%</span> of Roche&#x2019;s total outstanding voting and non-voting equity instruments at December 31, 2020.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Since full-year financial data for Roche is not available when Novartis produces its consolidated financial results, a survey of analyst estimates is used to estimate the Group&#x2019;s share of Roche&#x2019;s net income. Any differences between these estimates and actual results were adjusted in the Group&#x2019;s consolidated financial statements when available. As Novartis discontinued the use of equity method accounting starting from November 3, 2021, and the divestment closed on December 6, 2021, no such adjustment has been made to the 2022 Group&#x2019;s consolidated financial statements.</div>
              </div>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2021, dividends received from Roche in relation to the distribution of its 2020 net income amounted to USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:DividendsReceived" decimals="-6" scale="6" format="ixt:numdotdecimal">522</ix:nonFraction> million.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consolidated income statement effects from applying Novartis accounting principles for this investment in 2021 and 2020 are as follows:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:DisclosureOfAssociatesNetIncomeEffectTableTextBlock" id="SectionBlock_0cdc6c60-b2f5-45d0-bbda-3be63da68b49_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of Roche's  estimated current-year  consolidated net income</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:ShareOfCurrentYearNetIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">815</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:ShareOfCurrentYearNetIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">913</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prior-year adjustment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:PriorYearAdjustment" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:PriorYearAdjustment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">64</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of fair value adjustments relating to intangible assets, net of taxes of 2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million; 2020: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction> million</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">70</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">172</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on divestment of the  investment in Roche<sup style="white-space: nowrap"> &#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:GainOnDivestmentOfInterestsInAssociatedCompanies" decimals="-6" scale="6" format="ixt:numdotdecimal">14 556</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income effect</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">15 341</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">677</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> The gain on divestment of the investment in Roche includes the recycling of currency translation effects (see Note 8.1) and other comprehensive income effects totaling USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" decimals="-8" scale="9" format="ixt:numdotdecimal">3.2</ix:nonFraction> billion.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-26</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfInterestExpenseExplanatory" id="SectionBlock_3de967de-4f83-4eca-b632-79663a2799aa_0" escape="true">
          <div>
            <div id="anchorId001530570"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">5. Interest expense and&#xA0;other&#xA0;financial&#xA0;income&#xA0;and&#xA0;expense</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest expense</span>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:InterestExpenseTableTextBlock" id="SectionBlock_5dd2e4e6-1bb2-4f35-8425-e6ca87e052be_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">669</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">651</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">708</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense on lease liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:InterestExpenseOnLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:InterestExpenseOnLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:InterestExpenseOnLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense arising from  discounting long-term liabilities and capitalized borrowing costs</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">108</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">98</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total interest expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:InterestExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">837</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:InterestExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">811</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:InterestExpense" decimals="-6" scale="6" format="ixt:numdotdecimal">869</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other financial income and expense</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:OtherFinancialIncomeAndExpenseTableTextBlock" id="SectionBlock_08b62cd3-ec10-4822-aaac-f55b7a0cb47d_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:RevenueFromInterest" decimals="-6" scale="6" format="ixt:numdotdecimal">379</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:RevenueFromInterest" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:RevenueFromInterest" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:RevenueFromDividends" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:RevenueFromDividends" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:RevenueFromDividends" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherFinanceCost" decimals="-6" scale="6" format="ixt:numdotdecimal">194</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherFinanceCost" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherFinanceCost" decimals="-6" scale="6" format="ixt:numdotdecimal">52</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency result, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">184</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">69</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">135</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other financial income  and expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">80</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">78</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="SectionBlock_a6c2d24e-fed8-43e6-b56b-06189a0bea97_0" escape="true" continuedAt="SectionBlock_a6c2d24e-fed8-43e6-b56b-06189a0bea97_1">
          <div>
            <div id="anchorId001530822"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">6. Income taxes</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Income before taxes</span>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:IncomeBeforeTaxesTableTextBlock" id="SectionBlock_2e9c6764-3b65-478c-94c7-1a975843e011_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">5 986</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">22 028</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">9 786</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">2 385</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">4 109</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">92</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">8 371</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">26 137</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLossBeforeTax" decimals="-6" scale="6" format="ixt:numdotdecimal">9 878</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> The 2021 income before taxes in Switzerland includes a USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:GainOnDivestmentOfInterestsInAssociatedCompanies" decimals="-8" scale="9" format="ixt:numdotdecimal">14.6 </ix:nonFraction> billion non-taxable gain on the divestment of the Group&#x2019;s investment in Roche Holding AG (see Note 2 and Note 4).</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Current and deferred income tax expense</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:CurrentAndDeferredIncomeTaxExpenseTableTextBlock" id="SectionBlock_25722d4e-1832-4386-8464-0bfb5a531092_0" escape="true">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The significant components of the provision for income taxes are as follows:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="ifrs-full:CurrentTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">617</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="ifrs-full:CurrentTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">958</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="ifrs-full:CurrentTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">932</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember" name="ifrs-full:CurrentTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 454</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember" name="ifrs-full:CurrentTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 470</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember" name="ifrs-full:CurrentTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 168</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current income tax expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:CurrentTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">2 071</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CurrentTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">2 428</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CurrentTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">2 100</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="ifrs-full:DeferredTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">142</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="ifrs-full:DeferredTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">23</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember" name="ifrs-full:DeferredTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember" name="ifrs-full:DeferredTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">797</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember" name="ifrs-full:DeferredTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">286</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember" name="ifrs-full:DeferredTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">430</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Deferred tax income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DeferredTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">655</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DeferredTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">309</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:DeferredTaxExpenseIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">293</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income tax expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">1 416</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">2 119</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">1 807</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Analysis of tax rate</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has a substantial business presence in many countries and is therefore subject to income taxes in different tax jurisdictions. This leads to differences in income and expense items that are non-taxable or non-deductible (permanent differences) or are taxed at different statutory tax rates in those tax jurisdictions. As a result, there is a difference between our applicable tax rate and effective tax rate.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The applicable tax rate changes from year to year due to changes in the mix of the Group&#x2019;s pre-tax income and changes in statutory tax rates since it is calculated as the weighted average tax rate based on the pre-tax income of each subsidiary. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The main elements contributing to the difference between the Group&#x2019;s overall applicable tax rate and the effective tax rate are shown in the following table:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:AnalysisOfTaxRateTableTextBlock" id="SectionBlock_cb2544ab-2d86-47cf-9783-40a2c5c3a23c_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(As a percentage)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Applicable tax rate</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="ifrs-full:ApplicableTaxRate" decimals="3" scale="-2" format="ixt:numdotdecimal">16.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ApplicableTaxRate" decimals="3" scale="-2" format="ixt:numdotdecimal">14.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ApplicableTaxRate" decimals="3" scale="-2" format="ixt:numdotdecimal">13.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of disallowed expenditures</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" decimals="3" scale="-2" format="ixt:numdotdecimal">2.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" decimals="3" scale="-2" format="ixt:numdotdecimal">1.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" decimals="3" scale="-2" format="ixt:numdotdecimal">4.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of utilization of previously unrecognized tax losses brought forward from prior periods</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="ifrs-full:TaxRateEffectOfTaxLosses" decimals="3" scale="0" format="ixt:numdotdecimal">0.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="ifrs-full:TaxRateEffectOfTaxLosses" decimals="3" scale="0" format="ixt:numdotdecimal">0.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="ifrs-full:TaxRateEffectOfTaxLosses" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of income taxed at reduced rates</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:TaxRateEffectOfIncomeTaxedAtReducedRates" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:TaxRateEffectOfIncomeTaxedAtReducedRates" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:TaxRateEffectOfIncomeTaxedAtReducedRates" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of income not subject to tax<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">7.5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax credits and allowances</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:TaxRateEffectOfCreditsAndAllowances" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">3.8</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:TaxRateEffectOfCreditsAndAllowances" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">1.4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:TaxRateEffectOfCreditsAndAllowances" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">2.3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of release of  contingent consideration liability</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax rate change  on current and deferred  tax assets and liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="ifrs-full:TaxRateEffectFromChangeInTaxRate" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="ifrs-full:TaxRateEffectFromChangeInTaxRate" decimals="3" scale="0" format="ixt:numdotdecimal">0.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="ifrs-full:TaxRateEffectFromChangeInTaxRate" decimals="3" scale="-2" format="ixt:numdotdecimal">0.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of derecognition and reversals of derecognition  of deferred tax assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:EffectOfWriteoffOfDeferredTaxAssets" decimals="3" scale="-2" format="ixt:numdotdecimal">1.2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:EffectOfWriteoffOfDeferredTaxAssets" decimals="3" scale="0" format="ixt:numdotdecimal">0.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:EffectOfWriteoffOfDeferredTaxAssets" decimals="3" scale="-2" format="ixt:numdotdecimal">0.2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of write-down and reversal of  write-down of investments in subsidiaries</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" decimals="3" scale="0" format="ixt:numdotdecimal">0.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" decimals="3" scale="0" format="ixt:numdotdecimal">0.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.8</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of prior-year items</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" decimals="3" scale="-2" format="ixt:numdotdecimal">0.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" decimals="3" scale="-2" format="ixt:numdotdecimal">2.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of changes in uncertain tax positions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" decimals="3" scale="-2" format="ixt:numdotdecimal">1.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" decimals="3" scale="-2" format="ixt:numdotdecimal">1.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" decimals="3" scale="-2" format="ixt:numdotdecimal">2.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of other items</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" decimals="3" scale="-2" format="ixt:numdotdecimal">0.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" decimals="3" scale="0" format="ixt:numdotdecimal">0.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">0.1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Effective tax rate</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="ifrs-full:AverageEffectiveTaxRate" decimals="3" scale="-2" format="ixt:numdotdecimal">16.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AverageEffectiveTaxRate" decimals="3" scale="-2" format="ixt:numdotdecimal">8.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AverageEffectiveTaxRate" decimals="3" scale="-2" format="ixt:numdotdecimal">18.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <b></b>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> 2021 includes the effect of income not subject to tax (<span>-<ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1" name="nvs:EffectOfIncomeNotSubjectToTaxOnDivestmentGain" decimals="3" scale="-2" format="ixt:numdotdecimal" sign="-">7.3</ix:nonFraction></span>%) arising from the non-taxable gain on the divestment of our investment in Roche. See Notes 2 and 4 for further details.</span>
                            <b></b>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our effective tax rate fluctuates based primarily on, among other factors, changes in pre-tax income between countries with varying statutory tax rates, income taxed at reduced tax rates, effect of disallowed expenditures, effect of income not subject to tax, effect of tax credits and allowances, effect of prior-year items, changes in the measurement of deferred tax assets, changes in uncertain tax positions and changes in tax laws. The table above provides the details of the significant items </div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-27</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_a6c2d24e-fed8-43e6-b56b-06189a0bea97_1">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">that impact the comparability of the effective tax rate between years.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The utilization of tax-loss carry-forwards lowered the tax charge by USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" decimals="-6" scale="6">1</ix:nonFraction> million in 2022, by USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" decimals="-6" scale="6">5</ix:nonFraction> million in 2021, and by USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" decimals="-6" scale="6">29</ix:nonFraction> million in 2020.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:EarningsPerShareExplanatory" id="SectionBlock_fc4b2fa0-5650-4499-8258-8a1d50e13f3b_0" escape="true" continuedAt="SectionBlock_fc4b2fa0-5650-4499-8258-8a1d50e13f3b_1">
          <div>
            <div id="anchorId001531519"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">7. Earnings per share</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="SectionBlock_f27b9465-464d-48bc-8fed-b46b0c20679d_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income attributable to shareholders of Novartis AG (USD millions)</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">6 955</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">24 021</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" decimals="-6" scale="6" format="ixt:numdotdecimal">8 072</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Number of shares (in millions)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Weighted average number of shares outstanding used in basic earnings per share</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="ifrs-full:WeightedAverageShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 181</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="ifrs-full:WeightedAverageShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 243</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="ifrs-full:WeightedAverageShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 277</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average number of shares in diluted earnings per share</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="ifrs-full:AdjustedWeightedAverageShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 197</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdjustedWeightedAverageShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 260</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AdjustedWeightedAverageShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 296</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share (USD)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear" name="ifrs-full:BasicEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.19</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1" name="ifrs-full:BasicEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.71</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-2" name="ifrs-full:BasicEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.55</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Diluted earnings per share (USD)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear" name="ifrs-full:DilutedEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.17</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DilutedEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.63</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-2" name="ifrs-full:DilutedEarningsLossPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.52</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Basic earnings per share (EPS) is calculated by dividing net income attributable to shareholders of Novartis AG by the weighted average number of shares outstanding in a reporting period. This calculation excludes the average number of issued shares purchased by the Group and held as treasury shares.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For diluted EPS, the weighted average number of shares outstanding is adjusted to assume the vesting of all restricted shares, restricted share units, and the conversion of all potentially dilutive shares arising from options on Novartis shares that have been issued.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
                  <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:OptionsExcludedFromTheCalculation" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> options were excluded from the calculation of diluted EPS in 2022, 2021 or 2020, as all options were dilutive in all years.</div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-28</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_fc4b2fa0-5650-4499-8258-8a1d50e13f3b_1">
          <div>
            <div>
              <div></div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" id="SectionBlock_907e971b-ca25-482e-8a99-ce890ffdd23d_0" escape="true" continuedAt="SectionBlock_907e971b-ca25-482e-8a99-ce890ffdd23d_1">
          <div>
            <div id="anchorId001531738"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">8. Changes in consolidated statements of&#xA0;comprehensive income</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated statements of comprehensive income include the Group&#x2019;s net income for the year as well as all other valuation adjustments recorded in the Group&#x2019;s consolidated balance sheet, which under IFRS are not recorded in the consolidated income statement. These include fair value adjustments on financial instruments, actuarial gains or losses on defined benefit pension plans, and currency translation effects, net of taxes.</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfComprehensiveIncomeTableTextBlock" id="SectionBlock_143b27a6-3fa7-40e4-a8b3-7de95319364a_0" escape="true" continuedAt="SectionBlock_143b27a6-3fa7-40e4-a8b3-7de95319364a_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br />
                            <br /> Note</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Fair value<br /> adjustments <br /> on financial<br /> instruments</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Actuarial<br /> gains/(losses)<br /> from defined<br /> benefit plans</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Cumulative<br /> currency <br /> translation<br /> effects</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total value<br /> adjustments<br /> attributable to <br /> Novartis AG <br /> shareholders</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Non-<br /> controlling<br /> interest</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br /> Total value<br /> adjustments</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2019</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">120</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5 919</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 142</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 657</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">29</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 686</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, net of taxes of USD <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">36</ix:nonFraction></span> million<sup style="white-space: nowrap"> &#xA0;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember" name="nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">201</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">201</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">201</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes of USD <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span> million</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">143</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects, net of taxes of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   8.1</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal">3 193</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal">3 193</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal">3 194</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2020</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">2 992</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">3 387</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">3 386</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities  sold, reclassified to retained earnings</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">150</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">150</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">150</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2020</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">220</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5 773</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">4 134</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 419</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">29</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 448</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, net of taxes of USD <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">44</ix:nonFraction></span> million<sup style="white-space: nowrap"> &#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember" name="nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" decimals="-6" scale="6" format="ixt:numdotdecimal">194</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" decimals="-6" scale="6" format="ixt:numdotdecimal">194</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" decimals="-6" scale="6" format="ixt:numdotdecimal">194</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge, net of taxes of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4NetInvestmentHedgeMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction> million</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">216</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">216</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">216</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes of USD <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">323</ix:nonFraction></span> million</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">1 808</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">1 808</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">1 809</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects, net of taxes of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction> million</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   8.1</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 757</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 757</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 762</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">194</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 808</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 541</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 539</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 543</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities sold, reclassified to retained earnings net of taxes of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesSoldMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonFraction> million</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">164</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">164</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">164</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">62</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">65</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">65</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">188</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3 968</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">407</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 187</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">33</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 220</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, net of taxes of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">81</ix:nonFraction> million<sup style="white-space: nowrap"> &#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember" name="nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">382</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">382</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">382</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge, net of taxes of USD <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4NetInvestmentHedgeMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">30</ix:nonFraction></span> million</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes of USD <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">104</ix:nonFraction></span> million</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">104</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">104</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">103</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects, net of taxes of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction> million</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   8.1</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">444</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">444</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">450</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">382</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">104</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">353</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">839</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">844</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities sold, reclassified to retained earnings net of taxes of <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesSoldMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="0" format="ixt-sec:numwordsen">nil</ix:nonFraction></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:FairValueAdjustmentsOnFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments, net of taxes of USD <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ValueAdjustmentsRelatedToDivestmentsMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span> million</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:FairValueAdjustmentsRelatedToDivestments" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">198</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 038</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">760</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 996</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">38</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember" name="nvs:ValueAdjustmentOnComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5 034</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Includes fair value adjustments on equity securities designated as financial assets valued at fair value through other comprehensive income with no subsequent recycling into the consolidated income statement</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-29</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_907e971b-ca25-482e-8a99-ce890ffdd23d_1" continuedAt="SectionBlock_907e971b-ca25-482e-8a99-ce890ffdd23d_2">
          <div>
            <div>
              <ix:continuation id="SectionBlock_143b27a6-3fa7-40e4-a8b3-7de95319364a_1">
                <div></div>
              </ix:continuation>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:continuation id="SectionBlock_907e971b-ca25-482e-8a99-ce890ffdd23d_2">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">8.1) In 2022, net cumulative currency translation gains of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction> million were recycled through the income statement as a result of the divestments of subsidiaries. In 2021, net cumulative currency translation gains of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" decimals="-8" scale="9">3.2</ix:nonFraction> billion were recycled through the income statement as a result of the divestment of the investment in Roche. See Notes 2 and 4. In 2020, there were <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember" name="nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" decimals="-6" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> currency translation losses or gains recycled through the income statement.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="SectionBlock_3d3470b3-35bd-46aa-a7c8-353f9eb5aa88_0" escape="true" continuedAt="SectionBlock_3d3470b3-35bd-46aa-a7c8-353f9eb5aa88_1">
          <div>
            <div id="anchorId001533390"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">9. Property, plant and equipment</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:PropertyPlantAndEquipmentTableTextBlock" id="SectionBlock_685cb82a-be82-4971-b240-7e665d376acc_0" escape="true" continuedAt="SectionBlock_685cb82a-be82-4971-b240-7e665d376acc_1">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of property, plant and equipment during 2022:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Land</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Buildings</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Construction <br /> in progress</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Machinery <br /> and other <br /> equipment</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">492</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">11 819</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 508</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">13 328</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">27 147</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5 744</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">65</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9 786</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">15 602</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">6 075</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 443</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">3 542</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">11 545</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">6 075</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 443</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">3 542</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">11 545</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">297</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">964</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">667</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">124</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">780</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">312</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 219</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">155</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:DepreciationPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">437</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:DepreciationPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">726</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DepreciationPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 163</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">351</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">414</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">12</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">166</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">57</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">53</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">288</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">442</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">5 493</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 157</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">3 672</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">10 764</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">451</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">11 396</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 184</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">11 842</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">24 873</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5 903</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">27</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">8 170</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">14 109</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">442</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">5 493</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 157</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">3 672</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">10 764</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for purchases of property, plant and equipment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">549</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Capitalized borrowing costs</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:BorrowingCostsCapitalised" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-30</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_3d3470b3-35bd-46aa-a7c8-353f9eb5aa88_1">
          <div>
            <div>
              <ix:continuation id="SectionBlock_685cb82a-be82-4971-b240-7e665d376acc_1">
                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of property, plant and equipment during 2021:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Land</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Buildings</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Construction <br /> in progress</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Machinery <br /> and other <br /> equipment</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">555</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">12 377</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 248</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">14 038</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">28 218</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">19</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5 807</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">66</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10 063</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">15 955</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">536</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">6 570</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 182</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">3 975</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">12 263</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">536</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">6 570</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 182</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">3 975</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">12 263</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">197</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">610</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">413</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">109</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 027</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">293</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 430</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">78</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:DepreciationPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">453</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:DepreciationPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">755</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DepreciationPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 208</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">167</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">384</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">103</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">23</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">203</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">84</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">199</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">509</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">6 075</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 443</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">3 542</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">11 545</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">492</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">11 819</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 508</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">13 328</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">27 147</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5 744</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">65</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9 786</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">15 602</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">6 075</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 443</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">3 542</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:PropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">11 545</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for purchases of property, plant and equipment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Capitalized borrowing costs</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:BorrowingCostsCapitalised" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock" id="SectionBlock_55c2e1f6-fd15-488f-9c09-728086ad5978_0" escape="true">
                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the property, plant and equipment impairment charges and reversals by reporting segment:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment charges</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment reversals</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">411</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">315</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">326</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">121</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">59</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">414</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">384</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">447</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">103</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfLeasesExplanatory" id="SectionBlock_d7184423-5d62-4ca4-85f7-c68e3d487ded_0" escape="true" continuedAt="SectionBlock_d7184423-5d62-4ca4-85f7-c68e3d487ded_1">
          <div></div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-31</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_d7184423-5d62-4ca4-85f7-c68e3d487ded_1" continuedAt="SectionBlock_d7184423-5d62-4ca4-85f7-c68e3d487ded_2">
          <div>
            <div id="anchorId001534918"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">10. Right-of-use assets and lease liabilities</div>
            <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of the right-of-use assets:</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfRightofuseAssetsRollForwardTableTextBlock" id="SectionBlock_18a3572f-571c-4536-ba92-1b1cc73e5af5_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Right-of-use assets at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 561</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 676</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:AcquisitionsThroughBusinessCombinationsRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdditionsToRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">247</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdditionsToRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">321</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">300</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">318</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease contract terminations<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:LeaseContractTerminationsRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:LeaseContractTerminationsRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">66</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">52</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">52</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total right-of-use assets at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 431</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 561</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Impairment charges in 2022 were recorded in the Innovative Medicines segment.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Lease contract terminations also includes modifications to existing leases that result in reductions to the right-of-use assets, and reductions due to sub-leasing.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the right-of-use assets carrying value and depreciation charge at December 31, 2022 and 2021, by underlying class of asset: </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" id="SectionBlock_8ad36aeb-2695-4aca-9fb4-3e148a2ff005_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> December 31,<br /> 2022<br /> carrying value</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Depreciation <br /> charge<br /> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31,<br /> 2021<br /> carrying value</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Depreciation <br /> charge<br /> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Land</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">505</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">522</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">745</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">177</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">866</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">192</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vehicles</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">117</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">96</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">136</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and equipment, and other assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total right-of-use assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 431</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">300</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 561</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DepreciationRightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">318</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the lease liabilities by maturity at December 31, 2022 and 2021:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" id="SectionBlock_64e2c148-b3d5-4e05-8930-ffab01beba5a_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Lease liabilities<br /> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Lease liabilities<br /> undiscounted<br /> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Lease liabilities<br /> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Lease liabilities<br /> undiscounted<br /> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less than one year</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">251</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">297</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">275</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">324</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between one and two years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">190</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">232</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">216</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">258</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between two and three years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">167</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">201</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">162</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">198</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between three and four years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">172</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">139</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">172</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between four and five years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">122</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">154</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">122</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">154</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After five years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">922</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">2 149</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">982</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">2 243</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total lease liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 789</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">3 205</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 896</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:LeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">3 349</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion of lease liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">251</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:CurrentLeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">297</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">275</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:CurrentLeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">324</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current portion of lease liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NoncurrentLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 538</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:NoncurrentLeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">2 908</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NoncurrentLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 621</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:NoncurrentLeaseLiabilitiesUndiscounted" decimals="-6" scale="6" format="ixt:numdotdecimal">3 025</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for leases not yet commenced</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:CommitmentsForLeasesNotYetCommenced" decimals="-6" scale="6" format="ixt:numdotdecimal">83</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:CommitmentsForLeasesNotYetCommenced" decimals="-6" scale="6" format="ixt:numdotdecimal">134</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At December 31, 2022, and December 31, 2021, there were no material future cash outflows, including extension options, excluded from the measurement of lease liabilities. The Group&#x2019;s most material lease with a lease term extension, representing a lease liability value of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:MostMaterialLeaseWithLeaseTermExtension" decimals="-8" scale="9">0.7</ix:nonFraction> billion (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:MostMaterialLeaseWithLeaseTermExtension" decimals="-8" scale="9">0.6</ix:nonFraction> billion), has a determined lease term end date of <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:LeaseTermEndDate">2071</ix:nonNumeric> (2021: <ix:nonNumeric contextRef="AR_D-CurrentYear-1" name="nvs:LeaseTermEndDate">2071</ix:nonNumeric>). Non-enforceable extension options of up to 10 years have not been included within the measurement of this lease liability, and do not have a material impact to the carrying value of the lease for both 2022 and 2021. Should the landlord agree to a lease extension, rent will be referenced to the market rates as at the commencement of the extension period. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2022, the Group completed three sale and leaseback transactions for certain property, plant and equipment as part of the Groups plans to focus on key operating locations. The transactions resulted in net cash inflows of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember" name="nvs:CashInflowForSaleAndLeaseback" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">49</ix:nonFraction> million and the recognition of USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction> million of lease liabilities, and USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember" name="ifrs-full:RightofuseAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction> million of right-of-use assets. The right-of-use assets value reflects the proportion of the property, plant and equipment retained. Extension options have been included where management believe that such options will be exercised. The liabilities reflect the net present value of future lease payments. The net gain on the sale and leaseback transactions amounted to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember" name="ifrs-full:GainsLossesArisingFromSaleAndLeasebackTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction> million. There were no significant sale and leaseback transactions in 2021 or 2020.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table provides additional disclosures related to right-of-use assets and lease liabilities for 2022, 2021 and 2020:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" id="SectionBlock_777a9ce6-dd1c-4571-8437-11241c88dd8a_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense on lease liabilities<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:InterestExpenseOnLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:InterestExpenseOnLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:InterestExpenseOnLeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense on short-term leases</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense on low-value leases</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total cash outflows for leases</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:CashOutflowForLeases" decimals="-6" scale="6" format="ixt:numdotdecimal">355</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CashOutflowForLeases" decimals="-6" scale="6" format="ixt:numdotdecimal">381</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CashOutflowForLeases" decimals="-6" scale="6" format="ixt:numdotdecimal">379</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Thereof:</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Cash outflows for short-term leases and low-value leases<sup style="white-space: nowrap"> &#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:CashOutflowsForShortTermAndLowValueLeases" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:CashOutflowsForShortTermAndLowValueLeases" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:CashOutflowsForShortTermAndLowValueLeases" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Payments of interest<sup style="white-space: nowrap">&#xA0;3</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:CashOutflowsForPaymentsOfLeasesInterest" decimals="-6" scale="6" format="ixt:numdotdecimal">51</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:CashOutflowsForPaymentsOfLeasesInterest" decimals="-6" scale="6" format="ixt:numdotdecimal">52</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:CashOutflowsForPaymentsOfLeasesInterest" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#xA0;&#xA0;&#xA0;Payments of lease liabilities<sup style="white-space: nowrap">&#xA0;4</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">295</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">316</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">312</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> The weighted average interest rate is <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:WeightedAverageInterestRateLeaseLiabilities" decimals="3" scale="-2" format="ixt:numdotdecimal">3.3</ix:nonFraction>% (2021: <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:WeightedAverageInterestRateLeaseLiabilities" decimals="3" scale="-2" format="ixt:numdotdecimal">3.2</ix:nonFraction>%, 2020: <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:WeightedAverageInterestRateLeaseLiabilities" decimals="3" scale="-2" format="ixt:numdotdecimal">3.4</ix:nonFraction>%).</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Cash flows from short-term and low-value leases are included within total net cash flows from operating activities. The portfolio of short-term leases to which the Group is committed to at December 31, 2022, 2021 and 2020, is similar to the portfolio of short-term leases the Group entered into during 2022, 2021 and 2020.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;3&#xA0;</sup> Included within total net cash flows from operating activities</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;4&#xA0;</sup> Reported as cash outflows in financing activities net of lease incentives received, if any.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-32</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_d7184423-5d62-4ca4-85f7-c68e3d487ded_2">
          <div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The net investment held and income from subleasing right-of-use assets were not significant for 2022, 2021, and 2020. Income from leasing Novartis property, plant and equipment to third parties for 2022, 2021 and 2020 was not significant. </div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory" id="SectionBlock_692bb3d0-d3f7-4285-8381-30c3440ba114_0" escape="true" continuedAt="SectionBlock_692bb3d0-d3f7-4285-8381-30c3440ba114_1">
          <div>
            <div id="anchorId001535868"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">11. Goodwill and intangible assets</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" id="SectionBlock_6c2ac4c1-82bb-46fe-afc8-e160edb283e5_0" escape="true" continuedAt="SectionBlock_6c2ac4c1-82bb-46fe-afc8-e160edb283e5_1">
                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of goodwill and intangible assets in 2022:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible assets other than goodwill</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> In-process<br /> research and<br /> development</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Technologies</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently<br /> marketed <br /> products</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other<br /> intangible<br /> assets</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 900</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">8 013</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 080</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">56 213</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">2 905</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">68 211</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">305</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 514</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">903</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">29 107</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 505</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">34 029</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 595</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">5 499</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">177</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">27 106</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 400</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">34 182</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 595</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">5 499</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">177</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">27 106</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 400</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">34 182</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">161</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 209</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 209</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 429</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 403</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">330</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 175</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">588</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">2 093</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">95</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">3 603</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">342</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">3 982</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">917</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">322</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">72</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 326</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">427</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">176</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">243</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">432</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 301</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">4 421</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">121</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">25 513</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 589</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">31 644</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 596</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">7 092</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 038</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">58 249</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">3 305</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">69 684</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">295</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 671</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">917</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">32 736</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 716</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">38 040</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 301</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">4 421</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">121</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">25 513</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 589</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">31 644</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-33</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_692bb3d0-d3f7-4285-8381-30c3440ba114_1" continuedAt="SectionBlock_692bb3d0-d3f7-4285-8381-30c3440ba114_2">
          <div>
            <div>
              <ix:continuation id="SectionBlock_6c2ac4c1-82bb-46fe-afc8-e160edb283e5_1">
                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of goodwill and intangible assets in 2021:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Goodwill</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Intangible assets other than goodwill</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> In-process<br /> research and<br /> development</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Technologies</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Currently<br /> marketed <br /> products</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other<br /> intangible<br /> assets</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">30 321</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">6 893</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 115</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">57 333</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">2 384</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">67 725</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">322</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 193</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">885</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">26 566</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 272</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">30 916</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 999</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">4 700</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">230</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">30 767</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 112</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">36 809</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 999</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">4 700</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">230</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">30 767</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 112</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">36 809</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">238</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">262</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">292</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">98</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">652</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">20</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">958</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">270</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">508</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 736</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">36</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">3 607</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">255</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">3 903</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">350</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">403</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">642</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">51</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">584</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">27</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">672</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 595</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">5 499</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">177</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">27 106</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 400</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">34 182</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 900</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">8 013</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 080</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">56 213</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">2 905</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">68 211</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">305</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 514</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">903</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">29 107</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 505</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">34 029</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 595</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">5 499</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">177</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">27 106</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 400</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">34 182</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2022:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" id="SectionBlock_5f122fc4-96e9-42f7-8040-8feae55a3a2f_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill<sup>1</sup></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible assets other than goodwill</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> In-process<br /> research and<br /> development</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Technologies</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently<br /> marketed <br /> products</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other<br /> intangible<br /> assets</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">21 531</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">4 186</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">24 487</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 139</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 826</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">7 770</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">235</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">107</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 026</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">92</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 460</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">358</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">358</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 301</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">4 421</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">121</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">25 513</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 589</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">31 644</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> The Innovative Medicines and Sandoz Divisions&#x2019; represent the grouping of cash-generating units, to which goodwill is allocated.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2021:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Goodwill<sup>1</sup></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Intangible assets other than goodwill</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="1" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> In-process<br /> research and<br /> development</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Technologies</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Currently<br /> marketed <br /> products</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other<br /> intangible<br /> assets</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">21 562</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">5 313</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">25 938</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 091</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">32 357</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">8 026</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">186</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">162</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 168</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">61</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 577</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">248</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">248</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">29 595</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">5 499</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">177</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">27 106</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 400</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:IntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">34 182</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> The Innovative Medicines and Sandoz Divisions&#x2019; and Corporate represent the grouping of cash-generating units, to which goodwill is allocated.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As at December 31, 2022, the most significant intangible assets within currently marketed products category are <i>Leqvio</i> (Innovative Medicines: acquisition of The Medicines Company) and <i>Zolgensma</i> (Innovative Medicines: acquisition of Avexis Inc.). As at December 31, 2022, the carrying value and remaining amortization period for <i>Leqvio</i> is USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember" name="ifrs-full:IntangibleAssetsMaterialToEntity" decimals="-8" scale="9">7.4</ix:nonFraction> billion and <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" format="ixt-sec:duryear">13</ix:nonNumeric> years, respectively (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember" name="ifrs-full:IntangibleAssetsMaterialToEntity" decimals="-8" scale="9">7.9</ix:nonFraction> billion and <ix:nonNumeric contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" format="ixt-sec:duryear">14</ix:nonNumeric> years, respectively), and for <i>Zolgensma</i> USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember" name="ifrs-full:IntangibleAssetsMaterialToEntity" decimals="-8" scale="9">5.9</ix:nonFraction> billion and <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" format="ixt-sec:duryear">8</ix:nonNumeric> years, respectively (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember" name="ifrs-full:IntangibleAssetsMaterialToEntity" decimals="-8" scale="9">6.6</ix:nonFraction> billion and <ix:nonNumeric contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember" name="ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" format="ixt-sec:duryear">9</ix:nonNumeric> years, respectively). </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Innovative Medicines and Sandoz Divisions&#x2019; cash-generating units, to which goodwill is allocated, </div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-34</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_692bb3d0-d3f7-4285-8381-30c3440ba114_2" continuedAt="SectionBlock_692bb3d0-d3f7-4285-8381-30c3440ba114_3">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">each comprise a group of smaller cash-generating units. The valuation method of the recoverable amount of the group of cash-generating units, to which goodwill is allocated, is based on the fair value less costs of disposal. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following assumptions are used in the calculations:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:AssumptionsUsedInTheCalculationOfValuationTextBlock" id="SectionBlock_90835707-17a9-4670-ac39-d2cc3710f9ad_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(As a percentage)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative <br /> Medicines</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Sandoz</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Terminal growth rate</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" decimals="3" scale="-2" format="ixt:numdotdecimal">1.5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" decimals="3" scale="-2" format="ixt:numdotdecimal">1.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discount rate (post-tax)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" decimals="3" scale="-2" format="ixt:numdotdecimal">8.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" decimals="3" scale="-2" format="ixt:numdotdecimal">8.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The discount rates for all divisions consider the Group&#x2019;s weighted average cost of capital, adjusted to approximate the weighted average cost of capital of a comparable market participant.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value less costs of disposal, for all cash-generating units containing goodwill, is reviewed for the impact of reasonably possible changes in key assumptions. In particular, we considered an increase in the discount rate, a decrease in the terminal growth rate, and certain negative impacts on the forecasted cash flows. These reasonably possible changes in key assumptions did not indicate an impairment.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">&#x201C;Note 1. Significant accounting policies&#x2014;Impairment of goodwill and intangible assets&#x201D; provides additional disclosures on how the Group performs goodwill and intangible asset impairment testing.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the intangible asset impairment charges and reversals by reporting segment: </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:IntangibleAssetImpairmentChargesTextBlock" id="SectionBlock_f92d8281-9963-4ab9-a5f6-8e20241de9ad_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment charges</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment reversals</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 299</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">367</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">768</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">141</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">1 326</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">403</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-6" scale="6" format="ixt:numdotdecimal">914</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> 2022 includes an impairment of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction> billion related to the write-down of IPR&amp;D related to cessation of clinical development program UNR844.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                            <span> 2021 includes an impairment of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction> billion related to the write-down of IPR&amp;D related to cessation of clinical development program GTX312.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                            <span> 2020 includes an impairment of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction> billion related to the write-down of IPR&amp;D related to cessation of clinical development program ZPL389 for atopic dermatitis and USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction> billion related to a partial write-down of the <i>Votrient</i> currently marketed product (<i>Votrient</i> carrying value was USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-8" scale="9" format="ixt:numdotdecimal">0.9</ix:nonFraction> billion in 2022 and USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" decimals="-8" scale="9" format="ixt:numdotdecimal">1.3</ix:nonFraction> billion in 2021).</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-35</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_692bb3d0-d3f7-4285-8381-30c3440ba114_3">
          <div>
            <div>
              <div></div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfDeferredTaxesExplanatory" id="SectionBlock_213338fa-2acc-4dd4-9e0e-836ea6b11693_0" escape="true" continuedAt="SectionBlock_213338fa-2acc-4dd4-9e0e-836ea6b11693_1">
          <div>
            <div id="anchorId001538357"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">12. Deferred tax assets and liabilities </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="SectionBlock_ff893456-4a80-4fee-a6c3-39116d238e39_0" escape="true" continuedAt="SectionBlock_ff893456-4a80-4fee-a6c3-39116d238e39_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Property, <br /> plant and<br /> equipment</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Intangible<br /> assets</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pensions and<br /> other benefit <br /> obligations <br /> of employees</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br /> Inventories</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Tax loss<br /> carry-<br /> forwards</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Other assets,<br /> provisions<br /> and accruals</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax assets at January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 307</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 026</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 273</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">374</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 727</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">7 832</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax liabilities at January 1, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">381</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">4 704</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">591</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">148</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 335</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">7 159</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at January 1, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">256</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">3 397</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">435</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 125</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">374</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 392</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">673</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">256</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">3 397</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">435</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 125</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">374</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 392</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">673</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">69</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">628</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">43</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">655</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to equity</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to other comprehensive income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">104</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">43</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">300</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">55</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">244</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">19</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">185</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">3 059</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">319</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 076</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">425</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 477</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 053</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax assets at December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">158</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 726</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">739</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 214</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">425</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 789</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">8 051</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax liabilities at December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">343</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">4 785</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">420</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">138</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 312</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">6 998</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">185</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">3 059</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">319</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 076</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">425</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 477</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 053</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After offsetting the following amount of deferred tax  assets and liabilities within the same tax jurisdiction,  the balance amounts to:</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" decimals="-6" scale="6" format="ixt:numdotdecimal">4 312</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets at December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3 739</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities at December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 686</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 053</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax assets at January 1, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">189</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 351</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 137</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 502</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">507</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 658</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">8 344</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax liabilities at January 1, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">430</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 269</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">340</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">159</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 344</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">7 552</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at January 1, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">241</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">3 918</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">797</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 343</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">497</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 314</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">792</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">241</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">3 918</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">797</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 343</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">497</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 314</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">792</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">27</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">567</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">22</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">215</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">121</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">309</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to equity</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">35</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">35</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to other comprehensive income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">323</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">317</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">58</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">256</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">3 397</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">435</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 125</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">374</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 392</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">673</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax assets at December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 307</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 026</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 273</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">374</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 727</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:GrossDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">7 832</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax liabilities at December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">381</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">4 704</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">591</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">148</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 335</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:GrossDeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">7 159</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">256</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">3 397</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">435</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 125</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">374</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 392</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">673</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After offsetting the following amount of deferred tax  assets and liabilities within the same tax jurisdiction,  the balance amounts to:</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" decimals="-6" scale="6" format="ixt:numdotdecimal">4 089</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets at December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction id="fact_188392_1" unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3 743</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities at December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction id="fact_188393_1" unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DeferredTaxLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">3 070</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DeferredTaxLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">673</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                            <b></b>
                            <b></b>
                            <b></b>
                            <b></b>
                            <b></b>
                            <b></b>
                            <b></b>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                            <b></b>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-36</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_213338fa-2acc-4dd4-9e0e-836ea6b11693_1">
          <div>
            <div>
              <ix:continuation id="SectionBlock_ff893456-4a80-4fee-a6c3-39116d238e39_1">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Deferred tax liabilities have not been recognized for the withholding tax and other taxes that would be payable on the remittance of earnings of foreign subsidiaries, insofar as the Group has the ability to control any future reversal and the unremitted earnings are retained in the foreign subsidiaries for reinvestment. The total unremitted earnings retained for reinvestment in the Group&#x2019;s foreign subsidiaries that would be subject to withholding tax or other taxes if remitted to the Group are estimated at approximately USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" decimals="-9" scale="9" format="ixt:numdotdecimal">32</ix:nonFraction> billion in 2022, (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" decimals="-9" scale="9" format="ixt:numdotdecimal">29</ix:nonFraction> billion).</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The gross value of tax-loss carry-forwards that have or have not been recognized as deferred tax assets, with their expiry dates, is as follows:</div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" id="SectionBlock_fef8869f-0f3a-4e52-8a6c-79ebf75d0d16_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Unrecognized</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Recognized</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022 total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One year</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Two years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">42</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Three years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Four years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">138</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">138</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Five years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">79</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">688</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">767</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">More than five years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3 880</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 380</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">6 260</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not subject to expiry</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">433</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">452</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">885</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">4 610</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3 530</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">8 140</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Unrecognized</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rcognized</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021 total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One year</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Two years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Three years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Four years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Five years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">146</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">166</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">More than five years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3 536</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 872</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">5 408</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not subject to expiry</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">418</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">684</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 102</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">4 192</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 607</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">6 799</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tax losses carried forward  that expired</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ValueOfTaxLossCarryforwardsExpired" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ValueOfTaxLossCarryforwardsExpired" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ValueOfTaxLossCarryforwardsExpired" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Deferred tax assets related to carry-forwards of taxable losses and tax credits of relevant Group entities are recognized to the extent it is considered probable that future taxable profits will be available in the respective tax jurisdictions against which such losses and credits can be utilized.</div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" id="SectionBlock_da3e00ae-1a4e-44d3-a58b-8e0992f9a90a_0" escape="true">
          <div>
            <div id="anchorId001540616"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">13. Financial and other non-current assets</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Financial assets</span>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfFinancialAssetsTableTextBlock" id="SectionBlock_96ec1835-1b4c-4401-b9ac-13346ec5d9b3_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity securities</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:NoncurrentFinancialAssetsEquityInvestments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 145</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:NoncurrentFinancialAssetsEquityInvestments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 663</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:NoncurrentFinancialAsstetsDebtSecurities" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:NoncurrentFinancialAsstetsDebtSecurities" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:NoncurrentFinancialAssetsFundInvestments" decimals="-6" scale="6" format="ixt:numdotdecimal">281</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:NoncurrentFinancialAssetsFundInvestments" decimals="-6" scale="6" format="ixt:numdotdecimal">366</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial investments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:NoncurrentFinancialAssetsTotalFinancialInvestments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 463</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:NoncurrentFinancialAssetsTotalFinancialInvestments" decimals="-6" scale="6" format="ixt:numdotdecimal">2 063</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term receivables from finance subleases</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:LongTermReceivablesFromFinanceSubleases" decimals="-6" scale="6" format="ixt:numdotdecimal">59</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:LongTermReceivablesFromFinanceSubleases" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other long-term receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherNoncurrentReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">197</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherNoncurrentReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">184</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:ContingentConsiderationReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal">607</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:ContingentConsiderationReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal">641</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances and security deposits</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NoncurrentLoansAndReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">85</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NoncurrentLoansAndReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">78</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NoncurrentFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 411</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NoncurrentFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3 036</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other non-current assets</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfOtherNoncurrentAssetsTableTextBlock" id="SectionBlock_d7b430c9-9886-4b81-b4d2-31ef5f94ab42_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred compensation plans</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:DeferredCompensationPlansAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">419</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:DeferredCompensationPlansAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">520</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid post-employment benefit plans<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:PrepaidPostemploymentBenefitPlansAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">491</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:PrepaidPostemploymentBenefitPlansAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 415</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherNoncurrentNonfinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">200</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherNoncurrentNonfinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">275</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other non-current assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 110</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 210</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Note 25 provides additional disclosures related to post-emplyment benefits.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-37</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfInventoriesExplanatory" id="SectionBlock_5032009a-6aa4-4062-a7b9-d621a3480d37_0" escape="true">
          <div>
            <div id="anchorId001540869"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">14. Inventories</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfInventoryCurrentTableTextBlock" id="SectionBlock_f6e7fa3c-88fa-4413-8727-cf0fcb316ece_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Raw material, consumables</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryRawMaterialsGrossMember" name="ifrs-full:Inventories" decimals="-6" scale="6" format="ixt:numdotdecimal">934</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryRawMaterialsGrossMember" name="ifrs-full:Inventories" decimals="-6" scale="6" format="ixt:numdotdecimal">870</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Work in progress</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryWorkInProgressGrossMember" name="ifrs-full:Inventories" decimals="-6" scale="6" format="ixt:numdotdecimal">3 673</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryWorkInProgressGrossMember" name="ifrs-full:Inventories" decimals="-6" scale="6" format="ixt:numdotdecimal">3 160</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Finished products</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryFinishedGoodsGrossMember" name="ifrs-full:Inventories" decimals="-6" scale="6" format="ixt:numdotdecimal">2 568</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryFinishedGoodsGrossMember" name="ifrs-full:Inventories" decimals="-6" scale="6" format="ixt:numdotdecimal">2 636</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total inventories</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Inventories" decimals="-6" scale="6" format="ixt:numdotdecimal">7 175</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Inventories" decimals="-6" scale="6" format="ixt:numdotdecimal">6 666</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the amount of inventory recognized as an expense in &#x201C;Cost of goods sold&#x201D; in the consolidated income statements: </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" id="SectionBlock_df57547a-230d-496c-9cd5-296704619480_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod" decimals="-8" scale="9" format="ixt:numdotdecimal">8.6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod" decimals="-8" scale="9" format="ixt:numdotdecimal">8.8</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod" decimals="-8" scale="9" format="ixt:numdotdecimal">8.5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the recognized amount of inventory provision and reversals of inventory provision recorded in the consolidated income statements:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" id="SectionBlock_7fd1661e-2922-450e-b4de-f2a31c3b1a5b_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventory provisions</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:InventoryWritedown2011" decimals="-6" scale="6" format="ixt:numdotdecimal">633</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:InventoryWritedown2011" decimals="-6" scale="6" format="ixt:numdotdecimal">573</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:InventoryWritedown2011" decimals="-6" scale="6" format="ixt:numdotdecimal">702</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversals of inventory provisions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ReversalOfInventoryWritedown" decimals="-6" scale="6" format="ixt:numdotdecimal">161</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ReversalOfInventoryWritedown" decimals="-6" scale="6" format="ixt:numdotdecimal">158</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ReversalOfInventoryWritedown" decimals="-6" scale="6" format="ixt:numdotdecimal">255</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The reversals mainly result from the release of products initially requiring additional quality control inspections and from the reassessment of inventory values manufactured prior to regulatory approval but for which approval was subsequently received.</div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock" id="SectionBlock_f73ea36a-c75c-4818-a468-1dfad9f0c0d2_0" escape="true" continuedAt="SectionBlock_f73ea36a-c75c-4818-a468-1dfad9f0c0d2_1">
          <div>
            <div id="anchorId001541050"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">15. Trade receivables</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ProvisionsForTradeReceivablesTableTextBlock" id="SectionBlock_27283273-9f6e-461b-848e-dbcf49fd4433_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total gross trade receivables</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">8 128</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">8 088</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="nvs:ProvisionForDoubtfulReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">62</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="nvs:ProvisionForDoubtfulReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">83</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">8 066</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">8 005</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movement in the provision for doubtful trade receivables:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:TradeReceivablesProvisionMovementsTableTextBlock" id="SectionBlock_a4cf83ab-8b48-4784-905d-00ee1c71a054_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="nvs:ProvisionForDoubtfulReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">83</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="nvs:ProvisionForDoubtfulReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">93</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="nvs:ProvisionForDoubtfulReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">95</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables charged to the consolidated income statement</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">59</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Utilization of provisions for doubtful trade receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:ProvisionUsedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:ProvisionUsedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:ProvisionUsedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of provisions for doubtful trade receivables credited to the consolidated income statement</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:UnusedProvisionReversedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:UnusedProvisionReversedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:UnusedProvisionReversedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="nvs:ProvisionForDoubtfulReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">62</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="nvs:ProvisionForDoubtfulReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">83</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="nvs:ProvisionForDoubtfulReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">93</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the trade receivables that are not overdue as specified in the payment terms and conditions established with Novartis customers, as well as an analysis of overdue amounts and related provisions for doubtful trade receivables:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:OverdueAmountsAndRelatedProvisionsTableTextBlock" id="SectionBlock_42fac49b-73e1-4115-9e94-319208dd20ab_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not overdue</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022CurrentMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">7 664</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022CurrentMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">7 639</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for not more than one month</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">190</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">162</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one month  but less than three months</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">110</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">99</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than three months  but less than six months</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than six months  but less than one year</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanSixMonthsAndNotLaterThanOneYearMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanSixMonthsAndNotLaterThanOneYearMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one year</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneYearMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">79</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneYearMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="nvs:ProvisionForDoubtfulReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">62</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="nvs:ProvisionForDoubtfulReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">83</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">8 066</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">8 005</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Trade receivable balances represent amounts due from our customers, which are mainly drug wholesalers, retailers, private health systems, government agencies, managed care providers, pharmacy benefit managers and government-supported healthcare systems. We particularly monitor the level of trade receivables in countries deemed to have an elevated credit risk. We consider macroeconomic environment, historical experience, country and political risk, in addition to other relevant information when assessing risk. These risk factors are monitored regularly to determine any adjustments in risk classification. The majority of the past due trade receivables from elevated credit risk countries are due from local governments or from government-funded entities. Deteriorating credit and economic conditions as well as other factors in these elevated credit risk countries have resulted in, and may continue to result in, an increase in the average length of time that it takes to collect these </div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-38</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_f73ea36a-c75c-4818-a468-1dfad9f0c0d2_1">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">trade receivables, and may require the Group to re-evaluate the expected credit loss amount of these trade receivables in future periods. At December 31, 2022, amounts past due for more than one year are not significant in elevated credit risk countries.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total trade receivables include amounts denominated in the following major currencies:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" id="SectionBlock_4ed1c8a4-a4f0-4aaf-8bc0-1123b55cb042_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022USD" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">3 709</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022USD" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">3 344</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022EUR" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">1 426</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022EUR" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">1 408</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Russian ruble (RUB)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022RUB" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">430</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022RUB" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">473</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022JPY" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">177</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022JPY" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">383</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">British pound (GBP)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022GBP" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">176</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022GBP" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">200</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chinese yuan (CNY)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CNY" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">155</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CNY" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">197</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canadian dollar (CAD)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CAD" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">151</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CAD" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">139</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Brazilian real (BRL)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022BRL" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022BRL" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">129</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Australian dollar (AUD)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022AUD" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022AUD" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">139</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CHF" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">108</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CHF" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">106</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other currencies</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">1 452</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">1 487</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">8 066</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:CurrentTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">8 005</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" id="SectionBlock_fbde2a37-0b03-4c19-8afb-4b1a02a898d4_0" escape="true">
          <div>
            <div id="anchorId001541600"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">16. Marketable securities, commodities, time&#xA0;deposits, derivative financial instruments, and&#xA0;cash and cash equivalents</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Marketable securities, commodities, time&#xA0;deposits and derivative financial instruments</span>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" id="SectionBlock_b41d913b-b489-40a7-83fa-36416ec482f8_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:Commodities" decimals="-6" scale="6" format="ixt:numdotdecimal">111</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:Commodities" decimals="-6" scale="6" format="ixt:numdotdecimal">111</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DebtInstrumentsHeld" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DebtInstrumentsHeld" decimals="-6" scale="6" format="ixt:numdotdecimal">2 741</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">11 089</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">12 965</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DerivativeFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DerivativeFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities, commodities, time deposits and derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherCurrentFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">11 413</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherCurrentFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">15 922</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The vast majority of debt securities, time deposits and short-term investments with an original maturity of more than 90 days was denominated in USD as of December 31, 2022, and 2021.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Cash and cash equivalents</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:CashAndCashEquivalentsTableTextBlock" id="SectionBlock_c88db9cb-b5c8-4320-a87f-b61288c27692_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current accounts</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Cash" decimals="-6" scale="6" format="ixt:numdotdecimal">2 877</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Cash" decimals="-6" scale="6" format="ixt:numdotdecimal">3 396</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity less than 90 days</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">4 640</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">9 011</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total cash and cash equivalents</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">7 517</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">12 407</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-39</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory" id="SectionBlock_c32ba237-8240-447b-8878-1cd938c97e0c_0" escape="true">
          <div>
            <div id="anchorId001541756"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">17. Other current assets</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:OtherCurrentAssetsTableTextBlock" id="SectionBlock_1e96bbe9-d118-4208-9bf8-9c979a6e352c_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">VAT receivable</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentValueAddedTaxReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">509</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentValueAddedTaxReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">487</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Withholding tax recoverable</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:WithholdingTaxRecoverable" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:WithholdingTaxRecoverable" decimals="-6" scale="6" format="ixt:numdotdecimal">58</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid expenses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:CurrentPrepaidExpensesThirdParty" decimals="-6" scale="6" format="ixt:numdotdecimal">911</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:CurrentPrepaidExpensesThirdParty" decimals="-6" scale="6" format="ixt:numdotdecimal">1 102</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivable<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:ContingentConsiderationReceivableCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:OtherReceivablesAndCurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">958</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:OtherReceivablesAndCurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">793</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other current assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherCurrentNonfinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 471</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherCurrentNonfinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 440</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfEquityTextBlock" id="SectionBlock_65b76240-e213-4420-b104-9b747734330c_0" escape="true" continuedAt="SectionBlock_65b76240-e213-4420-b104-9b747734330c_1">
          <div>
            <div id="anchorId001541870"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">18. Equity</div>
            <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movement in the share capital:</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:MovementInTheShareCapitalTableTextBlock" id="SectionBlock_d25e93f2-0c04-4397-8626-86f2242c460a_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Jan 1, 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Movement<br /> in year</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Dec 31, 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Movement<br /> in year</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Dec 31, 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Movement<br /> in year</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br /> Dec 31, 2022</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Share capital<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3" name="ifrs-full:IssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">936</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:IssuedCapitalMovement" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">23</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:IssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">913</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:IssuedCapitalMovement" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">12</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:IssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">901</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:IssuedCapitalMovement" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">11</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:IssuedCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">890</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Treasury shares</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3" name="ifrs-full:TreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:TreasurySharesMovementOfPeriod" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:TreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:TreasurySharesMovementOfPeriod" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:TreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:TreasurySharesMovementOfPeriod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">44</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:TreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">92</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding share capital</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3" name="nvs:OutstandingShareCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">856</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:OutstandingShareCapitalMovement" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:OutstandingShareCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">860</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:OutstandingShareCapitalMovement" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:OutstandingShareCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">853</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:OutstandingShareCapitalMovement" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">55</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:OutstandingShareCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">798</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> The Novartis AG share capital consists of registered shares with a nominal value of CHF <ix:nonFraction unitRef="CHFPerShares" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:ParValuePerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.50</ix:nonFraction> each. No authorized and conditional capital exists.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movement in the shares:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:MovementInTheShareslTableTextBlock" id="SectionBlock_1d1ab5f2-9907-4658-a900-7ccd59ec7514_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />Number of outstanding shares <br />(in millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Note</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br /> Novartis <br /> shares</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br /> treasury <br /> shares<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br /> outstanding <br /> shares</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br /> Novartis <br /> shares</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br /> treasury <br /> shares<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br /> outstanding <br /> shares</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br /> Novartis <br /> shares</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br /> treasury <br /> shares<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br /> outstanding <br /> shares</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at beginning of year</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="ifrs-full:NumberOfSharesIssued" decimals="-5" scale="6" format="ixt:numdotdecimal">2 434.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:NumberOfTreasuryShares" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">199.5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NumberOfSharesOutstanding" decimals="-5" scale="6" format="ixt:numdotdecimal">2 234.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="ifrs-full:NumberOfSharesIssued" decimals="-5" scale="6" format="ixt:numdotdecimal">2 467.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:NumberOfTreasuryShares" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">210.2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:NumberOfSharesOutstanding" decimals="-5" scale="6" format="ixt:numdotdecimal">2 256.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="ifrs-full:NumberOfSharesIssued" decimals="-5" scale="6" format="ixt:numdotdecimal">2 527.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:NumberOfTreasuryShares" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">262.3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-3" name="ifrs-full:NumberOfSharesOutstanding" decimals="-5" scale="6" format="ixt:numdotdecimal">2 265.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares canceled for capital  reduction<sup style="white-space: nowrap"> &#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="nvs:SharesCancelledForCapitalReduction" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">30.7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:SharesCancelledForCapitalReduction" decimals="-5" scale="6" format="ixt:numdotdecimal">30.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="nvs:SharesCancelledForCapitalReduction" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">32.6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:SharesCancelledForCapitalReduction" decimals="-5" scale="6" format="ixt:numdotdecimal">32.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="nvs:SharesCancelledForCapitalReduction" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">60.3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:SharesCancelledForCapitalReduction" decimals="-5" scale="6" format="ixt:numdotdecimal">60.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be  canceled<sup style="white-space: nowrap"> &#xA0;3</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:TreasurySharesAcquiredToBeCancelled" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">126.2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:TreasurySharesAcquiredToBeCancelled" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">126.2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:TreasurySharesAcquiredToBeCancelled" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">30.7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:TreasurySharesAcquiredToBeCancelled" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">30.7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:TreasurySharesAcquiredToBeCancelled" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">32.6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:TreasurySharesAcquiredToBeCancelled" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">32.6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases<sup style="white-space: nowrap">&#xA0;4</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:OtherSharePurchases" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">1.4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:OtherSharePurchases" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">1.4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:OtherSharePurchases" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">1.5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:OtherSharePurchases" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">1.5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:OtherSharePurchases" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">1.7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:OtherSharePurchases" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">1.7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options  and employee transactions<sup style="white-space: nowrap"> &#xA0;5</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.9</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:ExerciseOfOptionsAndEmployeeTransactionsShares" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:ExerciseOfOptionsAndEmployeeTransactionsShares" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:ExerciseOfOptionsAndEmployeeTransactionsShares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:ExerciseOfOptionsAndEmployeeTransactionsShares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:ExerciseOfOptionsAndEmployeeTransactionsShares" decimals="-5" scale="6" format="ixt:numdotdecimal">14.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:ExerciseOfOptionsAndEmployeeTransactionsShares" decimals="-5" scale="6" format="ixt:numdotdecimal">14.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation<sup style="white-space: nowrap">&#xA0;5</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:EquityBasedCompensationShares" decimals="-5" scale="6" format="ixt:numdotdecimal">10.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:EquityBasedCompensationShares" decimals="-5" scale="6" format="ixt:numdotdecimal">10.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:EquityBasedCompensationShares" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:EquityBasedCompensationShares" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:EquityBasedCompensationShares" decimals="-5" scale="6" format="ixt:numdotdecimal">11.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:EquityBasedCompensationShares" decimals="-5" scale="6" format="ixt:numdotdecimal">11.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:SharesDeliveredToDivestedBusinessEmployees" decimals="-5" scale="0" format="ixt:numdotdecimal">0.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:SharesDeliveredToDivestedBusinessEmployees" decimals="-5" scale="0" format="ixt:numdotdecimal">0.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:SharesDeliveredToDivestedBusinessEmployees" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:SharesDeliveredToDivestedBusinessEmployees" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:SharesDeliveredToDivestedBusinessEmployees" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:SharesDeliveredToDivestedBusinessEmployees" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total movements</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="nvs:ShareMovements" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">30.7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:ShareMovements" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">84.6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:ShareMovements" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">115.3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="nvs:ShareMovements" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">32.6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:ShareMovements" decimals="-5" scale="6" format="ixt:numdotdecimal">10.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:ShareMovements" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">21.9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="nvs:ShareMovements" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">60.3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:ShareMovements" decimals="-5" scale="6" format="ixt:numdotdecimal">52.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:ShareMovements" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">8.2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at end of year</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="ifrs-full:NumberOfSharesIssued" decimals="-5" scale="6" format="ixt:numdotdecimal">2 403.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:NumberOfTreasuryShares" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">284.1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NumberOfSharesOutstanding" decimals="-5" scale="6" format="ixt:numdotdecimal">2 119.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="ifrs-full:NumberOfSharesIssued" decimals="-5" scale="6" format="ixt:numdotdecimal">2 434.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:NumberOfTreasuryShares" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">199.5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NumberOfSharesOutstanding" decimals="-5" scale="6" format="ixt:numdotdecimal">2 234.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember" name="ifrs-full:NumberOfSharesIssued" decimals="-5" scale="6" format="ixt:numdotdecimal">2 467.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:NumberOfTreasuryShares" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">210.2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:NumberOfSharesOutstanding" decimals="-5" scale="6" format="ixt:numdotdecimal">2 256.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> Approximately <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:TreasurySharesWithRestrictedUse" decimals="-5" scale="6" format="ixt:numdotdecimal">99.0</ix:nonFraction> million treasury shares (2021: <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:TreasurySharesWithRestrictedUse" decimals="-5" scale="6" format="ixt:numdotdecimal">102.5</ix:nonFraction> million; 2020: <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember" name="nvs:TreasurySharesWithRestrictedUse" decimals="-5" scale="6" format="ixt:numdotdecimal">103.0</ix:nonFraction> million) are held in Novartis entities that restrict their availability for use.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Novartis reduced its share capital by canceling shares that were repurchased on the SIX Swiss Exchange second trading line during previous years.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;3&#xA0;</sup>
                            <span> Shares repurchased on the SIX Swiss Exchange second trading line under a CHF <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd-2" name="nvs:StockRepurchaseProgramAuthorizedAmount1" decimals="-9" scale="9" format="ixt:numdotdecimal">10</ix:nonFraction> billion share buyback authority approved at the 2019 Annual General Meeting (AGM) for transactions after February 28, 2019, until March 2, 2021. Transactions after March 2, 2021, were executed under the CHF <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd-1" name="nvs:StockRepurchaseProgramAuthorizedAmount1" decimals="-9" scale="9" format="ixt:numdotdecimal">10</ix:nonFraction> billion share buyback authority approved at the 2021 AGM and the additional CHF <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd" name="nvs:StockRepurchaseProgramAuthorizedAmount1" decimals="-9" scale="9" format="ixt:numdotdecimal">10</ix:nonFraction> billion authority approved at the 2022 AGM.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;4&#xA0;</sup> Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;5&#xA0;</sup> Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">18.1) The amount available for distribution as a dividend to shareholders is based on the available distributable retained earnings of Novartis AG determined in accordance with the legal provisions of the Swiss Code of Obligations.</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DividendTableTextBlock" id="SectionBlock_e216b00c-07fd-49f5-8c14-87888746560c_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend per share (in CHF)</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHFPerShares" contextRef="AR_I-CurrentYearEnd" name="nvs:DividendsPayableAmountPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.10</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="CHFPerShares" contextRef="AR_I-CurrentYearEnd-1" name="nvs:DividendsPayableAmountPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.00</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="CHFPerShares" contextRef="AR_I-CurrentYearEnd-2" name="nvs:DividendsPayableAmountPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.95</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total dividend payment  (in USD billion)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DividendsPaid" decimals="-8" scale="9" format="ixt:numdotdecimal">7.5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DividendsPaid" decimals="-8" scale="9" format="ixt:numdotdecimal">7.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:DividendsPaid" decimals="-8" scale="9" format="ixt:numdotdecimal">7.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-40</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_65b76240-e213-4420-b104-9b747734330c_1" continuedAt="SectionBlock_65b76240-e213-4420-b104-9b747734330c_2">
          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">18.2) The following table summarizes the treasury shares movements:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:SummaryOfTreasurySharesMovementsTableTextBlock" id="SectionBlock_02eb7cbf-331a-4c27-83f1-344a6ae8754e_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br /> Note</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Number of <br /> outstanding <br /> shares<br /> (in millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Equity impact<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Number of <br /> outstanding <br /> shares<br /> (in millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Equity impact<br /> USD m</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Number of <br /> outstanding <br /> shares<br /> (in millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Equity impact<br /> USD m</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be canceled<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:TreasurySharesAcquiredToBeCancelled" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">126.2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:TreasurySharesAcquiredForCancellationValue" decimals="-6" scale="6" format="ixt:numdotdecimal">10 787</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:TreasurySharesAcquiredToBeCancelled" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">30.7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:TreasurySharesAcquiredForCancellationValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 775</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:TreasurySharesAcquiredToBeCancelled" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">32.6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:TreasurySharesAcquiredForCancellationValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 897</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:OtherSharePurchases" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">1.4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:OtherSharePurchasesValue" decimals="-6" scale="6" format="ixt:numdotdecimal">123</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:OtherSharePurchases" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">1.5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:OtherSharePurchasesValue" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:OtherSharePurchases" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">1.7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:OtherSharePurchasesValue" decimals="-6" scale="6" format="ixt:numdotdecimal">159</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:SharepurchaseOfTreasuryShares" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">127.6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">10 910</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:SharepurchaseOfTreasuryShares" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">32.2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 920</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:SharepurchaseOfTreasuryShares" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">34.3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:PurchaseOfTreasuryShares" decimals="-6" scale="6" format="ixt:numdotdecimal">3 056</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions<sup style="white-space: nowrap">&#xA0;3</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.9</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:ExerciseOfOptionsAndEmployeeTransactionsShares" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">88</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:ExerciseOfOptionsAndEmployeeTransactionsShares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:ExerciseOfOptionsAndEmployeeTransactionsShares" decimals="-5" scale="6" format="ixt:numdotdecimal">14.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" decimals="-6" scale="6" format="ixt:numdotdecimal">806</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation<sup style="white-space: nowrap">&#xA0;4</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:EquityBasedCompensationShares" decimals="-5" scale="6" format="ixt:numdotdecimal">10.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">854</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:EquityBasedCompensationShares" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">745</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:EquityBasedCompensationShares" decimals="-5" scale="6" format="ixt:numdotdecimal">11.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" decimals="-6" scale="6" format="ixt:numdotdecimal">730</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:SharesDeliveredToDivestedBusinessEmployees" decimals="-5" scale="0" format="ixt:numdotdecimal">0.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:SharesDeliveredToDivestedBusinessEmployees" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:SharesDeliveredToDivestedBusinessEmployees" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear" name="nvs:TreasurySharesMovement" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">115.3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:EquityImpactOfTreasuryShareMovements" decimals="-6" scale="6" format="ixt:numdotdecimal">9 963</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-1" name="nvs:TreasurySharesMovement" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">21.9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:EquityImpactOfTreasuryShareMovements" decimals="-6" scale="6" format="ixt:numdotdecimal">2 119</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Shares" contextRef="AR_D-CurrentYear-2" name="nvs:TreasurySharesMovement" decimals="-5" scale="6" format="ixt:numdotdecimal" sign="-">8.2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:EquityImpactOfTreasuryShareMovements" decimals="-6" scale="6" format="ixt:numdotdecimal">1 490</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> Shares repurchased on the SIX Swiss Exchange second trading line under a CHF <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd-2" name="nvs:StockRepurchaseProgramAuthorizedAmount1" decimals="-9" scale="9" format="ixt:numdotdecimal">10</ix:nonFraction> billion share buyback authority approved at the 2019 Annual General Meeting (AGM) for transactions after February 28, 2019, until March 2, 2021. Transactions after March 2, 2021, were executed under the CHF <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd-1" name="nvs:StockRepurchaseProgramAuthorizedAmount1" decimals="-9" scale="9" format="ixt:numdotdecimal">10</ix:nonFraction> billion share buyback authority approved at the 2021 AGM and the additional CHF <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd" name="nvs:StockRepurchaseProgramAuthorizedAmount1" decimals="-9" scale="9" format="ixt:numdotdecimal">10</ix:nonFraction> billion authority approved at the 2022 AGM.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;3&#xA0;</sup> Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price, reflecting the strike price of the options exercised.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;4&#xA0;</sup> Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax-deductible amounts exceeding the expense recognized in the income statement are credited to equity.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.3) In December 2021, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:MaximalAmountOfShareBuybackProgramm" decimals="-8" scale="9">15.0</ix:nonFraction> billion share buyback. The arrangement was updated in July 2022. Novartis is able to cancel this arrangement at any time but could be subject to a 90-day waiting period. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of December 31, 2022, these waiting period conditions were not applicable and as a result, there was no requirement to record a liability under this arrangement as of December 31, 2022. The liability under this arrangement amounted to USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:CommitmentForRepurchaseOwnShares" decimals="-8" scale="9">2.8</ix:nonFraction> billion as of December 31, 2021.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In June 2021, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares to mitigate dilution related to participation plans of employees. Novartis would have been able to cancel this arrangement at any time but would have been subject to a 90-day waiting period.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">This trading plan commitment was fully executed and expired in June 2021, and as a consequence, there is <span>no</span> liability related to this plan recognized as of December 31, 2021.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In November 2020, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:MaximalAmountOfShareBuybackProgramm" decimals="-8" scale="9">2.5</ix:nonFraction> billion share buyback. Novartis would have been able to cancel this arrangement at any time, but would have been subject to a 90-day waiting period. The commitment under this arrangement therefore reflected the obligated purchases by the bank under such trading plan over a rolling 90-day period, or if shorter, until the maturity date of such trading plan.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The commitment under this arrangement amounted to USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:CommitmentForRepurchaseOwnShares" decimals="-8" scale="9">1.8</ix:nonFraction> billion as of December 31, 2020. This trading plan commitment was fully executed and expired in March 2021, and as a consequence, there is no liability related to this plan recognized as of December 31, 2021.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In August 2020, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares to mitigate dilution related to participation plans of associates. Novartis would have been able to cancel this arrangement at any time but would have been subjected to a 90-day waiting period. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">This trading plan commitment was fully executed and expired, and as a consequence, there is no liability related to this plan recognized as of December 31, 2020.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.4) In October 2020, Novartis entered into an agreement with the market maker for its employee options to repurchase a portion of the outstanding written call options. A total of <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:NumberOfOptionsRepurchased" decimals="-5" scale="6" sign="-">3.7</ix:nonFraction> million options were repurchased under this agreement. This agreement was terminated in November 2020.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.5) The impact of change in ownership of consolidated entities represents the excess of the amount paid to non-controlling interest over their carrying value and equity allocation to non-controlling interest due to change in ownership percentage. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.6) Changes in non-controlling interests represent the impact on the non-controlling interest of transactions with minority shareholders, such as change in ownership percentage, dividend payments and other equity transactions. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.7) Other movements include, for subsidiaries in hyperinflationary economies, the impact of the restatement of the equity balances of the current year as well as restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period. See Note 29 for additional disclosures.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.8) In 2021, transaction costs that were directly attributable to the distribution (spin-off) of Alcon Inc. to Novartis AG shareholders and that would otherwise have been avoided, were recorded to equity.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-41</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_65b76240-e213-4420-b104-9b747734330c_2">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.9) At December 31, 2022, the market maker held <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd" name="nvs:WrittenCallOptionsHeldByMarketMaker" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction> million (2021: <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1" name="nvs:WrittenCallOptionsHeldByMarketMaker" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction> million; 2020: <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-2" name="nvs:WrittenCallOptionsHeldByMarketMaker" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction> million) written call options, originally issued as part of the share-based compensation for employees, that have not yet been exercised. The weighted average exercise price of these options is USD <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd" name="nvs:WrittenCallOptionsWeightedAverageExercisePrice" decimals="2" scale="0">66.07</ix:nonFraction> (2021: USD <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd-1" name="nvs:WrittenCallOptionsWeightedAverageExercisePrice" decimals="2" scale="0">61.45</ix:nonFraction>; 2020: USD <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd-2" name="nvs:WrittenCallOptionsWeightedAverageExercisePrice" decimals="2" scale="0">60.09</ix:nonFraction>), and they have contractual lives of <ix:nonFraction unitRef="Year" contextRef="AR_I-CurrentYearEnd" name="nvs:WrittenCallOptionsContractualLive" decimals="0" scale="0" format="ixt:numdotdecimal">10</ix:nonFraction> years, with remaining lives less than <ix:nonFraction unitRef="Year" contextRef="AR_I-CurrentYearEnd" name="nvs:WrittenCallOptionsContractualLiveRemaining" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> year (2021: <ix:nonFraction unitRef="Year" contextRef="AR_I-CurrentYearEnd-1" name="nvs:WrittenCallOptionsContractualLiveRemaining" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> years; 2020: <ix:nonFraction unitRef="Year" contextRef="AR_I-CurrentYearEnd-2" name="nvs:WrittenCallOptionsContractualLiveRemaining" decimals="0" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> years). </div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory" id="SectionBlock_9f7c9745-fccb-433d-bffe-01272e47b67a_0" escape="true" continuedAt="SectionBlock_9f7c9745-fccb-433d-bffe-01272e47b67a_1">
          <div>
            <div id="anchorId001543765"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">19. Non-current financial debt</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" id="SectionBlock_089a0f0d-4105-446d-925c-f53642b5ba05_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">22 341</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">25 296</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities to banks and other financial institutions<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:LiabilitiesToBanksAndOtherInstitutions" decimals="-6" scale="6" format="ixt:numdotdecimal">144</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:LiabilitiesToBanksAndOtherInstitutions" decimals="-6" scale="6" format="ixt:numdotdecimal">227</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total, including current portion of non-current financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">22 485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">25 523</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion of non-current financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentPortionOfLongtermBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 241</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentPortionOfLongtermBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 621</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">20 244</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">22 902</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> Average interest rate <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:AverageInterestRateOnLoansReceived" decimals="3" scale="-2" format="ixt:numdotdecimal">2.3</ix:nonFraction>% (2021: <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:AverageInterestRateOnLoansReceived" decimals="3" scale="-2" format="ixt:numdotdecimal">0.9</ix:nonFraction>%)</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All bonds are initially recorded at the amount of proceeds received, net of transaction costs. They are subsequently carried at amortized cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognized as a charge to the consolidated income statement over the period of the relevant bond. Financial debts, including current financial debts, contain only general default covenants. The Group is in compliance with these covenants.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The percentage of fixed-rate financial debt to total financial debt was <span><ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd" name="nvs:RatioFixedRateFinancialDebtToTotalFinancialDebt" decimals="2" scale="-2">86</ix:nonFraction>%</span> at December 31, 2022, and <span><ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1" name="nvs:RatioFixedRateFinancialDebtToTotalFinancialDebt" decimals="2" scale="-2">87</ix:nonFraction>%</span> at December 31, 2021.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The average interest rate on total financial debt in 2022 was <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:AverageInterestRateOnBorrowings" decimals="3" scale="-2">2.4</ix:nonFraction>%</span> (2021: <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:AverageInterestRateOnBorrowings" decimals="3" scale="-2">1.9</ix:nonFraction>%</span>).</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 29 contains a maturity table of the Group&#x2019;s future contractual interest payments commitments.</div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-42</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_9f7c9745-fccb-433d-bffe-01272e47b67a_1">
          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides a breakdown of straight bonds:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" id="SectionBlock_2d5c4bde-c17d-418d-a097-4126333e576c_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />Coupon</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Currency</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Notional <br /> amount<br /> (millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Issuance <br /> year</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Maturity <br /> year</div>
                        </td>
                        <td></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Issuer</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Issue price</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022<br /> (USD<br /> millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021<br /> (USD<br /> millions)</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">2.400</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 500</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" name="nvs:BorrowingsIssuanceDate">2012</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" name="ifrs-full:BorrowingsMaturity">2022</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.225</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 498</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">3.700</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" name="nvs:BorrowingsIssuanceDate">2012</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" name="ifrs-full:BorrowingsMaturity">2042</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">98.325</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">490</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">490</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">3.400</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">2 150</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" name="nvs:BorrowingsIssuanceDate">2014</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" name="ifrs-full:BorrowingsMaturity">2024</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.287</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">2 147</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">2 144</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">4.400</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 850</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" name="nvs:BorrowingsIssuanceDate">2014</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" name="ifrs-full:BorrowingsMaturity">2044</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.196</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 827</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 826</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">1.625</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" name="ifrs-full:BorrowingsOriginalCurrency">EUR</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">600</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" name="nvs:BorrowingsIssuanceDate">2014</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" name="ifrs-full:BorrowingsMaturity">2026</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" name="nvs:BorrowingsLender">Novartis Finance S.A., Luxembourg, Luxembourg</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.697</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">638</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">676</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">0.250</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" name="ifrs-full:BorrowingsOriginalCurrency">CHF</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" name="nvs:BorrowingsIssuanceDate">2015</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" name="ifrs-full:BorrowingsMaturity">2025</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" name="nvs:BorrowingsLender">Novartis AG, Basel, Switzerland</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">100.640</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">541</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">547</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">0.625</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" name="ifrs-full:BorrowingsOriginalCurrency">CHF</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">550</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" name="nvs:BorrowingsIssuanceDate">2015</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" name="ifrs-full:BorrowingsMaturity">2029</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" name="nvs:BorrowingsLender">Novartis AG, Basel, Switzerland</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">100.502</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">595</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">602</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">1.050</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" name="ifrs-full:BorrowingsOriginalCurrency">CHF</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">325</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" name="nvs:BorrowingsIssuanceDate">2015</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" name="ifrs-full:BorrowingsMaturity">2035</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" name="nvs:BorrowingsLender">Novartis AG, Basel, Switzerland</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">100.479</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">352</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">356</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">3.000</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 750</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" name="nvs:BorrowingsIssuanceDate">2015</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" name="ifrs-full:BorrowingsMaturity">2025</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.010</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 742</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 740</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">4.000</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 250</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" name="nvs:BorrowingsIssuanceDate">2015</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" name="ifrs-full:BorrowingsMaturity">2045</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">98.029</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 221</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 220</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" name="ifrs-full:BorrowingsOriginalCurrency">EUR</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 250</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" name="nvs:BorrowingsIssuanceDate">2016</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" name="ifrs-full:BorrowingsMaturity">2023</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" name="nvs:BorrowingsLender">Novartis Finance S.A., Luxembourg, Luxembourg</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.127</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 330</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 409</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">0.625</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" name="ifrs-full:BorrowingsOriginalCurrency">EUR</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" name="nvs:BorrowingsIssuanceDate">2016</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" name="ifrs-full:BorrowingsMaturity">2028</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" name="nvs:BorrowingsLender">Novartis Finance S.A., Luxembourg, Luxembourg</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">98.480</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">528</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">559</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">2.400</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 000</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" name="nvs:BorrowingsIssuanceDate">2017</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" name="ifrs-full:BorrowingsMaturity">2022</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.449</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 000</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">3.100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 000</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" name="nvs:BorrowingsIssuanceDate">2017</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" name="ifrs-full:BorrowingsMaturity">2027</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.109</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">994</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">993</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">1.125</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" name="ifrs-full:BorrowingsOriginalCurrency">EUR</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">600</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" name="nvs:BorrowingsIssuanceDate">2017</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" name="ifrs-full:BorrowingsMaturity">2027</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" name="nvs:BorrowingsLender">Novartis Finance S.A., Luxembourg, Luxembourg</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.874</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">638</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">677</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">0.500</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" name="ifrs-full:BorrowingsOriginalCurrency">EUR</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" name="nvs:BorrowingsIssuanceDate">2018</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" name="ifrs-full:BorrowingsMaturity">2023</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" name="nvs:BorrowingsLender">Novartis Finance S.A., Luxembourg, Luxembourg</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.655</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">798</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">846</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">1.375</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" name="ifrs-full:BorrowingsOriginalCurrency">EUR</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" name="nvs:BorrowingsIssuanceDate">2018</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" name="ifrs-full:BorrowingsMaturity">2030</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" name="nvs:BorrowingsLender">Novartis Finance S.A., Luxembourg, Luxembourg</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.957</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">797</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">846</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">1.700</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" name="ifrs-full:BorrowingsOriginalCurrency">EUR</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" name="nvs:BorrowingsIssuanceDate">2018</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" name="ifrs-full:BorrowingsMaturity">2038</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" name="nvs:BorrowingsLender">Novartis Finance S.A., Luxembourg, Luxembourg</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.217</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">792</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">840</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">1.750</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 000</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" name="nvs:BorrowingsIssuanceDate">2020</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" name="ifrs-full:BorrowingsMaturity">2025</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.852</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">998</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">998</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">2.000</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 250</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" name="nvs:BorrowingsIssuanceDate">2020</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" name="ifrs-full:BorrowingsMaturity">2027</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.909</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 246</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 246</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">2.200</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 500</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" name="nvs:BorrowingsIssuanceDate">2020</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" name="ifrs-full:BorrowingsMaturity">2030</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.869</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 494</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 493</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="-2" format="ixt:numdotdecimal">2.750</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" name="ifrs-full:BorrowingsOriginalCurrency">USD</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 250</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" name="nvs:BorrowingsIssuanceDate">2020</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" name="ifrs-full:BorrowingsMaturity">2050</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" name="nvs:BorrowingsLender">Novartis Capital Corporation, New York, United States</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">97.712</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 215</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 214</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="ifrs-full:BorrowingsInterestRate" decimals="5" scale="0" format="ixt:numdotdecimal">0.000</ix:nonFraction>%</span>
                            <sup style="white-space: nowrap">&#xA0;1</sup>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="ifrs-full:BorrowingsOriginalCurrency">EUR</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 850</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="nvs:BorrowingsIssuanceDate">2020</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="ifrs-full:BorrowingsMaturity">2028</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="nvs:BorrowingsLender">Novartis Finance S.A., Luxembourg, Luxembourg</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="nvs:BorrowingsPremiumDiscount" decimals="5" scale="-2" format="ixt:numdotdecimal">99.354</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">1 958</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">2 076</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total straight bonds</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">22 341</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">25 296</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> The EUR <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="ifrs-full:NotionalAmount" decimals="-6" scale="6" format="ixt:numdotdecimal">1 850</ix:nonFraction> million bond issued in 2020 features a coupon step-up of <span><ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="nvs:BorrowingsInterestRateStepUp" decimals="4" scale="0" format="ixt:numdotdecimal">0.25</ix:nonFraction>%</span> commencing with the first interest payment date after December 31, 2025, if one or both of the 2025 Patient Access Targets are not met. These 2025 Patient Access Targets are the 2025 Flagship Programs Patient Reach Target and the 2025 Strategic Innovative Therapies Patient Reach Target, as defined in the bond prospectus. As of December 31, 2022, there is no indication that these 2025 Patient Access Targets will not be met.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables provide a breakdown of total non-current financial debt, including current portion by maturity and currency:</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Breakdown by maturity:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" id="SectionBlock_42b92e33-c1a0-42ed-9682-3fd3dede1b88_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 621</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 241</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 342</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 147</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 144</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">3 281</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">3 284</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">638</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">693</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2027</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 909</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanFiveYearsAndNotLaterThanSixYearsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 916</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After 2027</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">11 269</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanSixYearsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">11 523</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">22 485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">25 523</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Breakdown by currency:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" id="SectionBlock_e8099986-8ca7-45d0-b780-a828b37cbf28_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022USD" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">13 376</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022USD" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">15 862</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022EUR" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">7 478</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022EUR" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">7 930</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022JPY" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022JPY" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">174</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022CHF" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">1 488</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022CHF" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">1 505</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">52</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">22 485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">25 523</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following table shows the comparison of balance sheet carrying value and fair value of total non-current financial debt, including current portion:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" id="SectionBlock_9b41517e-a496-4ec4-ab06-e0a79b5f8a38_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022<br /> Balance<br /> sheet</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022<br /> Fair<br /> values</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021<br /> Balance<br /> sheet</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021<br /> Fair<br /> values</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">22 341</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">20 277</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">25 296</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember" name="ifrs-full:BondsIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">27 079</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember" name="nvs:OtherNoncurrentFinancialDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">144</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember" name="nvs:OtherNoncurrentFinancialDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">144</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember" name="nvs:OtherNoncurrentFinancialDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">227</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember" name="nvs:OtherNoncurrentFinancialDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">227</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">22 485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">20 421</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">25 523</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember" name="ifrs-full:Borrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">27 306</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The fair values of straight bonds are determined by quoted market prices. Other financial debts are recorded at notional amounts, which are a reasonable approximation of the fair values.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-43</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" id="SectionBlock_62b40a60-48ad-4e8d-b0d9-00534a13e36e_0" escape="true" continuedAt="SectionBlock_62b40a60-48ad-4e8d-b0d9-00534a13e36e_1">
          <div>
            <div id="anchorId001545467"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">20. Provisions and other non-current liabilities</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfOtherProvisionsExplanatory" id="SectionBlock_908ad470-ac09-4465-8073-37ecc00bff88_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued liability for employee benefits:</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Defined benefit pension plans<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" decimals="-6" scale="6" format="ixt:numdotdecimal">1 723</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" decimals="-6" scale="6" format="ixt:numdotdecimal">2 640</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Other long-term employee benefits and deferred compensation</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:OtherLongtermEmployeeBenefitsAndDeferredCompensation" decimals="-6" scale="6" format="ixt:numdotdecimal">554</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:OtherLongtermEmployeeBenefitsAndDeferredCompensation" decimals="-6" scale="6" format="ixt:numdotdecimal">662</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Other post-employment benefits<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:OtherPostemploymentBenefits" decimals="-6" scale="6" format="ixt:numdotdecimal">362</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:OtherPostemploymentBenefits" decimals="-6" scale="6" format="ixt:numdotdecimal">487</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Environmental remediation provisions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:EnvironmentalRemediationProvisionNoncurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">535</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:EnvironmentalRemediationProvisionNoncurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">567</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for product liabilities, governmental investigations and other legal matters</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">154</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">341</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:ContingentConsiderationNonCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">704</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:ContingentConsiderationNonCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">956</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">874</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">519</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total provisions and other non-current liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherNoncurrentNonfinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">4 906</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherNoncurrentNonfinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">6 172</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Note 25 provides additional disclosures related to post-employment benefits.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis believes that its total provisions are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities in this area, Novartis may incur additional costs beyond the amounts provided. Management believes that such additional amounts, if any, would not be material to the Group&#x2019;s financial condition but could be material to the results of operations or cash flows in a given period.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Environmental remediation provisions</span>
                </div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movements in the environmental liability provisions:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:AccrualForEnvironmentalLossContingenciesTableTextBlock" id="SectionBlock_cd416968-caec-4175-9310-50ad300e2c5a_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:EnvironmentalProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">616</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:EnvironmentalProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">809</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3" name="nvs:EnvironmentalProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">714</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:EnvironmentalProvisionPayments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:EnvironmentalProvisionPayments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">169</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:EnvironmentalProvisionPayments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:EnvironmentalProvisionReleases" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>- <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:EnvironmentalProvisionReleases" decimals="-6" scale="6" format="ixt:numdotdecimal"> 105</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:EnvironmentalProvisionReleases" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:EnvironmentalProvisionAdditions" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:EnvironmentalProvisionAdditions" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:EnvironmentalProvisionAdditions" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">24</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:EnvironmentalProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">588</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:EnvironmentalProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">616</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:EnvironmentalProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">809</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current provision</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:EnvironmentalProvisionCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:EnvironmentalProvisionCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:EnvironmentalProvisionCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">167</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current environmental remediation provisions at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:EnvironmentalRemediationProvisionNoncurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">535</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:EnvironmentalRemediationProvisionNoncurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">567</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:EnvironmentalRemediationProvisionNoncurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">642</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The significant components of the environmental remediation provisions consist of costs to sufficiently clean and refurbish contaminated sites to the extent necessary, and to continue surveillance at sites where the environmental remediation exposure is less significant. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A substantial portion of the environmental remediation provisions relate to the remediation of Basel regional landfills in the adjacent border areas in Switzerland, Germany and France. The provisions are reassessed on an annual basis and adjusted as necessary.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the United States, Novartis has been named under federal legislation (the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended) as a potentially responsible party (PRP) in respect of certain sites. Novartis actively participates in, or monitors, the cleanup activities at the sites in which it is a PRP. The provision takes into consideration the number of other PRPs at each site as well as the identity and financial position of such parties in light of the joint and several nature of the liability. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The expected timing of the related cash outflows as of December 31, 2022, is currently projected as follows:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" id="SectionBlock_7fc3571b-36ae-44f5-8c11-163394c97132_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Expected <br /> cash outflows</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due within two years</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:20%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:EnvironmentalProvisionExpectedCashOutflowNextTwoYears" decimals="-6" scale="6" format="ixt:numdotdecimal">128</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due later than two years, but within five years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" decimals="-6" scale="6" format="ixt:numdotdecimal">163</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due later than five years, but within 10 years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" decimals="-6" scale="6" format="ixt:numdotdecimal">251</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due after 10 years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:EnvironmentalProvisionExpectedCashOutflowAfterTenYears" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total environmental remediation provisions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:EnvironmentalProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">588</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Provisions for product liabilities, governmental investigations and other legal matters </span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has established provisions for certain product liabilities, governmental investigations and other legal matters where a potential cash outflow is probable and Novartis can make a reliable estimate of the amount of the outflow. These provisions represent the Group&#x2019;s current best estimate of the total financial effect for the matters described below and for other less significant matters. Potential cash outflows reflected in a provision might be fully or partially offset by insurance in certain circumstances.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis has not established provisions for potential damage awards for certain additional legal claims against its subsidiaries if Novartis currently believes that a payment is either not probable or cannot be reliably estimated. These not-provisioned-for matters include individual product liability cases and certain other legal matters. Plaintiffs&#x2019; have alleged claims in these matters and the Group does not believe that information about the amount sought by plaintiffs, if that is known, would be meaningful with respect to those legal proceedings. This is due to a number of factors, including, but not limited to, the stage of proceedings, the entitlement of parties to appeal a decision and clarity as to theories of liability, damages and governing law. Therefore, it is not practicable to provide information about the potential financial impact of these matters. In addition, in some of </div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-44</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_62b40a60-48ad-4e8d-b0d9-00534a13e36e_1" continuedAt="SectionBlock_62b40a60-48ad-4e8d-b0d9-00534a13e36e_2">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">these matters there are claims for punitive or multiple (treble) damages, civil penalties and disgorgement of profits that in the view of Novartis are either wholly or partially unspecified, or wholly or partially unquantifiable at present; the Group believes that information about these amounts claimed by plaintiffs generally is not meaningful for purposes of determining a reliable estimate of a loss that is probable or more than remote.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A number of other legal matters are in such early stages or the issues presented are such that the Group has not made any provisions since it cannot currently estimate either a potential outcome or the amount of any potential losses. For these reasons, among others, the Group generally is unable to make a reliable estimate of possible loss with respect to such cases. It is therefore not practicable to provide information about the potential financial impact of those cases.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There might also be cases for which the Group was able to make a reliable estimate of the possible loss or the range of possible loss, but the Group believes that publication of such information on a case-by-case basis would seriously prejudice the Group&#x2019;s position in ongoing legal proceedings or in any related settlement discussions. Accordingly, in such cases, information has been disclosed with respect to the nature of the contingency, but no disclosure is provided as to an estimate of the possible loss or range of possible loss.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 28 contains additional information on contingent liabilities.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Summary of significant legal proceedings</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following is a summary of significant legal proceedings to which Novartis or its subsidiaries are currently a party, or were a party and that concluded in 2022.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Investigations and related litigations</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Southern District of New York (S.D.N.Y.) Gilenya marketing practices investigation and litigation</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2013, Novartis Pharmaceuticals Corporation (NPC) received a civil investigative demand from the United States Attorney&#x2019;s Office (USAO) for the S.D.N.Y. requesting the production of documents and information relating to marketing practices for <i>Gilenya</i>, including the remuneration of healthcare providers in connection therewith. In 2017, the S.D.N.Y. and New York State declined to intervene in claims raised by an individual relator in a qui tam complaint. In 2022, NPC&#x2019;s motion to dismiss this complaint was granted, which was appealed. The claims are being vigorously contested. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Government generic pricing antitrust investigations, antitrust class actions</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since 2016, Sandoz Inc. has received a grand jury subpoena and a civil investigative demand and interrogatories from the Antitrust and Civil Divisions of the US Department of Justice (DOJ) into alleged price fixing and market allocation of generic drugs in the United States as well as alleged federal False Claims Act (FCA) violations. Sandoz Inc. also received a subpoena and interrogatories from the Attorney General of the State of Connecticut in connection with a similar States&#x2019; investigation. In 2020, Sandoz Inc. reached a resolution with the DOJ Antitrust Division, pursuant to which Sandoz Inc. paid USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember" name="nvs:AmountOfSettlementInPrinciple" decimals="-6" scale="6" format="ixt:numdotdecimal">195</ix:nonFraction> million and entered into a deferred prosecution agreement. The Sandoz Inc. resolution related to instances of misconduct at the Company between 2013 and 2015 with regard to certain generic drugs sold in the United States. Under the terms of that agreement, Sandoz Inc. will continue to take steps to enhance its compliance program, employee training and monitoring, and will continue to cooperate with the US government&#x2019;s ongoing investigation into the generic pharmaceutical industry. Sandoz Inc. also finalized a resolution with the DOJ Civil Division and in 2021 paid USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember" name="nvs:AmountOfSettlementInPrinciple" decimals="-6" scale="6" format="ixt:numdotdecimal">185</ix:nonFraction> million, which includes interest from the date of the agreement in principle, to settle related claims arising under the FCA, and entered into a corporate integrity agreement with the Office of Inspector General (OIG) of the US Department of Health and Human Services (HHS). This resolution with the DOJ resolves all federal government matters related to price fixing allegations.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Since the third quarter of 2016, Sandoz Inc. and Fougera Pharmaceuticals Inc. have been sued alongside other generic pharmaceutical companies in numerous individual and putative class action complaints by direct and indirect private purchasers and by over  <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember" name="nvs:DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" decimals="0" scale="0" format="ixt:numdotdecimal">50</ix:nonFraction> US states and territories, represented by their respective Attorneys General. Plaintiffs claim that defendants, including Sandoz Inc., engaged in price fixing and market allocation of generic drugs in the United States, and seek damages and injunctive relief. The litigation includes complaints alleging product-specific conspiracies, as well as complaints alleging the existence of an overarching industry conspiracy, and assert claims for damages and penalties under federal and state antitrust and consumer protection acts. The cases have been consolidated for pretrial purposes in the United States District Court (USDC) for the Eastern District of Pennsylvania, and the claims are being vigorously contested.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Lucentis/Avastin&#xAE; matters</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In connection with an investigation into whether Novartis entities, F. Hoffmann-La Roche AG, Genentech Inc. and Roche S.p.A. colluded to artificially preserve the market positions of Avastin<sup>&#xAE;</sup> and <i>Lucentis</i>, in 2014 the Italian Competition Authority (ICA) imposed a fine equivalent to USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022IT_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NAGAndNovartisPharmaSpAMember" name="ifrs-full:EstimatedFinancialEffectOfContingentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction> million on the Novartis entities. Novartis paid the fine, subject to the right to later claim recoupment, and appealed before the Consiglio di Stato (CdS). In 2014 and 2015, the Italian Ministry of Health and the Lombardia region sent letters with payment requests for a total equivalent of approximately USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022IT_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember" name="nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" decimals="-8" scale="9">1.3</ix:nonFraction> billion in damages from Novartis and Roche entities based on these allegations. In 2019, the CdS upheld the ICA decision and fine. Following that CdS decision, several additional Italian regions and hospitals sent letters claiming damages for an aggregate amount of approximately USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022IT_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember" name="nvs:EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" decimals="-6" scale="6" format="ixt:numdotdecimal">330</ix:nonFraction> million. None of these claims have been asserted in legal proceedings and no further letters have been sent since. Novartis continues to appeal the CdS decision. In 2019, the French Competition Authority (FCA) issued a Statement of Objections against Novartis entities, alleging anti-competitive practices on the French market for anti-vascular endothelial growth factor treatments for wet age-related macular degeneration from 2008 to </div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-45</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_62b40a60-48ad-4e8d-b0d9-00534a13e36e_2" continuedAt="SectionBlock_62b40a60-48ad-4e8d-b0d9-00534a13e36e_3">
          <div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">2013. In 2020, the FCA issued a decision finding that the Novartis entities had infringed competition law by abusing a dominant position and imposing a fine equivalent to approximately USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022GeographicalAreasAxis_country-2022FR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4FHoffmanLaRocheAGAndRocheSpAMember" name="nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" decimals="-6" scale="6" format="ixt:numdotdecimal">452</ix:nonFraction> million. Novartis paid the fine, again subject to recoupment, and is appealing the FCA&#x2019;s decision. Novartis is the subject of similar investigations and proceedings involving competition authorities in Belgium and Greece and is currently in the appeal process in Turkey. Novartis continues to vigorously contest all claims in all those countries.  Novartis is also challenging policies and regulations allowing off-label/unlicensed use and reimbursement for economic reasons in Turkey.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Greece investigation</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Greek authorities are investigating legacy allegations of potentially inappropriate economic benefits to HCPs, government officials and others in Greece. These authorities include the Greek Coordinating Body for Inspection and Control, and the Greek Body of Prosecution of Financial Crime (SDOE), from which the Company received a summons in 2018 and 2020. Novartis has cooperated in these investigations. In 2021, SDOE imposed on Novartis Hellas a fine equivalent to approximately USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022GR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember" name="nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" decimals="-5" scale="6">1.2</ix:nonFraction> million, which Novartis Hellas has appealed. In 2022, the Greek State served a civil lawsuit on Novartis Hellas, seeking approximately USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022GR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember" name="nvs:EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" decimals="-6" scale="6" format="ixt:numdotdecimal">225</ix:nonFraction> million for moral damages allegedly arising from the conduct that was the subject of the Company&#x2019;s 2020 settlement with the DOJ regarding allegations of inappropriate economic benefits in Greece that was disclosed in the 2020 Annual Report and the 2020 Form 20-F. The claims are being vigorously contested.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">340B Drug Pricing Program investigations</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2021, NPC received a notification from the US Health Resources and Services Administration (HRSA) which stated that HRSA believes NPC&#x2019;s contract pharmacy policy violates the 340B statute, and threatened potential enforcement action. NPC subsequently sued HRSA in the USDC for the District of Columbia to challenge HRSA&#x2019;s determination and to enjoin HRSA from taking action with respect to NPC&#x2019;s contract pharmacy policy. HRSA then referred the matter regarding NPC&#x2019;s contract pharmacy policy to OIG, which could result in the imposition of civil monetary penalties on NPC. The USDC issued a decision rejecting HRSA&#x2019;s interpretation of the 340B statute, vacating the violation notification and remanding the matter to HRSA. HRSA appealed, and the United States Court of Appeals for the DC Circuit heard argument on the case in 2022. In addition, in 2021, Emory University Hospital Midtown filed an Administrative Dispute Resolution (ADR) proceeding against NPC, seeking the return of alleged overcharges resulting from NPC&#x2019;s contract pharmacy policy. NPC has moved to dismiss the proceeding pending resolution of the HRSA litigation. Finally, also in 2021, NPC received a civil investigative subpoena from the Office of the Attorney General of the State of Vermont requesting the production of documents and information concerning NPC&#x2019;s participation in the 340B Drug Pricing Program in Vermont; NPC provided documents and information to the Office of the Attorney General.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Swiss and EU investigation</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In September 2022, the Swiss Competition Commission (COMCO) initiated an investigation of Novartis acquisition of certain patents from Genentech in April 2020 and their subsequent enforcement against Eli Lilly and other parties, allegedly in an attempt to protect <i>Cosentyx</i> from competing products. COMCO is investigating whether enforcement of the patents violates the Swiss Cartel Act. The European Commission also requested information from Novartis regarding this matter. Novartis is cooperating with the authorities and will vigorously contest any allegations. </div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Antitrust class actions</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Exforge</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since 2018, Novartis Group companies as well as other pharmaceutical companies have been sued by various direct and indirect purchasers of <i>Exforge</i> in multiple US individual and putative class action complaints. They claim that Novartis made a reverse payment in the form of an agreement not to launch an authorized generic, alleging violations of federal antitrust law and state antitrust, consumer protection and common laws, and seeking damages as well as injunctive relief. The cases have been consolidated in the S.D.N.Y. In 2022, Novartis agreed to a settlement in principle to pay USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember" name="nvs:AmountOfSettlementInPrinciple" decimals="-6" scale="6" format="ixt:numdotdecimal">245</ix:nonFraction> million to resolve these cases. These settlements are subject to mutually agreeable terms, finalization of documentation and, in some cases, court approval.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Product liability litigation</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Reclast </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">NPC is a defendant in more than <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ReclastAclastaMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NPCAndOthersMember" name="nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" decimals="0" scale="0" format="ixt:numdotdecimal">20</ix:nonFraction> US product liability actions involving <i>Reclast</i> and alleging atypical femur fracture injuries, all of which are in New Jersey state or federal court and in California state court, coordinated with claims against other bisphosphonate manufacturers. The claims are being vigorously contested.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Taxotere&#xAE; (docetaxel)</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sandoz is a defendant in more than <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TaxotereMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember" name="nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" decimals="0" scale="0" format="ixt:numdotdecimal">3 100</ix:nonFraction> US product liability actions involving Taxotere&#xAE; (docetaxel), an oncology product, many of which have been transferred to a multidistrict litigation in the Eastern District of Louisiana. The complaints allege misleading marketing and that Sanofi, as innovator, and several 505(b)(2) NDA holders (including Sandoz) failed to warn of the risk of permanent alopecia/hair loss. In 2022, actions involving claims related to alleged eye injuries caused by the use of Taxotere&#xAE; were coordinated in a separate multidistrict litigation in the Eastern District of Louisiana. The claims are being vigorously contested.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Amiodarone</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sandoz entities are named in <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AmiodaroneMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember" name="nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> multi-plaintiff US product liability cases involving amiodarone, a cardiac drug indicated to treat life-threatening arrhythmias that have not responded to other treatment. The complaints allege failure to warn, off-label promotion, and failure to include medication guides to pharmacies. The claims are being vigorously contested.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-46</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_62b40a60-48ad-4e8d-b0d9-00534a13e36e_3" continuedAt="SectionBlock_62b40a60-48ad-4e8d-b0d9-00534a13e36e_4">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Sartans and ranitidine</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since 2018, claims have been brought against Sandoz and other pharmaceutical companies alleging injury from carcinogenic impurities found in valsartan and valsartan/HCT film-coated tablets and/or losartan marketed or manufactured by Sandoz. These claims include several putative class actions in Canada. Claims have also been brought alleging injury from carcinogenic impurities in ranitidine-containing medicines. These claims also include several putative class actions in Canada and a multidistrict litigation in Florida. All of these claims are being vigorously contested.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Tasigna</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">NPC is a defendant in more than <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NPCAndOthersMember" name="nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" decimals="0" scale="0" format="ixt:numdotdecimal">400</ix:nonFraction> US product liability actions involving <i>Tasigna</i>, alleging that the product caused various cardiovascular effects and that NPC failed to provide adequate warnings about those alleged side effects. State court actions are pending in a multicounty litigation in Bergen County, New Jersey, and federal cases are pending in a multidistrict litigation in the Middle District of Florida. The claims are being vigorously contested.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other matters</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Shareholder derivative lawsuit</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2021, NPC, Sandoz Inc., Novartis Capital Corporation and certain present and former directors and officers of Novartis were named as defendants, and Novartis was named as a nominal defendant, in a purported shareholder derivative lawsuit filed in New York state court. The plaintiffs, derivatively as purported Novartis shareholders on behalf of Novartis, seek damages and other remedies based on alleged conduct by the corporate and individual defendants. In 2022, the court granted Novartis motion to dismiss the lawsuit, which the plaintiffs have appealed.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Concluded legal matters</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Average Wholesale Price (AWP) litigation &#x2013; Concluded matter </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Lawsuits were brought, the latest in February 2016, by various US state governmental entities and private parties against various pharmaceutical companies, including NPC, alleging that they fraudulently overstated the AWP that is or has been used by payers, including state Medicaid agencies, to calculate reimbursements to healthcare providers. In 2022, NPC settled a putative class action brought by private payers in New Jersey, which resolved the last AWP lawsuit. This matter is now concluded.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Entresto matter&#x2013; Concluded matter</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2021, NPC received a civil investigative demand from the DOJ seeking information from 2016 to the present regarding the marketing and pricing of Entresto, including remuneration provided to HCPs.  In December 2022, the DOJ advised that it has no additional requests and that the matter is considered closed. This matter is now concluded.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">South Korea investigation &#x2013; Concluded matter</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2016, the Seoul Western District Prosecutor initiated a criminal investigation into, among other things, allegations that Novartis Korea utilized medical journals to provide inappropriate economic benefits to healthcare professionals (HCPs). This resulted in a non-material fine, which the prosecutor appealed. In 2021, the appellate court upheld the fine, and the prosecutor appealed that decision. In January 2023, the Supreme Court dismissed the appeal. This matter is now concluded.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Summary of product liability, governmental investigations and other legal matters provision movements</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" id="SectionBlock_d989c169-f695-4e42-a9e7-d4b161eb7171_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">397</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">487</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">1 369</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">105</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">292</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 863</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases of provisions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" decimals="-6" scale="6" format="ixt:numdotdecimal">52</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to provisions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" decimals="-6" scale="6" format="ixt:numdotdecimal">466</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" decimals="-6" scale="6" format="ixt:numdotdecimal">251</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" decimals="-6" scale="6" format="ixt:numdotdecimal">1 018</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">8</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">17</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">702</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">397</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">487</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">548</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">306</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current product  liabilities, governmental  investigations and other  legal matters provisions  at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">154</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">341</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">181</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis believes that its total provisions for investigations, product liability, arbitration and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, there can be no assurance that additional liabilities and costs will not be incurred beyond the amounts provided.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-47</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_62b40a60-48ad-4e8d-b0d9-00534a13e36e_4">
          <div>
            <div>
              <div></div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" id="SectionBlock_c04d4e4d-b7d0-43a4-bdb6-d1dde2e4654e_0" escape="true">
          <div>
            <div id="anchorId001546335"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">21. Current financial debt and&#xA0;derivative&#xA0;financial&#xA0;instruments</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" id="SectionBlock_f6bc1d5a-0b0c-46bb-a777-d357746e739e_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of employees  payable on demand<sup style="white-space: nowrap"> &#xA0;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:InterestBearningAccountsOfAssociatesPayableOnDemand" decimals="-6" scale="6" format="ixt:numdotdecimal">1 814</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other financial debt<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:ShorttermBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">863</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:ShorttermBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">899</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CommercialPapersIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">2 772</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CommercialPapersIssued" decimals="-6" scale="6" format="ixt:numdotdecimal">893</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current portion of non-current financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentPortionOfLongtermBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 241</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentPortionOfLongtermBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 621</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DerivativeFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DerivativeFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt and derivative  financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 931</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">6 295</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> Weighted average interest rate <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:WeightedAverageInterestRateAssociates" decimals="4" scale="-2" format="ixt:numdotdecimal">0.25</ix:nonFraction>% through September 30, 2022 (2021: <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:WeightedAverageInterestRateAssociates" decimals="4" scale="-2" format="ixt:numdotdecimal">0.25</ix:nonFraction>%)</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup>
                            <span> Weighted average interest rate <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:WeightedAverageInterestRateOnBankAndOtherFinancialDebt" decimals="3" scale="-2" format="ixt:numdotdecimal">9.7</ix:nonFraction>% (2021: <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:WeightedAverageInterestRateOnBankAndOtherFinancialDebt" decimals="3" scale="-2" format="ixt:numdotdecimal">6.1</ix:nonFraction>%)</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During the third quarter of 2022, Novartis closed the interest-bearing accounts of employees payable on demand, and paid out USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:PaymentOfInterestBearingAccountsToBeneficiaries" decimals="-8" scale="9">0.9</ix:nonFraction> billion to the respective beneficiaries on October 3, 2022. The net cash outflows from interest-bearing accounts of employees payable on demand were reported within the line change in current financial debts in the consolidated statements of cash flows. See Note 23.6.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The carrying amounts of current financial debt, other than the current portion of non-current financial debt, approximate the estimated fair value due to the short-term nature of these instruments.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Details on commercial papers and short-term borrowings are provided under &#x201C;Liquidity risk&#x201D; in Note&#xA0;29. </div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" id="SectionBlock_993e8eda-d1b7-4f4c-a345-cb3bd2bacc7b_0" escape="true" continuedAt="SectionBlock_993e8eda-d1b7-4f4c-a345-cb3bd2bacc7b_1">
          <div>
            <div id="anchorId001546511"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">22. Provisions and other current liabilities</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" id="SectionBlock_ac665d93-2eaf-4204-a85b-d310dce364cf_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes other than income taxes</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">836</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">619</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Restructuring provisions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:ShorttermRestructuringProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">1 131</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:ShorttermRestructuringProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">345</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued expenses for goods and services received but not invoiced</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:AccrualsClassifiedAsCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">1 059</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:AccrualsClassifiedAsCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">1 089</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accruals for royalties</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:AccruedRoyaltiesPayableClassifiedAsCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">767</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:AccruedRoyaltiesPayableClassifiedAsCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">752</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued interests on financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentInterestPayable" decimals="-6" scale="6" format="ixt:numdotdecimal">116</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentInterestPayable" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for deductions from revenue</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentRefundsProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">6 732</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentRefundsProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">6 481</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accruals for compensation and benefits, including social security</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" decimals="-6" scale="6" format="ixt:numdotdecimal">2 321</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" decimals="-6" scale="6" format="ixt:numdotdecimal">2 260</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Environmental remediation provisions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:EnvironmentalProvisionCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:EnvironmentalProvisionCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">123</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">123</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for product liabilities, governmental investigations and other legal matters<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">548</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued share-based payments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" decimals="-6" scale="6" format="ixt:numdotdecimal">235</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" decimals="-6" scale="6" format="ixt:numdotdecimal">253</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:ContingentConsiderationCurrentPortion" decimals="-6" scale="6" format="ixt:numdotdecimal">131</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:ContingentConsiderationCurrentPortion" decimals="-6" scale="6" format="ixt:numdotdecimal">119</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares<sup style="white-space: nowrap">&#xA0;3</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:CommitmentForRepurchaseOwnShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 809</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other payables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherCurrentPayables" decimals="-6" scale="6" format="ixt:numdotdecimal">743</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherCurrentPayables" decimals="-6" scale="6" format="ixt:numdotdecimal">588</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total provisions and other current liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherCurrentNonfinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">14 795</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherCurrentNonfinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">15 670</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Note 20 provides additional disclosures related to legal provisions.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;3&#xA0;</sup> Note 18.3 provides additional disclosures related to commitment for repurchase of own shares.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Provisions are based upon management&#x2019;s best estimate and adjusted for actual experience. Such adjustments to historic estimates have not been material.</div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-48</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_993e8eda-d1b7-4f4c-a345-cb3bd2bacc7b_1" continuedAt="SectionBlock_993e8eda-d1b7-4f4c-a345-cb3bd2bacc7b_2">
          <div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Provisions for deductions from revenue</span>
                </div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movement of the provisions for deductions from revenue:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ProvisionsForReductionOfRevenueTableTextBlock" id="SectionBlock_1a8d941e-8fbb-4d94-968b-b2f93a0838f5_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentRefundsProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">6 481</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:CurrentRefundsProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">6 256</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3" name="ifrs-full:CurrentRefundsProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">5 595</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of currency translation, business combinations</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">210</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">218</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">234</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments/utilizations</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ProvisionUsedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">22 261</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ProvisionUsedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">19 838</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ProvisionUsedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">19 294</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustments of prior years charged to income statement</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:IncomeStatementAdjustmentsOfPriorYear" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">322</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:IncomeStatementAdjustmentsOfPriorYear" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">245</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:IncomeStatementAdjustmentsOfPriorYear" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">151</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current year income statement charge</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:IncomeStatementAdjustmentsOfCurrentYear" decimals="-6" scale="6" format="ixt:numdotdecimal">23 072</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:IncomeStatementAdjustmentsOfCurrentYear" decimals="-6" scale="6" format="ixt:numdotdecimal">20 413</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:IncomeStatementAdjustmentsOfCurrentYear" decimals="-6" scale="6" format="ixt:numdotdecimal">19 773</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions offset against gross trade receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ChangesInOffsetAgainstGrossTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ChangesInOffsetAgainstGrossTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">113</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ChangesInOffsetAgainstGrossTradeReceivables" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">99</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CurrentRefundsProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">6 732</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CurrentRefundsProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">6 481</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:CurrentRefundsProvision" decimals="-6" scale="6" format="ixt:numdotdecimal">6 256</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The provisions for deductions from revenue include specific healthcare plans and program rebates as well as non-healthcare plans and program-related rebates, returns and other deductions. The provisions for deductions from revenue are adjusted to reflect experience and to reflect actual amounts as rebates, refunds, discounts and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these deductions from revenue.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Restructuring provisions movements</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:RestructuringProvisionsMovementsTableTextBlock" id="SectionBlock_8343cd2f-4cde-43cd-944b-e07ac310f492_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:OtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">345</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:OtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">459</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:OtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">438</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">1 368</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">328</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">354</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:ProvisionUsedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">468</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:ProvisionUsedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">344</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:ProvisionUsedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">268</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:UnusedProvisionReversedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">42</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:UnusedProvisionReversedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">54</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:UnusedProvisionReversedOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">87</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transfers</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">53</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">27</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">19</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">17</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:OtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">1 131</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:OtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">345</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:OtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">459</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, additions to provisions of USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-8" scale="9">1.4</ix:nonFraction> billion were mainly related to the following reorganizations:</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Initiative announced in April 2022 to implement a new streamlined organizational model designed to support innovation, growth and productivity.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The continuation of the Innovative Medicines Division and the Operation unit (formerly Novartis Technical Operations and the Customer &amp; Technology Solutions) 2021 restructuring initiatives.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2021, additions to provisions of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">328</ix:nonFraction> million were mainly related to the following reorganizations:</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The Innovative Medicines Division commenced a plan to restructure its field force and supporting functions in response to changes in its go-to-market structure with increased utilization of digital technology.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Group-wide initiatives to streamline manufacturing platforms and manufacturing functions and implement new technologies continued. In addition, the Operations unit (formerly Customer &amp; Technology Solutions) continued the phased implementation of the new operating model to transition activities to service centers.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, additions to provisions of USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember" name="ifrs-full:AdditionalProvisionsOtherProvisions" decimals="-6" scale="6" format="ixt:numdotdecimal">354</ix:nonFraction> million were mainly related to the following reorganizations:</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The Innovative Medicines Division restructured its field force and supporting functions in Region Europe.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  The Sandoz Division initiatives to realign its organizational structures to improve competitiveness that commenced in 2019 continued. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  Group-wide initiatives to streamline manufacturing platforms and manufacturing functions through the setup of operations centers and implementation of new technologies, in the Innovative Medicines Division and the Sandoz Division, continued. In addition, the Operations unit (formerly Customer &amp; Technology Solutions) continued the phased implementation of the new operating model to change outsourcing structures and transition activities to service centers.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-49</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_993e8eda-d1b7-4f4c-a345-cb3bd2bacc7b_2">
          <div>
            <div>
              <div></div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfCashFlowStatementExplanatory" id="SectionBlock_47eaf5bd-dcef-4558-9051-0614a90b32c7_0" escape="true" continuedAt="SectionBlock_47eaf5bd-dcef-4558-9051-0614a90b32c7_1">
          <div>
            <div id="anchorId001547161"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">
              <b>23. Details to the consolidated statements of cash flows</b>
            </div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.1) Non-cash items and other adjustments</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the reversal of non-cash items and other adjustments in the consolidated statements of</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">cash flows.</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" id="SectionBlock_80b672d8-83aa-4a43-99fb-4335d458992f_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments on:</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Property, plant and equipment</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">1 570</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">1 489</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">1 758</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Right-of-use assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">303</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">318</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">330</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Intangible assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">5 308</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">4 306</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">4 376</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Financial assets<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">260</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">38</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">335</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 403</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">896</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 411</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gains on disposal and other adjustments on property, plant and equipment; intangible assets;  financial assets; and other non-current assets, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">333</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">677</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">478</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-settled compensation expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdjustmentsForSharebasedPayments" decimals="-6" scale="6" format="ixt:numdotdecimal">823</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdjustmentsForSharebasedPayments" decimals="-6" scale="6" format="ixt:numdotdecimal">736</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AdjustmentsForSharebasedPayments" decimals="-6" scale="6" format="ixt:numdotdecimal">738</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Loss/(income) from associated companies<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">15 339</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" decimals="-6" scale="6" format="ixt:numdotdecimal">673</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">1 416</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">2 119</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncomeTaxExpenseContinuingOperations" decimals="-6" scale="6" format="ixt:numdotdecimal">1 807</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net financial expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdjustmentsForFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">817</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdjustmentsForFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">891</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AdjustmentsForFinanceIncomeCost" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">947</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:OtherAdjustmentsForNoncashItems" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">30</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdjustmentsForReconcileProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">11 546</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdjustmentsForReconcileProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5 299</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AdjustmentsForReconcileProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal">9 881</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Includes fair value changes</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup>
                            <span> 2021 included the gain of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="nvs:GainOnDivestmentOfInterestsInAssociatedCompanies" decimals="-8" scale="9" format="ixt:numdotdecimal">14.6</ix:nonFraction> billion recognized from the divestment of the Group's investment in Roche (see Notes 2 and 4).</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, other than through business combinations, there were USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember" name="nvs:AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">635</ix:nonFraction> million additions to intangible assets with deferred payments. In 2022, there were USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember" name="nvs:AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" decimals="-6" scale="6" format="ixt:numdotdecimal">247</ix:nonFraction> million (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember" name="nvs:AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" decimals="-6" scale="6" format="ixt:numdotdecimal">321</ix:nonFraction> million, 2020: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember" name="nvs:AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" decimals="-6" scale="6" format="ixt:numdotdecimal">346</ix:nonFraction> million) additions to right-of-use assets recognized.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.2) Total amount of income taxes paid </span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, the total amount of income taxes paid was USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:IncomeTaxesPaidRefund" decimals="-8" scale="9">2.0</ix:nonFraction> billion (2021: USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:IncomeTaxesPaidRefund" decimals="-8" scale="9">2.3</ix:nonFraction> billion), which was included within &#x201C;Net cash flows from operating activities.&#x201D;</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2020, the total amount of income taxes paid was USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncomeTaxesPaidRefund" decimals="-8" scale="9">1.9</ix:nonFraction> billion, of which USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" decimals="-8" scale="9">1.8</ix:nonFraction> billion was included within &#x201C;Net cash flows from operating activities,&#x201D; and USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022DiscontinuedOperationsMember" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">88</ix:nonFraction> million was included within &#x201C;Net cash flows used in investing activities from discontinued operations.&#x201D;</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.3) Cash flows from changes in working capital and other operating items included in the net cash flows from operating activities</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" id="SectionBlock_93d9a48a-3929-4034-8865-bb163e5fa7b1_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Increase)/decrease in inventories</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">830</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" decimals="-6" scale="6" format="ixt:numdotdecimal">81</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">543</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Increase)/decrease in trade receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">589</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">389</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Decrease in trade payables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">48</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">21</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">324</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other current and non-current assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">194</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">202</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">229</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other current liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">658</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">772</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">211</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other adjustments, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:OtherAdjustmentsToReconcileProfitLoss" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:OtherAdjustmentsToReconcileProfitLoss" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 003</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" decimals="-6" scale="6" format="ixt:numdotdecimal">241</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">291</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.4) Cash flows arising from acquisitions and divestments of interests in associated companies, net</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2021, acquisitions and divestments of interests in associated companies, net included USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" decimals="-8" scale="9">20.7</ix:nonFraction> billion proceeds from the divestment of the Group&#x2019;s investment in Roche (see Notes 2 and 4).</div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-50</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_47eaf5bd-dcef-4558-9051-0614a90b32c7_1" continuedAt="SectionBlock_47eaf5bd-dcef-4558-9051-0614a90b32c7_2">
          <div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.5) Cash flows arising from acquisitions and divestments of businesses, net</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table is a summary of the cash flow impact of acquisitions and divestments of businesses. The most significant transactions are described in Note 2.</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" id="SectionBlock_eea59c31-11f7-4069-be1e-8cb92d410063_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of acquisitions of businesses</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:CashFlowFromNetIdentifiableAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 077</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:CashFlowFromNetIdentifiableAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">735</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:CashFlowFromNetIdentifiableAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">10 173</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value of previously held equity interests</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">21</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">42</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:ReceivablesAndPayablesContingentConsiderationNet" decimals="-6" scale="6" format="ixt:numdotdecimal">205</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:ReceivablesAndPayablesContingentConsiderationNet" decimals="-6" scale="6" format="ixt:numdotdecimal">59</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:ReceivablesAndPayablesContingentConsiderationNet" decimals="-6" scale="6" format="ixt:numdotdecimal">98</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments, deferred consideration and other adjustments, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:OtherPaymentsAndDeferredConsiderationNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">13</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:OtherPaymentsAndDeferredConsiderationNet" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:OtherPaymentsAndDeferredConsiderationNet" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions of businesses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">864</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">633</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10 006</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows (used for)/from divestments of businesses, net<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">15</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">66</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions and divestments of businesses, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">879</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">567</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">9 957</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> In 2022, USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">15</ix:nonFraction> million net cash outflows from divestments of businesses included USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:CashOutflowsDueToDerecognizedCashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction> million reduction to cash and cash equivalents due to the derecognized cash and cash equivalents following a loss of control of a company upon expiry of an option to purchase the company, partly offset by USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="ifrs-full:ConsiderationPaidReceived" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction> million net cash inflows from business divestments in 2022 and in prior years.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                            <span> In 2022, the net identifiable assets of divested businesses amounted to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:NetIdentifiableAssetsOfDivestedBusiness" decimals="-6" scale="6" format="ixt:numdotdecimal">173</ix:nonFraction> million, comprised of non-current assets of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:NoncurrentAssetsDivested" decimals="-6" scale="6" format="ixt:numdotdecimal">132</ix:nonFraction> million, current assets of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:CurrentAssetsDivested" decimals="-6" scale="6" format="ixt:numdotdecimal">113</ix:nonFraction> million, including USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction> million cash and cash equivalents and of non-current and current liabilities of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:NoncurrentAndCurrentLiabilitiesDivested" decimals="-6" scale="6" format="ixt:numdotdecimal">72</ix:nonFraction> million. Deferred sales price receivables and other adjustments amounted to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:DeferredSalePriceAndOtherAdjustments" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonFraction> million.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                            <span> In 2021, USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">66</ix:nonFraction> million included USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="ifrs-full:ConsiderationPaidReceived" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">52</ix:nonFraction> million net cash inflows from divestments in previous years, and a USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="ifrs-full:ConsiderationPaidReceived" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">14</ix:nonFraction> million net cash inflow from a business divestment in 2021, comprised of intangible assets.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                            <span> In 2020, USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember" name="nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction> million represented the net cash inflows from divestments in previous years.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Notes 2 and 24 provide further information regarding acquisitions and divestments of businesses. All acquisitions were for cash.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.6) Reconciliation of liabilities arising from financing activities</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" id="SectionBlock_e36c5d0b-3d14-4eb2-bef1-a17160d7f914_0" escape="true" continuedAt="SectionBlock_e36c5d0b-3d14-4eb2-bef1-a17160d7f914_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br /> Non-current <br /> financial <br /> debts</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Current <br /> financial <br /> debts and <br /> derivative <br /> financial <br /> instruments</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br />
                            <br /> Non-current <br /> lease liabilities</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br />
                            <br /> Current lease <br /> liabilities</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">22 902</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">6 295</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 621</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">275</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="ifrs-full:ProceedsFromNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of the current portion of non-current financial debts</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 575</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">295</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">295</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">51</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New, modified and terminated leases, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">173</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions and divestments of businesses, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, lease interest and other changes, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">60</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:AmortizationOfBondsDiscount" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">17</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:AmortizationOfBondsDiscount" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">366</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">401</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">41</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">14</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 325</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal">2 325</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">224</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal">224</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">20 244</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">5 931</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 538</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">251</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup>
                            <span> Change in current financial debts included net cash outflows from interest-bearing accounts of employees payable on demand amounting to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" decimals="-8" scale="9" format="ixt:numdotdecimal">1.7</ix:nonFraction> billion. See Note 21.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-51</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_47eaf5bd-dcef-4558-9051-0614a90b32c7_2">
          <div>
            <div>
              <ix:continuation id="SectionBlock_e36c5d0b-3d14-4eb2-bef1-a17160d7f914_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br />
                            <br /> Non-current <br /> financial <br /> debts</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Current <br /> financial <br /> debts and <br /> derivative <br /> financial <br /> instruments</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br />
                            <br />
                            <br /> Non-current <br /> lease liabilities</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br />
                            <br />
                            <br /> Current lease <br /> liabilities</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2021</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">26 259</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">9 785</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 719</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">286</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="ifrs-full:ProceedsFromNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of the current portion of non-current financial debts</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 162</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3 524</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">316</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">52</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New, modified and terminated leases, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">192</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">61</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, lease interest and other changes, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" decimals="-6" scale="6" format="ixt:numdotdecimal">124</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">62</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:AmortizationOfBondsDiscount" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">25</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:AmortizationOfBondsDiscount" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">774</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">309</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">43</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">13</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 624</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal">2 624</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">247</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal">247</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">22 902</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">6 295</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 621</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">275</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br />
                            <br /> Non-current <br /> financial <br /> debts</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Current <br /> financial <br /> debts and <br /> derivative <br /> financial <br /> instruments</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br />
                            <br />
                            <br /> Non-current <br /> lease liabilities</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br />
                            <br />
                            <br /> Current lease <br /> liabilities</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2020</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">20 353</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">7 031</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 703</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">246</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="ifrs-full:ProceedsFromNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">7 126</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of the current portion of non-current financial debts</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="ifrs-full:RepaymentsOfNoncurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 003</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" decimals="-6" scale="6" format="ixt:numdotdecimal">2 261</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">312</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">56</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New, modified and terminated leases, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">221</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">36</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, lease interest and other changes, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">65</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:AmortizationOfBondsDiscount" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">16</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:AmortizationOfBondsDiscount" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">832</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">392</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 067</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal">2 067</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">250</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:ReclassificationFromNoncurrentToCurrentNet" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2020</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">26 259</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">9 785</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 719</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember" name="nvs:FinancialDebtsAndDerivativeInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">286</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.7) Supplemental disclosures related to the Alcon business distributed to Novartis AG shareholders</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, net cash flows used in investing activities from discontinued operations of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">127</ix:nonFraction> million included the investing activities of the Alcon business, which was spun-off to Novartis AG shareholders on April 8, 2019, and cash outflows for transaction-related expenditures attributable to the series of portfolio transformation transactions completed in 2015. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2020, net cash flows used in financing activities from discontinued operations of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">50</ix:nonFraction> million were for transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders on April 8, 2019.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-52</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfBusinessCombinationsExplanatory" id="SectionBlock_9f830ff0-f99f-4cc3-9ec6-f7f2b5774c64_0" escape="true">
          <div>
            <div id="anchorId001549265"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">24. Acquisitions of businesses</div>
            <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Fair value of assets and liabilities arising from acquisitions of businesses:</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" id="SectionBlock_f2308544-9cb4-49c7-bced-9c9195b058de_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:RightOfUseAssetsAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:RightOfUseAssetsAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">292</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">196</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired research and development</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">1 209</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">262</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">8 600</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other intangible assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">98</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">218</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">476</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current financial and other assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:FinancialAndOtherAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:InventoryRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">84</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables and financial and other current assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">109</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">89</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">300</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">1 977</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current financial debts</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current lease liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables and other liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:TradePayablesAndOtherLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:TradePayablesAndOtherLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:TradePayablesAndOtherLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">144</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net identifiable assets acquired</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:IdentifiableAssetsAcquired" decimals="-6" scale="6" format="ixt:numdotdecimal">1 005</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:IdentifiableAssetsAcquired" decimals="-6" scale="6" format="ixt:numdotdecimal">612</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:IdentifiableAssetsAcquired" decimals="-6" scale="6" format="ixt:numdotdecimal">7 669</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired cash and cash equivalents</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:AcquiredCashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">89</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:AcquiredCashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="nvs:AcquiredCashAndCashEquivalents" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-controlling interests</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:GoodwillRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">161</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:GoodwillRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">238</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:GoodwillRecognisedAsOfAcquisitionDate" decimals="-6" scale="6" format="ixt:numdotdecimal">2 580</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of acquisitions of businesses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" decimals="-6" scale="6" format="ixt:numdotdecimal">1 077</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" decimals="-6" scale="6" format="ixt:numdotdecimal">735</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" decimals="-6" scale="6" format="ixt:numdotdecimal">10 173</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Note 2 details significant acquisitions of businesses, specifically of Gyroscope in 2022, the cephalosporin antibiotics business from GSK in 2021; and of the The Medicines Company and the Japanese business of AGI in 2020. The goodwill arising out of these acquisitions is attributable to the buyer-specific synergies, the assembled workforce, and the accounting for deferred tax liabilities on the acquired assets. In 2022, <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:GoodwillExpectedDeductibleForTaxPurposes" decimals="-6" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> goodwill (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:GoodwillExpectedDeductibleForTaxPurposes" decimals="-6" scale="6" format="ixt:numdotdecimal">107</ix:nonFraction> million; 2020: USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:GoodwillExpectedDeductibleForTaxPurposes" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonFraction> million) is tax deductible. </div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfEmployeeBenefitsExplanatory" id="SectionBlock_448431e3-dfe5-4f27-9bb5-7ce10f2ca56e_0" escape="true" continuedAt="SectionBlock_448431e3-dfe5-4f27-9bb5-7ce10f2ca56e_1">
          <div>
            <div id="anchorId001549649"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">25. Post-employment benefits for employees</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined benefit plans</span>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ConcentrationOfMajorPlansGeographic" id="SectionBlock_77f8ca46-8d50-4d9e-93e4-19bcf18d3935_0" escape="false">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition to the legally required social security schemes, the Group has numerous independent pension and other post-employment benefit plans. In most cases, these plans are externally funded in entities that are legally separate from the Group. For certain Group companies, however, no independent plan assets exist for the pension and other post-employment benefit obligations of employees. In these cases, the related unfunded liability is included in the balance sheet. The defined benefit obligations (DBOs) of all major pension and other post-employment benefit plans are reappraised annually by independent actuaries. Plan assets are recognized at fair value. The major plans are based in Switzerland, the United States, the United Kingdom, Germany and Japan, which represent <span><ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd" name="nvs:MajorPlansPercentageInGroupDBOPensions" decimals="2" scale="-2">95</ix:nonFraction>%</span> of the Group&#x2019;s total DBO for pension plans. Details of the plans in the two most significant countries, Switzerland and the United States, which represent <span><ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd" name="nvs:MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" decimals="2" scale="-2">83</ix:nonFraction>%</span> of the Group&#x2019;s total DBO for post-employment benefit plans, are provided below.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Swiss-based pension plans represent the most significant portion of the Group&#x2019;s total DBO and plan assets. For the active insured members the benefits are linked to contributions paid into the plan, interest credits granted and conversion rates applied. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">All benefits granted under Swiss-based pension plans are vested, and Swiss legislation prescribes that the employer has to contribute a fixed percentage of an employee&#x2019;s pay to an external pension fund. Additional employer contributions may be required whenever the plan&#x2019;s statutory funding ratio falls below a certain level. The employee also contributes to the plan. The pension plans are run by separate legal entities, each governed by a board of trustees that &#x2013; for the principal plans &#x2013; consists of representatives nominated by Novartis and the active insured employees. The boards of trustees are responsible for the plan design and asset investment strategy.</div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-53</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_448431e3-dfe5-4f27-9bb5-7ce10f2ca56e_1" continuedAt="SectionBlock_448431e3-dfe5-4f27-9bb5-7ce10f2ca56e_2">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In December 2020, the Board of Trustees of the Novartis Swiss Pension Fund agreed to adjust the annuity conversion rate at retirement with effect from January 1, 2022. This amendment did not affect existing pensioners, and its impact on existing plan participants will be mitigated by way of defined compensatory measures. This amendment resulted in a net pre-tax curtailment gain of USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="nvs:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" decimals="-6" scale="6" format="ixt:numdotdecimal">101</ix:nonFraction> million (CHF <ix:nonFraction unitRef="CHF" contextRef="AR_D-CurrentYear-2" name="nvs:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonFraction> million) recognized in 2020.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The United States pension plans represent the second-largest component of the Group&#x2019;s total DBO and plan assets. The principal plans (Qualified Plans) are funded, whereas plans providing additional benefits for executives (Restoration Plans) are unfunded. Employer contributions are required for Qualified Plans whenever the statutory funding ratio falls below a certain level. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Furthermore, in certain countries, employees are covered under other post-employment benefit plans and post-retirement medical plans.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the US, other post-employment benefit plans consist primarily of post-employment healthcare benefits, which have been closed to new members since 2015. Part of the costs of these plans is reimbursable under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. There is no statutory funding requirement for these plans. The Group is funding these plans to the extent that it is tax efficient.</div>
                <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables are a summary of the funded and unfunded defined benefit obligation for pension and other post-employment benefit plans of employees at December 31, 2022 and 2021:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfDefinedBenefitPlansTableTextBlock" id="SectionBlock_433d337a-3850-4a58-9c0d-8570d31a8d9e_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment  benefit plans</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">23 583</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">25 602</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">560</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">632</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current service cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">348</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">415</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanInterestCost" decimals="-6" scale="6" format="ixt:numdotdecimal">249</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanInterestCost" decimals="-6" scale="6" format="ixt:numdotdecimal">151</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanInterestCost" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanInterestCost" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past service costs and settlements</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">40</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Administrative expenses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:AdministrativeExpenseNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:AdministrativeExpenseNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurement gains arising from changes in financial assumptions<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">5 046</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">713</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurement (gains)/losses arising from changes in demographic assumptions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">377</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Experience-related remeasurement losses/(gains)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">199</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">531</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">650</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">865</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit payments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">1 253</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">1 450</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions of employees</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" decimals="-6" scale="6" format="ixt:numdotdecimal">174</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" decimals="-6" scale="6" format="ixt:numdotdecimal">179</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">17 533</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">23 583</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">422</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">560</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at January 1</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">22 420</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">22 317</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">89</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">220</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">105</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Return on plan assets excluding interest income</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">2 500</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 512</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">539</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">726</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Group contributions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">424</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">490</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions of employees</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">174</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">179</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Settlements</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanSettlementsPlanAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanSettlementsPlanAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit payments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">1 253</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">1 450</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">18 945</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">22 420</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal">1 412</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 163</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">362</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">487</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Limitation on recognition of fund surplus at January 1</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:LimitationOnRecognitionOfFundSurplus" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">62</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:LimitationOnRecognitionOfFundSurplus" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">51</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in limitation on recognition of fund surplus</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 504</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">16</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income on limitation of fund surplus</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:InterestIncomeOnLimitationOfFundSurplus" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:InterestIncomeOnLimitationOfFundSurplus" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Limitation on recognition of fund surplus at December 31<sup style="white-space: nowrap">&#xA0;2</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:LimitationOnRecognitionOfFundSurplus" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 644</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:LimitationOnRecognitionOfFundSurplus" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">62</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability in the balance sheet at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">1 232</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">1 225</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">362</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">487</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> The remeasurement gains arising from changes in financial assumptions is driven mainly by changes in the actuarial discount rates used to determine the benefit obligation.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup>
                            <span> As of December 31, 2022, the most significant pension plans where the asset ceiling was required to be applied were in Switzerland and amounted to USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:LimitationOnRecognitionOfFundSurplus" decimals="-6" scale="6" format="ixt:numdotdecimal">2 587</ix:nonFraction> million.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-54</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_448431e3-dfe5-4f27-9bb5-7ce10f2ca56e_2" continuedAt="SectionBlock_448431e3-dfe5-4f27-9bb5-7ce10f2ca56e_3">
          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The reconciliation of the net liability from January 1 to December 31 is as follows:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" id="SectionBlock_c1d0dc55-6f78-451b-b265-96c22462babc_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment  benefit plans</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">1 225</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">3 336</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">487</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">543</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current service cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">348</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">415</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net interest expense</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Administrative expenses</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">23</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">24</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past service costs and settlements</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">39</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurements</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">2 400</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">2 071</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">110</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">35</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">145</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Group contributions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">424</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">490</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in limitation on recognition of fund surplus</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2 504</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">16</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">1 232</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">1 225</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">362</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">487</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Amounts recognized in the consolidated balance sheet</div>
                        </td>
                        <td align="right"></td>
                        <td align="right"></td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right"></td>
                        <td align="right"></td>
                        <td align="right"></td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid benefit cost</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:PrepaidPostemploymentBenefitPlansAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">491</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:PrepaidPostemploymentBenefitPlansAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 415</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued benefit liability</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 723</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 640</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">362</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">487</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows a breakdown of the DBO for pension plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" id="SectionBlock_87184e57-05cb-43f4-85ae-09cfd21bd203_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Switzerland</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> United<br /> States</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of<br /> the world</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Total</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Switzerland</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> United<br /> States</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of<br /> the world</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">11 824</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 746</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 963</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">17 533</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">15 268</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">3 645</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">4 670</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">23 583</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof unfunded</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">556</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">363</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">919</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">688</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">439</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 127</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">By type of member</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Active</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">4 799</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">431</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">931</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">6 161</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">6 478</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">620</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 412</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">8 510</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Deferred pensioners</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">830</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">861</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 691</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 208</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 730</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 938</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Pensioners</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">7 025</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 171</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">9 681</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">8 790</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 817</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 528</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">12 135</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">14 701</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 978</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 266</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">18 945</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">16 436</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 551</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">3 433</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">22 420</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal">2 877</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">768</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">697</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal">1 412</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal">1 168</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 094</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 237</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 163</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows a breakdown of the DBO for other post-employment benefit plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" id="SectionBlock_624671d2-8652-4078-8166-89bb19fbbd6c_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> United<br /> States</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of<br /> the world</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Total</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> United<br /> States</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of<br /> the world</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">346</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">422</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">473</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">87</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">560</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof unfunded</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">286</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">362</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">400</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">87</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">487</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">By type of member</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Active</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">83</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Deferred pensioners</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Pensioners</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">308</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">58</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">366</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">400</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:DefinedBenefitObligationAtPresentValue" decimals="-6" scale="6" format="ixt:numdotdecimal">464</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:PlanAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">286</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">76</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">362</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">400</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">87</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:SurplusDeficitInPlan" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">487</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-55</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_448431e3-dfe5-4f27-9bb5-7ce10f2ca56e_3" continuedAt="SectionBlock_448431e3-dfe5-4f27-9bb5-7ce10f2ca56e_4">
          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the principal weighted average actuarial assumptions used for calculating defined benefit plans and other post-employment benefits of employees:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfAssumptionsUsedTableTextBlock" id="SectionBlock_1e83a3ec-23cd-4ff1-ae04-0dbf0adbb7fa_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment  benefit plans</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average assumptions used to determine  benefit obligations at December 31</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discount rate</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialAssumptionOfDiscountRates" decimals="3" scale="-2" format="ixt:numdotdecimal">3.0</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialAssumptionOfDiscountRates" decimals="3" scale="-2" format="ixt:numdotdecimal">0.9</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialAssumptionOfDiscountRates" decimals="3" scale="-2" format="ixt:numdotdecimal">0.6</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:ActuarialAssumptionOfDiscountRates" decimals="3" scale="-2" format="ixt:numdotdecimal">6.3</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:ActuarialAssumptionOfDiscountRates" decimals="3" scale="-2" format="ixt:numdotdecimal">3.3</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="ifrs-full:ActuarialAssumptionOfDiscountRates" decimals="3" scale="-2" format="ixt:numdotdecimal">2.9</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected rate of pension increase</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases" decimals="3" scale="-2" format="ixt:numdotdecimal">0.4</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases" decimals="3" scale="-2" format="ixt:numdotdecimal">0.5</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases" decimals="3" scale="-2" format="ixt:numdotdecimal">0.3</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected rate of salary increase</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" decimals="3" scale="-2" format="ixt:numdotdecimal">2.9</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" decimals="3" scale="-2" format="ixt:numdotdecimal">2.7</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" decimals="3" scale="-2" format="ixt:numdotdecimal">2.7</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest on savings account</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" decimals="3" scale="-2" format="ixt:numdotdecimal">2.2</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" decimals="3" scale="-2" format="ixt:numdotdecimal">0.5</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" decimals="3" scale="-2" format="ixt:numdotdecimal">0.1</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current average life expectancy  for a 65-year-old male in years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyMale" format="ixt-sec:duryear">22</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyMale" format="ixt-sec:duryear">22</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyMale" format="ixt-sec:duryear">22</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyMale" format="ixt-sec:duryear">21</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyMale" format="ixt-sec:duryear">21</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyMale" format="ixt-sec:duryear">21</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current average life expectancy  for a 65-year-old female in years</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyFemale" format="ixt-sec:duryear">24</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyFemale" format="ixt-sec:duryear">24</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyFemale" format="ixt-sec:duryear">24</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyFemale" format="ixt-sec:duryear">23</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyFemale" format="ixt-sec:duryear">23</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitAssumptionLifeExpectancyFemale" format="ixt-sec:duryear">23</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Changes in the aforementioned actuarial assumptions can result in significant volatility in the accounting for the Group&#x2019;s pension plans in the consolidated financial statements. This can result in substantial changes in the Group&#x2019;s other comprehensive income, long-term liabilities and prepaid pension assets.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The DBO is significantly impacted by assumptions regarding the rate that is used to discount the actuarially determined post-employment benefit liability. This rate is based on yields of high-quality corporate bonds in the country of the plan. Decreasing corporate bond yields decrease the discount rate, so that the DBO increases and the funded status decreases.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In Switzerland, an increase in the DBO due to lower discount rates is slightly offset by lower future benefits expected to be paid on the employee&#x2019;s savings account where the assumption on interest accrued often changes broadly in line with the discount rate.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The impact of decreasing interest rates on a plan&#x2019;s assets is more difficult to predict. A significant part of the plan assets is invested in bonds. Bond values usually rise when interest rates decrease and may therefore partially compensate for the decrease in the funded status. Furthermore, pension assets also include significant holdings of equity instruments. Share prices usually tend to rise when interest rates decrease and therefore often counteract the negative impact of the rising defined benefit obligation on the funded status (although the correlation of interest rates with equities is not as strong as with bonds, especially in the short term).</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The expected rate for pension increases significantly affects the DBO of most plans in Switzerland, Germany and the United Kingdom. Such pension increases also decrease the funded status, although there is no strong correlation between the value of the plan assets and pension/inflation increases.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Assumptions regarding life expectancy significantly impact the DBO. An increase in longevity increases the DBO. There is no offsetting impact from the plan assets, as no longevity bonds or swaps are held by the pension funds. The Group&#x2019;s actuaries use mortality tables which take into account historic patterns and expected changes, such as further increases in longevity. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2022 the mortality assumptions used for the pension plans in Switzerland were based on BVG 2020 tables with future improvements based on the BVG generational model. In US for the Pension and Postretirement Medical Benefit Plans, the Society of Actuaries Pri-2012 mortality tables with generational improvements based on Scale MP-2021 are used.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the sensitivity of the defined benefit pension obligation to the principal actuarial assumptions for the major plans in Switzerland, the United States, the United Kingdom, Germany and Japan on an aggregated basis:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" id="SectionBlock_babfaf05-061e-49a1-a421-1e1ce9f09a4d_0" escape="true" continuedAt="SectionBlock_babfaf05-061e-49a1-a421-1e1ce9f09a4d_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in 2022 <br /> year-end defined <br /> benefit pension <br /> obligation</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change in 2021 <br /> year-end defined <br /> benefit pension <br /> obligation</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in discount rate</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">466</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">790</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in discount rate</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal">491</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal">839</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One-year increase in life expectancy</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4LifeExpectancyMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Increase1YearMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal">535</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4LifeExpectancyMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Increase1YearMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal">869</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in rate of pension increase</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal">316</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal">512</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in rate of pension increase</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">63</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">136</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase of interest on savings account</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal">58</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease of interest on savings account</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">37</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">58</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in rate of salary increase</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal">54</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in rate of salary increase</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">37</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember" name="ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">54</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-56</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_448431e3-dfe5-4f27-9bb5-7ce10f2ca56e_4" continuedAt="SectionBlock_448431e3-dfe5-4f27-9bb5-7ce10f2ca56e_5">
          <div>
            <div>
              <ix:continuation id="SectionBlock_babfaf05-061e-49a1-a421-1e1ce9f09a4d_1">
                <div></div>
              </ix:continuation>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:continuation id="SectionBlock_448431e3-dfe5-4f27-9bb5-7ce10f2ca56e_5" continuedAt="SectionBlock_448431e3-dfe5-4f27-9bb5-7ce10f2ca56e_6">
          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The healthcare cost trend rate assumptions used for other post-employment benefits are as follows:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfHealthCareCostTrendRatesTableTextBlock" id="SectionBlock_4dc1c8f0-5fff-40c8-afd9-cc30af559e84_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Healthcare cost trend rate assumed for next year</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" decimals="3" scale="-2" format="ixt:numdotdecimal">6.5</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" decimals="3" scale="-2" format="ixt:numdotdecimal">6.0</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" decimals="3" scale="-2" format="ixt:numdotdecimal">6.3</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rate to which the cost trend rate is assumed to decline</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" decimals="3" scale="-2" format="ixt:numdotdecimal">4.5</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" decimals="3" scale="-2" format="ixt:numdotdecimal">4.5</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" decimals="3" scale="-2" format="ixt:numdotdecimal">4.5</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Year that the rate reaches the ultimate trend rate</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate">2031</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate">2028</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate">2028</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the weighted average plan asset allocation of funded defined benefit pension plans at December 31, 2022 and&#xA0;2021:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="SectionBlock_72b4173f-724b-418f-9d46-ff2f4d06224d_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(as a percentage)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-term <br /> target <br /> minimum</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-term <br /> target <br /> maximum</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />
                            <br /> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity securities</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">24</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">27</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" decimals="2" scale="-2" format="ixt:numdotdecimal">60</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">31</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">33</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Real estate</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" decimals="2" scale="-2" format="ixt:numdotdecimal">30</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">19</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alternative investments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" decimals="2" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and other investments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" decimals="2" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanPlanAssetAllocations" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash and most of the equity and debt securities have a quoted market price in an active market. Real estate and alternative investments, which include hedge fund, private equity, infrastructure and commodity investments, usually have a quoted market price or a regularly updated net asset value.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The strategic allocation of assets of the different pension plans is determined with the objective of achieving an investment return that, together with the contributions paid by the Group and its employees, is sufficient to maintain reasonable control over the various funding risks of the plans. Based upon the market and economic environments, actual asset allocations may temporarily be permitted to deviate from policy targets. The asset allocation currently includes investments in shares of Novartis AG as per the below table: </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" id="SectionBlock_e96ddc53-6ede-41e8-a590-5e80410d9f0e_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31, <br /> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31, <br /> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investment in shares of Novartis AG</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;&#xA0;&#xA0;Number of shares (in millions)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:EmployerSharesHeldByDefinedBenefitPlan" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Shares" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:EmployerSharesHeldByDefinedBenefitPlan" decimals="-5" scale="6" format="ixt:numdotdecimal">2.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Market value (in USD billions)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:ValueOfEmployerSharesHeldByDefinedBenefitPlan" decimals="-8" scale="9" format="ixt:numdotdecimal">0.2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:ValueOfEmployerSharesHeldByDefinedBenefitPlan" decimals="-8" scale="9" format="ixt:numdotdecimal">0.2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The weighted average duration of the defined benefit pension obligation is <ix:nonNumeric contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:WeightedAverageDurationOfDefinedBenefitObligationYears" format="ixt-sec:duryear">11.8</ix:nonNumeric> years (2021: <ix:nonNumeric contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:WeightedAverageDurationOfDefinedBenefitObligationYears" format="ixt-sec:duryear">14.9</ix:nonNumeric> years).</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s ordinary contribution to the various pension plans is based on the rules of each plan. Additional contributions are made whenever this is required by statute or law (i.e., usually when statutory funding levels fall below predetermined thresholds). The only significant plans that require additional funding are those in the United Kingdom and Germany.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The expected future cash flows in respect of pension and other post-employment benefit plans at December 31, 2022, were as follows:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="SectionBlock_52c7fbda-1ac5-4d45-a753-58114eef7455_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Pension plans</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-<br /> employment<br /> benefit plans</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis Group contributions</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023 (estimated)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" decimals="-6" scale="6" format="ixt:numdotdecimal">397</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Expected future benefit payments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 268</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 441</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 128</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 114</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2027</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">1 099</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2028&#x2013;2032</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">5 310</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember" name="nvs:DefinedBenefitPlanExpectedFutureBenefitPayment" decimals="-6" scale="6" format="ixt:numdotdecimal">171</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined contribution plans</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In many subsidiaries, employees are covered by defined contribution plans. Contributions charged to the consolidated income statement for the defined contribution plans were: </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfDefinedContributionPlansTableTextBlock" id="SectionBlock_3ceb567a-385a-4455-a995-e2c0a85441ee_0" escape="true" continuedAt="SectionBlock_3ceb567a-385a-4455-a995-e2c0a85441ee_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions for defined contribution plans</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember" name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">520</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember" name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">523</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember" name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" decimals="-6" scale="6" format="ixt:numdotdecimal">501</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s total personnel costs amounted to USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:EmployeeBenefitsExpense" decimals="-8" scale="9">14.9</ix:nonFraction> billion in 2022.</div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-57</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_448431e3-dfe5-4f27-9bb5-7ce10f2ca56e_6">
          <div>
            <div>
              <ix:continuation id="SectionBlock_3ceb567a-385a-4455-a995-e2c0a85441ee_1">
                <div></div>
              </ix:continuation>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="SectionBlock_f2d5a265-6acb-4c4a-a466-dfdd06d9709a_0" escape="true" continuedAt="SectionBlock_f2d5a265-6acb-4c4a-a466-dfdd06d9709a_1">
          <div>
            <div id="anchorId001552812"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">26. Equity-based participation plans for employees</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The expense related to all equity-based participation plans and the liabilities arising from equity-based payment transactions were as follows:</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" id="SectionBlock_538ab274-2ab8-4671-b568-ef8e6d7bf570_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense related to equity-based  participation plans</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">1 048</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">979</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" decimals="-6" scale="6" format="ixt:numdotdecimal">958</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities arising from equity-based  payment transactions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" decimals="-6" scale="6" format="ixt:numdotdecimal">235</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" decimals="-6" scale="6" format="ixt:numdotdecimal">253</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2" name="ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011" decimals="-6" scale="6" format="ixt:numdotdecimal">269</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Equity-based participation plans can be separated into the following plans:</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Annual Incentive</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentivePlanMember" name="ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement" id="SectionBlock_c8430cd3-3a4e-4475-a07d-233db9e6e560_0" escape="false">
                <div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Annual Incentive for the Novartis Group CEO and other Executive Committee members (ECN) is paid 50% in cash and 50% in Novartis restricted shares (RSs) or restricted share units (RSUs). For the Novartis Top Leaders (NTLs), the Annual Incentive is paid 70% in cash and 30% in RSs or RSUs. Both the ECN and NTLs can opt to invest up to the maximum cash portion of their Annual Incentive to receive further RSs or RSUs. Any cash is paid out during March in the year following the end of the performance period, and the shares are granted during January in the year following the end of the performance period. </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeShareOwnershipPlanMember" name="ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement" id="SectionBlock_47540b15-2a5a-457a-b1c1-320cf844d0bc_0" escape="false">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Employee share savings plan</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis operates employee share savings and purchase plans in certain countries. The most significant is described below.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Employee Share Ownership Plan (ESOP) in Switzerland offers participants to choose to receive their Annual Incentive (i) 100% in shares, (ii) 50% in shares and 50% in cash, or (iii) 100% in cash. After expiration of a three-year holding period for Novartis shares invested under the ESOP, participants will receive one matching share for every two invested shares. Employees eligible for the equity plan &#x201C;Select&#x201D; are not eligible to receive ESOP matching shares. The Novartis Group CEO, the other Executive Committee members and the NTLs are not eligible to participate in this plan.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeSharePurchasePlanMember" name="ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement" id="SectionBlock_36e09eae-8950-4e91-8ddc-4834307aac7e_0" escape="false">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis Employee share purchase plan</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022 Novartis started to grant shares under the Employee Share Purchase Plan. The plan enables employees to voluntarily purchase Novartis shares through payroll deductions at a discounted price. While the plan is global in scope, the first phase covers: North America (the US, Puerto Rico and Canada). The shares are not subject to a vesting period.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis equity plan &#x201C;Select&#x201D;</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectMember" name="ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement" id="SectionBlock_d205e2d1-642b-4834-9171-c26b78e56b54_0" escape="false">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The equity plan &#x201C;Select&#x201D; is a global equity incentive plan under which eligible employees may annually be awarded a grant subject to a three-year, and for selected units a four-year, staggered vesting period. No awards are granted for performance ratings below a certain threshold. Executive Committee members and NTLs are not eligible to participate in the equity plan &#x201C;Select.&#x201D;</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The equity plan &#x201C;Select&#x201D; currently allows participants employed and living in Switzerland to choose the form of their equity compensation in RSs or RSUs. In all other jurisdictions, RSs or RSUs are granted unilaterally. Until 2013, participants could also choose to receive part or the entire grant in the form of tradable share options.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Tradable share options expire on their 10<sup>th</sup> anniversary from the grant date, meaning all outstanding options exercisable at December 31, 2022, will expire in January 2023. Each tradable share option entitles the holder to purchase after vesting (and before the 10<sup>th</sup> anniversary from the grant date) one Novartis share at a stated exercise price that equals the closing market price of the underlying share at the grant date. As the exercise price does not reflect the decrease in the Novartis share due to the Alcon spin, one-fifth of an Alcon share will also be awarded to the option holder upon exercise.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Options under Novartis equity plan &#x201C;Select&#x201D; outside North America</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the activity associated with the share options during the period. The weighted average prices in the table below are translated from Swiss francs into USD at historical rates.</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" id="SectionBlock_b2a288f2-ef7e-4ccb-9e9e-3f4a1bf27fc0_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br /> Options<br /> (millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted<br /> average <br /> exercise <br /> price<br /> (USD)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br />
                            <br /> Options<br /> (millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted<br /> average <br /> exercise <br /> price<br /> (USD)</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Options outstanding  at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">63.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="-5" scale="6" format="ixt:numdotdecimal">2.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">62.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sold or exercised</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">62.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">58.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">66.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">63.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">66.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">63.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All share options were granted at an exercise price that was equal to the closing market price of the Group&#x2019;s shares at the grant date. The weighted average share price at the dates of sale or exercise was USD&#xA0;<ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" decimals="1" scale="0">86.1</ix:nonFraction>. </div>
              </div>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Options under Novartis equity plan &#x201C;Select&#x201D; for North America</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the activity associated with the ADR options during the period:</div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-58</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_f2d5a265-6acb-4c4a-a466-dfdd06d9709a_1" continuedAt="SectionBlock_f2d5a265-6acb-4c4a-a466-dfdd06d9709a_2">
          <div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" id="SectionBlock_9f4af6bb-79d8-44c8-a9da-d63643a8f013_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> ADR<br /> options<br /> (millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted<br /> average <br /> exercise <br /> price<br /> (USD)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> ADR<br /> options<br /> (millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted<br /> average <br /> exercise <br /> price<br /> (USD)</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Options outstanding  at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">64.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="-5" scale="6" format="ixt:numdotdecimal">6.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">62.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sold or exercised</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">63.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" decimals="-5" scale="6" format="ixt:numdotdecimal">2.7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">60.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">66.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:NumberOfOutstandingShareOptions" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">64.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">66.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" decimals="1" scale="0" format="ixt:numdotdecimal">64.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All ADR options were granted at an exercise price that was equal to the closing market price of the ADRs at the grant date. The weighted average ADR price at the dates of sale or exercise was USD&#xA0;<ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" decimals="1" scale="0">89.1</ix:nonFraction>. </div>
              </div>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Long-Term Performance Plan</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePlanMember" name="ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement" id="SectionBlock_d71a92c0-423e-4e0c-94aa-e1d9a69021e3_0" escape="false">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Long-Term Performance Plan (LTPP) is an equity plan for the ECN, the NTLs and employees of Group units with specific targets.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Participants are granted a target number of performance share units (PSUs) at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. The actual payout depends on the achievement of the performance measures and ranges between 0% and 200% of the granted amount. PSUs granted under the LTPP do not carry voting rights, but do carry dividend equivalents that are paid in unrestricted Novartis shares at the end of the performance period.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The LTPP awards are subject to a three-year performance and vesting period. Until 2018, the performance criteria were based on Novartis internal performance metrics. For LTPP awards starting in 2019, following the combination of the two LTPP and Long-Term Relative Performance Plan (LTRPP), the performance criteria are based on both Novartis internal performance metrics and variables that can be observed in the market, which is the ranking of the Novartis total shareholder return (TSR) relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">TSR for Novartis and the peer companies is calculated as the change in the company share price, which is translated to USD at the relevant exchange rate, including the reinvestment return of dividends, over the three-year performance period. The calculation is based on Bloomberg standard published TSR data, which is publicly available. The position of Novartis in the peer group determines the payout range based on a payout matrix. </div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Long-Term Relative Performance Plan</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The LTRPP was an equity plan for the Novartis ECN and NTLs and the awards were subject to a three-year performance and vesting period. The last grant under this plan was made in 2018. The LTRPP performance criteria were based on variables that could be observed in the market, which was the ranking of the Novartis TSR relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. The TSR for Novartis and the peer companies was calculated as described in the LTPP section above.</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Other share awards</span>
                </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationSpecialShareAwardsMember" name="ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement" id="SectionBlock_78352555-d93e-4072-b292-1fdc19ae2af1_0" escape="false" continuedAt="SectionBlock_78352555-d93e-4072-b292-1fdc19ae2af1_1">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Selected employees may exceptionally receive Special Share Awards of RSs or RSUs. These Special Share Awards provide an opportunity to reward outstanding achievements or exceptional performance, and aim to retain key contributors. They are based on a formal internal selection process, through which the individual performance of each candidate is thoroughly assessed at several management levels. Special Share Awards had a minimum three-year vesting period before 2021 and mainly three years thereafter. In exceptional circumstances, Special Share Awards may be awarded to attract special expertise and new talents to the organization. Externally recruited ECN members are eligible only for special awards that are &#x201C;buyouts&#x201D; in the case that it is to replace equity forfeited with their former employer. The equity is provided on a like-for-like basis as the forfeited equity, at the same value with the same vesting period, and with or without a performance condition.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Worldwide, employees at different levels in the organization were awarded RSs and RSUs in 2022, 2021 and 2020.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, in 2022, 2021 and 2020, Board members received unrestricted shares as part of their regular compensation.</div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-59</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_f2d5a265-6acb-4c4a-a466-dfdd06d9709a_2" continuedAt="SectionBlock_f2d5a265-6acb-4c4a-a466-dfdd06d9709a_3">
          <div>
            <div>
              <ix:continuation id="SectionBlock_78352555-d93e-4072-b292-1fdc19ae2af1_1">
                <div></div>
              </ix:continuation>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:continuation id="SectionBlock_f2d5a265-6acb-4c4a-a466-dfdd06d9709a_3">
          <div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Summary of share grants</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The table below provides a summary of share grants (shares, RSs, RSUs and PSUs) for all plans:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" id="SectionBlock_4ed1e050-966c-4244-a7dc-b8b0c147e444_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Number<br /> of shares<br /> in millions</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br /> average fair<br /> value at grant<br /> date in USD</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Number<br /> of shares<br /> in millions</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted <br /> average fair<br /> value at grant<br /> date in USD</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Annual Incentive</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; RSU</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">74.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">87.5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Restricted shares</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">85.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">97.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Share savings plans</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; RSU</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">86.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Shares</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">85.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">97.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis Employee Share Purchase Plan</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeSharePurchasePlanMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeSharePurchasePlanMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">82.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Select North America (RSU)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">4.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">74.5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">4.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">86.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Select outside North America</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; RSU</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">75.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">86.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Restricted shares</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">85.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">97.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Long-Term Performance Plan (PSU)</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">82.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">89.5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Other share awards</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; RSU</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">76.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">78.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Restricted shares</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">86.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Shares</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">86.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USDPerShares" contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" decimals="-5" scale="6" format="ixt:numdotdecimal">91.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="SectionBlock_c2cf8709-c703-4cbe-867a-d935e86cf837_0" escape="true" continuedAt="SectionBlock_c2cf8709-c703-4cbe-867a-d935e86cf837_1">
          <div></div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-60</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_c2cf8709-c703-4cbe-867a-d935e86cf837_1" continuedAt="SectionBlock_c2cf8709-c703-4cbe-867a-d935e86cf837_2">
          <div>
            <div id="anchorId001553909"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">27. Transactions with related parties</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Roche Holding AG</span>
            </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember" name="nvs:NumberOfContractsWithRelatedParties" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> agreements with Genentech, Inc., United States (Genentech), and <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SparkTherapeuticsInc.Member" name="nvs:NumberOfContractsWithRelatedParties" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> agreement with Spark Therapeutics, Inc., United States (Spark). Both companies are subsidiaries of Roche Holding AG (Roche), which were indirectly included in the consolidated financial statements using equity accounting until November 3, 2021, when Novartis entered into an agreement with Roche to divest its <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember" name="ifrs-full:ProportionOfVotingPowerHeldInAssociate" decimals="3" scale="-2">33.3</ix:nonFraction>%</span> of Roche voting shares. On December 6, 2021, Novartis divested its investment in Roche, on which date Roche ceased to be a related party (see Notes 2 and 4).</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                <i>Lucentis</i>
              </span>
            </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has licensed from Genentech/Roche the exclusive rights to develop and market <i>Lucentis</i> outside the United States for indications related to diseases of the eye. Novartis pays royalties on the net sales to third parties of <i>Lucentis</i> products outside the United States. From January 1, 2021 until December 6, 2021, <i>Lucentis</i> sales of USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-8" scale="9">2.0</ix:nonFraction> billion (2020: USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-8" scale="9">1.9</ix:nonFraction> billion) were recognized by Novartis.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                <i>Xolair</i>
              </span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis and Genentech/Roche are co-promoting <i>Xolair</i> in the United States, where Genentech/Roche records all sales. Novartis records sales outside the United States.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis markets <i>Xolair</i> and records all sales and related costs outside the United States as well as co-promotion costs in the US. Genentech/Roche and Novartis share the resulting profits from sales in the United States, Europe and other countries, according to agreed profit-sharing percentages. From January 1, 2021 until December 6, 2021, Novartis recognized total sales of <i>Xolair</i> of USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-8" scale="9">1.3</ix:nonFraction> billion (2020: USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember" name="nvs:RevenueFromSaleOfGoodsThirdParties" decimals="-8" scale="9">1.3</ix:nonFraction> billion), including sales to Genentech/Roche for the United States market.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                <i>Luxturna</i>
              </span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2018, Novartis entered into an exclusive licensing and commercialization agreement and a supply agreement with Spark for <i>Luxturna</i> outside the United States. The agreements include regulatory and sales milestones as well as royalties payable to Spark on ex-US sales. On December 17, 2019, Roche acquired Spark.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The net income for royalties, cost sharing and profit sharing arising out of the <i>Lucentis</i>, <i>Xolair</i> and <i>Luxturna</i> agreements with Roche totaled USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember" name="nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing" decimals="-6" scale="6" format="ixt:numdotdecimal">188</ix:nonFraction> million from January 1, 2021 until December 6, 2021 (net income in 2020: USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember" name="nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing" decimals="-6" scale="6" format="ixt:numdotdecimal">217</ix:nonFraction> million).</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Furthermore, Novartis has several patent license, supply and distribution agreements with Roche.</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis Pension Fund</span>
            </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2018, a Group subsidiary provided an uncommitted overnight credit facility to the Novartis Pension Fund, Switzerland, for up to USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-4_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisPensionFundMember" name="nvs:BorrowingsCreditFacilityUncommitted" decimals="-6" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction> million with interest at the US Federal Funds Rate. This credit facility was not utilized during the current and past years.</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Executive Officers and Non-Executive Directors compensation</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At December 31, 2022, there were <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:RelatedPartiesNumberOfExecutiveCommitteeMembers" decimals="0" scale="0" format="ixt:numdotdecimal">11</ix:nonFraction> Executive Committee members (&#x201C;Executive Officers&#x201D;). During 2022, <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" decimals="0" scale="0" format="ixt:numdotdecimal">5</ix:nonFraction> Executive Officers stepped down. At December 31, 2021, there were <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:RelatedPartiesNumberOfExecutiveCommitteeMembers" decimals="0" scale="0" format="ixt:numdotdecimal">12</ix:nonFraction> Executive Officers. During 2021, <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" decimals="0" scale="0" format="ixt:numdotdecimal">3</ix:nonFraction> Executive Officers stepped down. At December 31, 2020, there were <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:RelatedPartiesNumberOfExecutiveCommitteeMembers" decimals="0" scale="0" format="ixt:numdotdecimal">13</ix:nonFraction> Executive Officers. </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The total compensation for Executive Committee members and the <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:RelatedPartiesNumberOfNonexecutiveDirectors" decimals="0" scale="0" format="ixt:numdotdecimal">15</ix:nonFraction> Non-Executive Directors (<ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:RelatedPartiesNumberOfNonexecutiveDirectors" decimals="0" scale="0" format="ixt:numdotdecimal">14</ix:nonFraction> in 2021 and <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2" name="nvs:RelatedPartiesNumberOfNonexecutiveDirectors" decimals="0" scale="0" format="ixt:numdotdecimal">14</ix:nonFraction> in 2020) using the Group&#x2019;s accounting policies for equity-based compensation and pension benefits was as follows:</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:OfficerAndDirectorCompensationTableTextBlock" id="SectionBlock_9450489b-cf34-4d12-8af0-77d1b5f07ff8_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Executive Officers</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-Executive Directors</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="5" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and other compensation</div>
                        </td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">25.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">20.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">25.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">4.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">29.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">25.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">30.2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Post-employment benefits</div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">2.5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">2.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">2.5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" decimals="-5" scale="6" format="ixt:numdotdecimal">2.7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" decimals="-5" scale="6" format="ixt:numdotdecimal">42.6</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" decimals="-5" scale="6" format="ixt:numdotdecimal">37.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" decimals="-5" scale="6" format="ixt:numdotdecimal">41.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" decimals="-5" scale="6" format="ixt:numdotdecimal">4.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" decimals="-5" scale="6" format="ixt:numdotdecimal">5.2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" decimals="-5" scale="6" format="ixt:numdotdecimal">5.2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" decimals="-5" scale="6" format="ixt:numdotdecimal">47.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" decimals="-5" scale="6" format="ixt:numdotdecimal">42.5</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" decimals="-5" scale="6" format="ixt:numdotdecimal">46.3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensation" decimals="-5" scale="6" format="ixt:numdotdecimal">70.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensation" decimals="-5" scale="6" format="ixt:numdotdecimal">60.1</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember" name="ifrs-full:KeyManagementPersonnelCompensation" decimals="-5" scale="6" format="ixt:numdotdecimal">69.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember" name="ifrs-full:KeyManagementPersonnelCompensation" decimals="-5" scale="6" format="ixt:numdotdecimal">9.4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember" name="ifrs-full:KeyManagementPersonnelCompensation" decimals="-5" scale="6" format="ixt:numdotdecimal">9.9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember" name="ifrs-full:KeyManagementPersonnelCompensation" decimals="-5" scale="6" format="ixt:numdotdecimal">9.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:KeyManagementPersonnelCompensation" decimals="-5" scale="6" format="ixt:numdotdecimal">79.8</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:KeyManagementPersonnelCompensation" decimals="-5" scale="6" format="ixt:numdotdecimal">70.0</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-2" name="ifrs-full:KeyManagementPersonnelCompensation" decimals="-5" scale="6" format="ixt:numdotdecimal">79.2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022, there was an increase in the IFRS compensation expense for executive officers compared to 2021, driven by accelerated expenses (cash and other compensation and equity-based compensation) required under IFRS for the executive members who stepped down in 2022, in accordance with their employment contracts and the relevant incentive plan terms, compared to the accelerated expenses due to executive officers who stepped down in 2021.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-61</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_c2cf8709-c703-4cbe-867a-d935e86cf837_2">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">During 2021, the IFRS compensation expense decreased due to one role less at the ECN, and lower cash and equity compensation attributable to former ECN members, partially offset by the net increase of the IFRS compensation expense of current ECN members.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Annual Incentive award, which is fully included in equity-based compensation even when paid out in cash, is granted in January in the year following the reporting period.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The disclosures on Board and executive compensation required by the Swiss Code of Obligations and in accordance with the Swiss Ordinance against Excessive Compensation in Stock Exchange Listed Companies are shown in the Compensation Report of the Group.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Transactions with former members of the Board of Directors</span>
                </div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022, 2021 and 2020, the following payments (or waivers of claims) were made to former Board members or to &#x201C;persons closely&#x201D; linked to them:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" id="SectionBlock_c0eed6ed-0178-4c02-9ea0-6d3f0967f172_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currency</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dr. Krauer</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4DrAlexKrauerMember" name="ifrs-full:KeyManagementPersonnelCompensation" decimals="0" scale="0" format="ixt:numdotdecimal">60 000</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4DrAlexKrauerMember" name="ifrs-full:KeyManagementPersonnelCompensation" decimals="0" scale="0" format="ixt:numdotdecimal">60 000</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Dr. Alex Krauer, was an Honorary Chairman of Novartis and was entitled to an amount of CHF 60 000 for annual periods from one AGM to the next. This amount was fixed in 1998 upon his departure from the Board in 1999. The last payment under this arrangement was in 2021. </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfCommitmentsAndContingenciesTextBlock" id="SectionBlock_e24ce4d5-4d63-4dbc-9529-0ee39d5ad29f_0" escape="true" continuedAt="SectionBlock_e24ce4d5-4d63-4dbc-9529-0ee39d5ad29f_1">
          <div>
            <div id="anchorId001554354"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">28. Commitments and contingent liabilities</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Research and development commitments</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has entered into long-term research and development agreements with various institutions related to intangible assets. These agreements provide for potential milestone payments by Novartis, which are dependent on successful clinical development, or meeting specified sales targets, or other conditions which are specified in the agreements. </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of December 31, 2022, the amount and estimated timing of the Group&#x2019;s commitments to make payments under those agreements, which are shown without risk adjustment and on an undiscounted basis, were as follows:</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfLeasingCommitmentsTableTextBlock" id="SectionBlock_d24f4754-2136-4713-b0c0-535e2cfd988a_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:20%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember" name="nvs:CommitmentsUnderLongtermResearchAgreements" decimals="-6" scale="6" format="ixt:numdotdecimal">420</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember" name="nvs:CommitmentsUnderLongtermResearchAgreements" decimals="-6" scale="6" format="ixt:numdotdecimal">808</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember" name="nvs:CommitmentsUnderLongtermResearchAgreements" decimals="-6" scale="6" format="ixt:numdotdecimal">448</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember" name="nvs:CommitmentsUnderLongtermResearchAgreements" decimals="-6" scale="6" format="ixt:numdotdecimal">282</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2027</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember" name="nvs:CommitmentsUnderLongtermResearchAgreements" decimals="-6" scale="6" format="ixt:numdotdecimal">687</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Thereafter</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="nvs:CommitmentsUnderLongtermResearchAgreements" decimals="-6" scale="6" format="ixt:numdotdecimal">3 169</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:CommitmentsUnderLongtermResearchAgreements" decimals="-6" scale="6" format="ixt:numdotdecimal">5 814</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Commitments for capital calls</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group holds investments in funds in which it has committed to invest further upon future capital calls. As of December 31, 2022, the total uncalled capital commitments for the Group&#x2019;s investments in funds amounts to USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:UncalledCapitalCommitmentsForInvestmentsInFunds" decimals="-6" scale="6" format="ixt:numdotdecimal">83</ix:nonFraction> million. Note 29 contains further information on the Group&#x2019;s investments in funds.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Other commitments</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has entered into various purchase commitments for services and materials as well as for equipment in the ordinary course of business. These commitments are generally entered into at current market prices and reflect normal business operations. For disclosure of property, plant and equipment purchase commitments, see Note 9.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Guarantees issued</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has issued guarantees to third parties in the ordinary course of business, mostly for tax, customs or other governmental agencies. </div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Contingent liabilities</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Group companies have to observe the laws, government orders and regulations of the country in which they operate.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A number of Novartis companies are, and will likely continue to be, subject to various legal proceedings and investigations that arise from time to time, including proceedings regarding product liability; sales and marketing practices; commercial disputes; employment and wrongful discharge; and antitrust, securities, health and safety, environmental, tax, international trade, privacy and intellectual property matters. As a result, the Group may become subject to substantial liabilities that may not be covered by insurance and that could affect our business, financial position and reputation. While Novartis does not believe that any of these legal proceedings will have a material adverse effect on its financial position, litigation is inherently unpredictable and large judgments sometimes occur. As a consequence, Novartis may in the future incur judgments or enter into settlements of </div>
              </div>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-62</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_e24ce4d5-4d63-4dbc-9529-0ee39d5ad29f_1" continuedAt="SectionBlock_e24ce4d5-4d63-4dbc-9529-0ee39d5ad29f_2">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">claims that could have a material adverse effect on its results of operations or cash flow.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Governments and regulatory authorities around the world have been stepping up their compliance and law enforcement activities in recent years in key areas, including marketing practices, pricing, corruption, trade restrictions, embargo legislation, insider trading, antitrust, cyber security and data privacy. Further, when one government or regulatory authority undertakes an investigation, it is not uncommon for other governments or regulators to undertake investigations regarding the same or similar matters. Responding to such investigations is costly and requires an increasing amount of management&#x2019;s time and attention. In addition, such investigations may affect our reputation, create a risk of potential exclusion from government reimbursement programs in the United States and other countries, and lead to (or arise from) litigation. These factors have contributed to decisions by Novartis and other companies in the healthcare industry, when deemed in their interest, to enter into settlement agreements with governmental authorities around the world prior to any formal decision by the authorities or a court. These government settlements have involved and may in the future involve large cash payments, sometimes in the hundreds of millions of dollars or more, including the potential repayment of amounts allegedly obtained improperly and other penalties, including treble damages. In addition, settlements of government healthcare fraud cases and antitrust cases often require companies to enter into corporate integrity agreements, which are intended to regulate company behavior for a period of years. Our affiliates Novartis Corporation and Sandoz Inc. are parties to such agreements, which will expire in 2025 and 2026, respectively. Also, matters underlying governmental investigations and settlements may be the subject of separate private litigation.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">While provisions have been made for probable outflows of economic resources, which management deems to be reasonable or appropriate, there are uncertainties connected with these estimates.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 20 contains additional information on these matters.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A number of Group companies are involved in legal proceedings concerning intellectual property rights. The inherent unpredictability of such proceedings means that there can be no assurances as to their ultimate outcome. A negative result in any such proceeding could potentially adversely affect the ability of certain Novartis companies to sell their products, or require the payment of substantial damages or royalties. The timing and the outcome of legal proceedings and their potential financial effect are not predictable.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the opinion of management, however, the outcome of these actions will not materially affect the Group&#x2019;s financial position but could be material to the results of operations or cash flow in a given period.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s potential environmental remediation liability is assessed based on a risk assessment and investigation of the various sites identified by the Group as at risk for environmental remediation exposure. The Group&#x2019;s future remediation expenses are affected by a number of uncertainties. These uncertainties include, but are not limited to, the method and extent of remediation, the percentage of material attributable to the Group at the remediation sites relative to that attributable to other parties, and the financial capabilities of the other potentially responsible parties.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 20 contains additional information on environmental liabilities.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-63</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_e24ce4d5-4d63-4dbc-9529-0ee39d5ad29f_2">
          <div>
            <div>
              <div></div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" id="SectionBlock_9657e382-a398-47d8-820b-6fe42150461f_0" escape="true" continuedAt="SectionBlock_9657e382-a398-47d8-820b-6fe42150461f_1">
          <div>
            <div id="anchorId001554504"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">29. Financial instruments&#xA0;&#x2013;&#xA0;additional disclosures</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables show the carrying values of financial instruments by measurement category as of December 31, 2022 and 2021. Except for straight bonds (see Note 19), the carrying values are equal to, or a reasonable approximation of, the fair values.</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" id="SectionBlock_cbafe3ff-2c53-4d80-a7bf-e74ec1451300_0" escape="true" continuedAt="SectionBlock_cbafe3ff-2c53-4d80-a7bf-e74ec1451300_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br />
                            <br />
                            <br />
                            <br /> Note</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />
                            <br />
                            <br /> Financial<br /> instruments at<br /> amortized<br /> costs</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br /> Financial<br /> instruments at<br /> fair value<br /> through other<br /> comprehensive<br /> income</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Financial<br /> instruments at<br /> fair value<br /> through the<br /> consolidated<br /> income<br /> statement</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />
                            <br /> Other<br /> financial<br /> liabilities at<br /> amortized<br /> costs</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">7 517</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">11 089</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">8 066</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4OtherCurrentAssetsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">958</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities - debt securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableForSaleMarketableSecuritiesMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - equity securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">828</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">317</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - debt securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - fund investments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4FundInvestmentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">281</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances, security deposits and other long-term receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">341</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">129</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13/17</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">650</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">27 971</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">874</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 581</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other short-term financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4BankAndOtherFinancialDebtMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">863</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4CommercialPaperMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 772</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4StraightBondsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">22 341</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term liabilities to banks and other financial institutions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">144</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TradePayablesMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 146</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities (see Note 20/22) and other financial liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 067</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2022LeaseLiabilitiesMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 789</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">31 266</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 122</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 789</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-64</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_9657e382-a398-47d8-820b-6fe42150461f_1" continuedAt="SectionBlock_9657e382-a398-47d8-820b-6fe42150461f_2">
          <div>
            <div>
              <ix:continuation id="SectionBlock_cbafe3ff-2c53-4d80-a7bf-e74ec1451300_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br />
                            <br />
                            <br />
                            <br /> Note</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br />
                            <br /> Financial<br /> instruments at<br /> amortized<br /> costs</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Financial<br /> instruments at<br /> fair value<br /> through other<br /> comprehensive<br /> income</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Financial<br /> instruments at<br /> fair value<br /> through the<br /> consolidated<br /> income<br /> statement</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Other<br /> financial<br /> liabilities at<br /> amortized<br /> costs</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">10 397</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 010</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">12 965</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022TradeReceivablesMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">8 005</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4OtherCurrentAssetsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">793</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities - debt securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableForSaleMarketableSecuritiesMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 741</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - equity securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 195</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">468</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - debt securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - fund investments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4FundInvestmentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">366</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances, security deposits and other long-term receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">332</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">192</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">641</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">32 492</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">5 980</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember" name="ifrs-full:FinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1 772</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of employees payable on demand</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4InterestBearningAccountsOfAssociatesPayableOnDemandMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 814</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other short-term financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4BankAndOtherFinancialDebtMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">899</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4CommercialPaperMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">893</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4StraightBondsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">25 296</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term liabilities to banks and other financial institutions</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">227</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TradePayablesMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 553</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18/22</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommitmentForRepurchaseOfOwnSharesMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 809</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities (see Note 20/22) and other financial liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 094</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2022LeaseLiabilitiesMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 896</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">37 491</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 162</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember" name="ifrs-full:FinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 896</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Includes short-term highly rated government-backed debt securities, with an original maturity of three months or less</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Derivative financial instruments</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables show the contract or underlying principal amounts and fair values of derivative financial instruments analyzed by type of contract at December&#xA0;31, 2022 and 2021. Contract or underlying principal amounts indicate the gross volume of business outstanding at the consolidated balance sheet date and do not represent amounts at risk. The fair values are determined by reference to market prices or standard pricing models that use observable market inputs at December 31,&#xA0;2022 and 2021. </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory" id="SectionBlock_0966d48d-a793-44c7-a455-cd616c60f156_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Contract or underlying  principal amount</div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Positive fair values  </div>
                        </td>
                        <td></td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Negative fair values  </div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="3" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">7 907</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">13 248</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">189</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">92</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">41</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">35</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember" name="nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember" name="nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember" name="nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">14</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember" name="nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">33</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments included in  marketable securities and in current financial debts</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">8 043</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">13 347</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">55</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">68</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-65</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_9657e382-a398-47d8-820b-6fe42150461f_2" continuedAt="SectionBlock_9657e382-a398-47d8-820b-6fe42150461f_3">
          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows a breakdown by currency of the contract or underlying principal amount of derivative financial instruments at December&#xA0;31,&#xA0;2022 and 2021:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" id="SectionBlock_8dd542d6-c2de-4094-9d5e-93318eef01f0_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> EUR</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">687</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">5 659</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">1 561</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">7 907</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR" name="nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD" name="nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD" name="nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">767</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">5 715</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 561</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">8 043</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> EUR</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">1 485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">5 158</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">6 605</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" decimals="-6" scale="6" format="ixt:numdotdecimal">13 248</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD" name="nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD" name="nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 485</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">5 257</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">6 605</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember" name="nvs:DerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">13 347</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Derivative financial instruments effective for hedge accounting purposes</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At the end of 2022 and 2021, there were no open hedging instruments for anticipated transactions.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Fair value by hierarchy</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As required by IFRS, financial assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. There are three hierarchical levels, based on increasing subjectivity associated with the inputs to derive fair valuation for these assets and liabilities, which are as follows:</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The assets carried at Level 1 fair value are equity and debt securities as well as fund investments listed in active markets.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The assets generally included in Level 2 fair value hierarchy are derivatives, and certain debt securities. The liabilities generally included in this fair value hierarchy consist of derivatives. These are valued using corroborated market data.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Level 3 inputs are unobservable for the asset or liability. The assets generally included in Level 3 fair value hierarchy are various investments in funds and unquoted equity security investments. Contingent consideration and other financial liabilities carried at fair value are included in this category.</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfFairValueMeasurementExplanatory" id="SectionBlock_93d5d178-10e5-47a9-911e-ac685569bc4f_0" escape="true" continuedAt="SectionBlock_93d5d178-10e5-47a9-911e-ac685569bc4f_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 1</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 2</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 3</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Marketable securities</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities and derivative financial instruments at fair value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">213</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">213</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current contingent consideration receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Long-term financial investments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt and equity securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">473</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">699</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 182</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">261</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">281</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current contingent consideration receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">607</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">607</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total long-term financial investments at fair value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">493</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 567</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 070</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">129</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">129</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current contingent consideration liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">131</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">131</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial liabilities at fair values</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">131</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">186</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current contingent consideration liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4NoncurrentContingentConsiderationLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">704</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4NoncurrentContingentConsiderationLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">704</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">232</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">232</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial liabilities at fair value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">936</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">936</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-66</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_9657e382-a398-47d8-820b-6fe42150461f_3" continuedAt="SectionBlock_9657e382-a398-47d8-820b-6fe42150461f_4">
          <div>
            <div>
              <ix:continuation id="SectionBlock_93d5d178-10e5-47a9-911e-ac685569bc4f_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 1</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 2</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 3</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 010</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 010</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total cash and cash equivalents at fair value</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 010</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 010</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Marketable securities and derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 719</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 741</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities and derivative financial instruments at fair value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 719</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 846</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Long-term financial investments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt and equity securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 080</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">617</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 697</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">338</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">366</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">641</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">641</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total long-term financial investments at fair value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 108</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 596</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">2 704</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">192</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="ifrs-full:FinancialAssetsAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">192</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 075</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 075</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities at fair value</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 094</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember" name="ifrs-full:FinancialLiabilitiesAtFairValue" decimals="-6" scale="6" format="ixt:numdotdecimal">1 162</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Includes short-term highly rated government-backed debt securities, with an original maturity of three months or less</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The change in carrying values associated with Level 3 financial instruments, using significant unobservable inputs during the year ended December 31, is set forth below:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" id="SectionBlock_e07d3e8d-9265-49c0-90e7-f9c5dc37e973_0" escape="true" continuedAt="SectionBlock_e07d3e8d-9265-49c0-90e7-f9c5dc37e973_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Associated <br /> companies at <br /> fair value  through<br /> profit and loss</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Fund<br /> investments</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Long-term <br /> financial <br /> investments</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Contingent <br /> consideration <br /> receivables</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Contingent <br /> consideration <br /> liabilities</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br /> Other<br /> financial<br /> liabiltiies</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">192</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">338</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">617</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">641</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 075</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">19</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value gains and other adjustments, including from divestments  recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">530</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember" name="nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value losses (including impairments and amortizations) and  other adjustments recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">78</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">84</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">114</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember" name="nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments recognized in the consolidated statement   of comprehensive income, including currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:PurchaseFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:PurchaseFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:PurchaseFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">160</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:PurchaseFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">231</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember" name="nvs:PurchaseFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">238</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash receipts and payments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">44</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember" name="nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:DisposalsFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:DisposalsFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:ReclassificationFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:ReclassificationFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:ReclassificationFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">40</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">129</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">261</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">699</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">650</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">835</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">232</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of fair value gains and losses recognized   in the consolidated income statement for assets   and liabilities held at December 31, 2022</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">63</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">74</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">49</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" decimals="-6" scale="6" format="ixt:numdotdecimal">416</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember" name="nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-67</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_9657e382-a398-47d8-820b-6fe42150461f_4" continuedAt="SectionBlock_9657e382-a398-47d8-820b-6fe42150461f_5">
          <div>
            <div>
              <ix:continuation id="SectionBlock_e07d3e8d-9265-49c0-90e7-f9c5dc37e973_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Associated <br /> companies at <br /> fair value  through<br /> profit and loss</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Fund<br /> investments</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Long-term <br /> financial <br /> investments</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Contingent <br /> consideration <br /> receivables</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br /> Contingent <br /> consideration <br /> payables</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">211</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">366</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">460</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">625</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 046</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value gains and other adjustments, including from divestments  recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">69</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">124</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">182</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value losses (including impairments and amortizations) and  other adjustments recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">189</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments recognized in the consolidated statement   of comprehensive income, including currency translation effects</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">51</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">22</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:PurchaseFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:PurchaseFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:PurchaseFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:PurchaseFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">88</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash receipts and payments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">42</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:DisposalsFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:DisposalsFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:DisposalsFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:ReclassificationFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">30</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:ReclassificationFairValueMeasurementAssets" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">44</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">192</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">338</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">617</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal">641</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:FinancialInstrumentsCarryingValueLevel3" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 075</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of fair value gains and losses recognized   in the consolidated income statement for assets   and liabilities held at December 31, 2021</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">24</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember" name="nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember" name="nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember" name="nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember" name="nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">7</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:continuation>
            </div>
            <div>
              <div></div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets" id="SectionBlock_ef047e1e-0090-4067-aaad-f959928bff50_0" escape="false">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022, there was one transfer of equity securities from Level 3 to Level 1 for USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets" decimals="-6" scale="6">44</ix:nonFraction> million (2021: USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets" decimals="-6" scale="6">73</ix:nonFraction> million), due to Initial Public Offering of the invested company. During 2022, there were no transfers of equity securities from Level 1 to Level 3 due to de-listing (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction> million).</div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Realized gains and losses associated with Level 3 long-term financial investments measured at fair value through the consolidated income statement are recorded in the consolidated income statement under &#x201C;Other income&#x201D; or &#x201C;Other expense,&#x201D; respectively. Realized gains and losses associated with Level 3 long-term financial investments measured at fair value through other comprehensive income are not recycled through the consolidated income statement but are instead reclassified to retained earnings.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">During the year, the net loss and net gain recorded on associated companies, fund investments and long-term financial investments at fair value through profit and loss were USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" decimals="-6" scale="6" format="ixt:numdotdecimal">316</ix:nonFraction> million and USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction> million, respectively.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To determine the fair value of a contingent consideration, various unobservable inputs are used. A change in these inputs might result in a significantly higher or lower fair value measurement. The inputs used are, among others, the probability of success, sales forecast and assumptions regarding the discount rate and timing and different scenarios of triggering events. The inputs are interrelated. The significance and usage of these inputs to each contingent consideration may vary due to differences in the timing and triggering events for payments or in the nature of the asset related to the contingent consideration. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If the most significant parameters for the Level&#xA0;3 input were to change by 10% positively or negatively, or where the probability of success (POS) is the most significant input parameter, 10% were added or deducted from the applied probability of success, for contingent consideration payables and contingent consideration receivables, this would change the amounts recorded in the 2022 consolidated income statement by USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" decimals="-6" scale="6">154</ix:nonFraction> million and USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" decimals="-6" scale="6" sign="-">140</ix:nonFraction> million, respectively.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Equity securities measured at fair value through other comprehensive income</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Equity securities held as strategic investments, typically held outside the Novartis Venture Fund, are generally designated at date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. These are made up of individually non-significant investments. At December 31, 2022, the Group holds <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember" name="nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" decimals="0" scale="0" format="ixt:numdotdecimal">65</ix:nonFraction> non-listed equity securities (December 31, 2021: <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember" name="nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" decimals="0" scale="0" format="ixt:numdotdecimal">60</ix:nonFraction>) and <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember" name="nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" decimals="0" scale="0" format="ixt:numdotdecimal">46</ix:nonFraction> listed equity securities (December 31, 2021: <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember" name="nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" decimals="0" scale="0" format="ixt:numdotdecimal">40</ix:nonFraction>) in this category with the following fair values:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" id="SectionBlock_556822de-8efa-4919-9221-94a3ace6c5bc_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Listed equity securities</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember" name="ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">438</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember" name="ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">888</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-listed equity securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember" name="ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">390</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember" name="ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">307</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity securities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">828</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" decimals="-6" scale="6" format="ixt:numdotdecimal">1 195</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;&#xA0;&#xA0;&#xA0;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022 and 2021, dividends received from these equity securities were insignificant. In 2022, in accordance with the consolidated foundations Alcon Inc. shares divestment plans, Alcon Inc. shares with a fair value of USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember" name="nvs:FairValueOfOtherFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction> million were sold (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember" name="nvs:FairValueOfOtherFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction> million), and the USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember" name="nvs:GainLossOnSaleOfOtherFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction> million gain on disposal (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember" name="nvs:GainLossOnSaleOfOtherFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction> million gain) was transferred from other comprehensive income to retained earnings during 2022. In addition, in 2022, equity securities that were no longer considered strategic, with a fair value of USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:FairValueOfOtherFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction> million (2021: USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:FairValueOfOtherFinancialAssetsSold" decimals="-6" scale="6" format="ixt:numdotdecimal">254</ix:nonFraction> million), were sold, and the USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember" name="nvs:GainLossOnSaleOfOtherFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction> million loss on disposal (2021: USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember" name="nvs:GainLossOnSaleOfOtherFinancialAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">211</ix:nonFraction> million gain) was transferred from other comprehensive income to retained earnings (see Note 8).</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-68</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_9657e382-a398-47d8-820b-6fe42150461f_5" continuedAt="SectionBlock_9657e382-a398-47d8-820b-6fe42150461f_6">
          <div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Nature and extent of risks arising from financial instruments</span>
                </div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Market risk</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Market risk in general comprises currency risk, interest rate risk and price risk, such as commodity and equity prices. Novartis is exposed to market risk, primarily related to foreign currency exchange rates, interest rates and the market value of the investments. The Group actively monitors and seeks to reduce, where it deems it appropriate to do so, fluctuations in these exposures. It is the Group&#x2019;s policy and practice to enter into a variety of derivative financial instruments to manage the volatility of these exposures. It does not enter into any financial transactions containing a risk that cannot be quantified at the time the transaction is concluded. In addition, it does not sell short assets it does not have, or does not know it will have, in the future. The Group only sells existing assets or enters into transactions and future transactions (in the case of anticipatory hedges) that it confidently expects it will have in the future, based on past experience. </div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Foreign currency exchange rate risk</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group uses the US dollar as its reporting currency. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Japanese and emerging market currencies. Fluctuations in the exchange rates between the US dollar and other currencies can have a significant effect on both the Group&#x2019;s results of operations, including reported sales and earnings, as well as on the reported value of our assets, liabilities and cash flows. This, in turn, may significantly affect the comparability of period-to-period results of operations.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Because our expenditures in Swiss francs are significantly higher than our revenues in Swiss francs, volatility in the value of the Swiss franc can have a significant impact on the reported value of our earnings, assets and liabilities, and the timing and extent of such volatility can be difficult to predict.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There is also a risk that certain countries could experience a devaluation of their currency. If this occurs, it could impact the effective prices we would be able to charge for our products and also have an adverse impact on both our consolidated income statement and balance sheet.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Subsidiaries whose functional currencies have experienced a cumulative inflation rate of more than 100% over the past three years apply the principles of IAS 29 &#x201C;Financial reporting in Hyperinflationary Economies.&#x201D; The hyperinflationary economies in which Novartis operates are Argentina, Venezuela and Turkey. Venezuela and Argentina were hyperinflationary for all periods presented, and Turkey became hyperinflationary effective May 1, 2022, requiring retroactive implementation of hyperinflation accounting as of January 1, 2022. The impacts of applying IAS 29 were not significant in all years presented.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group manages its global currency exposure by engaging in hedging transactions where management deems appropriate. Novartis may enter into various contracts that reflect the changes in the value of foreign currency exchange rates to preserve the value of assets, commitments and anticipated transactions. Novartis also uses forward contracts and may enter into foreign currency option contracts to hedge.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net investments in subsidiaries in foreign countries are long-term investments. Their fair value changes through movements of foreign currency exchange rates. The Group has designated a certain portion of its long-term euro-denominated straight bonds, maturing in 2028, as hedges of the translation risk arising on certain of these net investments in foreign operations with euro functional currency. As of December 31, 2022, long-term financial debt with a carrying amount of EUR&#xA0;<ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd" name="nvs:LongtermFinancialDebtWithACarryingAmount" decimals="-8" scale="9">1.8</ix:nonFraction> billion (USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:LongtermFinancialDebtWithACarryingAmount" decimals="-8" scale="9">2.0</ix:nonFraction> billion; December 31, 2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:LongtermFinancialDebtWithACarryingAmount" decimals="-8" scale="9">2.1</ix:nonFraction> billion), has been designated as a hedge instrument. During 2022, USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonFraction> million of net of taxes unrealized income (2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" decimals="-6" scale="6" format="ixt:numdotdecimal">216</ix:nonFraction> million) was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge. The hedge remained effective since inception, and no amount was recognized in the consolidated income statement in 2022, 2021 and 2020.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Commodity price risk</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has only a very limited exposure to price risk related to anticipated purchases of certain commodities used as raw materials by the Group&#x2019;s businesses. A change in those prices may alter the gross margin of a specific business, but generally by not more than <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:MaximumMarginPercentageImpactOfCommodityPriceChange" decimals="2" scale="-2">10</ix:nonFraction>%</span> of the margin and thus below the Group&#x2019;s risk management tolerance levels. Accordingly, the Group does not enter into significant commodity futures, forward or option contracts to manage fluctuations in prices of anticipated purchases.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest rate risk</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group addresses its net exposure to interest rate risk mainly through the ratio of its fixed-rate financial debt to variable-rate financial debt contained in its total financial debt portfolio. To manage this mix, Novartis may enter into interest rate swap agreements, in which it exchanges periodic payments based on a notional amount and agreed-upon fixed and variable interest rates.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Equity risk</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group may purchase equities as investments of its liquid funds. As a policy, it limits its holdings in an unrelated company to less than <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:MaximumHoldingInUnrelatedCompany" decimals="2" scale="-2">5</ix:nonFraction>%</span> of its liquid funds. Potential investments are thoroughly analyzed. Call options are written on equities that the Group owns, and put options are written on equities that the Group wants to buy and for which cash is available.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Credit risk</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Credit risks arise from the possibility that customers may not be able to settle their obligations as agreed. To manage this risk, the Group periodically assesses country and customer credit risk, assigns individual credit limits, and takes actions to mitigate credit risk where appropriate (for example payment guarantees, credit insurance and factoring).</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The provisions for expected credit losses for customers are based on a forward-looking expected credit loss, which includes possible default events on the trade </div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-69</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_9657e382-a398-47d8-820b-6fe42150461f_6" continuedAt="SectionBlock_9657e382-a398-47d8-820b-6fe42150461f_7">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">receivables over the entire holding period of the trade receivables.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In measuring the expected credit losses, trade receivables are grouped based on shared credit risk characteristics (such as private versus public receivables) and days past due. In determining the expected credit loss rates, the Group considers current and forward-looking macroeconomic factors that may affect the ability of the customers to settle the receivables, and historical loss rates for each category of customers.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s largest customer accounted for approximately <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">16</ix:nonFraction>%</span> of net sales to third parties, and the second largest and third largest customers accounted for <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">11</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">7</ix:nonFraction>%</span> of net sales to third parties, respectively (2021: <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">17</ix:nonFraction>%</span>, <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">11</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">6</ix:nonFraction>%</span>, respectively; 2020: <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">17</ix:nonFraction>%</span>, <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">11</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember" name="ifrs-full:PercentageOfEntitysRevenue" decimals="2" scale="-2">6</ix:nonFraction>%</span>, respectively).</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The highest amounts of trade receivables outstanding were for these same three customers and amounted to <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">16</ix:nonFraction>%</span>, <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">14</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">7</ix:nonFraction>%</span>, respectively, of the Group&#x2019;s trade receivables at December 31, 2022 (2021: <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">16</ix:nonFraction>%</span>, <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">12</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember" name="nvs:PercentageOfEntitysTradeReceivable" decimals="2" scale="-2">7</ix:nonFraction>%</span>, respectively). There is no other significant concentration of customer credit risk.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Counterparty risk</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Counterparty risk encompasses issuer risk on marketable securities and money market instruments; credit risk on cash, time deposits and derivatives; as well as settlement risk for different instruments. Issuer risk is reduced by only buying securities that are at least A- rated. Counterparty credit risk and settlement risk are reduced by a policy of entering into transactions with counterparties (banks or financial institutions) that feature a strong credit rating. Exposure to these risks is closely monitored and kept within predetermined parameters. The limits are regularly assessed and determined based upon credit analysis, including financial statement and capital adequacy ratio reviews. In addition, reverse repurchasing agreements are contracted, and Novartis has entered into credit support agreements with various banks for derivative transactions. To further reduce the settlement risk, the Group has implemented a multi-currency payment system, Continuous Linked Settlement (CLS), providing multilateral netting (payment-versus-payment settlement) of cash flows from foreign exchange transactions.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s cash and cash equivalents are held with major regulated financial institutions; the three largest ones hold approximately <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4LargestFinancialInstitutionMember" name="nvs:CashAndCashEquivalentsHeldWithFinancialInstitution" decimals="3" scale="-2">13.2</ix:nonFraction>%</span>, <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4SecondLargestFinancialInstitutionMember" name="nvs:CashAndCashEquivalentsHeldWithFinancialInstitution" decimals="3" scale="-2">9.2</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4ThirdLargestFinancialInstitutionMember" name="nvs:CashAndCashEquivalentsHeldWithFinancialInstitution" decimals="3" scale="-2">6.8</ix:nonFraction>%</span>, respectively (2021: <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4LargestFinancialInstitutionMember" name="nvs:CashAndCashEquivalentsHeldWithFinancialInstitution" decimals="3" scale="-2">9.7</ix:nonFraction>%</span>, <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4SecondLargestFinancialInstitutionMember" name="nvs:CashAndCashEquivalentsHeldWithFinancialInstitution" decimals="3" scale="-2">9.7</ix:nonFraction>%</span> and <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4ThirdLargestFinancialInstitutionMember" name="nvs:CashAndCashEquivalentsHeldWithFinancialInstitution" decimals="3" scale="-2">7.6</ix:nonFraction>%</span>, respectively). As of December 31, 2021, the Group&#x2019;s cash and cash equivalents also included short-term highly rated government-backed debt securities, with an original maturity of three months or less, for approximately <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear-1" name="nvs:PercentageOfGovernmentBackedDebtSecurities" decimals="2" scale="-2">16</ix:nonFraction>%</span> (2022: <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:PercentageOfGovernmentBackedDebtSecurities" decimals="2" scale="0" format="ixt-sec:numwordsen">nil</ix:nonFraction>).</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Liquidity risk</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Liquidity risk is defined as the risk that the Group could not be able to settle or meet its obligations associated with financial liabilities that are settled by delivering cash or another financial asset. Group Treasury is responsible for liquidity, funding and settlement management. In addition, liquidity and funding risks, and related processes and policies, are overseen by management. Novartis manages its liquidity risk on a consolidated basis according to business needs and tax, capital or regulatory considerations, if applicable, through numerous sources of financing in order to maintain flexibility. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain countries have legal or economic restrictions on the ability of subsidiaries to transfer funds to the Group in the form of cash dividends, loans or advances, but these restrictions do not have an impact on the ability of the Group to meet its cash obligations.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Management monitors the Group&#x2019;s net debt or liquidity position through rolling forecasts on the basis of expected cash flows.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis has <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4USCommercialPaperProgramsMember" name="nvs:BorrowingsCommercialPaperNumberOfPrograms" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> US commercial paper programs under which it can issue up to USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4USCommercialPaperProgramsMember" name="nvs:BorrowingsCommercialPaperMaximumBorrowingAmount" decimals="-9" scale="9">9.0</ix:nonFraction> billion in the aggregate of unsecured commercial paper notes. Novartis also has <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4JPCommercialPaperProgramsMember" name="nvs:BorrowingsCommercialPaperNumberOfPrograms" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> Japanese commercial paper program under which it can issue up to JPY&#xA0;<ix:nonFraction unitRef="JPY" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4JPCommercialPaperProgramsMember" name="nvs:BorrowingsCommercialPaperMaximumBorrowingAmount" decimals="-9" scale="9">150</ix:nonFraction> billion (approximately USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4JPCommercialPaperProgramsMember" name="nvs:BorrowingsCommercialPaperMaximumBorrowingAmount" decimals="-8" scale="9">1.1</ix:nonFraction> billion) of unsecured commercial paper notes. Commercial paper notes totaling USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:BorrowingsCommercialPaperMaximumBorrowingAmount" decimals="-8" scale="9">2.8</ix:nonFraction> billion under these <ix:nonFraction unitRef="Pure" contextRef="AR_I-CurrentYearEnd" name="nvs:BorrowingsCommercialPaperNumberOfPrograms" decimals="0" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> programs were outstanding as per December 31, 2022 (2021: USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:BorrowingsCommercialPaperMaximumBorrowingAmount" decimals="-8" scale="9">0.9</ix:nonFraction> billion). Novartis further has a committed credit facility of USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:BorrowingsCreditFacilityCommitted" decimals="-9" scale="9">6.0</ix:nonFraction> billion, which was extended in September 2022. This credit facility is provided by a syndicate of banks and is intended to be used as a backstop for the US commercial paper programs. The facility matures in September 2025 and was undrawn as per December 31, 2022, and December 31, 2021.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-70</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_9657e382-a398-47d8-820b-6fe42150461f_7" continuedAt="SectionBlock_9657e382-a398-47d8-820b-6fe42150461f_8">
          <div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table sets forth how management monitors net debt or liquidity based on details of the remaining contractual maturities of current financial assets and liabilities, excluding trade receivables and payables as well as liabilities for contingent consideration at December 31, 2022, and December 31, 2021:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" id="SectionBlock_5d7581bc-0f65-4708-8690-162a3212588d_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Due within <br /> one month</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br /> one month <br /> but less than <br /> three months</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than<br />  three months <br /> but less than <br /> one year</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br /> one year <br /> but less than <br /> five years</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Due after <br /> five years</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, time deposits and short-term investments with original maturity more than 90 days and accrued interest</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">4 142</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">6 911</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">36</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">11 098</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">111</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">111</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">147</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">4 011</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">3 506</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">7 517</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">8 176</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">10 564</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">135</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">18 930</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">8 975</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">11 269</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">20 244</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">9 002</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">11 394</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">20 396</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">8 975</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">11 269</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">20 244</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">3 215</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">146</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 515</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 876</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">3 215</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">146</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 517</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 878</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">3 253</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">159</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 519</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 931</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 923</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">10 405</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">2 464</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">8 975</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">11 134</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">7 245</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="11" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Due within <br /> one month</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br /> one month <br /> but less than <br /> three months</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than<br />  three months <br /> but less than <br /> one year</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br /> one year <br /> but less than <br /> five years</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Due after <br /> five years</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, time deposits and short-term investments with original maturity more than 90 days and accrued interest</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">14 585</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 088</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">15 706</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">111</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">111</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">21</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">7 406</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">5 001</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">12 407</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">7 438</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">19 650</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">1 095</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">142</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" decimals="-6" scale="6" format="ixt:numdotdecimal">28 329</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">8 464</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">14 438</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">22 902</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">8 490</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">14 587</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">23 077</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">8 464</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">14 438</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherNoncurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">22 902</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 780</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">521</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 926</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">6 227</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 780</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">521</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 928</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">6 229</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 830</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">537</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 928</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:OtherCurrentFinancialLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">6 295</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#xA0;</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">4 608</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">19 113</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">1 833</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">8 460</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">14 296</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:NetDebt" decimals="-6" scale="6" format="ixt:numdotdecimal">868</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The carrying amounts of financial liabilities included in the above analysis are not materially different to the contractual amounts due on maturity. The positive and negative fair values on derivative financial instruments represent the net contractual amounts to be exchanged at maturity.</div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-71</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_9657e382-a398-47d8-820b-6fe42150461f_8" continuedAt="SectionBlock_9657e382-a398-47d8-820b-6fe42150461f_9">
          <div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s contractual undiscounted potential cash flows from derivative financial instruments to be settled on a gross basis are as follows:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" id="SectionBlock_04b824e3-8f23-43e2-9c3a-5c8c866d1028_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Due within <br /> one month</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br /> one month <br /> but less than <br /> three months</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than<br />  three months <br /> but less than <br /> one year</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br />
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Derivative financial instruments and accrued interest on derivative  financial instruments</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential outflows in various currencies - from financial derivative liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">2 029</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">4 598</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">316</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">6 943</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential inflows in various currencies - from financial derivative assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">2 029</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">4 712</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">321</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">7 062</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="7" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Due within <br /> one month</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br /> one month <br /> but less than <br /> three months</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than<br />  three months <br /> but less than <br /> one year</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br />
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Derivative financial instruments and accrued interest on derivative  financial instruments</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential outflows in various currencies - from financial derivative liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">843</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">5 482</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">461</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">6 786</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential inflows in various currencies - from financial derivative assets</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember" name="nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">847</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">5 516</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">457</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" decimals="-6" scale="6" format="ixt:numdotdecimal">6 820</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Other contractual liabilities that are not part of management&#x2019;s monitoring of the net debt or liquidity consist of the following items:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" id="SectionBlock_fa7d235f-5c9b-42a1-aefb-f0dc9087bdfc_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Due within <br /> three months</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than<br />  three months <br /> but less than <br /> one year</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br /> one year <br /> but less than <br /> five years</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br /> Due after <br /> five years</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contractual interest on non-current liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="nvs:ContractualInterestOnNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">64</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="nvs:ContractualInterestOnNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">412</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember" name="nvs:ContractualInterestOnNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 432</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="nvs:ContractualInterestOnNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3 624</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:ContractualInterestOnNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">5 532</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">616</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">922</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 789</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" decimals="-6" scale="6" format="ixt:numdotdecimal">5 020</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" decimals="-6" scale="6" format="ixt:numdotdecimal">126</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" decimals="-6" scale="6" format="ixt:numdotdecimal">5 146</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="nvs:ContingentConsiderationLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="nvs:ContingentConsiderationLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">115</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember" name="nvs:ContingentConsiderationLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">437</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="nvs:ContingentConsiderationLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">267</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:ContingentConsiderationLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">835</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Note 10 provides additional disclosures related to lease liabilities.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td></td>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:1;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr>
                        <td style=";height:3;"></td>
                        <td style=";height:1;"></td>
                        <td colspan="9" style=";height:3;"></td>
                        <td style=";height:1;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br />(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Due within <br /> three months</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than<br />  three months <br /> but less than <br /> one year</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br /> one year <br /> but less than <br /> five years</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br /> Due after <br /> five years</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br />
                            <br />
                            <br /> Total</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contractual interest on non-current liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="nvs:ContractualInterestOnNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">82</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="nvs:ContractualInterestOnNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">445</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember" name="nvs:ContractualInterestOnNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">1 628</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="nvs:ContractualInterestOnNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3 908</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:ContractualInterestOnNoncurrentLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">6 063</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities<sup style="white-space: nowrap">&#xA0;1</sup></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">78</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">197</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">639</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">982</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:LeaseLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 896</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" decimals="-6" scale="6" format="ixt:numdotdecimal">5 373</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" decimals="-6" scale="6" format="ixt:numdotdecimal">5 553</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="nvs:CommitmentForRepurchaseOwnShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 809</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"></div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:CommitmentForRepurchaseOwnShares" decimals="-6" scale="6" format="ixt:numdotdecimal">2 809</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember" name="nvs:ContingentConsiderationLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">54</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="nvs:ContingentConsiderationLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">65</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember" name="nvs:ContingentConsiderationLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">517</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember" name="nvs:ContingentConsiderationLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">439</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:ContingentConsiderationLiabilities" decimals="-6" scale="6" format="ixt:numdotdecimal">1 075</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Note 10 provides additional disclosures related to lease liabilities.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Capital risk management</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis strives to maintain a strong credit rating. In managing its capital, Novartis focuses on maintaining a strong balance sheet. As of December 31, 2022, Moody&#x2019;s Investors Service rated the Company A1 for long-term maturities and P-1 for short-term maturities, and S&amp;P Global Ratings rated the Company AA- for long-term maturities and A-1+ for short-term maturities. </div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Sensitivity analysis</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group uses sensitivity analysis disclosures to provide quantitative information about market risks to which it is exposed. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The sensitivity analysis disclosures are in line with the Group&#x2019;s financial risk management policy, and are based on a one-parameter risk model that considers a one-factor linear relationship between risk factors and </div>
              </div>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-72</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_9657e382-a398-47d8-820b-6fe42150461f_9">
          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">exposures. They consider aggregated risk exposures arising from the most significant risk factors (currency risk, interest rate risk and equity price risk) and include all financial assets and financial liabilities as set forth in the table on page F-64. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The disclosures below illustrate the potential impact on the Group&#x2019;s consolidated financial statements as a result of hypothetical market movements in foreign currency exchange rates, interest rates and equity prices. The range of variables chosen reflects management&#x2019;s view of changes that are reasonably possible over a one-year period. </div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Foreign currency exchange rate sensitivity</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group uses the US dollar as its reporting currency. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Japanese and emerging market currencies, as well as in the Swiss franc. A strengthening (weakening) of the US dollar against these currencies as of December 31, 2022 and 2021 would have affected the measurement of financial instruments denominated in these foreign currencies. This analysis assumes that all other variables, in particular interest rates, remain constant. A hypothetical <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" decimals="2" scale="-2">5</ix:nonFraction>%</span> increase or decrease in the foreign currency exchange rates against the US dollar would have impacted the Group&#x2019;s consolidated income statement as presented below: </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" id="SectionBlock_8ceefaad-86bb-44fe-84eb-91ccd9091b6f_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% increase in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember" name="nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">6</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember" name="nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% decrease in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember" name="nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember" name="nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">3</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As of December 31, 2022, the Group designated EUR <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd" name="nvs:LongtermFinancialDebtWithACarryingAmount" decimals="-8" scale="9">1.8</ix:nonFraction> billion (December 31, 2021: EUR <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd-1" name="nvs:LongtermFinancialDebtWithACarryingAmount" decimals="-8" scale="9">1.8</ix:nonFraction> billion) of its long-term euro-denominated straight bonds as hedges of the translation risk arising on certain net investments in foreign operations with euro functional currency. This analysis assumes that all other variables, in particular interest rates, remain constant. A hypothetical <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" decimals="2" scale="-2">5</ix:nonFraction>%</span> increase, or decrease, in the foreign currency exchange rates against the US dollar, without considering the translation effect of these net investments, would have impacted the Group&#x2019;s consolidated equity as presented below: </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" id="SectionBlock_7761cc88-8064-401e-b23a-519d70b147d7_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% increase in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember" name="nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">93</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember" name="nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">99</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% decrease in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember" name="nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">98</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember" name="nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">104</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest rate sensitivity</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our portfolio of fixed-income instruments as of December 31, 2022, was mainly composed of time deposits and debt securities. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis uses duration models to approximate the possible change in the value of fixed-income instruments. Based on these models, management believes that a 100-basis point change in interest is deemed a reasonable possible change over a one-year period.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Based on exposures in 2022 and 2021, a hypothetical 100-basis point increase (decrease) in interest rates would not have resulted in a significant increase (decrease) in the fair values of the fixed-income instruments. In addition, a hypothetical 100-basis point increase (decrease) in interest rates would not have resulted in a material increase (decrease) of cash flows attributable to such fixed-income instruments.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The vast majority of our outstanding financial debts are straight bonds with fixed interest rates and are therefore not affected by movements in interest rates.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Equity price sensitivity</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Fund investments and equity securities held by the Novartis Venture Fund are valued at fair value through profit and loss. Equity securities held as strategic investments, typically held outside the Novartis Venture Fund, are generally designated at date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of these fund investments and equity securities was USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd" name="nvs:FairValueOfFundInvestmentsAndEquitySecurities" decimals="-8" scale="9">1.6</ix:nonFraction> billion as of December 31, 2022 (December 31, 2021: USD <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd-1" name="nvs:FairValueOfFundInvestmentsAndEquitySecurities" decimals="-8" scale="9">2.2</ix:nonFraction> billion). The fair values of these investments are impacted by the volatility of the stock market, valuation parameters applied (for non-listed equities) and changes in general economic factors. This analysis assumes that all other variables, in particular interest rates, remain constant. A hypothetical increase or decrease of <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" decimals="2" scale="-2">15</ix:nonFraction>%</span> in the risk factors would have impacted the Group&#x2019;s consolidated income statement as presented below: </div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock" id="SectionBlock_597cc3e0-2978-4af4-a86a-cf54a0c07f41_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% increase in equity prices</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember" name="nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" decimals="-6" scale="6" format="ixt:numdotdecimal">109</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember" name="nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" decimals="-6" scale="6" format="ixt:numdotdecimal">154</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% decrease in equity prices</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember" name="nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">109</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember" name="nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">154</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">A hypothetical increase or decrease of <span><ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear" name="nvs:HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" decimals="2" scale="-2">15</ix:nonFraction>%</span> in the risk factors would have impacted the Group&#x2019;s consolidated equity as presented below:</div>
              </div>
            </div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock" id="SectionBlock_737ff923-d299-4ecc-b660-69ac6a14484a_0" escape="true">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% increase in equity prices</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember" name="nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">124</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember" name="nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" decimals="-6" scale="6" format="ixt:numdotdecimal">179</ix:nonFraction>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% decrease in equity prices</div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember" name="nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">124</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember" name="nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" decimals="-6" scale="6" format="ixt:numdotdecimal" sign="-">179</ix:nonFraction></span>
                          </div>
                        </td>
                        <td align="right"></td>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-73</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="SectionBlock_48c0e011-3c62-4dfe-881e-6e0ae310b015_0" escape="true">
          <div>
            <div id="anchorId001561678"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">30. Events subsequent to the December 31, 2022, consolidated balance sheet date</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">South Korea investigation &#x2013; Concluded matter</span>
            </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In January 2023, the Supreme Court dismissed the appeal by the Seoul Western District Prosecutor on the criminal investigation on, among other things, allegations that Novartis Korea utilized medical journals to provide inappropriate economic benefits to healthcare professionals (HCPs). This matter is now concluded. For additional information see Note 20.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Dividend proposal for 2022 and approval of&#xA0;the Group&#x2019;s 2022 consolidated financial statements  </span>
            </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On January 31, 2023, the Novartis AG Board of Directors proposed the acceptance of the 2022 consolidated financial statements of the Novartis Group for approval by the Annual General Meeting on March 7, 2023. Furthermore, also on January 31, 2023, the Board proposed a dividend of CHF <ix:nonFraction unitRef="CHFPerShares" contextRef="AR_D-CurrentYear_nvs-2022Q4SubsequentEventTypAxis_nvs-2022Q4SubsequentEventMember" name="ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" decimals="2" scale="0">3.20</ix:nonFraction> per share to be approved at the Annual General Meeting on March 7, 2023. If approved, total dividend payments would amount to approximately USD <ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" decimals="-8" scale="9">7.3</ix:nonFraction> billion (2021: USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear-1" name="ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" decimals="-8" scale="9">7.5</ix:nonFraction>  billion), using the CHF/USD December 31, 2022, exchange rate.</div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-74</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <div></div>
      </div>
      <div>
        <ix:nonNumeric contextRef="AR_D-CurrentYear" name="ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" id="SectionBlock_70183878-a85a-4760-afef-64a72f590faa_0" escape="true" continuedAt="SectionBlock_70183878-a85a-4760-afef-64a72f590faa_1">
          <div>
            <div id="anchorId001561713"></div>
            <div id="anchorNote31"></div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">31. Principal Group subsidiaries and&#xA0;associated&#xA0;companies </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table lists the principal subsidiaries controlled by Novartis, associated companies in which &#xAD;Novartis is deemed to have significant influence, and foundations required to be consolidated under IFRS. It includes all subsidiaries, associated companies and consolidated foundations with total assets or net sales to third parties in excess of USD&#xA0;<ix:nonFraction unitRef="USD" contextRef="AR_D-CurrentYear" name="nvs:PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction>&#xA0;million. The equity interest percentage shown in the table also represents the share in voting rights in those entities.</div>
            <div>
              <ix:nonNumeric contextRef="AR_D-CurrentYear" name="nvs:PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" id="SectionBlock_c1fa9f5f-f4f8-4475-a7fc-98ba99290473_0" escape="true" continuedAt="SectionBlock_c1fa9f5f-f4f8-4475-a7fc-98ba99290473_1">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />As at December 31, 2022</div>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br /> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br /> interest</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Algeria</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Soci&#xE9;t&#xE9; par actions SANDOZ</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Algiers</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DZD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="DZD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">650.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Argentina</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Argentina S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Buenos Aires</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ARS</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="ARS" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">906.1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Australia</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Australia Pty Ltd</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Macquarie Park, NSW</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="AUD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">2</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharmaceuticals
Australia Pty Ltd</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Macquarie Park, NSW</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="AUD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">3.8</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Pty Ltd</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Macquarie Park, NSW</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="AUD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">11.6</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Austria</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Austria GmbH</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Vienna</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma GmbH</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Vienna</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz GmbH</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Kundl</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">32.7</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">EBEWE Pharma Ges.m.b.H Nfg. KG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Unterach am Attersee</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Bangladesh</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis (Bangladesh) Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Gazipur</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BDT</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="BDT" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">162.5</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">60</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Belgium</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma NV</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Vilvoorde</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">72.1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz NV</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Vilvoorde</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">19.2</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Alcon - Couvreur NV</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Puurs</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">110.6</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Bermuda</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Investment Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Hamilton</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">12 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Securities Investment Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Hamilton</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">30 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Finance Services Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Hamilton</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">20 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Triangle International Reinsurance Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Hamilton</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Trinity River Insurance Co Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Hamilton</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">370 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Brazil</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Bioci&#xEA;ncias S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">S&#xE3;o Paulo</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRL</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="BRL" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">507.1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz do Brasil Ind&#xFA;stria Farmac&#xEA;utica Ltda.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Camb&#xE9;, PR</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRL</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="BRL" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">190.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Canada</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharmaceuticals Canada Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Dorval, Quebec</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CAD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Canada Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Boucherville, Quebec</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CAD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">80.8</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Chile</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Chile S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Santiago de Chile</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CLP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CLP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-8" scale="9" format="ixt:numdotdecimal">2.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">China</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Beijing Novartis Pharma Co., Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Beijing</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">30.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharmaceuticals (HK) Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Hong Kong</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HKD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="HKD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">200</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">China Novartis Institutes for
BioMedical Research Co., Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Shanghai</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">320.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Suzhou Novartis Technical
Development Co., Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Changshu</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Shanghai Novartis Trading Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Shanghai</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz (China) Pharmaceutical
Co., Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Zhongshan</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">57.6</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Colombia</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis de Colombia S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Santaf&#xE9; de Bogot&#xE1;</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> COP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="COP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-8" scale="9" format="ixt:numdotdecimal">7.9</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Croatia</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz d.o.o. farmaceutska industrija</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Zagreb</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HRK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="HRK" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">25.6</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Czech Republic</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis s.r.o.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Prague</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CZK" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">51.5</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz s.r.o.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Prague</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CZK" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">44.7</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Denmark</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Healthcare A/S</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Copenhagen</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="DKK" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">14.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz A/S</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Copenhagen</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="DKK" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ecuador</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Ecuador S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Quito</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Egypt</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma S.A.E.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Cairo</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EGP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EGP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-8" scale="9" format="ixt:numdotdecimal">1.3</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">99.96</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Egypt Pharma S.A.E.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">New Cairo City</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EGP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EGP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">250 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Finland</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Finland Oy</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Espoo</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">459 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />As at December 31, 2022</div>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br /> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br /> interest</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">France</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Groupe France S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Rueil-Malmaison</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">903.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma S.A.S.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Rueil-Malmaison</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">43.4</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Gene Therapies France SAS</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Rueil-Malmaison</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-6" scale="6" format="ixt:numdotdecimal">10 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Advanced Accelerator Applications S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Rueil-Malmaison</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">9.6</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">99.23</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Advanced Accelerator Applications
Molecular Imaging France</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Saint-Genis-Pouilly</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">7.5</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">99.23</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">CELLforCURE</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Les Ulis</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz S.A.S.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Levallois-Perret</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">5.4</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Germany</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Deutschland GmbH</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Nuremberg</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">155.5</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Business Services GmbH</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Wehr</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">25 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma GmbH</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Nuremberg</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">25.6</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma Produktions GmbH</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Wehr</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz International GmbH</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Holzkirchen</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">100 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">1 A Pharma GmbH</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Holzkirchen</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">26 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">HEXAL AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Holzkirchen</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">93.7</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Salutas Pharma GmbH</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Barleben</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">42.1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Aeropharm GmbH</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Rudolstadt</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">26 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Greece</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis (Hellas) S.A.C.I.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Metamorphosis / Athens</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">233.9</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Hungary</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Hungary Healthcare Limited Liability
Company</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Budapest</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HUF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="HUF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">545.6</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Hungary Limited Liability Company</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Budapest</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HUF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="HUF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">883.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">India</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis India Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Mumbai</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="INR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">123.5</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">70.68</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Healthcare Private Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Mumbai</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="INR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Private Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Mumbai</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="INR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">32.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Indonesia</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">PT. Novartis Indonesia</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Jakarta</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IDR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="IDR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-8" scale="9" format="ixt:numdotdecimal">7.7</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ireland</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Ireland Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Dublin</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">25 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Integrated Services Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Cork City</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Gene Therapies EU Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Dublin</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Israel</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Israel Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Tel Aviv</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ILS</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="ILS" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Italy</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Farma S.p.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Milan</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">18.2</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Advanced Accelerator Applications (Italy) S.r.l.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Pozzilli</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">119 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">99.23</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz S.p.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Origgio</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Japan</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma K.K.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Tokyo</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="JPY" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Ciba-Geigy Japan Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Tokyo</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="JPY" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz K.K.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Tokyo</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="JPY" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Latvia</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Baltics SIA</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Riga</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Luxembourg</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Investments S.&#xE0; r.l.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Luxembourg City</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Finance S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Luxembourg City</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">100 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Malaysia</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Corporation (Malaysia) Sdn. Bhd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Petaling Jaya</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MYR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="MYR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">3.3</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Mexico</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Farmac&#xE9;utica, S.A. de C.V.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Mexico City</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="MXN" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">205.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz, S.A. de C.V.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Mexico City</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="MXN" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">468.2</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Morocco</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma Maroc SA</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Casablanca</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MAD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="MAD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">80.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Netherlands</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Netherlands B.V.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Amsterdam</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma B.V.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Amsterdam</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">4.5</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">IDB Holland BV</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Baarle-Nassau</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">18 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">99.23</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz B.V.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Almere</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">907 560</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">New Zealand</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis New Zealand Ltd</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Auckland</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NZD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="NZD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">820 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:nonNumeric>
            </div>
          </div>
        </ix:nonNumeric>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-75</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_70183878-a85a-4760-afef-64a72f590faa_1" continuedAt="SectionBlock_70183878-a85a-4760-afef-64a72f590faa_2">
          <div>
            <div>
              <ix:continuation id="SectionBlock_c1fa9f5f-f4f8-4475-a7fc-98ba99290473_1" continuedAt="SectionBlock_c1fa9f5f-f4f8-4475-a7fc-98ba99290473_2">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />As at December 31, 2022</div>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br /> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br /> interest</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Norway</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Norge AS</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Oslo</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NOK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="NOK" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Pakistan</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma (Pakistan) Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Karachi</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PKR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="PKR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-8" scale="9" format="ixt:numdotdecimal">6.7</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">99.99</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Panama</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma (Logistics), Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Panama City</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">10 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Philippines</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Healthcare Philippines, Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Makati City</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PHP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="PHP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">298.8</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Philippines Corporation</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Makati City</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PHP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="PHP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">30.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Poland</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Poland Sp. z o.o.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Warsaw</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="PLN" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">44.2</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Polska Sp. z o.o.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Warsaw</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="PLN" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">25.6</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Lek S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Strykow</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="PLN" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">11.4</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Portugal</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Portugal, S.G.P.S., Lda.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Porto Salvo</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">500 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Farma - Produtos Farmac&#xEA;uticos, S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Porto Salvo</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">2.4</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Farmac&#xEA;utica, Lda.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Porto Salvo</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">499 900</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Romania</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma Services Romania S.R.L.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Bucharest</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="RON" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz S.R.L.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Targu-Mures</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="RON" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">119.5</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Russian Federation</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma LLC</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Moscow</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="RUB" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Neva LLC</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">St. Petersburg</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="RUB" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">500.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">JSC Sandoz</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Moscow</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="RUB" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">57.4</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Saudi Arabia</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Saudi Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Riyadh</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SAR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="SAR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">30.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Singapore</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis (Singapore) Pte Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Singapore</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="SGD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">100 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Singapore Pharmaceutical
Manufacturing Pte Ltd</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Singapore</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="SGD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">45.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Asia Pacific Pharmaceuticals
Pte Ltd</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Singapore</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="SGD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">39.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Slovakia</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Slovakia s.r.o.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Bratislava</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Slovenia</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Lek Pharmaceuticals d.d.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Ljubljana</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">48.4</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Pharmaceuticals d.d.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Ljubljana</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">South Africa</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis South Africa (Pty) Ltd</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Midrand</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="ZAR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">86.3</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz South Africa (Pty) Ltd</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Midrand</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="ZAR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">South Korea</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Korea Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Seoul</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> KRW</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="KRW" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-8" scale="9" format="ixt:numdotdecimal">24.5</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Spain</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Farmac&#xE9;utica, S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Barcelona</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">63.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Advanced Accelerator Applications
Iberica, S.L.U.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Esplugues de Llobregat</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">22.6</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">99.23</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Farmac&#xE9;utica S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Madrid</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">270 450</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Industrial Products
S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Les Franqueses del Vall&#xE9;s / Barcelona</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">9.3</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Abadia Retuerta S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Sard&#xF3;n de Duero / Valladolid</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="EUR" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sweden</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Sverige AB</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Stockholm</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SEK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="SEK" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis International AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Holding AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">100.2</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis International Pharmaceutical Investment AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">100 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Bioventures AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">100 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisForschungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Forschungsstiftung</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisForschungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Stiftung f&#xFC;r Kaderausbildung</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis-Mitarbeiterbeteiligungsstiftung</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Stiftung f&#xFC;r Mensch und Umwelt</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Stiftung der Novartis AG f&#xFC;r Erziehung,
Ausbildung und Bildung</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Overseas Investments AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Japat AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">50 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">350.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma Services AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma Schweizerhalle AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Muttenz</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">18.9</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma Stein AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Stein</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">251 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharma Schweiz AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Risch</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Cellerys AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Schlieren</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">129 630</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Arctos Medical AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Bern</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">360 020</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Innovative Therapies AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Risch</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">100 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Advanced Accelerator Applications International SA</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Geneva</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">9.3</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">99.23</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Basel</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Pharmaceuticals AG</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Risch</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="CHF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">100 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br />As at December 31, 2022</div>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br /> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td></td>
                        <td></td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br /> interest</div>
                        </td>
                        <td></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Taiwan</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis (Taiwan) Co., Ltd.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Taipei</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TWD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="TWD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">170.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Thailand</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis (Thailand) Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Bangkok</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> THB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="THB" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">302.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Turkey</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Saglik, Gida ve Tarim &#xDC;r&#xFC;nleri Sanayi
ve Ticaret A.S.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Istanbul</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="TRY" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">448.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Farmanova Saglik Hizmetleri Ltd. Sti.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Istanbul</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="TRY" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">6.7</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Ila&#xE7; Sanayi ve Ticaret A.S.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Istanbul</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="TRY" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">880.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">99.99</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Grup Saglik &#xDC;r&#xFC;nleri
Ila&#xE7;lari Sanayi ve Ticaret A.S.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Gebze - Kocaeli</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="TRY" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">96.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ukraine</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Ukraine LLC</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Kyiv</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> UAH</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="UAH" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">8.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United Arab Emirates</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Middle East FZE</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Dubai</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AED</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="AED" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">7.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United Kingdom</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis UK Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">London</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="GBP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">25.5</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharmaceuticals UK Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">London</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="GBP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">5.4</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Grimsby Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">London</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="GBP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">250.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Advanced Accelerator Applications (UK &amp; Ireland)</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">London</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="GBP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">100</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">99.23</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Neutec Pharma Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">London</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="GBP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="1" scale="0" format="ixt:numdotdecimal">7.7</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Gyroscope Therapeutics Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">London</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="GBP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1 492</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Frimley / Camberley</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="GBP" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United States of America</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Corporation</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">East Hanover, NJ</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">72.2</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Finance Corporation</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">East Hanover, NJ</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Capital Corporation</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">East Hanover, NJ</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Services, Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">East Hanover, NJ</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis US Foundation</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">East Hanover, NJ</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Pharmaceuticals Corporation</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">East Hanover, NJ</ix:nonNumeric>
                            <sup style="white-space: nowrap">&#xA0;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">650</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Advanced Accelerator Applications USA, Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Millburn, NJ</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="4" scale="-2" format="ixt:numdotdecimal">99.23</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Gene Therapies, Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Bannockburn, IL</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Technology LLC</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">East Hanover, NJ</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Institutes for BioMedical
Research, Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Cambridge, MA</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Cadent Therapeutics</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Cambridge, MA</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="1" scale="0" format="ixt:numdotdecimal">0.1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Endocyte, Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">East Hanover, NJ</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Navigate BioPharma Services, Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Carlsbad, CA</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">The Medicines Company</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">East Hanover, NJ</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Sandoz Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Princeton, NJ</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">25 000</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Oriel Therapeutics, Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Durham, NC</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Fougera Pharmaceuticals Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Melville, NY</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Eon Labs, Inc.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Princeton, NJ</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="USD" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Venezuela</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis de Venezuela, S.A.</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Caracas</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VES</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="VEF" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="0" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Vietnam</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:NameOfSubsidiary">Novartis Vietnam Company Limited</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonNumeric contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary">Ho Chi Minh City</ix:nonNumeric>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VND</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <ix:nonFraction unitRef="VND" contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="nvs:SharePaidinCapital" decimals="-9" scale="9" format="ixt:numdotdecimal">70</ix:nonFraction>
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              <ix:nonFraction unitRef="Pure" contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"></td>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"></td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">In addition, the Group is represented by subsidiaries and associated companies with total assets or net sales to third parties below USD 25 million in the following countries: Bosnia and Herzegovina, Bulgaria, Cameroon, Dominican Republic, Ghana, Guatemala, Ivory Coast, Kazakhstan, Kenya, Kuwait, North Macedonia, Nigeria, Peru, Senegal and Uruguay.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;1&#xA0;</sup> Share capital may not reflect the taxable share capital and does not include any paid-in surplus.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;2&#xA0;</sup> Significant subsidiary under SEC Regulation S-X Rule 1-02(w)</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#xA0;3&#xA0;</sup> Fully consolidated Foundation</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">m = million; bn = billion</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              </ix:continuation>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-76</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <ix:continuation id="SectionBlock_70183878-a85a-4760-afef-64a72f590faa_2">
          <div>
            <div>
              <ix:continuation id="SectionBlock_c1fa9f5f-f4f8-4475-a7fc-98ba99290473_2">
                <div></div>
              </ix:continuation>
            </div>
          </div>
        </ix:continuation>
      </div>
      <div>
        <div>
          <div id="anchorAudit"></div>
          <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Report of Independent Registered Public Accounting Firm</p>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">To the shareholders and the Board of Directors of Novartis AG</span>
          </div>
          <div>
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Opinions on the Consolidated Financial Statements and Internal Control Over Financial Reporting</span>
          </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We have audited the accompanying consolidated balance sheet of Novartis AG, and its consolidated subsidiaries (the Group) as of December&#xA0;31, 2022, the related consolidated statements of income, comprehensive income, changes in equity, and cash flows for the year ended December&#xA0;31, 2022, and the related notes (collectively, the consolidated financial statements). We also have audited the Group&#x2019;s internal control over financial reporting as of December&#xA0;31, 2022, based on criteria established in Internal Control &#x2013; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).  </div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Group as of December&#xA0;31, 2022, and the results of its operations and its cash flows for the year ended December&#xA0;31, 2022, in conformity with International Financial Reporting Standards (&#x201C;IFRS&#x201D;) as issued by the International Accounting Standards Board. Also in our opinion, the Group maintained, in all material respects, effective internal control over financial reporting as of December&#xA0;31, 2022 based on criteria established in Internal Control &#x2013; Integrated Framework (2013) issued by the COSO.  </div>
          <div>
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Basis for Opinions</span>
          </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Report of Novartis Management on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Group&#x2019;s consolidated financial statements and an opinion on the Group&#x2019;s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Group in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects. </div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Our audit of the consolidated  financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</div>
          <div>
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Definition and Limitations of Internal Control Over Financial Reporting</span>
          </div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">A company&#x2019;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#x2019;s internal control over financial reporting includes those policies and procedures that (1)&#xA0;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#xA0;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&#xA0;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#x2019;s assets that could have a material effect on the financial statements.</div>
        </div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-77</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <div></div>
      </div>
      <div>
        <div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</div>
          <div>
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Critical Audit Matters</span>
          </div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</div>
          <div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;font-style:italic;">Assessment of the recoverable amount for the Leqvio and Xiidra intangible assets</div>
          </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As discussed in Note 1 to the consolidated financial statements, the Group determined the recoverable amount of the intangible assets other than goodwill based on the fair value less costs of disposal method for which no directly observable market inputs were available. As discussed in Note 11, the Group has intangible assets in its Innovative Medicines Division other than goodwill totaling USD 29 826 million as at December 31, 2022, a portion of which related to the currently marketed products <i>Leqvio</i> and <i>Xiidra</i>. </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">We identified the assessment of the recoverable amount, specifically the sales forecasts of the <i>Leqvio</i> and <i>Xiidra</i> intangible assets, as a critical audit matter. Significant auditor judgment and subjectivity was required to assess the sales forecasts assumptions which were a significant input in the determination of the recoverable amount of these intangible assets.</div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following are the primary procedures we performed to address this critical audit matter:</div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  We evaluated the design and tested the operating effectiveness of a certain internal control related to the Group&#x2019;s intangible asset impairment process for Leqvio and Xiidra, including the development of the sales forecasts;</div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  We evaluated the reasonableness of management&#x2019;s sales forecasts for Leqvio and Xiidra by (1) comparing certain underlying assumptions to company-specific operational information and management&#x2019;s communications to the board of directors, (2) comparing the most recent sales performance to previous drug launches, and (3) comparing certain underlying assumptions to available external market and industry data; and </div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  We assessed management&#x2019;s ability to accurately forecast sales by comparing historical sales forecasts for Leqvio and Xiidra to actual results.</div>
          <div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;font-style:italic;">Provisions for deductions from revenue related to Innovative Medicines US Managed Care, Medicare Part D and Medicaid rebate programs</div>
          </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As discussed in Note 1 to the consolidated financial statements, the Group records provisions for estimated rebates as a deduction from revenue when the related revenue is recognized. Rebates involve the use of assumptions and judgements in the determination of the provision rates at the time revenues are recorded. Provision rates are influenced by the terms and conditions in the individual agreements, historical experience, product sales and growth rate, population growth, product pricing, the mix of contracts and products, the level of inventory in the distribution channel, regulations, contracts, and channels and payers. As discussed in Note 22, provisions for deductions from revenue totaled USD 6 732 million as at December 31, 2022, a portion of which related to Innovative Medicines US Managed Care, Medicare Part D and Medicaid rebate programs (hereafter &#x201C;IM US rebates&#x201D;). </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">We identified the estimation of the IM US rebates provisions, specifically the provision rebate rates, as a critical audit matter. The evaluation of the provision rebate rates required a high degree of subjective auditor judgment as it involved estimating the portion of the Group&#x2019;s revenue which will ultimately be subject to a related rebate.</div>
        </div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-78</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <div></div>
      </div>
      <div>
        <div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following are the primary audit procedures we performed to address this critical audit matter:</div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  We evaluated the design and tested the operating effectiveness of certain internal controls over the Group&#x2019;s IM US rebates process related to the development of the provision rebate rates;</div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  We developed our own independent expectation of the IM US rebates provisions, by using internal information, including historical experience and trend analysis of actual rebate claims paid, and comparing it to management&#x2019;s actual recorded balances;</div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  For a sample of actual rebate claims processed by the Group, we evaluated the claims against the contractual and mandated terms of the rebate arrangements; and</div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022;  We assessed management&#x2019;s ability to accurately estimate the IM US rebates provisions by comparing historically recorded provisions to the actual amount that was ultimately paid by the Group.</div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">/s/ <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:AuditorName">KPMG AG</ix:nonNumeric></div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">We have served as the Company&#x2019;s auditor since 2022.</div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">
            <ix:nonNumeric contextRef="AR_D-CurrentYear" name="dei:AuditorLocation">Basel, Switzerland</ix:nonNumeric>
          </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">January 31, 2023</div>
        </div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-79</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <div>
        <div>
          <div id="anchorAudit2"></div>
          <p style="font-family:arial,helvetica,sans-serif; font-size:24pt; color:#000000; font-weight:bold;">Report of Independent Registered Public Accounting Firm</p>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">To the shareholders and Board of Directors of Novartis AG</span>
          </div>
          <div>
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Opinion on the Financial Statements</span>
          </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">We have audited the consolidated balance sheet of Novartis AG and its subsidiaries (the &#x201C;Group&#x201D;) as of December 31, 2021, and the related consolidated income statements, consolidated statements of comprehensive income, consolidated statements of changes in equity, and consolidated statements of cash flows, for each of the two years in the period ended December 31, 2021, including the related notes appearing in item 18 (collectively referred to as the &#x201C;consolidated financial statements&#x201D;).</div>
          <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Group as of December 31, 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021 in conformity with International Financial Reporting Standards (&#x201C;IFRS&#x201D;) as issued by the International Accounting Standards Board.  </div>
          <div>
            <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Basis for Opinion</span>
          </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">These consolidated financial statements are the responsibility of the Group&#x2019;s management. Our responsibility is to express an opinion on the Group&#x2019;s consolidated financial statements based on our audits.  We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.  </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.</div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">/s/ <ix:nonNumeric contextRef="AR_D-CurrentYear-1" name="dei:AuditorName">PricewaterhouseCoopers AG</ix:nonNumeric></div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">
            <ix:nonNumeric contextRef="AR_D-CurrentYear-1" name="dei:AuditorLocation">Basel, Switzerland</ix:nonNumeric>
          </div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">February 1, 2022</div>
          <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">We served as the Company&#x2019;s auditor from at least 1940 to 2022. We have not been able to determine the specific year we began serving as auditor of the Group&#x2019;s predecessors.</div>
        </div>
      </div>
      <div style="padding-bottom:10px;"></div>
      <div style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
        <div style="TEXT-ALIGN: center; WIDTH: 100%">
          <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">F-80</span>
          <div style="padding-bottom:10px;"></div>
        </div>
        <div style="border-top: solid #000000 3px;"></div>
        <div style="padding-bottom:30px;"></div>
      </div>
      <br />
      <img src="x_coverback.jpg" alt="picture" />
      <br />
      <br />
    </div>
  </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2
<SEQUENCE>2
<FILENAME>a23020120f-ex2_4.htm
<DESCRIPTION>EXHIBIT 2.4
<TEXT>

<html>
<head>
<title>EXHIBIT 2.4</title>
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: Arial" bgcolor="#ffffff" text="#000000">


   <div>&#160;</div>
  <div>
    <div style="font-family: 'Times New Roman'; font-weight: bold; text-align: right;">Exhibit 2.4</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman'; font-weight: bold; text-align: center;">DESCRIPTION OF SECURITIES</div>
    <div style="font-family: 'Times New Roman'; font-weight: bold; text-align: center;">REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman'; text-align: justify;">As of December 31, 2022 Novartis&#160;AG (&#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) had the following series of securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended
      (the &#8220;Exchange Act&#8221;):</div>
    <div style="font-family: 'Times New Roman'; text-align: justify;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" id="zf3d380f10de04350b72b628de721e065">

        <tr>
          <td style="WIDTH: 30%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
            <div style="font-weight: bold; color: #000000; text-align: center;">Title of each class</div>
          </td>
          <td style="WIDTH: 5%; VERTICAL-ALIGN: bottom">
            <div style="text-align: left;">&#160;</div>
          </td>
          <td style="WIDTH: 30%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
            <div style="font-weight: bold; color: #000000; text-align: center;">Trading symbol(s)</div>
          </td>
          <td style="WIDTH: 5%; VERTICAL-ALIGN: top">
            <div style="text-align: left;">&#160;</div>
          </td>
          <td style="WIDTH: 30%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
            <div style="font-weight: bold; color: #000000; text-align: center;">Name of each exchange on which registered</div>
          </td>
        </tr>
        <tr>
          <td style="WIDTH: 30%; VERTICAL-ALIGN: top">
            <div style="font-weight: bold; color: #000000; text-align: center;">Ordinary shares, nominal value CHF 0.50 per share</div>
            <div style="text-align: left;">&#160;</div>
            <div style="font-weight: bold; color: #000000; text-align: center;">American Depositary Shares,<br>
              each representing 1 share</div>
          </td>
          <td style="WIDTH: 5%; VERTICAL-ALIGN: top">
            <div style="text-align: left;">&#160;</div>
          </td>
          <td style="WIDTH: 30%; VERTICAL-ALIGN: top">
            <div style="font-weight: bold; color: #000000; text-align: center;">NOVN</div>
            <div style="text-align: left;">&#160;</div>
            <div style="text-align: left;">&#160;</div>
            <div style="font-weight: bold; color: #000000; text-align: center;">NVS</div>
          </td>
          <td style="WIDTH: 5%; VERTICAL-ALIGN: top">
            <div style="text-align: left;">&#160;</div>
          </td>
          <td style="WIDTH: 30%; VERTICAL-ALIGN: top">
            <div style="font-weight: bold; color: #000000; text-align: center;">New York Stock Exchange</div>
            <div style="text-align: left;">&#160;</div>
            <div>&#160;</div>
            <div style="font-weight: bold; color: #000000; text-align: center;">New York Stock Exchange</div>
          </td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman'; color: #000000; text-align: justify;">&#160;</div>
    <div style="font-family: 'Times New Roman'; color: #000000; text-align: justify;"><br>
    </div>
    <div style="font-family: 'Times New Roman'; color: #000000; text-align: justify;">
      <div style="color: #000000;">Our shares are listed in Switzerland on the SIX Swiss Exchange (the &#8220;SIX&#8221;). American Depositary Shares (&#8220;ADSs&#8221;), each representing one ordinary share, nominal value 0.50 Swiss Francs per share of Novartis&#160;AG (the
        &#8220;shares&#8221;), have been available in the US through an American Depositary Receipt (&#8220;ADR&#8221;) program since December 1996. This program was established pursuant to the deposit agreement, as amended and restated from time to time, that we entered into
        with JPMorgan Chase Bank, N.A., New York (&#8220;JPMorgan Chase&#8221;), as depositary (the &#8220;Deposit Agreement&#8221;). Our ADRs have been listed on the New York Stock Exchange (the &#8220;NYSE&#8221;) since May 2000 and are traded under the symbol NVS. In connection with this
        listing (but not for trading), the shares are registered under Section&#160;12(b) of the Exchange Act. This exhibit contains a description of the rights of (i) the holders of the shares and (ii) ADR holders. Shares underlying the ADSs are held by
        JPMorgan Chase, the depositary, and holders of ADSs will not be treated as holders of the shares.</div>
    </div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman'; text-align: justify;">
      <div style="color: #000000;">The following summary is subject to and qualified in its entirety by Novartis&#160;AG&#8217;s Articles of Incorporation (the &#8220;Articles&#8221;), Regulations (the &#8220;Board Regulations&#8221;) of the Novartis&#160;AG Board (the &#8220;Board&#8221;), and by Swiss
        law, particularly the Swiss Code of Obligations (the &#8220;Swiss CO&#8221;). This is not a summary of all the significant provisions of the Articles, the Board Regulations, or of Swiss law and does not purport to be complete. Capitalized terms used but not
        defined herein have the meanings given to them in Novartis&#160;AG&#8217;s annual report on Form 20-F for the fiscal year ended December 31, 2022 and in the Deposit Agreement, which is an exhibit to our registration statement on Form F-6 filed with the SEC on
        December 16, 2022.</div>
    </div>
    <div style="font-family: 'Times New Roman'; text-align: justify;">&#160;</div>
    <div style="font-family: 'Times New Roman'; font-weight: bold; text-align: center;">&#160;</div>
    <div style="font-family: 'Times New Roman'; font-weight: bold; text-align: center;">&#160;</div>
    <div style="font-family: 'Times New Roman'; font-weight: bold; text-align: center;">ORDINARY SHARES</div>
    <div style="font-family: 'Times New Roman'; font-weight: bold; color: #000000; text-align: left;">Item 9. General</div>
    <br>
    <div style="font-family: 'Times New Roman'; font-weight: bold; color: #000000; text-align: justify;">9.A.3 Pre-emptive rights</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman'; color: #000000; text-align: justify;">If a capital increase is approved, then our shareholders would generally have certain pre-emptive rights to obtain newly issued shares in an amount proportional to the
      nominal value of the shares they already hold. These pre-emptive rights could be excluded in certain limited circumstances with the approval of a resolution adopted at a General Meeting of Shareholders (&#8220;General Meeting&#8221;) by a supermajority of two
      thirds of the votes. Pre-emptive rights, if not excluded, are transferable during the subscription period relating to a particular offering of shares and may be quoted on the SIX. US holders of shares, or US holders of ADRs, may not be able to
      exercise the pre-emptive rights attached to the shares or to the shares underlying their ADRs unless a registration statement under the US Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), is effective with respect to such rights and the
      related shares, or an exemption from this registration requirement is available. If pre-emptive rights could not be exercised by an ADR holder, the depositary would, if possible, sell the holder&#8217;s pre-emptive rights and distribute the net proceeds of
      the sale to the holder. If the depositary determines, in its discretion, that the rights could not be sold, the depositary might allow such rights to lapse.</div>
    <div>
      <div style="font-family: 'Times New Roman'; text-align: justify;">&#160;</div>
      <div style="font-family: 'Times New Roman'; text-align: justify;">&#160;</div>
      <div style="font-family: 'Times New Roman'; text-align: center;">
        <div style="text-align: justify;">&#160;</div>
        <div style="text-align: justify;">
          <div>
            <div>
              <div style="font-weight: normal; text-align: center;">1</div>
              <div style="text-align: center;">&#160;</div>
            </div>
            <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
              <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
                <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
            </div>
          </div>
          <div>&#160;</div>
        </div>
      </div>
    </div>
    <div style="font-family: 'Times New Roman'; color: #000000; text-align: justify;">
      <div style="text-align: left; color: #000000; font-weight: bold;">9.A.5 Type and class of securities</div>
      <div><br>
      </div>
      <div style="color: #000000;">Each share has nominal value of 0.50 Swiss Francs per share. The respective number of shares that have been issued as of December 31, 2022 is given in Item 6.C of the annual report on Form 20-F for the fiscal year ended
        December&#160;31,&#160;2022. Novartis&#160;AG shares are issued as uncertificated securities (in the sense of the Swiss Code of Obligations) and as book entry securities (in terms of the Swiss Act on Intermediated Securities). All shares have equal voting rights
        and carry equal entitlements to dividends. No participation certificates, non-voting equity securities (Genussscheine) or profit-sharing certificates have been issued.</div>
      <div><br>
      </div>
      <div style="color: #000000; font-weight: bold;">Item 9.A.6. Limitations or qualifications</div>
      <div><br>
      </div>
      <div style="color: #000000;">Not applicable.</div>
      <div><br>
      </div>
      <div style="color: #000000; font-weight: bold;">Item 9.A.7. Other rights</div>
      <div><br>
      </div>
      <div style="color: #000000;">Not applicable.</div>
    </div>
    <div style="font-family: 'Times New Roman'; text-align: justify;">&#160;</div>
    <div style="font-family: 'Times New Roman'; text-align: justify;"><font style="font-weight: bold;">Item 10.B Memorandum and articles of association</font></div>
    <div style="font-family: 'Times New Roman'; text-align: justify;"><font style="font-weight: bold;"> <br>
      </font></div>
    <div style="margin: 0px 0px 3pt; color: #272118; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">10.B.3 Shareholder rights</div>
    <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; color: #272118; text-align: justify; margin-top: 3pt;">Because Novartis&#160;AG has only one class of registered shares, the following information applies to all shareholders.</div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; color: #272118; text-align: justify; margin-top: 3pt;">
      <table cellspacing="0" cellpadding="0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" id="z2594a8f351db471cbbf03c7b2bc4d6de">

          <tr>
            <td style="WIDTH: 15.01%; VERTICAL-ALIGN: top">
              <div style="color: #272118; text-align: left;">(a)</div>
            </td>
            <td colspan="2" style="WIDTH: 84.99%; VERTICAL-ALIGN: top">
              <div style="text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif;">Under the Swiss CO, we may only pay dividends out of balance sheet profits or out of distributable reserves. In any event, under the Swiss CO, while the Board may propose that a
                  dividend be paid, we may only pay dividends upon shareholders&#8217; approval at a General Meeting. Furthermore, the Swiss CO requires us to accrue general legal reserves under certain circumstances so long as these reserves amount to less than
                  20% of our registered share capital, and Swiss law and the Articles permit us to accrue additional reserves beyond the statutory reserves. Our auditors must confirm that the dividend proposal of our Board conforms with the Swiss CO and
                  the Articles. Our Board expects to recommend the payment of a dividend in respect of each financial year. See <font style="color: #272118;">&#8220;Item 6. Directors, Senior Management and Employees&#8212;Item 6.C Board Practices&#8212;Capital
                    Structure&#8212;Limitation on transferability&#8212;Per-share information&#8221; and </font>&#8220;Item 8. Financial Information&#8212;Item 8.A. Consolidated statements and other financial information&#8212;Dividend policy.&#8221; of our Form 20-F for the fiscal year ended
                  December 31, 2022.</div>
              </div>
              <div style="text-align: justify; text-indent: 14.15pt;"><font style="color: #272118;">Dividends are usually due and payable shortly after the shareholders have passed a resolution approving the payment. Dividends that have not been claimed
                  within five years after the due date revert to us and are allocated to our general reserves.</font>&#160;<font style="color: #272118;">For information about deduction of the withholding tax or other duties from dividend payments, see &#8220;Item 10.
                  Additional Information&#8212;Item&#160;10.E Taxation&#8221; of our Form 20-F for the fiscal year ended December 31, 2022.</font></div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="WIDTH: 15.01%; VERTICAL-ALIGN: top">
              <div style="color: #272118; text-align: left;">(b)</div>
            </td>
            <td colspan="2" style="WIDTH: 84.99%; VERTICAL-ALIGN: top">
              <div style="color: #272118; text-align: justify;">Each share is entitled to one vote at a General Meeting. Voting rights may only be exercised for shares registered with the right to vote on the record date for the applicable General Meeting.
                In order to do so, the shareholder must file&#160;a share registration form with us, setting forth the shareholder&#8217;s name, address and citizenship (or, in the case of a legal entity, its registered office). If the shareholder has not timely
                registered its shares, then the shareholder may not vote at, or participate in, a General Meeting.</div>
              <div style="color: #272118; text-align: justify; text-indent: 14.15pt;">To vote its shares, the shareholder must also explicitly declare that it has acquired the shares in its own name and for its own account. If the shareholder refuses to
                make such a declaration, the shares may not be voted unless the Board recognizes such shareholder as a nominee.</div>
              <div style="color: #272118; text-align: justify; text-indent: 14.15pt;">The Articles provide that no shareholder shall be registered with the right to vote shares comprising more than 2% of the registered share capital. The Board may, upon
                request, grant an exemption from this restriction. Considerations include whether the shareholder supports our goal of creating sustainable value and has a long&#8209;term investment horizon. Furthermore, the Articles provide that no nominee
                shall be registered with the right to vote shares comprising more than 0.5% of the registered share capital. The Board may, upon request, grant an exemption from this restriction if the nominee discloses the names, addresses, and number of
                shares of the persons for whose account it holds 0.5% or more of the registered share capital. The same restrictions indirectly apply to ADR holders. We have in the past granted exemptions from the 2% rule for shareholders and the 0.5% rule
                for nominees.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; color: #272118; text-align: center; margin-top: 3pt;">
      <div style="text-align: justify;">&#160;</div>
      <div style="text-align: justify;">
        <div>
          <div>
            <div style="text-align: center;">2</div>
            <div style="text-align: center;">&#160;</div>
          </div>
          <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
            <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
              <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
        </div>
        <div style="text-align: center;">
          <div style="text-align: justify;">&#160;</div>
          <div style="text-align: justify;">
            <table cellspacing="0" cellpadding="0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" id="z8dec3fedbf904a668c08b1524e1208c0">

                <tr>
                  <td style="WIDTH: 15.01%; VERTICAL-ALIGN: top"></td>
                  <td colspan="2" style="width: 84.99%; vertical-align: top;">
                    <div style="TEXT-INDENT: 14.15pt">
                      <div style="text-align: justify; text-indent: 14.15pt; color: #272118; font-family: 'Times New Roman', Times, serif;">For purposes of the 2% rule for shareholders and the 0.5% rule for nominees, groups of companies and groups of
                        shareholders acting in concert are considered to be one shareholder. These rules also apply to shares acquired or subscribed by the exercise of subscription, option or conversion rights.</div>
                      <div style="text-align: justify; text-indent: 14.15pt; color: #272118; font-family: 'Times New Roman', Times, serif;">After hearing the registered shareholder or nominee, the Board may cancel, with retroactive effect as of the date of
                        registration, the registration of the shareholders if the registration was effected based on false information.</div>
                      <div style="text-align: justify; text-indent: 14.15pt; color: #272118; font-family: 'Times New Roman', Times, serif;">Registration restrictions in the Articles may only be removed upon a resolution carrying a two&#8209;thirds majority of
                        the votes represented at a General Meeting.</div>
                      <div style="text-align: left; color: #272118; font-family: 'Times New Roman', Times, serif;">Except as noted below, shareholders&#8217; resolutions require the approval of an absolute majority of the votes present at a General Meeting. As a
                        result, abstentions have the effect of votes against such resolutions. Some examples of shareholders&#8217; resolutions requiring a vote by such &#8220;absolute majority of the votes&#8221; are:</div>
                    </div>
                    <ul>
                      <li>Adoption and amendment of the Articles </li>
                      <li>Election and removal of the Chairman, the Board and Compensation Committee members, the Independent Proxy and the external auditor </li>
                      <li>Approval of the management report and of the consolidated financial statements </li>
                      <li>
                        <div>Approval of the financial statements of Novartis&#160;AG, and decision on the appropriation of available earnings shown on the balance sheet, including dividends, if any</div>
                      </li>
                      <li>Approval of the maximum aggregate compensation of the Board (from an Annual General Meeting of Shareholders (&#8220;AGM&#8221;) until the next AGM) and of the Executive Committee (for the financial year following the AGM) </li>
                      <li>Discharge of Board and Executive Committee members from liability for matters disclosed to the General Meeting </li>
                      <li>Decision on other matters that are reserved by law or by the Articles (e.g., advisory vote on the Compensation Report) to the General Meeting </li>
                    </ul>
                    <div style="TEXT-INDENT: 14.15pt">According to the Articles and Swiss law, the following matters require the approval of a &#8220;supermajority&#8221; of at least two&#8209;thirds of the votes present at a General Meeting:</div>
                    <ul>
                      <li>Alteration of the purpose of Novartis&#160;AG </li>
                      <li>Creation of shares with increased voting powers </li>
                      <li>Implementation of restrictions on the transfer of registered shares, and the removal of such restrictions </li>
                      <li>Authorized or conditional increase of the share capital </li>
                      <li>Increase of the share capital out of equity, by contribution in kind, for the purpose of an acquisition of property or the grant of special rights </li>
                      <li>Restriction or cancellation of subscription rights </li>
                      <li>Change of the registered office of Novartis&#160;AG </li>
                      <li>Dissolution of Novartis&#160;AG </li>
                    </ul>
                    <div style="TEXT-INDENT: 14.15pt">
                      <div style="text-align: justify; text-indent: 14.15pt; color: #272118; font-family: 'Times New Roman', Times, serif;">In addition, the law provides for a qualified majority for other resolutions, such as a merger or demerger.</div>
                      <div style="text-align: justify; text-indent: 14.15pt; color: #272118; font-family: 'Times New Roman', Times, serif;">Our shareholders are required to annually elect all Directors (including the Chairman), the Compensation Committee
                        members, the external auditor and the Independent Proxy. The Articles do not provide for cumulative voting of shares.</div>
                      <div style="text-align: justify; text-indent: 14.15pt; color: #272118; font-family: 'Times New Roman', Times, serif;">At a General Meeting, shareholders can be represented by a proxy, which must either be the shareholder&#8217;s legal
                        representative, another shareholder with the right to vote, or the Independent Proxy. Votes are taken either by a show of hands or by electronic voting, unless the General Meeting resolves to have a ballot or where a ballot is
                        ordered by the chair of the meeting. <br>
                      </div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="text-align: justify;">
            <div>
              <div>
                <div style="text-align: center;">&#160;</div>
                <div style="text-align: center;">&#160;</div>
                <div style="text-align: center;">3</div>
                <div style="text-align: center;">&#160;</div>
              </div>
              <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
                <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
                  <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
              </div>
            </div>
            <div style="text-align: center;">
              <div style="text-align: justify;">&#160;</div>
              <div style="text-align: justify;">
                <table cellspacing="0" cellpadding="0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" id="zde2693d640274a6ca6b0182711f28a61">

                    <tr>
                      <td style="width: 14.99%; vertical-align: top;"></td>
                      <td colspan="2" style="width: 85.01%; vertical-align: top;">
                        <div style="color: #272118; text-align: justify; text-indent: 13.7pt;">
                          <div style="text-indent: 14.15pt; color: #272118; font-family: 'Times New Roman', Times, serif;">ADSs, each representing one Novartis AG share and evidenced by ADRs, are issued by our depositary JPMorgan Chase, and not by us. The
                            ADR is vested with rights defined and enumerated in the Deposit Agreement (such as the rights to vote, to receive a dividend and to receive a share of Novartis AG in exchange for a certain number of ADRs). The enumeration of
                            rights, including any limitations on those rights in the Deposit Agreement, is final. There are no other rights given to the ADR holders. Only the ADS depositary, holding our shares underlying the ADRs, is registered as
                            shareholder in our share register. An ADR is not a Novartis AG share and an ADR holder is not a Novartis AG shareholder.</div>
                          <div style="text-align: left; color: #272118; font-family: 'Times New Roman', Times, serif;">The Deposit Agreement between our depositary, the ADR holder and us has granted certain indirect rights to vote to the ADR holders. ADR
                            holders may not attend a General Meeting in person. ADR holders exercise their voting rights by instructing JPMorgan Chase., our depositary, to exercise the voting rights attached to the registered shares underlying the ADRs.
                            Each ADR represents one Novartis AG share. JPMorgan Chase exercises the voting rights for registered shares underlying ADRs for which no voting instructions have been given by providing a discretionary proxy to an uninstructed
                            independent designee. Such designee has to be a shareholder of Novartis AG. The same voting restrictions apply to ADR holders as to those holding Novartis AG shares (i.e., the right to vote up to 2% of the Novartis AG registered
                            share capital &#8211; unless otherwise granted an exemption by the Board &#8211; and the disclosure requirement for nominees).</div>
                        </div>
                        <div>&#160;</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 14.99%; vertical-align: top;" rowspan="1">(c)</td>
                      <td style="width: 85.01%; vertical-align: top;" rowspan="1" colspan="2">
                        <div>Shareholders have the right to allocate the profit shown on our balance sheet and to distribute dividends by vote taken at the General Meeting, subject to the legal requirements described in &#8220;&#8212;Item 10.B.3(a) Shareholder
                          rights.&#8221;</div>
                        <div>&#160; <br>
                        </div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 14.99%; vertical-align: top;" rowspan="1">(d) <br>
                      </td>
                      <td style="width: 85.01%; vertical-align: top;" rowspan="1" colspan="2">
                        <div>Under the Swiss CO, any surplus arising out of a liquidation of Novartis AG (i.e., after the settlement of all claims of all creditors) would be distributed to the shareholders in proportion to the paid&#8209;in nominal value of
                          their shares. <br>
                        </div>
                        <div> <br>
                        </div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 14.99%; vertical-align: top;" rowspan="1">(e) <br>
                      </td>
                      <td style="width: 85.01%; vertical-align: top;" rowspan="1" colspan="2">
                        <div style="text-align: justify; color: #272118; font-family: 'Times New Roman', Times, serif;">The Swiss CO limits a corporation&#8217;s ability to hold or repurchase its own shares. We and our subsidiaries may only repurchase shares if
                          we have sufficient freely disposable equity in the amount of the purchase price of the acquired shares. The aggregate nominal value of all Novartis AG shares held by us and our subsidiaries may not exceed 10% of our registered
                          share capital. However, it is accepted that a Swiss corporation may repurchase its own shares beyond the statutory limit of 10% if the repurchased shares are clearly earmarked for cancellation. In addition, we are required to
                          recognize a negative position, or if our subsidiaries acquire our shares, to create a special reserve on our balance sheet in the amount of the purchase price of the acquired shares. Repurchased shares held by us or our
                          subsidiaries do not carry any rights to vote at a General Meeting, but are entitled to the economic benefits generally connected with the shares. The definition of subsidiaries, and therefore, treasury shares, for purposes of the
                          above-described reserves requirement and voting restrictions, differs from the definition of subsidiaries for purposes of consolidation in our consolidated financial statements. The definition in the consolidated financial
                          statements requires consolidation for financial reporting purposes of special purpose entities in instances where we have the power to govern the financial and operating policies of the entity so as to obtain benefits from its
                          activities. Therefore, our consolidated financial statements include special purpose entities, mainly foundations, which do not qualify as subsidiaries subject to the reserve requirements and voting restrictions of the Swiss CO
                          because we do not hold a majority participation in these special purpose entities. Accordingly, no reserve requirements apply to shares held by such special purpose entities, and such entities are not restricted from independently
                          voting their shares.</div>
                        <div style="text-align: justify; text-indent: 14.15pt; color: #272118; font-family: 'Times New Roman', Times, serif;">Under the Swiss CO, we may not cancel treasury shares without the approval of a capital reduction by our
                          shareholders.</div>
                        &#160;</td>
                    </tr>
                    <tr>
                      <td style="width: 14.99%; vertical-align: top;">
                        <div style="color: #272118; text-align: left;">(f)</div>
                      </td>
                      <td style="width: 60.08%; vertical-align: top;">
                        <div style="color: #272118; text-align: justify;">Not applicable.</div>
                      </td>
                      <td style="width: 24.94%; vertical-align: top;">&#160;</td>
                    </tr>

                </table>
              </div>
              <div style="text-align: justify;">&#160;</div>
              <div style="text-align: justify;">&#160;</div>
              <div style="text-align: justify;">
                <div>
                  <div>
                    <div style="text-align: center;">4</div>
                    <div style="text-align: center;">&#160;</div>
                  </div>
                  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
                    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
                      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
                  </div>
                </div>
                <div>&#160;</div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" id="zdf03bce7cdb64fa08d67975b7e04003c">

        <tr>
          <td style="WIDTH: 15.01%; VERTICAL-ALIGN: top">
            <div style="color: #272118; text-align: left;">(g)</div>
          </td>
          <td colspan="2" style="WIDTH: 84.99%; VERTICAL-ALIGN: top">
            <div style="color: #272118; text-align: justify;">Since all of our issued and outstanding shares have been fully paid in, our shareholders are not obliged to make further contributions with respect to their shares.</div>
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="WIDTH: 15.01%; VERTICAL-ALIGN: top">
            <div style="color: #272118; text-align: left;">(h)</div>
          </td>
          <td colspan="2" style="WIDTH: 84.99%; VERTICAL-ALIGN: top">
            <div style="color: #272118; text-align: justify;">See &#8220;&#8212;Item&#160;10.B.3(b) Shareholder rights&#8221; and &#8220;&#8212;Item&#160;10.B.7 Change in control.&#8221;</div>
            <div>&#160;</div>
          </td>
        </tr>

    </table>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; font-weight: bold; color: #272118; text-align: left; margin-top: 3pt;">10.B.4 Changes to shareholder rights</div>
    <div style="font-family: 'Times New Roman'; color: #272118; text-align: justify; margin-left: 1.35pt;">Under the Swiss CO, we may not issue new shares without the prior approval of a capital increase by our shareholders. If a capital increase is
      approved, then our shareholders would generally have certain pre-emptive rights to obtain newly issued shares in an amount proportional to the nominal value of the shares they already hold. These pre-emptive rights could be excluded in certain
      limited circumstances with the approval of a resolution adopted at a General Meeting by a supermajority of two-thirds of the votes. In addition, we may not create shares with increased voting powers or place restrictions on the transfer of registered
      shares without the approval of a resolution adopted at a General Meeting by a supermajority of votes. In addition, see &#8220;&#8212;Item&#160;10.B.3(b) Shareholder rights&#8221; with regard to the Board&#8217;s ability to cancel the registration of shares under limited
      circumstances.</div>
    <div><br>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; font-weight: bold; color: #272118; text-align: left; margin-top: 3pt;">10.B.6 Limitations</div>
    <div style="font-family: 'Times New Roman'; color: #272118; text-align: justify; margin-left: 1.35pt;">There are no limitations under the Swiss CO or our Articles on the right of non&#8209;Swiss residents or nationals to own or vote shares other than the
      restrictions applicable to all shareholders. But see &#8220;&#8212;Item&#160;10.B.3(b) Shareholder rights&#8221; regarding conditions for exercising an ADR holder&#8217;s right to vote at a shareholder meeting.</div>
    <div><br>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; font-weight: bold; color: #272118; text-align: left; margin-top: 3pt;">10.B.7 Change in control</div>
    <div style="font-family: 'Times New Roman'; color: #272118; text-align: justify; margin-left: 1.35pt;">The Articles and the Board Regulations contain no provision that would have an effect of delaying, deferring or preventing a change in control of
      Novartis&#160;AG and that would operate only with respect to a merger, acquisition or corporate restructuring involving us or any of our subsidiaries.</div>
    <div style="font-family: 'Times New Roman'; color: #272118; text-align: justify; margin-left: 1.35pt; text-indent: 14.15pt;">According to the Swiss Merger Act, shareholders may pass a resolution to merge with another corporation at any time. Such a
      resolution would require the consent of at least two&#8209;thirds of all votes present at the necessary General Meeting.</div>
    <div style="font-family: 'Times New Roman'; color: #272118; text-align: justify; margin-left: 1.35pt; text-indent: 14.15pt;">Under the Swiss Financial Market Infrastructure Act, shareholders and groups of shareholders acting in concert who acquire more
      than 33 1/3% of our shares would be under an obligation to make an offer to acquire all remaining Novartis&#160;AG shares. Novartis&#160;AG has neither opted out from the mandatory takeover offer obligation nor opted to increase the threshold for mandatory
      takeover offers in its Articles.</div>
    <div><br>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; font-weight: bold; color: #272118; text-align: left; margin-top: 3pt;">10.B.8 Disclosure of shareholdings</div>
    <div style="font-family: 'Times New Roman'; color: #272118; text-align: justify; margin-left: 1.35pt;">Under the Swiss Financial Market Infrastructure Act, persons who directly, indirectly or in concert with other parties acquire or dispose of our
      shares or purchase or sale rights relating to our shares are required to notify us and the SIX of the level of their holdings whenever such holdings reach, exceed or fall below certain thresholds &#8211; 3%, 5%, 10%, 15%, 20%, 25%, 33 1/3%, 50% and 66 2/3%
      &#8211; of the voting rights represented by our share capital (whether exercisable or not). This also applies to anyone who has discretionary power to exercise voting rights associated with our shares. Following receipt of such notification, we are
      required to inform the public by publishing the information via the electronic publication platform operated by the SIX.</div>
    <div style="font-family: 'Times New Roman'; color: #272118; text-align: justify; margin-left: 1.35pt; text-indent: 14.15pt;">An additional disclosure obligation exists under the Swiss CO that requires us to disclose, once a year in the notes to the
      financial statements published in our Annual Report, the identity of all of our shareholders (or related groups of shareholders) who have been granted exemption entitling them to vote more than 2% of our registered share capital, as described in
      &#8220;&#8212;Item&#160;10.B.3(b) Shareholder rights.&#8221;</div>
    <div><br>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; font-weight: bold; color: #272118; text-align: left; margin-top: 3pt;">10.B.9 Differences in the law</div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; color: #272118; text-align: justify; margin-top: 3pt;">See the references to Swiss law throughout this &#8220;&#8212;Item&#160;10.B Memorandum and articles of association.&#8221;</div>
    <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; font-weight: bold; color: #272118; text-align: left; margin-top: 3pt;">10.B.10 Changes in capital</div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; color: #272118; text-align: justify; margin-top: 3pt;">The requirements of the Articles regarding changes in capital are not more stringent than the requirements of Swiss law.</div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; color: #272118; text-align: justify; margin-top: 3pt;">&#160;</div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; color: #272118; text-align: justify; margin-top: 3pt;">
      <div>&#160;</div>
      <div>
        <div>
          <div>
            <div style="text-align: center;">5</div>
            <div style="text-align: center;">&#160;</div>
          </div>
          <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
            <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
              <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
        </div>
        <div>&#160;</div>
      </div>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000; text-align: center; margin-top: 3pt;">AMERICAN DEPOSITARY SHARES</div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000; text-align: left; margin-top: 3pt;">Item 12. Other securities</div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; color: #000000; text-align: left; margin-top: 3pt;">Disclosures under Items 12.A, 12.B, and 12.C are not applicable.</div>
    <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000; text-align: left; margin-top: 3pt;">12.D.1 Depositary</div>
    <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; color: #000000; text-align: justify; margin-top: 3pt;">
      <div style="margin-top: 3pt; margin-bottom: 3pt; color: #000000;">JPMorgan Chase has been appointed as the depositary pursuant to the Deposit Agreement. JPMorgan Chase&#8217;s principal executive office is located at 383 Madison Avenue, Floor 11, New York,
        NY 10179.</div>
    </div>
    <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000; text-align: justify; margin-top: 3pt;">12.D.2 Provisions</div>
    <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; color: #000000; text-align: justify; margin-top: 3pt;">ADSs are issued by the depositary, and not by us. The ADR is vested with rights defined and enumerated in the Deposit Agreement (such
      as the rights to vote, to receive a dividend and to receive a share of Novartis&#160;AG in exchange for a certain number of ADRs). The enumeration of rights, including any limitations on those rights in the Deposit Agreement, is final. There are no other
      rights given to the ADR holders. Only the depositary is registered as shareholder in our share register. An ADR is not a Novartis&#160;AG share and an ADR holder is not a Novartis&#160;AG shareholder.</div>
    <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; color: #000000; text-align: justify; margin-top: 3pt;">The following is a summary of the material provisions of the Deposit Agreement. For more complete information, you should read the
      Deposit Agreement and form of ADR. The Deposit Agreement has been filed with the SEC as an exhibit to the Form F-6 filed with the SEC on December 16, 2022. </div>
    <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000; text-align: justify; margin-top: 3pt;">Voting rights</div>
    <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
    </div>
    <div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt; font-family: 'Times New Roman';"><font style="color: #272118;"> The</font><font style="color: #000000;"> Deposit Agreement has granted certain indirect rights to vote to the ADR
        holders. ADR holders may not attend Novartis&#160;AG general meetings in person. ADR holders exercise their voting rights by instructing the depositary to exercise the voting rights attached to the registered shares underlying the ADRs. The same voting
        restrictions apply to ADR holders as to those holding Novartis&#160;AG shares (i.e., the right to vote up to 2% of the Novartis&#160;AG registered share capital &#8211; unless otherwise granted an exemption by the Board &#8211; and the disclosure requirement for
        nominees).</font></div>
    <div style="font-family: 'Times New Roman'; text-align: justify; margin-left: 1.35pt; text-indent: 14.15pt;">
      <div style="margin: 0px 0px 3pt; font-family: 'Times New Roman', Times, serif; text-indent: 14.15pt;">
        <div style="margin-top: 3pt; margin-bottom: 3pt; font-family: 'Times New Roman';"><font style="color: #272118;">As</font><font style="color: #000000;"> soon as practicable after receipt from Novartis&#160;AG of notice of any meeting or solicitation of
            consents or proxies of holders of shares or other deposited securities, the depositary shall fix the ADR record date in accordance with the Deposit Agreement, provided that if the depositary receives a written request from Novartis AG in a
            timely manner and at least 30 days prior to the date of such vote or meeting the depositary shall, at Novartis AG&#8217;s expense, distribute to holders a notice (the &#8220;Voting Notice&#8221;) stating (a) such information as is contained in such notice and
            any solicitation materials (or a summary thereof), (b) that each holder on the record date set by the depositary therefor will be entitled, subject to applicable law and the provisions of or governing deposited securities to instruct the
            depositary as to the exercise of the voting rights, if any, pertaining to the deposited securities represented by the ADSs evidenced by such holder&#8217;s ADRs and (c) the manner in which such instructions may be given, including instructions to
            give a discretionary proxy to a person designated by Novartis AG.</font></div>
        <div style="margin-top: 3pt; margin-bottom: 3pt; font-family: 'Times New Roman';">
          <div style="margin-top: 3pt; margin-bottom: 3pt; color: #000000;">Upon actual receipt of instructions of a holder on such record date in the manner and on or before the date established by the depositary for such purpose, the depositary will
            endeavor insofar as practicable and permitted under the provisions of or governing deposited securities to vote or cause to be voted (or to grant a discretionary proxy to a person designated by Novartis&#160;AG) the deposited securities represented
            by the ADSs evidenced by such holder&#8217;s ADRs in accordance with such instructions. The depositary will not itself exercise any voting discretion in respect of any deposited securities. To the extent that (a) the depositary has been provided 35
            days&#8217; notice of the proposed meeting from Novartis AG, (b) the Voting Notice is sent to holders and beneficial owners no less than 14 days prior to the date of the meeting or the cut-off date for the solicitation of consents and (c) the
            depositary does not receive instructions on a particular agenda item from a holder in a timely manner, such holder shall be deemed and the depositary shall deem such holder to have so instructed the depositary to give a discretionary proxy to a
            person designated by Novartis&#160;AG and the depositary shall endeavor insofar as practicable and permitted under the provisions of or governing deposited securities to give a discretionary proxy to a person designated by Novartis&#160;AG to vote the
            deposited securities represented by the ADSs evidenced by such holder&#8217;s ADRs as to which such instructions are so given with respect to such agenda item(s), provided that no such instruction shall be deemed given unless Novartis AG promptly
            informs the depositary in writing that Novartis AG wishes such proxy be given with respect to such agenda item(s).</div>
          <font style="color: #000000;"> </font></div>
        <font style="color: #000000;"> </font></div>
      <font style="color: #000000;"></font></div>
    <div style="font-family: 'Times New Roman'; text-align: justify; margin-left: 1.35pt; text-indent: 14.15pt;">
      <div style="margin-bottom: 3pt; color: #272118; margin-top: 3pt;">
        <div>&#160;</div>
        <div>
          <div>
            <div>
              <div style="text-align: center;">6</div>
              <div style="text-align: center;">&#160;</div>
            </div>
            <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
              <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always">
                <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
            </div>
          </div>
          <div style="margin-bottom: 3pt; color: #000000; margin-top: 3pt;"> <br>
          </div>
          <div style="margin-bottom: 3pt; color: #000000; margin-top: 3pt;">Notwithstanding anything contained in the Deposit Agreement or any ADR, the depositary may, to the extent not prohibited by any law, rule or regulation or the rules and/or
            requirements of the stock exchange on which the ADSs are listed, in lieu of distribution of the materials provided to the depositary in connection with any meeting of or solicitation of consents or proxies from holders of deposited securities,
            distribute to the holders a notice that provides holders with or otherwise publicizes to holders instructions on how to retrieve such materials or receive such materials upon request (i.e., by reference to a website containing the materials for
            retrieval or a contact for requesting copies of the materials).&#160; Holders are strongly encouraged to forward their voting instructions as soon as possible.&#160; Voting instructions will not be deemed received until such time as the ADR department
            responsible for proxies and voting has received such instructions, notwithstanding that such instructions may have been physically received by JPMorgan, prior to such time. <br>
          </div>
          <div style="margin-bottom: 3pt; color: #000000; margin-top: 3pt;"> <br>
          </div>
        </div>
      </div>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000; text-align: left; margin-top: 3pt;">Share dividends and other distributions</div>
    <div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt; color: #000000; font-family: 'Times New Roman';">
      <div style="margin-bottom: 3pt; color: #000000; text-align: justify; margin-top: 3pt;">&#160;</div>
      The depositary will distribute to each ADR holder on the record date set by the depositary at such ADR holder&#8217;s address shown on the ADR Register, in proportion to the number of deposited securities (on which the following distributions on deposited
      securities are received by the custodian) represented by ADSs evidenced by such holder&#8217;s ADRs:</div>
    <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><font style="font-family: 'Times New Roman'; background-color: #ffffff;"><font style="background-color: #ffffff;"> </font></font></div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; color: #000000; text-align: justify; margin-top: 3pt;">
      <div style="margin-bottom: 3pt; color: #000000; text-align: left; margin-top: 3pt;"><font style="background-color: #ffffff;"></font>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" id="z20b246e3c7844c14968b878c38d4823d">

          <tr>
            <td style="WIDTH: 15.38%; VERTICAL-ALIGN: top">
              <div style="color: #000000; text-align: left;">(a)</div>
            </td>
            <td style="WIDTH: 84.62%; VERTICAL-ALIGN: top">
              <div style="text-align: left; color: #000000;"><font style="background-color: #ffffff;"></font><font style="font-style: italic;">Cash: </font>Any US dollars available to the depositary resulting from a cash dividend or other cash
                distribution or the net proceeds of sales of any other distribution or portion thereof authorized in paragraph 10 (&#8220;Cash&#8221;) of the form of ADR, on an averaged or other practicable basis, subject to (i) appropriate adjustments for taxes
                withheld, (ii) such distribution being impermissible or impracticable with respect to certain holders, and (iii) deduction of the depositary&#8217;s and/or its agent&#8217;s fees and expenses in (1) converting any foreign currency to US dollars by sale
                or in such other manner as the depositary may determine to the extent that it determines that such conversion may be made on a reasonable basis, (2) transferring foreign currency or US dollars to the US by such means as the depositary may
                determine to the extent that it determines that such transfer may be made on a reasonable basis, (3) obtaining any approval or license of any governmental authority required for such conversion or transfer, which is obtainable at a
                reasonable cost and within a reasonable time and (4) making any sale by public or private means in any commercially reasonable manner.</div>
              <div style="color: #000000; text-align: justify;"><font style="background-color: #ffffff;"> </font></div>
            </td>
          </tr>

      </table>
      <div style="margin-bottom: 3pt; color: #000000; text-align: left; margin-top: 3pt;"><font style="background-color: #ffffff;"></font>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" id="z80f5e8df809942bd9fa772021814a174">

          <tr>
            <td style="WIDTH: 15.38%; VERTICAL-ALIGN: top">
              <div style="color: #000000; text-align: left;">(b)</div>
            </td>
            <td style="WIDTH: 84.62%; VERTICAL-ALIGN: top">
              <div style="color: #000000; text-align: justify;"><font style="font-style: italic;">Shares</font><font style="background-color: #ffffff;">. (i) Additional ADRs evidencing whole ADSs representing any shares available to the depositary
                  resulting from a dividend or free distribution on deposited securities consisting of shares (a &#8220;Share Distribution&#8221;) and (ii) US dollars available to it resulting from the net proceeds of sales of shares received in a Share Distribution,
                  which shares would give rise to fractional ADSs if additional ADRs were issued therefor, as in the case of Cash.</font></div>
            </td>
          </tr>

      </table>
      <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><font style="background-color: #ffffff;"><br>
        </font></div>
      <table cellspacing="0" cellpadding="0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" id="zf1eb8a4fbdb54d60b6befc6b5c4cc387">

          <tr>
            <td style="WIDTH: 15.38%; VERTICAL-ALIGN: top">
              <div style="color: #000000; text-align: left;">(c)</div>
            </td>
            <td style="WIDTH: 84.62%; VERTICAL-ALIGN: top">
              <div style="text-align: left; color: #000000;"><font style="font-style: italic;">Rights</font>. (i) Warrants or other instruments in the discretion of the depositary representing rights to acquire additional ADRs in respect of any rights to
                subscribe for additional shares or rights of any nature available to the depositary as a result of a distribution on deposited securities (&#8220;Rights&#8221;), to the extent that Novartis&#160;AG timely furnishes to the depositary evidence satisfactory to
                the depositary that the depositary may lawfully distribute the same (Novartis&#160;AG has no obligation to so furnish such evidence), or (ii) to the extent Novartis&#160;AG does not so furnish such evidence and sales of Rights are practicable, any US
                dollars available to the depositary from the net proceeds of sales of Rights as in the case of Cash, or (iii) to the extent Novartis&#160;AG does not so furnish such evidence and such sales cannot practicably be accomplished by reason of the
                nontransferability of the Rights, limited markets therefor, their short duration or otherwise, nothing (and any Rights may lapse).</div>
              <div style="color: #000000; text-align: justify;"><font style="background-color: #ffffff;"> </font></div>
            </td>
          </tr>

      </table>
      <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><font style="background-color: #ffffff;"><br>
        </font></div>
      <table cellspacing="0" cellpadding="0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; WIDTH: 100%" id="zbdc0962b7c4545adae5d80ce14756133">

          <tr>
            <td style="WIDTH: 15.38%; VERTICAL-ALIGN: top">
              <div style="color: #000000; text-align: left;">(d)</div>
            </td>
            <td style="WIDTH: 84.62%; VERTICAL-ALIGN: top">
              <div style="color: #000000; text-align: justify;"><font style="font-style: italic;">Other Distributions</font><font style="background-color: #ffffff;">. (i) Securities or property available to the depositary resulting from any distribution on
                  deposited securities other than Cash, Share Distributions and Rights (&#8220;Other Distributions&#8221;), by any means that the depositary may deem equitable and practicable, or (ii) to the extent the depositary deems distribution of such securities
                  or property not to be equitable and practicable, any US dollars available to the depositary from the net proceeds of sales of Other Distributions as in the case of Cash. The depositary shall endeavor to conduct any sales hereunder in a
                  commercially reasonable manner.</font></div>
            </td>
          </tr>

      </table>
      <div style="BACKGROUND-COLOR: #ffffff"><font style="background-color: #ffffff;"></font>
        <div><font style="background-color: #ffffff;"><br>
          </font></div>
        <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><font style="background-color: #ffffff;"></font>
          <div style="margin-bottom: 3pt; color: #272118; margin-top: 3pt;"><font style="background-color: #ffffff;"></font>
            <div><font style="background-color: #ffffff;"></font>&#160;</div>
            <div><font style="background-color: #ffffff;"></font>
              <div><font style="background-color: #ffffff;"></font>
                <div><font style="background-color: #ffffff;"></font>
                  <div style="text-align: center;"><font style="background-color: #ffffff;"></font>
                    <div><font style="background-color: #ffffff;">7</font></div>
                    <div><font style="background-color: #ffffff;"></font>&#160;</div>
                    <font style="background-color: #ffffff;"></font></div>
                </div>
                <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt"><font style="background-color: #ffffff;"></font>
                  <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always"><font style="background-color: #ffffff;"></font>
                    <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
                </div>
              </div>
              <div><font style="background-color: #ffffff;"></font><br>
                &#160;</div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; color: #000000; text-align: justify; margin-top: 3pt;"><font style="background-color: #ffffff;">The depositary will distribute US dollars by checks drawn on a bank in the US for whole
        dollars and cents (any fractional cents being withheld without liability for interest and dealt with by the depositary in accordance with its then current procedures), pursuant to paragraph 10 of the form of ADR.</font></div>
    <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000; text-align: left; margin-top: 3pt;">Deposit, withdrawal and cancellation</div>
    <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; color: #000000; text-align: justify; margin-top: 3pt;">
      <div style="margin-top: 3pt; margin-bottom: 3pt; color: #000000;">Subject to paragraphs 4 and 5 of the form of ADR, upon surrender of (i) a certificated ADR in a form satisfactory to the depositary at the transfer office or (ii) proper instructions
        and documentation in the case of a Direct Registration ADR, the holder hereof is entitled to delivery at, or to the extent in dematerialized form from, the custodian&#8217;s office of the deposited securities at the time represented by the ADSs evidenced
        by this ADR. At the request, risk and expense of the holder, the depositary may deliver such deposited securities at such other place as may have been requested by the holder. Notwithstanding any other provision of the deposit agreement or this
        ADR, the withdrawal of deposited securities may be restricted only for the reasons set forth in General Instruction I.A.(1) of Form F-6 (as such instructions may be amended from time to time) under the Securities Act.</div>
      <font style="background-color: #ffffff;"> </font></div>
    <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000; text-align: left; margin-top: 3pt;">Reclassification, recapitalizations and mergers</div>
    <div style="margin: 0px; color: #000000; font-family: 'Times New Roman'; text-align: justify;">
      <div style="margin-bottom: 3pt; color: #000000; margin-top: 3pt;">&#160;</div>
      The depositary may, in its discretion, and shall if reasonably requested by Novartis AG, amend the ADR or distribute additional or amended ADRs (with or without calling existing ADRs for exchange) or cash, securities or property on the record date
      set by the depositary therefor to reflect any change in par value, split-up, consolidation, cancellation or other reclassification of deposited securities, any share distribution or other distribution not distributed to holders or any cash,
      securities or property available to the depositary in respect of deposited securities from (and the depositary is authorized under the Deposit Agreement to surrender any deposited securities to any person and, irrespective of whether such deposited
      securities are surrendered or otherwise cancelled by operation of law, rule, regulation or otherwise, to sell by public or private sale any property received in connection with) any recapitalization, reorganization, merger, consolidation,
      liquidation, receivership, bankruptcy or sale of all or substantially all the assets of Novartis AG.</div>
    <div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt; color: #000000; font-family: 'Times New Roman';">
      <div style="margin: 0px; color: #000000; text-indent: 14pt;">To the extent the depositary does not so amend the ADR or make a distribution to holders to reflect any of the foregoing, or the net proceeds thereof, whatever cash, securities or property
        results from any of the foregoing shall constitute deposited securities and each ADS evidenced by the ADRs shall automatically represent its pro rata interest in the deposited securities as then constituted.</div>
      <div style="margin: 0px; color: #000000; text-indent: 14pt;">Promptly upon the occurrence of any of the aforementioned changes affecting deposited securities, Novartis AG shall notify the depositary in writing of such occurrence and as soon as
        practicable after receipt of such notice from Novartis AG, may instruct the depositary to give notice thereof, at Novartis AG&#8217;s expense, to holders in accordance with the provisions hereof. Upon receipt of such instruction, the depositary shall
        give notice to the holders in accordance with the terms thereof, as soon as reasonably practicable.</div>
    </div>
    <div style="BACKGROUND-COLOR: #ffffff">
      <div>
        <div><br>
        </div>
      </div>
      <font style="FONT-FAMILY: 'Times New Roman'"> </font></div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000; text-align: left; margin-top: 3pt;">Amendment and termination</div>
    <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
    </div>
    <div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt; color: #000000; font-family: 'Times New Roman';">The ADRs and the Deposit Agreement may be amended by Novartis&#160;AG and the depositary, provided that any amendment that imposes or
      increases any fees or charges on a per ADS basis (other than stock transfer or other taxes and other governmental charges, transfer or registration fees, a transaction fee per cancellation request (including through SWIFT, telex or facsimile
      transmission), applicable delivery expenses or other such fees, charges or expenses), or that shall otherwise prejudice any substantial existing right of holders or beneficial owners, shall become effective 30 days after notice of such amendment
      shall have been given to the holders. Every holder and beneficial owner at the time any amendment to the Deposit Agreement so becomes effective shall be deemed, by continuing to hold such ADR, to consent and agree to such amendment and to be bound by
      the Deposit Agreement as amended thereby. Any amendments or supplements which (i) are reasonably necessary (as agreed by Novartis AG and the depositary) in order for (a) the ADSs to be registered on Form F-6 under the Securities Act or (b) the ADSs
      or Shares to be traded solely in electronic book-entry form and (ii) do not in either such case impose or increase any fees or charges to be borne by holders, shall be deemed not to prejudice any substantial rights of holders or beneficial owners.&#160;
      Notwithstanding the foregoing, if any governmental body or regulatory body should adopt new laws, rules or regulations which would require amendment or supplement of the Deposit Agreement or the form of ADR to ensure compliance therewith, Novartis AG
      and the depositary may amend or supplement the Deposit Agreement and the ADR at any time in accordance with such changed laws, rules or regulations.</div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; color: #000000; text-align: justify; margin-left: 1.35pt; margin-top: 3pt; text-indent: 14.15pt;"><font style="background-color: #ffffff;"></font>
      <div style="BACKGROUND-COLOR: #ffffff"><font style="background-color: #ffffff;"></font>
        <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt">
          <div style="margin-bottom: 3pt; color: #272118; margin-top: 3pt;">
            <div><font style="background-color: #ffffff;"></font>&#160;</div>
            <div><font style="background-color: #ffffff;"></font>
              <div><font style="background-color: #ffffff;"></font>
                <div><font style="background-color: #ffffff;"></font>
                  <div style="text-align: center;"><font style="background-color: #ffffff;"></font>
                    <div><font style="background-color: #ffffff;"><font style="background-color: #ffffff;">8</font></font></div>
                  </div>
                  <div style="text-align: center;"><font style="background-color: #ffffff;"></font>&#160;</div>
                </div>
                <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt"><font style="background-color: #ffffff;"></font>
                  <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always"><font style="background-color: #ffffff;"></font>
                    <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
                </div>
              </div>
              <div><br>
              </div>
              <div>
                <div style="margin: 3pt 0px; color: #000000; text-indent: 0px;">Such amendment or supplement to the Deposit Agreement in such circumstances may become effective before a notice of such amendment or supplement is given to holders or within
                  any other period of time as required for compliance. Notice of any amendment to the Deposit Agreement or form of ADRs shall not need to describe in detail the specific amendments effectuated thereby, and failure to describe the specific
                  amendments in any such notice shall not render such notice invalid, provided, however, that, in each such case, the notice given to the holders identifies a means for holders and beneficial owners to retrieve or receive the text of such
                  amendment (i.e., upon retrieval from the SEC&#8217;s, the depositary&#8217;s or Novartis AG&#8217;s website or upon request from the depositary).&#160; </div>
                <div style="color: #000000; margin-left: 1.35pt; text-indent: 14.15pt;">
                  <div style="margin-top: 3pt; margin-bottom: 3pt; color: #000000;">The depositary may, and shall at the written direction of Novartis&#160;AG, terminate the Deposit Agreement and this ADR by mailing notice of such termination to the holders at
                    least 30 days prior to the date fixed in such notice for such termination; provided, however, if the depositary shall have (i) resigned as depositary hereunder, notice of such termination by the depositary shall not be provided to
                    holders unless a successor depositary shall not be operating hereunder within 60 days of the date of such resignation, or (ii) been removed as depositary hereunder, notice of such termination by the depositary shall not be provided to
                    holders unless a successor depositary shall not be operating hereunder on the 60th day after Novartis AG&#8217;s notice of removal was first provided to the depositary.</div>
                </div>
              </div>
              <div>
                <div style="margin-top: 3pt; margin-bottom: 3pt; color: #000000;">Notwithstanding anything to the contrary in the Deposit Agreement, the depositary may terminate the Deposit Agreement without notice to Novartis AG, but subject to giving 30
                  days&#8217; notice to the holders, under the following circumstances: (i) in the event of Novartis AG&#8217;s bankruptcy or insolvency, (ii) if the shares cease to be listed on an internationally recognized stock exchange, (iii) if Novartis AG
                  effects (or will effect) a redemption of all or substantially all of the deposited securities, or a cash or share distribution representing a return of all or substantially all of the value of the deposited securities, or (iv) there
                  occurs a merger, consolidation, sale of assets or other transaction as a result of which securities or other property are delivered in exchange for or in lieu of deposited securities.</div>
                <div style="margin-top: 3pt; margin-bottom: 3pt; color: #000000;">
                  <div style="margin-top: 3pt; margin-bottom: 3pt;"><font style="color: #000000;">After the date so fixed for termination, the depositary and its agents will perform no further acts under the Deposit Agreement and this ADR, except to
                      receive and hold (or sell) distributions on deposited securities and deliver deposited securities being withdrawn. As soon as practicable after the date so fixed for termination, the depositary shall use its reasonable efforts to sell
                      the deposited securities and shall thereafter (as long as it may lawfully do so) hold in an account (which may be a segregated or unsegregated account) the net proceeds of such sales, together with any other cash then held by it under
                      the Deposit Agreement, without liability for interest, in trust for the pro rata benefit of the holders of ADRs not theretofore surrendered. After making such sale, the depositary shall be discharged from all obligations in respect of
                      the Deposit</font><font style="color: #272118;"> Agreement and this ADR, except to account for such net proceeds and other cash. After the date so fixed for termination, Novartis&#160;AG will be discharged from all obligations under the
                      Deposit Agreement except for its obligations to the depositary and its agents.</font></div>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; color: #000000; text-align: left; margin-top: 3pt;">&#160;</div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000; text-align: left; margin-top: 3pt;">Limitation on obligations and liability to ADR holders</div>
    <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
    </div>
    <div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt; color: #000000; font-family: 'Times New Roman';">The depositary, Novartis&#160;AG, their respective directors, officers, employees, agents and affiliates and each of them shall: (i) incur
      no liability to holders or beneficial owners (a) if any present or future law, rule, regulation, fiat, order or decree of the US, Switzerland or any other country or jurisdiction, or of any governmental or regulatory authority or any securities
      exchange or market or automated quotation system, the provisions of or governing any deposited securities, any present or future provision of Novartis AG&#8217;s Articles, any act of God, war, terrorism, nationalization, epidemic, pandemic, expropriation,
      currency restrictions, work stoppage, strike, civil unrest, revolutions, rebellions, explosions, computer failure or circumstance beyond its direct and immediate control shall prevent or delay, or shall cause any of them to be subject to any civil or
      criminal penalty in connection with, any act which the Deposit Agreement or the ADR provides shall be done or performed by it, or (b) by reason of any non-performance or delay, caused as aforesaid, in the performance of any act or things which by the
      terms of the Deposit Agreement it is provided shall or may be done or performed or any exercise or failure to exercise any discretion given it in the Deposit Agreement or the ADR (including, without limitation, any failure to determine that any
      distribution or action may be lawful or reasonably practicable); (ii) not incur or assume any liability to holders or beneficial owners except to perform its obligations to the extent they are specifically set forth in the ADR and the Deposit
      Agreement without gross negligence or willful misconduct and the depositary shall not be a fiduciary or have any fiduciary duty to holders or beneficial owners; (iii) in the case of the depositary and its agents, be under no obligation to appear in,
      prosecute or defend any action, suit or other proceeding in respect of any deposited securities, ADSs or the ADR; (iv) in the case of Novartis AG and its agents hereunder be under no obligation to appear in, prosecute or defend any action, suit or
      other proceeding in respect of any deposited securities, the ADSs, or the ADR, which in its opinion may involve it in expense or liability, unless indemnity satisfactory to it in its sole discretion against all expense (including fees and
      disbursements of counsel) and liability be furnished as often as may be required; and (v) not be liable to holders or beneficial owners for any action or inaction by it in reliance upon the advice of or information from legal counsel, accountants,
      any person presenting shares for deposit, any holder, any other person believed by it to be competent to give such advice or information, or in the case of the depositary only, Novartis AG.</div>
    <div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt; color: #000000; font-family: 'Times New Roman';">
      <div style="margin: 3pt 0px; color: #000000; text-indent: 14pt;">
        <div>&#160;</div>
        <div>
          <div>
            <div>
              <div style="text-align: center;">
                <div><font style="background-color: #ffffff;"><font style="background-color: #ffffff;">9</font></font></div>
              </div>
              <div style="text-align: center;">&#160;</div>
            </div>
            <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt"><font style="background-color: #ffffff;"></font>
              <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always"><font style="background-color: #ffffff;"></font>
                <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
            </div>
          </div>
        </div>
      </div>
      <div style="margin: 3pt 0px; color: #000000; text-indent: 14pt;"> <br>
      </div>
      <div style="margin: 3pt 0px; color: #000000; text-indent: 14pt;">
        <div style="margin-top: 3pt; margin-bottom: 3pt; color: #000000;"> The depositary shall not be responsible for, and shall incur no liability in connection with or arising from, the insolvency of any custodian that is not a branch or affiliate of
          JPMorgan. The depositary shall not have any liability for the price received in connection with any sale of securities, the timing thereof or any delay in action or omission to act nor shall it be responsible for any error or delay in action,
          omission to act, default or negligence on the part of the party so retained in connection with any such sale or proposed sale. Notwithstanding anything to the contrary contained in the Deposit Agreement and any ADRs, the depositary shall not be
          responsible for, and shall incur no liability in connection with or arising from, any act or omission to act on the part of the custodian except to the extent that any holder has incurred liability directly as a result of the custodian having (i)
          committed fraud or willful misconduct in the provision of custodial services to the depositary or (ii) failed to use reasonable care in the provision of custodial services to the depositary as determined in accordance with the standards
          prevailing in the jurisdiction in which the custodian is located. Notwithstanding anything to the contrary contained in the Deposit Agreement or any ADRs, the depositary and the custodian(s) may use third party delivery services and providers of
          information regarding matters such as pricing, proxy voting, corporate actions, class action litigation and other services in connection herewith and the Deposit Agreement, and use local agents to provide services such as, but not limited to,
          attendance at any meetings of security holders. Although the depositary and the custodian will use reasonable care (and cause their agents to use reasonable care) in the selection and retention of such third-party providers and local agents, they
          will not be responsible for any errors or omissions made by them in providing the relevant information or services.</div>
        <div style="margin-top: 3pt; margin-bottom: 3pt; color: #000000;">The depositary has no obligation to inform holders or beneficial owners about the requirements of the laws, rules or regulations or any changes therein or thereto of any country or
          jurisdiction or of any governmental or regulatory authority or any securities exchange or market or automated quotation system. Additionally, the depositary is under no obligation to provide the holders and beneficial owners, or any of them, with
          any information about the tax status of Novartis AG. The depositary and Novartis AG shall not incur any liability for any tax or tax consequences that may be incurred by holders or beneficial owners on account of their ownership or disposition of
          the ADRs or ADSs. None of the depositary, the custodian or Novartis AG shall be liable for the failure by any holder or beneficial owner to obtain the benefits of credits or refunds of non-US tax paid against such holder&#8217;s or beneficial owner&#8217;s
          income tax liability.</div>
        <div style="margin-top: 3pt; margin-bottom: 3pt; color: #000000;">
          <div style="margin-top: 3pt; margin-bottom: 3pt; color: #000000;">The depositary, its agents and Novartis&#160;AG may rely and shall be protected in acting upon any written notice, request, direction, instruction or document believed by them to be
            genuine and to have been signed, presented or given by the proper party or parties. The depositary and its agents will not be responsible for any failure to carry out any instructions to vote any of the deposited securities, for the manner in
            which any such vote is cast or for the effect of any such vote. Additionally, the depositary may rely upon instructions from Novartis AG or its counsel in respect of any approval or license required for any currency conversion, transfer or
            distribution. The depositary shall not incur any liability for the content of any information submitted to it by or on behalf of Novartis AG for distribution to the holders or for any inaccuracy of any translation thereof, for any investment
            risk associated with acquiring an interest in the deposited securities, for the validity or worth of the deposited securities, for the credit-worthiness of any third party, for allowing any rights to lapse upon the terms of the deposit
            agreement or for the failure or timeliness of any notice from Novartis AG. The depositary shall not be liable for any acts or omissions made by a successor depositary whether in connection with a previous act or omission of the depositary or in
            connection with any matter arising wholly after the removal or resignation of the depositary. Novartis&#160;AG has agreed to indemnify the depositary and its agents under certain circumstances and the depositary has agreed to indemnify Novartis&#160;AG
            under certain circumstances.</div>
          <div style="margin-top: 3pt; margin-bottom: 3pt; color: #000000;">
            <div style="margin-top: 3pt; margin-bottom: 3pt; color: #000000;">Neither Novartis AG, the depositary nor any of their respective agents shall be liable to holders or beneficial owners for any indirect, special, punitive or consequential
              damages (including, without limitation, legal fees and expenses) or lost profits, in each case of any form incurred by any person or entity (including, without limitation, holders and beneficial owners), whether or not foreseeable and
              regardless of the type of action in which such a claim may be brought.</div>
            <div style="margin-top: 3pt; margin-bottom: 3pt; color: #000000;">No provision of the Deposit Agreement or the ADR is intended to constitute a wavier or limitation of any rights which holders or beneficial owners may have under the Securities
              Act or the Exchange Act, to the extent applicable.</div>
            <div style="margin-top: 3pt; margin-bottom: 3pt; color: #000000;">
              <div style="margin-top: 3pt; margin-bottom: 3pt; color: #000000;">The depositary and its agents may own and deal in any class of securities of Novartis&#160;AG and its affiliates and in ADRs.</div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; color: #000000; text-align: justify; margin-top: 3pt;"> </div>
    <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
    </div>
    <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt">
      <div>&#160;</div>
      <div>
        <div>
          <div>
            <div style="text-align: center;"> <font style="font-family: 'Times New Roman';">10</font><br>
            </div>
            <div style="text-align: center;">&#160;</div>
          </div>
          <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt"><font style="background-color: #ffffff;"></font>
            <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always"><font style="background-color: #ffffff;"></font>
              <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
        </div>
      </div>
    </div>
    <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; font-weight: bold; color: #000000; text-align: left; margin-top: 3pt;">Books of depositary</div>
    <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
    </div>
    <div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt; color: #000000; font-family: 'Times New Roman';">The depositary or its agent will maintain, at a designated office, a register for the registration, registration of transfer,
      combination and split-up of ADRs, and, in the case of Direct Registration ADRs, shall include the Direct Registration System. Holders of ADRs may inspect such records at the depositary&#8217;s office at all reasonable times, but solely for the purpose of
      communicating with other holders in the interest of the business Novartis AG or a matter relating to the deposit agreement.<font style="font-family: 'Times New Roman', serif; font-size: 12pt;">&#160;</font>The depositary will maintain facilities for the
      delivery and receipt of ADRs.</div>
    <div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt; color: #000000; font-family: 'Times New Roman';">
      <div>
        <div><br>
        </div>
        <div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt; color: #272118; font-weight: bold;">Governing Law</div>
        <div style="margin-top: 3pt; margin-bottom: 3pt;"><br>
        </div>
        <div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt; color: #272118;">The Deposit Agreement, the ADSs and the ADRs are governed by and construed in accordance with the internal laws of the State of New York. In the Deposit
          Agreement, Novartis AG irrevocably agrees that any legal suit, action or proceeding against Novartis AG brought by the depositary or any holder, arising out of or based upon this Deposit Agreement, the ADSs or the ADRs or the transactions
          contemplated hereby or thereby, may be instituted in any state or federal court in New York, NY, and irrevocably waives any objection which it may now or hereafter have to the laying of venue of any such proceeding, and irrevocably submits to the
          non-exclusive jurisdiction of such courts in any such suit, action or proceeding. Novartis AG also irrevocably agrees that any legal suit, action or proceeding against the depositary brought by it, arising out of or based upon this Deposit
          Agreement or the transactions contemplated hereby, may only be instituted in a state or federal court in New York, NY.</div>
        <div style="margin: 3pt 0px; color: #272118; text-align: justify; text-indent: 14pt;">Under the Deposit Agreement, by holding an ADS or an interest therein, holders and beneficial owners each irrevocably agree that any legal suit, action or
          proceeding against or involving Novartis AG or the depositary, arising out of or based upon this Deposit Agreement, the ADSs, the ADRs or the transactions contemplated herein, therein or hereby, may only be instituted in a state or federal court
          in New York, NY, and by holding an ADS or an interest therein each irrevocably waives any objection which it may now or hereafter have to the laying of venue of any such proceeding, and irrevocably submits to the exclusive jurisdiction of such
          courts in any such suit, action or proceeding.</div>
        <div style="margin: 3pt 0px; color: #272118; text-align: justify; text-indent: 14pt;">Notwithstanding the foregoing, any action against Novartis AG based on the Deposit Agreement, the ADSs or the ADRs or the transactions contemplated hereby or
          thereby, may be instituted by the depositary in any competent court in Switzerland and/or the US.</div>
        <div style="margin-top: 3pt; margin-bottom: 3pt;"><br>
        </div>
        <div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt; color: #272118; font-weight: bold;">Jury Trial Waiver</div>
        <div style="margin-top: 3pt; margin-bottom: 3pt;"><br>
        </div>
        <div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt; color: #272118;">Each party to the Deposit Agreement (including, for avoidance of doubt, each holder and beneficial owner and/or holder of interests in ADSs and ADRs) irrevocably
          waives, to the fullest extent permitted by applicable law, any right it may have to a trial by jury in any suit, action or proceeding against the depositary and/or us directly or indirectly arising out of or relating to the shares or other
          deposited securities, the ADSs or the ADRs, the deposit agreement or any transaction contemplated therein, or the breach thereof (whether based on contract, tort, common law or any other theory), including any suit, action, claim or proceeding
          under the US federal securities laws.</div>
        <div><br>
        </div>
      </div>
    </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; text-align: justify; margin-top: 3pt;"> </div>
    <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; text-align: left; margin-top: 3pt;">&#160;</div>
    <div class="BRPFPageFooter">
      <div style="margin-bottom: 3pt; font-family: 'Times New Roman'; color: #000000; text-align: justify; margin-top: 3pt;"><font style="background-color: #ffffff;"></font>
        <div style="BACKGROUND-COLOR: #ffffff"><font style="background-color: #ffffff;"></font>
          <div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><font style="background-color: #ffffff;"></font>
            <div style="margin-bottom: 3pt; color: #272118; margin-top: 3pt;"><font style="background-color: #ffffff;"></font>
              <div><font style="background-color: #ffffff;"></font>&#160;</div>
              <div><font style="background-color: #ffffff;"></font>&#160;</div>
              <div><font style="background-color: #ffffff;"></font>
                <div><font style="background-color: #ffffff;"></font>
                  <div><font style="background-color: #ffffff;"></font>
                    <div style="text-align: center;"> 11<br>
                    </div>
                    <div style="text-align: center;"><font style="background-color: #ffffff;"></font>&#160;</div>
                  </div>
                  <div class="BRPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt"><font style="background-color: #ffffff;"></font>
                    <div class="BRPFPageBreak" style="PAGE-BREAK-AFTER: always"><font style="background-color: #ffffff;"></font>
                      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
                  </div>
                </div>
                <div><font style="background-color: #ffffff;"></font><br>
                  &#160;</div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>


</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12
<SEQUENCE>3
<FILENAME>a23020120f-ex12_1.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>

<html>
<head>
<title>EXHIBIT 12.1</title>
</head>
<body bgcolor="#ffffff">



    <div style="text-align:right;font-weight: bold;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Exhibit&nbsp;12.1 </div>
<div style="text-align:center;font-weight: bold;padding-bottom:30px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">CERTIFICATION</div>
<div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">I, Vasant Narasimhan, certify that: </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">1.   I have reviewed this annual report on Form&nbsp;20-F of Novartis AG; </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">2.  Based on my knowledge, this report does not contain any untrue statement of a material
   fact or omit to state a material fact necessary to make the statements made, in light
   of the circumstances under which such statements were made, not misleading with respect
   to the period covered by this report;
</div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">3.  Based on my knowledge, the financial statements, and other financial information included
   in this report, fairly present in all material respects the financial condition, results
   of operations and cash flows of the company as of, and for, the periods presented
   in this report;
</div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">4.   The company&#x2019;s other certifying officer and I are responsible for establishing and
   maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the company and have:
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">a)  designed such disclosure controls and procedures, or caused such disclosure controls
   and procedures to be designed under our supervision, to ensure that material information
   relating to the company, including its consolidated subsidiaries, is made known to
   us by others within those entities, particularly during the period in which this report
   is being prepared;
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">b)  designed such internal control over financial reporting, or caused such internal control
   over financial reporting to be designed under our supervision, to provide reasonable
   assurance regarding the reliability of financial reporting and the preparation of
   financial statements for external purposes in accordance with generally accepted accounting
   principles;
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">c)  evaluated the effectiveness of the company&#x2019;s disclosure controls and procedures and
   presented in this report our conclusions about the effectiveness of the disclosure
   controls and procedures, as of the end of the period covered by this report based
   on such evaluation; and
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">d)  disclosed in this report any change in the company&#x2019;s internal control over financial
   reporting that occurred during the period covered by the annual report that has materially
   affected, or is reasonably likely to materially affect, the company&#x2019;s internal control
   over financial reporting; and
</div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">5.  The company&#x2019;s other certifying officer and I have disclosed, based on our most recent
   evaluation of internal control over financial reporting, to the company&#x2019;s auditors
   and the audit committee of the company&#x2019;s board of directors (or persons performing
   the equivalent functions):
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">a)  all significant deficiencies and material weaknesses in the design or operation of
   internal control over financial reporting which are reasonably likely to adversely
   affect the company&#x2019;s ability to record, process, summarize and report financial information;
   and
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">b)  any fraud, whether or not material, that involves management or other employees who
   have a significant role in the company&#x2019;s internal control over financial reporting.

</div>
<div style="padding-bottom:15px;padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Date: February 1, 2023</div>
<div style="text-decoration:underline;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">By:&nbsp;&nbsp; /s/&nbsp;&nbsp;VASANT NARASIMHAN</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Name:&nbsp;&nbsp;Vasant Narasimhan</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Title:&nbsp;&nbsp;<i>Chief Executive Officer</i></div>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12
<SEQUENCE>4
<FILENAME>a23020120f-ex12_2.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>

<html>
<head>
<title>EXHIBIT 12.2</title>
</head>
<body bgcolor="#ffffff">



    <div style="text-align:right;font-weight: bold;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Exhibit&nbsp;12.2 </div>
<div style="text-align:center;font-weight: bold;padding-bottom:30px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">CERTIFICATION</div>
<div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">I, Harry Kirsch, certify that: </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">1.   I have reviewed this annual report on Form&nbsp;20-F of Novartis AG; </div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">2.  Based on my knowledge, this report does not contain any untrue statement of a material
   fact or omit to state a material fact necessary to make the statements made, in light
   of the circumstances under which such statements were made, not misleading with respect
   to the period covered by this report;
</div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">3.  Based on my knowledge, the financial statements, and other financial information included
   in this report, fairly present in all material respects the financial condition, results
   of operations and cash flows of the company as of, and for, the periods presented
   in this report;
</div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">4.   The company&#x2019;s other certifying officer and I are responsible for establishing and
   maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the company and have:
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">a)  designed such disclosure controls and procedures, or caused such disclosure controls
   and procedures to be designed under our supervision, to ensure that material information
   relating to the company, including its consolidated subsidiaries, is made known to
   us by others within those entities, particularly during the period in which this report
   is being prepared;
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">b)  designed such internal control over financial reporting, or caused such internal control
   over financial reporting to be designed under our supervision, to provide reasonable
   assurance regarding the reliability of financial reporting and the preparation of
   financial statements for external purposes in accordance with generally accepted accounting
   principles;
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">c)  evaluated the effectiveness of the company&#x2019;s disclosure controls and procedures and
   presented in this report our conclusions about the effectiveness of the disclosure
   controls and procedures, as of the end of the period covered by this report based
   on such evaluation; and
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">d)  disclosed in this report any change in the company&#x2019;s internal control over financial
   reporting that occurred during the period covered by the annual report that has materially
   affected, or is reasonably likely to materially affect, the company&#x2019;s internal control
   over financial reporting; and
</div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">5.  The company&#x2019;s other certifying officer and I have disclosed, based on our most recent
   evaluation of internal control over financial reporting, to the company&#x2019;s auditors
   and the audit committee of the company&#x2019;s board of directors (or persons performing
   the equivalent functions):
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">a)  all significant deficiencies and material weaknesses in the design or operation of
   internal control over financial reporting which are reasonably likely to adversely
   affect the company&#x2019;s ability to record, process, summarize and report financial information;
   and
</div>
<div style="margin-left:32px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">b)  any fraud, whether or not material, that involves management or other employees who
   have a significant role in the company&#x2019;s internal control over financial reporting.

</div>
<div style="padding-bottom:15px;padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Date: February 1, 2023</div>
<div style="text-decoration:underline;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">By:&nbsp;&nbsp; /s/&nbsp;&nbsp;HARRY KIRSCH</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Name:&nbsp;&nbsp;Harry Kirsch</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Title:&nbsp;&nbsp;<i>Chief Financial Officer</i></div>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13
<SEQUENCE>5
<FILENAME>a23020120f-ex13_1.htm
<DESCRIPTION>EXHIBIT 13.1
<TEXT>

<html>
<head>
<title>EXHIBIT 13.1</title>
</head>
<body bgcolor="#ffffff">



    <div style="text-align:right;font-weight: bold;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Exhibit&nbsp;13.1 </div>
<div style="text-align:center;font-weight: bold;padding-bottom:30px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">CERTIFICATION OF VASANT NARASIMHAN, CHIEF EXECUTIVE OFFICER OF   NOVARTIS AG PURSUANT TO SECTION 18 U.S.C. SECTION 1350,   AS ADOPTED PURSUANT TO SECTION 906   OF THE SARBANES-OXLEY ACT OF 2002 </div>
<div style="padding-bottom:10px;text-indent:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;"> Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b)
   of Section 1350, Chapter 63 of Title 18, United States Code), the undersigned officer
   of Novartis AG, a Swiss corporation (the &#x201c;Company&#x201d;), hereby certifies, to the best
   of such officer&#x2019;s knowledge, that:
</div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">1.  The Annual Report on Form 20-F for the year ended December 31, 2021 (the &#x201c;Form 20-F&#x201d;)
   of the Company fully complies with the requirements of Section 13(a) or 15(d) of the
   Securities Exchange Act of 1934; and
</div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">2.  The information contained in the Form 20-F fairly presents, in all material respects,
   the financial condition and results of operations of the Company.
</div>
<div style="padding-bottom:15px;padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Date: February 1, 2023</div>
<div style="text-decoration:underline;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">By:&nbsp;&nbsp; /s/&nbsp;&nbsp;VASANT NARASIMHAN</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Name:&nbsp;&nbsp;Vasant Narasimhan</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Title:&nbsp;&nbsp;<i>Chief Executive Officer</i></div>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13
<SEQUENCE>6
<FILENAME>a23020120f-ex13_2.htm
<DESCRIPTION>EXHIBIT 13.2
<TEXT>

<html>
<head>
<title>EXHIBIT 13.2</title>
</head>
<body bgcolor="#ffffff">



    <div style="text-align:right;font-weight: bold;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Exhibit&nbsp;13.2 </div>
<div style="text-align:center;font-weight: bold;padding-bottom:30px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">CERTIFICATION OF HARRY KIRSCH, CHIEF FINANCIAL OFFICER OF   NOVARTIS AG PURSUANT TO SECTION 18 U.S.C. SECTION 1350,    AS ADOPTED PURSUANT TO SECTION 906   OF THE SARBANES-OXLEY ACT OF 2002 </div>
<div style="padding-bottom:10px;text-indent:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b)
   of Section 1350, Chapter 63 of Title 18, United States Code), the undersigned officer
   of Novartis AG, a Swiss corporation (the &#x201c;Company&#x201d;), hereby certifies, to the best
   of such officer&#x2019;s knowledge, that:
</div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">1.  The Annual Report on Form 20-F for the year ended December 31, 2021 (the &#x201c;Form 20-F&#x201d;)
   of the Company fully complies with the requirements of Section 13(a) or 15(d) of the
   Securities Exchange Act of 1934; and
</div>
<div style="margin-left:16px;text-indent:-16px;padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">2.  The information contained in the Form 20-F fairly presents, in all material respects,
   the financial condition and results of operations of the Company.
</div>
<div style="padding-bottom:15px;padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Date: February 1, 2023</div>
<div style="text-decoration:underline;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">By:&nbsp;&nbsp; /s/&nbsp;&nbsp;HARRY KIRSCH</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Name:&nbsp;&nbsp;Harry Kirsch</div>
<div style="margin-left:22px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Title:&nbsp;&nbsp;<i>Chief Financial Officer</i></div>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15
<SEQUENCE>7
<FILENAME>a23020120f-ex15_1.htm
<DESCRIPTION>EXHIBIT 15.1
<TEXT>

<html>
<head>
<title>EXHIBIT 15.1</title>
</head>
<body bgcolor="#ffffff">





<br>
<img src="x_kpmg.gif">
<br>


    <div style="text-align:right;font-weight: bold;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Exhibit&nbsp;15.1</div>
<div style="text-align:center;font-weight: bold;padding-bottom:30px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">&nbsp;</div>
<div style="text-align:center;font-weight: bold;padding-bottom:30px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>
<div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">We consent to the incorporation by reference in the registration statements (Nos.
   333-171739, 333-198706, 333-250207 and 333-258081) on Form S-8 of our report dated
   January 31 2023, with respect to the consolidated financial statements of Novartis
   AG and the effectiveness of internal control over financial reporting.
</div>
<div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">&nbsp;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">/s/ KPMG AG</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Basel, Switzerland</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">February 1, 2023</div>
<div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">&nbsp;</div>
<div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">&nbsp;</div>
<div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">&nbsp;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">  </div>



</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15
<SEQUENCE>8
<FILENAME>a23020120f-ex15_2.htm
<DESCRIPTION>EXHIBIT 15.2
<TEXT>

<html>
<head>
<title>EXHIBIT 15.2</title>
</head>
<body bgcolor="#ffffff">







    <div style="text-align:right;font-weight: bold;padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Exhibit&nbsp;15.2</div>
<div style="text-align:center;font-weight: bold;padding-bottom:30px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">&nbsp;</div>
<div style="text-align:center;font-weight: bold;padding-bottom:30px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>
<div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">We hereby consent to the incorporation by reference in the Registration Statements
   on Form S-8 (Nos. 333-171739, 333-198706, 333-250207 and 333-258081) of Novartis AG
   of our report dated February 1, 2022 relating to the financial statements, which appears
   in this Form 20-F.
</div>
<div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">&nbsp;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">/s/ PricewaterhouseCoopers AG</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">Basel, Switzerland</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">January 31, 2023</div>
<div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">&nbsp;</div>
<div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">&nbsp;</div>
<div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">&nbsp;</div>
<div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;">  </div>



</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>nvs-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical" xlink:href="nvs-20221231.xsd#statementsOfCashFlowParenthetical" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails" xlink:href="nvs-20221231.xsd#disclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementOfComprehensiveIncomeCalc2" xlink:href="nvs-20221231.xsd#statementOfComprehensiveIncomeCalc2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementOfIncomeCalc2" xlink:href="nvs-20221231.xsd#statementOfIncomeCalc2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails" xlink:href="nvs-20221231.xsd#disclosureMarketableSecuritiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails" xlink:href="nvs-20221231.xsd#disclosureFinancialAndOtherNoncurrentAssetsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails" xlink:href="nvs-20221231.xsd#disclosureAcquisitionsOfBusinessesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:href="nvs-20221231.xsd#disclosureCommitmentsAndContingenciesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails" xlink:href="nvs-20221231.xsd#disclosureOtherCurrentAssetsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:href="nvs-20221231.xsd#disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails" xlink:href="nvs-20221231.xsd#disclosureEquityDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4" xlink:href="nvs-20221231.xsd#disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2" xlink:href="nvs-20221231.xsd#disclosureTransactionsWithRelatedPartiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementOfComprehensiveIncome" xlink:href="nvs-20221231.xsd#statementOfComprehensiveIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementsOfCashFlow" xlink:href="nvs-20221231.xsd#statementsOfCashFlow" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2" xlink:href="nvs-20221231.xsd#disclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementOfIncome" xlink:href="nvs-20221231.xsd#statementOfIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:href="nvs-20221231.xsd#disclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2" xlink:href="nvs-20221231.xsd#disclosureFinancialAndOtherNoncurrentAssetsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails2" xlink:href="nvs-20221231.xsd#disclosureMarketableSecuritiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails" xlink:href="nvs-20221231.xsd#disclosureEarningsPerShareDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/BalanceSheet" xlink:href="nvs-20221231.xsd#balanceSheet" xlink:type="simple"/>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/BalanceSheet" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="lbl_CurrentAssets" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Assets" xlink:to="lbl_CurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="lbl_NoncurrentAssets" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Assets" xlink:to="lbl_NoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="lbl_EquityAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Equity" xlink:to="lbl_EquityAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterests" xlink:label="lbl_NoncontrollingInterests" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Equity" xlink:to="lbl_NoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_EquityAttributableToOwnersOfParent" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves" xlink:label="lbl_OtherReserves" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_EquityAttributableToOwnersOfParent" xlink:to="lbl_OtherReserves" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_EquityAttributableToOwnersOfParent" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="lbl_CurrentLiabilities" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Liabilities" xlink:to="lbl_CurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="lbl_NoncurrentLiabilities" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Liabilities" xlink:to="lbl_NoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentLiabilities" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="lbl_EquityAndLiabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_EquityAndLiabilities" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_EquityAndLiabilities" xlink:to="lbl_Liabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="lbl_Goodwill" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_Goodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="lbl_NoncurrentFinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_NoncurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_OtherNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentLiabilities" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilities" xlink:to="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilities" xlink:to="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="lbl_CurrentAssets1" xlink:type="locator"/>
      <link:calculationArc order="10.2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssets1" xlink:to="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:calculationArc order="17.2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssets" xlink:to="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="lbl_OtherCurrentFinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_OtherCurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_OtherCurrentNonfinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="lbl_NoncurrentLeaseLiabilities" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentLiabilities" xlink:to="lbl_NoncurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_CurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="lbl_CurrentTaxAssetsCurrent" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_CurrentTaxAssetsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentLiabilities" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="lbl_BasicEarningsLossPerShare" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_BasicEarningsLossPerShare" xlink:to="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_BasicEarningsLossPerShare" xlink:to="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="lbl_DilutedEarningsLossPerShare" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_DilutedEarningsLossPerShare" xlink:to="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_DilutedEarningsLossPerShare" xlink:to="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Cash" xlink:label="lbl_Cash" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashAndCashEquivalents" xlink:to="lbl_Cash" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashEquivalents" xlink:label="lbl_CashEquivalents" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashAndCashEquivalents" xlink:to="lbl_CashEquivalents" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredCompensationPlansAssets" xlink:label="lbl_DeferredCompensationPlansAssets" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentAssets" xlink:to="lbl_DeferredCompensationPlansAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:label="lbl_OtherNoncurrentNonfinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentAssets" xlink:to="lbl_OtherNoncurrentNonfinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrepaidPostemploymentBenefitPlansAssets" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentAssets" xlink:to="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommercialPapersIssued" xlink:label="lbl_CommercialPapersIssued" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialLiabilities" xlink:to="lbl_CommercialPapersIssued" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermBorrowings" xlink:label="lbl_ShorttermBorrowings" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialLiabilities" xlink:to="lbl_ShorttermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialLiabilities" xlink:to="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="lbl_DerivativeFinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialLiabilities" xlink:to="lbl_DerivativeFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialLiabilities" xlink:to="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/StatementOfIncome" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossBeforeTax" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossBeforeTax" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossBeforeTax" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GrossProfit" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GrossProfit" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_RevenueFromSaleOfGoods" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossBeforeTax" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GrossProfit" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:calculationArc order="1.5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_RevenueFromSaleOfGoods" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLoss" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLoss" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:label="lbl_GainsLossesOnAvailableforsaleFinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_GainsLossesOnAvailableforsaleFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnNetMonetaryPosition" xlink:label="lbl_GainsLossesOnNetMonetaryPosition" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_GainsLossesOnNetMonetaryPosition" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:label="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:type="locator"/>
      <link:calculationArc order="5.5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromInterest" xlink:label="lbl_RevenueFromInterest" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_RevenueFromInterest" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromDividends" xlink:label="lbl_RevenueFromDividends" xlink:type="locator"/>
      <link:calculationArc order="10.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_RevenueFromDividends" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceCost" xlink:label="lbl_OtherFinanceCost" xlink:type="locator"/>
      <link:calculationArc order="11.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_OtherFinanceCost" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeOnForwardContractsAndOptions" xlink:label="lbl_IncomeOnForwardContractsAndOptions" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_IncomeOnForwardContractsAndOptions" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Borrowings" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LiabilitiesToBanksAndOtherInstitutions" xlink:label="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_Borrowings" xlink:to="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/StatementsOfCashFlow" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivities" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivities" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:label="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="11.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="12.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="13.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:calculationArc order="15.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:calculationArc order="2.5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:to="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:label="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:to="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:calculationArc order="14.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivities" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="15.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivities" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCostsRecordedInEquityPaid" xlink:label="lbl_TransactionCostsRecordedInEquityPaid" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_TransactionCostsRecordedInEquityPaid" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:calculationArc order="10.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="arc"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="arc"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="arc"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="lbl_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:calculationArc order="16.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="lbl_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:calculationArc order="17.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="15.7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:calculationArc order="15.5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/StatementOfComprehensiveIncome" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:calculationArc order="2.8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="lbl_KeyManagementPersonnelCompensation" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_KeyManagementPersonnelCompensation" xlink:to="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_KeyManagementPersonnelCompensation" xlink:to="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="locator"/>
      <link:calculationArc order="1.5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_KeyManagementPersonnelCompensation" xlink:to="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:label="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OutstandingShareCapital" xlink:label="lbl_OutstandingShareCapital" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OutstandingShareCapital" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OutstandingShareCapitalMovement" xlink:label="lbl_OutstandingShareCapitalMovement" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IssuedCapitalMovement" xlink:label="lbl_IssuedCapitalMovement" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OutstandingShareCapitalMovement" xlink:to="lbl_IssuedCapitalMovement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OutstandingShareCapital" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesMovementOfPeriod" xlink:label="lbl_TreasurySharesMovementOfPeriod" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OutstandingShareCapitalMovement" xlink:to="lbl_TreasurySharesMovementOfPeriod" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:label="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:label="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefits" xlink:label="lbl_OtherPostemploymentBenefits" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalRemediationProvisionNoncurrent" xlink:label="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationNonCurrent" xlink:label="lbl_ContingentConsiderationNonCurrent" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="lbl_OtherNoncurrentLiabilities" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="arc"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:type="arc"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_OtherPostemploymentBenefits" xlink:type="arc"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="arc"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_ContingentConsiderationNonCurrent" xlink:type="arc"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_OtherNoncurrentLiabilities" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome1" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:label="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:type="arc"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc"/>
      <link:calculationArc order="10.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:calculationArc order="11.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPrepaidExpensesAssociatedCompanies" xlink:label="lbl_CurrentPrepaidExpensesAssociatedCompanies" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_CurrentPrepaidExpensesAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPrepaidExpensesThirdParty" xlink:label="lbl_CurrentPrepaidExpensesThirdParty" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_CurrentPrepaidExpensesThirdParty" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="lbl_CurrentValueAddedTaxReceivables" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_CurrentValueAddedTaxReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherReceivablesAndCurrentAssets" xlink:label="lbl_OtherReceivablesAndCurrentAssets" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_OtherReceivablesAndCurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReceivablesAssociatedCompanies" xlink:label="lbl_ReceivablesAssociatedCompanies" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_ReceivablesAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WithholdingTaxRecoverable" xlink:label="lbl_WithholdingTaxRecoverable" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_WithholdingTaxRecoverable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivableCurrent" xlink:label="lbl_ContingentConsiderationReceivableCurrent" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_ContingentConsiderationReceivableCurrent" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentsUnderLongtermResearchAgreements" xlink:label="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:label="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:to="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherIntangiblePurchaseCommitments" xlink:label="lbl_OtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:to="lbl_OtherIntangiblePurchaseCommitments" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IdentifiableAssetsAcquired" xlink:label="lbl_IdentifiableAssetsAcquired" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialAndOtherAssets" xlink:label="lbl_FinancialAndOtherAssets" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_FinancialAndOtherAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="10.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="11.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradePayablesAndOtherLiabilities" xlink:label="lbl_TradePayablesAndOtherLiabilities" xlink:type="locator"/>
      <link:calculationArc order="12.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_TradePayablesAndOtherLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RightOfUseAssetsAsOfAcquisitionDate" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="13.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="locator"/>
      <link:calculationArc order="14.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermRestructuringProvision" xlink:label="lbl_ShorttermRestructuringProvision" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_ShorttermRestructuringProvision" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="lbl_AccrualsClassifiedAsCurrent" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_AccrualsClassifiedAsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:label="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentInterestPayable" xlink:label="lbl_CurrentInterestPayable" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_CurrentInterestPayable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RefundsProvision" xlink:label="lbl_RefundsProvision" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_RefundsProvision" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="lbl_ShorttermEmployeeBenefitsAccruals" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_ShorttermEmployeeBenefitsAccruals" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionCurrent" xlink:label="lbl_EnvironmentalProvisionCurrent" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_EnvironmentalProvisionCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="locator"/>
      <link:calculationArc order="10.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="locator"/>
      <link:calculationArc order="11.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationCurrentPortion" xlink:label="lbl_ContingentConsiderationCurrentPortion" xlink:type="locator"/>
      <link:calculationArc order="12.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_ContingentConsiderationCurrentPortion" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentForRepurchaseOwnShares" xlink:label="lbl_CommitmentForRepurchaseOwnShares" xlink:type="locator"/>
      <link:calculationArc order="13.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_CommitmentForRepurchaseOwnShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentPayables" xlink:label="lbl_OtherCurrentPayables" xlink:type="locator"/>
      <link:calculationArc order="14.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_OtherCurrentPayables" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentRefundsProvision" xlink:label="lbl_CurrentRefundsProvision" xlink:type="locator"/>
      <link:calculationArc order="15.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_CurrentRefundsProvision" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="lbl_NoncurrentFinancialAssets" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:label="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentTradeReceivables" xlink:label="lbl_NoncurrentTradeReceivables" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_NoncurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinanceLeaseReceivables" xlink:label="lbl_NoncurrentFinanceLeaseReceivables" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_NoncurrentFinanceLeaseReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivable" xlink:label="lbl_ContingentConsiderationReceivable" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_ContingentConsiderationReceivable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLoansAndReceivables" xlink:label="lbl_NoncurrentLoansAndReceivables" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_NoncurrentLoansAndReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAssetsEquityInvestments" xlink:label="lbl_NoncurrentFinancialAssetsEquityInvestments" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:to="lbl_NoncurrentFinancialAssetsEquityInvestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAsstetsDebtSecurities" xlink:label="lbl_NoncurrentFinancialAsstetsDebtSecurities" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:to="lbl_NoncurrentFinancialAsstetsDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAssetsFundInvestments" xlink:label="lbl_NoncurrentFinancialAssetsFundInvestments" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:to="lbl_NoncurrentFinancialAssetsFundInvestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongTermReceivablesFromFinanceSubleases" xlink:label="lbl_LongTermReceivablesFromFinanceSubleases" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_LongTermReceivablesFromFinanceSubleases" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="lbl_OtherNoncurrentReceivables" xlink:type="locator"/>
      <link:calculationArc order="10.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_OtherNoncurrentReceivables" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="lbl_OtherCurrentFinancialAssets" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketableSecurities" xlink:label="lbl_MarketableSecurities" xlink:type="locator"/>
      <link:calculationArc order="4.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialAssets" xlink:to="lbl_MarketableSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Commodities" xlink:label="lbl_Commodities" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialAssets" xlink:to="lbl_Commodities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:label="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialAssets" xlink:to="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativeFinancialAssets" xlink:label="lbl_DerivativeFinancialAssets" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialAssets" xlink:to="lbl_DerivativeFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivable" xlink:label="lbl_InterestReceivable" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_OtherCurrentFinancialAssets" xlink:to="lbl_InterestReceivable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtInstrumentsHeld" xlink:label="lbl_DebtInstrumentsHeld" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_MarketableSecurities" xlink:to="lbl_DebtInstrumentsHeld" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityInstrumentsHeld" xlink:label="lbl_EquityInstrumentsHeld" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_MarketableSecurities" xlink:to="lbl_EquityInstrumentsHeld" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FundInstrumentsHeld" xlink:label="lbl_FundInstrumentsHeld" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_MarketableSecurities" xlink:to="lbl_FundInstrumentsHeld" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/StatementOfIncomeCalc2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLoss" xlink:to="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ProfitLoss" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/StatementOfComprehensiveIncomeCalc2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_InterestExpense" xlink:to="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_InterestExpense" xlink:to="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_InterestExpense" xlink:to="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="arc"/>
   </link:calculationLink>
   <link:calculationLink xlink:role="http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:calculationArc order="5.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsReceivedClassifiedAsOperatingActivities" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:calculationArc order="6.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:calculationArc order="7.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:calculationArc order="9.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:calculationArc order="8.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:calculationArc order="10.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:calculationArc order="11.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:calculationArc order="2.0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:calculationArc order="1.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="locator"/>
      <link:calculationArc order="3.0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:calculationArc order="4.5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
   </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>nvs-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3" xlink:href="nvs-20221231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails" xlink:href="nvs-20221231.xsd#disclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails7" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4" xlink:href="nvs-20221231.xsd#disclosureTradeReceivablesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails11" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails7" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6" xlink:href="nvs-20221231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5" xlink:href="nvs-20221231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4" xlink:href="nvs-20221231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2" xlink:href="nvs-20221231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTaxesDetails3" xlink:href="nvs-20221231.xsd#disclosureTaxesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:href="nvs-20221231.xsd#disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3" xlink:href="nvs-20221231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails10" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="nvs-20221231.xsd#disclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssetsDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4" xlink:href="nvs-20221231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails17" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables" xlink:href="nvs-20221231.xsd#disclosureAssociatedCompaniesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails" xlink:href="nvs-20221231.xsd#disclosureAcquisitionsOfBusinessesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails10" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails12" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails1" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2" xlink:href="nvs-20221231.xsd#disclosureSignificantTransactionsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails" xlink:href="nvs-20221231.xsd#disclosureSignificantTransactionsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails" xlink:href="nvs-20221231.xsd#disclosureSignificantAccountingPoliciesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DocumentAndEntityInformation" xlink:href="nvs-20221231.xsd#documentAndEntityInformation" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementOfIncome" xlink:href="nvs-20221231.xsd#statementOfIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="nvs-20221231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1" xlink:href="nvs-20221231.xsd#disclosureTransactionsWithRelatedPartiesDetails1_1df9063b" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails14" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails13" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails12" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails16" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails15" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails7" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6" xlink:href="nvs-20221231.xsd#disclosureAssociatedCompaniesDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3" xlink:href="nvs-20221231.xsd#disclosureAssociatedCompaniesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTaxesDetails" xlink:href="nvs-20221231.xsd#disclosureTaxesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementsOfCashFlow" xlink:href="nvs-20221231.xsd#statementsOfCashFlow" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails10" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3" xlink:href="nvs-20221231.xsd#disclosureTradeReceivablesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementOfComprehensiveIncome" xlink:href="nvs-20221231.xsd#statementOfComprehensiveIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/BalanceSheet" xlink:href="nvs-20221231.xsd#balanceSheet" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2" xlink:href="nvs-20221231.xsd#disclosurePropertyPlantAndEquipmentDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails2" xlink:href="nvs-20221231.xsd#disclosureSubsequentEventsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails" xlink:href="nvs-20221231.xsd#disclosureSubsequentEventsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssetsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails" xlink:href="nvs-20221231.xsd#disclosureCommitmentsAndContingenciesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails2" xlink:href="nvs-20221231.xsd#disclosureEquityDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails" xlink:href="nvs-20221231.xsd#disclosurePropertyPlantAndEquipmentDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2" xlink:href="nvs-20221231.xsd#disclosureTradeReceivablesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails" xlink:href="nvs-20221231.xsd#disclosureEquityDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherCurrentLiabilitiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails" xlink:href="nvs-20221231.xsd#disclosureTradeReceivablesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementOfChangesInEquity" xlink:href="nvs-20221231.xsd#statementOfChangesInEquity" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5" xlink:href="nvs-20221231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails11" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails9" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:href="nvs-20221231.xsd#disclosureCommitmentsAndContingenciesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3" xlink:href="nvs-20221231.xsd#disclosureTransactionsWithRelatedPartiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2" xlink:href="nvs-20221231.xsd#disclosureTransactionsWithRelatedPartiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails9" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails7" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherCurrentLiabilitiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails5" xlink:href="nvs-20221231.xsd#disclosureTradeReceivablesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureInventoriesDetails" xlink:href="nvs-20221231.xsd#disclosureInventoriesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssetsDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssetsDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssetsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails" xlink:href="nvs-20221231.xsd#disclosureEarningsPerShareDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTaxesDetails2" xlink:href="nvs-20221231.xsd#disclosureTaxesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails" xlink:href="nvs-20221231.xsd#disclosureAssociatedCompaniesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails3" xlink:href="nvs-20221231.xsd#disclosureEquityDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails5" xlink:href="nvs-20221231.xsd#disclosureEquityDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails6" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:href="nvs-20221231.xsd#disclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails3" xlink:href="nvs-20221231.xsd#disclosureFinancialAndOtherNoncurrentAssetsDetails3" xlink:type="simple"/>
   <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
   <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
   <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
   <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
   <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
   <link:definitionLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryMember" xlink:label="lbl_InventoryMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryAxis" xlink:label="lbl_InventoryAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_InventoryAxis" xlink:to="lbl_InventoryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_RangeAxis" xlink:to="lbl_RangesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_YearOfExpiryMember" xlink:label="lbl_YearOfExpiryMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_YearOfExpiryAxis" xlink:label="lbl_YearOfExpiryAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_YearOfExpiryAxis" xlink:to="lbl_YearOfExpiryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetTreatmentMember" xlink:label="lbl_BalanceSheetTreatmentMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetTreatmentAxis" xlink:label="lbl_BalanceSheetTreatmentAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_BalanceSheetTreatmentAxis" xlink:to="lbl_BalanceSheetTreatmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementLocationMember" xlink:label="lbl_IncomeStatementLocationMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementLocationAxis" xlink:label="lbl_IncomeStatementLocationAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_IncomeStatementLocationAxis" xlink:to="lbl_IncomeStatementLocationMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="lbl_ClassesOfShareCapitalMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="lbl_ClassesOfShareCapitalAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfShareCapitalAxis" xlink:to="lbl_ClassesOfShareCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypeMember" xlink:label="lbl_SubsequentEventTypeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypAxis" xlink:label="lbl_SubsequentEventTypAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_SubsequentEventTypAxis" xlink:to="lbl_SubsequentEventTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueByMeasurementBasisMember" xlink:label="lbl_FairValueByMeasurementBasisMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueByMeasurementBasisAxis" xlink:label="lbl_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_FairValueByMeasurementBasisAxis" xlink:to="lbl_FairValueByMeasurementBasisMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="lbl_EntitysTotalForSubsidiariesMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lbl_EntitysTotalForSubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_OtherProvisionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusAxis" xlink:label="lbl_PastDueStatusAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_PastDueStatusAxis" xlink:to="lbl_PastDueStatusMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="lbl_DefinedBenefitPlansMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="lbl_DefinedBenefitPlansAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_DefinedBenefitPlansAxis" xlink:to="lbl_DefinedBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ObligationByTypeMember" xlink:label="lbl_ObligationByTypeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ObligationByTypeAxis" xlink:label="lbl_ObligationByTypeAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ObligationByTypeAxis" xlink:to="lbl_ObligationByTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInActuarialAssumptionMember" xlink:label="lbl_ChangeInActuarialAssumptionMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInActuarialAssumptionAxis" xlink:label="lbl_ChangeInActuarialAssumptionAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ChangeInActuarialAssumptionAxis" xlink:to="lbl_ChangeInActuarialAssumptionMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="lbl_ActuarialAssumptionsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="lbl_ActuarialAssumptionsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ActuarialAssumptionsAxis" xlink:to="lbl_ActuarialAssumptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsAndDivestmentsMember" xlink:label="lbl_AcquisitionsAndDivestmentsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsAndDivestmentsAxis" xlink:label="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_AcquisitionsAndDivestmentsAxis" xlink:to="lbl_AcquisitionsAndDivestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="lbl_BusinessCombinationsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_BusinessCombinationsAxis" xlink:to="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusMember" xlink:label="lbl_PastDueStatusMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="lbl_MajorCustomersMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="lbl_MajorCustomersAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_MajorCustomersAxis" xlink:to="lbl_MajorCustomersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="lbl_FinancialLiabilitiesMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:to="lbl_FinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="lbl_FinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lbl_FinancialLiabilitiesCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemMember" xlink:label="lbl_BalanceSheetItemMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemAxis" xlink:label="lbl_BalanceSheetItemAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_BalanceSheetItemAxis" xlink:to="lbl_BalanceSheetItemMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="lbl_FinancialAssetsCategoryMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="lbl_CategoriesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_CategoriesOfFinancialAssetsAxis" xlink:to="lbl_FinancialAssetsCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="lbl_FinancialAssetsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="lbl_ClassesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfFinancialAssetsAxis" xlink:to="lbl_FinancialAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsMember" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsAxis" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_AggregatedMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember" xlink:label="lbl_LiabilitiesMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="lbl_ClassesOfLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ClassesOfLiabilitiesAxis" xlink:to="lbl_LiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactLocationMember" xlink:label="lbl_ImpactLocationMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactLocationAxis" xlink:label="lbl_ImpactLocationAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ImpactLocationAxis" xlink:to="lbl_ImpactLocationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VendorMember" xlink:label="lbl_VendorMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VendorAxis" xlink:label="lbl_VendorAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_VendorAxis" xlink:to="lbl_VendorMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:to="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PlansAndProgramRebatesMember" xlink:label="lbl_PlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PlansAndProgramRebatesAxis" xlink:label="lbl_PlansAndProgramRebatesAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_PlansAndProgramRebatesAxis" xlink:to="lbl_PlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis1" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_CurrencyAxis1" xlink:to="lbl_AllCurrenciesDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LitigationCaseMember" xlink:label="lbl_LitigationCaseMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="lbl_LitigationCaseAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_LitigationCaseAxis" xlink:to="lbl_LitigationCaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="lbl_AddressTypeDomain" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="lbl_EntityAddressesAddressTypeAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_EntityAddressesAddressTypeAxis" xlink:to="lbl_AddressTypeDomain" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="lbl_ScenarioUnspecifiedDomain" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="lbl_StatementScenarioAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_StatementScenarioAxis" xlink:to="lbl_ScenarioUnspecifiedDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsAxis" xlink:label="lbl_BrandsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_BrandsAxis" xlink:to="lbl_BrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsMember" xlink:label="lbl_BrandsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:to="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_FranchiseMember" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" xlink:label="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermBorrowings" xlink:label="lbl_ShorttermBorrowings" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ShorttermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommercialPapersIssued" xlink:label="lbl_CommercialPapersIssued" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CommercialPapersIssued" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="lbl_DerivativeFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_WeightedAverageInterestRateAssociates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageInterestRateAssociates" xlink:label="lbl_WeightedAverageInterestRateAssociates" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:label="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:type="locator"/>
      <link:definitionArc order="7.2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PaymentOfInterestBearingAccountsToBeneficiaries" xlink:label="lbl_PaymentOfInterestBearingAccountsToBeneficiaries" xlink:type="locator"/>
      <link:definitionArc order="8.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_PaymentOfInterestBearingAccountsToBeneficiaries" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails6" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" xlink:label="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:label="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:to="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialDebtsCoveredByCollateral" xlink:label="lbl_NoncurrentFinancialDebtsCoveredByCollateral" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:to="lbl_NoncurrentFinancialDebtsCoveredByCollateral" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:label="lbl_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:to="lbl_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" xlink:label="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:label="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageInterestRateOnLoansReceived" xlink:label="lbl_AverageInterestRateOnLoansReceived" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_AverageInterestRateOnLoansReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:label="lbl_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageInterestRateOnBorrowings" xlink:label="lbl_AverageInterestRateOnBorrowings" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_AverageInterestRateOnBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LiabilitiesToBanksAndOtherInstitutions" xlink:label="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:type="locator"/>
      <link:definitionArc order="2.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinanceLeaseLiabilities" xlink:label="lbl_FinanceLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_FinanceLeaseLiabilities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaximalAmountOfShareBuybackProgramm" xlink:label="lbl_MaximalAmountOfShareBuybackProgramm" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_MaximalAmountOfShareBuybackProgramm" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsHeldByMarketMaker" xlink:label="lbl_WrittenCallOptionsHeldByMarketMaker" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsHeldByMarketMaker" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsContractualLive" xlink:label="lbl_WrittenCallOptionsContractualLive" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsContractualLive" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsContractualLiveRemaining" xlink:label="lbl_WrittenCallOptionsContractualLiveRemaining" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsContractualLiveRemaining" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsWeightedAverageExercisePrice" xlink:label="lbl_WrittenCallOptionsWeightedAverageExercisePrice" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsWeightedAverageExercisePrice" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountRecordedInEquityRelatedToHyperinflation" xlink:label="lbl_AmountRecordedInEquityRelatedToHyperinflation" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_AmountRecordedInEquityRelatedToHyperinflation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxOnTransactionCostsRecordedInEquity" xlink:label="lbl_TaxOnTransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:definitionArc order="2.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TaxOnTransactionCostsRecordedInEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCostsRecordedInEquity" xlink:label="lbl_TransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:definitionArc order="2.2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TransactionCostsRecordedInEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentForRepurchaseOwnShares" xlink:label="lbl_CommitmentForRepurchaseOwnShares" xlink:type="locator"/>
      <link:definitionArc order="2.1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_CommitmentForRepurchaseOwnShares" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DividendsPayableAmountPerShare" xlink:label="lbl_DividendsPayableAmountPerShare" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_DividendsPayableAmountPerShare" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaid" xlink:label="lbl_DividendsPaid" xlink:type="locator"/>
      <link:definitionArc order="0.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_DividendsPaid" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:label="lbl_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureTaxesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="lbl_CurrentTaxExpenseIncome" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentTaxExpenseIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="lbl_DeferredTaxExpenseIncome" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxExpenseIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxExpenseIncomeDiscontinuingOperations" xlink:label="lbl_TaxExpenseIncomeDiscontinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxExpenseIncomeDiscontinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeTaxExpense" xlink:label="lbl_IncomeTaxExpense" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:definitionArc order="0.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareTable" xlink:label="lbl_EarningsPerShareTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_EarningsPerShareTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareLineItems" xlink:label="lbl_EarningsPerShareLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_EarningsPerShareTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares" xlink:label="lbl_WeightedAverageShares" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_WeightedAverageShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:label="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="lbl_AdjustedWeightedAverageShares" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_AdjustedWeightedAverageShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="lbl_BasicEarningsLossPerShare" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_BasicEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="lbl_DilutedEarningsLossPerShare" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutedEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OptionsExcludedFromTheCalculation" xlink:label="lbl_OptionsExcludedFromTheCalculation" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_OptionsExcludedFromTheCalculation" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_GoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AlconBrandNameMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_OtherIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_UnallocatedAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="lbl_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_UnallocatedAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:label="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:label="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_UnallocatedAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VotrientMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SerelaxinMember" xlink:label="lbl_SerelaxinMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SerelaxinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CyPassMember" xlink:label="lbl_CyPassMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_CyPassMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_GoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AlconBrandNameMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_OtherIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:label="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherProductsMember" xlink:label="lbl_OtherProductsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureInventoriesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryAxis" xlink:label="lbl_InventoryAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryCurrentTable" xlink:label="lbl_InventoryCurrentTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_InventoryCurrentTable" xlink:to="lbl_InventoryAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryMember" xlink:label="lbl_InventoryMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_InventoryAxis" xlink:to="lbl_InventoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryRawMaterialsGrossMember" xlink:label="lbl_InventoryRawMaterialsGrossMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InventoryMember" xlink:to="lbl_InventoryRawMaterialsGrossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryWorkInProgressGrossMember" xlink:label="lbl_InventoryWorkInProgressGrossMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InventoryMember" xlink:to="lbl_InventoryWorkInProgressGrossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryFinishedGoodsGrossMember" xlink:label="lbl_InventoryFinishedGoodsGrossMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InventoryMember" xlink:to="lbl_InventoryFinishedGoodsGrossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryLineItems" xlink:label="lbl_InventoryLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_InventoryCurrentTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:label="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoryWritedown2011" xlink:label="lbl_InventoryWritedown2011" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_InventoryWritedown2011" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfInventoryWritedown" xlink:label="lbl_ReversalOfInventoryWritedown" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_ReversalOfInventoryWritedown" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:label="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:label="lbl_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanSixYearsMember" xlink:label="lbl_LaterThanSixYearsMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanSixYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:to="lbl_CurrencyAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CurrencyAxis" xlink:to="lbl_AllCurrenciesDomain" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="lbl_USD" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_USD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="lbl_EUR" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_EUR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY" xlink:label="lbl_JPY" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_JPY" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF" xlink:label="lbl_CHF" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CHF" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyOthersMember" xlink:label="lbl_CurrencyOthersMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CurrencyOthersMember" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueByMeasurementBasisAxis" xlink:label="lbl_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_FairValueByMeasurementBasisAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueByMeasurementBasisMember" xlink:label="lbl_FairValueByMeasurementBasisMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_FairValueByMeasurementBasisAxis" xlink:to="lbl_FairValueByMeasurementBasisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CarryingReportedAmountFairValueDisclosureMember" xlink:label="lbl_CarryingReportedAmountFairValueDisclosureMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueByMeasurementBasisMember" xlink:to="lbl_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueDisclosureItemAmountsMember" xlink:label="lbl_FairValueDisclosureItemAmountsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueByMeasurementBasisMember" xlink:to="lbl_FairValueDisclosureItemAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherNoncurrentFinancialDebt" xlink:label="lbl_OtherNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_OtherNoncurrentFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:label="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:label="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefits" xlink:label="lbl_OtherPostemploymentBenefits" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherPostemploymentBenefits" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalRemediationProvisionNoncurrent" xlink:label="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationNonCurrent" xlink:label="lbl_ContingentConsiderationNonCurrent" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ContingentConsiderationNonCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="lbl_OtherNoncurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherNoncurrentLiabilities" xlink:type="arc"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestructuringProvisionsMovementsTable" xlink:label="lbl_RestructuringProvisionsMovementsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_RestructuringProvisionsMovementsTable" xlink:to="lbl_ClassesOfProvisionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_OtherProvisionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestructuringProvisionMember" xlink:label="lbl_RestructuringProvisionMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_RestructuringProvisionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PlansAndProgramRebatesMember" xlink:label="lbl_PlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_PlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:label="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:to="lbl_RestructuringProvisionsMovementsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestructuringProvisionsMovementsRollForward" xlink:label="lbl_RestructuringProvisionsMovementsRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:to="lbl_RestructuringProvisionsMovementsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisions" xlink:label="lbl_OtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_OtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="lbl_AdditionalProvisionsOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_AdditionalProvisionsOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="lbl_ProvisionUsedOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_ProvisionUsedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="6.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_RestructuringProvisionsMovementsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="lbl_DefinedBenefitPlansAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_DefinedBenefitPlansAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="lbl_DefinedBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_DefinedBenefitPlansAxis" xlink:to="lbl_DefinedBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConcentrationOfMajorPlansGeographic" xlink:label="lbl_ConcentrationOfMajorPlansGeographic" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ConcentrationOfMajorPlansGeographic" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements" xlink:label="lbl_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MajorPlansPercentageInGroupDBOPensions" xlink:label="lbl_MajorPlansPercentageInGroupDBOPensions" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_MajorPlansPercentageInGroupDBOPensions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:label="lbl_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:label="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ObligationByTypeAxis" xlink:label="lbl_ObligationByTypeAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_ObligationByTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ObligationByTypeMember" xlink:label="lbl_ObligationByTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ObligationByTypeAxis" xlink:to="lbl_ObligationByTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnfundedMember" xlink:label="lbl_UnfundedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_UnfundedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActiveMember" xlink:label="lbl_ActiveMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_ActiveMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredPensionersMember" xlink:label="lbl_DeferredPensionersMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_DeferredPensionersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionersMember" xlink:label="lbl_PensionersMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_PensionersMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="lbl_PlanAssetsAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_PlanAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="lbl_SurplusDeficitInPlan" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_SurplusDeficitInPlan" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:label="lbl_ActuarialAssumptionOfDiscountRates" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfDiscountRates" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitAssumptionLifeExpectancyMale" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyMale" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitAssumptionLifeExpectancyMale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="lbl_ActuarialAssumptionsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:label="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="lbl_ActuarialAssumptionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="lbl_ActuarialAssumptionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ActuarialAssumptionsAxis" xlink:to="lbl_ActuarialAssumptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:label="lbl_ActuarialAssumptionOfDiscountRatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfDiscountRatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LifeExpectancyMember" xlink:label="lbl_LifeExpectancyMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_LifeExpectancyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInActuarialAssumptionAxis" xlink:label="lbl_ChangeInActuarialAssumptionAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="lbl_ChangeInActuarialAssumptionAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInActuarialAssumptionMember" xlink:label="lbl_ChangeInActuarialAssumptionMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeInActuarialAssumptionAxis" xlink:to="lbl_ChangeInActuarialAssumptionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Increase25BasisPointMember" xlink:label="lbl_Increase25BasisPointMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Increase25BasisPointMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Decrease25BasisPointMember" xlink:label="lbl_Decrease25BasisPointMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Decrease25BasisPointMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Change25BasisPointMember" xlink:label="lbl_Change25BasisPointMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Change25BasisPointMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Increase1YearMember" xlink:label="lbl_Increase1YearMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Increase1YearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:label="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:label="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:label="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfHealthCareCostTrendRatesTable" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:label="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAllocationOfPlanAssetsTable" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityInvestmentsMember" xlink:label="lbl_EquityInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_EquityInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_DebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RealEstateMember" xlink:label="lbl_RealEstateMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_RealEstateMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlternativeInvestmentsMember" xlink:label="lbl_AlternativeInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_AlternativeInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndOtherInvestmentsMember" xlink:label="lbl_CashAndOtherInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_CashAndOtherInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:label="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:label="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanPlanAssetAllocations" xlink:label="lbl_DefinedBenefitPlanPlanAssetAllocations" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanPlanAssetAllocations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EmployerSharesHeldByDefinedBenefitPlan" xlink:label="lbl_EmployerSharesHeldByDefinedBenefitPlan" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_EmployerSharesHeldByDefinedBenefitPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:label="lbl_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:label="lbl_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfExpectedBenefitPaymentsTable" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:label="lbl_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:to="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:to="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:label="lbl_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:to="lbl_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:label="lbl_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:to="lbl_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="lbl_NumberOfOutstandingShareOptions" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonExecutiveDirectorMember" xlink:label="lbl_NonExecutiveDirectorMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_NonExecutiveDirectorMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="lbl_KeyManagementPersonnelCompensation" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensation" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfDrBrodyMember" xlink:label="lbl_ProfDrBrodyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_ProfDrBrodyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfDrZinkernagelMember" xlink:label="lbl_ProfDrZinkernagelMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_ProfDrZinkernagelMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DrAlexKrauerMember" xlink:label="lbl_DrAlexKrauerMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_DrAlexKrauerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DrDanielVasellaMember" xlink:label="lbl_DrDanielVasellaMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_DrDanielVasellaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DrJamesBradnerMember" xlink:label="lbl_DrJamesBradnerMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_DrJamesBradnerMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPensionFundMember" xlink:label="lbl_NovartisPensionFundMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NovartisPensionFundMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="lbl_KeyManagementPersonnelCompensation" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationDailyRate" xlink:label="lbl_KeyManagementPersonnelCompensationDailyRate" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationDailyRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:label="lbl_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationSharesAcquired" xlink:label="lbl_KeyManagementPersonnelCompensationSharesAcquired" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationSharesAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:label="lbl_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:label="lbl_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCreditFacilityUncommitted" xlink:label="lbl_BorrowingsCreditFacilityUncommitted" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_BorrowingsCreditFacilityUncommitted" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:label="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:label="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentsUnderLongtermResearchAgreements" xlink:label="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherIntangiblePurchaseCommitments" xlink:label="lbl_OtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_OtherIntangiblePurchaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:label="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:label="lbl_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:type="locator"/>
      <link:definitionArc order="1.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:label="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="lbl_NotLaterThanOneMonthMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneMonthMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:label="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketableSecuritiesAndTimeDepositsMember" xlink:label="lbl_MarketableSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_MarketableSecuritiesAndTimeDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommoditiesMember" xlink:label="lbl_CommoditiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CommoditiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:label="lbl_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMember" xlink:label="lbl_CashAndCashEquivalentsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CashAndCashEquivalentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialDebtMember" xlink:label="lbl_FinancialDebtMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialDebtUndiscountedMember" xlink:label="lbl_FinancialDebtUndiscountedMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FinancialDebtUndiscountedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaturityOfNetDebtLineItems" xlink:label="lbl_MaturityOfNetDebtLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDebt" xlink:label="lbl_NetDebt" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_NetDebt" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="lbl_NotLaterThanOneMonthMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneMonthMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:label="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:label="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:label="lbl_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TenDayLossFairValueVARModelTable" xlink:label="lbl_TenDayLossFairValueVARModelTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_TenDayLossFairValueVARModelTable" xlink:to="lbl_RangeAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RangeAxis" xlink:to="lbl_RangesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageMember" xlink:label="lbl_WeightedAverageMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesMember" xlink:to="lbl_WeightedAverageMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="lbl_TopOfRangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesMember" xlink:to="lbl_TopOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="lbl_BottomOfRangeMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesMember" xlink:to="lbl_BottomOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WorstCaseLossScenarioMember" xlink:label="lbl_WorstCaseLossScenarioMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesMember" xlink:to="lbl_WorstCaseLossScenarioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TenDayLossFairValueVARModelLineItems" xlink:label="lbl_TenDayLossFairValueVARModelLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_TenDayLossFairValueVARModelTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputation" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputation" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionRollForward" xlink:label="lbl_EnvironmentalProvisionRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvision" xlink:label="lbl_EnvironmentalProvision" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvision" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionPayments" xlink:label="lbl_EnvironmentalProvisionPayments" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionPayments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionReleases" xlink:label="lbl_EnvironmentalProvisionReleases" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionReleases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionAdditions" xlink:label="lbl_EnvironmentalProvisionAdditions" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionAdditions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:label="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionCurrent" xlink:label="lbl_EnvironmentalProvisionCurrent" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalRemediationProvisionNoncurrent" xlink:label="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="lbl_IncomeTaxesPaidRefund" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefund" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactLocationAxis" xlink:label="lbl_ImpactLocationAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ImpactLocationAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactLocationMember" xlink:label="lbl_ImpactLocationMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ImpactLocationAxis" xlink:to="lbl_ImpactLocationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementMember" xlink:label="lbl_IncomeStatementMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ImpactLocationMember" xlink:to="lbl_IncomeStatementMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ImpactLocationMember" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:label="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:label="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:label="lbl_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:label="lbl_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:label="lbl_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:label="lbl_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/StatementOfChangesInEquity" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="lbl_StatementOfChangesInEquityTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="lbl_IssuedCapitalMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_IssuedCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TreasurySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="lbl_RetainedEarningsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_RetainedEarningsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_NoncontrollingInterestsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_RestatedValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="lbl_StatementOfChangesInEquityLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_StatementOfChangesInEquityTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="lbl_OtherComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaid" xlink:label="lbl_DividendsPaid" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_DividendsPaid" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DividendPaidNoncashAssetsDistribution" xlink:label="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="lbl_PurchaseOfTreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_PurchaseOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReductionOfIssuedCapital" xlink:label="lbl_ReductionOfIssuedCapital" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ReductionOfIssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherShareSales" xlink:label="lbl_OtherShareSales" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherShareSales" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxesOnTreasuryShares" xlink:label="lbl_TaxesOnTreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TaxesOnTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCostsRecordedInEquity" xlink:label="lbl_TransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TransactionCostsRecordedInEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnFinancialAssetsSold" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeMaketableSecurities" xlink:label="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:label="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseInNoncontrolingInterests" xlink:label="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsRelatedToDivestments" xlink:label="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInEquity" xlink:label="lbl_ChangesInEquity" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ChangesInEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:label="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RepurchaseOfOptions" xlink:label="lbl_RepurchaseOfOptions" xlink:type="locator"/>
      <link:definitionArc order="9.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_RepurchaseOfOptions" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixTable" xlink:label="lbl_DisclosureOfProvisionMatrixTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivableMember" xlink:label="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_DisclosureOfProvisionMatrixTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivable" xlink:label="lbl_ProvisionForDoubtfulReceivable" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ProvisionForDoubtfulReceivable" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDeductionFromRevenueTable" xlink:label="lbl_ProvisionForDeductionFromRevenueTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ProvisionForDeductionFromRevenueTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PlansAndProgramRebatesAxis" xlink:label="lbl_PlansAndProgramRebatesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ProvisionForDeductionFromRevenueTable" xlink:to="lbl_PlansAndProgramRebatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PlansAndProgramRebatesMember" xlink:label="lbl_PlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_PlansAndProgramRebatesAxis" xlink:to="lbl_PlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_USspecificHealthcarePlansAndProgramRebatesMember" xlink:label="lbl_USspecificHealthcarePlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PlansAndProgramRebatesMember" xlink:to="lbl_USspecificHealthcarePlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:label="lbl_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PlansAndProgramRebatesMember" xlink:to="lbl_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:label="lbl_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PlansAndProgramRebatesMember" xlink:to="lbl_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:label="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:to="lbl_ProvisionForDeductionFromRevenueTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsForDeductionsFromRevenueRollForward" xlink:label="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:to="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentRefundsProvision" xlink:label="lbl_CurrentRefundsProvision" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_CurrentRefundsProvision" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentRefundsProvisionDiscontinuedOperations" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="lbl_ProvisionUsedOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_ProvisionUsedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementAdjustmentsOfPriorYear" xlink:label="lbl_IncomeStatementAdjustmentsOfPriorYear" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_IncomeStatementAdjustmentsOfPriorYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementAdjustmentsOfCurrentYear" xlink:label="lbl_IncomeStatementAdjustmentsOfCurrentYear" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_IncomeStatementAdjustmentsOfCurrentYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInOffsetAgainstGrossTradeReceivables" xlink:label="lbl_ChangesInOffsetAgainstGrossTradeReceivables" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_ChangesInOffsetAgainstGrossTradeReceivables" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OutstandingShareCapital" xlink:label="lbl_OutstandingShareCapital" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OutstandingShareCapital" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IssuedCapitalMovement" xlink:label="lbl_IssuedCapitalMovement" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_IssuedCapitalMovement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="lbl_SaleOrIssueOfTreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_SaleOrIssueOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesMovementOfPeriod" xlink:label="lbl_TreasurySharesMovementOfPeriod" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesMovementOfPeriod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="lbl_ParValuePerShare" xlink:type="locator"/>
      <link:definitionArc order="6.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_ParValuePerShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OutstandingShareCapitalMovement" xlink:label="lbl_OutstandingShareCapitalMovement" xlink:type="locator"/>
      <link:definitionArc order="6.2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OutstandingShareCapitalMovement" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixTable" xlink:label="lbl_DisclosureOfProvisionMatrixTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivableMember" xlink:label="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_DisclosureOfProvisionMatrixTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivable" xlink:label="lbl_ProvisionForDoubtfulReceivable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ProvisionForDoubtfulReceivable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfDivestmentsOtherProvisions" xlink:label="lbl_ImpactOfDivestmentsOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ImpactOfDivestmentsOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="lbl_AdditionalProvisionsOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_AdditionalProvisionsOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="lbl_ProvisionUsedOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ProvisionUsedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LandMember" xlink:label="lbl_LandMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_LandMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember" xlink:label="lbl_BuildingsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_BuildingsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="lbl_ConstructionInProgressMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_ConstructionInProgressMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MachineryMember" xlink:label="lbl_MachineryMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_MachineryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:label="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:label="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:label="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:label="lbl_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:label="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingCostsCapitalised" xlink:label="lbl_BorrowingCostsCapitalised" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_BorrowingCostsCapitalised" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:label="lbl_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:label="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:label="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="lbl_ClassesOfShareCapitalAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_ClassesOfShareCapitalAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="lbl_ClassesOfShareCapitalMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfShareCapitalAxis" xlink:to="lbl_ClassesOfShareCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="lbl_OrdinarySharesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_OrdinarySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_TreasurySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="lbl_NumberOfSharesIssued" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfSharesIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfTreasuryShares" xlink:label="lbl_NumberOfTreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="lbl_NumberOfSharesOutstanding" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfSharesOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharesCancelledForCapitalReduction" xlink:label="lbl_SharesCancelledForCapitalReduction" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_SharesCancelledForCapitalReduction" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredToBeHeld" xlink:label="lbl_TreasurySharesAcquiredToBeHeld" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesAcquiredToBeHeld" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredToBeCancelled" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherSharePurchases" xlink:label="lbl_OtherSharePurchases" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OtherSharePurchases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:label="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedCompensationShares" xlink:label="lbl_EquityBasedCompensationShares" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_EquityBasedCompensationShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployees" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfOtherShareSales" xlink:label="lbl_NumberOfOtherShareSales" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfOtherShareSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShareMovements" xlink:label="lbl_ShareMovements" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_ShareMovements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesWithRestrictedUse" xlink:label="lbl_TreasurySharesWithRestrictedUse" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesWithRestrictedUse" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StockRepurchaseProgramAuthorizedAmount1" xlink:label="lbl_StockRepurchaseProgramAuthorizedAmount1" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:label="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:label="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:to="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:label="lbl_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:to="lbl_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_GoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AlconBrandNameMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_OtherIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="lbl_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:label="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:label="lbl_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:label="lbl_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:label="lbl_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:label="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:label="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypAxis" xlink:label="lbl_SubsequentEventTypAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_SubsequentEventTypAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypeMember" xlink:label="lbl_SubsequentEventTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SubsequentEventTypAxis" xlink:to="lbl_SubsequentEventTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventMember" xlink:label="lbl_SubsequentEventMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SubsequentEventTypeMember" xlink:to="lbl_SubsequentEventMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypAxis" xlink:label="lbl_SubsequentEventTypAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_SubsequentEventTypAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypeMember" xlink:label="lbl_SubsequentEventTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SubsequentEventTypAxis" xlink:to="lbl_SubsequentEventTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventMember" xlink:label="lbl_SubsequentEventMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SubsequentEventTypeMember" xlink:to="lbl_SubsequentEventMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:label="lbl_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lbl_BorrowingsByNameAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:label="lbl_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:label="lbl_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:label="lbl_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:label="lbl_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:label="lbl_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:label="lbl_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:label="lbl_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:label="lbl_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:label="lbl_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:label="lbl_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:label="lbl_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:label="lbl_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:label="lbl_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:label="lbl_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:label="lbl_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:label="lbl_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:label="lbl_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:label="lbl_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:label="lbl_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:label="lbl_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:label="lbl_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:label="lbl_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:label="lbl_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:label="lbl_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:label="lbl_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:label="lbl_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:label="lbl_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:label="lbl_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:label="lbl_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:type="locator"/>
      <link:definitionArc order="30.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:type="locator"/>
      <link:definitionArc order="31.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:type="locator"/>
      <link:definitionArc order="32.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:type="locator"/>
      <link:definitionArc order="33.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="lbl_BorrowingsInterestRate" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsInterestRate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsOriginalCurrency" xlink:label="lbl_BorrowingsOriginalCurrency" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsOriginalCurrency" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotionalAmount" xlink:label="lbl_NotionalAmount" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_NotionalAmount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsIssuanceDate" xlink:label="lbl_BorrowingsIssuanceDate" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsIssuanceDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsMaturity" xlink:label="lbl_BorrowingsMaturity" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsMaturity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsLender" xlink:label="lbl_BorrowingsLender" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsLender" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsPremiumDiscount" xlink:label="lbl_BorrowingsPremiumDiscount" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsPremiumDiscount" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsInterestRateStepUp" xlink:label="lbl_BorrowingsInterestRateStepUp" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsInterestRateStepUp" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/BalanceSheet" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="lbl_AssetsAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="lbl_NoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_NoncurrentAssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="lbl_Goodwill" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_Goodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="lbl_NoncurrentFinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_OtherNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="lbl_NoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_NoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="lbl_CurrentAssetsAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_CurrentAssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="lbl_CurrentTaxAssetsCurrent" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentTaxAssetsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="lbl_OtherCurrentFinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_OtherCurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_OtherCurrentNonfinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="lbl_CurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_Assets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="lbl_EquityAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EquityAndLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract" xlink:label="lbl_EquityAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_EquityAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves" xlink:label="lbl_OtherReserves" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_OtherReserves" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="lbl_EquityAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_EquityAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterests" xlink:label="lbl_NoncontrollingInterests" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_NoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAbstract" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="lbl_LiabilitiesAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_LiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="lbl_NoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_NoncurrentLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="lbl_NoncurrentLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_NoncurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="lbl_NoncurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_NoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="lbl_CurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_CurrentLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="lbl_CurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_Liabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="lbl_EquityAndLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_EquityAndLiabilities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/StatementOfComprehensiveIncome" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:to="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:to="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AnalysisOfOverdueAmountsTable" xlink:label="lbl_AnalysisOfOverdueAmountsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivableMember" xlink:label="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusAxis" xlink:label="lbl_PastDueStatusAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_PastDueStatusAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusMember" xlink:label="lbl_PastDueStatusMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_PastDueStatusAxis" xlink:to="lbl_PastDueStatusMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentMember" xlink:label="lbl_CurrentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_PastDueStatusMember" xlink:to="lbl_CurrentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="lbl_NotLaterThanOneMonthMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentMember" xlink:to="lbl_NotLaterThanOneMonthMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:label="lbl_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:label="lbl_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="lbl_LaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AnalysisOfOverdueAmountsLineItems" xlink:label="lbl_AnalysisOfOverdueAmountsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_AnalysisOfOverdueAmountsLineItems" xlink:to="lbl_AnalysisOfOverdueAmountsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AnalysisOfOverdueAmountsLineItems" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivable" xlink:label="lbl_ProvisionForDoubtfulReceivable" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AnalysisOfOverdueAmountsLineItems" xlink:to="lbl_ProvisionForDoubtfulReceivable" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:label="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractualInterestOnNoncurrentLiabilities" xlink:label="lbl_ContractualInterestOnNoncurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ContractualInterestOnNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentForRepurchaseOwnShares" xlink:label="lbl_CommitmentForRepurchaseOwnShares" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CommitmentForRepurchaseOwnShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationLiabilities" xlink:label="lbl_ContingentConsiderationLiabilities" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ContingentConsiderationLiabilities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/StatementsOfCashFlow" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsReceivedClassifiedAsOperatingActivities" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:label="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="lbl_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="lbl_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="30.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="locator"/>
      <link:definitionArc order="31.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="locator"/>
      <link:definitionArc order="32.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="33.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="34.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="35.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="36.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="locator"/>
      <link:definitionArc order="37.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="38.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="39.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="40.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="41.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="locator"/>
      <link:definitionArc order="42.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="43.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="44.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="45.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="1.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureTaxesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccountingProfit" xlink:label="lbl_AccountingProfit" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AccountingProfit" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_RangeAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RangeAxis" xlink:to="lbl_RangesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="lbl_TopOfRangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesMember" xlink:to="lbl_TopOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="lbl_ProportionOfOwnershipInterestInAssociate" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ProportionOfOwnershipInterestInAssociate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsReceived" xlink:label="lbl_DividendsReceived" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_DividendsReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContributionOfBusinessToJointVenture" xlink:label="lbl_ContributionOfBusinessToJointVenture" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ContributionOfBusinessToJointVenture" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsolidatedIncomeStatementEffectsTable" xlink:label="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationEffectsMember" xlink:label="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShareOfCurrentYearNetIncome" xlink:label="lbl_ShareOfCurrentYearNetIncome" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfCurrentYearNetIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PriorYearAdjustment" xlink:label="lbl_PriorYearAdjustment" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_PriorYearAdjustment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:label="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:label="lbl_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:to="lbl_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:label="lbl_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:label="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice46.4Member" xlink:label="lbl_ExercisePrice46.4Member" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.4Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice46.7Member" xlink:label="lbl_ExercisePrice46.7Member" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.7Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice53.7Member" xlink:label="lbl_ExercisePrice53.7Member" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice53.7Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice54.5Member" xlink:label="lbl_ExercisePrice54.5Member" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice54.5Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.0Member" xlink:label="lbl_ExercisePrice57.0Member" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.0Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.1Member" xlink:label="lbl_ExercisePrice57.1Member" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.1Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.6Member" xlink:label="lbl_ExercisePrice57.6Member" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.6Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice58.3Member" xlink:label="lbl_ExercisePrice58.3Member" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice58.3Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice65.9Member" xlink:label="lbl_ExercisePrice65.9Member" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice65.9Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice66.0Member" xlink:label="lbl_ExercisePrice66.0Member" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.0Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice66.1Member" xlink:label="lbl_ExercisePrice66.1Member" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.1Member" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="lbl_NumberOfOutstandingShareOptions" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="2.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:label="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FundInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AvailableforsaleFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongTermFinancialInvestmentsMember" xlink:label="lbl_LongTermFinancialInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_LongTermFinancialInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationPayablesMember" xlink:label="lbl_ContingentConsiderationPayablesMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationPayablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_OtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsCarryingValueLevel3" xlink:label="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="lbl_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:label="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PurchaseFairValueMeasurementAssets" xlink:label="lbl_PurchaseFairValueMeasurementAssets" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_PurchaseFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:label="lbl_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisposalsFairValueMeasurementAssets" xlink:label="lbl_DisposalsFairValueMeasurementAssets" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DisposalsFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclassificationFairValueMeasurementAssets" xlink:label="lbl_ReclassificationFairValueMeasurementAssets" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ReclassificationFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:label="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="lbl_StatementScenarioAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementScenarioAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="lbl_ScenarioUnspecifiedDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_StatementScenarioAxis" xlink:to="lbl_ScenarioUnspecifiedDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical5IncreaseMember" xlink:label="lbl_Hypothetical5IncreaseMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical5IncreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical5DecreaseMember" xlink:label="lbl_Hypothetical5DecreaseMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical5DecreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" xlink:label="lbl_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="lbl_StatementScenarioAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementScenarioAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="lbl_ScenarioUnspecifiedDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_StatementScenarioAxis" xlink:to="lbl_ScenarioUnspecifiedDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical15IncreaseMember" xlink:label="lbl_Hypothetical15IncreaseMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical15IncreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical15DecreaseMember" xlink:label="lbl_Hypothetical15DecreaseMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical15DecreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" xlink:label="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" xlink:label="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" xlink:label="lbl_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:label="lbl_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:label="lbl_OtherAdjustmentsToReconcileProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherAdjustmentsToReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VendorAxis" xlink:label="lbl_VendorAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:label="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:to="lbl_VendorAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VendorMember" xlink:label="lbl_VendorMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_VendorAxis" xlink:to="lbl_VendorMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LargestFinancialInstitutionMember" xlink:label="lbl_LargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_VendorMember" xlink:to="lbl_LargestFinancialInstitutionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SecondLargestFinancialInstitutionMember" xlink:label="lbl_SecondLargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_VendorMember" xlink:to="lbl_SecondLargestFinancialInstitutionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ThirdLargestFinancialInstitutionMember" xlink:label="lbl_ThirdLargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_VendorMember" xlink:to="lbl_ThirdLargestFinancialInstitutionMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:to="lbl_BorrowingsByNameAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_USCommercialPaperProgramsMember" xlink:label="lbl_USCommercialPaperProgramsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_USCommercialPaperProgramsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JPCommercialPaperProgramsMember" xlink:label="lbl_JPCommercialPaperProgramsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_JPCommercialPaperProgramsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OpenHedgesForAnticipatedTransactions" xlink:label="lbl_OpenHedgesForAnticipatedTransactions" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_OpenHedgesForAnticipatedTransactions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:label="lbl_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueOfOtherFinancialAssetsSold" xlink:label="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MostSignificantForeignExchangeLosses" xlink:label="lbl_MostSignificantForeignExchangeLosses" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_MostSignificantForeignExchangeLosses" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongtermFinancialDebtWithACarryingAmount" xlink:label="lbl_LongtermFinancialDebtWithACarryingAmount" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_LongtermFinancialDebtWithACarryingAmount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:label="lbl_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaximumHoldingInUnrelatedCompany" xlink:label="lbl_MaximumHoldingInUnrelatedCompany" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_MaximumHoldingInUnrelatedCompany" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:label="lbl_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:label="lbl_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:label="lbl_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:label="lbl_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:label="lbl_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:label="lbl_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCommercialPaperNumberOfPrograms" xlink:label="lbl_BorrowingsCommercialPaperNumberOfPrograms" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCommercialPaperNumberOfPrograms" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCreditFacilityCommitted" xlink:label="lbl_BorrowingsCreditFacilityCommitted" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCreditFacilityCommitted" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCreditFacilityShortTerm" xlink:label="lbl_BorrowingsCreditFacilityShortTerm" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCreditFacilityShortTerm" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountBorrowedUnderTheCreditFacility" xlink:label="lbl_AmountBorrowedUnderTheCreditFacility" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountBorrowedUnderTheCreditFacility" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DebtEquityRatio" xlink:label="lbl_DebtEquityRatio" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DebtEquityRatio" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VAREstimateConfidenceInterval" xlink:label="lbl_VAREstimateConfidenceInterval" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_VAREstimateConfidenceInterval" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:label="lbl_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueOfFundInvestmentsAndEquitySecurities" xlink:label="lbl_FairValueOfFundInvestmentsAndEquitySecurities" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FairValueOfFundInvestmentsAndEquitySecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CounterpartyRiskAbstract" xlink:label="lbl_CounterpartyRiskAbstract" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CounterpartyRiskAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:label="lbl_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CounterpartyRiskAbstract" xlink:to="lbl_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="lbl_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:definitionArc order="3.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="lbl_MajorCustomersAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersTable" xlink:label="lbl_DisclosureOfMajorCustomersTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfMajorCustomersTable" xlink:to="lbl_MajorCustomersAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="lbl_MajorCustomersMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MajorCustomersAxis" xlink:to="lbl_MajorCustomersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LargestCustomerMember" xlink:label="lbl_LargestCustomerMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_LargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SecondLargestCustomerMember" xlink:label="lbl_SecondLargestCustomerMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_SecondLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ThirdLargestCustomerMember" xlink:label="lbl_ThirdLargestCustomerMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_ThirdLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:label="lbl_DisclosureOfMajorCustomersLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_DisclosureOfMajorCustomersTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="lbl_PercentageOfEntitysRevenue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysRevenue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfEntitysTradeReceivable" xlink:label="lbl_PercentageOfEntitysTradeReceivable" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysTradeReceivable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CustomersWithNetSalesOverFivePercent" xlink:label="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfGovernmentBackedDebtSecurities" xlink:label="lbl_PercentageOfGovernmentBackedDebtSecurities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfGovernmentBackedDebtSecurities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:to="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ListedEquitySecuritiesMember" xlink:label="lbl_ListedEquitySecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_ListedEquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonlistedEquitySecuritiesMember" xlink:label="lbl_NonlistedEquitySecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_NonlistedEquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalFairValueAdjustmentsMember" xlink:label="lbl_TotalFairValueAdjustmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalFairValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:label="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueOfOtherFinancialAssetsSold" xlink:label="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainLossOnSaleOfOtherFinancialAssets" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" xlink:label="lbl_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod" xlink:label="lbl_DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonExecutiveDirectorMember" xlink:label="lbl_NonExecutiveDirectorMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_NonExecutiveDirectorMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GenentechRocheMember" xlink:label="lbl_GenentechRocheMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GenentechRocheMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GenentechInc.USAMember" xlink:label="lbl_GenentechInc.USAMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GenentechInc.USAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SparkTherapeuticsInc.Member" xlink:label="lbl_SparkTherapeuticsInc.Member" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_SparkTherapeuticsInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XolairMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:label="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfContractsWithRelatedParties" xlink:label="lbl_NumberOfContractsWithRelatedParties" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_NumberOfContractsWithRelatedParties" xlink:type="arc"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembers" xlink:type="arc"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:label="lbl_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" xlink:label="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RelatedPartiesNumberOfExecutiveCommitteeMembers" xlink:label="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembers" xlink:type="locator"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:label="lbl_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoriesMember" xlink:label="lbl_InventoriesMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_InventoriesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxLossCarryforwardsMember" xlink:label="lbl_TaxLossCarryforwardsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_TaxLossCarryforwardsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherAssetsProvisionsAccrualsMember" xlink:label="lbl_OtherAssetsProvisionsAccrualsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_OtherAssetsProvisionsAccrualsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_RestatedValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossDeferredTaxAssets" xlink:label="lbl_GrossDeferredTaxAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossDeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossDeferredTaxLiabilities" xlink:label="lbl_GrossDeferredTaxLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossDeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="lbl_DeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementInDeferredTaxBalanceRollForward" xlink:label="lbl_MovementInDeferredTaxBalanceRollForward" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_MovementInDeferredTaxBalanceRollForward" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:label="lbl_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:type="arc"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember" xlink:label="lbl_IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember" xlink:type="locator"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/StatementOfIncome" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="lbl_ProfitLossAttributableToAbstract" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossAttributableToAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsPerShareAbstract" xlink:label="lbl_BasicEarningsPerShareAbstract" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_BasicEarningsPerShareAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="lbl_BasicEarningsLossPerShare" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BasicEarningsPerShareAbstract" xlink:to="lbl_BasicEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsPerShareAbstract" xlink:label="lbl_DilutedEarningsPerShareAbstract" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DilutedEarningsPerShareAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="lbl_DilutedEarningsLossPerShare" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DilutedEarningsPerShareAbstract" xlink:to="lbl_DilutedEarningsLossPerShare" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DocumentAndEntityInformation" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="lbl_EntityAddressesAddressTypeAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="lbl_DocumentInformationTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DocumentInformationTable" xlink:to="lbl_EntityAddressesAddressTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="lbl_AddressTypeDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_EntityAddressesAddressTypeAxis" xlink:to="lbl_AddressTypeDomain" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="lbl_BusinessContactMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AddressTypeDomain" xlink:to="lbl_BusinessContactMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="lbl_DocumentInformationLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentInformationTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="lbl_DocumentType" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentType" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="lbl_AmendmentFlag" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_AmendmentFlag" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="lbl_DocumentAnnualReport" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentAnnualReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="lbl_DocumentTransitionReport" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentTransitionReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="lbl_DocumentShellCompanyReport" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentShellCompanyReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="lbl_DocumentPeriodEndDate" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentPeriodEndDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="lbl_DocumentFiscalYearFocus" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentFiscalYearFocus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="lbl_DocumentFiscalPeriodFocus" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentFiscalPeriodFocus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="lbl_TradingSymbol" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="lbl_EntityRegistrantName" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityRegistrantName" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="lbl_EntityCentralIndexKey" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCentralIndexKey" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="lbl_CurrentFiscalYearEndDate" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_CurrentFiscalYearEndDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="lbl_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="lbl_EntityCurrentReportingStatus" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCurrentReportingStatus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="lbl_EntityVoluntaryFilers" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityVoluntaryFilers" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="lbl_EntityFilerCategory" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityFilerCategory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="lbl_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="lbl_EntityPublicFloat" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityPublicFloat" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="lbl_EntityShellCompany" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityShellCompany" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="lbl_EntityEmergingGrowthCompany" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityEmergingGrowthCompany" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="lbl_EntityInteractiveDataCurrent" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityInteractiveDataCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="lbl_IcfrAuditorAttestationFlag" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_IcfrAuditorAttestationFlag" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="lbl_AuditorName" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_AuditorName" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="lbl_AuditorLocation" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_AuditorLocation" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="lbl_AuditorFirmId" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_AuditorFirmId" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="lbl_EntityFileNumber" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityFileNumber" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="lbl_EntityIncorporationStateCountryCode" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityIncorporationStateCountryCode" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="lbl_EntityAddressAddressLine1" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityAddressAddressLine1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="lbl_EntityAddressCityOrTown" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityAddressCityOrTown" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="lbl_EntityAddressPostalZipCode" xlink:type="locator"/>
      <link:definitionArc order="30.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityAddressPostalZipCode" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="lbl_EntityAddressCountry" xlink:type="locator"/>
      <link:definitionArc order="31.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityAddressCountry" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="lbl_DocumentRegistrationStatement" xlink:type="locator"/>
      <link:definitionArc order="32.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentRegistrationStatement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="lbl_DocumentAccountingStandard" xlink:type="locator"/>
      <link:definitionArc order="33.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentAccountingStandard" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="lbl_ContactPersonnelName" xlink:type="locator"/>
      <link:definitionArc order="34.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_ContactPersonnelName" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="lbl_CountryRegion" xlink:type="locator"/>
      <link:definitionArc order="35.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_CountryRegion" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="lbl_CityAreaCode" xlink:type="locator"/>
      <link:definitionArc order="36.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_CityAreaCode" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="lbl_LocalPhoneNumber" xlink:type="locator"/>
      <link:definitionArc order="37.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_LocalPhoneNumber" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelFaxNumber" xlink:label="lbl_ContactPersonnelFaxNumber" xlink:type="locator"/>
      <link:definitionArc order="38.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_ContactPersonnelFaxNumber" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="lbl_ClassesOfShareCapitalAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DocumentInformationTable" xlink:to="lbl_ClassesOfShareCapitalAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="lbl_ClassesOfShareCapitalMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfShareCapitalAxis" xlink:to="lbl_ClassesOfShareCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmericanDepositarySharesEachRepresenting1ShareMember" xlink:label="lbl_AmericanDepositarySharesEachRepresenting1ShareMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_AmericanDepositarySharesEachRepresenting1ShareMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OrdinarySharesNominalValueCHF0.50PerShareMember" xlink:label="lbl_OrdinarySharesNominalValueCHF0.50PerShareMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_OrdinarySharesNominalValueCHF0.50PerShareMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="lbl_Security12bTitle" xlink:type="locator"/>
      <link:definitionArc order="39.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_Security12bTitle" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="lbl_DocumentInformationLineItems1" xlink:type="locator"/>
      <link:definitionArc order="40.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems1" xlink:to="lbl_TradingSymbol" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="lbl_SecurityExchangeName" xlink:type="locator"/>
      <link:definitionArc order="41.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_SecurityExchangeName" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:type="arc"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsNetSalesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesTableTextBlock" xlink:type="locator"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="lbl_IssuedCapitalMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_IssuedCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TreasurySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="lbl_RetainedEarningsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_RetainedEarningsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_NoncontrollingInterestsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="lbl_ParValuePerShare" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ParValuePerShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:label="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UndiscountedOperatingLeaseCommitments" xlink:label="lbl_UndiscountedOperatingLeaseCommitments" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_UndiscountedOperatingLeaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShortTermLeasesAndLowValueLeases" xlink:label="lbl_ShortTermLeasesAndLowValueLeases" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ShortTermLeasesAndLowValueLeases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RemainingLeaseCommitments" xlink:label="lbl_RemainingLeaseCommitments" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RemainingLeaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseLiabilitiesToBeRecognized" xlink:label="lbl_LeaseLiabilitiesToBeRecognized" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_LeaseLiabilitiesToBeRecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RightOfUseAssetsToBeRecognized" xlink:label="lbl_RightOfUseAssetsToBeRecognized" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RightOfUseAssetsToBeRecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrepaymentsAndAccruedLeasePayments" xlink:label="lbl_PrepaymentsAndAccruedLeasePayments" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PrepaymentsAndAccruedLeasePayments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="lbl_GrossLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:label="lbl_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NewLeaseArrangements" xlink:label="lbl_NewLeaseArrangements" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NewLeaseArrangements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UndiscountedFutureLeasePayments" xlink:label="lbl_UndiscountedFutureLeasePayments" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_UndiscountedFutureLeasePayments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfDiscounting" xlink:label="lbl_EffectOfDiscounting" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfDiscounting" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="lbl_EntitysTotalForSubsidiariesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lbl_EntitysTotalForSubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubsidiariesMember" xlink:label="lbl_SubsidiariesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSubsidiariesMember" xlink:to="lbl_SubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementLocationAxis" xlink:label="lbl_IncomeStatementLocationAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_IncomeStatementLocationAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementLocationMember" xlink:label="lbl_IncomeStatementLocationMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_IncomeStatementLocationAxis" xlink:to="lbl_IncomeStatementLocationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OperatingIncomeMember" xlink:label="lbl_OperatingIncomeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncomeStatementLocationMember" xlink:to="lbl_OperatingIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsAAAMember" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AspenGlobalIncorporatedMember" xlink:label="lbl_AspenGlobalIncorporatedMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AspenGlobalIncorporatedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TheMedicinesCompanyMember" xlink:label="lbl_TheMedicinesCompanyMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TheMedicinesCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AveXisIncMember" xlink:label="lbl_AveXisIncMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AveXisIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EndocyteMember" xlink:label="lbl_EndocyteMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EndocyteMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TranscendMedicalIncMember" xlink:label="lbl_TranscendMedicalIncMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TranscendMedicalIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelexysPharmaceuticalsCorporationMember" xlink:label="lbl_SelexysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SelexysPharmaceuticalsCorporationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReprixysPharmaceuticalsCorporationMember" xlink:label="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZiarcoGroupLimitedMember" xlink:label="lbl_ZiarcoGroupLimitedMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ZiarcoGroupLimitedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EncoreVisionIncMember" xlink:label="lbl_EncoreVisionIncMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EncoreVisionIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EliLillyAndCompanyMember" xlink:label="lbl_EliLillyAndCompanyMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EliLillyAndCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKOncologyProductsMember" xlink:label="lbl_GSKOncologyProductsMember" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKOncologyProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKVaccinesMember" xlink:label="lbl_GSKVaccinesMember" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKVaccinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKConsumerHealthcareMember" xlink:label="lbl_GSKConsumerHealthcareMember" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKConsumerHealthcareMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKTotalTransactionMember" xlink:label="lbl_GSKTotalTransactionMember" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKTotalTransactionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CSLMember" xlink:label="lbl_CSLMember" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CSLMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SpinifexMember" xlink:label="lbl_SpinifexMember" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SpinifexMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdmuneTheraputicsMember" xlink:label="lbl_AdmuneTheraputicsMember" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdmuneTheraputicsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IFMTreInc.Member" xlink:label="lbl_IFMTreInc.Member" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_IFMTreInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PowerVisionInc.Member" xlink:label="lbl_PowerVisionInc.Member" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_PowerVisionInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:label="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlinePlcGSKMember" xlink:label="lbl_GlaxoSmithKlinePlcGSKMember" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GlaxoSmithKlinePlcGSKMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GyroscopeTherapeuticsHoldingsPlcMember" xlink:label="lbl_GyroscopeTherapeuticsHoldingsPlcMember" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GyroscopeTherapeuticsHoldingsPlcMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_BorrowingsByNameAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsUSDMember" xlink:label="lbl_BorrowingsUSDMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_BorrowingsUSDMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsEURMember" xlink:label="lbl_BorrowingsEURMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_BorrowingsEURMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DetailedInformationAboutSignificantTransaction" xlink:label="lbl_DetailedInformationAboutSignificantTransaction" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DetailedInformationAboutSignificantTransaction" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RepaymentOfIntercompanyBalances" xlink:label="lbl_RepaymentOfIntercompanyBalances" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RepaymentOfIntercompanyBalances" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="lbl_AdditionalRecognitionGoodwill" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AdditionalRecognitionGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:label="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:label="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentiallyRefundableConsiderationFromAcquisition" xlink:label="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:label="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractRightOfFirstNegotiationTerm" xlink:label="lbl_ContractRightOfFirstNegotiationTerm" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContractRightOfFirstNegotiationTerm" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueOfAcquiree" xlink:label="lbl_RevenueOfAcquiree" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueOfAcquiree" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueOfAcquireeFullYear" xlink:label="lbl_RevenueOfAcquireeFullYear" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueOfAcquireeFullYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfVotingEquityInterestsContributed" xlink:label="lbl_PercentageOfVotingEquityInterestsContributed" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfVotingEquityInterestsContributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionRelatedCosts" xlink:label="lbl_TransactionRelatedCosts" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionRelatedCosts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionRelatedCostsPaid" xlink:label="lbl_TransactionRelatedCostsPaid" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionRelatedCostsPaid" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLoss" xlink:label="lbl_ImpairmentLoss" xlink:type="locator"/>
      <link:definitionArc order="30.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ImpairmentLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLoss" xlink:label="lbl_ReversalOfImpairmentLoss" xlink:type="locator"/>
      <link:definitionArc order="31.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ReversalOfImpairmentLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PreTaxProfitLossFromDivestmentOfBusiness" xlink:label="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:type="locator"/>
      <link:definitionArc order="32.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:definitionArc order="33.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialReceivableFromDivestment" xlink:label="lbl_PotentialReceivableFromDivestment" xlink:type="locator"/>
      <link:definitionArc order="34.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentialReceivableFromDivestment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentFairValueOfContingentConsiderationReceived" xlink:label="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:type="locator"/>
      <link:definitionArc order="35.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MilestonePaymentAlreadyReceived" xlink:label="lbl_MilestonePaymentAlreadyReceived" xlink:type="locator"/>
      <link:definitionArc order="36.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_MilestonePaymentAlreadyReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FuturePutOptionToSellBusiness" xlink:label="lbl_FuturePutOptionToSellBusiness" xlink:type="locator"/>
      <link:definitionArc order="37.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_FuturePutOptionToSellBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PaymentPutOption" xlink:label="lbl_PaymentPutOption" xlink:type="locator"/>
      <link:definitionArc order="38.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PaymentPutOption" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExchanged" xlink:label="lbl_InterestExchanged" xlink:type="locator"/>
      <link:definitionArc order="39.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_InterestExchanged" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="lbl_ParValuePerShare" xlink:type="locator"/>
      <link:definitionArc order="40.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ParValuePerShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfShareCapitalInTenderOffer" xlink:label="lbl_PercentageOfShareCapitalInTenderOffer" xlink:type="locator"/>
      <link:definitionArc order="41.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalInTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOfferPerOrdinaryShare" xlink:label="lbl_CashOfferPerOrdinaryShare" xlink:type="locator"/>
      <link:definitionArc order="42.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CashOfferPerOrdinaryShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOfferPerADS" xlink:label="lbl_CashOfferPerADS" xlink:type="locator"/>
      <link:definitionArc order="43.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CashOfferPerADS" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfOrdinarySharePerADS" xlink:label="lbl_NumberOfOrdinarySharePerADS" xlink:type="locator"/>
      <link:definitionArc order="44.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfOrdinarySharePerADS" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueOfEquity" xlink:label="lbl_ValueOfEquity" xlink:type="locator"/>
      <link:definitionArc order="45.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ValueOfEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:type="locator"/>
      <link:definitionArc order="46.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherNetAssets" xlink:label="lbl_OtherNetAssets" xlink:type="locator"/>
      <link:definitionArc order="47.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_OtherNetAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="lbl_DeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="48.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="49.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentCostToSell" xlink:label="lbl_DivestmentCostToSell" xlink:type="locator"/>
      <link:definitionArc order="50.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentCostToSell" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:definitionArc order="51.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:definitionArc order="52.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:definitionArc order="53.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CarryingValueOfTheDivestedBusiness" xlink:label="lbl_CarryingValueOfTheDivestedBusiness" xlink:type="locator"/>
      <link:definitionArc order="54.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CarryingValueOfTheDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfProductsInPortfolioToBeSold" xlink:label="lbl_NumberOfProductsInPortfolioToBeSold" xlink:type="locator"/>
      <link:definitionArc order="55.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfProductsInPortfolioToBeSold" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:definitionArc order="56.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProformaNetSales" xlink:label="lbl_ProformaNetSales" xlink:type="locator"/>
      <link:definitionArc order="57.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProformaNetSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfBrandsInPortfolioToAcquire" xlink:label="lbl_NumberOfBrandsInPortfolioToAcquire" xlink:type="locator"/>
      <link:definitionArc order="58.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfBrandsInPortfolioToAcquire" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfMarketsForTheAcquiredBrands" xlink:label="lbl_NumberOfMarketsForTheAcquiredBrands" xlink:type="locator"/>
      <link:definitionArc order="59.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfMarketsForTheAcquiredBrands" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherBorrowings" xlink:label="lbl_OtherBorrowings" xlink:type="locator"/>
      <link:definitionArc order="60.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_OtherBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPayable" xlink:label="lbl_DividendsPayable" xlink:type="locator"/>
      <link:definitionArc order="61.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DividendsPayable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:definitionArc order="62.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:label="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:definitionArc order="63.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="lbl_NetAssetsLiabilities" xlink:type="locator"/>
      <link:definitionArc order="64.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NetAssetsLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="lbl_FinancialAssetsAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="65.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_FinancialAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="locator"/>
      <link:definitionArc order="66.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:definitionArc order="67.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:label="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:type="locator"/>
      <link:definitionArc order="68.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialMilestoneMaximumPayments" xlink:label="lbl_PotentialMilestoneMaximumPayments" xlink:type="locator"/>
      <link:definitionArc order="69.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentialMilestoneMaximumPayments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:label="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:type="locator"/>
      <link:definitionArc order="70.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionalBorrowings" xlink:label="lbl_AdditionalBorrowings" xlink:type="locator"/>
      <link:definitionArc order="71.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AdditionalBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfEquityInterestSharesReceived" xlink:label="lbl_PercentageOfEquityInterestSharesReceived" xlink:type="locator"/>
      <link:definitionArc order="72.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfEquityInterestSharesReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:label="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:type="locator"/>
      <link:definitionArc order="73.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator"/>
      <link:definitionArc order="74.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CustomaryPurchasePriceAdjustment" xlink:label="lbl_CustomaryPurchasePriceAdjustment" xlink:type="locator"/>
      <link:definitionArc order="75.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CustomaryPurchasePriceAdjustment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="76.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="77.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="78.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashTransferred" xlink:label="lbl_CashTransferred" xlink:type="locator"/>
      <link:definitionArc order="79.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CashTransferred" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:label="lbl_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="80.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfBearerShares" xlink:label="lbl_NumberOfBearerShares" xlink:type="locator"/>
      <link:definitionArc order="81.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfBearerShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:definitionArc order="82.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetAssetsDerecognized" xlink:label="lbl_NetAssetsDerecognized" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NetAssetsDerecognized" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPayable" xlink:label="lbl_DividendsPayable" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DividendsPayable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DistributionOfDividendToDividendBearingShares" xlink:label="lbl_DistributionOfDividendToDividendBearingShares" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DistributionOfDividendToDividendBearingShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCosts" xlink:label="lbl_TransactionCosts" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionCosts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsumerHealthMember" xlink:label="lbl_ConsumerHealthMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_ConsumerHealthMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfReportableSegments" xlink:label="lbl_NumberOfReportableSegments" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfReportableSegments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfBusinessUnits" xlink:label="lbl_NumberOfBusinessUnits" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfBusinessUnits" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfCommercialOrganizationalUnits" xlink:label="lbl_NumberOfCommercialOrganizationalUnits" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfCommercialOrganizationalUnits" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfFranchises" xlink:label="lbl_NumberOfFranchises" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfFranchises" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdministrativeExpense" xlink:label="lbl_AdministrativeExpense" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:label="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="lbl_ProfitLossAttributableToAbstract" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossAttributableToAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Assets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Liabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDebt" xlink:label="lbl_NetDebt" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetDebt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetOperatingAssets" xlink:label="lbl_NetOperatingAssets" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetOperatingAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="lbl_AdditionsToRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsToRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="lbl_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionsToInvestmentInAssociatedCompanies" xlink:label="lbl_AdditionsToInvestmentInAssociatedCompanies" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsToInvestmentInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialDebtsAndDerivativeInstruments" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:label="lbl_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="lbl_GB" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_GB" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR" xlink:label="lbl_FR" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_FR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="lbl_DE" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_DE" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP" xlink:label="lbl_JP" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_JP" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN" xlink:label="lbl_CN" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CN" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCountriesMember" xlink:label="lbl_OtherCountriesMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_OtherCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="lbl_EuropeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EuropeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AmericasMember" xlink:label="lbl_AmericasMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_AmericasMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AsiaAfricaAustralasiaMember" xlink:label="lbl_AsiaAfricaAustralasiaMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_AsiaAfricaAustralasiaMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="lbl_MajorCustomersAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersTable" xlink:label="lbl_DisclosureOfMajorCustomersTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfMajorCustomersTable" xlink:to="lbl_MajorCustomersAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="lbl_MajorCustomersMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MajorCustomersAxis" xlink:to="lbl_MajorCustomersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LargestCustomerMember" xlink:label="lbl_LargestCustomerMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_LargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SecondLargestCustomerMember" xlink:label="lbl_SecondLargestCustomerMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_SecondLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ThirdLargestCustomerMember" xlink:label="lbl_ThirdLargestCustomerMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_ThirdLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:label="lbl_DisclosureOfMajorCustomersLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_DisclosureOfMajorCustomersTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="lbl_PercentageOfEntitysRevenue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysRevenue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfEntitysTradeReceivable" xlink:label="lbl_PercentageOfEntitysTradeReceivable" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysTradeReceivable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CustomersWithNetSalesOverFivePercent" xlink:label="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="lbl_EuropeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EuropeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AsiaAfricaAustralasiaMember" xlink:label="lbl_AsiaAfricaAustralasiaMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_AsiaAfricaAustralasiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CanadaAndLatinAmericaMember" xlink:label="lbl_CanadaAndLatinAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CanadaAndLatinAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstablishedMarketsMember" xlink:label="lbl_EstablishedMarketsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EstablishedMarketsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EmergingGrowthMarketsMember" xlink:label="lbl_EmergingGrowthMarketsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EmergingGrowthMarketsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfitSharingIncome" xlink:label="lbl_ProfitSharingIncome" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitSharingIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromRoyalties" xlink:label="lbl_RevenueFromRoyalties" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromRoyalties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MilestoneIncome" xlink:label="lbl_MilestoneIncome" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_MilestoneIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherRevenueOther" xlink:label="lbl_OtherRevenueOther" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenueOther" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsAndDivestmentsAxis" xlink:label="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsAndDivestmentsMember" xlink:label="lbl_AcquisitionsAndDivestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AcquisitionsAndDivestmentsAxis" xlink:to="lbl_AcquisitionsAndDivestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsMember" xlink:label="lbl_AcquisitionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AcquisitionsAndDivestmentsMember" xlink:to="lbl_AcquisitionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentsMember" xlink:label="lbl_DivestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AcquisitionsAndDivestmentsMember" xlink:to="lbl_DivestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="lbl_BusinessCombinationsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_BusinessCombinationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BusinessCombinationsAxis" xlink:to="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TranscendMedicalIncMember" xlink:label="lbl_TranscendMedicalIncMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForBusinessCombinationsMember" xlink:to="lbl_TranscendMedicalIncMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentAssetsMember" xlink:label="lbl_NoncurrentAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NoncurrentAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLiabilitiesMember" xlink:label="lbl_CurrentLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_CurrentLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentLiabilitiesMember" xlink:label="lbl_NoncurrentLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NoncurrentLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowFromNetIdentifiableAssets" xlink:label="lbl_CashFlowFromNetIdentifiableAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowFromNetIdentifiableAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReceivablesAndPayablesContingentConsiderationNet" xlink:label="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPaymentsAndDeferredConsiderationNet" xlink:label="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationPaid" xlink:label="lbl_ContingentConsiderationPaid" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ContingentConsiderationPaid" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentAssetsDivested" xlink:label="lbl_NoncurrentAssetsDivested" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NoncurrentAssetsDivested" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="lbl_ConsiderationPaidReceived" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ConsiderationPaidReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashOutflowsFromDivestments" xlink:label="lbl_NetCashOutflowsFromDivestments" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashOutflowsFromDivestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentAssetsDivested" xlink:label="lbl_CurrentAssetsDivested" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentAssetsDivested" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLiabilitiesDivested" xlink:label="lbl_CurrentLiabilitiesDivested" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentLiabilitiesDivested" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredSalePriceAndOtherAdjustments" xlink:label="lbl_DeferredSalePriceAndOtherAdjustments" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredSalePriceAndOtherAdjustments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherNetCashInflowsFromDivestments" xlink:label="lbl_OtherNetCashInflowsFromDivestments" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherNetCashInflowsFromDivestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsDueToDerecognizedCashAndCashEquivalents" xlink:label="lbl_CashOutflowsDueToDerecognizedCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashOutflowsDueToDerecognizedCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentAndCurrentLiabilitiesDivested" xlink:label="lbl_NoncurrentAndCurrentLiabilitiesDivested" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NoncurrentAndCurrentLiabilitiesDivested" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetIdentifiableAssetsOfDivestedBusiness" xlink:label="lbl_NetIdentifiableAssetsOfDivestedBusiness" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetIdentifiableAssetsOfDivestedBusiness" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RightOfUseAssetsAsOfAcquisitionDate" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialAndOtherAssets" xlink:label="lbl_FinancialAndOtherAssets" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_FinancialAndOtherAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradePayablesAndOtherLiabilities" xlink:label="lbl_TradePayablesAndOtherLiabilities" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_TradePayablesAndOtherLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IdentifiableAssetsAcquired" xlink:label="lbl_IdentifiableAssetsAcquired" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_IdentifiableAssetsAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredCashAndCashEquivalents" xlink:label="lbl_AcquiredCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_AcquiredCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="lbl_GoodwillRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_GoodwillRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillExpectedDeductibleForTaxPurposes" xlink:label="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="lbl_ClassesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="lbl_DisclosureOfFinancialAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_ClassesOfFinancialAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="lbl_FinancialAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfFinancialAssetsAxis" xlink:to="lbl_FinancialAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMember" xlink:label="lbl_CashAndCashEquivalentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialAssetsMember" xlink:to="lbl_CashAndCashEquivalentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueMember" xlink:label="lbl_FinancialAssetsAtFairValueMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialAssetsMember" xlink:to="lbl_FinancialAssetsAtFairValueMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="lbl_FinancialAssetsAtAmortisedCostMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialAssetsMember" xlink:to="lbl_FinancialAssetsAtAmortisedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="lbl_CategoriesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_CategoriesOfFinancialAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="lbl_FinancialAssetsCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CategoriesOfFinancialAssetsAxis" xlink:to="lbl_FinancialAssetsCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="lbl_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialAssetsCategoryMember" xlink:to="lbl_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:label="lbl_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialAssetsCategoryMember" xlink:to="lbl_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="lbl_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialAssetsCategoryMember" xlink:to="lbl_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AvailableForSaleMarketableSecuritiesMember" xlink:label="lbl_AvailableForSaleMarketableSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AvailableForSaleMarketableSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtMember" xlink:label="lbl_CurrentFinancialDebtMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CurrentFinancialDebtMember" xlink:type="arc"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CashAndCashEquivalentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemAxis" xlink:label="lbl_BalanceSheetItemAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_BalanceSheetItemAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemMember" xlink:label="lbl_BalanceSheetItemMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BalanceSheetItemAxis" xlink:to="lbl_BalanceSheetItemMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquitySecuritiesMember" xlink:label="lbl_EquitySecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_EquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_FundInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCurrentAssetsMember" xlink:label="lbl_OtherCurrentAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_OtherCurrentAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:label="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:label="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:label="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="lbl_DisclosureOfFinancialAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfFinancialAssetsLineItems" xlink:to="lbl_DisclosureOfFinancialAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="lbl_FinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFinancialAssetsLineItems" xlink:to="lbl_FinancialAssets" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="lbl_FinancialLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:to="lbl_FinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="lbl_FinancialLiabilitiesAtAmortisedCostMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialLiabilitiesMember" xlink:to="lbl_FinancialLiabilitiesAtAmortisedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="lbl_FinancialLiabilitiesAtFairValueMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialLiabilitiesMember" xlink:to="lbl_FinancialLiabilitiesAtFairValueMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="lbl_FinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lbl_FinancialLiabilitiesCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="lbl_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialLiabilitiesCategoryMember" xlink:to="lbl_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="lbl_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialLiabilitiesCategoryMember" xlink:to="lbl_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialLiabilitiesCategoryMember" xlink:label="lbl_OtherFinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialLiabilitiesCategoryMember" xlink:to="lbl_OtherFinancialLiabilitiesCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtMember" xlink:label="lbl_CurrentFinancialDebtMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CurrentFinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialDebtMember" xlink:label="lbl_NoncurrentFinancialDebtMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_NoncurrentFinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="lbl_LeaseLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_LeaseLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradePayablesMember" xlink:label="lbl_TradePayablesMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_TradePayablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentForRepurchaseOfOwnSharesMember" xlink:label="lbl_CommitmentForRepurchaseOfOwnSharesMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CommitmentForRepurchaseOfOwnSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_OtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemAxis" xlink:label="lbl_BalanceSheetItemAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_BalanceSheetItemAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemMember" xlink:label="lbl_BalanceSheetItemMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BalanceSheetItemAxis" xlink:to="lbl_BalanceSheetItemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BankAndOtherFinancialDebtMember" xlink:label="lbl_BankAndOtherFinancialDebtMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_BankAndOtherFinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommercialPaperMember" xlink:label="lbl_CommercialPaperMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_CommercialPaperMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPortionOfNoncurrentDebtMember" xlink:label="lbl_CurrentPortionOfNoncurrentDebtMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_CurrentPortionOfNoncurrentDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StraightBondsMember" xlink:label="lbl_StraightBondsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_StraightBondsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:label="lbl_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinanceLeaseObligationsMember" xlink:label="lbl_FinanceLeaseObligationsMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_FinanceLeaseObligationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:label="lbl_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:label="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilities" xlink:label="lbl_FinancialLiabilities" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="lbl_FinancialLiabilities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:label="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:to="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsAxis" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsMember" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractOrUnderlyingPrincipalAmoutMember" xlink:label="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PositiveFairValuesMember" xlink:label="lbl_PositiveFairValuesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_PositiveFairValuesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NegativeFairValuesMember" xlink:label="lbl_NegativeFairValuesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_NegativeFairValuesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:label="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:label="lbl_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:label="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:label="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstruments" xlink:label="lbl_DerivativeFinancialInstruments" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstruments" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_MeasurementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_AggregatedMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RecurringFairValueMeasurementMember" xlink:label="lbl_RecurringFairValueMeasurementMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedMeasurementMember" xlink:to="lbl_RecurringFairValueMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="lbl_Level1OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level1OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="lbl_Level2OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level2OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="lbl_Level3OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level3OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValuedAtAmortizedCostMember" xlink:label="lbl_ValuedAtAmortizedCostMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_ValuedAtAmortizedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialLiabilitiesAtFairValueMember" xlink:label="lbl_CurrentFinancialLiabilitiesAtFairValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CurrentFinancialLiabilitiesAtFairValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialLiabilitiesAtFairValueMember" xlink:label="lbl_NoncurrentFinancialLiabilitiesAtFairValueMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_NoncurrentFinancialLiabilitiesAtFairValueMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="lbl_ClassesOfLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_ClassesOfLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember" xlink:label="lbl_LiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfLiabilitiesAxis" xlink:to="lbl_LiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationPayablesMember" xlink:label="lbl_ContingentConsiderationPayablesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_ContingentConsiderationPayablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_OtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentContingentConsiderationLiabilitiesMember" xlink:label="lbl_NoncurrentContingentConsiderationLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_NoncurrentContingentConsiderationLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="lbl_FinancialLiabilitiesAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_FinancialLiabilitiesAtFairValue" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:label="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:to="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsAxis" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsMember" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractOrUnderlyingPrincipalAmoutMember" xlink:label="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_CurrencyAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CurrencyAxis" xlink:to="lbl_AllCurrenciesDomain" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="lbl_EUR" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_EUR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="lbl_USD" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_USD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY" xlink:label="lbl_JPY" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_JPY" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyOthersMember" xlink:label="lbl_CurrencyOthersMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CurrencyOthersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:label="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:label="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:label="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstruments" xlink:label="lbl_DerivativeFinancialInstruments" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstruments" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:label="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:label="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:label="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="lbl_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:label="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:label="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:label="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:label="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:label="lbl_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PurchasePriceAllocationAssociatesTableTextBlock" xlink:label="lbl_PurchasePriceAllocationAssociatesTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchasePriceAllocationAssociatesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:label="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="lbl_RightofuseAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_RightofuseAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ClassesOfProvisionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_OtherProvisionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestructuringProvisionMember" xlink:label="lbl_RestructuringProvisionMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_RestructuringProvisionMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromInterest" xlink:label="lbl_RevenueFromInterest" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromInterest" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="lbl_DepreciationAndAmortisationExpense" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DepreciationAndAmortisationExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:label="lbl_ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="lbl_AdditionalProvisionsOtherProvisions" xlink:type="locator"/>
      <link:definitionArc order="4.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionalProvisionsOtherProvisions" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestedCashAndCashEquivalents" xlink:label="lbl_DivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DivestedCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsAttributableToDivestedBusiness" xlink:label="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="lbl_StatementScenarioAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementScenarioAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="lbl_ScenarioUnspecifiedDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_StatementScenarioAxis" xlink:to="lbl_ScenarioUnspecifiedDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical100basisPointIncreaseMember" xlink:label="lbl_Hypothetical100basisPointIncreaseMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical100basisPointIncreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical100basisPointDecreaseMember" xlink:label="lbl_Hypothetical100basisPointDecreaseMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical100basisPointDecreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestRateSensitivityImpactInTheIncomeStatement" xlink:label="lbl_InterestRateSensitivityImpactInTheIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestRateSensitivityImpactInTheIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity" xlink:label="lbl_HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:label="lbl_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZolgensmaMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsMaterialToEntity" xlink:label="lbl_IntangibleAssetsMaterialToEntity" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IntangibleAssetsMaterialToEntity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:label="lbl_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeqvioMember" xlink:label="lbl_LeqvioMember" xlink:type="locator"/>
      <link:definitionArc order="0.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LeqvioMember" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCostsRecordedInEquityTextBlock" xlink:label="lbl_TransactionCostsRecordedInEquityTextBlock" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TransactionCostsRecordedInEquityTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DistributionByWayOfDivindendInKindToShareholders" xlink:label="lbl_DistributionByWayOfDivindendInKindToShareholders" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DistributionByWayOfDivindendInKindToShareholders" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:label="lbl_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:label="lbl_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:label="lbl_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:type="locator"/>
      <link:definitionArc order="30.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="locator"/>
      <link:definitionArc order="31.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="32.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:definitionArc order="33.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:type="locator"/>
      <link:definitionArc order="34.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:type="locator"/>
      <link:definitionArc order="35.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice46.4Member" xlink:label="lbl_ExercisePrice46.4Member" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.4Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice46.7Member" xlink:label="lbl_ExercisePrice46.7Member" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.7Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice53.7Member" xlink:label="lbl_ExercisePrice53.7Member" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice53.7Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice54.5Member" xlink:label="lbl_ExercisePrice54.5Member" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice54.5Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.0Member" xlink:label="lbl_ExercisePrice57.0Member" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.0Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.1Member" xlink:label="lbl_ExercisePrice57.1Member" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.1Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.6Member" xlink:label="lbl_ExercisePrice57.6Member" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.6Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice58.3Member" xlink:label="lbl_ExercisePrice58.3Member" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice58.3Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice65.9Member" xlink:label="lbl_ExercisePrice65.9Member" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice65.9Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice66.0Member" xlink:label="lbl_ExercisePrice66.0Member" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.0Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice66.1Member" xlink:label="lbl_ExercisePrice66.1Member" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.1Member" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="lbl_NumberOfOutstandingShareOptions" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:to="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:to="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="lbl_EmployeeBenefitsExpense" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:to="lbl_EmployeeBenefitsExpense" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentivePlanMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:label="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationUKShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationUKShareSavingsPlanMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationUKShareSavingsPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:label="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermPerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationRestrictedSharesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:to="lbl_EquityBasedParticipationRestrictedSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationSpecialShareAwardsMember" xlink:label="lbl_EquityBasedParticipationSpecialShareAwardsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:to="lbl_EquityBasedParticipationSpecialShareAwardsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_RangeAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RangeAxis" xlink:to="lbl_RangesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="lbl_BottomOfRangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesMember" xlink:to="lbl_BottomOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="lbl_TopOfRangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RangesMember" xlink:to="lbl_TopOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:label="lbl_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAnnualIncentive" xlink:label="lbl_DescriptionOfAnnualIncentive" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_DescriptionOfAnnualIncentive" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentiveRSUMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveRSUMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentiveRSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentiveSharesMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveSharesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentiveSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationShareSavingsPlansRSUMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlansRSUMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlansRSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationShareSavingsPlansSharesMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlansSharesMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlansSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:label="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" xlink:label="lbl_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermPerformancePSUPlanMember" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePSUPlanMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermPerformancePSUPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermRelativePerformancePlanPSUMember" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanPSUMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermRelativePerformancePlanPSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsRSUMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsRSUMember" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsRSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsSharesMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsSharesMember" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_MeasurementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_AggregatedMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RecurringFairValueMeasurementMember" xlink:label="lbl_RecurringFairValueMeasurementMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedMeasurementMember" xlink:to="lbl_RecurringFairValueMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="lbl_Level1OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level1OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="lbl_Level2OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level2OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="lbl_Level3OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level3OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValuedAtAmortizedCostMember" xlink:label="lbl_ValuedAtAmortizedCostMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_ValuedAtAmortizedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMember" xlink:label="lbl_CashAndCashEquivalentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CashAndCashEquivalentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:label="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:label="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivablesShorttermMember" xlink:label="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_DebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquitySecuritiesMember" xlink:label="lbl_EquitySecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_EquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_FundInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalAvailableforsaleMarketableSecuritiesMember" xlink:label="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:label="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:label="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AvailableforsaleFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="arc"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:label="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="lbl_FinancialAssetsAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="lbl_FinancialAssetsAtFairValue" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="lbl_RightofuseAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_RightofuseAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsImpairedMember" xlink:label="lbl_FinancialAssetsImpairedMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_FinancialAssetsImpairedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:label="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:to="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:label="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:label="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="lbl_AdjustmentsForSharebasedPayments" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForSharebasedPayments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="lbl_AdjustmentsForFinanceIncomeCost" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAdjustmentsForNoncashItems" xlink:label="lbl_OtherAdjustmentsForNoncashItems" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherAdjustmentsForNoncashItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:label="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" xlink:label="lbl_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" xlink:label="lbl_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementsOfTheRightofuseAssetsRollForward" xlink:label="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="lbl_AdditionsToRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_AdditionsToRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="lbl_DepreciationRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_DepreciationRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseContractTerminationsRightofuseAssets" xlink:label="lbl_LeaseContractTerminationsRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_LeaseContractTerminationsRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisposalsAndRetirementsRightofuseAssets" xlink:label="lbl_DisposalsAndRetirementsRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_DisposalsAndRetirementsRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:label="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:label="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnEquitySecuritiesSoldMember" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesSoldMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnEquitySecuritiesSoldMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetInvestmentHedgeMember" xlink:label="lbl_NetInvestmentHedgeMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_NetInvestmentHedgeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActuarialLossesFromDefinedBenefitPlansMember" xlink:label="lbl_ActuarialLossesFromDefinedBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_ActuarialLossesFromDefinedBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationEffectsMember" xlink:label="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_NoncontrollingInterestsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalFairValueAdjustmentsMember" xlink:label="lbl_TotalFairValueAdjustmentsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EquityMember" xlink:to="lbl_TotalFairValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:label="lbl_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_RestatedValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:label="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeDebtSecurities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainLossOnSaleOfOtherFinancialAssets" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnFinancialAssetsSold" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsRelatedToDivestments" xlink:label="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:label="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes" xlink:label="lbl_CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueAdjustmentsRelatedToDivestmentsMember" xlink:label="lbl_ValueAdjustmentsRelatedToDivestmentsMember" xlink:type="locator"/>
      <link:definitionArc order="5.5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_ValueAdjustmentsRelatedToDivestmentsMember" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureTaxesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ApplicableTaxRate" xlink:label="lbl_ApplicableTaxRate" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ApplicableTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfTaxLosses" xlink:label="lbl_TaxRateEffectOfTaxLosses" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfTaxLosses" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:label="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:label="lbl_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectOfCreditsAndAllowances" xlink:label="lbl_TaxRateEffectOfCreditsAndAllowances" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfCreditsAndAllowances" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:label="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:label="lbl_TaxRateEffectFromChangeInTaxRate" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromChangeInTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfWriteoffOfDeferredTaxAssets" xlink:label="lbl_EffectOfWriteoffOfDeferredTaxAssets" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfWriteoffOfDeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:label="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectFromBenefitsExpiring" xlink:label="lbl_TaxRateEffectFromBenefitsExpiring" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromBenefitsExpiring" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectFromNondeductibleLossesInRegion" xlink:label="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageEffectiveTaxRateContinuingOperations" xlink:label="lbl_AverageEffectiveTaxRateContinuingOperations" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AverageEffectiveTaxRateContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageEffectiveTaxRateDiscontinuedOperations" xlink:label="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageEffectiveTaxRate" xlink:label="lbl_AverageEffectiveTaxRate" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AverageEffectiveTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:label="lbl_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:label="lbl_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfUSTaxReformLegislation" xlink:label="lbl_EffectOfUSTaxReformLegislation" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfUSTaxReformLegislation" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:label="lbl_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ClassesOfProvisionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_OtherProvisionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LegalProceedingsProvisionMember" xlink:label="lbl_LegalProceedingsProvisionMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_LegalProceedingsProvisionMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT" xlink:label="lbl_IT" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_IT" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP" xlink:label="lbl_JP" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_JP" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA" xlink:label="lbl_CA" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CA" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR" xlink:label="lbl_KR" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_KR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR" xlink:label="lbl_FR" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_FR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GR" xlink:label="lbl_GR" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_GR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NAGAndNovartisPharmaSpAMember" xlink:label="lbl_NAGAndNovartisPharmaSpAMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NAGAndNovartisPharmaSpAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FHoffmanLaRocheAGAndRocheSpAMember" xlink:label="lbl_FHoffmanLaRocheAGAndRocheSpAMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_FHoffmanLaRocheAGAndRocheSpAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaKKMember" xlink:label="lbl_NovartisPharmaKKMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NovartisPharmaKKMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NAGMember" xlink:label="lbl_NAGMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NPCAndOthersMember" xlink:label="lbl_NPCAndOthersMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NPCAndOthersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNCMember" xlink:label="lbl_NovartisNCMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NovartisNCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:label="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SolodynMember" xlink:label="lbl_SolodynMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SolodynMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnoxaparinMember" xlink:label="lbl_EnoxaparinMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_EnoxaparinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContactLensesMember" xlink:label="lbl_ContactLensesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ContactLensesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GleevecMember" xlink:label="lbl_GleevecMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GleevecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclastAclastaMember" xlink:label="lbl_ReclastAclastaMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ReclastAclastaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TekturnaRasilezValturnaMember" xlink:label="lbl_TekturnaRasilezValturnaMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TekturnaRasilezValturnaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxotereMember" xlink:label="lbl_TaxotereMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TaxotereMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmiodaroneMember" xlink:label="lbl_AmiodaroneMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AmiodaroneMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TasignaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExforgeGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="lbl_LitigationCaseAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_LitigationCaseAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LitigationCaseMember" xlink:label="lbl_LitigationCaseMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LitigationCaseAxis" xlink:to="lbl_LitigationCaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TennesseeClassActionMember" xlink:label="lbl_TennesseeClassActionMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LitigationCaseMember" xlink:to="lbl_TennesseeClassActionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MassachusettsCaseMember" xlink:label="lbl_MassachusettsCaseMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_LitigationCaseMember" xlink:to="lbl_MassachusettsCaseMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:label="lbl_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:label="lbl_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilities" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfSettlementInPrinciple" xlink:label="lbl_AmountOfSettlementInPrinciple" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_AmountOfSettlementInPrinciple" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionalAmountOfSettlementInPrinciple" xlink:label="lbl_AdditionalAmountOfSettlementInPrinciple" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_AdditionalAmountOfSettlementInPrinciple" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfResolvedAction" xlink:label="lbl_AmountOfResolvedAction" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_AmountOfResolvedAction" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:label="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:label="lbl_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:label="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:label="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:label="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrepaidPostemploymentBenefitPlansAssets" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:to="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:label="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:to="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LandMember" xlink:label="lbl_LandMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_LandMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember" xlink:label="lbl_BuildingsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_BuildingsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_VehiclesMember" xlink:label="lbl_VehiclesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_VehiclesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssetsMember" xlink:label="lbl_OtherAssetsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_OtherAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="lbl_DepreciationRightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_DepreciationRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:label="lbl_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseLiabilitiesUndiscounted" xlink:label="lbl_LeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_LeaseLiabilitiesUndiscounted" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_CurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLeaseLiabilitiesUndiscounted" xlink:label="lbl_CurrentLeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_CurrentLeaseLiabilitiesUndiscounted" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="lbl_NoncurrentLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_NoncurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentLeaseLiabilitiesUndiscounted" xlink:label="lbl_NoncurrentLeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_NoncurrentLeaseLiabilitiesUndiscounted" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentsForLeasesNotYetCommenced" xlink:label="lbl_CommitmentsForLeasesNotYetCommenced" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_CommitmentsForLeasesNotYetCommenced" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MostMaterialLeaseWithLeaseTermExtension" xlink:label="lbl_MostMaterialLeaseWithLeaseTermExtension" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_MostMaterialLeaseWithLeaseTermExtension" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseTermEndDate" xlink:label="lbl_LeaseTermEndDate" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_LeaseTermEndDate" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleAndLeaseBackMember" xlink:label="lbl_SaleAndLeaseBackMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lbl_SaleAndLeaseBackMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowForSaleAndLeaseback" xlink:label="lbl_CashInflowForSaleAndLeaseback" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashInflowForSaleAndLeaseback" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:label="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOutflowForLeases" xlink:label="lbl_CashOutflowForLeases" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashOutflowForLeases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsForShortTermAndLowValueLeases" xlink:label="lbl_CashOutflowsForShortTermAndLowValueLeases" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashOutflowsForShortTermAndLowValueLeases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsForPaymentsOfLeasesInterest" xlink:label="lbl_CashOutflowsForPaymentsOfLeasesInterest" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashOutflowsForPaymentsOfLeasesInterest" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowForSaleAndLeaseback" xlink:label="lbl_CashInflowForSaleAndLeaseback" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashInflowForSaleAndLeaseback" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RepaymentOfLeaseLiability" xlink:label="lbl_RepaymentOfLeaseLiability" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_RepaymentOfLeaseLiability" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:label="lbl_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageInterestRateLeaseLiabilities" xlink:label="lbl_WeightedAverageInterestRateLeaseLiabilities" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_WeightedAverageInterestRateLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseIncentives" xlink:label="lbl_LeaseIncentives" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_LeaseIncentives" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_FranchiseAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_FranchiseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetailGenericsMember" xlink:label="lbl_RetailGenericsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_RetailGenericsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BiopharmaceuticalsMember" xlink:label="lbl_BiopharmaceuticalsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_BiopharmaceuticalsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AntiInfectivesMember" xlink:label="lbl_AntiInfectivesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_FranchiseMember" xlink:to="lbl_AntiInfectivesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AntiInfectivesSoldUnderSandozNameMember" xlink:label="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalAntiinfectivesNetSalesMember" xlink:label="lbl_TotalAntiinfectivesNetSalesMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_TotalAntiinfectivesNetSalesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsAxis" xlink:label="lbl_BrandsAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_BrandsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsMember" xlink:label="lbl_BrandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BrandsAxis" xlink:to="lbl_BrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PromotedBrandsMember" xlink:label="lbl_PromotedBrandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BrandsMember" xlink:to="lbl_PromotedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstablishedBrandsMember" xlink:label="lbl_EstablishedBrandsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BrandsMember" xlink:to="lbl_EstablishedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:to="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CardiovascularMember" xlink:label="lbl_CardiovascularMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_CardiovascularMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImmunologyMember" xlink:label="lbl_ImmunologyMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_ImmunologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeuroscienceMember" xlink:label="lbl_NeuroscienceMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_NeuroscienceMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SolidTumorMember" xlink:label="lbl_SolidTumorMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_SolidTumorMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HematologyMember" xlink:label="lbl_HematologyMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_HematologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPromotedBrandsMember" xlink:label="lbl_OtherPromotedBrandsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_OtherPromotedBrandsMember" xlink:type="arc"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_EstablishedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_COPDMember" xlink:label="lbl_COPDMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_COPDMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EntrestoMember" xlink:label="lbl_EntrestoMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_EntrestoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeqvioMember" xlink:label="lbl_LeqvioMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LeqvioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CosentyxMember" xlink:label="lbl_CosentyxMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_CosentyxMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XolairMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IlarisMember" xlink:label="lbl_IlarisMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_IlarisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GilenyaMember" xlink:label="lbl_GilenyaMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GilenyaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZolgensmaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KesimptaMember" xlink:label="lbl_KesimptaMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KesimptaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MayzentMember" xlink:label="lbl_MayzentMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_MayzentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AimovigMember" xlink:label="lbl_AimovigMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AimovigMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TafinlarMekinistMember" xlink:label="lbl_TafinlarMekinistMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TafinlarMekinistMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KisqaliMember" xlink:label="lbl_KisqaliMember" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KisqaliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VotrientMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LutatheraMember" xlink:label="lbl_LutatheraMember" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LutatheraMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PiqrayMember" xlink:label="lbl_PiqrayMember" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PiqrayMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PluvictoMember" xlink:label="lbl_PluvictoMember" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PluvictoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TabrectaMember" xlink:label="lbl_TabrectaMember" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TabrectaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PromactaRevoladeMember" xlink:label="lbl_PromactaRevoladeMember" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PromactaRevoladeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TasignaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JakaviMember" xlink:label="lbl_JakaviMember" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_JakaviMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KymriahMember" xlink:label="lbl_KymriahMember" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KymriahMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdakveoMember" xlink:label="lbl_AdakveoMember" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AdakveoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScemblixMember" xlink:label="lbl_ScemblixMember" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ScemblixMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherHematologyMember" xlink:label="lbl_OtherHematologyMember" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherHematologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_XiidraMember" xlink:label="lbl_XiidraMember" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XiidraMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UltibroGroupMember" xlink:label="lbl_UltibroGroupMember" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_UltibroGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BeovuMember" xlink:label="lbl_BeovuMember" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_BeovuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherRespiratoryMember" xlink:label="lbl_OtherRespiratoryMember" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherRespiratoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandostatinMember" xlink:label="lbl_SandostatinMember" xlink:type="locator"/>
      <link:definitionArc order="30.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SandostatinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GalvusGroupMember" xlink:label="lbl_GalvusGroupMember" xlink:type="locator"/>
      <link:definitionArc order="31.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GalvusGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GleevecGlivecMember" xlink:label="lbl_GleevecGlivecMember" xlink:type="locator"/>
      <link:definitionArc order="32.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GleevecGlivecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:definitionArc order="33.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExforgeGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DiovanGroupMember" xlink:label="lbl_DiovanGroupMember" xlink:type="locator"/>
      <link:definitionArc order="34.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_DiovanGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AfinitorVotubiaMember" xlink:label="lbl_AfinitorVotubiaMember" xlink:type="locator"/>
      <link:definitionArc order="35.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AfinitorVotubiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VoltarenCataflamMember" xlink:label="lbl_VoltarenCataflamMember" xlink:type="locator"/>
      <link:definitionArc order="36.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VoltarenCataflamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZortressCerticanMember" xlink:label="lbl_ZortressCerticanMember" xlink:type="locator"/>
      <link:definitionArc order="37.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZortressCerticanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExjadeJadenuMember" xlink:label="lbl_ExjadeJadenuMember" xlink:type="locator"/>
      <link:definitionArc order="38.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExjadeJadenuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeoralSandimmunEMember" xlink:label="lbl_NeoralSandimmunEMember" xlink:type="locator"/>
      <link:definitionArc order="39.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_NeoralSandimmunEMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractManufacturingMember" xlink:label="lbl_ContractManufacturingMember" xlink:type="locator"/>
      <link:definitionArc order="40.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ContractManufacturingMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherProductsMember" xlink:label="lbl_OtherProductsMember" xlink:type="locator"/>
      <link:definitionArc order="41.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MatureOphthaMember" xlink:label="lbl_MatureOphthaMember" xlink:type="locator"/>
      <link:definitionArc order="42.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_MatureOphthaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UltibroBreezhalerMember" xlink:label="lbl_UltibroBreezhalerMember" xlink:type="locator"/>
      <link:definitionArc order="43.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_UltibroBreezhalerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherSolidTumorMember" xlink:label="lbl_OtherSolidTumorMember" xlink:type="locator"/>
      <link:definitionArc order="44.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherSolidTumorMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TravoprostGroupMember" xlink:label="lbl_TravoprostGroupMember" xlink:type="locator"/>
      <link:definitionArc order="45.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TravoprostGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SeebriBreezhalerMember" xlink:label="lbl_SeebriBreezhalerMember" xlink:type="locator"/>
      <link:definitionArc order="46.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SeebriBreezhalerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OnbrezBreezhalerMember" xlink:label="lbl_OnbrezBreezhalerMember" xlink:type="locator"/>
      <link:definitionArc order="47.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OnbrezBreezhalerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SystaneGroupMember" xlink:label="lbl_SystaneGroupMember" xlink:type="locator"/>
      <link:definitionArc order="48.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SystaneGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TopicalOlopatadineGroupMember" xlink:label="lbl_TopicalOlopatadineGroupMember" xlink:type="locator"/>
      <link:definitionArc order="49.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TopicalOlopatadineGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MyforticMember" xlink:label="lbl_MyforticMember" xlink:type="locator"/>
      <link:definitionArc order="50.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_MyforticMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExelonExelonPatchMember" xlink:label="lbl_ExelonExelonPatchMember" xlink:type="locator"/>
      <link:definitionArc order="51.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExelonExelonPatchMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RitalinFocalinMember" xlink:label="lbl_RitalinFocalinMember" xlink:type="locator"/>
      <link:definitionArc order="52.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_RitalinFocalinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestOfTheWorldMember" xlink:label="lbl_RestOfTheWorldMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_RestOfTheWorldMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsAxis" xlink:label="lbl_BrandsAxis" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_BrandsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsMember" xlink:label="lbl_BrandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BrandsAxis" xlink:to="lbl_BrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PromotedBrandsMember" xlink:label="lbl_PromotedBrandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BrandsMember" xlink:to="lbl_PromotedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstablishedBrandsMember" xlink:label="lbl_EstablishedBrandsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BrandsMember" xlink:to="lbl_EstablishedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:to="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CardiovascularMember" xlink:label="lbl_CardiovascularMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_CardiovascularMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImmunologyMember" xlink:label="lbl_ImmunologyMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_ImmunologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeuroscienceMember" xlink:label="lbl_NeuroscienceMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_NeuroscienceMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SolidTumorMember" xlink:label="lbl_SolidTumorMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_SolidTumorMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HematologyMember" xlink:label="lbl_HematologyMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_HematologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPromotedBrandsMember" xlink:label="lbl_OtherPromotedBrandsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_OtherPromotedBrandsMember" xlink:type="arc"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_EstablishedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Top20ProductsMember" xlink:label="lbl_Top20ProductsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_Top20ProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestOfPortfolioMember" xlink:label="lbl_RestOfPortfolioMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_RestOfPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CosentyxMember" xlink:label="lbl_CosentyxMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_CosentyxMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EntrestoMember" xlink:label="lbl_EntrestoMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_EntrestoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PromactaRevoladeMember" xlink:label="lbl_PromactaRevoladeMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PromactaRevoladeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GilenyaMember" xlink:label="lbl_GilenyaMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GilenyaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TasignaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TafinlarMekinistMember" xlink:label="lbl_TafinlarMekinistMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TafinlarMekinistMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JakaviMember" xlink:label="lbl_JakaviMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_JakaviMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZolgensmaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XolairMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandostatinMember" xlink:label="lbl_SandostatinMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SandostatinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KisqaliMember" xlink:label="lbl_KisqaliMember" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KisqaliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IlarisMember" xlink:label="lbl_IlarisMember" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_IlarisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KesimptaMember" xlink:label="lbl_KesimptaMember" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KesimptaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GalvusGroupMember" xlink:label="lbl_GalvusGroupMember" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GalvusGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GleevecGlivecMember" xlink:label="lbl_GleevecGlivecMember" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GleevecGlivecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExforgeGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DiovanGroupMember" xlink:label="lbl_DiovanGroupMember" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_DiovanGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KymriahMember" xlink:label="lbl_KymriahMember" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KymriahMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AfinitorVotubiaMember" xlink:label="lbl_AfinitorVotubiaMember" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AfinitorVotubiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExjadeJadenuMember" xlink:label="lbl_ExjadeJadenuMember" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExjadeJadenuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VotrientMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZortressCerticanMember" xlink:label="lbl_ZortressCerticanMember" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZortressCerticanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TravoprostGroupMember" xlink:label="lbl_TravoprostGroupMember" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TravoprostGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeoralSandimmunEMember" xlink:label="lbl_NeoralSandimmunEMember" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_NeoralSandimmunEMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VoltarenCataflamMember" xlink:label="lbl_VoltarenCataflamMember" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VoltarenCataflamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExelonExelonPatchMember" xlink:label="lbl_ExelonExelonPatchMember" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExelonExelonPatchMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdakveoMember" xlink:label="lbl_AdakveoMember" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AdakveoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UltibroGroupMember" xlink:label="lbl_UltibroGroupMember" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_UltibroGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:label="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:to="lbl_CurrencyAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_CurrencyAxis" xlink:to="lbl_AllCurrenciesDomain" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="lbl_USD" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_USD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="lbl_EUR" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_EUR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_RUB" xlink:label="lbl_RUB" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_RUB" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY" xlink:label="lbl_JPY" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_JPY" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_GBP" xlink:label="lbl_GBP" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_GBP" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CNY" xlink:label="lbl_CNY" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CNY" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CAD" xlink:label="lbl_CAD" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CAD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_BRL" xlink:label="lbl_BRL" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_BRL" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD" xlink:label="lbl_AUD" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_AUD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF" xlink:label="lbl_CHF" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CHF" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyOthersMember" xlink:label="lbl_CurrencyOthersMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CurrencyOthersMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonCurrentFinancialDebtsMember" xlink:label="lbl_NonCurrentFinancialDebtsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NonCurrentFinancialDebtsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:label="lbl_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentLeaseLiabilitiesMember" xlink:label="lbl_NoncurrentLeaseLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NoncurrentLeaseLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLeaseLiabilitiesMember" xlink:label="lbl_CurrentLeaseLiabilitiesMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_CurrentLeaseLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialDebtsAndDerivativeInstruments" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:label="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:label="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:label="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationOfBondsDiscount" xlink:label="lbl_AmortizationOfBondsDiscount" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AmortizationOfBondsDiscount" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclassificationFromNoncurrentToCurrentNet" xlink:label="lbl_ReclassificationFromNoncurrentToCurrentNet" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ReclassificationFromNoncurrentToCurrentNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPortionOfNoncurrentFinancialDebt" xlink:label="lbl_CurrentPortionOfNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentPortionOfNoncurrentFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:label="lbl_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" xlink:label="lbl_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" xlink:type="arc"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="lbl_EntitysTotalForSubsidiariesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lbl_EntitysTotalForSubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubsidiariesMember" xlink:label="lbl_SubsidiariesMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntitysTotalForSubsidiariesMember" xlink:to="lbl_SubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SocieteParActionsSANDOZAlgiersMember" xlink:label="lbl_SocieteParActionsSANDOZAlgiersMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SocieteParActionsSANDOZAlgiersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisArgentinaS.A.BuenosAiresMember" xlink:label="lbl_NovartisArgentinaS.A.BuenosAiresMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisArgentinaS.A.BuenosAiresMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPtyLtdMacquarieParkNSWMember" xlink:label="lbl_SandozPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisAustriaGmbHViennaMember" xlink:label="lbl_NovartisAustriaGmbHViennaMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisAustriaGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaGmbHViennaMember" xlink:label="lbl_NovartisPharmaGmbHViennaMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozGmbHViennaMember" xlink:label="lbl_SandozGmbHViennaMember" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:label="lbl_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBangladeshLimitedGazipurMember" xlink:label="lbl_NovartisBangladeshLimitedGazipurMember" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBangladeshLimitedGazipurMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaNVVilvoordeMember" xlink:label="lbl_NovartisPharmaNVVilvoordeMember" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaNVVilvoordeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozNVVilvoordeMember" xlink:label="lbl_SandozNVVilvoordeMember" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozNVVilvoordeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCouvreurNVPuursMember" xlink:label="lbl_AlconCouvreurNVPuursMember" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCouvreurNVPuursMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInvestmentLtd.HamiltonMember" xlink:label="lbl_NovartisInvestmentLtd.HamiltonMember" xlink:type="locator"/>
      <link:definitionArc order="14.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInvestmentLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:label="lbl_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:type="locator"/>
      <link:definitionArc order="15.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceServicesLtd.HamiltonMember" xlink:label="lbl_NovartisFinanceServicesLtd.HamiltonMember" xlink:type="locator"/>
      <link:definitionArc order="16.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceServicesLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:label="lbl_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:type="locator"/>
      <link:definitionArc order="17.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:label="lbl_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:type="locator"/>
      <link:definitionArc order="18.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBiocienciasS.A.SaoPauloMember" xlink:label="lbl_NovartisBiocienciasS.A.SaoPauloMember" xlink:type="locator"/>
      <link:definitionArc order="19.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBiocienciasS.A.SaoPauloMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:label="lbl_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:type="locator"/>
      <link:definitionArc order="20.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:label="lbl_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:type="locator"/>
      <link:definitionArc order="21.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozCanadaInc.BouchervilleQuebecMember" xlink:label="lbl_SandozCanadaInc.BouchervilleQuebecMember" xlink:type="locator"/>
      <link:definitionArc order="22.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozCanadaInc.BouchervilleQuebecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisChileS.A.SantiagoDeChileMember" xlink:label="lbl_NovartisChileS.A.SantiagoDeChileMember" xlink:type="locator"/>
      <link:definitionArc order="23.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisChileS.A.SantiagoDeChileMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:label="lbl_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:type="locator"/>
      <link:definitionArc order="24.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:label="lbl_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:type="locator"/>
      <link:definitionArc order="25.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:label="lbl_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:type="locator"/>
      <link:definitionArc order="26.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:label="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:type="locator"/>
      <link:definitionArc order="27.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:label="lbl_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:type="locator"/>
      <link:definitionArc order="28.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:label="lbl_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:type="locator"/>
      <link:definitionArc order="29.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:label="lbl_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:type="locator"/>
      <link:definitionArc order="30.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:label="lbl_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:type="locator"/>
      <link:definitionArc order="31.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisS.r.o.PragueMember" xlink:label="lbl_NovartisS.r.o.PragueMember" xlink:type="locator"/>
      <link:definitionArc order="32.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisS.r.o.PragueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.r.o.PragueMember" xlink:label="lbl_SandozS.r.o.PragueMember" xlink:type="locator"/>
      <link:definitionArc order="33.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.r.o.PragueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHealthcareASCopenhagenMember" xlink:label="lbl_NovartisHealthcareASCopenhagenMember" xlink:type="locator"/>
      <link:definitionArc order="34.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHealthcareASCopenhagenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozASCopenhagenMember" xlink:label="lbl_SandozASCopenhagenMember" xlink:type="locator"/>
      <link:definitionArc order="35.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozASCopenhagenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisEcuadorS.A.QuitoMember" xlink:label="lbl_NovartisEcuadorS.A.QuitoMember" xlink:type="locator"/>
      <link:definitionArc order="36.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisEcuadorS.A.QuitoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaS.A.E.CairoMember" xlink:label="lbl_NovartisPharmaS.A.E.CairoMember" xlink:type="locator"/>
      <link:definitionArc order="37.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaS.A.E.CairoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:label="lbl_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:type="locator"/>
      <link:definitionArc order="38.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinlandOyEspooMember" xlink:label="lbl_NovartisFinlandOyEspooMember" xlink:type="locator"/>
      <link:definitionArc order="39.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinlandOyEspooMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:label="lbl_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:type="locator"/>
      <link:definitionArc order="40.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:label="lbl_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:definitionArc order="41.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember" xlink:label="lbl_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:definitionArc order="42.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember" xlink:type="arc"/>
      <link:definitionArc order="43.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember" xlink:label="lbl_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember" xlink:type="locator"/>
      <link:definitionArc order="44.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CELLforCURELesUlisMember" xlink:label="lbl_CELLforCURELesUlisMember" xlink:type="locator"/>
      <link:definitionArc order="45.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CELLforCURELesUlisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.A.S.LevalloisPerretMember" xlink:label="lbl_SandozS.A.S.LevalloisPerretMember" xlink:type="locator"/>
      <link:definitionArc order="46.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.A.S.LevalloisPerretMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeutschlandGmbHNurembergMember" xlink:label="lbl_NovartisDeutschlandGmbHNurembergMember" xlink:type="locator"/>
      <link:definitionArc order="47.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeutschlandGmbHNurembergMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBusinessServicesGmbHWehrMember" xlink:label="lbl_NovartisBusinessServicesGmbHWehrMember" xlink:type="locator"/>
      <link:definitionArc order="48.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBusinessServicesGmbHWehrMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaGmbHNurembergMember" xlink:label="lbl_NovartisPharmaGmbHNurembergMember" xlink:type="locator"/>
      <link:definitionArc order="49.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaGmbHNurembergMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaProduktionsGmbHWehrMember" xlink:label="lbl_NovartisPharmaProduktionsGmbHWehrMember" xlink:type="locator"/>
      <link:definitionArc order="50.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaProduktionsGmbHWehrMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozInternationalGmbHHolzkirchenMember" xlink:label="lbl_SandozInternationalGmbHHolzkirchenMember" xlink:type="locator"/>
      <link:definitionArc order="51.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozInternationalGmbHHolzkirchenMember" xlink:type="arc"/>
      <link:definitionArc order="52.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_A1APharmaGmbHHolzkirchenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HEXALAGHolzkirchenMember" xlink:label="lbl_HEXALAGHolzkirchenMember" xlink:type="locator"/>
      <link:definitionArc order="53.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_HEXALAGHolzkirchenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SalutasPharmaGmbHBarlebenMember" xlink:label="lbl_SalutasPharmaGmbHBarlebenMember" xlink:type="locator"/>
      <link:definitionArc order="54.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SalutasPharmaGmbHBarlebenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AeropharmGmbHRudolstadtMember" xlink:label="lbl_AeropharmGmbHRudolstadtMember" xlink:type="locator"/>
      <link:definitionArc order="55.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AeropharmGmbHRudolstadtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:label="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="locator"/>
      <link:definitionArc order="56.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:label="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:type="locator"/>
      <link:definitionArc order="57.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:label="lbl_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:type="locator"/>
      <link:definitionArc order="58.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIndiaLimitedMumbaiMember" xlink:label="lbl_NovartisIndiaLimitedMumbaiMember" xlink:type="locator"/>
      <link:definitionArc order="59.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIndiaLimitedMumbaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:label="lbl_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:type="locator"/>
      <link:definitionArc order="60.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPrivateLimitedMumbaiMember" xlink:label="lbl_SandozPrivateLimitedMumbaiMember" xlink:type="locator"/>
      <link:definitionArc order="61.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPrivateLimitedMumbaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PT.NovartisIndonesiaJakartaMember" xlink:label="lbl_PT.NovartisIndonesiaJakartaMember" xlink:type="locator"/>
      <link:definitionArc order="62.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_PT.NovartisIndonesiaJakartaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIrelandLimitedDublinMember" xlink:label="lbl_NovartisIrelandLimitedDublinMember" xlink:type="locator"/>
      <link:definitionArc order="63.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIrelandLimitedDublinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:label="lbl_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:type="locator"/>
      <link:definitionArc order="64.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGeneTherapiesEULimitedDublinMember" xlink:label="lbl_NovartisGeneTherapiesEULimitedDublinMember" xlink:type="locator"/>
      <link:definitionArc order="65.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGeneTherapiesEULimitedDublinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIsraelLtd.TelAvivMember" xlink:label="lbl_NovartisIsraelLtd.TelAvivMember" xlink:type="locator"/>
      <link:definitionArc order="66.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIsraelLtd.TelAvivMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaS.p.A.MilanMember" xlink:label="lbl_NovartisFarmaS.p.A.MilanMember" xlink:type="locator"/>
      <link:definitionArc order="67.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaS.p.A.MilanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:label="lbl_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:type="locator"/>
      <link:definitionArc order="68.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.p.A.OriggioMember" xlink:label="lbl_SandozS.p.A.OriggioMember" xlink:type="locator"/>
      <link:definitionArc order="69.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.p.A.OriggioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaK.K.TokyoMember" xlink:label="lbl_NovartisPharmaK.K.TokyoMember" xlink:type="locator"/>
      <link:definitionArc order="70.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CibaGeigyJapanLimitedTokyoMember" xlink:label="lbl_CibaGeigyJapanLimitedTokyoMember" xlink:type="locator"/>
      <link:definitionArc order="71.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CibaGeigyJapanLimitedTokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozK.K.TokyoMember" xlink:label="lbl_SandozK.K.TokyoMember" xlink:type="locator"/>
      <link:definitionArc order="72.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBalticsSIARigaMember" xlink:label="lbl_NovartisBalticsSIARigaMember" xlink:type="locator"/>
      <link:definitionArc order="73.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBalticsSIARigaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:label="lbl_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:type="locator"/>
      <link:definitionArc order="74.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceS.A.LuxembourgCityMember" xlink:label="lbl_NovartisFinanceS.A.LuxembourgCityMember" xlink:type="locator"/>
      <link:definitionArc order="75.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceS.A.LuxembourgCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember" xlink:label="lbl_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="locator"/>
      <link:definitionArc order="76.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:label="lbl_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:definitionArc order="77.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.A.DeC.V.MexicoCityMember" xlink:label="lbl_SandozS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:definitionArc order="78.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.A.DeC.V.MexicoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaMarocSACasablancaMember" xlink:label="lbl_NovartisPharmaMarocSACasablancaMember" xlink:type="locator"/>
      <link:definitionArc order="79.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaMarocSACasablancaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNetherlandsB.V.AmsterdamMember" xlink:label="lbl_NovartisNetherlandsB.V.AmsterdamMember" xlink:type="locator"/>
      <link:definitionArc order="80.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNetherlandsB.V.AmsterdamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaB.V.AmsterdamMember" xlink:label="lbl_NovartisPharmaB.V.AmsterdamMember" xlink:type="locator"/>
      <link:definitionArc order="81.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaB.V.AmsterdamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IDBHollandBVBaarleNassauMember" xlink:label="lbl_IDBHollandBVBaarleNassauMember" xlink:type="locator"/>
      <link:definitionArc order="82.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_IDBHollandBVBaarleNassauMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozB.V.AlmereMember" xlink:label="lbl_SandozB.V.AlmereMember" xlink:type="locator"/>
      <link:definitionArc order="83.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozB.V.AlmereMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNewZealandLtdAucklandMember" xlink:label="lbl_NovartisNewZealandLtdAucklandMember" xlink:type="locator"/>
      <link:definitionArc order="84.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNewZealandLtdAucklandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNorgeASOsloMember" xlink:label="lbl_NovartisNorgeASOsloMember" xlink:type="locator"/>
      <link:definitionArc order="85.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNorgeASOsloMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaPakistanLimitedKarachiMember" xlink:label="lbl_NovartisPharmaPakistanLimitedKarachiMember" xlink:type="locator"/>
      <link:definitionArc order="86.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaPakistanLimitedKarachiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:label="lbl_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:type="locator"/>
      <link:definitionArc order="87.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:label="lbl_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:type="locator"/>
      <link:definitionArc order="88.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPhilippinesCorporationMakatiCityMember" xlink:label="lbl_SandozPhilippinesCorporationMakatiCityMember" xlink:type="locator"/>
      <link:definitionArc order="89.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPhilippinesCorporationMakatiCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPolandSp.ZO.o.WarsawMember" xlink:label="lbl_NovartisPolandSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:definitionArc order="90.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPolandSp.ZO.o.WarsawMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPolskaSp.ZO.o.WarsawMember" xlink:label="lbl_SandozPolskaSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:definitionArc order="91.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPolskaSp.ZO.o.WarsawMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LekS.A.StrykowMember" xlink:label="lbl_LekS.A.StrykowMember" xlink:type="locator"/>
      <link:definitionArc order="92.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_LekS.A.StrykowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:label="lbl_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:type="locator"/>
      <link:definitionArc order="93.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:label="lbl_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:type="locator"/>
      <link:definitionArc order="94.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozFarmaceuticaLda.PortoSalvoMember" xlink:label="lbl_SandozFarmaceuticaLda.PortoSalvoMember" xlink:type="locator"/>
      <link:definitionArc order="95.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozFarmaceuticaLda.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:label="lbl_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:type="locator"/>
      <link:definitionArc order="96.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.R.L.TarguMuresMember" xlink:label="lbl_SandozS.R.L.TarguMuresMember" xlink:type="locator"/>
      <link:definitionArc order="97.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.R.L.TarguMuresMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaLLCMoscowMember" xlink:label="lbl_NovartisPharmaLLCMoscowMember" xlink:type="locator"/>
      <link:definitionArc order="98.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaLLCMoscowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNevaLLCSt.PetersburgMember" xlink:label="lbl_NovartisNevaLLCSt.PetersburgMember" xlink:type="locator"/>
      <link:definitionArc order="99.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNevaLLCSt.PetersburgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JSCSandozMoscowMember" xlink:label="lbl_JSCSandozMoscowMember" xlink:type="locator"/>
      <link:definitionArc order="100.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_JSCSandozMoscowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSaudiLtd.RiyadhMember" xlink:label="lbl_NovartisSaudiLtd.RiyadhMember" xlink:type="locator"/>
      <link:definitionArc order="101.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSaudiLtd.RiyadhMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSingaporePteLtd.SingaporeMember" xlink:label="lbl_NovartisSingaporePteLtd.SingaporeMember" xlink:type="locator"/>
      <link:definitionArc order="102.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSingaporePteLtd.SingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:label="lbl_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:type="locator"/>
      <link:definitionArc order="103.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:label="lbl_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:type="locator"/>
      <link:definitionArc order="104.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSlovakiaS.r.o.BratislavaMember" xlink:label="lbl_NovartisSlovakiaS.r.o.BratislavaMember" xlink:type="locator"/>
      <link:definitionArc order="105.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSlovakiaS.r.o.BratislavaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LekPharmaceuticalsD.d.LjubjanaMember" xlink:label="lbl_LekPharmaceuticalsD.d.LjubjanaMember" xlink:type="locator"/>
      <link:definitionArc order="106.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_LekPharmaceuticalsD.d.LjubjanaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:label="lbl_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:type="locator"/>
      <link:definitionArc order="107.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSouthAfricaPtyLtdMidrandMember" xlink:label="lbl_NovartisSouthAfricaPtyLtdMidrandMember" xlink:type="locator"/>
      <link:definitionArc order="108.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSouthAfricaPtyLtdMidrandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozSouthAfricaPtyLtdMidrandMember" xlink:label="lbl_SandozSouthAfricaPtyLtdMidrandMember" xlink:type="locator"/>
      <link:definitionArc order="109.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozSouthAfricaPtyLtdMidrandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisKoreaLtd.SeoulMember" xlink:label="lbl_NovartisKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:definitionArc order="110.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisKoreaLtd.SeoulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:label="lbl_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:type="locator"/>
      <link:definitionArc order="111.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:label="lbl_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:type="locator"/>
      <link:definitionArc order="112.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozFarmaceuticaS.A.MadridMember" xlink:label="lbl_SandozFarmaceuticaS.A.MadridMember" xlink:type="locator"/>
      <link:definitionArc order="113.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozFarmaceuticaS.A.MadridMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember" xlink:label="lbl_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember" xlink:type="locator"/>
      <link:definitionArc order="114.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:label="lbl_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:type="locator"/>
      <link:definitionArc order="115.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSverigeABStockholmMember" xlink:label="lbl_NovartisSverigeABStockholmMember" xlink:type="locator"/>
      <link:definitionArc order="116.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSverigeABStockholmMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHoldingAGBaselMember" xlink:label="lbl_NovartisHoldingAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="117.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHoldingAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:label="lbl_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="118.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBioventuresAGBaselMember" xlink:label="lbl_NovartisBioventuresAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="119.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBioventuresAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisForschungsstiftungBaselMember" xlink:label="lbl_NovartisForschungsstiftungBaselMember" xlink:type="locator"/>
      <link:definitionArc order="120.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisForschungsstiftungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisStiftungFuerKaderausbildungBaselMember" xlink:label="lbl_NovartisStiftungFuerKaderausbildungBaselMember" xlink:type="locator"/>
      <link:definitionArc order="121.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisStiftungFuerKaderausbildungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:label="lbl_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:type="locator"/>
      <link:definitionArc order="122.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:label="lbl_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:type="locator"/>
      <link:definitionArc order="123.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:label="lbl_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:type="locator"/>
      <link:definitionArc order="124.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisOverseasInvestmentsAGBaselMember" xlink:label="lbl_NovartisOverseasInvestmentsAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="125.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisOverseasInvestmentsAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JapatAGBaselMember" xlink:label="lbl_JapatAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="126.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_JapatAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaAGBaselMember" xlink:label="lbl_NovartisPharmaAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="127.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaServicesAGBaselMember" xlink:label="lbl_NovartisPharmaServicesAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="128.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaServicesAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:label="lbl_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:type="locator"/>
      <link:definitionArc order="129.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaSteinAGSteinMember" xlink:label="lbl_NovartisPharmaSteinAGSteinMember" xlink:type="locator"/>
      <link:definitionArc order="130.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaSteinAGSteinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaSchweizAGRischMember" xlink:label="lbl_NovartisPharmaSchweizAGRischMember" xlink:type="locator"/>
      <link:definitionArc order="131.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaSchweizAGRischMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CellerysAGSchlierenMember" xlink:label="lbl_CellerysAGSchlierenMember" xlink:type="locator"/>
      <link:definitionArc order="132.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CellerysAGSchlierenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ArctosMedicalAGBernMember" xlink:label="lbl_ArctosMedicalAGBernMember" xlink:type="locator"/>
      <link:definitionArc order="133.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ArctosMedicalAGBernMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInnovativeTherapiesAGRischMember" xlink:label="lbl_NovartisInnovativeTherapiesAGRischMember" xlink:type="locator"/>
      <link:definitionArc order="134.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInnovativeTherapiesAGRischMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:label="lbl_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:type="locator"/>
      <link:definitionArc order="135.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozAGBaselMember" xlink:label="lbl_SandozAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="136.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPharmaceuticalsAGRischMember" xlink:label="lbl_SandozPharmaceuticalsAGRischMember" xlink:type="locator"/>
      <link:definitionArc order="137.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPharmaceuticalsAGRischMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:label="lbl_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:type="locator"/>
      <link:definitionArc order="138.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisThailandLimitedBangkokMember" xlink:label="lbl_NovartisThailandLimitedBangkokMember" xlink:type="locator"/>
      <link:definitionArc order="139.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisThailandLimitedBangkokMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:label="lbl_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:definitionArc order="140.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:label="lbl_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:type="locator"/>
      <link:definitionArc order="141.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:label="lbl_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:definitionArc order="142.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:label="lbl_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:type="locator"/>
      <link:definitionArc order="143.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozUkraineLLCKievMember" xlink:label="lbl_SandozUkraineLLCKievMember" xlink:type="locator"/>
      <link:definitionArc order="144.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozUkraineLLCKievMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisMiddleEastFZEDubaiMember" xlink:label="lbl_NovartisMiddleEastFZEDubaiMember" xlink:type="locator"/>
      <link:definitionArc order="145.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisMiddleEastFZEDubaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUKLimitedLondonMember" xlink:label="lbl_NovartisUKLimitedLondonMember" xlink:type="locator"/>
      <link:definitionArc order="146.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUKLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:label="lbl_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:type="locator"/>
      <link:definitionArc order="147.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGrimsbyLimitedLondonMember" xlink:label="lbl_NovartisGrimsbyLimitedLondonMember" xlink:type="locator"/>
      <link:definitionArc order="148.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGrimsbyLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:type="locator"/>
      <link:definitionArc order="149.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeutecPharmaLimitedLondonMember" xlink:label="lbl_NeutecPharmaLimitedLondonMember" xlink:type="locator"/>
      <link:definitionArc order="150.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NeutecPharmaLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GyroscopeTherapeuticsLimitedLondonMember" xlink:label="lbl_GyroscopeTherapeuticsLimitedLondonMember" xlink:type="locator"/>
      <link:definitionArc order="151.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GyroscopeTherapeuticsLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozLimitedFrimleyCamberleyMember" xlink:label="lbl_SandozLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:definitionArc order="152.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCorporationEastHanoverNYMember" xlink:label="lbl_NovartisCorporationEastHanoverNYMember" xlink:type="locator"/>
      <link:definitionArc order="153.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCorporationEastHanoverNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceCorporationNewYorkNYMember" xlink:label="lbl_NovartisFinanceCorporationNewYorkNYMember" xlink:type="locator"/>
      <link:definitionArc order="154.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceCorporationNewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationEastHanoverNJMember" xlink:label="lbl_NovartisCapitalCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="155.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCapitalCorporationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisServicesInc.EastHanoverNYMember" xlink:label="lbl_NovartisServicesInc.EastHanoverNYMember" xlink:type="locator"/>
      <link:definitionArc order="156.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisServicesInc.EastHanoverNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUSFoundationEastHanoverNJMember" xlink:label="lbl_NovartisUSFoundationEastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="157.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUSFoundationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:label="lbl_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:type="locator"/>
      <link:definitionArc order="158.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:type="locator"/>
      <link:definitionArc order="159.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGeneTherapiesInc.BannockburnILMember" xlink:label="lbl_NovartisGeneTherapiesInc.BannockburnILMember" xlink:type="locator"/>
      <link:definitionArc order="160.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGeneTherapiesInc.BannockburnILMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:label="lbl_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="161.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:label="lbl_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:type="locator"/>
      <link:definitionArc order="162.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CadentTherapeuticsCambridgeMAMember" xlink:label="lbl_CadentTherapeuticsCambridgeMAMember" xlink:type="locator"/>
      <link:definitionArc order="163.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CadentTherapeuticsCambridgeMAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EndocyteInc.EastHanoverNJMember" xlink:label="lbl_EndocyteInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="164.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EndocyteInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:label="lbl_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:type="locator"/>
      <link:definitionArc order="165.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TheMedicinesCompanyMember" xlink:label="lbl_TheMedicinesCompanyMember" xlink:type="locator"/>
      <link:definitionArc order="166.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TheMedicinesCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozInc.PrincetonNJMember" xlink:label="lbl_SandozInc.PrincetonNJMember" xlink:type="locator"/>
      <link:definitionArc order="167.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozInc.PrincetonNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OrielTherapeuticsInc.DurhamNCMember" xlink:label="lbl_OrielTherapeuticsInc.DurhamNCMember" xlink:type="locator"/>
      <link:definitionArc order="168.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_OrielTherapeuticsInc.DurhamNCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:label="lbl_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:type="locator"/>
      <link:definitionArc order="169.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EonLabsInc.PrincetonNJMember" xlink:label="lbl_EonLabsInc.PrincetonNJMember" xlink:type="locator"/>
      <link:definitionArc order="170.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EonLabsInc.PrincetonNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeVenezuelaS.A.CaracasMember" xlink:label="lbl_NovartisDeVenezuelaS.A.CaracasMember" xlink:type="locator"/>
      <link:definitionArc order="171.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeVenezuelaS.A.CaracasMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:label="lbl_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:type="locator"/>
      <link:definitionArc order="172.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozManufacturingInc.Member" xlink:label="lbl_SandozManufacturingInc.Member" xlink:type="locator"/>
      <link:definitionArc order="173.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozManufacturingInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KedalionTherapeuticsInc.MenloParkCAMember" xlink:label="lbl_KedalionTherapeuticsInc.MenloParkCAMember" xlink:type="locator"/>
      <link:definitionArc order="174.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_KedalionTherapeuticsInc.MenloParkCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CortheraInc.SanMateoCAMember" xlink:label="lbl_CortheraInc.SanMateoCAMember" xlink:type="locator"/>
      <link:definitionArc order="175.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CortheraInc.SanMateoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:label="lbl_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:type="locator"/>
      <link:definitionArc order="176.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EncoreVisionInc.NewYorkNYMember" xlink:label="lbl_EncoreVisionInc.NewYorkNYMember" xlink:type="locator"/>
      <link:definitionArc order="177.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EncoreVisionInc.NewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EncoreVisionInc.EastHanoverNJMember" xlink:label="lbl_EncoreVisionInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="178.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EncoreVisionInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EndocyteInc.LafayetteINMember" xlink:label="lbl_EndocyteInc.LafayetteINMember" xlink:type="locator"/>
      <link:definitionArc order="179.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_EndocyteInc.LafayetteINMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:label="lbl_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="180.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:label="lbl_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:type="locator"/>
      <link:definitionArc order="181.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:label="lbl_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="182.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:label="lbl_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:type="locator"/>
      <link:definitionArc order="183.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:type="locator"/>
      <link:definitionArc order="184.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:label="lbl_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="185.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:label="lbl_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="186.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmblyotechInc.EastHanoverNJMember" xlink:label="lbl_AmblyotechInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="187.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AmblyotechInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesInc.FortWorthTXMember" xlink:label="lbl_AlconLaboratoriesInc.FortWorthTXMember" xlink:type="locator"/>
      <link:definitionArc order="188.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesInc.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:label="lbl_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:type="locator"/>
      <link:definitionArc order="189.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconResearchLtd.FortWorthTXMember" xlink:label="lbl_AlconResearchLtd.FortWorthTXMember" xlink:type="locator"/>
      <link:definitionArc order="190.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconResearchLtd.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLensxInc.AlisoViejoCAMember" xlink:label="lbl_AlconLensxInc.AlisoViejoCAMember" xlink:type="locator"/>
      <link:definitionArc order="191.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLensxInc.AlisoViejoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:label="lbl_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:type="locator"/>
      <link:definitionArc order="192.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WaveLightInc.SterlingVAMember" xlink:label="lbl_WaveLightInc.SterlingVAMember" xlink:type="locator"/>
      <link:definitionArc order="193.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_WaveLightInc.SterlingVAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TearFilmInnovationsInc.FortWorthTXMember" xlink:label="lbl_TearFilmInnovationsInc.FortWorthTXMember" xlink:type="locator"/>
      <link:definitionArc order="194.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TearFilmInnovationsInc.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TrueVisionSystemsInc.FortWorthTXMember" xlink:label="lbl_TrueVisionSystemsInc.FortWorthTXMember" xlink:type="locator"/>
      <link:definitionArc order="195.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TrueVisionSystemsInc.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionCorporationLLCDuluthGAMember" xlink:label="lbl_CIBAVisionCorporationLLCDuluthGAMember" xlink:type="locator"/>
      <link:definitionArc order="196.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionCorporationLLCDuluthGAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:label="lbl_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:type="locator"/>
      <link:definitionArc order="197.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:label="lbl_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="198.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:label="lbl_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:type="locator"/>
      <link:definitionArc order="199.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TranscendMedicalInc.LakeForestILMember" xlink:label="lbl_TranscendMedicalInc.LakeForestILMember" xlink:type="locator"/>
      <link:definitionArc order="200.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_TranscendMedicalInc.LakeForestILMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaceuticalC.A.CaracasMember" xlink:label="lbl_AlconPharmaceuticalC.A.CaracasMember" xlink:type="locator"/>
      <link:definitionArc order="201.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaceuticalC.A.CaracasMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsAAAMember" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="locator"/>
      <link:definitionArc order="202.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:label="lbl_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:type="locator"/>
      <link:definitionArc order="203.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:label="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:type="locator"/>
      <link:definitionArc order="204.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisManufacturingGmbHMember" xlink:label="lbl_NovartisManufacturingGmbHMember" xlink:type="locator"/>
      <link:definitionArc order="205.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisManufacturingGmbHMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisManufacturingGmbHMarburgMember" xlink:label="lbl_NovartisManufacturingGmbHMarburgMember" xlink:type="locator"/>
      <link:definitionArc order="206.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisManufacturingGmbHMarburgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisTechnologyLLCMember" xlink:label="lbl_NovartisTechnologyLLCMember" xlink:type="locator"/>
      <link:definitionArc order="207.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisTechnologyLLCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInflammasomeResearchInc.Member" xlink:label="lbl_NovartisInflammasomeResearchInc.Member" xlink:type="locator"/>
      <link:definitionArc order="208.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInflammasomeResearchInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:label="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:type="locator"/>
      <link:definitionArc order="209.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:label="lbl_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:type="locator"/>
      <link:definitionArc order="210.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:label="lbl_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:type="locator"/>
      <link:definitionArc order="211.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImagingEquipmentLtdMember" xlink:label="lbl_ImagingEquipmentLtdMember" xlink:type="locator"/>
      <link:definitionArc order="212.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ImagingEquipmentLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IDBHollandBVMember" xlink:label="lbl_IDBHollandBVMember" xlink:type="locator"/>
      <link:definitionArc order="213.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_IDBHollandBVMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CELLforCUREMember" xlink:label="lbl_CELLforCUREMember" xlink:type="locator"/>
      <link:definitionArc order="214.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CELLforCUREMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriosS.A.BuenosAiresMember" xlink:label="lbl_AlconLaboratoriosS.A.BuenosAiresMember" xlink:type="locator"/>
      <link:definitionArc order="215.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriosS.A.BuenosAiresMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:definitionArc order="216.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconOphthalmikaGmbHViennaMember" xlink:label="lbl_AlconOphthalmikaGmbHViennaMember" xlink:type="locator"/>
      <link:definitionArc order="217.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconOphthalmikaGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:label="lbl_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:type="locator"/>
      <link:definitionArc order="218.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconNVVilvoordeMember" xlink:label="lbl_AlconNVVilvoordeMember" xlink:type="locator"/>
      <link:definitionArc order="219.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconNVVilvoordeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisB2Ltd.HamiltonMember" xlink:label="lbl_NovartisB2Ltd.HamiltonMember" xlink:type="locator"/>
      <link:definitionArc order="220.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisB2Ltd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisB3Ltd.HamiltonMember" xlink:label="lbl_NovartisB3Ltd.HamiltonMember" xlink:type="locator"/>
      <link:definitionArc order="221.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisB3Ltd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCanadaInc.MississaugaOntarioMember" xlink:label="lbl_AlconCanadaInc.MississaugaOntarioMember" xlink:type="locator"/>
      <link:definitionArc order="222.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCanadaInc.MississaugaOntarioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:label="lbl_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:type="locator"/>
      <link:definitionArc order="223.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:label="lbl_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:type="locator"/>
      <link:definitionArc order="224.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:label="lbl_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:type="locator"/>
      <link:definitionArc order="225.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconHongKongLimitedHongKongMember" xlink:label="lbl_AlconHongKongLimitedHongKongMember" xlink:type="locator"/>
      <link:definitionArc order="226.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconHongKongLimitedHongKongMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:label="lbl_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:type="locator"/>
      <link:definitionArc order="227.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:label="lbl_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:type="locator"/>
      <link:definitionArc order="228.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:label="lbl_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:type="locator"/>
      <link:definitionArc order="229.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconNordicASCopenhagenMember" xlink:label="lbl_AlconNordicASCopenhagenMember" xlink:type="locator"/>
      <link:definitionArc order="230.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconNordicASCopenhagenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:label="lbl_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:definitionArc order="231.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeutschlandGmbHWehrMember" xlink:label="lbl_NovartisDeutschlandGmbHWehrMember" xlink:type="locator"/>
      <link:definitionArc order="232.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeutschlandGmbHWehrMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:label="lbl_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:type="locator"/>
      <link:definitionArc order="233.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WaveLightGmbHErlangenMember" xlink:label="lbl_WaveLightGmbHErlangenMember" xlink:type="locator"/>
      <link:definitionArc order="234.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_WaveLightGmbHErlangenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionGmbHGrosswallstadtMember" xlink:label="lbl_CIBAVisionGmbHGrosswallstadtMember" xlink:type="locator"/>
      <link:definitionArc order="235.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionGmbHGrosswallstadtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovistaInsuranceLimitedGibraltarCityMember" xlink:label="lbl_NovistaInsuranceLimitedGibraltarCityMember" xlink:type="locator"/>
      <link:definitionArc order="236.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovistaInsuranceLimitedGibraltarCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:label="lbl_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:type="locator"/>
      <link:definitionArc order="237.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:label="lbl_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:type="locator"/>
      <link:definitionArc order="238.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PT.CIBAVisionBatamBatamMember" xlink:label="lbl_PT.CIBAVisionBatamBatamMember" xlink:type="locator"/>
      <link:definitionArc order="239.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_PT.CIBAVisionBatamBatamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:label="lbl_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:type="locator"/>
      <link:definitionArc order="240.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:label="lbl_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:type="locator"/>
      <link:definitionArc order="241.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OptonolLtd.NeveIlanMember" xlink:label="lbl_OptonolLtd.NeveIlanMember" xlink:type="locator"/>
      <link:definitionArc order="242.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_OptonolLtd.NeveIlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:label="lbl_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:type="locator"/>
      <link:definitionArc order="243.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconItaliaS.p.A.MilanMember" xlink:label="lbl_AlconItaliaS.p.A.MilanMember" xlink:type="locator"/>
      <link:definitionArc order="244.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconItaliaS.p.A.MilanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHoldingJapanK.K.TokyoMember" xlink:label="lbl_NovartisHoldingJapanK.K.TokyoMember" xlink:type="locator"/>
      <link:definitionArc order="245.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHoldingJapanK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AspenJapanK.K.TokyoMember" xlink:label="lbl_AspenJapanK.K.TokyoMember" xlink:type="locator"/>
      <link:definitionArc order="246.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AspenJapanK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconJapanLtd.TokyoMember" xlink:label="lbl_AlconJapanLtd.TokyoMember" xlink:type="locator"/>
      <link:definitionArc order="247.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconJapanLtd.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:label="lbl_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="locator"/>
      <link:definitionArc order="248.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:label="lbl_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:type="locator"/>
      <link:definitionArc order="249.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:label="lbl_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:definitionArc order="250.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNetherlandsB.V.ArnhemMember" xlink:label="lbl_NovartisNetherlandsB.V.ArnhemMember" xlink:type="locator"/>
      <link:definitionArc order="251.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNetherlandsB.V.ArnhemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaB.V.ArnhemMember" xlink:label="lbl_NovartisPharmaB.V.ArnhemMember" xlink:type="locator"/>
      <link:definitionArc order="252.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaB.V.ArnhemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconNederlandB.V.ArnhemMember" xlink:label="lbl_AlconNederlandB.V.ArnhemMember" xlink:type="locator"/>
      <link:definitionArc order="253.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconNederlandB.V.ArnhemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCentroamericaS.A.PanamaCityMember" xlink:label="lbl_AlconCentroamericaS.A.PanamaCityMember" xlink:type="locator"/>
      <link:definitionArc order="254.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCentroamericaS.A.PanamaCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBiosciencesPeruS.A.LimaMember" xlink:label="lbl_NovartisBiosciencesPeruS.A.LimaMember" xlink:type="locator"/>
      <link:definitionArc order="255.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBiosciencesPeruS.A.LimaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPolskaSp.ZO.o.WarsawMember" xlink:label="lbl_AlconPolskaSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:definitionArc order="256.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPolskaSp.ZO.o.WarsawMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:label="lbl_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:type="locator"/>
      <link:definitionArc order="257.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconRomaniaS.R.L.BucharestMember" xlink:label="lbl_AlconRomaniaS.R.L.BucharestMember" xlink:type="locator"/>
      <link:definitionArc order="258.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconRomaniaS.R.L.BucharestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconFarmacevtikaLLCMoscowMember" xlink:label="lbl_AlconFarmacevtikaLLCMoscowMember" xlink:type="locator"/>
      <link:definitionArc order="259.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconFarmacevtikaLLCMoscowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:label="lbl_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:type="locator"/>
      <link:definitionArc order="260.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:label="lbl_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:type="locator"/>
      <link:definitionArc order="261.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPteLtdSingaporeMember" xlink:label="lbl_AlconPteLtdSingaporeMember" xlink:type="locator"/>
      <link:definitionArc order="262.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:label="lbl_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:type="locator"/>
      <link:definitionArc order="263.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:label="lbl_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:type="locator"/>
      <link:definitionArc order="264.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:label="lbl_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:type="locator"/>
      <link:definitionArc order="265.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozKoreaLtd.SeoulMember" xlink:label="lbl_SandozKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:definitionArc order="266.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozKoreaLtd.SeoulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconKoreaLtd.SeoulMember" xlink:label="lbl_AlconKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:definitionArc order="267.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconKoreaLtd.SeoulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:label="lbl_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:type="locator"/>
      <link:definitionArc order="268.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconHealthcareS.A.BarcelonaMember" xlink:label="lbl_AlconHealthcareS.A.BarcelonaMember" xlink:type="locator"/>
      <link:definitionArc order="269.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconHealthcareS.A.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCusiS.A.BarcelonaMember" xlink:label="lbl_AlconCusiS.A.BarcelonaMember" xlink:type="locator"/>
      <link:definitionArc order="270.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCusiS.A.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInternationalAGBaselMember" xlink:label="lbl_NovartisInternationalAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="271.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInternationalAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInternationalPharmaceuticalAGBaselMember" xlink:label="lbl_NovartisInternationalPharmaceuticalAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="272.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInternationalPharmaceuticalAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:label="lbl_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:type="locator"/>
      <link:definitionArc order="273.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconAGFribourgMember" xlink:label="lbl_AlconAGFribourgMember" xlink:type="locator"/>
      <link:definitionArc order="274.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconAGFribourgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconManagementSAGenevaMember" xlink:label="lbl_AlconManagementSAGenevaMember" xlink:type="locator"/>
      <link:definitionArc order="275.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconManagementSAGenevaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconSwitzerlandSARischMember" xlink:label="lbl_AlconSwitzerlandSARischMember" xlink:type="locator"/>
      <link:definitionArc order="276.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconSwitzerlandSARischMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaceuticalsLtd.FribourgMember" xlink:label="lbl_AlconPharmaceuticalsLtd.FribourgMember" xlink:type="locator"/>
      <link:definitionArc order="277.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaceuticalsLtd.FribourgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGBaselMember" xlink:label="lbl_RocheHoldingAGBaselMember" xlink:type="locator"/>
      <link:definitionArc order="278.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_RocheHoldingAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesThailandLimitedBangkokMember" xlink:label="lbl_AlconLaboratoriesThailandLimitedBangkokMember" xlink:type="locator"/>
      <link:definitionArc order="279.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesThailandLimitedBangkokMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:label="lbl_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:type="locator"/>
      <link:definitionArc order="280.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:label="lbl_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:definitionArc order="281.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUKLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:definitionArc order="282.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUKLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:definitionArc order="283.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:definitionArc order="284.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImagingEquipmentLtdLondonMember" xlink:label="lbl_ImagingEquipmentLtdLondonMember" xlink:type="locator"/>
      <link:definitionArc order="285.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ImagingEquipmentLtdLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VivactaLimitedFrimleyCamberleySurreyMember" xlink:label="lbl_VivactaLimitedFrimleyCamberleySurreyMember" xlink:type="locator"/>
      <link:definitionArc order="286.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_VivactaLimitedFrimleyCamberleySurreyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:label="lbl_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:type="locator"/>
      <link:definitionArc order="287.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZiarcoGroupLimitedLondonMember" xlink:label="lbl_ZiarcoGroupLimitedLondonMember" xlink:type="locator"/>
      <link:definitionArc order="288.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_ZiarcoGroupLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:label="lbl_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:type="locator"/>
      <link:definitionArc order="289.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:label="lbl_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:definitionArc order="290.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:label="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="locator"/>
      <link:definitionArc order="291.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceCorporationEastHanoverNJMember" xlink:label="lbl_NovartisFinanceCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:definitionArc order="292.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceCorporationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkNYMember" xlink:label="lbl_NovartisCapitalCorporationNewYorkNYMember" xlink:type="locator"/>
      <link:definitionArc order="293.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCapitalCorporationNewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUSFoundationNewYorkNYMember" xlink:label="lbl_NovartisUSFoundationNewYorkNYMember" xlink:type="locator"/>
      <link:definitionArc order="294.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUSFoundationNewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NameOfSubsidiary" xlink:label="lbl_NameOfSubsidiary" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_NameOfSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xlink:label="lbl_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:label="lbl_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharePaidinCapital" xlink:label="lbl_SharePaidinCapital" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_SharePaidinCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:label="lbl_ProportionOfVotingPowerHeldInSubsidiary" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_ProportionOfVotingPowerHeldInSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:label="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember" xlink:label="lbl_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1APharmaGmbHHolzkirchenMember" xlink:label="lbl_A1APharmaGmbHHolzkirchenMember" xlink:type="locator"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:label="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_DefinedBenefitPlanInterestCost" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="9.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:label="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="11.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:type="locator"/>
      <link:definitionArc order="12.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:type="locator"/>
      <link:definitionArc order="13.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="lbl_PlanAssetsAtFairValue" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_PlanAssetsAtFairValue" xlink:type="arc"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanSettlementsPlanAssets" xlink:label="lbl_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="locator"/>
      <link:definitionArc order="8.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:definitionArc order="10.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="lbl_SurplusDeficitInPlan" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_SurplusDeficitInPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LimitationOnRecognitionOfFundSurplus" xlink:label="lbl_LimitationOnRecognitionOfFundSurplus" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_LimitationOnRecognitionOfFundSurplus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:label="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestIncomeOnLimitationOfFundSurplus" xlink:label="lbl_InterestIncomeOnLimitationOfFundSurplus" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_InterestIncomeOnLimitationOfFundSurplus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanInterestCost" xlink:label="lbl_DefinedBenefitPlanInterestCost" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:label="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:label="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:type="locator"/>
   </link:definitionLink>
   <link:definitionLink xlink:role="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetTreatmentAxis" xlink:label="lbl_BalanceSheetTreatmentAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lbl_BalanceSheetTreatmentAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetTreatmentMember" xlink:label="lbl_BalanceSheetTreatmentMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_BalanceSheetTreatmentAxis" xlink:to="lbl_BalanceSheetTreatmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CapitalizedMember" xlink:label="lbl_CapitalizedMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetTreatmentMember" xlink:to="lbl_CapitalizedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NotCapitalizedMember" xlink:label="lbl_NotCapitalizedMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_BalanceSheetTreatmentMember" xlink:to="lbl_NotCapitalizedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_YearOfExpiryAxis" xlink:label="lbl_YearOfExpiryAxis" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lbl_YearOfExpiryAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_YearOfExpiryMember" xlink:label="lbl_YearOfExpiryMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="lbl_YearOfExpiryAxis" xlink:to="lbl_YearOfExpiryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OneYearMember" xlink:label="lbl_OneYearMember" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_OneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TwoYearsMember" xlink:label="lbl_TwoYearsMember" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_TwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ThreeYearsMember" xlink:label="lbl_ThreeYearsMember" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_ThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FourYearsMember" xlink:label="lbl_FourYearsMember" xlink:type="locator"/>
      <link:definitionArc order="4.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_FourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FiveYearsMember" xlink:label="lbl_FiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="5.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_FiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MoreThanFiveYearsMember" xlink:label="lbl_MoreThanFiveYearsMember" xlink:type="locator"/>
      <link:definitionArc order="6.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_MoreThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NotSubjectToExpiryMember" xlink:label="lbl_NotSubjectToExpiryMember" xlink:type="locator"/>
      <link:definitionArc order="7.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_NotSubjectToExpiryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:definitionArc order="1.0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:label="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:type="locator"/>
      <link:definitionArc order="1.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueOfTaxLossCarryforwardsExpired" xlink:label="lbl_ValueOfTaxLossCarryforwardsExpired" xlink:type="locator"/>
      <link:definitionArc order="2.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ValueOfTaxLossCarryforwardsExpired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxLossCarryForwards" xlink:label="lbl_TaxLossCarryForwards" xlink:type="locator"/>
      <link:definitionArc order="3.0" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxLossCarryForwards" xlink:type="arc"/>
   </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>nvs-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
   <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
   <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
   <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
   <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
   <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
   <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
      <link:label id="id_33621d8b" xlink:label="lbl_CHF_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland, Francs</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF" xlink:label="lbl_CHF" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CHF" xlink:to="lbl_CHF_labels" xlink:type="arc"/>
      <link:label id="id_2109f0bd" xlink:label="lbl_label554299581" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CH" xlink:label="lbl_CH" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CH" xlink:to="lbl_label554299581" xlink:type="arc"/>
      <link:label id="id_30237143" xlink:label="lbl_label807629123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="lbl_DocumentType" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentType" xlink:to="lbl_label807629123" xlink:type="arc"/>
      <link:label id="id_bb438c4" xlink:label="lbl_NoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="lbl_NoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssets" xlink:to="lbl_NoncurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_7fdd0dd5" xlink:label="lbl_NoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current assets</link:label>
      <link:label id="id_18b26df5" xlink:label="lbl_CurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="lbl_CurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAssets" xlink:to="lbl_CurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_2d4bde06" xlink:label="lbl_CurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
      <link:label id="id_e8d83cc" xlink:label="lbl_Assets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Assets" xlink:to="lbl_Assets_labels" xlink:type="arc"/>
      <link:label id="id_1c011115" xlink:label="lbl_Assets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
      <link:label id="id_17d32c44" xlink:label="lbl_TreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasuryShares" xlink:to="lbl_TreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_210754dc" xlink:label="lbl_EquityAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity attributable to owners of parent</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="lbl_EquityAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityAttributableToOwnersOfParent" xlink:to="lbl_EquityAttributableToOwnersOfParent_labels" xlink:type="arc"/>
      <link:label id="id_5c95b1b" xlink:label="lbl_EquityAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Equity attributable to Novartis AG shareholders</link:label>
      <link:label id="id_6ada4c7f" xlink:label="lbl_Equity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Equity" xlink:to="lbl_Equity_labels" xlink:type="arc"/>
      <link:label id="id_217508c4" xlink:label="lbl_Equity_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
      <link:label id="id_202888aa" xlink:label="lbl_NoncurrentProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current provisions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentProvisions" xlink:label="lbl_NoncurrentProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentProvisions" xlink:to="lbl_NoncurrentProvisions_labels" xlink:type="arc"/>
      <link:label id="id_30c761c7" xlink:label="lbl_NoncurrentProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current provisions</link:label>
      <link:label id="id_70a3cca2" xlink:label="lbl_NoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="lbl_NoncurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLiabilities" xlink:to="lbl_NoncurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_46c178af" xlink:label="lbl_NoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
      <link:label id="id_37698457" xlink:label="lbl_CurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="lbl_CurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLiabilities" xlink:to="lbl_CurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_422c0184" xlink:label="lbl_CurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
      <link:label id="id_6a28968d" xlink:label="lbl_Liabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Liabilities" xlink:to="lbl_Liabilities_labels" xlink:type="arc"/>
      <link:label id="id_35c7371a" xlink:label="lbl_Liabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
      <link:label id="id_6baaabed" xlink:label="lbl_EquityAndLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="lbl_EquityAndLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityAndLiabilities" xlink:to="lbl_EquityAndLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_3794ff9e" xlink:label="lbl_EquityAndLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity and liabilities</link:label>
      <link:label id="id_5ecd50fe" xlink:label="lbl_PropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipment" xlink:to="lbl_PropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_5f7f6e84" xlink:label="lbl_label1602186884" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="lbl_Goodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Goodwill" xlink:to="lbl_label1602186884" xlink:type="arc"/>
      <link:label id="id_78569540" xlink:label="lbl_label2018940224" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IntangibleAssetsOtherThanGoodwill" xlink:to="lbl_label2018940224" xlink:type="arc"/>
      <link:label id="id_600994ad" xlink:label="lbl_DeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxAssets" xlink:to="lbl_DeferredTaxAssets_labels" xlink:type="arc"/>
      <link:label id="id_76aa2451" xlink:label="lbl_OtherNoncurrentNonfinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current non-financial assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:label="lbl_OtherNoncurrentNonfinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentNonfinancialAssets" xlink:to="lbl_OtherNoncurrentNonfinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_2dffac3d" xlink:label="lbl_Inventories_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current inventories</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Inventories" xlink:to="lbl_Inventories_labels" xlink:type="arc"/>
      <link:label id="id_3b71d990" xlink:label="lbl_OtherCurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current financial assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="lbl_OtherCurrentFinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentFinancialAssets" xlink:to="lbl_OtherCurrentFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_47798f64" xlink:label="lbl_CashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalents" xlink:to="lbl_CashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_c46389d" xlink:label="lbl_IssuedCapital_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IssuedCapital" xlink:to="lbl_IssuedCapital_labels" xlink:type="arc"/>
      <link:label id="id_7fe108cb" xlink:label="lbl_OtherReserves_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other reserves</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves" xlink:label="lbl_OtherReserves" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherReserves" xlink:to="lbl_OtherReserves_labels" xlink:type="arc"/>
      <link:label id="id_62ed78ce" xlink:label="lbl_label1659730126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterests" xlink:label="lbl_NoncontrollingInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncontrollingInterests" xlink:to="lbl_label1659730126" xlink:type="arc"/>
      <link:label id="id_40cd0a97" xlink:label="lbl_label1087179415" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other non-current payables</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentPayables" xlink:label="lbl_NoncurrentPayables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentPayables" xlink:to="lbl_label1087179415" xlink:type="arc"/>
      <link:label id="id_314a7125" xlink:label="lbl_DeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxLiabilities" xlink:to="lbl_DeferredTaxLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_15149ace" xlink:label="lbl_OtherNoncurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current financial liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentFinancialLiabilities" xlink:to="lbl_OtherNoncurrentFinancialLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_48a2d168" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current non-financial liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_65fe4156" xlink:label="lbl_OtherCurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current financial liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentFinancialLiabilities" xlink:to="lbl_OtherCurrentFinancialLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_4f6a78d8" xlink:label="lbl_CurrentTaxLiabilitiesCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax liabilities, current</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTaxLiabilitiesCurrent" xlink:to="lbl_CurrentTaxLiabilitiesCurrent_labels" xlink:type="arc"/>
      <link:label id="id_63598632" xlink:label="lbl_OtherCurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current non-financial liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentNonfinancialLiabilities" xlink:to="lbl_OtherCurrentNonfinancialLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_654cedce" xlink:label="lbl_Inventories_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:label id="id_288deb92" xlink:label="lbl_IssuedCapital_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
      <link:label id="id_b623bea" xlink:label="lbl_OtherReserves_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserves</link:label>
      <link:label id="id_3c0375d2" xlink:label="lbl_OtherNoncurrentNonfinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
      <link:label id="id_5eaf97e4" xlink:label="lbl_NoncurrentProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other non-current liabilities</link:label>
      <link:label id="id_48a98684" xlink:label="lbl_OtherNoncurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial debts</link:label>
      <link:label id="id_126c9e67" xlink:label="lbl_OtherCurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial debts and derivative financial instruments</link:label>
      <link:label id="id_4f2ac258" xlink:label="lbl_CurrentTaxLiabilitiesCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current income tax liabilities</link:label>
      <link:label id="id_1abd43d3" xlink:label="lbl_label448611283" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DocumentAndEntityInformationAbstract" xlink:label="lbl_DocumentAndEntityInformationAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentAndEntityInformationAbstract" xlink:to="lbl_label448611283" xlink:type="arc"/>
      <link:label id="id_3da2017e" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments accounted for using equity method</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InvestmentAccountedForUsingEquityMethod" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod_labels" xlink:type="arc"/>
      <link:label id="id_6c3d0a" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in associated companies</link:label>
      <link:label id="id_551c0fc4" xlink:label="lbl_label1427902404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="lbl_NoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_label1427902404" xlink:type="arc"/>
      <link:label id="id_42437f89" xlink:label="lbl_label1111719817" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="lbl_CurrentAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_label1111719817" xlink:type="arc"/>
      <link:label id="id_6e6b7ee6" xlink:label="lbl_TreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares</link:label>
      <link:label id="id_47a37331" xlink:label="lbl_label1201894193" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="lbl_EquityAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_label1201894193" xlink:type="arc"/>
      <link:label id="id_131d39b3" xlink:label="lbl_label320682419" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract" xlink:label="lbl_EquityAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityAbstract" xlink:to="lbl_label320682419" xlink:type="arc"/>
      <link:label id="id_7f542d" xlink:label="lbl_label8344621" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="lbl_LiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_label8344621" xlink:type="arc"/>
      <link:label id="id_622df1d" xlink:label="lbl_label102948637" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="lbl_NoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_label102948637" xlink:type="arc"/>
      <link:label id="id_7ba5a5ef" xlink:label="lbl_label2074453487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="lbl_CurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_label2074453487" xlink:type="arc"/>
      <link:label id="id_88ddaa5" xlink:label="lbl_label143514277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lbl_label143514277" xlink:type="arc"/>
      <link:label id="id_47732be6" xlink:label="lbl_label1198730214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_label1198730214" xlink:type="arc"/>
      <link:label id="id_47bd73ec" xlink:label="lbl_label1203598316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lbl_label1203598316" xlink:type="arc"/>
      <link:label id="id_bca487e" xlink:label="lbl_PropertyPlantAndEquipmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_PropertyPlantAndEquipmentMember_labels" xlink:type="arc"/>
      <link:label id="id_567bb83c" xlink:label="lbl_LandMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LandMember" xlink:label="lbl_LandMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LandMember" xlink:to="lbl_LandMember_labels" xlink:type="arc"/>
      <link:label id="id_16f548da" xlink:label="lbl_LandMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
      <link:label id="id_a7eb90b" xlink:label="lbl_BuildingsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Buildings [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember" xlink:label="lbl_BuildingsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BuildingsMember" xlink:to="lbl_BuildingsMember_labels" xlink:type="arc"/>
      <link:label id="id_4d69998b" xlink:label="lbl_BuildingsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings</link:label>
      <link:label id="id_62ebaccc" xlink:label="lbl_ConstructionInProgressMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in progress [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="lbl_ConstructionInProgressMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConstructionInProgressMember" xlink:to="lbl_ConstructionInProgressMember_labels" xlink:type="arc"/>
      <link:label id="id_74f44044" xlink:label="lbl_ConstructionInProgressMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
      <link:label id="id_451f7511" xlink:label="lbl_MachineryMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MachineryMember" xlink:label="lbl_MachineryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MachineryMember" xlink:to="lbl_MachineryMember_labels" xlink:type="arc"/>
      <link:label id="id_50dda083" xlink:label="lbl_MachineryMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and other equipment</link:label>
      <link:label id="id_6f28e51b" xlink:label="lbl_label1864951067" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_label1864951067" xlink:type="arc"/>
      <link:label id="id_7c438c3d" xlink:label="lbl_label2084801597" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_label2084801597" xlink:type="arc"/>
      <link:label id="id_5e0af6ee" xlink:label="lbl_label1577776878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_label1577776878" xlink:type="arc"/>
      <link:label id="id_345f7738" xlink:label="lbl_GrossCarryingAmountMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross carrying amount [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossCarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember_labels" xlink:type="arc"/>
      <link:label id="id_77df9cb5" xlink:label="lbl_PropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment at beginning of period</link:label>
      <link:label id="id_4145517b" xlink:label="lbl_PropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment at end of period</link:label>
      <link:label id="id_1f5560c5" xlink:label="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers from construction in progress, property, plant and equipment</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:to="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_7baa32ee" xlink:label="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
      <link:label id="id_3eb55d39" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_31501db" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
      <link:label id="id_53833bce" xlink:label="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals and retirements, property, plant and equipment</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:label="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:to="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_648c3365" xlink:label="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposals and derecognitions</link:label>
      <link:label id="id_5803c369" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_54f4afbb" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, property, plant and equipment</link:label>
      <link:label id="id_f07d187" xlink:label="lbl_DepreciationPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, property, plant and equipment</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationPropertyPlantAndEquipment" xlink:to="lbl_DepreciationPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_57f67848" xlink:label="lbl_DepreciationPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation charge</link:label>
      <link:label id="id_6a50bcb" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_4bc845d6" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, property, plant and equipment</link:label>
      <link:label id="id_6bc0d1d9" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reversal of impairment loss recognised in profit or loss, property, plant and equipment</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_3cc1cda9" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversal of impairment charge</link:label>
      <link:label id="id_2b7f313a" xlink:label="lbl_label729755962" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net book value of Property, plant and equipment under finance lease contracts</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:label="lbl_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:to="lbl_label729755962" xlink:type="arc"/>
      <link:label id="id_260ca259" xlink:label="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual commitments for acquisition of property, plant and equipment</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:label="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:to="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_34818382" xlink:label="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments for purchases of property, plant and equipment</link:label>
      <link:label id="id_54bcbe9d" xlink:label="lbl_BorrowingCostsCapitalised_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowing costs capitalised</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingCostsCapitalised" xlink:label="lbl_BorrowingCostsCapitalised" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingCostsCapitalised" xlink:to="lbl_BorrowingCostsCapitalised_labels" xlink:type="arc"/>
      <link:label id="id_555c8c31" xlink:label="lbl_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalisation rate of borrowing costs eligible for capitalisation</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:label="lbl_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation" xlink:to="lbl_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_labels" xlink:type="arc"/>
      <link:label id="id_4c298205" xlink:label="lbl_BorrowingsInterestRate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, interest rate</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="lbl_BorrowingsInterestRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsInterestRate" xlink:to="lbl_BorrowingsInterestRate_labels" xlink:type="arc"/>
      <link:label id="id_4611e1b4" xlink:label="lbl_BorrowingsInterestRate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate on borrowings for new additions</link:label>
      <link:label id="id_3caaa61e" xlink:label="lbl_BorrowingCostsCapitalised_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized borrowing costs</link:label>
      <link:label id="id_5cb7a23f" xlink:label="lbl_CapitalisationRateOfBorrowingCostsEligibleForCapitalisation_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalization rate used to determine the amount of borrowing costs eligible for capitalization</link:label>
      <link:label id="id_556c754b" xlink:label="lbl_label1433171275" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementTable" xlink:to="lbl_label1433171275" xlink:type="arc"/>
      <link:label id="id_17e10fbe" xlink:label="lbl_label241915143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementLineItems" xlink:to="lbl_label241915143" xlink:type="arc"/>
      <link:label id="id_556e2a5d" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_62e43be9" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
      <link:label id="id_7abef04f" xlink:label="lbl_label782106324" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PropertyPlantAndEquipmentTableTextBlock" xlink:label="lbl_PropertyPlantAndEquipmentTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentTableTextBlock" xlink:to="lbl_label782106324" xlink:type="arc"/>
      <link:label id="id_611528f2" xlink:label="lbl_label1628776690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories Disclosure [abstract]</link:label>
      <link:label id="id_7f461082" xlink:label="lbl_DisclosureOfInventoriesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of inventories [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="lbl_DisclosureOfInventoriesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfInventoriesExplanatory" xlink:to="lbl_DisclosureOfInventoriesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_6d592b5d" xlink:label="lbl_DisclosureOfInventoriesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoriesDisclosureAbstract" xlink:label="lbl_InventoriesDisclosureAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoriesDisclosureAbstract" xlink:to="lbl_label1628776690" xlink:type="arc"/>
      <link:label id="id_47e475f1" xlink:label="lbl_ScheduleOfInventoryCurrentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="lbl_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lbl_ScheduleOfInventoryCurrentTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1795799b" xlink:label="lbl_ScheduleOfInventoryCurrentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories by class</link:label>
      <link:label id="id_543a8d3d" xlink:label="lbl_label1413123389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryCurrentTable" xlink:label="lbl_InventoryCurrentTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryCurrentTable" xlink:to="lbl_label1413123389" xlink:type="arc"/>
      <link:label id="id_781cb00d" xlink:label="lbl_label2015145997" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryAxis" xlink:label="lbl_InventoryAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryAxis" xlink:to="lbl_label2015145997" xlink:type="arc"/>
      <link:label id="id_b0e25e5" xlink:label="lbl_label185476581" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryMember" xlink:label="lbl_InventoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryMember" xlink:to="lbl_label185476581" xlink:type="arc"/>
      <link:label id="id_1b583e85" xlink:label="lbl_InventoryRawMaterialsGrossMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryRawMaterialsGrossMember" xlink:label="lbl_InventoryRawMaterialsGrossMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryRawMaterialsGrossMember" xlink:to="lbl_InventoryRawMaterialsGrossMember_labels" xlink:type="arc"/>
      <link:label id="id_2bb8c828" xlink:label="lbl_InventoryRawMaterialsGrossMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw material, consumables</link:label>
      <link:label id="id_9dcab16" xlink:label="lbl_InventoryWorkInProgressGrossMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in progress, Gross [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryWorkInProgressGrossMember" xlink:label="lbl_InventoryWorkInProgressGrossMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryWorkInProgressGrossMember" xlink:to="lbl_InventoryWorkInProgressGrossMember_labels" xlink:type="arc"/>
      <link:label id="id_696df603" xlink:label="lbl_InventoryWorkInProgressGrossMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in progress</link:label>
      <link:label id="id_5b4c39ad" xlink:label="lbl_label1531722157" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished products</link:label>
      <link:label id="id_2f569fbd" xlink:label="lbl_label794206141" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished goods, Gross [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryFinishedGoodsGrossMember" xlink:label="lbl_InventoryFinishedGoodsGrossMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryFinishedGoodsGrossMember" xlink:to="lbl_label794206141" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryFinishedGoodsGrossMember" xlink:to="lbl_label1531722157" xlink:type="arc"/>
      <link:label id="id_4819bb17" xlink:label="lbl_InventoryLineItems_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryLineItems" xlink:label="lbl_InventoryLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_InventoryLineItems_labels" xlink:type="arc"/>
      <link:label id="id_29f36af5" xlink:label="lbl_InventoryLineItems_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
      <link:label id="id_4b29af41" xlink:label="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of inventories recognised as expense during period</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:label="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:to="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod_labels" xlink:type="arc"/>
      <link:label id="id_2b41374" xlink:label="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amount of inventory recognized as expense</link:label>
      <link:label id="id_11cae639" xlink:label="lbl_InventoryWritedown2011_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory write-down</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoryWritedown2011" xlink:label="lbl_InventoryWritedown2011" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryWritedown2011" xlink:to="lbl_InventoryWritedown2011_labels" xlink:type="arc"/>
      <link:label id="id_1fa3a1d8" xlink:label="lbl_InventoryWritedown2011_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory provisions</link:label>
      <link:label id="id_6f7b4a87" xlink:label="lbl_ReversalOfInventoryWritedown_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversals of inventory provisions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfInventoryWritedown" xlink:label="lbl_ReversalOfInventoryWritedown" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReversalOfInventoryWritedown" xlink:to="lbl_ReversalOfInventoryWritedown_labels" xlink:type="arc"/>
      <link:label id="id_56e8eb36" xlink:label="lbl_ReversalOfInventoryWritedown_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reversal of inventory write-down</link:label>
      <link:label id="id_39ec1db2" xlink:label="lbl_label971775410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="lbl_EarningsPerShareAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EarningsPerShareAbstract" xlink:to="lbl_label971775410" xlink:type="arc"/>
      <link:label id="id_58dc47d3" xlink:label="lbl_EarningsPerShareExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="lbl_EarningsPerShareExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EarningsPerShareExplanatory" xlink:to="lbl_EarningsPerShareExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_20fad442" xlink:label="lbl_EarningsPerShareExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share</link:label>
      <link:label id="id_5ead42de" xlink:label="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5719e1f6" xlink:label="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share</link:label>
      <link:label id="id_531039b4" xlink:label="lbl_label1393572276" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareTable" xlink:label="lbl_EarningsPerShareTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EarningsPerShareTable" xlink:to="lbl_label1393572276" xlink:type="arc"/>
      <link:label id="id_6cb953c7" xlink:label="lbl_label1824084935" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareLineItems" xlink:label="lbl_EarningsPerShareLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_label1824084935" xlink:type="arc"/>
      <link:label id="id_1efe1d89" xlink:label="lbl_label519970185" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Continuing and discontinued operations [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_label519970185" xlink:type="arc"/>
      <link:label id="id_26f22885" xlink:label="lbl_label653404293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate continuing and discontinued operations [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_label653404293" xlink:type="arc"/>
      <link:label id="id_a503764" xlink:label="lbl_ContinuingOperationsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Continuing operations [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContinuingOperationsMember" xlink:to="lbl_ContinuingOperationsMember_labels" xlink:type="arc"/>
      <link:label id="id_64674183" xlink:label="lbl_DiscontinuedOperationsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued operations [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember_labels" xlink:type="arc"/>
      <link:label id="id_7aa601bd" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit/loss attributable to shareholders of Novartis AG</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossAttributableToOwnersOfParent" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent_labels" xlink:type="arc"/>
      <link:label id="id_68d30e6d" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to owners of parent</link:label>
      <link:label id="id_5a4aec87" xlink:label="lbl_WeightedAverageShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares outstanding</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares" xlink:label="lbl_WeightedAverageShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageShares" xlink:to="lbl_WeightedAverageShares_labels" xlink:type="arc"/>
      <link:label id="id_1d84ebe1" xlink:label="lbl_WeightedAverageShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares outstanding used in the basic earnings per share</link:label>
      <link:label id="id_4e4dd4b7" xlink:label="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive effect of share options on number of ordinary shares</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:label="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:to="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_labels" xlink:type="arc"/>
      <link:label id="id_4486a95d" xlink:label="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options</link:label>
      <link:label id="id_627adbc2" xlink:label="lbl_AdjustedWeightedAverageShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjusted weighted average number of ordinary shares outstanding</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="lbl_AdjustedWeightedAverageShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustedWeightedAverageShares" xlink:to="lbl_AdjustedWeightedAverageShares_labels" xlink:type="arc"/>
      <link:label id="id_3ec2f3b5" xlink:label="lbl_AdjustedWeightedAverageShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares in diluted earnings per share</link:label>
      <link:label id="id_75396e0c" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share from continuing operation</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:to="lbl_BasicEarningsLossPerShareFromContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_35298166" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share, Continuing operations</link:label>
      <link:label id="id_4d75874f" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share from discontinued operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:to="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_57208e0e" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share, Discontinued operations</link:label>
      <link:label id="id_3bf5aca3" xlink:label="lbl_BasicEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="lbl_BasicEarningsLossPerShare" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BasicEarningsLossPerShare" xlink:to="lbl_BasicEarningsLossPerShare_labels" xlink:type="arc"/>
      <link:label id="id_51010c7c" xlink:label="lbl_BasicEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total basic earnings per share</link:label>
      <link:label id="id_48b2fef8" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share from continuing operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:to="lbl_DilutedEarningsLossPerShareFromContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_2cf2996b" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share from discontinued operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:to="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_4e26e1ff" xlink:label="lbl_DilutedEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="lbl_DilutedEarningsLossPerShare" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DilutedEarningsLossPerShare" xlink:to="lbl_DilutedEarningsLossPerShare_labels" xlink:type="arc"/>
      <link:label id="id_28929982" xlink:label="lbl_DilutedEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total diluted earnings per share</link:label>
      <link:label id="id_3969c29" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share, Continuing operations</link:label>
      <link:label id="id_aa58d2a" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share, Discontinued operations</link:label>
      <link:label id="id_10d604a9" xlink:label="lbl_label282461353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="lbl_AssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_label282461353" xlink:type="arc"/>
      <link:label id="id_6b10381b" xlink:label="lbl_label1796225051" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="lbl_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfFinancialPositionAbstract" xlink:to="lbl_label1796225051" xlink:type="arc"/>
      <link:label id="id_40fad394" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfIntangibleAssetsAbstract_labels" xlink:type="arc"/>
      <link:label id="id_43e147c6" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and intangible assets</link:label>
      <link:label id="id_56bb2315" xlink:label="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and intangible assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:label="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:to="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_51b234f9" xlink:label="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of intangible assets and goodwill [text block]</link:label>
      <link:label id="id_4c34e5bc" xlink:label="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Movements of goodwill and intangible assets [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" xlink:label="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" xlink:to="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_49099ca4" xlink:label="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movements of goodwill and intangible assets</link:label>
      <link:label id="id_73128ea8" xlink:label="lbl_label1930596008" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocation of net book values of goodwill and intangible assets by reporting segment</link:label>
      <link:label id="id_4a2c58f" xlink:label="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assumptions used in the calculation of valuation [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssumptionsUsedInTheCalculationOfValuationTextBlock" xlink:label="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock" xlink:to="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_77ac0526" xlink:label="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumptions used in the calculation of valuation</link:label>
      <link:label id="id_63728238" xlink:label="lbl_label1668448824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocation of net book values of goodwill and intangible assets by reporting segment [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:label="lbl_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:to="lbl_label1668448824" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:to="lbl_label1930596008" xlink:type="arc"/>
      <link:label id="id_db941d3" xlink:label="lbl_label230244819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Income Tax [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfIncomeTaxAbstract" xlink:label="lbl_DisclosureOfIncomeTaxAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfIncomeTaxAbstract" xlink:to="lbl_label230244819" xlink:type="arc"/>
      <link:label id="id_21d3fbe0" xlink:label="lbl_DisclosureOfIncomeTaxExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="lbl_DisclosureOfIncomeTaxExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfIncomeTaxExplanatory" xlink:to="lbl_DisclosureOfIncomeTaxExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_3e9356c7" xlink:label="lbl_DisclosureOfIncomeTaxExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
      <link:label id="id_78295b76" xlink:label="lbl_IncomeBeforeTaxesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Before Taxes [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeBeforeTaxesTableTextBlock" xlink:label="lbl_IncomeBeforeTaxesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeBeforeTaxesTableTextBlock" xlink:to="lbl_IncomeBeforeTaxesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4c349cd3" xlink:label="lbl_IncomeBeforeTaxesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before taxes</link:label>
      <link:label id="id_12bf41b8" xlink:label="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current and deferred Income Tax Expense [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" xlink:label="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" xlink:to="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_47b0c493" xlink:label="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current and deferred income tax expense</link:label>
      <link:label id="id_553ce855" xlink:label="lbl_AnalysisOfTaxRateTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of Tax Rate [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AnalysisOfTaxRateTableTextBlock" xlink:label="lbl_AnalysisOfTaxRateTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AnalysisOfTaxRateTableTextBlock" xlink:to="lbl_AnalysisOfTaxRateTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3410484d" xlink:label="lbl_AnalysisOfTaxRateTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Analysis of tax rate</link:label>
      <link:label id="id_58de322f" xlink:label="lbl_label1490956847" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Interest Expense and Other Financial Income and Expense [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:label="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_label1490956847" xlink:type="arc"/>
      <link:label id="id_643ddbd0" xlink:label="lbl_DisclosureOfInterestExpenseExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of interest expense [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInterestExpenseExplanatory" xlink:label="lbl_DisclosureOfInterestExpenseExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfInterestExpenseExplanatory" xlink:to="lbl_DisclosureOfInterestExpenseExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_54a1e622" xlink:label="lbl_DisclosureOfInterestExpenseExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense and other financial income and expense</link:label>
      <link:label id="id_1f6de87d" xlink:label="lbl_InterestExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExpenseTableTextBlock" xlink:label="lbl_InterestExpenseTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseTableTextBlock" xlink:to="lbl_InterestExpenseTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6f7654df" xlink:label="lbl_InterestExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
      <link:label id="id_3d171b85" xlink:label="lbl_OtherFinancialIncomeAndExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financial Income and Expense [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialIncomeAndExpenseTableTextBlock" xlink:label="lbl_OtherFinancialIncomeAndExpenseTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinancialIncomeAndExpenseTableTextBlock" xlink:to="lbl_OtherFinancialIncomeAndExpenseTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_94ad887" xlink:label="lbl_OtherFinancialIncomeAndExpenseTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial income and expense</link:label>
      <link:label id="id_4a94ff2f" xlink:label="lbl_label1934317586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Deferred Tax Assets and Liabilities [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_label1934317586" xlink:type="arc"/>
      <link:label id="id_7354dcb2" xlink:label="lbl_DisclosureOfDeferredTaxesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of deferred taxes [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:label="lbl_DisclosureOfDeferredTaxesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDeferredTaxesExplanatory" xlink:to="lbl_DisclosureOfDeferredTaxesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_7f591b1f" xlink:label="lbl_DisclosureOfDeferredTaxesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets and liablities</link:label>
      <link:label id="id_1f4ff3aa" xlink:label="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_21fac415" xlink:label="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
      <link:label id="id_36d33958" xlink:label="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</link:label>
      <link:label id="id_59f2fa2f" xlink:label="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Differences On Which No Deferred Tax Assets Have Been Provided [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" xlink:label="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" xlink:to="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_73861c88" xlink:label="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary differences on which no deferred tax assets have been provided</link:label>
      <link:label id="id_34022912" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:to="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_1ccd7026" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross value of tax-loss carry-forwards</link:label>
      <link:label id="id_3232a79c" xlink:label="lbl_label842180508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SignificantAccountingPoliciesAbstract" xlink:label="lbl_SignificantAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_label842180508" xlink:type="arc"/>
      <link:label id="id_4b3b4099" xlink:label="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of significant accounting policies [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_3f1625ed" xlink:label="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant accounting policies</link:label>
      <link:label id="id_3d96e2f9" xlink:label="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Respective Useful Lives of property, plant and equipment [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_56feb2c8" xlink:label="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Respective Useful Lives of property, plant and equipment</link:label>
      <link:label id="id_8ac126c" xlink:label="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Respective Useful Lives of Available-for-Use Intangible Assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:label="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:to="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4312f4e1" xlink:label="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Respective Useful Lives of Available-for-Use Intangible Assets</link:label>
      <link:label id="id_16da82f9" xlink:label="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for subsidiaries [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_61c4e7e5" xlink:label="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scope of consolidation</link:label>
      <link:label id="id_2b17ff8e" xlink:label="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_57c3715e" xlink:label="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currencies</link:label>
      <link:label id="id_18360a81" xlink:label="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for business combinations [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_6b7df679" xlink:label="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of assets</link:label>
      <link:label id="id_9c406cf" xlink:label="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_634a44d" xlink:label="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property plant and equipment</link:label>
      <link:label id="id_785c05c7" xlink:label="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for goodwill [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_64f7217c" xlink:label="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
      <link:label id="id_5fb6702a" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for Intangible assets available-for-use [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_27c2e0c0" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets available-for-use</link:label>
      <link:label id="id_980511b" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for Intangible assets not yet available-for-use [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_31c63f04" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets not yet available-for-use</link:label>
      <link:label id="id_1a22e85b" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for Impairment of goodwill and intangible assets [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5ecba446" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill and intangible assets</link:label>
      <link:label id="id_35764af6" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for Impairment of associated companies accounted for at equity [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_547afa65" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of associated companies accounted for at equity</link:label>
      <link:label id="id_2741bbc2" xlink:label="lbl_label710888359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial assets [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:to="lbl_label710888359" xlink:type="arc"/>
      <link:label id="id_4c9d021c" xlink:label="lbl_DescriptionOfAccountingPolicyForMeasuringInventories_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for measuring inventories [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:label="lbl_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:to="lbl_DescriptionOfAccountingPolicyForMeasuringInventories_labels" xlink:type="arc"/>
      <link:label id="id_2dc53cba" xlink:label="lbl_DescriptionOfAccountingPolicyForMeasuringInventories_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:label id="id_4f18679b" xlink:label="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for trade and other receivables [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_7ee3df7f" xlink:label="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
      <link:label id="id_5def73f" xlink:label="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for provisions [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_63d0690f" xlink:label="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal and environmental liabilities</link:label>
      <link:label id="id_7371c5cb" xlink:label="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for contingent liabilities and contingent assets [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_55214b7d" xlink:label="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
      <link:label id="id_7e49b25a" xlink:label="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for employee benefits [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_23e7bf92" xlink:label="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit pension plans and other post retirement benefits</link:label>
      <link:label id="id_f50de43" xlink:label="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for treasury shares [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_21b13d04" xlink:label="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Shares</link:label>
      <link:label id="id_7b5ef0a7" xlink:label="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue_labels" xlink:type="arc"/>
      <link:label id="id_4f9fa5aa" xlink:label="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
      <link:label id="id_7912cc37" xlink:label="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_28239f2f" xlink:label="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
      <link:label id="id_20541755" xlink:label="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_6b599b81" xlink:label="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
      <link:label id="id_1cb64794" xlink:label="lbl_DescriptionOfAccountingPolicyForGovernmentGrants_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for government grants [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:label="lbl_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:to="lbl_DescriptionOfAccountingPolicyForGovernmentGrants_labels" xlink:type="arc"/>
      <link:label id="id_35eedb65" xlink:label="lbl_DescriptionOfAccountingPolicyForGovernmentGrants_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government grants</link:label>
      <link:label id="id_11f1b42e" xlink:label="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for decommissioning, restoration and rehabilitation provisions [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_40e153e3" xlink:label="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
      <link:label id="id_2726a264" xlink:label="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for income tax [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_13936f53" xlink:label="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes</link:label>
      <link:label id="id_4a557154" xlink:label="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for non-current assets or disposal groups classified as held for sale [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_7d2f6bd5" xlink:label="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets held for sale or held for distribution to owners</link:label>
      <link:label id="id_27c082e4" xlink:label="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:to="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_labels" xlink:type="arc"/>
      <link:label id="id_455ebc" xlink:label="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of adopting significant new IFRS standards</link:label>
      <link:label id="id_11c5047" xlink:label="lbl_label18632775" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentAbstract" xlink:label="lbl_PropertyPlantAndEquipmentAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentAbstract" xlink:to="lbl_label18632775" xlink:type="arc"/>
      <link:label id="id_7e2f70e6" xlink:label="lbl_label2117038310" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RangeAxis" xlink:to="lbl_label2117038310" xlink:type="arc"/>
      <link:label id="id_6a60d490" xlink:label="lbl_label1784730768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RangesMember" xlink:to="lbl_label1784730768" xlink:type="arc"/>
      <link:label id="id_64d1e224" xlink:label="lbl_BottomOfRangeMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bottom of range [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="lbl_BottomOfRangeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BottomOfRangeMember" xlink:to="lbl_BottomOfRangeMember_labels" xlink:type="arc"/>
      <link:label id="id_5e09e4ca" xlink:label="lbl_TopOfRangeMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top of range [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="lbl_TopOfRangeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TopOfRangeMember" xlink:to="lbl_TopOfRangeMember_labels" xlink:type="arc"/>
      <link:label id="id_28553079" xlink:label="lbl_ComputerEquipmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer equipment [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="lbl_ComputerEquipmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComputerEquipmentMember" xlink:to="lbl_ComputerEquipmentMember_labels" xlink:type="arc"/>
      <link:label id="id_2be121a7" xlink:label="lbl_FurnitureAndVehiclesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and vehicles [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FurnitureAndVehiclesMember" xlink:label="lbl_FurnitureAndVehiclesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FurnitureAndVehiclesMember" xlink:to="lbl_FurnitureAndVehiclesMember_labels" xlink:type="arc"/>
      <link:label id="id_613b73ea" xlink:label="lbl_FurnitureAndVehiclesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and vehicles</link:label>
      <link:label id="id_593b0650" xlink:label="lbl_label1497040464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lbl_label1497040464" xlink:type="arc"/>
      <link:label id="id_42d9f411" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember_labels" xlink:type="arc"/>
      <link:label id="id_3c815062" xlink:label="lbl_BrandNamesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Brand names [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BrandNamesMember" xlink:label="lbl_BrandNamesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BrandNamesMember" xlink:to="lbl_BrandNamesMember_labels" xlink:type="arc"/>
      <link:label id="id_37b4dbd2" xlink:label="lbl_OtherIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other intangible assets [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherIntangibleAssetsMember" xlink:to="lbl_OtherIntangibleAssetsMember_labels" xlink:type="arc"/>
      <link:label id="id_7fe96854" xlink:label="lbl_TechnologybasedIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology-based intangible assets [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TechnologybasedIntangibleAssetsMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember_labels" xlink:type="arc"/>
      <link:label id="id_2340963a" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketing related intangible assets [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MarketingRelatedIntangibleAssetsMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember_labels" xlink:type="arc"/>
      <link:label id="id_44d0b847" xlink:label="lbl_CurrentlyMarketedProductsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currently marketed products [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentlyMarketedProductsMember" xlink:to="lbl_CurrentlyMarketedProductsMember_labels" xlink:type="arc"/>
      <link:label id="id_796a6b5e" xlink:label="lbl_label2037017438" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income statement location [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementLocationAxis" xlink:label="lbl_IncomeStatementLocationAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementLocationAxis" xlink:to="lbl_label2037017438" xlink:type="arc"/>
      <link:label id="id_bc5c8b8" xlink:label="lbl_label197511352" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income statement location [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementLocationMember" xlink:label="lbl_IncomeStatementLocationMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementLocationMember" xlink:to="lbl_label197511352" xlink:type="arc"/>
      <link:label id="id_2449d337" xlink:label="lbl_label608817975" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of sales or Research and Development [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CostOfSalesOrResearchAndDevelopmentMember" xlink:label="lbl_CostOfSalesOrResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CostOfSalesOrResearchAndDevelopmentMember" xlink:to="lbl_label608817975" xlink:type="arc"/>
      <link:label id="id_5073642b" xlink:label="lbl_label1349739563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExpenseAbstract" xlink:label="lbl_InterestExpenseAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseAbstract" xlink:to="lbl_label1349739563" xlink:type="arc"/>
      <link:label id="id_7fef39d4" xlink:label="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense due to unwinding of discount on provisions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:to="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions_labels" xlink:type="arc"/>
      <link:label id="id_1de5231e" xlink:label="lbl_InterestExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpense" xlink:to="lbl_InterestExpense_labels" xlink:type="arc"/>
      <link:label id="id_f4773bc" xlink:label="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expense arising from discounting long-term liabilities and capitalized borrowing costs</link:label>
      <link:label id="id_5a15aac0" xlink:label="lbl_label1549022431" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
      <link:label id="id_7a288c00" xlink:label="lbl_InterestExpense_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Interest Expense</link:label>
      <link:label id="id_55d5704a" xlink:label="lbl_label1440051274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other financial income and expense [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialIncomeAndExpenseAbstract" xlink:label="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_label1440051274" xlink:type="arc"/>
      <link:label id="id_1c654137" xlink:label="lbl_label476397879" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income on forward contracts and options</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeOnForwardContractsAndOptions" xlink:label="lbl_IncomeOnForwardContractsAndOptions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeOnForwardContractsAndOptions" xlink:to="lbl_label476397879" xlink:type="arc"/>
      <link:label id="id_545ae83" xlink:label="lbl_GainsLossesOnNetMonetaryPosition_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on net monetary position</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnNetMonetaryPosition" xlink:label="lbl_GainsLossesOnNetMonetaryPosition" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesOnNetMonetaryPosition" xlink:to="lbl_GainsLossesOnNetMonetaryPosition_labels" xlink:type="arc"/>
      <link:label id="id_550f9fc0" xlink:label="lbl_GainsLossesOnNetMonetaryPosition_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monetary loss from hyperinflation</link:label>
      <link:label id="id_76a4da02" xlink:label="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_labels" xlink:type="arc"/>
      <link:label id="id_26393d9c" xlink:label="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency result, net</link:label>
      <link:label id="id_32d2b6d5" xlink:label="lbl_label852670165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major components of tax expense (income) [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="lbl_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="lbl_label852670165" xlink:type="arc"/>
      <link:label id="id_66ab5be5" xlink:label="lbl_label1722506213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_label1722506213" xlink:type="arc"/>
      <link:label id="id_4667b9e2" xlink:label="lbl_label1181202914" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_label1181202914" xlink:type="arc"/>
      <link:label id="id_3f3ab48" xlink:label="lbl_CountryOfDomicileMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Country of domicile [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CountryOfDomicileMember" xlink:to="lbl_CountryOfDomicileMember_labels" xlink:type="arc"/>
      <link:label id="id_14841da" xlink:label="lbl_ForeignCountriesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign countries [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ForeignCountriesMember" xlink:to="lbl_ForeignCountriesMember_labels" xlink:type="arc"/>
      <link:label id="id_56fc0dcb" xlink:label="lbl_CountryOfDomicileMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Switzerland</link:label>
      <link:label id="id_7d96a380" xlink:label="lbl_ForeignCountriesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
      <link:label id="id_58ec016" xlink:label="lbl_ProfitLossBeforeTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) before tax</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossBeforeTax" xlink:to="lbl_ProfitLossBeforeTax_labels" xlink:type="arc"/>
      <link:label id="id_55d23fd3" xlink:label="lbl_AccountingProfit_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting profit</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccountingProfit" xlink:label="lbl_AccountingProfit" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccountingProfit" xlink:to="lbl_AccountingProfit_labels" xlink:type="arc"/>
      <link:label id="id_1207c251" xlink:label="lbl_ProfitLossBeforeTax_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before taxes</link:label>
      <link:label id="id_d3303df" xlink:label="lbl_AccountingProfit_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Income before taxes</link:label>
      <link:label id="id_5fb2cb43" xlink:label="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income), continuing operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxExpenseContinuingOperations" xlink:to="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_477ea68" xlink:label="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
      <link:label id="id_4390e563" xlink:label="lbl_IncomeTaxExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeTaxExpense" xlink:label="lbl_IncomeTaxExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxExpense" xlink:to="lbl_IncomeTaxExpense_labels" xlink:type="arc"/>
      <link:label id="id_c99559f" xlink:label="lbl_IncomeTaxExpense_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Income Tax Expense</link:label>
      <link:label id="id_750153b3" xlink:label="lbl_label1963021235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of average effective tax rate and applicable tax rate [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract" xlink:label="lbl_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract" xlink:to="lbl_label1963021235" xlink:type="arc"/>
      <link:label id="id_5d2df8ac" xlink:label="lbl_ApplicableTaxRate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Applicable tax rate</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ApplicableTaxRate" xlink:label="lbl_ApplicableTaxRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ApplicableTaxRate" xlink:to="lbl_ApplicableTaxRate_labels" xlink:type="arc"/>
      <link:label id="id_74bd6dfe" xlink:label="lbl_ApplicableTaxRate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Applicable tax rate</link:label>
      <link:label id="id_2c804df7" xlink:label="lbl_TaxRateEffectOfCreditsAndAllowances_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of credits and allowances</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectOfCreditsAndAllowances" xlink:label="lbl_TaxRateEffectOfCreditsAndAllowances" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfCreditsAndAllowances" xlink:to="lbl_TaxRateEffectOfCreditsAndAllowances_labels" xlink:type="arc"/>
      <link:label id="id_1d59fda1" xlink:label="lbl_TaxRateEffectOfCreditsAndAllowances_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of tax credits and allowances</link:label>
      <link:label id="id_682f727c" xlink:label="lbl_TaxRateEffectOfWriteOffOfDeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of write off of deferred tax assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectOfWriteOffOfDeferredTaxAssets" xlink:label="lbl_TaxRateEffectOfWriteOffOfDeferredTaxAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfWriteOffOfDeferredTaxAssets" xlink:to="lbl_TaxRateEffectOfWriteOffOfDeferredTaxAssets_labels" xlink:type="arc"/>
      <link:label id="id_514b6bd9" xlink:label="lbl_TaxRateEffectOfWriteOffOfDeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of write off of deferred tax assets</link:label>
      <link:label id="id_6710a9a" xlink:label="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect from write down and reversal of write down of invest subsidiaries</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:label="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:to="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries_labels" xlink:type="arc"/>
      <link:label id="id_175786ff" xlink:label="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of write down and reversal of write down of investments in subsidiaries</link:label>
      <link:label id="id_574b8256" xlink:label="lbl_label1464566358" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of tax benefits expiring in 2017</link:label>
      <link:label id="id_5de8eaa3" xlink:label="lbl_label1575545507" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect from benefits expiring</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectFromBenefitsExpiring" xlink:label="lbl_TaxRateEffectFromBenefitsExpiring" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromBenefitsExpiring" xlink:to="lbl_label1575545507" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromBenefitsExpiring" xlink:to="lbl_label1464566358" xlink:type="arc"/>
      <link:label id="id_536d84ea" xlink:label="lbl_label1131311877" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of non-deductible losses in Venezuela</link:label>
      <link:label id="id_4741211a" xlink:label="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate effect of adjustments for current tax of prior periods</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:to="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods_labels" xlink:type="arc"/>
      <link:label id="id_3fc4f53a" xlink:label="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of prior year items</link:label>
      <link:label id="id_665323a" xlink:label="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of other items</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_labels" xlink:type="arc"/>
      <link:label id="id_dea5852" xlink:label="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other tax rate effects for reconciliation between accounting profit and tax expense (income)</link:label>
      <link:label id="id_ee48bb4" xlink:label="lbl_AverageEffectiveTaxRateContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average effective tax rate continuing operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageEffectiveTaxRateContinuingOperations" xlink:label="lbl_AverageEffectiveTaxRateContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageEffectiveTaxRateContinuingOperations" xlink:to="lbl_AverageEffectiveTaxRateContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_37da283b" xlink:label="lbl_AverageEffectiveTaxRateContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate for continuing operations</link:label>
      <link:label id="id_47841719" xlink:label="lbl_label1199839001" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate for discontinued operations</link:label>
      <link:label id="id_f9778dc" xlink:label="lbl_label261585116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average effective tax rate discontinued operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageEffectiveTaxRateDiscontinuedOperations" xlink:label="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:to="lbl_label261585116" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:to="lbl_label1199839001" xlink:type="arc"/>
      <link:label id="id_51bf64bc" xlink:label="lbl_AverageEffectiveTaxRate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageEffectiveTaxRate" xlink:label="lbl_AverageEffectiveTaxRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageEffectiveTaxRate" xlink:to="lbl_AverageEffectiveTaxRate_labels" xlink:type="arc"/>
      <link:label id="id_4e4514d0" xlink:label="lbl_AverageEffectiveTaxRate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average effective tax rate</link:label>
      <link:label id="id_65d06a2f" xlink:label="lbl_label1708157487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax assets and liabilities [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_label1708157487" xlink:type="arc"/>
      <link:label id="id_482aa0f2" xlink:label="lbl_label1210753266" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_label1210753266" xlink:type="arc"/>
      <link:label id="id_75d207b8" xlink:label="lbl_label1976698808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_label1976698808" xlink:type="arc"/>
      <link:label id="id_1bb2f625" xlink:label="lbl_label464713253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pensions and other benefit obligations of associates [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:label="lbl_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:to="lbl_label464713253" xlink:type="arc"/>
      <link:label id="id_6d0f55ad" xlink:label="lbl_InventoriesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoriesMember" xlink:label="lbl_InventoriesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoriesMember" xlink:to="lbl_InventoriesMember_labels" xlink:type="arc"/>
      <link:label id="id_7e43c96a" xlink:label="lbl_label2118371690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax loss carryforwards [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxLossCarryforwardsMember" xlink:label="lbl_TaxLossCarryforwardsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxLossCarryforwardsMember" xlink:to="lbl_label2118371690" xlink:type="arc"/>
      <link:label id="id_112eae32" xlink:label="lbl_label288271922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets, provisions and accruals [member]</link:label>
      <link:label id="id_4d44190d" xlink:label="lbl_DeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
      <link:label id="id_69dcdf60" xlink:label="lbl_DeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:label id="id_65498be7" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="lbl_DeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxLiabilityAsset" xlink:to="lbl_DeferredTaxLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_46ad922f" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax balance</link:label>
      <link:label id="id_637b5bc7" xlink:label="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credited/(charged) to income</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:to="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:type="arc"/>
      <link:label id="id_50e2e919" xlink:label="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax expense (income) recognised in profit or loss</link:label>
      <link:label id="id_54101181" xlink:label="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax relating to items credited (charged) directly to equity</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:to="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_labels" xlink:type="arc"/>
      <link:label id="id_8409b0d" xlink:label="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charged to equity</link:label>
      <link:label id="id_5e5bb1e8" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax relating to components of other comprehensive income</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:to="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_495f93f4" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credited/(charged) to other comprehensive income</link:label>
      <link:label id="id_22e658d6" xlink:label="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through business combinations, deferred tax liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:to="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_36e0af13" xlink:label="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_35a4b23c" xlink:label="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through other movements deferred tax liability (asset)</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:to="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_6e9211d6" xlink:label="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other movements</link:label>
      <link:label id="id_1e95490a" xlink:label="lbl_label513100042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offsetting of deferred tax assets and liabilities within the same tax jurisdiction</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:label="lbl_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:to="lbl_label513100042" xlink:type="arc"/>
      <link:label id="id_7845a7b2" xlink:label="lbl_label2017830834" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary differences on which no deferred tax assets have been provided [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" xlink:label="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" xlink:to="lbl_label2017830834" xlink:type="arc"/>
      <link:label id="id_76d7af65" xlink:label="lbl_label1993846629" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in subsidiaries [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InvestmentsInSubsidiariesMember" xlink:label="lbl_InvestmentsInSubsidiariesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InvestmentsInSubsidiariesMember" xlink:to="lbl_label1993846629" xlink:type="arc"/>
      <link:label id="id_155fe654" xlink:label="lbl_label358606420" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill from acquisitions [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GoodwillFromAcquisitionsMember" xlink:label="lbl_GoodwillFromAcquisitionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GoodwillFromAcquisitionsMember" xlink:to="lbl_label358606420" xlink:type="arc"/>
      <link:label id="id_2439e7db" xlink:label="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deductible temporary differences for which no deferred tax asset is recognised</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:to="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_labels" xlink:type="arc"/>
      <link:label id="id_720fdd61" xlink:label="lbl_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary differences on which no deferred tax has been provided as they are permanent in nature</link:label>
      <link:label id="id_193f7081" xlink:label="lbl_label423587969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="lbl_label423587969" xlink:type="arc"/>
      <link:label id="id_6b884d65" xlink:label="lbl_label1804094821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lbl_label1804094821" xlink:type="arc"/>
      <link:label id="id_37fff575" xlink:label="lbl_label939521397" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance sheet treatment [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetTreatmentAxis" xlink:label="lbl_BalanceSheetTreatmentAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BalanceSheetTreatmentAxis" xlink:to="lbl_label939521397" xlink:type="arc"/>
      <link:label id="id_53909ff0" xlink:label="lbl_label1401987056" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance sheet treatment [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetTreatmentMember" xlink:label="lbl_BalanceSheetTreatmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BalanceSheetTreatmentMember" xlink:to="lbl_label1401987056" xlink:type="arc"/>
      <link:label id="id_439c0ffd" xlink:label="lbl_label1134301181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CapitalizedMember" xlink:label="lbl_CapitalizedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CapitalizedMember" xlink:to="lbl_label1134301181" xlink:type="arc"/>
      <link:label id="id_4f2ca3b1" xlink:label="lbl_label1328325553" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not capitalized [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NotCapitalizedMember" xlink:label="lbl_NotCapitalizedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NotCapitalizedMember" xlink:to="lbl_label1328325553" xlink:type="arc"/>
      <link:label id="id_2654c6dd" xlink:label="lbl_label643090141" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year of expiry [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_YearOfExpiryAxis" xlink:label="lbl_YearOfExpiryAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_YearOfExpiryAxis" xlink:to="lbl_label643090141" xlink:type="arc"/>
      <link:label id="id_4110ec53" xlink:label="lbl_label1091628115" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year of expiry [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_YearOfExpiryMember" xlink:label="lbl_YearOfExpiryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_label1091628115" xlink:type="arc"/>
      <link:label id="id_5e6070e2" xlink:label="lbl_label1583378658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One year [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OneYearMember" xlink:label="lbl_OneYearMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OneYearMember" xlink:to="lbl_label1583378658" xlink:type="arc"/>
      <link:label id="id_4ad3dc4f" xlink:label="lbl_label1255398479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two years [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TwoYearsMember" xlink:label="lbl_TwoYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TwoYearsMember" xlink:to="lbl_label1255398479" xlink:type="arc"/>
      <link:label id="id_5915ca9f" xlink:label="lbl_label1494600351" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Three years [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ThreeYearsMember" xlink:label="lbl_ThreeYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ThreeYearsMember" xlink:to="lbl_label1494600351" xlink:type="arc"/>
      <link:label id="id_7bb728cd" xlink:label="lbl_label2075601101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Four years [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FourYearsMember" xlink:label="lbl_FourYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FourYearsMember" xlink:to="lbl_label2075601101" xlink:type="arc"/>
      <link:label id="id_742ed8cf" xlink:label="lbl_label1949227215" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Five years [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FiveYearsMember" xlink:label="lbl_FiveYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FiveYearsMember" xlink:to="lbl_label1949227215" xlink:type="arc"/>
      <link:label id="id_347afbb1" xlink:label="lbl_label880475057" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">More than five years [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MoreThanFiveYearsMember" xlink:label="lbl_MoreThanFiveYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MoreThanFiveYearsMember" xlink:to="lbl_label880475057" xlink:type="arc"/>
      <link:label id="id_74c41296" xlink:label="lbl_label94266701" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</link:label>
      <link:label id="id_14f7a19b" xlink:label="lbl_ValueOfTaxLossCarryforwardsExpired_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value of tax loss carryforwards expired</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueOfTaxLossCarryforwardsExpired" xlink:label="lbl_ValueOfTaxLossCarryforwardsExpired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueOfTaxLossCarryforwardsExpired" xlink:to="lbl_ValueOfTaxLossCarryforwardsExpired_labels" xlink:type="arc"/>
      <link:label id="id_6a5eff98" xlink:label="lbl_ValueOfTaxLossCarryforwardsExpired_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax loss carryforwards expired</link:label>
      <link:label id="id_70fd1364" xlink:label="lbl_label1895633764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax asset expected to have an impact on current taxes payable after more than 12 months</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:label="lbl_DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:to="lbl_label1895633764" xlink:type="arc"/>
      <link:label id="id_522d9018" xlink:label="lbl_label1378717720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities expected to have an impact on current taxes payable after more than 12 months</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:label="lbl_DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" xlink:to="lbl_label1378717720" xlink:type="arc"/>
      <link:label id="id_2f7867e" xlink:label="lbl_label49776254" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unremitted earnings retained by consolidated entities for reinvestment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:label="lbl_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:to="lbl_label49776254" xlink:type="arc"/>
      <link:label id="id_5d6e151" xlink:label="lbl_label97968465" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for income taxes on unremitted earnings</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForIncomeTaxesOnUnremittedEarnings" xlink:label="lbl_ProvisionForIncomeTaxesOnUnremittedEarnings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionForIncomeTaxesOnUnremittedEarnings" xlink:to="lbl_label97968465" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:label="lbl_GainsLossesOnAvailableforsaleFinancialAssets1" xlink:type="locator"/>
      <link:label id="id_7db0af99" xlink:label="lbl_GainsLossesOnAvailableforsaleFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net capital losses on available-for-sale securities</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesOnAvailableforsaleFinancialAssets1" xlink:to="lbl_GainsLossesOnAvailableforsaleFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_27062936" xlink:label="lbl_GainsLossesOnAvailableforsaleFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on available-for-sale financial assets</link:label>
      <link:label id="id_71a78a3a" xlink:label="lbl_label1906805306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial and other non-current assets [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:to="lbl_label1906805306" xlink:type="arc"/>
      <link:label id="id_52927dd" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial and other non-current assets [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" xlink:to="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4f2bb8aa" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial and other non-current assets</link:label>
      <link:label id="id_67e73888" xlink:label="lbl_DisclosureOfFinancialAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialAssetsTableTextBlock" xlink:label="lbl_DisclosureOfFinancialAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAssetsTableTextBlock" xlink:to="lbl_DisclosureOfFinancialAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_634e228d" xlink:label="lbl_DisclosureOfFinancialAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
      <link:label id="id_57b4381e" xlink:label="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other non-current assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:label="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:to="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6832ec2" xlink:label="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
      <link:label id="id_1f868b2b" xlink:label="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of minimum finance lease payments [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:label="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:to="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2e528ce3" xlink:label="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum finance lease payments</link:label>
      <link:label id="id_6a1e58d8" xlink:label="lbl_label1780373720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current assets [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCurrentAssetsAbstract" xlink:label="lbl_OtherCurrentAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_label1780373720" xlink:type="arc"/>
      <link:label id="id_574b2687" xlink:label="lbl_DisclosureOfOtherCurrentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other current assets [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:label="lbl_DisclosureOfOtherCurrentAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherCurrentAssetsExplanatory" xlink:to="lbl_DisclosureOfOtherCurrentAssetsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_2fe53b2a" xlink:label="lbl_DisclosureOfOtherCurrentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
      <link:label id="id_2f9ef8c8" xlink:label="lbl_OtherCurrentAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCurrentAssetsTableTextBlock" xlink:label="lbl_OtherCurrentAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentAssetsTableTextBlock" xlink:to="lbl_OtherCurrentAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6c3d724c" xlink:label="lbl_OtherCurrentAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
      <link:label id="id_229f76b0" xlink:label="lbl_CurrentValueAddedTaxReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current value added tax receivables</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="lbl_CurrentValueAddedTaxReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentValueAddedTaxReceivables" xlink:to="lbl_CurrentValueAddedTaxReceivables_labels" xlink:type="arc"/>
      <link:label id="id_5dea7085" xlink:label="lbl_CurrentValueAddedTaxReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VAT Receivable</link:label>
      <link:label id="id_68e173a" xlink:label="lbl_label1024297901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Withholding tax recoverable</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WithholdingTaxRecoverable" xlink:label="lbl_WithholdingTaxRecoverable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WithholdingTaxRecoverable" xlink:to="lbl_label1024297901" xlink:type="arc"/>
      <link:label id="id_7437ef3d" xlink:label="lbl_label905656156" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses - third party</link:label>
      <link:label id="id_6210dea9" xlink:label="lbl_CurrentPrepaidExpensesAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current prepaid expenses associated companies</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPrepaidExpensesAssociatedCompanies" xlink:label="lbl_CurrentPrepaidExpensesAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPrepaidExpensesAssociatedCompanies" xlink:to="lbl_CurrentPrepaidExpensesAssociatedCompanies_labels" xlink:type="arc"/>
      <link:label id="id_2201baf2" xlink:label="lbl_CurrentPrepaidExpensesAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses - associated companies</link:label>
      <link:label id="id_61baeb33" xlink:label="lbl_label1639639859" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables associated companies</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReceivablesAssociatedCompanies" xlink:label="lbl_ReceivablesAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReceivablesAssociatedCompanies" xlink:to="lbl_label1639639859" xlink:type="arc"/>
      <link:label id="id_3ac7e1da" xlink:label="lbl_label986178010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other receivables and current assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherReceivablesAndCurrentAssets" xlink:label="lbl_OtherReceivablesAndCurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherReceivablesAndCurrentAssets" xlink:to="lbl_label986178010" xlink:type="arc"/>
      <link:label id="id_4072377e" xlink:label="lbl_OtherCurrentNonfinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other current assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentNonfinancialAssets" xlink:to="lbl_OtherCurrentNonfinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_e3db8e7" xlink:label="lbl_OtherCurrentNonfinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current non-financial assets</link:label>
      <link:label id="id_d18502c" xlink:label="lbl_label219697196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of marketable securities commodities deposits derivative instruments and cash [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_label219697196" xlink:type="arc"/>
      <link:label id="id_69021d0e" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of marketable securities commodities deposits derivative instruments and cash [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" xlink:to="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4984da50" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of marketable securities commodities deposits derivative instruments and cash</link:label>
      <link:label id="id_24a0b3b8" xlink:label="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities, commodities, timedeposits, and derivative financial instruments [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" xlink:label="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" xlink:to="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_443173b3" xlink:label="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, commodities, timedeposits, and derivative financial instruments</link:label>
      <link:label id="id_34fe6088" xlink:label="lbl_CashAndCashEquivalentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsTableTextBlock" xlink:label="lbl_CashAndCashEquivalentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsTableTextBlock" xlink:to="lbl_CashAndCashEquivalentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1b8f74ee" xlink:label="lbl_CashAndCashEquivalentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:label id="id_808126e" xlink:label="lbl_DebtInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt instruments held</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtInstrumentsHeld" xlink:label="lbl_DebtInstrumentsHeld" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DebtInstrumentsHeld" xlink:to="lbl_DebtInstrumentsHeld_labels" xlink:type="arc"/>
      <link:label id="id_6e00ca4f" xlink:label="lbl_DebtInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities</link:label>
      <link:label id="id_22a6b8a5" xlink:label="lbl_EquityInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity instruments held</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityInstrumentsHeld" xlink:label="lbl_EquityInstrumentsHeld" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityInstrumentsHeld" xlink:to="lbl_EquityInstrumentsHeld_labels" xlink:type="arc"/>
      <link:label id="id_724851f6" xlink:label="lbl_EquityInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
      <link:label id="id_419c6f6a" xlink:label="lbl_FundInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fund instruments held</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FundInstrumentsHeld" xlink:label="lbl_FundInstrumentsHeld" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FundInstrumentsHeld" xlink:to="lbl_FundInstrumentsHeld_labels" xlink:type="arc"/>
      <link:label id="id_53712316" xlink:label="lbl_FundInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fund investments</link:label>
      <link:label id="id_17079bd" xlink:label="lbl_label1789088932" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commodities</link:label>
      <link:label id="id_6c508a7b" xlink:label="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term deposits, not classified as cash equivalents</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:label="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:to="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_24ec6e77" xlink:label="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time deposits and short-term investments with original maturity more than 90 days</link:label>
      <link:label id="id_ef5ab87" xlink:label="lbl_DerivativeFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial instruments</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativeFinancialAssets" xlink:label="lbl_DerivativeFinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialAssets" xlink:to="lbl_DerivativeFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_4954716a" xlink:label="lbl_DerivativeFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial assets</link:label>
      <link:label id="id_57e2aa2d" xlink:label="lbl_InterestReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivable" xlink:label="lbl_InterestReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestReceivable" xlink:to="lbl_InterestReceivable_labels" xlink:type="arc"/>
      <link:label id="id_6996ac87" xlink:label="lbl_InterestReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest on debt securities and time deposits</link:label>
      <link:label id="id_70ff77e4" xlink:label="lbl_Cash_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current accounts</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Cash" xlink:label="lbl_Cash" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Cash" xlink:to="lbl_Cash_labels" xlink:type="arc"/>
      <link:label id="id_502a929f" xlink:label="lbl_Cash_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash</link:label>
      <link:label id="id_436c5591" xlink:label="lbl_label1131173265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="lbl_CashAndCashEquivalentsAbstract1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsAbstract1" xlink:to="lbl_label1131173265" xlink:type="arc"/>
      <link:label id="id_20053f5" xlink:label="lbl_CashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash and cash equivalents</link:label>
      <link:label id="id_47b73cba" xlink:label="lbl_CashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time deposits and short term investments with original maturity less than 90 days</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashEquivalents" xlink:label="lbl_CashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashEquivalents" xlink:to="lbl_CashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_178a6550" xlink:label="lbl_CashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
      <link:label id="id_25a7d307" xlink:label="lbl_label631755527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt securities denominations [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DebtSecuritiesDenominationsAbstract" xlink:label="lbl_DebtSecuritiesDenominationsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DebtSecuritiesDenominationsAbstract" xlink:to="lbl_label631755527" xlink:type="arc"/>
      <link:label id="id_6e4a0bf9" xlink:label="lbl_DebtInstrumentsHeld_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt securities held</link:label>
      <link:label id="id_3758e5ae" xlink:label="lbl_ComputerEquipmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
      <link:label id="id_487fbdc1" xlink:label="lbl_label1216331201" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in deferred tax balance [roll forward]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementInDeferredTaxBalanceRollForward" xlink:label="lbl_MovementInDeferredTaxBalanceRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_label1216331201" xlink:type="arc"/>
      <link:label id="id_41df7536" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax balance at beginning of period</link:label>
      <link:label id="id_2e28206a" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax balance at end of period</link:label>
      <link:label id="id_4c171394" xlink:label="lbl_label1276580756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_label1276580756" xlink:type="arc"/>
      <link:label id="id_767010e4" xlink:label="lbl_ContingentConsiderationReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Receivable</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivable" xlink:label="lbl_ContingentConsiderationReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationReceivable" xlink:to="lbl_ContingentConsiderationReceivable_labels" xlink:type="arc"/>
      <link:label id="id_1c964d9b" xlink:label="lbl_ContingentConsiderationReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration receivables</link:label>
      <link:label id="id_1cc013c7" xlink:label="lbl_NoncurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="lbl_NoncurrentFinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAssets" xlink:to="lbl_NoncurrentFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_47c06050" xlink:label="lbl_NoncurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets</link:label>
      <link:label id="id_2038ebb3" xlink:label="lbl_NoncurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total financial assets</link:label>
      <link:label id="id_7a406b1b" xlink:label="lbl_NoncurrentLoansAndReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current loans and receivables</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLoansAndReceivables" xlink:label="lbl_NoncurrentLoansAndReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLoansAndReceivables" xlink:to="lbl_NoncurrentLoansAndReceivables_labels" xlink:type="arc"/>
      <link:label id="id_69fe82c8" xlink:label="lbl_NoncurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current trade receivables</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentTradeReceivables" xlink:label="lbl_NoncurrentTradeReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentTradeReceivables" xlink:to="lbl_NoncurrentTradeReceivables_labels" xlink:type="arc"/>
      <link:label id="id_56c9fa84" xlink:label="lbl_NoncurrentFinancialAssetsAvailableforsale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets available-for-sale</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinancialAssetsAvailableforsale" xlink:label="lbl_NoncurrentFinancialAssetsAvailableforsale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAssetsAvailableforsale" xlink:to="lbl_NoncurrentFinancialAssetsAvailableforsale_labels" xlink:type="arc"/>
      <link:label id="id_7f86a75a" xlink:label="lbl_NoncurrentFinancialAssetsAvailableforsale_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale long-term financial investments</link:label>
      <link:label id="id_416abfec" xlink:label="lbl_NoncurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term receivables from customers</link:label>
      <link:label id="id_614e0e43" xlink:label="lbl_NoncurrentLoansAndReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term loans, advances and security deposits</link:label>
      <link:label id="id_2adc1935" xlink:label="lbl_label719067445" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other non-current assets [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:label="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:to="lbl_label719067445" xlink:type="arc"/>
      <link:label id="id_372134b4" xlink:label="lbl_OtherNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentAssets" xlink:to="lbl_OtherNoncurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_36e85d79" xlink:label="lbl_OtherNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other non-current assets</link:label>
      <link:label id="id_3d890a89" xlink:label="lbl_label503420728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred compensation plans assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredCompensationPlansAssets" xlink:label="lbl_DeferredCompensationPlansAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredCompensationPlansAssets" xlink:to="lbl_label503420728" xlink:type="arc"/>
      <link:label id="id_5743c2dd" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid post-employment benefit plans assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrepaidPostemploymentBenefitPlansAssets" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:to="lbl_PrepaidPostemploymentBenefitPlansAssets_labels" xlink:type="arc"/>
      <link:label id="id_509c8962" xlink:label="lbl_label1352436066" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaturityAxis" xlink:to="lbl_label1352436066" xlink:type="arc"/>
      <link:label id="id_36becdba" xlink:label="lbl_label918474170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregated time bands [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_label918474170" xlink:type="arc"/>
      <link:label id="id_19bac06a" xlink:label="lbl_NotLaterThanOneYearMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one year [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NotLaterThanOneYearMember" xlink:to="lbl_NotLaterThanOneYearMember_labels" xlink:type="arc"/>
      <link:label id="id_40351209" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than five years [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember_labels" xlink:type="arc"/>
      <link:label id="id_26dc6723" xlink:label="lbl_LaterThanFiveYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanFiveYearsMember" xlink:to="lbl_LaterThanFiveYearsMember_labels" xlink:type="arc"/>
      <link:label id="id_678942b3" xlink:label="lbl_NotLaterThanOneYearMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not later than one year</link:label>
      <link:label id="id_65bceee2" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Between one and five years</link:label>
      <link:label id="id_2043ab6e" xlink:label="lbl_LaterThanFiveYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Later than five years</link:label>
      <link:label id="id_1c8984aa" xlink:label="lbl_FinanceLeaseProvision_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance lease provision</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinanceLeaseProvision" xlink:label="lbl_FinanceLeaseProvision" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceLeaseProvision" xlink:to="lbl_FinanceLeaseProvision_labels" xlink:type="arc"/>
      <link:label id="id_4a3761d0" xlink:label="lbl_FinanceLeaseProvision_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Provision</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinanceLeaseReceivables" xlink:label="lbl_NoncurrentFinanceLeaseReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinanceLeaseReceivables" xlink:to="lbl_NoncurrentFinanceLeaseReceivables_labels" xlink:type="arc"/>
      <link:label id="id_5712ddf0" xlink:label="lbl_NoncurrentFinanceLeaseReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current finance lease receivables</link:label>
      <link:label id="id_3c5105da" xlink:label="lbl_IncomeStatementAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit or loss [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="lbl_IncomeStatementAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementAbstract" xlink:to="lbl_IncomeStatementAbstract_labels" xlink:type="arc"/>
      <link:label id="id_3f03b5f7" xlink:label="lbl_IncomeStatementAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated income statements [abstract]</link:label>
      <link:label id="id_6acd9405" xlink:label="lbl_RevenueFromSaleOfGoods_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoods" xlink:to="lbl_RevenueFromSaleOfGoods_labels" xlink:type="arc"/>
      <link:label id="id_3a842f2" xlink:label="lbl_RevenueFromSaleOfGoods_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales</link:label>
      <link:label id="id_150c2b7f" xlink:label="lbl_OtherRevenue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherRevenue" xlink:to="lbl_OtherRevenue_labels" xlink:type="arc"/>
      <link:label id="id_127d952" xlink:label="lbl_OtherRevenue_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
      <link:label id="id_2760bdf6" xlink:label="lbl_CostOfSales_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CostOfSales" xlink:to="lbl_CostOfSales_labels" xlink:type="arc"/>
      <link:label id="id_2b80a016" xlink:label="lbl_CostOfSales_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
      <link:label id="id_57c5a20d" xlink:label="lbl_GrossProfit_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossProfit" xlink:to="lbl_GrossProfit_labels" xlink:type="arc"/>
      <link:label id="id_526b4f9e" xlink:label="lbl_GrossProfit_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
      <link:label id="id_39d76e39" xlink:label="lbl_SalesAndMarketingExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales and marketing expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="lbl_SalesAndMarketingExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SalesAndMarketingExpense" xlink:to="lbl_SalesAndMarketingExpense_labels" xlink:type="arc"/>
      <link:label id="id_28a0f9b9" xlink:label="lbl_SalesAndMarketingExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Marketing and Sales</link:label>
      <link:label id="id_10d069b8" xlink:label="lbl_ResearchAndDevelopmentExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ResearchAndDevelopmentExpense" xlink:to="lbl_ResearchAndDevelopmentExpense_labels" xlink:type="arc"/>
      <link:label id="id_6d2fdc24" xlink:label="lbl_ResearchAndDevelopmentExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
      <link:label id="id_57c6dbd9" xlink:label="lbl_label1472650201" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherIncome" xlink:to="lbl_label1472650201" xlink:type="arc"/>
      <link:label id="id_5f87ab8e" xlink:label="lbl_ProfitLossFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from operating activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_ProfitLossFromOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_17803288" xlink:label="lbl_ProfitLossFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income</link:label>
      <link:label id="id_1fe0c0c6" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of profit (loss) of associates and joint ventures accounted for using equity method</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:type="arc"/>
      <link:label id="id_487c7d01" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Loss)/income from associated companies</link:label>
      <link:label id="id_36251eec" xlink:label="lbl_ProfitLossFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from continuing operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossFromContinuingOperations" xlink:to="lbl_ProfitLossFromContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_6dd27571" xlink:label="lbl_ProfitLossFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
      <link:label id="id_706453ab" xlink:label="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
      <link:label id="id_1efbdca8" xlink:label="lbl_ProfitLossFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from discontinued operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossFromDiscontinuedOperations" xlink:to="lbl_ProfitLossFromDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_1ee0d5e9" xlink:label="lbl_ProfitLossFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income from discontinued operations</link:label>
      <link:label id="id_390e92f5" xlink:label="lbl_ProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLoss" xlink:to="lbl_ProfitLoss_labels" xlink:type="arc"/>
      <link:label id="id_62e876b4" xlink:label="lbl_ProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
      <link:label id="id_6b81cf74" xlink:label="lbl_ProfitLossAttributableToAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="lbl_ProfitLossAttributableToAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToAbstract_labels" xlink:type="arc"/>
      <link:label id="id_1f2a4c4f" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to non-controlling interests</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:to="lbl_ProfitLossAttributableToNoncontrollingInterests_labels" xlink:type="arc"/>
      <link:label id="id_41604097" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:label id="id_68a67dec" xlink:label="lbl_label1755741676" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings per share [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsPerShareAbstract" xlink:label="lbl_BasicEarningsPerShareAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BasicEarningsPerShareAbstract" xlink:to="lbl_label1755741676" xlink:type="arc"/>
      <link:label id="id_4e036998" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Continuing operations</link:label>
      <link:label id="id_fc632c9" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations</link:label>
      <link:label id="id_6d6e73d7" xlink:label="lbl_label1835955159" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings per share [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsPerShareAbstract" xlink:label="lbl_DilutedEarningsPerShareAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DilutedEarningsPerShareAbstract" xlink:to="lbl_label1835955159" xlink:type="arc"/>
      <link:label id="id_78a7e003" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Continuing operations</link:label>
      <link:label id="id_2685ed2a" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations</link:label>
      <link:label id="id_506c062c" xlink:label="lbl_ProfitLossBeforeTax_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before taxes</link:label>
      <link:label id="id_4ec1d679" xlink:label="lbl_label1321326201" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="lbl_DisclosureOfClassesOfShareCapitalAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="lbl_label1321326201" xlink:type="arc"/>
      <link:label id="id_28aa5281" xlink:label="lbl_MovementInTheShareCapitalTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in the share capital [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementInTheShareCapitalTableTextBlock" xlink:label="lbl_MovementInTheShareCapitalTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MovementInTheShareCapitalTableTextBlock" xlink:to="lbl_MovementInTheShareCapitalTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_61f390ae" xlink:label="lbl_MovementInTheShareCapitalTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to movement in the share capital</link:label>
      <link:label id="id_696322e3" xlink:label="lbl_MovementInTheShareslTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in the shares [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementInTheShareslTableTextBlock" xlink:label="lbl_MovementInTheShareslTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MovementInTheShareslTableTextBlock" xlink:to="lbl_MovementInTheShareslTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3b7d854" xlink:label="lbl_MovementInTheShareslTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to movement in the shares</link:label>
      <link:label id="id_21fc0b5b" xlink:label="lbl_label570166107" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_label570166107" xlink:type="arc"/>
      <link:label id="id_69f171dc" xlink:label="lbl_label1777431004" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_label1777431004" xlink:type="arc"/>
      <link:label id="id_66229f4a" xlink:label="lbl_label1713545034" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="lbl_ClassesOfShareCapitalAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfShareCapitalAxis" xlink:to="lbl_label1713545034" xlink:type="arc"/>
      <link:label id="id_6258cf3f" xlink:label="lbl_ClassesOfShareCapitalMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share capital [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="lbl_ClassesOfShareCapitalMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_ClassesOfShareCapitalMember_labels" xlink:type="arc"/>
      <link:label id="id_45684f10" xlink:label="lbl_ChangesInEquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in equity</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInEquity" xlink:label="lbl_ChangesInEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangesInEquity" xlink:to="lbl_ChangesInEquity_labels" xlink:type="arc"/>
      <link:label id="id_29e71b73" xlink:label="lbl_ChangesInEquity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movement in the year</link:label>
      <link:label id="id_4ed5effa" xlink:label="lbl_TreasurySharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesMember" xlink:to="lbl_TreasurySharesMember_labels" xlink:type="arc"/>
      <link:label id="id_17794e38" xlink:label="lbl_OrdinarySharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="lbl_OrdinarySharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OrdinarySharesMember" xlink:to="lbl_OrdinarySharesMember_labels" xlink:type="arc"/>
      <link:label id="id_b03287e" xlink:label="lbl_NumberOfSharesIssuedAndFullyPaid_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued and fully paid</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="lbl_NumberOfSharesIssuedAndFullyPaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfSharesIssuedAndFullyPaid" xlink:to="lbl_NumberOfSharesIssuedAndFullyPaid_labels" xlink:type="arc"/>
      <link:label id="id_1d73737e" xlink:label="lbl_NumberOfSharesOutstanding_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares outstanding</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="lbl_NumberOfSharesOutstanding" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfSharesOutstanding" xlink:to="lbl_NumberOfSharesOutstanding_labels" xlink:type="arc"/>
      <link:label id="id_4825d127" xlink:label="lbl_label1210437927" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in number of shares outstanding</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:label="lbl_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:to="lbl_label1210437927" xlink:type="arc"/>
      <link:label id="id_4881ff43" xlink:label="lbl_NumberOfSharesOutstanding_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of shares outstanding at beginning of period</link:label>
      <link:label id="id_40051e5a" xlink:label="lbl_NumberOfSharesOutstanding_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of shares outstanding at end of period</link:label>
      <link:label id="id_3bcbca2a" xlink:label="lbl_NumberOfSharesIssuedAndFullyPaid_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued and fully paid at beginning of period</link:label>
      <link:label id="id_733911db" xlink:label="lbl_NumberOfSharesIssuedAndFullyPaid_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued and fully paid at end of period</link:label>
      <link:label id="id_623febca" xlink:label="lbl_IssuedCapital_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Share capital at beginning of period</link:label>
      <link:label id="id_35d913cc" xlink:label="lbl_IssuedCapital_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Share capital at end of period</link:label>
      <link:label id="id_288f270c" xlink:label="lbl_TreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Treasury shares at end of period</link:label>
      <link:label id="id_140833fe" xlink:label="lbl_TreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Treasury shares at beginning of period</link:label>
      <link:label id="id_c7e7a97" xlink:label="lbl_Equity_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Equity at end of period</link:label>
      <link:label id="id_81b3b28" xlink:label="lbl_Equity_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Equity at beginning of period</link:label>
      <link:label id="id_102df8b6" xlink:label="lbl_PurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="lbl_PurchaseOfTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfTreasuryShares" xlink:to="lbl_PurchaseOfTreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_151d9a8b" xlink:label="lbl_SaleOrIssueOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale or issue of treasury shares</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="lbl_SaleOrIssueOfTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOrIssueOfTreasuryShares" xlink:to="lbl_SaleOrIssueOfTreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_20b3b802" xlink:label="lbl_label548648962" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lbl_label548648962" xlink:type="arc"/>
      <link:label id="id_435514ee" xlink:label="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of events after reporting period [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_176c4f1e" xlink:label="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Events subsequent to the December 31 consolidated balance sheet date</link:label>
      <link:label id="id_34460981" xlink:label="lbl_label877005185" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Typ [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypAxis" xlink:label="lbl_SubsequentEventTypAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SubsequentEventTypAxis" xlink:to="lbl_label877005185" xlink:type="arc"/>
      <link:label id="id_72e1dec5" xlink:label="lbl_label1927405253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypeMember" xlink:label="lbl_SubsequentEventTypeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SubsequentEventTypeMember" xlink:to="lbl_label1927405253" xlink:type="arc"/>
      <link:label id="id_1da2a9c4" xlink:label="lbl_label497199556" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventMember" xlink:label="lbl_SubsequentEventMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SubsequentEventMember" xlink:to="lbl_label497199556" xlink:type="arc"/>
      <link:label id="id_7f877b78" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:to="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners_labels" xlink:type="arc"/>
      <link:label id="id_7b380046" xlink:label="lbl_label2067267654" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and contingencies [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentsAndContingenciesAbstract" xlink:label="lbl_CommitmentsAndContingenciesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommitmentsAndContingenciesAbstract" xlink:to="lbl_label2067267654" xlink:type="arc"/>
      <link:label id="id_16b78de2" xlink:label="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of commitments and contingencies [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCommitmentsAndContingenciesTextBlock" xlink:label="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock" xlink:to="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4488d3fd" xlink:label="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:label id="id_2de2541f" xlink:label="lbl_label769807391" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of significant transactions [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfSignificantTransactionsAbstract" xlink:label="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:to="lbl_label769807391" xlink:type="arc"/>
      <link:label id="id_157aa47d" xlink:label="lbl_DisclosureOfSignificantTransactionsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Significant transactions [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfSignificantTransactionsTextBlock" xlink:label="lbl_DisclosureOfSignificantTransactionsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantTransactionsTextBlock" xlink:to="lbl_DisclosureOfSignificantTransactionsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_17fcde6d" xlink:label="lbl_DisclosureOfSignificantTransactionsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant transactions</link:label>
      <link:label id="id_60f273a7" xlink:label="lbl_label1626502055" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_label1626502055" xlink:type="arc"/>
      <link:label id="id_7edd823a" xlink:label="lbl_DisclosureOfFinancialLiabilitiesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:label="lbl_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="lbl_DisclosureOfFinancialLiabilitiesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_7e94d6aa" xlink:label="lbl_DisclosureOfFinancialLiabilitiesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial debt</link:label>
      <link:label id="id_594cd676" xlink:label="lbl_label1498207862" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of current financial debt and derivative instruments [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_label1498207862" xlink:type="arc"/>
      <link:label id="id_716dfcd6" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of current financial debt and derivative instruments [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" xlink:to="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4ab48078" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current financial debt and derivative financial instruments</link:label>
      <link:label id="id_3d80ff4e" xlink:label="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-current portion of non-current borrowings by type [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" xlink:label="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" xlink:to="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5bcb7f48" xlink:label="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-current portion of non-current borrowings by type</link:label>
      <link:label id="id_84597e5" xlink:label="lbl_label138778597" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings</link:label>
      <link:label id="id_77855829" xlink:label="lbl_label2005227561" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:to="lbl_label2005227561" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:to="lbl_label138778597" xlink:type="arc"/>
      <link:label id="id_689e379d" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-current financial debt including current portion by maturity [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" xlink:to="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4824ba8c" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial debt including current portion by maturity</link:label>
      <link:label id="id_780939b8" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-current financial debt including current portion by currency [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" xlink:to="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_43204093" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial debt including current portion by currency</link:label>
      <link:label id="id_75f0b654" xlink:label="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of comparison of balance sheet and fair value of total non-current financial debt including current portion [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" xlink:label="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" xlink:to="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_18f19ce6" xlink:label="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comparison of balance sheet and fair value of total non-current financial debt including current portion</link:label>
      <link:label id="id_6962ebc4" xlink:label="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of collaerallized non-current financial debt and pledged assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" xlink:label="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" xlink:to="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1220efab" xlink:label="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaerallized non-current financial debt and pledged assets</link:label>
      <link:label id="id_4abca4e3" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of current financial debt and derivative instruments [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" xlink:to="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1f8d2d9c" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current financial debt and derivative instruments</link:label>
      <link:label id="id_8188b7e" xlink:label="lbl_DisclosureOfLeasingCommitmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Leasing commitments [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfLeasingCommitmentsTableTextBlock" xlink:label="lbl_DisclosureOfLeasingCommitmentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfLeasingCommitmentsTableTextBlock" xlink:to="lbl_DisclosureOfLeasingCommitmentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_77b05f18" xlink:label="lbl_DisclosureOfLeasingCommitmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasing commitments</link:label>
      <link:label id="id_6662e9d6" xlink:label="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of research and development commitments [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" xlink:label="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" xlink:to="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3f2ee562" xlink:label="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development and other intangible purchase commitments</link:label>
      <link:label id="id_2a65b84f" xlink:label="lbl_label711309391" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasing commitments [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeasingCommitmentsAbstract" xlink:label="lbl_LeasingCommitmentsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeasingCommitmentsAbstract" xlink:to="lbl_label711309391" xlink:type="arc"/>
      <link:label id="id_1173f4bb" xlink:label="lbl_label292811963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule for commitments under fixed term operating leases [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:label="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:to="lbl_label292811963" xlink:type="arc"/>
      <link:label id="id_59b1ae19" xlink:label="lbl_label1504816665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule for commitments under fixed term operating leases [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:label="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:to="lbl_label1504816665" xlink:type="arc"/>
      <link:label id="id_a4d7aae" xlink:label="lbl_label172849838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than two years [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="lbl_label172849838" xlink:type="arc"/>
      <link:label id="id_717d4be6" xlink:label="lbl_label1904036838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than two years and not later than three years [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:to="lbl_label1904036838" xlink:type="arc"/>
      <link:label id="id_4d7a925b" xlink:label="lbl_label1299878491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than three years and not later than four years [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:to="lbl_label1299878491" xlink:type="arc"/>
      <link:label id="id_3b47450e" xlink:label="lbl_label994526478" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than four years and not later than five years [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:to="lbl_label994526478" xlink:type="arc"/>
      <link:label id="id_4b9f759a" xlink:label="lbl_label1268741530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development and other intangible asset purchase commitments [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ResearchAndDevelopmentCommitmentsAbstract" xlink:label="lbl_ResearchAndDevelopmentCommitmentsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ResearchAndDevelopmentCommitmentsAbstract" xlink:to="lbl_label1268741530" xlink:type="arc"/>
      <link:label id="id_714a8ba3" xlink:label="lbl_label1900710819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule for commitments under research and development and other intangible asset purchase [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:label="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:to="lbl_label1900710819" xlink:type="arc"/>
      <link:label id="id_36fa2fba" xlink:label="lbl_label922365882" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule for commitments under research and development and other intangible asset purchase [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:label="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_label922365882" xlink:type="arc"/>
      <link:label id="id_5ab4de42" xlink:label="lbl_label632134259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments under long-term research and development agreements</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentsUnderLongtermResearchAgreements" xlink:label="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:to="lbl_label632134259" xlink:type="arc"/>
      <link:label id="id_2ceef672" xlink:label="lbl_label753858162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial debt and derivative financial instruments [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" xlink:label="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" xlink:to="lbl_label753858162" xlink:type="arc"/>
      <link:label id="id_68d6c1f6" xlink:label="lbl_label1758904822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial debt and derivative financial instruments [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_label1758904822" xlink:type="arc"/>
      <link:label id="id_797bb3cc" xlink:label="lbl_label2038150092" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest bearning accounts of associates payable on demand</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:to="lbl_label2038150092" xlink:type="arc"/>
      <link:label id="id_7b1552fe" xlink:label="lbl_ShorttermBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current borrowings</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermBorrowings" xlink:label="lbl_ShorttermBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShorttermBorrowings" xlink:to="lbl_ShorttermBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_5020629f" xlink:label="lbl_ShorttermBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bank and other financial debt</link:label>
      <link:label id="id_13e39c07" xlink:label="lbl_CommercialPapersIssued_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial papers issued</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommercialPapersIssued" xlink:label="lbl_CommercialPapersIssued" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommercialPapersIssued" xlink:to="lbl_CommercialPapersIssued_labels" xlink:type="arc"/>
      <link:label id="id_4fdebda8" xlink:label="lbl_CommercialPapersIssued_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Papers</link:label>
      <link:label id="id_46dd5b19" xlink:label="lbl_CurrentPortionOfLongtermBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current portion of non-current borrowings</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPortionOfLongtermBorrowings" xlink:to="lbl_CurrentPortionOfLongtermBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_7558c2a6" xlink:label="lbl_CurrentPortionOfLongtermBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of non-current financial debt</link:label>
      <link:label id="id_36b8e550" xlink:label="lbl_label918086992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit derivative, fair value</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditDerivativeFairValue" xlink:label="lbl_CreditDerivativeFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CreditDerivativeFairValue" xlink:to="lbl_label918086992" xlink:type="arc"/>
      <link:label id="id_3a9947a0" xlink:label="lbl_DerivativeFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="lbl_DerivativeFinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialLiabilities" xlink:to="lbl_DerivativeFinancialLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_6dcd1b42" xlink:label="lbl_DerivativeFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of derivative financial instruments</link:label>
      <link:label id="id_1dcb5ef8" xlink:label="lbl_WeightedAverageInterestRateAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average interest rate, associates</link:label>
      <link:label id="id_2863fd2b" xlink:label="lbl_OtherCurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current financial debt and derivative financial instruments</link:label>
      <link:label id="id_5aca2f89" xlink:label="lbl_InterestExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
      <link:label id="id_74374cb6" xlink:label="lbl_label1949781174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of components of non-current financial debts [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:label="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_label1949781174" xlink:type="arc"/>
      <link:label id="id_7edb9957" xlink:label="lbl_label2128320855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of components of non-current financial debts [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" xlink:label="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" xlink:to="lbl_label2128320855" xlink:type="arc"/>
      <link:label id="id_10bc1963" xlink:label="lbl_label280762723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of components of non-current financial debts [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:label="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" xlink:to="lbl_label280762723" xlink:type="arc"/>
      <link:label id="id_300b69ab" xlink:label="lbl_BondsIssued_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Straight bonds</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BondsIssued" xlink:to="lbl_BondsIssued_labels" xlink:type="arc"/>
      <link:label id="id_1e4e0830" xlink:label="lbl_BondsIssued_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bonds issued</link:label>
      <link:label id="id_203f2415" xlink:label="lbl_Borrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total including current portion of non-current financial debt</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Borrowings" xlink:to="lbl_Borrowings_labels" xlink:type="arc"/>
      <link:label id="id_1bc6ed35" xlink:label="lbl_Borrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
      <link:label id="id_2e986311" xlink:label="lbl_CurrentPortionOfLongtermBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less current portion of non-current financial debt</link:label>
      <link:label id="id_355479bd" xlink:label="lbl_OtherNoncurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current financial debts</link:label>
      <link:label id="id_162b1eed" xlink:label="lbl_Borrowings_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">The amount of outstanding funds that the entity is obligated to repay</link:label>
      <link:label id="id_9d2aa80" xlink:label="lbl_label164801152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years and not later than six years [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:label="lbl_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:to="lbl_label164801152" xlink:type="arc"/>
      <link:label id="id_adae114" xlink:label="lbl_LaterThanSixYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than six years [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanSixYearsMember" xlink:label="lbl_LaterThanSixYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanSixYearsMember" xlink:to="lbl_LaterThanSixYearsMember_labels" xlink:type="arc"/>
      <link:label id="id_2050f0fd" xlink:label="lbl_LaterThanSixYearsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Later than six years</link:label>
      <link:label id="id_7e44b35f" xlink:label="lbl_label72836716" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Others</link:label>
      <link:label id="id_6a9e2b6" xlink:label="lbl_label111796918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of the collateralized non-current financial debt and pledged assets [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:label="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:to="lbl_label111796918" xlink:type="arc"/>
      <link:label id="id_57bebc13" xlink:label="lbl_label1472117779" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of the collateralized non-current financial debt and pledged assets [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" xlink:label="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" xlink:to="lbl_label1472117779" xlink:type="arc"/>
      <link:label id="id_6cdc708" xlink:label="lbl_label114149128" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of the collateralized non-current financial debt and pledged assets [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:label="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" xlink:to="lbl_label114149128" xlink:type="arc"/>
      <link:label id="id_1ad42498" xlink:label="lbl_PropertyPlantAndEquipmentPledgedAsSecurity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, pledged as security</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:label="lbl_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:to="lbl_PropertyPlantAndEquipmentPledgedAsSecurity_labels" xlink:type="arc"/>
      <link:label id="id_4cf075ff" xlink:label="lbl_NoncurrentFinancialDebtsCoveredByCollateral_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial debts covered by collateral</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialDebtsCoveredByCollateral" xlink:label="lbl_NoncurrentFinancialDebtsCoveredByCollateral" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialDebtsCoveredByCollateral" xlink:to="lbl_NoncurrentFinancialDebtsCoveredByCollateral_labels" xlink:type="arc"/>
      <link:label id="id_cf0451a" xlink:label="lbl_NoncurrentFinancialDebtsCoveredByCollateral_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total amount of collateralized non-current financial debts</link:label>
      <link:label id="id_6e3a2d82" xlink:label="lbl_PropertyPlantAndEquipmentPledgedAsSecurity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total net book value of property, plant and equipment pledged as collateral for non-current financial debts</link:label>
      <link:label id="id_139c747e" xlink:label="lbl_label329020542" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:to="lbl_label329020542" xlink:type="arc"/>
      <link:label id="id_75a8b438" xlink:label="lbl_label1973990456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lbl_label1973990456" xlink:type="arc"/>
      <link:label id="id_3e0c6c47" xlink:label="lbl_label1041001543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_label1041001543" xlink:type="arc"/>
      <link:label id="id_776f09d7" xlink:label="lbl_label2003765719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_label2003765719" xlink:type="arc"/>
      <link:label id="id_227fd573" xlink:label="lbl_label578803059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_label578803059" xlink:type="arc"/>
      <link:label id="id_40a70df4" xlink:label="lbl_label1084689908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.25% EUR 1 500 million bond 2009/2016 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.757% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:label="lbl_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:to="lbl_label1084689908" xlink:type="arc"/>
      <link:label id="id_59ab4811" xlink:label="lbl_label1504397329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.4% USD 1 000 million bond 2010/2020 of Novartis Capital Corporation, New York United States, issued at 99.237% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:label="lbl_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:to="lbl_label1504397329" xlink:type="arc"/>
      <link:label id="id_57804983" xlink:label="lbl_label1468025219" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.4% USD 1 500 million bond 2012/2022 of Novartis Capital Corporation, New York United States, issued at 99.225% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:label="lbl_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:to="lbl_label1468025219" xlink:type="arc"/>
      <link:label id="id_7920acbc" xlink:label="lbl_label2032184508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.7% USD 500 million bond 2012/2042 of Novartis Capital Corporation, New York United States, issued at 98.325% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:label="lbl_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:to="lbl_label2032184508" xlink:type="arc"/>
      <link:label id="id_3ab016cd" xlink:label="lbl_label984618701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.4% USD 2 150 million bond 2014/2024 of Novartis Capital Corporation, New York United States, issued at 99.287% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:label="lbl_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:to="lbl_label984618701" xlink:type="arc"/>
      <link:label id="id_40a1b86b" xlink:label="lbl_label1084340331" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.4% USD 1 850 million bond 2014/2044 of Novartis Capital Corporation, New York United States, issued at 99.196% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:label="lbl_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:to="lbl_label1084340331" xlink:type="arc"/>
      <link:label id="id_78372e25" xlink:label="lbl_label2016882213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.75% EUR 600 million bond 2014/2021 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.134% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:label="lbl_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:to="lbl_label2016882213" xlink:type="arc"/>
      <link:label id="id_6e2b28f3" xlink:label="lbl_label1848322291" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.625% EUR 600 million bond 2014/2026 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.697% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:label="lbl_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:to="lbl_label1848322291" xlink:type="arc"/>
      <link:label id="id_7c889c9" xlink:label="lbl_label130582985" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.25% CHF 500 million bond 2015/2025 of Novartis AG Basel Switzerland, issued at 100.64% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:label="lbl_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:to="lbl_label130582985" xlink:type="arc"/>
      <link:label id="id_1321f0b" xlink:label="lbl_label20061963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.625% CHF 550 million bond 2015/2029 of Novartis AG Basel Switzerland, issued at 100.502% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:label="lbl_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:to="lbl_label20061963" xlink:type="arc"/>
      <link:label id="id_66ae9900" xlink:label="lbl_label1722718464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.050% CHF 325 million bond 2015/2035 of Novartis AG Basel Switzerland, issued at 100.479% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:label="lbl_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:to="lbl_label1722718464" xlink:type="arc"/>
      <link:label id="id_45d38312" xlink:label="lbl_label1171489554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.0% USD 1 750 million bond 2015/2025 of Novartis Capital Corporation, New York United States, issued at 99.010% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:label="lbl_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:to="lbl_label1171489554" xlink:type="arc"/>
      <link:label id="id_63c4e1e7" xlink:label="lbl_label1673847271" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">4.0% USD 1 250 million bond 2015/2045 of Novartis Capital Corporation, New York United States, issued at 98.029% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:label="lbl_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:to="lbl_label1673847271" xlink:type="arc"/>
      <link:label id="id_497f0505" xlink:label="lbl_label1233061125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.125% EUR 1 250 million bond 2016/2023 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.127% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:label="lbl_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:to="lbl_label1233061125" xlink:type="arc"/>
      <link:label id="id_5233650c" xlink:label="lbl_label1379099916" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.625% EUR 500 million bond 2016/2028 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 98.48% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:label="lbl_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:to="lbl_label1379099916" xlink:type="arc"/>
      <link:label id="id_5f125bc1" xlink:label="lbl_label1595038657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notional amount</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotionalAmount" xlink:label="lbl_NotionalAmount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NotionalAmount" xlink:to="lbl_label1595038657" xlink:type="arc"/>
      <link:label id="id_4a9f133" xlink:label="lbl_label78246195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, original currency</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsOriginalCurrency" xlink:label="lbl_BorrowingsOriginalCurrency" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsOriginalCurrency" xlink:to="lbl_label78246195" xlink:type="arc"/>
      <link:label id="id_3d3b01c0" xlink:label="lbl_BorrowingsMaturity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, maturity</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsMaturity" xlink:label="lbl_BorrowingsMaturity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsMaturity" xlink:to="lbl_BorrowingsMaturity_labels" xlink:type="arc"/>
      <link:label id="id_6970167" xlink:label="lbl_BorrowingsLender_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, lender</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsLender" xlink:label="lbl_BorrowingsLender" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsLender" xlink:to="lbl_BorrowingsLender_labels" xlink:type="arc"/>
      <link:label id="id_2d26d7a1" xlink:label="lbl_BorrowingsPremiumDiscount_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, premium discount</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsPremiumDiscount" xlink:label="lbl_BorrowingsPremiumDiscount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsPremiumDiscount" xlink:to="lbl_BorrowingsPremiumDiscount_labels" xlink:type="arc"/>
      <link:label id="id_43d0ad58" xlink:label="lbl_label1137749336" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:to="lbl_label1137749336" xlink:type="arc"/>
      <link:label id="id_5168eb51" xlink:label="lbl_label1365830481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_label1365830481" xlink:type="arc"/>
      <link:label id="id_6ac35618" xlink:label="lbl_label1791186456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_label1791186456" xlink:type="arc"/>
      <link:label id="id_34e65236" xlink:label="lbl_label887509558" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_label887509558" xlink:type="arc"/>
      <link:label id="id_71bada1c" xlink:label="lbl_label1908070940" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All levels of fair value hierarchy [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_label1908070940" xlink:type="arc"/>
      <link:label id="id_7515173f" xlink:label="lbl_label1964316479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Level 1 of fair value hierarchy [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="lbl_Level1OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Level1OfFairValueHierarchyMember" xlink:to="lbl_label1964316479" xlink:type="arc"/>
      <link:label id="id_17ccd63f" xlink:label="lbl_label399300159" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Level 2 of fair value hierarchy [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="lbl_Level2OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Level2OfFairValueHierarchyMember" xlink:to="lbl_label399300159" xlink:type="arc"/>
      <link:label id="id_93d606b" xlink:label="lbl_label155017323" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Level 3 of fair value hierarchy [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="lbl_Level3OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Level3OfFairValueHierarchyMember" xlink:to="lbl_label155017323" xlink:type="arc"/>
      <link:label id="id_7c0df05a" xlink:label="lbl_OtherNoncurrentFinancialDebt_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current financial debt</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherNoncurrentFinancialDebt" xlink:label="lbl_OtherNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentFinancialDebt" xlink:to="lbl_OtherNoncurrentFinancialDebt_labels" xlink:type="arc"/>
      <link:label id="id_3aec21a3" xlink:label="lbl_OtherNoncurrentFinancialDebt_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Others</link:label>
      <link:label id="id_661a115" xlink:label="lbl_Borrowings_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
      <link:label id="id_45aae97f" xlink:label="lbl_label1168828799" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value by measurement basis [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueByMeasurementBasisAxis" xlink:label="lbl_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueByMeasurementBasisAxis" xlink:to="lbl_label1168828799" xlink:type="arc"/>
      <link:label id="id_374d1399" xlink:label="lbl_label927798169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value by measurement basis [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueByMeasurementBasisMember" xlink:label="lbl_FairValueByMeasurementBasisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueByMeasurementBasisMember" xlink:to="lbl_label927798169" xlink:type="arc"/>
      <link:label id="id_5786569c" xlink:label="lbl_CarryingReportedAmountFairValueDisclosureMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying reported amount fair value disclosure [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CarryingReportedAmountFairValueDisclosureMember" xlink:label="lbl_CarryingReportedAmountFairValueDisclosureMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lbl_CarryingReportedAmountFairValueDisclosureMember_labels" xlink:type="arc"/>
      <link:label id="id_53a58f58" xlink:label="lbl_FairValueDisclosureItemAmountsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value disclosure item amounts [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueDisclosureItemAmountsMember" xlink:label="lbl_FairValueDisclosureItemAmountsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueDisclosureItemAmountsMember" xlink:to="lbl_FairValueDisclosureItemAmountsMember_labels" xlink:type="arc"/>
      <link:label id="id_5d4ffc36" xlink:label="lbl_FairValueDisclosureItemAmountsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair values</link:label>
      <link:label id="id_749b453a" xlink:label="lbl_CarryingReportedAmountFairValueDisclosureMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance sheet</link:label>
      <link:label id="id_670f6333" xlink:label="lbl_label1729061683" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of comprehensive income [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="lbl_StatementOfComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfComprehensiveIncomeAbstract" xlink:to="lbl_label1729061683" xlink:type="arc"/>
      <link:label id="id_2d51324" xlink:label="lbl_ProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
      <link:label id="id_669b15d1" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels" xlink:type="arc"/>
      <link:label id="id_624c557e" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income never to be recycled into the consolidated income statement</link:label>
      <link:label id="id_543798f6" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, available-for-sale financial assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_6e3138d0" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on marketable securities, net of taxes</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges_labels" xlink:type="arc"/>
      <link:label id="id_f9a3fe1" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on deferred cash flow hedges, net of taxes</link:label>
      <link:label id="id_63d7965" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, financial instruments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments_labels" xlink:type="arc"/>
      <link:label id="id_57f5d574" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total fair value adjustments on financial instruments, net of taxes</link:label>
      <link:label id="id_4fc35e7b" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_labels" xlink:type="arc"/>
      <link:label id="id_5227f572" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_6b11bff3" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will be reclassified to profit or loss, net of tax</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:type="arc"/>
      <link:label id="id_1e6e2048" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total of items to eventually recycle</link:label>
      <link:label id="id_485691e" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels1" xlink:type="arc"/>
      <link:label id="id_6465e8d4" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_labels1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income to be eventually recycled into the consolidated income statement</link:label>
      <link:label id="id_2f7e508d" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:type="arc"/>
      <link:label id="id_7c43d9ec" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/losses from defined benefit plans, net of taxes</link:label>
      <link:label id="id_20ffa710" xlink:label="lbl_ComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComprehensiveIncome" xlink:to="lbl_ComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_27277ccb" xlink:label="lbl_ComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive income</link:label>
      <link:label id="id_5e2ce732" xlink:label="lbl_ComprehensiveIncomeAttributableToAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:to="lbl_ComprehensiveIncomeAttributableToAbstract_labels" xlink:type="arc"/>
      <link:label id="id_5ce83165" xlink:label="lbl_ComprehensiveIncomeAttributableToAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to</link:label>
      <link:label id="id_37725a9f" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income, attributable to owners of parent</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="lbl_ComprehensiveIncomeAttributableToOwnersOfParent_labels" xlink:type="arc"/>
      <link:label id="id_31bd4ac6" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders of Novartis AG</link:label>
      <link:label id="id_77aebdaf" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income, attributable to non-controlling interests</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:to="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests_labels" xlink:type="arc"/>
      <link:label id="id_30557ca" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:label id="id_3783d7c" xlink:label="lbl_ContinuingOperationsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Continuing operations</link:label>
      <link:label id="id_411d9c7f" xlink:label="lbl_DiscontinuedOperationsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations</link:label>
      <link:label id="id_4c054c08" xlink:label="lbl_OtherFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other financial income and expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinanceIncomeCost" xlink:to="lbl_OtherFinanceIncomeCost_labels" xlink:type="arc"/>
      <link:label id="id_f2e2db3" xlink:label="lbl_OtherFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other financial income and expense</link:label>
      <link:label id="id_53dc86a1" xlink:label="lbl_OtherFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial income and expense</link:label>
      <link:label id="id_12f9d391" xlink:label="lbl_OtherFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other financial income and expense</link:label>
      <link:label id="id_76e0ee52" xlink:label="lbl_ProfitLossAttributableToAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to</link:label>
      <link:label id="id_533d4513" xlink:label="lbl_label1396524307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="lbl_StatementOfCashFlowsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfCashFlowsAbstract" xlink:to="lbl_label1396524307" xlink:type="arc"/>
      <link:label id="id_1706da9a" xlink:label="lbl_label386325146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_label386325146" xlink:type="arc"/>
      <link:label id="id_23f6c7e5" xlink:label="lbl_label603375589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="lbl_StatementOfChangesInEquityTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_label603375589" xlink:type="arc"/>
      <link:label id="id_37845a12" xlink:label="lbl_label931420690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_label931420690" xlink:type="arc"/>
      <link:label id="id_ba7f520" xlink:label="lbl_label160680069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityMember" xlink:to="lbl_label160680069" xlink:type="arc"/>
      <link:label id="id_3004ac5a" xlink:label="lbl_label805612634" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity attributable to owners of parent [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_label805612634" xlink:type="arc"/>
      <link:label id="id_4221701b" xlink:label="lbl_label1109487643" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-controlling interests [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncontrollingInterestsMember" xlink:to="lbl_label1109487643" xlink:type="arc"/>
      <link:label id="id_6ac2ea98" xlink:label="lbl_IssuedCapitalMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="lbl_IssuedCapitalMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IssuedCapitalMember" xlink:to="lbl_IssuedCapitalMember_labels" xlink:type="arc"/>
      <link:label id="id_37852f90" xlink:label="lbl_RetainedEarningsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="lbl_RetainedEarningsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RetainedEarningsMember" xlink:to="lbl_RetainedEarningsMember_labels" xlink:type="arc"/>
      <link:label id="id_3014527f" xlink:label="lbl_label806638207" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="lbl_StatementOfChangesInEquityLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_label806638207" xlink:type="arc"/>
      <link:label id="id_7cb9019e" xlink:label="lbl_label2092499358" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="lbl_OtherComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncome" xlink:to="lbl_label2092499358" xlink:type="arc"/>
      <link:label id="id_14c74049" xlink:label="lbl_DividendsPaid_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends recognised as distributions to owners</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaid" xlink:label="lbl_DividendsPaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsPaid" xlink:to="lbl_DividendsPaid_labels" xlink:type="arc"/>
      <link:label id="id_55c8d5fc" xlink:label="lbl_DividendsPaid_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividends</link:label>
      <link:label id="id_290fddfc" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase/decrease of treasury share repurchase obligation under a share buyback trading plan</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:to="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan_labels" xlink:type="arc"/>
      <link:label id="id_35016d1a" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:to="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:type="arc"/>
      <link:label id="id_4817c0e9" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of change in ownership of consolidated entities</link:label>
      <link:label id="id_4d8eb67a" xlink:label="lbl_ChangesInEquity_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total of other equity movements</link:label>
      <link:label id="id_67a41ed4" xlink:label="lbl_label1738809044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments related to divestments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsRelatedToDivestments" xlink:label="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:to="lbl_label1738809044" xlink:type="arc"/>
      <link:label id="id_63274027" xlink:label="lbl_IssuedCapitalMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
      <link:label id="id_403fccbc" xlink:label="lbl_TreasurySharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares</link:label>
      <link:label id="id_74d7e6ee" xlink:label="lbl_RetainedEarningsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
      <link:label id="id_b4d100c" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, fair value adjustments on deferred cash flow hedges</link:label>
      <link:label id="id_780100c2" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest received, classified as operating activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:to="lbl_InterestReceivedClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_62d0936a" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest received</link:label>
      <link:label id="id_7b5cb6f6" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest paid, classified as operating activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:to="lbl_InterestPaidClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_39ba29d5" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
      <link:label id="id_1c3cdb2b" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund), classified as operating activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_66b0d29c" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid</link:label>
      <link:label id="id_72973404" xlink:label="lbl_label1922511876" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from operating activities before working capital and provision changes</link:label>
      <link:label id="id_2f19480a" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments out of provisions and other net cash movements in non-current liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:to="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_2fccc455" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in net current assets and other operating cash flow items</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems_labels" xlink:type="arc"/>
      <link:label id="id_7e94f37" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities, continuing operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_364038a2" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from operating activities from continuing operations</link:label>
      <link:label id="id_2c0f5fb2" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities, discontinued operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_658b02cd" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from operating activities from discontinued operations</link:label>
      <link:label id="id_77c3c41b" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInOperatingActivities" xlink:to="lbl_CashFlowsFromUsedInOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_4017c1c6" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from operating activities</link:label>
      <link:label id="id_668e4218" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_6c172e00" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
      <link:label id="id_79511d66" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales of property, plant and equipment</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_5310686b" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_4e39a447" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of intangible assets</link:label>
      <link:label id="id_209f49b7" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales of intangible assets, classified as investing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_2fc66d2d" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of intangible assets</link:label>
      <link:label id="id_4799c790" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of other long-term assets, classified as investing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:to="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_5d62cc13" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of other non-current assets</link:label>
      <link:label id="id_4b05fa70" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales of other long-term assets, classified as investing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:to="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_2f0edb6a" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of other non-current assets</link:label>
      <link:label id="id_220d8b31" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities, continuing operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_1940f2ef" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash flows used in investing activities from continuing operations</link:label>
      <link:label id="id_bda8617" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities, discontinued operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_741f077b" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows used in/from investing activities from discontinued operations</link:label>
      <link:label id="id_34225142" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInInvestingActivities" xlink:to="lbl_CashFlowsFromUsedInInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_140f33b4" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash flows used in investing activities</link:label>
      <link:label id="id_643efdb2" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to acquire or redeem entity's shares</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:to="lbl_PaymentsToAcquireOrRedeemEntitysShares_labels" xlink:type="arc"/>
      <link:label id="id_6226a1d0" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of treasury shares</link:label>
      <link:label id="id_4f16d177" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of options and other treasury share transactions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:to="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions_labels" xlink:type="arc"/>
      <link:label id="id_1e868ebc" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInFinancingActivities" xlink:to="lbl_CashFlowsFromUsedInFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_2bab504d" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in financing activities</link:label>
      <link:label id="id_5774a6d0" xlink:label="lbl_label1467262672" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lbl_label1467262672" xlink:type="arc"/>
      <link:label id="id_649add65" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_605d8076" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
      <link:label id="id_153736f0" xlink:label="lbl_CashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
      <link:label id="id_354ffdea" xlink:label="lbl_CashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
      <link:label id="id_433b1725" xlink:label="lbl_label1127946021" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows before working capital and provision changes</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:label="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:to="lbl_label1127946021" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:to="lbl_label1922511876" xlink:type="arc"/>
      <link:label id="id_7f2f5c65" xlink:label="lbl_label2133810277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">5.125% USD 3 000 million bond 2009/2019 of Novaritis Securities Investment Ltd., Hamilton, Bermuda issued at 99.822% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:label="lbl_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:to="lbl_label2133810277" xlink:type="arc"/>
      <link:label id="id_429c1826" xlink:label="lbl_BorrowingsIssuanceDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, issuance date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsIssuanceDate" xlink:label="lbl_BorrowingsIssuanceDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsIssuanceDate" xlink:to="lbl_BorrowingsIssuanceDate_labels" xlink:type="arc"/>
      <link:label id="id_2669d99c" xlink:label="lbl_label644471196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency, others [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyOthersMember" xlink:label="lbl_CurrencyOthersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrencyOthersMember" xlink:to="lbl_label644471196" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrencyOthersMember" xlink:to="lbl_label72836716" xlink:type="arc"/>
      <link:label id="id_27412435" xlink:label="lbl_CurrentPortionOfLongtermBorrowings_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less current portion of non-current financial debt</link:label>
      <link:label id="id_45c60d00" xlink:label="lbl_label1170607360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:to="lbl_label1170607360" xlink:type="arc"/>
      <link:label id="id_388165d3" xlink:label="lbl_label948004307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_label948004307" xlink:type="arc"/>
      <link:label id="id_7de10318" xlink:label="lbl_label2111898392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_label2111898392" xlink:type="arc"/>
      <link:label id="id_1b1dbf0c" xlink:label="lbl_label454934284" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lbl_label454934284" xlink:type="arc"/>
      <link:label id="id_1eb1092a" xlink:label="lbl_label514918698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for subsidiaries [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="lbl_EntitysTotalForSubsidiariesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntitysTotalForSubsidiariesMember" xlink:to="lbl_label514918698" xlink:type="arc"/>
      <link:label id="id_3d371bfe" xlink:label="lbl_label1027021822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiaries [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubsidiariesMember" xlink:label="lbl_SubsidiariesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SubsidiariesMember" xlink:to="lbl_label1027021822" xlink:type="arc"/>
      <link:label id="id_644266d7" xlink:label="lbl_label1682073303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating income [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OperatingIncomeMember" xlink:label="lbl_OperatingIncomeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OperatingIncomeMember" xlink:to="lbl_label1682073303" xlink:type="arc"/>
      <link:label id="id_41ead269" xlink:label="lbl_TranscendMedicalIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transcend Medical Inc [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TranscendMedicalIncMember" xlink:label="lbl_TranscendMedicalIncMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TranscendMedicalIncMember" xlink:to="lbl_TranscendMedicalIncMember_labels" xlink:type="arc"/>
      <link:label id="id_7cc6732" xlink:label="lbl_TranscendMedicalIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transcend Medical Inc.</link:label>
      <link:label id="id_5c37cd24" xlink:label="lbl_SelexysPharmaceuticalsCorporationMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selexys Pharmaceuticals Corporation [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelexysPharmaceuticalsCorporationMember" xlink:label="lbl_SelexysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SelexysPharmaceuticalsCorporationMember" xlink:to="lbl_SelexysPharmaceuticalsCorporationMember_labels" xlink:type="arc"/>
      <link:label id="id_26bb8728" xlink:label="lbl_SelexysPharmaceuticalsCorporationMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selexys Pharmaceuticals Corporation</link:label>
      <link:label id="id_f0f7125" xlink:label="lbl_ZiarcoGroupLimitedMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ziarco Group Limited [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZiarcoGroupLimitedMember" xlink:label="lbl_ZiarcoGroupLimitedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZiarcoGroupLimitedMember" xlink:to="lbl_ZiarcoGroupLimitedMember_labels" xlink:type="arc"/>
      <link:label id="id_74cc0f0d" xlink:label="lbl_ZiarcoGroupLimitedMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ziarco Group Limited</link:label>
      <link:label id="id_2cf9a6d0" xlink:label="lbl_EncoreVisionIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Encore Vision, Inc [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EncoreVisionIncMember" xlink:label="lbl_EncoreVisionIncMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EncoreVisionIncMember" xlink:to="lbl_EncoreVisionIncMember_labels" xlink:type="arc"/>
      <link:label id="id_14700202" xlink:label="lbl_EncoreVisionIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Encore Vision, Inc.</link:label>
      <link:label id="id_4323a92b" xlink:label="lbl_EliLillyAndCompanyMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eli Lilly and Company [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EliLillyAndCompanyMember" xlink:label="lbl_EliLillyAndCompanyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EliLillyAndCompanyMember" xlink:to="lbl_EliLillyAndCompanyMember_labels" xlink:type="arc"/>
      <link:label id="id_7d1163f7" xlink:label="lbl_EliLillyAndCompanyMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eli Lilly and Company</link:label>
      <link:label id="id_406cf0bb" xlink:label="lbl_GSKOncologyProductsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK Oncology Products [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKOncologyProductsMember" xlink:label="lbl_GSKOncologyProductsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GSKOncologyProductsMember" xlink:to="lbl_GSKOncologyProductsMember_labels" xlink:type="arc"/>
      <link:label id="id_4dee8051" xlink:label="lbl_GSKOncologyProductsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK Oncology Products</link:label>
      <link:label id="id_543b3534" xlink:label="lbl_GSKVaccinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK Vaccines [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKVaccinesMember" xlink:label="lbl_GSKVaccinesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GSKVaccinesMember" xlink:to="lbl_GSKVaccinesMember_labels" xlink:type="arc"/>
      <link:label id="id_50145ee" xlink:label="lbl_GSKVaccinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK Vaccines</link:label>
      <link:label id="id_258b2077" xlink:label="lbl_GSKConsumerHealthcareMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK Consumer Healthcare [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKConsumerHealthcareMember" xlink:label="lbl_GSKConsumerHealthcareMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GSKConsumerHealthcareMember" xlink:to="lbl_GSKConsumerHealthcareMember_labels" xlink:type="arc"/>
      <link:label id="id_5cb81481" xlink:label="lbl_GSKConsumerHealthcareMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK Consumer Healthcare</link:label>
      <link:label id="id_2c752dc" xlink:label="lbl_GSKTotalTransactionMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK Total Transaction [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKTotalTransactionMember" xlink:label="lbl_GSKTotalTransactionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GSKTotalTransactionMember" xlink:to="lbl_GSKTotalTransactionMember_labels" xlink:type="arc"/>
      <link:label id="id_366ab1d6" xlink:label="lbl_GSKTotalTransactionMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK Total Transaction</link:label>
      <link:label id="id_2144f8b2" xlink:label="lbl_CSLMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CSL [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CSLMember" xlink:label="lbl_CSLMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CSLMember" xlink:to="lbl_CSLMember_labels" xlink:type="arc"/>
      <link:label id="id_5f983746" xlink:label="lbl_CSLMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CSL</link:label>
      <link:label id="id_1961772e" xlink:label="lbl_SpinifexMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Spinifex [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SpinifexMember" xlink:label="lbl_SpinifexMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SpinifexMember" xlink:to="lbl_SpinifexMember_labels" xlink:type="arc"/>
      <link:label id="id_7bf72331" xlink:label="lbl_SpinifexMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Spinifex</link:label>
      <link:label id="id_72aed040" xlink:label="lbl_AdmuneTheraputicsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Admune Theraputics [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdmuneTheraputicsMember" xlink:label="lbl_AdmuneTheraputicsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdmuneTheraputicsMember" xlink:to="lbl_AdmuneTheraputicsMember_labels" xlink:type="arc"/>
      <link:label id="id_1b618d38" xlink:label="lbl_AdmuneTheraputicsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Admune Theraputics</link:label>
      <link:label id="id_2608381e" xlink:label="lbl_label638072862" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration transferred, acquisition-date fair value</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:to="lbl_label638072862" xlink:type="arc"/>
      <link:label id="id_6adf03f3" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion of consideration paid (received) consisting of cash and cash equivalents</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_29fb9219" xlink:label="lbl_label704352793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent liabilities recognised as of acquisition date</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lbl_label704352793" xlink:type="arc"/>
      <link:label id="id_7589cc7b" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Identifiable assets acquired (liabilities assumed)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed_labels" xlink:type="arc"/>
      <link:label id="id_770a51dc" xlink:label="lbl_AdditionalRecognitionGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional recognition, goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="lbl_AdditionalRecognitionGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionalRecognitionGoodwill" xlink:to="lbl_AdditionalRecognitionGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_159fb0c8" xlink:label="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_labels" xlink:type="arc"/>
      <link:label id="id_bb4840e" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition-date fair value of equity interest in acquiree held by acquirer immediately before acquisition date</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:to="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_1f8e7785" xlink:label="lbl_label529430405" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (loss) recognised as result of remeasuring to fair value equity interest in acquiree held by acquirer before business combination</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:label="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:to="lbl_label529430405" xlink:type="arc"/>
      <link:label id="id_7a59b5df" xlink:label="lbl_label2052699615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of voting equity interests acquired</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:to="lbl_label2052699615" xlink:type="arc"/>
      <link:label id="id_3ce5a3b3" xlink:label="lbl_label1021682611" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:to="lbl_label1021682611" xlink:type="arc"/>
      <link:label id="id_4e581a" xlink:label="lbl_label5134362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of arrangement for contingent consideration arrangements and indemnification assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:label="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:to="lbl_label5134362" xlink:type="arc"/>
      <link:label id="id_3ebaa53a" xlink:label="lbl_label1052419386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of provisions and other current liabilities [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_label1052419386" xlink:type="arc"/>
      <link:label id="id_280373ad" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of provisions and other current liabilities explanatory [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" xlink:to="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_58be9555" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other current liabilities</link:label>
      <link:label id="id_6f3dfdd7" xlink:label="lbl_label1866333655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of acquisition of businesses [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:label="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:to="lbl_label1866333655" xlink:type="arc"/>
      <link:label id="id_74ec4e33" xlink:label="lbl_DisclosureOfBusinessCombinationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of business combinations [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:label="lbl_DisclosureOfBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfBusinessCombinationsExplanatory" xlink:to="lbl_DisclosureOfBusinessCombinationsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_1fdc2fef" xlink:label="lbl_DisclosureOfBusinessCombinationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of businesses</link:label>
      <link:label id="id_32cb811d" xlink:label="lbl_label852197661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_label852197661" xlink:type="arc"/>
      <link:label id="id_503f4b80" xlink:label="lbl_DisclosureOfEmployeeBenefitsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of employee benefits [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="lbl_DisclosureOfEmployeeBenefitsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="lbl_DisclosureOfEmployeeBenefitsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_4572e29d" xlink:label="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of provisions and other current liabilities [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7df1458c" xlink:label="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other current liabilities</link:label>
      <link:label id="id_330b4ffd" xlink:label="lbl_ProvisionsForReductionOfRevenueTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions for reduction of revenue [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsForReductionOfRevenueTableTextBlock" xlink:label="lbl_ProvisionsForReductionOfRevenueTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionsForReductionOfRevenueTableTextBlock" xlink:to="lbl_ProvisionsForReductionOfRevenueTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2487cf91" xlink:label="lbl_ProvisionsForReductionOfRevenueTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for reduction of revenue</link:label>
      <link:label id="id_cda5e36" xlink:label="lbl_RestructuringProvisionsMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring provisions movements [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestructuringProvisionsMovementsTableTextBlock" xlink:label="lbl_RestructuringProvisionsMovementsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestructuringProvisionsMovementsTableTextBlock" xlink:to="lbl_RestructuringProvisionsMovementsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_50653a58" xlink:label="lbl_RestructuringProvisionsMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring provisions movements</link:label>
      <link:label id="id_51adf498" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of assets and liabilities arising from acquisitions [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:to="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_55fc13ca" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of assets and liabilities arising from acquisitions</link:label>
      <link:label id="id_43a17f70" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:to="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4ac74a65" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of the funded and unfunded defined benefit obligation for pension and other post retirement benefit plans table</link:label>
      <link:label id="id_7580bb7" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:to="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5d57abea" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of the net liability table</link:label>
      <link:label id="id_8f2e3e1" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Breakdown of defined benefit obligation for pension plans and other post-employment benefit [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:to="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_26221373" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Breakdown of defined benefit obligation for pension plans and other post-employment benefit</link:label>
      <link:label id="id_7b5fd886" xlink:label="lbl_ScheduleOfAssumptionsUsedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of assumptions used [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="lbl_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lbl_ScheduleOfAssumptionsUsedTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_83b4487" xlink:label="lbl_ScheduleOfAssumptionsUsedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal weighted average actuarial assumptions</link:label>
      <link:label id="id_5a767463" xlink:label="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of sensitivity analysis for actuarial assumptions [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:label="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:to="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7c6a492e" xlink:label="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The sensitivity of the defined benefit pension obligation to the principal actuarial assumptions</link:label>
      <link:label id="id_40d21ce7" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of health care cost trend rates [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:to="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_28fc355" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The healthcare cost trend rate assumptions used for other post-employment benefits</link:label>
      <link:label id="id_37e4cfa4" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of allocation of plan assets [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_a47f671" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The weighted average plan asset allocation of funded defined benefit pension plans</link:label>
      <link:label id="id_14ebebe1" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of expected benefit payments [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7cfc7cde" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The expected future cash flows in respect of pension and other post- employment benefit plans</link:label>
      <link:label id="id_5cc7b4f2" xlink:label="lbl_label1556591858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="lbl_label1556591858" xlink:type="arc"/>
      <link:label id="id_751ab231" xlink:label="lbl_label1964683825" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:to="lbl_label1964683825" xlink:type="arc"/>
      <link:label id="id_4f2027d2" xlink:label="lbl_label1327507410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_label1327507410" xlink:type="arc"/>
      <link:label id="id_44180645" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currently marketed products intangible assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_7b396a57" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currently marketed products</link:label>
      <link:label id="id_2a66227f" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired research and development intangible assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_520a49db" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired research and development</link:label>
      <link:label id="id_79560b48" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other intangible assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_2e2e2336" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
      <link:label id="id_2367c616" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_5161ba57" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
      <link:label id="id_62ae6b6f" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory recognised as of acquisition date</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:to="lbl_InventoryRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_4affdfb9" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:label id="id_5c47e1cf" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables and other current assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_59b962bd" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables and financial and other current assets</link:label>
      <link:label id="id_13b05f40" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents recognised as of acquisition date</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:to="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_33b144aa" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:label id="id_262ed31" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net assets recognized as a result of acquisitions of business</link:label>
      <link:label id="id_7c2d8d71" xlink:label="lbl_label2083360113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill expected to be deductible for tax purposes</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillExpectedDeductibleForTaxPurposes" xlink:label="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:to="lbl_label2083360113" xlink:type="arc"/>
      <link:label id="id_1e18b9d2" xlink:label="lbl_label504936914" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions and other current liabilities [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsAndOtherCurrentLiabilitiesTable" xlink:label="lbl_ProvisionsAndOtherCurrentLiabilitiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesTable" xlink:to="lbl_label504936914" xlink:type="arc"/>
      <link:label id="id_77fdfffd" xlink:label="lbl_label2013134845" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potentially refundable consideration from acquisition</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentiallyRefundableConsiderationFromAcquisition" xlink:label="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:to="lbl_label2013134845" xlink:type="arc"/>
      <link:label id="id_240ec6" xlink:label="lbl_label2363078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of potentially refundable contingent consideration</link:label>
      <link:label id="id_5bb1899c" xlink:label="lbl_label1538361756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract right of first negotiation term</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractRightOfFirstNegotiationTerm" xlink:label="lbl_ContractRightOfFirstNegotiationTerm" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContractRightOfFirstNegotiationTerm" xlink:to="lbl_label1538361756" xlink:type="arc"/>
      <link:label id="id_3eeb75f2" xlink:label="lbl_label1055618546" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue of acquiree since acquisition date</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueOfAcquiree" xlink:label="lbl_RevenueOfAcquiree" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueOfAcquiree" xlink:to="lbl_label1055618546" xlink:type="arc"/>
      <link:label id="id_742dd0f8" xlink:label="lbl_label1949159672" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue of acquiree full year</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueOfAcquireeFullYear" xlink:label="lbl_RevenueOfAcquireeFullYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueOfAcquireeFullYear" xlink:to="lbl_label1949159672" xlink:type="arc"/>
      <link:label id="id_37ba66ca" xlink:label="lbl_label934962890" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of business assets arising from contingencies amount recognized</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:to="lbl_label934962890" xlink:type="arc"/>
      <link:label id="id_53d61f56" xlink:label="lbl_label1406541654" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of business assets arising from contingencies amount recognized other than at fair value</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:to="lbl_label1406541654" xlink:type="arc"/>
      <link:label id="id_6acd7a2d" xlink:label="lbl_label1791851053" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of business, contingent consideration arrangements, range of outcomes, value, high</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lbl_label1791851053" xlink:type="arc"/>
      <link:label id="id_c33fcc1" xlink:label="lbl_label204733633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of business, contingent option arrangements, range of outcomes, value, high</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:to="lbl_label204733633" xlink:type="arc"/>
      <link:label id="id_22e7f31e" xlink:label="lbl_label585626398" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of business, contingent option arrangements, fee paid</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:to="lbl_label585626398" xlink:type="arc"/>
      <link:label id="id_4739cf42" xlink:label="lbl_label1194970946" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in subsidiaries, joint ventures and associates</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:to="lbl_label1194970946" xlink:type="arc"/>
      <link:label id="id_7e1ee3b5" xlink:label="lbl_label2115953589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of voting equity interests contributed</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfVotingEquityInterestsContributed" xlink:label="lbl_PercentageOfVotingEquityInterestsContributed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfVotingEquityInterestsContributed" xlink:to="lbl_label2115953589" xlink:type="arc"/>
      <link:label id="id_376f146e" xlink:label="lbl_TransactionRelatedCosts_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction related costs</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionRelatedCosts" xlink:label="lbl_TransactionRelatedCosts" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionRelatedCosts" xlink:to="lbl_TransactionRelatedCosts_labels" xlink:type="arc"/>
      <link:label id="id_2d34f9e9" xlink:label="lbl_TransactionRelatedCostsPaid_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction related costs paid</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionRelatedCostsPaid" xlink:label="lbl_TransactionRelatedCostsPaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionRelatedCostsPaid" xlink:to="lbl_TransactionRelatedCostsPaid_labels" xlink:type="arc"/>
      <link:label id="id_7a2e51fc" xlink:label="lbl_label690911032" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLoss" xlink:label="lbl_ImpairmentLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLoss" xlink:to="lbl_label690911032" xlink:type="arc"/>
      <link:label id="id_67f3701a" xlink:label="lbl_label1744007194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reversal of impairment loss</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLoss" xlink:label="lbl_ReversalOfImpairmentLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReversalOfImpairmentLoss" xlink:to="lbl_label1744007194" xlink:type="arc"/>
      <link:label id="id_7cff95a1" xlink:label="lbl_label2097124769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions and other current liabilities [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:label="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:to="lbl_label2097124769" xlink:type="arc"/>
      <link:label id="id_772301d6" xlink:label="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for taxes other than income taxes, current</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent_labels" xlink:type="arc"/>
      <link:label id="id_2dc3de10" xlink:label="lbl_ShorttermRestructuringProvision_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current restructuring provision</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermRestructuringProvision" xlink:label="lbl_ShorttermRestructuringProvision" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShorttermRestructuringProvision" xlink:to="lbl_ShorttermRestructuringProvision_labels" xlink:type="arc"/>
      <link:label id="id_5b202ec3" xlink:label="lbl_ShorttermRestructuringProvision_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring provisions</link:label>
      <link:label id="id_6d2493bb" xlink:label="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued royalties payable classified as current</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:label="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:to="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent_labels" xlink:type="arc"/>
      <link:label id="id_198471b1" xlink:label="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals for royalties</link:label>
      <link:label id="id_3eae10b2" xlink:label="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes other than income taxes</link:label>
      <link:label id="id_4d2d81e4" xlink:label="lbl_ShorttermEmployeeBenefitsAccruals_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term employee benefits accruals</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="lbl_ShorttermEmployeeBenefitsAccruals" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShorttermEmployeeBenefitsAccruals" xlink:to="lbl_ShorttermEmployeeBenefitsAccruals_labels" xlink:type="arc"/>
      <link:label id="id_28ce7ee" xlink:label="lbl_ShorttermEmployeeBenefitsAccruals_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals for compensation and benefits including social security</link:label>
      <link:label id="id_dfd6824" xlink:label="lbl_ShorttermLegalProceedingsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current legal proceedings provision</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermLegalProceedingsProvision" xlink:label="lbl_ShorttermLegalProceedingsProvision" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShorttermLegalProceedingsProvision" xlink:to="lbl_ShorttermLegalProceedingsProvision_labels" xlink:type="arc"/>
      <link:label id="id_3dc37367" xlink:label="lbl_ShorttermLegalProceedingsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for product liabilities, governmental investigations and other legal matters</link:label>
      <link:label id="id_7364ea66" xlink:label="lbl_OtherCurrentPayables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current payables</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentPayables" xlink:label="lbl_OtherCurrentPayables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentPayables" xlink:to="lbl_OtherCurrentPayables_labels" xlink:type="arc"/>
      <link:label id="id_53bd8e15" xlink:label="lbl_OtherCurrentPayables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other payables</link:label>
      <link:label id="id_16646c9e" xlink:label="lbl_label375680158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue [roll forward]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsForDeductionsFromRevenueRollForward" xlink:label="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_label375680158" xlink:type="arc"/>
      <link:label id="id_236d2862" xlink:label="lbl_label594356322" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of other provisions [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_label594356322" xlink:type="arc"/>
      <link:label id="id_4ebad11d" xlink:label="lbl_label1320866077" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other provisions [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_label1320866077" xlink:type="arc"/>
      <link:label id="id_40fd93ca" xlink:label="lbl_RefundsProvisionMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Refunds provision [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RefundsProvisionMember" xlink:label="lbl_RefundsProvisionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RefundsProvisionMember" xlink:to="lbl_RefundsProvisionMember_labels" xlink:type="arc"/>
      <link:label id="id_134ebfe2" xlink:label="lbl_RefundsProvisionMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deductions from revenue</link:label>
      <link:label id="id_5e5b3081" xlink:label="lbl_OtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other provisions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisions" xlink:label="lbl_OtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherProvisions" xlink:to="lbl_OtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_21da05f2" xlink:label="lbl_OtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Provision at end of period</link:label>
      <link:label id="id_3b690ec5" xlink:label="lbl_OtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Provision at beginning of period</link:label>
      <link:label id="id_7d787c31" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through loss of control of subsidiary, other provisions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:to="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_ff50d0a" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Provisions related to discontinued operations</link:label>
      <link:label id="id_5bf5caac" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, other provisions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_2a95f348" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_27eafa" xlink:label="lbl_AdditionalProvisionsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional provisions, other provisions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="lbl_AdditionalProvisionsOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionalProvisionsOtherProvisions" xlink:to="lbl_AdditionalProvisionsOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_2c66d271" xlink:label="lbl_AdditionalProvisionsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
      <link:label id="id_fe1b238" xlink:label="lbl_ProvisionUsedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision used, other provisions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="lbl_ProvisionUsedOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionUsedOtherProvisions" xlink:to="lbl_ProvisionUsedOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_36a5293f" xlink:label="lbl_ProvisionUsedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/utilizations</link:label>
      <link:label id="id_359f477c" xlink:label="lbl_ChangesInOffsetAgainstGrossTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in offset against gross trade receivables</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInOffsetAgainstGrossTradeReceivables" xlink:label="lbl_ChangesInOffsetAgainstGrossTradeReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangesInOffsetAgainstGrossTradeReceivables" xlink:to="lbl_ChangesInOffsetAgainstGrossTradeReceivables_labels" xlink:type="arc"/>
      <link:label id="id_18735dbe" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, other provisions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_16f119f6" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_482a71cf" xlink:label="lbl_UnusedProvisionReversedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused provision reversed, other provisions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnusedProvisionReversedOtherProvisions" xlink:to="lbl_UnusedProvisionReversedOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_28d3a14e" xlink:label="lbl_ProvisionUsedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash payments</link:label>
      <link:label id="id_45b7ba0b" xlink:label="lbl_UnusedProvisionReversedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Releases</link:label>
      <link:label id="id_26660dfe" xlink:label="lbl_RestructuringProvisionMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring provision [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestructuringProvisionMember" xlink:label="lbl_RestructuringProvisionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestructuringProvisionMember" xlink:to="lbl_RestructuringProvisionMember_labels" xlink:type="arc"/>
      <link:label id="id_23d5363a" xlink:label="lbl_RestructuringProvisionMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring provision</link:label>
      <link:label id="id_79614e6" xlink:label="lbl_label127276262" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring provisions movements [roll forward]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestructuringProvisionsMovementsRollForward" xlink:label="lbl_RestructuringProvisionsMovementsRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_label127276262" xlink:type="arc"/>
      <link:label id="id_51cb80cd" xlink:label="lbl_label1372291277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of trade receivables [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTradeReceivablesAbstract" xlink:label="lbl_DisclosureOfTradeReceivablesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTradeReceivablesAbstract" xlink:to="lbl_label1372291277" xlink:type="arc"/>
      <link:label id="id_2ea0d5c3" xlink:label="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of trade receivables explanatory [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTradeReceivablesExplanatoryTextBlock" xlink:label="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock" xlink:to="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6dd7d3e3" xlink:label="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
      <link:label id="id_2c1cad42" xlink:label="lbl_ProvisionsForTradeReceivablesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions for trade receivables [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsForTradeReceivablesTableTextBlock" xlink:label="lbl_ProvisionsForTradeReceivablesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionsForTradeReceivablesTableTextBlock" xlink:to="lbl_ProvisionsForTradeReceivablesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3b131312" xlink:label="lbl_ProvisionsForTradeReceivablesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for trade receivables</link:label>
      <link:label id="id_2ef5991b" xlink:label="lbl_TradeReceivablesProvisionMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables provision movements [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesProvisionMovementsTableTextBlock" xlink:label="lbl_TradeReceivablesProvisionMovementsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesProvisionMovementsTableTextBlock" xlink:to="lbl_TradeReceivablesProvisionMovementsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_77f758ca" xlink:label="lbl_TradeReceivablesProvisionMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables provision movements</link:label>
      <link:label id="id_5d967f7b" xlink:label="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Overdue amounts and related provisions [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OverdueAmountsAndRelatedProvisionsTableTextBlock" xlink:label="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock" xlink:to="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2b0e9f8f" xlink:label="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overdue amounts and related provision</link:label>
      <link:label id="id_22339022" xlink:label="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables denominated in other currencies [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" xlink:label="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" xlink:to="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1c976f04" xlink:label="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables denominated in other currencies</link:label>
      <link:label id="id_3cb8d68f" xlink:label="lbl_label1018746511" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of provision matrix [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixAbstract" xlink:label="lbl_DisclosureOfProvisionMatrixAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfProvisionMatrixAbstract" xlink:to="lbl_label1018746511" xlink:type="arc"/>
      <link:label id="id_43d6f278" xlink:label="lbl_label1138160248" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of provision matrix [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixTable" xlink:label="lbl_DisclosureOfProvisionMatrixTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_label1138160248" xlink:type="arc"/>
      <link:label id="id_4c9afaa7" xlink:label="lbl_label1285225127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of provision matrix [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_label1285225127" xlink:type="arc"/>
      <link:label id="id_3182649e" xlink:label="lbl_label830629022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_label830629022" xlink:type="arc"/>
      <link:label id="id_5ff48884" xlink:label="lbl_label1609861252" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, class [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_label1609861252" xlink:type="arc"/>
      <link:label id="id_75e5081d" xlink:label="lbl_label123214748" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesMember" xlink:to="lbl_label123214748" xlink:type="arc"/>
      <link:label id="id_2e086500" xlink:label="lbl_CurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTradeReceivables" xlink:to="lbl_CurrentTradeReceivables_labels" xlink:type="arc"/>
      <link:label id="id_79f9d46a" xlink:label="lbl_CurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total trade receivables, net</link:label>
      <link:label id="id_3425f2e0" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for doubtful trade receivables related to discontinued operations</link:label>
      <link:label id="id_4ce7ed6d" xlink:label="lbl_AdditionalProvisionsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Provisions for doubtful trade receivables charged to the consolidated income statement</link:label>
      <link:label id="id_53792c91" xlink:label="lbl_ProvisionUsedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Utilization of provisions for doubtful trade receivables</link:label>
      <link:label id="id_74c340b1" xlink:label="lbl_label1958953137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of overdue amounts [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AnalysisOfOverdueAmountsTable" xlink:label="lbl_AnalysisOfOverdueAmountsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_label1958953137" xlink:type="arc"/>
      <link:label id="id_6ce050f6" xlink:label="lbl_label1826640118" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Past due status [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusAxis" xlink:label="lbl_PastDueStatusAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PastDueStatusAxis" xlink:to="lbl_label1826640118" xlink:type="arc"/>
      <link:label id="id_3284c13a" xlink:label="lbl_label847561018" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Past due status [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusMember" xlink:label="lbl_PastDueStatusMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PastDueStatusMember" xlink:to="lbl_label847561018" xlink:type="arc"/>
      <link:label id="id_21859e37" xlink:label="lbl_label562404919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentMember" xlink:label="lbl_CurrentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentMember" xlink:to="lbl_label562404919" xlink:type="arc"/>
      <link:label id="id_36a38547" xlink:label="lbl_label916686151" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of overdue amounts [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AnalysisOfOverdueAmountsLineItems" xlink:label="lbl_AnalysisOfOverdueAmountsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AnalysisOfOverdueAmountsLineItems" xlink:to="lbl_label916686151" xlink:type="arc"/>
      <link:label id="id_5fbcb687" xlink:label="lbl_label1606203015" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of receivables denominated in various currencies [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:label="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:to="lbl_label1606203015" xlink:type="arc"/>
      <link:label id="id_2efadcc4" xlink:label="lbl_label788192452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables from closely monitored countries</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountries" xlink:to="lbl_label788192452" xlink:type="arc"/>
      <link:label id="id_d85c974" xlink:label="lbl_label226871668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables from closely monitored countries past due more than one year</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" xlink:to="lbl_label226871668" xlink:type="arc"/>
      <link:label id="id_5358f3b4" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables from closely monitored countries past due more than one year, provisions recorded</link:label>
      <link:label id="id_7e49d670" xlink:label="lbl_label2118768240" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="lbl_label2118768240" xlink:type="arc"/>
      <link:label id="id_5081e337" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:to="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_172e52ca" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Group subsidiaries and associated companies</link:label>
      <link:label id="id_2f049798" xlink:label="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal Group subsidiaries and associated companies [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" xlink:label="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" xlink:to="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_678c8520" xlink:label="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal Group subsidiaries and associated companies</link:label>
      <link:label id="id_171309e1" xlink:label="lbl_label387123681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lbl_label387123681" xlink:type="arc"/>
      <link:label id="id_7e6d2d55" xlink:label="lbl_label2121084245" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_label2121084245" xlink:type="arc"/>
      <link:label id="id_5b223713" xlink:label="lbl_label1528968979" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of subsidiary</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NameOfSubsidiary" xlink:label="lbl_NameOfSubsidiary" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NameOfSubsidiary" xlink:to="lbl_label1528968979" xlink:type="arc"/>
      <link:label id="id_2bc20f05" xlink:label="lbl_label734138117" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal place of business of subsidiary</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xlink:label="lbl_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrincipalPlaceOfBusinessOfSubsidiary" xlink:to="lbl_label734138117" xlink:type="arc"/>
      <link:label id="id_5cbe6246" xlink:label="lbl_label1555980870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Country of incorporation of subsidiary</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:label="lbl_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:to="lbl_label1555980870" xlink:type="arc"/>
      <link:label id="id_77c5a25c" xlink:label="lbl_label2009440860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in subsidiary</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:to="lbl_label2009440860" xlink:type="arc"/>
      <link:label id="id_64c53647" xlink:label="lbl_label1690646087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of voting rights held in subsidiary</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:label="lbl_ProportionOfVotingPowerHeldInSubsidiary" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProportionOfVotingPowerHeldInSubsidiary" xlink:to="lbl_label1690646087" xlink:type="arc"/>
      <link:label id="id_5c37870a" xlink:label="lbl_label1547142922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share/paid-in capital</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharePaidinCapital" xlink:label="lbl_SharePaidinCapital" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharePaidinCapital" xlink:to="lbl_label1547142922" xlink:type="arc"/>
      <link:label id="id_3c7cb5b5" xlink:label="lbl_label1014805941" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Societe par actions SANDOZ, Algiers [member]</link:label>
      <link:label id="id_1fee848b" xlink:label="lbl_label535725195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Argentina S.A., Buenos Aires [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisArgentinaS.A.BuenosAiresMember" xlink:label="lbl_NovartisArgentinaS.A.BuenosAiresMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisArgentinaS.A.BuenosAiresMember" xlink:to="lbl_label535725195" xlink:type="arc"/>
      <link:label id="id_37e7fad0" xlink:label="lbl_label937949904" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratorios S.A., Buenos Aires [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriosS.A.BuenosAiresMember" xlink:label="lbl_AlconLaboratoriosS.A.BuenosAiresMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriosS.A.BuenosAiresMember" xlink:to="lbl_label937949904" xlink:type="arc"/>
      <link:label id="id_3ea304fe" xlink:label="lbl_label1050871038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Holding AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGBaselMember" xlink:label="lbl_RocheHoldingAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RocheHoldingAGBaselMember" xlink:to="lbl_label1050871038" xlink:type="arc"/>
      <link:label id="id_6ed1f5c4" xlink:label="lbl_label1859253700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_label1859253700" xlink:type="arc"/>
      <link:label id="id_258b1d67" xlink:label="lbl_label629874023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of defined benefit plans [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_label629874023" xlink:type="arc"/>
      <link:label id="id_d3021ba" xlink:label="lbl_label221258170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_label221258170" xlink:type="arc"/>
      <link:label id="id_7226aa6a" xlink:label="lbl_ForeignCountriesMember_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Rest of the world</link:label>
      <link:label id="id_494ba6f4" xlink:label="lbl_label1229694708" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plans [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="lbl_DefinedBenefitPlansMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlansMember" xlink:to="lbl_label1229694708" xlink:type="arc"/>
      <link:label id="id_1d4af2d7" xlink:label="lbl_label491451095" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic defined benefit plans [member]</link:label>
      <link:label id="id_48d21535" xlink:label="lbl_label1221727541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign defined benefit plans [member]</link:label>
      <link:label id="id_53109a65" xlink:label="lbl_ConcentrationOfMajorPlansGeographic_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration of major plans, geographic</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConcentrationOfMajorPlansGeographic" xlink:label="lbl_ConcentrationOfMajorPlansGeographic" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConcentrationOfMajorPlansGeographic" xlink:to="lbl_ConcentrationOfMajorPlansGeographic_labels" xlink:type="arc"/>
      <link:label id="id_6dd86874" xlink:label="lbl_ConcentrationOfMajorPlansGeographic_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description of the major plans and the concentration of the Group's DBO by geography.</link:label>
      <link:label id="id_55c3f642" xlink:label="lbl_label1438905922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of plan amendments, curtailments and settlements</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements" xlink:label="lbl_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements1" xlink:to="lbl_label1438905922" xlink:type="arc"/>
      <link:label id="id_5774006e" xlink:label="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, recognized net gain (loss) due to curtailments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:label="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:to="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_labels" xlink:type="arc"/>
      <link:label id="id_1a9c795a" xlink:label="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Pre-tax curtailment gain (loss)</link:label>
      <link:label id="id_3ccdda27" xlink:label="lbl_label1020123687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plans [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="lbl_DefinedBenefitPlansAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlansAxis" xlink:to="lbl_label1020123687" xlink:type="arc"/>
      <link:label id="id_66c824b2" xlink:label="lbl_label1724392626" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement plan type [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_label1724392626" xlink:type="arc"/>
      <link:label id="id_1c17a6ba" xlink:label="lbl_label471312058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement plan type [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_label471312058" xlink:type="arc"/>
      <link:label id="id_2219e14f" xlink:label="lbl_PensionPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension plan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PensionPlanMember" xlink:to="lbl_PensionPlanMember_labels" xlink:type="arc"/>
      <link:label id="id_35fad562" xlink:label="lbl_OtherPostemploymentBenefitPlansMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other post-employment benefit plans [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherPostemploymentBenefitPlansMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember_labels" xlink:type="arc"/>
      <link:label id="id_2e4ea0d1" xlink:label="lbl_PensionPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension plans</link:label>
      <link:label id="id_67c584f7" xlink:label="lbl_OtherPostemploymentBenefitPlansMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other post-employment benefit plans</link:label>
      <link:label id="id_3d342709" xlink:label="lbl_DefinedBenefitObligationAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit obligation, at present value</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitObligationAtPresentValue" xlink:to="lbl_DefinedBenefitObligationAtPresentValue_labels" xlink:type="arc"/>
      <link:label id="id_22ca7a55" xlink:label="lbl_DefinedBenefitObligationAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Benefit obligation at beginning of period</link:label>
      <link:label id="id_7de6506d" xlink:label="lbl_DefinedBenefitObligationAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Benefit obligation at end of period</link:label>
      <link:label id="id_30925057" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current service cost, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:to="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_38d91a7e" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current service cost</link:label>
      <link:label id="id_4281521a" xlink:label="lbl_AdministrativeExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Administrative expenses</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdministrativeExpense" xlink:label="lbl_AdministrativeExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdministrativeExpense" xlink:to="lbl_AdministrativeExpense_labels" xlink:type="arc"/>
      <link:label id="id_603d3cd8" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial gains (losses) arising from changes in financial assumptions, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_48f72a8" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Remeasurement losses/(gains) arising from changes in financial assumptions</link:label>
      <link:label id="id_3f236d51" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial gains (losses) arising from changes in demographic assumptions, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_78d171f" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Remeasurement (gains) arising from changes in demographic assumptions</link:label>
      <link:label id="id_783c6ad8" xlink:label="lbl_label220841955" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_45220e6b" xlink:label="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments from plan, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:label="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:to="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_1ebcfd45" xlink:label="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Benefit payments</link:label>
      <link:label id="id_6368b27" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contributions to plan by plan participants, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_481bb1bf" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributions of associates</link:label>
      <link:label id="id_8f2ae87" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through acquisitions, divestments or transfers, benefit obligation</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1_labels" xlink:type="arc"/>
      <link:label id="id_474719e9" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of acquisitions, divestments or transfers</link:label>
      <link:label id="id_26d72366" xlink:label="lbl_PlanAssetsAtFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan assets, at fair value</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="lbl_PlanAssetsAtFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PlanAssetsAtFairValue" xlink:to="lbl_PlanAssetsAtFairValue_labels" xlink:type="arc"/>
      <link:label id="id_753e351c" xlink:label="lbl_PlanAssetsAtFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan assets at beginning of period</link:label>
      <link:label id="id_432fa1b8" xlink:label="lbl_PlanAssetsAtFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan assets at end of period</link:label>
      <link:label id="id_66d6f9ff" xlink:label="lbl_label1273555602" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_37b55377" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contributions to plan by employer, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_12bfbc9" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis Group contributions</link:label>
      <link:label id="id_2adf4a42" xlink:label="lbl_DefinedBenefitPlanSettlementsPlanAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Settlements, Plan Assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanSettlementsPlanAssets" xlink:label="lbl_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="lbl_DefinedBenefitPlanSettlementsPlanAssets_labels" xlink:type="arc"/>
      <link:label id="id_6615f676" xlink:label="lbl_DefinedBenefitPlanSettlementsPlanAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
      <link:label id="id_4cd3f00b" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through acquisitions, divestments or transfers, defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1_labels" xlink:type="arc"/>
      <link:label id="id_410b8f27" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of acquisitions, divestments or transfers</link:label>
      <link:label id="id_c41cf6c" xlink:label="lbl_label205639532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, change in benefit obligation [roll forward]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_label205639532" xlink:type="arc"/>
      <link:label id="id_3bf9f9ba" xlink:label="lbl_label1006238138" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, change in fair value of plan assets [roll forward]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_label1006238138" xlink:type="arc"/>
      <link:label id="id_290f00a6" xlink:label="lbl_SurplusDeficitInPlan_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Surplus (deficit) in plan</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="lbl_SurplusDeficitInPlan" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SurplusDeficitInPlan" xlink:to="lbl_SurplusDeficitInPlan_labels" xlink:type="arc"/>
      <link:label id="id_9610a9f" xlink:label="lbl_SurplusDeficitInPlan_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Funded status</link:label>
      <link:label id="id_5aa411ee" xlink:label="lbl_label1520701934" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, change in limitation on recognition of fund surplus [roll forward]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_label1520701934" xlink:type="arc"/>
      <link:label id="id_161add1b" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:to="lbl_LiabilityAssetOfDefinedBenefitPlans_labels" xlink:type="arc"/>
      <link:label id="id_37321747" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net liability in the balance sheet at end of period</link:label>
      <link:label id="id_5bdc9111" xlink:label="lbl_LimitationOnRecognitionOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Limitation on recognition of fund surplus</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LimitationOnRecognitionOfFundSurplus" xlink:label="lbl_LimitationOnRecognitionOfFundSurplus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LimitationOnRecognitionOfFundSurplus" xlink:to="lbl_LimitationOnRecognitionOfFundSurplus_labels" xlink:type="arc"/>
      <link:label id="id_76d185b5" xlink:label="lbl_LimitationOnRecognitionOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Limitation on recognition of fund surplus at beginning of period</link:label>
      <link:label id="id_1ada4e58" xlink:label="lbl_LimitationOnRecognitionOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Limitation on recognition of fund surplus at end of period</link:label>
      <link:label id="id_155f6c71" xlink:label="lbl_label358575217" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net defined benefit liability (asset) [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lbl_label358575217" xlink:type="arc"/>
      <link:label id="id_25ebb8ae" xlink:label="lbl_label636205230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, change in net liability [roll forward]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_label636205230" xlink:type="arc"/>
      <link:label id="id_54f9f34f" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Net liability at end of period</link:label>
      <link:label id="id_56e703b2" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Net liability at beginning of period</link:label>
      <link:label id="id_4c3018ba" xlink:label="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense (income), net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:label="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:to="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_493d88c7" xlink:label="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net interest expense</link:label>
      <link:label id="id_58444b6a" xlink:label="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (loss) on remeasurement, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:label="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:to="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_b032860" xlink:label="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remeasurements</link:label>
      <link:label id="id_16e626ad" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through changes in foreign exchange rates, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_6f51c69e" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_3d05f86e" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through acquisitions, divestments or transfers, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1_labels" xlink:type="arc"/>
      <link:label id="id_594017b5" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of acquisitions, divestments or transfers</link:label>
      <link:label id="id_f5fa1d1" xlink:label="lbl_label257925585" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amounts recognized in the consolidated balance sheet [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:label="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:to="lbl_label257925585" xlink:type="arc"/>
      <link:label id="id_5b08b7db" xlink:label="lbl_label1527298011" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued benefit liability</link:label>
      <link:label id="id_1ec53fdb" xlink:label="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit pension plan, accrued benefit liability</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:label="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:to="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities_labels" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:to="lbl_label1527298011" xlink:type="arc"/>
      <link:label id="id_1b1c172d" xlink:label="lbl_label454825773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Breakdown of defined benefit obligation for pension plans [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_label454825773" xlink:type="arc"/>
      <link:label id="id_574cbf67" xlink:label="lbl_label1464647527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Obligation by type [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ObligationByTypeAxis" xlink:label="lbl_ObligationByTypeAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ObligationByTypeAxis" xlink:to="lbl_label1464647527" xlink:type="arc"/>
      <link:label id="id_59c768c3" xlink:label="lbl_ObligationByTypeMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Obligation by type [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ObligationByTypeMember" xlink:label="lbl_ObligationByTypeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_ObligationByTypeMember_labels" xlink:type="arc"/>
      <link:label id="id_e411de0" xlink:label="lbl_UnfundedMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unfunded [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnfundedMember" xlink:label="lbl_UnfundedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnfundedMember" xlink:to="lbl_UnfundedMember_labels" xlink:type="arc"/>
      <link:label id="id_206ca87f" xlink:label="lbl_ObligationByTypeMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Obligation by type</link:label>
      <link:label id="id_4964c411" xlink:label="lbl_UnfundedMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unfunded</link:label>
      <link:label id="id_15c93075" xlink:label="lbl_ActiveMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Active [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActiveMember" xlink:label="lbl_ActiveMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActiveMember" xlink:to="lbl_ActiveMember_labels" xlink:type="arc"/>
      <link:label id="id_4cc31394" xlink:label="lbl_ActiveMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Active</link:label>
      <link:label id="id_4cfa00d5" xlink:label="lbl_DeferredPensionersMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred pensioners [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredPensionersMember" xlink:label="lbl_DeferredPensionersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredPensionersMember" xlink:to="lbl_DeferredPensionersMember_labels" xlink:type="arc"/>
      <link:label id="id_452ea3f3" xlink:label="lbl_DeferredPensionersMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred pensioners</link:label>
      <link:label id="id_9ccd7d0" xlink:label="lbl_PensionersMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pensioners [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionersMember" xlink:label="lbl_PensionersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PensionersMember" xlink:to="lbl_PensionersMember_labels" xlink:type="arc"/>
      <link:label id="id_77f4d5bf" xlink:label="lbl_PensionersMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pensioners</link:label>
      <link:label id="id_41aa0977" xlink:label="lbl_label1101662583" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of defined benefit plans disclosures [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lbl_label1101662583" xlink:type="arc"/>
      <link:label id="id_70b19e47" xlink:label="lbl_ActuarialAssumptionOfDiscountRates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of discount rates</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:label="lbl_ActuarialAssumptionOfDiscountRates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfDiscountRates" xlink:to="lbl_ActuarialAssumptionOfDiscountRates_labels" xlink:type="arc"/>
      <link:label id="id_30e2ed44" xlink:label="lbl_ActuarialAssumptionOfDiscountRates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
      <link:label id="id_228400f7" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of pension increases</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_labels" xlink:type="arc"/>
      <link:label id="id_5ba9eb34" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected rate of pension increase</link:label>
      <link:label id="id_4f7f1dac" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of salary increases</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_labels" xlink:type="arc"/>
      <link:label id="id_2cc2bb1f" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected rate of salary increase</link:label>
      <link:label id="id_1baffc03" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of interest on savings account</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount_labels" xlink:type="arc"/>
      <link:label id="id_56eba13" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on savings account</link:label>
      <link:label id="id_646262cf" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyMale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit assumption life expectancy, male</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitAssumptionLifeExpectancyMale" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyMale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitAssumptionLifeExpectancyMale" xlink:to="lbl_DefinedBenefitAssumptionLifeExpectancyMale_labels" xlink:type="arc"/>
      <link:label id="id_32829bee" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyMale_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current life expectancy for a 65-year-old male</link:label>
      <link:label id="id_d9d966" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyFemale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit assumption life expectancy, female</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:to="lbl_DefinedBenefitAssumptionLifeExpectancyFemale_labels" xlink:type="arc"/>
      <link:label id="id_5516dd19" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyFemale_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current life expectancy for a 65-year-old female</link:label>
      <link:label id="id_5918de81" xlink:label="lbl_label1494802049" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:label="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="lbl_label1494802049" xlink:type="arc"/>
      <link:label id="id_689d3554" xlink:label="lbl_label1755133268" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:label="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="lbl_label1755133268" xlink:type="arc"/>
      <link:label id="id_3e1a9660" xlink:label="lbl_label1041929824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumptions [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="lbl_ActuarialAssumptionsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionsAxis" xlink:to="lbl_label1041929824" xlink:type="arc"/>
      <link:label id="id_2737de6b" xlink:label="lbl_label657972843" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumptions [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="lbl_ActuarialAssumptionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_label657972843" xlink:type="arc"/>
      <link:label id="id_70f6e61c" xlink:label="lbl_ActuarialAssumptionOfDiscountRatesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of discount rates [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:label="lbl_ActuarialAssumptionOfDiscountRatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfDiscountRatesMember" xlink:to="lbl_ActuarialAssumptionOfDiscountRatesMember_labels" xlink:type="arc"/>
      <link:label id="id_1b153ebb" xlink:label="lbl_ActuarialAssumptionOfDiscountRatesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
      <link:label id="id_761309a6" xlink:label="lbl_LifeExpectancyMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Life expectancy [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LifeExpectancyMember" xlink:label="lbl_LifeExpectancyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LifeExpectancyMember" xlink:to="lbl_LifeExpectancyMember_labels" xlink:type="arc"/>
      <link:label id="id_527cf7bb" xlink:label="lbl_LifeExpectancyMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Life expectancy</link:label>
      <link:label id="id_70b51d3d" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of pension increases [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_labels" xlink:type="arc"/>
      <link:label id="id_5b5a9ebb" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate of pension increase</link:label>
      <link:label id="id_47824990" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of interest on savings account [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_labels" xlink:type="arc"/>
      <link:label id="id_32d0ccd0" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on savings account</link:label>
      <link:label id="id_742d5c34" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial assumption of expected rates of salary increases [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_labels" xlink:type="arc"/>
      <link:label id="id_795db79c" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Salary increase</link:label>
      <link:label id="id_72dd0a47" xlink:label="lbl_label1927088711" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in actuarial assumption [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInActuarialAssumptionAxis" xlink:label="lbl_ChangeInActuarialAssumptionAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangeInActuarialAssumptionAxis" xlink:to="lbl_label1927088711" xlink:type="arc"/>
      <link:label id="id_6778fca" xlink:label="lbl_label108498890" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in actuarial assumption [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInActuarialAssumptionMember" xlink:label="lbl_ChangeInActuarialAssumptionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_label108498890" xlink:type="arc"/>
      <link:label id="id_47ad1e48" xlink:label="lbl_Decrease25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease, 25 basis point [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Decrease25BasisPointMember" xlink:label="lbl_Decrease25BasisPointMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Decrease25BasisPointMember" xlink:to="lbl_Decrease25BasisPointMember_labels" xlink:type="arc"/>
      <link:label id="id_56d62cdb" xlink:label="lbl_Decrease25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">25 basis point decrease</link:label>
      <link:label id="id_3867e568" xlink:label="lbl_Increase25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase, 25 basis point [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Increase25BasisPointMember" xlink:label="lbl_Increase25BasisPointMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Increase25BasisPointMember" xlink:to="lbl_Increase25BasisPointMember_labels" xlink:type="arc"/>
      <link:label id="id_5197441d" xlink:label="lbl_Increase25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">25 basis point increase</link:label>
      <link:label id="id_1471972b" xlink:label="lbl_Increase1YearMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase, 1 year [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Increase1YearMember" xlink:label="lbl_Increase1YearMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Increase1YearMember" xlink:to="lbl_Increase1YearMember_labels" xlink:type="arc"/>
      <link:label id="id_4ce59d83" xlink:label="lbl_Increase1YearMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1 year increase</link:label>
      <link:label id="id_290932d1" xlink:label="lbl_label688468689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:label="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:to="lbl_label688468689" xlink:type="arc"/>
      <link:label id="id_7dde43af" xlink:label="lbl_label2111718319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:label="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:to="lbl_label2111718319" xlink:type="arc"/>
      <link:label id="id_a6a337a" xlink:label="lbl_label174732154" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of health care cost trend rates [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfHealthCareCostTrendRatesTable" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:to="lbl_label174732154" xlink:type="arc"/>
      <link:label id="id_3aac73e2" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:to="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_labels" xlink:type="arc"/>
      <link:label id="id_6a35725f" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Healthcare cost trend rate assumed for next year</link:label>
      <link:label id="id_41b83777" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Health Care Cost Trend Rate Assumed to Decline</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:to="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline_labels" xlink:type="arc"/>
      <link:label id="id_4f8e05fa" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate to which the cost trend rate is assumed to decline</link:label>
      <link:label id="id_6b154ebb" xlink:label="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Year that Rate Reaches Ultimate Trend Rate</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:label="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:to="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_labels" xlink:type="arc"/>
      <link:label id="id_1990f79d" xlink:label="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year that the rate reaches the ultimate trend rate</link:label>
      <link:label id="id_6d01266f" xlink:label="lbl_label1828791919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of allocation of plan assets [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAllocationOfPlanAssetsTable" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:to="lbl_label1828791919" xlink:type="arc"/>
      <link:label id="id_546e2ee7" xlink:label="lbl_label1416507111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of assets [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_label1416507111" xlink:type="arc"/>
      <link:label id="id_351e0eb0" xlink:label="lbl_label891162288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_label891162288" xlink:type="arc"/>
      <link:label id="id_124636b7" xlink:label="lbl_EquityInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity investments [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityInvestmentsMember" xlink:label="lbl_EquityInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityInvestmentsMember" xlink:to="lbl_EquityInvestmentsMember_labels" xlink:type="arc"/>
      <link:label id="id_77cea25b" xlink:label="lbl_EquityInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
      <link:label id="id_1387f503" xlink:label="lbl_DebtSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt securities [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DebtSecuritiesMember" xlink:to="lbl_DebtSecuritiesMember_labels" xlink:type="arc"/>
      <link:label id="id_3f4271a5" xlink:label="lbl_DebtSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities</link:label>
      <link:label id="id_3fb49996" xlink:label="lbl_RealEstateMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Real estate [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RealEstateMember" xlink:label="lbl_RealEstateMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RealEstateMember" xlink:to="lbl_RealEstateMember_labels" xlink:type="arc"/>
      <link:label id="id_3b683c06" xlink:label="lbl_RealEstateMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Real estate</link:label>
      <link:label id="id_40e14f9f" xlink:label="lbl_AlternativeInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alternative investments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlternativeInvestmentsMember" xlink:label="lbl_AlternativeInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlternativeInvestmentsMember" xlink:to="lbl_AlternativeInvestmentsMember_labels" xlink:type="arc"/>
      <link:label id="id_63169a31" xlink:label="lbl_AlternativeInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alternative investments</link:label>
      <link:label id="id_2f33748b" xlink:label="lbl_CashAndOtherInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and other investments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndOtherInvestmentsMember" xlink:label="lbl_CashAndOtherInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndOtherInvestmentsMember" xlink:to="lbl_CashAndOtherInvestmentsMember_labels" xlink:type="arc"/>
      <link:label id="id_6087023c" xlink:label="lbl_CashAndOtherInvestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and other investments</link:label>
      <link:label id="id_36f85bd1" xlink:label="lbl_label922246097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, target plan asset allocations range minimum</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:label="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:to="lbl_label922246097" xlink:type="arc"/>
      <link:label id="id_568969aa" xlink:label="lbl_label1451846058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, target plan asset allocations range maximum</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:label="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:to="lbl_label1451846058" xlink:type="arc"/>
      <link:label id="id_73a6e694" xlink:label="lbl_label1940317844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, plan asset allocations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanPlanAssetAllocations" xlink:label="lbl_DefinedBenefitPlanPlanAssetAllocations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanPlanAssetAllocations" xlink:to="lbl_label1940317844" xlink:type="arc"/>
      <link:label id="id_7df88f41" xlink:label="lbl_label2113441601" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares held by defined benefit plan</link:label>
      <link:label id="id_638e4e2e" xlink:label="lbl_label1670270510" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value of shares held by defined benefit plan</link:label>
      <link:label id="id_1fe80675" xlink:label="lbl_label535299701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average duration of defined benefit obligation years</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:label="lbl_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:to="lbl_label535299701" xlink:type="arc"/>
      <link:label id="id_3b7d1376" xlink:label="lbl_label998052726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined contribution pension and other post-retirement plans disclosure [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="lbl_label998052726" xlink:type="arc"/>
      <link:label id="id_3dd16606" xlink:label="lbl_label1037133318" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined contribution pension and other post-retirement plans disclosure [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:to="lbl_label1037133318" xlink:type="arc"/>
      <link:label id="id_123e0aae" xlink:label="lbl_label306055854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined contribution pension and other post-retirement plans disclosure [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:to="lbl_label306055854" xlink:type="arc"/>
      <link:label id="id_f1ad7e6" xlink:label="lbl_label253417446" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Post-employment benefit expense, defined contribution plans</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:to="lbl_label253417446" xlink:type="arc"/>
      <link:label id="id_103a32b5" xlink:label="lbl_label272249525" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of expected benefit payments [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfExpectedBenefitPaymentsTable" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:to="lbl_label272249525" xlink:type="arc"/>
      <link:label id="id_3fa24799" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, expected future benefit payment [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:to="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract_labels" xlink:type="arc"/>
      <link:label id="id_7a2e1ca0" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, expected future employer contributions [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:to="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract_labels" xlink:type="arc"/>
      <link:label id="id_6e3282e0" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis Group contributions</link:label>
      <link:label id="id_723df25e" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future benefit payments</link:label>
      <link:label id="id_b004db7" xlink:label="lbl_label910647463" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributions, next fiscal year (estimated)</link:label>
      <link:label id="id_489bf9be" xlink:label="lbl_label839490648" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future benefit payment</link:label>
      <link:label id="id_20bc42c3" xlink:label="lbl_label549208771" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Past service cost and settlements</link:label>
      <link:label id="id_12ce3901" xlink:label="lbl_label315504897" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Past service cost and gains losses arising from settlements, defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:to="lbl_label315504897" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:to="lbl_label549208771" xlink:type="arc"/>
      <link:label id="id_47519d57" xlink:label="lbl_label1196531031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, expected future employer contributions, next fiscal year</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lbl_label1196531031" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lbl_label910647463" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SocieteParActionsSANDOZAlgiersMember" xlink:label="lbl_SocieteParActionsSANDOZAlgiersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SocieteParActionsSANDOZAlgiersMember" xlink:to="lbl_label1014805941" xlink:type="arc"/>
      <link:label id="id_1b677399" xlink:label="lbl_label459764633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:label="lbl_AnalysisOfIncomeAndExpenseAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AnalysisOfIncomeAndExpenseAbstract" xlink:to="lbl_label459764633" xlink:type="arc"/>
      <link:label id="id_33287a64" xlink:label="lbl_DisclosureOfDiscontinuedOperationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of discontinued operations [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDiscontinuedOperationsExplanatory" xlink:label="lbl_DisclosureOfDiscontinuedOperationsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDiscontinuedOperationsExplanatory" xlink:to="lbl_DisclosureOfDiscontinuedOperationsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_2e310112" xlink:label="lbl_DisclosureOfDiscontinuedOperationsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations</link:label>
      <link:label id="id_6868ef6e" xlink:label="lbl_label1751707502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of details to the consolidated statements of cash flows [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_label1751707502" xlink:type="arc"/>
      <link:label id="id_6b1bab45" xlink:label="lbl_DisclosureOfCashFlowStatementExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Details to the consolidated statements of cash flows</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:label="lbl_DisclosureOfCashFlowStatementExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfCashFlowStatementExplanatory" xlink:to="lbl_DisclosureOfCashFlowStatementExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_d3696d1" xlink:label="lbl_DisclosureOfCashFlowStatementExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of cash flow statement [text block]</link:label>
      <link:label id="id_5827fd3a" xlink:label="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for non-cash items from continuing operations [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:label="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:to="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4b12a0b7" xlink:label="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for non-cash items from continuing operations</link:label>
      <link:label id="id_31e67efa" xlink:label="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" xlink:label="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" xlink:to="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3971a54e" xlink:label="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations</link:label>
      <link:label id="id_1118f1b5" xlink:label="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows arising from acquisitions and divestments of businesses [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:label="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:to="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4c64ba26" xlink:label="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows arising from acquisitions and divestments of businesses</link:label>
      <link:label id="id_4c022ee6" xlink:label="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from discontinued operations [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsFromDiscontinuedOperationsTableTextBlock" xlink:label="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock" xlink:to="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5bd72b36" xlink:label="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from discontinued operations</link:label>
      <link:label id="id_2f1afbf8" xlink:label="lbl_ConsolidatedIncomeStatementSegmentationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated income statement segmentation [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsolidatedIncomeStatementSegmentationTableTextBlock" xlink:label="lbl_ConsolidatedIncomeStatementSegmentationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedIncomeStatementSegmentationTableTextBlock" xlink:to="lbl_ConsolidatedIncomeStatementSegmentationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5cbbe15" xlink:label="lbl_ConsolidatedIncomeStatementSegmentationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated income statement segmentation</link:label>
      <link:label id="id_5a01c254" xlink:label="lbl_ExpensesIncludedInNetIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses included in net income [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExpensesIncludedInNetIncomeTableTextBlock" xlink:label="lbl_ExpensesIncludedInNetIncomeTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpensesIncludedInNetIncomeTableTextBlock" xlink:to="lbl_ExpensesIncludedInNetIncomeTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2004e8bf" xlink:label="lbl_ExpensesIncludedInNetIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses included in net income</link:label>
      <link:label id="id_10dd18ca" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToContinuingSegments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, sales to continuing segments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsSalesToContinuingSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToContinuingSegments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsSalesToContinuingSegments" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToContinuingSegments_labels" xlink:type="arc"/>
      <link:label id="id_2d4849c4" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToContinuingSegments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales to continuing segments</link:label>
      <link:label id="id_398e8ede" xlink:label="lbl_label965643998" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_label965643998" xlink:type="arc"/>
      <link:label id="id_136ba9dd" xlink:label="lbl_label325822941" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SegmentsMember" xlink:to="lbl_label325822941" xlink:type="arc"/>
      <link:label id="id_211fcf4d" xlink:label="lbl_VaccinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vaccines [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VaccinesMember" xlink:label="lbl_VaccinesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VaccinesMember" xlink:to="lbl_VaccinesMember_labels" xlink:type="arc"/>
      <link:label id="id_5b74f3f8" xlink:label="lbl_ConsumerHealthMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumer Health [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsumerHealthMember" xlink:label="lbl_ConsumerHealthMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsumerHealthMember" xlink:to="lbl_ConsumerHealthMember_labels" xlink:type="arc"/>
      <link:label id="id_56f765a5" xlink:label="lbl_CorporateMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CorporateMember" xlink:to="lbl_CorporateMember_labels" xlink:type="arc"/>
      <link:label id="id_18ef0ff6" xlink:label="lbl_VaccinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vaccines</link:label>
      <link:label id="id_461a031f" xlink:label="lbl_ConsumerHealthMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consumer Health</link:label>
      <link:label id="id_53139d8a" xlink:label="lbl_CorporateMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate</link:label>
      <link:label id="id_448d3c2a" xlink:label="lbl_OperatingIncomeLossOfDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating income/loss of discontinued operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OperatingIncomeLossOfDiscontinuedOperations" xlink:label="lbl_OperatingIncomeLossOfDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OperatingIncomeLossOfDiscontinuedOperations" xlink:to="lbl_OperatingIncomeLossOfDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_720983c3" xlink:label="lbl_OperatingIncomeLossOfDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income/loss of discontinued operations</link:label>
      <link:label id="id_72fd7ee5" xlink:label="lbl_IncomeTaxExpenseOfDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax expense of discontinued operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeTaxExpenseOfDiscontinuedOperations" xlink:label="lbl_IncomeTaxExpenseOfDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxExpenseOfDiscontinuedOperations" xlink:to="lbl_IncomeTaxExpenseOfDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_28dd046" xlink:label="lbl_IncomeTaxExpenseOfDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense of discontinued operations</link:label>
      <link:label id="id_1f5a1a52" xlink:label="lbl_ProfitLossFromDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income from discontinued operations</link:label>
      <link:label id="id_6a72e089" xlink:label="lbl_label1785913481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationExpense" xlink:label="lbl_DepreciationExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationExpense" xlink:to="lbl_label1785913481" xlink:type="arc"/>
      <link:label id="id_25726f06" xlink:label="lbl_label628256518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortisation expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationExpense" xlink:label="lbl_AmortisationExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortisationExpense" xlink:to="lbl_label628256518" xlink:type="arc"/>
      <link:label id="id_411f99ec" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss (reversal of impairment loss) recognised in profit or loss</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_labels" xlink:type="arc"/>
      <link:label id="id_3b138d2b" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions with employees</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees_labels" xlink:type="arc"/>
      <link:label id="id_16efc802" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation of Novartis equity plans</link:label>
      <link:label id="id_1bd6fe9" xlink:label="lbl_IntangibleAssetsAndGoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember_labels" xlink:type="arc"/>
      <link:label id="id_1b76fc8a" xlink:label="lbl_IntangibleAssetsAndGoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
      <link:label id="id_7b8e06f2" xlink:label="lbl_PropertyPlantAndEquipmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
      <link:label id="id_199a6c29" xlink:label="lbl_FinancialAssetsImpairedMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets impaired [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsImpairedMember" xlink:label="lbl_FinancialAssetsImpairedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsImpairedMember" xlink:to="lbl_FinancialAssetsImpairedMember_labels" xlink:type="arc"/>
      <link:label id="id_430aa9fa" xlink:label="lbl_FinancialAssetsImpairedMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
      <link:label id="id_580bc98f" xlink:label="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:label="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:to="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract_labels" xlink:type="arc"/>
      <link:label id="id_12db58d" xlink:label="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and impairments on:</link:label>
      <link:label id="id_7cae4caa" xlink:label="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for losses (gains) on disposal of non-current assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:label="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:to="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_7ed21581" xlink:label="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains on disposal and other adjustments on property, plant and equipment; intangible assets;financial assets; and other non-current assets, net</link:label>
      <link:label id="id_353f4e60" xlink:label="lbl_AdjustmentsForSharebasedPayments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment for share based payments</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="lbl_AdjustmentsForSharebasedPayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForSharebasedPayments" xlink:to="lbl_AdjustmentsForSharebasedPayments_labels" xlink:type="arc"/>
      <link:label id="id_728a3fc5" xlink:label="lbl_AdjustmentsForSharebasedPayments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-settled compensation expense</link:label>
      <link:label id="id_71026a6c" xlink:label="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment for change in provisions and other non-current liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:label="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:to="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_7a811d6" xlink:label="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in provisions and other non-current liabilities</link:label>
      <link:label id="id_5215d26" xlink:label="lbl_AdjustmentsForFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for finance income (cost)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="lbl_AdjustmentsForFinanceIncomeCost" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForFinanceIncomeCost" xlink:to="lbl_AdjustmentsForFinanceIncomeCost_labels" xlink:type="arc"/>
      <link:label id="id_1e915c0" xlink:label="lbl_AdjustmentsForFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net financial expense</link:label>
      <link:label id="id_162e6aad" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInInventories_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in inventories</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInInventories_labels" xlink:type="arc"/>
      <link:label id="id_7b5bcf12" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInInventories_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase)/decrease in inventories</link:label>
      <link:label id="id_672b8eea" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_labels" xlink:type="arc"/>
      <link:label id="id_47cff5e1" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase)/decrease in trade receivables</link:label>
      <link:label id="id_543bdc2c" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts payable</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_labels" xlink:type="arc"/>
      <link:label id="id_4059a0ed" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in trade payables</link:label>
      <link:label id="id_b388f81" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other inflows (outflows) of cash</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_64e8a2fc" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in other net current assets and other operating cash flow items</link:label>
      <link:label id="id_63e2f9e4" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
      <link:label id="id_118bdd59" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents, discontinued operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_671e3a1e" xlink:label="lbl_label1730034206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions and divestments [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsAndDivestmentsAxis" xlink:label="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsAndDivestmentsAxis" xlink:to="lbl_label1730034206" xlink:type="arc"/>
      <link:label id="id_141b97fd" xlink:label="lbl_label337352701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions and divestments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsAndDivestmentsMember" xlink:label="lbl_AcquisitionsAndDivestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsAndDivestmentsMember" xlink:to="lbl_label337352701" xlink:type="arc"/>
      <link:label id="id_12050514" xlink:label="lbl_AcquisitionsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsMember" xlink:label="lbl_AcquisitionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsMember" xlink:to="lbl_AcquisitionsMember_labels" xlink:type="arc"/>
      <link:label id="id_7f5f8169" xlink:label="lbl_AcquisitionsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
      <link:label id="id_415fd821" xlink:label="lbl_DivestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divestments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentsMember" xlink:label="lbl_DivestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestmentsMember" xlink:to="lbl_DivestmentsMember_labels" xlink:type="arc"/>
      <link:label id="id_7b19873c" xlink:label="lbl_DivestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestments</link:label>
      <link:label id="id_177d8886" xlink:label="lbl_OtherAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial and other assets including deferred tax assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssetsMember" xlink:label="lbl_OtherAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherAssetsMember" xlink:to="lbl_OtherAssetsMember_labels" xlink:type="arc"/>
      <link:label id="id_fdd065b" xlink:label="lbl_OtherAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets [member]</link:label>
      <link:label id="id_7f9f59b1" xlink:label="lbl_OtherIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
      <link:label id="id_1a3864c5" xlink:label="lbl_TechnologybasedIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technologies</link:label>
      <link:label id="id_5b13ac00" xlink:label="lbl_BrandNamesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brand names</link:label>
      <link:label id="id_7d41899d" xlink:label="lbl_InventoriesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:label id="id_50dd9de4" xlink:label="lbl_CashFlowFromNetIdentifiableAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net identifiable assets (acquired) or divested</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowFromNetIdentifiableAssets" xlink:label="lbl_CashFlowFromNetIdentifiableAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowFromNetIdentifiableAssets" xlink:to="lbl_CashFlowFromNetIdentifiableAssets_labels" xlink:type="arc"/>
      <link:label id="id_4169909f" xlink:label="lbl_CashFlowFromNetIdentifiableAssets_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow) from Net identifiable assets (acquired) or divested</link:label>
      <link:label id="id_6da3acb5" xlink:label="lbl_CashInflowOutflowCurrencyTranslationEffects_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow), currency translation effects</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowOutflowCurrencyTranslationEffects" xlink:label="lbl_CashInflowOutflowCurrencyTranslationEffects" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowCurrencyTranslationEffects" xlink:to="lbl_CashInflowOutflowCurrencyTranslationEffects_labels" xlink:type="arc"/>
      <link:label id="id_28a59cd9" xlink:label="lbl_CashInflowOutflowCurrencyTranslationEffects_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_6046e1a8" xlink:label="lbl_CashInflowOutflowCurrencyTranslationEffects_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_4ec913e7" xlink:label="lbl_CashInflowOutflowAcquiredDivestedLiquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow), acquired/(divested) liquity</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowOutflowAcquiredDivestedLiquity" xlink:label="lbl_CashInflowOutflowAcquiredDivestedLiquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowAcquiredDivestedLiquity" xlink:to="lbl_CashInflowOutflowAcquiredDivestedLiquity_labels" xlink:type="arc"/>
      <link:label id="id_470c377e" xlink:label="lbl_CashInflowOutflowAcquiredDivestedLiquity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired/(divested) liquity</link:label>
      <link:label id="id_50fcd8ec" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
      <link:label id="id_51ec5468" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow) from Net identifiable assets (acquired) or divested, currency translation effects, Acquired/(divested) liquidity and fair value of previously held equity interests.</link:label>
      <link:label id="id_33a842e" xlink:label="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash provided by refinancing of intercompany financial debt, net</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet" xlink:label="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet" xlink:to="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet_labels" xlink:type="arc"/>
      <link:label id="id_cbc3f6c" xlink:label="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Refinancing of intercompany financial debt, net</link:label>
      <link:label id="id_2f2298e2" xlink:label="lbl_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash provided by refinancing of intercompany financial debt, net.</link:label>
      <link:label id="id_7e82bd81" xlink:label="lbl_CashInflowOutflowGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow), Goodwill</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowOutflowGoodwill" xlink:label="lbl_CashInflowOutflowGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowGoodwill" xlink:to="lbl_CashInflowOutflowGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_3c41ff79" xlink:label="lbl_CashInflowOutflowGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
      <link:label id="id_4f404f29" xlink:label="lbl_label1329614633" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestment gain</link:label>
      <link:label id="id_250b8244" xlink:label="lbl_label621511236" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow), Divestment gain (loss)</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowOutflowDivestmentGainLoss" xlink:label="lbl_CashInflowOutflowDivestmentGainLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowDivestmentGainLoss" xlink:to="lbl_label621511236" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowDivestmentGainLoss" xlink:to="lbl_label1329614633" xlink:type="arc"/>
      <link:label id="id_48ec9225" xlink:label="lbl_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes paid and other portfolio transformation related cash flows</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows" xlink:label="lbl_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows" xlink:to="lbl_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows_labels" xlink:type="arc"/>
      <link:label id="id_69b7f35f" xlink:label="lbl_ReceivablesAndPayablesContingentConsiderationNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables and payables contingent consideration, net</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReceivablesAndPayablesContingentConsiderationNet" xlink:label="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:to="lbl_ReceivablesAndPayablesContingentConsiderationNet_labels" xlink:type="arc"/>
      <link:label id="id_66ca8618" xlink:label="lbl_OtherPaymentsAndDeferredConsiderationNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other payments and deferred consideration, net</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPaymentsAndDeferredConsiderationNet" xlink:label="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:to="lbl_OtherPaymentsAndDeferredConsiderationNet_labels" xlink:type="arc"/>
      <link:label id="id_7403ad6c" xlink:label="lbl_DeferredPrepaidPortionOfSalesPrice_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">(Deferred)/prepaid portion of sales price</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredPrepaidPortionOfSalesPrice" xlink:label="lbl_DeferredPrepaidPortionOfSalesPrice" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredPrepaidPortionOfSalesPrice" xlink:to="lbl_DeferredPrepaidPortionOfSalesPrice_labels" xlink:type="arc"/>
      <link:label id="id_7290427c" xlink:label="lbl_DeferredPrepaidPortionOfSalesPrice_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">(Deferred)/prepaid portion of sales price to cash flows (used in) provided by acquisitions/divestments of businesses.</link:label>
      <link:label id="id_55c25b5" xlink:label="lbl_label1423033786" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows</link:label>
      <link:label id="id_35ffff76" xlink:label="lbl_label905969526" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration paid</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationPaid" xlink:label="lbl_ContingentConsiderationPaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationPaid" xlink:to="lbl_label905969526" xlink:type="arc"/>
      <link:label id="id_344a7417" xlink:label="lbl_label877294615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business combinations [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="lbl_BusinessCombinationsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BusinessCombinationsAxis" xlink:to="lbl_label877294615" xlink:type="arc"/>
      <link:label id="id_2a937996" xlink:label="lbl_label714307990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for business combinations [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntitysTotalForBusinessCombinationsMember" xlink:to="lbl_label714307990" xlink:type="arc"/>
      <link:label id="id_e12f433" xlink:label="lbl_Change25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change, 25 basis point [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Change25BasisPointMember" xlink:label="lbl_Change25BasisPointMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Change25BasisPointMember" xlink:to="lbl_Change25BasisPointMember_labels" xlink:type="arc"/>
      <link:label id="id_a3f5c53" xlink:label="lbl_Change25BasisPointMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">25 basis point change</link:label>
      <link:label id="id_375463d0" xlink:label="lbl_label928277456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends payable, amount per share</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DividendsPayableAmountPerShare" xlink:label="lbl_DividendsPayableAmountPerShare" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsPayableAmountPerShare" xlink:to="lbl_label928277456" xlink:type="arc"/>
      <link:label id="id_43bd571e" xlink:label="lbl_label1136482078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares acquired to be held</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredToBeHeld" xlink:label="lbl_TreasurySharesAcquiredToBeHeld" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesAcquiredToBeHeld" xlink:to="lbl_label1136482078" xlink:type="arc"/>
      <link:label id="id_57fc5a54" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares acquired to be cancelled</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredToBeCancelled" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesAcquiredToBeCancelled" xlink:to="lbl_TreasurySharesAcquiredToBeCancelled_labels" xlink:type="arc"/>
      <link:label id="id_324c0bd9" xlink:label="lbl_label843844569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other share purchases</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherSharePurchases" xlink:label="lbl_OtherSharePurchases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherSharePurchases" xlink:to="lbl_label843844569" xlink:type="arc"/>
      <link:label id="id_4ae190e3" xlink:label="lbl_SharepurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-purchase of treasury shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharepurchaseOfTreasuryShares" xlink:label="lbl_SharepurchaseOfTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharepurchaseOfTreasuryShares" xlink:to="lbl_SharepurchaseOfTreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_191f6daa" xlink:label="lbl_label421490090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares acquired to be held, equity impact</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredToBeHeldValue" xlink:label="lbl_TreasurySharesAcquiredToBeHeldValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesAcquiredToBeHeldValue" xlink:to="lbl_label421490090" xlink:type="arc"/>
      <link:label id="id_3ea88f28" xlink:label="lbl_TreasurySharesAcquiredForCancellationValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares acquired for cancellation, equity impact</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredForCancellationValue" xlink:label="lbl_TreasurySharesAcquiredForCancellationValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesAcquiredForCancellationValue" xlink:to="lbl_TreasurySharesAcquiredForCancellationValue_labels" xlink:type="arc"/>
      <link:label id="id_6fbbc8cc" xlink:label="lbl_OtherSharePurchasesValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other share purchases, equity impact</link:label>
      <link:label id="id_5d0bb4f" xlink:label="lbl_label97565519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAbstract" xlink:label="lbl_ComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_label97565519" xlink:type="arc"/>
      <link:label id="id_663e6f69" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in consolidated statements of comprehensive income [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" xlink:to="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1fe06852" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in consolidated statements of comprehensive income</link:label>
      <link:label id="id_72bd6f82" xlink:label="lbl_ScheduleOfComprehensiveIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of comprehensive income [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfComprehensiveIncomeTableTextBlock" xlink:label="lbl_ScheduleOfComprehensiveIncomeTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfComprehensiveIncomeTableTextBlock" xlink:to="lbl_ScheduleOfComprehensiveIncomeTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3ec5912e" xlink:label="lbl_ScheduleOfComprehensiveIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
      <link:label id="id_55c48a63" xlink:label="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments financial instruments reconciliation [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" xlink:label="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" xlink:to="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_b6f9702" xlink:label="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments financial instruments reconciliation</link:label>
      <link:label id="id_56e22f6a" xlink:label="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of defined benefit plan amounts recognized in other comprehensive income [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" xlink:label="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" xlink:to="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_8052d36" xlink:label="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of defined benefit plan amounts recognized in other comprehensive income</link:label>
      <link:label id="id_639839a6" xlink:label="lbl_label1670920614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_label1670920614" xlink:type="arc"/>
      <link:label id="id_46f3d26a" xlink:label="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_3abc74f9" xlink:label="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based participation plans for employees</link:label>
      <link:label id="id_36b95a30" xlink:label="lbl_label918116912" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lbl_label918116912" xlink:type="arc"/>
      <link:label id="id_4f551c1c" xlink:label="lbl_DisclosureOfRelatedPartyExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of related party [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="lbl_DisclosureOfRelatedPartyExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfRelatedPartyExplanatory" xlink:to="lbl_DisclosureOfRelatedPartyExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_2142f37a" xlink:label="lbl_DisclosureOfRelatedPartyExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transactions with related parties</link:label>
      <link:label id="id_21a37a9f" xlink:label="lbl_DisclosureOfEmployeeBenefitsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Post-employment benefits for employees</link:label>
      <link:label id="id_250e99ed" xlink:label="lbl_OfficerAndDirectorCompensationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Officer and director compensation [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OfficerAndDirectorCompensationTableTextBlock" xlink:label="lbl_OfficerAndDirectorCompensationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OfficerAndDirectorCompensationTableTextBlock" xlink:to="lbl_OfficerAndDirectorCompensationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_30161311" xlink:label="lbl_OfficerAndDirectorCompensationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Officers and Non-Executive Directors Compensation</link:label>
      <link:label id="id_332db2e6" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_5ba16f3" xlink:label="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:label="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:to="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_23eec797" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of unvested restricted stock units roll forward [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4f141a24" xlink:label="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of share-based compensation, activity [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:label="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:to="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2cdc96dc" xlink:label="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of share-based compensation, activity</link:label>
      <link:label id="id_5c5154d5" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of unvested restricted stock units roll forward</link:label>
      <link:label id="id_44099e5b" xlink:label="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options</link:label>
      <link:label id="id_2a634859" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options</link:label>
      <link:label id="id_2b301a02" xlink:label="lbl_label724572674" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_label724572674" xlink:type="arc"/>
      <link:label id="id_499d66e9" xlink:label="lbl_label1235052265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_label1235052265" xlink:type="arc"/>
      <link:label id="id_4bff5af2" xlink:label="lbl_label1275026162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of related parties [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_label1275026162" xlink:type="arc"/>
      <link:label id="id_4175504c" xlink:label="lbl_label1098207308" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for related parties [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_label1098207308" xlink:type="arc"/>
      <link:label id="id_52e5607c" xlink:label="lbl_label1390764156" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel of entity or parent [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_label1390764156" xlink:type="arc"/>
      <link:label id="id_51571277" xlink:label="lbl_label1364660855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Executive Director [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonExecutiveDirectorMember" xlink:label="lbl_NonExecutiveDirectorMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonExecutiveDirectorMember" xlink:to="lbl_label1364660855" xlink:type="arc"/>
      <link:label id="id_77564460" xlink:label="lbl_label2002142304" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associates [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_label2002142304" xlink:type="arc"/>
      <link:label id="id_7f01623c" xlink:label="lbl_label2130797116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for associates [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_label2130797116" xlink:type="arc"/>
      <link:label id="id_2d55a2fa" xlink:label="lbl_RocheHoldingAGMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Holding AG [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RocheHoldingAGMember" xlink:to="lbl_RocheHoldingAGMember_labels" xlink:type="arc"/>
      <link:label id="id_102c1151" xlink:label="lbl_label271323473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and services [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_label271323473" xlink:type="arc"/>
      <link:label id="id_7a1d10b6" xlink:label="lbl_label2048725174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and services [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_label2048725174" xlink:type="arc"/>
      <link:label id="id_4b6874" xlink:label="lbl_label4941940" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lucentis [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LucentisMember" xlink:to="lbl_label4941940" xlink:type="arc"/>
      <link:label id="id_4da120c0" xlink:label="lbl_label1302405312" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xolair [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_XolairMember" xlink:to="lbl_label1302405312" xlink:type="arc"/>
      <link:label id="id_40080a70" xlink:label="lbl_label1074268784" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of voting rights held in associate</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:to="lbl_label1074268784" xlink:type="arc"/>
      <link:label id="id_4fef4e77" xlink:label="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net expense, royalties cost sharing and profit sharing</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:label="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:to="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing_labels" xlink:type="arc"/>
      <link:label id="id_5866119e" xlink:label="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, post-employment benefits</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits_labels" xlink:type="arc"/>
      <link:label id="id_32134034" xlink:label="lbl_KeyManagementPersonnelCompensationSharebasedPayment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, share-based payment</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="lbl_KeyManagementPersonnelCompensationSharebasedPayment_labels" xlink:type="arc"/>
      <link:label id="id_40914b3d" xlink:label="lbl_KeyManagementPersonnelCompensation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="lbl_KeyManagementPersonnelCompensation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensation" xlink:to="lbl_KeyManagementPersonnelCompensation_labels" xlink:type="arc"/>
      <link:label id="id_34c1eea8" xlink:label="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Post-employment benefits</link:label>
      <link:label id="id_24fee3be" xlink:label="lbl_KeyManagementPersonnelCompensationSharebasedPayment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation</link:label>
      <link:label id="id_5994538d" xlink:label="lbl_KeyManagementPersonnelCompensation_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
      <link:label id="id_a202e7c" xlink:label="lbl_label169881212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genentech, Inc., USA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GenentechInc.USAMember" xlink:label="lbl_GenentechInc.USAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GenentechInc.USAMember" xlink:to="lbl_label169881212" xlink:type="arc"/>
      <link:label id="id_3ecec9c1" xlink:label="lbl_label1053739457" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prof. Dr. Brody [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfDrBrodyMember" xlink:label="lbl_ProfDrBrodyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfDrBrodyMember" xlink:to="lbl_label1053739457" xlink:type="arc"/>
      <link:label id="id_60abf97a" xlink:label="lbl_label1621883258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prof. Dr. Zinkernagel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfDrZinkernagelMember" xlink:label="lbl_ProfDrZinkernagelMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfDrZinkernagelMember" xlink:to="lbl_label1621883258" xlink:type="arc"/>
      <link:label id="id_707fbae9" xlink:label="lbl_label1887419113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dr. Alex Krauer [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DrAlexKrauerMember" xlink:label="lbl_DrAlexKrauerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DrAlexKrauerMember" xlink:to="lbl_label1887419113" xlink:type="arc"/>
      <link:label id="id_5f1c0cdd" xlink:label="lbl_label1595673821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dr. Daniel Vasella [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DrDanielVasellaMember" xlink:label="lbl_DrDanielVasellaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DrDanielVasellaMember" xlink:to="lbl_label1595673821" xlink:type="arc"/>
      <link:label id="id_49199deb" xlink:label="lbl_label1226415595" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dr. James Bradner [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DrJamesBradnerMember" xlink:label="lbl_DrJamesBradnerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DrJamesBradnerMember" xlink:to="lbl_label1226415595" xlink:type="arc"/>
      <link:label id="id_12139c9c" xlink:label="lbl_label303275164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, daily rate</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationDailyRate" xlink:label="lbl_KeyManagementPersonnelCompensationDailyRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationDailyRate" xlink:to="lbl_label303275164" xlink:type="arc"/>
      <link:label id="id_34648bf4" xlink:label="lbl_label879004660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, annual guaranteed minimum</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:label="lbl_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:to="lbl_label879004660" xlink:type="arc"/>
      <link:label id="id_475cd1c7" xlink:label="lbl_label1197265351" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, shares acquired</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationSharesAcquired" xlink:label="lbl_KeyManagementPersonnelCompensationSharesAcquired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationSharesAcquired" xlink:to="lbl_label1197265351" xlink:type="arc"/>
      <link:label id="id_7d46110e" xlink:label="lbl_label2101743886" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, ownership interest acquired</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:label="lbl_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:to="lbl_label2101743886" xlink:type="arc"/>
      <link:label id="id_41061f2c" xlink:label="lbl_label1090920236" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in consolidated statements of comprehensive income [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:to="lbl_label1090920236" xlink:type="arc"/>
      <link:label id="id_2d82d11f" xlink:label="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on marketable securities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:to="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember_labels" xlink:type="arc"/>
      <link:label id="id_2c74381f" xlink:label="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on marketable securities</link:label>
      <link:label id="id_1315ebbc" xlink:label="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on deferred cash flow hedges [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:label="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:to="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember_labels" xlink:type="arc"/>
      <link:label id="id_2feb765f" xlink:label="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on deferred cash flow hedges</link:label>
      <link:label id="id_41098a9f" xlink:label="lbl_ActuarialLossesFromDefinedBenefitPlansMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Actuarial gains/losses from defined benefit plans [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActuarialLossesFromDefinedBenefitPlansMember" xlink:label="lbl_ActuarialLossesFromDefinedBenefitPlansMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialLossesFromDefinedBenefitPlansMember" xlink:to="lbl_ActuarialLossesFromDefinedBenefitPlansMember_labels" xlink:type="arc"/>
      <link:label id="id_66cb76c9" xlink:label="lbl_ActuarialLossesFromDefinedBenefitPlansMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial gains/losses from defined benefit plans</link:label>
      <link:label id="id_2dc02a48" xlink:label="lbl_CumulativeCurrencyTranslationEffectsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative currency translation effects [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationEffectsMember" xlink:label="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:to="lbl_CumulativeCurrencyTranslationEffectsMember_labels" xlink:type="arc"/>
      <link:label id="id_167b29ff" xlink:label="lbl_CumulativeCurrencyTranslationEffectsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative currency translation effects</link:label>
      <link:label id="id_23f99baf" xlink:label="lbl_label603560879" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in consolidated statements of comprehensive income [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_label603560879" xlink:type="arc"/>
      <link:label id="id_525fbfa4" xlink:label="lbl_label98094011" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Value adjustments on comprehensive income at end of period</link:label>
      <link:label id="id_5f2ad26f" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net actuarial gains/losses from defined benefit plans, net of taxes</link:label>
      <link:label id="id_56084e2" xlink:label="lbl_label492438188" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total value adjustments</link:label>
      <link:label id="id_4f1abe21" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on financial instruments</link:label>
      <link:label id="id_44ea9064" xlink:label="lbl_label521267934" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale financial investments</link:label>
      <link:label id="id_172d7365" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale marketable securities</link:label>
      <link:label id="id_1d877185" xlink:label="lbl_GainLossOnSaleOfMarketableInvestments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (loss) on sale of marketable investments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainLossOnSaleOfMarketableInvestments" xlink:label="lbl_GainLossOnSaleOfMarketableInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainLossOnSaleOfMarketableInvestments" xlink:to="lbl_GainLossOnSaleOfMarketableInvestments_labels" xlink:type="arc"/>
      <link:label id="id_67ba82da" xlink:label="lbl_GainLossOnSaleOfMarketableInvestments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities sold</link:label>
      <link:label id="id_2adbb944" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (loss) on sale of other financial assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainLossOnSaleOfOtherFinancialAssets" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:to="lbl_GainLossOnSaleOfOtherFinancialAssets_labels" xlink:type="arc"/>
      <link:label id="id_24c923e8" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial assets sold</link:label>
      <link:label id="id_334897f4" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments during the year</link:label>
      <link:label id="id_36328be7" xlink:label="lbl_label909282279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remeasurements from defined benefit plans [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RemeasurementsFromDefinedBenefitPlansLineItems" xlink:label="lbl_RemeasurementsFromDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RemeasurementsFromDefinedBenefitPlansLineItems" xlink:to="lbl_label909282279" xlink:type="arc"/>
      <link:label id="id_598b1d0a" xlink:label="lbl_label1502289162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_label1502289162" xlink:type="arc"/>
      <link:label id="id_42afb056" xlink:label="lbl_label1118810198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets and goodwill [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_label1118810198" xlink:type="arc"/>
      <link:label id="id_4854e53b" xlink:label="lbl_GoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GoodwillMember" xlink:to="lbl_GoodwillMember_labels" xlink:type="arc"/>
      <link:label id="id_5a809ba7" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets other than Goodwill</link:label>
      <link:label id="id_6fcb9ca9" xlink:label="lbl_GoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
      <link:label id="id_789924e3" xlink:label="lbl_CurrentlyMarketedProductsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currently marketed products</link:label>
      <link:label id="id_6768eaf7" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketing know-how</link:label>
      <link:label id="id_1878d8ce" xlink:label="lbl_label410573006" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_label410573006" xlink:type="arc"/>
      <link:label id="id_5927b5e9" xlink:label="lbl_IntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="lbl_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IntangibleAssetsAndGoodwill" xlink:to="lbl_IntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_7c0ed12" xlink:label="lbl_IntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill at beginning of period</link:label>
      <link:label id="id_747bc8d6" xlink:label="lbl_IntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill at end of period</link:label>
      <link:label id="id_4eee4a8f" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, intangible assets and goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_4295643b" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_fd8bae8" xlink:label="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers, intangible assets and goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:to="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_2975d791" xlink:label="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
      <link:label id="id_37bb77c5" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_31d55821" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
      <link:label id="id_4b244fff" xlink:label="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals and retirements, intangible assets and goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:label="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:to="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_c2fe7ed" xlink:label="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Disposals and derecognitions</link:label>
      <link:label id="id_13c2a444" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets and goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_7e269b8c" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_3f53b387" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortisation, intangible assets other than goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_AmortisationIntangibleAssetsOtherThanGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_6e93cf7f" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization charge</link:label>
      <link:label id="id_4895c20f" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets and goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_31bd23bf" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge</link:label>
      <link:label id="id_4c0505b8" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_3a8c745b" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversal of impairment charge</link:label>
      <link:label id="id_46823638" xlink:label="lbl_IntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net book value</link:label>
      <link:label id="id_71feba23" xlink:label="lbl_label1912519203" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment consolidation items [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_label1912519203" xlink:type="arc"/>
      <link:label id="id_76bd9383" xlink:label="lbl_label1992135555" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for segment consolidation items [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_label1992135555" xlink:type="arc"/>
      <link:label id="id_e23d9e6" xlink:label="lbl_label237230566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating segments [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OperatingSegmentsMember" xlink:to="lbl_label237230566" xlink:type="arc"/>
      <link:label id="id_4e99f014" xlink:label="lbl_InnovativeMedicinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Innovative Medicines [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InnovativeMedicinesMember" xlink:to="lbl_InnovativeMedicinesMember_labels" xlink:type="arc"/>
      <link:label id="id_5cce9bca" xlink:label="lbl_InnovativeMedicinesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Innovative Medicines</link:label>
      <link:label id="id_62947297" xlink:label="lbl_SandozMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozMember" xlink:to="lbl_SandozMember_labels" xlink:type="arc"/>
      <link:label id="id_2d171b79" xlink:label="lbl_SandozMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sandoz</link:label>
      <link:label id="id_19f7b763" xlink:label="lbl_AlconMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconMember" xlink:to="lbl_AlconMember_labels" xlink:type="arc"/>
      <link:label id="id_82cbe5b" xlink:label="lbl_AlconMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alcon</link:label>
      <link:label id="id_40af0c2d" xlink:label="lbl_label1085213741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unallocated amounts [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnallocatedAmountsMember" xlink:to="lbl_label1085213741" xlink:type="arc"/>
      <link:label id="id_2f427f57" xlink:label="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Growth rate used to extrapolate cash flow projections</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:label="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:to="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_labels" xlink:type="arc"/>
      <link:label id="id_1f6b21d" xlink:label="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Terminal Growth Rate</link:label>
      <link:label id="id_6e31860b" xlink:label="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discount rate used in current measurement of fair value less costs of disposal</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:label="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:to="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal_labels" xlink:type="arc"/>
      <link:label id="id_59daa167" xlink:label="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount Rate (post-tax)</link:label>
      <link:label id="id_32f31c92" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets other than goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_6067b5a3" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment charges</link:label>
      <link:label id="id_6697be1e" xlink:label="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of justification for using growth rate that exceeds long-term average growth rate</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:label="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:to="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate_labels" xlink:type="arc"/>
      <link:label id="id_576cfb66" xlink:label="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of growth rate</link:label>
      <link:label id="id_645c105b" xlink:label="lbl_label1683755099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_label1683755099" xlink:type="arc"/>
      <link:label id="id_86ca8ac" xlink:label="lbl_label141338796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_label141338796" xlink:type="arc"/>
      <link:label id="id_3cced209" xlink:label="lbl_label1020187145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_label1020187145" xlink:type="arc"/>
      <link:label id="id_b0eee5a" xlink:label="lbl_label185527898" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_label185527898" xlink:type="arc"/>
      <link:label id="id_7bf97c21" xlink:label="lbl_EquityBasedParticipationAnnualIncentivePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Annual Incentive Plan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentivePlanMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentivePlanMember_labels" xlink:type="arc"/>
      <link:label id="id_2ae4d862" xlink:label="lbl_EquityBasedParticipationShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Share Savings Plan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlanMember_labels" xlink:type="arc"/>
      <link:label id="id_6fae6c02" xlink:label="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Leveraged Share Savings Plan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember_labels" xlink:type="arc"/>
      <link:label id="id_4b1054ab" xlink:label="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Employee Share Ownership Plan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:label="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:to="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember_labels" xlink:type="arc"/>
      <link:label id="id_28d147a5" xlink:label="lbl_EquityBasedParticipationUKShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation UK Share Savings Plan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationUKShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationUKShareSavingsPlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationUKShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationUKShareSavingsPlanMember_labels" xlink:type="arc"/>
      <link:label id="id_43a6ccb8" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Novartis Equity Plan "Select" [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember_labels" xlink:type="arc"/>
      <link:label id="id_3073fb0" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Long-Term Performance Plan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermPerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:to="lbl_EquityBasedParticipationLongTermPerformancePlanMember_labels" xlink:type="arc"/>
      <link:label id="id_547a9da" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Long Term Relative Performance Plan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:to="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember_labels" xlink:type="arc"/>
      <link:label id="id_1f01ff40" xlink:label="lbl_EquityBasedParticipationSpecialShareAwardsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Special Share Awards [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationSpecialShareAwardsMember" xlink:label="lbl_EquityBasedParticipationSpecialShareAwardsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationSpecialShareAwardsMember" xlink:to="lbl_EquityBasedParticipationSpecialShareAwardsMember_labels" xlink:type="arc"/>
      <link:label id="id_89e9c6a" xlink:label="lbl_label144612458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:label="lbl_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:to="lbl_label144612458" xlink:type="arc"/>
      <link:label id="id_25616927" xlink:label="lbl_label627140903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of method of settlement for share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" xlink:label="lbl_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfMethodOfSettlementForSharebasedPaymentArrangement" xlink:to="lbl_label627140903" xlink:type="arc"/>
      <link:label id="id_7e605438" xlink:label="lbl_label2120242232" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of vesting requirements for share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:label="lbl_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:to="lbl_label2120242232" xlink:type="arc"/>
      <link:label id="id_73de771d" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities from share-based payment transactions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:to="lbl_LiabilitiesFromSharebasedPaymentTransactions2011_labels" xlink:type="arc"/>
      <link:label id="id_41659fd5" xlink:label="lbl_label1097179093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_label1097179093" xlink:type="arc"/>
      <link:label id="id_70e32ac1" xlink:label="lbl_label1893935809" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_label1893935809" xlink:type="arc"/>
      <link:label id="id_1e53f765" xlink:label="lbl_NumberOfOutstandingShareOptions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="lbl_NumberOfOutstandingShareOptions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOutstandingShareOptions" xlink:to="lbl_NumberOfOutstandingShareOptions_labels" xlink:type="arc"/>
      <link:label id="id_71aeacaf" xlink:label="lbl_NumberOfOutstandingShareOptions_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of share options outstanding at beginning of period</link:label>
      <link:label id="id_5962c0d" xlink:label="lbl_NumberOfOutstandingShareOptions_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of share options outstanding at end of period</link:label>
      <link:label id="id_7fce5b76" xlink:label="lbl_label2144230262" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [roll forward]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_label2144230262" xlink:type="arc"/>
      <link:label id="id_3d4fe5a6" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_18341635" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_1df4b58c" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_4c6be67e" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercised or sold</link:label>
      <link:label id="id_476e4360" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options forfeited or expired</link:label>
      <link:label id="id_3c8a636c" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercisable</link:label>
      <link:label id="id_18fcb954" xlink:label="lbl_label419215700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_label419215700" xlink:type="arc"/>
      <link:label id="id_3e8e4697" xlink:label="lbl_label1049511575" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lbl_label1049511575" xlink:type="arc"/>
      <link:label id="id_2cfcdafb" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember_labels" xlink:type="arc"/>
      <link:label id="id_5fb4ce8d" xlink:label="lbl_EquityBasedParticipationRestrictedSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Restricted Shares [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationRestrictedSharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationRestrictedSharesMember" xlink:to="lbl_EquityBasedParticipationRestrictedSharesMember_labels" xlink:type="arc"/>
      <link:label id="id_6a904dd3" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Remeasurements from defined benefit plans, total after tax</link:label>
      <link:label id="id_77782278" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, before taxes, gains (losses) on remeasurements of defined benefit plans</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:type="arc"/>
      <link:label id="id_5e993e53" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit pension plans before tax</link:label>
      <link:label id="id_70219b11" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, before taxes, gains (losses) on remeasurements of other post-employment benefit plans</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" xlink:to="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans_labels" xlink:type="arc"/>
      <link:label id="id_24653928" xlink:label="lbl_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other post-employment benefit plans before tax</link:label>
      <link:label id="id_2e31d75a" xlink:label="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, gains (losses) on remeasurements of defined and other post-employment benefit plans, taxation</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:label="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:to="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation_labels" xlink:type="arc"/>
      <link:label id="id_258900b0" xlink:label="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxation on above items</link:label>
      <link:label id="id_7496cde" xlink:label="lbl_label122252510" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, shares acquired, price</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:label="lbl_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:to="lbl_label122252510" xlink:type="arc"/>
      <link:label id="id_77be955a" xlink:label="lbl_ValueAdjustmentOnComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value adjustment on comprehensive income</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_ValueAdjustmentOnComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_19d019b2" xlink:label="lbl_ValueAdjustmentOnComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Value adjustments on comprehensive income at beginning of period</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_label98094011" xlink:type="arc"/>
      <link:label id="id_53394b08" xlink:label="lbl_label1396263688" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on value adjustment on comprehensive income</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_label1396263688" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:to="lbl_label492438188" xlink:type="arc"/>
      <link:label id="id_5127c80" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total value adjustments attributable to Novartis shareholders [Member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember_labels" xlink:type="arc"/>
      <link:label id="id_11f1c5d1" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total value adjustments</link:label>
      <link:label id="id_4fa34414" xlink:label="lbl_label1336099860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon, Inc., equity plan, converted, Novartis share options [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:label="lbl_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:to="lbl_label1336099860" xlink:type="arc"/>
      <link:label id="id_47c79757" xlink:label="lbl_label1204262743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon, Inc., equity plan, converted, Share-settled appreciation rights (SSAR) [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:label="lbl_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:to="lbl_label1204262743" xlink:type="arc"/>
      <link:label id="id_5c4a8ca3" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercised</link:label>
      <link:label id="id_5368a3e4" xlink:label="lbl_label1399366628" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of unvested restricted stock units roll forward [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:to="lbl_label1399366628" xlink:type="arc"/>
      <link:label id="id_2ded6718" xlink:label="lbl_EquityBasedParticipationAnnualIncentivePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual incentive</link:label>
      <link:label id="id_5e84f23d" xlink:label="lbl_EquityBasedParticipationShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share savings plans</link:label>
      <link:label id="id_47fd4dbd" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Select</link:label>
      <link:label id="id_779d196a" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Performance Plan</link:label>
      <link:label id="id_39c41311" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Relative Performance Plan</link:label>
      <link:label id="id_1cf8204b" xlink:label="lbl_EquityBasedParticipationSpecialShareAwardsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Special share awards</link:label>
      <link:label id="id_4b5d1837" xlink:label="lbl_label679367036" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value at grante date at end of period</link:label>
      <link:label id="id_569121e3" xlink:label="lbl_label1373999706" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested, fair value at grante date</link:label>
      <link:label id="id_6bf6969c" xlink:label="lbl_label766376780" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited, fair value at grante date</link:label>
      <link:label id="id_6a253a0a" xlink:label="lbl_label1695476906" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted, fair value at grante date</link:label>
      <link:label id="id_5dafe477" xlink:label="lbl_label1571808375" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_label1571808375" xlink:type="arc"/>
      <link:label id="id_64b72c46" xlink:label="lbl_label1689726022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_label1689726022" xlink:type="arc"/>
      <link:label id="id_195ec04a" xlink:label="lbl_label425640010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_label425640010" xlink:type="arc"/>
      <link:label id="id_776b087e" xlink:label="lbl_label2003503230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material reconciling items [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaterialReconcilingItemsMember" xlink:to="lbl_label2003503230" xlink:type="arc"/>
      <link:label id="id_13fb62a8" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, sales to other segments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments_labels" xlink:type="arc"/>
      <link:label id="id_71f1654a" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales to discontinued segment</link:label>
      <link:label id="id_425f6b3f" xlink:label="lbl_label1113549631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromInterest" xlink:label="lbl_RevenueFromInterest" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromInterest" xlink:to="lbl_label1113549631" xlink:type="arc"/>
      <link:label id="id_6ed59bdd" xlink:label="lbl_DepreciationAndAmortisationExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortisation expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="lbl_DepreciationAndAmortisationExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationAndAmortisationExpense" xlink:to="lbl_DepreciationAndAmortisationExpense_labels" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:to="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet_labels" xlink:type="arc"/>
      <link:label id="id_60788cbc" xlink:label="lbl_Liabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
      <link:label id="id_2bf65413" xlink:label="lbl_NetOperatingAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net operating assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetOperatingAssets" xlink:label="lbl_NetOperatingAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetOperatingAssets" xlink:to="lbl_NetOperatingAssets_labels" xlink:type="arc"/>
      <link:label id="id_3832e6c2" xlink:label="lbl_NetOperatingAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net operating assets</link:label>
      <link:label id="id_216a6d7c" xlink:label="lbl_PurchaseOfInterestsInAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of interests in associates</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfInterestsInAssociates" xlink:label="lbl_PurchaseOfInterestsInAssociates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfInterestsInAssociates" xlink:to="lbl_PurchaseOfInterestsInAssociates_labels" xlink:type="arc"/>
      <link:label id="id_41f96a5e" xlink:label="lbl_PurchaseOfInterestsInAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions to investment in associated companies</link:label>
      <link:label id="id_5e202521" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:to="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments_labels" xlink:type="arc"/>
      <link:label id="id_3b72597a" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial debts and derivative instruments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialDebtsAndDerivativeInstruments" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialDebtsAndDerivativeInstruments" xlink:to="lbl_FinancialDebtsAndDerivativeInstruments_labels" xlink:type="arc"/>
      <link:label id="id_6e43b10" xlink:label="lbl_label1241182885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current income tax liabilities and deferred tax liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:label="lbl_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:to="lbl_label1241182885" xlink:type="arc"/>
      <link:label id="id_2c7e10a7" xlink:label="lbl_label102429242" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales (in % of total net sales)</link:label>
      <link:label id="id_7f20a04d" xlink:label="lbl_SelectedNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total of selected non-current assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SelectedNoncurrentAssets" xlink:to="lbl_SelectedNoncurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_615b5ab6" xlink:label="lbl_SelectedNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies</link:label>
      <link:label id="id_46b9a3b0" xlink:label="lbl_label1358337308" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies. As percent of total selected non-current assets.</link:label>
      <link:label id="id_439913bb" xlink:label="lbl_label1134105531" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
      <link:label id="id_557072dd" xlink:label="lbl_label1433432797" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other countries [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCountriesMember" xlink:label="lbl_OtherCountriesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCountriesMember" xlink:to="lbl_label1433432797" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCountriesMember" xlink:to="lbl_label1134105531" xlink:type="arc"/>
      <link:label id="id_56b7dac7" xlink:label="lbl_label1638353244" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asia/Africa/Australasia [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AsiaAfricaAustralasiaMember" xlink:label="lbl_AsiaAfricaAustralasiaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AsiaAfricaAustralasiaMember" xlink:to="lbl_label1638353244" xlink:type="arc"/>
      <link:label id="id_7ec1f871" xlink:label="lbl_label2126641265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of entity's revenue</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="lbl_PercentageOfEntitysRevenue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfEntitysRevenue" xlink:to="lbl_label2126641265" xlink:type="arc"/>
      <link:label id="id_4a42fa89" xlink:label="lbl_label1245903497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of major customers [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersAbstract" xlink:label="lbl_DisclosureOfMajorCustomersAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMajorCustomersAbstract" xlink:to="lbl_label1245903497" xlink:type="arc"/>
      <link:label id="id_77148ff4" xlink:label="lbl_label1997836276" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of major customers [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersTable" xlink:label="lbl_DisclosureOfMajorCustomersTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMajorCustomersTable" xlink:to="lbl_label1997836276" xlink:type="arc"/>
      <link:label id="id_3a785089" xlink:label="lbl_label980963465" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of major customers [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:label="lbl_DisclosureOfMajorCustomersLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_label980963465" xlink:type="arc"/>
      <link:label id="id_7a5a32d3" xlink:label="lbl_label2052731603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major customers [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="lbl_MajorCustomersAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MajorCustomersAxis" xlink:to="lbl_label2052731603" xlink:type="arc"/>
      <link:label id="id_54ab46d" xlink:label="lbl_label88781933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customers [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="lbl_MajorCustomersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_label88781933" xlink:type="arc"/>
      <link:label id="id_329eef9f" xlink:label="lbl_label849276831" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Largest customer [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LargestCustomerMember" xlink:label="lbl_LargestCustomerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LargestCustomerMember" xlink:to="lbl_label849276831" xlink:type="arc"/>
      <link:label id="id_3eacc0a0" xlink:label="lbl_label1051508896" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second largest customer [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SecondLargestCustomerMember" xlink:label="lbl_SecondLargestCustomerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SecondLargestCustomerMember" xlink:to="lbl_label1051508896" xlink:type="arc"/>
      <link:label id="id_54e36398" xlink:label="lbl_label1424188312" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third largest customer [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ThirdLargestCustomerMember" xlink:label="lbl_ThirdLargestCustomerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ThirdLargestCustomerMember" xlink:to="lbl_label1424188312" xlink:type="arc"/>
      <link:label id="id_51bc0ac2" xlink:label="lbl_DisclosureOfEntitysReportableSegmentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of entity's operating segments [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:label="lbl_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="lbl_DisclosureOfEntitysReportableSegmentsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_76ba88df" xlink:label="lbl_DisclosureOfEntitysReportableSegmentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segmentation of key figures</link:label>
      <link:label id="id_596e3d72" xlink:label="lbl_DisclosureOfOperatingSegmentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:to="lbl_DisclosureOfOperatingSegmentsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_3d44b3a2" xlink:label="lbl_DisclosureOfOperatingSegmentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segmentation - Consolidated income statements</link:label>
      <link:label id="id_910173d" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, balance sheet [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:to="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_f1f9461" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segmentation - Consolidated balance sheets</link:label>
      <link:label id="id_68241853" xlink:label="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, by countries and regions [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:to="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_8ba3eb7" xlink:label="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales and total of selected non-current assets, by countries and regions</link:label>
      <link:label id="id_11d66710" xlink:label="lbl_label1965771458" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales</link:label>
      <link:label id="id_1b7ab5f2" xlink:label="lbl_label461026802" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="lbl_label461026802" xlink:type="arc"/>
      <link:label id="id_15494420" xlink:label="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of investments accounted for using equity method [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:label="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_2bcfd6a6" xlink:label="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Associated companies</link:label>
      <link:label id="id_113707b2" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_38388c12" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to associates</link:label>
      <link:label id="id_27f02648" xlink:label="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates balance sheet [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:label="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:to="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_ebb669f" xlink:label="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to associates, balance sheet value</link:label>
      <link:label id="id_52795c5f" xlink:label="lbl_AssociatesSummarizedFinancialInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associates summarized financial information [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:label="lbl_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:to="lbl_AssociatesSummarizedFinancialInformationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6a736cd0" xlink:label="lbl_PurchasePriceAllocationAssociatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase price allocation associates [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PurchasePriceAllocationAssociatesTableTextBlock" xlink:label="lbl_PurchasePriceAllocationAssociatesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchasePriceAllocationAssociatesTableTextBlock" xlink:to="lbl_PurchasePriceAllocationAssociatesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_467a3bcc" xlink:label="lbl_label1182415820" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_label1182415820" xlink:type="arc"/>
      <link:label id="id_3a1d7e" xlink:label="lbl_label3808638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_label3808638" xlink:type="arc"/>
      <link:label id="id_6360193f" xlink:label="lbl_RocheHoldingAGMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Roche Holding AG, Switzerland</link:label>
      <link:label id="id_5e0c8ce9" xlink:label="lbl_label1577880809" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK</link:label>
      <link:label id="id_197b34b2" xlink:label="lbl_label427504818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline Consumer Healthcare Holdings Ltd. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:to="lbl_label427504818" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:to="lbl_label1577880809" xlink:type="arc"/>
      <link:label id="id_49715fd2" xlink:label="lbl_OthersAssociatesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Others associates [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OthersAssociatesMember" xlink:to="lbl_OthersAssociatesMember_labels" xlink:type="arc"/>
      <link:label id="id_4dbe4327" xlink:label="lbl_OthersAssociatesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Others</link:label>
      <link:label id="id_54a1c758" xlink:label="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of total comprehensive income of associates and joint ventures accounted for using equity method</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:to="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:type="arc"/>
      <link:label id="id_33c07958" xlink:label="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive income effect</link:label>
      <link:label id="id_4b6b0442" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Balance sheet value</link:label>
      <link:label id="id_2f5ba89e" xlink:label="lbl_label794536094" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in associate</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="lbl_ProportionOfOwnershipInterestInAssociate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProportionOfOwnershipInterestInAssociate" xlink:to="lbl_label794536094" xlink:type="arc"/>
      <link:label id="id_5dfb85ae" xlink:label="lbl_label1576764846" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends received</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsReceived" xlink:label="lbl_DividendsReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsReceived" xlink:to="lbl_label1576764846" xlink:type="arc"/>
      <link:label id="id_6e7640ef" xlink:label="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revaluation increase (decrease), intangible assets other than goodwil</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_20824625" xlink:label="lbl_RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis share of re-appraised intangible assets</link:label>
      <link:label id="id_3ec70a2" xlink:label="lbl_AdditionalRecognitionGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Implicit Novartis goodwill</link:label>
      <link:label id="id_2f773be1" xlink:label="lbl_ShareOfEstimatedNetAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of estimated net assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShareOfEstimatedNetAssets" xlink:label="lbl_ShareOfEstimatedNetAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareOfEstimatedNetAssets" xlink:to="lbl_ShareOfEstimatedNetAssets_labels" xlink:type="arc"/>
      <link:label id="id_7ae8d097" xlink:label="lbl_ShareOfEstimatedNetAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis share of estimated net assets</link:label>
      <link:label id="id_df32051" xlink:label="lbl_label234037329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current value of share in net identifiable assets and goodwill</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" xlink:label="lbl_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" xlink:to="lbl_label234037329" xlink:type="arc"/>
      <link:label id="id_2274c64a" xlink:label="lbl_label578078282" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated equity accounting adjustments and translation effects less dividends received</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" xlink:label="lbl_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" xlink:to="lbl_label578078282" xlink:type="arc"/>
      <link:label id="id_4dcb8141" xlink:label="lbl_label1305182529" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated income statement effects [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsolidatedIncomeStatementEffectsTable" xlink:label="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:to="lbl_label1305182529" xlink:type="arc"/>
      <link:label id="id_139af9b9" xlink:label="lbl_label328923577" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis share of current year consolidated net income</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShareOfCurrentYearNetIncome" xlink:label="lbl_ShareOfCurrentYearNetIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareOfCurrentYearNetIncome" xlink:to="lbl_label328923577" xlink:type="arc"/>
      <link:label id="id_9a810fe" xlink:label="lbl_label162009342" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior year adjustment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PriorYearAdjustment" xlink:label="lbl_PriorYearAdjustment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PriorYearAdjustment" xlink:to="lbl_label162009342" xlink:type="arc"/>
      <link:label id="id_78fa72de" xlink:label="lbl_label2029679326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of fair value adjustments relating to intangible assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:label="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:to="lbl_label2029679326" xlink:type="arc"/>
      <link:label id="id_691026f" xlink:label="lbl_label110166639" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes on Amortization of fair value adjustments relating to intangible assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:label="lbl_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:to="lbl_label110166639" xlink:type="arc"/>
      <link:label id="id_7f5dcb1f" xlink:label="lbl_label2136853279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about provisions and non-current liabilities [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_label2136853279" xlink:type="arc"/>
      <link:label id="id_ff7eee9" xlink:label="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions, contingent liabilities and contingent assets [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:label="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:to="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_3d543140" xlink:label="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other non-current liabilities</link:label>
      <link:label id="id_55d4757f" xlink:label="lbl_label1439987071" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:label="lbl_DisclosureOfOtherProvisionsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherProvisionsExplanatory" xlink:to="lbl_label1439987071" xlink:type="arc"/>
      <link:label id="id_5b6a3526" xlink:label="lbl_label1533687078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccrualForEnvironmentalLossContingenciesTableTextBlock" xlink:label="lbl_AccrualForEnvironmentalLossContingenciesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccrualForEnvironmentalLossContingenciesTableTextBlock" xlink:to="lbl_label1533687078" xlink:type="arc"/>
      <link:label id="id_60a92ef1" xlink:label="lbl_label1621700337" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, fiscal year maturity [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" xlink:label="lbl_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" xlink:to="lbl_label1621700337" xlink:type="arc"/>
      <link:label id="id_345b34eb" xlink:label="lbl_label878392555" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for product liabilities government investigations other legal matters loss contingencies [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" xlink:label="lbl_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" xlink:to="lbl_label878392555" xlink:type="arc"/>
      <link:label id="id_48374a1f" xlink:label="lbl_label1211583007" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_label1211583007" xlink:type="arc"/>
      <link:label id="id_31459c86" xlink:label="lbl_label826645638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other provisions [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_label826645638" xlink:type="arc"/>
      <link:label id="id_2ad08cd6" xlink:label="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current net defined benefit liability</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:label="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:to="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_labels" xlink:type="arc"/>
      <link:label id="id_7487a2cd" xlink:label="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit pension plans</link:label>
      <link:label id="id_74710a33" xlink:label="lbl_label1953565235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other long-term employee benefits and deferred compensation</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:label="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:to="lbl_label1953565235" xlink:type="arc"/>
      <link:label id="id_26d5ce13" xlink:label="lbl_label651546131" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other post-employment benefits</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefits" xlink:label="lbl_OtherPostemploymentBenefits" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherPostemploymentBenefits" xlink:to="lbl_label651546131" xlink:type="arc"/>
      <link:label id="id_70976fa3" xlink:label="lbl_label304425068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental remediation provisions, non-current</link:label>
      <link:label id="id_5e14a65" xlink:label="lbl_label98650725" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
      <link:label id="id_5ed0917e" xlink:label="lbl_label1590727038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision [roll forward]</link:label>
      <link:label id="id_6aa8f98d" xlink:label="lbl_label448335871" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash payments</link:label>
      <link:label id="id_70108f36" xlink:label="lbl_label2143979670" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Releases</link:label>
      <link:label id="id_52a74241" xlink:label="lbl_label1560928630" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
      <link:label id="id_57e9d2a0" xlink:label="lbl_label42481781" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_5d09f298" xlink:label="lbl_label1902698328" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less current provision</link:label>
      <link:label id="id_6048622c" xlink:label="lbl_label1615356460" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision, fiscal year maturity [abstract]</link:label>
      <link:label id="id_f98ea01" xlink:label="lbl_label1750372676" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total environmental remediation liability provisions</link:label>
      <link:label id="id_2ccb9fb2" xlink:label="lbl_label1351152500" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due within two years</link:label>
      <link:label id="id_78ad40b" xlink:label="lbl_label771700847" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due later than two years, but within five years</link:label>
      <link:label id="id_7cc5fad5" xlink:label="lbl_label1968177093" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due later than five years, but within ten years</link:label>
      <link:label id="id_6e61547b" xlink:label="lbl_label757561900" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after ten years</link:label>
      <link:label id="id_4bc380f7" xlink:label="lbl_label1271103735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions [roll forward]</link:label>
      <link:label id="id_68422c0a" xlink:label="lbl_label1583004694" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions related to discontinued operations</link:label>
      <link:label id="id_efc629e" xlink:label="lbl_label1339267684" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash payments</link:label>
      <link:label id="id_6285ec7c" xlink:label="lbl_label1568927014" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Releases</link:label>
      <link:label id="id_3f37b15b" xlink:label="lbl_label1379712140" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
      <link:label id="id_50e2f2bd" xlink:label="lbl_label1424862979" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_73b301e7" xlink:label="lbl_label252843510" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Product liabilities government investigations other legal matters provisions at end of period</link:label>
      <link:label id="id_29a7abc" xlink:label="lbl_label438797926" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less current provision</link:label>
      <link:label id="id_2ace6c03" xlink:label="lbl_label1363494370" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-current product liabilities, governmental investigations and other legal matters provisions at end of period</link:label>
      <link:label id="id_39eddf10" xlink:label="lbl_label971890448" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal proceedings provision [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LegalProceedingsProvisionMember" xlink:label="lbl_LegalProceedingsProvisionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LegalProceedingsProvisionMember" xlink:to="lbl_label971890448" xlink:type="arc"/>
      <link:label id="id_1f2f7122" xlink:label="lbl_label523202850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Solodyn [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SolodynMember" xlink:label="lbl_SolodynMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SolodynMember" xlink:to="lbl_label523202850" xlink:type="arc"/>
      <link:label id="id_10d3ac94" xlink:label="lbl_label282307732" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contact Lenses [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContactLensesMember" xlink:label="lbl_ContactLensesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContactLensesMember" xlink:to="lbl_label282307732" xlink:type="arc"/>
      <link:label id="id_3e0809a2" xlink:label="lbl_label1040714146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gleevec [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GleevecMember" xlink:label="lbl_GleevecMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GleevecMember" xlink:to="lbl_label1040714146" xlink:type="arc"/>
      <link:label id="id_7edbae34" xlink:label="lbl_label2128326196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclast/Aclasta [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclastAclastaMember" xlink:label="lbl_ReclastAclastaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclastAclastaMember" xlink:to="lbl_label2128326196" xlink:type="arc"/>
      <link:label id="id_2b94eceb" xlink:label="lbl_label731180267" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tekturna/Rasilez/Valturna [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TekturnaRasilezValturnaMember" xlink:label="lbl_TekturnaRasilezValturnaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TekturnaRasilezValturnaMember" xlink:to="lbl_label731180267" xlink:type="arc"/>
      <link:label id="id_6962e490" xlink:label="lbl_label1392715101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NAG and Novartis Pharma SpA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NAGAndNovartisPharmaSpAMember" xlink:label="lbl_NAGAndNovartisPharmaSpAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NAGAndNovartisPharmaSpAMember" xlink:to="lbl_label1392715101" xlink:type="arc"/>
      <link:label id="id_13f125ec" xlink:label="lbl_label400121727" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">F Hoffman La Roche AG and Roche SpA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FHoffmanLaRocheAGAndRocheSpAMember" xlink:label="lbl_FHoffmanLaRocheAGAndRocheSpAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FHoffmanLaRocheAGAndRocheSpAMember" xlink:to="lbl_label400121727" xlink:type="arc"/>
      <link:label id="id_5ce126b6" xlink:label="lbl_label1365859055" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma K.K. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaKKMember" xlink:label="lbl_NovartisPharmaKKMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaKKMember" xlink:to="lbl_label1365859055" xlink:type="arc"/>
      <link:label id="id_4f6a2c55" xlink:label="lbl_label1494155554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NAG [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NAGMember" xlink:label="lbl_NAGMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NAGMember" xlink:to="lbl_label1494155554" xlink:type="arc"/>
      <link:label id="id_514c724a" xlink:label="lbl_label201735145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NPC and others [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NPCAndOthersMember" xlink:label="lbl_NPCAndOthersMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NPCAndOthersMember" xlink:to="lbl_label201735145" xlink:type="arc"/>
      <link:label id="id_41e7b3b9" xlink:label="lbl_label770853776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis NC [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNCMember" xlink:label="lbl_NovartisNCMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNCMember" xlink:to="lbl_label770853776" xlink:type="arc"/>
      <link:label id="id_51394769" xlink:label="lbl_label1362708329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability contingency, loss exposure not accrued, number of cases</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:label="lbl_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:to="lbl_label1362708329" xlink:type="arc"/>
      <link:label id="id_241b918a" xlink:label="lbl_label605786506" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability contingency, loss exposure not accrued, best estimate</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:label="lbl_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:to="lbl_label605786506" xlink:type="arc"/>
      <link:label id="id_2225e7d2" xlink:label="lbl_label572909522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated financial effect of contingent liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstimatedFinancialEffectOfContingentLiabilities" xlink:to="lbl_label572909522" xlink:type="arc"/>
      <link:label id="id_7a029719" xlink:label="lbl_label2046990105" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of obligation contingent liabilities, number of legal questions referred to court</link:label>
      <link:label id="id_5477d4dd" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated financial effect of contingent liabilities, maximum fine</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine_labels" xlink:type="arc"/>
      <link:label id="id_4b15d12d" xlink:label="lbl_label1259721005" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of obligation contingent liabilities, number of putative cases referred to court</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:to="lbl_label1259721005" xlink:type="arc"/>
      <link:label id="id_2dbbe7e6" xlink:label="lbl_label767289318" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of obligation contingent liabilities, number of other cases referred to court</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:to="lbl_label767289318" xlink:type="arc"/>
      <link:label id="id_2ca8b224" xlink:label="lbl_label749253156" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of obligation contingent liabilities, number of states with alleged violations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:to="lbl_label749253156" xlink:type="arc"/>
      <link:label id="id_5f79ad81" xlink:label="lbl_label1601809793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of obligation contingent liabilities, number of cases still pending</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:to="lbl_label1601809793" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:to="lbl_label2046990105" xlink:type="arc"/>
      <link:label id="id_206c121e" xlink:label="lbl_label543953438" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Revenue" xlink:label="lbl_Revenue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Revenue" xlink:to="lbl_label543953438" xlink:type="arc"/>
      <link:label id="id_16a8694f" xlink:label="lbl_label380135759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.800% USD 1'000 million 2017/2020 of Novartis Capital Corporation, New York, United States, issued at 99.609% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:label="lbl_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:to="lbl_label380135759" xlink:type="arc"/>
      <link:label id="id_37595e6f" xlink:label="lbl_label928603759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.400% USD 1'000 million 2017/2022 of Novartis Capital Corporation, New York, United States, issued at 99.449% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:label="lbl_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:to="lbl_label928603759" xlink:type="arc"/>
      <link:label id="id_3742c395" xlink:label="lbl_label927122325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.100% USD 1'000 million 2017/2027 of Novartis Capital Corporation, New York, United States, issued at 99.109% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:label="lbl_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:to="lbl_label927122325" xlink:type="arc"/>
      <link:label id="id_5358e820" xlink:label="lbl_label1398335520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.000% EUR 1'250 million 2017/2021 of Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.133% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:label="lbl_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:to="lbl_label1398335520" xlink:type="arc"/>
      <link:label id="id_7779807a" xlink:label="lbl_label2004451450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.125% EUR 600 million 2017/2027 of Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.874% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:label="lbl_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:to="lbl_label2004451450" xlink:type="arc"/>
      <link:label id="id_2af5dc98" xlink:label="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transactions with former members of the Board of Directors [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" xlink:label="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" xlink:to="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3ade93c7" xlink:label="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transactions with former members of the Board of Directors</link:label>
      <link:label id="id_3e931ad0" xlink:label="lbl_TotalFairValueAdjustmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total fair value adjustments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalFairValueAdjustmentsMember" xlink:label="lbl_TotalFairValueAdjustmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TotalFairValueAdjustmentsMember" xlink:to="lbl_TotalFairValueAdjustmentsMember_labels" xlink:type="arc"/>
      <link:label id="id_5fef6f2d" xlink:label="lbl_TotalFairValueAdjustmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value adjustments</link:label>
      <link:label id="id_2b0a5355" xlink:label="lbl_CurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Provisions at beginning of period</link:label>
      <link:label id="id_7633694e" xlink:label="lbl_CurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Provisions at end of period</link:label>
      <link:label id="id_55d5426d" xlink:label="lbl_label1440039533" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current prepaid expenses, third party</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPrepaidExpensesThirdParty" xlink:label="lbl_CurrentPrepaidExpensesThirdParty" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPrepaidExpensesThirdParty" xlink:to="lbl_label1440039533" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPrepaidExpensesThirdParty" xlink:to="lbl_label905656156" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract1" xlink:type="locator"/>
      <link:label id="id_4ecd5cc2" xlink:label="lbl_label1322081474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [abstract]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract1" xlink:to="lbl_label1322081474" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:type="locator"/>
      <link:label id="id_3ada3bfa" xlink:label="lbl_label987380730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [line items]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:to="lbl_label987380730" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:type="locator"/>
      <link:label id="id_7e01564" xlink:label="lbl_label132126052" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for non-derivative financial liabilities [table]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:to="lbl_label132126052" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember1" xlink:type="locator"/>
      <link:label id="id_545eb47a" xlink:label="lbl_label1415492730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one month and not later than three months [member]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember1" xlink:to="lbl_label1415492730" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="lbl_LaterThanOneYearMember1" xlink:type="locator"/>
      <link:label id="id_7cfc55ea" xlink:label="lbl_label2096911850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year [member]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanOneYearMember1" xlink:to="lbl_label2096911850" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:label="lbl_LaterThanSixMonthsAndNotLaterThanOneYearMember1" xlink:type="locator"/>
      <link:label id="id_22980743" xlink:label="lbl_label580388675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than six months and not later than one year [member]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanSixMonthsAndNotLaterThanOneYearMember1" xlink:to="lbl_label580388675" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:label="lbl_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember1" xlink:type="locator"/>
      <link:label id="id_1f823f0f" xlink:label="lbl_label528629519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than three months and not later than six months [member]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember1" xlink:to="lbl_label528629519" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="lbl_NotLaterThanOneMonthMember" xlink:type="locator"/>
      <link:label id="id_1d54f07" xlink:label="lbl_label30756615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one month [member]</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NotLaterThanOneMonthMember" xlink:to="lbl_label30756615" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="lbl_OtherNoncurrentLiabilities1" xlink:type="locator"/>
      <link:label id="id_69518" xlink:label="lbl_label431384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentLiabilities1" xlink:to="lbl_label431384" xlink:type="arc"/>
      <link:label id="id_7b946bcb" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Past service cost and gains losses arising from settlements, net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset1" xlink:to="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_11be10a7" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Past service cost and settlements</link:label>
      <link:label id="id_529b4b2a" xlink:label="lbl_TaxRateEffectFromChangeInTaxRate_labels1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect from change in tax rate</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:label="lbl_TaxRateEffectFromChangeInTaxRate1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromChangeInTaxRate1" xlink:to="lbl_TaxRateEffectFromChangeInTaxRate_labels1" xlink:type="arc"/>
      <link:label id="id_9416195" xlink:label="lbl_TaxRateEffectFromChangeInTaxRate_labels1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of tax rate change on current and deferred tax assets and liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss1" xlink:type="locator"/>
      <link:label id="id_753a14cc" xlink:label="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of expense not deductible in determining taxable profit tax loss</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss1" xlink:to="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_labels" xlink:type="arc"/>
      <link:label id="id_4ff9c19a" xlink:label="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of disallowed expenditures</link:label>
      <link:label id="id_72f99baf" xlink:label="lbl_TaxRateEffectOfTaxLosses_labels1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of tax losses</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfTaxLosses" xlink:label="lbl_TaxRateEffectOfTaxLosses1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfTaxLosses1" xlink:to="lbl_TaxRateEffectOfTaxLosses_labels1" xlink:type="arc"/>
      <link:label id="id_3858f2af" xlink:label="lbl_TaxRateEffectOfTaxLosses_labels1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of utilization of tax losses brought forward from prior periods</link:label>
      <link:label id="id_6100ccc9" xlink:label="lbl_OtherExpenseByFunction_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherExpenseByFunction" xlink:to="lbl_OtherExpenseByFunction_labels" xlink:type="arc"/>
      <link:label id="id_7b7f0633" xlink:label="lbl_OtherExpenseByFunction_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other expense, by function</link:label>
      <link:label id="id_295deb1d" xlink:label="lbl_label694020893" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Par value per share</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="lbl_ParValuePerShare" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ParValuePerShare" xlink:to="lbl_label694020893" xlink:type="arc"/>
      <link:label id="id_223c2b0a" xlink:label="lbl_OtherCurrentNonfinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
      <link:label id="id_7418af90" xlink:label="lbl_OtherCurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, commodities, time deposits and derivative financial instruments</link:label>
      <link:label id="id_7592952b" xlink:label="lbl_OtherCurrentFinancialAssets_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total marketable securities, commodities, time deposits and derivative financial instruments</link:label>
      <link:label id="id_6a995f9c" xlink:label="lbl_label1788436380" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxotere [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxotereMember" xlink:label="lbl_TaxotereMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxotereMember" xlink:to="lbl_label1788436380" xlink:type="arc"/>
      <link:label id="id_578eb571" xlink:label="lbl_label1468970353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amiodarone [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmiodaroneMember" xlink:label="lbl_AmiodaroneMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmiodaroneMember" xlink:to="lbl_label1468970353" xlink:type="arc"/>
      <link:label id="id_3bc6fd49" xlink:label="lbl_label1002896713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of equity [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfEquityAbstract" xlink:label="lbl_DisclosureOfEquityAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfEquityAbstract" xlink:to="lbl_label1002896713" xlink:type="arc"/>
      <link:label id="id_5120693" xlink:label="lbl_DisclosureOfEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of equity [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfEquityTextBlock" xlink:label="lbl_DisclosureOfEquityTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfEquityTextBlock" xlink:to="lbl_DisclosureOfEquityTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6726d861" xlink:label="lbl_DisclosureOfEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
      <link:label id="id_3dc60187" xlink:label="lbl_DividendTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DividendTableTextBlock" xlink:label="lbl_DividendTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendTableTextBlock" xlink:to="lbl_DividendTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_258e3af2" xlink:label="lbl_DividendTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to Dividend</link:label>
      <link:label id="id_cb435c9" xlink:label="lbl_label213136841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="lbl_AmendmentFlag" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmendmentFlag" xlink:to="lbl_label213136841" xlink:type="arc"/>
      <link:label id="id_5d388f3d" xlink:label="lbl_label1563987773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="lbl_DocumentPeriodEndDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentPeriodEndDate" xlink:to="lbl_label1563987773" xlink:type="arc"/>
      <link:label id="id_1e619d64" xlink:label="lbl_label509713764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="lbl_DocumentFiscalYearFocus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentFiscalYearFocus" xlink:to="lbl_label509713764" xlink:type="arc"/>
      <link:label id="id_7fb4d619" xlink:label="lbl_label2142557721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="lbl_DocumentFiscalPeriodFocus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentFiscalPeriodFocus" xlink:to="lbl_label2142557721" xlink:type="arc"/>
      <link:label id="id_29f6dab9" xlink:label="lbl_label704043705" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="lbl_TradingSymbol" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradingSymbol" xlink:to="lbl_label704043705" xlink:type="arc"/>
      <link:label id="id_30c984d" xlink:label="lbl_label51157069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="lbl_EntityRegistrantName" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityRegistrantName" xlink:to="lbl_label51157069" xlink:type="arc"/>
      <link:label id="id_387f1769" xlink:label="lbl_label947853161" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="lbl_EntityCentralIndexKey" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityCentralIndexKey" xlink:to="lbl_label947853161" xlink:type="arc"/>
      <link:label id="id_6f6c1fbf" xlink:label="lbl_label1869356991" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="lbl_CurrentFiscalYearEndDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentFiscalYearEndDate" xlink:to="lbl_label1869356991" xlink:type="arc"/>
      <link:label id="id_6f81ea6f" xlink:label="lbl_label1870785135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="lbl_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityWellKnownSeasonedIssuer" xlink:to="lbl_label1870785135" xlink:type="arc"/>
      <link:label id="id_593907e" xlink:label="lbl_label93556862" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="lbl_EntityCurrentReportingStatus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityCurrentReportingStatus" xlink:to="lbl_label93556862" xlink:type="arc"/>
      <link:label id="id_a350bde" xlink:label="lbl_label171248606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="lbl_EntityVoluntaryFilers" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityVoluntaryFilers" xlink:to="lbl_label171248606" xlink:type="arc"/>
      <link:label id="id_1ebbff8e" xlink:label="lbl_label515637134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="lbl_EntityFilerCategory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityFilerCategory" xlink:to="lbl_label515637134" xlink:type="arc"/>
      <link:label id="id_2df8f48d" xlink:label="lbl_label771290253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="lbl_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityCommonStockSharesOutstanding" xlink:to="lbl_label771290253" xlink:type="arc"/>
      <link:label id="id_6a10c99a" xlink:label="lbl_label1779485082" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="lbl_EntityPublicFloat" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityPublicFloat" xlink:to="lbl_label1779485082" xlink:type="arc"/>
      <link:label id="id_60ad1327" xlink:label="lbl_US_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_US" xlink:to="lbl_US_labels" xlink:type="arc"/>
      <link:label id="id_45b4f0b8" xlink:label="lbl_GB_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED KINGDOM</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="lbl_GB" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GB" xlink:to="lbl_GB_labels" xlink:type="arc"/>
      <link:label id="id_fa4133c" xlink:label="lbl_DE_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GERMANY</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="lbl_DE" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DE" xlink:to="lbl_DE_labels" xlink:type="arc"/>
      <link:label id="id_4fab4920" xlink:label="lbl_FR_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FRANCE</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR" xlink:label="lbl_FR" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FR" xlink:to="lbl_FR_labels" xlink:type="arc"/>
      <link:label id="id_2409370a" xlink:label="lbl_JP_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP" xlink:label="lbl_JP" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_JP" xlink:to="lbl_JP_labels" xlink:type="arc"/>
      <link:label id="id_7e84627" xlink:label="lbl_US_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US</link:label>
      <link:label id="id_35cc0588" xlink:label="lbl_GB_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UK</link:label>
      <link:label id="id_11499416" xlink:label="lbl_DE_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Germany</link:label>
      <link:label id="id_50732a2" xlink:label="lbl_FR_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">France</link:label>
      <link:label id="id_16ecebec" xlink:label="lbl_JP_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan</link:label>
      <link:label id="id_47d2ec01" xlink:label="lbl_IT_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ITALY</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT" xlink:label="lbl_IT" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IT" xlink:to="lbl_IT_labels" xlink:type="arc"/>
      <link:label id="id_3b372d9d" xlink:label="lbl_IT_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Italy</link:label>
      <link:label id="id_53d1a5ee" xlink:label="lbl_CA_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CANADA</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA" xlink:label="lbl_CA" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CA" xlink:to="lbl_CA_labels" xlink:type="arc"/>
      <link:label id="id_68cbde64" xlink:label="lbl_CA_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canada</link:label>
      <link:label id="id_87623f2" xlink:label="lbl_USD_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United States of America, Dollars</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="lbl_USD" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_USD" xlink:to="lbl_USD_labels" xlink:type="arc"/>
      <link:label id="id_73a7c19e" xlink:label="lbl_USD_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">USD</link:label>
      <link:label id="id_78126268" xlink:label="lbl_EUR_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="lbl_EUR" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EUR" xlink:to="lbl_EUR_labels" xlink:type="arc"/>
      <link:label id="id_70708ef7" xlink:label="lbl_EUR_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EUR</link:label>
      <link:label id="id_12746a38" xlink:label="lbl_JPY_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY" xlink:label="lbl_JPY" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_JPY" xlink:to="lbl_JPY_labels" xlink:type="arc"/>
      <link:label id="id_7b8f8056" xlink:label="lbl_JPY_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">JPY</link:label>
      <link:label id="id_7a7394c2" xlink:label="lbl_CNY_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">China, Yuan Renminbi</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CNY" xlink:label="lbl_CNY" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CNY" xlink:to="lbl_CNY_labels" xlink:type="arc"/>
      <link:label id="id_4d265dd0" xlink:label="lbl_CNY_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CNY</link:label>
      <link:label id="id_1c17f7c4" xlink:label="lbl_GBP_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_GBP" xlink:label="lbl_GBP" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GBP" xlink:to="lbl_GBP_labels" xlink:type="arc"/>
      <link:label id="id_1728da67" xlink:label="lbl_GBP_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GBP</link:label>
      <link:label id="id_436074ee" xlink:label="lbl_CHF_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CHF</link:label>
      <link:label id="id_1da98c1e" xlink:label="lbl_label497650718" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="lbl_DocumentInformationTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentInformationTable" xlink:to="lbl_label497650718" xlink:type="arc"/>
      <link:label id="id_12b84aa7" xlink:label="lbl_label314067623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="lbl_DocumentInformationLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_label314067623" xlink:type="arc"/>
      <link:label id="id_165ab5d4" xlink:label="lbl_label375043540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_label375043540" xlink:type="arc"/>
      <link:label id="id_238135db" xlink:label="lbl_label595670491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityDomain" xlink:to="lbl_label595670491" xlink:type="arc"/>
      <link:label id="id_1d17e2f2" xlink:label="lbl_label488104690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_label488104690" xlink:type="arc"/>
      <link:label id="id_1d7da856" xlink:label="lbl_AdministrativeExpense_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Need new ITEM here</link:label>
      <link:label id="id_751ef3e9" xlink:label="lbl_AdministrativeExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">General and Administration</link:label>
      <link:label id="id_20c355f9" xlink:label="lbl_IncreaseDecreaseInNoncontrolingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in non-controling interests</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseInNoncontrolingInterests" xlink:label="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:to="lbl_IncreaseDecreaseInNoncontrolingInterests_labels" xlink:type="arc"/>
      <link:label id="id_71d21c6b" xlink:label="lbl_IncreaseDecreaseInNoncontrolingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in non-controlling interests</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsReceivedClassifiedAsOperatingActivities" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:label id="id_7d6a6449" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends received from associated companies and others</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:to="lbl_DividendsReceivedClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_4bdcb2fd" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends received, classified as operating activities</link:label>
      <link:label id="id_d7b5832" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance income received, classified as operating activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:to="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_7e7ea58d" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financial receipts</link:label>
      <link:label id="id_44baadd4" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance costs paid, classified as operating activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:to="lbl_FinanceCostsPaidClassifiedAsOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_68d65042" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other financial payments</link:label>
      <link:label id="id_36d7aeb1" xlink:label="lbl_ProceedsFromSalesOfInterestsInAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales of interests in associates</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfInterestsInAssociates" xlink:label="lbl_ProceedsFromSalesOfInterestsInAssociates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromSalesOfInterestsInAssociates" xlink:to="lbl_ProceedsFromSalesOfInterestsInAssociates_labels" xlink:type="arc"/>
      <link:label id="id_df43529" xlink:label="lbl_ProceedsFromSalesOfInterestsInAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and divestments of interests in associated companies, net</link:label>
      <link:label id="id_789b89ac" xlink:label="lbl_label1718040268" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and divestments of businesses, net</link:label>
      <link:label id="id_197c150c" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividends paid to shareholders of Novartis AG</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:to="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_3ec8bcea" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends paid to equity holders of parent, classified as financing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="locator"/>
      <link:label id="id_7cc199f7" xlink:label="lbl_ProceedsFromNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from non-current financial debts</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromNoncurrentBorrowings" xlink:to="lbl_ProceedsFromNoncurrentBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_2e7bd9f2" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of non-current borrowings</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RepaymentsOfNoncurrentBorrowings" xlink:to="lbl_RepaymentsOfNoncurrentBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_106de250" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of non-current financial debts</link:label>
      <link:label id="id_40f4d6a8" xlink:label="lbl_ProceedsFromNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from non-current borrowings</link:label>
      <link:label id="id_1bde8770" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) increase (decrease) in current borrowings</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:to="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_104baa70" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in current financial debts</link:label>
      <link:label id="id_367ad3ce" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financing cash flows, net</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_2a649f3d" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other inflows (outflows) of cash, classified as financing activities</link:label>
      <link:label id="id_3f82a721" xlink:label="lbl_IncomeTaxesPaidRefund_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="lbl_IncomeTaxesPaidRefund" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxesPaidRefund" xlink:to="lbl_IncomeTaxesPaidRefund_labels" xlink:type="arc"/>
      <link:label id="id_53191c38" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund), classified as investing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_16a1607" xlink:label="lbl_label23729671" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfReportableSegments" xlink:label="lbl_NumberOfReportableSegments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfReportableSegments" xlink:to="lbl_label23729671" xlink:type="arc"/>
      <link:label id="id_ff1b344" xlink:label="lbl_label267498308" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Business Units</link:label>
      <link:label id="id_19aaa924" xlink:label="lbl_label430614820" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Franchises</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfFranchises" xlink:label="lbl_NumberOfFranchises" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfFranchises" xlink:to="lbl_label430614820" xlink:type="arc"/>
      <link:label id="id_3b0ef23" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additions to property, plant and equipment</link:label>
      <link:label id="id_528839cf" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additions to intangible assets and goodwill</link:label>
      <link:label id="id_40106876" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, third parties and other segments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties_labels" xlink:type="arc"/>
      <link:label id="id_7458433e" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales to third parties</link:label>
      <link:label id="id_541cacbc" xlink:label="lbl_label1411165372" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, third parties and other segments, as percent of total net sales</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:to="lbl_label1411165372" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:to="lbl_label102429242" xlink:type="arc"/>
      <link:label id="id_5aa03955" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selected non-current assets, as percent</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:to="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets_labels" xlink:type="arc"/>
      <link:label id="id_6c200908" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected non-current assets (in % of total selected non-current assets)</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:to="lbl_label1358337308" xlink:type="arc"/>
      <link:label id="id_6d471c75" xlink:label="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of investments in associates for which there are quoted market prices</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished" xlink:label="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished" xlink:to="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished_labels" xlink:type="arc"/>
      <link:label id="id_6319607c" xlink:label="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in subsidiaries, joint ventures and associates</link:label>
      <link:label id="id_51c4430d" xlink:label="lbl_label1371816717" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense, gross</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:to="lbl_label1371816717" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:to="lbl_label1549022431" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromDividends" xlink:label="lbl_RevenueFromDividends" xlink:type="locator"/>
      <link:label id="id_752e4898" xlink:label="lbl_label1965967512" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other financial income</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromDividends" xlink:to="lbl_label1965967512" xlink:type="arc"/>
      <link:label id="id_6b7200d3" xlink:label="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss on commodities and available-for-sale securities, net</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:label="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:to="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet_labels" xlink:type="arc"/>
      <link:label id="id_4fa6704a" xlink:label="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment of commodities and available-for-sale securities, net</link:label>
      <link:label id="id_6fd24c63" xlink:label="lbl_OtherFinanceCost_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other finance cost</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceCost" xlink:label="lbl_OtherFinanceCost" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinanceCost" xlink:to="lbl_OtherFinanceCost_labels" xlink:type="arc"/>
      <link:label id="id_2d3e7598" xlink:label="lbl_OtherFinanceCost_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Financial expense</link:label>
      <link:label id="id_2b07fd1f" xlink:label="lbl_TaxExpenseIncomeDiscontinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income), discontinuing operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxExpenseIncomeDiscontinuingOperations" xlink:label="lbl_TaxExpenseIncomeDiscontinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxExpenseIncomeDiscontinuingOperations" xlink:to="lbl_TaxExpenseIncomeDiscontinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_671db01c" xlink:label="lbl_TaxExpenseIncomeDiscontinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense from discontinued operations</link:label>
      <link:label id="id_772c2e3e" xlink:label="lbl_label1999384126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect from non-deductible losses</link:label>
      <link:label id="id_199436bd" xlink:label="lbl_label429143741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation change in uncertain tax positions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:to="lbl_label429143741" xlink:type="arc"/>
      <link:label id="id_2016529c" xlink:label="lbl_label538333852" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation change in enacted tax rate</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lbl_label538333852" xlink:type="arc"/>
      <link:label id="id_2aa51152" xlink:label="lbl_label1640547073" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income net of tax gains/losses on remeasurements of defined benefit plans related to discontinued operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:to="lbl_label1640547073" xlink:type="arc"/>
      <link:label id="id_596243a4" xlink:label="lbl_label1689586548" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income net of tax exchange differences on translation related to discontinued operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:to="lbl_label1689586548" xlink:type="arc"/>
      <link:label id="id_1a035b8a" xlink:label="lbl_label436427658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Brands [axis]</link:label>
      <link:label id="id_7dfe6553" xlink:label="lbl_label2113824083" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Brands [member]</link:label>
      <link:label id="id_1c8ae042" xlink:label="lbl_label478863426" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Established Brands [member]</link:label>
      <link:label id="id_6b138679" xlink:label="lbl_label1796441721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Promoted Brands [member]</link:label>
      <link:label id="id_73d27a10" xlink:label="lbl_label1943173648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Core therapeutic area; other promoted brands; and established brands [axis]</link:label>
      <link:label id="id_578f16d9" xlink:label="lbl_label1468995289" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Core therapeutic area; other promoted brands; and established brands [member]</link:label>
      <link:label id="id_7a3bb683" xlink:label="lbl_label2050733699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ophthalmology [member]</link:label>
      <link:label id="id_29ccb106" xlink:label="lbl_label701280518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neuroscience [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeuroscienceMember" xlink:label="lbl_NeuroscienceMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NeuroscienceMember" xlink:to="lbl_label701280518" xlink:type="arc"/>
      <link:label id="id_1b0191fc" xlink:label="lbl_label453087740" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Respiratory and Allergy [member]</link:label>
      <link:label id="id_43a1daf0" xlink:label="lbl_label1134680816" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cardiovascular [member]</link:label>
      <link:label id="id_393ea837" xlink:label="lbl_label960407607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Established Medicines [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstablishedMedicinesMember" xlink:label="lbl_EstablishedMedicinesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstablishedMedicinesMember" xlink:to="lbl_label960407607" xlink:type="arc"/>
      <link:label id="id_5bf06316" xlink:label="lbl_label1542480662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product portfolio [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_label1542480662" xlink:type="arc"/>
      <link:label id="id_38b2f5ea" xlink:label="lbl_label951252458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product portfolio [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_label951252458" xlink:type="arc"/>
      <link:label id="id_77b41933" xlink:label="lbl_label2008291635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COPD [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_COPDMember" xlink:label="lbl_COPDMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_COPDMember" xlink:to="lbl_label2008291635" xlink:type="arc"/>
      <link:label id="id_7bd53aee" xlink:label="lbl_label2077571822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gleevec/Glivec [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GleevecGlivecMember" xlink:label="lbl_GleevecGlivecMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GleevecGlivecMember" xlink:to="lbl_label2077571822" xlink:type="arc"/>
      <link:label id="id_b0600c4" xlink:label="lbl_label184942788" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tasigna [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TasignaMember" xlink:to="lbl_label184942788" xlink:type="arc"/>
      <link:label id="id_3f81d4ef" xlink:label="lbl_label1065473263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandostatin [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandostatinMember" xlink:label="lbl_SandostatinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandostatinMember" xlink:to="lbl_label1065473263" xlink:type="arc"/>
      <link:label id="id_b64c3a5" xlink:label="lbl_label191153061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Afinitor/Votubia [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AfinitorVotubiaMember" xlink:label="lbl_AfinitorVotubiaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AfinitorVotubiaMember" xlink:to="lbl_label191153061" xlink:type="arc"/>
      <link:label id="id_7ee4b441" xlink:label="lbl_label2128917569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exjade/Jadenu [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExjadeJadenuMember" xlink:label="lbl_ExjadeJadenuMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExjadeJadenuMember" xlink:to="lbl_label2128917569" xlink:type="arc"/>
      <link:label id="id_28e14893" xlink:label="lbl_label685852819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tafinlar + Mekinist [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TafinlarMekinistMember" xlink:label="lbl_TafinlarMekinistMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TafinlarMekinistMember" xlink:to="lbl_label685852819" xlink:type="arc"/>
      <link:label id="id_67d8ca2f" xlink:label="lbl_label1742260783" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Promacta/Revolade [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PromactaRevoladeMember" xlink:label="lbl_PromactaRevoladeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PromactaRevoladeMember" xlink:to="lbl_label1742260783" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OphthalmologyMember" xlink:label="lbl_OphthalmologyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OphthalmologyMember" xlink:to="lbl_label2050733699" xlink:type="arc"/>
      <link:label id="id_647651d6" xlink:label="lbl_label1685475798" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Votrient [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VotrientMember" xlink:to="lbl_label1685475798" xlink:type="arc"/>
      <link:label id="id_2746717b" xlink:label="lbl_label658927995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jakavi [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JakaviMember" xlink:label="lbl_JakaviMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_JakaviMember" xlink:to="lbl_label658927995" xlink:type="arc"/>
      <link:label id="id_72117eb7" xlink:label="lbl_label1913749175" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kisqali [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KisqaliMember" xlink:label="lbl_KisqaliMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KisqaliMember" xlink:to="lbl_label1913749175" xlink:type="arc"/>
      <link:label id="id_4dee8d50" xlink:label="lbl_label1307479376" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherProductsMember" xlink:label="lbl_OtherProductsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherProductsMember" xlink:to="lbl_label1307479376" xlink:type="arc"/>
      <link:label id="id_6a7a37e6" xlink:label="lbl_label1786394598" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Travoprost Group [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TravoprostGroupMember" xlink:label="lbl_TravoprostGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TravoprostGroupMember" xlink:to="lbl_label1786394598" xlink:type="arc"/>
      <link:label id="id_3e01b08f" xlink:label="lbl_label1040298127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Systane Group [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SystaneGroupMember" xlink:label="lbl_SystaneGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SystaneGroupMember" xlink:to="lbl_label1040298127" xlink:type="arc"/>
      <link:label id="id_3ffa23d" xlink:label="lbl_label67084861" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Topical Olopatadine Group [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TopicalOlopatadineGroupMember" xlink:label="lbl_TopicalOlopatadineGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TopicalOlopatadineGroupMember" xlink:to="lbl_label67084861" xlink:type="arc"/>
      <link:label id="id_931b1f9" xlink:label="lbl_label154251769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cosentyx [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CosentyxMember" xlink:label="lbl_CosentyxMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CosentyxMember" xlink:to="lbl_label154251769" xlink:type="arc"/>
      <link:label id="id_31cd0397" xlink:label="lbl_label835519383" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neoral/Sandimmun(e) [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeoralSandimmunEMember" xlink:label="lbl_NeoralSandimmunEMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NeoralSandimmunEMember" xlink:to="lbl_label835519383" xlink:type="arc"/>
      <link:label id="id_48585481" xlink:label="lbl_label1213748353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zortress/Certican [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZortressCerticanMember" xlink:label="lbl_ZortressCerticanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZortressCerticanMember" xlink:to="lbl_label1213748353" xlink:type="arc"/>
      <link:label id="id_d8aed9" xlink:label="lbl_label14200537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ilaris [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IlarisMember" xlink:label="lbl_IlarisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IlarisMember" xlink:to="lbl_label14200537" xlink:type="arc"/>
      <link:label id="id_612117f4" xlink:label="lbl_label1629558772" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Myfortic [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MyforticMember" xlink:label="lbl_MyforticMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MyforticMember" xlink:to="lbl_label1629558772" xlink:type="arc"/>
      <link:label id="id_63153a75" xlink:label="lbl_label1662335605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gilenya [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GilenyaMember" xlink:label="lbl_GilenyaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GilenyaMember" xlink:to="lbl_label1662335605" xlink:type="arc"/>
      <link:label id="id_79c9c9f8" xlink:label="lbl_label2043267576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ultibro Breezhaler [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UltibroBreezhalerMember" xlink:label="lbl_UltibroBreezhalerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UltibroBreezhalerMember" xlink:to="lbl_label2043267576" xlink:type="arc"/>
      <link:label id="id_39edf745" xlink:label="lbl_label971896645" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seebri Breezhaler [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SeebriBreezhalerMember" xlink:label="lbl_SeebriBreezhalerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SeebriBreezhalerMember" xlink:to="lbl_label971896645" xlink:type="arc"/>
      <link:label id="id_3093cd1d" xlink:label="lbl_label814992669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Onbrez Breezhaler [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OnbrezBreezhalerMember" xlink:label="lbl_OnbrezBreezhalerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OnbrezBreezhalerMember" xlink:to="lbl_label814992669" xlink:type="arc"/>
      <link:label id="id_61b9d990" xlink:label="lbl_label1639569808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entresto [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EntrestoMember" xlink:label="lbl_EntrestoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntrestoMember" xlink:to="lbl_label1639569808" xlink:type="arc"/>
      <link:label id="id_ba5bf3e" xlink:label="lbl_label195411774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Galvus Group [member]</link:label>
      <link:label id="id_4a18d85e" xlink:label="lbl_label1243142238" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exforge Group [member]</link:label>
      <link:label id="id_75a7ce71" xlink:label="lbl_label1973931633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diovan Group [member]</link:label>
      <link:label id="id_2e0075fc" xlink:label="lbl_label771782140" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Voltaren/Cataflam [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VoltarenCataflamMember" xlink:label="lbl_VoltarenCataflamMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VoltarenCataflamMember" xlink:to="lbl_label771782140" xlink:type="arc"/>
      <link:label id="id_5304aa12" xlink:label="lbl_label1392814610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exelon/Exelon Patch [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExelonExelonPatchMember" xlink:label="lbl_ExelonExelonPatchMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExelonExelonPatchMember" xlink:to="lbl_label1392814610" xlink:type="arc"/>
      <link:label id="id_10a15386" xlink:label="lbl_label279008134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ritalin/Focalin [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RitalinFocalinMember" xlink:label="lbl_RitalinFocalinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RitalinFocalinMember" xlink:to="lbl_label279008134" xlink:type="arc"/>
      <link:label id="id_26f1359c" xlink:label="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated depreciation on disposals, property plant and equipment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:label="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:to="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_1c74ede2" xlink:label="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation on disposals and derecognitions</link:label>
      <link:label id="id_22aa91df" xlink:label="lbl_label1255943452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated impairments on disposals and derecognition</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:label="lbl_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:to="lbl_label1255943452" xlink:type="arc"/>
      <link:label id="id_626451ea" xlink:label="lbl_AcquiredResearchAndDevelopmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired research and development [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquiredResearchAndDevelopmentMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember_labels" xlink:type="arc"/>
      <link:label id="id_d6a6395" xlink:label="lbl_AcquiredResearchAndDevelopmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired research and development</link:label>
      <link:label id="id_52b9d0b7" xlink:label="lbl_AlconBrandNameMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon brand name [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconBrandNameMember" xlink:to="lbl_AlconBrandNameMember_labels" xlink:type="arc"/>
      <link:label id="id_4db335d9" xlink:label="lbl_AlconBrandNameMember_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Alcon brand name</link:label>
      <link:label id="id_52290b49" xlink:label="lbl_label1378421577" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross value of tax loss carry forwards expiring in future years</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:label="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:to="lbl_label1378421577" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:to="lbl_label94266701" xlink:type="arc"/>
      <link:label id="id_70e22198" xlink:label="lbl_label198642827" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales, change in %</link:label>
      <link:label id="id_330af3ff" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shareholders of Novartis AG</link:label>
      <link:label id="id_2b7d0eda" xlink:label="lbl_label729616090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative currency translation gains/losses recycled through income statement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:to="lbl_label729616090" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:label="lbl_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:type="locator"/>
      <link:label id="id_19f22bed" xlink:label="lbl_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impaired loss on financial assets transferred to the income statement</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:to="lbl_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax_labels" xlink:type="arc"/>
      <link:label id="id_2ac3f739" xlink:label="lbl_ReclassificationAdjustmentsOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification adjustments on financial assets measured at fair value through other comprehensive income, net of tax</link:label>
      <link:label id="id_1bf8cda2" xlink:label="lbl_label469290402" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, available-for-sale financial investments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" xlink:label="lbl_OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" xlink:to="lbl_label469290402" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" xlink:to="lbl_label521267934" xlink:type="arc"/>
      <link:label id="id_523cf50c" xlink:label="lbl_OtherComprehensiveIncomeMaketableSecurities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, maketable securities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeMaketableSecurities" xlink:label="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:to="lbl_OtherComprehensiveIncomeMaketableSecurities_labels" xlink:type="arc"/>
      <link:label id="id_64b0e4db" xlink:label="lbl_OtherComprehensiveIncomeMaketableSecurities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale marketable securities</link:label>
      <link:label id="id_37e931e5" xlink:label="lbl_FinanceLeaseReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net book value</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceLeaseReceivables" xlink:label="lbl_FinanceLeaseReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceLeaseReceivables" xlink:to="lbl_FinanceLeaseReceivables_labels" xlink:type="arc"/>
      <link:label id="id_f9fb296" xlink:label="lbl_FinanceLeaseReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance lease receivables</link:label>
      <link:label id="id_18330ebd" xlink:label="lbl_NoncurrentFinanceLeaseReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments from finance lease agreements</link:label>
      <link:label id="id_5342799f" xlink:label="lbl_label1396865439" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for doubtful receivable [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivableMember" xlink:label="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionForDoubtfulReceivableMember" xlink:to="lbl_label1396865439" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" xlink:to="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded_labels" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Commodities" xlink:label="lbl_Commodities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Commodities" xlink:to="lbl_label1789088932" xlink:type="arc"/>
      <link:label id="id_2985d64f" xlink:label="lbl_OutstandingShareCapital_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding share capital</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OutstandingShareCapital" xlink:label="lbl_OutstandingShareCapital" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OutstandingShareCapital" xlink:to="lbl_OutstandingShareCapital_labels" xlink:type="arc"/>
      <link:label id="id_550535ae" xlink:label="lbl_OutstandingShareCapital_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Total outstanding share capital at beginning of period</link:label>
      <link:label id="id_75bd4d3d" xlink:label="lbl_OutstandingShareCapital_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Total outstanding share capital at end of period</link:label>
      <link:label id="id_551db3e0" xlink:label="lbl_SaleOrIssueOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares movement of period</link:label>
      <link:label id="id_736416f8" xlink:label="lbl_IssuedCapitalMovement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital, movement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IssuedCapitalMovement" xlink:label="lbl_IssuedCapitalMovement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IssuedCapitalMovement" xlink:to="lbl_IssuedCapitalMovement_labels" xlink:type="arc"/>
      <link:label id="id_58515153" xlink:label="lbl_IssuedCapitalMovement_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital movement of period</link:label>
      <link:label id="id_416f3b0f" xlink:label="lbl_OutstandingShareCapitalMovement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding share capital, movement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OutstandingShareCapitalMovement" xlink:label="lbl_OutstandingShareCapitalMovement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OutstandingShareCapitalMovement" xlink:to="lbl_OutstandingShareCapitalMovement_labels" xlink:type="arc"/>
      <link:label id="id_578dd06d" xlink:label="lbl_OutstandingShareCapitalMovement_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total shares outstanding movement of period</link:label>
      <link:label id="id_6cc370cc" xlink:label="lbl_label1824747724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares cancelled for capital reduction</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharesCancelledForCapitalReduction" xlink:label="lbl_SharesCancelledForCapitalReduction" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharesCancelledForCapitalReduction" xlink:to="lbl_label1824747724" xlink:type="arc"/>
      <link:label id="id_138eeec4" xlink:label="lbl_TreasurySharesMovement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares, movement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesMovement" xlink:label="lbl_TreasurySharesMovement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesMovement" xlink:to="lbl_TreasurySharesMovement_labels" xlink:type="arc"/>
      <link:label id="id_296c7c9b" xlink:label="lbl_TreasurySharesMovement_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total number of outstanding treasury shares</link:label>
      <link:label id="id_3fd2a1c9" xlink:label="lbl_SharepurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares</link:label>
      <link:label id="id_4f72913c" xlink:label="lbl_PurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares, equity impact</link:label>
      <link:label id="id_10472e97" xlink:label="lbl_EquityImpactOfTreasuryShareMovements_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity impact of treasury share movements</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityImpactOfTreasuryShareMovements" xlink:label="lbl_EquityImpactOfTreasuryShareMovements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityImpactOfTreasuryShareMovements" xlink:to="lbl_EquityImpactOfTreasuryShareMovements_labels" xlink:type="arc"/>
      <link:label id="id_1cdf067d" xlink:label="lbl_EquityImpactOfTreasuryShareMovements_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity impact of treasury share movements</link:label>
      <link:label id="id_495f6f85" xlink:label="lbl_label903405960" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average interest rate on loans received</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageInterestRateOnLoansReceived" xlink:label="lbl_AverageInterestRateOnLoansReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageInterestRateOnLoansReceived" xlink:to="lbl_label903405960" xlink:type="arc"/>
      <link:label id="id_57858aea" xlink:label="lbl_label1766025212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ratio fixed rate financial debt to total financial debt</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:label="lbl_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:to="lbl_label1766025212" xlink:type="arc"/>
      <link:label id="id_10cf25f4" xlink:label="lbl_label1048419104" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average interest rate on borrowings</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageInterestRateOnBorrowings" xlink:label="lbl_AverageInterestRateOnBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AverageInterestRateOnBorrowings" xlink:to="lbl_label1048419104" xlink:type="arc"/>
      <link:label id="id_2aee42a4" xlink:label="lbl_BorrowingsInterestRate_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, coupon</link:label>
      <link:label id="id_176fa55a" xlink:label="lbl_BorrowingsIssuanceDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, issuance year</link:label>
      <link:label id="id_6ff69971" xlink:label="lbl_BorrowingsMaturity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, maturity year</link:label>
      <link:label id="id_7a5c6046" xlink:label="lbl_BorrowingsLender_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, issuer</link:label>
      <link:label id="id_30da0d60" xlink:label="lbl_BorrowingsPremiumDiscount_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, issue price</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationNonCurrent" xlink:label="lbl_ContingentConsiderationNonCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationNonCurrent" xlink:to="lbl_label98650725" xlink:type="arc"/>
      <link:label id="id_38f01585" xlink:label="lbl_label955258245" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Environmental remediation provisions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionRollForward" xlink:label="lbl_EnvironmentalProvisionRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_label1590727038" xlink:type="arc"/>
      <link:label id="id_26f523d7" xlink:label="lbl_EnvironmentalProvision_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvision" xlink:label="lbl_EnvironmentalProvision" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvision" xlink:to="lbl_EnvironmentalProvision_labels" xlink:type="arc"/>
      <link:label id="id_2f8c0636" xlink:label="lbl_EnvironmentalProvision_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Environmental liabilities provision at beginning of period</link:label>
      <link:label id="id_3ca05f15" xlink:label="lbl_EnvironmentalProvision_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Environmental liabilities provision at end of period</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvision" xlink:to="lbl_label1750372676" xlink:type="arc"/>
      <link:label id="id_5bf2bac7" xlink:label="lbl_label1542634183" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, payments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionPayments" xlink:label="lbl_EnvironmentalProvisionPayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionPayments" xlink:to="lbl_label1542634183" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionPayments" xlink:to="lbl_label448335871" xlink:type="arc"/>
      <link:label id="id_1bbf0a1c" xlink:label="lbl_label465504796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, releases</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionReleases" xlink:label="lbl_EnvironmentalProvisionReleases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionReleases" xlink:to="lbl_label465504796" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionReleases" xlink:to="lbl_label2143979670" xlink:type="arc"/>
      <link:label id="id_30109c5e" xlink:label="lbl_label806394974" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, additions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionAdditions" xlink:label="lbl_EnvironmentalProvisionAdditions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionAdditions" xlink:to="lbl_label806394974" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionAdditions" xlink:to="lbl_label1560928630" xlink:type="arc"/>
      <link:label id="id_6528e847" xlink:label="lbl_label1697179719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, foreign currency translation gain (loss)</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:label="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:to="lbl_label1697179719" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:to="lbl_label42481781" xlink:type="arc"/>
      <link:label id="id_69c992c5" xlink:label="lbl_EnvironmentalProvisionCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for environmental loss contingencies, Current</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionCurrent" xlink:label="lbl_EnvironmentalProvisionCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionCurrent" xlink:to="lbl_EnvironmentalProvisionCurrent_labels" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionCurrent" xlink:to="lbl_label1902698328" xlink:type="arc"/>
      <link:label id="id_76c21b8c" xlink:label="lbl_label1992432524" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-current environmental remediation provisions at end of period</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalRemediationProvisionNoncurrent" xlink:label="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:to="lbl_label1992432524" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:to="lbl_label955258245" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:to="lbl_label304425068" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:label="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:to="lbl_label1615356460" xlink:type="arc"/>
      <link:label id="id_6deab0eb" xlink:label="lbl_label1844097259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision, expected cash outflow, next two years</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:to="lbl_label1844097259" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:to="lbl_label1351152500" xlink:type="arc"/>
      <link:label id="id_54b46e40" xlink:label="lbl_label1421110848" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision, expected cash outflow, later than two years, but within five years</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:to="lbl_label1421110848" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:to="lbl_label771700847" xlink:type="arc"/>
      <link:label id="id_366842e4" xlink:label="lbl_label912802532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision, expected cash outflow, later than five years, but within ten years</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:to="lbl_label912802532" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:to="lbl_label1968177093" xlink:type="arc"/>
      <link:label id="id_53179e3c" xlink:label="lbl_label1394056764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental provision, expected cash outflow, after ten years</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:to="lbl_label1394056764" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:to="lbl_label757561900" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_label1271103735" xlink:type="arc"/>
      <link:label id="id_5e9e598e" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions_labels" xlink:type="arc"/>
      <link:label id="id_1dcf084" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Product liabilities government investigations other legal matters provisions at beginning of period</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:to="lbl_label252843510" xlink:type="arc"/>
      <link:label id="id_71839c4e" xlink:label="lbl_label1904450638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, discontinued operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:to="lbl_label1904450638" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:to="lbl_label1583004694" xlink:type="arc"/>
      <link:label id="id_53472504" xlink:label="lbl_label1397171460" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, payments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:to="lbl_label1397171460" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:to="lbl_label1339267684" xlink:type="arc"/>
      <link:label id="id_3e905f98" xlink:label="lbl_label1049649048" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, releases</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:to="lbl_label1049649048" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:to="lbl_label1568927014" xlink:type="arc"/>
      <link:label id="id_61e84c26" xlink:label="lbl_label1642613798" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, additions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:to="lbl_label1642613798" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:to="lbl_label1379712140" xlink:type="arc"/>
      <link:label id="id_6c695b53" xlink:label="lbl_label1818843987" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, foreign currency translation gain (loss)</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:to="lbl_label1818843987" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:to="lbl_label1424862979" xlink:type="arc"/>
      <link:label id="id_54a4e6a7" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, current</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent_labels" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:to="lbl_label438797926" xlink:type="arc"/>
      <link:label id="id_acc6217" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, non-current</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent_labels" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:to="lbl_label1363494370" xlink:type="arc"/>
      <link:label id="id_d93a8b" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageInterestRateAssociates" xlink:label="lbl_WeightedAverageInterestRateAssociates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageInterestRateAssociates" xlink:to="lbl_WeightedAverageInterestRateAssociates_labels" xlink:type="arc"/>
      <link:label id="id_6be37912" xlink:label="lbl_WeightedAverageInterestRateAssociates_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average interest rate on interest bearning accounts of associates payable on demand.</link:label>
      <link:label id="id_1a1c62e1" xlink:label="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average interest rate on Bank and other financial debt</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:label="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:to="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt_labels" xlink:type="arc"/>
      <link:label id="id_1401b9c9" xlink:label="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average interest rate on Bank and other financial debt</link:label>
      <link:label id="id_7df4e11d" xlink:label="lbl_EnvironmentalProvisionCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Environmental remediation liabilities</link:label>
      <link:label id="id_19219108" xlink:label="lbl_AccrualsClassifiedAsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses for goods and services received but not invoiced</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="lbl_AccrualsClassifiedAsCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccrualsClassifiedAsCurrent" xlink:to="lbl_AccrualsClassifiedAsCurrent_labels" xlink:type="arc"/>
      <link:label id="id_2731b8ee" xlink:label="lbl_AccrualsClassifiedAsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accruals classified as current</link:label>
      <link:label id="id_1dcdc504" xlink:label="lbl_ContingentConsiderationCurrentPortion_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration, current portion</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationCurrentPortion" xlink:label="lbl_ContingentConsiderationCurrentPortion" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationCurrentPortion" xlink:to="lbl_ContingentConsiderationCurrentPortion_labels" xlink:type="arc"/>
      <link:label id="id_cecd050" xlink:label="lbl_ContingentConsiderationCurrentPortion_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
      <link:label id="id_66cb3d62" xlink:label="lbl_label1724595554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for deduction from revenue [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDeductionFromRevenueTable" xlink:label="lbl_ProvisionForDeductionFromRevenueTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionForDeductionFromRevenueTable" xlink:to="lbl_label1724595554" xlink:type="arc"/>
      <link:label id="id_62196d01" xlink:label="lbl_label1645833473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring provisions movements [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestructuringProvisionsMovementsTable" xlink:label="lbl_RestructuringProvisionsMovementsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestructuringProvisionsMovementsTable" xlink:to="lbl_label1645833473" xlink:type="arc"/>
      <link:label id="id_5c0c0960" xlink:label="lbl_RestructuringProvisionTransfers_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring provision transfers</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestructuringProvisionTransfers" xlink:label="lbl_RestructuringProvisionTransfers" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestructuringProvisionTransfers" xlink:to="lbl_RestructuringProvisionTransfers_labels" xlink:type="arc"/>
      <link:label id="id_2238ed4d" xlink:label="lbl_RestructuringProvisionTransfers_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transfers</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:label="lbl_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:type="locator"/>
      <link:label id="id_78c7fbb0" xlink:label="lbl_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification adjustments on cash flow hedges, net of tax</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:to="lbl_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_labels" xlink:type="arc"/>
      <link:label id="id_b7c54f9" xlink:label="lbl_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized net losses on cash flow hedges transferred to the consolidated income statement</link:label>
      <link:label id="id_58b3a333" xlink:label="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other payables and deferred tax liabilities recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_5a90c79" xlink:label="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payables and other liabilities including deferred tax liabilities</link:label>
      <link:label id="id_2856a2a3" xlink:label="lbl_IdentifiableAssetsAcquired_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Identifiable assets acquired</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IdentifiableAssetsAcquired" xlink:label="lbl_IdentifiableAssetsAcquired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IdentifiableAssetsAcquired" xlink:to="lbl_IdentifiableAssetsAcquired_labels" xlink:type="arc"/>
      <link:label id="id_205b065c" xlink:label="lbl_IdentifiableAssetsAcquired_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net identifiable assets acquired</link:label>
      <link:label id="id_62f623d2" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property plant and equipment recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_59f5d7c5" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
      <link:label id="id_28728c08" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currently marketed products intangible assets recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_4dd002d2" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currently marketed products</link:label>
      <link:label id="id_3be633c" xlink:label="lbl_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired divested research and development intangible assets recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_3369d331" xlink:label="lbl_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Acquired)/divested research and development</link:label>
      <link:label id="id_44229a8b" xlink:label="lbl_TechnologiesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technologies recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TechnologiesRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_TechnologiesRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TechnologiesRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_TechnologiesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_3e9ce44a" xlink:label="lbl_TechnologiesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technologies</link:label>
      <link:label id="id_33f9a377" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other intangible assets recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_52667216" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
      <link:label id="id_2879f83e" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and other assets including deferred tax assets recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_64556efa" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial and other assets including deferred tax assets</link:label>
      <link:label id="id_63e0564e" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InventoryRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_InventoryRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_7a3f0241" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
      <link:label id="id_4427bc74" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables and other current assets recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_5681fbbf" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables and other current assets</link:label>
      <link:label id="id_6359834c" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_47a6ced3" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:label id="id_4d854151" xlink:label="lbl_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current and non-current financial debts recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_3ea67aa0" xlink:label="lbl_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current and non-current financial debts</link:label>
      <link:label id="id_1be55693" xlink:label="lbl_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other payables recognised as of acquisition divestment date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate" xlink:label="lbl_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate" xlink:to="lbl_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:type="arc"/>
      <link:label id="id_65a5731d" xlink:label="lbl_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Trade payables and other liabilities including deferred tax liabilities</link:label>
      <link:label id="id_5d12057a" xlink:label="lbl_label1419113480" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Animal health [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AnimalHealthMember" xlink:label="lbl_AnimalHealthMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AnimalHealthMember" xlink:to="lbl_label1419113480" xlink:type="arc"/>
      <link:label id="id_6ab963bf" xlink:label="lbl_label1790534591" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sale of business</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProceedsFromSaleOfBusiness" xlink:label="lbl_ProceedsFromSaleOfBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromSaleOfBusiness" xlink:to="lbl_label1790534591" xlink:type="arc"/>
      <link:label id="id_2cda3a42" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash flows used in/from investing activities from discontinued operations</link:label>
      <link:label id="id_7f35ae76" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Financial debts and derivative instruments at beginning of period</link:label>
      <link:label id="id_5e88cc26" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Financial debts and derivative instruments at end of period</link:label>
      <link:label id="id_32b354fd" xlink:label="lbl_label1199806184" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair values, lease interest and other changes, net</link:label>
      <link:label id="id_3eaf2bac" xlink:label="lbl_AmortizationOfBondsDiscount_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of bonds discount</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationOfBondsDiscount" xlink:label="lbl_AmortizationOfBondsDiscount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortizationOfBondsDiscount" xlink:to="lbl_AmortizationOfBondsDiscount_labels" xlink:type="arc"/>
      <link:label id="id_4b9e2882" xlink:label="lbl_label1268656258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial debts [member]</link:label>
      <link:label id="id_24db2ae3" xlink:label="lbl_label618343139" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial debts and derivative financial instruments [member]</link:label>
      <link:label id="id_20254569" xlink:label="lbl_label539313513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current portion of non-current financial debt</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPortionOfNoncurrentFinancialDebt" xlink:label="lbl_CurrentPortionOfNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPortionOfNoncurrentFinancialDebt" xlink:to="lbl_label539313513" xlink:type="arc"/>
      <link:label id="id_4171dffa" xlink:label="lbl_label1097981946" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genentech / Roche [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GenentechRocheMember" xlink:label="lbl_GenentechRocheMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GenentechRocheMember" xlink:to="lbl_label1097981946" xlink:type="arc"/>
      <link:label id="id_21b59c45" xlink:label="lbl_label565550149" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of contracts with related parties</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfContractsWithRelatedParties" xlink:label="lbl_NumberOfContractsWithRelatedParties" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfContractsWithRelatedParties" xlink:to="lbl_label565550149" xlink:type="arc"/>
      <link:label id="id_12cdd92b" xlink:label="lbl_label1424538747" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Committee members</link:label>
      <link:label id="id_4d39a061" xlink:label="lbl_RelatedPartiesNumberOfNonexecutiveDirectors_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related parties, number of non-executive directors</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:label="lbl_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:to="lbl_RelatedPartiesNumberOfNonexecutiveDirectors_labels" xlink:type="arc"/>
      <link:label id="id_2b93879e" xlink:label="lbl_RelatedPartiesNumberOfNonexecutiveDirectors_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-executive directors</link:label>
      <link:label id="id_4c2ae7af" xlink:label="lbl_label1277880239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, expected future benefit payment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:to="lbl_label1277880239" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:to="lbl_label839490648" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EmployerSharesHeldByDefinedBenefitPlan" xlink:label="lbl_EmployerSharesHeldByDefinedBenefitPlan" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EmployerSharesHeldByDefinedBenefitPlan" xlink:to="lbl_label2113441601" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:label="lbl_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:to="lbl_label1670270510" xlink:type="arc"/>
      <link:label id="id_45a2931c" xlink:label="lbl_label1168282396" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, foreign currency exchange rate gain (loss)</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:to="lbl_label1168282396" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:to="lbl_label220841955" xlink:type="arc"/>
      <link:label id="id_329368f1" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through changes in foreign exchange rates, defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset_labels" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:to="lbl_label1273555602" xlink:type="arc"/>
      <link:label id="id_5b9bb55e" xlink:label="lbl_label1536931166" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years and not later than ten years [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:label="lbl_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:to="lbl_label1536931166" xlink:type="arc"/>
      <link:label id="id_7cbb695f" xlink:label="lbl_label2092656991" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="lbl_DisclosureOfFinancialAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_label2092656991" xlink:type="arc"/>
      <link:label id="id_675e88e3" xlink:label="lbl_label1734248675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="lbl_DisclosureOfFinancialAssetsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAssetsLineItems" xlink:to="lbl_label1734248675" xlink:type="arc"/>
      <link:label id="id_6f8cf207" xlink:label="lbl_label1871507975" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="lbl_FinancialAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssets" xlink:to="lbl_label1871507975" xlink:type="arc"/>
      <link:label id="id_31c4b50a" xlink:label="lbl_label834974986" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial assets [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="lbl_ClassesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfFinancialAssetsAxis" xlink:to="lbl_label834974986" xlink:type="arc"/>
      <link:label id="id_3b500f38" xlink:label="lbl_label995102520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets, class [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="lbl_FinancialAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsMember" xlink:to="lbl_label995102520" xlink:type="arc"/>
      <link:label id="id_5853963a" xlink:label="lbl_label1481872954" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at amortised cost, class [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="lbl_FinancialAssetsAtAmortisedCostMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtAmortisedCostMember" xlink:to="lbl_label1481872954" xlink:type="arc"/>
      <link:label id="id_15228c3a" xlink:label="lbl_label354585658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMember" xlink:label="lbl_CashAndCashEquivalentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsMember" xlink:to="lbl_label354585658" xlink:type="arc"/>
      <link:label id="id_2ea70" xlink:label="lbl_label191088" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial assets [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="lbl_CategoriesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CategoriesOfFinancialAssetsAxis" xlink:to="lbl_label191088" xlink:type="arc"/>
      <link:label id="id_5fa2081d" xlink:label="lbl_label1604454429" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets, category [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="lbl_FinancialAssetsCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsCategoryMember" xlink:to="lbl_label1604454429" xlink:type="arc"/>
      <link:label id="id_7ddd290" xlink:label="lbl_label131977872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale marketable securities [member]</link:label>
      <link:label id="id_36737cf8" xlink:label="lbl_label913538296" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale long-term financial investments [member]</link:label>
      <link:label id="id_5632a636" xlink:label="lbl_label1446159926" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance sheet item [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemAxis" xlink:label="lbl_BalanceSheetItemAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BalanceSheetItemAxis" xlink:to="lbl_label1446159926" xlink:type="arc"/>
      <link:label id="id_77e6aae0" xlink:label="lbl_label2011605728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance sheet item [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemMember" xlink:label="lbl_BalanceSheetItemMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_label2011605728" xlink:type="arc"/>
      <link:label id="id_39f42abc" xlink:label="lbl_label972303036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity securities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquitySecuritiesMember" xlink:label="lbl_EquitySecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquitySecuritiesMember" xlink:to="lbl_label972303036" xlink:type="arc"/>
      <link:label id="id_34461243" xlink:label="lbl_label877007427" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fund investments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FundInvestmentsMember" xlink:to="lbl_label877007427" xlink:type="arc"/>
      <link:label id="id_3c80f6bd" xlink:label="lbl_label1015084733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables and other current assets excluding pre-payments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:to="lbl_label1015084733" xlink:type="arc"/>
      <link:label id="id_71d621f1" xlink:label="lbl_label1909858801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration receivables [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationReceivablesMember" xlink:to="lbl_label1909858801" xlink:type="arc"/>
      <link:label id="id_266ee04f" xlink:label="lbl_label644800591" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued interest on debt securities and time deposits [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:label="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:to="lbl_label644800591" xlink:type="arc"/>
      <link:label id="id_462cba41" xlink:label="lbl_label1177336385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time deposits with original maturity more than 90 days [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:label="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:to="lbl_label1177336385" xlink:type="arc"/>
      <link:label id="id_1ada2efd" xlink:label="lbl_label450506493" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term loans and receivables from customers and finance lease, advances, security deposits [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:label="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:to="lbl_label450506493" xlink:type="arc"/>
      <link:label id="id_7c347590" xlink:label="lbl_label2083812752" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Associated companies at fair value through profit and loss [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:to="lbl_label2083812752" xlink:type="arc"/>
      <link:label id="id_533b50d9" xlink:label="lbl_label1396396249" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsMember" xlink:to="lbl_label1396396249" xlink:type="arc"/>
      <link:label id="id_551fe4b1" xlink:label="lbl_label1428153521" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_label1428153521" xlink:type="arc"/>
      <link:label id="id_114f7584" xlink:label="lbl_label290420100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:to="lbl_label290420100" xlink:type="arc"/>
      <link:label id="id_3b35b195" xlink:label="lbl_label993374613" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities, class [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="lbl_FinancialLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesMember" xlink:to="lbl_label993374613" xlink:type="arc"/>
      <link:label id="id_68a64911" xlink:label="lbl_label1755728145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at amortised cost, class [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="lbl_FinancialLiabilitiesAtAmortisedCostMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesAtAmortisedCostMember" xlink:to="lbl_label1755728145" xlink:type="arc"/>
      <link:label id="id_6d1d78f2" xlink:label="lbl_label1830648050" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at fair value, class [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="lbl_FinancialLiabilitiesAtFairValueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesAtFairValueMember" xlink:to="lbl_label1830648050" xlink:type="arc"/>
      <link:label id="id_27bb9ea8" xlink:label="lbl_label666607272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Groups of financial assets/liabilities [axis]</link:label>
      <link:label id="id_7cf4bc91" xlink:label="lbl_label2096413841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Groups of financial assets/liabilities [member]</link:label>
      <link:label id="id_68ba85b6" xlink:label="lbl_label1757054390" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at fair value, class [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueMember" xlink:label="lbl_FinancialAssetsAtFairValueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtFairValueMember" xlink:to="lbl_label1757054390" xlink:type="arc"/>
      <link:label id="id_3cee5982" xlink:label="lbl_label1022253442" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at fair value through profit or loss, category [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="lbl_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:to="lbl_label1022253442" xlink:type="arc"/>
      <link:label id="id_2d611cc9" xlink:label="lbl_label761339081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at fair value through other comprehensive income, category [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:label="lbl_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:to="lbl_label761339081" xlink:type="arc"/>
      <link:label id="id_2c7b189f" xlink:label="lbl_label746264735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities, category [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="lbl_FinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesCategoryMember" xlink:to="lbl_label746264735" xlink:type="arc"/>
      <link:label id="id_153859c4" xlink:label="lbl_label356014532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lbl_label356014532" xlink:type="arc"/>
      <link:label id="id_14968138" xlink:label="lbl_label345407800" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at fair value through profit or loss, category [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="lbl_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:to="lbl_label345407800" xlink:type="arc"/>
      <link:label id="id_2576e32b" xlink:label="lbl_label628548395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at amortised cost, category [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="lbl_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:to="lbl_label628548395" xlink:type="arc"/>
      <link:label id="id_5a840ece" xlink:label="lbl_label1518603982" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at amortised cost, category [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="lbl_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtAmortisedCostCategoryMember" xlink:to="lbl_label1518603982" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_label666607272" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_label2096413841" xlink:type="arc"/>
      <link:label id="id_4718921c" xlink:label="lbl_label1192792604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial debt [member]</link:label>
      <link:label id="id_1748f73f" xlink:label="lbl_label390657855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial debt [member]</link:label>
      <link:label id="id_7d47f3b5" xlink:label="lbl_label2101867445" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade payables [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradePayablesMember" xlink:label="lbl_TradePayablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradePayablesMember" xlink:to="lbl_label2101867445" xlink:type="arc"/>
      <link:label id="id_1ed425bd" xlink:label="lbl_label517219773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest bearning accounts of associates payable on demand [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:to="lbl_label517219773" xlink:type="arc"/>
      <link:label id="id_7fb53de5" xlink:label="lbl_label2142584293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bank and other financial debt [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BankAndOtherFinancialDebtMember" xlink:label="lbl_BankAndOtherFinancialDebtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BankAndOtherFinancialDebtMember" xlink:to="lbl_label2142584293" xlink:type="arc"/>
      <link:label id="id_36f483b7" xlink:label="lbl_label921994167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial paper [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommercialPaperMember" xlink:label="lbl_CommercialPaperMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommercialPaperMember" xlink:to="lbl_label921994167" xlink:type="arc"/>
      <link:label id="id_2993bf16" xlink:label="lbl_label697548566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current portion of non-current debt [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPortionOfNoncurrentDebtMember" xlink:label="lbl_CurrentPortionOfNoncurrentDebtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentPortionOfNoncurrentDebtMember" xlink:to="lbl_label697548566" xlink:type="arc"/>
      <link:label id="id_7aa4522e" xlink:label="lbl_label2057589294" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Straight bonds [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StraightBondsMember" xlink:label="lbl_StraightBondsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StraightBondsMember" xlink:to="lbl_label2057589294" xlink:type="arc"/>
      <link:label id="id_2e89197f" xlink:label="lbl_label780736895" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities to banks and other financial institutions [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:label="lbl_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:to="lbl_label780736895" xlink:type="arc"/>
      <link:label id="id_3cfbed2" xlink:label="lbl_label63946450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance lease obligations [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinanceLeaseObligationsMember" xlink:label="lbl_FinanceLeaseObligationsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceLeaseObligationsMember" xlink:to="lbl_label63946450" xlink:type="arc"/>
      <link:label id="id_47b3aade" xlink:label="lbl_label1202957022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration and other financial liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:label="lbl_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:to="lbl_label1202957022" xlink:type="arc"/>
      <link:label id="id_74b2144b" xlink:label="lbl_label1957827659" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments, by type of contract [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:to="lbl_label1957827659" xlink:type="arc"/>
      <link:label id="id_11a7e82b" xlink:label="lbl_label296216619" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instrument, nature of instrument [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:to="lbl_label296216619" xlink:type="arc"/>
      <link:label id="id_5a462aee" xlink:label="lbl_label1514547950" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instrument, nature of instrument [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:to="lbl_label1514547950" xlink:type="arc"/>
      <link:label id="id_75469247" xlink:label="lbl_label1967559239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments, at fair value currency related [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:label="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:to="lbl_label1967559239" xlink:type="arc"/>
      <link:label id="id_3583f9fa" xlink:label="lbl_label897841658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, principal amounts [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsAxis" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:to="lbl_label897841658" xlink:type="arc"/>
      <link:label id="id_102b0f85" xlink:label="lbl_label271257477" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, principal amounts [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsMember" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_label271257477" xlink:type="arc"/>
      <link:label id="id_3f464064" xlink:label="lbl_label1061568612" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract or underlying principal amout [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractOrUnderlyingPrincipalAmoutMember" xlink:label="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:to="lbl_label1061568612" xlink:type="arc"/>
      <link:label id="id_24f6d45c" xlink:label="lbl_label620155996" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Positive fair values [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PositiveFairValuesMember" xlink:label="lbl_PositiveFairValuesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PositiveFairValuesMember" xlink:to="lbl_label620155996" xlink:type="arc"/>
      <link:label id="id_42b35305" xlink:label="lbl_label1119048453" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Negative fair values [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NegativeFairValuesMember" xlink:label="lbl_NegativeFairValuesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NegativeFairValuesMember" xlink:to="lbl_label1119048453" xlink:type="arc"/>
      <link:label id="id_4c8abefe" xlink:label="lbl_label1284161278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_label1284161278" xlink:type="arc"/>
      <link:label id="id_5286c358" xlink:label="lbl_label1384563544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="lbl_label1384563544" xlink:type="arc"/>
      <link:label id="id_487fc207" xlink:label="lbl_label1216332295" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilities" xlink:label="lbl_FinancialLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilities" xlink:to="lbl_label1216332295" xlink:type="arc"/>
      <link:label id="id_453bddb" xlink:label="lbl_label72596955" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstruments" xlink:label="lbl_DerivativeFinancialInstruments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstruments" xlink:to="lbl_label72596955" xlink:type="arc"/>
      <link:label id="id_397d852b" xlink:label="lbl_label964527403" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments, forward foreign exchange rate contracts</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:label="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:to="lbl_label964527403" xlink:type="arc"/>
      <link:label id="id_b3aed83" xlink:label="lbl_label188411267" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments, over-the-counter currency options</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:label="lbl_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:to="lbl_label188411267" xlink:type="arc"/>
      <link:label id="id_24aeca58" xlink:label="lbl_label615434840" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments, by currency contract [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_label615434840" xlink:type="arc"/>
      <link:label id="id_3d32bab6" xlink:label="lbl_label1026734774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of assets [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_label1026734774" xlink:type="arc"/>
      <link:label id="id_3f252a8f" xlink:label="lbl_label1059400335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_label1059400335" xlink:type="arc"/>
      <link:label id="id_59852144" xlink:label="lbl_label1501897028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregated measurement [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AggregatedMeasurementMember" xlink:to="lbl_label1501897028" xlink:type="arc"/>
      <link:label id="id_640cd1b3" xlink:label="lbl_label1678561715" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recurring fair value measurement [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RecurringFairValueMeasurementMember" xlink:label="lbl_RecurringFairValueMeasurementMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RecurringFairValueMeasurementMember" xlink:to="lbl_label1678561715" xlink:type="arc"/>
      <link:label id="id_6df52bda" xlink:label="lbl_label1844784090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities, time deposits and derivative financial instruments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:label="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:to="lbl_label1844784090" xlink:type="arc"/>
      <link:label id="id_469d8a26" xlink:label="lbl_label1184729638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial investments and long-term loans [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:label="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:to="lbl_label1184729638" xlink:type="arc"/>
      <link:label id="id_3e1a7df6" xlink:label="lbl_label1041923574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total available-for-sale marketable securities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalAvailableforsaleMarketableSecuritiesMember" xlink:label="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:to="lbl_label1041923574" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AvailableForSaleMarketableSecuritiesMember" xlink:label="lbl_AvailableForSaleMarketableSecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AvailableForSaleMarketableSecuritiesMember" xlink:to="lbl_label131977872" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:to="lbl_label913538296" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtMember" xlink:label="lbl_CurrentFinancialDebtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentFinancialDebtMember" xlink:to="lbl_label1192792604" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialDebtMember" xlink:label="lbl_NoncurrentFinancialDebtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialDebtMember" xlink:to="lbl_label390657855" xlink:type="arc"/>
      <link:label id="id_55c289f5" xlink:label="lbl_label1438812661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale financial investments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AvailableforsaleFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:to="lbl_label1438812661" xlink:type="arc"/>
      <link:label id="id_4af993b7" xlink:label="lbl_label1257870263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of assets [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="lbl_label1257870263" xlink:type="arc"/>
      <link:label id="id_5b807bec" xlink:label="lbl_label1535146988" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valued at amortized cost [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValuedAtAmortizedCostMember" xlink:label="lbl_ValuedAtAmortizedCostMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValuedAtAmortizedCostMember" xlink:to="lbl_label1535146988" xlink:type="arc"/>
      <link:label id="id_6163f2e6" xlink:label="lbl_label1633940198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of liabilities [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="lbl_ClassesOfLiabilitiesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClassesOfLiabilitiesAxis" xlink:to="lbl_label1633940198" xlink:type="arc"/>
      <link:label id="id_39b2a3b6" xlink:label="lbl_label968008630" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember" xlink:label="lbl_LiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_label968008630" xlink:type="arc"/>
      <link:label id="id_2dde0229" xlink:label="lbl_label769524265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration payables [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationPayablesMember" xlink:label="lbl_ContingentConsiderationPayablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationPayablesMember" xlink:to="lbl_label769524265" xlink:type="arc"/>
      <link:label id="id_648479c6" xlink:label="lbl_label1686403526" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other financial liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinancialLiabilitiesMember" xlink:to="lbl_label1686403526" xlink:type="arc"/>
      <link:label id="id_7d19861f" xlink:label="lbl_label2098824735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">China Novartis Institutes for BioMedical Research Co., Ltd., Shanghai [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:label="lbl_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:to="lbl_label2098824735" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare1" xlink:type="locator"/>
      <link:label id="id_6e8d8711" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends proposed, cash per share</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare1" xlink:to="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare_labels" xlink:type="arc"/>
      <link:label id="id_5643fad7" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners per share</link:label>
      <link:label id="id_65bb0a73" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends proposed</link:label>
      <link:label id="id_738a993" xlink:label="lbl_label121153939" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase/decrease in fair value measurement liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:label="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:to="lbl_label121153939" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:to="lbl_label1199806184" xlink:type="arc"/>
      <link:label id="id_7ebb8632" xlink:label="lbl_label2126218802" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets, at fair value</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="lbl_FinancialAssetsAtFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAssetsAtFairValue" xlink:to="lbl_label2126218802" xlink:type="arc"/>
      <link:label id="id_5083795f" xlink:label="lbl_FinancialLiabilitiesAtFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities, at fair value</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="lbl_FinancialLiabilitiesAtFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesAtFairValue" xlink:to="lbl_FinancialLiabilitiesAtFairValue_labels" xlink:type="arc"/>
      <link:label id="id_2d43301f" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, hedges of net investments in foreign operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations_labels" xlink:type="arc"/>
      <link:label id="id_43e5ded1" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net investment hedge</link:label>
      <link:label id="id_72a89a91" xlink:label="lbl_label1923652241" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Australia Pty Ltd, Macquarie Park, NSW [member]</link:label>
      <link:label id="id_731902b7" xlink:label="lbl_label1931018935" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals Australia Pty Ltd, Macquarie Park, NSW [member]</link:label>
      <link:label id="id_1867bb0f" xlink:label="lbl_label409451279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories (Australia) Pty Ltd, Macquarie Park, NSW [member]</link:label>
      <link:label id="id_3d795141" xlink:label="lbl_label1031360833" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Pty Ltd, Macquarie Park, NSW [member]</link:label>
      <link:label id="id_5d546db3" xlink:label="lbl_label1565814195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Austria GmbH, Vienna [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisAustriaGmbHViennaMember" xlink:label="lbl_NovartisAustriaGmbHViennaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisAustriaGmbHViennaMember" xlink:to="lbl_label1565814195" xlink:type="arc"/>
      <link:label id="id_2234921c" xlink:label="lbl_label573870620" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma GmbH, Vienna [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaGmbHViennaMember" xlink:label="lbl_NovartisPharmaGmbHViennaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaGmbHViennaMember" xlink:to="lbl_label573870620" xlink:type="arc"/>
      <link:label id="id_7dcc65cd" xlink:label="lbl_label2110547405" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Ophthalmika GmbH, Vienna [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconOphthalmikaGmbHViennaMember" xlink:label="lbl_AlconOphthalmikaGmbHViennaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconOphthalmikaGmbHViennaMember" xlink:to="lbl_label2110547405" xlink:type="arc"/>
      <link:label id="id_6649a095" xlink:label="lbl_label1716101269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz GmbH, Kundl [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozGmbHViennaMember" xlink:label="lbl_SandozGmbHViennaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozGmbHViennaMember" xlink:to="lbl_label1716101269" xlink:type="arc"/>
      <link:label id="id_2af5dc99" xlink:label="lbl_label720755864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EBEWE Pharma Ges.m.b.H Nfg. KG, Unterach am Attersee [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:label="lbl_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:to="lbl_label720755864" xlink:type="arc"/>
      <link:label id="id_710ef91f" xlink:label="lbl_label1896806687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis (Bangladesh) Limited, Gazipur [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBangladeshLimitedGazipurMember" xlink:label="lbl_NovartisBangladeshLimitedGazipurMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBangladeshLimitedGazipurMember" xlink:to="lbl_label1896806687" xlink:type="arc"/>
      <link:label id="id_33533709" xlink:label="lbl_label861091593" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma NV, Vilvoorde [member]</link:label>
      <link:label id="id_6bd26090" xlink:label="lbl_label1808949392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon - Couvreur NV, Puurs [member]</link:label>
      <link:label id="id_471d9dcf" xlink:label="lbl_label1193123279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon NV, Vilvoorde [member]</link:label>
      <link:label id="id_61e985d" xlink:label="lbl_label102668381" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz NV, Vilvoorde [member]</link:label>
      <link:label id="id_3d34517c" xlink:label="lbl_label1026838908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Securities Investment Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:label="lbl_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:to="lbl_label1026838908" xlink:type="arc"/>
      <link:label id="id_2e061bfd" xlink:label="lbl_label772152317" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Biociencias S.A., Sao Paulo [member]</link:label>
      <link:label id="id_608a61f5" xlink:label="lbl_label1619681781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz do Brasil Industria Farmaceutica Ltda., Cambe, PR [member]</link:label>
      <link:label id="id_20501724" xlink:label="lbl_label542119716" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals Canada Inc., Dorval, Quebec [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:label="lbl_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:to="lbl_label542119716" xlink:type="arc"/>
      <link:label id="id_b170914" xlink:label="lbl_label186059028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Canada Inc., Mississauga, Ontario [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCanadaInc.MississaugaOntarioMember" xlink:label="lbl_AlconCanadaInc.MississaugaOntarioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconCanadaInc.MississaugaOntarioMember" xlink:to="lbl_label186059028" xlink:type="arc"/>
      <link:label id="id_3382e919" xlink:label="lbl_label864217369" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIBA Vision Canada Inc., Mississauga, Ontario [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:label="lbl_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:to="lbl_label864217369" xlink:type="arc"/>
      <link:label id="id_4aad4cdd" xlink:label="lbl_label1252871389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Canada Inc., Boucherville, Quebec [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozCanadaInc.BouchervilleQuebecMember" xlink:label="lbl_SandozCanadaInc.BouchervilleQuebecMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozCanadaInc.BouchervilleQuebecMember" xlink:to="lbl_label1252871389" xlink:type="arc"/>
      <link:label id="id_467b0e02" xlink:label="lbl_label1182469634" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Chile S.A., Santiago de Chile [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisChileS.A.SantiagoDeChileMember" xlink:label="lbl_NovartisChileS.A.SantiagoDeChileMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisChileS.A.SantiagoDeChileMember" xlink:to="lbl_label1182469634" xlink:type="arc"/>
      <link:label id="id_4a31b636" xlink:label="lbl_label1244771894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratorios Chile Ltd., Santiago de Chile [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:label="lbl_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:to="lbl_label1244771894" xlink:type="arc"/>
      <link:label id="id_61f8aada" xlink:label="lbl_label1643686618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beijing Novartis Pharma Co., Ltd., Beijing [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:label="lbl_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:to="lbl_label1643686618" xlink:type="arc"/>
      <link:label id="id_344a1881" xlink:label="lbl_label877271169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals (HK) Limited, Hong Kong [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:label="lbl_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:to="lbl_label877271169" xlink:type="arc"/>
      <link:label id="id_2c879a70" xlink:label="lbl_label747084400" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Suzhou Novartis Pharma Technology Co., Ltd., Changshu [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:label="lbl_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:to="lbl_label747084400" xlink:type="arc"/>
      <link:label id="id_44f2dcf0" xlink:label="lbl_label1156766960" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shanghai Novartis Trading Ltd., Shanghai [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:label="lbl_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:to="lbl_label1156766960" xlink:type="arc"/>
      <link:label id="id_2b1815d1" xlink:label="lbl_label722998737" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Hong Kong Limited, Hong Kong [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconHongKongLimitedHongKongMember" xlink:label="lbl_AlconHongKongLimitedHongKongMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconHongKongLimitedHongKongMember" xlink:to="lbl_label722998737" xlink:type="arc"/>
      <link:label id="id_57ba8d14" xlink:label="lbl_label1471843604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon (China) Ophthalmic Product Co., Ltd., Beijing [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:label="lbl_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:to="lbl_label1471843604" xlink:type="arc"/>
      <link:label id="id_252cd53d" xlink:label="lbl_label623695165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz (China) Pharmaceutical Co., Ltd., Zhongshan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:label="lbl_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:to="lbl_label623695165" xlink:type="arc"/>
      <link:label id="id_65e89b36" xlink:label="lbl_label1709742902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis de Colombia S.A., Santafe de Bogota [member]</link:label>
      <link:label id="id_1522bd0" xlink:label="lbl_label22162384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratorios Alcon de Colombia S.A., Santafe de Bogota [member]</link:label>
      <link:label id="id_2d82460" xlink:label="lbl_label47719520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz d.o.o. farmaceutska industrija, Zagreb [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:label="lbl_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:to="lbl_label47719520" xlink:type="arc"/>
      <link:label id="id_c60eb2a" xlink:label="lbl_label207678250" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis s.r.o., Prague [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisS.r.o.PragueMember" xlink:label="lbl_NovartisS.r.o.PragueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisS.r.o.PragueMember" xlink:to="lbl_label207678250" xlink:type="arc"/>
      <link:label id="id_402474ef" xlink:label="lbl_label1076131055" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Pharmaceuticals (Czech Republic) s.r.o., Prague [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:label="lbl_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:to="lbl_label1076131055" xlink:type="arc"/>
      <link:label id="id_f1c4dd" xlink:label="lbl_label15844573" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz s.r.o., Prague [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.r.o.PragueMember" xlink:label="lbl_SandozS.r.o.PragueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozS.r.o.PragueMember" xlink:to="lbl_label15844573" xlink:type="arc"/>
      <link:label id="id_6ea1eef6" xlink:label="lbl_label1856106230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Healthcare A/S, Copenhagen [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHealthcareASCopenhagenMember" xlink:label="lbl_NovartisHealthcareASCopenhagenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHealthcareASCopenhagenMember" xlink:to="lbl_label1856106230" xlink:type="arc"/>
      <link:label id="id_2dbeb314" xlink:label="lbl_label767472404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Nordic A/S, Copenhagen [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconNordicASCopenhagenMember" xlink:label="lbl_AlconNordicASCopenhagenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconNordicASCopenhagenMember" xlink:to="lbl_label767472404" xlink:type="arc"/>
      <link:label id="id_1e75de5c" xlink:label="lbl_label511041116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz A/S, Copenhagen [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozASCopenhagenMember" xlink:label="lbl_SandozASCopenhagenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozASCopenhagenMember" xlink:to="lbl_label511041116" xlink:type="arc"/>
      <link:label id="id_574d51cf" xlink:label="lbl_label1464685007" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Ecuador S.A., Quito [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisEcuadorS.A.QuitoMember" xlink:label="lbl_NovartisEcuadorS.A.QuitoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisEcuadorS.A.QuitoMember" xlink:to="lbl_label1464685007" xlink:type="arc"/>
      <link:label id="id_679520f0" xlink:label="lbl_label1737826544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma S.A.E., Cairo [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaS.A.E.CairoMember" xlink:label="lbl_NovartisPharmaS.A.E.CairoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaS.A.E.CairoMember" xlink:to="lbl_label1737826544" xlink:type="arc"/>
      <link:label id="id_575ca2d" xlink:label="lbl_label91605549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Egypt Pharma S.A.E., New Cairo City [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:label="lbl_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:to="lbl_label91605549" xlink:type="arc"/>
      <link:label id="id_37f4e561" xlink:label="lbl_label938796385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Finland Oy, Espoo [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinlandOyEspooMember" xlink:label="lbl_NovartisFinlandOyEspooMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFinlandOyEspooMember" xlink:to="lbl_label938796385" xlink:type="arc"/>
      <link:label id="id_42a0d3e7" xlink:label="lbl_label1117836263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Groupe France S.A., Rueil-Malmaison [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:label="lbl_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:to="lbl_label1117836263" xlink:type="arc"/>
      <link:label id="id_7ba00702" xlink:label="lbl_label2074085122" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma S.A.S., Rueil-Malmaison [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:label="lbl_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:to="lbl_label2074085122" xlink:type="arc"/>
      <link:label id="id_d3dae7a" xlink:label="lbl_label222146170" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratoires Alcon S.A.S., Rueil-Malmaison [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:label="lbl_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:to="lbl_label222146170" xlink:type="arc"/>
      <link:label id="id_3116dc5e" xlink:label="lbl_label823581790" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz S.A.S., Levallois-Perret [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.A.S.LevalloisPerretMember" xlink:label="lbl_SandozS.A.S.LevalloisPerretMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozS.A.S.LevalloisPerretMember" xlink:to="lbl_label823581790" xlink:type="arc"/>
      <link:label id="id_6e409e90" xlink:label="lbl_label1849728656" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Deutschland GmbH, Wehr [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeutschlandGmbHWehrMember" xlink:label="lbl_NovartisDeutschlandGmbHWehrMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisDeutschlandGmbHWehrMember" xlink:to="lbl_label1849728656" xlink:type="arc"/>
      <link:label id="id_17634123" xlink:label="lbl_label392380707" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma GmbH, Nuremberg [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaGmbHNurembergMember" xlink:label="lbl_NovartisPharmaGmbHNurembergMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaGmbHNurembergMember" xlink:to="lbl_label392380707" xlink:type="arc"/>
      <link:label id="id_1cd787d" xlink:label="lbl_label30242941" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Produktions GmbH, Wehr [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaProduktionsGmbHWehrMember" xlink:label="lbl_NovartisPharmaProduktionsGmbHWehrMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaProduktionsGmbHWehrMember" xlink:to="lbl_label30242941" xlink:type="arc"/>
      <link:label id="id_401bb4ef" xlink:label="lbl_label1075557615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Business Services GmbH, Wehr [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBusinessServicesGmbHWehrMember" xlink:label="lbl_NovartisBusinessServicesGmbHWehrMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBusinessServicesGmbHWehrMember" xlink:to="lbl_label1075557615" xlink:type="arc"/>
      <link:label id="id_3672a73d" xlink:label="lbl_label913483581" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Pharma GmbH, Freiburg im Breisgau [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:label="lbl_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:to="lbl_label913483581" xlink:type="arc"/>
      <link:label id="id_1fd8572e" xlink:label="lbl_label534271790" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">WaveLight GmbH, Erlangen [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WaveLightGmbHErlangenMember" xlink:label="lbl_WaveLightGmbHErlangenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WaveLightGmbHErlangenMember" xlink:to="lbl_label534271790" xlink:type="arc"/>
      <link:label id="id_4649f215" xlink:label="lbl_label1179251221" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIBA Vision GmbH, Grosswallstadt [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionGmbHGrosswallstadtMember" xlink:label="lbl_CIBAVisionGmbHGrosswallstadtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CIBAVisionGmbHGrosswallstadtMember" xlink:to="lbl_label1179251221" xlink:type="arc"/>
      <link:label id="id_72338a4a" xlink:label="lbl_label1915980362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz International GmbH, Holzkirchen [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozInternationalGmbHHolzkirchenMember" xlink:label="lbl_SandozInternationalGmbHHolzkirchenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozInternationalGmbHHolzkirchenMember" xlink:to="lbl_label1915980362" xlink:type="arc"/>
      <link:label id="id_2c6debd5" xlink:label="lbl_label745401301" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">HEXAL AG, Holzkirchen [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HEXALAGHolzkirchenMember" xlink:label="lbl_HEXALAGHolzkirchenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_HEXALAGHolzkirchenMember" xlink:to="lbl_label745401301" xlink:type="arc"/>
      <link:label id="id_3b790099" xlink:label="lbl_label997785753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Salutas Pharma GmbH, Barleben [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SalutasPharmaGmbHBarlebenMember" xlink:label="lbl_SalutasPharmaGmbHBarlebenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SalutasPharmaGmbHBarlebenMember" xlink:to="lbl_label997785753" xlink:type="arc"/>
      <link:label id="id_5a59fba6" xlink:label="lbl_label1515846566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1 A Pharma GmbH, Holzkirchen [member]</link:label>
      <link:label id="id_63faa754" xlink:label="lbl_label1677371220" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aeropharm GmbH, Rudolstadt [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AeropharmGmbHRudolstadtMember" xlink:label="lbl_AeropharmGmbHRudolstadtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AeropharmGmbHRudolstadtMember" xlink:to="lbl_label1677371220" xlink:type="arc"/>
      <link:label id="id_53a147c7" xlink:label="lbl_label1403078599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novista Insurance Limited, Gibraltar City [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovistaInsuranceLimitedGibraltarCityMember" xlink:label="lbl_NovistaInsuranceLimitedGibraltarCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovistaInsuranceLimitedGibraltarCityMember" xlink:to="lbl_label1403078599" xlink:type="arc"/>
      <link:label id="id_2881adea" xlink:label="lbl_label679587306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis (Hellas) S.A.C.I., Metamorphosis/Athens [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:label="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:to="lbl_label679587306" xlink:type="arc"/>
      <link:label id="id_24c810e" xlink:label="lbl_label38568206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories Hellas Commercial and Industrial S.A., Maroussi, Athens [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:label="lbl_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:to="lbl_label38568206" xlink:type="arc"/>
      <link:label id="id_20010fd1" xlink:label="lbl_label536940497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Hungary Healthcare Limited Liability Company, Budapest [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:label="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:to="lbl_label536940497" xlink:type="arc"/>
      <link:label id="id_3e0a5b35" xlink:label="lbl_label1040866101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Hungary Limited Liability Company, Budapest [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:label="lbl_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:to="lbl_label1040866101" xlink:type="arc"/>
      <link:label id="id_866e747" xlink:label="lbl_label140961607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis India Limited, Mumbai [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIndiaLimitedMumbaiMember" xlink:label="lbl_NovartisIndiaLimitedMumbaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisIndiaLimitedMumbaiMember" xlink:to="lbl_label140961607" xlink:type="arc"/>
      <link:label id="id_5d283d4e" xlink:label="lbl_label1562918222" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Healthcare Private Limited, Mumbai [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:label="lbl_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:to="lbl_label1562918222" xlink:type="arc"/>
      <link:label id="id_209ec8c8" xlink:label="lbl_label547277000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories (India) Private Limited, Bangalore [member]</link:label>
      <link:label id="id_2bccb2e" xlink:label="lbl_label45927214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Private Limited, Mumbai [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPrivateLimitedMumbaiMember" xlink:label="lbl_SandozPrivateLimitedMumbaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPrivateLimitedMumbaiMember" xlink:to="lbl_label45927214" xlink:type="arc"/>
      <link:label id="id_30564a91" xlink:label="lbl_label810961553" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PT. Novartis Indonesia, Jakarta [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PT.NovartisIndonesiaJakartaMember" xlink:label="lbl_PT.NovartisIndonesiaJakartaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PT.NovartisIndonesiaJakartaMember" xlink:to="lbl_label810961553" xlink:type="arc"/>
      <link:label id="id_bca100f" xlink:label="lbl_label197791759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PT. CIBA Vision Batam, Batam [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PT.CIBAVisionBatamBatamMember" xlink:label="lbl_PT.CIBAVisionBatamBatamMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PT.CIBAVisionBatamBatamMember" xlink:to="lbl_label197791759" xlink:type="arc"/>
      <link:label id="id_4fcc5f83" xlink:label="lbl_label1338793859" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Ireland Limited, Dublin [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIrelandLimitedDublinMember" xlink:label="lbl_NovartisIrelandLimitedDublinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisIrelandLimitedDublinMember" xlink:to="lbl_label1338793859" xlink:type="arc"/>
      <link:label id="id_74708b2c" xlink:label="lbl_label1953532716" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Ringaskiddy Limited, Ringaskiddy, County Cork [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:label="lbl_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:to="lbl_label1953532716" xlink:type="arc"/>
      <link:label id="id_169e129" xlink:label="lbl_label23716137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories Ireland Limited, Cork City [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:label="lbl_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:to="lbl_label23716137" xlink:type="arc"/>
      <link:label id="id_1a15ed68" xlink:label="lbl_label437644648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Israel Ltd., Tel Aviv [member]</link:label>
      <link:label id="id_79225a64" xlink:label="lbl_label2032294500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Optonol Ltd., Neve-Ilan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OptonolLtd.NeveIlanMember" xlink:label="lbl_OptonolLtd.NeveIlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OptonolLtd.NeveIlanMember" xlink:to="lbl_label2032294500" xlink:type="arc"/>
      <link:label id="id_572859e2" xlink:label="lbl_label1462262242" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Farma S.p.A., Milan [member]</link:label>
      <link:label id="id_51e555ae" xlink:label="lbl_label1373984174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Italia S.p.A., Milan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconItaliaS.p.A.MilanMember" xlink:label="lbl_AlconItaliaS.p.A.MilanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconItaliaS.p.A.MilanMember" xlink:to="lbl_label1373984174" xlink:type="arc"/>
      <link:label id="id_39182a7" xlink:label="lbl_label59867815" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz S.p.A., Origgio [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.p.A.OriggioMember" xlink:label="lbl_SandozS.p.A.OriggioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozS.p.A.OriggioMember" xlink:to="lbl_label59867815" xlink:type="arc"/>
      <link:label id="id_23768229" xlink:label="lbl_label594969129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Industrial Products S.p.A., Rovereto [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:label="lbl_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:to="lbl_label594969129" xlink:type="arc"/>
      <link:label id="id_46070173" xlink:label="lbl_label1174864243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Holding Japan K.K., Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHoldingJapanK.K.TokyoMember" xlink:label="lbl_NovartisHoldingJapanK.K.TokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHoldingJapanK.K.TokyoMember" xlink:to="lbl_label1174864243" xlink:type="arc"/>
      <link:label id="id_30b5637" xlink:label="lbl_label51074615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma K.K., Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaK.K.TokyoMember" xlink:label="lbl_NovartisPharmaK.K.TokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaK.K.TokyoMember" xlink:to="lbl_label51074615" xlink:type="arc"/>
      <link:label id="id_2358b28" xlink:label="lbl_label37063464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Japan Ltd., Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconJapanLtd.TokyoMember" xlink:label="lbl_AlconJapanLtd.TokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconJapanLtd.TokyoMember" xlink:to="lbl_label37063464" xlink:type="arc"/>
      <link:label id="id_90ace63" xlink:label="lbl_label151703139" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz K.K., Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozK.K.TokyoMember" xlink:label="lbl_SandozK.K.TokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozK.K.TokyoMember" xlink:to="lbl_label151703139" xlink:type="arc"/>
      <link:label id="id_2d24611e" xlink:label="lbl_label757358878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Investments S.a r.l., Luxembourg City [member]</link:label>
      <link:label id="id_6373cce9" xlink:label="lbl_label1668533481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Finance S.A., Luxembourg City [member]</link:label>
      <link:label id="id_495a738b" xlink:label="lbl_label1230664587" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Corporation (Malaysia) Sdn. Bhd., Petaling Jaya [member]</link:label>
      <link:label id="id_30ea85e" xlink:label="lbl_label51292254" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories (Malaysia) Sdn. Bhd., Petaling Jaya [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:label="lbl_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:to="lbl_label51292254" xlink:type="arc"/>
      <link:label id="id_2040f9e0" xlink:label="lbl_label541129184" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIBA Vision Johor Sdn. Bhd., Kuala Lumpur [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:label="lbl_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:to="lbl_label541129184" xlink:type="arc"/>
      <link:label id="id_23d9a520" xlink:label="lbl_label601466144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Farmaceutica, S.A. de C.V., Mexico City [member]</link:label>
      <link:label id="id_7bc6228f" xlink:label="lbl_label2076582543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratorios, S.A. de C.V., Mexico City [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:label="lbl_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:to="lbl_label2076582543" xlink:type="arc"/>
      <link:label id="id_77370b0a" xlink:label="lbl_label2000096010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz, S.A. de C.V., Mexico City [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.A.DeC.V.MexicoCityMember" xlink:label="lbl_SandozS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozS.A.DeC.V.MexicoCityMember" xlink:to="lbl_label2000096010" xlink:type="arc"/>
      <link:label id="id_7143fa4f" xlink:label="lbl_label1900280399" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Maroc SA, Casablanca [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaMarocSACasablancaMember" xlink:label="lbl_NovartisPharmaMarocSACasablancaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaMarocSACasablancaMember" xlink:to="lbl_label1900280399" xlink:type="arc"/>
      <link:label id="id_30236580" xlink:label="lbl_label807626112" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Netherlands B.V., Arnhem [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNetherlandsB.V.ArnhemMember" xlink:label="lbl_NovartisNetherlandsB.V.ArnhemMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNetherlandsB.V.ArnhemMember" xlink:to="lbl_label807626112" xlink:type="arc"/>
      <link:label id="id_1fa13a8d" xlink:label="lbl_label530659981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma B.V., Arnhem [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaB.V.ArnhemMember" xlink:label="lbl_NovartisPharmaB.V.ArnhemMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaB.V.ArnhemMember" xlink:to="lbl_label530659981" xlink:type="arc"/>
      <link:label id="id_6a5dd736" xlink:label="lbl_label1784534838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Nederland B.V., Arnhem [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconNederlandB.V.ArnhemMember" xlink:label="lbl_AlconNederlandB.V.ArnhemMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconNederlandB.V.ArnhemMember" xlink:to="lbl_label1784534838" xlink:type="arc"/>
      <link:label id="id_89b7931" xlink:label="lbl_label144406833" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz B.V., Almere [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozB.V.AlmereMember" xlink:label="lbl_SandozB.V.AlmereMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozB.V.AlmereMember" xlink:to="lbl_label144406833" xlink:type="arc"/>
      <link:label id="id_7ae0d9be" xlink:label="lbl_label2061556158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis New Zealand Ltd, Auckland [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNewZealandLtdAucklandMember" xlink:label="lbl_NovartisNewZealandLtdAucklandMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNewZealandLtdAucklandMember" xlink:to="lbl_label2061556158" xlink:type="arc"/>
      <link:label id="id_659fd8fc" xlink:label="lbl_label1704974588" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Norge AS, Oslo [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNorgeASOsloMember" xlink:label="lbl_NovartisNorgeASOsloMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNorgeASOsloMember" xlink:to="lbl_label1704974588" xlink:type="arc"/>
      <link:label id="id_53e6555" xlink:label="lbl_label87975253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma (Pakistan) Limited, Karachi [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaPakistanLimitedKarachiMember" xlink:label="lbl_NovartisPharmaPakistanLimitedKarachiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaPakistanLimitedKarachiMember" xlink:to="lbl_label87975253" xlink:type="arc"/>
      <link:label id="id_2f1259ff" xlink:label="lbl_label789731839" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma (Logistics), Inc., Panama City [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:label="lbl_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:to="lbl_label789731839" xlink:type="arc"/>
      <link:label id="id_51335372" xlink:label="lbl_label1362318194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Centroamerica S.A., Panama City [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCentroamericaS.A.PanamaCityMember" xlink:label="lbl_AlconCentroamericaS.A.PanamaCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconCentroamericaS.A.PanamaCityMember" xlink:to="lbl_label1362318194" xlink:type="arc"/>
      <link:label id="id_240f2db1" xlink:label="lbl_label604974513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Healthcare Philippines, Inc., Makati City [member]</link:label>
      <link:label id="id_2050b70f" xlink:label="lbl_label542160655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Philippines Corporation, Makati City [member]</link:label>
      <link:label id="id_5fffa6cd" xlink:label="lbl_label1610589901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Poland Sp. z o.o., Warsaw [member]</link:label>
      <link:label id="id_74c896dd" xlink:label="lbl_label1959302877" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Polska Sp. z o.o., Warsaw [member]</link:label>
      <link:label id="id_712c39fe" xlink:label="lbl_label1898723838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Polska Sp. z o.o., Warsaw [member]</link:label>
      <link:label id="id_4ba5de33" xlink:label="lbl_label1269161523" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lek S.A., Strykow [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LekS.A.StrykowMember" xlink:label="lbl_LekS.A.StrykowMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LekS.A.StrykowMember" xlink:to="lbl_label1269161523" xlink:type="arc"/>
      <link:label id="id_520521db" xlink:label="lbl_label1376068059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Portugal SGPS Lda., Porto Salvo [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:label="lbl_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:to="lbl_label1376068059" xlink:type="arc"/>
      <link:label id="id_c95dd37" xlink:label="lbl_label211148087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Farma - Produtos Farmaceuticos S.A., Porto Salvo [member]</link:label>
      <link:label id="id_881ce5c" xlink:label="lbl_label142724700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Portugal-Produtos e Equipamentos Oftalmologicos Lda., Porto Salvo [member]</link:label>
      <link:label id="id_1c2378c4" xlink:label="lbl_label472086724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Farmaceutica Lda., Porto Salvo [member]</link:label>
      <link:label id="id_4a9bb1ea" xlink:label="lbl_label1251717610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Services Romania S.R.L., Bucharest [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:label="lbl_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:to="lbl_label1251717610" xlink:type="arc"/>
      <link:label id="id_30d12469" xlink:label="lbl_label819012713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Romania S.R.L., Bucharest [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconRomaniaS.R.L.BucharestMember" xlink:label="lbl_AlconRomaniaS.R.L.BucharestMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconRomaniaS.R.L.BucharestMember" xlink:to="lbl_label819012713" xlink:type="arc"/>
      <link:label id="id_1a1b1a89" xlink:label="lbl_label437983881" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz S.R.L., Targu-Mures [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.R.L.TarguMuresMember" xlink:label="lbl_SandozS.R.L.TarguMuresMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozS.R.L.TarguMuresMember" xlink:to="lbl_label437983881" xlink:type="arc"/>
      <link:label id="id_620cd72f" xlink:label="lbl_label1645008687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma LLC, Moscow [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaLLCMoscowMember" xlink:label="lbl_NovartisPharmaLLCMoscowMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaLLCMoscowMember" xlink:to="lbl_label1645008687" xlink:type="arc"/>
      <link:label id="id_a4d4ccd" xlink:label="lbl_label172838093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Farmacevtika LLC, Moscow [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconFarmacevtikaLLCMoscowMember" xlink:label="lbl_AlconFarmacevtikaLLCMoscowMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconFarmacevtikaLLCMoscowMember" xlink:to="lbl_label172838093" xlink:type="arc"/>
      <link:label id="id_4f8c203f" xlink:label="lbl_label1334583359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JSC Sandoz, Moscow [member]</link:label>
      <link:label id="id_3b17514" xlink:label="lbl_label61961492" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Neva LLC, St. Petersburg [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNevaLLCSt.PetersburgMember" xlink:label="lbl_NovartisNevaLLCSt.PetersburgMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNevaLLCSt.PetersburgMember" xlink:to="lbl_label61961492" xlink:type="arc"/>
      <link:label id="id_2d25f558" xlink:label="lbl_label757462360" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Saudi Pharmaceutical Distribution Co. Ltd., Riyadh [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:label="lbl_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:to="lbl_label757462360" xlink:type="arc"/>
      <link:label id="id_ef37254" xlink:label="lbl_label250835540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis (Singapore) Pte Ltd., Singapore [member]</link:label>
      <link:label id="id_27535d56" xlink:label="lbl_label659774806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Singapore Pharmaceutical Manufacturing Pte Ltd, Singapore [member]</link:label>
      <link:label id="id_73caa11d" xlink:label="lbl_label1942659357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Asia Pacific Pharmaceuticals Pte Ltd, Singapore [member]</link:label>
      <link:label id="id_5ac408db" xlink:label="lbl_label1522796763" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Institute for Tropical Diseases Pte Ltd, Singapore [member]</link:label>
      <link:label id="id_405feadd" xlink:label="lbl_label1080027869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Singapore Manufacturing Pte. Ltd., Singapore [member]</link:label>
      <link:label id="id_5ad357d3" xlink:label="lbl_label1523800019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIBA Vision Asian Manufacturing and Logistics Pte Ltd., Singapore [member]</link:label>
      <link:label id="id_5654aaaa" xlink:label="lbl_label1448389290" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Pte Ltd, Singapore [member]</link:label>
      <link:label id="id_1f0269e9" xlink:label="lbl_label520251881" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Slovakia s.r.o., Bratislava [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSlovakiaS.r.o.BratislavaMember" xlink:label="lbl_NovartisSlovakiaS.r.o.BratislavaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSlovakiaS.r.o.BratislavaMember" xlink:to="lbl_label520251881" xlink:type="arc"/>
      <link:label id="id_3337da30" xlink:label="lbl_label859298352" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lek Pharmaceuticals d.d., Ljubjana [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LekPharmaceuticalsD.d.LjubjanaMember" xlink:label="lbl_LekPharmaceuticalsD.d.LjubjanaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LekPharmaceuticalsD.d.LjubjanaMember" xlink:to="lbl_label859298352" xlink:type="arc"/>
      <link:label id="id_24583ab1" xlink:label="lbl_label609761969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Pharmaceuticals d.d., Ljubjana [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:label="lbl_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:to="lbl_label609761969" xlink:type="arc"/>
      <link:label id="id_25162424" xlink:label="lbl_label622208036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis South Africa (Pty) Ltd, Midrand [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSouthAfricaPtyLtdMidrandMember" xlink:label="lbl_NovartisSouthAfricaPtyLtdMidrandMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSouthAfricaPtyLtdMidrandMember" xlink:to="lbl_label622208036" xlink:type="arc"/>
      <link:label id="id_c4640a" xlink:label="lbl_label12870666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories (South Africa) (Pty) Ltd., Midrand [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:label="lbl_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:to="lbl_label12870666" xlink:type="arc"/>
      <link:label id="id_44cecbf4" xlink:label="lbl_label1154403316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz South Africa (Pty) Ltd, Midrand [member]</link:label>
      <link:label id="id_51e9e54d" xlink:label="lbl_label1374283085" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Korea Ltd., Seoul [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisKoreaLtd.SeoulMember" xlink:label="lbl_NovartisKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisKoreaLtd.SeoulMember" xlink:to="lbl_label1374283085" xlink:type="arc"/>
      <link:label id="id_2fbc9bcb" xlink:label="lbl_label800889803" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Korea Ltd., Seoul [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconKoreaLtd.SeoulMember" xlink:label="lbl_AlconKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconKoreaLtd.SeoulMember" xlink:to="lbl_label800889803" xlink:type="arc"/>
      <link:label id="id_3acd65c6" xlink:label="lbl_label986539462" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Korea Ltd., Seoul [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozKoreaLtd.SeoulMember" xlink:label="lbl_SandozKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozKoreaLtd.SeoulMember" xlink:to="lbl_label986539462" xlink:type="arc"/>
      <link:label id="id_2cb12411" xlink:label="lbl_label749806609" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Farmaceutica, S.A., Barcelona [member]</link:label>
      <link:label id="id_1788ee4f" xlink:label="lbl_label394849871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Cusi S.A., Barcelona [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCusiS.A.BarcelonaMember" xlink:label="lbl_AlconCusiS.A.BarcelonaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconCusiS.A.BarcelonaMember" xlink:to="lbl_label394849871" xlink:type="arc"/>
      <link:label id="id_25c7e6c1" xlink:label="lbl_label633857729" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Farmaceutica S.A., Madrid [member]</link:label>
      <link:label id="id_578d972e" xlink:label="lbl_label1468897070" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Industrial Products S.A., Les Franqueses del Vall?s / Barcelona [member]</link:label>
      <link:label id="id_6a673c57" xlink:label="lbl_label1785150551" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Abadia Retuerta S.A., Sardon de Duero/Valladolid [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:label="lbl_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:to="lbl_label1785150551" xlink:type="arc"/>
      <link:label id="id_6cfceac6" xlink:label="lbl_label1828514502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Sverige AB, Stockholm [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSverigeABStockholmMember" xlink:label="lbl_NovartisSverigeABStockholmMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSverigeABStockholmMember" xlink:to="lbl_label1828514502" xlink:type="arc"/>
      <link:label id="id_1784eaf5" xlink:label="lbl_label394586869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis International AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInternationalAGBaselMember" xlink:label="lbl_NovartisInternationalAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInternationalAGBaselMember" xlink:to="lbl_label394586869" xlink:type="arc"/>
      <link:label id="id_1cfce538" xlink:label="lbl_label486335800" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Holding AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHoldingAGBaselMember" xlink:label="lbl_NovartisHoldingAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHoldingAGBaselMember" xlink:to="lbl_label486335800" xlink:type="arc"/>
      <link:label id="id_523c2f36" xlink:label="lbl_label1379675958" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis International Pharmaceutical AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInternationalPharmaceuticalAGBaselMember" xlink:label="lbl_NovartisInternationalPharmaceuticalAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInternationalPharmaceuticalAGBaselMember" xlink:to="lbl_label1379675958" xlink:type="arc"/>
      <link:label id="id_31c15b81" xlink:label="lbl_label834755457" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaAGBaselMember" xlink:label="lbl_NovartisPharmaAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaAGBaselMember" xlink:to="lbl_label834755457" xlink:type="arc"/>
      <link:label id="id_6bb5d046" xlink:label="lbl_label1807077446" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Services AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaServicesAGBaselMember" xlink:label="lbl_NovartisPharmaServicesAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaServicesAGBaselMember" xlink:to="lbl_label1807077446" xlink:type="arc"/>
      <link:label id="id_151ca66f" xlink:label="lbl_label354199151" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Schweizerhalle AG, Muttenz [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:label="lbl_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:to="lbl_label354199151" xlink:type="arc"/>
      <link:label id="id_7888d993" xlink:label="lbl_label2022234515" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Stein AG, Stein [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaSteinAGSteinMember" xlink:label="lbl_NovartisPharmaSteinAGSteinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaSteinAGSteinMember" xlink:to="lbl_label2022234515" xlink:type="arc"/>
      <link:label id="id_46b0e62c" xlink:label="lbl_label1185998380" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma Schweiz AG, Risch [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaSchweizAGRischMember" xlink:label="lbl_NovartisPharmaSchweizAGRischMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaSchweizAGRischMember" xlink:to="lbl_label1185998380" xlink:type="arc"/>
      <link:label id="id_175b3164" xlink:label="lbl_label391852388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Switzerland SA, Risch [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconSwitzerlandSARischMember" xlink:label="lbl_AlconSwitzerlandSARischMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconSwitzerlandSARischMember" xlink:to="lbl_label391852388" xlink:type="arc"/>
      <link:label id="id_6dde1079" xlink:label="lbl_label1843269753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Pharmaceuticals Ltd., Fribourg [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaceuticalsLtd.FribourgMember" xlink:label="lbl_AlconPharmaceuticalsLtd.FribourgMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPharmaceuticalsLtd.FribourgMember" xlink:to="lbl_label1843269753" xlink:type="arc"/>
      <link:label id="id_2056dcf1" xlink:label="lbl_label542563569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozAGBaselMember" xlink:label="lbl_SandozAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozAGBaselMember" xlink:to="lbl_label542563569" xlink:type="arc"/>
      <link:label id="id_c4607df" xlink:label="lbl_label205916127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Pharmaceuticals AG, Risch [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPharmaceuticalsAGRischMember" xlink:label="lbl_SandozPharmaceuticalsAGRischMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPharmaceuticalsAGRischMember" xlink:to="lbl_label205916127" xlink:type="arc"/>
      <link:label id="id_2bda8165" xlink:label="lbl_label735740261" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis (Taiwan) Co., Ltd., Taipei [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:label="lbl_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:to="lbl_label735740261" xlink:type="arc"/>
      <link:label id="id_1cc3a1bc" xlink:label="lbl_label482582972" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis (Thailand) Limited, Bangkok [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisThailandLimitedBangkokMember" xlink:label="lbl_NovartisThailandLimitedBangkokMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisThailandLimitedBangkokMember" xlink:to="lbl_label482582972" xlink:type="arc"/>
      <link:label id="id_1e10820d" xlink:label="lbl_label504398349" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories (Thailand) Limited, Bangkok [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesThailandLimitedBangkokMember" xlink:label="lbl_AlconLaboratoriesThailandLimitedBangkokMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesThailandLimitedBangkokMember" xlink:to="lbl_label504398349" xlink:type="arc"/>
      <link:label id="id_76d30813" xlink:label="lbl_label1993541651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Saglik, Gida ve Tarim Urunleri Sanayi ve Ticaret A.S., Istanbul [member]</link:label>
      <link:label id="id_7653b21e" xlink:label="lbl_label1985196574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratuvarlari Ticaret A.S., Istanbul [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:label="lbl_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:to="lbl_label1985196574" xlink:type="arc"/>
      <link:label id="id_6083f415" xlink:label="lbl_label1619260437" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Ilac Sanayi ve Ticaret A.S., Istanbul [member]</link:label>
      <link:label id="id_2c3cd0a2" xlink:label="lbl_label742183074" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Grup Saglik Urunleri Ilaclari Sanayi ve Ticaret A.S., Gebze - Kocaeli [member]</link:label>
      <link:label id="id_775d02f4" xlink:label="lbl_label2002584308" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Middle East FZE, Dubai [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisMiddleEastFZEDubaiMember" xlink:label="lbl_NovartisMiddleEastFZEDubaiMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisMiddleEastFZEDubaiMember" xlink:to="lbl_label2002584308" xlink:type="arc"/>
      <link:label id="id_629f2d5a" xlink:label="lbl_label1654599002" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis UK Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUKLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisUKLimitedFrimleyCamberleyMember" xlink:to="lbl_label1654599002" xlink:type="arc"/>
      <link:label id="id_24628050" xlink:label="lbl_label610435152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals UK Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:to="lbl_label610435152" xlink:type="arc"/>
      <link:label id="id_72101279" xlink:label="lbl_label1913655929" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Grimsby Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:to="lbl_label1913655929" xlink:type="arc"/>
      <link:label id="id_41ed60da" xlink:label="lbl_label1106075866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Eye Care UK Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:label="lbl_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:to="lbl_label1106075866" xlink:type="arc"/>
      <link:label id="id_61fe5165" xlink:label="lbl_label1644056933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozLimitedFrimleyCamberleyMember" xlink:label="lbl_SandozLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozLimitedFrimleyCamberleyMember" xlink:to="lbl_label1644056933" xlink:type="arc"/>
      <link:label id="id_5fa82378" xlink:label="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Glaxosmithkline Consumer Healthcare Holdings Limited, Brentford, Middlesex [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:label="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:to="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember_labels" xlink:type="arc"/>
      <link:label id="id_4687124a" xlink:label="lbl_label1183257162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Corporation, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCorporationEastHanoverNYMember" xlink:label="lbl_NovartisCorporationEastHanoverNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCorporationEastHanoverNYMember" xlink:to="lbl_label1183257162" xlink:type="arc"/>
      <link:label id="id_739f0d6b" xlink:label="lbl_label1939803499" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Finance Corporation, New York, NY [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceCorporationNewYorkNYMember" xlink:label="lbl_NovartisFinanceCorporationNewYorkNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFinanceCorporationNewYorkNYMember" xlink:to="lbl_label1939803499" xlink:type="arc"/>
      <link:label id="id_6a2defad" xlink:label="lbl_label1781395373" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, New York, NY [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkNYMember" xlink:label="lbl_NovartisCapitalCorporationNewYorkNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationNewYorkNYMember" xlink:to="lbl_label1781395373" xlink:type="arc"/>
      <link:label id="id_2951cebe" xlink:label="lbl_label693227198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals Corporation, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:label="lbl_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:to="lbl_label693227198" xlink:type="arc"/>
      <link:label id="id_10d13d66" xlink:label="lbl_label282148198" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Institutes for BioMedical Research, Inc., Cambridge, MA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:label="lbl_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:to="lbl_label282148198" xlink:type="arc"/>
      <link:label id="id_2e63ddd" xlink:label="lbl_label48643549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Institute for Functional Genomics, Inc., San Diego, CA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:label="lbl_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:to="lbl_label48643549" xlink:type="arc"/>
      <link:label id="id_13ee6af1" xlink:label="lbl_label334392049" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Vaccines and Diagnostics, Inc., Cambridge, MA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:label="lbl_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:to="lbl_label334392049" xlink:type="arc"/>
      <link:label id="id_5eea5c27" xlink:label="lbl_label1592417319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Services, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisServicesInc.EastHanoverNYMember" xlink:label="lbl_NovartisServicesInc.EastHanoverNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisServicesInc.EastHanoverNYMember" xlink:to="lbl_label1592417319" xlink:type="arc"/>
      <link:label id="id_51dba865" xlink:label="lbl_label1373349989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories Holding Corporation, Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:label="lbl_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:to="lbl_label1373349989" xlink:type="arc"/>
      <link:label id="id_31a31f0b" xlink:label="lbl_label832773899" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories, Inc., Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesInc.FortWorthTXMember" xlink:label="lbl_AlconLaboratoriesInc.FortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesInc.FortWorthTXMember" xlink:to="lbl_label832773899" xlink:type="arc"/>
      <link:label id="id_c4acd60" xlink:label="lbl_label206228832" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Refractivehorizons, LLC, Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:label="lbl_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:to="lbl_label206228832" xlink:type="arc"/>
      <link:label id="id_48c065e" xlink:label="lbl_label76285534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Research, Ltd., Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconResearchLtd.FortWorthTXMember" xlink:label="lbl_AlconResearchLtd.FortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconResearchLtd.FortWorthTXMember" xlink:to="lbl_label76285534" xlink:type="arc"/>
      <link:label id="id_17312f5" xlink:label="lbl_label24318709" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Lensx, Inc., Aliso Viejo, CA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLensxInc.AlisoViejoCAMember" xlink:label="lbl_AlconLensxInc.AlisoViejoCAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLensxInc.AlisoViejoCAMember" xlink:to="lbl_label24318709" xlink:type="arc"/>
      <link:label id="id_305f2824" xlink:label="lbl_label811542564" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Inc., Princeton, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozInc.PrincetonNJMember" xlink:label="lbl_SandozInc.PrincetonNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozInc.PrincetonNJMember" xlink:to="lbl_label811542564" xlink:type="arc"/>
      <link:label id="id_1810f51f" xlink:label="lbl_label403764511" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eon Labs, Inc., Princeton, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EonLabsInc.PrincetonNJMember" xlink:label="lbl_EonLabsInc.PrincetonNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EonLabsInc.PrincetonNJMember" xlink:to="lbl_label403764511" xlink:type="arc"/>
      <link:label id="id_1c839601" xlink:label="lbl_label478385665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fougera Pharmaceuticals Inc., Melville, NY [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:label="lbl_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:to="lbl_label478385665" xlink:type="arc"/>
      <link:label id="id_7af3c86c" xlink:label="lbl_label2062796908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis de Venezuela, S.A., Caracas [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeVenezuelaS.A.CaracasMember" xlink:label="lbl_NovartisDeVenezuelaS.A.CaracasMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisDeVenezuelaS.A.CaracasMember" xlink:to="lbl_label2062796908" xlink:type="arc"/>
      <link:label id="id_51d78d0e" xlink:label="lbl_label1373080846" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Pharmaceutical, C.A., Caracas [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaceuticalC.A.CaracasMember" xlink:label="lbl_AlconPharmaceuticalC.A.CaracasMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPharmaceuticalC.A.CaracasMember" xlink:to="lbl_label1373080846" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBiocienciasS.A.SaoPauloMember" xlink:label="lbl_NovartisBiocienciasS.A.SaoPauloMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBiocienciasS.A.SaoPauloMember" xlink:to="lbl_label772152317" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:label="lbl_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:to="lbl_label1619681781" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:label="lbl_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:to="lbl_label1709742902" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:label="lbl_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:to="lbl_label22162384" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:label="lbl_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:to="lbl_label601466144" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:label="lbl_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:to="lbl_label211148087" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:label="lbl_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:to="lbl_label142724700" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozFarmaceuticaLda.PortoSalvoMember" xlink:label="lbl_SandozFarmaceuticaLda.PortoSalvoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozFarmaceuticaLda.PortoSalvoMember" xlink:to="lbl_label472086724" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:label="lbl_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:to="lbl_label749806609" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozFarmaceuticaS.A.MadridMember" xlink:label="lbl_SandozFarmaceuticaS.A.MadridMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozFarmaceuticaS.A.MadridMember" xlink:to="lbl_label633857729" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:label="lbl_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:to="lbl_label1993541651" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:label="lbl_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:to="lbl_label1619260437" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:label="lbl_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:to="lbl_label742183074" xlink:type="arc"/>
      <link:label id="id_5219f8cb" xlink:label="lbl_label1377433803" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments - additional disclosure [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_label1377433803" xlink:type="arc"/>
      <link:label id="id_7be99054" xlink:label="lbl_label2078904404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in fair value measurement [table]</link:label>
      <link:label id="id_373151e5" xlink:label="lbl_FinancialInstrumentsCarryingValueLevel3_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value measurement, carrying value, level 3</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsCarryingValueLevel3" xlink:label="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:to="lbl_FinancialInstrumentsCarryingValueLevel3_labels" xlink:type="arc"/>
      <link:label id="id_3bebbf6d" xlink:label="lbl_FinancialInstrumentsCarryingValueLevel3_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value measurement, carrying value, level 3, at beginning of period</link:label>
      <link:label id="id_fde9a71" xlink:label="lbl_FinancialInstrumentsCarryingValueLevel3_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value measurement, carrying value, level 3, at end of period</link:label>
      <link:label id="id_38539773" xlink:label="lbl_label945002355" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value gains and other adjustments including from divestments recognized in the consolidated income statement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="lbl_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:to="lbl_label945002355" xlink:type="arc"/>
      <link:label id="id_3f162228" xlink:label="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:to="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets_labels" xlink:type="arc"/>
      <link:label id="id_34d2b17f" xlink:label="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments recognized in the consolidated statement of comprehensive income</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:label="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:to="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_1f17c4f4" xlink:label="lbl_label521651444" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchases fair value measurement assets</link:label>
      <link:label id="id_712f0e18" xlink:label="lbl_DisposalsFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals fair value measurement assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisposalsFairValueMeasurementAssets" xlink:label="lbl_DisposalsFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalsFairValueMeasurementAssets" xlink:to="lbl_DisposalsFairValueMeasurementAssets_labels" xlink:type="arc"/>
      <link:label id="id_6183f24" xlink:label="lbl_ReclassificationFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification fair value measurement assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclassificationFairValueMeasurementAssets" xlink:label="lbl_ReclassificationFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclassificationFairValueMeasurementAssets" xlink:to="lbl_ReclassificationFairValueMeasurementAssets_labels" xlink:type="arc"/>
      <link:label id="id_21602cfa" xlink:label="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value gains and losses recognized in the consolidated income statement for assets and liabilities held</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:label="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:to="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld_labels" xlink:type="arc"/>
      <link:label id="id_d0e5228" xlink:label="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end</link:label>
      <link:label id="id_28030b1e" xlink:label="lbl_label671288094" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Monitoring of net debt or liquidity based on contractual maturities [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:label="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:to="lbl_label671288094" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:label="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_label2078904404" xlink:type="arc"/>
      <link:label id="id_2f39f660" xlink:label="lbl_label792327776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity of net debt [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaturityOfNetDebtLineItems" xlink:label="lbl_MaturityOfNetDebtLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_label792327776" xlink:type="arc"/>
      <link:label id="id_58c89014" xlink:label="lbl_OtherNoncurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-current financial debts</link:label>
      <link:label id="id_7d6c1038" xlink:label="lbl_OtherCurrentFinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current financial debt</link:label>
      <link:label id="id_2fc36503" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current financial assets</link:label>
      <link:label id="id_54e7be06" xlink:label="lbl_label1424473606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities and time deposits [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketableSecuritiesAndTimeDepositsMember" xlink:label="lbl_MarketableSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MarketableSecuritiesAndTimeDepositsMember" xlink:to="lbl_label1424473606" xlink:type="arc"/>
      <link:label id="id_2cb9fd3b" xlink:label="lbl_label750386491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commodities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommoditiesMember" xlink:label="lbl_CommoditiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommoditiesMember" xlink:to="lbl_label750386491" xlink:type="arc"/>
      <link:label id="id_31b4a926" xlink:label="lbl_label833923366" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deriviative financial instruments and accrued interest [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:label="lbl_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:to="lbl_label833923366" xlink:type="arc"/>
      <link:label id="id_75dba3db" xlink:label="lbl_label1977328603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial debt [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialDebtMember" xlink:label="lbl_FinancialDebtMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialDebtMember" xlink:to="lbl_label1977328603" xlink:type="arc"/>
      <link:label id="id_24faa4a5" xlink:label="lbl_label620405925" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial debt - undiscounted [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialDebtUndiscountedMember" xlink:label="lbl_FinancialDebtUndiscountedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialDebtUndiscountedMember" xlink:to="lbl_label620405925" xlink:type="arc"/>
      <link:label id="id_2e5c234f" xlink:label="lbl_label777790287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than three month and not later than twelve months [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:label="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:to="lbl_label777790287" xlink:type="arc"/>
      <link:label id="id_106ff37d" xlink:label="lbl_label275772285" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments and accrued interest on derivative financial instruments [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_label275772285" xlink:type="arc"/>
      <link:label id="id_7c18c756" xlink:label="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential outflows in various currencies - from financial derivative liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:label="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:to="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_4ab97cb3" xlink:label="lbl_label1253670067" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential inflows in various currencies - from financial derivative assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:label="lbl_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:to="lbl_label1253670067" xlink:type="arc"/>
      <link:label id="id_68a3968f" xlink:label="lbl_label1755551375" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments and accrued interest on derivative financial instruments [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:to="lbl_label1755551375" xlink:type="arc"/>
      <link:label id="id_6f45bf77" xlink:label="lbl_ContractualInterestOnNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual interest on non-current liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractualInterestOnNoncurrentLiabilities" xlink:label="lbl_ContractualInterestOnNoncurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContractualInterestOnNoncurrentLiabilities" xlink:to="lbl_ContractualInterestOnNoncurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_60f25e47" xlink:label="lbl_ContractualInterestOnNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual interest on non-current liabilities</link:label>
      <link:label id="id_26c3488c" xlink:label="lbl_label650332300" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ten day loss fair value VAR model [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TenDayLossFairValueVARModelTable" xlink:label="lbl_TenDayLossFairValueVARModelTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TenDayLossFairValueVARModelTable" xlink:to="lbl_label650332300" xlink:type="arc"/>
      <link:label id="id_3ecf37ac" xlink:label="lbl_label1053767596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ten day loss fair value VAR model [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TenDayLossFairValueVARModelLineItems" xlink:label="lbl_TenDayLossFairValueVARModelLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_label1053767596" xlink:type="arc"/>
      <link:label id="id_1d7eaa93" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, value at risk computation</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputation" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsValueAtRiskComputation" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputation_labels" xlink:type="arc"/>
      <link:label id="id_4d7520d9" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, value at risk computation, sensitive to foreign currency exchange rates</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates_labels" xlink:type="arc"/>
      <link:label id="id_bc6d63c" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, value at risk computation, sensitive to equity market movements</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements_labels" xlink:type="arc"/>
      <link:label id="id_7e591031" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, value at risk computation, sensitive to interest rates</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates_labels" xlink:type="arc"/>
      <link:label id="id_1a9805f" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputation_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All financial instruments</link:label>
      <link:label id="id_2ef01715" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instruments sensitive to foreign currency exchange rates</link:label>
      <link:label id="id_74cd5fab" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instruments sensitive to equity market movements</link:label>
      <link:label id="id_3073f174" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instruments sensitive to interest rates</link:label>
      <link:label id="id_69bd9251" xlink:label="lbl_WeightedAverageMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageMember" xlink:label="lbl_WeightedAverageMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageMember" xlink:to="lbl_WeightedAverageMember_labels" xlink:type="arc"/>
      <link:label id="id_301d16c7" xlink:label="lbl_WeightedAverageMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average</link:label>
      <link:label id="id_2a5fb07c" xlink:label="lbl_TopOfRangeMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">High</link:label>
      <link:label id="id_6654bf44" xlink:label="lbl_BottomOfRangeMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Low</link:label>
      <link:label id="id_405da1b9" xlink:label="lbl_WorstCaseLossScenarioMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Worst case loss scenario [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WorstCaseLossScenarioMember" xlink:label="lbl_WorstCaseLossScenarioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WorstCaseLossScenarioMember" xlink:to="lbl_WorstCaseLossScenarioMember_labels" xlink:type="arc"/>
      <link:label id="id_2e992db9" xlink:label="lbl_WorstCaseLossScenarioMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Worst case loss scenario</link:label>
      <link:label id="id_4ee2f2eb" xlink:label="lbl_label1323496171" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash receipts and payments fair value measurement assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:label="lbl_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:to="lbl_label1323496171" xlink:type="arc"/>
      <link:label id="id_2d2549bd" xlink:label="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Potential outflows in various currencies - from financial derivative liabilities</link:label>
      <link:label id="id_6773649" xlink:label="lbl_DeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:label id="id_7a7f8744" xlink:label="lbl_Liabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
      <link:label id="id_5793c543" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax balance</link:label>
      <link:label id="id_786524e" xlink:label="lbl_UnusedProvisionReversedOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversal of provisions for doubtful trade receivables</link:label>
      <link:label id="id_6744ae33" xlink:label="lbl_FairValueOfInvestmentsInAssociatesWherePriceQuotationsPublished_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Publicly quoted market value of the Novartis interest</link:label>
      <link:label id="id_24696e1c" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current service cost</link:label>
      <link:label id="id_471bbf88" xlink:label="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net interest expense</link:label>
      <link:label id="id_2f35efb7" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Novartis Equity Plan "Select", outside North America [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_labels" xlink:type="arc"/>
      <link:label id="id_58a34798" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Select outside North America</link:label>
      <link:label id="id_5e36913a" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Novartis Equity Plan "Select", North America [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_labels" xlink:type="arc"/>
      <link:label id="id_49d8c8f7" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Select North America</link:label>
      <link:label id="id_7c2b7da9" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon, Inc., equity plans, granted to associates prior merger [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:to="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember_labels" xlink:type="arc"/>
      <link:label id="id_3be795e9" xlink:label="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_3e622c14" xlink:label="lbl_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited, number of shares</link:label>
      <link:label id="id_179f71dc" xlink:label="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding, Number</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_13e82d94" xlink:label="lbl_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested, number of shares</link:label>
      <link:label id="id_676b945a" xlink:label="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Granted, Number of Shares</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted_labels" xlink:type="arc"/>
      <link:label id="id_7c12048" xlink:label="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted, number of shares</link:label>
      <link:label id="id_36172efd" xlink:label="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of shares at end of period</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_labels" xlink:type="arc"/>
      <link:label id="id_60b0a4e9" xlink:label="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of shares at beginning of period</link:label>
      <link:label id="id_3531edda" xlink:label="lbl_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
      <link:label id="id_7874e637" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss/(income) from associated companies</link:label>
      <link:label id="id_32b80bd7" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Other Share Awards [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsMember_labels" xlink:type="arc"/>
      <link:label id="id_18282520" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other share awards</link:label>
      <link:label id="id_46ef7a38" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alcon equity plans granted to associates prior merger</link:label>
      <link:label id="id_5f28436" xlink:label="lbl_EquityBasedParticipationRestrictedSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Shares</link:label>
      <link:label id="id_68171cd3" xlink:label="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leveraged Share Savings Plan (LSSP)</link:label>
      <link:label id="id_33a3b55c" xlink:label="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Share Ownership Plan (ESOP)</link:label>
      <link:label id="id_48de40b0" xlink:label="lbl_EquityBasedParticipationUKShareSavingsPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UK Share Savings Plan</link:label>
      <link:label id="id_71e8eb1f" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for product liabilities, governmental investigations and other legal matters</link:label>
      <link:label id="id_68f6d949" xlink:label="lbl_ShareMovements_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share movements in period</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShareMovements" xlink:label="lbl_ShareMovements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareMovements" xlink:to="lbl_ShareMovements_labels" xlink:type="arc"/>
      <link:label id="id_10047f77" xlink:label="lbl_ShareMovements_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total movements</link:label>
      <link:label id="id_5da2c69" xlink:label="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net expense, royalties cost sharing and profit sharing</link:label>
      <link:label id="id_1b2e9a2e" xlink:label="lbl_NetInvestmentHedgeMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net investment hedge [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetInvestmentHedgeMember" xlink:label="lbl_NetInvestmentHedgeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetInvestmentHedgeMember" xlink:to="lbl_NetInvestmentHedgeMember_labels" xlink:type="arc"/>
      <link:label id="id_6aadffe9" xlink:label="lbl_label1789788137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written call options held by market maker</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsHeldByMarketMaker" xlink:label="lbl_WrittenCallOptionsHeldByMarketMaker" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WrittenCallOptionsHeldByMarketMaker" xlink:to="lbl_label1789788137" xlink:type="arc"/>
      <link:label id="id_29617d6b" xlink:label="lbl_label694254955" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written call options, contractual live</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsContractualLive" xlink:label="lbl_WrittenCallOptionsContractualLive" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WrittenCallOptionsContractualLive" xlink:to="lbl_label694254955" xlink:type="arc"/>
      <link:label id="id_b107ceb" xlink:label="lbl_label185629931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written call options, contractual live, remaining</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsContractualLiveRemaining" xlink:label="lbl_WrittenCallOptionsContractualLiveRemaining" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WrittenCallOptionsContractualLiveRemaining" xlink:to="lbl_label185629931" xlink:type="arc"/>
      <link:label id="id_292f5855" xlink:label="lbl_label690968661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written call options, weighted average exercise price</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsWeightedAverageExercisePrice" xlink:label="lbl_WrittenCallOptionsWeightedAverageExercisePrice" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WrittenCallOptionsWeightedAverageExercisePrice" xlink:to="lbl_label690968661" xlink:type="arc"/>
      <link:label id="id_1e74829a" xlink:label="lbl_InterestExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total interest expense</link:label>
      <link:label id="id_764458f" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in current financial debts</link:label>
      <link:label id="id_657faa04" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividends paid to non-controlling interests and other financing cash flows</link:label>
      <link:label id="id_4f246ab" xlink:label="lbl_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables and other liabilities including deferred tax liabilities</link:label>
      <link:label id="id_3f1c8d8f" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income taxes paid</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PurchaseFairValueMeasurementAssets" xlink:label="lbl_PurchaseFairValueMeasurementAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseFairValueMeasurementAssets" xlink:to="lbl_label521651444" xlink:type="arc"/>
      <link:label id="id_cca13ad" xlink:label="lbl_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid and other portfolio transformation related cash flows</link:label>
      <link:label id="id_7ef7b9ed" xlink:label="lbl_OtherPaymentsAndDeferredConsiderationNet_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments, deferred consideration and other adjustments, net</link:label>
      <link:label id="id_47b366a2" xlink:label="lbl_DeferredPrepaidPortionOfSalesPrice_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred portion of sales price</link:label>
      <link:label id="id_547e2ca5" xlink:label="lbl_StockRepurchaseProgramAuthorizedAmount1_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StockRepurchaseProgramAuthorizedAmount1" xlink:label="lbl_StockRepurchaseProgramAuthorizedAmount1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lbl_StockRepurchaseProgramAuthorizedAmount1_labels" xlink:type="arc"/>
      <link:label id="id_73838734" xlink:label="lbl_StockRepurchaseProgramAuthorizedAmount1_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares repurchased on the SIX Swiss Exchange second trading line under the share buyback authority approved</link:label>
      <link:label id="id_56c435e" xlink:label="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</link:label>
      <link:label id="id_12b02f16" xlink:label="lbl_DisposalsFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Disposals fair value measurement assets</link:label>
      <link:label id="id_26be22ce" xlink:label="lbl_AdjustmentsForReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversal of non-cash items and other adjustments</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForReconcileProfitLoss" xlink:to="lbl_AdjustmentsForReconcileProfitLoss_labels" xlink:type="arc"/>
      <link:label id="id_2cafaaf8" xlink:label="lbl_AdjustmentsForReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total reversal of non-cash items</link:label>
      <link:label id="id_4b753731" xlink:label="lbl_AdjustmentsForReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile profit (loss)</link:label>
      <link:label id="id_38c3816c" xlink:label="lbl_IncomeTaxesPaidRefund_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income taxes (paid)/refund</link:label>
      <link:label id="id_156023e7" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income taxes (paid)/refund, classified as investing activities</link:label>
      <link:label id="id_4b858d4a" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income taxes refund/(paid), classified as operating activities</link:label>
      <link:label id="id_486e2543" xlink:label="lbl_DepreciationAndAmortisationExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortisation expense</link:label>
      <link:label id="id_bf2d3c0" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss (reversal of impairment loss) recognised in profit or loss</link:label>
      <link:label id="id_555a0937" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges and fair value gains on financial assets, net</link:label>
      <link:label id="id_775477cb" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation of Novartis equity plans</link:label>
      <link:label id="id_408b9f0d" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income statement effect</link:label>
      <link:label id="id_2a46b40e" xlink:label="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of income taxed at reduced rates</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:label="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:to="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates_labels" xlink:type="arc"/>
      <link:label id="id_55aa23f7" xlink:label="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of income taxed at reduced rates</link:label>
      <link:label id="id_17e76531" xlink:label="lbl_label401040689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movements of property, plant and equipment [roll forward]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:label="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_label401040689" xlink:type="arc"/>
      <link:label id="id_3d749f5d" xlink:label="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Disposals and derecognitions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherAssetsProvisionsAccrualsMember" xlink:label="lbl_OtherAssetsProvisionsAccrualsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherAssetsProvisionsAccrualsMember" xlink:to="lbl_label288271922" xlink:type="arc"/>
      <link:label id="id_5ac948f0" xlink:label="lbl_IntangibleAssetsAndGoodwillMember_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets [member]</link:label>
      <link:label id="id_6dbb9ba2" xlink:label="lbl_label1841011618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="lbl_label1841011618" xlink:type="arc"/>
      <link:label id="id_44d33d7" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, NonVested in Period, Fair Value</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:to="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue_labels" xlink:type="arc"/>
      <link:label id="id_46c4badd" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value at grante date at beginning of period</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" xlink:to="lbl_label679367036" xlink:type="arc"/>
      <link:label id="id_1c16a93d" xlink:label="lbl_label471247165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Fair Value</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" xlink:to="lbl_label471247165" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" xlink:to="lbl_label1695476906" xlink:type="arc"/>
      <link:label id="id_657887a0" xlink:label="lbl_label1702397856" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" xlink:to="lbl_label1702397856" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" xlink:to="lbl_label1373999706" xlink:type="arc"/>
      <link:label id="id_6cec499" xlink:label="lbl_label114214041" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited in Period, Fair Value</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" xlink:label="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" xlink:to="lbl_label114214041" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" xlink:to="lbl_label766376780" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSingaporePteLtd.SingaporeMember" xlink:label="lbl_NovartisSingaporePteLtd.SingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSingaporePteLtd.SingaporeMember" xlink:to="lbl_label250835540" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:label="lbl_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:to="lbl_label659774806" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:label="lbl_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:to="lbl_label1942659357" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:label="lbl_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:to="lbl_label1522796763" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:label="lbl_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:to="lbl_label1080027869" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:label="lbl_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:to="lbl_label1523800019" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPteLtdSingaporeMember" xlink:label="lbl_AlconPteLtdSingaporeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPteLtdSingaporeMember" xlink:to="lbl_label1448389290" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:label="lbl_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:to="lbl_label547277000" xlink:type="arc"/>
      <link:label id="id_3f303d9f" xlink:label="lbl_label1060126111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Spinifex Pharmaceuticals, Inc., Wilmington, NC [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:label="lbl_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:to="lbl_label1060126111" xlink:type="arc"/>
      <link:label id="id_7ab53501" xlink:label="lbl_label2058695937" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Encore Vision, Inc., New York, NY [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EncoreVisionInc.NewYorkNYMember" xlink:label="lbl_EncoreVisionInc.NewYorkNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EncoreVisionInc.NewYorkNYMember" xlink:to="lbl_label2058695937" xlink:type="arc"/>
      <link:label id="id_71637428" xlink:label="lbl_label1902343208" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Investment Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInvestmentLtd.HamiltonMember" xlink:label="lbl_NovartisInvestmentLtd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInvestmentLtd.HamiltonMember" xlink:to="lbl_label1902343208" xlink:type="arc"/>
      <link:label id="id_631dbefb" xlink:label="lbl_label1662893819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Finance Services Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceServicesLtd.HamiltonMember" xlink:label="lbl_NovartisFinanceServicesLtd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFinanceServicesLtd.HamiltonMember" xlink:to="lbl_label1662893819" xlink:type="arc"/>
      <link:label id="id_682001cf" xlink:label="lbl_label1746928079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis B2 Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisB2Ltd.HamiltonMember" xlink:label="lbl_NovartisB2Ltd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisB2Ltd.HamiltonMember" xlink:to="lbl_label1746928079" xlink:type="arc"/>
      <link:label id="id_60c6aa6" xlink:label="lbl_label101477030" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis B3 Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisB3Ltd.HamiltonMember" xlink:label="lbl_NovartisB3Ltd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisB3Ltd.HamiltonMember" xlink:to="lbl_label101477030" xlink:type="arc"/>
      <link:label id="id_4bc526b5" xlink:label="lbl_label1271211701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ciba-Geigy Japan Limited, Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CibaGeigyJapanLimitedTokyoMember" xlink:label="lbl_CibaGeigyJapanLimitedTokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CibaGeigyJapanLimitedTokyoMember" xlink:to="lbl_label1271211701" xlink:type="arc"/>
      <link:label id="id_518a9aeb" xlink:label="lbl_label1368038123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis International Pharmaceutical Investment AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:label="lbl_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:to="lbl_label1368038123" xlink:type="arc"/>
      <link:label id="id_614bc25c" xlink:label="lbl_label1632354908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Bioventures AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBioventuresAGBaselMember" xlink:label="lbl_NovartisBioventuresAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBioventuresAGBaselMember" xlink:to="lbl_label1632354908" xlink:type="arc"/>
      <link:label id="id_8fecb9d" xlink:label="lbl_label150915997" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Forschungsstiftung, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisForschungsstiftungBaselMember" xlink:label="lbl_NovartisForschungsstiftungBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisForschungsstiftungBaselMember" xlink:to="lbl_label150915997" xlink:type="arc"/>
      <link:label id="id_600bda82" xlink:label="lbl_label1611389570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Stiftung fuer Kaderausbildung, Basel [member]</link:label>
      <link:label id="id_6fd3a22a" xlink:label="lbl_label1876140586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Mitarbeiterbeteiligungsstiftung, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:label="lbl_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:to="lbl_label1876140586" xlink:type="arc"/>
      <link:label id="id_2d8acaf0" xlink:label="lbl_label764070640" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Stiftung fuer Mensch und Umwelt, Basel [member]</link:label>
      <link:label id="id_7d992496" xlink:label="lbl_label2107188374" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stiftung der Novartis AG fuer Erziehung, Ausbildung und Bildung, Basel [member]</link:label>
      <link:label id="id_2bb02e62" xlink:label="lbl_label732966498" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Farmanova Saglik Hizmetleri Ltd. Sti., Istanbul [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:label="lbl_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:to="lbl_label732966498" xlink:type="arc"/>
      <link:label id="id_6c99f32" xlink:label="lbl_label113876786" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ziarco Group Limited, Frimley/Camberley [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:label="lbl_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:to="lbl_label113876786" xlink:type="arc"/>
      <link:label id="id_7dfa0e77" xlink:label="lbl_label2113539703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vivacta Limited, Frimley/Camberley, Surrey [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VivactaLimitedFrimleyCamberleySurreyMember" xlink:label="lbl_VivactaLimitedFrimleyCamberleySurreyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VivactaLimitedFrimleyCamberleySurreyMember" xlink:to="lbl_label2113539703" xlink:type="arc"/>
      <link:label id="id_5489f125" xlink:label="lbl_label1418326309" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis US Foundation, New York, NY [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUSFoundationNewYorkNYMember" xlink:label="lbl_NovartisUSFoundationNewYorkNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisUSFoundationNewYorkNYMember" xlink:to="lbl_label1418326309" xlink:type="arc"/>
      <link:label id="id_1c9b37d8" xlink:label="lbl_label479934424" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corthera, Inc., San Mateo, CA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CortheraInc.SanMateoCAMember" xlink:label="lbl_CortheraInc.SanMateoCAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CortheraInc.SanMateoCAMember" xlink:to="lbl_label479934424" xlink:type="arc"/>
      <link:label id="id_32e0fe6b" xlink:label="lbl_label853605995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CoStim Pharmaceuticals Inc., Cambridge, MA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:label="lbl_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:to="lbl_label853605995" xlink:type="arc"/>
      <link:label id="id_39cff8c0" xlink:label="lbl_label969930944" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Navigate BioPharma Services, Inc., Carlsbad, CA [member]</link:label>
      <link:label id="id_196cf67c" xlink:label="lbl_label426571388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reprixys Pharmaceuticals Corporation, East Hanover, NJ [member]</link:label>
      <link:label id="id_72f336af" xlink:label="lbl_label1928541871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ClarVista Medical, Inc., Aliso Viejo, CA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:label="lbl_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:to="lbl_label1928541871" xlink:type="arc"/>
      <link:label id="id_55c01a35" xlink:label="lbl_label1438652981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transcend Medical, Inc., Lake Forest, IL [member]</link:label>
      <link:label id="id_4148f290" xlink:label="lbl_label1095299728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Triangle International Reinsurance Limited, Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:label="lbl_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:to="lbl_label1095299728" xlink:type="arc"/>
      <link:label id="id_75fcbca" xlink:label="lbl_label123718602" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trinity River Insurance Co Ltd., Hamilton [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:label="lbl_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:to="lbl_label123718602" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisStiftungFuerKaderausbildungBaselMember" xlink:label="lbl_NovartisStiftungFuerKaderausbildungBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisStiftungFuerKaderausbildungBaselMember" xlink:to="lbl_label1611389570" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:label="lbl_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:to="lbl_label764070640" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:label="lbl_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:to="lbl_label2107188374" xlink:type="arc"/>
      <link:label id="id_7fb34e52" xlink:label="lbl_label2142457426" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Syntek Ilac Hammaddeleri Sanayi ve Ticaret A.S., Istanbul [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:label="lbl_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:to="lbl_label2142457426" xlink:type="arc"/>
      <link:label id="id_48e7e2a8" xlink:label="lbl_RUB_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Russia, Rubles</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_RUB" xlink:label="lbl_RUB" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RUB" xlink:to="lbl_RUB_labels" xlink:type="arc"/>
      <link:label id="id_2b6714e7" xlink:label="lbl_RUB_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RUB</link:label>
      <link:label id="id_6b134c2" xlink:label="lbl_BRL_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BRL</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_BRL" xlink:label="lbl_BRL" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BRL" xlink:to="lbl_BRL_labels" xlink:type="arc"/>
      <link:label id="id_19bb001f" xlink:label="lbl_BRL_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Brazil, Brazil Real</link:label>
      <link:label id="id_26408b72" xlink:label="lbl_AUD_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Australia, Dollars</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD" xlink:label="lbl_AUD" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AUD" xlink:to="lbl_AUD_labels" xlink:type="arc"/>
      <link:label id="id_1c95476e" xlink:label="lbl_AUD_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AUD</link:label>
      <link:label id="id_547736b0" xlink:label="lbl_CAD_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CAD</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CAD" xlink:label="lbl_CAD" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CAD" xlink:to="lbl_CAD_labels" xlink:type="arc"/>
      <link:label id="id_5eb5601a" xlink:label="lbl_CAD_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada, Dollars</link:label>
      <link:label id="id_58b8f0b8" xlink:label="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_435d0149" xlink:label="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of associates, net income effect [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:label="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:to="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_71b428a4" xlink:label="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related to associates, net income effect</link:label>
      <link:label id="id_d71a4cc" xlink:label="lbl_AssociatesSummarizedFinancialInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Associates summarized financial information</link:label>
      <link:label id="id_303f5b81" xlink:label="lbl_PurchasePriceAllocationAssociatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price allocation associates</link:label>
      <link:label id="id_3ea56c51" xlink:label="lbl_label1051028561" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets/liabilities, expected to have impact on current taxes payable</link:label>
      <link:label id="id_549c77e3" xlink:label="lbl_label1419540451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of deferred tax assets and liabilities, expected to have impact on current taxes payable [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:label="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:to="lbl_label1419540451" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:to="lbl_label1051028561" xlink:type="arc"/>
      <link:label id="id_686d8bfd" xlink:label="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of unremitted earnings retained by consolidated entities for reinvestment [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" xlink:label="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" xlink:to="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4726a0d4" xlink:label="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unremitted earnings retained by consolidated entities for reinvestment</link:label>
      <link:label id="id_2be0cf3f" xlink:label="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of amount of inventory recognized as an expense in cost of goods sold [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" xlink:label="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" xlink:to="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_26e57cfe" xlink:label="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of inventory recognized as an expense in cost of goods sold</link:label>
      <link:label id="id_30833089" xlink:label="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of recognized amount of inventory provisions and reversals of inventory provision [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" xlink:label="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" xlink:to="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3124df13" xlink:label="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognized amount of inventory provisions and reversals of inventory provision</link:label>
      <link:label id="id_4d23afdc" xlink:label="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross trade receivable from closely monitored countries [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" xlink:label="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" xlink:to="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5f55c02d" xlink:label="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross trade receivable from closely monitored countries</link:label>
      <link:label id="id_540d35ce" xlink:label="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt securities, breakdown by currency [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DebtSecuritiesBreakdownByCurrencyTableTextBlock" xlink:label="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock" xlink:to="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_295129f0" xlink:label="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, breakdown by currency</link:label>
      <link:label id="id_22b42dd0" xlink:label="lbl_SummaryOfTreasurySharesMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of treasury shares movements [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:label="lbl_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:to="lbl_SummaryOfTreasurySharesMovementsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7493f0ce" xlink:label="lbl_SummaryOfTreasurySharesMovementsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule disclosing information related treasury shares movements</link:label>
      <link:label id="id_28836a6a" xlink:label="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" xlink:label="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" xlink:to="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_77bb4dc1" xlink:label="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities</link:label>
      <link:label id="id_63da54e2" xlink:label="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of liabilities arising from financing activities [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" xlink:label="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" xlink:to="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_ea1dc4a" xlink:label="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of liabilities arising from financing activities</link:label>
      <link:label id="id_ecb4868" xlink:label="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of asset allocation, investments in shares of Novartis AG [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:label="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:to="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6d5c5887" xlink:label="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset allocation, investments in shares of Novartis AG</link:label>
      <link:label id="id_583fe5ec" xlink:label="lbl_ScheduleOfDefinedContributionPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of defined contribution plans [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:label="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:to="lbl_ScheduleOfDefinedContributionPlansTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4176cd8b" xlink:label="lbl_ScheduleOfDefinedContributionPlansTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contribution plans</link:label>
      <link:label id="id_5864530c" xlink:label="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of expense related to all equity-based participation and liabilities arising from equity-based payment transactions [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:label="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:to="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_19e39c55" xlink:label="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense related to all equity-based participation and liabilities arising from equity-based payment transactions</link:label>
      <link:label id="id_12c92048" xlink:label="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets and financial liabilities [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:label="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:to="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6a3159a6" xlink:label="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets and financial liabilities</link:label>
      <link:label id="id_5070bcfa" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_5e4ef11c" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial instruments</link:label>
      <link:label id="id_4b298c60" xlink:label="lbl_label1261014112" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract or underlying principal amount the derivative financial instruments, by currency</link:label>
      <link:label id="id_6bba442" xlink:label="lbl_label112960578" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments, contract or underlying principal amount the derivative financial instruments, by currency [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:to="lbl_label112960578" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:to="lbl_label1261014112" xlink:type="arc"/>
      <link:label id="id_7def025f" xlink:label="lbl_DisclosureOfFairValueMeasurementExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="lbl_DisclosureOfFairValueMeasurementExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueMeasurementExplanatory" xlink:to="lbl_DisclosureOfFairValueMeasurementExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_77677ae5" xlink:label="lbl_DisclosureOfFairValueMeasurementExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value by hierarchy</link:label>
      <link:label id="id_3e022541" xlink:label="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in fair value measurement [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" xlink:label="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" xlink:to="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_1b36ee5a" xlink:label="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in fair value measurement</link:label>
      <link:label id="id_fde92c1" xlink:label="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of monitoring of net debt or liquidity based on contractual maturities [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" xlink:label="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" xlink:to="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2293ad67" xlink:label="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monitoring of net debt or liquidity based on contractual maturities</link:label>
      <link:label id="id_1cfe8d17" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments and accrued interest on derivative financial instruments [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5ab7d205" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative financial instruments and accrued interest on derivative financial instruments</link:label>
      <link:label id="id_36cdbc5" xlink:label="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other contractual liabilities of the net debt or liquidity [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" xlink:label="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" xlink:to="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_36a9094b" xlink:label="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other contractual liabilities of the net debt or liquidity</link:label>
      <link:label id="id_6873d3e4" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of ten day loss fair value VAR model [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" xlink:to="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_52a21cc6" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ten day loss fair value VAR model</link:label>
      <link:label id="id_5cc8b03e" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of ten day loss fair value VAR model, average, high, and low VAR amounts [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" xlink:to="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_13881ac7" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ten day loss fair value VAR model, average, high, and low VAR amounts</link:label>
      <link:label id="id_41e588b8" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of ten day loss fair value VAR model, worst case loss scenario [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" xlink:to="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7c01a973" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ten day loss fair value VAR model, worst case loss scenario</link:label>
      <link:label id="id_5ec493de" xlink:label="lbl_KR_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">KOREA, REPUBLIC OF</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR" xlink:label="lbl_KR" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KR" xlink:to="lbl_KR_labels" xlink:type="arc"/>
      <link:label id="id_685d93ad" xlink:label="lbl_KR_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">South Korea</link:label>
      <link:label id="id_25a8beb4" xlink:label="lbl_PurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares</link:label>
      <link:label id="id_43c445c8" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of change in ownership of consolidated entities</link:label>
      <link:label id="id_53037399" xlink:label="lbl_PurchaseOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury shares, equity impact</link:label>
      <link:label id="id_449dfef2" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments out of provisions and other net cash movements in non-current liabilities</link:label>
      <link:label id="id_5f336b49" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Portion of consideration paid (received) consisting of cash and cash equivalents</link:label>
      <link:label id="id_1ebe8e22" xlink:label="lbl_ReprixysPharmaceuticalsCorporationMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reprixys Pharmaceuticals Corporation [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReprixysPharmaceuticalsCorporationMember" xlink:label="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:to="lbl_ReprixysPharmaceuticalsCorporationMember_labels" xlink:type="arc"/>
      <link:label id="id_7c3b4ddb" xlink:label="lbl_ReprixysPharmaceuticalsCorporationMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reprixys Pharmaceuticals Corporation</link:label>
      <link:label id="id_37f79dee" xlink:label="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of release of contingent consideration liability</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:label="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:to="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability_labels" xlink:type="arc"/>
      <link:label id="id_7767d800" xlink:label="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of release of contingent consideration liability</link:label>
      <link:label id="id_3fbded99" xlink:label="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectFromNondeductibleLossesInRegion" xlink:label="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:to="lbl_label1999384126" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:to="lbl_label1131311877" xlink:type="arc"/>
      <link:label id="id_7da827c0" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_3b199e63" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_9457980" xlink:label="lbl_label155548032" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax asset and liability valuation [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:label="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_label155548032" xlink:type="arc"/>
      <link:label id="id_1c2a973a" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law deferred tax expense income recognised in profit or loss</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:to="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:type="arc"/>
      <link:label id="id_44e2d573" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law deferred tax relating to components of other comprehensive income</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:to="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_31998635" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law increase decrease in deferred tax liability asset</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:to="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_3ecc5b67" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law increase decrease in current income tax liability</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:to="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability_labels" xlink:type="arc"/>
      <link:label id="id_16a647a9" xlink:label="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law change in deferred tax assets and liabilities and current tax liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:label="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:to="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_549d9bf8" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Items previously recognized in consolidated income statement</link:label>
      <link:label id="id_5370a381" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Items previously recognized in other comprehensive income</link:label>
      <link:label id="id_584b4926" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total revaluation of deferred tax assets and liabilities</link:label>
      <link:label id="id_1d65bc0" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total revaluation of current income tax liabilities</link:label>
      <link:label id="id_67c3f632" xlink:label="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total revaluation of deferred tax assets and liabilities and current income tax liabilities</link:label>
      <link:label id="id_25c7d443" xlink:label="lbl_label633852995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact location [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactLocationAxis" xlink:label="lbl_ImpactLocationAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactLocationAxis" xlink:to="lbl_label633852995" xlink:type="arc"/>
      <link:label id="id_49f0b616" xlink:label="lbl_label1240512022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact location [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactLocationMember" xlink:label="lbl_ImpactLocationMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactLocationMember" xlink:to="lbl_label1240512022" xlink:type="arc"/>
      <link:label id="id_2bcc20cf" xlink:label="lbl_label734798031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income statement [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementMember" xlink:label="lbl_IncomeStatementMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementMember" xlink:to="lbl_label734798031" xlink:type="arc"/>
      <link:label id="id_5659c922" xlink:label="lbl_label1448724770" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase to retained earnings arising from first application of IFRS 9</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:label="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:to="lbl_label1448724770" xlink:type="arc"/>
      <link:label id="id_2a7f4c39" xlink:label="lbl_label712985657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undiscounted operating lease commitments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UndiscountedOperatingLeaseCommitments" xlink:label="lbl_UndiscountedOperatingLeaseCommitments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UndiscountedOperatingLeaseCommitments" xlink:to="lbl_label712985657" xlink:type="arc"/>
      <link:label id="id_78817d05" xlink:label="lbl_label2021752069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contribution of business to joint venture</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContributionOfBusinessToJointVenture" xlink:label="lbl_ContributionOfBusinessToJointVenture" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContributionOfBusinessToJointVenture" xlink:to="lbl_label2021752069" xlink:type="arc"/>
      <link:label id="id_77130f8a" xlink:label="lbl_label1997737866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of income not subject to tax on the divestment gain on GSK investment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:label="lbl_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:to="lbl_label1997737866" xlink:type="arc"/>
      <link:label id="id_5b6d1716" xlink:label="lbl_label1533875990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:label="lbl_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:to="lbl_label1533875990" xlink:type="arc"/>
      <link:label id="id_11cc9e15" xlink:label="lbl_label298622485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to available-for-sale financia investments previously recognized through OCI</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToAvailableforsaleFinanciaInvestmentsPreviouslyRecognizedThroughOCI" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToAvailableforsaleFinanciaInvestmentsPreviouslyRecognizedThroughOCI" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToAvailableforsaleFinanciaInvestmentsPreviouslyRecognizedThroughOCI" xlink:to="lbl_label298622485" xlink:type="arc"/>
      <link:label id="id_7418c9fe" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to deferred tax assets on US post retirement previously recognized through OCI</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:type="arc"/>
      <link:label id="id_12e2c645" xlink:label="lbl_label316851781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law effective tax rate after implemetation of new law changes</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:label="lbl_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:to="lbl_label316851781" xlink:type="arc"/>
      <link:label id="id_2bfd3952" xlink:label="lbl_label738015570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law tax on unremitted earnings period allowed for payment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:label="lbl_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:to="lbl_label738015570" xlink:type="arc"/>
      <link:label id="id_34cb50dd" xlink:label="lbl_label885739741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to deferred tax assets on unremitted earnings</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:to="lbl_label885739741" xlink:type="arc"/>
      <link:label id="id_73b04098" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to revaluation of deferred tax assets on equity based compensation that were previously recognized through retained earnings</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings_labels" xlink:type="arc"/>
      <link:label id="id_75b59f04" xlink:label="lbl_label1713201135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through finance lease contracts property plant and equipment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:label="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:to="lbl_label1713201135" xlink:type="arc"/>
      <link:label id="id_3eec7519" xlink:label="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal group companies materiality of assets or sales to third parties</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:label="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:to="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties_labels" xlink:type="arc"/>
      <link:label id="id_c93c456" xlink:label="lbl_label211010646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other intangible asset purchase commitments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherIntangiblePurchaseCommitments" xlink:label="lbl_OtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherIntangiblePurchaseCommitments" xlink:to="lbl_label211010646" xlink:type="arc"/>
      <link:label id="id_6759fd06" xlink:label="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development and other intangible asset purchase commitments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:label="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:to="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments_labels" xlink:type="arc"/>
      <link:label id="id_624861c8" xlink:label="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
      <link:label id="id_2f002958" xlink:label="lbl_label788539736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial instruments - narrative [table]</link:label>
      <link:label id="id_684e1ed4" xlink:label="lbl_label1749950164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Open hedges for anticipated transactions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OpenHedgesForAnticipatedTransactions" xlink:label="lbl_OpenHedgesForAnticipatedTransactions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OpenHedgesForAnticipatedTransactions" xlink:to="lbl_label1749950164" xlink:type="arc"/>
      <link:label id="id_38f600d1" xlink:label="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transfers out of Level 3 of fair value hierarchy, assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:to="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets_labels" xlink:type="arc"/>
      <link:label id="id_24d61d6" xlink:label="lbl_label38625750" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of change in OCI when pricing parameters for level 3 change more than 10%</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:to="lbl_label38625750" xlink:type="arc"/>
      <link:label id="id_8d1d7d" xlink:label="lbl_label9248125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Most significant foreign exchange losses</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MostSignificantForeignExchangeLosses" xlink:label="lbl_MostSignificantForeignExchangeLosses" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MostSignificantForeignExchangeLosses" xlink:to="lbl_label9248125" xlink:type="arc"/>
      <link:label id="id_75c586da" xlink:label="lbl_label1975879386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term financial debt with a carrying amount</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongtermFinancialDebtWithACarryingAmount" xlink:label="lbl_LongtermFinancialDebtWithACarryingAmount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LongtermFinancialDebtWithACarryingAmount" xlink:to="lbl_label1975879386" xlink:type="arc"/>
      <link:label id="id_189f8e8f" xlink:label="lbl_label413109903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized loss was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:label="lbl_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:to="lbl_label413109903" xlink:type="arc"/>
      <link:label id="id_19e141a6" xlink:label="lbl_label434192806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net investment hedge recognized in the income statement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:label="lbl_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:to="lbl_label434192806" xlink:type="arc"/>
      <link:label id="id_7d454e3e" xlink:label="lbl_label2101694014" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upper limit on holdings on unrelated company</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:label="lbl_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:to="lbl_label2101694014" xlink:type="arc"/>
      <link:label id="id_1ccfbaa5" xlink:label="lbl_label483375781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings commercial paper maximum borrowing amount</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:label="lbl_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:to="lbl_label483375781" xlink:type="arc"/>
      <link:label id="id_665a2289" xlink:label="lbl_label1717183113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt/equity ratio</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DebtEquityRatio" xlink:label="lbl_DebtEquityRatio" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DebtEquityRatio" xlink:to="lbl_label1717183113" xlink:type="arc"/>
      <link:label id="id_5597d347" xlink:label="lbl_label1436013383" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">VAR estimate confidence interval</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VAREstimateConfidenceInterval" xlink:label="lbl_VAREstimateConfidenceInterval" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VAREstimateConfidenceInterval" xlink:to="lbl_label1436013383" xlink:type="arc"/>
      <link:label id="id_42729374" xlink:label="lbl_label1114805108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings commercial paper maximum amount outstanding</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:label="lbl_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:to="lbl_label1114805108" xlink:type="arc"/>
      <link:label id="id_6e4f3f5e" xlink:label="lbl_label1850687326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings credit facility committed</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCreditFacilityCommitted" xlink:label="lbl_BorrowingsCreditFacilityCommitted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCreditFacilityCommitted" xlink:to="lbl_label1850687326" xlink:type="arc"/>
      <link:label id="id_40060c01" xlink:label="lbl_label1074138113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty risk [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CounterpartyRiskAbstract" xlink:label="lbl_CounterpartyRiskAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CounterpartyRiskAbstract" xlink:to="lbl_label1074138113" xlink:type="arc"/>
      <link:label id="id_16edbe31" xlink:label="lbl_label384679473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of entity's cash and cash equivalents held with financial institution</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:label="lbl_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:to="lbl_label384679473" xlink:type="arc"/>
      <link:label id="id_367e78c8" xlink:label="lbl_label914258120" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vendor [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VendorAxis" xlink:label="lbl_VendorAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VendorAxis" xlink:to="lbl_label914258120" xlink:type="arc"/>
      <link:label id="id_45057e7f" xlink:label="lbl_label1157987967" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vendor [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VendorMember" xlink:label="lbl_VendorMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VendorMember" xlink:to="lbl_label1157987967" xlink:type="arc"/>
      <link:label id="id_bcf5c90" xlink:label="lbl_label198139024" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Largest financial institution [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LargestFinancialInstitutionMember" xlink:label="lbl_LargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LargestFinancialInstitutionMember" xlink:to="lbl_label198139024" xlink:type="arc"/>
      <link:label id="id_561f18c8" xlink:label="lbl_label1444878536" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second largest financial institution [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SecondLargestFinancialInstitutionMember" xlink:label="lbl_SecondLargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SecondLargestFinancialInstitutionMember" xlink:to="lbl_label1444878536" xlink:type="arc"/>
      <link:label id="id_cbf0fed" xlink:label="lbl_label213848045" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third largest financial institution [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ThirdLargestFinancialInstitutionMember" xlink:label="lbl_ThirdLargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ThirdLargestFinancialInstitutionMember" xlink:to="lbl_label213848045" xlink:type="arc"/>
      <link:label id="id_3a76e486" xlink:label="lbl_label980870278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre tax profit (loss) from divestment of business</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PreTaxProfitLossFromDivestmentOfBusiness" xlink:label="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:to="lbl_label980870278" xlink:type="arc"/>
      <link:label id="id_5810372f" xlink:label="lbl_label1477457711" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration transferred, divestment-date fair value</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:to="lbl_label1477457711" xlink:type="arc"/>
      <link:label id="id_4121b29e" xlink:label="lbl_label1092727454" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential receivable from divestment</link:label>
      <link:label id="id_3cc9e79a" xlink:label="lbl_label1019864986" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration received</link:label>
      <link:label id="id_5b569e4" xlink:label="lbl_label95775204" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone payment already received</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MilestonePaymentAlreadyReceived" xlink:label="lbl_MilestonePaymentAlreadyReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MilestonePaymentAlreadyReceived" xlink:to="lbl_label95775204" xlink:type="arc"/>
      <link:label id="id_63dee19f" xlink:label="lbl_label1675551135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future put option to sell business</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FuturePutOptionToSellBusiness" xlink:label="lbl_FuturePutOptionToSellBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FuturePutOptionToSellBusiness" xlink:to="lbl_label1675551135" xlink:type="arc"/>
      <link:label id="id_7e35f229" xlink:label="lbl_label2117464617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment put option</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PaymentPutOption" xlink:label="lbl_PaymentPutOption" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentPutOption" xlink:to="lbl_label2117464617" xlink:type="arc"/>
      <link:label id="id_4b717d8e" xlink:label="lbl_label1265728910" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest exchanged</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExchanged" xlink:label="lbl_InterestExchanged" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExchanged" xlink:to="lbl_label1265728910" xlink:type="arc"/>
      <link:label id="id_8fd1ef1" xlink:label="lbl_ChangesInOffsetAgainstGrossTradeReceivables_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in offset against gross trade receivables</link:label>
      <link:label id="id_2ef82d23" xlink:label="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefit payments</link:label>
      <link:label id="id_7c796053" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercised</link:label>
      <link:label id="id_64515558" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercised or sold</link:label>
      <link:label id="id_79b0131b" xlink:label="lbl_FinancialLiabilitiesAtFairValue_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities, at fair value</link:label>
      <link:label id="id_18855477" xlink:label="lbl_ClassesOfShareCapitalMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total outstanding shares</link:label>
      <link:label id="id_34b6a8cb" xlink:label="lbl_OrdinarySharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Novartis shares</link:label>
      <link:label id="id_20b38808" xlink:label="lbl_TreasurySharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total treasury shares</link:label>
      <link:label id="id_5dca543c" xlink:label="lbl_LiabilitiesToBanksAndOtherInstitutions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities to banks and other institutions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LiabilitiesToBanksAndOtherInstitutions" xlink:label="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:to="lbl_LiabilitiesToBanksAndOtherInstitutions_labels" xlink:type="arc"/>
      <link:label id="id_3901e819" xlink:label="lbl_LiabilitiesToBanksAndOtherInstitutions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Liabilities to banks and other financial institutions</link:label>
      <link:label id="id_551ca7d0" xlink:label="lbl_ContingentConsiderationReceivableCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration receivable, current</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivableCurrent" xlink:label="lbl_ContingentConsiderationReceivableCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationReceivableCurrent" xlink:to="lbl_ContingentConsiderationReceivableCurrent_labels" xlink:type="arc"/>
      <link:label id="id_15fc798c" xlink:label="lbl_ContingentConsiderationReceivableCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration receivable</link:label>
      <link:label id="id_249fb0f8" xlink:label="lbl_ImpactOfDivestmentsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of divestments, other provisions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfDivestmentsOtherProvisions" xlink:label="lbl_ImpactOfDivestmentsOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfDivestmentsOtherProvisions" xlink:to="lbl_ImpactOfDivestmentsOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_77b9898f" xlink:label="lbl_ImpactOfDivestmentsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of divestments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:label="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:to="lbl_label788539736" xlink:type="arc"/>
      <link:label id="id_4241ab2c" xlink:label="lbl_GrossCarryingAmountMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross carrying amount</link:label>
      <link:label id="id_1264a0dc" xlink:label="lbl_label308584668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customers with net sales over five percent</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CustomersWithNetSalesOverFivePercent" xlink:label="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CustomersWithNetSalesOverFivePercent" xlink:to="lbl_label308584668" xlink:type="arc"/>
      <link:label id="id_2af199bf" xlink:label="lbl_label720476607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net cash flows used in acquisitions and divestments of businesses, classified as investing activities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:to="lbl_label720476607" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:to="lbl_label1718040268" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:to="lbl_label1423033786" xlink:type="arc"/>
      <link:label id="id_2cbb9926" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Impairment (loss) reversal of impairment loss recognised in profit or loss</link:label>
      <link:label id="id_eadbcd2" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquired cash and cash equivalents</link:label>
      <link:label id="id_36976720" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid benefit cost</link:label>
      <link:label id="id_1c757af9" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued share-based payments</link:label>
      <link:label id="id_79c38d68" xlink:label="lbl_Inventories_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
      <link:label id="id_1dbfe68b" xlink:label="lbl_CurrentTradeReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
      <link:label id="id_7bc2e092" xlink:label="lbl_label2076369042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration receivables short-term [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivablesShorttermMember" xlink:label="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:to="lbl_label2076369042" xlink:type="arc"/>
      <link:label id="id_1fd99bd1" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Increase)/decrease of treasury share repurchase obligation under a share buyback trading plan</link:label>
      <link:label id="id_2da8b675" xlink:label="lbl_label329619167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options excluded from the calculation</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OptionsExcludedFromTheCalculation" xlink:label="lbl_OptionsExcludedFromTheCalculation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OptionsExcludedFromTheCalculation" xlink:to="lbl_label329619167" xlink:type="arc"/>
      <link:label id="id_171116a0" xlink:label="lbl_label386995872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US commercial paper programs [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_USCommercialPaperProgramsMember" xlink:label="lbl_USCommercialPaperProgramsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_USCommercialPaperProgramsMember" xlink:to="lbl_label386995872" xlink:type="arc"/>
      <link:label id="id_1fb8b12f" xlink:label="lbl_label532197679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JP commercial paper programs [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JPCommercialPaperProgramsMember" xlink:label="lbl_JPCommercialPaperProgramsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_JPCommercialPaperProgramsMember" xlink:to="lbl_label532197679" xlink:type="arc"/>
      <link:label id="id_68bfdd9c" xlink:label="lbl_label1757404572" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings commercial paper, number of programs</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCommercialPaperNumberOfPrograms" xlink:label="lbl_BorrowingsCommercialPaperNumberOfPrograms" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCommercialPaperNumberOfPrograms" xlink:to="lbl_label1757404572" xlink:type="arc"/>
      <link:label id="id_4e21d3c" xlink:label="lbl_label81927484" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of change in OCI when most significant parameters for level 3 change more than 10%</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:to="lbl_label81927484" xlink:type="arc"/>
      <link:label id="id_5ccfc0db" xlink:label="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of change in OCI when POS for level 3 change more than 10%</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:to="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10_labels" xlink:type="arc"/>
      <link:label id="id_17ec29fe" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications (AAA) [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsAAAMember" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:to="lbl_AdvancedAcceleratorApplicationsAAAMember_labels" xlink:type="arc"/>
      <link:label id="id_4991ae50" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications (AAA)</link:label>
      <link:label id="id_69548c9f" xlink:label="lbl_label1767148703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Share capital in tender offer</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfShareCapitalInTenderOffer" xlink:label="lbl_PercentageOfShareCapitalInTenderOffer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfShareCapitalInTenderOffer" xlink:to="lbl_label1767148703" xlink:type="arc"/>
      <link:label id="id_5c76d079" xlink:label="lbl_CashOfferPerOrdinaryShare_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash offer per ordinary share</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOfferPerOrdinaryShare" xlink:label="lbl_CashOfferPerOrdinaryShare" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOfferPerOrdinaryShare" xlink:to="lbl_CashOfferPerOrdinaryShare_labels" xlink:type="arc"/>
      <link:label id="id_741421fb" xlink:label="lbl_CashOfferPerADS_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash offer per ADS</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOfferPerADS" xlink:label="lbl_CashOfferPerADS" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOfferPerADS" xlink:to="lbl_CashOfferPerADS_labels" xlink:type="arc"/>
      <link:label id="id_4236be0f" xlink:label="lbl_label1110883855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of ordinary share per ADS</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfOrdinarySharePerADS" xlink:label="lbl_NumberOfOrdinarySharePerADS" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOrdinarySharePerADS" xlink:to="lbl_label1110883855" xlink:type="arc"/>
      <link:label id="id_471c5e7e" xlink:label="lbl_label1193041534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value of equity</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueOfEquity" xlink:label="lbl_ValueOfEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueOfEquity" xlink:to="lbl_label1193041534" xlink:type="arc"/>
      <link:label id="id_72ec4d21" xlink:label="lbl_label454367578" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximal amount of share buyback programm</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaximalAmountOfShareBuybackProgramm" xlink:label="lbl_MaximalAmountOfShareBuybackProgramm" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaximalAmountOfShareBuybackProgramm" xlink:to="lbl_label454367578" xlink:type="arc"/>
      <link:label id="id_6eb334f8" xlink:label="lbl_label1857238264" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of Annual Incentive</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAnnualIncentive" xlink:label="lbl_DescriptionOfAnnualIncentive" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAnnualIncentive" xlink:to="lbl_label1857238264" xlink:type="arc"/>
      <link:label id="id_5c74f412" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade payables</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:to="lbl_TradeAndOtherPayablesToTradeSuppliers_labels" xlink:type="arc"/>
      <link:label id="id_5ba6657f" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Trade payables</link:label>
      <link:label id="id_7ae769dd" xlink:label="lbl_OtherCurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other current liabilities</link:label>
      <link:label id="id_49cb7900" xlink:label="lbl_OtherCurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total provisions and other current liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfBusinessUnits" xlink:label="lbl_NumberOfBusinessUnits" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfBusinessUnits" xlink:to="lbl_label267498308" xlink:type="arc"/>
      <link:label id="id_8b05ce2" xlink:label="lbl_label145775842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, third parties, change in percent</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:to="lbl_label145775842" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:to="lbl_label198642827" xlink:type="arc"/>
      <link:label id="id_5eb218a8" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to deferred tax assets on US post retirement previously recognized through OCI</link:label>
      <link:label id="id_4b99efa9" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax on above items</link:label>
      <link:label id="id_5952def9" xlink:label="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefits other than equity-based compensation</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_labels" xlink:type="arc"/>
      <link:label id="id_389a5b52" xlink:label="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonCurrentFinancialDebtsMember" xlink:label="lbl_NonCurrentFinancialDebtsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonCurrentFinancialDebtsMember" xlink:to="lbl_label1268656258" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:label="lbl_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:to="lbl_label618343139" xlink:type="arc"/>
      <link:label id="id_6987695e" xlink:label="lbl_IntangibleAssetImpairmentChargesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible asset impairment charges [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IntangibleAssetImpairmentChargesTextBlock" xlink:label="lbl_IntangibleAssetImpairmentChargesTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IntangibleAssetImpairmentChargesTextBlock" xlink:to="lbl_IntangibleAssetImpairmentChargesTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_76ff2ee3" xlink:label="lbl_IntangibleAssetImpairmentChargesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment charges and reversals</link:label>
      <link:label id="id_2dd3bece" xlink:label="lbl_label768851662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of share capital tendered at the expiration of the tender offer</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:to="lbl_label768851662" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:label="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:to="lbl_label2363078" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentFairValueOfContingentConsiderationReceived" xlink:label="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:to="lbl_label1019864986" xlink:type="arc"/>
      <link:label id="id_4875601b" xlink:label="lbl_TransactionRelatedCostsPaid_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction related costs paid</link:label>
      <link:label id="id_5201dd1d" xlink:label="lbl_TransactionRelatedCosts_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction related costs</link:label>
      <link:label id="id_b9d0509" xlink:label="lbl_label770091111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of fair value adjustments relating to intangible assets tax</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:label="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:to="lbl_label770091111" xlink:type="arc"/>
      <link:label id="id_55cbca11" xlink:label="lbl_label1439418897" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum margin percentage impact of commodity price change</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:label="lbl_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:to="lbl_label1439418897" xlink:type="arc"/>
      <link:label id="id_a88bf0e" xlink:label="lbl_label176733966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum holding in unrelated company</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaximumHoldingInUnrelatedCompany" xlink:label="lbl_MaximumHoldingInUnrelatedCompany" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MaximumHoldingInUnrelatedCompany" xlink:to="lbl_label176733966" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialReceivableFromDivestment" xlink:label="lbl_PotentialReceivableFromDivestment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialReceivableFromDivestment" xlink:to="lbl_label1092727454" xlink:type="arc"/>
      <link:label id="id_2fe8aa88" xlink:label="lbl_CashOfferPerADS_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This expresses the amount of cash Novartis paid to the owners of AAA per ADS.</link:label>
      <link:label id="id_74cb8111" xlink:label="lbl_CashOfferPerOrdinaryShare_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This expresses the amount of cash Novartis paid to the owners of AAA per ordinary share.</link:label>
      <link:label id="id_4036843c" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This expresses a maximal amount.</link:label>
      <link:label id="id_64640b79" xlink:label="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This expresses a limit.</link:label>
      <link:label id="id_177cac6" xlink:label="lbl_ReclassificationFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This is a reclassification that can be debit or credit.</link:label>
      <link:label id="id_5fdbc2b7" xlink:label="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This amount can be a debit or a credit as the table discloses the fair value gain and loses on assets and liabilities.</link:label>
      <link:label id="id_314a813f" xlink:label="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This amount can be a debit or a credit as the table discloses the fair value gain and loses on assets and liabilities.</link:label>
      <link:label id="id_4962d3fd" xlink:label="lbl_SellingGeneralAndAdministrativeExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SellingGeneralAndAdministrativeExpense" xlink:to="lbl_SellingGeneralAndAdministrativeExpense_labels" xlink:type="arc"/>
      <link:label id="id_1f242104" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through other changes, equity</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_labels" xlink:type="arc"/>
      <link:label id="id_5aa89188" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other movements</link:label>
      <link:label id="id_94ddbe4" xlink:label="lbl_label156097508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change over period [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_label156097508" xlink:type="arc"/>
      <link:label id="id_4cdc11a9" xlink:label="lbl_label1289490857" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reported value [member]</link:label>
      <link:label id="id_501954f0" xlink:label="lbl_label1343837424" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change over period [member]</link:label>
      <link:label id="id_22153d9b" xlink:label="lbl_label571817371" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change to prior year-end [member]</link:label>
      <link:label id="id_dc043" xlink:label="lbl_NetDebt_labels2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net debt</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDebt" xlink:label="lbl_NetDebt1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetDebt1" xlink:to="lbl_NetDebt_labels2" xlink:type="arc"/>
      <link:label id="id_8969c68" xlink:label="lbl_NetDebt_labels2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net debt</link:label>
      <link:label id="id_641074d9" xlink:label="lbl_NetDebt_labels2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net debt</link:label>
      <link:label id="id_476a5a91" xlink:label="lbl_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="lbl_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lbl_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_1548f70e" xlink:label="lbl_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of preparation</link:label>
      <link:label id="id_2c18deb" xlink:label="lbl_label46239211" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of preparation [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BasisOfPreparationAbstract" xlink:label="lbl_BasisOfPreparationAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BasisOfPreparationAbstract" xlink:to="lbl_label46239211" xlink:type="arc"/>
      <link:label id="id_2df428b0" xlink:label="lbl_label770975920" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selected critical accounting policies [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelectedCriticalAccountingPoliciesAbstract" xlink:label="lbl_SelectedCriticalAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SelectedCriticalAccountingPoliciesAbstract" xlink:to="lbl_label770975920" xlink:type="arc"/>
      <link:label id="id_2a3a2ba4" xlink:label="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selected critical accounting policies</link:label>
      <link:label id="id_6b45f171" xlink:label="lbl_DisclosureOfEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of equity attributable to Novartis AG shareholders</link:label>
      <link:label id="id_2c2ab3f2" xlink:label="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial instruments</link:label>
      <link:label id="id_4dd6c758" xlink:label="lbl_label1305921368" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal proceedings update [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LegalProceedingsUpdateAbstract" xlink:label="lbl_LegalProceedingsUpdateAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LegalProceedingsUpdateAbstract" xlink:to="lbl_label1305921368" xlink:type="arc"/>
      <link:label id="id_62d75963" xlink:label="lbl_LegalProceedingsUpdateTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal proceedings update [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LegalProceedingsUpdateTextBlock" xlink:label="lbl_LegalProceedingsUpdateTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LegalProceedingsUpdateTextBlock" xlink:to="lbl_LegalProceedingsUpdateTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_47116fe6" xlink:label="lbl_LegalProceedingsUpdateTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal proceedings update</link:label>
      <link:label id="id_6f65ab76" xlink:label="lbl_label1868934006" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impacts of adoption of new IFRS standards [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactsOfAdoptionOfNewIFRSStandardsAbstract" xlink:label="lbl_ImpactsOfAdoptionOfNewIFRSStandardsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactsOfAdoptionOfNewIFRSStandardsAbstract" xlink:to="lbl_label1868934006" xlink:type="arc"/>
      <link:label id="id_73aff3ab" xlink:label="lbl_label200796173" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impacts of adoption of new IFRS standards [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactsOfAdoptionOfNewIFRSStandardsTextBlock" xlink:label="lbl_ImpactsOfAdoptionOfNewIFRSStandardsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactsOfAdoptionOfNewIFRSStandardsTextBlock" xlink:to="lbl_label200796173" xlink:type="arc"/>
      <link:label id="id_9aad709" xlink:label="lbl_label162191113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for available-for-sale financial assets [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:to="lbl_label162191113" xlink:type="arc"/>
      <link:label id="id_59f07686" xlink:label="lbl_label1508931206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="lbl_label1508931206" xlink:type="arc"/>
      <link:label id="id_4a00f82a" xlink:label="lbl_label1241577514" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for Revenue from Contracts with Customers [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:to="lbl_label1241577514" xlink:type="arc"/>
      <link:label id="id_68958299" xlink:label="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for other revenue [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_68991831" xlink:label="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
      <link:label id="id_5460feda" xlink:label="lbl_label1415642842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated balance sheet by the adoption of IFRS 15 [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsolidatedBalanceSheetByTheAdoptionOfIFRS15TableTextBlock" xlink:label="lbl_ConsolidatedBalanceSheetByTheAdoptionOfIFRS15TableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedBalanceSheetByTheAdoptionOfIFRS15TableTextBlock" xlink:to="lbl_label1415642842" xlink:type="arc"/>
      <link:label id="id_5b4e8ef2" xlink:label="lbl_label1531875058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated statement of changes in equity by the adoption of IFRS 9 and IFRS 15 [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsolidatedStatementOfChangesInEquityByTheAdoptionOfIFRS9AndIFRS15TableTextBlock" xlink:label="lbl_ConsolidatedStatementOfChangesInEquityByTheAdoptionOfIFRS9AndIFRS15TableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedStatementOfChangesInEquityByTheAdoptionOfIFRS9AndIFRS15TableTextBlock" xlink:to="lbl_label1531875058" xlink:type="arc"/>
      <link:label id="id_e7f3472" xlink:label="lbl_label243217522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments additional disclosures table by the adoption of IFRS 9 [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosuresTableByTheAdoptionOfIFRS9TableTextBlock" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosuresTableByTheAdoptionOfIFRS9TableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosuresTableByTheAdoptionOfIFRS9TableTextBlock" xlink:to="lbl_label243217522" xlink:type="arc"/>
      <link:label id="id_71771d90" xlink:label="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net sales by region</link:label>
      <link:label id="id_4f219465" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, net sales of Top 20 products [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:to="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2b8de385" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales of Top 20 products</link:label>
      <link:label id="id_45ec2147" xlink:label="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, other revenue [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:to="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7f01fd05" xlink:label="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
      <link:label id="id_1894478a" xlink:label="lbl_AveXisIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AveXis, Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AveXisIncMember" xlink:label="lbl_AveXisIncMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AveXisIncMember" xlink:to="lbl_AveXisIncMember_labels" xlink:type="arc"/>
      <link:label id="id_43b60602" xlink:label="lbl_AveXisIncMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AveXis, Inc.</link:label>
      <link:label id="id_6a7073ad" xlink:label="lbl_label1785754541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retrospective application and retrospective restatement [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_label1785754541" xlink:type="arc"/>
      <link:label id="id_33459cb3" xlink:label="lbl_label860200115" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currently stated [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestatedMember" xlink:to="lbl_label860200115" xlink:type="arc"/>
      <link:label id="id_41804a67" xlink:label="lbl_label1098926695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously stated [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PreviouslyStatedMember" xlink:to="lbl_label1098926695" xlink:type="arc"/>
      <link:label id="id_d0e08b6" xlink:label="lbl_label217930333" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy and corrections of prior period errors [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_label217930333" xlink:type="arc"/>
      <link:label id="id_4a438f95" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy, IFRS 9 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member_labels" xlink:type="arc"/>
      <link:label id="id_68a9252d" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment, IFRS 9</link:label>
      <link:label id="id_3803c2cc" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy, IFRS 15 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member_labels" xlink:type="arc"/>
      <link:label id="id_7f440478" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment, IFRS 15</link:label>
      <link:label id="id_6cbd5ed8" xlink:label="lbl_OCIReservesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI reserves [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OCIReservesMember" xlink:label="lbl_OCIReservesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OCIReservesMember" xlink:to="lbl_OCIReservesMember_labels" xlink:type="arc"/>
      <link:label id="id_37bd32c4" xlink:label="lbl_OCIReservesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OCI reserves</link:label>
      <link:label id="id_3071cdbf" xlink:label="lbl_label812764607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retail Generics [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetailGenericsMember" xlink:label="lbl_RetailGenericsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RetailGenericsMember" xlink:to="lbl_label812764607" xlink:type="arc"/>
      <link:label id="id_22d00e67" xlink:label="lbl_label584060519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biopharmaceuticals [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BiopharmaceuticalsMember" xlink:label="lbl_BiopharmaceuticalsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BiopharmaceuticalsMember" xlink:to="lbl_label584060519" xlink:type="arc"/>
      <link:label id="id_74e760f" xlink:label="lbl_label122582543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anti Infectives [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AntiInfectivesMember" xlink:label="lbl_AntiInfectivesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AntiInfectivesMember" xlink:to="lbl_label122582543" xlink:type="arc"/>
      <link:label id="id_2e5631da" xlink:label="lbl_label777400794" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Surgical [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SurgicalMember" xlink:label="lbl_SurgicalMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SurgicalMember" xlink:to="lbl_label777400794" xlink:type="arc"/>
      <link:label id="id_5a63105" xlink:label="lbl_label94777605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vision Care [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VisionCareMember" xlink:label="lbl_VisionCareMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VisionCareMember" xlink:to="lbl_label94777605" xlink:type="arc"/>
      <link:label id="id_33d2b620" xlink:label="lbl_label869447200" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumables [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsumablesMember" xlink:label="lbl_ConsumablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsumablesMember" xlink:to="lbl_label869447200" xlink:type="arc"/>
      <link:label id="id_3fe1336c" xlink:label="lbl_label1071723372" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Implantables [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImplantablesMember" xlink:label="lbl_ImplantablesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImplantablesMember" xlink:to="lbl_label1071723372" xlink:type="arc"/>
      <link:label id="id_6d32d4c6" xlink:label="lbl_label1832047814" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment/Other [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquipmentOtherMember" xlink:label="lbl_EquipmentOtherMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquipmentOtherMember" xlink:to="lbl_label1832047814" xlink:type="arc"/>
      <link:label id="id_9208315" xlink:label="lbl_label153125653" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ophthalmic OTC [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OphthalmicOTCMember" xlink:label="lbl_OphthalmicOTCMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OphthalmicOTCMember" xlink:to="lbl_label153125653" xlink:type="arc"/>
      <link:label id="id_3d77d223" xlink:label="lbl_label1031262755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contact lens care [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContactLensCareMember" xlink:label="lbl_ContactLensCareMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContactLensCareMember" xlink:to="lbl_label1031262755" xlink:type="arc"/>
      <link:label id="id_5ff6168e" xlink:label="lbl_label1609963150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top 20 products [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Top20ProductsMember" xlink:label="lbl_Top20ProductsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Top20ProductsMember" xlink:to="lbl_label1609963150" xlink:type="arc"/>
      <link:label id="id_1bc8878f" xlink:label="lbl_label466126735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rest of portfolio [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestOfPortfolioMember" xlink:label="lbl_RestOfPortfolioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestOfPortfolioMember" xlink:to="lbl_label466126735" xlink:type="arc"/>
      <link:label id="id_60f02df8" xlink:label="lbl_label1626353144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty income</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromRoyalties" xlink:label="lbl_RevenueFromRoyalties" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromRoyalties" xlink:to="lbl_label1626353144" xlink:type="arc"/>
      <link:label id="id_132c5856" xlink:label="lbl_label321673302" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit sharing income</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfitSharingIncome" xlink:label="lbl_ProfitSharingIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitSharingIncome" xlink:to="lbl_label321673302" xlink:type="arc"/>
      <link:label id="id_dd742a8" xlink:label="lbl_label232211112" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone income</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MilestoneIncome" xlink:label="lbl_MilestoneIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MilestoneIncome" xlink:to="lbl_label232211112" xlink:type="arc"/>
      <link:label id="id_31af75cd" xlink:label="lbl_OtherRevenueOther_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenue, other</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherRevenueOther" xlink:label="lbl_OtherRevenueOther" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherRevenueOther" xlink:to="lbl_OtherRevenueOther_labels" xlink:type="arc"/>
      <link:label id="id_41473bf" xlink:label="lbl_OtherRevenueOther_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
      <link:label id="id_22e4d15f" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from operating activities, as a percentage from net sales</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:to="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales_labels" xlink:type="arc"/>
      <link:label id="id_3e5bb44f" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating income as % of net sales</link:label>
      <link:label id="id_3761b8d8" xlink:label="lbl_label929151192" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada and Latin America [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CanadaAndLatinAmericaMember" xlink:label="lbl_CanadaAndLatinAmericaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CanadaAndLatinAmericaMember" xlink:to="lbl_label929151192" xlink:type="arc"/>
      <link:label id="id_35dc7c05" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from sale of goods, third parties, change in percent, cc</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc_labels" xlink:type="arc"/>
      <link:label id="id_2402bc9" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales, change in %, cc</link:label>
      <link:label id="id_11578a03" xlink:label="lbl_label290949635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Established Markets [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstablishedMarketsMember" xlink:label="lbl_EstablishedMarketsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstablishedMarketsMember" xlink:to="lbl_label290949635" xlink:type="arc"/>
      <link:label id="id_1e6859ac" xlink:label="lbl_label510155180" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Emerging Growth Markets [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EmergingGrowthMarketsMember" xlink:label="lbl_EmergingGrowthMarketsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EmergingGrowthMarketsMember" xlink:to="lbl_label510155180" xlink:type="arc"/>
      <link:label id="id_395d61a2" xlink:label="lbl_label962421154" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rest of the world [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestOfTheWorldMember" xlink:label="lbl_RestOfTheWorldMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestOfTheWorldMember" xlink:to="lbl_label962421154" xlink:type="arc"/>
      <link:label id="id_2aeb33db" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares acquired to be cancelled</link:label>
      <link:label id="id_16be2f1a" xlink:label="lbl_TreasurySharesAcquiredForCancellationValue_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares acquired for cancellation, equity impact</link:label>
      <link:label id="id_14bac1b3" xlink:label="lbl_StockRepurchaseProgramAuthorizedAmount1_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase of treasury share repurchase obligation under a share buyback trading plan</link:label>
      <link:label id="id_10768f17" xlink:label="lbl_label276205335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.5% EUR 750 million 2018/2023 of Novartis [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.5EUR750Million20182023OfNovartisMember" xlink:label="lbl_A0.5EUR750Million20182023OfNovartisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.5EUR750Million20182023OfNovartisMember" xlink:to="lbl_label276205335" xlink:type="arc"/>
      <link:label id="id_6c222bbb" xlink:label="lbl_label1814178747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.375% EUR 750 million 2018/2030 of Novartis [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.375EUR750Million20182030OfNovartisMember" xlink:label="lbl_A1.375EUR750Million20182030OfNovartisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.375EUR750Million20182030OfNovartisMember" xlink:to="lbl_label1814178747" xlink:type="arc"/>
      <link:label id="id_42e49e27" xlink:label="lbl_label1122278951" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.7% EUR 750 million 2018/2038 of Novartis [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.7EUR750Million20182038OfNovartisMember" xlink:label="lbl_A1.7EUR750Million20182038OfNovartisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.7EUR750Million20182038OfNovartisMember" xlink:to="lbl_label1122278951" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GalvusGroupMember" xlink:label="lbl_GalvusGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GalvusGroupMember" xlink:to="lbl_label195411774" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DiovanGroupMember" xlink:label="lbl_DiovanGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DiovanGroupMember" xlink:to="lbl_label1973931633" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExforgeGroupMember" xlink:to="lbl_label1243142238" xlink:type="arc"/>
      <link:label id="id_15727011" xlink:label="lbl_label359821329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Immunology [member]</link:label>
      <link:label id="id_86e5c43" xlink:label="lbl_label141450307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anti Infectives sold under Sandoz name [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AntiInfectivesSoldUnderSandozNameMember" xlink:label="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:to="lbl_label141450307" xlink:type="arc"/>
      <link:label id="id_194d5f34" xlink:label="lbl_label424501044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combinations [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:label="lbl_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:to="lbl_label424501044" xlink:type="arc"/>
      <link:label id="id_4f78aa77" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on financial assets sold</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnFinancialAssetsSold" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:to="lbl_FairValueAdjustmentsOnFinancialAssetsSold_labels" xlink:type="arc"/>
      <link:label id="id_73e25c53" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets or disposal groups classified as held for sale</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_7e4ea322" xlink:label="lbl_label2119082786" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_label2119082786" xlink:type="arc"/>
      <link:label id="id_306dde36" xlink:label="lbl_label812506678" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy required by IFRSs [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:to="lbl_label812506678" xlink:type="arc"/>
      <link:label id="id_474e15ff" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets of disposal group held for sale</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherSharePurchasesValue" xlink:label="lbl_OtherSharePurchasesValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherSharePurchasesValue" xlink:to="lbl_OtherSharePurchasesValue_labels" xlink:type="arc"/>
      <link:label id="id_6ae68310" xlink:label="lbl_label1793491728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lutathera [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LutatheraMember" xlink:label="lbl_LutatheraMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LutatheraMember" xlink:to="lbl_label1793491728" xlink:type="arc"/>
      <link:label id="id_5ba5546c" xlink:label="lbl_label1537561708" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kymriah [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KymriahMember" xlink:label="lbl_KymriahMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KymriahMember" xlink:to="lbl_label1537561708" xlink:type="arc"/>
      <link:label id="id_6c54b8f7" xlink:label="lbl_label1817491703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of share capital tendered at the subsequent offering period of the tender offer</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:to="lbl_label1817491703" xlink:type="arc"/>
      <link:label id="id_a269182" xlink:label="lbl_label170299778" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration paid for share capital tendered at the subsequent offering period of the tender offer</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:to="lbl_label170299778" xlink:type="arc"/>
      <link:label id="id_7317bbcb" xlink:label="lbl_label1930935243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total percentage of share capital tendered after the subsequent offering period of the tender offer</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:to="lbl_label1930935243" xlink:type="arc"/>
      <link:label id="id_57adc4f7" xlink:label="lbl_TransactionCostsRecordedInEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction costs recorded in Equity [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCostsRecordedInEquityTextBlock" xlink:label="lbl_TransactionCostsRecordedInEquityTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionCostsRecordedInEquityTextBlock" xlink:to="lbl_TransactionCostsRecordedInEquityTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_281ffdcd" xlink:label="lbl_TransactionCostsRecordedInEquityTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs recorded in Equity</link:label>
      <link:label id="id_2cc49159" xlink:label="lbl_TransactionCostsRecordedInEquityPaid_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction costs recorded in equity paid</link:label>
      <link:label id="id_7df5c0c1" xlink:label="lbl_label2113257665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transactions with related parties [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionsWithRelatedPartiesAbstract" xlink:label="lbl_TransactionsWithRelatedPartiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionsWithRelatedPartiesAbstract" xlink:to="lbl_label2113257665" xlink:type="arc"/>
      <link:label id="id_5c1d5da7" xlink:label="lbl_label1309162706" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transactions with related parties [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionsWithRelatedPartiesTextBlock" xlink:label="lbl_TransactionsWithRelatedPartiesTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionsWithRelatedPartiesTextBlock" xlink:to="lbl_label1309162706" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCostsRecordedInEquityPaid" xlink:label="lbl_TransactionCostsRecordedInEquityPaid" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionCostsRecordedInEquityPaid" xlink:to="lbl_TransactionCostsRecordedInEquityPaid_labels" xlink:type="arc"/>
      <link:label id="id_5de3849f" xlink:label="lbl_TransactionCostsRecordedInEquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction costs recorded in equity</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCostsRecordedInEquity" xlink:label="lbl_TransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionCostsRecordedInEquity" xlink:to="lbl_TransactionCostsRecordedInEquity_labels" xlink:type="arc"/>
      <link:label id="id_154fa58" xlink:label="lbl_label22346328" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income recycled into the consolidated income statement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:label="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:to="lbl_label22346328" xlink:type="arc"/>
      <link:label id="id_7c9a09e2" xlink:label="lbl_label2090469858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase to retained earnings arising from first application of IFRS 9 fund investments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9FundInvestments" xlink:label="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9FundInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9FundInvestments" xlink:to="lbl_label2090469858" xlink:type="arc"/>
      <link:label id="id_36de49a0" xlink:label="lbl_label920537504" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase to retained earnings arising from first application of IFRS 9 equity securities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9EquitySecurities" xlink:label="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9EquitySecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9EquitySecurities" xlink:to="lbl_label920537504" xlink:type="arc"/>
      <link:label id="id_1e72baf" xlink:label="lbl_label31927215" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pension Fund [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPensionFundMember" xlink:label="lbl_NovartisPensionFundMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPensionFundMember" xlink:to="lbl_label31927215" xlink:type="arc"/>
      <link:label id="id_6d9924d1" xlink:label="lbl_label1838752977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings credit facility uncommitted</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCreditFacilityUncommitted" xlink:label="lbl_BorrowingsCreditFacilityUncommitted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCreditFacilityUncommitted" xlink:to="lbl_label1838752977" xlink:type="arc"/>
      <link:label id="id_60aed585" xlink:label="lbl_label1622070661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other net assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherNetAssets" xlink:label="lbl_OtherNetAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNetAssets" xlink:to="lbl_label1622070661" xlink:type="arc"/>
      <link:label id="id_25566515" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments from changes in ownership interests in subsidiaries that do not result in loss of control</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:to="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_labels" xlink:type="arc"/>
      <link:label id="id_73ce5e23" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of change in ownership of consolidated entities</link:label>
      <link:label id="id_68208ecc" xlink:label="lbl_label1746964172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ocular health [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OcularHealthMember" xlink:label="lbl_OcularHealthMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OcularHealthMember" xlink:to="lbl_label1746964172" xlink:type="arc"/>
      <link:label id="id_7d654567" xlink:label="lbl_label2103788903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.500% EUR 750 million 2018/2023 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.655% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:label="lbl_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:to="lbl_label2103788903" xlink:type="arc"/>
      <link:label id="id_a1b491f" xlink:label="lbl_label169560351" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.375% EUR 750 million 2018/2030 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.957% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:label="lbl_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:to="lbl_label169560351" xlink:type="arc"/>
      <link:label id="id_1f1416" xlink:label="lbl_label2036758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.700% EUR 750 million 2018/2038 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.217% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:label="lbl_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:to="lbl_label2036758" xlink:type="arc"/>
      <link:label id="id_63baf8ea" xlink:label="lbl_label1673197802" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications International SA, Geneve [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:label="lbl_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:to="lbl_label1673197802" xlink:type="arc"/>
      <link:label id="id_4bc832fa" xlink:label="lbl_label1271411450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications Switzerland SA, Geneve [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:label="lbl_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:to="lbl_label1271411450" xlink:type="arc"/>
      <link:label id="id_2658ed55" xlink:label="lbl_label643362133" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Gene Therapies, Inc., Bannockburn, IL [member]</link:label>
      <link:label id="id_358de13" xlink:label="lbl_label56155667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications S.A., Rueil-Malmaison [member]</link:label>
      <link:label id="id_480bc7a" xlink:label="lbl_BasicEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share</link:label>
      <link:label id="id_4f788787" xlink:label="lbl_DilutedEarningsLossPerShare_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share</link:label>
      <link:label id="id_579c77e7" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_labels" xlink:type="arc"/>
      <link:label id="id_6e4a53e8" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets without disposal group</link:label>
      <link:label id="id_4c7ed954" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities other than liabilities included in disposal groups classified as held for sale</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_6f67d848" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities included in disposal groups classified as held for sale</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:to="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_41ef90c7" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities of disposal group held for sale</link:label>
      <link:label id="id_15dcecbd" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities without disposal group</link:label>
      <link:label id="id_6be52fb3" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share of other comprehensive income of associates and joint ventures accounted for using equity method that will be reclassified to profit or loss, net of tax</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:type="arc"/>
      <link:label id="id_2cc5f4f3" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will not be reclassified to profit or loss, net of tax</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:type="arc"/>
      <link:label id="id_4201ce33" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total of items never to be recycled</link:label>
      <link:label id="id_3dedbea0" xlink:label="lbl_SellingGeneralAndAdministrativeExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administration</link:label>
      <link:label id="id_24ee551" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, property, plant and equipment</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_50cb4109" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_24ba2cbb" xlink:label="lbl_label616180923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal group held for sale [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisposalGroupHeldForSaleAbstract" xlink:label="lbl_DisposalGroupHeldForSaleAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalGroupHeldForSaleAbstract" xlink:to="lbl_label616180923" xlink:type="arc"/>
      <link:label id="id_2e51c9a9" xlink:label="lbl_label777111977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities not classified as held for sale [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_label777111977" xlink:type="arc"/>
      <link:label id="id_54b5ab16" xlink:label="lbl_label1421191958" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities classified as held for sale [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lbl_label1421191958" xlink:type="arc"/>
      <link:label id="id_620a76ae" xlink:label="lbl_label1644852910" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets held for sale [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsHeldForSaleMember" xlink:label="lbl_NoncurrentAssetsHeldForSaleMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssetsHeldForSaleMember" xlink:to="lbl_label1644852910" xlink:type="arc"/>
      <link:label id="id_35b1993" xlink:label="lbl_label56301971" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal groups classified as held for sale [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:to="lbl_label56301971" xlink:type="arc"/>
      <link:label id="id_775bbb23" xlink:label="lbl_label2002500387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and liabilities classified as held for sale [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_label2002500387" xlink:type="arc"/>
      <link:label id="id_76d4000c" xlink:label="lbl_label1993605132" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal group held for sale [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisposalGroupHeldForSaleLineItems" xlink:label="lbl_DisposalGroupHeldForSaleLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalGroupHeldForSaleLineItems" xlink:to="lbl_label1993605132" xlink:type="arc"/>
      <link:label id="id_511c252" xlink:label="lbl_label85049938" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets of disposal group classified as held for sale [abstract]</link:label>
      <link:label id="id_3a8a761b" xlink:label="lbl_label982152731" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities of disposal group classified as held for sale [abstract]</link:label>
      <link:label id="id_2004a2a3" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in other current liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_5c1266c3" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in other current liabilities</link:label>
      <link:label id="id_1b44e5e7" xlink:label="lbl_OtherAdjustmentsToReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other adjustments to reconcile profit (loss)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:label="lbl_OtherAdjustmentsToReconcileProfitLoss" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherAdjustmentsToReconcileProfitLoss" xlink:to="lbl_OtherAdjustmentsToReconcileProfitLoss_labels" xlink:type="arc"/>
      <link:label id="id_753e354c" xlink:label="lbl_label1967011148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in cash settled share based payments liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:label="lbl_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:to="lbl_label1967011148" xlink:type="arc"/>
      <link:label id="id_3fb8017" xlink:label="lbl_OtherAdjustmentsToReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other adjustments, net</link:label>
      <link:label id="id_45184c03" xlink:label="lbl_CashInflowOutflowNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow (outflow), Non-controlling interests</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowOutflowNoncontrollingInterests" xlink:label="lbl_CashInflowOutflowNoncontrollingInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowNoncontrollingInterests" xlink:to="lbl_CashInflowOutflowNoncontrollingInterests_labels" xlink:type="arc"/>
      <link:label id="id_3e6c4694" xlink:label="lbl_CashInflowOutflowNoncontrollingInterests_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:label id="id_773be135" xlink:label="lbl_label1852230229" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount recorded in equity related to hyperinflation</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountRecordedInEquityRelatedToHyperinflation" xlink:label="lbl_AmountRecordedInEquityRelatedToHyperinflation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountRecordedInEquityRelatedToHyperinflation" xlink:to="lbl_label1852230229" xlink:type="arc"/>
      <link:label id="id_73d5e167" xlink:label="lbl_AdditionsToInvestmentInAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions to investment in associated companies</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionsToInvestmentInAssociatedCompanies" xlink:label="lbl_AdditionsToInvestmentInAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsToInvestmentInAssociatedCompanies" xlink:to="lbl_AdditionsToInvestmentInAssociatedCompanies_labels" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:label id="id_1341dbff" xlink:label="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:to="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_346b395c" xlink:label="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_4b1ad4e8" xlink:label="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through obtaining or losing control of subsidiaries or other businesses, liabilities arising from financing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:to="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_2fcaf057" xlink:label="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of acquisitions and divestments of businesses, net</link:label>
      <link:label id="id_17118b46" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment recognised as of acquisition date</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:to="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_1d85e3c0" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
      <link:label id="id_4b8f7d44" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and other assets including deferred tax assets recognised as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:to="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_2918e43e" xlink:label="lbl_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial and other assets including deferred tax assets</link:label>
      <link:label id="id_5abfc6c6" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities recognised as of acquisition date</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_40924196" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current and non-current financial debts</link:label>
      <link:label id="id_4016f674" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-controlling interest in acquiree recognised at acquisition date</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:to="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_2ea65efd" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:label id="id_2375ce31" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, debt securities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities_labels" xlink:type="arc"/>
      <link:label id="id_56d0df79" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on debt securities, net of taxes</link:label>
      <link:label id="id_4663183e" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator"/>
      <link:label id="id_40c6b8fb" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions_labels" xlink:type="arc"/>
      <link:label id="id_3261fe4" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation, equity impact</link:label>
      <link:label id="id_cb4c548" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
      <link:label id="id_2a76513b" xlink:label="lbl_TransactionCosts_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCosts" xlink:label="lbl_TransactionCosts" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransactionCosts" xlink:to="lbl_TransactionCosts_labels" xlink:type="arc"/>
      <link:label id="id_19c4929e" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on divestment of interests in associated companies</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:to="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies_labels" xlink:type="arc"/>
      <link:label id="id_2500459a" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on divestment</link:label>
      <link:label id="id_198075f2" xlink:label="lbl_FairValueAdjustmentsOnDebtSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on debt securities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:to="lbl_FairValueAdjustmentsOnDebtSecuritiesMember_labels" xlink:type="arc"/>
      <link:label id="id_3f9715cf" xlink:label="lbl_FairValueAdjustmentsOnDebtSecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on debt securities</link:label>
      <link:label id="id_76d81b48" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on equity securities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:to="lbl_FairValueAdjustmentsOnEquitySecuritiesMember_labels" xlink:type="arc"/>
      <link:label id="id_57bce160" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on equity securities</link:label>
      <link:label id="id_1fb67de2" xlink:label="lbl_label532053474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification to presentation required under IFRS 9 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:label="lbl_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:to="lbl_label532053474" xlink:type="arc"/>
      <link:label id="id_714a2d9" xlink:label="lbl_label118792921" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restated Value Adjustments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RestatedValueAdjustmentsMember" xlink:to="lbl_label118792921" xlink:type="arc"/>
      <link:label id="id_4587be64" xlink:label="lbl_label1595406142" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets, equity securities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAssetsEquityInvestments" xlink:label="lbl_NoncurrentFinancialAssetsEquityInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAssetsEquityInvestments" xlink:to="lbl_label1595406142" xlink:type="arc"/>
      <link:label id="id_2b6a8c9e" xlink:label="lbl_label858249235" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets, fund investments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAssetsFundInvestments" xlink:label="lbl_NoncurrentFinancialAssetsFundInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAssetsFundInvestments" xlink:to="lbl_label858249235" xlink:type="arc"/>
      <link:label id="id_6be6dda0" xlink:label="lbl_label1810292128" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:to="lbl_label1810292128" xlink:type="arc"/>
      <link:label id="id_ea4af2a" xlink:label="lbl_label245673770" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_label245673770" xlink:type="arc"/>
      <link:label id="id_341eabcf" xlink:label="lbl_label874425295" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_label874425295" xlink:type="arc"/>
      <link:label id="id_2ef67b59" xlink:label="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in equity instruments designated at fair value through other comprehensive income</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:label="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:to="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_labels" xlink:type="arc"/>
      <link:label id="id_2bbf6984" xlink:label="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
      <link:label id="id_5be6a6ba" xlink:label="lbl_label1541842618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in equity instruments designated at fair value through other comprehensive income [axis]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:to="lbl_label1541842618" xlink:type="arc"/>
      <link:label id="id_5b1cb05e" xlink:label="lbl_label1528606814" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in equity instruments designated at fair value through other comprehensive income [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_label1528606814" xlink:type="arc"/>
      <link:label id="id_131c72f5" xlink:label="lbl_label320631541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Listed equity securities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ListedEquitySecuritiesMember" xlink:label="lbl_ListedEquitySecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ListedEquitySecuritiesMember" xlink:to="lbl_label320631541" xlink:type="arc"/>
      <link:label id="id_58943bff" xlink:label="lbl_label1486109695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-listed equity securities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonlistedEquitySecuritiesMember" xlink:label="lbl_NonlistedEquitySecuritiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonlistedEquitySecuritiesMember" xlink:to="lbl_label1486109695" xlink:type="arc"/>
      <link:label id="id_466ea37d" xlink:label="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of assets of disposal group classified as held for sale [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:label="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:to="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_328aa9b8" xlink:label="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets of disposal group classified as held for sale</link:label>
      <link:label id="id_663782d5" xlink:label="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of liabilities of disposal group classified as held for sale [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:label="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:to="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5f98604f" xlink:label="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities of disposal group classified as held for sale</link:label>
      <link:label id="id_1786ac50" xlink:label="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:label="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:to="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_33784e41" xlink:label="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities measured at fair value through other comprehensive income</link:label>
      <link:label id="id_2785f328" xlink:label="lbl_EndocyteMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Endocyte [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EndocyteMember" xlink:label="lbl_EndocyteMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EndocyteMember" xlink:to="lbl_EndocyteMember_labels" xlink:type="arc"/>
      <link:label id="id_1ab891f2" xlink:label="lbl_EndocyteMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Endocyte</link:label>
      <link:label id="id_559cd899" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial assets, cash and cash equivalents [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_63b9b41c" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:label id="id_172750e3" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial assets, marketable securities, commodities and non-current financial assets [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_7ca31c97" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, commodities and non-current financial assets</link:label>
      <link:label id="id_447d705c" xlink:label="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net sales and selected non-current assets, by countries and regions [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:to="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_36daedff" xlink:label="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales and selected non-current assets, by countries and regions</link:label>
      <link:label id="id_24f609b0" xlink:label="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net sales, by segements and regions [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:to="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_27432d26" xlink:label="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales by region</link:label>
      <link:label id="id_4192e6ea" xlink:label="lbl_label235032989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of nature of change in accounting policy</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:label="lbl_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:to="lbl_label235032989" xlink:type="arc"/>
      <link:label id="id_457ba061" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divestments aquisitions of interests in associated companies</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:to="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies_labels" xlink:type="arc"/>
      <link:label id="id_49d2e101" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through classified as held for sale, property, plant and equipment</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:to="lbl_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_625c07b4" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of assets related to disposal group held for sale</link:label>
      <link:label id="id_6066a3c9" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through classified as held for sale, intangible assets and goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:to="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_580b40b6" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of assets related to disposal group held for sale</link:label>
      <link:label id="id_3af4fc23" xlink:label="lbl_DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of assets related to disposal group held for sale</link:label>
      <link:label id="id_6cd0a23e" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net deferred tax balance related to disposal group held for sale</link:label>
      <link:label id="id_7f1eeac9" xlink:label="lbl_OtherShareSales_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other share sales</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherShareSales" xlink:label="lbl_OtherShareSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherShareSales" xlink:to="lbl_OtherShareSales_labels" xlink:type="arc"/>
      <link:label id="id_7be3c1db" xlink:label="lbl_OtherShareSales_labels" xlink:role="http://www.xbrl.org/2003/role/negativeLabel" xlink:type="resource" xml:lang="en-US">Other share sales</link:label>
      <link:label id="id_6d6afa95" xlink:label="lbl_label1359067097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other share sales, equity impact</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherShareSalesEquityImpact" xlink:label="lbl_OtherShareSalesEquityImpact" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherShareSalesEquityImpact" xlink:to="lbl_label1359067097" xlink:type="arc"/>
      <link:label id="id_3b6caa8a" xlink:label="lbl_NumberOfOtherShareSales_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other share sales</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfOtherShareSales" xlink:label="lbl_NumberOfOtherShareSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOtherShareSales" xlink:to="lbl_NumberOfOtherShareSales_labels" xlink:type="arc"/>
      <link:label id="id_6db1b7c2" xlink:label="lbl_NumberOfOtherShareSales_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other share sales</link:label>
      <link:label id="id_2d79675e" xlink:label="lbl_NumberOfOtherShareSalesEquityImpact_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other share sales, equity impact</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfOtherShareSalesEquityImpact" xlink:label="lbl_NumberOfOtherShareSalesEquityImpact" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOtherShareSalesEquityImpact" xlink:to="lbl_NumberOfOtherShareSalesEquityImpact_labels" xlink:type="arc"/>
      <link:label id="id_4f13fea7" xlink:label="lbl_NumberOfOtherShareSalesEquityImpact_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other share sales, equity impact</link:label>
      <link:label id="id_35d72bee" xlink:label="lbl_label903293934" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, debt securities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeDebtSecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeDebtSecurities" xlink:to="lbl_label903293934" xlink:type="arc"/>
      <link:label id="id_269c946a" xlink:label="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, equity securities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:to="lbl_label1931018935" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:to="lbl_label1923652241" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPtyLtdMacquarieParkNSWMember" xlink:label="lbl_SandozPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPtyLtdMacquarieParkNSWMember" xlink:to="lbl_label1031360833" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:to="lbl_label409451279" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaNVVilvoordeMember" xlink:label="lbl_NovartisPharmaNVVilvoordeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaNVVilvoordeMember" xlink:to="lbl_label861091593" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozNVVilvoordeMember" xlink:label="lbl_SandozNVVilvoordeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozNVVilvoordeMember" xlink:to="lbl_label102668381" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCouvreurNVPuursMember" xlink:label="lbl_AlconCouvreurNVPuursMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconCouvreurNVPuursMember" xlink:to="lbl_label1808949392" xlink:type="arc"/>
      <link:label id="id_20428b8c" xlink:label="lbl_label541232012" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Laboratories Belgium BVBA, Puurs [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:label="lbl_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:to="lbl_label541232012" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconNVVilvoordeMember" xlink:label="lbl_AlconNVVilvoordeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconNVVilvoordeMember" xlink:to="lbl_label1193123279" xlink:type="arc"/>
      <link:label id="id_7f713e00" xlink:label="lbl_label2138127872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon AG, Fribourg [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconAGFribourgMember" xlink:label="lbl_AlconAGFribourgMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconAGFribourgMember" xlink:to="lbl_label2138127872" xlink:type="arc"/>
      <link:label id="id_3e12064" xlink:label="lbl_label65085540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications USA, Inc., New York, NY [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:to="lbl_label65085540" xlink:type="arc"/>
      <link:label id="id_749e4361" xlink:label="lbl_label1956528993" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIBA Vision Corporation LLC, Duluth, GA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionCorporationLLCDuluthGAMember" xlink:label="lbl_CIBAVisionCorporationLLCDuluthGAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CIBAVisionCorporationLLCDuluthGAMember" xlink:to="lbl_label1956528993" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:label="lbl_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:to="lbl_label426571388" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPolandSp.ZO.o.WarsawMember" xlink:label="lbl_NovartisPolandSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPolandSp.ZO.o.WarsawMember" xlink:to="lbl_label1610589901" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPolskaSp.ZO.o.WarsawMember" xlink:label="lbl_SandozPolskaSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPolskaSp.ZO.o.WarsawMember" xlink:to="lbl_label1898723838" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPolskaSp.ZO.o.WarsawMember" xlink:label="lbl_AlconPolskaSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconPolskaSp.ZO.o.WarsawMember" xlink:to="lbl_label1959302877" xlink:type="arc"/>
      <link:label id="id_6d8d3375" xlink:label="lbl_label1837970293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Healthcare, S.A., Barcelona [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconHealthcareS.A.BarcelonaMember" xlink:label="lbl_AlconHealthcareS.A.BarcelonaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconHealthcareS.A.BarcelonaMember" xlink:to="lbl_label1837970293" xlink:type="arc"/>
      <link:label id="id_3892d07e" xlink:label="lbl_label949145726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Innovative Therapies AG, Risch [member]</link:label>
      <link:label id="id_5097f514" xlink:label="lbl_label1352135956" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Ukraine LLC, Kyiv [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozUkraineLLCKievMember" xlink:label="lbl_SandozUkraineLLCKievMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozUkraineLLCKievMember" xlink:to="lbl_label1352135956" xlink:type="arc"/>
      <link:label id="id_68b9cbd5" xlink:label="lbl_label1757006805" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divestment cost to sell</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentCostToSell" xlink:label="lbl_DivestmentCostToSell" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestmentCostToSell" xlink:to="lbl_label1757006805" xlink:type="arc"/>
      <link:label id="id_3bde338f" xlink:label="lbl_label1004417935" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of settlement in principle</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfSettlementInPrinciple" xlink:label="lbl_AmountOfSettlementInPrinciple" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountOfSettlementInPrinciple" xlink:to="lbl_label1004417935" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:label="lbl_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:to="lbl_label969930944" xlink:type="arc"/>
      <link:label id="id_54d2c7cf" xlink:label="lbl_label1423099855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of products in portfolio to be sold</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfProductsInPortfolioToBeSold" xlink:label="lbl_NumberOfProductsInPortfolioToBeSold" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfProductsInPortfolioToBeSold" xlink:to="lbl_label1423099855" xlink:type="arc"/>
      <link:label id="id_4f5a93ca" xlink:label="lbl_label1331336138" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying value of the divested business</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CarryingValueOfTheDivestedBusiness" xlink:label="lbl_CarryingValueOfTheDivestedBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CarryingValueOfTheDivestedBusiness" xlink:to="lbl_label1331336138" xlink:type="arc"/>
      <link:label id="id_2bfacba6" xlink:label="lbl_label737856422" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short term leases and low value leases</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShortTermLeasesAndLowValueLeases" xlink:label="lbl_ShortTermLeasesAndLowValueLeases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ShortTermLeasesAndLowValueLeases" xlink:to="lbl_label737856422" xlink:type="arc"/>
      <link:label id="id_1638753" xlink:label="lbl_label23299923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining lease commitments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RemainingLeaseCommitments" xlink:label="lbl_RemainingLeaseCommitments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RemainingLeaseCommitments" xlink:to="lbl_label23299923" xlink:type="arc"/>
      <link:label id="id_3c454913" xlink:label="lbl_label1011173651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities to be recognized</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseLiabilitiesToBeRecognized" xlink:label="lbl_LeaseLiabilitiesToBeRecognized" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilitiesToBeRecognized" xlink:to="lbl_label1011173651" xlink:type="arc"/>
      <link:label id="id_46c00732" xlink:label="lbl_label1186989874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right of use assets to be recognized</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RightOfUseAssetsToBeRecognized" xlink:label="lbl_RightOfUseAssetsToBeRecognized" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RightOfUseAssetsToBeRecognized" xlink:to="lbl_label1186989874" xlink:type="arc"/>
      <link:label id="id_5c114913" xlink:label="lbl_label1544636691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss/gain recorded on equity securities and fund investments at fair value through the consolidated income statement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:label="lbl_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:to="lbl_label1544636691" xlink:type="arc"/>
      <link:label id="id_c04ac79" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on equity securities, net of taxes</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_labels" xlink:type="arc"/>
      <link:label id="id_5fb3768f" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, gains (losses) from investments in equity instruments</link:label>
      <link:label id="id_4dc28e6d" xlink:label="lbl_DeferredTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax expense (income)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="lbl_DeferredTaxExpenseIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxExpenseIncome" xlink:to="lbl_DeferredTaxExpenseIncome_labels" xlink:type="arc"/>
      <link:label id="id_77e968c5" xlink:label="lbl_DeferredTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax income</link:label>
      <link:label id="id_2d4a780d" xlink:label="lbl_CurrentTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current income tax expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="lbl_CurrentTaxExpenseIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTaxExpenseIncome" xlink:to="lbl_CurrentTaxExpenseIncome_labels" xlink:type="arc"/>
      <link:label id="id_bbe9642" xlink:label="lbl_CurrentTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax expense (income)</link:label>
      <link:label id="id_5ac027e9" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income effect</link:label>
      <link:label id="id_2c40f598" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Associated companies' movements in comprehensive income</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:label="lbl_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:to="lbl_label757358878" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceS.A.LuxembourgCityMember" xlink:label="lbl_NovartisFinanceS.A.LuxembourgCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFinanceS.A.LuxembourgCityMember" xlink:to="lbl_label1668533481" xlink:type="arc"/>
      <link:label id="id_3d20cd78" xlink:label="lbl_label1025559928" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Endocyte, Inc., Lafayette, IN [member]</link:label>
      <link:label id="id_151d2726" xlink:label="lbl_label354232102" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tear Film Innovations, Inc., Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TearFilmInnovationsInc.FortWorthTXMember" xlink:label="lbl_TearFilmInnovationsInc.FortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TearFilmInnovationsInc.FortWorthTXMember" xlink:to="lbl_label354232102" xlink:type="arc"/>
      <link:label id="id_1a32a075" xlink:label="lbl_label439525493" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TrueVision Systems, Inc., Fort Worth, TX [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TrueVisionSystemsInc.FortWorthTXMember" xlink:label="lbl_TrueVisionSystemsInc.FortWorthTXMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TrueVisionSystemsInc.FortWorthTXMember" xlink:to="lbl_label439525493" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TranscendMedicalInc.LakeForestILMember" xlink:label="lbl_TranscendMedicalInc.LakeForestILMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TranscendMedicalInc.LakeForestILMember" xlink:to="lbl_label1438652981" xlink:type="arc"/>
      <link:label id="id_279b1df4" xlink:label="lbl_label664477172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Baltics SIA, Riga [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBalticsSIARigaMember" xlink:label="lbl_NovartisBalticsSIARigaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBalticsSIARigaMember" xlink:to="lbl_label664477172" xlink:type="arc"/>
      <link:label id="id_5e85347d" xlink:label="lbl_label1585788029" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Biosciences Peru S.A., Lima [member]</link:label>
      <link:label id="id_62d68d5f" xlink:label="lbl_label1658228063" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Overseas Investments AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisOverseasInvestmentsAGBaselMember" xlink:label="lbl_NovartisOverseasInvestmentsAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisOverseasInvestmentsAGBaselMember" xlink:to="lbl_label1658228063" xlink:type="arc"/>
      <link:label id="id_254382a8" xlink:label="lbl_label625181352" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japat AG, Basel [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JapatAGBaselMember" xlink:label="lbl_JapatAGBaselMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_JapatAGBaselMember" xlink:to="lbl_label625181352" xlink:type="arc"/>
      <link:label id="id_4cd3abe4" xlink:label="lbl_label1288940516" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcon Management SA, Geneva [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconManagementSAGenevaMember" xlink:label="lbl_AlconManagementSAGenevaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AlconManagementSAGenevaMember" xlink:to="lbl_label1288940516" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EndocyteInc.LafayetteINMember" xlink:label="lbl_EndocyteInc.LafayetteINMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EndocyteInc.LafayetteINMember" xlink:to="lbl_label1025559928" xlink:type="arc"/>
      <link:label id="id_68b5f06f" xlink:label="lbl_label1756754031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oriel Therapeutics, Inc., Durham, NC [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OrielTherapeuticsInc.DurhamNCMember" xlink:label="lbl_OrielTherapeuticsInc.DurhamNCMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OrielTherapeuticsInc.DurhamNCMember" xlink:to="lbl_label1756754031" xlink:type="arc"/>
      <link:label id="id_60eaa13f" xlink:label="lbl_label1625989439" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">WaveLight, Inc., Sterling, VA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WaveLightInc.SterlingVAMember" xlink:label="lbl_WaveLightInc.SterlingVAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WaveLightInc.SterlingVAMember" xlink:to="lbl_label1625989439" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBiosciencesPeruS.A.LimaMember" xlink:label="lbl_NovartisBiosciencesPeruS.A.LimaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisBiosciencesPeruS.A.LimaMember" xlink:to="lbl_label1585788029" xlink:type="arc"/>
      <link:label id="id_5bdf673e" xlink:label="lbl_label1541367614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares with restricted use</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesWithRestrictedUse" xlink:label="lbl_TreasurySharesWithRestrictedUse" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesWithRestrictedUse" xlink:to="lbl_label1541367614" xlink:type="arc"/>
      <link:label id="id_7fb088b9" xlink:label="lbl_label2142275769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate effect of revenues exempt from taxation</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:label="lbl_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:to="lbl_label2142275769" xlink:type="arc"/>
      <link:label id="id_6108aeff" xlink:label="lbl_CurrentInterestPayable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current interest payable</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentInterestPayable" xlink:label="lbl_CurrentInterestPayable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentInterestPayable" xlink:to="lbl_CurrentInterestPayable_labels" xlink:type="arc"/>
      <link:label id="id_1fc5ed9f" xlink:label="lbl_CurrentInterestPayable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interests on financial debt</link:label>
      <link:label id="id_6b7c4e62" xlink:label="lbl_CommitmentForRepurchaseOwnShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitment for repurchase own shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentForRepurchaseOwnShares" xlink:label="lbl_CommitmentForRepurchaseOwnShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommitmentForRepurchaseOwnShares" xlink:to="lbl_CommitmentForRepurchaseOwnShares_labels" xlink:type="arc"/>
      <link:label id="id_5e285341" xlink:label="lbl_label130728687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial asstets debt securities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAsstetsDebtSecurities" xlink:label="lbl_NoncurrentFinancialAsstetsDebtSecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAsstetsDebtSecurities" xlink:to="lbl_label130728687" xlink:type="arc"/>
      <link:label id="id_1f883fd2" xlink:label="lbl_label826017497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions included in disposal group prior to classification to assets held for sale</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:label="lbl_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:to="lbl_label826017497" xlink:type="arc"/>
      <link:label id="id_256b0374" xlink:label="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation charge prior to classification to assets held for sale</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:label="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:to="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_4b6e3676" xlink:label="lbl_NoncurrentFinancialAssetsAvailableforsale_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total financial investments</link:label>
      <link:label id="id_2b3e006" xlink:label="lbl_label1209757713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proforma net sales</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProformaNetSales" xlink:label="lbl_ProformaNetSales" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProformaNetSales" xlink:to="lbl_label1209757713" xlink:type="arc"/>
      <link:label id="id_2888ddc2" xlink:label="lbl_label680058306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Serelaxin [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SerelaxinMember" xlink:label="lbl_SerelaxinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SerelaxinMember" xlink:to="lbl_label680058306" xlink:type="arc"/>
      <link:label id="id_4e4f9507" xlink:label="lbl_label1313838343" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CyPass [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CyPassMember" xlink:label="lbl_CyPassMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CyPassMember" xlink:to="lbl_label1313838343" xlink:type="arc"/>
      <link:label id="id_52281715" xlink:label="lbl_IncomeStatementAdjustmentsOfPriorYear_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income statement adjustments of prior year</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementAdjustmentsOfPriorYear" xlink:label="lbl_IncomeStatementAdjustmentsOfPriorYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementAdjustmentsOfPriorYear" xlink:to="lbl_IncomeStatementAdjustmentsOfPriorYear_labels" xlink:type="arc"/>
      <link:label id="id_68901646" xlink:label="lbl_IncomeStatementAdjustmentsOfPriorYear_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions prior year</link:label>
      <link:label id="id_12f0be52" xlink:label="lbl_IncomeStatementAdjustmentsOfCurrentYear_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income statement adjustments of current year</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementAdjustmentsOfCurrentYear" xlink:label="lbl_IncomeStatementAdjustmentsOfCurrentYear" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncomeStatementAdjustmentsOfCurrentYear" xlink:to="lbl_IncomeStatementAdjustmentsOfCurrentYear_labels" xlink:type="arc"/>
      <link:label id="id_10001b20" xlink:label="lbl_IncomeStatementAdjustmentsOfCurrentYear_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions current year</link:label>
      <link:label id="id_53e07f22" xlink:label="lbl_label1407221538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plans and program rebates [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PlansAndProgramRebatesAxis" xlink:label="lbl_PlansAndProgramRebatesAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PlansAndProgramRebatesAxis" xlink:to="lbl_label1407221538" xlink:type="arc"/>
      <link:label id="id_64c2e5e1" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, other provisions and increase (decrease) through net exchange differences, other provisions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_359d5a9f" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effects of currency translation and business combinations</link:label>
      <link:label id="id_73fc698b" xlink:label="lbl_label1945921931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment charges related to disposal group held for sale</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:label="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:to="lbl_label1945921931" xlink:type="arc"/>
      <link:label id="id_6ee3c039" xlink:label="lbl_label1860419641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment charges related to disposal group held for sale to the date of reclassification</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:label="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:to="lbl_label1860419641" xlink:type="arc"/>
      <link:label id="id_4ed2e3f9" xlink:label="lbl_label1322443769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions included in disposal group to the date of reclassification</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:label="lbl_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:to="lbl_label1322443769" xlink:type="arc"/>
      <link:label id="id_7be11426" xlink:label="lbl_label1459075477" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net cash flows used in from divestments of businesses classified as investing activities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:to="lbl_label1459075477" xlink:type="arc"/>
      <link:label id="id_63a31bcb" xlink:label="lbl_label625103893" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets divested</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentAssetsDivested" xlink:label="lbl_NoncurrentAssetsDivested" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssetsDivested" xlink:to="lbl_label625103893" xlink:type="arc"/>
      <link:label id="id_7f3ccd67" xlink:label="lbl_label654491613" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets divested</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentAssetsDivested" xlink:label="lbl_CurrentAssetsDivested" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAssetsDivested" xlink:to="lbl_label654491613" xlink:type="arc"/>
      <link:label id="id_28fd0d0c" xlink:label="lbl_label2062437885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities divested</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLiabilitiesDivested" xlink:label="lbl_CurrentLiabilitiesDivested" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLiabilitiesDivested" xlink:to="lbl_label2062437885" xlink:type="arc"/>
      <link:label id="id_217212a3" xlink:label="lbl_label1484079992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial and other assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialAndOtherAssets" xlink:label="lbl_FinancialAndOtherAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAndOtherAssets" xlink:to="lbl_label1484079992" xlink:type="arc"/>
      <link:label id="id_3b6cb989" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities recognised as of acquisition date</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_411a4e68" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:label id="id_481dd512" xlink:label="lbl_label1209914642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow outflow from net identifiable assets divested acquired</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:to="lbl_label1209914642" xlink:type="arc"/>
      <link:label id="id_2dad0e04" xlink:label="lbl_TradePayablesAndOtherLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade payables and other liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradePayablesAndOtherLiabilities" xlink:label="lbl_TradePayablesAndOtherLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradePayablesAndOtherLiabilities" xlink:to="lbl_TradePayablesAndOtherLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_1551e337" xlink:label="lbl_TradePayablesAndOtherLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Trade payables and other liabilities</link:label>
      <link:label id="id_29a54c7d" xlink:label="lbl_label698698877" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow outflow from net identifiable assets currency translation effects liquidity and fair value of equity interests</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests" xlink:to="lbl_label698698877" xlink:type="arc"/>
      <link:label id="id_72d7c22d" xlink:label="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from losing control of subsidiaries or other businesses, classified as investing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_469e951e" xlink:label="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divested business</link:label>
      <link:label id="id_79d4ff23" xlink:label="lbl_label2044002083" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of other financial assets sold</link:label>
      <link:label id="id_f9b4624" xlink:label="lbl_label261834276" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities, fair value through other comprehensive income [member]</link:label>
      <link:label id="id_3f7b625a" xlink:label="lbl_label1065050714" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term financial investments, fair value through other comprehensive income [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_label1065050714" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_label261834276" xlink:type="arc"/>
      <link:label id="id_3373fda5" xlink:label="lbl_label863239589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plans and program rebates [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PlansAndProgramRebatesMember" xlink:label="lbl_PlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PlansAndProgramRebatesMember" xlink:to="lbl_label863239589" xlink:type="arc"/>
      <link:label id="id_52f984e4" xlink:label="lbl_label1392084196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US-specific healthcare plans and program rebates [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_USspecificHealthcarePlansAndProgramRebatesMember" xlink:label="lbl_USspecificHealthcarePlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_USspecificHealthcarePlansAndProgramRebatesMember" xlink:to="lbl_label1392084196" xlink:type="arc"/>
      <link:label id="id_3a1be35a" xlink:label="lbl_label974906202" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US-specific healthcare plans and program rebates [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:label="lbl_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:to="lbl_label974906202" xlink:type="arc"/>
      <link:label id="id_52817cee" xlink:label="lbl_label1384217838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-healthcare plans and program-related rebates, returns and other deductions [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:label="lbl_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:to="lbl_label1384217838" xlink:type="arc"/>
      <link:label id="id_518b30b7" xlink:label="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation charge prior to classification to assets held for sale</link:label>
      <link:label id="id_611b2741" xlink:label="lbl_DeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
      <link:label id="id_35974485" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise prices for outstanding share options [member]</link:label>
      <link:label id="id_3da6037c" xlink:label="lbl_label1034290044" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">46.7</link:label>
      <link:label id="id_5698bfcb" xlink:label="lbl_label1452851147" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 46.7 [member]</link:label>
      <link:label id="id_df65a83" xlink:label="lbl_label1098297979" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">54.5</link:label>
      <link:label id="id_26baf973" xlink:label="lbl_label1238972312" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">57.0</link:label>
      <link:label id="id_5d51017e" xlink:label="lbl_label1565589886" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">57.6</link:label>
      <link:label id="id_7925df2" xlink:label="lbl_label127032818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 57.6 [member]</link:label>
      <link:label id="id_50442a73" xlink:label="lbl_label61576322" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">66.0</link:label>
      <link:label id="id_77b11616" xlink:label="lbl_label2008094230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized income was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:label="lbl_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:to="lbl_label2008094230" xlink:type="arc"/>
      <link:label id="id_13923e74" xlink:label="lbl_label328351348" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">46.4</link:label>
      <link:label id="id_26b025e5" xlink:label="lbl_label649078245" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">53.7</link:label>
      <link:label id="id_15297d64" xlink:label="lbl_label355040612" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">57.1</link:label>
      <link:label id="id_37ef180d" xlink:label="lbl_label938416141" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">58.3</link:label>
      <link:label id="id_7963b4c" xlink:label="lbl_label127286092" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">66.1</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice46.7Member" xlink:label="lbl_ExercisePrice46.7Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice46.7Member" xlink:to="lbl_label1452851147" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice46.7Member" xlink:to="lbl_label1034290044" xlink:type="arc"/>
      <link:label id="id_7638cc32" xlink:label="lbl_label1983433778" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 54.5 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice54.5Member" xlink:label="lbl_ExercisePrice54.5Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice54.5Member" xlink:to="lbl_label1983433778" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice54.5Member" xlink:to="lbl_label1098297979" xlink:type="arc"/>
      <link:label id="id_625d280f" xlink:label="lbl_label1650272271" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 57.0 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.0Member" xlink:label="lbl_ExercisePrice57.0Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.0Member" xlink:to="lbl_label1650272271" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.0Member" xlink:to="lbl_label1238972312" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.6Member" xlink:label="lbl_ExercisePrice57.6Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.6Member" xlink:to="lbl_label127032818" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.6Member" xlink:to="lbl_label1565589886" xlink:type="arc"/>
      <link:label id="id_7f8b8ef4" xlink:label="lbl_label2139852532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 66.0 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice66.0Member" xlink:label="lbl_ExercisePrice66.0Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice66.0Member" xlink:to="lbl_label2139852532" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice66.0Member" xlink:to="lbl_label61576322" xlink:type="arc"/>
      <link:label id="id_1c214787" xlink:label="lbl_label471943047" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 46.4 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice46.4Member" xlink:label="lbl_ExercisePrice46.4Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice46.4Member" xlink:to="lbl_label471943047" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice46.4Member" xlink:to="lbl_label328351348" xlink:type="arc"/>
      <link:label id="id_60064b00" xlink:label="lbl_label1611025152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 53.7 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice53.7Member" xlink:label="lbl_ExercisePrice53.7Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice53.7Member" xlink:to="lbl_label1611025152" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice53.7Member" xlink:to="lbl_label649078245" xlink:type="arc"/>
      <link:label id="id_3d7bc5f9" xlink:label="lbl_label1031521785" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 57.1 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.1Member" xlink:label="lbl_ExercisePrice57.1Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.1Member" xlink:to="lbl_label1031521785" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice57.1Member" xlink:to="lbl_label355040612" xlink:type="arc"/>
      <link:label id="id_5312799d" xlink:label="lbl_label1393719709" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 58.3 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice58.3Member" xlink:label="lbl_ExercisePrice58.3Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice58.3Member" xlink:to="lbl_label1393719709" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice58.3Member" xlink:to="lbl_label938416141" xlink:type="arc"/>
      <link:label id="id_11afcf8b" xlink:label="lbl_label296734603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 66.1 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice66.1Member" xlink:label="lbl_ExercisePrice66.1Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice66.1Member" xlink:to="lbl_label296734603" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice66.1Member" xlink:to="lbl_label127286092" xlink:type="arc"/>
      <link:label id="id_602d9a64" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions and divestments of interests in associated companies, net</link:label>
      <link:label id="id_1640eef1" xlink:label="lbl_TransactionCostsRecordedInEquityPaid_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs payments</link:label>
      <link:label id="id_4305d26a" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in investing activities from discontinued operations</link:label>
      <link:label id="id_1cb46ce6" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to revaluation of deferred tax assets on equity based compensation that were previously recognized through retained earnings</link:label>
      <link:label id="id_45074031" xlink:label="lbl_label1158103089" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepayments and accrued lease payments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrepaymentsAndAccruedLeasePayments" xlink:label="lbl_PrepaymentsAndAccruedLeasePayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrepaymentsAndAccruedLeasePayments" xlink:to="lbl_label1158103089" xlink:type="arc"/>
      <link:label id="id_1787fdbc" xlink:label="lbl_label1284506961" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recycling of the Novartis share of other comprehensive income from associated companies</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:label="lbl_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:to="lbl_label1284506961" xlink:type="arc"/>
      <link:label id="id_7702ef73" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase/decrease of treasury share repurchase obligation under a share buyback trading plan</link:label>
      <link:label id="id_135f3eb7" xlink:label="lbl_TransactionCostsRecordedInEquityPaid_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs payments</link:label>
      <link:label id="id_1765273e" xlink:label="lbl_CashFlowFromNetIdentifiableAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net assets recognized as a result of acquistions of businesses</link:label>
      <link:label id="id_4a08e514" xlink:label="lbl_CurrentTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current tax expense (income)</link:label>
      <link:label id="id_71e76093" xlink:label="lbl_DeferredTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax expense (income)</link:label>
      <link:label id="id_608223c4" xlink:label="lbl_IncomeTaxExpense_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total Income Tax Expense</link:label>
      <link:label id="id_352bb146" xlink:label="lbl_TaxExpenseIncomeDiscontinuingOperations_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense from discontinued operations</link:label>
      <link:label id="id_6348f872" xlink:label="lbl_TransactionCostsRecordedInEquity_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs recorded in equity</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:label="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_label85049938" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:label="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" xlink:to="lbl_label982152731" xlink:type="arc"/>
      <link:label id="id_31ca37cf" xlink:label="lbl_label835336143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization prior to classification to assets held for sale</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:label="lbl_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:to="lbl_label835336143" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:to="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_43b1908f" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax assets or deferred tax liabilities related to disposal group held for sale</link:label>
      <link:label id="id_3b7e23ba" xlink:label="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accrued benefit liability</link:label>
      <link:label id="id_774651e9" xlink:label="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_5fb55436" xlink:label="lbl_TreasurySharesAcquiredForCancellationValue_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Shares acquired for cancellation, equity impact</link:label>
      <link:label id="id_71230227" xlink:label="lbl_DisposalsFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposals fair value measurement assets</link:label>
      <link:label id="id_757b03e4" xlink:label="lbl_EquityImpactOfTreasuryShareMovements_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total equity impact of treasury share movements</link:label>
      <link:label id="id_9217c59" xlink:label="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</link:label>
      <link:label id="id_eb62348" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment charges and fair value gains on financial assets, net</link:label>
      <link:label id="id_2ec0dcb9" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of acquisitions, divestments or transfers</link:label>
      <link:label id="id_48bf4d53" xlink:label="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other movements</link:label>
      <link:label id="id_1a35a04f" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interests</link:label>
      <link:label id="id_39d0eccc" xlink:label="lbl_OtherSharePurchasesValue_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other share purchases, equity impact</link:label>
      <link:label id="id_5209e6b5" xlink:label="lbl_SurplusDeficitInPlan_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Funded status</link:label>
      <link:label id="id_2a14e1da" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges and fair value gains on financial assets, net</link:label>
      <link:label id="id_74f13ac0" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on financial assets sold</link:label>
      <link:label id="id_180b00c2" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from/(used in) investing activities from continuing operations</link:label>
      <link:label id="id_aca6a21" xlink:label="lbl_ProceedsFromNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase in non-current financial debts</link:label>
      <link:label id="id_5e5a2737" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows from/(used in) investing activities</link:label>
      <link:label id="id_12daaf08" xlink:label="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divested interest in associate</link:label>
      <link:label id="id_595a0496" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in discontinued operations</link:label>
      <link:label id="id_6f1acb28" xlink:label="lbl_label1864026920" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long term financial investments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongTermFinancialInvestmentsMember" xlink:label="lbl_LongTermFinancialInvestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LongTermFinancialInvestmentsMember" xlink:to="lbl_label1864026920" xlink:type="arc"/>
      <link:label id="id_24014c8f" xlink:label="lbl_label1836731146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketableSecurities" xlink:label="lbl_MarketableSecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MarketableSecurities" xlink:to="lbl_label1836731146" xlink:type="arc"/>
      <link:label id="id_7323afac" xlink:label="lbl_label1544871888" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major plans percentage in group DBO pensions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MajorPlansPercentageInGroupDBOPensions" xlink:label="lbl_MajorPlansPercentageInGroupDBOPensions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MajorPlansPercentageInGroupDBOPensions" xlink:to="lbl_label1544871888" xlink:type="arc"/>
      <link:label id="id_192e72f5" xlink:label="lbl_label456555172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Most signigicant countries percentage on group DBO post employment benefit plans</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:label="lbl_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:to="lbl_label456555172" xlink:type="arc"/>
      <link:label id="id_7686c3c0" xlink:label="lbl_DefinedBenefitPlanSettlementsPlanAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
      <link:label id="id_4d6d4f53" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Past service cost and settlements</link:label>
      <link:label id="id_764909d2" xlink:label="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial assets, total financial investments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:label="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:to="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments_labels" xlink:type="arc"/>
      <link:label id="id_2ba0d9fa" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on equity securities sold, reclassified to retained earnings</link:label>
      <link:label id="id_751d39ac" xlink:label="lbl_label1964849580" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss from discontinued operations before gain on distribution</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:label="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:to="lbl_label1964849580" xlink:type="arc"/>
      <link:label id="id_3a463b8c" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed_labels" xlink:type="arc"/>
      <link:label id="id_2c57b1ca" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on distribution</link:label>
      <link:label id="id_291f69d6" xlink:label="lbl_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax on Pension plans previously recognized in OCI</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI" xlink:label="lbl_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI" xlink:to="lbl_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI_labels" xlink:type="arc"/>
      <link:label id="id_2f7fc540" xlink:label="lbl_RightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RightofuseAssets" xlink:to="lbl_RightofuseAssets_labels" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPayable" xlink:label="lbl_DividendsPayable" xlink:type="locator"/>
      <link:label id="id_6acaf180" xlink:label="lbl_DividendsPayable_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend in kind distribution liability</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsPayable" xlink:to="lbl_DividendsPayable_labels" xlink:type="arc"/>
      <link:label id="id_34ce2448" xlink:label="lbl_DividendsPayable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends payable, non-cash assets distributions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:label="lbl_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:type="locator"/>
      <link:label id="id_484edcc4" xlink:label="lbl_DividendsRecognisedAsDistributionsToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividend in kind</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsRecognisedAsDistributionsToOwnersOfParent" xlink:to="lbl_DividendsRecognisedAsDistributionsToOwnersOfParent_labels" xlink:type="arc"/>
      <link:label id="id_7adfa754" xlink:label="lbl_DividendsRecognisedAsDistributionsToOwnersOfParent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends recognised as distributions to owners of paren</link:label>
      <link:label id="id_590635ac" xlink:label="lbl_SaleOrIssueOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sale of treasury shares</link:label>
      <link:label id="id_2476e743" xlink:label="lbl_ProfitLossFromContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income from continuing operations</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:label id="id_1ffd83cc" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in financing activities from discontinued operations</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:label id="id_6a49a8cd" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in financing activities from continuing operations</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_labels" xlink:type="arc"/>
      <link:label id="id_59187aa8" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities, discontinued operations</link:label>
      <link:label id="id_1d15aff4" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities, continuing operations</link:label>
      <link:label id="id_100aa035" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents before effect of exchange rate changes</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_labels" xlink:type="arc"/>
      <link:label id="id_50620c89" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</link:label>
      <link:label id="id_96ecbb0" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents of discontinued operations</link:label>
      <link:label id="id_2334b78" xlink:label="lbl_label36916088" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of discontinued operations [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDiscontinuedOperationsAbstract" xlink:label="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:to="lbl_label36916088" xlink:type="arc"/>
      <link:label id="id_76c64958" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sales to other segments</link:label>
      <link:label id="id_36af0a7f" xlink:label="lbl_RevenueFromSaleOfGoods_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net sales</link:label>
      <link:label id="id_58501f6b" xlink:label="lbl_label1481645931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change over period, YoY [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_YoYChangeMember" xlink:label="lbl_YoYChangeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_YoYChangeMember" xlink:to="lbl_label1481645931" xlink:type="arc"/>
      <link:label id="id_3ed48330" xlink:label="lbl_label1054114608" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="lbl_label1054114608" xlink:type="arc"/>
      <link:label id="id_43a1a553" xlink:label="lbl_label1134667091" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_label1134667091" xlink:type="arc"/>
      <link:label id="id_3045b2a1" xlink:label="lbl_label809874081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vehicles [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_VehiclesMember" xlink:label="lbl_VehiclesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_VehiclesMember" xlink:to="lbl_label809874081" xlink:type="arc"/>
      <link:label id="id_64acc522" xlink:label="lbl_label1689044258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_label1689044258" xlink:type="arc"/>
      <link:label id="id_5367393f" xlink:label="lbl_DepreciationRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, right-of-use assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="lbl_DepreciationRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DepreciationRightofuseAssets" xlink:to="lbl_DepreciationRightofuseAssets_labels" xlink:type="arc"/>
      <link:label id="id_4a6ffe17" xlink:label="lbl_DepreciationRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation charge</link:label>
      <link:label id="id_1b8dfafc" xlink:label="lbl_OtherAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Machinery &amp; equipment and other assets</link:label>
      <link:label id="id_2da47e8f" xlink:label="lbl_NoncurrentLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="lbl_NoncurrentLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLeaseLiabilities" xlink:to="lbl_NoncurrentLeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_5905e579" xlink:label="lbl_NoncurrentLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
      <link:label id="id_328c2a61" xlink:label="lbl_CurrentLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLeaseLiabilities" xlink:to="lbl_CurrentLeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_543a77a3" xlink:label="lbl_CurrentLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
      <link:label id="id_234e965a" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments of lease liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_e7d4ee5" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</link:label>
      <link:label id="id_7097e6f" xlink:label="lbl_label118062703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Presentation of leases for lessee [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="lbl_PresentationOfLeasesForLesseeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PresentationOfLeasesForLesseeAbstract" xlink:to="lbl_label118062703" xlink:type="arc"/>
      <link:label id="id_171d0edf" xlink:label="lbl_LeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilities" xlink:to="lbl_LeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_1c665876" xlink:label="lbl_GrossLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross lease liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="lbl_GrossLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossLeaseLiabilities" xlink:to="lbl_GrossLeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_2c03c1ee" xlink:label="lbl_GrossLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease commitments</link:label>
      <link:label id="id_1b0667c7" xlink:label="lbl_label453404615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Presentation of leases for lesses [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PresentationOfLeasesForLessesTable" xlink:label="lbl_PresentationOfLeasesForLessesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PresentationOfLeasesForLessesTable" xlink:to="lbl_label453404615" xlink:type="arc"/>
      <link:label id="id_72b5e1b" xlink:label="lbl_label120282651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Presentation of leases for lessee [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PresentationOfLeasesForLesseeLineItems" xlink:label="lbl_PresentationOfLeasesForLesseeLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PresentationOfLeasesForLesseeLineItems" xlink:to="lbl_label120282651" xlink:type="arc"/>
      <link:label id="id_3a8f2f5a" xlink:label="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense relating to short-term leases for which recognition exemption has been used</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:to="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_labels" xlink:type="arc"/>
      <link:label id="id_3f6e27d0" xlink:label="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognition exemption for short term leases</link:label>
      <link:label id="id_7a5f05cd" xlink:label="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense relating to leases of low-value assets for which recognition exemption has been used</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:label="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:to="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_labels" xlink:type="arc"/>
      <link:label id="id_3ae50249" xlink:label="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognition exception for low value leases</link:label>
      <link:label id="id_375e4cce" xlink:label="lbl_label928926926" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New lease arrangements</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NewLeaseArrangements" xlink:label="lbl_NewLeaseArrangements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NewLeaseArrangements" xlink:to="lbl_label928926926" xlink:type="arc"/>
      <link:label id="id_c8ad2dc" xlink:label="lbl_label210424540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undiscounted future lease payments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UndiscountedFutureLeasePayments" xlink:label="lbl_UndiscountedFutureLeasePayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UndiscountedFutureLeasePayments" xlink:to="lbl_label210424540" xlink:type="arc"/>
      <link:label id="id_75283e38" xlink:label="lbl_EffectOfDiscounting_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of discounting</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfDiscounting" xlink:label="lbl_EffectOfDiscounting" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectOfDiscounting" xlink:to="lbl_EffectOfDiscounting_labels" xlink:type="arc"/>
      <link:label id="id_6ac0bebc" xlink:label="lbl_LeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
      <link:label id="id_6447e039" xlink:label="lbl_label1682432057" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about leases for lessee [abstract]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="lbl_label1682432057" xlink:type="arc"/>
      <link:label id="id_3e0ced0d" xlink:label="lbl_InterestExpenseOnLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseOnLeaseLiabilities" xlink:to="lbl_InterestExpenseOnLeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_7693425d" xlink:label="lbl_label1989362269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflow</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOutflowForLeases" xlink:label="lbl_CashOutflowForLeases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOutflowForLeases" xlink:to="lbl_label1989362269" xlink:type="arc"/>
      <link:label id="id_26c71205" xlink:label="lbl_label650580485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense relating to variable lease payments not included in measurement of lease liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:label="lbl_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:to="lbl_label650580485" xlink:type="arc"/>
      <link:label id="id_63dc6855" xlink:label="lbl_label1675389013" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of total lease liabilities [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" xlink:to="lbl_label1675389013" xlink:type="arc"/>
      <link:label id="id_10622a16" xlink:label="lbl_label274868758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of total lease liabilities [table]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:to="lbl_label274868758" xlink:type="arc"/>
      <link:label id="id_24f1a439" xlink:label="lbl_label619815993" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of total lease liabilities [line items]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_label619815993" xlink:type="arc"/>
      <link:label id="id_67bf33b0" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net sales to third parties of discontinued operations</link:label>
      <link:label id="id_327f346c" xlink:label="lbl_ProfitLossFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating income of discontinued operations</link:label>
      <link:label id="id_64213541" xlink:label="lbl_label1679897921" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restated [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentStatedMember" xlink:label="lbl_CurrentStatedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentStatedMember" xlink:to="lbl_label1679897921" xlink:type="arc"/>
      <link:label id="id_5ebed7b4" xlink:label="lbl_SaleOrIssueOfTreasurySharesNumberOfShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of treasury shares, number of shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOrIssueOfTreasurySharesNumberOfShares" xlink:label="lbl_SaleOrIssueOfTreasurySharesNumberOfShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleOrIssueOfTreasurySharesNumberOfShares" xlink:to="lbl_SaleOrIssueOfTreasurySharesNumberOfShares_labels" xlink:type="arc"/>
      <link:label id="id_22f85f35" xlink:label="lbl_SaleOrIssueOfTreasurySharesNumberOfShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of treasury shares</link:label>
      <link:label id="id_25cdb408" xlink:label="lbl_label634237960" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Detailed information about significant transaction</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DetailedInformationAboutSignificantTransaction" xlink:label="lbl_DetailedInformationAboutSignificantTransaction" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DetailedInformationAboutSignificantTransaction" xlink:to="lbl_label634237960" xlink:type="arc"/>
      <link:label id="id_7eb3758e" xlink:label="lbl_TakedaPharmaceuticalCompanyLimitedMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceutical Company Limited [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="lbl_TakedaPharmaceuticalCompanyLimitedMember_labels" xlink:type="arc"/>
      <link:label id="id_6db37ab5" xlink:label="lbl_TakedaPharmaceuticalCompanyLimitedMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceutical Company Limited</link:label>
      <link:label id="id_ff14c14" xlink:label="lbl_IFMTreInc.Member_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IFM Tre, Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IFMTreInc.Member" xlink:label="lbl_IFMTreInc.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IFMTreInc.Member" xlink:to="lbl_IFMTreInc.Member_labels" xlink:type="arc"/>
      <link:label id="id_5b8c5fe7" xlink:label="lbl_IFMTreInc.Member_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IFM Tre, Inc.</link:label>
      <link:label id="id_33428670" xlink:label="lbl_PowerVisionInc.Member_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PowerVision, Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PowerVisionInc.Member" xlink:label="lbl_PowerVisionInc.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PowerVisionInc.Member" xlink:to="lbl_PowerVisionInc.Member_labels" xlink:type="arc"/>
      <link:label id="id_7001a921" xlink:label="lbl_PowerVisionInc.Member_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PowerVision, Inc.</link:label>
      <link:label id="id_6bb5fe48" xlink:label="lbl_label1807089224" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for prepayments and accrued lease payments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:label="lbl_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:to="lbl_label1807089224" xlink:type="arc"/>
      <link:label id="id_10d3bb4e" xlink:label="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:to="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_labels" xlink:type="arc"/>
      <link:label id="id_e7bd10a" xlink:label="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average incremental borrowing rate</link:label>
      <link:label id="id_390e560d" xlink:label="lbl_label957240845" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions to right-of-use assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="lbl_AdditionsToRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionsToRightofuseAssets" xlink:to="lbl_label957240845" xlink:type="arc"/>
      <link:label id="id_f3aa39f" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) arising from sale and leaseback transactions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:to="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions_labels" xlink:type="arc"/>
      <link:label id="id_1dfe7c52" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains or losses from sales leaseback</link:label>
      <link:label id="id_50d6583f" xlink:label="lbl_label1356224575" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other borrowings</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherBorrowings" xlink:label="lbl_OtherBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherBorrowings" xlink:to="lbl_label1356224575" xlink:type="arc"/>
      <link:label id="id_589c1537" xlink:label="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in dividends payable through change in fair value of non-cash assets held for distribution to owners</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:label="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:to="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners_labels" xlink:type="arc"/>
      <link:label id="id_1a2e3f6" xlink:label="lbl_NetAssetsLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net assets liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="lbl_NetAssetsLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetAssetsLiabilities" xlink:to="lbl_NetAssetsLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_4d789f55" xlink:label="lbl_NetAssetsLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net assets</link:label>
      <link:label id="id_7d2cba5f" xlink:label="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease of distribution liability</link:label>
      <link:label id="id_24596c04" xlink:label="lbl_label609840132" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential milestone maximum payments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialMilestoneMaximumPayments" xlink:label="lbl_PotentialMilestoneMaximumPayments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialMilestoneMaximumPayments" xlink:to="lbl_label609840132" xlink:type="arc"/>
      <link:label id="id_3dc6ce5a" xlink:label="lbl_label1036439130" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of employees associated with the product transfer</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:label="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:to="lbl_label1036439130" xlink:type="arc"/>
      <link:label id="id_3954535f" xlink:label="lbl_label961827679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional borrowings</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionalBorrowings" xlink:label="lbl_AdditionalBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionalBorrowings" xlink:to="lbl_label961827679" xlink:type="arc"/>
      <link:label id="id_43740ee2" xlink:label="lbl_label1131679458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of equity interest shares received</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfEquityInterestSharesReceived" xlink:label="lbl_PercentageOfEquityInterestSharesReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfEquityInterestSharesReceived" xlink:to="lbl_label1131679458" xlink:type="arc"/>
      <link:label id="id_79732968" xlink:label="lbl_label2037590376" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between fair value of distribution liability and net assets at the date of distribution</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:label="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:to="lbl_label2037590376" xlink:type="arc"/>
      <link:label id="id_431c3dd4" xlink:label="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution of dividend to dividend bearing shares to consolidated foundations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:label="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:to="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations_labels" xlink:type="arc"/>
      <link:label id="id_ff7c4c3" xlink:label="lbl_label267896003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aimovig [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AimovigMember" xlink:label="lbl_AimovigMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AimovigMember" xlink:to="lbl_label267896003" xlink:type="arc"/>
      <link:label id="id_4945ceaa" xlink:label="lbl_label1229311658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities and Right of use assets Disclosure Abstract</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" xlink:label="lbl_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" xlink:to="lbl_label1229311658" xlink:type="arc"/>
      <link:label id="id_79212b70" xlink:label="lbl_label2032216944" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of leases [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="lbl_DisclosureOfLeasesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfLeasesExplanatory" xlink:to="lbl_label2032216944" xlink:type="arc"/>
      <link:label id="id_4b496242" xlink:label="lbl_ReductionOfIssuedCapital_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction of issued capital</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReductionOfIssuedCapital" xlink:label="lbl_ReductionOfIssuedCapital" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReductionOfIssuedCapital" xlink:to="lbl_ReductionOfIssuedCapital_labels" xlink:type="arc"/>
      <link:label id="id_211a2da" xlink:label="lbl_ReductionOfIssuedCapital_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reduction of share capital</link:label>
      <link:label id="id_610df533" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through exercise of options, equity</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="lbl_IncreaseDecreaseThroughExerciseOfOptions_labels" xlink:type="arc"/>
      <link:label id="id_169b45c8" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options and employee transactions, equity impact</link:label>
      <link:label id="id_76378de3" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptionsShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase decrease through exercise of options shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:to="lbl_IncreaseDecreaseThroughExerciseOfOptionsShares_labels" xlink:type="arc"/>
      <link:label id="id_4cd892b4" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptionsShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options and employee transactions shares</link:label>
      <link:label id="id_1efc7c8b" xlink:label="lbl_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase decrease through share based payment transactions shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares" xlink:label="lbl_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares" xlink:to="lbl_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares_labels" xlink:type="arc"/>
      <link:label id="id_1d05cf3d" xlink:label="lbl_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity based compensation shares</link:label>
      <link:label id="id_1a5eff2" xlink:label="lbl_label27652082" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayment of lease liability</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RepaymentOfLeaseLiability" xlink:label="lbl_RepaymentOfLeaseLiability" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RepaymentOfLeaseLiability" xlink:to="lbl_label27652082" xlink:type="arc"/>
      <link:label id="id_7a957c7" xlink:label="lbl_label128538567" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average interest rate lease liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageInterestRateLeaseLiabilities" xlink:label="lbl_WeightedAverageInterestRateLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageInterestRateLeaseLiabilities" xlink:to="lbl_label128538567" xlink:type="arc"/>
      <link:label id="id_50834b9f" xlink:label="lbl_label1350781855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movements of the right-of-use assets [roll forward]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementsOfTheRightofuseAssetsRollForward" xlink:label="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_label1350781855" xlink:type="arc"/>
      <link:label id="id_4004db36" xlink:label="lbl_RightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets at beginning of period</link:label>
      <link:label id="id_63713767" xlink:label="lbl_RightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets at end of period</link:label>
      <link:label id="id_491fa8b0" xlink:label="lbl_LeaseContractTerminationsRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease contract terminations, right-of-use assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseContractTerminationsRightofuseAssets" xlink:label="lbl_LeaseContractTerminationsRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseContractTerminationsRightofuseAssets" xlink:to="lbl_LeaseContractTerminationsRightofuseAssets_labels" xlink:type="arc"/>
      <link:label id="id_43e3ea12" xlink:label="lbl_label79581278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase decrease through net exchange differences, right-of-use assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:to="lbl_label79581278" xlink:type="arc"/>
      <link:label id="id_750ea0e7" xlink:label="lbl_label1963892967" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares delivered to divested business employees, equity impact</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:to="lbl_label1963892967" xlink:type="arc"/>
      <link:label id="id_23a4b8a2" xlink:label="lbl_TaxesOnTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes on treasury shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxesOnTreasuryShares" xlink:label="lbl_TaxesOnTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxesOnTreasuryShares" xlink:to="lbl_TaxesOnTreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_2a977fac" xlink:label="lbl_label714571692" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease incentives</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseIncentives" xlink:label="lbl_LeaseIncentives" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseIncentives" xlink:to="lbl_label714571692" xlink:type="arc"/>
      <link:label id="id_752a730a" xlink:label="lbl_label1965716234" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow for leases</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowForLeases" xlink:label="lbl_CashInflowForLeases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowForLeases" xlink:to="lbl_label1965716234" xlink:type="arc"/>
      <link:label id="id_56ca2a36" xlink:label="lbl_NetAssetsDerecognized_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net assets derecognized</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetAssetsDerecognized" xlink:label="lbl_NetAssetsDerecognized" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetAssetsDerecognized" xlink:to="lbl_NetAssetsDerecognized_labels" xlink:type="arc"/>
      <link:label id="id_1b28c052" xlink:label="lbl_DividendsPayable_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derecognition of distribution liability</link:label>
      <link:label id="id_32e2fa92" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Difference between net assets and distribution liability</link:label>
      <link:label id="id_5a5595b5" xlink:label="lbl_label1515558325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution of dividend to dividend bearing shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DistributionOfDividendToDividendBearingShares" xlink:label="lbl_DistributionOfDividendToDividendBearingShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DistributionOfDividendToDividendBearingShares" xlink:to="lbl_label1515558325" xlink:type="arc"/>
      <link:label id="id_76193299" xlink:label="lbl_TransactionCosts_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs recognized in the consolidated income statement</link:label>
      <link:label id="id_1fe7672a" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed, Net</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet_labels" xlink:type="arc"/>
      <link:label id="id_4fbc2a8c" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on distribution of Alcon Inc. to Novartis AG shareholders</link:label>
      <link:label id="id_1b6a6442" xlink:label="lbl_label459957314" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net provisions for transaction costs recognized in the income statement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetProvisionsForTransactionCostsRecognizedInTheIncomeStatement" xlink:label="lbl_NetProvisionsForTransactionCostsRecognizedInTheIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetProvisionsForTransactionCostsRecognizedInTheIncomeStatement" xlink:to="lbl_label459957314" xlink:type="arc"/>
      <link:label id="id_68457d8c" xlink:label="lbl_CashFlowsAttributableToDivestedBusiness_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows attributable to divested business</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsAttributableToDivestedBusiness" xlink:label="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsAttributableToDivestedBusiness" xlink:to="lbl_CashFlowsAttributableToDivestedBusiness_labels" xlink:type="arc"/>
      <link:label id="id_4f1d6584" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other cash flows used in investing activities, net</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_1bf16062" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other inflows (outflows) of cash, classified as investing activities</link:label>
      <link:label id="id_1d66e74c" xlink:label="lbl_label493283148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and other non-current assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialAndOtherNoncurrentAssets" xlink:label="lbl_FinancialAndOtherNoncurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinancialAndOtherNoncurrentAssets" xlink:to="lbl_label493283148" xlink:type="arc"/>
      <link:label id="id_2b5de5f3" xlink:label="lbl_label727574003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables and other current assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesAndOtherCurrentAssets" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradeReceivablesAndOtherCurrentAssets" xlink:to="lbl_label727574003" xlink:type="arc"/>
      <link:label id="id_54b5d55e" xlink:label="lbl_LeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current and non-current lease liabilities</link:label>
      <link:label id="id_5b8463eb" xlink:label="lbl_TradePayablesProvisionsAndOtherLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade payables, provisions and other liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradePayablesProvisionsAndOtherLiabilities" xlink:label="lbl_TradePayablesProvisionsAndOtherLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TradePayablesProvisionsAndOtherLiabilities" xlink:to="lbl_TradePayablesProvisionsAndOtherLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_cbbfa93" xlink:label="lbl_CurrentAndNoncurrentFinancialDebt_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current and non-current financial debt</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentAndNoncurrentFinancialDebt" xlink:label="lbl_CurrentAndNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAndNoncurrentFinancialDebt" xlink:to="lbl_CurrentAndNoncurrentFinancialDebt_labels" xlink:type="arc"/>
      <link:label id="id_2ce3e4d1" xlink:label="lbl_label753132753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right of use assets Disclosure and Lease liabilities [abstract]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:label="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_label753132753" xlink:type="arc"/>
      <link:label id="id_7eea5c8b" xlink:label="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of lease commitment and lease liability [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" xlink:label="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" xlink:to="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_179a66c8" xlink:label="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of lease commitment and lease liability</link:label>
      <link:label id="id_61aad0c8" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_41e189f8" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets</link:label>
      <link:label id="id_74f2bff0" xlink:label="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Right-of-use assets roll forward [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" xlink:label="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" xlink:to="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4b1c78b0" xlink:label="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Right-of-use assets roll forward</link:label>
      <link:label id="id_21983c62" xlink:label="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of right-of-use assets carrying value and depreciation charge [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" xlink:label="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" xlink:to="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_3cad94ea" xlink:label="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of right-of-use assets carrying value and depreciation charge</link:label>
      <link:label id="id_59a39235" xlink:label="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of lease liability [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" xlink:label="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" xlink:to="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_16173223" xlink:label="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of lease liability</link:label>
      <link:label id="id_349af9f2" xlink:label="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional disclosures related to right-of-use assets and lease liabilities [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:label="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:to="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2b0fa89e" xlink:label="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional disclosures related to right-of-use assets and lease liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="lbl_GoodwillRecognisedAsOfAcquisitionDate1" xlink:type="locator"/>
      <link:label id="id_41a9be15" xlink:label="lbl_GoodwillRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill recognised as of acquisition date</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GoodwillRecognisedAsOfAcquisitionDate1" xlink:to="lbl_GoodwillRecognisedAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_5f4cbeb8" xlink:label="lbl_GoodwillRecognisedAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
      <link:label id="id_20d2348f" xlink:label="lbl_IncomeTaxExpenseContinuingOperations_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
      <link:label id="id_24522acb" xlink:label="lbl_AdjustmentsForFinanceIncomeCost_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net financial expense</link:label>
      <link:label id="id_2dbe7019" xlink:label="lbl_AdjustmentsForReconcileProfitLoss_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
      <link:label id="id_665e2bc2" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value of previously held equity interests</link:label>
      <link:label id="id_2124eb92" xlink:label="lbl_label556067730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentLeaseLiabilitiesMember" xlink:label="lbl_NoncurrentLeaseLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLeaseLiabilitiesMember" xlink:to="lbl_label556067730" xlink:type="arc"/>
      <link:label id="id_25d32b75" xlink:label="lbl_label634596213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLeaseLiabilitiesMember" xlink:label="lbl_CurrentLeaseLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLeaseLiabilitiesMember" xlink:to="lbl_label634596213" xlink:type="arc"/>
      <link:label id="id_7905e1d7" xlink:label="lbl_label203360922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Applicable tax rate, excluding exceptional items</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ApplicableTaxRateExcludingExceptionalItems" xlink:label="lbl_ApplicableTaxRateExcludingExceptionalItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ApplicableTaxRateExcludingExceptionalItems" xlink:to="lbl_label203360922" xlink:type="arc"/>
      <link:label id="id_65b2ed83" xlink:label="lbl_CurrentAndNoncurrentFinancialDebt_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current and non-current financial debt</link:label>
      <link:label id="id_2db983d5" xlink:label="lbl_TradePayablesProvisionsAndOtherLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Trade payables, provisions and other liabilities</link:label>
      <link:label id="id_71df6444" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flows Attributable to divested business before divested cash and cash equivalents</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:to="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_43e3fc7" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments out of provisions for transaction costs attributable to the divested business</link:label>
      <link:label id="id_4fb71438" xlink:label="lbl_DivestedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divested cash and cash equivalents</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestedCashAndCashEquivalents" xlink:label="lbl_DivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DivestedCashAndCashEquivalents" xlink:to="lbl_DivestedCashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_74caa513" xlink:label="lbl_DivestedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Divested cash and cash equivalents</link:label>
      <link:label id="id_3a16e3f2" xlink:label="lbl_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax on Pension plans previously recognized in OCI</link:label>
      <link:label id="id_5bc61768" xlink:label="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares obtained through consolidated foundation</link:label>
      <link:label id="id_32f424a5" xlink:label="lbl_label854860965" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customary purchase price adjustment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CustomaryPurchasePriceAdjustment" xlink:label="lbl_CustomaryPurchasePriceAdjustment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CustomaryPurchasePriceAdjustment" xlink:to="lbl_label854860965" xlink:type="arc"/>
      <link:label id="id_4b0dbe44" xlink:label="lbl_RepaymentOfIntercompanyBalances_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayment of intercompany balances</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RepaymentOfIntercompanyBalances" xlink:label="lbl_RepaymentOfIntercompanyBalances" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RepaymentOfIntercompanyBalances" xlink:to="lbl_RepaymentOfIntercompanyBalances_labels" xlink:type="arc"/>
      <link:label id="id_3ce6e6d2" xlink:label="lbl_label1021765330" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax reform impact on deferred tax on treasury shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:label="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:to="lbl_label1021765330" xlink:type="arc"/>
      <link:label id="id_1d9b087f" xlink:label="lbl_DividendPaidNoncashAssetsDistribution_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend paid, non-cash assets distribution</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DividendPaidNoncashAssetsDistribution" xlink:label="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendPaidNoncashAssetsDistribution" xlink:to="lbl_DividendPaidNoncashAssetsDistribution_labels" xlink:type="arc"/>
      <link:label id="id_49b7a9d9" xlink:label="lbl_DividendPaidNoncashAssetsDistribution_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividend in kind</link:label>
      <link:label id="id_4f1253e8" xlink:label="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net gain at completion of spin-off [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:label="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:to="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_cd2ba12" xlink:label="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gain at completion of spin-off</link:label>
      <link:label id="id_4a895e0" xlink:label="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of assets and liabilities of disposal group classified as held for sale [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:label="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:to="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_399cb44f" xlink:label="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities of disposal group classified as held for sale</link:label>
      <link:label id="id_333e63f1" xlink:label="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated income statement, discontinued operations [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:label="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" xlink:to="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2b60d5f0" xlink:label="lbl_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated income statement, discontinued operations</link:label>
      <link:label id="id_6f1a698a" xlink:label="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of items included in net income from discontinued operations [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" xlink:label="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" xlink:to="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6b21ae09" xlink:label="lbl_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of items included in net income from discontinued operations</link:label>
      <link:label id="id_4a52c922" xlink:label="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of net assets derecognized [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetAssetsDerecognizedTableTextBlock" xlink:label="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock" xlink:to="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_54e8c608" xlink:label="lbl_DisclosureOfNetAssetsDerecognizedTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of net assets derecognized</link:label>
      <link:label id="id_68686f96" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of assets and liabilities arising from divestments [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" xlink:to="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_74c77dde" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of assets and liabilities arising from divestments</link:label>
      <link:label id="id_3a5e6480" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:type="arc"/>
      <link:label id="id_2aebe53" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement at beginning of period</link:label>
      <link:label id="id_14e1d56d" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement at end of period</link:label>
      <link:label id="id_16d7d1ab" xlink:label="lbl_label383242667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options exercised in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="lbl_label383242667" xlink:type="arc"/>
      <link:label id="id_364362e8" xlink:label="lbl_label910385896" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="lbl_label910385896" xlink:type="arc"/>
      <link:label id="id_3ff27324" xlink:label="lbl_label1072853796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="lbl_label1072853796" xlink:type="arc"/>
      <link:label id="id_218c01ed" xlink:label="lbl_label562823661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="lbl_label562823661" xlink:type="arc"/>
      <link:label id="id_7e9fd619" xlink:label="lbl_label2124404249" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price of outstanding share options</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:to="lbl_label2124404249" xlink:type="arc"/>
      <link:label id="id_726c27cc" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:type="arc"/>
      <link:label id="id_5f37a474" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement at beginning of period</link:label>
      <link:label id="id_88d7a8d" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement at end of period</link:label>
      <link:label id="id_4f1e5db1" xlink:label="lbl_label1327390129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:to="lbl_label1327390129" xlink:type="arc"/>
      <link:label id="id_738f9077" xlink:label="lbl_label1938788471" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:to="lbl_label1938788471" xlink:type="arc"/>
      <link:label id="id_236bf45e" xlink:label="lbl_label594277470" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:to="lbl_label594277470" xlink:type="arc"/>
      <link:label id="id_1e452462" xlink:label="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for leases</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory_labels" xlink:type="arc"/>
      <link:label id="id_19961677" xlink:label="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases and right-of-use assets</link:label>
      <link:label id="id_7213f224" xlink:label="lbl_DistributionByWayOfDivindendInKindToShareholders_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for distribution by way of divindend in kind to shareholders</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DistributionByWayOfDivindendInKindToShareholders" xlink:label="lbl_DistributionByWayOfDivindendInKindToShareholders" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DistributionByWayOfDivindendInKindToShareholders" xlink:to="lbl_DistributionByWayOfDivindendInKindToShareholders_labels" xlink:type="arc"/>
      <link:label id="id_73c6a1d7" xlink:label="lbl_DistributionByWayOfDivindendInKindToShareholders_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution by way of dividend in kind to shareholders</link:label>
      <link:label id="id_3b0bcb35" xlink:label="lbl_label373468922" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aspen Global Incorporated</link:label>
      <link:label id="id_505899ea" xlink:label="lbl_TheMedicinesCompanyMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Medicines Company, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TheMedicinesCompanyMember" xlink:label="lbl_TheMedicinesCompanyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TheMedicinesCompanyMember" xlink:to="lbl_TheMedicinesCompanyMember_labels" xlink:type="arc"/>
      <link:label id="id_3d4865bf" xlink:label="lbl_TheMedicinesCompanyMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Medicines Company</link:label>
      <link:label id="id_26a553b7" xlink:label="lbl_label648369079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Piqray [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PiqrayMember" xlink:label="lbl_PiqrayMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PiqrayMember" xlink:to="lbl_label648369079" xlink:type="arc"/>
      <link:label id="id_3dbe8202" xlink:label="lbl_label1035895298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xiidra [member]</link:label>
      <link:label id="id_725b9be" xlink:label="lbl_label119912894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zolgensma [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZolgensmaMember" xlink:to="lbl_label119912894" xlink:type="arc"/>
      <link:label id="id_7679d6e" xlink:label="lbl_label124231022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mayzent [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MayzentMember" xlink:label="lbl_MayzentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MayzentMember" xlink:to="lbl_label124231022" xlink:type="arc"/>
      <link:label id="id_18490fef" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through assets related to discontinued operations</link:label>
      <link:label id="id_c87ee03" xlink:label="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through reclassification to right-of-use assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:to="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:to="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_479a229e" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Costs of assets related to discontinued operations</link:label>
      <link:label id="id_18f65009" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through assets related to discontinued operations, intangible assets and goodwill</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:to="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_4ee2113e" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of assets related to discontinued operations</link:label>
      <link:label id="id_6422c211" xlink:label="lbl_label1679999505" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated amortization/impairments on assets related to discontinued operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:to="lbl_label1679999505" xlink:type="arc"/>
      <link:label id="id_36a944c" xlink:label="lbl_DeferredTaxLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax balance at beginning of period continuing operations</link:label>
      <link:label id="id_f49321b" xlink:label="lbl_label256455195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net deferred tax balance related to discontinued operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:to="lbl_label256455195" xlink:type="arc"/>
      <link:label id="id_59b158e6" xlink:label="lbl_label1504794854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aspen Global Incorporated [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AspenGlobalIncorporatedMember" xlink:label="lbl_AspenGlobalIncorporatedMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AspenGlobalIncorporatedMember" xlink:to="lbl_label1504794854" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AspenGlobalIncorporatedMember" xlink:to="lbl_label373468922" xlink:type="arc"/>
      <link:label id="id_3dc8af6f" xlink:label="lbl_UndiscountedFinanceLeasePaymentsToBeReceived_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undiscounted finance lease payments to be received</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UndiscountedFinanceLeasePaymentsToBeReceived" xlink:label="lbl_UndiscountedFinanceLeasePaymentsToBeReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UndiscountedFinanceLeasePaymentsToBeReceived" xlink:to="lbl_UndiscountedFinanceLeasePaymentsToBeReceived_labels" xlink:type="arc"/>
      <link:label id="id_334ff648" xlink:label="lbl_UndiscountedFinanceLeasePaymentsToBeReceived_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total future payments</link:label>
      <link:label id="id_4ca139f0" xlink:label="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unearned finance income relating to finance lease payments receivable</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:label="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:to="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable_labels" xlink:type="arc"/>
      <link:label id="id_32f71aba" xlink:label="lbl_UnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unearned interest income</link:label>
      <link:label id="id_32d528ec" xlink:label="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum finace lease payments receivable at present value</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MinimumFinaceLeasePaymentsReceivableAtPresentValue" xlink:label="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue" xlink:to="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue_labels" xlink:type="arc"/>
      <link:label id="id_200aacc" xlink:label="lbl_MinimumFinaceLeasePaymentsReceivableAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments from finance lease agreements, at present value</link:label>
      <link:label id="id_5e2f001b" xlink:label="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest payments for amounts included in lease liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:label="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:to="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities_labels" xlink:type="arc"/>
      <link:label id="id_270f5b37" xlink:label="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest payments for amounts included in lease liabilities classified as cash flows from operating activities</link:label>
      <link:label id="id_60c53887" xlink:label="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase through new leases, liabilities arising from financing activities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:to="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_3255d072" xlink:label="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New leases</link:label>
      <link:label id="id_78469395" xlink:label="lbl_label2017891221" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from non-current to current, net</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclassificationFromNoncurrentToCurrentNet" xlink:label="lbl_ReclassificationFromNoncurrentToCurrentNet" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReclassificationFromNoncurrentToCurrentNet" xlink:to="lbl_label2017891221" xlink:type="arc"/>
      <link:label id="id_37080272" xlink:label="lbl_InterestExpenseOnLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
      <link:label id="id_22d1162d" xlink:label="lbl_label584128045" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="lbl_LeaseLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilitiesMember" xlink:to="lbl_label584128045" xlink:type="arc"/>
      <link:label id="id_5bd2b859" xlink:label="lbl_label1540536409" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration payable</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationPayable" xlink:label="lbl_ContingentConsiderationPayable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationPayable" xlink:to="lbl_label1540536409" xlink:type="arc"/>
      <link:label id="id_11db2be0" xlink:label="lbl_label299576288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Useful life measured as period of time, intangible assets other than goodwill</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:to="lbl_label299576288" xlink:type="arc"/>
      <link:label id="id_358bdb60" xlink:label="lbl_label2144120781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) due to changes in accounting policy, IFRS 16 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:to="lbl_label2144120781" xlink:type="arc"/>
      <link:label id="id_5776de2" xlink:label="lbl_label91712994" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, USD [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsUSDMember" xlink:label="lbl_BorrowingsUSDMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsUSDMember" xlink:to="lbl_label91712994" xlink:type="arc"/>
      <link:label id="id_37cf6b5c" xlink:label="lbl_label936340316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, EUR [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsEURMember" xlink:label="lbl_BorrowingsEURMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsEURMember" xlink:to="lbl_label936340316" xlink:type="arc"/>
      <link:label id="id_4e1f7ea0" xlink:label="lbl_FinanceLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance lease liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinanceLeaseLiabilities" xlink:label="lbl_FinanceLeaseLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FinanceLeaseLiabilities" xlink:to="lbl_FinanceLeaseLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_495a6466" xlink:label="lbl_FinanceLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease obligations</link:label>
      <link:label id="id_633ca478" xlink:label="lbl_label1664918648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity based compensation shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedCompensationShares" xlink:label="lbl_EquityBasedCompensationShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedCompensationShares" xlink:to="lbl_label1664918648" xlink:type="arc"/>
      <link:label id="id_79aa7a52" xlink:label="lbl_label2041215570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of options and employee transactions shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:label="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:to="lbl_label2041215570" xlink:type="arc"/>
      <link:label id="id_6d34d6c2" xlink:label="lbl_label1832179394" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options and employee transactions, equity impact</link:label>
      <link:label id="id_6fef109e" xlink:label="lbl_label1877938334" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of options and employee transactions</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExerciseOfOptionsAndEmployeeTransactionsValue" xlink:label="lbl_ExerciseOfOptionsAndEmployeeTransactionsValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExerciseOfOptionsAndEmployeeTransactionsValue" xlink:to="lbl_label1877938334" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExerciseOfOptionsAndEmployeeTransactionsValue" xlink:to="lbl_label1832179394" xlink:type="arc"/>
      <link:label id="id_347a007d" xlink:label="lbl_OtherNoncurrentReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current receivables</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="lbl_OtherNoncurrentReceivables" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNoncurrentReceivables" xlink:to="lbl_OtherNoncurrentReceivables_labels" xlink:type="arc"/>
      <link:label id="id_4871e871" xlink:label="lbl_OtherNoncurrentReceivables_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term receivables</link:label>
      <link:label id="id_4529bc84" xlink:label="lbl_label1160363140" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares delivered to divested business employees</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployees" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:to="lbl_label1160363140" xlink:type="arc"/>
      <link:label id="id_5b371f8c" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product liability, government investigations, other legal matters provisions, impact of business combinations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations_labels" xlink:type="arc"/>
      <link:label id="id_3787190c" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_4001cae9" xlink:label="lbl_LeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Impact of adoption of IFRS 16 Leases</link:label>
      <link:label id="id_2f708bd6" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Financial debts cash flows from continuing operations</link:label>
      <link:label id="id_7a3ed482" xlink:label="lbl_label2050937986" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously reported finance lease obligation of divested business</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:label="lbl_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:to="lbl_label2050937986" xlink:type="arc"/>
      <link:label id="id_34924f0b" xlink:label="lbl_label882003723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net cash flows used in acquisitions and divestments of businesses classified as investing activities from continuing operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:to="lbl_label882003723" xlink:type="arc"/>
      <link:label id="id_15f358a7" xlink:label="lbl_label368269479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments, options on equity securities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:label="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:to="lbl_label368269479" xlink:type="arc"/>
      <link:label id="id_61acf165" xlink:label="lbl_label1591563240" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated financial effect of contingent liabilities, damages claimed</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:to="lbl_label1591563240" xlink:type="arc"/>
      <link:label id="id_49032bd4" xlink:label="lbl_label1224944596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional amount of settlement in principle</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionalAmountOfSettlementInPrinciple" xlink:label="lbl_AdditionalAmountOfSettlementInPrinciple" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdditionalAmountOfSettlementInPrinciple" xlink:to="lbl_label1224944596" xlink:type="arc"/>
      <link:label id="id_4b8a0c94" xlink:label="lbl_label1267338388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of resolved action</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfResolvedAction" xlink:label="lbl_AmountOfResolvedAction" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountOfResolvedAction" xlink:to="lbl_label1267338388" xlink:type="arc"/>
      <link:label id="id_54d844bf" xlink:label="lbl_label1423459519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enoxaparin [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnoxaparinMember" xlink:label="lbl_EnoxaparinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EnoxaparinMember" xlink:to="lbl_label1423459519" xlink:type="arc"/>
      <link:label id="id_29f14990" xlink:label="lbl_label703678864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sandoz Manufacturing Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozManufacturingInc.Member" xlink:label="lbl_SandozManufacturingInc.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozManufacturingInc.Member" xlink:to="lbl_label703678864" xlink:type="arc"/>
      <link:label id="id_1755f369" xlink:label="lbl_label391508841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">China Novartis Institute for BioMedical Research Co.,Ltd. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:label="lbl_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:to="lbl_label391508841" xlink:type="arc"/>
      <link:label id="id_6dee5dc4" xlink:label="lbl_label1844338116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Suzhou Novartis Technical Development Co., Ltd. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:label="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:to="lbl_label1844338116" xlink:type="arc"/>
      <link:label id="id_5443c473" xlink:label="lbl_label1413727347" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CELLforCURE [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CELLforCUREMember" xlink:label="lbl_CELLforCUREMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CELLforCUREMember" xlink:to="lbl_label1413727347" xlink:type="arc"/>
      <link:label id="id_4cf512" xlink:label="lbl_label5043474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Manufacturing GmbH [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisManufacturingGmbHMember" xlink:label="lbl_NovartisManufacturingGmbHMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisManufacturingGmbHMember" xlink:to="lbl_label5043474" xlink:type="arc"/>
      <link:label id="id_4471df2c" xlink:label="lbl_label1148313388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Hungary Healthcare Limited Liability Company [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:label="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:to="lbl_label1148313388" xlink:type="arc"/>
      <link:label id="id_424beb28" xlink:label="lbl_label1112271656" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advaced Accelerator Applications (Italy) S.r.l. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:label="lbl_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:to="lbl_label1112271656" xlink:type="arc"/>
      <link:label id="id_5fad9749" xlink:label="lbl_label1605211977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IDB Holland BV [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IDBHollandBVMember" xlink:label="lbl_IDBHollandBVMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IDBHollandBVMember" xlink:to="lbl_label1605211977" xlink:type="arc"/>
      <link:label id="id_50283594" xlink:label="lbl_label1344812436" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advaced Accelerator Applications Iberica, S.L.U. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:label="lbl_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:to="lbl_label1344812436" xlink:type="arc"/>
      <link:label id="id_6345aa6d" xlink:label="lbl_label1665509997" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Imaging Equipment Ltd [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImagingEquipmentLtdMember" xlink:label="lbl_ImagingEquipmentLtdMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImagingEquipmentLtdMember" xlink:to="lbl_label1665509997" xlink:type="arc"/>
      <link:label id="id_2031baeb" xlink:label="lbl_label540130027" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Inflammasome Research, Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInflammasomeResearchInc.Member" xlink:label="lbl_NovartisInflammasomeResearchInc.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInflammasomeResearchInc.Member" xlink:to="lbl_label540130027" xlink:type="arc"/>
      <link:label id="id_1af84be1" xlink:label="lbl_label452479969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Technology LLC [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisTechnologyLLCMember" xlink:label="lbl_NovartisTechnologyLLCMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisTechnologyLLCMember" xlink:to="lbl_label452479969" xlink:type="arc"/>
      <link:label id="id_388a06e4" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion of consideration paid (received) consisting of cash and cash equivalents upfront payment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment_labels" xlink:type="arc"/>
      <link:label id="id_3b18f468" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Portion of consideration paid consisting of cash and cash equivalents upfront payment</link:label>
      <link:label id="id_47a0c115" xlink:label="lbl_label1201717525" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Partial release of deferred tax liability recognized</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:label="lbl_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:to="lbl_label1201717525" xlink:type="arc"/>
      <link:label id="id_300e3078" xlink:label="lbl_label464719186" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities undiscounted</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseLiabilitiesUndiscounted" xlink:label="lbl_LeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilitiesUndiscounted" xlink:to="lbl_label464719186" xlink:type="arc"/>
      <link:label id="id_34d806ab" xlink:label="lbl_label1619923269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Most material lease with lease term extension</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MostMaterialLeaseWithLeaseTermExtension" xlink:label="lbl_MostMaterialLeaseWithLeaseTermExtension" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MostMaterialLeaseWithLeaseTermExtension" xlink:to="lbl_label1619923269" xlink:type="arc"/>
      <link:label id="id_53edcb" xlink:label="lbl_label5500363" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflows for short term and low value leases</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsForShortTermAndLowValueLeases" xlink:label="lbl_CashOutflowsForShortTermAndLowValueLeases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOutflowsForShortTermAndLowValueLeases" xlink:to="lbl_label5500363" xlink:type="arc"/>
      <link:label id="id_30ae4b2" xlink:label="lbl_label51045554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflows for payments of leases interest</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsForPaymentsOfLeasesInterest" xlink:label="lbl_CashOutflowsForPaymentsOfLeasesInterest" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOutflowsForPaymentsOfLeasesInterest" xlink:to="lbl_label51045554" xlink:type="arc"/>
      <link:label id="id_5a4733e9" xlink:label="lbl_label1514615785" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax reform applicable tax rate after implemetation of new reform changes</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:label="lbl_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:to="lbl_label1514615785" xlink:type="arc"/>
      <link:label id="id_63ed288d" xlink:label="lbl_label1676486797" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax reform applicable blended tax rate after implemetation of new reform changes</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:label="lbl_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:to="lbl_label1676486797" xlink:type="arc"/>
      <link:label id="id_3af42b4" xlink:label="lbl_label2021190939" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long term receivables from finance subleases</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongTermReceivablesFromFinanceSubleases" xlink:label="lbl_LongTermReceivablesFromFinanceSubleases" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LongTermReceivablesFromFinanceSubleases" xlink:to="lbl_label2021190939" xlink:type="arc"/>
      <link:label id="id_115b6ebf" xlink:label="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through liabilities related to discontinued operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:label="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:to="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_64b9f08d" xlink:label="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial debts and lease liabilities related to discontinued operations</link:label>
      <link:label id="id_a7c0098" xlink:label="lbl_label175898776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings credit facility short term</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCreditFacilityShortTerm" xlink:label="lbl_BorrowingsCreditFacilityShortTerm" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsCreditFacilityShortTerm" xlink:to="lbl_label175898776" xlink:type="arc"/>
      <link:label id="id_3f8e8cf1" xlink:label="lbl_label1066306801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lbl_label1066306801" xlink:type="arc"/>
      <link:label id="id_44dffa85" xlink:label="lbl_label1155529349" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lbl_label1155529349" xlink:type="arc"/>
      <link:label id="id_7feaeddc" xlink:label="lbl_label167109794" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [axis]</link:label>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrencyAxis" xlink:to="lbl_label167109794" xlink:type="arc"/>
      <link:label id="id_2246514e" xlink:label="lbl_label2121837386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [member]</link:label>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="lbl_EuropeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EuropeMember" xlink:to="lbl_label2121837386" xlink:type="arc"/>
      <link:label id="id_4c9a1836" xlink:label="lbl_label849028726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Americas [member]</link:label>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AmericasMember" xlink:label="lbl_AmericasMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmericasMember" xlink:to="lbl_label849028726" xlink:type="arc"/>
      <link:label id="id_295e5e69" xlink:label="lbl_RightofuseAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="lbl_RightofuseAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RightofuseAssetsMember" xlink:to="lbl_RightofuseAssetsMember_labels" xlink:type="arc"/>
      <link:label id="id_164ca513" xlink:label="lbl_RightofuseAssetsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
      <link:label id="id_4947c6a9" xlink:label="lbl_label1229440681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beovu [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BeovuMember" xlink:label="lbl_BeovuMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BeovuMember" xlink:to="lbl_label1229440681" xlink:type="arc"/>
      <link:label id="id_22f028b0" xlink:label="lbl_ConsiderationPaidReceived_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration paid (received)</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="lbl_ConsiderationPaidReceived" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsiderationPaidReceived" xlink:to="lbl_ConsiderationPaidReceived_labels" xlink:type="arc"/>
      <link:label id="id_3dc9426c" xlink:label="lbl_ConsiderationPaidReceived_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash inflows from divestment</link:label>
      <link:label id="id_56521fba" xlink:label="lbl_label1448222650" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net cash outflows from divestments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashOutflowsFromDivestments" xlink:label="lbl_NetCashOutflowsFromDivestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetCashOutflowsFromDivestments" xlink:to="lbl_label1448222650" xlink:type="arc"/>
      <link:label id="id_1d2114e2" xlink:label="lbl_label488707298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents in subsidiary or businesses acquired or disposed</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:to="lbl_label488707298" xlink:type="arc"/>
      <link:label id="id_45aec51d" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through transfers and other changes, other provisions</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_labels" xlink:type="arc"/>
      <link:label id="id_6eb0eb0c" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfers</link:label>
      <link:label id="id_6bada554" xlink:label="lbl_label1806542164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLiabilitiesMember" xlink:label="lbl_CurrentLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLiabilitiesMember" xlink:to="lbl_label1806542164" xlink:type="arc"/>
      <link:label id="id_61717448" xlink:label="lbl_label1634825288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentLiabilitiesMember" xlink:label="lbl_NoncurrentLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLiabilitiesMember" xlink:to="lbl_label1634825288" xlink:type="arc"/>
      <link:label id="id_2e9b8dad" xlink:label="lbl_label781946285" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities in subsidiary or businesses acquired or disposed</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:to="lbl_label781946285" xlink:type="arc"/>
      <link:label id="id_508846a9" xlink:label="lbl_CurrentLeaseLiabilitiesUndiscounted_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities undiscounted</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLeaseLiabilitiesUndiscounted" xlink:label="lbl_CurrentLeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentLeaseLiabilitiesUndiscounted" xlink:to="lbl_CurrentLeaseLiabilitiesUndiscounted_labels" xlink:type="arc"/>
      <link:label id="id_420e4c77" xlink:label="lbl_label1108233335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities undiscounted</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentLeaseLiabilitiesUndiscounted" xlink:label="lbl_NoncurrentLeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentLeaseLiabilitiesUndiscounted" xlink:to="lbl_label1108233335" xlink:type="arc"/>
      <link:label id="id_5c23b63c" xlink:label="lbl_CurrentLeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less current lease liabilities</link:label>
      <link:label id="id_77f7d595" xlink:label="lbl_CurrentLeaseLiabilitiesUndiscounted_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less current lease liabilities undiscounted</link:label>
      <link:label id="id_16b54793" xlink:label="lbl_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax expense arising from write-down or reversal of write-down of deferred tax asset</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset" xlink:label="lbl_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset" xlink:to="lbl_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset_labels" xlink:type="arc"/>
      <link:label id="id_45e19527" xlink:label="lbl_DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of write-off of deferred tax assets</link:label>
      <link:label id="id_63e83d46" xlink:label="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment charge prior to classification to assets held for sale</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:label="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:to="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale_labels" xlink:type="arc"/>
      <link:label id="id_226b60a4" xlink:label="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge prior to classification to assets held for sale</link:label>
      <link:label id="id_557effd1" xlink:label="lbl_label1434386385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax on transaction costs recorded in equity</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxOnTransactionCostsRecordedInEquity" xlink:label="lbl_TaxOnTransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxOnTransactionCostsRecordedInEquity" xlink:to="lbl_label1434386385" xlink:type="arc"/>
      <link:label id="id_5c1a2168" xlink:label="lbl_EffectOfWriteoffOfDeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax rate, effect of write-off of deferred tax assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfWriteoffOfDeferredTaxAssets" xlink:label="lbl_EffectOfWriteoffOfDeferredTaxAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectOfWriteoffOfDeferredTaxAssets" xlink:to="lbl_EffectOfWriteoffOfDeferredTaxAssets_labels" xlink:type="arc"/>
      <link:label id="id_59102729" xlink:label="lbl_EffectOfWriteoffOfDeferredTaxAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of derecognition and reversals of derecognition of deferred tax assets</link:label>
      <link:label id="id_3df76505" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from current and non-current borrowings</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:to="lbl_ProceedsFromCurrentAndNoncurrentBorrowings_labels" xlink:type="arc"/>
      <link:label id="id_64441db" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs payment</link:label>
      <link:label id="id_11959a05" xlink:label="lbl_label295016965" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Uncalled capital commitments for investments in funds</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:label="lbl_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:to="lbl_label295016965" xlink:type="arc"/>
      <link:label id="id_12c8e5a0" xlink:label="lbl_label315155872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LitigationCaseMember" xlink:label="lbl_LitigationCaseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LitigationCaseMember" xlink:to="lbl_label315155872" xlink:type="arc"/>
      <link:label id="id_73c71c69" xlink:label="lbl_label1942428777" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tennessee class action [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TennesseeClassActionMember" xlink:label="lbl_TennesseeClassActionMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TennesseeClassActionMember" xlink:to="lbl_label1942428777" xlink:type="arc"/>
      <link:label id="id_17248af4" xlink:label="lbl_label388270836" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Massachusetts case [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MassachusettsCaseMember" xlink:label="lbl_MassachusettsCaseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MassachusettsCaseMember" xlink:to="lbl_label388270836" xlink:type="arc"/>
      <link:label id="id_23bc1d31" xlink:label="lbl_label599530801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="lbl_DocumentAnnualReport" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentAnnualReport" xlink:to="lbl_label599530801" xlink:type="arc"/>
      <link:label id="id_34b5e034" xlink:label="lbl_label884334644" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="lbl_EntityShellCompany" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityShellCompany" xlink:to="lbl_label884334644" xlink:type="arc"/>
      <link:label id="id_481345ce" xlink:label="lbl_label1209222606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="lbl_EntityEmergingGrowthCompany" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityEmergingGrowthCompany" xlink:to="lbl_label1209222606" xlink:type="arc"/>
      <link:label id="id_448d1a1f" xlink:label="lbl_label1150097951" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="lbl_EntityInteractiveDataCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityInteractiveDataCurrent" xlink:to="lbl_label1150097951" xlink:type="arc"/>
      <link:label id="id_8e53da4" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash inflow from borrowings</link:label>
      <link:label id="id_39e22a7b" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Transaction cost payments</link:label>
      <link:label id="id_4f32f729" xlink:label="lbl_label1328740137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossDeferredTaxAssets" xlink:label="lbl_GrossDeferredTaxAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossDeferredTaxAssets" xlink:to="lbl_label1328740137" xlink:type="arc"/>
      <link:label id="id_182b8b94" xlink:label="lbl_GrossDeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross deferred tax liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossDeferredTaxLiabilities" xlink:label="lbl_GrossDeferredTaxLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossDeferredTaxLiabilities" xlink:to="lbl_GrossDeferredTaxLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_3fcaf800" xlink:label="lbl_GrossDeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax liabilities</link:label>
      <link:label id="id_12baf088" xlink:label="lbl_label314241160" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount borrowed under the credit facility</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountBorrowedUnderTheCreditFacility" xlink:label="lbl_AmountBorrowedUnderTheCreditFacility" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmountBorrowedUnderTheCreditFacility" xlink:to="lbl_label314241160" xlink:type="arc"/>
      <link:label id="id_24f2fc6a" xlink:label="lbl_ContingentConsiderationLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationLiabilities" xlink:label="lbl_ContingentConsiderationLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationLiabilities" xlink:to="lbl_ContingentConsiderationLiabilities_labels" xlink:type="arc"/>
      <link:label id="id_596ae769" xlink:label="lbl_label1500178281" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation case [axis]</link:label>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="lbl_LitigationCaseAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LitigationCaseAxis" xlink:to="lbl_label1500178281" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_XiidraMember" xlink:label="lbl_XiidraMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_XiidraMember" xlink:to="lbl_label1035895298" xlink:type="arc"/>
      <link:label id="id_6dadd046" xlink:label="lbl_label1840107590" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="lbl_DocumentTransitionReport" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentTransitionReport" xlink:to="lbl_label1840107590" xlink:type="arc"/>
      <link:label id="id_287ed480" xlink:label="lbl_label679400576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="lbl_DocumentShellCompanyReport" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentShellCompanyReport" xlink:to="lbl_label679400576" xlink:type="arc"/>
      <link:label id="id_6eada512" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated depreciation, amortisation and impairment [member]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember_labels" xlink:type="arc"/>
      <link:label id="id_b2dfb88" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation, amortisation and impairment</link:label>
      <link:label id="id_4be49960" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to deferred tax assets on Swiss post retirement previously recognized through OCI</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:type="arc"/>
      <link:label id="id_7d4d613b" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of new tax law income tax relating to deferred tax assets on Swiss post retirement previously recognized through OCI</link:label>
      <link:label id="id_4eb0928b" xlink:label="lbl_TaxesOnTreasuryShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes on treasury shares</link:label>
      <link:label id="id_22a0ea85" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs of assets related to discontinued operations</link:label>
      <link:label id="id_15b36c9d" xlink:label="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease through reclassification to right-of-use assets</link:label>
      <link:label id="id_55dcd44c" xlink:label="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Recognition exemption for short term leases</link:label>
      <link:label id="id_7a35ce5" xlink:label="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Recognition exception for low value leases</link:label>
      <link:label id="id_40e677f7" xlink:label="lbl_EffectOfDiscounting_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of discounting</link:label>
      <link:label id="id_2d2e026c" xlink:label="lbl_DepreciationRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation charge</link:label>
      <link:label id="id_1ac53b1b" xlink:label="lbl_LeaseContractTerminationsRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Lease contract terminations, right-of-use assets</link:label>
      <link:label id="id_e5f5961" xlink:label="lbl_CurrentLeaseLiabilitiesUndiscounted_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less current lease liabilities undiscounted</link:label>
      <link:label id="id_7d7ce79e" xlink:label="lbl_InventoryWritedown2011_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory provisions</link:label>
      <link:label id="id_42fb2d2e" xlink:label="lbl_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current trade receivables from closely monitored countries past due more than one year, provisions recorded</link:label>
      <link:label id="id_4eb32c65" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of previously held equity interests</link:label>
      <link:label id="id_27322091" xlink:label="lbl_ProceedsFromNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from non-current financial debts</link:label>
      <link:label id="id_7e6f87d8" xlink:label="lbl_AmortizationOfBondsDiscount_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of bonds discount</link:label>
      <link:label id="id_25b1f7fc" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contributions of associates</link:label>
      <link:label id="id_148d311b" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_67019b8d" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of acquisitions, divestments or transfers</link:label>
      <link:label id="id_6e294aeb" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_4bbdbc8c" xlink:label="lbl_ContingentConsiderationLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration liabilities</link:label>
      <link:label id="id_45ca4585" xlink:label="lbl_NetAssetsDerecognized_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net assets derecognized</link:label>
      <link:label id="id_42ccca61" xlink:label="lbl_label1120717409" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of entitys trade receivable</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfEntitysTradeReceivable" xlink:label="lbl_PercentageOfEntitysTradeReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfEntitysTradeReceivable" xlink:to="lbl_label1120717409" xlink:type="arc"/>
      <link:label id="id_43ec36aa" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of lease liability</link:label>
      <link:label id="id_677ffa06" xlink:label="lbl_CashInflowForSaleAndLeaseback_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash inflow for sale and leaseback</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowForSaleAndLeaseback" xlink:label="lbl_CashInflowForSaleAndLeaseback" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashInflowForSaleAndLeaseback" xlink:to="lbl_CashInflowForSaleAndLeaseback_labels" xlink:type="arc"/>
      <link:label id="id_5bdc50eb" xlink:label="lbl_SaleAndLeaseBackMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale and lease back [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleAndLeaseBackMember" xlink:label="lbl_SaleAndLeaseBackMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SaleAndLeaseBackMember" xlink:to="lbl_SaleAndLeaseBackMember_labels" xlink:type="arc"/>
      <link:label id="id_73fe88ea" xlink:label="lbl_SaleAndLeaseBackMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale and leaseback</link:label>
      <link:label id="id_1b2ddb15" xlink:label="lbl_CurrentRefundsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current refunds provision</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentRefundsProvision" xlink:label="lbl_CurrentRefundsProvision" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentRefundsProvision" xlink:to="lbl_CurrentRefundsProvision_labels" xlink:type="arc"/>
      <link:label id="id_6f9ec2d7" xlink:label="lbl_CurrentRefundsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue</link:label>
      <link:label id="id_782da91f" xlink:label="lbl_CurrentRefundsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue, at beginning of period</link:label>
      <link:label id="id_67f2691b" xlink:label="lbl_CurrentRefundsProvision_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue, at end of period</link:label>
      <link:label id="id_376d9857" xlink:label="lbl_label929929303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial instruments, commodity purchase contract</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:label="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:to="lbl_label929929303" xlink:type="arc"/>
      <link:label id="id_4c17362a" xlink:label="lbl_DisposalsAndRetirementsRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals and retirements, right-of-use assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisposalsAndRetirementsRightofuseAssets" xlink:label="lbl_DisposalsAndRetirementsRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisposalsAndRetirementsRightofuseAssets" xlink:to="lbl_DisposalsAndRetirementsRightofuseAssets_labels" xlink:type="arc"/>
      <link:label id="id_328352cc" xlink:label="lbl_DisposalsAndRetirementsRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impact of divestments</link:label>
      <link:label id="id_5a93baa1" xlink:label="lbl_LeaseLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
      <link:label id="id_1917780" xlink:label="lbl_label26310528" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of income not subject to tax on divestment gain</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:label="lbl_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:to="lbl_label26310528" xlink:type="arc"/>
      <link:label id="id_6025ab0" xlink:label="lbl_CashInflowForSaleAndLeaseback_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash inflow for sale and leaseback</link:label>
      <link:label id="id_642f7fec" xlink:label="lbl_label1680834540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Suzhou Novartis Technical Development Co., Ltd., Changshu [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:label="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:to="lbl_label1680834540" xlink:type="arc"/>
      <link:label id="id_14fc3a32" xlink:label="lbl_label352074290" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CELLforCURE, Les Ulis [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CELLforCURELesUlisMember" xlink:label="lbl_CELLforCURELesUlisMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CELLforCURELesUlisMember" xlink:to="lbl_label352074290" xlink:type="arc"/>
      <link:label id="id_372a8238" xlink:label="lbl_label925532728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications (Italy) S.r.l., Pozzilli [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:label="lbl_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:to="lbl_label925532728" xlink:type="arc"/>
      <link:label id="id_12a3185f" xlink:label="lbl_label312678495" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Netherlands B.V., Amsterdam [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNetherlandsB.V.AmsterdamMember" xlink:label="lbl_NovartisNetherlandsB.V.AmsterdamMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisNetherlandsB.V.AmsterdamMember" xlink:to="lbl_label312678495" xlink:type="arc"/>
      <link:label id="id_495d47ae" xlink:label="lbl_label1230849966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma B.V., Amsterdam [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaB.V.AmsterdamMember" xlink:label="lbl_NovartisPharmaB.V.AmsterdamMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaB.V.AmsterdamMember" xlink:to="lbl_label1230849966" xlink:type="arc"/>
      <link:label id="id_3b55a7b7" xlink:label="lbl_label995469239" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IDB Holland BV, Baarle-Nassau [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IDBHollandBVBaarleNassauMember" xlink:label="lbl_IDBHollandBVBaarleNassauMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IDBHollandBVBaarleNassauMember" xlink:to="lbl_label995469239" xlink:type="arc"/>
      <link:label id="id_33884b38" xlink:label="lbl_label864570168" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Saudi Ltd., Riyadh [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSaudiLtd.RiyadhMember" xlink:label="lbl_NovartisSaudiLtd.RiyadhMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisSaudiLtd.RiyadhMember" xlink:to="lbl_label864570168" xlink:type="arc"/>
      <link:label id="id_222bb2dd" xlink:label="lbl_label573289181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications Iberica, S.L.U., Barcelona [member]</link:label>
      <link:label id="id_10409dbe" xlink:label="lbl_label272670142" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis UK Limited, London [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUKLimitedLondonMember" xlink:label="lbl_NovartisUKLimitedLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisUKLimitedLondonMember" xlink:to="lbl_label272670142" xlink:type="arc"/>
      <link:label id="id_63d11071" xlink:label="lbl_label1674645617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharmaceuticals UK Limited, London [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:label="lbl_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:to="lbl_label1674645617" xlink:type="arc"/>
      <link:label id="id_19392a8e" xlink:label="lbl_label423176846" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Grimsby Limited, London [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGrimsbyLimitedLondonMember" xlink:label="lbl_NovartisGrimsbyLimitedLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisGrimsbyLimitedLondonMember" xlink:to="lbl_label423176846" xlink:type="arc"/>
      <link:label id="id_7c7620c7" xlink:label="lbl_label2088116423" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Imaging Equipment Ltd, London [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImagingEquipmentLtdLondonMember" xlink:label="lbl_ImagingEquipmentLtdLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImagingEquipmentLtdLondonMember" xlink:to="lbl_label2088116423" xlink:type="arc"/>
      <link:label id="id_51082ea6" xlink:label="lbl_label1359490726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ziarco Group Limited, London [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZiarcoGroupLimitedLondonMember" xlink:label="lbl_ZiarcoGroupLimitedLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZiarcoGroupLimitedLondonMember" xlink:to="lbl_label1359490726" xlink:type="arc"/>
      <link:label id="id_70da7012" xlink:label="lbl_label1893363730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Finance Corporation, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceCorporationEastHanoverNJMember" xlink:label="lbl_NovartisFinanceCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFinanceCorporationEastHanoverNJMember" xlink:to="lbl_label1893363730" xlink:type="arc"/>
      <link:label id="id_1a5c8917" xlink:label="lbl_label442272023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationEastHanoverNJMember" xlink:label="lbl_NovartisCapitalCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationEastHanoverNJMember" xlink:to="lbl_label442272023" xlink:type="arc"/>
      <link:label id="id_2db5a3fb" xlink:label="lbl_label766878715" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis US Foundation, East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUSFoundationEastHanoverNJMember" xlink:label="lbl_NovartisUSFoundationEastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisUSFoundationEastHanoverNJMember" xlink:to="lbl_label766878715" xlink:type="arc"/>
      <link:label id="id_5bd187f1" xlink:label="lbl_label1540458481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications USA, Inc., Millburn, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:to="lbl_label1540458481" xlink:type="arc"/>
      <link:label id="id_25dd15b1" xlink:label="lbl_label635246001" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Inflammasome Research, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:label="lbl_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:to="lbl_label635246001" xlink:type="arc"/>
      <link:label id="id_561808b5" xlink:label="lbl_label1444415669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Technology LLC, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:label="lbl_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:to="lbl_label1444415669" xlink:type="arc"/>
      <link:label id="id_7ffed34c" xlink:label="lbl_label2147406668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Encore Vision, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EncoreVisionInc.EastHanoverNJMember" xlink:label="lbl_EncoreVisionInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EncoreVisionInc.EastHanoverNJMember" xlink:to="lbl_label2147406668" xlink:type="arc"/>
      <link:label id="id_4458c6ff" xlink:label="lbl_label1146668799" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Endocyte, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EndocyteInc.EastHanoverNJMember" xlink:label="lbl_EndocyteInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EndocyteInc.EastHanoverNJMember" xlink:to="lbl_label1146668799" xlink:type="arc"/>
      <link:label id="id_68546348" xlink:label="lbl_label1750360904" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Vaccines and Diagnostics, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:label="lbl_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:to="lbl_label1750360904" xlink:type="arc"/>
      <link:label id="id_2d054e5d" xlink:label="lbl_label755322461" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Spinifex Pharmaceuticals, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:label="lbl_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:to="lbl_label755322461" xlink:type="arc"/>
      <link:label id="id_75833aa3" xlink:label="lbl_label1971534499" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Manufacturing GmbH, Marburg [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisManufacturingGmbHMarburgMember" xlink:label="lbl_NovartisManufacturingGmbHMarburgMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisManufacturingGmbHMarburgMember" xlink:to="lbl_label1971534499" xlink:type="arc"/>
      <link:label id="id_3ce1ce66" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payments of lease liabilities, net</link:label>
      <link:label id="id_7d5a543d" xlink:label="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest payments for amounts included in lease liabilities classified as cash flows from operating activities</link:label>
      <link:label id="id_264ae6cd" xlink:label="lbl_AmortizationOfBondsDiscount_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of bonds discount</link:label>
      <link:label id="id_541ef56a" xlink:label="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transfers out of Level 3 of fair value hierarchy, assets</link:label>
      <link:label id="id_4edf1e96" xlink:label="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amount of change in OCI when POS for level 3 change more than 10%</link:label>
      <link:label id="id_2efc8f07" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments of the current portion of non-current financial debts</link:label>
      <link:label id="id_2d28f541" xlink:label="lbl_label757658945" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of US tax reform legislation</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfUSTaxReformLegislation" xlink:label="lbl_EffectOfUSTaxReformLegislation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EffectOfUSTaxReformLegislation" xlink:to="lbl_label757658945" xlink:type="arc"/>
      <link:label id="id_3c578d43" xlink:label="lbl_AcquiredCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired cash and cash equivalents</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredCashAndCashEquivalents" xlink:label="lbl_AcquiredCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquiredCashAndCashEquivalents" xlink:to="lbl_AcquiredCashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_25ec28ce" xlink:label="lbl_AcquiredCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquired cash and cash equivalents</link:label>
      <link:label id="id_4dc21030" xlink:label="lbl_label1304563760" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of impact on adoption of IFRS 16</link:label>
      <link:label id="id_284baaac" xlink:label="lbl_label676047532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of impact on adoption of IFRS 16 [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:label="lbl_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:to="lbl_label676047532" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:to="lbl_label1304563760" xlink:type="arc"/>
      <link:label id="id_7cee5446" xlink:label="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated income statement, additional information [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" xlink:label="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" xlink:to="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_43467410" xlink:label="lbl_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated income statement, additional information</link:label>
      <link:label id="id_47cec299" xlink:label="lbl_BalanceSheetAdditionalInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance sheet, additional information [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetAdditionalInformationTableTextBlock" xlink:label="lbl_BalanceSheetAdditionalInformationTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BalanceSheetAdditionalInformationTableTextBlock" xlink:to="lbl_BalanceSheetAdditionalInformationTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_557771c9" xlink:label="lbl_BalanceSheetAdditionalInformationTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance sheet, additional information</link:label>
      <link:label id="id_6c2f9126" xlink:label="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows used in investing activities [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:label="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock" xlink:to="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6c013712" xlink:label="lbl_CashFlowsUsedInInvestingActivitiesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows used in investing activities</link:label>
      <link:label id="id_cd95e1f" xlink:label="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CH Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" xlink:label="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" xlink:to="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_5424fa1a" xlink:label="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CH Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities</link:label>
      <link:label id="id_71dfb6f6" xlink:label="lbl_label1910486774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ultibro Group [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UltibroGroupMember" xlink:label="lbl_UltibroGroupMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_UltibroGroupMember" xlink:to="lbl_label1910486774" xlink:type="arc"/>
      <link:label id="id_86983fb" xlink:label="lbl_label141132795" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adakveo [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdakveoMember" xlink:label="lbl_AdakveoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdakveoMember" xlink:to="lbl_label141132795" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_label1289490857" xlink:type="arc"/>
      <link:label id="id_4b6d4dbb" xlink:label="lbl_label1265454523" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, New York, United States, 1.75%, 2025 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:to="lbl_label1265454523" xlink:type="arc"/>
      <link:label id="id_506f7c31" xlink:label="lbl_label1349483569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, New York, United States, 2.00%, 2027 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:to="lbl_label1349483569" xlink:type="arc"/>
      <link:label id="id_2f497fb1" xlink:label="lbl_label793345969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, New York, United States, 2.20%, 2030 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:to="lbl_label793345969" xlink:type="arc"/>
      <link:label id="id_27dd04e2" xlink:label="lbl_label668796130" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Capital Corporation, New York, United States, 2.75%, 2050 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:to="lbl_label668796130" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PoPChangeMember" xlink:to="lbl_label1343837424" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PoPYEChangeMember" xlink:to="lbl_label571817371" xlink:type="arc"/>
      <link:label id="id_baa97ec" xlink:label="lbl_CurrentTaxAssetsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax assets, current</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="lbl_CurrentTaxAssetsCurrent" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentTaxAssetsCurrent" xlink:to="lbl_CurrentTaxAssetsCurrent_labels" xlink:type="arc"/>
      <link:label id="id_6f03bc65" xlink:label="lbl_CurrentTaxAssetsCurrent_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax receivable</link:label>
      <link:label id="id_1b60e90f" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions and other non-current liabilities</link:label>
      <link:label id="id_4606d526" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total provisions and other non-current liabilities</link:label>
      <link:label id="id_f38218c" xlink:label="lbl_label255336844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZPL389 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZPL389Member" xlink:label="lbl_ZPL389Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ZPL389Member" xlink:to="lbl_label255336844" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueOfOtherFinancialAssetsSold" xlink:label="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfOtherFinancialAssetsSold" xlink:to="lbl_label2044002083" xlink:type="arc"/>
      <link:label id="id_4fe64fe" xlink:label="lbl_RepaymentOfIntercompanyBalances_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of intercompany balances</link:label>
      <link:label id="id_17ced1e3" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right of use assets as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RightOfUseAssetsAsOfAcquisitionDate" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:to="lbl_RightOfUseAssetsAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_78162c1a" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
      <link:label id="id_23e031e7" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current and non current lease liabilities as of acquisition date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:to="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate_labels" xlink:type="arc"/>
      <link:label id="id_5e1a35c1" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current and non-current lease liabilities</link:label>
      <link:label id="id_2d827166" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payments attributable to the spin-off of the Alcon business</link:label>
      <link:label id="id_5854f481" xlink:label="lbl_CashFlowsAttributableToDivestedBusiness_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows attributable to the spin-off of the Alcon business</link:label>
      <link:label id="id_280cd5b1" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of property, plant and equipment</link:label>
      <link:label id="id_4ae04f6d" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercised options and other treasury share transactions, net</link:label>
      <link:label id="id_1829dad9" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, intangible assets and goodwill</link:label>
      <link:label id="id_452d236c" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge</link:label>
      <link:label id="id_1af64409" xlink:label="lbl_TransactionCosts_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs recognized in the consolidated income statement</link:label>
      <link:label id="id_7a659997" xlink:label="lbl_label2053478807" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid sales price for a business divestment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrepaidSalesPriceForABusinessDivestment" xlink:label="lbl_PrepaidSalesPriceForABusinessDivestment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PrepaidSalesPriceForABusinessDivestment" xlink:to="lbl_label2053478807" xlink:type="arc"/>
      <link:label id="id_137fddb" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current refunds provision, Discontinued operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentRefundsProvisionDiscontinuedOperations" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:to="lbl_CurrentRefundsProvisionDiscontinuedOperations_labels" xlink:type="arc"/>
      <link:label id="id_5ae43d2a" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue, discontinued operations</link:label>
      <link:label id="id_2214c4b6" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue, discontinued operations, at beginning of period</link:label>
      <link:label id="id_64fab371" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Provisions for deductions from revenue, discontinued operations, at end of period</link:label>
      <link:label id="id_305e08c1" xlink:label="lbl_ProvisionForDoubtfulReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for doubtful receivable</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivable" xlink:label="lbl_ProvisionForDoubtfulReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProvisionForDoubtfulReceivable" xlink:to="lbl_ProvisionForDoubtfulReceivable_labels" xlink:type="arc"/>
      <link:label id="id_17c9358" xlink:label="lbl_ProvisionForDoubtfulReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Provision for doubtful receivable at beginning of period</link:label>
      <link:label id="id_7c5a57a4" xlink:label="lbl_ProvisionForDoubtfulReceivable_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Provision for doubtful receivable at end of period</link:label>
      <link:label id="id_569afc65" xlink:label="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit obligation, Discontinued operations, at present value</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:label="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:to="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue_labels" xlink:type="arc"/>
      <link:label id="id_6cf5f158" xlink:label="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Benefit obligation, Discontinued operations at beginning of period</link:label>
      <link:label id="id_4998d875" xlink:label="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Benefit obligation, Discontinued operations at end of period</link:label>
      <link:label id="id_11da36c7" xlink:label="lbl_label299513543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities, impact of adoption of IFRS 16</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseLiabilitiesImpactOfAdoptionOfIFRS16" xlink:label="lbl_LeaseLiabilitiesImpactOfAdoptionOfIFRS16" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseLiabilitiesImpactOfAdoptionOfIFRS16" xlink:to="lbl_label299513543" xlink:type="arc"/>
      <link:label id="id_664f7869" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contributions to plan by plan participants, net defined benefit liability (asset), benefit obligation</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:to="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation_labels" xlink:type="arc"/>
      <link:label id="id_5209ef33" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributions of associates</link:label>
      <link:label id="id_34fc26b" xlink:label="lbl_label55558763" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease commitments, discontinued operations</link:label>
      <link:label id="id_61a2309d" xlink:label="lbl_label1638019229" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross lease liabilities, Discontinued operations</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:label="lbl_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:to="lbl_label1638019229" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:to="lbl_label55558763" xlink:type="arc"/>
      <link:label id="id_4087a31" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase/Decrease through classified as held for sale, intangible assets and goodwill</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:to="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_28188a68" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of assets related to disposal group held for sale</link:label>
      <link:label id="id_1caaba88" xlink:label="lbl_TreasurySharesMovementOfPeriod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury shares movement of period</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesMovementOfPeriod" xlink:label="lbl_TreasurySharesMovementOfPeriod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TreasurySharesMovementOfPeriod" xlink:to="lbl_TreasurySharesMovementOfPeriod_labels" xlink:type="arc"/>
      <link:label id="id_21690868" xlink:label="lbl_TreasurySharesMovementOfPeriod_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury shares movement of period</link:label>
      <link:label id="id_5def5bff" xlink:label="lbl_label1575967743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease in finance leases receivable due to unearned finance income relating to finance lease payments receivable</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseInFinanceLeasesReceivableDueToUnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:label="lbl_DecreaseInFinanceLeasesReceivableDueToUnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DecreaseInFinanceLeasesReceivableDueToUnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" xlink:to="lbl_label1575967743" xlink:type="arc"/>
      <link:label id="id_34d7edcd" xlink:label="lbl_label886566349" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other financial liabilities, category [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialLiabilitiesCategoryMember" xlink:label="lbl_OtherFinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherFinancialLiabilitiesCategoryMember" xlink:to="lbl_label886566349" xlink:type="arc"/>
      <link:label id="id_eec52d1" xlink:label="lbl_label250368721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current assets [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCurrentAssetsMember" xlink:label="lbl_OtherCurrentAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherCurrentAssetsMember" xlink:to="lbl_label250368721" xlink:type="arc"/>
      <link:label id="id_354fdd57" xlink:label="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on financial instruments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:label="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember_labels" xlink:type="arc"/>
      <link:label id="id_273f4f15" xlink:label="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_1_Fair value adjustments on marketable securities</link:label>
      <link:label id="id_38a75dc3" xlink:label="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value Adjustment Increase Decrease Through Changes In Ownership Interests In Subsidiaries That Do Not Result In Loss Of Control</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:to="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:type="arc"/>
      <link:label id="id_e0e9730" xlink:label="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of change in ownership of consolidated entities</link:label>
      <link:label id="id_92da590" xlink:label="lbl_RepurchaseOfOptions_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase of options</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RepurchaseOfOptions" xlink:label="lbl_RepurchaseOfOptions" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RepurchaseOfOptions" xlink:to="lbl_RepurchaseOfOptions_labels" xlink:type="arc"/>
      <link:label id="id_4e1c053" xlink:label="lbl_RepurchaseOfOptions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of options</link:label>
      <link:label id="id_3b79b108" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations right-of-use assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets_labels" xlink:type="arc"/>
      <link:label id="id_4848a24f" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of business combinations</link:label>
      <link:label id="id_780c70ab" xlink:label="lbl_label2014081195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabrecta [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TabrectaMember" xlink:label="lbl_TabrectaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TabrectaMember" xlink:to="lbl_label2014081195" xlink:type="arc"/>
      <link:label id="id_127152f2" xlink:label="lbl_label309416690" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kesimpta [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KesimptaMember" xlink:label="lbl_KesimptaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KesimptaMember" xlink:to="lbl_label309416690" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:label="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:to="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes_labels" xlink:type="arc"/>
      <link:label id="id_5de4f6ff" xlink:label="lbl_label1575286527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">1.750% USD 1 000 million 2020/2025 Novartis Capital Corporation, New York, United States, issued at 99.852% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:label="lbl_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:to="lbl_label1575286527" xlink:type="arc"/>
      <link:label id="id_5914d9cb" xlink:label="lbl_label1494538699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.000% USD 1 250 million 2020/2027 Novartis Capital Corporation, New York, United States, issued at 99.909% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:label="lbl_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:to="lbl_label1494538699" xlink:type="arc"/>
      <link:label id="id_5f78509e" xlink:label="lbl_label1601720478" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.200% USD 1 500 million 2020/2030 Novartis Capital Corporation, New York, United States, issued at 99.869% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:label="lbl_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:to="lbl_label1601720478" xlink:type="arc"/>
      <link:label id="id_1a77a5e5" xlink:label="lbl_label444048869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.750% USD 1 250 million 2020/2050 Novartis Capital Corporation, New York, United States, issued at 97.712% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:label="lbl_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:to="lbl_label444048869" xlink:type="arc"/>
      <link:label id="id_57a4b51a" xlink:label="lbl_label1470412058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">0.000% 1 EUR 1 850 million 2020/2028 Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.354% [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:label="lbl_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:to="lbl_label1470412058" xlink:type="arc"/>
      <link:label id="id_467a5e1d" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated amortization/impairments on assets held for sale intangible assets and goodwill</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:type="arc"/>
      <link:label id="id_28811564" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization/impairments on assets reclassified out of assets of disposal group held for sale</link:label>
      <link:label id="id_7e37dc46" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase decrease through classified as held for sale property plant and equipment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:to="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_75e51f1c" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of assets reclassified out of assets of disposal group held for sale</link:label>
      <link:label id="id_7eed015a" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated amortization/impairments on assets held for sale property plant and equipment</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment_labels" xlink:type="arc"/>
      <link:label id="id_3eecdcaa" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation on assets reclassified out of assets of disposal group held for sale</link:label>
      <link:label id="id_653fa5ee" xlink:label="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on equity securities, net of taxes</link:label>
      <link:label id="id_6448b9fc" xlink:label="lbl_label1682487804" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of options repurchased</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfOptionsRepurchased" xlink:label="lbl_NumberOfOptionsRepurchased" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfOptionsRepurchased" xlink:to="lbl_label1682487804" xlink:type="arc"/>
      <link:label id="id_55dc85a" xlink:label="lbl_DepreciationPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation charge</link:label>
      <link:label id="id_40c54b4d" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, property, plant and equipment</link:label>
      <link:label id="id_7d17c10a" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization charge</link:label>
      <link:label id="id_3c338d36" xlink:label="lbl_NumberOfSharesIssued_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="lbl_NumberOfSharesIssued" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfSharesIssued" xlink:to="lbl_NumberOfSharesIssued_labels" xlink:type="arc"/>
      <link:label id="id_74f409ec" xlink:label="lbl_NumberOfSharesIssued_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued at beginning of period</link:label>
      <link:label id="id_5895e9b5" xlink:label="lbl_NumberOfSharesIssued_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued at end of period</link:label>
      <link:label id="id_4ad28146" xlink:label="lbl_NumberOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of treasury shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfTreasuryShares" xlink:label="lbl_NumberOfTreasuryShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfTreasuryShares" xlink:to="lbl_NumberOfTreasuryShares_labels" xlink:type="arc"/>
      <link:label id="id_3deddf6f" xlink:label="lbl_NumberOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of treasury shares at beginning of period</link:label>
      <link:label id="id_74b615a9" xlink:label="lbl_NumberOfTreasuryShares_labels" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of treasury shares at end of period</link:label>
      <link:label id="id_7f6e02de" xlink:label="lbl_label2137916126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not subject to expiry [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NotSubjectToExpiryMember" xlink:label="lbl_NotSubjectToExpiryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NotSubjectToExpiryMember" xlink:to="lbl_label2137916126" xlink:type="arc"/>
      <link:label id="id_3faff48a" xlink:label="lbl_label1068496010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitment for repurchase of own shares [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentForRepurchaseOfOwnSharesMember" xlink:label="lbl_CommitmentForRepurchaseOfOwnSharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommitmentForRepurchaseOfOwnSharesMember" xlink:to="lbl_label1068496010" xlink:type="arc"/>
      <link:label id="id_3f65b5b6" xlink:label="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for healthcare contributions [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:to="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_340a972f" xlink:label="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Healthcare contributions</link:label>
      <link:label id="id_53107fec" xlink:label="lbl_label1393590252" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development commitments for transactions entered into current year, closed after current year end</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:label="lbl_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:to="lbl_label1393590252" xlink:type="arc"/>
      <link:label id="id_3851ffb1" xlink:label="lbl_ReceivablesAndPayablesContingentConsiderationNet_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration payables, net</link:label>
      <link:label id="id_27060644" xlink:label="lbl_CN_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CHINA</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN" xlink:label="lbl_CN" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CN" xlink:to="lbl_CN_labels" xlink:type="arc"/>
      <link:label id="id_cac1bd6" xlink:label="lbl_CN_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">China</link:label>
      <link:label id="id_38628cbd" xlink:label="lbl_TaxLossCarryForwards_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax loss carry forwards</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxLossCarryForwards" xlink:label="lbl_TaxLossCarryForwards" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TaxLossCarryForwards" xlink:to="lbl_TaxLossCarryForwards_labels" xlink:type="arc"/>
      <link:label id="id_3d3df970" xlink:label="lbl_TaxLossCarryForwards_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_1_Tax loss carryforwards expired</link:label>
      <link:label id="id_7429e4f6" xlink:label="lbl_label1948902646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:to="lbl_label1948902646" xlink:type="arc"/>
      <link:label id="id_5c2d9c4d" xlink:label="lbl_AdditionsToInvestmentInAssociatedCompanies_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Additions to investment in associated companies</link:label>
      <link:label id="id_35a27c09" xlink:label="lbl_DeferredTaxLiabilities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
      <link:label id="id_5725466" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, right of use assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets_labels" xlink:type="arc"/>
      <link:label id="id_536cdf9" xlink:label="lbl_BorrowingsInterestRateStepUp_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings interest rate step up</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsInterestRateStepUp" xlink:label="lbl_BorrowingsInterestRateStepUp" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BorrowingsInterestRateStepUp" xlink:to="lbl_BorrowingsInterestRateStepUp_labels" xlink:type="arc"/>
      <link:label id="id_3f1e4d31" xlink:label="lbl_BorrowingsInterestRateStepUp_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_1_Straight bonds</link:label>
      <link:label id="id_653e892c" xlink:label="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets other than cash or cash equivalents in subsidiary or businesses acquired or disposed</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:to="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013_labels" xlink:type="arc"/>
      <link:label id="id_2997004f" xlink:label="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets divested</link:label>
      <link:label id="id_3110a540" xlink:label="lbl_label823174464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentAssetsMember" xlink:label="lbl_NoncurrentAssetsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAssetsMember" xlink:to="lbl_label823174464" xlink:type="arc"/>
      <link:label id="id_6718df7c" xlink:label="lbl_EstimatedAcquisitionFairValueOfTotalConsideration_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated acquisition fair value of total consideration</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:label="lbl_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:to="lbl_EstimatedAcquisitionFairValueOfTotalConsideration_labels" xlink:type="arc"/>
      <link:label id="id_28d66ca1" xlink:label="lbl_EstimatedAcquisitionFairValueOfTotalConsideration_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value purchase price</link:label>
      <link:label id="id_7dd0ab04" xlink:label="lbl_label2110827268" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="lbl_IcfrAuditorAttestationFlag" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IcfrAuditorAttestationFlag" xlink:to="lbl_label2110827268" xlink:type="arc"/>
      <link:label id="id_76f3c7f1" xlink:label="lbl_label937578086" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis Group contributions</link:label>
      <link:label id="id_7ce6c764" xlink:label="lbl_label2095499108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Spark Therapeutics, Inc. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SparkTherapeuticsInc.Member" xlink:label="lbl_SparkTherapeuticsInc.Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SparkTherapeuticsInc.Member" xlink:to="lbl_label2095499108" xlink:type="arc"/>
      <link:label id="id_704e7977" xlink:label="lbl_label1884191095" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Integrated Services Limited, Ringaskiddy, County Cork [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:label="lbl_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:to="lbl_label1884191095" xlink:type="arc"/>
      <link:label id="id_8bbdcdf" xlink:label="lbl_label146529503" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Gene Therapies EU Limited, Dublin [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGeneTherapiesEULimitedDublinMember" xlink:label="lbl_NovartisGeneTherapiesEULimitedDublinMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisGeneTherapiesEULimitedDublinMember" xlink:to="lbl_label146529503" xlink:type="arc"/>
      <link:label id="id_6c2d9048" xlink:label="lbl_label1814925384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aspen Japan K.K., Tokyo [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AspenJapanK.K.TokyoMember" xlink:label="lbl_AspenJapanK.K.TokyoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AspenJapanK.K.TokyoMember" xlink:to="lbl_label1814925384" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPhilippinesCorporationMakatiCityMember" xlink:label="lbl_SandozPhilippinesCorporationMakatiCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozPhilippinesCorporationMakatiCityMember" xlink:to="lbl_label542160655" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIsraelLtd.TelAvivMember" xlink:label="lbl_NovartisIsraelLtd.TelAvivMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisIsraelLtd.TelAvivMember" xlink:to="lbl_label437644648" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:label="lbl_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:to="lbl_label604974513" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:label="lbl_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:to="lbl_label573289181" xlink:type="arc"/>
      <link:label id="id_2e2703c1" xlink:label="lbl_label774308801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Catalana de Dispensacion sau (Cadisa), Esplugues de Llobregat [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:label="lbl_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:to="lbl_label774308801" xlink:type="arc"/>
      <link:label id="id_49af070a" xlink:label="lbl_label1236207370" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications (UK &amp; Ireland), London [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:to="lbl_label1236207370" xlink:type="arc"/>
      <link:label id="id_2d344762" xlink:label="lbl_label758400866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neutec Pharma Limited, London [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeutecPharmaLimitedLondonMember" xlink:label="lbl_NeutecPharmaLimitedLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NeutecPharmaLimitedLondonMember" xlink:to="lbl_label758400866" xlink:type="arc"/>
      <link:label id="id_5f46d997" xlink:label="lbl_label1598478743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Coalesce Product Development Limited, Cambridge, Cambs [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:label="lbl_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:to="lbl_label1598478743" xlink:type="arc"/>
      <link:label id="id_2252cc66" xlink:label="lbl_label575851622" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Optogenetics Research, Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:label="lbl_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:to="lbl_label575851622" xlink:type="arc"/>
      <link:label id="id_454fa68d" xlink:label="lbl_label1162847885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amblyotech Inc., East Hanover, NJ [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmblyotechInc.EastHanoverNJMember" xlink:label="lbl_AmblyotechInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmblyotechInc.EastHanoverNJMember" xlink:to="lbl_label1162847885" xlink:type="arc"/>
      <link:label id="id_2caf6f16" xlink:label="lbl_label749694742" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Vietnam Company Limited, Ho Chi Minh City [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:label="lbl_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:to="lbl_label749694742" xlink:type="arc"/>
      <link:label id="id_c2bfc15" xlink:label="lbl_label204209173" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Deutschland GmbH, Nuremberg [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeutschlandGmbHNurembergMember" xlink:label="lbl_NovartisDeutschlandGmbHNurembergMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisDeutschlandGmbHNurembergMember" xlink:to="lbl_label204209173" xlink:type="arc"/>
      <link:label id="id_3fb4623e" xlink:label="lbl_CommitmentForRepurchaseOwnShares_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Commitment for repurchase own shares</link:label>
      <link:label id="id_28b07024" xlink:label="lbl_DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of other accounting policies relevant to understanding of financial statements [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements" xlink:label="lbl_DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements" xlink:to="lbl_DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements_labels" xlink:type="arc"/>
      <link:label id="id_11b1fb8b" xlink:label="lbl_DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected critical accounting policies</link:label>
      <link:label id="id_3843cb01" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, balance sheet and income statement [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:to="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_98f2233" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segmentation - Consolidated balance sheets and income statement</link:label>
      <link:label id="id_2c3b8a35" xlink:label="lbl_label742099509" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of brands in portfolio to acquire</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfBrandsInPortfolioToAcquire" xlink:label="lbl_NumberOfBrandsInPortfolioToAcquire" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfBrandsInPortfolioToAcquire" xlink:to="lbl_label742099509" xlink:type="arc"/>
      <link:label id="id_3cf6b00d" xlink:label="lbl_label1022799885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of markets for the acquired brands</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfMarketsForTheAcquiredBrands" xlink:label="lbl_NumberOfMarketsForTheAcquiredBrands" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfMarketsForTheAcquiredBrands" xlink:to="lbl_label1022799885" xlink:type="arc"/>
      <link:label id="id_47dc0ad" xlink:label="lbl_label75350189" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total anti-infectives net sales [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalAntiinfectivesNetSalesMember" xlink:label="lbl_TotalAntiinfectivesNetSalesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TotalAntiinfectivesNetSalesMember" xlink:to="lbl_label75350189" xlink:type="arc"/>
      <link:label id="id_ee96e7" xlink:label="lbl_GlaxoSmithKlinePlcGSKMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline plc (GSK) [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlinePlcGSKMember" xlink:label="lbl_GlaxoSmithKlinePlcGSKMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GlaxoSmithKlinePlcGSKMember" xlink:to="lbl_GlaxoSmithKlinePlcGSKMember_labels" xlink:type="arc"/>
      <link:label id="id_54094d6d" xlink:label="lbl_label1409895789" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Solid Tumors [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SolidTumorMember" xlink:label="lbl_SolidTumorMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SolidTumorMember" xlink:to="lbl_label1409895789" xlink:type="arc"/>
      <link:label id="id_1962519a" xlink:label="lbl_label425873818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hematology [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HematologyMember" xlink:label="lbl_HematologyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_HematologyMember" xlink:to="lbl_label425873818" xlink:type="arc"/>
      <link:label id="id_77ba142f" xlink:label="lbl_label2008683567" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current deferred income other than current contract liabilities</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:label="lbl_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:to="lbl_label2008683567" xlink:type="arc"/>
      <link:label id="id_20b013e7" xlink:label="lbl_label548410343" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leqvio [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeqvioMember" xlink:label="lbl_LeqvioMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeqvioMember" xlink:to="lbl_label548410343" xlink:type="arc"/>
      <link:label id="id_66cbd7ad" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveRSUMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Annual Incentive RSU [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentiveRSUMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveRSUMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationAnnualIncentiveRSUMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentiveRSUMember_labels" xlink:type="arc"/>
      <link:label id="id_bc0b0d9" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveRSUMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_1_Annual incentive</link:label>
      <link:label id="id_14778812" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Based Participation Annual Incentive Restricted Shares [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember_labels" xlink:type="arc"/>
      <link:label id="id_76867cfb" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_2_Annual incentive</link:label>
      <link:label id="id_416bc8c8" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Based Participation Annual Incentive Shares [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentiveSharesMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveSharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationAnnualIncentiveSharesMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentiveSharesMember_labels" xlink:type="arc"/>
      <link:label id="id_69e1d51b" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_3_Annual incentive</link:label>
      <link:label id="id_584cbdc1" xlink:label="lbl_EquityBasedParticipationShareSavingsPlansRSUMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Based Participation Share savings plans RSU [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationShareSavingsPlansRSUMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlansRSUMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationShareSavingsPlansRSUMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlansRSUMember_labels" xlink:type="arc"/>
      <link:label id="id_42d79120" xlink:label="lbl_EquityBasedParticipationShareSavingsPlansRSUMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_4_Annual incentive</link:label>
      <link:label id="id_75440e22" xlink:label="lbl_EquityBasedParticipationShareSavingsPlansSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Based Participation Share savings plans Shares [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationShareSavingsPlansSharesMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlansSharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationShareSavingsPlansSharesMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlansSharesMember_labels" xlink:type="arc"/>
      <link:label id="id_184477d8" xlink:label="lbl_EquityBasedParticipationShareSavingsPlansSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_5_Annual incentive</link:label>
      <link:label id="id_552e7090" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Based Participation Novartis Equity Plan Select North America RSU [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember_labels" xlink:type="arc"/>
      <link:label id="id_21165e34" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_6_Annual incentive</link:label>
      <link:label id="id_265acda6" xlink:label="lbl_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Based Participation Novartis Equity Plan Select outside North America RSU [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" xlink:label="lbl_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" xlink:to="lbl_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember_labels" xlink:type="arc"/>
      <link:label id="id_26e7b908" xlink:label="lbl_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_7_Annual incentive</link:label>
      <link:label id="id_1b9c56ed" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Based Participation Novartis Equity Plan Select outside North America Restricted Shares [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember_labels" xlink:type="arc"/>
      <link:label id="id_12d62a5f" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_8_Annual incentive</link:label>
      <link:label id="id_5176ec6e" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePSUPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Based Participation Long Term Performance PSU Plan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermPerformancePSUPlanMember" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePSUPlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationLongTermPerformancePSUPlanMember" xlink:to="lbl_EquityBasedParticipationLongTermPerformancePSUPlanMember_labels" xlink:type="arc"/>
      <link:label id="id_1da39f37" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePSUPlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_9_Annual incentive</link:label>
      <link:label id="id_72a01f6d" xlink:label="lbl_label879628916" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Based Participation Long Term Relative Performance Plan PSU [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermRelativePerformancePlanPSUMember" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanPSUMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationLongTermRelativePerformancePlanPSUMember" xlink:to="lbl_label879628916" xlink:type="arc"/>
      <link:label id="id_faf6a0a" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsRSUMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Based Participation Other share awards RSU [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsRSUMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsRSUMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationOtherShareAwardsRSUMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsRSUMember_labels" xlink:type="arc"/>
      <link:label id="id_222e1d60" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsRSUMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_11_Annual incentive</link:label>
      <link:label id="id_300c474e" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Based Participation Other share awards Restricted Shares [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember_labels" xlink:type="arc"/>
      <link:label id="id_4ab462d9" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_12_Annual incentive</link:label>
      <link:label id="id_5d4c3be2" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Based Participation Other share awards Shares [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsSharesMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsSharesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationOtherShareAwardsSharesMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsSharesMember_labels" xlink:type="arc"/>
      <link:label id="id_2af8ae97" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsSharesMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_13_Annual incentive</link:label>
      <link:label id="id_10c1e834" xlink:label="lbl_label281143348" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash transferred</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashTransferred" xlink:label="lbl_CashTransferred" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashTransferred" xlink:to="lbl_label281143348" xlink:type="arc"/>
      <link:label id="id_54fd1d1d" xlink:label="lbl_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of investments other than investments accounted for using equity method</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="lbl_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:to="lbl_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_labels" xlink:type="arc"/>
      <link:label id="id_4a9a940e" xlink:label="lbl_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of financial assets</link:label>
      <link:label id="id_d3a0157" xlink:label="lbl_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales of investments other than investments accounted for using equity method</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="lbl_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:to="lbl_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_labels" xlink:type="arc"/>
      <link:label id="id_64262234" xlink:label="lbl_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of financial assets</link:label>
      <link:label id="id_7cc530c9" xlink:label="lbl_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities, commodities and time deposits</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="lbl_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_6063858" xlink:label="lbl_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of financial instruments, classified as investing activities</link:label>
      <link:label id="id_57cdae3e" xlink:label="lbl_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of marketable securities, commodities and time deposits</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="lbl_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_labels" xlink:type="arc"/>
      <link:label id="id_32d638e5" xlink:label="lbl_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales or maturity of financial instruments, classified as investing activities</link:label>
      <link:label id="id_25e69fb8" xlink:label="lbl_label635871160" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment impairment charges and reversals [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock" xlink:label="lbl_PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock" xlink:to="lbl_label635871160" xlink:type="arc"/>
      <link:label id="id_5371a3bc" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated income statement due to increase (decrease) in currency exchange rates [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:to="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_6da7434" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated income statement due to increase (decrease) in currency exchange rates</link:label>
      <link:label id="id_638aba8b" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated income statement due to increase (decrease) in equity prices [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:to="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_21ea725d" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated income statement due to increase (decrease) in equity prices</link:label>
      <link:label id="id_4ed81682" xlink:label="lbl_PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated statements of comprehensive income due to increase (decrease) in equity prices [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:to="lbl_PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_2c8bb21f" xlink:label="lbl_PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated statements of comprehensive income due to increase (decrease) in equity prices</link:label>
      <link:label id="id_70fedb84" xlink:label="lbl_GyroscopeTherapeuticsHoldingsPlcMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gyroscope Therapeutics Holdings plc. [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GyroscopeTherapeuticsHoldingsPlcMember" xlink:label="lbl_GyroscopeTherapeuticsHoldingsPlcMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GyroscopeTherapeuticsHoldingsPlcMember" xlink:to="lbl_GyroscopeTherapeuticsHoldingsPlcMember_labels" xlink:type="arc"/>
      <link:label id="id_c88323e" xlink:label="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Glaxosmithkline Consumer Healthcare Holdings Limited, Brentford, Middlesex</link:label>
      <link:label id="id_670c36c1" xlink:label="lbl_GlaxoSmithKlinePlcGSKMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GlaxoSmithKline plc (GSK)</link:label>
      <link:label id="id_66b2b8c9" xlink:label="lbl_GyroscopeTherapeuticsHoldingsPlcMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gyroscope Therapeutics Holdings plc.</link:label>
      <link:label id="id_3b328671" xlink:label="lbl_label993166961" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="lbl_AuditorFirmId" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AuditorFirmId" xlink:to="lbl_label993166961" xlink:type="arc"/>
      <link:label id="id_52eb17e9" xlink:label="lbl_label1391138793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="lbl_AuditorName" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AuditorName" xlink:to="lbl_label1391138793" xlink:type="arc"/>
      <link:label id="id_69b54c63" xlink:label="lbl_label1773489251" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="lbl_AuditorLocation" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AuditorLocation" xlink:to="lbl_label1773489251" xlink:type="arc"/>
      <link:label id="id_4daa9a92" xlink:label="lbl_label1303026322" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Contact [Member]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="lbl_BusinessContactMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BusinessContactMember" xlink:to="lbl_label1303026322" xlink:type="arc"/>
      <link:label id="id_c0b25fa" xlink:label="lbl_label202057210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Address Type [Domain]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="lbl_AddressTypeDomain" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AddressTypeDomain" xlink:to="lbl_label202057210" xlink:type="arc"/>
      <link:label id="id_7d6bc756" xlink:label="lbl_label2104215382" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="lbl_EntityAddressesAddressTypeAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityAddressesAddressTypeAxis" xlink:to="lbl_label2104215382" xlink:type="arc"/>
      <link:label id="id_4b15f6ce" xlink:label="lbl_label1259730638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="lbl_EntityFileNumber" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityFileNumber" xlink:to="lbl_label1259730638" xlink:type="arc"/>
      <link:label id="id_cb4c549" xlink:label="lbl_label213173576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="lbl_EntityIncorporationStateCountryCode" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityIncorporationStateCountryCode" xlink:to="lbl_label213173576" xlink:type="arc"/>
      <link:label id="id_7002066c" xlink:label="lbl_label1879180908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="lbl_EntityAddressAddressLine1" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityAddressAddressLine1" xlink:to="lbl_label1879180908" xlink:type="arc"/>
      <link:label id="id_231d9907" xlink:label="lbl_label589142279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="lbl_EntityAddressCityOrTown" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityAddressCityOrTown" xlink:to="lbl_label589142279" xlink:type="arc"/>
      <link:label id="id_759bc02e" xlink:label="lbl_label1973141550" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="lbl_EntityAddressPostalZipCode" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityAddressPostalZipCode" xlink:to="lbl_label1973141550" xlink:type="arc"/>
      <link:label id="id_36117107" xlink:label="lbl_label907112711" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="lbl_EntityAddressCountry" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EntityAddressCountry" xlink:to="lbl_label907112711" xlink:type="arc"/>
      <link:label id="id_1349334c" xlink:label="lbl_label323564364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="lbl_DocumentRegistrationStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentRegistrationStatement" xlink:to="lbl_label323564364" xlink:type="arc"/>
      <link:label id="id_8bcd64b" xlink:label="lbl_label146593355" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="lbl_DocumentAccountingStandard" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DocumentAccountingStandard" xlink:to="lbl_label146593355" xlink:type="arc"/>
      <link:label id="id_1ece2873" xlink:label="lbl_label516827251" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contact Personnel Name</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="lbl_ContactPersonnelName" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContactPersonnelName" xlink:to="lbl_label516827251" xlink:type="arc"/>
      <link:label id="id_5d3ab2af" xlink:label="lbl_label1564127919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="lbl_LocalPhoneNumber" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LocalPhoneNumber" xlink:to="lbl_label1564127919" xlink:type="arc"/>
      <link:label id="id_259830c2" xlink:label="lbl_label630730946" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contact Personnel Fax Number</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelFaxNumber" xlink:label="lbl_ContactPersonnelFaxNumber" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContactPersonnelFaxNumber" xlink:to="lbl_label630730946" xlink:type="arc"/>
      <link:label id="id_6de35884" xlink:label="lbl_NetInvestmentHedgeMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net investment hedge</link:label>
      <link:label id="id_6ca6935d" xlink:label="lbl_label1822856029" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments for leases not yet commenced</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentsForLeasesNotYetCommenced" xlink:label="lbl_CommitmentsForLeasesNotYetCommenced" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CommitmentsForLeasesNotYetCommenced" xlink:to="lbl_label1822856029" xlink:type="arc"/>
      <link:label id="id_13bf3f02" xlink:label="lbl_GR_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GREECE</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GR" xlink:label="lbl_GR" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GR" xlink:to="lbl_GR_labels" xlink:type="arc"/>
      <link:label id="id_39e4c772" xlink:label="lbl_GR_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Greece</link:label>
      <link:label id="id_61475ff3" xlink:label="lbl_label1632067571" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transfers into Level 3 of fair value hierarchy, assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:label="lbl_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:to="lbl_label1632067571" xlink:type="arc"/>
      <link:label id="id_b7f875c" xlink:label="lbl_label192907100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract manufacturing [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractManufacturingMember" xlink:label="lbl_ContractManufacturingMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContractManufacturingMember" xlink:to="lbl_label192907100" xlink:type="arc"/>
      <link:label id="id_55e87fb3" xlink:label="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated equity due to increase (decrease) in currency exchange rates [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:to="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4a80d6e0" xlink:label="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated equity due to increase (decrease) in currency exchange rates</link:label>
      <link:label id="id_dc4b8a1" xlink:label="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated equity due to increase (decrease) in equity prices [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:to="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_27fefcf1" xlink:label="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated equity due to increase (decrease) in equity prices</link:label>
      <link:label id="id_20bc3fae" xlink:label="lbl_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase/(Decrease) through new, modified, terminated leases, arising from financing activities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" xlink:to="lbl_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities_labels" xlink:type="arc"/>
      <link:label id="id_1d1ed0d6" xlink:label="lbl_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New, modified and terminated leases, net</link:label>
      <link:label id="id_530db955" xlink:label="lbl_ExercisePrice65.9Member_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, 65.9 [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice65.9Member" xlink:label="lbl_ExercisePrice65.9Member" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ExercisePrice65.9Member" xlink:to="lbl_ExercisePrice65.9Member_labels" xlink:type="arc"/>
      <link:label id="id_74475349" xlink:label="lbl_ExercisePrice65.9Member_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">65.9</link:label>
      <link:label id="id_1acbddfa" xlink:label="lbl_label449568250" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="lbl_ScenarioUnspecifiedDomain" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_label449568250" xlink:type="arc"/>
      <link:label id="id_3e4ee4c3" xlink:label="lbl_label1045357763" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="lbl_StatementScenarioAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_StatementScenarioAxis" xlink:to="lbl_label1045357763" xlink:type="arc"/>
      <link:label id="id_7a98072b" xlink:label="lbl_label2056783659" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hypothetical 5% increase [member]</link:label>
      <link:label id="id_47d3e5de" xlink:label="lbl_label1205069278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hypothetical 5% decrease [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical5DecreaseMember" xlink:label="lbl_Hypothetical5DecreaseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Hypothetical5DecreaseMember" xlink:to="lbl_label1205069278" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical5IncreaseMember" xlink:label="lbl_Hypothetical5IncreaseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Hypothetical5IncreaseMember" xlink:to="lbl_label2056783659" xlink:type="arc"/>
      <link:label id="id_31d2c983" xlink:label="lbl_label835897731" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hypothetical 15% decrease [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical15DecreaseMember" xlink:label="lbl_Hypothetical15DecreaseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Hypothetical15DecreaseMember" xlink:to="lbl_label835897731" xlink:type="arc"/>
      <link:label id="id_abead02" xlink:label="lbl_label180268290" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hypothetical 15% increase [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical15IncreaseMember" xlink:label="lbl_Hypothetical15IncreaseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Hypothetical15IncreaseMember" xlink:to="lbl_label180268290" xlink:type="arc"/>
      <link:label id="id_1ee533e3" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency exchange rate sensitivity impact against USD in the income statement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:to="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement_labels" xlink:type="arc"/>
      <link:label id="id_2b84a753" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency exchange rate sensitivity impact against USD in the equity</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" xlink:to="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity_labels" xlink:type="arc"/>
      <link:label id="id_525e31ad" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.</link:label>
      <link:label id="id_41ba09ce" xlink:label="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity price sensitivity impact of the risk factors in the income statement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" xlink:label="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" xlink:to="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement_labels" xlink:type="arc"/>
      <link:label id="id_7f9c7937" xlink:label="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.</link:label>
      <link:label id="id_7bfe27c4" xlink:label="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity price sensitivity impact of the risk factors in the equity</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" xlink:label="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" xlink:to="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity_labels" xlink:type="arc"/>
      <link:label id="id_5220467c" xlink:label="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.</link:label>
      <link:label id="id_66ef14bd" xlink:label="lbl_label420328400" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hypothetical increase decrease percentage in currency rate sensitivity</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" xlink:label="lbl_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" xlink:to="lbl_label420328400" xlink:type="arc"/>
      <link:label id="id_49e83ca3" xlink:label="lbl_label1418742448" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hypothetical increase decrease percentage in equity price sensitivity</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" xlink:label="lbl_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" xlink:to="lbl_label1418742448" xlink:type="arc"/>
      <link:label id="id_c163c14" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RespiratoryAndAllergyMember" xlink:label="lbl_RespiratoryAndAllergyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RespiratoryAndAllergyMember" xlink:to="lbl_label453087740" xlink:type="arc"/>
      <link:label id="id_402111c4" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInOtherAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in other current and non-current assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInOtherAssets_labels" xlink:type="arc"/>
      <link:label id="id_6350e48" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInOtherAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in other assets</link:label>
      <link:label id="id_75acf913" xlink:label="lbl_label1974270227" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursements from plan to employer net defined benefit liability (asset)</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:to="lbl_label1974270227" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:to="lbl_label937578086" xlink:type="arc"/>
      <link:label id="id_464a259d" xlink:label="lbl_label1179264413" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent consideration recognised as of acquisition date</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:label="lbl_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:to="lbl_label1179264413" xlink:type="arc"/>
      <link:label id="id_547cb455" xlink:label="lbl_label1417458773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of fund investments and equity securities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueOfFundInvestmentsAndEquitySecurities" xlink:label="lbl_FairValueOfFundInvestmentsAndEquitySecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueOfFundInvestmentsAndEquitySecurities" xlink:to="lbl_label1417458773" xlink:type="arc"/>
      <link:label id="id_72e0d44b" xlink:label="lbl_label1927337035" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of government backed debt securities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfGovernmentBackedDebtSecurities" xlink:label="lbl_PercentageOfGovernmentBackedDebtSecurities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PercentageOfGovernmentBackedDebtSecurities" xlink:to="lbl_label1927337035" xlink:type="arc"/>
      <link:label id="id_1d2f42f6" xlink:label="lbl_label489636598" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of investments in equity instruments designated at fair value through other comprehensive income</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" xlink:label="lbl_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" xlink:to="lbl_label489636598" xlink:type="arc"/>
      <link:label id="id_2702fb61" xlink:label="lbl_label654506849" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends recognised for investments in equity instruments designated at fair value through other comprehensive income, held at end of reporting period</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod" xlink:label="lbl_DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod" xlink:to="lbl_label654506849" xlink:type="arc"/>
      <link:label id="id_161f1ca2" xlink:label="lbl_label371137698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cellerys AG, Schlieren [member]</link:label>
      <link:label id="id_6e71caee" xlink:label="lbl_label1852951278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arctos Medical AG, Bern [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ArctosMedicalAGBernMember" xlink:label="lbl_ArctosMedicalAGBernMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ArctosMedicalAGBernMember" xlink:to="lbl_label1852951278" xlink:type="arc"/>
      <link:label id="id_4ab85f4d" xlink:label="lbl_label1253597005" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kedalion Therapeutics, Inc., Menlo Park, CA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KedalionTherapeuticsInc.MenloParkCAMember" xlink:label="lbl_KedalionTherapeuticsInc.MenloParkCAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_KedalionTherapeuticsInc.MenloParkCAMember" xlink:to="lbl_label1253597005" xlink:type="arc"/>
      <link:label id="id_742fae52" xlink:label="lbl_label1949281874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cadent Therapeutics, Cambridge, MA [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CadentTherapeuticsCambridgeMAMember" xlink:label="lbl_CadentTherapeuticsCambridgeMAMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CadentTherapeuticsCambridgeMAMember" xlink:to="lbl_label1949281874" xlink:type="arc"/>
      <link:label id="id_570d756" xlink:label="lbl_label91281238" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of bearer shares</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfBearerShares" xlink:label="lbl_NumberOfBearerShares" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfBearerShares" xlink:to="lbl_label91281238" xlink:type="arc"/>
      <link:label id="id_566fb369" xlink:label="lbl_label1450161001" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Committee members who stepped down</link:label>
      <link:label id="id_182b9df6" xlink:label="lbl_label405511670" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related parties, number of executive committee members who stepped down</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" xlink:label="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" xlink:to="lbl_label405511670" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" xlink:to="lbl_label1450161001" xlink:type="arc"/>
      <link:label id="id_10b270a" xlink:label="lbl_label17508106" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related parties, number of executive committee members</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RelatedPartiesNumberOfExecutiveCommitteeMembers" xlink:label="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembers" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembers" xlink:to="lbl_label17508106" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembers" xlink:to="lbl_label1424538747" xlink:type="arc"/>
      <link:label id="id_2e777aef" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesSoldMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value adjustments on equity securities sold [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnEquitySecuritiesSoldMember" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesSoldMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FairValueAdjustmentsOnEquitySecuritiesSoldMember" xlink:to="lbl_FairValueAdjustmentsOnEquitySecuritiesSoldMember_labels" xlink:type="arc"/>
      <link:label id="id_5d11279b" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesSoldMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments on equity securities sold</link:label>
      <link:label id="id_57b96d8e" xlink:label="lbl_label1471769998" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase/decrease due to revision of prior year amounts [member]</link:label>
      <link:label id="id_16a7a6d4" xlink:label="lbl_label380085972" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="lbl_CountryRegion" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CountryRegion" xlink:to="lbl_label380085972" xlink:type="arc"/>
      <link:label id="id_2a46da4c" xlink:label="lbl_label709286476" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="lbl_CityAreaCode" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CityAreaCode" xlink:to="lbl_label709286476" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember" xlink:label="lbl_IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember" xlink:to="lbl_label1471769998" xlink:type="arc"/>
      <link:label id="id_618f056b" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, right of use assets</link:label>
      <link:label id="id_9fa0ce0" xlink:label="lbl_label167382240" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reversal impairment loss recognised in profit or loss, right of use assets</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:label="lbl_ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:to="lbl_label167382240" xlink:type="arc"/>
      <link:label id="id_6b57cec" xlink:label="lbl_label112557292" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Promoted Brands [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPromotedBrandsMember" xlink:label="lbl_OtherPromotedBrandsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherPromotedBrandsMember" xlink:to="lbl_label112557292" xlink:type="arc"/>
      <link:label id="id_7dc6145f" xlink:label="lbl_label2110133343" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pluvicto [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PluvictoMember" xlink:label="lbl_PluvictoMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PluvictoMember" xlink:to="lbl_label2110133343" xlink:type="arc"/>
      <link:label id="id_2f37d592" xlink:label="lbl_label792188306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scemblix [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScemblixMember" xlink:label="lbl_ScemblixMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScemblixMember" xlink:to="lbl_label792188306" xlink:type="arc"/>
      <link:label id="id_123a75a0" xlink:label="lbl_label305821088" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mature Ophtha [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MatureOphthaMember" xlink:label="lbl_MatureOphthaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_MatureOphthaMember" xlink:to="lbl_label305821088" xlink:type="arc"/>
      <link:label id="id_f65a030" xlink:label="lbl_label258318384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Respiratory [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherRespiratoryMember" xlink:label="lbl_OtherRespiratoryMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherRespiratoryMember" xlink:to="lbl_label258318384" xlink:type="arc"/>
      <link:label id="id_55b7f134" xlink:label="lbl_label1438118196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current contingent consideration liabilities [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentContingentConsiderationLiabilitiesMember" xlink:label="lbl_NoncurrentContingentConsiderationLiabilitiesMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentContingentConsiderationLiabilitiesMember" xlink:to="lbl_label1438118196" xlink:type="arc"/>
      <link:label id="id_1e2fd44" xlink:label="lbl_label31653188" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial liabilities at fair value [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialLiabilitiesAtFairValueMember" xlink:label="lbl_CurrentFinancialLiabilitiesAtFairValueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrentFinancialLiabilitiesAtFairValueMember" xlink:to="lbl_label31653188" xlink:type="arc"/>
      <link:label id="id_4cc26a40" xlink:label="lbl_label1287809600" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current financial liabilities at fair value [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialLiabilitiesAtFairValueMember" xlink:label="lbl_NoncurrentFinancialLiabilitiesAtFairValueMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentFinancialLiabilitiesAtFairValueMember" xlink:to="lbl_label1287809600" xlink:type="arc"/>
      <link:label id="id_1d3f9d8" xlink:label="lbl_label30669272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of impairment loss and reversal of impairment loss [text block]</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory" xlink:label="lbl_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfImpairmentLossAndReversalOfImpairmentLossExplanatory" xlink:to="lbl_label30669272" xlink:type="arc"/>
      <link:label id="id_1f15808c" xlink:label="lbl_label521502860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Hematology [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherHematologyMember" xlink:label="lbl_OtherHematologyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherHematologyMember" xlink:to="lbl_label521502860" xlink:type="arc"/>
      <link:label id="id_64919d1" xlink:label="lbl_label105454033" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Solid Tumor [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherSolidTumorMember" xlink:label="lbl_OtherSolidTumorMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherSolidTumorMember" xlink:to="lbl_label105454033" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsAxis" xlink:label="lbl_BrandsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BrandsAxis" xlink:to="lbl_label436427658" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PromotedBrandsMember" xlink:label="lbl_PromotedBrandsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PromotedBrandsMember" xlink:to="lbl_label1796441721" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstablishedBrandsMember" xlink:label="lbl_EstablishedBrandsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstablishedBrandsMember" xlink:to="lbl_label478863426" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImmunologyMember" xlink:label="lbl_ImmunologyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ImmunologyMember" xlink:to="lbl_label359821329" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CardiovascularMember" xlink:label="lbl_CardiovascularMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CardiovascularMember" xlink:to="lbl_label1134680816" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsMember" xlink:label="lbl_BrandsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_BrandsMember" xlink:to="lbl_label2113824083" xlink:type="arc"/>
      <link:label id="id_5fe8e377" xlink:label="lbl_DeferredSalePriceAndOtherAdjustments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred sale price and other adjustments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredSalePriceAndOtherAdjustments" xlink:label="lbl_DeferredSalePriceAndOtherAdjustments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DeferredSalePriceAndOtherAdjustments" xlink:to="lbl_DeferredSalePriceAndOtherAdjustments_labels" xlink:type="arc"/>
      <link:label id="id_53b25b83" xlink:label="lbl_DeferredSalePriceAndOtherAdjustments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_1_Divested business</link:label>
      <link:label id="id_7788c9c4" xlink:label="lbl_label2005453252" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated financial effect of contingent liabilities, compensation for moral damages</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" xlink:to="lbl_label2005453252" xlink:type="arc"/>
      <link:label id="id_5bea283f" xlink:label="lbl_OtherNetCashInflowsFromDivestments_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other net cash inflows from divestments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherNetCashInflowsFromDivestments" xlink:label="lbl_OtherNetCashInflowsFromDivestments" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherNetCashInflowsFromDivestments" xlink:to="lbl_OtherNetCashInflowsFromDivestments_labels" xlink:type="arc"/>
      <link:label id="id_9e5f36a" xlink:label="lbl_OtherNetCashInflowsFromDivestments_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_2_Divested business</link:label>
      <link:label id="id_624a7149" xlink:label="lbl_CashOutflowsDueToDerecognizedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflows due to derecognized cash and cash equivalents</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsDueToDerecognizedCashAndCashEquivalents" xlink:label="lbl_CashOutflowsDueToDerecognizedCashAndCashEquivalents" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOutflowsDueToDerecognizedCashAndCashEquivalents" xlink:to="lbl_CashOutflowsDueToDerecognizedCashAndCashEquivalents_labels" xlink:type="arc"/>
      <link:label id="id_7dadb6b8" xlink:label="lbl_CashOutflowsDueToDerecognizedCashAndCashEquivalents_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">dup_3_Divested business</link:label>
      <link:label id="id_365227bd" xlink:label="lbl_label911353789" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition of assets (other than through business combinations) by assuming directly related liabilities</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" xlink:label="lbl_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" xlink:to="lbl_label911353789" xlink:type="arc"/>
      <link:label id="id_7e67b1d4" xlink:label="lbl_label2120724948" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition of assets (right of use assets) through leasing</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" xlink:label="lbl_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" xlink:to="lbl_label2120724948" xlink:type="arc"/>
      <link:label id="id_5c839b8c" xlink:label="lbl_label1552128908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of commercial organizational units</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfCommercialOrganizationalUnits" xlink:label="lbl_NumberOfCommercialOrganizationalUnits" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NumberOfCommercialOrganizationalUnits" xlink:to="lbl_label1552128908" xlink:type="arc"/>
      <link:label id="id_12b75cc4" xlink:label="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of share value adjustments currency translation effects [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" xlink:label="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" xlink:to="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_19625a5a" xlink:label="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of share value adjustments currency translation effects</link:label>
      <link:label id="id_3214fdb5" xlink:label="lbl_label840236469" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Franchise [axis]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_label840236469" xlink:type="arc"/>
      <link:label id="id_6920b611" xlink:label="lbl_label1763751441" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Franchise [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_FranchiseMember" xlink:to="lbl_label1763751441" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:to="lbl_label1943173648" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_label1468995289" xlink:type="arc"/>
      <link:label id="id_4b05579c" xlink:label="lbl_label1258641308" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current and current liabilities divested</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentAndCurrentLiabilitiesDivested" xlink:label="lbl_NoncurrentAndCurrentLiabilitiesDivested" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NoncurrentAndCurrentLiabilitiesDivested" xlink:to="lbl_label1258641308" xlink:type="arc"/>
      <link:label id="id_423971d8" xlink:label="lbl_label1111060952" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net identifiable assets of divested business</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetIdentifiableAssetsOfDivestedBusiness" xlink:label="lbl_NetIdentifiableAssetsOfDivestedBusiness" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NetIdentifiableAssetsOfDivestedBusiness" xlink:to="lbl_label1111060952" xlink:type="arc"/>
      <link:label id="id_2ab1410a" xlink:label="lbl_OtherAdjustmentsForNoncashItems_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other adjustments for non-cash items</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAdjustmentsForNoncashItems" xlink:label="lbl_OtherAdjustmentsForNoncashItems" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherAdjustmentsForNoncashItems" xlink:to="lbl_OtherAdjustmentsForNoncashItems_labels" xlink:type="arc"/>
      <link:label id="id_4860e3bc" xlink:label="lbl_OtherAdjustmentsForNoncashItems_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
      <link:label id="id_7c4df0f8" xlink:label="lbl_AdditionalProvisionsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Additions to restructuring provisions</link:label>
      <link:label id="id_4eb8c0a5" xlink:label="lbl_label1320730789" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments, net sales [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsNetSalesTableTextBlock" xlink:to="lbl_label1320730789" xlink:type="arc"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DisclosureOfOperatingSegmentsNetSalesTableTextBlock" xlink:to="lbl_label1965771458" xlink:type="arc"/>
      <link:label id="id_3e695006" xlink:label="lbl_Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying value and remaining amortization period of the most significant assets within currently marketed products [text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock" xlink:label="lbl_Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock" xlink:to="lbl_Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_4e16bbbd" xlink:label="lbl_Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying value and remaining amortization period of the most significant assets within currently marketed products</link:label>
      <link:label id="id_301c3c1f" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated income statement due to increase (decrease) in interest rates [table text block]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock" xlink:to="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock_labels" xlink:type="arc"/>
      <link:label id="id_38a5c91d" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential impact on the consolidated income statement due to increase (decrease) in interest rates</link:label>
      <link:label id="id_38fcc081" xlink:label="lbl_label956088449" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency translation reserve for net investment hedge, net of taxes</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes" xlink:label="lbl_CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes" xlink:to="lbl_label956088449" xlink:type="arc"/>
      <link:label id="id_5d2c3af7" xlink:label="lbl_label1563179767" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease term end date</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseTermEndDate" xlink:label="lbl_LeaseTermEndDate" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_LeaseTermEndDate" xlink:to="lbl_label1563179767" xlink:type="arc"/>
      <link:label id="id_218619d0" xlink:label="lbl_label562436560" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hypothetical 100-basis point increase [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical100basisPointIncreaseMember" xlink:label="lbl_Hypothetical100basisPointIncreaseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Hypothetical100basisPointIncreaseMember" xlink:to="lbl_label562436560" xlink:type="arc"/>
      <link:label id="id_6fe554fc" xlink:label="lbl_label1877300476" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hypothetical 100-basis point decrease [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical100basisPointDecreaseMember" xlink:label="lbl_Hypothetical100basisPointDecreaseMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Hypothetical100basisPointDecreaseMember" xlink:to="lbl_label1877300476" xlink:type="arc"/>
      <link:label id="id_d62236b" xlink:label="lbl_InterestRateSensitivityImpactInTheIncomeStatement_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest rate sensitivity impact in the income statement</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestRateSensitivityImpactInTheIncomeStatement" xlink:label="lbl_InterestRateSensitivityImpactInTheIncomeStatement" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestRateSensitivityImpactInTheIncomeStatement" xlink:to="lbl_InterestRateSensitivityImpactInTheIncomeStatement_labels" xlink:type="arc"/>
      <link:label id="id_48b220e" xlink:label="lbl_label76227086" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hypothetical increase decrease basis point in interest rate sensitivity</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity" xlink:label="lbl_HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity" xlink:to="lbl_label76227086" xlink:type="arc"/>
      <link:label id="id_188250f1" xlink:label="lbl_IntangibleAssetsMaterialToEntity_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets material to entity</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsMaterialToEntity" xlink:label="lbl_IntangibleAssetsMaterialToEntity" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IntangibleAssetsMaterialToEntity" xlink:to="lbl_IntangibleAssetsMaterialToEntity_labels" xlink:type="arc"/>
      <link:label id="id_7df5095a" xlink:label="lbl_IntangibleAssetsMaterialToEntity_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying value</link:label>
      <link:label id="id_6daa6720" xlink:label="lbl_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining amortisation period of intangible assets material to entity</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:label="lbl_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:to="lbl_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_labels" xlink:type="arc"/>
      <link:label id="id_6b853f8c" xlink:label="lbl_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining amortisation period</link:label>
      <link:label id="id_2ceac042" xlink:label="lbl_AdditionalProvisionsOtherProvisions_labels" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Provisions for doubtful trade receivables charged to the consolidated income statement</link:label>
      <link:label id="id_52fdf5e3" xlink:label="lbl_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation other adjustments</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="lbl_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="lbl_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_labels" xlink:type="arc"/>
      <link:label id="id_420accaa" xlink:label="lbl_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other tax effects for reconciliation between accounting profit and tax expense (income)</link:label>
      <link:label id="id_7c633bc" xlink:label="lbl_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_4b13c9e9" xlink:label="lbl_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Experience-related remeasurement losses/(gains)</link:label>
      <link:label id="id_821dab6" xlink:label="lbl_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:to="lbl_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_45985738" xlink:label="lbl_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Return on plan assets excluding interest income</link:label>
      <link:label id="id_4d969c16" xlink:label="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on changes in effect of limiting net defined benefit asset to asset ceiling excluding interest income or expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:label="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:to="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling_labels" xlink:type="arc"/>
      <link:label id="id_7762e663" xlink:label="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in limitation on recognition of fund surplus</link:label>
      <link:label id="id_281010e4" xlink:label="lbl_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in net defined benefit liability (asset) resulting from administration costs not reflected in return on plan assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:label="lbl_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:to="lbl_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets_labels" xlink:type="arc"/>
      <link:label id="id_1e65e677" xlink:label="lbl_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Administrative expenses</link:label>
      <link:label id="id_57c0f5b" xlink:label="lbl_EmployeeBenefitsExpense_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee benefits expense</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="lbl_EmployeeBenefitsExpense" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EmployeeBenefitsExpense" xlink:to="lbl_EmployeeBenefitsExpense_labels" xlink:type="arc"/>
      <link:label id="id_7284cb4" xlink:label="lbl_EmployeeBenefitsExpense_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Personnel costs</link:label>
      <link:label id="id_6c89a7d6" xlink:label="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Participation Employee share purchase plan [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:label="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:to="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember_labels" xlink:type="arc"/>
      <link:label id="id_55a47bda" xlink:label="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share purchase plans</link:label>
      <link:label id="id_374e200" xlink:label="lbl_label57991680" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Gene Therapies France S.A.S., Rueil-Malmaison [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember" xlink:label="lbl_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember" xlink:to="lbl_label57991680" xlink:type="arc"/>
      <link:label id="id_4d21bf40" xlink:label="lbl_label1294057280" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advanced Accelerator Applications Molecular Imaging France, Saint Genis Pouilly [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember" xlink:label="lbl_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember" xlink:to="lbl_label1294057280" xlink:type="arc"/>
      <link:label id="id_7529fd98" xlink:label="lbl_InterestIncomeOnLimitationOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income on limitation of fund surplus</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestIncomeOnLimitationOfFundSurplus" xlink:label="lbl_InterestIncomeOnLimitationOfFundSurplus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestIncomeOnLimitationOfFundSurplus" xlink:to="lbl_InterestIncomeOnLimitationOfFundSurplus_labels" xlink:type="arc"/>
      <link:label id="id_1cdaf114" xlink:label="lbl_InterestIncomeOnLimitationOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income on limitation of fund surplus</link:label>
      <link:label id="id_39b2fbdf" xlink:label="lbl_InterestIncomeOnLimitationOfFundSurplus_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest income on limitation of fund surplus</link:label>
      <link:label id="id_1ca9d034" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase/Decrease through changes in foreign exchange rates fund surplus</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus_labels" xlink:type="arc"/>
      <link:label id="id_38e9ba3f" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_22acd556" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus_labels" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Currency translation effects</link:label>
      <link:label id="id_4738c409" xlink:label="lbl_ValueAdjustmentsRelatedToDivestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value adjustments related to divestments [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueAdjustmentsRelatedToDivestmentsMember" xlink:label="lbl_ValueAdjustmentsRelatedToDivestmentsMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_ValueAdjustmentsRelatedToDivestmentsMember" xlink:to="lbl_ValueAdjustmentsRelatedToDivestmentsMember_labels" xlink:type="arc"/>
      <link:label id="id_357ac9f9" xlink:label="lbl_ValueAdjustmentsRelatedToDivestmentsMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value adjustments related to divestments</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaS.p.A.MilanMember" xlink:label="lbl_NovartisFarmaS.p.A.MilanMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisFarmaS.p.A.MilanMember" xlink:to="lbl_label1462262242" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember" xlink:label="lbl_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember" xlink:to="lbl_label1230664587" xlink:type="arc"/>
      <link:label id="id_47bdaceb" xlink:label="lbl_label1203612907" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gyroscope Therapeutics Limited, London [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GyroscopeTherapeuticsLimitedLondonMember" xlink:label="lbl_GyroscopeTherapeuticsLimitedLondonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_GyroscopeTherapeuticsLimitedLondonMember" xlink:to="lbl_label1203612907" xlink:type="arc"/>
      <link:label id="id_8a9c069" xlink:label="lbl_label145342569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment of interest bearing accounts to beneficiaries</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PaymentOfInterestBearingAccountsToBeneficiaries" xlink:label="lbl_PaymentOfInterestBearingAccountsToBeneficiaries" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_PaymentOfInterestBearingAccountsToBeneficiaries" xlink:to="lbl_label145342569" xlink:type="arc"/>
      <link:label id="id_2c032f3e" xlink:label="lbl_label738406206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflows from interest bearing accounts of employees payable on demand</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" xlink:label="lbl_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" xlink:to="lbl_label738406206" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JSCSandozMoscowMember" xlink:label="lbl_JSCSandozMoscowMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_JSCSandozMoscowMember" xlink:to="lbl_label1334583359" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozSouthAfricaPtyLtdMidrandMember" xlink:label="lbl_SandozSouthAfricaPtyLtdMidrandMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozSouthAfricaPtyLtdMidrandMember" xlink:to="lbl_label1154403316" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember" xlink:label="lbl_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember" xlink:to="lbl_label1468897070" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CellerysAGSchlierenMember" xlink:label="lbl_CellerysAGSchlierenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_CellerysAGSchlierenMember" xlink:to="lbl_label371137698" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGeneTherapiesInc.BannockburnILMember" xlink:label="lbl_NovartisGeneTherapiesInc.BannockburnILMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisGeneTherapiesInc.BannockburnILMember" xlink:to="lbl_label643362133" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInnovativeTherapiesAGRischMember" xlink:label="lbl_NovartisInnovativeTherapiesAGRischMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_NovartisInnovativeTherapiesAGRischMember" xlink:to="lbl_label949145726" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember" xlink:label="lbl_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember" xlink:to="lbl_label56155667" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1APharmaGmbHHolzkirchenMember" xlink:label="lbl_A1APharmaGmbHHolzkirchenMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_A1APharmaGmbHHolzkirchenMember" xlink:to="lbl_label1515846566" xlink:type="arc"/>
      <link:label id="id_4655e166" xlink:label="lbl_label1410133910" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest cost</link:label>
      <link:label id="id_7cb5c64" xlink:label="lbl_label345068222" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Administrative expenses</link:label>
      <link:label id="id_6bca1932" xlink:label="lbl_label1064847955" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
      <link:label id="id_447ba916" xlink:label="lbl_DefinedBenefitPlanInterestCost_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined benefit plan, interest cost</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanInterestCost" xlink:label="lbl_DefinedBenefitPlanInterestCost" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanInterestCost" xlink:to="lbl_DefinedBenefitPlanInterestCost_labels" xlink:type="arc"/>
      <link:label id="id_5799a148" xlink:label="lbl_DefinedBenefitPlanInterestCost_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase in a defined benefit pension plan's projected benefit obligation or a defined benefit postretirement plan's accumulated postretirement benefit obligation due to the passage of time.</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DefinedBenefitPlanInterestCost" xlink:to="lbl_label1410133910" xlink:type="arc"/>
      <link:label id="id_469b45e" xlink:label="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Administration costs not reflected in return on plan assets, defined benefit plans</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:label="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:to="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_181c98c6" xlink:label="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Administrative expenses</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:to="lbl_label345068222" xlink:type="arc"/>
      <link:label id="id_1115ed8d" xlink:label="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income, defined benefit plans</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:label="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:to="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset_labels" xlink:type="arc"/>
      <link:label id="id_1749266f" xlink:label="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:to="lbl_label1064847955" xlink:type="arc"/>
      <link:label id="id_60426bce" xlink:label="lbl_AmericanDepositarySharesEachRepresenting1ShareMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">American Depositary Shares each representing 1 share [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmericanDepositarySharesEachRepresenting1ShareMember" xlink:label="lbl_AmericanDepositarySharesEachRepresenting1ShareMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_AmericanDepositarySharesEachRepresenting1ShareMember" xlink:to="lbl_AmericanDepositarySharesEachRepresenting1ShareMember_labels" xlink:type="arc"/>
      <link:label id="id_12cd80ee" xlink:label="lbl_AmericanDepositarySharesEachRepresenting1ShareMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">American Depositary Shares each representing 1 share</link:label>
      <link:label id="id_7ca4bc9d" xlink:label="lbl_OrdinarySharesNominalValueCHF0.50PerShareMember_labels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares, nominal value CHF 0.50 per share [member]</link:label>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OrdinarySharesNominalValueCHF0.50PerShareMember" xlink:label="lbl_OrdinarySharesNominalValueCHF0.50PerShareMember" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_OrdinarySharesNominalValueCHF0.50PerShareMember" xlink:to="lbl_OrdinarySharesNominalValueCHF0.50PerShareMember_labels" xlink:type="arc"/>
      <link:label id="id_6d66b543" xlink:label="lbl_OrdinarySharesNominalValueCHF0.50PerShareMember_labels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, nominal value CHF 0.50 per share*</link:label>
      <link:label id="id_49b6063d" xlink:label="lbl_label1236665917" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="lbl_Security12bTitle" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_Security12bTitle" xlink:to="lbl_label1236665917" xlink:type="arc"/>
      <link:label id="id_385a1eff" xlink:label="lbl_label945430271" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="lbl_SecurityExchangeName" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_SecurityExchangeName" xlink:to="lbl_label945430271" xlink:type="arc"/>
      <link:label id="id_4d772ce7" xlink:label="lbl_InterestRateSensitivityImpactInTheIncomeStatement_labels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.</link:label>
      <link:label id="id_3875ffaa" xlink:label="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments_labels" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Non-current financial assets, total financial investments</link:label>
      <link:label id="id_78a9e94a" xlink:label="lbl_label2024401226" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of reasons for transfers out of Level 3 of fair value hierarchy, assets</link:label>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="lbl_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:labelArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbl_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:to="lbl_label2024401226" xlink:type="arc"/>
   </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>nvs-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6" xlink:href="nvs-20221231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssetsDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails17" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails" xlink:href="nvs-20221231.xsd#disclosureAcquisitionsOfBusinessesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="nvs-20221231.xsd#disclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2" xlink:href="nvs-20221231.xsd#disclosureSignificantTransactionsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails" xlink:href="nvs-20221231.xsd#disclosureSignificantTransactionsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables" xlink:href="nvs-20221231.xsd#disclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="nvs-20221231.xsd#disclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesTables" xlink:href="nvs-20221231.xsd#disclosureTransactionsWithRelatedPartiesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesTables" xlink:href="nvs-20221231.xsd#disclosureAcquisitionsOfBusinessesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables" xlink:href="nvs-20221231.xsd#disclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityTables" xlink:href="nvs-20221231.xsd#disclosureEquityTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsTables" xlink:href="nvs-20221231.xsd#disclosureOtherCurrentAssetsTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesTables" xlink:href="nvs-20221231.xsd#disclosureMarketableSecuritiesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesTables" xlink:href="nvs-20221231.xsd#disclosureTradeReceivablesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureInventoriesTables" xlink:href="nvs-20221231.xsd#disclosureInventoriesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables" xlink:href="nvs-20221231.xsd#disclosureFinancialAndOtherNoncurrentAssetsTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables" xlink:href="nvs-20221231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssetsTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables" xlink:href="nvs-20221231.xsd#disclosureRightOfUseAssetsAndLeaseLiabilityTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentTables" xlink:href="nvs-20221231.xsd#disclosurePropertyPlantAndEquipmentTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables" xlink:href="nvs-20221231.xsd#disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEarningsPerShareTables" xlink:href="nvs-20221231.xsd#disclosureEarningsPerShareTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTaxesTables" xlink:href="nvs-20221231.xsd#disclosureTaxesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables" xlink:href="nvs-20221231.xsd#disclosureInterestExpenseAndOtherFinancialIncomeExpenseTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables" xlink:href="nvs-20221231.xsd#disclosureAssociatedCompaniesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsTables" xlink:href="nvs-20221231.xsd#disclosureSignificantTransactionsTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="nvs-20221231.xsd#disclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompanies" xlink:href="nvs-20221231.xsd#disclosurePrincipalGroupSubsidiariesAndAssociatedCompanies" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSubsequentEvents" xlink:href="nvs-20221231.xsd#disclosureSubsequentEvents" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosures" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosures" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingencies" xlink:href="nvs-20221231.xsd#disclosureCommitmentsAndContingencies" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedParties" xlink:href="nvs-20221231.xsd#disclosureTransactionsWithRelatedParties" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociates" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociates" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociates" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociates" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinesses" xlink:href="nvs-20221231.xsd#disclosureAcquisitionsOfBusinesses" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatements" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatements" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilities" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherCurrentLiabilities" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstruments" xlink:href="nvs-20221231.xsd#disclosureCurrentFinancialDebtAndDerivativeFinancialInstruments" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilities" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilities" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebt" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebt" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquity" xlink:href="nvs-20221231.xsd#disclosureEquity" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureOtherCurrentAssets" xlink:href="nvs-20221231.xsd#disclosureOtherCurrentAssets" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureMarketableSecurities" xlink:href="nvs-20221231.xsd#disclosureMarketableSecurities" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivables" xlink:href="nvs-20221231.xsd#disclosureTradeReceivables" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureInventories" xlink:href="nvs-20221231.xsd#disclosureInventories" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssets" xlink:href="nvs-20221231.xsd#disclosureFinancialAndOtherNoncurrentAssets" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilities" xlink:href="nvs-20221231.xsd#disclosureDeferredTaxAssetsAndLiabilities" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssets" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssets" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiability" xlink:href="nvs-20221231.xsd#disclosureRightOfUseAssetsAndLeaseLiability" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipment" xlink:href="nvs-20221231.xsd#disclosurePropertyPlantAndEquipment" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncome" xlink:href="nvs-20221231.xsd#disclosureChangesInConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEarningsPerShare" xlink:href="nvs-20221231.xsd#disclosureEarningsPerShare" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTaxes" xlink:href="nvs-20221231.xsd#disclosureTaxes" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpense" xlink:href="nvs-20221231.xsd#disclosureInterestExpenseAndOtherFinancialIncomeExpense" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompanies" xlink:href="nvs-20221231.xsd#disclosureAssociatedCompanies" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactions" xlink:href="nvs-20221231.xsd#disclosureSignificantTransactions" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFigures" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFigures" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="nvs-20221231.xsd#disclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails16" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails15" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails3" xlink:href="nvs-20221231.xsd#disclosureMarketableSecuritiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4" xlink:href="nvs-20221231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails3" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails4" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails7" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2" xlink:href="nvs-20221231.xsd#disclosurePropertyPlantAndEquipmentDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails2" xlink:href="nvs-20221231.xsd#disclosureSubsequentEventsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails" xlink:href="nvs-20221231.xsd#disclosureSignificantAccountingPoliciesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5" xlink:href="nvs-20221231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4" xlink:href="nvs-20221231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3" xlink:href="nvs-20221231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2" xlink:href="nvs-20221231.xsd#disclosureLeaseLiabilityAndRightOfUseAssetsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails1" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails12" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails11" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails14" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails10" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1" xlink:href="nvs-20221231.xsd#disclosureTransactionsWithRelatedPartiesDetails1_1df9063b" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails13" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails12" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5" xlink:href="nvs-20221231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails11" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails10" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails9" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails7" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5" xlink:href="nvs-20221231.xsd#disclosureFinancialInstrumentsAdditionalDisclosuresDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails5" xlink:href="nvs-20221231.xsd#disclosureEquityDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails7" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails4" xlink:href="nvs-20221231.xsd#disclosureEquityDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails3" xlink:href="nvs-20221231.xsd#disclosureEquityDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails2" xlink:href="nvs-20221231.xsd#disclosureEquityDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails" xlink:href="nvs-20221231.xsd#disclosureEquityDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6" xlink:href="nvs-20221231.xsd#disclosureAssociatedCompaniesDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3" xlink:href="nvs-20221231.xsd#disclosureAssociatedCompaniesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails" xlink:href="nvs-20221231.xsd#disclosureAssociatedCompaniesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails" xlink:href="nvs-20221231.xsd#disclosureSegmentationOfKeyFiguresDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails" xlink:href="nvs-20221231.xsd#disclosureEquityBasedParticipationPlansForAssociatesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssetsDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssetsDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssetsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails" xlink:href="nvs-20221231.xsd#disclosureGoodwillAndIntangibleAssetsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails3" xlink:href="nvs-20221231.xsd#disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:href="nvs-20221231.xsd#disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3" xlink:href="nvs-20221231.xsd#disclosureTransactionsWithRelatedPartiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2" xlink:href="nvs-20221231.xsd#disclosureTransactionsWithRelatedPartiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails" xlink:href="nvs-20221231.xsd#disclosureDetailsConsolidatedCashFlowStatementsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails9" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails10" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails8" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails7" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails" xlink:href="nvs-20221231.xsd#disclosurePostEmploymentBenefitsForAssociatesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails" xlink:href="nvs-20221231.xsd#disclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4" xlink:href="nvs-20221231.xsd#disclosureTradeReceivablesDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3" xlink:href="nvs-20221231.xsd#disclosureTradeReceivablesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2" xlink:href="nvs-20221231.xsd#disclosureTradeReceivablesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails" xlink:href="nvs-20221231.xsd#disclosureTradeReceivablesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherCurrentLiabilitiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2" xlink:href="nvs-20221231.xsd#disclosureProvisionsAndOtherCurrentLiabilitiesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementOfChangesInEquity" xlink:href="nvs-20221231.xsd#statementOfChangesInEquity" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementsOfCashFlow" xlink:href="nvs-20221231.xsd#statementsOfCashFlow" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementOfComprehensiveIncome" xlink:href="nvs-20221231.xsd#statementOfComprehensiveIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails5" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails6" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails6" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails4" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails" xlink:href="nvs-20221231.xsd#disclosureNonCurrentFinancialDebtDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:href="nvs-20221231.xsd#disclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:href="nvs-20221231.xsd#disclosureCommitmentsAndContingenciesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails" xlink:href="nvs-20221231.xsd#disclosureCommitmentsAndContingenciesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails" xlink:href="nvs-20221231.xsd#disclosureSubsequentEventsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/StatementOfIncome" xlink:href="nvs-20221231.xsd#statementOfIncome" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2" xlink:href="nvs-20221231.xsd#disclosureFinancialAndOtherNoncurrentAssetsDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails" xlink:href="nvs-20221231.xsd#disclosureFinancialAndOtherNoncurrentAssetsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails" xlink:href="nvs-20221231.xsd#disclosureMarketableSecuritiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails" xlink:href="nvs-20221231.xsd#disclosureOtherCurrentAssetsDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3" xlink:href="nvs-20221231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="nvs-20221231.xsd#disclosureDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTaxesDetails3" xlink:href="nvs-20221231.xsd#disclosureTaxesDetails3" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTaxesDetails2" xlink:href="nvs-20221231.xsd#disclosureTaxesDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureTaxesDetails" xlink:href="nvs-20221231.xsd#disclosureTaxesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2" xlink:href="nvs-20221231.xsd#disclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails" xlink:href="nvs-20221231.xsd#disclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails" xlink:href="nvs-20221231.xsd#disclosureEarningsPerShareDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosureInventoriesDetails" xlink:href="nvs-20221231.xsd#disclosureInventoriesDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails" xlink:href="nvs-20221231.xsd#disclosurePropertyPlantAndEquipmentDetails" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/BalanceSheet" xlink:href="nvs-20221231.xsd#balanceSheet" xlink:type="simple"/>
   <link:roleRef roleURI="http://novartis.com/20221231/role/DocumentAndEntityInformation" xlink:href="nvs-20221231.xsd#documentAndEntityInformation" xlink:type="simple"/>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DocumentAndEntityInformation" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="lbl_DocumentInformationTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DocumentAndEntityInformationAbstract" xlink:label="lbl_DocumentAndEntityInformationAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentAndEntityInformationAbstract" xlink:to="lbl_DocumentInformationTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="lbl_DocumentInformationLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="lbl_DocumentType" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentType" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="lbl_AmendmentFlag" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_AmendmentFlag" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="lbl_DocumentFiscalPeriodFocus" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentFiscalPeriodFocus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="lbl_EntityCentralIndexKey" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCentralIndexKey" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="lbl_EntityCurrentReportingStatus" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCurrentReportingStatus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="lbl_EntityPublicFloat" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityPublicFloat" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="lbl_DocumentPeriodEndDate" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentPeriodEndDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="lbl_DocumentFiscalYearFocus" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentFiscalYearFocus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="lbl_TradingSymbol" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="lbl_EntityRegistrantName" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityRegistrantName" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="lbl_CurrentFiscalYearEndDate" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_CurrentFiscalYearEndDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="lbl_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="lbl_EntityVoluntaryFilers" xlink:type="locator"/>
      <link:presentationArc order="9.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityVoluntaryFilers" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="lbl_EntityFilerCategory" xlink:type="locator"/>
      <link:presentationArc order="9.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityFilerCategory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="lbl_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
      <link:presentationArc order="9.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="lbl_DocumentAnnualReport" xlink:type="locator"/>
      <link:presentationArc order="2.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentAnnualReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="lbl_EntityShellCompany" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityShellCompany" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="lbl_EntityEmergingGrowthCompany" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityEmergingGrowthCompany" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="lbl_EntityInteractiveDataCurrent" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityInteractiveDataCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="lbl_DocumentTransitionReport" xlink:type="locator"/>
      <link:presentationArc order="2.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentTransitionReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="lbl_DocumentShellCompanyReport" xlink:type="locator"/>
      <link:presentationArc order="2.4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentShellCompanyReport" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="lbl_IcfrAuditorAttestationFlag" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_IcfrAuditorAttestationFlag" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="lbl_AuditorName" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_AuditorName" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="lbl_AuditorLocation" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_AuditorLocation" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="lbl_AuditorFirmId" xlink:type="locator"/>
      <link:presentationArc order="17.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_AuditorFirmId" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="lbl_EntityFileNumber" xlink:type="locator"/>
      <link:presentationArc order="18.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityFileNumber" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="lbl_EntityIncorporationStateCountryCode" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityIncorporationStateCountryCode" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="lbl_EntityAddressAddressLine1" xlink:type="locator"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityAddressAddressLine1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="lbl_EntityAddressCityOrTown" xlink:type="locator"/>
      <link:presentationArc order="21.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityAddressCityOrTown" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="lbl_EntityAddressPostalZipCode" xlink:type="locator"/>
      <link:presentationArc order="22.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityAddressPostalZipCode" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="lbl_EntityAddressCountry" xlink:type="locator"/>
      <link:presentationArc order="23.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_EntityAddressCountry" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="lbl_DocumentRegistrationStatement" xlink:type="locator"/>
      <link:presentationArc order="24.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentRegistrationStatement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="lbl_DocumentAccountingStandard" xlink:type="locator"/>
      <link:presentationArc order="25.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_DocumentAccountingStandard" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="lbl_ContactPersonnelName" xlink:type="locator"/>
      <link:presentationArc order="26.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_ContactPersonnelName" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="lbl_EntityAddressesAddressTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationTable" xlink:to="lbl_EntityAddressesAddressTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="lbl_AddressTypeDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityAddressesAddressTypeAxis" xlink:to="lbl_AddressTypeDomain" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="lbl_BusinessContactMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AddressTypeDomain" xlink:to="lbl_BusinessContactMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="lbl_LocalPhoneNumber" xlink:type="locator"/>
      <link:presentationArc order="27.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_LocalPhoneNumber" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelFaxNumber" xlink:label="lbl_ContactPersonnelFaxNumber" xlink:type="locator"/>
      <link:presentationArc order="28.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_ContactPersonnelFaxNumber" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="lbl_CountryRegion" xlink:type="locator"/>
      <link:presentationArc order="26.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_CountryRegion" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="lbl_CityAreaCode" xlink:type="locator"/>
      <link:presentationArc order="26.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_CityAreaCode" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="lbl_ClassesOfShareCapitalAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationTable" xlink:to="lbl_ClassesOfShareCapitalAxis" xlink:type="arc"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationTable" xlink:to="lbl_DocumentInformationLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="lbl_ClassesOfShareCapitalMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfShareCapitalAxis" xlink:to="lbl_ClassesOfShareCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmericanDepositarySharesEachRepresenting1ShareMember" xlink:label="lbl_AmericanDepositarySharesEachRepresenting1ShareMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_AmericanDepositarySharesEachRepresenting1ShareMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OrdinarySharesNominalValueCHF0.50PerShareMember" xlink:label="lbl_OrdinarySharesNominalValueCHF0.50PerShareMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_OrdinarySharesNominalValueCHF0.50PerShareMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="lbl_Security12bTitle" xlink:type="locator"/>
      <link:presentationArc order="29.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_Security12bTitle" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="lbl_DocumentInformationLineItems1" xlink:type="locator"/>
      <link:presentationArc order="30.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems1" xlink:to="lbl_TradingSymbol" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="lbl_SecurityExchangeName" xlink:type="locator"/>
      <link:presentationArc order="31.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DocumentInformationLineItems" xlink:to="lbl_SecurityExchangeName" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/BalanceSheet" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="lbl_AssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="lbl_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="lbl_NoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_NoncurrentAssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="lbl_NoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_NoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="lbl_CurrentAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_CurrentAssetsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="lbl_CurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAbstract" xlink:to="lbl_Assets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="lbl_EquityAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract" xlink:label="lbl_EquityAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_EquityAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves" xlink:label="lbl_OtherReserves" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_OtherReserves" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="lbl_LiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_LiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="lbl_NoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_NoncurrentLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="lbl_NoncurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_NoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="lbl_CurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_CurrentLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentTaxLiabilitiesCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="lbl_CurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesAbstract" xlink:to="lbl_Liabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="lbl_EquityAndLiabilities" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAndLiabilitiesAbstract" xlink:to="lbl_EquityAndLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Goodwill" xlink:label="lbl_Goodwill" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_Goodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="lbl_EquityAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_EquityAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterests" xlink:label="lbl_NoncontrollingInterests" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_NoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="lbl_NoncurrentFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="7.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfFinancialPositionAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AssetsAbstract" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EquityAndLiabilitiesAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="5.3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_OtherCurrentNonfinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="8.8" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_OtherNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="lbl_OtherCurrentFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="3.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_OtherCurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAbstract" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:presentationArc order="2.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:presentationArc order="5.9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="4.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="5.92" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentAssetsAbstract" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="lbl_NoncurrentLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_NoncurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:label="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="4.6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentLiabilitiesAbstract" xlink:to="lbl_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="lbl_CurrentTaxAssetsCurrent" xlink:type="locator"/>
      <link:presentationArc order="2.9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentAssetsAbstract" xlink:to="lbl_CurrentTaxAssetsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_NoncurrentLiabilitiesAbstract" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LandMember" xlink:label="lbl_LandMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_LandMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember" xlink:label="lbl_BuildingsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_BuildingsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MachineryMember" xlink:label="lbl_MachineryMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_MachineryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="lbl_ConstructionInProgressMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PropertyPlantAndEquipmentMember" xlink:to="lbl_ConstructionInProgressMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:label="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:label="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:label="lbl_MovementsOfPropertyPlantAndEquipmentRollForward1" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward1" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:label="lbl_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:label="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingCostsCapitalised" xlink:label="lbl_BorrowingCostsCapitalised" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_BorrowingCostsCapitalised" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="9.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:label="lbl_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="13.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:label="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_DepreciationChargePriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:label="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DisposalsAndRetirementsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:label="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_ImpairmentChargePriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:label="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.15" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="7.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfPropertyPlantAndEquipmentRollForward" xlink:to="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureInventoriesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryCurrentTable" xlink:label="lbl_InventoryCurrentTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoriesDisclosureAbstract" xlink:label="lbl_InventoriesDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoriesDisclosureAbstract" xlink:to="lbl_InventoryCurrentTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryAxis" xlink:label="lbl_InventoryAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryCurrentTable" xlink:to="lbl_InventoryAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryMember" xlink:label="lbl_InventoryMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryRawMaterialsGrossMember" xlink:label="lbl_InventoryRawMaterialsGrossMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryMember" xlink:to="lbl_InventoryRawMaterialsGrossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryWorkInProgressGrossMember" xlink:label="lbl_InventoryWorkInProgressGrossMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryMember" xlink:to="lbl_InventoryWorkInProgressGrossMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryMember" xlink:to="lbl_InventoryFinishedGoodsGrossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryFinishedGoodsGrossMember" xlink:label="lbl_InventoryFinishedGoodsGrossMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoryLineItems" xlink:label="lbl_InventoryLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryCurrentTable" xlink:to="lbl_InventoryLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfInventoryWritedown" xlink:label="lbl_ReversalOfInventoryWritedown" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_ReversalOfInventoryWritedown" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryAxis" xlink:to="lbl_InventoryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:label="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_CostOfInventoriesRecognisedAsExpenseDuringPeriod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories" xlink:label="lbl_Inventories" xlink:type="locator"/>
      <link:presentationArc order="0.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_Inventories" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoryWritedown2011" xlink:label="lbl_InventoryWritedown2011" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoryLineItems" xlink:to="lbl_InventoryWritedown2011" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareTable" xlink:label="lbl_EarningsPerShareTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="lbl_EarningsPerShareAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareAbstract" xlink:to="lbl_EarningsPerShareTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareLineItems" xlink:label="lbl_EarningsPerShareLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareTable" xlink:to="lbl_EarningsPerShareLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares" xlink:label="lbl_WeightedAverageShares" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_WeightedAverageShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:label="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="lbl_AdjustedWeightedAverageShares" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_AdjustedWeightedAverageShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_BasicEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_BasicEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="lbl_BasicEarningsLossPerShare" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_BasicEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutedEarningsLossPerShareFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="lbl_DilutedEarningsLossPerShare" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutedEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:label="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_DilutedEarningsLossPerShareFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OptionsExcludedFromTheCalculation" xlink:label="lbl_OptionsExcludedFromTheCalculation" xlink:type="locator"/>
      <link:presentationArc order="10.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareLineItems" xlink:to="lbl_OptionsExcludedFromTheCalculation" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExpenseAbstract" xlink:label="lbl_InterestExpenseAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InterestExpenseAbstract" xlink:to="lbl_ExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InterestExpenseAbstract" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:label="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InterestExpenseAbstract" xlink:to="lbl_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InterestExpenseAbstract" xlink:to="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialIncomeAndExpenseAbstract" xlink:label="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeOnForwardContractsAndOptions" xlink:label="lbl_IncomeOnForwardContractsAndOptions" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_IncomeOnForwardContractsAndOptions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnNetMonetaryPosition" xlink:label="lbl_GainsLossesOnNetMonetaryPosition" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_GainsLossesOnNetMonetaryPosition" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets" xlink:label="lbl_GainsLossesOnAvailableforsaleFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_GainsLossesOnAvailableforsaleFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromInterest" xlink:label="lbl_RevenueFromInterest" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_RevenueFromInterest" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromDividends" xlink:label="lbl_RevenueFromDividends" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_RevenueFromDividends" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:label="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:type="locator"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceCost" xlink:label="lbl_OtherFinanceCost" xlink:type="locator"/>
      <link:presentationArc order="7.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_OtherFinanceCost" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTaxesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="lbl_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccountingProfit" xlink:label="lbl_AccountingProfit" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AccountingProfit" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTaxesDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="lbl_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="lbl_CurrentTaxExpenseIncome" xlink:type="locator"/>
      <link:presentationArc order="1.55" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentTaxExpenseIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeTaxExpense" xlink:label="lbl_IncomeTaxExpense" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="lbl_DeferredTaxExpenseIncome" xlink:type="locator"/>
      <link:presentationArc order="1.65" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxExpenseIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxExpenseIncomeDiscontinuingOperations" xlink:label="lbl_TaxExpenseIncomeDiscontinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="1.8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxExpenseIncomeDiscontinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTaxesDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract" xlink:label="lbl_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ApplicableTaxRate" xlink:label="lbl_ApplicableTaxRate" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ApplicableTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectOfCreditsAndAllowances" xlink:label="lbl_TaxRateEffectOfCreditsAndAllowances" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfCreditsAndAllowances" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:label="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectFromBenefitsExpiring" xlink:label="lbl_TaxRateEffectFromBenefitsExpiring" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromBenefitsExpiring" xlink:type="arc"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageEffectiveTaxRateContinuingOperations" xlink:label="lbl_AverageEffectiveTaxRateContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AverageEffectiveTaxRateContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageEffectiveTaxRateDiscontinuedOperations" xlink:label="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AverageEffectiveTaxRateDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss1" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfTaxLosses" xlink:label="lbl_TaxRateEffectOfTaxLosses1" xlink:type="locator"/>
      <link:presentationArc order="3.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfTaxLosses1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectFromChangeInTaxRate" xlink:label="lbl_TaxRateEffectFromChangeInTaxRate" xlink:type="locator"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectFromChangeInTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="lbl_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
      <link:presentationArc order="18.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:label="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:type="locator"/>
      <link:presentationArc order="4.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfIncomeTaxedAtReducedRates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:label="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:type="locator"/>
      <link:presentationArc order="5.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfReleaseOfContingentConsiderationLiability" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxRateEffectFromNondeductibleLossesInRegion" xlink:label="lbl_TaxRateEffectFromNondeductibleLossesInRegion" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:label="lbl_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:label="lbl_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:type="locator"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:label="lbl_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:type="locator"/>
      <link:presentationArc order="4.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxRateEffectOfRevenuesExemptFromTaxation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:label="lbl_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:type="locator"/>
      <link:presentationArc order="19.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfUSTaxReformLegislation" xlink:label="lbl_EffectOfUSTaxReformLegislation" xlink:type="locator"/>
      <link:presentationArc order="19.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfUSTaxReformLegislation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfWriteoffOfDeferredTaxAssets" xlink:label="lbl_EffectOfWriteoffOfDeferredTaxAssets" xlink:type="locator"/>
      <link:presentationArc order="7.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfWriteoffOfDeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageEffectiveTaxRate" xlink:label="lbl_AverageEffectiveTaxRate" xlink:type="locator"/>
      <link:presentationArc order="17.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AverageEffectiveTaxRate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="locator"/>
      <link:presentationArc order="17.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:label="lbl_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_PensionsAndOtherBenefitObligationsOfAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoriesMember" xlink:label="lbl_InventoriesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_InventoriesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxLossCarryforwardsMember" xlink:label="lbl_TaxLossCarryforwardsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_TaxLossCarryforwardsMember" xlink:type="arc"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_OtherAssetsProvisionsAccrualsMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="lbl_DeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementInDeferredTaxBalanceRollForward" xlink:label="lbl_MovementInDeferredTaxBalanceRollForward" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_MovementInDeferredTaxBalanceRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:label="lbl_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssets" xlink:label="lbl_DeferredTaxAssets" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="lbl_DeferredTaxLiabilities" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherAssetsProvisionsAccrualsMember" xlink:label="lbl_OtherAssetsProvisionsAccrualsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementInDeferredTaxBalanceRollForward" xlink:label="lbl_MovementInDeferredTaxBalanceRollForward1" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward1" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:presentationArc order="0.5" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="1.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:label="lbl_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="1.1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems1" xlink:type="locator"/>
      <link:presentationArc order="2.6" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems1" xlink:to="lbl_DeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossDeferredTaxAssets" xlink:label="lbl_GrossDeferredTaxAssets" xlink:type="locator"/>
      <link:presentationArc order="2.55" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossDeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossDeferredTaxLiabilities" xlink:label="lbl_GrossDeferredTaxLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.75" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossDeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementInDeferredTaxBalanceRollForward" xlink:to="lbl_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:presentationArc order="2.8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems1" xlink:to="lbl_DeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_RestatedValueAdjustmentsMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember" xlink:label="lbl_IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract" xlink:to="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetTreatmentAxis" xlink:label="lbl_BalanceSheetTreatmentAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lbl_BalanceSheetTreatmentAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetTreatmentMember" xlink:label="lbl_BalanceSheetTreatmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetTreatmentAxis" xlink:to="lbl_BalanceSheetTreatmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CapitalizedMember" xlink:label="lbl_CapitalizedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetTreatmentMember" xlink:to="lbl_CapitalizedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NotCapitalizedMember" xlink:label="lbl_NotCapitalizedMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetTreatmentMember" xlink:to="lbl_NotCapitalizedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_YearOfExpiryAxis" xlink:label="lbl_YearOfExpiryAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lbl_YearOfExpiryAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_YearOfExpiryMember" xlink:label="lbl_YearOfExpiryMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryAxis" xlink:to="lbl_YearOfExpiryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OneYearMember" xlink:label="lbl_OneYearMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_OneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TwoYearsMember" xlink:label="lbl_TwoYearsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_TwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ThreeYearsMember" xlink:label="lbl_ThreeYearsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_ThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FourYearsMember" xlink:label="lbl_FourYearsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_FourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FiveYearsMember" xlink:label="lbl_FiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_FiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MoreThanFiveYearsMember" xlink:label="lbl_MoreThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_MoreThanFiveYearsMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueOfTaxLossCarryforwardsExpired" xlink:label="lbl_ValueOfTaxLossCarryforwardsExpired" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ValueOfTaxLossCarryforwardsExpired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:label="lbl_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NotSubjectToExpiryMember" xlink:label="lbl_NotSubjectToExpiryMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_YearOfExpiryMember" xlink:to="lbl_NotSubjectToExpiryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxLossCarryForwards" xlink:label="lbl_TaxLossCarryForwards" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TaxLossCarryForwards" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCurrentAssetsAbstract" xlink:label="lbl_OtherCurrentAssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="lbl_CurrentValueAddedTaxReceivables" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_CurrentValueAddedTaxReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WithholdingTaxRecoverable" xlink:label="lbl_WithholdingTaxRecoverable" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_WithholdingTaxRecoverable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPrepaidExpensesThirdParty" xlink:label="lbl_CurrentPrepaidExpensesThirdParty" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_CurrentPrepaidExpensesThirdParty" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPrepaidExpensesAssociatedCompanies" xlink:label="lbl_CurrentPrepaidExpensesAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_CurrentPrepaidExpensesAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReceivablesAssociatedCompanies" xlink:label="lbl_ReceivablesAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_ReceivablesAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivableCurrent" xlink:label="lbl_ContingentConsiderationReceivableCurrent" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_ContingentConsiderationReceivableCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherReceivablesAndCurrentAssets" xlink:label="lbl_OtherReceivablesAndCurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_OtherReceivablesAndCurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialAssets" xlink:label="lbl_OtherCurrentNonfinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_OtherCurrentNonfinancialAssets" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtInstrumentsHeld" xlink:label="lbl_DebtInstrumentsHeld" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_DebtInstrumentsHeld" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityInstrumentsHeld" xlink:label="lbl_EquityInstrumentsHeld" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_EquityInstrumentsHeld" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FundInstrumentsHeld" xlink:label="lbl_FundInstrumentsHeld" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_FundInstrumentsHeld" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketableSecurities" xlink:label="lbl_MarketableSecurities" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_MarketableSecurities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:label="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_ShorttermDepositsNotClassifiedAsCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativeFinancialAssets" xlink:label="lbl_DerivativeFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_DerivativeFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivable" xlink:label="lbl_InterestReceivable" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_InterestReceivable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="lbl_OtherCurrentFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_OtherCurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Commodities" xlink:label="lbl_Commodities" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_Commodities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAssetsEquityInvestments" xlink:label="lbl_NoncurrentFinancialAssetsEquityInvestments" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAssetsEquityInvestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAsstetsDebtSecurities" xlink:label="lbl_NoncurrentFinancialAsstetsDebtSecurities" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAsstetsDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAssetsFundInvestments" xlink:label="lbl_NoncurrentFinancialAssetsFundInvestments" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAssetsFundInvestments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentTradeReceivables" xlink:label="lbl_NoncurrentTradeReceivables" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinanceLeaseReceivables" xlink:label="lbl_NoncurrentFinanceLeaseReceivables" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentFinanceLeaseReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivable" xlink:label="lbl_ContingentConsiderationReceivable" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_ContingentConsiderationReceivable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLoansAndReceivables" xlink:label="lbl_NoncurrentLoansAndReceivables" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentLoansAndReceivables" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="lbl_NoncurrentFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="lbl_OtherNoncurrentReceivables" xlink:type="locator"/>
      <link:presentationArc order="7.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_OtherNoncurrentReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongTermReceivablesFromFinanceSubleases" xlink:label="lbl_LongTermReceivablesFromFinanceSubleases" xlink:type="locator"/>
      <link:presentationArc order="7.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_LongTermReceivablesFromFinanceSubleases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:label="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_NoncurrentFinancialAssetsTotalFinancialInvestments" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:label="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredCompensationPlansAssets" xlink:label="lbl_DeferredCompensationPlansAssets" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:to="lbl_DeferredCompensationPlansAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrepaidPostemploymentBenefitPlansAssets" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:to="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:label="lbl_OtherNoncurrentNonfinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:to="lbl_OtherNoncurrentNonfinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="lbl_OtherNoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherNoncurrentAssetsAbstract" xlink:to="lbl_OtherNoncurrentAssets" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/StatementOfIncome" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="lbl_IncomeStatementAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncomeStatementAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="lbl_ProfitLossAttributableToAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsPerShareAbstract" xlink:label="lbl_BasicEarningsPerShareAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsPerShareAbstract" xlink:label="lbl_DilutedEarningsPerShareAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLossAttributableToAbstract" xlink:type="arc"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_BasicEarningsPerShareAbstract" xlink:type="arc"/>
      <link:presentationArc order="21.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DilutedEarningsPerShareAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:presentationArc order="9.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:presentationArc order="13.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:presentationArc order="3.2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="lbl_BasicEarningsLossPerShare" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BasicEarningsPerShareAbstract" xlink:to="lbl_BasicEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="lbl_DilutedEarningsLossPerShare" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DilutedEarningsPerShareAbstract" xlink:to="lbl_DilutedEarningsLossPerShare" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypAxis" xlink:label="lbl_SubsequentEventTypAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_SubsequentEventTypAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypeMember" xlink:label="lbl_SubsequentEventTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SubsequentEventTypAxis" xlink:to="lbl_SubsequentEventTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventMember" xlink:label="lbl_SubsequentEventMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SubsequentEventTypeMember" xlink:to="lbl_SubsequentEventMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:label="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:label="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeasingCommitmentsAbstract" xlink:label="lbl_LeasingCommitmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LeasingCommitmentsAbstract" xlink:to="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:label="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" xlink:to="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:presentationArc order="1.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="1.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:label="lbl_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" xlink:to="lbl_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:label="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ResearchAndDevelopmentCommitmentsAbstract" xlink:label="lbl_ResearchAndDevelopmentCommitmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ResearchAndDevelopmentCommitmentsAbstract" xlink:to="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:label="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" xlink:to="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentsUnderLongtermResearchAgreements" xlink:label="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_CommitmentsUnderLongtermResearchAgreements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherIntangiblePurchaseCommitments" xlink:label="lbl_OtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_OtherIntangiblePurchaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:label="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:label="lbl_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" xlink:to="lbl_UncalledCapitalCommitmentsForInvestmentsInFunds" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermBorrowings" xlink:label="lbl_ShorttermBorrowings" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_ShorttermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommercialPapersIssued" xlink:label="lbl_CommercialPapersIssued" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_CommercialPapersIssued" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="lbl_DerivativeFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_DerivativeFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageInterestRateAssociates" xlink:label="lbl_WeightedAverageInterestRateAssociates" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_WeightedAverageInterestRateAssociates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:label="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PaymentOfInterestBearingAccountsToBeneficiaries" xlink:label="lbl_PaymentOfInterestBearingAccountsToBeneficiaries" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_PaymentOfInterestBearingAccountsToBeneficiaries" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_InterestBearningAccountsOfAssociatesPayableOnDemand" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:label="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LiabilitiesToBanksAndOtherInstitutions" xlink:label="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_LiabilitiesToBanksAndOtherInstitutions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_CurrentPortionOfLongtermBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageInterestRateOnLoansReceived" xlink:label="lbl_AverageInterestRateOnLoansReceived" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_AverageInterestRateOnLoansReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:label="lbl_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_RatioFixedRateFinancialDebtToTotalFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AverageInterestRateOnBorrowings" xlink:label="lbl_AverageInterestRateOnBorrowings" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_AverageInterestRateOnBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinanceLeaseLiabilities" xlink:label="lbl_FinanceLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" xlink:to="lbl_FinanceLeaseLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:label="lbl_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:type="locator"/>
      <link:presentationArc order="5.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsAndNotLaterThanSixYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanSixYearsMember" xlink:label="lbl_LaterThanSixYearsMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanSixYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract1" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract1" xlink:to="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:to="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyOthersMember" xlink:label="lbl_CurrencyOthersMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CurrencyOthersMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract1" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract1" xlink:to="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="lbl_USD" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_USD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="lbl_EUR" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_EUR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY" xlink:label="lbl_JPY" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_JPY" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF" xlink:label="lbl_CHF" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CHF" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis1" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:to="lbl_CurrencyAxis1" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrencyAxis1" xlink:to="lbl_AllCurrenciesDomain" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable1" xlink:to="lbl_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems1" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails6" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:label="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialDebtsCoveredByCollateral" xlink:label="lbl_NoncurrentFinancialDebtsCoveredByCollateral" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:to="lbl_NoncurrentFinancialDebtsCoveredByCollateral" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:label="lbl_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" xlink:to="lbl_PropertyPlantAndEquipmentPledgedAsSecurity" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:to="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lbl_BorrowingsByNameAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:label="lbl_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:label="lbl_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:label="lbl_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:label="lbl_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:label="lbl_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:label="lbl_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:label="lbl_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:label="lbl_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:label="lbl_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:label="lbl_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:label="lbl_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:label="lbl_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:label="lbl_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:label="lbl_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:label="lbl_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:label="lbl_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:type="locator"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotionalAmount" xlink:label="lbl_NotionalAmount" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_NotionalAmount" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsOriginalCurrency" xlink:label="lbl_BorrowingsOriginalCurrency" xlink:type="locator"/>
      <link:presentationArc order="3.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsOriginalCurrency" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:label="lbl_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:label="lbl_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:type="locator"/>
      <link:presentationArc order="17.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:label="lbl_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:type="locator"/>
      <link:presentationArc order="18.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:label="lbl_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:label="lbl_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:type="locator"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="lbl_BorrowingsInterestRate" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsInterestRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsIssuanceDate" xlink:label="lbl_BorrowingsIssuanceDate" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsIssuanceDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsMaturity" xlink:label="lbl_BorrowingsMaturity" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsMaturity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsLender" xlink:label="lbl_BorrowingsLender" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsLender" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsPremiumDiscount" xlink:label="lbl_BorrowingsPremiumDiscount" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsPremiumDiscount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:label="lbl_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:type="locator"/>
      <link:presentationArc order="21.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:label="lbl_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:type="locator"/>
      <link:presentationArc order="22.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:label="lbl_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:type="locator"/>
      <link:presentationArc order="23.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:label="lbl_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:type="locator"/>
      <link:presentationArc order="24.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:label="lbl_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:type="locator"/>
      <link:presentationArc order="25.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:label="lbl_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:type="locator"/>
      <link:presentationArc order="26.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:label="lbl_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:type="locator"/>
      <link:presentationArc order="27.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:label="lbl_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:type="locator"/>
      <link:presentationArc order="28.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsInterestRateStepUp" xlink:label="lbl_BorrowingsInterestRateStepUp" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lbl_BorrowingsInterestRateStepUp" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:type="locator"/>
      <link:presentationArc order="29.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:type="locator"/>
      <link:presentationArc order="30.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:type="locator"/>
      <link:presentationArc order="31.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:label="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:type="locator"/>
      <link:presentationArc order="32.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:to="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BondsIssued" xlink:label="lbl_BondsIssued" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_BondsIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherNoncurrentFinancialDebt" xlink:label="lbl_OtherNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_OtherNoncurrentFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueByMeasurementBasisAxis" xlink:label="lbl_FairValueByMeasurementBasisAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_FairValueByMeasurementBasisAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueByMeasurementBasisMember" xlink:label="lbl_FairValueByMeasurementBasisMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueByMeasurementBasisAxis" xlink:to="lbl_FairValueByMeasurementBasisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueDisclosureItemAmountsMember" xlink:label="lbl_FairValueDisclosureItemAmountsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueByMeasurementBasisMember" xlink:to="lbl_FairValueDisclosureItemAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CarryingReportedAmountFairValueDisclosureMember" xlink:label="lbl_CarryingReportedAmountFairValueDisclosureMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueByMeasurementBasisMember" xlink:to="lbl_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/StatementOfComprehensiveIncome" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="lbl_StatementOfComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfComprehensiveIncomeAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="arc"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="locator"/>
      <link:presentationArc order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc"/>
      <link:presentationArc order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="25.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:type="locator"/>
      <link:presentationArc order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:to="lbl_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:label="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAttributableToAbstract" xlink:to="lbl_ComprehensiveIncomeAttributableToNoncontrollingInterests" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="1.6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:presentationArc order="2.3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:presentationArc order="4.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:presentationArc order="1.9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract1" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/StatementsOfCashFlow" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="lbl_StatementOfCashFlowsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfCashFlowsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestPaidClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="21.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:presentationArc order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="locator"/>
      <link:presentationArc order="32.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsToAcquireOrRedeemEntitysShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="38.5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="39.5" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="40.5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems1" xlink:type="locator"/>
      <link:presentationArc order="41.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems1" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:presentationArc order="41.5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:label="lbl_CashFlowsBeforeWorkingCapitalAndProvisionChanges" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsReceivedClassifiedAsOperatingActivities" xlink:label="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="7.2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:label="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="31.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="35.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="2.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="36.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="38.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:label="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:label="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="locator"/>
      <link:presentationArc order="37.6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsFromChangesInOwnershipInterestsInSubsidiaries" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:label="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="24.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="29.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="34.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="38.45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="38.35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="locator"/>
      <link:presentationArc order="39.1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="37.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:label="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInOperatingActivitiesContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:label="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="locator"/>
      <link:presentationArc order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="lbl_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="lbl_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="20.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:presentationArc order="19.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="lbl_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="27.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="lbl_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="26.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="1.8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/StatementOfChangesInEquity" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="lbl_StatementOfChangesInEquityTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_StatementOfChangesInEquityTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_NoncontrollingInterestsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="lbl_StatementOfChangesInEquityLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_StatementOfChangesInEquityLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="lbl_OtherComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="lbl_ComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaid" xlink:label="lbl_DividendsPaid" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_DividendsPaid" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInEquity" xlink:label="lbl_ChangesInEquity" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ChangesInEquity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="lbl_StatementOfChangesInEquityLineItems1" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems1" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsRelatedToDivestments" xlink:label="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="locator"/>
      <link:presentationArc order="10.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="lbl_IssuedCapitalMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_IssuedCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TreasurySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="lbl_RetainedEarningsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_RetainedEarningsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseInNoncontrolingInterests" xlink:label="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:type="locator"/>
      <link:presentationArc order="10.1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseInNoncontrolingInterests" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="lbl_PurchaseOfTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="6.2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_PurchaseOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="lbl_StatementOfChangesInEquityLineItems2" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems2" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:label="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="9.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator"/>
      <link:presentationArc order="8.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="locator"/>
      <link:presentationArc order="10.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherShareSales" xlink:label="lbl_OtherShareSales" xlink:type="locator"/>
      <link:presentationArc order="7.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherShareSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeMaketableSecurities" xlink:label="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:type="locator"/>
      <link:presentationArc order="9.75" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_OtherComprehensiveIncomeMaketableSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_RestatedValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCostsRecordedInEquity" xlink:label="lbl_TransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:presentationArc order="9.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TransactionCostsRecordedInEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:label="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReductionOfIssuedCapital" xlink:label="lbl_ReductionOfIssuedCapital" xlink:type="locator"/>
      <link:presentationArc order="6.3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_ReductionOfIssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="locator"/>
      <link:presentationArc order="6.9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="locator"/>
      <link:presentationArc order="8.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:label="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TaxReformImpactOnDeferredTaxOnTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DividendPaidNoncashAssetsDistribution" xlink:label="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_DividendPaidNoncashAssetsDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxesOnTreasuryShares" xlink:label="lbl_TaxesOnTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="8.8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_TaxesOnTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnFinancialAssetsSold" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="locator"/>
      <link:presentationArc order="9.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:presentationArc order="10.6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RepurchaseOfOptions" xlink:label="lbl_RepurchaseOfOptions" xlink:type="locator"/>
      <link:presentationArc order="7.3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityLineItems" xlink:to="lbl_RepurchaseOfOptions" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsForDeductionsFromRevenueRollForward" xlink:label="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDeductionFromRevenueTable" xlink:label="lbl_ProvisionForDeductionFromRevenueTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementAdjustmentsOfPriorYear" xlink:label="lbl_IncomeStatementAdjustmentsOfPriorYear" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_IncomeStatementAdjustmentsOfPriorYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementAdjustmentsOfCurrentYear" xlink:label="lbl_IncomeStatementAdjustmentsOfCurrentYear" xlink:type="locator"/>
      <link:presentationArc order="4.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_IncomeStatementAdjustmentsOfCurrentYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PlansAndProgramRebatesAxis" xlink:label="lbl_PlansAndProgramRebatesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionForDeductionFromRevenueTable" xlink:to="lbl_PlansAndProgramRebatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="lbl_ProvisionUsedOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_ProvisionUsedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="1.55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PlansAndProgramRebatesMember" xlink:label="lbl_PlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PlansAndProgramRebatesAxis" xlink:to="lbl_PlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_USspecificHealthcarePlansAndProgramRebatesMember" xlink:label="lbl_USspecificHealthcarePlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PlansAndProgramRebatesMember" xlink:to="lbl_USspecificHealthcarePlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:label="lbl_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PlansAndProgramRebatesMember" xlink:to="lbl_NonUSspecificHealthcarePlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:label="lbl_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PlansAndProgramRebatesMember" xlink:to="lbl_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_ProvisionForDeductionFromRevenueTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:label="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionForDeductionFromRevenueTable" xlink:to="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:to="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionForDeductionFromRevenueTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInOffsetAgainstGrossTradeReceivables" xlink:label="lbl_ChangesInOffsetAgainstGrossTradeReceivables" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_ChangesInOffsetAgainstGrossTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentRefundsProvision" xlink:label="lbl_CurrentRefundsProvision" xlink:type="locator"/>
      <link:presentationArc order="1.3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_CurrentRefundsProvision" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsForDeductionsFromRevenueRollForward" xlink:label="lbl_ProvisionsForDeductionsFromRevenueRollForward1" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward1" xlink:to="lbl_CurrentRefundsProvision" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentRefundsProvisionDiscontinuedOperations" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="1.4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward" xlink:to="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="arc"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsForDeductionsFromRevenueRollForward1" xlink:to="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermRestructuringProvision" xlink:label="lbl_ShorttermRestructuringProvision" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_ShorttermRestructuringProvision" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="lbl_AccrualsClassifiedAsCurrent" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_AccrualsClassifiedAsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:label="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_AccruedRoyaltiesPayableClassifiedAsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentInterestPayable" xlink:label="lbl_CurrentInterestPayable" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_CurrentInterestPayable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="lbl_ShorttermEmployeeBenefitsAccruals" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_ShorttermEmployeeBenefitsAccruals" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionCurrent" xlink:label="lbl_EnvironmentalProvisionCurrent" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_EnvironmentalProvisionCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationCurrentPortion" xlink:label="lbl_ContingentConsiderationCurrentPortion" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_ContingentConsiderationCurrentPortion" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentForRepurchaseOwnShares" xlink:label="lbl_CommitmentForRepurchaseOwnShares" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_CommitmentForRepurchaseOwnShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentPayables" xlink:label="lbl_OtherCurrentPayables" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_OtherCurrentPayables" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:label="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_OtherCurrentNonfinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentRefundsProvision" xlink:label="lbl_CurrentRefundsProvision" xlink:type="locator"/>
      <link:presentationArc order="7.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_CurrentRefundsProvision" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RefundsProvision" xlink:label="lbl_RefundsProvision" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_RefundsProvision" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentRefundsProvisionDiscontinuedOperations" xlink:label="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="7.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_CurrentRefundsProvisionDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:label="lbl_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_CurrentDeferredIncomeOtherThanCurrentContractLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_OtherProvisionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestructuringProvisionMember" xlink:label="lbl_RestructuringProvisionMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_RestructuringProvisionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestructuringProvisionsMovementsRollForward" xlink:label="lbl_RestructuringProvisionsMovementsRollForward" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisions" xlink:label="lbl_OtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_OtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="lbl_AdditionalProvisionsOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_AdditionalProvisionsOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="lbl_ProvisionUsedOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_ProvisionUsedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestructuringProvisionsMovementsRollForward" xlink:label="lbl_RestructuringProvisionsMovementsRollForward1" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward1" xlink:to="lbl_OtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestructuringProvisionsMovementsTable" xlink:label="lbl_RestructuringProvisionsMovementsTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_RestructuringProvisionsMovementsTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsTable" xlink:to="lbl_ClassesOfProvisionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PlansAndProgramRebatesMember" xlink:label="lbl_PlansAndProgramRebatesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_PlansAndProgramRebatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:label="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsTable" xlink:to="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProvisionsAndOtherCurrentLiabilitiesLineItems" xlink:to="lbl_RestructuringProvisionsMovementsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="6.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsRollForward" xlink:to="lbl_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestructuringProvisionsMovementsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixTable" xlink:label="lbl_DisclosureOfProvisionMatrixTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixAbstract" xlink:label="lbl_DisclosureOfProvisionMatrixAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixAbstract" xlink:to="lbl_DisclosureOfProvisionMatrixTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivableMember" xlink:label="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivable" xlink:label="lbl_ProvisionForDoubtfulReceivable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ProvisionForDoubtfulReceivable" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixTable" xlink:label="lbl_DisclosureOfProvisionMatrixTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixAbstract" xlink:label="lbl_DisclosureOfProvisionMatrixAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixAbstract" xlink:to="lbl_DisclosureOfProvisionMatrixTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:label="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="lbl_ProvisionUsedOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ProvisionUsedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems1" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivableMember" xlink:label="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnusedProvisionReversedOtherProvisions" xlink:label="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="5.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_UnusedProvisionReversedOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfDivestmentsOtherProvisions" xlink:label="lbl_ImpactOfDivestmentsOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="2.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ImpactOfDivestmentsOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="2.8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsOtherProvisions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivable" xlink:label="lbl_ProvisionForDoubtfulReceivable" xlink:type="locator"/>
      <link:presentationArc order="2.3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_ProvisionForDoubtfulReceivable" xlink:type="arc"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems1" xlink:to="lbl_ProvisionForDoubtfulReceivable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="lbl_AdditionalProvisionsOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_AdditionalProvisionsOtherProvisions" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AnalysisOfOverdueAmountsTable" xlink:label="lbl_AnalysisOfOverdueAmountsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixAbstract" xlink:label="lbl_DisclosureOfProvisionMatrixAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixAbstract" xlink:to="lbl_AnalysisOfOverdueAmountsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusAxis" xlink:label="lbl_PastDueStatusAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastDueStatusMember" xlink:label="lbl_PastDueStatusMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PastDueStatusAxis" xlink:to="lbl_PastDueStatusMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentMember" xlink:label="lbl_CurrentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_PastDueStatusMember" xlink:to="lbl_CurrentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AnalysisOfOverdueAmountsLineItems" xlink:label="lbl_AnalysisOfOverdueAmountsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_AnalysisOfOverdueAmountsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AnalysisOfOverdueAmountsLineItems" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:presentationArc order="1.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_PastDueStatusAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember1" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="lbl_LaterThanOneYearMember1" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanOneYearMember1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember" xlink:label="lbl_LaterThanSixMonthsAndNotLaterThanOneYearMember1" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanSixMonthsAndNotLaterThanOneYearMember1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember" xlink:label="lbl_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember1" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentMember" xlink:to="lbl_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="lbl_NotLaterThanOneMonthMember" xlink:type="locator"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrentMember" xlink:to="lbl_NotLaterThanOneMonthMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="1.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AnalysisOfOverdueAmountsTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivableMember" xlink:label="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_ProvisionForDoubtfulReceivableMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionForDoubtfulReceivable" xlink:label="lbl_ProvisionForDoubtfulReceivable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AnalysisOfOverdueAmountsLineItems" xlink:to="lbl_ProvisionForDoubtfulReceivable" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixAbstract" xlink:label="lbl_DisclosureOfProvisionMatrixAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsAxis" xlink:to="lbl_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialInstrumentsMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfProvisionMatrixLineItems" xlink:label="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyOthersMember" xlink:label="lbl_CurrencyOthersMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CurrencyOthersMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="lbl_CurrentTradeReceivables" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixLineItems" xlink:to="lbl_CurrentTradeReceivables" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:label="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionMatrixAbstract" xlink:to="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:to="lbl_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:to="lbl_DisclosureOfProvisionMatrixLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="lbl_USD" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_USD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="lbl_EUR" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_EUR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF" xlink:label="lbl_CHF" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CHF" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_BRL" xlink:label="lbl_BRL" xlink:type="locator"/>
      <link:presentationArc order="3.65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_BRL" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis1" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" xlink:to="lbl_CurrencyAxis1" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrencyAxis1" xlink:to="lbl_AllCurrenciesDomain" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_RUB" xlink:label="lbl_RUB" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_RUB" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CNY" xlink:label="lbl_CNY" xlink:type="locator"/>
      <link:presentationArc order="2.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CNY" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CAD" xlink:label="lbl_CAD" xlink:type="locator"/>
      <link:presentationArc order="3.4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CAD" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY" xlink:label="lbl_JPY" xlink:type="locator"/>
      <link:presentationArc order="2.6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_JPY" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_GBP" xlink:label="lbl_GBP" xlink:type="locator"/>
      <link:presentationArc order="2.65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_GBP" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AUD" xlink:label="lbl_AUD" xlink:type="locator"/>
      <link:presentationArc order="3.75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_AUD" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="lbl_EntitysTotalForSubsidiariesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lbl_EntitysTotalForSubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubsidiariesMember" xlink:label="lbl_SubsidiariesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSubsidiariesMember" xlink:to="lbl_SubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NameOfSubsidiary" xlink:label="lbl_NameOfSubsidiary" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_NameOfSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary" xlink:label="lbl_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_PrincipalPlaceOfBusinessOfSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:label="lbl_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_CountryOfIncorporationOrResidenceOfSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfVotingPowerHeldInSubsidiary" xlink:label="lbl_ProportionOfVotingPowerHeldInSubsidiary" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_ProportionOfVotingPowerHeldInSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharePaidinCapital" xlink:label="lbl_SharePaidinCapital" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_SharePaidinCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:label="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lbl_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SocieteParActionsSANDOZAlgiersMember" xlink:label="lbl_SocieteParActionsSANDOZAlgiersMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SocieteParActionsSANDOZAlgiersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisArgentinaS.A.BuenosAiresMember" xlink:label="lbl_NovartisArgentinaS.A.BuenosAiresMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisArgentinaS.A.BuenosAiresMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPtyLtdMacquarieParkNSWMember" xlink:label="lbl_SandozPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisAustriaGmbHViennaMember" xlink:label="lbl_NovartisAustriaGmbHViennaMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisAustriaGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaGmbHViennaMember" xlink:label="lbl_NovartisPharmaGmbHViennaMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozGmbHViennaMember" xlink:label="lbl_SandozGmbHViennaMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:label="lbl_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBangladeshLimitedGazipurMember" xlink:label="lbl_NovartisBangladeshLimitedGazipurMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBangladeshLimitedGazipurMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaNVVilvoordeMember" xlink:label="lbl_NovartisPharmaNVVilvoordeMember" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaNVVilvoordeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozNVVilvoordeMember" xlink:label="lbl_SandozNVVilvoordeMember" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozNVVilvoordeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCouvreurNVPuursMember" xlink:label="lbl_AlconCouvreurNVPuursMember" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCouvreurNVPuursMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInvestmentLtd.HamiltonMember" xlink:label="lbl_NovartisInvestmentLtd.HamiltonMember" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInvestmentLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:label="lbl_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSecuritiesInvestmentLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceServicesLtd.HamiltonMember" xlink:label="lbl_NovartisFinanceServicesLtd.HamiltonMember" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceServicesLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:label="lbl_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:type="locator"/>
      <link:presentationArc order="17.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TriangleInternationalReinsuranceLimitedHamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:label="lbl_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:type="locator"/>
      <link:presentationArc order="18.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TrinityRiverInsuranceCoLtd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBiocienciasS.A.SaoPauloMember" xlink:label="lbl_NovartisBiocienciasS.A.SaoPauloMember" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBiocienciasS.A.SaoPauloMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:label="lbl_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:type="locator"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:label="lbl_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:type="locator"/>
      <link:presentationArc order="21.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozCanadaInc.BouchervilleQuebecMember" xlink:label="lbl_SandozCanadaInc.BouchervilleQuebecMember" xlink:type="locator"/>
      <link:presentationArc order="22.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozCanadaInc.BouchervilleQuebecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisChileS.A.SantiagoDeChileMember" xlink:label="lbl_NovartisChileS.A.SantiagoDeChileMember" xlink:type="locator"/>
      <link:presentationArc order="23.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisChileS.A.SantiagoDeChileMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:label="lbl_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:type="locator"/>
      <link:presentationArc order="24.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_BeijingNovartisPharmaCo.Ltd.BeijingMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:label="lbl_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:type="locator"/>
      <link:presentationArc order="25.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsHKLimitedHongKongMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:label="lbl_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:type="locator"/>
      <link:presentationArc order="26.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:label="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:type="locator"/>
      <link:presentationArc order="27.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:label="lbl_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:type="locator"/>
      <link:presentationArc order="28.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ShanghaiNovartisTradingLtd.ShanghaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:label="lbl_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:type="locator"/>
      <link:presentationArc order="29.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:label="lbl_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:type="locator"/>
      <link:presentationArc order="30.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeColombiaS.A.SantafeDeBobotaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:label="lbl_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:type="locator"/>
      <link:presentationArc order="31.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisS.r.o.PragueMember" xlink:label="lbl_NovartisS.r.o.PragueMember" xlink:type="locator"/>
      <link:presentationArc order="32.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisS.r.o.PragueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.r.o.PragueMember" xlink:label="lbl_SandozS.r.o.PragueMember" xlink:type="locator"/>
      <link:presentationArc order="33.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.r.o.PragueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHealthcareASCopenhagenMember" xlink:label="lbl_NovartisHealthcareASCopenhagenMember" xlink:type="locator"/>
      <link:presentationArc order="34.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHealthcareASCopenhagenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozASCopenhagenMember" xlink:label="lbl_SandozASCopenhagenMember" xlink:type="locator"/>
      <link:presentationArc order="35.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozASCopenhagenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisEcuadorS.A.QuitoMember" xlink:label="lbl_NovartisEcuadorS.A.QuitoMember" xlink:type="locator"/>
      <link:presentationArc order="36.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisEcuadorS.A.QuitoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaS.A.E.CairoMember" xlink:label="lbl_NovartisPharmaS.A.E.CairoMember" xlink:type="locator"/>
      <link:presentationArc order="37.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaS.A.E.CairoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:label="lbl_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:type="locator"/>
      <link:presentationArc order="38.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozEgyptPharmaS.A.E.NewCairoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinlandOyEspooMember" xlink:label="lbl_NovartisFinlandOyEspooMember" xlink:type="locator"/>
      <link:presentationArc order="39.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinlandOyEspooMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:label="lbl_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:type="locator"/>
      <link:presentationArc order="40.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGroupeFranceS.A.RueilMalmaisonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:label="lbl_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:presentationArc order="41.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaS.A.S.RueilMalmaisonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember" xlink:label="lbl_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:presentationArc order="42.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember" xlink:type="arc"/>
      <link:presentationArc order="43.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember" xlink:label="lbl_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember" xlink:type="locator"/>
      <link:presentationArc order="44.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CELLforCURELesUlisMember" xlink:label="lbl_CELLforCURELesUlisMember" xlink:type="locator"/>
      <link:presentationArc order="45.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CELLforCURELesUlisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.A.S.LevalloisPerretMember" xlink:label="lbl_SandozS.A.S.LevalloisPerretMember" xlink:type="locator"/>
      <link:presentationArc order="46.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.A.S.LevalloisPerretMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeutschlandGmbHNurembergMember" xlink:label="lbl_NovartisDeutschlandGmbHNurembergMember" xlink:type="locator"/>
      <link:presentationArc order="47.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeutschlandGmbHNurembergMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBusinessServicesGmbHWehrMember" xlink:label="lbl_NovartisBusinessServicesGmbHWehrMember" xlink:type="locator"/>
      <link:presentationArc order="48.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBusinessServicesGmbHWehrMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaGmbHNurembergMember" xlink:label="lbl_NovartisPharmaGmbHNurembergMember" xlink:type="locator"/>
      <link:presentationArc order="49.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaGmbHNurembergMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaProduktionsGmbHWehrMember" xlink:label="lbl_NovartisPharmaProduktionsGmbHWehrMember" xlink:type="locator"/>
      <link:presentationArc order="50.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaProduktionsGmbHWehrMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozInternationalGmbHHolzkirchenMember" xlink:label="lbl_SandozInternationalGmbHHolzkirchenMember" xlink:type="locator"/>
      <link:presentationArc order="51.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozInternationalGmbHHolzkirchenMember" xlink:type="arc"/>
      <link:presentationArc order="52.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_A1APharmaGmbHHolzkirchenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HEXALAGHolzkirchenMember" xlink:label="lbl_HEXALAGHolzkirchenMember" xlink:type="locator"/>
      <link:presentationArc order="53.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_HEXALAGHolzkirchenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SalutasPharmaGmbHBarlebenMember" xlink:label="lbl_SalutasPharmaGmbHBarlebenMember" xlink:type="locator"/>
      <link:presentationArc order="54.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SalutasPharmaGmbHBarlebenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AeropharmGmbHRudolstadtMember" xlink:label="lbl_AeropharmGmbHRudolstadtMember" xlink:type="locator"/>
      <link:presentationArc order="55.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AeropharmGmbHRudolstadtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:label="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="locator"/>
      <link:presentationArc order="56.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:label="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:type="locator"/>
      <link:presentationArc order="57.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:label="lbl_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:type="locator"/>
      <link:presentationArc order="58.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozHungaryLimitedLiabilityCompanyBudapestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIndiaLimitedMumbaiMember" xlink:label="lbl_NovartisIndiaLimitedMumbaiMember" xlink:type="locator"/>
      <link:presentationArc order="59.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIndiaLimitedMumbaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:label="lbl_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:type="locator"/>
      <link:presentationArc order="60.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHealthcarePrivateLimitedMumbaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPrivateLimitedMumbaiMember" xlink:label="lbl_SandozPrivateLimitedMumbaiMember" xlink:type="locator"/>
      <link:presentationArc order="61.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPrivateLimitedMumbaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PT.NovartisIndonesiaJakartaMember" xlink:label="lbl_PT.NovartisIndonesiaJakartaMember" xlink:type="locator"/>
      <link:presentationArc order="62.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_PT.NovartisIndonesiaJakartaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIrelandLimitedDublinMember" xlink:label="lbl_NovartisIrelandLimitedDublinMember" xlink:type="locator"/>
      <link:presentationArc order="63.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIrelandLimitedDublinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:label="lbl_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:type="locator"/>
      <link:presentationArc order="64.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGeneTherapiesEULimitedDublinMember" xlink:label="lbl_NovartisGeneTherapiesEULimitedDublinMember" xlink:type="locator"/>
      <link:presentationArc order="65.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGeneTherapiesEULimitedDublinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisIsraelLtd.TelAvivMember" xlink:label="lbl_NovartisIsraelLtd.TelAvivMember" xlink:type="locator"/>
      <link:presentationArc order="66.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisIsraelLtd.TelAvivMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaS.p.A.MilanMember" xlink:label="lbl_NovartisFarmaS.p.A.MilanMember" xlink:type="locator"/>
      <link:presentationArc order="67.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaS.p.A.MilanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:label="lbl_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:type="locator"/>
      <link:presentationArc order="68.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.p.A.OriggioMember" xlink:label="lbl_SandozS.p.A.OriggioMember" xlink:type="locator"/>
      <link:presentationArc order="69.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.p.A.OriggioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaK.K.TokyoMember" xlink:label="lbl_NovartisPharmaK.K.TokyoMember" xlink:type="locator"/>
      <link:presentationArc order="70.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CibaGeigyJapanLimitedTokyoMember" xlink:label="lbl_CibaGeigyJapanLimitedTokyoMember" xlink:type="locator"/>
      <link:presentationArc order="71.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CibaGeigyJapanLimitedTokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozK.K.TokyoMember" xlink:label="lbl_SandozK.K.TokyoMember" xlink:type="locator"/>
      <link:presentationArc order="72.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBalticsSIARigaMember" xlink:label="lbl_NovartisBalticsSIARigaMember" xlink:type="locator"/>
      <link:presentationArc order="73.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBalticsSIARigaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:label="lbl_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:type="locator"/>
      <link:presentationArc order="74.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInvestmentsS.aR.l.LuxembourgCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceS.A.LuxembourgCityMember" xlink:label="lbl_NovartisFinanceS.A.LuxembourgCityMember" xlink:type="locator"/>
      <link:presentationArc order="75.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceS.A.LuxembourgCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember" xlink:label="lbl_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="locator"/>
      <link:presentationArc order="76.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:label="lbl_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:presentationArc order="77.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.A.DeC.V.MexicoCityMember" xlink:label="lbl_SandozS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:presentationArc order="78.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.A.DeC.V.MexicoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaMarocSACasablancaMember" xlink:label="lbl_NovartisPharmaMarocSACasablancaMember" xlink:type="locator"/>
      <link:presentationArc order="79.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaMarocSACasablancaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNetherlandsB.V.AmsterdamMember" xlink:label="lbl_NovartisNetherlandsB.V.AmsterdamMember" xlink:type="locator"/>
      <link:presentationArc order="80.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNetherlandsB.V.AmsterdamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaB.V.AmsterdamMember" xlink:label="lbl_NovartisPharmaB.V.AmsterdamMember" xlink:type="locator"/>
      <link:presentationArc order="81.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaB.V.AmsterdamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IDBHollandBVBaarleNassauMember" xlink:label="lbl_IDBHollandBVBaarleNassauMember" xlink:type="locator"/>
      <link:presentationArc order="82.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_IDBHollandBVBaarleNassauMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozB.V.AlmereMember" xlink:label="lbl_SandozB.V.AlmereMember" xlink:type="locator"/>
      <link:presentationArc order="83.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozB.V.AlmereMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNewZealandLtdAucklandMember" xlink:label="lbl_NovartisNewZealandLtdAucklandMember" xlink:type="locator"/>
      <link:presentationArc order="84.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNewZealandLtdAucklandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNorgeASOsloMember" xlink:label="lbl_NovartisNorgeASOsloMember" xlink:type="locator"/>
      <link:presentationArc order="85.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNorgeASOsloMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaPakistanLimitedKarachiMember" xlink:label="lbl_NovartisPharmaPakistanLimitedKarachiMember" xlink:type="locator"/>
      <link:presentationArc order="86.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaPakistanLimitedKarachiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:label="lbl_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:type="locator"/>
      <link:presentationArc order="87.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaLogisticsInc.PanamaCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:label="lbl_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:type="locator"/>
      <link:presentationArc order="88.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHealthcarePhilippinesInc.MakatiCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPhilippinesCorporationMakatiCityMember" xlink:label="lbl_SandozPhilippinesCorporationMakatiCityMember" xlink:type="locator"/>
      <link:presentationArc order="89.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPhilippinesCorporationMakatiCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPolandSp.ZO.o.WarsawMember" xlink:label="lbl_NovartisPolandSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:presentationArc order="90.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPolandSp.ZO.o.WarsawMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPolskaSp.ZO.o.WarsawMember" xlink:label="lbl_SandozPolskaSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:presentationArc order="91.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPolskaSp.ZO.o.WarsawMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LekS.A.StrykowMember" xlink:label="lbl_LekS.A.StrykowMember" xlink:type="locator"/>
      <link:presentationArc order="92.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_LekS.A.StrykowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:label="lbl_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:type="locator"/>
      <link:presentationArc order="93.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPortugalSGPSLda.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:label="lbl_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:type="locator"/>
      <link:presentationArc order="94.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozFarmaceuticaLda.PortoSalvoMember" xlink:label="lbl_SandozFarmaceuticaLda.PortoSalvoMember" xlink:type="locator"/>
      <link:presentationArc order="95.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozFarmaceuticaLda.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:label="lbl_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:type="locator"/>
      <link:presentationArc order="96.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozS.R.L.TarguMuresMember" xlink:label="lbl_SandozS.R.L.TarguMuresMember" xlink:type="locator"/>
      <link:presentationArc order="97.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozS.R.L.TarguMuresMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaLLCMoscowMember" xlink:label="lbl_NovartisPharmaLLCMoscowMember" xlink:type="locator"/>
      <link:presentationArc order="98.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaLLCMoscowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNevaLLCSt.PetersburgMember" xlink:label="lbl_NovartisNevaLLCSt.PetersburgMember" xlink:type="locator"/>
      <link:presentationArc order="99.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNevaLLCSt.PetersburgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JSCSandozMoscowMember" xlink:label="lbl_JSCSandozMoscowMember" xlink:type="locator"/>
      <link:presentationArc order="100.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_JSCSandozMoscowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSaudiLtd.RiyadhMember" xlink:label="lbl_NovartisSaudiLtd.RiyadhMember" xlink:type="locator"/>
      <link:presentationArc order="101.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSaudiLtd.RiyadhMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSingaporePteLtd.SingaporeMember" xlink:label="lbl_NovartisSingaporePteLtd.SingaporeMember" xlink:type="locator"/>
      <link:presentationArc order="102.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSingaporePteLtd.SingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:label="lbl_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:type="locator"/>
      <link:presentationArc order="103.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:label="lbl_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:type="locator"/>
      <link:presentationArc order="104.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSlovakiaS.r.o.BratislavaMember" xlink:label="lbl_NovartisSlovakiaS.r.o.BratislavaMember" xlink:type="locator"/>
      <link:presentationArc order="105.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSlovakiaS.r.o.BratislavaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LekPharmaceuticalsD.d.LjubjanaMember" xlink:label="lbl_LekPharmaceuticalsD.d.LjubjanaMember" xlink:type="locator"/>
      <link:presentationArc order="106.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_LekPharmaceuticalsD.d.LjubjanaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:label="lbl_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:type="locator"/>
      <link:presentationArc order="107.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPharmaceuticalsD.d.LjubjanaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSouthAfricaPtyLtdMidrandMember" xlink:label="lbl_NovartisSouthAfricaPtyLtdMidrandMember" xlink:type="locator"/>
      <link:presentationArc order="108.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSouthAfricaPtyLtdMidrandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozSouthAfricaPtyLtdMidrandMember" xlink:label="lbl_SandozSouthAfricaPtyLtdMidrandMember" xlink:type="locator"/>
      <link:presentationArc order="109.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozSouthAfricaPtyLtdMidrandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisKoreaLtd.SeoulMember" xlink:label="lbl_NovartisKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:presentationArc order="110.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisKoreaLtd.SeoulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:label="lbl_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:type="locator"/>
      <link:presentationArc order="111.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFarmaceuticaS.A.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:label="lbl_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:type="locator"/>
      <link:presentationArc order="112.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozFarmaceuticaS.A.MadridMember" xlink:label="lbl_SandozFarmaceuticaS.A.MadridMember" xlink:type="locator"/>
      <link:presentationArc order="113.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozFarmaceuticaS.A.MadridMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember" xlink:label="lbl_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember" xlink:type="locator"/>
      <link:presentationArc order="114.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:label="lbl_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:type="locator"/>
      <link:presentationArc order="115.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSverigeABStockholmMember" xlink:label="lbl_NovartisSverigeABStockholmMember" xlink:type="locator"/>
      <link:presentationArc order="116.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSverigeABStockholmMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHoldingAGBaselMember" xlink:label="lbl_NovartisHoldingAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="117.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHoldingAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:label="lbl_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="118.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBioventuresAGBaselMember" xlink:label="lbl_NovartisBioventuresAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="119.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBioventuresAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisForschungsstiftungBaselMember" xlink:label="lbl_NovartisForschungsstiftungBaselMember" xlink:type="locator"/>
      <link:presentationArc order="120.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisForschungsstiftungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisStiftungFuerKaderausbildungBaselMember" xlink:label="lbl_NovartisStiftungFuerKaderausbildungBaselMember" xlink:type="locator"/>
      <link:presentationArc order="121.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisStiftungFuerKaderausbildungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:label="lbl_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:type="locator"/>
      <link:presentationArc order="122.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisMitarbeiterbeteiligungsstiftungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:label="lbl_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:type="locator"/>
      <link:presentationArc order="123.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisStiftungFuerMenschUndUmweltBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:label="lbl_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:type="locator"/>
      <link:presentationArc order="124.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisOverseasInvestmentsAGBaselMember" xlink:label="lbl_NovartisOverseasInvestmentsAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="125.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisOverseasInvestmentsAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JapatAGBaselMember" xlink:label="lbl_JapatAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="126.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_JapatAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaAGBaselMember" xlink:label="lbl_NovartisPharmaAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="127.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaServicesAGBaselMember" xlink:label="lbl_NovartisPharmaServicesAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="128.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaServicesAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:label="lbl_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:type="locator"/>
      <link:presentationArc order="129.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaSchweizerhalleAGMuttenzMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaSteinAGSteinMember" xlink:label="lbl_NovartisPharmaSteinAGSteinMember" xlink:type="locator"/>
      <link:presentationArc order="130.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaSteinAGSteinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaSchweizAGRischMember" xlink:label="lbl_NovartisPharmaSchweizAGRischMember" xlink:type="locator"/>
      <link:presentationArc order="131.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaSchweizAGRischMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CellerysAGSchlierenMember" xlink:label="lbl_CellerysAGSchlierenMember" xlink:type="locator"/>
      <link:presentationArc order="132.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CellerysAGSchlierenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ArctosMedicalAGBernMember" xlink:label="lbl_ArctosMedicalAGBernMember" xlink:type="locator"/>
      <link:presentationArc order="133.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ArctosMedicalAGBernMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInnovativeTherapiesAGRischMember" xlink:label="lbl_NovartisInnovativeTherapiesAGRischMember" xlink:type="locator"/>
      <link:presentationArc order="134.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInnovativeTherapiesAGRischMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:label="lbl_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:type="locator"/>
      <link:presentationArc order="135.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozAGBaselMember" xlink:label="lbl_SandozAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="136.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozPharmaceuticalsAGRischMember" xlink:label="lbl_SandozPharmaceuticalsAGRischMember" xlink:type="locator"/>
      <link:presentationArc order="137.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozPharmaceuticalsAGRischMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:label="lbl_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:type="locator"/>
      <link:presentationArc order="138.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisTaiwanCo.Ltd.TaipeiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisThailandLimitedBangkokMember" xlink:label="lbl_NovartisThailandLimitedBangkokMember" xlink:type="locator"/>
      <link:presentationArc order="139.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisThailandLimitedBangkokMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:label="lbl_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:presentationArc order="140.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:label="lbl_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:type="locator"/>
      <link:presentationArc order="141.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:label="lbl_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:presentationArc order="142.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozIlacSanayiVeTicaretA.S.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:label="lbl_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:type="locator"/>
      <link:presentationArc order="143.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozUkraineLLCKievMember" xlink:label="lbl_SandozUkraineLLCKievMember" xlink:type="locator"/>
      <link:presentationArc order="144.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozUkraineLLCKievMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisMiddleEastFZEDubaiMember" xlink:label="lbl_NovartisMiddleEastFZEDubaiMember" xlink:type="locator"/>
      <link:presentationArc order="145.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisMiddleEastFZEDubaiMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUKLimitedLondonMember" xlink:label="lbl_NovartisUKLimitedLondonMember" xlink:type="locator"/>
      <link:presentationArc order="146.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUKLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:label="lbl_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:type="locator"/>
      <link:presentationArc order="147.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsUKLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGrimsbyLimitedLondonMember" xlink:label="lbl_NovartisGrimsbyLimitedLondonMember" xlink:type="locator"/>
      <link:presentationArc order="148.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGrimsbyLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:type="locator"/>
      <link:presentationArc order="149.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsUKIrelandLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeutecPharmaLimitedLondonMember" xlink:label="lbl_NeutecPharmaLimitedLondonMember" xlink:type="locator"/>
      <link:presentationArc order="150.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NeutecPharmaLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GyroscopeTherapeuticsLimitedLondonMember" xlink:label="lbl_GyroscopeTherapeuticsLimitedLondonMember" xlink:type="locator"/>
      <link:presentationArc order="151.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GyroscopeTherapeuticsLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozLimitedFrimleyCamberleyMember" xlink:label="lbl_SandozLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:presentationArc order="152.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCorporationEastHanoverNYMember" xlink:label="lbl_NovartisCorporationEastHanoverNYMember" xlink:type="locator"/>
      <link:presentationArc order="153.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCorporationEastHanoverNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceCorporationNewYorkNYMember" xlink:label="lbl_NovartisFinanceCorporationNewYorkNYMember" xlink:type="locator"/>
      <link:presentationArc order="154.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceCorporationNewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationEastHanoverNJMember" xlink:label="lbl_NovartisCapitalCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="155.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCapitalCorporationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisServicesInc.EastHanoverNYMember" xlink:label="lbl_NovartisServicesInc.EastHanoverNYMember" xlink:type="locator"/>
      <link:presentationArc order="156.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisServicesInc.EastHanoverNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUSFoundationEastHanoverNJMember" xlink:label="lbl_NovartisUSFoundationEastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="157.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUSFoundationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:label="lbl_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:type="locator"/>
      <link:presentationArc order="158.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsCorporationEastHanoverNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:type="locator"/>
      <link:presentationArc order="159.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGeneTherapiesInc.BannockburnILMember" xlink:label="lbl_NovartisGeneTherapiesInc.BannockburnILMember" xlink:type="locator"/>
      <link:presentationArc order="160.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGeneTherapiesInc.BannockburnILMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:label="lbl_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="161.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisTechnologyLLCInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:label="lbl_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:type="locator"/>
      <link:presentationArc order="162.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CadentTherapeuticsCambridgeMAMember" xlink:label="lbl_CadentTherapeuticsCambridgeMAMember" xlink:type="locator"/>
      <link:presentationArc order="163.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CadentTherapeuticsCambridgeMAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EndocyteInc.EastHanoverNJMember" xlink:label="lbl_EndocyteInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="164.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EndocyteInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:label="lbl_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:type="locator"/>
      <link:presentationArc order="165.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NavigateBioPharmaServicesInc.CarlsbadCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TheMedicinesCompanyMember" xlink:label="lbl_TheMedicinesCompanyMember" xlink:type="locator"/>
      <link:presentationArc order="166.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TheMedicinesCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozInc.PrincetonNJMember" xlink:label="lbl_SandozInc.PrincetonNJMember" xlink:type="locator"/>
      <link:presentationArc order="167.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozInc.PrincetonNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OrielTherapeuticsInc.DurhamNCMember" xlink:label="lbl_OrielTherapeuticsInc.DurhamNCMember" xlink:type="locator"/>
      <link:presentationArc order="168.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_OrielTherapeuticsInc.DurhamNCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:label="lbl_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:type="locator"/>
      <link:presentationArc order="169.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_FougeraPharmaceuticalsInc.MelvilleNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EonLabsInc.PrincetonNJMember" xlink:label="lbl_EonLabsInc.PrincetonNJMember" xlink:type="locator"/>
      <link:presentationArc order="170.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EonLabsInc.PrincetonNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeVenezuelaS.A.CaracasMember" xlink:label="lbl_NovartisDeVenezuelaS.A.CaracasMember" xlink:type="locator"/>
      <link:presentationArc order="171.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeVenezuelaS.A.CaracasMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:label="lbl_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:type="locator"/>
      <link:presentationArc order="172.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisVietnamCompanyLimitedHoChiMinhCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozManufacturingInc.Member" xlink:label="lbl_SandozManufacturingInc.Member" xlink:type="locator"/>
      <link:presentationArc order="173.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozManufacturingInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KedalionTherapeuticsInc.MenloParkCAMember" xlink:label="lbl_KedalionTherapeuticsInc.MenloParkCAMember" xlink:type="locator"/>
      <link:presentationArc order="174.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_KedalionTherapeuticsInc.MenloParkCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CortheraInc.SanMateoCAMember" xlink:label="lbl_CortheraInc.SanMateoCAMember" xlink:type="locator"/>
      <link:presentationArc order="175.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CortheraInc.SanMateoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:label="lbl_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:type="locator"/>
      <link:presentationArc order="176.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CoStimPharmaceuticalsInc.CambridgeMAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EncoreVisionInc.NewYorkNYMember" xlink:label="lbl_EncoreVisionInc.NewYorkNYMember" xlink:type="locator"/>
      <link:presentationArc order="177.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EncoreVisionInc.NewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EncoreVisionInc.EastHanoverNJMember" xlink:label="lbl_EncoreVisionInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="178.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EncoreVisionInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EndocyteInc.LafayetteINMember" xlink:label="lbl_EndocyteInc.LafayetteINMember" xlink:type="locator"/>
      <link:presentationArc order="179.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EndocyteInc.LafayetteINMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:label="lbl_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="180.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:label="lbl_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:type="locator"/>
      <link:presentationArc order="181.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SpinifexPharmaceuticalsInc.WilmingtonNCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:label="lbl_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="182.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SpinifexPharmaceuticalsInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:label="lbl_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:type="locator"/>
      <link:presentationArc order="183.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:label="lbl_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:type="locator"/>
      <link:presentationArc order="184.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:label="lbl_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="185.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInflammasomeResearchInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:label="lbl_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="186.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisOptogeneticsResearchInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmblyotechInc.EastHanoverNJMember" xlink:label="lbl_AmblyotechInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="187.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AmblyotechInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesInc.FortWorthTXMember" xlink:label="lbl_AlconLaboratoriesInc.FortWorthTXMember" xlink:type="locator"/>
      <link:presentationArc order="188.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesInc.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:label="lbl_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:type="locator"/>
      <link:presentationArc order="189.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconRefractivehorizonsLLCFortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconResearchLtd.FortWorthTXMember" xlink:label="lbl_AlconResearchLtd.FortWorthTXMember" xlink:type="locator"/>
      <link:presentationArc order="190.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconResearchLtd.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLensxInc.AlisoViejoCAMember" xlink:label="lbl_AlconLensxInc.AlisoViejoCAMember" xlink:type="locator"/>
      <link:presentationArc order="191.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLensxInc.AlisoViejoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:label="lbl_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:type="locator"/>
      <link:presentationArc order="192.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesHoldingCorporationFortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WaveLightInc.SterlingVAMember" xlink:label="lbl_WaveLightInc.SterlingVAMember" xlink:type="locator"/>
      <link:presentationArc order="193.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_WaveLightInc.SterlingVAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TearFilmInnovationsInc.FortWorthTXMember" xlink:label="lbl_TearFilmInnovationsInc.FortWorthTXMember" xlink:type="locator"/>
      <link:presentationArc order="194.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TearFilmInnovationsInc.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TrueVisionSystemsInc.FortWorthTXMember" xlink:label="lbl_TrueVisionSystemsInc.FortWorthTXMember" xlink:type="locator"/>
      <link:presentationArc order="195.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TrueVisionSystemsInc.FortWorthTXMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionCorporationLLCDuluthGAMember" xlink:label="lbl_CIBAVisionCorporationLLCDuluthGAMember" xlink:type="locator"/>
      <link:presentationArc order="196.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionCorporationLLCDuluthGAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:label="lbl_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:type="locator"/>
      <link:presentationArc order="197.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:label="lbl_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="198.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:label="lbl_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:type="locator"/>
      <link:presentationArc order="199.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ClarVistaMedicalInc.AlisoViejoCAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TranscendMedicalInc.LakeForestILMember" xlink:label="lbl_TranscendMedicalInc.LakeForestILMember" xlink:type="locator"/>
      <link:presentationArc order="200.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TranscendMedicalInc.LakeForestILMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaceuticalC.A.CaracasMember" xlink:label="lbl_AlconPharmaceuticalC.A.CaracasMember" xlink:type="locator"/>
      <link:presentationArc order="201.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaceuticalC.A.CaracasMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsAAAMember" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="locator"/>
      <link:presentationArc order="202.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:label="lbl_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:type="locator"/>
      <link:presentationArc order="203.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:label="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:type="locator"/>
      <link:presentationArc order="204.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisManufacturingGmbHMember" xlink:label="lbl_NovartisManufacturingGmbHMember" xlink:type="locator"/>
      <link:presentationArc order="205.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisManufacturingGmbHMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisManufacturingGmbHMarburgMember" xlink:label="lbl_NovartisManufacturingGmbHMarburgMember" xlink:type="locator"/>
      <link:presentationArc order="206.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisManufacturingGmbHMarburgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisTechnologyLLCMember" xlink:label="lbl_NovartisTechnologyLLCMember" xlink:type="locator"/>
      <link:presentationArc order="207.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisTechnologyLLCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInflammasomeResearchInc.Member" xlink:label="lbl_NovartisInflammasomeResearchInc.Member" xlink:type="locator"/>
      <link:presentationArc order="208.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInflammasomeResearchInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:label="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:type="locator"/>
      <link:presentationArc order="209.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:label="lbl_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:type="locator"/>
      <link:presentationArc order="210.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvacedAcceleratorApplicationsItalyS.r.l.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:label="lbl_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:type="locator"/>
      <link:presentationArc order="211.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImagingEquipmentLtdMember" xlink:label="lbl_ImagingEquipmentLtdMember" xlink:type="locator"/>
      <link:presentationArc order="212.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ImagingEquipmentLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IDBHollandBVMember" xlink:label="lbl_IDBHollandBVMember" xlink:type="locator"/>
      <link:presentationArc order="213.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_IDBHollandBVMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CELLforCUREMember" xlink:label="lbl_CELLforCUREMember" xlink:type="locator"/>
      <link:presentationArc order="214.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CELLforCUREMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriosS.A.BuenosAiresMember" xlink:label="lbl_AlconLaboratoriosS.A.BuenosAiresMember" xlink:type="locator"/>
      <link:presentationArc order="215.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriosS.A.BuenosAiresMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:label="lbl_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="locator"/>
      <link:presentationArc order="216.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconOphthalmikaGmbHViennaMember" xlink:label="lbl_AlconOphthalmikaGmbHViennaMember" xlink:type="locator"/>
      <link:presentationArc order="217.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconOphthalmikaGmbHViennaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:label="lbl_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:type="locator"/>
      <link:presentationArc order="218.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesBelgiumBVBAPuursMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconNVVilvoordeMember" xlink:label="lbl_AlconNVVilvoordeMember" xlink:type="locator"/>
      <link:presentationArc order="219.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconNVVilvoordeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisB2Ltd.HamiltonMember" xlink:label="lbl_NovartisB2Ltd.HamiltonMember" xlink:type="locator"/>
      <link:presentationArc order="220.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisB2Ltd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisB3Ltd.HamiltonMember" xlink:label="lbl_NovartisB3Ltd.HamiltonMember" xlink:type="locator"/>
      <link:presentationArc order="221.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisB3Ltd.HamiltonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCanadaInc.MississaugaOntarioMember" xlink:label="lbl_AlconCanadaInc.MississaugaOntarioMember" xlink:type="locator"/>
      <link:presentationArc order="222.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCanadaInc.MississaugaOntarioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:label="lbl_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:type="locator"/>
      <link:presentationArc order="223.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionCanadaInc.MississaugaOntarioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:label="lbl_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:type="locator"/>
      <link:presentationArc order="224.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriosChileLtd.SantiagoDeChileMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:label="lbl_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:type="locator"/>
      <link:presentationArc order="225.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconHongKongLimitedHongKongMember" xlink:label="lbl_AlconHongKongLimitedHongKongMember" xlink:type="locator"/>
      <link:presentationArc order="226.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconHongKongLimitedHongKongMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:label="lbl_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:type="locator"/>
      <link:presentationArc order="227.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:label="lbl_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:type="locator"/>
      <link:presentationArc order="228.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:label="lbl_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:type="locator"/>
      <link:presentationArc order="229.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconNordicASCopenhagenMember" xlink:label="lbl_AlconNordicASCopenhagenMember" xlink:type="locator"/>
      <link:presentationArc order="230.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconNordicASCopenhagenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:label="lbl_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:type="locator"/>
      <link:presentationArc order="231.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_LaboratoiresAlconS.A.S.RueilMalmaisonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisDeutschlandGmbHWehrMember" xlink:label="lbl_NovartisDeutschlandGmbHWehrMember" xlink:type="locator"/>
      <link:presentationArc order="232.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisDeutschlandGmbHWehrMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:label="lbl_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:type="locator"/>
      <link:presentationArc order="233.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaGmbHFreiburgImBreisgauMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WaveLightGmbHErlangenMember" xlink:label="lbl_WaveLightGmbHErlangenMember" xlink:type="locator"/>
      <link:presentationArc order="234.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_WaveLightGmbHErlangenMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionGmbHGrosswallstadtMember" xlink:label="lbl_CIBAVisionGmbHGrosswallstadtMember" xlink:type="locator"/>
      <link:presentationArc order="235.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionGmbHGrosswallstadtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovistaInsuranceLimitedGibraltarCityMember" xlink:label="lbl_NovistaInsuranceLimitedGibraltarCityMember" xlink:type="locator"/>
      <link:presentationArc order="236.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovistaInsuranceLimitedGibraltarCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:label="lbl_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:type="locator"/>
      <link:presentationArc order="237.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:label="lbl_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:type="locator"/>
      <link:presentationArc order="238.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PT.CIBAVisionBatamBatamMember" xlink:label="lbl_PT.CIBAVisionBatamBatamMember" xlink:type="locator"/>
      <link:presentationArc order="239.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_PT.CIBAVisionBatamBatamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:label="lbl_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:type="locator"/>
      <link:presentationArc order="240.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:label="lbl_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:type="locator"/>
      <link:presentationArc order="241.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesIrelandLimitedCorkCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OptonolLtd.NeveIlanMember" xlink:label="lbl_OptonolLtd.NeveIlanMember" xlink:type="locator"/>
      <link:presentationArc order="242.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_OptonolLtd.NeveIlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:label="lbl_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:type="locator"/>
      <link:presentationArc order="243.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozIndustrialProductsS.p.A.RoveretoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconItaliaS.p.A.MilanMember" xlink:label="lbl_AlconItaliaS.p.A.MilanMember" xlink:type="locator"/>
      <link:presentationArc order="244.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconItaliaS.p.A.MilanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHoldingJapanK.K.TokyoMember" xlink:label="lbl_NovartisHoldingJapanK.K.TokyoMember" xlink:type="locator"/>
      <link:presentationArc order="245.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisHoldingJapanK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AspenJapanK.K.TokyoMember" xlink:label="lbl_AspenJapanK.K.TokyoMember" xlink:type="locator"/>
      <link:presentationArc order="246.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AspenJapanK.K.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconJapanLtd.TokyoMember" xlink:label="lbl_AlconJapanLtd.TokyoMember" xlink:type="locator"/>
      <link:presentationArc order="247.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconJapanLtd.TokyoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:label="lbl_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="locator"/>
      <link:presentationArc order="248.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:label="lbl_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:type="locator"/>
      <link:presentationArc order="249.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:label="lbl_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:type="locator"/>
      <link:presentationArc order="250.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNetherlandsB.V.ArnhemMember" xlink:label="lbl_NovartisNetherlandsB.V.ArnhemMember" xlink:type="locator"/>
      <link:presentationArc order="251.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisNetherlandsB.V.ArnhemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaB.V.ArnhemMember" xlink:label="lbl_NovartisPharmaB.V.ArnhemMember" xlink:type="locator"/>
      <link:presentationArc order="252.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaB.V.ArnhemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconNederlandB.V.ArnhemMember" xlink:label="lbl_AlconNederlandB.V.ArnhemMember" xlink:type="locator"/>
      <link:presentationArc order="253.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconNederlandB.V.ArnhemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCentroamericaS.A.PanamaCityMember" xlink:label="lbl_AlconCentroamericaS.A.PanamaCityMember" xlink:type="locator"/>
      <link:presentationArc order="254.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCentroamericaS.A.PanamaCityMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisBiosciencesPeruS.A.LimaMember" xlink:label="lbl_NovartisBiosciencesPeruS.A.LimaMember" xlink:type="locator"/>
      <link:presentationArc order="255.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisBiosciencesPeruS.A.LimaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPolskaSp.ZO.o.WarsawMember" xlink:label="lbl_AlconPolskaSp.ZO.o.WarsawMember" xlink:type="locator"/>
      <link:presentationArc order="256.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPolskaSp.ZO.o.WarsawMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:label="lbl_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:type="locator"/>
      <link:presentationArc order="257.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconRomaniaS.R.L.BucharestMember" xlink:label="lbl_AlconRomaniaS.R.L.BucharestMember" xlink:type="locator"/>
      <link:presentationArc order="258.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconRomaniaS.R.L.BucharestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconFarmacevtikaLLCMoscowMember" xlink:label="lbl_AlconFarmacevtikaLLCMoscowMember" xlink:type="locator"/>
      <link:presentationArc order="259.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconFarmacevtikaLLCMoscowMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:label="lbl_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:type="locator"/>
      <link:presentationArc order="260.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:label="lbl_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:type="locator"/>
      <link:presentationArc order="261.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPteLtdSingaporeMember" xlink:label="lbl_AlconPteLtdSingaporeMember" xlink:type="locator"/>
      <link:presentationArc order="262.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:label="lbl_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:type="locator"/>
      <link:presentationArc order="263.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconSingaporeManufacturingPteLtdSingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:label="lbl_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:type="locator"/>
      <link:presentationArc order="264.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:label="lbl_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:type="locator"/>
      <link:presentationArc order="265.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozKoreaLtd.SeoulMember" xlink:label="lbl_SandozKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:presentationArc order="266.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozKoreaLtd.SeoulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconKoreaLtd.SeoulMember" xlink:label="lbl_AlconKoreaLtd.SeoulMember" xlink:type="locator"/>
      <link:presentationArc order="267.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconKoreaLtd.SeoulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:label="lbl_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:type="locator"/>
      <link:presentationArc order="268.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconHealthcareS.A.BarcelonaMember" xlink:label="lbl_AlconHealthcareS.A.BarcelonaMember" xlink:type="locator"/>
      <link:presentationArc order="269.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconHealthcareS.A.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconCusiS.A.BarcelonaMember" xlink:label="lbl_AlconCusiS.A.BarcelonaMember" xlink:type="locator"/>
      <link:presentationArc order="270.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconCusiS.A.BarcelonaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInternationalAGBaselMember" xlink:label="lbl_NovartisInternationalAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="271.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInternationalAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisInternationalPharmaceuticalAGBaselMember" xlink:label="lbl_NovartisInternationalPharmaceuticalAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="272.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisInternationalPharmaceuticalAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:label="lbl_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:type="locator"/>
      <link:presentationArc order="273.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconAGFribourgMember" xlink:label="lbl_AlconAGFribourgMember" xlink:type="locator"/>
      <link:presentationArc order="274.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconAGFribourgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconManagementSAGenevaMember" xlink:label="lbl_AlconManagementSAGenevaMember" xlink:type="locator"/>
      <link:presentationArc order="275.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconManagementSAGenevaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconSwitzerlandSARischMember" xlink:label="lbl_AlconSwitzerlandSARischMember" xlink:type="locator"/>
      <link:presentationArc order="276.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconSwitzerlandSARischMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconPharmaceuticalsLtd.FribourgMember" xlink:label="lbl_AlconPharmaceuticalsLtd.FribourgMember" xlink:type="locator"/>
      <link:presentationArc order="277.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconPharmaceuticalsLtd.FribourgMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGBaselMember" xlink:label="lbl_RocheHoldingAGBaselMember" xlink:type="locator"/>
      <link:presentationArc order="278.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_RocheHoldingAGBaselMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratoriesThailandLimitedBangkokMember" xlink:label="lbl_AlconLaboratoriesThailandLimitedBangkokMember" xlink:type="locator"/>
      <link:presentationArc order="279.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratoriesThailandLimitedBangkokMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:label="lbl_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:type="locator"/>
      <link:presentationArc order="280.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:label="lbl_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:type="locator"/>
      <link:presentationArc order="281.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconLaboratuvarlariTicaretA.S.IstanbulMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUKLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:presentationArc order="282.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUKLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:presentationArc order="283.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:label="lbl_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:presentationArc order="284.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisGrimsbyLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImagingEquipmentLtdLondonMember" xlink:label="lbl_ImagingEquipmentLtdLondonMember" xlink:type="locator"/>
      <link:presentationArc order="285.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ImagingEquipmentLtdLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VivactaLimitedFrimleyCamberleySurreyMember" xlink:label="lbl_VivactaLimitedFrimleyCamberleySurreyMember" xlink:type="locator"/>
      <link:presentationArc order="286.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_VivactaLimitedFrimleyCamberleySurreyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:label="lbl_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:type="locator"/>
      <link:presentationArc order="287.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZiarcoGroupLimitedLondonMember" xlink:label="lbl_ZiarcoGroupLimitedLondonMember" xlink:type="locator"/>
      <link:presentationArc order="288.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ZiarcoGroupLimitedLondonMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:label="lbl_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:type="locator"/>
      <link:presentationArc order="289.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CoalesceProductDevelopmentLimitedCambridgeCambsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:label="lbl_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:type="locator"/>
      <link:presentationArc order="290.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AlconEyeCareUKLimitedFrimleyCamberleyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:label="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="locator"/>
      <link:presentationArc order="291.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisFinanceCorporationEastHanoverNJMember" xlink:label="lbl_NovartisFinanceCorporationEastHanoverNJMember" xlink:type="locator"/>
      <link:presentationArc order="292.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisFinanceCorporationEastHanoverNJMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisCapitalCorporationNewYorkNYMember" xlink:label="lbl_NovartisCapitalCorporationNewYorkNYMember" xlink:type="locator"/>
      <link:presentationArc order="293.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisCapitalCorporationNewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisUSFoundationNewYorkNYMember" xlink:label="lbl_NovartisUSFoundationNewYorkNYMember" xlink:type="locator"/>
      <link:presentationArc order="294.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_NovartisUSFoundationNewYorkNYMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember" xlink:label="lbl_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_A1APharmaGmbHHolzkirchenMember" xlink:label="lbl_A1APharmaGmbHHolzkirchenMember" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="lbl_DefinedBenefitPlansAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_DefinedBenefitPlansAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="lbl_DefinedBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlansAxis" xlink:to="lbl_DefinedBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConcentrationOfMajorPlansGeographic" xlink:label="lbl_ConcentrationOfMajorPlansGeographic" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ConcentrationOfMajorPlansGeographic" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements" xlink:label="lbl_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements1" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements1" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:label="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MajorPlansPercentageInGroupDBOPensions" xlink:label="lbl_MajorPlansPercentageInGroupDBOPensions" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_MajorPlansPercentageInGroupDBOPensions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:label="lbl_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:type="locator"/>
      <link:presentationArc order="3.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:label="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="locator"/>
      <link:presentationArc order="24.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward1" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward1" xlink:to="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="locator"/>
      <link:presentationArc order="25.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="lbl_PlanAssetsAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_PlanAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward1" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward1" xlink:to="lbl_PlanAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:type="locator"/>
      <link:presentationArc order="26.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LimitationOnRecognitionOfFundSurplus" xlink:label="lbl_LimitationOnRecognitionOfFundSurplus" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward1" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward1" xlink:to="lbl_LimitationOnRecognitionOfFundSurplus" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_LimitationOnRecognitionOfFundSurplus" xlink:type="arc"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:presentationArc order="27.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_PaymentsFromPlanNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanSettlementsPlanAssets" xlink:label="lbl_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="-0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:label="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:type="arc"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward1" xlink:to="lbl_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:label="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:type="locator"/>
      <link:presentationArc order="11.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" xlink:type="arc"/>
      <link:presentationArc order="5.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="lbl_SurplusDeficitInPlan" xlink:type="locator"/>
      <link:presentationArc order="25.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_SurplusDeficitInPlan" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="8.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="0.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestIncomeOnLimitationOfFundSurplus" xlink:label="lbl_InterestIncomeOnLimitationOfFundSurplus" xlink:type="locator"/>
      <link:presentationArc order="1.9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_InterestIncomeOnLimitationOfFundSurplus" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:label="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:type="locator"/>
      <link:presentationArc order="1.6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" xlink:to="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:type="arc"/>
      <link:presentationArc order="4.1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_DefinedBenefitPlanInterestCost" xlink:type="arc"/>
      <link:presentationArc order="5.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanInterestCost" xlink:label="lbl_DefinedBenefitPlanInterestCost" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:label="lbl_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:label="lbl_InterestExpenseIncomeDefinedBenefitLiabilityAsset" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:label="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:label="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward1" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:label="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:label="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_CurrentServiceCostNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:label="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward1" xlink:to="lbl_LiabilityAssetOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrepaidPostemploymentBenefitPlansAssets" xlink:label="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:to="lbl_PrepaidPostemploymentBenefitPlansAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:label="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" xlink:to="lbl_DefinedBenefitPensionPlanAccruedBenefitLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:label="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:label="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="5.9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:label="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:presentationArc order="8.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:label="lbl_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:label="lbl_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:type="locator"/>
      <link:presentationArc order="5.4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:label="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:type="locator"/>
      <link:presentationArc order="10.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanChangeInNetLiabilityRollForward" xlink:to="lbl_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ForeignCountriesMember" xlink:label="lbl_ForeignCountriesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_ForeignCountriesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ObligationByTypeAxis" xlink:label="lbl_ObligationByTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_ObligationByTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ObligationByTypeMember" xlink:label="lbl_ObligationByTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ObligationByTypeAxis" xlink:to="lbl_ObligationByTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnfundedMember" xlink:label="lbl_UnfundedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_UnfundedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActiveMember" xlink:label="lbl_ActiveMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_ActiveMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredPensionersMember" xlink:label="lbl_DeferredPensionersMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_DeferredPensionersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionersMember" xlink:label="lbl_PensionersMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ObligationByTypeMember" xlink:to="lbl_PensionersMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SurplusDeficitInPlan" xlink:label="lbl_SurplusDeficitInPlan" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_SurplusDeficitInPlan" xlink:type="arc"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_DefinedBenefitObligationAtPresentValue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PlanAssetsAtFairValue" xlink:label="lbl_PlanAssetsAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems" xlink:to="lbl_PlanAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="2.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:presentationArc order="2.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTable" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRates" xlink:label="lbl_ActuarialAssumptionOfDiscountRates" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfDiscountRates" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreases" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitAssumptionLifeExpectancyMale" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyMale" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitAssumptionLifeExpectancyMale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:label="lbl_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitAssumptionLifeExpectancyFemale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:label="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="lbl_ActuarialAssumptionsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="lbl_ActuarialAssumptionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:label="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="lbl_ActuarialAssumptionsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ActuarialAssumptionsAxis" xlink:to="lbl_ActuarialAssumptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfDiscountRatesMember" xlink:label="lbl_ActuarialAssumptionOfDiscountRatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfDiscountRatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LifeExpectancyMember" xlink:label="lbl_LifeExpectancyMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_LifeExpectancyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:label="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ActuarialAssumptionsMember" xlink:to="lbl_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInActuarialAssumptionAxis" xlink:label="lbl_ChangeInActuarialAssumptionAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable" xlink:to="lbl_ChangeInActuarialAssumptionAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInActuarialAssumptionMember" xlink:label="lbl_ChangeInActuarialAssumptionMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeInActuarialAssumptionAxis" xlink:to="lbl_ChangeInActuarialAssumptionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Decrease25BasisPointMember" xlink:label="lbl_Decrease25BasisPointMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Decrease25BasisPointMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Increase1YearMember" xlink:label="lbl_Increase1YearMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Increase1YearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:label="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:label="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems" xlink:to="lbl_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Increase25BasisPointMember" xlink:label="lbl_Increase25BasisPointMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Increase25BasisPointMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Change25BasisPointMember" xlink:label="lbl_Change25BasisPointMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeInActuarialAssumptionMember" xlink:to="lbl_Change25BasisPointMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfHealthCareCostTrendRatesTable" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfHealthCareCostTrendRatesTable" xlink:to="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:label="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:label="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAllocationOfPlanAssetsTable" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfAllocationOfPlanAssetsTable" xlink:to="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_DebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityInvestmentsMember" xlink:label="lbl_EquityInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_EquityInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RealEstateMember" xlink:label="lbl_RealEstateMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_RealEstateMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlternativeInvestmentsMember" xlink:label="lbl_AlternativeInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_AlternativeInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndOtherInvestmentsMember" xlink:label="lbl_CashAndOtherInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_CashAndOtherInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:label="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:label="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanPlanAssetAllocations" xlink:label="lbl_DefinedBenefitPlanPlanAssetAllocations" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanPlanAssetAllocations" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_EmployerSharesHeldByDefinedBenefitPlan" xlink:type="arc"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:label="lbl_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_WeightedAverageDurationOfDefinedBenefitObligationYears" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EmployerSharesHeldByDefinedBenefitPlan" xlink:label="lbl_EmployerSharesHeldByDefinedBenefitPlan" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:label="lbl_ValueOfEmployerSharesHeldByDefinedBenefitPlan" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:label="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" xlink:to="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:to="lbl_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="lbl_EmployeeBenefitsExpense" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" xlink:to="lbl_EmployeeBenefitsExpense" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfExpectedBenefitPaymentsTable" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:to="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" xlink:to="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" xlink:to="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="lbl_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfExpectedBenefitPaymentsTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:label="lbl_DefinedBenefitPlanExpectedFutureBenefitPayment" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:label="lbl_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsAndNotLaterThanTenYearsMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsImpairedMember" xlink:label="lbl_FinancialAssetsImpairedMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_FinancialAssetsImpairedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="lbl_RightofuseAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_RightofuseAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:label="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract" xlink:to="lbl_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:label="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:label="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="lbl_AdjustmentsForSharebasedPayments" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForSharebasedPayments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="lbl_AdjustmentsForFinanceIncomeCost" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAdjustmentsForNoncashItems" xlink:label="lbl_OtherAdjustmentsForNoncashItems" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherAdjustmentsForNoncashItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:label="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" xlink:label="lbl_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" xlink:label="lbl_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonExecutiveDirectorMember" xlink:label="lbl_NonExecutiveDirectorMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_NonExecutiveDirectorMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="lbl_KeyManagementPersonnelCompensation" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensation" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfDrBrodyMember" xlink:label="lbl_ProfDrBrodyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_ProfDrBrodyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfDrZinkernagelMember" xlink:label="lbl_ProfDrZinkernagelMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_ProfDrZinkernagelMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DrAlexKrauerMember" xlink:label="lbl_DrAlexKrauerMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_DrAlexKrauerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DrDanielVasellaMember" xlink:label="lbl_DrDanielVasellaMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_DrDanielVasellaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DrJamesBradnerMember" xlink:label="lbl_DrJamesBradnerMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="lbl_DrJamesBradnerMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="lbl_KeyManagementPersonnelCompensation" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationDailyRate" xlink:label="lbl_KeyManagementPersonnelCompensationDailyRate" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationDailyRate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:label="lbl_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationSharesAcquired" xlink:label="lbl_KeyManagementPersonnelCompensationSharesAcquired" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationSharesAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:label="lbl_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationOwnershipInterestAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:label="lbl_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:type="locator"/>
      <link:presentationArc order="8.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_KeyManagementPersonnelCompensationSharesAcquiredPrice" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCreditFacilityUncommitted" xlink:label="lbl_BorrowingsCreditFacilityUncommitted" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_BorrowingsCreditFacilityUncommitted" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPensionFundMember" xlink:label="lbl_NovartisPensionFundMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NovartisPensionFundMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAbstract" xlink:label="lbl_ComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:to="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ActuarialLossesFromDefinedBenefitPlansMember" xlink:label="lbl_ActuarialLossesFromDefinedBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_ActuarialLossesFromDefinedBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationEffectsMember" xlink:label="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:label="lbl_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_ReclassificationToPresentationRequiredUnderIFRS9Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestatedValueAdjustmentsMember" xlink:label="lbl_RestatedValueAdjustmentsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_RestatedValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnFinancialAssetsSold" xlink:label="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="locator"/>
      <link:presentationArc order="2.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_FairValueAdjustmentsOnFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:label="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnMarketableSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnDebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:label="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnEquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_NoncontrollingInterestsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="locator"/>
      <link:presentationArc order="2.65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="2.67" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="locator"/>
      <link:presentationArc order="2.68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:label="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="2.69" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_GainsLossesOnValueAdjustmentOnComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainLossOnSaleOfOtherFinancialAssets" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="2.695" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems1" xlink:type="locator"/>
      <link:presentationArc order="2.8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems1" xlink:to="lbl_ValueAdjustmentOnComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeDebtSecurities" xlink:type="locator"/>
      <link:presentationArc order="2.62" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsRelatedToDivestments" xlink:label="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="locator"/>
      <link:presentationArc order="2.75" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_FairValueAdjustmentsRelatedToDivestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:label="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="locator"/>
      <link:presentationArc order="2.77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:label="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="locator"/>
      <link:presentationArc order="2.66" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="locator"/>
      <link:presentationArc order="2.57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:label="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="locator"/>
      <link:presentationArc order="2.58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeNetOfTaxCashFlowHedges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:label="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:type="locator"/>
      <link:presentationArc order="2.6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalFairValueAdjustmentsMember" xlink:label="lbl_TotalFairValueAdjustmentsMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_TotalFairValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetInvestmentHedgeMember" xlink:label="lbl_NetInvestmentHedgeMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_NetInvestmentHedgeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsOnEquitySecuritiesSoldMember" xlink:label="lbl_FairValueAdjustmentsOnEquitySecuritiesSoldMember" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_FairValueAdjustmentsOnEquitySecuritiesSoldMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes" xlink:label="lbl_CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes" xlink:type="locator"/>
      <link:presentationArc order="10.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" xlink:to="lbl_CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueAdjustmentsRelatedToDivestmentsMember" xlink:label="lbl_ValueAdjustmentsRelatedToDivestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="4.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FairValueAdjustmentsOnFinancialInstrumentsMember" xlink:to="lbl_ValueAdjustmentsRelatedToDivestmentsMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAbstract" xlink:label="lbl_ComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_GoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_OtherIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:label="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DisposalsAndRetirementsIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="lbl_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems1" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems1" xlink:to="lbl_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AlconBrandNameMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="10.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:presentationArc order="12.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:label="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSale" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:label="lbl_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AccumulatedImpairmentsOnDisposalsAndDerecognitions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:label="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:label="lbl_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:type="locator"/>
      <link:presentationArc order="12.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:label="lbl_AmortizationPriorToClassificationToAssetsHeldForSale" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:label="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="1.7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="8.5" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:label="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:label="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="1.6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_GoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_OtherIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="lbl_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_UnallocatedAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AlconBrandNameMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:presentationArc order="6.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_UnallocatedAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:label="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:label="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnallocatedAmountsMember" xlink:label="lbl_UnallocatedAmountsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_UnallocatedAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:label="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VotrientMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SerelaxinMember" xlink:label="lbl_SerelaxinMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SerelaxinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CyPassMember" xlink:label="lbl_CyPassMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_CyPassMember" xlink:type="arc"/>
      <link:presentationArc order="2.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:presentationArc order="3.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:presentationArc order="4.1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillMember" xlink:label="lbl_GoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_GoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredResearchAndDevelopmentMember" xlink:label="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AcquiredResearchAndDevelopmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconBrandNameMember" xlink:label="lbl_AlconBrandNameMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_AlconBrandNameMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TechnologybasedIntangibleAssetsMember" xlink:label="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_TechnologybasedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketingRelatedIntangibleAssetsMember" xlink:label="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_MarketingRelatedIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIntangibleAssetsMember" xlink:label="lbl_OtherIntangibleAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_OtherIntangibleAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:presentationArc order="0.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherProductsMember" xlink:label="lbl_OtherProductsMember" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="lbl_GrossCarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_GrossCarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:label="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_LiabilitiesFromSharebasedPaymentTransactions2011" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="4.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_RangeAxis" xlink:type="arc"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangeAxis" xlink:to="lbl_RangesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="lbl_BottomOfRangeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesMember" xlink:to="lbl_BottomOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="lbl_TopOfRangeMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesMember" xlink:to="lbl_TopOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:label="lbl_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_ExplanationOfShareOptionsInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentivePlanMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentivePlanMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationLeveragedShareSavingsPlanMember" xlink:type="arc"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermPerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermPerformancePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="arc"/>
      <link:presentationArc order="14.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationRestrictedSharesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:to="lbl_EquityBasedParticipationRestrictedSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationSpecialShareAwardsMember" xlink:label="lbl_EquityBasedParticipationSpecialShareAwardsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationOtherShareAwardsMember" xlink:to="lbl_EquityBasedParticipationSpecialShareAwardsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:label="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationEmployeeShareOwnershipPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationUKShareSavingsPlanMember" xlink:label="lbl_EquityBasedParticipationUKShareSavingsPlanMember" xlink:type="locator"/>
      <link:presentationArc order="0.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationShareSavingsPlanMember" xlink:to="lbl_EquityBasedParticipationUKShareSavingsPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAnnualIncentive" xlink:label="lbl_DescriptionOfAnnualIncentive" xlink:type="locator"/>
      <link:presentationArc order="4.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_DescriptionOfAnnualIncentive" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:label="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="lbl_NumberOfOutstandingShareOptions" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.7Member" xlink:type="arc"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice54.5Member" xlink:type="arc"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.0Member" xlink:type="arc"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.6Member" xlink:type="arc"/>
      <link:presentationArc order="5.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.0Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice46.7Member" xlink:label="lbl_ExercisePrice46.7Member" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice54.5Member" xlink:label="lbl_ExercisePrice54.5Member" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.0Member" xlink:label="lbl_ExercisePrice57.0Member" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.6Member" xlink:label="lbl_ExercisePrice57.6Member" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice66.0Member" xlink:label="lbl_ExercisePrice66.0Member" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:presentationArc order="1.2" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:presentationArc order="0.7" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice66.1Member" xlink:label="lbl_ExercisePrice66.1Member" xlink:type="locator"/>
      <link:presentationArc order="10.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.1Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice46.4Member" xlink:label="lbl_ExercisePrice46.4Member" xlink:type="locator"/>
      <link:presentationArc order="0.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.4Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice53.7Member" xlink:label="lbl_ExercisePrice53.7Member" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice53.7Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.1Member" xlink:label="lbl_ExercisePrice57.1Member" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.1Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice58.3Member" xlink:label="lbl_ExercisePrice58.3Member" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice58.3Member" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice65.9Member" xlink:label="lbl_ExercisePrice65.9Member" xlink:type="locator"/>
      <link:presentationArc order="5.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice65.9Member" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="lbl_NumberOfOutstandingShareOptions" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract" xlink:to="lbl_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice46.4Member" xlink:label="lbl_ExercisePrice46.4Member" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.4Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice46.7Member" xlink:label="lbl_ExercisePrice46.7Member" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice46.7Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice53.7Member" xlink:label="lbl_ExercisePrice53.7Member" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice53.7Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice54.5Member" xlink:label="lbl_ExercisePrice54.5Member" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice54.5Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.0Member" xlink:label="lbl_ExercisePrice57.0Member" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.0Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.1Member" xlink:label="lbl_ExercisePrice57.1Member" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.1Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice57.6Member" xlink:label="lbl_ExercisePrice57.6Member" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice57.6Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice58.3Member" xlink:label="lbl_ExercisePrice58.3Member" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice58.3Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice66.0Member" xlink:label="lbl_ExercisePrice66.0Member" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.0Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice66.1Member" xlink:label="lbl_ExercisePrice66.1Member" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice66.1Member" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:label="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExercisePrice65.9Member" xlink:label="lbl_ExercisePrice65.9Member" xlink:type="locator"/>
      <link:presentationArc order="8.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lbl_ExercisePrice65.9Member" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfReportableSegments" xlink:label="lbl_NumberOfReportableSegments" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfReportableSegments" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfBusinessUnits" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfFranchises" xlink:label="lbl_NumberOfFranchises" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfFranchises" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsumerHealthMember" xlink:label="lbl_ConsumerHealthMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_ConsumerHealthMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfBusinessUnits" xlink:label="lbl_NumberOfBusinessUnits" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfCommercialOrganizationalUnits" xlink:label="lbl_NumberOfCommercialOrganizationalUnits" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NumberOfCommercialOrganizationalUnits" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="lbl_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromInterest" xlink:label="lbl_RevenueFromInterest" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromInterest" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="lbl_DepreciationAndAmortisationExpense" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DepreciationAndAmortisationExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:label="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:label="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="lbl_RightofuseAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_RightofuseAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:presentationArc order="2.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="2.65" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:label="lbl_ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.67" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ClassesOfProvisionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_OtherProvisionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestructuringProvisionMember" xlink:label="lbl_RestructuringProvisionMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_RestructuringProvisionMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalProvisionsOtherProvisions" xlink:label="lbl_AdditionalProvisionsOtherProvisions" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionalProvisionsOtherProvisions" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="lbl_Assets" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Assets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="lbl_Equity" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Equity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetOperatingAssets" xlink:label="lbl_NetOperatingAssets" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetOperatingAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="lbl_PropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_PropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="lbl_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_InvestmentAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialDebtsAndDerivativeInstruments" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:label="lbl_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_CurrentIncomeTaxAndDeferredTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="6.7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="8.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="lbl_Liabilities" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_Liabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDebt" xlink:label="lbl_NetDebt" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetDebt" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="lbl_AdditionsToRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="6.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsToRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="6.75" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionsToInvestmentInAssociatedCompanies" xlink:label="lbl_AdditionsToInvestmentInAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="10.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdditionsToInvestmentInAssociatedCompanies" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssets" xlink:type="arc"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="lbl_CountryOfDomicileMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CountryOfDomicileMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCountriesMember" xlink:label="lbl_OtherCountriesMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_OtherCountriesMember" xlink:type="arc"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB" xlink:label="lbl_GB" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_GB" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="lbl_DE" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_DE" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP" xlink:label="lbl_JP" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_JP" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR" xlink:label="lbl_FR" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_FR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN" xlink:label="lbl_CN" xlink:type="locator"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CN" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssets" xlink:type="arc"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AsiaAfricaAustralasiaMember" xlink:label="lbl_AsiaAfricaAustralasiaMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:label="lbl_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="lbl_EuropeMember1" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AmericasMember" xlink:label="lbl_AmericasMember1" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EuropeMember1" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_AsiaAfricaAustralasiaMember" xlink:type="arc"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_AmericasMember1" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersTable" xlink:label="lbl_DisclosureOfMajorCustomersTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersAbstract" xlink:label="lbl_DisclosureOfMajorCustomersAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersAbstract" xlink:to="lbl_DisclosureOfMajorCustomersTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:label="lbl_DisclosureOfMajorCustomersLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="lbl_PercentageOfEntitysRevenue" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysRevenue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="lbl_MajorCustomersAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersTable" xlink:to="lbl_MajorCustomersAxis" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersTable" xlink:to="lbl_DisclosureOfMajorCustomersLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="lbl_MajorCustomersMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersAxis" xlink:to="lbl_MajorCustomersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LargestCustomerMember" xlink:label="lbl_LargestCustomerMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_LargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SecondLargestCustomerMember" xlink:label="lbl_SecondLargestCustomerMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_SecondLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ThirdLargestCustomerMember" xlink:label="lbl_ThirdLargestCustomerMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_ThirdLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CustomersWithNetSalesOverFivePercent" xlink:label="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfEntitysTradeReceivable" xlink:label="lbl_PercentageOfEntitysTradeReceivable" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysTradeReceivable" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="locator"/>
      <link:presentationArc order="2.7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:label="lbl_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_RangeAxis" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangeAxis" xlink:to="lbl_RangesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="lbl_TopOfRangeMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesMember" xlink:to="lbl_TopOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="lbl_ProportionOfOwnershipInterestInAssociate" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ProportionOfOwnershipInterestInAssociate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsReceived" xlink:label="lbl_DividendsReceived" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_DividendsReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContributionOfBusinessToJointVenture" xlink:label="lbl_ContributionOfBusinessToJointVenture" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ContributionOfBusinessToJointVenture" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsolidatedIncomeStatementEffectsTable" xlink:label="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShareOfCurrentYearNetIncome" xlink:label="lbl_ShareOfCurrentYearNetIncome" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfCurrentYearNetIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PriorYearAdjustment" xlink:label="lbl_PriorYearAdjustment" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_PriorYearAdjustment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:label="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:label="lbl_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:to="lbl_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:label="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:label="lbl_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_PartialReleaseOfDeferredTaxLiabilityRecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ConsolidatedIncomeStatementEffectsTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationEffectsMember" xlink:label="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_CumulativeCurrencyTranslationEffectsMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:label="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:label="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherLongtermEmployeeBenefitsAndDeferredCompensation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefits" xlink:label="lbl_OtherPostemploymentBenefits" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherPostemploymentBenefits" xlink:type="arc"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="arc"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ContingentConsiderationNonCurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="lbl_OtherNoncurrentLiabilities1" xlink:type="locator"/>
      <link:presentationArc order="8.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherNoncurrentLiabilities1" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationNonCurrent" xlink:label="lbl_ContingentConsiderationNonCurrent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalRemediationProvisionNoncurrent" xlink:label="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentNonfinancialLiabilities" xlink:label="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_OtherNoncurrentNonfinancialLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionRollForward" xlink:label="lbl_EnvironmentalProvisionRollForward" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionAdditions" xlink:type="arc"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionRollForward" xlink:label="lbl_EnvironmentalProvisionRollForward1" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvision" xlink:label="lbl_EnvironmentalProvision" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvision" xlink:type="arc"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward1" xlink:to="lbl_EnvironmentalProvision" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionAdditions" xlink:label="lbl_EnvironmentalProvisionAdditions" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:label="lbl_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalRemediationProvisionNoncurrent" xlink:label="lbl_EnvironmentalRemediationProvisionNoncurrent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionCurrent" xlink:label="lbl_EnvironmentalProvisionCurrent" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionReleases" xlink:label="lbl_EnvironmentalProvisionReleases" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionReleases" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_EnvironmentalProvisionRollForward" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionPayments" xlink:label="lbl_EnvironmentalProvisionPayments" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionRollForward" xlink:to="lbl_EnvironmentalProvisionPayments" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvision" xlink:label="lbl_EnvironmentalProvision" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:label="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:to="lbl_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:to="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:type="arc"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:to="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:type="arc"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:to="lbl_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:type="arc"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EnvironmentalProvisionFiscalYearMaturityAbstract" xlink:to="lbl_EnvironmentalProvision" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:label="lbl_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:type="arc"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:type="arc"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward1" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="arc"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward1" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="lbl_DisclosureOfOtherProvisionsTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_DisclosureOfOtherProvisionsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="lbl_ClassesOfProvisionsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ClassesOfProvisionsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="lbl_OtherProvisionsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfProvisionsAxis" xlink:to="lbl_OtherProvisionsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LegalProceedingsProvisionMember" xlink:label="lbl_LegalProceedingsProvisionMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherProvisionsMember" xlink:to="lbl_LegalProceedingsProvisionMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_DisclosureOfOtherProvisionsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SolodynMember" xlink:label="lbl_SolodynMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SolodynMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContactLensesMember" xlink:label="lbl_ContactLensesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ContactLensesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GleevecMember" xlink:label="lbl_GleevecMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GleevecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclastAclastaMember" xlink:label="lbl_ReclastAclastaMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ReclastAclastaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TekturnaRasilezValturnaMember" xlink:label="lbl_TekturnaRasilezValturnaMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TekturnaRasilezValturnaMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="3.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NAGAndNovartisPharmaSpAMember" xlink:label="lbl_NAGAndNovartisPharmaSpAMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NAGAndNovartisPharmaSpAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FHoffmanLaRocheAGAndRocheSpAMember" xlink:label="lbl_FHoffmanLaRocheAGAndRocheSpAMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_FHoffmanLaRocheAGAndRocheSpAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisPharmaKKMember" xlink:label="lbl_NovartisPharmaKKMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NovartisPharmaKKMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NAGMember" xlink:label="lbl_NAGMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NPCAndOthersMember" xlink:label="lbl_NPCAndOthersMember" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NPCAndOthersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisNCMember" xlink:label="lbl_NovartisNCMember" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NovartisNCMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:label="lbl_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:label="lbl_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilities" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:label="lbl_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxotereMember" xlink:label="lbl_TaxotereMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TaxotereMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmiodaroneMember" xlink:label="lbl_AmiodaroneMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AmiodaroneMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:presentationArc order="0.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP" xlink:label="lbl_JP" xlink:type="locator"/>
      <link:presentationArc order="0.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_JP" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT" xlink:label="lbl_IT" xlink:type="locator"/>
      <link:presentationArc order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_IT" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA" xlink:label="lbl_CA" xlink:type="locator"/>
      <link:presentationArc order="0.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CA" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR" xlink:label="lbl_KR" xlink:type="locator"/>
      <link:presentationArc order="1.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_KR" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfSettlementInPrinciple" xlink:label="lbl_AmountOfSettlementInPrinciple" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_AmountOfSettlementInPrinciple" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:label="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:type="locator"/>
      <link:presentationArc order="5.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionalAmountOfSettlementInPrinciple" xlink:label="lbl_AdditionalAmountOfSettlementInPrinciple" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_AdditionalAmountOfSettlementInPrinciple" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfResolvedAction" xlink:label="lbl_AmountOfResolvedAction" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_AmountOfResolvedAction" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EnoxaparinMember" xlink:label="lbl_EnoxaparinMember" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_EnoxaparinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LitigationCaseMember" xlink:label="lbl_LitigationCaseMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TennesseeClassActionMember" xlink:label="lbl_TennesseeClassActionMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LitigationCaseMember" xlink:to="lbl_TennesseeClassActionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MassachusettsCaseMember" xlink:label="lbl_MassachusettsCaseMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LitigationCaseMember" xlink:to="lbl_MassachusettsCaseMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="lbl_LitigationCaseAxis1" xlink:type="locator"/>
      <link:presentationArc order="4.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsTable" xlink:to="lbl_LitigationCaseAxis1" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LitigationCaseAxis1" xlink:to="lbl_LitigationCaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TasignaMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GR" xlink:label="lbl_GR" xlink:type="locator"/>
      <link:presentationArc order="3.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_GR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR" xlink:label="lbl_FR" xlink:type="locator"/>
      <link:presentationArc order="2.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_FR" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:label="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_NovartisHellasS.A.C.I.MetamorphosisAthensMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" xlink:label="lbl_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" xlink:type="locator"/>
      <link:presentationArc order="5.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOtherProvisionsLineItems" xlink:to="lbl_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExforgeGroupMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="lbl_DisclosureOfClassesOfShareCapitalAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="lbl_IssuedCapital" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:to="lbl_IssuedCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="lbl_TreasuryShares" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OutstandingShareCapital" xlink:label="lbl_OutstandingShareCapital" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OutstandingShareCapital" xlink:type="arc"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:to="lbl_OutstandingShareCapital" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="lbl_SaleOrIssueOfTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_SaleOrIssueOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IssuedCapitalMovement" xlink:label="lbl_IssuedCapitalMovement" xlink:type="locator"/>
      <link:presentationArc order="4.2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_IssuedCapitalMovement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OutstandingShareCapitalMovement" xlink:label="lbl_OutstandingShareCapitalMovement" xlink:type="locator"/>
      <link:presentationArc order="4.7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OutstandingShareCapitalMovement" xlink:type="arc"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:to="lbl_TreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesMovementOfPeriod" xlink:label="lbl_TreasurySharesMovementOfPeriod" xlink:type="locator"/>
      <link:presentationArc order="4.6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesMovementOfPeriod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="lbl_ParValuePerShare" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_ParValuePerShare" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="lbl_DisclosureOfClassesOfShareCapitalAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="lbl_ClassesOfShareCapitalAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_ClassesOfShareCapitalAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="lbl_ClassesOfShareCapitalMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalTable" xlink:to="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="lbl_NumberOfSharesOutstanding" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfSharesOutstanding" xlink:type="arc"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:to="lbl_NumberOfSharesOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredToBeHeld" xlink:label="lbl_TreasurySharesAcquiredToBeHeld" xlink:type="locator"/>
      <link:presentationArc order="8.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesAcquiredToBeHeld" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherSharePurchases" xlink:label="lbl_OtherSharePurchases" xlink:type="locator"/>
      <link:presentationArc order="8.4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_OtherSharePurchases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredToBeCancelled" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="locator"/>
      <link:presentationArc order="8.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharesCancelledForCapitalReduction" xlink:label="lbl_SharesCancelledForCapitalReduction" xlink:type="locator"/>
      <link:presentationArc order="7.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_SharesCancelledForCapitalReduction" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShareMovements" xlink:label="lbl_ShareMovements" xlink:type="locator"/>
      <link:presentationArc order="8.67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_ShareMovements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StockRepurchaseProgramAuthorizedAmount1" xlink:label="lbl_StockRepurchaseProgramAuthorizedAmount1" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfShareCapitalAxis" xlink:to="lbl_ClassesOfShareCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="lbl_OrdinarySharesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_OrdinarySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfShareCapitalMember" xlink:to="lbl_TreasurySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesWithRestrictedUse" xlink:label="lbl_TreasurySharesWithRestrictedUse" xlink:type="locator"/>
      <link:presentationArc order="9.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_TreasurySharesWithRestrictedUse" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedCompensationShares" xlink:label="lbl_EquityBasedCompensationShares" xlink:type="locator"/>
      <link:presentationArc order="8.51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_EquityBasedCompensationShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:label="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="locator"/>
      <link:presentationArc order="8.46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfOtherShareSales" xlink:label="lbl_NumberOfOtherShareSales" xlink:type="locator"/>
      <link:presentationArc order="8.63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfOtherShareSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployees" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="locator"/>
      <link:presentationArc order="8.55" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="lbl_NumberOfSharesIssued" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfSharesIssued" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfTreasuryShares" xlink:label="lbl_NumberOfTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="6.5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lbl_NumberOfTreasuryShares" xlink:type="arc"/>
      <link:presentationArc order="8.77" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:to="lbl_NumberOfSharesIssued" xlink:type="arc"/>
      <link:presentationArc order="8.87" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfClassesOfShareCapitalLineItems1" xlink:to="lbl_NumberOfTreasuryShares" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DividendsPayableAmountPerShare" xlink:label="lbl_DividendsPayableAmountPerShare" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_DividendsPayableAmountPerShare" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPaid" xlink:label="lbl_DividendsPaid" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_DividendsPaid" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredToBeHeld" xlink:label="lbl_TreasurySharesAcquiredToBeHeld" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TreasurySharesAcquiredToBeHeld" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredToBeHeldValue" xlink:label="lbl_TreasurySharesAcquiredToBeHeldValue" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TreasurySharesAcquiredToBeHeldValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredToBeCancelled" xlink:label="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TreasurySharesAcquiredToBeCancelled" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesAcquiredForCancellationValue" xlink:label="lbl_TreasurySharesAcquiredForCancellationValue" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TreasurySharesAcquiredForCancellationValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherSharePurchases" xlink:label="lbl_OtherSharePurchases" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_OtherSharePurchases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherSharePurchasesValue" xlink:label="lbl_OtherSharePurchasesValue" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_OtherSharePurchasesValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharepurchaseOfTreasuryShares" xlink:label="lbl_SharepurchaseOfTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_SharepurchaseOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="lbl_PurchaseOfTreasuryShares" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_PurchaseOfTreasuryShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfOtherShareSales" xlink:label="lbl_NumberOfOtherShareSales" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_NumberOfOtherShareSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherShareSalesEquityImpact" xlink:label="lbl_OtherShareSalesEquityImpact" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_OtherShareSalesEquityImpact" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TreasurySharesMovement" xlink:label="lbl_TreasurySharesMovement" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TreasurySharesMovement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityImpactOfTreasuryShareMovements" xlink:label="lbl_EquityImpactOfTreasuryShareMovements" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_EquityImpactOfTreasuryShareMovements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedCompensationShares" xlink:label="lbl_EquityBasedCompensationShares" xlink:type="locator"/>
      <link:presentationArc order="11.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_EquityBasedCompensationShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:label="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="locator"/>
      <link:presentationArc order="11.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_ExerciseOfOptionsAndEmployeeTransactionsShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="locator"/>
      <link:presentationArc order="12.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SharesDeliveredToDivestedBusinessEmployees" xlink:label="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="locator"/>
      <link:presentationArc order="12.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_SharesDeliveredToDivestedBusinessEmployees" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="locator"/>
      <link:presentationArc order="11.25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:presentationArc order="2.4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_COPDMember" xlink:label="lbl_COPDMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_COPDMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TravoprostGroupMember" xlink:label="lbl_TravoprostGroupMember" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TravoprostGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SystaneGroupMember" xlink:label="lbl_SystaneGroupMember" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SystaneGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TopicalOlopatadineGroupMember" xlink:label="lbl_TopicalOlopatadineGroupMember" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TopicalOlopatadineGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MyforticMember" xlink:label="lbl_MyforticMember" xlink:type="locator"/>
      <link:presentationArc order="21.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_MyforticMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExelonExelonPatchMember" xlink:label="lbl_ExelonExelonPatchMember" xlink:type="locator"/>
      <link:presentationArc order="32.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExelonExelonPatchMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RitalinFocalinMember" xlink:label="lbl_RitalinFocalinMember" xlink:type="locator"/>
      <link:presentationArc order="33.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_RitalinFocalinMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TasignaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SeebriBreezhalerMember" xlink:label="lbl_SeebriBreezhalerMember" xlink:type="locator"/>
      <link:presentationArc order="14.995" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SeebriBreezhalerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OnbrezBreezhalerMember" xlink:label="lbl_OnbrezBreezhalerMember" xlink:type="locator"/>
      <link:presentationArc order="14.997" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OnbrezBreezhalerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UltibroBreezhalerMember" xlink:label="lbl_UltibroBreezhalerMember" xlink:type="locator"/>
      <link:presentationArc order="13.998" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_UltibroBreezhalerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HematologyMember" xlink:label="lbl_HematologyMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsAxis" xlink:label="lbl_BrandsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_BrandsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstablishedBrandsMember" xlink:label="lbl_EstablishedBrandsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsMember" xlink:label="lbl_BrandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BrandsAxis" xlink:to="lbl_BrandsMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BrandsMember" xlink:to="lbl_EstablishedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:to="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:type="arc"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_HematologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPromotedBrandsMember" xlink:label="lbl_OtherPromotedBrandsMember" xlink:type="locator"/>
      <link:presentationArc order="3.55" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_OtherPromotedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MatureOphthaMember" xlink:label="lbl_MatureOphthaMember" xlink:type="locator"/>
      <link:presentationArc order="1.4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_MatureOphthaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PromotedBrandsMember" xlink:label="lbl_PromotedBrandsMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BrandsMember" xlink:to="lbl_PromotedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
      <link:presentationArc order="4.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_EstablishedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EntrestoMember" xlink:label="lbl_EntrestoMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_EntrestoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeqvioMember" xlink:label="lbl_LeqvioMember" xlink:type="locator"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LeqvioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CosentyxMember" xlink:label="lbl_CosentyxMember" xlink:type="locator"/>
      <link:presentationArc order="0.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_CosentyxMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:presentationArc order="0.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XolairMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IlarisMember" xlink:label="lbl_IlarisMember" xlink:type="locator"/>
      <link:presentationArc order="0.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_IlarisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherSolidTumorMember" xlink:label="lbl_OtherSolidTumorMember" xlink:type="locator"/>
      <link:presentationArc order="13.99955" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherSolidTumorMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GilenyaMember" xlink:label="lbl_GilenyaMember" xlink:type="locator"/>
      <link:presentationArc order="0.95" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GilenyaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:presentationArc order="0.97" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZolgensmaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KesimptaMember" xlink:label="lbl_KesimptaMember" xlink:type="locator"/>
      <link:presentationArc order="0.98" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KesimptaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MayzentMember" xlink:label="lbl_MayzentMember" xlink:type="locator"/>
      <link:presentationArc order="0.99" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_MayzentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AimovigMember" xlink:label="lbl_AimovigMember" xlink:type="locator"/>
      <link:presentationArc order="0.995" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AimovigMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TafinlarMekinistMember" xlink:label="lbl_TafinlarMekinistMember" xlink:type="locator"/>
      <link:presentationArc order="0.997" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TafinlarMekinistMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KisqaliMember" xlink:label="lbl_KisqaliMember" xlink:type="locator"/>
      <link:presentationArc order="0.998" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KisqaliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:presentationArc order="0.999" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VotrientMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LutatheraMember" xlink:label="lbl_LutatheraMember" xlink:type="locator"/>
      <link:presentationArc order="0.9995" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LutatheraMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PiqrayMember" xlink:label="lbl_PiqrayMember" xlink:type="locator"/>
      <link:presentationArc order="0.9997" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PiqrayMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PluvictoMember" xlink:label="lbl_PluvictoMember" xlink:type="locator"/>
      <link:presentationArc order="0.9998" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PluvictoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TabrectaMember" xlink:label="lbl_TabrectaMember" xlink:type="locator"/>
      <link:presentationArc order="0.9999" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TabrectaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PromactaRevoladeMember" xlink:label="lbl_PromactaRevoladeMember" xlink:type="locator"/>
      <link:presentationArc order="0.99995" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PromactaRevoladeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JakaviMember" xlink:label="lbl_JakaviMember" xlink:type="locator"/>
      <link:presentationArc order="1.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_JakaviMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KymriahMember" xlink:label="lbl_KymriahMember" xlink:type="locator"/>
      <link:presentationArc order="1.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KymriahMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdakveoMember" xlink:label="lbl_AdakveoMember" xlink:type="locator"/>
      <link:presentationArc order="1.35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AdakveoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScemblixMember" xlink:label="lbl_ScemblixMember" xlink:type="locator"/>
      <link:presentationArc order="1.37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ScemblixMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherHematologyMember" xlink:label="lbl_OtherHematologyMember" xlink:type="locator"/>
      <link:presentationArc order="1.38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherHematologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:presentationArc order="1.39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_XiidraMember" xlink:label="lbl_XiidraMember" xlink:type="locator"/>
      <link:presentationArc order="1.395" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XiidraMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UltibroGroupMember" xlink:label="lbl_UltibroGroupMember" xlink:type="locator"/>
      <link:presentationArc order="1.397" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_UltibroGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BeovuMember" xlink:label="lbl_BeovuMember" xlink:type="locator"/>
      <link:presentationArc order="1.398" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_BeovuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherRespiratoryMember" xlink:label="lbl_OtherRespiratoryMember" xlink:type="locator"/>
      <link:presentationArc order="1.399" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherRespiratoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandostatinMember" xlink:label="lbl_SandostatinMember" xlink:type="locator"/>
      <link:presentationArc order="1.3995" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SandostatinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GalvusGroupMember" xlink:label="lbl_GalvusGroupMember" xlink:type="locator"/>
      <link:presentationArc order="1.3997" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GalvusGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GleevecGlivecMember" xlink:label="lbl_GleevecGlivecMember" xlink:type="locator"/>
      <link:presentationArc order="1.3998" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GleevecGlivecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:presentationArc order="1.3999" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExforgeGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DiovanGroupMember" xlink:label="lbl_DiovanGroupMember" xlink:type="locator"/>
      <link:presentationArc order="1.39995" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_DiovanGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AfinitorVotubiaMember" xlink:label="lbl_AfinitorVotubiaMember" xlink:type="locator"/>
      <link:presentationArc order="1.39997" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AfinitorVotubiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VoltarenCataflamMember" xlink:label="lbl_VoltarenCataflamMember" xlink:type="locator"/>
      <link:presentationArc order="1.39998" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VoltarenCataflamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZortressCerticanMember" xlink:label="lbl_ZortressCerticanMember" xlink:type="locator"/>
      <link:presentationArc order="1.39999" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZortressCerticanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExjadeJadenuMember" xlink:label="lbl_ExjadeJadenuMember" xlink:type="locator"/>
      <link:presentationArc order="1.399995" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExjadeJadenuMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeoralSandimmunEMember" xlink:label="lbl_NeoralSandimmunEMember" xlink:type="locator"/>
      <link:presentationArc order="1.399997" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_NeoralSandimmunEMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractManufacturingMember" xlink:label="lbl_ContractManufacturingMember" xlink:type="locator"/>
      <link:presentationArc order="1.399998" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ContractManufacturingMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherProductsMember" xlink:label="lbl_OtherProductsMember" xlink:type="locator"/>
      <link:presentationArc order="1.399999" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_OtherProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CardiovascularMember" xlink:label="lbl_CardiovascularMember" xlink:type="locator"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_CardiovascularMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImmunologyMember" xlink:label="lbl_ImmunologyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_ImmunologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeuroscienceMember" xlink:label="lbl_NeuroscienceMember" xlink:type="locator"/>
      <link:presentationArc order="1.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_NeuroscienceMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SolidTumorMember" xlink:label="lbl_SolidTumorMember" xlink:type="locator"/>
      <link:presentationArc order="1.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_SolidTumorMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="lbl_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsHeldByMarketMaker" xlink:label="lbl_WrittenCallOptionsHeldByMarketMaker" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsHeldByMarketMaker" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsContractualLive" xlink:label="lbl_WrittenCallOptionsContractualLive" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsContractualLive" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsContractualLiveRemaining" xlink:label="lbl_WrittenCallOptionsContractualLiveRemaining" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsContractualLiveRemaining" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WrittenCallOptionsWeightedAverageExercisePrice" xlink:label="lbl_WrittenCallOptionsWeightedAverageExercisePrice" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_WrittenCallOptionsWeightedAverageExercisePrice" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaximalAmountOfShareBuybackProgramm" xlink:label="lbl_MaximalAmountOfShareBuybackProgramm" xlink:type="locator"/>
      <link:presentationArc order="7.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_MaximalAmountOfShareBuybackProgramm" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountRecordedInEquityRelatedToHyperinflation" xlink:label="lbl_AmountRecordedInEquityRelatedToHyperinflation" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_AmountRecordedInEquityRelatedToHyperinflation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TaxOnTransactionCostsRecordedInEquity" xlink:label="lbl_TaxOnTransactionCostsRecordedInEquity" xlink:type="locator"/>
      <link:presentationArc order="7.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_TaxOnTransactionCostsRecordedInEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfOptionsRepurchased" xlink:label="lbl_NumberOfOptionsRepurchased" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_NumberOfOptionsRepurchased" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentForRepurchaseOwnShares" xlink:label="lbl_CommitmentForRepurchaseOwnShares" xlink:type="locator"/>
      <link:presentationArc order="7.1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementOfChangesInEquityAbstract" xlink:to="lbl_CommitmentForRepurchaseOwnShares" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="lbl_Level1OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level1OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="lbl_Level2OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level2OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="lbl_Level3OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level3OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_MeasurementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_AggregatedMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RecurringFairValueMeasurementMember" xlink:label="lbl_RecurringFairValueMeasurementMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedMeasurementMember" xlink:to="lbl_RecurringFairValueMeasurementMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_DebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:label="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:label="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FinancialInvestmentsAndLongtermLoansGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_FundInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalAvailableforsaleMarketableSecuritiesMember" xlink:label="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_TotalAvailableforsaleMarketableSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:label="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:label="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AvailableforsaleFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:label="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValuedAtAmortizedCostMember" xlink:label="lbl_ValuedAtAmortizedCostMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_ValuedAtAmortizedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="lbl_FinancialAssetsAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="lbl_FinancialAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquitySecuritiesMember" xlink:label="lbl_EquitySecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_EquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivablesShorttermMember" xlink:label="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationReceivablesShorttermMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMember" xlink:label="lbl_CashAndCashEquivalentsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CashAndCashEquivalentsMember" xlink:type="arc"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="lbl_DisclosureOfFinancialAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsAbstract" xlink:to="lbl_DisclosureOfFinancialAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="lbl_DisclosureOfFinancialAssetsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="lbl_ClassesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_ClassesOfFinancialAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="lbl_FinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsLineItems" xlink:to="lbl_FinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="lbl_FinancialAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialAssetsAxis" xlink:to="lbl_FinancialAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="lbl_FinancialAssetsAtAmortisedCostMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialAssetsMember" xlink:to="lbl_FinancialAssetsAtAmortisedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMember" xlink:label="lbl_CashAndCashEquivalentsMember" xlink:type="locator"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialAssetsMember" xlink:to="lbl_CashAndCashEquivalentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="lbl_CategoriesOfFinancialAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_CategoriesOfFinancialAssetsAxis" xlink:type="arc"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_DisclosureOfFinancialAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="lbl_FinancialAssetsCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CategoriesOfFinancialAssetsAxis" xlink:to="lbl_FinancialAssetsCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemAxis" xlink:label="lbl_BalanceSheetItemAxis" xlink:type="locator"/>
      <link:presentationArc order="5.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_BalanceSheetItemAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemMember" xlink:label="lbl_BalanceSheetItemMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemAxis" xlink:to="lbl_BalanceSheetItemMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DebtSecuritiesMember" xlink:label="lbl_DebtSecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DebtSecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquitySecuritiesMember" xlink:label="lbl_EquitySecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_EquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_FundInvestmentsMember" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:label="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:label="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:label="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueMember" xlink:label="lbl_FinancialAssetsAtFairValueMember" xlink:type="locator"/>
      <link:presentationArc order="0.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialAssetsMember" xlink:to="lbl_FinancialAssetsAtFairValueMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="lbl_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialAssetsCategoryMember" xlink:to="lbl_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="lbl_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialAssetsCategoryMember" xlink:to="lbl_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="5.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAssetsTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AvailableForSaleMarketableSecuritiesMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CurrentFinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AvailableForSaleMarketableSecuritiesMember" xlink:label="lbl_AvailableForSaleMarketableSecuritiesMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleLongtermFinancialInvestmentsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtMember" xlink:label="lbl_CurrentFinancialDebtMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:presentationArc order="1.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeReceivablesMember" xlink:label="lbl_TradeReceivablesMember" xlink:type="locator"/>
      <link:presentationArc order="5.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_TradeReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCurrentAssetsMember" xlink:label="lbl_OtherCurrentAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="5.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_OtherCurrentAssetsMember" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CashAndCashEquivalentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:label="lbl_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialAssetsCategoryMember" xlink:to="lbl_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:label="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="lbl_FinancialLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfFinancialLiabilitiesAxis" xlink:to="lbl_FinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="lbl_FinancialLiabilitiesAtAmortisedCostMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialLiabilitiesMember" xlink:to="lbl_FinancialLiabilitiesAtAmortisedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="lbl_FinancialLiabilitiesAtFairValueMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialLiabilitiesMember" xlink:to="lbl_FinancialLiabilitiesAtFairValueMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="lbl_FinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lbl_FinancialLiabilitiesCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="lbl_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialLiabilitiesCategoryMember" xlink:to="lbl_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CurrentFinancialDebtMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_NoncurrentFinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradePayablesMember" xlink:label="lbl_TradePayablesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_TradePayablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemAxis" xlink:label="lbl_BalanceSheetItemAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_BalanceSheetItemAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BalanceSheetItemMember" xlink:label="lbl_BalanceSheetItemMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemAxis" xlink:to="lbl_BalanceSheetItemMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:label="lbl_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_InterestBearningAccountsOfAssociatesPayableOnDemandMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BankAndOtherFinancialDebtMember" xlink:label="lbl_BankAndOtherFinancialDebtMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_BankAndOtherFinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommercialPaperMember" xlink:label="lbl_CommercialPaperMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_CommercialPaperMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPortionOfNoncurrentDebtMember" xlink:label="lbl_CurrentPortionOfNoncurrentDebtMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_CurrentPortionOfNoncurrentDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StraightBondsMember" xlink:label="lbl_StraightBondsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_StraightBondsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:label="lbl_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinanceLeaseObligationsMember" xlink:label="lbl_FinanceLeaseObligationsMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_FinanceLeaseObligationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:label="lbl_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_ContingentConsiderationAndOtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:label="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BalanceSheetItemMember" xlink:to="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesTable" xlink:to="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilities" xlink:label="lbl_FinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="lbl_FinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtMember" xlink:label="lbl_CurrentFinancialDebtMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialDebtMember" xlink:label="lbl_NoncurrentFinancialDebtMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="lbl_LeaseLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_LeaseLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialLiabilitiesCategoryMember" xlink:label="lbl_OtherFinancialLiabilitiesCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialLiabilitiesCategoryMember" xlink:to="lbl_OtherFinancialLiabilitiesCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_OtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="lbl_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialLiabilitiesCategoryMember" xlink:to="lbl_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentForRepurchaseOfOwnSharesMember" xlink:label="lbl_CommitmentForRepurchaseOfOwnSharesMember" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CommitmentForRepurchaseOfOwnSharesMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:label="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:to="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsAxis" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsMember" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractOrUnderlyingPrincipalAmoutMember" xlink:label="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PositiveFairValuesMember" xlink:label="lbl_PositiveFairValuesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_PositiveFairValuesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NegativeFairValuesMember" xlink:label="lbl_NegativeFairValuesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_NegativeFairValuesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:label="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstruments" xlink:label="lbl_DerivativeFinancialInstruments" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:label="lbl_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:label="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="locator"/>
      <link:presentationArc order="2.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:label="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="locator"/>
      <link:presentationArc order="2.75" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:label="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentAxis" xlink:to="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:label="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentNatureOfInstrumentMember" xlink:to="lbl_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsAxis" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsPrincipalAmountsMember" xlink:label="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsAxis" xlink:to="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractOrUnderlyingPrincipalAmoutMember" xlink:label="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsPrincipalAmountsMember" xlink:to="lbl_ContractOrUnderlyingPrincipalAmoutMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:label="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstruments" xlink:label="lbl_DerivativeFinancialInstruments" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="lbl_AllCurrenciesDomain" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="lbl_EUR" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_EUR" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_JPY" xlink:label="lbl_JPY" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_JPY" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyOthersMember" xlink:label="lbl_CurrencyOthersMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_CurrencyOthersMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="lbl_USD" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllCurrenciesDomain" xlink:to="lbl_USD" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="lbl_CurrencyAxis1" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_CurrencyAxis1" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CurrencyAxis1" xlink:to="lbl_AllCurrenciesDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:label="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:label="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="locator"/>
      <link:presentationArc order="2.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DerivativeFinancialInstrumentsCommodityPurchaseContract" xlink:type="arc"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:to="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="lbl_MeasurementAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_MeasurementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="lbl_AggregatedMeasurementMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MeasurementAxis" xlink:to="lbl_AggregatedMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RecurringFairValueMeasurementMember" xlink:label="lbl_RecurringFairValueMeasurementMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedMeasurementMember" xlink:to="lbl_RecurringFairValueMeasurementMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_LevelsOfFairValueHierarchyAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LevelsOfFairValueHierarchyAxis" xlink:to="lbl_AllLevelsOfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="lbl_Level1OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level1OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="lbl_Level2OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level2OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="lbl_Level3OfFairValueHierarchyMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_Level3OfFairValueHierarchyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValuedAtAmortizedCostMember" xlink:label="lbl_ValuedAtAmortizedCostMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AllLevelsOfFairValueHierarchyMember" xlink:to="lbl_ValuedAtAmortizedCostMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="lbl_ClassesOfLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_ClassesOfLiabilitiesAxis" xlink:type="arc"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember" xlink:label="lbl_LiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfLiabilitiesAxis" xlink:to="lbl_LiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationPayablesMember" xlink:label="lbl_ContingentConsiderationPayablesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_ContingentConsiderationPayablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_OtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="lbl_FinancialLiabilitiesAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lbl_FinancialLiabilitiesAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialLiabilitiesAtFairValueMember" xlink:label="lbl_CurrentFinancialLiabilitiesAtFairValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CurrentFinancialLiabilitiesAtFairValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentFinancialLiabilitiesAtFairValueMember" xlink:label="lbl_NoncurrentFinancialLiabilitiesAtFairValueMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_NoncurrentFinancialLiabilitiesAtFairValueMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentContingentConsiderationLiabilitiesMember" xlink:label="lbl_NoncurrentContingentConsiderationLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LiabilitiesMember" xlink:to="lbl_NoncurrentContingentConsiderationLiabilitiesMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsCarryingValueLevel3" xlink:label="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="lbl_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:label="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" xlink:type="arc"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_PurchaseFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclassificationFairValueMeasurementAssets" xlink:label="lbl_ReclassificationFairValueMeasurementAssets" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ReclassificationFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems1" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems1" xlink:to="lbl_FinancialInstrumentsCarryingValueLevel3" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:label="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:label="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:label="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FundInvestmentsMember" xlink:label="lbl_FundInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FundInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AvailableforsaleFinancialInvestmentsMember" xlink:label="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_AvailableforsaleFinancialInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationReceivablesMember" xlink:label="lbl_ContingentConsiderationReceivablesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationReceivablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationPayablesMember" xlink:label="lbl_ContingentConsiderationPayablesMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_ContingentConsiderationPayablesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialLiabilitiesMember" xlink:label="lbl_OtherFinancialLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_OtherFinancialLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:label="lbl_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:type="locator"/>
      <link:presentationArc order="5.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CashReceiptsAndPaymentsFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PurchaseFairValueMeasurementAssets" xlink:label="lbl_PurchaseFairValueMeasurementAssets" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:to="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:label="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:label="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember" xlink:to="lbl_DisposalGroupsClassifiedAsHeldForSaleMember" xlink:type="arc"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisposalsFairValueMeasurementAssets" xlink:label="lbl_DisposalsFairValueMeasurementAssets" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DisposalsFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:label="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongTermFinancialInvestmentsMember" xlink:label="lbl_LongTermFinancialInvestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_LongTermFinancialInvestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReconciliationOfChangesInFairValueMeasurementAssetsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:label="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaturityOfNetDebtLineItems" xlink:label="lbl_MaturityOfNetDebtLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:label="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GroupsOfFinancialAssetsLiabilitiesMember" xlink:label="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesAxis" xlink:to="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:to="lbl_MaturityOfNetDebtLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketableSecuritiesAndTimeDepositsMember" xlink:label="lbl_MarketableSecuritiesAndTimeDepositsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_MarketableSecuritiesAndTimeDepositsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommoditiesMember" xlink:label="lbl_CommoditiesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CommoditiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:label="lbl_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_DeriviativeFinancialInstrumentsAndAccruedInterestMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsMember" xlink:label="lbl_CashAndCashEquivalentsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_CashAndCashEquivalentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialDebtMember" xlink:label="lbl_FinancialDebtMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FinancialDebtMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialDebtUndiscountedMember" xlink:label="lbl_FinancialDebtUndiscountedMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_FinancialDebtUndiscountedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsMember" xlink:label="lbl_DerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GroupsOfFinancialAssetsLiabilitiesMember" xlink:to="lbl_DerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="lbl_OtherCurrentFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_OtherCurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialLiabilities" xlink:label="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_OtherNoncurrentFinancialLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="lbl_NotLaterThanOneMonthMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneMonthMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:label="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="locator"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDebt" xlink:label="lbl_NetDebt1" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityOfNetDebtLineItems" xlink:to="lbl_NetDebt1" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="lbl_NotLaterThanOneMonthMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneMonthMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:label="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:label="lbl_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:to="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:label="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:label="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneMonthAndNotLaterThanThreeMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:label="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" xlink:to="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_TradeAndOtherPayablesToTradeSuppliers" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationLiabilities" xlink:label="lbl_ContingentConsiderationLiabilities" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ContingentConsiderationLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractualInterestOnNoncurrentLiabilities" xlink:label="lbl_ContractualInterestOnNoncurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_ContractualInterestOnNoncurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentForRepurchaseOwnShares" xlink:label="lbl_CommitmentForRepurchaseOwnShares" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CommitmentForRepurchaseOwnShares" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TenDayLossFairValueVARModelTable" xlink:label="lbl_TenDayLossFairValueVARModelTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_TenDayLossFairValueVARModelTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TenDayLossFairValueVARModelLineItems" xlink:label="lbl_TenDayLossFairValueVARModelLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="lbl_RangeAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TenDayLossFairValueVARModelTable" xlink:to="lbl_RangeAxis" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TenDayLossFairValueVARModelTable" xlink:to="lbl_TenDayLossFairValueVARModelLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="lbl_RangesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangeAxis" xlink:to="lbl_RangesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageMember" xlink:label="lbl_WeightedAverageMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesMember" xlink:to="lbl_WeightedAverageMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="lbl_TopOfRangeMember" xlink:type="locator"/>
      <link:presentationArc order="0.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesMember" xlink:to="lbl_TopOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="lbl_BottomOfRangeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesMember" xlink:to="lbl_BottomOfRangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WorstCaseLossScenarioMember" xlink:label="lbl_WorstCaseLossScenarioMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RangesMember" xlink:to="lbl_WorstCaseLossScenarioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputation" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputation" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputation" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:label="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TenDayLossFairValueVARModelLineItems" xlink:to="lbl_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" xlink:to="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentiveRSUMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveRSUMember" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentiveRSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" xlink:type="locator"/>
      <link:presentationArc order="1.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationAnnualIncentiveSharesMember" xlink:label="lbl_EquityBasedParticipationAnnualIncentiveSharesMember" xlink:type="locator"/>
      <link:presentationArc order="1.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationAnnualIncentiveSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationShareSavingsPlansRSUMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlansRSUMember" xlink:type="locator"/>
      <link:presentationArc order="2.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlansRSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationShareSavingsPlansSharesMember" xlink:label="lbl_EquityBasedParticipationShareSavingsPlansSharesMember" xlink:type="locator"/>
      <link:presentationArc order="3.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationShareSavingsPlansSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" xlink:type="locator"/>
      <link:presentationArc order="4.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" xlink:label="lbl_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" xlink:type="locator"/>
      <link:presentationArc order="5.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" xlink:type="locator"/>
      <link:presentationArc order="6.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermPerformancePSUPlanMember" xlink:label="lbl_EquityBasedParticipationLongTermPerformancePSUPlanMember" xlink:type="locator"/>
      <link:presentationArc order="7.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermPerformancePSUPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermRelativePerformancePlanPSUMember" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanPSUMember" xlink:type="locator"/>
      <link:presentationArc order="8.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermRelativePerformancePlanPSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsRSUMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsRSUMember" xlink:type="locator"/>
      <link:presentationArc order="9.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsRSUMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" xlink:type="locator"/>
      <link:presentationArc order="10.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationOtherShareAwardsSharesMember" xlink:label="lbl_EquityBasedParticipationOtherShareAwardsSharesMember" xlink:type="locator"/>
      <link:presentationArc order="11.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationOtherShareAwardsSharesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lbl_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:label="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="locator"/>
      <link:presentationArc order="9.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationLongTermRelativePerformancePlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:label="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:type="locator"/>
      <link:presentationArc order="4.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationEmployeeSharePurchasePlanMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:label="lbl_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:to="lbl_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:label="lbl_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:to="lbl_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="lbl_NumberOfOutstandingShareOptions" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward1" xlink:to="lbl_NumberOfOutstandingShareOptions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" xlink:to="lbl_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:label="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactLocationAxis" xlink:label="lbl_ImpactLocationAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ImpactLocationAxis" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactLocationMember" xlink:label="lbl_ImpactLocationMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ImpactLocationAxis" xlink:to="lbl_ImpactLocationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementMember" xlink:label="lbl_IncomeStatementMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ImpactLocationMember" xlink:to="lbl_IncomeStatementMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember1" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ImpactLocationMember" xlink:to="lbl_EquityMember1" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:label="lbl_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:label="lbl_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:label="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:label="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:label="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:label="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:label="lbl_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:type="locator"/>
      <link:presentationArc order="7.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:label="lbl_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:type="locator"/>
      <link:presentationArc order="7.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetAndLiabilityValuationAbstract" xlink:to="lbl_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OpenHedgesForAnticipatedTransactions" xlink:label="lbl_OpenHedgesForAnticipatedTransactions" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_OpenHedgesForAnticipatedTransactions" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_MostSignificantForeignExchangeLosses" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MostSignificantForeignExchangeLosses" xlink:label="lbl_MostSignificantForeignExchangeLosses" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LongtermFinancialDebtWithACarryingAmount" xlink:label="lbl_LongtermFinancialDebtWithACarryingAmount" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_LongtermFinancialDebtWithACarryingAmount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:label="lbl_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:label="lbl_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_NetInvestmentHedgeRecognizedInTheIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:label="lbl_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_UpperLimitOnHoldingsOnUnrelatedCompany" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:label="lbl_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCommercialPaperMaximumBorrowingAmount" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DebtEquityRatio" xlink:label="lbl_DebtEquityRatio" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DebtEquityRatio" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VAREstimateConfidenceInterval" xlink:label="lbl_VAREstimateConfidenceInterval" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_VAREstimateConfidenceInterval" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:label="lbl_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:type="locator"/>
      <link:presentationArc order="9.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCommercialPaperMaximumAmountOutstanding" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCreditFacilityCommitted" xlink:label="lbl_BorrowingsCreditFacilityCommitted" xlink:type="locator"/>
      <link:presentationArc order="9.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCreditFacilityCommitted" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CounterpartyRiskAbstract" xlink:label="lbl_CounterpartyRiskAbstract" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_CounterpartyRiskAbstract" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:label="lbl_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CounterpartyRiskAbstract" xlink:to="lbl_CashAndCashEquivalentsHeldWithFinancialInstitution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VendorAxis" xlink:label="lbl_VendorAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VendorMember" xlink:label="lbl_VendorMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_VendorAxis" xlink:to="lbl_VendorMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LargestFinancialInstitutionMember" xlink:label="lbl_LargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_VendorMember" xlink:to="lbl_LargestFinancialInstitutionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SecondLargestFinancialInstitutionMember" xlink:label="lbl_SecondLargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_VendorMember" xlink:to="lbl_SecondLargestFinancialInstitutionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ThirdLargestFinancialInstitutionMember" xlink:label="lbl_ThirdLargestFinancialInstitutionMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_VendorMember" xlink:to="lbl_ThirdLargestFinancialInstitutionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:label="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:type="arc"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:to="lbl_VendorAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialInstrumentsNarrativeTable" xlink:to="lbl_BorrowingsByNameAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_USCommercialPaperProgramsMember" xlink:label="lbl_USCommercialPaperProgramsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_USCommercialPaperProgramsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JPCommercialPaperProgramsMember" xlink:label="lbl_JPCommercialPaperProgramsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_JPCommercialPaperProgramsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCommercialPaperNumberOfPrograms" xlink:label="lbl_BorrowingsCommercialPaperNumberOfPrograms" xlink:type="locator"/>
      <link:presentationArc order="9.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCommercialPaperNumberOfPrograms" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:label="lbl_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:type="locator"/>
      <link:presentationArc order="5.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_MaximumMarginPercentageImpactOfCommodityPriceChange" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MaximumHoldingInUnrelatedCompany" xlink:label="lbl_MaximumHoldingInUnrelatedCompany" xlink:type="locator"/>
      <link:presentationArc order="5.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_MaximumHoldingInUnrelatedCompany" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:label="lbl_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="11.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" xlink:type="arc"/>
      <link:presentationArc order="3.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:label="lbl_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="locator"/>
      <link:presentationArc order="6.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsCreditFacilityShortTerm" xlink:label="lbl_BorrowingsCreditFacilityShortTerm" xlink:type="locator"/>
      <link:presentationArc order="9.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_BorrowingsCreditFacilityShortTerm" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountBorrowedUnderTheCreditFacility" xlink:label="lbl_AmountBorrowedUnderTheCreditFacility" xlink:type="locator"/>
      <link:presentationArc order="9.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountBorrowedUnderTheCreditFacility" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:label="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:type="locator"/>
      <link:presentationArc order="3.7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueOfOtherFinancialAssetsSold" xlink:label="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:label="lbl_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueOfFundInvestmentsAndEquitySecurities" xlink:label="lbl_FairValueOfFundInvestmentsAndEquitySecurities" xlink:type="locator"/>
      <link:presentationArc order="11.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_FairValueOfFundInvestmentsAndEquitySecurities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="lbl_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDerivativeFinancialInstrumentsLineItems" xlink:to="lbl_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersTable" xlink:label="lbl_DisclosureOfMajorCustomersTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfMajorCustomersTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="lbl_MajorCustomersAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersTable" xlink:to="lbl_MajorCustomersAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="lbl_MajorCustomersMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersAxis" xlink:to="lbl_MajorCustomersMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LargestCustomerMember" xlink:label="lbl_LargestCustomerMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_LargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SecondLargestCustomerMember" xlink:label="lbl_SecondLargestCustomerMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_SecondLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ThirdLargestCustomerMember" xlink:label="lbl_ThirdLargestCustomerMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MajorCustomersMember" xlink:to="lbl_ThirdLargestCustomerMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:label="lbl_DisclosureOfMajorCustomersLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersTable" xlink:to="lbl_DisclosureOfMajorCustomersLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="lbl_PercentageOfEntitysRevenue" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysRevenue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfEntitysTradeReceivable" xlink:label="lbl_PercentageOfEntitysTradeReceivable" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfEntitysTradeReceivable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfGovernmentBackedDebtSecurities" xlink:label="lbl_PercentageOfGovernmentBackedDebtSecurities" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_PercentageOfGovernmentBackedDebtSecurities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CustomersWithNetSalesOverFivePercent" xlink:label="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="locator"/>
      <link:presentationArc order="2.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMajorCustomersLineItems" xlink:to="lbl_CustomersWithNetSalesOverFivePercent" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CategoriesOfRelatedPartiesAxis" xlink:to="lbl_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonExecutiveDirectorMember" xlink:label="lbl_NonExecutiveDirectorMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForRelatedPartiesMember" xlink:to="lbl_NonExecutiveDirectorMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GenentechRocheMember" xlink:label="lbl_GenentechRocheMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GenentechRocheMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GenentechInc.USAMember" xlink:label="lbl_GenentechInc.USAMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GenentechInc.USAMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XolairMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfVotingPowerHeldInAssociate" xlink:label="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_ProportionOfVotingPowerHeldInAssociate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:label="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_NetExpenseRoyaltiesCostSharingAndProfitSharing" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfContractsWithRelatedParties" xlink:label="lbl_NumberOfContractsWithRelatedParties" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_NumberOfContractsWithRelatedParties" xlink:type="arc"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembers" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:label="lbl_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_RelatedPartiesNumberOfNonexecutiveDirectors" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SparkTherapeuticsInc.Member" xlink:label="lbl_SparkTherapeuticsInc.Member" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_SparkTherapeuticsInc.Member" xlink:type="arc"/>
      <link:presentationArc order="5.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" xlink:label="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RelatedPartiesNumberOfExecutiveCommitteeMembers" xlink:label="lbl_RelatedPartiesNumberOfExecutiveCommitteeMembers" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfitSharingIncome" xlink:label="lbl_ProfitSharingIncome" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitSharingIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromRoyalties" xlink:label="lbl_RevenueFromRoyalties" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromRoyalties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MilestoneIncome" xlink:label="lbl_MilestoneIncome" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_MilestoneIncome" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherRevenueOther" xlink:label="lbl_OtherRevenueOther" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenueOther" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetailGenericsMember" xlink:label="lbl_RetailGenericsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BiopharmaceuticalsMember" xlink:label="lbl_BiopharmaceuticalsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AntiInfectivesMember" xlink:label="lbl_AntiInfectivesMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AntiInfectivesSoldUnderSandozNameMember" xlink:label="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_AntiInfectivesSoldUnderSandozNameMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:presentationArc order="4.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalAntiinfectivesNetSalesMember" xlink:label="lbl_TotalAntiinfectivesNetSalesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_TotalAntiinfectivesNetSalesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FranchiseAxis" xlink:label="lbl_FranchiseAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FranchiseMember" xlink:label="lbl_FranchiseMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseAxis" xlink:to="lbl_FranchiseMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_RetailGenericsMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_BiopharmaceuticalsMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FranchiseMember" xlink:to="lbl_AntiInfectivesMember" xlink:type="arc"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_FranchiseAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract" xlink:to="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:label="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:label="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:label="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:to="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ListedEquitySecuritiesMember" xlink:label="lbl_ListedEquitySecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_ListedEquitySecuritiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonlistedEquitySecuritiesMember" xlink:label="lbl_NonlistedEquitySecuritiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember" xlink:to="lbl_NonlistedEquitySecuritiesMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainLossOnSaleOfOtherFinancialAssets" xlink:label="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_GainLossOnSaleOfOtherFinancialAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:presentationArc order="2.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalFairValueAdjustmentsMember" xlink:label="lbl_TotalFairValueAdjustmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalFairValueAdjustmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueOfOtherFinancialAssetsSold" xlink:label="lbl_FairValueOfOtherFinancialAssetsSold" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" xlink:label="lbl_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod" xlink:label="lbl_DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems" xlink:to="lbl_DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioAxis" xlink:label="lbl_ProductPortfolioAxis" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductPortfolioAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProductPortfolioMember" xlink:label="lbl_ProductPortfolioMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioAxis" xlink:to="lbl_ProductPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExjadeJadenuMember" xlink:label="lbl_ExjadeJadenuMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExjadeJadenuMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Top20ProductsMember" xlink:label="lbl_Top20ProductsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_Top20ProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestOfPortfolioMember" xlink:label="lbl_RestOfPortfolioMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductPortfolioMember" xlink:to="lbl_RestOfPortfolioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CosentyxMember" xlink:label="lbl_CosentyxMember" xlink:type="locator"/>
      <link:presentationArc order="0.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_CosentyxMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LucentisMember" xlink:label="lbl_LucentisMember" xlink:type="locator"/>
      <link:presentationArc order="0.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LucentisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandostatinMember" xlink:label="lbl_SandostatinMember" xlink:type="locator"/>
      <link:presentationArc order="0.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_SandostatinMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VotrientMember" xlink:label="lbl_VotrientMember" xlink:type="locator"/>
      <link:presentationArc order="7.85" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VotrientMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TravoprostGroupMember" xlink:label="lbl_TravoprostGroupMember" xlink:type="locator"/>
      <link:presentationArc order="8.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TravoprostGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeoralSandimmunEMember" xlink:label="lbl_NeoralSandimmunEMember" xlink:type="locator"/>
      <link:presentationArc order="9.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_NeoralSandimmunEMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_VoltarenCataflamMember" xlink:label="lbl_VoltarenCataflamMember" xlink:type="locator"/>
      <link:presentationArc order="9.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_VoltarenCataflamMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExelonExelonPatchMember" xlink:label="lbl_ExelonExelonPatchMember" xlink:type="locator"/>
      <link:presentationArc order="9.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExelonExelonPatchMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:presentationArc order="6.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestOfTheWorldMember" xlink:label="lbl_RestOfTheWorldMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GilenyaMember" xlink:label="lbl_GilenyaMember" xlink:type="locator"/>
      <link:presentationArc order="0.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GilenyaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AfinitorVotubiaMember" xlink:label="lbl_AfinitorVotubiaMember" xlink:type="locator"/>
      <link:presentationArc order="0.95" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AfinitorVotubiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZortressCerticanMember" xlink:label="lbl_ZortressCerticanMember" xlink:type="locator"/>
      <link:presentationArc order="8.4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZortressCerticanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="2.7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_RestOfTheWorldMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdakveoMember" xlink:label="lbl_AdakveoMember" xlink:type="locator"/>
      <link:presentationArc order="11.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_AdakveoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UltibroGroupMember" xlink:label="lbl_UltibroGroupMember" xlink:type="locator"/>
      <link:presentationArc order="14.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_UltibroGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsAxis" xlink:label="lbl_BrandsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_BrandsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PromotedBrandsMember" xlink:label="lbl_PromotedBrandsMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BrandsMember" xlink:label="lbl_BrandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BrandsAxis" xlink:to="lbl_BrandsMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BrandsMember" xlink:to="lbl_PromotedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:label="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" xlink:to="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPromotedBrandsMember" xlink:label="lbl_OtherPromotedBrandsMember" xlink:type="locator"/>
      <link:presentationArc order="4.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_OtherPromotedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HematologyMember" xlink:label="lbl_HematologyMember" xlink:type="locator"/>
      <link:presentationArc order="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_HematologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstablishedBrandsMember" xlink:label="lbl_EstablishedBrandsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BrandsMember" xlink:to="lbl_EstablishedBrandsMember" xlink:type="arc"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_EstablishedBrandsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EntrestoMember" xlink:label="lbl_EntrestoMember" xlink:type="locator"/>
      <link:presentationArc order="0.55" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_EntrestoMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PromactaRevoladeMember" xlink:label="lbl_PromactaRevoladeMember" xlink:type="locator"/>
      <link:presentationArc order="0.57" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_PromactaRevoladeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TasignaMember" xlink:label="lbl_TasignaMember" xlink:type="locator"/>
      <link:presentationArc order="0.65" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TasignaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TafinlarMekinistMember" xlink:label="lbl_TafinlarMekinistMember" xlink:type="locator"/>
      <link:presentationArc order="0.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_TafinlarMekinistMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_JakaviMember" xlink:label="lbl_JakaviMember" xlink:type="locator"/>
      <link:presentationArc order="0.85" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_JakaviMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:presentationArc order="0.87" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZolgensmaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_XolairMember" xlink:label="lbl_XolairMember" xlink:type="locator"/>
      <link:presentationArc order="0.88" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_XolairMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KisqaliMember" xlink:label="lbl_KisqaliMember" xlink:type="locator"/>
      <link:presentationArc order="0.92" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KisqaliMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IlarisMember" xlink:label="lbl_IlarisMember" xlink:type="locator"/>
      <link:presentationArc order="0.93" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_IlarisMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KesimptaMember" xlink:label="lbl_KesimptaMember" xlink:type="locator"/>
      <link:presentationArc order="0.94" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KesimptaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GalvusGroupMember" xlink:label="lbl_GalvusGroupMember" xlink:type="locator"/>
      <link:presentationArc order="0.945" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GalvusGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GleevecGlivecMember" xlink:label="lbl_GleevecGlivecMember" xlink:type="locator"/>
      <link:presentationArc order="0.947" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_GleevecGlivecMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ExforgeGroupMember" xlink:label="lbl_ExforgeGroupMember" xlink:type="locator"/>
      <link:presentationArc order="0.948" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ExforgeGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DiovanGroupMember" xlink:label="lbl_DiovanGroupMember" xlink:type="locator"/>
      <link:presentationArc order="0.949" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_DiovanGroupMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_KymriahMember" xlink:label="lbl_KymriahMember" xlink:type="locator"/>
      <link:presentationArc order="0.9495" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_KymriahMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CardiovascularMember" xlink:label="lbl_CardiovascularMember" xlink:type="locator"/>
      <link:presentationArc order="-2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_CardiovascularMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImmunologyMember" xlink:label="lbl_ImmunologyMember" xlink:type="locator"/>
      <link:presentationArc order="-1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_ImmunologyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NeuroscienceMember" xlink:label="lbl_NeuroscienceMember" xlink:type="locator"/>
      <link:presentationArc order="-1.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_NeuroscienceMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SolidTumorMember" xlink:label="lbl_SolidTumorMember" xlink:type="locator"/>
      <link:presentationArc order="-1.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" xlink:to="lbl_SolidTumorMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeOverPeriodAxis" xlink:label="lbl_ChangeOverPeriodAxis" xlink:type="locator"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_ChangeOverPeriodAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReportedValueMember" xlink:label="lbl_ReportedValueMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ChangeOverPeriodAxis" xlink:to="lbl_ReportedValueMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPYEChangeMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ReportedValueMember" xlink:to="lbl_PoPChangeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPChangeMember" xlink:label="lbl_PoPChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PoPYEChangeMember" xlink:label="lbl_PoPYEChangeMember" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="1.35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AsiaAfricaAustralasiaMember" xlink:label="lbl_AsiaAfricaAustralasiaMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_AsiaAfricaAustralasiaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CanadaAndLatinAmericaMember" xlink:label="lbl_CanadaAndLatinAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_CanadaAndLatinAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstablishedMarketsMember" xlink:label="lbl_EstablishedMarketsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EstablishedMarketsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EmergingGrowthMarketsMember" xlink:label="lbl_EmergingGrowthMarketsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EmergingGrowthMarketsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="lbl_EuropeMember" xlink:type="locator"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_EuropeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:label="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfOperatingSegmentsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="lbl_SegmentConsolidationItemsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentConsolidationItemsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentConsolidationItemsAxis" xlink:to="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingSegmentsMember" xlink:label="lbl_OperatingSegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_OperatingSegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaterialReconcilingItemsMember" xlink:label="lbl_MaterialReconcilingItemsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSegmentConsolidationItemsMember" xlink:to="lbl_MaterialReconcilingItemsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsTable" xlink:to="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsThirdParties" xlink:label="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsThirdParties" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:label="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoodsSalesToOtherSegments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherRevenue" xlink:label="lbl_OtherRevenue" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherRevenue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="lbl_CostOfSales" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_CostOfSales" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossProfit" xlink:label="lbl_GrossProfit" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_GrossProfit" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="lbl_ResearchAndDevelopmentExpense" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ResearchAndDevelopmentExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdministrativeExpense" xlink:label="lbl_AdministrativeExpense" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_AdministrativeExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome" xlink:label="lbl_OtherIncome" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherIncome" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherExpenseByFunction" xlink:label="lbl_OtherExpenseByFunction" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherExpenseByFunction" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="lbl_ProfitLossFromOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:label="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense" xlink:label="lbl_InterestExpense" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_InterestExpense" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost" xlink:label="lbl_OtherFinanceIncomeCost" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_OtherFinanceIncomeCost" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="lbl_ProfitLossBeforeTax" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossBeforeTax" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromContinuingOperations" xlink:label="lbl_ProfitLossFromContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:label="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="locator"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:presentationArc order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="lbl_ProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="22.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:label="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProfitLossFromOperatingActivities" xlink:to="lbl_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="lbl_ProfitLossAttributableToAbstract" xlink:type="locator"/>
      <link:presentationArc order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsLineItems" xlink:to="lbl_ProfitLossAttributableToAbstract" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToOwnersOfParent" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProfitLossAttributableToAbstract" xlink:to="lbl_ProfitLossAttributableToNoncontrollingInterests" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="lbl_ClassesOfAssetsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_ClassesOfAssetsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="lbl_ClassesOfAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsAxis" xlink:to="lbl_ClassesOfAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LandMember" xlink:label="lbl_LandMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_LandMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember" xlink:label="lbl_BuildingsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_BuildingsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_VehiclesMember" xlink:label="lbl_VehiclesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_VehiclesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssetsMember" xlink:label="lbl_OtherAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfAssetsMember" xlink:to="lbl_OtherAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:label="lbl_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_AdjustmentsForPrepaymentsAndAccruedLeasePayments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="lbl_DepreciationRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_DepreciationRightofuseAssets" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementsOfTheRightofuseAssetsRollForward" xlink:label="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="lbl_AdditionsToRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_AdditionsToRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:label="lbl_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementsOfTheRightofuseAssetsRollForward" xlink:label="lbl_MovementsOfTheRightofuseAssetsRollForward1" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward1" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseContractTerminationsRightofuseAssets" xlink:label="lbl_LeaseContractTerminationsRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_LeaseContractTerminationsRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisposalsAndRetirementsRightofuseAssets" xlink:label="lbl_DisposalsAndRetirementsRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="4.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_DisposalsAndRetirementsRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="lbl_DepreciationRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_DepreciationRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:label="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_AcquisitionsThroughBusinessCombinationsRightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="locator"/>
      <link:presentationArc order="4.2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MovementsOfTheRightofuseAssetsRollForward" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" xlink:to="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="lbl_MaturityAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:to="lbl_MaturityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="lbl_AggregatedTimeBandsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_MaturityAxis" xlink:to="lbl_AggregatedTimeBandsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="lbl_NotLaterThanOneYearMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_NotLaterThanOneYearMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:label="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanTwoYearsAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:label="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanThreeYearsAndNotLaterThanFourYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:label="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFourYearsAndNotLaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="lbl_LaterThanFiveYearsMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregatedTimeBandsMember" xlink:to="lbl_LaterThanFiveYearsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:label="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" xlink:to="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MostMaterialLeaseWithLeaseTermExtension" xlink:label="lbl_MostMaterialLeaseWithLeaseTermExtension" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_MostMaterialLeaseWithLeaseTermExtension" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="lbl_NoncurrentLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.7" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_NoncurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentLeaseLiabilitiesUndiscounted" xlink:label="lbl_NoncurrentLeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:presentationArc order="2.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_NoncurrentLeaseLiabilitiesUndiscounted" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLeaseLiabilitiesUndiscounted" xlink:label="lbl_CurrentLeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:presentationArc order="2.6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_CurrentLeaseLiabilitiesUndiscounted" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="lbl_CurrentLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_CurrentLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseLiabilitiesUndiscounted" xlink:label="lbl_LeaseLiabilitiesUndiscounted" xlink:type="locator"/>
      <link:presentationArc order="1.6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_LeaseLiabilitiesUndiscounted" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseTermEndDate" xlink:label="lbl_LeaseTermEndDate" xlink:type="locator"/>
      <link:presentationArc order="3.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_LeaseTermEndDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentsForLeasesNotYetCommenced" xlink:label="lbl_CommitmentsForLeasesNotYetCommenced" xlink:type="locator"/>
      <link:presentationArc order="2.9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" xlink:to="lbl_CommitmentsForLeasesNotYetCommenced" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowForSaleAndLeaseback" xlink:label="lbl_CashInflowForSaleAndLeaseback" xlink:type="locator"/>
      <link:presentationArc order="2.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashInflowForSaleAndLeaseback" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleAndLeaseBackMember" xlink:label="lbl_SaleAndLeaseBackMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lbl_SaleAndLeaseBackMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="lbl_LeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="3.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_LeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="lbl_RightofuseAssets" xlink:type="locator"/>
      <link:presentationArc order="4.8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_RightofuseAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="locator"/>
      <link:presentationArc order="5.8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:label="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:label="lbl_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ChangeInCashSettledShareBasedPaymentsLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:label="lbl_OtherAdjustmentsToReconcileProfitLoss" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherAdjustmentsToReconcileProfitLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:label="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="lbl_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="locator"/>
      <link:presentationArc order="5.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefund" xlink:label="lbl_IncomeTaxesPaidRefund" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefund" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SignificantAccountingPoliciesAbstract" xlink:label="lbl_SignificantAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="lbl_ParValuePerShare" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ParValuePerShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:label="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UndiscountedOperatingLeaseCommitments" xlink:label="lbl_UndiscountedOperatingLeaseCommitments" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_UndiscountedOperatingLeaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ShortTermLeasesAndLowValueLeases" xlink:label="lbl_ShortTermLeasesAndLowValueLeases" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ShortTermLeasesAndLowValueLeases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RemainingLeaseCommitments" xlink:label="lbl_RemainingLeaseCommitments" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RemainingLeaseCommitments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseLiabilitiesToBeRecognized" xlink:label="lbl_LeaseLiabilitiesToBeRecognized" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_LeaseLiabilitiesToBeRecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RightOfUseAssetsToBeRecognized" xlink:label="lbl_RightOfUseAssetsToBeRecognized" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RightOfUseAssetsToBeRecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrepaymentsAndAccruedLeasePayments" xlink:label="lbl_PrepaymentsAndAccruedLeasePayments" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PrepaymentsAndAccruedLeasePayments" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="lbl_ComponentsOfEquityAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ComponentsOfEquityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="lbl_EquityMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComponentsOfEquityAxis" xlink:to="lbl_EquityMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_EquityAttributableToOwnersOfParentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="lbl_IssuedCapitalMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_IssuedCapitalMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="lbl_TreasurySharesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TreasurySharesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="lbl_RetainedEarningsMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_RetainedEarningsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:label="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityAttributableToOwnersOfParentMember" xlink:to="lbl_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="lbl_NoncontrollingInterestsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityMember" xlink:to="lbl_NoncontrollingInterestsMember" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:presentationArc order="4.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember" xlink:to="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:label="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember" xlink:to="lbl_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="lbl_GrossLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:label="lbl_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_GrossLeaseLiabilitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NewLeaseArrangements" xlink:label="lbl_NewLeaseArrangements" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NewLeaseArrangements" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UndiscountedFutureLeasePayments" xlink:label="lbl_UndiscountedFutureLeasePayments" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_UndiscountedFutureLeasePayments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EffectOfDiscounting" xlink:label="lbl_EffectOfDiscounting" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EffectOfDiscounting" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:label="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails2" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypAxis" xlink:label="lbl_SubsequentEventTypAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_SubsequentEventTypAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventTypeMember" xlink:label="lbl_SubsequentEventTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SubsequentEventTypAxis" xlink:to="lbl_SubsequentEventTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SubsequentEventMember" xlink:label="lbl_SubsequentEventMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SubsequentEventTypeMember" xlink:to="lbl_SubsequentEventMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:label="lbl_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EstimatedAcquisitionFairValueOfTotalConsideration" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountMember" xlink:to="lbl_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lbl_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NonCurrentFinancialDebtsMember" xlink:label="lbl_NonCurrentFinancialDebtsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NonCurrentFinancialDebtsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:label="lbl_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentLeaseLiabilitiesMember" xlink:label="lbl_NoncurrentLeaseLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NoncurrentLeaseLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLeaseLiabilitiesMember" xlink:label="lbl_CurrentLeaseLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_CurrentLeaseLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialDebtsAndDerivativeInstruments" xlink:label="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:label="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromNoncurrentBorrowings" xlink:label="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_RepaymentsOfNoncurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:label="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:label="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:label="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmortizationOfBondsDiscount" xlink:label="lbl_AmortizationOfBondsDiscount" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AmortizationOfBondsDiscount" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReclassificationFromNoncurrentToCurrentNet" xlink:label="lbl_ReclassificationFromNoncurrentToCurrentNet" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ReclassificationFromNoncurrentToCurrentNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentPortionOfNoncurrentFinancialDebt" xlink:label="lbl_CurrentPortionOfNoncurrentFinancialDebt" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentPortionOfNoncurrentFinancialDebt" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems1" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems1" xlink:to="lbl_FinancialDebtsAndDerivativeInstruments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:label="lbl_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:type="locator"/>
      <link:presentationArc order="18.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" xlink:label="lbl_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="10.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" xlink:label="lbl_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails4" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfInterestsInAssociates" xlink:label="lbl_ProceedsFromSalesOfInterestsInAssociates" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_ProceedsFromSalesOfInterestsInAssociates" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:label="lbl_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="lbl_GeographicalAreasAxis" xlink:type="locator"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_GeographicalAreasAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="lbl_GeographicalAreasMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasAxis" xlink:to="lbl_GeographicalAreasMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="lbl_US" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_GeographicalAreasMember" xlink:to="lbl_US" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails3" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Cash" xlink:label="lbl_Cash" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="lbl_CashAndCashEquivalentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CashAndCashEquivalentsAbstract" xlink:to="lbl_Cash" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashEquivalents" xlink:label="lbl_CashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CashAndCashEquivalentsAbstract" xlink:to="lbl_CashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="lbl_CashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CashAndCashEquivalentsAbstract" xlink:to="lbl_CashAndCashEquivalents" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="lbl_StatementScenarioAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementScenarioAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="lbl_ScenarioUnspecifiedDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementScenarioAxis" xlink:to="lbl_ScenarioUnspecifiedDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical5IncreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical5DecreaseMember" xlink:label="lbl_Hypothetical5DecreaseMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical5DecreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical5IncreaseMember" xlink:label="lbl_Hypothetical5IncreaseMember" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" xlink:label="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" xlink:label="lbl_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="lbl_StatementScenarioAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementScenarioAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="lbl_ScenarioUnspecifiedDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementScenarioAxis" xlink:to="lbl_ScenarioUnspecifiedDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical15IncreaseMember" xlink:label="lbl_Hypothetical15IncreaseMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical15IncreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical15DecreaseMember" xlink:label="lbl_Hypothetical15DecreaseMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical15DecreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" xlink:label="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" xlink:label="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" xlink:label="lbl_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SignificantAccountingPoliciesAbstract" xlink:label="lbl_SignificantAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFigures" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:label="lbl_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSignificantTransactions" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfSignificantTransactionsTextBlock" xlink:label="lbl_DisclosureOfSignificantTransactionsTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfSignificantTransactionsAbstract" xlink:label="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:to="lbl_DisclosureOfSignificantTransactionsTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureAssociatedCompanies" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:label="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="lbl_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpense" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInterestExpenseExplanatory" xlink:label="lbl_DisclosureOfInterestExpenseExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:label="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_DisclosureOfInterestExpenseExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTaxes" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="lbl_DisclosureOfIncomeTaxExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfIncomeTaxAbstract" xlink:label="lbl_DisclosureOfIncomeTaxAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIncomeTaxAbstract" xlink:to="lbl_DisclosureOfIncomeTaxExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEarningsPerShare" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="lbl_EarningsPerShareExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="lbl_EarningsPerShareAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareAbstract" xlink:to="lbl_EarningsPerShareExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" xlink:label="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAbstract" xlink:label="lbl_ComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipment" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lbl_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiability" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="lbl_DisclosureOfLeasesExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" xlink:label="lbl_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" xlink:to="lbl_DisclosureOfLeasesExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssets" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:label="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfIntangibleAssetsAndGoodwillExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilities" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:label="lbl_DisclosureOfDeferredTaxesExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_DisclosureOfDeferredTaxesExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssets" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:to="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureInventories" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="lbl_DisclosureOfInventoriesExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoriesDisclosureAbstract" xlink:label="lbl_InventoriesDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoriesDisclosureAbstract" xlink:to="lbl_DisclosureOfInventoriesExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTradeReceivables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTradeReceivablesExplanatoryTextBlock" xlink:label="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTradeReceivablesAbstract" xlink:label="lbl_DisclosureOfTradeReceivablesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTradeReceivablesAbstract" xlink:to="lbl_DisclosureOfTradeReceivablesExplanatoryTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureMarketableSecurities" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureOtherCurrentAssets" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:label="lbl_DisclosureOfOtherCurrentAssetsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCurrentAssetsAbstract" xlink:label="lbl_OtherCurrentAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_DisclosureOfOtherCurrentAssetsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquity" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfEquityTextBlock" xlink:label="lbl_DisclosureOfEquityTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfEquityAbstract" xlink:label="lbl_DisclosureOfEquityAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfEquityAbstract" xlink:to="lbl_DisclosureOfEquityTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebt" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:label="lbl_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilities" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:label="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstruments" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilities" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatements" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:label="lbl_DisclosureOfCashFlowStatementExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_DisclosureOfCashFlowStatementExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinesses" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:label="lbl_DisclosureOfBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:label="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:to="lbl_DisclosureOfBusinessCombinationsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociates" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="lbl_DisclosureOfEmployeeBenefitsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_DisclosureOfEmployeeBenefitsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociates" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedParties" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="lbl_DisclosureOfRelatedPartyExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lbl_DisclosureOfRelatedPartyExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingencies" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCommitmentsAndContingenciesTextBlock" xlink:label="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentsAndContingenciesAbstract" xlink:label="lbl_CommitmentsAndContingenciesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CommitmentsAndContingenciesAbstract" xlink:to="lbl_DisclosureOfCommitmentsAndContingenciesTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosures" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSubsequentEvents" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="lbl_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompanies" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SignificantAccountingPoliciesAbstract" xlink:label="lbl_SignificantAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:label="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSignificantTransactionsTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfSignificantTransactionsAbstract" xlink:label="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:label="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:to="lbl_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:label="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:to="lbl_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:label="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:to="lbl_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:label="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantTransactionsAbstract" xlink:to="lbl_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfOperatingSegmentsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:label="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" xlink:type="arc"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsNetSalesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOperatingSegmentsNetSalesTableTextBlock" xlink:label="lbl_DisclosureOfOperatingSegmentsNetSalesTableTextBlock" xlink:type="locator"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInAssociatesAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:label="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfSignificantInvestmentsInAssociatesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:label="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfAssociatesBalanceSheetTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:label="lbl_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AssociatesSummarizedFinancialInformationTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PurchasePriceAllocationAssociatesTableTextBlock" xlink:label="lbl_PurchasePriceAllocationAssociatesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_PurchasePriceAllocationAssociatesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:label="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:label="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExpenseTableTextBlock" xlink:label="lbl_InterestExpenseTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_InterestExpenseTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherFinancialIncomeAndExpenseTableTextBlock" xlink:label="lbl_OtherFinancialIncomeAndExpenseTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" xlink:to="lbl_OtherFinancialIncomeAndExpenseTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTaxesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfIncomeTaxAbstract" xlink:label="lbl_DisclosureOfIncomeTaxAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeBeforeTaxesTableTextBlock" xlink:label="lbl_IncomeBeforeTaxesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIncomeTaxAbstract" xlink:to="lbl_IncomeBeforeTaxesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" xlink:label="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIncomeTaxAbstract" xlink:to="lbl_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AnalysisOfTaxRateTableTextBlock" xlink:label="lbl_AnalysisOfTaxRateTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIncomeTaxAbstract" xlink:to="lbl_AnalysisOfTaxRateTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEarningsPerShareTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="lbl_EarningsPerShareAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EarningsPerShareAbstract" xlink:to="lbl_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAbstract" xlink:label="lbl_ComprehensiveIncomeAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" xlink:label="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" xlink:label="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfComprehensiveIncomeTableTextBlock" xlink:label="lbl_ScheduleOfComprehensiveIncomeTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_ScheduleOfComprehensiveIncomeTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" xlink:label="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ComprehensiveIncomeAbstract" xlink:to="lbl_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PropertyPlantAndEquipmentTableTextBlock" xlink:label="lbl_PropertyPlantAndEquipmentTableTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lbl_PropertyPlantAndEquipmentTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock" xlink:label="lbl_PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lbl_PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:label="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" xlink:label="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:label="lbl_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" xlink:label="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" xlink:label="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" xlink:label="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:label="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" xlink:to="lbl_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" xlink:label="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:label="lbl_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AssumptionsUsedInTheCalculationOfValuationTextBlock" xlink:label="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_AssumptionsUsedInTheCalculationOfValuationTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IntangibleAssetImpairmentChargesTextBlock" xlink:label="lbl_IntangibleAssetImpairmentChargesTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_IntangibleAssetImpairmentChargesTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock" xlink:label="lbl_Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:label="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" xlink:label="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" xlink:label="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" xlink:label="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" xlink:label="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lbl_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:label="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialAssetsTableTextBlock" xlink:label="lbl_DisclosureOfFinancialAssetsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:to="lbl_DisclosureOfFinancialAssetsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:label="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:to="lbl_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:label="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" xlink:to="lbl_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureInventoriesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InventoriesDisclosureAbstract" xlink:label="lbl_InventoriesDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="lbl_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoriesDisclosureAbstract" xlink:to="lbl_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" xlink:label="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoriesDisclosureAbstract" xlink:to="lbl_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" xlink:label="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_InventoriesDisclosureAbstract" xlink:to="lbl_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTradeReceivablesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTradeReceivablesAbstract" xlink:label="lbl_DisclosureOfTradeReceivablesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsForTradeReceivablesTableTextBlock" xlink:label="lbl_ProvisionsForTradeReceivablesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTradeReceivablesAbstract" xlink:to="lbl_ProvisionsForTradeReceivablesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesProvisionMovementsTableTextBlock" xlink:label="lbl_TradeReceivablesProvisionMovementsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTradeReceivablesAbstract" xlink:to="lbl_TradeReceivablesProvisionMovementsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OverdueAmountsAndRelatedProvisionsTableTextBlock" xlink:label="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTradeReceivablesAbstract" xlink:to="lbl_OverdueAmountsAndRelatedProvisionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" xlink:label="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTradeReceivablesAbstract" xlink:to="lbl_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" xlink:label="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTradeReceivablesAbstract" xlink:to="lbl_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:label="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" xlink:label="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DebtSecuritiesBreakdownByCurrencyTableTextBlock" xlink:label="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_DebtSecuritiesBreakdownByCurrencyTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashAndCashEquivalentsTableTextBlock" xlink:label="lbl_CashAndCashEquivalentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" xlink:to="lbl_CashAndCashEquivalentsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCurrentAssetsTableTextBlock" xlink:label="lbl_OtherCurrentAssetsTableTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherCurrentAssetsAbstract" xlink:label="lbl_OtherCurrentAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_OtherCurrentAssetsAbstract" xlink:to="lbl_OtherCurrentAssetsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfEquityAbstract" xlink:label="lbl_DisclosureOfEquityAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementInTheShareCapitalTableTextBlock" xlink:label="lbl_MovementInTheShareCapitalTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfEquityAbstract" xlink:to="lbl_MovementInTheShareCapitalTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MovementInTheShareslTableTextBlock" xlink:label="lbl_MovementInTheShareslTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfEquityAbstract" xlink:to="lbl_MovementInTheShareslTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DividendTableTextBlock" xlink:label="lbl_DividendTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfEquityAbstract" xlink:to="lbl_DividendTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:label="lbl_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfEquityAbstract" xlink:to="lbl_SummaryOfTreasurySharesMovementsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesAbstract" xlink:label="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" xlink:label="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:label="lbl_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" xlink:label="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" xlink:label="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" xlink:label="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfFinancialLiabilitiesAbstract" xlink:to="lbl_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherProvisionsExplanatory" xlink:label="lbl_DisclosureOfOtherProvisionsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_DisclosureOfOtherProvisionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccrualForEnvironmentalLossContingenciesTableTextBlock" xlink:label="lbl_AccrualForEnvironmentalLossContingenciesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_AccrualForEnvironmentalLossContingenciesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" xlink:label="lbl_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" xlink:label="lbl_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" xlink:to="lbl_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:label="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" xlink:to="lbl_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:label="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProvisionsForReductionOfRevenueTableTextBlock" xlink:label="lbl_ProvisionsForReductionOfRevenueTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_ProvisionsForReductionOfRevenueTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RestructuringProvisionsMovementsTableTextBlock" xlink:label="lbl_RestructuringProvisionsMovementsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" xlink:to="lbl_RestructuringProvisionsMovementsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:label="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" xlink:label="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:label="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsFromDiscontinuedOperationsTableTextBlock" xlink:label="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_CashFlowsFromDiscontinuedOperationsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" xlink:label="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:label="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:label="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfAcquisitionOfBusinessesAbstract" xlink:to="lbl_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansAbstract" xlink:label="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDefinedBenefitPlansAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeAxis" xlink:label="lbl_RetirementPlanTypeAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_RetirementPlanTypeAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RetirementPlanTypeMember" xlink:label="lbl_RetirementPlanTypeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeAxis" xlink:to="lbl_RetirementPlanTypeMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PensionPlanMember" xlink:label="lbl_PensionPlanMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_PensionPlanMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPostemploymentBenefitPlansMember" xlink:label="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetirementPlanTypeMember" xlink:to="lbl_OtherPostemploymentBenefitPlansMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:label="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfDefinedBenefitPlansTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:label="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:label="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="lbl_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:label="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:label="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:label="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:label="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:label="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:label="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfDefinedContributionPlansTableTextBlock" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="lbl_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lbl_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SharebasedPaymentArrangementsMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:label="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:label="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EquityBasedParticipationNovartisEquityPlanSelectMember" xlink:to="lbl_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:label="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:label="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:label="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ScheduleOfSharebasedCompensationActivityTableTextBlock" xlink:type="arc"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesTables" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OfficerAndDirectorCompensationTableTextBlock" xlink:label="lbl_OfficerAndDirectorCompensationTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lbl_OfficerAndDirectorCompensationTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" xlink:label="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="lbl_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CommitmentsAndContingenciesAbstract" xlink:label="lbl_CommitmentsAndContingenciesAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfLeasingCommitmentsTableTextBlock" xlink:label="lbl_DisclosureOfLeasingCommitmentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CommitmentsAndContingenciesAbstract" xlink:to="lbl_DisclosureOfLeasingCommitmentsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" xlink:label="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CommitmentsAndContingenciesAbstract" xlink:to="lbl_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:label="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="lbl_DisclosureOfFairValueMeasurementExplanatory" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfFairValueMeasurementExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" xlink:label="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:label="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" xlink:label="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" xlink:label="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" xlink:label="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" xlink:label="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock" xlink:label="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock" xlink:type="locator"/>
      <link:presentationArc order="14.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" xlink:label="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:label="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="lbl_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:to="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="lbl_EntitysTotalForSubsidiariesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInSubsidiariesAxis" xlink:to="lbl_EntitysTotalForSubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubsidiariesMember" xlink:label="lbl_SubsidiariesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForSubsidiariesMember" xlink:to="lbl_SubsidiariesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementLocationAxis" xlink:label="lbl_IncomeStatementLocationAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_IncomeStatementLocationAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IncomeStatementLocationMember" xlink:label="lbl_IncomeStatementLocationMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncomeStatementLocationAxis" xlink:to="lbl_IncomeStatementLocationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OperatingIncomeMember" xlink:label="lbl_OperatingIncomeMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IncomeStatementLocationMember" xlink:to="lbl_OperatingIncomeMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="lbl_LegalEntityAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_LegalEntityAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="lbl_EntityDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_LegalEntityAxis" xlink:to="lbl_EntityDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdvancedAcceleratorApplicationsAAAMember" xlink:label="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdvancedAcceleratorApplicationsAAAMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AspenGlobalIncorporatedMember" xlink:label="lbl_AspenGlobalIncorporatedMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AspenGlobalIncorporatedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TheMedicinesCompanyMember" xlink:label="lbl_TheMedicinesCompanyMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TheMedicinesCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AveXisIncMember" xlink:label="lbl_AveXisIncMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AveXisIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EndocyteMember" xlink:label="lbl_EndocyteMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EndocyteMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TranscendMedicalIncMember" xlink:label="lbl_TranscendMedicalIncMember" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TranscendMedicalIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SelexysPharmaceuticalsCorporationMember" xlink:label="lbl_SelexysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SelexysPharmaceuticalsCorporationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReprixysPharmaceuticalsCorporationMember" xlink:label="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ReprixysPharmaceuticalsCorporationMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZiarcoGroupLimitedMember" xlink:label="lbl_ZiarcoGroupLimitedMember" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_ZiarcoGroupLimitedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EncoreVisionIncMember" xlink:label="lbl_EncoreVisionIncMember" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EncoreVisionIncMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_EliLillyAndCompanyMember" xlink:label="lbl_EliLillyAndCompanyMember" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_EliLillyAndCompanyMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKOncologyProductsMember" xlink:label="lbl_GSKOncologyProductsMember" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKOncologyProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKVaccinesMember" xlink:label="lbl_GSKVaccinesMember" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKVaccinesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKConsumerHealthcareMember" xlink:label="lbl_GSKConsumerHealthcareMember" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKConsumerHealthcareMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GSKTotalTransactionMember" xlink:label="lbl_GSKTotalTransactionMember" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GSKTotalTransactionMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CSLMember" xlink:label="lbl_CSLMember" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_CSLMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SpinifexMember" xlink:label="lbl_SpinifexMember" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_SpinifexMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdmuneTheraputicsMember" xlink:label="lbl_AdmuneTheraputicsMember" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_AdmuneTheraputicsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="locator"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IFMTreInc.Member" xlink:label="lbl_IFMTreInc.Member" xlink:type="locator"/>
      <link:presentationArc order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_IFMTreInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PowerVisionInc.Member" xlink:label="lbl_PowerVisionInc.Member" xlink:type="locator"/>
      <link:presentationArc order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_PowerVisionInc.Member" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:label="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="locator"/>
      <link:presentationArc order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlinePlcGSKMember" xlink:label="lbl_GlaxoSmithKlinePlcGSKMember" xlink:type="locator"/>
      <link:presentationArc order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GlaxoSmithKlinePlcGSKMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GyroscopeTherapeuticsHoldingsPlcMember" xlink:label="lbl_GyroscopeTherapeuticsHoldingsPlcMember" xlink:type="locator"/>
      <link:presentationArc order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntityDomain" xlink:to="lbl_GyroscopeTherapeuticsHoldingsPlcMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RocheHoldingAGMember" xlink:label="lbl_RocheHoldingAGMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_RocheHoldingAGMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:label="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OthersAssociatesMember" xlink:label="lbl_OthersAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_OthersAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SandozMember" xlink:label="lbl_SandozMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InnovativeMedicinesMember" xlink:label="lbl_InnovativeMedicinesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_InnovativeMedicinesMember" xlink:type="arc"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_SandozMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CorporateMember" xlink:label="lbl_CorporateMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_CorporateMember" xlink:type="arc"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="lbl_BorrowingsByNameAxis" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_BorrowingsByNameAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="lbl_BorrowingsByNameMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameAxis" xlink:to="lbl_BorrowingsByNameMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsUSDMember" xlink:label="lbl_BorrowingsUSDMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_BorrowingsUSDMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BorrowingsEURMember" xlink:label="lbl_BorrowingsEURMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BorrowingsByNameMember" xlink:to="lbl_BorrowingsEURMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DetailedInformationAboutSignificantTransaction" xlink:label="lbl_DetailedInformationAboutSignificantTransaction" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DetailedInformationAboutSignificantTransaction" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:label="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RepaymentOfIntercompanyBalances" xlink:label="lbl_RepaymentOfIntercompanyBalances" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RepaymentOfIntercompanyBalances" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContingentLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionalRecognitionGoodwill" xlink:label="lbl_AdditionalRecognitionGoodwill" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AdditionalRecognitionGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:label="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfVotingEquityInterestsAcquired" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:label="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromDiscontinuedOperations" xlink:label="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProfitLossFromDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:label="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentiallyRefundableConsiderationFromAcquisition" xlink:label="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentiallyRefundableConsiderationFromAcquisition" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:label="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:type="locator"/>
      <link:presentationArc order="17.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AcquisitionFairValuePotentiallyRefundableContingentConsideration" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContractRightOfFirstNegotiationTerm" xlink:label="lbl_ContractRightOfFirstNegotiationTerm" xlink:type="locator"/>
      <link:presentationArc order="18.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContractRightOfFirstNegotiationTerm" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueOfAcquiree" xlink:label="lbl_RevenueOfAcquiree" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueOfAcquiree" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RevenueOfAcquireeFullYear" xlink:label="lbl_RevenueOfAcquireeFullYear" xlink:type="locator"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueOfAcquireeFullYear" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="21.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:label="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:type="locator"/>
      <link:presentationArc order="22.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:presentationArc order="23.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:type="locator"/>
      <link:presentationArc order="24.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:label="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:type="locator"/>
      <link:presentationArc order="25.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_SaleOfBusinessContingentOptionArrangementsFeePaid" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:label="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="locator"/>
      <link:presentationArc order="26.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_InvestmentsInSubsidiariesJointVenturesAndAssociates" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfVotingEquityInterestsContributed" xlink:label="lbl_PercentageOfVotingEquityInterestsContributed" xlink:type="locator"/>
      <link:presentationArc order="27.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfVotingEquityInterestsContributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionRelatedCosts" xlink:label="lbl_TransactionRelatedCosts" xlink:type="locator"/>
      <link:presentationArc order="28.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionRelatedCosts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionRelatedCostsPaid" xlink:label="lbl_TransactionRelatedCostsPaid" xlink:type="locator"/>
      <link:presentationArc order="29.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionRelatedCostsPaid" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLoss" xlink:label="lbl_ImpairmentLoss" xlink:type="locator"/>
      <link:presentationArc order="30.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ImpairmentLoss" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLoss" xlink:label="lbl_ReversalOfImpairmentLoss" xlink:type="locator"/>
      <link:presentationArc order="31.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ReversalOfImpairmentLoss" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PreTaxProfitLossFromDivestmentOfBusiness" xlink:label="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:type="locator"/>
      <link:presentationArc order="32.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PreTaxProfitLossFromDivestmentOfBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:label="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:type="locator"/>
      <link:presentationArc order="33.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentDateFairValueOfTotalConsiderationTransferred" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialReceivableFromDivestment" xlink:label="lbl_PotentialReceivableFromDivestment" xlink:type="locator"/>
      <link:presentationArc order="34.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentialReceivableFromDivestment" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentFairValueOfContingentConsiderationReceived" xlink:label="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:type="locator"/>
      <link:presentationArc order="35.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentFairValueOfContingentConsiderationReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_MilestonePaymentAlreadyReceived" xlink:label="lbl_MilestonePaymentAlreadyReceived" xlink:type="locator"/>
      <link:presentationArc order="36.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_MilestonePaymentAlreadyReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FuturePutOptionToSellBusiness" xlink:label="lbl_FuturePutOptionToSellBusiness" xlink:type="locator"/>
      <link:presentationArc order="37.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_FuturePutOptionToSellBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PaymentPutOption" xlink:label="lbl_PaymentPutOption" xlink:type="locator"/>
      <link:presentationArc order="38.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PaymentPutOption" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestExchanged" xlink:label="lbl_InterestExchanged" xlink:type="locator"/>
      <link:presentationArc order="39.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_InterestExchanged" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="lbl_ParValuePerShare" xlink:type="locator"/>
      <link:presentationArc order="40.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ParValuePerShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfShareCapitalInTenderOffer" xlink:label="lbl_PercentageOfShareCapitalInTenderOffer" xlink:type="locator"/>
      <link:presentationArc order="41.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalInTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOfferPerOrdinaryShare" xlink:label="lbl_CashOfferPerOrdinaryShare" xlink:type="locator"/>
      <link:presentationArc order="42.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CashOfferPerOrdinaryShare" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOfferPerADS" xlink:label="lbl_CashOfferPerADS" xlink:type="locator"/>
      <link:presentationArc order="43.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CashOfferPerADS" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfOrdinarySharePerADS" xlink:label="lbl_NumberOfOrdinarySharePerADS" xlink:type="locator"/>
      <link:presentationArc order="44.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfOrdinarySharePerADS" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ValueOfEquity" xlink:label="lbl_ValueOfEquity" xlink:type="locator"/>
      <link:presentationArc order="45.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ValueOfEquity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:type="locator"/>
      <link:presentationArc order="46.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherNetAssets" xlink:label="lbl_OtherNetAssets" xlink:type="locator"/>
      <link:presentationArc order="47.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_OtherNetAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="lbl_DeferredTaxLiabilityAsset" xlink:type="locator"/>
      <link:presentationArc order="48.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DeferredTaxLiabilityAsset" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="49.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentCostToSell" xlink:label="lbl_DivestmentCostToSell" xlink:type="locator"/>
      <link:presentationArc order="50.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DivestmentCostToSell" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:presentationArc order="51.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:presentationArc order="52.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:label="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="locator"/>
      <link:presentationArc order="53.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CarryingValueOfTheDivestedBusiness" xlink:label="lbl_CarryingValueOfTheDivestedBusiness" xlink:type="locator"/>
      <link:presentationArc order="54.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CarryingValueOfTheDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfProductsInPortfolioToBeSold" xlink:label="lbl_NumberOfProductsInPortfolioToBeSold" xlink:type="locator"/>
      <link:presentationArc order="55.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfProductsInPortfolioToBeSold" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="lbl_RevenueFromSaleOfGoods" xlink:type="locator"/>
      <link:presentationArc order="56.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_RevenueFromSaleOfGoods" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProformaNetSales" xlink:label="lbl_ProformaNetSales" xlink:type="locator"/>
      <link:presentationArc order="57.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProformaNetSales" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfBrandsInPortfolioToAcquire" xlink:label="lbl_NumberOfBrandsInPortfolioToAcquire" xlink:type="locator"/>
      <link:presentationArc order="58.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfBrandsInPortfolioToAcquire" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfMarketsForTheAcquiredBrands" xlink:label="lbl_NumberOfMarketsForTheAcquiredBrands" xlink:type="locator"/>
      <link:presentationArc order="59.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfMarketsForTheAcquiredBrands" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherBorrowings" xlink:label="lbl_OtherBorrowings" xlink:type="locator"/>
      <link:presentationArc order="60.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_OtherBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPayable" xlink:label="lbl_DividendsPayable" xlink:type="locator"/>
      <link:presentationArc order="61.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DividendsPayable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings" xlink:label="lbl_Borrowings" xlink:type="locator"/>
      <link:presentationArc order="62.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_Borrowings" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:label="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:type="locator"/>
      <link:presentationArc order="63.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="lbl_NetAssetsLiabilities" xlink:type="locator"/>
      <link:presentationArc order="64.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NetAssetsLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="lbl_FinancialAssetsAtFairValue" xlink:type="locator"/>
      <link:presentationArc order="65.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_FinancialAssetsAtFairValue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="locator"/>
      <link:presentationArc order="66.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:presentationArc order="67.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:label="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:type="locator"/>
      <link:presentationArc order="68.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PotentialMilestoneMaximumPayments" xlink:label="lbl_PotentialMilestoneMaximumPayments" xlink:type="locator"/>
      <link:presentationArc order="69.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PotentialMilestoneMaximumPayments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:label="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:type="locator"/>
      <link:presentationArc order="70.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfEmployeesAssociatedWithTheProductTransfer" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AdditionalBorrowings" xlink:label="lbl_AdditionalBorrowings" xlink:type="locator"/>
      <link:presentationArc order="71.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AdditionalBorrowings" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_PercentageOfEquityInterestSharesReceived" xlink:label="lbl_PercentageOfEquityInterestSharesReceived" xlink:type="locator"/>
      <link:presentationArc order="72.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_PercentageOfEquityInterestSharesReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:label="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:type="locator"/>
      <link:presentationArc order="73.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DistributionOfDividendBearingSharesToConsolidatedFoundations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="locator"/>
      <link:presentationArc order="74.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ProportionOfOwnershipInterestInSubsidiary" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CustomaryPurchasePriceAdjustment" xlink:label="lbl_CustomaryPurchasePriceAdjustment" xlink:type="locator"/>
      <link:presentationArc order="75.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CustomaryPurchasePriceAdjustment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="locator"/>
      <link:presentationArc order="76.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DepreciationPropertyPlantAndEquipment" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
      <link:presentationArc order="77.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:label="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="locator"/>
      <link:presentationArc order="78.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashTransferred" xlink:label="lbl_CashTransferred" xlink:type="locator"/>
      <link:presentationArc order="79.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CashTransferred" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:label="lbl_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="80.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_ContingentConsiderationRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NumberOfBearerShares" xlink:label="lbl_NumberOfBearerShares" xlink:type="locator"/>
      <link:presentationArc order="81.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NumberOfBearerShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:label="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="locator"/>
      <link:presentationArc order="82.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_GainOnDivestmentOfInterestsInAssociatedCompanies" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:label="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsAbstract" xlink:to="lbl_DisclosureOfBusinessCombinationsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis" xlink:label="lbl_SegmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_SegmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember" xlink:label="lbl_SegmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsAxis" xlink:to="lbl_SegmentsMember" xlink:type="arc"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SegmentsMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsTable" xlink:to="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetAssetsDerecognized" xlink:label="lbl_NetAssetsDerecognized" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_NetAssetsDerecognized" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DividendsPayable" xlink:label="lbl_DividendsPayable" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DividendsPayable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DistributionOfDividendToDividendBearingShares" xlink:label="lbl_DistributionOfDividendToDividendBearingShares" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DistributionOfDividendToDividendBearingShares" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:label="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCosts" xlink:label="lbl_TransactionCosts" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_TransactionCosts" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:label="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfBusinessCombinationsLineItems" xlink:to="lbl_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_SignificantAccountingPoliciesAbstract" xlink:label="lbl_SignificantAccountingPoliciesAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantAccountingPoliciesAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForSubsidiariesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DistributionByWayOfDivindendInKindToShareholders" xlink:label="lbl_DistributionByWayOfDivindendInKindToShareholders" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DistributionByWayOfDivindendInKindToShareholders" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:label="lbl_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:type="locator"/>
      <link:presentationArc order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForTreasurySharesExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="locator"/>
      <link:presentationArc order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:label="lbl_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="locator"/>
      <link:presentationArc order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems1" xlink:type="locator"/>
      <link:presentationArc order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems1" xlink:to="lbl_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="locator"/>
      <link:presentationArc order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="31.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="32.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:type="locator"/>
      <link:presentationArc order="33.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:label="lbl_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:type="locator"/>
      <link:presentationArc order="29.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfNatureOfChangeInAccountingPolicy" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="locator"/>
      <link:presentationArc order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:type="locator"/>
      <link:presentationArc order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="locator"/>
      <link:presentationArc order="22.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:label="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:type="locator"/>
      <link:presentationArc order="26.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TransactionCostsRecordedInEquityTextBlock" xlink:label="lbl_TransactionCostsRecordedInEquityTextBlock" xlink:type="locator"/>
      <link:presentationArc order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_TransactionCostsRecordedInEquityTextBlock" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:label="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsAndDivestmentsAxis" xlink:label="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_AcquisitionsAndDivestmentsAxis" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsAndDivestmentsMember" xlink:label="lbl_AcquisitionsAndDivestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AcquisitionsAndDivestmentsAxis" xlink:to="lbl_AcquisitionsAndDivestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquisitionsMember" xlink:label="lbl_AcquisitionsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AcquisitionsAndDivestmentsMember" xlink:to="lbl_AcquisitionsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestmentsMember" xlink:label="lbl_DivestmentsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AcquisitionsAndDivestmentsMember" xlink:to="lbl_DivestmentsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="lbl_BusinessCombinationsAxis" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_BusinessCombinationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_BusinessCombinationsAxis" xlink:to="lbl_EntitysTotalForBusinessCombinationsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TranscendMedicalIncMember" xlink:label="lbl_TranscendMedicalIncMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForBusinessCombinationsMember" xlink:to="lbl_TranscendMedicalIncMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="lbl_AssetsAndLiabilitiesAxis" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_AssetsAndLiabilitiesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="lbl_AssetsAndLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesAxis" xlink:to="lbl_AssetsAndLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentAssetsMember" xlink:label="lbl_NoncurrentAssetsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NoncurrentAssetsMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLiabilitiesMember" xlink:label="lbl_CurrentLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_CurrentLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentLiabilitiesMember" xlink:label="lbl_NoncurrentLiabilitiesMember" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_NoncurrentLiabilitiesMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AssetsAndLiabilitiesMember" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowFromNetIdentifiableAssets" xlink:label="lbl_CashFlowFromNetIdentifiableAssets" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowFromNetIdentifiableAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:label="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:label="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ReceivablesAndPayablesContingentConsiderationNet" xlink:label="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ReceivablesAndPayablesContingentConsiderationNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherPaymentsAndDeferredConsiderationNet" xlink:label="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherPaymentsAndDeferredConsiderationNet" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:label="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ContingentConsiderationPaid" xlink:label="lbl_ContingentConsiderationPaid" xlink:type="locator"/>
      <link:presentationArc order="9.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ContingentConsiderationPaid" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentAssetsDivested" xlink:label="lbl_NoncurrentAssetsDivested" xlink:type="locator"/>
      <link:presentationArc order="10.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NoncurrentAssetsDivested" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="lbl_ConsiderationPaidReceived" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ConsiderationPaidReceived" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetCashOutflowsFromDivestments" xlink:label="lbl_NetCashOutflowsFromDivestments" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetCashOutflowsFromDivestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentAssetsDivested" xlink:label="lbl_CurrentAssetsDivested" xlink:type="locator"/>
      <link:presentationArc order="14.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentAssetsDivested" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:presentationArc order="15.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentLiabilitiesDivested" xlink:label="lbl_CurrentLiabilitiesDivested" xlink:type="locator"/>
      <link:presentationArc order="16.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CurrentLiabilitiesDivested" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:label="lbl_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="locator"/>
      <link:presentationArc order="17.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DeferredSalePriceAndOtherAdjustments" xlink:label="lbl_DeferredSalePriceAndOtherAdjustments" xlink:type="locator"/>
      <link:presentationArc order="19.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DeferredSalePriceAndOtherAdjustments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherNetCashInflowsFromDivestments" xlink:label="lbl_OtherNetCashInflowsFromDivestments" xlink:type="locator"/>
      <link:presentationArc order="20.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherNetCashInflowsFromDivestments" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsDueToDerecognizedCashAndCashEquivalents" xlink:label="lbl_CashOutflowsDueToDerecognizedCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="21.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashOutflowsDueToDerecognizedCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NoncurrentAndCurrentLiabilitiesDivested" xlink:label="lbl_NoncurrentAndCurrentLiabilitiesDivested" xlink:type="locator"/>
      <link:presentationArc order="22.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NoncurrentAndCurrentLiabilitiesDivested" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_NetIdentifiableAssetsOfDivestedBusiness" xlink:label="lbl_NetIdentifiableAssetsOfDivestedBusiness" xlink:type="locator"/>
      <link:presentationArc order="23.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_NetIdentifiableAssetsOfDivestedBusiness" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:label="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" xlink:to="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:label="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RightOfUseAssetsAsOfAcquisitionDate" xlink:label="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_RightOfUseAssetsAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_DeferredTaxAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialAndOtherAssets" xlink:label="lbl_FinancialAndOtherAssets" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_FinancialAndOtherAssets" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoryRecognisedAsOfAcquisitionDate" xlink:label="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_InventoryRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:label="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:label="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:label="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:label="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_TradePayablesAndOtherLiabilities" xlink:label="lbl_TradePayablesAndOtherLiabilities" xlink:type="locator"/>
      <link:presentationArc order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_TradePayablesAndOtherLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_IdentifiableAssetsAcquired" xlink:label="lbl_IdentifiableAssetsAcquired" xlink:type="locator"/>
      <link:presentationArc order="15.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_IdentifiableAssetsAcquired" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AcquiredCashAndCashEquivalents" xlink:label="lbl_AcquiredCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="16.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_AcquiredCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:label="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="17.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:label="lbl_GoodwillRecognisedAsOfAcquisitionDate" xlink:type="locator"/>
      <link:presentationArc order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_GoodwillRecognisedAsOfAcquisitionDate" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:label="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="locator"/>
      <link:presentationArc order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillExpectedDeductibleForTaxPurposes" xlink:label="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:type="locator"/>
      <link:presentationArc order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" xlink:to="lbl_GoodwillExpectedDeductibleForTaxPurposes" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8" xlink:type="extended">
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DisclosureOfDiscontinuedOperationsAbstract" xlink:label="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfDiscontinuedOperationsAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_SignificantInvestmentsInAssociatesAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="lbl_EntitysTotalForAssociatesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_SignificantInvestmentsInAssociatesAxis" xlink:to="lbl_EntitysTotalForAssociatesMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_AlconMember" xlink:label="lbl_AlconMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_EntitysTotalForAssociatesMember" xlink:to="lbl_AlconMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:label="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_DivestedCashAndCashEquivalents" xlink:label="lbl_DivestedCashAndCashEquivalents" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_DivestedCashAndCashEquivalents" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashFlowsAttributableToDivestedBusiness" xlink:label="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="locator"/>
      <link:presentationArc order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsAttributableToDivestedBusiness" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:label="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:label="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="locator"/>
      <link:presentationArc order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:label="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="locator"/>
      <link:presentationArc order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_ProceedsFromCurrentAndNoncurrentBorrowings" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="lbl_StatementScenarioAxis" xlink:type="locator"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementTable" xlink:label="lbl_StatementTable" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementScenarioAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="lbl_ScenarioUnspecifiedDomain" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementScenarioAxis" xlink:to="lbl_ScenarioUnspecifiedDomain" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical100basisPointIncreaseMember" xlink:label="lbl_Hypothetical100basisPointIncreaseMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical100basisPointIncreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_Hypothetical100basisPointDecreaseMember" xlink:label="lbl_Hypothetical100basisPointDecreaseMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ScenarioUnspecifiedDomain" xlink:to="lbl_Hypothetical100basisPointDecreaseMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_StatementLineItems" xlink:label="lbl_StatementLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementTable" xlink:to="lbl_StatementLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_InterestRateSensitivityImpactInTheIncomeStatement" xlink:label="lbl_InterestRateSensitivityImpactInTheIncomeStatement" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_InterestRateSensitivityImpactInTheIncomeStatement" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity" xlink:label="lbl_HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_StatementLineItems" xlink:to="lbl_HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:label="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_FinancialInstrumentsAdditionalDisclosureAbstract" xlink:to="lbl_StatementTable" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:label="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsAbstract" xlink:label="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsAbstract" xlink:to="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="lbl_CarryingAmountMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lbl_CarryingAmountMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lbl_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsAndGoodwillMember" xlink:to="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CurrentlyMarketedProductsMember" xlink:label="lbl_CurrentlyMarketedProductsMember" xlink:type="locator"/>
      <link:presentationArc order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lbl_CurrentlyMarketedProductsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="lbl_ProductsAndServicesAxis" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="lbl_ProductsAndServicesMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesAxis" xlink:to="lbl_ProductsAndServicesMember" xlink:type="arc"/>
      <link:presentationArc order="1.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ProductsAndServicesAxis" xlink:type="arc"/>
      <link:presentationArc order="0.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="2.5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable" xlink:to="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeqvioMember" xlink:label="lbl_LeqvioMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_LeqvioMember" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_ZolgensmaMember" xlink:label="lbl_ZolgensmaMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ProductsAndServicesMember" xlink:to="lbl_ZolgensmaMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsMaterialToEntity" xlink:label="lbl_IntangibleAssetsMaterialToEntity" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_IntangibleAssetsMaterialToEntity" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:label="lbl_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfIntangibleAssetsLineItems" xlink:to="lbl_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019" xlink:type="arc"/>
   </link:presentationLink>
   <link:presentationLink xlink:role="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6" xlink:type="extended">
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="locator"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingAndDiscontinuedOperationsAxis" xlink:label="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember" xlink:label="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_ContinuingAndDiscontinuedOperationsAxis" xlink:to="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContinuingOperationsMember" xlink:label="lbl_ContinuingOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_ContinuingOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DiscontinuedOperationsMember" xlink:label="lbl_DiscontinuedOperationsMember" xlink:type="locator"/>
      <link:presentationArc order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_AggregateContinuingAndDiscontinuedOperationsMember" xlink:to="lbl_DiscontinuedOperationsMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="lbl_RestatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="lbl_RestatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="lbl_PreviouslyStatedMember" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_RestatedMember" xlink:to="lbl_PreviouslyStatedMember" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_InterestExpenseOnLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator"/>
      <link:presentationArc order="2.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:label="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="locator"/>
      <link:presentationArc order="3.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOutflowForLeases" xlink:label="lbl_CashOutflowForLeases" xlink:type="locator"/>
      <link:presentationArc order="4.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashOutflowForLeases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsForShortTermAndLowValueLeases" xlink:label="lbl_CashOutflowsForShortTermAndLowValueLeases" xlink:type="locator"/>
      <link:presentationArc order="5.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashOutflowsForShortTermAndLowValueLeases" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashOutflowsForPaymentsOfLeasesInterest" xlink:label="lbl_CashOutflowsForPaymentsOfLeasesInterest" xlink:type="locator"/>
      <link:presentationArc order="6.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashOutflowsForPaymentsOfLeasesInterest" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_CashInflowForSaleAndLeaseback" xlink:label="lbl_CashInflowForSaleAndLeaseback" xlink:type="locator"/>
      <link:presentationArc order="7.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_CashInflowForSaleAndLeaseback" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_RepaymentOfLeaseLiability" xlink:label="lbl_RepaymentOfLeaseLiability" xlink:type="locator"/>
      <link:presentationArc order="8.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_RepaymentOfLeaseLiability" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="locator"/>
      <link:presentationArc order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:label="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="locator"/>
      <link:presentationArc order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_GainsLossesArisingFromSaleAndLeasebackTransactions" xlink:type="arc"/>
      <link:loc xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:label="lbl_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="11.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_WeightedAverageInterestRateLeaseLiabilities" xlink:label="lbl_WeightedAverageInterestRateLeaseLiabilities" xlink:type="locator"/>
      <link:presentationArc order="12.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_WeightedAverageInterestRateLeaseLiabilities" xlink:type="arc"/>
      <link:loc xlink:href="nvs-20221231.xsd#nvs_LeaseIncentives" xlink:label="lbl_LeaseIncentives" xlink:type="locator"/>
      <link:presentationArc order="13.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbl_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lbl_LeaseIncentives" xlink:type="arc"/>
   </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>nvs-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nvs="http://novartis.com/20221231" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" blockDefault="" elementFormDefault="qualified" finalDefault="" targetNamespace="http://novartis.com/20221231">
   <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
   <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
   <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
   <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
   <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
   <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
   <xsd:import namespace="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd"/>
   <xsd:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
   <xsd:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
   <xsd:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd"/>
   <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
   <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
   <xsd:annotation>
      <xsd:appinfo>

      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvs-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
	  <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvs-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
	  <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvs-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
	  <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvs-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
	  <link:roleType id="documentAndEntityInformation" roleURI="http://novartis.com/20221231/role/DocumentAndEntityInformation">
            <link:definition>0001000 - Document - Document and Entity Information</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementOfIncome" roleURI="http://novartis.com/20221231/role/StatementOfIncome">
            <link:definition>1001000 - Statement - Consolidated income statements</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementOfComprehensiveIncome" roleURI="http://novartis.com/20221231/role/StatementOfComprehensiveIncome">
            <link:definition>1002000 - Statement - Consolidated statements of comprehensive income</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementOfChangesInEquity" roleURI="http://novartis.com/20221231/role/StatementOfChangesInEquity">
            <link:definition>1004000 - Statement - Consolidated statements of changes in equity</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="balanceSheet" roleURI="http://novartis.com/20221231/role/BalanceSheet">
            <link:definition>1003000 - Statement - Consolidated balance sheets</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementsOfCashFlow" roleURI="http://novartis.com/20221231/role/StatementsOfCashFlow">
            <link:definition>1005000 - Statement - Consolidated cash flow statements</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePropertyPlantAndEquipmentDetails" roleURI="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails">
            <link:definition>2400900 - Disclosure - Property, plant and equipment (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePropertyPlantAndEquipmentDetails2" roleURI="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2">
            <link:definition>2400901 - Disclosure - Property, plant and equipment (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePropertyPlantAndEquipment" roleURI="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipment">
            <link:definition>2100900 - Disclosure - Property, plant and equipment</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePropertyPlantAndEquipmentTables" roleURI="http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentTables">
            <link:definition>2300900 - Disclosure - Property, plant and equipment (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInventories" roleURI="http://novartis.com/20221231/role/DisclosureInventories">
            <link:definition>2101400 - Disclosure - Inventories</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInventoriesTables" roleURI="http://novartis.com/20221231/role/DisclosureInventoriesTables">
            <link:definition>2301400 - Disclosure - Inventories (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInventoriesDetails" roleURI="http://novartis.com/20221231/role/DisclosureInventoriesDetails">
            <link:definition>2401400 - Disclosure - Inventories (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEarningsPerShare" roleURI="http://novartis.com/20221231/role/DisclosureEarningsPerShare">
            <link:definition>2100700 - Disclosure - Earnings per share</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEarningsPerShareTables" roleURI="http://novartis.com/20221231/role/DisclosureEarningsPerShareTables">
            <link:definition>2300700 - Disclosure - Earnings per share (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEarningsPerShareDetails" roleURI="http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails">
            <link:definition>2400700 - Disclosure - Earnings per share (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfSignificantAccountingPolicies" roleURI="http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPolicies">
            <link:definition>2100100 - Disclosure - Significant accounting policies</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInterestExpenseAndOtherFinancialIncomeExpense" roleURI="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpense">
            <link:definition>2100500 - Disclosure - Interest expense and other financial income and expense</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTaxes" roleURI="http://novartis.com/20221231/role/DisclosureTaxes">
            <link:definition>2100600 - Disclosure - Income taxes</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssets" roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssets">
            <link:definition>2101100 - Disclosure - Goodwill and intangible assets</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilities" roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilities">
            <link:definition>2101200 - Disclosure - Deferred tax assets and liabilities</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
            <link:definition>2200100 - Disclosure - Significant accounting policies (Policies)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
            <link:definition>2300100 - Disclosure - Significant accounting policies (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInterestExpenseAndOtherFinancialIncomeExpenseTables" roleURI="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables">
            <link:definition>2300500 - Disclosure - Interest expense and other financial income and expense (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssetsTables" roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables">
            <link:definition>2301100 - Disclosure - Goodwill and intangible assets (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesTables" roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables">
            <link:definition>2301200 - Disclosure - Deferred tax assets and liabilities (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantAccountingPoliciesDetails" roleURI="http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails">
            <link:definition>2400100 - Disclosure - Significant accounting policies (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails" roleURI="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails">
            <link:definition>2400500 - Disclosure - Interest expense and other financial income and expense (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2" roleURI="http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2">
            <link:definition>2400501 - Disclosure - Interest expense and other financial income and expense (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTaxesTables" roleURI="http://novartis.com/20221231/role/DisclosureTaxesTables">
            <link:definition>2300600 - Disclosure - Income taxes (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTaxesDetails" roleURI="http://novartis.com/20221231/role/DisclosureTaxesDetails">
            <link:definition>2400600 - Disclosure - Income taxes (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTaxesDetails2" roleURI="http://novartis.com/20221231/role/DisclosureTaxesDetails2">
            <link:definition>2400601 - Disclosure - Income taxes (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTaxesDetails3" roleURI="http://novartis.com/20221231/role/DisclosureTaxesDetails3">
            <link:definition>2400602 - Disclosure - Income taxes (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssetsDetails" roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails">
            <link:definition>2401100 - Disclosure - Goodwill and intangible assets (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssetsDetails2" roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2">
            <link:definition>2401101 - Disclosure - Goodwill and intangible assets (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails">
            <link:definition>2401200 - Disclosure - Deferred tax assets and liabilities (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesDetails2" roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails2">
            <link:definition>2401201 - Disclosure - Deferred tax assets and liabilities (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesDetails3" roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3">
            <link:definition>2401201 - Disclosure - Deferred tax assets and liabilities (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesDetails4" roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4">
            <link:definition>2401202 - Disclosure - Deferred tax assets and liabilities (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantAccountingPoliciesDetails2" roleURI="http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails2">
            <link:definition>2400101 - Disclosure - Significant accounting policies (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialAndOtherNoncurrentAssets" roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssets">
            <link:definition>2101300 - Disclosure - Financial and other non-current assets</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialAndOtherNoncurrentAssetsTables" roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables">
            <link:definition>2301300 - Disclosure - Financial and other non-current assets (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialAndOtherNoncurrentAssetsDetails" roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails">
            <link:definition>2401300 - Disclosure - Financial and other non-current assets (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialAndOtherNoncurrentAssetsDetails2" roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2">
            <link:definition>2401301 - Disclosure - Financial and other non-current assets (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialAndOtherNoncurrentAssetsDetails3" roleURI="http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails3">
            <link:definition>2401302 - Disclosure - Financial and other non-current assets (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureOtherCurrentAssets" roleURI="http://novartis.com/20221231/role/DisclosureOtherCurrentAssets">
            <link:definition>2101700 - Disclosure - Other current assets</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureOtherCurrentAssetsTables" roleURI="http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsTables">
            <link:definition>2301700 - Disclosure - Other current assets (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureOtherCurrentAssetsDetails" roleURI="http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails">
            <link:definition>2401700 - Disclosure - Other current assets (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureMarketableSecurities" roleURI="http://novartis.com/20221231/role/DisclosureMarketableSecurities">
            <link:definition>2101600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureMarketableSecuritiesTables" roleURI="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesTables">
            <link:definition>2301600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureMarketableSecuritiesDetails" roleURI="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails">
            <link:definition>2401600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureMarketableSecuritiesDetails2" roleURI="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails2">
            <link:definition>2401601 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureMarketableSecuritiesDetails3" roleURI="http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails3">
            <link:definition>2401601 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebt" roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebt">
            <link:definition>2101900 - Disclosure - Non-current financial debt</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactions" roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactions">
            <link:definition>2100200 - Disclosure - Significant transactions</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCurrentFinancialDebtAndDerivativeFinancialInstruments" roleURI="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstruments">
            <link:definition>2102100 - Disclosure - Current financial debt and derivative financial instruments</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCommitmentsAndContingencies" roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingencies">
            <link:definition>2102800 - Disclosure - Commitments and contingencies</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSubsequentEventsDetails" roleURI="http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails">
            <link:definition>2403000 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtTables" roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables">
            <link:definition>2301900 - Disclosure - Non-current financial debt (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables" roleURI="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables">
            <link:definition>2302100 - Disclosure - Current financial debt and derivative financial instruments (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCommitmentsAndContingenciesTables" roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesTables">
            <link:definition>2302800 - Disclosure - Commitments and contingencies (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsDetails" roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails">
            <link:definition>2400200 - Disclosure - Significant transactions (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails" roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails">
            <link:definition>2401900 - Disclosure - Non-current financial debt (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails2" roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2">
            <link:definition>2401901 - Disclosure - Non-current financial debt (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails3" roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3">
            <link:definition>2401902 - Disclosure - Non-current financial debt (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails4" roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4">
            <link:definition>2401903 - Disclosure - Non-current financial debt (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails5" roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5">
            <link:definition>2401904 - Disclosure - Non-current financial debt (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureNonCurrentFinancialDebtDetails6" roleURI="http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails6">
            <link:definition>2401905 - Disclosure - Non-current financial debt (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails" roleURI="http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails">
            <link:definition>2402100 - Disclosure - Current financial debt and derivative financial instruments (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCommitmentsAndContingenciesDetails" roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails">
            <link:definition>2402800 - Disclosure - Commitments and contingencies (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCommitmentsAndContingenciesDetails2" roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2">
            <link:definition>2402801 - Disclosure - Commitments and contingencies (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSubsequentEvents" roleURI="http://novartis.com/20221231/role/DisclosureSubsequentEvents">
            <link:definition>2103000 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType>
		 <link:roleType id="disclosureProvisionsAndOtherCurrentLiabilities" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilities">
            <link:definition>2102200 - Disclosure - Provisions and other current liabilities</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionsOfBusinesses" roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinesses">
            <link:definition>2102400 - Disclosure - Acquisitions of businesses</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociates" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociates">
            <link:definition>2102500 - Disclosure - Post-employment benefits for employees</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherCurrentLiabilitiesTables" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables">
            <link:definition>2302200 - Disclosure - Provisions and other current liabilities (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionsOfBusinessesTables" roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesTables">
            <link:definition>2302400 - Disclosure - Acquisitions of businesses (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesTables" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables">
            <link:definition>2302500 - Disclosure - Post-employment benefits for employees (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherCurrentLiabilitiesDetails" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails">
            <link:definition>2402200 - Disclosure - Provisions and other current liabilities (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherCurrentLiabilitiesDetails2" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2">
            <link:definition>2402201 - Disclosure - Provisions and other current liabilities (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherCurrentLiabilitiesDetails3" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3">
            <link:definition>2402202 - Disclosure - Provisions and other current liabilities (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionsOfBusinessesDetails" roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails">
            <link:definition>2402400 - Disclosure - Acquisitions of businesses (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails">
            <link:definition>2402500 - Disclosure - Post-employment benefits for employees (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails2" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2">
            <link:definition>2402501 - Disclosure - Post-employment benefits for employees (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails3" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3">
            <link:definition>2402502 - Disclosure - Post-employment benefits for employees (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails4" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4">
            <link:definition>2402503 - Disclosure - Post-employment benefits for employees (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails5" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5">
            <link:definition>2402504 - Disclosure - Post-employment benefits for employees (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails6" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6">
            <link:definition>2402505 - Disclosure - Post-employment benefits for employees (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails7" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7">
            <link:definition>2402506 - Disclosure - Post-employment benefits for employees (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails8" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8">
            <link:definition>2402507 - Disclosure - Post-employment benefits for employees (Details 7)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails9" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9">
            <link:definition>2402508 - Disclosure - Post-employment benefits for employees (Details 8)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePostEmploymentBenefitsForAssociatesDetails10" roleURI="http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10">
            <link:definition>2402509 - Disclosure - Post-employment benefits for employees (Details 9)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesDetails3" roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3">
            <link:definition>2401502 - Disclosure - Trade receivables (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesDetails2" roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2">
            <link:definition>2401501 - Disclosure - Trade receivables (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesDetails" roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails">
            <link:definition>2401500 - Disclosure - Trade receivables (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesTables" roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesTables">
            <link:definition>2301500 - Disclosure - Trade receivables (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivables" roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivables">
            <link:definition>2101500 - Disclosure - Trade receivables</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesDetails4" roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4">
            <link:definition>2401503 - Disclosure - Trade receivables (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTradeReceivablesDetails5" roleURI="http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails5">
            <link:definition>2401504 - Disclosure - Trade receivables (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePrincipalGroupSubsidiariesAndAssociatedCompanies" roleURI="http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompanies">
            <link:definition>2103100 - Disclosure - Principal Group subsidiaries and associated companies</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables" roleURI="http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables">
            <link:definition>2303100 - Disclosure - Principal Group subsidiaries and associated companies (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails" roleURI="http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails">
            <link:definition>2403100 - Disclosure - Principal Group subsidiaries and associated companies (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails2" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails2">
            <link:definition>2403001 - Disclosure - Discontinued operations (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails">
            <link:definition>2403000 - Disclosure - Discontinued operations (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsTables" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsTables">
            <link:definition>2303000 - Disclosure - Discontinued operations (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperations" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperations">
            <link:definition>2103000 - Disclosure - Discontinued operations</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails4" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails4">
            <link:definition>2402304 - Disclosure - Details to the consolidated cash flow statements (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails3" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails3">
            <link:definition>2402303 - Disclosure - Details to the consolidated cash flow statements (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails2" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2">
            <link:definition>2402301 - Disclosure - Details to the consolidated cash flow statements (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails">
            <link:definition>2402300 - Disclosure - Details to the consolidated cash flow statements (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsTables" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables">
            <link:definition>2302300 - Disclosure - Details to the consolidated statements of cash flows (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatements" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatements">
            <link:definition>2102300 - Disclosure - Details to the consolidated statements of cash flows</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFigures" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFigures">
            <link:definition>2100300 - Disclosure - Segmentation of key figures</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompanies" roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompanies">
            <link:definition>2100400 - Disclosure - Associated companies</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncome" roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncome">
            <link:definition>2100800 - Disclosure - Changes in consolidated statements of comprehensive income</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilities" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilities">
            <link:definition>2102000 - Disclosure - Provisions and other non-current liabilities</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociates" roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociates">
            <link:definition>2102600 - Disclosure - Equity-based participation plans for employees</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedParties" roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedParties">
            <link:definition>2102700 - Disclosure - Transactions with related parties</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosures" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosures">
            <link:definition>2102900 - Disclosure - Financial instruments - additional disclosures</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresTables" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables">
            <link:definition>2300300 - Disclosure - Segmentation of key figures (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesTables" roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables">
            <link:definition>2300400 - Disclosure - Associated companies (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables" roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables">
            <link:definition>2300800 - Disclosure - Changes in consolidated statements of comprehensive income (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesTables" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables">
            <link:definition>2302000 - Disclosure - Provisions and other non-current liabilities (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesTables" roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables">
            <link:definition>2302600 - Disclosure - Equity-based participation plans for employees (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesTables" roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesTables">
            <link:definition>2302700 - Disclosure - Transactions with related parties (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresTables" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables">
            <link:definition>2302900 - Disclosure - Financial instruments - additional disclosures (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails">
            <link:definition>2400300 - Disclosure - Segmentation of key figures (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails" roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails">
            <link:definition>2400400 - Disclosure - Associated companies (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails" roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails">
            <link:definition>2400800 - Disclosure - Changes in consolidated statements of comprehensive income (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails2" roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails2">
            <link:definition>2400801 - Disclosure - Changes in consolidated statements of comprehensive income (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails3" roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails3">
            <link:definition>2400801 - Disclosure - Changes in consolidated statements of comprehensive income (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4" roleURI="http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4">
            <link:definition>2400803 - Disclosure - Changes in consolidated statements of comprehensive income (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails">
            <link:definition>2402000 - Disclosure - Provisions and other non-current liabilities (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails" roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails">
            <link:definition>2402600 - Disclosure - Equity-based participation plans for employees (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails2" roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2">
            <link:definition>2402601 - Disclosure - Equity-based participation plans for employees (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails3" roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3">
            <link:definition>2402602 - Disclosure - Equity-based participation plans for employees (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails4" roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4">
            <link:definition>2402603 - Disclosure - Equity-based participation plans for employees (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails5" roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5">
            <link:definition>2402604 - Disclosure - Equity-based participation plans for employees (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails6" roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6">
            <link:definition>2402605 - Disclosure - Equity-based participation plans for employees (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails7" roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails7">
            <link:definition>2402606 - Disclosure - Equity-based participation plans for employees (Details 7)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails8" roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails8">
            <link:definition>2402607 - Disclosure - Equity-based participation plans for employees (Details 8)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityBasedParticipationPlansForAssociatesDetails9" roleURI="http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails9">
            <link:definition>2402608 - Disclosure - Equity-based participation plans for employees (Details 9)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesDetails" roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails">
            <link:definition>2041200 - Disclosure - Transactions with related parties (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesDetails2" roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2">
            <link:definition>2402701 - Disclosure - Transactions with related parties (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesDetails3" roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3">
            <link:definition>2402702 - Disclosure - Transactions with related parties (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails">
            <link:definition>2402900 - Disclosure - Financial instruments - additional disclosures (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssetsDetails3" roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3">
            <link:definition>2401102 - Disclosure - Goodwill and intangible assets (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssetsDetails4" roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4">
            <link:definition>2401104 - Disclosure - Goodwill and intangible assets (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType>
		 <link:roleType id="disclosureSegmentationOfKeyFiguresDetails2" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2">
            <link:definition>2400302 - Disclosure - Segmentation of key figures (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails3" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3">
            <link:definition>2400303 - Disclosure - Segmentation of key figures (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails4" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4">
            <link:definition>2400304 - Disclosure - Segmentation of key figures (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails5" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5">
            <link:definition>2400305 - Disclosure - Segmentation of key figures (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails6" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6">
            <link:definition>2400306 - Disclosure - Segmentation of key figures (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails7" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7">
            <link:definition>2400308 - Disclosure - Segmentation of key figures (Details 8)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails2" roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails2">
            <link:definition>2400401 - Disclosure - Associated companies (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails3" roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3">
            <link:definition>2400401 - Disclosure - Associated companies (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails4" roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails4">
            <link:definition>2400403 - Disclosure - Associated companies (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails5" roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails5">
            <link:definition>2400404 - Disclosure - Associated companies (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAssociatedCompaniesDetails6" roleURI="http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6">
            <link:definition>2400402 - Disclosure - Associated companies (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2">
            <link:definition>2402001 - Disclosure - Provisions and other non-current liabilities (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3">
            <link:definition>2402002 - Disclosure - Provisions and other non-current liabilities (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4">
            <link:definition>2402003 - Disclosure - Provisions and other non-current liabilities (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5">
            <link:definition>2402004 - Disclosure - Provisions and other non-current liabilities (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails6" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails6">
            <link:definition>2402005 - Disclosure - Provisions and other non-current liabilities (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquity" roleURI="http://novartis.com/20221231/role/DisclosureEquity">
            <link:definition>2101800 - Disclosure - Equity</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityTables" roleURI="http://novartis.com/20221231/role/DisclosureEquityTables">
            <link:definition>2301800 - Disclosure - Equity (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityDetails" roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails">
            <link:definition>2401800 - Disclosure - Equity (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityDetails2" roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails2">
            <link:definition>2401801 - Disclosure - Equity (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityDetails3" roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails3">
            <link:definition>2401802 - Disclosure - Equity (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityDetails4" roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails4">
            <link:definition>2401803 - Disclosure - Equity (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementsOfCashFlowParenthetical" roleURI="http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical">
            <link:definition>1005010 - Statement - Consolidated cash flow statements (Parenthetical)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails1" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1">
            <link:definition>2400301 - Disclosure - Segmentation of key figures (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureEquityDetails5" roleURI="http://novartis.com/20221231/role/DisclosureEquityDetails5">
            <link:definition>2401804 - Disclosure - Equity (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails5" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5">
            <link:definition>2402305 - Disclosure - Details to the consolidated cash flow statements (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails2" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2">
            <link:definition>2402901 - Disclosure - Financial instruments - additional disclosures (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails3" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3">
            <link:definition>2402902 - Disclosure - Financial instruments - additional disclosures (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails4" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4">
            <link:definition>2402903 - Disclosure - Financial instruments - additional disclosures (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:labelLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails5" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5">
            <link:definition>2402904 - Disclosure - Financial instruments - additional disclosures (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails6" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6">
            <link:definition>2402905 - Disclosure - Financial instruments - additional disclosures (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails7" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7">
            <link:definition>2402906 - Disclosure - Financial instruments - additional disclosures (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails8" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8">
            <link:definition>2402907 - Disclosure - Financial instruments - additional disclosures (Details 7)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails9" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9">
            <link:definition>2402908 - Disclosure - Financial instruments - additional disclosures (Details 8)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails10" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10">
            <link:definition>2402909 - Disclosure - Financial instruments - additional disclosures (Details 9)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails11" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11">
            <link:definition>2402916 - Disclosure - Financial instruments - additional disclosures (Details 16)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails12" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12">
            <link:definition>2402910 - Disclosure - Financial instruments - additional disclosures (Details 10)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails13" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13">
            <link:definition>2402911 - Disclosure - Financial instruments - additional disclosures (Details 11)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDeferredTaxAssetsAndLiabilitiesDetails5" roleURI="http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5">
            <link:definition>2401203 - Disclosure - Deferred tax assets and liabilities (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantAccountingPoliciesDetails3" roleURI="http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails3">
            <link:definition>2400102 - Disclosure - Significant accounting policies (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureBasisOfPreparationQ" roleURI="http://novartis.com/20221231/role/DisclosureBasisOfPreparationQ">
            <link:definition>2010100 - Disclosure - Basis of preparation</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSelectedCriticalAccountingPoliciesQ" roleURI="http://novartis.com/20221231/role/DisclosureSelectedCriticalAccountingPoliciesQ">
            <link:definition>2010200 - Disclosure - Selected critical accounting policies</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsQ" roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsQ">
            <link:definition>2010300 - Disclosure - Significant transactions</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfEquityToShareholdersQ" roleURI="http://novartis.com/20221231/role/DisclosureSummaryOfEquityToShareholdersQ">
            <link:definition>2010400 - Disclosure - Summary of equity attributable to Novartis AG shareholders</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsQ" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsQ">
            <link:definition>2010500 - Disclosure - Financial instruments</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLegalProceedingsUpdateQ" roleURI="http://novartis.com/20221231/role/DisclosureLegalProceedingsUpdateQ">
            <link:definition>2010800 - Disclosure - Legal proceedings update</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsQ" roleURI="http://novartis.com/20221231/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsQ">
            <link:definition>2102900 - Disclosure - Impacts of adoption of new IFRS standards</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSubsequentEventsQ" roleURI="http://novartis.com/20221231/role/DisclosureSubsequentEventsQ">
            <link:definition>2011100 - Disclosure - Subsequent events</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresQ" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresQ">
            <link:definition>2010900 - Disclosure - Segmentation of key figures</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSelectedCriticalAccountingPoliciesPoliciesQ" roleURI="http://novartis.com/20221231/role/DisclosureSelectedCriticalAccountingPoliciesPoliciesQ">
            <link:definition>2020200 - Disclosure - Selected critical accounting policies (Policies)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfEquityToShareholdersTablesQ" roleURI="http://novartis.com/20221231/role/DisclosureSummaryOfEquityToShareholdersTablesQ">
            <link:definition>2030400 - Disclosure - Summary of equity attributable to Novartis AG shareholders (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsTablesQ" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsTablesQ">
            <link:definition>2030500 - Disclosure - Financial instruments (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsTablesQ" roleURI="http://novartis.com/20221231/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsTablesQ">
            <link:definition>2302900 - Disclosure - Impacts of adoption of new IFRS standards (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresTablesQ" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTablesQ">
            <link:definition>2031000 - Disclosure - Segmentation of key figures (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSelectedCriticalAccountingPoliciesDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureSelectedCriticalAccountingPoliciesDetailsQ">
            <link:definition>2040200 - Disclosure - Selected critical accounting policies (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetailsQ">
            <link:definition>2040300 - Disclosure - Significant transactions (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSummaryOfEquityToShareholdersDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureSummaryOfEquityToShareholdersDetailsQ">
            <link:definition>2040400 - Disclosure - Summary of equity attributable to Novartis AG shareholders (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsDetailsQ">
            <link:definition>2040500 - Disclosure - Financial instruments (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsDetails2Q" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsDetails2Q">
            <link:definition>2040501 - Disclosure - Financial instruments (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsDetailsQ">
            <link:definition>2402900 - Disclosure - Impacts of adoption of new IFRS standards (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsDetails2Q" roleURI="http://novartis.com/20221231/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsDetails2Q">
            <link:definition>2402901 - Disclosure - Impacts of adoption of new IFRS standards (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetailsQ">
            <link:definition>2040900 - Disclosure - Segmentation of key figures (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails2Q" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2Q">
            <link:definition>2040901 - Disclosure - Segmentation of key figures (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails3Q" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3Q">
            <link:definition>2040902 - Disclosure - Segmentation of key figures (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails4Q" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4Q">
            <link:definition>2040903 - Disclosure - Segmentation of key figures (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails5Q" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5Q">
            <link:definition>2040904 - Disclosure - Segmentation of key figures (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails6Q" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6Q">
            <link:definition>2040905 - Disclosure - Segmentation of key figures (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails7Q" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7Q">
            <link:definition>2040906 - Disclosure - Segmentation of key figures (Details 7)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails8Q" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8Q">
            <link:definition>2040907 - Disclosure - Segmentation of key figures (Details 8)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails9Q" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails9Q">
            <link:definition>2040908 - Disclosure - Segmentation of key figures (Details 9)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsDetails3Q" roleURI="http://novartis.com/20221231/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsDetails3Q">
            <link:definition>2402902 - Disclosure - Impacts of adoption of new IFRS standards (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsDetails4Q" roleURI="http://novartis.com/20221231/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsDetails4Q">
            <link:definition>2402903 - Disclosure - Impacts of adoption of new IFRS standards (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsDetails3Q" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsDetails3Q">
            <link:definition>2040502 - Disclosure - Financial instruments (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsDetails4Q" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsDetails4Q">
            <link:definition>2040503 - Disclosure - Financial instruments (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesDetails1_1df9063b" roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1">
            <link:definition>2402700 - Disclosure - Transaction with related parties (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureImpactOfAdaptionOfNewIfrsStandardsDetails5Q" roleURI="http://novartis.com/20221231/role/DisclosureImpactOfAdaptionOfNewIfrsStandardsDetails5Q">
            <link:definition>2402904 - Disclosure - Impacts of adoption of new IFRS standards (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureTransactionsWithRelatedPartiesDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetailsQ">
            <link:definition>2011100 - Disclosure - Transactions with related parties</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails8" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8">
            <link:definition>2400310 - Disclosure - Segmentation of key figures (Details 10)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails9" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails9">
            <link:definition>2400312 - Disclosure - Segmentation of key figures (Details 12)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails10" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10">
            <link:definition>2400311 - Disclosure - Segmentation of key figures (Details 11)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDisposalGroupHeldForSaleDetails" roleURI="http://novartis.com/20221231/role/DisclosureDisposalGroupHeldForSaleDetails">
            <link:definition>2400202 - Disclosure - Significant transactions (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails14" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14">
            <link:definition>2402912 - Disclosure - Financial instruments - additional disclosures (Details 12)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsTables" roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsTables">
            <link:definition>2300200 - Disclosure - Significant transactions (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails11" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11">
            <link:definition>2400309 - Disclosure - Segmentation of key figures - Top 20 (Details 9)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails12" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12">
            <link:definition>2400307 - Disclosure - Segmentation of key figures - Net sales by region (Details 7)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails6" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6">
            <link:definition>2402302 - Disclosure - Details to the consolidated cash flow statements (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsQ" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsQ">
            <link:definition>2011000 - Disclosure - Discontinued operations</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsQ" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsQ">
            <link:definition>2010600 - Disclosure - Lease liabilities and right-of-use assets</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedStatementsCashFlowsQ" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedStatementsCashFlowsQ">
            <link:definition>2010600 - Disclosure - Details to the consolidated statements of cash flows</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsTablesQ" roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsTablesQ">
            <link:definition>2030300 - Disclosure - Significant transactions (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsTablesQ" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsTablesQ">
            <link:definition>2030600 - Disclosure - Lease liability and Right-of-use assets (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedStatementsCashFlowsTablesQ" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedStatementsCashFlowsTablesQ">
            <link:definition>2030600 - Disclosure - Details to the consolidated statements of cash flows (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsTablesQ" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsTablesQ">
            <link:definition>2031100 - Disclosure - Discontinued operations (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetailsQ">
            <link:definition>2040600 - Disclosure - Lease liability and Right-of-use assets (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails1Q" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails1Q">
            <link:definition>2040601 - Disclosure - Lease liability and Right-of-use assets (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails2Q" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2Q">
            <link:definition>2040602 - Disclosure - Lease liability and Right-of-use assets (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails3Q" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3Q">
            <link:definition>2040603 - Disclosure - Lease liability and Right-of-use assets (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsDetails1Q" roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails1Q">
            <link:definition>2040301 - Disclosure - Significant transactions (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetailsQ">
            <link:definition>2041000 - Disclosure - Discontinued operations (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedStatementsCashFlowsDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetailsQ">
            <link:definition>2040600 - Disclosure - Details to the consolidated statements of cash flows (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedStatementsCashFlowsDetails1Q" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetails1Q">
            <link:definition>2040601 - Disclosure - Details to the consolidated statements of cash flows (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionOfBusinessesQ" roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionOfBusinessesQ">
            <link:definition>2010700 - Disclosure - Acquisition of businesses</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionOfBusinessesTablesQ" roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionOfBusinessesTablesQ">
            <link:definition>2030800 - Disclosure - Acquisition of businesses (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionOfBusinessesDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionOfBusinessesDetailsQ">
            <link:definition>2040701 - Disclosure - Acquisition of businesses (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails1Q" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails1Q">
            <link:definition>2041001 - Disclosure - Discontinued operations (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails2Q" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails2Q">
            <link:definition>2041002 - Disclosure - Discontinued operations (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails4Q" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4Q">
            <link:definition>2040604 - Disclosure - Lease liability and Right-of-use assets (Details 5)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails5Q" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5Q">
            <link:definition>2040605 - Disclosure - Lease liability and Right-of-use assets (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType>
		 <link:roleType id="disclosureSignificantTransactionsDetails2Q" roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2Q">
            <link:definition>2040302 - Disclosure - Significant transactions (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails3Q" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails3Q">
            <link:definition>2041003 - Disclosure - Discontinued operations (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureRightOfUseAssetsAndLeaseLiability" roleURI="http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiability">
            <link:definition>2101000 - Disclosure - Right-of-use assets and lease liabilities</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureRightOfUseAssetsAndLeaseLiabilityTables" roleURI="http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables">
            <link:definition>2301000 - Disclosure - Right-of-use assets and lease liabilities (Tables)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSignificantTransactionsDetails2" roleURI="http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2">
            <link:definition>2400201 - Disclosure - Significant transactions (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails3" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails3">
            <link:definition>2403005 - Disclosure - Discontinued operations (Details 6)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails4" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails4">
            <link:definition>2403003 - Disclosure - Discontinued operations (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails">
            <link:definition>2401000 - Disclosure - Lease liability and Right-of-use assets (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails2" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2">
            <link:definition>2401001 - Disclosure - Lease liability and Right-of-use assets (Details 1)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails3" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3">
            <link:definition>2401000 - Disclosure - Lease liability and Right-of-use assets (Details)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails4" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4">
            <link:definition>2401002 - Disclosure - Lease liability and Right-of-use assets (Details 2)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails5" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5">
            <link:definition>2401003 - Disclosure - Lease liability and Right-of-use assets (Details 3)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails6" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6">
            <link:definition>2401004 - Disclosure - Lease liability and Right-of-use assets (Details 4)</link:definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails5" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails5">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2403004 - Disclosure - Discontinued operations (Details 5)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails6" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails6">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2403002 - Disclosure - Discontinued operations (Details 3)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureLeaseLiabilityAndRightOfUseAssetsDetails7" roleURI="http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails7">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2401006 - Disclosure - Lease liability and Right-of-use assets (Details 7)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails7" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails7">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2403006 - Disclosure - Discontinued operations (Details 7)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails8" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails8">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2403007 - Disclosure - Discontinued operations (Details 8)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedStatementsCashFlowsDetails2Q" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedStatementsCashFlowsDetails2Q">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2040602 - Disclosure - Details to the consolidated statements of cash flows (Details 3)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureAcquisitionOfBusinessesDetails2Q" roleURI="http://novartis.com/20221231/role/DisclosureAcquisitionOfBusinessesDetails2Q">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2040702 - Disclosure - Acquisition of businesses (Details 2)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureProvisionsAndOtherNonCurrentLiabilitiesDetails1Q" roleURI="http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails1Q">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2040800 - Disclosure - Provisions and other non-current liabilities (Details)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDiscontinuedOperationsDetails9" roleURI="http://novartis.com/20221231/role/DisclosureDiscontinuedOperationsDetails9">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2403008 - Disclosure - Discontinued operations (Details 9)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSubsequentEventsDetails2" roleURI="http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails2">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2403001 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date (Details 1)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementOfIncomeCalc2" roleURI="http://novartis.com/20221231/role/StatementOfIncomeCalc2">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">1001000 - Statement - Consolidated income statements (Calc 2)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="statementOfComprehensiveIncomeCalc2" roleURI="http://novartis.com/20221231/role/StatementOfComprehensiveIncomeCalc2">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">1002000 - Statement - Consolidated statements of comprehensive income (Calc 2)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCommitmentsAndContingenciesQ" roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesQ">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2011000 - Disclosure - Commitments and contingencies</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureCommitmentsAndContingenciesDetailsQ" roleURI="http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetailsQ">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2041000 - Disclosure - Commitments and contingencies (Details)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails7" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2402306 - Disclosure - Details to the consolidated cash flow statements (Details 6)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureDetailsConsolidatedCashFlowStatementsDetails8" roleURI="http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2402307 - Disclosure - Details to the consolidated cash flow statements (Details 7)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails15" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2402913 - Disclosure - Financial instruments - additional disclosures (Details 13)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails16" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2402915 - Disclosure - Financial instruments - additional disclosures (Details 15)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureSegmentationOfKeyFiguresDetails10Q" roleURI="http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10Q">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2040909 - Disclosure - Segmentation of key figures (Details 10)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureFinancialInstrumentsAdditionalDisclosuresDetails17" roleURI="http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2402914 - Disclosure - Financial instruments - additional disclosures (Details 14)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType><link:roleType id="disclosureGoodwillAndIntangibleAssetsDetails5" roleURI="http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5">
            <definition xmlns="http://www.xbrl.org/2003/linkbase">2401103 - Disclosure - Goodwill and intangible assets (Details 3)</definition>
            <link:usedOn>link:calculationLink</link:usedOn>
            <link:usedOn>link:definitionLink</link:usedOn>
            <link:usedOn>link:presentationLink</link:usedOn>
         </link:roleType></xsd:appinfo>
   </xsd:annotation>
   <xsd:element abstract="true" id="nvs_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" name="NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_StatementTable" name="StatementTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_StatementLineItems" name="StatementLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PropertyPlantAndEquipmentTableTextBlock" name="PropertyPlantAndEquipmentTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoriesDisclosureAbstract" name="InventoriesDisclosureAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfInventoryCurrentTableTextBlock" name="ScheduleOfInventoryCurrentTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryCurrentTable" name="InventoryCurrentTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryAxis" name="InventoryAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryMember" name="InventoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryRawMaterialsGrossMember" name="InventoryRawMaterialsGrossMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryWorkInProgressGrossMember" name="InventoryWorkInProgressGrossMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryFinishedGoodsGrossMember" name="InventoryFinishedGoodsGrossMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoryLineItems" name="InventoryLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" name="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" name="DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AssumptionsUsedInTheCalculationOfValuationTextBlock" name="AssumptionsUsedInTheCalculationOfValuationTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" name="AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfIncomeTaxAbstract" name="DisclosureOfIncomeTaxAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeBeforeTaxesTableTextBlock" name="IncomeBeforeTaxesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentAndDeferredIncomeTaxExpenseTableTextBlock" name="CurrentAndDeferredIncomeTaxExpenseTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AnalysisOfTaxRateTableTextBlock" name="AnalysisOfTaxRateTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" name="DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_InterestExpenseTableTextBlock" name="InterestExpenseTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherFinancialIncomeAndExpenseTableTextBlock" name="OtherFinancialIncomeAndExpenseTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" name="DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" name="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" name="TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SignificantAccountingPoliciesAbstract" name="SignificantAccountingPoliciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" name="RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" name="RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" name="DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" name="DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" name="DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" name="DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FurnitureAndVehiclesMember" name="FurnitureAndVehiclesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MarketingRelatedIntangibleAssetsMember" name="MarketingRelatedIntangibleAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentlyMarketedProductsMember" name="CurrentlyMarketedProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IncomeStatementLocationAxis" name="IncomeStatementLocationAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IncomeStatementLocationMember" name="IncomeStatementLocationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CostOfSalesOrResearchAndDevelopmentMember" name="CostOfSalesOrResearchAndDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InterestExpenseAbstract" name="InterestExpenseAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherFinancialIncomeAndExpenseAbstract" name="OtherFinancialIncomeAndExpenseAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeOnForwardContractsAndOptions" name="IncomeOnForwardContractsAndOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeTaxExpense" name="IncomeTaxExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectOfCreditsAndAllowances" name="TaxRateEffectOfCreditsAndAllowances" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectOfWriteOffOfDeferredTaxAssets" name="TaxRateEffectOfWriteOffOfDeferredTaxAssets" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" name="TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectFromBenefitsExpiring" name="TaxRateEffectFromBenefitsExpiring" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AverageEffectiveTaxRateContinuingOperations" name="AverageEffectiveTaxRateContinuingOperations" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AverageEffectiveTaxRateDiscontinuedOperations" name="AverageEffectiveTaxRateDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PensionsAndOtherBenefitObligationsOfAssociatesMember" name="PensionsAndOtherBenefitObligationsOfAssociatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InventoriesMember" name="InventoriesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TaxLossCarryforwardsMember" name="TaxLossCarryforwardsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" name="IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" name="OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" name="TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InvestmentsInSubsidiariesMember" name="InvestmentsInSubsidiariesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GoodwillFromAcquisitionsMember" name="GoodwillFromAcquisitionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BalanceSheetTreatmentAxis" name="BalanceSheetTreatmentAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BalanceSheetTreatmentMember" name="BalanceSheetTreatmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CapitalizedMember" name="CapitalizedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NotCapitalizedMember" name="NotCapitalizedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_YearOfExpiryAxis" name="YearOfExpiryAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_YearOfExpiryMember" name="YearOfExpiryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OneYearMember" name="OneYearMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TwoYearsMember" name="TwoYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ThreeYearsMember" name="ThreeYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FourYearsMember" name="FourYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FiveYearsMember" name="FiveYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MoreThanFiveYearsMember" name="MoreThanFiveYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ValueOfTaxLossCarryforwardsExpired" name="ValueOfTaxLossCarryforwardsExpired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" name="DeferredTaxAssetExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" name="DeferredTaxLiabilitiesExpectedToHaveAnImpactOnCurrentTaxesPayableAfterMoreThan12Months" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" name="UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProvisionForIncomeTaxesOnUnremittedEarnings" name="ProvisionForIncomeTaxesOnUnremittedEarnings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" name="DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" name="DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfFinancialAssetsTableTextBlock" name="DisclosureOfFinancialAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOtherNoncurrentAssetsTableTextBlock" name="DisclosureOfOtherNoncurrentAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" name="DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherCurrentAssetsAbstract" name="OtherCurrentAssetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherCurrentAssetsTableTextBlock" name="OtherCurrentAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_WithholdingTaxRecoverable" name="WithholdingTaxRecoverable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CurrentPrepaidExpensesAssociatedCompanies" name="CurrentPrepaidExpensesAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ReceivablesAssociatedCompanies" name="ReceivablesAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OtherReceivablesAndCurrentAssets" name="OtherReceivablesAndCurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" name="DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" name="DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" name="MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashAndCashEquivalentsTableTextBlock" name="CashAndCashEquivalentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FundInstrumentsHeld" name="FundInstrumentsHeld" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DebtSecuritiesDenominationsAbstract" name="DebtSecuritiesDenominationsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MovementInDeferredTaxBalanceRollForward" name="MovementInDeferredTaxBalanceRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationReceivable" name="ContingentConsiderationReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfOtherNoncurrentAssetsAbstract" name="DisclosureOfOtherNoncurrentAssetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeferredCompensationPlansAssets" name="DeferredCompensationPlansAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PrepaidPostemploymentBenefitPlansAssets" name="PrepaidPostemploymentBenefitPlansAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FinanceLeaseProvision" name="FinanceLeaseProvision" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_MovementInTheShareCapitalTableTextBlock" name="MovementInTheShareCapitalTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MovementInTheShareslTableTextBlock" name="MovementInTheShareslTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SubsequentEventTypAxis" name="SubsequentEventTypAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SubsequentEventTypeMember" name="SubsequentEventTypeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SubsequentEventMember" name="SubsequentEventMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CommitmentsAndContingenciesAbstract" name="CommitmentsAndContingenciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfCommitmentsAndContingenciesTextBlock" name="DisclosureOfCommitmentsAndContingenciesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfSignificantTransactionsAbstract" name="DisclosureOfSignificantTransactionsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfSignificantTransactionsTextBlock" name="DisclosureOfSignificantTransactionsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" name="DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" name="DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" name="DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" name="DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" name="DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" name="DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" name="DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" name="DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" name="DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfLeasingCommitmentsTableTextBlock" name="DisclosureOfLeasingCommitmentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" name="DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LeasingCommitmentsAbstract" name="LeasingCommitmentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" name="ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" name="ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ResearchAndDevelopmentCommitmentsAbstract" name="ResearchAndDevelopmentCommitmentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentTable" name="ScheduleForCommitmentsUnderResearchAndDevelopmentTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" name="ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CommitmentsUnderLongtermResearchAgreements" name="CommitmentsUnderLongtermResearchAgreements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" name="CurrentFinancialDebtAndDerivativeFinancialInstrumentsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" name="CurrentFinancialDebtAndDerivativeFinancialInstrumentsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_InterestBearningAccountsOfAssociatesPayableOnDemand" name="InterestBearningAccountsOfAssociatesPayableOnDemand" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" name="DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" name="DisclosureOfComponentsOfNoncurrentFinancialDebtsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" name="DisclosureOfComponentsOfNoncurrentFinancialDebtsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LaterThanFiveYearsAndNotLaterThanSixYearsMember" name="LaterThanFiveYearsAndNotLaterThanSixYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LaterThanSixYearsMember" name="LaterThanSixYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" name="DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" name="DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" name="DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NoncurrentFinancialDebtsCoveredByCollateral" name="NoncurrentFinancialDebtsCoveredByCollateral" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" name="A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" name="A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" name="A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" name="A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" name="A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" name="A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" name="A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" name="A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" name="A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" name="A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" name="A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" name="A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" name="A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" name="A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" name="A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsLender" name="BorrowingsLender" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsPremiumDiscount" name="BorrowingsPremiumDiscount" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherNoncurrentFinancialDebt" name="OtherNoncurrentFinancialDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_FairValueByMeasurementBasisAxis" name="FairValueByMeasurementBasisAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueByMeasurementBasisMember" name="FairValueByMeasurementBasisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CarryingReportedAmountFairValueDisclosureMember" name="CarryingReportedAmountFairValueDisclosureMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueDisclosureItemAmountsMember" name="FairValueDisclosureItemAmountsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments" name="OtherComprehensiveIncomeNetOfTaxFinancialInstruments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" name="IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueAdjustmentsRelatedToDivestments" name="FairValueAdjustmentsRelatedToDivestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" name="PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" name="ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" name="ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges" name="CashFlowsBeforeWorkingCapitalAndProvisionChanges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" name="A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsIssuanceDate" name="BorrowingsIssuanceDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrencyOthersMember" name="CurrencyOthersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OperatingIncomeMember" name="OperatingIncomeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TranscendMedicalIncMember" name="TranscendMedicalIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SelexysPharmaceuticalsCorporationMember" name="SelexysPharmaceuticalsCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZiarcoGroupLimitedMember" name="ZiarcoGroupLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EncoreVisionIncMember" name="EncoreVisionIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EliLillyAndCompanyMember" name="EliLillyAndCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GSKOncologyProductsMember" name="GSKOncologyProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GSKVaccinesMember" name="GSKVaccinesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GSKConsumerHealthcareMember" name="GSKConsumerHealthcareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GSKTotalTransactionMember" name="GSKTotalTransactionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CSLMember" name="CSLMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SpinifexMember" name="SpinifexMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdmuneTheraputicsMember" name="AdmuneTheraputicsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" name="BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" name="DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" name="DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfAcquisitionOfBusinessesAbstract" name="DisclosureOfAcquisitionOfBusinessesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" name="ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProvisionsForReductionOfRevenueTableTextBlock" name="ProvisionsForReductionOfRevenueTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RestructuringProvisionsMovementsTableTextBlock" name="RestructuringProvisionsMovementsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" name="FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfDefinedBenefitPlansTableTextBlock" name="DisclosureOfDefinedBenefitPlansTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" name="DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" name="BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfAssumptionsUsedTableTextBlock" name="ScheduleOfAssumptionsUsedTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" name="ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock" name="ScheduleOfHealthCareCostTrendRatesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock" name="ScheduleOfAllocationOfPlanAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock" name="ScheduleOfExpectedBenefitPaymentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" name="AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" name="AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" name="CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" name="AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" name="OtherIntangibleAssetsRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" name="TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PotentiallyRefundableConsiderationFromAcquisition" name="PotentiallyRefundableConsiderationFromAcquisition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueOfAcquireeFullYear" name="RevenueOfAcquireeFullYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" name="SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" name="SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" name="SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" name="SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOfBusinessContingentOptionArrangementsFeePaid" name="SaleOfBusinessContingentOptionArrangementsFeePaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PercentageOfVotingEquityInterestsContributed" name="PercentageOfVotingEquityInterestsContributed" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionRelatedCosts" name="TransactionRelatedCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionRelatedCostsPaid" name="TransactionRelatedCostsPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProvisionsAndOtherCurrentLiabilitiesLineItems" name="ProvisionsAndOtherCurrentLiabilitiesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccrualForTaxesOtherThanIncomeTaxesCurrent" name="AccrualForTaxesOtherThanIncomeTaxesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AccruedRoyaltiesPayableClassifiedAsCurrent" name="AccruedRoyaltiesPayableClassifiedAsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ProvisionsForDeductionsFromRevenueRollForward" name="ProvisionsForDeductionsFromRevenueRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ChangesInOffsetAgainstGrossTradeReceivables" name="ChangesInOffsetAgainstGrossTradeReceivables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RestructuringProvisionsMovementsRollForward" name="RestructuringProvisionsMovementsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfTradeReceivablesAbstract" name="DisclosureOfTradeReceivablesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfTradeReceivablesExplanatoryTextBlock" name="DisclosureOfTradeReceivablesExplanatoryTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProvisionsForTradeReceivablesTableTextBlock" name="ProvisionsForTradeReceivablesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradeReceivablesProvisionMovementsTableTextBlock" name="TradeReceivablesProvisionMovementsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OverdueAmountsAndRelatedProvisionsTableTextBlock" name="OverdueAmountsAndRelatedProvisionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" name="TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AnalysisOfOverdueAmountsTable" name="AnalysisOfOverdueAmountsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AnalysisOfOverdueAmountsLineItems" name="AnalysisOfOverdueAmountsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" name="DisclosureOfReceivablesDenominatedInVariousCurrenciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentTradeReceivablesFromCloselyMonitoredCountries" name="CurrentTradeReceivablesFromCloselyMonitoredCountries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" name="CurrentTradeReceivablesFromCloselyMonitoredCountriesPastDueMoreThanOneYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" name="PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharePaidinCapital" name="SharePaidinCapital" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_NovartisArgentinaS.A.BuenosAiresMember" name="NovartisArgentinaS.A.BuenosAiresMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriosS.A.BuenosAiresMember" name="AlconLaboratoriosS.A.BuenosAiresMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RocheHoldingAGBaselMember" name="RocheHoldingAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConcentrationOfMajorPlansGeographic" name="ConcentrationOfMajorPlansGeographic" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" name="DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RetirementPlanTypeAxis" name="RetirementPlanTypeAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RetirementPlanTypeMember" name="RetirementPlanTypeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PensionPlanMember" name="PensionPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherPostemploymentBenefitPlansMember" name="OtherPostemploymentBenefitPlansMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" name="IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanSettlementsPlanAssets" name="DefinedBenefitPlanSettlementsPlanAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" name="IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward" name="DefinedBenefitPlanChangeInBenefitObligationRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" name="DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" name="DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LimitationOnRecognitionOfFundSurplus" name="LimitationOnRecognitionOfFundSurplus" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward" name="DefinedBenefitPlanChangeInNetLiabilityRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" name="IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" name="AmountsRecognizedInTheConsolidatedBalanceSheetAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities" name="DefinedBenefitPensionPlanAccruedBenefitLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTable" name="BreakdownOfDefinedBenefitObligationForPensionPlansTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ObligationByTypeAxis" name="ObligationByTypeAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ObligationByTypeMember" name="ObligationByTypeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_UnfundedMember" name="UnfundedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ActiveMember" name="ActiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DeferredPensionersMember" name="DeferredPensionersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PensionersMember" name="PensionersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleOfDefinedBenefitPlansDisclosuresTable" name="ScheduleOfDefinedBenefitPlansDisclosuresTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" name="ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitAssumptionLifeExpectancyMale" name="DefinedBenefitAssumptionLifeExpectancyMale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitAssumptionLifeExpectancyFemale" name="DefinedBenefitAssumptionLifeExpectancyFemale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LifeExpectancyMember" name="LifeExpectancyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" name="ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChangeInActuarialAssumptionAxis" name="ChangeInActuarialAssumptionAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChangeInActuarialAssumptionMember" name="ChangeInActuarialAssumptionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Decrease25BasisPointMember" name="Decrease25BasisPointMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Increase25BasisPointMember" name="Increase25BasisPointMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Increase1YearMember" name="Increase1YearMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleOfHealthCareCostTrendRatesTable" name="ScheduleOfHealthCareCostTrendRatesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" name="DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" name="DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" name="DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:gYearItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleOfAllocationOfPlanAssetsTable" name="ScheduleOfAllocationOfPlanAssetsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RealEstateMember" name="RealEstateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlternativeInvestmentsMember" name="AlternativeInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CashAndOtherInvestmentsMember" name="CashAndOtherInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" name="DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" name="DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanPlanAssetAllocations" name="DefinedBenefitPlanPlanAssetAllocations" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_WeightedAverageDurationOfDefinedBenefitObligationYears" name="WeightedAverageDurationOfDefinedBenefitObligationYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" name="DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" name="DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" name="DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleOfExpectedBenefitPaymentsTable" name="ScheduleOfExpectedBenefitPaymentsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" name="DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" name="DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" name="PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" name="DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_SocieteParActionsSANDOZAlgiersMember" name="SocieteParActionsSANDOZAlgiersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" name="DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" name="AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" name="CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" name="CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsFromDiscontinuedOperationsTableTextBlock" name="CashFlowsFromDiscontinuedOperationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConsolidatedIncomeStatementSegmentationTableTextBlock" name="ConsolidatedIncomeStatementSegmentationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ExpensesIncludedInNetIncomeTableTextBlock" name="ExpensesIncludedInNetIncomeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsSalesToContinuingSegments" name="RevenueFromSaleOfGoodsSalesToContinuingSegments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VaccinesMember" name="VaccinesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ConsumerHealthMember" name="ConsumerHealthMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CorporateMember" name="CorporateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OperatingIncomeLossOfDiscontinuedOperations" name="OperatingIncomeLossOfDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeTaxExpenseOfDiscontinuedOperations" name="IncomeTaxExpenseOfDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" name="AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AcquisitionsAndDivestmentsAxis" name="AcquisitionsAndDivestmentsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AcquisitionsAndDivestmentsMember" name="AcquisitionsAndDivestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AcquisitionsMember" name="AcquisitionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DivestmentsMember" name="DivestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowCurrencyTranslationEffects" name="CashInflowOutflowCurrencyTranslationEffects" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowAcquiredDivestedLiquity" name="CashInflowOutflowAcquiredDivestedLiquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashProvidedByRefinancingOfIntercompanyFinancialDebtNet" name="CashProvidedByRefinancingOfIntercompanyFinancialDebtNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowGoodwill" name="CashInflowOutflowGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowDivestmentGainLoss" name="CashInflowOutflowDivestmentGainLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows" name="TaxesPaidAndOtherPortfolioTransformationRelatedCashFlows" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReceivablesAndPayablesContingentConsiderationNet" name="ReceivablesAndPayablesContingentConsiderationNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherPaymentsAndDeferredConsiderationNet" name="OtherPaymentsAndDeferredConsiderationNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeferredPrepaidPortionOfSalesPrice" name="DeferredPrepaidPortionOfSalesPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationPaid" name="ContingentConsiderationPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Change25BasisPointMember" name="Change25BasisPointMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DividendsPayableAmountPerShare" name="DividendsPayableAmountPerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesAcquiredToBeHeld" name="TreasurySharesAcquiredToBeHeld" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesAcquiredToBeCancelled" name="TreasurySharesAcquiredToBeCancelled" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherSharePurchases" name="OtherSharePurchases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharepurchaseOfTreasuryShares" name="SharepurchaseOfTreasuryShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesAcquiredToBeHeldValue" name="TreasurySharesAcquiredToBeHeldValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesAcquiredForCancellationValue" name="TreasurySharesAcquiredForCancellationValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" name="ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfComprehensiveIncomeTableTextBlock" name="ScheduleOfComprehensiveIncomeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" name="FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" name="ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OfficerAndDirectorCompensationTableTextBlock" name="OfficerAndDirectorCompensationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" name="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfSharebasedCompensationActivityTableTextBlock" name="ScheduleOfSharebasedCompensationActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonExecutiveDirectorMember" name="NonExecutiveDirectorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RocheHoldingAGMember" name="RocheHoldingAGMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LucentisMember" name="LucentisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_XolairMember" name="XolairMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetExpenseRoyaltiesCostSharingAndProfitSharing" name="NetExpenseRoyaltiesCostSharingAndProfitSharing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GenentechInc.USAMember" name="GenentechInc.USAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProfDrBrodyMember" name="ProfDrBrodyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProfDrZinkernagelMember" name="ProfDrZinkernagelMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DrAlexKrauerMember" name="DrAlexKrauerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DrDanielVasellaMember" name="DrDanielVasellaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DrJamesBradnerMember" name="DrJamesBradnerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_KeyManagementPersonnelCompensationDailyRate" name="KeyManagementPersonnelCompensationDailyRate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" name="KeyManagementPersonnelCompensationAnnualGuaranteedMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_KeyManagementPersonnelCompensationSharesAcquired" name="KeyManagementPersonnelCompensationSharesAcquired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_KeyManagementPersonnelCompensationOwnershipInterestAcquired" name="KeyManagementPersonnelCompensationOwnershipInterestAcquired" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" name="ChangesInConsolidatedStatementsOfComprehensiveIncomeTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueAdjustmentsOnMarketableSecuritiesMember" name="FairValueAdjustmentsOnMarketableSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueAdjustmentsOnDeferredCashFlowHedgesMember" name="FairValueAdjustmentsOnDeferredCashFlowHedgesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ActuarialLossesFromDefinedBenefitPlansMember" name="ActuarialLossesFromDefinedBenefitPlansMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CumulativeCurrencyTranslationEffectsMember" name="CumulativeCurrencyTranslationEffectsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" name="ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GainLossOnSaleOfMarketableInvestments" name="GainLossOnSaleOfMarketableInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GainLossOnSaleOfOtherFinancialAssets" name="GainLossOnSaleOfOtherFinancialAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RemeasurementsFromDefinedBenefitPlansLineItems" name="RemeasurementsFromDefinedBenefitPlansLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InnovativeMedicinesMember" name="InnovativeMedicinesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozMember" name="SandozMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconMember" name="AlconMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationAnnualIncentivePlanMember" name="EquityBasedParticipationAnnualIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationShareSavingsPlanMember" name="EquityBasedParticipationShareSavingsPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationLeveragedShareSavingsPlanMember" name="EquityBasedParticipationLeveragedShareSavingsPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationEmployeeShareOwnershipPlanMember" name="EquityBasedParticipationEmployeeShareOwnershipPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationUKShareSavingsPlanMember" name="EquityBasedParticipationUKShareSavingsPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationNovartisEquityPlanSelectMember" name="EquityBasedParticipationNovartisEquityPlanSelectMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationLongTermPerformancePlanMember" name="EquityBasedParticipationLongTermPerformancePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationLongTermRelativePerformancePlanMember" name="EquityBasedParticipationLongTermRelativePerformancePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationSpecialShareAwardsMember" name="EquityBasedParticipationSpecialShareAwardsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" name="DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationRestrictedSharesMember" name="EquityBasedParticipationRestrictedSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" name="OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" name="OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" name="OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_KeyManagementPersonnelCompensationSharesAcquiredPrice" name="KeyManagementPersonnelCompensationSharesAcquiredPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ValueAdjustmentOnComprehensiveIncome" name="ValueAdjustmentOnComprehensiveIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome" name="GainsLossesOnValueAdjustmentOnComprehensiveIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember" name="TotalValueAdjustmentsAttributableToNovartisShareholdersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconInc.EquityPlanConvertedNovartisShareOptionsMember" name="AlconInc.EquityPlanConvertedNovartisShareOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" name="AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" name="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsSalesToOtherSegments" name="RevenueFromSaleOfGoodsSalesToOtherSegments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" name="ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetOperatingAssets" name="NetOperatingAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" name="CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FinancialDebtsAndDerivativeInstruments" name="FinancialDebtsAndDerivativeInstruments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CurrentIncomeTaxAndDeferredTaxLiabilities" name="CurrentIncomeTaxAndDeferredTaxLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_SelectedNoncurrentAssets" name="SelectedNoncurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_OtherCountriesMember" name="OtherCountriesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AsiaAfricaAustralasiaMember" name="AsiaAfricaAustralasiaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LargestCustomerMember" name="LargestCustomerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SecondLargestCustomerMember" name="SecondLargestCustomerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ThirdLargestCustomerMember" name="ThirdLargestCustomerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" name="DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" name="DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfAssociatesBalanceSheetTableTextBlock" name="DisclosureOfAssociatesBalanceSheetTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AssociatesSummarizedFinancialInformationTableTextBlock" name="AssociatesSummarizedFinancialInformationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PurchasePriceAllocationAssociatesTableTextBlock" name="PurchasePriceAllocationAssociatesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" name="GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OthersAssociatesMember" name="OthersAssociatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ShareOfEstimatedNetAssets" name="ShareOfEstimatedNetAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" name="CurrentValueOfShareInNetIdentifiableAssetsAndGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" name="AccumulatedEquityAccountingAdjustmentsAndTranslationEffectsLessDividendsReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ConsolidatedIncomeStatementEffectsTable" name="ConsolidatedIncomeStatementEffectsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ShareOfCurrentYearNetIncome" name="ShareOfCurrentYearNetIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PriorYearAdjustment" name="PriorYearAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" name="AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" name="TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" name="DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccrualForEnvironmentalLossContingenciesTableTextBlock" name="AccrualForEnvironmentalLossContingenciesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" name="AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" name="AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation" name="OtherLongtermEmployeeBenefitsAndDeferredCompensation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OtherPostemploymentBenefits" name="OtherPostemploymentBenefits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_SolodynMember" name="SolodynMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContactLensesMember" name="ContactLensesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GleevecMember" name="GleevecMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReclastAclastaMember" name="ReclastAclastaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TekturnaRasilezValturnaMember" name="TekturnaRasilezValturnaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NAGAndNovartisPharmaSpAMember" name="NAGAndNovartisPharmaSpAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FHoffmanLaRocheAGAndRocheSpAMember" name="FHoffmanLaRocheAGAndRocheSpAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaKKMember" name="NovartisPharmaKKMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NAGMember" name="NAGMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NPCAndOthersMember" name="NPCAndOthersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNCMember" name="NovartisNCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" name="ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" name="ProductLiabilityContingencyLossExposureNotAccruedBestEstimate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" name="EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" name="DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" name="DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" name="DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" name="DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" name="DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" name="A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" name="A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" name="A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" name="A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" name="A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" name="TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TotalFairValueAdjustmentsMember" name="TotalFairValueAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentPrepaidExpensesThirdParty" name="CurrentPrepaidExpensesThirdParty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_TaxotereMember" name="TaxotereMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AmiodaroneMember" name="AmiodaroneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfEquityAbstract" name="DisclosureOfEquityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfEquityTextBlock" name="DisclosureOfEquityTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DividendTableTextBlock" name="DividendTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseInNoncontrolingInterests" name="IncreaseDecreaseInNoncontrolingInterests" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfReportableSegments" name="NumberOfReportableSegments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfFranchises" name="NumberOfFranchises" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsThirdParties" name="RevenueFromSaleOfGoodsThirdParties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" name="RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" name="SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" name="InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" name="ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxExpenseIncomeDiscontinuingOperations" name="TaxExpenseIncomeDiscontinuingOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" name="EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" name="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" name="OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" name="OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NeuroscienceMember" name="NeuroscienceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EstablishedMedicinesMember" name="EstablishedMedicinesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProductPortfolioMember" name="ProductPortfolioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_COPDMember" name="COPDMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GleevecGlivecMember" name="GleevecGlivecMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TasignaMember" name="TasignaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandostatinMember" name="SandostatinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AfinitorVotubiaMember" name="AfinitorVotubiaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExjadeJadenuMember" name="ExjadeJadenuMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TafinlarMekinistMember" name="TafinlarMekinistMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PromactaRevoladeMember" name="PromactaRevoladeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OphthalmologyMember" name="OphthalmologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VotrientMember" name="VotrientMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_JakaviMember" name="JakaviMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_KisqaliMember" name="KisqaliMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherProductsMember" name="OtherProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TravoprostGroupMember" name="TravoprostGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SystaneGroupMember" name="SystaneGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TopicalOlopatadineGroupMember" name="TopicalOlopatadineGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CosentyxMember" name="CosentyxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NeoralSandimmunEMember" name="NeoralSandimmunEMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZortressCerticanMember" name="ZortressCerticanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IlarisMember" name="IlarisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MyforticMember" name="MyforticMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GilenyaMember" name="GilenyaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_UltibroBreezhalerMember" name="UltibroBreezhalerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SeebriBreezhalerMember" name="SeebriBreezhalerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OnbrezBreezhalerMember" name="OnbrezBreezhalerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EntrestoMember" name="EntrestoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VoltarenCataflamMember" name="VoltarenCataflamMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExelonExelonPatchMember" name="ExelonExelonPatchMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RitalinFocalinMember" name="RitalinFocalinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" name="AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccumulatedImpairmentsOnDisposalsAndDerecognitions" name="AccumulatedImpairmentsOnDisposalsAndDerecognitions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AcquiredResearchAndDevelopmentMember" name="AcquiredResearchAndDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconBrandNameMember" name="AlconBrandNameMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" name="GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" name="CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" name="OtherComprehensiveIncomeAvailableforsaleFinancialInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeMaketableSecurities" name="OtherComprehensiveIncomeMaketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProvisionForDoubtfulReceivableMember" name="ProvisionForDoubtfulReceivableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" name="CurrentTradeReceivablesFromCloselyMonitoredCountriesProvisionsRecorded" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_Commodities" name="Commodities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OutstandingShareCapital" name="OutstandingShareCapital" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_IssuedCapitalMovement" name="IssuedCapitalMovement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OutstandingShareCapitalMovement" name="OutstandingShareCapitalMovement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharesCancelledForCapitalReduction" name="SharesCancelledForCapitalReduction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesMovement" name="TreasurySharesMovement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EquityImpactOfTreasuryShareMovements" name="EquityImpactOfTreasuryShareMovements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AverageInterestRateOnLoansReceived" name="AverageInterestRateOnLoansReceived" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RatioFixedRateFinancialDebtToTotalFinancialDebt" name="RatioFixedRateFinancialDebtToTotalFinancialDebt" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AverageInterestRateOnBorrowings" name="AverageInterestRateOnBorrowings" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationNonCurrent" name="ContingentConsiderationNonCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_EnvironmentalProvisionRollForward" name="EnvironmentalProvisionRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvision" name="EnvironmentalProvision" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionPayments" name="EnvironmentalProvisionPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionReleases" name="EnvironmentalProvisionReleases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionAdditions" name="EnvironmentalProvisionAdditions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionForeignCurrencyTranslationGainLoss" name="EnvironmentalProvisionForeignCurrencyTranslationGainLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionCurrent" name="EnvironmentalProvisionCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalRemediationProvisionNoncurrent" name="EnvironmentalRemediationProvisionNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_EnvironmentalProvisionFiscalYearMaturityAbstract" name="EnvironmentalProvisionFiscalYearMaturityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionExpectedCashOutflowNextTwoYears" name="EnvironmentalProvisionExpectedCashOutflowNextTwoYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" name="EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" name="EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EnvironmentalProvisionExpectedCashOutflowAfterTenYears" name="EnvironmentalProvisionExpectedCashOutflowAfterTenYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_WeightedAverageInterestRateAssociates" name="WeightedAverageInterestRateAssociates" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_WeightedAverageInterestRateOnBankAndOtherFinancialDebt" name="WeightedAverageInterestRateOnBankAndOtherFinancialDebt" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationCurrentPortion" name="ContingentConsiderationCurrentPortion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ProvisionForDeductionFromRevenueTable" name="ProvisionForDeductionFromRevenueTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProvisionsAndOtherCurrentLiabilitiesTable" name="ProvisionsAndOtherCurrentLiabilitiesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RestructuringProvisionsMovementsTable" name="RestructuringProvisionsMovementsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RestructuringProvisionTransfers" name="RestructuringProvisionTransfers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" name="TradeAndOtherPayablesAndDeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_IdentifiableAssetsAcquired" name="IdentifiableAssetsAcquired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashFlowFromNetIdentifiableAssets" name="CashFlowFromNetIdentifiableAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate" name="PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" name="CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" name="AcquiredDivestedResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TechnologiesRecognisedAsOfAcquisitionDivestmentDate" name="TechnologiesRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" name="OtherIntangibleAssetsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate" name="FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_InventoryRecognisedAsOfAcquisitionDivestmentDate" name="InventoryRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate" name="TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate" name="CashAndCashEquivalentsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate" name="CurrentAndNoncurrentFinancialDebtsRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate" name="TradeAndOtherPayablesRecognisedAsOfAcquisitionDivestmentDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AnimalHealthMember" name="AnimalHealthMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProceedsFromSaleOfBusiness" name="ProceedsFromSaleOfBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmortizationOfBondsDiscount" name="AmortizationOfBondsDiscount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentPortionOfNoncurrentFinancialDebt" name="CurrentPortionOfNoncurrentFinancialDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GenentechRocheMember" name="GenentechRocheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfContractsWithRelatedParties" name="NumberOfContractsWithRelatedParties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RelatedPartiesNumberOfNonexecutiveDirectors" name="RelatedPartiesNumberOfNonexecutiveDirectors" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanExpectedFutureBenefitPayment" name="DefinedBenefitPlanExpectedFutureBenefitPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EmployerSharesHeldByDefinedBenefitPlan" name="EmployerSharesHeldByDefinedBenefitPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ValueOfEmployerSharesHeldByDefinedBenefitPlan" name="ValueOfEmployerSharesHeldByDefinedBenefitPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" name="IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" name="IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CashAndCashEquivalentsMember" name="CashAndCashEquivalentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BalanceSheetItemAxis" name="BalanceSheetItemAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BalanceSheetItemMember" name="BalanceSheetItemMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquitySecuritiesMember" name="EquitySecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FundInvestmentsMember" name="FundInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" name="TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContingentConsiderationReceivablesMember" name="ContingentConsiderationReceivablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" name="AccruedInterestOnDebtSecuritiesAndTimeDepositsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember" name="TimeDepositsWithOriginalMaturityMoreThan90DaysMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" name="LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember" name="AssociatedCompaniesAtFairValueThroughProfitAndLossMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentsMember" name="DerivativeFinancialInstrumentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GroupsOfFinancialAssetsLiabilitiesAxis" name="GroupsOfFinancialAssetsLiabilitiesAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GroupsOfFinancialAssetsLiabilitiesMember" name="GroupsOfFinancialAssetsLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TradePayablesMember" name="TradePayablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_InterestBearningAccountsOfAssociatesPayableOnDemandMember" name="InterestBearningAccountsOfAssociatesPayableOnDemandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BankAndOtherFinancialDebtMember" name="BankAndOtherFinancialDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CommercialPaperMember" name="CommercialPaperMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentPortionOfNoncurrentDebtMember" name="CurrentPortionOfNoncurrentDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_StraightBondsMember" name="StraightBondsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LiabilitiesToBanksAndOtherFinancialInstitutionsMember" name="LiabilitiesToBanksAndOtherFinancialInstitutionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinanceLeaseObligationsMember" name="FinanceLeaseObligationsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContingentConsiderationAndOtherFinancialLiabilitiesMember" name="ContingentConsiderationAndOtherFinancialLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" name="DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis" name="DerivativeFinancialInstrumentNatureOfInstrumentAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember" name="DerivativeFinancialInstrumentNatureOfInstrumentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" name="DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialInstrumentsPrincipalAmountsAxis" name="FinancialInstrumentsPrincipalAmountsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialInstrumentsPrincipalAmountsMember" name="FinancialInstrumentsPrincipalAmountsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContractOrUnderlyingPrincipalAmoutMember" name="ContractOrUnderlyingPrincipalAmoutMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PositiveFairValuesMember" name="PositiveFairValuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NegativeFairValuesMember" name="NegativeFairValuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems" name="DisclosureOfDerivativeFinancialInstrumentsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DerivativeFinancialInstruments" name="DerivativeFinancialInstruments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" name="DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" name="DerivativeFinancialInstrumentsOverthecounterCurrencyOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" name="DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" name="TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialInvestmentsAndLongtermLoansGroupMember" name="FinancialInvestmentsAndLongtermLoansGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TotalAvailableforsaleMarketableSecuritiesMember" name="TotalAvailableforsaleMarketableSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AvailableForSaleMarketableSecuritiesMember" name="AvailableForSaleMarketableSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AvailableforsaleLongtermFinancialInvestmentsMember" name="AvailableforsaleLongtermFinancialInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentFinancialDebtMember" name="CurrentFinancialDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NoncurrentFinancialDebtMember" name="NoncurrentFinancialDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AvailableforsaleFinancialInvestmentsMember" name="AvailableforsaleFinancialInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ValuedAtAmortizedCostMember" name="ValuedAtAmortizedCostMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContingentConsiderationPayablesMember" name="ContingentConsiderationPayablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherFinancialLiabilitiesMember" name="OtherFinancialLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" name="ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" name="IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisAustriaGmbHViennaMember" name="NovartisAustriaGmbHViennaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaGmbHViennaMember" name="NovartisPharmaGmbHViennaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconOphthalmikaGmbHViennaMember" name="AlconOphthalmikaGmbHViennaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozGmbHViennaMember" name="SandozGmbHViennaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EBEWEPharmaGes.m.b.HNfg.KGViennaMember" name="EBEWEPharmaGes.m.b.HNfg.KGViennaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBangladeshLimitedGazipurMember" name="NovartisBangladeshLimitedGazipurMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSecuritiesInvestmentLtd.HamiltonMember" name="NovartisSecuritiesInvestmentLtd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" name="NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconCanadaInc.MississaugaOntarioMember" name="AlconCanadaInc.MississaugaOntarioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CIBAVisionCanadaInc.MississaugaOntarioMember" name="CIBAVisionCanadaInc.MississaugaOntarioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozCanadaInc.BouchervilleQuebecMember" name="SandozCanadaInc.BouchervilleQuebecMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisChileS.A.SantiagoDeChileMember" name="NovartisChileS.A.SantiagoDeChileMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriosChileLtd.SantiagoDeChileMember" name="AlconLaboratoriosChileLtd.SantiagoDeChileMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BeijingNovartisPharmaCo.Ltd.BeijingMember" name="BeijingNovartisPharmaCo.Ltd.BeijingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsHKLimitedHongKongMember" name="NovartisPharmaceuticalsHKLimitedHongKongMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" name="SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ShanghaiNovartisTradingLtd.ShanghaiMember" name="ShanghaiNovartisTradingLtd.ShanghaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconHongKongLimitedHongKongMember" name="AlconHongKongLimitedHongKongMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconChinaOphthalmicProductCo.Ltd.BeijingMember" name="AlconChinaOphthalmicProductCo.Ltd.BeijingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" name="SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" name="SandozD.o.o.FarmaceutskaIndustrijaZagrebMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisS.r.o.PragueMember" name="NovartisS.r.o.PragueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" name="AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozS.r.o.PragueMember" name="SandozS.r.o.PragueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHealthcareASCopenhagenMember" name="NovartisHealthcareASCopenhagenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconNordicASCopenhagenMember" name="AlconNordicASCopenhagenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozASCopenhagenMember" name="SandozASCopenhagenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisEcuadorS.A.QuitoMember" name="NovartisEcuadorS.A.QuitoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaS.A.E.CairoMember" name="NovartisPharmaS.A.E.CairoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozEgyptPharmaS.A.E.NewCairoCityMember" name="SandozEgyptPharmaS.A.E.NewCairoCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFinlandOyEspooMember" name="NovartisFinlandOyEspooMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisGroupeFranceS.A.RueilMalmaisonMember" name="NovartisGroupeFranceS.A.RueilMalmaisonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaS.A.S.RueilMalmaisonMember" name="NovartisPharmaS.A.S.RueilMalmaisonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LaboratoiresAlconS.A.S.RueilMalmaisonMember" name="LaboratoiresAlconS.A.S.RueilMalmaisonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozS.A.S.LevalloisPerretMember" name="SandozS.A.S.LevalloisPerretMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisDeutschlandGmbHWehrMember" name="NovartisDeutschlandGmbHWehrMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaGmbHNurembergMember" name="NovartisPharmaGmbHNurembergMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaProduktionsGmbHWehrMember" name="NovartisPharmaProduktionsGmbHWehrMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBusinessServicesGmbHWehrMember" name="NovartisBusinessServicesGmbHWehrMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPharmaGmbHFreiburgImBreisgauMember" name="AlconPharmaGmbHFreiburgImBreisgauMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_WaveLightGmbHErlangenMember" name="WaveLightGmbHErlangenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CIBAVisionGmbHGrosswallstadtMember" name="CIBAVisionGmbHGrosswallstadtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozInternationalGmbHHolzkirchenMember" name="SandozInternationalGmbHHolzkirchenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_HEXALAGHolzkirchenMember" name="HEXALAGHolzkirchenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SalutasPharmaGmbHBarlebenMember" name="SalutasPharmaGmbHBarlebenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AeropharmGmbHRudolstadtMember" name="AeropharmGmbHRudolstadtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovistaInsuranceLimitedGibraltarCityMember" name="NovistaInsuranceLimitedGibraltarCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember" name="NovartisHellasS.A.C.I.MetamorphosisAthensMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" name="AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" name="NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozHungaryLimitedLiabilityCompanyBudapestMember" name="SandozHungaryLimitedLiabilityCompanyBudapestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisIndiaLimitedMumbaiMember" name="NovartisIndiaLimitedMumbaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHealthcarePrivateLimitedMumbaiMember" name="NovartisHealthcarePrivateLimitedMumbaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPrivateLimitedMumbaiMember" name="SandozPrivateLimitedMumbaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PT.NovartisIndonesiaJakartaMember" name="PT.NovartisIndonesiaJakartaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PT.CIBAVisionBatamBatamMember" name="PT.CIBAVisionBatamBatamMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisIrelandLimitedDublinMember" name="NovartisIrelandLimitedDublinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" name="NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesIrelandLimitedCorkCityMember" name="AlconLaboratoriesIrelandLimitedCorkCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OptonolLtd.NeveIlanMember" name="OptonolLtd.NeveIlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconItaliaS.p.A.MilanMember" name="AlconItaliaS.p.A.MilanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozS.p.A.OriggioMember" name="SandozS.p.A.OriggioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozIndustrialProductsS.p.A.RoveretoMember" name="SandozIndustrialProductsS.p.A.RoveretoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHoldingJapanK.K.TokyoMember" name="NovartisHoldingJapanK.K.TokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaK.K.TokyoMember" name="NovartisPharmaK.K.TokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconJapanLtd.TokyoMember" name="AlconJapanLtd.TokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozK.K.TokyoMember" name="SandozK.K.TokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" name="AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CIBAVisionJohorSdn.Bhd.KualaLumpurMember" name="CIBAVisionJohorSdn.Bhd.KualaLumpurMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriosS.A.DeC.V.MexicoCityMember" name="AlconLaboratoriosS.A.DeC.V.MexicoCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozS.A.DeC.V.MexicoCityMember" name="SandozS.A.DeC.V.MexicoCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaMarocSACasablancaMember" name="NovartisPharmaMarocSACasablancaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNetherlandsB.V.ArnhemMember" name="NovartisNetherlandsB.V.ArnhemMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaB.V.ArnhemMember" name="NovartisPharmaB.V.ArnhemMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconNederlandB.V.ArnhemMember" name="AlconNederlandB.V.ArnhemMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozB.V.AlmereMember" name="SandozB.V.AlmereMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNewZealandLtdAucklandMember" name="NovartisNewZealandLtdAucklandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNorgeASOsloMember" name="NovartisNorgeASOsloMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaPakistanLimitedKarachiMember" name="NovartisPharmaPakistanLimitedKarachiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaLogisticsInc.PanamaCityMember" name="NovartisPharmaLogisticsInc.PanamaCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconCentroamericaS.A.PanamaCityMember" name="AlconCentroamericaS.A.PanamaCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LekS.A.StrykowMember" name="LekS.A.StrykowMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPortugalSGPSLda.PortoSalvoMember" name="NovartisPortugalSGPSLda.PortoSalvoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaServicesRomaniaS.R.L.BucharestMember" name="NovartisPharmaServicesRomaniaS.R.L.BucharestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconRomaniaS.R.L.BucharestMember" name="AlconRomaniaS.R.L.BucharestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozS.R.L.TarguMuresMember" name="SandozS.R.L.TarguMuresMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaLLCMoscowMember" name="NovartisPharmaLLCMoscowMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconFarmacevtikaLLCMoscowMember" name="AlconFarmacevtikaLLCMoscowMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNevaLLCSt.PetersburgMember" name="NovartisNevaLLCSt.PetersburgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" name="SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSlovakiaS.r.o.BratislavaMember" name="NovartisSlovakiaS.r.o.BratislavaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LekPharmaceuticalsD.d.LjubjanaMember" name="LekPharmaceuticalsD.d.LjubjanaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPharmaceuticalsD.d.LjubjanaMember" name="SandozPharmaceuticalsD.d.LjubjanaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSouthAfricaPtyLtdMidrandMember" name="NovartisSouthAfricaPtyLtdMidrandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" name="AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisKoreaLtd.SeoulMember" name="NovartisKoreaLtd.SeoulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconKoreaLtd.SeoulMember" name="AlconKoreaLtd.SeoulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozKoreaLtd.SeoulMember" name="SandozKoreaLtd.SeoulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconCusiS.A.BarcelonaMember" name="AlconCusiS.A.BarcelonaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AbadiaRetuertaS.A.SardonDeDueroValladolidMember" name="AbadiaRetuertaS.A.SardonDeDueroValladolidMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSverigeABStockholmMember" name="NovartisSverigeABStockholmMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInternationalAGBaselMember" name="NovartisInternationalAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHoldingAGBaselMember" name="NovartisHoldingAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInternationalPharmaceuticalAGBaselMember" name="NovartisInternationalPharmaceuticalAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaAGBaselMember" name="NovartisPharmaAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaServicesAGBaselMember" name="NovartisPharmaServicesAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaSchweizerhalleAGMuttenzMember" name="NovartisPharmaSchweizerhalleAGMuttenzMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaSteinAGSteinMember" name="NovartisPharmaSteinAGSteinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaSchweizAGRischMember" name="NovartisPharmaSchweizAGRischMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconSwitzerlandSARischMember" name="AlconSwitzerlandSARischMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPharmaceuticalsLtd.FribourgMember" name="AlconPharmaceuticalsLtd.FribourgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozAGBaselMember" name="SandozAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPharmaceuticalsAGRischMember" name="SandozPharmaceuticalsAGRischMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisTaiwanCo.Ltd.TaipeiMember" name="NovartisTaiwanCo.Ltd.TaipeiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisThailandLimitedBangkokMember" name="NovartisThailandLimitedBangkokMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesThailandLimitedBangkokMember" name="AlconLaboratoriesThailandLimitedBangkokMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratuvarlariTicaretA.S.IstanbulMember" name="AlconLaboratuvarlariTicaretA.S.IstanbulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisMiddleEastFZEDubaiMember" name="NovartisMiddleEastFZEDubaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisUKLimitedFrimleyCamberleyMember" name="NovartisUKLimitedFrimleyCamberleyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" name="NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisGrimsbyLimitedFrimleyCamberleyMember" name="NovartisGrimsbyLimitedFrimleyCamberleyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconEyeCareUKLimitedFrimleyCamberleyMember" name="AlconEyeCareUKLimitedFrimleyCamberleyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozLimitedFrimleyCamberleyMember" name="SandozLimitedFrimleyCamberleyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" name="GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCorporationEastHanoverNYMember" name="NovartisCorporationEastHanoverNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFinanceCorporationNewYorkNYMember" name="NovartisFinanceCorporationNewYorkNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationNewYorkNYMember" name="NovartisCapitalCorporationNewYorkNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsCorporationEastHanoverNYMember" name="NovartisPharmaceuticalsCorporationEastHanoverNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" name="NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" name="NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" name="NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisServicesInc.EastHanoverNYMember" name="NovartisServicesInc.EastHanoverNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesHoldingCorporationFortWorthTXMember" name="AlconLaboratoriesHoldingCorporationFortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesInc.FortWorthTXMember" name="AlconLaboratoriesInc.FortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconRefractivehorizonsLLCFortWorthTXMember" name="AlconRefractivehorizonsLLCFortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconResearchLtd.FortWorthTXMember" name="AlconResearchLtd.FortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLensxInc.AlisoViejoCAMember" name="AlconLensxInc.AlisoViejoCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozInc.PrincetonNJMember" name="SandozInc.PrincetonNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EonLabsInc.PrincetonNJMember" name="EonLabsInc.PrincetonNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FougeraPharmaceuticalsInc.MelvilleNYMember" name="FougeraPharmaceuticalsInc.MelvilleNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisDeVenezuelaS.A.CaracasMember" name="NovartisDeVenezuelaS.A.CaracasMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPharmaceuticalC.A.CaracasMember" name="AlconPharmaceuticalC.A.CaracasMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBiocienciasS.A.SaoPauloMember" name="NovartisBiocienciasS.A.SaoPauloMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" name="SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisDeColombiaS.A.SantafeDeBobotaMember" name="NovartisDeColombiaS.A.SantafeDeBobotaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" name="LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" name="NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" name="NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" name="AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozFarmaceuticaLda.PortoSalvoMember" name="SandozFarmaceuticaLda.PortoSalvoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFarmaceuticaS.A.BarcelonaMember" name="NovartisFarmaceuticaS.A.BarcelonaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozFarmaceuticaS.A.MadridMember" name="SandozFarmaceuticaS.A.MadridMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" name="NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozIlacSanayiVeTicaretA.S.IstanbulMember" name="SandozIlacSanayiVeTicaretA.S.IstanbulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" name="SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialInstrumentsAdditionalDisclosureAbstract" name="FinancialInstrumentsAdditionalDisclosureAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsCarryingValueLevel3" name="FinancialInstrumentsCarryingValueLevel3" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets" name="GainsRecognisedInProfitOrLossFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets" name="LossesRecognisedInProfitOrLossFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" name="FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisposalsFairValueMeasurementAssets" name="DisposalsFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReclassificationFairValueMeasurementAssets" name="ReclassificationFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" name="FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" name="MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReconciliationOfChangesInFairValueMeasurementAssetsTable" name="ReconciliationOfChangesInFairValueMeasurementAssetsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MaturityOfNetDebtLineItems" name="MaturityOfNetDebtLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MarketableSecuritiesAndTimeDepositsMember" name="MarketableSecuritiesAndTimeDepositsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CommoditiesMember" name="CommoditiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DeriviativeFinancialInstrumentsAndAccruedInterestMember" name="DeriviativeFinancialInstrumentsAndAccruedInterestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialDebtMember" name="FinancialDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FinancialDebtUndiscountedMember" name="FinancialDebtUndiscountedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" name="LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" name="DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" name="PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" name="PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" name="DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContractualInterestOnNoncurrentLiabilities" name="ContractualInterestOnNoncurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_TenDayLossFairValueVARModelTable" name="TenDayLossFairValueVARModelTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TenDayLossFairValueVARModelLineItems" name="TenDayLossFairValueVARModelLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsValueAtRiskComputation" name="FinancialInstrumentsValueAtRiskComputation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" name="FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" name="FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" name="FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_WorstCaseLossScenarioMember" name="WorstCaseLossScenarioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets" name="CashReceiptsAndPaymentsFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" name="EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" name="EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" name="AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationOtherShareAwardsMember" name="EquityBasedParticipationOtherShareAwardsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ShareMovements" name="ShareMovements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NetInvestmentHedgeMember" name="NetInvestmentHedgeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_WrittenCallOptionsHeldByMarketMaker" name="WrittenCallOptionsHeldByMarketMaker" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_WrittenCallOptionsContractualLive" name="WrittenCallOptionsContractualLive" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_WrittenCallOptionsContractualLiveRemaining" name="WrittenCallOptionsContractualLiveRemaining" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_WrittenCallOptionsWeightedAverageExercisePrice" name="WrittenCallOptionsWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PurchaseFairValueMeasurementAssets" name="PurchaseFairValueMeasurementAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_StockRepurchaseProgramAuthorizedAmount1" name="StockRepurchaseProgramAuthorizedAmount1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectOfIncomeTaxedAtReducedRates" name="TaxRateEffectOfIncomeTaxedAtReducedRates" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MovementsOfPropertyPlantAndEquipmentRollForward" name="MovementsOfPropertyPlantAndEquipmentRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherAssetsProvisionsAccrualsMember" name="OtherAssetsProvisionsAccrualsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" name="SharebasedCompensationArrangementByOtherEquityInstrumentsNonVestedInPeriodFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" name="SharebasedCompensationArrangementByOtherEquityInstrumentsGrantedInPeriodFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" name="SharebasedCompensationArrangementByOtherEquityInstrumentsVestedInPeriodFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" name="SharebasedCompensationArrangementByOtherEquityInstrumentsForfeitedInPeriodFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSingaporePteLtd.SingaporeMember" name="NovartisSingaporePteLtd.SingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" name="NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" name="NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" name="NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconSingaporeManufacturingPteLtdSingaporeMember" name="AlconSingaporeManufacturingPteLtdSingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" name="CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPteLtdSingaporeMember" name="AlconPteLtdSingaporeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" name="AlconLaboratoriesIndiaPrivateLimitedBangaloreMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SpinifexPharmaceuticalsInc.WilmingtonNCMember" name="SpinifexPharmaceuticalsInc.WilmingtonNCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EncoreVisionInc.NewYorkNYMember" name="EncoreVisionInc.NewYorkNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInvestmentLtd.HamiltonMember" name="NovartisInvestmentLtd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFinanceServicesLtd.HamiltonMember" name="NovartisFinanceServicesLtd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisB2Ltd.HamiltonMember" name="NovartisB2Ltd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisB3Ltd.HamiltonMember" name="NovartisB3Ltd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CibaGeigyJapanLimitedTokyoMember" name="CibaGeigyJapanLimitedTokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInternationalPharmaceuticalInvestmentAGBaselMember" name="NovartisInternationalPharmaceuticalInvestmentAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBioventuresAGBaselMember" name="NovartisBioventuresAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisForschungsstiftungBaselMember" name="NovartisForschungsstiftungBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisMitarbeiterbeteiligungsstiftungBaselMember" name="NovartisMitarbeiterbeteiligungsstiftungBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" name="FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZiarcoGroupLimitedFrimleyCamberleySurreyMember" name="ZiarcoGroupLimitedFrimleyCamberleySurreyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VivactaLimitedFrimleyCamberleySurreyMember" name="VivactaLimitedFrimleyCamberleySurreyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisUSFoundationNewYorkNYMember" name="NovartisUSFoundationNewYorkNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CortheraInc.SanMateoCAMember" name="CortheraInc.SanMateoCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CoStimPharmaceuticalsInc.CambridgeMAMember" name="CoStimPharmaceuticalsInc.CambridgeMAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ClarVistaMedicalInc.AlisoViejoCAMember" name="ClarVistaMedicalInc.AlisoViejoCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TriangleInternationalReinsuranceLimitedHamiltonMember" name="TriangleInternationalReinsuranceLimitedHamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TrinityRiverInsuranceCoLtd.HamiltonMember" name="TrinityRiverInsuranceCoLtd.HamiltonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisStiftungFuerKaderausbildungBaselMember" name="NovartisStiftungFuerKaderausbildungBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisStiftungFuerMenschUndUmweltBaselMember" name="NovartisStiftungFuerMenschUndUmweltBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" name="StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" name="SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock" name="DisclosureOfAssociatesNetIncomeEffectTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" name="DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" name="DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" name="DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" name="DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" name="GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DebtSecuritiesBreakdownByCurrencyTableTextBlock" name="DebtSecuritiesBreakdownByCurrencyTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SummaryOfTreasurySharesMovementsTableTextBlock" name="SummaryOfTreasurySharesMovementsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" name="USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" name="ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" name="ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfDefinedContributionPlansTableTextBlock" name="ScheduleOfDefinedContributionPlansTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" name="ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" name="DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" name="DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" name="DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" name="DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" name="DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" name="DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfTenDayLossFairValueVARModelTableTextBlock" name="DisclosureOfTenDayLossFairValueVARModelTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" name="DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" name="DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReprixysPharmaceuticalsCorporationMember" name="ReprixysPharmaceuticalsCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability" name="TaxRateEffectOfReleaseOfContingentConsiderationLiability" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxRateEffectFromNondeductibleLossesInRegion" name="TaxRateEffectFromNondeductibleLossesInRegion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DeferredTaxAssetAndLiabilityValuationAbstract" name="DeferredTaxAssetAndLiabilityValuationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" name="ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" name="ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" name="ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" name="ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" name="ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImpactLocationAxis" name="ImpactLocationAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImpactLocationMember" name="ImpactLocationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IncomeStatementMember" name="IncomeStatementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" name="IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_UndiscountedOperatingLeaseCommitments" name="UndiscountedOperatingLeaseCommitments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ContributionOfBusinessToJointVenture" name="ContributionOfBusinessToJointVenture" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" name="PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncomeTaxRelatingToAvailableforsaleFinanciaInvestmentsPreviouslyRecognizedThroughOCI" name="ImpactOfNewTaxLawIncomeTaxRelatingToAvailableforsaleFinanciaInvestmentsPreviouslyRecognizedThroughOCI" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI" name="ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUSPostRetirementPreviouslyRecognizedThroughOCI" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" name="ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" name="ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" name="ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" name="ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" name="AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" name="PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherIntangiblePurchaseCommitments" name="OtherIntangiblePurchaseCommitments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" name="ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OpenHedgesForAnticipatedTransactions" name="OpenHedgesForAnticipatedTransactions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" name="AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MostSignificantForeignExchangeLosses" name="MostSignificantForeignExchangeLosses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LongtermFinancialDebtWithACarryingAmount" name="LongtermFinancialDebtWithACarryingAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" name="UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NetInvestmentHedgeRecognizedInTheIncomeStatement" name="NetInvestmentHedgeRecognizedInTheIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_UpperLimitOnHoldingsOnUnrelatedCompany" name="UpperLimitOnHoldingsOnUnrelatedCompany" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCommercialPaperMaximumBorrowingAmount" name="BorrowingsCommercialPaperMaximumBorrowingAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DebtEquityRatio" name="DebtEquityRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_VAREstimateConfidenceInterval" name="VAREstimateConfidenceInterval" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCommercialPaperMaximumAmountOutstanding" name="BorrowingsCommercialPaperMaximumAmountOutstanding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCreditFacilityCommitted" name="BorrowingsCreditFacilityCommitted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_CounterpartyRiskAbstract" name="CounterpartyRiskAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashAndCashEquivalentsHeldWithFinancialInstitution" name="CashAndCashEquivalentsHeldWithFinancialInstitution" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VendorAxis" name="VendorAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VendorMember" name="VendorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LargestFinancialInstitutionMember" name="LargestFinancialInstitutionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SecondLargestFinancialInstitutionMember" name="SecondLargestFinancialInstitutionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ThirdLargestFinancialInstitutionMember" name="ThirdLargestFinancialInstitutionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PreTaxProfitLossFromDivestmentOfBusiness" name="PreTaxProfitLossFromDivestmentOfBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DivestmentDateFairValueOfTotalConsiderationTransferred" name="DivestmentDateFairValueOfTotalConsiderationTransferred" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_FuturePutOptionToSellBusiness" name="FuturePutOptionToSellBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PaymentPutOption" name="PaymentPutOption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_InterestExchanged" name="InterestExchanged" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LiabilitiesToBanksAndOtherInstitutions" name="LiabilitiesToBanksAndOtherInstitutions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationReceivableCurrent" name="ContingentConsiderationReceivableCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfDivestmentsOtherProvisions" name="ImpactOfDivestmentsOtherProvisions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfFinancialInstrumentsNarrativeTable" name="DisclosureOfFinancialInstrumentsNarrativeTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CustomersWithNetSalesOverFivePercent" name="CustomersWithNetSalesOverFivePercent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" name="NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContingentConsiderationReceivablesShorttermMember" name="ContingentConsiderationReceivablesShorttermMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OptionsExcludedFromTheCalculation" name="OptionsExcludedFromTheCalculation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MilestonePaymentAlreadyReceived" name="MilestonePaymentAlreadyReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_USCommercialPaperProgramsMember" name="USCommercialPaperProgramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_JPCommercialPaperProgramsMember" name="JPCommercialPaperProgramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCommercialPaperNumberOfPrograms" name="BorrowingsCommercialPaperNumberOfPrograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" name="AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" name="AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsAAAMember" name="AdvancedAcceleratorApplicationsAAAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PercentageOfShareCapitalInTenderOffer" name="PercentageOfShareCapitalInTenderOffer" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashOfferPerOrdinaryShare" name="CashOfferPerOrdinaryShare" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashOfferPerADS" name="CashOfferPerADS" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NumberOfOrdinarySharePerADS" name="NumberOfOrdinarySharePerADS" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ValueOfEquity" name="ValueOfEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_MaximalAmountOfShareBuybackProgramm" name="MaximalAmountOfShareBuybackProgramm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAnnualIncentive" name="DescriptionOfAnnualIncentive" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfBusinessUnits" name="NumberOfBusinessUnits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" name="RevenueFromSaleOfGoodsThirdPartiesChangeInPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonCurrentFinancialDebtsMember" name="NonCurrentFinancialDebtsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" name="CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContractRightOfFirstNegotiationTerm" name="ContractRightOfFirstNegotiationTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_IntangibleAssetImpairmentChargesTextBlock" name="IntangibleAssetImpairmentChargesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" name="PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AcquisitionFairValuePotentiallyRefundableContingentConsideration" name="AcquisitionFairValuePotentiallyRefundableContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DivestmentFairValueOfContingentConsiderationReceived" name="DivestmentFairValueOfContingentConsiderationReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" name="AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MaximumMarginPercentageImpactOfCommodityPriceChange" name="MaximumMarginPercentageImpactOfCommodityPriceChange" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MaximumHoldingInUnrelatedCompany" name="MaximumHoldingInUnrelatedCompany" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialReceivableFromDivestment" name="PotentialReceivableFromDivestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ChangeOverPeriodAxis" name="ChangeOverPeriodAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BasisOfPreparationAbstract" name="BasisOfPreparationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SelectedCriticalAccountingPoliciesAbstract" name="SelectedCriticalAccountingPoliciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LegalProceedingsUpdateAbstract" name="LegalProceedingsUpdateAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LegalProceedingsUpdateTextBlock" name="LegalProceedingsUpdateTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImpactsOfAdoptionOfNewIFRSStandardsAbstract" name="ImpactsOfAdoptionOfNewIFRSStandardsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactsOfAdoptionOfNewIFRSStandardsTextBlock" name="ImpactsOfAdoptionOfNewIFRSStandardsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" name="DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForOtherRevenueTextBlock" name="DescriptionOfAccountingPolicyForOtherRevenueTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConsolidatedBalanceSheetByTheAdoptionOfIFRS15TableTextBlock" name="ConsolidatedBalanceSheetByTheAdoptionOfIFRS15TableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConsolidatedStatementOfChangesInEquityByTheAdoptionOfIFRS9AndIFRS15TableTextBlock" name="ConsolidatedStatementOfChangesInEquityByTheAdoptionOfIFRS9AndIFRS15TableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialInstrumentsAdditionalDisclosuresTableByTheAdoptionOfIFRS9TableTextBlock" name="FinancialInstrumentsAdditionalDisclosuresTableByTheAdoptionOfIFRS9TableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" name="DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" name="DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AveXisIncMember" name="AveXisIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" name="IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member" name="IncreaseDecreaseDueToChangesInAccountingPolicyIFRS15Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OCIReservesMember" name="OCIReservesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RetailGenericsMember" name="RetailGenericsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BiopharmaceuticalsMember" name="BiopharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AntiInfectivesMember" name="AntiInfectivesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SurgicalMember" name="SurgicalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_VisionCareMember" name="VisionCareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ConsumablesMember" name="ConsumablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImplantablesMember" name="ImplantablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquipmentOtherMember" name="EquipmentOtherMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OphthalmicOTCMember" name="OphthalmicOTCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ContactLensCareMember" name="ContactLensCareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Top20ProductsMember" name="Top20ProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RestOfPortfolioMember" name="RestOfPortfolioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProfitSharingIncome" name="ProfitSharingIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MilestoneIncome" name="MilestoneIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherRevenueOther" name="OtherRevenueOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" name="ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CanadaAndLatinAmericaMember" name="CanadaAndLatinAmericaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" name="RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EstablishedMarketsMember" name="EstablishedMarketsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EmergingGrowthMarketsMember" name="EmergingGrowthMarketsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RestOfTheWorldMember" name="RestOfTheWorldMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.5EUR750Million20182023OfNovartisMember" name="A0.5EUR750Million20182023OfNovartisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.375EUR750Million20182030OfNovartisMember" name="A1.375EUR750Million20182030OfNovartisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.7EUR750Million20182038OfNovartisMember" name="A1.7EUR750Million20182038OfNovartisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GalvusGroupMember" name="GalvusGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DiovanGroupMember" name="DiovanGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExforgeGroupMember" name="ExforgeGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AntiInfectivesSoldUnderSandozNameMember" name="AntiInfectivesSoldUnderSandozNameMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueAdjustmentsOnFinancialAssetsSold" name="FairValueAdjustmentsOnFinancialAssetsSold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ProductPortfolioAxis" name="ProductPortfolioAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherSharePurchasesValue" name="OtherSharePurchasesValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LutatheraMember" name="LutatheraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_KymriahMember" name="KymriahMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" name="PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" name="ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" name="TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TransactionCostsRecordedInEquityTextBlock" name="TransactionCostsRecordedInEquityTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TransactionsWithRelatedPartiesAbstract" name="TransactionsWithRelatedPartiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionsWithRelatedPartiesTextBlock" name="TransactionsWithRelatedPartiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionCostsRecordedInEquityPaid" name="TransactionCostsRecordedInEquityPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionCostsRecordedInEquity" name="TransactionCostsRecordedInEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" name="OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9FundInvestments" name="IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9FundInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9EquitySecurities" name="IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9EquitySecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPensionFundMember" name="NovartisPensionFundMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCreditFacilityUncommitted" name="BorrowingsCreditFacilityUncommitted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OtherNetAssets" name="OtherNetAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_OcularHealthMember" name="OcularHealthMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" name="A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" name="A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" name="A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsInternationalSAGeneveMember" name="AdvancedAcceleratorApplicationsInternationalSAGeneveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" name="AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisposalGroupHeldForSaleAbstract" name="DisposalGroupHeldForSaleAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisposalGroupHeldForSaleLineItems" name="DisposalGroupHeldForSaleLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ChangeInCashSettledShareBasedPaymentsLiabilities" name="ChangeInCashSettledShareBasedPaymentsLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowNoncontrollingInterests" name="CashInflowOutflowNoncontrollingInterests" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmountRecordedInEquityRelatedToHyperinflation" name="AmountRecordedInEquityRelatedToHyperinflation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdditionsToInvestmentInAssociatedCompanies" name="AdditionsToInvestmentInAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate" name="FinancialAndOtherAssetsIncludingDeferredTaxAssetsRecognisedAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities" name="OtherComprehensiveIncomeNetOfTaxDebtSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TransactionCosts" name="TransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GainOnDivestmentOfInterestsInAssociatedCompanies" name="GainOnDivestmentOfInterestsInAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueAdjustmentsOnDebtSecuritiesMember" name="FairValueAdjustmentsOnDebtSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueAdjustmentsOnEquitySecuritiesMember" name="FairValueAdjustmentsOnEquitySecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReclassificationToPresentationRequiredUnderIFRS9Member" name="ReclassificationToPresentationRequiredUnderIFRS9Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RestatedValueAdjustmentsMember" name="RestatedValueAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NoncurrentFinancialAssetsEquityInvestments" name="NoncurrentFinancialAssetsEquityInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NoncurrentFinancialAssetsFundInvestments" name="NoncurrentFinancialAssetsFundInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ListedEquitySecuritiesMember" name="ListedEquitySecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonlistedEquitySecuritiesMember" name="NonlistedEquitySecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" name="DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" name="DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EndocyteMember" name="EndocyteMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" name="DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" name="DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" name="DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" name="DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies" name="DivestmentsAquisitionsOfInterestsInAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherShareSales" name="OtherShareSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherShareSalesEquityImpact" name="OtherShareSalesEquityImpact" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfOtherShareSales" name="NumberOfOtherShareSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfOtherShareSalesEquityImpact" name="NumberOfOtherShareSalesEquityImpact" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeDebtSecurities" name="OtherComprehensiveIncomeDebtSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" name="NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisAustraliaPtyLtdMacquarieParkNSWMember" name="NovartisAustraliaPtyLtdMacquarieParkNSWMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPtyLtdMacquarieParkNSWMember" name="SandozPtyLtdMacquarieParkNSWMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" name="AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaNVVilvoordeMember" name="NovartisPharmaNVVilvoordeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozNVVilvoordeMember" name="SandozNVVilvoordeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconCouvreurNVPuursMember" name="AlconCouvreurNVPuursMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconLaboratoriesBelgiumBVBAPuursMember" name="AlconLaboratoriesBelgiumBVBAPuursMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconNVVilvoordeMember" name="AlconNVVilvoordeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconAGFribourgMember" name="AlconAGFribourgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" name="AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CIBAVisionCorporationLLCDuluthGAMember" name="CIBAVisionCorporationLLCDuluthGAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReprixysPharmaceuticalsCorporationEastHanoverNJMember" name="ReprixysPharmaceuticalsCorporationEastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPolandSp.ZO.o.WarsawMember" name="NovartisPolandSp.ZO.o.WarsawMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPolskaSp.ZO.o.WarsawMember" name="SandozPolskaSp.ZO.o.WarsawMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconPolskaSp.ZO.o.WarsawMember" name="AlconPolskaSp.ZO.o.WarsawMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconHealthcareS.A.BarcelonaMember" name="AlconHealthcareS.A.BarcelonaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozUkraineLLCKievMember" name="SandozUkraineLLCKievMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DivestmentCostToSell" name="DivestmentCostToSell" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmountOfSettlementInPrinciple" name="AmountOfSettlementInPrinciple" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_NavigateBioPharmaServicesInc.CarlsbadCAMember" name="NavigateBioPharmaServicesInc.CarlsbadCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfProductsInPortfolioToBeSold" name="NumberOfProductsInPortfolioToBeSold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CarryingValueOfTheDivestedBusiness" name="CarryingValueOfTheDivestedBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ShortTermLeasesAndLowValueLeases" name="ShortTermLeasesAndLowValueLeases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_RemainingLeaseCommitments" name="RemainingLeaseCommitments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_LeaseLiabilitiesToBeRecognized" name="LeaseLiabilitiesToBeRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_RightOfUseAssetsToBeRecognized" name="RightOfUseAssetsToBeRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" name="NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_NovartisInvestmentsS.aR.l.LuxembourgCityMember" name="NovartisInvestmentsS.aR.l.LuxembourgCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFinanceS.A.LuxembourgCityMember" name="NovartisFinanceS.A.LuxembourgCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TearFilmInnovationsInc.FortWorthTXMember" name="TearFilmInnovationsInc.FortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TrueVisionSystemsInc.FortWorthTXMember" name="TrueVisionSystemsInc.FortWorthTXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TranscendMedicalInc.LakeForestILMember" name="TranscendMedicalInc.LakeForestILMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBalticsSIARigaMember" name="NovartisBalticsSIARigaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisOverseasInvestmentsAGBaselMember" name="NovartisOverseasInvestmentsAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_JapatAGBaselMember" name="JapatAGBaselMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AlconManagementSAGenevaMember" name="AlconManagementSAGenevaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EndocyteInc.LafayetteINMember" name="EndocyteInc.LafayetteINMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OrielTherapeuticsInc.DurhamNCMember" name="OrielTherapeuticsInc.DurhamNCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_WaveLightInc.SterlingVAMember" name="WaveLightInc.SterlingVAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisBiosciencesPeruS.A.LimaMember" name="NovartisBiosciencesPeruS.A.LimaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesWithRestrictedUse" name="TreasurySharesWithRestrictedUse" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CommitmentForRepurchaseOwnShares" name="CommitmentForRepurchaseOwnShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NoncurrentFinancialAsstetsDebtSecurities" name="NoncurrentFinancialAsstetsDebtSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" name="AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DepreciationChargePriorToClassificationToAssetsHeldForSale" name="DepreciationChargePriorToClassificationToAssetsHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProformaNetSales" name="ProformaNetSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SerelaxinMember" name="SerelaxinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CyPassMember" name="CyPassMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeStatementAdjustmentsOfPriorYear" name="IncomeStatementAdjustmentsOfPriorYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncomeStatementAdjustmentsOfCurrentYear" name="IncomeStatementAdjustmentsOfCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PlansAndProgramRebatesAxis" name="PlansAndProgramRebatesAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" name="AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSale" name="ImpairmentChargesRelatedToDisposalGroupHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" name="ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdditionsIncludedInDisposalGroupToTheDateOfReclassification" name="AdditionsIncludedInDisposalGroupToTheDateOfReclassification" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" name="NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NoncurrentAssetsDivested" name="NoncurrentAssetsDivested" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentAssetsDivested" name="CurrentAssetsDivested" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentLiabilitiesDivested" name="CurrentLiabilitiesDivested" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialAndOtherAssets" name="FinancialAndOtherAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" name="CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TradePayablesAndOtherLiabilities" name="TradePayablesAndOtherLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests" name="CashInflowOutflowFromNetIdentifiableAssetsCurrencyTranslationEffectsLiquidityAndFairValueOfEquityInterests" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" name="LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" name="MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PlansAndProgramRebatesMember" name="PlansAndProgramRebatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_USspecificHealthcarePlansAndProgramRebatesMember" name="USspecificHealthcarePlansAndProgramRebatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonUSspecificHealthcarePlansAndProgramRebatesMember" name="NonUSspecificHealthcarePlansAndProgramRebatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" name="NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" name="UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice46.7Member" name="ExercisePrice46.7Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice54.5Member" name="ExercisePrice54.5Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice57.0Member" name="ExercisePrice57.0Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice57.6Member" name="ExercisePrice57.6Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice66.0Member" name="ExercisePrice66.0Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice46.4Member" name="ExercisePrice46.4Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice53.7Member" name="ExercisePrice53.7Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice57.1Member" name="ExercisePrice57.1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice58.3Member" name="ExercisePrice58.3Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice66.1Member" name="ExercisePrice66.1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PrepaymentsAndAccruedLeasePayments" name="PrepaymentsAndAccruedLeasePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" name="RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" name="AssetsOfDisposalGroupClassifiedAsHeldForSaleAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" name="LiabilitiesOfDisposalGroupClassifiedAsHeldForSaleAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AmortizationPriorToClassificationToAssetsHeldForSale" name="AmortizationPriorToClassificationToAssetsHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" name="NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LongTermFinancialInvestmentsMember" name="LongTermFinancialInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MarketableSecurities" name="MarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_MajorPlansPercentageInGroupDBOPensions" name="MajorPlansPercentageInGroupDBOPensions" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" name="MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NoncurrentFinancialAssetsTotalFinancialInvestments" name="NoncurrentFinancialAssetsTotalFinancialInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" name="NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI" name="DeferredTaxOnPensionPlansPreviouslyRecognizedInOCI" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfDiscontinuedOperationsAbstract" name="DisclosureOfDiscontinuedOperationsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_YoYChangeMember" name="YoYChangeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PresentationOfLeasesForLessesTable" name="PresentationOfLeasesForLessesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PresentationOfLeasesForLesseeLineItems" name="PresentationOfLeasesForLesseeLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NewLeaseArrangements" name="NewLeaseArrangements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_UndiscountedFutureLeasePayments" name="UndiscountedFutureLeasePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectOfDiscounting" name="EffectOfDiscounting" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" name="DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" name="DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" name="DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentStatedMember" name="CurrentStatedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SaleOrIssueOfTreasurySharesNumberOfShares" name="SaleOrIssueOfTreasurySharesNumberOfShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DetailedInformationAboutSignificantTransaction" name="DetailedInformationAboutSignificantTransaction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TakedaPharmaceuticalCompanyLimitedMember" name="TakedaPharmaceuticalCompanyLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IFMTreInc.Member" name="IFMTreInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PowerVisionInc.Member" name="PowerVisionInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdjustmentsForPrepaymentsAndAccruedLeasePayments" name="AdjustmentsForPrepaymentsAndAccruedLeasePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialMilestoneMaximumPayments" name="PotentialMilestoneMaximumPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfEmployeesAssociatedWithTheProductTransfer" name="NumberOfEmployeesAssociatedWithTheProductTransfer" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AdditionalBorrowings" name="AdditionalBorrowings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PercentageOfEquityInterestSharesReceived" name="PercentageOfEquityInterestSharesReceived" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" name="DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DistributionOfDividendBearingSharesToConsolidatedFoundations" name="DistributionOfDividendBearingSharesToConsolidatedFoundations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AimovigMember" name="AimovigMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" name="LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughExerciseOfOptionsShares" name="IncreaseDecreaseThroughExerciseOfOptionsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares" name="IncreaseDecreaseThroughShareBasedPaymentTransactionsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RepaymentOfLeaseLiability" name="RepaymentOfLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_WeightedAverageInterestRateLeaseLiabilities" name="WeightedAverageInterestRateLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MovementsOfTheRightofuseAssetsRollForward" name="MovementsOfTheRightofuseAssetsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LeaseContractTerminationsRightofuseAssets" name="LeaseContractTerminationsRightofuseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" name="IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" name="SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxesOnTreasuryShares" name="TaxesOnTreasuryShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LeaseIncentives" name="LeaseIncentives" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowForLeases" name="CashInflowForLeases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetAssetsDerecognized" name="NetAssetsDerecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DistributionOfDividendToDividendBearingShares" name="DistributionOfDividendToDividendBearingShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" name="DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetProvisionsForTransactionCostsRecognizedInTheIncomeStatement" name="NetProvisionsForTransactionCostsRecognizedInTheIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsAttributableToDivestedBusiness" name="CashFlowsAttributableToDivestedBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinancialAndOtherNoncurrentAssets" name="FinancialAndOtherNoncurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TradeReceivablesAndOtherCurrentAssets" name="TradeReceivablesAndOtherCurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TradePayablesProvisionsAndOtherLiabilities" name="TradePayablesProvisionsAndOtherLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CurrentAndNoncurrentFinancialDebt" name="CurrentAndNoncurrentFinancialDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" name="RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" name="ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfRightofuseAssetsRollForwardTableTextBlock" name="DisclosureOfRightofuseAssetsRollForwardTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" name="DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" name="DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" name="AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NoncurrentLeaseLiabilitiesMember" name="NoncurrentLeaseLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentLeaseLiabilitiesMember" name="CurrentLeaseLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ApplicableTaxRateExcludingExceptionalItems" name="ApplicableTaxRateExcludingExceptionalItems" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" name="CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DivestedCashAndCashEquivalents" name="DivestedCashAndCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CustomaryPurchasePriceAdjustment" name="CustomaryPurchasePriceAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RepaymentOfIntercompanyBalances" name="RepaymentOfIntercompanyBalances" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxReformImpactOnDeferredTaxOnTreasuryShares" name="TaxReformImpactOnDeferredTaxOnTreasuryShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DividendPaidNoncashAssetsDistribution" name="DividendPaidNoncashAssetsDistribution" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" name="DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" name="DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" name="ConsolidatedIncomeStatementDiscontinuedOperationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" name="DisclosureOfItemsIncludedInNetIncomeFromDiscontinuedOperationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfNetAssetsDerecognizedTableTextBlock" name="DisclosureOfNetAssetsDerecognizedTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" name="FairValueOfAssetsAndLiabilitiesArisingFromDivestmentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DistributionByWayOfDivindendInKindToShareholders" name="DistributionByWayOfDivindendInKindToShareholders" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TheMedicinesCompanyMember" name="TheMedicinesCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PiqrayMember" name="PiqrayMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZolgensmaMember" name="ZolgensmaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MayzentMember" name="MayzentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" name="DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" name="DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" name="DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" name="AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetDeferredTaxBalanceRelatedToDiscontinuedOperations" name="NetDeferredTaxBalanceRelatedToDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AspenGlobalIncorporatedMember" name="AspenGlobalIncorporatedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_MinimumFinaceLeasePaymentsReceivableAtPresentValue" name="MinimumFinaceLeasePaymentsReceivableAtPresentValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" name="InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReclassificationFromNoncurrentToCurrentNet" name="ReclassificationFromNoncurrentToCurrentNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationPayable" name="ContingentConsiderationPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" name="IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BorrowingsUSDMember" name="BorrowingsUSDMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BorrowingsEURMember" name="BorrowingsEURMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FinanceLeaseLiabilities" name="FinanceLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EquityBasedCompensationShares" name="EquityBasedCompensationShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ExerciseOfOptionsAndEmployeeTransactionsShares" name="ExerciseOfOptionsAndEmployeeTransactionsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ExerciseOfOptionsAndEmployeeTransactionsValue" name="ExerciseOfOptionsAndEmployeeTransactionsValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_SharesDeliveredToDivestedBusinessEmployees" name="SharesDeliveredToDivestedBusinessEmployees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" name="ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" name="PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" name="NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities" name="DerivativeFinancialInstrumentsOptionsOnEquitySecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" name="EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AdditionalAmountOfSettlementInPrinciple" name="AdditionalAmountOfSettlementInPrinciple" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AmountOfResolvedAction" name="AmountOfResolvedAction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_EnoxaparinMember" name="EnoxaparinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozManufacturingInc.Member" name="SandozManufacturingInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" name="ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" name="SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CELLforCUREMember" name="CELLforCUREMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisManufacturingGmbHMember" name="NovartisManufacturingGmbHMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyMember" name="NovartisHungaryHealthcareLimitedLiabilityCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvacedAcceleratorApplicationsItalyS.r.l.Member" name="AdvacedAcceleratorApplicationsItalyS.r.l.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IDBHollandBVMember" name="IDBHollandBVMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvacedAcceleratorApplicationsIbericaS.L.U.Member" name="AdvacedAcceleratorApplicationsIbericaS.L.U.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImagingEquipmentLtdMember" name="ImagingEquipmentLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInflammasomeResearchInc.Member" name="NovartisInflammasomeResearchInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisTechnologyLLCMember" name="NovartisTechnologyLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" name="PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PartialReleaseOfDeferredTaxLiabilityRecognized" name="PartialReleaseOfDeferredTaxLiabilityRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LeaseLiabilitiesUndiscounted" name="LeaseLiabilitiesUndiscounted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_MostMaterialLeaseWithLeaseTermExtension" name="MostMaterialLeaseWithLeaseTermExtension" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CashOutflowsForShortTermAndLowValueLeases" name="CashOutflowsForShortTermAndLowValueLeases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashOutflowsForPaymentsOfLeasesInterest" name="CashOutflowsForPaymentsOfLeasesInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" name="ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" name="ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_LongTermReceivablesFromFinanceSubleases" name="LongTermReceivablesFromFinanceSubleases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" name="DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_BorrowingsCreditFacilityShortTerm" name="BorrowingsCreditFacilityShortTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_BeovuMember" name="BeovuMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetCashOutflowsFromDivestments" name="NetCashOutflowsFromDivestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentLiabilitiesMember" name="CurrentLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NoncurrentLiabilitiesMember" name="NoncurrentLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentLeaseLiabilitiesUndiscounted" name="CurrentLeaseLiabilitiesUndiscounted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NoncurrentLeaseLiabilitiesUndiscounted" name="NoncurrentLeaseLiabilitiesUndiscounted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ImpairmentChargePriorToClassificationToAssetsHeldForSale" name="ImpairmentChargePriorToClassificationToAssetsHeldForSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TaxOnTransactionCostsRecordedInEquity" name="TaxOnTransactionCostsRecordedInEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectOfWriteoffOfDeferredTaxAssets" name="EffectOfWriteoffOfDeferredTaxAssets" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ProceedsFromCurrentAndNoncurrentBorrowings" name="ProceedsFromCurrentAndNoncurrentBorrowings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_UncalledCapitalCommitmentsForInvestmentsInFunds" name="UncalledCapitalCommitmentsForInvestmentsInFunds" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_LitigationCaseMember" name="LitigationCaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TennesseeClassActionMember" name="TennesseeClassActionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MassachusettsCaseMember" name="MassachusettsCaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GrossDeferredTaxAssets" name="GrossDeferredTaxAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_GrossDeferredTaxLiabilities" name="GrossDeferredTaxLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AmountBorrowedUnderTheCreditFacility" name="AmountBorrowedUnderTheCreditFacility" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ContingentConsiderationLiabilities" name="ContingentConsiderationLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_XiidraMember" name="XiidraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" name="ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PercentageOfEntitysTradeReceivable" name="PercentageOfEntitysTradeReceivable" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashInflowForSaleAndLeaseback" name="CashInflowForSaleAndLeaseback" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SaleAndLeaseBackMember" name="SaleAndLeaseBackMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract" name="DerivativeFinancialInstrumentsCommodityPurchaseContract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DisposalsAndRetirementsRightofuseAssets" name="DisposalsAndRetirementsRightofuseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain" name="EffectOfIncomeNotSubjectToTaxOnDivestmentGain" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" name="SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CELLforCURELesUlisMember" name="CELLforCURELesUlisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" name="AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisNetherlandsB.V.AmsterdamMember" name="NovartisNetherlandsB.V.AmsterdamMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaB.V.AmsterdamMember" name="NovartisPharmaB.V.AmsterdamMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IDBHollandBVBaarleNassauMember" name="IDBHollandBVBaarleNassauMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisSaudiLtd.RiyadhMember" name="NovartisSaudiLtd.RiyadhMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisUKLimitedLondonMember" name="NovartisUKLimitedLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisPharmaceuticalsUKLimitedLondonMember" name="NovartisPharmaceuticalsUKLimitedLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisGrimsbyLimitedLondonMember" name="NovartisGrimsbyLimitedLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImagingEquipmentLtdLondonMember" name="ImagingEquipmentLtdLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZiarcoGroupLimitedLondonMember" name="ZiarcoGroupLimitedLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFinanceCorporationEastHanoverNJMember" name="NovartisFinanceCorporationEastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationEastHanoverNJMember" name="NovartisCapitalCorporationEastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisUSFoundationEastHanoverNJMember" name="NovartisUSFoundationEastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" name="AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInflammasomeResearchInc.EastHanoverNJMember" name="NovartisInflammasomeResearchInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisTechnologyLLCInc.EastHanoverNJMember" name="NovartisTechnologyLLCInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EncoreVisionInc.EastHanoverNJMember" name="EncoreVisionInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EndocyteInc.EastHanoverNJMember" name="EndocyteInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" name="NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SpinifexPharmaceuticalsInc.EastHanoverNJMember" name="SpinifexPharmaceuticalsInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisManufacturingGmbHMarburgMember" name="NovartisManufacturingGmbHMarburgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EffectOfUSTaxReformLegislation" name="EffectOfUSTaxReformLegislation" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_AcquiredCashAndCashEquivalents" name="AcquiredCashAndCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" name="DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" name="ConsolidatedIncomeStatementAdditionalInformationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BalanceSheetAdditionalInformationTableTextBlock" name="BalanceSheetAdditionalInformationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashFlowsUsedInInvestingActivitiesTableTextBlock" name="CashFlowsUsedInInvestingActivitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" name="CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_UltibroGroupMember" name="UltibroGroupMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdakveoMember" name="AdakveoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ReportedValueMember" name="ReportedValueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" name="NovartisCapitalCorporationNewYorkUnitedStates1.752025Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" name="NovartisCapitalCorporationNewYorkUnitedStates2.002027Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" name="NovartisCapitalCorporationNewYorkUnitedStates2.202030Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" name="NovartisCapitalCorporationNewYorkUnitedStates2.752050Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PoPChangeMember" name="PoPChangeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PoPYEChangeMember" name="PoPYEChangeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ZPL389Member" name="ZPL389Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueOfOtherFinancialAssetsSold" name="FairValueOfOtherFinancialAssetsSold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RightOfUseAssetsAsOfAcquisitionDate" name="RightOfUseAssetsAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" name="CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PrepaidSalesPriceForABusinessDivestment" name="PrepaidSalesPriceForABusinessDivestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrentRefundsProvisionDiscontinuedOperations" name="CurrentRefundsProvisionDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ProvisionForDoubtfulReceivable" name="ProvisionForDoubtfulReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" name="DefinedBenefitObligationDiscontinuedOperationsAtPresentValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_LeaseLiabilitiesImpactOfAdoptionOfIFRS16" name="LeaseLiabilitiesImpactOfAdoptionOfIFRS16" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" name="ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_GrossLeaseLiabilitiesDiscontinuedOperations" name="GrossLeaseLiabilitiesDiscontinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" name="IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_TreasurySharesMovementOfPeriod" name="TreasurySharesMovementOfPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DecreaseInFinanceLeasesReceivableDueToUnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" name="DecreaseInFinanceLeasesReceivableDueToUnearnedFinanceIncomeRelatingToFinanceLeasePaymentsReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_OtherFinancialLiabilitiesCategoryMember" name="OtherFinancialLiabilitiesCategoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherCurrentAssetsMember" name="OtherCurrentAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueAdjustmentsOnFinancialInstrumentsMember" name="FairValueAdjustmentsOnFinancialInstrumentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" name="ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RepurchaseOfOptions" name="RepurchaseOfOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets" name="AcquisitionsThroughBusinessCombinationsRightofuseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_TabrectaMember" name="TabrectaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_KesimptaMember" name="KesimptaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" name="OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" name="A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" name="A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" name="A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" name="A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" name="A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" name="AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" name="IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" name="AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfOptionsRepurchased" name="NumberOfOptionsRepurchased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfTreasuryShares" name="NumberOfTreasuryShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_NotSubjectToExpiryMember" name="NotSubjectToExpiryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CommitmentForRepurchaseOfOwnSharesMember" name="CommitmentForRepurchaseOfOwnSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" name="DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" name="ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_TaxLossCarryForwards" name="TaxLossCarryForwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" name="ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_BorrowingsInterestRateStepUp" name="BorrowingsInterestRateStepUp" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_NoncurrentAssetsMember" name="NoncurrentAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EstimatedAcquisitionFairValueOfTotalConsideration" name="EstimatedAcquisitionFairValueOfTotalConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_SparkTherapeuticsInc.Member" name="SparkTherapeuticsInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" name="NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisGeneTherapiesEULimitedDublinMember" name="NovartisGeneTherapiesEULimitedDublinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AspenJapanK.K.TokyoMember" name="AspenJapanK.K.TokyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozPhilippinesCorporationMakatiCityMember" name="SandozPhilippinesCorporationMakatiCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisIsraelLtd.TelAvivMember" name="NovartisIsraelLtd.TelAvivMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisHealthcarePhilippinesInc.MakatiCityMember" name="NovartisHealthcarePhilippinesInc.MakatiCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" name="AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" name="CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsUKIrelandLondonMember" name="AdvancedAcceleratorApplicationsUKIrelandLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NeutecPharmaLimitedLondonMember" name="NeutecPharmaLimitedLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CoalesceProductDevelopmentLimitedCambridgeCambsMember" name="CoalesceProductDevelopmentLimitedCambridgeCambsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisOptogeneticsResearchInc.EastHanoverNJMember" name="NovartisOptogeneticsResearchInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AmblyotechInc.EastHanoverNJMember" name="AmblyotechInc.EastHanoverNJMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisVietnamCompanyLimitedHoChiMinhCityMember" name="NovartisVietnamCompanyLimitedHoChiMinhCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisDeutschlandGmbHNurembergMember" name="NovartisDeutschlandGmbHNurembergMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" name="DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfBrandsInPortfolioToAcquire" name="NumberOfBrandsInPortfolioToAcquire" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_NumberOfMarketsForTheAcquiredBrands" name="NumberOfMarketsForTheAcquiredBrands" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_TotalAntiinfectivesNetSalesMember" name="TotalAntiinfectivesNetSalesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GlaxoSmithKlinePlcGSKMember" name="GlaxoSmithKlinePlcGSKMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SolidTumorMember" name="SolidTumorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_HematologyMember" name="HematologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_LeqvioMember" name="LeqvioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationAnnualIncentiveRSUMember" name="EquityBasedParticipationAnnualIncentiveRSUMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" name="EquityBasedParticipationAnnualIncentiveRestrictedSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationAnnualIncentiveSharesMember" name="EquityBasedParticipationAnnualIncentiveSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationShareSavingsPlansRSUMember" name="EquityBasedParticipationShareSavingsPlansRSUMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationShareSavingsPlansSharesMember" name="EquityBasedParticipationShareSavingsPlansSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" name="EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" name="BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" name="EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationLongTermPerformancePSUPlanMember" name="EquityBasedParticipationLongTermPerformancePSUPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationLongTermRelativePerformancePlanPSUMember" name="EquityBasedParticipationLongTermRelativePerformancePlanPSUMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationOtherShareAwardsRSUMember" name="EquityBasedParticipationOtherShareAwardsRSUMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" name="EquityBasedParticipationOtherShareAwardsRestrictedSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationOtherShareAwardsSharesMember" name="EquityBasedParticipationOtherShareAwardsSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock" name="PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" name="PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock" name="PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock" name="PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GyroscopeTherapeuticsHoldingsPlcMember" name="GyroscopeTherapeuticsHoldingsPlcMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CommitmentsForLeasesNotYetCommenced" name="CommitmentsForLeasesNotYetCommenced" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="true" id="nvs_ContractManufacturingMember" name="ContractManufacturingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" name="PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock" name="PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" name="IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ExercisePrice65.9Member" name="ExercisePrice65.9Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" name="CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" name="CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" name="EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" name="EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" name="HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" name="HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_RespiratoryAndAllergyMember" name="RespiratoryAndAllergyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" name="ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_FairValueOfFundInvestmentsAndEquitySecurities" name="FairValueOfFundInvestmentsAndEquitySecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_PercentageOfGovernmentBackedDebtSecurities" name="PercentageOfGovernmentBackedDebtSecurities" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" name="NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ArctosMedicalAGBernMember" name="ArctosMedicalAGBernMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_KedalionTherapeuticsInc.MenloParkCAMember" name="KedalionTherapeuticsInc.MenloParkCAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CadentTherapeuticsCambridgeMAMember" name="CadentTherapeuticsCambridgeMAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfBearerShares" name="NumberOfBearerShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" name="RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_RelatedPartiesNumberOfExecutiveCommitteeMembers" name="RelatedPartiesNumberOfExecutiveCommitteeMembers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FairValueAdjustmentsOnEquitySecuritiesSoldMember" name="FairValueAdjustmentsOnEquitySecuritiesSoldMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember" name="IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" name="ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherPromotedBrandsMember" name="OtherPromotedBrandsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PluvictoMember" name="PluvictoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ScemblixMember" name="ScemblixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_MatureOphthaMember" name="MatureOphthaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherRespiratoryMember" name="OtherRespiratoryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NoncurrentContingentConsiderationLiabilitiesMember" name="NoncurrentContingentConsiderationLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CurrentFinancialLiabilitiesAtFairValueMember" name="CurrentFinancialLiabilitiesAtFairValueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NoncurrentFinancialLiabilitiesAtFairValueMember" name="NoncurrentFinancialLiabilitiesAtFairValueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherHematologyMember" name="OtherHematologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OtherSolidTumorMember" name="OtherSolidTumorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BrandsAxis" name="BrandsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_PromotedBrandsMember" name="PromotedBrandsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EstablishedBrandsMember" name="EstablishedBrandsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ImmunologyMember" name="ImmunologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CardiovascularMember" name="CardiovascularMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_BrandsMember" name="BrandsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DeferredSalePriceAndOtherAdjustments" name="DeferredSalePriceAndOtherAdjustments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" name="EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
   <xsd:element abstract="false" id="nvs_OtherNetCashInflowsFromDivestments" name="OtherNetCashInflowsFromDivestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashOutflowsDueToDerecognizedCashAndCashEquivalents" name="CashOutflowsDueToDerecognizedCashAndCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" name="AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" name="AcquisitionOfAssetsRightOfUseAssetsThroughLeasing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NumberOfCommercialOrganizationalUnits" name="NumberOfCommercialOrganizationalUnits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" name="ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FranchiseAxis" name="FranchiseAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_FranchiseMember" name="FranchiseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" name="CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" name="CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NoncurrentAndCurrentLiabilitiesDivested" name="NoncurrentAndCurrentLiabilitiesDivested" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_NetIdentifiableAssetsOfDivestedBusiness" name="NetIdentifiableAssetsOfDivestedBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DisclosureOfOperatingSegmentsNetSalesTableTextBlock" name="DisclosureOfOperatingSegmentsNetSalesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock" name="Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock" name="PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes" name="CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_InterestRateSensitivityImpactInTheIncomeStatement" name="InterestRateSensitivityImpactInTheIncomeStatement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_LeaseTermEndDate" name="LeaseTermEndDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:gYearItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity" name="HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember" name="EquityBasedParticipationEmployeeSharePurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember" name="NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember" name="AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_InterestIncomeOnLimitationOfFundSurplus" name="InterestIncomeOnLimitationOfFundSurplus" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" name="IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_ValueAdjustmentsRelatedToDivestmentsMember" name="ValueAdjustmentsRelatedToDivestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisFarmaS.p.A.MilanMember" name="NovartisFarmaS.p.A.MilanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember" name="NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_GyroscopeTherapeuticsLimitedLondonMember" name="GyroscopeTherapeuticsLimitedLondonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_PaymentOfInterestBearingAccountsToBeneficiaries" name="PaymentOfInterestBearingAccountsToBeneficiaries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" name="CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_JSCSandozMoscowMember" name="JSCSandozMoscowMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozSouthAfricaPtyLtdMidrandMember" name="SandozSouthAfricaPtyLtdMidrandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember" name="SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_CellerysAGSchlierenMember" name="CellerysAGSchlierenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisGeneTherapiesInc.BannockburnILMember" name="NovartisGeneTherapiesInc.BannockburnILMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_NovartisInnovativeTherapiesAGRischMember" name="NovartisInnovativeTherapiesAGRischMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember" name="AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_A1APharmaGmbHHolzkirchenMember" name="A1APharmaGmbHHolzkirchenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_DefinedBenefitPlanInterestCost" name="DefinedBenefitPlanInterestCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset" name="AdministrativeExpenseNetDefinedBenefitLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="false" id="nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset" name="InterestExpenseIncomeDefinedBenefitLiabilityAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_AmericanDepositarySharesEachRepresenting1ShareMember" name="AmericanDepositarySharesEachRepresenting1ShareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_OrdinarySharesNominalValueCHF0.50PerShareMember" name="OrdinarySharesNominalValueCHF0.50PerShareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Hypothetical100basisPointIncreaseMember" name="Hypothetical100basisPointIncreaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Hypothetical100basisPointDecreaseMember" name="Hypothetical100basisPointDecreaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Hypothetical15DecreaseMember" name="Hypothetical15DecreaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Hypothetical15IncreaseMember" name="Hypothetical15IncreaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Hypothetical5IncreaseMember" name="Hypothetical5IncreaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
   <xsd:element abstract="true" id="nvs_Hypothetical5DecreaseMember" name="Hypothetical5DecreaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>x_kpmg.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 x_kpmg.gif
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MS]74U-C7U]W<W>#?W^;EYNSL[/#O\/3S\_CW]_[^_@
M
M
M                                                 "'Y!
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MP1(*:( 1],A1L3J L+:2+T:TK5 -@!@ )W ]0[A@8X(R@ J8( DBK !M"V@
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'^M>T" 0 .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>x_coverfront.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 x_coverfront.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" 5/ \$# 1$  A$! Q$!_\0
M'0    <! 0$              0(#! 4&!P ("?_$ &80  $# P,!!@0$ P0%
M!0H 'P$" P0 !1$&$B$Q!Q,B05%A"!0R<4*!D:$5(U(S8K'!%B13<M$)%T."
MDB4THK*SM-+A\/$U1&-D<Y.5H],8&3=%5%5E=(,H5E=UE,(F)S9'A(7#_\0
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M39'!'6E?D/:-ULX.,4VA6)N-$)XQ0D*78;N)(J1!! C/6D.P>[&<4!8LVP"
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MX'_9J+F/8.F;;LX*/VJ/B$U!BP@H .0*6ZR6VA!^*RI)! JV+*I(B)-N;).
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M K814DJ&WBDQ]PH<(\Z7 Z"K>Z9- 4$+N?.D.@I<.>M 4!O]_P!Z!G;CZT
M5IQUI\""E8 R*0Q-2RH8Q30!:D F[C'6FB$NXU4KGBD!P61Y4 '3XO.B@' \
MJ"0HGZA28Q0<5$#E'(J4>X"3G3-28#5UQ1XHBR,D-E'CK3$-5K.2/2A$&K82
M@5"2GB/*F*QJ](X(H7<).T-''O>I$!)3W'6@!-4GWI!8GWW'-(DN1,JR>M(8
MDM9R13(!02>,T *!GSS10K%$LY-22%88L44%@I9/IF@.XH&U'R- J#H;.>E)
MH!RTE23FE19'L2T-PC'%1)^9-1,$X542SR'W=MI02#4B/<(K9CK2#D16M(]*
M5C$N]'G33!JPCKB2FFP2H8.I"R::[$&N1LIC)Z4#H2=C9\J;8)#9V+X3Q4;!
MK@;F)ZYHLC0@[&'0YXIIV#03Y9'I4R-'L4-#H1Q7!H])0A(:7M\(XJ4'3(35
MHBW4%.0KSJU-E+BB*E@!?'I5\)-*C/-*Q-E2T*W T^Y&VNQ*L3@$@%7055+&
MK;-$<CI)CT2F2.O[U%P1:IQ9QD(]3BHT@;H;N2VTG-2459!S9&3)X/"3YU8H
MHID[&*I*49.3D^M3V*BK<XO@;JG9/5/Z4TJ'=AD2DJ3DJ%#Y&G2%.^;4!DT4
M@MD;+>2I1 ]:LVI%+DR*DY42/6G17N9%26.<8-3[!W(]V/SYU--ON1DDE8S=
M;6D\4V(*$K)J+8TA9#1QG%%L*0Y80 >>M+EBH?MN!L#'6G062L29C'-5;47;
MF3,6\*96E04GPGS%0<51*,W9(G4!=;(4I/Y"H;(ECG(:*G]ZHC(Q2VI=AIWW
M&[[J<9!Y%24$R+E1&N2UDX)'Z58HI%4Y-C9Y94,YJ=E8Q>=6D8!HW,:0S<4?
M6A<DA .*SUJRD4AT.+"AS0TJ&A_'2IPBJV339*,QU(3G'6E9(72VHCD4 ' Q
MUI,$A]$>[M()I)(=M"KTS'.ZDX(5L;B6H$'=4=B&F[)6%=5I'U#]*@X(OCD:
M)-FYA:<*4/TJEP3+UFE5!7;FA R%"G'&B,LDB"N5R6\K)4//RJV$$K*,DVZ(
MA;N2>:M[%;Y$U*!.:'8J%&0":$#2)F#(V8 Q466IDB[)2MM0]0:K\R?D,5R
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MBI<C!^4>NZIQ0I,:N2E*X"JM2*9,3WD]#2H5BB'<)QDT423#?,@<9HH+$%.
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M0<T!8(:4>:!V.&VE$C-5$R0:BDC)'-2\A6',921G%+L%AVXY5G/I0V-,8SV
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M*A;@0^:5"W ]^?>B@W!PL$9J#)6<'>>* W,62]Y&BB=CAMS)ZBD^PXOD=LN
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MGYA+O\&_/Y/^3+CIE(.ONT3;YS[9_P"8(K=I_P!_F^<?_P!4YVJ_V^#Y2_\
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M(5WMJ<E*N4><3DHN*?#_ *&9?$VL*[*)(!_^R$/_ ,95<OK7^T?S1V/9]?\
M?E\F77LW='_-]IE)\K1$'_SI-;-'_M\?_2OR.?KE>JR?]3_,S'MI9U3HKM#L
MO;+9;<;C!@11#FM<D-)\8.[&2E*DN'"\8"ASUYY?4EETVHCK(*TE3_SXWW.U
MTEX=3I9Z#(Z;=K^7Y5V]"[Z6[4.SOM<MCME:D O26_Y]KF?RWL A64X.%@$
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M'N*S=0U4-/IY-]WPOFS9T[2RU.HBEV3M_)?J8Q\&VAKK$%VU[)96S#E1TVV
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MBP>RR2/_ +X1/_&57)ZU_M'\T=OV?=ZY?)ES[.G -!:; ZBTQ/\ R2:VZ/\
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M>4SZC+J,KS3?O?Y5?(\P:Z^$C5<&ZO/Z!E0[C:W5E3,>3)#,AA)Z()5X5@=
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M]4ZEAZABC'&FJ=\UZ?,DNVGX?;+VH23?K=,3:+^E 0N06RMF4E(PD.I'.0.
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M^U<A]2FG]D["Z3!K[3(U?_*-:E<&%=D5A_\ FK(_]"K/]7G_ ,%^)#_1<?\
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M:;NLJWSFVW&D2(JREP(<04+2"/ZDJ(_3S KFPG+&]T'3.MDQPRQVS5HW:?\
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MH-V1_ +=_P":MUZO$OV<?DOR/%YG^UE\W^9\NOBA?9_^F*[1 I]L'^/OY!6
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M!I]+%\7ZMT>S?A2[%-=:!TO+O_:7<KF[?[]W9$"9-<?-OC(R4H5N40'5$[E
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MYL=125^:HM';)\:^O>UC1DO0[>E[5IZW7)*47!R.^Z^\^V%!7=A2P A!(&<
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M\4#"*R?2@5,+N- ^0IRH8!Y-1H=G J1]1S0T2C-)VP2K/E4*+5D3"+R1Q37
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MHJR/1VF=G1./^<#2_/\ ]^HO_IU7XL/5?B:%@R?\7^#!<[2.SE2<#M#TO_\
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MK'Z5+Q>:%X)'3+,US@#/VJU9"IXD1$NP)QN!')Z;:FLE%4\2?"&Z=/[NF/\
MLT_%*_ !_@ 0>?\ Q:/$LE'#0L+.UW?/7[4>(A^$,W[.VI1 'GZ4U,B\?D-7
M=*%P$AKK[4>-0>!95[Q9U1"<JZ?W<58GR52B5R2"G(Q5Z7!G?<;\^5 P%(61
MP#3 1<;<2,X- [&;ZE^A%(A+N-E.<<J-!$:NNKR< XJ5\$7W$U.!0QTHL3&Z
MDK QN/Z5.T4[9":TN%/4TK'MD)*0YCS_ $I6&V00MN>8-"8]K\PBT+ ^DT-A
MM$-KAZ"EW)I4CMB_Z:8P=OO0 0C /-( B2<]*8@5$^GG0P!;;.2<]:@T3B"I
M!]*(JR3E0BMM0YH<1;T%"%'RHVCW'!M1.*-HMR#=VND3L,&5T!N![E7I10;C
M@TK/04!N#]VKTIAN/5AN"R,;!6?8:?%87YQ1ZI%'AH3R-@IG;>"!S0H(-[%D
M3T <XI[$-3="PN#9')HVH>\06^E3J5)/58_QIN-T0\1IGR NK3)NLX]RW_WV
M_P#@'^T57@9);F?2H-[43=O[+.T&[06+E:^SJ_3(DI <8?8M+KC;J#T4E03@
MCW%6QTV6:W1@VOD4RU6"#<932:^*'/\ S-=J/_Z*]3?_ #$>_P#0I_5,_P#P
M?X,C]=T__P"8OQ1[$^ JPZGT-8=:1]1:;N-E7,GPG&DS(:XY="6G 2D* W $
M@?G7:Z3IYQC/>FN5Y' ZUJ<<Y0\.2?#[.SU1_'%?B6#]S76\%'%\<#^- =<<
M^M'@H/'"NW@J1X0FI+"DB+SN^!NJY*4.=H_.I*"1%Y6_(X2\C/%2VH-P/S2?
M(IHVAN8*9.3Y4J!R#]_GC%)QL%*CDO9Y!I>&A^(Q=J5C(P.*'!$HS8LB5DXP
M.:A18G8N%DC-1:)&'?%1\1)[#--0X5@9CR=4WT+^10^G<U%91@+D.)_%@D)2
MGH59SPD@X-=JOJL4H_:?^6=#I^B^MS;E]E=_T/GY>-=]K?:I>B+GJ74^H[@^
M2I,9EUYWCSV,->%*1_=2 *\_++FSRY;;/31PX-/'A)+_ #S"V?7/:QV6WK%J
MU+J;3EQCD%<=QYYHCT"V7?"H'T4D@T1RY<$N&TPEBPZB/*31]!OA3^(M?;II
MN;;M1,1XVJ;"&S-#"=C4MA9(1(0G\'B!2M(X"L$<* '?T.K^LQ:E]I?Y9YSJ
M&B^J33C]E_R^!7?BQ^*M[LB<3H'00CO:LDL)>E2GD!QNUM+'@\!X6\H>(!7A
M2G"B#D"J]=KO _9X_M?D6=/Z?]9_:9/L_G_8\0_.]L_;)>'W6I&L-87%([QX
M,JD2BV#T)2CPMCT& /2N)>;4/SDSOU@TT?**^Y#S2_:MVT]B]_5'M6I+_99D
M18$FUW N*:/GM=C/<8(]@?0CK3AFS:>7#:^#_0CDT^#51MI->J_5'T7^'#M]
MM';UHYRYHC-V^_6M26+O;TK*DMK4"4.MD\EI>#C/*2%).<9/?TFI6IA?FNYY
MK6Z26DG7=/LS7 @$9S6HQAT^'H* /-/_ "A*4J[ 60M*5#_22!P1G\#]<[JG
M[C[T=7I'&H^Y_P!#YRVJQS[]<8]GLEF>N$^6ONV(L6,77758)PE"02HX!.!Z
M5P%%R=17)Z24E!;I.D6H=AG:^>G8_JW\K!(_]"K?J^7_ (/\"GZUA_YK\0'>
MPKMB4RX!V.ZN.4*&/X!(]/\ <I?5\O\ P?X#^LX?^:_$^NO9[&D0NS_2T*7'
M6P_'L=O:=:<24J;6F,V%)4#R""""/(BO38U4(I^B/(Y7>237J_S+(T@$;LTV
MZ8X=A7*D\ #%1MEB= ^](#CR,4"$%-@ G)JQ2*7$*V/'UH<K1&*IV*[12)OD
M2=0..301VG(;!&=QZT!M.6DHZ<T#2H!!W<$4[&(N'&0!4^$1H9N1E/D Y!Z4
M6/:<FU)Q_,X%24VB#Q)BS-NCH5D9/W%$\CDJ'CPI2L?IC,J0!L Q53=EZBD&
M$9H?AI;G$*08-(!R$TG)L=4*;04XZ5$!9/"0/:@ ^T5#<2HY(&:-UA0H#B@9
MVXT"9VXT"L,E1Q29.,F#N-%$MS%D_2*1) T =D>M.D0W,!0"AC-' -MA"TD_
MBID0BT!&-ISF@ 4-A8RHXI/D P:3ZFBZ)*-G%E)\S2'M.[I/J>*DE9&B%O<Y
M45HJ2E)R#FK88TVFRC)-QNBAW2?(?)[M!(-;4HKL8)9)-=B"=B2GU9V*R:M4
MTC.TY"0M$W/TJYI^(A;&.$V*:1E*5_I2ED1*.)L6CVB6TX-S:_TJ*R*R?A2]
M"Q6V)*4$H[K JK)-.5HT8H2I$\U;'% 9"A6:4C7'$VB0BVTM]4J/Y5'?8]C0
MNXRI*2-M15;KLDU*F1ST515D#BK=U%7AV)_P[OO"H$8YXHEDM4$</)PM:6\D
M9/WI*0Y8V-I$8 8*>:FI%;BT,_DUK. DXI6.@R+4H\D$?E4MSJ@4%W'RF6XS
M8R<\>?VJMV6*,:,_U-$$M9V)P#Z5O[/@YS2HI\JPK))PJM$9NJ9CE!78T-E<
M2?H53W(>T.W:'"<;#1XB0O#L5<T\ZL#"3^E#R6&P;+T@\YT!Q]J6\/#ON$5H
MAS8"4D_E1O#PQH[HQP>1J>_@K>+D35I';^$T;T'A!%:4S^''Y4[);4%.DC[_
M *"E8G$*K22B.AH;%0U=TLL$#9^U$94*4;$'=,.XP&_VI[A>&,G=-/H40&S^
ME24E1&46F-S8'\_V:OTI;D+;(#^ .?[-6?M2W? GL$G["MI)!0<X]*9!]A@Y
M;74?A-#I$+8DJWN$8"31PPMBS-JE*_Z-6*31.+8[1I^4X,A"Q^5)<$VMP)TY
M( \25YI[F+8)&POI.-J_TIIJA.+0(L;@_"Y^E.T+:Q3^ 2,_V:OTJ-HE3#?P
M%\<EM7Z46A4P#9G1^!7Z4K'0 M#F>4*_2BPKU#_P=?\ 2JG8<&\=[[U':6[@
MI>).,TMH]P53G0Y-&P-P!>4?.C8+?0'>J_J-&P/%%F9"@MOG\0_QIJ(.5H^3
M5S_^"LT__'3W_E%5\\E]I_,^H0^RODOR/=G8MVZ=DNGNR72-CO7:/9H,^!:6
M6),9U]06TL9RE0">M>LT6MTV/30C.:32/%=0Z?J\NJR3AC;3?#+M_P#3(=B6
MT@]J]A  R?\ 6%_^C6I]0TG_ .8C$^EZY_\ A,LFH]=Z;TMH^1KV[W4"S,14
MRQ(1XN]0L MAL?B4O<D)'F5#I5V3-CQ8WFD_=[_Y\S+BT^;-F6""]ZZ_6_D>
M).T#XN^UK65R7'TG<'=,6U:]D>+;P%2E@G"=[V"HJ/'",#/ SUKRNHZMJ,TO
MV?NKX=_Q_0]II>B:;3QO+[[]7V_#]2 >[5OB5T%(CSKQJO6MM,@[FA=D.EI[
MS(VOI*5?:J7JM;@=RE)?/^YH6CZ?J4U&,7\O['I_X</B@;[5)/\ H9K*/'@Z
MF2VIR,['!2Q<$I&5!*23L= Y*<D* )&,$5W.G=26J?A9%4OY/^YY[J?27HEX
MN+F'\U_8HOQ6=N':KV>=J+6G]&:PD6RWJM$626$,,K!=6IT*5E:">=H\_*LO
M5=9GT^?9CE2I>GQ-G1]#I]5IM^6-NWZ_ I*/C([38G9RW96;TJ7JF5.D.2+O
M(C-9BQ-J TVT@)""LGO"5$':,=2>,G^K9EAVW[UOGT1M_P!%P//NJH)+CU?G
M9):&[>.UU[L/[1-6/]H5REW:U7.S-0I3Y;=5'0\XL.I2"DI 4 ,\>7&*LPZW
M4/2Y,CF[3C7WE>HT&F6KQ8U!)-2O[NQ!Z#^,/M9LNH4W/6>IY=^MK,63BW*8
M8:2_(+1#(4M" I*0X4DD'H#5.'JN>$]V1VN>./N+]1T;3SAMQ1VOCGGMYE.U
M'\2?;?J>YJN<GM)N\/<HK;C6R08D=H9X"$-XX'JHJ/J36?)K]3EEN<VOEP:<
M73=+BCM6-/Y\LU;LQ^.#5NF],7>V:^CKU+<F8^ZR2U@(6X]D#NY*DXW( .[>
M!N\)2<Y!&[3]7GC@XY?>?E_<P:GHF/)DC+#[J\U^AE&H/B1[<=27)5SE=IUZ
MBJ6HK;8MTDQ&&QGHAMO P/?)]2:PSU^HR/<YO[N#H8^G:7$MJ@OOY/0_PE?%
M%J_5&KF.S'M)NBKJNXMK_A5S=2D2 \A)4675  .!24JVJ(W C!)!XZ73M?/)
M/P<KN^S.5U/IV/%C\?"JKNO+YGL]M9P!GBNR^YPURCQI\6WP_P#;;VK]K9U#
MI#2?\1LT>TQ(<9XW".UXD[U. )<6%#QK/..:XFOTF?/FW05JO5'?Z=K=/IL&
MV<J=OR9JWP<=BEZ[']$7-_6-A;MVI[O<%]^H/-NK$-M*0R@+;) 227%%(/4\
M]!6GI^FEIX/>JDW_ ",?4]5'59%X;N*7\S*O^4;FZ76=%P$K97J5M4IUS!!=
M1;U)2$!9Z[2Z"4@^BR/.LO6''W%_%_0V=$4_??\ #Q^)1_\ D^TR6>V*]7,A
M0M\+3,IR<H?2$]ZR4 _FE1'V-9^E_OF_*C5UBG@2\V^/YGGW76KI^N=87S6U
MU=4Y(O,Y^>X2>B5*)2D>R4;4CV2*P9,CR3<WYG1Q8UB@L<?+@^I'PT=GMN[-
MNQ;3-HAQD-R[A!9NES= PI^4^@.**CY[4J2@9Z!(Q7I-)B6+#%+YL\GKLSSY
MY2?9<+Y(QS_E#.S^VW/L^M/:4S%0FZ66X-6Y]\#Q.Q'PH)0H^80XE)3GIO5Z
MUDZIB3QK)YHV]'S..5XO)J_O1YW^";6,K2OQ!6.WH>4F+J9MZS249X45H+C1
M/N'&TX^Y]:P=/R.&=+UX.GU3$LFF;].3Z@H VC[5Z,\J#@4 >:O^4*2!V L$
M?_G) _\ $?KG=3_<?>CK=)_W'W/^AXD^&S45CTEV[:*U)J6ZL6RUV^Y=]*EO
MJ*6V4=TX-RB,X&2!^=<C2RC#-&4G21VM="633SC!6VCZ1-_%/\.J #_ST::S
MC'_?2_\ T:[[UFG_ .:/-+0ZG_\ +9-Z2[>^QW7-\9TUH[M,LMXNLE#CC4.*
M^I3BTH25+(!2. D$FB&HQ9);82389--FQQW3BTB_DI.,=?.KS.+L_15<NY;#
ML'J)(Z@#J "$9&#4D5L(E("ABF07<%Q12!B@D)E8/UT <%XX1TH XN*(P<4
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M^@?I2N0Z1EU=L\X%63@<T $R?6@ * .Q0!R/[5'^\/\ &@'V/E9<O_@I,_\
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MD_R/(?PH\_$+HS_\*?\ _-7J\_TW_=P_SR9Z;JW.CG_GFCV?\6H__)XU:?\
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M3,79X2(BI"6R@.E.?$$DDCKTR:[^FQ?5\,<5W2H\WJ\OUK//-5;G=%C;:45
M8-7[C,ER.%069D=V)+C-OL/MJ;=:<0%(<0H84E0/!!!((/7-0E35,OA<7:[G
MF;M#^!.VW2<]<^S34S5G0ZHJ_AEQ;6XPV3Y-.IRM*?1*@K'K7G-3T6+>[#*O
M@_U/4:7K\XQVZB-_%?U13K5\ _:._*2B\ZRTW"C9\3D</R%D>R2A S]U"LD>
MBY6_>DDOO-D_:#"E[L&W]R_4]0=C?8/HOL7M;K&GVWIERF)"9MTE =^^!R$
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MK*W-#=R45'/E4U$A*0@MQ74FIQC3*7(2+V> >E641L34Z#U-1:"PBGDI\Z5
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M?()T%/>MIR0,4J);@H<<5TQ10;@%E9QN('VHH%((2,]::1%R#)Y3UHH6Y"B
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M18T=;)&!0"&;D,K)R#^E2783?(#4!+?)Y^]-<$6Q8,H2.!4J"S@ !BE8@%'
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MQ3\ALJWI6,X'Z4;GZE;@EY"8B!'(\J%)LKX'+22!4NP*5\"F#Z46ATP"C=3
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M5(U8_LBZ7 /(U M2#[A4B)VX4 =N% ';A0!VX4 &"CC@T!0.]7K0*@XY H$
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MJ2PTVL/<EL)VXSY*1Y'WK57%F7?Y47[LG[89VDKBB/"[MJ(3L4PI>X/$'Q*
M]A6K3:EXY=CGZO1K,NY[B[--46;76GT7&SR%+"G<+"_J1GV\OM7;66.2.Y'
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MJ+"CMI'2BPH!0/'-#84<$\4)A08# Z4F- X'I0,[ ]* .P/2@#L#TH [ ]*
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M),7Q(J"^PRB1+4XXM2VMH0HY3^E-CX*=-6\LRU+>"5% (2/+[5<BA^96+OW
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M\8ZBF,16#N. :=D'&Q(]:*8K0DM))Z&@=IA<&I$*8!!QTIH*8D00>15B*Y(
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M'(]113'N0WID#J!=@<9H[!8(;/7!I62B@=A]#19*C4B0.M<@[@*"#TI,!5!
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M669[/>*3@YX&:-GP*UEHJF+5<8X8$A!>"RXWM/A/%%-#\15R6?33EJ5!_ER
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M?''NX,F3(HJT)_Q$+X"^GO4_!*?K (FDG^TJ,L5$HY['3,K^7C?YU!XRV.4
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MVJR,?4KR9*=HBYVC8\:,[/DWT(0"!L<2#G/L>*U8X)LRSU#,6[0>VRPZ&>7
MC3&4+)V=[N.3Z@)&171PZ2,^YSL^NE'B)BFJ/B<D=\F+II$AY)SO2ILI*UGS
M&1P*U/1XZ,RUV2Q"U]I.I]3)CF=$E)2A1W;VR-WL#Z5EG@CC[&_'FEE7)LV@
M]7WZZ3+=IB# 9BP6UA;ZDI\2^>:P98*-R9OPR<FHI<'L'2T8W)F(X4G8D_\
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MV;MZOMT533;K_P#,0LY((.,_GBN1K\GBZ=2^9W^FX'IL[QLR_34)^<XZA*$
M$\>'J:\Y=(]55LN,6_*TI$=O4V$ZMB*@E;B$?RU\8VYZI/\ C6"4-TJ1T$]L
M;9BNJY*]27YO7/:-'?@,!:38K9*5PU'V\+<0?I4Z0H^H2G/G71TZVK;#[S%E
MCO>^?'H0%U^)G7FHY2]+]CVG"XXU&*I,E22X6TH]#Y@ <?M73PX8I^\8LN><
ME^S1C.I>VW4*=+3Y&I^T[6*M7!:A&M46*DQ&B#PI;A/[ 5U8X8;>3AY]7F@_
M<?)!:%OW;!K5UJ1=KD)"E>)D/G!4C')&.:R9HP@C?H<FHU$JD:CV6OLR[])A
MW9<Z J&2B0\VVON4K/TY4!QUKGYEOA:._B@H35\'J;LP[-G+4I_4=QNCZUL@
M%#:U>%X;N%)]4XZ&N5EE2JCHRV[>&>A;!?VU2D19LQ99[OD;N2?+)K)I)?M&
M8]3A;Q19CG;?>;7$NDARV2DH5LY"3@ ^=2F]V0OP8MN,\$]H=VC7N^NN+96H
M.DH/FHGSQ7>T\=J.#J7OD.NQS1^I]37B7-@E<>) (:C(2@)!]2KRX&>M79,B
MCPR&GPRF[7D>@9DSLYTJRQ+D7%6H]2(>2S%9AE4A:5D<)' 0E6>N!CT-56WQ
MY'1PXH1>Y\LMEFO_ ,2-^L$I_0^@(L2V(;6YNN*PWL4@94$I/GCSJ[!M4E1G
MUBGS:HPG6OQJ=K&DVX>G[_-%RE.H4)3#< H#'/ 2Z2>\( /05TLN*,TK//QU
M,L+;B4]_MG?U=:Y2V\2&76DNSXI="T/ D\!/ET\L5EGIDW:+8ZZ4D]Q4)_:-
M:GF# <:D/PFE -,H7A;7'TD'D@53]7IV6K4IJO(N>B]5R;H]MM-@DR06^[;$
MCPI5D?2A Y/W-4Y8[5R:L4W+L6G4FF'%:7,$1T)N$HKRTD;4M)4075$GDX "
M1GSR:KQY?>+,V"X?$PB/97'+T^49[MA.U*D<I*\X(/L/6NGN.,H42266XH5W
M@\0\Q2[CJA-5Q0?Y0S4DB$F1]PDH41XDI/'"CU^U3*RZZ6N"S&9C$%(6HE((
M_I3Y>N<@?E4XE,RVP;@E.G,M[7%;DNE">J>>H^]:8ND4=^#W]V":D<UEV:6B
MZM/!QZ,R&I"$C!&PXQ]SQ^E=W39XRQ*SS&KTTEGM&MPI5SBJ[MP$[>#Z<42C
M#S'CS94Z0M+NMT6/"#S[5&,8=D63SYAFF[7ED@D'CVJ;A#S*8YLQ+VZZSY"@
MEP8&/2JYP@E:+\>7+*52[#]+\L*SN&#[51M-&YCM,AU0\1&1[5&2HG!OS#"2
MM/''Z5 LL[YDGK28TPXD\"@!P.1FF  W>=+D U,#J $G^@I,!LX.14HND5S5
ML3*$DY-.R.T MI(Q4T,:J:3D]:8A$-'TID-H.P)\0'2@:C0.]5(F"/'UH '8
MF@ 0 .!0!V.<T ".M)E:[AJ@RU=@-WM4J(;@4JYI4%WP&W$]: ? TE=!^=3Q
MJ[(9+XH9*)0KZN*GM2(<CJ/+"4XW<5!XU)V61FXJA^S<$CJJHO$BU91^W-:4
M.169KDMWH*XZE:2/:C;R#D,E(&"KS%6HBQ)9VIS4F+L,GWBH8%61*9L9+459
M!Z5>C-)V1,Z"V^<*3Q6B&7;P8,N#>13]A1SM2=OES6J.?@QRT7-D6]92@G"#
MQ4_&*):9HC5VM\=&E5;XAG\!B?\ "I!X[HT+(/P !9Y)XV$5+Q4+ZNQ-RUR4
M?4G%"RI]B,L+BK"?(/>E/>0\-F[*<VI^KBO,[6>[X0JB2I*3M7BE*)).NP#<
MI9))6:CM&Y +=4L\JHH+0FH)6-JL$5*V+W2&F(0AU6T8YK3!MI689Q5NA@7%
M#)STJ])/N5-M"*I60<*/Z4*$5Y$=TF(G<XK<33VH3=\,2=W#/-3C%/N53X[$
M>])<1U6<"KE!+L9Y3:&;L\'J>E2215*;&3TQTK\"SBK8P5%$LL[I,;+>4H^)
M1-3VHJ<F^XBX[Q@&BDB+85N*XZM/)/-/FN!)<HD$0UM<XJEMON:4DNP]8><0
M E*B#2?"LFK;' 6LC)-0LER*,NJ0<@U&1.#:'0F.E0_F&HN*?<L622[,D(+Y
MR%*.:A**78T8Y;E[PY>F;<[58J*BBR<J[$3*DJP?%5U(QN;]1B7E$XW5*D5[
MW8*5%1P3FDE0V[[A@A(.0*DG)D:B@0$^8I^\*X@[4>E%,+B=A'I2VL>](;NI
M3DD"FDR$FF-U.)!P*M2*6T"'6"<!')J/<EP@^0D<<44-R [WW%*B.X'O5'HJ
MBF-2H#>KUHVV&X.VL \\U%Q)QDB0:?P@8-4R3+XSKL2$1T$C-*2X+8.W98(S
MBDI&#66:-V.0^865$9.:STR]-"ZTC;1&[)<4,WH#+H)2T-WG5ZE+R*)P@^Z(
MZ3"6VM(2, @Y%262NY1X:ED27;FSS+\=5\NNF.Q1N[P-RD,7V/\ ,( !"F]J
MC@_F,?G7&ZVVMNW_ #N>B]F8QEFR)KMV_D0UFNT)78<I,-04Q*D,O((Z86G=
M_G7#RY8RP**/4>#.&H<Y=R)T9?HT2Z,PI0"@Z2<'BN-EBU&T=G"[[BNHX_:8
M+C)=BV1F>RH[H D20A#9/1193]6/+-9XJ#7+-<I279$8.P29J)*=6=I=U>ND
M]*BHL;]R Z0!D^N0 ,>0K9#(HJH*BM8E-IY.1KIFRMV.[J$.-$=5%4=\F$D,
M.E Z-D?2H#[5;',X\V7^#"7"2(FX]F_8E=[K+G:@[(KE<9LA9>2M"<EP^8&U
M0 )]:V/63<:LYW^F8G-O:,(]JT9HB8\_8.SEFV("#W;DV4IYY)/X%))P!Z 5
MGG.654V:,6&.F=Q5&E]AN@9U^N8U,^T] CRUE+WT(:5D8_LU @\>H)JO9)IJ
M/8MGG<5;?<V>\6>%8D,V2VL)'<DH 2O> ,YX/I6#4/8N1:>4LDB)96(N^0=S
MF#E..GYU@Q246W$Z657%19YT^)J5,9"+K"E*2ESAQM'3[5JT;62;4BC5WBQ)
MQ/-T>"\X\U<"ZGNDO$[BG\1KMIUP<*KY9O?P\V.SW=V-I*>^X XVXJ8CD-D@
M^+>1SS474I*R:E*$&DST?=NS30]B5&5:[5#?E!I/RCTA_ ; ^D)3ST\LT."9
M;@U&2'*8]&M=5:=[INV1X:XRFLHBLS$-85T4HH5E*L^E3C)8.4/*EJW67D\[
M=J^E] :HFJDZK[&5J4I2E_,1Y!;6'"?J 3Q5_P!;R3_B,DM!@CV@83JO0>G+
M2UNTUI)ZU/,^,RI$HG*?))!X_+'G4X9Y7391ET.)PM1Y,9NVE[E+O(N5JV$A
MP*D(!\)_S)-:'D1RWIY)\&PZ"E)C&.U;[8EJX*2 MR7*[L)'H.00/M6+-4KL
MZ.F3A2-L:@-?Z,3'7;A9F'$,* 1#*WU^/ZE%2B#S[G[5S6ZDJ.HT]CY//EYB
M,6JY+;B8[O;L)2L'*?<#I]ZZV.3DN3AY8J#X(.0WWBSX\I5Y5<NYGD-46K>H
MO(Z=*FBIH:SK<\$Y&,>9Q4D1?!9-+PDP[/+N#[RG7$90T">4Y2,D?I^]61*)
M-#M>I(UE;-QE,O*;;=0TZTTD'(." ![#BK;XHH<6W:/<OP3=KG9/=7I>E[#?
MI$>\7-27X]LF,ALJ6T.5-*)PXI0/T<8QYUIT^5+ALQ:C#.3L]D]RVH#<WSY[
MA@Y]_>MC;9C4=H(8:S_9BA.AOD2D167/#W2>:&VR25 ,Q@T?I %)MC0Z2@*&
M,5#?(L44+LQPH'PTMS99LB<N*G/T46PVQ$5QO$< 4T_4JE%WP)EE8. :+0;6
M*H>=R,K-)L:'[9*AXCFD3I!MB?2BPH I2/*BPH34E*NHSBFN2+&[J$A7 J:1
M 14 #Q28 5),@WR-3U/WIVP\@*D,35]0'E0 "@ .!0 ".II CG%$8P:9%N@G
M>*_JH([F'221DFI(5L.$KZBJWW&#S1P/W@#TJRB 7)]:*0P=ZAYTJ06Q-TDX
M_.FN.P=QDZ!DU)<B? CC:DD<&HV^PJL,ATHY4<U-<D6WY#UAXYZU3**+(R;'
MX6K')JG^*C0DJL;NR%#("JO445.3&ZGU$84<U)13(;F-E.(YR*FHI=B$I6,W
MED*&S@5;%&?(^>!!2E9R34]L642E)=A1"%N@#/%)M1X+(*4E8<VQ"QE;8)I>
M(2\"^Z%#9(I^II-1^M3]23Z? 259HB5C&VG]8F_,C]2@A"5!B-((&TFIQRS?
M<KGI<:[$/+CQ,#>E.,\5HA*3[&//CAC5L:]Q!]$_K5ES]3-^S]"YJE* R:YF
MU'H]P9F823D_K491)1D.#() VX%0VHEN ^94.IHI#L[YA2N :*06,I"7RLG:
M",U;%49IOED:[_+R#YU>BAC<I!!&!4R%AT%*!C%(.XVEN#!J<2N9 SGL8_.M
M6-68<SJB,<<R:M44992$E*XP.*=5P1NSFQQSS0 =+:2<X%19&+MDBRE+(S@>
MM0W,T1A:L!Q:G#PHBDW9(6C(\63Z5&78E#ECG:/2J[+:%F&PH'@4=QT*]U]J
M* 7CDI.W-0DB['*A5]7%)(LG(B'5*)QDU;1B;$@A6[J:E17NY#G*!NS2[$KL
M35(*1DFIX^60FZ0W7.>!\'-6.)7O"_Q%P?7UI;0W "Z$*Q_G10;F)R)JE#<%
M'FI41<B-=G+S]:NOK5B15*8*)*\\*.?+FH)43WB[4J0I82M2L'WHIAN'*75
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MZ /RJ3*T.6>E(L%*0'8S3 0>!3YTR#&ZB2>34T1$E_528@*D5ON-3U/WH'Y
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M^?<_I-&T/%!;GKW@E)Z&J\JX+,4[FI/XC&]W#Y:V2KBI81\FVIT%1P,@$_\
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M7W/XG&'*)+;R4;<?GFB6)-TC5BUDTO>Y,LUIVLZUGK3\FP\XI0ZK4D_N:G#
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M?!>82ZE;P0K*$JYQY&N9JM:L"<7WHW:;#XC4F>19JNU>^R9UW@W5UJ(I96V
M#N2FO'.4LC<HH[UPBJ+UV$=H=WM-[:@:IG!67-BEN'&]7K^=4?7-1#B/D3Q8
M,+EN9M.O>U"$VVV[;YD-MY.<D+&<4_KF5_:-<L6%K@Q74/:_-U(AVW%#10L*
M;2^KS/L:TX,^3S,<L:[E?AQ]0VNV?.LI*VE$K(2<?O706HGB6\HGC4N#9M!N
M7"7I)-QV+2]C<H%/3CUKHZ?536-R.;EPK?17](V65K+5SDC4+16W'<W-A8QR
M#Y5AT\7K-0W+R+\K\#'P:]JS5D#L\L+DF-%2$H22$#^K''[UZ'4YUIH*,3DX
M[S3MDSV7Z]N6JM--W29$<C.NME26UC!J.FFM5CN:+,M8Y4F5A[MU:LNMW=-7
MQMR(DK\#KOA2H^6#62?5,4)^#DCP7K3N<=T3:[/>(UUC-R&5I=0I(.Y)R,XK
M7&<<J]WL0MQX)/:3Y4W':6+(P$LN9^FEPA[FP>X43TYH<T@V.0<0GB,AM6/M
M2\5!X;"*AN>:2*E'*B$\+80P%*5T.:EXB(^ .HEH5N"E(/-0G--%N+#3++;G
M$PP % 8&.M<W*K9V,+VHDI5Q+XP5>541[FJ4K1&E"E*R!Q6A6D9N["/L(4@Y
M/-23"4;$6XH0K<,]*G95&%.Q423'R#@9]:K<;++H,+B?+!H4&@\0[YS=R:>P
M7B"2Y'B)%"@R+R(;*DC)Y%2V,J>1 H=<<()<'VI[&'B)BXZ\\4.-$D^0=R$\
MJP12I$[85QY"<;!@U."3LA.;0=B:6E@YZ53DQ[BR&:B2-[WH"=XQ5<<5%CU
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M9NRQRK@5'87+/0Z1=R#G-)XRQ:D61=N\R%* Q5<L9?#4)B;DH+.0:@H YV%
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M-H;V)E90?6I"M!5O';T_>BK$Y)"?>GTIT0<K\@I)-#!? #[TAG8I$D&2@JH
M-LYQFG0ER#L]Z1)1!*,^=%$P.[SY_M0N .[K_P!L4["O@?/[L-[%;JJP3%&*
M"'%;MJN#GUKPT=^:]J/1Y98X\6;#K6Y"!V9R(1 ;=;C%*TGR(XK3GU;6C6%^
MISH:6+S[T89V8B.]<E*+)6A*MJTI] .M<&VH6CI9>%1.ZVMUF=D,2(J1WB3N
M4$G.TYZ5'ZPW&I$\,'=D:;XXZ4QDM>$\%1SBJ);5&R]1;D,G41H5P2MQE2E*
M.4K2*SWOCP:FE5%T@2$OQTO;1_+'0^=<_)!Q94X,R_M0TU%GM&YM11N2K>H@
M<D5U=%J>-C(N*(;1VJXK,9=J2<*!VX/E5F;%)3WH')-;1]+0MF4/]4"DGQ@I
MH@G(78NFF'%!E*'4X2H>'-+58&\?!4I*RYV=V2A3<1"U=VZ>1Y=:XLMT*1>T
MFCT!:NQVT2[$W/D00MQ;6XJ*1Z5Z[0Z#Q]*IM\G-S9-LZ1457"%HV7W2HP4B
M-D-C%<O4ZB6GEL+\./?R4>[]JS+]Y4A$,-M)Y24Y\)_.N4]5ME3\RYXV#>M1
MVB[Q=K;@W*Y*<#"C[UIGG48?,KC!V5M7S,**XB.YM#@R /\ *GI-3M=6&7%N
MY'6@>V6]=G0DL7MER1 >5N:"<[Q_EBN_@R>]OLRY86J1GO:'VT.:GU8;I;6R
MRRE&SQ$Y//G6U\*T0VNJ96WM5*6M<SO0IQ7K55,7AME?E7N9<'BM:_8 59&!
M8H477LDU?)TYJR"Z[)4W%W[G$YRDG[5;BEX>2_(63$Y1/2UY[6FG[A <AM;X
MS*\N.8Y^]=KZY&:5'/\ !:LU;1/;7;K_ '$6.*5%QO!7ST%:H:J.9[8D)P<%
M;-+5JNW1W&D/2V4.N*X258XJZ32C3[E,)-R)RWWVWS49COH('4[JIVWV-D<E
M#Q[<X@+"AMSP11&.UVRR<]R20I$E+84"%FJ<N.,B>/+*!,LZB?;  (_6L4]&
MI=C9#6N/<<KOSLJ/W2@D^_G57U7PR]ZKQ50PW$DDDU?&'!3NY&<QP)\ZTXXF
M7-(:(F@*">.31ML@LL8DBW\JI/>/*P!YU#(]J+HU/D87"[6^*E2OF&6P.BE'
MBI8FN[*LTMAC':3\0^G=%S$0%36UO+) V>N*LEK,>'@R/=E7!CMRF+[<)X:N
M\UUNUM'<ID.$!S)SS545#52N;X(3G+ N.XV[0F>SWL\LZF8B6"XR-J @Y6!C
MBHZO)I]*O#Q\BT[RY7;/."[]?>T763%DL[SD=IU0(6XKC'G@5YY06?)PSI2]
MR-L]8]GFCM.=E%N1>KM);2XK&^0^1N6?,CVKT&/3X=)!3F^3G^+/,Z1I=J^(
MG3SH#,196PD\.\X-9\W48R=0-N/#)*V3-I[>+7>;^W:X2PZ%$#=DX"O?VJMZ
MQ&J,#2[AK>T6.&S,E2V4A8!5N5TS5<];&B^$*Y)'37:3I?4#J6(-P96H]0%<
MU5]863L777):EO,J3N2L'TQ5V*+[LC.>[L1\B8I*@1C %:H0LSRR;1/Y]M0R
MM7/I4_#Y$LJ:Y&$U]"@2@]:OC SRRI$6\OO!C_"K,2,F62GV(O55K-]TC=K*
MZCO428:V@@\@D X-8>JXE+2Y'_Y6;.C99XM?AOMN1\_9KM[L-Q++CX+T1:VM
MQ'5.[@?8C-?.:43[7%O+CM$KH>]6L:A<,C:79/\ ,4I9R0L8QCT'7BK''BS)
M&/O4STUH^YM3[4(DE:5.+5M]R*S2!Q:9TJSM/)4MQY2$I*@< <8-4R3;X+8C
M)NT0.[<E_+!Y2,)[S>K!3_21TH2D7)AU.P&6$)3!9*DY.U/4>U71[$9)M\$-
M,>WR$LV^VM-E0RH]T"<U.R#3&+S:I!!>85M))<PD=!_QJNBU(@9MG:ER-K<4
MM,YY5YI%23H)QM<$S$BLQ6FXW\L*60E))X_.HME:BV93VU]H;L.V)MMH<;0L
MLJP<9*@#M4#^?2M>EQ*<N3-J)."I'D>\:@=!>#7\QQ6=ZE*R.?PXKMPA2.73
MEP%MFK)EGT\[;X;BBN0WW2G,?22?3J?+]*'%-ET(/'!EST?!F2H#<)A*VV5)
M[R7(QE*2.B4CJ>.ON:RYJ3LUZ:#E[J&VH'5.NKCM%:XS:.Y9'N/3V%1Q^IJG
M%=O(H=U<2V0A)!(X-;H(YF>D)1"D-E3P"=PJ;[F)<1W$47%S9W>X*@"4I2/P
M_:K.R.=-J<['7?+$EJW-.9?>.$@?AXZG[4-TK+M-IGJ,BBBY6FUMQX[;: ?Y
M8P?=7F:Y\\G)]4T6B^J:94N2UZ"U/<=#:ULVK;:]L<M4UN3STV@C=TY^G(IX
MLFU[EW(]1T,=1HY8IKEK^Q]98.LM.3D,S85QC+;FMHD,A*QREQ(4,^_./RKU
MV+50RI<^2/SWGP2TF6>*7DW^9++N:%M@ )W8YQ5V3&VK10LB""4GS4/UIK'P
M0>56&^;;_J'ZU+8+Q4=WS)3D&DD$IH;K>;)XQ4J*[4N [<X).T&C98UFV\"B
MW%.4JHDY;@6$#!))SFDQH4=?2TC /2FHV@<J&:[HI QQ4E JEFID7-GN.=%8
MJ^.)&6>=M$4Y*6#R>/6M48*J,,\CNPOS0/&ZGLH7BV$#NU6_/6EML>_;R'5/
M4D  XI[!>,-WWR^<G'3%3@J13DEN=B21M&,U,K#-K() JI]RV+I#MMP'%1HN
MBQQW_L*JY+[ #P!S_G2IA8HB3SP11MLDI4'5))'7.*2A1)SW#93^<@GI4E&R
MN3 WI/)4:=4*,N#MR?4D4$MPFLA7&34RERY$2HCG/2@-P1R5N;4 GJ.*",F,
M%=\I>2,#VIK@A]KA $*\P34TT0E!@%)/DJI6BK9(#NUGZ0:+0;&%[M>>0:3Y
M)Q5=Q9IM=1+4.ANP.*0 T $6C(S0 GL)ZTT#.+>/.G9&@-N*.XTJ"J(!H[!P
M%*P/2F*P4O;>F* W'!PYZ"HMDHBB5 ]:18@5* &10,!#P!YJ,B<'3Y#=^FH\
MD]R/+>B>T^TZ0B.V^?&+:2#M7C)^U>*T'6884TH]S;J-!ER.[,Z[5.U2V:B8
ME6VWQ=A=;+2%*. 1_P :JUFJQZGB*HOT>FGB;<V4+L[>DVV4ZZD!Q*QX^[.?
M_=7,EDI;4=">-2[EP<2W>75NH2$*/EC'-9<R5HGC;@AC$AJM<P)F,;FU'PJZ
M@?E561[HTBW'/FRWR['$?MB94=M"U*2%#CI67%+;+:RZ?:T0"!+::"20V,XV
MXYK3-194I3"S;8JZL_*H 4#Y8JG'!8Y[B)D-^TPC35\+K8[LN*YW'/6NY&?B
MPID=J3M%R1;P]9^]#_CV\$=2?2L>]XYT2:M$#:]3W.TW%$29$4IM)("O6NC*
M2GC*-JLW?1TBV3X*'G'4A_ 6V KI[5R9X<3>Z:[$O??V37CV_0[%IU5N>8[Q
M]IKN]@&-W%=/1]2\+'M\S+DT\G*V8M-U'?-37%V4IH!IQ14A'](]*Y?4,L<C
MW>9NP0:X*W=;7(CR%..M* 5UKDN$)^\^Z+7:9'O1EL/!P.G8DYP#0LRR^XR#
MX)"3<8UQB(:8D%#S8P/%6G#IE'D@Y7W*[<V)TH_*K=*RH83BNYA6R.YF65-F
M>W31]\C7,1$H5AXX3D9Q75PY%E5%?!;U=A&O(UC_ (Y\DM^,$;B ,&M"QRES
MZ IQ3HHT*&M,U,62"A2E[3Q])H::+D:C*[)7XEB:OL:X94,.;2,9'M1*"V)E
M7B-RVCB-JJY0H!93!W I !4DX ^]4[I8^8E4X%A[%M22+!K"3/FN*2E]!W9Y
M\O*IZ'5^#E]XISXU*-(O^HM1R=1ZE$OYY]B,PW_+*5;<GWQ76^NX\V3N9E!X
MXTBRZ)UK/LDKN6KFN2VI:4E).X\FM,<\%YC4)2[GJ/34E^=;6WG%X"@" :OW
M+(J1*$6F2:]R"/%G-1>.^Q)MH.DG'6DM\%0E3[CF.\4<"H23EW+X/;V'7S7&
M<\U#;Y%KGYC:3XP2?.K8VBC(]Q&)0YN"B>AJZDC"E*7<6DEU<5QH.!&Y. <9
MP:AX<)NI&F.2<(\'C_XA!VCZ9E.W&)J)QN(HXVA'K7/U./)C^QV)QS>+PSQW
MJV^7V[7=Y=UN3[[K:LI*CC ]JY,I-OWC3CA$D-+]HFL+?NC1I[R$ ;1@XXI/
M-)*DQ2Q18%XU+>[H\I4QU<M:E945J)P*S24Y\MDH1C$6T_.?M=PCWF#_ "GF
M%]X%#G)_SJF,I87<>Y.24E3+?JWM(U!JQAIJX/N);0!U/'Z5++JYYOM,IQXX
MP?!H_8K<]//0EIN4UIA>TY#JO#T]*ICE\/N:BX:28M-MOTZXV>ZI4<E0W'*5
M?[M6O-&78G<44WM6[:+U/?599+BD-((2%(&WH:<8;GSV+-[:J(V[-.T*Y:4F
M,W*)*=D)*AWB2LGPYS6J,5'L0<GYGNC0_:M;[U9F)BG&FRM*?Y:G/%G%=W3X
MXY(6S'ESN#I%P-^;E-A82E 4. %9S[UH6":[%+SQ?<B[G>T0&C(<7A ZU:L+
MKGN43S^41O:M3PKL@=PXA1/(&[D59&#2Y*5EM^\2;(.>Z5RM7(/D!4%[WOKL
M60CL?A/F3\_+U'7S$2#!ESK@[W$>*A9??60$-I"3E7/6N;U/40Q:>>_A-,Z_
M2]+FU.KQX<"W2M'@+M!MS((U&PAQ3*GU,NE1^M(SL6/3BOF\IJ<N#[/APO38
ME&?VNS,NU(BYV6=#U'9/YK84%%OKD>=:,4MRVLJR8]OO'H3LHUY!OD*+<F)7
MCVC;GC*O,D>7IBJ<L-I7:F[1K2+W'$8I+S:W7<N;%'J?6J8(G))!';YW3 :D
M,,H;=3N):'''E]S4QQH26Y$<:2&5I0HC.Y:2!^HHX\R5T1CBV(JW93[BD=V.
M%!6X'WP*E[K(6R!B:@+C;JDLDYSU5QA(_P"--QX)MU*B(DW>3/="0ZPVV>7=
MKGD.>*48^H3;[(IFINT)F+#D9W;U)4VC"QEM/G^?H:<<3<J*W*DV><.TG7*[
MC) AJ[P-([E*<<A./7S.?.NQIL,8JSFYLDI221EDET,-!^2V#XMR1^+-;TD2
MGBCACN+!HJRO7F>)+B=W.4[O(>E9\TMG8JQ3EG=&O,M-VJU&.Q-3&4 0LA/B
M(] :YTI.;Y.O@PJ**#J%UM*5EMQ:01D'/)]Q]ZTX>73'E@DN2CNM&4HJ.1MY
M^];KV]CBYX[G[HRNTKY6)X5>)T@,I]/7/K4H*V8=5-8\2C'N,67!;X2GEA17
MU !Y)/D*L[ODY^UTJ[LM&C+&\\&[E)9P\[D@*ZI3Z5CSYMO"/>>SG2XTLV5%
M\:BMM-D8P<USI3;=GN-C:I_9\AG(+2$!!/57'^=70ON9]:U]KS++ISMFU+IN
MX,.KN3[L6(TV&6PK\(KHX,TXL^%^TNFCCZA-+LTG^)[Q['^W&RZOML>,X^DR
MNZ2?KY''.:]7HLWUF&V/<\1J)>!.Y]C54W:.]RU*2,UN^KS]3++41?,0GSSA
M(VK'6AK''W9=RKQLE\=A;^)AOAQP#WJ&W&NZ+O%DPS<H.'>V^DU%J'H3QY6I
M"J'<*W*51C:FZ2)2:;MCP7 (2,$4MC;=DUE2[A1=<=5"D\5DEG2$7[D%@^(5
M..(A+.F1DB:?(U:L9CR9K&QE+Q]0JU1HJ>1L;N.;TD'SJ<;LKG6UB24BK6C/
M%AR24@&HHLD[0&P*ZYX]Z+%&*8(; ^FBR3@@"E0/6BQ;4"VT=V?.JVW9-15#
MA* GI0-!]H]ZKHT';1[T4!P %/D :.6"5 ;![TN0:LXI '&:?(EP<GZ12Y&#
M@4[9%Q3"AI!/-'(;4*&+'(P5"BV#C%G)C16SNSG\Z+81A"+L,40SU;_>BY$W
ML"*;B#HG'YT;I"VP?826W&)X'[T.38;(A"Q')S@_K1OD0>.-@I:93T!_6C=(
M-D4 0WZ?O5B(.A%:D@X% 4%R:1$"@#L"@ CG XJ2 065'D4F(;*4K<<FI*-H
M@^X&Y7K3VH0;OEXZT;424F<A]S<!D4MJ1-38J7%$8-*D2W,+N-&U!N8.X^U&
MU"W,\.ZTFNPTB1L;4R"/$!ZU\>TTI2=4>[EM*L[-TO*V.[T*=4GE(&<'UK5)
M3CR4M)EFT1"M<;QM1$A+F>HZUCS2D6J%H?M6\*NRD0F@DJ).$U'Q/=ME<\?)
M!W]V[V>ZI:FL$MK4 -U3AMFN"B:VELL%Q^8*6!PG RGRK%G6QV78LFY) :EL
MLA;GS,1&?M2PY=W<O=$/#C7. ?F/%@<U9++%LKHJ>O;0B_1/F0TD/)YW>>:Z
M>ERUP1:H+I..MBU(;FN%:D>:JKU#N7 >16=8Q[@ZZ9-MC;U-'.!YCSJ_#*N&
M425L=]F-\O,:^[I\93492AM1GA-5:I<4C1C:1HVN^]4ZQ+C.$[L$8J&GA%0]
M[N&1J4K)#3D6<F$U+WI2#Y$UR^HS4>$782RS(\*\0BVE:>]2,$^]<O3YG+@L
MG S.=;K@Q.,1\J[L=":M4>=R,[7D*-:594A3[3^QP\\'J:W8M1DX1"6.D<JV
M3HCK$I"7'NXX7MY)]S7H<:E/"89*I!]07>(Y<H,D,);4AQ&[CFM>C3AP5-'H
MIWM9T5#T&VQ-?;0IAA2.[/1S(Z'\Z[N'/&$&F998Y.2:/'D15K<UB+E<=C4=
MY:G,'IDGBL^[>S<FTN#UQV>]G%OU;%B2U3%N1BV"$'Z5#[5H\+<J,[R[62_:
MMH?3&GM//(9MZ3W;0P&VQX>*JU.#9$CXFYGCB_ZD>MD[=;EJ1S^&N/CQ.<S1
MMX'MCOTN>')1F.-N$9P5=:EX<X-T5M)$WH_74FR7YMQYW<T',KYZU.&>>-^\
M-I4>EG_B=AV&V,AM:E@I!!'EQ76_U)/&E'N4QAR-K%\7<:?<&F)27$-K4!N/
M2I8.H2<N19(<'H?3.L(.I83<B,ZDAS!!37<A-95:,>YHGTJ5GA9/O3<"<9@&
M4L**2H\4O#'XG([#Z5)&1GBAJB:=B*G4@=*7<BY)"8?"R$^M*4>""G;HH_:=
MV?QM=1C"G(!;5@CCS'E5LMN6.UE&[PY6CR]VK_"HTRC^(6MI*2WG>0,=!7(U
M/3I?:B;L.I3X9D<WL.O'R27;<<%1QE/7\JX\L;@Z9LC-,L%L[-H^@K$;C>T!
MYLJR[WC>Y9SY"FVHJA26Y\&2WBZQU7I2+8@);*B4I"<<9]*Q9598H#^+;WI[
M9W^#/)K&\L<7<J?#%6;3+C.G:ZM/V--9H9>Q/>3MDU'.L;G=]XLH_%SY55).
M#L'R,M2R6]0/?,)&"!S6[!G3X8X2V.Q;2MQMUN28\M20 #U/G75CD@E8YR<^
MQ*CM.U%;KFP+2Y(,=(3PVK@UKAJ$VE$KEBX;9ZI[*.U^\WUN+;I%KE-> $K6
M.M>CT\]T:HX&?W9\,O7:!K6';[,^;BYW*0PK;@]58X-2RRCCAO9#&I3R4CSM
MV,]K%W_TSE0KM=RN$ZO_ %=3JASD]*PZ;/XT]K-VJQ;(6NY['9U-;85E<N\^
M<TS$BI"GGE'@I]-O]7I574-1#I\'ER]C=T?1:CJF2.CTO,F><NU/M4N.OK@J
M+$6[$L$3B-%"\=\#P''0/J4?3R%?*.K];R=1S7Y'ZM]B?832>R^GA/-SEEW^
M'Y>A785N%]L)@RCN9DL_+*W= I/17Y&L>/+P<;KNF4-?)KLS$KQ"N5AEKL,S
M<YW+A2$J\A^$_F*Z<))QW(X.1.,J8MI2ZNZ<>*&I*HS4APJ64<=R1^(??I4Y
M>^C,H[6;+8>TF*J.ROO?YZ$[2K@E0-4N%$FU*B?3VAV1:=TMI#800K_K>M1:
M?D6*,?,9K[084V2B1$DJ5'4HYP<@CW]/RI.#)**D[1"ZE[48C3*HD=[:%]5
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M,FS9=%:^;T\TVS%6WM4G"DD>=2TFKVNY&3+!R+19=9V*!K.%>[F6=NPY>5P
M2>!6['JH/*IE4HR<:1Z:T[VL669:P]#F,/-[<;D'(XKU&">/4K<<K)+)C>TE
M]-]HELO[RV(TEIU2#@@'I5KQXLW"\B$LV2'<M;;NXX3R1[5"D7+(P[CV&U;@
M2 ,\=:A)<%GB-(P'MO[5=2:*6A^W,E4<G#G/(/-9>I9WH\>Z!+!!97R91H77
M'_.I>ELZQGK2R?$(A5@.)]Z\KDU\LTEN.K##M7!!]L&G;-8KY#C:6=+&3O\
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M":V;J1Q/#WR+):;4@ ':#CVK+DR'6TVE1:85O2E(\/OTK#.=G>T^!11,,1P
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M>M6*%G-U&38F4FXNE]60,^U=&/!YW(]['EIM04L%2??I5>3+2-.ETJE(N$"
ME"!X.OM6*<VSOX=,HDQ&CA(Y%9VZ-T84/4-IQD"HV6T&+>>E1L4GR'2WX1S1
M9&Q9  &*2Y?(U&TVRG7%0N>J'"V=R+8V$8\@ZOE6/<) _6MBK'C^9R([-3JF
MD_L?F_[!Y#>P]ZE?T^1XS48N3XHUY6X>ZXV_@2,66YE/=N.)('DGC]:KE%ON
M='%AVXU-I<_'G\!TAQB1E,V)N5Y/,C8H??VJ<7L[&6>%TXOLR*NNC]/7)9DI
MA-K<^E2HY*'!GS('"JW8==.*IGS_ *M[!],UK<H)PD_17?XF>:FT5,M/>OL
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MZ5?NI49EB<W;)B#:DY!JJ60UX\*)V/%2C\(_2L[9HC#:.@WMYQ4;+*#4@.H
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MS1#PFKZN)\O(RM;B>2GRJ]^$^6R*3=(B18)5M+K\M>U95D;O2H.4<G$13A&
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M!SC.:>TDI@,QTQFU!0W8'7I49*B:=\!FWDI: 1P2>3GK4!T"5I2G*U[B>G%
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M(WD!1ZUX58VX'J+Y)\=I3>B62W(6EU2D\)%9OJ+U#KM1;O20QB=I6F+U*_B
MC-_.>6!T/O4YZ+-CX3X(.:(74G:+<C)0'6&RA*LI">N*TX--[I'<F66P7NTW
M**+NZP&U)\*DJ'(-9LV&494GP-,K7:AW$,Q+O;DI3TW%/&X>]:]%[R<9<BDO
M,@0^W=@P\'"5J'*O.M*CL=HK(&X-R-.SG9<//\SZR.IJ::S*I<@BS:1O%DN3
M)DNR$B6V>!GG-9,\'%_ E9;Y&MX=Y^78<(0[#6!GS4>E4;91Y0FHONAQK;16
MGK[;F;I."FU*&5*;X].M1QZF<);6Q14?X44N,S'LKPM_S!?@N\ J.0/+%:G-
MR=Q)D5'C2-#ZB9O%GN![EUW)3N^D'KBK)KQ(4^XU*G1M*-4QKW"8DIFMES@J
M&>AKS>339,>5M]BUR318PU'G6X84,X'^%+93M(RK)MD1MMN#$^:JQO (6W^/
MS-#C7)HR2XX)EIT6:2I,AQ26TC( /U5ER1E-5$EBI<ON1UUN=IO+G?--J);Z
M^].&"25(O;4GR'@O.J:VQ(Z@A/KTJ4(Q3J97*==AQ&0PQ,1(>925CG)ZBHSB
MW]C@%./\19'W&+A%+><*556-*#Y%D;DN"$D-/VILA )2.<^M;GE<E2?!F>%-
M6UR-[9>G9C[S"\I2/*L.=)<DX1HA+S8965&'*3E><XJ>'+[GO$[2[%D[-($J
MUEU]Q:"H#)(ZFM6BEMGN1FSQ4HNT1^O[XIUY2&TY5D59J7O=LEIHJ**UJ;6-
MOLVD%E]I!=4.!CZE>0K#IL$IYKB^QT94X4QUV5R?FM.MS2D!$QQ3Z0/3) _P
MK/U*59FD?I'Z.-+'%T#%/(KE*4G_ #I&@K6A:$YX.*YT8.+/?-Y'*6V-JQI)
M'=,=V#_:G%7-KT'OC'[:H,D&''#:_J4.?>JW*^2<%&3W+L1G>=XZ1DXS5T)*
MN2,XV^"29\ JI\DJL*^Z=IY-"0J0+ SXJ&-!G'CPV#@GBDD1F*,,]V"2.3SF
MA\D6*DX&:K:B^[HDI<57ZC)UPNNJ0-O!\JLCX<5;D3QX7)^ZG]XJ.$@;5=*5
MQ?83BU+[41K(6H#*4+R!D<5)->I)IU]J/XA[1>$R'!!D':\#D?WO:I3CM]Y/
M@YLIJ,MC9,DG&/*JG.^S+HRBP*CW)4 >>M"20GP"E1Z9\ZL0GR,+\5?PB;M^
MKNB?TYK9IN9),IRO9%RCW,>^'^YOWCM5N]UFO+RE+41)4?Z$\5ZFE&*2/@'6
MWNZCJ'%5[S/<-N+ABE1634&<E(*^T'\K(R1S5++>!O\ +.;3M44CVJ,J\B40
MRV$(9QG))Q]C5=-DVZH!N.ZA ^E:AR5+Y"1ZTE&^7P7-^&U&*W-E3U)JJ'![
MR%:I"E.I5A<A7*1[@5S]3J:X1[SH/LO/(UGS1NS/ID]:U+45+RH[BI2L[_[W
MYUSY9+/IV+!CPQ6.*HC$OAQ13FH_$T_NO=]"0B1]W)&:3(RR,?EK'44J,:FI
M.XB8V)PDIIW2+&I);GS0E(?2A)!/7BCF? 8]K=U1G/:1)#5H%M&5R)LR.TPG
MS4KO 3^@!)]JW:2#C+<^U&'K+_8J"=MR22+*VTVA2FMB?!CH..163)DD_,[<
M)S4*;%@!CI5;2"'"X!Q11.Q%8\1J5!;"@#-.A6.,#TJND%G8'I12'9V!Z4Z0
M;FCL#TI=NP[<NX1U:4)IJV)TAF5ETD9JU%7?@<1XXP.!4&R<8T/DI"1P,5$0
M8=:!!QR:AV&(29&P;$CQ$X%22ON0E*NPTDR&[1%<F2W<;4DE2O*IXXO)*BG4
M98X,;G)F86M<G6FL!(DN;XK"B4I)R.O!KLS4=/BJ*/(Z>>3J>KW3=Q1L\<I:
M0E*!@ <8K@S>YGK8)#:[OAB,ISH$BI8L:E+E%DIO'"T4JPN_Q"_*E9SL)YK?
MJ56/8^QRM)+Q]0YEY"MHVI&!Z5SECBE5'9FW.6Z7+!9BL%1#P&3^$C@^U-JV
MGZ=O@1<VTX/L^X9&QG>H)  XP.,#_*K;\3B7)3+''AI=C+^U_7"]/0RF(M+:
MB!D$XS76Z=IE*2M<'E?:;K'U/"Y+[3564OX>;?+N%SN6J+DG<[)\04KD\UJZ
MQ+P\:C#@X'L;I\FISO59>4[*EVF+#O:^Z2<E#+0)_*NAHEMTW!Q^OS3Z_+9Y
M47!Y0F2;<A1P$#]:S-;4VCO2?BY(.0?M#C=Q+L.HFD#P*,1\#TZIS^?%1T,G
M4H/[BSK2<<F+5+NN/T- ^";4HT;\4)TVA[NX&M[<^P HX3\P@!QLX]<I5C[U
MV]#D<7SW/DGM=I8JU"/#][[_ #/I8S%7G)KM\GS%#CY; W8%*VF3:5 =P%\!
M(I[B&QG?*D>0H[B<=H1<19QMIT *(J@.:* -\J?:B@$5-$*(]*+: #NS1; [
MNO:BV*D%4PDC!3FFFQ-((8J".$ 5+<R-(3$89(P*:R;>X.&[L&^6'H*?C"\)
MADQ$$<H%&[=R/905<1 'T"E8MHQ=:VGBK-S*W%!2A./I%&YBVH*&TGC:*E;(
M[4<IA./IIIL6U"2V\8Q4U9"20DMK/49ID!-32$CZ10"00,(5R4CF@?!WRR/Z
M!0%H Q!@^$4 (&*,=/VH!]A-47(Q@T[9':@GR1/0=*?+[B:2"_*'TH$?,#5^
MC98U.$V.+A<A7*CY&O(:;/&>.V>GG&BT,]B#KEO2_J.\^)2<D$9(J,M2HOW2
MG=?!2YW93'L<MR9:KLI32>M6_7$^&B2C8AIZTQ5W+OKK<$J1NV\\XJ>3)4+B
M2VE[NS&D;6S&89G'9)4!D"L'OS5LDHCOM MUKCZ/0N&1, :& !GR]:-')K(T
MQ3/.$74=TCSPR&B$[L #/ S7;<%1&BYROF[Q VM-;G . ?,UF7[.0D,=&Q7+
M/>I#4VW84OQ#GVI9UNC9+N.9UV:9N;P;C%I15P?6B..XBHT;2FJ'+A!%IN']
MFL ))YKE:B*@[&D1VK=#WUGNWH+ <C+7NR#TJ_3:B,HC(O\ T&N$II:%Y&1T
M)SBKUJ8H37F(:1LJ+7??X3=+FM!*]K8R<"HZJ<7#<D2@K-JTK(;94] WE822
M 2<URIJU9FRQJ5DM$BLQ[C\V8B0002>,US\DWV-48VD25PM[=WEI4DG!33PR
MXY&WM8WDVYFT)4@,)42GIC%.67;R6QMHJ;W: S:I0A.1BC<K XZFK8X%-;B#
M7).?.2%Q4W0(RVHCC&:R*>V3@3\.^287*<<B,R&$X!QG I0CNER3<=J%4S$2
MW%-O %24<C\JU+%42B4J,]U/=G8CC@MJ2%A1!P,5!XD^XH2*O9KK?[E-(4I8
M'W-2U...)<$4[-8T;*?B6M\/Y[SG!-40R;6DA25ID/(@IERG9CRR2%=,\49<
MK?!+%P5#6MKC7)"VW!X6P5@8\P*T:6?A.S8N>"[:-BM6^T0(+*0&VHR$# QY
M5QM2WDDYOU/UUT;1+IO3<.G7E&+_ !5EAC%*0MM9.4JP,_:J7/<D=G]M!W#[
M)$7W4EEL4EH7NZLPFG.4*=5P36W2Z26H5Q1R^J>T6@Z;4=8ZO_/00.N-*7,%
M$+4EN?6>B4R$Y_0FIY=#/&ZVLHTG7]#JDI8<D:?96OZT.H2PYEYO"AZI.161
MXFN&CJX]3#)S%I_)ICWYY!.SH3Q4-I;O78$'>=N>M%T.QPM]N/'*EJ2D <DD
M#%147)\"E..-7)I?-B<!3,I >;?;7G^E85_A4I0DO)_@5+489]IK\5^H^/"<
M$XQ5=-=R?Q(34MWFV>V/S8,!ZX/)3M8BL@;W7#T&?(>I\A6C38<.;)61T<WJ
M>MGI,#GI\+R9/*I5_+L9@OM/[6+7E^X]F)2QY[-ZS_VDYX^XKT<>CZ'+'B9\
MWS^V'M#HY_\ ?=(]OP?]4$3\25LC^&[Z7N45Q/"PDA6%>?7%5OV=3?NRX_SX
MET?I/T^-*,]+)/YO_P#9"/?$EIP(RFSW18/DE+9__>H_[._^;_/Q+?\ [4]'
M7&FE^/\ _*1,WXBM)J6DKLUUCNJ^E94C(/V!R:;Z!*/G_GXF&?TFZ7._>PM?
MY\C0^S'MOTOV@S?X)'DNLW!MHN!M](1WH'!V\]1YBN3K>CRT<'E78]3T'VUT
M?6\RTD(U-J^?AZ&FUR3V *<<T"9WG^=61$-;LUWEOE#IENM>G=21GU'V&8)\
M/JC%UU>&7N J<YCU'->JD_=3/@/4E>OSW_R9[LL,I+L=(!SM2//VJJSGM#V=
M,0TT)!1@8R1BH2[$$_>2&5DDLWAAYPA:<JP <CI52LO?8?&''B@R5O\ =H:R
MI:U<[1ZCWJ4FL:W,EAQ2U&18H\MF=ZJUT9[1M=K<,:/^):OK<YZ_:N1J=4Y/
M@^K= ]DHZ.*U&KY_S[R@7&8O<X<^'& 1YBN:V\C3/H>#/BA4(1I$4W(<?.P$
MXZ5+80RIK)N1(P()R%*ZFHMUP&65R<B5!#(YP!ZT(SMWV&[]P2CPD]:DHWV#
M!AI64G6?:II/22>YG7+?*5PW&C?S'5GTP.E:\&DGF?;@XO4O:#3=.FH3E;]%
MRR%AZ@[2]4LIDVBTQ+!!7REZX$O/J'J&D\#\S6B>'!@[NW\#/BUNOZFD\&-8
MH_\ FY?X(?VK1KC-R1?+_?)-ZN+8_EJ<2$-L ]=B!P/OUK-DU.Y;(*D=72=(
MR8,BU&IFYR\O1?)%D;V@J \N,^IK%RV=NN*0LG&*DQ137< ]:"0B>IJ0"@ ]
M!40%*0'4 =0 FXX$#[T5870U*BXKSJ=40?(LRSD@XI-C2)!M(2@)XXJ#Y+$=
M3*V<."*'V$$D/;$E0\JBD)B;:03WZO*B3\D"7/)G/:IJ-?=_PQCJO@\UU]#A
MI;F>1Z[K'^ZB/>S.V")";>4D;EC).*KUT^:1KZ!IZ@Y&E- =V%8KD6[.\U16
M-<W$1+>I23R?#BMVFA<S'KLJQX/B1NA(A:C&0L<K.X_G5NK=\%/2L=0W,LLR
MYMQ/"D@N'H.M98PW&_)D4>W<7LH<<*I+QR5],^5*?=)"BWMM@7%_N25>5."]
MZAR?N-GF?MYGKE38T%)SOSG/WKUG3H)1;/D?M?D>5K'\38>R*QHL^C&^,%;8
M5TYX%<;J67Q,ZB?0/9S2K1]+QOS=LP'6<GYOM3N3W].U->ATZK!1\KZCD\7K
M.27Q+Q9079$8G\(%8\G"9ZK3^].).Z\C.R]'S6XX_FM(3(1Q^)"MW^ -9M-+
M;E2]3I=7@\FBR5W7)!]DU_3;>U_LUU9'&3;;_"/N6UN;5C]%5VL3V9J/G76M
M.M5H(Y?2SZ_%>"1TY->B;/B$5S08*4D9Y.*CYD[I6!WQ5P$XIT+>P"I1\Z*H
MBY6&2LI\S4DQ *<.:+ +WAHL I.32 "@#J "N*PDTT)C<.'=YTR(=QT) SYT
MU#</=M$U2@D=*?A!XHE\Z1ZU)0I%<LO)WSOK3VD?$$BZDG-,!)SKQ0)A4]:D
M1!*L#DTT(;/+W=#4T5R$AGZB?WJ1 *MT9H'0"G4A/! H"A R0#C- ^3OF?[Q
MH#D#OP>,T"?8*MW"<Y_>BR(BI_(Z_O30,+WA]:9$\"ZDNMNMKHN8<#:DI&#G
MS]*^?Z-.2IGJ)&7:C[1-6WUQP0W)2F&^FW(!_.NQ##$KJA6U=H4R+9)$.XV$
MO.E/A).X].?M4)X(N5C(73>HHUU8E(GV+N$[B!M3R#3GC<7[I,L%B?LDA?\
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M[BL8R+5#F%1EV^,^"2?YK*5Y_45;'5Y8*D9-7HM!G5Y()OSX05K3UG9&&K-
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M*IQ**=27(DG%E3[+K_)AQG9CTE17N)W*\Z-3CC=(E+D5U_K*7,DE+,S>',)
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ME]J[7,G"8C2LA'NM0Z?;K74TG3LF?WGPCR77/;31='3P8OVD_@>=]5=H6O\
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M^=TW8WVRU*L\%Y!&"E;"3_E3CK=1'G>_Q-&?I/3-5#;FT\+^$8K^A3;]V&Z
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MOP-M.D 5YX-%*MIYYZT<"H.BYI"<!/- P?FPOQ''-% (ORRGH15BBJ*GD=T
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MJ+43ZYTGV>P=/J616R^0H#<5(2$@8Z5SG*2X9Z9QQ\;!Z$#Z0.M0)=@VU*>
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MXJ<X-[WF#C^<@H_45OQ]CC9XM0:HJR ';<<J(7@YP,\]!6A+FSD*.^#1Z4^
M#4S,+5NI-".C:Y=XJ)S*MW)6P?$D#U*5?L:WZ*2C.GYGB/:;32R8]\*XY[GN
MQE@(VJW%0.1GRXKKU7!\_B]WO#YU3>P!!.<<U)$6-5R&(Z?YR,Y/D,TZ*SDO
M0U'?M4,^B:*"PSTIE:0E#? &.10 F)R%@@('I18PS+*%J!-,BPCC37>\]* '
M*/EVTY/VYH$<J;&90HC;S3 B)=P0^Z C@8QTI#7 5I[8K)H&+NA#Z?"1D^M
M"3HV  *3^M.A4-RM>.O[T@H696E"=ZL\4$6.4G<G>.E-*Q4)AV.LE"U8Q[44
M'(D]'1M*D$$5)<!W&2(Z7E''4>M' <C=]G.X-8RGKFI+L'89-R'$J(4>GI18
MZ'K<EM'!SD^U-,5!'Y"5<)/-#"A%M3JP5(YQ0/@06M]3FW&,>M(35BN7O:G9
M':SS9KFU]D2NRC#BW7IL1LAAQ2\E) _PKYCHLFI^L-2['I)**['E>%JQNX-)
MM\1W<4)(('7 /!KU2PIJV1H?0M034-JBRCM8)P KK4)X(]T(CY>F92G_ .(V
MR0MT'E3>?#C_ (T\>3;[LB++/H/64S1ET^:AJ6RP\H(EL$]3TS]JKU>GCJ8T
MA-6;X41[Q;6;HTE*X\M&[P]!7G98GADXOR*7=DSV2:JLVC;M(LFI2@6F7_9J
M= (23Y&NGT[4*3_:&?/"4E<>YJ.M^S33]RLRI=C82[%?1WI2V.!GI[8K;J<$
M7[^,P8<^2,JF>8[_ *=N6BKPZ([1,=PD\]/M7+R8?$5^9VL6535$'JB/;_E$
M7MB '5='F\ E(QFK=%FG%[)LLHC;+J#3LID+0WW0'U)QR/O6^=]PID_#L-GU
M".\AMX_O'@5EEJGC=,'!I$E!TC9K8HNN2VDN]$C<, U5DU4Y\11&%BA[-&M3
M22Y.N:5H4<I2VO Q54=0\?=$Y3:1,6[LAT3 <!D3 %CC;NYS5>3J&1\)"MLM
MC$.PV2.6(3S#:0#C)&:SK)ER>16X6RHZELUEOSG^NR&G<=$[N#45//CEPBZ,
M4BO([/M/H!3'M#*P3G*<4I:O4[J)-JB1C65%K:Q'B(C =,)JJ4L^7NQ;T'V,
M;5!YU(0H=,55X.1,/$0K&-F&$(?;R!CBE/'DH-UC:ZW2TVT!(<!7YD4H:;+-
M"(N!K*)\^&$32@>?I6E:.<40E"PMZU[I^4ERSRN[+BP0E0QC-..*2_:HLQIQ
M@HF:Z(T7/C]I+4U^&M# P^%D^$XZ&NGKM7&6B<?5'LO8;1O6=;Q.K497^!NU
MQ4XI5O8;:4YWDQ*58\DCS/M7E\79OX'Z;G';LC5W(GF6MRP\H<)!(_,U1+T.
MG'U"NK <+RCE1^D#RJ4>U"O^+S!0LN$8ZDY-2? 78_)\.T<50RX*A!!W'G-
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MZ5&6H;E4D0\%ZB&^+37JO,);8RU2"0C*33S.XVB.GQ8G.I/DT>QVAV66+>C
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MLJ+>G5)1Y;G4@XJ&/H&J3N4'9HS^VO1IKW<O\_[#.V]AO:9/22+-#0#R-\Q
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M%1BT^]HN>E_!@]" *PZCD]+TQ;2ZM2" C'X?2N;L/31R50TU#>BQ%P23N
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M_,2@K"?*.LDE+RN>.M&Y,GLKLP4M/[@>\5CS&:=H4DT/&QQFH,D*CI4&!U(
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M3=O>R<G^4$9/_5Q6S'U/4XU[LF<+/[,="U#W9M+"3^7]RLW+L.[/Y@_D6MV
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M:9'GM-:+3:2L* !XQ6/*>JTDI46.,AQ1 SQ621V<2;HG8;!*=JJRS[G7P0M
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M),LVI'?Y;ASCVK%IER=KJ.5N+;,GOKV7E$')W&N]B5(\%K<GO,<:82IV4WM
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M0C*T*VN8S[5V(T^3PS4H/WAS'=)6$^53[\$;HE6X^YKO#@5'<UP.D,G%]V>
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MH)T14TNPO:>SA;;XDS+JRV,_@&3FJ,NN4>RL6Y#M?9':WKNBXIO2D*]6V_\
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MRI6TDGRYK5&*.?DRNR.6ZM:B5$[O3-6J)DE-@I"P-Q/[TVA)L.R\=Q'-*@W
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M=9BEXN@SN,5SM=MOX+E$GH%F4AZ:9"%I!"0 59!Y\NM</VIU.@UL8O2QI_\
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M@")@)4K@<#IQ4W)T-:9OF@5V]2U94!QZ"HJ= ].WW&KUL]LXJ:R%&3!2(:=
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M(UP=F,?XO4?L]#5,C7 =M))Y%5-FCS'2 4IP:BR2#I&30+S%*@2#AQ)..:=
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M#BD #C2B J@!)?=KX*\8]*!@/I:#90!R1P: &K)()!Z"D#%%*3BF PE.;!N
MSS420V==+B01QY4B2$E1,(#H)4?2E1*Q1L;DA(XIH@^XNW'<'/&*8@5$HY2K
M-(D$^86K@CK1R,;/H61N0.<T@0D_W;C/=K'-'<9&_(H_VA_2E0RWL3(-GMZ(
M\.-WCN .>>:\9XZBJ8EBW.V5F[7*UQW_ )W4%XBQ 3]!4 3["J81EJ)5%%]-
M*HF>:Z^(S0^G+=(BZ669MR2D@( ZG_.NC@Z?!<RLE#')_:/*%\US?-5WAR\3
M92T.*6? .B1_3SY5U(8U#A&I1V*A:PZA>@W,;\8/ECC)\_O2S04U3!FSZ=[1
MI#%I,.<T+E /]JVL95M]C6&$'&6U=BO8KM%XMM@TUJ#2J[MH92%#.76TG)3[
M4;5CR<&;)EDG4C,==KD2+,N*XAUN1'7E!'!216J+W,TXU%=BU]G;\75>ETR'
M.[3.C)VK&,$@5BUD$BN3DI? K&IG)3:'?D4A+K*_"<<U+ TXTRU Z)U1+LTC
MY68X$AT J!\\]<UEU.%/F'<FU8OK941YEQR!M)=1E6.G6EH<DXSJ84A#LZM\
M6;IF>T^\E)8#CH"CU4#Q73S2<)6B#23*38X:%7!]:N4I<.W'2GE=POS+"#UQ
M>EVY\-Q$ ND_B&15FG@FB4(V^2CRKB]<U]Y):3O_ *D#&?O6N*4>Q;M42P:3
MVR8CT9> H<)-0EWLJFN;'MOB1--23<GE'<E63SY&E);XT)MRX+UK!E%\T(F_
M6X$Y!R!Y#%<_3R<,S@Q+N88.%)*<@^>:Z3[FD43_ "GT%/XNN:'V%WB3[[,1
MZVE'>?S4C)&:KYNS.N'9K_8C#:@:;*LA2Y#@4K%>;ZW.6]>@W[\F6B_.ICMO
MR'5 (KCX,>]K:-L\[W^\/W/4$EQ+NYLDLC[5[/3XEAQJB48II6>A.Q-D_P"A
M,%U0QWSK[_'NL@?X5YOJ[_;.O@?H?Z/(>%[/1DN\I._NDT::R"H!1],5Q6Z1
M]$PK:W'[Q^RG ^]4MV;8H>-#C[5!EJ%<XI#;!%  T#.H %'U"DP%4]:B :@
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MXG5\&_"Y$9))[D7'M+F/LV.2EDE))V@_>N7TO'MR[609BD*S+&7%.Y(RLGW
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M>\(XZ4K'0DN2XLX5TH ,'$;"D_4>E QNI*MV"H4@$7%K962#N'M0/N+-7)U
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MR9**+[:(I;0,E*MW)&:S39M@BY1 AA:5H;(2L)!3GJ!T&:I-"5 *\1?[M("
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MVH$9"M/SK;BW%87CP@?YU.1CQ0W=R^=D&@+G>$WK4C*4);M03$PH_4LC*O\
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M4CDY6Y,:&,Z$D'KZU;:,4M.WR)_PPKYR11N12](V*)MB$\>?VI>(*.B:%FH
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M.]L@[#UQ7.UL>S1IZ')^^C5X:TW&9WS9+C;9.,<J)]_M^]<Z5I';B[9;X<'
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M45#U9:GCG_$U^)P=!_I&/Z2#_A3<4O.QM1CQ&5AN]\/7BE06$[S)IT1L#?\
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M3[XK!J>BZ'6<XYTOA1NT?MKUSI*V9X_"G:(65\),)Q*Q9^T M[>0S)AC"<]
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M/SQ_,2CH==7E(*CG\/)S5B22IE&/?DEO\C>/A:LG\8[1W;I(B!QNTQW'$/\
M]+J@$I'Z9-<O7S484=7I6%SS[CU;(AW2"ZI-N=*TKY3W@'!K@3]X]7%;#K?9
M-5R) E2"VRGHHJ>Y7[[1TJ+<4J"*DY63S6FD+"529"U*!SCRJ#E1>H)AG+'$
M9>!WJ+CRMK8/TC[^E"DP<$AA+M[24K1N0VM*RD*.<+(Z@8J2;(.*&4F*CY22
MYXT.@AM:0/%D>0\B/>FG3HA)<,CG;:HR@E);BJ<0D%QP[_?:!ZXJZ,N#+*/)
M'SF$I;Q%*TN+0K(/U)"1UQ_G6B+LS9%M*_-F(DNH2;HR4M%'F<+4>>..0?\
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M?6(I<J@CEW9;_M5A./ZB!2V-B>LQQ\QM_I):693??RTX6DG"1NJ2P3DN"/\
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M4V8AHFY1=6/N69T)^84L]V/5/K75S0486D7;:[FI2.Q:+.L04W'4J5%_F%(
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M,W<'C$; *R/+WJN3H#6-)Z>7;(C66@%%L DBL&6>_L4SEM-"T=I,WR>I#_\
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MV!X-!(,-N.@I,:!'6HLG'N''6HE@<':HX\Q0^X^S#)2=W)\J!H H.3B@5!%
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M -,MB%V@<Y%!*J.X7U% =P=B!QB@=('8/0T!2#II#0!0G/ -,*.*,C%(*$G
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MA81E.+#CF>*:L&/.^[Y80#D#K3 72$.>!*_$.<4Q ?+N>] CQ)>;&_&49UN
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MDPY)$>Y8IIX+9-6>-%&*>ARR\Q%.G)KG1H\>HIO-%$)=,FO.SEZ9?'B6D?8
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M*HC@$93^=*6C0WA2'37:7<+HI3T@!A YW-DU%Z9(-B NNIKRPT'&)KBE.#*
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MWK!*?FSD9)O(3!B+;C175HV.%U [M2L9QD=:INY VE"AZY&7#EN(#24N+ 4
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M$;O/(Q5T5YBW,9WJUVUS(2\U^HJSL&YD+;XT:/+2@*!&>HJQ<CMEU<G6]F&
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M:R;[ EK'-,385DY'6H*5R#N:MHFXPGVRM_"CCS\JZ>&EW*I(L<-MA^?O;"0
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M(Y4#E/ZT=^X*X]@WRI_I%%(>Y^@=,? P101:;Y!^7'I0&T)W(]* H,&,'.*
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MY'2)\,I*<C%=&/8SMV$<2L)&.@]Z/,@Q+*O0T6Q'GW1EY8?NK41$<*:0X-Y
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M!RT)1C I@$*059(H ;NMK4O '% "2$J;6=R2I/F1Y4 -94N-DA+Z#CHD=30
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MF:>5QX*@_JB^/M#NX+A*0IT!"=P)_"D?T^N:OC!(RRR29"3[A,MY5(FF0M6
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MDXY)QZ]:@N2YLO<2SHM[#:8Z4E0.#Q4DB-CI]IMMG /)H!#!#$AS<A"05>5
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M7-_@62/W,!&'#X4I\_0&I1MCQVS,6RY(DF7.<2MYT@#!Z5:7,TRW-A,)K/!
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MT3NR9;;='A!) Z5,1&7&0"I+3"2IM"@5A/7'G41@Q$J2'5--.@.?0DN9Q^5
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MEH*_FIP"?/%.A#NP&.@17G8 <6SA8!/7VP*$!=$NMK4A"XK9^8/>(2WSM/\
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M0=93E9R0I*?_  171TRK$D1Q\Q*ZRC"SW:E<>]7E@]"N,'GCSJ("12L#ZQ0
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M,>Q)DM9>T5+[JHMS;Y!\*B,9%9\NGM7$7AI<EC>?1/=2B(=Z3C.#TJF$'#N
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M.*Q3;ND;X145;[%<[:.U%R>SIWLETE='46+L\AN169#"/#<)8!$B6K'X25*
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MA(.K)P2GP\<4 #WV,X_:@!%QXE"L@_G0)C5W<O:0#TQTH$)IR%T +%TCC!-
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M6R@=#0(.CNU9R:!I6 K:#X3D4!0% F"?*@ , \8ZT (Q\_)J:\@[0-OS 6V
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MDY'7FLT_>Y(OWG8HN/W8VG@CK6>46*@$N,LGDC-1V@/$34#J!4=K )+OXCI
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ML<T .D%#F%+/2@ -K17X1S0 #B7$C^7U/6@!N(JE[BLY_P J &SK);/ X]:
M&[P.<8H 2"$XY/-  ^U  ;@UP@Y'M0 "GCMH 0?4I:-H!ZT#0@E)2L*4,8H&
MQ^2F2UWI(_E#%!$30C>,D=>GN* #%M2>-IH 3+CX. Z !Y4 &'/3F@#J .H
MZ@#J %8R@'1R* )  [LGICK0 Z9YY% #H)..E !N\5T3U- "R%N@>)6:8!5
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M."@\<4 (O*6DC*3^E  ![)P?\* "-J#:5%9QDT (/DG!1_PH :O*< QCK[T
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M52 64^%J#;N$J\P?6K%( Z8$5T^+FFE9-RHD8\!A@>!/VJQ1KDJ<K)2.VI1
M \JLB09(MH 0 L5:5BG<H]J /)D'4EPAO!QXKWI5N2I*^E<B6)-4=1I(VS1.
MO4:A9;M]P2I+@3X7#R,_:N1J--+$]Z95*.[L1NM>SZV:A2X^4(;DH!*5XZ_\
M*UZ?4UQ(J4W%T4CN5Z%D1''E]\ETI04IXQDUL:CG5(OJT:4^VI4!N[VU96VM
M(+C*N!^6:X4X[<CB5+W7R5>8R\^YWJW2D'D-#Z<^];\25$9N^Q)PV$6YOY@
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M;;D+<PX!'WJ X.>E6Q6T&Z(AJ<7!(4ZD%2U9!'E4I-$),F=/-PIL%Y+Z/%C
MR,TX,A5@P8#"70@@*PKKBI*%LBX472#$B=VD);\0J^,**VDBRVZ4F/ 4QW R
M!C.>E3O@@T5.XQ7I$PN,J"<DY%(E5$E#BN-C*SG%32:(-V3D H<*0I/G5T>2
<%$HE 2? ,5:N"+%TC<,*YQ4RMN@=@]:!;C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>comp_0028.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0028.gif
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M[/#O[_/S\____P
M
M                                                 "'Y!
M(?\+26UA9V5-86=I8VL-9V%M;6$],"XT-30U-0 L     ,\ 4   !_Z 6(*#
MA(6&AXB)BHN,C8Z/D)&2DY25EI>8F9J;G)V>GZ"AHJ.DI::GJ*FJJZRMKJ^P
ML;*SM+6T5[:YNJM(2;N_P)Q7-B$# B(TN,'+S(Y%% $ 'B4" !]4S=G:A#<$
M!1LY@DH@ "';Y\PN RA*ABP /5C*Z/2T.0;MA;A4"17U_[.4!/BAB$4#@ A=
M76EP8A$2 D@22DP%PX$B7$@ $)G(D=03 P07&6$P15_'DYAP9>#0:$B$0U!X
MS M%10?*91F+R%MDXR A*"L< $!!J@> )3=3JLB0K],&EHU42"#4XX$ !BF:
MD*(  5O22E<^$""0P5.3 !L977$0#Y<2 _X$*$0D=2, U*^44!!HH$#"S$P>
M'GA=1(0 %$%4*C X4:64$P8&8N"EY,(  P8%9G1R0L#FWT,E+"ACH:"Q*0\'
M#B"='(D' 04,$FSX?.D& ]J&H!RP*:\!C%-!$CRH8)JUHRD/#$AH0"!>IP<V
M=BZR\$ 9%05..DEY@NB"@0(N3A:?=*5#@!E5'C@XK D7CP"K"0,0,FA&@'";
MA## ;D@_!_ZKX(8)%2U \(%.D^@ P&_\@. )!?XP,@4$%,Q# @ M2'<)$@8H
MD$!\@V@0@PD13C0#  @$,, -&C92A00''%;"?)L1($,C)@" GR />="B(.,U
MPL0#L#%PV#Q(,/Y@'PZ:\)#6(E?P<(,-)\1 0TF;7$'! 23PD%Q3ACPQ X*#
MT " @TL8@(& E-"0 )NXV"  <814X4 !.V(!A0P60* !EHQ8L65L$@3I08>"
M(;*$#"30P,0B39 @  $[+ *%! ((8" '"##P9"%6B) G(R\.$ 06+0#0T"$L
M,"!  \5-$0$!2DB!*1">5  !FUCX8$ #W!6B0@ 2X  $$"\DI\ !"0"ZR RO
M0E9"(5,X@-FTASAQ0 $&'$  "[0-X4(#!CAP0$B)D!" !?%)L8"/A]@0P %@
MHFJ!%(C0$, &6, P0 1_.:%" ?L!O-,)!BR @P< D.#)% >PJ(@2KOXR^=<5
M&PA@P'?,(E!  ^A"J@ &"C0@ &^#Z$# 92 .<L42!Q!W!1$)9.#5S"!D8(
M)0N'VP]+:'MN(2(X^-D&"1SPZ3T"..SR3D\X8$ &%!C@()!$> #990F0Z<,!
ME^U\09"9M$! %!.3Z_0A5Y!P&;D-A& #OHYP8((3'3:0'2$<)&" Q(<T08 #
M,00A<  8_,!"<@%\C,$"D$47I@@&1(2! *-:8,[36 Q1L@(>]-!##O]=Y@"9
MA2"1  (**)"!#SV$($'2!R3<  ,@X!![ I<=H( *9&?"@0%['Y+D 0VP9P@N
M5?"5P QT/Y+D%3<PBT$A4CQP@ :X.4'$!OX% $!  K E$$  $%3 @Q-00*$
M F49@@0$& J20P /&#%($$T; D/KW4+ 6 (@@-H98'4;4($"%7B"#8#@,@K8
M&0  H"($'& #-G"5 0@8 ,LLZP;*Z\04)$" (2C*7 GXU"&HX+P3\,H0'-#!
M%<"&  L4H@C,F@LAW%. LM"  PNPX ) )X3!8.$)#"  X'8RA08,0 7*N ((
M>$8")OP@ 0586Q5V@ $"'- $I6N !T;P 1X4:%G>&(LW:M<Z"9R@!3*000QB
M0 2M8 $)<%0!!C+ %P:@SA-"6%GQ"/&$!B!@ 2I$A TL4X (_%$12[#A!Q!
M+L#A @4'M&,AB/Z *&4PH0A#(*$OGD:$'!HB!@'H@#Y*X+?6,6 !%2@!"38@
ME  TH 1V?,(3G"6/)[2O?5)HGR^A\(3@(8)#2AL%# 2@@4-(H0+DTY\C6&"
M!P1@B8LX 058L+(%)&!ON @"L^)7B"I$(((C:!$#FFF(&A"@4(9H00#268@?
M7 8!&]N9 !+0CQ/,8)"9H,T\*B.94,P@"1\0P/6P!R,#.*<*P6*;GC8000^\
M$$@.:&5&X2D((;1. 0\H212Q4 ++, "@>+N+(' ! P*$5'Z^4T$+./"!#US
MBPFP  QF8 (;(($*5+AH)ZZ@NJN!(CT^@!$/GC8%"]0./_.3W#$A4/X["_!2
M$3WXE0%X,(1&*N,'"BB M0Q 'T*8[0$V,L0& A >0RC!;S[X4082(  "9LH
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M084'8& P+1" Q$I0 :%"@@26^9 @8,#/ T1'"!T, 2X^\P/+;/5'%VD5[QA
MA6<: %>+D$(/YA$"+VJ. %?A+R*B@ ,>Z$"&N\@ .;' C^LIPPC&M$1F#["Y
M$XQO <R]P@K4/ @H9/0 2XU$0KF6  Q4( "2,7)]K/*J%40/(3(X0&.4P0,
MJ( 4?C4 #*#0@0(<P +9740W$E #&CO'92'X6 !PD ,O$D TE9#""W000DA(
M&A55B%@A/"" 1/YZ @/(\P!S$@ N2-B 8"&,0A'FDMH 6'003-AG B0&W WT
MVCC9G IBI0;03QPXO02H0'P?46L&5$ )2K !DP%0(2K@4\9U\@ $4@UN2" A
M /29!Q$$\($\:P(*7%/ "WZ]TA!H.P$3A  ,O(*#%;"7<_V>1 A>4H@; "#1
MH8#"\ Q @4?ZV@81X*<*>/#MC'-""@/0J\LH$ $C>@('-J9 #@S^B"HH(<$8
M=WDF3N" ORA! "8(A1(T$( $V,#F0@?&$X3<(N6N>Q-00%@ 3 #TJ <#!@P(
MTA4J(.Y.+%@ 'C"VUX&!%4,L8>N;R0  ,*#VM?]B" BX.!9L (#H,/[\$%-H
MJ08(;?=@>( "RX.&5"^1 PVTH%Z%9T84G&Z(ZT0@L)B PM\C'PO2=AT( 5@;
MYUV.BQ# 2U@  //HA4X% WQ:'W/%_.HS+@3B&8*S"NCZ[%GC@1(1 EH8X/GN
M48*!%!SB0H<=/KCQMI&9:$D FMF\\L]A'[V7D@'\GCY*6'H;0\Q@ (C7/FNN
M (&%%@($!%B3^"<S!0.((#<.&$#=US\1*1@@0S/I00 ^('WZ-Z,( , DA1 "
M ?!J_G<3'H=-5R !9'6 7Y$C4N46!U =#I@4)@!WA, " 7 C_5>!O[ " 6!4
M1^0S'G@31@ VFN1QBU>"'-%$F#,(?G55+"LH$=2P.7S75C-X$F_E>N[E%SEX
:$S& 9FA&>#^8$$3P 1(P8T68%,)7"8$  #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>comp_0029.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0029.gif
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MX.3DY.CGY^CGZ.SL[/#O[^_O\/#O\._P\/3T]/CW]O_Z]_;W^?CW^/___P
M
M
M
M
M
M
M
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M, T+ D" !#P@C?.)S]3(Y*D5 $ !!CA =K[VH XLH@ ; X  1& !G=Y0($P
M  @(%%$T,&(# *#G U)COPX H <G*  ##"#.%I1(9.DLQ $>T-,X@ !J! "
M!40@ %6-"Y8&B,  +K"(0R2  1+XZ , \;$#$  ! ""!.I,Z@ 9PZ"U?2R<D
M]I C/9C0$(\(Z /H^:H= . "" B  %P@&$@<H9IP($%#(5$" #"!#N$<R(.L
MT(<0;/8$G@4MD00"@@ T04(II?Z#9@6"VB/H00"KA<3)V&A:@:   $7X@P@V
MBZ^,0J(( *!  @80@!"\10CLC!DD;EL!2VFA2O1<@B$J(( &$( !XQ)! !YT
M@D$@\Z0"*,$$ !  (AEBO1!(P#-)T%X"G!,)1;.  $3F@-3 X5<""\%G6@
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M  H  ?XF-&VP0H$(0V EID\?$P!SEP'.MGOIE&45T -9=BH,<#@#H3CBU ,
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M)%.3$]!TZ40'"6 !CX !!K 'C?Y0"$-P*B)  %L0=\$T(K\Y&R0 B72  !F
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MHWDJ^$(REP6<T^*N!2NOIE&U0V91$]!>S4$! E ![PH?@X%:*5 UV@%3JQ8
M#< !$P OD""*\#$(X&J!1G-+2   !A!6R1I"6[!<OV( V7%9=L5>%0H'*E*X
MDV,0096XR0H]C#M/ U  KQ6Y@%MT8B*YF7=T*))\&# ;^/( 2T,!C.!%T;E
M \  T*('## DRY4=-$,>>_!%FK0  JAQRM>W_U(K0]=9H 8 MZ0'#6!N?WLJ
M36" S"20&B(:2<,4X=,#U LWK_Y2-4@P B7@C88@/CWP ]8[(CL@/D @/HCS
M!XJ44G"0 TT#!+-7>3AP!R.2 Z(!='SR"$)  D( =*<"""P  I^% ]/TOF\!
M=*"V0IK4 T/P%MW[ 2<0GN71 B#  A(7!3G ,GW OH;6 H5GP<RC!1H\$$U
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M"$) !]<-WZFW" [0 AM@/CY LPK1=EC3)1!P2QCQ%BYEX"T!!P=P! SP*AQ
M,A9B"-8&; *!>:E1X!4& #B(XAA^(7I@ "WC +D#O17F AIP J0D!2JI)@(A
M!,]7 ^"# QD  D#4 G10 JDA!-X!-ST[Y!RB!<%" OW<XB/Q%CT@9""  G2
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M#$ MH8<W*%!WT9WV%6'E!#, ?:#AZR&*<;*R@] '*R(A\_8$CO!D])$ Q.(
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MJ4AQ K*/C^QF-R=))0H8P@4]D$+]'D (1K3  RS 5V@,H#](6($D&E ($T(
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MK)TMDS^X6]R@C1[@@%"#6_N*C<](DK9EVH+0 JA\#B]+@*>( @@H@A:(@-L
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M"'Z(J/FB<'F-#R"C-$*;-*J#/WF7C_2 4K)'#FE")P@"(PB")!!A"D ) 6.
M1]@K8-N;QJ&(!Q@$%0 !YNRI+3A*-"D$$<" H]6"(W$$+1 " 6@2"3 =8QF
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MD)3@@[@EY) 1)$><X,*Q,&[@POY"@X10KR$66&$!OQO,61 C*BRR" 0\0=(
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M*N$W*/Y=20(#WFL4"4B7L1A8 P4R(@A#,&*%F@&!0C P"..&Y A0\4"MBM"
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M144/-,#6P$%TL$ 0P E(" $&C( +1$5%.!(_M< %D !Y(& &; !$0$(.%&7
MM8 /+(<6D$ <%<03<$ 'B*)S,/Z 'SR2(-2,<F@!'1T6JA0,1.3 \!2$IDF*
M0$H3018DCG6@7%Q?=;"!#F!!%CX2V W5BTA $^@!"S! 2]"! LS)(X ='>2
MUD42,#* Z F!!-!!(I3 .'I@Y4&C6VS! Z" \4G!P(5$"U!1'Q#8Q7B %N!2
MN&C!]W5);Q;"_BC$A@U"'## 'AC"!'C5#M3*"#P %10"')C-V= !SD0!(P!!
MUCA "@Q"$Z"*%D3 YVR V:PDFS$! L3!(%@ $$ "![2 (62!F^W !AB"($Q
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ME=8V#F(=SN:*+@0(;$"])(TC<?Z LW8 U5  @!B"!-Q)#B1"ES1K07A 5#Q
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M$?"1$GXL"&B ]W8+"'PL'1A""&  2.3 9NL'7]"!-=Z'$#3WCPV(2:R?"EP
M9VS5?E !$EC,(T@!$HB5B!;"2>_J\9P &>V'MGCJKLX':PR"C< !(QL5$(A
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MT"!64! 6>& #0W ("WH @@)UT7A1E"*WJ,A(2<K/?C7,HKIP.$D>_4\U6FC
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MD&\-^TL*HPH."6P1%H C&/ QRD7K$''@SK 0O07J*O'"%/[QFBZ0O1Y" T)
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M\;IC*G8 .D#@/."@!"A$"&[Q7!AN!JK$584#5H-C!NXST%[C2W<*$OH 1GP
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M$!H@3% @D%(730(*![2 !;+"?S&"!#8&$NJ (I[ +FXC4T:"$3*7#CI@CR0
M!16P($1B$2A.#_Y@ >; $:P8!&0$E\WYG)W1/M "!T1 .TJ@!FQ"!/H@ PQ!
M"J"#/** <K(1WP0J2^(,$DYICD&@KASF]5A "/[  6I [W"@#[*1(R&A RS$
MB=&YHBV:L0AB\R A#AI (![! =!B*ASU83IB_]X#,*,"$MZI3$)@)&2E(%3
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JN[S-^R.\T3N]U7N]V;N]W?N]X3N^Y7N^Z;N^[?N^\3N_]7N_!SD@   [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>comp_0030.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0030.gif
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M^OCW^/?Z_/___P
M
M
M
M
M
M
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MJ2*@F(@43J0YU"06-' 8!PLHEH<35!R62.Q=L%=%081, 46:LJJ@QQ. ():
MB(A%845R _D#' Y!!2W K!!2>(+ Y- &D/FA@:J+H 0UTH( 9( !G'F" "YP
M@ ", #$1($ $*'  W4'K !20  $@D+^)44 !&)A$'@A0 08$  *)F(2M*$
M+.2A ?[>B@()%%"(XRA@!XEXP 4Z$ #S0(TG!7%! -KP" -,B0D P$ #($"=
M '   &W800 248< C+"$B5" !"C K*T9@%Q<2( $&$ !QA1$!02P0 )$YZ05
M6J  >4@" ,)& 0@H0CRGFZ B%XD^!YWH"@%P@20T< !**"$ </L  4PXPQIU
M(9*42 !,^ 0%0AA  X]  @#<L"D]?:"25P  W#RP@*49 %2Q?$(BM. ]H;0A
M $GH @!N$P4H>*I571@ !L+6@@$D @X[<!(P'_&?2<AA "AX1 %&]P  [4$
MH(($):38)!($P ]QD*0<@'D( 20A$0)HPB,(4()%VO.>"?YI@P@L0,(_6 $
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M3@F$58<0@0&:( ((*8( !P 7IQ@1 %HE(0 H,($!G.@@ DR ! 2@;$J=0 (
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M1OB=$"UH3B" V .R]SV0=4&B,(]@A+M( @DF:%?=(+<)!_X>(! H-(  !,#
M=)1  ):BX !Z8 0$&I  !1A@ CO+@P@BX(&P@4P/(I" !SY.B2UL( (H4-JN
MU>JTHS#" @Q(  (<T"1ARWIW%B! IWR#LUX7S>M=?_5"RFTWA8BS"P3X,]'^
M< *6WFRK"1D$ 4 E!PV@? '/HL0%*%"01$!@4E9(0 ,.H( !@ HX5\" !%I
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M E20 3K'8!!P!53@ !Z (H1  @\@ 4T"!QX0!1D@ 9U""5-02'1&"8,@ @V
M 6XW%RK0 B^!&"%PADZ3?8-6 0[0 5MS 0P@ 7\6A@XPAH=@ @VP C0U)IRU
M! "0=_YZL(41" %MTP"< 4D*B#,08"VJU :E(VJP 0F;@BB$ $-.P@$18 %P
M(X,PT8"F6!(=4$N#$&%F@P0K! $SEQF/P !UR $:(# %<1R'(8.<<1R*\0@/
M@ %I5"8(J"  X 1Q8 '&! 4!X#0+.!,% 8P1X 9R4 ( @ 58T"=80 #,P4,.
MD 2  !MIEHTH0 4$4",H$  -0 )U4',I$$(;P"HB4@()  </X@?") $K,'B/
M$$LGX 0 ,#HI% <B< "?DQ 80  / "H5( %P0 *B=5_I0P IT(XUX@)O1 B5
MP@1<8 !$I3!(< (%,"D"84HBDE+381IZ!(L0\!^:,@ 6\/X!&< _PD, Y$()
MP@0%!?9P4B0'%30=E+ !#) ($U !;/<!(*,!WW&*3!D2&>  E/ 'K(@WG8$$
M P "*J "%K![CP!$-#4!T",0&#"4E/ ($$!9&;  NP@!1ID #4)7 [ "950!
M+: %I/%^25)N/,$($9  *D4 M*(!#$ %5N  "C!)"W"0494F&% D5!( @W!A
M<,-:'X0$ J!0#  3A] %6B J;?!+QK0"&^(!FI<'?H @/N@"Q_@(*. F0Y(
M?D );1 B4 ( 4" 'MDD)<= %3L  <_)YFL,!"A %6! !"# (#5"*3#40>T
M&B,JT ,U$]6:)^"254  QC(!M/Y2$')  *+V24X02_]V86V@?T!I*X20 09@
M E!PD!^@ -?7E/*)$1J@>1#   <9!17@!TVP5I1@ @.0!QJ8);@!8K%)"(#"
M5@9 /P@ $P]  >*T)$F DR4@+2)B(=_UC#1AEA+@!FV0!P41/BAP CN0!(^P
M=W$S/=-1 3A'"4P0 'N0!!"XBMSBBK$IA?_) "C03!X: +?13'M0+0(Q,EI
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M K&8#04"A-< 3M,YN4(("#"O5D().+HC$? !!J %?-(IS20P9'L #5 Q6*
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M!LAV" :<"-)+5P% NP2A!VX@O8=@OXCQB[[;$.\[MX\0!W5P&NNCOR79!7D
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M<167.I. ".@]&.B]WNS=WNUM".Z-"/#MWO,=W_3]WH90W^V=".B=W_:MWW_
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M8@F(7!"4B@I"< $%2JB@*8H1HAAD/H@8&:$%#BR0(B<1.E@!"@T240*##C@
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MI!U0@0<X)"@=D-9+@K\\ 2EP I"""$60@!5P@24HSC\H-4JX NA\@FJM@$2
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M!"J@Z@\0 1[\#Q  @0Y@.J0@A%;;*4HXA)1-VK)6@;-.!+5VBCAH@19 3RY
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M27B$XNR/0: ();@ 2L@ -PF*"1C0)F2"<L\ _DAWE? ;/_XHNFJ/ P\+BBB
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MZL7BFSKKG#&2@@*]G93&!Y2<.10@#!"]8@=Y4$U)&Q(4!D?=),'A@;B)>/#
M77,R]/Z$!!I%P99"(&"X@WX55*$1!E'T5(4$&:S>.F9Y-*#D(PZTR1 (N5&R
M0^U82)"6%]"11 @'#BM!%?G]^_\_U"!!B"I<S22'V!PE%,$!+21B"LXA20>D
MH#>&D<<%<6!!I+1#@9]]( HBD*"=T@"X,)'D$160 Q1*I1$6M" 1=># S^)P
M 2Y4(&$ S$PB!C,)-US@97I@A$!.L ,9;0@_CF&(!O)&"2?P[X9.?"(4\;26
M:Q&Q)TYH0 @8$!6&3.%+XQM-"M@6(IXP1 7%4P)@-O"V+R*H.%/HR2 H4)L6
M1,!A>GA !ZZBD4=@( ]ZB%X4.5.(#R  5_J* @0BX)0.>/Z/(1QP@D:<X(&>
M+$$Y; PD)C.IR<],L22#@$!6M$ !)<7Q9Q:XE(!J<H(O)4T"V2$$! ;#!0KL
MH1 94$)A[/0($U! /]I1@'QV0)8(R$<$L_G "B!A!0GHP8:;?(PD&*&'"=1J
MCX\HSP=45),--)("@%L1S9XISG&2\S(,Z4(!>_*$VM5$!8"IB0=4)(<)A%-
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M!E"%"33 !Q@;(&3  ]3-%A"@<AS@12D0"7  3QR"!&3>YFW@LHQ /[F3]""
M)'0!!_X\00AL00H< A.TR5QL *XPP@0XA@9LCW8(AJW8QB-0@&.H4>61 $-X
MP-M$ .4M2Q=X  1T!TGX 0/DC0@D@0A,00MT :)42QQ @+!4P7UPE9HM4>U4
MX6!@(27\T5 P@??L0>E)0?79V6%M  4XA0YJQ&A1 @K@7Q,HP17$P1/0S"=E
M3!= @ !E8$E<06]\4G?T886YDF[91F(H B, (@<^8K&T@06,@)(HP@9X  F,
M  5DAQ8@02&40!IX@!-D -(00@0031*00(9$Q5Q,':N!DD8H@2KRX'$0'@1L
MCQ!RRQ]L@0FDP'(D@=MHA"(H@19T00M0@0C@'V&@&V PQ/[F (),@4CM])]"
M4$ >#(),<8$2F$#T3$'%^8\>M(=M>($$!(GK@9035$$<H( 6?  2S!\E0,$D
MU00&=,%)$0W#]484M%U-9, 62,(I:D0;* $*E DC!"0D)J2=0$\3$1\7N,$>
M5$!:@ @3: $^G0 (F2(JSF+>C,@C3$ A) )"RB(E\& 72( 3$ (*2)#Q04L2
M-!HA-  A2 ('*-Q)@ #'M8$D7$ N4:-&3( >7(FU0(%S4*,SUD$<:80)=  7
MY$%O.-"O1<TCN #1M $$2$*%54$B.$$)V(L(U($)Y T&8)0\*D0]3EW,68<^
M3A)#9  7 *22;!L6_($&$ (,:OZ@0N9E@L!! M2!)/R!L"S!79V *NI:/VU!
M/X' %MU@ OV=5FR/1SI =U@@)32B6$*2UM&$!'C/ U3=G0@?43Q.";S%(0#"
MPNU>;G@  UG B,@!O5'!?>1!Z8W'$WR)%U)"%4Q &#Z DC3 IFC! NQ>79'/
MC]!%VF0 )$W=D!0&%@"&"<0(8B@;2H&<'\Z<>EU'TCP H'0!="1" PR&F%""
M&RA KSD 7NHE>OZ.$T" !EA !; 3"61 RID*)3S!&TG""7Q "3P7_G@ !F"(
M"!B*1J@ !0Q"(G! !_QG:'*!)7Z "B#!!A0"!^3:L#S""&Q-!42*!EP AT:
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M)P4 !E   $R2'   8%!"%@! ;C   3#  B@ S?'% %A  G2FQ&$  !3/!P2
M 1!  %2)" A  @3 !H03$@! &B0!  S  !Q Z3("!1! !0" W8TM[YI&821!
M '!)U1QC6G!G+]4$%[1 $PC+% 0O26Q!',!!1VK!"EC!7-0!$NQ =TP"!3@>
M%NB'%UC!%6"!8<&!"S@!T3 "%#P!%Q  )(W((# !$C0=%[C %(C+(UC!'FB!
M$AS"("3!77 !'+C!#GQ3'+A $Z#/%>S!%B!!QE "("@!!NW1%:R % P%%20
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M)0!98$$ < $A!$!ZN$$ ( $C)/Z /L8M' C I1S" M0P2<@! C" V4INX44
M @C   2SO;3  #0  62 DM2$%BC '@R" .2&%\1.N@5 $S5! (C/>-BS?%0!
M +R-"05U$O2R%1NT:5=&0M>G90L, @"=25O'!E2 !1@ 15NT1J"-1D ! 1PN
M!C /T95- 8STU4" [+0  ,1('62R;(N?63M&'@C 1U$"<=,K%9PUIB@ 5A!
M>K0  63' N!3VVJ$""Q &M2M;$= "B!SW5A!  ASZCY WD !!EC !#3 AAT
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M ( OH@  #,(D$$#;6< !?');4P(3", ';  !>,$A,.X^!?,> , M'< )Z($
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M& &(%N 2"1N@E")5,",7Z#*")]B!!YI B2:LX'E4, $)9/4$%(@ )&THP0E
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M A,DT80+/ ()4BC$'DH5APX49 4/<!<2=%JL1W"@ GI0@@A4(-,4M15/ MD
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MIJG'KL(Z#I!C/"! 9$J7D, %E(\2M" %D* #"&%F]$"%K/X ^ #G"93 !;P
MA.)@"G"*#%=H3;2  ]"H(+B  SY #^(@  FA$36/X$1 #E! "I#@"N/ #P*0
MPT@&$CX SY J$I-@%@4"!;3 !4 B"C9 "9  !0JA#3A@9?Z@ J3Q!"@.))+
MHG*O(.+O<? ,!/:@!48@"7:@!4CFPBCA#U0(!)C$'%< B0Y!!/3  I1@!U"@
M#9 @8MHL1:* "0AH9N21$HJHB +HTBAA"C: ! AA$&9FQQZA#5 @"32 $$2
MGE9 !)+ !5:@0EA "UK 6T*1!)) $<A,A0I!!!PL"2@O8BAA!1S- P:A7P1"
M#P#H"JQHJ[P  [9QQ(*/_P3B _[^P!DIH0U20 DR0!&2H .UP'?6#B&QA 3D
MX 3V0!( : ]42 36I MNI0/V<06 JSWF<(7V( F4BF-00 -R1 3V! 6P !):
M  D\  ODH.$2 0.0 *.H0%<T *<$(@U60 N2 -GV$07D8 0Y(&):P(\L8 =
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M#Z#@@P9!7-@S9L!0R#S #YK@@_BGZIA$"Q1A!2)&#V(G$TG@$?X @&S2-97
MBE+ =WQ$5J9@.@&($?1P IA$W3:R@WRG$#;-#3[@>7:@X3QHQV:)X#) $C9
M6+I@2J!@;R"T0@O,XF8,LY)2HW ."T!&#_#FM/925P@' N@)"I,@FBCQ>?+N
M<?8$ _2 !/)@$O F3R/.CYP@BX)Q"P[! TZB"BJMBWC)CQ!B3BA! [@ !71U
MR>H&A*Q &2.N1+S #[; 6C@ Z?XF(4+RX E)9E6M8!(:00)XR4B -( &X58H
M 0NVQK2>)Z] <5A:H T *!%:(!$VH..(Q@(8H0-TE05<P ]&(.+8CQ!4P$P\
MTB-4Z! D@!%.8!1/0$(H@03:( 06I 5:0 Y2U8],0%:@=0EFI O$;R]71 L@
M01UMKNLT0&/D!P6\@/=$0%6WI@L " I'H)O^@ I(2@OB<4,B)@].CF;4376D
M8 \HM" TP-%$@*1H<(6T8%-#Y'!$=$':A1(!:"'2[4"N8.!J4PH^B,,F(0X
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M'V<$(4J@BM)G!18D"K:&$E*@#MQ@ UQ !6=RNTB*.%>T"G9L!4S@=1%-!48
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M$>:+O_'EK6A"<M[17.ZCU1W"98[<(AC!UM>&$$8,00LA$1@E><6&$6Y](?1
M"!5AV:$\$0KA$(R;V6'&N4-&)]I"/79=+# M*@:!DL>C4-2"/UA C8;B$.2I
M"<I]3+@$/=2=*N;=*O)]*O:=0"Q$* QT.XQ"F%! KZ%BWUD$(0Z!8D7D2]3B
M$=0T*[IC1! >0Y;#W_6=,BJ^-#8>049CWSM^,T+>X\L',<I]Y$F^+U >*U8^
MY5W^Y6$^YF4>,K1#>$(^/OX]Y_Y;?N9YON=]GBJ<B2O$/3T:,D<P_N>1/NF5
M_B@4)[$RP@V$!4 >5 \JP$OA8,08 1(R&-6$!0[$)!&X8)TEX0^2Y!W=8"$*
MP0N()P[P!,U+!1+:($B2=2#D;^GM_N[Q_DM_C[63:7IW%02D( H<P*)6RP1F
M! 4ZP)/XT@/T2]T&H0.BP"6K1@D\@*2<0(%FAK*<P 24IUM'0$<3%P5X+Z&[
M0'1G$@E6P.#S?O59'^;7N@J(TP,F(0\&\0+VI!:G-D8SD@1 Q =Q- !#Z!&\
MA02BX [?4;8T($"D@(?]: 7NBQ)5B!%:%V]0H N8P$ST0 NB0 E@QUHG0+];
M/_S%O_X_QC$.&M@#H( )H@ 0%%GH9DP:UYA=%H2*I@M&"A,0L.P$J  ^29-K
MAV;F $*)$RV4*#EQ47 2)1-82% B05"2P298.$!AXN10P8T<.WK\"#*DR)$D
M2YH\B3*ERI4L6[I\"3.FS)DT:]J\B3.GSIT\>WY4^ $))20[]GB@1.@)HPV/
MD&Z@!&?#I#\8'HGH0JD-"(,M*)WHHD+)0R=Z/E "E.&1!CF4/ Q*4852E38%
MXVB8M*=#5@I,#)J0NR.*"T(<*"7J&T>CS\6,&SM^##FRY,F4*UN^C#GGB<TF
M$E&*(@($P19-$R&D1(6$""Z4E.2AE$>LEBF4GK091&('%.XD>L06ZNIFA @G
M2$^,0.&Y8&H16R@]DJ"G(!(2(PYM@4))BH@0<5G0S0P^O/CQY,N;/X\^O7J/
M(.@J+/CH/<CX)^5_;+H1/T=)I57\S6\?)9)(M%Z!!AZ(8((*+LA@@RFU40@E
M =(TH80<5<@1(4XD!Q*!#GX(8H@BCDABB2:>B&***J[(8HLNO@ACC#+.2&.-
M-MZ(8XXZ[LACCS[^"&200@Y)9)%&'HEDDDHNR6233CX)99123DEEE59>B666
M6F[)99=>?@EFF&*.26:99IZ)9IIJKLEFFVZ^"6><<LY)9YUVWHEGGGKNR6>?
%)04$ #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>comp_0003.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0003.gif
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M^>O[__/T]/;W^/?X^O____CW]_#O[^#?X
M
M
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M-0^ ( TKR^L1 *N?Z_YFG:Z,CCKWS->&=>'LMS_0*Q>H@1H#%TCS@0*$'Z/
M"+)<X&TT])/&'L"G @0(3P\%<$ !V+ *!.A!%@<0P3- \ !DR"(#!C# !^JT
MB@<(( ,@,("X9*$ $EA   TPA#0,P0 $', "R$C" %@A#2080&G3X,$ %'"
M,4@#$/X&L$$#!" "3PV!6BXPP!"6DX0"N$ ! _#!:=9@  08P%M W &PBBB-
M3SC   78@32 D$ #&.(%&6#% AA@ !](8P<+@,  RN ^S<"B -K;7@"09X0$
M($ !AS'# 8X@ $"TH  ,:  Q]G"  QB !].@1@-6\($/L,( +X"  (#0LP)X
MBQ4/<.$$I*(""*P 69(B!@H*4  (T) 5$ #C"HZVG#,<( D"Z,,S1%   TR
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M! $@;S9M ( ACA& *[!BNM5=[1HBBP1BO$  U&##!Y#QBMY)(Y9O8$4B.0H
M0AA# #YX1GH%H9H7!( 'K1!! %S!"@L,8AH36.T%;EN& -!.L" NDRLR   ?
M3 .9]3N-!1SPN!&7N#>LN (%*$"QTY ! *T08 #:(! 2!$",U5  !7A@.P6X
MHIH"L4$"<!I$@1R2:'LX@@C.)HT)?" 6 ;"60&S%@P<<X!C<DA1< 7&& .08
M%EM=#OX2UJ9',YQ! "W@@6G/0"[YP=6@1.2!5IVK @4\[@,+0%H O$4,.5H
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M4J[@G4_E T/%4 C:I$M)# H@1@IQ20QPB4YZI1&1?QVAI0TUFGAW$""0 #M
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M +2P;6X0"B,P )6@UQX.XN2^_NH?[HB=[@,MV'N\_GE,[Z>AP*SL"55  #7
M[[",MP"!"(PC3Y(@(8+TB ZC3)$T':(3"1$C29$B<5)$AXZ#!QH7;1+(2%,D
M1H<R*7KD:%$F.H@\/0KSJ"$D3S42<-&$\!$8F9 T,6JIJ6&G0V 8=8KTR"0B
M.IE..HB 2%.5+Y$.,8HD21$B22 ';K(85JS%BF/-CNTD3>U:MFW=OH4;5^Y<
MNG7MWL7KEABR8L6(/=,38 V$$<>6V4'08L$ $<O>&&C!@/$Q5@A\2 ,TP$RT
M,084(/YX\6Q/ #70?CW[@4#%@0)&CB&S48#!@<U\&D1 <,$5-#,&$"!8LXP8
ML&5C%$A(8".9JPNR&12"]J'!+UC-&3#8(\W' A\&UC!X$2W6@1W/]O9%GU[]
M>O;KC1&+]M8\,F++!@E@H;90@!_37A0XX#EIAE"@A0(2 &*96"YHH($#"'FE
M@1>@B64$ PZ08)!HCCC 0 23(:8^-613+9D](),,A%>:8>. !$: @()CVJ.Q
M1AMOQ-%&9.**IA8?=0'E B*$\04"!W8QH8!*A*'% 0ELH<$$79BA88!*[H"C
MEV&JK&07'[\$,TPQO[3%%C)K,7-,'],,TTQ=U(03S#?/1/[S3#;CC+-,4YJ!
MRY1&(J&I"@)JT 023B+)I 8%%M7!$SH4",&! 2APJ8;?-EA@AI<@@2023R)Y
MP %)--&D!L\4J.*4)A28(8$J8&C A $8>.*! 218B:89".#B$ 1*D+0"EZI8
M0 $#8$!4T453=4*!$Q1(( 1-2E!@@:@TV,"1!CK81)$%2J@)@0,6H&(DL<HZ
MBZRLU!4KK;S>A3=>>>>E-YH0^_IK!0.(,7 5:=@0X((^5@" D-$$)KB05P;H
M 3, S$@&A".B20* 5@ AS31H@ C@AEA<   05BRP8YH/#C F P9^604(5@@!
M8(QE@!B@E62.@<4 %)+18XA?[/ZP@)5<$! AN@:.>>,"H1$80;L!(ACC%Q00
M*(8- /YHYKP<MTX//OF(><\^ RQ8HXP+ .!C#0#V. 8$!I9)(@ 5 +%@@%S,
M"/F7(_3(F81H5!B@CU@:A%MNN@M@!41B4/"!,P , 40 "O:X 0 ]B#$  E;&
M2""#&;D&/731BWGO&![!M$477W8A(H >?)'@@5EJN>4#!2[999=@YBB@@EIV
M&48. P9((QA:4*\S^3675U[-.Y5_7LTY\:2^>3'3+)-.YL'D\RU3(,DDT$$]
MX72J02&!(0 OZ$B@ 2YF".")0P@H 9$8"-"T$TT^32I41CRA @&L,"T%1,()
M[:O!(OY20  <4,%85:@! 9RPB4=T(H*],H #WD> )C B 1I81 X&( 8N!&"
M)S  ))Y   V(@0,C9,1M#M$()WGB! 5X!!=XU043VA !BSA4NH2XKK"4Q5WT
M0F(2E;C$NY#.+\=PQ0%(L(PU!& ,TF@# -8@C3E<K0]:_%< ^+"P'T0C<F00
MSQI^0($!$ )F:HC&:6C&"LP$  G1,,087M  !?Q""0%@  K8$(TA%, %.R !
M + 0C6H40P0"D, + +&,8O0!"5,#P3- T !B),.2*D# !Z)AA #\01K0L$,
M^F #!A!C=%Q[3WS<8IZP#>( GY'-$98! @7L@ <6 ( HQOX0 %&,4@"Q($0"
M$) !+% ' 2[XA6J6$0TE & 56 C (*1AA &((FO)@,4:?$"!!/!!$#&3QAX
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M#PB@%7P @!K^M39UGB&T>LB% 2:@!Q%H$1  *,,S0.;&;/['$1H^D!LA4 "
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M. 9\(OZ[]*"/^9JE$*D/43B %5@&8 B1L/N! JC!S4 " R@P)#@ 5H %"T"
M!6  </,_:' %$C  <=,0)3  09"&)#B 55@&8_@%/(0 #.2#01A :?@# Y2&
M-4   A !(OR<*[1$&C&[MT"[6N %2E@ "2@6 Y" 6NB%-%"  3  (=@%6J"
M4+DE [B$4.B  1@ !1""R;NR7+0>*+LH*9,>."&IRNO%*8N\-=F3/OF30%D
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MGNU982Y:<>P #4#994:4L-#.8!Y?\DW9#>" F1#?FGT(N#H!.B@43>""$M"
M)HA<1LB!#2B!*IA6)N  #[""['6(0X@!#4B!,!@);RZ!#?[0@8O0!#J(@0TX
M 7K6!#&(@1G  1CX B-^WRQ6:,IBY(:N7S!&7;!](FB@:(^+!@L\AFB@2U&0
M!I;S4VAX!FCXZ&2 AK:$!G4R VDHTA6C:&A(4I .:9'VBYA^!F#8-A]PA88#
MR@)H&BJ-!FB8!N%P:!N18&83$UI P=OQ$MWQA1M;ZF#0G6#@A40=AJ<6WJ@6
MX5Z@A  @@F"8A5Z0@0"H@QN[L6#HA3GIA6 PZT,U:ZC^';,FZUD0!A8@ %J0
M9!:8A;4F187:A;+V$DM%7H_5Y>2UD^>=8&G8O+!H8B@^T)% XO#989\(XO#I
M!'C\%"36X0I8@$X)8O[!YB"6;/X+A4>:\&% @8H>UF'L180&0( -\ PZ8$<"
MB  .H!^G\  6:H !J )-J #ZZ6U)L]!$8&T-$)<P\ 0G&( )N&UI682#Y(#B
M'@48(( &<(! HZ"P2.B%UNZ[V.*A]FY!A>BUH"7Z *<D(($?8 5H:(/;VP%@
M2(($8 ,?:('G2@91L $1( .R[!E1 (+G6H8]$( K0 (2T(.6.X8R$($7, 2P
M' ([6 ,4&(/ZX@,54 $[2+D+4( 5<",C< 4DV,@D, 97 ((1L('G2EOO=N0)
M#I-@D(,"" (#P *HEH,@J#L:P(.(ZH$[B (3<(.(NH$[" 8_N %*"(9+Z($0
MD(%*&/X&/Q@ N!ME&1B .MB%($ #-PB!** %1DT#$V !/UB=61""$.B!2^B%
M2@B".I@"$T"#7H #"&@ &+@$.(B"68B"*/B=- @"#2X",<<="^[ED,I;+>.H
M%5ZIZ#4(30"#$^  .V.$&*""3?B"&%@)'<B!@%;T&OC.)\@!.H"!":T!#J "
M#MCL3' "#B@!*@@BG_""$RB!)_ K&' )3@<#3[""$CB!+MB$1I" "G"(50=U
M9-T$(5!/5$"U)I"$XX"$4[B?+SB$ ( !;"R!YM8!5<B$XY!9GVB"^$&%)Q
M'="$!7B 9-\5+W@"$T*% ,*!5*!F A4*D<SN[8;WN3"&L?[][GHG.X#E2QW,
M!0LP@.I"@%CX#@90 5A(@@* @+IY@(<S@ XX@@&P@6CX@0"(O4%X.CXH  =0
M@0D0  >T@008 @\P@%: !0"AJ  @@T<4@!=X@0!X T.0  6P #ZH&$+@D ?P
M 6*0CC;X  <8+GOOFA0WZC0994 &90ZPA6$0]@>H&P:H!;EC@ M8  &@!#\
M@"A@!BP @#FHA0"1 H[XY 'HZE'N 0'  UKX#0N @ "( F%@*!.@  "0 U_
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MB2JZZ$C($#,-3!D! \T0 QBRS"L,C #-" V\$HT1>-DU0"LCE/5 !Q2L,D8
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MH$$3A0P/-F87E0A !W91BUZ$  "4F ( Y, ,(0"@$GX 0!"4$44IS (!!9B
M ](:'A/TH $!P$0EX"K$8-   +D9@ 5Z$9P.#",(IG/J'':Q@0*8T6!O#8(P
MZ@" *"BC!P%H0"5&,("4X8$  9A#;3I V0H4@!)B?0_/AG;'V ;-/>C9XT+Z
M&(E-S$  ,#C!E!Y!20"<30(!H$(JB/3;*7&B P1 1"8XH;D*1*  "\A$#0(
M@QH0 '"0.%(")- ![6J"$R480 DTH8D<C*D"Q]6$ACS!A014( 4)*$$F3#2#
M "B@O_X$T$$JJ#" !E2  &KB0@"FI  "<" 3$1B !B)  !A821.GV*\"%F
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M/"9$-%@B7;:?^@DE;<*F7_8F@N8FN<56)1;G7QY-TOP1%01 Y7P7!Q"  21
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M"W!@"1PA$Q9R$9J@$31A"P"2$_X(+!+,3@!^ $+6  #6P <" ,(L0 &DH0T
M@ 0 8 ]^0  LX  "0 2F81I68  L8 !(8!J(H0$L0 4 X BDH0\2  (:8 %<
MH?'L4GPLS)1X8 =Z3!J.X .B@0\F8 V0X )^80\FX /X8! H0,PN  G68 (
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ML/(H #L]=PB000$, 74_X1@<P X@9 6.X!<: !8@! 7,\P$"K\M@80A40,0
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M0 F:(1G:  (LP 9>@7V6@1 N((7&K*Y?  1^(!H>FP)>X!60@0(H^!G*P 4
M(0,,&QJ,\QDD8!5(; )6@1A00 (R@ VB81 NUT*7@7DE !I6H R@ 0(J8@*N
M4 )<87K;P! 8P 9<H#G7(!J,  (H  GNZH'B9P#5JLX:H S^0 ]@>_S<]AA
M@ UBC/[]6L$.2. 9+$ 4 +@-QL &HD&N+H 5Y,\&5N %+H#+(H\%W'89E$ "
M=B"_+Z"K(2"Y,7@"T \6(" U6V $=F 9*( 0I($-1(!(1$ /UN !G/L&** 5
MV&"]"TT$*AP$CBP95N&A7$![VV"]FV$-4. 87IL8EL$.4."(>\V9*B2'SG $
M:. .Y  +)* 2=$$"3.!-A954*Z$'X( &+H$"0,$7TL $=F "HF"5HR 8>&$$
ML"#90F$"2J$66 "R78MP@@$-4F 82H$7-N .;N "6.")+Z 4VIP7IC@(;D 9
MN#P8UOP"\$ ..B 8:,$7-* .A@'0#XX%HD 8[B U0R!/9?Z@"!A%!N;P 1YG
M&)2!!2R !N)\ RZ!M[25X:Q(F'V'F!F@"K[ "SS@!$[A"1@ !J!V L3@"SR
M#F"@":R@"6# $PX!!D[@!+Z9$1[ $32!#AX C#R!'U/A"S2@ CK@$.)Y$>CY
M!'1@$QAA$S2 "\1  YR%"RK@%"J "S)!$KK  ZRN B:@"HAN"=YU F"@!$I@
M AJA!F;@6+9  S1A$SS@"4:!#B) X\PQ$3@@ C3@:&=@734!!THZ$7P=V!FA
M"_!=$ZB  5(@UK=@$2J@ CP O) 2$ 8@<B7$!@Q 2RX  AXX*R&$!P2@+OL
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M!DR]R%' '+5(\0 O?CS@QRU1I#",!'(,-4P/-#"#1P-^U"+$!<*D<<%0NTQ
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M'<$("!$-/AQA&<N0*31@X0(7(".=R<"9"_3P@S(08@C+>(9,-[6##+@ "TC
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M"6+@JA (J[.JO="9EIFX R/P 6,P#7/0 G>B J)@##<P!B-  4UE*R(@ A_
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MKB !L2 -;^ !T4 &,I,,)/ #TF #.I4+$\ &L  !F*T'("!IQI0$1B -Q/
M>L8 0_[P2 I #%T$K"0P 3FX#!3P!IG] OCY [$0I-$@" [ PO-ZC<^@!Q*P
MURHP"*X  :Q@)A_P2!+POS_P M+ "B1@F9]7Q&BY#*M0 $>P"NVB!H+@)<^P
M D=+ :QP!"X@::GV )\0"PFP+F4 W3[ )K$P C2S M, #60B#0XP4<0 "*PM
M#2*P!M) 1LE@" K@"K#0 'N0#&SP ,]@!#<@#>V2+PN V4<01[\P90] LZ^0
MR,GP"AG0"M(P!DJ$ DD@#1,P"+G@ 'L0+@SP"W8P &H0"\<P FH@#:\0WZ[
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MQW#VR^W"<98,JR !/W#:,'X!?] &=F  H@ +$@"O;^  2+ '+?IY$TK>J_
MB10-*Z &L/  .\ &(YM'#<!LS4(!J\ *$Y ,T, *$I ,9W($>Y D2O ".@,$
M0! -$OY "+'-XG_ !A,PH!.@*=1  :VP!@ J:*R0"Q!P!7; !RZ0,R,@ F=
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M RM C(4)A.L! SR#!.Z8J >(@A4.^$4S#-& 9;18"3".!2L:\(,C.& (T7@
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MP@,8R($'H!,)#WA !Q&8P7<TP84'Y" %$8@$S"?CO0CHP ,<T,1OEH ##T0
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M/@R"%;E8!BSLL (J0B,#?Q@4G/Z,01&"02<8<?B PEB@E@G<H1>WJ  EXN
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M"3$<L(H6*F0'6U55I!H8@5]( U'2@,4#7K&"(4AC&10@0ZJN, UHE&&K9Y#
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M#.AO%6#"D#20@P8)-*#62UT%6 ?1"D2/RGDK$9:9%]!(,( .JHC$"1:14TW
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M_HFIF";41$(%"UCLRQ6 @ 4T]'>,7^A+I@S"((P+JP #(?ZP0C.(2S&(0BQ
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MY\FU3OXE=/2"#(Q )<"! U!",%Q Q]4! ]1!,#1 '?C"!B3!+!"!" 1#)3A
M&F#"![C +(B "1!3 U@B</3"!<!!'1R2)=5!+T@ ',Q"" C!*Y\-6^/!+'1
M&I@O ]R!'S" &P@#"XA )6 ! CAM+4"M%&S 7%J &P2#!$A!+?0 #3 ##="O
M ^ ! ;_%+@0=*$1!" A#&GQ2'#S )>P"+?0"&DC )52"!%3",$Q "%""&RA
M*&#" K@!)8R  :=M-W/3$U3 (^#8(F@?##C"%AC "?0.#)1 )&3!!$A"%CQ
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M)$(D/ )Y_T<$.,(I8, 2"&,.5,#W>.. Y, I1( 8L(Z$T"9O\BM!^W>_BFB
MK[ D$*>B+;2!:_M0_7BW^XFE/6X#68 *_D$#_, +V, -#,(:J$ TO$(R=$ L
M$,(%_!H?9$"JC($TJ $([, 07  QE M5E<$+#(*G>. :0(1E?0H%$((T_,$(
M0  (L +)@D!U>CM4PK&0UP(OX,%_S<(M9<4%5((M\,)O"#<B/< -T( ,T, E
MI  6:+G(] +5>'8=*$,(R$$:R  O2  +L/S&]4(HN-P# *T<@P(,A( 1A(#4
MH+: <?X7)D@ %@9#$*"OT09#!Z"!,[N,*?, #90 +],O=8FAHZ?! Y2V#,B
M'\SV!D" "<Q";M_A"!QR!<C!,%P T$8,'M" %( -T3VWWZ'B=EB!!D0 \&Q"
M1Z5"%7" )C2")E2!!IQ #42 (C3"1''"!'@ #)Q "NC (O#ZC.  #JC"#,Q
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M%HGN%4TO(8GN"VE1=6B  2R  AZ [9 G!#[ !#;@$GAA _#@#3F@ 2&D!X3
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M]L HJ9QRRB:UT3&#%8F D<D7CAC7!2.1X$?% SHDPG0FF232A7>^<<&())F
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MV$1(4V$?26" "I)8@ ><X($-:*<")WB"!Q; B$R\1PP,>,(3)I (X]#&/9(
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M:'S3.(VP-!C@4A789_(7"8S@ (]0 SF0!3HP V%P E20"A60!12U",GQ )&
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M#7UP <N%HTB@![#P BT7"ZS[<QG@7SNP#'IP!!9!""/@"L=@##L@"M.@!QX
M DK  Z*@7VI$!D#0(R.  F=@!CS@"C8PBWQ;G[!A+YRADB:P 19 D2R6!A=@
M 31@"I_1"W@@!;VP"WX0 B;P>ILQ"S3P 1N !L%P"2P0 D4@!PPC!QL  AV
M!\,0!6DP?5,0P$F)JLYT,PYC"[2 &+8P?JC!P*<*30BLJB"VE!1L&D\)%F:6
M"8?@ 1KPP1I0 I"0"3-0 280 R5P"F'PP4L  RUU GRVKF' "8U6 Z.@"7,V
M"M4Q:D[X&SJ  1L0 X^P"03H ?X5\ 6;T @IX &0, ->T*]\]@@GH#B,@ -9
MD 4BR#<P\!V0  ,>[ 2;4%*-  8Q@#5+@ '^ZAN;L 3]-&I=8+ S( ;9J@@(
M.,4,8@4YH&I-]1N;Z0$Z0 5,/"&1T EI(G*8:,BPX0H X%B('!:QL (&< &-
M?":3W+667+W2.R[0$!/0$'JLY7,3 0VY\ N;+!(28<I\F\K!=5P7&A:5<A7
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MA86PH(X2,^)())'.!,D66M*<:_Y-EW1@8((JOJ@ !PVN.F6))4J X10J-/#
M T<RR00'##R8P:BNDCKA"TTV>6*&5*SXW@-%,GD$ANQGT&21%)Z(((RL,IE!
M!ZM2J-4CLH>!)VS"?O@+PPP6@($NC,)['CC!(T;1A"6 +PPGP$$$8I %#T2
M"HJ2'_A<,@,<=# &DLI"!;)W"++@8 ,;.&&PVO*51G1"63?$80YUZ!=C4,N'
M/P1B$!V##&-8"UOQ>08?)!"-9:A@$+$8@!F, 0@%Q (6$&!%-/C0 ?5 P!7)
M^($*I$$"+%##!3XXAB$<L P]/, T/Y@8,$:S C9(@Q 3D,8:$""*9;B@!;)9
M03)8(?X!%T#C%W.LXR F$ TU<(P$8R#& @!Q##8D(!:Q2$"YU  !+5Z@&-%
M@@VDL0,5E 8"*VC&:%K1@%_ X@&B5$,(HO$ 0!3C FL S@':D(PU2, \B1E0
M70J$D0ETP 028 &.'D )7M#"%Q:(0R4F0(D+4((%EZ $'G;!$5^,  O**,4$
M*E$*!LCA%E@8 "C2\(%@!$,(+&!&"H(@#!G(X!:A<$#6TM"!7F3H$J70!2V"
MT8,0Z"(4%0B!,(J0@F$,(P58&(8,:%"+4$R3&7Z@@"_B,  IA.(2"+!!)70A
M BD(8Q86&&<#Y+"+-"3 #R7ZG9G$1*;@:81X<E&)4#2PA/Y-<.$ 8M!$##B
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MR)XGT $=R )(R(((@ D/.*H(6/X$FX $3?" +N">+L" 1'" "=0!*P@#1XB
M1'"*1\@?LP(J2* V2*B!&* J49,4#W""4_"JQ\) +O  *D@%#* "/&&@&,"!
M46 $23"*"H"!)< !)TBVHU"*J4BXAM/"+=PA9M&MB0/#,)0MT;B6BQL.U6B#
M-3")(;"!5S@ 5I &]P($0*  3#N#9SB"%3")/2 !:; NFS.$"<!#,9*&/U"!
M[4@&43B 9) &48@ :5 #%7B&9[ .:;" -C")%XBZT5B% YB:57B /.*8LXND
M/: D W"% @N/WEJ&(_@C:7B%-IB&6S()4IJ[91"%=_D%O=N!9#B&"P"$:+B
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M!E@$/_G #L*!&?"L4<B"!\ !&'B 1*"V1$"41VB ,#"@"E!"!QA,&("!LKK
M3-@$'OX\A41@ $G@U":8 17:A DP3$VH "J(*@]8@@C(@5'HJQ3  0<XPJ$P
MN*'(3,X$UW 5IN$0S7(UU\4X0XL[37(=#5<H@RL8A&@0A0%K.6,X!N+8 R38
M@V= !O-H@RLP!'Y=A5@XAE5@A6-XA4$@!FHHAC;  D-8!LL@N35H@V(0A4&
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MAS1Z//",-".P\8H"K$@3S01\N#+H$"T,% L#R?@PA#1LD$!, [$,E $?@D@
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M+]3!S$N!E*:!',A ",3!GLU"=<A *.C"JYD "\B!V G!!Z1!+UV=J\$!"[!
M&@Q]#XA :DAI)=" "1#!U-]!:P1#*51'#Y0"U[M <L#2+!"!"L  )?0");@!
M'-  +UP"#8@ ''1 ?G,U#PKB[NP=L8&DY1FZ%W! "IS RIR !W'"$GC "83!
M)EB! WA %A >)S2!!WA %PSJ(L3 MRU"*C34*&2"YD>^)JS0YEL!9L>Z+X9D
MZ"DB7$?">0*" .Q W1X! +Q!*PB "@!! "!!'PF  RP *_   CP $+P"!"@
M$"A  V12 $"  (R!'@  !&3  /X\P 5,  !@B@T  !*\  "820,,  5X/Q"
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MG;HNZM)K8:<^MAG8EZ8:28HD29&)&9'0:P)3X1&#+*A.Q$@UHX0C+A$6'8H
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M%.+@$FBA%,YS*[,4([,3/3^S,Z6R^K+32\5REMKC3S4!%=(F$R+A$3! !SQ
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M)" .A&$7/L /+H$!0D$82J$!+D$._&48(" (G.$.'F 8X  !EI<2%* 6YL
M*$&R', 7A, $G&$8HH 6X& #F$$&0@!@T$48( #-\"P-0,$"7B\SLQ+8V%8C
MP95+_]=MJ^,KS] E2M,<B8:[0&0U-Z&25"$%<" 5OL !("$3*K<&<$!?$S5.
M9T #MJW9((F!YY *"I=P/0 ',("[O@ #)#<,3@ 2<( *&C0+(H W3S0F;8EC
M3713.U5V??A3FX5^=I=W>Y?M=)>(2_!WHP)';;87>8$2)&#WXFH8IB %AJ$4
MAH$&I/Y #D8@&(Q7#CQH H(!#4S@BGMAJ^(@!(;A-![ 7"J@ VZ@$H0!#3Z
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M'LOK,(P/R, /,M"R"H2PBP8$JP<(0/GF/@>!. @##A+8Q3!"4 1F!$&M:6A
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M=*WZGR=+H$;:E<N)+;1*LDY:$J: JWO'%&'(!0Q I>C#"%3@45V0>"VB,PH
M+SIQK8XP"AY0 S2%"M]W)"A2A9MP" D4":A@ C5P"AP0!G1 ,:=P E2@"AX
M!E2  ZCP%:.0 S]%<!^*G>P:KSBQEV\1J&OKO>[IBW*[8UC#B[@9ON([8\+H
MGI.9&I,C \)0!ZC4 1;0 [XP"P_P-NVA 7%0"1-0""?' I= "2@X@@R0A$F:
MLLC9JO:XP,\TJZOJG$G*6_6XI 3QN5*Z%-++ >;CD" T \NK Z?@!0[@,(S
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M!*C  3$P"C&) ^73:[^VI0G@ 1S  :JG"1Y0 350 270M56 :YP0 MQD>!7
M;:29EU!\MD[CIWRZ%HT@Q9Q-KSGYV:5=-H@)MQ-.X61SVD>EJ@0Q#"Y02Z0Z
M!5AP3/[#00MI$ 65@$F7D*JV@ 9IX NA( $'?-40G)PCR]PKN[)-:MPJJZKM
MS+X7S*%G404Y4 4ZH0ABL)>/T 6-("-=H -/H$"'X"_<79&+P*5-<0HQ@ .2
MT 4G?,+>Q<\YP 5!D@ETP @K(C$%Y6XG#:]HN=()#J\+OMD0+JA8D^%3E<47
MGN=,U<5#"9^78"W#T8RY%0Q<UA"&PA#J(0=I0!_%O=PYGBTXOIDZ#J"8J=4:
M(>1DJ0F>$"]OJA:;T"\2HI=(PR\5N9J2L A=[J XL@F8YPFKJ:&?B"-/4*PL
M+>=[^L1O'A>04.=V3IY70Q@8WN=M\K;[&K?%;C8;_IZ4V?ZC$C&5D>E8-9['
M[<PHK&J4T(FY]R'I,;J<T9V/9SG+4P&7NAZ2Y =43C'KVCG=9%N]"/Z6O@[L
M4SP8,:;LH2W:TD#:]U[A?[Z^WBZ9 MKCUT*<@-SCRAVR6^WC?/QC?>R5FB[=
M#+[@#*[K%<_N% _O[H[Q&@]4#S[OP9Z;_&XV-JV>(I]%_@ZP75GP"I_P6^WL
M?QSI>ZS'^;G.E&X+X!Z6%J_SHUF02G$5Y:Z]LIR]TUV=-=)$V&MP'[^VR6[R
M%&?AR$[L31\FS)[CML <V_$YD-ZC)B&<VI(;11H=GQ,,'>Z$NI&.1=H=VF['
MW+[I<A&0.R^0O"J3[#Y[L LE]?ZU"9[^CZ)N$W%($U8^]$+/Q'@I[N&I]#+-
M]%)/)IMQ[*.=^(H_)G3KJ%B-$E_6 1U  TE82MI"E0-A"Z! "9<V$03/'KT0
M!<IT9 4Z$+H0"CTP"QXQU4'@CE29^JP?^K4@ _T'E1MA6Z @!$]0* *+Z4=Y
MP;"X%IEP""GP"#^O%LO?_!L/](WM:R>0YD5![E1Q_9\X TN@)(RH XJ 7HE
M!>-_Y)+P!#F0AV1ZQ"E !41B]+>,EZP)"1Y_^+$9]9#_&:31^/H>\OCO)B@/
M$-($1K-5R^!!A+U8F*B$208$6L(NR!FF:Y>O8 :'#0M&:UB="L(,]N)HD):N
M8,-\7?Y$4\=7K909$=;BM='6KDL+9I7TY2?-+EJ[-NHZ&!,F'@L5I50*MLO@
MKEY!4P*MM2M8TUYRA%"B5;#@S*\&PQX,Z[56,X%ITYIJ%,EM)$AN)472!.:
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ML$3.L/["3*"# \@\#6" &4",SG +9<.C.)D+27B$$V -_YI,2Y2$;RR!"J@
M!?@]==.!"(B!$W" RH&$"(B S'L #7B$KH($3LB$W3N%+:@ #DBXO\ !%ZT
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MZ,$83, 1G $R?  2C,$'M((>?/[ &?C "[CC1K#""KS&-*R!$D@ &;P!4V1
M$I !" #"4% #""0DD>A!!I0!$+S ,:Q 23;D4!)E*[Z"'@"%#_P?1_QD1K7
M1O0!$NP!&VP$"+R"-"P5$DD#*^Q 1^B!#RC!-,!"&8P!$!S#-"C!$8Q!3D[#
M4VZE$20!,KS"&8R!*ZS!&!P!(.P 4M*&6P*"#QS#$0Q!*TC#&YB!'K !!0S"
M,20!$-0D&Y2!'JQ"&?B 'IP!#R #->#E'DA#&ZP!#W!F*P"!$:CC'@!!&4S#
M;[ !1$H#";2"#T1#(!R!$LAE&9"!#]134>KF;G;B*W#F1O' 1";4"KA"1HV
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M<OAM/I:NZ0+%Z'8$X0ZDZRKDD%3NY[0ND<PN?]PNZ*INYA;E(+0!DW)$&9#
M#J@ JOXRQ3/4I!Y,Y$":00NT0%CF+D>TK#3 K#0 0O0J!7G6RQYH*5&TPN1*
MPRIX[&R< ?C*!I;5#%<BQ_=*@ZD*Q<L*A1YTY6L [48(PK:ZQO<2PZT2A2OP
M;VM$ ].R0M]6U!H0<#-VKU&D*.@JP4LJ!;?Q[C:R BO\KPU49S1,PS1<Y3-X
M+"M4YT;$P@=[[#,<@R!\ #+ PBLH[3JN9Q\@U6^LP0X<UUYB)2!\(S4@PRHX
MQ40^0PX[174B@RL@0P:L@D;R<!^,;[5ZKEP:@C080J\JL30@@RPT,:\2:BL
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M\8I -?0!#Y0!2?) L^X!$K !$OR+'ICV#SPHG0*E$1!#2'KS-&@M:;8!T'Y
M)V]$*_Z,P2JD[!J0P!J  #+\ !",P5/R )/: #$ P1[P "SLP1JPJ!%4@P6P
M 0I<[PZ4@0WL 3%HK6S[P%J_P#.TP!$( AGH :?^@%V>@71N!'$3 P5T=_<:
MM50CPQZTP!I0@"P,@3I&-P\<@V"O0E<*PA!LA _(@A'X !D$Y15HJV1:P"
M@A$<:MN^ 1E M@N, 0]<Z9::-@_P@2!,0/?"0@M@+"P  A(<*JCR 5$SYQJ,
M@#X7=#(B01G$XV_XP Z<P16H(S)8 $1^@!Z8,"O(M2N\PE,.PA4\PY4>P2K8
M@9*^ 1(@P2>H %6VIES\2QOP*"SP@"#4\P^<,A ,PI62]/XT $& 2L,.J.>5
MZD$+K$(2& $2),$GK !KKH!3H"02K((2),$JF.</5,,QJ( T*($A+*LT:'@+
M4&T&O((-_!]<5G.C7BD0$"9)!H*6WZ\AR*DTV($*!+J&B^J4FV? 2@,?JT%U
MDL6-MNEZ)KHTZ+DTO,('C..>D\$SRT(2',$G0/H05,,1Q )UO@ ;&,('Q&,+
MO,(S)+I[XV;[ @*:2X,((+M'9M0*0 A[OT%-DL495&>T2G<?J, G7,$0K,'(
MKN@(*H$1 $(&2,-\._HJ ($ZKL SU+4TV  U-',+O"QV2P,?'$&32\,>@'O*
M4BL2#,$J'+L1$*8*S&@@#P&#(OX#;GX IV4 A*S"P*/DBV^$PG\"> ,!H,8W
M:>K[F;8!9[8 I"[E#KP"$'P"H5)#3_+S-%RI"K1!LJ]"+*R"&1S!()BJT4+E
MS5*#"CQ#/7\\9\J"JT8>"$1Y&;@S&S#M&#AKCFNC#YCO*X@ TXY (*P"$KLE
M+, "G)H[,C#J1E/#$"1!-0#!&JP"()@M#_!E&T@I1!+#F*=L75<#$@S"S>K]
M$1C"S::W-,#I&\@G(+""#ZC!VYOM#@2Q#TC#PQK!&7S]*V F+-3SH/O -XX!
M&WCJUQ^V+$1S*R3!S3:J$52J(0_F#I"^^(XF<KP!#[Q]*Z0\$IC!V\-"O0<J
M,HS!1/YFL!+$@L%O*<1G-.K'@@BLPB (PAI@MP8;P>WC*6;6>1(8:!]\/7+D
MI^5+ QE0-U)1?1)\HPA8?Q]XJPMX?Q^P 6>2Q15,)$K"@E12NA]#_1N\ 4R1
M $>N,QM0I<,; 9.F]PX A"QI/ SM6*5$4)\UTJ3Q.0+KAS0];0"9D?;LU9$Q
MJP"Y A)+VHMI93Z]BFCD"A]J'U9] O1,VJHD$!N.86AD(R!6.XY)2Q(+R*N0
MQ%I(,]-'VIXC2:8QY '+""MI.ZHA8S5FR#,;TE3HX0BQSYXR@&R:9,CG"D,5
MQ'8TE79$D#1DLL:LV?F,F* =>O24D:8$J5N&@PD7-GP8<?YBQ8L9-W;\&')D
MR9,I5[9\&7/FS#M4(#'"YAD*8DK>M!D#R(BT,4C>M$#6E8>19Q9B*=$CK<4+
M:7U^"!HB5-HK$&/,?)!%3 6?'WT& 9%F@Q4R(()\3&5%;+IS%0M7L*GV I 2
M0ZMV^(:EEI@KW4;&\Z NJP4Q6.L'O?"AA\2Q-5< #9FVXKP=^F"C.FD J8Z'
M58[Y 9 66%%!B9!2:^J[\ QAXXV=! %"EE5<V$,$6-IX 2:C?D!.CR'88(@Z
M:::YKR\4>="#%1N:D\4&5Z:QX QISE "-6H86N$5^-X21 \C]'#AF!>D6@/(
M(8241@TE77AF##Y<]'$'9%"09OX^9%H Y(I!U-CCC86:VJ/ /8QHHT<?5@%"
M*A6>(>.(-T;HHX566C!#CQXE\D$]B:YXIJL?WE!O0XCJ?(8-]W9HZ(&>AGB#
M#YMB&@*6HO2(,"8;!#'B%3: V(,"6:K4(P-D2)"&C15ZZN"-+5^ !8A6N$)&
MR3UV>.8#)(] #182#"E#!&)0T .(%1@ZI@4]CEAC&A4&>Y /%>9D0Q +5A$5
M"3;T(.,M+34[%]UTU5V7W7;=?1?>Q6 !)"Q6J 'I&:GZ: ,9A@!A0TA9](A%
MJ%9@J8:8X(!CI0U7"*-&CS?ZE888-E:1YICS7'EF&EB0.0\6:CJFYKQ7!@GN
M9%G:./Y9&H8=9DC'9QQ^I5^&08IE&IF#.^855M@ #A!^I=$18PS=RGAHD4'Z
MI ]B5J&FA8L'(Z:-0*0YKN4V0)(FEH8O>HFA9Y ZA@U#!D/:Q3?T@*EBL[,&
M:6.N)PXZ89B?T9EF:01AH]^X#6RC;A;Y#F[BBP)!6F>JXY(%&80'@R7A::8A
M..&00QXZFH8^.6^5/F2YKAJ&/DY<*&2X92@6NX:&2<=I B%&*&JD<I&O$GG6
M&1G@N&YC]CWV^.%B/C[1T6'7J2&&A, W?D7(F-\ F.N+!6E#(%CT(*:5::AF
M17>RX^*:H<Q%!(D:/F)QA1BJ]Z!8J+SC?1_^^.6?G_[Z[?Z_'__,S- TL<SS
M_Q^ \=.:8H!0*_\%$($)5. "&=C ^QUP2PP1C& ,0T'$3' Q$+0@!2V(&0A&
MIH.$">$'%1-""1)&@R5L# DCB,+^&8:%E3&A8F)8F!J:T((Q[& -':/#"M+P
M,#QTX!")6$0CTD]V*'S%*^13C6D(23 D+-P)!X/#9QW-+0=,H0@)<XP2<=$P
M(I,&!&'A%@R"48+1F-(T)D9""+*0&#/THHMFZ,+!D)"#&+M@"W-6HCK>37)W
M),PS9'$Y*C*DC'2L(A7?^$3"K&)VU."8'<\XF-P9DH\MC" '"RD0::RQDL_"
M&2Q@T9.P&>)EU'C%P42W2B%)[?Z(L93E+&DY2[6M+VQ > $%7G &LBR&& VX
M6!T3 X3S2&,YDSE&C_3 ,L8,X66#T0,/IA29MF3-,F8X1A]F5Y@]6.TRSQ#4
M86Q S,$\;S$660,N$7.%#_R !"LJ3!]L8$K(O&((8WP&$)*@RVFLX3:1:8$*
M>+"GR32E6T! @1&FL8-J!O$OK6C#!WQ @H7 P@9*>$&$QD!1%-ADH#SX0"S,
ML#XAUA*E*57I2M4%B-L<D!K.VDT!Y4F6K36E#39  D-6(8@QG&<0?3 #7G1%
ML*28P6$\>)D-^F"R,\0E&GHP0^G,P ;)&4*HU$!5+$BYBJ:8S:=;<]$:WO 4
M:;S!#/[(. 8(E#"-8Y1A14[C RQ8T8=84*,,;6@*,@!U36+<=1 3(8Q/9Z<0
M0:1'*$_C'@J.( NW":(IL1"('M3@R98=)1;(6(4>D$$,N+(QL&W8#05TA=:$
M\94/UYS&R:Q"C4_80:^[@5*M"!L]/30%%A-0R!7:@!1I#((,4FF*$0#QR9&>
M-:W/($$^7U%2N:QB#W3EICC;("22LB$U+1L!0_CUABNL 2G/>$,9$M:Y5E#W
MBRN R2J^](HRW.88AM##0ESA, 51HPUL,.4>TL*55OP +V>PZC$"2ZUGO0H)
M2%G)*]Y0((L B2$9F,8+^F4('GR'I1G6\(8Y'!FOJ*$PU?ZPEMX^,(@6"&)4
MK'C!RZ91SA-) P1GZ(,+D &!0%QA#(:(B!+VP HSQ (%TP#"4EM1AA4( @3$
M((X@XI.@3ST# F11 BL^4(T$#X$5LF!05&RP-2.801 0X*O%>/*",33T$V\8
M RL>H =93."G/I!O$A"UAXDRI \_@8 A7E"KI$3E!:]HD" H (@SB/96.0)"
M&8Y! FJXHBC22' ;D+ *OX")!!L:L@, -N6\NF+/-AC8!UY!AC:TP@;5: $?
M)MJ48X@@)D8 ]2=VL =!O$ 0']C#*GR@8A%98 \4&@'#5""($;S"$'2R@:ZD
M801<VH8-9V@%A7EP!1RQX@IZ@/[% ]X@"PLH 5>"4(HL1! ((/! @D- 01(<
MM@84&-MZ7M$-!9 0[C[X1RT^4(((5N&E05RA#+#8,P_XP :_\  H>NA#0/DT
M"#Z,0!8\>,856+&&,LABSSY8B#0^490C!-0,:T!4"\C0DRNH8 Q_XLH;FF,3
M1W<8YC&7.4ME(0A[,@0Y>$X"K-Y@!".\0=0,8<4$VF"!6KEF(/,!4Q(^D9HS
M\(%L;!#!,:#)$!NL8IW-!@2Z>0H"@[_ 2/BD!KK%,PB ]N$(*K)!K:!U$U:@
M0,#).T.6/V!P'MP;8U]R1=W+4)[L_J I@0AN/OEPZ=BPX05*D<H;_O6&:?SF
M!_JQ6OX9]L &WXZA#_-1 K/?T*-7K#DB'._Y&("2E!ZA>P15?4$;=CX0F%!#
M-]@NO9VG?-8]*$%%M6:#: >#[C6LR BM4((/RLI[(_CVNS:H*@E><6I Q%,)
M44%W:*[V 3CQ(*_!<4X@8<$&"L1B]W\Y[.Y50(TO$:/N[IZ2"MX@"(O/UT4O
M:(YLX6^$6 #"S, )Q ?&H 20D*@5WD )9@+=R(1%MB() HH,!.4J,N 8QB )
M#($/>$!,@& ,]&H:2&"*9HX#.] #BPAY\.P(?$0/KD"_! $XDN *]L596D 6
M6JQ3I$'X!B&?B&L,SH :[&3(&.(%5N$,;@,(OJ4GO$(%<O[GL)R%%88 &;8"
M"8*-!WZ &HY OP9!(!!%2%H@%EZ@%9"A#YY!"0:!&$0@=P8!-:9!U88F>5Y!
M$ KE&%2@*<B"%:H#3FZBNEX'"8H+2 "**UZ! D_C:G8 "*9D#/3 %:SB RJL
M!?!KRIQ#.%YA#\@@%M"-#41.-U! 00!AVC[)#3'F50PA*@"/#=A@#-;G"L2"
MT0:A&@1LC'AP&E213FZ0P([I^"CF ]1C$+8)2P3!$.J)%5BA%9SC-2A&!*JA
MYJ2%X[@.[_Y"7!;"" 9A!P#A.V)*&JIA!!"FN!@B$3%&!/8@GW#DO\ZJ#=+D
M.58A%IYA#[XD*79*@G;@%8XM//Y>82O0 F:L)0G6!QDRH+GDB01(RK= @!5X
M('"\Y ,'DB +$H"003<,)$+:P,W^Y,6>H07<0@5> 0@2Y@?XL&62X#7(P%CX
M8 CT0 0$00E>!GC:8'TX!1!V(.VF@0R2($^T@FL8*EBR;@B<PQ64CP<\Z0U>
MH P.<>NP0C7B D^4I!5V#AFXS@R.8%J:;0B28!,%H0Q8(37$<6A>P RZ!!94
M@ P^ !" [ Q 0#J(80]4H"=\("V:P@SHA2>S@B'T  F.8,I2XQAVH V4@ <
M8>?@;P1L;0>PP@N-  E0P'^:\@=(+Y_T@ UD@03&8$^(8@RZA"''J"F&(.1N
M(PE6@?X8K-*LI,&=7F!9#(0'R  (6A$IS!)X8D$NM\)' ),2D6 '\LE%?" V
MRB\4)<T'Q^ -2& 5 $P:UL (E.#2<$,$6D $@! )KLX5\FD/UN 5X X$/@\E
M-*4/=JHIHL$'B$'CQL!&4J,/-&4:$E$-,N %2*!69$$%AN 'JJ,,,J %2&"G
M;*",FB+/5M$@Z],^[Y-=_ @F<N:36,%_HF$_Z:A$.&8_8>(9XA-,^N48!,-
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M^J"TD&$/S$!BD& (=.53QF!*D&$,CF!]T,I=DP#+) @L>:J0]H,8^@ (E.!
M;Z,K?7 (SHPAQE(2;8(;S6 :WB#*&*(,JF,:/L%UX!(98D$Y*5-[DC(N@K>X
MO@,%^H4$!$)_&8H,#(%<& ((6"9X PH96N$5U$ )9 &$A_X )!;"$?EJ#'[
MD_1 ;4F@%\O@-YMB#2[EM\H@K92X#Z@!!&R &&XK1J%#(GX 4!BB.:=!#=9
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MH@P/0L(5HL&&,0#!$ QQ!1#&D!?/M $91E!FBOI@A"OL@2C$$$P;=I"08]B
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M#&0)%ZZ@!-/P 57)!B3($%>D!XOC)K# >6VB H*P!R8Q!$8!7F3EE>\E#6J
MD9)T=).)3S81")_XA=]C Z]P!%K!>E@2"#=9=M'P!CMA!GT@(-SH"OUF WRC
M%SR :/]7!H P(&6P!PKQ)&90,U<@"X"0! SV@[+@,X)0=OXOX).& $XS 2 S
M801[0 9& 0A7X%ZR!@M7\ G2T <*"F)G]B""8!?:9@A[]PE7(&AHY@J#R1!?
M=H[2H +_\P*A(0LC4)PZ"5 3QXVCX5&?4 9JL!\W- 8V.A.GP1 D0!_2 !N"
M< :L< 9KP!:L4';3\#]2)QIY$:#T] -F0!0I<@Q&L 9Z8 ;Y\0)MXQ(<- T[
M<(L8@A42-P(;,6QE- T9  N?<'>HQ0;U8@:RP K>E &K<')5<5[/R0HZ> P-
M8 BZ 7FYHQ)LP IP)Q+/T(!G.0T0,"!]A0QE$)P(BG'6^$\60((6,1+(,(0O
MD0&JV( O4 TAR'QET'MEQ H\\/Y8Q* 'G\ &20,"#O02(" G"\ *T\!YQT4=
MA5%VUS1X@Z '@%AMY[0V(N4;+L$#9X ,%_!N%O%,2,!<8Y G&=D&KH "S*05
M2N! (A -ERA4QW"J9C!;(I GJV (D#0"T/%U,#%#* @+UE$:U^,#?# FR* &
MLKD&Z$:"M<9!^*H'[[$"KK #MN04LG !IS<4A4$"L!!^^^8*$P +/) =>E!1
M:W PL3 !K@"MF552QR!:UGA%  1U(8@3K?!U;V & +BQ#O0#^&H$8W ,&1 +
MKO$,^.H*#\ 6SP0+JO$*DB2)3T<3R#1U*F!O%,![S] "11>R^0AL8S (_):,
M9.!\G/[7/>RG!D-6H' 7LL=01B<'"!]PGF_ &D#;"CX0%2H'"^KT)"M"M.1J
M!CO9 LV8%X @ F1%!K @ C6T"G,1'R)Q=]LD'8#@)T;P XSZ *V@!\U5ABV(
M297U $ZR9<\@ J-#JO@V$X+P 8"@!UG*.!_P"610!JS0 8-PAIQX5;' !N#V
M'OI&1:!Z?LC !D, "_T2""[0;2.:@/FQ(R.AL-(  AXU<,0P <<0?K"@H^PW
MLJ^ <6/R"OU2/N6Q!J,X%B38JV: %]20AS?*!]&+#"/K"BZPMK$@H)_5$ WT
M \<  M\&,&5 !NMQ#&:@!VJ@E$5D/L=S6Q^&#!RT J^P"OYZ8+S8:*FP@*$(
MB R"ZD$TJ@1]L 8*/ +ZE(-CT HDL0+^^H32( *N()F! +$@  AM,%D?\ PH
M@$\PP6K30 $0^!\O0 TD@"NV""EZ, 1'4"RN4+YLT@I7( C() @NT0;?<Q>"
MD#S(XPIBEXTB(T_KHP=M$+QK*PW*.(+_UX(VL08/PW:D(16P69$#H33$< 5Z
MT >&  BAD<5=\H79I[J"H!9?* B&T +'X"0I\W]#("<MB846 1-(94U[XB2(
M93=?B"CAY"18B:;'T <_9$V"X'IWP25[, B"@"!\, U]$,CQPQ;/4 :R]R0(
M$G&!%0U\2@V:/ AX\<>R*3:BT?X>D0,;X821# %-2K &,+%\#E3*R_@*Y44X
MT"&B!R4+1Y $1B9U@\ &"+)E8R =0B;)@/ <P(Q!;9%)C',,D9L:2/R##M1"
ML^$DWHPWT!$5>G $ +-.=V$&;] '<.P<;+(&]J)7:M/'4:H5']%$8@(=9ZH'
M;7,72B VR! (R, 6V"8:0Z @L8#/36D$9+ B:@ A(YHZ3O()5_,#9$ 8_MM2
M@G W>DL-'"<5+>+*S!<CJ] &K9 =]'0&@I S5(H,>J45L1 (K+ ""X%:TK "
MM<,&/J!)Q. *B,*)S#$(^/0&"['&Q- 'T] V,%$&)N$G>.%7 FT&;  (?4 -
MZ;H'K_[P&'M#GN'J"O@T",5R!ACZ?T:@!%'WB;"PU8J\"K" 3X8 %AW($'T@
MHB"*<JP "V90#5AZ6=2 QT2(C5E2RM14&4=P!30W#>3H)(! &K"0@+XB=HS*
MQ8+]#!CY"H+P#)XGSR\G*X^=,"_!,+[Z&,B@!$;0"J \T!"I!-6@V1GW&&/B
M%.3XR2U0*RRH3)41"$J@ND1(#%6SSFS@R"@'"U%!3W^'*N)D%,K6E(^A!YC#
M(W4A"WVP(GO0,-+R"7W)CQ]R!H*Q+B"!ULQQ,N8]+G ((JTPGA2"%')ZWH[2
M!F]#(<>@ AFAW1I"'EKX@_D1&92R!Y4L+:] -/A=(J]0QOX4D@3,!M\?P@H%
MSN >$@V?,BR<\@QEW"R<XB<UDN&=@C^=LBS1,N$, 0L!WN$P 3,AD^(>+B$@
M+B')HB&?,B48ON*Y9"P<CHL48BIBM"(BSN(NSN.E0JTOWN$T#BO$X^.;8B0]
M;N0U;N)(3N,9SD(V[N*TI"PN7N.<TJ!^D>1.;B'5,@TWSDI>_N0-,^&%(D9!
M_N1I3B-"(N4X'N-$WN0Y+BHTGB(Z/N>Y@N44ON93[N';\MX1GN)EH1TR#N&&
M?NB(GNB*ONB,WNB._NB1H@<1,A-Z\#>0?NF8GNF:ONF<WNF>[B[$T'\Q$@O>
M"!T!^H5-8U7W>Z B&@V\\^FP'O[KLC[KM%[KM@[AWO8&@I"]@V $;" +*N"U
M#]H'GO<3U& #:["VD0&SM][LSO[LT![MT@[M;, #<A)Z[6'M #,-7+("9] &
MO8=;-#&.IO/@TW[NZ)[NZK[N[&XBD?$,CYT75(: C4P&#,8*"6U943%X0P#H
M[?[O !_P C_PLQX-/N!7;>!H2/ "QKH#5P"Q-TD=QV%-+1 C+R =YD[P&K_Q
M'-_Q'J\NFS,3Z"CR"X%?-W$PJ<,*)# ]']_R+O_R,!_S[I+5,E_S-G_S.)_S
M.K_S/-_S/O_S0!_T0C_T1%_T1G_T2)_T2K_T3-_T3O_T4!_U4C_U5%_U5G_U
)6)_UE@(2$  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>comp_0006.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0006.gif
M1TE&.#EA=@'  ?<   H&!Q$-#A,/$!82$QD5%AL7&!X:&R$='B,?("8B(RDE
M)BLG*"TJ*S$M+C,O,#4R,SDU-CLW.#TZ.T$]/D(_0$5"0TE%1DI'2$U*2U%-
M3E)/4%524UE65EI76%U:6V%>7F)?8&5B8VAF9VIG:&UJ:W!N;W)O<'5R<WAV
M=WIW>'UZ>X!^?P!,H@!4I@!=J@!7J !CK@MDK@!GL !KL@INM MGL!-MLQMJ
ML@UPM1-RMAISMAIWN!IYN1=WN!)EKR1]NRI^O"9VN#-]NP!&GX%_@"V"OB>
MO3&#OSJ#OC2&P#F(P3B'P4*-Q$>+PT60Q4J3QTV5R%*6R529REN<S%&1QE2/
MQ6*=S%^@SF.BSFNBSF>DT&JFT6ZHTG.KTWJNU7*FT7RQUG^TV'&ASH6#@XB&
MAXF'B(Z,C)".CI&/D)22DYB6EYF7F)V;FZ">GZ&?H*2CHZBFIZFGJ*RKJ["O
MK[&OL+2SL[BWM[FWN+R[N\"_OX&QUX2UV8RZVXFWV9.]W9B_W8&LU,&_P);
MWIG!WYS$X*+&XJ7)XZO,Y;#.YK/1Y[;3Z+W6ZK_8ZZ_0YL3#P\C'Q\C'R,S+
MR]#/S]#/T-33T]C7U]C7V-S;W.#?W\3;[,C>[N#?X,S@[\_B\-3E\MSJ]-GG
M\]#A[^3DY.CGY^CGZ.SL[/#O[^3N]O#O\.?P]^SS^>CQ^/3T]/CW]_+W^_CW
M^/7Y_/___P
M
M
M
M
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MO$YDJ R<$ 3*$C*\F6FH,B"I2@ZWMNMNJ3"<ZI C!V@KD 5DQ/)*0ANHH>]
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M4N +YJ;B-;X0)$!U!(F$ K2%@33$8@6(? 4#C!6 %$@B%AF8X09<^(C3N8$
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M,$ZZ"80!HV #W1A@!CG0P0.UV]<9C(M"5C2@6Y2(Z ?. #>1\>]M#PA@+-;
M 5$D0 YQJ(,#R!!7L34@%G=8  IJ*Y!2X*$-$,A9'3 :BPA0(@X8&$@'V&"'
M ,="#@:>V2-*\8 0M.%U%W#A)1S "@D000YR($$%1,$ A1GQ7V^HG4 @$(C8
MQ<)G I%# ^KPACH4X!$H0,% >/6(Q4V@9A38'P2Z1<$0')@" R'!R?;UB@?,
MCK]XL$ I%, &.=#.QR032-!T^80GF)8'F5#%(52I!%XJ0A&JL),,U,2(%W A
M%E> %?XH7&&#4YP"M7#FE/@*\@H53(")!E'!".20 8&<00(IJ ,%*D$)"/Q+
MH[$(@?O>X,8T0#D6#[A$&Y:[@C*4@0T<HZ&/FV7=2[SB%;V-!0AREM=IF>%M
M$*C$I^6P 4HHX QD, ,;*'&)!B@K9+=&004:((I(0$ $;U#A@<.:,DK,C7$B
M.(,=+E#'!,=" APK!1DV<%Z"8."$>26%!$Y@:37@(1(/^'0L4J "QAF,<19
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M'/,-!AC!"AY0[C($6/(G.($"+!;D"I!A A,#;OGG $PD1BA$=K$P;<]6 2I
M @U +!#%.@\P+ EP:TKW!@E !"D0:>]401@P :40"0=  D7&,2=  6-@ 3[&
M!OS%@@0!4I>@ "0P!A"04 IS07= "@>00PU  BJ@ #5C!@VP B1P &,D$!]@
M 2KP 0004@;@3C^S+RD0 364 9^V 6+D #-$"0@0 NO'2"J  &=S,P: 0"M
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M?R]C$(^04 HQ!@D0!Y$ ?S;8$I!P.AIQ;>W)$(SR!$M@!%T !9F"65L !DD
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M!W'("A/C 9NS 6S ,K%P G!71I#6BY+@".E;@8PF$ ^04-T4"R8D$"FP5@U
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MK\ V:W ^%4"S-5:":F/6$8!GQQP+%)"F^^(!@!0+#' )#(8X;0TW;W  </4
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M-Q#."D#\"FE@8!!0,XZP ,]D 9[8T0L <7J7,F10.@Q0C2? ;**P (3= &<
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M@P5BP0$&,.\ S0M!!R#!!@/PZP%XN,0&X,9&-][A$AC@P",B<8!86$!MHD@
M*=XP 4I  @)G=, <1'$!3Q6%%0]@ RE(0()8A.  *L #*RJ ADN,@0,6\0 *
M1*$"#*QQ8R'8P"/>$(#)!0 %CC@!!"HU 5:H  )UB 7I8OXQ 11$8@4->,4E
M%. (45B #;'PGB/>8(!+.-($E)"#!5[! 'V50@$*\Q,##!4"!;R"%0D0A2DO
M40<(B((4!F"%,MO@B! ,(!9C4$ ='*& -XSO 75@Q0;&<(DSM/(2":#;!A3
MJY'I9P9@P"%%L@"#DN6 !DF$01&>0 ,FP"(3,/C.%%S A&#=0 HEW$$L.#'2
M$EZ+#RW @2L\ 5(><@(6/6C!(6*QA"[$P@HWZ$,LG!"%6&3"!E"$S]DN0HD
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M+-)P*?X.[&^-;XB$+HM$D0Q@0 0A&$%OVTH1#\!M!!NCA /,Z8!2>$!?#?A
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M(SD^Q(-D-+6*\("P8@4[(!4*?01.7!CT84'@H0 %7:>#^:M74)A7<02"$06
MP@A(D%&*8(4ZT*)702T_0Q(D$04)2 -34*V*2+<1.(,85<=LQ(,1P8,E%<7#
MM A*N/Z#5[" :/RK#JT$TV(W4JB##WT%T\$#.72;.F!(J/ 5*;@,3; !9@,I
M3\A!'&HO6. !+( %G8H%8=.".J6(/F 26!"I(HBH3-"!;_$$N8,%*/@!EA"$
MM?3+,Q2)JV( $8B%.X  $+" /A&!X;N$ R"5-(R%$<" [C,4$0 !"5@?#+
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M60I(2#T6!;N-"$@A"CMX*P*_\@]0\, >42A@47Z7"N5;E@$VY,$!@5= R\P
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M-9*$D*E!"(6 &8C"&'@;8]@%W)"$"K 7BHP "EP"&QQ:;-*)O*@ 7MU!"(#
M $$";E*"DE&"&RS27["!(YB !_R*&FQ"X*' ")3,6E ""?Q%)9!$C<4!!XS!
M'1@?6ZC!"J1$&WS "*P3DEQ<"'C8!?6F?JCG\J7!3MR![JEF1?A="G@A)9Q
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MD_,RG?.5B/,ZQS,WPY [:]4!RS,^QS.A%K!HZNDCYS- 9VL]-UTZ[Q:;8FM
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M$CV 1\PDG5B !R!=5*0!=T7 4CP"IPP8ZHT_IRBQ^.BD71R D^P'(E<&"4C
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M,"@YMM;H&*='5C!#H$LRNR2N"NQX X4F65%C!;18&>.!-R Z-@W &+MD##,
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MU( HZA  .P@P%J.*" 9(08D'U/,2.V0%&0A "CX:A T\/<$%2%&)!US4( Y
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M$CIQ$HD1.L)P\G9.]_*$%"#  \B@ E* B1P) V10 6;- \HF#4!')$IM!2@
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MDSW1,_XDSG-- J,\RU,^S\0\Y3,^T_,]Z?-/WA,_^W,]_?-, K0^W1,^[;-
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M.5@1XC86P  +8H$37N /8H$+CB!O8\ 35,$&I((0/A@6F& *A+,')H\,%P<
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M)4)@B%DA X@/+2 !$D]@!1A >WP003- =VV)$NZ@:A0K+HS'(#J #01(!5"
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M\(BEO(<5'K#[!IB(-P 8)56L8,";"A:A-SQ\EV^XP% H$0(E(HX2#\A))"
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M;"F(Y/(!#7 "1*  #>,!;,(&F/8!=[C+-#D!YO8P%A Q2_@!!B!$%M !8\
MU#,"MA@"%O *:8"MTA8"9'"NSBNTL= &S9<'"J "*""W.Q&JH8*!2J$ *Q "
M=HP@(OZ= .QB"0_P8 R@7@X0RXN<$Q501F4"*A- !BA0K9);,I+;,((Z!@[
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M Z+.#_D*:Q!F/I:A$) &(H!FC5("U-86<4X&)_  'T &$G")'M  *C &KVA
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M4 L&4 ,\J( BBP4B ("_$ 4%> ,Y*@!*6 .-D@L[.  V>/X%!: $(7L#1[@
MCU@942B ALL2S1HPD5B#Y2&#!Y@#,PB )PHV/#@!55.!!KB#.RBQKQF#"7"$
M_^( 5L :&L.#5WB %+B#$@  &P.B +"X%*  "E R!B@#/,@ K_$ O?L -EL
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M "%:&U;@H11 'S;X@ _XQL- @\@2A10@A3;0LC48H3'J@#IP RT#1S)0@11
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M![BB!"A(#E  #* $49B 6@)#LOYH  X( 51\'!)P #R@! A(+ ]X!; Z+!*
MI0UH@+6!A AX1Z^AA D8@0<0!3-(  E(Q<,0@0L0USRX! E8  \PHTN%@ _
M@'6-A=<S,P@HA6/S ):"(P@  0BX(1) . BHHQ.X !* @!$@(P6(G!/  $*:
MO5&X  ^PV--PV!"8@.O!5Q+   V("!7@0 F8@XQ V%*P@+]@@PB86:P0!9+U
M  9(P<JC !.  #*(A"T]U(DM Y%E@"GEN X@!4J0 #P:B%&0 !'8  A8@0^H
M  QHSYB8&6O"T5@0!!_H)BF( 69B+O99@ER] N7R!"'8@UAX@FU: AWH RG
M2Z)P4/X,@M"7<8#OD<$L"1Y1>("(T(#]BH408+T%T!Y66 ##4( 2B(@U\(H&
M^!X(^QH0,*Q,U*C0/45M'8!<D[E[DPLUR+X[H*N1$PT'J"/S4PAYU;Y2J(,!
M0%4,;(QM984V^#P@8J\2N!Y2$( Z4H&?(H&I38,(L-RX0X$B>X 6BP4%N(0T
M8"DSD%,3J#R-.L&/B(! $(4$&*$P?(1]TYZ'(#T-:S%6,"2_B 4U^*D$2 M)
M0*%'0-X)^ L->XH_)(C:8X"G',N ^01#V#18< %"^#D78"8L8 %FPE5OBH)8
MP (7B 'RL(*/T 1K;-;,X YH?0"':*R$HBCS^I@&* $44/X!"Q ABI(+$<"4
M!B"M.E !$NC>2W" E8''\FJ B-AA$D@ 2]@$Y8L%"O@+XL@ 3)&+!Z"$#40)
M2*CAK[B>!U@;4M@KQ$L),_BNT"@-'(JW$V@QI&V,+;+<FA0%D>#6%-@DC9*
M-9J /$!:"B"!>2(%,T !"_BI.T!>M9&#ZXD($J@+!HB(R'6^+&&J%6@,MS&_
MIR #!N  <8R%//B\2TB EUP!"!"X!A@+,G@R)HX<%%4.=4D*3?@"+\ "+("!
M"/Z!%F F+7"!6L7;#-[@UGE1& !<]E$$PV6:W53<UD#A2H"A2&!AR0W#-\ #
M/(B$WDGDC\@ G=KBCPB!"T@P"_[P'ACZ""'FK^ 9@6P6A0N 9LF%&U.VLOV2
MB]&] Q*U"RPNO%B88ASRXNLYK%?ZFE+M@#>2XDLX@:-%8?RML,OMOE"6 !/$
MU!$2*1@SY3M0@0-P!%%@ 'T:L"RA !B+!#FX@*\9@4EB@+$0!0? 3XH5@04X
M" GXH+C@+S:P ([.Y%C A)-U9FTEA:(B Y.(A0DPU+'$"4]0!2#H.=;JLSVP
M 0-M@5I5@BN(A2N0ND] @JW#@C[PA!ZP 5@ A6#.2\1]#@C,&\:E!" &&P?@
M+P9HC XH'S,P# [@@$=@ P)XBMZ-!00('$ BW<," 61+ 2Z*:/X2L4N0YO/E
MR#88OOXX"!X]FDP(>,@HBH4%J*,Y( !6>(.++:\=5 OJF:B(D(/C(1]P'%W\
MO1X2*,(R6)X1H"G\50A_^@@(@ 05V%X,,,$%^(@4T"@[4#6(Q8/H6QL7A 14
M &EP9 #T>04,@#<%^*(3B( :FH N/0 @<H"(J(!X/ %'V-S&&(,.@EA%[6D'
MD9%J4@(7>()K8@(I< 4K>($M4 6\504.EH)5&%;>P!98.(4GV&H25I^NYIL(
MP 1\G9N[P"$,B("#L  ,P "#^ @R>.T.P!0)F"?J_0 >$@&#/2R!G:$" RH(
M\  5^( 0B/"34($$J"/B.($)X  I(XO)CB$)V( *,&TV8/X #9!>BOVNE!A5
M#G@ *7I#$M<>WP-'"5!CU3L!"Z#PM"B%#;@ #7"VQX&W"GB$2X" #<@ "_!4
M#-@ $=#$/7T #!#NR)&#"." "'@C,PUI">!3LGB #J  N'"A = RA>N "& ]
M"^TU@U5Q,"P% (^%,L@]"UC#GC:0(H!1GI$!'.A1&K"N0L>)'$#0']T9]CB"
M):B?=J)O;+QOE?B,T-"XD7@>66)*]-'"4A!"61J)T>  )7($4.^^2>T^U;B$
M1Q@;DV'R"AW*)3&94G $1BPO4]<W2[?4RR6%/-@:2=#*E<8A>LQ4:#8S-J53
MXD %B>;'%$N)6B>M[ZW0S>+'M/Y[A'EZ!5/0=7T[99;@S^R,%WD9=[7T%_1H
M#DEW#FY,#C.0@ ^8 +VCB0]X(X<A@?))#F\7C6O-5 A)&&;-CG2?34I_C5*
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M&:"$DD$L,QT>ON$0BP%.%2,@/WKPL,Z$6&P?5ECS*H%J4@8>-R!>+!) 0HH
M;CP40@5#D9'1 Y*(0@!.CS PU/Y#H\@42PCJQ8+!&;$\  E^=T 6"5X:%F2
M4X\\-D$:L912AH9H=877 >)!\E@%+Z(2E&DP#B!'+&-DH.$*#Z5 U5D/,1!(
MAT)6]48$0T&B "N/U%?5*Q*\\= &9ES2P% 05%)'1K$X8I$*"CA%"55=427!
M;0QD9IV=UAGWW')Z1C<#GWT"&JB?@5)GW24$ ! "9%IVY=U#FSU$B7P;;*!"
M"B,H &<L$8@XU",0S%=?!R?9QX:DD(6PQB4)K' "$0RD(4H#57FPQD-AL@(!
MA \,5<D#$STDB@,@?;!="&>(<@!I1#AP8J2M-E"0"@QP\%A(#&0PQEL/B)""
M"AMD]/YJM4/5@>T8I,0B0E"B?!0+&QKD%((*W]:7&GZ 6= E9![(.%1JD$)V
M"0/ TC<@))181$(%I)U@ "M)5G7)&"<\@-<$=K3"@&YW<ER5H!^#'++(@<90
MG75SG( N=]X-%<D#K<3B<BP:H)#''9&()XD%CCA459H/X6%1!]M56XD#D(&@
MJ@*.X($'):1("FRMMS; 2@00.C!1U%7Q!%((0<7R0:Q+XY$')2 -]48#IJ)
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M( (DPD//JO*215H( ^H9"A& ^0 AH>!$",O*&)JR@=M 0&5&Q-,2N^G-D,'
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MV+N!E2^;0U:R;>(& V,HP?QB488*L&$$ZHD$ C;@@5*P80$<P(,C&E &,C"
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MZ9_>*9\J0I_RJ9X>JIT*ZJ+>J:+2:9T&JJ!**IPZ:I_&:2:XZ:9R*E2Y  R
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M>-\DL?Z3]WU$"+[!*T1"-DH5<\SJ)D^KGY1O+'1!"\R *GP"#9R"*LBJ*;.
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M#KB 'V@RW?X *-S]8#/PWP6F1FAVNLS0!+P)!X1(&PQ8/O9VI^C/Y8L&TJ'
M">QL!@3%)5C\D*@'#(?&RXW?"GQ -JE^!+F+ A !"CS )HA$&:@ !K3B&AC
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M'_! !G[#@ <0(19O,*$%A,<&?Y7@ B3 @ ,R8Q@&$.0!:TF#!$00@3B4H@&
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M]"R;2,"GY3F8!$2B!")@9\$@L)<II: A;ZAX"J@J@HPZ,B$G<,10F<V ##.
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M#"A@OHSO%11 $EXA2;-+ H2T%%"H#1;L (I+,8IDIA(" U#H 22- 2J#(NJ
M #*#$@Z@+=P,IT3![F*A R!55!_I#2* (B!! 5Y!!1A@9(:S.(?U*T+R$@@
M / 22Q, '77*SY:M#OR% 9Q+!2S 7QR U"!!!4Z  :QN$1O SQS#S"C! 8*K
MY3K@IK2K#>( N2"00"FB S! !5* !'PN!/9%%$8H%M(@H3P@73'!H"3@$"4
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>GN[KWN[O'N_S7N_WGN_[WN__'O #7_ '/R," @ [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>comp_0005.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0005.gif
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MY>CGY^CGZ.WL[/#O[^/M]O#O\.;P]^SS^>CP]_7U]?+W^_7Y_/____CW]P
M
M
M
M
M
M                     "'Y!       (?\+26UA9V5-86=I8VL-9V%M;6$]
M,"XT-30U-0 L     '8!N   "/X 6[5BA8E0(E8"6W4ZF#!A*4*$/B5$9<F2
M)DN=&K;ZE*B40T2I- I<B'!C(E0*+6JZZ"EAJD09$UIT:;'BQ5*K,,5DA;&A
M)4*(5C5D=>E2PTN6D'(J62K1RHN<CJJ,V:JB2DLA+VHJBK454J4E-78B9,BC
MP*8US2:\!!3E2(8*3[;2VE.DW;MX\^K=R[>OW[^  S?L9"1&#!A!HK9:,H.J
M0#TU8,28P06AH1DU9FBN$I8)C"H#6WEY$<BNDQB*P< XU(J)YLDOL(3N$N.'
MT%:H;/0H">@%YLPONG1Z067D#","/S$Y',-(1H2*-"<2B*H'#<TS@F!JI2<&
M#<,PAOXD7-7C]8PEIUCUR*SY!9]6Y6? W@,?^XP?TQ.RTC)#LHT\ NV!F68T
M9(%0*:<=Y@-KK9RFB4!6P##=#^8IT9)@&&:HX88<=CB>$#%L8<EH.0C%V$ZM
M[/&"$8<DPD1PK1@2 Q.''/+B( )=0D,/-I@U6FEA">2:8A$:TAIE?^2A!R("
ML3+$#C/@B)L./I3$B1YYK/>%'D5]EMP,2 R$! Q:6,+%"^)!2$,-60BTR@XZ
M#%*(%LVUDL=G2>I1FIOK>;$'%"]8T<H.-NB19T;K8:DDHC8(8L@6,0C1T)DT
M$L*#"X38"8,5B 1R! R"M-($#%E<\L<-C;4"10P/MA+AA/XU>/''%%YZ:.NM
MN.8*6"";)I2(("B=V% 0,QC5BB<UX-!*(J0*A,<+F;;"!0VTO2?:"X#8Y5JK
M1;:&FDB*Q,"%#<7A9D.5&@51@UF8Q ":0L>U0@@,423D!14>Y48%$S8(A<H.
MN[62B@W*W@F@2&_J<,I&-1"AG@YNN;G##K<UV0/%N.V PVVY]9A<( ^JJ(=
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M< (D4&ASP)"M$ %UT I^T "F(! 1L B1P  GV0H20 >M</X!9- *&) &>_@
MHZ &&# 0E9  -<AZ95B-#G!]D8"3K6 "'6D*#S"$'5F*"&@")6" S3@"+" 0
M(3 &C(80(_""=1 !V2<!UP<*KC *$8"(<O  $Z@*C8 09["3P7<'!\"&IL
M;!B1K>  B @*U"@&@]@*C9  K: !V]@*C,!^:]D*:' !G]@*)9  '= !IVB#
M%O"+&0 'D,"#$[@!-ED&&C *#E"#JN  HQ &$4 "RO<!B,AZ&.  '< !!;"-
MC2 !$V@"XZ<*#P *)#"3SKB*'W !(Z!\RS<"NGF5XYAH2CD!': !!2".<B@!
M#J"'HP !CP@'&1 ::I !)0 "??X)"@=PD1.XDB,0 B'0 6M@"J+9"J#@ *YP
M A1@FB(0 J!  >)8?FR@ 9>X 80V"@\0!Y  "6W0C(P0 24Q 790E"5! 7#0
M"I-  6&P?-B'DV?0E]5XA*Z&$"NY"(TP"6' @Y$0 1/(@K88 :(PC*W0!@YP
MCE6)?8\HG +!HHSF!A,0"8Y "2$P J4(FA*PC1!P?7"PDS:X *'0"G-0BZV0
M >.7$)X9@J P"F19@Z!@CBS0E*R B!? A*78!G^9"398G8-V!J0H$ GP!I$@
M "V0"1O(BF1JI@_P?2 0 ',@$*H @J%9!J"P HK)>B4PB,$'"@/P"+$X@2*
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M$2$@ (/)9QU0E6/F!J$,"AHPT(96 1O0@B&@ 85*!V<P?2V]"&K0EV3I"F6
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M'3 "$5"#%3 "=, !M<@"SM<*+/Y@X]]% 1* E!T@WZ'*AF3@ :Z0 "M@!R&
MT'.   [( A4P!RU0_*W  (X0&L$7!PNH"@>0?Y!P !@( FC9"I7P "OPD8(:
M\C;8G0 QIT*95JQ:@7K@@<T9!BU:25I YLV%"*W.-'!39(";5@LBS0F@8LZ&
M#ZW<A)RC 40KEBU=OH094R;+#0Y(? BQP<XH!*W>4&!IL$.#$1\ZM "5P!6<
MBB1,L#QIIV!0"Q[<B+ @09++,@A2E,DZJI4C!V?</&#3ZH+4F6W=OH7;%@Z9
M,F30@&(Y9RLI,B34&!P%2A6H40[PCNJ+QE6K1FP;QX4<6::<NG;QFA3+>$ZK
M2BQ&E/XQ57#-&99P2!2Y[$;4RTIP\CYJ-:K-XE9.IW8FP;&5G48M&YW(_7+4
M&1(GZ+2,=(*%0(-M2-B9$ZE5FU&3H(LPHZI5).@CSM"6''YWW3)FPC1BU:85
M)=<M[92!/Z:-*O697"]:Q-+. YBFQHCX#HX[6EJL$15(.",T@R)1H80!6UEC
M$O$FI+#"@QY 8Y$.0K"P0P\_#&^2,!C8"D28)'' 1!57=,F5-B(@@T499WS)
ME<4,"JHE@\";I(43%"-P*AI-9.5&EL#3,<<D@P(/QY><#%*2YV!R$DHC8;HR
MR%'4.!+)*EM!,LLACP132!R1G,I&)7-TA87O8G(232:Q=/X)RC'OQ#-//??D
MLT\__P242CD#)50R5^PL--$/$56T44<?A31222>EM%)++\744E5LY+133S_=
MU)50/R75TU!'-;745$5EE=13586UU4\9[3)64&U$U59=556EUU5SU7735W?E
M5%A:B[1UV%MA5;945$_U===HB:76TS#$$.-:;*\-@UMLO\U6VVRW_99;;\$-
MMUQRU_6V77'5?7=;<;6=-]UXTP6W6S%88 NF'O-]EUYTQ\UW77+U59?@@P-6
M6-Z$Z]67878--K=A<)&2:0X6QKT788+KY;AACP4V>&"*X64XWHH?+MCCCPN.
M,5.99Z:Y9IMOQCEGF0?5N6>??_X&.FBAAR:Z:$>+5)%6#WF&]% 0&57:Z#NC
MEKIJ#ZFV.FM*%YLDC3-Z8PF2U2A\Y PT)'1K%.E<B@0O\!H)I25&(-ENM4:8
M!A02L]=^2!17P):LD=!:4@6.,N#03J9'$I<);T!=68115= ;LI$S*)EI%,!?
MH@1SQ_4D8P$02%C@*;74P[I.ELIP0(43&%AC)H/H &H2$!;#( TE(XB]%346
MH/L"+A\H<4U 7Q\AA 1BYJ -2AA(O4R6'F"$< PT*&*#"2ZS<@)'A*0P>A E
M0<#M)#-A(+-%7[(C A4DP/S)Z5*4_P33VU+Z<\@,F@,!M$$I )<PH!M74")Q
M7FI))?X2IPH&P&8W#$@<*T*QF%&H3SN-<(!V-J">R[2" K%;PP+0U@$N,8X5
MH$ 28?@T!@<,KA$!J)YV(A$!V@2&-6-CB2E6(X'O&>0,%Y@*")Y"01PZ+38=
M9,E@6J3"EMB00)30'X46 Y'+N"(3M,E$!$PQBL$E$8F!@1(3FZB^J9@@!:W
M )=B @<)--%\*6#!0: T"AP>A(PG1)-@+*0!A^ (%'C!@'KF@ $05$ JD<!
MW$B@GD9H0 ,4X)(K'#"&EF2",2!H001$$ <-/( TCAC!*#3   V((@0D&$$$
M1K 8"<QA/Q(RR 9BMX%1O($$**" !3!'BA%DX )AV-,#WOX@)$K$+05QR.)B
MR& !E8@E%!_P  :* )4)9& %$NB-0>#@$2^"R007N( )%@,"V)2A AKX %["
MD((12* #VJE$!S(PD-5=8 ,>6,TB,. !"FQ&?.&A8BOTN8$*Q&$]$VA!!A[
M)3( 1P(:$$L;+M"!"T@'%-&T #!;40(6@. !*&"?!N(@ 23FR UM;,4*+H"!
M$(AE!1XP@00P(!83=#0"3S$%"#AP 16PI!$9T$ %U+,($*S  A'(SX18\8#C
MN,(.<*"#= ;8"@WXH15Q &(K3&"". #%%1%0SR0:D)\Y/  "&R@#*5K!" )(
MI0(8:,4=%"!0_O@A ICK0 =8H?X*!VS& B0HP$IP),N.@ (-"<"<!T[0"A'$
MD:K#_">%0+$ S*EB#G"P ^8VD 90I @.%UA,&$C0"C'TU!4/H$0E$M";,Q!
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M"O  ,6  TB"!"S"#%)" I^B #0B##T  P%$%[3F0!> (SU,\XFF%L5(+(WR
M&/& :8HYAV"#!Q #$  M5\" #AB#!Z"DF*(^#> YN&"(%'" %6 )%J@ ,KB
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M 1!@A5%08,QS -< 7JM2 T)>C%&;BA$  -?(0<8XOP4HD1?KE0W@CPMP@TA
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/V&&+/3;999M]-L ! 0 [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>comp_0007.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0007.gif
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M^OCW^/7Y_/___P
M
M
M
M
M
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M#<F08>"0UY@& % "AD&.;O$ #8"+BV$()K "$O  +$ "B: %'  9ZGAO@L
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M"M#M "1@R0!0"5HP (=  1V@" ?@LR1P  WP"14P 3!KB2?@SE=9X%+^VBC
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M6!=(9)-/6$ $'\  8RJ!@1"<X H2:$/8,-#%T51 AVR00"9*,$8L8* GA?A
M"<1PH;!9P .H 4LH3F !*\;,4\OJS1<H4$F-F& "(A"!2$@@/PEP@ 08 )--
MWE*"1^X*#%R<@ '!,DJR6. K6R 1"<9X!0QTH1)42\@%QOXFB!T-@@(>L( )
MAN("!NC&)C31%S*E)IYC4@!,8+C5!BH#1B.1@ ,0 )L**O!(92&"BZ+ P-B
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M*)K=D  V8 ,%F(-,:( N$(02. !$\ U!>  S( 0,$) NH !!" 0(R @% (%
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M.5[.69]3)?[TA#8HK#(C9('68X5&6T6.YX'&V1;XN&P5!$$K WSA6F0EPDI
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MX(+PP TU<($ND*)%T((KB!L+H ";6 0NN(+4@) C:X/E^ I,* ,>Y;@54)U
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MC$$0@+\F  +8]P#0^0)0,P"0FC0 @-[(@ #8@ 38;S,  (JF@ 9X^@# ERL
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M0(J?"HPA)B"2$P!!%.VBHQ8\8 ()#$4+F9H XQ2%0!)D $<A<)(H'O& 48P
M#&ELHRP1@<C@C8($61A%V1J7J_!EACTI,XHH*("(+81 %'^Q "&>(XK;A,($
M!PM!%Q#!ITD=[7.8D("&NN"!$TC 9Y+3@AY1@$+P%4(%9B"!(BCPB39&*Q'4
M\H 7W*DQ3@4&$RSX@ D>, B]18L0#2!!"$B @?^(9 R1"85+P4E+$7"@4A<@
M! O,(()%5"!%F6%!$]>G40O02OXDF6@!2"$@.9'(TA.B<"0B18&&#&!BFF%P
M  G>: '5B0)IB*RJ%K5C 4ZMY@L#I4!%3J"D4*" )XHRJPDJT"VUAD0%+H @
M)D0A3S.HZB6E*D%*(2 *->!')"FHB"CT5A>4DD "JO%"!"A @D^, :LI)6IF
M,,$!"9#S$X0+*:W(R8:4=@ S*^#)7^ZC,8(9$49:4\ !#,   IRA$@/X5"$&
MP+\!^.80NEU$ 'AR!@"881  ,($EN " 0S )<%AZP%],0  U,( "B1C$_C Q
MB$.800(** 0"/-"T06 %,(<@;PL $!8"!,(3#,", EG"7IQX8!$$N&6I$! "
M!!BEM?[^_:]_18)$RXR@-%JHE ,($8I/9()9[%* PKI' $]\8"B3:T FNO"O
M"LR!(;+R0)@4=T((#.(3H6AP5^\8"@D@XA&XM$ 6V-" .^JT5!00B0?$(,W5
MM  %E7AD(<J8&2VXZUTKJ(0#5N."2DG *%(K30>LU.11/'DBZN+3(W19F@KD
MR@-7$(4G0E$)44 @$)_XA"=26:H3CL)V=;R$"S*PB%&H@ NCJ$0&PE"LU<#%
M* @<!0@.5JII?NQI$/#$!,H;G&X>; ($HP!6+M#AK*#L. 2; ")B"J="_#A:
M'W"IAD30A4LDN6@'@P#C/+&1*UA 0RTX&*0K$:U#<.!!6?X!@@HFV]9*)4("
MS:-6"81HDL^5)@,H2-$&"*%8R3 'DR[,2I6?'#(P>T(U5TC!9%7 @AZ*I 4A
M(@%/X-1?EIR@.1T ">HDD*)'. "%7O" )Z9YAO1%*UBKJ<"P$O$ 48P/?!+Y
M"Q8JP#@L*(FNHTB!D@*3!8&/(@L\:6NM[@J!%EF"6IKV:P.^$*TR$O8W*@C1
MG6L# 2]$JP*9L,1*$M&;0$Q@<J*P=VD8AXDT)$ 1M6S1!T++!NC-X:GK84$*
M,J-%EP8&P+_!PH\648DQ<> 0 *@4(=1;B:<#!P N,(\"2 "!*@4" "PX P4
M0(@Q/1 " N" "@;0:@-4+00 V/Z"F5@@B HHP!,H$  7NK" BB#2 @I@PQ<
MT 4.)& -5P# >B2P-0L4_O ;4 35 Q,*#Q   T4W.N8SWRB4!JYP>-R*"CA0
MB45<P$I%%\,!OF (-.Q=3 F^A @*=X6MD!DD:Z!6".Q8"0R$J"^5> 0&%L(
M%3.@$F" P"(\ 0(L=-<3BLA !IRO@#2(@@,'RX *+C&'&9NJD9I;C2<LL(%
M%"(\JIFB]AN E088!0SXR4"8U#^*,. ' V.H! /N#.&- \$2:Q I)N3:*+@
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MB "V\5ZTA()64J4):(@R:HA6FOY )H2""G1 "K#!!W18"V1 )F"!<5P",VF
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M)MS1$"E;$6&"V_+L(>PAHQ1"I;[((I@!X!I"Y(9JCP!NUV[NS8K$&:S Y#S
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M3<Y.BK,*B( )4$ 'K(118X)*>_YU.5U! U2 DY"$4RN"9J5(%]B:"&R7!H3
M!10$&J" "I3$(7CE"6P 8J!." !!!7" &7P ! @1$&R !WQ BI1 %TQ &JQ!
M21!"!M 125AV75B  X" @XU58H0U!HP4!Z3(>FH7:TM.&:R'M+( !C33)Z3!
MQ A"IKB?9:N&%EP!2,6U97N FHDC;$K 5=HG!DC$&IS .J^.Y/RD!MA+::@!
M9[  OI43_07HV6)  _QF:3Q"!C0 9GL "N2>;\ >%T" (63"!SRHG2E.D&(
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MA,(!B*?!A(0%!$)7805"YV0F6%\F:($%-/P)9(HRO6+!:&%:D)PH L<TM<$
M=,$B0"V%C_V_FM.J0@!=HJXEG/X!<11$I?EQ;<"%0Y6X9?P+F54"")! &8S!
M%2B &8W!K9=&^WR"\K2 "ZQ 5[UL!1S4OW1!ICR >QXJ9HB$(75*14@PXUP"
M&D 6 @IY:7P!W5G8!Y  &?!] @@&[_SN(\R%&82!&1C (?#R +8 _EV(&3Q
M%U0<M)8,&N3:)X# 0HS,*-"5(Y7&(C&K(IB!%G!A5LQ!&5V!;X2 %T".[3L$
M(:1/,X)]+4>Z1-B\H[\/!7#:N2P"[BEERD^O!#0L&9! ^HA"(8S!"E +&SC
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M L# Q-K% A4@61P@52Q -%Q@U;Y(6#9 #4[@0[A@U1BB#!R "S*R>:X@ \A
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M+!YN 5ZK$M#H$S_T)2[F>4Q51.R'(;( -=LH!+0 98HC6N9C=TCB"GHR!5K
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M3"#:3D 7LT #,D!QLH ,=,($-& #()@0/B O+S>#-7B#^<;67J4 ,=CT_A0
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M$S(%A7M8\FCO#'("]@(C#<H.G)=.F8VYG(=P"%U8FXNY(?24DV_Y"^['$[)
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MB2*,81,%_D,U1YK!$^''$X6@'@/(%@7!?5?1,0!W")T!27 B@04A@#BA$)4
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M/1GP$YZ0A$]R 9_X&)6 >>+IH]\H"A P))"A'HE  IP7+8F@!6)P 5=P""2
M 4"2!F' !;XG@%C# 6CV!6.@ A> 9FO0 1X ! 5A"2?@ ?XAD B?0 (/( *7
M( @UV@(;\ '/\0E98'5JQ!,*]I>#@#/HP@$_$3Y<B@&#@& G\#!:8 8>( *)
M< 464#*/U05?TP9L( &.VA:CA@("R 8?P $ .E=B!P*)  1>JFLBX $GX EK
M4#*>X (5B*@?@*:-BF:$( (?8 *:H7CFP0+8P0$>T)DXD0(?  (9J#DB\ 73
M,0A7X@+1D@FF%3X>X ')Q078!CE8@& L@ A0^HGFP:E9P!:RP@)-.@HI6@&&
M- <?\ $L()#D:DB54 (<( *DV 4/D %L$#5=X'N5,1Z]"J,X81J"T 7X2@([
MD0DI@ %:( (@D066  9[=@9F@/X(R246&* "5R 97G"@72 13^H!)1 M%]HW
M658"BGJ J8$"+' %%_ F*<$"Z$JG5^ !'[!GEO"N)H!YEF "'2 "!T@[ *00
MJM(W(. !+I :8Y &+7 %A( S!Q(M;$$"VZ8&(3"TJ;$%9E 59A-:&@ &&;!G
M#<,2B<H!*D0&9P $EF,02E&U)F !@(H))[ !(;!^9> !'0"H7&"U&' EP80!
M9B *6I (+N 5RXH1'/ !+9*H7L<6+3 I1)(&%%*U<D%O/RJYIBA4[LD3EP !
M7L"H)4(( \ %A% J@? %"] 2!! &M+HH;$ !A& )7N<1$X!0"C 'G]!>E[ !
M:+$!+O[P"5L['A!@!I]P!8OB 220" JF'@H@ H00!CQ".*8C45M0 84 NJ_B
M 1  L >0M!1@&LA+""2@ &8@" GP' M "**2!96@"!PP E18 5^T>*.@+(-@
M"2!P$432 ,-J @I0!H&@ ((0I+][ BWP" HP8!4 /O=+"">@ &,@"!T2I&?@
M"2C03!\0!IX%)+-1"8S9(FSQ 2K@"36F30S !C6$&P(T"H)R.Y90""RF)VU0
M"!)P!8J@" .0M!@P 6Q !@I H1$0("(@,2+@ (' '&>P"&<J@A  .1\ $JFA
M""   H.0"12 !8G !6@4*A3@ HI@!@A !H6@ 322'8J0"/YJQ!:)0&,#T,4:
MH"$D&P8'@!9I @:@$C=Z9SBKRP800!8?42&O(@%B\ F*2T\\$0*[6HEEJ0(+
M9@@98!PB8 *OL2=>@ &8$ @1D)T8T 68@%G@ P(>O 6CT6GX P'JP9J5X !-
MR %*@0()< 7RBQ#FL3H\\78S)8*GS!@:0 @SE@AZY:1 0 "/9":C( 80L$,8
M(#$I@ !78)Y+82 4D &WG #J\6^($*F?4&.)('W*P<R#L ;/? @5H *(8 D*
M< D2 #"!D&(L( *6H"R*L)Z*$'G*,08SQ!;SU1.#NLTH.;GY_&<#X9*&@Q<G
MP@9UI!"7E$>>@%*A^" CH )BO/Z\=])L\!*D0%!^9&JC73 !I_-5)_ (XC$1
M-!+*"B$!<)$:QF67$)"!JALP2G%=+)$%(_!"DREB=W(E8)DJ.Q=L6%(!]7@(
M!U ))G "8DP&!,$3(3T*:,!-'? JE> )"=P7'/ J=(N+1(U-'Y!< 6D(*$ 6
M)" "#6">$A &\H@"Y+1DGI (P30*(U!YN $&6:,>*H$)#_@%O>(XG<4@H_#+
M+U0)*D ",G4&6W4S UTO$3-1*T!D*6C7:B$&H.(1KT(D7,MI?],N/:&YBJ!U
MEH%(2X%549-11-(!(.$R8H()190TB\(BA#$:(H!F0C+6AL "'0&R!7$"&F!.
MXC<*)O[P&S;Q"99 UF. 3 _P(C)Y!A*P"#Q$29:! AH .12895X&)!; !I]P
M"7_( 6I!SPH!321@&D0R(?:""=(M,16PE-_$!N7!&&'Q)= ,,,:D,>A\(_$4
M-PIQ 7,0"!=M$IZ0 5D@PUFP)^_]%13B 9*V((8S*3<MPKDTW9G0 %H@306Q
M8FYHUXN!IQE0G/I,X7WF"0RP+MSGI"V  EX2, TE 6PQ A>!N9[ !1V>&A-
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M;!0U$*@DC0; "*,!,D*ZY($NS"@A 3;"\V(,#!88!0RW/*")! ,P8>. +]+
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M"/@$+K" &FP86 J!;/D$.AL+-J  ,.$ 8<D #S"!"4@9REL$>2&!$)@ J,F
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M<,F[80!ZL8!L,83,*(&&NX*/J(#[\M#(O!T;N9L!,24+$?X$MR@!+$R/4;"
MR @$ ^"*#T@))KF(KZ" *^J FE  ;ZD$!;B2AFL81=@O%F 2+?@(>?&$SAD%
M11"/0%B \2 #"^%(,1V,$,RE Q03[TRA@=""KV"!)62:R#R#+*"2C4 5+9"
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M0/B$(_0$$RB(0;" #1C @<" 3PL%( 8)3/" #<@ $: 7_,@+1)@ V(,3C<
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MT0 S6.( 6CB$"K#S$"ULP!*)^-TH%B "0Y0A 9_(0@<\H099":(!"CG#>4+
M "T4XC^$P$0(E)>!+'SB"K7CCH'7P#@5C,(#HC0#@#X@(U%0H)R$NE\(5(")
M-5 @$QW(PB@>T0!,>"&^BK" (GETB =@HA(4 -XH,,N_#(@!6@I8W2 "B EB
MJ>L!'RB$"A)@!D(H@ VAL&PF"B0L K# , Z8PR$H<(5.ZD0#@P@P&E9KAE"P
M8#M9R, GYD"J0TA@$)@H@8RR0 %#M $"M0-<0BU(" *T$ 5&3( GNOSE-!S
M#(?@0 EF](!!I&$ BG[J*+X0P/Y#0* +GB@ ",;@B3!@X!&5P$!,)S"&4 #A
MFUW(@"?,@PE$2" 0F#@!ACW\"2L_! 0B0 09$-"@$IA0$!.@;0%,0 @S*  1
MHL# %S(!AA>=80"P]8"J)6"(0$ @51=81"4R4"L)Y'$-"3@$XXC$G4.<5Q$J
MB)\*-H3I%EX$$0ZH!"8(V50.%,(2"/" &#RA @X@ MN&H8 &"L&&<?<2L6 (
M *,46Y>+@- I6?AF0D$PBET>@@%?.,35"&$DA1!R$0TPR2X58H%!@&'"GF#
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MF$*$P!9@6R(40B(H "&L0=*E0?Q0@+(@G4ZL%R)< 8#T2NN4&0?\D4+\RD-
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M0I"!>T7=& !(I6V'!'@@&#R"!%1$E[4$/$Z13WAB*-P9&42-!)A!U8DD=H@
M%RS$!/G'K:EF EPAH83>&KP< @B$CA$("7P (IS.%GJ"8XY"(;"1";3 ![!/
M!:3?)20$'\[!.-)2[61$"#3:*)3 H[B20J1 Z(U"P]E>?_Z<@>2-PNJ-XD-(
MV<T]1 7T25E218@I1 N@P!H$"3GZDQBTWQAD00XJ!(=40$RABN1\P0?D8 N
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M90 &?/X$"'Q RG,($9) 8%G<0^ K> Z;&#U\I(R$!)  !<R:C%#3NJV 0JR
MM(=  ZBSHR],T4GA* !W>6H4TBN" :3?(GAA)BA)ZPP6 V 2%]RFZX["&7BA
M@BL$!#R"!6Y3D*RG0I2!$;&)1XYCX*R3!SP*'+5.&*R<>+K6LU=: [#/("B
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MU4(P+9,-+ !W# IN,L.T$!(*#221,E'2/4,DN"0^!P;O>@P&R 0*/O(Q@5#
M"Z((@0FV)@&MA< @$$@9B-; KE&<P2XDL(LG+J 1^E&@!*$0!0828H'0A2($
MA+B$ X1FG2MD@@$H,L0"$E&)!?[T)@T$&(0GT$ _J_T0B$$4XA").#5/6( $
M';# "4)#" MLH (&(<32!I*(#+0+ QRP@(0^D0'DC$LDH]C 3@*AD2]4X -7
M,,$)$J&!T!3":*-HP04VD(&Y.%%]+O"A(-"X BQ8P!,GN,PH2B"I-% @ R7@
M0&+<XH4+D& #%,C2%Q@8&D-@0'T0^QCQ,/&!#.@F)O7:B 9ZHS$+?$ %6KA
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M#$Y@20:B$EK@&WWC.Y!I(-: %?TD$52@!<9P(!8!'INF,)H&#9##$\C@$]C
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MV&41&@ +P@ #\$,1*(!H+" QPOXO+3Y! 63G+T4!1I>E67C" 2)%+(2& TC
M#$1 (PX! 3S@!"ZAG\  GX"@"Q0 .$I@ [[4C#0B!+R@)FZB#2  LF[(# P@
M"\#@ 1(B#2"@T12 #>[C3ZAH!>)B#"QC"QX@+M0@G\2  @YG%C$  \Q@$13@
M!,*  Y:F$BI "]#@ LI190@!N$8!"R3Q"C @%#;@(CC@\B80 EJ- <#Q T(
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M$V)8(;0B"Z-%13*@#2RU3LP6.^/62OGB 3S@$/2P)T0  2H  BC@ ,S # !
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M5* +7&  U@ 3!!D3QB  5@(, @"9&1<GG-D,$B $$D#R $ +?H8FT%20+<
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MM4[K"EA !++D@YIF#"69)S@ #"C;LJ=O?OG* 0;K6@HE]D+!T0<B2A*RM;H
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M:A8%>;&!!@Y64BF)&;30Q76BN)"!"5\@2M^%PEZ4B ==8(+"8I:HL-@:'FR
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M)$6$@, EKJ0A3")"EJ<C"$$R@0CJ'$44B[%()GKXLF;:KWJA6,P7,/")4%!
M$94 )TLH8"HNS.40E,01.->YQ418LSF? .CI*&#+6[J,()[0%W.HQ4S-+<(2
ME=C)11#A@(."98JY.\3XEN>)\5$4:>53J"\#NH$1Y4Z<HU!C0C6'"7:^=!0G
M.(%%TKD<-1J3.9YP0+'.=9%'R'*<<DO$\Y!:D$3(=" 6$ -+5$"":28TH#5E
M7VG(9M-#@%01*<J$W,J@'$1L,:OEH]8A9DC,MKI5@83(P/X&+  K0GB@!0!R
MD%U9@($(4(@,%N  ]T8QGA90 !$?:$ &+/&%&[D 41Y@ 0<@X#-"?  3'6B
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M9 $(V17C%4A  @A@X0IA'H7 MO!>,[#! 1#PBAH ;(%.52BP&P G"5+@ 0F
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MT():8 !*XA6$!0$AT 7;Y'O$6(Q_DP9VLAA:4 *(X!,6(1^)X!,$ 0)AH 7
MD2+AYWT:0@$HX0)5IP(^ P& X@D0L @:YR@2@!(=0 :2- 9@  9IT"B>\ 4D
ML !()/Z$[D<A'Q >\T<?V88L!;&.7F !8^ %8K &7^0)DJ@"AW "5^ S.9>
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M!HL@&2_# (:@"&$84PQ0"((  031&-RG(3='?0OQ%*XACC$E >9X&7%H$1T
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M!@Z04P)["">QJJJ[NLRA"&+04&VDE0TE",,Z!O<A'@58$$.W')8P!\Q2!HB
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MW,[N_/[.\!S/\CS/]/R;N$-&,%7/^KS/_-S/"<3$N2,Z@Q"]"5(;T3$'JF1
M>"P;TS,'6W01#/W(A*!/C)/(_[Q,@0#(T!$(&+P@G] &&GTV:C")AO %#XT@
M@0!2 V0(9S G]\M6;,.^G^S/@ ,!+E7)CVP19E!U[Q=3"2)(%EVR%6!3=\-)
MF7S'=;MO^KH<72"#"$("D'3)!1(""-$%3\D<(<TV64"5T_$)%G!(KF$(J70@
M<_"4$/# ":)+CL( "8W5\[/)9+  $5)KP=/)SX$ZH;$<6WA'AD.C$O@5(=
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M!@Q@32>0^FNU ("B!@2 "6;  $PB>+=T(\%H$&O!4Q]0- W@,Y6@ (M0"0S
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M&.B2!-;@E$!4@@&/&(6I+N&6#/Y)Q07&7$@7/! ")Y%@E(( @S4%/& "%]C
M3P*- Q(' 5 I1@,<,,$#S%")!M1K#0[ 1*Y.D &->&(#$'Z <2M@@A(\H%Z!
M4(!'/""5%5C@!!2PC2"(-XJ:["0"*EC!I9QE3L5PP ,G&,HHVJ2>JIA! BC0
M0 B2MP$,G& #T/& I_)H41*((@,;0$$%/"6(%/_$ M:R  HXB2T]KH@#0([5
M[$RP 0U\(H\A.($$V/")!V"2(:>[\RA,?#$F:X$"1!):%S@X@29&@%408&J
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M,).%](]Q(Q45<(]"6(!<##D.,(,QH  \TSJOG*2ER,,%"8,$N((S8 $$J#W
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MFIO889:35I#@"'\J =OH@GUN@0/$@D,.6+18B# X'0;SG?[\D%\*GE]20:N
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M! 1>9(@&C"(,#E#!"19 ED)0H*Q=A>I7'A50MD#@!"1X@%?&0 $7?.!0A8J
M"4X  >%@ 01\*<$H0$ "(#3@-YO#A )*@!P,?8(#(F@!!=HPBBQD( L4P)!.
MKO !#$Q)%"38; -&4X(*G* $#?X0R"$JH (48  R9I" "CYP@5" @0.5R, #
M?GI:-W+F QDP$$5.4-4,>* $)6! ]<S TP_$910BX, 6+-"0+60 "Q7X:1<X
M,) KQ,4C%$A#)=*J @O 1S97:( 87@>3Z'J">UH(P63"8(%1E& M9T"N"#*
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MT(4NE*&)#_#N"2XPF:Z^3@1*V:>"(& )+XP -3--T!<LF^H #^+%[TTU4SU
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M6$)<#80$"$+^^5@F8, <B"+SH0"FS<[E0<L^<40FN 4B( *.A(+Z!:!P9$"
MH88#8,*ZR84$*$88 -PH:$ :^$X95,(8M)X'-%P'C $B6)LQ88('7($B',(C
M5()_].%&B(%\C<(&G$$BG-0A*,("T<0:> (*R%@:!0(+-$!I_<8HL-HBA" -
M08 :),(AX(A+/$(97%VR=>(HF$!A> ($8 )8K$$FJ(#-/$0:Q.- '(*U^<A
M=$&B/8#E5,(A)(*U9<&AM$ + !;3@5 #,&0B],]P?$&BJ?[/,QT*$*# DF3"
M&GR Q=%;+'(@"Z3C.H:")P9""S3 ):";%RP &U0"(7B/2V2"&EB7>=G,*"Q"
M1DZ &3#D(UC"(=S=*!@"-U['&60<"6P!)FR:0[ (19  <TC _7#!"%Q" QP"
M(B1"AQ " XC!(JC!C[B$( #! F0"&#P*3(X"!4A-19$!0[Z'3'C"&DC5@*B!
MI7G"!/P?)E1 I=4A)CB ?X2!Q3G54E# &)BE)8RC?Z! 84#/SH&!I=VE2<0(
M]3A>QAG=*$C :S;DAKB$4P@71MK'RX082^*C)S18)A6D0$S:*#R"M9U :QR$
M?\!BCDPFF3S )V1 ((38(]QC)?Z$SR]*BP0TQ"?XAPCLG,;]QE\.1P@H1;/A
M10M8&A;TY)\5TQ<DG 6H0>&) @?\R ;X!0<XF8PI0@(D@G@92!>XFQ9!0#&!
M@<4QFF0V!"9LP")\ '18 @-X!010!6AE0@B<@ @60"#48XR(E9V9@1AD' I,
MADS E8*0P%K,)28D3W0T@!5%'UG$R%RQQ<QUP76<0 A\PB=8 !=4&;-U8K5U
MQ@-$$B$8@(Q1@(QE @=DA4R( 0%LQ!CLV1A(0%9! #,U &2P >4-VURB&UT=
M%UZ$ 451P!UYP@)4@@DLF@48!$>D99KNF4W!1R42Q*.HP%Y8@.R Z"#0X5-
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M&E3 :C!&<&7 "GB (%3"!OB')X@ !D!LA3BM!FQ 'QT"2^7%IFX 6F* !ZP
M%V  ?*1! DR)440&?([!3UG(TTZ&482")X0 ;^'E021$"8! )"$"1%@ L[K1
MB6) !4C-CKZ7W+J7R]X1"HB!8\B$4<B$56A !FQ$T+JL[!C%!L2&2PR(5;@L
M42Q$A&G _J@M!MS%2SA'!2B%&4S&9O*%5R@"Z6*=ZD:'UIKM2_P>2=&0DI$
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MSTXEG %%F(#4U)8OFLX9#$ #^"T!*$"7A(=5-#)]! ( *,6,R(0* ,#^? $
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MB%1*C0%*&"@+ +XXY  *. B@+P82D" ! *X0I8('6E" @E!$ &"10Q)H8(,
M2!BE"P D<&  !EC\I (T&W#@DR_8=(  !2ZQA $#+)" @/XK/GLO  LP & ,
M,Q1@(((@"6ASSTL.08 "#P(8,H0!)!C .!,,H* " BCPQ),*%/C   \6RW//
M1^1,( 0"2#!L@0:N*$-1+ Y@((-*-&B !08DX*C(8Y%-%ED+!"$AR34DJ$N"
M,=2PX Q,$L@L PLK6< 3#\@8Q '?T)  M$QF)(2#+$;1X@ @QK @30\<Z&(,
M!MP:0X(RQ( @J0NV&$4!<%F P!,S'$"!D$,D"*-:DKR @ PN&#!!J0Q42 .-
M,S24DPM/&&ACE!4\8..*##[Y)(,3T/A @U$PZ&L4"L[(B8,T"E%@YC"N8N 2
M%SA@(XL,.'*)A0\*!<VO&<_ @/Z%44!P8 P5&D!AC'JAEEJ%A*\F2H%!",$@
MH; W,",4#E1H@P2+%:'@BS4P< NT!S8@PP,)L A# 0=;X* -+3#X))$"4A"#
M @R^<,&!\!)H@8P-0O"K B_80'P4$AH@(2((V$B# 0==0H0!,P2I("W,1S!C
M$=(J_R*W4:[8@ TM+/A$$0@6JV 4%BPH8PL"B%H@$$P4$(&,@C^IY(%/+&$]
M Z)<JN0$";SPY ,1TD A<$42X""%^*27X M/Q";C"@:L^@"%.4Y(LU#@8+>V
MBP<$NJ(",[988)%*&!CCH)],T *E?" J)=!=&QX0!C-(P"T>$. H,N"%3Q"@
M!&40@?Z%O""L2K!@ 9I+!)]&08@&&&MF% ##%Q2@AG9E@ U>J  F+G$ $@Q&
M=RP(@64L1 ;<:>%^7G@ 9"C0.RTL(#,N20,!5# &#V0@,A:(3 /8 "U%>,(
M,R2![D;AFS1 D0T2F*(,RW#%T$#@"F3@@,\P$H@'@&&!7\B$"B!0F@Y@8 Q;
M4(!$1$""-JB 52WHH%N4U9$#."!0 U! )3Z0@$I\8@,)P 2J%&&)!&S $@+P
M@"$* 9D2&* 2(>#D[@#0'@&L(!0M $!2@"(&08Q"!0! !!H"H()2 D 0:\H+
M%@# K@TMP(DP2\ H7#" S( A "D0!1  H#8$*.(3'## )_Y4$(#6?,(E* @
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MP@'O\8 HX#20#Q"% H0@'HLR, 9,/& 4+8@M;<LRD$!<8!1J2.PH+D"&3R3
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M F [POX@4P;B$A#@JJ"& #RA!09 (L8@ 'CF#=G  _0G"-L@%%! SY0"!09
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M KSB$I99 SX"#!J C&!&$5J  :S%>CZ AJW#-[S@(]KGBC: *ZGJ*RPFW"O
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M2. C&N C0F'P5.H1&$ @#L%G3@\H(*!8P>P+D*8B&-0F7*)3!6(.". 2SJ
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M9:,&:WD #/  EW ""8 ! ^ !-_ZX@JWQ":)P B(0"G+2!1#  BBP &@P"H)
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M%4_Q$QB@J&B$L(=R1",J'EWK+8VH"&9R*P[PC9&"H6[!!2;0FBK!+9\8&9D
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M)UWP"9>/%X:A K.ZR;''$(GP '.!"-G_?Z1!%"S +2B %A(0>X9P  .3$BH
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M0B6PT/[8-F 5%'"*#! ),*"1*Z 1$&,<48  KRB3P&" B'")35$("BB6-E
M]DF$"M""2S"#!%B#U9,3+1B70PJ.CU"$ 6"!CM% 2R  $A"_M,*$V'N$+; ,
M06B 0+ $$J 1!PB$3!@ %6A!FGB 4!B$"4B$4$ N?OJ $K"$0B 4'A0!^PJ,
M M""<H$ 0@B$!,"$1)  P/" T'" -L@$ LB"2N@""! %08  0;,KZ'B<XQ $
M-B" -*@$$4@,$7 *"?@ 11"$!"@;!0B$1TB!!(@5AH!#3Y  M_D(0VB M."
M,W@$"[B"2K"$ Q !XB !$:B$S0H."3":04B 1$B$0:P$%?Y @-T9! @P@TP
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MCHH-J\S1$= *"Q"$%M * 5&$_AR%U[P($  #1( /.WT8@OZ2$X:0@$- RX\
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M_8 DV?XJPB$#F717X7@8D\" D@"##KB(,>"I"PB.!3HT#EH V[  L(T 5*D
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M@&FYB#289$O0-E%6 #8XA&$^4B^  *U@@!@)A0:8MP:XCX_(@KLZ$0GP A2
M ,#  $+^  6 0E;. @982PWH@DHXW(M8@P;(@BR "> ##Q4P@-!P1 /@%1*P
M #?S! @(8;IQ !'PA ^8%@_0BBO 3!7HG),  P,@- M@C$%8@%9V*BHV@0.4
M$]K+Q0\Y! 78GPE @1#I*@_   NI@% P8B_8@L>\"$/\$ @P& _H*C9(@/B8
MSKQ=O!<QU[4Q,*N$JRO0 E\^"?Y%8(#0*H&/6FI4>8!WU47724E,J( 3^ )C
M/@Y<9  Q-(&GSKZ_*0$O !Q^0CLO6($(V @40*^+4(14%DCT2H@QD  PV!0,
MJ%4VR,6(50#6@0 /J(1( P,7> #&D&K*(V#"VL.\]1<)*)1C- $J,8D2X #"
M?H!;<2\%: $PP #""0$)V.LN'#/,Y!PAB0 $EH#@V(()V "P=B;M58B;O((N
M*+L*P4P6T(A1R)4MV ![!6O"IH#O*01JY@+;1NV+4.V3V&FR#AO\@  PV (,
MT#6.\.O4<H'$\(1&^0(+< HS:"Q(#F\Y,@/M @,50&#-((,K $(O^) T6 '8
MI"HL8/X!0L  (0F$%D@#0H@1-E $3_"7BRC9%JA"2$'*_Z8;?\&$+&"!.<N6
M^U $VL:$-?BAW'"+!0\VQMF3K0 #/SH$!?X^%= "QOE'^L8 A<!O_8Z1.4B$
M S>)0VB!%EA)HU"!-1B$='*+-C@$,'6F"4B3["$$+O $04BG0$BG-6"!+#BA
M1+C(%- N&64!_29.+5 !,(B50$"$S?V(3*AP3)AR[QN#%;B"Z&D#%F@!>WKK
M0GKFG4FG-+ 7-> ?#:>=+DB$N7MK]D $%V@!=3&)1/#.?:.*(Q.0/=E<AOCO
M6/$$A/.7/5D$/\<"JMAR+4]T @D$)&><_=8,0X^-#=/P-/X @C3X!## !#:P
M!)P]]$]W'5JMD#NU!'O9DTJPG$5(DT%P&S6(GCNLA$IX44LPWSSBY$(X2\V
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M4!<J0"+0$$(!)F !!%2@MC,\8 LJR( H#"%8%4C L K;0%(@X($6;  #;_G
M!EC@ ?ZC2.80#EB>(,+B 2R,2 (K2$T9)-.0,S@F#8EE00:T)($RCF(+#=A
M&C"1 1*X0 *#\X($.(""0VS@ 89E4A8NP!0MV*ZM(ECH!KA  ?5!9A&C'05^
M1.$!$'C! E(AP04PT 5%," 40FG!%L@X"@MP@ 4D2 Z$1H."X6& > XQ1&15
M\(#C+?8*ZAD%(A9  A1(@ 0I\,!3QM  $Z0  D_*Q 9*< 4*N*X$$FC!"13@
MTQ"80 L-D H6*. %$8"F"PW(P!K&@('(1)8%$@ *!3;0@@]0P'*6F( *K&N>
M+&B@"Q9@B* <ZH41@$9A9+"L9EJ0@2QDX JD\1,)*! *+_X$<!17T P% A$(
M"5#@;0UIP06NL($4/T #_?N* [0 ! OHQ (9: $()M"?2U @!=8%D04TH((2
M/  \=_JS \!C!@FX@ 1PMH0"1)$&!:1 !0SPPB4\\  48()/++# !TR  @8<
M[PP3Z$X'1&&)!8B !170# L:$ *=<O<!6;A"!2X!A@=D@";PP4!@PU0"PRJ"
M B=H 00$,8@'0*8,&/A$!4[0!;:,(@,;L$ :U#GJ4V-"G5HX@03JV526;,BG
M'_A3)11PE$28!S+E'AHB!!$*"1QE$6&1;UD,ZX'?94!E#]' &;S+@4^HX<5;
M>(J6F9:3G01"$0K0"7X>8@81<?Y&$0OP2L,_]H&D.  -#5$-&[93B -4 A%#
MX8!45&#O+WC"*(]A !E$WI TO-@,/MV,3V_[D N8AP4@:$@A&O#!!:@E#0%<
M@W5PXHDPQ D3$H#,E!JB<8=X("DL(-/LO& [$F3@.D,Y1!D:$@*F/&!V(S"L
M! Y!B.TP:FB0J6Y#M@"&0CA 4! (!";,/0H4V$XIE4!# [14[H9J9A1M&$H)
M0#.*#S!% 4"I!(K$J(@,1;LM8 C@\,1T@5%, $AS_Q@B@ 1<]J"VD \1XR,@
M_Y8S)$ Y@HB 0W*RA:R/ @U'AV 60(/A40!!LC'2C01NR%N6G8=[%4 1!:0"
MH9\)%/Y(,5V+E$>1 BZ[H"$H( L$0#2*$K @%#(":4/(\)1!$+SI@4B ECZ
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M913<CD# )7S"!T" !@ )_%#@1T"&"7C !7E! QS"97A"&W@ !(U")LA&&WP
M"(1"_DBE**A??;2%"S:$!] '1!R"_Z5!&G@6>&A!X&F!"23"<T1')7C"V;&4
ME3F$>H!'!BA"&<)'5; ,%-+<%%9"9C@$O)7ACF# &F39!X3!XSG$!X@!:XQ"
MP(W"F8&'!AR/S0G*!;0%!\R.]ER"&,0)9)A!UFV!!ER"(ES"(HC"%\2)(DC
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MB$ F*)U4D&M=@8@@:.3'L  'Q/ZD!61!)C2 ZZP! T!'WXW"":C/)[A5&AC
MR(0!PJ9!?HQ"%VC&CWI=%O0K>*S!!#Q"ZLVL BQ/!6C!3+T89F6")WB ^E2?
MB:#(6Q3>"DD8A Q.RN72(R" WW@!T'Z,&&R@)3S 4[:4)R!&0V# & 1"3E3"
M!(!&!+C."GB )0@*6O1;(/ .>ZR9U'+7 6B<!/@I!3SE6YR 9EA"9(5"!7A
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M<:*TV)B4!"T^>6"SK[=@ X)U!4& $#5:WZGU#3X@0[29]"7C@37$+1R$:,E
MX/2")[7 :PO"?L!X!>JCB0+KY3YCTJ^U$ 6"G;-8;:) !OZ6GWX*# &"@VC-
M,$ 4+-#(*%"P-X!=K#Z96,0:4-"Z004H:V9@@R PX((L* =GF_M<%Y"E HE
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M* HS[,F..]G3*#B6"0G(1Q0K<($9('#$%FSA$6=8WAB6=X4.,& E9ZA "<*
M@?IH8 PLW0 ]K7FZ0NV.)A8(S$0$0=,K++,+U6+-(/B(DRY CHH>#(6G7) _
M07CB ?Z5$$59<4*!0ECTB$#P0BA40!66OF]KH[A &D0A @T X0I.>R!-#M$
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M Q:KSUAJ=T]@ 10A#2)@^4+! U!@"QA T@HE%#B _BR@(KZ  5A !1;@P[)
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M>4DPVB@4C";*11@DV$;GHFQAKQEY5=8 9BU,.\JRPJ*@E?XE$K" "0.Q!>*
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M LDS"F#0%2+ 4B*@!9] 0 OA 25Q$7SH$BQ% DRA OY!!K$S$)4T"D!1&1S
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M8,;<P3(+<0$D0 BQ.RYPN[F6?,D9A@DLL $=\$F580(=L )HI CB-@8RX0E
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M!H6 "2"@^1IR^ ^+ B"@!A@@;8. =QYA!B'Q"5TP%(IP'80 _!<Z"%V0%(/
M<6A0ZFU2"9F_<!DP!MW(+*CL$^#%X\VO%[PB8&G0!O^BNS?A'Z( $R;@=-0+
M BB+Q"%P E.#"6+ !A]PQ\_D4YS'P2%R"&20%0#!PA,F$?X0@& :-6K0F(26
MNHQ2A"+$EX0J6'CA\/#3&$^C%J$ H27AA30)PX0X<2CA2@L, P4:%2IAQ! /
M5]Y<^?&#%E$)NX@HH7)4(!(DR(RR5"$-"1%"<3Z%&E7J5*I5K5[%FE7K5JY=
MO>*L$$:4ITL6'A8MQ 5#*$(21A62D$80!C-L("0LH2*4 S")/EP9Q0&"&3,)
M!A&R ()-3(48/JS!!.&+7\!?XA9.0\@QFT(/PK#)H&+4E@,EPF228*80A8<]
M!RT8U<4 &#42 (.YK("-H@>C7'Q(>(+$*"UQPS 8?B($H2X8.B9< V'%(44)
M6J0)H6'4F J!U% @E+!G"A&%O/Y<R,1&@:<6'D8=(E "30L(F41EP%((Q8CW
MDME44 &3$R@@(Q,-KM!/A%$(82",-#"0H*=1,&' D%&B&T4$$1+I(H-1ON!@
ME Q$&J4"AC) D+R;RH @C30@&$- "<CXI"$5*!CC$PLX2(,+!BX)90,7#%%!
MP80^ >,!+2HYXP$7(0!C%!(80&&-0S;@\1,A"U$!A%$^8"&3%&84I;U"PK
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M@BA# W0(@2L(8@4!@$F-6H"!0S0I!$TNP*O"$(#%S+\09X" #Q"%$+"U!5$
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M$(DV$#WBRX*8Y *AT *5P(05\  3T*2$*(.2Z(E#D,4KJ!$46(%\02*4O)=
M&($3H#N1. 02\(!J\@D/" 'OP82//+NC((X*P@06Z,H*8HZ(Y *"V8)KN8DV
M$+/6HDL7J!$NL\22N +.*8&ZK)&KO,L0H*N5F .Q24D6"(^YM*..&,BC.<R0
M&44/@$R%( $3" 0R (PUD#N!2"9'D4=1(*A#Y,W>],W?!,[@W H&$<[B-,ZJ
M"(3!\:01>)7CY*\3F$"KR *$(YDP<L[KQ,Y"S*_S(CY#@OZ*[<2)W)F*_#(F
M[C1/[Q3/DXR*D"$N[\2)G@B9]'1/\$PJJ:#/-W0!F<BF]_1.\NS.].R)^YS/
M\%3/\WP*^N1/]V0, :U/^3Q0!2W0"'70 I60W-G.]DS0D"FD^DS0!7W0^I00
M,2!)I[E0@3M/]C30#RU0"U71DYQ0"EVLFWC1(>M0]<PU[&%1&)7/GMC0[/31
M'P72(!72(272(C72(T72)%72WD30)4V9%RW2)G72*>5-*'U2*L72+-72+>72
M+D49*?72,!73,15.;7H*-=#)ISC"[\0R[Y&*2=H*,)6*-1@:T-HD.S6D,W#'
MI[A1\)0)-J#._,*$9*Q1W\2$+/Z@*SG]"D6-"C3 +U!J _,!T.S!K*OP!&RB
M"CQ-@Z_,BI"ZU$^PTI3IB45HRK/C5*P TT_ HU)E5*JXT?$DTUC%.&V$'_0Z
M"OG4@/  TRNP,P<-A08(*J@(U:OH"1+@DY#<"BBM-$Q,"$_0 #?L3DMPCJK@
M@*]R4$-@@%<MSNRX&F)=5*UX #_SI/%HFBNX(YSX!'+"BCRBT0<-A$*# #2P
M3S;5@E=1!$#4N(E9"0]8C&&UBF(]"F0EF9XHA.V1U8/5+X10A"$+A&#%LN:+
M"2W0 "!Q%,JY"4^8 YV\A E@G&3KUIAH@TOP)IPPH4^A*2BZB41@@R'K"$CR
MV*>@4?Z$""E!T,EL4B<,<$=#" 0'92U%J!%/:(,T5;D6$RH12 $UJ5@\Q960
M5;,'8*2$$ 2'Q00V"(6,PHF&3;8*&#VA-2$)<91*&+*HO8EQ6],^FH.A(9B.
M")J5Z(A+F /Q%-N84-M0R(0*D-=MV1NA&H5,H+Z.$ 2%)=J(; ,)Z8A#"-P)
MN:Z;&(3#70E!Z%8+((1#R-L%>=MF%2HG.X3!Q0G[2 A' =5/8 -W!*U0$(XA
M&[?GP )ZV4[.U=NQ*15/& 2$0X0=)!A^R10+$ 1$^-BI%5V92--/0 $1P(1'
MH !!0KA$"(2RY2%U9%OQ8-B]Z=GG"(1%8(-V4U4UF]R54/Z$.<BU0+"0SA6V
MO<&$#,B"COA9Q/4@T&66YYA:3;+90- D-)" 2DA/K+7<1,A>A-5?JV@S%GB
M0, $Q^" NSD!#A !\&F+!S !3.  %7  0C !B@"V#] ]OF$ "] 8$M@ $,B
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M":@11UH#-$B#0="D-  (%@S C"KA8E0A":)&C9+P:(N(4:%&60KU2$(F40_
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M%H2-HLAQQ:%%1LPHIB$2MVM4-T<E#21]@B=F@'K20BT<9=QNPQ:M(] <4X1
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M$ (R (T#%-#")\;@"4N( 0T?P(^C0G""-*"3(65X5 =&7[00D& GBAB#($B
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M BC"(0P $/PB<43/&*@!!BC'27A  XP!7?2A%SB<&DQ (AP" 8! %IP6!+#
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MG8&.?/Y B:0*BY3( RP")OS*N7@+!.P=!#Q"&1".%WB"3H*5RXW$IYS$8Y#
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M)PA<5S% 2:566# ,%;E$!OQQ* 0".)_KJ;!!D&2=6BG$!20"&LSR"F?B/%D
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MX1ET("B 84C/*#B _K7GB_C/R#2*B8J"&<A&"AS2F1)"(GR R!>SGG!)3QS
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M!C-0+A)A J;F$20 (T* +D3 "Q1A"9L0 I[K+:)C%" @!8#@"CA@>T2A#%Q
M!-*M>#AO$*^@$+- =[QB$*YM4#Q@*=["R<H VL;@?F1-)^ZGN^I+ZW9P*33"
MR5  =\JMOAY !$+0*VA.)Z"M#.Y'(\ "5"RJ 2& [U8  DA@,7[M"EQ "R3
M11(B _[*8!2XC2I KM),X JNX -,#YRZ;]JR\0H\('5J#BC*8.%&@0*<(A,D
MH!+2H$'P#]M:K0DEX I**5,(SU',H$%.@'R8#PA@!S54P 5NT!,>H>:TX )-
M " =0"!S0O"NX]VH\04EX+D:[RTLH2%5  .PP 5:( '>0Q!P@@$"@1.[X (K
M@ 2T$<%$X0,HP 0*+!0H8"QH*J:HZA#_;P[68'L^ "$\X0N X!'K*P4R1:\T
M8HY0D )*H, ,L"GUQ!/:D3+$X@'8( W40";8Q#"0#UXND"HVX P4,%/BK21
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M!41@#>BR$&Z" KX $3P@+<8)2--1"]+@#/0H(=QPPS(%AAX'$39L>T@ )RW
MS^(- S"A,52@.K<GZQPE$+HQ XRC#:[@ 9ZK@YRR4'=$%!J@[/ZO"T+! 9 '
M!2JA$*X-^1Z!UU@#$1C $@+A 8@C#8PM4Y)MW>CP$"+ .C0"#/+3 ]Z2 S:G
MX5CB!*A";03* RRO!.HG%#-%/C?U;?(N&-.$)2) <E0@$0:A 8B##>XM4S;
M'R<@2?[*0 )RP@4@8#&TH!M9"@7=Y K$#@@>X"T^@'Q(0@'RPH$681':#SX0
M,C^OH '^1!%P4#<3 EXAH%%88"R&,^J>JSS,(/),Q 'T3@.N!RH;904.81%<
MM22LS#@@0!#,H#, +./ X 3! ,DXP/(ZH"LD($+B)$28C@*4SE_E<Q1$0 LL
MH:(.@0%$ 1'DQUUU0NSH+U,2H0%60K$\@026CYB&22T80-+(HP5 @^24$0*
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M1[$_ 1(D#8,:!2%(\(%!88(%'PA!FLQ  D^805Q;6 1!FGBA2K!!%!0P6(Y
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MT,%I< "(HA&7L 8S4PB6P)IF0!*BD(1@ $84D AIL$AG:P9D,7@_D04+7 +
MQZD$(0(^"&.%8 8AH!4MP +E9DLJK!&+@ 9 H!R6,@ID^'<2@"TD8&LC(&R(
MH0AG$&T;P(:(\"P$P0;41@+"=@):L 80P 9FL 9O \7W^HTE,0;1!GT_@2@.
M/ HHP/Y .7$3*!(J9G &PVB1HU &ET(![[((#^ )TSLNE?&]2,0<I>%$)[ Y
M(4L0C.()$& 1Q-%TU &,$V!BE?  ,1<(;!(*BY &6>"=:E !$&!K*. !&C,&
M!W 32U$"PA8"7I"I*8<"%KD1'2!_U):6\U8J:< "RG$!<T"SIX0!:+!#&[ &
M ]R&+4 =VWD3Q.$^T3NI\\;.P]$ HN "RS:BEJ%[HVH4_N(M*$  (V@ %L !
M'% "+0"I9T*X9J J - &F/$ )="9R0( 1B.?:[!P7G2"^IHEAU" GK !#$!
M B"ZS[F;NV'2"Z$% ' &%\ ?8Q1GL*LLF)  'K ( Z "Z?[Y$Q0Z %NR-U=
M %O22,2+IA*#O)]!:Q5@Q ]S$+&BL_OF FN@%8&P&Q= T<A1'B.Z%"HP)B3P
ML&#0%#A7R^-G@_AQ-FMR,L^ROUIP!5?P!9-ROQ2P$W-=UUV0"%C@<1MA 95
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M6; (!V! #I%^5\(@"@!&$$,BHXH).?J(M*PF3I372U$)#O :9E )>T<0BI
M&C:D)"D3!I'8\Z8NA# 'H;)%$H! &U$G8Q0!)?$ ]!T""3-&9R(T9S1O8M0%
M&Y )#2!C'S (8W FSEWAE_  6Y0&?RH@.8<RHRX?YV,R0O[!!H-@*&-P. Q@
M8LBK!F($!*-H+(, )A4P"*$R16=@ )90Q4(#$1E00H>P<0W0Q$DG-*#Q!2GR
M 3&C@!L E0>P$QY"$"U 0$[V(=5,$%D@+QUB.&80;1J %5 =(/XMRP11 EJ
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MR>!AU!8-HP0]:-$"@B""$C9;^!0["Q80#PP)2O#3RP,L2)"@DJTPN8"$+"3
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M"@@%3)"1+J" ']&*2V  3'%"*FF 2O@-09  "P"#AYDQ"_B(0H( %_@8L.$
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M;QD;>+#!(HE4 ($(GESRP0884*TPB%FT8 (%SX\BR-X8G#Y*&!ADX$&]JI,
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M!G*-XA!I',@A-L"RTP7"!%>0@ K,L $)D$%Q+D!!!3; E/X5/"D3)7#B;KH
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MYFH$I@$@K0$$QUE-!B[A"1!<R01\P@0%GI.4-!C@#)GX @1"$0C:9J&9*J"
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M0O)2)3@ LXR!)12.0"!" O1?8G' ;B! XHG*3B5?_V@!KQ'"9G6/F2"?0'B
M&'@" US1*[X93:@?34@  .W*O/2+*%" 40BB(B#"!*Q&OU# 47U I,$DGP2"
M:D0+!HB"")P'C+0@ X1"&IC)@20 )KB V$5+&7P"%27 UHT"W @$%Z26"H;
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MW!DD"X8*!!BT0!OX4TCUF'T8'A?2FKQ8"%*.@DJN <-XP#NJ!A"H2_?<& M
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M#)3B-, 5M, $T$0(1, <J-,DAH"C$D("/ D8/,#,'%U#>/Y!Y.VJD$J("6!
M%F! !F; $$K <W@ 'BE"FN$,M!"" \A< ^!=0W1! F3FMUY!MAH"S,@(S[FE
M(&B6#HT?"TA "E2" KCJTJS%9HW!EH0 B/1K%U3" LQ)!@QIN64<!6B!"61
MI2"?"K@ CD)(BX@ B(2'&2  "<C0DWB"QVX2'HF QXP B=+F"3# &$AEYN5%
M&5R0]IC%"@B,:90!Q*9/ ;$> \@L!^0:0;" !62!!F 3"5P)&"3 %IB6IPD
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MR<F9XTI5! +E;(PE/ (86)H7C<(<$((BM-CT,E2FF(9@L(&-1U*<;XPBY+I
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M"'2 "%P 6XA"H,L+"0@,"^#H4_[\=0DH$*.&(Y2(@ A,0#.) @EL0 A8(T%
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M8D,(J1Y"(-T@=50H$PPR&&(# 86'!F3T\MVP8I26!A2^1!Z%*<,&$HE/>_B
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M.%+,$B0H2%9:1P%T%$,:*.B2!@S!Q( O0OF$@DLM6(.]$E0H*0T'%*(  @J
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M101:X ]""-$ %X0/ GY1U5)( !JIC$@]BC #!!ZTE*PTH -8( H:OC4*-K@
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M@@T2 ,$&.""*+BQ-=1X0@0:X70D,=& #&D@M;A3@UF?N4X,7^  %)&B:2FA
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M/99DO.IC10XA$RI2/5:D)#'A2VSH0P1E#-3)3A\54B-54B?U11DF!$) 0])
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M1'1J%Y=Q&]=Q _(04JT+JD0!0>1G_'!*G@T"[ T3OLJD-*00$N!RGRD-CM9
M(^-6)I':#+$"OA("+B6Q'J%*BC5.!I=T1@%O/^!('Y=W>]=W?S=P,J8+ J$$
M'L0$*B 0(M8,V( $%( 0U 8+/(&MTL ,'(!6/X("YD!YF;=@R80M,&#'0F$!
M%($0&"#[6J -KN  /&(!,B -QD !$L$02@8+Q(3CR$ !QF IV*!8SD1W@1>
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" #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>comp_0008.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0008.gif
M1TE&.#EA_P(S O<   ,! 0D%!@L'" X)"A$-#A,/$!41$AD5%AL7&!T:&R$=
M'B,?("8B(RDE)BLG*"TJ*S$M+C,O,#4R,SDU-CLW.#TZ.T$]/D(_0$5"0TE%
M1DI'2$U*2U%-3E)/4%524UE65EI76%U:6V%>7F)?8&5B8VAF9FIG:&UJ:W!N
M;G)O<'5R<WAV=WIW>'UZ>X!^?X" ?P!,H@!4I@%7J !<J@!BK@%GL -JL0IM
MLPAGL!)MLPYQM1-SMAQZNAAVN"-]NR9\NP!%GH%_@"R"OB> O3*#OS2'P#>)
MP3N+PT.-Q$:1QDN2QDV6R$Z8R529RER>S%*4QUZ@SF*BSFJFT6FFT76LU'BM
MU'VQUF.?S86"@XB&AXF'B(V*BY".CY&/D)63DYB6EYF7F)R;FZ">GZ&?H*6C
MI*BFIZFGJ*RKJ["OK[&OL+2SL[BWM[FWN+R[O,"_OX2UV8Z\W(BVV9*^W9B_
MWL"_P)G!WY;!WIS$X*7)XZS-Y:''XK#/YK/1Y[W1Y[S5Z;_8Z[;3Z,3#P\C'
MQ\C'R,O*R]#/S]#/T-34U-C7U]C7V-S;W.#?W\'6ZL/:[,G>[N#?X,SA[\_B
M\-/D\=SJ]-CG\^3DY.CGY^CGZ.SL[/#O[^/M]O#O\.SS^>CP]_3T]/CW]_'V
M^OCW^/7Y_/___P
M
M
M
M
M
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MA,"*H5 )[_B<#%D)F3 *GU )K_Y8"8*0E:-P!@.0F/3G 0B0"-F)D%W9$)5
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M!O "H\ & Q &HX %!L  !V "W\F3$[D!!:"@!T ""1"9)PF5". % CH!!V
M&X )HC !&+ ! 7  @1 &!-  6AL$#$ (5ON?#? !H1 "!G  #]"5#>EBF^
M$["E"!"WBE !!U  &( )9&  #F  ;* %"+ (:W  *V  F3D"!H  #2"1*:
M)$  "> %&#"<Z<@&/FL 0%L)"N !$R  'WL&!>  !]"2AGB9/JL"H\ %!Y
M"/ %HX &!E"X7Z %CDL 33NY#8 (F-  )3 *&# !'I"U!%D)%F  "J  @7 &
M!M  !J &@H  .OL%"!"GJ%L)"_[@ 14PG&P["BQP ""@  1P J%@ 60Z"AL
M 06: @?   N0"!S@ !T@E6* D!A@  9@ >T8M"?0$%MK":&@ JN; #JK!@9
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MH  (D &;< C>N[(5<)0\>P 9H "HF\GVZP&]2(A9,+V*/ H?< !VG)YJ$0@
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M!@8@ 6>PE6:@EH@=UT5:  J  C_*D&@0OCU> $"> B2-E$![W&U@" ,  6>
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M9- %7/F?*8L)!V#.C%_,&&RE[@FCGC  +K"3V_O*#+!.8/T1%B"S#/#));
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M##$,8:-&A%80@)!0*@A2 !4\,8!)"Q[P)!0+SH+R!#8DH/Y@E"P$N/ U,K@
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M0$8 \)>9: $1'D!,2"3&@@#$ZHL<&$ + E&! ''@78A( (D.P\$6I/!M"3A
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M#CB %J" 5)D)O["N0S"!!(" ;TO2&(RI$(  CEHW)VF 5$D)!Z@ !!@*A&R
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MZ)) "*)*B)DSB X,^+,!6*I#8,NA)=[BC<.2F3N;((,*F  -( "#:0$% (#
M,AN$@(#4ZC<):( *B !,4806((!;8P *:$P*4 04")#J08I6X8*!XU[FQ0+2
M58PV>*$-,U[U48@RH(E(,8&A"(5+2  2""*4\1P,2+/KL;("8"*SW *NA;[Z
M0@@38-E"$M[J!  %D*XSP  )T( ": %/&">$(-Q*R !*F22[[9\!\\B\:  2
M<*U'Y(ZX&(43*  2?LWNG0!"8 ,+X.!T;8JG8 RN;8_GJY1 JY26PF&A,L2+
M6( 8&OX%$1"F#/#(4 @)+]""%"*SP.B2+U ($46(A6PO7YF "B@!3%"!O>"S
MVTL %%"! P@%+#  ,F'>,!@$5T$(1?   @B !X"*=;S?/P9D#RFDF2$#QS2
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M]2FD##!# 03,HQ -#*@,^XL4S$80!(6P8$4J4<0#.L: B@QO%"!@F0>0.(%
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MNXY^:FA# P:VKS.@5275RL G B$!UYWAZRT0F@H "2F1I&"=88!ILK6!O9%
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M@ 8H,.428,%'+MW'@2*E2I#!YM"7?R2H+V&"L407?4"H@/Z'A?('2AHH$+D
M [C=A?Z&J(B.*(F6*'_TAHG^!W.D*"+L98KZ)R:HI7Q4 FF^J(W>*([FJ([N
M*(_VJ(_^*) &J9 .*9$6J9$>*9(FJ9(N*9,VJ9,^*91&J91.*956J95>*99F
MJ99N*9=VJ9=^*9B&J9B.*9F6J9F>*9JFJ9JN*9NVJ9N^*9S&J9S.*=]DZ'S8
MJ7WA*9T"T9[VJ9_^*: &JJ .:;ZX#2J6P"/1UX)Z@%$DZ' N!")L)T1XYGM
M**4^ID*H0 B(IH/RZ:1ZAG>&XV59JH&6B*.6&J;&5*>:JC*!0"P>:"[Y2V<>
M0K*IJJH>*"% F*+&1R*<94!68:J>1"*@  9@@ M@X*6RZOZG?JJCVNJ!&@*-
MU$2S+FN$H,0'L "U=FI,*2NE!L(&Q$2&#N<A( *I9JNV>BJUVNFE5D==(0(*
M< "/G1J[IFNP[JJYZNF@6BDA (!$M@$ K!,0K0  ..=\8  #U)<IRBA^! (
M0*&UN0Z^YD<H((":^<<'1("+PL>^;F(!@.B==@P 7-9\>$ "B 0+ $#MR8<J
M*<  8, $ $ &X"9^60 !G$#&YH<G2$#%]HT9 (#RU(<#C): ;L  "$6^'JU^
M8 #FC0(+!$ '>0(9; %U8,$ T-5:6,6(;<4A>,%$_,L#G$'6A8'4KD90E<16
M*(22:6-0I0U#; $9#$<89$'MK?[!IY!6YR0"&GP$V++!69C(&6S!IWP"%AA
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M$D #'  "'$(((, W5X1*K !$2_[ <QR !-3Q0FR 3B<  &0)T[ZU2;CU!"
M7']" DB  G!,%P, !2B  ,".L@U !92T4P2 !@3 "9C  30 WZF!5I?U0FW
M 53  !"" _1P*(< 1D\ GB4  F#  *P(!Q3 8_]K56R 5LOV(3   T@  93/
M%F?I(12M(E"V)06 -0+ (6P!&F." :Q/( 0O)@PV202 (6/ I%F'"_Q$ L!,
M!A# "A"$"1  )GQ! ,3O*&RW"EANT48Q "1QR&*"&R0$!DR?"33O)WQ  8!N
M 'Q );@  (!M"T27!QS [ 2 G"C" 9# )1! S53" =R&!AQ 2>1V5AC @A]
M,S9  OZ$0;!AP@)<T",0@.L00@!@@2>DLA?$, & 0"6,P'J77MEEP,%BP8A;
M@@<,@"((0@L@19@<1 "8BAKXK"<0 $DEP+Z\=AI86P3<!!NT<OP-@ E@0@&X
M3@.D&Y<%SX($0 M4P@<(0"7(N%*0  $,\0"\]$(\<[CX:PM\PC\K0A@$@ =@
M0@APN1< @ IXPIQ[@2>T@%^)P !LPA?<<B6$0  L@A8$0$X  $;AA@.<$YKW
MRBV'P@,<@!>H!G*[P&@,@& ,P(<L  >$@@)4 +JH@>#V]Y<D1H ;Q0<, ":
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M84\$!Z0?#8G )RC ;8Q3**>Y!RR]:RB -HD!RNI\!R$W6B- )OHKSR3 K1-
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M<08,O$B*5C(#!1J0@=FEA! A>, #2H ?0GB@ 15 TV-6$#9#CL(+N=P7"R8
M@0UAH@0. ($6-!#.<1YJBA(Z /X%9(.43X! 3O-D  7NZ8%\SH0,"YW;CC:
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M6X/56 &U6)6U5IWU6J457']57#W55Z]U5[L56[VU6=,U4\,U5CWU6Q$A#,1
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M9B,+HH)%C8*\F*TXI53X8O@H".,0BH6\+&'$=BP06/.]VJ I?D((=8TG_F+
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M@B: 3H/@ TB8NGIG0KSP^B8@  (04;*?=+KLFK%'=+(;[+,C>[&].B<X2Q$
M( 6T=*Q!FS8J0\JL&@+D [A6."6<>KN. @(\H")>AQ".0P($0 *DKSZ 6[@3
MP0 (H@T&(#2^60$.P%JF8L[BK  LX0P0H 1RJ$(H0GH.0*TFX !TT#4FX +>
M.@'H(/X,", !#B 0[/D--2?6""L$P#GIF"LK$P $QD4$@B"3"2(<#R"W7H<"
M+*"\+\4-1B9&9*8-%" !$L "^LT U%L-*F%J$& "('(",, #D@X!K*4%\S)9
M8FU+1F$!VB,45 !WRN,,<LL! H$,-. 2JK"C0N,+'H !0  EJ-(+(* " N$$
M;-RA]0,"M*H2,&"7&> #/$$-%J"#%B0K)0!WK+,--H+'-\>>;"D,K.D!>-S'
M/P Q/:!I1H $$OD"E,X%'J !#&L-$J !'( -$(&G9B,#&H "+@7W7, $?H.-
M6\  L$ "'@!-/&":5& #UB@(<HL"%&$#'L">+6 Z[9D!LOXI)?@"70)N!*S$
MB0#E11#IFLA #!B RDO@Z#Z]/_ZMQC? 7W#I*/^\$B[@+CR! [1.0B1@ 1[
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M"P%4@@D!*;,P "$97-81&0^%T$!7P@Y-=-'&*H!; !AX@DD"&)Q!1J&C:!$
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M=[G;J*42^!.! ,Z B "H0'5<6,O*R,,G-3"G!6<(@D42,8"<D.QR)9SA*#J
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M A7XA 0<$(*>I*!=BSI# $A !C(4!P6LNZJ$H!4 9DDHI@/0'=C.H!@RP @
MA8CU6FYDB8NA2YNI,0&D)"B<1#R"!%QM92@@<+F=QO0$.1U%3 Z (18$0 T&
M5<$CB0;$B@DT202SI88)T)GF=079GSR &KY@  ?-"G, Z(NR,>$! KB!$ F8
MP"?*MJ6.G" !"DB=2O\]M$T\0/X"77G$ 5@)QG%Z10!H"$5=%+$& )35! ,@
M3QNX"E*=J)4OF$CUBK] B*E6E5GK.D,H#C&"NG$,;9[ 9B*ZD!BG=.0K8[/
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M!?"'5]44RK,"$@0GLQ->$)  GS8U C !&I  A^,0A)0P@A ?(]01J2% /O$
M!N"0-9-D'G$!!3!"8C  #9   ] &GO  3G,!$K=8RE4 UR$&!-  EI$Z)5D\
M%H  GT G&  !#3"(74$(3ND8@5$)"%,"J0$@BJ$%H["57<E$GV"$PM)+ ! "
M>KDO;N4!FR !5&F5R/<ZK)<D8Y( ?MD5W3.41A9% =(B'5$&\;$ "? Y&C
MZX0)"*!72'<GAT & 9"/77E$%5=Z!? )B.  !J  !% FD<@ ##   ]45GG C
MCD%5J?Z!4J'T  >P #(R6Z8X&I^3 $["=$#!C[XA 813"0H@ )PU (@0>TTI
M %<5A@#0 ;<A6V%TDQA  1)D2:/@)H& "0X@  DPGLK3%8D  0=@FV4B&UJ2
M /O";!60 =,U"O7)'X5F*2M@ =F3"$,ICF^V*)@06<*C)9B@@ N*"5WAH!^1
M;XG@F?EF"#;V":$0H1[!-%S1H0HH-)A0+(N""%FEH!\162MF":'PH2JZ*(]
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M84!+'@&M5=$&FY!(DU<5B$.M$+&R7N"G\LJLH9 &3Q$AJ &UA! *6/ %"I@
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M?+'/"L  A(Q3%) >E0< '   9J!&]($(68$!"7 YV,056 1"G$4 $H<>#;
M;E )4RD! U!EBK4A R "1[8 WX(N P(T3MC4"B "Y(,! U "S%$F,2*.)4 (
MM9D T/( 94T /Q4(P"0!%4  H+S5G64=2-5C!!  T5$=%1"?B* (2D, 'U )
M$*  WU(F6E  (1"<@^A "/FV7$  $>#3^$LO"?!\6S  $-D ZT0BRK@TB4
MES8 !/X02?2B &W0%$8-<O(9)%E"<]@[T\--W,5MW!E,=4OH-UX# &L@> "
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M(* ",>G/BQ=2AF*/7=$ %.!6&. &=!)3M9(N8GX!'. )%]!O/O,%BD'LGXM
M80 H"?ZQDE5Z]Q>=%6=@"08@ 6( -MT= &H1V79"=1F "#K>$7Z#!5XP /9E
MRD;O_,\/_:SL!7GE!67,,0IO 8I2"1J@8HD  EA4EVJ  :"L!1BP3I[0&!S
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MH-A$C_[(R%<R0@)P0:PS*ACE!!3L=8PW%$Y0F=@'K6)S5@#TJLH-+9 4#04
M\H36M0X4H-2V41 AX*F992,WLD"P^ 23 $:@*NE1/H$@@U&V"( %-LB@  !"
M! $@A$4"8<  3]@ @ 6T!#!AW:DV.-=+#$)@-<LW(\3D$T2D&HNU2J@&%A/!
MH0,-2T(F .V32ZH*?$J  0TEL D*J0H3@">WB@2V$Z>1M*<+VSNT3T03,^G(
MV3Q$ M&^""&NJ4082*/1IZ0M# \ 1/WR;:?"Q+3:QYI57<=/AFLLVBIQ $O,
M7Y-VJ@H("9TJ0+FM_A/:/JF>=BA#V9[&R"\'V)+#)6C2>_[?2L*R!5V%GSJ3
M3"+8&%A *T$2@S&JWGUPQ% 800,VI>$"HT#!"K"R&/MERD4ML%4FYE<]T_W&
M#!<H0P7.$ H3,* !6=#(&2;P@ BHX1 .:  #PM"&"I"A FH(PP9<Y 4(-" $
MFR"# AP  3=DS0$,^!=#/*" $W @ 4W"A D>X( 04(D (P@! T@0F#98H $1
M ,,HU)!""X;B!!K$@FBP<(' H( #H\C"!KKP  GHI0L>0(00&R"U+43  1<8
ME]@XJ 4 >"1K>51#KD94HT^L86MH"8!/M@ !!UB )%H(0+TZXQ4/% ("KCG1
M*!:A@1&9P8 KX  '3.":%GAA _YP:0$%/+ ""\3% QS P%FF0A8/9& @GRC!
M0116@@U@@(-3.40)MC !3%2" QO(@%X$X3<N8& #)) (+&59-15L8 ,J< U'
MI#FL"F+ !1.85M50D($,K* @6&A!"21  M<4A P.B, 6$#$!+&!  GKT @8T
M\$3JQ?("O\+@00*Q!3(430,6.$$)/ *"2JRA! *S &'\%4NXK*Y9!N% "RQ@
M@86$@(.5^$ &]CF66%H@5"T<!2$X0!@15*(-"ZV !;;DB1)4( 0J.!Y(<QE0
M19 @GFDL"0DJ,((2@ !8B=! !:*9D4)PX ,7T$M9-+ 0%6A  W>[BB<<P*%1
M9( %'OZ P,ANE8$-/-6**V@!!D8A"+!NH)MD/ L9#K:!*L5%IQB @,W<J@$.
M^&P4F2B!!S9P-T* $P,*&T59,W""TF$"!,0\BR(@$)BO;  $@3E!&%(X"BQL
M0*F>6 ,:GT((#1#3D5RHP%\IT*1*>" PGO@ )@X!5@V0!!,D8"5<MM" "9"!
M$&_CP@I.8,K !,("%UA!"-8Z%4\\(!'%U @:!JB"IX!&#1KX@$P\X0$7B0%3
M)Y.14EOY$11@H0+>VT %3O !MF$!K#V<BAHV4%V2> $+.AE%(:0YDLYL80 +
MB%X)#+ &4H7A$P9@XPD\H(@3&( $A0A# /A+B!( H!)D /[ "4BU 41@( $N
MJ$08 . %-B! J!L(P!94@ "-:00+ &!#&RAP!D4@8 $GV("O0N& #! B! '
M!(494(% ))B% >!"U48Q @&X2,.CB# &5G  !F 0 (<(PP$Z0@?<'*(#+O-*
MS4;!R!.0 888P)P$ $  ":B ,'TTX*T"H )"9-F3-).5G12S@8!2P"-;4-<9
M#J"7#82!$,3+0!E&X8$'K $3!\&<!R) 0)\DP@,2&:<!K>8B!G@@$*%00<I&
MH0&]E&L +C@2!@Q="0E4XA#'.@,&"K*"%& VNAIKP[%& 0(;06#-9D4$ P+A
M"2T8@# %0<$'/(&)BA[Z I7 !/X$#%T03XA !5I"P!D\X06IG,$"H.0R0709
MBD1 P",/V,"F/9"1"N2,$ <(: ,2<08#2"\$4M."IR&@"$4P2RQD,$ ;/M&%
M8\EN%!9PFF/1, H,."T1#% $&42@B'EJQ &(\#,A/$&"UZF  YZHA 6$"IU
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MUX&X4&@!,0R%5*,1-@@#"#@+N=.(#$C"9?&]!VB!-3 -15"#VR*,!PB+3WB
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M"^(""F@!$UV(2L "[20$TN*"+  H3"@G(\,HVKDW@OC'$'#%#^@"Z=C-DIH
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MB2[  H BBRTH"$PX+9L,T0KH.JY(4C(@#$0HJSR,OK,X@P$Z@38S 2UPO*G
M %BEG@:0IA\JV%2"+K&X+@_@ E%2D_;# C7 @A4(%8%1R'WE"(U !.(;)Y<!
M-@ -*&CS@ [@@B_ FA6P%3*(@"[PU[C*C,_4"^,S*X-@@TH@@1SR @ (!"S\
M!#%P3?^JA!,(@$'XA R(LO!4F! X /LK"@9(M4!8@!3+&E;YA :X@$0@@+=!
MSBWHHX!J 0#P0  (J.1J2#)( [$P@0%0@[$\%A0@@+ H@0,P"0)@$@+#!#4H
M 1<9 ?X!U BU"14\2L(3 (!$,-I"'=H@Q 0"@( V, 00>-M * $5)($ \(2E
M):S.H(#.1$A9J2<#4@$,^)4+0(HV7$%7*@%/^X)':X$JR2WH4(!I61Z$M)R!
MTZ- @,LLE<2)6495DPK?HIV XEV)PX0SD)72,P$N38I02 /28P@%0,GORAIU
M^8!0859@(<DL=0V;8U(:24(::8!A\0"XX,<0L-(*<)KH#"ADA%-K5$8%X!!M
M7 0)R-.GE$0&^ 02Z(J9W+DN.N!#$P1U'(45L#T)2 1F3(HQ6H$-X#@+D!I[
MU<8."A-]+!JIZ%X#\QUWTP@)*(H#D,=C:3:)T !7(@2/Z/X=JPHZB>20Z/E'
M:_R$,B >8YD*KA,+7\($6T&$2$S)#\XWVB,>16@ +/%*C="U1&B 9B&S@!R%
MW@H%Y>H@1,#'-8*.LZ@ PNH)C0C(%4B9'DX*3]@"VU,#!J 4$3B!MQD$6S.(
M3P"QG6.5O)@5LTJ!N^'CU2L#USL EI".S?O!5*I)%3"@@CB#%O0]K&'3#5B#
MZ]* 2L@$[%S?C0#:/>0072*$7;(LL6#C#JK86%.3;^R.S>""M]4(-3  !D!/
M0*X  9C:"? $1$@  - "6DG"$.B9Y7/E 0B5,1B  !#:!S" !ZBPK F  O"+
M2>D@ (  #"" ,%B$7%&3**R$!/Y@  RH@*.E%5=:@P.0OP"H,RL:@ 'P"P5@
MLK9E4QXS@2D+A0L @ Q8.!$\@!  #4Q0 *%:L9YC6S4(!1 0  (@@$MQC2TP
M  $8  'X ,-4@ /( 'P>A1  SLTHE%T4BQ8@O408@(#Z MOL@@G(@K+:@%#8
M@/ --Q2P**G@@@;  A6@ )\1 0Z Z0A@E0:8ED!H .AJ@'HIB$'X1AAR@1#8
M5T*08KH3 1=X@%\9@0W( A7HJK&D*9ZJ3"RP %WI  ]P 1!( ,L1Q)H-Q@V8
M'9B0CBU( #) A+4K*:2V@'UY@/#UBH0,@0R0B)S>.0["A/)2@0PX"P9(!)*B
M/:S!)?Z0E0 64.L\#0,%, $7D !6<5^#2$@1(+.?B  L*.I/^ )7"P4JJCI$
MF+V)>.0/%0'ZL@TQB$,1,!]%.+ZBV4XW:( 66 $(P%8'M.P3J+Z!(\D3:  !
MBP!*1MD46 $&\+<'H&&-\(3]G0K,?6*<.('YS8#<^0JQ^%#U<NBI:X%0J( .
MR*QNBV)E/;Y/V(!]D8 "+;V$6P$*D!I4BB>IZ9L48('BAD,7J(L_:6.I=5\)
MB,40ZB (P (7X !@(@,$X"#TSBP.F)P*( $7V( &.)]1* ,6TXB3R"R3/H-C
M)4B2, $':(-Z9#)/,X'CO"B!R2%Q$XL(.(N5#-PUD H0%_X+B&N!^6H (4SH
MP% F@N" ?7&),&"#4$4Y+$ !!N"P!B#)U!,+:ER!& \$)BV(QB;2"[8S#9&1
MJ7B$,%#$]@*H3-"(1% #)I'R_W,-3"B#+^@F&'X33SB#,9^*0 #41&@#TP$#
M+F")-G@I-R ,P%8#3&@#S&F#O(F+*@<40@B#1$ $1$&$-I (0V>(0Z<1-2")
M,T_;JFB! %@$E9J12D>+*L<JAG _K#IS+?"(10@ 5H'RPU"$M<*$'+H5B?@1
MC6@#0 T%-(@3$:41@+J$:2&$+>C&VD!S3+ $CP@$) E%+Z 43]!T7"<#>YT6
MI=4"(>G4HO#UN*#1;E*#+"#=4/X@ ^LCA$V@'B_X@B9I$8T ]^K VT_@$$]P
MI$_ ]N,:!4, *-#8DW ?$=+%LUO1'B%1-8(@2F83T]B+"T4X!"T@K$-0035Q
M=UX"J)6\=Y*(6DL WDI8B$!HDBWH.ZHXA"T0 ]<X]X(H]X)(A$^O!$.X&2P0
M$8<* S+@&Y(XS, 0]AF)^&+A$W@OJ29I@T\?B[5J@RS0HZE !&%]Q(-;EP^I
M&F#/]RU8=Q;:=XUP@YSWG2_@ BQ!A&^5B'.GC3+0 D>*^9)*<SS?" ZA^9\O
MB2_X@H<''3>?"J6G6RWW BZHDD^ L1])A"I)A)M\V*1S>8)P R@)!&9;"+BG
M'AZ]E?ZP2)&3S9.NX[H,9'5TQ8) 4(0M630M2/57"@.]" 2Y1\E;R8+M*PY2
MSQ"-R 0+F)W,X,3"X7S2=PP3$(C)'GV'R0PTU((5>)[2CWWA^ 0<YP+QEOW5
M#Q!JV?VE"1"BX?W><!9N$?YJ ?YWR100>1D @9CE-S+E8 WF?QGHKY;?[_WT
M 7YHB?[B_P_=CPW28(TV\(*3AQ9@^0[KWWWMW_DOL/+K?PWN-W[>M[.'X8V)
MTA3O;W_I/W_JUWWE?W]1N7^ &#4J31<U D>%.JAP(4.%"1LR?'A0HL"'$BE.
MA)A1(\>.'C^"#"ER),F2)D^B3*ER)<N6+E_"C"ES)LV:-OYOXLRI<R?/GCY_
M@L0(5.A&A"B)+D1:,Y32D$T=LD0J%2C)IU2O6GQI]6I0KEZ_@@TK=BS9LF;/
MHDVK=BW;MC.GGN&"\*&8+$6A"@R$2:&G0)\F"L5TXL/?N4D%LL%PQG#"3R02
MC3JDJ.E%ABT6)V2Z\)/?45H,%J[(\2G%S <K$5J(6F *R*4EKH[(D,MBT8='
MRQ:8B$1HTUC(& U^%V_$TL)M'T\N'!&B48I(>!I%J!+QX<DUB\9>^7INCQBQ
M'P[4 O#I$"=&G0AD]/OW46'"&*U$8B_R@Y@")6PQ"'Q]A^PW/H2)":$$@H)_
M4"7TWBBAB0%?15(]1,AX_1GFEOZ%%WZ$A0<+L8'91Q*D]E E#U!HE!H24.<1
M!5]X\AT7U)& !4IDJ*?1B EML 5.":&!048]"N1 :A EI,8%WHWR@8Q;D52)
M%T21X49:":UP7B5;_&6!04QB*% 9%1R7T!884.=%<R.58&!"F&P1G4:$2""0
M! ;-A,D"F!SR!4@GE)#1">=Q>6*7@Q(JD"5;8*%>*&S\]0D;HVR! B$JT%D)
M9)%AH<5>";71PA=_G>C"F9]T 4$8>R6"!18I"E1)"1@P.DJG7D2'R72TM@&!
M%I ADBE]A'R"B 8AZ-5&J^KII89!;+HPY$&)8.*)((EX&MHG7T! JPA?G*&"
MLYV&$?Z:0)APT>PHA0R)B;&CD-$"G8D@$L@*BV&"0@5G%%;OO9]<T(87+:2(
MB18N##(*)BGLJY :GKHID @ZCN)&M16%<5EDZ3[*;@MIZ'8((@XN6$A"GGS1
MPKJ*4!>(DRZDF"H6EYZV10N","2>%_21;+) BAP2B J(?*(%%]%-I\8*ZSJG
M*G6(>. !':&D%L@$WHZ2\[K3M5&;0)_\BW0E66!QILI>>#&*SS7J53',8K10
MQLZ$$+("<(G4*"M] HW1 G!YN;#%W0(A(O<9&[0*MB*C)-*T>H=\8@G<<HMH
M^$%LJ$#'"A,*E!IJA+! AD2;M# !&9]HH(;:!YW1-D,N-_['V=>:+JBR%K!7
M$D&TAQ3N NX"M>OY*"NX(&_&*ZB0>0M#*X0:M>&.HH:/B&,11'-]?>UWH=>+
MY0D&6(3! !JA+'!X(@RXUX *64C@PB@N<##*&A-\@44%U,GO!0D58/)% \2.
MJX+YE>0*40\(T2@0L0$)R$@+%?"""2S@"4(PP ,AP$08&O"!-@1" EZ07R5"
MP0!$M$$"&* 1B49QA@F, @04X  9*E&!%H1A G02B :^4 D#G$"!)#B()_QW
M@DJ<8 )::($"4K.%"X3!!!^ C05@*(% J &%H\#"!T81@A"(80/C^4("7) %
M!HA!$1Y 8&$2\8$(8,$3%># %OY(((%05*(!6R##! @A1C1&ATJ*.8$(1","
M+8R""Q8(PPD\D! ,E. ,&0B#&^(TBBQLB 0?R.)X*NB!X@GD$ KX!"8L< (O
M"'$4'A@/!#301@A\HA(3"(,7&."L$<UQ G4;Q1<T> +;><*37JB C,B @""T
M  (AP (&0C"*$CR@!5AH@!A&(0@-;F$"=*- !<*@B 5\@@P/\( :,'&!3_+R
MF!+H0-G6A $3> &-TD'C%B"PAE%,  -;R  &5("%(HZ" MMK00-2LP$1#$Y&
M9SA "[30 #,Q(#J(: !]0M$!@'9 1FJH !E6 (%-F:T!JI+ A@@Q@2UX00+Q
MLL "1_[Q@$"TP0 KR,(#9%0("8!T H6 5 2TH (&+&D4E4A *-1P@!5HH:7Q
M(4$R/;&!#' !!0Z@C@HX((8/G.<@@6# >R90"4PP0$ENQ 16M2J!3&#B 3V-
M0&0BT((M-  -HOS &3[ @O4EDZ5E4X&!Z%@Q#&3"*&Q(0 F("8+F@2D0#:AJ
M)3*A !!L@0,9P!YCO5()!<RT$H?P!(J<$Z<O2#$1#0@%%_HH0X&8@ 6>8 !]
M6("["N!.1%*\ET"^0#C4;2B.EA#(!UYT@#.-P@*XHP#'1I&"XH$(/3IJ Y@&
MXJ,KLB:J$Q7-)"O!@+P> @*FP804W2H0#X2+M *QP&+^HOX"Y8)) C.U "$R
MN#72DL$"K6V?&EY[D/8*! )T@H!DUO4!N\!7(6=(""&D:Y00=.$3#4@1!LP0
MBMIX84,12 T&!C$(1WH0$V=H@)L2@@BRNL"8.F7 )TP R#G%]Q 01)5K$+<N
M$>04$PZX5 L*L84J;M@3)Q1(20]!HA/\M7DDTH"#L&#,%KPU$1+82^G6!V-+
M)%0%&E@(%753O V4S81@HJBLR)<D0$Z@"P)A@3%K0P8?S7@49?#1"$?1 C4M
MR,L^VH(%_D*(NV5 3[_S$0>BG-@IIF"[@@BA0,Z@7@YH&5(@"$4#=G<!]26D
M$F]<@R//\#S^JG<4U12(+!-10OZ3$C 0NZO &D*A@!IEH&R?%DB<0_$ 1ZG7
M S)JGEQJ<P8PM6#)9B,1\3!-6T!R*J$"^6 @P 2W[1J$ ;CSQ( ;:VR@B $"
M$YB/)R!P.$60=0N "@6*[#>*_8F !!DP&9BT4P$Z*.00$?!$6#L8BD.\T2AA
M(-QR/Q$*+XQ $5(4" 7P\X 0B$ $&C#0@H^I/C=0H,\^PNYU,S "$7P@ PUK
M;KH]JA A4^<#>@H%",9P" :0( 0CF'1"/&!P$8!@L29X$0JU (&,NU$19*AB
M*+ZP(3)H("LP3T@=F5)'6G[ !!ID5P8H@H@29+P"H0G!%Q*Q )1;H&QJ",&K
MC.EA3/[$B0LG#P$))H (,FQ((HB P"@X$(90_,7J)Y"1! 21D JH!PL/H, *
MQ!6&G$M +@F16H6\KID*$.(,'4!(!M00"D/$J03E5+0+/2""$7# F%4*A9#W
M4F8.?.'ND\KI=9]DD0@<@BF5@(#VC*6&Q8:"!(#$.U.6VP:J:^#EA#OP8L/0
M/KPKQ VHW] G2A"!"L@9(2 J/>$F8'@1<*"*+BC!V0?1AL6:<+$5^#T'2A#=
MOX2B!2LX#8D^CQ T(%\@Q#WDHT)A@4"DH0$EH#H%MK0@+(# ! ]H V5;% HL
MG. 3$FC1% ?D@$^LX4BR!+M4J<X!PMD34X35)TC?:(T U?YA *(U#^'\Q0:<
M 2& R2=D0?H]0*<] '5@0@2PRK%Q($Y$2P&1  >$PD7I%-=U5D50F!?TD0,,
M@B> E:V0E4"H 63 WD,@ @J9VJ70@10EA!BTCR!PG4"T@ HH0KK1F'J<E">0
M&R906VJ(WBBP0:0929)$F0=D 2>E$G.%P2*D6R%,@$04X5^ 0)2!0!A4@@-$
M"R?=C:IQDB=0QQJ$@!<4CQ=L0"A@0BJ% AC F,NQBWMY2?O TY!,@")@P04T
MQPKH"!D 8JLP !EPE068!M%A D,IX56U 0/@AQI4$1M(W'E\0<\Q80?YX$)L
MW2C$R$%<8 [!4XU4@"!4@IMEP/YY_(4+6$!S%)116-I#M$$BG(#Z",0%#@ZI
M+0:<'-.J*<(#>$+YD9L;C@(+!-G\C4+?C8((^*))50+P9 0)3,@GN,T$K$LB
M2-<%/(KS",0(Z(@L\8X':!)^! +AP%R?+1DFC- BFHT"N %GM,_A>$(;/$ S
M49J4)!\\X4NTT$]4D5<;/(\BY=,9+&,E/ (R"L0)C$>B29?UC0+VB88;/ \&
MT,D%! + V6$JA<8'B, B)$D;?((#N D*O)4#Y!5ZC,>IK8&/5$"EL($F,0HA
M+)8*8)(E-("9M5T#)((2<M5[19JDN4&OI5 ('$X(& 0$8* &=N!4WL14B8P7
M8("IV?Y0"QS *'@! ; !)K2 >OG8*#05)E1"!@ '!K3 ?20 [D3 S> B [!!
M]&U )2Q"!4",0(0!Z&W;?;C2(3B 1$C HZP !Z#E!@!'/YDB""@"(GR:(FP
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M!9*5CL(@'!4'J$?J" 0:C <F@$"ZMLK!AMZ9E #*?, HH<$&<!4(B(!$?")
MH0"N31%P8(*S8D S?<(*;, ):*)!W.I!$,(&8, &J >SBH:B10<9_.H(T ]P
MD,#NE,!,$5,&A "KX.@HM5=U&DP):$"9)5\&Y&OS3)]OJ<=NC (*D( )8,!\
M) 0Q8?Y VT7&]G1L=)P!!2R&(F% TF8!R!P$]A43?6C!N#;G,45-5/U&-+;
M!U@ HK7 !I2 )K+!I&@?)@V" KQD1=3MW88 &M0>/:E ;ZA V&+!A*1M!ARN
M>T","2 "(1A(Q&!2XZI ='@G!J  #!F%A)I-Y18(7Y! !X2""M1(>A10!SQK
MQF3.!G@ %Y !4R;J!EA ,[D0%M@N?$@HU$05%_RJ"E3M!I" &H" &J0.BO8L
M+96-)YP /5EFD20@!F  LIR'(<"N%JR<?!QK)HS WZ1J^+H$^#:$FU0"!YC
M07R"N%2-2+B;1S1,1_!'2<1O2]0O7W3$)KP$^Q))1]0O__XRQ/VJKQ>$ID (
M<$.$@@ #\-8PQ (O1 C8!?CR7T@<\$+4[P1WQ!.UK_IRQ"?L1OHV< ,#\/UB
ML%.P+_FRQ '#QF>&1AQYPOMJ1 D3Q0'#\'N!B0J+;PY[A6EP(LRD!)=$14X
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M[8S+W6BF5(OTW;2 /.,T K?*"1>&)QRG0_MU#M=>&("(NPA$"= ,?37/RG(
M9+!!ZE5O R>J!U" ,7: RAK$"C  :XU)!H  =;3+">P=&[#J8G^N!S2 !KA*
M"93 LD6'(E0V!@3K073!RD+'%+7 :M=V(6" !:Q G 7'\:FLV9FV!NR.)WS
M:0,1":SV"+2V%BL&NS9 !;"!S+9 !6  9 2!%W# >& E\>[%)Z" !NPJ8(1"
M" S)%N@(5FK ]QJ,"'B<C"2"X$G *6_/!U# A*!C(+ J!OZL2R!@0-%*R3"Y
MAPA\@AH4S^(2,PCLQ41=P J(@ ]GP1I5=W3HK@1]@G!*P'CH]P9L  $IQ)=5
M]B(H@@7<FR<@0O!A@-L8#0MH@">(0 -<MQ? Q]A]  3X(A=0@!8A[">(  /$
MN!9\@('TI0:0MAJ80 M(@-QH@ 1HS2>, (PC0@N8QP2HL4Z!@,I*\1;D> M0
M0+20@!:/AQI 0 1,'R%HP%'1#+O^*O&).00LK?99P-6*P"%@0@E@2R*(T0=\
MK$[%2 9(@,W"N!7_]: ;VR=DE5\8[6=!@(A'P.&<0<QYK9C9=44\0 F@90,L
M!FM5 @4HPB6X:39I( $NF1>(JOXB"!ED8)]$9%#F^>I5X69NN8TJ'4Y".-I?
MU+4H5>BK:Y"C%, 8B*8#M$%//8"M0 #05,0@8%[HY;H9="APJ!+,8 (%D($G
MB$$1?0+561%I2EB;K4_ZJ@ (L]!"1#6U'0(;"%VW>T94.5LE$, *%$)H2(""
M6\(#  >(3*+?M<%236*G"6?HA8&Y0\87^(@(S ]E33M=7C@!- >M7R FC #Y
M$,+S> "ME( )5((JI48;<#M?"-LC\6H81.DTPD=TF=  @ %DB)O9B4!,6CHB
M)$ E")8B.*J9&H6XX0<**  LL\$#(,*[H=! O=G^9()@B\;6^84*6)4G3$#9
MU-DH9/Y"#>J8S)^  HR"&/31*#R1\\Z'*JF'(%0 .Q-3M# =>)=K@.!F@1,
M(7B" 9A :IR EBD"*F&" ;#(A#'>23DPH>M]E_CRF2BF0/2+25F"%VA)&9R!
M 2@"EV^!LSB$L_GH"8R/&I2!&CR 7-3;*/!81: A'T(*IYD!T(LF-!)<"H61
M]Y"!F.M(QY5 &IR!%E!]&0I$"%A3$(I2.0F:42CF)T2 N,!LDLB9"("!<YW!
MY$, Y8FC5\*8ZZ60LH+ ""#O%B@ U&W!&9R!L[H'%KB AI*(&Z@7OB$O%R3
M7U2"&K02(MS(0F0T.C>Z(AZ$!Y!!&;A7(H0""F3  0R)\OZ+@&62P!>L0?9=
M  $!Q(<MHT8E@O!I%*8V82@,5*%B5!@):LRH.="&8,90'C9X241P#0:"H1"=
M:0%A5!F1!#%)J#2J!)91$P@1I'!H10N"E2H@9.D2)@N"(V02A)!(S0:"&\X4
ME. S(="8!%%@\;2 S!DU%2 B)+KS :91E=1\><!F5(L3H\A 4$-&30(U&2?0
MV=E@%):UHT*-.K-R5 9"GAJ()9CH3! (GC =3 @!4RB@&2E7MGP9<V;-FSEW
M]OP9=&C1HTF7-GT:]>E/$1#U9=H7 ]JP6"QPR;*EC-@R)1Z0Z$OYTX1*?;>4
M(-3 ]A8QAT95<#,*0].^$"J%"?Y!T,6%+;?/O"2(2()8#UX(>B!3J(&7VV.8
M+QVQW4M3$.1'F2<T@>\H$N3[MB@Q"J$0O,@$LOQ&402H#[@H+XQ#TM-"B^4H
MLV N+SX@Z L/1@%AP?I"T"(++]1HJ84LL@@#(R]66(&Y#-I882 .0M@"B_A"
M^6*"%=# @! $H2*H@H]"$8.#42)(A(OK/!E%A"^L S"C$C;@(@."PE!*A"P(
M"B&,-:H$LJ:^. B#KTHD"$60"4H@@P295$!AE"TH2(X,[RK[0@0&=%(#@[Y0
MP "+,RI@J\B^+IE $?UDF@"C423 2:>Q)OAM+ D2G:H^+T)!B )"U/@R@Z8.
M>2JCEOX^,B'2$K2HA($M( PCS$Q#":6E4,B80(4S-)C+OU&^D*"+V\A(E"\)
M".FK$@?R,L% /C.Z(!!/"AQEA0L"K0"32J@;"[+5$$D-W'#%'9?<<LT]%UUP
M/Y'@6^C( +"!0$:A;HU!"1*C$HCX2F X2D-YH*E1/K"J@2792M2Y450@@:!
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M@DZ0R8&/)&:N+RPTE)AP" *60-X5X P$I7O%ZFM@@LB@8)0@]F*I@3,^4<.
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MCP>"EP@$)((,(O% 43X0O$!8X (K.%U&S'2"%F0 +VW)@@LV@*TP)& @**B
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M!16MF.@.)@RQDT*,XA O@6!6VS,6+WC!3I61@!H!E-6:_"P,E<#$&CS!-<I
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MP* OS -!H*0$L+<0',>)(@!WE_Z(!4* -Q(A$0;%[%;%C_5C"];'5XH& D!
M!$8@ U8@$/ #(5(P65U8DJ/--D< F,Z@ 92K>B2&$\<&$R9L,3SA$RK!$])X
M_+;@$S!AE.MC;$[@ M=3B,) 0[3  VAEE$-A3)X&/S@I.C2$$"!#E E3KPBA
M'=-R@1U'0#0&@KVC B9X4F!GL1A@+OK" E;@)3) $11ADST@L;:YFWWE.@;)
M$S8!$S[+<32F7R=9G:=-ZZ+K'!/8!3#!#1"@$M;@ <SG T8@@:WB/@8.+]#
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M ",J0-<;E?G& I>>!0- @.?<@ $0P  \,Q1&@ $@@ !R:/X"4IGPU.^1VN
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M!@1@,/Y&)0EPX,D9 )QQ" !;?.(%%Z-4L, H+?1(R 0#),*& !6<,4*9E50
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ML8$&'$(!T2M.KNQRP 22(  ;8%+T;(6G%@Q $>^"C@;V-*1!\*EY&L$""!)
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M 6H9IF"C, 0!*B!ZD9"19P; 0"4^(10&*, Z(DD+(500!GQYRP ;'( :$O$
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M!;DG:VB]NP-XQ<$ :(#/.:$"6Z(&T+$4)J 7*O X:>_B:OX?(FQ +6J02AA
M!IX0 ?V#"7F>)_2]&B!2[9K"*BH0K59$^2SFBN3^^K!O>F&0 "X !B'@ (N@
M*;F;(+8!UA&@!F?0 &I0"0<PPT7/'I\Q"B7PJ5S0O466!6P@4%V,!>[E"16@
M FU0 KUH KJC!G5< 2%0"8ZA,,6S[U\PN6Y!B[)Q AG !LT_UA" !6Q0 @)
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MAG>ZYQ V#&E%X8,)E<HSG8M@0 !D):"+G $ LCK(!@BPI_Z2$G)>'[ 5" #
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M0P7\X@ M\.G'&'C3"1C0  Y]X 2?P4 ESI  !SR $&'@P"$\L+%/>( U7G
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MP (R@P 480 /"(102 $40 @-</XW&R& ,_@$DQN%,I  18B[#<"6#6BNY5@
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MC#88BPPP S)( *0Z*H1X -)H@0% $1,@ "0#@#;8@@%0! U@ #&P,  ($4+
M BW(@BS @OJB  O A -  4\P )";/@*HR >@M@.8-@[@0160QU$@@0'PA$
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M"H4+.  ,P  &, !$4 0!2 $;&?X KQ  %0B%0Q  K_"[*0$ ,=B$#% S$0B
M>82_TBJ 2[ I60F#?50!EEP5!+" #_" %("1"?@JJS2*&6V.$J#(3T" BL.
M4)@ !P@!#T !%0B1YTL !#@  FB3B\ "!/"" 7 #<O1!5DO1#7#)$S@ Y>"
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M11#8-L4(QA5  01H@T1(@!>)-N&=D@=0YNC5BX;[@ P(BP]0K_2 YS8 +A'
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MP-T0$@9/' (""4A+&"3^YS1L9YNY/CG*4WX3D7+@#&&P /ZM1Z$ QZSY*1-
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MCBS)Y@0FA*>-J!\8G,' R@2EY@?'B80G9('%EJS-<JP:=/YI2C' ]80 ?GJ
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M*6$@9/1'*((7;(%!>S07X%LA2!,A8 )$>P3^>H0(G*,_U_ZT[JI E)X$'7@
M!;1L3XC!! 0?)K@ /]NT46?B) [CT$9L-/(64Y_/%W2BQQXBT4XL( 7" AVU
M5F^UHQ0U5W^UQGHU6(\U69>U6?>Q'2ZU,AYB)0[2&(D"+Z[U),(U*NUA71]M
M5>,U5>=U6E?U*=%B6U=L7(,$7<NB5=OU6N^U(,)182LU7L\U7C?V7^L18T?V
M8"NV8X\"7%?V71\V9QLV9D-V9X?V9SNVQ%HU9J>V7D_V97N$9"-V9K^V7">V
M7M=V'<*V:(/V8Y<V:X^V:[<V8(?$9@LW<%,V<?,V;E<V<LMU8)^U<S]W2P .
M(4CW= O"N%#W($@W=FOWN$PW=?Y[=W=/=Z]<=W=C=WB3]W5_=W=;-WJ'MWG[
MBGN7-WMO=WMG=WUS]W7/=WGC-WB+=WJ?MW^+-WR?-^ <$JBT=WBS=X"7]WXS
M>( /@G[_]X/S]W<KN'I/.( 3@H(GN(/'MX2?]X:O=X=WN'T#>(B/BX4#N'E?
M>(H3>(.K=XM[>'^#^(C?MWA3.([;.(:[^(=S.(+K.(W_^(./MW_3]XYC=X3/
M.(D##HS7^(X'^8+7]XW[>)0_.953^84;.91CN8HWN(EG>(PO>8:+]^"5N9F?
M.9JGN9JO.9NWN9N_.9S'N9S/.9V_>1BV 1F409WO.9_WN9__.: 'NJ /.J$7
MNJ$?.OZB)[JB+SJC-SH9:#1T1[JD U(^[74R_M&253I5>VRE<WJF;[HL7KJE
ML_6H:WI;>_JG)Y6G8[JJISJF3[6ID_I4!V(EBCJK=[JLD_H<BKJKAWJK_SJJ
M[R*G[]&J@WJMM[JMYSJPJSJOAU&S?_JK(WNO3_NSHSJL5_L=@KJN1[NT4[NW
M$WNJ+_NM)_NN;WNV?[NW_SJT&[NXFSLR8CN[KWNQ4WNRD[NU;WJ]MWNLO[NT
MVWNZ.[MJ3[K /[=8&W=FIY-/%+P8OL>L"S8F6:S"*VS$HV'PB/7$.WPE7;P<
M*:Q-:_S ?SQ,* (7X.XEEN 7RTP8? '$8KR,>0':^O52:_ZADP0"%DBH>_!1
M&GS!VMH\2X3"&( !&'R!& @T&!%B(.QE38B2S"<2(<K$)VQ!(]4V*A%B)6 !
MT:>$[$0F2GQ"%KE<7X.$)3#NL]!VTMX$<>)D*<$\RY<$UQO%%N"&)2X]0D)Z
M.IWV2/"@RZ/V4^N]'ZD$/@V2[+Q\27C"(YD<0N,R&(U!&:P$/VN'+JJU8 <.
MYA4 :L#MQH-$]QGTPL)E,8G W41*!OC&2*1S(+8$)B@  1S  0B  71F'VV!
M @#*O" ^TBJL%RC WW[$(/37T2H]2&2=4Y7]%RA ,Y%<,/-]4MD-=IT$"4Q
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M! (1@X '# @DB 4(F:!/3QKPX),0"CC@ 98T<\JJ!$"@   1L!B @!8XI<
M!1@(9)0**N @@ 0H=:.! 2S X  .4TW  DQ,.( !!BJIQ )C)2C,VP\:("0!
M$SA%@*"F/'E @H40F(#3"IC% !,R"G#  #:T2* 2-5PU8(M01C! 4CI&46$!
M$@A(P L+!'A@.S88$.\$J!3P@/Z"HA4YH^4#RH@M*P4:.""%4;J(] !D?UVA
M@"^V2 !HH3$(P %$,&&@A%$PF,"# ! @PR$+[E4@$#0*:,  -0(YX(M1ODA
M/((J:;H" 2" J"H6#O@@ 0)0",4""!32 (*[4#B@@>DX:("# 1 (PR$,##C
M@H:J0@, C@L*) Q+0NG<<-/5 )8! 58P(8 #3,]  @\&.&"+T^]E@%(7%"#!
M@ %6J"2!3=L.H2!%'DZ @U'&2/6 I3%9( 0++#!H PI(*&"JK T0@:DP#E#@
M '$QP:"!K-4819 (5,W@D5$X$($/%&]P7U! ! P@+KEP(%(/"$3;&'  %!!B
M !YX@/X ,-"003P  08(P2?:]H&X=:4!#+C4)Q10@;3E:Q1DB!\"-O")P(G
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MJ0K L@P6A=8!WID !F"B!1X(!1L \(5*4,!HHPBC(!"A@ E\X@($T !C-I"
M48@! &YP"B8>P  2D("IZ<P Q!)A@!/\A !G^ P 'J$?!JP@$5P 0!L\88$'
MC&(%!U4# ^QI5RQ\X@ <\(1IOOZ3 #)J 0 K\,0)VLJ5IXQA "T :18^X=&9
MM7(%B.B-"?Y* #!X 0 N\ 0!0 "W 6#A5Q08Q1DJ< A/($ #G]F()]0 @# @
MXEV/8&Q1#$>&+0!@:U5I00!$0 @3N).K#X2>U2IQ5JIL8+5G2(#)/""S1R3
M>E49[N 4]04 ;*$2'P! (@(A@ JH(0, *($:$N!:6JT@$!480"784(&E**!\
M00C !]10STH #;<AC4UI"&""1Q!" "!XQ'##\(D(@B!__R0 !L* B09@P!-(
M'9P'2BG>09#!-Y[ 0E$<T #T:@J E4U# B+@B05PN V6-8A+UZ ("#  M_NQ
M1!L,(/Z!,YP  &(8!0,6UB$OA,)E'Z!4;,Y .:\\( %A  , O!@"CH7AKH88
M  3.D +=6NT# 4!!(+"8"$5HR!/#7="]3M 1!TP $9Z8  ,0$0@";& 4 ZR
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M%!=P&PF&C@@L!" GRAS%(@+@ C<(@ ,E$ $ /(!3ZVV=8XLOS):J$HBD\I4
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M>9<+&"#.7W__^;___?__ 6*4P($$"QH\B#"APH4,&PK\=&!"FU .*UID* 8
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M,00%<%122"> #U5QG>QLISO?V3HOL&T##1B [#PP !)8P$/8V8CO8$*2#PA
M!!- DI+J,PHP $"!'P" )3XQ  Q@,S80J%8+%<BR-6#B 0GXP  >X(FD=*"A
M$GLA %Q ,C44,:$MTY$)3I"  GR"!"4CR9GT.8"V1&M'52(D QA $4B-HDP!
M&\  O, R$G0H<T%IY$TF$HJ2R/XK(@D( '!*9X!+&: H'J#)"<2%B8$9Q2$D
M"$ (CA2=6?V')"4(@ <J&HA/2&";#.!6)0#@@7]6C64'<,-0NB 00AS@ 2*
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M3[Q'!!40 0HX=H*BC((RBG!/*%S  1U  D%A F$P ?J'""! $94  D!G?!@
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MYQ*9T_2E'7L"/)%D]C@03ZD&&@FO.I8(9^ "$8",O1(W@M$ H9 "3].B %-
M@B!:6' J)]!L(M0&@!0W;7!N1XL%$+!"9Q!"-*L?3?,%#^ &F2 !(A &[F4!
M;> )$P"W$,<!&V%! ^%S;< 3//[&A8(!;&L0F1Z0>A'P"2IX!F>@ A3'=A00
M G&KK?H7E60B!IN* 2"AL2(4 ;.A/F,% F4P;L'( @RG J=8'Y9 ML'1N7KJ
M6!3!!0Q @QJPN1N !B60""Y*2&LP 2=P!O,IK +Q+"1Q"'^K%I)X;X%PF03$
M!@_@!5FP!6-@"((1!!S  +(32!%[!DMF;V$00#X3/"5!!I7"257AEI6P!17
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M,;=J( $J< 8;,&%9\ $/9#5%@0FFS  W6!+4,0H@H*&>' AMH![%@@7U40G
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M)?"]9T!QIAHP9KU6@K<!\QP&4OZC5 +1?Y"Q OOC'97P4GC9("%[LVQM'1B
M"?PJ$"8C0@2Q!1JIF)XPR@*QQPMX $&1L4R& E*J!I'RR +1!1JY" P <90L
M$"10 @)!AZ>D>P>P"8(AKD;AGN_8 '39.]<<"+GZ!5)C 3_LVT/' ?DX?6R'
M-7D,9"X $KO<GB'4 ?D(S#(QSXE@@FR0JS)K-7G8 C%1LJ=4")Y@;Y*"2^<[
M2WMH"6YP&ED)$H%K"85*WG)WSNM$!PH0HC8R30*P$9$U&UTP 5K0 N87"AO
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M$2>0!6Z0!4Z$"),&3EE_$.D_$'T4&$ 3,,GG"60P!I*F[)5@_-(_$&H !HH
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M+8HXP_Y;!T*6,T!@ V?P1 9(X 4+9+2(X_4/6<B@ET\X "(-0!JZ"-( V$2
M?1%1!'L30MQ1. "OT$W(!=10B03 ! )K\(1DLJ"7,2:$ V3 !$%'48&_CJ(,
M%8C) 3#!A5*J":@?2"070# *S"J8#(*( $8<8,-17. BA&! 30XQ.@M(1@4F
M* TB%" \"'1D B=LL5L5)U=,P#<A(O#+ RC*27"-8@+N(C'.; 0!1%2" 3]!
MA -&T0)YC:(0+6@P3 !8FA5D&'RC@)A9L1 *!@CO@L\;Q9>OG.'>T(&>$=E7
M0B"0B-"J9W0F&!\;=IR3!VSRNXE8P-P28</Z,J02Q\*"7OZ.YP!>N8%IHY
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M>X#=0/X# L"=%BM&!L"9!^B?,1' %=B$0Y"]TA@H AV?/)H9#DB!C$B 1"A
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MC%-.955>959N95=^95A^BD1@ P1!&CVV5$A."43(Y(B(,OXXA$Z^"KUQ#$Q
ML8UH(0[Y!(WC.#*-"D+PB&6V"MGQ#.VP"D2X9;98FN-QXJ>H!/ E'VQFE X*
MBVNN#$\XBG*.98:!)[6<"A?: !N9#8YBFK(=9(+0PW)9A+Q5Q2/#D%&@W<X
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MF"D_M?Z)OFT!!G@^1,BR-J"QNMD (BDI#2B!J@F%$:@$17 E#)!IC/" !M
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M+H3< HK"A'6U@(7; IL"@:Y6@8^L@ U@B#(C]Y8EN(AP@Q.00PK0&(1,! ^
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MJ3!8<@]RO-"GPDU@$(29P"&VL"8,F*0H'SC7UG8WJS!:P!-:8!+D0G'-*DT
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M WP$3Z9E&&0 B(0!!I"!F!AE X2 U]F%!TC %K2  @P&_FQ!"!Q X[4)!5E
MK36 %Y!!C_ D!BA-"(C 1,*(5V)F9FKF9G(F:235C'R" VR* V "&LP%)C2
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M0FS$2NS$4FS%6NS%8FS&:NS&QOYJ+V:FM"8CQXKLR))LR9KL/(8""HC "(C
M"EB=/OYBTH&+ %U/*69CB!3.S1)C'-H<#L%L,1YB*3+/)YR!!32<\#T'(6P
M#'H+!_Q'H,G:RAWD RWCR5JMNJ83 3Q  PP  =@I* 8" /P9 " '/VI&)1#
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MAL(F> )W8($   <D#P8(&, G9/(?>\(&+$0@&(#R9('Y$L8G1( ZR<I=80$
M*$(7  #2J<$AA,*7V&8!AZT'[*( .-4!*,P&Q%HF[\D&%+(*#, SZ; 7.[.V
MAJ\#-- 3JT$0&, %3( (<\$G;$$&5$ "]$D;P'&J , ]H8$J&\0!O-HHQ'(4
M-W-A6 ("E(!*K'/;1G$ ],8*$( B<("=A($LAX$ &$"N8$$  (<%,( %4( $
M#( AQ/*F6$![88(!R L9  #,5?[" 9 N)$MN !2"=@2  6P < 0""6" !!
M&X3M9=0&!MC5C'! K 5! %@%!Q1R( 3 &(@ !'#Q,_MT@A[N1X"-LFA! )0!
M(A""4(K  (3@ ^"$&@2 =YC!.)]! ) ,)B3 JJ!  "SE +0=5I, &Z]*"G U
M%@S GJ@  5C""01 &V "!Q# (1!""U0/.P_ 8&C  H ?(;0!#GLU86# K&1T
M/?WS52L KW#  6Q"02L?(1!"LE@ (0B !RB"13,, /R'7FT 5BN,3;-S!@N/
M:A%$!6A  UA:3_]T:CMG.ITR  O 0""" 5@&"?#;!AR &W"!  R'.$. &MQM
MWE@T+?X1#&9[00#DR0DT\W.@[4.H '$/@)<5</E6PNNTKPU;W2YC@$@!P D4
M1Y\T]YI,@ )XCP!8R#\+=WYL=PD8@"/G,"*,<1A0\ :$[0E@%@"P@1L 0 *8
M%AQ[PG,;<E)$MP<$  EHE $@0-VJ=H+G*:!R  =LP G4["AE  -4@),&0@:4
MV@F\&A^3""'DY^AA$43P\=:BP$=X009<Y%O_FH$Y0(FC#@8,QHE70DNXKA8(
M0&^P1960P 2DP: 0LGR_N(&<  A0T09,Q1JLBZV   .00!#(5UTF B([  -T
MP& 8&$)I0" 8@GAA^ I0D0; R0H\1%WV1B!PP'FRB0'4B_Z"LSFUHG8M?D9Q
MMT 8T#"V N,Y?@:OWF)I?($%C'.; [J>>JS93A*T0D0H;,%"B\#;>BN<5RUF
MK&U;5  6O'F@6_JE8WJF:_JF<WJGBV.E>WJH+^0%FHPG0%TD?<*IF\PG,'HT
M9D0D#:]!S.IF'(*=B_JM=V$*$$"K"^0@JJ@@ FT6P!RT!H(JE4P)D/0$V'HB
MJ@&K$@8;./N=*^()%*5MB@07(ROJ]*7I?,:=/3JN@_O,80(&A( )$88E!%=*
MG&UA6,VDS.ISJ%%A%-CA: 8F+& F?4;G>0L.53%!C!H5K3LA=AZA8"+!*[<J
M*O=FY&AA3 !6AD+PZ'MF6&AFJ/XF?^G30W@"WTS\A7Q$!0A4N(,\%B*9!QQ"
M]] )!V" 71+&%J1\"'Q$(G# HO9X(%P-RVM "7!'"W@!<YE1@Y= 539 IHP"
MDC.K@;A !7C "D@I81!""#S/!_R$@V- CW_"#&E "H0"O(72H[*SOFTG=R""
M-Y^ <F3&&#2;!@ A!4! 6#.]VI/ FN*/B1QD"7B!1RA"!EC V$,%KF[ AVL]
M<*7*<V6 !X1X82CM!WSX&9!)!41VJJA "S#^GNQ3"]"2F?8]R2@G!KA [81\
MYU_A!M 2!4#%)U2 %U *RF%2AY; VU? 92R"1_#%H"Q]]D2%PV!"&ZQ*!I"!
M)WR "OY@@IDX2?W4$6AA@E].R@-8!0*UE9-"AB6D$F& 0""0I580 II>@"4H
MT66(Y9H>P'ECP@687*"% A=D0.=]@HS7S67P)B(0  O A 5H :4< #2I?"4\
M(":\''<\F%U4@'>HP3H#1*A1(<B,$A1A5!@";3QQ@3"*S "&7AXDY##*0Y91
M&,2,LC1!4:4%@3QY*7!H5$J5*UFV=/D29DR9,VG6M'D39TZ=.WGV]/D3:%"A
M0XD6-7JTZ",&:@B%"#'*C025BSYM"),RE")!#="44=- C"*$'DR@.9-% <8N
M*C&Q"0/A*@DLH[184%/FC %%'ZZ.(B1UE, 5*D9E:).(0?X:,FH<>*GTP 09
M3"DK!/(K%43?$&$J/4PIHF_*3X'(<! !<8-*@6=2!SYT1L6$48<JCD+D>90(
M,B+/+(:@L8*;P"F_>!C58H(602Q#(3JS0FH8XRD?*"JMLOIU$%\J,3CC%0(8
M,AU42EB.%'UZ]>O9MW?_'GY\^?/I8QW%A4&'#1D>?%I38;B4+#@C%(%&6>,!
M+[+80HQ$_AIE Q*VP.(+-##JBXT)3BACN]SF:N$"+A8L Q,-"&RN @-'"02#
M2E)T(\$LM!B#D%$JP8(#!MH8I0(V0GGP R]2\D ,3&H;Z"J!*L$@A"^P>(J,
MU%2,LL 2,LB"# MFD^ 3VR0P,/Z$,A!A0,$94;)KI>)2.L,$"#[H,C 3KB0#
MP"](&*7+"@@AX[0N*=@SM0^^2*2!,L-()(O3!++ LOH<?1322"6=E-)*+86O
M@C/*,R,3!BI)20-$7+AS%#5(L*0!3U+:[1"I4D AI4H*\J O##0JK" 0MACE
M# ")&^6$$U(* R'5/"BA!1L=R&153'I+:86G)*CQP0Y'"7*4Y#XA) %-!>)"
MRU&P."V,B^R+<K8#4B($H4,F$"B4"K38MMM/&IB,UT1&H> \@;YX2MB4$D D
M)4022*F0A]Z*50%/R/!,I$_$("\$+T)IX%->%6FC6$44*&0452\=F>2233X9
MY9159O[)C054%0BY4;R0 (L/-@@%$POD<D#3+1YP 80*/ FD(DPH$,&%![[8
M2$B9)\BB!0PT^ 2MJT3  (L*[E3D 11:L "PX;8(P)"4* HB!*$#84 %+"2P
ML(-I#V$ PEWKMG&#"E#(8(SA"'D "RQ >."00!!0044W$E AYQ.R.*&!,P@U
M$).\4=  C%&^> #M"CX%08(=OTU-A J>Y !.3"XPX7&NSE# !"PF2%8,!DIP
M.]DM,L!HKC!^%F&"3SW8 .@#$/D;SI657Y[YYIU_GGE%:F0K$($(T:(, R7>
M@N!UMRAH%$RFWQZEV3(>I8TO4"*PU.G5T((-MK@H<GKJ5_XBY'L#*_E"B^F=
MK60TLWE$2@[QJ1VE) />2DDBOA _-BAB16M@22#4$+XPD"$4AR!$*!H5B@..
M0@/@NQX&4_(_E52B?&S0 AE$5L(+_N@081A!(; 0/\V1X! UC!7(#@'!413B
M>\DCPQ8J08A,#$U%T%/B$IG81"<^<2A)A*)+2+ !+H0  RTD2@DT<,4,:'$H
M7-" :F2VNYA(<8II5.,:V=A&*!:H)2I*HAR94T?[V!&-<61.'O68$C9XH0S)
M(^-*^'C'/+;!"V009"'OV$A"JD1Z 1J%5B1I$T:Z$9.9U.0F.=E)3WX2E*$4
MY2A)64J87#(HJ#3E*EG92E>^$OZ6L93E+&E92UO>$I>YU.4N>=E+7_X2F,$4
MYC")64QC'A.9R53F,IG93&<^$YK1E.8TJ5E-:UX3F]G4YC:YV4UO?A.<X13G
M.,E93G.>$YWI5.<ZV=E.=[X3GO&4YSSI64][3DJ5]]3G/?.)3_;T,XKM :@T
M![I/@ZKD$X),J$M"\8F"NJ>A0O'$0R$JR)LP"R<-+6@HP$@33.!+4A1MB4.1
M0M(V6O2@OR1# KA00@EP %[VV0(#"$;' *GH#&%('AP=:5-##E(U*L+  U[6
M2)_>41%;J%$E$G":X? 4*WR,:517\HDPJ&&.9#305.^X 09,E*OVT1\7EM,&
M "PMIOYR1&,@$H#604I1#6%0%1<4L)RLHO$,%#@  C10O[!RU:92S.I-'XD5
M,TB  8MXZF"U&M3P-<!<8:WD4[6:534@H" [Q:,8V/=(J$X6CF@4K"0E6]K"
MKF8""JAI)0%+VL:*=8ZB3>D3$V& %/$* "YP20L 4+^96.!@[L%""5!J$T*<
M-7PB:*E10D$ <_5DN,5UR7%WA8@-2+ F F$# .PV$PX0 &8 :-1,SA  !K0
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M(($@>,(3D3Y!C61]!C3,Q8_$+OY!)=3@ 3^'8H7A6T&$&H4(%"083H$0@0?
M() VW%D%(6C4HE40A@#TK057P02$4R*&#^!Z%%D8<PM:Z DMD*5&GYBUG542
M!BTL^@0^],06$)Z2B5?\$RY8C&Y3X@86X#D$P@D9%C80\4FV.9%?4  $7,#A
M,GP@!$0.0Q8(@60LD.$,M#IV" Y(B"KB."%94+?))ZD";XLL$"'H /@ ##V!
MA &Y#9 -(0P@@1,0  /B$D B*@& .P6"NY@00 (L\   D"$,"FC !S"A!@!\
M( @!6,$H((  !5" J0@!^UP$@FH%1" 4)2B "C!P@) 4@"\*  '=U>5V"7@
M 0 XA/[;&U !! S@$)@@ ,T6T*(--#L,EP! :DP0 "L!0%,2(, $)@  1:7D
M!*;7  #0H/D&%. IL$\ !&!5 @*L  ,&0(3M"7 "MS^@ @:H?.M/,X$"C&(%
M (A !0;@  ^.'@L"4($G- #Z[<XE]E4,0$&HSWH +%X@:S"  SS0^C:0X;[7
M&D#&P-  !GB@$EH@P/0)T(!/(.( ,& %".!.!.(0G"M $LH3@N\$)$#X,,$
M!$T!$( "*,  &"#C * !,B !C,<3$( !L* !*H*W(* "". !'B,M$ $  @;Z
M$L !0J 2-*#X'/ 0/.$ &.  +D(@7   )N $(8 "(@  N/X@% :  B!$ <+
MJS!!$1"@ 40   "DO#*@! +@3K   )"/ !A@$PAA !Y@< ;@*@9@=Q(! $I@
M%%0  #R@ F@/"Q( ,D2&^P;@!";  #8( 1;@ *0$0@(@ C)@ "1@$T*!!DT
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M#.00!* +,B#K5,("4K,,;&OZ*D!89BH #& %0L$"_&\#4O[S"S+4K);&[<[
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M0/989$@@ $0@ P* #5B0 K1@9ST!U1RJ! S@ 3B@ !!AN\#,OL[ OD) !11
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M@LS;&C1\OD $2("$0N;@4H!@/"$+^D:W<ZT%,F$+"" ,\NR]_>WA1GFR]87
MG]F,5&,+^N+B5"#6PLT^Z  +]&4,=B7:".3$'=PT#D@15O[  ^I[+4N +P3"
MS?0E$%S@4]8@!-H,"VHDQUU["XB,0["[8%K S^35"SP !5#B$VI\)3Z@ <J
MDR6NRF'-XL(<R[5<);R #%$ X$*&XJ;-1G0H,+Q@:=8D!$2 R,X "Y@ERZ_B
M1H3CW0!("_A"#;(@%/!\,LQ P6RD!0X\)03!! 1%I P[E 2/ &SH)^#/ CY
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MONC;7I\2 8-)Y=0JH1!D@R78X( LNP-:R+(SH!(\ 20"0>0*1@TLH246LE$
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M>,(@%A&$1UQ@^J9(Q2I:\8HF\<(7MJA%+F[Q"UT$XQ?#2,8OBI&+811C%[W
M1C-JD8QI?",:XWA&,-)QC6/,H_X7]UC',NK1CFX\(QOO.$9"VM&08BQ<2,Z
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:4(VJ5*=*U:I:]:I8S:I6M\K5KGK5I $! #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>comp_0009.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0009.gif
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MZ.SK[/#O[^/N]O#O\.;P]^SS^>CQ^/3T]/CW]_'V^_CW^/;Y_/___P
M
M
M
M
M
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M?83:HG95;E5K1M"I-)T6@0528*:_\N8HLA,%=T666F:AZ[*D5KLGHA1M%%R
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M#+OACZE*,@B$V&H#%D&8+6HT" (7 J&'LA%D"UN@B!/T0"39V2 'K1,"'X+
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MF((3,."#C1C:!R LT6?#28+A]8 #^!@A5:50!0&R!>'V&C"A.+ F*03($C+
M9$XP [Q4/18C!5S&"C?P!9]$:WI &810 \+'!')% Y0Q!3. :C>@8)?0!#H7
M! $2!#R01CMP"29A,4$P!/85!,G$"0#2"A2H%#:P/"FX1#0D;XM'&:=  P%B
M!#A0"IHP ]7!!4#P+%<0 _#Q=J; !T, 'WL0*5.@=M8'"#=7=I1A">*1"#LP
M!%L"!#.R-#.R YW2!S@@0$S@2:8@!:I3<GV6.#(0*?6B"8AU+AJ#$/^A=O4D
M V3')?ZGH(-(A@0"Y /J<@B$L$1=D FF8$BZ\WV-U I;  .:< K6MP<_L'"$
M8#& Q!61L@EP1!J70 @,0X:=8 K3X159\ +1Q26*5SVEL D]4'<)!XO> SQ%
M<0/HQA2<( 1K(P,5)Q*9D 3)5 JC*!(YL$0_  ,IUPI.\'JLL ,QD"I<D"I]
M0(VJLP0O\(HP$(J$  -#D 6"8#51H'5?X )>,05+T JM0A#8UPJ)0 @"DRLT
M0$N:0 CPT0DT< J6H'6;Z -8( @K!$2M0$^;8 HH80J=4!A3\ =+- @O(##3
MF'TSP@,PX([SR <N0$LF@2>2TS0L<0.>QA2E(%G"LH-/@?X2;+0#K+!,H\8$
MQ/($+F )K!!4S7,#PB8#)M<*0F QAD (*_0$E $%+H"!2? LK: )7)!!IH=*
MQR&1]<0*F5 #J2"0,!!.3D 94> "R^,$DS2/@( ^FZ *.W *IC"*(;$#WB8%
M+S CD+@A4O L6O "X=,*Y45^+S"/5-0*?T #K !_AGD)-(!??2 PB? "+0@#
M#/,# 2($,!!=@6!]@> "#&5'_#(5-S!M]3(**J)1;)4A80-*,P #ZJ(%,H!2
M-  #JD,$C:@Z?, %67 %2O"*DB$$3' #G7(%+A!.>TDLJI,$H:@)7L %5F %
MAH$J>B PA.!M@Q &S%E"=]=MFOY(BUO"=:>0$Z. -U$Y$(J7AZ:Y%<&QDDMQ
M&P5H3!@A _XF!3E@6S+@ ZW0"<MI!>:V"=G(%;P#!=@8363'!5HG?GO5"DHP
M V)6 ]8G"&TY"E: ?EJG!R_@;?((=R]0 TPP!+S3!UZ0!5; !-3C%8>0GU@6
M"*JP:SO  Z8 H>,Q!330D*]G"M6#E0+#!YTR" D'2$BV!&WX JG2!2$Y&ZW@
MFN9Y,@$4&,:Q/0#$@=18 YHP"D& E3<Y'E$0 SRI Z%H"#K0"ID@E (T!!;S
M!5R !5@P!..!9=7A,T_ !R?R!T@@;%8PFQZX"3"0 ZR@"?(VD:,6EJT@%FO*
M/_,H"/[4^(IM>0HQ= 58D -B^0(,HP=<L 5GZ@4\6#TSXF+K1Y+6ERNJ@$EX
MF@DPP&1]\ 2L0(86,XT,LP,MR)V $ 3$%P-:MU;4 CY)IRIDHTJ!J!(W(#"'
M8 73Q@G@V0I]4 4A80,!,@2I\GA>< @XH&!@H 0AH9V'( 3/D@4P$ 1_Y'8T
MD FJ@ 1", BVQ!5]T E!(&_91GX\X 2&T',KM 4W0*)$X*J%\)KM5P,HA61[
MQ@J;YRZ[XRFL0$YK\1_P\03;TTHK-0CLT@G]V:]T.1Y[0 0G,@2T! ;5\R#7
MR'% 0GSSN <Q8#%/D"I\4*&:* .F4&;CH0>N.@@X< 6'</X<HB.10[ $A<!)
MJ5*JFB2L,1 @ B%L,' B7# <\Z-,,4 9&'DB77 #V4<:O2<POKEC(OM1[ $#
M"E89N"H10J5SBA &TOD"TW8%2#!P%\B#,7 B;/1)-B D7$"JE2@&K7![77 (
M/_BG+\ [1:<)*]H*A3""0,!;-Z<*4A"*\"= :U<*%K@\4_ "U9$QVY<*4< [
M-"I 3\ #@(!P1#L$I'%[7 "W+UH]=.0#0*D),$!V8.!)8+AP(N2EACD*,] I
MCVDQ_)>JM#0(1& QI-4*A*IU=I2'SS$=E($Y&8-'JJ&J(S&MST-G\+8%D-D*
MQS%Q(M$'0L4MHV 9/7 )K, '4/YP"G-1 X1@"N+'H# S"DI02$:P0OK:<U"P
M39:@(ED@)$1U(F\69S*P"9V0$YMP":;8!U! B4>Z','1NTI3M3$A T5&3=[!
M PI7"DMC"?LJ ]"V-#>0=*:PB=?;1[L3:C)P"0(Y$X&PJ^E&"*< !4O O3 0
M!1$, TS0)(2P6EKP%X,0%5G7))I@C#9P"75XIPPS"ML+1*< 2M?;D/7;KZI0
M"*.@HU- $PHT3JDS-EH0NJ?@+8I$@'$$==[&7& A%L0#&3VPDBU, S_ 9 M'
ML T, XAP"A#VEC=PF"MD"E&PF)^W8^(A4,AG9$F@%*S0"4G  RO4"89@"DL0
M?ZJ0-?ZC8 DTL .>Q@D]QP41]\9JU&TAD0F7@$]+-C8"$00;TBIMO <SP 5J
MS#_;"U2CD @F? I;,*5V- J*:0.C@ A9Q@JJ8 B<X'KGBZ"!\#B[ Q:J8$M+
M< K?F,O>8A>)=#5/L;]MT5E)P&($T4:)A1Y+L"%'0#T[@)P0F&))\!\T\P,V
M< -FA''K= 0;9CTT4%--50,>YDP[4%0,@<S(##I_,R&$D A(0':)T)ZO<IYH
ME2J!,1=7]"$7M!"F9 1<,40%L<^\U -)L%HW@LRBHP.>$Q5F5 -' %H8!-!.
M9$@65DDYD 0S]3<#803T 1'J3#-& -$Y84:L55KJ#"2XH?[.]71$%W0CK&53
MB-30#<TH9+%0=K,44!O !)W1?]5;SV-<ZTP0&)1,FG #1E!>O/0#!3T6;/0W
MH -B21 <#''44)$3@UQ4#6U*/BTZ$Y+0X,+%_HS-!.4#C*=0-:!M3L6,=*'0
M3BW44:'0%[300HT27!558ET8+/U/&$87']W0_\,V-%8OF[@>B>%+O\05NR8(
MVEQ0!!4;D,$0^"),1*)/!OA+3] DE@!639-<L1'83-%'AF$E'9$^[1D=A^W8
M;.,C6T,1)ZG:SV50(])!2-%J3"%K)OE$#+$YC/T0.Q#([O1<TT+97<)/V>*>
M!\4V$WT0NF-6,>9-".'2GXE$C_[Q,:H"%K84.IR=(;\#)M7C SS=)FIB QU5
M$V#AF96S$5%\WKJJ<Y*"<'X6T"KAUVN1WAA"W[HQC(/B7$BBWH0]%*T$&,9B
MW_P]X$.1GH$!*L),X JN7 +$7+5!*0D.(]F]X%U#1DGJX(;PVA2^X?#R'?TZ
M/@+.X5^C*%)[,?$<XB*>XE87.$QQ)]NFXANN./Z[%)N0 R@.XZ)M+=HY**E&
M/U$RX?GB+E$" ]X&&'@#Y*N$(Y7]WNN!*H$Q."3SXT(N>LM5+QV"XQ-S."[-
M,TPAI?*,Y2I^-(*R%*HP7TF.36#>'CVP38/BB5\^XFE^$=HD-HM7&#?^UW'^
M(FK"4?X] \!Y7C-R8P-"-BBJ0$._6-PHR3)(GC.(KA!*%!B_^S"1,R4(<N8\
M(CY, 05^?IHL4NF)'C>,H3OJJ25+$]I_?NH6SBTA$^&H_BZ,,1T-3MZ:R*2M
MWNH?KB55O.FU+F.%,QW5X>"#;2V+#N.C!AAX"";#WC$N FCU8A*F3NGG3=/^
ML3B>TBJVD^R^$>U2<3E,8=Z #NHH=!A.7B^Y&^?8+NEK\18.3IBZ/FB[?B%R
M<M,D >'OON&.(>;U8BSU7NM(PTUOON^5\P-L7A-I O"HSN>X;G'G;O#L<<TY
MP&A+@0AWSO#J?0,O(RF:0_%GA2SX32.7(%1.I,TV()-_$_Y4AJ$#AN$Y!)'R
MR9W<L6/R*\_RGP/?)3]9-J_R$YT3-W#R+D]&\)T3*&$8(E_S.G_R,N_S+5]!
M--_S-D_R+Q_R)P_T-O]<./_R.Q_S)?_668_T$_V<#.,D147R3!_T3O3T1;_R
M3%_S9=_T\;3V.0_SDW7T-#_S:J_T-4_V55_R5Q_W3B3T5"_V9\_W;B_W=:_W
M1K_U2V_W>/_V4+_R.@_?@"\ZP2&:2W$>;[_W*(_XCU_R8I_VBG_SC!_X;(WS
MD'_YAS_XB%_XC2_XI._Y:._T1 _W+,_Y8Y_Z=B_ZA,_XJM_W:Z_R%SXHB9!)
MU3/\Q%_\QG_\R&_\U)/\S"^4_/Y#_.@S_-'?_-1?_--?_=B?_><#_<\O_=RO
M_=0_2=,#_LV__-#?QC51U-=O_=]/_LR__NX?_][O_>;O_/,O__BO_?4/_NA3
M_]</_P A0^! @@4-&H2AI]5"AJQ:==H!X^!$BA4'2J1!4.)%BQT%;O08TF!&
MD04Q:D194F7*CS)(KNRX$21%&%P8WL294TN4*5)\_@0:5.A0HD6-'D6:5.E2
MIDV=/H4:E6@4/CD9?H'24^I6KEV]?@4;5BS0*&"L+MSS1.M8MFW=OH4;U^99
MNG7MWL6;5^]>OGW]_@4<6/!@PH4-'T:<6/%BQHT=/X8<6?)DAZTJ6[Y9^?+F
MAITQ?_[F_%GT99RD18_.O- TYM4-26OVK%KV[-.R6]/&?3KT[-V@>?^FO1NV
M[]IUAY=.C?MXY]N67P=/+CRGP^:FK2?7#=US[^/2@7?77CSW<^6YB?]N7AZU
M^>7+QV,GW[MV_-C>AX?V/AUY_>CZL[/VC[_UBJ..+O(&G"Q!!1=DL$$''X0P
M0@DGI+!""R_$,$,--^2P0P\_!#%$$4<DL4033T0Q11579+%%%U^$,4899Z2Q
M1AMOQ#%''7?DL4<??P0R2"&')+)((X\\<A4DEV121B6;#/))OJ2$\BQ40@GE
M2E!0:045*NMZ,A)'I$3E2BQ#D3(41B0)D4N[OOQP%3<Q-/ZSSB[AM"N21N9<
MY<Q0MF0(E48BN6E.PSP)Y40\>923Q$;?] L44/PR-"\QR?0S488H:<230GWT
M((()1(T@A%8ZD*,5..%<9 )7':!C(18:L& ""AY(=944'JA@@@H(O6G58''"
M\\E%53WKRS?PZ-*"29 ]2X,WH+W)$S/</)9:AHQ="(X[%BK66V)S,N/9-$I0
M5=@'1R#550]6N8!0=6]RQ-4*&IBV%3,8J("""AQ@8Z$B'.AU D86TB!7;;>U
M2DHEG]P7#FB+'9;ABJE]>-R<BA6V7B[55=(1-68L(8)*P;48TI0MIO++>1F6
MHX-Q5UFCD5;>T #E9(-U@X$T)OY>>2$[)/:D@DGSNB,""FZUH\L,E*; 5TI:
MJ42#""IX8 0N4:G D85ME)21!"*1M)4+ZK#T #:4E", FT,HP1.Y/>'2A DF
MD7.,!#R]4,D.SF@E% ?XIFL237.:A '"E/R@C*\9 L'Q;!VP>0Q3,PS%DT@6
M6$3251YX%B]/$CA#R3L&:#H%#T"9F\M9"44EC0,(32'?PB9@-ML-40'V+CLF
M4!%/2BR@(%41Z[C@K OB: 64T/?*8%K=D;6\%4\:./DL1PZ(0TDX!B#4 3GF
M]D3.!TY(U),,-EAH!&9]I(2!HUO9P(P3+ BXE4A"V( %0T% %T/2@#80C $G
MDT  X?[H=P)DH<(,=O! !M#FP$5TP&9IV "J%I(&.YS@ H!;B!HXH$']A< #
M)S@:!CWPK5;8H0,>*(.4X@"!"[QA%11X P@R\+XZ>* #/VM%&[QFA@H>+' C
M<  )I@:'#_RP2V4H8BO(@ $5L(%YK4C#"YLF!QJNH15W\"$9YL3%"P1L$B70
M@ GFUXHR-,"":0!!&BR  C>E@0,>:%J$0L& T*VB FP(00;R2(D1=" %AC*!
M!V[2AFFEP 0X\00">M>*$8"@%75 125&X(&XW80-=5C!!<:@)%2P8 ,@(!0E
MTG"'#8!"#6YL6ALZT($V+(0-=TA!&D)1!CA<@ 5GQ$ >Z_X  A@NQ QR&,'9
M%N*)$FR@DT&<Y1P8%HE"JG&#&3@!(S?HPU2!P@RM8(0:TH"!$DQJ$1[P@/\H
MH0$(K"![BF)C"=[  60IB1&,M"0H2L !:[:B$1_0@#L7$H<.<,"+6)2#"#PP
M"3-<@ P;1.9"S^!0)8'"!,[T5"/2L 8,C(!O'$U!&=C7BC4T<5IL<( @)S&R
M5L2, T",PQO&<($62 FE&6">(_@GT$98\0-/6D34S.")";RA QHPHB- L($B
M<&L#*;B)&9CE@$EB$7B!2@"S4J54#Z3@<"X"!0 /IZ1)+,!32MI !AAQ!TF"
M(@)T\(0CH06!.L#)!!=(@QG,\/XS-UP566R@0* 0X %&R"$!8T) !M* BID^
M8A$/8!X&'G '1C@ <"VX@",>R[P*J"$4)AA!*XK0 4\T8@*10 4#'.&),B(K
M$ADH@2-0X8 2:'0!K<A#!!Q1B0W\; (!2X!B^88*-CP DWAX "5 @;M6*$"Q
MH2!#U^Z0@$>.H0.5J->@8/L(3U!.?2-3TFM'L-H(I"$2+:C G!@1@3)X@@T)
MF$.]6L#&#7BB7D:,#"HJN4;K,0!8JX# >-^;I:)ZH@@?@-9OZ\D0%DP@KWIM
MH0-@]@"&;( ,H5B!(I$%@@74P;0L:$4(4N").DP@%),H0 C8(*@(C$&5$VB$
M:7_&8?XR.((2 2 #(WJ%!S<L8!6.: #9+I J!GB@$7!(P)8F0(9(L(#":\@
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M55BOD+.#((PT2H@ -)'#74N%^V$ SZ.MQ3N!8YL$$)B !WB?R8LA4<"]P(D
M3,B@$J#"A]J :4DN:EF]1(F$#?" F;)$O$$%", ;+#J!50A$*JPE$" #):&$
M$)@ !V A)1F!8$N!1O& NRL[/%B%,K@<,A@!4UP\$T"!6I*,2#C$JOJ\WHF
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MYY.BRV%.9#$#!W@25.">5C!,>ID=AH@#!#B:(5T(L2G">].? KC"?)$W5)"
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M.J!S;Y03<VJ9..BR5>" .1#O.:&$->N2#L^<8"'T.C_E+HD#!VX>#1BQ1<
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MV= "&@#!!VJD\!8TH!%PD-0:+K3?#$RHF9'(#1NTQ 8_3>("J/I 38S H%1
MP-R?4O@?"(! 331"!&1 "F# ';"%!Y0 -SE"')#=*G2 "7C !81 84B%&63
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M!G  Y_#84O%% O $)0SB"(25(P ;Z"J+WRB)'*#*&E! -;8!!VA BD6"!D!
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M0/66@0%A@K\8%B,HJ=7QX*FA0B,,0 DTV06H0"2< 0%X&3&QP22, 06D0B-
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M!X@1"IPM\&"D#2U "Y0!U3T(*F# "DS"&^C([+QM!XC&"AS &/"4 LR!(X"
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MQ1!]WNF]WNV]+28A AP@&^^ >CH@ Q0DE$*$I\^S .9 HX1G3>5(O+KW#,:
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M(95XQ"X2I15$0,?Q)3@BH 76X/:#(@*""@_>2"S;_OK#;Q+LYP(8@()%JMW
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M&EJ!\!RWE1F:$N[&R=FJ \\'5R?@$5D"46-X()(G;VGP5BMW!"72)!%<E=5
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M\N_")T8)@\,?CWSRO:M 8)1J<>=?E">!HA])$UR% K07P-$*(]=C190#"46
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M6FN0VIA59""8E_,7*A:0!I[ZS*0K0.<D&) *DV: 3ZI9!![6@( Z])0RC4A
MXB[#@(3<044F12I'!ID:/- U,'.8 $O_"MC&Q.$!)M#=".QPE*DP8B@N$TDH
M$D NL_[EQ Y^%4P&H#65,<B&H"88PQW\6M,8L> $QFM$"E+PB!BA*$9!0<49
M3I &\,2ALS+R! OV&)XTP%:4IET!I5!!!A.P 36.R-Y6%S*&$FR2=G4802-
MH8(6),ZT*G!;)%8PAE7(803DBD0%'D%"CG0D#934%",80890M&$5GFC!"58K
M//%(SB"3#&0D&.&([(KD$1K( !TFPHCPBH1*)C!>:2 :F#N88 5/"X4=P+L"
M\7IB!2IHA!U&.A5F!68-):!?*R:Q"$>DMZ?"705Y*>411]P*%76(1 I6<#<5
MG("N=J#MAW=: E]A:SR>F(2/6Q0*T85B#": [^-2$('AYOZN%2U^<6UONUH[
M1*(,)7 J&TKP':I02@XF8$%"ZB"KP(IYS(.!@P-($(DW*, ,;&# 6T06!S:X
MSB-W6*)@[." G>*AH5=%<8P24(D,-\ ,:ZA C_*$ES34P0%O6?0:TI  _#8@
M3&PIP0CPT 'LL*$">&!!!-@[@33(H0*>LS2F=S,2RL:A#:;"RPH6T0$^V<%B
M:E@ 0R:P@3:HP 'S\@@;#& &,SC@ ]G:C1TBL.I6.T #D)I "W@5"4\L  1L
M^-95/% ".X  G3(%@7Y7<0$SW"$"GJD<&\9 MY.L 0]WP,,JY,*".&CL(PCX
M@'[5@H$+Q$':)6"#!W("B@J0 ?[,)]-)N:=RA@G H0P/\%H!2.#OG'CB 2QH
M0P<4\$E;,N!KQT*L"%HAAP-X8 R40, (U#"!<+=@XU-Q!!1!<8"CZ+-[C&[#
M CR7)#F8@0(,'< 8V! !HJ2A 2GP1 E2,(D%,"D#J*C &.KPHI& X@0/,,,J
M2G""511 YL4!10.RNCV\5.#<"TC("$)7JE68X#PLX/099%4'"Y!Y[G.O@%00
MW1 "1<",?3J/1^!0V3LC( .$GX C/*$ N V8 :GUR C((X>DJ@$$JUA 6I"V
MB@DPB YSB$1EP>RB%5P%,&/( $<BL8H4A/0.(<F Z*D2& H$<@4BJ)J%'C*!
MU=:!>_X/X&,$E-6*-H29 FYHQ2-"4@%ZL@ [$6#(K$O#!E(@0$::MVEX%.")
M.DPZ:PT0'=(JAX<  , E'AG(! BO@544@29:D8X=&) ICXSA@Y1@.2B2.@94
M=XMN'$#PXQH -UV%"O:75&9 (%3A$ZC@"8(C$BHV+WD  :C! ).0!U 4(XRR
M'K8A 7H!$5 4"G'U?QJ4((NP!JC0 )2R 6M@?:U@!\51$QSQ8@IA1AFP"&Q@
M&TAU4)$P(GW"'0P0:"88"J!@5$>G$)[3"A2 !QHF$D4@"BT +7@P>LUR!RY(
M=U7X5Q3 $/,Q)#3A "   B'0 43A$7@P:<ZS"G" "G?0(_Z8P0#*,DP)4#3"
M$263X%=J\!"?%0$:, FKX "4L IA93T>80>RXCZ<$A1J%P'DEA\7$ )>V $*
MJ $2H'E9$P$>\(5MT@IE00(:0 *MX!OP- '*$HHCL0;-<P$7)D(#88E@""T3
MP C:U1ZKX %M(!>O1 ))T0"-& (9$ EQ\!"9L@@4$ &\6#F1L  %@"+EYP";
M9!H"@1<6%HN!44>K !/S0@DA,0(4( *.^#4DXA+OU"%1L@I0=Q#6Z"W9M0JA
MX%=M((GJT0@-,"]KX  C\ $B<"1VD!/L)42KX%X=D1<CX7*H<! <X0D1(!>-
M($Y(-0(@( +,=@=A)@>R<A#3(OX_K= ")C 0:F<>7L@!X21('51+)C1Q"7$&
M&X ^W%$!=> 1%; (<1"+J'%:$.&%)< ?4VB%-YE*%" 59X!J:> J0J. 67-S
M4]$( 9"&@3<5'L!^(I$"898Y"4)$K: &(5 V0^97OX=(=N (E36(JY!:# 6'
ME()4>& "KE0@:0.6<+,*-A$>V;< !5$'NP$P>8,BHYAYP&>#(I$!02%"F<='
M0?F/<H ?LQ@*=K83+3@5?E@6@0$*!1$*9J FE#,)6Q4>#^ SSA,@4]&'=: G
MR<0"1%&-+W$<)V Z9A,8IA$8M@(>:? !)S$O$Q<B84:&Y0>.&#0O<K"#+Z%=
M^%&0'/YQD2+!D@!Y*P,9(P]R 7P7"8@#@@81"E 7)CFAC@EQ A\4"1N@!M>2
M M?B$8I'$BY(0JWP  09$@F7$&9 %!; (!>0!XT0F6OP,1\TE'AQ&W*'D_5)
M2A.P H\)(F30'F-0 ;DS 4;H$75P &3 "&^0 ,DA!PCP:&F !IY3?Y>V"":0
M -0$&VU8G0L@'QW@"0=0!Z!P!L5A!J:"5',S4XZ0 7[U .WS1*%0 AK@"90
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M">]S =QAW!]@ 9N#FY.M%R< VR; <XFY 5Z"66]P?B:@ 9*@=N'- 1RQ 9$
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ML$*I8&(<$$K_2 H(L2FD<!L7\,B_@\<' !ALD!L^*Q)F<!Z>LC.K0,J LP"
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M&"#$,.U]*DBM",7L//!$$WCM8?ZK@, ;4'$^.&PR%&:0&V$8L A4U*H5H#A
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M!SB!25"#!4B#-U@ B7B#RF&#"?"$54  4$@#!%#)EP@!#8"#%#@ .W@$]8&
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M2HB,TUF$V- -28J#Z5"<DJ,W9PG%.Z@/9\F0<&$?1T@ <$M2#!*<+O$(F/$
M2ZEACBL<3FI=5LC75JB #0B!$/@ $B J$CF-H+F1"'BV5; D/%B $0 !$<@
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MX,2@AS%=2>@ VVX31SB-ETB#4+ #"@%MFE@ D& $EY #0715/!AV16F!':*
MOP0?)84[Q9D (RJ,#("0@< <3/ZBFDMY=6@&M7/%H*M2@17H9KP)A;AMTQ1
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ML"$!(5#!!+B(2?#)C1(4",4J"D81$LSD>"=D"R@6L!04PJ424B14!L.6BM:
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MQ%$]RLY&@$D.$WBJ4W':&HQ,XJ<4B<0!F-J*"%AJKC\=ZRVU:IEA2J*93''
MB%!Q@32,\Z04"6O1-/9.O\:5+<>$#!XM$\-5.#9YJS!!!OQ2B5:8P00><"1&
M[,#)5L3A6"0H00@FX %4H"(#GDC! BQP%HR$ @0?&*V 2C"&":"A%9SE0&Z:
MF8%V:D %&'" !T%P!T<\P $F"(4&/LN"#(0@ ^8I3BL<$/Z9)[:B#5YQ:@@L
MX($17* 5:4B!EB[P@0F8B#V::D4>JBJ'FUY C7MQ1'XG4"HV5* #%B 7*D90
M@?.F=ZX9$) )B!A;(,TA#@N( (4F@((./.!FH.   PJFA@N<0)+F:<2!*[!1
MT;6R,G*H $9*4+\3K(+#&:!$"3Q @E*^[ T->( 9(A$!%63  :-IQ0HPL $.
MR-4"B5K%!!+SB MLX *ELL,%1&!B+8U@! -)0RE-$('UK8%GN$T/"<X[@0Q8
MY0X7,/ 3W7 L%<QJ/!CA:0HP$(&SM((%%V!/,"?@@ ^@ F-1'H\D/,""!W@"
M%2NES\<FD=P*9( -'OAQ74K  ?X0;, J$Z@,JRIR+ ^<P ,0@(F6(I"!$FCW
ME)]KBFV>A#XR6& #%2#7>E(P@1&D00,.>&(+2H!>G=0E!'X9@8! ,*,(',L3
M&_@ B .W9@HLPA,4^'-NTV.' %/@B2U;@:Z_B)$9S=,3E:'$="Z0 HR$0+01
M2$,)*'"!4(!" W8T\:2]TC)0E& !%VC$&A8P@2>68<\9"&R!IQ,"RN&! AOX
M]PT[ ((.C& 5\5:!KIV$%E!X@*H1=Q>\-^ !#)0 (WBH  <H@*KAD2$#OQQ#
M3\>  .NA10[A;,4:!G*!$*PB%0Y(#P,2'8%&S+05<R B03R8 0I$8A5E<&2>
MV8L5!OZ PA$%(!>76X$!WQP)%:%H@(>J&BN"&,<!H9A#!81BG"KV=!5J5(P(
MNGL6/(RG TZ_@!P8P;,WI#<$-@Q%R$= 1+X/- ("6D39R8 !=,MS%1&H3 9Z
MR@B3:$ -:M]*5IPS"5NVQA$1L$H:&BH"@2Z^+L FW0@PLX(&F,>[:KBBCY?R
M< 'U1)RL($& (H& ],2A)3T2SK'0L@$('%FZHO=-*")@G!$,)A(0""\!ZM#.
MC6B) 'P2[K&,IF78TV4$XY-$2W+=BA$0]JD(&5$<@@B'GJK7D5M"!9/IHL\X
MA&( 9%B*K"@" N?$JP 04B,J/($ 4#R"'[4"C2R$(Z0 T?[57'=A1BUUE0*8
MQR)('^I(R -4C1Q @%7D7BO(P0'@Q0-H41T$$0HTE)ZU0@J0FJ#<%7N%@@)0
M@O>YA">L@@<L11ST%-G!WOXPP+A%$2H<0&+,T<]XAQE%R06<P4+ 1!P,@'E0
M %T4@'&8@ .0 BHX8"@P@&Y$ )]H !NL0AW,W'+DV7B=0%XQ!0-TSP.$@ARH
M $4LU2H<P&@P D2T!AP<R!H&T1HDF E0 A6FAR<X0&7,DNA0P(50X2J,P7BU
M1ATD&!NP% 9<T@QUUU)(0$11PAJ000-XT 4XS*FE01H\(5J(@ADR0MGEQ41H
MP&BDP0?4Q3:E"AR8004040:$'?Y>1( D>(+@H84%>%!>F,08',NAH8 'H8)W
M]0TJW($H$HS0-< (K(& @* (L(&M%(&)F4$:% "Y.4PCR-.M]%A73,(8L-<&
M/%$(.(D^P<_HM8(DV&(9:)&#F$ D+, :F,$:, #^A4YI+5@)L  ;0$+9H0$J
M3D($/(H') H(%"%:E("E8.-<F<1HI<$9K( " *$)U$$=2(0<1$)+8$0:<-(J
M- <)F,0:5!49,%T!MD8*C*13M11KC "%K (>I(%'D@8'#. 7H<4IHL4#3,((
M=( :G $+((!ZI)?FH84:O$H0744$K, F>D!Z800Z8H0*8 :3C8@GL$$90(!S
M2-(",/[2%9F4&D:"%V+$!2B6Z0!1-ZF=Q=U5)-3!0+2"!GC010I7I/ A*%!
M"FQB:RU$9;1"!2Q")#@ "* !-,F!&6P 2Q6C&CJ"'*2=2XP!*CQ 40$D6FC
MH##-*E"" P1%'*17!:0''B18"93!*IAA*Y !J5$ (SBF%6:)!OB&0*S!&9 !
M GC"!9C )HZ 26#$EC33+TW"&HP! S3/8Z8*!,A5;_YF](C=17: &2P%'&
M-:$ >Q7/!-Q6,*+"& A46B@F1;P!2\&B4'A00WU96K!!! C&!XS&=[:"!:S
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MD]!@7>R<4*B!NX#)<E($'?0*8=AB"D J<8Z24#C'%:X" \P$&\CD4JDA:C+
M&GA"&ECNZJ3 YDD* Y!&L?H3&;WN?[IJ2Z0 ^KV!28# E(W&!% )N)+!D&E
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MEL1!HBW5#$N1'5S^2:G!"#1FF)A@(\C!*@S]X^HEZZ> CGRV 99 8+'! Y3
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MN*..">QX [TC-XA#A0-JL@R_1AVU[Z$T$ CA#%0T6 &/$/:+Y $SY(B@!9Z
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M"%X,10.'[00E($'56)#-'F>Y!/X.J 1[R8R7/!R@FB28%ALD"9,1?:@B@F$
M'/R$BD64TS?EQ "=V0835-A8#@I Q57]Y!?]#:1SD="))RY@!MC"A!*H*$-%
M",( F"7)82QK@'M"43X:/W5_GYER#M/0 <L\ @$9H40Y8P03)C$/)A:P@UE;
MX8A^#L0$^REC"$@RM'UYHA&W;L4%W!"U,NLU4I1.P_IF=J1=>N(,%RX)FQ:K
MSX'$JD2,Y5$K-C @2;;FN -10VN760:VGF$@%_@,!=JHW-JTFE*T;8]P0.'D
MJ)F 7FR&R05&:!0+M+&S:^@:#T$#)E(X8#X,J^N^Y[ (Y-6A:R'8I<0'$@D
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M8LNL0/XT%EG'YF6X-"P0<0*N4B_>@ !4IP,28%%(IC3O="!:X %JEA(.8 -
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ME_VYE7-9#BH ,5+@;*ZR!=X !*X'F#1LUNCE8X!YAM)F ZCH;*8')AK! SK
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MT5ZACL'^\KEAD$1R<+72!7BH<,%;<:'"" 42.:+!'2W(008+=-V77PMQ1,)
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M@#GP; %O8,P)UA !O6S@7LZ[5BM&$*9,>:(-%1@;&#LPAE5$@ 5$5( <4,$
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M3OF4I^8)"-![Y>0)94,"2.D ):(!=3 )#'!1$; KHB$J6>%&F'89DU 1!M$
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M$3P824"9!L*""; A6Z%P1$;6\C.DB,0J:&#$9LJ7@*-P)04_0<B1</0JT:T
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MF&"# Q'! M8@!P>4H14@6$ )TAE#/*# A)-@0!KJH($%F*D ^$3%!E;0<A&
MY *TKJ0D'M!G!OB(*VF@P#U-\ @2X*>D6DX/V&]<,+'G\/[!0/9-A6V<;;:W
M?35IB%Q,CL((V:2!!*!(85'68*)(1 (5=\AZ)$2". OZ45&HB,R"'$@:2KZA
M-DU)@<U!,Y(Z,/,$/S%?3.20BE6H $@Z^^L3[7"1$)BEV*U@ !M"D8J-3(!
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MF$7TR!T;"#+PB*JBIXNXMURQLS0(@+USCDIH@!" B5X$$0>(@U!(@#MP!!-
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M28R ?AJ(-7  #(B#I*.*":BQ@?"$#G" %1F#"&"!%$@ 'V&!"S"#3]49=-&
MWA@#7?[5  ^2 XCJ1;L+$%.]@#EP-U0 JE>I)#(0UH)BC=NY#;I:@^2I*N6\
M (0,T&_EOD@H@]AS&#NP@$B@! Z0H0(;MLU$F Z0O/+8$D>@! _8H&M+"IB@
M! .0!,5I!0PPBY3H +-@ YN;@.ZH/F.ZM2%\"7VZB<"HA 40!;:""0^I#HS3
MU%:8@X90"9; @P3H)YL$!7\M 3*@(M+0S#2P)SL@F0U(B;' I 7 $$=XQA0
M$A)@+J70#(TBH(&(!)UM!<V\ XAZ@Z:@))OP-(S8U-XH/ZLAC0?(+,TXBM=0
M@PMX@+LBB G0@$.L@!$@(G %6_[",M-H@PRH3NU .R(CGOZT?8T]^H#P:0XB
M2C(':S*U+0VAPT<1(PTX@,T:K=O<2-L(\R4S"!"N6,R% XT.](!-=(0'BPGC
MT,L/J#,-P(\5*('548H/J#&NH(!&&#J"D(/ "+02* % ,;[(&8@+ #;\D"4\
M&%JK,(,Z8  _=  [6(4.@( ,,$.8**M5\ #_D*4I&0@\H("!X V8 )_1,X%'
MLU;C7:,WB-4Z<P _P -$"H46 $(<TH"]*]8"0:2!D=WE-0&4 %RKVK!0D(,"
M4*H(*)(V, '1"-OXE=_Y);%2Y:B8P,PF_(^:*AIN]!'Q.YS:HH242967H 3&
MR#'2@ !)L(/ *$[2:(0%B -0P/X#HH #T76_.\#@1J@GV 74VTR9Z'N5.$@J
MG=D ,!H!0)L A1A>>[)3Y"V#/)@ $(88?RHHAP.%2O $B%FX58B %J $5*B
MIN  I9(#$Y*L#HZW'-YAZ8" HW@5":"V%(#)Z459**;?+!9;P768P/TQMJ,$
MFUH%.!  29 #1"J@D9!9,\" VG"0&XJC,=" ] .?5E"!#KC-%!*HB#@#D8 #
M1#(^1 K(@5J%$;"].B" .U@%$EZ%.R@ 19;4118)/7/6\9J;%/"C7+$3F,
M9%H$R%J%-(C+C\"#B^*DGQBCX$B)2+@ )30!%* -"%AE"PB%.J@ 5&@;,SF
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MW):419*1:5QB)J:699IY9G<@:$#&&%*10&$K))A!"01@K4#A1IZ(9$)SK91
MX02.&14)&U(A=H(*1DTR0ARM%%'!"FQ0$$HH))G7P20/;+3*'-11@%0K%#BV
M41R&MH*!'2EDT (+8ZRQ"@K-?=7""*V@8:J*J#S 8"L5S/Z%1P6LM#("&:N
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MW.  ,ZR  2!R0!GDMP!&I  ":6#!!$+QOA24X0'TB@"_2+8",S"@*!3H@!I
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M" E QQD_+" $9?#  N!2!NF-@ 0?*(I;+# &%CB@5E,)&)K(:AD2 (A,J+A
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M:F=@P?Z/9=* @ Q<X (5 ,4B&B"F1C! /1CP+"C@A+8&9*1 ?IF.A,*'@C&
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M@GK081'= 5=1AB3< <UYAR?\H2<LDFCQ5F5X0HF$E[U%PE-,!B-@A62 @AW
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ME08+E!DJ$*)GM $"((0G>, $=*-D/$)&C(%A,4*=F$FXG/[D1OZD3:$""WC
M\J6, Y2 )\A!!\0!!ZR >JP!")1 28!"&SC""+C(1FS &E0&&I2B&7P%5)8
MF*!""Q E@\@!);W!EU2 !; !*@22&DP1''S-'81 "-RB;&V%.(U >4S""716
M[L2!L\@!)9! ")2$'=B!&6Q )"Q"!ZC 5[!B)/@9&WC""$! "WAD5(YE$7P
M"^0B5R@F8S*"!T#FM&RFR+4!'G@ I8F;8[@%'I0 "-P,):Q,X=A!'JP!;^2!
M"(0 % $E<%X4*F3 "2Q""TQ 0BP0*-0! J1!5WC/"GB (RB$!AU  2Z2!X
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M!A(5/D:9.0>+( ;/L<!QDH (]!4JK$"B;$2-1( %P!>QYOXL0D&I9&2 \$0
MRSFK7\ !R[A;6X!"#@KK!D!J,UU \G@"<#3@'^JG9+" *"R=HVZES+:%#OI&
M1?2*1%3(9%2 7$&" "".8;4" Q@B?41)*TA"=J@ 6ZQ-2;B!76"J%4(-^C$
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MODP ;YQ <>!!!'# "'"U0%! "'RN@PFU U!")%  NK0.&D1 !XR  4L&EW5
M"3"U"H]U!U2@7-,USZ!"". U4WO N%Z !3"(8?=78C/$"1@A*D!)#!H2?=R!
M7AS/"%! :JU"7G] ".A@C64 "4"@(SC"3(H<!5R,B#S "N1@"7P :V]=]4Q
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M2E! M6W$&*3%4'R[$47()/B<N1?]XX!"!D"AAR[""A3'1IP %DJA9)@V"%R
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M3R1 9P(4O,T!JZC GH)WN AR;A%]:P4J)L &1BP )WA 3ATP0!#$,2(\!-%
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M@ )0(""5(P0Z8!5$(? N8#0B+P,F;R%5\!N)@Q)$X,0$)P-ZY.R,)H),@+4
MMW1-UREXC"S,S,P0C<<<[71A-R9V#]-.+Y4BI%9V<3=W=7=W>;=W??=W@3=X
/A7=XB;=XC?=XB2(@   [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>comp_0010.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0010.gif
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MZ_/O[?/P[^[O\/#O\._P\?/S\_CW]_;W^/CW^/?X^?___P   "'Y!
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M")# C@?D=$ 4@D!T  (%&%F  _$-\H&9.^;Y0$QQ6.!E 3 J,, %_?"40&!
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M05RU31"/*%)+WOY0@C?Y,(6@#*4H,V0&E]SJ 0Y(Y0+80X%^ .^&\HD5^_R
M$ 2P#(@$4 +3B!BAW75L:A=KE 5<D )M;>]V4*I< A"PQ4'4X'->.$$ SN0
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MG$8'*L >(&A2 WX@A19HBSUKU6];T8/5]!* -MZ-LI2GO(H4>"H T8A'E :
M   TH07MB*)\)A. AD@@3A<8A!/,A&4_ ,&/+'* !@A '.L&*0$%&(  +&
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MPDJX;<"3<XL'YGJOC-NXB;H):  $2: !%9 $/T '.X!TL^!W#4 (&Q"RKN
MS/"U>Y0#-LL)0<"PH> !6-L)0/ OJ^ &AZ,(#_ =D1 $'F4)0N!OAU"YJ$"Z
M@Z ")J (%^ 40E !E/ &.;"T@U $R"L$'#NU<5 #?N$&#-!3C( $]H "+3"U
MFJ"]WEL*/5 !!P0.33 MFT"F<H '(Q  .X '>_ #M 8'29 %<R '3] $<C '
M2\ #4:"W8G $;? $75 %3="I6Y $9R $5;"^8@ $0G &>9 %2="I3U %=G &
M2> %<["XCOO!(+R6GH "#9$).W "9- "#/YK!CL !%Z:!T7@ D07%4F0 W1%
M-F\ !#U0%UTG"&80'U^@ S]P%5Z .78R!%G@ B5$-D*,'2S\ W"!!"[P'8>0
M!3E0!"+Q!OJ",GL01\92!#E ='(4!5:0!DN<!<_AP_U@Q43@%VCPPZ4FQ427
M!2)A%6,I"%IPQ11!QY C/&: ,FBP T/\0R=+ CUP"$H@PX,0!_H2!H,@MD'
M%D$ 'RW NW\\"%+ %F)K!)' R#K@.UMA!;R[)! @!&P1!T"P#()0 :>507[
M!G5A%4.P W!A!#FP%VFL++'L!D&P T2,&J2Q!T20 XWGPX(,%T[0 FWE!CW
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M^HH(2."RA_ ()R "@P,$#M ".:  PQ8%$O #+8 !Y6L!);!C3O$!$Z #*,
M4N$ 'I"Y:-,".)(V.V0$#E $+9 !9(.^AB "%; "+L  Z( $J=T"&H$&$P $
MLTT:). !18 !.JLJ%F $(8 VLJL#02 !* ,!7^!!)) $&' -QZT!2. $'C,U
M$*!E#9!!%8 $(H V@Z#8'B T)0#< B</ S('(14"/@($%2 $(H!9$^ 40'
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M?M!"4:($;^"RE%Y/^PX=$G 59) [D$Y+1F !1$<"Q1(!I08!81 &:.X'<>
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MCUW["#*D'#EM[(A9($'.G#9X,!P0DP4 $!(*\(Q @,'"! !#CLCT0W(!B2
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MEM<<5X@5A&"  K@8C+'''G1D(<$/02CC!AUO0%+(/6^TXH4.%D1D BVM2L&
M%&@Z\L$\A9"!P1"H7D.!%Y"XH<0"!Q$#A$#)9$2'&Y!L8 0'\(00!!L.O/'&
M')7[G$,+<9!P0J,/1+''&]XV=,T'FT#R R)NS"%B#1:@UKD;HA02Q1Q%H,KD
M1ZX6 =\8D\<1![@Y5(":"K&(($U(;D@@//&I22-!%$E8PB*,+U(P!NF6G78-
M+'Y08$4A%<RFP70BN'"-GM9P0(*(&LB(22%.S-%C(6.$843\/O]@)211:&F"
M&A1B6,48AULV /ZD-(U(&1)(0N@L=PTT3"()N\"3'Z)7B(4<K1PM6,$\T/"
M5_C"#V:81/42800T*(!63E &I;"5D2 HP S70$%E7F' "X+!7!0P0D8@"!(5
M&%!V<\! $?2P.A'-BAPZ.(<)4. <+Y@K'M.1PC_RPX,W*& Z@DJ- 9?EA\T4
M(@MN:,$YW% '-Q"C$!+(P1SF4($XU $";/ #J^:0@=ST0W_H$LE(Y("'*B#
M ",P00(,L 0\[($%!$!D'YXP ! \@0036 ,0 ! $C^%A"088 *>J$("L>,
M0AB"!-!7A4YZP2<-*(,=1E*R6,IREK)\5A_I4B$F.B(5U<@E'SQP)OY(]. ?
M>=# *C30J$S0@@&HR<-F3+D',S  ?0R@%5S&X+N/?" "(N( %*OI!R40@ Q
MN"()5.!,N34! V1;%!0O*)PPH8$!TF@ &XA ".@HHP/[62,*&J#'0O#! 6;@
M'(]\*,P&R>X@S[!%$!H0ID5)PP*Q<(,%N/"-!- *! Z API0%8)&26 34B!
MH_[F@+D$RP]^\4,:&J /#*#/# DP@P;]  0U\:<8#?"A'S0@P#=8  TG.,=+
M??$!?=CT(VY@ !3\, *C-L 7$" ?%)/JAP>\" )R.U412J  H>%#@)]CXT$J
M$(LH**D<O8I/8J1@@"CHP0$^5((K=("!7/[IHP% <@(#*I> V9  %208(0DJ
MHP(.D D(URH$!O11!(]$MAP:$ 8)DN<'-#3@%A<8T3%4H(PX5  3Y_0#&22
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MU] $" 820,9[8;E]77D-TW<-H&DD$3B8!OZY>]FGFMFW5C8$EJ7)D_'0,B%
M7HTIE7U4!UH9@)30691)#A\!@0 9E)8QFMQ#%_.(CPMVC$M)$D[IG$^I@6X
M L=R$#FP"600 GQ !BKP Q90 =N5!<<" C14!#N@ HYP O 0!!JP >A4#G@A
M 2FP#"&P:WJTGAK@GB#!!1;0 QGP*W[@!1&5!5"$=![  7N2!-)P C]P+\D4
MGAN@978T I=V)K&5<"/$"CG@ A6P <U1:!H@:]_ )#N@5A,0"UG GAN $=L9
M!$NS LF  5EP A+P3F3P :8V%TVP BW H=(86TVF*%IP+!Y 0^B' AZ0 9M
M5#R@ ?7C!S] *OYJ\R'>YP :X :VA@(28 +"L#F[MEW7L! ;8'ZOD!M.@ )[
M( (-H**QA6?)0VU$D@4JL*$:  ]F\ $?L$2,^1$NT*;*T@,?  &;$&Z%D )>
M$ 1GH@*1Y4,YL&LW] -E)@%V<:4]0 $BH 4AT#7VPP&"AAI.H (U,%IN8%%\
MX7LQ P0Y8!XD  ES\!<80 M1T (Z@ BLFG#3@5,;P $B9UJGL@%%(JL:X U-
M8$P1>@U2<"H<$!'+Y63$$&P80 2IH&LJ  EFX &F=A!D4*T:((6OT  :8 8N
M( (J, $YYP=U$"D:<&51PP!B>1!QD )%$"-;LFMV<P(8P0<E\ 9>H/X".S!:
MFD)](N !&.!#<:HV&/!W %$!(L ".A5;X$ D+3"N6!(G:QH$/V ")K '#B"-
M)0 :U'HL&/%/>7:<:H&,R@D62%F"SZFR.\:2YY(W?A &$S '*E1JL> % < #
M?- *P2,!&#$$RO #)F4&?-!:3F !MD! 54$YX&0!^E /;V"T_$! /7 0PC &
M!B -=I4']\$*_U !B1$$CJ *?L  ** '49  ;P0<:(((*^ (7H (43 )>K !
MLT%V!$ K+J EF<D/-(D/#( $CQ,FLI,;&1=-!( "?N, @=$"!Y % 387'M H
M_V,(CNLSY] "&G!_'J8'LG$+NU (#^('=/X  6Z0!@- "SPP01H;!X Z:5)0
M55NB'J=P)ANP"&A  31$#%%  62R F&B!).C7?00NSD  H7 .!<4A8)  +,Q
M'_BP"5SC!T,@DN5PO)EP)@\@ GO@!0D0!S"769OEEA!@ 4[ !]95$1PP#MN!
M!G3P $:0!P0P#[:!!NFE.!C4!,>0! 1P$-N"4TN#)K::6;B5 @[ !GD@ 8W2
M 6$R!F$5!0&P ZC!$6Y@+>EQ#R @#1R@#TT 'SR *AY "PUP$"V H;YR$ R*
M#G&4!S+U/>/"!U!:@!X0)AV /AR\*#7,L ="*RT  6:P!Q,@#2'@"Z*%$?VA
M#E&@!304!P@@ OZSD1E\P 81<"8&\0L$E04! !I @%M>@%E;@CYD$$)1@+=^
M@ +*,#RL0V<?80$<H = 4%N=VRC_J4&-.P2F( $8>0Y\8 '3D045D <EU 0&
MB9SUJ(]PB(PKB\BRY ;^^'C%%05.X 4.$&8*8$!?Z5A*$ 06X 5.X 0&\ 9!
MT"!Z4+J\H052T .NP"B*401F@ KVLP<@< *EW .X=0)G0@P-X23E,P9.0T%;
M8D1G@ QVL;;QP08MNLE18 !F$+P]X#>FY0 M$ 6SA\*/T%&$(45 D "W BV^
ML ,BJ0%&\ 8-,'T[\D*S\ MN$ 4N0 BY@U.K$+L9$0=!, '''%A"UOX.1-
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MP5D?@IF\EB8P1<@K$H#VW (;^,"-C*[W(EA=Z_Y0?GKP@":0@ (4,:P)%MB
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M&*  8S!M(U  53"38( ! <"S=N ';5 " # ";YD*0%#+)A  6U $ 5!A*P
M2R &"( !<1D +5 &!7 ,29"K<_ #M7P" 5 %9V  );"A09#,?O $ G ":^ #
M8S 'Q&L'*0  0B &3] &40"?>[ $ - "BHL'$Z  3] %5<"[/Q#+%I  =K "
M ^ %9:#.<O#*<H " V "!5@!$6 ''X  D/[; 0;0!AB0 /\<!5.&"]AU/AFR
M"1Q0$QQ@!)T<(F+2"UO*I"=P(H8@!!? "3G  %I@TQ2Q"9?I!TJ )3^@#3R
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M#^ '',"D_" !8= $(1 %+K #R$(.?_SI* 8XL1V6L=@'14  &2 &2;D'.0
MYS &"T !?4 $!( !8##@7<  #= $BUFMM6M//&#,R*P//R  33 &!5 "?9 %
M!% #9?"\F!$ 1/ $ ' ,VQX%9W  X0RCN'H750"Z-0  1T#""K &5= $:J $
M"8 !3? :>' &5= %__8$WERZM0X 1! ;@?[* @0P!B[ [Q3_T !\=Q1M!QG
M +&\!=[\!%&@!NQI I@YI%A$P+PPKYO0 3W6 4BP%J?C!DC$SN>P"4H0 9L0
M BV1!1% /+=A5:,"RQ&2Y$O>Y$R*#T: 5SV2"):N5U%;LOSP \LE%W/PP%2/
M7(:P V;^%L&"1%EP":(=!4T@]G="PD) !Q@]*GONV!&0,!.,!GS !<(1!P[
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MI$"C( "  V-P0PH < );Q,$CM,B#%\Y2(PG " 0ZJ,4;:AG)+Q3E RQ(%*%
M1\<OD.$6;KB 4VCQ!@QHEA9ST (F]< +S,;!"VO\ 0G\P-M>DH  K/[ZW 2N
M58&6NL"D3S)I' Y (S0H0 M[.( FI4N5"N1S=36  #D,,(:DK)86+EB*$WS"
MF"9P0 !#B=P>WN"&/1BAH#VPB1$D$"H''&D.#J!1+30P#CI@M@.1]0,'4'!+
M!Q@A37<1JX,?'$0' N^)=KVK^.#Z3 M?6(!6U' #=58TQL!W,6@P@ 7H&(45
M"#8 O[5%!0Y QCI(( &8] ,2\.L'+5@@!!;0A0H8,($H)($!$&BI$"P@ @O
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M@1,X0,R68<B#@0:D@9-!"!P0!4.@  /@!EY 4#R@ SJ0 WG !  @ 4H@!1Z
M")!F:_Q%1CJP6A5@@WY(??*4 Z,&>WX0 BV5!Q(@;4A@'8/B"[1@!#Z5<! 0
M!W&@ 19 $&QH!@E0+$W@A,57:\5B!MX%!%](=HXSAG40<[2P 4KG!R@P:D*
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M(@( H L.8 !HH <-8 #,6[O<P (   $F0 $ 8&TU  #*\@, 0 1!$/X!%F
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M$K  .; #.?"U.8X 09#6(W  "<T .S $)\  $D< **#=\"H!MYD%!X 121
M"M D/7I?Y+4!FG(!?!";&&(&.SL.'X "7V"W?I &7A4%$X#2;"X08Z #@J$!
M0N %B'BN<_9/.F 3+: "3'<"&V &A)Y'6?Z7KB%@!<Y):@F@ W1\"SJP?UKK
M0W$. 67*:4N5$XHA!=22%7[@ R;U!FB: V0GKX5F!7C@ "#J $60! ^@&"@
M <^A 1J0!#J@ -6@=5]P K^7!%G'DBYU "6P:1;0XI6X)%XP[&*8 $70 @U0
M DI@YT_2 .+@57Y@!1*0I$KE!Q9 G&-0 Q]@!B;@S)B]?$T0 5*!ZS_ T'F@
M KFN!T0-#@H *B,@L"HP?%(SW $O\'"0NHPQ!.@4+K30! $0G*D'<LZ-63U0
M "!L  E0  'Q >L[NX>\!Q"0  J@  1E2%NN  F0  -P['%, !"5>B:? !7M
MT:)]F@" W]WL!OX)@&LB@-%D8  A0 8#$%E:<  *,/0!P"J1TYJ]//.ZP L\
MSQ HI0/3+ $ET &V)@0$P ,&8 0G0 $L8(MH(.&10\ $Z0?Z3"M!0  ,8/($
MH"UHK_8O[RIU,0!D60)(@  \@! YX?(&4%"#Q0(4H.P'@/=2,6/0=@"=WA#K
MBP (0&/=\/&U6 &8) 030)5 ;PL_4%#-1RM%W0NN,H;87EF_W@(MAMI^L (F
M5P&7Y0#O!7\9X"@Y0(<@2:Y4<178@-E^E 7>I02K[P<,5SIO:':9:)J\D .&
MNZ,I  %Q\@!$&@S*?:^.XP9'QPL=X0=!@&LLQPWYQW*]DM>]\ R4C/Z%A;:W
MS.@%7[<'## &4M  MO0&E%4#H]86%TX+KID#UL9?5!$$&*$"[FAK',!]F \(
M?A8Z?GXD(GI^9H6%&S^%60]^616,D)5^%T.%%E%F#GN%#E&6I::GJ*FJ?G"M
MKJ^PL;*SM+6VM[BYNKN\O7!R<ZE9"0I9I5X#'8QN"A.)@@ENA3\ /7EY0P M
M?A\$QG=Y?GD.#4%%&P=&?J%: R)^='FAA1\)%0=>X@X0;WOQ?D$ N/"3R$L2
M/3L )"D$! "00F@26&!$8D ^/QH@Z C0Q(\7 B'$Y7E6:(("-(7H*!F3;5NA
M* %"AF"014$.!4D\.  8((H%$A5:[ B QO[, !",7 !01W*# 91^LNT0%RPJ
M@*EYJA8:$Z '"PHE,$0!0,1/A 9N]ESSPY5'"["= &R2T"".GS@.%/@YT1->
M.#\F@1CQ8""(GS?AS!29(,!8J""5LC0@$6($!R&"E!12D<(/#P@E0HC80";$
MH[]^5* H1,%*)BE&0DKX($*$!Q6,\D"8TZ+%F(D3%E;Y$*+$!#]&.!3B\8$@
MGT)%E/LY5TH'"3_/2T$!'4P/!&//+10IM*,!#TL]&$PM9.1X'KN,O!S8\,%"
M73\5I.C6*L&8'S>@2(%)!:3@IT42#H0VVA=.:%"*&Q#8Y<()K)&!( D@C#9&
M"[C%,<$B13AXPOY _T'@!@8<U/8!A1@X4<@<(D0 P4.,3%#@&P_4D<5QE@@8
M"@8="6)%$Y.)MD&!JR2I9)*^-.GDDU!&*64O;LBABAF+F#(! 2[Z40, N!6"
M00)O, 0 9GXH$< V(120SS5ZZ#9!.,B$5,A'U\F3QW-(@)E% !N( X$$=JV5
M!@(.C'&8! #$480VA9B@4"%N)( !101<],,!%3P0S$?OR#-/(2Q ZD=#)\QQ
M@ .+Z!'"4GZ$D, <&T#P0!RU6N6%#@S0Q,, ;I@!4E( :&8).E 1T95(>/BA
M['G7H#;& #W4Q( .7@ PG@0.E+E''7Z0,0 /-3600[;;.A!,'A88$/Z'"@*0
MHM8Z$Z@;K@&!?C! @24$X&(B34B"AKV'V:5!D"K@-L0%C"QB0IAN].#'"BL4
M4H$Q/*A0 A* !9F'-'W (X$;8W" PGD3.+%' J2X<1P2@?J!Q$2%]+ 'S-!)
MQ\@.UYFBA 2*,L)!#H7$T8"B+FR FI=*6Y*#!Z>@$$(847@AP7@7T[$;(Q5P
M[-%.4ER:28$5:!$%!8R@U(2#V?TG09DYF&#Q&%+PZ =**K#@QQP4D#&=@RI0
M&.Y.&*@C#DI $G21%PI<Y <&X['5P"0T,V(%S8D_;D46$BRS])*@A\[*E*27
M;OKII\NANNC/27'  !I0 ( %\/DAP0!E^OZ1T"/(@>G'!@ HH, "!5R7P +!
MI$& W7\>(+P"!WSQA@$'+/+!57XH0( "QQ/P"! "'* ! P+]YT  %E 0  5T
M0#3 <<]=[Y\9!P!00B%:A/_\ ?[=A0$ $KB  !J $O =@ ,. , [_."! .PA
M(5"3@%X:DH5LZ44% $B#&0"@G%"L %:6J !1I@$ 8G!O<@$Q80*ZM15(*0
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M::,!#< !:G0($E"4/C%6HR=E:/B<=[:&JJ !$Z"4KG5<?8@)$Z!Q<S !X\<
MB] $G:,!D5,!]C@06>!,(3 04D !4T<*W0ES)74*0( )/5 )'Q H7#  '?$!
MJZ&4'C$ F@$"N-$ 3U8!74("VV U=D$) /XA'3R3-@VP!R9X/SL0$BGC!W5
M 6:@/#LP$@@J#A3@.(+5ED- !PWP,:#A&<TQCCR %")@16, GE%! &ZPEE#%
M#7(31KCG!P[P!6Y0 "Z"(,@A >"R U # 1\@#2>0=R$@,230$5[@3$6V-R5
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MM450>Q$[L5AL:S[78Y80HZ3@!!" !$$P!$V0!RUP/U?X.X9S 1U! D2S(^(
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M00+#FS"*L#5FL+B,0*T'32)G5\!$( 1! ,N,X(4MD 4HL U"( )2X" AT(=
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M!/*:P"QV0((^.( :7OBD![A\:T.$6G\2( ,;(I D,O30#SW(GQ!<)OZ!.?
M ID6P08 58CHBI4H,\U!4O7 !PJXX=A^(,)?)F +\?) 9N.A@!G0^Z2@H:$$
M'U EH-CLAQ](0 (E. [?-H " 6MB Q*H *TV'"@2F!+>/IAWD7,@,_R ( AC
M^.1'@@#$*%0@ AJP'*E#0()O]L!BX[% 5S@!<3^(('DC-\0=4!QA/RR;W2+0
M0$C^X@=4VT,"M,G#-$/QR4#E .9^$$(#7L$%A_MA"'95P< ,871-2* .FHB
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M,D.1OG8!$0,!M-("%6 +*Q N<O@C=6B8S?[B';(1!R>P 1Q@!5:I%"O0#DG
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M@[&A!Q-@  - -&G0  U@ "*J&KNZ"V[0  Q0VS5X'J<M @3@  JP !P0!Q)
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M[8"&N^[>>:Z/T]GS#?#5F;W; R!V5CD #9  0D_9 L "PU3U5Z_9 ^!U%T
MB2WP#;  "3#DJJ $!H  43_7PNV( I#8&/Y/ !OP!A</ 0?PZ;,M  .#! 6@
M &7MWIL]]IZXWQ8  68=90]Q\91>ZXM- #!7B@:P #:_  1@'&A4  S@ ! @
MUS[OWD3! 0/0^7D>]6\P!  0[HHMW'>@ 0A Z!]_W>%N !B0!U^-\1DPW*CN
M+2H?T B>  (2!F2P PFP  Y.!BZ@]PG@ V: !$)O /G#\_*M 2L@ 0G0  >0
M/Q/@WFG: P%P  /@!DVP]@70#AH0\PKP VAP_=?= ,JS]CBO 2PP 91-Z*H
M"%X!!P$J<6X@" L,?DH%# L%&BT3" T'&WX^ PX(%4E*%@@,"A!T?JAO#0H+
M$$IH/ D-!1]Y7OX3"@<A9FYNJPP'$"L;!Z0,>7$+"P@85F,H!PT$47X:Q0H(
M"@XKJ'YIQLQ&11.R!$75!@P-269 L@,N?BT%JP<@*@WE+7XNG @Z9II 6&"
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MH((ZHM4ES1!^0,9!-A7XP0%;!R  P08YH':6:01D<=LE6808&20&G,#8+$(
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MH( +F*A)#"C!_A8A@"R4Z7_S*D*_%-  #_2/ 0'@1A)@.J^_>" !"[# Q$C
M$06 J@(<(<5B# #4;GS .27R%%&WQ #<=,1/)E%! /(A 0_\@@!&0(4&N,H
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M)V. =BO@7 FD) TG X (+"" TQ7@ .= A1 4<&*4&>  ^Q P $X6M/X[$@
MJ<J"! @P7!X3  1NVT-9 ;!:5$@@  '@97<0P.,!\%((O2E   1PL@?\5K=8
MSK*6M_RK(!!&!_EA21R $((.=*!H?NB#'_3'@QP$S0]&V,$.>N2'/!BA!!O0
M@ =44*,UY\ '.5B7'\QP) QP0 6/ U\/ -(-(^A@!T$(H!N.M&<RQ($P+4)#
M#GJ0@X_ 1<Y!Z(873*"!2<Q!"SG8 1 "B HMJ( #&/! #G23/QVHX 1%R ,/
M>* #F69ATSI83JM5T $.A( 'PO9#$72@ SJ?) \_:+,6WJ""4I_@MVC0P0<X
MX($6/"X*.N#!#AX6;1V0EPY"$$&Q32!3^O[L0 =Q1<40Y)QB/Y#!UB> X*!U
M ()2AP (;N.RP =.\((;_. (3[C"%\YPAD^,)7^92<1=,G&8L+HE%4=)Q@G$
MAXAOW(T]N?A,1/Y%BYN$Y U/N<I7SO*6N_SE,(^YS&=.<X^JN>8XS[G.=\[S
MGOO\YT /NM"'3O2B&_WH2$^ZTI?.]*8[_>E0C[K4IT[UJEO]ZEC/NM:WOO6;
MK\3K* '[2<0>]IJ0?>QE;\G934+VM;-=[6E'.]?G3O>ZV_WN>,\[RVW ][[[
M_>^ #[S@!T_XPAO^\(A/O.(7S_B_W^#Q-^ [Y/L.^<G;H/*2MSSF+_]XRE<^
M\ISO?.A!OWG+C_X^\Z(O/>DUKWG49S[TJ%]]ZED_>]##_O:=9WWL=\]YWI?>
M];VGO>R'[WO1XW[VQR\^\D_/?-F_7OC*)_[MC[_ZY#=?]]=//?!S7WOIJ[[V
MGG=^\)?__>IGG_3;CSSTSZ_\\*??^N5_??;[CH,9S( &^,___?//__[CW_[^
M!X#^-X $:'_[IW\'J'\$N( !F(#_QX 0^'\.2 ,3&('])X +. ,RL($<* ,Q
M\($=N($Q$((>.((D:((E6((HR($K*((M*((L.((?^((O&((F.(,GZ((XB(,Y
M2((^"(,J>((R.(1!V(,_V(,\V($W.(,RZ($^6(-'N(0TJ(,@V(1&>/Z$2DB%
M0%B%3%B%3XB%2 B"-DB%35B#4/B#4AB&*&B%8PB&65B$;]B%3DB#9_B%<,B"
M9#B'=NB&6RB&<<B$>GB%;IB&;=B%,S '<3 'BD@'=*"(B]B(C@B)<\"(<6 '
MCCB)CIB(CWB)BQB)GC@'=B 'EBB)B!B)I,B(G[B)J:B(FCB)IRB)KWB)I%B*
MJEB+L;B*L(B)GD@'?:!FO>B+-_>+P)AFO4B,7O*+Q B,OGB,Q=B,SLB,RIB,
M:0:-TNB,SUB,R3B,V+B-U6B-QFB-VAB.WQB,P=B-T7B-R/B,V3B.QSB.YXB.
MZZB.PLB.[)B.Z!B.\%B/RSB-]OB.XCB/\OYHC\:HC_Y(D.(8C_CHCN9HD/0(
MD,-(D-V89GR CP?ID -YCPMYCQ4ID-N8D/W(D &9C[TH!V_0"W+@!B4)!VX@
M!W*@DBX)!W#P!C")DBS)DC )DR1IDBC9"S>9DCLYDR@IDW @!VUPDRM9DBOY
MDT.)DBXIDVX E&_0DB<9!S>9DTF9DDOIE#'YDKT0E4M)E3B)E">)E6/9E%Q)
MDU_9DT^YEF]0DB<9DW*@=W(YEPU'DC6IDD+YDC>YET')DFW0DE49E3;)E#TI
ME&VIDB39EG>YEW8YF'FIEU@YDY')F(+9DH0YDVK)EY,9F'=YF9#YE$:YF3"Y
MF:#9DC))EZB9FOX$QY=5N9>N^9I$69.+B9FO69M#:9-[^9>X29NVV9N^R9N_
M&9RN"9K"69R]*96JF9S*F5N,"9B[^9NRJ9N B9/3"9W$696S>9O&:9S/N9V^
MV9W>Z9UQN9SD69Z09)MO*9RR69-%69O569SK&9[R.9_T69_':9[XF9\&!)N]
MP)/!Z9?Q^9K^N9WL^9[V>: (FJ",.90WX7;Z^: 0ZA/-V09SL =X8 ?M"9ON
MJ9L+"@=X, < ZIZQ":"RJ: F>J('RI(1NJ(LRBO-.19+D 1BL <"JIVN6:+8
M*0=/, 8@*I6PN9X%:J H.J1$VIMN$& P<09>D 59,$<UL0=O)A1O$/ZE+)$'
M@B83:#">.C$'33 '1TH3:!!P8<,V!$*F+S$'M(8&\X(&-D1 9IH32X)R,9$&
MM$8V9M"F0O$1'P<VN8D'.8   B  , :BBLF3-EF=TJF2*]D&>) % ! ">R"=
M3WF2BPJ@TIF=19JIFEJ5-8$!#E!J## S,Q$%M=4?.P "+6$"J)$%$2!Q?N !
M9Z(3>X !&/ &(= #?N $>N42'V!*>XIQJ! %N]H34C!.'W F/!!J*1$')("D
M-A$"ONH2/X 5JM.L%% C<KH2*& 6!#(')+ <(_ 4V=H2:  !(/ P7I P*J$"
M79-Q)2"J-/%P_9&NJ% !RR6E#A!F F24>_X ! !@ 4O0!!I02LC0HY;(J!B*
M!WCPEW:@L'^)!RT)BFW@ DL0BGO DGDPE! +!PTK!W, L4"ZJ2*KJ4]9$Q60
M8F:0 'TV!WCJ!WB IXK8#0^##"@AIB?Q!JPV!Q7G-CX02"81!Q,G =3@!1Y&
M!P$4!RU;<1\ 038+$BZ#"G6 IWR@K^4Z)GG 04206#2;$OEQJ]T0!R17H2;!
MLHV66#\;0'F I#;+!W%P+T90(G7&028PK-W@"_H:LQ&4;"<GIGO@<4A*MB'"
M04D0-4^KKZB0B,_6IA4@7RBALRO1M"!1<7L N8?; ..3!T-BN( C<FG;#4X
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M/_ &<8#E?F %#,"E T Z'^0'4@ ;>U4923  0# ^8U#E?D "^[ .T\P ;$,
M$&0$,HX*1<Q!() P15 !ACOIB.@ <94%#1 ;&'#!]%,C08 5)1!CD!-73L
M>Z %#:#2'J8"#C ':Y$[)8"J*K! ?F "F7"J-',F$X _:)  :1#E?A ''# ^
M&& 609 )1B#6I34O#G .6@#@>6  N*KE0S($@50!6: '!G F2< (4@#@ J8
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M GTA-9:2>$,@ 4"  H9A! Y@@7'0 #R" 7TQ&=ZV/GZA 188"6-  =+Z%!4
MJ1BP 2C@ @J@&1:  2Z@ D7S%X.  4'@ =:Q <H3 CGP!@RZ Q/P%$5  4*
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MT,_00 5W 5E@C1'3 U; VXM ;R00 N!M/ZJ@%RIP?WG0!->0*3X'QGGQ)E)
M0)B=!??9"3+( 7M$<^H'M>^W?3W!A:IM[.(2C.HBT7O !@T0944S#1ZP!W-@
M ; 1!QC T?\B#7@S!WG@ =* !(MBYP4!2PU ,$O8X[]#)SE;AAVZ,0Z0-&M3
MLM/1QK.F /VA!$U ;Z#C'(@]!_5D'(K0!+=, GV<33EP '2:,Y6D%T'  $QG
MOU-A 9HQ=Y*:!?XH=@!<L0(;T.>BT"??(2JG\<!PT11%L" ;D$T.H"03P .>
M_0%1CMA^@-E.X "\<]S:H &0T$9T\@"G @&? R#?D>/4L0D:4 @QV@61@#=
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MY@*#AA,[213+4J)0C2)^-*CX4,&CGQ+%O S#@*U0SDPN<)XX&H>$K1[?_')
MD^D-B1W;SK[Y0#4)!C=-*FRPX.3;!0R;_:#A8.&$"JZ%QG#X5-OANTGO"IG
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M[  (70<G&2:08S?TP >1F(,*+""%X&:A",7-1!-R4)DTF,$,["@$%QK0H?0
M9"=QV,L8S%"'1B8A![3.@@Z&L*00 ,$+->!\+W* T$*@H0<_T/3L^QX''A1!
M"Q,P)8%[L <T('^(.3#"P[1D!AT4 PD\B/[$&"K@!AX07?:TU\3M$9,&[*=Z
M^O;$2CK0=5XD 2V07"& !BY :_47>5Y"1M[@7N/1)<FE Q@A7CR@2>;U2WLP
M!A.P C#F!G40*EQP%$Y0 [16"$;  #-2 C;Q!CV0>>/Q!D-W;@T6!S6H!=R%
M6!62!!  >&1  2M0(0"F SOT!CS0 P2X'3E@3UCA!I!F5.<W"F:@13LP!V_P
M-ID0!CI0!$>A)6Z@ ]/3!#K $&E  ?L&!!?2"]"E"N@Q-^+5 U*7"5&0 ^LF
M"!30 II&!A:  O\T&CD@0H7P>$)P)ARP 173;QL"'UV"!GNQ!\60!T+@?H50
MA5X04:PF"E=$!OY_1V\:,G>@""!WE@0AY0WCPPM'$5<MX (*,#=1( $]L (7
M ")'54PCH@02P :WUT1UP "BT"%?\#V9@ 0.4 0MT'@0L%H<< 'KTP$ZP#97
MY =)X !#8 Z%$$$%-0I9$ $UT )TY 8:  $Y0 <5\'(>@'@EX %#@ &8\%@>
M\%!((P$;T 3[\E'L\ ,'\ X8D 2RXP<KX %&<%H65 %&0 GU40*-X0(-\ ^'
MD 3)IAL5P ,YL !=8@+JR([M #LNH $4P&.OHP/#40(NP #L(%9!8#^JH@ N
M* $BL *.IBH.$ (@.5"MP %#H 'R$ U4X081J0,)- K@ 00:P M T/X_T564
MH9 $#* "/ED27C !.N "%>!I(-0$\&8&#&$&"F &;\ EB6$"0$ !^O!%+5!8
MHN  Q1 '#H &1M  &J %1H !"54A7K!$*[ !0[ !\N!*'N 1'6(B@F" .0 !
MV% !&J #B$ ^6>4'AHF8'$ ^6_D&#$!UAD4&;:D!M<$2U;1N'I@#.5 !<P@"
M'I $&X )Q.@!O'",>:ER#Z,"#Y #E% ".=  )3%V0' "=R69(N "$Q "*C "
M&A,'$/ !.>!H.Z&:&Y "^# !&K #>G !.B!%H7(3/^ W?C Z&'"'\.  E"$%
M#) ".M  F) $$W";&_ B>S ! 7$61F !JOXR 4PI#5M22\P(GT5  0S)##LP
M?Q,0>0LP!QXH!"KP/*\2B@:Z'V*6! -  ()8'R= "#S" XWG JG <X50 BR
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M\^<&)0 $.A %&U2= #$!$P "G/<&'  !&K!N/$ !_7E(;.&K[?"S'T ! N0
M%H )/&"WR49&'L 6J[(3.Q$"2H$&$Q ).U "9K  )Q ")R !0? &!H4"50=.
M;* Q#^-\1>  #UH"9&0$0NJ/#W !L>8'.Y *>3$0%M"@EK%N5UH(0O +$@ "
M)% "&Z S>?  Q5 D,S(X2V$!)C "(4!_$O[P7N9#JQ-0(5AWD]>Y01;@!<$[
MO(29"1P@#QV"'OJZ%VCP ,&%#4V0KR,0'Q5 P/DJ CXP(1\2 1;63?5C 24@
M NF+!HI$ G9U5T.4.+/3%HW'1R@0 B8  ;4Q/ND0!Q- &D,  M%3 B-0 A2@
M X2T//<P 25H4*WP-@V OUK@ HX1I9[K K88!'<E0+0E$?I[%E91"*2)HB0@
M B9@ :-F/MFDP>%C/I7Q!@ZP!SD0%=@:K2)P A.0#BH0%3N!MCST +DB A"
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M!#SC %Q@VSWD /4B4\NC 3M!Q6FD%$!@ !520$*0KUX5'US\#UF  2"R!Q3
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MB<5/I=JU;'VUQ&7$ 8D0#I1,BC)A6Q]9>"",B;9'0P4ST;SDK2:AJ9]$620
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M#A]( (0?:#3J1Q$8:$!"(Q9X*\$/A#21@_X+%6SPEQ*;>N :!QMPT!0)GYY
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M@QL8X 0],( P)7 7 \@PAP;D;@@.\,,8"# $B5& $%&00&LP$ 1!3" *;@A
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M $HMEPB)H%T*ED5[ &)H<!@W9P(74@1KX@.U(H!9A!99L $AL ="X $$Q <
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M D,@ 7VV<B@0! ^@'!J0/YPY4B90.'UF2[KD 42B(<\D"*B970Q@"3^07BI
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MAXY;7@:4%&A@;BKP;WDP!"XP!FP017G@I))UL3Q;9IMC4HKQ!3E0!'60!&-
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M0: Q?H $4V0&%<!:<JD"$+!:"@#.MI8;$OX 1Y*WRP[0 \]""Y+^+*64!1,
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M E'8Q,&!!!O<](4$V$A!3 E*-IG1"9&Z,>D.;D@GP@D3[# ':"SXPH>?)U@
MH@CSF&0"42N Y$<<+I 00BI)""0)%Q$P1)\?%ESIAQ(:F-& "9M.H$,>#]!Q
M401TY.$!!#[&(Y $OEKZ#%$,'683@-A@ $443?FV:0-9$.<B(WL\&VTG(22"
M3059U+!7*"XX@,$.SI!!YP8 :@CF37/M 8%N;R2K 21. 3A&!1)\H$4H&$0Q
M2!3$8'#3&"B8L/Z!0"KLM0(*?B !004EN!$*'3F0( (X(@V"1 ,-58<$;[;5
M;//-..>LL\YR]-S;SX,$44D>$I Q$",[=+"'&6^X$4Z'1HSA0!QN5!UR,DTR
M()8%^Y0 "H2#Z(#BQ'QL4 (:>UR ACK.R0GF-',X,$<08_^PGR1%P".!6@*[
M\0,'>9A!-3;8?*!C!&KY,<%H:!1AEQ=D)=$4"#YTF,/2<;Q!7.(]!#,0'WEP
M\0'@#_ PAQDC?<87!?N<\. ^V!1!P@XL#"*)!Y$*+/@FH>B -2XH8@ *-E%0
MZ8#1NVG5B1')D(!M5&-$D>L@.7C>Y^@9.)!!'BLX!*8A*$2CS#2AY/YPRS,>
M8#"&$37Y\4&D6/J1!A(*1(%&*B$]:A*7?IBP_Z5S:( 9JN8T-T2@$2UP503,
M@ (4+.T-:>@?3U85D8G,(0(Y>,,;DE&K(!EA R;RA,1ZLH$W")" >2"1BR0P
MAW"@(0GU@X) )@ 5,F1$!=A"P?.0T#X*9"$*.1&!!XS&@:E @!-L." VTI"$
M!@A"$B68U]Y<,*_T\&$.6;" "I)2A#Q$02!Y> 0&PG$!)Q#(9 7S P@2L18
M-<(,/U! ""V@A$$XQA%.>(,"NIB%G'2,&KYHA!=00)9!4& %;IA#!;PXDE]-
M8 YH:-K32+.S2EKRDIC,Y&H2";2? <$">?[8@P, DH>"I*$!:HD"@'JDHPF
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MA?0S.^ ]3P8!&-  $F !%# '(J C4D@:[+5<#2 "V) #"@!I%P !X9$')>
M'( !#X P&+!B! B -)*&HQ>,0&.!O>$%9OXG@\X@!-;8"2"@)!, 7;T1!RK
M"3\0&688C%K $SEU AB  ?L6-F&":R00!R;@ 1\0 B% %!\4 H*70?<%!0PP
M+_<3"]@P!&^V&ZMV@\[P!D=TBENXBAKYA5<7@,$8C)G0"=C !;!H32*9;+9X
MD@WF!\CF 4.">[P! 7NQ!Q( $I35+$]3 A40<4A@  _3 C?!!YH8@:.W**'
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M,2"0#X@B892QJDZ1*U$  >209CIQ GMP"1+C "(P!U:0 ''P!</$!QIP&49
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M $P0$^CQ ?GP "&E PQ@-!)  FFV$'$3 GN WSPP 46P F+U[H-@)6.0 #H
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M  1>A8&(:8"!P9A#'C=0@D%D80*(M$ /6M0*IM3O:4FH@ @LD @C<  %&X
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MJB^N=F: 1#3! 0'N&@FPYX -F2$!9VH(&@[@2C<P( QN@  EPM!:(R2 $BM
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M I2P$)C@S_%  <>-?&2U#A!( ALQ!BI0W^?214 @3#M  D#PHE&0!"&0!6Z
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MYRJE:!]DL' EZ&]%H"S:X$6?, )VN703 "Y!T&]FT "[00(Y, ;])8!#Q9J
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M\AS#^9@3![/XHA3D?&@''ZJ'/FS"!.4J1!Z\0(>,#*$#\6DI&6:F&7$5XI9
M-$4<))H&E +#%/X0JFS>0 ;N(8$"&WE#%_,@&S,@<0]C8(YV!NH'[NUAJ<#@
MZD<^H(YLG$ =/P3&&)C*TJNF52,>%.M5SUDY^ "4-'W)S0W9"@PA+*!+:3!
MSFBVT6Y41 \@!08:F&K.HFXB#_?T2!PP"O[1+NYQ7=A,[1TIJ)$XG'8]18
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M\Z$<LB$6)< !%&F1K^4I1N8'U?94.J"!/_ #13 !#V$!&Z #EQ);1= #0Y
MEZ (*  ?JU@(OI!HFR 6*( ?$U .N.@&QK@)%. %XT61.W  _\0H&H$&RT$7
M=G$!PR %)F<"Z@ !7:("7^,$QB$+[5@(<ZD!W(%_;4631'-#/C,$.U GM2)1
M[=*%A!E '9$'7G-89V@&#M #YH<!1]!!$$!$&# &!K@!'V $36!^N]"$0C!S
M>#D'04 ""C ,V< %-R>(G6<C<,(%GN$'*] "0[!(#L,%&*$((? #SY$-40!6
MB@".'H $+: 0G6D:A0 $G,@#11 $2O!#A/[@ HND"!_ #!7 %#]P'#\0#8TI
MC$DP4+T(#"%0AF,@ 7&@D,O)!..0<YI'!B%0 D@ !$@ ?L>H$#59"$RP @ZP
MEWZ !C?H! WUB6RE"%E0B8J0BDKQ14CE!RO7A!4@CMQ 7840!" P!P_ '!55
M".SX$#H (*8@B(H@!'D! 7E%!A1 6QC:#150 DT0!,: &7F)!A$@%G.IA_C(
M EF  M<U ID1<EEP&[>0(4802<26$16@GEJWE/9  3O@!1K@!44P<TUX?"BI
M Y$(%HH@ B$ I%G 0QG! ==E5]IB CKP!@Q !$(0!$W0%WE0!"? )$D@ >\Y
M!%%0,"= --7)E/Y>\()Y:0I)Z0<3($54YP:NT808D 6XIJ6>A89-*'= \ :Q
M89_F=P&9$@4F=TL0P!PM4"X6D*6*,9?<\A!!( )1H'!CUX2B)P$ZH 4<H 1O
MHH5;6)BP6CTG<0$Y P0*( LM "!B=HUX8DQ9H "FH 3<P .OD TL:AMNX)>%
MD +%>AT30 AXQE^Q@6_KH!5CL#@;,P8(,% <B&XW5QI_@0'SX $?8!8]$ T6
M4(8>\ H8(%])@#JS\*B;01U6Z#+4, T:X*[#\)V;T"^%T -VD:]'D2G]YXMH
M8(<"Q0PD*0(+231>0'3!T80_8'(ND!<, Q[P 9CKH05!8"41"Z)*(_Z)7G
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MC)4'4C '<]!$4T4:2( $S('/&8$&<Z %E/*41H $GI7.Z1P%0Y C)?W/@\&
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MHRG<3:"6%7'%)_!#4; '/^  -2 (22#&#I[I3&\@FR[CG7Z8#< S.<  @N
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MH7,DX,4<*"20A^"=\("-#A6@848#1B@675Q95+ZK)T488$0>*C3$>S9V"6&
M$V8XP(D8#("8U \BO>.VF0[84\%%&M T+="WTJ$" G.$U D0[;" P1M:--"D
M X\PP$D8#1#G@CUX@0%U@ (#QG \NHRO$Q-HRO*DL<!=F8$!49B#/U)# 3.X
M 0/F\4,:"*"".21! 6D@3@_V( 1P)*L3(8!<G^:@!71Q0U$,V,,<&#"/$V!
M:5C2PJ2Z!L0@"G&(JAB;$8^(Q-Z8315W(PD&BB 9%* &8QK0P-6L ?ZZ>SQC
M#B?80.*4L*,=;& ?G= !(0I!"&KX029^4(++\C "#^P@"B%XPPDBLH*3!.@-
M)/  #Z+P@3W\0!VI8484O B$%H"G$RS8AAGBQ(-J\$ =1.  ":+0@B)883Y.
M$)WW%N<'-CPC#GV<8QU;P!B9  $A& A!3SJY$P]\H A%4($;+L.&.$5!=$Z
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MV,,)& B0"I"0! P\KRR2*4$52;#:+&! !!U'Y@FZ>(^G6X ?G4#""4P@$H8
MW4PJD, &5A"7(L3)#SY@F0?&\(8/Z, !;G"#X/E1A F8]V*=N/D$H+@##'!
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M)'"S*#153B%+$T$P%EK@ $( !/G975B[.Q7 FR&[!R' 'V9@%;W))>CP"!'
M"5S@ +V:GW/  Q(R(O7P">/H!QR@)MR D6YH)B"PGCTP!(0P*!\A$T,@ F [
M(C(A!1*@ E%P EE'J90GMC\0LJAQ)V5Z1FAZ$A+@ D*0)_:PL460%"P[ HOC
M!!:P-%#$LAHJ%*6F@B40D2$ J]@PEA/ ##T 8>/ 1FX  0#1 HZZ?U,2N2[F
M!15@!A7@.'.@ 2' J[B;14V@ @[0)6;"'+=6#130 D+P T7@!5.R6B5@=3\P
M!,PP,\CT 00'C_[E*P05Y DZ] -14 '8X7]SH#DUFS2:L[J2,0$$H@*-0ZK&
MB0%T<*W+89"&<P)1L +/H+?W)JX1_"GD6@K^QK MYSIY$ <. !X_\ 8>(1/+
M2Q &<6)!*RM6$0Z2LQP6$C\78I%650'SQ (R4GP'4;$2D!4Y,!7<:3@YG+%^
MVPPLTP0HG >:@2KD$"P7E@\_V@%0U !P P3 0QI]F1?!:P3_XP=?L#TYT'1V
M(;2=, 2BTP)-\GWSX"?$\K0S$CIE-&%CD   804?D1-?Y@ 1$02K [8=$1E[
MH!DY,!9"P#?V!2?<P#'O^)\#$01HL!5S0CMY*QHZ(*)PZSA=ES$.X?Y\)* 9
M#G!&[X &C1D'=4("+PD^*! GBXPQ\D:[ G*FA' !TB!'5'$2PP:G1N !<W
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M9;WF1Q3;L>$'&Y6UX$*'>_281$)CL.'&!ALX<>,BF1$2!1D\H+"0%"JX0-B
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M!&%9L,$0*#C 3!$0?$!&$@KD8(0#'$<A01%"3 #-BPR0PLH;$["@A 7O%&&
M#CHX$$(0TOIA0@,Y!-' )4DTX$01$LSAQ@$D5(FL%=4T0)$2%63A0M&$O '!
M"D5L,.X)[_ P@1$Y0' 4!A?\L ,#FJR @18M6&E$0H10@$$1'%2PPOX///OA
MP^FINQ%' Q\,<4+4;B303T;NO&$!NQ=JLP=?A%A000\[!/^#!*A#T%4%4>21
M0!Y>.-!#$ P4!,$W&+3@! ;FM."!%R!8&>G^_,.#Z?\ #*  <Z&76NC! 2X*
M00[F0!,_2, *0M"?#D0B 1>=X 3MT$$U) "-S/DA!2;Y@EC&$07.]6 $?H!
MC_;@@/L(:PXK>-HZ)' 4-S3+" +Q@QD2P)^H56T0'A#"'A@0)#_L[A F2-(<
M6J*#B7EF Q[PTG$:T!T_5$ GQLG' O#P Y'X@06"<(**(N"',3Q *-,:A Y"
M]B455<R&_ @!$/3  ,*40! 1>(T$WA("%/X<PF>2$$$,_0 "F@E%$B'@@0-=
MY  R2"&+=&A 70;Q 7.$P -OB() 2*!!)."N@H.00&>,^(TBY!!PVQK"(%PP
ML7$TP0&;,,4*O.@&!N0A"3FL@#G2YX<3>-$)%?-"7?8@ 1.%:E^P;$%/D  3
M/^@@AV,0RR!RD$8M5*P$27K&(%10 @=>0F0ABP(_Q@!+3QZB JQQ@@,2P[&F
M;?,$?%# /S @A#Q43 D9(9W(,.B''(BD"<VTHCG\X()I-> ?L[1B^6#I 47Z
MR!P5\ (03/(O<O'S"_W+J$9A,<".>O2CR2C@56BHQA(Q@ 0A$($%G.1%'?3$
M;R 0P08$(0(-$OZS+A- #0DB,(%UH,5K?MB!2"  #7N^(0?=- 40UR$^/Z0!
M GQP04_TP(<)F($,9/S -Y6%AJBA!$)*+<$[_& $#Y0@ U-U8 X1(84&E.!H
M%F@"$$1BB@K$X0=L7$$*)I'2$$1D#!6;Z"",$+?6I%0$%,@'RV0XAJ@=1!+%
M#&4J/A!#I0[B9^325SL4Z;-3A8!C$OB- \T0! >4(*6_\L,XAH"*C"4!1>3J
M)$PF\)9ZC1(#\ J"273KP ^(0 0<X.<D&F"5).RADO&:0!B48# -W,,+9"R!
M0]D @3C,004?.($#O! '"(C%#!4K0\5$,-!!G. !$Z#9.+ YB#08Q_X$.W!#
MT0QAA(QXD*P9^8((0D""J#'S$"OU$4Q$  3J2A,)&XB#!!Q%.F<\KY<Q;$$W
M\P%+$BAR$1;HD8\T0 ;O#@*7"KU>'"8P2BMF8045(,$'0L"A.7   A0H"%$V
M2N/^@?3&.,YQ+C1E"V)BU \K& PL!]&A'GAQ!STYZ"#JT!U.;K N'AR#(;3
M "^AH8[306$$H'&]-V"V%)<( 80<<!0T5*P'::P#!-)@AJB!X)L@6(<VZY4A
M0[#7" TX"FLO*P*M'B)]TNP.$ R6!Z_UH"=^0$$+]J" ;YA!(&2(6A"F!=ZW
MN6$!3-"A0-PP@3@"X0T-D&8+1#*!?Y1Z6_X^!<<AR>50$7 ,D)EUH*G-\))X
M57$0;N  "I20A1/<SP\CZ*3^[GM?)GVC/8,8@B0@\)H\W-H/#EB'(<9 @#F<
M8)"%=D,2]*>!@H"D8V,EIQ\TL#0-<%<"8NFJ=#PPZ [U08=B(8,#P!I4@T&!
M'B?001X:R -)7'$0/^B 'Q; &KKU0W^#L$!0YC>($?S &0'K 0A8&+!$\@&6
M .VE2EK@QW& X <<(,P@*H"?"-;! 54$N4+M*2 <?0%>$94P(MR@AZ[L(0H)
M<%J-=YY1'?O\YP&TRBSTH( 0O.$+"M &!E1P&:_Q((W' C*'W& !57[ !:70
MI@22M.(]=-=%(_XO"#7]P ",.H,,A2;"'E)'#G-$8#@K.("S&YV'%@2 #>+R
M P<<R@&.[: Z*&  O!91 @[L00@2V$,:-)"1>;SARF\;Q 90<!GQS8$!2LB#
M"PQ AR20V0L*2%$"HKD"!5QG7#^PT@-(0) OH$$!8=A#Z>,0!P6<Y0,:#&X>
MLF Y:%,$=BSL2@X*B!%J:?!I&CQ(1CR@00=09+LIO,00*"#-08B@6-<S& BP
MGCA-3$0BH[2 ((0 DR!D9 <5<,,;-*!9[R!@!V&(0@,$H84&1*$.)["2^4<.
MKXJJH %:D <<T!,3H$A)8 !)\ :%90;$Y2,*,%:#8 (:0 =8H4J#D/X'%A "
M.K !44,"@I!2Z*,X#H0!;H &#L :"9 *.7  <8 $:^5 0=$$4?,T21("(3 '
M_U(^ Z "2Z0 :%![=I%8).!'+8 !A!$%#+ TA( !&H &;O  E[!?<_ %#I!I
M?&$^GB$!9A '%? .?%%+VM "IU(!@L" :. %AL1S:K@40->&;A@5<B ';<!C
MS; "0M !&.!3;T "&D O1D S2.!0.8 !&. #@\ #@W<"1P$16; '?(@![:=&
M(1.(O408)K 6': !8M-/F98%&N I*M A\Z,!/Z ";N &W:0#F=9/+H*&:? W
M?\9^0#9Y61 "7K ^EY4DA# ')8 !&X ?4?[ A.A7%RW@.SL (8 C E"P D 0
M!]W4!'GA6QXP4WXP!!L@ D[0 APS,'/P V=A;1KPBX,@'^8U!]L6=HC@!%:S
M SC"C@?R#NYX I.$ G4Q!M/H 3_F%=3P11F"B'[ BRB$ F^3 I,T&YF3!6,5
M!5@W'8RGBX>0!1M0 19@2-&B 2? #PHY""N0"F;032AP BA@ 2<@'5S0 8JQ
M+&Y@ F+Q!BKI(<%#"'F0 HRWD(=@!$7P;3_ &M?5ASC2 I-V 313)="2 SS@
M!1#H!Y-1#TOCCWF@ GUX%F^@ @B! 07AC).@$C\ (6;@ 6.5!TFW"1N0 R&
M <>7!RO0AQDR&?Y[4 +287X8H(LJD I1T(<BT!UH$ (;D(?]L(]KV)=(\8:
M&9C$( =N( ="5PLS!BGCP E[H $54F,?X&V2Y J)&0T/4)!^20@<H&$K(')+
M85F9R13N$"^T\ ;/- M1P &/8"IJ6)FEB7Z< $JA.9NT>0N">9NX"0=RL&.Z
M69NV8#QJB#_3B"/]4P)%-)M[0!A[\&P[YYJ^>0BK$@TL$%&TT ,<P $B$##/
M&0O%*!OF11&+N9WBJ8:Y69Z N9N[,)[JV9SKV9[N^9[P&9_RR1#($(>#B9["
M8)_)$(=RJ O\>0SXZ9\!RI\#6J !.@P'B@OZR0N%N6/+,)\0&J$2.OZA%%JA
M%KJ=OY"@O.F?&;H+&JJ@'NH+"TJ@ =J@O:"?"ZJ;"6JB"HJ>(ZH++.JA+EJ@
M#/JA*=J;%YJC.KJC/-JC/BJA*MJB*OJ?1$J@0VJ?19JD2+JD2KJ;3'JD)"J'
M1LJD3FJD4+JD+1JE54JE57JD4)JE4XJ?5"JD=/BC9GJF:)JF:KJFM0 ';8 +
M;^JFISBG<^JF<GB*<DJG=3J';8"G?:JG?GJG;I"G@,JG4LJG<WBHA FH;O"F
MAIJH?%J8?\JH;]JHCKJ;CTJH>GJIAGJHDLJHH'J*@GJ*;%JJIGJJJ)JJ\;D'
M>,"J>?"JL)H'>Q"K>\"JLQJKKWJKN6JKN/Z:J[3*J[VJJ[XZJ[?:!\+:J[A*
MK+*:JZV*K,BJK+<*K,Y*J\L:K<TZK=2JK+)ZK:"IJM[ZK> :KN(Z$CW0 S[@
M ^7* ^C* SW KNWJ SP0K^ZJKNU:K^\JK_.ZKO:JKOB:KOJ:K_@:L/#JKN7J
MK^D:L/@ZL/%:L ;;K@B;L/+*L.]ZL _+KQ'+L/3JL!5KL<?H"N<2KSL@KR&+
MKR,;L"-;LCR LB(+LAJKLB#+LBN+L"4;LBI;LS&;LCAKLR1[LS-KLC[[LCL;
MM#C[LC3[LSPKLCM0M$(+M#>[M$W[M$SKM%'[M#VKM%1[M%.KLT.[M5K+M%6[
MM5G+L]P#MF3;L_YA*[,P.[5J2[9KZ[)#F[1E:[1F&[=".[==R[5&Z[58>[5Z
M>[;<\P-X$+AXD =S@*N#6[BO&KBOBKBP>KB-.[B$:[B1F[B0R[B).[FP:@>Q
M*KB4N[B7BZN:^[AYH+B5^[FQ&KJ="[FC.[FJF[F;.[BDZ[FK"[J;N[J%ZPK8
MFKNZN[N\V[N^^[O &[S".[S$6[S&>[S"6P?(N[S,F[O*V[S0&[W2.[W4.Z[6
M>[W8F[W:N[W<V[W>^[W@&[[B.[[D6[[F>[[HF[[JN[[LV[[N^[[P&[_R.[_T
M6[_V>[_XF[_ZN[_\V[_^^[\ ', "/, $7, &?, (G, *O, ,W, ._)_ $!S!
M$CS!%%S!%GS!&)S!&KS!'-S!'OS!(!S"(CS")%S")GS"*)S"*KS"+-S"+OS"
M,!S#,CS#-%S#-GS#.)S#.KS#/-S#/OS#0!S$0CS$1%S$1GS$2)S$2KS$3-S$
M3OS$4!S%4CS%5%S%5GS%6)S%6KS%7-S%7OS%8!S&8CS&9%S&9GS&:)S&:KS&
6;-S&;OS&<!S'<CS'=%S'=HS%@0  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>comp_0012.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0012.gif
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M_/3S]/____;X^@
M
M
M
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M#RW FO[\D%B)QVHM/:HL"A0(TN,LE1@-X9&JDH\J"*GPH!6L\^<?4S#"7B#
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M@V0G<&XG<"B(6ZQ0@[A5 18@=XZ0 !% A#+X@AV8@ES(@E)H"D88A6\G"W0
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M8 ARL H,*ZH%0*H"0 :S< A8.0MR8  =,)^D@*BN< J%4/X(2(:KKND00.I
M0AJL*QF!$92L7>&;&>BK\ -<LG "VSD+<"  'J ##@  A2"77'D*:S@ #: !
M^CD)#,  ,5"UDS )"S  )A!WKC #6_F"AS  _KD "X!;!A !JK  @VH*"BH+
M$[I\!'"V)5H#)T"9KF !"O!^C4  #. *)A  A1"9CC )A6D"<VL*<S  %< "
MZ"D+)J"TD=D(>C  !( $CA  )R +I@ !  !]JX $1LN6-5!V-79D-N:C)@FM
M6_$)(Z )<,:;>Q$*-^ 08- '811F6R&;1%J;P,"24H$''U "+H ")2 "HC!@
MN@L,FH +#H$'7?!&]S5%P! *H?X #*+@ C%$%1^",<P*%9M8,[8!!A]  B^
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M0PX,*R#PHL[SO  ,'U ''6 +HO[ ^KK "Y8/OC21R$JZ&\">X;S0 &;P"[=
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M*."  !Z%$VS=CR<I9N3#)KUYYY=#_6WHI9^>]%96S_T7OI;GHN_.?G'@ B8
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MDRFR!>V2#"#" S 0A4NHHY;$@V#@@U @N)[X ]A828:X! 3R@_JX$5L( R^
MFJS$2@#"A3IP(6?!!7<DB3[8 3NP/9]X06NLE!RD%VUT-\RCR](YA7"22TU
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M0&NS=FO%5MU2F(44" !$^.L5%^Q56 56J(X<-P57P/'EL'$89X$9=P7)]O'
M7@X<E_X%5C@%N#8%5G %N/YKYI %4WAL*\]QQ'8# !B#6<!RTG5K56 %6?AK
M'2^%&FB#68@! $@$63"$&# $'-=Q5G#QOS9K]!Y3X"B#!2B@.R" 7Y$R"]:$
M A"38"@0U?2#$$@ ^;F!K<*$ZWJ+!QB%7PB!!4&#O]" TR@!"OP)7)J ENJ)
M7\ E9/*)L3&*08H-"W<*$EB(8'H3:2&)49>548=U#B>(>_SP7+=JZ*B  CB$
M69 %1$B !U %)0 !*(  "I"#55!>5R #!6  ")@#5Y@!!W  %6AL$YB!)/
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MN!% $KX@4H )<P 0HBD.5' *!0<<(HLL<@2@AB]J",#&+/XZ"(#(AT@$ T4
M;D"D@B\U#)"(+V,$B80 4!02 P!NB ' "6+H01)(IYBTI4E:FH+*8RNQA08
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M*0J8P"$;K)R"00.35!#!*:7(TH8 8LQ"1I"^7)0(AV3,HB0<C0P0X,G]C0%
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M+PA@K (),$4,FC8+)43I0P&"@P!B@(@ J$ 6AHC(*B(0@5*80A9L"  2GA8
M)9C" P*KVM4$D#4 S8(% Y"#$X/4$#>(2 R-($,-5-8 "*@L;F[<$DJ(DRZ5
MX&!VP+C$ $:!BP;XYE:(*<"T(/,[OK$D K^8S6,TH*L/$/X.&'QP %O8(@,[
M!.-4GQ@D,/"@&,<\0%,7T)2S.H"#E!CF)X$*A@1*)0&VU X870@,N+KPB@(H
MY1(2 -Y*2O""E*R! Z(P0"T5 P;1E.X.E]AD,.Y /U[L0"FX4, G'D"67T0
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MX$<4.& '81C43VY06P7XX0P,.(,7JCE9#J1A Y)-R0@R$(<7= X%(:B##1Q
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M.$W 9Z'!L=A!<.252L LM69IKMI=E\2NELEN$I[F[(KF[>8NL9H$+_H1'PP
M L1B2MC" OB?FB4 3)#NX++*%[1 ,#A ^+V !A"&9,2$#+ &+N@"<*8$'@!
MXMS" Y1 WFJ #1Q3X:0$$\@KO>I6)5F3**A/86Q6"PP6_>#" IQ22FC"+Z1O
MZ)  &KS"[%C6+T  64I6!GR6^:[/&L2A*$# FS( #*  #*@%&C@ 3[C  \0G
M8Z2$!O[L3>KP @2(KPMLP'960+-8K.C4 5*,"QK$@06C  9_@AW8*UND@0.D
M9RTQCIU^)01\UMBRQ;6V!EF\P!^@0!J$ 2Q]*0VX4F <2PN05YAX[5E:GSN>
MEDI<0%#@0A\$ PSXP0JDP0:S12:H"EO40>?8P!*O!!ZL  Q @*ZT@!>D1 N
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M,/2!;L' .%E.NL9A*</N*>OBL-XBW 0K*R^V=N!<[R+')11 &+Q"JA6 13[
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M,P4-W<,*SXFM;]Y#2# Z ($S% \A:X# !I+'D6 XX!.'L?Z% :JXD4\P !?
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MNQP&!Y#Q"Z=UP$!DP#P-=$$4+8!!8UKP@#3TP0%+) $*;N&%#R@6 DY=P!]
M,8&W,N #?_ " Y*G 1EH8@47 (8=*'")/DP C"CXP"5V4 #-_L6,FO@# \HJ
M:UK;V@X/8.P#JEH"!KQ $;:(@!TVL8$E-IL/>5@ 04M0@EN$80/ 2$,!6I"&
M8%# !I=HP0&2# Q1/, ,F+@ #8!!@PU@X@QP!H8#.O"'+RP %Y=X@ RJ6 $O
MX*(%CA6!D0'NAR\D !AUH  P6L  /. A 3N%P08N888!H $8;P7NR0''QP-
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MQ2<>D#Q-E+H%@/:B'43! %O\90)WL,6322WO"731L,"(P%8G$ H\V#H8MDB
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M#=4@ -Q@%D#@  P! Q:@ AS %0_!$53  C#  #Q %J!@ 0*@ %1@%4HQ\92
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M[S NH+* X0.6Z'XN(2'_(@V0, A-T(TN0 '-@ -@@ 2LK 24, +N: *<D .
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M !J #4!@ #9/ !; ,@.@Z   "EQA%>#@\6J@6C-@ *"@!@( 7?/&)R8B% I
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M@0-:L@5"0/T"%A@:X(X<P"Q1X!?Z@ % 01,Z8/=(P,@F<" :X!-PC?>,C/<
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M8 7Y"@V[?@*,T_'")U$)51Z0]A *N!(H)?#"0S8"C&4AZQ.;H !=E%.'!JP
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M(H )E_Z@ =?22PX8B<]J XC;:Y8''AUJ TT*N6N -+]PO'A:/Y6W)P'@2K8
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M8@^@BD3Q$O4G"@X &[>P5V&P$V2I "NP Q/ 2HKP0X,!#&G  )OR3>(=,L
M Q=@U;BP "V0B"T@ R-@3+KP&&<0 9L *C\D"BCG(R+P!1.0%WBP #20 PM0
M<DPC @X  Y(C$S.U%7O@ "ZP Q&P,\'0B#Y$$:'P4C@@OL0B$]K!- P@X1/@
M HM& 4;1!1I@!AM@&@ZA"6K'!!>0>'Q@Y#E0 <.R!E$&!OYTLKOVN^,JQR$<
M@((NP !$NV+!< & IB_Z8Q2VT #"&Z\*&-/Y:L$S'6O?>N>L2]/T2E5?J30
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M9X!+M,XA&A#7-H "9X<+/1]QZJ(!E&).*SW3+4W!A3_!G[KG,$NP7OD*"1
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M4+&#2];J5C!>3!+%#@6*VJ"H"-(SUR_ @+$%@FYS("Z"4.)X0!'"Z,M!ALF
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MTP%V[JH%=O!"SS[P)SY<X ,9>"!$?M$"#60 8\% 00X^0(&S!2,"5<F#0"\
M2F" X0(<"(%[7O&_8(B@21U@@D$1JH&K9=2BZ>'2 _X4$10<$B([B  %1M M
MIO3A,8C$)TN[\JGW7( 7$ EH!X!:!XPA<@5_0$%!/M"D$,S$#*?C0\]LD(8=
M8348G?Z[Q 4^421=0004&Q"!#<X@RA+H)1@PN( &$A617Z"@ RXPXB7\ ,8;
MH*$K9GA!5[G6 ::(X@-,,0,%.L !%>&"!!D@ 0T,<Q,8G T7Z('("*HBNC_\
M89-YV"1$;"$"HUI&/3#,@0AP<=?\8.(!7<!%!\C"!PILL LEL$65%#;8VG9
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M$5&X 3.8 !G0!!*8@,P1A1S0H0R0J3\0 1%  ?<H S. @0DP#".#"$Q8/XA
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M>=B+0[YUXI87?C;>@U\N^.26@VYPTD /IJ_11/^<[^E,R_YUM-.MMX6**:U
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MZO#0'?/[;VMHP)@98)951N "%YB !A14] E\X $EB/O1!P:#"VIO(E\(9.)
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M@ W,7B6A$@VX5@Z(P >(H2CL@!UDP"W@ @ID0 YTP6_@ @Q@H7-X 0-H@%G
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M1[%BS81! ?S!6'[5!O0C'R3 *_!"!&A&&;P4'C3 )X@"!]C>06@ F(&!U^W
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MR;[")6S !;G :I6 *'QMV-Z*U/;4%_R" NR**&A 7[*'W-+M?+Y %_R"$-E
MWFI"'AS +Y#D0:"!.T*4 Y2(&=@0!;1&Y4Y$!SQ43AG(4%P &'S")^S ]:FF
M XW3#8R WO+! 71$"SB G@RFQWG3K2!L^GU"&@A1%\22<0$#',KN :3<$IUJ
M*#'O%8V7T^1/:.7:J58@6HB"WFF<X%P@4\B>1;I ,#B #&!3#AQN:=!7581
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M9>-" Q0(!X1=8J[&8FS 5[2 A;V X@*N276!A?$":6@ 2R3R@B[(.C8V3ER
MC6A 90/#;#]'8^&!27! [HE"(-E">"XSA&X8&#%&&?+?*HW1'O_K)117 JC&
M*]3Q'Z1K&B1 LO[K+RAW$YG>Z-5:5$V@]#Z;/9-/PZP \/Y5A7*NV4O9@0.@
M@1DL@&:4'0&L !Z@ 'WMP"^# 01X'0<,!P/<@8(N&!C0EA?8T W,I0R(<0>0
MP!Z$A<,<U#>/TT3D(!]PN+$X0!H0N+-\  GP08RK:V'DP 3@P0UH+EB4 !^
M.%BL !_@P )<$",/5 /LI )X76'X@8D6%@KP00XD0!AT\6"UF0M$8O%.@!W@
MP([+I"A\ 86C 01T]0;R 1A,@ B +]LTP*84I8(/0%=_P03P01A$ !*9:8Z;
M5!H$U1D,A0C,)Q-X10X84VD$P"9WP:"#B"@L0.WN1#'9A@B$P!Z0P/"A05!=
M.G*9J#/#0!^,*%J@.1[D0 3TD/YBVPP8*, >,+J0B(("I%\$K.U"# X)I)*4
M#\0O)( &D( (D,"/ 4,8&  ,?$$(+( 69HQ+F $%#$5_B$D$P,!1:-]!X  %
MB#H!7! 8/( == $#J 8)V'0<(/L%+#L.X+HN\,($//M8@14#K($9T!U:G(%7
M,,$#+ 8$M(9.,T4)V+3UE;!!; 08K &[,P7[.5"CU_0+0+M$F^&"\A8)7-H.
M$#D>/$#83< -Y($,)( 8>D$$B( +*-<O%&4>:(!7WG8GN7-]ERJSR3?,U46]
M'<PER&-3[,8FR",F9,?#W4(?: (,@,&B\=<-_,$ME$$RJH8?W$ =\$(:C(*+
M\.)N[/X!#'A!=# (#"0)+U+*)KS$1$C(X96()MR\:XS8<HB(GE#&X5W2:\
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MW)+++KW\$LPPQ0RS2BD/M))*%3=#<"PLK8RQK4U<H"&''&AHX9-+XDAOJ%'
MR!&8-(+B4ZC;"F7IST/;6P^Y18_3LSFA^"#A$_1RU(4D8, 0CKO1O+"!!AID
ML"&GM?[4>X478/XXPZTZ1.C !N$B9531M%J2B*:";KE%4?T 92]'._JP+LDX
M"$(-.CP0JLZB4K_[!8P0/F BU;AR^Z5.8+ZHE$=:H=L6O#WV$.H66<M#C[11
M;NR4+=(^,0,8/E8J"LUZ4[07WWP]2VHV4'8P@X((S,CAEFC5NJ0!I"3B -[
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M#V@(+QY0J0UH]@-X 48)2-#283GD 1QYC0TVH($<[/<#.X@ /=/ @8* @03
MT$!*2_  . (B A%@&7=_P0"A30";FW@ $VZ@@5_<H@$?QB8P4,"!'2P&&!/@
M" PV@ 8-A $8H\KF)2:@X>-"X PE."L?(D""F;;T!BU(0'SJ"@8-E-$&#/C
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M'8_K,!A K=91'8-A!<J(-"Z@NG* QB:&9TJ#;!X"#%X !?2M,0H"#^9((C9
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M$W2! ?Y>"13<K? RP"<T8>IDH &\4Q][+@?^9%,+X@5HH" XP&.3:!CM)P(
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M)K;)8K(9.J%-!#14F[=[V[=_&[@% ZA+VR:&VTMD&[/%C_ZAE?NRFQN:G#M
M5&&T@YNZJ]NZKQN[LWL_/(.RU\1>UC2WH5M!*%J[R]N\SQN]TUN]#;K\3H1
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MV@-^!#/ #O0]4%$$>]( @V)<IK$!,"5DVL%#XY&PPT,=G.$HI& X@.2(9DR
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M%[0J+!)8B0:&!L<(B&(%AQK/>'+0GE#-YP'0"8/$P/ "33#@!C*@ 7Q"$8&
M*0)"5D'!M!Y0&YB)8@,D0)%61- UQ4B-:H(2A6YDV($1>*=K+^"2)B3%"Z2)
M(#,/X/Z0#&Z@PO'  #2_:$$'N@"#Q)AA;IKASW@F8(LS1" ':6&"+6X!@=T$
M(PP?:(#E'G(X#Z* (B5PR!<R8(,O4  \\RO@"DA&@@_@X)<.X=P7+D"#>?[B
M%O,+1@1T>8,UK(0C6YF;55HPJB9I0#9K6%L:^%.!%G#D!GBH&##LH$PX?6%
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M 45"H!T<,. /G]#++1C@@F"8TP^4&= .3I[R\?PA (7BPU#3L*"5S/P/EV#
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MB7#WL@,IH:INV0"?B*T%.AZ[)!.0$:8/,6,@4B[OIRMMN4$J\0L'0##<NA*
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M'FTR'L?DK_[# ;ZQ.V1( 9@0$0Y937"R;0^1!RW7 #7%:EVR/G6@ %:10KA
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M9G#N*L4I9; [X_$)DA)U*=8"=D4! 2;E4U:PK--<$8 )1H721^--),-6HY
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M'"B;VHP+@=BL)PD#K@@#G7  %%;AW:L(WTL,&B" D.B"", !&.B,X&P:IX
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M^,A=+6D-ZLN 3$#L @^& \>(Y=P)%F/Q8'#Q")")"1CE#5#N*=& 2TAQGE(
M[T8,8, !_;VX+B"=37@1/GA)$3 27+OI)X=R5H.UPV,RDMD!0""!6M$ *26!
M P@&O_D"N0D-#2BF#4@(#J O#H@+3;B=XB.).G" .DB#!> 1E &&,X"=5+*%
M 6@!/N!)A3@A?]H0[56(5UB '%"$$IA?C.B %O@#$BA8!Z#-5:;;Y*2;O[@#
M!JB#.( 7U#& #U@!%"#1Z+-S$:@5#D !/T"!^- .+[#NXE!'/$"!JCF>;T*#
MCO&" /Z8J@?D@XKS/3PP != [ 60"3YP@#B(@P88'Q$HCK.L"K\D3[Z8(H7@
M@'%)DP*JI1UP@"#I0E6/#^?+@3Z@ -(CKP< @SYX 0/(A#9]")G\ Q3( !'B
M P9(@SI8 #R8$;[XT159@# P]O6A]SK0]-*9ZXH+KEX*!458@#2P@X$/R3[H
M@@$8WA1LBQ$@@3\@(1'2&C#0$%]EC!O@ [TZ&CIIEY H@_B89#X@TXO8=H5(
M'#2X]VV"*JORKP5HQK/Q QE(@+9P@!7 A:LX SR@]\\( WAI%[0X2UP@71OH
M RZ:"0WP S-HC*LP SQP (83B07(&!0( 3]X@7B'$C@*!?[\5(@["!JJM_J$
MP,>581<#"(8]< B6:/0+:(T(N#C4BP 94$J2*(&%- ,(J(H'0('@(HSO_?O
M9\914@0O8 #"VLW+P(/[\0(\^  "" 8[>  _F(_J(;K4Z8(\J/Q@6(,$L .X
M_X,^"')B/2Q5N&DDZ\HH5[4(7C('%.6Z4ZA-P(-JNH$6&)^XJ3GW+B 6]'TJ
MJ8.)N(2I @0N=CI0?8PIT5Q<P(-+<($GE8O.-@/'N%P8PP$7 (/Q^H4PZ**
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M@(3)_A6E[%)%"E00L_@BP16' , )9)%0^UJ61.LU5YR,=($(B. #'$ !,$(
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M6X2 !!L(LB:@0!<\ "YLP@5L@ N(@$)LP@:$P 4PA@TL  4X10M\0 >T0)W
M0 B(0 E$QPUT@08$&1-DP >0P-N!@0;X7WE\ @>(0 8PQ@TLP 3\W4+(P >(
MP @8Q00X  H@V1TT  2DV078P @\  XLA!=H0 G^6@NX0 M<0 =P!"AT@ MV
M2!U,0 ?8(-5]0$24  U<P 301 G@0!'> $-P(1Z4@ V H6EM0@9H@ N0 )[Q
M 0E>P)SE@ PVQT*@X URA"V,  EP@!F^7_I1P)RY0 FX !:FQ$/@@0.8GRUP
M(1^0@/X-9$ $E,0E;, *9 !\B(((Y$ '.,"$O8 &Q%]*D$!)W$ )BH!J34#+
M/<0.G!\@;%@8*.$'<,0MD  )9"$PC$()>,$#2(@FQ-\%7-@H?&(H7A@NE, %
ME$ +B(!%#",*9 #7B<(#O%\+&(4&:$ +D,"%H< -E, #>!A$E(!"7,(%J%87
MG $FP( M7$ #0&,.B  ,4  '_!PP@$$>XD($Y, '/, 9=(0,;, &P$"=V$ '
M?, '!,,?/&)LE, 7.( 8[B**Z>,$!.097$"#L44PM  %D( +T,"/C08Z?@ %
M, 9$A($,N, %9 !-V*%FQ)\&C,8?4*(&1("G< 4)= $'1/[ >=Q""8#! Y2$
M#6@ !XP :+W #HS !)! =.1B!VA O;6$!C C5MA"@V6 @!C=!M" (4+5B)""
M*ZB  ,R!*S1" YS ))!E)XR! )S>(=0  -2 &"0  2#"(0C #"""!RC ))!!
M 7# '(2(+,Q  !P6!JB!*2@ !B#"# A (11" U@ &Y0"8&9 (1Q" )B:!2!
M"CPF",@"!A" &"S! $  K;7)Q82(5GU(*$0 !"P=,&P !91 @]'$!M3!*PS
M:)Q!!%A&"2P$!Q!% L38)R2 URV :>$!! ##!W@%";#$'TQ /@8G1)C!0@)#
M%Z09+SS +83" 'S!+01#!, '*/X00$Q,@$+<P@24AWI&Q&]^!9,!PQ]89P=<
M& DXP&/$ ;0!@Q>XP,0M %N 04!&'%>$(3!\)43,XD*$ ->=P0;4";TMQ ,$
M62@@)QYLP$)\039"1 M,@&JU (1=0$SP0AC>0@*4Q!X, +@Q ##$@0&PA0M
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MRAL-0",4/L0&U%L'F&$P9$ 8  ,#C(8=/,ES,MT?!,,"O!D?# !+ !Z)C.4
MS $W(8(<B $&#, AL$$ S, LJ$(%5( J^,(,#$ CU&P-D/Z!"0  &YC" ,3
M+'24+"1! &# #,"!++0!I9%!#02 "<Q"!4# -S4" ;# +!P" :2 *UB !213
M V" (Q1 "LR"*V0 :K[)FBQ?O[R(VHY):[K*&0   '!=G6B #/"!'=0!:'U
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M7$ H?$)\?BI0A$ >; (#K($9G,%Z&"]7F$$)+(!"/,1!Y_XR"GB%" 2D<[9
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ME"Y$;EJ\:MU\9I_?)01Z'@19_N9J1N!W=D% O6\;,'  ?)B!^"9N_OH<+G#
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MAP@-O("A</ G:!VB-D(@U90 !DI@90Z8 >8@$T8'FH!Q>/H@#4:-+2; L-$
M:!V97G$!T[0APU51HA@ .],!HQG*#BYE?+!IU )@:"A+Y@ ,%XH)-T*@P8@Q
MQX6K-OXP4N"S.N.'#U =VK@@\L(*8#FP4J !C,3"FUE1RH ![%/D-*-ACNY
MHHL-!VEL,;"Y,]BH"2]D/!#X0-.?!]5)4/@U@:Q?8#1.UNZ0X\%2'!>^V,C@
M C)8VA^HL^&!,W!A(#'(@MFD 1IDF""$_P(<$)<$@,$#J5]:H, &$<  !@*@
M@)D 1(TP$2"S'!;0R ZD/EF@!&!>@ T8%VX("A@9$NBCP,1>T<Z6"%"PCBR-
M?D1AAPG6 ,:. L# 98%;,/)B I$VN,B&!/ @;@,F'O "(S H*&'#$/, 1DHF
M,FB!MAT>< $J.T+D(Y@(8-@!A@8P\6,"C/*@8+5;'K@MA/X-@L&E 5LPL@4B
M 3/[X +E'/ $F#\BN &%"Z D83<.EOO# 1M0B$ 48&R@8 <4%)B-ME6!,<75
M5U=)1(])3%G%$3+F*&762695914H6$#$E0P4F&2550H10P]7?)UDCD-4,:44
M5AH90XQ#5JG5$#+<,,455PLII-9)Y#B$E$(04>600UQ=UY09:C!E$@4R^/;5
M>_'-U]5H]36%WWX!?O5?5T_!M^" $3Z%U859_20QVD+!)1B!!J)8DS5$">:/
M7SZQB3F4+C$#+V!"@5*7.^3\!!1<1J5M$T4P\J,.7'"Y9&*_]O#X@C*9.T-.
MIOQ ])8ZS@!EU8LS_B,84:#$&?Z-EE<+A@\S,L,(%#-^!H:7H&F[.)1)P=JD
MZM4N$:ACC,X.9H\SOJ:-Z4O.@#J4,_;0Z)8^,,+%@5<4(ZUM7+X^^^,$4VK[
MEJ_Y\&^#E]S"Q Q,5G-X5:G/H'A2.VA61*-,J,:(:<\174T41 D'/&^!?L$C
MCZ7Q^D2CB37BI8XU'CY[DS4$^@/PAU=;(0?:^*A\M3_JN(47I2U?+?751=$$
M]HQ<!^85GW$Q.NH\\& =F$U($XB/AS^0:Q/_)(_:^92LQX5B4,BR)?31:=.8
M[TU>C_X7.[!;E1<\1%X-$[S.AY%+U,$6OP!$1OXPJF#X07C *%ME/L"<AVW"
M# =T#_X-=A"*,%!,<D,CBR8R1C'U_6D"HJC#'>KGEM2EH6D<X ,@T- T8-@B
M#=D;GAGZ@!(:VL%CDS*#*"+&L-7H:Q6R.%@195$K5?A*%:58A1P,<( $$$ ,
MKBA%K5QA+U>Q(EL"DX4LNHA%9L&*7Z=P!2N46*LN'HL521A  @J@@$*$$6%U
MM*.^!G9'/0(,%4+TXQ\!&4A!#A)&&@B#;=Q"2$4NDI&-9%@B,[(!$H"I1HY<
M%0TN$(81< "2EO3D)QNYB1 \@&^@-"6K@ .&$FA %Z=TY2N#PH<'[(!1@82!
M1SHYR%LP('2 U @%[@!+0/;KBJ\JIKZ^)0<X" M?Q]2C,_[W*"UO-<(-<C 6
MP/*(KVS6<9O1S-?!] 7.>Q4,%;ETI3E9A<Y!HA,3:_!#(M%I3G7:*)V3\Z4G
M@Q%/>T;M#VF G"LUD08^]#!^]]RG,.GIQURJ$Q=U&$4]%3E/@S+L=JM#:$0?
M*4B)KL86=K!#+_\8BK8M;*/!P,0\$ZF)Q$"2I1 M:""]F2]?N8*.,;4I'K/8
M1('=-&#=Y&D=Q1E44_3QHD4UZE&1FE2E+I6I377J4Z$:5:7^E*JF$&=5L9I5
M/&KUFU+UZE=?]]67OG*C8C7K6=%ZU+*F]:A<=>M;^^73G<+58-_48RO8FE>]
M[I6O??7K7P'[5[IJ]:J#-6R_"O[+4U6LU2\NX%M9W=)2]R0TH?ET:=0PBUEX
M=BUYBDE>+@&!*#P@YZ"K*4T'/M"!$GSVLO34B"A<(-FIN. #_@'&#E#;@15P
M3RBP04ED7:H)UAZTD[^ 00?\TTGEMI:RKLVL/8G4 L8&EKK5M>["$@8PH<(U
ML5R5ZV&S2LY%!H,!G;VN/5'P._>4X'?JC,!LOA#!L:[J%@8PPQ_^  ,'$'21
M"I)GA2#0RM5 Y!)\N($!R'*)+!%2(R[P;2-E*>"\0H:_Y[7PA2T<S>Z"E\-N
MS>.&O9E8HA+R%Q301'Y&Q8>6O4)5S,G$'EX "EO8  PH^8,-=M R/WR""3=H
MV2=R8/Z#L=7!!7RX1-OR  ,SV.06?\C$"^0$AAN4\A75J5K9T@"#S&Q" R1H
M#W.Z?,!@9'D-B>0#!&2 BS.TX!(NJ,-J^""#,A!4;Q3C10+P,F88I $EH:"E
M!8]LARR%P@9AT%,B/W&#&W /%R[8F5LVX!"-7&6&>%&$*.X03%MT@08PT\@F
M%,V]3U2)++CX@@Q4!0I,9*)#F[9!BTGC @JL+AAK@ $:;((+/U29=\"X@PR^
MD)A07.(2M];(L(N-AF-?0A,=FA0-NH H/[1-; ZT 0X$$HH(5!C#W?9V7P<+
M8H+95;'9->QWQYGN<.I188K\A00^<(8<:(<&*,"(#=2DD?XR&" ,]$'!&BZP
MG#,\ !!FN$ ^&2 "(D> .0NH Q\F@!<97, ..1A EG+0 3_0((*:(  -SA"!
M\+E@3Z^80!CZE*41/  -7S# )S0Q 0[L(2B7H, &:"Z"$O!!Y[39"@I"40<%
M>"$-#)#+#C;@!QO(%R.[C$,F-,&$%P$C!"78 PE(0#(&I$%/,"M!!$: A^QT
MX0P7D(!;^C"@,SA $;P@003"T$-#!N43!@@&&C00E@>0X ZXF$ 7^$ !./GA
M 68X@P+*1@$-\.$6I\$#!1:2A@10!Q@;\(*GY$*DK\>]!"3@ PD>%(H$B, %
MI+N1!C1A%*T40 9QZ,WJ;>!Z-?[58?2_ \,$[L"F7^0@ZWE) R 6T(<U3. 7
MHG@ M[^=?.6+%;Q7W2Y=-RSN?6&SJB"6OL'&VP!5H8 )>@-+Q(,2AM \()@0
M=^"H</$ HST 9K]XP.BJUH$U_(*7&+G 'GA1_SB-P@&)68$+2*,!>(%!, (/
M&*XX,$($Y*(%O(0V7" KZL!/,.(G;.0"R,(,-N!+4. 7%B!T!"\H;L$!;DX#
M%L!+\&!/)O /;J%J0J!#2L#>8,0CE,0!:&,"X$0HD,(.0F,U-"#S9B@!&NHB
M5F#J:. %,*(/(. AWLS7DD0&<.!&U 08$.0.]HLT&& V1F@U\" #]Z "5D-$
M<,$ 1OYF>!)#$VC0#A@N)8 0#QZ@Z13@%O:@ 7*- =H&!F[ %AZ@4"" %S9!
M(.9$I8YO^01Q$+TJ8 [F^M[J$.,*KI:HPVRJNUIANN:D9;X@ZS8 #S(A ]SC
M"WPC&"X 9OS 3UX!!DC@!1[@:R  =2) (+I !,(##T)A H+!)DA@#S1A 5R
M!%8@ _9 VQK,2]+/%DI@ X80](C#(9)B 7< LUK@=VY 36AQ*5!"-H!!E;[$
M!39A 5J !%I  Y+$;LJ+*:X0#.S-)DJ@0UH1!BK (4A +BJO+YA#%J?" 3BH
M#>T@ VE# \J [A)@S"*H!/912U8 !4I !&PA%>E),/)"-?XT @) P0X>1"/Z
M8 )$;J0J).^ZX$5L @6:) ^/!@5 <D_2(.LT8@(4+.ML8@(P 0_DZQ(BP++6
M8#0N0,%&("5L8 3T:Q/PT":FBQ!]\B<;*;RN#Q$)RQ'O!=W(S=ST9<0&Z1<B
M@+>>$1C6H 5NP!V_Q#<> A21(@*^(",NX&M6<2 BX!:6SB9:($D6P'K>2Q3B
M8X840QX?D#0@ !=*P$ORZ:%( !G;$1@8D)[B\I""0@.6$",TX *GS@P<JPI3
M@G<,Q0^3H@ON !^!(0/XH LXP"9<8!])(" G28!><C4BH&HHI4)V$",B+2AP
M8$_.X"+.$2-(8!GS"5$BH#TR(?Y+9.!W2F 9M:8!AN9!2&-4?N%(W&,+84(R
M72+]",H6%"!+O$,KH ,83I$X,2(ZY2L4', _O"#KNN &8 !.+N &- +U  7Y
M@+(\S=.2>(HHC=(HD;+#F%*C%( $;B$;R:(I(N!A)JTF@^$!R*(/&*X!WFP-
M$." &(![@J$#6P  +R$!EM$+(@ ,8& Y*\\&?N$22.D3XH.]K/ 6%*$!G,<%
M + #EH(A.J0%#-(!10 70K#,S" 0O]#VY L,(H@#9. 7,"$LF^X P ![=J
M.N8Z@L$,:- %[.T2%J!&/J K*X0.;4$$/",HO. ";.$5** K 6Y5+J $^N .
M7B !(/X' Y.B 0&! 3#A%V3 WJ+4?1Q@'X^K9AC@$GZ!MH#!,C B% P *-)
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MX@ &4_YXOB0*):Z8-CC21I:K;V,GV!)XLOIGB]V" CQ-B"G@ O$B#9A.D"A
MS,ZXM&[7+6C@39MKL[:8B0=X=5/X@:'*JAYW5H%*5L^W@^W(IZR7>A79D"%Y
MDGMWO&PA&'*Q.T)6B_46 =6I.1IX5:*'D#:#-C@&=DO@"77!O)QJ$]J094#I
M$SSRC^"G!89C3L:&-D(54<X@@@AY87;9;63(E+(#I/[H P=)</SH;#[P%A0H
MF4-9J0SE:W[9@C&"D8TR@[$9@QU)!E!8E<Q  V# 8WK9\U9E-4?@)?8@ BZ
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M\%]&<>SY$ 67\*%2HYJT ,9/$VA"[$\)+?1?2@25T)T,.MH"PP4,F'70LGR
M:@<'-M6A@0M=3"#4 [@ DV1]N)1P4H$7/%KF!I\T<*&@1ZT+S(CF1>"I4@T
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M8%B9I1@[B&TB#P##)61@ #_<0@'K$L4"Y+>) G S(QJ8 ![LL("WG8L/9UC
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M6^Q !I?01!@$?!:^V"(85A)!&='PO30DA1=>*$$7JHJ)%MC@$G50I"9V;(>
M\<%3N.C"2;2LO>\=I \V^,4G?JN)W]8!!31H*?A^:P>RV&+ H[A!?S-BAQ:T
M@(M^$%Q&UMR4/('"+'@('P7L*P,:!P,,*/!"TP3<H3]X:4DOL(,MNF!"&M<A
M3R@.*4I(P <2?/G/&:F#K R]AH?<V5>LM@$F1&$63+B@!?X4LP4.4) #?AVD
M#K8 ]D$^P2WPV> &O,OU^U*5!I$R()<VV4 =VJB0@W&),[S(]D364#GI_,T/
MX0Z%6>S &2@C!@9_^,1  KUL0>< !<K5Q N([1E)_L06^SZ#2+U ;WL+N"::
M"!-X'X['];)7XH.L.,\HCO&<U88XR5$:Q#_^W0_(! Q'!"\N0@ JD*O\CB.0
MP2?"8,>5RWSF>0S% LA$\\ZDP7<Y[[E-_D "8-DD K'T><]?<08&A-OH3(>9
M>#>>\8G73+U1KSK17(.*F2N2PQG9.F@XW"%%XN(++[B!IJ'C-,\4"!=FR)--
MO/[V3,F]ZVC_^D_4?O>XWUV1NOX  ^D<Q/6\SYWK@:>[X/%N=\(C?NX_@7MH
MQ!Z&AX!=[X8/^^-M<N;#&U[S:1?\Y.M.^<&C_0PPD%]GT, AT'.>\:M?/.<#
MS^%7M"#:C0]]X9O^<:N/]^*M(:1Y+8[QHU&]9K\W12)QC_SD*W_YS&^^\Y\/
M_>A+?_J?,:3N^UC\J@__^C8#/O&I#U[)@Q_\MQ^_^<^/_LVG?_W@Y[[$LZ][
MCKM?X\9GO_WOC__\ZW___.^_'N=_?:50"H4T@*Q1@*9P@(6T?0BH&@F8@$;#
M=.47@=\E@?YG@<I7@1>H@:21@:(A@1VX@:O "JL@@B,H@B1(@B;("BK(@JJP
M@BLH@OZN@((D*(,R2(.K4(,XJ(,X:(,TF(.N\(- V(,RJ((SR((^V(,Z"(0\
M:(-#Z(,HZ(0Y>(-3R(-56(5"*(54"(2JH JRL(%?"(9A*(9C2(;V5PB%< AG
MF(9HJ(9MR(9ON(9Q>(9S2(=U:(=WB(=YJ(=K.(=RJ(=[^(9]*(ATR(>!Z(=_
MV(9^R(>'4'B?X F/Z F:X F;L G7M F/6(F?0(F;R(F4Z(B3R(F@:(F:R(FD
MJ F=B(JC2(FGN FD2(J@N(FB2(JHV(FPV(F6*(N0F(F72(N[F(NRR(N9J(NX
M6(NK^(G&>(F3:(F]N(NO"(G+>(F?H G+"(F1Z(R/2(W/./Z+GB"-V8B-UVB-
ME*B,F@B,P#B+GEB,M$B,H8B,Y8B,O2B-XMB+ZWA-PTB.QHB)OMB.X[B)G_B-
MJ7B.[RB.D<B-_3B-X B-W'B0 _F/I1B,]8B)T-B)YQB0 4F+FLB*O\B/&JF/
MPAB1]^B1&XF/'_F0_KB+K3@&*:F2*\F28T &+/F2+IF2+TD&,<D&*WF3*IF3
M*JD&+=F3+3D&/\F2/?F30FF40,F3*:D&9+"40AF42*F2,0F54RF52KF23CF3
M4$D&;Q :>! '=0"682F68TF696F69OF59ZF6:\F6;>F6;PF7<2F7<TF7=6F7
M=9F6=ZF7>\F7?>F7?RF7>0F8@_[YEW8@"ZP@"Z[ "JZ0F(D)A(?)F+*0F(LI
MF8BY@HUYF)5IF8CYF%B(A8XIA(T9FJ(9FIXIF9')F*-YFJLIFJN)FJS9FK&)
MFIY)F[5IF[=)FZ?I"K10AKWIF[\)G,$IG*2Q&@-8@ <X@*20&L99G*8A@*_Q
M@ PHG<<IG0RHG*MQG<[IG,RIG=QIG,QYG-XIGM/IG0UH@+L1G<VYG-OI<8DW
M$>)'()D")04RG^^Y=_!9G_%)G_C)G_?IG_OYG_8)H #:>/TIGP':GP,JH/9Y
MH JJGPL:GP4J=Y8G>A6:=Q1ZH9M'GP\ZH0D*H?D)H@8J>1[*H2$:H"5*HB;J
MH"HZH?X:NG>>1W<;FJ$6BJ&6)Z(H>J(LBJ,K*GXIZJ,Y^J,\>A  2*1%2C0+
M6%ZR,9Q+RJ1-ZJ1/>G[G^9Q&2J55:G6JD$<R"J4P X+AYW]=VJ4:&*;C-Z9O
M5Z9;ZG.K@9B2*0NK@'%<:*7OAS2^$76ST9YHBJ=YJJ=[RJ>=H1JJ, 9(  5)
M  6'P H45PJ3D)Z^=W4[TZB]QZCD=:<P\PDYT 5@$ 9,8'::T!"?UWD?%PS*
M!C/Z<7B!-VB?<0L#%AJ_D"8Q@PL/D6>E"AIC-R/JQZ49L0?1DRHL<7FJYQF\
M4%&V<&V?FA&\VH%G:G<3(:H4V)4VT$/(=WN>RGAI0&.M1_X7G?$+85 &FX!D
MLNJK-L$'2Q<>XMJK-@%C.'>AHNIXKPHSH! 'RZ<:JT ! D   S  !, &K% *
M+NBFIK *L;$*O>&"AVH: 0L<;LH*-:  B-"O_HH:_:J#I^&FJN"FL>$*JG *
M<"H;%_NG'.M'\A>G/G,*8;H),, $$?  .] "KP &4=%\HD !Z&JK#]$!R0(S
MFL  7!=*E[<#%& E&;@!!@$&+ 0S:!  ((*L<>=.Q5, TY.T/V$#(/())'"L
M): UR<=A?$"T-(<)"V 'A5>F3SLS*T!DES<DG7$&UL0', !QCJ1<F8(?K1<:
MML _:7<).R$:O[ ['"@\4Y-\\?[J 070!HC !@9@ :8@"X@P!X?@IH;0"*;1
M"(9@"JS0"(L;L*5@").@"I.0N::@ @@@!ZJ!"(\KN:Z@N(? A9RK"HA0",!Q
M"J> AJ;0N90[!X9PJ!E;"'/0"*XPIY!Z2$B:<5CG7>E#'3+ "W=0K7G%;1EQ
M"\%P9\KF;E8B%,R[+GD5,#7D$4DQ/)@0=H P0$F&!P%# FN05\J65V@4#'PP
MC1AA%((1#)M 0T+RO5TG @9S$)> !Z;'"W6!1J_@/OS4 K^ ;T!!JI[! 5]P
M 4%B&<\;8;^0!]%3%X)1.79 8RAP3L"@"PV02[; "[F:$;_0!WU )I]@:V9D
M9]\;#/XHX *Z$ R\,+T'\0JZAKR=T30U] N0YA$A3":A4&D>P;\UE+[Y!0SN
MIC5TH0NHHPD#; 87( H/ 0IW,"-W=K5 \49\('Z#$3U&P0MS<@89P*ZB< =%
M;!E6,F5<HQ3Y.Q&*@ ??T[S#TB&9L,89,1A"[!%[P <CG+_->Q!J_#U-0Q>W
M$,89@0EQW!2[0R:*YA 5)6$\+&>; &^"\0N,G!&BT,.I$B3<JC50]'.$/&7#
M0B9_  @VA'F$7 <-@KV6HQ1I=A";\ !Y(%)XH @V<6>'\1 ]A M[  AB^S)_
MZ@$(\ B^$ L0H "DL 0(H  %D *ET  4@!H.@ &RT 8*D/X !  "IG (!# #
MLP ' ? &9#  #7  ;L"[IF !&. !"[ *-8  "W  *N *8D  )F   ^ !IA$"
M Y  &%  9# +;*  !D  *; *I. !#.  !" &XRQ(\'=]=CI>D]H9TYAV+[ "
MJ<)/$R #);  CZ)7-Z !7I$1*! "*S "#Y!+6M4%&6 &2[$NP3 !G_!/P!08
MG'0P5S$"#, \&>$")& ##A#+>Q !,* !%;T"'0 #'Q !2<$'6K(!!H,+'/!4
M(B V7C U-M %27(0)! ",G !G/$0=^  $; IM (#$_ V:+ !(H!1D<0 #53*
M,H ""O V%V$#&Q \&8$6P2! "?Y43Q^@+DGR B[@ $SP(!4-##G0$2[0 5U
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M*CQ^!XH1:P01;ANP.CRQ8Q-P";=0MZ,00Z\ TA_"()B 0NO23U\Q)Y?PKG_
M<\"P RY 5!)16%GM%:,6$0330;*&"PI@'K>@ ;]P Z7C:'0#.*7CQ" M ]#4
MVP=A38JE/6435K&<">"A"&*#6J+S((_B)*_:( A!,1]P![R@ ()F )L "&(S
M 3N& E21IKSA 0:0  60 !Z0"*:;!"H0 010"(C Z$@@ ),@Z6HP"Z90 14
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ME,\^R.&3/S81Q69@7E"- \:H<L"6-$9H[Z@,_ #&# MO:R&4!C*ID6BD_'"
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M!@]> @H%!WD%/_@#57RA79GM44!EP8K8"\C72DLM!OD%#: K>K5KA&:US*
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M WDC2"I8>R6BI'@%%VA!,I8<-7KB)U9:(4*AK/W)" W6+OQ 4O) $,0")?2
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MS'U"!#P 2&C"!-A YSS(!,! JQ?(+WR N8R 7IB!261 "[1 !( -,.P JZ/
M!-Q/,FY"C P>4TP <\1!_WA%&/ (!=C"+5P +X@ <PR@VNP',/!" KS"'NB%
M5] $8%"&5Y  &-B"7N !"MB"\#T\HD7\M/DYF4X\%A)6*!R-5.6.%X $,,
M6:!!L+R"P>/!A$B309B!8P2(H16 3^1!S^7 F-C 7'S* KR;+63&)D3&)1B
ML/%D!SB&5VP 'C$!=GA%'H2%#;@ #'A!&H"!*&3+8+F 7G0!L0##'H1%!U1,
M\I@$!_YT@:7;P!_\@4F]/=P+-T.7:43/M4L3)U)+&A^:U2@L0-&O>0*4TXW
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M0 9DT (7K& 41)L)!VZ3G3$"@P9@F,E$1)$!72R(!K6\#BX0 HP_1* %(=C
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M0;'$E,@&6K"""$1&%Q]8 0DR4-.Z7F(/$: 7'^K3 BJU8%F[$H$91M&:.ZS
M%B& I$PNP8<()&0",;T#2E^0S8F,( RO: T>T*O>NOY7.VVBV^@6RL;0.>Z7
MY@+*!AZP@0Q,X%IG" $:8,.+!F#R%Q<011@Z-"".?$"N5?Z2JP+R(XH"X.$7
M; 7&'0*[I A,9!,3F(BA.'#:30Q .+9(P"<V\6*;'N8X"CD#1UK@'&#8P#J8
M.(PH(I 1#@&C 3 "Q@0ZRP"YWD(!M_ #!,HJ6@#CH@()F<@7(K"!B6R@F3+8
MRP; T $^R  0?F#"(F^BB_<&XP(HT.P#\B,2DIB$ U_XP!YLX(<_=(&4 %8T
M40*71 (S#L$-Q6ND$S>>JK0"*!?HPB<P@8E'MN  QD(NKX#Q 1)X@0DNT.X#
M;+"#+VB@!1;JR C2XH('M" /:M'(!,!P@RX8 !/ "(4 C*R)XDQ$!&M(0P3
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MD&L%&$LB(@L%(@ 0@*&\0N #-H!>TN !4& %# 482(#K*O[ 1X"!S#9K)#9
M27@! @ !%!P !6J0X&(+G"+@-EQ  [*M7]8@ :2)!#K@!9C@ N1* R;@%]*
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M0PR5(LAP SX@2T9!!"X L/2C SH@'L$ J78"#XSL"^AD!$X&$#(@ S;@H]*
M T@@F8(A!^R45.=H2D/O2!?U;XQH<!XU/7-B!!0@UR:B!1*@J_XT)G2A5R
M'5'F*=O%*2-G%V6B4"5#.";B%_ZN:2+2(/L,;R8H22T$E21Q8P(RH@NR+T"
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M!\R ,BC@!N%6U33@%4,"!;X@!\#@#G;E!79,(40 6GZ,L'"@"S)Y!7$N)BX
MD[ZN!>I@!$8B#I3X 6ZA"TQB5VB-L'9%UH !KAI@+\YR>17" 38A#C1C5])
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ME56%%C9UU8478CAAATN9@@I/%_YT(<HG:!2 2Q<P//9 > M\< DN"8'E10C
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M )3!"Q'0'A, )6<(#!>P0F9 (%0YE6NP2&_T2&CY5'4P1[_@ *L$#'W@'R$
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M"@80 8> ! "0!(X0 #,P"VX0 %!@"B!0 &/0"%(Q^C'@"',@ ":0""80 'K
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M 0'>D/Z%E-P4<D65&1!(@( 43 M@#!=30."051R@H$:=%$1 @ P6  &[59!
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M4F,W.\BNL(B 3["%!% T3&@ /?[<-1CP.7.[ #^XA00 +$UH/UN(  8K 3
M!@<HK@UP,Q+H-G9+B]:#+ ;RBC!@ !N0@1)8 - " ]=*@^R:@*_*@9AC ,QJ
M/%N 0F!0!-*[A4P,BV!D,#[PK0G(A%!@@-G"!1' !5X01@?@MK?KN E00B1B
MNZ]P@0<$!!>XA#5 @>;["@+\BML#!C_(@+#PJ&C"K</P"A2P1AD8 0U@L B8
MQ@_0*S"8+3Q@-QKHN LX,Q'@Q!+H@J\ @ZAS@ ,#A@FX,,C0L9 #**Z0R!B$
M*F[:)VT2,I,SCTV2*1Z<BP_(OAL@@*^Z!((#AB $AA'0*PS3JP< N@BX!6#
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M; P4Z !ZVX$(&(518 "VE $0! 90H*L-T#5_! : /$-= _X&NK.L#_B 4'@
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M8/RR$A"!XN* 31C+K[@$5/M+4?YP@&@#!C3(+@I02"3B@_;3H0_@!13@, V
MLPOLM/;[@W0$"P!$*'D"J?8 ."0*@1L(A@78!'5[A5^XO#3@!4"0+^V\ /=:
M@^3["A53S5?XJP; -ANXQL1X2,3XL?I\*992C["!I/FTJAH\A8RI+KSPBAW(
M+J^XA +X!4WHPY-LOPY8.F\%!@; M# X  R[.5M8@.[B@*4#ADT8 ,C3A 3
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M'+!06["!'."#"_"*+[B #M@ 9;,%Y&V+\;2%#O"*4/@ K[BW#N@ P H%_;T
M%12%^^TP^N6\O\R!I>N"H04&,*  ]C6WNQ!,R&HF,]C2+5+.%JB##<"T/B@
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M+0JL8+#@U;!X1HX:"U7S(5$P9$D#S+'0! UXHU_XLK&X!0I;*./4+E'U-_@
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MF2/BO$ZKL/""WUQL,A8!4/@*(%V!%/4"YAZ+5R@!#<"]6M, #8CC6WB!"]
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M^A1!$S 8, PN^(2'0 Y<'1"BL $,4 1@=B8 D\% DZ@&:8 ]^/-KP Y<8!H
M0Q,A5*@)'8 % P9LPP8.#R8"@Z H)K ,>$!%^,6!CXT^N$3-G&E+ ; U&H!M
MFI!T9J8%?UZ52'!1 RY>'.( H_XP,D$P%S* X6)@"T_77QU 7HB0!I>=#+C>
M@BQ1 E>> UUZWBJ[(P&F5Q#,] PF010,$A<O  O%( ^N'% CW*'X -@%D&$^
M /,CP(:?8&LB7 (V 0^N!:]HVNFIE+924[=+J?)0((&! 0/$K-)S"-&) 8?F
M!'#S)L A/0"0^"JEP(,A!#-FP1D Q=<, HYDE3(ER\0!4B <J,*@8(XA#P@0
M45B0>P$%62D&-%(28(ZO0DE,F6$ 1Y008 Q'9@" #5EN:]#!4QPT!4(((ZSP
M-@HMO$V5#"L\!<,.&_RPP]IH0P,  ,X@T1:.@&G!A9E:^&(V8%;P IA+(I!)
M$XM(L/Y!E%#08$ I31K01)-1'*A#% ATG."7!PH"!@<4>M+D 9F L>'%%@";
M2287 -M11XM*D$&43]98@+;49LJA!5L6,'*4N5;$9291A I)-=$J *:$'&8Z
M0X29*.#CQHR"X<463"Y(,0),9GI E#HX\/(/7B)8 Y178(!IID\>T&6F#NK(
M8RHC#Q"EK4\M0H&)F7AIX!8N9U+DRMIX><%0./<(AH%/E+J@#F"^X& -/'+H
M@P,.\N@I%(OJ<  /4;"<*8X-O(02&%U$Z:.!36SAK(4=9L+D@5]Z:L'&"?Z8
M:0+59&KA!EC;]0J4,QP Y@X'[* 6F%$>L%.4!W@AT2L@.?[#HU)@ZH I C]F
M"L-3F?B 2BR(5].D#Y8T^22!=F6"X8699"C!ED_X.$"C>7%Y !1@T@@A+5Y"
M22-?/+"%85Z-<!#K$EX<L#/<8#@8EN%!O90!C[0< ,D!>('A(#$SI.[#!D4Z
M(%6IH?EHH(Y0L)1)!K2 ^:2!7S;X0A11F,CH@I'.S<0B/&"ZP(M01/'"(@U
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M]$:\D(J.,!>!<,+ DC+QB"UF4H)YJ0MR+;*1)D((C!T!PP4]2PL@:/, C,%
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MO10 ( *F6$4A#K  #@C@!*I0  -NHP +S,($ #"$*2I0@ P,  .N2$%S8%X
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M0 ('T&)@@*$,!N42*(#M9X(#*&H'N*DVSL!B/D%-;&!0<*$ (NH+8 (&&-\
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MWD\3KW B0Q#X%MDM%;"51F8O@&C9LYE=@.<.,#"T@XQK4+ R4EKJ+0I:HC@
M&S"A\')'D\:!P21#'20'BH+I4G3!)3>T<$LFHB %YI>1?85'!&%> ,.U%^#"
M=X8TY/!+ ]';$:D&>.2Y!Z?T)@T*L ,P-E"VILCM$CM80$@JL! *G&$4)CO@
M_Q11,1ADJB01F%2P@H6K$)IB5ZD*(0E1=4(1BBJ%O%+A"DOHPA;&D%6H^* -
M)2(P8)0@3&+*PR8B("<[^ 0-&4!(#CM F0<DQQ8): K-@'&&(JZ(!@T)4T)J
M,A&LR/ZI?<!XP$N"$:0S5(P$+_L 3J 8J16%"0)+<U!(C%,38(@@3 WX#$6
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M2*M9%!&!B82T)"VU13#X0!!VSG"QC!4A"QL+V<A*]E0U9*?C-O!'7(A@ QM
M 4%N0 $13, /TCM,,##+D!8D1Q,:$ $%A-8%!I 6M!_0P$)$H0%UH6!]I[S
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M>))[RP%%''!^$^!!K<@' $,1>% Q$* M]6A[:?!=P4<!9J$):_5[&U!=M\
M2!$':<1^A,1^%S!?R#<1=E Q.<%#Q:<!E($+&GEUH(!64!8!6\40TM6.5S<1
M72 <\G*.-\0'$:%\&ZA"UPA^/HF#/^E_[^:-MG=6W3$*)OYV"8=H!R\P$-YA
M!BZ0!A/A!^/"!T%W 2*@"+QP";^ !S#'!XP& V  <W1S P?#8GR "2Z0!\'@
M!3(0$KUQ S( 47P ,J_PCV?B FB0CF: 88<(#'E 58&3!S# +0-C S=@1Y8(
M!NYW43#P$IH )BC'!Z_P!4V!"31P Y$GF(=Y)B]@8J*P";> 5L'PE<$0E7)6
M$G_P,\&D,&GP,B4AF3;P&7Q@"V"P2\  "'_1 OBHFYKY$K@0EF_B!P]P<D#7
M!2\P*;C@ A1@!XG%G!.P!K]P)U\0/V=Q!B^@FA2Q"39  Y_Q"V#P GS)$'D@
M TP0$FM  I=@8YY",M9I1WP  _X[8'FVB3V7  $M,)J[] E@TFF7H D8YIMG
M46!E("<S)0,'$PQG\ #X@P?KV9YS8IBI\PL0)0H BC84H9YAH%(_\0E><)RB
M\ =_@%P3H0B?\0<+\0MA\ )G0$X60A$B<")V"9\$ZI2)U9\V<#!]\ E?\ )-
MP8DK0!B $ QY("1^\!)]  ,- G1+HPF:8 <ML)((T0$\QA!V\%VA,)<7\0DO
M(E)F: 8O8 8$<0F?L =I8 O/Q0?!  @$T0>8$GD,X0>8DB'/=PDN  9H,9NC
M] NVR01L,:<[("2?(!. F8T?")3:J*@!R(.'"H"/E4(^>7H\.8"):@H_*#AA
M$(\,<?X!.Z )(ZI $3"58#4@'T WF1$,#L8''2 <%&!B#\"C#78)F<  H&$6
MI',+3- !BG #F:$4?9 &?N$5FD  R_4 'W &,* PG[  =\")HI #IW8#YH(6
M'X "?: 3#C,!:1 &!M 4.% E.3 !1)$#&; '.0!$H'!2=;  +Y$#'0 ([UH2
M=N  +1 *?N  A/, $(46$) !*! *G)@'"L46.Z!6]P$;(@ #ET "5 0&'T!M
M@*HP)+"P)#"2P% '#J (:U!,4/(LBD25#U X#X GAH(""N0P#. %:\  59&Q
M@"!=OW Q"HL+>>  BN$5MA !.[ '%\ $.Q8!8PI>+1"TP?Y0875P PWP9B30
M I=0 I>(5 ^ !FN 9<UD Y\P B=B!Q. "4S0 (&9 $R !P^@:#!S3V"@ (3Q
M!120!UT@+@5S 26@"<5) J)0!W7B'&BP,?^S)6=P!@D F#KT)RW CP&I3Q0!
M!O4AG 8@MA)"+AKP!UV@ <%@"P#%!P=  CGP=AB!!J03/1.@ 7:0 PIP6 2P
M V-[%R. -AR $QH0/Q8+#'< HP R(1-P :*[ $31 A_0!R@0*852!^TS2A1P
M 760 PN "W\  220";BP1Q^@:&"T"7?[!V!P 6IW!SYA PE@!GWDF\%@,!J@
M:'40*9KP &805WC K')R!DWB8/Z?@ *>@P,,0 )U( H<< %XP$1<&0&7$ ;,
MH6']6P8+\ N7D !E. &>LV%\L <1, J_L  .=I(N\F>ZH LEQ@<+@(_;2*D<
M[,%$^7EU$  !8'T4L0$/T 'EY3DP$1P\$PH-\&01\ =$)5(3@AQY@B<HH&B7
M$!%@\#)H@ *X ,"@T0>7 ,!(-Q&? #W#,3QP8@NV0!@8D08[!1M<ZQ7DRQ"Z
M,"'J""!3G+L, 3L0+"0ZK E?' JZ0#I"XJH]0VL%@U9Q($4,$6<5@5:X$0P+
M8'E?,%0ZB0L*@ MQH!4D\!\N8 :*P,=P,ZQ(H1;7X@ ?6Q+.>:61THD"U (&
M=E'SP?X6O  !H]E$%*$!]/4E<?0*#-"GLUN>,!H!Q*<0! ,,O,  [ (,&2!G
M?$!7?S 17&$2&9#$P, _#(%-:"&=IV0NK_PEIC0!/#,1"(2Q7:$! @(,#2PF
M*]P")S(1R@L^R:',:($+$$ 4!/F274',DN&BC0P4YV@@1+$!9G*4!?.I.HFE
M#O-?(T 9?B"'32*[MY2YS61BG+8)#L ?.Z +(K!.8,"/Q5L1>/(!=/4111HI
M@#"Y#O 9(A"]SUQ$N,$0<N$4$0 *@D0VD?(!C@$(/N$_#9$<?D 06)P#%C(1
M7E 3MW @L20GH:!R:R!+"^$<<U(GE<.I 90 ]/4 G48"7OZ@"][J-N/RP=QX
MU*X'J?%&6:UX"0=@ -K2'4<)+#!  $_% "U0 CP6N:9T<]N#P\/!&Y=0 7?G
M$R.P!V7L DR[ 0;D!54F _VF"<4$#"Z@:-L<$CL@ C(@JAA1!YJ D9>$16@Q
M O8B G^M,!,1!BVP&+>L%6   1$P/$;< B0P'25,:V"4(3"Q%!01 4VA*"2P
MU1^P)(F-%F#P &O-8TF9&75@4K9@!JF]U1M@1[8  WO-)L_CR/SB "#S"4OA
M&?>& F=D(.T' R/P+Z-S()X\I<CJ%9[A!W%L3-]EQ:#Q"3:BVANP2VN2B QQ
M!R+0:L(1##00V;P1!T[#(H\<Q?YW\ &;  %Y5 <6,@&==D $EAD/\!FZ;9BD
MU%>*'2UB$AFA"W2SL\PO*0*AD-7WE<Y& 6#\Z"EG0 !;S0"*U,;LS ?\R,L6
M0AP,00)5438/=A!]5Q)OU4PO1@$!.B44X5PH@ +@'<M>JB<< #&OX "Z,#.X
M8 -?(,0H<%\=P"'/'"DTT&?IPQ\Q,R B(.(RS! M%0SBF1"PP0<CT (CP(]$
M#@Q !F>IDP.1'3L4L0.1'1G-,B=%A.,A( .P.C-$ 0H.P.,HT 'C6V4E("2L
MPH3=R'W5*(*+2N>'.D,L1(T'^'HWM EH61+Y^RF7L->FA G+[3;D K)5P0'[
MC"<M\/X?/)P3:< !P=#/:&%8R8(BJS&L.MD"O+'-O" #(F <57%H-] X:&$&
M3K.@.F0O]4LZ: $FMM  B74#+X#&A)8#I)-8X%+H%_'3<JJ3G:% ;)06O*#$
M,%<'H[ &LTM2-:D!Z7T&LVM8*AX[&7 M"@(M''2(G%@PHQ1E&PX,F: @G9HG
MU]+9>>*EQI$T^6,+?C"[$Y$'&#[?V_0)(LX05@,S7KJ4@(#(#]H;!!$*([.J
M+PE]HR42(R#$T9.*S701VO,_YUTP^*@)C;S?&]4VO3P1'VU!0!<!1&$'W&$'
MR#C$N/ +MJ @>( YGKPD?X '%9E6)CZW,(H'U52V'4 M"?ZP$ F?\_@\(1?@
MI1>0";)!$6F "P*.$$2A)W:"T$LT\@YC!B$P/0Q@>>WG%6*>/@/RB!)QXA*A
M 2.@%1G CDH<#)YD!C5AP"_Q!Q9BY2R-(A!P"TCW"A/0,:  &SJ;!H ]YG)D
M8!^PIMPL4C0O4KA@"T@AB$Z#U$,9E$G-YTWH^$?=?:UP>Q6@6F> !F:P+R3;
M192Q 310H>*R4U.\ PKR8/(B "^" B&@"QD_$6EP 'W6 3+ "W_@ +=@(\U#
MXA.1"?ZL0Q.""\CK N;"5!/R"WV2?^$RQ6[;$([AXQ@! ]BW $T1 B_ "WX0
M%G50D?D4)A_P @6<0]L4&6!  ?[G,P%GQ!!UQ!!>< &O\ H7(" AT +9;P 5
M]P NB@:(A.$V8 #) 1"X'ISYA8;"+V )(YP!5H< GU +@*'AD# 8L# 41(F:
M$ 98@TL)1;YH@ G7!AG (I1I.("/* 8($U*X<4NDI@9_<+7X .P.!9$)^3 (
M^2 D,*-(S?Q:,P'A13,30KUZ$.</ URV.DP ]F(#+EP1_.#)D#"-!F 7@5'H
M( I4@SC 2I3 =8G!'V .\%[4  -8'*!108VZL$/NC80H$%\,-@',KS0.<*VU
MDS8A+@9H&@+=# P%74T/,N%*  P/4+7 +AF8G'!"#F 0^"C4Q(=S':X[+MCB
M(P!/IOX%MFR1>."3<\(.-I#.5CE;0A?(I>-$ '6K0Y?FKO$ V]""UZW@P/PD
M6)&PQ0A<FR#L-1T!& R_[^.G;: IH:8 :.L\^&1K V)@2%  KS\6>.66$AP
MQH87+/MB E%N42"8+B:XY1<-/+HH!PM_R:".2XH#A@_W-L!AQ +0^"4\8&0(
MX99/(+@D$P,P >8&$=(RY113>O3QQQ]Y!%)(((OTD<@CC4QR2":-1')'):-\
M$LHH@ZR22BNSO+)(5$Q!)2@PPPR*B1!$,%.#3_@P3+4&<7&!@P_P F83$CA
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M4A/S>_##%W]\\LO_OBZBS%=_??;;=_]],4G SGOXZ[=?_ C8"XK^^_OW_W\
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MRX?.7H8!-:, Q_!P@7@?R@L7V!F>/M&!>+/N$SVY0PON%0%,!$,$#.# ?3]
M@@NL*R&R5HLH'F"+"<B)YB+) '9<MJ$-V*P$%% HF$)AXXO@>$'2/B]% ^;3
M[81B!#GHP ,H5X(S7.+%>?H 6!;P9-,XX %>X @.JJX\&[S\ \'H@]CCM@,L
MXX("]LF#IJQ<AZ!;-M0B,+L#]FH&I996+@S0 (B9[0(-; !/P? *2KQ',I!/
M>.W $->"2N""#'  3SLPEBB6F@%X_4&I!O?, C1P%%'\E%NV$,$'-&#/MC]
M.7_0P+[GQ@<7V$ #OVC! BXPT?X/N-XCMEA[&!80 3S\X6' 6(-R6@"&"+!.
M41UP@?=8WX$++"P-2BV\>'2L 0@H@EH;T("_85."2Z3A^&GX10<FH_MOA:H,
M+7C!!#80JCID .:9*!56>"&"'/@ !X"7A' !!J" 3_B"CZ$ IAFPUM, ;1$)
M/V"UM&  \6. GDF(6Z"U7,*U7?+ ZFHE7:.NZ2)!1V*C'HJ N+@%![@$41
M,-C H,B!AY$!0A$!*P,$ 9B-$% .84../+ % ?@"F^@ AH  RA$%!Q"%2R 5
M8.B N4D [%@K8MH#$4D,OYB V;B%"7B%4!  UM&$!!"%5U@ ^[B$!?@E""C
M33BZ]/Z: (7R@ZT+ <II !+ DSRPLTZQ#,PP S_H R_H %Z@K5!1!*"P@PA(
M'!P8 6"X (7"!0@)!0;X"P+@OS1H &  A0=(E1L@%5M @<F BL2ZB"\@%1I,
M"$"8-33KK UP 4#@@S4(ED;4#$5H$":8FXO(L%&C ,W !1)@@ MP 6L:A?31
MA."P!0+8#CR8Q!7@F 7 %HU)" C8@\M*,E$P &54$$R@*Q+@F!<@E(0X#6#X
M@P0PEA(  UR0"#O(.[Q"QLK(@TGD@V,#AC1P#U& @+2R 0<(%1GH"08Q#\*Z
MA :X"!L !%N("6  A.+0QU A&5%!C VXG O(A%]@@$:Y!/X'X 5;X(^@R(.#
MX([Y43J1N(&'L04':)1/,! =7(/)> 4(P)A 28L+N 1=6(#)V "&Z)N$^((7
MHX ,P!8F6+X7D+DGA(U?R!]-8(!0L8/B\ ,"L(_<:40QDT)@F(#MX "&.,A@
M\ *T:)$<N8$'2)R5 08& (2&P!J12$E=^(442<@T;)UD X9AFXP.@(T/@!>!
ML8P)-*2<$ \(>( .  -M8JZ3DB0ZNJ1:NB42'$$I^L!56B!>4Y\_H, <D(%0
M,+$PB0 F" 4O< "$$ '-^(0*F(PN:) & (,TP(,/*('+5 L1J(,8Z2:$L 4\
M,(,'F)L(,*T(P)B+L,)Y08&P6?Z .CB#93P#6Z# $*@#-'BQB^B -?@%","Z
M5Z \.[L L\R3VGP UDD*A;B$HPRF6V@ :RD!J@0#JSR#-2B 3U@XB_B%3&"
M.$ #/'B ,KB%XD #ND**B7J R? #!X"!.EBF1[FQ&P"%,, *\5!%*".5#XB
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MH(@# XA@1"D CND-;)%$Q)(+K($)Q\U([OJ '8" N/@%MP8[X8:!&Q"KWXF
M%I"!%F3<!Q V'N,N#;B!#^ *&X@  6< A7(!V,@#!["!H;.)"NF""]#D"Z
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M;$ !.]C  "'R@@;\D(,KA2(!(G!!UVR!@@B8X1<7^$ <9.   Y6@!8 809)
MTP(;@ 9EC6, &3\Q%CXP  U?<("6_A !.Z1!@Z"X@ ;P@(L+=($/%P#A"QY
M CO8P@ ?:,$OSI !/^Q@ QWI0 GJ@(($!-$CMZ" #? P ?X<  ,, ^Q"!"18
MAP]0X 9F2$ F@#&!"Y3!"PH(8A@NP(<NR"X/!-A!'1ZP V#<@ 2:($$'NL4
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M@@%I1L$"%0V:J8%&!)ZBCV$A\(N.Z->L7N*#4%%0HPF("@\<^(2V<5T'/G
MJLU\Q0<B$-91V6 $,.@2,E\PH!65H$8=\54?YIINCWCUW&FUP2\>H"8S\(X"
MJGE!#CP"@X[CD\$+KK!  5H4SE4(3A9N"LH'HB>69-%+FUC9)WCWAZ6)X#7&
MOLH%;+&)"70DT![A0!R"L2A>T" #7IF )TC88S[T@0&+0H.80N%?%(1&%/:$
M[LK,@'7L_*(."K!%!$3%!_QZ) *U!,8.7F +[0K,:;DYUR6XYR/Z+$K4P(B
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M\!0@'  :C$)[C(!(Y$ &X *I-1,87, KW$(?3I7!70(#4/[+#5QC"7A@*#
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M2#"A8 #!XY:'&(0/%^GP"# ^/&Q!@P2&1,F@BQ$4V@!"ATAH"9<&-E&( B^
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MP@1NL)!00'(%&VC)"I()#!'4X1<3"*4H-@ (73C0!=),2 D\*(+SE<@%"^"
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M S  #C4(0 U<H8("P.$4$6! *0XQ T.(Q3"F< 4+!N (.0"@#84(0 Q.40,
ML,$4$;" ;%(P $3,X*QZ@, !2L$&LC;B!#&312E,@0$$>" K U"!*R"@@$*X
MX0"CB_Y!<MG6"#((8 EB#4 25@&%)!"G=JJPR"4.4(!'/.0"E[A$ H*A" C4
MLB7 P$/!+O!+&TPS!XBZ1,'.D !\ 6,-+?G% UZ1OH2DP5R?0$ >CG35A$S@
M$WXHV VSTX)(;8( ' 9&".KP"0;$Y!,M%44$PM4!".5IE@O(CBT2L(:*[&'$
M: B%* S0I(Z.I)PB@% #I@F,#]S8!<E,@$K^P.'S[&!(FGC #1M9RQII8);
MT"I#?&G.,&N ?PYYQ92#P0!F=4$$#AM00K!3$4PP "&AV$ PZD!38!P/& ]@
M:I[N&0P(7(H)0U1F\R:,"S1H@#D.",8ML@@P(SV ?U 4Q?X:V B,.&Q9(<9K
M3RBVC()N L,%+6%A0CY@I ,KTP%T-M6J;H"0-7  U6+\P"P9 $-=E.1A> 9&
M)@BP"5PP !A?6 XF_NL")@"C 3WD!; C,"P-),D %-$$LDF @WF^:@.SM 7_
M%-+M>;84!49:\1J"00 T)(0"[<HVB!8 C#HT#QAY8(""MA<@ANK4AA. H9AI
MZI PM$03\:. 'Q*R 3Z(8@$.N0,,=X"P5S1@0PM R*/_[.<+J/M(0$T(!.Z
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M 6 D#<0(5@I@!]*@ R!MA,J@(D0A 5"E 5R@"[J@DL1%!/Q/613""^QO(?+
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MP*_N3A8*@0!F( &28!;XHA%4SQ?D .[<0 !B@ S(H WT0._\KA#V+O)48!8
M+P$&+V@(@ 56817ZR@V0( #@P/X7N)(-' $!_.X0$,!E: ,17($4X& ),F"]
MA ,I3($X&L $)N#P5H#Y? $1", $9*$"(& 59B$%$&#V"D$P;X\KW6 7DB
MR,!Q5.$O2V$5AL\4$@ #'(>B9@,!#-/V)@$.!& ,9L$4$($,2H=PXO(F4,$B
M@L$,R(UW& X7(( #7<K'Q"6B1$$#Y/!(U&<3*@08P*#H3*HE#&U6-,$,%N#=
M'$(3(L AQD03+@$3/L%?C),!((00,P$%5PP/S  ,FV3&^L,![.02/@$7 &'$
MQL\UE?,XUV 4F!-$&"P"2@X&^ <&Q>4![$01/F&41"&;BBY>OE$3K@<8@C A
MN!,8 OXJ(0BT(IB@2#90QT8HS2 LUH)D5G#! .!#$\Z  4 *#&K$(9K$!3K
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MQ2%PX.ET80249?V *0P^ 1 ^(20?XB;^P@/X,@4F( #JAF7\SA0F( $6 !$
M9P#B"@!48 XH( "0P!0(P .P @3T !'.:A8.00!F@!4LX #:0 D(@ $: 15<
M@6548!5<83?88!+ZA@*HKVL$ "H-MO)6 +T0(0- 8!7>;@DF00&20#A*019.
MCVM>)@#L+@4"X UD00(20 Q60?;&RS#Y A%4M@ P@/IZSW(:X"_T#BIG(  @
MH (, #!IBS/K52A# !':( ':0/X63H PLT_[C@._>@BI"H"-RB #$J(,.HV>
M^&>_VL,,&B#9P)#C@J$!;.$,'&8E%.T!Q24">B@84&#<\!9\QJ^;, '4G&P-
M,$(E  '90@&)@($$XF@':(H!>D@4"L#'#,[J@($&8, 6/E$38NT#O$W](.0!
MX*,$3JT+\. 3** ]?E$A-L'F(*S>SB# S* E/J";@N$"A# A' "F'.(#F$JI
MO"0/#L#'MC$[',(!%"$1$R('GA44&*!),N'%@!<80"$!L@,"5*4$0 [5)B Y
M7>("/D EU@ %X^"_+BY DA10_TP3;$$!XB 3MG A4&!40B'6ZJ !BN4!BJX$
M1J4%;/[HBFY(C+H@D!QB#49,!M#M2E_U0'^)QV;I0Q6 R@9 .A/U#"[ /P<X
MT%()(Y)I A#J!31&V$0!;EL 89SL53* X=HL0QQB!5;X UK*!1R&Q^X BCQD
M A2!%Q+5$[VD.C4AEQY5EY;EU&"@FRA @F1@X$Q*.8!)@F! $_@@3\, TG)@
M.6P!XY**%]D(A#2A#A)@8>+C $2"%QH@283D2$K@0#I-#_\@$Q*5#Y -#R#
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M@0)-K_ZBG[/W*30@W@1UVAL3'Y2@YQX0:("Q2'^0( *5P'BAP0YWV$&DGL"
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M( I11"!Y(-'$ O*@B0\8U<' R(&1)C !,.#B#H1]P0+^(.,[ ",".Q#%%P1
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M$ .LPH(EU1=9L3?KMA@#TA@N 2'_ A)?8"1V=R0=\ $PT (NX 6V$ %#% :
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M>"H\!9,!#'0+E558+= "TW4#DL@4P6 '.($+08H)A?>5OP !.$&/>R)5M[,
MF$$#DJ@)<LH!L^,B>J(!GD0# K@^78 F+Q42W[*6=-$WC;  ## #%(!-C@
M)C +V0:%Y"10!2 JL"8' 4 !2+  $[ *G]8RV#0+2A  "2 'IK   G "J]
M"N *>O!0*C  (" +"W4(JZ  #A"$LS8+(#  )E !T88( ' "%3AKOG"M"0 '
M4R@1LSD8L8E2?2,3+] !F. %LR@"UC(9F\  9P (%%!F7Q !BI &"G R-D !
M?M % H )1366 >";%W #FK #!?Y0!T6E/PQ@!HI  2?C.B'! 2(D Q9;/@9@
M119ILDR 7I^P 'N4 'BP!@9P,FO@ 'N0!PR0.R8R "UP"3<@5;C  %W !Q0
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M!?%WFX =V\IC ]HH%84<"FC@ &)W$KHP 6@@"MTCVYKQ"Q10!J)P Q]:&9H
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M8MT" @1)E!<>$ 8OY. "FPF&%R+P@ NLP2,KL)3V,I6#'_T"# 3Y()@4,!-
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M6H$N- R,#M3,(YJ80**.FH8-?,(/F)C)&>X,C >(@@2-_$6C26#0I)JFIQ2
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M#4F$*R:(1=@;[2O-!<'UW"//H7D3RXT0],@.,F(6$O6PR5O&XQH,<-Y@W"E
M_=L  7JI,+B%"7@(16@P)2J>4,JR.M"?@I 58" !IL&/,I(CNA*63+&#[(&M
M%ZH,/B@ 7; Y8("M%N"A.K R8  $",N+LUB 30@&!I@)WUJ*3)$!D5L!R+$!
M/.(]G< %% B&-0@[,*"C"!(Y7*"  L"$YED(6\"D,[B E/YZ@.C(O4O0L_(*
MI'GK@%N@ +JX.Y40A2Z,BP7HN7O#A#](P!VP,AB@.CR8@#]3(P[P.0>XMFLI
MB) 9E>PSB.TQ"%$H@%$0!=W#!5N@ 08@B%A*%#[\@#E4A& 0D[.#Q-+P#6YB
MN]VHQ-QX#;ACL> P#DVDQ+6)F]0(IX9AD(\X@PF(%SO8G3@R SRRA0\(@0X@
M ;BPDJ58@ ?YA2[\!,C3! 7"!!)X@31 *$UQ@.^ J7_;%S.(@'B)*8, A0-X
MF.T@ >M@" Z010J8"3LP #,0A4 CO8(X@Q4X"R_@@#1H*M2! '\1%]NI@'C)
MCC,0N6"X $21@0L8@0M8B%\@C_Y<*0\I^@B%00$=T0Y<N8#ODB@&P8,$H*J%
M2(-VK "02H.4X@!4T80XPH6U"BVZP,?Y6H@<4 !E48D;N  2Z!:+P:LNZ#9@
M^(,("(9?*($($ $*"('"F"4->( 12(L)&($/^(!> H87L ^%68$)J!F#T( '
M(3IDA)@1<($O&!1<N( /* $2P"-<P)G0>H4^##0\8!1T^X@X<  14!A<V -&
MN8.,@ %1\0@<H  2F(#-J(,(0 %JE,#>RP'=@1-7T\<.P ^Z\(,%X"\[6,8)
M"*(6&,D6T "?# , \0@_* "?F8" ;*1;6(!&J@,): $<<($1L 4*V#H4< !1
M\ /.R?Z!R)R 1KK#"1A* 8J8@N" GN#)IE2P"DJ4'4#%"$!(N;P TIDX7<&9
MB;@!K*(42_$(+7+""$!.$<"*'(*(!O@%/H" $NB\,X&\2+1.8+C$LM%$&6.;
M3YS$[+RFY6BFZ2B-6[B$PFC)LU"=8'B>CR#/MQB:@ABSA_"#HNR,NG ,D5")
M][2%2\ K@P@6D8"*C]B$2U =GWB(J5A/L_ "!(L T(L+5].$> ,&\T2P] 2)
M/L0$O&G/H;@$R/DK17"Z7[@$"DV)ETA0@^A/^%,=\@R&8-D$YQ * #6(6SC0
MW[J$)@E0]?R(K>M/"A6*37"ZL\@$3<";]WP%$<7/5FK15O[2A-VJHQ+%4$TQ
MTKI04(VX489 E"OET??$T0/%!4 X+XV8&ATUB.9H$K'P"3[ZB.: 3X-PJ1X=
M&C:EB"8Y,X^@BP %"AYEB#\8TH934OV<N%;ZA*S$!5Z(4X-X!2N<4]+H"QE-
M5(/0!;Q)SX2#B<0(T$D5BHWCT^N,1+7S3O 4U5&5IE#TU+ 9Q;"QA7<A21D]
M55$4FS"@@!;X&HA@O[-3)I70A(5[U69*U5X%5NO\U6 EUF(UU@@[UF155A0K
MFU#-SK<AU6B=C5 5SV6-1#2UUF;"!4SXTV#8NFP%UW 5UW%5C6$EUW-%UW3U
MU-=P5FF5UG9MUMG8SK4YA5,P5_YUQ==\U==]Y==^]==_!=AC==??@%:S:==Y
M33N$11M3,-6 !16'A=B(E=B)I=B*M=C4&%C8F+%4< UXC59G]5AYO=B1)=F2
M-=F31=F41;O>J 13* 67=8V7]<Z6;8V7-06.G8U)>(V7M=E2X%G6>%F:=5F;
MI0V?K5F8!=J8#0ZA_5FB'5JD_5F@)=J6M5F<U=F=C=JLK=;3B-/-&ZZO312P
M%=NPC3"OC:O-TXCA.MNT7=NS55NT!5NR)=NQI=NYE=NN?5BS15NWY=NWS5N_
M[5NVK=O!M=LFT=N\M=NVQ5O%!=S#O=O"A5S"E=S(I=R_55S!1=RXW=O%W5R_
MA5O*G?[<MVU<S&7<M>5<R]U<TL7;T 5=.%5=U$7<1)&%V94%5J!=VYU=5\A=
M5]!=6>C=VKU=VN5=VO5=XJW=WS7>W$U>WF7>X15>XV4%Y$7>XE7>Z@7>V<7=
MZ_5=W6U>Y^7>[]W=[W5>ZTU>XIW>\94%E57?]67?]G7?]R56*)#?^:5?^14#
M,8 ",LC?^N7?^;W?,>C? !9@ ,9?,=!? _Y? 1Y@^BW@ E9@_KU?_=U?"88"
M )Y@*'!@#"8#!+;@!^9?"W9@_&6#4>R0-%B#$T;A%%;A%6;A%DYA$W;A-8!A
M%Y[A%JYA%K[A%<[A&.;A'GYA'M[A'@YB%!YB'S9B' ;B)->.X2*6824^XB>&
M8BAFXBEV8ANNXBC&XA.FXBC>XBSVXBZV8BVN TX@XS(VXS-&XS0VXT[H!#5V
MXS>&XSB6XSFF8S)FXSK&XS?N!-0(A=V+GU#XXSX6Y-TCY$$VY$)&Y$$&A3]F
M9#]V9$!^Y$:&Y$F6Y$J.Y$N>Y$/6Y$3FY$,N9$NF9$P&Y5$6Y5(.A4U&Y4[F
MY$4V95(.Y5=VY5C>O52F956NY5M695:&Y5;FY5WV95#&Y6 FY$_N95G^Y6)^
;9&'&Y4]89&,V9OB%YFB6YFFFYFJVYHH-"  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>comp_0014.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0014.gif
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M\/#O\.;P]^_P\>OS^?3T]/CW]_7W^?CW^/7X^_____CX]P
M
M
M
M
M
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MN__]\(^__.?/Z%4@Q/[T/S_^[X___=\?+_TW+/Z7?P18@/0W@ :8@&\U"&C
M!FW@!FO !FR@"H. "!=1"H" @(HA")WP19GP!GM1"FY0"G>Q"B.((9P @EK3
M"6\P@(D0!IKP%YS@!GZQ"%_0 F70@0(1"!(H@6K0!OOG!BZ0!6U0%X+ !FK0
M@(M0%XT "!E2@5N#"(-0&)D@!HFP+(M@@=S#@@VQ"H% @HFF @T@ 0MP !$
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M8F !&4("*+ U*.".@W$("="0Q&(*;+DU3;F4I6"2AV%_;E")(8@ (XDU6?
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M""'0 !K@!H/P .E9 5^ $&S  1O F1<A 2L B"(JAQ,@CA?1!@8@B>NH"IV
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M)H !1*L)(-  &X &>\H!&8"M92"OG>"H.)H";(@A*"F5<T@""M %'BF5@T
MI8 ("M &@] !&6"'@Z  ;+"L&)"M#9 %@\ %#M (JL &"1 &@$ "#] );3 !
M(4"#"J"UG\F##-"?B#  'L &:&  U&I_)&  *^ &66  %B@""A "XL@%$/ &
M@% !;#@&#C (@0 !;-B/+3 (7<  2P@!#U &;^"XJU &#: "@[ (D3L((D !
M^Z<)6M  7Z );&  )^ &7Y"HJOX@N&T0""1JAXO  /?Y!A(@ MF* %R0"&"@
ME$4YA1:PG6_0 $Z( @2@!6]P @K0@2%@ 6_ !@Q0IU_0 &T@"*[:AAJ  6\
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MSPA1 IG0 N+-L7U;!@@PE,Z-$ \0"('PEP+1!F(*"%KHDSU9Y@*! AR $!C
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M%'"(<LNH'O !!B (9:#?A1 !2YD%"@ !'>"$('"J?_K'"B"'[,B&"G#?FNT
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M8*<&/!3#5PQ88FN13+2H !'Q%E0E RW&/$$FTIPKPP(,S*,(D4XX<&%,-AJ
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MX@$9:,&MIM-#!CQ@$&A0;$BZ4!$&@  %#% 3:9B6 1&@  %(<H,"4( "$TB
M!)Q 0"$2]H$5!!,"I>"?8!*P1#$H(($*4-T@&N#9!@C'IRD0P04$11T)7"!C
M$I@("B"P @]$(#M96E0#RL4BS!0D!0Y0P0<8:A:JJ8 !+ &$ DR@ A-,  2P
M[:XJM*  %>SSEQ01@V+_XM;BDBT!N%MC*23  #:,,# ;8-1?.*""!Y1@C85#
M %X>\(#@8<  $)CP QBH"DYH( $;X( ",)"=3 S@8J3)  (D( $()& $;#G!
M UA0 O[NL($,=2E#5XX7'%4DP$-@"-L'/J-4 "W *.$C6P4PD (0D)4G:$@
M"5KP  (EA -:U9:];C/.PH6-N1I8@01 P!8ND'4LF&&! V;,'3/$SBFE0&-X
M'="ZF3# A*C!C"8FD($53( #I;C@F22&@)UPH@)@EH#0&D &IS3@:A)X) ;4
MQ($*U#8$J<&L4R9XS0:$0 4*V&Q^'J "#FRXD44#07!(,#B>Y%85+*@;%]K7
M":6NH (9*$4G2E9;#D" $V! P D.>JTR&* Q%I"71=^, 5EYRU-92 !4+N"
ML56R, 5511;DM1BMJL #AD4* TQ@ K%VXG:9V5<8$B!L[?ZJ0A )H, B$*&
M$JC@!'AQ&>%DS1$)-(!CTFOK"M2<&PZ89DX(@(-3'KQ3ADN/< 4Z$T< 82-
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M0#CDA"JTPS?X-WL$A#$L1P5I."_4Q$40 TW0!+YCQ%+(/29" S9H S=@ S9
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M0<@"NFH!#>" YQN$#6B #AB$-O <CG !#:@GP/. #""![,@""*@ 1G**0/
M#2"!B!.#,NB6#7BX,GA3ZPF$+"@$#=@(-/" N9H(+8  "O *PS,),^#3%6 +
M3F@!0!B!"V"!1)F+70U557"#T7B\%AB$6S)6HM "3N485W6##)"IN02K7\D
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M3DB?'*^+_*IVV;"GLZ3HF\(?9\D0 \V"3$(F)/E,@\"G:_YW"JI2!0\ 3@R
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M*)5! C0&!P0%0()D:Z[COIQ,<\ )6XC-%H#>9LYF.S;'^I4D:VA"%G!@,I(
M=+RF;IXD-38%)V2!OYB! '%FW2"+1CKE0@8D/,9C]O@-4XAD-UZG0JZ""2"
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M?Z# :@R""HA!4\3M"H!!2<"KOS+A9JC O0Y&LKHE1? IK&A"&:3 F)E<%ZQ
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MP0E(@)$V@ 6H#02L%0DXFBJ,0 3P6FQ-" *\ 2)L0 .( $Z1Q2(X@ BTC@>
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M&$0"E @:+  +0-=%%$+(25<!P/[I!Q4J)CG R)X5W8+'"92""CA "4C;$+E
MS.CR"W_0@P5*6Q R"KA  L14)\#9&(  AM4-)+=  E#%53U8"&1U)@Q B$E
M&,@5<ES ]=P/=VS :I" 9X/V>$G !KCR(2UU!J!1JBS "FB!]5P&D;'L!"@/
M!?1J32Q""#  "!!F:K9 "!Q39=R6'U-*;QC D)9')IRQ"G6"D=9-$%B'O!R
MW"$H%_S.:K0/Q#5 "W#!;<5.!7  DHR;J)!W7&$ !+@$"UQS!I/'"51 %RA'
M"::H"=ST3ZC* U6 !@C<!'!(*4@ !I" "XP&"G5"!F< I>P$8O!6%OR6Z!1
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M)P3" I1$!8@7<74AF]).&;@ "2! ]S2 %*4";E#$0GG =4O$GJ1RJKC/=6!
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M7'#C"QL!X0!/'*0,*6  Y"0P!H>LH@SJHM'*5O( N6#  EP ! DNA8@M>(
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M[*)E $$$="<- U$$G$@,$FIQLD!P2H'N1  ./ *OX !7 OY!"PEP%;H@!%A
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M+( #(&0HG/,V.P$U_Y,_W_-!AR) V7- ^],\^9(V7S,])S0XY],ZNU,]Y;-
M6S-%530ROV5%7?1%831&971&:;1&!=,42--&=71'>;1'?;0QV?-'A71(B;1(
MC?1(D31)E71)%S-(F?1)A]1)H71**S,ZXY-*L31+M71+N;1+O?1+NS1'TQ!,
MR;1,C?0UW6"-]A(1/!!%'<?!]E,R!X(#^*\ESH \]/,\!T'7/."[J*\[]1)0
MY=0_]Y($N)%#.S0O0< 0"Y0EW( #WF9/<1,_$94Y@Q00-/X [@0UC9+N/5<!
M!#KB8-Q4+]F44A>3$VII5*\T7Y+GNA !(%&4)=J@5:7B#0Y46S(  R[  C!
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M CJ@ 11($$8F;9A#JE1!B9].!"(@1RSE=3@@!#0  2Z%"Q;@AS, @HA&ECU
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M%P-$F(4#;ZPB1@+D?;&9*BLPH ()%#R4$5$(B,%)&P0 1UH)%222B0B#(3(
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M@DX4(#FED( "!E&& -S% 0@ 7@#<DX +J,($!=@: Y*C@(>88 "E4 $!MM:
MIH @ /XL& ,"$%"&%02=$P(H02FXP"Q$$, !95 ! ,#] %R2!A&\ST]U*@ !
M3@P"AX<W@$3-$/129 $,JVC 0S)Q@&9&(/"!4(&)*P__^%<:Q0$HPRHV8(#X
M!<"J8@D% QZ","!@"@RP ?X# 2=@/@'0"2M@'GZG"@\  4OU  ' "?/#$ R@
M$($  &%P!@,  B<@ @#@?@$@&8,@>H<75*312-3W!=5"(B=0  _0>6P"/0B
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M$00$4"*3X@$%8)"-$0(*((P/D/X<;W W#9$ "*"/G8 (!L "!6$ =Y$%"+
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M$7>J, *D&:T#$ $#0 %*H08 8/[-B_!X$4!O<8*?CE<0 % 3;2"3#P  ??,
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M<,"@6/ZM:8F-6YT@!F( %U#H!C(R""U CF(0U 7!'2GG!FQ0V[;]%6C0%F<
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MYQ:G ^_U<CK3D@D>]T:Q@V6T:/X:C9ON\L<&!G"3C#F.$5WN:K$LVJ%ND5
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M$-9\;R7K!FF!@(BF9Z.4$0R:]W\ !E"  R1@ 0W8&C8(( 47P4CSM$(0!D%
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M''#!+0(;7(4$,K *!T"@%)I@@ B>N8). "!$&2V% 2C6,>J5X #O:T &4/$
M"UCD#&[01 !$H I T&X0)T *"02P" SDBPW-R=D #G&1T.C4#8$@*H0"T):R
M=$*KG?Y8WI6^8$P"K!%8;[@G "B'"N;]"P1KE$ 0+U(!!IPF VLB9QU=U0D%
M9* 35ZJCJ=#B.#2L @,)L(A7I%,XMV!@ 20( 0D8L* L>)*3 A E4#@9@$P(
M @ HR 0) A (O<F$! .(Y>AZHKA/*@"7>"5!2S%@"D08P$!SJE@8)$%,B G
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M!\B1BE@$YH*#Q&.N59BD'(&#Y,P13K@3V72#ML@$"-B?M^"$-U"$MR@YYN*
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M@0A8 60E6 I8A"C;BC4* :=X@PH(@0R@&$2@@!/P  ?848DUJ \)@3YJ 1+
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M*6X# VX!#C:#A.',08C0MV  1*"HB)!?^H4>#"B?']5?_I6(_\VQ]N DOX"
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M!*I\$<*,!;[!EXB%Z"BGJ'"6X@$$/*G(07>MP<%7)QIHT4DG+2!@@B8(L?$
MGS)VDH$*#@RR" 8@; !"*9PXIPHB9P:"P0D;/*!H@2(4:X%2(H@00@85$"AL
M"!R0H/ZBKP\$TLD&(I"P02EB,"#!%X.<J>6S#U1U1@3@4D 90H,0^D4&\PZR
M2B88>+ !!V9U44$($U0)+PH98, %"!)@N0H)'(2 P6&9A8LI!0N+L6,&'G"P
MP7,H="Q0EUJUH188[861@2JFK >"*A2LXHD%I7 0HP4AQS>JT$,3;= ;9DA0
MRB)L@##4FAR<L0@:/EY8* 2F(++@4A @A) )('"W @K05@5"&8OH^H7-(FSV
MAL(85*P!";6E7+3=?I6RP0DVZ\6!!R$C@H%V:G[1P 0(AL%%%P-I(;,J@[2@
MQ1>=F*( BJIDH"@(+:SRP'.(0/ X 4\NLH!4JKC 09:$;OX FBHE:)I!R*IX
MX)T"*SS:1A8";> =9$%=R@4$3I5PPBH-',G) OJJ LBE70ROR@GA;N"TV8@T
M\-PB#&B"" )*E;RC J5XP7<8F@ZTP>Z!.- 6O*6 T*@J(^S)Q98*"<+ HP*9
M@<$#6JT@7$XYPYE.@ (3<"$,8$"$"_@2OUW=+8(2C!,G)* 6%;2 3Q@#VP,H
M(Q!!=$ !>4'#F1"R" <\!R&T418!ZN >$RQJ#)D(G=I4P8$O=.XHJZB =QJ
MH$XP0"M!FR 12[)#-U1 *2 0P]]4$27>F4$5'9C=<R1D/X$$@@0G,$# 'M"6
M3#R -6^P0"<@T!9$7.H-]UL4T/Y448&CJ.@!G?  JE2CB0>TP 59N, (5/$
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MD LZ,Y!$,( 3I=A=@1)0BC*LD0NNJR8@N- H$FPF<_K<*U]9T@AJ2B^#"ME
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M6N!DA4D5B!AH@5)H EPL E\,@N8APA9,CD L I<VR4"4018<)T*\07N4@7&
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M66S GBB$H F$&F257NA*!!P)0B09&M@,":"!&&Q&8I +N490U#C%&)P)IH@
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M[6A""^R)3'6V9R<')$D'%C$ E94!3^>T;\$!(,#T"32*N:) *9# "@@63BT
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MT #!>:&6&UC!%Q@P1Y\U8!  $X$%,@"&3ER@!%F00.JRP$=5I, $<=P "TH
M/QY-8&.+B)HJ)' &33R@D%=K@"I(D+KPC<!]6?# OBA95'*=!A$/8)XFG$C
M.FI!C1R 0Q:09U2K=FL0&SC!_51A A54(&PNR, 7/)""1=ZR?]<[004:@('
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MM3TX$@@A$C:!$!CATQ'ZO!=9N[?<S=N8PVO[I3$\%9!\H%/8$ 9HA8NQ#MB
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M4( 1O&$!\"F#I892E$R4@H8C<(,#(G"*#20 #D%XP""X ( RG.$!7RC%!!R
MAA$,0!" ""$@+C""5'3@ '78@A++ (!6+0 !&!B! #R@"A,0X M;", 64B&!
M F@@! 'XP"9&<( .K"$4F3C%"@*P BT$( 1[-, &-),;$ C@#:5@1!T0,0A0
ME$$ #'# &=@0@ Z$@0$,X 0:W***+   #FH(P ).L $ 4)!G6U" Z@AAQU18
M0  9"/Z! "Z@"C*0< T%^$ J0I(!$>PR%2P(@ E68!=)#("7*!@ &;P   2]
MYBJ@8$,$%K""V7'P"P#(@BHN4  &0*X"??%  #)0Q 2D004!4,,;MMG-% A@
M#6)P0!K>=(H+#& 3IHP "<YH" E]0 !!& $ OM )!RP #.H\ R<64( .=
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M58@!  @8 "'6(( 0C(4#"%A$+_X!, 8&?T$5<:P#)UF@"@%G )N;>$TJ&)$
M#Z B PJ(A"HBM0E)U $0%JQ *(PHY J<!,!C80,;7E8*1,"A#B4YP2=>,YA-
MJ ($"P 0(ZX<A$R9L !J4 4<!D#C333  X080 C<, 8"\!($"? R"0)0@B\
M0D2EZ$">N6 I- G #8Q1J0E4(5U"?'@,JHA$ C;0T FD0A(*^  C3)*%,S#B
M%(<80 O@<@@X *($ A##( 90 E6X 5VJ@  OL<LN (2AQF6(Q!<$D.84%" 2
M81! "E*A56FJ8A 5/>X!)M )5C%F 1S8M A4 0HTO&$3LD;$ 3AP7 1,0+@.
M"$(:&/ZQDNO1SWR(%8A=Q2<D^E')K"!B:V'A;4"^LEM$(Y*06SN!H;U>2!+8
M*RU"^GWN?P<<@,<+T_CH>G  ;H+@[V.XNQ'^<(5;3^(NHCC$2XOQ].UOXPL'
M^,0=[B$Q'<!G%BC# <90 !<,I0/=CL">"K"(ZW)! #3NA"J8..H4+, +AS;$
M 2B@@0R,( 62B, $4E*'3XW  @OHQ!DL55U-486V#WCZ NIZ H8<P')9F$ !
M!-"%,A0  QC@@ BR<+D#"* #H(A$"APP  .X(;U.,X$!$-'0"PQ" 1,H^@B(
M>X$'&*0"$D!O"U-QG$,88 2<.5<=7IVM3:0B!2U4!2,(T?X! @RB+4[;A 4>
M$,A7<Z$-?5*%%P(P>197) (40 LC%J"!4YS6 \-L0"1*4?AJLVII$SA%!A:P
MB%!<0 *'4( '2M&F2"J  Z?80LU*8( 3A.*:">G  B(1_098H 0'P),&B)^*
M->>\ 1]P@P$LH($-B& %I0 S(VXWMP(4  QO"@6*-T%HL#\2,FXP ,"R%*4D
M &QP"IP0 14@"0Z0 :'@&AS@:H(F !; "7&V @B( @Q@= , !H- 2 LF %E0
M"FRS$IJ "OU'$Z60"ET  &ZP)Q8&!@" !H<1 @B " MV !60 4:746QC,@[0
M 80@$D81%9E .74P=!J@ 2.  OZ@4 <?L  #, $=<2-O95EL53T6]SZCE5EH
M56_G=E?[!B3(8R,=(B$C0B'1 S_[5F]WE2$703YB6#]O52%Q.'$"UU9BJ"UL
M.(?[4X<$<8<9EX=?N(>".".$6')H=8AGY7" R(=* BL%D )DL  @8 & @%#(
MMH,]& HI5% &P0@.@ !DH @%E@#WY08* #Q%M@ 9L"YFL :@H'1>IE!G@@$+
M  IFL$,&H"F2D HC$ !GD@$,P @MX&!P$  H0 8N$!L., &$0$@/IFIND **
MD HAT%]!  :J4 <AM :D= ('< B=0#GE6 %C<09H  H5  'I80&)EUY!,#R=
M( $.P/Y;%W  F= & 9 %J* )O $'!4!%G7-&A- 6+K0Q _""+   ;] 6*Y )
M(#  D]=)I_ &!> !;P(*BV!.MM=CJ( !#A )QA<!QH< :U$SH: !(UD*&! !
MF] WBM )%+ !K@$"FV  &* *A5!?H+  '=!E@:8 @R!<O'0(!' ")K0 C(!=
M$&  7" " _ !F!("U$8&YR5H%9,%7* *AX  M1=('J  FQ!4/14$ _ &@\$(
M"' !@+, *E 7*J *;R  )=!4%_" "[ P[J4*+>"0AC  )E *=9$"J@ 48[!J
M<_D& S""#T !> $@J*>49V  :?!A7@ 2", ('S92I2 ""/Z@,1&V :I0"F3
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MA& &FX (:8 (FY &=3 AH$"X:S (:?!!A!L$A' 3A! $*_[P1[GA!BW@!8M
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M$'@[LM& 04A#35 !9UJ!+UB$!] $0&C"#0B$3H@O#U@%XU.%$:B#,BB]+\"
M4N  1"B%#5@$0NR$+U L9B*U/VR!3@ !-:@[54"!>LL >0K '2N!2@P!-KBT
M54 #V.*Q1= $#%"% *LH4LR 1Y0\#\@$#M J1F3%,G"!7#/%$M $!\B$,*B
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M,="]+)C).K!%1#C$#?B"!7U-XXHD,M"]%LL[+5@$O,3(99*$#,@JXVK)0="
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M>EU5B%U5< $16T!89=A,R%,+8_[)!2X#+1B#K&6]W2*A1L" 2 H%O&S;1?@
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MS\L 8'*N2"J#TKRE*5>#+Q"Q01B!+." 0<@$[!9156!N#ZI#TX, R'8Q+L"
M0D@X]9PP.B99$&NG+"@!%]A:-*B ]4);>=N ,@B$1!XSH&0!%'B[-?YC%_N"
M#-"P4/[< -.3 -R#+1-@JDSX@.VSJE*0 *LR]$9PQZ%+620K3-Y-\/]60Q8
M;18(!-(,@@WH M)43Q"4@&KU++'$K( ZO! H@PKOZR"O*%CC7%5( 75ZR5+X
M@!YTO0QH Q$079<251GNH&]W)R[8,A9( 13XUS3,6-.%K2S0@M\<LS)@ ]2]
M<+L:0"Y8QM],,T[[6XCBPS0C* R(Z6L3@16H< O+ *,\@U50.5@S3OP2 16
M[K\NI_@,W_J4WE ,@2LT0R$TK3*'+2[X@"X 7$2 @$#X @_X CX>J!(0 ]H-
M69B7,_7\PUK*77VW,U@>IQ!7,>Y&,I@/SF^:8$20 $!@</X7_FLM7]>4XN#=
MXH1>R@0WJ*],T#21RH0R3&Z-TH1. "I$>,OZRKG/ND\5:ZC=ZOLG>RY%["7B
MP_OGTL<.0GP%HZA../Q>0G%:4K'U DC(!WQF>@,D5#% @/Q9X@0B8S0G%*C=
M"H3RZD9)<H-$8*;;@FP5ZZ5VKJG=POR ^BP/$H3LPGP0>DV,>!P/VORCLGT(
M!03.IR6Z9U:]EW2ZW_U." 3(#H64A>Q5"'R#7H/[A;!JHIO,CSTD' 2U2OW;
MHGX4=GMHXN#79'QBXL^N#<'$Y\\5]R!%Y#NORH3?UUM53$3>OJBS^B"UE["W
M!(A.G50-<K-*%<*$JSBI,E5*5?ZGAZH0O4F(2&)"A($6K<JT:J"J58@0 AJ$
MD!-&5:4 15ST89&;AX!()*H(46*I-XL2<CI8:N# A:J^(-+D(5#"129WJM+9
M2=.&BID"_5399J0J32B!/NP9\DVBD Q5C<5:$&-$L@<9K@*$4A/7FS]7#<J0
M<N)!04@SJG(S4M-!54S?C*S:5B#"08.J-L5Z,B-AA*7<F%2)2"A"I:4D1K8<
MTNU KU7']A0CB!,)-"$1=B8(R**;L8L8(G(#,G$A59D8CPWT9NW'M3G/</JB
M8O5F5:$PULFMEFS(VX)1/F1<DB_V[-JW<^_N_3OX\.+'DR]O_KQW,7NW!Q*#
M'GNF%?XE6$A_;_]^0C0G3*@.C/__?ZMDX=\B7=S7QGYE?#=(%G<!^"!"F8#@
M!H056JA=(/M]<6%YFK!@P@KU<3@B0OZMAIV)&:4HWHHDNO@BC."U&".-]LUX
MX8WAY9ACC=SQV".0Z/T8I(]$&GDDDDDJN223.#;YI(S?K3(DE%4"226-6%JY
M)9=,MJCED6 VN>*,*9IH9I?EB;GEFFE".*6**,;999MNVGDGGGGJN5V=>_KY
MIY)] KI=*5WX]V53%"+Z72>-H+C3(F"<J",79B15RBIB.,C7CSRB*>=J952&
MIB:9J"+JI*DJ1)!J)8:GQFLFBC$6J$6"VJE*7P16"E/9??ZAB:K='92)=%CR
MR,5KVAV$1B"9*,@75=@%\H4@^?TJV1B::O3%>@BUX)%WF82A;';&9J15K2BN
M8N 9(QUT$" 5!0;&0V1FM A&O*H2B**$[O1&?ZZN2NY0SPJ64IEQZCMP=I(,
MI&\@9P0[J2"6SMC)N Q'N5TG8I0A48$VJ9+(%VU8"U@+(G*:G1B*L*B;R@+S
M54:O"'5B:K"K?"'1*DP9B\:06;1@GQLH#-R)!UF93%Y=IAX4PD@;W(6K=WVZ
M43-V7W"A2AM8$RR&">6QL#5?&#@V\8,IEE(!R"!LIP:MXZ6P]'@\9M) V-P!
M@@@@2;MJ1@)WB=&!&!FHIL()7_YDH$DI&W"1!0>G<E"XQ >Y00)XB&3@8A9C
M3.JI:B&H(3 79*N$ ;!H(P1U0C.IPH46W06"^2#)EH<(!CL=1$)E.B:&^9S8
ME?#:("%,)#)W%'&W" 86<I+!%RP8+T@&88!@(" 8B %"%JJ0L,(7%W2BM:J;
M9N1!O^&ML,9X'"0;&!HKK+9B!:D;15XIDH;!10A??/%!1;+ !1%L#7:J.$,)
M3C"2+&PA!&5H 0AV@D %"HA_&R*!!-!0"A:<@ 6E"$,#P+ (]PSB!"1P3QM<
MT((0Z&XB)B"!YTA0 38@I X0.($F0J % D*$!24PW2):H(4/T! 1)RB!:H:6
MB*&U)_XA7S#!"7;RN"VH0@LC:,'6P'8"DVR!?[&C&1M(H +,S<0$;.C$!LRF
MAI%\@00FD.( 8Y<)%)Q@:V4X3E9:D 41H $%)6 (&$B@0(*$ (+N"20*3.4!
MIF3B!"?0 EU:X((/7 2+(%#0(DRX-4"0D REL"0F-:F2+)B@0:\+ >0DTH('
MN$<,)"B!8^C%ABR@@ 29R((G7I>)093 !!1B@PEU,@$/9$(3HAP$%U)0.Q/2
M,$(J,,'6$*%'#[Q/%5GP @E&HH8LK$ $^.)""\KPAD$(8@0G"H0(0)"ZA S2
M#2'0Q.9>EP5%&$T59EN!2=[0@=6<P%)J2*#)M";&*;'@>_[&4P4@)$4&!1$%
M$28HP>C:P 44:"*,@SS(_L3X$#24@'><N, &*K/!$[2@%%DP%5'*&%!5^/*3
M)UA!*<I  A> (&H"^9#I5!&&!"H% B0 UBI. ($VG$$$-!T)&TQ@@E$)M0V"
MB(D>4^/(@;11!4"=B G'E8(,(D00$A!!)V9W HF5@0LJ6 4;"AFB3Y8 DBN
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M0* JL $X @]"E !2#((^8H#CF8P9X*,JJ$!!KD 6).0BF/Y30G !!X0(&V#
MX[R3"L !07C;"KH!$Z$ '.C@36*%_[T!'!Y4*9C*K$V$'K5>%HR._P#"<;C!
M<; !"ZQ ((* J93"!W0D1N20"0P$Z47;2 0" )9("WB 20">='#"%NRC&X"E
M"[V!3:: #+: /')-WO@/)X  "+@'"ZB&_M7C:F2!>VB!!U@D'091%J!.'A:@
M;.ED%GB6.JFAVS@BQ<7,MP5B;YF:_JT"ZJC""I2!&'S!&\RA;20-(AC/!0*"
M;2)-+GF:8*I""0R-"[B'* ;"6\:3"J"!8T&:368"$L*FJ$ E0:J"?E%<(H1
M1>!58IA3)A 3R36%QG$ %PC8T/X<A MLC80M)K"(@?L5F1NT7B 8#S%A)QX:
M75=(@$=L#A>HW5)AEDI,& L5X(TIB >R03U!(!H<1RVVH$K8&*J1P!G<4594
M! >XS+W%D!O*#QP\H=N4 @=D0L:]SA>X 3Z.@0J40M* J-$Q!!D8D8(@ B(8
MHFZP#4) 8/2$Q,(]XK]Y#F:M @GDWR)$YQMH E+FE0U22. -11:4D$I0""+
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ME(+MB2H-Q03@+8W(J0+86$4!!D(&U(%U<@(;'(<)C(M24/ZHDX%$5GJ>8&P
MCX28]YB$J35"A6$ 24G-%U#1E*% \>&FVYQ!II( "Z! "ZR"J5'<(F2"!+2!
M&82 *V&.!G!!(6 .%XP "X  F3KG:K21]*R$31Y$"WR JC)$! G"!RC@7L3A
MEPX%"61![<G;N,S0:O@J!"F(!XS%%PQG_GG %P2!!N@?L$00"_@>!G24)@S7
M%V  ( #"O;) K($ 3;G'6C;BC*+ &'@ &"QH9KB-K5J3IH# "DF*%H" %E3
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M"FP 2I 4+$E&"#R>\71!FPZG+_UA0>F@?/#RSK= S]>2"E0 S@RE1F]&!YG
M&Q@=Y&P-7:I ]JJ"-?.N*G 0*JMA*=%8)G3 "F7J?G,!":2 [TI&B)O8(-R0
M4'E.8 !"!+@?%[R0H+.L Y1G"(0 &G0=*96"%:G PO&?)G;""DC Q\2]R90
M <F<6>*?^R&$%P2!IS6"V^C?"J#E"E1$"[S!SK7 T/ /*%9 ",1')ZC!2YT
MG'QL&(2 "N0.&CQ IK:1;*U&N9+26!3"!(0 )PCQ[G=D"M 8'+A 4URM;'D
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M'D %5H$!&" !)* 4)F  3N !),<#%, !4& 52(  1. !'$ 35@$#!  #(
M@ 0%K28 +& " $"97@0!'N #!( JRJ#=,H !"& O ( JQ&  /" #"( ^Q, (
M*0  ?/X$!26 $%* X%H  )8M AB $RQ  4@  ?2##02 _@+@=BPB"PY@$!I
M/\@@Y!I"#,3P# P@$R(@FCYEKU@@ #R@!=_@#1J  2+ :\RB DCP.S2  $"
M 10@$[H@SPBH"ZX0! *@-SJ@]C[M 3:@#0!@JRJ  ":@ 0! 3E3@X1Y  .(M
M#74B! "@$P8! "C@!%S0-IR/5$X@ .(# !Q  @R  "AD P: Y!* $S2! 2!
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M2@$,   0IC(+[/(H1L  :&(H62 J#W(MM"  VB 3$&";4'+)- $K-($--
MV( 3L-(S(D RZT,,*F "*(  "*$3X%$5P,  *@ ")* !6( 532\!5 4"$M,
M=.XA)& "4L(- & ,6-%>0H$!-B 3!B %2E("(" ")" #5 X['J(%<A-+!F N
M)"#5"/Z.!0R  B"@ A@@##Z#  +@ 1R&WP:@30& 2%*" AX@JA;@ ;) ,"E1
M$.$$*T"@##A *K:T(=9 ,U/" Q"@,8IQ2P#A.E5  &"S$QC 13B  5XG$#Q
M BS  +!C4E_'/@: !<#@%75B"O]B QK@*:,/51>!"P+ _D[  #AA5C!5_)HO
MYDX@*G\QI7K2# 0S$!)K Q1 3,D4$#(R/%A5)QS 19+412XS##; .CP@ 2K@
M 2J@ : K)0*AZ![B(-\ TB2@ CJA =#B,E<C"/#S#PE!71* *AJ@+)HOD4K
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M"N!U*/X  5;87E: X*82 C   0@ '-=R!0K2-FC.@2CS%Z&#2+] ?@S !!K
M-A^/ EI@&4L!*NG#7)=M @) 7Q# 9Y\2 !#@* H! 2:@!1X  DKABV.N%D?@
M(O_C%57  @3@/0R@1 (! !ZC%@M!# C  4C@%M<" 4K$X=J 2).)5CT (Y/0
MX>RE! ; 8^D7$6:Q>Y=LD&:X!2:G#4C@4UR 6+ G [($!>SO.() 7;(  SR
M2#HA$/ C9?5DF+U- S1 "1OB@C# !=(E$%( F+/9+ Q 68HI [[ %*)X S)
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MJA8)+) I]<"  A"C'$AHLX' HBP(+(@I1>%!F1 #$)5BD, %!@ G$/%4=0(
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M8!DRD($3["@$*CC!!%:PS4%@)P3<^T(#LX!*<Z+  QF($=-:X((*>(!M6=A
M!BB8A:A9\$PRTTP)L'.B+#3  FYX Q>RT %WAL #&AB7A3QPB#QE8 ,9)*L%
M5K "0'SA@X.035C>X $.?.!,7^ ""B:@V,* H (M $$_F0C/5;#  QOP E'P
MJ I 9  #0_UF*4K0@.RL@ 0JF$ )Y%2*$VQ  P)5A1<>$B,VF%8$J^+"S_+T
MG!9\(?X$$R@I0RRP 2Y08%5EX$ 'XH1(";!@(X)0A1M,2]FMK&"H1951)C;P
M@!"(3P7[74A8!D&T,FA!!1(H0QDPH(&AN$ ,(J@ "]YU!@Y0\ T<R  (,M$)
M$FAD%2=HA"9 H $/H#4L8M! !C@8!A=W(6I8@@@^3U !=L8H"V?P0!=4464-
M"!,1PE0%%]!X@I70*!!?^( +)M#5L"""!5\ D141T0(Q6.! +;!R2<OP@ F<
M^5:'4*LJQK"!#?SX1PYFI"D-LMG.BJX->VVI&3=P84\@P@(0.$$G6H &"_@H
M"U9N9!>XX%@.JA<#65#!_V1[@9^=P<HD<)H6$+O$.!OD!/ZA>:T&/NC3^%"D
M%( 8 !HTH=_?)6D#P9' &E7A@9(24YPGZDHG&H!LR"WU-;QM'@/&@X$8 :("
M2W8,5L>R @FL0 4IV' 9'"VC>X?%%*+J1 U5D0+95 !@JIB CQ*  DFP(0&E
M<,,#"L$)$.SK@HE8! ,N%8%QB4$K9GB \SB04J)H85^<$)6-#@ (37 @."UH
M5B<P (@Q=.L-!CB1"(BV(Q<X#!$8X 0HO\"),@R "QT&04G?H-8Z0. -I= "
M"$K1B0U,Y<J: (0!SN"&E$X5GQ483Q;:)0((($(2#P 8U=E@ #2Z\P$L\H!!
M)/"I!\ AGV70!!<*$!&)! (";?XH!8T1D0D(]"8$1%O$!&SH&PMD@94-  0G
M,*L*PA.EO*J0P <D,8@$+*(0#!!$)DB@@%4T<54AR(@)0'"FDUC\4EHX2AL&
MP 9-E,#MSBS#OTF@XD&>B#!L>"@*$1$(!+#@\PZS0 6<-X%^8@ "9L@$1=K0
M"0FKP@( 0^0J,$ &5<"!W?FNH07W=8+@1%Y0"?  ],-B@@]H@O.DT8!,,G$&
ML4/0A P8"HC(19PFEJ$37V! (#*! 413+5V2"66P $$U "I@12NP 9JP"!.D
M<K96"@O0/(3$!A6@":M0 CM#&(% *2'0!8N@ 'FR(B77".8C 4/$ N_V;4-!
M H"4!?X88!,/D %J4 I9D &9 ("" @(34'$.@ 8W\6Q?, #_\X!?H ENX !\
MPF)Y@@&+D D30$$,,$2:P "EP 7 @@@7P#_)QA[+!@<60!3K1A:#@ $<L",G
M(2--%1;QMT5$$7\;1A8A9$M1TQ3*TP"!X :#X  Q0AB,518J4 %9$ 1!T$]C
M,"%AL53FQ$P&@0AM  (KXD%$@0'#$@&\(P&9$ (99 H1X0$N!@)F4 85, AO
M0'.:F$$.]3N<, AEX "(]P4.@V9N)WB $ @D@(80L JU]D:'EV\/T 7&H@H8
M8$5A(#!( 0A:0$C^MB,1\ 6   @FL &=X !Y0P(4! %#)/X!9Y(DI; (;D "
M;O>"1&$"&>$ 2>)=,K(($2 GG3 (9^  XW)X:'",$C N=R4!JU("O80"63"!
M;? &@W!<0,,!/T,"<J@*$) (*M!((- ;]S1]@C!O0?, G2-J;) !&Y8%'S5]
M@Q $SE5YJR&&JO &(UDM1_%M77$&<R0U8CB1<S(4"S2,!\8&%" <GL4"'4(4
M$S (9@ L*, %%!$( 0EN,I(!=OAMJ] "I.$8)=4 S>1,"BERP:$!&71LSM0
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M6B!W'=1('" H2Y58_Q86$L 4FOY0 2@ !@U&DFG,!8WG&&X[ @C ?PSP!5W
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M.Y[&\7 !/')J4[K?[NI?\+A_+!55\-AO4<*#(#;)\]E4ID 3UG-Q46K!_A(
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MC0HT664$YA3JQ 4-$"GE 14:84,!3S*1 #[7(B2 BT$TF2 Y%?KDX(%!),%
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M#7#,L8 $S*"),D@ $9H P5-"@+4VJ"B"$\1 =1+ "=<=2PL@2)("FE8![I3
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M0";,4/X[J'J4]5D$#CB!MP !8&*ZU%B(!%@$#U@G,= "S5&(,T"9,OB 4D
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M50@""?@"%!B)\"*($# /_;DAD-*""MB 4G@#! B/AD*/@QB$A.$$"E !,)
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MGL" $$BS4L"B#8"@$-B>,CC-1<AEC/!N4PNU#3@!$(" +]2""=B $IA$B;@
M$;> @T $4;8X#QBD4O  NZD/#Z@,#/"*O2APND"$B*$RGXN1LO. ]NY,;,0
M$,@ GB"![0(!-VB#!HB +&@$#F<!:*F Q\T"#= 5^-C#">6-P_" 5K-R%9@:
MU#B!"MB>"7 6@F"#!X" UI& %( 9YD #@L(P_2MPTW(!)6^DCV"<#[B H7"!
M"F)PMF EC5#R%N&/#6@!IT2$"3@7!6>G5L( %.  !^".&OZ'\ IBDZU4B!8
MH&WT"BWX\^00@1(0@0EHO1*I@ B_7Y50< PH8X? +O'&OECQ@ [PBKM9+X<
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M/BV7NMPE+YOVK'BU8!4BR!ZX .$P54P 1@]P@RH2 *,*C$$5#O!$(%02 K^
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M?NB\@A@B5 "B<,"WA$")7@R"@(&^61?"F T)> 7[=!Q[#-<# $4=U)@%P(C
M>< $8(4'A  )4$!TEH(&H$#6E/[H%Q@=!0C$<6D"!W2 !H0 ?2S"!63 "'!
MK54 3GH.>YR "7#G!5"1!]C(LVA9&2Q/ VS 6S' !*#!*J1 IUW B<1<!=0:
M!JB !7S4!T# ]V" "%3 >=JCDH7 !A#$!E C!##&B6Z "5B90:!);NJ*!TS/
MBC"&%MR5![3  ]1GE$0."YQL)X" !VP 1+!!*VK"!<R?QDR !G!:-)5!C0U0
M0;B UUD AJ! !23:4ZB!C<V%7)1 !81)O(79!*0."G" "5!:3VS :+0 !GP
M!IR(&TSM!'"HCSZ 7]!L1FA$F3*7"$Q 1[1!!S3%JV$ !6 $(!@<!E0(;*B
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M%9W& >BD<A# MV2" B!")@P 5H,%G$3 >I0"!;C>54='"%2(]VC$HBC,5X5
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M!$D#A8#Q"%0!$:J6I(<&N\ )$_Y-3<5*YIQ \416"6 :0:V";T92A \""H3
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M _+"4^4!@4J)X"(6*BA!@I:R$$$51"H( 80,.!F("PM4..&$@1 A0$C[JL2
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M>202E$6B;*C+/S%I42:U@0(>,"B39MJD-R2H2#6=5;Y<:JE6]?1)Q],I]U;
M@(@"%:E)5:H_ASHDG3;5J4J"ZM548E!-L.$-=@E$+S&R"&=6E3^66FI8#1J]
M)97U2/Y#1>8;; 8BE8:52 8%!!O,&5<3UG5;<8VJ5 O:I*GN%:Q&TH0;U"K6
M[)75+NBC:EX7F]8D_75(7M7K6 E2"KE,M;"6&@3V DM9SWX6M*$5[6A)6UK3
M&@FRIU7M:EG;6M>^%K8[N60".\L?-CR&*7(91!984%*:QK4-^$2K"SA+D$"$
M80QH* ,9^ 8(@40ON(T]+&,E&MQ2$&81E3)L]U9Q!H=*E[I.10,>LQO>JF:V
M%$[<;ENT&UN"9&*54^V$"UW*$U-$=[(J:8-V2W&&Y^947\C![YD(F%^X8L2Y
MX,WI@ &+6B>MP@TC!-U&')PD9:H$$%G$2(3=VV'0GL F;/X HY)*D8!#[$8#
MD3J# UK A4-5F,0+:.N0-G 1-CQ')6+P20(L((*>;< +&"F%!:K)) YP%:R9
MV,!$9IK:(@UY$8A0@$@"9A<V_(>[(GF >,Y*I%(@X"LX"G/WN% 61%A@GUCY
M4%[+O%[1\@0-8N$K(A" U\<N20PPR80%)-$D"2B R:H( P 4TE0+D&$5%?BO
MI4 POR?Q) -=^.V0-0QC[I4" Q?Q0$H&(9GN(8(!L]+ "$EP5(P83!6F\/"J
MDUJ*#7 AO1X9A Q5D0AS"9EQNX&-*BC@4&/QMU#JXB!&.A$(]?6O%!*H3"1G
MG4P)$!8M%56)!4KJ 31H G^J)O[1B8A4"+ET8@)L$),'55T*8]\L3UBSF768
M/)G*)M:LYR-1H1(4AC6O(DHCG(@?"X6_B409(XBX[$EWDXD.BM54_]835SN1
M@0>@9TL$$?CY<M>_0*20R9I8A7XFHNU5#&+&/)D(!Y^8 A&XVSJT5I @##J1
M3-QZWO*>-PY!;E>*F._&!"G$K7W8,40X8%&J1D1E]CT(']8\YC)'A-^RX $+
MEEO(-VLK7,A&D \\H#T4L1DV50$"\G1L$?A[(D\&8<ZP8P3;'>.)!\XP;)DG
MW=L$4;7(C8X1I+>EEYRH^Y#<+5MYEQLO'_],(? H;TWHUB@=FP@BQ(*(!]1/
M3/,&>/YADBF(-+,:\V1^@ 3&  @)J,#ALUD%"3;@ 0\(T1,-N,C:%1."3">6
M(*'8  HV, $PA$!<$RG#Q2I@DR^0X ,A8-$',:"0.HC+ @I! 0,LP!P1G*2F
M%4#T1$(@MPIH8#*E0L0%1&"!!B9S7!SH0"F*6@$B<F %$IBOLBHPAE)XH $U
M[D35-F "GKQA AK 21W8\*%%Y HKL P# @,1,J 4,F 1%D05P !W"H4S"&4%
MG*,%2,<G-D!=K@4$9(=$1,#T,J 3SN !($ T6  #/, "&J(,Y,8C0. $/"!0
MVL0#9ZGY&. BON J2&<#.&#)T, W5*$-K(8+>&\C6  %,OZ@!=X@!%L@$W*E
M$30@!#*@!)Y(%7A0%8( !$P  RJ $T " DZ"#2K !%LB>DR  T8  3$B!%(
M!"R  T9H U+B +UJ UH =C @45!*"M_@)3(  A1B#=A"$S@@!#X !.!"/+P@
M4G@"$1H ES( !3S@ <J""SP "R= (*#& S* 4+2 7KI !4I!$$&@9^!  A[@
M!#H! SI!!!Q*!-HN SS )%2" TR@!P%A SZ@)90L$U.@0"0 "O'B9 3"*SK@
M @0"!-C@_U1@ QK )C:N]#A 7<J@QR1 .%9";#*@5+K.DSC@#4J!$*MF,BY
M$\Y@]OBP(3B!_G:D!9PP+52A#/XP0%.:$2-2<""*KU"P+P,0(0L8@ *(Z/.6
M,3#L8@7D!@*R8 4P  (N(M/()Q4]!Z,8  ,6805:P@-4P -R#RU2H@S$Q?PR
MSR/Y"2Z^8!7>( %J\#-<8#]4H06NA$1RK3\40Q-"P $.I9=*80$48A]'J $&
MZ2?T12RX  $ H11"80(0 01THA,DX")*P1)7X7JV(HJ*A +DT0.P3 )F@Q%1
M #Q*004DC"9PJ@4:@@(:9A *  Q(K2$0(4'4<E%"H"] (# >8#8T00%XJ 'J
M1PL(Q8,D(A,B #RXX#\>;S46L ?_9@-@)2%7(1!\I^M:H@$.0CN:8BL&27!4
M(2QT3_XKS*  H@L"RF(,#$ @)D >.R$".D$+EL(&'29U5 $%2& 5'$ @W++K
M1L@J6+,!ZHX%3H R&H CN$054F")W)$M3@#-AN,@5@ \B*(A:&9R$"$E3P!B
M"$)<>&(#LJ65^.3+6F!1]H8V>&H@W(!25$$0%("6EL(,4*H"U.(Y.E(1&0"5
M$L VI$P5LD ")@($1 ,#9N+55F,B+. -WH!>9(,C_J,3B@(,HD@3(, 30 !I
MW,/1+. +S:4$ND V(6H@.. ,3.%;**( "(,1OT!*5'(_IF81#  %$X0+/D0+
M]N,!"&,0\+#K#- ["*6*"N,-M$(E&Z(!-$$,&'$L]@,$,OZCZ\9@%<C3'17B
M*E6A$%#*4C)!(CSG+_]#<A)M(^@L0M@ 1U?B*A!A )CC._#D(CCA 3A! ?O2
M5((43W;$ JAG$%!DA*KE\CY23I6$04OC.0#A,S"E"[C !+*45LR%)S[ 9,CG
M#5#  %Q$Y"3 5+Z 4(9C-DH!#5)T*;(@)4=% G#T#1K@"[3@"Q@ :8Y%%;;
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M\V-G!0),H07HQ04^L0%PRPT^HP*,C0(4,5L;8#8 4V>'*47*0 16@0&R8 M
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M&$ A6,8] E)VSZ #[(("!@D-2 )X!\(3'D)?"M)J(* 0//[( 6A"!/10=4Z
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M[((% %J@3QPCMB !R/=MAW96<A!H*@I!1L8!3,90," $+/Z @F=IHJM7%2[
MA7 \,5J4"RH5 L8'<$PA*W B!"9B;%("0ZA[QB: /%2- UB:/!P@$]3@5C+@
M?=22=YZ2!!P@$+Z;1&XQ5,)@5#! @R9@7+)V)XBSZ=K## Y Y50!4_P" 3;"
M6(8N)+Y@NV^& ?XC=DU'<.1%$RB@+C9%$R2 =YX-L7="!#0 4)@CXAQ"AI\#
M>*-WHG>B8/7"#G&O,E+ TS:#!%2@8 )A:PF;>6)D%>H  DA U'?C'1T&I4Y
M-,X@ 41CDDN@ IA4%>   @3'!)2-(#9 _T*  I C#!Y ;AY $4)!PU4A$""
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MN>Z5Z0U> )<:(' &B2#B"V<XF?X> X2&":C"!1!@P0D6,"6#P($!*"C!!$J
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M*0,\@ A!KF($(3C! #P4 A!,,H\K$D$'7% !+:C"#!8H2!A$MM0+>$@5G8
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M<7@&"&_@<:I !BP592'1"1+0$2Z@4C$7"("FA&V08IJ@15AQ;EF7:5C1B9K
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ML20!+I )B) )FX85:I"L9@FK>!5!)@>/1@@H4J<CF0!2#- )AT  F/$&"\!
M#O 3;<!2+7 KY?IO6-$)#< )9&!;JJ %#E<0$$!"8C !-;$"C J1$8M/:*!D
M'U83)?[P=RKP;@10"&  GOL2'B40 HAJ(4/;:1OZ /+3ALKH *IP!@X@-"^X
M;EOB 1\3$E_0MP-K$ESPJ[@ZC25@"H%@ )CA70!9-0D@$5WPJR(P=!6@!OEV
MKR3 M$(AKBK! " Q G-G :6B+E,JI6^@&%R )ZT;'L?G*R?@(9K 5()@ 1[@
M B&C"1Z@$5] *YX#-HV5 1Z@'(A0 1H5!B10 AF  6'Q!6O&"1[@ 2<@!A:
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M*)!Q$O[P 5 I" V  @M;%(,@<(T$$Q. 7QN@4X"=5:CT$QBU ANPH\'%3R"
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MDP_*6&451#K*(KV-1CB*#0I5 <&,QU19Q(()/ BM!0FZ.^$!G%HDP0%$-FH
M@Q96 80!%$@X00+W(FOQ* @R^>*BJ*:"X,Q.,@Q)C.Q$@#.#K21 ),D)<**.
M#1),>  ,522H:X)%NK@H) L".2J,P%89PP.0P"BAA 8*F4T5%#2#((02*/N
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M#]@ %V"1+S@!"C!"56@##_" $2@)#Q@#33B!#H&9-M  #C@!$_$"HT"##>B
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M!0 $31" %E@$-%" Y% )]4,Q_RL%CCB$50B!(%B% -.$3G" ,LB$+,@C_7F
M:/F ",BGX0@!%B"T$%B$1D@ +F@$+M@]@P@B[F!'"+@;+C*,!N < @C%+X"
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MG9$;3CB+!]@1,\$=N24#<L(<X HE8VD#C2"2SC*,6UTJ.,"+4I#;,F@ GZ
MG.@[N?B=P4F=9?I5_ &.:Q2.0,!)"!B#3-B]6Z$/"> LX(I*Z@#89J&2$QB$
M0! #!3"7-!L!Y$*!_PJP) G9F' /ZMP_SZA3>ID(%8 (;%7.CAB#"'FE"4 $
M0! $X]S8DE%?Z@ $:Q*$"@#>#!@E"+BS/R%*]3$%R'B^O+$G\N&""$ %)QL$
M$J" .V&#!V@!J<@"1 @$X "7K/Y=DA#X@J(Y#6,9!,3"1<,(@:I86@NP6)"
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MU3B#RHBD  *$3'A@W&& P"L%$ "!R00!#O )G5(5B% $SWB, %J$- L$?J4
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MQ>"'LT%08&9,^X)&;(; M,6O*_YM@(!%'H"GGHF "Y'3"2=80#W(!0%"7?
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MA.DL8JTT?8P4$P*&?)9D%6O]P/Y,=K*"+V3 (UI:ISU780J?GD %"=2)&C;
M@1/\I05E $$%)LJ"3&AB!6#(@ 5RHK0NS%<+.H+ !+BP" Q (+'8/#.Z2& "
M582B ==:,R(Z^08*J*($)WBD"U1Q A.88A$58%-"T$#,,$ E Q(8Q"(FI@H)
M%"4+%ZN =R3 A4R(@0#1E>@JX% !Z"%" F+H! LV8+X)Y)4##PB.-"_VAC9^
M00& R,0%"ML"H8*D$X@8P G:L(H.<&$5P[0U L+0XG&VX0&#R 0)LBA+5:!
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M&$ (!+2>0@S?"L1+&Z3<_1VEN%P (J# MH$;&&P:'$Q1"JQ 0A1@*33 -*U
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M9:D^;U@L @$PGH^>0*TL0!FHBXXP !=D 0)X61DX0$1@7,X8W IT@03LGP=
M !=\ <.J0@5\0!F<0,7YZVUNP*00P)QLE1B<@ 3<3I;F!!I P!=PP0.TW@7D
MU72L0%09L"9H03--K<6(P0HP !@<!,VT@%M=8?\9Z\6I0B&NE01<%%&1TP.$
M@18P@$:P00-P 1>\+_DUQ#J5@4^5PA9DWT:\,+;@6"?@G E\005,40@P0!:$
M00/,R0;03PUWP@.00">(P$6T0/X#E$0#O$8#/ 8'5 "FM!$(@, 82/&@E*XT
M.4 12V)%Q LG<-6[ *+Z*> X 2G-A #^A@" A8 %E$$0C! 8- !B2$"1+"L
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M^& !D$2))PAV. $"P@F7JEHPD-#F3 44&" $4C6RPP83&B66(N&A*"=59BJ
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MZA,Y+2(O-)HXI0A*D#1^J: ")8@ %WZ)G#8X@&,2( $)'E"&H10&I<-QU0A
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M8%@IRKN*12""RX@(\H4E N4N(P(I?K66>:V;9C6OF<UM]F<+6G::OB414JN
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M8!'>@$O8@  08EPV)2D>P)S,<2JILBI=(A,48 ,20*4D( ,4 $HR80-L$F-
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M$0IT# +@L'*QA?8C 4Y@-'&S0 /!,S<"0#8B XIQCH:Q4/.1 ++ #0:@J5:
M"U1J$%;  @A 4!L# G1%(D:@$3G!;D#  %JH ]3@JS(F"+J3 5!B2%5U53?0
M2%7 #1;@JA A/"-2!41S2E+  /AF*"A  'KE"Q2  -1 $@8 6UXQ"SI!"P!
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M.G4[$H$Q2L$-=O<J$>QO3@ %^JD-%((VXI GJW=]V?<!W?9]&$T %:TU6%
M4X$UZM<T\I=?#DTUZDP$)ZU_XW<<;X. IZO2J,R Z?=O!$V!0X72^#?1!@V
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M-:@XB1F,>J.) T  !!Z@3"*X-CQ@3@)C'0FX;VQ1AFLC" [BTA(D+"5-J$@
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MKK-705"Q$!"$@Q@\OO#4KL-,=VZ".O*)K))G.3Q7@A<[8IU)E;0J.2S@ S#
MBDY@G35 ?,+2 S( D.)0!3S@ 83D!!A@*O1Z3S) !-+</E;&Q+DL QJBS--R
MG6>R%"C@!.J<E[;# UB  ^+JT;/@ 5(')C-@! )D$3"@SSF@/D! #<""*G*4
M RJ "U:! QK@*!6!MBS T6NE-\L 0Q$D#+ %)MJ 1MY9$U"[$T*@*]C'G2:
M9$6  _Y@697:( (T(@0VD4[B@PT4@(3#C"ZN5B-P1CM60'('P6Q<XEWRH@Q"
M@#/M< -4X (RX&4D@'PY'2% 9 ($H1.&RB,L "LZ0@UF!RCFP@VVIC0\X O:
M("BB<"F./3DRH*U:P@7\)01*8"S$ *8G*1%/@ ,>H#)0@ % 0!-L902(AT0>
M8(W0H#=M41">(PNX5R(FB\''@)  + ,^FHYFO>7;X"TR( )4Z@V<AG_:IQ0
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MT+ZAN" E!9%>6520G4DEHGE;Z0K%]N*G@C2,#>XJ9"$:X"RA\&0B)  ?"<]
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MCW:FS $TF,("(2 !"#"0GA!,0!-F8%D+(!"Z@KB@1D)B0 8RT( =%]<#)'A
M.B50\PE H,A# 8%$0I""B5BL)?C2T@1B E:*F.1LZ<U KB6@O15<,YNH6G%+
MPB !W('@,[^:"#FOHX$2@(!6!1&$!+8=K4)[P&7 ^4*_,="4+@1EW("A+47:
M+@(HKL)5QS((5ZYS,?!J# T,P, &^C21,'4 Y?MYD@0H, $<IPEW0\F4;5B0
M\@E\9R(>R-HB'L#2H'3@1Y7Y0OY;'!\O$VP !,3;]>80D3!.,0$FH (G\ "
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M8N L:0<']9H1"MD)YSD^+#L(N@.**Y !@Z!;:<J#P7H4._X[2+4*!FLT"!)
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MY (<8"UXXS=0Z\=_S&H/V$6K8 %KQ!>S5!:<D !1 ;:.H1W-T0(I &>LT@#
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MV!!@1<1B&5R@ )E0O7!0"B+@2]P9 AL/\Y;1!0LP.WL45YSP[B]_1<"R 6K
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M@8L,-.'@+Y$R.:$%-"Q0I9,0XB.!/@<6$XG'##184)45,! A# _&0..$'4/
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M!*M#%<!03-G BK#AA!#@@"PH@=(TJF/]EA:-2%5 @V^DG4R0@ A=@19X@S;
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M!"B%COX0"388+5VB@&UM6(]1@33\ H94@(S;X$Y8 - X@9@[ 0L8@Q.0 (G
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M12 '=WC @8 NB-P_8QI-^(+G)I0PUHXSR*3I00,!_HXOD O^2>N.VXXR"/F
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MC*$49\! *00!@3*0[BVL4HH&.("(0"0 $:5(@#PML(JI,/$C:!C)(@S L"S
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M;1VRB@ET[B,MT((6V* "-VA@A/XDT$ +5)!4PT5  Z1#! DJ (&>R)+#IJA
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M%H" 1;D!&:D"(*30%[!$ P#?WY0"!D".>/1?0FA!\D5-&?E)*2#$!O"&)G"
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MB!P,((C'&XC!D?JL3FB"&PP""F3!B' "$;U!:#!<*:!7%J! BR "CW2M*KA
MZKE'H+5!>[B!V0I4GI;@"00:&LR9VW)&WYP!<P ""XB!-?:$X:E *]H8SN8I
M&G""/!V4A/)06U590L!!3Y2"\_YA+4O4(U"4+1>@0$\DI,AM!-921"E$1B#T
M!!HL2-!2"6X%@AOX"!O41 EF028 PAEH@J .R("<@.C]&,6J0B%H 2<L@KPJ
M2H1([+LLAAE0!!RH  J@64+0%)4 ;T(, LAVPAD@1!FDP J\UBKDR"J(00L
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M%9)2Y,9O(GQ CB3 B?M11JL0@4,I;.*W!/1,(FJ@ +FN8H$<E:0"M>*)5A4
M5E]YI@4MS4()A_.%+7#A!!+X'43\(IQ,-.!($BF#?J#5"53UR383$$3C5.&"
M&'6" :%(0:U,H%==$6<I_HS(F$JA@$9 ) -G< ';3I E!B2L-V'*P!HZ^R&(
M7"4#9( (%TKU6\>I11!8,8$'C"61E\IL$0;@!" ,8"4(I*4DN('(%P:% -Q*
M(+4E8/[N*N@DK424PH_\@=9>Q#<DB/1R+XBH4YC:AH%#Z*QM&:D '!_0D.$]
MK"2 * 7!H)J3_I2 JH,8P"+<JXI;=H"KBC )>+_ I"X86")?")<F&+"*+/@6
M!%J U[U<E;-&Z >>JBA!.%41-;!V0@&9&,,'):#+K\VU;>MDVQ>T$BV-T TB
ME<K==:QS!KY)8!%FJ%D9>&.U7D456C(K 0N IXI$##&B6=;REKF,AIIEP":+
M2( I5K"!,FCA 2: <<]@G(E28, $X/K0&!P0!BXP(*40*0,$Q,"%!R0W"[S;
MSPH>D 4N2."IM@I+9T2R@#",00)MN!$*RJ"!#]D4(AK(S?X'-#"V/I60)N4I
M@6]+ H>:$1H-I=C "-(5(PQH !'>.0,7(C#22;T$ V%I@06,2H(RM*"OB. 3
MW%I0!@G *@,;,$,+*B"Y57@@!&7XP <D$@$,T:L-":C-!CKZ!@:<0 PL4$!Y
M6N 4$6223/ZA&41"D)L23" ,8'B:IPJ@@C%H $5@>!$(8-6 0+@1,A1801DJ
MH%40"# $R$ZW6N  XR.AP+<-&,18/C &%71(#!(X0X4QT(DOU'BP/0.!4H5X
M@JE^B T,",,7(!"NN!( !6/@@)?P@@ $\H<$#F#!"AK@G)M 8 MBV$ &@@<1
M#DS@"V!@0$HJ,' 5.%H5C4B "_X@(H8'V'E2K:U>28C% 3&XH &=>$/<RG!U
M+BQ@$)F8NADVT ))*, %9M!?#R7P!14,H"%Q2X$%RH ""%BVKY-%0R<PP*+W
M8F "65!! K+T!@= Y T-X(E/%,#+&$?>#&'(P"LET@4#L(#@.7F# KK A01D
M@1,* #T(@(4!PG18%8%@0%\@T )(PRK7RZY+"R!0!C! 0)8M=D 9A&[(+Y2*
MN"K& !E:0 "P2B0%GDF^*KIPF#&\:!4,: @#B,\!""#"*R08Q0=@E9]?0T 3
MBU! KQ"Q (9R&?[QEW^!,B&R-O#2#%]K 2 T\852I#HB(,@D$ N_'(R9<&L_
M  $%6/Z@>J#"/]Q !=QB/\0@CW(E$':.@3HB"U" OMB@>M@ ,#*!"ZJG O#K
M#7)$$PI01C( 0SCA"Z[BJ\"M)!9!(-J&!=Z@$[J@$]B J2("#$X@" "#$[C
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M!0Q)"QA@ MB R3KA CX(!%0Q"S!@ QYX%4*@ 8CWSB2@##1!2B_ Y[+@ CI
M T*V AP !"++&C% !3   MJ \&0F!-8W$U88 TY@%;:  33N#?#D1=Z@ CC@
M4GIV \KL ;)D/2X@!$; P"#"#4! !2P  NB+"X07UGQ%!3@ !0#A 2 @)^#
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M+01J1Y/XXP*NH@(P)#+2HA&^+_X\YJA=&B WA,T=:\17$B(+P,I(!N$O,*,
M0N%3'D@!=$8#RF 1'N\+&&!#2*"HG0-"N",!EN(+$@-C7*(_.($!8G=G;".$
M?-959'80?$ZR#H,-%" Q/$!#V0:R%6-#Q.#YOL4 R.0,.NP+:B4"%$$3"( E
M:P=,5D$,!J4G;":ANBAR)VL5(&=LWJP,5L$%*-<3V(!)Q, ZT. "&(H-#& R
MV$#RMIDFEF)&!H4R^"@#E)$-!J ,.D$3&@!1_,(T#*",O*TW!F45>"10VH
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MT(*AN+$!(D"CKT2 @>C1Y@1W49"]A(."1@:*9*K@ERK@( &2E* %I:  "5:
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M<"((:^ Y69H%17H&<*();0!2B:"G;@!/62  BV!&"-  ZT$"#0 '@, &<3,
M]((PD+,0B3  -Z6FK-JJ/Y@)## !"J :GJH >Q,*;E!T@1("!K"BV1$ !.$
M$V ! 6  4Q$""; ! R  !,$)&V  #&  8M LD[%&HV<!!/  !O %'=< !I S
M!B ?98  "V  &" 8$2 !Q%H  X<!H"(&'S !"3 O%; !9Y %%W:GK3,(:S-[
M,N>J !NPX)<)"M !"G 2#L !"E :@,  "O!+G? %!=  "& 4J] &P,H:!^ ;
MD!A- = "W9, I; " - &G> ! _Y@(@$ J26["![ $Q:@ +43 %>"" .0 IQ
M !LP"F\0 /)! <;Z!@<@<\(C<R)@ )K0"0:  !.P  # .17@KK9S!F<  I/E
MKG\FL%J[M7"7"0A  HV!" 3@ @C0) Z &(M0 ">P"B1@ (/ ,3W!K"&U) _P
M$R1  /,R @B0"12P-F@  (X* &6@ @B0&7"@ AS  -OA!H*[)ZIZI&AB 6XS
M 1?(&GAT).>R&;RJ":O@!A<6BTM7"N3%!G"A %I@ $J1 1'#M:S;NFRG"0:P
M BX@/74T %S01,K4 9M*3P7P51BK,1" -;?G) 8@(B20 )I0 0A#%0#0?"!
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MTS;KH0(1\* LD  (0 'V-0@/\$I[4@$)T $D( $H!0((H/X%G.  &A,(%8
M"H ""Z$!_Z(!M[,< )!^I>02G6$ 4A<\&R BB& !#N !J\"]MU&@3-S)GJQ3
MW4(0*D D\4(;F< !" ")^D;'0IJ(^Y2.GV8D0A-HM"55'3ICC>8PZR@!;QK+
M82&A8UD0%C!/GUS,QCQM.J()-9>U/O*.;7:A->?*.,()+7!OQWS-V&QMEF:@
MPY;+TDR0W4R'G'QM)8IL)!@DYRQ^XXR.V9QS!;G.QKR Y*@<[?Q]FL %4].A
M\?08;E4*9U S2Q$(82".@2H&6]C,Q%9L2\$&:+*AE+8* 1QOGQ%>8R &L_S-
MJ);1!A<3BI/.!F'0639D&.W+2_[Q!B&0=:36C_K<H(@0)AXJ-)/6!2>1!5T%
MTALQET' S(.P G^Q A"B(&XE!JV\&FH0 AV  D42!EE7$(6@(22MTCM2"E!C
M(XG 9KCF:XEP0C?R!2X=*"QP8<:V"%:-T".-:2F]%%UPT:OQ!F+6H 41"&J8
MT4B%$@W*"5T S]E8"'NK(_MQ$PT@$@X2 B(  =@1-L>C)R.$2]?2D%3!9C["
M -8<V"3  *XA"! @40\PU(8VPIB6!2.Z4V"SJGWV %X@H5\V!I/A:X"\(\>$
M4@A B180&RXP 6CP(A8 6^)FNED I"OZ)RB! 1JSCJH04U]P!I,M(FT2T-*7
M92O\8?XDP08RJU,?T"<V4@%(BQ+2VU&4-@@H@M><]M<Y@@8<*,WBIALYX@%-
M,FG)PLST.5"LE0F$!U(&80';U )6X0'2QP63$0@& *(*D&\&D!E'(M\\\U1D
M!"=A1N!G-2Q9AP8 G4)E$&4& 0AAD%>EX(L&D0@DL0AA *ALU0ERM!0>H"=<
MP"X60"&W4B-AMB8G%@;8<3>$QTMWTPEK,@CD-1*IL@B"H0EC(.&(X!YG-0::
MW0D+45=L8 ;R]L]D=%>U90KKX:LQ$0(D "<V_CY$R@DWOM81  C3* 8^>E87
MT74?VLI.?E0B 0AN8A!L( 8*MAZ D F5 3??X@86K1 /,?X(2SH&SL5X0_%'
M7[4!.O0 =6 0YV$C7T M] <@A)[>JX$H.N-#X')*8Y 9I!(6'%;A#>+E9+8(
MFLX>_OS9;& W%%!H0.>%1P70M05C*#0('1X3^Z74E)%GJQ$"%* XYE0!3];J
M3,%D$GY6 @)<$B,&,<8SJQ#JC=4&2,XSAE%.R%7DWR(@(X$&8_ M]X=;)19O
MRE@*K*XSHC5987 Y0L4SLL(GF7 "BF/CJ;(*5^4@[#V?Z_TI)U "#<!0*/0%
M=R4&&+ *G)I" 5,(U!U2@) ()P<!D[447] 7"A C;9 ^C*)-JP$"'K KGL!Y
M*J!/W9.*%. 2*+ !+" S'?-'"_XQ@+4S 2RP =+'2"90'C_#K22Q!MUQ""#J
M DEJ$%E@ 5RP 1HC'"7@J2>A\R3P #VO3/?! AB@ A40!*QA%,6!" <4!"?
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MR$05^;R3@*L' %/E Q=4D4 0#C5Q X%$O,J$@<M6L "D!A!9I N03&BA,A-
M*B,$CVP#PR95!$$MD!A782 0519!L"L)E,H$/ U5V2 +[[*8X($)\/N*# 0N
MH* ""1;Y#I']K/R*@R"F[ H#-/XE (1(55SXZ+$3:#(SP@QG"B//!S11A0'
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M =NH0OX+'6O *0L10F-F 52-D-)7+  (323E/>;Z3A80@0CSU%!Q,A'$;CP
MAC0!KA09$*),OO >M-*$:X7SCK2LPYPSD& ,Y,(2&SB1@J-(H!!<6<0;Z>8O
M<=$')%!4S4Q8 AI5D!(D&FC#WF8B C&8 0.+D*4+:S6[Y_71N<^%;A\1H0!
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M'0%!N\OCG"YJCM'SGU6(O(BX$U.(O!FZDU7 + TIA1 X/!(@#!;0 /D8A L
M 17@ @S0A Y !!?* ,/SN_, E1.PEA.@+%OJ.BLI U!!A HP'@X8'4"@@ PH
MB-% @Q>L *400@O@ +#Q/9P#Q5#$N0WIGJ\HA2@KE?!)D"A#Q0ABQ25A(;1
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M!901B_OC! 10@3UU@?[P@KIH' +@I^-4"V3!C"Q(/+)8@1P1E@M%"S8@LK$
M@1PI 8DJS T8'39 5=[4A!*@Q1C%C$5@ $A%BPJ@FQ#8@)1$BRR8E(L* :,B
M&!;(/G^Q+S?( D5M3E,\#"W%UFS%5BX(JODXU--;E$$H!5@KI (BC$48 _AJ
MH@O( K[(A#(@J<#X"U4(@K5I(OX&6 7NF DWJ"9S4]4&68R9D  $28$T]">!
MF(DLJ)5,$(-XC3,S( Q-Z(0Z,#E-.#"LP8!!* /]P*<"4HX-D<LJ*D\L\PHP
M<-,628D,\$NOH--O*:!!$ -V1(0PR 03J _YT 00.($X]<B4**"5ZH3U3(D*
MF) R0(PVB%F0D 1-D[WRD9Y2@-D FME%N-3R!%DQD+U.* .C79*[XYGX0 .N
M?=JH_0J8U8]!V!!]DM@RF"0VP$(;,P4W$-LX*P/*.,HZ>-ORW,@P^ TW&(-B
MS)<P,#^N0 0QT!A-:ZFC+)-2J( [D4_=6@5*.P.7 P0S2)QC))6ZXH0R. ,(
MR8 VX/[1LC7<0NJ$:_J-[$&$%>J*04" 8%J!7S);@.3<71F$/O'.PF6T4A@#
MW"B%WUB$3@@ED&A*;27>XD5+$?@Z"D"#_CFH<C,?3H B#2F<$:0)"E"!"O",
M+%@ $GC7"5B!#8@F^5 80(&6*4&$!? $3F" $\@JL:" ,NA03F#1AU*)V"B#
M0V$1!E"!7+Q?%;@\ZZB U\T M\D %N"8%1"!" B%MJB@8;$.U-B@WCH*$&"0
M#9& 28F208A?OO@"BTJ-H?*4HEF?$,C33+R)"M")!UB1,(  A'L ?+L]"> "
M6)$/-Y J$]B "^@"79* _K  FSF\* ,!$%@!BU %',8 ]?YICH\X@0 .@1DY
MCP= . BHCWDEU>OUC$" @!98O%+H@@80'31@JD6X !($+16P7A%P$3;)0Q:X
M@/IHBF>Q"32  !)PBASQA,O+ @HPD3]4@:XKA5+8 !18@1GI!$82C-R3 ,HR
M8!48@35& 0]P@0<8#OSS  <0 4\( ^NEQ/*< !$@6O.U# K0N ANC@V@#8V0
M@/>T %#1)1 P@0'A!%G1'Q!XGP@@ 16 @#79$#?>@@RPDBR0 !5(-\!H%!+8
MB""4CP]HGX!Y']M@@0(FY261BA.8'%4 "A>8 #*@B0=P 1)H@$Q !+_YT$*3
MG@;@A&W2)@XP4.-UYW?N(PQ %OX7V("9 H%2.J ']I0<J;$-0 -?S1#]BMRZ
M0#"9F->/4:!GX1KQ%1KK  $(>  0N,H,:+H*@( [ 80'&,=?09 <^T1$V( &
M"(&44)B4<*&6 !$N(A&E>*.R680SH "N0-@R$ KD];D.8-,-^8[W<X#]LP J
MI@F+:IP%6)$O("1A0I,PZ)<0,"9S"127^XZCV)!3;9!T(H^Z, $+B$-4)3@9
M600PR"8WP.IKG9(Q$ H2:# /J(\&0)P'J.)48@"^$.128 /EH[S^JAC5>55_
M8:H3R*80X.4F8@[UF"4*L+P,88,$ )1,4(#PT;@38!"O4X] 6 0% (DW$-<&
MP [E\?[54FB!H"*!]F$ 4LF$6J-#@F:DVS"Y!)# F4"#!,@ !?@6(_&.F% 8
MVQAD52B$W8@DVZBAH="8"3 =-!.^P- "^0"$W<@"\^",'9& 6K, S^B+#_D*
MT;,Q@#E 'LD$,PBJ04"-$(@[#% *%+C94!8!*V$XRVMG>&;O]AX80^T"+JBU
M"E@L"Y /,1"7_K%)(>J@()P)FJX=S^ *E9:@A*Y7\V4 Q56P#D$AFA4?0-%B
MQ'ANGWNT<#P_!2((-A&$!5 !$T !"(!4VH$,Z9F 55 !F<$7JK8 $,$ _,T7
M!P",* &$\"%)H)J23/@XFF"JKUB$.[, UPBC^2"C*2D!C?YSLMO!M:M6!7@J
MSA2(NWFJ#$0H 0PHV/]1A2(OE3&P*)N^<OMD#BU;$]P0 ]#IBC(X 1,8E:9B
M::&  ,/1!$<9<6SVON: HY=I  09! "8GS.P":XP0I]# 120 "M!J*X:G1-X
M@'L;V2NW$JX8K"S(SQ7PC#!X@.9YGM/ #HOB"BZV#U%:TPLK/PZ- +L"E9/Q
M#OIN#JYY&Y  @Z+AA#! X+H(@P;3 AXKI"#X(// =0WYFE5P@+I2W<1)%S;Y
M70+W"S)YZ!,8\ PX'A#XB%!F7#.Y .7S #:8'51T 0*HJVIU[V[W=MU@D=T(
M2SE'E!(  W+)PCKRCA?)$=L"B?X(,!SKV(MGZ=;I6@4M0"206 "7\PH*B%>0
M"(ZN^*B2^@HU #I*000\S!=$. /P2R5$,(4VJ)-X(0_S2!60,"XJD9=K/J)B
M]8J!+<]?]XHP@!A-T Y;L=>9R#$L1(/W</>!$BZ0((&;!0E";A"I\KFZF/GB
M5 %4->(HSV54LLJ;Z(^N,.N;0!,2Z((WGXD2L!+<X.XI$5<2X( W* 4/4!6*
M!W!) HE&X!:3 (D3F'/10RX:V73M,M%NK0! 4(./BJ'(5KX+< /8,H,)8($(
M6<(IL0SJ)(T5D ^8"@'[GA+[F8N&>0P&N2&OT("CH(WYT0 VT,.;R#IS5H$1
M^1WY*/YRR3DE-A 7$T"3$(!AASJE03"/#'\6%/#UNM*"K^1H:M0.#-"8.A-?
M$K@ P#R#Q4*$3- $UVFB$B\%"J@K%N "$\"/04@]=?7VY%=^M-""V$'%XEZ!
M\2@$!2BW<<Z E#B#TA>75>" ',& X0"#^*N=@Z>-R_@Q-*A&#_@(.#" -HBR
M?^F$0>#("1A]5/*$$F(!^>4"9+*5HA&$J0&(3 G$J%*%)D&I+QE4K?K@(I,#
M3JH @5#EPH2J3A 2J>)"0E6"%*HX/2BCZH$F01-4L8%02D4)AC)#M%"5B0$;
M1(-TKD*$H$PG320LK%+E@8LJ-YID?J%0,,0&HTA5@4!:4OZ5SR\%"YY0@57!
MHE4E)*@*D47F"1*E5$D 5! "HC82UIZ):59F43$+[ZH2<18"P44)D$( U(F!
M6T$+.$DX@S7!&U45OJPJ<T'5"@]K2X101:*FJA(L9&IR(,@FAU)FG(9 P=+
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M  )Z48\#7%I+%M[ @?A\0<=BXID'0K KGG% RN++  10T(D,?"$$%@ JSS9
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M!O/#"0:4 1$H0, B.C$!-92""X0NCP?6N]F)/. -B_# 1QJ  3%PH@LB3>3
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MFZC!!-@D(B0 2VU%&]!'&=!'O<B=8Q7$!R %\$3 *G!" VB7*G1!121>1D@
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M<,)*9(\*/-L'N40E7DB<L87U#?X5)Z!!5!Q0&5A*!CC&(9CE,N;>!R BG:E
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M 7U*BEN\P65<)E26PGR@3]>M@5=Z&OQ<Y5HLPDJL[ U9B%M*QGB9P:R*22=
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MC-E69$+; <E5"AP'>$6\BD$'*/[ 1 P JH3 0K@!@#Z?323 JW7&!(0 &JQ
M!G1"!4 S"]"'(D-'LZK !*33 JR.]AV$&)Q!W 6)8)J' J#.&;@'&# OU!7$
M&32 &'P!3CC0)1;$ U#*BRZI"9Q!"RA %PR5"I1!"!# AK"9&1C; !F6FRJ
M&QRNA$$ 4BP 2[UH&(2! U!*0J$!OG2"BG%T!?2-NPR&3$8*8O C")B!"&#
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M8W45A,]&_5'H!D ,4C5PX"I57T*H,DBP($&#(((H9'@PP_Y$@B3>6-2XD>-
M$2PD-M08RH,FCHLF=.HH,5,#3BM-H%!EH<W*B8,2F+18"L0BD38Y+@0ZL(V"
M+$)##F5HL(P*59PH^$1JT> 9IU,[&LQ20M49F:48%/JI="-6LC8-=MEP=NG
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M#1X% 9!2.&!A@P?RE#I7$F2:BP%3  %!!0L@0$,5$AC P/X-55JX=P.?2M8
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M#85"(0>R59>%H>$,:R%1L3P0@4&4P@UB7-BH.B ;@VQ@#)D@0$9,6)D$5&8
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MQ@=(!Q$*2 X#5(!.")2A%-]3A1;$^ 4#R)(N8@E$ S)1H3=L0'0M\<D66I>
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M!1+ O/[8,ZD)%Z38 IE(0!!ND_C(%1*(]B)T$7(=[]&1?G0VB/O%W.W$K\0
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M#41@[,0.!#("LTZ%X"SC1^)#.3+!(,( ! C$!,Z WJ)H(%@@,>PB850!#AJ
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M [I./A?' E!  A[E"QY 4C#@Y.Q)/ B@7;X  53B#1 JN31@%;9 BK*@R$R
M GK&1 ;!>DB ,SM ;8Z$@<93=%R3HSR,7^30 _)DDT;0($:@/CK! 52C 4
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MD&L64!OJ(@%G  <JL0HGH $;  *"00(K@'@G<%6<H#,;X+RP<0*(AQ?FH6Q
MRSO1.[V<A0$I0 $SMA!A@+L8<"$DP "HY"UM>K6'4%?59 88(+B> 0>E@@&M
M5P*G)P$C\!8_Y0&=VR,3H %]UTXGP "-IBFJ8 )&%@%R40$64!&:4+(9$ 2J
MX D0H F(D!0GH+\I8A$8T $6\!B=( (>D $E\*85J\(K_*>/93TQ%"1OL"<6
MH$\*P!$N &X$$1W*N*K#9Q$$4&B D!U<T "<T D(,#-:\!TL$ (:0J+RZ1Y1
MD5\;H :KT  Q! @&$"C(5 I]J_X=D?49J]I2?QM[%1$"AC(!$&)+8M8%.)$O
M8<L>%0 !&= "T;IG'_ !&E#!FA 2"U$& =)!7*NHI<!V(F@A[(%<B^ BF8 *
M.>49%',0V'8"Q+MPCYQ))6*')M!7?QP*Q9MB)\>T;Q$P?.P23=8(G$  @8(&
M??4%I,<Q;#&EJC &[^,K@E$!8= )"W A9D  A< 94%81**K C^%<I7!/JU &
MO,$"'/ 63.$5SGMF$YJAIOLR%>"\N8Q\MB(24#$&(C8!!;D =L$&!  A"\$7
MT(@&RF-(@U E@,$C68 9=]H!!L$&[^-G%W*S5R0"II!F,Q@P\\(===  %>$;
M5\<[=?ZQ"O)&6R!0"FTP !"2 1SB >8#KQ,D6/6Q=:7 0,O1$KP32)S%0N#(
MPB--TGR:L6+A BX0"@:%D40<0QB@ 5F CL8<T\08 ?HX:JV:K5\P>!6 2&Z
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MQITMZ)$T6R30!162+PC@RSZ?*V_  9J  %PT?(@>*+T. G'W!=\A8*C47P\
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M@,8>0()N6J4!:*( ;;)0@3*PP &9*,,#0D J#)1B >N$P'[JP 9;7S(!$Y'
MQB;@&_X,:*&F74Q>"VJ"B %<)PNN"0$)V" "XZ)D!2%P0UXF$H$QE&$"C^G"
M!,:0!09P BT&F?9@&@"",'3" EE  P9TTX8&?.$+$7#-0TT @<B&P0)HX,('
M-8$ $H0!!&FQB0H4D 4#^58%[^:)!500D_K(^^(;J,\7''""19#1#8@4FDFX
M,(9B=X+4"SV+!&+,@%V1V,3N>8,!6!"&"M0'Y2]_# H\P(83>*;F)@"#!S2P
MBL6>X#%$;8";2H"S54P@LG>V"2(4L(I4FNTG;LB <3411J.U-24-T, 77-"
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M,D"$Z"@@@\" F0F#FD"#\*L WQA"%YP9R.2$"1A,$>" ^H"#"I  #6@J";F
MHKJVOK3*4PN!$<" 9!03#Y  "E J%2),%2B$"  /E!"##C (+G"H$O"MMZC)
M$.  3:  H0HN4!0?4V0E$9#-#< J[;.E") =F\F"C2B%7FN!(E*+/"P(#* K
M[RR(#+B."/"-3@ !"9@ 9AQ"\*@M3AB$"1":18  3Y#,$4A/52BA?T*F# #(
M3I#,,VA+$)A--PB$E&RT+W"*>]J(-NBUP?" 0&BM#50;HDJ 5=BV'8(JJ\@
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M)3-VX'^4"9B "O![G?=RW%]U!5J$"G@BE6<9+7 H,$AB3I@A=2P$!* J1'"
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MU 0 (2D/KH( <.,"!" "$3%<H!16Z00;@K((!2 B"QZ0"R<,0()!H &'G5
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MDVH "A]5J,%V$9' 6Q/"B0<0Y?ZI+E"%C(RZP+WD-D*VXX()8E+9W:AB!2C
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ML%T+5K#I4D @G@UF@X0/@NZV_\?""+G9 T2P%,VJXB4OYT(=5JI-_SQ 2A.
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MN<%!00$"M#45[&W?$UI 4Q%*:3E$(ICA^5%D10X-"JS7%V"30I1  [@ %VP
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M& ">5,#IJ$"9M-@@'"":'<2YA  (*)DJF$"+B0$^8>=Y=&(8? $"7 F.\.0
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M  9T[,IL@ FD!G2\;.- J L<5LLD@AG@4BFTV"E%!2:UP?<XB.I(F!B8QP4
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MPKV75@40#"!-!BK) +.F\@M=J0 90U#/P*XF@H-0@%'8H,0+O$\5'(@91CC
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M 3<$HH2"0,0B*$5B$$#% ET8A" 6<9B! 8(3%^"$@A'R]DY80!.=L@T<7*"
M17"@<ETN2 :T,(A M-TK'LA 5C@@51-_K@V#6":+=KT%%"#B9I(GNXEYJ,0-
M\'<UU\S\,CMQRX*\F2880008@@R&-N=R#%*^U0D>1V]-A& %B!"[EQ&K&C&X
MI; 8R809,N Y":Q@F3YA<T%*2/X>YB."!+15Q8O/X,L14!2B%E'!3! 1 <"H
MX$I/9:L%KEF( 9D@6R5XW JNY-TS3#TJ9LU""3IQ B^49Q$2@-Y.B$\04L/O
MU"# *%P@EI3)$YZ+(%0@"]I@V52A!+: ,PI# @[C=]B@$T @D:@*K RE6U(O
MEX)"#<#ME^#@#8)L$=+,K&*&$]  !/1M\+K.#0#!)RXG>#X LAIBP4! ;3(!
M DHA [A@[1(A$S3! =Y \Q3CL$*AWBB (.# )\8K 5.)('2"5 ANUTROV!"*
MX$9"!6#'!0:A$#J#"XKN(BK@UB@%8%2A!8+' 51#QW()!-[ $S!@$1)ARE0!
M#K)@ ?ZVZTL8X%+8@&56(2D(HKX2(>2^I+BDBY-R;0)88! 2 0.B!*&FK2P
M0]YHXJ=(@ /:0&"$0P*2(^/(  +,0!-6X((  1 L#>M6D14S @*&[@*D2GQ@
M1ZTN4#7>10+0116X8)Z^( M6(0&P PX0(,&4*&""$=^(41"4B ,@2ZG*H'K<
M:*$PH@L62@Q<8@.^8*XZXED (Z) 8";,:E1NAB"T0 22RE"0;!%VBU,N*0RB
M\;*>:E1, 036$;6DB0 $J0MV205,0!-.2A4$P0\["L14HA0\#AHQX@QBAB!
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M@E=B@>&'3WO3^>+O+BX8(ER-O32A J0V@R/8)-S  A0O*)>BK>B"!!@3(=X
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M(,0 DB$@$YCI,.#@(5I@E[( G!KR<13RDMA ?)DTLLK"!>)E#?\ZTA3  Q!
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MH VM:$=+VM*:]K2H3:UJ5\O:UKKVM;"-K6QG2]O:VO:VN,VM;G?+V][Z]K?
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/4IOZU*A.M:I7?=^    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>comp_0026.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0026.gif
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M^OCW^/;Y_/____CX]_#P[P
M
M
M
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M.(JD6(JF>(JHF(JJN(JLV(JN^(JP&(NR.(NT6(NV>(NXF(NZN(N\V(N^^(O
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M ",:#/XX  !GX)Z "0 XH GG^0 %4 !R$ QR<  4X  -8*,.( $1T "], (
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M D *=@  IZF<EJ ' E "L."S>( ' %"Q9V !F@"L@TD""7"8O1 !%H 0<0
MD9H "C "&0  ?TD&$0 !84 #-9 '&2 #:0D& 2"R#SNZI#LTY=D"'# "CE
M8G  R,D '3"C"&"S+F  32J<RQD,O! ,<UL#L"  ." 0(?  ><  %& !Y4H!
MPU !MBD0A+ "&T !!2"R%E !J_Z9MKU M#8QMW# O<$ !P# H' P A?P  X@
M#$H0K +ALL=K 9GZN9\J$!4@M"P:KQ?@OA'0"QZ@JC4@ /=Z !R O * !GF0
MNW4  'BPK0PK$!G0 !E0 1-0 ((@$#&; 0C!!G0;#)9PH!R@ 'SY"(\ "Q>
M!UM* 7\)!N%;NBJ\PG(""P<P V(0 3@  7U0 &2P"92*O Q@FS)0 +>;!P7
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M& MF<@Z<82%,"P9P@C4 JVHT+ LPQ$0X(YC!4K( .QKD<X&!I'R"(P(VOLC
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M/OG"^[#C4L/88@)@$8-%@I$!1MR!.-!U023R!@N'0I0#3BN(&$C@@B^1H07
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MW"\-)9B[5K@?$:E@_W-2>3]5L-/QJ;1_8QNY?E;JKYE#74G_].^*^DD&#*B
MUJU?1-2?7.!?]\4?^/'? C;@ UY%^S53VW6?_T$@& 7@!8)15LA% /Z?!.8?
M!_+*!O[JG_IIWP$>Q 4BH &V( AR(/]M(!C!0@V8@ L<'"2UE.[!0H_-W@=>
M22 Y4O4-(1'BF P6(1(FH1+:V \NX1 VX1 >H1-.(1568>CIWAL=A+],!2]D
MH8V]$11B11@6(?<=X1@"WQEJ3!KZ( -VH!766!JNX1O.H540'QW>823)T6&A
M2!Y80 =P  >$1G98 "&. /HYGA?2@0MD"[\YGEK(10CTQ0;TQG+@ !'!H -Z
MGQG@Q!C*P0B$0.\\Q2_-P!NUCKBX663(@!"Z8 .VWT9$PA91$&ML7T2DP4JP
MGU5L! ST$ J:@6E<H/JQX*ILC51\ '^P3%*DH HNA!TJ(/Z];<#6<(44'@HF
M) @'? M5^)\,X!&,/,"/6$5DX,!8< !@W9]-[-'W+6,;@N,+5@6O;,2ZL$D=
M<L(9T.)4&!M9=, $R2 OZ&,ZYJ)5Q$"3[4F)8.,_XB%")B0>VD$ ,8=J!<,#
M$$8OU,!26((",,(F5 (,I,[G5((,R-A"C!0:B$&11$;V3,4CT$(O4$\C3,!)
MX.!6*!!7O,$#A$H$C 4L0$ 8,$()E-<% !4./(#J; 08 (!!:@Q(183;9(49
M#,U6E$ CLH^;=8PC>&$P^,]4V((#6&7&C$XT3A(CW$9*2B,%#<#*; 09#$"J
M9$4,&$HC5.!"8,(A_AXP-$(3;OZ)5M"*4LS"5BS*7'9%4=):OE2 (, ! QRE
M0B:F8EJA'41++T3 %S' 0+*!,&1$V]V,9[@ !^B%_-C-_C50&GQ #6Q&)0C#
M:#0%7@ 6')" "<0/+YR!':S "'REU=W+:&I"(YK!P64 I#%DBIA&&#E"\UE
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MK !9&8PFI)5?\(L,I--=;$0)?$$OC,@W?5$E.,=9[)\89("628 M5(( 6!*
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M+ZB7(YQ!\AV$(V1 NIDF"^0!&"!)6 I")7" H3T->IB)&#@"#"A$!1@:#22
M2>17"CD'AX;J0DP"DGR!TIP!9WZJ\S[O[!FO"G89ZN:G JP$)J159)@!X0Z.
M](7M"#1"+("!@2V$\A[$]/3""*S,:3K%%^C) Q!9'/P&>N1$:!"E")0/DF0+
MT:P$%[J !%Q.7VS$I)&<!,C*!_S.=%'%)O1"15R$)000"IE 9N!!0YX,OY'
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M1&*?X48&2(?%+81%__+\\()*?/Z0>DF*&(RK5." 6A"KZ1A(BJ1*#I\'+\!
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M$0<T.(0!MF #[QH2AA$$ P?V840$0!DMC<!S)!:P!"?XZ($,?*$$%3!!,-C
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MGN)%(",D.$,L4#PU"M B#NFR@%Y&%C 7],4"D(V 7JSB M72H"\5 ,\(_*,
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MV/3Q(+I*!-*E SX)*?V"I]BN///.*E-B"/$@ FYL;28 $S"!&_E#;-#@=\R
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M$C+ !!#P)DR@!?"V%\;1!#S@6FA!H$:@ EQC ^HJ&&JGDB)"#$@@!/Y)!BR
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M9,(P4E1ZX:DG)PE?]!:!1)$X$*9"C!Q@42\P,&C' 8\H9 <#M,#BP"._BJ$
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MH 4LD%#!83\%4\*]A%EB 8HM<#!"!1:= 13L%Z%R@0DNX. L')0&@\9-<4A
MP@H7W+L0#A5@38)$EF3PM 3!*1%8+WM_0,$D"S&BMADBB(!JD!7(2<OA(62@
M2?@?[&T1ZR9\T(%$CE!  @<FV!*,&Y538& O),0T PX*U1 !.<G@ B6@0'!<
MH 2%].$ !"'#?XH&P0A*<((4K* %::.)//!&5KM*CH(@Y_[!@DR,%KZ8""-F
M0:]>>.DI!@I&)2# "V%(9(,;7 @L> ,+#7:&%X\P&4=XP0A&3&QKL;BA9U:H
MD%G@85];"R%GAM$;'_)B0+0P"&\V6(FYG&5BO8 B1TA&KQCRIA?T"T8L=%A#
M>N4!2@MQA X+XD47,@PG''D$&YW8$<@]XHT6L",(!6$]JHR-(P29(E4X8HD\
M3,R0S$D0&2\(R4A*<I*4K*0E1V,+IZ6  G"XI"<C:($YXHD6)'A CCZ)RE2J
M<I6L;&5I+,&(-+IREG."A9PX@R+:/(*)M.RE+W\)S& *<YC$+*8QCXG,9"IS
MF<QLIC.?"<UH2G.:U*RF-:^)S?YL:G.;W.RF-[\)SG"*<YS&O"4YSYDG8:CS
M+.8\C27R@\Z?Y?).O#"("ML)-$W$*IOX)!HM*M'/2ZJP( ,=34!#,\]X3G &
M%,B !1Z: 5ZL8&I)26A2Y%"!C%H #QRQJ&<\JI"EH"@$?2/-04$S@C0$(PX@
M/ U(1<.(F26%##UYZ6S@T*G2G!0T,I# !2R0@0I\8(@<D9-!9H WFZ).EF?A
M2!V PA$V2""C&1 $0C]C44%,31,58&I'74.VC:"!ET?\3!ZTTQ]&C$H$I1%#
MC#J#HIV6AA:;M,"_2B,'$%K4IJ,!1FG0P)^@2,"A0*V )0YJD#?DU#26<(MH
MY*K06OYJHBQG4$DP.$#1T<@! 728(AMH!9LS)&B7>'H$04PP'\C&AA:G3(HF
M[FBG+>$)%I:H! /B,-G1K,!_H.E%2SV#K(48A T*P(.7R(  N[SF"Y@!(IY\
MJQ!]L:8/"%M(MX)AA^KV=E.8P1/K4.%;!;10-"68%M#,):=8O-,".%")7!&$
MFDH$,+(6#%EXSD #J9T%!R.002R2(H$**>0+";'$&^P0@A8@9Q,N& ' @H$'
M/*1A+(]H@0E658D.6& ^<K@*+& 0 AH,2!-ID,,(6K 187RA!"WPX5G(,$.D
M,"(.6_J"07#;!PIT8&Z<^<((5N!#1ZR !"W, XW%]@@3K/Z ((R0PQL^, /Z
MY<$.<* !+50:##'L9U>/F%H<[/ %#Q!/$RL(21K(*@<3F(!S;CAE&NR#!D:D
M@(G;4@@=2& "CBH$!Q\PPQLLP@L<H,F'E4C!"&1<H5Z(0981Z"!S2, "']*"
M!OW=B&'$T($6H@$/(-[,,-A@$#N8H 2+XH0,2C #B?CGAP[8S$)@T!XZX($,
M'Y@6'D;MZC14P@5>3L&:@\$(#EC #+Q(PX!N/8*YV<$.9/" BBK1+AM3"\N,
M>,D;\# #_?8B#;800P12T%J%B$').;)$B4/@@O\&HPXBD$$:'!(Y'=NA#QTP
ML0OVU0=?9W; V)&S"18UC&RG@?X-5Z%%#6RW+SD3&;L %\. ;OP CMC!?[JN
M"4'>8((4;(8.%>B >F 1@Q'40")].#(>'@'I?35BR'-[@R-J<)*%#$/0+B (
M)] @A^ A!PT?^$* .L,!+$>I! OSVX]W!;LW>"#5*P7S!XB7'17LBB@#>L20
M(<4($JC #FA0]+[RP&/ZVDD"4S-("#B AS@HP'HDF($ES/ !@Z H+[9<B&U]
M.P :X$$&1>':FUEPGB\@  9RB$4$XK")0\-B!1S8S 6,30$P.*(QP!X &/)
M@L#4@ 2;($,%AG@?@KPG&&5 P!OR(('Y9. ,RS/!;U-  D:8H0'_A  <&.$!
M&##G /YQB(,#\LPVGQ1 #'D( 4G,< !>.\(!&OO )M)@%C$XA 016#8#&$:!
M+_1A!@. )QLHD <\2. E'&BA!0I? !(L^B*B#08;WL2(K!$H!(Q(PP!.8@(5
MR"19$4A#L&/P'A(A?A9%"Q#@%#)@ I7@-A+! 3+ " P5##TE:PS0(H:3!VG@
M*["  ,% !Q)@!WD  ?=2 6( <E.A=%^$,AS!" P0@0B0!KZA>W*0-8Z0 9MA
M :%3"1U8"9$@ 96@"23@ 4ND +R !]47?P 3&7*0!P_P$JNG"2.@>PO!!A^!
M:<$ 5'@ !PJ@";R0 +!@!](!3S,P)1P'80- ?"% $W(  ?[+IF-?E $K\ B,
MH !G2"EY4 %Y\ @<\!)R@@.=D@?@%PEZV!(J('L"L#0=( .PX&/ !@$L10%B
MP @0,%Q (B93T4X6,#<5X0@I$8F5D(>NQS5?$"H.00:\YWMY1@(W\3YW$ D?
M<!(C\  T($HE<6^T%@R1, !*D <F\!]@ 'YPX "+Q1'EIQ!IL %Q*'\M, *,
M8#>TH'9L8(>540+5URN;T0+T]P8#H1LN% %LP @G=HM,>%;,)W(*L0%")W9U
M0@&9Q0&=E!EV8 D/, LW% %3@R*/$!&$%!&;N! 44'\=P NQ4 D)( S-1C4$
ML0DM@!DS$1YV\ 8)TC",8"(T4_X4-< !CM +ZI8<%+ 1FE 49K [(!D,U[4"
M99 PU&(6#+%XJ[(U#A ?VF$!=P!L'_E O4![;_ 1CU 48I U*V03I',H)0"-
M0$(8''&'"H$'14$"Q/,!=D +M)<49T 2?),R,S "O)""I',2EB!#<F 6+F S
M6Z,>(W O1\$96&D1 E$)L< +&W &C%!=:= ++E 9P7 [P7"45AA+$B ,F*40
ME; 9F4 O7_ ?</! 2)F2"X&/C((=\5@H9D +W38NPX,1M, +0K(T87 >L# !
MO> ![OA"C!*%,Q #>%D#FB ,&KE27/*3?GE94[,;#;-/3^$E??  0/01\1<,
M'H!E./Z9%":@4GB ,' YDF"0,FA0%!=Q&2.) [9P91=0%@O! 2UB,K&0!@PR
M GA#+\%1@R,9'')B F&9%!^P*!G@",MW!Y8I$2V -W"W$!70"&F@'4=)G"80
M9<X8<6W'&28S"V]0%)4P 4]1%!30" IAE9VQ 2UD0"F#@/<A)W*@"6PP.8&!
M6@J1 F6@,G)" S!@>&(2([V ,F'QET71"$7!5>F()Q+ .9E!46B'!P_@ BG0
M BF@19CC0P;1!\R7!QYP$<D&!A7  BNP BQ "V!P'L+0"S. B"-P'F20(9H!
M%A,QDG!@"<.), 43 >*Y-1,@>@$J!MWU!3T1 O>2 BRY$/XH0@?CLD[\0E'"
M$!-H0!/"(']VF&7G81!/PI"WR!(:DP$1<![FLG E 0=OL"'\$DA;LQR],"$D
M$'.:P9D%I1"]@Q)*)J1FH D3D$LN8)*&N0(RD! AH%*W% =QQY%G:8#!T @.
MH) K8 )V,#JWM (LV0+^DY<6T C*P36[<DMAT $NL *!\0:'V28,\%\/&G$N
M@!0R1!@<$#Q"NBH9()-!0@(B5P&;L9P9,0M9@R)5L2EA*0.E"0M[0W8<$:PU
M01*NV7B]H!&], &.QBL><!L40 N"8#!V,"Y'Z5OPEC#JAUWC @QY,"ZL(Z0M
MPQ'7<5DA,+!?< ?C8A#_%A0=T/X"E&<!-K(09+ "7$-4E(9(>$.>"M%X*\4!
M$A "&U&F=JE[ Y)L&$<7%H$'W_$! VLS)(".*](!G3HN.LDA%L"9!-$+;[ [
M24&,RI$"0IH":- ''R$G\5(3;&4"VBFS)C)<(P ++)$>Z_0DR'HBG# S@R,&
MNJ=:**H:%; T!N$!%-4!=S A"H$)-30"4)49F(%Z_<B,:+4K7X =/'DNY_&E
M"G&V)V@ACC )N3DNKF8+#T"Q52$1F@ !S-%=82"F]V("XX5($3=@F#"K"A$+
M#M +LA,,&S 7ON$37-(+#F +:; ["X)=5!,!:4<2@2JS>2$1E5 ?1JEG@](2
M<[-1L/XP)$E19Q0P1Y>IKC(I#(DS# =@,L/ (# 0A;!P&+W0<]V5%+P0 6GY
M ')2/MGE(L,  [*Z*J$D'+=J%HJB$!>8!R[9&X$!!^TQ3QP0A0I1 6/A FJ#
M"0_0EQ2EJ)?E:AL6'G.! Z7)"13P"Z82#).PN#/@K370"ZZ&!_"!+URB99>U
M*)J!$A)1 ;S$"PR@10S"" :SL)DQ-W%@, M! B]Q!QLPONOBBG;75#@P%2G\
ME_=A%T_)")B@ !N!">/"KRZT*K#P 3A@,RB"(M6B7 HS+AG .?X(1OHQ%9'K
M$X=) 8Z0IQE@$0"+&--B%XQZ$0IA"5I(+PF!NC23$$_\/_YN*YTQYX\*80OZ
M=)L* 0:50*C%>":'D@)F, SF&X'^Q1)@234HDP8&(U4&008N8 +A!K:UT0!]
M4P&X^Q)HR C>QDM3&P)L\&Y=!6P(, ." (%?@@.,P'B, A1I\,1U %2TD"_<
M*9<4L,DKP*,@.+X19P*/<P<5D<46  -WD (;N(C! #W\@A0M(,5TQ4MEU@=D
MX"OQZ(T-""!<(@$<]:('@0"0. (DP1X=P8(ND#5Y8!5GX! =\& ? ##&DW$2
MX&+NYX%V,'Z;4@%W0 8#@ ?OT4YFX!!O4'U%J%+F; (L,'Z\X "WYP()D"01
M\)8<@!VER# 690L(<( <T ?9:/X7O<H(,% 4]JD0^@D!T6J M)  '!@!=' '
M#B 'D^  C( '(: 1<*!=0>( (XP&%L ! T(##."-%F S7JF$CX@2G'-BC' &
M#. _WF8'L#"$V%S32+$"V!&QPN  2N (8A GBLD +!(!)&% "K&.P5##* &
M"T$19L (-8  >8#-O&(6<F"X@W+2O/@(12C6O<&$?7 !=7E4E&*;IY<!8_$&
M$J!D$3 V#' '^<8 E> (XIA]_Y, XRQN"O %<+ "?ST9T H& N (<<  QL$!
MO=P47%,#V#,N7Q ]JXM=9O$(#^!_'' >E9W%P; )'MT'+:  E5 )S!<,RZ<Q
MO@L'#/Z0(0!V*&E0SHDC)A^@TPHP"V;P0&7@$#VG$"&00"WP 7UP!MK( ,)
M6;BG-E939AFPK<!3R'8B!HZ&!AV4!KO""U]  C5WECZF?G*2!^3)I/OR8210
M \?6-T(1!K#@=KV  ZN"!@4*"S)  C@P8MJI"=JI9:WJ6BS0 G=@('W@CGG0
M2=[8)B[ G3)Y2T[:8@IA=5@,;'-CJ6V"%%^S+>^=X1AQ*,U1 E/S(<'P9RO"
M""J40WAI,O,D:@1^(N(=!V_&"^8E*Q5"!VI&45-D7"J -WVP C 0"6]P$H_
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MV 0&G(O*DKSW@ !]L11L&;M@2 &!: '*D(M84  :DK0(:/Z,1VB NPB,^8B
MLN@%"OB),QB!@?" ;HF 6;"W>5/"(SF/$4B#3:  N7@$3DL(.1H(04B*#G W
MN2@V1B !-C"#-#"#%<";")B!O3,#1Q,!.P"#IP@!W, !,9 #7K" @@(YK3,!
M:KF44NK ,[B?67 9!W"$'PH#N3.JFUM$1NR-&H@- G.I%D@=/$B*OWL<Y'@
M6)FW9&N*7\F#I%"O(Q0PMI"#^<*ND>@#,:JO8/@"A\NO[PJ:_HHC:KD;7OBB
M!=&$,\ \_,JP<U,*N0 ?@>"$BAL(.8 %.C@W35" /;&P@9@J$S"8$&B-2A"!
MQ N&1ZBL90,6(VP!$NB%6;  &?[0!(-A!#$:B%F8D8$@ <-0,^I@ .^)!01P
M!%H0@(\+A@OXC ?HFDI(@&Y1DQ3H&AEH&CMPG8]P@%EP(H*PP"_S+NBS%#08
MAMB(@Y=A 8_(ES-@-U5P %Z0@YJB2)B!!03 $%B(#55<%QPP)0D (!K[LSR
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M#DB@I#$H1K #3K.^[RDT&,@ 6A"&"O" 4Y$+&>  ,7"U%5"37O@ /D29>9*
M+X !((**<I&0,4.C"L"!E*P$7G I.]@W.JBLL8"!+W@ 1#F#"  #&6B +KF+
M.%" +^"$":@!,5B!*_(VU["$#,@ &.@>Y?#/$L@ &[D)9C*7$9,!]2.:A, #
M!@B!%J" $, 0#4L!"A6D8&@!!?X0& K@@#8B 5PAC@KX AJ(@(.X@P=P 1D8
MMAUQ@(<(EH'(@-9@ %@@ ]'RC&!P@-28.#' +," @(IH!%.J@;>$BBZB P9
M#@O('PFX.N 9" @H$W.L@1IX@!\9A@9(S#M; 3"0 (O1Q .9+1 Y/ULH 8,9
M ;<Q@P== 09\! :8@?Y$%!L%@P\8@>8J3I[MV81XPS# *^0P S#H&DM(#SH0
M TV@1^2( U'].'C[@O1HA+(@RZ%5 @[*JS0X UB %4TPD*\%#*YPK/L) 9J[
M S)X!,>2"T;X@C20B[#=NKVPVGGZ@JR]@^1HVR[BA3.P,*:-O2\( QK! S.@
M&@S)D_X.^I&X#5M'Z(6*P$J\2 ,< ""$< 2W59-*N,&!J(0S,(-[W#HSJ &Q
MZ04'DP/=7(A(^ (R6!%A*!@%"08Y4-WL 0QC^3A'X(H?Z=K[^(DD^H@T^(*/
M(RX5R4,0.8,T&(9*P(--^)F8@<0X* --H 5WPR):R$/=-9<O*+F!F)4FH0-2
MH@6Q(8B"Z9_[  /BFPNN,+S-/16R? -G)%WD@-J/6\*B)8@^J $\T(3T( @[
M<#1-,(-NR8-*T(0IV23 ^X\\^(*KBYGW0@A,  /ME5N02P,R>-T\<MO&L 0[
MD ,YT!*$:(39Q8,O$ ,M^=\O$+Q@D*BMRT.J/9"MNY_;#?X&Y#+&+W TY+@H
M6Y"*2A!:&5X16+@HOOT"H;U>1QB7[14#,5@1/'D/- #>N1@)6A!7A+"$X,Q<
MH* 1RSV#NX %,5"">Z0#):!<GQUC,B[CJJ"%NC3CW3 #"@C="'B(W9A%-0X5
MI, !-H[+.29.81"!2R$!=LMC0)X-.?:*60ED0S[DKAAD1(:41$:(68P/AH@+
MWW $,B E1];CJE#DFX,%-!"#$M/D4 'EC!#EA"#EJ5!D.1"#.&BNG0454[:(
M5O;95R8(2,XKBYAEJL#E1=YE7NYE7_YE8 YF81[F429F8R;FV?7E#8&44WFD
MMN"$_AD&/"B2KN@%S;7,19R%[/[!!.'TBDUHHSB+94=FWJ[@A#:"!4D!%71>
MB&6.B.FIBF2F#JS8A'0&D281YZ[0!)K#(5YPE]^@9XOX+()X9[R@@S?87UAX
M!(7V9X5@CZG(#D+FBY]PYG4^9HM>Q$"""UU>1$5V@=2X@RL<B(*=KS!(V(S
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M WV $&"@>8E+&& #_D&#LTD:&ZD$L.& L$@#T5(3#L !$IB N'0$=(ET5/F
M$&"!Z- $TPJM,W!QXF@-IN&%W)/Q@#6BR2L;?.F%3!J![UL(30@!<1P!C\B@
M3TN#.& $7'D$3/H #["? _FQ8/Z%8\0Q3Q*X Q.8@)S  \F@=C,8%!D  Q.@
MTJ?N  \J"]%U#1J@F+*A!4=8+6%( >:5\5YXA!K_,UKH@ C <'&C'Q+0\VY]
M  YPA#C8#K5)GZ*PA?+L  I8X/4@'N.A #I'"$: '=EA@QJ  8>!"XZO\F!@
M@S" *V*JG[V0@QDT 4O0!,I(EAF( #)8"CR,F100]L]( VDIBD#S@,.91E@H
M@;MXE?.^Q[=63=M^YQEXRR_=WS?PG@,?B0Z !5%5$0=H#,A$B#!0 A:8@#AH
M<@^@GDW@.E!O17=C&LP8%#'?]:PM\1(_ Z;@A0[0!)G9HB_HA3T"&,K0HD88
M %ZJ ?ZF2('QL00'&)T &YMR5:93X0G F"\YFH0*&(9'$  <2"5N":O(1A5Q
MZBN;L0.H\22>88#C<A CLJ/LZA*)I(5)&&V!* $:X O/%AH,GX7BZ84OF'L9
MAJTY:HTWH P98 Y%DJQG Z8#( ,]TR+P&0@D<@W[PY 9^(N!=(0<;/S&5:U@
M (: AX .R(->4($*T(19B-A8!)#* G'?=@%:D-E-L 7E$C-'D*=@&(%!R0 <
M&(8\.  UXLCE:1HX&"_2H@6 ,'"&5IH(P>X\L$1KA8-@(\ $LS,B&,6*P3K,
MH)4'@9A@%2S@X;6B!B\&L(+!D-&+0IY@?2Q$+-"'%HR)%/YA'1!#RT1"2PPL
M!>/0)Q@;#\%:N A&@<0L30HTY<EPT4RP6!$T5?S"@-&P%B2".7!TL$)%6@QX
M,2IPA]8,HW(J .T@)^B=8'$Z!+-$P4XO&2J"F4A!"U:%-,$.?*%EQX$MB\*"
MK4@Q#)8%,[QJC,!:L4.=8'2D@CDP<P;,, <$L84IYD :398>Y.'U1@(M7A3D
MA/G:YT$P,0HL:4(0@U8-#L%JP AF2X(F6B-FP-)$H5(P.$9'H DFH>XC";PJ
M1F 4[/$*%L$P98@P(C%%&28L2HAC\3R.#-D?*2#! 0)5/!0J:A+!28^54 $L
M=Q0PD @S@%7))@:E$8)#7P1%DOXE$>012P%IT'*&!/.!&**((Y)8HHDGHIBB
MBBNR6&(?$<Q@QW?!].+(73( !E$&XD5@"R-2!</(!=II]@6.*7!P!E 4D==:
M"RO0\L47E3B !QUY.""')1^Z!($><N3Q0':]!/-%"N!A18L@L\$13 1+!F/!
M(T'"%,R!9SP 2R3_B?&>(__9@1=%O%Q%$2/_P2%A,)M00"8,%Y@QR7@2F&''
M'2;@U0*%%75740APP/)A'L;1& P)*]Q1AQD*?)>" ]39V:AV9=AAQPIX22 >
M8%0=!5$OFMA1PX=IV$11!7-Z5(D<+-&!!P+BT<(('!6< 0MO%)E (0=Y,.*"
M"KVP0/Y5!8[0,L%-'ZZPJ280E%D!&<C.%V!%(\5I!T4NU!!,"(89:(<$>5R9
M "-Y"!IH1:%^!T8+%&70$B_*WAJ,# QF@ =%VPH9$4QI?%61##@&0PMO-225
M0D=DTN)='AM0]%(PC]0I5S"\6$*'"Z1.%PP-.#Y "T5V&"?!+#12H%E9#\3R
M,TQFO&=1+S7# -,7*U#4RP.\B$$UC0_80D;'.&@=5)N:2/ !F8R0%89Y<8K%
M2)VPX&'&FY!!!$;#=-1Q0"PF4"7&5S+04)$PN5;$PL(4.6+&!\]*W#1%%+PQ
M'R9?C)!<)5\,C5\L>?SW&"P0G(0M5;!0X#/32E5"=C 1 OY6+;L493T+EYI,
M0&:+M^.>N^Z[\[ZB)3)P<!4L&9APA@O)R9&95"G;(DB=>&S02Z%EQD!1&CPE
M5]$;+9S!!AELD/!('A"(@<,79V#22)UT1!"&E&A01Z:1I5)@"=HLO"$"&]K!
M&J<@0?Z'#!:801PLH(E*F$L,9PI&!AP! ZJ027:AZ]0;%*47GP7C#2EX0 N6
M,X,O*,$,%FL!#DKU,JF0R00=V=$,R&"1$&0+!V*(PW=@D(!(4$0ZM.B%!#[X
MA3)8;%P4,1FV.@(##N" #1M3E+%T5;\T4,!]7V@-S%9P/3/H93S!B$$)OU"#
M+^B!!G+X %;&E3*?J6X$O)I%!?X:(X<52& $MJN((\Q%$1KDRP(M"88+ H>&
M%51"*FB(HI2J10=2R4%0=I+ 27!P. LPHA<D^( 8Q/ !E. H _8*Q@4&!J2B
ME6 NMI/!ILZH"0O$P@*A"UD$>($'(-E!*FZ[V%Q,X $PF,$HMA'+SG@! 0Q&
M93EID@ GYL,)VACJ/V8H@=-2<$LSX&5^PN A+,0 ,NW @@Q:<P&.OC.",X2,
M ASXSJ&"$88%5D \>(")  F8@3FE*Q@SR  8<  &#I$ G*2#!0<D]1@W-6)F
M1UD8&6;$1PFY9YHSVXH6UP*>36I1+NNJ2"4B,(R*J# 8FC!0,,!P)@DX:%@2
MRF<6K?XW H3E10)S[!U+6^K2E[:4#'LD 1C$H*B)!6,8(7 !A9CW(XKD84@D
M,$^HOM 7BM!" 4-#:@A&L E'A. K$Z5('&BA/HI@PB!47:48@.23BX2!(AV@
M@W;@E+.,*0"';N+%GGJS0#208 1+I8@%(M>;2Q(KAQ3@12\81!$%P*(#FQ1?
M,%(05MM5@@&;H,@$[$6LDUID!DF969O.8((7?4<Z#)M+,"K1$B$6MB.%-0,M
M#D"1++*A6''2E04J4<>*["\%V2L!.!V@&0MTI!(?* $OQJ@U.3%/HQ_Z0M/L
M$ 'BV(X!8IFCR):T 8CH\5[Y@L5..\((+F6P%W005"*# ?Z,6)WD"X_T[+6Z
M"P.*;7(#C& $R\I4 A+8CDPU$!0C(D"F%,C6A"GKQ<I^QC*WD:D#>7 $ WZ&
MPJ+I+#D4L)C.J":!Q=*" JHPH7?W0A',!(,,CG-)@8.1!ZF1BDJ]J9.(PZ"U
M-]3):G,*P1N(&Z2T_66UP<"#<10 *T8"QH5O !)13)4=/J8@;'0M(44BT!$&
MB):/?PO;"GA\$2('XP&,B(-->.$ 'LE'9ZHU@0LWZC,Q_&4ZFQC61/C6BU=1
MI 1@2-EW]&)0F,(YSG*><T7BX ![2L 1+R(#&$)0 :S(8 ! ,8LM\L"E.WR(
M%R2X  M&D"\.>$##\+5("1*M@/[ E8D"8#"!!7CQHJQHFM,^(Y,9' "#+TB
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M"-\S ,"""S#R'43  Y 6!V"T"@! L9!!5_L'5<0  'R!&0C WP# LQ&UFRB
M/ W &Z0! )@!)G1  LB )L ! !B&!7!<#A7 X8!! < ""3" S_2S[53 U;3>
M#%! '>!%'MAC#0A %I_T;--V;5.4 'P!'H,3+50  J3+ !C'8[M &B0 672
M 01#(T"V)@R "M@!(6.0'1A !KA "UA !#@"<^?+'>0Q+ P CJ P)T% U07
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M!#1$'H#P0;-PJ52" @@VVN=0 PA  U"  %0"'E? OE,(&PR  +2A610 _@*
MK.#PG,   #P%!3  F1QT14@[!81  5#(BCL !%3<'2   SA  =A+!"2 AQV
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M0"5;/A2B5\$FE!*8D0) JPSVW(F^DM*+$%#@#'!8@0(NTA S["LA'G G"@>
MD& X (UG4MB>%/"%..   30S :<:T@$ 8,(AP0C!W#(R$U@H@&)Y ,#N5O"
M+RAA! J@8AI'4+V$;*( >_D" FS: @5$(B<CD, 9WK FH^R*!C.@@0OX1P$2
MV*%JD7L$ V: !^%Q*J)YU:M4>J&G-%@P#]"S1!## *6$Q&$%)OB"!7.RV(2<
M818U.0--TF"F.U Q(8^ P4[!FA \K(86I\*(&0S[6)&<H?XF;[ +([XPJ#0X
M] RE!9A+&0&#%-1 MG%@00IHYJP:**$&7Y@!CLR0QU'% @<K:$$0]]I<Y\Y
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M5UHG&$A@!%@@ SB@-2Q )%;@ TB@ V@A$BQ@)R8A:,0@ U+  JAH&'BI!$C
MGFJ"@/;)V=@@X7KAA<Z !7I!#FB"Y=ZE#@##*<Y@=SJ !4R  K[G#"K !"H
MM5R@!3)@6%K@ TP@ X J$BZ@!4;@>V;@ U3E(ACA DR  [@)(S*@$F"A K[E
M <*@)N @$3\@ I:"%TB !)X1%N@@ OXI&.0O&&"@ TQ@ _))!D*@!<R*3"3
M2S!B!E:  Q0C!OXQ \!*$S8 ,DQ@\'JE MA1!MJF RK@U0IQ3PHH&#H@$G!
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MC4DC>RXA8*!XRBHAZ*"<TD!/*O[ $53/G'QF!MCT \B12Z!'!2R %K0S&%R
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MDX(A!1Z@321@@$YX*)8(B5O%$BR !$*  V1K!C)@!6J ().'B#"EK:]U*2A
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MT@):9& %):" P5I%@P=8  ]OL$#V'L 76'R@!")(06,>L8'\2>!EC^@ #"1
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MU@MWD#FEX1M^HSQB8P?]8PE"UQMW@"VIP4I&$0G241&.4!E>L15)05Y!<A;
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M%=59)B1PE&NB"0^@F85)/& P P:)!Y!6 \&(&#)  E]0$I60=8]0.W!0"3,
M!Q41!XU0-0+:"VE@"2U@%HS  B9 C'E08&]@36Z &VC &Q#A G'A E)&&+TP
M :/16RF FVD0*VF@";/@!G9  AIZ(RT0$21A 73@ B2 &K,P R2@<+VP3##P
M.6_ "[/ !G=0 BVZ79$)$P+* /[D%PQH8$T?@)O3% Q/^G%'10M^)0>[I@1Y
MT70M,!J34!",T%1YT"Z]  8A\ 8JT'-GD$V\ 0LO&FTVP@LNX0+(P0F;QPOP
M8A$O=6(/9P=VP#!)4P)\ZE8I8&:Y4Q'&)@,C\$8)"@/?\A=I4 (K0'Z9X#%V
M@ =F$ *V1P8C( :,=A8X8#-Q$67G5"-GL#..X +8%0RSL (2@ /D$:HU(#>6
ML (I8 <0>092&)5]536W: :%&BMO4 (M\!?V9@(-)1<D4 -I@'TD$08E  -A
M8@EO0 =UMQF]P :"D$!+B@>VZC&5X $68 :\$ ?D 0LR(*A"D0=R@ 8B<)3H
MQP*5(?Y,%2$,;] +-K6B12H')I "-D(&)  #F?$&=L!EL2 #)M!L/H*PZ.D(
M[_0(+6 "A*()%6<+9+ 5,V "8? +3@)3@1$#(UH2<@!E(2"@)/$%(1 'JSH4
M%<<+Y I9*4"G"N%!QK9Q9)BQ8  ])Y&I5HBF*_ 7=@!W;V0+(Y>?S6,"+G!'
M[/F/JV0;]H0';P-28E(!8, (*W 3<6!/9X!"#B0#?%$2'B !<" '#E [#- !
M-0 +C?  ;Y '&8!5=O  <3 SUE0!)AMN#D4">? %GTD&$I &8O- O/  )SH"
M.R-7"1$!>: ) H #=Y!\;A4!;'!@6(5_=L"W&_40$&LP8?Y@D61  44A# Q@
M"9@@ #5P!R2 4Q:!&[S  ,?&.KV@GK1@"83Q!=94"5P!!BOX<,Z4!@>@:!2
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MB5>O* TNO A5.!6I0Y<7<# 0" *L"4$#-$ +Z]E&9V +AV<+F_P&>/!WO>
M+$TA=@"Z>K%7_'-@=H')J9D0= "ZMH#)]-D\<.5L324&-^%B"=$".>L A"$'
M]N%'+C!E+O RAY<0*P#!"$0"9Y40%' 5,4!RM# 6L& S;O4VR&P+$--TCD$3
M"7T18Y(!*(D&%E,)0\,(<$4'$< (2B(,^Q8WMX1P!9(&NO[EG0E! F?0TL34
M%2:-:&O!'[3#I"\A9,-P!KPVSI.5$(AB('7C"(/DL%TQU^ET(S0C :B1!Y*3
M,&P]=JRS B_3"\.6!AP0-YHPQLU3$"DP QLE!PBBL<%  G)0!QG "Q2M +2
M!A[;"Z,Q"]'<J9N=!K%PI!8 :Q2Q L:SJN2'IQ-@$"0U @72 7UP!\=D"Q55
MA_&A(GI-(P7Q(>A5"1Z,!W8Q##QL%[. 2S(P98R-G?NX @[P 2&@ *_CS5);
M$BN  XTCI8SV=VE@,?>,E%)J!R7AL!?!&S\T$0'M1C=B32&N=8]P![5X(Q0P
M#'#S0,&  Q\  R+ <":K14"Q7?XTDP%T<#J!UCLU!0848*LKH *9 $@7(&6-
M,0&:\-%N10&=T@(2\','=H74I)TI\!@&9P*2\0@T@08DYVF18$\<&PR40!.M
M#4@TT-(1W&,.T )P1P)VX'U"P0$V8F/)=*@)(0?2QEYI$ $L '<E(#,#9@8.
M!G<F4 DE8%6P(.@61WZ]0(L6]Q<M$ 8E32X)$0><A%7<MG<440/J[ (5$ $H
M<1$JX@)8%2TR\ $RT %8E0<6( QL  $1BT.50 -3ACM9\4DJ:Q0<,)O>G >V
M)KYA<@89@'^]  ,68*LIP *5CH2FL;ML8#%"H5_(%@Q#?1943EC^;'W:)Z
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M(1GT^8EOR:&>V4=% F8P"0"1(5@P/!P&!J-% 15"";Q&R!A(0DXP,2R"#9O
MZ\R(@Q(JF6DQ\(N+8 XF!K/ R]&%@[TDT'ID82"C#,(D1!HH1XZF" =7?-%4
M86"*, QYI?EPT-+!1D))B%&*T/Z#F13!S(0X6,FJB6"]@J&AX!5.U1%G(K*!
M]>!@!S0';74XPQ63 JVT9)XA$>P#G($9!-4Q.'#IP8$FE,RD$(R"V6 ;-$72
M-#3&'8&"@Z6H,?"1!*^$/7\&'5KT:-*E39]&G5IUZ2\R#RJHPT@M#!4'9TT0
MXXA%TDH,X-BAD+1"&L\A*-AA%(%-, 61@R670W-&,#D/\."Q("%8BPY]P SH
M$XR$B49E'-#2Q.#,L(&\&,"*(V$2G@P9:,'@D">, $>3',S\SY$'XG#$@LP8
MP,F]2GBA0 E'9)!I!0X<840"0082I@%,*OGON0X)"B",,+X *I@O)+ ##@?L
M0,D",_Z^4.*-8"YP$4:^-&O J@X&(F/'%4)@) T%.$F/H!7E8("D$$QPY P!
MR AFA0\8>>,!2WJ)0 Q&9!"@D8%@,<F1&!3PTJL[&(@CF CR""8#&1PYL9<T
M*NO%33@3>Z2!Z$)0()>#ZLL##P?J4)/%RR""H0-&X&A.CL12@"A*DO"0((46
M*#"CJV X*.$1.R+01)@':."E!9*" 2.#2.R08 1>&F& #6$^:,$1,5ZZC(,6
M2*B EHLLV)&P#([+8T UTW"DA@,<*0,"1AZIX U:(B##$2F#@0."/.Z@0*B#
M1EBA$3$BH(72@5@]B!8&(E.7EA52F(0-!J9#XP$[U-TDH?XP'.$NF!FX"H8&
MKB2H]HL#\D@NW?<2#J;88,BH0! [&&!QO"8C@*41M8(9 0>$WAN&@B\>Y* 7
MKQ@)<$!&/(A4A@+N0$CD!V4" RNOXHC@D3PXL("6#Z *Q@.H/EC!$3,$8&R@
M&@9@49,5'7$! 4W,,&@&"_(XFL4*:D@V)<],0+.I+U"JX1$S#HAC8CL>"<%C
M"V9P1(G$4*Y#D \8Z&PUO??FNV^__R:-#)B%&2B-.&"!*D7"-&E!A!IX.7>$
M&NH@S@PO,>18#!D^((Z7+WP=J \32#"+\#A$:,&.3'F1880XS-"JER_ '0R-
M%D W,1:K4@ #$QDBZ64&$E[7!/Z6HH+19.SG4A@A4Q-A$0EZ6%QXR-=>P!AA
MA),& H.66;X )AA.CG]N!A=,96&P-$(@ >9@PI"AA196R!1^4U< .AA8Q@YR
MIK;>'X$*'J&_XZ5A!&)X0YIL,8,/F($-;$+5")@T$$PPCW@'Z4,*7/ (-#BO
M*U^ B!B60HO6N0!ZC$C:+$H(/8(LR0YBR!M<7/"!-%'$.6D;R%5,P(A@&"T8
M./PABWC!BSJ04'D(D0$)2@!!.:0@%G:@ X; D((R:,(%D1$#26@Q@Q&T(#*0
MTUE"V*,7,'@&#7:@GHQZN((6,"(.1<%+60;"N!',8(QO"($+[)"T8/"B!EV,
M3"6@%/X,2^1/&-T+QB%Y04(5O.$1,.C%,&0P-C#, GDM^$ -_*2X8"CN$6S,
M QW"@#C"?,$6I$0>T-Y @A$82G8C8(%6-'&\-^"ACXB$10M&$ /<S7(F)CA@
M5F;0F>F-  :^RL-R#A(7H,B@$G&P93#2$!X2-C -$!Q()630&3R8( :/$$,<
M.-A'&HS@#6<8("Q@8$S=>>8-<JA! ^?8@A38(0_3D4,)1/ %K\PB!B,PX4#N
M$$ ZD %R@$-H0A6Z4(8VU (U;&A$)3I1BE84<!'@84)7, --V.$!CI@HM!BA
M"17D!1-GP%@B+;I2EK;4I2^%:4QE.M/0$$ZEH"&<30G3"_Z=>D9+>LO;07K:
M4\P)E3 Y'8A7@IJ:O"VUJ*GQ15)'H]30.+6JHR'J9[*JMZV2IJNEU$I":4$#
M$J0 FZGYJJ8(8X<5F* &[+G#!PSU&:L>]:DM'2I0^Y96FLZ4KZ99ZE_[.EC"
M%M:PAT5L8A6[6,8VUK&/A6QD^\K"S\#BH ,)WVDL.QI8^&H3":7L0&@16LF6
MUK1]%>QI5;M:UK;6M9650&26RH$;K88#,C(9:#H !RPMI:ZHH85'@@$#K8 !
M8)^QPQ=L^MN:>D8& WQM=*4[7>I6U[K7_=ME/8.[/J:+-+^E1=ZT.Q /R*B=
M4O7,&$T#.@GP\ LAX:Y7T) 4[_Z*9KS=/0@%,HI=_O;7O_\%<(!CNB4QU"<\
MC*"!&3J@3NCAH0,=&$%D:L!#%Y#A Q108QPRT(&1<%=IC;!B@3, TH-\0$:W
MLP0,"GR!RYWAP=,Y"!N4MP(V8:(%O# A#AS  11*K@(C.&\CLN."7M!"EW )
MAC;18 %<<.(#;I(!FV!A@@]T@$TU>  'HBA@+G?9RU\&,Y?Q4( TQ.(-#N %
M(P10MEDX(!::>$ >;-$:E*3I #B(!1T8@#P&,((68#B AV<DATH,0 ZTJ$%@
M!K*78+SG$89&M$#@P '(L6!L)^M)>J8C!HXXP!*PP/ PS.  1]#" S#NXQ<^
ML!0<:/[Q)86> 2.$D8'NY:$ :>) 6RI1 5C (EJ"#G.PA3UL8A>[KW:H#$KR
M\(C$7(0S-0B)9O0R$0GH#DN\$$-5$ED!2WI&KI5P38$(XX$T26 6X@X&M/02
M93R(X4,HT40<8+""8(2 VI&Q $B_0.^M$.8-'!%M'^H%BTKT)!B3T$Y$ZN"T
M/""'6BC9K[$E/G&*5]SBJ:F#S>I-(-=,BQ<PR$P,[XV0"%POVKV@ &F#T0$[
M1,(U>7"-5SS %W*ANP\RZ4 *<%"#,/#V(# P0ZQ;< <.^$H"F A&!=CT!6U/
ML2M>.0-6K&(!&,#! IJH! 4(Q^R#D&!M#P!##7!@A@%:(/Z:%T=[VM6^]B_C
MX0$VM1)-1-N0-U0&%DGY +4_&UQ:]$8K:6" H.4Z"=?(O<1IJGGA(^0QA&R9
M<'GX0%6B#H,^4B R%"@NO[--&+QT10'0;0BXDSH!XEA" ?=Z0&?L +T*0)?M
MKX=][&5_VCPX '\=R MP!M+F3?3B R0P0P6F4X$TK>MCD7E#!3H @PKPP@[T
M]8H%Y/ (@^/!X'U9SGL:8? \]&03$U!Q!#PXD ?0^Q$!(-0P'*"5#EQ@EGD)
MAA+@?RX%9$:)9I#! \00B8T% Q,;R( 6V  9^0(*$(-+@9X/L(!*8(2PF+T'
MA, (E,"6LH,0B(0:4"98P*8\@/Z<7G@#&C 41F@P;NH%6/"M7G@ 7M@$2CL(
M0; L"**%LQ)!@D (&(1!,L !$B,,1D"Z7KB#@\H#7X&%,M,$$BM"S["#B9 3
M,8"%>+,%; (I]NB &LJ#&C@#8DJ#SIJK">3"+O3"+S0-1U$H3:" &I@3B'@$
MB)*N$B"!-&@!^P##.)3#.:1#PH"%+00<6C #)<##ZHJ#+T"#^ZK#023$0C3$
M0T3$1%3$163$1G3$1X3$2)3$2:3$2K3$2\3$3-1$1&2N3?1$ANK$00S%3R3%
M4C3%4T3%Q/H"0KDD%I*#-*@$&*L$7XD#&>FJ4>0;7!P(.,B4)NR;SN"%2LBL
M]JB$H/Y**]4Q$??A&TN B%XHQM%@1EW4'QKHI#+Z#$V0@<QB+E@8)L*8Q<]P
M)M!0@L'H1%K003AA@Z"B@R^8*VS;,D*R!=/@-&!3#3@@#J_ 1J]X!"H+ 374
MGWE[%^<! ]<#G$(2 ^>P+YPH#3!HA%X(*-&0QM @@PLQC>(Q*L\@'$U@O(&8
MA/E9 19P)1CX+- 81M*H!,KKA4D(13((@</P#%[4K,PPC3!XQXC$1$P:"#0
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M.[ #;^&%!WB,L20!^%*+,@@68_ED5*F*5>H*"+"E-$@X"[ #6W@ T(E=36@
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M;IP_Y.$ "@@!-CERR)&!2$F!,\"#CO:*$> +YL8!"J"G%8@M6." "OB L^(
M.\=A@W =-1V(/& C"R )%@85Y*$ 7V$##8H &6GM8*@!2$\!2;>$O,LFUR <
M,=04$OZ8#N%*N3?@B@\@FA4H@:*K@,&XN^!@$:[39MVQA9= @]I0BO5C%?K
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M@)<F"!8'5@C#*PUM@1(JR4@1##"-8!(>T9% *QB-IFF^"X3[17 P"S5X.7*
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M+[N)LWPAM)6@A1V^T$Q-"(,7=J.MTUB+I8.01A.:J,07Q,0<Q1C+;ME-KL?
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M+[" =<!"!*2)"?0(+4S #"Q41^0!6@Y=4^#!8]I!;*6C95XF9CY3H<A !UB
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MX8MHP$(+T&!"=.S!=-6HO*LY;N%#L!T9M0]5J46/+(0<*/[?#'1*!M !+T1
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M&U# 3:V 8+C W*3 GF0$'K .FR!(@>S7!-Q4"Y@ ,'P*&9" WQF+#'2*&!B
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M0H.!0S$94N(EA*):4 )28(M=R_Z":%N#% U&<A8#T>L.LB0$$VBQ8X2^>(D
M*49:.D@B$^&$)0];$$!KF C<0U3(I;([:(,^-('[H#AX(:-E1AR@92^]1TK)
MO:E4G  M,42*J!&@@JD!!O[\BX"7-USKQ0%8&.$IF#P\9\B!ZV[]P.*ZPQ I
MOF$$4G.B$DG$D(2L&$$X&#G,#!989U?:M:869%SRIH$CZ 6O-!'B)0,X,:VD
M <$)8N2."Q"28]Y&#G(VA;4: 1BU@[ZG("M,&'#.[!&3FLP#Y"7(HTQ+39#[
M<P>"$:,]$VJ !3:&&C#404M )J0OH>1B*:K.J!"80 4ND($-5* #T$>9G%G
M.0I "O[NQ%"#RP1#"1(0U@'TP@8*>  & *N!P&;0%Y/ 909DD(#-\.  )>"
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M@4)= 'D'8\HZ-_$ &)RA S@QR0F#P8"6V,(!-\*$ $8055:11J@UV&0PV""
M%$@5%G$  !A'D)$^=. ZCD" 6DC@( B%P P<*,H(2'"&&42 !A)U@!PJ0;\P
MW'&O0LH !UK  9N9I \1 ,,7(OZ@%S,(1P8'R(,F&H U%<$K#%9%F",<4 -
MRB!L*SA#"(#5AP34@!86F,$96L" .SP$0DH[Z( DZT#9SI:VM9VM'0S:!_3H
MEC58JP0.PF#0.'RA$HR(Q2QV93P(\&)A6:N4FL2  _4P1 E]F$1+[& +2^4!
M>D*Z W1Q\%Q8^ =98/ /'&"AB6P.3%7<#88EAF.<)3UB.$'"'B.0DH=J$NMS
MFQ##%SAQ$$Z(X0R\L*AZ$0(+Y# (*?#] E)@06!;6)1SYCQ#+QQ1-D?@4"6V
M802-(GR&84@O$L8+V-[2B18$"TDOW-5$!B:! S'P%SMX,$,-\MM=38!!"3>J
M!"^(E?Z&I32B;,'  QCR( PVT((1:%';01I!(TU4UC8KL!E"'J&>.94TG=W]
MG$%A,1SUT,(,9*!%)535"S34P#;N.XB;;R<=^!Q6$X)<DAPT:Z0J)@\/)K%$
MI;A+BVA58B9NM@-_T\#F@SQ910O&PP<>00,T7"<.87C$,) G!__<81C!B$4&
M*X7?@^!-)6G0"RURH\7WSH33![D#?VDA!SB\ 0YIN%&8:U V3<CA#;UF R]V
MW>M>TP(6&8 >DRT1%JR]@0;HXT4:I*F)$?6"#8S@Q416C. @">X#5SZ()K[P
M8(3P)A)-[L5W+Q4'S3XW$E^P0W%Y9(89>!L/(PHQD]VG%_Y'W&C?MO7WOP$>
M<($+.(YN .G $9YPA8<*B]!.;*@JL2=,06"]G*I)&L0G!E_*EA<>6_C'$4Y2
MD'^\$CD3N F>Y (+>'GD+7?YRV&NP-@BI":S,,,7]&7Q2]D)5%@3!L\S!?1.
M_1R!O1#Z@S!U]-@"7>C7:?JHKG,=1H A#$4^.J:&00>3")T.:)GYDB3;"#"
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M[D"9L.D@]@JA--#Y6+ %7? %87"!:*QNL$9P>F0^ZN41<F=3.,0@O(S&8$<
M+X580L!F)JFI7*V@$*+3+ 7^3*(2H.G;] @A2&_V!&])0,0*%VT'#R*G-,%#
M1$(,)/X $\!P282)%C#A 19,"V/#/5*B >LE>8805+J+%AY <&@!:^!O[>RP
MN_:P!6!C^ [B=SP@O21@+60@ X"C @;"$A1 #LB,^I(##AXA#Z8K!C$Q$S5Q
M$ROO#3Y@:P0GDH")!HY*+[BO$O(G!"# !"J!3%#0.:Z#0V(!$V(@&-Y "68@
MF+C-9LX@^WI!!CS  ZZL$D(@ [Z@ S#D\U3A#M4DHA@A!#I@!%IB$F1 ##;
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M'@ 6*OY!;X1! N@R*?8# M( 2$V 6E;@41#B X#F/X2O3BZE$AH2+3Z/3CO
MH/#@ ,* %^!BL Z" F9"#M2*!);,3-#@#9M%$UJG/%>F9=[ < (UFSY+)=3F
M"P!F)00'8VC! >P 2$O2%G*G3(QG F9!62S UBR%';\-;EI@0&9G[3XGF-PS
M%B-@3'MAKB8"#[Y <-P 0#PT6(5U6+U2$SY@!,B@B_@#.?) ,3I 599K11W!
M OBK L:#%UE !;Y+ IA,,4YSB$3B TA@-FUJ!FB@!L" $23C04P@38ZPNRJ
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M1D0!C!)N(*MX/8T!5G )&8#)]"B%UJ,O+" K[*"@\B@,<. !]&(%.( ,7.
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M Q:8H#MQ*!49,*66"E9)2<6ZDPM:T(%1E5$B<4C>DR1" P0NYPQRXQ4CY/
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M8["^$@*^LG*.,(N\, P-00<FH ";@ D"2P<<,"Y@ !N[#/ZPOU8!,V ',#
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M+#9"L>)E)RAQ!C!PVE]@!RU@OVM_*33\02Z <A70-:^2!@7Q!GC82W[Q 2X
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MC CNJ#.L/"*PPY$,Z@L#@3<>&4$C&;@*@85'S&" %Q52J"0.!F@()@,T0WN
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M<(A1CTB!"O"02UX>Y*P'@<,'6" 'K6W$#EH#0Y%\.8*C76\&)FA:"S0#41K
M(2R/D,%/S. <2\# $FQ [#TO\H40I#88C+C8J<) RC<TC"&\H$%]%!H7B\ B
MFA-1"OZLL$F:Y_0!. 8]"'>_X!6!YE&S+# !'>PP@UA\H7V*9&][W?M>]\Z
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M".YF@/X2AE@!$1BM ="1G'L<CY"$ :"!SYL)-LB /I"#" D&"." NS _\J&
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M@ 5R&T=@C190%B29I.ZJC154E!'Y"!,)"5I0@MK(.V*2-#N B>5A" O(#(M
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M&=B/?MFB#&@$ZOD/Q,&#*@&.,QFN!_#+U1FI2( P(E&4>"F1TP$3,1!1/(@
MM2 #%H$.!P!/O9F0,) $&MB/KG*!6,D@4GL#"4"I9&R-HT$_S&B35VL3,Z
M1F $"<B*,Y*T"@B#2B"# \@*%\@ 1^@8P$.;?PD&,CF('OYLB8YI"14($5ZH
MHCL83D;H@ J@!1&XNQZA+000.G%K $O @0^H!#IX@!8 D^,+0W7)&@BI@4@
M VEIA!YIA!  PS0@"T%5(?"9!3Q\P.Y:B!;X@$>H@^',@P2X@Z#(DA4 0"$]
M5W1-5PX3A'V1@S#0#$M0*I/+DYX!N!"85SH("]H@ 1\9@3#P)OPP@Z/3A/L*
M0[7@A1E0JX:RA&':+$=; 21;)A(PC6#H _XZ""6@IIYR$[MQ 5KH4!2["[PB
M@4YBB%C811) I7%"K>L@V(/8! ,)EA'0D;B8D4K /#NP@Q#1A$=9ECP9* /)
M@SZQ6/ 8,J>ZB(QU-)"K!!APA/ZVPZN^< 0RR!>-0JA>6"TSF(0C8PB%FJJ#
M\*VJ"H&MQ:O@DH/T<(1+HB@_#(99> Y' *=&N"0PV)?1D(.*F@&D@('U5%>^
M[5N_M;,*H%E"ZP7>A+H'^+N_35S%75S&+;3U*JT9&S1-\-,4.+JJ>#,+BS1K
M:US.[5S/_5S0#5W1'5W2+5W3/5W435W575W6;5W7?5W8C5W9G5W:K5W;O5W<
MS5W=W5W>[5W?_5W@#5[A'5[B+5[C/5[D35[E75[F;5[G?5[HC5[IG5[JK5[K
MO5[LS5[MW5[N[5[O_5[P#5_Q'5_R+5_S/5_T35_U75_V;5_W?5_XC5_YG5_Z
MK5_[O?Y?_,U?_=U?_NU?__W?2@-@ 1Y@!0N/.?,. DY@!=:$#M@ #K  $R /
M,,B>R8%1,TB7"HA@4JT #MB "XC$#V 46.B #'!@"S#%C="83L*#"IB.%:@#
M4>7@#>B NZHT%Z" "M"<@W !Y9(#,+J#"L,A"YB<!YX+$0# &GB.K^, #LB
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MDQ88 3K@0AA^@^L<E9H9YI2(@#,X'T9Y$S;P/#CPISGR" YH&#:(R@3(-@Y
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M4%-'\O  ,TBU 7( PZB"(8&L>D29>; /0<@J# GT8@9A@,%&-,,&,-PT&"&
M4X(,HLP^1( $9)@:0>QHP_S$(K!/^\*<'& &,)CAJ[!X7D$RT)$(N*42N3(!
M<J)R/OX8E"N7(-'$&;X0@7B)CR 5(*TY1Y++&>3T:C:A06L)DA+.WDL.M)#
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M I8F6]_)SL(FC##J!NJ 7T8$!M6JQ@JN>I$'HXX@7IK(U1T6))(FAT$&O7C
M&W"-!TWLUB$5(L@%&)$'_L$A#HR8A2#8&NQ'!!-H:8C$!B"CXI/:Q\4XI@4)
M5IESN@C^TG*[C=+]A0>=$L0DC& KZ_(I SG P0XM^0(.8% )&7S0@G6A@%<N
M'8LSN"=#P&H@[4@0+YM$(@P<$& (_-F!_@&<(&DXLUM /0EEKL\$DUV+!>X
M%)-PVOXEPRMSGLW BP<$QP1^'KDE)B!H0V,_^]KOSR4M4)-*/,!>TQU5'FAG
M$ID3A ZYPL&H#+02"=2!%@R(@R9HH  7'2D"=@I&#6CQV O*0"68DQU4 *ZX
M10W 0F 45B?!WO,,PP/0604<11I8P%G,0#\)4P2I@%Z]W@Q<W!<\3PO &JH
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M%80%Q!E!9-E7+%\PH$&>C4@(K( FV $"Z)9\K=/U;=]",J3V>< PFE7R9(U
M_H]-@ $%J$ *1,#$U$!9C1.7X/Y3)7S !YB!!<@*6Y&*!%R(>RR;A53 (_3"
M!W1 "U# 4<"!2F; VJ0 !ZA #''-+%A !@R#'%@+![2?00Z0*=U'!;1 #,!
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M.!U25$ EY &GE@\)"0._/H)BP/[ <WI'1<RJP0;#>MC4Q/Q%O"9IRJJL]M&
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MH4$=?@4C,,"=*9,8R!<>A!(9P-5)A5(8?-/;<4?VA$$$_4H'2!<))"UE/3/
M6G-#._1#0W2AS<!-40#93)&-]?X"'W]E!-C!AB (V:2!2J()>[*5.9-(!A3S
MFK0DC*!LUI3 5_(/&JCD"D2 XHB!M= TV7A30=2 FU# E."=T+E !#R")E1
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M#?2/([3 "L29K\! X<Y&"\" .0^2KI$L&]37OC.6NIQZP<Z E!06+6C"!V0
M'.!U0;@!:+_!G,/"!>"!H+O%(PBZNQ.$'%0"F3-JHL- 5EGKP==1"K@ 9\0"
MJ$=\'KR!Z[U$"%P [?B*"QB)(WPQ(]P8U+, F!,$'JQ "Y"%)J!]&JQ%Q=X9
M9-!"D/""8X>!2'""'.1!XO3Z"JQ$)60[K)WZL'GZIJ'E'<#!"'QH0= !\:X
M+ C"O!7Q"ES%>]Q!')1 GTP]J7-&)2BZ(-R8)L1 "MS8&AL'+#"""8B!4K#!
M%P]$+/ZHV@JXP$"8%LC/-NK80@58 JSL;%/+ <U8; ,X#BRD@66]2D8H0 K
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M/A(B@&.&!V (SHQ@3"@ADB\^>.T ,^20 +(SLK*# EXT><!0Z(+1A (V\N@
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M7IP")?+ "!^&F#X #-# 1^!P5OJ !$+@Q(*!$0!H$Y,P!$I@@KY $8,!#T8
M6HPF!&H C98C!4""$4H@!+Y I#213D31;P@"%EI $%T##11/870Q!6HKB>+
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M#4U $6D +$K&$D8P##S 17Z!P2(@<("U TC@+]5"7$;@&3FB!9 B#@CC#5R
M%]")5IXC!%S %H!A C0!%I3N#/X80@Q>H@0JIP)&Y!$R0 +*L)?"((LT<6,X
MPHK"@"$4\3DZ@ ;J)05D  ;BU6?$9@;,@ -L)BUF("ID(.IVQ@4ZP .<$ 8X
M@6)Y 0_(  RNZU J( 63:5;#0PS"((,:H0,X  QDP"DJP5=+0#%6X &4"27(
MP -Z[VXDP%4_[0-P@&48X>/H(PW0X@O$X#--56F7EFF;UC /Q5X8H!%@P0+H
M!,-B00X8H*8*I4 Y "GR8"/DP%3P"%HJP$%PRP6.:K"Z8@*0-@T*P D5Y@-F
MP#(?@ Y@H0R2*TGA* /F22W.(%TP@0(L@03BXE(;"25F0<%,@)\ZB$92IA)6
M!$Q,(/X#+&$^[, 6<( #*@%%^84C4N E3@D!)DL&M.4.+  6A*$%1H1R(]<!
MLBCA-$$ SF 3E !'9J #4A2?4 (P=/=F."<8.F88XF  P-#8VL<IWJN4"J,
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M"R;AI#+8 _ L 1T #&+A 69 E7&@#^2 H;CN7-3"!$)E=<GIK$".!#K #,"
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MTJ %FL]SRXP".L %WICKDBR7>X$_@K$CA#8,Q" "#B0.5O[4/APA8NK+!=#
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M^>BG'U1\LB.TPK:F16#!979\8$+AS7E5@1P(=8!D"YX)#@5R8XD*#",8PN@
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MT +#9,,#9!"""L3"9Q&(0:]?311SY80#O-G)"CZ0!SP8ARAI>").'L V@DA
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MD0$+$.<- 12.2H&# [.,@-RD9+OLZNY'L6S"%GV>Q>FPZT>F]('UD3D#!?+
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M!6A@-NW#,3'2KL]R'VBJ"8R2$C(@!GCP!2Y0"2V@2IH IL5S927T "U@J!D
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M.B@,(T &-! +4<4L(5 "8/,!C=!]<N"/'<*L'0 +EC!=%C;").PJ6TP1TK:
MBH$)C_YP$/'(/WW  '7' &+ "9)@,+C@ &3 "8\P";2@5 /1,W)@UM AJ&:0
M 4P1!K39/RBJ&O0**B$ *E(A(1\P \*0!P;@"%FA.'"P(2HP3"L0%@_ /U98
M);U@ 4C2''=2V<R* ' J'>W3DS(0*8R@ (T0CV C!X[C B4@%A\ *B8 S2D
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MNE1%5F3%02J(,, $@KN#P$FC@)HD,.@ S\"N&GD (-FG7A"$2\N(".B7/A@
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MHP"\HX ,N(I*<-4*R%M>F,Z=(8&_'4[7H5L/B"N66($/6/X!-. 71JB #["
MOVH!#MB\CA@!1[A<&)LJ.YBJ9"I?FSI'-,R 7_.CG0&5H R&O<0O9EK)\#I#
M.>T >BQ"+L*O5E%!&2 !#C !DC !"I((HS4L'X67&@@#4#F_WPN![ZE/>'PQ
MA6#:%-"9%*@##V8F$#;#A'#>A'@#"^#=^)V$:;J 6$IAATB#"R !,8 !&*B$
MDWJ$D:N!"_B Y^V\%(C(6%H!"QB!;VD(6TB!OW4!B8B#W"6(.CC:"U ZO#(!
M]6P!@(H(%K" H[6(&=J 5ZN/6WR$1C'6#QT20<A2I34K&$@(6E@!$KA%'N.
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M!-/!@3.<) 9!:#QE@G(?].7 ([158L9VP=Q17#"V1"":3&!)4%8P(P9S7P@
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M,<Y0,KC!#G[P%XYE!NSTZ31Y@&M0SG"2W,:&1-")0)XR )[<(.5K!'&$ \X
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M#,"+)JR')? J(P0;:T2IYKZ4&QC*Z 5N&#6"(_PJ5G[!"OZ$4932K#09Q&Y
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MZ""5%IZTIQ*$'<!&&)RI4"PH"8^/@E3" Z@.R?7539]C&&1%"%A,>*T >)@
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M,&$&W/X.D,.%E? M+9L%&53 81I*<2!U#<R H%  +/AV4%  )D!6,,SP%U!
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MS38K'R#C$1,8",8.-C?JA8,1^JBD!H9@B2 -35I(BX8.*F$D@J1"J !("<C
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M!6S21 (NPH$!: P/WT*% N3 B/[CDD0&(=@$+=Z @)7(X .<0/ ! #@0"\A
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M(, Z2" R!L( "*6HO"B\& #NGOXO!2'J$0[@"\A #,3 #'CA+BJ0<1K$^LQ
M)RJA "XB$A2@!?#@UP3B78RM #B!% S@"V 0>1XI#:;D#,R  V2-25K #B2P
M)YQDRR+A"Q1 - I@)8 MO Q +,2E!EY0#,*@%[[  >+@$>)  1X"!]C0#>%P
M]R*@5.X"3Q+E+ARA 'BA/S;B 89D!A3@#/( !PY E"IGY*8&%@X@)IC$!.Z
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M%S* 39M"!D; !3[@3*]B!8KT*::L05T =IJ"%V"K3;#NC^S  <) *6CA 2I
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M-_!  B+@4#T@#KRF(GCK>I\CL#;+'H-!$!1X4X.A=4ML2+28!#R B2O"!1S
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MQ4#W).!#) !-KIE:4-5H[N(. ."8$4D.(D(RV.MU"<("7(,",+HZM(\OY&
MXH 6. $"2.(H+($#PR.46V 9[Z(%X((">J+>2()T?@(O+(!'LL:CYR(#7 2#
M]&9O#V &. $80B#4.*!V1N B[$#60N!^M!21/N!^A$&,<4";-\)$>"8"M,,V
M+B+,RA<YY%0.>F$"K(,6LF,%X"(6;I@-NLL%(HP71"4\#%=Y"K B-H .+(!>
M7" C%I4$/N<#DN(!SK@ \F 2OF7S*F<&=@,"W., 2&*<):-:Z'$CAB$# H!>
MBHH#DH(#'HA,*<!E9>."O"0H</X7(SPB]@;" \Q")_I@17H[&+C[D6C (\[
MUAI9(-*@ WC3 B:H BP!NL%Y!,H@Q^@E#PH %CAAL2<A1MA@S6" (LH:_\@@
M%OX:?]B:HD@:#6YX!.2@!4HE UP "F' _+8.#L1C>V9 LO,3-%B #>ZBC:%0
M!G2B!B9 !L8< EH@#2J' UA RR.BR3D"/!"I!9"#!0SZ+F*<+I+B+L#[9&#
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M2WGIPE7!2-!'F0@]DE$%1 GE@HY.I<8 )@-%($>'' 83B0.;:%2&?1S(5(%
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M"6O5FT$)-D +VZA$!B*@:+#,TX@&R/",+OA !WBQ430<A00ZM 1ZPN";8.!
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M,(MYS,-S#IG/C.8C/8);HS)9FB<S@@N^><YTKK.=[XSG/"_5%AJ<@06TI.=
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M 0[1"R:0 22P CSQ"!U0 A: =+.0D8HQ(F@0D\TX'KR0 A8@F2,R#"E  B-
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M-: 4PC "1Q$#&2""'6 I,\"5*G%TBI$GL4 !0,@&ZA&++Y,G:/$(:#$>=E
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M!F3 !FIC!J-7KS70/W;+-AB4/9ZC%) "!F: !AVP HNC$B%P$ 0A'4P!!BR
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MAF#P(&P@ 2[@ 3'K"!/0SO8!,&O$"]6;0BLD!P\  RFP 5!URRWU 3?!(;1
MD</PC]DD+G  /Q]0=/I4NSLB'8'> GIJOF.2&N@QMVQU.V=P%!=E B!_%<WD
M @ Z&2:,$ .$$!9T,PX@&14@<D_Z"\&0DQK1!PW YB3@[&:2 EI1$8=BAL$@
M B.00A2 !BM\M2K!" [P@FGC"  C%6:0 2MP)<% J/ M)7&@ (,7!A(  WG$
M%!V0/7 A,1]04HT.%-7A9Q<OE-0D,2JP$!P +COL12,0%8P  5Y: 4"X([3
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MG 0/"DC,&670 6]#AP,AD$$%P)H'!B3&!1R0@0PN4(-'')@10(%%!5CBDF#
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M77;.X>]V\[CN;US( SJX[_Q>Z^6M T%0<K+%A4"@ SWOY1#.7@^.<SMW@TK
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MH->$"5@ ,Y@$-U" !IB$N&WRS#565$ %8'AB7]!<8$ %3&!Y7WB# ' #4C@
M%FAX6MA^3(!R69AZ3+!^F\^%3,@$EZT%B\\$5/"%#OX%4K@$7/!W][8$@-@$
MC%8M6;QH:>+%BY2L7 T7DLI%BY8L@PQS\9(#0,PO611Q\4*5D%:N.@%BT(I%
M:U8N7)A('<RUH0$JB@8+^J*%"57,#0IJTH+("Y<L7+@T28R52XX:7$%E9<+E
M<"))7)EJ';S$H 2P2[2,TC&3LA<L3+9RS7H:%=>O+P#H+ SCB"+5BKERD4*5
MDY8OD?Y\)WKT2!>PX+J#"U<4+*N688* J5)E/%%R8\6'Z5)V#%@R8LV0!]<5
MS#CP8\***8LN#9EQYLJ/+:L&O5BUQ]:Q;4ZF"]OFZ<:</WMN#9NT;L^>9\LV
MWCAT;N*(*V[V?=NQ[<O%DR]'WKEZ8<*YHR?G_AFZ8^>A>Y?^_9DU<.OF8T-7
MC*M2 PD-'@5ST8!!C8%X><H"C H"/,*+1V2<% PMP2@!0!EN-(!',&<T$ @J
M(C30@ L4;9"""QC0HD2&$\ 1C!L N($* BH XU$N(C9 8B]Y9 !! RI )8*-
M&SP"C" 6*.  &1+) ,$#$<3Q2R U,I "+7%$4,,$"IQ! _X"$]SA"RDF*' C
M8R&(P,*5@DR280,Q&(@+*BKL%X(FDSB0H0H.Y<+(!C:60$L,"#P P25?4"!&
M X+@(0$##LSP2PP)'/D(+BGLIT)$CW"   <B;" +"RB@DDL8#RB@@2 .-50'
M!0T\( 8OES3@@0@(;" )+RIXP%,8##"0 21&B0&J!8_4H0 $#+@!"05N* %!
MCTH\, DF&^":A%1*2&"C&P9VY]YKD)'GG778S:;>>.T]-IIAJ9G;'&BHE7<N
MM]V1MUMGUP4F'+G?2I=NNX6QJR]QWGHK;V7L@<;MO;4EA^ZZUQW7[K;,02QP
M:>8AMQQPN^6[\+_]%JPPOPQSW/X9O"-/G-W#]8Y++L:^Y4+?3&< 0\%,,@2#
MB0BXNL"+& G86$=(+ CP1DB\V"& "XXD.!,M(PSJQ@!*^#+! 1. @4<#2I!2
M[2]P!)#B 2STPE,@5VLRP0,R-8!)'!Y,HD0 >#PB0AJT-+#!)$D$D$<> 'RQ
M9@R_=," )7%\\,@; & @A@0%E*#$ !_\4@("@NQ1 ,T7"*""XQ[@4H,!+3C:
MT(!HR&$ !R$:H((@%/7R00*5T/%!'H]@\  ;N<0PP ,J/+*!!YO( ( @M#_@
M!BTJ&(!''0:X$$P( Y@AQ@$0H+)! K2D$4 +=300@8N/&+"!("P   <J#2CP
MA1H"?/[0RP8(T'(B&9%0,,$O)[+ O9\K&)"$)G9L! \. D8$+) +"T0@$F;H
M6B5.@HH8J. 6Y;+81)P2F90!1US=NN"^@!(8TF1&,=DJV<+>E;#U8!"%LAFA
M<F3A0=P@S&(%2=ENA/.O?WV'@AQ\3@;5Y<+7@-!@N+D8"5MXPX*UD%P:9*%P
M7A@?XW1GAD*LX7B..,+A<) Y(E.A#K_#PQYRRXE!E*%S&D(?%5! !94X@ L8
M$(-@@* !C7!# ,*@"=>5@103 =H;PD:TS 5#9I,P  U(D8 -D$$)"(" +"R0
MMF#(XA%Q2)8#:,$UKZF@%RJAQ2/DH(0(-$ 6*@B !V80B/Y@B"$ %H"!&X(Q
MA\R5808 2$$D"@ !%9@!%;]( 2EI< <3!: ,P6A! 2;QBPAL0"L9$ ,8,E2]
M!RP( _:[0P#4$ Q4X.(2"A#!+X(1@P!,@A%UO*9!6!  $,P #VSYP -FX4T!
MI$%!F*B#&3I0@%9^H %X:8 %Q" H!92)!,$(!M-JD4]:W P5P<C$(RKR"[?]
M$A,)( $JMCG05Y$"0[(0@0*20(8/ " /)D@ *8*A"4;\H@QY"T8=!/"%7#2@
M!(\(YB,&,()$"F #AFR "<1P":*H1CV,J8D5<P@O"OJK+A8LHF:V0Y'J/-4[
M,01C41MFLM6 ZRM3Q&HM]#4:J/YJ9XQ4/:%5:8/">7UDJSLTS%=5QAFQJK"J
M[+KJ!>?ED:7BBS5>C6I[PHH9)98'K&_]:WM^L\6R8J>NKL$KQO2*Q+JT[  Q
M: $&T-  -QQ "9HPP ?$H 1&>=, F#@(+<Q@M&#@(A@U ( 2@H&#JQ6 3(>$
MH!+$@ H*6* A>ZB;$GQBR:ZAX@ JX$4L>,$]"R@A<#41PP<8,  TF*@$#PC
M#. P !&TP 5*0,,O\D!9 5A@%K/X* ,"  <Y!, ,P&C! 2:!"PC$B@$68('F
MQE"]"=3$ AC(2#6OF8M)K(@7P< ;(_ 0 "5TA"IE"$$#@AF,#7C/FP,0!"^>
MY8 8Q/X@:'"$)JLLX +-A:$2#P#!+WX!@@>@P@.A/'&GH%*37R1! 'GXQ?E$
M4%$3_*(7R)L$AB[4@!:L@ 8UB!M-T)()7HPA +\T26M5$"71WJ$ 'V!!"Y1
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M+,C!/_8"+<Q #* "*D# !>"")#345V@C05(%+S0"&Z@343"")LSD(_S7!31
M1&2C&SB"VQG%5=[D) 2")L "(\ D+H034?&")KB!'!C$6=P!&MP!)9X9$AV1
MNWQ,NCS140G5QCC,89X0I9'0FO[=(E35(L@LYA=ERQ9A)J%IB[LHWL(8)MX9
M3&)ZYF& 9F:F$!:-2V0RHN@5)FD.FNJ!IN5I9B06E6-NIL&H9J*QY@5]YFOJ
M4+PP0B5D$R/00EQ: DF00AR48U%( A[H45HP!B_XPD$4!DC$XB\,A8LL52X
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ME-\N"Z;+<_DR3A_C)2^%.4Q^54(3@E#  B0PQ284@ !Q!*$(,T$)6ZR  )#
MY!P.D(%+;/ # IB#'9H "5+DX0MYJ 4=7#"#/@#-#&[(0RTAH007B&&*:B"
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M&P%DL L7$,#3<]## 2AP@06HX19O2, #)@" )M2B! "PK@(>,8< >#H&"$9
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M$WB !2A! 0EHI1)*T$ %(." 2^@9#9)80 H<%__YU[\2WN ! L"F2LH""*
M+B /S/Y@ 2R@C1B@!#3AOP@@ L:@%M@  @A0!"J!O7QA!21,%2 @ Y"*=]1O
M C#O]%3! B9 %=Z  )J -,[I $S@*FA  .Q@#P*@!@!J-)[,ISYF#]X@$TB@
M .: $@B!$#C!#A9 ^GR($""@F2X!%O1L>"@A FAN##K  B)  2 A!]/J#4+
MC0K #?:@[WS!#?0.!P3@OB:I%C*  1SPS-[@ QQ $E0A#:N0%,: QQ1@!2ZA
M S2O$FH!&""!VD:CDN1 ]N8 %PCA 2*  B: Z/;@ ?2M$G9A&#1A#D2  BK
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M!,$7T$ %^L#,5&$78@  0 K*5&$2(, 8+9(.**&-0J@&9, ./H\4TC -](
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M>!@7]@<'C1 ,87"$A!$+B)@8C\ &$0(+O! ,C5"&>-&)P1" %<5WI8 ! H
M!B  !K &IR!ZIU *[U8*L/@)LMAR"=ANI?"*^1:"IY $#! (K;B"M.>"CD>,
MPOA^<2&#..  '? %,L +)( #=[$"&= "#P &!O$&$< "&6 "!D$+&3 "*_
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M, F@R8GIJ8GY)Y^]4 EK2@MO8*4&T8/328AUB85V< ?Y1_X'M)DP("=Z((
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MD> (CZ )?%@#%/X0=_T0FTR@(_Y@ FG8"Q]0 H48#!W S 9A 2[[ ")J$&"
MUP8!"PC0F6^@U!/^".)<"8TPN[=:O?*'!XV9!M@>#"L !NXMAK8]B 8:#&FP
MW1<  XP "QG0"W80[G+@W_0ZB)H@!Q5@"8Y0"9I@"Q A#'DP WR9!^%.!QY
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MI'HCJ !)7)"!%)#A V0 74%H,+D,M.8-NJL 3F B@PVD0 PA$$,6=6,46'3
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M !EXA%^)A:9X UHXHV! @P*@ 3R@!26P@#Q+ 1/0A#MX@-:(@ LP@_ZKCS=
M !QXA$Y:#9"C _G0A 'X@DFH@0H@$ J@" DPE!7(.$6YJV"8A BH!%[P #:
MA9J;B6  !DXP@;);@0NQ U&,@SND XX @THH P%X!&'0@#.@!30XDAR! ^0
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M@)F\E^7L#Q:P5#E@@%ZH $KZ0_[8E$U\P22=X 4&(-%-R( 3?0/XH05>X(1
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MC#;T"M J+6"["DNHUDVI Q*!"2!%@]8"P?G8CX00VG>DI!4H#15&#C-8@6%
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M?BDQ &!-*!=8^ ++H04<6(&K00Z+R .E+5D\Z$?$*FP9V)<Y$80W6 &C(B)
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M1@84:/Z:P9*:L.$(0<XFVVL<<@2I'B.T6")!'*+6UP<<SA(D:C#*UJ'B)!+
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M(.D4<*%-.."7%" ('H!$2#.4(!@4\&4%\$ +!WBN3XR( Y(P<5P\?-"*9%%
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MW, !9<J!7,FV)R-(PR0)DH>.0^"#/-($?V6VQ!2,AQ84@,4U.YZ""F@94&=
M90CBX/Z(,QJ$##.N(@G8X"1[SF"-6<S "B9AD Y\$"AY..-.SD!,R,)!! 1Y
MNG-5%7!<U2 &&4"E"6Z]@@.[T>L8*T@EV X_,?R.!CME0"7B(-2,38 6$L:*
MN2DP$'P:/A@>($LE)F#:+3[@$2_?R28,;@+^ $71'9\!!7;8$Q*,9R<6*),R
M"_+H7IUAHVLR]U#W;:\--"(.W2Z(OQE)R*G6Y%%7/<Q6M2I^5*L$.0IQP0[!
M .+#OZ$%"X95,!"/Z^Y6(@T02$-!*\&(2FB"%[8FR"846T'P0EAHEM<Q&YW
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M)A@<0519!8A-,+B!4!G:(\A>_-@!+81 P_0<KA@<,F*>)41 (U2@)KA'3Z1
M LK7A4A =>U$"Y".!;C S,A6E04#*-H@05R (T @YO4"#L+.J+E&5I&?C&1'
M^-T.[XP)3UG" V +A\V"'!16(2F0"8A))2! 'X@>0=1 "L3" P3()D@4&U1
M3X@14 C#!=C+9?'"BUE9 K[!<3D:DM2!2&9 %:F V!3/'=1  HS(,*C3++81
M074A'*S)F\@6'%#E!\#"!*A')8Q8!EK1@?7"!4#7DKA ([W<#BI0"_#4 [A,
M9K7, _Z(P1V8  1$B1"&"P<40!\067H]  =:@ GL1 5PCV611:>MB)N1ERA1
M )AP0GPA6# \@'K0 F7R4'Z$00?L! [HDY$45R%Q(T&(@0. RQD8W!=,4&;Q
MQP-@PN$)SYLD6$$\P@&4224H "P\@L%U@*99YB+! @=D@,70RC'2R:390AIT
MX1OP5!K]F]1\0)6L%"PTP(,87B\=HB]1 &UIP@H,D@5\4$_,)+,HP011P"+1
MP@1H".B,X"$62 0TDGR] 3 1A JX"0EH6C$=6!Y9@)]I"JX<@(98UB/ PDL&
M0TQ>X_5EEGI8@"_90F$Z%SBR@5IQ@(;H)@_%B28D@.U%@/ZH:,)<V0$[EL$%
M"$,&0,@*% N(JD<<X-O+60PI!4,!.(4<* !YK4DO=(#45,"26, =#,,#5(LE
M,  MR !\@E*':(9+4*227B1VE%KO*,0,)& <6$#XN$L-9$ (9,"(K!T'R !<
M\<((=$"68DL<5$#X5-$*&)1(%00PC< %[% OF$#/T0!^TL((B  +D($%V,$L
M4&DP6 *6%@]0U$ )0&"/X$!0?@4#N<CZT<(UK8">XD$?$-.[$-,75, (/&@?
MZ),F>$"6#E@(V$L-" \M; "8P &(T<"!64!E<8#+M< *0!"1H $(&HL"5,L=
MF"F#WI4$W!H=5  )T, ,;"4'U/X.#*QB(\";!63JK1T>69#+U!0K!47 A411
M"'2 Y_0$+Z2 !T!J!Q1(3X0!17T !5P(< J16UT FL#"!W1 !Z#003!"!<0/
M!8P'(R )-)6 6'& 4]1GO*J5"_ '+4@K# 0J@@"J!U12(Z4 ]S#"!J@3G9A!
MTJ%IE3@"E68/K% I!PR:0=  EG) @#Q"H,(F!Q ,,1[C!V6 "@21U*3C".1I
M!3#"#-Q:"]Q:*'UBH/WI"GU !419F89/@;Q!CV6,M%8"!V0I?'[;+_78")!%
M))C7?9E XY4 )W! ?&B"U0X/E2KDGW+ !V1 "R"%(:G3A0QLHT4I &W [@5K
M,+02(OXUT@>\&5E $!%Q3PTHP4KF(_=19' PJ6?X;47"Q%<]!"]$PJO @G_V
M"IH(1:ZPA^WMDVMR!2\\@KYD2T)<8+@$"9$,:+:,&H&"2R]\0+.>#$% 1;,@
M5GP8!5#0PN.NB#,6#5@5Q4ZH+JPDH!U0 .W214'0#;,T2+BPS/8YC>M.3>ON
M[O &+]48:.(VBWKT0I340",Y E)@PNP&;Z+I#8CXS"2XQ_#R LL(PV.]C>X.
M1;,L[R3\F/560NV(H>]&0J-5PO*^C%3]S?H:[_;YHB8DKB4@%E+TA##T @=4
M$2,T8R4<E_H:Q.1&R5D8Q"343C4-C?W2 O#^@G\8Q2Q@"_X#-UKF)"Y7& 4L
M .^?BDKU)D3K$H4P\,ECZ [@*BD+M\0HF%^=6,25ME+%5L '7!)TT *WDD %
M5$L,3P08W).'R(P<-@0>4,#0_C!%9(#)Z$5"- (%>!-!<&Y/6((%L(@29[%%
MM'!B=!47HQHH=(*J:?%$. PN*(X6PX*JD#'Y(@364,1=7%Y#^ +VLG%#Z$E$
MU'%!R+$=]W%%)&E(7,<*(P;YC<8@XPXHC+$?+S(C-[(C/S(D9T:,'#*-4/(7
M?X(B1[)!^(<F=W)D<+(GA[(H0P9I6/(D7W*,#.XHKW)DX#$KO_(KXS LH_+X
MG7)UF,9@-(H7PT1&'@5#L,5.@/Z!AKP%4<!"'W7)5=!;1&X?%MMO&Q^%=/G1
M^WU(&E1 F&W%^,*-297%,SLS0\A 'S56!UA05F1S403##*"-5C0S4;2 TCA$
M5>Q(@)2I;,:N-ULO0E@"3)TS0^  A0"%_ZD*4LB!\!C%"GRP%',S00>O)A3+
M7>AP=57()!XI-]_S18#!-'W !XQ ?0@%*%?T0:!!!EC 0)FS]<( P7"%'8CI
M!V3I(SP"?.(SHIB:*9=&39<:#,,%">@M0T 07+!!$6/&HMD!.$K$ _@-1<A!
MUL'%.Q$2)CR ',""*DUT1#C97,1!_#Y$+#B :SI7'#0S132"55+$![P?0:"!
M*YN29_X2! 1$ BU4$4*8 2^"A7DY!"TP +94W/5=1K?B@1VX"%@CA C9@2;0
M 7A!! 7<C$&(06+_-3HJ=730LG90E63?3B:?3!Y80I0Z!09NPA>XS!W(P!=P
M[R^U0!ZT '_(P8_9 ;/0PLV1!2VX0&$&'@RP$9O*0)[\*2.<-EPS@@NP 1N,
M'DO!@AC(@*;<@7E<2"7,  VH"A[  AG 0+?(@0R @7M80B-$0@*:06T3Q!E$
MP!=\L*KT00PD ;@, QY8 @W@@)ZD002( 9AH O2N7B-H@AW =4,_ @R007RL
M]!3/P P@""^D=PW4P-TP@F^'E]2)=MD8I LX@@BXRUJ)9OXE1-DL?($,)%@>
M:((9/'A!G($+-$(JFA8,B$%\,((9X%\<1 DO0&)W/4(EW$$+P,$4JP<>8 (.
MT( &OPR&EPDO?,$$I $MT$$$X("F](+"/,N2, +!-,(,F#>*S$(8;*E8130F
M$00=I/09P$" *LT=.$ODL4$+@",C=&B4-J!!LL!I=U<%8(L/;\*9D\49K !O
M9TP+?&?&8/@[.TT$1#084.IR!W@P1(*];'BOX MYE3BSR$'O9G8P+'<-=#4>
MS((9]-'\'81T5?JCST -^.<=P$!N%X0E(("SX,'Z.?D,:(IFTX#)<  =D($+
M)&Y>%L3$%0ST7H@EO,C^87E:4_X&(5=5+E=V99/$DR+$24;C*SVZ HQ _HB!
M!;"!^:B']C2? A1(3T[7)M!"!<P &T@ &,"""5  ?\R %8Y $GLI'M" X;T!
M GS!=],)'3R &?A7<XF7('V! Q!,!9P3(SP"!:1!-6/+OHL!&#C A<Q !N!!
M#4Q0'"A I;A>"Y@ZZ8S! \  )[3 H2Q5&GR!]= " JR X*E5KXC! \3Z([QW
M&DC !\G  PS;3M@! KB &;3T6LE6'HP0,&W","A K)& ;.'! =# &6A1A;P3
M]CB%"80 K2J TG@=!Z!!M[P<&-P!!WP0!PQ4+(*)"4!G"RA G!R5&QC/@.-V
M!N!;0?Z8P%@4S_ H  V8P03LT/:T%PG,.7X=A'9]01I0 !KP@@Q   ZHS .P
MP"S6U/ @0'SHZ/Z\P:_  A9V0 E@PAU0P!N8@074SD<5TIGT@E') 9S=M:0Y
M0( 42@68@1C@=7LU<)&3SYJD@0.XNP/XD@18@B8PF0SB@.I76@. P1D\P!F
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M4M9FJ?4E24&))0Y@K2K" B,:"4;&T/. 1GD-%G(8@$TK@ --)&$!M'C$ _(
M"Q/L2PYZ!08%OD"+CUR1 8X@$@)@\089I8$X->  +!PA 3R:R@.6J(3;%!15
M,U3 $K#X0*LL\ %+"/$-O6! K;YP@+Z>DC.TT$0)SB6S-/ZT[T0J, $L&O$
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MZ,!>S& Q,[PE#GH=W7+3L!<R1/Z5+ K(:#!F !$Q6.!)&0!#,(9!@;<\(JY
M:D$L&O$IARA NV2P@"8VT8%+1>"I=C",?SAP:)*41R0(L<0F7CN[%,#B6V*$
M% />\(@T(  P%@@#+>AP #G@@0&3& 8,YB2![U! .08)0XTV>*$T3"#-'B!<
M+S*P%TTD( 9@M?:NT!K#;&^;V]V>"2A2,HD,D$%13]5$"_QC"Q=TX /?42P'
M:O"%L#W" R% @PPF:H</?, %&J%%"^:DMU794B112X$=:G &1C@Q#Z@!,@=6
M0(8OD,0#7S !!UH5C/^-9,X=<'@'!L4!_43-!';  1D>,4PPS"\/+$AA&3H
M"S88AOX7@OG FFCA@JW]VZX%<<%5LN0!AZ-!=I.$40="L$>Y5(($M)-#"F:!
M5$2C.Q)W<X1<A('D](ED$B$(-0UP/))'7+P#1;0F26?0!Q)HX@L4K(%Y(N%U
M,- @/;!8 =)QC ,3-#T$QPD&(T;@@0\\U>(TX,!Q66.>G_N<G2.):%P,L@D8
M^ <&8!)))4R@D3-,7%"*NE0P7("GSGL@RYHXT6;8$XD1=( $QZ&% OPNJ.^
M03DND%X:X*#+S8C:#H<./2RT&YI87\@.G"\^65B0%GUW0 1CD=Q(F"AZ.#J<
M#*LRU!<&F()R-6?='[!E+T@0]F"0&^0BD4&YXK#+8. @A?[^T?CV#](!H8O$
M%C!@-\%'PKP,U/+R(R#!&>*@([*D U:@*6; ?@YP).1@F$2"$20D&,Y _ASN
M($1M!5SMVC"0)+J-K;RM SW06$!A%$HA)3["VO(I)4Z0)%)PA590 NQ'A23@
M C-P!GG%(/3"<6@PQTS"_7*0!M>E!N9D!7MP"'ME72I!!JAJ5S"&%GHA^7K%
M#DB "5=@3HJ0"$^"!U>($43-"L%*"+GP"U<HK3[06<;0K#BP#-M**5; "\'P
M"UM@J'K%!5ZP)-A0A;#0#E."$0BG#?FP!GME<E#B#DM"$/N0A5P <E9(&+X@
M!/AM952B%U8NDWB%$%FP#>FI$/Y1!1,U\=K.B@//$ W%2B@^,=O ;1--\111
M,155<159L15=\15A,19/ B>*8A25!11Q,1=G0H>(L YE\1>!,1B%<1B)L1B-
ML15U\0-M,1F)A2;<ZABA,1JE<1JIL1JM\1I-@AFU$2=\(B<^<11MT29*<0@K
M 0Y\$1I[ 0XYQ!0QP<4*0@9[)1;@4!4=X1P+<<BB)6P8H>=F,+,<,1AY81ZM
MD!?F<"0L@1/6<2ZV!@QYX0*?I \?81@D"QM;:!MI8ADMTH5@Z"=X,0<GX0%T
MCB(-\EPPD!!Y@00:#R5:X$0,8FE2DE?DP*)4\5HFBB0H\:TD90;U#B48@0%J
M0&8L#_X#_6CMA-$"_ZX"[)&%PF Q=(D?1:($6B4,;(IQX'$(MV-K,$,%[D8'
MB?!3Y,!BP H&YB4#TX !,Q"'D 4C,Y(60Q$4QS$E8,&K1*(78@^E9J0WU.(?
M>X$VV$@M2@(3_G&I1@(64E(3_G%7-*'Q?,LD\JDF9^$?I6<D$K,D-($VV@9,
M"/,O66,KKR6F#O,D-&$8^D!&SJ,P_['G+"&?%A/Z(E,D1H4Q@V$=*_,D8"&Z
M1((7(E,BG/(\"&(D5E,R[>H+V,,=1Z(,*F.1CJ,76O,*U6(A1Z(2I"-,YG(Y
M@T'TAN$E@8$34E(Y2R(S;=*N)C.G;G,DN),DJ/,VZ]([L?YB#U>0-DQD/%&J
M-<O3),)S,)V3*A[$:$:B!7Y$)#:A*VXR&.H2T>@03SC@J793,AWQ->&#>%S3
M,QH/-^ES)'8R!\DJ(\]0+3O1*-1*0X%B%#JR)"S!!'"  RB@F@@F!#J@4>(
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M*$!]2  ']B\ *6 /.>L#HF?\LHM.:2$/R*/::/ BAP4IUI(9/=18.F$$WZH
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MP $?40)K4@$D8 (I\ $SX A:@A RUR,4$ *$0J$T\0B+MUER  '!P )4T:#
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M>/=N='$&)S&$(T$!9>#!&LM#C4&OE1"><= (#4 +FU "%# ,&3 #M$!_5?0
MLO,%Y\58FU )]-H8+; FHGP7%+!@%;!4O?  9\ C7=)=%D$"L/#,%P*1#U '
M8YL!"$$&#N.>:V()H!<,('Q?LF,&!6 )?7 5,U# VNR.9V#/EJ@)P_ !95 )
M\F4+7_[ G#4P"S=""PD("[00 F8@?0$= GC++60 ?>$VGG% "V8 C:ATCRJ!
M!D@J!M"S B00?HG$"#-:,HX "[/2&%X:!W!@!F ($3( "WG@ )4 "PHP(3+
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M @LIT $>L#B]\%<<  /5R@'Q=_X4:%0'B5(#(L0(OSH"A,+CO"$18!T5F"Q
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M,B(XK\\,(C"!EA!@*(%>A1C)( 0.PN5)!CYSLR3+$<28"?Z/!V8R@86/XNB
MA(:#R<,$&BI@X8T/)!@TF!DXZ&#@8+XP:X:+2, A93/B<B"#1])PR8493*"
MXV 8N8 #%T: 2R$S'K@P&!I<)L'1"A"P1"%+6I"#EP8JH(476BQ@X!=' $#N
MHZ+2.* O00"@X<\,*!B&D4=H\847CA2R0(+<-@B!! ?:>P,&GE[,PXX#9&($
M !P:.0"" X TSBE.,LCJC1HPJ: &#B20B8U>+=DU@YR%Y-SSCT@XKX40/EA!
M4HS("*'7OR)2PH1@5C@[& [@L*2#8.Q8@6"C-&D] Y?BF+<[A92GP%M'/"B!
M@XOD<"$&N^B("@;5@\&# X:E)?[A@8Z"^3/X%11*02581AAFA4?$<( ".>S(
M@(8+*I 6AYQ_-0'AB("!6'&P'PTL0 &J!$,&'O@ X9J4 C%$ !._(T$'5&*'
M$LQ@ PC<20LN0 (7(*<7,NB !UPP$T>X+$^Y>T &YI(IPI2J4S*<(64^14,<
M>F8RE7G,*$J3%M0$XP$RZ(4F%$ +.TB@-S0P% Q.Z)U!#;&(#+ $+RSPAEZ<
M 7@4H -=0F +"63%$1;@"4]:\("LL" $P3##V90(!MP%@P*/R$,$LG*&YY
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M><_+"/YAW+@P=NB##%*0*Y54 "X=^)R!Y0"\%B1EN\%PX4<\D"^4*<0.P*L
M#234@IBJ)P+MJ<0;:!!:TP;/+B]6R!W6: &:O<$%->6)+"/B@NY,(#VY/4MH
M0$/<40$7,@@?#<,5GIE1(-<HM%B5'*45C/R2P"E X84$OF &,[R!*A5((,EY
M)Y,TK+$2&=B$@LA@ 320X0QTZ U/5J 2=?,"CS7 @WB]0P<<N"0$.>/)4%R
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MB .XFE'+&+_(GKD;@4'1A)IJ@;,IMKAH$PM0"<!SP-ZP(Z@Y(0Z@$&H;+#-
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M%$A,#]Q &E&(&?#!#(BUAY& _7N .E"@#:@!&;C,G:  S!R!$: !"5 ).G
M%X !!TB7-%" 4'J83U0""^ <CM&$P)F)V=*)8E&(WZR!<ON8*+L#!^  $WB
MR@J1_+& "$C% SHQ![ PA8 %"N"[,Q($/(BI#G *W:PD"V"!7H.+M!-/!U )
M!Y"36; S,)S(&B@."["H%4J6#*@!>HL(&G" -Y@%"] ="4@]A0 #@A  *5$/
M%N&)9#N T . 6)N)&@  !B@ @Q@/GFB[ 5   3"!AQD !$"  6">IHI):J0
M#AV 2*)'!2B  0"^8'@1(.G.C_[8A & S0+H#4:8-4?8I35*@PD8.^<#24<
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LVJFGGX(:JJBCDEJJJ:>BFJJJJ[+:JJNOPAJKK+/26JNMM^*:JZZ[#AD0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>comp_0016.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0016.gif
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MN0IGL !PO UQM1)SMAUYN1EVN!-NLR-\NRE\NS-\NR)CD1U^P8%_@"R"OB>
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M]O#O\.WT^>CP]_3S\_CW]_'V^O7Y_/____CW^._P[P
M
M
M
M
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M!$AX6RB"+9YPA>3E*6F0*,49@,"%6PU1"<B+A2V81PA%>&$(> P"$ZYXA5.
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M6(F>6(J$V(F7Z(EK&(JDF(J*R(JJ.(J9&(N6*(J?*(N.V"A/2(4UMHN\^(O
M&(RRL17$6(R?(!G&F(S*N(S,. K(R(S&^(S0F(S2.(W6>(W.&(U;00K<V(W>
M^(W@&([@^ GB6([F>([HF([JN([LV([N^([P&(_R.(_T6(_V>(_XF(_ZN(_\
MV(_T*%M%PB$!.9 #*3 "HVL(B9 ;DI 'V9!%HFL'29 (Z9 /N9 "Z9 4*9$&
MR9 ,29$1R2$;.9$#:9$2*9(!&9(8^9 -:9$H&9$(\APOB?X@,2F3-%F3[6:3
M(H*3%J>3/-F3.TF3,%F303F3/EF40VF31UF42IF42?F3,MF42BF4/0F54:F3
M3(F35UF5/$F53JF5/IF54@F47FF54SF61AF6:$F49OF49;F66YF6;%F30G _
MD%27]Y,$=@E)>%F7>WF7=MF7=(F7>RF8@9F7?4F8?OF7>6F8?%F8B>F7AVF8
M@[F8B#F9D'F9=-F8F*F9DSF82U (T1*:HCF:I%F:IGF:J)F:JKF:K-F:KOF:
ML!F;LCF;M%F;MGF;N)F;NKF;O-F;ONF;!P>2PCF<Q%F<QGF<R)F<RKF<S-F<
MSOF<Q0F1R1DZOBB,UGF=V,EMT/ZYG=S9G=[YG> )GLRQ!(XG6"/8AN99B(KS
M@>?9GG1XAP/AGNOIA>\9G_3IGO9IG_B9GNQ9G^FIG_>IG@$*H/(IH 0*G^@Y
MG_G)GP':GP[:H/0)H ?ZH/UYH M*H0BJH PJH?^YH0DJH!H:HA!ZH2/ZH07Z
MH!PJHBGZGAA*HOO9HB8*HC*ZHB\JHR<:H1Y:H3DZ$.'9HS[ZHT :I-%Y4=E9
MI$9ZI-LFI$JZI$S:I$-:G4@:I5(ZI6?CI%9ZI5CJG=1)I5S:I5Z:-ED:IF(Z
MIL2YI5]ZIFB:IH=BG,Q!ILG9IFX:I\MIIJ4!AW HI;A@IZUQIVHZ%'PJ&W]Z
M@8%*I?[1:2(_>I+-Z1S#21W'::AR^J@.EZ:SH JH,:BG@0N<T*>:6J3$&03:
M,@C2V::B"I+, :>ERB%%4 1#\ 6@0 5'0)RF"J?3U63TA :>$&"GVAQE  E.
M )&I^JAAJJJ1^A&L  ,I@ (G< .L\!&!"H> 8 %[P*R7JJ?2*A5Y2A-_>JVD
MH:TST FP@ZW9BJVL<:<VP >WD F9*A#:.A0M$*TPH (I< (VL*RWX <D<*_1
M>@MOH ??2@DS4*VWD * L*W6"K!^>JG?RJQWN@F;(*[BJ@HST*P?80GT.K&4
M"K%PPJ>!"K&SD+ &JZ[?Z@<VH+#5"H<BZ[ ?2[(?@0<70/X)'S$+E="Q<Y '
MMT +!RL5ED"ID\ &'DNP-VL:&ENP*#NT/0NRMZ '(3 )ZAJN ,NT">NT1NNS
M0/L1E3"R*;NT/PNR>% 'J>&TK% )JE&F 9)KS:&0(+E5%B>0&V*HU)%9$*.0
M$.FH4M)DL6 W*-(<8J)<-F(P/R >#F4C&P*L6#J>VL8)!_ &>Z '%W "JD$!
M<V"I9X,+#V )C%('@G +*S"R@PHGDT !M\ *". &B2L"(G +E,  ?< )?Y
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M YD$<)F!M5 %YK"$$4 !+*2]%4B)0\2?$3B!D&(%;PD!$6L)/Q !4(0-2D@
MV)@%&*B_Z)@$SV"VWX.!I[F%&Q ;/U"!/\"#])@#FU&%$[@ J^A"D!@LD, ?
M$2B!!L&?\GN+67"!<KLYG.,40GD2V7(2V>JN(?!&(OA&0O'&<<RYK?M&3CD"
M;-2M[B*"'^C&(>"[;]3&W2("<P3'(-C&(X 2?/R[?O3'4?Y!HVID$NL0R%\1
M2%7!1<Q*2()<$F,"'H2\.5I(2$5ZR(/\"#ABDA7HB8IDBUF@!2;A2((T 4
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M!%5-1952VV14MJ"!AC%)2@@ ]HD)GV(+2P"7"J@WV!Q(%X )%SBY2%T2%*"
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M:"3,0:P;;ZC@@(99U@%8'1'(T4(%)[E@@1PC*":2)1'8P(8#_,'PN0C9;<+
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MW<(.ANG$;A)" 4K\H?J72$!6;Q$'Y$,*9T%I 7*J7Z("\P$P+4 0"= !+C
M=9Q ',3&L+@&C]P"+4C QPR$&CE%'"!(!8@'*PC"@%C@=:C 41A@GO"&L^2)
M \R&'_Y4WRJ$WPTH1B"46.^UH N^H)0!GPP&V? MC J\@,[AC&FQ@03 @ I
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M8B:F8NI11C:F:@T!$WC*LAD.# 1<)MP #XE$((0 "9" O)@$3X1 25 $'I4
M?V1"=HA&:O[!#6$,'HF 5^#!#1R&*I! =JC""8S !>!''EC [+6 4^$!I,S
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M:2<P0!^<7 LHA_#VFMF80(><Q!TH1PR(D5@>1I\\CP2X# FXQQ]8A!P0P$%
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MR*C":J@ " >/LPHD!:Q+<1_&'CB &XQ;^>61'<3)0P:"'82,S'03@_@!)4P
M&^A&96+L::N 8?A!EKB$>%N&?94A'_1-'R",?=U"<@;")-A/1-@7,%]RDB#"
M8;1 _8WR))A*0K"F90B(R?J!B? !PO S!7!;0T!(!'S&RHJ&HVPW ^P!=KNC
MN/ZTC/X%M9@&P5 7"X;*07?\7],4X61CC M,0&M&BA"ZQ N(P!O, 5'  0NH
M$D.XA 500@S8;D)<YR4DH1PX(2"(P#V?Q )A"'S%1PJHP!O8P!NX1WC8)1[
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M0[ALNV?XNUOI4!\ 3CV%(#C "KC.(-XSFI/ (++!0-@ !7 4TBG= W!"5,S
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MBX@#$4Q0P049;-#!!R&,4,()*:S0P@N)"&()6_2;!9#3YF*%#AOH8 4Y/=[
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M#RH "@.A2_S@ LYC)B+B%"OB"%^Q(FC!1%8A$#K![Q+D%6ZAWGY ")Q@"8*
M$5[!$'81"WC,$QQ/\$[A%DZA",I@+KI@"(( #9CN%LK@!PSO%F+!"X" #&Z!
M$&YA#0PA%@S/%LR@%&[A%9B X @!"+;@%L1 "0KN![;@&)5@]S1'=OXF,:1"
M/1C  M"$%4S  4A %5S@!& C!$P$#BS@!2H 6RHB!DJ@!2!@$_;  23 .6:
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M!>3"#58@.(:S*H[T%MY@*FX!#Z+##IIP*US +BPA 99D#V0&!4!N!>+ ,PP
M.U1! 3:!#K2"#MQ#!>JR(BS -]Z@3?(@.E8@.??R >2" 81266\!1Z)$ CBA
M$PX (OP@,E. %9>#$R!@,3/!5641 HQO%BP@$ZQ5)5Q5 OID*3(!#V@C!>AP
M+.BP8D@ !>R #EJ /B)# A[@ N! +E: (VH",KG4[6;!!GYE!O#"/FXA#PP
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M!:;R 6#9F"O!#Y"U-D9 +(#Y]TX 5[L7#B0 96\A;KO&/F"222% +L)V%B[
MTZ;S%MA !4[ /("7*L!.6%! !*JV(C(Y(B@ 1IAU*RJ!Z/9 YO1@*B3 TFR9
M!*RE!A( %V9 /&%@)D;W%EKS%F+B=_W@#X*BF!6@3VK";2NB<U771#@A#MA
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MG7_WLTL@#^1=%6;@N2;A!&JB#R)3!822#=K$!=QN.+:"5X]<YNCU#FC#;59
M* L96*+CBRMB#O+ ,PZ )UB! 3)!#AH^$(3R!(BX M 56?.@6K.U7C.0Y&_!
MNZ%B4!2@RVO"$GHY!>B<C#FA1O[QG?\@H"VO Y_U$E5]WA(H-CBPD [\I>5"
MH(QK(C<@ PYD9@X88!5>. 5L68U#(&A)PT1($J0;WA)JE!5DX%=4( 68)3$+
MW4T2H$:ZW@X:?IQ)\2 @X,)9H01/0#SULS8@ #L"X0!FX0I1Q2X>P#<V?@Y4
M 63K_L/QXP+$N8GQP"0D $VF8"_6V3M8X?)1^.+1. YBUZ4C$P\>(!.R.(ZE
MHP0"E\"3545JU JASB5@I YX&S46(&DKXJ-=@'3K7$K!8R9JEZ!G@@:"-0_:
M! 9D@@<? $9F80;FS@)8<05B8!84- ;BF 2@K@+0A*9Q85?R3D&-515/0!!Z
MXD!;OOYX#_\2HN0!*F%YSZ-Y&2 X8W<WT-DY0M(W3@!;'L!7Y$]HS.P,<L81
M&N$5 "((HUM/AA")="N6HUMIG-QJ!.3*+4) NMBZ!69(D2");ET)HF3A+5MB
M@)"Y)2;(D($%99'Z@67BCX&W%I91<FO1CX6Q'DT,0B2HT*%$BQH]BC2ITJ5)
MARRY>"NJU%LV5-S"A>O6"1FW7# (=/46JPL59JFH$_4$6C827$B $Q:7BA N
M*."Y12?!'%846L"P 6%3BSEAZR1X(Q57"Q$K*%"Z9>?$U%N&YV2BD-42A5NJ
M+)PX<4&55$P05+2@,.-JBQ M) "ZA8)PU M@%8LXC>A6"OXY4>=8O64![*0*
MM]Q4B%'CQ(M-%&;=NLQ9Q&<1K&Z]:4L!L=1 ?4.\B,K)P)^HB+JWP(N"<P@3
M)RJPJN2@>E81O+-*G0$!!0D)DZ["<"""!"2(%H@$*YQ G50LD/!7!77L44)8
M<D10%QM3X6)#"'"<Q8H$SMW"P@@QV.#@'I+=@H<)SST@V1P0U'7#<Q2DL.!O
M6<WQ@ INP1*#A5U9J <$*[!0 6)S8&<#BA$F1E4"@?A!0E1X1$F)@2.<X-R-
M!T@0 002N*)9"R.LP-F7MW!"075XA-!C>EG9IY6/K)! @@H4<-)A=;?\=<LJ
M$VQ"F629.7 +E%'M,8)8)I2@@OX%HL5000L0W#5B5#/44.AA?H@0U1\%]'?+
M'2^B%E56=+( &BNL0#!+)FW%,(,$<_H1E064\"&!5+.,@ (,-TCPQQXOBJ "
MG,-)28$+%23I1PBWT) :'LE6$.-S!_0'QP/.X?$B">FYX,)DXHY+;KGC%A4$
M$UA<H1$31"C!1!%!'7'%%4<PH<00^!)1Q!)*$#&$$DX48="[\085Q!5;* %4
M$?$:!*^\^_:;A$%74'&OQ/D246^Z_S(%<L@BC[P4P4^1J\J'4<VRRE6:J'Q+
MJV)]R,J'F_PAVF26^,&)5)R(QHH@/7,R"RPPXZGS'Q_.HN=42+=2:LNWT"+(
M)#!74OX6()E,9<D?>M8L%2MP=DWSTE]GQ714F4R""RV<X*(G+CGC4C6<G/ L
M+BM_7"*5(!+ J3??,>LYRR1LQXQ"TV"+JPH@5D^ERB2 2@4+((+ ?(LEEHBE
M"MR0XSW5'#E7H =G4U6R.2LI$_[UY*K\T?/*6J<]52:4I+WXXJ^O'I4J?DQ.
M^V2;S$([[:P LOE4LZC"//-H(Q^U5*+MD=LM-9P'9U2+7T5)(%DV3?Q58@^>
M&-3%Q]V]RIGX\779O7<>]_B]_S&Y5+1M @C-6;$2B&C#YWZ+3?QF99/8&O,X
M\X?'**]IKP->=5CABOG53RQH8V "]X<Y<VEP@U,YRA".$/Z4@A4,84 9@D%&
MB,(1SFLH0U")O  F%!3&4"@J&0I0$'9"DNEPASQDRLDX"$1Q92^(1"PB$#.#
M&2,J<8E,XN ,%G"7(&:%$Z!BHA4U^(;CA(!,5^RB%[\(IR%*91(3:$$*+!"[
M+ZIQC;6BE1(U-RXQLG&.:N3A"WO8PSL&Y8YZQ*,?_TBR'])Q@W(,2Q$+R<19
MB,*01D3D(,D%ITQL;3*.;&0<P3@N501BDET<8B4U*,9/@E*-K#!<!LLE2B5Z
MDHXI8^2%O%C)6#Z2C8"LI2UOB<M< DR0L^RE+W\)S& *<YC$+*8QCXG,9%I1
ME\QLIC.?R2^G0$69U*RF-:]IKOY48G.;W.RF-X4)S7"*<YPZY.4WSXG.=*IS
MG>QLISOG2,YXRG.>"#/G.^^)SWSJ<Y_\[.<5Z0G0@#K3GOXLJ$$/BM"$*A2<
M FVH0_THS85*=*(4K:A%*?K0C&HT9/(BZ$4_"M*0BG2DQ-RH24]JE(BF$RK3
MC,I%6CH2<;44IC.="DPG4U.;ZE0J-]VI2W'JTY_VDJ8Q]>E+>1K4F[(4J3HE
MZD^GF5.A[A2J0(WJ(ZGJU)A2E:E29>I6D9K5HW;5JD+]:EF[2M)!HG2M*%5I
M6M\*U[C*=:Z38:M=->K6;\JB%*?HZRE0T5? ^E6PA 6L8?\J6,3^=;"+145B
M'8O8P_X:]K&'#6QC*1O9QBHVL)75K&!+@8I>EH*OA/7K8D^+VM1*%K.2M:QK
M$WO:QYH6MJL=;&M+^]K9_K44L9AE+/BJ6M<&E[&3M:UGA8O;W HWN,7E['%1
MF]S.@I:N7KRK=07:T9Y>\R)G"$(0?O!=\(KWN][]P7C):][RGG>\X@5O>,F+
M7O2Z-[WSC6]ZWUM?]LYWO?;-+TAZ.\A8,$R]\<6O?>';7@+GE[T%IB^"&<Q@
M^2JXO :.L(/S2XBBKO$B::#P>B'<X/<:6,(@KO"$2YS@$2<8Q1^FL+ZT2]T@
M7G?&],RK-\_P@S.H(0T[[G$:?OQC'_.8QSL.\I"'K(8D$_X9R$+NL9*5;.0B
M.]G)3#[RE)<<Y2@_N<@\1L,@J% $ -,Q%D7(0B&0#.0L!WG+6ZZRE)><Y"NK
MV<U,9C.5U4SE.!.9RT(&\B#*$(0,/Q(-/RC#(-(\9SW'^<YH1O*5]3SG1-L9
MRXW.,YOI;.4=#\()38!QC#E(XU"3T\;=!+0L/BT5+Q!!S'.,!1&^H.$@>IJ#
ML]Y@K358ZXN<X@<9OK42.WR*(OJZ7,,F5[''=6PO%.'8J):*J)\-35)C\R*
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M2P20EJI!]$IX("JB '  (D KS/$ &&@""M )ED  9UH! S #@.  "3"I=0
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MY.M%_OAI\6KO]X[OH:;OQ_1YIV;!D\$&T/@&%0D?=&"-Z'D"B!$!-E '+J
ME,#FAE0)!!#JQ:ZQ8S:.'@[B=&#R<\ I<! !=0 #:9*.(F!^B4+VY>TLDX
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MU*VF !70DQ2J6;A""7" UK-?E_A0G&"%:C6-8R/;BOCA0UWBA*#6GFC2OA*
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M P:PX[WSJVH<@1"H@72&9KR<YFK6I;[T#R-V*RIF*UG3LDLV"LEMXU4\B#<
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M46PM234G&PS(-FG\/:MF7(JFF([&?KNU8[M4=EC.]FP@ FG_F*?6/II_OJR
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M=@< !.!AE\H$ VR(%H>&H 0EL,##(*"'&%5 #TWM5!TH  &;G<4/#+CD&TA
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M@ J0@" 9R1X\D2M8P(W^C@H\0 W @ *4H7?N")]XU![XCL"0 $*:"9]D@@.
M:8^\7B=FY\.]FY/, @G8S":$ /X)C( (V% =2$ )2  <W8(-H  )& \KN$"H
M5F>,;$+B;<K$B0 %(.(+5 !'&B4>2( )U&HHD4 )@!(-E.3/L%<-^*J12("$
ME47PE F?O( ,*(^'OFFYFJM7Q"F-T  %/.<$U, MN$($2)@;/)&3HD4FI.>O
MG8P,6-G.<%&EX"M:S *4;LJEE,4<&%%9G,R1?223QH@-0)597((!,!0KV.MU
M9D+" !B?#.Q'VM"MT4$(\,DE/$ G;(HEN)?F7*RE'!E#;4+*!FQ:W (G!,S
MEL5*X<++HH7%:@RG\!HD74+/H@4=P(XE -]9M%BEW($%<&S,1,U'L9VG7,*N
M?53*WOY"'50  CS2"=B 6<" [_#;* 6" K ")PP1'?A.QRC/+* LJ!"LVJD"
M)TA 60C9$-VJ\+256=C 0UK"0MV"2#V2!5Q")PQ1(+P;L'""P]Z"'FBAP%;"
MK@WL(OV:XAILQ5C"TUY $_*)'BC1#*&%E3ZMP 2MI4SMC(#4SG+I+<3 N\9.
MV[Y,X"ULZ,[EN=)NFZ*H*EBMIS@ 3C(L(.@=#3! [M3!!<1 "$C *+6""9R
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MG\R E5F '9Q 'MB 'US"F)Z%[7Q4E*E"#3Z<(-L!N]Y"#>C=S(R 8QMS#I.
MK1G;N[G #-S #.B!#;#"&VSL+<@ M\V;Q?'!A5U*#,"1)D29'SCU+=P 8,$
MT]Y"",A!*X#JWT)5)J@ G[@ #*TSS/R! ;!:(.@==$LW#,GUXHI." Q-",QR
M)33WQ]P""HP2'I2;,\_;?7%"E &"  1BM\%0(_;:[(+S?OY_IJ0HZ,O4 0
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M\;) ( 7]%>U!PHJ 'L1 )KP &[PKI2>5'S#5 X0]'@!"W%[Z1VGZ1D4 [B;
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M00'TI03LP 7VHR!881-$8!7^Q2,LH"J@;A]?$S:##JN:D!$( 12DT@EN01&
M("K-\"(((20Q<@N"0!%N8291D@F6,A;.0 DTLA"TX">V0/[\TF ('*$,?" 1
M;N$)UN 6/N$)(N$6L" *"V$(-)()BO,)?J 47D&JK&#\KD C'>$)!)((%,$6
MLB (2B$6AN +'J$)FF AB^ 6'N$1SX (EO(+@& 0M#,JEU,)BC,D2T$6AN 3
M:D$)G@ -J,#L+,4!#040#*  0F-_ZL,2$H 5?&,&7N B[$ AZ" ]ND(5&( H
M*"$T\* C6B./2*,&5!0Y4F,";H83\@ C(L3W,.)79@$7). M6@ LD.,$6J &
M9@%N5N!Y+J!@,&(24L0C6"$$I,)3W@ =O40PEH,-;%0%8@@%&L(U8Y--V[3K
M%(]"#?(J':$)EK(4/&$4;J$1<O[3$8" "'Z@.*T@"&1A"G^ .[W "R@2"'X
M(].S%DH!"-S3$"*5$"#A)J\@*L>@!\;@%K0@.Z%@"(+ 3[O2$T!!(+%@JJA
M*C?5"7L )9W@*$'!5&_A$P/O*#TA"%#R%D@A01%409\R40_!!XB@*V55(+-
M_+@R#:"IZ:H-(_1@  2@^3""-T0G!7S#7V( !E2 -.I 9##"#1Y !'8E*>C
M!5K  52A56ZA!$A 6[FU5RP@!BXH1KE1-3SD#12 #3S%0K;U(B;A#:; 1.'&
M!N: #DJ 6O[5 50$9!Z #;A(;RAA82WG^%P@$$* $BA 6$Z@(=S48S_6YURB
M"5$U??Z4LB.[ %&O0%458?N(DU:#X!5DX0B 8"NY("K78 B. ".I@ ABH10>
M\18&X0DV\@H6U JBD@R H""Q@!#"TP=>D0E* 2N_(!.9@ B"( ND$@@<T@N
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MM%*:59E8P?=P@4 *A)CB!W["VC3A2!/@+HR6J*"BAA, KIOXIP)\Z=YNH16
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M#=C (#CH!BS@!>*@R)/B!D2=#2Q@!?3F#41 !)A7/1Y"!80ET.F@ FH@$U3
M K0E$U* +=L(=3Q"#[1E!FI@#M)C#Q[ P?F[,@U%!,[I(C;]/*21%:YD1\(B
M;$* ?D+'!434C)L\SL]=SNE<W<M'N>V\0$[@!.".2$&"%;)F%MX@%RV! %Z
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MXP4:8A8VPPXJ@!,JP1(0@"^Z@@(*UR, (6\*@GE?@%K04?X"Q ,6'( "EMP
M[CEL'L"C<.$&H!XY:F \ E,]4D %-D$%*L$%$#9(8F3MQQ^EW=[\)P6XX]$"
M\#I^4L;;;X$&,L$&5!0R3  /&.8B!KX&8F &;""60@ @\-S"->N!JCDM;LW"
M)<%2BA,U8M" <PL%G5NW,HU((8?$G%LMV"B$H(J."HQO5MR"8 FC'!<#!Y*L
MDP(EBUL/-@W$=<L&S%D5Z:B" -2%2%8/6,&A8 /&##:<,-XZ,6/G+3QO;L%8
M(&+$@Q*WWEBPNLD!JUD,*F$,Q$!53)Q^,%J2L,(M3ZFL'.CD*2<.GI,D]$R]
M\5:JX<.($RM>S+BQX\>0(TN>3/ZYLN7+F#-KWLRY,T8BH$.+'DVZM.G3J%.K
M7LVZM>O7L(D,66)K\:S:B&&$D&I)@*H]8V56RD2!YZ:D&"?9O>6B:D8'M^3L
MOJ6* 2X8-3"R"A048PD:&"W>6N%&H815)C'&.8DB!D81,*3:FJ"JSLGH)RGL
M<7D'$ 6I$$S"27%:B31+!*T )U4@0/'D1P*=2.5 5@Y,0E F"W R"P+[\<3&
M :S XD F&.'RP"2&B1#'+9Q( (AA,M0AEUG:D7 +&^"U\!$%@GGFXX] !BGD
MD$06:>21D\6FY)),-NGDDZ\5001ME,T2P@1NU)" @22T\$<))TT"'48S5. '
M#09)M?X)!&SL(4%6<R1@@Q\5Q'?<#7M$8,,M(LB!D0TA!/*&!"C<4L,#+[;5
M$4HGW-(*"2&L0()[/.'2UAPVAF7C'@_8,0<#*)*PPA\G-&J) T"I !XK#.@T
M @JD9BI5#0K4,.@(M\P!08FW5%"5'@FT( <**52@RBP'J(61 Q?=Y4:C,!@P
M0PLJO' +( JP,<<#(O$4PT635 "(L:H@A^2YZ*:K[KKLMGLNE/#&*^^\],I&
M)66XX.$4BAC-\E(=/+'2(T9ZO, &*X>I<@,,+X;EPA\MR(A1)TW%=<L?) Y4
MQPR J/+&++.\\<=5LV32L"4O:N@6&S#=I4?)#9LLUPPSM/ZDT!PNU &4P!@)
MHA8N>2#LKPMS '78)#/ @ =0@0AB&"7[W;+)#2[0@0N#^2*,D1^4&,:*!*I0
M,L<;<L!!!U"9T "#Q5L;_0<,3D\!D[MTUVWWW7CG#62]?/?M]]^@S8:;W1Z"
M==>/'@9:AP-=Z^TC'1)?=EU4CE=N^>689UXDX)QW[CEL@F-V.*^C&U9I8J-7
M8O'HI9LNU5VM(^;'##;8_#JON!=V.V*#(Q:[[K^3[OKNAU5J_/"HPZ[Y\LPW
M[_SSGWTN_?34%Q$Z]-AGK_WVW'?O?6?4AR\^X-<['GQDN)R?_OG?M^_^^_#'
M;]GX]-<O[[WM+Y29_O+W[___ /[<GOT&2,#8E"\R<E"6[G)'/,4<#A9NR57C
M%DC!C-Q'8'6(8$8J80E*("P3<XC@+"BG!^<$\(0H3*$*V57 %KH0-0?T76(>
MT"P?\:0.C>K)R-AW&!3X:1,44($+',"=3#B !"2H "54$0(VB !A>-C30"@P
MP15:\8I8S")E7LC%+H(&?Y&Q@$ V,8L][ $H(V2%';A3(C]D\!:LT,E ,L$3
M0,R!1+BP@0@V@8NS8(02=+!9&M=X&$XXP"TG2$A8*G"+.BC20U51@4!&L)P:
M)(2'6LRD)C?9/R]ZLH Q-,PDV'B8"@A$ JJR %@JP8#F.. H)%!5!"9Q'%?<
M8A+_0?Z!#RD0"$Y4  )5.8&?9M!$"HCD5$[A%J_P\)]<V4P/$C#4#.00 [6X
MP3TH\(,<_!03/D23D^ ,ISCA]\ERTL]Z8#0,( Q@@(89QI2W8,!^6,6*3"C
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M@T#V8*,+<,<%1IT*-^7-\I;[J-[UQK5?!<*3&32*%3&(94LHT4P<ED D>X!
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M@3!  WW5=(GE!U!V B<1 ]Z&"R(@12B1=FC"=#$1 _'!$[-P KZD"H*P&Y2
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M"?;R"8, !%=P"XS0L];#JH,82CR!" )@  $0  "0 )4  .V7&3S!";J[0*Q
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MIX %/V %6PT*:OVPML9?DS  UB(53"02T14#!S !*#(++Z  "A ")'("M7P
MUPM'+L#7+4 +JW !A+$)(\#7O\8*"7 2-9< #A !BR4""?ZP .@V%2IP Q&
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M%1( %.H+93- AR7P,0S0-9;  *+0"@5@ W'\3PJQ5-T$ 0A3!]&T!P2 (GK
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M[6ZA@%#*CZ.#N3<<<+4"RRD(@9,#7+K%%5LD=\F%!&HD(+S1KYJ3)-57<(,
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MS,"+SDGA);TH F[=(%&,4E0C83B'ZHB@A[?XP[]<$$!2<HL&+] #A6[!ANI
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M+%E%X<,#:( ""U!Y>B6P@;YND0<'!%@"#)G%"4B0=ZFL0,!^>  ;YDX!9"V
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M)JV$2C5,5L!)$3?%5%0%$R>(+:D$RP-4%E_MJQR1PJSQ#Y7O'"\<LDGM20"
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MGTV4#) 8# "(\,8""> R@X9O,)# +'@ $,,D$9#H0@"J9 + &ZH88 ,K%#"
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M5L"M6V1"41VI09HZ H$_X$$">Z #'@[@F/W9P :<8  >Z+"'!\A!%7XZ@>'
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MV9M>:>A@*9.^:9P*2D>P0E!R%87P1YSB IMVA(O@Z47=J475Z9R2Z#-!J25
MV'':J?Z?CDZ;(JJ;$JJE3NJ7S@)LDJ:EO@2E[N@*N:2G1JJG&NJACFJBHFI_
MU"FFFBJI@BF:QJJL-HB:DJFMWBJNYJJN[BJO]JJO_BJP!JNP#NM^S*JQ'BN!
MU&JA?JFK$NN.-JNS/NF2JLF/?NJ5V@2V3JNP!FJEXNBRWJJK0BNT1BNYOBBR
MGNNQ%H&REBN[MJN[OFN3BB"\SNN<CBN]WJNNHJN^RNJZ4L@S50)2.@F4V@0G
M],RH/E,F! 6<_AG#JLD-B >;6NM+N$(+G, 7 6K#6H[&"FR?EJK'^NFB=JO&
M\L$4J.JI;BPNJ,!99JL?5).@?B6EOL!'WI]NXD%FWL0,T/[ 1]I!#'!5P?:'
M#:Q$"HCB"N "#"B+Q'*$&S3'"&CGG[B)P8BLU'8JEMZ !:P A<X",OZ$"2AL
MMGXL'/ $JV9L(/C-TW;LZ'2"9^C+>+KIIPXLQ[+,EZA"8,P":IILW#(L*[0
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M@B%UQ"30J)VP B!8P@RXP1>M AO(0+WA30S(P7NRPA:KBR4X$B[TP2S@0AW
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M"?R('/S('TA 'LQ!(+:17<?-_FR.*F16"/6VQFB)#=C!; 3- N"0[\Y""DA
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M_8K Q&!"CU$>P[/"!-@)"71'2F18#4+-;-W"%)Q<(*S,V(/EW5A998 R1YC
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M2D*F6Q5"8\$$&#)Q@(446A!!IX)4Z&T5"6B)H0(75%!AA%DF.:K %20*@8Y
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MHRU4,XE9T  E$*!.MU(R-SHP@&248@4)%L4)!M@A6@>8F%PFD0"#2606F9
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M-QRKGTAW.&WB^8'XPUE8D0<BX<(/@FS[^.M=B;SC(OUR4<7N>XW> O#4)J\
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M2,R4(W2F#O#  #+!G]I8+N0X)6Z$$B##HEP#?>X #_3@!9IB6Q3C1F;-!FP
M!5] #O9@:7BB#_# #7!,5F)"#LAC4]IGJ=21%?R@GFKEEOI) 7*N!!) <^9
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M4C('0>E.QLDD@DPR";JL:CT9V,'A,8>>DR#E\Z%Z<C(''G9%_$=7A:,:T2R
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MP0ILD@D*N""MG)" "EY0@=3Z@0(S&(%JV," "^!*!#%H 05(-@(8&#U#;+"
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M 5^WH''PEF@DTE@*8!T/H DHLA DX  7$ ()D%JW8 ,2($DS8 &F$A&YYX>
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M!1\Q^2)K\AOF%]]"8XY'!24(#R#2O\,)1(-#[^.JDEVN400\K$ "$N"8UR-
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MK,%ODA8\%T1Q!@H Q"4<8* XC8MGF^2D=X;V25"&4I17B8]+.A%"2R1@%FR
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M84X/3MJ#=6YC/X&<@ VX8  E4L@I2_RFJ=$2'1LT2DQ!_(8@<IK$;_YY"4!
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MU;<L DW 5AK5/RQ 1(538%LX(5K7UF&6>/67W^7X (BQ@1)_P#1B.5V!NT$
M%R)(W![RM9=;'#Y*PR'(4A550YLXP%A3,A8,*A0=@]ZF+1:@1"76]E\]".+V
MLWB )@!11A,8:!-+PH^_,#2#P(PUCC:( ;:=_WR!=%OZTS_NMQO"B=<(A!(
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M5C$]5Y\85W8-5W5U5Q2%5W6E5GE%5WFE5VQ%5V5U5G4U G_]5X U B+P5R)
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MEA!0M=##2G\9'8,T]DM9,8\?^/Y,B Y6P'A_T?C9R(,3H(6)CSFR%(BD,8Q
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MXL>#S.EQRR04N%""7JI X!L*NJ$ TV^SS:>'*A3(L!AN%53("24/K.""!'
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MA0YILKSC4< \;9E%'6J0 CBV@'DJJ /I&#H+";R@!C<H ?L21!/"TN PK)#
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M"S@ (OXQ0*:9ET1P AL8  .P@ .<A0A,@.K, AW4 " PP%P( @04@ &(0$7
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M[3&%.._P) "1'"L$'3P1'H3I#:OV;\# ]KDQ!(Q=&O.!(^WPD>6!47AR.*K
M1)'V,_[?WEG(@4<[<R# D6#LP915\@T %"E3@@-T* ,X&*RP003400O !W,]
MP!Q4R*NP\1V,P(K0!P>I#W/&2F&K]WH7S#LG-ARPP<G-A%'%M4:Y )BRPF-0
M@B/. .+,@AWXM:;9@. Z4B8<ZMLDF VT=N?NP4E2[PV\0>[. 0U\WF#< !L,
MSANX@"7$0(5KE+Z-&E"PP:MDP@W4]6"PQ25P B98@AV\+?5. 1N<]&7M*'FY
MQ284XL[-PAS$=7?\1B78P(E3!>+NP0RT]BWT 0W,P?GN'"X 0I[HP0SD =IM
MPLY]K2J,  IL,2O  0V$J9-3+NA4@BKX@1^<<B9$A^*,N/[US42">X7UO8$-
MG!7NRL$-*.TD<,(-T&)/0&JHY $-2$C>S8 ?2(Y@<(**A"DK3/A4Y*UV9H(%
M)'J21<<2T8=O_'F@N]K?L$(EW#78N@$;[84J /9;YY[B=B@L.R@,M (,N $S
MOGD$S0 *F74-O('3ND%]ZPDG ,*%;$(@E(BBU\!9L8(<V("#X2X=X/HM\,$,
MX$$!5T(E,+NVS@"TMT8ES((J/'NT)P0>3#LEO"3D;F)U X(-Y)Z;) C.'04-
M9.'QG-4F@*X-P)SJ\ %ZT0!?'T^'#HXJI, (3 *ZTU,1@<Z.>[FFX?N&3,(F
ML$&MOR- V@%SXPP"O,V$"(T"(/[.'!Z%>JGA'\P%&TP4"<C&D;%WR(M\E2'V
M(X7 "ES;Y;P84TL [I* !-!!(+30"4@ L2_ X&1J.W[- 9/[120(<H? 'KR8
MNE. #XEH2@D&6=3!\76&@ 2"CA(.!, W W "+$Z!'#  #BF$)1S FDK "2S.
MFB#WTE/ %%+ !00"'3# ";R!)= 5J;W!@APU50!&((B #QT6'!#83,B%N3'
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MM]Y(F#-CP= 'DP09L!%TJ(H1=5X4H 3QU@P'->0XD'.+#85 -$[@<A#H881
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MTP.D5R96,( 5-R !ETF@F1:<\ T+(Y"!V.+@!]1A%9.+2YA)T)@3P"N$L%!
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M)T (6T(0(#VT5@_'&=+&B9*G6;0 -7%E?D8K4(<_M'83:9J"",8O-**I^_F
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M+]'&1,4# $L 8BRA$&.@!0ZE#@#P!(1E!@*!$P@N!"C@4.SH!$+@$@8# EZ
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M:P-@1%I  "K   + +HC<R)'<,2C  "1  *X) A@@1PN@!#Z' $2  %CD A1
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MR-@4P/XW2N %]" SUN;'*7A)G74 1F0&!N!71L  6,$& F#S.W\& @ A9@
M-NKT P$ 7'4&"*4$#H#+8#EB#F!$)$ LU1P7;B  W& 62(  6*$& ,"852!
MY.!3\$#/D ,/..@!/-I$+JXT3"6H["\&6/$!LM)$9F! Z@#*@JI&YF N<FB8
MRRWJLX43 N$^6D'Z-:9&Q*=$]"*^*<;DKBD%OF(U<%<%O^565D ]^*82_ ,@
M6#G@=*M@!3H%$Q8,4:=@G1"W).RYM><!KELDYMR"@/#6BQ>W'&1:J(<5 U&W
M,CVX-8+-+5:3;FWZ4U"%RQDS;FF*<(L-BH*;&.#24Z$@'?X2MRZR6F!)X<5
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M$4R,9V!H8=5:6$&?MLRB%8="#_[[%'B+%9PE)<&J0'58B)<8',I@A"1A02Q
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M"SI@;!8G$-H+"J.0/?36N*3D\46:B.#>F$1A#JC5' "XT@P^#5>3.  >:,$
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M$90R;T ^&($'K3 9)80;G)"P;Z 7K.4'-3 >X%,0D;P1#=06=4 !@J '?G
MVW$P@# '#D E96@'IT$"WG$:W?('@2"R=/(")1%W)5 'H'-#%*$6HK(*#, '
M>Z _#G<O,@$!MG"W67(1+> 2T4(0%QUC?Z"% 5T0F+ 2;]+/<W"@";$R%FTF
M-RD!I_YQ$33PN9L02KZQ$B^  H+@!W2  +=)"9"VH^B4$K5J$GKPTQ1@ URA
M8(;B E:T%:H0%'4]"16 -Z^4M7A0"3RF$' @1R]P FE=!VQ= 7Y'C(QD$)0
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M"A"@D/"&*X)#<M)VW(6"%^L17#VQ'M:H$!1 >3 @-)M  BB003"*$TI/&9S
M$]M:$*U0L %,$XP3!YJ@T+,09\=N5 7A!YL@YWH-&XE""2< OG7J!TE_LE$/
M "&=$'"0* 4])]]Q''*0$Q4 02M5"26Z%ZQR G^$!V 1 U;T ,OA$88$1L-Q
M %2B"AY3E7<1Y $D7GV[&JS0,@5A M"Q"8;B3 !QBQ6%3/ZW\)"X%:+/K1LN
M;MU"1.&6)0BS'N+!10>A0#RW<.%Z^!#"GX>X'I $R8J!H(<A\+ Y\1 &C8<K
M5,"XE<D!JX<5\LQRH.H6GP>W9DDH&#(D$:9-G3Z%&E7J5*I5K5[%FE7K5JY$
MABRQI53L"A)S+,QX^&"2QY V(K@1$5.L4@E^;JF@P$:$"(N<(+2@X0#EK4DI
M'K*HP>(-6UP11K"! <&5I0=OW*!XP*F%A3DK2@BLH!B"G%M['+B9\8"%TCD2
MY*C@>XM!)8\/+(5D!<$$+CF?;[WY'"<"'!84>(*LP^"%' DV0*^  V%QB<46
M\5AXZ$+$G! O)CH >>N$FUN;@O[>8F.8 @PY+QC\J3/BX1SYE"#8J.&@H L+
M<D(8#LD%$NB808(9<*$ !3I&H"E!C62XI9(':+"! 4HR86 &."3(XY8$YQ !
MK0<",:B"ATA8C([*6I!@%DX8L A#7&B1@(1.V%+!.548X.2WF"I8#@8&\)@%
M AC@<F"66?Z+C@VE*+" C=0VD>F!\$*B(X$Z=N3)O%EP"0$%YIP,20\&7&"#
MA IXFH$S$52XI06TZGC #1<@8(7+6U[\D@05Y(  #H,JBZS'AU210 4:X@K!
MHI)^,]&HN.)H+B<#V7!@K;H>DH"2/R+-P\1,+GT D%M<B.&6/*1[@0*A*K$@
MA!DJ6/[K%AI@%&N6$HP\(0&[=!4SKUOTD"@A.LICX)88<&)%OUOJN. 6"?0P
M*('%,EF@A5ML<.T$$3PBX03FT)*3+=,>;6$C@1X@P8T6)/KC 3G8*,'56_X0
M@"6&*ICCA!- \M:-$QZPR (+DE*J*X479KAAAQ_FZJNPY@J)#S9,?6@2GL0*
MY(8]KJ28DHT!84,/1P62PPTJ0\I$**/FZ%"I2E2AXXV-,Y$#$%S\Z-$/-NIP
M=)8ZV+CM(4O8X+GHD"IA@\B'*'&4$EB4RB0/7%0INI.BF78Z)#E<R,0&C(T:
MNFA+7+Y%%=H>^N/BAV:I=:(>X0:)DX)8J8/(2D0N&NM#X_Z 0RB0?+9+*5ST
MD$,551::Y:6/C7(\/%7@>,-E5>:EY.W(;Q$Y[;7/-OIGB^!^>Q*0-L%CZH<R
MF1OJM&_#VXY9+"&1E3?F4,7UQMG(7&95[*B<K1?0$FMGTRD!B6[(>9^+9C;V
M.)ED/T#*9.5,W*B#)^5G0=ZCE^+&!/N-<9O#C8+^0/LA3M9>/FY6Y'ACY<XY
M9X65M=5^Z/TW#*U^]3>R-TK<(- [&3B$8H&X'=IP\9+>L:)W,PM@>0J"BTE8
M!'^=P\4?2#01/=#B%H%X7GAPD0<VZ"L3",N$TM*FKUNLH@(XF\/&*O$&0>""
M#T+Y0[$>(H@0ONT.6ZH$2%2!A_[T/01B1T1B$I6XQ"(0 2P4@V(4I3A%*E;1
MBE?$8A8I!I(WJ$N+7P1C&,4X1C*6D2V9:,$#5F;&N8",C6^$HQ1'H (\E, P
MFW"!L^*XQR^JI(BYPM2QRKA$0A;2D(>,BL2FZ$8H,K*-Q7MD%!WY*,,5#V0?
M@>06V5+%28;$C>O;I"<[6<E1-I*2C73C)$7XJ$MFTI.1#.4K97G*,*;RE*.4
M'!P09LI;2I*7L/2EX1P)DHEQTI595*52:+&'-SR.%7!0(2136<I25G*6T_SB
M+ !AD5:&Q Z%.V8UC8A(<I;3G M3)!_5N4YVMM.=[X1G/.4Y3WK6TY[WG,LY
M];E/?OY")9VUC"=(L$G%80H3F%<4)QL3BL][+I2A^'3H0X\92XG2,Z)3[&=&
M-8K((ORSHA\%:4A%.E*2EM2D)UWG1E6Z4B1ZE&HTH>B59B=.6\K2D9.X$2O\
ML >>.LIV-HBF6#CQAANP#Q=VH %)</,&H(9D$C0H&O=^F384."<DEAB?1VI*
MT5"J8I>X>,$:A\E(3-Y"#G89I47B4+BRW@(0BWD>5]MJTT>JXD!*P4,(BM96
M1L[N9)J<PQZX.E%I&I225[H$#JVJ5<*6=1)D,JPH,YF'$/1NKK&\TE9+HEE:
MHM2S<61I:$6KL"=2;!)%F6(F"+;.'=EE#@YP00I4T*4'Q/[ #0X0+,4N\8 9
ML$$!U)H%"4S0&ICZ10:W[9 E+("'"O0(#D[J)$AB@(*_2H!$%ZUD7@T7/# "
M#+)3'$\H04*?9R'BC1@Z6;/^D%!5/,!E!57!% :[3@M0:Q)U^")(M!M&H#SN
ML_\%<!1'.V "4\6E3A6!*GXF0CS8X+K,(6(%TU8K2]QM7@C3!!O@<!Q*3.X-
MJU *<PY (A9T1"DGJ,%#_& EBHV >'60B!RBE;8%T.8$,/6# ]!#DQ9@9 1_
M#0DE;$"'OHB@!0@3A 1N,+<[V$"I9P,$253Q!CELHH$7%DB;MLFR&+EA?W/A
M@PWX4+=,4*(&2E5!#-D7B+_^H?X&:%P,+O;@Y(?0(2:;8,4FBL8*\Y:&SA-1
M12 *MX<SAV3*=: $!4Y6!PCH@2>5N$$,G\8*/"@-#Q"@ RM:%HCUZHL5:VG!
MAM=&P:Q2X@9 RTFM*E$0H=T@;J9&-?>F+ >>)'H&G-#TH2QC/4[XH0:6;3 ?
M+H*0\'38#FPP5(1./3J1T6$5>W@ 'G@R.38DA763\ ,K+%$)&V1B%G*0@Z,V
MP08W&*K#0TNV'VQ@-5V[X48!AK<8"SQO>GNEM'.AA .@$ZZ'J$ %E"7-"QP0
M U500+!O2(!%*J '7%1@R!0@$2 H,(<;6( G#A#7";"#FR79900W8$$++F$4
MV[QM@/[BO44?5@;C6Y" -!8YP6)*_I$':*(.VCI!VTPLEC=4@ [\H: $EAN2
MUZ)@+2%PP1]",(>[5( $>,B%!&+PAA!(0" AH$$=K,N*$D2 #2=SP-DH4#,&
M[+(%):@#";15AP38X T,.!8*ZB AD%""Q0]A P7:LX!CM0 %>1B!<^;PF1+(
M(1!6OX7 XG0"/9# .>\JRZD8[_BT2=T-(5!T20+3@B%*8 XP6).'2$""#<XB
M/RY@!0PH\'2=@ 00$8B3'"R1I(FL]B%UJ  >8/ 93BR@90S8!)A<, ?I/"OW
M+^ ] U3P!HT/B@268.Y$),"&-Y3J%B]X !M\FSD__6$$Y/[!@WQ"4@$1W& &
M#ABY'7(/ X3LZ 0H&+<#6,")34A@"F\8R2U@(($1X.$/"*B! EF!RX.30'
M.Y"#"@"Q"@@!.'"!!^")& B!.BB!F,@$"GB#-R"(>.- +:JW#QRP>Q.+2E"
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MGV$;!5 =W%"!_B4--R 3.H"0O/X2@100BE58 1%8NO*H@!L@@:%3E0@ !$K
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MBA*!!UAB!R >LIH8.UB WYPEJY:G4HJ!"K@ !:@ "X@):-M0!VCC$G" O9"
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MN7P/1H'GBY.O"X$'F"W'4X&8_^71\WS(]Q8G4048T+J"L/Z!O2#<0UD.$:"
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M"1@0 &V !/""('*UL-:*K51B"0T"5!3" ZL)P$D@ /A!!_X JKP1P!N3S #
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M?"L$X?Z#B  NE8 7G.!',S" "4BP A<<\C$T$)I%-C&'SY6)  EZ0.EFX08
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M ^!&YF$(V+!!M,!P'(:.LY4/>0A&&9D+)^"!DSEG@ \XY0Y!@F&J@5?+#2B
MA2O N#^&I]=X/";4&TA@*+Y XTB )J" "+@ "Z" L^SS!,!$!#!'';#."/S!
M&]23E' "!;120N5+BD\)D8!+(*P #%B 3QP7!1A-!%A<"T1 )]0!_$X:"[S
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M)_&?S"%K.+&)2BQ #Z*@7@A$*2>+B& &JLA$)B 03IY,8F6??("7/"(#^MB
M!+2PV0'L<@,+:&02$##ZW)&??(+?G?D)SSMK-J&8]^6J$E,@FRHT.Q$LQ^ !
M*%W!&]Q  @#-0FVM=X\=_%!#C=;!$BX@$2!:H *5X*(.@7#!"1+B'9<F!/LH
MT/[V4& &,L56\"!#ZB#]7&"7%$(%5 !7]( 2V$ R B$ \6 W#B1^ .0!([#?
MVB]V>&(&NH^W/&(%W. -2"!U6/XA7FPF*/R ;.1@!?2 !&Q *DPH!H:+#U:
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M1"$!"LMZ]N MBV*J-N)Q$%-2I&N'M&A<CD(A8@7SBF(/(D<%Q@4]5B"<,*1
M>"P%K&= 5.%:8"!@<B,OGB0K58 5Q,<E*  /IF9:-@0&)@H];#-7 N-H)NXK
MN.+SJ"(O*L 2*"$%@.,%Y,"09@$65B$!.($.WF+'L -7C,P!VLH@+N$&2D !
M5, EJ+&8%&##),0W\&!9EJ+?/L\C9H!%0#$%' !/CA*%K@;NFK(^[3/.2 9E
MH'(_2Z,0B^(&1F &:HA9!DJJ%",K,$M,+,($!NH$]* 2&. %6"#^)B$3)H W
M#HDGGN,B6J $;* "4B<"X$)$F/[C %I@^.Q$ EZ +U:@$\3/(#R$ER2 $S3A
M0_3O(KH%1J\E!2@,0"XA+TY !,ZG!51%!6Y'+$0@=6@A+3,!-!TD!6 *!0@D
M5B#$(#(A+.;@A."@!7[B!>9(!1I##T)  DB@('+35F"@26P .%QB!6HR2V_A
M ?:0' M#L73NJ3AA#HR/+[CT)2S@ 6  .V*F.L^*%:XS?,ZC<NZC$M8'/38A
M5O  %>M@\MHQQVA /RJA2DJ 2XYR*A2(/N\S5$5UP$A&$/GS5#_C^3R":Q)K
M01@TL50N$ZHD$SYG0"K(+*%'0FCAD;KCGG !3\J#N=1$4D94 CI!3 J#*>2
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M#RAAAG.L$C(!07)CH":!I-1F!=IJ#XA8^WQ1*>L#!JY/0 \8/2@AB_@ !5!
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M 2  #A3 8:[[%FH  %2!!.(2 GR#! Q@ 5S@#Q[  79"!!  %ZHKI*Z,! *
M!%0  -CB#=C\!0" #P(! .A;>B_AN"O! 1S #5C! $(N!0A Q@F $RP! !Q
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M'L^6^U-(Z2ILXQZ!W/+& 73]RO)MH[:,9K -!4(  S:T ( %MW 2  WLZ@'
M'PX![8=!G P@V+PA458> #;<0G2]4D^=*5\D&,KN) #@<8L@ - Q,-5NSJ(
M4P[<4(%@+SS=4$@N#%#'=PF<Q1$N"9Q@4@(UW )SWW['K*I"(QA@(!XPE%?
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M( %>W-D!(# #!@1@%7"X9@4R(0$'H%$"1P$ 8VB$"P480 4A  #OJG8+-P@
M1"\1@0U>@ =6A F6,(#!UB8! 0;$8#MSH"(>9L& W1F@!;?P$D<I 8 1P$ H
MAUQ@# A0B3LD@ (P8<-%WXC6M )'9@M110),<" &$"  ?&#% -Y@B:V=<&N!
ML.DA 5"225C"FG_H:]%V9H"VR"$ G'B# .I0B:=T9Q*50($!6H$45K"B /+;
MW!UN$4E<D  "?%&))2QAAP/(@!4(&,TM1.  0%Q)9P8) 05"(@$1V)(&EX@!
M "8124   DNL.."# A$ S0W $OYO"$# O.9,3 !@#G\ ["U4$('72D S%9A
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MN,",*S)TY)W9U@84&$V&#>)C(/-8 A)0]ALP_&W'5N+)'%=KE!4B!P"<H!*
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M8Q)O %F,T0EL<#JC8PER0 ?5FR0UP 8J4!U_4 -%X[Y6.XZGD0DDG"=X@#<
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M ?_!"N"R!W03=AX\!\]KU?(D/X&@7R%0$"N@!WKPO$ A5!AX,BJ<'+V+ B-
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MMSO3PY]N"=,<A9AR^1!R,H%  W5PB1^)" ?!!P8,")M0"7A0![9?$DC,NIG
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M*+^" #G($_?)D*D220'F,09^H $I^[H'%Q1O$RC Y9'?4 D'1^34J[1C'D[
M"DV#_(E[M2P,TOG!6W#BC9/6@PO.!@<[;(YX;"!;#>J@R3]80 YLD(,J;N#.
M\X'M!$SYP_@X08%!HP00&IVTDA'AMZG?0@\SF,3D;D$#]/Y+>B^8B"K>B +N
MWB+5$?E#"QQ]"Q0@^@1^X/4M*O'#/%A@!4@#Q$YGO@HREU+3HF%W60X>D1N0
M#0\H@( JK"MMO%MB!="\["5<D&W+GH_S-XR>'$:@@A'X,BTZ7W<YV7Z]\ZUW
M!<F< ;Q1P@8_J& 6,T@F)4:0 OX3L%HBG!!OZ=!(!_MQ480JV0,=;#")/\"
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M"3V  5RH !A( >VC@P?@A,*;@1!H%L_"!960 [+)(*2*@^ZZ*!L@ 1=XHQJ
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MG1?<]Y97M1!!+W\71\O^Y3?  AXP@3/;WP,G3KKZ>H-+*A$C.Q:7*V^ W!Y
M@UR$L/X"(W-H!0(K8HD8X==YEH #B=ZPK-T>KR*9\-)",J$"BRED$LC""(E"
MG,$_T, &-(A):&S "JE%<;>IW,1*9G!.,"+1#]K1WBT,:ER%9$(.EY (*_*"
MBTI,(A!_+7#N_! MW=4A7YNH"((ER]WU!4'!4\)% JPE!Y#T-A, H'$*YC5
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M"0!1@4OX(0:L 'L&_0P#%;!H!?XJD%H+V#"' K&! BZ8!1U(@ <*6"(RKJ@
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M)>@&(!+$%&B&"TB 64C("?0'"E2".3:A);@ M 7.+=2 "- !I!#$&U0 "5A
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M( 7:#!(YAP'^@#!"<05 RU1,( :J0P]T)4).@ (@J 6RL5XZ0034(A-JQ +
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M_@ .W/[  @!XVV:2#=C ,UBA(/,W@$J@JBB#!C"#$N1F#OY $RC.:"3H/TB
M?'"!#0"!!!;B#1:3? ;C!4X !0SB#^;@#2Q@!8I/#N" /*JSA>6@7C9A!4A@
M!3!C??%@!$; ,]9W#T9 %=X@*2A!!7(%*42 88YB!DA@A4^#=%^J#O@I0Q#"
M$DI@!.J@ M!B$UB ATDE99?DBBW@!E3I!0KC#=[PI2"XX#AA/E1 $TZ##51A
M#AQ !, K@+;J4"IAB5M@*>3*IF9 )5B-!-0)$48D!HCSCBOA#>+ L 2"!"
M!EP!%R:)!/CX(#JA!49 !50E4&;G(.Z@#FB@ FK )B9A1/ZX%U-()1.>I XL
M0'GD^"V38A+D(*W*8HEM214J&09FX0U(A1-<@ 14 ")2]K1$8(^L8P8<X 0P
M0>]&I-<^.06HHI)?H"*F8#$OR0W^X 3(ASK">3!:X 3REPXN20X68A;8@#,/
MI;3F( 10X#]OP16<Q 3LB TNC8D.@DFF!Q"89Y[;$ZM(P'M,P@(M BST8 [
MQ9!7PF38P 7D!X0!9"%8@0W^( 0X@00"80]\KA.D8YA!& _82]OH( 16@ ZZ
ML,"JUZ5I[GKG4W#\0  J"(3>R!(B@';F8 $.I (2:7(V00"<HK 88F$V0@4L
MH&D60'E.X&$J8,/F@ !NH!)8(?[;2D7KY,  #L0"H@)*=$T R,>I+_-\! $"
M: %!;',* _  EB(")D$5#J"!QN.49E/DE,<!'&<6["L[:)DA3&!"]$!]Z(
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M!C2'<VT* A['!9)$9:Q#0O8ZBN1@ M#"!5!@%=)L(RA@ NA@>,ZK3@ST%E9
M?NK@O$S[($@@>\Q9%2@A 3)A$O".%2J1(4*E(:Y*?;0F+SJA(F4" 88B!0@(
M#RZ )A+Y2S@A[G9(DAHINP&'$G4M ?8#!G1E.XX3 4X@#YPQ$$;')H9H7P[%
M &B@%>2 7/) S3;A MIQ>E\:T!,LIAF"?@+0!?:#4>))D3S##6+J#;B).>A'
M)6B*T,6,0#X(#[C<$C*A*-(O@&)-).2.!2#<T5M@%7CH%OY,P(\LP1**P@ZX
M? Y^=*^JPP5:8-#$Q!)2", L[]=< -,,B30X/3031EXW(0[$A [DQ14<8"_D
MQ5_VHKWF(+E" ,M(YQ:Z&':J"!5[0NY> &'R($]>1-X@JVK])GL(Q?I<*MD;
M(WCUP,^69RA.S?IN2)2.HV=JSP'B($'MX-U[+C^_.-2VT[M#/1-@($"\O1]9
MD [8[D$4"0;\M&\J(!/\H+R 6'O.:UR0IW.^) ]$%Q!FH0+ *\U*)4,VRN'+
M<C@NP0^LT!;4#!"&!<,2P!(@YG7D+HKYH[U0$1#,+L(HFX2RN\VL6K+DE1,P
M_##,;DQP81+,3A68_2#DH#H>;/ZW;(=V8^M']-7D;\'5:,'I14,5R.06^* =
MBSU69N$/J+YQ/>E7JI#/N.L-.F%]D\QXLD9,:D#KG L7'* ]62 J^I'32T Z
M4L5O*H@"-J);)L@J(" IWF46".H@^("2_CS0)_^8?B-.?Z0%**$%_L!3*(&>
M2D1YW   !>H!5&'&)B')EJHB2L#G2D /*L$!-*O?O.;1&^.3)5I7WH!BWN %
M."$"KB(%J"GVT:4&/&,2II$:;4+D)N$% *$&YN!2S"<XO+++\..D'D<"V,JJ
M72!*:$"=H%8\(N2E-+*2,L$.I++\[\ R4\PX5$ .5(&>[BIRZN<@)NK]1H -
M8*!>.OYE*&5_P7<"($*\N:5B(,&!N&ZQ47%KUJT*G. P=*@"#JL'MUJXN450
MSD6'&>7<2GBKTHH*$%2]2=$P(YN1'#E2F'3+PIZ8'$/<G 6#!!L8)VZ]J !C
MHH06,V#,L'.+58P0#O#@I)!I#PF.>*[VN7"+D@1<"?&,@/DF**V$LR14XL@)
M(XR7MUQ,N:5J!M0[MRA8JA/4X05+>![8@"'#ABJK'''%&'%C1M _%F0"+M'R
M!9M9#UC=XA1!<T)6$3;=HF,!QIL*N.A0!LL14(5;ER#,2K@G1$U ,/V<D"!"
M<TPY)!RXB L7A1U5#QR2K,UQCPB<I$U74'5+-V_?'$O0N?[%G/OS"BJ2SMC.
M5H+F2Q)NT9C!<<8-5@Y8):QA [X,&#%H )H5@?HMG0K!L,EK__EQRP/4J0(!
M+"3HT=I5.$4H(4=$5&CAA1AFJ.&&'';HX8<@ABCBB"262,002]@R84)LH, >
M#"@,- D%,E%RRQLM</3&<"EE0B E!":4"04.G5 '1R?@ 9]OE/AW(PLZ$HCC
MC2OHF.,#-ZFB@!\7,<D*(+@)565,+:@@QRPKG/#'+990D%";#QEXRR:9Y&6)
M3&O.>4E,F2! '9RD<:0* [/8$1E=#LQ2!PK-$7B+!($,ZE\%>ZCR%4<2<()'
M>K?,P5)6FR'(49,2B@ '0:=F%/X'3'D<N@H#G  R04P4 *)@7 :U,) $4L%W
M9$*!Y#E#"U[%1.DM*AI+TP5YQA2"@75 P)$=06ET"P125>#@9IFH<N0M@3A
MTD.9\ $AJ'S8!E^=M\PP7$* <#I+"ZR00)X?Z5G&D0MOS$(>(@S49,DDG*Y+
MR:P<!<(=A'M@= NH?MCV4"652)L3'K- H)FEV+%"@2JL(% G)^E- D%"N- [
M2628W7E+#55:D*<>+HL %RYS:#:+ IG$8 -'(ASI@,LV!"+(<[?P\=QG"=1I
MZ2Q[N$S"SR21()5S'$5\"PES"&HC6YG= HBT-;#7;@VW., N"C\_L">;G+@B
M@7\B\/ZQ60FF >T'+BDU%8$M;%!V"PQ+3VCX+28FKOCBC#?NN(DI'F[) %V_
M(8!HDSAL 0FLE,41&RS!:HFX73F TZ#LD2#2+2,,!(/,-HC*8E"W_.% 'WB(
MD-X;)NA(F2 4F. "!5+-4($?-B3Z1P)U_%'!=B35$<"=)SR04"6D5Q+P'@[4
M40<#:S*P%G?=U^& @9\]((<?+BA0B1X'V/!'"#G6@4 -\^?X!H1;KP!("I31
M1 )6X(<8T"@3B>*(VK"WAZS()A )&(@-*L '-L3'$B$ 25Y><@*X=! FN""*
M'UA @#N50 6 4,%5,A&P%!1G+I6@  E:4(%?@2L!<_C#!?Y.=4) K& L<S ;
M1QZ@,!*$P&79N< F1J<'/)P@/BU &R+\- D&T $/#M #+A@P@T"T@%$Q49L>
M#E6'R$PB 1MQ P7\P(8'< (G*$!!(%9@FT \H Z!D8H*T$:0GSD !H%X05 @
M@!L+M. /+Q  34Z@)AH^C$"CRX,>GJ@*2Z#Q46M*P0D T0+;#$HSG&! QQA
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MVX,+3KJ9;S7G3G]P&2"0V)0;M& 2E6H(7/.:U<FVYDY'%0T*NA:32K@KIK.
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M..FH&6[@ B[P &_0CA*P)RA $X&PE15 4B(%ES]C?!=P B&P%H!P C00 A)
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M#Q">.(&WJ]97'&$F-2$GD8P5O#('=. 'L[ >'%$82\)T&;&ZDEQS#5S1EO;
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M"3EDO74 5H*RXS 8?P H*$]& 9?@!_DU$I/PANQRWG7@'ZS@8&<_*E$?(9Q
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M/  D='BI3V&ZB0<HKWR/E /J"A*"%U;RIW)HWP.@Q8J12*!EVR$!*6^!5E5
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M_Y>_GN@, 21 (AC  RQ !#1 !61  E1  TS !?2)!H3 "J3 SC"" ;3 "-S
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M< ,WI$DD(JN#^>(01QSF$!#M:OY('51H@SKTBA(OR"*6 #$_C:A"#H-LB5U
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MS %HF4IH1'R<4"O 2D-0 @18 B500B:,D01\S. ]0+91G_[1(-[R((J_[5/
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M J2) <H%*[J'2NR! 6#("QQ (*+$ UX4!1PD]7&<!<C H(3 QY! N[ ""I
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M?RO$5FRIPORO/T"P:K5J%2M6!5493,A*5<&!!0\R5#A1H?[#@@0-"KRX:J#
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%,@," #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>comp_0031.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0031.gif
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ML QQM09PM1-SMAQZNAEVN!1LLR)]NRA\NS9\LD=PFE)\ID)=C8%_@"R"OB>
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M]O+V^O;Y_/____CW^/;P[>;CWP
M
M
M
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M73P0FT #MN#,2=P+$H  9[S%#F  A9P';K#%Q%P00ET+#@ !0DW1/-$+#N
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M RH0#)Y Q47,!P#PXQ)0V-GL +10 07 !C#@T<%@T'V0W@[P @Y0U;6=RR&
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M0 %%_-:*_>)VH.PX4<1QT.X$\>D&H-@M4 $W$ @E ..>[?X $[ )(6 'LLP
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M3;0.3.#J2= L.P!L; (PP=.>! IJN0A@)]A"J!?]+ 9 8Y2!"L"$33@P*D4
M-J).!/Z8 9F-V*6E39]&G5KU:M:M@S;M>R,8B0 ('# P$$(4 @ B1! XP(FT
M"!O!8AC8Y. $Z5*\1SL D"+8K0H#9L08("(8"@![>H48$. ! A&]' BHR%TQ
M! (2"DD(P$H/PV"= CAP>@#  0D$'D] H!37!B2P0 ,/1/! 40K0C@T W%))
M 5%( $""$A (@ [2V @!+0#\:$&!7FH2QH+>@DD!  A&A $ %&Q0  %:%B(I
M!@( >,NP%0"8(Y@X %@A&,04X",/ & 8145AQ@I@E%$<"$" CV((ID5 2$LP
M2RVWY+++ TLQ@ 2+2"AA!!)$"%*4%1QPH(1";"*EA!%I4?[! 1($M F&$(2S
MH0)!:IJEA;=<Z.@&/VOQA(]".C&@/!5&("48-BIX3! 1)B#DA1!L(:2"T481
MH85>2AFD#U1F &"06@H0TTM77X4U5EG%JD#$-D(H@01=19BEEQDD:, "Q6KJ
M!85-Q+J!@0G>#(N."A3CHX(VB+T! @9*Z"28/BJ 0Q=2^@ADE@H2J(4-"O[<
M]M,4),BCD KDF"4$@81108119MEDCT0!"&T"!;B:-6"!!R88-82.Y:F7$7M:
M6*A>PKJIKQ/VX(X&I7K!+ XZ$#B %@=A*CADD4<>N2\W>AK(IX9?6[DF4 R0
M8(\:>H/XJ!= VV,"  H!#"J2?_X&.FA82Z&!III)_.GHH8[NA0T'#F!@AI:)
M:LH3$@Z@[$\YW%!::*^_!GNIIC7<J6N<S%ZZ)CX^0N"$M9!JBI86$#  @C?0
MJJ&CL/?FNV^^A:EEZJ1JJ<5OPP]'/.1:;D'M*K03ASSRH!_GDO*D+)<\<\VW
MQ/SPSC<'/7311R>]=--/1SUUU5=GO7777X<]=MEGI[UVVV_'/7?==^>]=]]_
M!SYXX8<GOGCCCT<^>>679[YYYY^'/GKIIZ>^>NNOQSY[[;?GOGOOOP<_?/''
M)[]\\\]'_^^;/K>)_0,[5[KKH]U'.OW5YR^*?@(QEU^G^/.W7P %.$ "%E!S
MH[ !3?Z"T;1A_8]8I1A1'Z36OK/Q!&(U"PO^SJ:T6?B!$(*SR2P$(0B U603
M?HB437I!"$"4D!1YT!LM1%&VFVR"!H\A%BE6YD LK4^%I&"< 6=E!S8LK! V
MB-22<@*Q672D%C!@5OTH2,,>^M"*%<R)*/J0K9YT8HLWZ> ';Z)%X=C$#X.P
MB2>FUA2(U6(.-2@<H/0F1?_548[Z$^*7!E"!IA2"7SYI"B$"D*VYE=!5?3C
M ?:(IYQL8@$$&  #CE6+$PP@ 00XF3!$ 8$"&$ !?^J$<B 0J13$ 67!( 4!
M&J"8IM@GBG KR0#0B,<\J@95?PH&>.;8DPJ(B10#&$VL'OZ"  &(RG\O&( B
M8= 4/R22 !,0D#!L0( $#& %(VI!!29@,4],((X]0<P)N-(4$E3@-">@0"T+
MU@(#K(4& Y@A+?:P!X )PP]SR)8NV#" .<Q"B\&@Q29Z(0@_+(P4=@ %*2I2
MDX#VHA!<X8L=.D(06@Q&;[78 R'PM;!!T.%M-0$3KS8Q !7041@0,( H-F&
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MK8R6R(8&*T!,$)A 33P!@#;0(@ ^6T@GWC"!7BR #RI0(!@EH(#^"((4MV'
MM%!I+?X&\,$3 Y! !0[0B5J$:0 VZ$4%" "!!Q!@ABDX  4(8 =:T'A8U:W<
M!/ C$IC0@#($"(T@#H""B<PB!@A0P IN_!P'0,"2QTK! !P@@0'@<"RUT@X)
MLF. QAS  @0(@"GC$ !E$0 JS?17"((8C!848*(,T$XC:="1S'H"$!^J"0H.
MT L8"* CPF# "'I!%SNXIU4X>4-[#E">&22  1706PW<(@)Z!4 $!R@I#!(P
ME5[L(9(3($!)7RL!9=V"#:8>P:"A_"I:)$ %I B ;$C  (4AH 6T&,DL>!:,
M0   $H0^@%,"D+>KU0(%_YJ% SI4$UN3H+>#&(T?F=RH6?XXJ!/S^2"2;[$'
M ! 6!0A8V T"0%AA8&<4HVIB$VU2"A$DI!<(:!4I"A #3@ @F'X 0!YH08$)
MK$ /*N"$O"XMI %$B@0($ 8A  "3L-SW,85@@S#LXX82,\ /&/U0+UQ @%D\
M^D\N*$ O-OP8Z@Y;*0X2Q0L,T M0 ,"4F9W%# 9)BD%P90+:&<4 3C:![@X"
M &](4AMZ\88 H%$L%C! /YNV"6&00 '!F$&;9Z& \EB8( 2H03 8(*8-WZTI
M(EC ."<@@5X$O(G?3&^'V!  9J5]%/<>9P7PXX8R^^$$@K!!"&;;E*A#1>1W
MJX $<$*"##>-)B@P@*0"T )1F/[' CJGLT; ,HID!V,$FO<YK)IR @BX 9X:
M<4 '+/  <[+! #C.B!\(CVVG .!8+CC +"C0*G221B0*1 4-+- ! ]BA%L#L
M[!$GC=X!Z"(&!PA!!2JP@(5F]DT<OP7$L4: O ?##V#^TRT:,.ZH(]$OY.[.
M CTAC!$(PJ<F,*V:F( .J(DY" !2\*/),R%(FP4;Z( 0,( WZ(4">(&:J($"
MX(H^" !:L('<$#^*V#"0B;T$:25@FH#EF ,""#\+2 "[FH  .*N.>+K:&H!I
ML1-4&H W$ 0 $ Y12 @2B0 "% O'"X$RJY+MDP 10 4"D#$%L(%92+(*L  &
M: '2./Z!!!@GN1(&-DLDAPN&65 ! &B!PLDL!9JY0#& 2Y. # N&>^D#%W"#
M"?"#E*H)B*.)7F  T\H\G+B4FA $% @!:^D%&QB ISH BPD&!X"!6U"PZ6L
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MX5P8!C#7FLB#T&"#T3@!3Q"%*JR94EB1[2")FJ#C$?F.5246"!!!/0@26HB
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M2819JUGHD3J8(4\8%G05A!1P SZX$CO(89^OB3C8I3> BAF'@1AP 04"A!.
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MH)D7*7R&\>$&8 B#D-A?8=R>C:@-@Y0(=;0 @[247Z"<S8V> SY:+YQ %(E
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M.%H-]! &2@8-+ MI; +:S(("L%%4" 1-6, @L$^>, ! ALQ=2,9 ^!)!/ !
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M*4A&?<S #-! #YU \/R%"$R@ZE 15 A"'.Q!#+C'@5"%76Q"$@&%*+3**"A
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M%@=*W9$;V) ,[58*S,4FF$ +V/X%'U# G%J 1;0!">CD+'3"!$A :3:('T
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M#50 "4Q@MYA X(2C\*K5&T1 "$R +0,%'[ P4/3"NH2 !+B 0B!1KG[T?:-
M#[G,(?Z$[F' 268#U/=!G"9326<S=Y5)0A!@-XJC^',_=XJWN(N_.!$,@16@
MMU^<0 A@;#8-!!OPWV41!2?X4V6,P@'L[P0<0 .Z!P'4  H  (,X !LP'7>8
M0,)!\T&41 NK +2H0 B@KLTT!*/*#!],0"_30@S8R!YWN& < AQH>(_[]KYM
M-G",.(G#%^WY@HG#.)[GN9X/P7G?T2:$@-\2!2JD0$!S"P5(P!P(0PPTA.?1
M1 ND0 DD H?DGFVP00 <!"T00*LH1+1>> 6$ "T8@-0@ "U00'4) HA"0-!
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MP?DL(@D?=(^0/3+*3X DDC<B3QA]6&1*>K'$U_G!#@2T"!)+@#4(L$(B)YB
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M%BF%&GL!"D5R2[VRI:/VZ!I?H%R!&.ZU[WWQ6R+@M:NY%6D!3'1K'(\TQ!,
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MAK[V)EE2!U,MD1L6A".SFM:UMG71EDLB4^B6#3.P0YP:4@@2D  &O?!$!21
MTABL:A/MH84+4F""1 2#$UNC34V"(0@ 2+(7RW'( 5Q0" 3HK02CL'9P9Y 5
MR*RJ(:+ X!Q<P <L[N'<H]!5'S3-"0<P1 +_DQ>E[O":L^V$!C90@4X\,9]@
MS. $4.E%("!0 <TTA$$N"(%./*V"8KI/ HYA.%16=8,3K" $2+UUB!#F(UAW
MSP=7@.W)63V+Z'IN4Y9<)+R X?X'0,)\7KT(Q;Q$T0M@ "-NH^J$,"*P*B1N
MXMDNZ,4,5*"E",R&#W:K@4[^1N<W*'6E,'! "CAK!P2D( 0.*(5RYB"!.+!
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M!#I!TR"B(UD PJ;1 4: HWJA!1Q@!6A!REX@DX*A#^ $G^) P5I !!R#!DQ
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M1N72L/X422LB!N$WZ(($/D8$7$ "!*-CB 1D1(9D2& &4$9E["8$)D[#".
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M4=M3*)[2OLKG0R+I7GHUKYAU)7KO1EZ--QMF#0N6G69! 4Z $V8   BA%PC
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M"$4&*F 0?KAXOG?)&-?WB.RUF'B1N8H6. F [*>RF)=H!_Y*485RB1DY1"R
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M&++]*-1==_F5KN'=LN8  >2,$"0@^5ZQ%WKX!#+X!#.B%RR@!7R'$'YQ)5I
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M@022<4 ?0&$!0?"'P"?8!,MFX4HU^\P/#PX&* !PN1?$0! D(!\,4$"+&<R
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M"VYPG.81##OI B71"<15 WK",JD1%\.(:X%C&2MPC2=@<R?0!Z50."HA#"F
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MKW.79C,0&K$E<U]1" R -9W*$"X0'C2 1OYJ9"1 ,VP@K _F CQ4 ZJFMZ7
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MXI<CJ8$C"IR30"J0",O#@"1H$2:&0J),,_X*XWL0 [-  3HR"J2 DFZAHWW
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M-E"-A:,%!["+%!"%%T:[JP@&9(N#)3,S*"2(WXLQT) :?K,#H_6#A_ #XW*
MYU@!.^$W$^@$Q2.(&VBS4I2;,$$!S:.!$D %*NL0+NZ=/*!!:]44.M"E$5NQ
MDZV%RPN&:@N;U9B 3A@$KNB\*/F/^D %XL"0N;LS4;  ] A.ZD X^'F*-BB%
M1?.F1.T)0L@QNO $/N *QBOA6O[ G K G$V  #H3DLG"L;7,B07+CS=8C#$+
MA@Z0"%&(@Z,@"!N0V[L+@7/"C]_)8THF/51#L0ZV@%*8 Z>XT%[0&A$HQ#FX
MG@F^1F5C-0^N@5IP@07M@S]^%?^U5NW(8I&@-.]JB9]48Y#6R*];%VL5A$Y8
M0Q(86O8;A,(-BNZRPCE80U*0UY5X@#:( 1G;-QN(@10@$[C[/11[@1O@)5+0
MKWM=":[P@YXV <+ITMH-!A,@A)$XP*NHPT2$D!50B>D2B:B:@RX%A F(@Q68
M+-900180@50A@3]M"=\HA!AT7.1RP5D0!0<@X+ZJ*MY9*A<(9H)XP!5#Q/H@
M 6_%O_Z08(//6->=70&I$@7@H(X\,, 1D.JMHH'N4F;T<($X*+QFK9<)X ,W
MF"Q/Z !(8P,8& MR' %96:A!Z#^D0#$5>(,)8+NL=H,'$(7 \+0;^*[_P,(9
M (X:Z;\54"NC\8A(X]/,_AN@9::%FH/".(%IZ;$E8P%66X$8L('!F+? S8]-
MP*H;D #WJX '*\20'F^;K,5A>8Y9Z(. <[<<"81'0ACE0I$!\Q.%H(Z"AA)T
MG$>L8$>1J(UY.9WGJ(7:0!+E\@1A) A4"$@DX1=1Z(,!LXV>@M)!>!$UV<<7
MV@3FT,5-,)O?H  P\01"0,>DT@YV6@U!4)H<<<5MG(NQ(?Z%@4Q'""G*+PH3
M[>;%U<@5%P\2$F 48FP<%B\*5((DU:O%49CQGDSO69!$I[E&A0D&4N@#:QJ$
M1&!D$^?CT408:)3$DEK&#$F,&1]'K-!8EF)R=U;O")%QCH%9D1 =Z#0*0<A&
M=^8#\21O.J_S]^$#LT0M.G!<0(KH%WAM-JJ@/@!<.R]T0Z>C!OIH'%+TY[DB
MDDRB+9(>1^^BYJD@6LA!1A<E)&JDC(ST+>KT#'(E3S]T4B]U4S]U5$]U55]U
M.<IT5G]U+@L2Y9'UI%R>J_P7@#+*-?)-VU@DZ=E)Z5G=6L>>[#R>7)>?IY00
M=9HGY 'V1S]*6(]VB$2PY-F#//Z?GEJHG^1A#<]"RR=JD>=>'A9XFUF B1L0
MG"I2GA8(W>E9 2UCHE 8F8ET"?/""J/]EXWP%QB8/!GZKW3"P1!RBF&32@F9
M P5VGFN7=H5//ZIC V>ZS-70#I"%F_,8J3W9S^OLBGV:ITK^)T[HJ5_QS5'H
M)SO YD4)>5[1CEMXW,SY&4_XE)4?A0X1!OT[T <ME2"!S36I!?DS"C>;!1+7
M,MZ!E<=]D!5Q\B"9SIHZF3$")X)93>T&S>XL*$[(CX1^#EW@!$5B(>LTBJ=G
MC[%91:YG'_0C$05+IU\IIQD0'!@1>KTHNMP*J:XWY,I#3IW?E'>G!:3XE:-_
M3J-0KOZQ 86_L<\Y7WC#'SC6V(/T,@'<(IT0?9V_Z*X]< .+J($46-#Y"::0
ML /VZ*Y:4($I*('[,V$7:($0  92(*^ZY82K$(82H(5-BP'<V@J7*($\59,3
M:($6L #F,($_1P'+,H$@@;>Q/EH3\"LY.0$)0/?7:2Q:L 4+V*[N^@\5F($)
M2(QX#AR_<('J#P94(*\3N! 4: $8H("360'+H@H4@/VY:K@8#H$8Z$$,F>:J
MZNGJ<NY9L*H2Z(@]=K$8B%2 F'4"1@D[O51 R$/JQ T1@H()"[9B!8P*B8+-
M00'CQ"Q1%D(4BDCH13 5*V)4*!2,SHD7)&@54M$K1*]@*?XV24PQ@\+#&3!<
MW @VBT2+BK."!:MU(I@+%2@)(0T6QX&-62%BM AQE :,%T&1$H* @E0I$C92
M^!%&@F*P.B1HA+ 1K$97N7,<S*@9=2_?OG[_ @XL>##APH8/(TZL>#'CQHX?
M0XXL>3+ERL'LD$ : A2=&<$\A0@F8DXP0K7L3*$EH68(4G-@!.LE@=8)TH5J
M=8)0"V;4$X!*2RBY)]@F"\%"U-KD8I2(B"<$"7(AK *I8(),!*O0)UBAT!94
M5AATG-0>%[$GS*(AMY"(8'T\1W1/*]@)0KUT!QO1*8]YV3B#E1(:#(#XH0)2
M,^@" VFB5-"+"+^Q<0,M#LS2"_Y4(LQR@V>;A!:")\'LD5E$@U 0$0J"=/+
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M 6\3R;)!#$ZPMN&PAS@.V$Z\%&FU"<:Q/K6P@ UNX(#L52 8,,A#+TQ@ QB
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M;$# R!'" ^A%_*%..3H I>R?=02'ZB& %?Z+'F250,P $9E(&R!%'U@ N*6
M8[K'ZJ3 ;UA *92"*?7%A(Q7'O@=(>P!5;D!F)Q74<8DR>E!4^D%Y* <7ED(
M33ID5I%"!;0!8_;"'$S $<' &UQCSP4#/8("7]1""RA ,=814JS47H3 "<*A
MF1C?Z@P"29Q7+]C!;GI6'O 5:UG(SHG"+1 1+>AD@-B \3V&"M2!"YC'++2)
M"P @$L8E/]%"1PD"!+#!"F!3(4Q "I" QCB 3!02?;@ #?Z08WS8@ 6T@0@X
MYKUH! 2H! J,P R@  3<PB8$1_2LP R@AQV(8QO03 R\104$2:+<B@C<X8A
MP!2T0 I F#O]A ,$A2A0 %:, .0Y0 4(#42H  O00 .(!QO8IEE(!9C(*%:0
M0$V8!('286PP $[$!RV<SBL.YANTQX>YHV A(8Y)T@S0TO8Y0 A4X)HX%>[
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M1'F&K:!7A+"OR\[ &[P!48!;@-8$"SAF>%A;)_+!!)R?R%+ *&"4F(!B+]2
M(,1 &["!><2'3N 6)>\!=@1C]WE"<%!*'(!)3?0F(4"*-1,'!'0 #$"6!%!5
M'S2+ US$ D9$"%R()"*%"M@(A*4$^97"((1&1+CA=*A 5)] AZQ7,'3 )OA!
M]QW(_C) L\@ !3A,XY+ "<*O1:V<&V3@'L<+ PC"%.2%Z<2+\8K (+CN9\Q
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M*!@V!%S8'/3SY$1L1/!!QY(OV=&""@B-,'S(Q.[%"IA *78)O$;% Y#"*##
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M !S9H,,7'=)#M*. ];#7DA40PBB]0,$)<F:!3;"!.20@&0D\013(H& A<W
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MI >'@^]HYR="H$GB@(AB!:%HX$VNYY;D4",J1R,F@!,X=BJ^13-F@'TX84F
MQ.A(0T)@XRXVP5B4(WD4@&00ES&.8@]^PA-&HQ?B!D\/(CJ$(0XX!4#GASFF
M)(TD;@\BP",8:PXXI1060!C:1/XN5CO)PC8T8_UR DA$@/X0^B!#4($!3K0-
MBL,TO\1X^. DF"4L( 22'*#D'$ 7YL $-.(-S.1[PS>S]K9@#BAE.NLP<F=#
M+ !+-A<F\D0"3$,&&F=N36-JG6-M&Q,!"DE^#^0W3F(%@ =3BV,"<,03N**4
MFH/DA&YN79'32F%%;B1 !&\HE (V1F$3*& HN"($ FD0^.#D_D8E3U;8B%(S
MM/<WLL,%5J0!<.3'?*,"5A<%S&3Y* )LAJ,.*L CYLJAE$+L-.(]+P(E6D H
M+  ZWC96A$$0(C3P*")W;T),>F.&:VA2P%<CY@73YJ!&W&! \-3TF*L4'B!=
M-(4%;H">DB,$,B;..(EOG.0I5OX/(FK@!& @ L3U(BZ$#"%B!0X')WJ! FK/
MD/M0A(4AA!]C!%9 !5) !2QL9<^D8,_8LPB!#0#A!&9A I@2A].C%VY@CT72
M1)KD#5A@G4@(BEH@!59@:68A6]R*!"0@;DR$;E1 !>A"(E?PE5F@ DC" @:!
MM61C2FI"&.R@)AQ5!5;@!/969 SF2^8 +5F@F7=H#^B")$0 IX9C#\H7*7.E
M!=S 7/JV)&1$&/8@5UKN*02A<"_T*=PQ.V@@A2()Z%+"B5$BA]>T!9I9!/R,
M!Y^"%B2@14X DJ_&1D"%)&[@3<@WJZ)%&"#@%G:-!H2A%D@SG<EF!O:X70MV
M(6;A ?Z@@@W>6"-D!I)10"61BPTD0 (>8@8FH)]7@ 1H022LQ4%*V3%.0 X\
M*@Y2("5(@)5&8!!6.J9)8#120G'I27I*X#!7  56('<"+?\>(WFD1ZEK00Z^
MI@V YVZ"A'4C@!90( ^>PMR2HP, (9XE8!1*(0+HJ@+2XPV 1QC>H 7P5)=9
MH 1F!R4H0*KM #<8H)]90 3TPFG-0P)J(3I0X2E(H2=4 $CFX&Q#8-8P8BB&
M" 8,UEE"3:W%FJ1[00(DV9GW324RPIV$03>D=#,X:K2\P@(@>9=YBJC:(%<*
M#IWW #E:H'\@H0(D@ 38*!@P)@_H( 8\@7L\09==8 )4@_X&6'JD'6J6/VZO
MI^,;8: "5J0"H$-CA0&D$2([:G4"[TH"="T8T.A8^N==_)4!K)D%1/1,V& %
MA$$%VN"-@7J[ %@C[ YEID(%G0426>,HQ"@87B#HMB884( %5&,%7D-C34@C
M$J$WVK$32%<]CMI#?%8E+F033D)H-6.E1,&6-.)]"^?O#,E!F,,%QB(Y<C@8
M6 !D.P4G3@!((BX86$$Q%-:H-&T"1.MB_0 !J$;:#H(/RC<Y2D$!TH,6_,.3
M(DF628(.LD:9@X1D]C,Y1@$"-.4$]F"*;[P30KHY%* 4:..<-2(/Q!F.6B .
M:J$G^(!3U'E^)*226FGMY$)&HOYE0VR 7O.9-![Q[S#G@&!@=F;A,"P@';5;
M.89D3VK$:&MHI\$:+Q[BHB>"S4D !D@"!0HAHCVB4OX&U1Q/=*=BI68N)5(E
M#^* @P^"P9,#I56#ADX Q;5&)>G[,0@!LC5#L7V##50R.GH!QO?L("H@D%Z3
MJKT:(@Y[#E1Y*-^D!*KZ8K/E!A0X#T0X1X D.F@!%;0QQ8_B?-\">,#.?3!*
M&"1@<]K !0"]E=0JQSM+&S%[=<@"2)I<(R3[PDFCS6PB%-0CMR: %%X CFIA
M4K@7(C!*.#0%$*;C!FI@!4 EO#="[E["!0YM*"K&#= YS$LB5UR@#?2J.:!(
MA0I!!?Y>H!2P"5UJ 2?U^89!9%^&@E88(NA(<VL\@G]((Q$\&N6EN#CJQ@16
MZJUC>$+DZ 3LP&T'"O_VA%T>QS<2?L>XLA0BO!!.C@]FH6?, VD/J!,6H+5\
M\Z'*[[URI01F@!8( 0'>@"K&TEBJ]C%88!8^8SI*%,N0<RQ1KA"&0SG]$-@Y
M' '<@!3R0")ZX7(ZA8,UHT PM9,KX.Z<90IJ805:@!8*00%*1 3DP#=@V>HZ
MPCGL8!:V1KL7H _D(SK:H.U[X63]T 54>4W%N[,4H)1HP,N#@0)J8*5F@0'V
MH!?FH#BB9"@K@+3B.'@&@ 9*P0_>MF O<31)X@4LH 9:P/Y.^!-3P[8W4,!X
MYJ46%, X_,,.(C04'B &-NYF05P%4"$1UC4&LC\EW@M+(L ]@B$"9FT"WF 6
MW#/H:X !:+5,,%4"0&&;5@0"LM+@(:*Z9R$IPVIZ-0(@7L (5LN!J&!V*@0+
M88.6( -V>BV8%6S6@EJE'/29%2-$L#T1.I4Z<2.8L& H4ZI<B?+&!%*T1,RA
MI7$6&Q'!/"T@=!(EB1FT!B%P$PR%"E,G3\Z1L"F8!3TH+?"AR<>FB*3!VA
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M!PG1I<2'"**P$F@PH_ 83!]?TM#+2J.H$ ()A01#2PJEV!9F2KVPL:DP-IQ
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MQX$U*!%AU_,R*>$ R]<+$? 6%9 :'-8'!% ED!$!LQ AWT$+$N <C)5B>8
M?<8 4V<'O14'&10!0;85EW(<?F"2E;,>(>!N$2(R)P$#9L$&#" R$3 *>F I
M$? Q"W L=G!=J&  ?2 ,*A !M2 ?3)49*M MZ-4+!4 P@L  BH(3,B$OTI@2
M%< ;HH  8-D4F34+B4 !,),9)B$(%0!S)*!PMV !KR([)$ 'O2 4(G,#.&$#
MWQ4,+R!VHG( ;Y$("T"!R/817P$V%>$ )1$#;U$+$/!>1OXT?+81 IM" WCA
M '(1>6=A <?("14A 64U ,JA:"?@!FB5 $T1!P12 ]_1"Q! "\( ESFQ %8C
M#&]P B^# DU1" KQ!@8@"/9&,*)@ (1 "EIY%A[1"0/V7PU0*@K0!OQ8"Z)
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MKDD+?;!$1#$!G."9)S$+WZJ?:HBGVHAC/?$")7&)'%DZ8&('<7  M>$K=N(
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MYV<NI^5F +B:)7:@CB[@  K7KD;' "EV B(P Q"P+E3G +A>"!'@W*:6,@Q
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M("@G6AHG3@BC8:'&# LP(6P*5F."49A@9[RH0,I@L!L5XOX,1FK &X.D)+2
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M@RG%#K4.6C F#@VTHZ,C,Z1%L&!&$4I$(/NHI9=-Q.S%NV &L<-+*.T()#X
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MQ %TI  CD8"E-0 N(2Q2' ;\#3]H<0 M>@$!(\U!LQ3I12\((8H9L&'(P6"
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M%,0$^#"'"BC$!2&P0PP0$,CE1*4$$J!#"R1 > 9,\P00:$/LI[F"$A0B!BJ
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M"4 *)(0!$4BZ":@:!: !.JB ZYH0.^ )6B@ QMB##M@R-B $[/N.$2"$%^B
MX" !"7B#.%" ]T"!%"B$%X")34  %)B!5'J^6C !/T@$"+B,Z$.-3W.!/3@!
M(X,K&/Y@@Q 8 0RI@#D(K&FB 1+@,^""*Q<P+#I(/3J@@!JX!01X& ?0%&&0
M  XI@178@U8,A@G B3<H *&H $#@+#XXQ%(0!@B CI:X#%@<A!* /Q5P@/1S
M .T8! G8 SN8 %(0!@<@@>R#@- (@1:@ Q50 'L,!A-H' <8@?;JC+50@4'(
M+/1H@SZP@(1:@6V"@%& C0D4+#E @,I@@PFP S8P #$<#$(0K#EP .""! G(
M X)L"0G /N>;#A98 4!@ ?)X 0=( >T0@1<HA!3XB1>P(^!8RJ;\"1A@@)%2
M +5HR3I2@&T*% >( T*H $9B@TZS 05H' K@JQ.8 !J8 _X% !$'((1-(  ;
MJ ,)F(%@.,%@*(%TFIS1&04A$8% .,B"D(!::(')RH,. )QE\8,\9 /-F@+\
M$BX4^*:*N8HOR:HW&$$VL(N@RTLZ,($2P(N'"!ODH@4'*$()V(36")%)FH4\
M]*QEZ21:8( ,@8"$NHPW@+\3:)Q94(#IN $CJPF#Z .>6)9"R"I3.I+&\8,1
M9) L,X@6F"0+^)'+< 'RJ!L%5!X18 PVJ$,[:!T(=(#@D 'XHP4=N8Q:D "%
M. $7H 51: K\H !02$VAF(4'>![@DT>&& Q09! 3$(&JX46#J 5OS EE H7R
MG,&*T8J:VH[;#)4I8(  <0!?\OZ]P: %%' ;/:1"^/ $/:L 0Z( CQE!40"-
MG' !!A@!$9  $IB.$F"IIR"!@_0.SSS(6@#'6A"$.J2C+VN?06!,-C"!.O"L
MP-.*8$B$/.0WQ$(-6.J$)-T$V72(A22$$T *$-L[@Z !F'"!2)(9@RB!Y**C
MH5H6U7(9)F,0V22!A)( /5$!,<P#JPJ&NR"7AF@!DD(L/S&5S\B="7B/"J E
MZF,0!A"&&?@)._BR>9R%/QJ,WLH#^)N!$E@7"1 &)C2(&8")?X2/$+B!'IE
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M$9  "^@(%, )82"%VYN %,C9$LA+:(V)]GP#%J AF6O;6.V$RZ  PYJ%4[0
MM>#0UNT*%]BF"& N@Q56NMVVA9P0&F",;/EAVA"$%/"L862!$\"O"D@$'U:1
M UX!"P %&IB"G!"$$VB!$@ N<(T@-3Z!J !783!&@0@-8;B!V?"($@",S0 -
MVKB!O!QB(!DJ87"!Y*H P2ODU1F*Z^($"Y" $;B1U054R.$$(2&!_= #8F*I
M$%AA8: 73Z"K+QFJR=P_&2A,@ZB!RZ0%MIU<L^I8I$!0F2B(.7"!$MB/7GB
M!5$ON_[*"5+AS<'HN5'(0QLUT%GHA U,R)P(YA.HK5&87X[ER]I"NPI !0:P
M,==  3.B!>T0QNA9T,&P 9BH@-_HD0.@E\5YBB3=#@2@-#HT$JZ%%:<PB&T$
MD3#;K5I V8Z8$$$(7H.H3SM.C+^]C(",F9T*$00]QACI!0;PCEWT.0< &6'@
MB5F8WU<^9(- !2),4#L=#!(PHX-L"3<( 8 )ACA8V,$H!*MR)X.PSAO0SH/
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M @/(U@ODR2RX4BT< $T0@NKY :$IDR<PP!C! $U44M;54R\ 8E3H7(AX"PU
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M.6(*)Q;2=OR)#:A>#4R #1221U$0<_&!"AC )M""S D#1Y1  F"''7!EQ-D
MBGBD"6R"("! O( " ^!5!LZ'!%#(!" 8<R57:\R %&E$']PB(4R K6D$*92
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MUC$)(M:(2+A ",1!4=8"Q#&)20G##3TJA;((TEJ 2Y0 3<RG!/#/0PE&?\Y
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M,RW * PB+%N 6!KM#!#S?F:PI65?!6A&P-5"!Z1 *C[+"J1U":3=2L"K-))
M#"PU@\0  ZC ;HC<?23128S #&0U+@\NBC@DIH1O,BG ?#@ 0PC# T2V0+Q
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MO(&Q;N&-QXHH-"7?+$8IT &*)-9L><\HH$(N84AJY8HG&-=9-+KX=$*>)Z]
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M=2\.0>8]8GB19C:6!8D/!AYJH_Z&+"D0I(*V),"1(12Z4R$_@ORPCKR!-JF
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M PF"$8@'S.$-#+#)!&I "!$8C@8.J $M2."&8-B@ W:@P01H(0P'E& .+Y!
M1N8#@3G,P0$50H$$FC<S"XA ,A0XP1Q@  %AS*(";>!#!?Y2!1$(B. --V#
M:F @@HVMH!<+6$TO&#"*33A@EP]XBC>=YX!2^,$!*M#4JRA  SM(X# ,,$HM
M&$"+/B  !3>@!0.ZTPD'Q,X"?;#!"#9#P19 P V]$ $)YE!*:+5 !7Y0@:!
M @,'Q"$."@C0'"S AQN$H!=]@  *9$:0&YQ@$"9ZU48' <U@5" ]+D"!'U:
MQ4$\"$Q#'(@*3+,7D&@E&!)@V"CRV1(5/(T@,/!=?P01@1(0HA#\O!(*4D"(
M%ER)$ 8HW 1B$ P4S$!J->B%1FU0BZ[9X0U#ZD4#2)""6;RA3#6 0 OB, '3
MQ$$")2,I?4C0I8%"@&&S8$ M+OX9.!1 Q0 <DX )WM""/Y5B G'8PX.",0="
M&M)7$@#$'&8$SJ"40@&990 *V-"+$\# #R7(3QU(%H,)))0@*-2C [ HB+K-
M80)!@0 I1K$ 84Q ,K5PP%Q#T <:D$ 8HD# "5YS@L,X@ 1T2.8R'7 #.H3
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M @XCRMAI$#L@0&1  B8 $1W"Q!JB%-*#%!+@!%1 !&ZO%!: )6JA$#"(C%1
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M VDBH""")[?!H%=G!DI@PT,AD-"!0W[ ((,((LUR@EZ%^?$ !#2,5$@);+P
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M$:6Q!(,3$PC&#6@@"@?TP0Y^6,#B'" ,0>C* 7'( Q](8#6ID29/P1!!(>8
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M6N8J]]+/O0&.;IA#'/C0"6%(8#2O*\4)=/H&.P@&!68;A 1F  @5Y*B2#W%
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M$7Z0LVW  ++*L0\,P:ZT!^1JDN7Q0&Q !Q)@$S9 L@HQ R%@!\E'->M2" %
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M\50;#T,+ 4H+CU,*!Z \>X  HM/-GG@ QV*[KE3L(N$ .;)Y@B (?-  $WL
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MP6 X20(2?/(%0@E!>GK1@L3LZ)9SB, F:'$"%4F2!@RH +_8D)46:(P0*[*
M;#*RB1&D0)%<:D$;2C ![GTHFA8@Q"R0(Y 5>,*;([! L%"0GE_6@@T-J, :
MNX<"!XA %+5  0I&L"/WB: "FR %!1Z@ @%2R (&:L$<)& 72OU%!"$P3!8A
M("2"P, P)0G!(&8!.($\A!1F+/Y$"GI1Q*B08$>": $-)#"#/8P  FL,!F*
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MP2C&5K_:$DH"F^C%&T)0"V'$H#%?V@0&Y7IF-*>Y%X2P@Q]'W+Z,$4<@FZ!
M,&Q@ T\X !!Y ,1!&!L,/Z# JG/80Q]$P()@O#$8= BK"/XV$8<. $(/>R!
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M\,2P87#P%8RB!6*J0'\H-0&&Y*&((EBC)R(0#$Y,  9\V+A 2.$ 0;OH?2]
M$ _?0_[$I7@#@A"1$?,*&V@5"I"=;V&!7,LHFBB)"^L%!FBB('N*TPH!DYD
M84 %!A@,2GF4_M@RC'D 72 !/R@?I4M!%22:+X*28'@!E(@ ?CDC[INN0A@*
M&Z"!ZZ(4.QB,.5 !%/"*"9"-09B\"'B/.5B[*;LZ*BF(5*N[X NKC!B%!2BS
M.4@ 81"$Z8H2&BD1-\ -"J")Q9F\;*L)!*@-JQH,"0 4&6B562"Y5!,&!/!
M]4" .>.NIW  ,0F&')N% YBSQF&-$\"-ZRJRT(NU_NB$"<2U82.(4I@ C:E"
M@0BR/,.8"N@%/Z@^Q@*?$]B1"5! NW$ 3D20&*@<@1"$3_ZKA06HA3R(M_
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M5F5=5F9MUI<IUDPI&IWQ&&>M5FN]5FS-5FW=5F[MUI>IA9(@!8: H>G@F,D
M,Z@@!4J%5F]M5W=]5VQ5@: 2!%<D"+*3E/*#BDWX-'CM5W_]UW>=!1&X 5H8
M!.3P \V!BT(@*JA0B[[R#X8=3S\(FX=[4'"]A=IXE85=&X#M6(_]V'>T/0=
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M;5Q([TXF<E87"#!H[B"0;6# A5U0 Q\8 U[ !6"(A2$X FX.@Q\(@W,>ZQ\
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M$,*SYH&TFBH=S$$I%(*B\H&VZOXIMV;E+"# ! 1#)X3 %#!$"%AJ+2! "-@
M"K"!+J " /@!+<AL"<S!2M"" A1 +6P" $A ,%@I#<R"! 3  01 "@3#)@0
M! 1#'/@H C" NY;H!.!H -A!(0A  QC "7C" $A +3A  E   "QM+= "T18
M Q# SWH" 9" QX8ER+)M"!QJ,(A  &Q"(01 "\" "MB!A : '\R"C)+ S3I$
MSAH S_HLT%[IT!8MG"9M /SL&[AI C2 N^[! %! U5XM 3B  :3 GP;# H1L
MCT* V1*M :@MV[HMW([E8G9"ZS9$+\" U_:"()RI!#@  %2 ,+2  LSI'E3
M++S "OYX0F:^@*>^ 0$H "HDKR? @,P* PT P""0 @&$0"DP@ ((K 18:N8^
M@""P 0%0@#!(:0ST0B<80 74 @48P L40@4$P"!(J0N@PA040 A(: )(0,>Z
M;@(N)B?(;JW6J03T0@T   )4  ),:3"L /"&0!X,+PRPP/$RA NX:QPP;RG
M0 !X0@Q(+_5:+_9J+_>&@O=NPAX$@ .(+_D&PQL   ST AT @))*P/O&[_S6
M+RN,K_Z20@), )3^;U=NP@"40&:.0@@ P 0<*2UL JO60@<,0(/R01W<0@78
M@05T  HDP+1N; V80 4P@!M4P ,,K0*(P A,  "LP"@, /X)% (!''$PV
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M5P- 'V2F6'>Q#=PH:9NI'0@#6[MU","U7--U 10"7AN 7M-! / U#?.R!""
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M0B8\B!1!C NFDSX>&H &6F;10Y>#1"%$HV!FF:671%Y<#4F'>I& @E$\62$
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MP*P0'*I@/8HHXJ,"AQS0B>B#:" -@F7M<!H"5)M&B*(48MM(!?=\=.!$6A0
MK@:'7 #Y+Q$F@,"$8";HKQ0*%%@ @EGL"*"A"D*@!0(%)%! E%(.8($ -TA
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MDA<4H$T#F,@> -")0\Q4&"@P0"]H$( ]>(( _@3@8);4 !6H( &1U,-1; "
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M,@(;V;$04YA "^C] M<X9Q2HT9(P-N%=$F3F%C*H@3!^4P*>AL 3,>A#&^;
MG!OH=@\4(0$@1!&5LEV%(C!P+$4H0 LV2, %+0@Y+;ZUI%Y\W 4L&/D<\-)!
M@K87!7TPYBA@3H<WB3@8-IB!)Q@  WK?BQ3,Q(IW22&!(+G! @Z 05Y*80%1
MO$ 0-MA#$Q^@ GJS(%X3 (4P:A&!?-([7A0I1-6,R=F(_V8"HU@)0NR0MU&<
M8 (1D)(*ZB *[QH3!G78 P12GO)2\*$$%'+ "WY.B#FHH.PBH(U*1@ <IPC#
M!8\/!OZZ"!X,&+C!#WE+B+$B7W8RD\ "79J#-X,!SH-T8@(I^ AL*J_.8,R
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M EQ"242 ?V"$&V>)5,[L(/J '?XW(@6T<2-6(&X(:KS68MGBYC FP $H(@8
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MF/=T/<\)0S=]P5=\/0]V]81\Q5=W\_<O[E=_^]=__Q>  UB !S@QZ)> _]>
M^?> %WAZ4;>!%9B!(UB"*XL/XJQ]RVX3P+:!\5=[$8-_(1A6#Z\Y.B%SH4\J
MM(='Z3=\K?<GF^,$RG:"8UB&9YB&:]@P>N$ )DPJ: !YP/ZB;0L#A&WX% >
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M31) ;1"@#38AW$*@ P1 $+*B4NI,Q2&W!L(S!$A<[@YS,DIA 8IDO JJ%UK
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M^B#R8/[4=H<^22&'V8 !X@<&"N &UFH6^ #=U:(40N">'<"5&" JY"< $!4
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M=DJH*!3,4XVX/#T-(M7+ 0J5<W@22G&";+!2,%P4JC%JU@$;,TX0@LKY*2<
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M8@^ . $,;C2($]!@#QVH8Y=XLHD(3$E2U(*!"MK D$(((@\EL %%^+ )-I2
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MDCYA 8[Q+Q4R"(1422O5BTWQ!B, %*+P60A1DY(4 N9AD$4(%+5 FTLQ"B2
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M,P !SLD'"D"+P.-5*A !H3$+)+ ")W"PPB "+X "$Q '+S !I2(*#O ")^
M9)$J1TD5F0(1,< 0M8 "#C "2PHJ[+$0-C&<,E$#!3N+[E0!)?"O+*$"G68"
MA# +FO[&!@Q0 :2A$:Z' J1X,#80 C PBZ'6L>/W$,FV J%("A5@5$H9#"K
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M(@ )JE$!@W +#[6H*V#.RY4=54,AH@ *G.";@E!JB6$'O?EVJ<$'Q'*-+2"
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M,+TB [C2"P]0?>:^^53E-0PQ P@@ 1 0 0Q +,MF5R7!B1+0 C/ WK-0 2A
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M 1U$H ?EL&$.)>A%HF;A #Z(H@/!N$$*DB>*49Q5!/^YA0AH$ <)^!DTLYC
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M#^H;4MQ4(;ND'6*]'Y,*DN<;!";< \* M!;PI,9[ 1(@5W'JA9\*N+:HA0E
M(S]8 ?X(T,%0Z;,6$ 47V ,&_#L,[$J=F 4ZO=.@Q9\6@+Q@4 $W^D.9* 4%
M")U<\<&"L('IO(&SLE8THUH&$ 8W*,ZBFPX@C+L3B"%(^U)<&S.UDXE?&XD)
M&".21-77(P3H1"X1$084V)ZIJ #ZL ..# 'HH  568%J;3RP^$R"BE3/V$AF
MA;-<]8S^TY[$I8/EW(T>R5@FH0!\HH$7L! +BM*"D(#T@($I$-&1F %Z[=SE
M_(U"*(7R(PF16+-ME E(X+P(L: 'O)\]"#T*# 8;(*A"@,L\@"C/# :X4]G[
M<54:X;P(D"$*0(X:8*R?#08Y*%K)8<6"F-[B< P;V T'\/XTF;B!$K#$R&$,
MG2"!5?(*G:"%1'*W+%'?]67?]G7?]X7?^)7?^:5?]16W^L7?_-7?_>7?>1/:
MS]@\$9 !$G" [["O"IB"/Q2SSF#+TDD)TF$ &G@#"("+-V" &8@#"@Z&&E"A
MF&"#"I #:-J-3!R)9RR=$H  5)C)S@B%X_0<"&B#&X  $0D!./LZ&\"MF+B!
M"A@)%W!AXQD)%5"SH@,)!X"0P5RT?;$ 'FX!JYO)6WD#W/+:8(A$O<,)OCB!
M$#2!"CZO%P#:SG"#F@@&$+T/"G"!.(B &W@CYJJ!!YC.-T" /2 %UYS"J7
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ME"V\?3GOO?L>C 7;>N+ L'[89H$?HPPE# T/ %A '\(0L@ M)MQ T .;E.(
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M3PQ<CWOR@0.\ 4)VQ2@X0*YTW[$%C(L8RT*L25=X9Y0@C(J4!D'4PB;\1)J
MA'R:W";@!!UHB5ZX00102RT@DOX<5&,P5( ]2@@)A(Z9#$0:<H6I#(3-$)*J
M; ]/^&>6JHI8M@Z[5 ";?DKV$ )!UALMQ)W'[)[TZ. C!D,+B( ;L,$-#,L<
MJ"DD.L4<<(X'$>EF2)JY35@%.>JFC56!/"I72%J@C8BEFAO,<2JE:6JF(AJF
MDD79B1BF;NJE4NJCGJJD?NJIMDBKJBJLLFJJ?BIS%()*>5>JKL ?VA<7M8!
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MR$$*&/[ [*# LOE2.RD.';I0FK"! NS!*"A .SG '+A!_R:" DQ!HN+G!*R
M._$('R  #"0J7_"! C!+!1#84=9 &S@ @3F JNP4'=C  VQ2'"B '90" P0=
M* # ]>A"!<S ',   W1'0="" 0B$'P# L) " VB&"J!)!&8%APPQ ]C '$QH
M)T# #:Q?+'4" OB*!/BF!.A:#68U7D 1_T['"W3 '*3 H'!%O*Q #/!0;O0!
M RR-"M"'O]7R0- ! =Q:!W"0TMQ<C"8N' =VM705!'R*]14&_SB11G2*)X1
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M"<P.+;@ "EC*)L0G6M0"'MR!*8!%'!QR!4F B*@.0UF*'33 U<;4#(A 2*0
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MP(UF,8""H%  @)/P%%I@E%)L@*H7&[ K304#P(-*-3J0(^0 .NB80XX^&@(
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MD, %-"B. X1! CI$A0TE$-L%\P2#KRFD%BLP 0I>P@82D$!D>1.&"=HPBQ<
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M2#^,JB)O.(B1$C*'%H05!BR @03X5PBQ5&"%):B?=V 9C%D\0!@HX(,G:N4
M47!"K&*!@!_<<+J$5( 4HY@ /-WX$V%$8!9V.(CE5A ,!ZQ +"(X"!T<8($9
M<-03!X#!#"Q L3D(JB(AF 4=XB86!Y""#[\1AAT$-5R5K0D"M-C#;SK1 +H(
M<*VUJ,@(" $(XD2 %K=E+@EFT((#G"<8>_BC4M$K(*.FE[WM[8A>,-('!QR
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M%%#! 7!$D<('>$F#ZH*!#PS Q'YG\D1@.R$ .5#@!CK'#FCAACMM3=B8%EI
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MQ\^;&$#P:I 6-F$.((@0:H6;F(EE-^X&,JZ7.D$!-F$*GC!A.,FAH3NZ?^U
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MSQ#,(DP<+)QDP2:0,& S# \(XOZ)23=T! $JP=P"02TW3&"S"Q"4,HL%$YP
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M*^ &I7)DG9  <0%@<_&.B($1$($7#Z$"-[ G1U:$LT!G$_XQ?\%U$BK0.[6
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M4M&&.R20 MX9#((0KH6J )LP!7S:A2/(% 2ICT>1@CZA"[K3!RH  4C#!C$
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MG+Y/'[I##- 3<>#E,]"C#C ?EH'ME-<&V#IY[A,"$^O,5AL" MO%)F@',,
M?  ,$( "K. )#M &U0H?:;PIZDX8W+*3XVP'*M !#V$' '!E$  ?+1 "_=X!
MMX \!. 5%:"I 81C\Y+>2OD &<@ JJT <T '!+,2"Z$"L54(". "E7X^@GH2
M)G\08P4V>($0?L  ,3 '[(8:*)"YP1"&0-&8O4 "+(!V'?YAZD(1 P] "!,9
M&/CRNS6@D"<E6 '@ BC@],L#4VXP [ <#"H@\A#(,L.'HQ)0=:FU!TSO]/V7
M$(_(0 _Q42L @0!T]LUE70>! BF09?'="01PUW4<![\N"J. L+,0 3-0!Q&
M4#Y1"@/ :G8P ,;A!MKL!A7@$*6V%VE'?1*@ F]0 1Y$6L)0" PP Y'.D2BE
M!^-1 3L]G1-@3XYQ #V!$-B*TP=O Q:@2+4P 360[NO^$P[P4Q/)!G'  'X
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MH@8I @5U@Y&"+Q<=0@N<!0,HT@D("*,%F9=-+2!0BSU,X,@,R*((GBB"O72
M-1((%2T:P)J]D" 0GD  D7?HA_X(0 ;XP1!!7.PP1!1 A@^N]P,! #'405A@
M+Q. -^O5O1 ^D&M!#O#/OA+OG\1[HA<'X!(G6/\&UW<X0O>$P02%48)&V2#+
M,YB\!410E1FLL (K7+9%IJF'WL.77G #%R Z8;B!%6*8"N@%VH*!%G !9Q$&
M ERM;(, 2.*#%H !!\"-",@VTZL%&J CP^LD-B".$#"5"N@$4*  O; OT=J#
MZ@FP@: %;)L83G@!&*B #2J!3CL!/IBSB2$!$H !%T@!%M0*BY&I$9 NC&M"
M!!(%"1"&6D@Z&YB!9?L,0L@W=SF^%"D$"E"!(+$ M%@V!J2C)Z(P.2 G"'F
M#4DO:OY20_Q0*>OH$@5@)GL2"$_8(_.2@S>( 0?(H3GHEED !>VK@)=XNF"(
M QB 0H9XB%K(@S8( >(H 8["N=5X SDJD0=@H%YPP;UX@Q9(*8&  1SKP%'0
M/M4@J5*H S:  -9 @3H0B!68)'I3 128@S>H 040!CI8+QA,$4_(NA5X@V
M.X&8 %*H S/Z*A8@Q@>#D.!;C6ES$\8;1H%P@3=8MI6) 6+<BQ((E14(Q1U2
M@6XL1E'8@R$J =/JA3YX _]RD_3#$R<*A@J($LW:F*_8N.U+H\P0ACQ@O(=X
M@1NX-HJRJ5& @!/ "8AHE-J"B4;9OS< Q8T+ 62B(PLX#OYU8@.WZX4*.#9X
MX<@9&"4+Z(4]2+_."P8;4 %#F@7 "H$8&*4.R+9'2I$:VX1>: '3@@!E@X!;
MN($L$X:9W(L2#(8.>)!W$P5G<T$7F+Q@$ 06S(S>R@E"V,!9V(-)E"X3X(.#
M'(BG2LB<8,G3JD3(F 7@^S(R<D*T]!LH? @[" 'Z(\.]* 0M' @N5#<(J!1]
M(X0283;RV L8L*PY$"&@@@"90"]RF8-E;![X<A<+N*5-H( <VB-3XX,]$ 3_
MB($0H -/"(%2" 5GJT=/VB)/@H$\3!%M.L@9$(0XV*(3J$02B($^J,Q." P(
M4++JZ85$H+I$;(%2L":MJZ)>P/ZV4;@G:HD#0G@ -MB$%R!&%(@#@4B!0J*W
M$W@!RK3,O0 %-]"LH""%!5(-8HPL@9  4I@#]V.>9C1'?**%%. H81#%/6 \
M%@BY%LA&9H,YY]P+$XB+6GB -V!!%;C/8$BP6J" X>R%E((!L# L/F"\O2 $
MK;K(KY CUI@#K7*7$""I@4"!/? #@.PP&[@VF9B%&D2E%E  0FF4R&I0UZ,
M-J#,09 -BMR+. J&QA0("]B$.6"WM)  CWR77D@ZB#B 4G"DIU != (%!Z"(
M04@^!? /03" 4A &!^BD$/BRO#N)*>T(!QC$[GP# K!-=1,AMNH%0A  5Z$W
M#J&WROZ+@SWH@ I]HA4P% GH@P7KB'=T,8$@@=EC#5) @%+P@PF #$44+61!
MOU'$H;1,U-)92Y@[ .ZJ .E:@9<;TBTTK#[(NH*A 9K2 P.CJ0D@J:9+D1!
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ML-U"!A !$5@ J)B#&ZJ O)B%EDV\7N $!V@!%I@ FG B4I" -Q,!QANT@86
MEQ##$?YZN0JXI0[ #4Y KCFH@-DIGNH:!8\=%X"!)';*#(2 CJ0]"FTQB#@N
M"$$(.1L WNJ8G6SCHRZ!'EWXXQE4,LR-9- QT#C9$.,1$U2 'DHV)(0:!8NC
MN..9P>>HA0W)B041!.^H!6T1!E18#CNY$DKNB/LH!#\(DDX0"<80AF<1!O&+
M956NCCXP#P<QC%$@Y6.#A#[P2(^PGQGT Z_H!4BFA<^(4E"H %UPYN9YCHH
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MX+H)B"(1 AMCO51ED+Q8Q 5Q8!$;D_8O"_ !)WWXD)22!C<'#&00 AM("/C
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M8KIS6 '77"!B$@3BQD;EJCM'X8<6%((-;_###'9[D0E8!P8W&&,$9N&8$*_
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MN, )!%//L$0,Z$T'S4*Q6 0I",,*Q(])@)0=J$ O7$AQX(8>S%5/:0;5 =Q
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M)@P" N@- P .C+21'Z1(*71""&B7'0R '8B""XQ>:+B.B@W" 9#.&[2!"L%
MPM$" 8S")F0>YQE 7B# #) .&US2"X3 *(0,PBC 1 Y""!(" ^S&F(W"'@R
MZS@ )'00&XS"'+1,#%0 R$S ,[X/&]B4+C3, CQ7,.A!UWD"]MB4E) "=/#!
MX&WC#8P"E-1"Y$A)*4"'"P 4#/Z00/4I "=PC@N4@N7Q!P+LV@@L"1]$P"9X
M@@4,1PN8$JBPS"8D @., FM,D#P1A,#,  D4S@-\1*=X6!"E3QQT@@HPP VM
M "D4CXM@%E^@P F,PB# EB!(0/KLP2BTP0$(1'&ZB##D32_4P!GU2##40 B
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M6+0!"L =X6S"'.C(F+8$&SA+F[H "[!9"LC'#8@@O<["#+C@#(R",-0 F[4
M"N1=+T 5"?B3':! 2?RHN+H0+1"*1 J&#43&+/ D"QB$,+"!"<CJK"(,#; $
M+=3 O\B&"92 "IELR9Y+)_@&QT%F"QA$RS;>N>R!I[)!"9R AC8>#-C=:,P
M#-@ "9PL7_3!"9A A>3L0'R)6 C'OQE7)]  (9#"YGC"YA3C"5PC+<1FB.+$
M?/7!<-1"#-A=WF&CH0F"95#6<&Q""K  (>2!WBR("O8$'@Z"6_A!X;T!S]IM
M/ D;TZ@ "<! R?C!5+RMF^S!N?X$P@F0 B'XTR; @%;T @V00+!D1B?H31O&
M  D\7LEX[?FP@5+PQ;4>! RD %@X5QTP!EC0PI8)U[D,1+P4APW8G5N A!MD
M"0E\AG62  ID3+SP12*<0+B>B*E*TZRM!4OD@:?: #"UP)@5!H^I !^XK>L
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M$(]S.:-S.JOS.K-S.[OS.\-S/,OS/--S/=OS/?\P!UYAV<U"%(-&#2S-RMC
MK3*-&]S -:)(9W4",D$?.(.R2U$F$]K &^!69G"")V;C)J0&(:3R-R]*0VKC
MU-"!E/2"'_!!'PA"'^Q!6 R"E&Q"% =:9'2"B\R"0-!"O8I%_@D#1P^$(-B
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MW>,]HU? V%EI,"! #'1+UVGGDOZ\'4@ 22U8V*/=4 4,K!R]D%M@A_BD"%]
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MG4RHEQ%2V,/08-X +Q@WLHO((3L(/D@/]ZA"@!1!(& CD1;^,\%;4$HB 06
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MQ0%9"\8);B C&CS 1W: 0' *,<11%:TC-7'!!/ZS J;%(5W]65(1\9,3A1R
M$Q(:RR8(\)1@1(\T"#'!6I;X$Q<TAVP'F04*,,+%,)9" ?ZB.A=#$C(+$92@
M+Q9 50QAR(99X.0@-NC%I7($R"29#B$=((3+DF2KKP4# ?";0!]JP0"6".,!
MFP!=:F@G&8>0X$&#>-/JOE(#3Z#*#UKB)$OB8+M-)$*5O9C" V?%%ELE@B$T
M&!)7AJ2;YOT2F,$4YC")>9@\.& %+D!B;AJ"@@>0PF#!\,0$6L#&7I ,!C.
M <I.X"U(:"E<,:"!!9B6D!34+!A]& @)%O"38(QB B%H00A"(!)12* ")'#
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M%*0F6O[@#?1 !0@P4_*O!6;AE%9M$&I!%$) !##,!20@#CBB#^;O)6KA!EH
M;)!#WQ!/!5>0!<7-(=C@:^R@? I+!?C@!29 &/:@?BQ/!QG/#11 !0#F12"!
M 00A$21 %/+DU,8F 1@$F?8@! B#!BB$!#0(!E*@$&Q@239! A*!#QA@%/C
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MP@G"E.) "B^$X+. D,T@ T40*,F&NQ6\8!%1%HU<80H$SF+!"BU\2,L$+\P
M@YHUQ?[$ATU[//#"M1-+0$@P,ORT@IIONS!## Z$Z@#4FSS@P@DAU)(1"C!(
MT,=&#-Z7J .UT!)""B[<O&"+*U#P @H:D1+!"E6/+$-A%;2(5XN;A$#"&Q4L
M-^ONO/?N^^_ !R^\:;/ 14O#Q]\TB^X4D5(1*2'Q)XHGHMQ42WXWC=*3"03&
MY4?UGB2:AR@]Q=0+*<H+ K[DD/G8_BQ[]!D3(7SH/@MDO6"??#"H[$%D_N;3
MWR:D%1-0[,$L,2E%]P 8%]V18BK"&,0F +B\F'@"?<ZC0PMF,;[&-*P7?O!#
M]V)"BSUT@H$@%*'RF!>,0NRA816,"Q^(-(K<]>%OS8M)\?X22"!1F-"#,;D%
M]DJAI)L( Q!\(! (E22*63#P>C$AQ1Y((3D?$6@3>V!?,&XAB(>,(C^SX$1%
M:,&'01AQ$ >,C (#5+2.4600?6C?&EO8%NSU(GX4A,L<%4@*,_K( 2,<GB '
M2<A"&O*0B(Q5MA+)R)C-BH"4(04@&4G)SZA-!3.0@+HJR<E.>O*3H SE92 I
M&5(:<3*F+*5F2)E*R[02,Z\\S2S0!\E8TNJ6YA.%+5$)FEWRDC*O]*4O.S-,
MR13"#^@3I3*7R<QF.O.9T(RF-*=)S6I:\YK8)&8V557,;7I3D-W\ICC'2<YR
MFO.<Z$RG.M?)SG;20A"L1&4KD_ZBRE]6A"<J@$LM3QF9BHC"9W.H@1&E)0P5
MT,(3/:+(/EFY3U&LQWJ!F H-6F3*>!;-HH,JS#T7VLZ.>O2C( UI9T:Q*-_=
M)YF=:5PP.I&(C43FI+2@*&D\8:<Q-B F^%)-*' HTI[Z]*= ;6<M:""!-^A"
M$.BK!7F^<IA1X,J/-QF$)]ZP DC<9 \NN,%R^-"P33R$$#"@ ?IZ\:&;=,(3
M@P"2,.;P C80R!,N8$,@MD0*3A1%8W AJP)Q*(@6S,&K,1$$#&90O5E(L 4W
M:)\HXBH(KYB/#0_P" OF, <5\!2K'HG+($A! \C4H:W+\<0F",&".%2D%'W:
MQ&"KY_XC&L! =D&-K6QG2UM.UJ(&#G!#+U90F$$$0$E+D]H<BJ.BBHA@ GN(
M@P*JYX(2^&$XNX62!!+AAPH(P@X4<"($:!D,-RA !6HY@0HX,0.?X68.V/6*
M#5 4,C_<8 *T$,9;/,$ BSA@#W50@'?B,(%$[&$"O0 % 6BP!Q$0C;[HK8!C
MI<(&!["!%MVR QT0\! :G( 04Q"!,$"1@!/$0!B/XT0-4#0' ]@@#R%@07=M
M H@)"&(/$C!+!>90B BH)9RUS;&.=\SCSSS/L838$AM.H!8)S*(%$_O*)'&J
M+A'X818.D!8*YD * ('"*Q$@4@M( H'\5.0-6XJ)58/A!_Z-H"#)_PI&&V!
MBRC'9 4(>0!_O#(!'-9 ;)N #)1G,27Y3&0%$@I&'\9$0HTDQ#8GL$,M&* [
M"CQ9 5V=G\'LX-A;** 7=I#1!&1' Q4SP _)P5Z/1TWJ4ILZ,YV@P%1Z48%1
MN& 0,.C$8"I B)V0E;LDX(-Q!4$(F_1"&&Y83P1FT88J.6 %-3,!0B+ 73:(
MK2*#.,$*5F 3"\!SPUYA0PPVX95?R\%G#IB%)P#\H9W8P3NC6 $*8B!G45!@
M)YS02 A +8P:$K#*<$DT14ZP!U$PH 4U(P%2 5210DB[!5Z9PZZ"08&GR.@!
M*JC9";S$;0F(@+6GSKC&-Y[C3OZ$F2-: W%;J:(N*"^G(KG&J2!(>I.X :X-
M*AB( Q#8DUMOI VY(M% 2C$8\,2D$ !R0PRD=A-R!>,M#R)Y3%30F@>HR )\
M-G0G-$+D ADZBA!"07Q(]D(WQZ47_?&1 AY"%S]%)28.H$4>B :!/O6$%NB[
M11NNSO&ZV_WN[?2$ B(:#$(,(#PV,$#U!*&F49! 4(A1EP7"(P(9D((/,Y^6
M E!0$1N$8!3_:=$"N&L#H@4#% H(!2E>L(!9^,$!GO!$""QT QF5  :D8)GS
M(.V)F^*&7!#PD@/LP(HY$" 1-#V.A0#A@+.*H*8^6L >/+:A[VRH!"THQ2#P
MX^_3*OZ $Z2( 0)FP0<#3!$&@WG#R-Y  5&(H@(O/  @9O$&F^#]_?"/_S:%
MP085X,\%Z-L$XOU0 A+8YB9MT"=L\!"U$ ,Y4D3!$ .PY08D0 +#T@LTH$]D
MMDEY< (OL DV$!YS "]YP#1J40LSD"-V00/'XR4)8P>>, >,P0G8X0=[4 .S
M(% !(H-V( (JD >!=A-O< *], <X% =F!((D< (-4@HR*&@GX *)< -:@0)L
M( (;U'?--P?SHB(&1P(J@%+RMX5<V(5>J!DT0 .], H0,!W#PR-?F(9JN(;-
M1$!NF!FI%(>N!(?\](;\U$_!0 LS< +ZAH=%\TN5@5& B/Z'@F ;P<2&B)B(
MBKB(C-B(COB(D%A/D3B)E%B)EGB)F)B)FKB)G-B)GOB)H!B*HCB*I%B*IGB*
MJ)B*JKB*K-B*KOB*L!B+LCB+M%B+MGB+N)B+NKB+O-B+OOB+P!B,PCB,Q%B,
MQGB,R)B,RKB,S-B,SOB,P(ACA22-L4*-[62'T)B-VB@9O1!(LN*-R]2-VSB.
MW]1K#1@"G>6'=[B."C4#//6'=DA*;\ 4!'5*]$09M3 (@<0'$D!1^V2/[!A!
M<+$'-^!2 S49I0 Y(8 1 !D,+S =]S2(!KD1IC0+D%.0D7$+D$,")D "%5"0
M$=F0+:!+;WB/_,0&>N!2\;1+H_Y0 L=R% VIDG_HAQ'I!XR!"K4F%8(0$C.I
MCI/Q+,L1!VH12!7E K8C B7 4R$9D*=4"RO 0N1(BW;@ (E0"'K"&*71 2F)
M8X 5&JA@)Y'1CZ?1-<' !C*R&2(0@;,P TXR&>J3*H;S$?)#$9"@& I0"(6
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M95D!?- &VQ4;Z-<&!) '@QD2.D,@CSE >*@"*> '+J!A<K*@"S,'-@!(?F
M;M"DZ8(",$%IM? "$# 'M-"D-?Y "HVY!\7Q$'$0 H+P!AV0F$73I!'88.BE
M "TR!]8&9HGI(6V EVZ  LO1 B?@!S'0 <+09G]E <-" PR@ G9 "P]P8B20
M=FHZB\ @$PC0@!W0=GEH5\(0 ZTA 7(P%=H#MG_)!E]Y$UKJ3UY7,BJ#0/BQ
M$6S &#GU'<AT*D>W"9P09E<R"Q0P&150/;BSI:/9-9(4$UM&$9-Y$Q4P$&42
M$W$@(Q+@1S&0*S?15Q6@ %["!Q]G \)PGK? :!3S9).TN#!0& 'R!GN&&.,J
M+<WQ +V "H<!2>4Z%8 PN%*Q +3 GUX*)!) )!+@"5 V%5"F%+FR:"/;H@S0
M,(<C#/[/&Q,GD#(A,"P6NA&TP)X3"2TW80$BA+4V<)9=1@B\&P)J071^,#*U
M<Q,3 !DBH"YO,# .P%HF,#&D!%\<D2LSH'LX<V@420$3, (D\ "%P0E@"1ZU
M(+8O4!@U0#9LX'F>X+M9*Y4?1PC;YR<E4#5>(@HB( %UT6;(M@+XX@>^QG4;
MP0<C\VMNP!A=)@R.X65EB;>ZIK>B8!,[D2Z=X%A\0!3C1K/"4 $MY2@Q(0,S
MD!P)@;#,P@)OL+1E!;E_$VPQ 9LJ$W$K8 ), 40%8@";X&Q2<1,G,#[_I@(M
MX&2E( %302U%HFL$D@@,X (JP (.N!%S4 ' )@)$7(^%0/Z[9 (! +<"(X N
M=H#$,3$!2O(7QAL!OS8*!E,"@SP5Y0<#5$9PPL ')R 7XC@#0'(B?X%2CZFB
M%4$(HDHTOR:@O?  D)&;.Q%C@@ 3'G,Y^D)F(R,(%C!&$H ^$R!M*W ",P 6
M "?'-Q89M" !U1,#HLL1#\8 +% S)9 R10,!.!3$<> ',/%KLD$FKV<! B4#
M)K@TMI:F%0R+H3F:P8  J& '1N8G-+!A4@&J<9I,G;,)5Q<"EW,<S.*03-%E
M4E%6%4'$<_P=@" *"$H5750H9W)EA/L0;8"5;W"6#%<(,\.X0.(82QJY9/)0
M<; >J&<^GKD)?/L=#>$<?E)0>?X 9=+B1*,0+9\'("J09+1@!V A+;1@HC.B
M(C9  'KY<Q$0FB.30,)0&XT1'W51R$V$QE]A,"V0Q2I#"S 0!XM&(/6G,G:U
M(!\8OYYW$X\3&0G :PMF G;@%OS"NKTZ"&23<K&\OL$P"#W]-I#A8AQM<HT!
ME5(Q 7"1O2(Q!8_9,)T3&1$@/S/0 @@3$RE ![P*%V_@)9M"&"2$M>$<BW:@
M  Q1@S;A!E W;BA0'G,P"\07&R1 "M0RJ!'0!J5 !P%0SQ0A KHI>\*P /FQ
M:)SG,Q6@>'Q0"@3@!J,-2*2  (2PPR,S"CK;/<+ )+'A>8IB!Z7 !GZ!'"0C
M(=LKP_Z\<:%H6)9"P08=, KG-RS2TG^;(*H(\$ 00 ?'O2BW,R,N4 J%@!\Q
M/2T6@AN$4 HEL!Y):-X0@#,5 :J%D)\$T'Q_. @EDC 2$!%SX!<T-0@)231J
M@G;&>VE?L0#J3>!&2S),43/F3946D7N(HRYND !0I4,.H )X*0*^)C&W+3FF
M*P.,\9BD  B.A7[RH0#!4!Q]QP"%( RWX !SH%00<$$D,#%&BUIMUZ $=!]Q
MT O0$1-%_CBH-;P4Z0 QD <X>  -8@$V4 IZP#DR2PN-27G=84$,0 BDX (&
M(->-O8J;$",H< *V20,H8 .<H *C, HG,"]VP0;S,BP!<OXT;S" D>&C.6)7
M$)A7,\ \?: 6;-!29<D)JB<'(G "Y[$'>6H':F66+%0#9N$'P3P**D "4<A9
M,3$'+=(+@1X9U"P*A8 '@>7,99*W-]$+&;;H?4(*F9Y/9#*HMV" )O WG'5:
M1]QW'2F&P: +(=BLDB'9;S *41@9H;#K 1+K"$0(_3<#$I5,-( *>HB\T-YW
M<3X#(>'I4E$#' E5I1 1,  DM_'1V@L#(8".[],"6&@6:SD5#!$3,S +G6 ;
M>EX*)-'%4D$#*S 5=M#9@]* ;7!/S5$"O@%EK!6:),!]=IX'V%WPM"D,:HZJ
M*] GL^ ".3(0H.Z$;3X+*G$3@/XP+W9PH6->\IY1"(0FBN#5"PC<"<+0"25
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MPA.B0$ B2E(($1B$%KT0A9<J2(.56(@-:>*#!0Z"@CD(@P$;NHL8#9*"^9"
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M6<I65K(G"!_7@M$)CB%D LL9S@2XN$#=^>@$<I ?H&)ED#A\!05?F0-.@^$
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M UX&<F0'O"\$$\#0 ^:PAP8X!P6+(K5S.I [;[6!#Q+XH T",+E)58 /-G@
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MQ$JTQ$O$Q$P,1$<<#C32Q$\$Q5 4Q5'LP<00+%)$Q514Q55D13DQ0$*8EI4
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MS"T5W-*)"$J^04HP;\1@Y:5TG0"!!15(T :H3L**93 J[ 'LK,$$TH -<:%
M+ 43/!M,&RU86228T%[)QR#01ALLNK#*:A>SRGX;S!XJU+5D&R2(8 =<@Y0@
M@@U#>OZ" @DKE/)6+S2(4,(F=-4" PDD% (7'0WC^]:_)*C :S"AI& QQA17
M<&4P-$10 0045!"",#,X4"P$; 0CB@,56#!!!Z.X"[*R4.I(R+9-]N(&GW$E
M D,,,;102"<NS ##TN7>0$$;.I+B,KMOU7)"!0/#^D;0X49;Z5N;3-PDN,&0
M\*P=A 3#20C)LN&"N4EN4D<PO5A@\[EYKWMSU6^]T0 ?YL8QP@B!S\N&O7G
M)8B]5+\EQP@D!-YF#"64&TPG?MBE @EPB5)!G.;F+$P?* 2S K*Q%CF')\"V
M*WK<;\W1B;IX@<VWV6H+$^NE,=#P+NR%B7* '6J*PH#C@O[5XD MJM;E@"C!
MV #W7A/,L><F"CP\6 EC,]F"RT56\$8MLP!R0."S:,V7CBU,$7R!>W2N%PT5
M>%*( L_B#P@H(GA;"@/F((H83$!-)T"!*/:@@.@=R7^BL ,"HN<&"7!B$PZ@
MVRP<(, 92$ 8M B@*#@8ITXX($YURJ ?]A2,$\R %K381 (@00H%D*)\+K"
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M;A9O\$,)3)"P4L3!#R1 6#!*\09"E& 6PKA!"5#PL#ALSP^*>Z@)W#"D.(2
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MBXUD+PQ"6*$ OI3":3$2D.)-'!058K"  [ !%_7:$Q. VY'0'(B8RTR 2,*
M"0R"'#A ,S65!7TMJU'3]P+66]2 Z1P?(,@654I ",0 #*B  B3,"Y" (-B
M!)2/ Q31"BS0"%L="B3U (CD6^RL(-S IJU0BL$%!5@ D[(*&"'.;1:4%+I!
MK?X.'_Y  !\HD-K,  0( NV.6054BQO,3RDH !L00L7%!0G @""P@0+0P2PD
M0 OX 0VH52D@0 L 0F+WPBC4U5O8P!&Z <L% RTLP JGU$<#0@<4DATX@'(Q
M0(;!A0FX0&#K=1 ; &[!@ MHSO&P@7NZC T4@ W(Z0P "@Q0 !_00$"_RR8
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MY@$%B(#YW>3K:MAKS\  E(LO ?["#$1 +X@8\UK2#%5C"EXB0T:9H=&%(+B
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M[2;$ ";E#8RF#Y2B LP( 2 !*=J"#P:/(FZK K[HOP)$ B8%^-)K L"'!/R
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MH1/@-?[\AB@%M$\%2&LB8B!I0$$"3(.2*'$&+M;GB"T$=-83G%8$"H$$H(E
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M(FP'NX:H^/;4%LN/[ SB7V'"@@%R;WZ#%&J! F;@70&X_-C *B<$$'3+D_;
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M('^08AU"?&X\)IC9BAXPFE$@P X# 00!P%.XC)1B 0N1@!T@J"<+N( 4A'!
M(811B!"$ &MVL ,?*C"[N2E@#J2PPP.A*((I!@,&)/ $(!#P.,RI<8T\LH-%
MW@ (%)!@; 5A PI0D(B(P#$%<V1)'CK0FBLBI!0.:$HO%- +/TP (81@'T%(
M,0<_D  %N^E#"E P,S^0"V V$$8I7% "&&!$%)'K!!UZH2X7R(8@=CC!"?@0
M#%&$8 )3:,@F N U@K0 >W8 @!T(0@@ V" 8*A! U0BB@ERZ  "$44$!7P"
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M#EC(!/+8FEEX3)<.6X&!6"*(%5R)$#% " 0*00L66.!IMANDC=@(V]B2: *
M,P ,.O&&_U6)!BF@!43E<H#;YA93>Z@K;_9 @2J5@@&A<),W62<3TD6U2IL8
M@ TZX4TH0J 4LY@ )SRA6YKV0F:CL $+![&Z8!17&': @"#:$@PW6, 3FX#
M'FC1UR<29'HS:\A!YC" $.!5! -(4 H,0 ,YN &6UREOR8#18+/-[@4#2 L,
M!G#58"0" ()KJ"  L D6)$""*:T  HB24@O +RG"Z(,#^% +%Z! %'YPP&4>
M4($XH,;%,/8# OC@B1"4U@4PF/[%("I@E(%,P02XV00#XO &.;2!%,*P,6T8
MD,:^(&",#"C$)EX<C+AZ0A (((4@IGB"Q(D@#L1$@2?R< #!.6 3A1A 'CQ!
M@I;IX0&;@&@N!]*"$WAB#P> UYQ=D+Q:/% 0JVLOG>D7#!KX,Q$3*$4O"C"#
M3K3A <$@!0/ZT D4,*"@6*O :0([1A%T@@\&&.;9DN* 411B=1&(%<J"$8)J
MO>%I,K2KL4HQ G(I:Q.$0*,L7T#C"1 % F29&P3H, H:A$ 8F_@5:"00O2SU
M=0YO>,,-&+ 0"[2 VV\X9B*<"A)!>$T@A#QF+P1!@Q8T9!!3!$0)[$""$.A3
MMOSN]_Z"!B*"0 3#A<* 0-T*8R=!/'"\298 :/8 2)X@=Y ,J$ (= 6>/B!
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M8#,7X3IBT6A,!A%[  "3%0R#P/X&M-!+=T 0@   "5),@P [QM$+HI!D-0
M^_8B=0AB-A  GT 0+B  E_%A\,(2-#  R<0N(0 5=F  #G!]P0!GCL@3"_0=
MBR00>^ UWI4E,;$0=L _2J4"H^  ,O ",! #:!,,!<)B"O10Z442[K45+8$
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M;=V^W=O.C=S4S=NW/=O*C=VT[=S'K=M5T-W-7=NK?=W??=O9O0240!]CD-O
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M3'A%AE)*F[R(O$./5?&I[DA!*HBW6?(!.$-+M6P6.D'%"GF+-ER334@ !E"
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MK=Q.!54(@R; !!1?*$7@%R;WC6;M[M;)A/1\\9OH.0B!BCD  #_8B>=$1:=
M\Z$:@DF8;848@[K!A4K8#HC)A+)L[EUHA3!PWL^Q!%48Y37 !#5 )THXO0X9
M@V#AA4H(CY18A/".'C$H;Q>KA+L9@C78='.YA N?.U0/:SVC@1NP 5=_=5B/
M]1MP 00HZ[)F  +MA+4FQTW. DE A"420"R0!.;3@E\'C"@X!4? @!QX!%S
M!:*5A/XH(#YI[[3!1@1)> 3(0.-F#Z!3,&P<<(1<^ 59< 2:T8)34 6JE01)
MV($-8'<PP8%'HUJWT@&/A"215*P K(P74I.4K!K_A)ON@(GF^1/ND![^0!N#
M3YXB\(&7L$&8$ _?P(F%.H[]_N;NZ3?YB/C2.(+F>:,W\HT'^0A9V@D_X(,W
M,  1Z(,\D-TSM)""KR3H9 B9=P_I20GFDGD]8HB&4(FO( */9PB0!XN;!]<U
M%-^+Z 0]Z ,)6( ZV(-"V GBM0ZK(7B$?Q"5*/@+''B34 B#+WJ$SWJ:OT"Q
MUY?JD*:PB."-H(4]Z(,6(  9X ,^L''W-/NB%WF*=XF>'_X)FA?ZWT!XO!_X
MD%\(G?>DLR'\EK+Z7QEYH]?AG?B,-S>  C   IC\ KA\R[]\R2<  [!B6[]B
M!D  !=B$C&AKP6 AEBT3FL&K0U,AQV!9'@(,0\,K+@$:EL4A,6DAFXDAU/<T
MI,5]%7)]V$?C'LH9%<*!7."9'$"$J:&_GV&L3!9;?V<V 8,<1+E^EO;/0_$*
MKBE,:$H+FNAG /F\F@"76)IF84   !@ !CB   " .5CKX[G&%+E^?WZ3N!%_
M@NA^#!:7[UUS@" B<" 1)$$F!4N84%BP%P "*%@0 $ %A1;!!"E"<"/'@4@Z
M?NRH<6-(D!X)EMPX4F!*@D.&=/Z,*7,FQR!6+"J4! " @08$=I+"&:Q2$)DM
M"XI$27,IQX\O-\(DN)+C4Z5,B405F'7ID$S!@ D-EL>  P8-&)A%FQ9MV;01
M%\"-NX#! @."%.K0X&'OAKU^/_#=@&,#X0\?-. P3'CQ!L5[ 3_V*]D#XL6#
M!Q/V\*'P9L(X//3]7%EQ8\B:#6?  C8A,"T9-D^.#5IVW\D9HO@*JSNLFJ(T
MMUX-+GPX\>*_E_P*VT</FP,A]M 9)?25[ZO C6//?OWZ[^%!*GW%R<G.'@D*
MYM@A%!8C=N[9B;M_KW4XS*Q#;@HE1KZ% !A[\O1B$5B49"0?4_%Q9:""P@7A
ME5 ,C?[5EEH34JB67'(IT, !$X2"UVN2U08B8R-:1J)LDX78V 8:K+@9BX^I
M6!AE?K&X&&FP^558!CA$H444.60PF5XG@DCD![?MEB1KP?0VE4Q.GJ04@MH1
MH=%'*R'A))0+<H7<;J00T,)NKP 'W$@IP;2EEMDAT2:74W8W4U0&@;=;" L$
M*!18&&G$71%'#?3G0%%MR693&CG94J%0<3F034G. 8 ?NQ'E$D>(JH34?.VY
M>:F55C4J')Q8.8@30W4 <( !!JBZJJNLNJKJ 1<NH( "#A00 BT6Y66D82"4
M:)ABG0TF;%_"$CE;B8SE*&.S@64&FHW1\G48!AADH(%AR?[.EF.1W6J&I))*
M]M81<$%L-400ZU9'!+LNC=H1N^@.NJX/ZT9U;[OT8A7<E.G&-(02R3TH#"<
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M^A$\1H3N3D((0^#%@AN*RIN#GM U.;3.@[&)!*B% &Q82%CPYLG88L$6&/@
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M(KA2303B4 "/""X!MXI!:RX!N(H9(]B4&##"+_ K* )-J7K%9.H60W#" 2#
MI"S,H[E19VR #N3 J?U>,/"18(#H:Q!&^V6!#J0C#CP"/^)"/J(&%-#H(=EC
ML?E58Y"6:1T)[CG"([#"I&4 +B#"[EW *:1"!H  9>"":_X PRD\0M4^PLX^
M M#21B<QZ2;AGMU4U$GB9SI10B9D DE=@A,HP1DXQ;H PTX9A)>IPADH(P\L
M G1:S!;LPB^43\:!V26V5<18"33%0@5Y62JD@9E1@8$MZIO8G, TCZ*^74S\
M0!&<@2*HI3PIT!6^A _@ H$8A)$IWA"<&0_HFVMBPBX0Q51XS%ZJ@O9HA99Z
M3!F"*<6D62O\@"LL0@_8%/I 2</$G:/4R8FQF<?X0!@HPE!5PIK!UROP;9K$
M[G$E72I, @] ' ]:S$UF0IL."A>D$QQF4"%FB0@2V$MX61C$0G=50IF=&5']
M"PVY"W[(5W+&+NU"#2]T5 9%3/X]B9DJ^MGHC(3'J-A7U41B>M[;?>#D)ARI
M1LP6\$( I<)X!9[_!8VA.HI_RE<B'$ A@"W(F@9CQ*-B_*AK8( 6! ..'"B.
M/H(C9  P0 $'8$$N!-)M3)IE[*PEG ++;D9L9>UKX( JU((C1 $4&&W-SIYL
MT19J#(,6;  P/ (B0+$<Z=[,HF.R<<O7/FEU<40:,$(C+,(B_((J,,(2N-@S
M8440_$)'%00OO0)/ 8,2^, :W&"5?*$9)->^,()Y.:.Z@)C,O (F9(1!B$'Z
M=@',^0"&V6K%&L=';!.BM8)[($$D;($L]@! -<%R+9S(<&%&Y \7**:Z/=,8
M?!=!-/X>+$ B>&J%BY4<SW"!*N 9$?3 <A9LE0R>#\ ";ZD;]D(C1P20SET4
M5?0.B]W+ &;$*ZB"$.RQ1TB7LKX"P!X!,.PJA*T!S F#<-$.,,PASU"!*C0!
M@U78P5W=$+Q"N*K")$37+CA0H0U:E:UKV 9#TU %Q"E"Y0;!$[Z4Q[3"&41A
MT_#"/5L<<_$"694$?-FBD;&+$JC"?5X>0,&AO"+E)5!"(?+"4,&=Z%V'EI4>
M3GA"(G0PR()(.0KDL6& #G :X:A"#J/P9EP6")CC#N!>+Q2&!N3 SH+ R?I>
MULZ>M,26),A:"0=#35MDR2+MCB!)#N0H%/A"%%Q +SC"D/Y>P$CC0+$=FQ4O
MCF9\+?]5U+2*S,;\ *CVP,?A@A4<P1(L0OLB"BR,SC/KLRJ0U4A\Q^-A5>/6
MU#N'P1C8=;4AUQHLP1* 5+5AA1'$0K45 4+U0"K ,W^"T:$.2J+:H/\E&#!8
M 1,X@7:!#"6L71$P 0:^5! (573API5> B"'1/T\9;=B6W5@%3J/@1G8]5Z+
M4Q,D01G:G0\T H%\1ROT@!D 0\U1F1L2KZ*\*Q3E9#!T\W(FJUV/@=M521SW
M91 L C*6X3V]D#GU '*II5L[I:S:M1DT07S&@A4L06&NE$ <,E#1)"[X !@D
MEP5#9BH-P0TAVF%3CV8;@1/  OY]&<3%^>LOP)@30(U-R1A >5P0@-EVVS45
M"$$L\ (7,($5X$):_=\8D,F0 4,0Z.!V[K)U8'!&$ZBVY(B+G$(O0 $(Z, J
MV *P@$ P)&WB'(FH88LL-/5LH>.1/ (OP*P.[,)&9D!IY71IR)8MP"P6!(/W
MY< I (-+YT(^2HLD^((C=.,OC%HHU1$(.)^J-4(NZ !(CF1(<JUD..EQ,LGG
M78I +%UO+8$E ,,NI'D9^(:_@NX0G %QO<(NUL\ON!WD]L9'4!S!@ 4L4% :
MJ/E7.)R[I$'(&824JL(K"&=Q,!%7(MH<NT027$*:\^4]%<$D@&/UE<NA Y6[
MB,$NJ/X"+H!I%<8"(_1@)A"P0!P!+$1N>%#7%KP",,AZ);C0$#3!*RA!_BA!
M+&24&22R.BLV2OBVKGY>5NSWWO("IB;B:H#%WP7<*]3N$K2"*_#"*75,*^3O
M0:155GRFK(?'@GFFMVL"$N5/$KS"G2>!*K@">B9RO,R.E2'5Z@;,(GA[*NSB
MZK0">Q0!TGUV=>S[);C2>:/;$& "+X"%M_?&$F""MV,"NN73Z\34>9HZL"-V
MQ3/(AG-XDA3HB%QM+P"#*OBC3//"(IG&D;B?MK0?]]F"]^TP83R"+Q2M./[-
MT++L8[0?+P@#'SF?*JA"%)P"J*W"BJ]("5>M#M0"AVY %O[T@F+)0EYH !38
MPB_P4:F)Y$A^N7QI-4>0'=3X(%.Z"RU28?6$P;G"EQ% #1&D'$%4WM5=79QF
MQ!:H:KND'-0HP=B_;ZC4(%)!.L0T@1?4;NPN 5-2D+A9S!*$@4$,2A$@D58,
M01*4A.*S?=MO-15X@4FAA-[5!Q%XP2E^D7Q,%/%"9A <@=?[QA&L?>3/1YRJ
M'!A4P?34&R.F!-F17>55R1GW_2EF!1*H/DR  89GN%3DH$F^LZVJB^&W?@VI
M/E9P@>\+Q"LOF>.+F^,7@>GWB;K<?O@(Q.*?,1<H]]?L,G<81"5F/%(5J,BN
M" X,).*P" @ B[=T%J^A?^V)[/YF9$ .I+]E/&VS',D'),:*Y, .  2("R!P
M;"BX84.&'5DN<.#PP5>4@1EP[-BA08,'#Q0+:MR@$63(CR%)@OR0(4HPE2M9
MMG2I4DT0(C-I#J%9\R81)$."R$1RTR90F3F# C4Z!.G,HD1X$BEB5.C2G%.I
M5H4Z=<B272^YNGPUU"I/J4R#C)6*].Q9HFB51B5Z=&S5N%;ISBP29%(P8%WY
M!@,3Y*G<GF^9)L69LRQ6PDIM-L::^.=AFHFOUJU,->Z0+7W[4@(K^+/DF90O
MJW6\5*SBFZ0MMW:]6&DFSK-IN]21L21(C!D^?/B($.1(CP@W?,"A(4-QX1\_
M(-?P(?[XR.6^-3!'KIPXPN8Z@DG2HF65K.8>FF? K9&Z< _+109OCS[#E=I<
MTP!^?1]_U<!4]]>-G%^T^[+Z9;Z67IGKIOX2!)!!_@1L$+/6@JBDP);^\@_"
M!A6<JC\$ 4300Z*LJ)"E2D*CZK\,&=Q01=A:G$PV$F5LZ3;H<D//-^!NC*ZX
MZCI2SZ3UA-P1O9%L%+(X\HK+( ='3DD%D>../)+(*JL\"8H9]XKIQ2Z]_!*_
M 6<\$,PRS0Q+Q;ORFO&OIT(\$\XXZQIBQ!E-5/!-!O.44\4]AY!MKQEGO,U*
M]H #,KO?,'+/(RM+.O1&XGK3 (,,,+@@(R!STU1'31\%"?ZE8'R9D<L/RPPQ
M,]5@2Q7$.952@D 973F1J0A=;"N_/5U#%5<T>[U**A_6E)$+77.U-555+S,5
MPE2#J+/"O3S[=5EC^33K,-1LK;4M:XD((D9!!^7M/$=U=$]2Z=@C\K=&W46T
MT41[F]=1=X>\]]/HT,,@)4%C*F*(_O9S4V":"%[PJ8,-M@OAFR+K[V&'&9[I
MOX&G.L)@!5,L8D.,G?IX"%C'+*)BB3^F>.&4%0PLL( 7?-AEE76*>>*"(3XY
M89-/UBEEGB?V^6,DA,@KT K#</DGA7]6>F>+<P8ZL))1_AGGG)Z"N>"@,\[I
M)YJKCEACG8J ED03D=A/ZH6Q7O[P9*]9GKG@M7MV^F2ITX9ZZJ:Y9BIKDO\4
M5U =-@"!WL+G-?QP\@Z?%P?$'5=\<<5Q/+RX>2M'/,G%>X,<<<XE[UQS$$(=
M-=I@TOBAI]157YWUUEU_'?;899^=]MI?+V*KTE_QP?;>6>?)]^!_]P$(X(7W
M_8=(!-T"]>.=?Q[ZZ&/WH0E!*VE>^NRUW][V'\(%O,(<+K"4_ S*QZ!2\]4_
M7_WTW7]__?+-1[_]^"U-W_[ZU\=__O[E9U]^_&L?_@B(ODMER7IC0,,9S'"&
M,9R!@6:0H 09Z$ (3G""%7Q@!#&HP0MB$(0AI* (.=A!$IJ0@@]$809+6$(1
M2G ,:OXH6H5P,88&CC"$+L0A"#GXP09:L($;S&$0?9A!(NIPB ]4X0N-.$0G
M\C"%J1 4(\K@0@]:\8I,G. 2=[A"+S;QAT.T(!(IZ, .7G",6L2B ]<@*%5P
M$8IE%*,0SWC$.19QA&G4HAG@B$0_GK"+/\QB&<?P"O#)* M1P,(B&=E(1SX2
MDI&4Y"2QH,@H:(&2E%1D)#>924]",@J...0H25E*4YX2E:E4Y2I9V4I7OA*6
ML93E+&E9RAD*ZI:UK&71 M5+E?A2+[]<"2^%&4QC A.9QE0F,8NYS&&Z!)C'
M+&8RI5E-P#'3F<W$Y@RY.4UO5C.:S*3F.(6YS6=J\YS*)+<E.<'Y379F$Y[F
M3&<[Z4G-;+(SFM=,9S?KZ4Y_]A.@]I1G/.=YSW_JTI?)5*@W\5E,8?SSH?2,
M*#4G.LV%2O.BP"2=+CG:48]^%*0A%>E(25I2DYX4I2E5Z4I9VE*7OA2F,97I
M3&E:4YO>%*<YU>E.>=I3G_X4J$$5ZE")6E2C'A6I257J4IG:5*<^%:I1E>I4
HJ5I5JUX5JUG5ZE:YVE6O?A6L817K6,E:5K.>%:UI5>M:V5K+@   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>sign-half.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 sign-half.jpg
M_]C_X0.V17AI9@  34T *@    @ "0$.  (    8    >@$2  ,    !  $
M  $:  4    !    D@$;  4    !    F@$H  ,    !  (   $Q  (    ?
M    H@$R  (    4    P0$[  (    "(    (=I  0    !    V    012
M15-44DE#5$5$7TY/5D%25$E37TU$1   &W=    G$  ;=T   "<0061O8F4@
M4&AO=&]S:&]P(#(S+C @*%=I;F1O=W,I #(P,C(Z,#$Z,C<@,34Z,S@Z,3@
M      .@ 0 #     ?__  "@ @ $     0   !&@ P $     0   !,
M    !@$#  ,    !  8   $:  4    !   !4@$;  4    !   !6@$H  ,
M   !  (   (!  0    !   !8@("  0    !   "3         !(     0
M $@    !_]C_[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$(  @
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M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6)
M;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M        0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M            4G-L=%5N=$8C4'AL0&:            *=F5C=&]R1&%T86)O
M;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2
M;'0               !4;W @56YT1B-2;'0               !38VP@56YT
M1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O
M<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M  UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M   X0DE- ^T      !  M     $  @"T     0 ".$))300F       .
M         #^    X0DE-! T       0   !:.$))3009       $    'CA"
M24T#\P      "0           0 X0DE-)Q        H  0         ".$))
M30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       !
M #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M  !P  #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@  #A"24T$"       $     $   )
M   "0      X0DE-!!X       0     .$))300:      -'    !@
M        $P   !$    ) ', :0!G &X +0!F '4 ; !L     0
M               !               1    $P                     !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG    $P    !29VAT;&]N9P   !$
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3004       $     CA"24T$#      ":     $    '    "    !@
M  #    "3  8  '_V/_M  Q!9&]B95]#30 !_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ "  ' P$B  (1 0,1 ?_=  0  ?_$ 3\   $% 0$! 0$!          ,
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M "  4 !H &\ = !O ', : !O '     4 $$ 9 !O &( 90 @ %  : !O '0
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M!]<  P "  H !P I86-S<                                     $
M /;6  $     TRUB24-#G&TTI:VD1?84;9BP40P2;0
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M          IE8VE21T(@=C(           H 90!C &D 4@!' $( ( !V #(
M    "F5C:5)'0B!V,@
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M= =TEG4F=;9V1W;8=VEW_'B.>2%YM7I(>MU[<GP'?)U],WW*?F%^^7^1@"J
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M^'[Y;/I;^TK\.OTJ_AO_#?__6%E:(        *9X  !1_@    !865H@
M    +90  )H@   175A96B         BR0  $^(  ,'0_^X (4%D;V)E &1
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G>#SAE8U8C8>:E-GEKB<?T7+?4M%PXL119VW1%NM(EY&FJ<_/H__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>sign-full.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 sign-full.jpg
M_]C_X0.^17AI9@  34T *@    @ "0$.  (    8    >@$2  ,    !  $
M  $:  4    !    D@$;  4    !    F@$H  ,    !  (   $Q  (    ?
M    H@$R  (    4    P0$[  (    "(    (=I  0    !    V    012
M15-44DE#5$5$7TY/5D%25$E37TU$1   &W=    G$  ;=T   "<0061O8F4@
M4&AO=&]S:&]P(#(S+C @*%=I;F1O=W,I #(P,C(Z,#$Z,C<@,34Z,S<Z,S<
M      .@ 0 #     ?__  "@ @ $     0   !&@ P $     0   !(
M    !@$#  ,    !  8   $:  4    !   !4@$;  4    !   !6@$H  ,
M   !  (   (!  0    !   !8@("  0    !   "5         !(     0
M $@    !_]C_[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$(  <
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M .K6KZ>'_*?SG^%Q?]X__]G_[0O,4&AO=&]S:&]P(#,N,  X0DE-! 0
M #<< 5H  QLE1QP"   "   < G@ %U)%4U1224-4141?3D]605)425-?341$
M' )0  $@' (%  $@ #A"24T$)0      $,?F9;=5'9;+'O,66(CORZ<X0DE-
M!#H      /$    0     0      "W!R:6YT3W5T<'5T    !0    !0<W13
M8F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX
M=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $       ]P<FEN
M=%!R;V]F4V5T=7!/8FIC    $@!0 '( ;P!O &8 +0!% &D ;@!S '0 90!L
M &P =0!N &<       IP<F]O9E-E='5P     0    !";'1N96YU;0    QB
M=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O
M;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
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M9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO
M;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O
M<&QO;F<      #A"24T#[0      $ "T     0 " +0    !  (X0DE-!"8
M      X             /X   #A"24T$#0      !    %HX0DE-!!D
M  0    >.$))30/S       )           ! #A"24TG$       "@ !
M      (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:
M  8       $ ,@    $ 6@    8       $ -0    $ +0    8       $X
M0DE- _@      '   /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z   .$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      WT
M   &               2    $0   "0 ,@ P "T 1@!? $, ;P!M '  90!N
M ', 80!T &D ;P!N %\ 4 !D &8 4 !R &\ ;P!F "  10!. "T ,0 R #
M+0 R #0    !                          $              !$    2
M                      $                         $     $
M  !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<    2
M     %)G:'1L;VYG    $0    9S;&EC97-6;$QS     4]B:F,    !
M   %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N
M9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E
M;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG    $@    !29VAT;&]N9P
M !$    #=7)L5$585     $       !N=6QL5$585     $       !-<V=E
M5$585     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(
M5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N
M=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N
M96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R
M5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/
M=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M
M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
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M# P,# P,# P,# P,# S_P  1"  '  <# 2(  A$! Q$!_]T !  !_\0!/P
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M    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #(
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M1$)% D   &UN=')21T(@6%E:( ?7  ,  @ *  < *6%C<W
M                       !  #VU@ !     -,M8DE#0YQM-*6MI$7V%&V8
ML%$,$FT                                         "6-P<G0   #P
M    BF1E<V,   %\    >'=T<'0   'T    %')44D,   ((   %A&=44D,
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M &4 8P!I %( 1P!" "  =@ R      IE8VE21T(@=C(
M
M6%E:(        /;6  $     TRUC=7)V         KP    * !4 'P J #0
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M4_ [\23R#?+W\^'TS/6X]J3WD?A^^6SZ6_M*_#K]*OX;_PW__UA96B
M  "F>   4?X     6%E:(        "V4  ":(   $5U865H@        (LD
M !/B  #!T/_N "%!9&]B90!D0     $# ! # @,&                _]L
MA  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0$! 0$" @$" @,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P@ 1
M"  2 !$# 1$  A$! Q$!_\0 A  ! 0$                 "@ ( 0 # 0
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1OD' 00?[9/9O9_YQR/L__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>comp_0023.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 comp_0023.gif
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M]_3T]/CW]_'V^_CW^/;Y_/___P
M
M
M
M
M
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M=FU@ :'0F??7 *!G"FZ  :'P='W7E6;P "Q D2*Q >?IAZR9!F:@!@Q@!HH
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M@! =D 9<X':(-YY:T 5=0 9(:'-=,'ZF0 %6^ 92&94NX 87@ @[VHL\ZJ-
MNC*A4 +P)Q.=T)H200H14',+R*9N< (2P &D< D>&0I:X/ZCHO %)AIUH1"R
M<\<(CGD"@&J0+A";U+BC9G<"&, %:D !=^@%92@1]8D0$S (93@!BV ($W "
M9J"*@FIS3@=ZR;J/7("N>*H%HXH"<C<&$.JF7XIU(K %1QNC6F!_FJ"HE4F9
M*:!W91@!BX !*""P8S!X76"B9A !8 "N:!"-?.%W5A<*#: (H@ !H5 &'FF
ME#D!P1B;-PD!C#!W%!"Y*D " 4ET;N  I+ "/&B5VXF3H\H%'L!UB#<&FC"N
M"+&N*8NC"&&)BL"N;CL&\/H&4_B@-\D!$/A^9S ($\J)G<"MM6>%-@<&)FH*
M%F"%=5 !IJ  8OEW$VL*4#N&)O[TGFQH? C! ;9I"F#PI2: > J@".^9?H/
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MQ.'"H DV2" 4@F! (2Y! @0\1CL4'*)&+J&!RLUJ 5WLP@$V<AY]/6@C8]"
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M\!K.R/X7^5  #5$$3CJ#=AD$"Q"M"JBS#;";!)B+1> DW"D(,ZB9H8@1::H
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MVD\/2/[1MV"J;,L B^N"TM,"$&B!N3.<$PB!D !(,-B4"; ;R<B?$K  #YB
M+'.3#&B:+@C&$LBE$ B9EPL[4LN*#=@ #?B YJ" GPF\MD Y-ID*"?@<J-2$
M#  !$^B""2"$ZQ !4JC2'?& *B6!>,I4H1 ]#[B C0B2 D4O-!#/6RN(#GBR
MH0 !NZDY"9" 0!$*#="0-@C"$O@(4F73\5"$"[".^B0%$3"^%C A%="8E\O5
M#=&"RAF..DN9E^* BEB!LMB.3C&#IP". &&!CN0VR4&@4G53-\$ #AB^NZ@
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MV,6 CUBE#>" /[V$\=0H8VF!CG2 /RT!H/B (-@ 'RZ)$JB IK$R[?@ #;B
MGR$#H\H OW@#M9  .MV !T HMG4N\!L -7"U1@P7X9@;)(-430B%#D@/,+"
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M[05PM0&>' Q!D  ,40!P20"-R?Z&*:2CG70,!K1!$A%@^9F>/!+$)5)E!H3
M!41$"R17RX  !J#/('A "V" _NW%XVB !]@$(6! !_ *07C!!&R "DR  ^U=
M64* "W@!!D3 8)3 97% 1'P0^44+"Y&%!#S =#4$XGB !D!(D7D ! !756Y
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M($@MD2A"!JB$(F" 2C#C!ES ^(X :38$(F* .-*,68;1,98CJC2P.-H$W7"
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M%S@PI_F-"9! T##C!,2$"TA=!61 281""2C="5B$"*S !T2 ID ,YUA$;(2
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M0R%"EW&'[RQ"%[S5Y7C!(51 ])K!H8Z>&+6&+"M7G5@$(W_-346 37S!-(I
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MFM!""Q"ALL,@PCHWN81ONM.%$H !>X-  0H(01"OE" ,)AO0&Q1""IN5CX=
MP5Y5%($6[/V0*F\CHK=ZZ! >&E&)34SB$WL%K#:,X0$QA/[B%;&812UND8M=
M]"(2:P/&,%IEB#Y,C@I6H)(BFG&-3FQC$W_HM8,Q\8UB5.(1OS@^4AAJ?*&0
M&<8T\<?R^3$JFL#C]P1IE3,D,H^-=.0C(5F5AY@!!&-D8W/F:)2.X/&'H9!
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MX!*($!0F+) P@ERB :%X0Z0N40 7(((++TD# =" " \<Q 'N:X B"(4(472
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M%L.P:P1?6,PE(G#4*@^""ZPZ&!F&LY4+"$(%05 3(?8X@9L@8M@2L")!-O
M#6Q  =U21 0&9=G0G,$P>#G/!!2!"0]X0 MF-4JW3HE,4U0@814@A FX<"/%
MI H%*@@H!OQ"B@NLP10;N)<:$J.("6RB I?@C I>V((8GN @6Z5*'<1"$ ?T
M)#2+4  IML X%[!' E]XR$VX)OXR",1(!/=J5@B@95A2= !V&S#70UBWV)=S
MX2 02%,)J%-%4Y0A4AAP QOH=0D%A"(,/\E2)<T0NJ!H82N8!O85W9"7%81
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M&F!HW,J3;B(,Q$X#WD">@")&NJ"YNF XQJ"2K*8[TL!W!OX0BPBA109$$5I
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MO@ZE/!1 (2Y!-=S@-4C#%/JU2A8@U)(R=%@/6LI0!68)8TZ@6DP& JY'B;2
M.F+35_&M-MA  2R@ B:  G2"FN)#8GUE(GJS,#TSYKH#(C@'1*NL(MXL*<Q@
M+2)@!%QD [Q.9.+B(<8K4Q_"$/X:  5,( 4D8 MZK 60 AYUK#; ; *@0A$U
MH74^8#"7B0:#!<Q.@$K8X@)2H#[?XP*@SYW:12R;BZS.M4IH PU.X 0:X W2
MEBC&8@6!0JBJ9+TPJCKFP^3:1&;,P&&\AE&^" +FYPS@3218E3+QE3F-DY&
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MP (%&*<%$N<B#^!>\&1IAK7*CA@$SF8,)*"Y0*/*.N)![D4" @H-W Y6*RY
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M?0RA!;I $]3 +T(!)3UF:-)@HG+C-9("#(XB>36!"T"H)TI4 R?*L\F@!=Q
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M(!I,%^I<Y)$;G1F(>&A*JQ)T$1$&]$W F*^.:<)&CXTI*G+**J\\)!O0::*
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M0 HV5)$"@[@$M])T"1,$IW'GJ<!P?!HC.@(N!"BH0,!,40(-J$ "!!+$!%A
M @Z$8A,/B&,%PM: #11B3HMX@/<\))2;K25&$FB!"X92'/):H%^=0H$''F#6
M14A@!4&H +PF\)5"7&P%)=C )AI31!=4H"=>>, */H !$YC@ =X!@P1,<(+
MP60"*S"!!A(C"-.<8 (E,(47(' "$CR@)X=I@0>^2P(,H/X ! V@3T3 L!L2
M4& %(G" 66?C!@(, '$1><,#VM@%LK !$8/)V0>>PQ8S>(#,;%EE8Q2A@A-P
MZC?Q+(%5(, 6%;B +8OP4$1.,)TWG. $$+@LTR(R3#[CN00<+8&0&6(&%3?
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MJ+-SU,B8E^ "*G#!8] "A> & ]&[B- %J>$&*N &A/ 4:6 X@Z "+<"8&MU
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M&4-!YE,2F:(>X.X3F#*AICXD;4":@8%G*)*I_&L&4U$"I>(=@E  ])%TB-
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M%,Y.L 'P9610,OZ !8Y#B)=:8 -@Z !XK^-5#LSE!"1@J@9"488&2.!P*]A
M""@ 3<PXSP+940$#N,>5%32  FXP0P6T!X']: )\&S#!/Y&6!@  (%UA2MA<
M&J"&ZYJB W?9"O6XTAP2D %2*NB"%T"@%M440DXBX  8N-""8IT@"%Q)D?'2
M96A38#306R1%LAKM990P0@(72D'Z$L0%N3XF)CPVP::G-Q<S>$"^7> "&"@
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M$=@@<7N*+8  $^@R[ZF VIN _2BV]>%##" !"""*:>D(-Y" $U"!$IB 2[@
M'[*X+YB 2PPK"Z@]"6@F0^DY#"B-2Z@ $M Z"/B5-R" 84&!]$$YI/@*08
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M]FK2>1)2O@)2,*TB!=51=[H01/@535@IKLC0U$0$#_ JM-L +N"IU5B$$?"
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MT'G ]>ID#JB8"R"P2V@D.#! INL>#9A(\W  :$*!-]@E\]@(-G@9ZY$1Q[
M]>""T)$O36!!KO@(E- U-U"+"/Z . HHA&>3D57C@@MA $,8@9#+94TH*44@
M&R+"1!<(JQ+P !7XPQF<3[/< "11"ZP"&IU(YUAM@!$0 1(  :[9"N<J+/L3
M3QF\!!! C7KI"180BPVP$%)X/4B  !$0Z,DUA0:DNZBA  AHKR[8 +N*B3#@
M !<L6IS8)CI1M0*Q%U/N"$J[V^G@WHX( PT0A>01@Q)0@#8P@VL9@PO0"A&P
M@!#X@,X0!*#H@OOTO:> J[0#(*83G$(:@P@( Q5 O%"P )>@@.P8@WWY7H]0
M .7YP[+@:K#.CE5\BA/0 #%0*6J=DD$<@R 01%.X@ _P@@UP )GHJ '^)@=P
M 3 04?Y%?!>I!B(5T (0J)H-B+\/^)4\?(P66(3MN ^UR&#S: !2J*MP&1:&
M@ICU28P>3HG$^0"B>.C'Z+R0PY\,A"8UPC>M?8L6P3]!0(,K-@.]H!C?4Y@R
M4*@>DA(@Q,V8?A 50 V+\*%%\(Y+X (OT 1!\%;D]@Z"=;CUR9 6,-#8$*".
M<#NI$ 06T((D H/T2 D?8@0?<@.B>(,!#06L[A!"\,T=C!!1\!ZG( 4RT )#
M\!;/Z#5%4 __U8(K:K\6@"7V5H$PB-+? 4($T)NJ4@0S2("W78 K4@$3N(0$
M>&\1R#\N( #7\X"1JAB&)80W@ #\'#8O0 034(ON8X/ J/X6"\@E<^F)%.B,
M#X  -^@-?]$""B $0?#*!BZ+:R,!%OL(1$B#MA0$"[  33B#!CBE\0J%".@"
M1%B!X# 7.V& X?X=,9@ ,_B"!_"."\YR.D+!E."X,AB$$T@\CC@_,P"!%#C1
M-GB#,2#4K2L)B#OI#P!F%LK%%."(EO& 706#K+@$+>B)\_L .-$ Q$ *\+F,
M9=,*%P"3".( >6I(%T"$$_ K%4#1()@+\N, %/!THFL_,1_3+OT.0=BYRP+3
M'2U1,KT55O(9(567GGGU4D<:#("X6]]U7K_06G_/5F]/6;\9B$'-*35U6V?U
M,.]U$EUV9G]V:-=0\XQV:J]V:_Z_=FR'=60MFFQ_=ECMU7,N="U*T6'7]EF_
M$$+X@IL9@^X14VY']JAP@:K9F6D_=2!EHV3O=GUW]2/Z-4)H PA(']QP]@.5
MXU@* ST/GB" [^"I75P12JH; X:?BDOH@HFWT*%IUE@)UE(_!"QWD<X(NTL(
M@Q$]#';=7$5J#VD]>:CX6_6 K% XA)10!$W0S2[H+6\) ^DD!3ND$B]0CS/X
M@$6X^:BLZ!)9X)-[NS38BK_M+5$8@VA5>6@*K>-,R328"T4  WF:(&GUCC=H
M;N+L O70!$48^H=0G*8P=# 0UN_H-P\8@0]0 $(##SC=]M3<"C30"V;!;JHP
M 3/1T/XW2'C8V@ V"#\6<H"PG0"]< ,'Z *4Z@DQ>P-%N"H6J( O6@$,J.28
M4"Y3. ,#F N2=0,%T#H&R*77PZH*6(T+X( W' -%1YL== #2OPL1\!(&"(&Q
MLC*4,'(/J)C@\HKP2JFQ&ATSJ!O2*8I3>H /P(!+4+DV0>G/$ $4F #I#X&9
M3 P,&.GT:8/15X$&:.X/N E-0($0\/)T42RJ4(0&,#DWH-@":2/00B((N*QR
M\9!WLA-9O<-%$ 0E BUA#06 &'3)%$%3B @53!BJ(*F%!A$61%2(("DO&S29
M<DC*%*&!$1%EI&A*A0E3&QD.6E1PH2*0'T,FC"ES)LV:"?[K&!A@QF3"2RHH
M/+ @R-2B!8Q,*6I@BLT@@A*:2FA!D,,8@BY*\!STP"$$0F8\F')Q@8TI")K8
M0"!(1H,I#F (:B%A:H(*@AJT$$QC2DU:4V8LF#*!-P$<@A2J;FR30&6A!P4?
M7!J#(>\"OQL(@@%ARH(;4PG.F)0 T4-5!1.W4"#8]9*#QXL&.=BH)C6BU*8>
MM#%U-O )@HP\)DSJ\%("39<R?-!05].&%@\&L6!0H0VI$AH\8 #9A42'$H4P
MJ+# P8L'""X(JMA PL)$$NXI7#0%AX('"GA)F=CP80,FBAM#5!58527HM\%
MZ84P@2*%2/" "9I@< DB%Z37 /X9&:WW00@?))0"5@D-8L$'&+!@T@8G?!!!
M;Z2L!T((8(EDDXPSRO1& 3K%=!)1*BB@R2(2A$**(D"2 @8))30 %4*A2!#"
MD?KQQ$4((9V@A282:%+"&"T0,ID9'!!DQF43@% "@6!1,)0IA5 PP0<3?6D2
M&AD$I@63I&S4PHJFH'&9*60\<,(()CRG@A8;:3*!*6?XZ85F%+P1R@,8)64"
M"290X$(H$&1"RA:]F4(!(6PT(.@)#[@AR&2DM &8(!0LE,8#%9@P$"(@O<%
M RY%Q$ 78XQ!P90;7&C*!GHEH )&I$R D!9LF=(%8%PD, @I@QP $@9@(;)
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M *1M0/"%")I""V RQ:!LMQ-CF2$4#5@2!!8A)8(((F,QZ9,'^N."*<TS#(4
M*A%-$8;+2(P1J]Q(*P': $$@P@.'$Q\)0I$W2#X@:J&J"@0.89((*&(0"X #
M(CX0RV(B5D:::&)-2,%-'24D;S0!COTD.UF'U*20I$#;C"X!V;S5RR'<E-$E
M1MM9R)+V)&P(6DUD&A-#-*D#$<I>Z"82"@]P0'H(N0I!WC!7HVK,9:LT 0I4
M ('"!H@J?)+ >GH3B@YH0 01."%/,M* NF3$ ]&%@!M(X?Z!#)!@ E49! -,
ML"FU>G%W!'%#\[P0OH\A8 (2@ !@W,!<#$!, GYEUD38"P(P@+"ZB1TP@0M,
M(]02\Q+QL=])+L$!S!JXP(B L$PV.Y-0M$&O&M.19[N)+H)8UL*Z6<AF$>4&
ME2C"KL,1+1NNB=4/SX2S'L;L(-*P/H)<8GV>%;&%!5$]-(0/Q(L8\I 1U>*"
M='C#@^#C&A86X2=#.491KA^"IVSE*V,YRT^N30A*( $%)K8V(O"RAK5LYC.C
M.<UH/DF5#XQE!+=Y)G$>&2E\3.'&SLC'IE6S@3&Q9]+>.2-_MC(I(#&C;]$$
M$W,>&2-<S.='0SK2DIXR"?"2H_Z:4* . M[(&)9:X0AOI&7+^K0IQ"9EP^1F
MT7BN P-JEV8)(6(1+4&$JDD[Z )3ULH\*^;^8K*(6D_ZTC&!\$9&D#$*WWDC
M:6+(2DR+[)H$FM3!'>VSVQ#DS^H(SM NB!8@EF8M2  ## AWA 9<@I( >T9>
MT$N];CSEC70A7.D6B5L2MI.;.3K8-KD$"L"@ 4CE90/1-:T)3H""Z2TD2QO8
M !_A $XN0.U/XN%"701Q'C!PX> E6 @AD*F%%/!J*0(/P4#>H(4N:*#!*AC#
MOW?R(XRP8>$EX&8+*$""%2Q5"Q8(P>9,L8)#A (%9Z5 Z8"\@2VH ,+^SD!=
MZB"!"/Z 3<T;89J NX9G ?.D!* Z-4P4(A,2F^(#)12%)MI\YVB?O2!= "LQ
M>SV"\]Q,)?.&M"(( (9+>"$"M'P (=0(K8V<@ *(*.1./("7<>ZL 6BX1!<(
ML" &%.(2)TB ]5)3@N.VS RD@*,FS!" 7<XS29K0>:D%H(5A7L( *K@$'!2
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M04(%GE^D!@B4R$K6A1M,  :<P$$6!(1<S@3@!1DP80.88PD4Y"4$9BA8P B
MP0343JYT@19$ +28@ 6 @ AP"'=1(MTP4<+@7N"-6C&Z0!<\@%ZT@&;,G8%-
M ,68 @BPUF[<CE4X%P5,!!O024%HG;'<U+' H$-(GR_I!EEPP%,%9]A5Q96
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M8A6IZ Y8K3%NI*7;Z\+N[>(NFIDH*/K%UJ4N9 'O1BC"R9""!I!CE6U$@WE
M)V!=\UZN\\I(MC4OFR4O+<E%]:X13-AN[H;N]G*O#B7 C76!.@X8A?;6K<W$
M_]1NL*U43*RIOBG"0#SGJ*GNWM8OG3UOA2V:CGC!VTXO]_Z:F29H@ E "QB\
M#5*<0 BTSB6TCBF( N:HT2(N1"&T01NL +A(@)TTC?62@.42Q!B,P F,CB)P
MQIC=D1JXAUY=IPKDQAND\+!M00@HBUFI1+N4SXFA01IX0 ML E:]L%\@P@J0
M!1D,"D*D00>PP0YCQ" 0 BF8P2#@J>2:F4JZ93!.VKQM1 ;P+@ _&KM00 EU
M 9@HP@. P1ML0-*9!BU) +-L@2(<S9\8  F,@4](0%0] ,L\1QA%S4:0@04@
MPAA,BENJ !N00&J805<( E9.  6H ")0Z!O4DH:10G>\0<UYEU1X'DAH !D(
MP@!X 1M80&]TD1O4 05T1IN '/X;3$#GIN4;)$ 7L '!DD!O', 'I$$7,, =
MH1GXG,#K"5YYLH0F(,(6IL$T)D0Q2VZL482UE!H7#),F@,$7R)THG0%EM4L8
M]/ @5!1$K)9>J21'< &2$L47V",77YE+"O,!Q,YEG !V254H0%1@!$VJ:L%E
MM&Q!O &T0.GD*)%EF956HDW=))S+[ Q12$#4B!>XC@$D<0%;C)(7<>1 F0(+
MA  9Z!2&+4P;@! &8$XHN-=FO,\8B,:&==%ZI48\,\"-@8"EH1G]84!404 (
MM$ &7 :XO9^++.B%O*'S'$9,C$& F:\(\'15(,(#;,&"0L*F8 ?HP4$$M "!
M7L)#6?Y%-6V %M"%L52%PG3!!V!%;42J&)GSE%W)^J@ ")#!96P ,G:-J(0(
M*5# ^GB!!IP "' (*L4*!BA;82"B!&@ 975!!4" "10:9AIT*"S"AJS 08>*
M(#0$!7R ")" ;Q:$%UPB*:C "K@U(I" &Z" &UP&&D +:(>*!T"V")0(9_ $
M&  V"9""&JR*&@ &"J ?D9 "WWBO_8# 3FC"5&5$?78!X_R?;SB&&82/9O9.
M1JA@")1!1FJ,&4VA7>S$ K1NJ&QAY8JJLBF"^>I&N'2 &6B" W"3!!2"&SC&
MP>IR6$=8HJA$*&# !DAE"6#7YJF$!H@!AZ0!>)<,6) !6/YL1,P11 54ZGJ7
M )'*!Z*(%Y-@Q(^0@@68I08,1<290@64#BG(W1<5Q'CXX FX (NP#I] BZEI
M(46LST]BU:T>AD0OQ62@=!/%4)IMQ* ZUNLXELMH@:O]1 E ]J2TP 18"@F\
M#D)1P$ZH#2FXS([CJ8^#Q!A4C@/H!03,%(Y-RNPNT_:D0%U@UK$0 @.<P)B!
MH ]" +NB=Y3!X!T5 @!P"QP1@@>4BQ8, &B02B$(P@9@YA@ QB@MP,GPG2NW
M06'51=>HP$$2@@2T@284!U(H@.^HP"&,P0&\A2LN"JJ\BE9EA'(0PA9@2:E!
MCBF<  (,A!G8QAD@3!HT0!L, OX%! T$(*D+0( @%,($L(%]$00:Z%T)U(X"
MB, @F $#**J9?<"82L!1A)86I!-%&X=QO&,(^(BQ:X(B* )&%,(&R,\"(3LD
M\ P*;$![@ 8$3)^D\!0B- 48H( +! WM%019>  :%#4FE!;:8 0714#0W':8
MKX25R$N %,((#,U)*((*]+#U^"8BL, @( ($A0+2+>3ZI,$'=("F) 1Y]+IN
ML-'H:8P)C$ :P$%== &OI %=%TN&JH N@E@+8 0<[&<AO$\A:!4;?, W9WQ!
MA,'*MP[5$(3,IT$:A$*0;XB:K)DI=("R[+9*9"FYK\D#3$0:7$91%ST'(%@)
MY%49&?[Q96B -R)" E1%2L?$@-L5!(PI!E2 K30 ') "(%/D7+0."5_"%V#
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MCD+.8!)2V.A99G #9TAQ*T1P9@05T\2<PJ!*13! %*I:E^O.91# +@)";)@
M(A)@D$(,4UJJZ4)K*$"1_.%IROX$F8!JU?E+R)$B 1^9[4KTFI6F( )98FJ2
M&U3S)4%614E?2@HBV& ;@X0A*1AX58]ZDA=3<&I=!2$%(L BB#=<K0V7Z")#
M+H';3+1!S0N!<U,*#:6F: )+@WCTNL ":H,H@DJ*:$-2)IT2O"71(!"H6 (T
M\8:!+H0% S *&QX !BYL0 *7:,$O<60V+5 @#"Y@HO$VP(44$"D4"] +!SK0
M!?8L))]<:($XH^F!6LKK#68SSW$TH8!0C&$!*NB"!-!R"0F<H L/J!@&9&0*
M#8AA$PXH 1@T.ZP6@*$$#'#=!BJ B"_@27I:<,$#"D$*!J2S >DTQ:_-0V\3
M:(!<:_[6^,9-X84)E$ #(<CX:63+\126?"6"T(M)Q+(P)4U4(3CE&Q<J>@9-
M+*+.FL"N&KI0B%"801.#N$07N/ 24I3%(&9HP>@6H@B7Q47I%24,=@FQ<NQP
MX02"8 '3-0$&+8R%$!\9!$<T$886T TC7AB1J#%RUTN,11%;X,)(D+ZP3BAD
M$6-!PV:I9'+3H)SD#JGU._T>$<#_O?")5_Q,7/"VQ3\>\I$_?.231'G+/\3&
M$"F-HC&/<L1P7DM<<HJNT%0NT6->(9.G[>4?,G+6&][O5F)3YE]?>]@[1+:;
MCYKJ0<+[UQ/BW5K2O>Y/G_K5,\;X)><\&^I%?.,___A#T?[" ^J0E3&\Q&6N
M"7W3Z6<!"]1W^TERON]?3_[7]]WVBR_("FJ5_HN8X<(;[RA#&L5 :EFD$(!#
MQ/XS37G0=^;S7./_H,\S>N?Y3((-H&9=5B# U&P,W -J0N%13F D%($$4" I
M^@SU".(2-* #>J007*?RA(\$1Y @S*#_W$\AU$H#(,@L/F %-,H,"H$$+N$,
MWL $3$!M-J"23"$,F(DC+F$&:U AS  .3* $U :1OJ0%0L %?J(0T$!1^HP$
M2$ OS. #V, #8O#43B $*"4!?2U/0J $Q@+O4. #($0+'. $WFD+8&L16D %
M[J3>)/ #6B I"J(0Q&TATD $P?Z (P2!!$) ZCHE!$@ *[KN)]3&_![/ 5)0
M2S[@"SH#0TS@#53@2;*#0L9  72% T#@#5J 2$PA WBN7J[(]=)BQA8";>!)
M A10!14"$>X%@3! !02A!2J %!3! & ,:S: #42@ <(H ;Q#!3Z@$,R  OCB
M #Q "YHB C2@#4B  ;J #13 .P8&$5I@)\Q  ,(@#1K  ]B@!/0(E[3 #4(
M3Q;!4@K!&1E( 4[ #="@ A3A#+XG+8 (#.K@ W[)#!Z "SZ"%/YQ[M;P#'1C
M4#I@!1#A433MLLS #*S(*1+@$O1DJ23 #0:A FY$"RK@#<P@ 0I!$V@M++Z%
M)2X!!?Y 0 M,8AI%P'5"@0P&81#_ B8'H01 8#!(80M @ N=8A W(]/<@ 1$
M@&[80 (V@&X*(MP40@+&90%&H@N 95L48@,J!C/6@X&PHS0*X2;+0Q$X +K
MXHHF@ L*8@RJ\"^$D!!(H"VT %MFT""Z  100"/&X %" +MB44M8 "W, ,0P
M  U" 83.R3O< ,M ( P2"!% C=X$L_^FZ U2QQ2^<!"XQ24BI0TBJ043PVQ@
M2B&^AS6Z:!#P9RU:ZQ65I$=0ZC.- KP68GE,@:Q^PP40X4E<H@%<RBD4X -
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MS& !RE6-S8 \S2,$!@$,G@A6QOY $$2  !9(;$ @&=/M4#0@A] @ +I X;1
M(UH (SE15S;@ W Q$_&F/!2E$"C@G0BA <Q@$&PQ?_0()<Z  >CFO@B!"PX@
M#13JIR" #"& (F!V$,;  8R" DK SR#8EF\9EPV"$>;C"0E#!2:B$%1@/<Q
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M!"81 E*$!#;@EPI"$!J@D13")R!+*2B@$-:@N4A! ]A@T:;'="9((\2@N4@
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M:GI3X E7JN]C@H8= "6Z3 ON3P(*H97VPPL&PI#:E%J&S+YQ&CG,S3-$*KZ
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MI05*H($0M+.O$Y@+&C8P @W\BPT/B,"05H"!$ 2V,I<8SW@N< (/(&8L9J
M"2A0GA:<]02D" $(1#"!/Q7" B'8@%\9>@(0/. F=2K!!CB0L*BBT[:XS>UG
M+N>2!W0( U4:BPOYI8(/F$("A="$ <(0"E%0@*06$(1U8K((''Y+("0H#F$4
M.($NE69OI3F>&2:0,:ZRH0!P$&@0$C+>^[@08LY# -&2194'-.5;M>P*2C8F
M$NR,J@,;2@ ;TJ, 4X2A,UKHY1?AJ!!"!&HUA#-<024<'5ZBS6_]=*IN-ZRX
MI-U'!!NJP( EPI'[C 4%U4+N)?X@4!<HMD +$.B"&118,. (I(D*67$HHOL9
M"6A@!;)T*Y3&XJHV9&!"+4 0"+BPF=M0"#@G4D$+W." +;1@"PD0A MB%8H/
M( 8WB^#J6-B @6]MPD,0& \%,*""C;K/IPR84R$8,(8W8$!MY9-A"S3"X3XW
M55SMJLF<+##@?[FP8!/@72&@; I#. ".;I K&&CLDE!H0@(W#A<CN'J!-=)%
M#2I0@,W&$H(AYP81;3"L9UQ0G! PF<BX^1MP_B7E-DS@#6Q(Z7!N8F@M-* +
MFN"J0MAP0J>Y) +L84.H0^1%-G"  1$Y 9\OL8" F<$-Q;W$&3;0A;&00@L?
M,,&?0OXQ!C>0X /&ZL(#0H (DHEA UL8RR50W(+:^OG>B@--3"[1@ X1.D%O
M:( FQG."!YQ9Q<(NVXA5L$C]+D+@FOA>"4K& NZN$05L^MR<[G,&"=R'RJ08
M5#]7H)'VKLR^%-+$ 4Y"B@=0I0'L(<%P8I6&'8DD)!6 RN<N>*W>?J1>(,#P
M%TO Y-^,)0W"5@@&)N"&%2A "VYH 'H\0()!@,%IH4  "=S@ J[V1 N$9( 9
M.!(1#7!A$2,H&;[7KK@Q3  $%-"YR%R9@ E(0 (<6)8%DNOQ!K^]L?=QNV,C
M$@H/J&X3L_6 72U0$'1-X .*E] *4"L!W QV0FU0P$U6</X!QWK2,\ )00CV
M.I$(P'U_+?$0!_HJ@;D@H@(?Z"N3,&T*3$C 0!2 / 84W+ZQC(#)$NE6H4.%
MG@9%K@5AE@B(R[4L8YN-,%3LG()2H @FL?WZB;O$&S3C$/.-)[*5F:F'"H;2
MC?I40HOX%R'TY#R:"4(0A5.$3<D"7Y<T2A$L-6::BQK^-RRKF"@!'PG"?R55
M@$I1!_;&/KX')>F10$&6')*2*V-Q EL@,V1!"IXR$#%Q:3$A 383!"5#)AYR
M0P_0*]AW@KJE84^U8A"C@GY& D4G 6M (:"#+LB"$PGF00H!-L>U@;176J6A
M75H 6B,V" E0?RB8A ,%1BX(3?Y#T3A-"$8?@!PAP !=T +!4QF<%17$PS?%
M\36"T 5I%@H*\"=5\2<24 +Q87,L4"T.H )6=X-*.(=TJ$QUJ#YC)Q(M "L[
M4S!7XQ)@,&8#%@H,= (Q$1CW!6P;40*+( @J\P8G<0G%50)N=H>6V$^"\TR:
M.#!1N(27^(F@N'9C<08EDSXTXQD>H$T4D@9J0P*FAC<N<4( %6&,0!)=(#9I
MI1!OX$F,$PIA<!4M\&H1AHFSR'8$I8+>9B^%PTZA&(IC8!A1* &>UD]D0!.(
MP'NFA'(/HQ)N< )M4!P$-2S%6!E6P3>YV(SHF([-]!5!T11C,$UL(%J,80J'
M4 *N)OX*PP8"(1 BKH(&:W0)&6<0AL$&-E-G)\ !<[$($= ),C%@FL "4V@F
M@_ !)) &$Q *@[ (;R!+@W !%Q 1BF "'L S&--U)+ (+* "7J !W:8084"1
MA^ A8] &'M "EU 8GZ>..KF3$G,!+3 (*3 8SV@0E?<&$E >P:$(BV(0%K!^
MSW5<B& &E=,"@68&-/$!-_$ &_ &8W"$*V8*09 9H; HBB!-Z2%V;\ !VF@^
MBM! ;@ _83 (HE<9:/  P-9U:: QZ-$"'X (:I FRG4";J !P6$&"@!,/)F8
M.XE9%R 18T *9K W3-<8\U%#Z=<4%% & U<8QZ4G$? 3Q?YB"OAHE7RS(;>6
M*8/ 6I7#!K=W"9B0 (K0 I"3$@SI*&Q!'-;R$]XF 5=Q K$B9:3P%P,W)J8@
M<#-D<Q70>(JYG#Q))D?EF HD0Z009M/Y 10  ;@A 2%  MS)9!2 (R? !8C0
MF)M!FB1@FO"7&X.P"5JG0C(! 2; G22 "! !-9HP ? U%DE&"AX0B/>! =GC
M/+US JFW,U51 MPY KEC;%I0,M_)G!"JDVA0.3@1"C.6&R/F!A6@?0IQ!AY$
M 2%"*ZUB,X00%&SR+R]3FB.*FL$F$O/!!K4#&2I0(PV2@(0Q)"K 9RT73Y?6
M%!^C$"D0!,%I)M5Q:0+1H"5!4OX1NJ2@& HE(@@G !UA$!)G  %LT!-HH D)
MT 6$T (T@08.H 9M  'ET0"'(@+&Z9C0\0$M\6@*\0""H D*T!08L *DD $E
M( @MX'&(L #7Q@%'&&%<X'(KU@6"X 'D\B_)H@*:8 *80@()T0(6\ 9FP !R
M=9@W0T4.,HY,VJDH&!]8N5,$U 8B$ (CA@C>I *4T0:B-X]AL"PM0$6I5!YI
M@!M@L"Q@  F!<1^+P#.L\0&,*E(@L'7,52'Q 16+X$U>\#??Z%,C=J4*,0;#
MJB>:X 4?YZK8Z*G:NJV7, :AL:W@&J[WMHP2EHQ+J",F:%#6%% 39DT"Y8GJ
M2F'R*OZN]%JO]GJO^&J,^;JO_-JO_OJO !NP CNP!%NP!GNP")NP"KNP#-NP
M#ONP$!NQ$CNQ#CMPEN80%INQ&+NQ%]NQFK )&NNQ'!NR)#NR&KNQ*'NQ*3MP
M*VNR(ONR)0NS+ANS--L))ZNR.,NR.7NS+#NS/@NS(/NS-"NT.CNT,NNQ07NT
M1CNT+=NT.]NR2ONS7E!)4]L%56NU6)NU5SNU5=NUE82U7INU8$NU9$NV7;NU
M7XNV92NV:ONU9INV6KNV7%NV:!NV=4NW<'NV<"NW>\NV?6NW>8NW;QNW@QNV
M8TNXA^L%@%NX?+NXB=NX@INX;3NY?]NW;CNWC&NU4SLJ%$';N9[[N: ;NJ([
MNJ1;NJ9[NJB;NJJ[NJS;NJ[[NK ;N[([N[1;N[9[N[B;N[J[N[S;N[[[N\ ;
,O,([O,1;O.@8$  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>cogo_0002.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0002.gif
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M]/'V^O7Y_/____CW]_#P[P
M
M
M
M
M                     "'Y!       (?\+26UA9V5-86=I8VL-9V%M;6$]
M,"XT-30U-0 L     /\"L $ "/X 90D<2+"@P8,($RI<R+"APX<0(TJ<2+&B
MQ8L8,VK<R+&CQX\@0XH<2;*D28^S"J8\R?+BRI8P8\J<2;.FS9LX<^K<.?.5
MJ5<\@W;\*;2HT:-(DRI=RK0IQ%=M-D!X(($#G)=./;X*T<$#J8Q1-[21U48!
M!4NRL&9=R[:MV[=PX][$A&% @@,&#AP@T,%43;4: 1,4;(I! 0-H!3M,N4)
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MP0Z") \(8, !!"$0 ,&)-"*PA*L>X)Y96.!5>7@% _)6)'R5 @Z"<Q'2%I
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M9"1<I8!2@*!68TG)Y A AS/XKF8".:H!$I; /D;" %GDZ2Q(40D+7L(.,CM
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M(@0S.^D&]'7@O"7 BB_-P+B,I0*_F *B#NCH&5Q%3?I$($TR$B:T,@"')()
M%C)+@/Z\*(H; L)O!:2YC@6\F(?_P8X!*D#%A)1I@3? 57433<DK6O TXDS@
M?B(%@5X*L#Z\54MF"KB?'CQYYRH+)!(_)D  R@ME'GOZTZ"^R27R8 =*")HH
M [D$'NS +968XM5JJ60>\M"I$KXZ0:^^SZOE,VI3$^G6/D'U+'8](5)' C"4
MR(,>:DT05-S:%'G  [-+J <['-L@E+ V_'(MBU5P6SO)7K9*+!'MT(;ZW.A.
M]T@VMK%U6R36'6FWNN=-[WKG1#T+D3=X]*T0?C_D,HO)-T+TS1M[&_S@"$^X
MPA?.\(8[_.$0C[C$)T[QBEO\XAC/N,8WSO&.>_SC( ^YR/Y'3O*2F_SD*$^Y
MRE?.\I:[_.4PC[G,9T[SFMO\YCC/N<YWSO.>^_SG0 ^ZT(=.]*(;_>A(3[K2
ME\[TICO]Z5"/NG)<D8I6I,(56+\ZUEUA]5:T@NNL" 4KQG[ULE/=ZE1/>]53
M,?:QIQWK9&^[V<O>"E:HW15M?WLJ]FYWL^==ZWOG^]_Q+O>]WYWN;!\\W%F1
M>,8?WNIM[SOAR6YXR5]=\8&W_.3U'OC'-U[RBV_\W,\^^K5'_NV$%_WC-8]Y
MOM^]]8)W^^4+7WK2GU[KJ9>[YV\_><97_O6RS[KK_1Y\JG=^[I!7?.[)[OG=
M*S_NS$<^ZXN?>>"#/O"?3WODC_[O_.(OW_'(S_[L*7]YZW.>[>8'//<1S_NR
MPZ+CBL#!#N9/__KOX ;TOP$/G,!_)SS!__WW?P(8@/SW?_UW@ @(@ 8(@ BX
M@ F8@ [X@!'X@ 7(@ PX@10X@!5H@128@1T(@1^H@1?X@0<H@@.X@ :(@1)H
M@1.H@BL8@B1(@"BX@3%H@C08@R6(@S<(@C/(@3 X@S;H@QT8A#FH@RZX@T/(
M@DCH@3UXA$EHA#](@$+X!$_ !(C@<7T@ S:PA390 S70A5OXA5\X XT@$+&0
M$&=8$6G($VLX$6VH$V\8$7%HAA8QAS=AAPZ!AS6AAPQAAWRX$'\H$X&(AD(Q
MB"3G!?XSP(6*N(@S4 A2]XB0&!=4D(B+J(@S\ 61F(F:Z!2QL 246(DS4 6R
M8(B;6(JF"!.I$ 2?R(4UX 2D>(JP&(LC 0HYL(@U< 2M((NZN(LRP0A?&(8\
M$ J\.(S$6!*%D(@U@ .,4(S,V(P>L0<R, .'X(S46(T7405B8(W:N(T/\8K<
M^(W@&([B.([D6([F>([HF([JN([LV([N^([P&(^+!'"O81F6,1AMN!V @16*
M08_@L1OAL1( )Y#XQH_]1E:] 6\(.1CW")#SL1L*N9 .^9 2F1;XIAT""9$5
MZ8_RV)$<TV[^YI$BN1R\@P9QX!Z.$ =V4 =V( >D@ EP(/XAEP 'WB$'?F0'
M=E ND&"3.%D@ Q$)<% REP8'TV8*)R.4D1 '<X *24D'..F2KR '<X"3<Y '
MI#"5<X"5EQ );O 3<8 '*6$*<L GK[ L;: ;!,$T:B ALW"33FD'WS$+>8 &
M:R"4,RF4E$"3)325WV&43DD'C@ 4EA '=."4$?0*<# D-P0)*C*7;>"38AE0
M.B,'+!F8D4*85)D=?L22>=!">: &:B"4(QF/CO   #   /  V0$"X0(  0
M;0 ' -  :.%<:G ) F   +";"2 +(=": 8  \Y,6%   %Y42(: L!2%! >!F
M&2   V ))'":NPF;ES  R;*;#OX@FP%P& ( FR<  (YPG020(I$  #U#"AD0
M .QY % V"R<P .PY .%C&_*YFP3 )B(0  0 G>BC!@  &;+0 @# ([( !_PY
M))& G:XY !@@"\Z5+*\) I8  !=P8 !0,Z2  >&R:6-QG@\:'K^)F@$P 5L"
MH!(*  044:\I *KIF_SI2V@PFO"X"A)  ,$%H(AC CCZ"*1F"G"@%ZS1!@#
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M<0'V*A".0  9, L2L #,*@@", %N4 FE !1M$ "]&@E8.OX6Q!,"&;!+6TH
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M/I%P-P!0"2@@ &;@M,9!I+$I !PP &IPM(_B1P5"5QB0)YTK"W00 "OP"AM
M %MBKEYTAI,P "O@ 14@ 230OIC0OF60!WNSI7F[:G. 301UN>))"@,@ I+
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M P$'T"FO/)X ,#ND\ "R0Q8"<  DD $'8+^4/"X@\&';HOY8%2VOC[H:^Z,
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M*!(>IH\!0'F6)U &%N#Z(C4"'OY 9F31 O($ GYA!^OM 49. CX1 B  _2L
MZ?!S G @ 91 "ARP[I3 LI2\O.%C"1YP_H9Z(WH//R00YFM  B1@1K+ \7:@
M 81O^ !10I:L2B1FM>"PH84L1RO.;+!# 8*+2"IDY=' P8,E6;-DO6J0I^-
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M$@B\(N, 1V8Q@2P,*"#%E G4B"2 (BZ)I(&YU*"@E :D8J$$4B2X1!8U:&+
MJQ&8\T@2$V640)8,.$2% C)DH8 .ABB810,)['A%A84LB> 52R# B@([(AD
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MC@L91TLH@C:XA+FXA#. @X64"4=X25)LQZEP 94$QIZ0"5,0"6-DB-68 S/
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MI- *M= +Q= ,U= -Y= .]= /!=$%.<_)_$X1W<_4!,_#\<X,/5$":5'CJ,\
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M!#.H,!0P/?X K%)( U;E"3KUUQYY49Z@ &FMT8C5N3^)M(&=55_E6,.A!#.
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M>"?E*OZ6(R8+(6Z!%E   GH >:J$U=/A,*4[,T !O*&#*PXH65B#U]&UA?$
M$%"#"3B#-GR).* K"D@!.! =1V@ #R !3@D90_E2$5"JK:.C=^)C;:'8OZ(C
M.,##$WB A7"!PN, EZE"G5H\%\B6$[  3%H 9*2OZP@6#"@"-6" 7'P%"E !
M.LZ#61CB%FB-/WD %!#B^K *>4*#+/L 8LF#!" !,J  S4-3/:!D61@!B.(
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M["EM.EH#8K$$59*KM(JG/%"#+N1@.R"!$Y" ,RBLE]BN5D)9"A@!Z)8%.C
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M8 ,M"($J0&F;#'P+BK(P@05 T (+F8)ZM6D>0<1XPA6$(!)GV%-!6/!(SVE
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M:0<9@D LLRA"!S:P/$>TH&2OD$,,SS !G9:"!!](D"S:4 053 "7]HEA&29
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MW)]]V&, ML$UM@"0^4P(*$A",/ZC,Q9'1$:'&O1+#A$$!41"7%Y"Z)D"*5S
MC+B$0ZX6&1#,*U@ 0%V #:XD7>2!&AB &^ 8#1X@C>SES_1+_)!E'+P"6@(
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MC!H(,$!.6,!3M@ 9Y($(J.Q+E ($-,2.@@M#AD2ZYH4=/( 9M( +J,%IH09
MW1L9R($*U-O)R<="OH0)H,Q2"/YLNVYIESY<OUS" W $&&+%4[) &<P!3.FM
MV+8 RBP?]X1MXUE"!1P@5?DK0="!"$" ![C4_ZU%'%  968*"Z# U'Q &Y1
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M^$0$G, :;,!6SYL">$#Z4< <]/X,KFCA0JS A\X'4 ^+36@ !V1U P"( IA
M0LZ'' " @JP !;1!")A,0:R  IR "BS Q]TU+7[E?.B!8%QO4D1<!M2G); -
MU9A  ^0!*2A "<R"B:!!"S2 )6#" ]!U \#!3#*T'#B &K0 T^;!Z:A _H7
M>%B""'_H:9R 1$[U//7F6HB  B#U!C" #:K MH3 ]GZM&WR.!9BRN(J !K@!
M"1@ I::);02*?7R$"E0 8H]'!4CI ^C64U*" 9! &VP 0EPR7?N*(]!CJS2
M"L#!!:B!2 2548, ""BU6-RU4&<+'+B !*B 53-/ YB!&4R J(GH C@V U@(
M"F!.#/X^0!FTP0@$2FJ0@0,Q[I.MP(2K  ,@!Y8$]5MH+O-<]E-6 @*,0!O$
M'D"W-G"+S>E80)Z&0$U#0!FL@0@$RFC?7@.4@L4V7N#-PE+6#,TL=F.;>&37
M91-1=C:A,&8/Z1K7)Z $]B\Y@&B3]O;0=FI;0B?8N .XP5HL^&8#"*;,00/4
M-@.0Z^E(AY< "I9(0!F8 0/,A&Z[06++PGD31 I(P#Q1@"L]I$\G.I&YP0H$
M\))F$QQ$NAW0U"LP.F=B9U*8 AQ@0L&UAAF0027D 569@AJ<02E$@AV(,4%0
M I24PJ=;@J@71"3$01S @1RT@24(ID*<1BF<07N$4QNLP/Y#DCHZY@%M?8LC
MY 0JT,%-V<$*:$:-1 (9N$"GUTJC@W1.F((1'8BV)Y-8O (>7$6VPR7S0'LD
MN( 9-$:I_'K9"9S/H3L!&Y&S0WM7^/K\F0*Y.WL9B*O/U3H<Q(%..;L;T%29
M3#H<&"M-S0(<:(XC(-L104EWX HIR#L+0+L>9/NV6T*'1@(+N(%(N?JOEP)R
M]OI:M8K]@'2DPX$=F)5M6/H8Q4%2E (<3+QY5+PE+!V-2#NUK_K\L7JKF(%F
MV$$D0((IJ'K9D:S/3;N[5SH+/*1HMX:Q@\O$S\^SB]2ZM[H1B7S+TW6F5,*&
M@_M,.(+^Q;JKNT <OD*L@SM>0?["M"-GI5][-F&\SU5"MS//E*!]W+<&N3N"
MN1NN.MM[0F@]\WQ[K+/@&<2[M]O& 3K")01[P=A!Q6?*TP=6"^Q[M3J;HF>^
MYM\7?+W"H&U^CO16)&C;94T867V^["PXZ(M7>ZW!DZT^['?;MJU=K=6:;)%6
M:.W9MG&;[?-6D>C^<?E^G4&;[1._;['<:K&:;$G:\@__[QO_V#V7?S%_[0O_
M[B/7[1^_L/WB2^0^H?%TTUG_[)-"_X$=8^G^I[E=[2=74'D_@''7; E8]G<;
M\,N^]:._H<6^_N\___>_>ID^0,@2.)!@08,'$294N)!A0X</(4:4.)%B18L7
M,6;4N/Z1H\19%3_*"MF19$F0)E&F3!AR9,26*@V^W"AS(DV8-W'FU+F39T^?
M/X$&%3J4:%&C1Y$F5;J4:452*TR)E$KPXYE( F7.:IFUX$=*9+#&G'HIJE1(
M)4BDG3-P*]N'6=O.@3-5JDU+9<-2==O5*]BN>_]* MOB*J57>O.NU/NJ15FM
M?P6^JH0XYM:6ARF5T3NR+<%8 LU0HM1"UBL5*$RI<"S6X*L2>?Y*_MCB45BO
MFA.+M-GR$@@U _/XS4TW]T?."E^.+'5)5B07E(<WE3Z=>O6:LB@=*+60PMSC
M%^U(<,CA]\ V"=JT.9/ .^"2'U606-B2PQKB$L-3S$_FZOX#2O<I,H4!4B!S
MRQ$);,)/O(LFL,,2TM:0@!13&GM+%CD, .&@ P7B3Z_\$D1.EA!(B.HS-1;L
MJ+.#/BI#PT>$*]"Z&6FLT<9*&BA%,DO*L&,@/,P@98.U3&E##0)?H:3(-O":
MPPQ)1)*DE#7:.$R64L[ PPX,!'*D1X$N(<41#RW!  7F/FJ#RX_4P* 44BCQ
M$94VT+!$%E*NDL62/9DK+9*12%%##>9,J<02,WP4*!(R*FD!!:J<O$I,@?8D
MY0(5"#42R4A>F>.22DI1HTJ! AU4EBT+PN/+YLKB],HL4;WDE3PD4".J2]!@
M4B1.X=BNH%+[?,6--BR9@$!<=?XM])(SZ! )13M>F66.,QPIZ!4XS+AJ%DI"
M'?7.,^Q -3)NU<!#ECS.(% 64]Q H\]3RR"%@[5D)<$#2V:YY#-+SH##RDK.
M< .O@<C#($\E\W"D#0F@G7#=-M*P4UQ^_16HDEP'E@79J"RQH(7M/G+# HTO
M\3)/:<NH5B!(RJ#CHS#C5!;<@2Y)0]=7>-U.51]?(6$#3ON\1-2H"CTT41N1
M3EIIHBIAX!4]$CB!C ? .H$",D1@((]7*%B!C DJ><4!$%H @8+#0 AAC>YF
M82 $,C#@ +L'5%BA @UD(>."-CAXM 4'6F!! 4?L:  #.<P;6:"RSYA@ S),
MH4!J"/[R6(4!1V;Q3TV!YJ!@($H>.*/Q61-(86JPWH# A1,>("VD$-2F0(Y7
M+L^<< <PF"-RK\%^Y8$/-L@C A#*B%L624(_X^P\*B"HA WD>%R6!D62(!)2
M'D#!;KPM@$,-!CR@1'@R4)A 1P@^P("2EB1Q0'0*MLL !!<X>, 46LF?P!0]
M&"#A:Q-> 8('G. 5*  !'!Y@!JF\H@(G@,,$\M"V$!3/ [*H!-U60($-#,04
M#@A!"R80 A2(  *S( 4%4$ &"/@(!10H@P@&IX<*5*("$CB#@/8G 32<( /8
MH8 :4@"!@5FB 3UC@4 VH $-J,$$#2!@[EXQ :DU(!*.\/X<'B:PPPU28@)K
M0$$$HO*1\)"/ J:8PP,PT!XW>,X%@%N! F # @^@00)@(0,%T."!"GY- ]3J
MWQWE,\;RG0\$&+A$"C(0/3-<@@(2:,,<Q#/&$TR ="FDVM(PF4E-JJ02"WB%
M(QYP&#E@@(A1*44"'($"TLA"#1I20*(PX(8Y<*DY$BB% ZI%BB**8)4L,*3]
M1 *!9<E-%B@X@2P\T(:PP$$!)B !"!1 B3-(X# A4(% \C.'#9S@.:: P']\
M(Q7""00#>8A$$64QAY%1CIPKD$H;\(8="*23 R<H@D"2.:+GL-*5<Q%0+HL(
MB41=P)R>PXJN[. Y"YAK%A2P!/X)CBB+%G@N \V2P']6*! 5E$ 6"IC+)1I@
MIX^,4Q8$A0,M[:" R"5*!2J@1 (()*!*<%$@#_ 1*6#S$5(H4Q8KN.;E[N0T
M7BZN>0(Q10.J50:#1B 2*+BF+.A@ ="9$I56E,491+"N")"B K!!IBP-B@=U
MM2BK>#!H!C@J"T@8M)PI>"H<T."(YD$0GV 52![4)0N&"60%6<VG>3S7 F+:
MTPY%I<0)*.$ 7UG #B@ZC!X4$%,J6J!9LHA/1^?R"H1Z#JNGXM)>+8N"2(0R
MG47=Y&E1FUH+-6U6BK.#!^+0P\- SP,<0(L'-F *6W[$!2KXV@E$0(()1(("
M,8U *?X8>U</% ZX)X" 'LSP*%FPX)@>^$U(WO" ., !#LQ9@70IX%5OV@F:
M4BD!&69A2[:T000G0*HC7)L![)F"MX^"C^1&0(((3 ::(;&N+"S@@=OF%@*=
M6)=Z2P$! K&AO>\UJ,508((-;/ "/FIH)#!@KG.-+'>R@ "H@"D+/%S =TAR
MA)4$PE[W0D(%1YR%*2Q *_J>*GA<FFT<+$'-4T&  B3(Z[E(<((ZSD+!6D6N
MAO- 2ZT2Z SRD44Y,Y H&+M@@X?10$%E88807&D"!R+!"$Y@ 7>&  )I+(@%
M/%8" U2KP[*PXF$P8 <-\ R;&2A% TC07C&/" (9F NE0OYL5F1>-\6>\RE?
MR< "%W\$#K*=;@O.<,Q3.=H#*[# C/-@@5<4V8(H>![>M#SI^6+SRHH;L6I1
MG6I52X6UF<;F<A7W9#MT@ VON,0I3.%-=:F@!5C+5ZX3C(EU";'-<^A 'B:P
MBDN\2:*2IBXR>9JF"[B%!=*U .+N5$1*=* #:>@2!]CK/ Y,Y@-Y@$11Y6R*
M!_CJT/ AP:\)) D]>EL6'U F!:I$%EQ+@%#"''8!-S 9#Y@SUI9@@+\<T<,*
M,'0"DA@2-D>6@3KHU1*O:("Z8DMD QND!.-&IAY6)Y!2#'>K H$#!^0ZD I;
MPG.SB!8E5( @DS^@6F8X8I&]:?Z*-MLAUKIE3F<![ @._)F1FQ-(C-=ZU:R.
M/!(0B(0I2%&*7-_)#@Y0YD=&:R0X;("CAUM94>,,6U)%(@\94$4#) %U7$>K
M%%7G:2D>H"XYC,S>NI%%&P(K7:^1P021B80<3$N",^P0X@/)@!HHT*>3OJ+D
M34,XESJ;;@>H"PX>@*] 3KUJS6\>DY5(P*PF@,T*6'SB=@B (]Y@@8]XK:.D
M(<4"'(&CR<0A!$>-J=.*5YH-J%X"<;"@IEN0UA7(9P,L&$D;0F^<GO:=E6>3
M!0FV/ '=,0 2(B%AM4)B@3-@!P%VX-"I0J\!=UI" =?$^@/L%(<*2O^?LMB
M.]6@^OZ>HO?BZZK_476NP.QX7SP?R0,#/B*(9"$#2&,.!F!9;&P#/*<"UJ(!
MUB($.,H4ND@6&,# 3*%B/D+[L., ZB 2&$#87*  7B&X9 $5)@ .*($ ?,0.
M/.F<E@VIF@.=IJO*&JAM" 7W$O#!CHHY7$0@NNR!#N/+VJ993,\1.*0'\:^]
M=,]+*@B9GN,P3""K_"\!GLSWW,P![(0"[  (D8D%. 0$'N45-F!,FM #GN,C
M('!=?LC]RB/%(L"RF*^E2($!KD)YTDN9(F$!2,$%G,P1"H (G88$."J*E*D!
MF./_ G">S(!+["#T0*#O)! .OB^A.*\2+7%&+B$#9B$2MO[,S;:,>3! !4(
M-EK  C"@]G9' 17H0BI@ S* 4SA@.TRA Z*"! *L!?HN$C)@ S#@#60!#?PB
M#<!B#B#@ZM*I$P="& <";C @J]J ^> @JWYQGL+"$3#  \@ #4:Q#[?,$C;@
M H)L^T(B#BR %RW!#20-#K:,&.VC%#.@]EXA%M?% V31 W & SZ #-( !/+
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M94MV9#^692769E,V9DEV9C6V9_YI5F=A%F>#=B,B@0 ,  "8E@K)   T1 X
M( ,N@0  P  .P&H#$@ *   "  !"P!*4]FL)H(*2M@!\)!( 8(,$@@( X ,B
MXP$,0$!-;@ (0 ^0" "JQ104P !6@00"P&H'P&!D80T X R>=@ .P "^-A(J
M00("('*'BY4"8&D#X !6Z54U=W,M8A(.@+'H8 [J(!9B 0,&  XLP #^ PZT
MR0!:  XB 0X"@ 3P@ Y@-SLN8 [H@ , P U((0$28&0HH0 JU!$0@ $6P$ZB
MB % IB! ( $.X*E 8 #V]@&<Y@0&H 7L '#% PX 8)'@8#VZ!PXP@0(&P P
M9@#$P_X-9G<+(8  HG4C&"$+MB +[+=^[3=_MZ!^]Y<*L( + !B MR" !9B
MN6" "1B!#SB %5B!"SB!&3B"'UB"*7B"(=B %QB#';B".=B".7B#09B"&]B
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M9&&R/65M-:8!!, #3"$!'L -O,< P"@"PIJNEWJR58"[/   XL . "![+
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M-$NU0XD""@1^!K@ X3'>2F.!"@1^WN<4%HS@E:,@XTE>2D-A"3K>X^<T%&[
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MEL^RM)"!!FW(8LH*;6Q0P<MNMJ!!!J/KC88%&E2R'24'<*#92RW@ 0#NS0V
M@2D0 %J  @70(9A&L@"IA\T;F$(*D#5><D #E#C8P &EJ!!SOQ8.(,<K=31
M0"ERD);\9FG1[ +I?%^"0 .0/&;  T8;D"+U#DB25_:FQ & ,L@"%1-00"4L
M,(%+R,(1!- 9V!X(P0A*<(+>,9?9&."(2S3. J](P ?R8/X*"Y1A%G9H "DP
MX 99Y&$"IF" *4@0@E?D(0&)L4 *\V"!65 @3BV@D'LJ0(99X,%39C  'EXQ
M KE,X YJ4 #<)@"=!)A"!1XH3@1D= #BN*$!FI&."4" "DM P Z1 -\L3-"@
M[)31  E(P  ,X!L1 $!++*'$^4QPB4M4Q .48,M.2 6'AAC@ ->BP.+>$H #
M6.   8!."# D)T(!X ",) "R%&*&2P# @:22PV@.,,@ 9" A C# !&*R'P=M
MLD)J"( !%BD -"0$ "S8208 P#8 *  ## C &B@(S& *<YC$W,EWDE*)!50
M Q7P 'D<<#T[3( G)#@#'!!T OXRR$("D9"  I?G@D@X(!*"H 0#YD "#]CA
M7SO!PS1W(@(TH($$8^(BW<QP*1693 *2B(!;FK.!64! @<);G"D>\,TW>, 1
M%=B)'2RPG4Z<  4H.$$+OA0=-W@@ RFX7AM"L"U1J8 %E3 !LE0( A":0 4H
M4,$;5N&3/(@  R((T4>OYY,VK!0%9 BI(T!@AQ>>]*=YB$3@3J""$D!'A23
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M%"20& ?3'(YU?2L0":Q%**-S"1 P"QOP,GF0 7C 6C?6'"1P ACD"*EE!QI
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M"+(@"EBP!5W !510"+" !8FP$XU !5)0"%HQG*8I"X,0!M:!"%0 !0?ZF(,
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ME*1 @4$0FG"#&[0B%##@ RM>H!M9B&*OHL !#]B*@S[&( KU>0$,D_4%FL)
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M8@I+L$$?4H&#O[#"!U&H@56/[>8:V%P6.(=SS)E \UB$H@: "8)"P]:*'L0
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M#_D 8H4(/  5&L$ $9@ 2. 8C?Z1A60= 0PH!8Z9@&@U 0W@@%TU!63-  N
M Q"0@(8Y@70-@5<P!0Y8 0]X@#,PA0QH@ X@A1;8 ! 8UY!@@0T@ 0S A%=
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M3VYEV6F75.[>_L0,#R#C7!%BRSR%^W4#"3"#2/  /' $'HF(#I@#(]F43<&
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M&,OXC/7A=Z((8$$:L04O>,)\3VF%^JCGP BQ;PN%6% K!H$%/D3O98>0!2+
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M(SG)B?7D1&[E 1"\@G'YG< 95V"*.,P6=)Z3Q03R0 82'$0%*KB$ BQ!BA!
MH!(-H)PI&&"*/#P@$J6@P!D<48%(,,#,(6C *S 0Q5L500*8, 4&VH")!.#!
M%,]\11D,$(E*)&!:&+"R'!YP6OXPOZ(!D=AJ,B=]94NS ,RR4 &8/1 "4VB
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M1J2LQQ0P0:7PP"*HGXCTP0T8@8G\AJ>(B@S,WZDD"0[@B$'\@*JD% *JH/1
MU@JZX M21A_(0+D,3BH$@0P<P0W<@-FDA0ZH#=O(0LW #<[\@=S4C=0@C4%0
M00S@"-_4  [, .#$0,38!@Q:(=;,UU900AM,DBSH >7<2BE W%9 PE@]Q"SD
M 1<541RXP!J8(42\@E8AA)Q=81V"1R9XP1:HS@E9T![\CB)L$"(L1B%X4.R,
M BST@>V4D HEA")<S_ XSQ^XD"P<PA]88A] GAUJHI!DW^;) BD\P ETX0-0
M@*[(0>/,@@#"WBMX0%EE !T06?Y".$( J-*M5 ($9  +>  #C*%#E,($C)4'
M@ L%_-DF&N,Q(J,5NDI4F((;'80-[0H'-,#!R<(<5!99P5;I_%!;H8*VO,+'
M04#+$=$L5$(V8HL)G$ &F*$$N$"VP!.S,,0WRD)4#5D&V,$KE%4RZB-%,-1&
MK=1$J11 =A1+.=0^&B1FQ%U%W$H;6( '6$!:84 #<  F(,0%P,$##-D<"%4I
M>  '8( JA<#EK)(=Y($%D( %>%8/A1@+,( %1(()>-8'@  &U$I"V-4ED%>R
M,  1'40IZ,HKZ)0LM,$&'$0)M$$(D (*M*0CA  )B, $'-5!2N544J61:1Y%
MZ($#P/Z6'7B.(TP 3\["!%B"&C3.'"33!J3;&;6!&JP3*)+"/54C0F& !5S"
M+$#8D%% 'LB!4,V""8!+MC254"+4&5366+J!'73A!I!."<R6:TD"!/B7!&Q:
MJI7<757E96)F9AY6)T8$"@S7K5A 'E@"E27$! S9!*A!'F! 5)GA'&0 *4#
M5L'2*^2!&H# AOE9$<G8&=F!;(6 &KSA07C /<%! I@"0SYCR!% RRVDQY&
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M-9[ @:&5$Y$ SI'""JR 5U)DTW)NYQK*N%)$5*%!)&! +R5 CZT GSF" 9R
M''A ;XU6Z+2!!,B!C)*"(S" '>"!6$%" IS '(  46) '<B"!;A S%&5RDX
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M+$A<J%X"<JV!'90 RJE!!GC ).#8D$&"!VP 0"=$'!0<"<"6ALE!*<BU'9R
M([2C,K';0:V +HT:5_.0([# )%%"EIZ!"T3"*W!6!O@80N1!QJF!&<S!RTE.
M!D@8"YS"5;MV5<?L52B:TN(LA1SM:^-V;A>**8]GR94 LP+8<*%>O!+WR8I>
MZVD+0Y4>ZQD6PW(>[-VV;DNWRX+N=%OW=1\@ 2ODT!8@=GOW=U<2/H/W>)/W
MJU%Q1$29$C\NM#C"OYI"+U*2)8"+')9W?0>P=D]$EIK!"/[(E4.0P@2$LD/8
M 95%]U4TMTR-V@G,@H,1MWT[>,OR]D+8000@1!&LTSCN"A&90F'U5SYF"Q[
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M<%WG LC*BE)[@7%R2S.Q!MRB&9Y!3AO^]%?END?$"4" "9   TQ8" C5*R@
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M*24$#/ZJE(6,FCB5*-5*/23C U=SLD2.3CN2I0WZO$/5 [)J36J6!^QP[P0
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M@*IDN,@:;)('"9Q3MB!8&0/J8(<()*T O)S "F;!2'<.ZP%GB 0&'!*2E%G
M%"IX0!EF08$Y=.(!:(@#&&6! 0K @0P)> 4:])K-&\I"#%E!BD0BT8#4L:HF
MW@I*!S @"5+ P0!S^DVX*O.5X<PB#B"8  ,VZX%$RH(-X#3#3[EI%L:DA 0M
MFL4D9(&&%IGBG<?K8BEE<8:?GH$#/VR *68*8>6:Z@$.:L,27T&0E'" !;*
M@"E@+ M8I#4E(% #' HK"U*@] PML@.*'40&$D0B A*Q U53$HD'Z*I=Z_2+
M1$*P60? 014->$4(R" 9"9 " OZDF,4$++%"65SBR68P[P<6L@(6F"(!!7%-
MAKH(!ZHB,B5G $%[Z1,L.7;Y(1(P!01F08:?J@0%ZZR,""1,&D,%YA(.B(6A
M4Z(",K@AQ+* A +>BV-4D< 19'5$!IRLJP=((@W9G)%9Z@("0*]A Y9P@*X@
MH <,+.05L>&+!5!9(O+*9L04 ,T&WH A-/2X$@QX2 8^<*P.'%@-'$"SKLA
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M!#A @<@JO-: !2! 92:@RQ2 M*1+E3"@!=9O(1 @!.0@!,BJ#/0*XLC HL[
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M 241""B+'!ZLP->2KQ0AI0=K1,=!'@_(L88<_HFI0ATHRC+!L<*^FH>BLIS
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M "7*_)2J$":+")02 \Y!E:H^T"M2I(\"X2$!4+:9 %G$CU?1Z9Y%$**&4JC
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M]![1.^AA>8! "U8 @<6/_O6PC[WL*W8QG689-B=2@&YKK ('Z!8"'&#!!S!
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MKX!O=E"4G3!$EM$"MQ*3=GF7>.F2%:D>* !.YY45*2 "#&"5&S ")V !G-<
M$\ &+,  &U$)$J!4;(("%Q!^<" 'BCD'J$,Z4X(C&6"8B/[I" ]P B=01LL"
M ESQ)61@ 66AFJPY%#&E,CBB$B!E( _P"BR& H(95@U  ;7TF8=I"MDB*)=
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M:.K,B@T:)LZ!26>#YX<$C<XJDO6!S3,5956(9"8H!ZL60*Q8 6(#G RW96T
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MH0V^4=P7LR6'!RBV!"MPPP1,0107''%_'T2H6'6[VR4&D$G!>ED+:B*6,V3
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M   44 $$ $ &6:@A *CV0 ":1@D#&"!;LNF[)4Q @ &\! T#($!%'J" 28!
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M_),%S:,X2BB F(&#N3,% HB92! [#>3 N@. (H"/T8 $'/0..@" $[@$ _"
M X #-4@ #BB 2SB!!<@ ZVJ #5" BHB !7 L$L"_S9E![R"! J" #+".L"$
M"<" "\" \?F_-X3#O3BE.#0+'70 #8PF@K $R*N @1-!$GRF66" >X+ ,X@Z
M71&^^S,^22!"4D  E?J]6L% #," /)0%0Y27U'($ 0 7HLB# " !2QB $S@>
M#\B $A@ *52 %E" ,T@ ,D" BI  +E1$&)J$,"0($C" ,@P9-%3#-71#.A3&
M84R2@?[@'L/(K5%)QA52F-4C@%\Z"! 8N@$XF5< -]O3"0)@)5\A 3 " !9T
M0;<S/DH@PE92  Q( +!A1/LS"#H(@'5YA18 . 6   <S1#(@A0 0K@1  #-0
M@0"00@2X P=P  BX P-X/UI\01<D"$:$QH7<1GLY1&*DR(HT"+*R2%E("0IH
M@YRRBCD   \P"@-0C5D\@XZ,EAJD (E[  !P!$<   N ,08(O[9C/H) /FAL
M P-(@.F:A 2@ #98 S4HN! <@!:8!!4 @(<@ 0 @@8!C  .X!$L0 #+( P,X
M $A0@0' !!0P $O@  $0 4L@@/=C ,<B/I+!#;[[):(H ?X"6 &4)"@!"(&.
M1(-!RLB\]#_?TB!F1(A94 .Z:T#5\TNRF!_B&;G#F1^"FX4\H+C#9!QL),S!
MX!<# (     $H 0&& !C48.81(6?PTS,9 @7L,P , #NFH43((  "( #"">B
MP#V*BP2>(XA+4(  \*+*Q$P .  '6[;1I "O,(46Q$P&J)/:/(%5.  %D 41
M (!+<#MVRSU, (!!:0 #<"S<.QN"J,WBD(46'   $(#?J\'37$J]5,_^:['#
M( HX>  \6,83$HQ2^ #)/ A36 !\RD2Z>(37N(MCY M<.JY(@ 1*((4I(0H"
M#9P"-5#3D8,XV"KOG ,[F%"6ROX#!\.E]:H51]#0EXR$$ TOQLD#-\@#Q8P$
M.)@#Q\*E*H&$DJ@$1W@%2Q"$HLC05]"#*HD$1\ -2] #;-S0@HA1$?504\@#
M$84$YEG/)26W<ZN+5SB%5Z ##FU,:0HI:=&L7%F].1B?4IB%RL$<2Y FN>+0
M2I"#];*D2+#2FM*H@HB$%<W/HC"%2X!3B,B#4I" D-@;2I"#("J%.>!168@#
M":@$HB %.5 3B"JGHK"#B$R5^6322)74V@E L["E$A@!" #"5^" $"@;'+6
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M@L*&4K+09/C@0:^C"QA4A/#:(D.&H:9$D,&@(8\("2J .E;,>,,#.*8R//#
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5KN-V90N'-0W)69QW7 NJ9%I    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>cogo_0026.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0026.gif
M1TE&.#EA=@%\ ?<   0! 0X)"PH&!Q$-#A,/$!82$QD5%AL7&!X9&R$='B,?
M("8B(RDE)BLG*"TJ*S$M+C,O,#4R,SDU-CTZ.CHW.$ ]/@ M<P R=P V>0 \
M?0D]?0 E;@ :9T(_0 ) ?PM!?T5"0TA%1DU+2TI'2%!.3E)/4%124UU;7%E6
M5V!>7F%?8&1B8VUK;&AF9W%N;W1S<WQ[?'EW=W%O<(!^?@!"@0I%@PA+B11,
MAQQ3C =9F090CRA;D258CS=FF"YAE0%=K =EI@!DLP!LMP!ON0!WO IVO -Y
MO0Q[O@9RM1-]OAI^ORE^N4)NG4IRGTMUHE5[I@%\P11_P(!_@!B OUR"JV6&
MK&>+LGB6N&V1MAR#P16!P2*%PBR+Q2>)Q#.-Q3:/QSN1QC61R3N4RCN4R4.6
MRD29S4R;S$25R%2=RUJ>S5"?T%NAS%2BT5NETU^HU&2ESFNISVBGSF2IU6NM
MUFNNUW.LT7>OTW2RV7RTV&ZPV(6#A(R+C(B'AY23E)N;FYF7EY"/CX*<NY^?
MH(RCO:2CI*NKK*>GJ*ZOL+2TM+N[O+>WN*^OL*"?GXJEPY:LQ9RRS(2UU(2[
MW8FYUY2]UYB_UZ>WR[R_P:B\THV_X)W!V+[ PZ/$VJS(V[?+V[W1WX[!X)C&
MXZ3-YJC.YZS1Z+35ZKS:[;G7Z\/$Q,O,S<?(R<W/T,+-VL[0T<?3W-'3U-77
MV-?9VMK<W=C7U]#/S\74X,W9XL/=[LK7X]3<X]S?X-3>Z=[AX]SD[,OB\<?@
M\-/F\]OK]=;H].3EYNCGY^OHY^7GZ.?HZ>OKZ^CGZ//MZ?COZO3Q[>/L].WO
M\>_P\>;Q^.OT^>3P]_/T]/3W^?;Y^_____CW]^#?W\"_OP
M
M
M                     "'Y!       (?\+26UA9V5-86=I8VL-9V%M;6$]
M,"XT-30U-0 L     '8!? $ "/X JPD<2+"@P8,($RI<R+"APX<0(TJ<2+&B
MQ8L8,VK<R+&CQX\@0XH<2;*DR9,H4ZI<R;*ERY<P8\J<2;.FS9LX<^K<R;.G
MSY] @PH=2K2HT:-(DRI=RK2ITZ=0HTJ=2K6JU:M0K6F5)LV9LV-@P1H36ZS8
MV&-GPW*5IM4:UK=P@VZ5!K:8L+O"=N'=R[>OWUQ[[18[UNP86[=Q$RL^.1>M
M7;]\'T.>3'GR8,.(%VO>+''K,<F50XL>+1IS9LZH.5NC>XRTZ\J@7T/6*VSP
MX=2XKUK[*IOTL,"]@_LEK#6W\:6KB0E?WCOV:V3#FYT^3IVG5K"0G3/O^WN[
MY>"8J_Z+KZG5F&SM=P7O[=Z;/7#9[E^''T]?Y>K6WO/#]JV_KS&V]048TGW?
M+1??9 >BA]>!HS'(W'_3"2CA1'2!YF!_HRG8GX;" 3CAAPU9@U9P%YZ'X8D(
MAG9,A""V2!>*KI58F8QX00?C:Q"V"**(''I'(W,]HDBCABOJ&*"(!?;G7I!^
M_?@>9?$YYR1XTAA9G30V^N@7DS\R>>.7>(%E)6[2@+E=;%/V)>5=:9+F)67'
MC*G99TDN^*2:9JYWIW!OQLBF;$7*J9LS>18*7WX<_M9G9<ZP*&A391IJIXF3
MOK9HDR6VF=UH<3[Z5*1*XM4GFI)N62ISG7J:%);I94C9I?[][:*7K++>-2MM
MPN2"*XJPBMI@7U6J6A22I\8:)C+)))NL,LHHZ^RRS"9+3#+$#&-M7MCN"J:7
M/08K[$_$SHAAEDP^1ELQQ! 3[6^YU.)))YM0(@DD=M3Q1AQII(&&OFW  8<=
M=D B22:<>-(*+L(8XRPQR-BE[:]XMHKB+L8X^FU-^!6[7U_I2BN,NY1 $H<9
M8&P111%$$#&$RD.TS++++<<L\\I$)!%%%V>D4<<DG+22RS#**E>JIGA)=S%.
MUB0*Y9\GTC9MLKO<L@DD;X"1Q1$ONYSRUD9T[?778(>]]=9"#%&V$4EP848=
ME'B"R[3I"@WFA=T>35.XHKW9*_ZV3PMS"R5PG+%%$3*G'+818X^-N.&)-\XU
M$8B+W;(00M3L11J2=)*+ND(_G+>>)&9GL=TG@<K>WG[VI9>RN70"B1E;&!&S
MX5X[;OOCM^?N.-B0OYP$&'-L4LLPRLBM\62IDIZ2->89&)QS>BF<C#"NGQ&%
MRI5#7KONW.N^>/?:=\VU^"P7X<4;F[Q=_/'9>:M\2:"R'R:UM4R2QA0LTP[^
M_OPW_CWNN]N>RHYP!CNLHAC)*H;G++4<&R7O?2"Q1GL@%AJ]3&L8K; #& @W
M!"1 #@J*"^'B_@<^$HX-A+8SX>U46#N7=>$-G,A%LERC(45U"((@(=2&(E,9
M"RIC&/Z>J ,75$:[_ZF0>T=D7/]2N,00$C$*:=A$+IH%HS<]$(<7P=NI=H&L
M9&1PB-E+8O_$R,3<D=&)2D0BXEJF!!@"S1@+-).B1H=%A\2/.WQAT-Z2A0M)
MG($(V>O=_DAXQA5ZSXR,*Z0AD0"%-0ZA"W:@1;*&$<<3Q>:*=7Q(QE*WG60,
M@Q-IB$+9M.<_0QX2C4TL90G36$95#L$(9Z#$+M8'.G'9DC(5RR1$DH8A)DVK
MCUX@(OD0F4I!MI)_A#2E*@>)N+)%H0ZWH-;QZ*A+@=S14--J11R2T#(!)HZ%
MQUQE,<?YS52"L(-HX 2R^)(E,&&RF@,Y!JZ(%AK0K(X8G/Y @S 5R<IR$I.<
M2!SC$DG82")^@1+"F-X$>P.=0,&3(.V\Y1Z'<0DPN(R?_APD^% HT(RB4IE-
M[%K+EB")A&*K4L*QX9;<5\UKFFEZD_ "S3 *T)J.DZ:J+&0+E0 )&=[E&@P,
M#DOKJ,,\K6X8E.A"Y3CJT:VA,(DX-:8X,TK39"X3IT8X9Q0@L0M/2NJ=RL,/
MZGPU&6I=@@LSM6D_U9I*J()TJFILIA)*JM"@GH>:JHIHBNI)F6EQ0J:D+.89
M,:I(Q$6!#%EH7!&LBLS=L55\CYP$T"I)J2WA54[6T"M?SY.,59R!9N%L;%,=
M!]K;,35R0Q!#-8*!A!%^X1FF*/YG5$,KV&9^@1/2?-YKABHL"7[N4MU)!B[>
M(+NLCK:M_&LD&:YG1,:M;)BR,\,TIB&&5T)A"*"HQB_&USL5'D&,9)RMXF1'
M!#-$4S3TY(LS[.;2B"W'DY+@IE3G&U#Q$@$*)T,"%ZK1AE>.C68KXT(7OCF$
M-@##%Z 0 A20D(5G]*(7*X,"Y2CWO=I%@1EJ&,)WR6E?D1:A#EU-*7KODHR+
MM7=<R>@$8&<;WM#*C@[,D!T4@DG$K<TA#$(H S" P8Q27,]P0Y #,/#PC*X%
M(1*] ,4O7BD$-9#"%', ;<R$T(5JX!@8HQ ""UOLV']"=@N7H-8")=,EY EK
MDS7"4/XR<I$&T0(0H(L5Z7ZYH 0BD,$,4;"%&5Z9A6J (0K5H,,0\EP*+4-.
M"'-XQA:J4897/D,.H?"%RO!0#3S, 1BDZ!T>?F&+,IBA&J)D QM>Z4W:OOF4
M3E79&6JA##Z1!JP@0C-D:'0A9!"#$DJH7%5#^LW( 9)R1(A"=J-!BB", AA!
MZ,62A_#I(7RB%S^X;ABJ@=:N"8$.T$AV*(*@AFH8@12E"$*5O_"#( R!&F8P
M=C7L< =,!V/00TR9V8R9A7@'U*9"2 (DT@6F7<!:0K(^D7#-H&O&?A2-!E_K
M$+80B5'<P0A1B 0T,$$X;!-AOV$X\B^"0(IGV$+9P0!&H_ZM?8=G!($.TQ!"
M*;;=BV+?H1J@P,0=I!N)*F><RM4P11#D .J5A:$-:#UT*9[A7S?S>@A?:$6K
MMS6F@.^I-\F@!#>CRN53"S(+C38#,T"!!VI$8@A!$$6AB5"&:F0A"+:P11!*
M 0IC ^,+8;A:T8T@A$@ 8PA:F(89GO&%(/QB%$'XQ#/H\(E0E,(6;8@$T1LY
MA*T'0<E"B$(IIN&+9XP"9<$. WT/7E/$%<$._-YK XWD=*(Y1[AHT/5Q;3I,
M78?=%T&HQAV"\(,[0,-L)4?9HLL@A&EW(1AR" (;0!V$($3A%S(5*2C>/012
M$'MEO]CV'*A1?"$$@7"CL,40%OY+A&?,(0C :#LIH"'**$"C[5VX0\K":%^!
M(KT5==7MJRZ;&WDN-#3)V(02BFYTJY<29FTP"LTT"J) !)%0!$E ![] #4I%
M!CU7!-,@:$-0"J30"T,T!*/@=9  #;%E.$( "I)68-6P9T0 #=N6!- @"B?3
M;LX&#)6S<%9F!-7 !H!&<%%P<L@6"=50! R'/=W59?Z'4T4@"0KE)6E2#/2'
M&LWC/'ZQ"]7R!L_U5E*X>2NC!GC0:%6&"91#"J%@?9<6"E[ #'(@!%K :$%
M!-%7.=,6#%PC!T\F!VD4!3]V!&&P.&V@>4/ !;_ #-$0#6S0>[)7!%W@"]0
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M3[Q6!). D\SA'K:9&R?&B:[2%\H@"6MUB?-57+ZV,MGH@ !Y7;T0;J, #4E
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M1MSO'=0:S#U#D G&O!P@O!+)O"C$8%'87=:@JU%"P 6FH!#-(.6I?MBNSMB
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M,A #F@#2A[  ?& ),N  K* )!_X@ @2O"16@"=#@#!$ "+O@"@W@![F@" 2
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M@A#00!AAX&M9)!3/"@@0 A1$( %]R 4J=M$'!-1L*TO<UQ_?UCVM] $5BC"
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MZ<K4T2UG@\)QY, D*$J)L+J!6A355$Q95#)5>"IF$,9Y4:@+BCR"R )/U$?
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M.( 2>/Z(:WB !!  0*@&&!B NY[R!,"&:N@# 4!N!A   '!O:RB! *#R :
MSE&$ B" NS8  1"!:D $ 1@ "&@  )B :D@$!)CR :CJJ)Z! 5B !X!S)T_O
MB'"! E" !$#T1" QE=[?-*X&>!9M+ZR62Z!Q+'QDIHED3SC:DG00VW.L^AV>
M5SA"UCGN!7" $B"!!D!T$Y"&5"" CXB%1&B $;>&"DCT8W@!%V !+ ^ !'"!
M:^@#N]YU$C" !3 $88@ !2B :\"& F" X9X %I"&",AK/E $QP8 6=@#/S^
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MV%/=Q6,CT(+1?8C)VEYX!*PC-X#T3@5P'P!$X .KE@%4. 5LZ"%8D 99( 1
M6 $&8( !. 43>.H_2(53*/Y$</L!8  ^D 41.  #2'D"N&K;AOD*> A"6($4
M2(4](( ,O] FG_C_LZ,"0(1J^ -G3X 'B.NEN885KY^6!H@D1(P0*6B0H,&$
M!1$F9#A0(<2%!>$HVR7L(D9APRYNO%@L(\9J(D=6^P@2I,F3Q78EFS0DXD.8
M,ATJI%FP"\EJUEZYZNGS)]"@/U4)RVGT*-*<*0P@(*'3V@0% _ZX&I"@PBQ7
M+%*HD/X5P4&%8]5&)!B0BE& !"JN*4J!8L:L! DF5!OV8(&!6:<*)! Q\IB#
M! CZG'I0   J0 4,P*A&+()<62-1%%CP($:+!0L21""6]#-HD<)4"2UMVM4K
M:R2I:9D)TZ9,B0T3"H&3+&/*D[HOJLYY;#=PD"V'P*XYV_7KA4:&A,FY\S1T
MGZ]8%0UM?:1J$P(&A!A988" %]5B!"!0H(   (U? !BP0 *" !*D61,Q8$"!
M 0 "(++&@$ "#"1@@ $"H)+(=A6(I-HBYYUWP  K5 .# .%5<\P"^;DRTBP+
MX!? =@@8()]8UYE8S6@\0<=*=$9U01Q$Q1T7FW$U";'&;?[!Y<911KV1M&-P
M&)FTBS*2P)@<C3,F28008C@7'8NNL,+BE#U-B0HKJ)1XHG5ZB"!"8R)Y*8(>
M(AE20@0/F(#(@GV$X,![+%RS(!\@/$#!"K.(=$H($DA "!\BC'#*+"*0($-.
MIZ#P50=\J.;'EW]<F ())<2BDTC7Q! """3TD0@)*( @J8]<)G5,E$*I&%U/
MI5;S14PU+KDD;$8(D48R%@49G*LH[BJ,2;FQ!,F1LT8D8ZP'+5>&<ZHY^ZPU
MT4H;K33T65MMM;V:NNU(RTASU#'':)M,K]^>N,R6IFK++6C'J#*E*O&2]NZ4
MK,B+I;WTULN*JU\4BYP1R,Y*4/[ 1)B1XZ^[];H;D+LI0RP4LBHI6VRU%L0L
MNQEK?)2/I:[[V<>@4;/Q@B2#-LU%O_WVZS47[?)R+KNX&L9# B,4L,4,V3S$
MP;HF?-)1OW9TTK#)3FQLC#0M9X;)JS7]--112SVU=6*\A#36RLT6L! '_ZRP
M45][Y-&P,")K\=$S#<$&U28[6W+;F,8]-]V?E6'T0&@?1_!!RB8M!!H(-[SK
MPE\+^_"_ DN,]VM"J%$WU"%#/CGE7+I:QK]).J0XXP7W+#9(A8..43)&RF@3
MYV?;^KAOQA@3[C'.A"N[,]+$+DTSSNCN+;;9;IP,(HH(KP@BJ9@;]3"+*()-
MY<U3C?ZYS5DOKMP0@>LV-(]@YS0Z1BR9+CWGQP8\!,;8[7L^^NGOJV7&JITB
MP'D$&G#  WT8)3E2I2ZR'03.AR9,"E(@ _Q9YVUPTQ@9,H><8TT/=3S+%?=X
M8Y3!Z09(I2N6SF*$M((99WSE6]"J6&4:5J2+6ZA(@&8.<!X%)$  +FA:M*J!
M" -<Y8#^PTXU9$&  3Q@8\= S2M@\8HA#A$61CQB$(T8BR7"8HE+=)47DK4Y
MZ1U-9T/ D<]&=Q0*8@\EPF#))(1PMK3-1&D+&<(8GB3"TTRG.AE+Q0$VLP(]
MN$! #!@ FWKS"E3,2238PLX?JX&,6<SB>(C@BX)&<HU9N/ZQ&M;2"2HDLR!K
MF$L6>A))+-A'$F*@PA7'B]8R1&+)WKA"+A2@3\:$T4DK^20KJ6)15JQ4+RGQ
M*R?^RN#TJ$BQ@5PQ1Q0,4J]^&2264$*!&S0:SM36G-6L<46-Y!8<,Y0*D;B"
M 1E"@4@048$!*2 %<S(!!!JP")&@  (.,)X+&C _"3 BFP4X0"+YI  #*$ $
MTZQ&"AXP@3Y4  $(0 $RJK$'!CS@#RPX@ % ((L8"(8!A?!C#!CPS@CX022
M8( #^B"#!-"ODYH)T +V(#=3"2-5S0S**XP2Q?#UC7$NI0D4AO &"'HQ85N,
MH#"2L8F7X+*E V,I%XP2PI/^A/XZ&XNF 1(1PQ?PI7^),$\"* "A"5A##_=I
M00XY^@!KG$  !H   PPP@(HV**K5P(8!^ (9ON@)!.XI0 !H*( 45&,&5EF
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MK@AZ*N@%:4'!(D+0PC+-&(4S.$$".EW5 QR@,4@^935(P-%$$$,N#.B#'RI
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ML=1X[UDRZT@LZOC*[]YDY7S6)PJ;BC$,W]4"L28C8F\*P3+1\.ZJW1M+\L:
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MYCRZASW!&#@*DGI/F'K,!"Z+"/[#UD/.)%8)E%Q#$.T""R2 !"A #"A"!+!
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M@V(?BESJ6+"HSRSGQ0J?D'$+F/$1O-1TT1#*\ R..*,^_67F?32#"CKB(IF
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MF0;%0C:]3_X*<R!+%?>1FLBE=E1E'Y7.IKWBHTO4#"PT$0$)P( \%! !+!A
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M+HN^@D,)+N$KK&$_>DU6D*5VZB,5#*%B5&$$*  %5B "2OX V!) !0I!&%X
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M.U-S4(C!#(8,3:.23=D5!/,3 SR "1R!&;AI5:Q!&AI681*&7/\$57BA$7H
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..RWC&-*ZQC6^\HH   #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>cogo_0005.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0005.gif
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M\
M
M
M
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M!X42BD^ZIA3*)PB]\DEM!<'RR:X$A4*;D@44L,= ?JQ%4"Z@B&)21;E\@NM
M<;S'0D&Q5#L20;:&4B2R5X%B;IX%^4(?+UFVQT8NH6"B00'(R=%1*)Z\6Y"P
M_OJD[D\$O0(*K^NZYMT!NNEZ$D&B@$+L53L11%X!(L22"PN=,L#+)ARXN<
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M@)(=I T! ( '!I*!YK!A508H  D&8H?R** 7< AA!TC8G#;P8@'_\8V'"H
M!_0$#_X4^H!^G :UJAGQB$A,8D/:0 "R;8LGM=G#<@@0(?^L 6T+(, "'!"
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M I ^+-$F-'$432#T *% <0;JL(D6]R(CF^C4 70(!^8\$(">\E"E1OB!\C2
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M0#:Q@LK=$I#JFJ)5X2VM$EDJQA;L(28L)[J.-\<!G%W.7/Z*=3VM"20/Y3F
MW((F.K)5<Q,;L#>S_3U!CS\3%@LST_8(<.\:$\ J '3U1<A4 #]PH%,=]Z0
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MFNW'PFW:K#W<RXW*R5W(R%W<P_[=V]!=W9@=VM*MW,;=V=E-$$^0U[1M Z-
MW(U=CH$@ WH=V3-0!N7=WJIR"T(PVX<] X[@WB+;!?+MUS-P!?;=WS52@:W
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M05*"ET VMK%K3N.%"C*P"2E1I T'4,$*%'"U"#R$;+S(@-$*\J@/4(L7';@
M"0K4QP_8(0YO$($H,J 2.#2  BF(GQM+DX;&K211M>*%1E8"BS[!87I-B94(
MZ%.6"2A$?K@R 0,L@"H4F&"06HO%"@I4-EAH 'N*@04''/Z0 =V]H0$E" $)
M&J")/&#@9;[@&@0PH$L"#$19'EB#51[ "Q)0H 0B  $$-O.0G:G D9#AQ030
M"0%<<49<$-&$ CX""SG<X4IWL-M#2I &/UR ('?P)T(< """P$$$)+!++AC
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M2!P0=(%.U"H#KL0O>E5 )!%D$B)XB$ $'O &.5@1$Q?PE5;XD+<^Z.<#%L"
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MR9(<1]\Z)3=4 ,OP@U]#C8(L0S#L!1;8B.-21524A05XB8<0DTRLB"3Z0E%
M  #IA5<X ,B90P4H$3;8IH.DB#/$2).4RJFDRA11 =92%EA8@!*)!03 "EM2
M+.Y* PRX *2$A1&H'*TP)6_A@(-0 3CH@ @0I+YS$YV BH9JN]6ZB!+8LDV
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M&6T*3WB (22)+J3(93J;&P$!5-D HT&! 4D2:54!-8 %?/XB"$>EJQ%(HY7
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M("F8"$F(N'B)#T:0@>?@A4"0@4* #B&P 4; P"/0@5UHA)S&&"%PA'N1B!6
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M3B7*B;A9H=&$/H  %OB0I@ \W_ME##@7"+@#)9WCZW4RFU" 'X$ 6R(!!?
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M!D**+XSB%H0-!"$FD9%'C($0@"#$&$RA"C$0(A""H 1X'%&&UJ*6%+H8PR
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MV  (,.:.%LS]GB;/H@>$T$@)!C>0";3&GZ]8P!S\X(>)\:(/#\ ;0FC 3GC
M!X"""GR 6]74!9@ )O@!'&B*2\7&!6#"'OC!CF!)!J# )GS J&#*1,B)"F1
M)J1!&?YYP@%P@-[YG0JN($X!G@TD$GB00L"-69.97@T$G<OA#M.5@@S(&>#Q
M!W>0@1 ,09@1F0SXRB7Q@ WTPA4L&@SD@+C)@!!80;CP@,'A"@P\(2^H@@Q$
M@17,@")(A^<17Y@-@B,LVNGD!Q  P1C( "$X@0W V/#-CO$Y@2(!00WT0AC
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M5,(]K"L5:BCA"EU0E88R^ (^AQ>(>LE@%(9$A2+.B-95T$L(& 6$2GG!"AT
MX0:+>X@AH5:0&2!A$((XA"X, 0/\Z*(2J=@%$&P@AC)P8088XX$.;O"$6=1
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M&&X4B0("$H[0A8\8=5M0Y 473#8&>]M@%9"[12G$8$6FR* ,B_!=>EQAW(:
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M4,&*/@(FUJ-46J$'8H 5S*A4]@8&;# &&&%=# :Z>,$,3/Z&1)I %7B+%VY
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MC%0B5F$FOJ 5L$I-"D$*I" VYN6M'")8N)1%9X$2ND#*!/Y!9 JA3&5"H\9
M4'E!$KI@%"SU,PB!#%1J$J[@"<2 (%!!#":5#&2T#'A@R@:5(F9-.NOT*+4
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M&DE>Q%9F;BQD1G<7QDML![V*_,D'CD (JJ#QB&PGV\:&DO[ NJ_$J+XWA6
MS*CH71B,LVC9GQ;!?U9-N8>73FSL"?QH]D*)CT@A!6WE!\I@G4"1C!IB"7B@
M?S#I".2:MW:G"V3 7"0!!C:U!IU,@\"#(<" Q5K<(40J676**-RDAFS@"'!<
MQZF](6A!!<VN(=[)/ZA$L)J !][JJ&2 %41;"FS %'S@"72 .9S\47#-36CA
M?]P$A/Z<.2B)EKFH=)\-T_+NRV/G"X9 "HC@"J*@!G@90^R(>&R @BE:9,8@
M!BBA.I@#%>S&H/YK#&)GN7Y29@ZB"J0S="_KM-Q$%\!(I4#Q2N;K"GP "X;@
MUAI.!FA:"VY@#! =2$3=TLO55/ZD&9NF42%$QK:.0+:UP(:#MQ)4/CL:+J]:
M&34$H0F<1-8;2=:9[57$C"!^Z1;6)1( "82(0\GV(JI 0@:.P S @ >,9,5;
M7+";JB$<(0;P(]?*)&BK?>XK(MY_I\F8X.?&Z:UW( JF8 C:2T]6(;<%X09D
M/A!L@-U_#LK]0]X; H2D( PT@Y+BPBNR/71]V[M[HVB.T**SICK(]#H<(;NP
M;A*$$2BD.U*;D*E\P*CZIL*'*,9*I<O_]0J88!7$^W1]SED'00@J0;T35HOF
MZZ>O:SY&P7P@0>ILH!(2B@=/"^=?JK\=@M>]V$ULB\"35R:<]=8 P7P6AT1(
MX1%:E?XU".LC*ES6KX4'4MR)F,I'*?%=6A#I[G'#X#-4P?[B8& 2'HK%D_DA
MQ&S0 *(1##&\"O+:)<3&+(,,&SI\"#&BQ(D4*UJ\B#&CQHT<+2:94:G@F"&J
MQL 85)"2#":[;$A1-&-&&9.S"LF(=*0&CU(VGO"*(H.42!B,&-ZZ\<.@E* ,
M!YWL"#6J1C$PDBRR D,)+T<R>@PJ@V,&JU8R $F2H9!)#5Y79$ABN,N'#2M<
MHCP2*(CLD2Y=F,@H-$M&%%Z2:LP(PXMJ$D58M?ZP,<6*9%92*ULN.$E&#D%C
M9LB@54D&CT& ;LP0"N3(+!TR'A5R,4H2C$F 8!PY>H37X_Z%O K! ,20E."#
MO+BLY&(ERJA',I!(EB+HLO3I!F?1D#'FT1,8CV;-N!%(S(P<O,:\2/*(T PA
MNWBIDM&D8,(KR&?$=R+CELE'O*K,J,$*<TSP-80,E:AT!!A7W"!#*V7 ($DI
M,@B!G!6L^+5*00*!0=Q!CU%&78@BCDABB94U$D,/A7RAF2ZM&%9&(3VTQHM+
M+\HPBDFM^$9*&# \X9U/4<0@5'E$=4B+#4D5%,4,44@6A2J*R'#$%5:\9&*6
M$(%1@PPS,,%;(0S*X,,DO A7QBTVQ-?$#6S=U.$N0]@04PS9P5#((#$L4E I
M,TBAR@Q5%-060;N(T25\E"5D6/Y,J&@)*2^-\" #F6;RP@AK9/+'BQ!#\/+$
M#+3X%MMLPGW!2P[Q#7$#;X;$0$B'KCAI4!<ST$E##(I,\EU,,D@1:; /3>)#
MI8<5)&:E0+RERQ6)_C!*0:W8=^:O!<DY0RNAZN<6+ZWH4,,J6LA02D&,R$ &
M);W.P$.L8L0@227KGM9D*P5!(H.AU[+*F[#^_@MPP(.,*421DA0KPPV%\'*4
M3ZP>*@,K-KD2"0R$W/(G+TL5.88,B1AUPQ#M]7?K#-=%DDC)76H1L(FS5-+*
MR 7=0@HJ,K.B"R^SW,(P+;SH,HO,,\]BRRVV[+(+SK<$35PM0>]\+=0%V5*)
M*@;9LO[SSK:T/*(NI)"2LT%>@WUU+0PO!/1!0>\"-=2W^%P0T&%7Q_/0MA2]
M]BRT&$W+W%QKN4LJE?3+<"JJ",W***GX#37;=9^MR](_,WTV+U@;Q#8N;&L]
M\M+MZ?VVSY+'/8O?9PO]=^JJKYX1S:D(O<O7C^]=>=I (\TT[:-/CKK49Q?]
M-NY[+VTZZ\8?CWSRRB__$.K,/P]]]*L[+WWUS3M$O?7:3Y3]]MY?>_WWXH]/
M?OGFGX]^^NJOSW[[[K__?/;=MS<R[)A+5#]<X-_?(?S^L^^\ .*O(:C+7_\.
M>$"94:][_VN@ Q\(P0A*<((4K* %+QB558CA"5>@A$%N0?X(*4QA$>UAQ1>Z
M\);>=($@C-""&'+6BC!T(1*)$<,LQ-"%+^CP"I.@Q!7 H,,O@ $7@ A#$,&P
MBT7D4(A=*!(&GQBLJW"*%X3@@M4.-09>!&*)@\!%4ZYP13$0Y&>%D((4"L&S
M6^"P$051XA=T(0DK'.X+8N#9++10E(($X@I"H806@*C#,-PBCM$B3'+$ *)!
M7"$5!QG#&*$(R4@:KQ0,8M ,^#2+(<#@!C>( ;"$(P.?W()2-. %%F!@(%X
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MS* 0@N)%:LM EBM(Z[SIA9!)]-D>XJJ""3N6P2&.L-$2JYG$\72"04CAV(2
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MOEP0:3 !O0RY+OT!$  "<)P!)I !#5#5N9"O&O !#>H!*^  FSJA:KW'" #
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M*.NL?I"X.@^^;9 "KIT)$9P&(4"HF)#FR4/$;&  P.L0(] &/,\!=Q ';-P
MTOL'+\\!!7X!D/WEL? !U\P+&G '5?X&:B 'W!X+J%T'\DNH%X#0U4[(+NSR
M!3'WO) )/J\ I^ )+\\&;ZP)U7T\&H#5/1[E#=H'([T'B+ "0,L&@>VNJ@O+
M@5H'0EZVQMH 8)H'06T0;EJR!0$'4]P'[/SR<L#&[LO#%,S$!E[J#K$&#4NG
M'W"P'_[@T0:^!WC@ '&@!G!0 )L@ FL=P U;$!' "7O L76@L.'\!C-?OA*
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M@!H&DA7\M($ $V"B TKGAP5\@ 1KI-8#4#"!M8'  EF\"&&\Y@D\B$T@KZ!
M!T  Q\&@+25[,$RB%J"!"3A@6/YUP%,=!**&" Q% S;[$=]*(@*6S?$N>%B
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M(1>L 85WU'"Z.XS !,F>N+,LX#L*V#PERYY( YP*"S6   X]H9D'PE4C$;
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M6($#H)@(F( 1\ 0VP(!-: .RL ]B"0#36 $1B!]/< .J@?Y -B@!/U" GH@
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M (IA, >P93QY@PG@@*^@#3,C@3N UH#NDI"U/E_1@!2X@'<V,HDH 07@  Z
M  T@W XY@* 6ZP, E <8EE> @%Q A+98 >S) #.[ /@$@"6E6XG(IG$^8:9+
MG9#5 /Y;6A0/F#<-, VJ 4?4^$H., T%R-30Q2 +6+3**D(U2(S/A)')4 "M
M$ 4$H-X+$)0[4($#8+WX8(,X<X!9)@! $4D">0"2> .6>8#G7#)9<(!Z66>G
M30F-AC4>C9VCGH#(@("02*!0X(-*E .4 &L$HHU%\1&'@@.KY,4X0 !UMH#>
M'H@^F(L(R 0\6)L)R(1>( #3L)U*Z84(2.8-(*#[X ,NR8,?(;R!X("5C6,%
M,1<*R(1,( #Q4 .!.-\Y$@&1Q8.PF3>5D(,(V 0_0 1,8( _P(0%H(,VJ ,$
MP(.P6 &;2  V>(,ZH( 2X(2>HUL\:( ]P ,^*($!L> $QOX$/]"$+&8 -8 #
M#TD,JG$#.5F -*#Q]9@.[G5; +E@.M $'6X)%0@*"X#/-6['7>4V"%C1=LG(
M?G6H-_ ]8I$#%E" 3]"4(6F(5W@ (_&$&5V 'Y>R2W8#/A!>*"^)NX%B/(@
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M$YD S@3$50<.B$ #Q11!/4=P._X4E& @FOBQ"%39M"G"P@)Y_D@'ZK")O4
M%F45RLY>H=<+7"D"I0O.J[&:"3PL8 0? /%U'U*":X'MOVP: 1L\@+ % "87
M$<@%)A;,(<U9+D:8RR;70,& 7*AY(LSEA0>:DCN/0"<-F>:%$4QLJSI8@ -Q
M48.H#ZBY7!&%#Q?PEHWWVMLUA( 7<2AF+\ JF]X4>;'M4P Y&0OINA1@CA_)
M %0.;<X)U-,"".-<1TIP L'% @-OL)<GKKT@?;?9.5C)!0N*/.<)R-4/=EA
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M'*C!3X4$)K !')#?0T;E1[Q! 'R=F_"!SZ0)*!3 !6Q !B" ;:'$ZU' "62
M NP,O'"%'U#-7Z9C'QQ 4,#" <A-'BC UT <G04 >$1 '<S!6(5$&OP>/1+D
M!2! "Y'$!\SC2&C  OR$;AX0FZ# 8(R  E019'6)8"W*'2B !YA  T"+2*@
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M3E0$2@ I>B%?ZL $!&4%G@)'T?ZE#O S).H/%B!B$]!%?;Z42/Y&15CQ4$0
M!(1B#02C%PH&$^9B$^+%/CY FE!@0G)4YA@G).#  R@4%N1 )>C&*2)R#E+
M$]9@(M( %& !!!C'=1(B#C2  TS )1P(!.AI+N+@R6"!0U'@ V1"[$:5UU:@
M#ZCK:@0'43KJ]^"SHC2$ PI"*&3!;U+4=JR43V73<*"42*:2G]S 0\7/M3Y@
M+NB1A>X&556 #QJ&3G$B3H52(!JS)X<4/WBA#4P@6WO!:@)/!%8 2L!P PJ&
M#LPI!$" .>6 4MP /P\I.S3$<$BQ+TA #M:)#42!3E1"!42 (AL2/U\!G*;B
M%48@!/XX("1(3@54 !,X491XX5]T P2ZC0TV(0[>+A%[P6"8!@]0[@0^(#2
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MXQ<C'/<BW%=9W#<33H1^=[=_Y9=^>?=_^_=S>]!UE>43WF!T\?=]-9>!S7>
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M%):J#YX&*E\B!("-/QKFP<F-FS/!!([P M: #=@@$VZP&,EM#O9@J=K"@]Y
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M*#"%ISMK>$F<2+&BQ8L8,VK<R+&CQX\@0XH<2;*DR9,H4ZI<R;*ERY<4 P(
!.P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>cogo_0027.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0027.gif
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M\O7Z_/____3W^?#O[P
M
M
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MN-#0<L !^<:X  &;W!! OP.1,$ + I5)@ S)_ OG,XD0H$ M7&5BP &S\'*
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MZF )J,!6D%$! 3@@!AW@32V,02H0QN@  ""!(FAPO5^(K '0^)X"P/,,9$A
M 0@ WD!&@  9ID ^"C"&PCXX$!D$0 $Q:,$!4):W6^E%%+?J&*EN\ Q&#,
M*8@! @!P F))\ISH3.=)H&$!!D#@G1(X@2,&P@,$3,"3S_[@P1H):+04*"
M![  *$0% 02$:BNSL, !7@<!23P#!PJ0@">Y,+H2#(26!I@G6$9 @!*L0  &
M@$ GC':P)(Z&!PT(P  >D,3P,$ !#J7%2T$1C0<@0'#=7)< &$ #<ZKSIT -
M*D:B$0UD(",9ASL-,@X'C:62IA>SX)% G%H07LRB%C!JZN&2\0M/"HH$"%A
MT0A" @*HX!FVF(5VIHJ,M0[D&+2@15*-VA6Z/J.H8/DC+8XAU+[Z]:]-@0$
M#!  G!*D @!@'V 7R]C&8L6GI6&$"F#@EX+L( 6&=0AD'<O9SGKVLZ -K6A'
M2]K2FO:TJ$VM:E?+VM:Z]K6PC?ZM;&=+V]K:]K:XS:UN=\O;WOKVM\ -KG"'
M2]SB&O>XR$VN<I?+W.8Z][G0C:YTITO=ZEKWNMC-KG:WR]WN>O>[X VO>,=+
MWO+>9[/F02^9S,O>X28C!1T0'$)'D(*QBB87&N**"MA4GXKT@@0E2 8T6N
MZ!F#%FU,2"\>,%#]%/6VO"#!"/88VUZ4X 0G*,&%3S""U7&6E;<BWS,\\4S[
M&J1<!*#%,Y(Q3KRI5S1;R87SC-$,0E4B9 #0I$"@4I!*((  #;Z/)$H  0=8
M(!#XQ,@**%">OXJL  U(*D%>S%A:O$X M[M,+&M#91\:HP&C>]R(0VKBT$ C
M.F*K1?[N!D(LXIQ1(+EHSHAJ@;=G% ( ,5"(,6PUT"ZGA08#&  "=C6 $D@9
M(;,1#00 <&.&^!E9_&F !0B0+S-_);3($,4L0-&?&&Q:JL1RJV:GS+(LNI,
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M0H466HTS #@E#$Q3-,GP  ?@<NIA1H-@ %>C:A.@'9G@?<\0"M"2 K20#)Y
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M F+#-:48GFJ!,PJP;<) -A#P*I$R$+^P&8TR JKXAR9$+R.2"V!48PJ BL;
M"]%@/0I0'0ZZ)8PP-#@"#<W@ M.X%3,P 'A" 0PP+L<P&3&@")HG3)X5)@%0
M>A&46+,D:,A ;Q#@14Z4#"I4BB= .A,P8BN%3\@P 8FI""I <RWZ%L80AT&6
M @O0I-&0 H1E 3^  !;(/ ]0(,\P 0@ 03= *'_88'WD2C=@ '!B";OB)R6
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MP' ^SI"TF #SA)_\RD_XB&#XP?Z]U&3^_&A.!&  [?F1#,&@3)1/^9;?[M%
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M&3SN.TP_+_53PLG_V*MMDLVN1#,F5]I0HR '(813(=6:P/Z 0C$Y.JJ]#,#
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MN&<@)6"[;L5."%C5$C==V$50Z0$=^($L,.SH)0)I4>;S16['J%A,U3^W3FS
M&$*T1F?]05LQ"65F'N=I<89I)E.&.M&[*9[Z=,SA'B@*,<46GHY=+5(_Q4F;
MKF7?)5J>CF]^;44B[DD6TX6E-4H2TH$=$ $(->9?RV0K@88_PUJ'Q.*8=))&
MMI1B2&.Z5>=+BC()5H\A,%_-Y=^UC-N+9F/K6Z@VJ(,Q:,E0S-MBYEOIF(4R
MQ&-]ANW8KFN\UN/99D56Q$=>F![S(Y)DZ(4MF,,B(._TL.03!Y3HM-9EYL''
MSEXMCOX5T,6P!]\[KK)FP*N0S9;D)6B%M\81S?)8)^LR[T9)C@*M^@2E'Y^<
M]MB:Z4"%,JQM]_;AFZ;MPLUKWR3<W>X16^04HT2$&^""_S[J0KNJV7N&5C!R
MID[P[*5C6 'MDU:LT/9R1\SJ!\L7)6!JQ4 "4OZ526HR(O1B-WC5,6/KMNY2
MZ1A#]AY2]Y;M%;?KG:9O015:47BS'SF&9;B$'MASTX[>/DR3/YQT07RNPG:?
M[<7R YD;-G8T-UC5(>+R W0#-DBD2%L;%MUUQ(B")X!1+A["Z:9F<[T;X['A
M14I1&T3OW5 &&+]GP[7IVB;U5!_2?^V$52QB5HIU6[B!0/YPV#Y7<@W'@^KU
ML4&OFJ>&9R&;R0_A[C@%(N*+\*>:<+7Q "IG:L)[;K]P\!KU8FZ*2^'Y=*HR
MFO8@J=T8AK]=[QC'8V!%=]L6^;Q&A932%*\0AO@B[#[W@&.&E5PS&&;$T$)W
M'\-V:T!AACG8+#4.V8D?W?Y!FVYNP OW+6S=KXT%%- %^JM6 XZJ89=_%OQZ
M>%_PV=W5Z2#N!" &WKSN2U]5=Q[&[37SD6%P+?]^8FERY0\PG30I\&A';N9N
M[AQ^^*FHGS-P S<@#8.@(@=9=I^'UU#=2#H93XP @3&&^\18@F*0[#\0VP[G
M9 <1@T; "?'.5.N^+>G8U9S<9?Y4[V/_1/7?_?ATEW,0--AA8 9-P(&6=WD/
M6&@TJ5:8X_=+)7,QN55YMI178&PID((R\'TS, ._FX,Y: /BQW8C6K)S=O(D
M;&F;NN[$IZ'6K?NKH.PG;Y"/_52#@'K:K/TOS( MUHUZSDDU)WW15W%T[^'>
M77%_YH0C)2-DJ 4=4.36M]P_*0;UF7T$]_?R'*B*_A/S 0@H4)XL*?CD8!0H
M4J24.7/&C)LU;-I09&.1C<0V:S9*O.CQ(\B0(=?,<9+A@X>4*3, $>CR)<R8
M,F?2K DSRA)5SW;R[.GS)]"@0H<^NZ.FC<B/'4=6Q(A4Y-*D("FVD2-&T:)%
MC*YH4/[I]2O8L&+'DBWK54.09D37$K7%Z5.G3W)1P>W4Z>TG3GKQYHUK5V]>
MN7P#V[4;^"U@Q'7CZ@6%BQ<O7;I^"?LA @0(LYHW<P;;U>L'#*C8DBXMU-DS
M8$MLLF[M^O5+)9D[J\Q ^[99#$=,\^Z]<\^2A#4/'A08A6&9AA GMIG3AHZ;
MIU*G2UU#IPF&KR"$P.Y.\XGW):5\DS?-;,Y$ZNG56XS*/FE&-6^P(MKZ&?=*
M_+?OI_PPK#Q;G$"""2687(())IKL!9A<#<I56&%Y+;A@7X4IAM>%AB7&"2N0
MZ<*+,HJ(X,%L^IFH7VBG +AB4*\@(9QW,<($GHP"*7$BCOXH9D $BSWNA!IP
M,BJQQ$&K*83<0VY$1Q5%=;PGE1O79:?2!TQ(42.6X>WQ#&H^^EB,>T].IY&8
M\&F$E!B):,55B3FZ:59HNW@)5"6&((*((8L@LH@AC322%220- ())856@J F
MB5+H(*,12H@8I)'>U6 GGCRFRS">A/ FIYI]<,$H<_;XBI%9FBH3C31)H81M
MG;HJ%EK,B+IB'\&=*A!QJ2*GG))K,,DD1KZ2*5*438" $@A#W+JL34OT,>N*
MJ,F2AG1E5F<M5!NUH48<?VZ%09NOOOJIBM#N5,F>?F:U[KI[JJEG5GONN<B?
MB!1:*($%4I*H)IULLLE@C#H8U_ZC=W$"RH>WC"@NP_U=$(:YY;52ZDRI,GOK
MC0TSK %::D7<6QX67XRK$DI P<033!R9W$,0^4H'1734(1U''%UGVP="7-F:
MR,.]U+//-.&$Q\?EQ4)MM=A.I?14PE:5IGT:G\@?:*!R"2TTZ/[)+M==;\VN
MFG?&FP@BB9@M]M:,J&TH)8=J<LDE"DXJL%RS]%($U?JU*G5_&$Q2M&FHE6+K
MR(7'],3>?'.JP0?* $X::GE0;#BJN;JT4')EF '1DL!:AQT0*E->^-!7/PZY
M*]0RO3J4(ZT1AR+VA:NX?AR'!G'$E.39->^]9U5O(XA\[?N=[KK;"!EDITOO
MH(T86O[))9: 8L24M+OY*>ZGLV7*Y*-?+(40UB>N6=YG?7",]FRA0;CWKBVA
MA.68*\=Y24# B"70HR^!1Y?I#X5:ZI)F$0%>Q%>LHPX!*6*51UQA?&9QH/4\
M\ '&80 ,SX &UB"1B.'YKH._$]Z\/-C!K86P77<B6QQ6-01D1=!$&WB8_]8R
MN/:-+ I" $(+%]>X& YE?33$'Y$L=YR=_1!_-UE"'DS'PZ   FEB"I-'"#A
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M]Z1*@56B_IG%;-C>Z<06"BI"(XR!'(2?1VI+U*F=5-G$(*I6Y97C@*W&-&;
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MS,!;%KF%%(,/B,A"#%.8A5;=HRJ:5A4\NH@BV"T[#-6O)(6%(D]5*EW77XN
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M@ 2A] 0 8B ,!;!  9EXA@I^0+=G#(,4IR#%91_DBP,$8 (3":P ]%J100
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M856WK2+/.0%#11PQ@0-,@!&+40$"3 !+:%3@ - XA%A9=8D'($ 2SVC&#@
MBD2,&@*%2$$R&"%1 4ZA3@V9 E9@ ( )T" 3/KEK,T9;B61H%04'X(4%'C#3
M'? B 2,@P99)U M:-(,6*6B +Q(A@P'PX!(%2,8$>- "5;_M%./Z0 @P$ F
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M$'F)>$& ZD[D%M6%1M]/D(@3>((")] GT*1TB@M@Y@,72/)$>F& %DP !C>
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M-3N H0J0M@NJ8 \F1P:T"@<&P )D=&0!( 4D(0*RZU)8R@7$SZO 2JQFH*P
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M%C8OT"9 1.?C&!/2+FO*%W1KXV# &!" U$P-U::T3Y\!%NQE"?K@(BSA 0Y
M9-OEF!K +K?UM@A@O4Z  !;T1RX! A*@GJ(!V90MN!Y@$)[-$2A4/@DE_XA
M54^K$U[6)V J8 G@ 2*YKUJ  &Y@ A8 L.#2 C(! 'X@]GQ*JXR! "@@$ :@
M!?)3 63- )2++5+M&98, IJ!13\/ 3(!% ; $QA $$J %H3A4&&Y%<*B3I8
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M2NME XP 9%"_#5 !",'T!AP":@'R8J]WMP,:)  ")L+EP#!S(\LB-O  .M
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M!?IK!VCAUOSJRPL!Z"XA&BR !%CJG2IQ$TSN&0B-FB952AC!T2QA%D"!%@#
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MO,D$XFLM!!RBP"'/5. (IQIO?)X=::RQAAILD'K1)0;\8)($$/0BBB=R%8(
M9<*4R @ C#R3" "*X" #0@Y@?, S/)2P20D<3_M,,6FH 7(:@/#73 <1O%8@
M,@B<@/Z0( #,\@P7%*!UPPC'6'C## A-T$ H"#!@@)(X/%/ )BGL2:(S;2RM
M1AIMD'=1# & ,I<$!-#"R ] X5#))0P\< -A,:20R#.B!,!#("=LPN!%J*Y]
M"P4!'/##(0T\DT(,H)!0Z-&JKRX:'VJTT08;<RB#42\K*("K+0\\H"L!"I\
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MYX9F00 $P& 0-^B$ PA@"4LP0 '\Y-DS!. )2QQ@19LJ1AMR>H<V2"LC(S!
M<P84O;,TP $XJ84"-)HA:#A  (ZXQ ,,(!?[7<(BT8# +Q*A@&9$X&VH!(\S
MWJ &IOZIX0WK>48,", #1L!@ !! Q@@.,(MI'FL"#.C%]RX1#0N,P!,!Z Y)
M3TFA% !6<@+HV46X4(,'-H,1!JNI;VVHGN!V"1G+8%$,#$  !MQ,%((C@ 00
MN;!G!$(!$%   @20F>8RP!)>LL#,N-" !EB,8\+M4DZL52^,^,("!8$ =)]1
M NPVRC^U8&]R;R9= ]"M$%H2A@4B0 '?<*@8!"XP0LA340( @  68(@@ A
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MP3-1NBF&.0QB,I!8(A)@,0MD;-TD+WFAC6&(E"]B$ E$R @&( .&_"  T5P
MZJ Q @:@!$@VBL8#C&8!LQ7@$B-X*X>@P8B4&V(0C1!+M\9K"0MP]Q<T&,$/
MML*#2SCB$(XHA"=2P 5AX" %"3S$"5B N40$(A,IN$&XRZ,Y "B  ;>PP.=^
M4(C1E4Y))N^[WVN,\D4T8A&( !Q&>+$#(-Z@$MKJQ5(GX!.2@N+#<IQ1"C[Y
MC$HL@ (G^,$,9@&#.W>($HL0/"+P:Y&"Q<08PNA%,I+Q  ?@( $I2,8!%""
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M"9> 2\\P P' $+Q0 "T #23  S 0 X'@ JO" !$ "E@$#37@  O 1BFP #7
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M"8,07Y; BIA3 @U0"0,P"!!# C)@"15H "EA<^\!#5XJ S2  &,*"F7* S<
M Z0U/.-+P16L$>7KH* ::Z&#$*!0 "6 ,&3"JRIP7#(@" * ":PX%2B@OP/
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MT)!!M((,MD0DUXL,C) "%&  ,H"0!I\((T_6.3.G&;V_W8$,![#:X5("%2
M@V M(L&&,, (#T\#N,$(QA #@F !+3 !*1WP24]H:MX#.9 #-\#7&"$#-)<,
MD+P)$3 !26P)E] ,I#4!F\ JS'@#&;@5/=8 $N )GE )G;"BBE +"$ #VSX(
M^89F<)\S>Y("RTT 6C+6/ \ 7  *F5 )HG"&(F$+#-  <]X !'!GM1#Q I!Y
MUZCTDZ]GAA (@4 (@6 (8L&UX3,( ^"=Z30('X<GNVD"T #MHW@+ G!!R)<
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M> D=*I(&O9#!-,^3 JA%TZ"A9%<+DC&N4SY#!G-:VF>AH5)8XRH1R))!*%;
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*'5W2+5V@" @ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>cogo_0059.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0059.gif
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M^_____CW]P
M
M
M
M
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MAQ#@0 ()M'#* P-D, 0$C8XID 8!A)'(" &TR5D7AAA@P'NM3*#:G?N&*:!
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MC_E0P(4'!* I+0   AS0BC4 8($"40, 'F Y # @ 16@X@1,9 '&,*I1A I
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M@@HT(*&2$!K(($LW G#AL@1"^,* "B30 (,U2"!@E,M44/Y )C0@"4 %6,P
M0 XT +BM3UCB4.T2 -103X 38"DA@$AB8>""4DAHP(+R-I%  EA&(< $Z!K
M8(('WBA@T5/82X. -3/   T5 J@D%0,Z@(6V,C108$T-0##D@!!@>0. ,RH)
M8(4(CT66J%%*>" $#@R(I!78-*BD)ZTR2,. -TR8 *@DC+S!!K1@7 (56+
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MB 6$ 28HZ10-8 46  E $*"+1  H 98P $7P#30(:*"! "BX+WKU " !EA
M2*25W^,8G@,,)6E@ 5@J < $W2;H@*12(LE  1 2$ $6$@28@ &05@( 1*(4
M ,  +/Z.DX9*)" !$@! %T8!  W (C5B2 @ ^G<W#D:H!0" @ )L$A,#&,!U
MFMK4 RK1MP] 0$\_69$.:I )6 !A#S^!0B96 :X9:$$N,\"$3Z!@I-,5T8A,
MXH,DGD2PQO"D%&M8@\+64"U(>*$+D. )'+B '37P#0VK<0,<>+*&%J#!,G)0
M@U;>]X45N $6I5!#(MZ7AE%4@HYE"$ 9RO %4K2"CDY4@X<.H8926+!BAN#"
M&Q)!R#>XL16?,4TB%SF*+HC,$  P%K!:4 :M#+(4XHG#'*LU"C"X $6/1-$H
MTD"X2)0!11V$I8,0^04LDD(-;(#B=7A2B5!NB@5DV,H,POYE@R5 (0=)@,(3
MH! %* #A"4CH"Q&@0(0:W  *=, "$O1U1&YV<S W<%)C)L'$6)93*,=!E#D?
ME ( ,*  $*B6.N4Y3P?5K8-+T%<-NC*#&<2HG_K<)C^)R$\8>-.@!T6=(Y@(
M&9Y8AF\^<6A/(OH3>U:FHA!-448;^CXWR*EN%?UH3UXAT8W:TZ2P&"E/(I$&
M-ZBQH1?-Z$5#NE&:TE.=,)TH4&#*DR/LDR]$W M0]\)/??&S+_NL 1&3:H.N
M)-6I+&)J4YT*)*8NE45)E:H^H>I4JSXUJTLUDE&Y"M:H_G2L8&W<5<^J5'WR
M(1(*A2MCX&I3NM;5KG?%:SE#@?X)3W""KY[PQ%\Q\5?  M:O?2TL)Q1;6,9R
MPK"+36QB#VM8PQ+6L7WEZV4QBPG-1K:OD*7L8SG+V- J5K.=+>UH0]M8PZZ"
M;Z^-Q2M@FU?:FG.GM<5M;G6[6][VUK>_!6YP:SO2E ZEN+LEKCI3>MP(,9>Y
MPH5N=*4[7>I6U[K7Q6YVM;M=[G;7N]\%;WC%.U[REM>\YT5O>M6[7O:VU[WO
MA6]\Y3M?^M;7OO>MZW/QNU_^]M>__P7P?*_ !"<T(0I-0+"!$XQ@)S0X"@4N
M,(,CW. %4SC!%'[PA2,LX05S&,$/;O C1M$)$I?8Q"=&<8I5O&(6M]C%)K[O
M;0-,4OZ=$L4R1O@1474,T!8!29\XT'&0A1QD( -)H$,>,D")JF08X"$2BXAK
ME*4\92I7V<I7QG*5>T(*4I3"RW2+YUU;(:?=MF(3,Y;G$G"@@Z&R2%\WN$$/
MX&Q5'W>%S38(US#A7)@[[R7/?.GS,/L2KCQ48J&.F(3J$*WH1#L&T7)M-*,7
MO>C&4-K2XQQ8I%6G.BG-3@$,,, ']E,Q&9_4QC7U'_" \ER9HKK&#3($"P@G
M @ T0J,8G:\;,("4RW2A A80@V6^0 $5:,4-71#*BO \!U"  @M\F4$@0M$B
M+ #B!C6@0B9"\0=J)DG0^ZI!'I2XZ856>M/F%F>YH;3$1/Y;&A+C%!BFS_T8
M@?$D$0=XP A$ ((OP,$#E+@K*0BPD]H>)P]J"P$I 'QOP/&$UB@@ 0"^((<!
MN$$!((N &[<2UD#  A" ^%Q7>@"+.OP 7J^H@16&) A8H$)'"/5+N T];YH/
M+-,">W2FYYUSF_<<W3?7><T9"@D"I*<G;@A!)=P  C-HP )B+(4*)%"!Y*R!
M1$XG-1DN4($Q\,0-%W@ "]0HA@%<HA4KF/K>GL*!":B@D)4@P01"@$58H"%4
M+6@%=(P%"0]\!@1E\$ %[!,!!HPF#2(H!1E$4 8+!&Y0&+A %T!0L?>2H@$:
MN#S7\M0*2+@!/@^(F@G28/1@UOZ "!Z_ 1&:H 2FPFL'<6FY#?R B1O(@(9%
M$"K,98YSH3\&WI.0-[K5K5#@HQO3Q%_WSX4NI0- H 0E$,$HXF.(XSR  P1P
M0"Q0,  TM(;Z '! !PS0@%@<1P2T!@,B C ",1@@?+"P0 ;^9@9VN@$2 JC
M"A XB@<@H 4)( !2* , "($/(H%6,  (&)2C^!,&R!T&0(3< 8%(J(A*, 'E
MV8  X(!+0  & !'D>*]8:+Q1()L](0 ,2(#?40D"$(.+RX#-(!S&F0$J@ 4A
MJ<&>JH%0X 0900)76(5PF8$D0 L[V":88Q%Q(QAU(S>YBC>>2\)T4ZB@>Q)X
M<XQQDOZW)SPWRTB$!&  !5   Z@$,0@ 1*"--( %#4  4A@%* H! 4"# 2P:
M#D  2I  !82%-# $$BB +TB#"0  4B 6,ZR$-6 #$1@ ,5B! ) C.&"# 4P.
M2* CA[&,$#  0X" "AB4 .B""X(%0R0%/D$1.!F%5_&0!["  2P#6& #J)$Q
M\F(!!(@$2-"84RB#DHB#-5"3NLN ,N "$UB!!V@ ,_ 6IJH"6& %)WB"EJL!
M)( %*B"B5?C!?GJ"4("%0/@V([0!).P]<DNTXPL^FJ,TGZNT*_S&;6PB6)!%
MA/ R6-@/,@2 B@&! R"%5]P %1" -$ 0-P(!!( $!TB@R_YH!0]  !   14X
M >E#@$)J 070 !5@01.(D\J(F)OAB58HA2SAB1.H. B@@._I@J<I&A,0@%&@
M#3GHQ '8!!00 ,*9@%-T" N"&O>R@ %(  $R  X(%F2+&GELJ(0A@$KH @>0
M02> !3MX@1A BQN@ UAXN1UP!5;8 6R"@1>("R@H0IC3QG-;(N4[/D<#1V[,
MN4>[PJ]4OG,D.LKHB?TP!-JH& ]( $B0"+4!@#08P#6 !:4@A1 8 #DXA $P
M@3$XE%;X@F)K@/!IA0/ Q. H@S_Q&E&!@P'P@$NX0$4P@0"(@U%H  ?@/P9X
M P+B@M1(Q<HD2=4H!9'<A!00 /XLDH )2)D$* $(& !@:L7QBH,R2 ,Q*! X
MN!()2 0X0$RZ@043X(()(@4P8 !OP0$;R(%50 4E<()70(4;6(5 $";E?(4?
M-)<G.((@PB=L#*JLW#ES!#IQ+$NO+$]ZTTKSA 3+: 0"D+\&B0]W=",.*(!1
M@$@(P(#8S,>H"<!*D  "P+[U%!X$"  Q"!84B06(?( ,B(U8T$L#.(!4[((2
M(@"7:1@(70 W8H$!&  +(  7>)I4;)112 0& ( V4 $ N 04" #5%,I$" $0
M:('8E"^!,[HX4(@!>(!7BH0)*"0.,(GD@*&P6H)5X E62 *B7 (CJ8$<\$$;
M4 )SX?X)/TA.[]P+\!1/<ELW3<O2+CVWAI($,N,)0+3(:-F4& 2-6*B$+C/3
M.M**5I #.'"I1'@#.:DCGP"-5J@$,DN$CNH)I5,$B3*$-R@DGDC3-=730G+3
M30$:0(R%.K(,E(D$#5@-%! .^+(,/1V%NBF%.(@#EU+#AF(##V&<H-J!!MN!
M&>@!(/ +R&&1&UB"* ""W,-&+%5"18,2*DRW\/12]:0YWIK-WXH%%3B  _ _
M-(.0)?TI@0JJF.L+?:)5O^BS(RJT6Q5/1/-&:^U5\>2@8$4U;\6U<'6U<0T*
M&0-$A4-6<561@N(JIMHJ'V-2J$K.M=(JJ**JIV(K>@TJ:/Y5JW?-@[>JM"BD
M-[D:6"4DV'7;2BV%*T5+6%R-PG2%6&0)A69K-E&@6(JUV(O5V(WEV([UV(_E
M6(NEFU>@&]B*K9)]K58@69,]V5B@&Y65+;Y1692%+95UV=B2V9C-69I-6=D:
MV9Q]K8@5VJ$EVJ(UVJ-%VJ15VJ5EVJ9UVJ>%VJB5VJFEVJJUVJO%VJS5VJWE
MVJ[UVJ\%V[ 5V^\"5_DJVW2%@B @ B @@K9=6[=EV[:-V[=U6R. '+J%6[B-
M6[N=6[?UV[[56[D5W+GMV\+=V[OUV[R5VR-PA$JP!$JHA$F(7)2AA,>U!,O%
MW,I]7,J]7,WU7,ZM7,AU7$L86_[X@I&JXE=HU2=VA5<>>ZKD;-VU\JDZPRHF
MI2IFK0$<6"LW&RND.JO9K=W@U2I&&)@LH[+BE3+DO;**!) .ZM1"A25#D".;
M,H08W*4W@"E*, 27FJ\^^@E2J"@QO0RA6%(VZPH>T)R^2((D\#-HVX$=B-9!
MN\;VI=\E^39!PU_ R-^_")<=8 2 %<MWJ\)P%&!Z^ST"#F!.@P5%$(!_O)L6
M",!82@4%0"&22H,7O#4(082Y3!$/(!^,BK@P R_+$ ,-.#,'B0,*Z$ NL PW
M4.$&0+96"($'T  Y$8,7*M49B (A684ZP+,:V %8\(,7R %0\ -5)02>& 0@
MJ%(K]?XF_]TYGGNWA;+"1@O'1U.WR+A)H.BRBJ2Q!HF%PAS?,1X%[MW4,0ZI
M5F@ 3.2),N:)#^HE6/!>FLH[B+(,%%@ X+P,.'"!4ZB,2E CB*P6ER6I==P4
MGR@%= 5C\>4RGS %K;"G4A#3NB$S0VYCE\I4=(TXNAN*2C" "8"#%2  ^QB
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M"2;O=X2%#M 464QL.*D$%I4 $4"4$H#0!!AD6#@! 5BA@WB9N8P%5R'J1 (
M,/B;\D&#%=" V/ -POF",50?$\!C!#@$!: ,+T!SCEP#]S0!$%"-KC;)#$@
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ME:13*WNC&^-X1SO"<5,E64@B#H   0R@ 4.ACU_*X(%*K/ZJ.Z0P@'H6P@8
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MP (D<(@X), !#$"$'""@  > @3L8P "-%M  $0S@"YVHP%"^T%422" .7<A
M(BJP  5\810:4  #1A +,@  H<U3:*TP\ "_4( U)AC*(T/PA0; 8@,H^,()
M0J7+&A !$$\0@A-@T9\:?$(4,_C$B@)A T#,H9BP"$5&HLE&:@X5J=YT(VW)
MR1(0T7$FV4S7'8.Z$@M]R+?:!.<,26(3 VA@(:5H0 1>Q85$L&44'C! 7S'0
M 4APH)ZPB$0 U%") %# #!80P!<@ 8 60 *B99@  -P@@@!4X@L$"$$D7-"
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MQ!5D %-8./,B.97F3U7MH:'&S*?CQ!2+VX543/E192M^]4E8/,?98LBI!7"
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MG*P<0M5-*51 <,A)*QR?1HI*" ! ;M#'EPU%;"(.&23  !0 !Q0)&"#  1@
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MK@1+S%^/H=JH_9B\8A.:%I$B. 8 !   E$$L,$#6K5P8\"@<%%T:$)8AC$$
M/,"R/4 #5 *PLL!30< :@   Q$$)!$ 7B(&EKH$'!  DG $ID8($1$ I2( !
MD$&TJ< H($ &F (<>,!>$H 'P,(#2(";.$#$KL$)I$)%K4$E.( #B"H")$(9
M#(!M<!(:>  I "L8O$&PYF;BP%=$J48 \.8#G D$6  $B %>D8 +[*%]U(!T
MHEW=82<L0,$,P  2B.N(^0$LN/Y"4*:K!6TIX9'I;^485L9+PW4(J%E*<?44
M-\4KC#F5 5R (1A"')3"*2@ 6BE"/I4" :A "Q! *XR2(1 6&O!9 /!%+#R
M!<2! .P98;T!"6#N* A <' ! /!!"3!7!K"J'$B SEY"Z<)" D15*Y!!!U0
M GA +&@JC'!!I5( BQ(O4A! &2! :RZ$"0P ))1"%V@ !1! %[A!L%H.%<6"
MSQ) >AV Y'EL9XQ"&I"""'S!!)0 !71&]4F+#+HM+( "#/S!*^2 0808#O@
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M?,"I4BN-3, #H$"1E,(*Y.Q0@/Y!J!J"!4A %WC &,2QA5T.''AP!= E46P
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M.(R/N(O'..HP^$\>8_-4 AG 4]WH.'THP@3$01R401HD^1ETX"B0 1>0093
M0BFD0<>J2BMLP%'4HNX0S98CCZATN4)5)(]F.7>K3:_H.'C# @@<0"M@0 #X
MZVB>'&\B0  H@'0H @0   $$P $@% H,0/_M^"U& A+%"!7I@0CN)1P$ +7Z
M120@0BS4B5\R\7WRYU, >2L8Z([(R&Q$.1-%":<7^H\<0J +B2&0Z"A<Q6#T
MN0^9J#N9 2R8@0%D%@8(@ NTA@$8@.8!0!B@MZ#+62MX /X!"&P9M$*<2D##
MUD3T(@ &#$"6VU?/'0!BB($""&H+P&D&(X*SD\($$ !5G9F?)L )8( $5$
M,  \42H#'$ 8A.X$F'MTP,(8),!PN@ LR$$#&  !C,"0"-10:( !K($B( (C
MF3,(H$$D[ DB4!5W,-&!'D O_SH?1L(&K,$H)-TH-$89K!P8Q!P(( ((<&R>
M&( %)$)%<4&7+9(VNP$*!  I]%<CI&XD@"8+0 )ZH( >+,<8N.ZU<\ 9D$($
M, "W&X 81!L+5,( 9$ D),DA3$ $F.^_&G: U<4 ^"MRP(4   !Q1H+VE@ L
MD$()2"LDQ$(#6(#$T^(:A  &+/X !50" T0N$8^!S,5!C\X<)=&) 'C!EUE8
M>ZU M97!!DC *3R  W# !AP !<@! ;AO X!H)0A 8<O7!3  !/"PSH["YXK9
M6P;2!&A !D#50MPR* &\&1@"'*2HBGY!!GRS&PA +X^"S[ERV9]]\"6215$"
MN5\\6AE" (3!EZ6&F$E%(@B !YS"EWT!CW9NS,E&V2M H3F ?,1!&K"!XB/&
M;_BP ' !W8N G3; *'QH+$2"K6OO&#!>A2& KKQ!&N0U@'4NP/-E7Z@]CXS"
M D! )#2&K(3  ,!!+ @Q[7L;0,2"Q06 &#0%(%0R4 &6(0!<*@UX@.(!@!:P
M8*T8D/[@08$6I1(T&&-A@"%8)0 80 3+Q<,Q";I  E "5BD%$&#)9)$&@!<U
M"114:N  5B0 )DHQ4/"E(J00!,0,.9 &(Z( +F"19-#@@8$W7@ T"'$!  E8
M80 D #$A08 WHP*P@"408UV[=_'FU;N7;U^_?P$'%CR8<&'#AQ';'27B@0D5
M(49Y0%$T QE8:"10^*(!#:Q6C<RX>2- +B(.#3"\P6@H PJ!L;I :' B524,
M8#R#H+DI@YA6)1Z06/&AT@BSHS)\@97( VHXL$BA: "A2RN,L1YD@*6"@P<.
M'3 \%X/AP80AUB]G<, !#H=$:P#(23R??GW[]_'GU[__;F6I" Q<L$  DZ[C
M;R^Z^!(#@)7V0N\N!&&18 ((#:S0P@LQS#!#"@N<*Z]*3+@ !-4Z// O"#GL
M*\58W*#$PP?K0I#"5MRH1,,;<<Q1QQUY[-'''X$,4L@A\Z(K12*13%+))9D,
#"  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>cogo_0030.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0030.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
M'0   00# 0$             ! ,%!@<! @@) /_$ $40  $# P,!!00'! <'
M!0    $" P0 !1$&$B$Q!Q,B05$R87&!"!050E*1H2,DP=$)%C-3<K'2-51B
M9)3A\4-5@I*3_\0 ' $  04! 0$              P ! @0%!@<(_\0 ,A$
M @(! P,# @4"!P$       $" Q$$$B$%,4$3(E$&,A1A<9&A@;$'(T)2P?#Q
MHO_:  P# 0 "$0,1 #\ DC[&.:Z%Q9@J0(M'7'-#<1\@JQ@]*BXDXL3)YYI)
M#MF,BGP+<C0KP:1$P7#BED1HI62*3$).4PA/>$<YIFQL&CKRLX3UQTI+D3$1
M(]<<U)<"VY-2\=Q\-)L?:DC0NG\-+ L(UW<^+FFR)FQ(SP:9HCY/E' -)#^1
M,*XYJ3&8BZO''K29) I.#UI9)GW>$<"D(U+M,(SWM(1:;JDE)&:NM(J9 E#
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M)/'%,V14F#.,('E46LB4F!OLI2>*@T%3R/W9^XIN]I92X07L)!]#G JKJEG
M?22^XOBW/QK<B9 B)#Y;)4^\YX@X>O\ GFL?6O9!I&[TRO-N60^?*7*E.. A
M3CBO(G@>@]U<9;+,FV>E:=>G!*)*K')2F,A*&D[6\#Q=0JJN5%\%EN4H\DIC
MK0^SN+JE8.2-O)/F/A5J&)+DJ<Q? -(DI8=%O'>@+25@[N /,$^1]U/-X7 1
M>[E]QDF80PXWA1.[;N5Y<=*#)<9"K/@C$U7[1+00@)4,$)/ /G@T*32+,$V1
M=$%EZ>4NK"3R=JN11ZL293U'"8>SI=MC4-FN<=8!7A*R>AP?.NBTO%D4<AU&
M"LKDV!_29M3=LUE;9*&=AF6UM3A_$M)*2?\ *NVT<VX<G"ZA;9X\%2!1Q5Q3
M!86,F/:Y.<^ZB)\D19D 8HZ46AFPYE(S0IPP/N8;M1Z4/#'W,DR8J\?V=5TB
MON!Y$-PIR&R*GG \9#2[%<"N4FI]T3W&NQT'&TT-D6LF'"L#V#FAL;:"./N9
MZ=*<9("=>*SRDU!H)%$ET VVV]*N#V F*E"MQ\B5&JNJ7"8;3?=)%B6?5[$*
M&ZC"E*?22>>2">"*YGJ5NR!V?1:/4M [7)7*D+6^RI"%JV\JX"O3X5QLY[F\
M'H,:]B1*M/($E2&(ZE)0D%2E$>AYQZU!1;)S:BB86UN4<K;<\+63NSUSTXJW
M7!E)S0VWFY/0TN-K4A:<A8*1@DTUCP\!ZH;O<).1DS[3]80@>)6XCS)(XJ37
MMR*,L3P0ZZM+8>+:DA*U9  4,)]2/C5246RU"2P1]F/W,KO5JR%9Y/IFK%*P
MTREJ?<FB7%1>@-.+;24L26-JD^6Y02170Z-YVR.4UZVJ2!/I>1$,R]+D.!2@
MP^G'F!N'7YYKL]'PFC@M8\RRB@6V]V,5;W8*K? 6U"41[-34@._#,F.4'&.1
M5BN>0L7D49*DK )HTGP/@/J&1L%R,:6!5SCI3*",I6OY-Y6CLLY 'Y4I5DU:
M1Q_1[G?;1S258G<UY-E:)6$ X&?A4_11%7OY )&CG 34?21-7OY&J=I5YG[@
MY]U"E4$C<AH<TT^58"<GTH+KR6%<ER90\;)%FVYI.Y3H2J3C[B1[(^9(K%U6
MLIM?I52RUW-G3:"^EJVZ#47V;["R@^U 4XT03A''D-W(2/E7)]8;4<)\'=?3
MRCN>5R/[=S3:HXD A*70DA)\B>I^%<[".6=7=9M0= G3K@VB5;KZ]$2"0V0"
M0HCR/N]U$3C!XD5Y>I<LP&Z7VL]IFDE.-JAP)K*EG$D)R!CH"!5R&R2[X*LH
MW0?N616T]IDG4JDMW%D)6I62E&3\N>1S0+:UG*>2[I[6UAK!-AKQB*PIL-I1
M'C( X\^>AJ*D]V TZXQCN*KUCVZ6N&\4)MKLA9_LTI7P1[JLPTCGW,^_J,:?
MMY&&'VDWF]1FG8.G92.2>>0>?4U+T80XW<E9ZNVW$U'@L_2%]E7"R"V7- 8?
M5,CO#;Q_ZB>#[ZV=-'$4D8>L;FI9^&%_2?DNW35=IC('@8@=[GU*UGG]*[+2
M0]B^3S[76)3VOL5%&MKA4.*N^D_)G2U"[1'AFUK"<]*7IX6"M*YRED$F1>[5
M4H\%NNS*[@HCJ*PH#@45RR6\Y05L53;D,=31X#27.:.N#GE((DQ60@C(Y%37
M)/<,+L)H.\<U**(RDV8=::0WM*:(W@%N>0=N*TZ?9_2H=Q]S0'-M<9:""GS/
ME3R@L#1M>1K9L48O8/'7D_"JE\/\N6/@OZ6[_.AN[914$+3\I%ON$>/+65,N
M EIPE9<3G)VG]<>ZO('J%1J927?+_N?0%^C6HTE<6^-J>,?DC-IE-SEH@)R5
M1UE3RO0X\(QY5:ZK>K$E'L9/1*'7F3X\8'>ZVZ3=8?U".O"BV0.=I/KS6+&2
MB\G070<U@K^]ZOU#I*,J+IO2DG4,J.-I_;B-!;..BE\J62>, #FK%54+Y>]X
M_N5++IZ6/LCN?\$&@:X^D1KI$]=QTO9M&1+<6RS!<9/?S5K/B <*C[(Y\JT)
MZ/2TQW*664*M?K=1+;*"BBRNS;3FIX=W:U!=78Z4A208R5Y.\^:DGI699.+X
M1L0KFB7?21OMW@]GUQ&E&A"F.]P@+*>$)6L)6X/AFGTK3M61:Z$X4-IE&_U0
M[6M*6I5XTK#M5Q?C)0I*'T)=?F$GQ%*G#C('(!P/*M&J--SQ-X,F[\5IH;JD
MF:Z<[6^TY$2),[1>SMAML2U,R$6QTM28K60$R%-<I*2>-J3G@TIZ.BM[H2Y
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:+]PK5F.#J;[+N_\ N4K_ /!?\JM[C-V'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>skill-x.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 skill-x.jpg
M_]C_X01G17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  "OR    G$  *_(   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,#HP,3HR-B Q-SHQ.#HU,@   Z !
M  ,    !__\  * "  0    !    $J #  0    !    &0         & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
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M 0,1 ?_=  0  O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M259N/__9_^T,<%!H;W1O<VAO<" S+C  .$))300E       0
M         #A"24T$.@      \0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    2 %  <@!O &\ 9@ M $4
M:0!N ', = !E &P ; !U &X 9P      "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!2
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 $@    !  ( 2
M  $  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-!         (  3A"24T$ @      !      X0DE-!#        (! 3A"
M24T$+0      !@ !     CA"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      -+    !@              &0
M !(    + %4 ;@!B &4 ;@!A &X ;@!T "T ,0    $
M         0              $@   !D                      0
M                   0     0       &YU;&P    "    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   !D     4F=H=&QO;F<    2    !G-L
M:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)
M1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M#$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M"D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<    9     %)G:'1L;VYG    $@    -U<FQ415A4     0
M &YU;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%
M6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%
M6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
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M%       !     0X0DE-! P      TT    !    $@   !D    X   %>
M S$ &  !_]C_[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( !D
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M "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0
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M041"10)   !M;G1R4D="(%A96B 'UP #  ( "@ ' "EA8W-P
M                         0  ]M8  0    #3+6))0T.<;32EK:1%]A1M
MF+!1#!)M                                          EC<')T
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M96XO96-I4D="+G!H<    &1E<V,         "F5C:5)'0B!V,@
M"@!E &, :0!2 $< 0@ @ '8 ,@     *96-I4D="('8R
M
M %A96B        #VU@ !     -,M8W5R=@        *\    "@ 5 !\ *@ T
M #X 20!3 %T : !R 'T AP"1 )P I@"P +L Q0#0 -H Y #O /D! P$. 1@!
M(P$M 3<!0@%, 5<!80%K 78!@ &* 94!GP&J ;0!O@') =,!W0'H ?(!_0('
M A$"' (F C ".P)% E "6@)E G ">P*& I$"G *H K,"OP++ M<"XP+O OP#
M" ,5 R(#+P,\ TD#5@-D W(#?P.- YL#J@.X \8#U0/D _,$ @01!"$$, 1
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M[U/P._$D\@WR]_/A],SUN/:D]Y'X?OEL^EO[2OPZ_2K^&_\-__]865H@
M    IG@  %'^     %A96B         ME   FB   !%=6%E:(        "+)
M   3X@  P=#_[@ .061O8F4 9$     !_]L A  ! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,#
M P,# 0$! 0$! 0$! 0$" @$" @,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P/_P  1"  9 !(# 1$  A$! Q$!_]T
M!  #_\0!H@    8" P$             !P@&!00) PH" 0 + 0  !@,! 0$
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&O?NO=?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>skill-g.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 skill-g.jpg
M_]C_X03817AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  "OR    G$  *_(   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,#HP,3HR-B Q-SHQ.3HU-0   Z !
M  ,    !__\  * "  0    !    %: #  0    !    &          & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
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M 0,1 ?_=  0  O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M,  X0DE-!"4      !                      .$))300Z      #Q
M$     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN
M=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M      MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P
M3V)J8P   !( 4 !R &\ ;P!F "T 10!I &X <P!T &4 ; !L '4 ;@!G
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0%(            *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      !  2     $  @!(     0 ".$))300F       .
M     #^    X0DE-! T       0   !X.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         ".$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$         @ !.$))300"
M   $     #A"24T$,        @$!.$))300M       &  $    ".$))300(
M       0     0   D    )      #A"24T$'@      !      X0DE-!!H
M     TL    &               8    %0    L 50!N &( 90!N &$ ;@!N
M '0 +0 Q     0                         !               5
M&                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M&     !29VAT;&]N9P   !4    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   !@     4F=H=&QO;F<
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M# P,# P,# P,# P,# P,_\  $0@ &  5 P$B  (1 0,1 ?_=  0  O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0
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M041"10)   !M;G1R4D="(%A96B 'UP #  ( "@ ' "EA8W-P
M                         0  ]M8  0    #3+6))0T.<;32EK:1%]A1M
MF+!1#!)M                                          EC<')T
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M96XO96-I4D="+G!H<    &1E<V,         "F5C:5)'0B!V,@
M"@!E &, :0!2 $< 0@ @ '8 ,@     *96-I4D="('8R
M
M %A96B        #VU@ !     -,M8W5R=@        *\    "@ 5 !\ *@ T
M #X 20!3 %T : !R 'T AP"1 )P I@"P +L Q0#0 -H Y #O /D! P$. 1@!
M(P$M 3<!0@%, 5<!80%K 78!@ &* 94!GP&J ;0!O@') =,!W0'H ?(!_0('
M A$"' (F C ".P)% E "6@)E G ">P*& I$"G *H K,"OP++ M<"XP+O OP#
M" ,5 R(#+P,\ TD#5@-D W(#?P.- YL#J@.X \8#U0/D _,$ @01!"$$, 1
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M[U/P._$D\@WR]_/A],SUN/:D]Y'X?OEL^EO[2OPZ_2K^&_\-__]865H@
M    IG@  %'^     %A96B         ME   FB   !%=6%E:(        "+)
M   3X@  P=#_[@ .061O8F4 9$     !_]L A  ! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,#
M P,# 0$! 0$! 0$! 0$" @$" @,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P/_P  1"  8 !4# 1$  A$! Q$!_]T
M!  #_\0!H@    8" P$             !P@&!00) PH" 0 + 0  !@,! 0$
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L^K75U)G]1]M_</[G\0_5>/\ 4?4>'%J^JI3QO#T>%33^GX6CP_ _1IHZ_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>skill-l.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 skill-l.jpg
M_]C_X04417AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  "OR    G$  *_(   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,#HP,3HR." R,SHQ-CHU.0   Z !
M  ,    !__\  * "  0    !    &Z #  0    !    &          & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
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M 0,1 ?_=  0  O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M[0T<4&AO=&]S:&]P(#,N,  X0DE-!"4      !
M.$))300Z      #Q    $     $       MP<FEN=$]U='!U=     4
M4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN
M=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /
M<')I;G10<F]O9E-E='5P3V)J8P   !( 4 !R &\ ;P!F "T 10!I &X <P!T
M &4 ; !L '4 ;@!G       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0%(            *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M       $    'CA"24T#\P      "0           0 X0DE-)Q        H
M 0         ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ !
M *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M   !.$))30/X      !P  #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@  #A"24T$
M     @ !.$))300"       $     #A"24T$,        @$!.$))300M
M   &  $    ".$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      TL    &               8    &P    L
M50!N &( 90!N &$ ;@!N '0 +0 Q     0                         !
M               ;    &                      !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG    &     !29VAT;&]N9P   !L    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M !@     4F=H=&QO;F<    ;     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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M 0,1 ?_=  0  O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ',
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M(%A96B 'UP #  ( "@ ' "EA8W-P
M     0  ]M8  0    #3+6))0T.<;32EK:1%]A1MF+!1#!)M
M                              EC<')T    \    (ID97-C   !?
M 'AW='!T   !]    !1R5%)#   ""   !81G5%)#   ""   !81B5%)#   "
M"   !81R6%E:   'C    !1G6%E:   'H    !1B6%E:   'M    !1T97AT
M     $-O<'ER:6=H=" H0RD@,C P-R!B>2!#;VQO<B!3;VQU=&EO;G,L($%L
M;"!2:6=H=',@4F5S97)V960N($QI8V5N<V4@9&5T86EL<R!C86X@8F4@9F]U
M;F0@;VXZ(&AT=' Z+R]W=W<N96-I+F]R9R]E8VDO96XO96-I4D="+G!H<
M &1E<V,         "F5C:5)'0B!V,@          "@!E &, :0!2 $< 0@ @
M '8 ,@     *96-I4D="('8R
M                                         %A96B        #VU@ !
M     -,M8W5R=@        *\    "@ 5 !\ *@ T #X 20!3 %T : !R 'T
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M;0B&")\(N C2".P)!@D@"3H)50EO"8H)I0G!"=P)^ H4"C *30II"H8*HPK
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M P,# P,# P/_P  1"  8 !L# 1$  A$! Q$!_]T !  $_\0!H@    8" P$
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'7W:ZYZ__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>cogo_0061.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0061.gif
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MBLBEE]2LF]:HE=BQG<VSG<6KI=JTI-R[K-BVI<^UKN*XJ^&JE-W LN+"L^#
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MYH*:&2@.CJKEEJ&PZY:&_Y@%ZS2OTESOF@D]XV:NTSQTYD0&^>M=G10AC(Q
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M$ISL9.QT'+M%[[B\.([G3\>[Q$;P.*A K@184U@OA@C8OZJM5QRG7*\Y[M'
M'EHC-=::C6=,@@2(5 &986J""+.4Q'#^)A7@3(48R'E^'U"!",2Y2+S:((=Z
M]G,V6\R!*Q@V#6D PQ?&RP5'5-L15R@=(;)=.DXZ>L>2QK&E^Q=>TD56L928
MA#+O@C0 7Z/4>3&>5?GRCP 7I!DVLX9]L:Q:C$X#&ZN>1B>L26:X>F"E/I3?
MP8F-@@O'H.$DGN[\2$QB$WQ !!8O+K%=FE?[Y12G.>5 %/YD_(4TH,X1V\8V
MZKJ-NI-SNW0H5W3I(.$(FH<7YN76=HXG(:?;WFR:/Z-.S9Z,0?W6>U=GXIN3
ML:QO[0U3&N)(1A30>7!)>N #F;1K"K .4XK3] 0BN#@(/A!L89-=IF1/.UR+
M>S_J K:=Y\1 ";  [32X#G5<X$++]YZZO6^[T3I?M*._C7)(E&X2A/ADXN7$
MQB3?#"_?>%4WRG27@BADA 2)CM -C%JGVU8<CNA B\NI@H-?6.LJ(';:PTYV
MUI/]ZJ\O;DUA?[\0?&"2Y40G!M"YTYSZ&0,I. ,FI,WWXO,]"-E._LJ[K>UN
MH_SES6_^)^OE)FEP8WF>;B,V"/YJO)F-D-2OK26_GSE1A6*B!.BT@ DF2<X/
MH" (6I^IG&=Z<8N#0 0@ ,$)QC[VVU_\XB(0 B$P262W=BN6?@RP9RS&9PQ@
M 24@;5]P!5@ !E@P@1)X=U9@?-O&2<D7?=IV<AOH@2@7.R64'3K#1KH4?MU'
M$-IP,T<G6FW47^!0#GQD#.!P7])01EG08@R@ ;5V=6&' MYD Q;W:R(0=D<H
M C$P8DNX?_R7?ZUW O['>KAW<.JT3NG';!:PA2.0!5SP!15X=Q=X!:VS27VW
M<FC(=QO(27EG?,H'"7DW. 01&(K#$$IF,S53#C1#+YU&0XIS$-H##N( #N2
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M  8GV!W*$#U]6"_R4DO=H#<%\6XG^8<<%0Z".(CM@&74:/X,PQ ,RI )B[@
MWN@!(D"/00!V)V9Q&#<#[(B.AM!F.V"41QD#]Z>$ (B$2GEQ57A[Z]2#6-B/
M#-![$X !67!8B8=HPAB+9)B!65"!MH@%5G"69PF17- %!>D%9M %OF@&9J %
M75 &8E &:; =):A+?C%"KZ*'->."-'0-1Q<-WW"(@PB3+RF3P7 TE] !W,@
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M=E?'=AH0 >E41 #)8@VHE;EI"6E0H7 *!B:'!5NP!690@7DZBWAJIQC9!6&
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MM&^2NJH[#9-3$-OWG9$G;PR5HXKS6:\2M>$)'LT0#<.0.O7S?D)  SD@!$6
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MR$O !/YZ[LTZT+=!4)^+H&A7@$-$U $E( 7-#=W(B9S4_>@;&>-YO==]\ >
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M_@8<5LD9QA$K"CG*8R2KZ]57Q1>?O)>75_ZN*Z[*PLHJJYAU1>=>H0JXD,*
M\T%$*_X8X;-%C((3HN#&.^ !CVO  VEX(L33N% [R50&=[CK0H'<9;SCN2%?
M62M>A?*UAC"T<" <B<V_.D4J;'RCAM/;2#2>@;UC0$,3FG"&)H0Q-_")+WS=
M0&(YK&&^<JPC&LY!@0V",#@E).$I86I%=JIBBUG #'^/>]G]?.$+7'B'.RD[
MBRLP9S.W4 L1U6H%(AA1I" T(A=!&QK1)/@.210"$I!@$!8 U07,5":$E2&(
MOGRG0A0VDI'Y<N'NU. 2C_PK;=B W@U;5 VT14,9T<#>,"RA"4Q8P@_"$(8S
M!M$,;PC"&]T(GS6ZL<0DML,:DU@?"JA81:?T*HNRL$K*N/["BS"&T7Z\&&-7
M)+>E[+2"9*UHTBO@DKE6Q#$OBEA$(481BCN"0H\6Y,8H8F<%#A(J,YG!C!G$
M((6!O,M#%<+:"5'(2#=$L@Q>&)M'-@4P3V$2)=@@E32B,=#K:6(8I;2$*4])
MM^^]TANL; 82)5J.9DR"$!LCDA6=TKG, 3.8M] %,H_Y,I<1$YECR5+_S--,
MS45S6IE+H"+RPHA&[(47[PA%'HOF&DY(@A)6P,*?S'E.-(@A#6 XZN[H937A
M-3*%69M4&<+@&#ZM81K7.!CS8H0-KE9#>C6L!D&A@8P>#L.L"*U$&H3A!U4Z
M0Q#.^![W(AI1)%JCHE?0Y2*,A/ZD5C"A%-5$RU4^:M*2EI079K0%=_RWK"P"
MJQ5*,@6UJIE 1BB"$9<5VC^8$8H(QL-H_^ $)WX:5"Q@1@QH0&U1CQH&,$A5
M#5GS7;V<NBA&3K4,9B"4%ZAP#6E<HU,R[%0XJF%#DI1$H*#47G(/FM TG-(/
M>U#E'[@W7;HUHQG.F"4TOH#7P05!"$)HBC.Q@Y:S8&6,ON %+9")"V*2,9G[
MFP4MXAL+6, B.P'L'&2K>0I$U (6C-A$+7*AC%R\(VA$4T;10BN)#?X)#)I!
M[1G0L-ISA@$-!DF44V'+U'SM+H2$TD(DKEJVWF R'%S-1JBX6DFXQ<VLHK3$
M&2R1AO[F[J$/Q>B#,Z1+W>D.8AP5O6@A%A$$(C"E"26[+Y2D- M<S.*\[3TO
M+L981ER<!RVML"\M6-J$MG N+Z>@KX#O6(L$XY1H$51&,CB1IQ!&!@P6=H,;
MYC"'"=.8#&+8VH91V+44,I52CG$,;KU0!M_ZME/9,'$X4ARJ$W]$&J^I6\+,
M^HN$ON$,9_!#IFW<AQSSP1G+V/$@N#>-)W)7*81#]1+2LPI9:&7)4Z8%+9H<
M93+*NLKG:46L:4'?6'!T26TDQ1MA<0I&U")H!"XPT9B!4V4H@Q,;7!>#N% &
MU,IY#A)&;0OC#%LVY($Q*'SG\=9 5=R: 4%>< DEL;$2KOY*3\4 7;= XT;0
M2<?X#,W5M(WW4(QB&&,9W"O&=9T!'$O@-0M*043AC*"$(Z1"%JB(Q2UD+5^K
M-#F^\9VX5;+#Q2[&UQ>TJ&;(2_'2R%*+6FI2A+%SL?((OJ/9:58&,BX!":A1
M9MH1/H,;+HT&-_#<A!9YY#P7F2\UV-8,N,UMNJ_1[FQDDM'"!2CSCDMO40+#
ME&F80Z:UON]^%^/?<O6&-8R!"8U-\;M+&<(0BC"Z0RA"UA</YK)ZG9U88_E)
M=@]Y=*QX'<Y-2[)NE.,F LP,92R;&=EP>2B\M>9S2?L+9<#V&>;P!C200<YL
MB(-LV?#M#3^24E((H1G40*A)NOZ$JUAMMZ(7?>*5<"J'PXB&,9HQ#$K+0>MQ
MB(/6_= '8ABC&'_XP[^1V QC".,+@OMNVE\@!"(@@0A$2"!^L8P66IP%%L[\
MY63S@NJE+$'MU#%%F. "LKQ8LQ'%9D8M!O\.9BP[IQ#LQ ;-T" L<.&T7T #
MMGWN!MR31O/RA*?@6:'&H*K%D()(6+IVFZ&FRXU0H885\PUK(+6!FKUA$ :K
MNS0_B /;P[TY0"5A\+K@FRYH> 91*@04F 'O^JZS"P(1  $0: $:F(XW0@62
MN;YJ"J#KJQ8E* (BH($7>$$6> $<*(*&DPOX, *="9U64(3_*K9:@$)16+84
M(;R<*OX*J,&"*X@,+P #_$.M-XBSK<&].V@D@GBMXE$4 62A-2@WT-."+I""
M!%PQKZH-Z&$T@&J]$J&Z"[0]#=Q .: S.?@%8? WX/N#M_*&85"&9K"$0DC!
M%OBN%U@^(7@!"(@ "(" $'"!'!B"(V "1""%5#B%7*L[5P 9(Z%$$,#$3,R!
MZ4@%)D@[[U-"RF($6-B$8ELY*&P_9DB&4 @&3-"$20 4+"!&ROB"+Q"#,Y J
MU'JM.W!&B]BSI4I#HFN,J2D#/RD#F> J;>"JIU.Q4%F)&*F><9R]XELK#=3
MK -$.0 &8B"&X/.Z93 &8TB$(""$?P@"%(@!2:2!'YP!&OZ8@1CH1QF8 1=H
M@19P 1K(@2(D!8J;!6D: DIL 4ED@180 1%(R(5$ B3( 1U(NRJJ%D1H!%K8
M!%J PI,<L/93AE'X14KHHT6@@D(@A"HP YHCI*(R*OXCC3IP1N'1E\ZH$(N(
M@S8@@S(0 W4Q S]1 ZXR!VX,%7,(!W3PQG6KI&>80%"*O>(#AG.,@SG+0$NP
MO3T /GZ3QV PA!?X&4><@1>(P1^<R"" A5U[N$/@2!=@ 1:@@;]Z!?^AA5<0
M@A:HR.4K@K7#LE;@K]$I@B,!K]%9$UI@!%K(!?6#A540L&:KAV1P($P@!)BD
M E9P$R^HR4@@)#' OS0P(6=\QOXXV)=#Z8P,T1JC/,K)<!HIX,9J, >H=#=O
M#)47(352F[JL%(8]\ ,YR+TX0(-K2ZA?<,=E6 :R[ 9+L $8F")"D"*T1$L:
M&!U8X(I6H(&[;($<Z,>)) 59V(57V(7R5((7"($06+XA6()4<+Y3.(LJ@P54
MVZ7&#+!;K*S_VH24=+91H(( Y0%68 4J6 5)2,I'\((O.(/,((,Y8(,[$(T[
MR+P5VK#1F(,P((/<D4T_68.:T$;=_,85$\>!(BCB*[YBT#JOO#1@" 9BR /F
M]#VN"P+I-)T3F** %,S)K($/<  ':( &\( 73,CE,\_S+,\A8 'VE$0@7,\/
M"($/J/X!(H"%7I.I7"&R[+RL6E0@ ",S45"&H!$%*M@!5E %7<B%&^"!46@P
M+CC&,<BY.9!0A!!*2]FV1X'&#"U*#MT"/Z$";1@';H3*4*F-;R"'U8LWCAC'
M:+"N>2R&/1#.X41.&?L%.=@#YNP]?G.&1$#+GYDB$'B!&(C!(I !#UB ( 52
M!YB!&M#$(\"!'" %__$%O[S+%[!+%H  %C@=4W4 !EB!%U@$QTRXYVL$); L
M)^Q2 6.&7& &47"312#05;@%9NB!'AB%*SBZ*WB$8\PY-NB#1]$#"MT:$W(4
MU$@-XTR#,>@"=9T,0)DV;@14VS2';QC4J2R5US!1"B0^?OZ#U V\-AFS!&!H
MQV5P1V+P.C[8!"&8@49 OB"8@1D0@A!P@! X@14(T@7P #(-@1@XA"4H@NH
M)J> @8F<#AV  1CH@94[ 2 -T@;86"5HA498S(2[K/]B0EMDUF;;!#=A-1[8
M 33] <^\@BMHD&,$@^-T1CVP@SS 4#F+ PE5%(?H.:,< R^HV@5AD!"K"=O4
M!F\4!W)X.MZT!FD86Q-M!D:=+DC-M']-*$M )7F<1]\3A(2M(X<5@BGRP1!X
M@! PA%&P 0\84AM8!$/8@4/@KX_U*&DR61HH D1@ AW0 2<0L$+P@%YE@ ^P
M@?4<')]1@KWX+\=DA%PSMF9UD_Y$4 0";0$?.,\>D%Q"<-TM.,;\FP,YR -
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M926V96) I7D4A43( 23P+B);026PK_==A5CP7V1^W^AHN+78G"1  B-POKQ
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M(\BBM$ %:B&%NEB"0X"X*ETI65@% RH%4@ 9G>$^N*BF6N1C=58$1>B!!W@
M()CM)7B%'^ !69 $/OF",0#Q"$T4$L<\1$=Q.UAT-M#0H_XTW@2!A$B(A#6@
M L:@<:]JRML$^'4(5!O>AG$PM%6^*H&KWB'? SP8SG9\4;\F[&" ]2?B 2=
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MX,,?E@&T81PE&$II1C14*8I6UDD6K6 "^5[!+1CX8 BI*((+6  !$.3@$*1
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M&;+A'$A@ ^J!'I@A!F2 !^Y%E@BP /,# >/P#8>@ 77 ];P'!ES !_90!WR
M!WBAU )1$ -1W^A!'L1!#2B@!,6N MQ1 8IOM8SOIYS*C<SLJ4;K^: /S' 0
MJEH+3+9!&VIB&P@RH'+.=JZ!K7J1"]4*2S+A#"CA"ZZ %F61"R"!%B'!%JL0
M$B!!$C"!*[J0_I#P&NA/'")A 4I 'NCA'6K !W9)EW( EB8$/Z+1318$#N&P
M 9NN>V[ !WSR!H R!VZAZVZ/OO[,\=1 \!QY3@HH8!$/0 $H0 $J("HK(!*Q
M20KJ,08U$9S$J0K>#IRR8,%RT!/_<10)$DRN@2"O82W1DJW4ZBV'X1BPQ!*>
M<")ED2(WTB(MDB.9#1,\0?+H+R%KAQO. 1DN  "H@!WD(1\6H05*JM%,J:3R
M@R9OL@D: WJDC@_S"J):H/5BSQ<H:Y@T,!_P <KPX31-DQW 80HJX  6$2JC
M\@05P!%34+4\$2O-S ;#Z>W #+7(,@MT[AJR(2USSA37\CC7TBT;D@FGY5F>
M$!:O(#KUDB-KA3H)P>4P(1B2@=JXP?ZJ[1VV(0H&@ (B :OR011:@.H < =D
M:3WO(_YL;/(F,1/J^'"&BLX'[I 1[(WK3$TT<:\T_2T=C($U7?,U9W/X** U
M(;'*#&ZUY*ZIPNPKP7*T/-$3G^ X#S+GD'-#E;,AY1)+LJ02K@ 2*E(O+5(C
M.=(*'P$3CF$[ZT\8[6\; &X )@ 9Z.$8XV$&&(U"8G)"3*KIX#,_X,(RYW"C
M'FJO?#+V6L'>](%)-? TK^@T[T$>#A$=C&$$@D_@%J 1&W$V#V !$.  #N "
M1L ?L1+7LF WQ<GMR"D?GV]#X30M PT;UE+:Y/(8\/08-.$C)Z%/271$,9(6
M944*(0$[01+%-(_0P*$$#$  ." ;X$$EZ8$16D"68J][FOYHL=[B/>5P"%I/
MKXZ4&X$2%@#1/^T!'TC3-/V-2M-!'( A \2N! U 3!EQ$1=@5AM1[,BN!,+)
M*]_NCG2SP%[+0L.)&^+T6),3%-[R$_1T+BMA$D;T+JN0"PC!_,R/"B$/YIYK
M\LYA&IAR$4>@\Z@T'_RA$"@04P'P7B %"1H+"8Y ,W@ *!WJ2+>1!7S@$":+
MOD33'E[J-/UU57G.)"E 3&7U5A?Q8&UU 0A@81>  3: !)[@CL[439M*+&]P
MM0[NM;AA&I!U+<%30Z]!K4 A3_7T6>@2%PD56SD2%Q4O$_AL6[FA'H:A!";@
M5@N@!"((O_J!%V2 T7" /G% B/YXB%Z"]@@P! _WJJ)<0 9ZD@6((%_U=33[
MU5_/D4HQ2!RDH#6#[V!EE0 :%0 ,@   8$L5=F$1P )2T. *[. B-F+!\K,R
M=IRJ@&,[5BU!]BVA 4\?Z5G]]%JY8!(XLD=PL4^_8!+B;PLI;QZ2@68G($P-
M( JP"A[P*Q_L@0ABX%^&X)36]5&@;@>.  EZ8%[UL&<GD 5BH!?LK2BM"*;^
MU5\/D4G$@34K0. 0ME$/UFL!@  4-@#(-@$(0 $VX*>H0 JL:=:@J@IT\, ,
MK&.1<QO^X1J>]Q_REF3W=A+2('!3-!<A 7 +ER/[U#PT01FHBQ-*8 ,N0 )F
M]0"DX/X>L"KKFM0?:F 9(7 ]B<!=BR (=,F);F ;*ZJA@')I:V$_-3#?7 I5
M79=*]^%UC24#6E/@%I9V!>"!%Q$  @  <G=+=9=L*6 #C*]!(_:.I IYBW>I
MB+<*$K)N/98DKP$4E)59]=9D170C)X%'"G6& =<1)@&',<%ELR$<AD$+.,!\
M)X "$& VK6 ?ZD$>A(D0-T%M>."4=@ )W'6)V+-[Z'5I;P /:2" *8O?FHPT
M__4>Z&$?$EB!I4 "!$Y+(_B!V9&" ^"-U[AL%99L%R >AS>/N#)->W5-QPDX
MUU(;CO5Y098DU2I/P5<3*J$2KC=%><2&=\2&^[02AD$:E/YA$DK@ BY@ S9@
M A3  ,(4$O9A.;).7^-A$981BATE>Q9E,_40BX&2!O2329E,7U=5'NX!-:D4
M'NHA.Z# '1LUC8&Y@@$@C2G8C=]8=S,8@P6  C(@"L0)CYD*A,7)C8J7;BLI
M+=?2;M7R.-^29)N0;P$7<%VN3\F9G!]!DI$A$J9@ B8@ S0Y R0 3-TQ$N0!
MJY:8'^Z!']YA7X#6;=B5B;K'QC#C!F)O A5A/YN,E@]1)6W9EN_AH>$!D4;
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MODHS%Z@ !Y"@I'@@ '>@!WH@!WK@!A8A'GC/U%X;]U -J^;AH5_]R^MA'K1
M %HS*K=TP\,6PX%9HR'8S7]9PT4ZHRU8KIN; *:, .*1>#&4.+,YQ4'6L)\A
M_%BQ9"]!QI/+T/5,$F8*016  4X0R"^ ^$ZP'<?4&.I9'KSNTC']'12!!GC
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M;QD)T"@ TPQ%7(M&O4OI,T]Q<PTWT#BBP@6A9L=:20&@=-UWW?D8P$U=<7M
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M)S\148@%  J+BJ*-;0 0&SXYQSZN@0G666 "%W@=A%;BDIG,#B2[$Q%-!#
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;IY:UGFN]@0GL^0*,WD"M&0WL7@<;V+X."  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>cogo_0028.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0028.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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MY)I$-J<6T6J"M)3"=?*G6AE#HZ/#^M$J7R0?<A-?Z.M6N=/2+1/1\2"$*/\
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M3-UU&_"D3%<7-(AQJ&A]J+)66RX\206=\8P-\[T-V7_VO^@4NI2X4J?Z_P#
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M1^"YD]5?ER?S#'K6>U73^H*?>2B_RSDNM/U+IS@Z8[DOOC!HC[+_ /E[2/\
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G39?JTFWX3_/R$?\ !4O_ &=C?\.'_35?W+/YF77T>F_DC_GZG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>cogo_0032.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0032.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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M5(&1K)U:P20<](U9Z;'+#;DV82UF:.I^-8TO[EIH5KWW6'VZT]3V:,Y(*U3
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M)Z7$D*=743X:<CF!IR=^@B12C!6V8VIT7Q_5!+*L:LM*EY:\JA*O+"1,/LL
MI1S\J<G>*>75+*]L40PTSP*Y.S1[=HR)6K(:8'D\4G4$YR#$F)-2*V5[XM]6
M:+?<P*18=3=;.%(EO#;)_,LA/]Q,='H8*>1*2.;\AF^+33I\_P#Z<]R81L$@
M9Y _WQNREM5(Y.,4^7W^2>I[:SL"3"@_Z SZIDNF6<*.L31*TF,W::^M>4@_
MI!W0R5CRDM.L32=0AE(*B^F;*I1(].\27:(7PR/?7EI2M4 T'%E5J#FI2OG
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M9*LE9 Z':(B2AXIL-I6[T2D'/TAF.D0FE1_$!((5J!',&&9(:EPZ]H[B+P]
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M5>DZF5;=#4N"5NO@9\-/?T/2.1T>FEJ\RQ+_ '.FU>M6AP;I=^BWHLI%&?\
M=Y"B.2^GRAWQ MQ?KJ.<9CT#1^+TFE@I1@F_ZG!:OR^JU3<93:7]!]+VS-^)
MX295(4KF1OGYQJRRK''@RHPED?V(_BA?,KP*X95^_K@:2\Q2952V$!6E3[ZO
M*TT?FLCZ Q6RY56]=AQP[WL?1\6+NN:MWM<M2NRXIU<W5*M,N34V\XK45N+.
M3]!R'H!%0MV03Q[#ZPA#"=9;>2E;J!D'RDC=,"';0,%"?PU9U<]NL(2/Q&!D
M<H:A[/"-8(A)"3!%E1R4C)[=X<<],B5#4O8PAFCUN14%8.$[XW.\/P*WZ)23
MI65 +!*@<A(Z'OF"2 :3+#XUP?ZP57_[CO\ -!_[@TCO>6;RGH/G&FC"D0=_
MWC+\/K1G;G6SX\PWIEY%C./'FEG2VGY:B"?00V3(L47(+#B>:5(PF<F33J>W
M*3<XJ;J+A+T[,N?$_,*.IQ1],G [ "*$I&I&"714IR?4ZHMI.5D[[["(F[)(
MJNQ;# ;TI425JP3MS$"21(WB!5VI&DHI@605H,Q, ?Z(<DGYF'FU0T5?1]7_
M &9;>K,GPPH-5N%Y;M5N"3EJA4-62EM'@I2PRD'EX;8 Z9)),66ML4_96@[D
MUZ-J37*#+STO09I1EW5_Y%+K2@'#C?"AD';UBGDN*<W[+^-VU'\#*BV=3Z&B
M9EJ4R66GIEQY8'-6LYTY_*.D0Z72X-'>SM\AZK5Y]<TI]+@GVZ*Q+L^+X&IQ
M0TI"MR8EEJ')TB..!05L<RU);:"3X:0XH[JY0T\S0HP3/G+_ (5+C-+3=6H/
M RA39/V;IJ]:"3C\98PPRH=2!J7CID0L-OL6:H\Q/GMS)VQDYVB4B&K["VE%
MYG*@KXT$[&&'&TTH>!I<3D%0\, [D] /^<"'V#8DW02[,?$=]L8'I"$>J& #
MWA4)'B4*4H=!U)Z0Z0K'3,OD9R-SL0,_I"H>PYEV]*U.K&E(\R]\)Q"H0B79
M6X3,*)*0?)I 4 /6%0A^C984VH@)^,CS)^?<9Y0:(WV2GB-?F1^L.(^A#%NU
M\(&JWJH1U_H3O\L:<9P_)@N,ZNG_ &.?_:,IUZU:_+8M>1M.X'I"F*54IDMT
MR84V7-/D&0C!Q_&*6JRIS44S2T6)QQN5=E"GK;OA]Q3ALVXR>0S29G;_ /$5
MY35]EF,&#D+&O0JUN67<&XR<TJ8_DAK7Y'IOT/Y:S;O=G?\ -"X,(YG[*F,
M 9/[$"Y(-)_@F_9OX+U3BY[0=*I]]656ON^''I^:;FZ<^TVXTPG+;14I &ZM
M.V=]X+&HSERR.>['&TC[$6M0_=9%L)EU-AM(2A.C2$)Q@ #&V!M"U62_JF2:
M;$JMHEU4M.RDR^Z3E&6\Z3W&T0?,^B3XD/):4T9"D*)SDY'6(W+V2*/H*IM2
MUZBT=N7E.T!'Z]$CYX9!7S<LK8]HU6[ZA*S+[%$DG9M;3+*G'%Z4G 2E()4H
MG P!U@X5=-@SON*/A+Q$9XJ<2+WKE^5^SKG=J%>GG9UU2Z1,DIU*RE'P<DIT
MI'RBUN2X16<7*2;*P;!OW'^8ER?\'F?Y(5K\BIGAL._2-)L6Y0GKBC37\D+<
MOR*G^!FSPZX@3#QG5V!<VA *&@JC3("4_F/DYG$-%Q:NPYIQX2#/6'?X'A_<
M2YE;9R*+,C]VB'N/Y 6Y^ADOA]?ZB$_<*YL#_P!&FO\ IPMT?R'M?X';'#N_
M,$_<6YA@=*+,DG/_ +(2D@9)_@?*X><0$)2G[AW&EP[$_9<R E/;9N"M?D91
M8W?L._''@Q]P;A,NR<D)HTUYU?\ Q[P.Y?D>FO03_P /[X!)19US)'1O['F@
M/ELW#.2_(6U_@/+6'?1PI5C7*G3R I$SD'K@^'^XP2:_(#B['/W)OO\ U*N+
.._@LQ_P!.'W+\BVL__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>skill-m.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 skill-m.jpg
M_]C_X1#117AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  "OR    G$  *_(   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,#HP,3HR-B Q-SHR,#HU-P   Z !
M  ,    !__\  * "  0    !    &J #  0    !    %P         & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
M @$ !     $   $N @( !     $   ^;         $@    !    2     '_
MV/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.
M  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="                  #V
MU@ !     -,M2% @(
M                    $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0
M  'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)8
M65H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,
MAG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P
M    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0
M    0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY
M  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0              $G-2
M1T(@245#-C$Y-C8M,BXQ
M                          !865H@        \U$  0    $6S%A96B
M                    6%E:(        &^B   X]0   Y!865H@
M8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P         6245#
M(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N
M:65C+F-H
M         &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@
M8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M          !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I
M;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !
M6%E:(       3 E6 %    !7'^=M96%S          $
M       "CP    )S:6<@     $-25"!C=7)V        !      %  H #P 4
M !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($
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M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ %P : P$B  (1 0,1 ?_=  0  O_$ 3\   $% 0$! 0$!          ,
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MW/Z(=&1PG7.Y/2;^OO9FY#!ALI+78+7-_3>US;/6R=6O9N:W]%B[O9O]2_\
M2?HV=$EP#;B]7;^M^[Q)]R6IX/18]5_H_O<#_]#L^L U=<JR3CU9;?1K;74^
M]E3FVBRST7^G<1ZF[?\ H?\ A5'.SK'9>([/Z15]J8^</U<J@/W'V_HFN/Z3
MW;?[:^>4E9%U&^&^'3^>XN'_ *GZ6E*N*?#[G#Q>JONW!Q_]6];]*CJ/7)'^
M2"!.I^T5+57RJDF>B_\ )[?ZZF3];PG^>NQ_XFXO^\?_V?_M&-I0:&]T;W-H
M;W @,RXP #A"24T$)0      $                      X0DE-!#H
M /$    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q 4@            IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ !(     0 " $@    !  (X0DE-!"8       X
M            /X   #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          (X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300        "  $X0DE-
M! (       0     .$))300P       " 0$X0DE-!"T       8  0    (X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #2P    8              !<    :    "P!5 &X 8@!E &X
M80!N &X =  M #$    !                          $
M !H    7                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<    7     %)G:'1L;VYG    &@    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    %P    !29VAT
M;&]N9P   !H    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!0       0    ,.$))300,
M      ^W     0   !H    7    4   !S    ^; !@  ?_8_^(,6$E#0U]0
M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  7 !H# 2(
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MEJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#T5N1<>OOQMY]$8C+
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M29Z+_P GM_KJ9/UO"?YZ['_B;B_[Q__9 #A"24T$(0      50    $!
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M0YQM-*6MI$7V%&V8L%$,$FT
M    "6-P<G0   #P    BF1E<V,   %\    >'=T<'0   'T    %')44D,
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M('8R           * &4 8P!I %( 1P!" "  =@ R      IE8VE21T(@=C(
M
M                6%E:(        /;6  $     TRUC=7)V         KP
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#]?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>skill-z.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 skill-z.jpg
M_]C_X03Q17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  "OR    G$  *_(   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C R,#HP,3HR-B Q-SHQ.3HR.0   Z !
M  ,    !__\  * "  0    !    &Z #  0    !    %0         & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
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M 0,1 ?_=  0  O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M']#;_J3_ /_9_^T,^E!H;W1O<VAO<" S+C  .$))300E       0
M             #A"24T$.@      \0   !     !       +<')I;G1/=71P
M=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L
M<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M     0      #W!R:6YT4')O;V93971U<$]B:F,    2 %  <@!O &\ 9@ M
M $4 :0!N ', = !E &P ; !U &X 9P      "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
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M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 $@    !  (
M2     $  CA"24T$)@      #@             _@   .$))300-       $
M    >#A"24T$&0      !    !XX0DE- _,       D           $ .$))
M32<0       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M     0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M 0 M    !@       3A"24T#^       <   ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M   X0DE-!         (  3A"24T$ @      !      X0DE-!#        (!
M 3A"24T$+0      !@ !     CA"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      -+    !@
M%0   !L    + %4 ;@!B &4 ;@!A &X ;@!T "T ,0    $
M             0              &P   !4                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   !4     4F=H=&QO;F<    ;
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<    5     %)G:'1L;VYG    &P    -U<FQ415A4     0
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M &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %
M: !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$!@      !P (
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M(" @(" @(" @(#P_>'!A8VME="!E;F0](G<B/S[_X@?824-#7U!23T9)3$4
M 0$   ?(041"10)   !M;G1R4D="(%A96B 'UP #  ( "@ ' "EA8W-P
M                                 0  ]M8  0    #3+6))0T.<;32E
MK:1%]A1MF+!1#!)M                                          EC
M<')T    \    (ID97-C   !?    'AW='!T   !]    !1R5%)#   ""
M!81G5%)#   ""   !81B5%)#   ""   !81R6%E:   'C    !1G6%E:   '
MH    !1B6%E:   'M    !1T97AT     $-O<'ER:6=H=" H0RD@,C P-R!B
M>2!#;VQO<B!3;VQU=&EO;G,L($%L;"!2:6=H=',@4F5S97)V960N($QI8V5N
M<V4@9&5T86EL<R!C86X@8F4@9F]U;F0@;VXZ(&AT=' Z+R]W=W<N96-I+F]R
M9R]E8VDO96XO96-I4D="+G!H<    &1E<V,         "F5C:5)'0B!V,@
M        "@!E &, :0!2 $< 0@ @ '8 ,@     *96-I4D="('8R
M
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M65H@        IG@  %'^     %A96B         ME   FB   !%=6%E:(
M     "+)   3X@  P=#_[@ .061O8F4 9$     !_]L A  ! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @(" @(" @(#
M P,# P,# P,# 0$! 0$! 0$! 0$" @$" @,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P  1"  5 !L# 1$  A$!
M Q$!_]T !  $_\0!H@    8" P$             !P@&!00) PH" 0 + 0
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H<G^Z#ZGZ;QFU^/XGB^)1:ZO$_#HT>'X?Z/A:/!_3T]'$]@KH8]?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>cogo_0025.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0025.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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M"1T4"/U Y^F*]9H8XX8MT3P_E)9<F;;D?[$-+/G\W45LY_H<I*U<NQPVWD@
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LE)3S8WJ=DHM^PW&3,M:$(=4I;#A95\NJ3^U64FN!.2"NPCS2_5RKVQ-(_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>skill-y.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 skill-y.jpg
M_]C_X0/#17AI9@  34T *@    @ " $.  (    ^    ;@$2  ,    !  $
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M     0   !R@ P $     0   !4         !@$#  ,    !  8   $:  4
M   !   !:@$;  4    !   !<@$H  ,    !  (   (!  0    !   !>@("
M  0    !   "00        !(     0   $@    !_]C_[0 ,061O8F5?0TT
M ?_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$(  4 !P,!(@ "$0$#$0'_W0 $  '_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
M  $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B
M<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V
M%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G
M=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1
M%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1E
MXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>G
MM\?_V@ , P$  A$#$0 _ .ZJ&?ZL6.N]+8_:X-;Z7I[7;1L#_6W_ $/S_M'J
M_P# I+YP24VO%TV_JL.G#^EO_6?_V?_M"YI0:&]T;W-H;W @,RXP #A"24T$
M!       41P!6@ #&R5'' (   (  !P">  ]4D535%))0U1%1%].3U9!4E1)
M4U]-1$0L($YO="!4;R!"92!296QE87-E9"!"969O<F4Z,C R,2TP,2TR-@ X
M0DE-!"4      !#B 1<C!Y>:WYN=)$D4?"D2.$))300Z      #Q    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P   !( 4 !R &\ ;P!F "T 10!I &X <P!T &4 ; !L '4 ;@!G       *
M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! !+     $  @$L     0 ".$))300F       .
M #^    X0DE-! T       0   !:.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         ".$))30/U
M  !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    !
M %H    &       ! #4    ! "T    &       !.$))30/X      !P  #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      -#    !@
M%0   !P    ' ', :P!I &P ;  M 'D    !
M  $              !P    5                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<    5     %)G:'1L;VYG    '     9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M    %0    !29VAT;&]N9P   !P    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
M 0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E
M9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '
M9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y
M<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T
M;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S
M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!0
M  0    ".$))300,      )=     0    <    %    &    '@   )! !@
M ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  %  <# 2(
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M    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #
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M  H !P I86-S<                                     $  /;6  $
M    TRUB24-#G&TTI:VD1?84;9BP40P2;0
M               )8W!R=    /    "*9&5S8P   7P   !X=W1P=    ?0
M   4<E120P   @@   6$9U120P   @@   6$8E120P   @@   6$<EA96@
M!XP    49UA96@  !Z     48EA96@  ![0    4=&5X=     !#;W!Y<FEG
M:'0@*$,I(#(P,#<@8GD@0V]L;W(@4V]L=71I;VYS+"!!;&P@4FEG:'1S(%)E
M<V5R=F5D+B!,:6-E;G-E(&1E=&%I;',@8V%N(&)E(&9O=6YD(&]N.B!H='1P
M.B\O=W=W+F5C:2YO<F<O96-I+V5N+V5C:5)'0BYP:'    !D97-C
M  IE8VE21T(@=C(           H 90!C &D 4@!' $( ( !V #(     "F5C
M:5)'0B!V,@
M                          !865H@        ]M8  0    #3+6-U<G8
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M.,DY(CE\.=8Z,#J*.N4[0#N<._@\5#RQ/0X]:SW)/B<^AC[E/T0_I$ $0&1
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ML":PX[&ALE^S'K/=M)VU7K8>MN"WHKAEN2BYZ[JPNW2\.;S_O<:^C+]4P!S
MY,&MPG?#0<0,Q-?%H\9OQSS("<C7R:;*=<M%S!7,YLVWSHG/6] NT0+1UM*J
MTX#45=4LU@/6VM>RV(O99-H^VQC;\]S.W:K>A]]DX$+A(.'_XM[CON2?Y8#F
M8N=$Z"?I"NGNZM/KN.R>[83N:^]3\#OQ)/(-\O?SX?3,];CVI/>1^'[Y;/I;
M^TK\.OTJ_AO_#?__6%E:(        *9X  !1_@    !865H@        +90
M )H@   175A96B         BR0  $^(  ,'0_^X #D%D;V)E &1      ?_;
M (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$! @(! @(# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\
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F;*N^"ZD.Y37C0>&:"5+-5U5' V\C/6E<$::5J:TZ-][!'0GZ_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>cogo_0035.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0035.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
M'0   @(# 0$!            !@<$!0(#" $ "?_$ $D0  $# P,!!@,$!@0,
M!P$   $" P0 !1$&$B$Q!Q,B05%A,G&!"!05D2-"4J&QTA9BP=$7)3,U-E-R
MA9+"X? D)D-4@I.R\?_$ !L!  $% 0$               0! @,%!@ '_\0
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M2FYZ/&EW=RE+GFD^]-+L>1'[4(Q^\ -:VI:)R7&&PM<=TA39'Q(/!_*E1R#
MGKYS!NYVYF':5+2VDA#R5=.1GK12MDP=D!&9BN%'EVYBW@@C(D 'A(*1_P!:
MD!]9 5QQ*:58!%N##[CA4ZDDI43RE'F /3VIX;(C"N/-#N3I"+IR+;9DIP+9
M>FH;&3CA1Z8^1J%7+DB*0 ,PO?9B::DSY2FBIB5;9")"0.%K1C"@/]DTSOC$
M:0,$&5,>9)MM^E/QI2G6PJ.2DIV\!L<CYC%2UNW!C+*U.5CCTSJF5<+;'=)
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M9 ]/:JXIMET')Y,JI+9#[<EQ ;2VE2F$YYV^]2*<#$5N^8Y^P%M,O1*&$OM
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M@!Z5F;BX&6,U=(16P%YBHN]K;@3G6I2TI:2GO%[>=R^@!H<-NYAQ7"\P2O\
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M)QM/I0SU<9$-2_G!C @=HEJC(6I4EL;CD'=4!R.(8NTC,I+IV@VE3BI"I:%
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M9R,#UKKT.S(,6BQ5/F411!86LY3P3]:JPO$/-H].TD/IWM!(2-OY5'9I58<
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8Y_A5V_\ 9O\ _P!2O[JRV4^,O\-\)__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>cogo_0060.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0060.gif
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M87?I6R-I '_Y 1[@ 1V0G2GYHC'JHA]PHS<JHQN0 1G@@J>5 BL 2P:6 B9
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M!]HZ9/?6K!<+7&EU4A9J9F@+KO[@"NJ%$4J0 P$5O[LFM"6+6AV, 2:PR4;
M"]4 "T'+V!!@ 7H V3%L"9/MT]5@V98M89<-U(\<R7Z0!WJPU.R\ >]LN1.@
MR2WI@D,05KPE!!Z8.!G4!"=@I-&0VP*\VZ 0RT!@T/UJN@#+FU%["M;@S];
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M8[$K!>.03B'&4_@O?_?3%2J:4$2YB2 'H&(""KQ9EST>0()&91,Y*WB1#&!
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MV"@C(\I8I#)10-98^G;9'/0U1[#K6]]L8-G86,YO?86A%Y"PP-D&9$(1,)"
M  #@CG6IX 9>+#0)5,0_,2C"'VXP QM"0,:&KH@,<. U0/YH$+C#A71%)F!N
M<_>YS\K*\(<:)8@F]+L(9IH6#Y^%@"Q!L+4J20$3B+@"LXQB%+GT99.E#&4I
MVR*]MM"$,&L1;& +V^,?W_*QDYW?86!C%T,@F Y44#>/&('.U>Y96R',9PG
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M!3#:7AZ+VR(Z5C[%.<1_#G2<@^_J$+S@_7YX]@L['>:PAEEL,+ EI. ?1,P
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M/IBAR(B,R"BKA7=P!W5PAWUHAR7\2'T R8ZT12?\.UN$S'20!W?0AE7Z!R'
M@!7( =NP 2]Y%@P DP>[/4<D@/YJNPL%TX&>!("5<$;<TP : "YN>9"M@@'1
M*$"G H09, &N_ -!* +F,@%SFP G$ 15B GE%#XGJ(%\3,9-R@$7.8$#0 !&
M40$!0AB?R8%=$(9BN,OPS,N&),]B\ 7S/$^8@1GL>ZGL^X58/,Q7W =]H,_Z
M!$F1C$Q;9,+%7$(FC,7,Q)(#2($<^,70;* [R[&E.@T)*  !J+89( =52#
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M T @.K.R@=R%M-CB"*@JP!E(SJH;SAI"@>$L@(#M2>?UX+0 /B<HB2<@ 4Y
M!WNP!V?X:%[^Y?KEY69@!WA@AY16Z92N0O%3V0)N8Y"D!\Z=X%FDYFD^22;,
MYFP0A1O2AGQX!VW !>NR(Q:@LZ(R-!CJIX7P WWB X,P1TI8D*G!I\[@EG>M
M!$L $+,I)*K2.8"6 5..O=+ O: 3-Z@,SJKCK4[B$G+S8$ P (:M-@0P@11X
MFR9(D0-@ 5E0!WCXZ)#>97;8Y2N&A\(V[)1N!V2FPG-XYGM(8)8E8&O&Z6J>
M8P<.2?_,YM$URVRHAW=X!VR8A/XA^"F%FJZAW9 1#MZK-@Q"0 R!V!UIL(1
MZ*VK/@1+N(08)@Q,AJ%N7-0'T2T;=CU$-N$"W(,@[M3A5*N!2DT J $)L%L
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MWHC8D1^A[83B!AQT$(,,$$6DT_Z?,M! R""JV B4CDWP6$0-&!SPP PI8'?
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M &AD$$,*1" "D/0G!2R@@1DU@09.$&*.5/$,)NRM!B\0Q#,,$( <)&$4G#C
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M"MN_$=*F"ZXY[0G-',0[Y*'T;%[Y&LA@VM.>(;/=JA0(,'4ZVIR !  ;"KP
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M9NID'BHE>(AC.+9F:C;E,1A#;#8E4]8FT=1F51+-/>[F/18##:[5T6R3\KA
MA(Q;B62A 5C5"1CA-I #-6P#/XB#*L@ )0P"(*#E#5##'QC "2C@ .1E  !
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M)IYVYC&$J%*&:&<. Y[^PCT*ZB]T9C!8@SA  QV=EHI^QG$:9PWP@0Q4WMM
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M0BV4;B>T\<=^[ 2#@N[J+B[PPA^O:<VZ BVT BS @B$?LB'3 B*+\"W0 BY
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M9H,P87_P 3-RM=H AM&K(.%&N0A2(D4 0C.%Z<WR.XVUAIFJ!JAJFY7<1U)
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MD6-"$C1NI(/['H<"D)=[D'MPM59V8E=VD<-"*+"[JCO^D@,] 2<!?ALY+,P
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M#,Y@@<H."E='(BBB##CMK,HP /5M  GP]/1-"L8PC<P0=':Q"HAFC9"P"<M
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M*3IYN9)W:U1"#PZ1?=E&F; WRZX*H1<.QL"LDE<OLU.^ ?[KI%W1%<5[L;<
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M&()!"U'@PE""\RD,?4I)\X)+D[;0%26Q80M:4%)7YK*&*U1A+FR(UWW@8@9
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3-EF.R Q&=JF#,A02KU6M@   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>cogo_0066.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0066.gif
M1TE&.#EAL0"P /<  !$3&!@=(PH<,1TB*!8G.2(F+"4I+B@H+"8K,2HM-"HM
M.2PP-RTR.2<Q.3$U.S4X/38M+C$:%U S+FDY,TD>&E=#.V=%.G1'.S8[03H^
M1#@W1RTW2Q<Q3$D]16T_1#Q!1CY#235"2S=&6#9,8D)%3$=(3%=(2$A,4TU2
M65966E9,4W=7265:6WA<4VY-17AB65A;8TE6:&9>8EMB:EMI=E1L>EUL>E=G
M=5AQ?DMG>&AE9W9I:6!O?6=K<V)Q?FQR>7AU>'=O<8I73H=F6)=I69ER78AG
M4Z5K7*=S789L9IEV9X9X=Y%T;*AX9[9Z::]U;*9<7\1\<9B#>:B";+B$:ZF&
M=[B(=[N2>ZV0?L6';<:*=\R3>\>3>=68>]*,>-2<=5QT@UMVB%A[CF5U@VEV
M@VIYA6-VC&1\BVM\BV5XAW5\A61ZDVIZDV5ZFFI\FV-WE'%[DFE]H89^@5Z#
MEF6!C6N#CFJ AW."CGN#BF6#DVR$DVN*E6R$FVR+FV6'FG2%DW.)EG2+FWJ,
MG'6'F'22G7F3GVZ2G6R-H6F&HG2,HWF.I'.+I6J4J'23HWJ3I'N<JWB7J&N<
MLWB<LWNAK6RCNGFEN5^-HVRJQ'>KQ'FTS'FZU&VUT'NISGK#VV[#W7S)Y7[0
M[(B%AY:)AY>5F(R.EK:,@ZF2B+B6B*>8E[F;E:B+A+JDFJZCFH6:J8V=K86F
MN)*GLJBHJ+BHIJNTN+*RM*V;HLB8AM.;@]69ALJ5C,JAC-FCBL>FF-FIEMRQ
MFN.GBN2KE.:TFO&RF,:KI<FTJ=*TK>BZI>NXI\&;HNW!J_'#K<W"O(6KQ(>U
MRHB[UY.]V)FRQZ>WQZ^[RHB\WH?#W)/#W9?&VXS S[G%R;C'UZW'V(/&XH3*
MY8O+Y83-ZHK.ZHS#XI7)Y9;+Z9K-ZY?(Y(C2[9S2[(O5\H;4\Y[5\8G/\*+2
M[:+5\J/9]+'.YLK.T\G7Z=/<[=?;Y]/>\<?7[-KB[MOD\]?D],[B].3J]>KM
M]N;K]^SQ^>SN\^G6U,._P"'Y!       (?\+26UA9V5-86=I8VL-9V%M;6$]
M,"XT-30U-0 L     +$ L   "/X !0D<A$=003R \" 4] ?AGX9X&CY4\S#B
MG3]W+F9\>!%C1D :,XJ\4T</G#IHZMQ!<P?.2CAHT-A)&1,-'9DQ9^:LR1-G
MS30_T90A(W0HF3)(RZ0Y>C2-G:%CD/JPPS1-4J16TV@=P[7K&!\TNH8-RW7L
M&#!CS'+MP964P+>"!@D"- B01+L1'U8DF%<D2(<C-P:^8T>D2STC6<HDG'%G
M3#6*&T/N6;-,3,LQM6HM8\;,4*-#T9"Q.KI,5!]6L:9.BCJ-#Q]E4,/N2L;K
MVK1B<9>]C3OL&T=PY2HDR! B08D1%?Z!@[&B1XQY$_KU.)BQX<*-,ZK1"?G.
M]LEJMOXC58.T:%+S2BTOK4VFO?NF:,:43IIZS.JH\F,KM>]:_I@P7+W66UED
MY>85#3R4U8,BK9"2B"!NO07(A'_49=<?"3%7D44=2=3A2-15%]AB&<VT$DYV
MS,3=3.29AYYE[3VEU%9*O8>4>TMQ-5I34<V'%59<6=65':B=U94/7]U6( UJ
M,0D&D[N-\0:#$<(%2%P(_75A7G@PEY>''N&Q47,B>>322H&I)%)A,:VDTV.4
M69:4'3]<-9IK=I+1F6CNF=%>C_[5-N.-Z:4WFGRP2>5:&E[9,$:"ND5I%I0\
M5,K#I*0H\B!<<1G$4$)?<BFF7A_J9:J(J+HDTYEVU)&B3?XQW?0J3W(B]910
M:&B6GI]&]>FG>Z;EN.-G31$956Q\VO>55;)Q!09:.%2*6P]0'D@6@I6"<6E:
M-"CB;2N*<-KIA -)9*IRSX44(JK6J?H'8AJYJA-ACM%:!F0_3+7=#V3XD.\/
M3WW%%)_OO8<??D/A2=I1A1[\6K"MV<8#&9 .R.227#G:&PU/@BN(QZUP*M=<
M=#$T2$.#I&SJRBUQ1-VZ(Z+Q!QHGU>$JFCPUA@9Y:GB'Q@\B <PB82E*E:>>
M[HWAF6=1,0H:D&.(%C57IK578Y"SV=856Q:?!>6U8UDZI;<.)J+((N&.?*5
M%9IK$$$G;WBR1BZE*YB:(JDTL_Y,>'N'1WOA!:X&$ J%HD80A.,1'A _  &$
M'8\_KGB=9?P0$VQ_6HT&;*A=)616[#G-:&U*D^[L@5PER+5:9Z&%%@V..EGI
M@N NDJDB589+\A]S\5[A<"O'W9QS&G%4YF!U<)2\F'3:$9X<:BRA!AZ.]]##
M#S\$T7@HB.L PPPZA*_#]8Q3_F_E[,V7U:)(VJ>?CO#3YA]79FB=.K<#@@$#
M&#*@M3^"".(6D\#E+6\E8A&"4,0@PA6(*UVI+A6RBZ?:!D'G:(A,'1&,!B]"
M$87@ 7(_L%X/' >$Z2TA%$ (@OA6R((6IH %,$B!#&&@ \0![(9URM>?ZJ.4
M1#'*??Y%DI]_3".?/VD-4A6;% Q:U[\QS& ,-M 6V-!60+*%ZT$C"T3<Z)(R
M/*1,9<)1V<I<5KS!8$1PD1N?^'J@/<<M@83<6Z$.4J ".KZ0!7>40?@:=P<\
M"$TJI"O-5XSVL(?%QBOM@Y_I[/>HM23(+&CARO[ ,(.+7>Q)4R)@%1,8%P4.
M0HL4XN) "B(0+XI1>.9B3@9!U$<U8*\'X0/?#H* N""P47NT5*$<Q?<"/+)
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MNJ@TO](9<$D&<*F1"C)E4S8V:/Y#18F0"%I4<X8W;V!V88A'GJ>&?72P!WL
MD^\ #X>9F*PP8Z$(>Z^I!$4P!470!$U0!590"J5@"JFP"L,P#*M@"E4PF:,9
MFDQ0!:'Y!$^PGZJ9"JEP"E;PFJ\YFZ$XE:P0"ZS0H3,V"[! /;;$E7 @G%[I
M!L/I!BBJHBC:!L5IG,N)G+F8EKGH)]$I)3U G1J)G-?2D35716:S"(&P"%\D
M;R>9DJQ6AQ[VC']0!^JIGH6 #?@@#X@9"Z: =J%HH4: !$TP!51@!5;@!5X
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M"\$PN9.;#,F@#,K OL60#,80L])Z"UW !5H0K(?[!3M+!5S !:&["K) #+)
MJ#$(.4OGD#+JM2[JHN_:P.O:KB7:J"O*KL#9M;_+!L ;M@MH!FP@JE4DD@?T
M12HS;X-PL"=)='_IM'I@"+2:#>_P#O_P#\10P[J0!=S+O;_JN8?["U\@#+\
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M@@M>J,(06" #%JB !)?%P ,^4 $7L& '0=A!934P6@*45@ $Z  ,4C"#&>B
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M)* !$F X!4RH@A(ZF@05E* #&:B "2S 8 E4P,$01O0**&QA%6B  !P0P C
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M'5"Z#R" $."A;,N]!4L"5K ^#72 %S %(Y@ (S".%&BV&4@%63"%%.  &Z2
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M!N4A4V"%)< K'6B ,@6X024<+M "+6A3*] ?*^B%4G@ %A"]7C@& /,"&.
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MA2KP EQPBENX@N[Y3"K8 B9X@!=05(HJHG%&9W3.R6487@](!0#[!<5$YUT
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M:1$W(CJU:F#(!2^(%UG@!5MH=)GO<ZT><4:N5BX06F3P%&126SN&Z"C !2=
M!7=(AW)0WTY77R(O!_LE>"/?8O$F<O:^98[^XFYHW%=W45B%[)+%\I;F<G)
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M^(S%6 SB9%Y!U,WAQ2Q:>;GMCC#!9?:G'"##/I " !@ #?B #_P #OCM#=Q
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M(&L23S(EXVE2VJE1XNR9FJDG+_'.!K$3RZO42NW^4J[_JO+_#O0>;*8=9#$
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MRM:SL7KR)F-RYKZV*1L"'EAQ;-/R5>?VY)(N+&^F0<OR*U?U*P?TY.9K=+=
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MRD\!GQ.!$0R6*$B#.\!#-D"##WC[ 23 S2^ XR,  AA  YS #/3 ([,WIO/
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MH-&! RA  0) EK'**,:Q%*!RQ3H6,Z'DGF&]IP$GP,$?'*% A+P1$MV$!"/
M2<=#S'%H"'RC(SJHKG59S6KX0A%J8@(BE<P!7U\3GD( 40?E+2\&,$0!)H$@
MCWS$0QZT4$(I2TD]A)72"MDCXOYQ\F:34I5O A68  M0\0YZN ,6\'.'5W#I
MCC$$  +V&Z/D8"9&__GOF<F,SY3(X@ 4^$ 0K7A$(2#Q")U*PIMQ/(0<&ZA
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M[A.:RP4N4 &M5UGN*738!"((@2D3H( $<&S7":Q@&?WP[I*D$5[QAG<>KE!
M .S73)7R#Z5D5*Q;QOC8 R# ?@90RUH8$ -"Y)?+S<CO(_(["00CV+0V-7,A
M6B%FI0;R@ZZ-23T?\D@[]. &G+0MVT[0X13 0 8@1H$<[/[1#Q+;0PX>0((5
MG(M0[#&L"CR,;@LL=@$<YW@"%F#"._*1#2I^YZ/PD,<\X!$/>,"@?BX=8Y3S
MQY8#M$5F^W-IDN]G%ODXP $+>  *  $+77,YS C.[Y@G\>M7T$[-:+9=4Y_J
MVM?@022:L<,/7+CG#&L8AKE-05>[JN%8\$/0896#$([0!$2KN)0)FX*FBB"$
MJ@A!TA2X+HY=8 I_[ ,;UXA?^^A!CU#?0]2P2"\QB6D_E;HT9HJ=,I4/<)YD
M)MD]E5OUJM73 +6$( 9[>$5'>9U?_KY"$J]HQ2M<D5]BI[F#GV&J2&)RHA+-
MMB4XF':&IRU#W=Y6!SI@FR=_V_Z/?.0C%!8X@A*H8 LNZ(*AYPY*$8A@!"$H
MW0(2N'%VJH#IO7Y'&YVFAZCC@0]\9(/4]@,X%H_E6):Q>EA3&E86H9E,MZP:
M2^Q!  30\@ '). !)[!#*Z#A98WW%^09]SA2T]Q@=C7$#@XYD;^ )R([9#6&
MMM6PM;<:0VQG^ 1 L(<^NIT/.5B@"45H@HJYL 4=0E<)1B#"C%<@A*9+X ))
M8$6/ZX$K\$@#L/0 M:B[@H]64%D!BOVW>Z)LN?RQ>CWQ&7CED$E&E,(L6.F!
M@ /DW@ 0U* 5&/<[EV$Q[ 8;N\'LY-.#55*;EOR MQF./ Q+4(+<>GC#+_0G
M*?H1__YZS*,>0)A $S1U!17K8@NV:.BFD$#U[,H%A  +EL$?P@H>VJ=]W*$K
M;"^X",KVM.$$"@L! @[Y@$_X8F8!VN( J,3X@H_5&LYRE._)TD,]:"TM=,8&
M'.'B+(O+/H[+ND_PE,KD8&(D_@ B6FCRS,^?TL^?]FS/L@T%5( (9R'G\D'0
M@F "CL )@"[TOF +I- )CH *CB!(F* 6B,$?XH\?8L\=0J8KQ,OVYH'^XN$>
M[F$>Y, ]+-#WT N,4LI8.#!8VB(!#@Y_@$5RE R9#.#@IH0!'D ],  #'& ^
M0N &"&%)TLSO)F$4D,H1D8HSK*81#*&=."*?GJVK[HS:_/[I!/(,!6)@>21/
M%#TQMT2,8/QAQ': ":G \U1L"[R "[+ "9R@"6@,%?R!'W1Q'^P!U-H''L"P
M*\IP'GK1'@@*'^ !!7+FX(:E]\Y.^8#ER9[,6*AD<THP?U9F^)@O6-0#+1R
M$ NQ6>Y UYIALUZ!&<),J9#*$ 2/$"CQ( AA>.8,JV*NVO*L!$# $V-(PZZ-
M%'.KPS"-8/J!'_Q!!B: "&K1";A "[Q@"U8L"W;(%-[!']XAR.0A'GH1'H1,
MR(:1&$NL'O#A'F ! JA$L=9B2E#26%8M?Z;L)#V0/=XB2B:');61&KDHLN""
M >8C!>6. 6#@#RY.[\(,%FBP*/X?P?!L *M8@).TJA1/  32+Q_]Z9_P+!]S
M*P-T ![$RH;ZP1^2X""I\ FL@ L:D@JNX!2*P1_\81A(P59J(1HTRA?%:PR)
MT2-+K,1&#5FH9"_Y4CV"91K]\"2GA!H5+CY6TIEJ,M7>0N*T1.X($2TP8 3J
M(/N8(?N*$O#$#!80C!">#<2DS1YSZRGS$01&DS3WL1--$P4<0 WV 91L2!_\
M 0J8<!;%C2RSX J*04F@03-#;DF>0;#",-\ZLACM(:QVC\K2 R7-KO>>S"^E
M41JIQ&42P!IG,C$+;OB><P%H;0'HHQ"]$P7&4=<N4SPW:/QX2ZM 4S3QD01(
MDS0_0/[/[)$T/;$$'F 4YB&LZJ$>]L$?EL "A, *J* )J& AJ0 9_,&7=$57
MX >7_JJ7YC(>KJXC"0:LL*$$!D ]AF4O4=(YN8CXJ&0]V*(D#8 Z6P8[MVCX
M3I1EFL_LU$+B'F G4< .B!*IB%(\<6 &?L .@* 'RH_:[I$$GC($2( ]02 #
M0. #/D ^44 TB50J,R #8D$:L,$BX8$B4>%@:)$*LB +N #3\ $,LT$;I&&C
M.HWV!$N\XB$>RI!@@BNX\* M&$"QTJ/L?(^^GG-*[-18&"!. < :5PTGY5"Q
MXN-E8 99,- P010"Z(LG)2X&)N$::G02<$#Z>J!278AMEOXT_4I@2.63-$G@
M YX424E3_?+L2)/T TA@2;^Q%:0A%N2 %*1A%MY!'M2R&!!&"[@@"G!A5ALP
MW_1-W^!A'GS5?8BL+O.!_DJ,'["!! J UKCQ+S.4OD[2)5>42A1@1 $@6Z\Q
M9JXS63JT?JA,)5MR/:9U ?:T ;Q3\& !!P   >P #VC@!S!)AM)O2.V5/3<5
M23\  S(@2:$RSSA57T$@54&  1+ >:(!"&#UWK+A4I9AA[P@"W+A'2@6L.8!
M]])T&/--&N"R#+7R6'EQ'_AA% K 7*=U3O=2 9S3+Z7S+(HO +)56S&'4#DP
MI08SC JN0UW&)KDQXAH@/6B-1OYAP0Z@1 ?V@+=LKMKPL3U%=5./E%^;]E.7
MMDA)( -"($E/( 141@5R909 !AMD#[#D 1FJ0 MLX1B,T8: JQCGX=/*4-3:
M)WX&;4TO[QW$P@&<T0(Q]"]5=EKC% '28BU@-F:M$3NEL> @2V;"2&=;=B\Q
MM&;,E0$F0=<(X0$ P.YX2Q0SU3V1% /\]4@?X $^UU0Y-P.JM@*L\@.(:0P&
M2P7D@!;B)QJ^ RZ+(1>L(!=R<1Y:4Q]V[BY[$4(5T"ND 7:ULL2(<1]& 0'V
M-$[IZ\H6H&^%Y00S] !B-EMA-@"B\Z58#2>IU> $U3T:(%E:]B6'"5"5A2@-
M 05P9OX&>J ?_>EI,2 $Y-=?2V!?'\!SC_1(/_53D90$'B #'F T&4 !-, 5
MLD$.P& K8I447*&CLD$>WH$7<)<?[($?>'?^VG881<V&AC%7:.$?X$$_]>$=
M5.  \);65)8DU0-Z'Q=#UV( ^I0-W6)GVV,:\=0 .'#*&L /O96+9E+5,I0Y
MJ21GUH(H9P"&/V (,[5^,V 0!Q$$0J ]F]AS];6*JQB A]03/Z !"D %O"L&
MML)]:D$.8"%^Q(M6TW+G=JX>U/1B;4_?;*@7.[(B_^$?Y&$?2.$ M%-EX[1F
M>M8O/S1#3W MMO</9QB'Z[ Y^Q!/G[.0[[0/[5 Y2Q)RA_X6 _KTG_9L/N'7
MB9NV?N7"5/O5BO75?X=T4_%6 >)@L.0 &@"K(EUA%,846#UMY][65VWYZDA,
M'_9!=_>A'GX+@CGV!,["8!M  4J2OE1692>Y[!*@]TYR6(3%D?]23JGL.66X
M1)73?$'4[#0T?1$ 9V+('CWY?IT8?X=45(OT T*@ D197TV7!#9U 0Z@ ^2
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MD0FL5UA+ZD+4P()9!NA81X\A$--%@:6:9;R(S;K2?(,5Z61@^!8PT$4?F:0
M:@N4<--!"TDEFP;" 6543V\FE8$#%N_Y[&PV266B'?!@^QRVW"Z:#X[A1@IS
M6VS)M4_+^:AQP)&=,93>7YLN6)Z564H$9KT0-#   "M)]%=B^"'@7TH>0:G8
MP#HM0&JKKR,A)J3#?NZDD),[-<5AG1CT))N=&72@P4$YZ<D;",5-2U7*7LT#
MUCXU@Z<WN&A!FF.E;>V3UCLH%*"SD E6V9)@"A56DJD$*=S T0X@4!'31/]K
7DL(>74;T2($=9U!+M7XZWT<?*1 0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>cogo_0033.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0033.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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M1LBZ! VE0X]Z91=A(Z5>6T]2/UI4.L3]<L?ROWT*!920HBK5F5=A$J(YHU8
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MQ);<5M*DX .0D9\A5S#P5-331$ZXE=Y'C>+/>'?GVK4T/.=)?3,'R_&BM/\
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M_'V/CCN=N.4C/5..#GK79Z/0K2KTXKOLX?7Z]Z^7JR?"NCYW7+M?TQV-]O\
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C]VD(9NVR\+4L*M$[:.G^:N?V4A _JJZ_[(G?\JY_=I"/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>cogo_0038.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0038.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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MWB+(4L92E+HWG_A//Z5+715*&2/#7 8^(]U?\BOZ4+17M9S,2UL.2*J.H*X
M1@)S4(>H3D>)-0A\H) Z'GTJ !\F$IQU+K3O=K;/A7C/!ZC'I0:"G0NTVAE7
M@&2>I-2@[AUMZ?K4H&XS9&Q>0>/YTRX8LU<;1U5_T>O:8[K#L78TS=%)5+TS
M(<MS#F>2Q^-M*O<!2L>PJC+!KW&O#D3X-IB\D(W8)ST%4*1>5C]HKMPMW87V
M=3-3.Q$SKM*5\%9H.<F3,6GPY]$I_$KV]S2VY2&M51R1UM=^T>+JZY/]I*9$
M2^7?^WS'WAN=DJ7RES=TVD'  Z  5OC<5M:HS+W<V/OB(4ZW.2FV1O2VD_>#
MDGGS]:*BI(*=%Q?9ZTK"N^IH%^9<7$N=M>48,QE1#D=P$*"Q[]1\B15D,$9T
MGT4Y,SQ<Q[.AEWE'M#[+;A%DI"):8VV4R  "XD9"AZ!77]*JAB_+YZ?*!+-Y
ML=I<G'G6MI7IKM&OELQM2Q<'"D#CPJ.X?SJ^7$V4UP)7-OO?O4G!/-&7(JX(
MS/8#B@G;M .XGSXJIQ+$[&*0$')Y\A2]!'\9> "C&1TIDP.@I;KL[&<PA6,=
M,'%&Q;?P2^->ES4(/>NM26SN9D-.%+B%>1!%,X1ES\A61KACS]^NU3_US<?_
M )32;)?4EP^A4G='=R:6B69;!M(/I4H%GJ4I"4XJ42Q%TJ0ZD*'A.4D_/SJ4
M3<(K/B((Q1H-GJ-H&#0(*A61@"@ ] /"<].GI4^0OE4;A_Z.+7"K7VCWK0\B
M04L7R")3'/"9#!_%_P JC1<=R:&BVFJ.EC=VCFV/R9KS3*8P)DK6<)2$IR23
MY BL>3'R;XSXHH)&CE=K^L&>V#5[:W;?#2IO2UL<1]W&C%1_M*TG@NN$;N>B
M<"MFFA%>^1GS2:6Q KMK^S[8.VCL\?@NQ&F;S [UVV3 D!3+@!(03U[M7 (]
M\UHR263CY,L'+&[.;K<MRS-/Z=NT)PNH4Y%"61N^]059&1QY&DC+:J9JCRB]
M/LF:IAN:U185/H9?<=26T.82I8(.0 >N//%68Y?!7FA<3HF8;FG[8=3QVB\B
M/'6)<0#)?8 \7'J!DBLF>6Z5?0?%#:K^IRN^UI M=N[=KG(LCJ7+?=8<2YQ%
MIX"V7490?GCCZ&K93WU+YX*'':W$@9)=C!8'D*L^! ',0=W/2D8R!+H ."/,
MG%5L8RC+*'1MYW$#%1 8Y)+;IP. :(H<M$A1P<XP:LBR-?)(=Q_Q3^56"D#-
MHNI_\*G_ /2N?TK/:#3,%6N[@'_LJ=T_W5S^E2T1(]%INA;!-KG<8Z17/_K4
MM!VGRK1<W4J2;5.ST']E<_\ K4M$H;&TW98WJM,_.<'^RN=?^6A9-IXNTW8<
M"TSO^E<_I4X#1DW;+NKK:9W_ $KG]*'!*8LFU74+!%JG8\_[*Y_2H2F6)V W
MN\Z![8M):E1;9R6F;BU'?RPXD%ET]VK)QTPJFBU:L*M.T=<KCI^+J^THMUT1
M)##BD_$MLN*0'PE7X%X_$@@#(\Z$TNC1%M4PL[#2PPIAIDH2 $I2$X2D = /
M*I"K!)%?Z\U@[H30&JM2QXCKKL6&I$5L)/CDK\" !Y\JS]*>3MJQ=NY)'(_6
M<6\L7V"EBT7(%MQR4ZI##AWK/7H/>DR.FBV*M66%HQ=YT_=X.HH%O?C7"$XF
M1$<4PYN0X,'!\/0]#\ZLX3!%N2=G4CL:[5K;VNZ"A:EA0E1GEI^&N4-Q*@Y%
MD 86@\=#R0>FT^HK'->[<6=+:<[_ +:O9I<=-:DT[=6V)CY=1+M*DI84H-(C
M.[FD@@=-CE:>*4OJ8\CDVX_<IFV0+FN'@VN;G'^[.?TJV,K0C3&,ZSW172V3
M!_[9S^E+)C17)'Y%LO"7#NL\[H5$_#.8_E53'H<6^QW=U])%JFD)5U$9S'\J
M,78DD.[E8KJTX%"US3GTC.?TII4A:8O9+;="Z$*M<[@Y_P"[.?TJ18>:)+^R
0[C_Y9-_Z=?\ 2K+$IG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>cogo_0067.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0067.gif
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M5\&%Y\#8%(R-9'^*Y-@YAJ)CCJ$77:3H0\Q*9E*0BXKT7GOPG%/..>2HY))
M.Q$T(3?F<"N-9WNA$HHGDJ@AR3__J &)&O](XDDHJ&ASCCKGC#,@4#G]%UI%
M9%J5%;U,?Z5/<L4E5Q:( +_IKZ[5W=D--7M2@]*?^?SI7J(+/S88H!H!N1&C
M&;,M9,6=523.83J9YS&6^MT3BOX::92AQ1(LF/ ""S/(((,--]BPQ U+>)&&
M&CP3=16Y.57U[IC0S=L55^KH\]R]\QP7NNCWTNHAP'/JVM-UW=A5L$GD/22D
M1K33?G9&(0V6.TC.YL-[D"-Q])@Y'W]LV$KBD(;D7J$<@G,HH:RQ! @6Y,!
M AZ0, ())+P@PPV&5X$X"^3?H,49AX0B#3Z>4=>3B53QEM99&>J3JCZ<=_Z<
M_;.*3J*;QY&'/.84,('A"1O;V<[!&!*[]P#J@;2K6#0 DX]G.2LD%02)[WP7
MF<=\+!X=LX@YN-$9;>!#&Z'X1QB64 06D( %2UA<]2Q PQSDX ,X' $+7N ]
M&\C@!?Z,LX$++0!#-G@"%5S)%:K2<2%]B>6)^N/*T_#AN<[QSTWZ8DZ)YB'
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M6,K2FK:T^<K*$E$T'8/V!$]:0_[@=A::K/[@[FUIE0Q:UPK,>] C'L>L(\/
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MLCK"F,64HV-F:]M)U$$FSR!W#5I@Z0P4QT[U5H\!)@@#&?Z>4(04E  "#A@
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M$.2 =HCS=C@W B @ 0U0 4T0!G5P"(9@"(NP"!W8@7R !W40!D]P!!C0=Q(
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ML)&'"'<5< $/@ '%1PC+R(S,R BV8 NJX JJH BJX(R,P/X(B4 (V_@&/O
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MS1+)>?[[S.WB:(T;,Q8K1JT43)8V3YH\MMIDZYG";HXJ=:IF2TE+9*! $
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MQ!_^$&$)RZ&+4<#P&P@1BUSTB#JP6 0B\L!;)$S IP0@P  HD&('2*"9%4A
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MY'%">6$DXQ1?T((  XH!8P B"#T^.*U?>@(A (($(  !Z!L!0#$*4 '9.S!
M>P2MP#W=LX,V& (HF(,X> ,H&(/]V1^M^CD)&X,36+X-0 !J 0SJX@$)<#L>
MZX%*DX +$#(RR;LB(X(G" ,U0(5U6 AP< =W$(=R"#P):1[UDS+V^RNP^0@L
M$YB!<?Z4["D&^WL)ES"4E/ %8U &3^""+3BS'!C S$J )J"]C/$L,>B!"W"
MGEF  +"!*@B  >BQ'D@".& ?.LB#5<F%LZB%J9,#)]@!-X"#,1B#1$2"(NB!
M%$B!ZO.G-_"W 1@: 6"^:"F!ZGH %'" "G"K2GN "EB"$[*='R "(OL!)@B#
M([NK=7 '<]@,?&#"4.H&]>N&:V _/]%%'5(\^6*B@6DY8X,\C/I"8C &;*@E
M^R"!!#B !<BL &" )D@<0]@#GE,T#*" !R"#--@  : 6 G" *D"^0V0</+@#
M0#R+1R!$'_ !-Z #X4L"%< !%3   9@B Q@ !U !2J.6#?Z &)XI A(HK@HH
M 0N  !;@ 2+X@0NH ![ @!7(KA]H$R$0 B=@@B@(@T/0!FX0AR/4C/-;J)',
MQ8O81?=#28$9$6'XLB]C26$HAF)$!I(@B8 IAB]4E&2 A/J8%@,H  T0#I1J
M@"AP*7%"K210@G[\!T\@ @=X0 >( # XA#U(@C;XO3_8@T70A5S G%N BRA
M B>X@S^ @R3  39(!39(@"J@@BD*@!23@!38  CX"0'0@ U8 A0X 2*X !"
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M E6_S;0&SC10DV!)EZ13T"RB9'108XA)(\I"8? %85"&4BB#*K !&9A+OG$
M!WA+!P ]KU.%E^(VLAPZ,, !?P*#+2 "18R#/TB%QRF$!UL$'>6%6# T/( "
M,4# XIL#,/B"+5""!V@T!]C4+:"6Z=H  HB8 J#2XI* $EA4'N !^;R ![BI
M(%@/?G+'(7N"W3D$:5 '=PC)JDD'<^ :";G,=OC/S=R&S=3%:Q!-T+Q38*C3
M4NC34B")F=1"U.@>90 %+RB"0]T #_V;N6" "A "// Z6_Y ' ?;33W[.3(P
MP3OS@U8P6%7PND10!%MH-UE@A4)(M&PS!&'Q@U0(SB/P)W_Z@2.H@A^X-!PP
M 485 (%; ;ZD2(/4&RV5S\'<RR*H@ A(H?C,.R\J@B.;AR.4Q7#PI+]3/YW]
MSR>#,@,UT#K]3)1C25\@5\A#AIF<"6,SUS#[0F!0!DS@ BT(C _P2:!HINH+
M4D586&$1%E:H1G("A% MA$\UV%88#[ EG%CH#EEHA43  SEX@P93A50P!+2%
MJN <@RTP@B% @A6X &/:3@(H@ 5 @250@1YH H?LJ@OP 1X0@A]H@ H@@B!0
MCTE:5C=Y B 8@U20Q5@T!YTM!_Z'6(?_M$QMO4PH\]9OG2\[94FY40F84+ET
M9=J F5! )88PO +6&8$-"-&WC$O;"=*[507+<87'$1833816*(2TA5Y;&!9%
M4-A9  ]^G=O2Z@,V,MM$N-L;%;<Q (,CZ $@X($2@("'>=(*J*X3$ (,J  3
M8 !C]0$@<,\'  (A.($<]!96XUPA. *.)(<CM!-Q" >&\-EU:(?3;8<&YLP'
MO@;9\)?NT2A%28D&=5":;(E26%JF+0E?J#QE^ <.VH\,0( "$ "H+-\@($J$
M505=D07I5=XV.ECH5=LF4855\"9%L%Y><-A$V ,YH(,[Z(/GC52S-03&Z;:H
M>H(G /Z#)N"!"!@ B$D !2@"(L  ^R5,!Z" 8?6!$ZB !^@!(0B"!C".^$3,
M)V""(_"!-9"&<S"'!JY6RZ2:S-#9!FY@G6W=UFT;C.(>EWR)#D:&D4!78SB&
M9?@7G #AF%2#FAM(@ ,*?D0"(?"!* BF5I&%6$C>8#G>5L&163#86=@%@Y4<
M\_#>5SB+6U@%B*4#4REBL(W;4!4G/MB#G_NY,(@^"7Q2"+B!)G#?('  %*@
M L  =Q1,"\" (2B"!W" 'Q@"!C2")H[/O=,X=PB'.C%@A]!6!5X'>\#C:V@'
M<-YCER,VF/BR+2P);$"&#7:)$/E@F#R%%-D"R_K&1F7<O_ZUY%"%G )JBZLH
MH/&@A:]HA:[HBE9P$M!)A%68!5S8!5V(5 2\@RS:5UM07E#MU_;ALS$P A.8
MXDZ1 !-H@A\( B&H  S@:,CU 8FT@"YM @QH@!7P 2)X9FF.:8( AX]TB'"0
MUFSF9CQNX'78XW &U^[ITY=\R4!>VI#@X)9(!G?^X&0@!3:P@2VH 9[A&P'
MWR=@8S'  W)BA,AI"UK9BJN@!<P1$N\ 955@!(1>A5=(BU=8!=W*(C[H T2
M'/])6T^697$2 R-P:4X9  4 @2_R@?>M@!60@ 8H["!P2,@] AW /F<N['!Q
M@LFEC,<TW8^\$Z#.#'OP9I_>X_[-/$URKD*-(N=!/H:9I$E#;F=%F11?@&K-
M6P)ZWDX#J #7&H(XHP-R6H15B)RI> 61N8I<6)GNP*96D%[0601%,)FW9@5
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M-+?'T[4&D*E!7;HJ=&M5D^%ZC.'=9"A4HLC@(3#VH(4B4'D#) CL>@EP!$/
M-Q5[0.R@\H!2Q>HM#HA(#2(2\1A&4+;-JW"$9 HQ,3[0^0^$$.GW!H&(/N"A
M#W[(@Q\@K <!)N$V&1Z 8&E4 AZXA@=/L,T$2*P#(# ! R:0ZB)3Q]7DY.0)
M9)"&.[KQ$V_\D\?0O48XHF8-(0=9NV<R<IA.F5"$1O0[IO[PA!:". ,K0P
M@@T !/:0"E2@8@^\-- =[*#L?ME!#@UKHQX(E8A%^%0RD;%;A0"1BD[1V1"#
MH#/@[H!20"2[7V.N\*I8FV$&5(Y&$%!!#S9WA"AP-0'!\<$35A#5$_2@"1QT
MR8MQTJ2AA9K4_NQ&CQ.^PG  .6K4>/BLLS5*(GOENW05TREP#80BI,#*"0"
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MGR;:$%QQA5TA0S+8U5T%H5L93S& 7UF<PA+^P JP0 6@0*\9E;RL'_L!@ *
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M 08"&<;!&8:A($0C(<BA(^0!-,J!7N"D$Y2,:YQ- E1 !#Q #\R,#WP5!CB
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M]U:#RC9#;T;K]$UN,CQN*#:#,^#0#6FH7=V=$!(#DX$?7OF")W@!$;@%;^&
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M.!\UFT"#]W(?-C@#-8"O-31#.G^ESH+R]X$BU1@#,X!?B2+#5D>"%MP <UX
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MXJ^__=^__*O_)WQ"*$B")+ !0*184>1'"0</2IB ,(!!!! 0$C!0D*   (L
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MO!Q@@-%Z*.*$"$:K  ,F@ECA @GH->&'>B^86X<+FO $&V^XP68;<;K99N
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M:@0Y%8FKNK,2H,AJ*((;W.'2<QJ4H )91\""%30A9TT0@W1U%(7=W<H'%CC
M4@Z@Q"6&X ,06$ % &N #>!@!$SVDGH/2]$4$$$T5S%=!3Y4@0DXP7P&$<#8
M3%"!$YBO @Q1 RI.@8UJ0%C"RK"SA.MLL&8TXQE[QH:&Y?Z(*$@]RE$->Y0F
MZCC;QC7UMA+DXR14K,C>_E:KQ+5T5R$A!1?0X 4B( %S;["$)FQA"^]:PDI!
M4#-:UJRP&0A!!SX0:]8$%FL?&($(., !$7S B22 0.NL<@(@F-2R^:V !,YU
M 3!'9&P76!,&J). -*#B&*8PQC*6D8QE'",9R5 &,K ![F78><_E%B ST)UN
M9F3"88:Q!*+;O=01S]NIG:MWI=A)53Y>M<65R"JE0='5K@8<%%3P  Q>0%87
MS&X$)*A !4A S!S$.@<<\$ '.H!+#6@ :QLH+WA)L $%B* %N\YU82'PD BD
M0 5?#(T#!/" =*G*!&FJ@ 4JT/X:B#^@ A=H  -D( EI0.,8QS &,HI>]&XC
M8QG(0,;1DX&,J">#&,RH>C+4C6Y$/\K0FH#WN\'.5'#:NU*US3>GS#FY2+!8
MTBW>*G%!,0U. +<2+3B "%R0=Q>TP -][SL)_"X"P7.@9@K(0096A( %Q"X#
M$B7!!TA \A9T@ ,?\#@('IX"F*X 1 WP+]9*(+8@H, ![&) Z=W#  LXVPFA
M\$8VC)YM8\S>Z,@@QNQGCPQA[)X8O>]],8 ?_&(,8QB:4,PE$(,)Y,O6ZXFC
M-SNAWSFS-[42NX6TBJW*3JVZG=)=[40G?@&)%G!  [GV>]]'X($<J+]V&"=_
M+1>@@/["*IZP&XBUX$,@^,=S +PF (& 5X#E4F ")&!<5(7G0(0'?B !#* "
M(D("'DY[*D +RB 4R"$;L $:[,SHBLZ>C$$8[FGV=F_WBH'W@&\8AF\8A $%
MB\_KD,\%%</K$.WK$&W$H*\2- $'R^X&>? &L\K? (ZX?J$3..$7- $2J" &
M-DX##F"P"*]FH+!F;"G):$D!Y*_5L";_M# $\N\#=@T$2"#-1 0#3D4"WDL"
M5.4@0F^^'D  %&!<&H!=!L V/&LM_N3!FH[VBNX#1[ 41F$$21 %A>$75O 7
MB(_X.B$&D4\Q+.$%F^_K'H>=WNU2-F$R;I#Z>G"KO X4-/X!%$0!%,#/^S"-
M"FJ@RCC@  X@!Y9HXY:HL,JO9B@OUW*-\CX@_P1OK"1/_RQ@%T]$ E*F 09
M:C: 90[B2MRC @*  ![@= 2  "#@!CP!%:"!&[PA&OHC&I0!VY8A&(HN&)ZN
M&/YP%/X0$%<0!3MA&$8!_(9A"(>A,(Q/!D%!,3)A^60P[!*G$B?#ZR@#!W$P
M!WL0^CBQ$T$1%+MJ&@0N_*C !FC !4)@ 3@ XSJ@U5H-(A_2"V=1!#+N%D7
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MQAO8UCM2B;*87+50\O0R!,1*!%[ EDIV4@7O3I>UBL.;G_D<A,N;"K( T-$
M#2*!%( A0GE9P]+M&0*COJ=!R)D!TATW&!ZWTU-8RI5!E[M-RC%=RC<=3266
MW'G[&2"Y)]\A'GCV&$[]#"S(@KS@"\;@"[K9F_/.N9\;NBT8G0T7XTBVQ474
M(V<9!C9@ 5Q !C2 UUN@E!/.>(5ZK/K9XUL !C2V6(O:LFO\#-:@VIM.VP,#
M,-+-T3NA)V5>W&D^TJ-!J8,[TO[GW>8!V#\*_!F^X1L<UYJO&1ZB@<NG_0R4
MW@P W0O2P-5-NJYA8(O17+DVULRENR/I-LE:K9U?_ 4TK>1N5D1Q5 &D@,U#
M0$/7DN1:'&Z9%;SQ?-;+N\*O( NZH N.>IU(X1G888"X/5'0K=$;G1GL7>9G
M'I*MT3^$7NBM<1JL,>@77^A]/O&)GG:ON2=WUA0@80W*(-7+P O.X.Z]P.E7
MO;('OIP1/K(;6"XA=0F3"__:?I2-E0DUH I>  %(CF/[">$Z\L[+^\Z7U05$
M7J]3F@I*NK++( T\AA2BH>^981H$J!.* 8"DOQAB7N9IU_#]0^:GX:T9G,&)
MWIIY\OZM>=(_:-?F^Z,GXR$>H($4/ %TSB -E/[S/W_TR0#JN:"NZSJ3-\ZE
M?=JE 4*#A@,'!'9H@;"%"!$)$;YXX4)*BPX<,FS(\&)*@@TO6KB  >-%R!=2
M0K20@C+E290(4Z:D,64*%2M9:G(I<V8-I$^^GK%CQZP3-6;%B@T=1NT=.'!*
MESI]^JYI5*53IS*-RC3>4W#NX,6#!\W3&C1GRK IX^4+3C9=NICQ0L:+#2Y9
M:$BQ,D5*C1$><A!<(#"PX, '&R*$X>(PR(^).VSH8#*$%!@+<""F@1@D0A<0
M18 4"0-E:"F81\.(Z7**%2I7N'C)"0D2J&?/IC&[?1L9L?[=7^.]TZH5G%:J
M\-[!*ZX4^7'CQHL+!X=.>#QTW+*%@K2F#$ZT7KB;+=,ERY<T:;30)&W#RA4K
MI%MX\,!!8,'! A,F;K@XL\>)&3*8)-'"!CA4X9!E,!R6D$@Q:!81:9>E!))+
M*,6DVA179.$:&F/%1HHRM.&&6S+QC$ABB<6->-Q7[]#SU7'%O>CBB.#00V,T
MH8B51EG:Z;@C3F6%IT4:7FB!Q152I&=%#37<54-("'G000?O9>"!1_<9=F +
M$"$40@<: %88ERY4(84(.!B&66(Q3 8##2Z\B=A';:9$16H5ZD533%QTL2<;
M&NX43#0@%L5,B8;V9B@\]'B%J/YO-+[353PTHF.*)Y"<Y:-VF+)QAA>>EI%&
M&5Q<P<8:6GR!!7LVI%?#FNS1P-!F3XKPYDH)9=E0!QEH<!"<+N @9PMUBA#"
MFW*"!$,,,7@$&K*3O927A*G.A!=[[-5P(154N&5&&3I]$LPTUMR&5(DT'FKN
M<2RRZ!6-\,AC3SW3!?-);&S<>T:G/KYF5J?=A>H%%TVL\8466E"8'A98U !1
M#(EU=M*5;TIQY4119N!E8<B"9!<.$GF\ :T;+W92#!Y$M/%D(H$FFDM4Y#4%
M%E+$]#)*5&!QLVLXQ1:;+]'8ULFA+)H[-(U&&]TN/?7H0P\TD4!B%AL!0P+P
MOMUI]_ZOU'Q^0?#!4W"A119A8Y&%%2)PP(%[(KQ76)101@EWE T5*])D--Q-
M Q4NA+"!%#ADD-_(+2PK84HH>W2WA-K6.?-DK$EQL\(X9V%&6UV4$5LDX3Y#
MS= DKOOYT4;S,R(]^?"#NC:G>"+)I6R8H?59;G6:[VMEW:M=&05[^@6?6EC.
M)Q=TU: 0?&C')Z6N;D_$?$LC9V;7W<#2.L4&+I0V<F(2B<9QFZ'9%:'B5N U
MH<V,UXD^%<)?GD9LGI@2#362&CW__**/O@\]J/-#Z2>2K+&&-+"E+6;A$Y^\
M8,!\U0Y4H1+5>); A<JMCT]8$)ZU:I"86AFF)2?I(,78M/XQ7\'@3+^JP@M$
M4(,TM0!9'UD)".M6.)@PCD(Q68V%HF4SQ:T/5 #<"2@Z=RY)W>-H]M.?$?5'
MNF-$0@TYTI'6A'<3\-BD"_DB3XZZY2DS<"$-9+#"%Z (MM:DZ@I78)S*(M1!
M%WJ08O9IB43N$Y$S52$+.'A(FK@7/CE) 8:%0XW=+#2A&N)P3<HRG\(BF"\V
M9(X4I;O?_5!'(]3%0QKU0@-Y=(3 +E3!-6W)PA6J4 4M>$%(M<M7&=[2!2^L
M80E62!46^)0%LB5)272JDY9L=1*3<,E*%-M8Q%#RJY1DP82EV2/*(A2:E*$$
M?'9QR1UG1L:\F%$B:T))-2$GN?[+^2ESCI24HH[&#Q:ACE*6:B!.O%"YFF22
M"R\;7VO<TITJ7C$M;/B"#;0 P3T)3V&DB4%''.*D^T0I!%!J00@DXQ&7(,N%
M#?*;^DCS@KM%!&5W,TTRF^DR&N8E?%(H8T=5(@6<%4Y;=,F"6^X%"4D$<:7?
M!"?I4.$)3_Q#=FWYHN7V1(4L4*$*U+J0Y:[V%E1^P0NL_-TAH:BP\3GL,!W1
MI4&KU('MN61BESD0G/R&55 63GL2^DAJ<MBXF6GK)8B9R5T>!%;S+<XF9CB#
MG]2P*'0YDG1A^8<:(-$[+F#A=T,M@T[KQ%.>ELT*>TIE=P+F*;!YZIY+V"L6
MO@A%#/[I-"()"HGY))3&6V5P8A(2VT2ERI**8@]OA;M"M,IX/O#9##./NV8M
M%T<7G6%N#8I"EZ0D%4YZW,-&,KT4A@Y)09GQM)9EPU JN9-%+V#!!F>P)U(/
M^5N;+&ZZVOKK-#VXDF"%AB1Q\AL[/0928&)&,6VJ&T998Z24X'!"H3'2%+*@
M%[W P .UA)SZ?@HJ2,35MI&LT75X%AXNH*H+R\6"#/*V4_MF0353? LZ$<B%
M*6CA#.8AK'F@B%KJZK0F:S5C0L(KD3999KP0D4@H;<!18(:8!BMD9N%L=D/U
MVF4]5$#,S/)238:]>*SJVU.WUK#?%A%M4J:PU[V^8%+SI%&J!@JCPMT JRW5
MC*TMO%.8>=2R*BPTMI7"6]R.'8<^%;.$@]M#\#2!F04;>(RR#57("N=TYAM#
<+KV0@QE*U@-,UN!M23:PBPNG:U\?EP$- 0$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>cogo_0037.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0037.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
M'0   00# 0$             !0(#! 8!!P@) /_$ $80  $# P,!!@$)! 4,
M P    $" P0 !1$&$B$Q!Q,B05%A<0@4%3)"@9&AT18C4L$S4U2QT@D7)"4T
M-55B9'*4X4-$LO_$ !P!  (# 0$! 0            $"  ,$!08'"/_$ #,1
M  (" 00! @0% P,%       ! @,1!!(A,043010B46$&,G&!H4*QT0<CD152
MDN'P_]H # ,!  (1 Q$ /P#+R"GH*ZCB<G)'PK)XQ2XP,F(/7@&H-DP3CK1Q
MD23Y$DU,"#:U^0HA$Y'K1",*(W=:!!"U )]:C(UD:+G3B@L@X0E3A/0=*(4E
M(2IQ0/\ [J=!VH;4M94<>53(Z0@K-,B/@^ .>E 04>E0 @G HH496<T6/'L8
M4O:>*4=(07310LD?=\?2B 0MTFB0^WFH0V.XH8Y-6-%.2,YCCFJV@J1@(W#.
M*7:-O$K;.:BCD&Y,96THDXH[6%-#1:4.J:5Q81EP$#D4&'W&%DCK4#C @YS@
M=:F4A?S<(?;MZWD;G%I:1ZK./P%(YKV+8T_]PQ*=MEO6AD)=E/*^JD# JMVF
MB.G1%;D,/%>^(8RCP@()5D^G-#U&'T$A+V8ZT@#E0^JHXQ^M.K%[BRK:Z/DY
M=&] )!YZ5:IQ*)PDO8^*PGD\4Q7G!\5@@BH3L;/2H@)#+JP!P:+&CV1BXDYR
M:4LRAI3FW@$4<X UD;4ZK.?*ID&#[O!QD]:.088YO]ZF43#-AO*4#D^57M&8
MBJ>)./2DP3 M#^!S0:#T9+P)SFHA6^1:7$[1FG'3$KV'S'-':'<1).P=:1Q#
MN(K3:WUEMH95C)]AZU19A%]:<NPC*93:66G$8PILJ<=<Z^P36.=N#?70I/A%
M=<ND^X+6IIQ6WZJ05<_ETK+/4)'0AI-RZ#EFTM<91;6M2@G.\J4"3666L2]S
MHU^/RN@LNPJ@^)IW?)*MH*DYV >8'K06L&GH$@&Y993CA5.9=P5G]Z.F,_:K
M1#4)\F&W1X70TGNH$A(:>0M).TD \I]*TPO1SKM-+!]-MS;K)EP0H-]7&R,[
M?<>U;(V*71BMHV]@PH4DX(Z\_&KC-C AS.W&.:!"$_OQQ4(B ZI6[SJ##1<4
M!08R,)<4>*@1Y/(P:A![ ]*)#8K_ #DXK6V8B&1SFD7)&\&,D=*CCD&XP=QY
MS2?EX(UNY,;U <G H[ADL&0XD '.:._V"UA9&W$KDK0RPDJ<7PE(ZU+'M0*_
MG99!'AZ2LSW=LHF2W\;W'1G Z' ]JY.HU"BCMZ+3.;Y!5NTO.U2Z)]\=<:AH
M.&6AQO'P\JX5VLYP>IT^@BL29>K3I>V-@,Q8#332!PD)_//G7,MU4CM5:2O'
M0<19DQ 2E)VJ'A %9/B)&^-,,8P)<LS2=SI93E?(/I3QO9591!D1ZT,NI6RE
ML)*O,CK\:V0U#2.=;I<O"*O>M$M26UMMCQ)Z% Q6JO4MF&[2+!68$>1;Y7S9
M3B2%*Z*&1@>7PKK:749EAGG]7I]L<B;_ &A-MF[6SN;>2'&\CR/7%>AHQ;'@
MX%JV E3 /V*?TGDIW(CKB;L^'%+*MC)Y(;UM"CDX_"D<&%,CFWA(^KFEV9&4
ML#*H('1'-1Q#N$"*M-*PIY'.Y7Z5"&QI#75-:\9,9 6%#@#SJ8P!F0VK&<5!
M1"DD9XJN79,X([RB!@]!2X#DA.2"W\*CX(N2TZ#MRYSRK@D[ELJVH!_OJF^?
M!NTL$71O30GER3,84&F58VJ&-_G_ 'UYO77;7@]AXRA..0K'@MO.!1;Y'"4@
M< 5P+)-]'J*8)(/6^VH)R1Y=!5#S[EZDEP@T+<E: E+? \L4C2?1'/:1I=M[
MIHE"1YYS47 -^0)(C!L;@.33;PJ*:R0B@I4K"?K=36FF9DNBBHZ@M+,:6S.=
M04M[O&0.!73T]FZ:.+JJ5Z;1.UK8VW]&,W1+0+T$@[T_;:5T(KVNBL2:1\_O
MS&QQ9JP.I5@YZC-=2213D4%))/G53AD*8TO"N"D"AZ61]PV&@>,4'23<+^9[
MATJN5>";CY4!./J50X<C*1CYFC^KH; [BWRFPE616E)% /6CQ5)($B0TP%BD
MP5N6!2X*0,BIMR)N;(,F,@#:H4CB%2 T]E*1P.E5OLOCT6GL]86Y'E!+JVRA
MY&"V<]?:LFJXCE&_1\R2-TO);<@M%"E*WH'"AZ=37D-9:[)\GO=!6JZU@BQX
M^%%93P#@8KG/AG7B\+!:;3&[UHA"1A(R!2/E$;28;:CI"-R4Y4!C'O4A6D).
M;E^Q&G14AHK<1E*N>*DH(6,VW@J4V*.B2-N>*1Q1MA^4'/1M@XYS5]2,UP+N
M-L-SAOPTY^J2G/0$<@_&M=4W&63!JH*2RB9IJWJN>ETV5XC>I#[65\^^/AZ>
M]>K\;<Y0^Z/ ^7TWI79]F<_/LK@RG8;A.]I:FSGR*3BO01EN[.2^\& LYX)J
MU/"#TQ1/3K3QED@XUR<U:UD@082E0R>M4RB0RZGC..M5.OW)N$;$T/3)N+/*
MBN^:*1";@8MAW?\ 5-,T1L<"7 /JGBEP5OL2MUP)X2<5/80BONG9R.:1A TU
M:U*QCBJ6N31'HNF@D-Q].3)A&%JDA''!QMK%K'B#.CH>;$;!MTQ<A#82XKPI
MP.?*O%7O,SZ+IHX@BQ,,':@MIV@#)-9IF^*3?)8;6MQIO ;4KSX\A5.662C'
M(79D(2$J0/$#SD=*MKY11.*3X&5K=DQY"4X5A6/NII(6$>2I7",Z@$E&/OJE
MFV/"!['C7A1(^ZK:C+<$XMG2ZTYW8Y4<@^E="J&[DYEEFU;&+MMH1;+J-R24
MN;5^P(\OOKM^/>QX/,^9Q;%/Z'.W:9"$+M OC#0"4_.2H >6X UZ.$^,GEF
M&4C/U<DU<Y8*I2Y)B8BU *V]*:$N1-XKN-HR16E3YP6P>4/L<*VGIY58\#$A
M;9QTH+!6WR([D^U3"!N-SS='**.$@_=2>FCG*Y_4!C2*RZ00/PJ*O(_Q#78^
M=%*".@Y]J/H@^)($G1RP2 !CX4KKP%7I@JX:3=;03M%52K+HVI@1&DGI<M#
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M6)(KDR8NQO+;X'Y4R12V"WM/O!9!'Y4&F-"6"3 LSB%#CI[4N"U2#(MSVP#
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MU?:[W$$JVS$N)VY*!PI'Q3Y?'I4_01Q9.^EO^[\J&X3:>?((W=/7BGR:L#J
M 2:.28P.*Y(^%'(!"N.,YXH##;3CJ26BOI[=: 1:=H5G'/3/M48HAP)!!QC
M.?>E((0O;ZCT(-!<!?6#M#_)P=H<JWZNO_9O,N2D6R[P_I-B,GJN2WX%'=U
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M.X\@J4E2@0>.:F,DS@N^F=8S+2MJ6Q*6AUI2%Y!ZIS@@^H/I0<<<ASE&Y?\
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DNT=DGZ+GCHGB*YTS_P!M"3"HL+9OG_#KA_X[G^&EW(;:S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>cogo_0036.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0036.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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M+)/;YD:6Q)EP(B);/@!:4_>U-R X1Y4EM?Q=#OGI2W(7HM=@B/J*[1IJ7%P
MT\A9Y XHKR.XR.WM0;YIDGIP:Y+.ML__ "L@ABXP(SBG1X:5!/\ .M*]$GJ3
M[9JQ'42JF03T\4^ #J72<RR22RRVZ\T$!9/(0I/N1UQ5R.9>[*&7%+V0!RKH
MH$?.I[3Y1 MRX9G<;BDN14T8YL_2GZ[!33X0F\XD)QFGL*ALIP8ZTSY'7 BI
MU'4J%,(2\5/J**QC/BCUI6,6N<XVJVR%C-\D5'(2&#CJPK":&AZ- ^0?-M0M
M#/@4#^W6E0UFP=2>IHD),404;\QZ;?,^U%22LE3O@D_X*WIR ;C.N;424&LM
M^*>7E</0#Y [UG:K-7"+^GQ)]D1U7)<?1#MID/F,A'.\VRG*GM\D^3*@G?\
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M^NU&3[Y)M?HVZ'KS$12<%(S6BII&'--C(6YE:\I32:W<@+@7-H8*<D8]:AE
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MOZ5!)_=23SXHHXMS!R2VT=9:+X'(0X;UJ]:9]S=67723S)*SU))ZU-++&+I
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5JY_=2$:_@]S_ -DW#_I7/[J0Y__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>cogo_0063.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0063.gif
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M]^SS^>CQ]_3T]/CW]_'V^OCW^/7Y_/___P
M
M
M
M
M
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M!754=/43%3AP/-U)0S=@!"^'&SY !(1R4CT@D"GA2DHP3#2D Y\WGN-9$3H
M)BB%!.T$0.$""963=QJ$+Z'A%61F(0,!!$> GEN0 []#!&/E(DBQH3+@(MQI
M3(-A SR0(CWP>S:P [BAHE$!GI%"0@-A!.N1$3E 0BNDH6!9 S>0H)%"HW12
M2O'2)@?J/!7#$*TQ-U_!FD9D@Y1I SCZHX1B!&^$$CR 4#E@GG#3G[5D ^%9
M.L>SH[CA2G\&I=Q%(@!$47>RC^@">D=Q0UG$ WYQ!WI10[@A$WJ:0VJ1-"7$
M>+QQ"?Y)D!73V3BX800Y-1+O5H8-MA)B5!D[1$,%5*GL(2UET3L3H:9?.!LI
MDB9>861I61R:>A"7&AYMA1+"\I]RUSPNH87BH@7=<:B> VL>>C\7D3D=R1%J
MU%V/.B6P^A; R*GAHQ*[JCDT<:Q@V!$V4#1+P2P7N48TLQJ7,ACC<R=[%*VT
MBC.U5ALMQQ1Z0*QK&JWDVC@R )U,P0>IRD;ML:UR:F 9E"(XN"*JHJQF5J[X
M:JJDN12V$BGYRCFO)@/FU"EP(0C_,8__>B[N*"Z#(*X)^[!;P1MSTSH06['0
M9"IS PDU9;$<.Q,^]2L)U+$BZ[&OB1,W,K(HJQ+?Y1670/Y"#):R,!LIFR(N
ME= F4AJSH6(8PN<5E@!W.#NN@:,H*3)1'W*?^>JN00.JI6>T/]NT$'&7'Z*?
MH^JTN4(1.K S]I%R;D.UGE$Z2N&D3)&37/LO+7,#JM8;*&.O8_NO-%!'<_,;
M:KNV^'JNXA(8<2NW2FH:M+,43N"P>,LY8K@43W$U?ULJ^+4B</&(/XNT/2(P
MA[L45>"W'<NX7;MT?B.K=UNX2XHLK/<DC:JY.#MAD.4SM@:ZTL%X)3L2=$"Y
MILNNIK%[OY*M[-BZ[?H0,A U<R->M)L6BK(I8D9CL<.Z%+.[**&HO]),Q#NR
M-  SZ2JYR?LO0L04?^"\SRLJ(?[5EIZ""OU:O1-*KCJ O3@!",+KJ-S+JT!Z
MMDL!">6+*QIRK2OR)=)J3"^4/[@Z&/83*?CC."D:OVMDO[C*O_@CK13DK_?K
MKP3\OP+<OP@1P(42P 4LIO,;P0!<OP8\P&M4P H<P!0\P?[[0OF[P :\1C=P
M0.G[P1^<P!7<4 >AP0\<P2>\P0TLK0]LP2$<P_.[O_&[OQALP@@\01L\PPJ\
MPOX:PQV<PC=LQ F\PP;<PBHLL_,J$BU;.@,,)D <PCF,P$&,PTDLQ/C#Q"@\
MQ/+KP4'\OQH<Q$Q,Q$BLPUQ<$%Z\OV4,QAP<QO@KP5=\/_<+P9%" TET)U&R
M.[NS//ZZTSNZ \B#3,BP(\@R\,> O'C+H\B-;,B$;!*/G,B0S,B%?,F4/,B]
MX\B6G,F+C,B.C,F&',J;O,B-#$B9',J!/,F%#,JC[,J1#,F_P\J-C,B-3!]<
M@VN*W,E_K,J)#,N8O,NSS,G 7,NT+,JQ#,BES,J27,B^S,NF/,O(S,FC+,O%
MO,K3+,NG/,G/7,S4K,F>[,>2LQ0UZ\>>?,S)O#S+?,G-G,J5[,V'S,W&G,V0
M?,V_C,Z^O,BHW,OO3,O?3,GK?,_3;,_Y+,H!+<S1G,B@<R=9$ 554 51$-$2
M#=$/_= 2/=%18 44?=$6?=$1#=$.7=$>[= 9O=$>3=$F/?[2)!W2'?W1$PW2
M' W3+ZW2)-W2)UW2*_W1,JW3-(W2.3W2(%W1,@W3-@W4.XW1&OW31>W2+ W3
MX[P47,#134W3*RW44DW5(6W4*AW41^W223W41[W4+FW17<W45HW1/$W52;W5
M. W6;#W5-_W50)W595W5(HW65+W4A,44=O $5L#44BW7,WW29>W3=<W5-DW4
M=9W1>=W6,?W69QW8*8W19-W8< W82YW97<W5/>W8@_W8>;W3$+W0B%/:IGW:
MJ)W:JKW:K-W:KOW:L!W;LCW;M%W;MGW;N)W;NKW;LTVPL#D23A+<ORT2O@W<
MQ&TMQHTJPZW<KC$WJ;7<M%+<U_[)W,LMW=)-W=@=W= MW-E]W=/=%-:]W=GA
MW-Y=WL?M%<Z=W.>MW>K=W>*MWMR]WNX-W\B]WN;=W/6-WN_]W>DMWQ!RW_X-
MX-0=W_,=X/Y=X (.WKV1X.&MW\)JW]G-VQ(^X11>X19^X1B>X1J^X1S>X1[^
MX2 >XB(^XB1>XB9^XBB>XBJ^XBS>XB[^XC >XS(^XS1>XS9^XSB>XSJ^XSS>
MXS[^XT >Y$(^Y$1>Y$:.XZ&5VDD.XDN^VDU^Y%!NXDG^Y*U-Y2]NY1>.Y5?.
M%%H>Y5[^Y6 >YJ;=Y6)>YF;>%*9P"(2PYH1P""O2"8K0%(O YHN0VHS ":[=
M"'A>,OZ<P :CH.>HH BF0 IQ?N8ED^9LW@BJK0F*?MJ,;MN/CCB*, HKT@B%
ML.:%?MJ-H E+00AFL :4C@J<T.A>00IUON&<L.:&H.9RH F<<.K980J"#MN$
MGN1RD.DR3@IOD DB$5JDP 9D( >EG0FD;N.+@  7@ $84 $A8.5+'EIR, &]
M/A(3  $9D $.T.PA0>;;OA07D :HP.U4/N4X@0%GL!3CCA.<, $;H D: .X+
MH F&  %CC@I= .Y>K@D*0 $9@ $+T )/0NXX 08=@.;HCA,E0 BH0/#3/A+<
M[O!>$5IDH &H( <I</!+(09E$!(0H/ 0SQ0;P #7'@$:$/[JI0T"71#N(3$*
M'?  (( !#*#P9H !&!]:AP !E/[PMZT(%9 !$+  &3 !<, &%Q#KJ- (#K#G
M$8\*A6 "1J_RDI#TJ, "#8#O#<_E.*'S*K_UO_+D9@ &KF$*'4 !AM#M<N
M&! "%# !Q=[MI# "C?[LJ) "3O_T*;X(4K\4G*#T(<'I(2$'%B#J2Q$!;! 2
MG+  ;R 2G&#R(<'K62\2G+X!5J_X(4$*C#\*?(\*EF_X(J$!A>_WBL_XW1X2
MBA !*S_H#Z )AR#M?6_EB_\7'_ %7*_YH+_MF7_CG,  IWX(!T#JF=#DFM#D
MI)#YG&X&'C#[FD *.#$*HH\*$?X !Z@P!B" "K4OZLV_[4D>_".Q]UY!!AR
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MBP9 N1 />&$.[?0=<B"<.87,E&+Y0HE6[ ;<L(SBE+']928X<"L=,: B;9C
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M1=B\PS.%!^B)#[@,-O ^M%DO5/ ZA6"$<,.]'_2E\C$ .JL "G BT/ "%JB
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M3XUAF?Z 'O]QCMD $*!*M)C$8R6%11 LU:" $.  QT&%Q+ 8_[F $( :,8
M#Q@!!W@,J""%]D8!"M@B#O  $K  #/B[,"AS'$]"9=&$#&" 0CJ,>00QB-6$
MU%$!%V(!F%&!%#C$FLB V9 B4_!)_%$-F'@?A>@ CF$ 4\ ;A2@$^$ETA2"!
M,.@$!+AC4O&=!6B43%B$3H" GF@$:+3QA7@G$)!0GWRA0W##C:O?QI:^)TS
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MQ$^=4H(X&<*A%_ A)Y3JI C((1,3V  ([*D04Y3@JUW(P),TJ$ZA<,(!%(B
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M*:  U'A/7'FC@1YH>1@'BS4 )U345TA$)HP"B:G*^(R$?@R$(TBH(3R 5YB
M <W'ROZ@%PEPS2)D B=,@-;!R@)8A2&5Z(FFP5RHB:]X0!F0J(E.0%[BA F$
MP!IP J8H1!K@Q GP*">,3?"@'9U\BU@40DY,E)K029":C\)P@@J("^FMZ'(P
M@+2\@2.< $,!#B?,"2K 21/U5,4PH_0L0@:$ 2E@Z9@2"&#YZ!]J3R;$00)
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M1, <+D!NP($ 7*X)#/(8,,!&9&P&#80)3-087$W8" #X=-*35+,<?'--G $
M, H(+ ""#>\ZCZD[HT(8T,4;)$#4-@#',$"D#01W-4(T#<08$(<\KD%X3L8"
M'((DH,U/I( WAV4FY)$<8,![C %O=,!+M*T<D$$"2 (8=/"">< HT$;_C4O=
M>D ;F,  3*M>N2&)5, 'S,%)E=Z&L4 %;'0".,)M@($<: ")F(%K3-$AW"E^
M4H8"Y(<8\ 8(M$<7. #.="N!M ![F0$#-$4&A( <K !)-),<+-B:=41XX4$8
M\-.F:L4;("4</(#6=40*1-\#K/X &VQ YVDFXKR'5,N!2S:%#2D"&]"''#A
M7IKT U0+!, !*1P [W8)_J#"2)$ U3Q,9&W&AS31H71M@<!R!YC)7^=ES- S
M [0!&2G*(0P V'P!>:7! I2842)*!>3LO+4RKR6?A"+-WXU;;6/.;2];(Y
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MLD%-X'$(P*9N;, (L$$^=<0&1/Y%,IO4%](S#Y)?<406SO3U!:Q!)IB!''B
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M9& "P,%("3[2B 1T9PPDR 37NK" AJ0A B=0:C(?10$'D( 3%UCH!#[@%0I
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M1J$#9$P1#.P+&;$1'?$1">2\0 #O"J;]M(8^UB "." $TOXF\A3 JFC#%"J
M-DB@ B(E:T(@GD3 =ESB$QA +-Z@SA0!@5A@<-(@WT[,)20FL"Y@DM@+;"*@
M R*@S3+"0C8 M2I@DBR@.VI1I_;"B3!B>$X1)D"  2(@ AY O3*B S1@ S1
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M>08/K$]:+G!F7L"@"]PS$[R@!>I&O%3 $)P(%=H@!0[!B2"B25D@+@JI$;K
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M1F-L@ H("NTDTF"D,."?5FF8$NIWI$:%D0E]<H41E2"Q09 B#\@T9+ \$C(
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MCHH6F/T!&&=)&O0IAX6Y0>ZCQ@ +'#X_@K1A82W P 6P3<T,8$ #Y R)&"A
M@0JL*2R,ZH)44J !$[RA X08@U1&@#&0>$$JG!"!XX]#BA0D' X=@(,I2G !
M$72A//Z' (X%$L2F"X!@#2IH"]6E3I+C^QPD<E#:5#I5-J<\U0SY4L0&,) !
M)[4! QCXP'U(<0+A>R%.*@"#!RZP,&B! #MQVG[\BE8"*G&B ^S&"!BXKP*"
M+*(#V*>2)D9@()H0 J1 "B+@'V%0+O&'$7/@2:B0 GJ173(!!A>  2B0,YG0
M 1> 6, W(H8W"B%@()P0 @4R AV@ G"@ 8W0"&,7$HW@@2#(%##X!A1(?R$1
M!A3(?8)U%B? ?4.V!AC@ 6G  EV@"":#31]P 0@S9,C'A$WHA$\(A4/R5+(T
M$E1V'D%4$J2@ M>4'EC8(UY(A2AAA5D()&,XA6<Q$EHR=?Y1"%5@6!)(%A)C
M.(88,84.-X<EL38B<8=,XX9[B!)G^"-^2!)SJ'QHR(9$AH@7A(C!52>:0G6,
M6#DLX7"%:%>-J(C(0F24>(B;B'R3>(EKZ"/M<6B2:!*6&$'*IXF<V(:88XJ@
M^(E.F(H0AQ*QZ(JHZ(I=J(JYJ(N[R(N]Z(N_"(S!*(S#2(S%:(S'.(RTB(Q^
M!$[*B(S&Z(RX^(PG$8W3:(W7B(W9J(W;R(W=Z(W?"([A."2*0(!<>!ZD8(Z8
MTPAJ*"R-8'LDH0B"&!*:8 CC-$/"DF<CL0AF< ;L1@KHA!*"=D&I%X7QB(V.
M8&A+LR" *"0YPC0(N30$H4WB2/Z1%:F+P>4 C% 7V#0">P@&QP$I#"DL<U(Y
M0L(O)$ \<M I.Y,>7F  DD<!5A0L%%(Y+<  '] !"7 <N[175$<*;V$>G' T
M)=F$[B4LFEB-H&042[%"2^,($*$UF @427>+&:%81/F*)W$"H^6)/)("1FB1
M82F6S<B.):$)/4DZE3(B-Y4DGR [<4(*A(@1FG!\6$B7)9$S2:*,.@42;4-D
MSH81$; ('R42K044+7!0J$ "9G$RAHE-9;DLV,0L]A9Q?Q84 ; (F: A'#6/
M:FB%:F0"U^28R$<!U<2.736/)<$>(L&9:3B&&U684]B:(M$)D D2=75P5X@1
MLRD2DO[4-%8(&,Q7(G,Y$C*1E[OY5+P9$JM)9$XDF5)9ENM1F'G7@&-IG=?)
M-&]G 5T@ GDV0G,@*)K@%PF1$1&@@@#H 0R0 8LP(_S7(6G0 #O1"!T) M<T
M H>@"<"! 7@',R4@!@:3GV)G=AUP32&P"& @%1@HH&]B)G+P%V'1<RS1)H6A
M"8M  0X  EJB"!<*@(8G.5[6'!F0 1BS1M8R->#2)AC0 93""258=ZA0 F8P
M ;P2 BU$ B8:-DB""FW0"(XP 5UP 1!@=BW*?VV!"FW7?-DQ"D)7&!<@,DR(
M 2KP 1"P,)C1 1D:>1G8.2RQ?QF8H"/0!1@  6M2/B @=O[Y<@)@T $3H&%,
M\0&OIR"ZAP$/8$$8,6II(44?(!.*$!$FH"(5@*$M"A:D  +K. *>)6@?('8<
MN'48T  =L%,AX'A>AA <@ &+H D7X  =P F*,'F0\7QB812$0 HAX 5S>@89
MX5P>H (:,R)=!VU>Q2D4D&IGX@7, RK8MYX8L6,=X '^0684<!0-AYW%:JP]
MP@@^-6@!L&WVQ 8BX@7 ]4L0T CR%BY6Q$G )2&C  (_YVFHX 'EL4NFD %2
MH0G0)"4#L *(0 H88*X&$P)Q,JY=IA6IJ@EU1 *6U04( #I40A!R-C= :@IE
M< $-M39M0I<1\'.*4&B8%B7-0?X\7[  "J8!%6 @ /LVCR8HJ""3#Z! L=<!
MH] ($9 FT[4 4:(IC8  FG8&XS(&S_-9#: (;R  9E!_&% 4<3!"3$@!)< )
MC5!=BZ!HI:(0Y"D''X$?Y8)N@$$ 3+5O=:(!*M!1$2 5$: !.\49*/(IG. ]
MHT  3K8&'P(49<-1&0 &2K(CA# N)Z T?T>7$( '1B-H!5 "AV *$W,6%/!T
M=K4&$U T2J%3$Y"JM78FA]>W6$LEK)-; A &/S$!<$ *!3 &H_ &"H *86"Q
M029*M:(04]1;:W1BL0<3++!EF4 H=MLBYV8!,D$"<>)FI' ("?!:QTJ[M8LL
M)0<2!OX3.SLJ2H[P!F)P,4]2K1JBF3LB16\P!@T %B70%ALI!WK2 BQP;&R@
M!G#P *;1*W-&30Q O6)&!H%#-HSA 68PO6E@O610"&Y" BI@L\4D)],46W&P
MN03!18&),3X1'7&@!FU@ /Y*-A%@!F0P!AI0'AZ 2T\2)9* O Q@1)03-D)%
M/DI%D#!C3U.T(PLR!@Q,/XO !FY"9%V08I4G=?KD+\_!4U#1%EUPO95W;FS
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M10,^<P(&&<P@:9C;'*RXABRVCB 9,,,44;&&#'!' VLP!0*:=($T-((!!:%
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M 6P(C="*"N:*"N[  ZX()<'A+21#(]:+*[R-#L0,B7AA!9[A Y2(1L@$%K
MF4S= R6*-$"9N8*)#>/$D5B$\>6DEB"$615C5/@"%1J%=E*)-P@Q@J" XZ5A
M.J[C/P0#826(CN*C;_/.#_@ -S!$,K#<D  #Z%I=XOR G-.$+T@L/@$D3NA(
M%4"M%(@HRYO #P@!R"@O$U%2$/ 611B!>0DU.%@24AB" =T.'DF!#D@!$T$0
M/BH!T_J !Z#9I$P$"CB=%L&04&89A!"L%!B#%R*("QBE-P"#@1@#Z((,,."B
M AE=$1">@3 #0S !WGD#;<V4@_Y08Q HI3& .F^QX_F%X*T@"B+&"1Y.0<T
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MF(>84$'44#@*6*8"/D8%>#)A OX6Q,$,+CD#]9Q2N D@0FL/(P$@3R#F(Y.
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MI)Q<C/Z <U 38G@ "Y ")X#  Z0 )YB!(90 :=S)R[W0!5! =RQ"32Z'N&R
M":S!YG5!,Z4!9!5D7_KEUH7 %I&! 73'"81 ([#!!(Q"C65)C>1)([R!LF@<
M*:3C&1Q""'C 402 %\P!"6#+&@3 &=3.!E02MK !!1R"(B@=!(!+&BB>(:34
M]B"2 YC!(6RE4SA &>1&09"$(AA ;DQ :\3-(83! XP"&>1>!IA!'$#((D#
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M68C%DISE$8*)7*K.O*4SHD(+$ R97&'C"5X*S-BS;0"A1>O+PNPP\9\<@,$
M3(E[R0'@C @A!,!&L<!K <Z1($#B.  8R($&N$0;%$ 7R &#54Y%48!;((+E
MQ0$#I/X!;\6' ^C, \3*!HA4VD2$'&R 2[")OW9KMJ0  ,P&TLK!"BA+EO!(
M7ZP1(8Q! G@!)R0 4#F "0"=8BX S\'/$/XM(0Q!@A@" L1'!(B3!U1&W?X$
M<>'I S#M1V1)'?$?T"@" OR$>ZY3S'KNY[Z.9$01&[C(7Y  (C",%^CC&8!
M"0#6<31"<AB;1:Q$!_"17.395K22)J1&7=S%2D(D(_ &"IQ=(Z  :F@A&8 %
M>JR'5'D!CWG!!ZR H:2!.(U)"<#!(;1 5$J3')B )C3">&7"::1 %X[O!Z"
MX/Q&"[W1F)# &RC"3XS"$,2'(R3'7#9I)L0!Z* " XS(K?[M"N@*\ !3UAE4
MU!^*)"',002,EUW,&"=X 2L2\ 13<,Q,S$=Y##=ZQR$$I4-I\ =K'0;GDT)]
M<"Z^(D%,H@B;S*28<.B\*5TD9#F%8P73< W;\ WC< Y3F$"R#.KPL#%*(@KW
ML X3<1$;\1$C<1+'C"(T[\/0Z</T(5HH0@KP) G[HQ4'8R2*A3T5(\N,PAFL
M$ZD\\0CMQ^( S \K<1JKL5FP <%HS /(((VY$UH(11?*C&H(A;^.12;D;5I
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M(12.!)! *BF?[%E&KUF >UC$BLU!0<"!5N#:)4<JK*'$!VR+[(65IH9%&:4
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MJZBH$36%*$9A 18A$Q9@#C0A \S@$X;@41] +S @J<+  48!#KB#$)['GQX
M#DCA0!+DW&:$#![ #,B #,: $\C*)0K!UE0  51@53'@! ZA659) +J $!RL
M5"(@LT:@>HJF$4(@ ^1Q 4P@0<(E$Y2U$9C5GR[ 26'G/Q;! 2B !13I2LO5
M7 >#<1)E!,: % "04BY #(JC)C) #>3@:EQ']&KB3%)FV5!A", J&8=@ TF!
M(AI!3MQ@.F+.K$A@ PKA* =L!5"!$##.X")Q$48A$TAA$0))8CTM1@HA. V"
M ]* V_X,(@X&R,4TA5/$;9H48 1$H+V0)/^*#!56 (-0P6IJH@/,P! 6Q"#
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MLL,@^"=?'B .L@=6R(KRQN  4O[ !$[@ECA'!=I@ VR-!.HP@]B"!<Y4#@Q
MD$C TV(NAP="5 +E.!E@N&YN0[5G?AHY@>4  4[ #$P@ 71(#A* !=[ #!8
M1LIRA5-Y&N'(%"@.'4& D72K) RQ(3J \WA0@4_@ ]#(CU#!#8B"DKRB#/"E
MC$# "@\A=O/H!=EUG*#S]!S$[,R@549!!93'#&!E#$C #'())*3(+68)G4!@
M!5:GEP_3R?8H>*]D%,9 L0ZA!6B.!5+ *Q2!!%1 #KP"#@YG)," 3F&%#3:
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23+BPX<.($RM>S+BQXY<! 0 [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>cogo_0021.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0021.gif
M1TE&.#EA_P(@ ?<   0! 0D%!@X)"PL'"!$-#A,/$!82$QD5%AL7&!X:&R$=
M'B,?("8B(RDE)BLG*"TJ*S$M+C,O,#4R,SDU-CLW.#TZ.T$]/D(_0$5"0TE%
M1DI'2$U*2U%-3E)/4%524UE65EI76%U:6V%>7F)?8&5B8VAF9FIG:&UJ:W!N
M;G)O<'5R<WAV=WIW>'UZ>X!^?P!'GP!,H@!'H !4I@%7J %;J@%CK@EDK@)G
ML -JL@MLLPMGL!-MLPUQM1-SMAMTMQIWN!QZNA9WN!-CKB-\NRI]O"=UMS5Y
MN0 _FX%_@"R"OB: O3.$OSN"OC2&P#6(P3R+PSJ'P2^%P$6-PTV+PT61QDN3
MQTV6R$^8RE*7R52:REN=S%:2QE6-PV2=S&>6R5Z@SF2BSFFCSV:ET&JFT6ZI
MTG2KU'JNU7&FT7RQUGVSUTZ$OX6#@XB&AXF'B(R*BY".CY&/D)22DYB6EYF7
MF)R;FZ">GZ&?H*2CHZBGIZFGJ*RKJ["OK[&OL+2SL[BWM[R[N[FWN,"_OX.U
MV(RZVX:TV).]W9J[W(:OU<"_P);!WIK!WYW$X*+&X:7)XZO,Y;'/YK+1Y[;3
MZ+O5Z;[9Z[O1YZ_0YJ+!W\3#P\C'Q\S+R\C'R-#/S]#/T-33T]C7U]C7V-S;
MV];7V.#?W\/;[,G>[L'7ZN#?X,W@[\[B\-/D\=SJ]-CG\M#A[^3CY.CGY^SK
M[.CGZ/#O[^/N]NCO]_#O\.;P]^SS^>?Q]_3T]/#U^O;Z_/____CW]P
M
M
M
M
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M<K2@0B9_>)"?!"8T[8(+*WSVBOX;'F"PP0HO\\3""2N\\@8&%I@ 2I 5)+!
MX+O\40+0'+3PV2Z?J("V!B@LNJ'5?FCRP=9U$/2*"QM@P($;XH%R@@EOX,("
M!XL?JF8"G@RT!X $K!R3'R%@@ &^5$;^<]!MXH:ZZJQ?9[0;KZ"P-&*?E+#T
M&S$MFT %GIP@/!OTZ4)'WQH /E +)J#P"F!#.RU  0_T= <!"FBPBP( .+Z
MJ CA(@$";!(('B0% <R5ZP#N\9\""/ K""2  &W2@P$6  %>>.( Y9*-"@8%
M H&HP#BEF]?,1DC"$G;D!(/B&5!:$8A+0*L%!2C  ))$ !%HY@\!(  %*I _
MX[@  OX P&  WK"+-9C' O@;U #6P!-<>. \,T0/&P22B046AP"2(ML&
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M:(#$0 "!,$I@%V\PP / @X(,)* !!NC/"010,CW$P0%Q3%8("L  /;B"#@8
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M@ Z&=RF9P"D!B+B+/3CR80V-KWSGRQ ,$"H%!='%48Z"T0,,+1/EF@\F *L
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M7/]3QGG1 .( "JE*P"^?P,\"%O>*".2'Z0B0 !9 %N<V 7#P(O"''%NU"Q/
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MP:NS1 !*61"NH'JMM*DL !3U9P %(" J('=BMQ.:*BB:@OXF"E",?T4 !<L
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M-4 $NU &,K $0U #J9 *-! $._YPTY,0!C6  P_=($!@V,D] _?, T&0W##
MW#6P"I!0 U/@!#0@V_\\!G4G"310!3IP!;N  T"P"X\P SZ@WHN@"C- !#2
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M,R*H@510OK<(@G4-@J-+@QFP-E58"RG( ;88!4>PSJ-;!!@P0S28@5, @QI
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M4+0OVQ%;&(*I PHFA%_^VP%KAF^;^ Y[ZS"&<SA[0[?U^.\-@8X!#X\!=XL
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M$C+P;2H). "$ANN$"Y@ #7" $G *2 FGL;B$"V@F;<(%!QJ+/5  "Z@ "?"
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M/QKH8-B0:6 <#QS<[,(%(>+ .T8-.HC9P@^&3&XN2=RTZ\\&#7%:\-R%A^Y
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MI( X="(3$&@%+S90!U> 0 2=@,6 >%$'#22) I_@A 1"X H%T&</%,A(0=X
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MYZ4?7_Z]0@* AW-5S$?A#RCDP0=@DN5H@H1A0$P8A!T@@$<L@"8P%T>,0!M
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M=,"%0  ;W $)*,"W:  &> (SB?X+ UB(*4  "]"!! 37+;I4'R1 "*P!!SA
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M)CA </XX0!W@PKD$9HA]PCW510U&!@JX@>7DP8Y-!8HT1AR8P"4X3V.\ 0J
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MKPW[74.L@0:P@ 54&BYLP 2L  DDP%;L(IYP )/@22L\@$TVQ D   !R!0#
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M>$ /#\1Q=, )%%T<L$0K] <&7.7A;, (T,HFU>-,+BY_O: ^NE8%.( )O )
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MHA 5>8-R%S*(D(4\YVX39)<GJEC*D1E:U(64&9S *+0R8%AD%REF*&,72(R
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MBA=3.F(4\DWN#""1QEKH@JAD*,0,U%O,4:QB"SX089<$=0,EW,(6JJ@3MFI
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M&FH70L6)5 &Y@@ &%DN"VHT(G@\&"B$17H!F6*H&"D$,9/[ $:QO%X#.%J)
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M0 $7+@ #7,%.A_-)XX(-]/0"', /=L$-1$ V<0$"(E0VH?Z1$QY !!8T--9
M 3#  AX !!;4/.?S/7<A#D* 3@M"%"P !"H@0LOB$A*@ BQ  BC@4N>#-Z Q
M#CQ@8+Z2!-P@40\"&NO@3@_B4"6  RJ  C(A/O%S.I5S%^J #G9A$R"@5$]U
M6HO3*5J  C3@3)%5-WE!-P_D*S?@#X!5($( 0;^27*^S#V25/%E@5:&Q%3@
M1LO5(-YU/%B##YY5#S[@.\=S!8:U7YOC*W$A#S*T!9!@%UI!#X 3&G'A#D84
M&N&U(CC  TK5 S!@%RX 4M\U2%5T%SC 6F53 OJ %W!A7V&!00NB9 5"9E5T
M0TET(#0 64,C#A1 5C,! >Q@%_XZ(0($HA,@0"!<@5)C=EO?@@YZ5B#J@ !P
MX0U&8!<XE!>2]F8%X@XV #]5( 18UA4D8%B[=6;Y=2#B  2T%C_?X%=)H 7*
MMBN@\0\<H&5QX00^UB!HED1?UFQ)@ W6=FU/( 7*EA<J@ 2^D@T80$GU-B%:
M=B!4X 2L-DH556:3 AH]@ 0Z(1/NX  0%"* M" HH ]68Q?DM&Q+  "L=1=
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MYE1H.X"!/6$7X, .WG875J #-F!8^T ")& -7D$%%M0-W/[7!02"!>0 !"C
M3^^VAIW" Y97(#Y@#42A#RX!!79!%%1 !) 5%]C@;1UT#W3T%>KU#S2 =$%A
ME8-V%PZT!4! 7?5  CX 4O&3!$X@ M08%!Y@?5<@!,84%N3@*^E@0UV !-:
M%GAYBO_@#R3  _[@%4BW%52 !.) -T,@A?'@$GQ9=O' F#<A4A_@!$!A$S3A
M;B-@#6+A#BYT%^R@%>(@GM\9$TJ !&17G,E940_"#?*V(#:  T"A$Q*@$Q"A
M=T\ !7BA%2K@$EI! UH >'?! FHW!5)@0Q, %]I  30!HY<7 _#W#C[6!5#:
M%2I@>2F #6#!#Q8 4.O =._T#OXT8!=@5R \P74'XA,8 $0E(!-P(9@S@1<L
MX Y<@0%$= TH8!=4H 2PM@(RH1,"8 7^P'+-0A088)\)0@X4X!)<00-26 %
MX0\J !9X@01< !?60 ,Z0397@ ,@]!(40 _< &Q?(62!F@5>X1(<(!- (0#8
MP!3T0 %>00X&5@/\-!.LN" P8 "8F"S^X $X 4(W0 1<@0!,X*L_ ' [00)>
MP0U^M1,L !<HV'17P!7TP #H !<D0%WQX&/OH " ] -(X!5"@ 0^@3=88& Q
M=A=:( 1>@0!:P!3\0 $^ 1<H %+UX&--( 'H !0\V&J3^A5&8 1 P1,4@) K
M !0.%?YN'R $6H%6B[=K/0$#/#HI/ !NL78!_. /"" $W "CY> 2. !P3T!S
M4>!C'X /3-<$^. $#. 27H$"YN 2.@!P)4!.>584N)D$LG<@/" /X.!+/V&9
M7^&1_R!S=\$!Y#<3'( 7,& %.N$$2F 7FO4$-.$2)$ $-$$/CA8#W" 3,,!V
M/S $;-=6]4 .$B".G?4.?E</'J"C71P76  ":EMEK=8!+J$/'* %/H'&^\"M
M(57',V$#?!PBVJ!K@1,#2!>H_4 3+@ 7'$ /_L"_18!V478@*F $UN#.-_0!
M>&$-)'<7UN#%::$5_F %OM0%4-G/5V 3)& @E)H#[A07!/Z=T'<!4:&Q$QB@
M;P4"%!8 %T"AJH76T]_W#>)<(#3A%1[@#OX $SS@!#[\+5HWOB-U57=!#E85
M EQ!!$[@$BZ!9W<!#WYU/ET@ 30  RK #7@!R@/A$D0@!)1Y( R]%9X8J/7@
M#D2@%1@ $?Y $R# 3U\S!(K;#7"!!,8"&FEUV _W%4"A;H66 ;99$R3@#>AV
MQQ>4#M2[=P6B ^B@D37AS0_@$_2  P0B#WYZ!9S7(%9 ;9EC#0PXQ459#OP@
M O;]$@Z@$U3 QQL4$_#@ >27!5+8$R1 NC_7: WW<[4ZWC4!H8$"&DF  88=
M L2]#_0<N4& 93-AO$F V2$69/XQ 1,672 88!."6!=P(1,60,7_V )(EP/V
M@%4_8$Q//1;N> UDO<1=80U, +E3N$9Q(0X^]@+(=A<^ '_UX*<GP U&N$>A
M$<@_^H\OX ]@_EE=84$E0$=7P'8I6R L0%UQH0+>>0)T=)'+50XJ8!>4-VEA
MG2%@?CZ!FQ<V ']--]OAVP%8H 5:H T @7;'E""PUT8?@*Y?'+DEMP0PH 44
M&O0%8@5:X \^=E^!FDM%G_0S8-+O%!II@0%JE&5WP8Z9]^-W?T$UP ]:8 6$
M7B!:X0%0OXV3??#=@LW5=5]10!/H'1K=H&HAX!,^X ."?PVLE6N+<Y4Y7P5:
M@ 768/Z;![]EY4 $/N%+%U0$Y. .2" 3&L![2?_V=^$.)F 70OSFRV*S=?.T
M%]2P 6(-"Q9N+NWZ,X)"!5QT0G22L(O7KA-S[DAPP:*%&U=W-NS:1<=C"A6[
M='V,N,OB1UT2.;1X1:&D+A1K++I8T>*-JQ-K/NJI4((.AC^[5)S8]?"5A$Z\
M>+6"@,L"T5T5B/XA4:%"JY-<NWK]"C:LV+%D/WY \:G3UEUZ/.XB88%$"!(B
M7O$B00%"'*J:['#8A6N7ADLJXHH845>#GY(6%F^@\U'B21![+S6X%(&7"#>\
M F/P\XD"+PR:0&Z0^_?"GZ:[.,AA:V'7IPT3*$S]"&+%+OX+?21BZ+/+304(
M)'#ABI"I*(J#%2166,RK0B9=$C91]2 B>XI=HCI0D !<<MF($EJ<9 %!L)Z/
M0S59X+7T8Z;D'UYSI1!>XJL(N-@<W=5""YTD\%$@L;7PWTVN,!#8+B!\\D$?
M WZ$2&P;X!&11"HT]Q$N$+BP2R8<BAC8!G[T4<%'KW@ 4VDA=J))BN/-2&.-
M-MXHED0L4-"@)@.T(D<('[E!PBX0N**";H !1X<'7:T@0DDGV?81C*XXX(I9
M&R7PRD<27')'70XT^(<H*,F!094 K"<>CFZ^":=8?T @F42=\+B+*P]T>9 K
M<WSR405X]/$!+@QD254=FD#D$_XO=_P%TE\G@.C5*PSL]=$?!H "BP*F!+I'
M)HRRQ0M/'SD W"X4))>">9Y M(%]/U%E$%]T=/*1!FR@%&>OO7K04V1L:?"1
M42=]PDL@52K0R0:7_"'C+LBM4<))N'[&'G ;[/%5"/:M@,%[+A3YT0.E/?;7
M'PMLI8E'OZ'$P7IMX5*K'@RB%()N%Z2J6":!O6*!&[M(L)4*)/UQP4<4U"H!
M)P-O=<$=D8%"[T=[W%MC)PYLP$('#"1'@<2J^G&) [ODX8 ;+3B B6!O\+H+
M \"9M,LK"O#20I1%E?#* VW((0(#FN1<K) K6!!'"!CP8L$=/;L!- .7: #9
M2;AT /Z!"B@\$()$FHRYR]>!50#9!MY:<)0>*2.Q0">7/.!KW'+/W:$'69N0
M@,!K=/#1&DXRZPH$*,0!04]HGB21"4Z:))$?#K"Q!@-$K4&!'";PV(D"(20=
MFQL>K2%!'"= L%;-%7RP]P84@$)WZZYW)=$?"318)<9OZ)6" Z_$X4 <;D#P
M"1VQJ4!!'"H8(' (&\3! ;&'[R)'YPK4$55R)Y6\P0HA*"#Q)PM\$ =6@8F@
M01P>8*!+".:]Q0$=+3RPW!O<@W)S)@^LX88#1#TPE0.:W+$ WWWI=00$BTDT
M0!*)2.0.,OJ$ ^B0"1)\@&DDZ,0?'M *"NP!/FO(Q!H </Z)5C" #IP@@9,B
ML)Z!K6<#'P"%'X(ED0T(K#,2(  N6O$ ")I0(G$8P&LN\3%,? "#%&#3+CS@
M@4_H@0*6<D,GY+"0DW#@*!!((03^$(<'7*(3%:C#+AS0 EJ@H$B:X-XN0N"!
M2ZQA -9Y0 M<T0<'^"$3&%@#+A3@1#K@R48,64$<$/6'M?S!%:^82B9:P(:U
M7 )07/$#HB+C!UW J$JEZ<0:Z("+.7["19QPD1]6((? _(%UGKAD)C6!"=9U
MQ0\!NLTK%E,S6 :"=;R@PPI2N(M-M& -K'/%;0H(S&">A)4=_,@G:M6)EOFA
M2Z]PPPIJ=<RN9*)67.F$"]8 J/[8^3$P=-P$"^(0&+=E:@5OH%V'XK "X$A(
MF.R$$QR[DDGQ_($@? I$@' 53;:HX ^9P%5*5B R4-1*H("Y U%"@"'QO,*6
M;E#E)RS "8WP*24L\.(N,.'/6JZA$ZZP0T0,FLG @&(-+O#G(#.5I4L$R'KM
M!*8<^"#-EYED$R+P0 O^I0(D+H8-^"3!!NKP!NO0E ,L"(P3AX0K38" GQ(0
M#QV(XC45A),$+FE0*TZ J#OD1I=^H(.+0A2"4>ZJ$R84@3\_0H?UN,%Z;K .
M'#S  4SI 02M\(/$>$$D7KRB!![00T/9XI!=$,H#F"*K!P)KHS:U=+&,;:QC
M'TL63?XP +*4K6SK< %.LGA/L7+CK&4_^SI,O RTI!V/1&@&.V&IED:>A5F=
MO*+ U*[V*['-T4E,@EJ8Z;:TO,U0FUJ;(:YP-K<K(2[,7F'$VPK+LTVI;6^?
MNUO6P.ZWNU4M<%$B'ESH(3!MPBUM5\M9Z5;7N="]T76QB[B2./>URP5O>B<Z
M6]?JMKO!I:YUORM?7K%7O^FE66W96R?/$O>\Y2VP@2%+X+DE^, ,;K"#'PSA
M"$MXPA1>K"OXL(='QND5YB0++S1,(R7^P9STHD6>,*'7!5=XQ2RF["LNT>&P
MN,(3G>B$F3[BBA@#1I4G<47IPM(*7.CBQV(),E=:4>-.\/ZX@$X!;A\T@8L;
M?\3(%-M%*VC,T8EU@L:P\,E76PSF,.]B#1O;@ ."E=\$M^0UBF6O'"3VAZ;R
MRKA>P04)'L !##R 3;C80 72\H"Z2" YX16SH0]-P QVH$O[]0H)&( !#$2
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M23X3L<4-+G!2S/_N;E# /00</D'7(:-U!N)*(C^7HGE64)H^;$ #(=A*'#Z
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M"2&'"P9  B-V$B)0 0:#1($1 7^@,9?P"FR0(FYP BA@'J"  7H$/1O0:AY
M![S0?JX@!P( 8PE02Q3P":Z  2#R'-#S%Z^G0!(@!S6&(OXP!GW,<49!)WD@
MH0&M!CZ[8 )!UPGIT0(&<"N9H#^OP )SJ !KP!%@8Q*6DAQQ4!<'D!P?9R3
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M1P C-CMYJ!&2@T-N  <AP#)MJ$ *$!Z[81XG4 %Q  +)=@*5TP),]*0$T7Z
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M%;X<!KN0"T30 YA-TZ4PX#I0U)50 TJ0RSU@"V,@ [!,!31@"ZJPVSVP!#0
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M#PB^K<$%"\T$Z#S.B/NHQ:G4AV*#3(@#!H6<.G@S-KB$6MH%=M)5"1"%3""
M8%-/,ZN ;DR 1WPJ.F@:S<& 3/[P.DZ('@Q  E?X@"3<@P1 I*9I!7M;SL2)
MP.YQ@#NXA# <-P-(4J_:!0\X@5:  ]FY4YU< P+0L9M0@0?[&!*@@#[H@P3
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M.($QS1<-\ ,W@+A7H  .TP,-X(4)&#6M.0%-L)\6N*7)*@$3H*S;+0@6: %
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M$&C/'0PB7#" PXW4UTR!>GM%$&#<%Z.U@L %R2'=#4[DI'0^>_* V=N8'OZ
M.X@#!2BR/%T#9:V<$Q _!SBC.R CX_J#3VV%\]J%%#"!5DB /_B#$'CA%5@Z
M@[53$+B$-0"S.* X/6  ==265H  #J@#.B"B.70 2@*SO[.#-\/D97T#BMN#
M[;F$!(*]IMD%#L2%!9C !&@A)/[T@R\SIN(KB/HK" RH@R6\!#_ @ C6 P7(
M WC],U7$@&]:@Q"\H5=X06WT'P_@W*G9@%)E@XD;H>5" !>X@Q-8J"";7-1:
M0:-*PCY@T/SZI@Q69(G>)CTX+C\ A1:8M%=H 0\( 3RHB590@0]@@WRY0T7L
MFVN$G"2*HH@3-D PICX@ ;ER@U;"1).>N0^HTRD2@8JKB3P,2,X1,R#%)C/&
MGB"54$>#H@KZ!'!TO5-D5JD:MU\\ :EBQQ!(S#?PPWEUM >B@PK&Z,5:@UUZ
M@[X!2-NYA&7\G,=2ISE8R/[<Z'V%LJ?3%BA% 7G::B=*SSI<QQ ( 6J4U8D.
M[(F&/OY+%6S#/FS$/I[>/$F4.<J5M"'UNAR19,FX\4F-?)W!S.PT7&S,?IV4
MT<G>))Z\%,K!7.S*)$JB;,F(3FS6;FW7?FW8CFW9QIE/X#ATD9FSM%3M*N3"
MGFW?_NW7=K$*.!QYTDO-O&R<M!G&QIQ+N #5CC6O/ $(&&X1()] > "X6<(U
MR 0_NDG'7FW@#F_QACT_.  ^T"X6D!X-2<:<R 0R]AKZM$]0\(#=Q"O\.@&K
M>849'6_^[F_*E8"F1@$.PP3U><5T7 $/^ 3!'=-!8F4Q=(-&!=)G.E,GPH06
M8"!-*/!=X,R"D(,KK2""LQ@_6(";<  8/!Q9E0 -P /-*?X(=OP :H2%%$#J
M>46"IO9O',_Q-70%!CB9F]"$!X#!>N6 "/B#-4B .H, !E* JP(!]_.#!. $
M7+  .?B$%  >#W  %K@$NYK7_.F$!!@W"[BZ"* %I,.<6,::R[786>Z$#9CE
M3(!8.J"X/V" /> %"XB#3WAEOW6 .M-Q0 ]TIM,63V" J^RXUY*R$( #( 6T
M-6B=#5M'*EX\/;" 5W"%3T  6" !_$*\#6>MHC(%7*"%3- TI+,8W3T=%BBW
M$WBM<X/%KW.@@L"$2\"#"KAT4$" N(4U0>]U7S^S"$PX;2G'^WV90A.!U-JI
MZ4&"6XIT.O  ;=& ;X2 RRV!$OYH!1&8@X/  +1A&9EBQ3=W 0K[A+[U&C:0
MSZ#9HUT@@=JJK"*C-EBH7X-; PE0*VO']CBXR%_?=WXO(6T1@4ITA0'H!!-H
M=P3"A1!@(&6_((CC,Z.:6B%SW9K 'A"X(Q$XO4^0X:]CPH*XL::%9 1X3>3#
M'A.8VQ- @AW\.@IH(CVX1&+$GF#K=YF?>>2AMPV@@SA@ (@K=4*R +AQ+0A2
M;S[G0#FX@(+(,%ZH@!5P)G73 (%L&J]#-Q*W@!9 !#8X@)\%U)J8@P18@3MP
M 05X+?U2W&_"!/B\@YQR9L6I !4(!!10,0XX,/"F>;JO^V?!:6JJ"6E:7*[>
M<#B84+!CRFI81-1/>IH5*#Q:J'"OV7NG:05A,P44* %$" 0V<(4;AT5)JB*O
M >QUK"#+UY8^$(&KSIP5 (&,SFN[3WW5!TZG7'W7?WWD<>S1YDF41&Z-W"#3
MR/V=,&WA.<W3AGW@#W[A'W[B+W[C/W[D3W[E7W[F;W[G?W[HCW[IGW[JKW[K
MOW[LSW[MWW[N[W[O_W[P#W_Q'W_R+W_S/W_T3W_U7W_V;W_W?W_XCW_Y7YB
#   [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>60
<FILENAME>cogo_0039.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0039.gif
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M^?3T]/3V^?7Z_/____CW]_#O\
M
M
M                     "'Y!       (?\+26UA9V5-86=I8VL-9V%M;6$]
M,"XT-30U-0 L      $#9P$ "/X HPD<2+"@P8,($RI<R+"APX<0(TJ<2+&B
MQ8L8,VK<R+&CQX\@0XH<2;*DR9,H4ZI<R;*ERY<P8\J<2;.FS9LX<^K<R;.G
MSY] @PH=2K2HT:-(DRI=RK2ITZ=0HTJ=2K6JU:M8LVK=RK6KUZ\[I0D4FU4:
MV8%GP:I=R[:MVZEI/\9]2[>NW;MXKTJ;P<+%"Q<N_.R*)C;2@QAS,1:&@%C:
ML6.)01[KL\*&+Q(4=B%S@>)1WL^@0XL6+<T! 0,! @PPD,!SM!( !@Q.2SNN
MV8)DS\(.@&Q6@@29" M'2_#VV.+$B9]%1F$   N'   @A,P @!O"Q48>S;V[
M]^])I?Y-2 #A!0P3"A84V!1M5@I"(=W#IW7 @"R28G6QQG%,&8T7R.S"@ %]
M# ?>@0@FJ*!.XAD@PD" ((" "='(0@@FNQ0R""T"T4((=176T,(-LPC$"R&'
M(/.('X7%H((,P55(2"2\T/!;#)G0$@@AQPC$22"/D 4)(++8$H,+AXC%2R"'
M*+.B6,< \D(,AS@3S2XR*)  C,<HDJ* !50AT"Y]N"!#) NFJ>::;'K4H 7&
M68   ]/$ ( "O#@   L"K0  !-$ 0D!L 1!02#31*9 "  E(4T, !B@@   V
M1-,"  \<$@ ## 1  BW.^4%8!0"@0)@T$@ @ 0( $!# "_[1*'+GH@A4V.D
M @0P 3*9 ,!I !5D$@  G!RC  $X1).) H0*$$.;T$8K[;3%36" !<?!<  "
MNN!  * V?.N,,Q 8J@L!"1"R2X0('%.) 0XX: ,O WKVB 032'.# 1&H*"$B
M@Z5   G1V*(  F@*),+!+3Q"PK&T9&)  P[>@(P$!)00L00#I""-(@D@\(<O
MG4@HB[$$]%$: 3+L@HD# WBV';4TUVQS70V*<%8,!B!@2[@.2",+ @;,T@FZ
MQ^ P@ 2=T-))N85D0@ "L$9SS&\E] $)A]+00, #T=!BP &="*0( 0H<0\@
M$" SD C7"J3+L8!@,G75D?0<H_X?D1ZCGP%H;D*T*<<P0$ @FZ#]""VTF%"
MJ3='+OGD8&DWP0%POHV  LC<(*XT%03@1Q^>1H/" 0L,"RD ,&!2  +LB>4'
M I,.D !V,GPM- ('8"(6,A ,<(@+KZ(EP@ P$*9,N32X?@![@1:P@"Z$05+?
M+&(;X-DF]1&^  &#($)  [FV.D #,U.N_OKL(Y7S0(I(^&#N;4=CPP B6!
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M@ F1A1,'<$"/OBI40@2B1\ +@%L-A)N#I,46"6B ,T#%@!YMH@\.!>LQ#C$
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MFW$]5#?WFI_6I04$<;UPM"3::KA67R"NTP< 5$VH+&"5!/Y<@  :""03'!,
M QCY5@$9 !(#V44)7(6 &%@I$ 10P0O0/0'J]2'G ODYK*P9@XXS(AJ82/G*
MI25B!12B 030A2S&EVA6_8$3))B.,P!A;QQD8AHP"\XE+:"(&J"->D]&0 E4
ML  !'"(:67<!)^S407@[8Q901$8G4%" $A0"&1U7@5#+539>1),[P". A 7B
M"UJDF1<S1[<,K"0HG?-\NX!00  4@ ,&-*!'D*>YS2MD !(0V 7LDX8( A")
MQ#$9!P%P@!]>@  "/(O&"1A$CP-PU;%"8]?U4E[H:."PZT3CYPJ8@ L:,( 6
M1 ,' .C@\0& ^C^X$@$04#!K OZA" ?P/EKD-0 MH*\"33<@T9C(X@L$ "MG
M-  !@SE&N0B'@ 30F04 ,#D*!B#X:)Q  -B1"2(5#<94 =&@"W-R=Q#D"]'P
M!P#P+ 63@)TP )ES#$;&';-P1QDD#<K@"XGF-LY0 0) ?%F''<@W<LR'>IDP
M "5G U=V?LXP 2-8?-CA>G/"9>HS"PAP?M)0+I[A#!CC&CLG ]%@)\D2#8\P
M *:":3U$+P4 <T@8 !1R@%@&#8$@ !+@-DKS(*0C?1V'>GR3 )$@%K%4($BH
MA.!G&IV@# QP.Y[7([U@ Q9@;P: >K[P?B62>+*P"4OC#&(!"%(8#8OR!P(!
M P&0</[($ @DT  )H  2$('Q)G$G!GLN0!8F  ";  @ 8(;=(1:"@P!99 .;
M1Q[14$I3.#?H$PA+XS9]@#_]$P"H%ROC(PV1$(A4J%]#@P VP(0)(A:BB */
MH0)H*&(I9!:$D'_1( +8UP .T"D)T%-EY810Z#D.X #,:!VZH"F0HP@"@"VD
M SFD4WVEHS (8(T-X(S)!EQ6$R\95 @#\ "<X@RR( !XM E^X'%6\W[4\T$$
M@$/B(A!^$(@H$ !FZ +7@0P-$  H$ EVTT<(&&]XYP#!,'T0&"OY=P($P#7?
M,3<%X!J'( (D< "/2(W-:!H D(T < ("<0@"H#,E$ "!8/X6#QEH$&2-#V =
MM& +4)1QE(,J(3,VFZ, T16$A1@ )J=O5%((CX )OD-68N%R4'@_)? (B* (
MF! )B6B++.F- =!_7]B I3(0,P<#BJ"4F% )O'@7\F< (B4-(S G#)!(L"@0
M%@0KY-50B 8!!K"&=P1S+R8ZID.01=D'\VB 2/@_!YA?=P<O/8(# I "R/ [
MS*@ V'(@XE$ 4R@0?X"8CCF59@D)R$ (6NF*+TF(83,QSM ' N"9C'"5O3$Q
M/!DY8L$).^@",! #+^  !3 (T7 #?_(',$ TSP)]L;@+%P)7]/)R L%,%6 E
MSN ET1 (6DD 7 A,N[ +&X1Z@/X@ $LX?56S"X<08&QB+ %@< ;0,\XP";[B
M N@1 $'E#!$P ,@C#<Q2"=%0" )P *ST'&X#&Y42#2J0?]-D "O  H;C &'#
M@O)X)Q.I*1+B4CQ#2)89G0.@ #' "\)P"+_11WS8G$)U"&\GG2J)*!08#3/0
MDI#Q JA9F,X)HJ3'9.L3H)TT$(L23-(0 R+G @.0<,= *A/P9--15I\& #+3
M/[Y":=$W?5IUC'TT=9&R@PJII/SDHR=@'?"1EG6!#"Q@ G@&""C0 FX#"!7@
M #: "25PA+*@ B3 /YQQ0I%@ @P@ 183=%,I$(!0 O 1"23@ "G0"2J@ K.$
M BH@#?Z\< *$)E1]D$_494!-!%PM,&V; P![&I=&V@ GD$T=U'%+"@ .67L0
M,&(ATR,&R0 FT   ('B;P"BQ&3G.\ +P1!B_EPDGH *:X0R[0#WW:')64P,2
MT  F8)]P%60H<$J$,4_,QDB1<*8G5P(T(!:'8 $2 & EP#^0H*S\= ,3T  E
MT'LR)64@P0N).@ 4@J5J<0@G$ $2( /(8 .52!B!8 ''*A#)^I^98 *ZBG4.
M@ *;P (JD$F!0$\6P$BZ@ *'VDW"" .V@ D0P'K#81Q_]5N]1:Z?X544UF03
MUFG'@6)1Y42MT@!XMB!^F! 0*[*0!%57(H(  "DS(+'=1/ZQ]+6Q2<9>DH4,
MLM )Z?@=776Q3395[)6S&?M-0O,(D7!DV&58+%NT2)NT>:6T98&Q3/NT4!NU
MTM)AV8%74\6SMV&U&9L;6GLJV3$678NU!G*U/RNV/MMA9WL<:<NS#:NVR2&V
M8[NU3NM9.4NU6&NW;6L;81NV<KNV9=NW;]NV<ONU@!NW>1NX;&NVB/NW%*$=
M>_NUB>NU6DNV62NX9%NX:4NXAVNXE[NYF8NWA/NYG.NVC'M9/FNX&)L8JENQ
M@:NQ@]NZ%,NV@QN[/SN[22:[EGN[4MM#II )OHL)OAN\PCN\Q%N\QGN\R%N\
MP N\OYL)RRN\R_N\S<N\SEN]U/YKO=)KO<'[O-<;O=4[O=NKO>'KO,PKO==;
MO#=K6=*P"= [O-1[ON'+E-\[OLEKO-G+O>TKO^\[O_@;O_?+O^([O?^[O]F+
MO0!,P/,+OM:;O@AQ#)-0O\=;P/4+O_D;OPGLO0@,OMU+O@=LP1NLOQ:LP?D[
MP!Y,O_W[NUD$"84 HBL,HB[\PHC PH?0PC'\PB :PXBPPBULPRY<PS;LPS!<
M"#O\PD-\"$!LPT4LPS#,PRZ<Q#/\PTRLQ$@,Q4\\Q3V,Q#4,(A%Q#)FP"5[L
MQ0D6QIL@QF(,QF-\QF9<QF>LQF3\Q0EFQFA<Q@$$QW+\QG8<QW>\QF"<QW5,
MQWCLQ_YVS,=_',>#',9AS D?^Q"/L,(UW,*.+,513,1-#,E7S,,Q[,1%?,22
MS,.9',F83,5,_,E+',6B7,E,S",2<2)1K,E&/,E5;,FFO,JOO,FQ;,6V?,.>
M',J@S,FZ/,J]?,NM3,NX7 @)TUBTX ?N%0C*O,S,W,S._,S0',W2/,W,# C3
M;,W2C,W1K,W0K,W<_,S?[,SAW,SC7,V#\ ?%O+L]";GL/+GM_,[N',_O++E@
MV[!H>\_VG,]<J\_UO,_^W,\ 3<\"7;D#3;6?)<\(#<\*G= %S<\-_<\/'= $
M/='X#-$4[= 7;=&-N] <G= >C=$5+=$A'=$1/=(9+=(@G?[2^QQ9CEO/7OO2
MQA'3*RW3+DW3,%VU_/RX[DS/.LW./#W/E=O30AVZ.ZW.1GW42)W42KW43-W4
M3OW44!W54CW55%W55GW56)W56KW57-W57OW58!W68CW69%W69GW6:)W6:KW6
M;-W66 $-T'"TCZ1#<!T-OS=8OR?7;AU)#)'73'77S@78?UT1?KW7#"(-TX ,
MCR$,U[D+OM +0R $43 %6) %GT *OY ,SV 0@MU-G1T-SV ,KA +=6 '<C '
M5I#:3@ $D2T$E*T%GX *O[ ,G&W79-4,S5 ,PS ,KS ,KG *IY +OR ,RP"-
M!_'9AFT2@&U3R1 ,O* +N!#=TOZ-"[W0"[J "B"0 1<  A?0W1B  1\ !%"@
M!:/P"YM-$,C=2,WP"Z(@!V#0!$E@!/(]WT: !$G@ QB0 =_]W=Z= 3D !%.0
M!:20# 61WHX$#<4 "ZK !W@ !W%@!F00X6+ !CMP 1B@ 1H  A_P T$@!%C0
M".5MW )AX,G]$<Z@#,?PW-.M"RS>XB[."]CM 1K^ 33^ 1Z X1C0W1D X(WP
M"]XD#:X0"G/0!$A !/6=!$F@!$BN!$J>Y$EP!"#@ 34^Y1N@ ?IMX1L0!%@P
M"K1]X 31#*^P!W<0!V40!F8N!F(0X650!F10!FW  QM@XQK@ 73.WQ:. 3H@
M!.3=Y?X#0>(OU=FWX>>3HPS7N>(NWN*X -V*K@LP_@%13N>0'NDT[@%7K@%
M@ 6GH-?< =C-P IRP 1&0 3V[>1(7NJF7NH]H $?,.>1CN%27N-6;N$A  6>
M  SHO4/#D IW@ 9B$ 9I7@9F$.S!ON9KWN9OG@&13N=3;N/Z_=T;( 19< OG
M/;>-5-<4\7N"SB;.( RR8 F4< LN'MV+SN*)?N@P'N6/GNSJ/NG[#01:D M]
M/CG0X IRT 3RO>2GGN_YGNH8GNYTSNH _^H:D.,;  6?0.#L,PQ[  >]+@;
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MH@JY>=-ZQ0LG$[DESSP!+0M9N20NE)9'_>22/[=$C-3Z2!G(_)%;Q4P4,3$
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MR*%L"2QT&RT<F>))2BO*%J?,F[X4B3*$'G%$0_$X T]"&2NTR3R)-9U,$X9
MAK)\QT2HPWSQOYOCET#31RUH'/Y"?,8[(9T+H*VOX9\Q9$RE(XDEH,(#<4JH
MJ"R" (*\?!#N,\5QG$ANL<B?++&28QU5X,C(?*^WF+/#NY.%NB UV01W]$P;
M)(1:1!6]"RK- ; !(4*Z3)8<0L=$"Q,@>,-(@89F:+"(L2JK(LB1L!WJNTW
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M'59;&TCG7;_5BA;+M@WB/)!*=4RKWYD8IP =JA"VN^$.(Q:UP;-LSN::,PT
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M%5$9-&H4D<N/BI@&Y, %=,O 1L,I>"A<4ATO;1QB7:R3#E7#3NNP($48W,C
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M_M,V%ZG7S<;B$O%@O.QL#@$ IC0R_\0IK+-]FAPQ+[1%>_1":'06PY@8D(I
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MB&. #F#!MO-^5JL"430\\TCIW6\&'U"\\O-]-+B"$V#]8"Q!V>9Q:M'\6EU
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MK+#SH'32L"28 "./6%RI3$(BN=S/PFB$0<43+*  (@21,&A-S35'TD '(*#
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MH4$, .$ %W2B!!"@Y3%8P( *&/3 A%#!+%*PW#Y(0 *!0%H?(  !&"##%B4
M1 H<X&'-'$,!\$2!-!Y@  /TX0\0$"\-#@')LC6D$1RH208XT C%V2(!$D"
M+N)J9%T@@P6\W"=D^1CA"4_JI<XH 0.0\0@+["(:-P! )#9Y# +HH@+E75IJ
M,]"C'US&!00P01"=80(+<!, 49Q  E(@ @"X()K8V@0 2/[ B1H80 *[(,$#
M2$"($VQ"!"TPL] \X=Q07> 3^2GL;FT1(=N:-AK',( +D/'I8.DB 0]0 02P
M&XP$-& %J'[$(RP;B!,HP@86> 2V4EN7#/S 3C08P"PL@.5HB"  )1 ! 1BP
M G/R0@0*B,0*"+"+5"* !9$ 0!^"*X,7 . 0D0@ (0X!@#]H5@$J<  !'-L7
M:4A@!<<X  JB@0QKVV 6!?B# @(A@EUD(MU+B_3!1%+IL=C"  ,^1" 4@()H
MR^  F(@! #B1 @0<0P0,>$0*#!#%20'BRXKS!0H2X )IE* $+!#!#6IPC$@@
M=6G/ ,)J?^#:W [ !::P(@!0$/Z#"B2@!+9 QAIW+LQL'8(!!!"! VP<C5E(
MPP2%8  @2)""/I-,IC_:0 XP<%, #T "A.BC+TJP9Y:CP &$" ![?5L;9#1D
M%P8H0;P;P@NW1X,7^TZ!#2"@"'0+ZQFJ#5C,'^(,!U0@&N!=+@D0( U=!(#/
M,3C 'Q!0@D+0H*<N&$! .;%*"1 ^&OQV1B84$0,"R& 6 :!!-*H0@(!B1@9'
MGL4!MAN-3@#@])! 021N0(,70( !AUB:3"]0FJPK3A<#H($(4$ "$TA2%\>
MQ"%0,(!#I* !D2A TRE_^K13L],(P.]#>''E+2/C!2^010<.,?@.L'QHS_A
M0R\0@O[_(N,0$@" !<YO@0E4%@*$T&:\)4#8[,7Y,@$9=@$!I,XA(&$%:&$
MHH'H?B\:>HRF'$K(EFD67L  <NFX#  07NJEHB$2",T!A*Y+&N(12L"@9&$
MJJT$ DH6W.PA*H 62.#T$,#WMF\S^HYE/(!4@*4A*J$ &H "((  ( GQI&$6
M:"\:8L  <" !2  &8L &'L$$$D"(,F$ 9L !2$"*D($0#( $1(OTKBT:. ZM
M]J(A@ H!"H !#(#P,L'T'@(9+" +D0'$RL83^(LEI(OX!  '_.  #&#R!D 7
M9,  6. &!N#B&N 1PE *;4 1)H6GMBD:_.#THN$1RM#  /[AGJ*A )8K!X<$
M&CPA"TPQ"VY*(CB!!B($!@!@Z>S/ C +FAX&&8HN!HK0%) &&1[ YPS #RQ
M!<KF%[3 64SQ%B3B&&P@$W   "Q* 0A@]:1A @;@!82%%@I@ "P@ 02 $W:!
MD40@ 0: O2QQKFB@_\:,[\PD!'0@!(#@,EB  %Q "A?K&% @\900G6+@[- +
M&38A!63A'I/(F?Q !01@$S ! &*@!!# &63!])00FH++H$0Q(H ($PX! :*J
MF0!@!A1'!0AA%P  &7 @Z9;F$S9 !W3@!S:@TAIB\6P !C]+]#(! ;KP#[!K
M!1* %Q1 !/QQ!?HJ3TQ@ !RK!?ZN31;J"@=YX0%&3@6D@0!"D70B00:X#!D
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M WVUTU)TB/KT.V*%%8S5%2ZC(8[! <KP  4@  #  7C( FX)6MT2$$I3 "Q
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MG2$#WW 7SHL%*F %6& "4$  ), /H-$:P5 !% ":3D "3F  && NEV/D)J
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M(8 $NU2@UBE7P4D:+& !^@@_9K &Y0L'5X6_#0,R -PA6"  _L A'L'X5,
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MH64A?76A! A@[8RI.1K"F6Y LSKLIB'II9SW&!")!>;LTS>#%>P]Y5EAR (
MOSXP ">A#QI@%G RD0P@ C*1]OZ&<!:2,OJ<P98.X1$:X,K!([8<0 5(+H\(
M;8<B@?!60 0:$ T)AQ9D +<R<05, !#N2'&65!9>H 1J($6=X2I? %2)!!EL
M@ 1<(-P]M!(WH03*DG XX09PX 9L@ 8D.VT=(A)82II00/6&&N/[P 9$UN[I
MJ :T\B$ \W1K@ 3LW.3W(B -_!!BX/0"P0%XNQ><000*C F/";2$U@\J8!9P
MH %J4 1TH09\4AJB$#QD80*N_!$H0 $:0 ;6:!9:P"'^P $LH-_69A<H )W
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M-M@ 8(XZ @B-&6&((4889LP5S2'=&80# IG((HLNR##0 "VR( !!;7L)I,(
MND2#P@"T**" +(P 0$,@#$1C@0R\2/!6<JG\"&08JAC$"R 41A,# @I 6" G
METG3B6.)"60# 0A84"0 AT0#"/X BC"0"2\!(*/"HFV:!0T<9;1A1AEQ$-DE
M)M+<$("=B$DS68R8$#+0+K-8&8TNO=QU3 SB228 ";00 @ @CR#@# 0W(./
M,9?NB&RR7D$3!QEFF$%&'#.M , $AR"& @,TI #(=0#@&,T+ 1R9&" &/#)+
M!27LHD(@L0[P@B+ 0E"%"BHJZY J8CR+AIP'T0+  2_,(A @!#RB@ F8)0!!
M-)M\^]HAME80C2P&W&"+"PS0PD AF2CPB C)0:.&&&64(<:G!IDPP R;[(*,
M,R00>(@!G$BSP LO2( ,#0J =Y@(#"3P@*!P]3+!! 14@@P!+T1C2@"'$-(
MFC;<X/X'OEIOK5:F9)P<+9'.9.*" 2(X4T$"*I! YB$ N"M-'P \8EM>NS0P
M0 (!R#>0+! $P(DS(CA0 B$F<&*!"B)NK8J0S_K[6" 5+"W+ +)(8T *!]T
MP"Y]!/!G:-(H@*@T)02@0  0'M*  X8_<D,%=+]&LK-EA'W0)@T    #+" C
M-RXP ("#+'.CH$ D -10*R&! ! )+RK,7I<?<T=C ^H$0(#,+@R4X+H(NM!
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M OD# $PQ$ :@H ]5L\ -:J#02 M[V,2^\:0K;6E&**1L"D"  !3 "U.PU 7
M-$ :!Y")3$A5!3W-A ITT:4R#4!A<1&(\F00&P-,8!:$<T A2* +&92OV/2N
MM[T1?&Q$(.+22''!  HABT@H0/X$F!" &:-1@@1@+P#'*"LA5IH "@!"&B9
M@$ 4\!^[2",& S  *PET#$(($! 54 $$FGSOE*M\Y?9$!" 2(0A!($(A,!!
M)X[, $)X>B )=T8-!) 9 /3Q$85(:B%8P$UG+"#C=7$&+2:Q"5Y\SR"RB.<
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M(G0LD  Q,W6 MX/.X N9<Q",H/X"F21EZ8B1&8D^N\ +,]21"B$W!@ !!R
MF  ( R"'!.  O  !#& #%C WMM8_%(  ;M,',? MPQ,))# ITD  *4063S(
M+.   $@0QV!1TV  .% !T:613PF5Z(,),H ",'!S?4  @^ "+E!=T/4"F6 #
M3'(#EW$(?D +-M =XX@"*G((.. 1?6!998$,56 ",& T.M@WWG> 4<F7?;DC
MG'-S?BF8@UE\TB<+?3 8\D5?TB=?X3<3<+$;CTF8DTF9O/%[$29]_E69F\F9
MY=:9GPF:PO8(+[ E1F@;P.<1 L$++[ )CE5<>#$-LC +4C(8NP (@C)_H:F;
MNXD2T_Z #,K #'.F$-3"@QRA;7_ *\EECCMA;@$@ -0! [NP ,C3'2@P@;R)
MG=FI%8"!"]WI4@+Q @+0'8=I@Y'""Y^Q*R\T$+[P<(C!":6R"W^PEV8A$#B@
M *@P"[+@.0Z )C2@"XVTG-HIH!G)"[I@H+K "PFA1[, "01@ @T0)@D@ 02P
M H4P4 _ 39UP  Z@  W037GW/,49%\@3 [L6#8BPD%JU GHXH"VJG;R "P:*
M"Z\9+@ P"YO8"9U "+,0 0@ "+OP"(#@#')S"'V&>0;G<,GY=_19 0K  OWA
M J;C "CPBIE0 2M@(BZJI9\)#3 JH\4%G@$@FW]C "S ,?Z-UPG'6 $(@ ,2
MX  (!0$HL':#H*0O9B5I@QC?6 +A> CDN*1;"JA1J0NT@ NV$*,S 0,#P D&
M:9L L#,4A0Q8Q(\!4 @5H(JQL:AY1P@$A!>T( )_$&<M.1F*8*8"H$F!BJJ3
M&2/)@ RL.IP T DX>0/B$@B"5R /X)(5H"B/   FD%2,8#R ()-_2A;3 ),3
MP   H#_$H@O.L)05X$RI*JV<&0DD54 FD (M!I?/]0(PD E5T!V8H (IH"*[
M< -,8@,T:A>[I0(M\%>T8%FR@ (T, W3:J_WBJ_YJJ]DH9B2.5^/:1&^IW'^
MRA(!NJ\'B[ )J[ +R[ -Z[ /"_ZQ$2NQ$TNQ%6NQ%XNQ&:NQ&\NQ'>NQ'PNR
M(2NR(TNR)6NR)XNR*>N97)$L!JMA+LM%*AMIP#=7J=D5YAAG $(5,+LC-GN9
M@W(7/'L4)]$F0EM]0UIB@] !*U XT7!51"$0G1 Z2:$BLP N#2&U$A%>5IL2
MA- !*8 "*""+&;$)6W(#/M5?!M&G*& "4WL29QL-X14-FR84"3$+.-";K1<3
M00H4-;!#$1$)Z14#Y'41_MD'U44W=ZL2$"%Z8"NV$$$+>!L1,L W#G,9<"L4
MSK"U5TNLLW #&U<Q9@M^D"NY08$1 B$+;JL0O*"W1%LD**80SO "J$*N W&6
M#D&")_X*NQ%Q"+N;$KU[%$;&>V]97#'@!]US6R[0'=+0&@8Q"R55,2+RO"HA
M#;2@#%1W*BX@I)2!>[9; <BP"9?7O8-*$-J[%9D'OI=7FAYA$LSK&H(Q$S$
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M(L=X_,(.[ =H!+W3FYK(X,=C"WF6Y%(SH&PW. NCA0QJ1)K2H )]  /]$P.
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MEP.A,&LNXH3@!S)(&)H3JQV? M( ".1S MCCXJ=L_:W'"RLP#3U>=KI/AH#
M+<8_&33 @Q8S&!8 "-,O"\;_PM;!)=&  ^'% NLA X\ $(H>H0 $B!"R:-%0
M9$H8K<\Q%-*B\7I!"T8T0H"BR9!UJ%"T&+*BI5 6HQ>R% E3(+-E(>.@620
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)<8]]G*:    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>61
<FILENAME>cogo_0043.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0043.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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MI"N4E64[9(KA9\4,<VHGJM%EGEQ*4SFWB_<-=1-67*UR;M+8AL/J:86UE*5
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M<R)O,(\ U7N7+HC;PRLT2%L'<&#5H4U8F% )YNU.B)F"25 DTQ(2V(<R?6B
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MN57KO7O=(E'3P3X='RCR#>36991Y6Y\_\DTAK'A)/RIK,J/3W1X%1!2(VZZ
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K=LU'!12HO<T$R;@8>7.7QI#OE2$_I3Z#TH8P^06W($\:Z^C?[TS:@+/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>62
<FILENAME>cogo_0069.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0069.gif
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M'D;9A_X\H.0'$4A  1(0P0,"(  "+"  >![Q5W\K #H#X,\!&(  _EQ< 11
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M&M0( ?80MZ +HG8+M\I>FN (FA"LF/"RN7DZ4)&BUG>#N#64'^:$)B:)A&8
M%[ !_PJP'? "5]L!,? ",K"U7"L# $NU&#"O&I"O8SNO&) ! SND%'  Y"8
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M  A0M> MP7MMP85=TCV XMA=V->=TBB]U]G\ C&@M0 ;V2$@V3L*4/XT1![
M H]PSB21;^I\%[+'LPYH<.QUG&Z:H#Q,U?KKLD,,I_]M"1F%%X9 .X; 43^3
ML[QDE9[ VXEP"&UP"&\PX<-]!6B]RV29"^KPUG/5>2U&;N%L  B0 ;7;P22N
MQS< V/X[P -^_N<\X-<H;MT9'.@CG=@@;+LQL.@=0 (DL 'E/0$VVE4OYP&
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M*." KJ3^B@9R:SA+A\&&&$)K*/KL.OH!G^>/7;L09'ZP!A-;+(8:_HT,D$
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MYP(W_^>>7U "&8QU/NF2+G^H,(FA2Z$2E)C$).#"P^I!P6M^<FO6;F#IC*X
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MR -"$/Z2(>P2JG(.:]"%%K",NBF3 WB  \"M#."M,^0  7P!&G "-JR/#M@
M#1B!.83##!B!$C"7K8D"4XHQN+C $SLQ&SB!#:@ "9@ /*.V!$@?"3 !%OB]
MWV,!#Y  %G1!PBJ1$FD'L^LOBG$^,EH(8M-!N2.YW_#!G&J#RA&.-DB'[S,$
M0LBZ,A $1M $T*F&:P"YTHF%"ZJ-Q<N(]V,S\( @=&"!]"&3RC" !X" X&F/
M#?"PW0) J9&!&R@+&2B!#<B "X  ;$R ;<Q&#=B $:B!)=B:MGJ+*5 W%I.N
M'2B!$;" "YB 0SS$$*P %PB!%0 ^1V2!KFN!<O W(</$&?XT!X(C.&A0"%#
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M4>P4U9N9!2#-!"$%H/H2"<'\!%5X!6H)!..! 6U\@ GPP/2QI(T=P+'RTA*
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MCQZHQK^&P\XL@;(2;.': 4)I;,,P9G:?@M?38IA67$F(;DJ(%R9(\O;=XL+
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MB1F28Q3H1$X+SQP2=DBF.7"&L_X3F5@9!!N!"/28P2>'N,0H3!&-:X1D'?X
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MRN%1#ABD$W9\D^-]DP+!GP-A"2N$QWB,12-80B)8@B>80BQ4 _]]"CRI@R$
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M+3QY!-EZ@S(< S) @Q:(P*XR+PF7L+>@X>HMF495#XTI@8W%5;X G(E:G1*
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M'MS!+T##%\CA"ICP7?VQ#4R76JZ>'4)2<BJ@F0SN(UN=1B4K2''!4 ,Q"Z@
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MEV504AD%388+83B\30Z&&%D#A_Y_<D@-4'Y2%W[0@"JM-Z^,:N^5)#CB"4K
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MFJ&O[D37_ -<H.:PP*$;M"&'F$<<LD$:B"$;1H$%QL;R5*G_3  %\&4$CBT
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MYV />$&\MN$96@$8M"$8PJ %,D S-5/9TG!!08# P!$50P$8PB(_]W,/P)'
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M$VE;:!F0 1@^*[LNUA5G+;W\ KT8[U?YH JLH KDH'#9,.^B!C&51AA:01C
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M"JAM/ M$:PZ3+Q C,;9!'&R-$U0@ SKO;3*@!;Z$BKJ1#E+A#N! <*V@#^;
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D8[V+5[S/MA:@(7(E0)WXG51%20X<OQW&ZUSA*KBX2A4! 0 [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>63
<FILENAME>cogo_0068.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0068.gif
M1TE&.#EAL0"P /<  !<8&0P-#R@;&2\B'AP>(1TB)2LK+"8F)C4K*"TQ,S8V
M-S(P+R$?(4<Z-D\U+ULO)E-#/&Y'.CD]0@<V8T@^0SQ#1QI+=4A&1E=)1EA7
M6%)14F=,17=62F=:5W=;5&M227=E6VQA6E1;9%ML>5UH<&EF9WAJ961S?'-R
M<6A=83U!/XY1.HE94*Q66(9E6)9I69-K5JMN685K98AU:9=W:I=\<XYU;J=Y
M:J9\<[5U:[5;8\=U<,AR58$](IJ$>)> <+B#;*>'=[B)>+J2>ZJ)=<:*=\>4
M>]:6?<^)<>"2<R9IGUUR@TYNB6-T@V5ZBFI]C&=YAFU\BD]\JS-_P<!\@VR
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MG3Y1R<]+M6XANA,CN'9WC6N<<8RZ%$;NA-&+7G!0%\*HA$-3J%$_;A2D(#T
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M #D&DLB."=F.6Q! W\:05\AWDA99%NF%Y::+[<:0Z54-WN)3]75OC\=K![
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MLJ5PW"(NT51<T;7 W!1="[9@"[=P"R=>R[.\"JL0RWB-UTU<W/F;"(D0!$&
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M*/OGBQO+@T[%N+SSY>[B/@_70,\*L*P*UQW+URV_<YT*KG *GG\*B_ #$'
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M<3'^[5"',H-@;R,1=(23#A3L/0 !0, ,A@!X(N#@!R[X0 0^L($'Y&P  A#
M -H4<YI'@ 4Q2!+^&H(@R($<2 0=V(";@SF8 Q#&\P 7F($9< $9D($;8($>
MR+_$VP#$BST)J( %:  ,J(%4$ 8_V ,^*)IT82K=";38> TN0(1YV3-T S2K
MH@*L2@FP\SIC>+??HK=(*RM("QYZVS=+&X90X@7NZX6T*25F()&@V(9G8(<M
M8#@ ./X_!8 !K2@"(@BV8G,!UY,Y_P   6B5(+,Y!X@ &"@"*L !&T@!Q-L
M#^  _G. Q8L #J"!(0B%4A@"10B"GRN%(G@ _/L\H], "Y  #:" F$N!&]B!
M7^"%.M@#@K (<SJ:V6%!J6ND%\RP1\(Z>PDT*>BP0O.ZKY,DZ"D;LANN>V.#
MZ*.#.O"%7=@%7MB%MK.T7N@%N8,>4L*4G%B&:SB'?T $!6   KC"&0@%(4B$
M1, !#G@ !X@_:R&<T<. !F@ FNL_8TM#$,  14R (*.Y!]B #_@ #G !%^@
M#U!'"K0!'U@$5#B%RN(  :" \]N #,@ &ZB!%,@ "M@ &?YH@1;(A&&H ]HA
M%PDI#=" "$IL ]80 ZMY02S@@B_0,'MY(:L:@V;02!T\!G=C!N@AAF*(M'R+
MM.!YQ5CD!2-LNUR4NY8D&&E8AF< OVN@@FLJ1NM8  QX@1O(/)E[  X R@\P
M 1HX1\UK@ U 2OG[ !> @6A$@ 2(/0&(.0I@ 19@RA?P  > N0$P@//# '7$
M 5>8!7^P 0$XOP6P 5#XA%D8!0_0  ^H 2H R$_PA3W8@S<XR#8()]E1FC9
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MY+.4KP/)'C*N/S@Q!!VK?<N%7K"T/65)[NL79@@*;&@&9S@'6*""'*C*!A"
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MTQ?*UD"K@S8=U#]^MY"<AA[R@^*JONC#!3H@.\PT84PJFW>=Y'VAYSYV"6R
MAD^ K!J@@ [P@64,A2)(DAA8@;[E@:T CUSY6"XQKR2 @0%8@8\3A26KKU6@
M A90-B0 #_!@(,?J"O HO22 WU*8&7/ O)5V!;K< YCVHX0(A'N3$)N6DP+A
ML\/,UHOL:9_>@YMX!@T.&-$T$?XA6BC?]8,#78-V;FIS)6%=6-=CL*2/3 9G
M< :QO09F.(=?V"\JV  ,L %%4.)0Z(O /@*#!@_YR LL X*+S@%20(*Y)H56
M& 5G X(70#WO2H(CR!RQR+4C@ $60 (DJ-S+M2Q?=8'20[-,P 4\*%:=S0.%
M6 @)88..&(/)ONG60,S#;!HS."3\K(.?[NS.!A@3X=UH&(003C$@I(-V#BAW
MS@6S <FY.P:N VJ-9(9T^ 663H31DP%%$ (;%H622H(5 ,"[$"RRD(6*M>47
M$(4DL"\"FKR(%H*SQ>M5O6XI2X*[0 (@(&L>.-OA#I/"HAE?C4T6( 58\(5B
M51=PPOZ#0#C!/%!6C)#O,6A=*9=CQ*0PK=$(-$@77.AO_VX&: @Q$UF^<@ZE
M8@"$J2VKX*V#/,X%-M>A!B\;7#P&8&"&KYOM*+S@:T@'FIPL#Z  $P@"([-<
M6V.%$(<!(XB%6V@INVB%(\#K!VB!(PB%'="RRN-D_A)K)(@!8VN!&#AK'N>!
M4,\!).#Q)-@OP0 P<["!"&B!'6B%3]@#<P(G-5:0]_;+"^D(+9CRF]8(_,1/
MK<'RJ7G%_JZ)-MW@S\84:<"T03CSTM:W/&;D/+Y,'2H;8)AS'JQSV;X);KB)
M:^ &9?"O46"!"P"!0-_8+1,+)$C#D=TIN% %)%B!!UB!%OY( E)( DKG9).#
M;O\*N20@91$/]8#_:%+?@8\S!500G9TBG1=H 2HPN4P0!&\#)STXP6^)D)O6
M CEI70()@W?R=6O%5MG2;S1@E_Z^B9D \X#!E)#LH69W=CU8<\QD9'G#H;+9
MIV.@ZF10AF=(ATOF[&> !?^B@0;P@$"_WU$(D[ @!5*.@2(P!2QA;AYH 1%O
M^B-@[B.@V2F+Z,D*]RZ;VX /^!W@\>_^:,ERA6""(&EZA1:P4510A$J@'3B8
M1+M<XTGTRS<ND(VGR*JAP8^WUA=26CC0XQGV[,;TX*+N731/<SU8Y&C/8^""
M<V 0!K"9E$&=;6X(VY^'!46(;OX,V #ZN=]0" ]:F[*/YH$< 'L=&'N]/@+P
MKO?G/O'):J932 3 (V@DN/>/ONXD^6A1@*R6=2,(PBP=T(')@@5AF+"7MLL]
M"(2$6.PU>./)T/O6?:2/KX,)^Q#9DEW!1P/.1A$>O!0R7Z@^^-T_L -?D/F9
MQP4=TJ%+F!YZEFU[OF3I.GD;.P=%Z"L;\( 9P $AZ'!=!@A3HDBU:B5K%:E1
M.Y P3)+DR!$C128.'#5*%JF$HTY9# 4D!Y"&#C,*')CQHBQ;Z-"I-/<JU*A7
MKX3ERE,'SAP\>_($XK-GSYTU;,2(^3+F"](O8<:4,8,3SANH<."4J?KH:AHX
M5]$T>_[V#%JR9,:8)2/&C)DT:<0(^?FCTXZ>7;[F^LJ5"Q?>2I4N&1.&S%FS
MP%VW;?.VC1NW9UW391J5ZM0-&#>$" D%T90J@P57<4:H2M01AD60B"JRHR+G
M5J-0N4(U*A3LB3EX+'P(,7024J(LREKI&]TKB[;.Y;+S<^=/GGQ\WF$SM*C1
MI$O3H+ES9^K-J53+/++Z*$T:,XJ3?346-BPU9L2*%1O4IP^>.WM\S>?%BRZN
M294F%=-ES!@R@3GCU3/<$'98.=A@4R TI["R2B@VR "2$!!E1%!!&3G$$$,+
M%7&$**$4,5!GG(VRBFNC)!3*#CD@,1I#1R2!1"A(Z+::+/[F +?2++ D,HHY
MO^1Q1RYMM($''T@&$@@>>-2QAAB1C)&%&%ED\84C1)VQAG4_O;&'5'"D\4@C
M5UW5%(')@!7666>IQ=X?<?Y1QWQTW8>++OOMQ9=Y@256(&'==(--8MMX=0XM
MKK2"2@TTT("#$".*LALI"%VX$!(Y4+@#B!,=P9LL!ZWB2FNNR()*BSN8MD-(
M'#(T*8ZVO+(C.K L @LTE_"A!QMR\M'3DD U]YP88Q!5U!C.R7?<'ME1-::9
M9312AAA>D9?,,NA10TU9Q*RWRQUV&!?7+O;=-Q>>^OD7H%>(<>,--^" \PTX
M\2(&SC._?-+**E0XB@,0$X5BTOXH28"6:0PQY* J$$1(2AI!H<JRFBVVN#2+
M*SC<,!$20"C\$8RPE8)*+#+=\LH__OSC"4V[N(5'G(0LQX<??MCQ1QMD.&=&
M45D>R\8=;OGTTTU5B8F&&6EP%X8CC:2I;3+;4B,->\7]84<=>FB]"]>^W%D)
M+I<4$PR Y&WC3#J($>8-O.X6F-@GJ*#B[PTU "SP#E0D007",+S@(D2A:"K$
MPE2<N,J)%-=J$0X<Q'#$1"'%\$+"JNX0BMRDRO1/RO\(XTN<,..\!EM^#,)+
M'W98QT8:;/!<[!?%)LN&'37OY.Q4U*'Q79F-.&UMU%%+38VW5?]A79Q=FVM7
M+NKJ OZ,,,Y<,WW:U[#M33?R/H-O@>DT>(HB/XC_@\8!NYI##"RPL#%$D^YP
M PL;L& X*@GMA@HZG\B@?@0>4$&%B")W@Q>X( :J.D+F3N$*F9R#'9_S19.:
M%*=<_ $0?@ $+^3D'#(<JRA$:809N/0'VP'B)W!  QI.B$(S^>X13SL/-J1&
MM6)0$'DWXUJYZN(+/.6B$L\[1C+0)KVWP<L;VG,7-\[QC'3\XQ.+",+X<$"$
M'!1A""]"'P<X,)D 3J0(-^! !#X@ QP83A1Y<XT,-K !#&Q !V3, 8LH X0;
MT  $,(A!$5CSBE/  F7F.,?G>I*D/^1B%\4P'2$2V9:@./['.6* DAC, ,(V
M!*UF@3C.5!ZA0A2.B3N_>T8RL"&\X1V#/;JHX1WZ0"Y>R.4^N=#%)%X9#& D
MHQG72$<ZG.&NZVT/7VY3XCG^H0@?^$!\-P""^8  @_X180A#*$*D!)<#',A
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MIRZGM(LNC@%$EB9QEX)ZFVCCQ2 &GY8(/G6!"9;;6@R;,[8XL',BJ* ("7D
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M97%-,?"=98%9+O1")RH#/U[#,QC1R!UA^1'>5X8E-Z@?-@1&61[""?P "J"
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MEBZHO>AF$IV#K!+#)R#"$(A/P*) "92 F=8 A=V F[%*#-   %83-JG/"^#
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M=>O%BQ,Z-Z!S$3*Z9Q4A.;2#(:B !(C & V!T .]*9A"T+OS#VAZ"*B "FB
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M6KK/^\ QVE;GQ 0+S_#,@O+AI2[1L"BH': !%$8HW"8/QWQ "%&H!D[(!J(
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M&5(.'OHN2LG!/*+4/:]O+GUR+E.G6K[!/B'(!B4(-%5*Q2"H3!:OK^(A&J;
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M002$LYOC8!>D@4O"@?1X@1=*+QR\X1(6XUB%NIV\@?2&P0V4&G#?8 ^&(1P
MX9[E  ]X(1O686E'-R+#0CF[&*SMH:N]FJ /FA_ZP1_ZX1R&,96<B&(D 1-
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M7O ^_\Z.5_FO6=R.K1LGH&[&-_J.%H^EGBL168<8U, "1O[ #?Z &*:A#^
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MG3P%*PF#$&U:,SH(K8\K,XG14EC'E'&@17[#",<P;@BB;Y#C&]D T='^]A,
M)G*1IMI>R^ &M][4L8ZV"LI@^"$I*9Z#$E;4Q26T&(PM@J=N<\/'W,(S+1O-
MK1[S -[0?(?"4ODN)4^JQU^\\R[@^2Y>TB(C4+KHGS0Q3(]=:]%,7M(.SK@C
L2BQ#8E^V]4R>-5,PAOE1 =T621;A)20NRHM9.J !#6. 4QC0<(8SGA$0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>64
<FILENAME>cogo_0070.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0070.gif
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M^8@?$8D%N=6,Q01)M5($*[K209ITL4,<D/B ;VG:4KU"N,$1GC!QASOA!"0
MPPA(;OYR 0  DY))!6-Y&HABF2'&_>R6^60LF4#PX>].%K)K@I4*&.L!K_AE
MF'NZ!2-Z#)&,6>8C'8%O/382DXI8<&058:9^-]V2<^6G/^VP$3WF 0:X0D"F
M E#I!RI@@ FP>@(;V( &)BSK6$^@S 0X0(.-&X -LUD  RC BQ&F,!$ =3G2
M.2&+67PA/TM63= V2U1^%LR![.D@EZA880XS$2'7Z&N0R1'9EKR8'VT3THW!
MW;E7)@ZWU18,%(CI;GG;  IH0 ,;2$&MI7"#6L=: QB8P 0>,.$&Z)H :<XM
MFP$0@ "TN889>DN#1+BPGYGIIT'[\(O%!&(_0W9H_PI3T/[$P@'J6.T@% ,4
M1$;%'I;L#]SA7L<UQDW-3 >IHA:MT3;[$SPE[:\:)RAI 08 @ C\@P*R_L<4
M1C&%?VR W_V.==3O/6&"*^#@&3[XFHG.9@G\K$&W<6X'\?A*C.O9:/GLN)^O
M9YQ\$NWB?DD6RAG=62"?SMP8*0_K-A) )=\WT^(9CTPD$X^9O(UM<_-(.UC2
M#CS(--BI_@"^IS %*42!\E*@_ TR'W4<W  'L2;X PC> #,S(->[1H##V8P
M"'" GFX900=S6-A;W<;L>"93AEPH=L$9U8:#HY593*XG/NGB%MIVB$.BY8NN
M;08C\S"R/.J!P)F+I(+<FH8UL_Z!0(Z8YW8V(9)JV%$->EP"I1 (-@$^(/DI
M.&$/HXB"_"\OA?I7?@.>__P&/H\!##@ !QA < F@:V:6  00  BP<  P "&P
M*W9R)SE#1W1D=C<&2XX3 LY%5!-X%HB3+ ;!"[N@"^CE$/%B=\%0#?/!#O80
M?1J!'CF1$N1&/+9#29'A-N:0(S)!#LX@#DI2"+>U6Y!G ),7!:,0?T7("?,7
M!9:WA/77A#IP U (A3@@>J4W80:  &FV9@   70D<4LC'<"$78.6.+!T*QD(
M3P>3.69R<3_#.<.T++<0+SX&9+[0#.YE1-)G#MG */3%+>M!1-WG-C1(@QZ!
M&LQ4"/YMH %"-U,$T  J, 7P)PKQ%PA%2 J6: 56,'^9.']20 6=V(E/.(4/
M@ $%9W 9IH5%!U0"<P) U8I(A52M:&S&=D)! WRO2$=N5R9C8F,E1QW#!(*[
M$(=R"!$2X0O.8&[G, ^,1%I)-E^7%BJ=T1$,I2CK@ [L, \Y@2-XD (4(  0
M0%(?T&!3L FH, J46(1%B J62 I60 JC@(E1@(E6$']60 7SYXE2V']6QP!7
MAX4-MX 1, *JTB8#HRH#DU,GE) 65TMU\11CD7%"TS@J\#[$= N$Y&,_)BU.
M9@Y5Q8*D)7,APRTF<0U,<@UAHSH;H2@V\FW9: [-P(VI]OZ-PD4 &D +JH *
MI9"3I8 */*F.Z\B.[ B/\IB)]EB4^(@#2#F%#?  "J  "+=Z $ !!LF*QE9B
M/T-/0#4Y94@T>&0XN<%GTL4X')!B=580G]-#6&.1<W@)B;$8S71DCX%SC=)D
M?H@-AA(V'D.-\0 3'E$-%X$);: ""48 $(!7_T +J+ )-GF3I4 *//F3[@B4
MEYB)E&D%6$ %5%"/GB@%.Q"%FR<%&."4!+!P \ !3A&+#X.5KR2+"EE+QV9L
ML/B0_@(F;U=HT>"+G\,G<7B1C09&73,?SI01'BD9(-,HZW&"+%%)*-D1_,4.
M[3 -<_,,B? /NY4""E9OG! .M/Y "[. F*A@"J;@DZ< F9CXDT,9!51PF9BY
MGNNY SO F5(@!#$P@*KG<!!@&UER&PWB/;#Y2A+X87:FFJGY=HU%1Q%Y(0!%
M';>Y8\@W/^FU"(H@+4L$:<(9??-0#XL2,NPQ#:]#(^O $8H2-AZQ/]$Y-WC
M6U(1 1HP!9Q "_#0G=[9DSWYD^.YCEAPB:00!5@0C^@9C^RY U3@GNZI SN0
M P[ E*K'<!R0G[9A<=X#BUGRI'9F*VZ1,\9V2[#R+RP&7;?)(LS "[<0A[G
MFQ"*2-JW/Z,U#_H@?1_*3)?A**>#4%"D.HF"0-7H2?,0#2*U3@WP#YLP"[,
M#]NYG?XWR0HSZI.0>:-!&8^6N:.:R9Z<&:2<N0-$( 5$( ,6< #_B !T%*7
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MOD#H)&JA[3!JHP62(;/MOASDWOY.6O. #X6P4FS+HBVZF)W>\XH,GD _GJ%
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M6Y%%<:KA#49Y?O.IFN$$GB)'3E9)M:KFG*.JEJM.865BZZ(,92P]PG+2+%!
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M7D#4&A!3 ((,LJSK][YW"33H@1&,,(0@\)<,2?!!$;Q<!"4$X05N7H "JLP
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MA3B @"DHA4T8!2EHJ@;8@"E0 1@R  U( &I[ !QH@0O( !\(!# 9 YE; @M
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MS%@:<('HY@2WQNNXINCLYH:ZMNMND.LC5@9NJ/&.SNX?WX:.SFN]MH;!CH9
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M^A@;:>)A0WYULC7FJ)>E>BC0>;P#'K@AXO9$(0HK0.&54'*  B*:@ :H !"
MV!@H8H$=[*0G%)T@@U><$H0@$&MR+H#*#*0).ATTX9D[V$&78(D#&MS !T"0
M@RWJ< QK9>L6RMC67:*A#=?-:?Z0&@P7(<E%2&7<01G'F-KN),.+75CM:HEH
M!"/B^0QI$"^@R,.7/F\H#6M40VWMV*$]WC8/?4SO'>J8!2M:HM#M6<$*46A"
M^%CP  8<  $! $  4O"#*6 G"3;1@TV0U8FO'"$)7 H"#X*@N!?DR@8YL($.
M;$ $*NP@8EQR%BQI6D=#R.%T;[&%A'Y*M+MH@TUZ0<928SO(NQ@UMG5A*E.?
MJLZHLO,R5V5$09;A&8#5\ZL0T>0UFK>:LK8&H&IEZUKK4<I9=,H4VAL%72$F
ML>XDP%=+4  #%* !(+0"%DN@#A*$%)X@^  J^7OOKRXP ;Z&]P)T)$(3\@O-
M!(:6@?Y P /NSOD6IVH+&=&X"VL]&-L%Q[:I3$TD"">8N]WQ=JI5]5DBLBK/
M;&1#(@[Y:O7,D5QI8*1Y:ZN7HEC40Q:YPZ"KL-%UK9!0*TCA!BU8P 1<0"O]
M/< "%LA#'Q;PAUJ0 1:@((/B(/L"7UW  A< KU\1@  &A-<%-6 I%3S++%C*
M@ 9I 40=[& +0UCK+=E"!M%:QUH$.YC!"VYJ4[-5NCO0F1K0: :$),0,JEH5
M$8S0\#*DT8YL&$^&^)@':!B5FDYN2$5JI1Y!Y18C5)QB%)[8WAZN< 6\MJ!)
M-+B8'O(@LB HH3MC0 (9PB&+/Y"!8V08 ZP3$%$J,\ [3?Y2P (P@.4L=TZF
M+0B3#U)P"%R(F4^V(&0RE,&,U1D8S<DF9%V.O=1C+Y+:QU:D+>A,9]S9&3)Z
MAN<)+X,(K!:D,Y]I1PR/ASQ%;1)M[LZA.1P]FH&E-1\%G?1UMX==B.4 !Q?
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MN?F"N768A\@0BY@&B4@#I*Q-VX@21!Q:B,B#/=C#O;&$*"240EU!%!!!#>1
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M)'@1*JQ"IY3NO6Y"C- "*J1"^P1"<PS)(O(2['81>R5E?(2@ERFLK381#<B
M#.2@/OYN "!@PB100MH:;S $ QZ$P G4+?1*K_3&K1E8[QJ401NPP;+RJ<@*
M;K1J 3>$+^+*+",$"KAV1HK 'N3F$VKPK$6<PS_AWNUE SW$ SZ\ R'(( Q$
M 74%,-(& NH"L"JTS\($PAY8E"!"P2\A04_."@]DL)34@%56\-[46 [\;@QL
M0 !IP!2T @AK0O%:["], R: P0=X@ D\+PN?  DX+PIP0?5:;_;B:<I:JPSK
M;1EHP:!QP^'&[)]]ZY]UY#+,2_$TA#ZL[[II$KIV$KR]$/74(6C@@SNX@MOQ
M@ -(0:< L+VB0FZ,;HQT<?N, AA'@:JHRG(\01?9% W$8_Y2]FZ"8L 4P!(^
MZHP^FI'"^4&:4D(EI.TD&.^P3B@8H( AU^T(L' )*/*?7F\CXZD9_ /AE@$:
M[&T9M//W6D,[7#(\494F,X(N8.?-TL,]\8,"DK)R4:I">$/2'0KU;.Y"O(,K
ML* 2L, "3 '2/C0J;,(MT[+"*,PH[$$43,$O+P<7.8X/%',/]( 0" '?N/$R
MRU2"CFT,6, !_$ D9(((Z[$(&^\U-\,O-$,AH  (>( (F$ )?, A1R^@,O(Z
MAVP[KS.T.FL9['!%^N+_"2#Y!O$TC*OZEJL\4(1B-L])7L- NR2+X*\;AL,?
M( %5,+0#M(050+1+ #"GY,;"7/YT%/BRJOR(+Q>!#S@.2/> ?&3P!N, !FBB
ML/S/7DW 'VQ")LBT"!<O)5PS""/O)+@I"H@ ":1P4-NMB2)K#3OK(__I4<LP
M9F_!H&6#)6,DN%DG<-VS<-$+.^BS/57U$YO&[$V#CVZU<\'DI6!*.[1#*BPB
M#\  0S\ 97+C_R+M%@.PTRIM(/CR+SF!% @B<_< 7GM9!O\U#FP +$D!W^GC
M,R\  R! 'A3#)%A")(CP>",VA$X")&C"FCJ#QG[ !TRO&6C!%JCSLEIO.[,S
M.S.R.G_VN?2WC#YUMXX;(PA/,\Q+I*H;/W\5*<^>5F](/.#O\0RTTKDR%-@@
MDSC  _Y$0=)2)D2K0L)$=$L$@M)R@B\WMW/7F ] -QCIC PLLW5C !-A@';+
MP 4L@ (@@ 94PB!< B98@@B'<&*GK1Y# B1( B8 0R9<PB(( @H$<@DT+Q=L
MP3JW<_:V03M[+)4K:QLH:SL?+LR*X0_[&88$FF? !NQ%[E6;I%:?&$G )#WP
M@S<(]#SP SS\ 10H06_7N'?L0)*2PKVVA-.">"#D*W;%=5P+<ZHX011(P13<
M=8KS@ ;3 '9O  98]P9(@<ZT  8T *WQ028,@O%60B1,0@B7^B1L@@A#PB-
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MC*$\1RBZF)^7T@,5E4+%6>8@!S;6$<9X0'.-Z^A'..)(!B5<TW2GPP";+N0
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M.GF7B%/LE+T4%7P\91^^E@>7B(&.C$.3&./(>##0H8][(%"!#=:#'I1-NB(
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M!AW*8W()".,+21)'L9#0%X*!'-;!LLJ!_,2!',@A_,B/_)SA&W91V.SA%_Q
M$HR!$/S %4 A#SJA#\JPP4CG!W[@Y"R :S"@JV0NPT(/Q':N@@*C]&Z ")J@
MMI(J%*P "I0@"(H@%(Q!%HH!'>X!'8KA$?1)&"JA%<0F(BXM%99G8(ZH$AZ!
M#_R1#U"$(3;)O#81&,Z.&(#!\(@A!Q?O&X;!!K_!(>>N!STJ")&$"!7A%BY!
M%WIA&@1('C[+&8)L&OQG"G7Q"LGO&VK1'"ZQZ?Z #R1AM/I@#\IP9RSO!\C@
M#T!!!MH0 #',VN90,"Y(#K?M:?Z>8 \Z80\F#]GV !1281A+J[0(P1C0P1@L
M(=(HH:PPH2$Z,&XX0ZY,) \V)2+ #A.TLNQ"+1@^$10CLB$1LJ&>(1,B\AO
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M(FI4V"[A$AR32-/A',8SR.R&'-(!_9C.B?,)77_5;5J!:5LA95.V%4 A@ES
M!K;8S_B7:) JJ:H "4K!%4SC@/]Q0NFX0MDXCANXCN X*NN8<5W!N<3&7>])
M>3()KRK5=S^Q7\=A\+X94U<8',[!A=&V:\<!'=(A'1JYR:#!.N2A'=+A>F^Q
M8;]A$C"B/,G!&70!X5[180EO$@H!(Z34'!9/&-!AB1$Q#&,Y<>U)-F>9$")7
M%HP >)PU34MO**N5/ZK #PF!C*T44DBK#R9X#() C4N:F54ZFLG 'RVP@L.0
MK2RI[))SW=RNX]0!D4G8XSJN'/[6.3#1 1P&=Y[7^1K8UAJ@@1IBD1U&V1["
M<_"(X1)WD_Q^F+Q<L6'-H1QTLR(P83TU[@(UKFT2EW9?V@*M.$S34:+MU!CZ
M )X.)32%P$#?5.>0"HRA( E X7!#^B6AN:]1^IGE#Z7Y8 R^X)D-M>D,L5V/
M[Q>$ 0=?[&X6+X5S&AS2H5\_49WM89W7F4C5.1WN(1VR@7"H@2FH%W#=(9/)
M 1R&X7K(\PJ=0<A><4O*H:Z "!/ 3.,0VAV;V )AMX*)8;3D-V6U]34E@0=@
MP 840UZ$[DUKEFC V)K ,%[!E+1HL[K)P'WI^+K)0!"B\A_'P+NYC@PBH8)C
MS!((+OX'!8X&S;:%UP@<U"%3<3JSUWF-TD$=W&&=[[O)F((>J-<=Y/D)F52\
M+L)6RY,*+^$7GF$\SH$<+"%A?D&'J;3IU@BZ?+LJB0$JE5%R92%R8S(/6B
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M;"^"Z5@'D":3CESQ+!6@^,$?UD>('_H!*CSKG%_VTY<W&4U<X"KE8<B%*Z)
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6T#_O9:^(T(XQ(QMC0KA4+X;>(R  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>65
<FILENAME>cogo_0064.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0064.gif
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M14B2)"2J\8(2:<X3H"O@0 F,"$07 N$'V<WN"4T0 LE@@S9-:(%XQ4."!I&
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M+*SNNWDKJZ (?+,8D+YCBJP$X  7\,4^QP 00 %RE@$*FOXLI!5T%:  "\
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M<XD;OC]GT<(JS,2L 1AP8".@ P#-WA1  I9=P-9LQQA S)J'Q0K:K!^0;15
M 60F9NX=9RHPV.'6?@Q*="HT5.3JQT0MU)X X0Z^X! ^VJ@MX0Q>VV]9BAX<
MU3,ZH_[RG)?W:A)$T@4$TS5<#0<;F9A"$$PM$ 0)K>2NV=B#FRR9IXV#F^42
MP  %>+(9X $*, #\6\WD30,,.@(40,TC4,<%[ ,^  /FG8TY6<MP2MC""@$D
M'0%#?NEM?& 90 (G8 *WR;-09@,W4#P^7=0,[N#(/M2?$,X5SN 3+M1X_M1.
M'=N2NN=3W:.;:A:P,S>BX =HX.(;N9%"4 (,H -LP ,S$ 0[  /KONE,# ($
M=I\&D'F)30 !<'.@=Z6T[K\F8,T\H-#ZI0$G8,VJKN0^T .K3NH$H !T.@ $
M( $NL-$,KP ,\,I[JP"TW  9@%,:D-<^99LU8%A#&BM-</[:RQX*HD#:$![G
MRO[@K,W@GR ,3RWMM0V=LNWAD'*=I+"I1I(U!",(@< &<N#B'"D$05 #I27T
M\X<$HB[J'\#$.V?8(#"^0&X >3B3'H"_3*P"_<Z@/<"@/( !"W#J!=\#9I^A
M/F ")* !))W%"]^L&QUF*'MZ1ZP I9Z2_-U3X89NL")(Y$JN*!\*X>SR,,_@
MH_W@JUWXU#?M3VVU'G[S,XJIY_<)<[7;K) U@; J4/#A^JP',(X&(10$^[4$
MAM &QM($ZSX"^/4!C[MSS9B-AJVX W#O P".C3T"+Z#J-\X#+; #.X ! J\#
M9F_V9##\/H ")L#VL[YY"KK1#OY_ :(W 'O8Z<7TO]3<ZRE@ 1Q0 2=@6']O
MX( O"ANR\E:K^(I/^- NVQT^\WA>[<$ *;J]J:S(!9E?X'YP_UL]]"&Y 3,@
M!!_@ @"AYQ"/'#C\+(&1004&%45R2,C@X8,$B PP>"@P8( !!1AP+%0!0T</
MDCQ:P&BAD$8/(F%ZD"%)4H>/%R,P7+@@0<$"#!@D7"C $4*$  (2%% P8<,,
M%19*I'AQHL0)!R=^X!!B1(D?*$V@A KU2>Q8LF/#AC5;5A@K66W=M@4E2U0M
M5G5E@<+;"=2F3:I =>KDR0\3*$^8-!$49XD<.$18E)B!X\*-1FU4Y,B1Y% 0
M'"TP9/[X<$$!! D?*%S(0"&'"@@&""P8T0+'B) T>) <T@.&B=0J=-Q^&<9E
MF"%$=*!X 0,'"PP0+IA0H8*"@ %!#0C 'B""A HK6)Q(48,%"PL.'G#X(41]
M$"A0M+A'"ZKL?/IJV]I]^[8NJ[C!]';R2R^_0FF""2>P0-"/.=! 8X?P2I!A
MA1GLX(,'Z!0J8H<DDF@B"1<H<LZ%#S+(0+8%%$ * QIH@$&%%FC8@8<ADC C
M"!I4H,T$D6#P820RR!BB.!U@>( "VAY[P0475,AH@  .@, H 0 HH $..)!0
MAN]>L$ #\VH0X@<ED$#"*_C$DJ\^-64A2Q:V\FM+E&#<JOX++U'P^JNO3?ZZ
M@@DL1,'B"".6B,.,(4RP0$L.-C"#DCM@^) !BR!J84,C<)( @Q94()&&%B"
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MC$](Y(+)A2P)-\J "5X5*PV0H =FP$T/=+ Y"*:*!R5@  %$]8$1C8 Y$F@
M!JY4,!%R1 8SJ,$+7M "$Y0 40MX@%72XP0DV. '3 #+#6EHM5K(YVN?T%H/
M\P.*8.!%%IUX!2A>L0DN>$(4@>A$+YH@)B$000@IV($%6/[ !C:TH0]]Z,%G
M$,:B_ 7!!3S(P#-7), @F+$-%LI 3RB /XW5: >\.J )2*"#(83A#&LXQ!#V
MV(,UR$&"0Z"!!0*Y@ IP2@,OV$!J*-  *W%@  *(@ ) $(,2;( %+_@.542E
M2>$U@2!(T$(H,"%1&T*-:CF\VM7B5 M5N@D_^_D$8$)ARU"\APE'4$(3X,D"
M(9Q@!VP0@AT0T0<R^( $FDH.#=;0 Q30  ,C&&#A-A2$(0R0!M#Q3#0%:+(@
M\" D86A#&$S@@S:<P:IK>$.0?I,&.:#!4#QX@<L40#\+/$ \IEN<1610   D
M904<V.8&IH(T#BR   Y@5B?34_X#IT4A$Z&X! U!@</YR <7> %7*MLR)^>!
MM"Z?J%,GBBB*3[BG%T\8% ]J((,::*B%A.!#(NK 4Q)!!P8[U9$&-& ;RP4U
MJ+&RP8A"(B,S)&$W/&A#&_1(AL^MP:HF4X,.:F"&-ZP!=#;RR0*4VSN$9O,"
M%"A="SQ G0MT8#08*(%3#+H! A"@ D@;PKUJ,,4G6.$*6N!$*6QXT8J297F'
M35,M>!@G6<Q)L1YM"V3U.PJ]A (+G=C$%;K0"R;\X(T_8\$,A' #8Y)!#6Z
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M%  :JQ "(!"30-"$4. "O#C'WDP%%@7.:",&;'A18L@&&NU14<V&;?#1KN1
M61@%81 %SD "XP"30^$!.T!2XI, *&V. WC&"<@^!X" [1L@*'65'IB58@T#
MWDH#.J@#.["#N1,#^^0#_513.(@[,R".()&T5#&#-L J.S@F,C"!!R !%7B
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MZ(:*/?X')NZ&)L[;;%!?NJ5B7V $LRS)''@K#% "-HBTIZVP#1@ #XC!V#&
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M L-X B@X!5H(Z5O@;,Z>A5N Y?Z )6F2)H9SB&)=[N69EFE>3FTFSH;RK5M
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M_*R#.J#6L>:,L/9'AP"!$,",@FB".(@#0 "$>AY=M1:#'C@!!=!5>J++"]"
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MB8],@BLSN.+8JZ^1U%HL(LF>U$<9P/;Q&Q^.2%MK:-5&   $&4P@ 0%6'E
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M0U[U*B-)RT@?>H0(YBFO>7S882-2V A"V.$,.R@  +"D@,B P /5L4 %!!"
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M<*.XQBW'<9/+'N9N(Q?.Y9,YTH$.<P!9+H6RTW7UE UAB,(7VCC%$;R(/B*
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MEK((NXYTPJ-8>]&+."A!YW$8P@\R/HA)Q($&&5  =3*  QQ@0 - )<K3#\"
M#.@@#[W[:+H/NPP]PV98:E##&QJQC-^-H0=$J$.^(V&'(1!!#'$/0[REMH<Z
MO$$-R^K#'EYJ=TD7HA!$-"*WGDYB"6R. !QH@7,@@/L.6H !%5A*"K  #LB
MY/W *9Q#'=D)R$F5&)E<KMU"-RB9_9P#!9H%!<(%7!3*-H05,@2"$V!!6OW
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M9=H.H5U$(BA"(42-T=1*U+P$"IJ!' #"C.#!:1H$0KP!&L" Z'0+N13 !F"
M VA !?Y$P/5D"0-,Y ,L0 .,@ DHU0G 80DP03($ Q? PCJ1PS:QHQ[*#9S
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M'22)(BA"9^0.U*+!C,"!:<[(0>C!0<B!&9P !I!9UV1)>%"E;<I  PS B6&
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M ,,MO,DUP\>IHBJ]Q/%U/;4WVR@W?\,Y!X,H!)"M^L(>4TPR% (;[$ 0C$
M7  2N, "=([E;.ZWK#4 ', (?/Z'#X0!:YAN[ZQ;0B^('<B! [5 $HS",M2N
M-,AN8/.#.UC#[+)#[!+6,40#,HQ"$=!T!BP!&Z !2:2I'JQRB>@!&A#!$H@
M,PU ZQF !< @?;TGN&B  _P$ 81)(ZG-":P 7Y0 $F#!*@R#+;0'?% %G%2%
MYND".9,S-]PA5'=S.9!S &4#-KR"*PR#+_P#(T3,#YR +UB#' P!7[( !K!
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M)4 "$2C]9CR#/RQ#GD]])E_](EAT\8_")F]R@<(P#%=M'-!(21-$+<O!$G2
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MPQ_M4(< !G 0A'!$(00G.$,L\CV D$,<S/"Y%42@4(0RE($* ((*." %&\"
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M"[C@$C9!$ZX/[=0NMFJK^U*LQ("P%&)'$_ZAX%[L"8C+F60@!99 \-# #&
M23(  E: !H9 !TA@:EA !6@  R#  R+@]AA'!$3@#!& #?  #ZS"D>3@$9I!
M&I[A&=#&??2I ?? #MZ KP:0 -_P#?% VGY@!WK@ G_.#(!."'2@; 3LL3AB
M A @ !C@ :ZN E))E!; LU3*V_I, K3N=' D!\9O"RX!$T)!I_@MMA[-MF#1
MMDA!%7"&"%O,"98@N)P ")Y "&2 ")1 I8C@#(+Q!BY@<FY \5! XVB@!4:
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M40=>@% 0( WG-6OOHP!:(!/SU0=T ,.(0*6$P)5^  1<D -0*[7J\@>>8 M
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M91%@ CP "$+@ULR *QI!G\)Y8,@Y=/?IG]YT0N'T#-0 #@:Y=?MTD.MT#=8
M#>  #<Y@"8( *W5 !1RK ]*S_"2HDF/6 FH W5"(;&G@ 4!1!M!* OQN!H
M!Q*S"[1@"\H.WQ2M4SFAAWZ'F%!UJ/Z!%/Y@4[O@"HS ;<,O=8:9$0"A#9+@
MF+GI!5CH!EX@!HP "61 4CX@ _X*  *.+ =P0 9RP ;ZUP@FP  V  T*R)U$
MUSP*89P;\ 'Y:D+C- W4>9#KN757EX\11T[18*MI#PLIBP4D0-9"@!%\X1_
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M"-8O#II N<S<!H!@!G@ #79@93X  \R5!;(9!&8 "D2!"6S6 /0#"YB@")@
M[T(@ ##@!6 @MFN[$1XA$AX=MT-WC_[)#=; #=Z #NA X%MW:+DU3K^ZTQ-9
M: T74@&#PA0@ #C %W@<&53=%XS@,Q$ ! 2V>(M\LS:@4A(  7J]-D3%FDU'
MRI_ "X(A/$NL%5K!%4IL&'P*B/Z$"NY:# NXH N:Z@A^8 B<( [B8 E060AP
MX%?1@ ?*R 9NP =2( 3BX@)B@ EL( &B&P%X& F@P M^ 1B @0GP6@6"40D&
M0;<CP3Q*G!#">?0480_Z * "R> %WJH7'JL;F$)_^Y[A%*)H8,(@=03P=0!
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M@0Y)L&%((Y-6&DDCA402B5V%\,''7FJ4,8;*:ZQ!AUYON(%JS!Z&84880^C
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M 0^G+I.9_5A'.]0!#FI\PQK)H*(U_S '2(R!"(SP!1/ 8)H$&*  6TN!9&<
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MH 0V_ (8HC""$?[ AB0,H0F"Z(5E/0 "#Q2A%]^(!S\>C^E\8!K3]H#"  @
MR1.DX 5!$$K(0Y[*5.9!,6^@PQA*G_([T-H0+,^#'0Y#W.GQ6O;)?4 #5K0/
M)-_CY_XA1G:2F0KE%JTC1M: !!$@@?2BQ0AIS(?>:&J6I!K40 F,Z((1OB *
M+7A%KFE_MUWO>]]Z(FT8OHC#$L+;A'H)P0)&*4(1UG,$)*PI#.CD2@Y P+ N
MJ$-H]MB'_X?M?Q*W#\@P 9A7 QM0 O\A!X/ @"&7*:G$!W8@!BJC,@YB!W>
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M@ *_\(W]$ _]YX+YH&D]5VQ)QOY,S31\R4 -5N=TH0$,,7*#1\>#,L((-D
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MU-8%?R *4 !V8. +\$H/<1BP:;L/]Q!=]E!\V.0W<J '&J@7LF13$2L&;["
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M#-G@I]H J(IJBI!@!(%P#.XP-#);M9K[NJ/@!Z+@"'/@"\"@#5\0 N;&(NS
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0ZC<-W_%J++&B,BZ>@   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>66
<FILENAME>cogo_0047.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0047.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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MDW+LZBX0R,0/#S^DC/! ZT46XBY*V?IEO#B, #IFKDV6D@#<(" "%CCTH;=
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M5C,45@?*'=B0['4W<(Y \).'$#@.(],=L5S98G%G7CJDU:8_:7N GM[T $
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M=;24 A.4A7(R.OO3HY+Z,.3$[Y C<=QE[<3@#U& 31;F+V#/8I+SY2G8"%<
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@3[4F<K&1X)7FBH[=J@![4,71;C;LY^2__?XJ]Q5'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>67
<FILENAME>cogo_0065.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0065.gif
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M$&X(1-M)XV?L>-L&&X2WX.C&6&4(R!O>4&JE6VLSL[&-5G3X=<OUH>M&88C
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M?FMU,8SG?MOF43=G>6MP4^IT"8IU AH ;T+@=%% !;Y0G<) #,10#,10E\?
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M/ ;YHXG+!.NKM.VKM+%8#?'KJ)5+O_9[O_F+#)X;KS5:HZ^8"[YP"TNP RO
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M %S@YI8-37DQ/K^Q,5?  KD?H^XHG;,'0#SWN7%;*ZKPT%!2_((:T-!%$(
M!$K,#*/0G"DP<($+\D*!O$QH@A": (4=X,#**<B "C*0@ASX@ FYL-#-,!.[
M7N1"7KL8 A%TP (-6, "%]  "^#<@QY\XA?>JK."&XP*=/Y8(@9>* H@RMG0
M(<F!T(2^ R%HVX<4T@%Z&H[#4RE&SS"(,[>6?B>F6]P4Z715%GH;UOB(TK:
M5[RLT76NV0 !!U0L@TW ( +E.C%RO01CIC2%YF"EW 26 YOE.TAS!MB, Q\,
MP0E/\')DDP&:79_<"$3@00JZ[>T+N'D%Y/X!7NX(#=)<4Q\\;4<MQ/"%,*RA
M>A ;RFL'7>A].T\WC- P\^2 %-Y2V@MO6$.E]9 'IKPXTTQITL:>U(J(!XXH
M\3;;'N2P]WBO]0ZM@D,GE& $95##$ZFHQ<C[\XM<R'2F")F(E)W0>)K^!PHL
M_P&6<9 #'?! "#9_0A1P,0Q<[/X"%T]P@A.R;6QP%_W*/O"!$(A A$]\@NE,
M9YJWH/$/?^A"#&*P!7.=\V>SO38X=Y@#'0[]VCG0Z-] D0,(TVYV2/>VQ'KX
M1J;??B3I;*,5K8@2+%2ALD!<G=3G%S$9 BUBY?"]%)\H A)XT M=C(EJG="%
MR4\N4_1>/MA-N*LO@Q< D0@H4 (>*#8<P '/,P(G&+THB((GF((A&((BP($+
MN ":$[;*\H0IH*Q;T(5/J(7<X:,ZPP;6T =.$ ,]"I@7@ICD" [A,+0Y^(,^
M."KH ;L0B[Y) ZXM,+O<NBT]<+LAW(9,VACMH#OV6!P@@AOE,"T+.ZV(T;CF
M"(1/&/X"), !(:B_9[&%_M _7PB&6Q -T[@\)0BL8' (:?@6Q6@&*8B"*> !
M"UQ 'K"YGD.](> !',@ ;\N!!AR&P$@&7]B%7;B%7= %GLJ=.ZJS9X@4?>A"
MTEB#$%H#< ($/U@G.U"^.2B^# ,[UMH[<>I!+]B"J9J^-M"#/\B^=0B'[;.*
MZ "_7FF%56@<)I2W@(/"3<F#E>@#/Q@$Z?&#,,"$3SB"GRN"'[ %RCG&S$D(
M7XB"7\HB8%."*?@<9_"EB1BV*9@"(\##/,2!'1B")Z""G<,%*!@"/?PV',!&
M)8""*+B%6X""7(# 7-BCW:-':C@P1'RZ71B#70B#JGN#-O[( SG@Q1C<D5%Y
MK=>"K9PX%;-YITG;@H=\#1\$KD,( ^S[!A<3A^VKBKF+A214!8<JOXH#A*&B
M&#9@#DN4GEW4 U*PA2-X@B,8 B'@CR1(1HA@,C","(00K"GPI290 O8"L/52
M0/GC@3S,@!U0 BKPHFDX!EYP A;   O(0F[D/!\(2L\;@J7CJ5?#O6=@C7[0
M!2/X/4BCIS?X SGH@T$0!)=8*DVDL-=R"9B@"=HR"G%2@RZ 2"V0R# P12%<
MQ>QC"DR*#BCA)+J;12FT11!Z$1@Y25_D R]HM2,8Q%[8A2X,$;PP.0@$0V>0
MB%]Z0YA+@2K3  S   V8  O(@/X5T,,,,#8<Z#PID(;(:! GL  ,R$!D6[8,
M0 $+H("H1(%FZP%/R".FN\>E6S B0 (Q^(0O *XP."11H9'@6$M!>$L>X8U3
M>22!JPV(]$&)I*=3? JH^,MO. >K>))>B0572,(DRCC3NC"3W -+E,_') 5H
MZ(4G$ AI"(8F(!,U$:R)\*4H "9G0*\=D+D]U  4H( )T(  "(!E&THL[,:D
ME ;)6"#:E$K<3($5P( )H  'M0 52 $B^($5^(1G@)I_.+ #8PUH0(+D_ 2)
M] +U2PYV.A5!<"WIF1&F0B>V<2&[Q,LN$$49U8-31(>+5$5S8(JY@85.BX6]
M88]64OZH'#DMX[DZ/_"#/?B#YG"#6NB%(^@%9F@C(D R3P@L",PBA/ E:OS)
M8LN "R""3@"!#UW03R""#$""#.0!U3,"7#B&9+(,*-  '&""(KB #!""7U !
M!PT "A"#?Z"!"U@!%O !7=@% ,$CTJ@%;/B%#"@",0@#&S #D" U7K0)MB2$
M7GPD0B"$0E!(=;H[J]K.[F3.J3J$/_!+<CC23#L2K(B26/"DKQJ_5P*$FWB8
M$*H-W8+/+.4#/7"#0W@#+P5399@,8-"!'U@"RF*"*8"" ?U#7\+&*5 ")2 "
M,="%'J@ "]" %M %7> !UMQ37J."7BB&9&J07%! )U""SOZ#@F<0@]W$ !SX
MO1ZPRA3H@2$P+/JB!FSX!VA( D\=@S#0FJ%B"9N B1Y5%59U5::Z"4B2)WI*
M"34815%4NS 8A!9#AXP,!W! DED(CU>(A>-2PO(I!$"X ULDI.%I@ZMC#CW@
M@S> @S:H!<CJA=A)AG($L,N: B=H1F)P6FJDQEY2@B;8!4_8A4^(%I;C4R%P
M2= PAJ\]AMALD&$0@K+]1FR\A7T4 Q\0 R+P 2( P4\H6R?@D$R%!GWXAQVX
M@"/HA#(0)#?H SRP6!HI!$%X).6PB4*XSNS<@X^551Y\2+73@S! !W)8Q7!8
MBG,HSUX-#UGX*E:(CT(XI50QK?Z@:H-)=(,\B"$7XH,UL 7(4H9B>$DY7 &?
MC$8H((RG%8Q>@H)L) (G,$1=,$!M'((I> )>6*"O15YFD(9F8* FH, AT$;9
M(X(Q&(,XS $>**QVK*QN58P#PX9]>(8@8 $C^ 0S$-5,T9%": 2F$H3"7=6E
MLHD[N EY<X[3=8.I2E842[LVJ$@]&(1P( >5S<BFX+XIX9NR@(3X2(2:=2YD
M-0.I,D53K*2CR%].@-W[-((B, (>$# B&-=N)0;$, S!H +R<@(C6,?42[TG
MD, GR(5C2%YCZ 5CL(S+&(9PQ48CX.%LG$#/$P(SK*PSS85E6%$]^@4Q*-_?
MZ\<R4/X#Y*F)1;@)00"$/@@.YTL$^JU9HE"#J:*JTQ7%J8*T,#B$,M;5RCW2
M(]U<[]D83^L5DD&E("F$@ LA,SA=/7B#0W 5W'(.2W@&-CJ&EW1)(_"!'Q@"
M)E ")Y "82"&P]A=+9*"QI,ITRL]G#M>"/G:3*;6U^G=FP.-"+PY%W8";'2"
M=[R%QRMBU*&&3V@V'F"!,0#5R&T#.<#10;"1*=;1I;J#]K4)>:O+T_U'4DP[
M,39%B@P#<;#<59P5<6#9(X&%CH&%] 3=!1:B8OV[YI!$JG*#VY+5@;($5VN0
M^^P%RF0"$!Y7;EWD$48,P2 &7\"%0LD%7*"008PC,96&S?Y0!DUFAM>1@M23
M9]#@!=331AXV@J4U+-,01&! -S&X "0 ,+'<H#"F,$*0XNF<Z%:U@T98A"Q&
ME>9 "13[Q]Q*.X'JQULUV4,(!Q=;Q2/]AF:FA2?MIU5P!5: #X-2A" )N+&S
M8]_RK:JJC8&J!%OX!\H8YWQ.!ET -D161U\3!BHP#/]Y:M@YAF)(!M@IVC62
M#&F0X06J86.8#,THAB@ WF&PX:FF$!?>A5X0/818AOSYCV<0W_AC3=H3 RZ@
MM%/L T$8A%,]2%:MB9JHV3JX.ZDB;%*L/KXT9HK4@P$6!W1PL8O<7*L0CYB%
M!6J.8U6) SEX)ZIRULWNXBYV _XQJ$\V&N?*0(9?&(/*.N=F_,.GIA.@B8QJ
M6!T^D09FV&I-G@S+8""9&@9F<-YFV&<;5@9Z-89BR PQM<=]@ 86P,!/'8,M
MP((N/HJ!Q%&+MN(=E6(';@X6*0,?).RS>P.3)84P^(-!Z$<]<&S+Q0ZGH(5F
M3@_Q*!9$@(1$N&GA())<_,XO[F*I$JA1$ -7&VZ7&F=@$ /*\DEN]07">&K#
M^)\\T9/)D P^,8QC( 9]SNU]3H;&*X8%<MX%8H9]7J!\%HBAL4=J^(=>R%,D
M*()/Z(2'7,P\X,7WG6)-O&Z.)9L<<0ZI*H,UX"W>ZL<?_W'S'H1#4-F4QMQO
MF!LKB?[F^)[O!NZ-*AXQGI8G-<BM45R#?B0%7;#'HNZ%_[@%S$+D4EYD$B8=
M!9'-R> 6PS"&"N<%&TXC9=!J>(R"9/CP&Q;3$/_:81@:RD@P%67NY-0%2^""
M+A@M.2CO0; #PW5+C8O+7HZ#HR")[GX#B2SC,!CO1@CR?KS<62'/EF[9\/@J
M5V!@^C8.YKEO-BA2WT*)Z3N#-R"%2@@#6W"I *>&7K@%3UC'RUM'7&AJIR8=
M!X>,")^,YFT&X2YN7JCA--(,9. %L>8%Y_WP.A<:L*56/K\&%4WQ(_B%-["!
M-1">&C1<V0J.@%.J.LANX @X-]CO[EX#YJ0TD_WQ1L#T0_Y8[,M5TL!$\NY8
MA?3LE?A88%12CCL M%Q,=74G[#)H]8#B!%U(!LH8;F3X\D*$@M1K1EQ89]+Y
MG\> [>#.9&,H=BI WF;X:LV(!F0H/3_U<#4REWQ&!FE(L&K:!V!(@0P< VCP
M KN&-%H6!$P,#H1\K9U77.PL$L+>@B](.^G.@WX<A$'X@_+^@S#(@Y2]R'O/
MJB-Y4O5XXU$O)><R="T]16YF=?Y& SC@A%](AFJGAD&\=9GJ75_#!2J@ H]G
M\#Q9, -*(.4MAHXWAKCWZ@9A7M@Q^5U#7CO/C'RVX36Z$VPRO$,M F"H!2$M
ML3BH;D*@ [+91$$X-)CHY>8X>/X?/ ,G3@G; N"E-^\_R$5EWM7RS/>7!@]^
M%W6M+S4*T](M;=9*4H/NWH)6!]HWX 1;> 8V(>WMO:M;$/,M(F'%:' \<1WE
MU?NO!?EJ9QT:S@Q?N(5>"/$/][@(J>%EH@8&NX9;^%1=^ =1Z )Y&ICW;;Y"
M&(3F04M" 'H;$80L]2VI4H,S^'PO. D8&7W2-V^H5VG,!8ASW\Z=FT6+%BQ7
M"A6^>H4(4:)$@/8 DB.GSQX_&O7D:;/F8YDW9^"0M,3I%[5GR*@AN\7DUJY<
M4*!$B2*%2C-GS79*ZSFMVK1IO7A)X<7+F+&C1XT]><*K65!FQGHEHT;-&C(G
MN(P=4_ZF#-DQ8D.GKMRW#]LS:[J(]+KV[TT7/6SDT!%$AY @.X(  8H#B!"A
M0H,6%2I$R,\>-Q[7E%FSY>,:-F[^^!ED2/"@S'G^D$,7SIRY;Z+!':35$%9"
MAA 1&>*[QV*</G\&_=$CU_'C,V_>D(2CR9;5:,N2W8)R*]@M)S1KXA)&C-C.
MG<RF2Z72-,JP8\.H&%7&Z\B0)U2/';.>ZYDT:LF&.!'&:[NSY\.,\CH6S>P^
MJ\#&0/M7:\MF><0Q!V!VX#6('W$H&%@ABQ!F&&**>:3&%F688<8:;F0$B"&-
M7):9(!R%0PYHYA!$4&FSO#++0HA \A!??>U!QAY[_-&'1OZ)+59&&;KQ%@J0
MG$!SC375$'?++;D4%P443T317#'$Z&1,,\PXLTPQO%@WA13%'..+$5(\0<41
M110Q!)I&J&F$)T2\Q$0.0CAY$Q54N(<+%;@,$Y19T#Q#S2?]D;*%''GD,8<@
MC.0E""$X^A4'@X7<T4@A@NS!AV(@G<%C8QH",DAA@@GFAQY\D/.9: .E2,LL
M+++(#3>NP.B:'#4"TH<@"-;FD1D\NN$&)KYA$HHHP%D333*ZO(3D3#45I:4P
MQ3ACC#+%)%/G$T<8\80QS#1#A9DX(('$!1?@4(0...C PQ ^H)!!!N06,06]
M7$HAIG6[ &/56<_\<XTNO?PS2/X7>?31QQQS5*J7('X 4D<<==QQAX.% <('
MIK\N=L8:F_X*2&&)3 JA'WP<8LYG)]*"8JNONA*K-B^R-E&->\21$8Y]\'&;
M&CSNADD@FH02""FV0,,2,KZX5-Q,N>3RI!2^W!1M,<((PQ2:3BP3E'='D(L!
M!A984"X.9>/@ PL7A WO#O0.H802]C:URR[(7',W-M3\<_3 ;&PFB"!U,%(I
MX(T2(O$=CE#L2"%\\:$C9#Q^Y 8?'!9&*<D[MP/..9RC6!I"L,P"JRN0.#1S
MC7G4?/ @.O_:,V-KD 3DT*F(H@M+U.SBB2?,UF03+K@XZPOQOA0CQ1 \*)$,
M4-(L8_X,N!<@478&Y:* 0PXXK,!"]1=<+T3<<"O!PQ1/3.&$$[H \\S=U%RS
M#S3QA\'&'S8'KF@==?3%5QQW*.*((Q)AL8MI+'*,^=4A0%:(1&#.$!K1"#@B
M>*):G&-EK&H5K%KV(HG0K%9^8!T@2H8ID*QA-W  6B!"<0I-?,(6O^C%)\:
M).7<X@F[L(D4HO $*-P+"K[ Q138XPN@,*,GQV"*MH*8O!24JP(78 $+4,""
M%*A+"4V8 A3$%[?S.>$6ZZ,&6LSRCS'.CP^XJH.! J>_-2K"?P!4A"(:5[,]
ML*$-'FE,AB@7LD8P\$,E\P,[(L@Y"Q($%:SBQNA*%ZM9^?ZA4#421!\0I+/$
MQ*Z$O(%#*4J1PJ)Q0@QB,,(GED63I^'B7K^+FA1PX03V]((9TT &,J8AC604
M8RJ]V 5,F""$%&C  B! 00I2D ,?$&$(3#AF$Y0@!.6]30E=! 8P?C$D_/QC
M'6%0':X(,1A&0"Q&</R?(_YWA\9-1$-U](@;)N<&OERN$)C[U"$.L;D35;""
MI1$=+&#%C6[(S#5NH-^-(CF(BXT0,I<,!"9-$0I2V,Z38AB#)Z"@G*<Q)X<V
MD9HP5FD$7"0#ELJ8CDJ0 4VZ[0(Y2_B!#K*W@ASH@)A+."8RE:F$'303"L'X
M!4Z?819]Z.,;I+CF'Q)&AT4, OXPA^/+Q.#X1@'23$._^E4>*?<I=_*Q, /U
MPR'\($C/'80T+1N=/K7AD-8\3D,U.AB.".H&-1CT$+XI!2A*00JYGB(5J3#%
M)V9BG%LX*WCWDAH5I& $)3PI%[X8!BR3L3YH[@L8N]!%FX@@V1\(00A-<!,3
M/,&$ERXAF7 C'[V"(=II[D,?M2!%%\)0OP'=91%U $P?"!&';X83CI)R#1OV
M8!N-_>IQ4UV@5:^JD7G2LW.S (<WO,$-Y<+*= \)Q$0>A[/8XB@QZ<R0'4D2
M-%"  DB!4,4H0@&*4/:N6;EHSC"DYHNK4:%\OM@K%$@*36K,E[ZX),(MLC:$
MEV:V=_Z:W>P.M$@O* !#%[?XQ?OV@0XQ7#,,KPDJ(>PP"$C.H0_Y^R:&8V16
MRFFL#;_*"&!"954':D2>Q>T<:;R!7'UV@QO.+40@:N3;/MR*QC7ZYT?L>$GQ
M@D(4HE"%*@Q!._*^I*_"& 8NB&<U*3C!:;I,IB?HQEBKQ!(9BMT%^FYX/B9
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M961=[_Z=0Z.I6(M!6HOUT\7$2(R4G1N8@?,=G"8@7"FH0BD\' Y>'Q$TP1+
M#9?]E3-(S;T0PS(XP\U)035 @;'E0!(D 1,0 3"@Q2\,X!(L@6;]0 Z@ +)A
M@+D,P2[L$ ]1P1!* 3!$80'N@RV4 5LQH(4)':-X4R($$+@I@E^L4X?9QAN$
M@0;J00=F1AC@R ,5FB$8PN8($HHA5W*YPO"IX$-PD,W0F(UE3*9T3-KU!L.E
MT VJPBJH B)P0A)T%O@P@1/8!!FNEQ0$ Q(FH?]IG/C@EP^( 4Z55BW4PC-
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M.!-R("DEK"#".0<9.OJ!IUY3'G2!%QCF%IC!%FB!&<@VAL !;V@"T,3F&[B
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MKVO:;F!IL O2R9]\(/DJ"ILY(JQPH<F&'*SYQ,,YG)<!%\1VA>A&A,)"&8P
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M20\\XG$>^)B'*$R   I4H (@*,$):&8SF^4*5RQ C3M+> (0Z'.2%#@ "+*
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MON%XV\-?T8J\K*,5A\"""W!=&0@X8,#/E#"9?ZHQ,KNYS#XU^6@3QSAE)V
M6)#V/31\YWO(?!Y\+H=:QSD:I;KC'N)8DM!!< %)$C<"8@C>()CN[DA;X1&1
M( $ #'"9B&FJ0YJ!YG>I?N\A#UF\8-\K84%:WO;&\AS?V,8W:/&-;YQ#'+%P
M?BMD$8I1V"406NBVQCF@4,PHVZ=D#GFHYFB0;(Y_S3^E&/_0GVP">, 0]%#W
M:)X*^?[*SX,>]8#$%<  B:,IM1SI(,?F4\$$$$WT2D#TBFX"9J =^&$;-L#=
M%*#IGFX<I&X '$"N%HKO#.?\THAPYFJ&=F\$0B $Q$[47L#L7L"4GB?Y5) 6
MMH$6X"869"$O5B'ZEJD#/, #*N.F$F!Q2@Y4 @   N# "@#\_H?\$J#\TB\)
M#: !!  &QDF/P(F<ZF$>[.\*\ \2(F&@TB$=(F$+MY =ML"=Q(KHB@X$MH$?
MU@$&%$#UUM"Z'J$</ !$$B !%BH!!HSV&,"H-E S[DWW=J]IQNL$-JH$94"C
M3C &:"$181#Y8F$6G&\5I"_Z&F;(/.!"+N, $J#-ALT'/_X$"(.P( 8HFS;&
M  BH8D!%"97- 0;  ];!'N"!'BYL\G(KS^XA"TC "O(O'7Q''2*A%\>A%]TA
M&VP'!<9PJR1 != !'M2P 1UP ZRK$1K! 0! #ADJ C!P?\S/ /+PN]*(ZS"%
M]T"0HDKPE%")$!%1%F!0%M#1&])1'4EAF2Z$ R[$ZAQ@!RGFV PBV.:H$X-0
MJ,9/ 1PG$RLF_08R_1@/!NZ!'BQLW? ,S^P!$FSL"@X*$MK!'Z1+'<;!"S7I
M!F*&!23IA$! #.Q!'4B &=VM >$-&GEM8^C0&C'PNTB1@!X' ;XK?VXJ8O J
MO/3JR&1@!@I1B=0Q*-U1%F@!%OY*80OP3N.&S!H;0-FHB6,"SS/FR-<Z$0BG
M<6.*RG$T!MF4$!7GL/TVK!VFK1[@P18E\KH:X1[T01_\01W2(2/?4ATLX71N
MA1BU"@70P1[*H0H^0/7>K2^MH!$,H0%^4  NA>^NL:$*:&.$C28W95/2R ]U
M\O?,[GE.4"AG4!UC 18JI ,X(.\L S,.8&**T( V1L*$S>2\[P>G,9N6;28+
MLBOGL $(0 3(80KG 8:")QX2H;HD#;O(82WU01WT3Y,4J!9NX)!HQ(0NX O\
MP1ZR@2__TNDVX J@<00 0&/L$%.N\;O^YW\"0"O+C"8=\S']L,C("P8.\7G4
M\11*(?X59.$;9.$,3H#WADS[1K-_&L> 1'$?YXC,#&R.IO$J"4#9^D<)!\ @
M^6<.!0 +<A.&'K0L(PW'KNL1&@$=VH&3&B$2QJ$<C@8Y<2"$9L:=6( 4<FL=
M)/(OJ^L*2. #&*'&0"1R+D7 1+.ABI#,@.QBRG,@.V33=J\#.HV\3O &9* 4
M4"$HMP$37B $/A,T[VT!>/#8R&]C"(*:2JYC]G% 7=-B"B@FD]! #T !$D
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M*XGH@ <1/*226RX)9A==#0QVV/Y!X[W%(WP<21:D1^ZEQ)F1.EI7D&CWB96
M "[,T\\\1'&(CY;WS,/4ETO)PTX\D( 1B3Q;[J95E:P%Y\X\^*3FE0"2&>#
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+)N!F-WL)@H   #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>68
<FILENAME>cogo_0045.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0045.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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MC =2Z]UAJ^47=5ZPN%W>=7N![]1:^02,)3Y<"L[FV:UB2*MJ"AIOO>_3W/\
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M"O RS:[,UP(J9,7>I"U*0GW?3I_C2_607II/H;M]LGQ(Q;DQ1O9;6.4GWLC
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M7:T\:C9YG62N1+TC;&;39FV6B<N+4X?Q-;8.D<?-RPH;.4"K4S)+@;>)XK1
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MWHY&HGC<^&#L^SM7%]UM37Z8K6'ACHD'BNSIXIX^#S>LDEEKT#9B-QEJCMG
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MD1P.JV+2E(]X8_,8I)XXY<;A+V6:?4Y-/GCEQKIH&)VEC<;:K/>-!#ZN]+6
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MD.%2RKUJ-$&.]/K^="@\ !@5N.3V-*."1CK08T3K:\>[@8H#59)3THH"(TA
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MJ+'=0-QL\_)/C%<_RU+1!+MFNJEA!M$_&=Q_HKG/E]FC:)3$_5EW_P!BSO\
)X[O^6A:)3/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>69
<FILENAME>cogo_0071.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0071.gif
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MAR6=E3?HF"A8=;O"2!E2P%[&2RY8GY*+G3M232.A%GLFF:-HO526HZFEY@V
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MX8<][.$-6D5""#9^ Q)D  ,4L  &1'"!OI<\ QG@  ELD(,E<&$+4.B!#G2
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M =<W C8P A>0 1^@;#I0!#K0 S*'7#U@?C70 SV !$WP>#SP?D^P54NP SS
M"6<A'V=G%>9"2$2G79%V=.M 8]?%'S$$/XD%/ZNC:0F8@.G%)>_B'+.')OL2
M$8@C-1,A1@=W<#T11?SE,X7!+UWA@;HP#<N@#,I @L;@!W[P!42  [55 AO
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MXHKZ]#!-B4+(A(8AQI2AK!HT%2KH36J4H<899YY1\!A"O,6S#SWU(!="+*I
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MQ48G;8X'U]855FS,I7^$J36C9PF:3@(392'%\UP5#&/TU)'B/&<=X,"]\:G
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M9Y"&82 #+IJJ3VB$1N@"69V!JE(WT9L&0JO2XB*$/\DW(ZC)6OV'?P""(-"
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M:F"Q%E,NNXV&8GAM?>8 (LB"/G &XCHB TD0%NLY.*"NW2NJ#<"Y "" M@:
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MI ,D?.$)5*M9!_G@'>U8B73$H($%.#"M+B06>.JJH<QUEX$<6F#;[K' $,3
M!2Z(86TW2 $3]1H]"G![ %WY@+K3L 8^,[TC@CY!U 7-]#6XA;8@QMO63>QU
M>X>]J<+=-SK-/@I<T-C3.-;$)B;6B+F_034ODJY&W" %*8A!#FJ0@S&$<:LM
M@ $,4L"!#B0HA3?4[..*)\0@CG&,<<GD&5#@0!7<VPA/? (9CN@"%,A0#]#
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MY4T-,?@!';R*%20!FK&4"<"4!V2@(7K 5*9 'GC@5=ZC"H0 ;J[!GH!@&O0
M^5BB6>Z')N+-+1RD*K E+;B"*Z0"=*:"*J "*UBG_4PDCAF<P56&5TU"'*P!
M=5G.%;Q!:?S1&LA!') D'IR/'<0!&%"A%.3 !]C 8WV!UNS!'\#D'_C!,8@A
M-!Q%,3SC-#H"E6"#(#A"@B*;&*C<LY09Z:EF&\R!&#P!$;!4ZH6 "%R .P;
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MF*07X!P>@$$/-&*[ZS0%7$ )W(#M#($.% $6V,S\SF^G0^L?&(]XY6_^*OD
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M[O-!M)AQ$0P!#:C99GT !SBQP:=2VT/1PU,1 G % L1[3Q]J;\JC5=SNU&*
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M:* 1Z#!%*:S[ QV<X A2R(,7E+#=)[CQ2RD(052LQM=<HV#7>BTY>]P[B&.
M0A?#'K:QB9T)OOPE7X=0Q&6=O?[?(?(2S8E"1("CF!!L4^$)?4N!3LHC@@V>
M:%1VQD %&AD$DOFY1TRHPA?<0(>L(WH.E9'#2(!K;T=#>M\YN,$[4P#P&Z3@
M!FUW>]LWL@,.--SA$<?I$CCE!>Y>0;!44;(*4*!D6U\!UU=XPI/7<W+V#*QW
M7'MYEXVMB4PPF_)&9/8B%.%+9Q_"EX98A(#\BPA&]"OH"9D"%?H&O-8DUP,B
MF,%L3I.!BED !#OX 1 L8 $=V*@*8&@#'>:P]7BO9)SFM&.*)6TKL^_T[6TG
MP@V&0",BE"!P1R@!)]!Q#EYPPKI.Z-L1D' %*7R)[TJ(PJQ)$-91OF$*3^9[
M&MPDKO[UI.5X':TA)S 1<YACGO+]7[:SF\V7$$$O&($1'.0'YN:S.J'TI.#P
M<$#)H ('1*#!1D 'D(0#*J;<BHG')  !=N\)1B(,XBWKYL .[. .Z""*BL_X
M#@)$(JU&/L*=VDX'/@(CAL (GH\(H !AL$_[3*'[O \)_$8*D.!+V"@)'E (
M)DK7W$ LJ& J\L"\Y"0MS (/T,(-/LF5VL(2\B_R)J__+B_SQ)#9  2SGNT1
M&&%NZ(9N(,03W% ,SD!2&O (%,P&*&UH/F &BD#V9,^H:H#'>JP +*!&HJ#W
MV@ .YF .AD\8[( .V"PAFHI#S@D*EH!&*BTCG _Z9"0V9OXD^J! "IB $\Y!
M^U[A![N 1)J *J3@"5- ")Y R?YJR;ZDE=A L)Y@_DXH+/S@#JS0:N(CV#!A
M$HI-\L P#/N/$<C0,!2A$KJ@"P*&#=)@#>+@#CQA&81A 2WD7^ ,>&P@J);N
MJO@0PV2@$4JA%$SA!R;  HH@@*( #,(@$?D@$8'/!(>/Q,:I@!PMTJ)O'W.
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M#HQA&92A&8S!& 8B&KGH(*# ((Z$BCQH!GB@$4R!%\Z!'NCA'49A![I !HI
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M'R&G#4$\-;H+G"HD!T$9H$&Q\+@'G(!DEKF0$9 3Y$$>L#JKZV&PZ<$4@B
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MT@^'[=!$8 ^F.:?";B:@ /,++ #O?&>WH+8#+*"S20P.N.555_3U*7>"64'
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MQL>.>5S5^(74O/?(9\?.\0]'B$&USZ!&,LJ=,OF>.G3/B(8S1%U:TF C&M'
M!FI5^^[7@A%_(8T,+W8"!$Z4P_XQ)^F4MRMLSW.,0DV]?BM;U58^.6?7NPT@
MXGL:0%%_/4]N 9H;5CXN1;H46K 1 $*/R6O55X^0I/;P!ZT-[B%P_Z(1CD M
MRU*VLB1#XT4OJDBGBW%(:40#&JJME3.(KF!]^(.>([1'/SAQ'O0HP >2F(68
M#>[M%#(&'"]0#UP=+F);RMEZ#UB!^>#ZVSQ=O(G>TQ/'FRVW((K<N,RMBP(>
M8(H%-[WEC,X'/[:M#W/(@ZL7H@<^NOH/=+C1YM4@X#5R?G0.QI2#'"S(DQ%9
M$5K1BM/)^,<<%TR_^/4C%DH!@.E-'X$@,&(7^,2G"=_1#A^XYZVN%#$0USIG
M"*@Y/?X-V.A[.@Z7C>^IXW _&X$05'<&". %]= QHLD+^OCQHQ^D8,3%3 4,
M=!C^\!TS1Q?$ *QJW/S(]C8UY<]?$79BWOP<O#F/6&UM+_.X'Z=0BEE/CYX)
M  $=)*EPA5,(! )0>P^G4&V575J!-LWC)D347 DP=G)E8W*'4=&V40UX<6K6
M (CP=SS&#_(76_S #I P 0HP"X>W',G$&*;P"55 #)4E?H^W<^>W7Q3!0:0Q
M$$]E6D)W#;[B>:]V;8S&#S^ ?Z<7=>GA HCP"N]P$KG3#BET"*)$>V]E2L]#
M/F]%;&V"?Z;T6[_%%EVH+S# %C[@ S+@ S @AC[0A3!@AGLO4(9JJ(8PY /G
M,'W#LAGPTTC[4 _E\ ,P8" _\#?;MS\?\@_;\ G(8 W9H W98 V?DSF-B#-'
M!HF1> WBISG6@#FL=H>;H8G\L Y ( %!L"!W(8H 8B ^T CG0 \%]UCU\ HR
9X(9NZ(5F& .RJ(9M*(:-@HLP](9J&!  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>70
<FILENAME>cogo_0044.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0044.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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M@+4JUA%JF[T5K8X''NWB!.\&E!N6XA&:4,$FQX0GII&A7',"C;%R?!)R4\@
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MC.8?)4A3BDN7.]]8P>3JEA S-U.;F5+45+&8Z"\(?>QD6W7+$@D^MX7@6<F
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M%?$Y"?M";6I;<L6@VIMLJ)0DH&B2!8'O:_6"4RQ6FP.HCNM:7@MY+0;82D
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,_P"#<_3"X^XL'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>71
<FILENAME>cogo_0049.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0049.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" "P +$# 1$  A$! Q$!_\0
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MK.#&JYYYE922KUB"W3-6<2:K4+8(K+33KBKJ48FHIWG!E?4W;!D0QN%.RY4
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M3)[SERK$1-MS,2A,#L\XDQ0#F$9!I2'4J6-+Q<TI*-F#=<HM0@PTI2%H"M+
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MTB#TI8]8RLP$IL0><"JS@PY:,B%I)E*VU7/*#%>&6!V!1\P?,)0ETHS<X:N
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M.:QG-84=53*\TLM)(")@#ATOX0,%/K>Y>(5:PT</+"P3M)HM32EIJ=0IT6!
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MR,202TB6)-MCCH+F*K@'+&6JB5PHF:,0/&>QM4YX$6<J#C:/ZK=A^L%4!KI
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MA!L&1++P17ZCB;#DIAEFI*8ETM!U](Z:DV/D(\QZWHS^.:U%^XC$]"Z5J?\
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%1N#/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>72
<FILENAME>cogo_0062.gif
<DESCRIPTION>IMAGE
<TEXT>
begin 644 cogo_0062.gif
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M^.;P]_3S\_+W^_3X^_____KT^O#O[P
M
M
M
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MA3WB0A/#$-("P</@LF4KJ/@P8)KM0>'#9;&P:E8L.+RP$Q*DOO#**R_,<))
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M!9   ! 'H7  !V !"   ;>!JP5B1,8F(>$B7HVF+A*B/"_B1\$B:ZFB:KKF
M9IEVUTB5"A !!L"4M  !#_"7GT  &C ,*"  =S +>,  !T *I'  &4 ,LS +
M%*  GC +P. &G#D,LY !(?!J(OXYC!V9DR2IDR<XBR4)FSNI?*H)C<DXDQHY
MC^*HB,Y7@<DS!P$0!PY@ <, # _  +0P#)\@ +\I @"P!P)! @!@![50 !@P
M$!2  +,@$'<   XP GG0H-I9DV=YH1AJH?)HB:X(GG&9CQBIH0B((1F@ ,,@
M @, "L20GW_9"?YYH@&@!P4Y!P#@!@?ZFP*YH*0P$&W0  %@F&_@F=ZY?:$Y
MGJ!9A[3HDDAJI#)XGFBYCZ4IDZ^9ED>*=J7PDXQI !2@!R(0 )WY  VPGY[P
MH@ JH,-0 @!0![5@  DJD)JIE_<)#,7P"6V@  B@EP9Y:I^9H>@(=XZ'FAGJ
M?'_*I_Y46H"#RIJ :J'(9X/)\P8&L  &8*<4  P48 ![0 SRR0$G*@!R( IW
M *FAD)PX*@P6H  4.@($( ?W*0$'( JN1H"JL I.VGRBN9HH*:N/IPJZBH0&
MF JK@'NID I)F(BRN JJH(G6EWMHYZN]&*O$"G>ZRI(]&7VI2)0/8 #120H9
M$*!Y$  &T  "8 !>R0$ 8  "4*Z+V9@3,! 0( !PN@?F"@$,$ #9V6I[:@JI
MX 514 9-> F70(HA"G=8$ 6#<*S"MP52@ 6E,*38%P8$:PE#@ 6HZ*^]=Z@-
MF J)( 56\*\;6@H4>PI?$ 5J8+#F6 I8( 6(0++"MPDG>_X(L\JG*F@6M6 "
MBRD0>T "7JD'*! ")C"5PX ')M &;1 'H" 0,UNSPT ')K"? C$*)M !'% '
M>:IJZ9<*0, "3?"1@YH*BS #,Q )+_MXCK=Z;W=W-\ "7L *=Y<*C( V+7 (
MJG"H=X>*:=<#*S &:J ",8 )@T #/( )S_J JJ &+1 #E1"VIV>QQ7=VJ7 (
M-5 #E: *5XL%<=N>IX ),\ "9[ *@WH*E_ BFQMX9R>2G9NL!SB;*EFU0? "
M3B"KKHNOI[ *DH VEL"YJ[ *O8>[^"JKOFH*MYL*QQJLRQJLS+H)/1 #8X"[
MJ+@*8" I,3 %NFNL26BL:/>KL?X;!"TP!J>0!6K "H-@4Z?@I+(:NQ]YN[>J
M>^,KJZKP!S$P Y80OL&KLKZK"L!["JH0N^&KFKOJJU?*"'F"":N !"^P!;;0
M>R1+O;N*=O=[OSDULO:+>^-["=J#!KB;OKKKN_CJJZ[[J]5[P>PYC5A*# ;Y
MC\LQP@GY;29<$ 4):_>:"D/ NJ9@!2A[!3_@!))P"74B TWP!ZRP"%*0 T P
M!O@Z"%%P!HFP!(.P!5" "%GP TO ",$Z"$Z@ T"0!6N74\GK>,?;!#%P Y>0
M"I(@!5,@":MP" F+KV00!#^@!MC+!HPP!6+ "$'0ODZ0".<I!FHL!9)0"E.
MLA^9!?Y1X+)(!@12L BP\ <A4[N($ 4Y@ 1GH)I<*P5>@ A(  1?8 I8  1(
MD CAF[$Y$ 1EH J2H 2/U02'4#);< 8_$ 1PVWML@ 0Z  6#(*RFX 5   1J
M0"7=>PE;$ 1 4 6,L J6 #1HP J\' 0]( 50C'9;L,I_< 52, A]+ FI@ DR
M;,<B^(?M.&\MO+I08 H)DB QH#*2,"PR4 -H,+LM\ ,O @6V8"DW$ ,L@ 9
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M$&O!#:)@"56YS[,).V4I_:7=]W5V=2YL5V259S=EQ45::M )*K EK=4N%"[
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M;@J<7V0012X%B56!"4 TB;*F,/[[8S#QGI1):D2EZ,I&<+YR0%B]-?VKD"6
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M$Q )&5G:&9R"8&1!M4UTU4[.]7A*JG4!&07B$XJ$+P"!"Q3"V:.]K5/%E,1
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M?$^D??@G\&"  [!;#@%P0R/D@/Z" G"@#GJ0@P X@ <\W*$3H4  !?*0!P\
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M>,UX1 \ Y* .!, #_FX8Q,T#AZ$.L.\.Y$ .@,'H'L "(OY@YW 0 .(@#P;
M$3VP PP %#Y! +(O!WV+! A@ BA  1"@X8;P#>Y@#AI.^P3 #1#@ ZY0 21
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MX.".\ $>@!8(;@(L  ,@@ ^., ((@ %JX0H/  *$D PO$P+Z8#0+0 !N$@(
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M%K9 "G9A#,I@/TZH.D D!_KI2"+C#*3 %EBAA<9I/NAR%_Z@"FP!"0AI))3
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MXWJJ@!4P(4E:@RPQ(0FD8%6F)0NX2T&F("."=56UPE7)4CWAPU;9!$JLU@F
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MCP$YF_]$D(TVHC"!#0+ID5)!$KS 2<ZC% ;A-3#A$((')<2 ;^&CEUGC#]C
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MTB>=TDG,<26/L5O\JPM[U$&]TX.=M@-=SEW\SY][O;<7M(4C%F9@T9L]!UY
M"W"#"B0=UUM&RRM<_V0\U+<\RI-=QTG=QN,<T/-X)(#VMH;A%5Y].*R=!WQA
MZZS]UK%=7/'<VU?ZV.5[PL?:O7M]W.L<6@E[NC6/4#H\.%[AV86[R'&C$ X]
M$WC#UNL]4/:]NGG]Q=FPXHD=V(?=SR,;MEFZMO/[OF?\0YD=X=L=.%KAV5$[
MXJ]]XO\$LP51XS=\PFF>V/^=1/[O.,<#OM@Y?9JU7=7.FC><O0707&6& 0E:
M  FV==YA/M<9D.1!=+;-O>:KGN>OOL]%WK4O7N"]>16:_=49GL1G(!747>*?
MGD^46]>[$<4LW./Y/.IW]K-?3+K<6L.MWL;'75K!G<M/C8>$@]VAO3>._ 4$
M(;QOP^D9/NV=$MF9 ZNQ.L&"/M1\?>/HBV8@G_^.7=3@2]R-RSE>I//Y?=NE
MWKY/81.X>]V'_.AQHQ?6W#=6QND9/T]++:K9"!,&00UT7_<'(<=\/>7HJQ0Z
M2+NQWE 0@7C0V4)U_Y%N7K.CVA* IWE63I4SQS5J@A%").?!G;[9WM=^8V42
M?O!Q0_X+6B ''OTWT'[V%_LJ.123# 4^;J!7K&#^LV#&*)JOZ81$YS,OT/6S
M[E[& **4J8$$2PDD:.K@CTJI3EVZ,>6*%2Q*FI@Z57 @QH$&$7(\J+%4JD1C
M3JV:HF:5P(X(05Y$J(I1$RA*JF!454;)%"1E5'ED2?#4P8T)AV;TF!"I2Z1!
M6\(:!C6JU%<R7E :)DSJI!<O($G]*J4%E:]DRYH]BS:MVK5HB29<)>;%H54(
M-V),Q4@)J[U[5YDDF,JGJ56$?=YE17B@*J*+5?VXY!>C2,)T+P8N[%$5Y;N7
M6:4B2)C5*2 ,'?8XA7@5*R5?Z&I>);BQZL\#*0L^E2J5ZOY!3FY=/'5*E6[8
M@&<'1LI#36XG5VX% H))52D@@RJ;2I5:\?!5M >K-A4;,2N$V1=?W(S4;5U3
M3\^^FF'U:ZP<+;2@I2*6K?[]_/NC%:;>*F>\$ ,:*C&%5Q!"&=11( *=8LD@
MN*F!A1>,2!>3%UF@ =PAETAV2"EJ\/ %(Z4D$EPE7F#!!GB5*,+(BH=@=!,B
M*ZJ!&R.,+ +&%HQ\E@J%;&#2!"/ 8=*#)*9@@HF 47 72!86-H3()8=46 F&
M@V21!2+"Z7@)&XQ< <0?I2A2"2:)6/+%%89@J,@6/NI(U"IL3'$+=F&R$L4?
MK%S"RAE7L"+0*C%B\4=N.C("!OX6B7RF"B 57I)(EH>R40IPIJ"!11F8("(2
M)FQ@,4:F+S7%5"FOH/4*#O%)A9\.O@B3%590U1K66+?ZQVNOODH%H$>KE!%#
M56+XA51,22"F2K.!77$%;$J@P8H44R3R!Q",K)(($&HD<H43J0"QR&*70/?'
M#F)<@D@3K"S2PQF)8(&$*HG4@"@@/QBBDBIH##$((E%D<<L7.7@QR!D\5'*2
M%(FP(44/I5W2@RFIW0*%%[=< 04B@%"'<1!;(,(&#Y*PLD43APS"TRUE_""%
MA5B4J8H4:UPR@Q5J'!+$&;:H0=V6.:AABV"K.#&(*8$,@ITIEF""'2M-I%2*
M*H@ $?Y((E)<8<L?-6P!R!\Z)()R%(?\<44..I8YKQ2?-7$%(F<XH<.22'B1
MR!=*9+K4J4VQPJH,+5P5%2$MS(!*6OCI^FOCCO/G5BG#OH"#JU@@*$D.4D A
MA111 ")<$(J<@:<:4=S"RBV)0+$*$(C8@IT4BQ3Y&29*-)D$)JP@ @4K00P"
M^RU6E)B#2;?\T7O54S!RRRVCL?*%NZH(C\8B0+"BRNXQ?&C*)22B<08:5[B=
MB!*HWU()$JQ X43P94PA20^:$<H#)EY;S,HA4MBR2A6!7%(#0-D"$4HXQ0\L
M@9A4U& 0C%#.19K !B=LH0I D$1#8I(%($0K4Z= @B3.Y_[!0<AO>F/ @B5Z
MH!M6,&(&E_@"(%!GBR"(" K!4T,.5M&I7:QB%U[P0FJ0Q12.M,<L[XE/5F(!
M'RF@0A.<:*(3G]B$%CR!$YI8XJH>A\4L1B58IQI6L60P@Q:<P3H#P4L/$'&(
M-!["$M>I!!":(+DI^.@0B!#A(A24%. $X4<.00(FIG,RWF$""!P9B1,2X81^
M!8)UM3$%(PZ105;TD%"LP,(9Q'"L!P7!@@[)@16R@(4M $%C6%A>&A%1 TQ(
MH3J9DH03LK %E92"%5,(A!JJP(HF_4%<)PE$^E(A$MZ53SJ2JX(AMN235"0!
M"+.T!1J:()A+!.*9C\++#Q2QLOZ\H$%_JVC2&;:@A@V"IPF*\ PC$%&&')@"
M)0>Z1!),D80_)&(0BHA>)<)W!NZA:B"<N"(1PTBX8:#B!3*H"E=>T *N)/2@
M!37H"URP!2U*%(N1FUQ!7^ %]8"'$4B 3;,$ QX>**%9GO/"%DR*!@(2)3!!
M6,1G+G$[>)[L$/!#PD;PXH1#C%1RR.O7'Y2 A2^HH0FK,"DE+9F%,6K$"9RD
M&/X\4P-)I.P+6^B1&%(Q!2]EZA*<4^I@L("&/UB!4*L(!"^G, A+X%$5AX#"
M(9S@$\F!%79O"4(9<GD1TB0D.,X)0F 0H8,>@L&DD@B$%+K)BC)LX0Q9.) J
MH* C)?Y<P0N!: (FH# (PURB">>JD!=Z9 A%#-8+E="H1BS&*OA<)2NOX$$/
M>@"$U\KVM;%]+0YD@ /:VB -$^WMKP)$+!G$("4:Q<L0DI*465H!#2O:Q130
ML(L4.HV0"4G%(F3RHX3XT11[W)T42O&#3#6IK8L8*7AZ"B$>;$LT1-704=-0
M!A]RD#3 H5AI#;(*S)Y!8\TB*Q0"T4V\0*$,@_ICM0ZAAK%*;I&Z\9\E@ !,
MJSG!C>:1FAH$,\LJL &OID "(Z" ":&8IFH<999H5/$'*5"R#%EXZWAPTP-&
M_ XVK%A"*;;PA5M(+GZGV&31LA<=\70'54+Q9UFH\JI;T?YJR<((!I.;+(Q<
M+=G)OJUR?[AX$<FQX04WF(NI/)(@9^4&.X,@JBFTQ8BZ9>^G4O,9=Y*$--3=
M[\R :JLMHB &_JU""7_(BTI6@;PO]2 T9=#!+8PZRTY)@@>H884:ME??'NBS
M6F? 1 X@PXINY3<(A-G8%DJA T"I4 >J8(." 4W#55C!$&J%5"(Z*D'A!&(&
MF<6$8JYFDI\IP19*\.$J;.&%1%9-"6G 7BI^P(A!J%AR9[!"Z_ZPF#',@!'0
MV<L@;A 3'?Q(E3<<0^^R)\=N]HTI0SQR55;+'RJX@'%6;O=^L/P6@VW+(RME
M1 Z6L(0FY-L)BM"K*JQGBC,@X?X+6=BD*BR!A"N, 0EC8,4@@""&+5P!"9"9
M A%VY(1<-D'#S,D?-'DJ;*Q"X0Q!Q=JH$%NA@BF!#5>8 FD:0K%+?&:66[#"
M+=  A"]X(0ADFP(4IG G.)85"/$%PB%N86J5X 4(-KF"+X%P$YWZ1 I.< +$
M!J$&*!BM# R_PAY5 =,H>$$*0+ $C201A$[U^F>]T]V=;&$))VQ.#4I@!-?/
MP 4O- $+NU-"Y^@N$I_?R0E^"^)O4.L>U?IG<>YN_'[4P]9Y&QXXBZI\)2Q!
MFU1( C*20$,@HB,24V#]0E7K/"(@1) JE8*-P!E$]193BM)>!!/<ZY :&*%"
M15Q"G_Z[#\XBT""A2W"P%$H*"B:4I(I*J.$/,E^%V2X!?-!8X@_,]\DES X<
M0\W($I=P&HU6?PI&V*(4E]@%THA?)T:D(1#@L<PASB"A[OAD].;J_D5V?_P_
MF2*&DEC%[S-+*94P2PQS"6N5"&=P" UA>$H!.&7!6HI7*_K!>(Y'@?]17.IA
M6KCQ46,&9F640 A!&-VA&\E$$"!5@MP1%'9!(XH!&R*Q&$2A*=?1+(=71J=5
M@^?A%[,T-=E12(2A@@AQ')H2@\#Q6%NP>V60!"(Q9"X(>R=(1AL1@J?U@T"
M!KMG!5* (<0Q&(SP XEP"9*@!&-P(".X@.G13V@1"^?F'_ZY4H%M:!:FM4]Q
MR!'KD2IUV!)!!(/C5H;IH11PR!0;<1"JD 8_TA$KJ(=TV(>8  :=@P4RQX=[
M%8-E>(@N@@4E57@EF A3T#EH,&1[&$0-^$])MA]LZ(:E&!5^B(B>B(I_Z(E[
MN(JN:!>MF!FO*(>/2".1X1D+&(F3AX?TYA>Z88-@YAID)(LO 1RE4&YD@42B
M*($O4 6F:(I8MH*M&(O%6(PP6(O6V!2[J(V/F(K9J(O(]8VT&(Y*(8G:V(F_
M,4NL\E"38"O[\00K  706(KPUHWWB(_YJ(_[>%I&<8EW*(M\$X-?QH__6(;D
M6!>Z@Q:_L 59D#C](0A=0 CT6/Z*&,B*WUB0GI@;0:2 )NB-O?B'PJ$1UN&'
M6MB#YL$1P>&1SO*1@ $I=I%,W0&#*"F+)KF*Z<B++V%D%,F3CL-%&8B.&9DL
M*R,=F8%&IS (IF*1NLB-&C$D]24A"PAV?Y T,W=P?V (N%$HTY<TTH$;V")Y
MDX<7?[ *:8!]F' &(W$AZ<$&9J>*UX$&1I*/./DW/6F7CT.+"+F ?7-9E>")
MDB-QX]$2194%J> $(6:'0700MJ8>I1!C.2(%@)@L9P $6S %FQ08@Q $65 %
MF*D*9["97?!UFR4%6Z $6^"1/[$*:J!B2<!'DO #JP!.10F$R$:7_5A=KH,A
M:(5A>_XX9'2)C'<IG+X"AS?I+,)Q'-9!%]C!&:[A$ZH !) A.0T!1+7Q&;<0
M<61%G8.A<WL1'#"1?;A1&<)!'#,HDN<1'*F F=<Q'A]E$C?%"#PP2[<P!NZ2
M9I7 "C\#!(:R [IC"VQ@/E*0!?QS"F?DD2CH%X V5K1S"I+0!";1&,+QG:=0
M=]+!'57C$R@8GMB!!(G@$[;@5H(Y'L"(CQB1C,.)HFKQDQCI-R.Q?%3'")(P
M!4[@!64T!IU3!N !"*XG!4N0-%N0 ]>R"FC0.5GP92@6!7TR!ED@&F70.6)@
M,6+@!:HP!I4P!H!Q!D:2!9YS8:>0I03G<)U3!1]R"IA0B?Y34%Z2 !R5T")L
MH @<,P4?,DMBH& .L9]20BB#X9IH, 6Y9*?@94%-(B4'HAA$*@55@)^W9 L>
ME!OIHPIJ<%U4275IV6-&LIK4DHG6DEVGX 51(#MNY1,*\U]@5TI1< :W@2"3
M5V0IRJIK88^MN J $ .5-@@[L#R;I3$1P7U3@ 6W@ 4U$ B6L C(1FU)$PA*
M4 F7L 5PQ6Q(D*QE4 ,:,SZ[=P55@)U3V@.8$ 2'8"[,U 3KXJ!G< M-$%B2
M\'",@ EJD(2I@ 1B@ F,( 4U8';6Y5<W  6Z%VQ>R7U"L3O7@P29E1"5) :G
M<%^LT&^:EQ2\EA*@L7!I<@;NDOY@4L-)Z<,*5+ SL\H(;A0(OJ,(2(<$I<"%
MH/)P""0%C<@(OYI="#<&W0<$*UL)3> %Q%B,P=FJ-7L62YF-L:H^%K.MB$%3
M8(@Z>Q$$IB!QOF$+R\4*90=L5[ +B*$&IJ(M=,%K7N!.0;NHEQ!?JN!7:5 %
ML+%?-*5#.M91IWD+JX $EE"VO) %5-D$MF QDL!".:)UR-:"T$$CP#%J@Y"T
MV3487C!6>,L(.Y!9-[$*66!30'@&:(L]$!8(?5IW#4&Q6C (AZ ^JF +9U %
M,60):  %V-$Q.L0+^T5M?K$8-^"A%A,%@T"?>-)^96>-L7BB-FNSKVJ0()AB
M 08%C_ZB"H* *$. !E_ !F=0 S$BAL5TJE$+4TOP!8JPG!P%A67P!0^'!F7
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MG50*)TA!#%<@$V02<\+%06F ,_/SH:7G:$2;@KJ8\*!A2I'C1M=9FT810Q:
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M+#C6*)'Q0UBAZLFM+0 .=8%"MV"$S:AR_,JK.CT$CL $--@"-/B8(@,#S:)
M4R#SPB:41;!R"ZD>O<GS(+D$-E!R86&$JW+.)/^#7JV35+ $M\$C]K8+#P@
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M7CKF*4JI!B09"@N[N,(7;B'&)BP"");82B7^ R,V^>^"ZJH"&J: !KFPHI1
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MXSW6(93"#QR"):!!#^09B%6"]U0,W@Q"$ZS"]K#!&1C8#$B!R;CD>PE)!<W
M%KA+*?2 *92!%$B"):17QGA!)2B"#BB"+CG1&%A!QF1!8/X4*TS!%E@"(_3
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MS<(L4U%]<4,([L*Y"Q!<T X,[&'^@")80@R<(==8,9E8 D-L@9E*01HX$19
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M'9TEA$KQR9S $.Y+%:#@$!(!2)P#$90 8Q2A1 H"(E;A#*[ %L9#":1 $7/
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MW0Q"HW1KT7?_BI9DN79]O=9_VY=] 19_2RYHY]?4@-?5?G-N:5;6]&XR+E9
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0H ,:G3E9H N:GF$A(   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>73
<FILENAME>x_coverback.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 x_coverback.jpg
M_]C_X  02D9)1@ ! 0( )0 E  #_VP!#  ," @(" @," @(# P,#! 8$! 0$
M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P  1" 5/ \$# 1$  A$! Q$!_\0
M'@    <! 0$!              $" P0%!@<("0K_Q !E$  ! P,# 08#!@,$
M!@4% A\! @,$  41!A(A,0<3(D%1810R<0@C0E*!D14SH19BL<$))$-3<M$7
M5(*2X1@E-%5CDZ+P\416<Y0U-K/2&29%5W6#E;*TM<(W.%AD971VA):C_\0
M' $  P$! 0$! 0            $" P0%!@<(_\0 0!$  @(!!  % @,&!@$#
M! $%  $"$0,$$B$Q!1,B05$R8084<2-"@9&Q\!4SH<'1X5(D-&(')4/Q%C53
M<I*"_]H # ,!  (1 Q$ /P#T[7W9\.'UH , BFD2V*33&A5 P8)H &#0 H=*
M !0 * !0 * !0 *  >E F(/-!(6#0 ,&@ NE  P: #P: !@T )R*+'0K!H$
M T *H %  H %  H %  H ,))Y%.@'4#"0#4OLI"J0P4 "@ 4  =:$ JJ %
MH %)C0*10* !0 H))'%9R[*01&.*D P@GF@!-  K8D5L50 :4D')H 4H9&!0
M C8J@ ;%4 *2",YH ,J ZTT2P @\BF(.@!)4 <4 &#GFLWV 6\4@%5J * !0
M * !0 *F0 J !0 ,$T "@ 8-  P: %"@ 4 "@ 4 "@ 4 "@J/82J3+ FA '3
M %  H %  H 5L- K#"%9% 6.U @4 "@ 4 'C-  P: !@T &.* #H %  H %
M H %  H %   ).!0-"MBJ!@V*H 4D$=: #H % !X-  P: '!4FH= P4  #/%
M "DI(.30 N@#&]:Z#D# Q32);#IB%)&<T%(5M- PP,46 *5@"BP!18"MA]J+
M &P^U%@#8?:BP!L/M18 *2!FBP$GD46#""">F*+)H5W2O446%!%!'7%%A0@I
M)HL*#"3BBPH/::84#:: H3W8H"A6TT!05 @4 "E8 HL 46 823THL ]A]J+
M ;4?,4QT+2@@8XIIA0H<"I?92#I '@TZ &TT4 -IHH 8-"0!TP!0 *5CH.DV
M-( 23T-3N15 *<=31N04#]:-R"A25 #%0W;&A).3FD H+ &.: $T *""#GBM
M-R%0NC<@H%4(% @B<#)IT%A;Q2? 6&"#TI6%A*23TJHB;L('9P:8@]X]Z $$
MY.: %!0 Q4.+ 31M8#M/<@!1N0 HW( 4;D *-R %)NP!4@"@ P<4  C/- !C
M@4 "@ 4 "@ 4 "@K:P4!M8* VL% TJ"(S290 ,4( Z8 H % "PVHC(Q2L+!W
M2O:BPL7M-%DAX-%@'4@"@ 4 "@!2: #H %  H %  H %  H %  H %  H'0I
M'S4 D+H&"@ 4 &!F@ ;30 H).*+*2;#VFE8;6*I%@H&"@ T_,* '* !0!C@G
MGK72D<38K;[TQ V^] "D#&:"D*H&"DP!2 % "@C(SF@!= !T "@ 4 $H9&*
M$[#ZT &E.WSH 50 E2=WG0 6P^M  V'UH &P^M4@!L/K0 -A]: !L/K0 C8?
M6G1 -A]:&N "*,#.:@ J !0 I'4T +H 4GI312#IC!4L 4 *'2J %  H %
MH %)C0*10?E42&@TJVU P_GY'&* !L/K0 -A]: !L/K0 -A]: !L/K0 N@ 4
MUV *U)!30F$H9&*9(G8?6ID :4[:@!57$!M?6J 30 * !0 * 'JR %  H %
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M*SEV4@5( H %  H %,'T"J,@4X]@"M !4R %0 * !0 *TCT *8 K-]@"D *
M!0 * !0 * !0  ,T 'M% !@8H %  H ,T&BZ"H&"@ 4 "@ 4 "@!;8W&DQ,7
ML'K4B!L'K0 :4[: #H % "@* !M%  VB@ 8H .@ 4 "@ 4 "@ 4#0*!@H %
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M!33Y$XT"KW,D%)NP!2 %  H %--H 4]S %2 * !0 * !0 * !0 * #30 =
MH %  H %)LK<T"E8;F*"0:+*L<[I/O18K!W2?>BPL'=)]Z+"P=TGWHL+#2@)
M.1186'2 %  H % "@G./>@#GSWV@^Q"-J!>E'^U+3Z+PW,_ARH*GU=\)6_N^
MZQM^;?X<>M8?FL"ELWJ^CH_)YW'?L==G0B""01@@X-;G."@= H"@4"!0"!0.
M@4!0* H% ZH% "DI!&: #V#WH 4!@8H %  I6 =%@'@4@#H , 8H+2L5@ 9%
M2F5M2Y!5#!0%T"@=@H$"@!00",\T 'L'O0 -@]Z %4@%;12L= P*+"@Z0P4
M9&NLX@4 "@ 4 *2D$<T *V)H ,  8% !T "@ 4%@H % !I^84F"%X%24'@"@
M 4 "@ 4 "@ 4 )/6I8!4@#/6M20J8 - "<F@0*"04 "@ 4T *8 H %  H %
M J0!DT[ 53 %  H %3/HJ/88)'(K$L6E1)YJXB8JK$"@ 4 "@ 4 "LGV4"D
M* !0 * !30I= JC,%  H %  H %  H %  H %  H %  H %  H &<4 &#F@
MZ !0 * !4L 4@'@E. :"Q5  H %  H %  H ,#- !X% $*]P[I/M$R%8KF+=
M<GV5(ARU,I>2R\1X%*0KA:=V,@]1GH<&E)-IJ+ICBTFG)6CCOV8_M%_]-]IN
MUFU#;HUKU?IESNKG&C*)8?1N4@/LA1)2G>E25)).TXY(4,<>BU?YE-2XDNSN
MUVC_ "TE*+N+Z/(M\TN5_P"D!-@V'NW]>QYFW^XHHDG^F:\F4/\ [AM_^7_9
MZ\<G_P!NW?\ Q_Z/I5G=XCY\U]&?,@H*!0 *"04 @4%!I )YH 7L30 -B: !
ML30 8  P* !0 * !0 *D!6!0 =  H 4.E!I$5^&I1?L%5"!0 * !0 I*01DT
M + QQ0 * !0 *0"ZDH%  H % &1KK.(%  H % !@D=#0 M!)'- "J !04"@*
M!0,4 ,]* %;4^E390-H'E18!T@!0 I !/-- *VI]*= #:GTHH BD9Z5G)T^"
MD@L"IW,*&U?,:?8F%0(%.V% IVQ4"MJ(L! Q2:"Q-(0* !0 *: %4 * !0 *
M !0 *A@*P*8 J+8 HM@"BV *3=A= I4/<PP2.E7%!;!N5ZU=!8-RO6B@L6DD
MCFBA6*K*3:9<>4"EN95 JJ3%8*=(5@K(H%  H %-"ET"J,P4 "@ 4F5%6#-*
MRJ0*I$2X8*! H %  S4V:4@9HL*0,T6%(&:+"D#-%A2#'--!2#P/2F%('2@*
M0>: I!CI4MB:#P/2BQ!8%  P*04/#I0,%  H %  H ,<T '@4 'C%  H RW:
MEKZW=EW9[?\ 7US4.[LT);[:">77SX66Q[J<4@?J:SS95@QO(_8UP8GGR+&O
M<\2_Z.6TW:Y=J.KM6NJ48\:S=Q*<_"Y)DR4K ^OW3BJ\3PB+>64_M_5GN>,2
M4<48??\ HC;733&[_23VZ1W?@7;6[T>/-%M6WG_O)%;RA_\ <D_M?^AC&?\
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M,[-+[9KIHW7$ D/6"\A'>.@#<5,/()0\-OB&,$I\0!&34X=7#)-XI+;+X?\
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MT^E6I>U22?\ $H__ "DK^QI*'V@3?L\:[.F9D)NXBX0),"<6XJT[PZMEMWO
M-IR>.//%1^;DHJ;QNN_9E_DX[O+617_%'0^S/M1T/VO:8;U=H&])N%O6LLN
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M8I, #K20!X'I1+@ ;<]*BP!L-  V&@ 8QP:=@# ]*+ &!Z5:0 I@"L@!0 *
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M@ Z !0 *E]FD>@4A@I@"@ 4@!0 * !0 ,GUI@#)]: !D^M  I "@ 4P!D^M
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M7 MYU/JA)0A 5T*MV/E->?X1A:W97UTCT?&,Z>W$N^V>WZ]H\,% '+=,$?\
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M% 4QT4"H.@ 4 "@ 4 "@ 4 "@ 4 "@ 5+-(] I#!@^E  P?2@ 8/I0 ,'TH
M&#Z4 #!]* #2#GI30!J'M38"<'TJ0!@^E  P?2@ 8/I0 ,'TH 4.E4@!3 %
M"1UJ0%50 H /!]#0 -I/D:78 V$>5' !I!]*3$P\'TI"'$=* #H %!0>#Z4
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MHJOT_P"S3=L'89IKMOA-VC66I-4LVA!0X;7;;@B/%<=0HE+JTEI2E+&[ RK
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M=#B> * H/!I6BJ%TK0Z!M5Z5F4*0DA0XH =H$"@ 4 &FDRXBQ4V6*I@"@ 4
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M)!8=,D%  H 4FID7$/&:@L4.*I '3 %  H %  H % ![%>E.@ 4D<D4J *@
M4 $1F@35A;?>D+: C%-,B40J=BVB2#FF%4#!H &#0 ,&@ ;30  @9H 7A- !
M83Y4 "@ 4 "@ P">@I-6 -BO2B@!L5Z44 -BO2B@'!P!30 H %  H %  H %
M  H %  H %  H %  H %  H /!H &#0 ,&@ 8-  P: !@T #!H ,<4 '0 *
M!0 * !0 * !0  ,\"@!:4D')% "J !0 >,TF ,&D 8XH .@!0Z4&JZ#H&"@
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M9]J:(E38.[/H*9-!%M7EBFF2X@[I7M3L6UA;%4"!L50(&PT ) R<46 K8J@
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M '$C"0*AE+H50 * !0 * !2?0 K, 4 "@  9H /:: !M-  VF@ QP* !0 *
M!0 * # R<4 &4X&<T4 0&3B@!6P^M.@#2G;0D JF :>E!2#H&"@ 4 "@ 4 *
MP:D Z!H%!0* ,57H'F I-T"Y!Q4[AT&!GSHW%)!@8\Z-PZ!4MV-< I "@ 4
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ML*!W*?6BPH'<I]:+"A0&!CTJ'V G8/6D -@]: %4 "@ 4 "@ 4 "@ P,TTK
M/:** &T44 -HHH ;110 VBB@!M%% '3 74E!CDXH /8/6@ PG!SF@!5  J)
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M0#DU-CH/NAZFBPH'=#U-%A0.Z'J:+"A6P>]9[F, 0 <T;F JC<P!1N8 HW,
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M0 ,"F@!@50"5@ 4T)B*HD4GI4L Z0 H % "#UJ@!3 %02"FNP!6@ H %  H
M,#-)@ C%2P  #22 6D#%)C0>!0,&!0 * !0 #TH 1@55$@P** .F * #2 >M
M "MB: !L30 -B: !L30 XD8 %04@Z !0 *  .M9 *P* !@4 # H &!0 ,"@
M=* !0 * %A((S3H ]B:= *"$XHHL50 * !0 * !0 * !0 * !0 * !0 H 8H
M &!4EV%04'@4"L,<'(H%8942,&@ J !0 * !0 * %I2",F@ ]B: !L30 =
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M[1P.E @]B?RB@0G:GTK4 ;4^E  VI]* !M3Z4 #:GTH 2L #@4F BI &">E
M P1UH &!5(E]@P/2F(&!Z4 "@ 4 "@ 4 "@ 4 "@ 4 "@ 4 "@!Q*00.* #V
MI]* !M3Z4 #:GTH &T>E !!&#F@!5*70!CK68!X'I0 2J  E(/6@:5A[$^U%
MCV@V)]J+#:#8GVHL-H.G H$.!*<=*H0526"@ 4 "@ 4 "@ 4 "@!2 ".130"
MP .E, 4 "I8"@!CI0 >!Z4 # ]* !@>E  Q0 * !0- H* "1T-  ))ZT +2
M1R* "42#@<4 * !&2* !M3Z4 #:GTH &U/I0 -J?2@ ]H'E0 * !0 * !0 "
M >HH   '2@ 4 "@ 4 &>M0:H*@ 4 "@ 4 "@#)8'I76>8# ]* !0 * !0 *
M!0 H=*#1=!T#'1TH&"@ 4 "@ 4 "@:#23GK2&*\JF0 J !3 =; *>E- *I@'
M0 H 8Z5)0*!ACJ/K4%#JP-IX%!*&V_G%!3'L#T%!(,#T%  P!T%  H %  H
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M  P/2@ 8'I0 ,#TI, 8'I2 &!Z4 8VNT\\%  H %  P?2@ \'T- P8/H: %
M''2@T70L-Y - Q73B@ 4  =: %T $>E !)ZT#0JD,'E4R %0 XUC;SZU2 73
M .@ 4 *'2I+#'6D _@>E2 * !B@ 4 "@ 4 "@ 4 "@ 4 "@ 4 "@ 4 "D-=@
MJ30% !IZT *H )5 ": !0 *I$2[!3)!0 ,#TH %  /2FNP$UH0$1N&*E] !"
M"DYS4#%T""50 $T '0 * !0 * !0 * #'6@8J@H%  H %  H % "T=*: 53
M%  H %  H %  H %#''L%2: H %  H % "D]*")=AXH)!@^E #HZ"@ 4%@H
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MI0*Q>#4F89Z4@#H*!0 * !0 * !0 * !0 823R!0 73B@ 4 "@ PE7I0 Y0
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M  H ,=:3Z 568 H  &: #V^]  V^]  V^]  V^]  V^]  V^]  V^]  V^]
M!T  ]* $CK0 J@#+;17;N9S4#:*-S"@P,4;@H6A 5G)Z4F['5"NZ'J:0 [H>
MIH 4$ #&:!4&.*!@H &1ZT #(]: H'-39>T'-%AM!S18;04T[$U0*9(8&: #
MVB@ ;10 8XH +GR% "P@$9-.@#V#WI#H&P>] Z%Y]A0.P9]A0%A4#L%)CB^0
MP<5)88.: #H %  H %  H 6$ C/-  V#WH &P>]  * !GF@!%  H -(R<4 &
MI('2@ )2%9S0 2ACI0 5  IV)QL%%BVH%%AM0*+#:@46&U HL-J!18;4"BPV
MH%%AM0*:9,HT"F30* H% 4*2D$9H 6!@8H&-J^8T .#I0 *FR]J >!FBPVH2
M%DG&*+#:*HL-J!18;4"E=C2H% P4 "@ 4 "@!U/RBI9+#I"!0 * !0 * !0
M*&- I6.@46% HL*%H^6F@H50% H"@4!0* H% 4"@*!0% H"@4!0*!@H ,#-
M"@@'UJ7*@!L'O2W, ;![T;F -@]Z-S +:*-P![!ZFC<P%=T/4T;F7M!W0'F:
M-S8;0]@]:D-H-@]: V@",>= ;0$8H$U05!(1.* !N-  W&@ ;C0 -QH &XT
M#<: !DT %TH /<: ,V4<<9KK.6P@@D\T!8K8/>@+%(2$YQ0-"J!@H %  H %
M  P/2I-4N 8'I2'0= @]HH &WTH &T^=-$RZ!M%40&!B@ 4 "@ 4 'G% #@Y
M JD *DH% PZ #VB@ ;10 -HI,<>P;14F@8&* !0 * %)2",F@!6Q-  V)H /
MI0 * !0 ",\4 %L30 -B:  $@=* #(!ZT $ !TH !2#UH &Q-  V)H &Q-
MV)H ;H %  H %  H %  \J:)D"J(%)2#UH )0 /%  "B!@4 . Y&: &U?,:
M#WF@ ;U5!J *)X/G0 H) YH .@ 4 "@ 4 "@ 4 "@ 4 .I^45+)8=(0* !0
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MH"@;$^E 4'TXHL*% "@8>!2 + I6:;4'18;4"BPVH%*PI(% P4 "@!2 #U%
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MI0&U [M'I0&U [M'I0&U [M'I0&U![$^E PBE(!.* $4 "@ 4 $J@F0F@@%
M H %  H % !Y-.P"I "@ 4 "@"BP/2NLYPE 8Z4 )P/2@ 4 "@!2>E2RD.H^
M6A(8>!Z4Z &!Z44 *8 H +:GTI #:GTH / '04 "F " >M !;4^E( P .E
MI@"@ 4 * &* #H  ZT@!4FH* !0 * %( )YH 449Z"@ !&.HH , #I0 * !0
M * !0 * !0 * #3RKF@3%E(Z@=*F3I#BMSH(;7E9"]B1Z5BW9O&%"^[CXY>!
M-)9% J6+<,K<B-JVJ=&5=.:?YA$>0P9"!]VX2#363>)X]HMOE.33LG:*VCTI
MID27(-J?2G8J!M3Z5HA6-GK04%0 * !UZT # '04 "@!2 ">:!,7M3Z4"L&
M/*I8 P/2D(0OK5(I":8P4 "@!=00*P/2@ 8'I0 =  H %  H %  H %)E(6D
M IY%"&'M3Z4R6'0(6"<=:R+ * %8'I0 ,#TH &* !0 * "55Q 3@>E4 ,#TH
M &TGD46 -AHL 8H 760 /2@!-:@ =:3Z <2 3S4( U@ <"A@(I *307$6@ C
MD4%"MJ?2@ P,=* !0 * !0 * !0 .O6@!*@ .!0 B@ 4 & #U%-$R#VI]*9
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M0 * !0 * !0 * !0 * !0 XC&*I '@>E  P/2@ =T3SBB@!@>E, 8'I0 =
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M"0,#FJ0#@Z5,NP#J0$'K6BZ %,!=9 "@  <T *H %  H %  H %  H %  H
M% #H(QU%6 ,CU%  R/44 #(/G0 =  H % !IJ67$52*"*-W)I.@L4D;1BD2P
MZ0 H 2>M:D!4 "I %  H -/6DQH54E H &">@H <1P*!H.@8*I$L%,!L@YZ&
MI +!]#0 G!]#5% '6@!6:DD'6D ,$=10 * !0 1ZU2&A-,8>* "H %  H %
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MD')%:(Q;%TR04 "@ 4 "@ 4 "@ 4 "@ 4 '@T %0 * #P:&- P:DH,#% !T
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M(95)'B3PN#Y1JSCIC!]*T4DV927 -N>M79F#8!18<B5(!QBBT GN_:BT I*
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M6%BJD0* !0 *"@ 9.* %;#[4 #8?:@ ;#[4 *2".M !T "@ \9H &TT #::
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MI,Z.TE1;#3KK()4M.,^(?BXY!/49\Q7'DE9U1A1J;1-N3!9@RY"782E)5%?
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M8*$7VP^Z3ZFJWBV+V!W0]31O%L"+8'F:-XG&@;![T;A;1I3?B/6K7(@N[^M
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M])0TJM%H>B1NZ:O+JF8R<>+!4<GZ[:SG/EKX+A"HI_)MM52&K4Y%84>^9D+
M;/Y$,H(VGVW5QUN9U7M1YNTK;G=9ZHD:CD-EU#DD1VDJ'RR.]VE8],)Z5]!:
MQ0/#_P QV>XHT)=I%N90O#4;N5N-_A(P <^=>)ESJ;;/:Q8:C1)[38C"]-R/
M&EM,2XL36G/- W *_3"C66#+<B<N%J)G^T31AU-H>]:1:C,A]<-V1$6>"LJ
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ME $ =:VL@/ HL ;?2BV -OK0 ,"D ,"@ Z !0 * !0 * !0 8Y(% "]B?2@
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MLI(5W6/,4K'P*"<#'6DV%(/ ]* I P/2@*06PG\5(7 ?=*]?Z5-CI#K,"42
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M6L&S;:5L.0N<R92D%)6<X(Q5QD1DC0^,U:,T)7U%,8B@ 4 -J!R>*"D%@^E
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MB:J"U/#.<6>W6>>E3+4MI2T_A"N17S?BFH\R1]3X5IGBB7"M/I1'1W:"03U
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M%"E;B\.[SZ8Z@?H<UVX72,,R;I%GV8Z09?OO>J2"U;2I+Z?S+XVY%1JLC4>
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MOQ)HM+]4O]ST-/X;J,JN,2DF:U@LG=%MSA/YMV!^U?/ZS\>8L2K!#=?ZJO\
M0]##X'.;_:,JY&M;RZ"I/=LI/3:V":^=S_BO7:J5P]/\O^#T(>"X(?43M,7S
MO9+AN]P& ,H+B@#7O^ ^*3R<ZF=NSCU^A\N-88\%Y_:?3T1S8NY,J5R>.37U
M^?QK1XJW3/$Q>':F3^D\W?:L[8M2VVQS[5H21\*9$=2/B.A.>I KS(>-XM1F
M<<3X/=7@4_(4\BY/F]!UYJVS2Y"'[HXXZK*3N5DD^=>YAU'%V>3E\.C%]#=I
MU-KAFY+>M5U?+SAR$!1.<\UQ9-N1V>CC2QJD=][,M6]LD@AJ?:Y)940"IQ/0
M>M>;J<N&J3Y.C'":=M<'JGLQND:U79B\ZRA)&QL!&[I_Q#WK@P:Z$)[6S74:
M:62#V'>G>T'2J[)_$(%U0$+&$(*L$'TV]:];4>(X?RTH1?J?1XF+097G6Y<>
MYP^[1EW:?/N+,U+BY2LDE7(]J\'1S6)-S[/?>)051,#<='3TN%Y;25Y7SA0Z
M5Z&/-BG#U]G._.B^"-#TY&;N:)$MC"$<GC-9Y(1R+TFL,LU]12ZXCNRYB$0-
MR&TY QQGI6"\/4N9&_YQQZ*Y,:Y6^(DI=43C/6L9Z&2?I-8ZQ/LLM-N7I]+D
MM[>4MD@[CCI6,I:C3>E(M+%G]4F38NLV I27FDX0H@G%;1\0RX_J,Y:/'/HT
M$74MHE0]V4)&=N0/.NO'K<>17-\G)DTDX/T]!.10X2J.^/7KBNJ$L$_<YI^=
M#V I;C8 6SGBF\4ERB]\:Y(P<:6<_#*:/J@D8]ZA[D2VF7MG[0M3Z=6$6^Z.
MK;2<X63S6BRY8?49RPXY]'2=-=OTL=VS?(2' 3XECD@?2M\6NVOU'-/0WS$Z
M78NT_2MU2DF6W'6KR7Q7=CU^&3J_]#DR:++'DTK<^#-:W1GD/I/FDY%>G"<9
MJT>?/=C9FK@U!@2U27(K2%#DJR*[,:;Z.?(E]3)D>7'F?RW LX'3I^]:2AY?
M)$<KS>E>P]@))'I4.2&XL-"05A:^$]*G=NZ*C7N6S?=-I"4GRS7-DGM[-X1L
M7DGD=*B7JC:-%473.9=L.H9UAC,.-I4$%>21S7SVKU$\39ZFFQQFN!C1&M(=
MTBA3TL!PC 2H8->OX3D>?H\_7I8^S;LR&W$Y22??%>SFQRZ/*QY%-CV14F@"
M1B@!)Z44 G!IT!3@9.!729![#[4F.+Y%)21UI%MAE03UH%0$G=T% 4*"2: #
MV'VH '=^N* %@8&* !@^E J0,&BQ;4*V#UK.R]K#V9\Z+#:P^Z/K184PB@IY
MHL$F@ 9IC ?#U\Z:!\@"2>2G QG)J99*&H6934-PNEVDIT[II*T2)(V.RD@;
MHR,\J2/Q$^^,=:Y9Y=\J1U8\*BK9/@6*/882;7"B%.T$+D+.Y3BOQ*6KS4:W
MAMQJSES2E+A'".W'63"5BU1)*T&$DR@5<)*\;<*]J\KQ#.I]'K>%8)16Y]F+
M[()MONUJ=8-NP(KGQ$B4,%2GLY)2KKM]J\?*_0>ZVVRFUA=&YMPNNHI,I 1;
MA\,C)^9Q9XP//CJ:X)<I1._'&N68+3%OG6?2MWDWML)_B5P,@H'*@V>@ _-[
M5R9XJ<UM]CT-//RX/=[BM=2T6;3<"0D%+B$O2UI(Y4Z1M; ]1MZ^]<N-N4FC
MHG2BF>?)[L^^)C6]*%;POO'3Z+4>?TKU\7')Y>3E4>L;6A&FNRA;;64 0PR<
M]2LCG%>;EYRG;CX@><^V22\F3&M<1\LIC1D'>1R21E0_6NO33]R<\&DD<[G7
M%R5#@I2MPLN#83CD?6NR#Y//RPM(Z%H.YM0GU:6<=YE0EE1/RG(\C66:-M2#
M&TGL,UV;LOM,ZXTXI&Z++9,LCS2MLG)K7/'Z9!@=*43-MA]^T1$-(<=^'F!:
M"@^O&T_6MEZ3"7J2.SZ(L4?1FB[WJ22K$Z<4A+1.3WAZ@?3C-<>:?FS44=F*
M'EP<O<R6D.SV9JW5Z=87]]#=NLQ668^X_?K4.21CUK2>98L>Q=F6/ \F3=+I
M'0[H\U;+<_/M\COKB^K#D=:MJ@.G@]L8KA7KE3Z.^4?+C:[*:'<W8<-N2I*8
M$D[F7I"SXRE6%;4CS&>O2KG"^.R8RI7T:>3?%(CPT+=.$M%1!ZE?D:YXPY9J
MY]&"N<SX5\SU(4\\KH",@&O0Q1]CCG+W&K6_M"6DKW29;HW#T!\JUGQS\&45
MR= 2VMIKN5*3N"!T-<G,W9U="D0^[87]TM2U@A.T=:ZZ4(V3=\"[:8^FK1(N
M4@COGTEN-GJI7J/88P:Y\DO,=(J'[-6RET]IV7>)QNEQ0K83N63T//E43R;%
M2$DY.V,]IE[8:AJMT-!+2>!NXQBN7#!SE;-LLJ5(YBS*47T2<!*6VB, ^=>K
MCQ4N3D<[=G6NQ9:K=8K]<)"%(9,)P*6H<*4KR%>=KKEDBE\G7II;8R9RBX*?
MG2VK?'"G%2%^%*.2>:ZI>F%LQA<N$:V8B#HZV(M+#B%7!]O+H')1GR/O7+@A
M+/*Y='7DFL,=J[,[;0U'D)E25J45/@CS(R,<UWN-<(Y8N^30,:CDVYI3L5_+
MK:B%1L90L>_K327N4V_8"UVJ[L+F0(_P@>!RP?&@'V\^M9Y+CV+&]Y$<9G04
M,18BU)>RG!\AZUG"?-L>3'Q1ZI[,M0-76VPXSY+:+6REDK2.#'7\Z1Z\XK-\
MLY,UP^DX5]J^Y,Z6L4;L_@*WN6_42)JT$<J0X"E0QZ;5@BO0T,&LOF?8X]3)
M/$H^]G!U3W--:<N3,Q&R3W+D1;B3@*:/ *4^2L]?6NY1W3LYI3V0HSUFANPX
M5LM"73NCNJ0[S\P*@0?I@_I6DE5F:Z1Z9[+8Z)-JC1H7A0]?5K23QA+:*\'5
M<3M_![VG5XZ7R>UOL_7N/"N*M*WAT?ZVP0R>H5_=S^:N[PS(L;:^3QO$\>]I
M_!UC23*W+E/B-MN)+:E)4%C&"/\ PQ7O0RIS1X&HQ;59N8\((0G..!77*?)R
M17!)##>.0*G>/:P %L^%U7T(XH[$%]: 'J@U0CO&R.'$\^])OC@?ZC:I3+:P
MC?N5Z)YI1P7ZV*651X2%*>!1NX2?0G!-9RSX8JY2Z"+F^4B%)O\ ;(()E3&4
M8\BL$_MFO/S>,:'!W+^G_)U8]+JLWTQ_J96\=J^F;:H;BN2-X! 1D)]Z\C4?
MBO1Q<8QC?/\ ?N=^+P/42MY>$:&1*FW;3_QVG7TI>>;WLA8X^G->QDS3UFEW
MZ3AG%#'#39MN7HYV=,]JU[2K^(7IF(I*O %>8]L=:^$AX=X]JLLGGDVD^.7_
M ,'TGY[PW!':H\LZ#;H$YBULV^^O,SW%)"7%[,#;Z8]?>OO/#M XZ7R]3R?+
MZK5QCGWX51"A]G>D(;ZW6[&TO<K>.\&X9/M7-A_#VAYGM]V=.3Q?5S5;B]BV
MQF''+$-AF.TH_(T-@'TKV,.'3Z15%'G9,F;.[DQ]H*1X%ND@>77'Z^=7>*<F
MTB=SBJ8Z"IP;4A2<>M5.%KABMOEBN\P,@$^XJ'E@O<O:V-NS(K0/>/)'ZUS3
MUN*/U/@TC@G+I%:]J2VIW-,/I=> X0GG)]*X,OC&"/&#DZ5H,G;%LSIDM("6
M$M!7XB>1^E/'KL^6/,:7SR+R%B=R97ZCO']F[4]=YSBW4-D92!Z_2IUNHGI\
M6\O1Z=9\NU&4M.H=.:S677)*FG"G&"[CCZ5\O+-C\2;AGEM2Y_NSWIZ7+HJR
M8XW_  (-TBL6R8MAA[[K&4J)Z_KYU\[K?#8*3\N=_P COT^H\R*\Q40CN2CO
M"$E)/X17C9=)*#6XZXJ/_P"-D]ER*XA+1=0G(R=QP:UQ8DN#.:FN:'91M3;(
M9&UUTY*4  D_^%=^)0ASNIF$5DE/U+@R\BXW@2>[9MI80D'"L"N><I9,E2D>
MQBT^#;=GGCMNFR9-^1"GJW=XCD>M?0Z./E8]T#HRQCMC \Q]H'9TEEU5T@,J
M)R5%./.OH='X@VMLCQM3X<GZHCW9'9VHFJ[1,G,!2%R$-.(4.25'CCTK75:Q
M0]*.?\C2WGUFT[HJQVZT1"BSP$N!L*<'<[L^V:[]#X9'/C62?N?+:OQ'(LC@
MF<V[?K9\ Y;I$,QFVG =K.P#'[5Y6LT"P9N#T=#JWDPTSF<?43$:%\-(M[:R
MCE)2.0:Y<F&;:/0Q3C39/M5\B[3N80WN\P>:SEBDBMZ9;-RV5C>VI"\_A/I4
M<KL*3Z$O1HLK'>-8P?PBM8Y7$B42MFZ<@/94AL[O+<*Z89W[F3QV54C2JL!8
M0@[>@\JKS-P;:"D1Y$:UN1TQ4I"LY*136.,U;#S''A&#_LRF0A;"\H*E$G/!
MZTI::,BEG:+6!I",E^,PT^KNFT?>9/57M7!ET>1-N)UX]5"DI%1J&]2K1=?@
MX:ED))3GR.*P_+9TC?S\+)Z=92&$),I(Z#I1CU.:#J0Y8,35HL(>I&KJ I+9
M"3QG;BO0AXI&'$D<4M,GPB9\1:EJ6U\6C<!ZULO$H2?*,)Z":Z&Q'0OQ19*2
M1T&>:[8:C#DC1R/3YH.WT.19$A#J1W17X@DD*/G1%1O@4FZY/2N@'H^G-*JF
MSWU-(+>?&?/RZU[6FA*2/#U.2"?)5:MO<:?9)+Z+@T&U-E86E8.?;ZUZ$Y^5
M \Z#>7)2(?9;K&RQ+:AFX7 []V-RO,5Y*\0DY-,]>>AV14H^YU:-<+/<!WD2
M>RX#CHL<5W8M9&79R3TTT/.PVG0-J]V/)/-;O4PZLR>&428VVA+8&< <9H;C
M,24D.I *04GBHNGM+Y[,=KZS1;XB/ FI21NR/I7S_B>%RY/4T63:>7?M(27^
MR<6RZZ=DN)6X]LV@\?\ PJR\,U$L+.C4X%EC;.T]BNMG-5Z<3(>DMNN%02<'
MG.*^FTVJEJ>SPLVGC@?!U%0VG!%;V9[0<>6*+#:#Q?D4?THWAM!E?^Z7^U&\
M-I2A.WGK799S[;%).XXQ2;!1H4$DU-E"@CU-.P#"4BBP%A&1D4MP4'W1/F*6
MX=!=V?44['M!L/M3L-HL(..M3N'M!L/K2L-H-A]:DH,(P<YH 50*Q*^E-!=B
M@SA.[</I2<Z=4/:0KE.CP(KC[RTI*1X<GJ?0>M$I[%9,>71S2]ZWU%<(,PP&
M5L_#<*+F >>F!YUPSR/(Z1WPQJ"MF89/:;9>\6X[>Y,!P!]URR(3\0WD?D<&
M5# _":%CE!VQN<9+LLXVJXU]LBAIKM'EO2E/)CIC3U-,20L\*W-N;5#!]N?+
M-5EEOC2#&E%VU9QOMRLU\M-_D6MQ]J7(=0P'Y"D^'U*>//%>#JDXO:V?0:%Q
ME!-*B3:!_9?1YCQ64QGK@CO5L_B ]!7!++NC1W>6G(PUWF-0HL&,B$EQR3OE
MN%T[RE0/"2!YUFEN-G)1XH<LT*VWKO#<9CCB6"'"E)X4X>F/:LY0KHTCDLQG
M;$I=RG1+9&(S%22\0?"G'X?<URX$GR=<VZHQ6E-+-2]5P[="*GWISH0DA)VG
M')XZUZ$>(VSCFO5P=[[2VT_P^!IR(, %*W\=,#DC^E>9-TW([<2W\'E[M$E,
M7;54AMS.Q+^U(]BG ']*VTZ:0]1)2=&+$4PHB8[Z>.\5A/F$CG-=L9<G!/JA
MVTW!IJZV.:Z^>^VK941^(9R/Z&MY>I'+%.,E)LO='PY@[4+LTA*_AY%HDE+:
M3U\\FC(U*"-,:K(_T(^BH,J8FV%;(;8BK<?.$_.]N*6P?IC-+--1X)PQW4=-
MG)1,FQ;4X]M@6I!+CJN07U?,5>M<<;7/NSM:MI>R'M23VK/IOXJ(RJ,RVC"&
MSC<O^]]#UJ'<I4:I4MR.<:?O':9J1J5+LBHMQ0C/<,$MAUL^2<'DUT0QP3Y,
M)SRR5QY!;-/ZUARUWSM0;%J#GW3D9]U)4X2>-B1T&/.M'%36W&9QC->K+P:N
M^3&676V7E]T\A("49SQC@9''3%<L8N+HWE),Q-SU"^5AAM!*E#@9'%=V.!Q[
M[+C0;??7%4M]6];"=_'3(IYOI*QR2E9O6;@8R4K?4EQTJ)P/(>]812]D;.5E
MM#6]-=,9QTM!*>\?*?\ 9M^6/[Q\JG+/TT@QQ>[D)<!-PD&?+^\:00S&8Z%*
M/S8_3FN=RK@U<;Y&=1:E;TW#,-M>U:A@('44\>-Y;)G/:<;U#=Y<\[EJ)+JL
M!(Y)_2NK%C4&9SR6B;:=-39CL:WQHSC\I_ *$#Y/^+TK;+D7:,8*W1TW7\QG
M1NA6M+1G$)>=3E\(ZA1ZC/GTK@P8WFR[V=F6?EX]J.;=GMM9>O+4Z[2BU%![
ML.H!*D*\C]*UUEJ;B@TR7U/HUFI^QOM D=]?;3;TW^!RX)4%>]81_>3U%/!F
MQ_3TR=1"=N25F&;@R&(CBI*5([MT*/>>!0QU&#YUO+EBA6U.PI9$B0ES:IIU
M[H4G( ]32Z0W+[%S9XBT1T1XQ[U8&\*' &/K7+DGN.C''C@O82'[D>=J)"T[
M0M0\*5'SJ$N:(FV^3M'93&=MT1YJY-J990XB%@G)4H^8QU'G64Y;)49TG'E'
M*?MPV )U-I[5D=:ER[M"0CNT C=+CK WC/!&T#CK7NZ%7C/#U5^8FC@':"I^
M^:6GIB;5OMN)<<V@^%0(*\#J<\_M75BI2,9O<BIG7#X8)G-_,XPVVH9Z*.#G
M] ,UI*/()\'I#L(O,2/;[-&F+PM:W72?RA?&\^U>%J\;<G1[6GRJ.-)GK?LH
MCNWK62[2VV4E#RGB]T*&"D84D^M9PC*#5'-J&G%R^#T59;Q+^)CO3$-M.MJ5
M'D[1RI25;4D^Y24G-=N/5/S$F>-ETVZ#:?!N67$*058V^(\&OHW"3/%@TQ2G
M GD-J(]<<5FU).J&VD,F0 H!3:@5'CSR*Z&MD;,MUNJ$NRV6$[G5I3_Q* _Q
MKG>JP1^N:1L\$ZN*L3_%XAB?&MJ4XR 3N;&[I]*QAK,>3$\T>D:3PSQY%BDN
M3FMX[>K3&<>C0;/*ENM': XR0LGZ 5\QE_%<92EBA@E^MJCWH^ 2C!9)9(_I
MR;:RW%[4E@;GQV'+>Z^CD*;P4G]:]G%EU&NT7H>U_<\O-CQ:;+ZE:,O_ &$U
MI=@MJZ:I6AL+)20"<CRKYC%X!XEJ)-3S+;__ -'L0\4T6''Z,3O^!8PNRJTL
M@*N$V1+7CDDX!KT<7X7C'_/E?]_<Y9^.3_\ Q12+J+HZQ12 U;HYQYK1DUZF
M#P/P_ ]T<=O[TSAR>*:W)PY\%TAHH0EH;,)_N>5>OCQJ"VQ5(XW)R=R"$4%P
MJ2D >6*J$?*M1]R74I*3]@U-[,=\,D<Y"<U,Y>U\%249NT@PZ@C*2,#CTK/S
M<<.-U%;;&UW"*A1:4\G>.J<9-*6ITZ][#R\GL$B0%'<EA1!\ZP>IQM^E,I8?
M=L9D*GKSW.$_6L9O/D^AT;1C!=D5V%<'!XI"W,<X5P/Z5SRT^:?[W]1QS8X^
MQ#>TW)N(RY+# \TM9P1Z<USOPG/E=2FJ_B;K70@N(NR9:],VRU<QXVY:OF6L
MY/Z5WZ?P?3Z;E*V<\];ER]\%H&2D^#:$^F.:[I+C;5(YW*<NV5FIK<]<K-)A
ML+2'%IP,IS_2N/Q?!^9TSC!\G5X;FCI\Z<SSM+LK^G-0H%X2ID9"O, \^HXK
M\NU<'@CY>5/CW1^CX9XM5CO%),T%RU;;6241HZGEI&#CFO'>K2=8['B\,\UW
MD:*>3K&Z2F-C5O<2E/&0 ,5+\0W<9#T<?A>'$_3)!0[^B4WW$HJ0YG&XGFML
M>IQSZ#-H_+]1L])V>*B0)Y>4LH!/C.:]/20PSGYDV?-^(9E%.*5 OEZB?%%,
MA0;6K*0E(_:N[/'1Y'Z>&1H<.9+=N5'F3MLT!.U%J'^(VJYEIUK/A6"=Q]L5
MZ>B2AC2JT=.7-NGV8NU:1U4&_AKI; ^T..^W@#ZG-9ZJ-<PX/0TN:,E4B_L7
M9,B1J"TR(Z&FMDQAPY.1PKGI7#BEFSY;;X-=9/%CPU7)]"FL-M-%(2I)0$=0
M*_4M$]V!1CQ1^0ZCTYG)KLYWVNZ!NVM/A5VTMCX-*LJ4<C]A7EZ[%*>3<>CI
M,T(0VG!YVDK[:W7F)-O<46NJ@#@\^59*"DJVG=&>U7N*MR(\V<*:<0OTK&>"
MS2.4#3TV.HEIS!QC!]*Y9Z5LWAG2?))8OL]E?WBBH>U82TS1LLJD74;4K*PE
M,E*AZ'(KGECE$T319?Q.$X@=W);&?(TE-Q[0.%],4PZV\C:I*7$Y/(I[Y3?'
M!#BHO:^0G;%:WP75([M9''&=WTQ26HE%[2_*35E6]9]IW1R!@8P>O[5TK427
M#1D\4;[,M<]&/NRQ-?2D\YQCDUT0R*?L1+&X^Y6SM--2/"MA0 XJ/R\)%+-+
MIDU^TP[58.[@H(=4",UC+P^$G;-UJ4ET9BW:7E_#NW&0\1M22.O%83TOP:1U
M'R0;3J9NSO2') 6LMYVG/%4M--?2P_,0DJ8]IOM57<;IL1;W.X:7E1R/*O;T
M7AV6;ML^<\0\2Q8KBD:KM"[7;MJ&.U9X27688"=Z"KT\^*^MT^G\F-R/CM3J
M7FDE#Y,[9YLXL&.W<EAI0Y0M9.*\?6ZR%N"/IO#_  ^:@LDF:* N3'0 T]O
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M['IKM(US>>SO3<*ZP;<U+1W@:6E?7IG.:^OS>(9-+BC1^?8=-CU6:29RV/\
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M";C*MKK2H3KR-N])W1U\\*]4J_>O3U&"X[D>1I=0][BSNF@=*L/K9N=Q6EQ
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ML/K5D'><"L)+.F:1G&N!*=/7&*>]@W)$A/EDYIJ4OWAMH:D7.[V]2OCK6A]
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MYL8K3-@PZM1=DO+/$_0B[A-=PPRP1GNTXSGVK[G28(X<45$\[,][<GV2JZC
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M#9/T%<[TZEPD=$<^WELP_:-H41K2)"$J0E*=P(XQ^M7BTS@PR:F,T<8Q</\
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MGSN&2F:JQ:@:N#:%%0\0W"IRZ?9T;8\UFD8F-E(\0&/*N5XSI4[)'?1]A4H
MJ/\ 6LG%HT31"D22@?=?L*FAV5=Q<7\$6R#N)SBA/DKV,Q'BKBRG+D65!,4%
M)5Y 5CF=JB9QI[C(=L6HU2+Y"O;T%-VN4&&BW)=#P8:;2XL%#:P/YF<Y.?(U
M>D3V./29S9FMR?;.$=H)D1%RU.M]V]"?[LMH/@2O/.".N,U[^@DJH\;Q).*:
M,[:(;LYOO\$N$C %>AEEMX//TT+C9K[1'6Q,:8&=V<%-<&:?!Z>&-,V=P*K?
M9W'VTGO'?NT_6O+B[FST_I@:SLOMBHT)*&T%3BE@C'FH]17%J7;-]/':CT3I
M31L)%V8N]S&RV0(JG92U#PA85EM/ZJZ^U>;-NJ79V2E2H]9=CS3TN3/O@1\.
MU+;C);1Y9YW8_7^E=WAT/6J/F_%,FV&UHW.M[]>+(N,J,R25 92!SFE^(=9G
MQ95#%[?\'%X%HL&>,GE]RKTYKK5,Z]LV^;;2AE:\J\/.T^=<.@\;UDM7#%([
MM;X-HX:>>6)UA&Q*$I1\H''TK].MRYEV?$I)*D*R*!E5=F&7;>ZW<(X=9<.=
MA'0UYOB^.&73NSHT#RK,J9QEVZ0@^\XU%;2D.J0,#RZ&OQ#716'+)(_2(0R2
MQK<6%HOJ&7V^[005+2$_O75X?DVY8(Y]=I_V3.S-@*0"1TP?Z5^X8.<<6?G>
M14V+K<S!0 * !0 * !0 * !0 * !0 ,&@ 8-  H$U8G;N3A*L$5G@=8T.:Y1
MS+4N'KU-"'@?'@X\B!7XG^));M?D7_R?]3[GPOTZ>)71(ZT'!R<_TKPXH[IR
M$R6%MO@K=R%=!Z5H^"L4TXL<6C[O?@$CSSR*=\$)IR&4+=[LJ7N)R>2,<54+
MNS3:FZ,AVHS.[T?);<5C<E0&?.NK3-O(CM\.Q*&6SR[:]Z7"2.5$G^M>_EY1
M]%BXF7T1IU2B5.;1FO/FST*XL]%?9>0I4J]R%)/##*,^^37U/X-7[67]_)\#
M^/Y?^GP+[R_V/1#717M7Z)/I'YO%W.156PYU!<P.H+7^%>?'_--9?2B]/0_6
MNU]HP8C!JA '6IE]+*B46MGS%TE>) 5@MPW3_P"]KAU__M)'1H_\Y(\.H/>)
M2XI>=^5?UKX>/#/LG]*-YV06H7+6\!LH)#3@<)],5T:57E1QZR6V#/6D]LN.
M,)2,CO?\J^NS+U+]$?+PE:9+0WW:B!TKHPQX,Y.Q#Z4);><W#GK[4:I4D/$^
M144%,?:K@XZ5>'_+'EY8X.@K9=&(ESYA0QHXY]I-Q*-!-QEJ"?B+BV$@^8S_
M ,J^3_%\O_31K^^&?7_@N-ZV5_WRCS;!*XKQ;:22#7YWFE>.)^M8U61AJ>=<
ME#*3UQ5X^(F=7.SJOV;&%2->/O*02(T)63Z#.*^B_#4?_6O_ /Q?^Q\?^-LB
M>A4?_DO]ST\@8>6XK@$#G]#7Z-#A'Y6,V\A4?(/XU4X>JT*2&;Y9(%_@K@7%
MGO&E>0ZBL<F%2-L<W!\'-;GV VMU17:IKC>1PE?0&N5XIQ=1.AZB^RNM_8),
M;EE-QN3:X^#G9UJ<F/-1:U$:/.';CV$HAZVEL65Q:DEA!.?(^E>;#Q!X,LL<
M_8]*&E_,8U->YQ>/V9Z@B:AV.,!T-]?#TKI6NCD9FM XODWN@.SV>N\S;F[;
MW0TA.-^.*6+*G*BIPVFV0T&>'/#CUK;)R9Q8M""HY&"/K2H5CZ&QN&>E"B.Z
M,-VWO.1M&N%LE)[I6#5I<B7)X\^.D?[ZM#2C[D76Z6^U1G)=REMQ8[(W.NNG
M:A*?J>,U[F.+DN#Y=R2[/"_VI?M2Z<U$M&G=*O=Y&9>"FP\]AIUQ&<+4GSP>
M0/4"NC'"49<FEQ4>.SR?J/4LJXK,NX,.A:G \XAX[5O>94<'&TGG@5VII+DQ
MEN;*.5J"Y2I*),Q"7E27 D%I/B2C\(5Z4MP#SMS,B[?PR0Y%C.MH6M'=I!4I
MS'51]:+YH9+3?G+@RO:VV_<CM94ZD86A X)I[R6N30P8,IUQ(N#P=CJ;VL;5
M;UK('50' _6GN^14_89>E0;'I]4F9+9=?2M2AWJ<[E9("1C(&!CRJDU5B:KL
MPU^AVB1"1?V)"F9P3X^[.&W1[J/17I@4W'BS.[%V.^O3K%_&X+4=#[9+:V5C
MO% #C<HJ^7/ZYJH2DE82C%\#]FUM"D7926[G*D["'G4NH*RC'D ,<>_2MXYT
MGV<\L5DR[733][BW.XL27V'(JMR%J(.0>NWRQ2<HRMHM1:*"=KZ(F:Q_#GT3
M@EG8&]OA0K'S>X]JB61>PTN>3/IU==Y9^'EZ@D3WG72GX9*5(0WZ#/G]!Q6.
M]OW+X*I]-\D.2@Y$<F(;(+B%LY#0]5#K^YJ6VQ\%O!99M7=_#SE!IQ)20WR4
MJ(Z GA(]>M+HM&>?5$;NS;2+DRHI4$N*&4*;]<$C_#K4,T0B3.>::EQPP7!&
M)6EQT!!<!Z$J.32D^**BJ=G2>R'54.RR+Q:A)*V6;. ^X=R5 *5N64Y^?S!!
MX.*X<^.4UZ3LQ343.6:#:E?Q*9IE^"Z9+I*E.@E49K))*A^'CD)\JVBI/'M,
MYN.ZT>FNQ&W65SL+O$JW2';I\3<SW[R1M6^EM/.T==HX^M?-^*W">UGNZ!;\
M5HR\.<Y:->6:[M]]\>T"N*UM(2T,\@CSW#S\J,>#]C:*GF3G2[+7MKO\>W7N
MQV&+<6XJ'6WKD^PH92%/CPJ4>F!U]JG2893;X(U.9025G W>T*U:ANL9<.Y1
MW;A& B293[2BS*V$A V8VA.> :]"6&45T<4<F_HZEV%=B[=_U3)O5S>E2E)_
MUB6IU\J#.>=@3TVIQQ7!J).71W8(^4=NUE=K3&+-IMJ6F8[([A25IP5>X/3-
M>1FB[L]7#D<ER>>M1H=;=EWCN2ISO^YBIVX(0#UQ],U6-IO::/TIR9G?@9C?
MQ%X4IMER8E$2*DJ 4IL'*CCJ/UKNC2X9Q2N3M'4-"V-&G.S1JVLK+WQ+JWLG
M@N**CA/Z UYFJFI9#T=-#9C*Q=LD.R56> "MY:D(4D#"DK4< $^0&>O2LH?^
M4NC3)RJ1!UI.MR^U#379=8T%4&S)._NSG>^D9?=W=#D^$>U=ZCLPO++W.-N\
MRA'I'/-8Z@O:=02@TII+:W#M"1G"<X&!5Z>*<1:C(T[._P#9'*_L)H6;K_59
M.Q+2DP6B,=X\<!/]36>>.^6R(L4JBYLX9K:]7;4EW??NSW?/.+[Q1SD GG&>
MG'2NS#%8THD6Y<LZI]FFQI93>[H[X'Y$)T1L^:4CGGRK@\4?43NT:7+1F-31
M<R!;HGR+/C)_$2,J(/ZUU8$XI-'--6Z.-:CFZA[+=4B\V=;BH:L%YA9RE8]1
MZ*KVL*AECR>7G>3%+T'>] Z^T_K"''E;  ^WO!Z'TSCZUYF;39(NJ/8T^6.H
MQ^9'HZ"F*N,$X&4*Y2L<_K7-]#J79JJ<>#1:;U(6R8<Y8QT254I8G+E!'*H<
M2.IZ:=B)B]XH)&[D&DG3VDSY5HK]2S@7MJ"@@<\*K#+%LZ].BCB2$HDI?2D*
M /-<+79ZB7!<N@7F2TF0$I;2DA)) SG%8)I.D3-7V>5>W"TH5K:6(R@0@C&T
M\5]+X<_V5,^>\059>!O1=Q>90AIUT^$XKIRX[[,L62CI%MGA0_F9->?D@CT,
M<U19HF H W<UQ3@SHC(6B0G/WG^%92X1T1Y$R&TO-%Y7#8_$K@5SN5ND6^.6
M4MA[4- Z$M6I]5W9IF?*VIA6N&\DJ8DR#\Q5ZXZYK*6FRZB:QKV[.>6ICC4I
MGEQ^_P Z=J/,/O5)1+5.9:*0IK?NW$A)Z\\ 'RKW88H88>OWX/)CEE)W']34
MZKTTY-T1J&Y7&#%?U#,G]XY'AJ)3'9#8<6X!TX&,I\B:PTN=+4**Z.G58=^!
MRE]5G+=#;7;M&@K(!4ZDD'R3GD_UKV=5;CN1XVG53VG1I]I3&U'),='W00%M
MJ\CTKRIY/33/6CCJ7!HE6]-W9C0VAN#F/T6>!7$KBW)G7*FDCH6A[0JT3T6Z
M2@AR/XE@<X5^E<>5[N3LQI)4CN6HK@Y;[=I;3[:DH;O$.XS9BL@9++66TY^H
MKG6/AS^*,M]S47]STG]G"]1+KI.&PZ>[<GQ6);?]Y8'C /MP:Z_#IQCD<?N>
M%XS%RVS1V206Y=WCQY*$*0GJ",\UVYU#-KU":XI?T/(BWAT[E!\E=.CK7K*"
MAO<T@,J)0D#&?K4:C20Q^*P\M=?]%X<TWX?-3[9KV<]TC.<X\^M?9R:D[1X$
M5MBDQS!I%%9>2M=O\2,#!YW5Y'CC<=.]AV>'SEYRM'#6FVH\194-RB\YGZ%5
M?B.KFE.4LGL?I6.4Y12HM(C'<O1RXW@*<0$G'J16FCENSXXQ]_\ @Y=9D4\<
MDO8[<A7(0/0$_M7[WIH[<,4^S\TFVYL76P@4 "@ 4 "@ 4 "@ 4 "@ 4 *H
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MDYQFK3MV76U4>@NQ)F,G3FLKG@[+)9WG&DI''CX ^N:\_7K=E@ON=FG=1DS
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MIT?B#)[=D-ZM\>.[!+[AWK)0[]V$YXY/.X>GG558D:!I+T>'\%;%I;?A-A*
MXX&PC:<X4KS.?*J&6%MCS;W"_M%<66XJ6UCOTNJ(WJ/F/5)Q32;Y!ES<;/(<
MC?'P(Z&D)2%*?2/YB"<8%:;&U:(W4):@662Q,M$AMSOV4!]0VD(3QXD[_P Q
MH\N^!;N29I]:'K?%AMSVF&K>V5I2I(*$ISD)"QR5>OO655P:(H^U%4JZ/L.N
M.RF0VTE"7EG>@[O3' 'K4WR*2LXW?)S;=IE--*84EE:6\%[Q9SRK;^*K;X(4
M&C 2W7E2E/,RE!UL!2%J1XDK!]?(8K"S8NTN_P 80S.4RA2U(^^\DA7ZU2Y
M?MMTD+>+#Q*&<G">[*0HCH"1Y?2F@9H-.]U/D*MWQ3RV4G<TIC*%()ZG:,8/
MU-:19E+@M[>PQ"7)AL34(F!P!"Y+9+@1^+:X/ #CW-4G\$63[Y/C0$1[>ZT]
M.DE)/>(66V%)(\T8R5#WX]*<N.!QY9B;I=XUS2U;@AYQ>#NCJ3L*5@\* %9,
MV2*\0W')9[S8TL@*6EQ65DCT2.,"IJQM#%U2\U'>B)DJ:*2E1;6<I4>N<"DU
M0(K6I$B\W$CXE<= 2 <)V[@/(8X-)<=@^6:6RR?OE*"%+,8@!M/@*T^>5_A^
MGG5-6AIT=8^S3VF,:3[4F+7=I"C#O#RK:^%I+;8;<&4(QC)(5Z^]>9XE@>3#
M2[/0T&11R4S8:VTM/[/M83[W!MOQ\.\=XQ;);2MP2HK^5U/0 '("3[&O,T>9
M9EY3[.W5X7@?F7:.,:EA_"37)<%M#R8[W=SB7BI32E'Y5?F'^!KT%%Q>TXMR
MER+1KJVV&RN_!2B\M,A#4M#1.<_[-H_W?,XIO$Y.@>90XHL.Q:TZ]U;JB1/O
M$GNH3DGXEM:21GRV)23E*,>HKS_$)PQQ9W>'XYY9([!V@W.TZ;MS-O@2E/S0
MZ%O(:&0@9ZD]*\7!>5W['M9ZQ1VWR7FM-//:PL]MAVAL/+DM-K3[@X!-88WY
M>5V=66#GB5&\#UL[)[9;[7;MK=Q8C#OE)QE'')KDSYO-R;37#C6*"DSANKKT
M](:D7>Y);?WK5EQS."DG-:0@_,4$5EDO+<CG7:_JJ?;]*Z=T[$<,<W$JN,G!
MP4)Y2VG].#]*^AT6GJ3D_8^;UF9MQB=&TM'AZ+["K7;[JKNINL9OQ;B]IW*;
M:'&?8JY_6N/,O/U+V_NG=ADL6))_O%/VJSE::TRB/ =$>;>VPP_*2HA3,=1R
MYC'3( I^'^K))?#%XDG""DO<PG9S;/\ S)%N#R5MF0J2A(SR$E7@4<^HKIU4
MDG2.?2)J.Z1H(P;:DH0E2E%K#9!ZD^U3&+VIG2WS2/2VDK&]HW[.M[NZT[9E
M^E-L=W^,L'S^F:XIUFU,:]CJQO9C:^3E=MBK;BQVT$!"0I!SZE6>*[TZ(:XI
M%U=81F6=,()^4Y-$/3*REN2HY!J;2$MJ="U?IQ*FKM;%E!<;.%J0>OZ^E=D)
M^Q.JTBU,=R7J.C]A&O\ 2R=!S=.:ZGM-714IUXO71W*'@>B03P,>AZ^59Y$T
M[1YG[;"DDZ^32WGL6S8F+YIBZ_!W1U9>4E3A4PZV?EV>:<_M5PRIJI(VAJE'
MZ^SGTJXZKM>^/J*R/+6SX0_'3O&?3<.*4\:D_2=<9X\G*X8NVZV1'<0M33W!
MSM<2<)/O6<L-KLTC]F:^)KN_7]A49Z\R&(>=OPC*-J%)]>.<5R3TRNUR:J<H
MKUND-W"7HZRLER[W.+":'B)6Z"3_ -GK4QPY'PC.4\?1CIFNK#/?6C35NES4
M@\/! 2@_3/-;QP3Q_4S";4OI0W=;DN9;E,R82TJ6CP!('"_+-=.-T<DDRRTJ
MF=$9C-3@0K:,_P#.C-79MCM<,Z?:X2P@2E@=V?EP>2/6O'S9.3OQQ;Y$ZJO:
M;5:)<EZ0!'92 RUG/>.5PNY2X.V'"Y.%QHDB_BZ.274)?4KXD=XK 2<X S^M
M;K(H48N%IV<>UA#N=MU=<X$AQIEUE/<*[MT.)*P>B5)R%?I7N89+)A21X.HQ
MRAE_0[WV./6S42+/HN3/;MMK1,C"YW%QXM)BL;P5J*AT5Z5XN7%MU/F/WX/6
M>64]*XPXI'M3MRO/9[K?M7T38+7J:WW:QWR Y:;HM-P'PRTLJ[R.77!P%$IP
M,^M<^K;DFL?#1AX>UBAOS1NSYU=O>F(=A[2K];;2RMF Q.<,9"E;AW2B2"#Y
MCR!'6O6T$VL24NS+4QN;I%[V,AJ79KG;&R,M$K0%>F./_@]ZYM?PTSJT3I-$
MR:T\U*@W..DA;+R5K]4@'G]C7'%<<G4W[HZ^P_:=1P8T9Q>$O)*'C^*,\#PX
M?;ITYYKC:<'9UI)H[/H@HU9IJ7I6]!@MR(BX,I#P\"E)_EJX_-BB/IY1CD=]
MH[;HO2:=3:9?T>$HAE5K1W*TCQ19C7A2L>F0$CZ5,(;I4CAU.:4:G\?W_H;_
M +!=5SYT.3I.\A*+S:%%N8SC 0OT2/R\9!]Z]7PY..2.-OJW_,\GQ>$<D/.A
MT=)1A_4A>0> QS^^*WFF_$O,3X__ $>6I+\JXEZG!2,5]))^YYZJ@\>]).Q\
M&?U84FU**G @[%<'Z5\Y^(VEBH]7PC_-1R-AX,, H0I:QYI'6ORAXMKE\GWF
M;FO@N+!?KI/N-O@J;7M4Z"2KR379X;J99]=BC_XT<&LT<,&&>7CE'7&E;O%@
M^+^E?MUTHH_/8O=N:':8 H %  H %  H &/>@ ]IQFDG;H'P$ :3E4MH+D*H
M\WFFF50-V"!@]:U]K(;IT+- Q)!QQBIDK5 )\>>HJFHR5,$V#8C/R #^[P:R
MC@ACY@N2M[?812H<()Y]5&KN?M1+"::[O=E2O%_>)IW)_4)JPU-(/EGZT-6)
M07N!*-HQM3CV%34D_2S3T55!A"0<@5>Z7N9[(IC;JAL</=?(,Y Y-99IY(QX
M96.,9SIH@1RW.;[UI"$<9( \588<[;Y1OGTV."YLE15#8IM]"<*ZD$\U=PQW
M2,8.=4Q]I62K[U)!XQFG"2:8]DD[&H]O9C/NOM#Q/K*U^YQ@5,<>U]E/):HD
MXKHB_8S;L .*IJ@$/+(2,-J7ST%1+E-(-VTR>O7V/X(J!,MJY;$M10M(&=J<
M9YQ7C^);LF%XUPST?#H;<F]G-3V<]FEWVOLL.0W!C<$I4.??->!'3MPVWR>X
MM0XOE&Q[/-+V+2'>LVN:VXEWE2BL9'MCZ5W>'Q>F=RY//\0G^87I5&N_BB5S
MU?#+#HX''K7=EU499U2?1Q0PM8JD6T=3A:WNIPH9)%>SBFMAY\H^HHYMX8DW
MABVM.['0<J2HUYLM5&6=XTCOC@DL2R/HT:3X<>@KTX+;&V<-VZ$[36@AMX;D
MDCTH!.N3S;]I*8E6J+"P..ZBO.*S[D8_PK\[_%TMV3;\?]GZ;^ \=1GE]G?^
MQR"))6Y/0E"@ 5<U\95+D^]FW+TH7>'VMA4V/$!@'WKT\6%Y7M3./SO+Q4U_
M=G>/LJ1U"TWZ62"EQY"!^B*^J_"L/5.7QP?GOXXR;\^/]'_4[BX=L)2CY&OM
M/8^%]QUH;6D)]LU<!,<!Q5B$.*"3GU&*45NE0.6Q;F,E>UW!!\8X]L5A)..*
M;'U-?<\:ZR3*7K:Y7*/*(#DU>4Y]\5^<RS++)TC[S#A>/"E9VCLGEN1X+S:6
MPJ0X0=^.*]CPU;7;/)UT=W3.GVI:R^%K\NHKW-&O6>5J)>FBY20X>.,5[614
M>9%BL\]*7J+](;I'=*\(5QT/G1).2H(I-GFS[7T&VL:1M]V9C;98G)2 CS2.
M#7RGC$8XW3/J?PW.4YO['G7^.G_<NU\3Y$3]+_.?9GEJQZ#OCEQD250'5M+(
M2!LV%L'J%I\L^1K]ZC%V?@;1,8[/W(>I'+:5O//[>]BMAP (5Z>A/-:;*=$(
MUFF^SAUR065OI;CA1+X=2%@KZY!/S?7]*N./D&R?>D0(EK+2V8]P6R]W82O&
M5*/R@)R,#CK5I*B),H57BZ1'3,N:$Q;='20VUMRV7?3</(#^M6K7+,Y,SC%V
M?NK4QBRN-*BLC=(=6LI<<*S@*P>,#Z^5':X%?)(M%T8T_%,.<&IH2KP$MEM&
M_P T^><^5<\O3V;Q=D>[76W7*RN0E2FE2'G%)#<9)2A!/1*U=>*S5/@KW..Z
MBM7\-G3%3[+ 0\T!W94Z70WM]_.A\#,M.29]N7,<#06L[=C:3G=^WZUDQD&T
M.M,/-HN4A00ZHI0S\RG,>?'RT)@;$,-Y")\=]MI20MM8\2$#R5Y5H#)"[TQ-
M#"8T6,\$J")3@.U;A!X4K;C@>E59FT:!^_2HD$2FXC6%+.QQK!V@="IL\)SY
M'J:NZ1&TIQ=6'&\R6.^2I14=P4!N/YB3G]J3&N'9#7?FD*="[<&ULG(;> 2E
M Z @CDBI;-$RI5*7.<+MO:47UJ4VM*00A7LD]:E_8H#]N>D. *M\UN0E 2Y'
M#>U*4CH,GG'UJ6FP#M.G;A<98^%1;;='9&S>[(_%YG:,FDHL"Z&D("GPB;K)
M"$E0\,5!.5>92?(_7BJJ@";&GH%V;<1%EW*3%<.Q^3)* D\8.1Z>7G[U$DII
MIE*3A31V7_I6B7JP2D7*8XVRXX(L]2#]Y%?VC8^D?WAT_6O#RX-F2X'L8L_F
M8ZF<6UI/O^C[^S;9KC2H[[:E"4PI*6Y3*N>\R0=W')\Z]"&5/']S@FG%EUHW
M30FW!YRY27G5R5**&FX>4N,JP$JR!R??RKBU.J\N''9V:;#YW9V*,YH_LLLS
ML&PVU,:X.)^]<+I=SG\.XG(KYZ4LFJ?/1[\80TJX[.:ZDU#*O*%.( :96YL0
MM'^V<\T_05TPAY:.>4WDD>DOLVHD7ZP#^(H6%V9D]ZYGG>?EQZ#->?JX[/6C
MT=-DW)092:UEB;-F7&8LC*UH=*SG8E/4UY\%OFJ.^:4(-L\X3M9R>T+M(B:?
MMR@;/ 0M3VSY7$)\_;G%?28M,L6#<^SYV6JEFR;?8R7:C=U:@U?WAQA?=Q4D
M'PL-C Q^P)KT])A<<5GF:C,I94>CNVZXMPD6RUP9#;D73ULA26V W_-94R,E
M)\LGFO)QXFLLG\GJ9<J>U+V*'M(LZ-:6FU2VDIV.*0GP#A*5)&0?6N##-X,D
ME]SOU$%GQ19S/M'U,WI*V_!0'4M/+PVRD>:T\#Z5[&CQ/.]TCR-?F6"*C$/L
MZU"F_/QBXK_6VWDA])YPKJ3]*Z\^#;=#TFH4J3[/9%SOJKKV1Q-KH*%W PF1
MCA+:$?-CSR2:\*&/;F/4G/<K1B6+6@1VT!."A63Q75NY-$N";!9*W"IT?=<B
MJL:,=.M3]KEO[=W</+&%CQ#Z5MC]1U8<Z3Y*:]]F=DU*HR6RU%>4 5E: I*U
M#H2#Q6CN)U3TN+5<?)&;O_:[H**J%;=0K?@L@[$R63(8 /ECJ!Z8/%0Y1L\K
M5>$Y,?T\FETU]HNUQ;%'@:JTV\Q+0LF0Y;T)7%>)ZJ(5@H/MS2>Y]'G/!.$:
M95.]O.AH*;J^]HD.3<K^ \2%H=21@%>!X>3G;[=:N,4^S)8]0OH.,/I[5]81
MVK8PZN'!?4IQ;C64KPH_+D8(2!6WF8\7)K#0ZW-QEZ]C5Z1[$&N]0NY]_**"
M"KOEJ6,_J:QR:N*5(]/'H/*CZCH\FR0;%%#%OCI2[C:D(& !7/',\G)G.ET6
MVG["VS'^(F-!QYS\*AG JG.C*,#10=-+N#WQ'PW=L-8WN+X2/8>M<V;4&\<5
MLN9,O3EC987?+@B)"4OD%6''DCJ$#S^M>7*4IOCL[(QC%>IG*>T[M$M>N]0-
M6_25N^"L%L/<PRZG:\O=\RG#^(^]*,'C3W=DRR[VJZ+%>F(#5B%WLS"9T>,&
MXSZ7D\=ZKJ,?B X.>,US/*]VU\&TXIQW1Y1CNWC3.E=23H5ZTS;(]FN+B5,R
M;8EHC=+:3RM!'&%_,$CD8YKO\*S9,4-N5W]SBUN.&6>Z'#^#E U8K0$J%IEB
M1 FB$H/2I3:-V[?R6\>?H003Z5[#Q+/"4E\'G9,SPS4/8]F]@UD[*NU-4?XF
MU&$[<T-L-S;6X6RU*Z-K4W\J@#\P(KY_(LF&53?!ZD\F.>+=C7*.)_::L28%
MZ;C.RV)$NS+?L<KNV4(4DLKX4K;@'.?F(YS7HZ.7/V.;-)3A9S[LBGN0-1A*
M5X:DC8H>IXQ_45MK(;H$Z=[9';H>FOXH_-$&(7Y&U<^,@='DI'WS7U\P?:O(
MW4J9Z%>Z(%I0]9+\8BR?@;PV'F%GC<2.?^7U%3/U1^Z+@VG7LSO'9U,;6=SI
M*7U(2A:?-13\BOVKGY29K)*K9Z.[/+H]#U'$N0=VJE1^Y=/X"Z"""H>8QY>M
M/#*F>/K(.2:1L-:1E:-U[;.TJVL!MJ8ZB!<TIX#K:AA+F?(IKJ6Z.;S5TSCP
MI9\#T\NT=5ALEVX_Q!C"F%1O 0?FYKVM-@C+)YC9X>:X+86H*DA(QE)\P>E>
MW')&3I'"X27 L[L93S^M.62,.P49&<UDVJ1#(4T0$ME6X'S]*^4\>3RX]Q[/
MAGHR69&R1URK:ZEN$E3N"A/NKH*^-T7A\M7&5+I'O:S5^7-.RTTOHZ[0[@Q/
MFEM*6CDH Y_>O3\(\ GBSK,T<FN\5CFPO$GV;I"=@V_M7Z7VD?*16UM"ZDH%
M  H % !*.T9QF@ D**ADC% !*2HG(5B@!$B8F%&<?DC#;0Z@YS^E<^KS+3X7
MD9ICCO>U"F9:)#0>;Y24A7Z5AI=2LVG\XJ>-P=,CH>R5!IQM:@K:4A?(/4 _
MIS77@U6+51N#,)XIPY):"2 3Y&I@VY-,N--"ZV) >: "(Q0 5   S0 ",4 "
M@ 4 "@!MU>T*!'*D[0 ,YI2JN1[75Q(42((;9V!*5*]5\_M7-4;X-<;D_K"N
M#GP47XEP_I6>7A%15ND4\.Z)WB8I_"5G'=G_ )UA')1OLXHNHUUAON%#3Z5+
M3U&ZK\\R>(>,@*>21T^M-9^1/%2) 6#STK>.;<9[!#JO#X3SG@9QDUIYJARP
M2VD29<8<0I1+6TG=U2I0)/L/6E.6"4;FQ)9V[BA8A0'E[41FB@@$\#!KFCCT
MF=U!\HTEDRJK&O[.V<N*=-KCI4.A Y-7+28XKTC6:?R-P;/%MLA;S*<A1R$^
ME<L-.I9-S-99M\*+)I_#;CSPPD?X5Z61K% Y%'<Z1SY+34KM)8GL*.Q2,D>M
M?/8Y*6JD_N>QD6W2I'14JP2,5])^XCPX_4P]WM5(8VX3E;0'.TX_:@3Z/)_V
MF3(&M8Z]V S;T<>F3S7Y[^)HK)J&C]0_!#<-);_OHY';I3BM[K84K9SD"OGY
M:-RB?90UD(RY!\6J0ZD$G(6.#YC-=.+%+'F?Z?[&&3-">*U_?)ZF^RTR6M$S
MW%IY>G.8/L !7TOX5@U#)+[_ .Q^;?C+)NU4(_"_W.P2O!#6WUR1S7UQ\??)
M( V[4^B!5P$&!FK ;?&,?6C']?\  G+]"&)"BAM3F.4-K(]^*PR_Y$S5?7 ^
M?>J^TV)9]3RXUPBO[OC5\CD?,?:O@,&FWQ4D?;SS;8T>L^QZ;9INE6;I'.%O
M-)5XASR*]O0Q4>&>'K)2;X.A6I]D+.59YKTM'_F,\_4?26[?A.?6O:R>QY\1
M=(H"CN!% X]G!OM.(C*L5G;=0%*5*6K!^E?&_B*5,^R_!\'+)+^_D\^?",?[
MI'_=KXC>?HOEG,(L2WV]I]^WR9RWEI\:$MES=[+7_P#!BOZ%4JZ/P*K*2[V_
M3UE9CS)7Q,B1+5N,=E2>]R?1><)%7&O<B7"M&>O&HKI)DI1;$("D)V[%N=VA
MH>F[H5>P^M4[?1%E"[$L]P05+<9G2UYRAM_H1\R21Y=.G6G&*(G(RU]FQKT5
M-N71QWN#W<F!#<V)&!X0KZ>W)H;LBC,//W%$J*FX2GHK.PMB,I8VK]-P'0@4
MMS]QJ/N:%I]:4,P;MJ):DD)[ALH"&RWYJW=2H>51+[LM<%7JEE%M)1;&EK9?
M5M0ZV3O<5Y*/M[UFXUT6G9C;W+O$=AZ#<[>F.MXE25)VI64>86<]*F5^Y:Y,
M[%?N*>[3$6\EA VA0QLV^0R?\?,5FQE/=50R]AW:9)45 M' !]AY5(&_TU)_
MM'9RDJ2M2$I9<:><2I*BGSR.?TZ5K%V)D"9;%6N0TR^MIE<Q&2RWA?<I.1R.
MNX>E40:2!9U1(K$-F;'DN.-AW#BONTI!^9YW\:O0#I6BX$2QI[1ZE/7&\SU7
M!]OAQ@J*&V_0A0X*?ZT-Q[8F9V[Z[TO&28"[;#?;_"]'3PWCH23R:AS7P4D5
MLSM/A/15MQ7X[?@2C,;[H*Q^(@>=2\A=44EP[14&,F.U*D2G0.58VJ(]"H=?
MUI>8.B"UVB.-I[MN&IOPXP!GGW..:6\39#3JN8ZEUPP$-NJ4%(<"B"G'MTH<
MA6(MC\Z[ST+N5N=DI6Z%K6T\6RG^\1T.,5FVT6N39VLBXQ+Q;92G&$W%2TMD
MKRIQ32=[8W>HYKE<>;9TQEQ2'(3]EU38&]$7MMYYN.%.6J9G^2YYMDG\)]*Y
MY1\N6\W4UE2BT=[[,M*W%GLZ9OL%A2+A,!@LL.*)= :')3SA.>M>3J\JG/D]
MG1X]D=R.)=IVJ7-.W)NQM)<672KXAY;AVAWT.??TKHTFGC/%OLY-;J98LFRC
M>:>L1<TYHE;P[V.N.W/>= \.YQ>,J]O*N#43^I'?@ZC+V/5W8^S&TM?[I8%K
M;";E;VGTH'&XMN'?C]Q7GZAO)ISMP^G468#MJL;IM-_B6Q>QZ7N#"B/""KUQ
MY>]>?H);<L4ST]8O,PR2/(NCV3I(7R:W'4S*4Y\#L<24[5]5X)ZC/G7V$I+/
M*,4?)1AY*E.1A+S,?7*G D+0M[[XE6"$@<X_K7M8H+;L9X>:3\SS$=[AZNCW
MSLFTIVB79TJ7;N\TI>3\RBEL$Q75 _AVG"O3 KQY0V9G%'K8Y[\2R,T?9E>5
M2;:_:)SZ7DMH^)C/).4J;YR$_0\5XVOPO%+S$>UH<OG0\M_J>>>U%+\N\'O5
M%T!U10K/\LY-?2:!Q6),^;U^^65I^Q5:8U._I;4GQ^XAE:$MOI\RC\PKLR8E
ML.;#J'')9[0T_JZ/=>R>'\)(;7W$I#F KR/XC]:^?R87#);/IL&99(<&VM38
MNC:'4#:',$XYVYKFFMO)Z>/UDI5O[EPLC.PYXJ8RLTE"BAD0U1$*B _=*_,,
MXKIPO:8QR.+Z*"8DQ,H:^\3YY%=6[<>AAS1Z(O\ $WVU J3A XV_A_:H>)2.
MGSJ][$NM6.2@%RW1\_B^['BK*4&EP.,X2?J2("--Z:+Z7V+/'2L) .UL $>I
M'K6+W+MCN"^E&IL^GW7T!,..$-)Y4K;C ]*Q<DB<F>5*C1(B1;:QW;?B7CQ*
MQUK'MG!.3?9GDPDRYZUK!R.4C%=":2X.?;%]LU%IL[B]BY! R<)&,E7L*SR9
M> A%6#6&M--Z'AB*^A^=<'1]Q$84%!"O5SR%<NW>KLUG-8W\G&=1LWGM.GLK
MU%-;8<"B8I;!"X_T'DGV\S51VXU<3FR3E/ZAG1UGUQIV^?PZRZ.@ZV3 <5ET
M/=TZIK&2C8KC>D>6>:)X89([I2VV5CS2CPHV=+U!JG5$'45O7IGL:N-JL2T-
M.RF[Z\EAR0^CD.*0G(+.>#@YXKC_ "N-Q>[);-WJ,JEZ<=(SUMTO=O[8-3]0
M+:NETDS47-AMD?ZNPM2N$1_3 Z#KCK5:C*GC:BJ0]/%+(I2=OLY]]JCLNE6K
M6D?5]LM7P:[BVLO.,I2$K=0<EST!'G79X-KGY?EOFC#Q710ED\V+[^Q5_9YU
MEJ'1>I$/(1)24N!2FSYJ\E-E/GY^]5XK".:#HST+ECGM:-1]J34]DU-KY^ZV
M%X.?&Q6532D;!\6$_>' ZY//L16/A4)K'4S7Q#9&?H.1Z=E.09#$E)*5(>!S
M7I9/6MK.:'R>NNQ^X-W!ZTR&5 .1SNW=<@_,/H37A:B.QM'H87O:0KMATD(F
MEY-RAC8W9+N6T+2.4M.D*V_0*_QK''+G]4:S_P#'X9L=*3V%"T7;N0RB=$;?
M4H'\2?"?ZBL;<;B;SK)R>@HBE0YT!+: $/,"6W@]0@9./K_E6?TJT<;6Z5,Z
MA*?&K--.QI<E B2H:BWGE2%XR%#WJO/WI1;HXIZ?RLKG$M=!W:[7/2[,-AY)
M>A(1LY_FH'AY].E=N+)D<'&+/-U&*,,JG-=CL/M2@VJ8]:[PM??-@D)]J>'Q
MJ>FELG&ZXLO)X1+,O,Q>Y3SOM"VU^?\ PZRVMUP]"M9P,TM7^(IM7&"_F:Z7
M\/RGQE=?P-?I;42]::33<764-EQ)1@DG.*[(ZA^(:1N4:.#4X%H-4H1=EWI^
MUMVZ$D)\1=.XY'2O0\&\-CH\.^[W'!K]4\N7;7"+7NU;PHNJP/+RKW8U&.U(
MX:>ZQ9&5!6>E)<*@:MV'0,%  H % !8YS0 9()X&* !0!47Y09M\E0 ._&23
MTQ[5\O\ BO6/2>&SG%7S7/'LSLT6/=E5=E''U2VFWF.E*4N;0,IR1^OG7P/A
MWX[Q8],]#CBI3J^_G]/T/6S^%9)O=9RK[.LK6]SUIVF:BU/'E,6R7?V(UG;D
M9&$--;5+2#^$\5]K^#-/GCI%DS\-V_\ 5\?P,/&I+'E\K'S5?T1Z #RDR0T4
M !0*LYK[&*]#G+AV>$UMR*"^+).[VH*!N]J  3F@ J  #B@ $YJ6Z %+< 1.
M*3FP&U.J!P$Y_6EYC^!T9[6E_GV/3\RXV]E"G&0#E1Z&N7499*+I'J>$:7%J
M]0L6231QBW=O.IF7"94)MX9\D]:\Z&IDGT?=ZC\'Z>4$X9&OX&E:[=;1<(WP
MUSMDA'JH'.*J>M4^)(\R?X-U./F$DRP9U]HJY0^Y8G!M7JL8Q4QRP?N>?E\
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M<'&3Y&LK920I^S6G!"V$*< PAQ!'B]<C'%(JA+46*A#49ED?=@EQ9'./:@*
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M*/\ =GS-RQ:S-BR/E5_0Z!'R^EJ05<J3G],UU9?VD%%?*9EA3?[27P3*98*
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M1Q;J(:6HMVB&1 =2Z5-O(!VG!/0@CE/E7HZ/*W#;\&>J@HSW)<,IKK"M\.%
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M2AH**.Z?*CSO'Y?0GFJ3IB'[C*@+U \\J>OX5U&WX1Y)VNJ\D((_"/(^=#[
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M4)>!*S]?*L9ZN/NC58MPU_:-/_J!?_N+G_TM8?F_L;>6C&(TC&GD7 J>>80
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M^6AMZI'Q\Y7DD_NQN,IM9DLE6%JX_2E=097PSPW]KG2;4W7L=I\+=V,9&XY
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MKX;8!3\@_>O(G*>62C7!VY)0P)2OEG1>SQ</1^DV]27:0SL;W-I2KD;EIRI
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MYS_V?TK?62E".U^Z,='CQY7Z>K3_ )'A70]K=U#IQ^YPTI<UCKRZ"Y14D_\
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MVM#JE%Q82=Z5I/"./3RQ7!K'<+9Z&CC)3J!KK'V?72R=IB6V8ZE12ZEU&""
M1\I'N.GTKY7595L^Y]7IL33]1V'54A.M==L6Z*R1;M/Q@^XTCG=*4-H!]QG/
MZ5QX6L>.Y/EG1)/)/T]+^I>3H4U,(W/NTNP(2?A5R=X <;QXUI/XB#U YJ=C
MNT-YH_2V97L/<_M)J&[O2W (JK@B4T<'PI;&S:/^(8_:GGA+A1['AEZ92ET>
MN>R!N*O73B2V@./1'5[",[?(5Z'AF"$IM9?9'A^,Y)>5</D[<^XMF"!M2LH
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M>5XCI<V'%ZC5-*=V))">GG7T<JMG@0<]J'1O]$U!HG(/</2H\N)5A8-)XU7
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M;KM;HJ7;:U#=-P5E"E'Y8Z4],G\/OYDFE:7 %U8+PS.MTF.]);FW-QDI#A:
M0PTDYSGRQY>9HNQDAN\6E^VH2]+F?#A9 EJ42H \9;3GC/.2?:G%H1A+I B6
M);@>6J8RX\%H==;&4-D\%M.,J)/)-%4!FIZY\UY]EMU4G:@K2@KW.!>?(?3'
M Z4AG1-,6YU-G,>0\TH-)+G<NIVJ:)'&XGJCSK2*X$5#J+@B$6K5,?D+1D!(
M .]1/. ?P^A/-3^@R"W;+[8)&76>X;* IY)PK(ZC<?PYI4T,1=WV[DXJZN!
MGL[7$/M)[IL\8#:AZ(ZYJ6[ 7#DNP8K$2Y?^<'EN[TG"E(2DC)4H#CCT_>A
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ML[5%'A601C;Z BLW("+$;89M;C+<6:(SA6B%'^(*49'S*[S.5$'DI''K2N@
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M3#\DM6S/ZA=0X\&%CPGS\Z^1\?D\K4/O_P GL:&.WU(YOK:S-W1Q"$A6U/'
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M#EP/E$U17G QD=:UC-O(X>QDEQ814L=?2K@W*;7L)\#C9)2":H$ ]:!@H /
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M6F62:VF,%-/=([#JF]Z5[5M23=42]:/:?N5V;CIN]N<MZWT..( 2%1G4_AP
MH)5C:<]17(\>T[-RR<ME;JBY66<NW:?LC28UITPRY$8?> ,B6IP[W'5D'PYQ
M@)\LU441)#"%$QE6]"-[:(J74R,@ */.WGSQ0^ 2'[((+3:'EJ)=>2I(;6E*
MDG(X('D>.M%V4D7MENC<>2P66.]W)*UG9M*DYX/!SU)H*+F.W#8CLPE.I6@S
MN[<0=P"$X)2C)'(\1\^*9+-Y8F8<C3+SS\'X.7M7'4&TX1W@Z9&>.,'-6NB3
MGLFW.,*4TZ\)+C32U/*;^4Y^7CIGVK+W+B8>_P *&_;&'4+DH4@G?@>$$=1_
ME1[EOHS+2F!*7)2$J0XG:"4]:TZ,#0:=[QEIII3!++)45A/4@],#_&LV;P-E
M;K="F.LW!Y:O@EA+;:6<E:%$]"/0]<U)HS(=K$ID:E9MPF.+3!C;0D'H":T1
MSR=E+"0AT;0O9M3N!QD@^O-2RX&TU!&=L%BM]@?2WWD]Q-P4E*L[&?P?3)YK
M.2-UPC<]A.F/XOJ>!.EL8BPY.XHQ\R1SSZ\UA);O2:PXY/L']F]YNY]E$&8R
MD=RIZ3W9W<YWXKSI:9Y=-.*^_P#0RU&5+);)6I]/SE/F2(_>!:B#QT%?EF3P
M;/I=1+._<^H\/UV*4% =[/93\:^&WJ40A;15M(\QT_QKW_PMJYY-;LD_[IF/
MCN&#P[XFSO\ >'[+%;G[2M"'4I?P/PGC/M7W7B&7\O%Y%\GRNEQK)<2X8<;?
M;#B2%)4 H$>A%=&CR>9B63Y,LL*X'4C KJ,D'@4#!@4 "@ 8%  H8 ('7TJ)
M\P:0ZN5E!-M3$^>M+R H)P>N*^(U'A,M3J^#UL>H>/"DBTC0VXJ$I!X P!7T
M_A^C6EC3/.SYG-DKC:,=*]!/U,Q7/8VN.R_PX#CV)%<\M*F]QHLM<(7L2VD(
M0, 5M'E40^P D56T0841T-2U0$:8M02O!_V2J3&CGP)4HY]37.^S<O[!%/+R
MAR.AIHM&A2 GI0(.@81X!-0)C*G%9QGBKQJY4)]$0K/><FMH/M&:[&5(67%.
MJ/.*\UXUYS9Z474"EN3:G=G><I+J=P]LUX>II9T=>"7I+&8P'H[J4YY4G;R?
M(5]7-WBA_$\S'S.1.BE1;:W')"<&G#LJ9RS[1SH%JLS1)P7G"1GKX>*^6_%T
MJP17W_V/M/P)CO5YI?\ Q7]3BMM;$EQ+6< J2"?K7Q$5;BS]#U,]C?Z/^AZT
MMEO1 T[;HA^5EEL=?;-?K?A\-FCBOL?A.?)YVKE+[GEN3WC^H[PMQ&[?.=43
MCT40*^>U4_VI])%;<2)#]BB2^9<8.#'GFDLUG+"#CR87M*[*XDZQF?"\:%)4
M2UC)3Q71BS-2-9I3C3/,4G1<FQW%;J&RZQG*TG@I%>HLZ:/)R:9Q9;R+4S&;
M9FQ5%+A&=M3++:H<<6WDT-B_UA "AX@.M0C=%JY9I-X4F$T,J)S5.XJT+(K1
M$N79O>XRBE"TMJQQO!Q0IR.=Q-QV!=E5Y8UPQ?)Q;4U&Y);&!SZ_M71B>Y.S
M&4?<]_Z4<0+8E*U!*E#:/KBM<4HJ1RYX2H@:X>;L]G5.?E):0R0MQP^0')J=
M1I'KM0HKX%I<GE0:9\L/M,=L;NKM97)Q$C>AD+1'RG<D)2#XL#C/'4U^@Z#;
MH<&SW./57/A'FI[4:%RUOOJ2N8AO[M:UX* ?,C\9J):MR=G+#%4:*]IZ,W&4
M_/<989"2E92V2I2?G<"1_>40-WD.*A9;[+V#<B>CNUN.=VE:D)6\V$DK5SEM
MA/KQUI[Q;1!:<7'?CRYBV <.2U)/A6>O<M^B?(T.7 5R./(<<<)6>[>?0$N*
M0<MQ6!^3ZC^M2W8R#_Z4C^(,M%0#GPL!*B1GU)]CC@^Q-3M]P#47%)4-J5-0
M1RGIWKQ/'/F!Q^IJ7P A<:6O$#<4OOCOICR#@-I'1 \QZ>O!J>2H]C2ISC8=
MNK:U.-G_ %6 SYK4>.\]O0^U+[E5[#+D=31;L[L@)4?OYKR>-V?^?3Z"I]Z?
M1,@_B KOKBYG<Y_J\%KH%XX!QY _X"A.^7_ D;+6P)M27L1XZ#*FO9X))_$?
MJ,?2I?/'\2E\C"'U/*<NCN[O9.&HJ3Y)\UX]_P# 4MW[Q0ESNMSD<* CQ4(=
M6I/5;OD,?U/Z5/V]@&BIU@..*;(ESOF]6D?Y #D^YI7P XY(;1W(;1EJ$G:$
MD9W.>ON<TK 0#(++<-<@@J/?RW/R)(X1^E%A8ZW(G(1WS:U-&0G8VD*Y0@?B
M-"G8R3,7;KO'6E+?P<ALI0'T=7!Y\=.:4J? NBJD0IMN=2MQL$MG8TD'PI]5
M?6LF@[&OCWO]\JH%1T1VW3HS3<==[2UM2EI;:25+V#H..N/.M.1C=QO=J;"9
M)9>?DMN@LN/?*K .1M]"?\J38$4N1Q:2XF2\A<\+?6I6=^<\Y(Y2GZ4_8"ON
M2]]Q1'2A?<ME'=)[D-!2MN<D#G'UJ& 4RV)2TJ=)ENMMJ;&]AM)\7/*B?+GB
M@"A<8F-S\QV41X[R2X&@YNR$CPI]O/BI8$"8M*MDE2-K[GB6/P@^E( @IAV0
M$OH0I13QCI0 S*AL]UO9."D8(7\HH"AJ%<'4$-.LA"D_*H?Y4Z N+7,;?#K+
MAP<[FTC@_04 6DD9B?$QF4 J'B*AT'KQT^E# @.J>:9#H8*D.^!8\T^^?2I8
M+L;6^Q'?2%I2CO0<J_3BI+(#O)[MQWG=N"O/'I30F+@;%WAIQQTLM)!R_D?=
MY&,U1)+2A#5P"8R\M]Y@NIX#JO,XH MURC,C]XRZR)+;APXXK"N/(>5 #4UV
M00F5)4VMX)V%"% A..1T]:3&FR)%3-6]WK:1'*@DJ0'"G'.<8^M921HBRDR9
MZ+FI08[XOX(!"5(/'.2?/-9TBD[#N=K4U&^(-U:C[T]XF*I'RGTH')&3FPOB
M5)4^L+)&3Z5<694-1X+,>;X% <5M9#2)B)O>J6 @MMI.Q:QQG-3)%1X9K[1
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MP\1B_<F>CG[#*;K.9(DR8KD<M+R KQ>+INKLCJU+HY98)(GP[Y'"]P:2ZJ&
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MZS#5%&%%)R  L^(G_E30F,LA4DD?#IPD;%)QQQYU1(^PE45H/.)4X=Q./2@
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MOOI#J6HR4C.5D\<4KY*1LOX#K3_U#_\ \*?(RT7<H2W22_->2EE1<?5'W)"
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MPB;&NDL7%0RYR.[S^M=VFUD<4:DJ)>LFWPC+O?9.O+36&I[P6//</\JZ%XI
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M*FD9;7O*]H*#MR"#[UHC BK3*;2=J 5 9&#S5 *+#[C3"BXI96=SC?3Q>N:
M2MDYQE$5LL3X9>;&%I.>4E72I13X&'),9#;#GW@D(=X3MQQ['RJC-,N['=I,
M.0N0K/@4HI=5T2L= ,?YU)LI,V%XEPKC!CW)26&79[02IQ"-JG5],* X!SYB
MH9M[&5M"T)O14]L83'):#:U'\/4*QR<^N*<40R5H>7*M&NWRAX]TRH*" ,A:
M"?D_0\Y-6256H6!&U;>HBD[4_$$X'0!8R/ZTO<0GLQ2\C6,26);K1BSF^]2T
MO!4,\)!]^GZTV-'>]/3;<YKN\VE,1QM@S''8C*D#:K<G);6#CQ$YY]JS?91G
M^TBS2+C:9W=*4\MK[H @A3B4\@>><)/KY5?L29+LTL$M5[:=N-O6<R6U-+'(
M&1RX<=,8Z5$@.Q]J3Z2ZB Y)4ZRQ';0O#?R$CQ$>N1CB@9PV^K996(D%U+:=
MWXA@[:!HH&>\:D+BM.N/*4LKV!!X0>I/H*0&HM6DT7?"&4*C-N$#?[>I!_RI
MB9UJ3%0[98FF74OE2<%;;"LA6!QSZGK28[.9]IMR9%Y:@7*8V[;M.+"'896,
MO2%) [O^\!M S]:(HSDS&6M<VZ3G[FXTIMUX[!E. T/( >?UJI%09?/3'6HS
M4%Y <0<*40<9/E_6ILUH?A*CP?OWG%-I:6""$[AN!R!],\4,$B7"BNMJ[E:F
MU./R,MD^04?,>E+H35G8;-89G\'6$VQ]4.1M0-B,H1M_"!Z9S6,LNUFRQVC1
MZ8TQ8FRJ-,AH2"" 5MIX%9O45[&L<7!NQIWLUC6CX!]+!6H@AP("2D_I5QU:
M7<3.>%-]T874?9E"O-R-PT_J]MA*4A(:2:RGJD_W1K!_\C>=B>D[[IK4#4N[
M7$2&T_*HC<<>U>?JI>:N$=NF?E/EGI63K&YH3F)WRTI& 5("B/;Z5XSA),]N
M$H27(BT:VU5(GH;0MQM*%9 4SX#5^A?7V3*%_3T=6M/:)>V AN3:X;BDCE:>
M,_I5QRXU['!ETCE[FCC:_P"_QO@L-J/7Q'K5K+CNZ.9Z.2X3+%C7 *=RHZL#
MCA0KHCJ<2.>6@FQQC7$ G[Q3_P"]:?FL1E^1RDP:RM9&?B0/?;0M5BL/R.1<
ML?:U9:',?^<V\^Z"*T_,82/RTO@=_CEO>.$SHZQ^4'&:3RXI<(/)E'FAU,J,
MO^6EM?LE0)J?2*IBBM*@/]6IJ,9=A<D)6VVI.5L!/UI^5!@LDD17(K2VU%+.
M2/2I<%'HM9&^REE-KW[5,8&*Y<B1T1;(JHJ%_P"QXK#HU38CX,XVAM(3[IHL
MH97;&5'Q-H_[E4IM"&%V9M?_ ,3,X_X13\P.AMZRAP84H'']T5FGD0>8R(YI
MN,\H+<;62.1RFMM^2J$LC&).D;?)2H/Q K<.0I*2#]>*RBLB_>-?.95N=FFG
M7CEVS1B/,!L5NIY%^\"S5R0I79#I24DMKL44I/.%-Y%5YF3_ ,BOS+*63]G?
M0,E14YIJ&2?,)(J9:C+CY4K''4T5$K[*O9U(.Y5G"?9H[:<==E13U**YS[(7
M9Z\2$-2V3_=<K7_$,BCR"U";H>L/V0="6FZMW5<B:X8IWMMK7E*E>A]JZ(Z[
M?A<6-9U#(F:&1V7R8SRRAIL)6KO E*@ D'RKY'4^'^>W,^NT?C\=/!09(LT3
M4&C+NY<;<D$=WL S71X;IY:62://\6\3Q:Z.U@U]VB:PO%E>MJ;7&65X&5 @
MGZU]!GU+R1IGS>#'''*XG+Y&J^T!*4Q6[#;BPVD)&2O.17#!J+NSKG/<B"-1
M:]4?O--VS]UU>]?)E1+:U%KPI*%:7MN%#!X71O0#T:;J8$!W3-NS_=<6#^AJ
M-WW)X)Z9M\4-KFF6<'KB4NC=?%B=>P^V[/7PO36/^&4<_P!13HFR4$.N-A*]
M.O#_ /RO_"@ C;G',?\ F)Y&/,2,T#W4._#2VH[[<>W.(#C12HJ7G]JJ/ I2
MX/1'9/:7[+H.V1'!A2D%9&>F37LZ*'I;/'SSN9K0HEQ0/4IJT^3%\GG3[4^E
MV[UI^7(?*0AI(4X%G"5-[>?_ (58Y\E'H:3E4>#],2HK%KGZ9$]+S<%[O(HS
MG<RL_A]P201Y<5Y^6%R\P]?3SI;"HFH_ASFT9V+/A6H8'Z4X.S67!-L[#4IW
M>>GJ:ESHN,$S;6QVSP4A:P'"GA22.*G<V;*$4'*N]H<7A@ML)'1)'"O8GR%:
MVS)I DWB B(DJD0$A')PXH_T\Z:;L*1A]3WN(V#\.Y$<*B,*"E CGWK:+9G.
M*]C!7:ZR''NY(0 ><A7%6G9C)45#CQ+FT$$'KS3(L9D.E([MD DTXNB9*RJG
MVY+K"]_*CY5KCG3(G!-4<YOMD;;<+JFDN ?@5DCZXZ9KT<6HVJCS,VG,X^V^
MVHNQEK#J1L2I9!2A)ZX2*]''D4T>5D@X,C*?0E6&VL):.]+21@O*QR?8>=7+
MA\$)MKD-D]ZC<'BHASO'5#IG\OTJ: -2EJ66TX!E*W.<_P IL>7ZT&B' E$D
M!PCN^]7X_P"XRGS^AQ0 0;!4MP$[,=^L'C _ G]:JRQ):R2@*VA"@HGSR?+Z
M4K'8'$GE\J.]6 JE8AS<KUH <N6A+O9GG5I8^(9;!*BSE6T8]*E4C)IE'&<&
M[!6E(/(SYTTTP<:)K4I#2PIT+QY$=*"209;N2IM?S?+F@!Z%/2X'$NI2I21D
M9]: L<,C#:%G:E:ARD'D^] QQ$]M.&ULD ^HYH"Q_$4H"D$CUI 1W'T-J22E
M10?3K3 "'9+S;C*V%I0OY2.N* (<E[N2&&LMH'IUH KYKCCH)2#C'-,2(#9&
M<$&A,9:-)3'"<Y)5TQ1V(?2V.$*YW'(Q28AQG^9@#@'% QT-)2"EWR.>/>@=
M#B66&]A.4DG<">A2.M 4353FPTZU@*:>'!3Y#_G0!$1'CF)WKTC8$':G=QD#
MIS0"'RSF(PM,AQMSG(SG'/'-9R*CP%<G]D=*%K#BL<*'G4Q*;L@-PUS%-I:
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M@**)ZELN#JVI!R/UZ478F@T^)PNLD$*21G.,51(E4E]Y 0I21MXSYT@%B0E
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M$LT:#?&6(=S(;6-K;C39"$[^BBGGE0ZYI2!&GU983;(;-JD(;<<C8+SJ7.
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M:Z8Y;.=X6B',[MDCP*.WIS\W_%ZUO&5F;BT$B001@8.>,T-")4;O0A+22%)
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MTKHM0)5MMB&5*=D->!QO+:L923Y@UG)L=4=.T;IN#;(KNJ[\66($%M/=MN*
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MO- #@<7GYJ "43US0 630 1<*//K0 $NJ5^*@ ^\(ZDT &'B. : "*RHYS0
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M*V\J'% F4\Y<]LAL--A6XYJD)CQ<EEG8N.#L'*D\DTP&0I$F.4%Q0!'*3U%
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M:VI86VM((X+9\(]#2M1)43I'9=V47;M2U%;],:0MZOB)[V'I+HX@-)/B?7[
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MHAK(95M5X2?(T;@(3ZU%S8W\X\AU%:F9'7(=WAR1G<UXA0 ZASOCWJTG'N*
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M[U="C\H%>'DSRR.ST885%6:P\#('[5C=F@C?^8''TH -*T9\*3GZ4 +R3Y4
M.,D G)Q0 M9!/!S0 TM3H/@Z4 &WO/*^M $A)&!S0 KKTH "VP10)#?P?G0,
M/NU>6<T & _F@0HE]'BH#@-#SRE86#BBADIM9QTH&AU"LYS0,-1'K0)@21CK
M0(/?C@4%(/[T\I( ]Z !O?'&1^]!($YSXNM #O3K0 RLC(Y%  RD\;A^]  P
MD<[A^] !*<"1D$4 $W* )^E "').3QS0 CX@^E "T/%0Z4 $M63DT 1Y"SC
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M\'S!I(ECN<=0?N;+\?;P4X!*_P"[^M.F3=,U]N5$3#$6"ZCN607,K&"A9XV
M^QYR>IIT.T5J=TB0&8CA=22&PI0(#FWJI.>H))H8";C$0IW>E6XMDI(3P<IY
M_IYT@(RS##+4QAUP--A8<"\Y7N_#^_2FA/L9<BE,4HFD[ CO4[3T]?T%58AB
M1&4B.F6DA;CF%HV^0]:=@.(GM3&N[>2%+_%[FDT!!5_J@+A8PG/6J 4%2D\+
M4SW:NC0&<?M2 &T(VM>0/B!]** C&68SC@6[O3^!/I3H",[<5+^1&#ZT=!0T
MN6ZH8/\ C3L$A(E.)S@]:+ 07"3G'/K2= /Q;M*B+W+674?D)J'QV/\ 0MH=
M]C25[7-K)/0>]2USP/HGQPM2LNKR ?E]O6DQ6'/B,.;I+16-WD#C]LTTQIC$
M-:VY# D(5W:@/F\J8RWAR(S+DJ,VI"')8*&5-G)!_6HD-(FJM[Z(""Z"XEQ.
MY*B?$1ZUGN2-XK@K.^+/<K"M[:?G /4>E48E>\MCXI4II+RP3D-YZ57L%DJ:
MD]ZEUIQ:04\@GBDD'9"=9^[0M3OR_-3!HFN*C-P"ZJ."@CQ+]!_C23%17)AM
M-\,*RHC>A/L:O<%6,.6PR I2DX<'456Y"VE6$%EPA8*<''(JUST0R>F,MY "
M$[B<#@^O2AR2[#:V2$65YX?!F*M+J<D\5F\B^2U%DN!HRZ.2PRTVI!'S*4,@
MU/FI%+')^QH'&CHM2&F+9#7-([Q$ES)[M1\PGS/M6>YMC<7'LJY6I-4R752E
MNM[T\*X]?\*JD^Q=&RT5HW4\_35XU_.@O&R693:&WE#:B3/4/ PA7GP-ZL<
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MD]#CZTA"Q,*CC- "TN.+X2"?UIV \R'=QWI(X]:0#N,4 #&: &W4*)X'E33
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M>$)\JQE(NG9-[-.W6P:7>FMW^W2$Y95\(ZRA*\J\@M)_QK6$TNV1*+NST/\
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M!63XE#T_2I<32.2C062:Y)F)CQY3C 2024>?HD^]9M&T96;AFS6;6K<F%,C
MK:!6EYL?>,NA.$'W3GJFD5)6C#:HT8-*V]^=."<@! <1R@J(X -$9.Z,YP25
MG/8LR9!F_%VW<W( &5]48^E;-)]F%M,]'?9JT->^U365N:@0'&$QWDNNO#Y-
MH()R>@SBO/U.50B=NFQ>H^K$>.IA*&$#[MAI#3?/D$X-?-9)N<TSV8\1H=4A
M6T\5I8AHMJ/ XH ,,8YW9-%@&&=W446 XW&2<Y%*P#5$0>G^-%@ 00>@_K18
M!_"!/&/ZT6 8:4!@4@%B,@@$CDT #X=KTH 1M3C^7_2@T&\)/1N@&N!UIK)
MQUH,Q]$8;AA/- $EII23R*8#P!%( SS@4 *#:P,D=: ##9/44 *" !@T 'M3
MZT !* #F@!7='TH (H ZT )<2<]/.@!6#0 -I]* ##:CQB@ BG;0 5  H %
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M%I"<8:3\J@.4J63CG%0WQP4J,%:K9J&0Q-TLW#>>C7^XK=<@QTJ7(E2.=K;
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MY'-.C2,%%E%JCM0MMN:6VVIF.A7^[.U2L>OD:SCCE(J4XHP7_3A;_P#KBO\
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M(5B\GUH& A1& 30 C8X.2K/Z4VP $J-(!0210 H))H /8: %):R* #V;>,4
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MESGMW#6,Q+"TA2&D'_9_A03U''IBO/E)MVST8Q4>(\&$;L+PE[&UJ<('C4I
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M/.ZBABN[%2  V!0 %)3B@ MJ/6@ P$CIS0 8P?*@ ]Z$<*_PH ,.IQX4@B@
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M!@I?)Z3[/[^IVW-I4LE8;"B?[OI6:;4C?AQ-A,[4VM/6V0ZS;FUNMM*"5K)
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M;12 ;2\1GQ4T4A865\YIC"W*!QFDS.78?7DTT(3L/O0:+H/8G\HH&(VJ]30
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M4IL\%MM.5D>F?*F^! ;?O#Y*8+"(32NI4-RR/<GD5/JL"UCITPW'4+LH./\
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MRYCS4%!22>I2HCH:UPR<9KX,\T%*%4>>_M)(1?\ 1VE[W'0$R9$42P4<;$N
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M?0#LN[&]*=G-H1:['93#A929#KY29D]0_&ZOC'LD83CR-?!ZOQ&6MF\N7O\
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M#C(*^7 ,D^1^GM7C2DE*T>W"-JA:9;\9">J4J.!]:TCD<F6\,8JS168M26'
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M0@8QQ0-!!0/0UK%T#!E?Y32LB@!:@>AHL=,,NY'!J2Z$*7D8H&-K^6@!L<G
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M#+=N/?\ "L\=OEOL]77*:P2.^>!2LY"O+)/_ ,*O)C&CZ&N+)5F;#<Y"WD$
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M;/G\FJ<[,NF2B0]XVN^=/JHJ)KHV8\?9@]T^C5Z>T)K>_+!LFF9:T+QD]T0
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M[;?8,JX)421YFG2)M@=CNN#(5UJT@L2VA:?F--<$BCW8PE1R*=@.-G:,(X%
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MK./+%>?JM#&4>$=>#.\+]1V'4': W]H6=:W]&P4.V1]87W\915W384,]Z/\
M9J]4J]>*^;RQ>F;;/8CG69<'I&+L@,M--)&UA*&4X'R[4^7I1&:E"P<7*7!D
MO^FF+_U1K_NUR<_)T^6?)?M=T_)MMV;D(4'8Z_D6GR'OBOJ\?KB>#F]$D>NO
MLIA=U[-(=W6,]VI3)\^1Q7A:OC-1]1HWOTZF>F[/;O\ 46T8_EG;T]>:RB:2
M9?0XG=+2KUJSGD2'QSQZU:$)=6?A^[]LU3!.F9VY062K<L8)HB7+H5"8BH &
M[I[U9FNBP,Q,9A82<@=** IHUPE,-/W9D=ZYDLQ8NWF6L]1[8]::_9$R_;<$
MFZ7V>F&E^[N(BS2-FQM(5@'C ]/2LYX?S'+.G#'R48]NS01(7)3;<[Q@E7)_
MK6N*&TC+%(>;MC-H>1<+.QA25!3N?(>?]*T<[=&%4;>4W;G41YEM/^K/)&/4
M+_%6<^BXF4U9#V.ET'C8>AK)=E;MO)DK9<41]P<Z9Q5.-C4[-)%OT7"2."GH
M1Y5#3B-P4R@U[V<]FO:M:U6C5]F:W*R&KBR 'XQ/F/S#/)KHQZIPX9S9M#&:
M/!7;7V+ZJ['K\EF<7I5I?*OX;<]GA6@\85CH<"O3P95EC9X6HP/!+:SFZY#C
M(:WI;PE"<%'((\B:Z%T8$R/<8ZE;B!S5#'FY$=4KO1G[S[KCTJ6)EFS%*9:#
M(E>! "4@>E( T1OB7C"C' &2T3Z>= "95K2ML!.":%(FB*]:GE;" ,],8_RJ
ME(&C9:!L;ZGV#=&U.6^2X$J#;V%)2.5''E@ U++B.ZLOC5]MEZO\$)#-RN8@
MLNJ>RMYIO!2,>@2.?K27/(,JNS-QE=LUA<)C16VY;G%N$#Q)\6$[3]<?I3C3
M5HD@6JXR93 9<A#N-Q2M23T1@<^Q!\QTH&BUA-NPEF/;92FWF"G>\,$N,J.1
M@'@X/7UH&=-M+W\9;BVQ0@,'=(>[](/>/#C*58^;E/3RXI[D)Q;Z.H:9T?<M
M9L&Q:>BOQPPWW;LI:BE"=HY*E?B_SKEU&IC!';H_#\FH?!U6/IVUV6!%AWBY
MIDIB1/AT("0E.,Y)'ZUY>HU,LJ48GTNB\&C@DY9>4><^W[1NHNU?78O5WU=%
MC6BW1&H=OB!:G"U'3T0E/1/F<>]>O@\8CI<2T\>SS-1X-YFH<ET9*S=F>G]/
M2$B.KO2<'?)')]T^@KS-5KLN3TH[\/AV+3FQA7*';"N,,9'2N7R95N9M/(I>
MF)0ZHN%TN<=263M0 =QZ<5LHJ)R6\BL5I71<]*K3>G7DR6W)!<4@\)90C!RI
M7F3C %;X\/FNCEU&I\E-'3NT;6-_[4;C_$-77)4IV*G9&;(PEEL )2$CIP!7
M?BT4<71XV74O(^3 )L&I&7D"UK$M)/"2?E%;[MO",''<APW8V^0J%>(O</CD
MK!R/I33<A;7$L&GV'D!;3V_=T&>E:*-<L-U\"TAU"N3P>G- $A"2OYO*AH:8
M_L ;Q04-;01BI8K B.E&5$T"%M[$\T#%N+\\<4 ,I<">#YT 24=V!G/(I@)4
ME1^\2KI[TR1/=*4=ZC0 E9\>ST&:!AH46O$><\4 $J2<G _I0 M3R7$I&#NQ
MQQ0 62V,.$Y/- #C#0D'NT).[Z4_N2XVS=]GO9->M8S&BS#=>84^F.2ALDK<
M5\C:/[W4GR Y\JSEEKHT4$NST5;9FE^R:+/[/^Q1%KOFMH[W=W[5\I ?M5@R
M,=VDI_G2@,[6$<[AN64I'.-^8W8TGDX]CBVL>TNS=FR[C8-$IN>I]9:B*G;M
M=I3@?N5Q4.KLIX\,LI'1 PV@8QD\UAEU-^F'\SJCIET<!N5QU!-N7\:5%EZK
MU ,EHQX+KT2!_P#(.,.*_P#:']*XIS;.A(8L?9_VH:]N^9]EOR0ZH+43%6GC
MZD5DYKI&B@WRST5H#L6NFD[:7H.DER9BTX[V8XD;#ZUDXSD^S:,H1]B\B=GV
MI[BKN]6ZWMEO;WY1%;<05 #G&$\U<<;3Y%.::-G%TE8XR$(3>84HH3C<5[ ?
M>M/*3,O,HFQ]/VA#A6)<9HD?.TLJ)]J?Y>+!9F+D:8M+S1:_BX'>>9J'IXH?
MG,K1IZSVX%"IR7_<D<5G+"BXYF,NKL3/S3D-D>7!S64L5&JRV8OM"UGI^T6P
ML,S/B)#W#;:?7]*A1:=%N2HY=*U!+@L;W^)DD<(SGND__"YJ^R.C$ZDGN[1E
MTK_O$_-5IF<C.VQM5WF,PF>52)"6ZINB4K='1.T(IL4%^:ACQ1F6FV6\_P P
M]$I_SK*')K-4<(N0NBI;UQFOA^2^H$_3TKJ2^#!]\E/>-30[ TIZ2\"\H'#
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M9^<>*PE*<HXOJY('8K,M6G;=<KL],90A$C>ZL*'A0GDDU\]^.LF+(HXH=_\
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MS3*B6EM7O:<4HJ5C&T'%"9H:&%'0"@KP5'D"DP.S=@Z2-:1YP;(7 8=>0<9
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MD@CRQTH[8HLS4IZ0^6'Y#[R'I#*I*UM+ #JE*\.#Y%!V^^#6+=RH=FWA:=U
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MRVYS20#K4.2\<)841ZXJE%L5FMTU8VDQ&I3J/&XDJ.3[U25(E\C%XCXGMO\
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MN!82<80*A%(5>VRS<%GH5@9]ZH3(]P?^$L^P'!*3TI4A'.WU%;F5$DD^=9S
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M:9=6Y%O@7*:T69CC9!D-H24DMI_$.<;CP":X=5.T=."/)Z"_Z$.SG_UG>/\
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M-REN9Z.'&DJ-E:G2D)"N3CUJTK0Y<.C0M?#$#/6BB6PW ASPA(HH5D65& /
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M<K2NI(=ZBN%)9< 7CS03S3AP[+C+;),]?=H?V@BWHR!!T^TT^S=HW=R$*YP
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M6FB7#O!2D%(.#FDY6*A_4@<M-D:5.U(_(>6TD[5$$HR,[?ZTK!&-M=D5>Y8
M*BE:@2:&!UBTZ8B6R.@NCQ8P/I5*(UR5/:'"M4+2\R0-H>6D(2">3FHRI*+*
M79SF'K61;(ZH\.!'7O;2E2U)R>$@<UEOI*A5;*1RXON/+>6 %+45$)Z?I361
M^X;17\2D+;*2YBFI6%415K2M:U'SZ5+:;8Z"8:=DO-QX[:G'75!"$)&2I1.
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MCKD>E5-PGV:1@WT?,WML^SB.S!Z=J?L&[5F]96)E)?7![Q3%VA-A6"%)( ?
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MI@0;BM$>08 ;>6I3>Y22KG'K]*5T#*Y:BPR>Y9:(0,;,<XJDS-HA@K6"_'9
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MI19.VB\_BB?]PW2W$T>(J]T\4%  H 5Q6D1,6C;G*N?:M(\=DL>4V[WC6\$
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M;3@?B/G]:YE[HZ&WPSSM8VGKFI15&4E/X3^:B@NR]_@$C_<N56T7)XDKVSQ
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M' G>WA2AW@V^A\J8QAU;"$)?2HE!5A7UH1+&7"U.6[&V%;S?C(1\P3Y8I]B
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M'8ZTTVV"4+))Z<4<C2H2["<DJ2"GUH']70I4$0$E.Q).-P.1^W]*EAM/6/\
MH_\ 73LS3>K.S21)R-/3V[S!!/(C/C8XD>P7Y4X]G'GB]UGLIAQ4Q"7'$)2
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MLV+BT\A(!4A"U8)!Z&K4D%$\RVUN+:6M.Y(V[<?,GV/0TW3$0)]M;;:<FM+
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M.1>P<0G9XLTDPVI 4_Y$9HL8E+F3R*.PZ%!P>E%"L'!-- $%#)SQ2 <;9?D
M_#M;]OS<]*7;X 96G83D<U:9C(96DG)IC2X E*DTTJ&'WE*@W,4EX@T4&XD-
M/^5)HJ,B8A[< *S<392LD(<(Z*J=HR4T\0>3DBI:!*RPC3UI&U2CY=#_ (U$
M\:FJ9K&6TS.LNS/3FLFU24,IB7 CAUD8R?<5Y&L\(AF]4>SIQYJ.'Z@TQJC0
MLC$V.5Q\X2\$\'Z^E?.9]/ETSJ:LZ8S4NA%MU RXK8IS8M7!]#6.Y-\%_J:&
M)<_ARAMOH??I33 L#<@"2IP@>B1D55D"T3-O@;=RDC@?6G8%O#N!0$,.N)66
MD[DC'"?8&M%(181;AN;6  $E1*T'D*S_ (52$+N$5]24%GNUI(RYQ^'T]J'$
M"I>:*!E6T-E/AP?F]ZSDJ&$&F2T&U\%?7C.!4 5DRTL.NE*$=ZV$YW'J#28R
MHAK9BOI7'9"5)44D$]/>L7+DWQP-=;I"Y6Q"$@K]AUHHZEP:BU6UYA0<D-;5
M$Y QY4TBK1IFHLEW8X. GVJT)\LL/X>96&Y" K(W9STI,:1,$*.R\AJ,I+BP
M,$ XP:ELT7 [+4B)+7&[P+V-!PJ'')'RU#9:(CTB,4A304C/MFI;&D1_APE7
M"O%YFH9:1+;99V K4,>?%19I0[!5%6XK/AV]*I.F)JT1YLY04I23DC@#U%-S
M%L(3)5)7O"3N/7_.LY2&HE@@,<L[CN0,GWK)R-$DAH3 RA3"SX>HJ&RRO7*;
M>.%$K*3@#/E18J&Y:6UM!L.);PO>1UR,<BA,B:O@]9_8IUT5Z O.CW'TNKTQ
M=DOQ&R"I0CRTD;>.@2L9_6M%(Y)0H](IN@0.]=F/J (6 WCP#C( /OFKW48[
M;/$'^D>>M%WTGI:Y.3[DER#='HCSS(\0"FSE./JG/'K7;![HHY,D:9\\GS:D
MOI?MZ;JHJ_VKN!_@#3M=TS <A? NW%I-Z?>8BO!06M!<4I) Z#/6C[/H/T-3
M%O>B],6M4BTP7I,]Y*FVY2HZD)1^_4U6Z$%:"FS'29T6XJ DMRMA65J*49.3
M4.:DNF.FB3)_@D6$M4.TSPI:-G>.HPGFBXKV#LISW#B%@17!X0=ZU' Q]!4\
M-#Z-AIG4<O33\QZRQ._EOI:^Z:W.#:!U/ZUM%[;:[(['M1ZUUG>6@J7:0SD$
M!32/%^M4\C]T-)&.4NZ.Y+P<VI^=2ADCZU%S;^P^!AJWS)1*VVEK3Y*]:S\M
MR=L>Y(TEMT@AS8]<G"$G'@!QGV)\JW6-,C<;NW:#TXF.)#L H; SX^M:J"2)
M<F1+I;]+MX:A13WPX00/*BD.R-'A71"U,JC.%M8X2!6;0D1F93ELD/1T )4W
MUW'''K46T:(KYE]#BBEI_O5$>?G2;;"AB-\3(6/!@JZ9-($B^M]HE2T[E#:$
M]<C(JDAV'-$2"DA;B,CC //[4FP*;X]LY[IK)'/6@*)$:0ZK[US!6 =H(H3&
MD9ZXW>2RZMF; ;(5G;E/A5]:)9(KB2)VM/@V/9IV^:C[.Y4:,VDS[,RX7!;Y
M"R4M*/4H(Z#VZ5Y^HP8\ZW'7@U,\3KV/0FB]6VWM&N+][MVOF'9[HW_ +0E"
MFAY#!Z_7SKR98YX'PN#T5.&=7?)8ZBC=H*$K*)T-Q(&4I6P4*^GI5J3?J9GM
MVJC 3]2:OMQ=@-S(ZI94<ML,GO!]59K5.+[,VWTC7:-UE>XL)A5\#BG]W#RE
MXP/3%3**]BH2E[F_MW:*73\/*G-R4^@!S_A63C\'3&:]R^@OM/\ ^MVO[I2^
M.Z< _;'E2;%19Q[NF(^C#J4G(#B$GJ?0CTJ!U[#NI]*VW4+:G8*$%]* HJ2*
MJ,FB)0,'_8FY?]576MF-,^>2$$FO>C$\IL> :0G*R?:M545R0VV3K7#4ZH/%
M& KBJ7')$W[&D:;*$;4J(HLE(  'S*H '>H;&T>=*O<.N1YE7A4X1TKV?#\6
MY[F<^:=JAX* '!KWET<$G0V">^'D">M4A;B8D^=:(AL.JL5@)*CE'3SHL88Z
MC%,$. YIC#H7!,N@CTIV30>5;>//^E-.QQ5"QG:!CI04*0D*."2*:$U8O:E/
M 433LG:&$DTPVB]I &$FF% #1/48JD(-)":!"N]'D@4!09>?40 <#SQ3ML.$
M$4+/4D_K3H>X4&21YBBA.8M+/UHVDN=#C<?)\Z:5"3W]DA$9(X)JN@<+'41D
M#SH;&HT/)821BG8Z%)1CC%(M.E0L CIFD/<. <#BD3VQS&>,<4K+4+'#A/3F
MDS4,*SP:56%T G;S2<2MX [O&,4*(G*P$ CI0T2(VK\Q4@&$$^M,!12<=:*&
M'GSQSTIT(=CR'8R5%I>W>,&A(!@JR/$K)IJ-&4A6T$"J*707'I0 UM-,G:#8
M?6@-H25*2L4KY'5$QF1M4*EFD71+2X#@YJ&:Q=CX<(.0/*I:+7I'T/'CGK44
M2W9+:D*3C"L<YS3:L<62)"+==F%P[C&;>2XG:0H9XKGSX(9E4D:+(T<6U_V*
MRH&^\:7!=8^8L#YAZ[?6OE]=X3+&]^([<6>U3.:(GSX#RF):7$+;."E7!%>.
MI.+K(J.COE%Q;K^L*P%@'UZYJT[Z%1=Q;HP$E[<%K]":KD3)+5TWN(0G&Q2M
MV,]/;--2%1;LS=KR%)<)*/F3Y&M5(5&IMD\!994XE25)W%74?2M5*Q$M^/&G
M+"&4IV#R">GM1))H""Y;3$<4%M*==7PA 'E4/'0G+DHK^^W;1W"2M"EIYXX_
M2L)NC2*LR,9XKN"&D J+B@E('52C7-5L[(^E'6--,V^W++;P2X\V0'#^%*L>
M1\Q70HI"4K[-<ZII24.;TG)XQY"B5(M1;)4A];26U,*&P@;O:LG,V4..1V*E
MQV.N8ZZI(6.[; ZJQU5CT%*['5#C;L>&E2 EQ3ROQ^M.N!7R*2RVXI"GI!RX
MA143U!'E4-&B8TNX1@5MY&$8P<=:ALT0P).5!U!*F_4UFY%HDR;C 2D)#I2H
MIZ$<U#9IV5J+JRA)"3XSGBDI<A7 ZI]2DMNNI2E3B3@ Y&*;8TB&NY"&L!N2
M$J)P D9)]JANQOCH><FRXP1,F-*2V[PE7D<5#!?(W,NK"VTN I/D #Y>]1=%
ME=(NL6(TX\#N6>130GP8V9JM3KP<1)4 I120?+%71BY>H[-]C3M*GVCM8FZ<
M:N)CM:HM4B*5CKWS([UK'J?"JFB9JSV)+UK.=;C,L+2$N(+B%GE8RG.2?,G-
M-F"7!YQ^V-(NEP[,42Y=S80B'.CS0A:-X2%("<&NS3RW*CBS]G@N?,!=3C4;
M:T)/"66BG_#%;;E?9RU]AB,^Y'N#,J&YM<8<&Q3^"$Y_NY.:=4(M[I<)LYHR
M(^H79/<9[P&/W;>_T \Z:N7N'14-7/4;D1R4W( :1P2$#-0E-^X^"%-N#SS2
M"+A*>6L96"2 GZ#SI2=+AMC78V_,>,-#??+(/!!<)_I1-U$27)=Z++LV] FY
MR(3B&]PEM* [K X!3T(-.'+[!\(T\J;#8DI<D3BF:1E;[21W;P\CMZ ^M;/[
MD(9G3;;<BB))G18[*O$ZXC&5CT(HX]Q]DFWFU7)1%I8[J%".S?CEU7]WUJHT
M^@:HUMFTR$N(NETV'/++)_"/(D>9K5*B27?',)2RZM2W'#AM ' %#"@6_3C:
M,2903NQDC;T]J%$5$;56MQ8(OPMIM)F/].]'"$_6E*=*D4D<3N-PN-VG./R%
M86X>=IX'M7-*VZ+M(M+/:U!0<<&3FEM#<:)+]M@@*E/ !/*D^=-1#<5MYU[(
MDI^ L;?<M8P5^9Q3N^$'79FVU*=>[U^0XMXG))/E0H<@F7#=PAQDA:\ ],"D
MXE6(-Z9><^Z.T U-")3BX-S9^%F))W#*5C\*OK0TFJ8]QFYMAN$*0&>Z4XE8
MRE:1D8K#RI)\!:)L>'-BAI^(\ME]I64J:5M4DCSR*W>.#5-$*4E[G0[-]H?M
M3TRTFUJO NC!'C9G(#I4C'3=U%<N72QET=$,\DN2WT]VZV"3)4O4.G#"+BLK
MDQCO ^OF*XI:3X9O'45VCI%MO^C]8I:%MU3 =:1T9+H:<^F%XS67E3C[&_FQ
MD39LJ?;Y"95L"@R1N)0@*.WUXJ::[0FU?#)$#4T%U9+Y6Q*)R752% +3]!TI
M.)HLC?L;.W2I3[K$V2WWX1C8MI7A*??S/ZU#C&NS12?;1M-)293$\NB4K:^<
M%"OPCVJ.$5RSHVR/_OD_THW(7EGR'0 @;B.E?4I4> W?"%Q63)= VG'6BKY8
MI/;T:J PEIL )Z#I3?)!)6K:"H"BJ 9)RG=0(;2=S@&.:TQ8W.8F2@H!!1Z^
ME?2Z>*QQHX,T^0T$>O%=5G,V+.#P:M,+),=17X3T%:Q)8Y5!0/8<4DP#' P*
MM A23ZTQB_+B@3$\^8H)'&U8&,4T.AP8/K5 .-H&<GI0D K"$GK3H+!O&3@"
MJ0@DN/$\'BBV ,.*7@DU1+'.[73H5BDMD< "G0K'VV < ^=-(38YW.WZ55"L
M4EO/% 58M#.#UH#8/(; S04HT+"$F@8K:!0 H+V^E "T*R* %'!YH&&.14@A
MT8VXI,VB *2?.I* I?((%%B% Y%.P%(&> !3 ,^#YNE2P'2M!2-HJ1B#S3[
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M>0D;S\HXX]ZN*37([:'IUN;<)" @*S\X "A^M0U%]H6YBV;GJ>V+"K9?9S0
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M R:I,*0E3K*1E(JD1+CH1\0H#H,_2@G<Q9>6L#=_0578K#"%+.><44.V/H9
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M%<Y]\U#5HI2HZ6JUQ-31D)EM!2)48.$$>>>/ZUC*'!M#);,__P!#2/\ V?\
'2N;DZC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864235696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Novartis AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001114448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">2,119,609,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG AG<span></span>
</td>
<td class="text">PricewaterhouseCoopers AG<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Basel, Switzerland<span></span>
</td>
<td class="text">Basel, Switzerland<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">3240<span></span>
</td>
<td class="text">1358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-15024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">V8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Lichtstrasse 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">4056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=nvs_AmericanDepositarySharesEachRepresenting1ShareMember', window );">American Depositary Shares each representing 1 share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares each representing 1 share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NVS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=nvs_OrdinarySharesNominalValueCHF0.50PerShareMember', window );">Ordinary shares, nominal value CHF 0.50 per share*</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, nominal value CHF 0.50 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NOVN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Lichtstrasse 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">4056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Karen L. Hale<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">324-1111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelFaxNumber', window );">Contact Personnel Fax Number</a></td>
<td class="text">324-7826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelFaxNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fax Number of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelFaxNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=nvs_AmericanDepositarySharesEachRepresenting1ShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=nvs_AmericanDepositarySharesEachRepresenting1ShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=nvs_OrdinarySharesNominalValueCHF0.50PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=nvs_OrdinarySharesNominalValueCHF0.50PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571858286928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated income statements - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">$ 50,545<span></span>
</td>
<td class="nump">$ 51,626<span></span>
</td>
<td class="nump">$ 48,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,283<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
<td class="nump">1,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="num">(15,486)<span></span>
</td>
<td class="num">(15,867)<span></span>
</td>
<td class="num">(15,121)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="nump">36,342<span></span>
</td>
<td class="nump">37,010<span></span>
</td>
<td class="nump">34,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="num">(14,253)<span></span>
</td>
<td class="num">(14,886)<span></span>
</td>
<td class="num">(14,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(9,996)<span></span>
</td>
<td class="num">(9,540)<span></span>
</td>
<td class="num">(8,980)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">1,852<span></span>
</td>
<td class="nump">1,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expense</a></td>
<td class="num">(3,701)<span></span>
</td>
<td class="num">(2,747)<span></span>
</td>
<td class="num">(3,190)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income</a></td>
<td class="nump">9,197<span></span>
</td>
<td class="nump">11,689<span></span>
</td>
<td class="nump">10,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">(Loss)/income from associated companies</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">15,339<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="num">(837)<span></span>
</td>
<td class="num">(811)<span></span>
</td>
<td class="num">(869)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other financial income and expense</a></td>
<td class="nump">20<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income before taxes</a></td>
<td class="nump">8,371<span></span>
</td>
<td class="nump">26,137<span></span>
</td>
<td class="nump">9,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income taxes</a></td>
<td class="num">(1,416)<span></span>
</td>
<td class="num">(2,119)<span></span>
</td>
<td class="num">(1,807)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">6,955<span></span>
</td>
<td class="nump">24,018<span></span>
</td>
<td class="nump">8,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>Attributable to</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Shareholders of Novartis AG</a></td>
<td class="nump">6,955<span></span>
</td>
<td class="nump">24,021<span></span>
</td>
<td class="nump">8,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsPerShareAbstract', window );"><strong>Basic earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic earnings per share</a></td>
<td class="nump">$ 3.19<span></span>
</td>
<td class="nump">$ 10.71<span></span>
</td>
<td class="nump">$ 3.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsPerShareAbstract', window );"><strong>Diluted earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted earnings per share</a></td>
<td class="nump">$ 3.17<span></span>
</td>
<td class="nump">$ 10.63<span></span>
</td>
<td class="nump">$ 3.52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByFunction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByFunction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2022-03-24<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39M<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571858063120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated statements of comprehensive income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 6,955<span></span>
</td>
<td class="nump">$ 24,018<span></span>
</td>
<td class="nump">$ 8,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Other comprehensive income to be eventually recycled into the consolidated income statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Associated companies' movements in comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations', window );">Net investment hedge</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="num">(201)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation effects</a></td>
<td class="num">(450)<span></span>
</td>
<td class="num">(4,762)<span></span>
</td>
<td class="nump">3,194<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Total of items to eventually recycle</a></td>
<td class="num">(359)<span></span>
</td>
<td class="num">(4,500)<span></span>
</td>
<td class="nump">2,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Other comprehensive income never to be recycled into the consolidated income statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Actuarial gains/losses from defined benefit plans, net of taxes</a></td>
<td class="num">(103)<span></span>
</td>
<td class="nump">1,809<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments', window );">Fair value adjustments on equity securities, net of taxes</a></td>
<td class="num">(382)<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Total of items never to be recycled</a></td>
<td class="num">(485)<span></span>
</td>
<td class="nump">2,003<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="nump">6,111<span></span>
</td>
<td class="nump">21,521<span></span>
</td>
<td class="nump">11,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract', window );"><strong>Attributable to</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Shareholders of Novartis AG</a></td>
<td class="nump">6,116<span></span>
</td>
<td class="nump">21,528<span></span>
</td>
<td class="nump">11,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests', window );">Comprehensive income, attributable to non-controlling interests</a></td>
<td class="num">$ (5)<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) from changes in the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income applying paragraph 5.7.5 of IFRS 9. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to hedges of net investments in foreign operations. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 39<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=39&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 9<br> -IssueDate 2022-03-24<br> -Paragraph 6.5.13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=9&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_6.5.13_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share of the other comprehensive income of associates and joint ventures accounted for using the equity method that will be reclassified to profit or loss, net of tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571863834000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated balance sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">$ 10,764<span></span>
</td>
<td class="nump">$ 11,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1,431<span></span>
</td>
<td class="nump">1,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">29,301<span></span>
</td>
<td class="nump">29,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="nump">31,644<span></span>
</td>
<td class="nump">34,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investment in associated companies</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">3,739<span></span>
</td>
<td class="nump">3,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Financial assets</a></td>
<td class="nump">2,411<span></span>
</td>
<td class="nump">3,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">1,110<span></span>
</td>
<td class="nump">2,210<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">80,543<span></span>
</td>
<td class="nump">86,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">7,175<span></span>
</td>
<td class="nump">6,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Current trade receivables</a></td>
<td class="nump">8,066<span></span>
</td>
<td class="nump">8,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssetsCurrent', window );">Income tax receivable</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Marketable securities, commodities, time deposits and derivative financial instruments</a></td>
<td class="nump">11,413<span></span>
</td>
<td class="nump">15,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">7,517<span></span>
</td>
<td class="nump">12,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialAssets', window );">Other current assets</a></td>
<td class="nump">2,471<span></span>
</td>
<td class="nump">2,440<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">36,910<span></span>
</td>
<td class="nump">45,718<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">117,453<span></span>
</td>
<td class="nump">131,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">890<span></span>
</td>
<td class="nump">901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury shares</a></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserves</a></td>
<td class="nump">58,544<span></span>
</td>
<td class="nump">66,802<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Equity attributable to Novartis AG shareholders</a></td>
<td class="nump">59,342<span></span>
</td>
<td class="nump">67,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">59,423<span></span>
</td>
<td class="nump">67,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Financial debts</a></td>
<td class="nump">20,244<span></span>
</td>
<td class="nump">22,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">1,538<span></span>
</td>
<td class="nump">1,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">2,686<span></span>
</td>
<td class="nump">3,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentNonfinancialLiabilities', window );">Provisions and other non-current liabilities</a></td>
<td class="nump">4,906<span></span>
</td>
<td class="nump">6,172<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">29,374<span></span>
</td>
<td class="nump">33,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">5,146<span></span>
</td>
<td class="nump">5,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Financial debts and derivative financial instruments</a></td>
<td class="nump">5,931<span></span>
</td>
<td class="nump">6,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">251<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesCurrent', window );">Current income tax liabilities</a></td>
<td class="nump">2,533<span></span>
</td>
<td class="nump">2,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialLiabilities', window );">Provisions and other current liabilities</a></td>
<td class="nump">14,795<span></span>
</td>
<td class="nump">15,670<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">28,656<span></span>
</td>
<td class="nump">30,208<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">58,030<span></span>
</td>
<td class="nump">63,973<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="nump">$ 117,453<span></span>
</td>
<td class="nump">$ 131,795<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.
Effective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax assets. [Refer: Current tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2022-03-24<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentNonfinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentNonfinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentNonfinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentNonfinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2022-03-24<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571855272528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated statements of changes in equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Equity attributable to owners of parent [member]</div></th>
<th class="th"><div>Share capital</div></th>
<th class="th"><div>Treasury shares</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Total value adjustments</div></th>
<th class="th"><div>Non-controlling interests [member]</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity | Restated Value Adjustments [member]</a></td>
<td class="nump">$ 55,551<span></span>
</td>
<td class="nump">$ 55,474<span></span>
</td>
<td class="nump">$ 936<span></span>
</td>
<td class="num">$ (80)<span></span>
</td>
<td class="nump">$ 59,275<span></span>
</td>
<td class="num">$ (4,657)<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at beginning of period (Restated Value Adjustments [member]) at Dec. 31, 2019</a></td>
<td class="nump">55,551<span></span>
</td>
<td class="nump">55,474<span></span>
</td>
<td class="nump">936<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="nump">59,275<span></span>
</td>
<td class="num">(4,657)<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">8,071<span></span>
</td>
<td class="nump">8,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="nump">3,330<span></span>
</td>
<td class="nump">3,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="nump">3,387<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="nump">11,401<span></span>
</td>
<td class="nump">11,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,016<span></span>
</td>
<td class="nump">3,387<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaid', window );">Dividends</a></td>
<td class="num">(6,987)<span></span>
</td>
<td class="num">(6,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="num">(3,056)<span></span>
</td>
<td class="num">(3,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(3,038)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options and employee transactions, equity impact</a></td>
<td class="nump">806<span></span>
</td>
<td class="nump">806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RepurchaseOfOptions', window );">Repurchase of options</a></td>
<td class="num">(89)<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-based compensation</a></td>
<td class="nump">730<span></span>
</td>
<td class="nump">730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff', window );">Shares delivered to divested business employees, equity impact</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TaxesOnTreasuryShares', window );">Taxes on treasury shares</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan', window );">(Increase)/decrease of treasury share repurchase obligation under a share buyback trading plan</a></td>
<td class="num">(1,769)<span></span>
</td>
<td class="num">(1,769)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,769)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold', window );">Fair value adjustments on equity securities sold, reclassified to retained earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRelatedToDivestments', window );">Fair value adjustments related to divestments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other movements</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquity', window );">Total of other equity movements</a></td>
<td class="num">(10,286)<span></span>
</td>
<td class="num">(10,279)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="num">(10,134)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2020</a></td>
<td class="nump">56,666<span></span>
</td>
<td class="nump">56,598<span></span>
</td>
<td class="nump">913<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="nump">57,157<span></span>
</td>
<td class="num">(1,419)<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="nump">56,666<span></span>
</td>
<td class="nump">56,598<span></span>
</td>
<td class="nump">913<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="nump">57,157<span></span>
</td>
<td class="num">(1,419)<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">24,018<span></span>
</td>
<td class="nump">24,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="num">(2,497)<span></span>
</td>
<td class="num">(2,493)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="num">(2,539)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="nump">21,521<span></span>
</td>
<td class="nump">21,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,067<span></span>
</td>
<td class="num">(2,539)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaid', window );">Dividends</a></td>
<td class="num">(7,368)<span></span>
</td>
<td class="num">(7,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="num">(2,920)<span></span>
</td>
<td class="num">(2,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(2,902)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options and employee transactions, equity impact</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-based compensation</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff', window );">Shares delivered to divested business employees, equity impact</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TaxesOnTreasuryShares', window );">Taxes on treasury shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan', window );">(Increase)/decrease of treasury share repurchase obligation under a share buyback trading plan</a></td>
<td class="num">(1,040)<span></span>
</td>
<td class="num">(1,040)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,040)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TransactionCostsRecordedInEquity', window );">Transaction costs recorded in equity</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold', window );">Fair value adjustments on equity securities sold, reclassified to retained earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="num">(164)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseInNoncontrolingInterests', window );">Changes in non-controlling interests</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRelatedToDivestments', window );">Fair value adjustments related to divestments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="nump">102<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other movements</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquity', window );">Total of other equity movements</a></td>
<td class="num">(10,365)<span></span>
</td>
<td class="num">(10,471)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(10,235)<span></span>
</td>
<td class="num">(229)<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2021</a></td>
<td class="nump">67,822<span></span>
</td>
<td class="nump">67,655<span></span>
</td>
<td class="nump">901<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">70,989<span></span>
</td>
<td class="num">(4,187)<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="nump">67,822<span></span>
</td>
<td class="nump">67,655<span></span>
</td>
<td class="nump">901<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">70,989<span></span>
</td>
<td class="num">(4,187)<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">6,955<span></span>
</td>
<td class="nump">6,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="num">(844)<span></span>
</td>
<td class="num">(839)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(839)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="nump">6,111<span></span>
</td>
<td class="nump">6,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,955<span></span>
</td>
<td class="num">(839)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaid', window );">Dividends</a></td>
<td class="num">(7,506)<span></span>
</td>
<td class="num">(7,506)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,506)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="num">(10,910)<span></span>
</td>
<td class="num">(10,910)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="num">(10,844)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReductionOfIssuedCapital', window );">Reduction of share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options and employee transactions, equity impact</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-based compensation</a></td>
<td class="nump">854<span></span>
</td>
<td class="nump">854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff', window );">Shares delivered to divested business employees, equity impact</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TaxesOnTreasuryShares', window );">Taxes on treasury shares</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan', window );">(Increase)/decrease of treasury share repurchase obligation under a share buyback trading plan</a></td>
<td class="nump">2,809<span></span>
</td>
<td class="nump">2,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold', window );">Fair value adjustments on equity securities sold, reclassified to retained earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseInNoncontrolingInterests', window );">Changes in non-controlling interests</a></td>
<td class="num">(81)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRelatedToDivestments', window );">Fair value adjustments related to divestments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other movements</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquity', window );">Total of other equity movements</a></td>
<td class="num">(14,510)<span></span>
</td>
<td class="num">(14,429)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="num">(14,404)<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at end of period at Dec. 31, 2022</a></td>
<td class="nump">59,423<span></span>
</td>
<td class="nump">59,342<span></span>
</td>
<td class="nump">890<span></span>
</td>
<td class="num">(92)<span></span>
</td>
<td class="nump">63,540<span></span>
</td>
<td class="num">(4,996)<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="nump">$ 59,423<span></span>
</td>
<td class="nump">$ 59,342<span></span>
</td>
<td class="nump">$ 890<span></span>
</td>
<td class="num">$ (92)<span></span>
</td>
<td class="nump">$ 63,540<span></span>
</td>
<td class="num">$ (4,996)<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends recognised as distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 107<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_107&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity through changes in ownership interests in subsidiaries that do not result in loss of control. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReductionOfIssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from a reduction in issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReductionOfIssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueAdjustmentsOnFinancialAssetsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueAdjustmentsRelatedToDivestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueAdjustmentsRelatedToDivestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseInNoncontrolingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseInNoncontrolingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RepurchaseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RepurchaseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TaxesOnTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TaxesOnTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TransactionCostsRecordedInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TransactionCostsRecordedInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=nvs_RestatedValueAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=nvs_RestatedValueAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571863653088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated cash flow statements - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 6,955<span></span>
</td>
<td class="nump">$ 24,018<span></span>
</td>
<td class="nump">$ 8,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLoss', window );">Reversal of non-cash items and other adjustments</a></td>
<td class="nump">11,546<span></span>
</td>
<td class="num">(5,299)<span></span>
</td>
<td class="nump">9,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsReceivedClassifiedAsOperatingActivities', window );">Dividends received from associated companies and others</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="num">(696)<span></span>
</td>
<td class="num">(664)<span></span>
</td>
<td class="num">(703)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities', window );">Other financial receipts</a></td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities', window );">Other financial payments</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(302)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Income taxes paid</a></td>
<td class="num">(1,975)<span></span>
</td>
<td class="num">(2,342)<span></span>
</td>
<td class="num">(1,833)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges', window );">Net cash flows from operating activities before working capital and provision changes</a></td>
<td class="nump">16,124<span></span>
</td>
<td class="nump">15,949<span></span>
</td>
<td class="nump">16,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities', window );">Payments out of provisions and other net cash movements in non-current liabilities</a></td>
<td class="num">(885)<span></span>
</td>
<td class="num">(1,119)<span></span>
</td>
<td class="num">(2,437)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems', window );">Change in net current assets and other operating cash flow items</a></td>
<td class="num">(1,003)<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="num">(291)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash flows from operating activities</a></td>
<td class="nump">14,236<span></span>
</td>
<td class="nump">15,071<span></span>
</td>
<td class="nump">13,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(1,198)<span></span>
</td>
<td class="num">(1,378)<span></span>
</td>
<td class="num">(1,275)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Proceeds from sale of property, plant and equipment</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchases of intangible assets</a></td>
<td class="num">(1,473)<span></span>
</td>
<td class="num">(1,593)<span></span>
</td>
<td class="num">(1,310)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Proceeds from sale of intangible assets</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">748<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Purchases of financial assets</a></td>
<td class="num">(121)<span></span>
</td>
<td class="num">(191)<span></span>
</td>
<td class="num">(230)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Proceeds from sale of financial assets</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="nump">723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities', window );">Purchases of other non-current assets</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities', window );">Proceeds from sale of other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies', window );">Acquisitions and divestments of interests in associated companies, net</a></td>
<td class="num">(24)<span></span>
</td>
<td class="nump">20,669<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities', window );">Acquisitions and divestments of businesses, net</a></td>
<td class="num">(879)<span></span>
</td>
<td class="num">(567)<span></span>
</td>
<td class="num">(9,957)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Purchases of marketable securities, commodities and time deposits</a></td>
<td class="num">(34,695)<span></span>
</td>
<td class="num">(16,403)<span></span>
</td>
<td class="num">(1,900)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Proceeds from sale of marketable securities, commodities and time deposits</a></td>
<td class="nump">39,357<span></span>
</td>
<td class="nump">2,298<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations', window );">Net cash flows from/(used in) investing activities from continuing operations</a></td>
<td class="nump">1,468<span></span>
</td>
<td class="nump">4,208<span></span>
</td>
<td class="num">(13,055)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash flows used in investing activities from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash flows from/(used in) investing activities</a></td>
<td class="nump">1,468<span></span>
</td>
<td class="nump">4,208<span></span>
</td>
<td class="num">(13,182)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities', window );">Dividends paid to shareholders of Novartis AG</a></td>
<td class="num">(7,506)<span></span>
</td>
<td class="num">(7,368)<span></span>
</td>
<td class="num">(6,987)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares', window );">Acquisitions of treasury shares</a></td>
<td class="num">(10,652)<span></span>
</td>
<td class="num">(3,057)<span></span>
</td>
<td class="num">(2,842)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions', window );">Proceeds from exercised options and other treasury share transactions, net</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Increase in non-current financial debts</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">7,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfNoncurrentBorrowings', window );">Repayments of the current portion of non-current financial debts</a></td>
<td class="num">(2,575)<span></span>
</td>
<td class="num">(2,162)<span></span>
</td>
<td class="num">(2,003)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings', window );">Change in current financial debts</a></td>
<td class="nump">295<span></span>
</td>
<td class="num">(3,524)<span></span>
</td>
<td class="nump">2,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payments of lease liabilities</a></td>
<td class="num">(295)<span></span>
</td>
<td class="num">(316)<span></span>
</td>
<td class="num">(312)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities', window );">Other financing cash flows, net</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="num">(147)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations', window );">Net cash flows used in financing activities from continuing operations</a></td>
<td class="num">(20,562)<span></span>
</td>
<td class="num">(16,264)<span></span>
</td>
<td class="num">(2,158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash flows used in financing activities from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash flows used in financing activities</a></td>
<td class="num">(20,562)<span></span>
</td>
<td class="num">(16,264)<span></span>
</td>
<td class="num">(2,208)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net change in cash and cash equivalents before effect of exchange rate changes</a></td>
<td class="num">(4,858)<span></span>
</td>
<td class="nump">3,015<span></span>
</td>
<td class="num">(1,740)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(266)<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(4,890)<span></span>
</td>
<td class="nump">2,749<span></span>
</td>
<td class="num">(1,454)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">12,407<span></span>
</td>
<td class="nump">9,658<span></span>
</td>
<td class="nump">11,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 7,517<span></span>
</td>
<td class="nump">$ 12,407<span></span>
</td>
<td class="nump">$ 9,658<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's financing activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's financing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to an increase (decrease) in current borrowings. [Refer: Current borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's investing activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) investing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's investing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) investing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for dividends paid to equity holders of the parent, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from dividends received, classified as operating activities. [Refer: Dividends received]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for finance costs paid, classified as operating activities. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from finance income received, classified as operating activities. [Refer: Finance income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 14<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inflows (outflows) of cash, classified as financing activities, that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 21<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_21&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for changes in ownership interests in subsidiaries that do not result in a loss of control. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 42A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_42A&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 42B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_42B&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire or redeem entity's shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsToAcquireOrRedeemEntitysShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from non-current borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859579136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">Significant accounting policies</a></td>
<td class="text">
          <div>
            <div id="anchorId001516732"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">1. Significant accounting policies</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Novartis Group (Novartis or Group) is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of innovative pharmaceuticals and cost-saving generic medicines. The Group is headquartered in Basel, Switzerland.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consolidated financial statements of the Group are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). They are prepared in accordance with the historical cost convention, except for items that are required to be accounted for at fair value.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#8217;s financial year-end is December 31, which is also the annual closing date of the individual entities&#8217; financial statements incorporated into the Group&#8217;s consolidated financial statements.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The preparation of financial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the year, which affect the reported amounts of revenues, expenses, assets, liabilities and contingent amounts.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Estimates are based on historical experience and other assumptions that are considered reasonable under the given circumstances and are regularly monitored. Actual outcomes and results could differ from those estimates and assumptions. Revisions to estimates are recognized in the period in which the estimate is revised.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Listed below are accounting policies of significance to Novartis or, in cases where IFRS provides alternatives, the option adopted by Novartis.</div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Scope of consolidation </span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated financial statements include all entities, including structured entities, over which Novartis AG, Basel, Switzerland, directly or indirectly has control (generally as a result of owning more than 50% of the entity&#8217;s voting interest). Consolidated entities are also referred to as &#8220;subsidiaries.&#8221; </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In cases where Novartis does not fully own a subsidiary, it has elected to value any remaining outstanding non-controlling interest at the time of acquiring control of the subsidiary at its proportionate share of the fair value of the net identified assets.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Investments in associated companies (generally defined as investments in entities in which Novartis holds between 20% and 50% of voting shares or over which it otherwise has significant influence) and joint ventures are accounted for using the equity method, except for selected venture fund investments for which the Group has elected to apply the method of fair value through the consolidated income statement.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Foreign currencies</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated financial statements of Novartis are presented in US dollars (USD). The functional currency of a subsidiary is generally the local currency of that respective entity. The functional currency used for the reporting of certain Swiss and foreign finance entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in this currency.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For subsidiaries not operating in hyperinflationary economies, the subsidiary&#8217;s results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates:</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Income, expense and cash flows for each month using the average exchange rate, with the US dollar values for each month being aggregated during the year</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Balance sheet using year-end exchange rates</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Resulting exchange rate differences are recognized in other comprehensive income</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For subsidiaries operating in hyperinflationary economies, the impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period is recorded in retained earnings in equity. The subsequent gains or losses resulting from the restatement of non-monetary assets are recorded in &#8220;Other financial income and expense&#8221; in the consolidated income statement. </div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Non-current assets held for sale or held for distribution to owners</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Non-current assets are accounted for as assets held for sale or as related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell and any resulting impairment is recognized. Assets related to discontinued operations and assets of a disposal group held for sale are not depreciated or amortized. The prior year consolidated balance sheet is not restated.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If in a subsequent period, the criteria for classification as held for sale are no longer met, the recoverable amount of assets and liabilities are reclassified out of assets held for sale into the respective balance sheet lines and the prior year consolidated balance sheet is not restated. The cumulative amount of depreciation and amortization not recorded since the date of their classification as assets held for sale, and any required </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">adjustments to the recoverable amounts of assets are recognized in the consolidated income statement.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Acquisition of assets and businesses</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Assets separately acquired are recorded at cost, which includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment and restore the site when it is no longer used are included in their cost.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Acquired businesses are accounted for by applying the acquisition method, unless the optional concentration test is applied. The optional concentration test allows for an election on a transaction-by-transaction basis to account for the acquired business as an asset separately acquired when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The acquisition method requires that the assets acquired and liabilities assumed be recorded at their respective fair values on the date the Group obtains control. The excess of the fair value of the total purchase consideration transferred over the fair value of the acquired assets and assumed liabilities is recognized as goodwill. The valuations are based on information available at the acquisition date. Acquisition related costs are expensed as incurred.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The application of the acquisition method requires certain estimates and assumptions to be made, especially concerning the fair values of the acquired intangible assets, inventories, property, plant and equipment and the liabilities assumed at the acquisition date, and the useful lives of the intangible assets and property, plant and equipment. Estimates of fair value require the use of valuation techniques. These valuations require the use of management assumptions and estimates, including the value of comparable assets in the market, amount and timing of future cash flows, outcomes and costs of research and development activities, probability of obtaining regulatory approval, long-term sales forecasts, actions of competitors, discount rates and terminal growth rates. The section &#8220;&#8212;Impairment of goodwill and intangible assets&#8221; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Property, plant and equipment</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Property, plant and equipment is depreciated on a straight-line basis in the consolidated income statement over the estimated useful life of the individual asset. Freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Property, plant and equipment is assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections over the useful life.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the estimated useful life by major categories for property, plant and equipment:</div>
                  <div>

                      <div>
                        <div style="padding-top:10px; padding-bottom:30px;">
                          <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                            <tr valign="bottom">
                              <td style=";height:12;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                              </td>
                              <td/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Useful life</div>
                              </td>
                              <td/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 2px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                              <td align="right" style=";width:20%;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20 to 40 years</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and other equipment</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Machinery and equipment</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7 to 20 years</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Furniture and vehicles</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 10 years</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Computer hardware</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                          </table>
                        </div>
                      </div>

                  </div>
                  <div>
                    <div>
                      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Government grants obtained for construction activities, including any related equipment, are deducted from the gross acquisition cost to arrive at the balance sheet carrying value of the related assets.</div>
                    </div>
                  </div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Leases and right-of-use assets</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As lessee, at inception and upon the modification of a contract, the Group assesses whether the contract contains a lease. The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative standalone price of each component. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases. For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease to the end of the lease term. The lease term includes the period of any lease extension that management assess as reasonably certain to be exercised by the Group. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the Novartis incremental borrowing rate for the asset subject to the lease in the relevant market.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The portion of the lease payments attributable to the repayment of lease liabilities is recognized in cash flows used in financing activities, and the portion attributable to the payment of interest is included in cash flows from operating activities.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease incentive received, and any initial direct costs incurred by Novartis, and expected costs for obligations to dismantle and remove right-of-use assets when they are no longer used.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">the shorter of the useful life of the right-of-use asset or the end of the lease term. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In arrangements where the Group is the lessor, it determines at lease inception whether the lease is a finance lease or an operating lease. Leases that transfer substantially all of the risk and rewards incidental to ownership of the underlying asset to the counterparty (the lessee) are accounted for as finance leases. Leases that do not transfer substantially all of the risks and rewards of ownership are accounted for as operating leases. Operating lease payments received are recognized on a straight-line basis over the lease term in the consolidated income statement in &#8220;Other income.&#8221; </div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Goodwill and intangible assets</span>
                  </div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Goodwill</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Goodwill arises on applying the acquisition method on the acquisition of a business and is the excess of the fair value of the consideration transferred to acquire the business over the underlying fair value of the net identified assets acquired. It is allocated to groups of cash-generating units (CGUs), that are expected to benefit from the synergies of the combination, and which are usually represented by the reported segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under &#8220;Other expense&#8221; in the consolidated income statement.</div>
                </div>

            </div>
            <div>

                <div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intangible assets available for use</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has the following classes of available for use intangible assets: currently marketed products; technologies and other intangible assets (including software).</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Currently marketed products represent the composite value of acquired intellectual property (IP), patents, distribution rights and product trade names.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Technologies represent identified and separable acquired know-how used in the research, development and production processes.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Significant investments in internally developed and acquired computer software are capitalized and included in the &#8220;Other&#8221; category, and amortized once available for use.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Intangible assets available for use with a definite useful life are amortized over their estimated useful lives on a straight-line basis and are evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the estimated useful life by major categories for intangible assets available for use and the line in the consolidated income statement in which the amortization and any potential impairment charge is recognized:</div>
                  <div>

                      <div>
                        <div style="padding-top:10px; padding-bottom:30px;">
                          <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                            <tr valign="bottom">
                              <td style=";height:12;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                              </td>
                              <td/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                                  <br/>
                                  <br/> Useful life</div>
                              </td>
                              <td/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement line<br/> for amortization and<br/> impairment charges</div>
                              </td>
                              <td/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 20 years</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Technologies</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10 to 20 years    </div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"   or "Research   and development"</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other (including software)</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 12 years  </div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> In the relevant   functional expense</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                          </table>
                        </div>
                      </div>

                  </div>
                </div>

            </div>
            <div>

                <div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intangible assets not yet available for use</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Acquired research and development intangible assets that have not yet obtained marketing approval are recognized as in-process research and development (IPR&amp;D).</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">IPR&amp;D is not amortized, but is evaluated for potential impairment on an annual basis or when facts and circumstances warrant. Any impairment charge is recorded in the consolidated income statement under &#8220;Research and development.&#8221; Once a project included in IPR&amp;D has received marketing approval from a regulatory authority, it is transferred to the &#8220;Currently marketed products&#8221; category.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impairment of goodwill and intangible assets</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">An asset, a CGU or a grouping of CGUs is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value-in-use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGU, and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset. These valuations are classified as &#8220;Level 3&#8221; in the fair value hierarchy.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group&#8217;s activities with regard to:</div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Amount and timing of projected future cash flows</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Sales forecasts </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Actions of competitors (launch of competing products, marketing initiatives, etc.)</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Sales erosion rates after the end of patent or other intellectual property rights protection, and timing of the entry of generic competition</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Outcome of research and development activities (compound efficacy, results of clinical trials, etc.)</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Amount and timing of projected costs to develop IPR&amp;D into commercially viable products</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Profit margins</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Probability of obtaining regulatory approval</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Future tax rate</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Appropriate terminal growth rate</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Appropriate discount rate</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Generally, for intangible assets with a definite useful life, Novartis uses cash flow projections for the whole useful life of these assets. For goodwill, Novartis generally utilizes cash flow projections for a three-year period based on management forecasts, with a terminal value based on cash flow projections usually in line with inflation rates for later periods. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Probability-weighted scenarios are typically used.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Discount rates used consider the Group&#8217;s estimated weighted average cost of capital, adjusted for specific asset, country and currency risks associated with cash flow projections, to approximate the discount rate that market participants would use to value the asset.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Due to the above factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques. </div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Cash and cash equivalents</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash and cash equivalents include highly liquid investments with original maturities of three months or less, which are readily convertible to known amounts of cash. Bank overdrafts are presented within current financial debts on the consolidated balance sheet.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Marketable securities, commodities and non-current financial assets </span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Commodities, which include gold bullion or coins, are valued at the lower of cost or fair value using current market prices. The changes in fair value below cost are immediately recorded in &#8220;Other financial income and expense.&#8221;</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities are financial assets held for short-term purposes which are principally traded in liquid markets and are classified within current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#8220;Other financial income and expense&#8221; in the consolidated income statement. Non-current financial assets held for long-term strategic purposes are classified within non-current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#8220;Other income&#8221; and &#8220;Other expense&#8221; in the consolidated income statement.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities and non-current financial assets are initially recorded at fair value on their trade date, which is different from the settlement date when the transaction is ultimately effected. Quoted securities are remeasured at each reporting date to fair value based on current market prices. If the market for a financial asset is not active or no market is available, fair values are established using valuation techniques. The majority of non-quoted investments are initially valued at fair value through the purchase price established between a willing buyer and seller. Non-quoted investments are subsequently adjusted based on values derived from discounted cash flow analysis or other pricing models. These investment values are classified as &#8220;Level 3&#8221; in the fair value hierarchy.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group classifies and accounts for its marketable securities and non-current financial assets in the following categories:</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Debt securities are valued at fair value through other comprehensive income with subsequent recycling into the consolidated income statement, as they meet both the &#8220;solely payment of principal and interest&#8221; and the business model criteria. Unrealized gains and losses, except exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are recognized in the consolidated income statement when the debt instrument is sold, at which time the gain is transferred to &#8220;Other financial income and expense.&#8221; Exchange gains and losses related to debt instruments are immediately recognized in the consolidated income statement in &#8220;Other financial income and expense.&#8221;</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Fund investments and equity securities of the Novartis Venture Fund are valued at fair value through profit and loss (FVPL). Unrealized gains and losses, including exchange gains and losses, are recognized in the consolidated income statement in &#8220;Other income&#8221; for gains and &#8220;Other expense&#8221; for losses.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Equity securities held as strategic investments, typically held outside of the Novartis Venture Fund, are generally designated at the date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. Unrealized gains and losses, including exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are reclassified to retained earnings when the equity security is sold. If these equity securities are not designated at the date of acquisition as financial assets valued at fair value through other comprehensive income, they are valued at FVPL, as described above.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Other non-current financial assets, such as loans and long-term receivables from customers, advances and other deposits, are valued at amortized cost, which reflects the time value of money less any allowances for expected credit losses.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group assesses on a forward-looking basis the expected credit losses associated with its debt securities valued at fair value through other comprehensive </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">income. Impairments on debt securities are recorded in &#8220;Other financial income and expense.&#8221;</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For other financial assets valued at amortized cost, impairments, which are based on their expected credit losses, and exchange rate losses are included in &#8220;Other expense&#8221; in the consolidated income statement. Exchange rate gains and interest income, using the effective interest rate method, are included in &#8220;Other income&#8221; or &#8220;Other financial income&#8221; in the consolidated income statement, depending on the nature of the item.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Derivative financial instruments</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Derivative financial instruments are initially recognized in the balance sheet at fair value and are remeasured to their current fair value at the end of each subsequent reporting period. The valuation of a forward exchange rate contract is based on the discounted cash flow model, using interest rate curves and forward rates at the reporting date as observable inputs.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Options are valued based on a modified Black-Scholes model using volatility and exercise prices as major observable inputs.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group enters into certain derivative financial instruments for the purpose of hedging to reduce the volatility in the Group&#8217;s performance due to the exposure to various business-related risks. The risk mitigation is obtained because the derivative&#8217;s value or cash flows are expected, wholly or partly, to offset changes in the value or cash flows of the recognized assets or liabilities. The overall strategy is aiming to mitigate the currency and interest rate risk of positions that are contractually agreed, and to partially mitigate the exposure risk of selected anticipated transactions.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain derivative financial instruments meet the criteria for hedge accounting treatment. A prerequisite for obtaining this accounting-hedge relationship is extensive documentation on inception and proving on a regular basis that the economic hedge is effective for accounting purposes. Other derivative financial instruments do not meet the criteria to qualify for hedge accounting or are not designated in a hedge relationship. Changes in the fair value of these derivative instruments are recognized immediately in &#8220;Other financial income and expense&#8221; in the consolidated income statement.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, the Group has designated certain long-term debt components as hedges of the translation risk arising on certain net investments in foreign operations. On consolidation, foreign currency differences arising on long-term debt designated as net investment hedges of a foreign operation are recognized in other comprehensive income and accumulated in currency translation effects, to the extent that the hedge is effective. The foreign currency differences arising from hedge ineffectiveness are recognized in the income statement in &#8220;Other financial income and expense.&#8221;</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">When a hedged net investment is disposed of, the proportionate portion of the cumulative amount recognized in equity in relation to the hedged net investment is transferred to the consolidated income statement as an adjustment to the gain or loss on disposal.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Inventories</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inventory is valued at the lower of acquisition or production cost determined on a first-in, first-out basis and net realizable value. This value is used for the &#8220;Cost of goods sold&#8221; in the consolidated income statement. Unsaleable inventory is fully written off in the consolidated income statement under &#8220;Cost of goods sold.&#8221;</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Trade receivables</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as rebates, chargebacks and cash discounts.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions for doubtful trade receivables are established using a forward-looking expected credit loss model (ECL), which includes possible default events on the trade receivables over the entire holding period of the trade receivable. These provisions represent the difference between the trade receivable&#8217;s carrying amount in the consolidated balance sheet and the estimated collectible amount. Charges for doubtful trade receivables are recorded as marketing and selling costs recognized in the consolidated income statement within &#8220;Selling, general and administration&#8221; expenses.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Legal and environmental liabilities</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis and its subsidiaries are subject to contingencies arising in the ordinary course of business, such as patent litigation, environmental remediation liabilities and other product-related and commercial litigation, and governmental investigations and proceedings. A provision is recorded when there is a probable outflow of resources for which a reliable estimate can be made of the outcome of the legal or other disputes against the subsidiary.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Contingent consideration</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In the acquisition or divestment of a business, it is necessary to recognize contingent future amounts due to previous owners, representing contractually defined potential amounts as a liability or an asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at fair value, which is then remeasured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance, and are adjusted for the probability of their likelihood of payment, and are appropriately discounted to reflect the impact of time.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in &#8220;Cost of goods sold&#8221; for currently marketed products and in &#8220;Research and development&#8221; for IPR&amp;D. Changes in contingent consideration assets are recognized in &#8220;Other income&#8221; or &#8220;Other expense,&#8221; depending on their nature. </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The effect of unwinding the discount over time is recognized for contingent consideration liabilities in &#8220;Interest expense&#8221; and for contingent consideration assets as interest income recognized in the consolidated income statement within &#8220;Other financial income and expense.&#8221;</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined benefit pension plans and&#160;other&#160;post-employment benefits</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The liability in respect of defined benefit pension plans and other post-employment benefits is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions in which employees are employed, while the net interest on the net defined benefit liability or asset is recognized as &#8220;Other expense&#8221; or &#8220;Other income.&#8221;</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Treasury shares</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Treasury shares are initially recorded at fair value on their trade date, which is different from the settlement date, when the transaction is ultimately effected. Treasury shares are deducted from consolidated equity at their nominal value of CHF&#160;0.50 per share. Differences between the nominal amount and the transaction price on purchases or sales of treasury shares with third parties, or the value of services received for the shares allocated to employees as part of share-based compensation arrangements, are recorded in &#8220;Retained earnings&#8221; in the consolidated statement of changes in equity.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Revenue recognition</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Revenue on the sale of Novartis Group products and services, which is recorded as &#8220;Net sales to third parties&#8221; in the consolidated income statement, is recognized when a contractual promise to a customer (performance obligation) has been fulfilled by transferring control over the promised goods and services to the customer, substantially all of which is at the point in time of shipment to or receipt of the products by the customer or when the services are performed. If contracts contain customer acceptance provisions, revenue is recognized upon the satisfaction of the acceptance criteria. If a contract contains more than one performance obligation, the consideration is allocated based on the standalone selling price of each performance obligation. The amount of revenue recognized is based on the consideration Novartis expects to receive in exchange for its goods and services, when it is highly probable that a significant reversal will not occur.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consideration Novartis receives in exchange for its goods or services may be fixed or variable. Variable consideration is recognized when it is highly probable that a significant reversal will not occur. The most common elements of variable consideration are listed below.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Rebates and discounts granted to wholesalers, retailers, government agencies (including US Medicaid and US Federal Medicare programs), government supported healthcare systems, private health systems, pharmacy benefit managers, managed healthcare organizations, purchasing organizations and other direct and indirect customers, as well as chargebacks are provisioned and recorded as revenue deductions at the time the related revenues are recorded, or when the incentives are offered. These rebates and discounts, applied using provision rates, are estimated based on the terms and conditions in the individual states, plans and customer agreements, historical experience, product sales and growth rate, population growth, product pricing including inflation impacts, the mix of contracts and products, the level of inventory in the distribution channel, regulations, contracts, channels and payers, as appropriate to the individual rebate and discount arrangements.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Refunds granted to healthcare providers under innovative pay-for-performance agreements (i.e. outcome based arrangements) are provisioned and recorded as a revenue deduction at the time the related sales are recorded. They are calculated on the basis of historical experience and clinical data available for the product, as well as specific terms of the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until the uncertainty is resolved, until such history is available or the period when the refund right has expired. The provisions for revenue deductions under the innovative pay-for-performance agreements are adjusted periodically based on established processes and actual experience, including the products actual outcomes achieved compared with the anticipated predefined targets.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Cash discounts are offered to customers to encourage prompt payment and are provisioned and recorded as revenue deductions at the time the related sales are recorded.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Shelf stock adjustments are generally granted to customers, primarily of the Sandoz Division, to cover the inventory held by them at the time a price decline becomes effective. Revenue deduction provisions for shelf stock adjustments are recorded when the price decline is anticipated, based on the impact of the price decline on the customer&#8217;s estimated inventory levels. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Sales returns provisions are recognized and recorded as revenue deductions when there is historical experience of Novartis agreeing to customer returns and Novartis can reasonably estimate expected future returns. In doing so, the estimated rate of return is applied, determined on the basis of historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a resale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Net sales to third parties and provisions for revenue deductions are adjusted periodically to reflect experience and to reflect actual amounts as rebates, refunds, </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">discounts and returns are processed. There is often a time lag between recording of revenue deductions and the final accounting for them. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these revenue deductions.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">&#8220;Other revenue&#8221; includes income from profit-sharing arrangements with our collaboration partners, and royalty and milestone income from the out-licensing of intellectual property when Novartis retains an interest in the intellectual property through a license. Royalty income earned from a license is recognized when the underlying sales have occurred. Milestone income is recognized at the point in time when it is highly probable that the relevant milestone event criteria are met, and the risk of reversal of revenue recognition is remote. &#8220;Other revenue&#8221; also includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties, and is recognized when control transfers to the third party and our performance obligations are satisfied. </div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Research and development</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Internal research and development (R&amp;D) costs are fully charged to &#8220;Research and development&#8221; in the consolidated income statement in the period in which they are incurred. The Group considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland or Japan.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&amp;D, that are deemed not to transfer intellectual property to Novartis are expensed as internal R&amp;D expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been received from a regulatory authority in a major market.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are capitalized, as are payments for other assets, such as technologies to be used in R&amp;D activities. If additional payments are made to the originator company to continue performing R&amp;D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&amp;D services not resulting in an additional transfer of intellectual property rights to Novartis. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Novartis of additional intellectual property developed at the risk of the originator company. Subsequent internal R&amp;D costs in relation to IPR&amp;D and other assets are expensed, since the technical feasibility of the internal R&amp;D activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval in a major market are capitalized and recognized as currently marketed products.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Inventory produced ahead of regulatory approval is fully provisioned, and the charge is included in &#8220;Other expense&#8221; in the consolidated income statement, as its ultimate use cannot be assured. If this inventory can subsequently be sold, the provision is released to &#8220;Other income&#8221; in the consolidated income statement, either on approval by the appropriate regulatory authority or, exceptionally in Europe, on recommendation by the Committee for Medicinal Products for Human Use (CHMP), if approval is virtually certain.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Share-based compensation</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Vested Novartis shares and American Depositary Receipts (ADRs) that are granted as compensation are valued at their market value on the grant date and are immediately expensed in the consolidated income statement.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair values of unvested restricted shares (RSs), restricted share units (RSUs) and performance share units (PSUs) in Novartis shares and ADRs granted to employees as compensation are recognized as an expense over the related vesting period. The expense recorded in the consolidated income statement is included in the personnel expenses of the various functions in which the employees are employed.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Unvested restricted shares, restricted ADRs and RSUs are only conditional on the provision of services by the plan participant during the vesting period. They are valued at fair value on the grant date. As RSUs do not entitle the holder to dividends, the fair value is based on the Novartis share price at the grant date adjusted for the net present value of the dividends expected to be paid during the holding period. The fair value of these grants, after making adjustments for assumptions related to forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">PSUs are subject to the achievement of certain performance criteria during the vesting period and require plan participants to provide services during this period. The following paragraphs provide an overview of the accounting policies for the share-based compensation plan that grant PSUs. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs that are subject to performance criteria based on Novartis internal performance metrics and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on assumptions concerning the expected performance against the internal performance metrics throughout the vesting period. The assumptions are based on the Group&#8217;s targets for those performance metrics, and the expected forfeitures due to plan participants not meeting their service conditions. The </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">assumptions are periodically adjusted over the vesting period. Any change in estimates for past services is recorded immediately as an expense or income in the consolidated income statement, and amounts for the remaining vesting period are expensed on a straight-line basis. As a result, at the end of the vesting period, the charge during the entire vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs that are subject to performance criteria based on variables that can be observed in the market, which for Novartis plans is the Novartis total shareholder return (TSR) relative to a specific peer group of companies over the vesting period, and that are conditional on the provision of services by the plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on the total fair value of the grant over the vesting period. IFRS requires that these variables that can be observed in the market are taken into account in determining the fair value of the PSUs at the grant date. Novartis determined the fair value of these PSUs at the date of grant using a Monte Carlo simulation model. Adjustments to the number of equity instruments granted are only made if a plan participant does not fulfill the service conditions.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs granted under plans that are subject to both performance criteria based on Novartis internal performance metrics and Novartis TSR relative to a specific  peer group of companies over the vesting period and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on a bifurcation into the components based on the performance criteria related to Novartis internal performance metrics and TSR, as described in the paragraphs above.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Measuring the fair values of PSUs granted that include TSR performance criteria requires use of estimates. The Monte Carlo simulation used to determine the fair value of the PSUs TSR performance criteria requires the probability of factors related to uncertain future events; the term of the award; the grant price of underlying shares or ADRs; expected volatilities; the expected correlation matrix of the underlying equity instruments with those of the peer group of companies; and the risk-free interest rate as input parameters.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If a plan participant leaves Novartis for reasons other than retirement, disability or death, then unvested restricted shares, restricted ADRs, RSUs and PSUs are forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Novartis Board of Directors, for example, in connection with a reorganization or divestment.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Government grants</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Grants from governments or similar organizations are recognized at their fair value when there is reasonable assurance that the grant will be received and the Group will comply with all attached conditions.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Government grants received to compensate costs are deferred and recognized in the consolidated income statement over the period necessary to match them against the related costs that they are intended to compensate.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The accounting policy for property, plant and equipment describes the treatment of any related grants.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Restructuring charges</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Restructuring provisions are recognized for the direct expenditure arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Charges to increase restructuring provisions are included in &#8220;Other expense&#8221; in the consolidated income statements. </div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Healthcare contributions</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Healthcare cost contribution levies and fees under governmental programs that require the Group to contribute to a country&#8217;s healthcare costs, other than programs described in &#8220;Revenue recognition&#8221; in this Note 1, are recognized in &#8220;Other expense&#8221; in the consolidated income statement. Provisions for healthcare cost contributions are adjusted to the actual amounts levied. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these healthcare cost contributions. </div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Income taxes</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Income taxes comprise current income taxes and deferred income taxes and are recognized in the same periods as the revenues and expenses to which they relate. Income taxes include interest and penalties incurred during the period, insofar as they are considered an income tax. Income taxes related to items recognized directly to other comprehensive income or to equity are recognized together with the corresponding item, to which the income tax is attributable, directly in other comprehensive income or in equity.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Deferred income taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax base of an asset or liability and its carrying value for financial reporting purposes, except for those temporary differences related to investments in subsidiaries and associated companies, where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary&#8217;s retained earnings are only recognized when a dividend is declared or has been planned. Furthermore, deferred income taxes are recognized for the net tax effects of net operating loss carryforwards and tax credits. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The carrying amount of deferred tax assets is reduced to the extent that it is not probable that sufficient taxable profits will be available to enable all or part of the asset to be recovered. In evaluating our ability to recover our deferred tax assets in the jurisdiction from </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimated amounts for current and deferred tax assets or liabilities, including amounts related to any uncertain tax positions, are based on applicable tax law and regulations in the various tax jurisdictions, in which the Group operates, which are subject to interpretations based on currently known facts and circumstances.  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Tax returns are based on an interpretation of tax laws and regulations, and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made requiring payments of additional tax, interest or penalties. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The calculation of income tax assets and liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions across our global operations. As a result, inherent uncertainties exist in the estimates of the tax positions. Tax liabilities for uncertain tax provisions are recognized on the consolidated balance sheets within current income tax liabilities.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of new IFRS standards, amendments and interpretations in 2022</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There were no new IFRS standards adopted by the Group in 2022. In addition, new IFRS amendments or interpretations that became effective in 2022 did not have a material impact to the Group&#8217;s consolidated financial statements. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Based on the Group&#8217;s assessment, there are no IFRS standards, amendments or interpretations not yet effective in 2022 that would be expected to have a material impact on the Group&#8217;s consolidated financial statements.</div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of adopting significant new IFRS standard in 2021</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following new IFRS standard has been adopted by Novartis from January 1, 2021:</div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest Rate Benchmark Reform &#8211; Phase 2, Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 (Interest Benchmark Reform Amendments)</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Interest Benchmark Reform Amendments became effective from January 1, 2021. These amendments address issues that might affect financial reporting when an existing interest rate benchmark (i.e. Interbank offered rate &#8211; IBOR) is replaced with an alternative benchmark interest rate. The effects of interest rate benchmark reform on the Group&#8217;s financial instruments and risk management strategies did not have a material impact on the Group&#8217;s consolidated financial statements.</div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of adopting significant new IFRS standard in 2020</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following new IFRS standard has been adopted by Novartis from January 1, 2020:</div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">IFRS 3 Business Combinations amendments</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The IASB issued amendments to IFRS 3 Business Combinations that revised the definition of a business, which assist entities with the evaluation of when an asset or group of assets acquired should be considered a business. This amended standard has been applied to transactions entered into on or after January 1, 2020. The amended standard allows an entity to apply an optional concentration test, on a transaction-by-transaction basis, to evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this optional concentration test is met, the set of activities and assets is determined not to be a business. The adoption of this amended standard on January 1, 2020, did not have a significant impact on our consolidated financial statements and is not expected to have a significant impact in future periods. However, this will depend on the facts and circumstances of future transactions and if the Group decides to apply the optional concentration test in the assessment of whether an acquired set of activities and assets is or is not a business.</div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div/>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859550576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfSignificantTransactionsAbstract', window );"><strong>Disclosure of significant transactions [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfSignificantTransactionsTextBlock', window );">Significant transactions</a></td>
<td class="text">
          <div>
            <div id="anchorId001517396"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">2. Significant transactions</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group applied the acquisition method of accounting for businesses acquired, and did not elect to apply the optional concentration test to account for acquired business as an asset separately acquired.</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2022</span>
            </div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &#8211; acquisition of Gyroscope Therapeutics Holdings plc</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On December 22, 2021, Novartis entered into an agreement to acquire all outstanding shares of Gyroscope Therapeutics Holdings plc (Gyroscope), a UK-based ocular gene therapy company. Gyroscope focuses on the discovery and development of gene therapy treatments for retinal indications. The purchase price consisted of a cash payment of USD 0.8 billion, subject to certain customary purchase price adjustments, and potential additional milestone payments of up to USD 0.7 billion, which Gyroscope shareholders are eligible to receive upon achievement of specified milestones. The acquisition closed on February 17, 2022. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD 1.0 billion. The amount consisted of an upfront cash payment of USD 0.8 billion (including customary purchase price adjustments) and the fair value of contingent consideration of USD 0.2 billion, which Gyroscope shareholders are eligible to receive upon achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD 0.9 billion, consisting primarily of intangible assets of USD 1.1 billion and net deferred tax liabilities of USD 0.2 billion. Goodwill amounted to USD 0.1 billion.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The results of operations since the date of acquisition are not material.</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2021</span>
            </div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz &#8211; acquisition of GSK&#8217;s cephalosporin antibiotics business</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On February 10, 2021, Sandoz entered into an agreement with certain subsidiaries of GlaxoSmithKline plc (GSK) for the acquisition of the GSK&#8217;s cephalosporin antibiotics business. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Under the agreement, Sandoz acquired the global rights to three established brands (Zinnat&#174;, Zinacef&#174; and Fortum&#174;) in more than 100 markets. It excluded the rights in the US, Australia and Germany to certain of those brands, which were previously divested by GSK, and the rights in India, Pakistan, Egypt, Japan (to certain of the brands) and China, which will be retained by GSK. The transaction closed on October 8, 2021.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The purchase price consisted of a USD 350 million upfront payment paid at closing and potential milestone payments up to USD 150 million, which GSK will be eligible to receive upon the achievement of certain annual sales milestones for the portfolio.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD 415 million. The amount consisted of a payment of USD 351 million, including purchase price adjustments, and the fair value of contingent consideration of USD 64 million, which GSK is eligible to receive upon the achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD 308 million, consisting of USD 292 million intangible assets and USD 16 million deferred tax assets. Goodwill amounted to USD 107 million. </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The 2021 results of operations since the date of acquisition were not material.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Corporate &#8211; divestment of the investment in Roche Holding AG </span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 3, 2021, Novartis entered into a Share Repurchase Agreement with Roche Holding AG under which Novartis agreed to sell 53.3 million (approximately <span>33.3%</span>) bearer shares of Roche Holding AG voting shares in a bilateral transaction to Roche Holding AG for a total consideration of USD 20.7 billion. As a result, Novartis discontinued the use of equity method accounting starting from November 3, 2021.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The transaction closed on December 6, 2021. Novartis realized a gain of USD 14.6 billion, recorded in income from associated companies.</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Significant transactions in 2020</span>
            </div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines &#8211; acquisition of The&#160;Medicines Company</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 23, 2019, Novartis entered into an agreement and plan of merger (&#8220;the Merger Agreement&#8221;) with The Medicines Company, a US-based pharmaceutical company headquartered in Parsippany, New Jersey, USA. Pursuant to the Merger Agreement, on December 5, 2019, Novartis, through a subsidiary, commenced a tender offer to acquire all outstanding shares of The Medicines Company for USD 85 per share, or a total consideration of approximately USD 9.6 billion in cash on a fully diluted basis, including the equivalent share value related to The Medicines Company&#8217;s convertible notes, in accordance with their terms. The tender offer expired on January 3, 2020, and on January 6, 2020, the acquiring subsidiary merged with and into The Medicines Company, resulting in The Medicines Company becoming an indirect wholly owned subsidiary of Novartis. Novartis financed the transaction through available cash, and short- and long-term borrowings. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Medicines Company is focused on the development of inclisiran, a potentially first-in-class, twice yearly therapy that allows administration during patients&#8217; routine visits to their healthcare professionals and will potentially contribute to improved patient adherence and sustained lower LDL-C levels.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was USD 9.6 billion. The purchase price allocation resulted in net identifiable assets of approximately USD 7.1 billion, consisting of USD 8.5 billion intangible assets, USD 1.4</div>
          </div>

          <div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "> billion net deferred tax liabilities and goodwill of approximately USD 2.5 billion. </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The 2020 results of operations since the date of acquisition were not material.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz &#8211; acquisition of the Japanese business of Aspen Global Incorporated </span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 11, 2019, Sandoz entered into an agreement for the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Under the agreement, Sandoz acquired the shares in Aspen Japan K.K. and associated assets held by AGI. The transaction closed on January 31, 2020.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Aspen&#8217;s portfolio in Japan consisted of off-patent medicines with a focus on anesthetics and specialty brands. The acquisition will enable Sandoz to expand its presence in the third-largest worldwide generics marketplace.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The purchase price consisted of EUR 274 million (USD 303 million) upfront payment, less customary purchase price adjustment of EUR 27 million (USD 30 million), plus potential milestone payments of up to EUR 70 million (USD 77 million), which AGI is eligible to receive upon the achievement of specified milestones.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration was EUR 294 million (USD 324 million). The amount consisted of a cash payment of EUR 247 million (USD 273 million) and the fair value of contingent consideration of EUR 47 million (USD 51 million), which AGI is eligible to receive upon the achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD 238 million, consisting of USD 196 million intangible assets, USD 26 million other net assets and USD 16 million net deferred tax assets. Goodwill amounted to USD 86 million. </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The 2020 results of operations since the date of acquisition were not material.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz &#8211; retention of US dermatology business and generic US oral solids portfolio, previously planned to be divested</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On September 6, 2018, Novartis announced that it entered into a stock and asset purchase agreement (SAPA) with Aurobindo Pharma USA Inc. (Aurobindo) for the sale of selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, for USD 0.8 billion in cash and potential earnouts. The closing was conditional on obtaining regulatory approval.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In March 2020, Novartis took the decision to retain the Sandoz US generic oral solids and dermatology businesses and on April 2, 2020 entered into a mutual agreement with Aurobindo to terminate the transaction. The decision was taken as approval from the US Federal Trade Commission for the transaction was not obtained within the agreed timelines.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The cumulative amount of the depreciation on property, plant and equipment (USD 38 million) and amortization on intangible assets (USD 102 million) not recorded in the consolidated income statement since the date of classification as held for sale was recognized in the consolidated income statement in the first quarter of 2020. In addition, an impairment of currently marketed products of USD 42 million was recognized in the first quarter of 2020 consolidated income statement.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As at March 31, 2020, the assets and liabilities of the Sandoz US generic oral solids and dermatology businesses were reclassified out of assets and liabilities of disposal group held for sale. The prior year balance sheet was not required to be restated.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There were no cumulative income or expenses included in the other comprehensive income relating to the disposal group.</div>
          </div>

          <div/>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfSignificantTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfSignificantTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfSignificantTransactionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfSignificantTransactionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859550576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">Segmentation of key figures</a></td>
<td class="text">
          <div>
            <div id="anchorId001517643"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">3. Segmentation of key figures 2022, 2021 and 2020</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The businesses of Novartis are divided operationally on a worldwide basis into two identified reporting segments: Innovative Medicines and Sandoz. In addition, we separately report Corporate activities.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Reporting segments are presented in a manner consistent with the internal reporting to the chief operating decision-maker, which is the Executive Committee of Novartis. The reporting segments are managed separately because they each research, develop, manufacture, distribute and sell distinct products that require differing marketing strategies. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Executive Committee of Novartis is responsible for allocating resources and assessing the performance of the reporting segments.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The reporting segments are as follows:</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Innovative Medicines researches, develops, manufactures, distributes and sells patented pharmaceuticals. Effective as of April 4, 2022, the Innovative Medicines Division is organized in two commercial organizational units: Innovative Medicines International and Innovative Medicines US, and is focused on the core therapeutic areas: cardiovascular; immunology; neuroscience; solid tumors and hematology; as well as other promoted brands (in the therapeutic areas of ophthalmology and respiratory) and established brands. Prior to the announcement on April 4, 2022, the Innovative Medicines Division was organized into two global business units: Novartis Oncology and Novartis Pharmaceuticals.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sandoz develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. Sandoz is organized globally into three franchises: Retail Generics, Anti-Infectives and Biopharmaceuticals. In Retail Generics, Sandoz develops, manufactures and markets finished dosage forms of small molecule pharmaceuticals for sale to third parties across a broad range of therapeutic areas, including finished dosage form of anti-infectives sold to third parties. In Anti-Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by Retail Generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products, including biosimilars, and provides biotechnology manufacturing services to other companies.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Income and expenses relating to Corporate include the costs of the Group headquarters and those of corporate coordination functions in major countries. In addition, Corporate includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights, certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships. Usually, no allocation of Corporate items is made to the segments. As a result, Corporate assets and liabilities principally consist of net debt (cash and cash equivalents, marketable securities less financial debts), investments in associated companies, and current and deferred taxes and non-segment-specific environmental remediation and post-employment benefit liabilities. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Our divisions are supported by Novartis Institutes for BioMedical Research, Global Drug Development, and the Operations unit. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  The Novartis Institutes for BioMedical Research (NIBR) conducts research activities for the Innovative Medicines Division and also collaborates with Sandoz. </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  The Global Drug Development organization oversees all drug development activities for our Innovative Medicines Division and collaborates with our Sandoz Division on the development of its biosimilars portfolio.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  The Operations unit, combines the Novartis Technical Operations (NTO) and Customer &amp; Technology Solutions (CTS), following the internal reorganization announced on April 4, 2022. The Operations unit manages our manufacturing operations across our Innovative Medicines and Sandoz Divisions, and delivers business support services across the Group, such as information technology, real estate and facility services and procurement.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The accounting policies mentioned in Note 1 are used in the reporting of segment results. Inter-segmental sales are made at amounts that are considered to approximate arm&#8217;s length transactions. The Executive Committee of Novartis evaluates segmental performance and allocates resources among the segments based on a number of measures, including net sales to third parties, operating income and net operating assets. Segment net operating assets consist primarily of property, plant and equipment; right-of-use assets; intangible assets; goodwill; inventories; and trade and other operating receivables less operating liabilities.</div>
          </div>

          <div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#8211; consolidated income statements</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate  (including eliminations)<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group  </div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            41 296
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            41 995
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 249
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 631
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            50 545
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to other segments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            825
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            795
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            180
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 030</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            42 121
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            42 790
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 454
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 811
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 030</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            50 545
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 179
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            61
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 283
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-11 569</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-11 751</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4 978</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 147</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 061
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 031
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-15 486</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 867</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 801
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            32 218
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 504
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 725
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            67
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            36 342
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            37 010
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-11 679</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-12 306</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 062</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 062</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-512</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-518</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-14 253</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14 886</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9 172</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8 641</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-824</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-899</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9 996</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9 540</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            531
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 149
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            103
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            233
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            171
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            470
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            805
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 852
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 695</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 732</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-273</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-733</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-618</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 701</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 747</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 786
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10 688
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 448
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 600
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 037</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-599</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 689
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Loss)/income from associated companies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 332
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 339
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-837</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-811</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-80</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 371
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 137
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 416</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 119</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 955
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            24 018
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Shareholders of Novartis AG</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            6 955
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            24 021
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Non-controlling interests</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net income are:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Interest income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            379
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            71
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Depreciation of property, plant and equipment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-837</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-859</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-204</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-210</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-122</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-139</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 163</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 208</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Depreciation of right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-252</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-265</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-33</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-39</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-15</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-300</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-318</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Amortization of intangible assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 728</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 638</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-222</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-238</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-32</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 982</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 903</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges on property, plant and equipment, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-407</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-271</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-407</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-281</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment of right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges on intangible assets, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 299</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-367</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-25</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 326</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-403</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges and fair value changes on financial assets, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-134</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-126</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-260</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to restructuring provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 069</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-240</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-40</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-259</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-26</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 368</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-328</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Equity-based compensation of Novartis equity plans</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-706</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-721</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-280</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-193</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 048</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-979</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate  (including eliminations)<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group  </div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            41 995
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            39 013
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 631
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 646
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            48 659
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to other segments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            795
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            792
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            180
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            189
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-981</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            42 790
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            39 805
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 811
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 835
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-981</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            48 659
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 179
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            61
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 239
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-11 751</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-10 927</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 147</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 252</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 031
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 058
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 867</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 121</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            32 218
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 896
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 725
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 636
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            67
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            245
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            37 010
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            34 777
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-12 306</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-11 657</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 062</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 076</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-518</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-464</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14 886</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14 197</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8 641</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8 118</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-899</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-862</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9 540</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8 980</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 149
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            922
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            233
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            176
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            470
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            644
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 852
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 742
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 732</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 871</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-831</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-618</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-488</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 747</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 190</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10 688
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 172
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 600
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 043
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-599</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-63</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 689
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10 152
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 332
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            670
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 339
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-811</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-869</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-80</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-78</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 878
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 119</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 807</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            24 018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 071
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Shareholders of Novartis AG</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            24 021
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            8 072
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Non-controlling interests</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net income are:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Interest income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            71
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            91
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Depreciation of property, plant and equipment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-859</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-912</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-210</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-282</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-139</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-124</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 208</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 318</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Depreciation of right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-265</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-273</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-39</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-41</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-318</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-330</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Amortization of intangible assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 638</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 080</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-238</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-370</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 903</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 462</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges on property, plant and equipment, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-271</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-324</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-116</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-281</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-440</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges on intangible assets, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-367</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-768</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-141</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-403</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-914</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges and fair value changes on financial assets, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            153
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            182
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            335
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to restructuring provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-240</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-217</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-98</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-26</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-39</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-328</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-354</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Equity-based compensation of Novartis equity plans</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-721</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-714</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-64</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-193</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-180</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-979</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-958</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#8211; consolidated balance sheets</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate  (including eliminations)<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group  </div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total assets</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            75 510
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            79 220
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            16 078
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            16 192
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            25 865
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            36 383
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            117 453
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            131 795
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-16 966</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-15 929</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 710</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 632</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-37 354</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-44 412</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-58 030</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-63 973</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            59 423
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            67 822
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net debt<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 245
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            868
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 245
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            868
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net operating assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            58 544
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            63 291
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            12 368
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12 560
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 244</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-7 161</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            66 668
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            68 690
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in assets and liabilities are:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Total property, plant and equipment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 488
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 861
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 901
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            415
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            476
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 764
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11 545
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to property, plant and equipment<sup style="white-space: nowrap"> &#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            842
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            991
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            292
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            349
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            85
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            90
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 219
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 430
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Total right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 233
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 349
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            90
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            104
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            108
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            108
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 431
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to right-of-use assets<sup style="white-space: nowrap">&#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            196
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            222
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            31
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            26
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            247
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            321
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Total goodwill and intangible assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            51 357
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            53 919
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9 230
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 603
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            358
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            255
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            60 945
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            63 777
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to goodwill and intangible assets<sup style="white-space: nowrap"> &#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 791
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 491
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            163
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            102
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            139
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            143
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 093
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 736
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Total investment in associated companies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            107
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            170
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            27
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            143
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            205
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to investment in associated companies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18 930
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28 329
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18 930
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28 329
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Financial debts and derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            26 175
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            29 197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            26 175
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            29 197
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Current income tax liabilities and deferred tax liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 219
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 219
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 485
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Eliminations mainly relate to the elimination of intercompany receivables and payables to other segments and inventories</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Note 29 provides additional disclosures related to net debt</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup> Excluding the impact of business acquisitions</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows countries that accounted for more than 5% of at least one of the respective Group totals, as well as regional information for net sales to third parties for the years ended December 31, 2022, 2021 and 2020, and for selected non-current assets for the years ended December 31, 2022 and 2021:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net sales to third parties<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total of selected non-current assets<sup>2</sup></div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Country</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            970
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            800
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23 708
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            32
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25 770
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            33
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United States</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            17 653
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16 818
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            33
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16 484
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35 353
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            48
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37 054
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            48
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">France</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 257
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 522
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 442
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 188
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 615
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Germany</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 278
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 870
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 518
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 229
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 378
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">China</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 128
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 052
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 573
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            599
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            703
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japan</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 683
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 804
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            165
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            217
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20 054
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            41
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20 808
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            40
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19 038
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 351
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            50 545
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            48 659
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            73 483
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            77 088
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Region</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18 467
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20 197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18 715
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35 896
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37 525
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Americas</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21 536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            42
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20 463
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            40
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19 725
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            41
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35 806
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37 522
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 966
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 219
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 781
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 041
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            50 545
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            48 659
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            73 483
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            77 088
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Net sales to third parties by location of customer</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Total of property, plant and equipment; right-of-use assets; goodwill; intangible assets; investment in associated companies and other non-current assets excluding post-employment benefit assets</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>
              <div/>
            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#8217;s largest, second-largest and third-largest customers account for approximately <span>16%</span>, <span>11%</span> and <span>7%</span> of net sales to third parties, respectively (2021: <span>17%</span>, <span>11%</span> and <span>6%</span>, respectively; 2020: <span>17%</span>, <span>11%</span> and <span>6%</span>, respectively). All segments had sales to these customers in 2022, 2021 and 2020.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The highest amounts of trade receivables outstanding were for these same three customers and amounted to approximately <span>16%</span>, <span>14%</span> and <span>7%</span>, respectively, of the trade receivables at December 31, 2022 (2021: <span>16%</span>, <span>12%</span> and <span>7%</span>, respectively).</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#8211; net sales to third parties</span>
                  </div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties by region<sup>1</sup></span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> 2022<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2021<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br/> (2021<br/> to 2022)<br/> USD %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2020<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br/> (2020<br/> to 2021)<br/> USD %</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13 554
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 919
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13 484
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15 899
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 999
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 342
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 929
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 304
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 718
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 914
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 773
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 469
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            41 296
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            41 995
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            39 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Established Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30 548
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            31 459
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            29 643
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Emerging Growth Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 748
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 370
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 913
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 278
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 231
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 754
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 819
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 142
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 613
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 662
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 501
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            969
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            872
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            772
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 631
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 646
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Established Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 460
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 855
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 089
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Emerging Growth Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 789
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 776
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 557
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18 467
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20 197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18 715
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            17 653
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16 818
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16 484
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 966
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 219
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 883
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 645
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            50 545
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            48 659
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Established Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37 008
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            38 314
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            36 732
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Emerging Growth Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13 537
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13 312
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11 927
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Net sales to third parties by location of customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div/>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines Division net sales to third parties by core therapeutic area; other promoted brands; and established brands</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> 2022<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2021<br/> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br/> (2021 to<br/> 2022)<br/> USD %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2020<br/> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br/> (2020 to<br/> 2021)<br/> USD %</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cardiovascular</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 644
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 548
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            31
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 497
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            42
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Leqvio</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            112
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Cardiovascular</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 756
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 560
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 497
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Immunology</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 788
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 718
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 995
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 365
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 428
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 133
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 059
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Immunology</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            7 287
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            7 205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 119
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Neuroscience</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 787
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 003
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 370
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 351
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            920
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            47
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            372
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Mayzent</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            357
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            281
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            27
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            170
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            65
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Aimovig</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            218
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            215
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            164
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            31
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Neuroscience</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 051
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 007
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 272
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Solid Tumors</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 770
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 693
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 231
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            937
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            31
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            687
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            36
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            474
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            577
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-18</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            635
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            471
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            475
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            445
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            373
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            329
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            320
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Pluvicto</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            271
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tabrecta</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            133
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            90
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            48
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            35
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            157
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Solid Tumors</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 723
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 101
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 666
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Hematology</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 088
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 016
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 738
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 923
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 060
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 958
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 339
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            587
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            474
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Adakveo</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            164
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Scemblix</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            149
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-67</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Hematology</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 452
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 430
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 617
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            14
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> 2022<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2021<br/> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br/> (2021 to<br/> 2022)<br/> USD %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2020<br/> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br/> (2020 to<br/> 2021)<br/> USD %</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Other Promoted Brands</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 874
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 160
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 933
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xiidra</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            487
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            468
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            376
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Ultibro</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            479
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            584
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-18</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            623
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Beovu</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            203
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            186
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            190
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other respiratory</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            84
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            58
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            26
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            104
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Other Promoted  Brands</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 127
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 451
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 148
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Promoted  Brands</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 396
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 754
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 319
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 238
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 413
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 439
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            859
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-21</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 199
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            745
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 024
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 188
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            743
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            901
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-18</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            980
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            652
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            773
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 003
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-23</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            512
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            938
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-45</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 083
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <i>Voltaren/Cataflam</i>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            334
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            373
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            360
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            329
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            431
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-24</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            452
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            323
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            563
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            653
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Neoral/Sandimmun(e)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            310
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            368
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            393
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contract manufacturing</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            214
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            108
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            98
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 641
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 257
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 944
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Established  Brands</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 900
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12 241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            13 694
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-11</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            41 296
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            41 995
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            39 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Reclassified to reflect the new Innovative Medicines divisional structures announced on April 4, 2022</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties of the top 20 Innovative Medicines Division brands in 2022</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>Brands</div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by<br/> therapeutic area, other<br/> promoted brands or<br/> established brands</div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Key indications</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> US<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Rest of <br/> world<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> Total<br/> USD m</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO),   ankylosing spondylitis  (AS), psoriatic arthritis   (PsA), non-radiographic   axial spondyloarthritis   (nr-axSPA)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 770
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 018
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 788
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure,  hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 354
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 290
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 644
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune   thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 083
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 005
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 088
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis  (RMS)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 153
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            860
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 013
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia  (CML)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            877
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 046
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 923
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related   macular degeneration (AMD),   diabetic macular edema (DME),  retinal vein occlusion (RVO)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 874
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 874
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic   adjuvant melanoma,  advanced non-small cell   lung cancer (NSCLC),   tumor agnostic with   BRAF mutation indication</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            678
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 770
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology      </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycytomia vera (PV),   graft-versus-host disease  (GvHD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy  (SMA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            434
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            936
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 370
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA),   chronic spontaneous urticaria   (CSU), nasal polyps</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 365
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 365
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors,  acromegaly</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            800
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            438
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 238
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2-   metastatic breast cancer</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            472
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            759
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 231
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,  TRAPS, HIDS/MKD, FMF,  SJIA, AOSD, gout)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            570
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            563
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 133
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing-remitting   multiple sclerosis (RRMS)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            921
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            171
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            859
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            859
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands      </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid  leukemia (CML),   gastrointestinal stromal  tumors (GIST)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            540
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            745
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            14
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            729
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            743
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            55
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            597
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            652
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology        </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> r/r pediatric and young   adults acute lymphoblastic   leukemia (ALL), diffuse large   B-cell lymphoma (DLBCL),   follicular lymphoma (FL)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            196
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            340
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            536
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/  tuberous sclerosis complex   (TSC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            171
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            512
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 brands total</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            12 753
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            19 384
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            32 137
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 146
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9 159
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            15 899
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            25 397
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            41 296
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="top">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties of the top 20 Innovative Medicines Division brands in 2021</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>Brands</div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by<br/> therapeutic area, other<br/> promoted brands or<br/> established brands<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Key indications</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> US<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Rest of <br/> world<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;">
                            <br/>
                            <br/> Total<br/> USD m</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology        </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO), ankylosing   spondylitis (AS),   psoriatic arthritis (PsA),  non-radiographic axial   spondyloarthritis (nr-axSPA)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 883
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 835
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 718
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 712
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 836
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 548
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis (RMS)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 427
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 360
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 787
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular   degeneration (AMD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 160
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 160
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia (CML)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            882
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 178
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 060
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            947
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 069
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 016
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors      </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic   adjuvant melanoma,  advanced non-small cell   lung cancer (NSCLC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            606
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 087
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 693
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycythemia vera (PV)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 595
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA),   chronic spontaneous urticaria   (CSU), nasal polyps</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 428
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 428
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors, acromegaly</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            843
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            570
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 413
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy (SMA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            469
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            882
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 351
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF,   SJIA, AOSD, gout)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            501
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            558
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 059
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia   (CML), gastrointestinal   stromal tumors (GIST)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            263
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            761
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 024
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/  tuberous sclerosis complex (TSC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            521
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            417
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            938
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2-   metastatic breast cancer</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            339
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            598
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            937
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            887
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            901
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            51
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            722
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            773
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology      </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> r/r pediatric and young   adults acute lymphoblastic   leukemia (ALL), diffuse large   B-cell lymphoma (DLBCL)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            230
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            357
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            587
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Ultibro</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cronic obstructive  pulmonary disease  (COPD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            584
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            584
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 688
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            20 976
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            32 664
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 311
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 331
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            14 999
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 996
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            41 995
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="top">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.</div>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties of the top 20 Innovative Medicines Division brands in 2020</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>Brands</div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by<br/> therapeutic area, other<br/> promoted brands or<br/> established brands<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Key indications</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> US<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Rest of <br/> world<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;">
                            <br/>
                            <br/> Total<br/> USD m</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology  </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO), ankylosing   spondylitis (AS), psoriatic arthritis (PsA)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 516
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 479
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 995
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis (RMS)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 562
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 441
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 003
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 277
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 220
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 497
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia (CML)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            859
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 099
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 958
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular   degeneration (AMD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 933
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 933
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune   thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            833
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            905
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 738
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors      </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic  adjuvant melanoma,   advanced non-small cell   lung cancer (NSCLC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            569
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            973
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 542
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors,  acromegaly</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            837
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            602
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 439
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycythemia vera (PV)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 339
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 339
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA),  chronic spontaneous urticaria   (CSU)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 199
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 199
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia (CML),  gastrointestinal stromal tumors (GIST)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            315
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 188
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/  tuberous sclerosis complex (TSC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            644
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            439
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 083
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            124
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            879
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 003
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            964
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            980
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy  (SMA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            459
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            461
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            920
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF,   SJIA, AOSD gout)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            473
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2-   metastatic breast cancer</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            318
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            369
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            687
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic iron overload</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            138
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            515
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            653
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma (RCC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            259
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            376
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            635
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 126
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            18 790
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 916
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 216
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 881
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 097
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            14 342
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            24 671
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            39 013
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="top">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.</div>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>

                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz Division net sales to third parties by business franchise</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> 2022<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2021<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br/> (2021 to<br/> 2022)<br/> USD %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2020<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br/> (2020 to<br/> 2021)<br/> USD %</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Retail Generics<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 776
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 092
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 244
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Biopharmaceuticals</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 093
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 116
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 928
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Anti-Infectives<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            380
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            423
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            474
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-11</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales to third parties</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 631
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 646
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Sandoz total anti-infectives net sales to third parties amounted to USD 1.2 billion (2021: USD 1.1 billion; 2020: USD 1.2 billion), of which USD 777 million (2021: USD 707 million; 2020: USD 694 million) is sold through the Retail Generics business franchise and USD 380 million (2021: USD 423 million; 2020: USD 474 million) is sold to other third-party companies through the Anti-Infectives business franchise.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The product portfolio of Sandoz is widely spread in 2022, 2021 and 2020.</div>
              </div>
            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#8211; other revenue</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate   (including eliminations)</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group  </div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Profit-sharing income</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            921
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            835
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            921
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            835
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Royalty income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            74
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            107
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            52
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            109
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            300
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Milestone income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            127
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            148
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            155
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            50
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            155
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            162
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            114
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            54
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other revenues</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 179
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            61
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 283
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 239
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="26" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="26">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24__IFRS08_g20-24_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859589664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associated companies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract', window );"><strong>Disclosure of associates [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory', window );">Associated companies</a></td>
<td class="text">
          <div>
            <div id="anchorId001530097"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">4. Associated companies</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net income statement effect</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other comprehensive income effect<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total comprehensive income effect</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Roche Holding AG, Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 341
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            677
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            46
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-56</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 387
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            621
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 339
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            46
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-56</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 385
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            617
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="20" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="20">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> In 2021, Novartis share of other comprehensive income recognized by associated companies, net of taxes of USD 3 million was recycled into the consolidated income statement as a result of the divestment of the investment in Roche Holding AG. No Novartis share of other comprehensive income recognized by associated companies was recycled to the consolidated income statement in 2022 and 2020.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has certain non-significant investments and had a significant investment in Roche Holding AG, Basel (Roche), which was divested to Roche on December 6, 2021, that are accounted for as associated companies. </div>
              </div>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Roche Holding AG </span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 3, 2021, Novartis entered into an agreement with Roche Holding AG to divest its <span>33.3%</span> of Roche Holding AG (Roche) voting shares, representing approximately <span>6.2%</span> of Roche&#8217;s total outstanding voting and non-voting equity instruments, to Roche for USD 20.7 billion in cash. As a result, Novartis discontinued the use of equity method accounting starting from November 3, 2021.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The divestment transaction closed on December 6, 2021, and Novartis realized a gain of USD 14.6 billion, recorded in income from associated companies. See Note 2.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#8217;s holding in Roche voting shares was <span>33.3%</span> at December 31, 2020. This investment represented approximately <span>6.2%</span> of Roche&#8217;s total outstanding voting and non-voting equity instruments at December 31, 2020.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Since full-year financial data for Roche is not available when Novartis produces its consolidated financial results, a survey of analyst estimates is used to estimate the Group&#8217;s share of Roche&#8217;s net income. Any differences between these estimates and actual results were adjusted in the Group&#8217;s consolidated financial statements when available. As Novartis discontinued the use of equity method accounting starting from November 3, 2021, and the divestment closed on December 6, 2021, no such adjustment has been made to the 2022 Group&#8217;s consolidated financial statements.</div>
              </div>
            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2021, dividends received from Roche in relation to the distribution of its 2020 net income amounted to USD&#160;522 million.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consolidated income statement effects from applying Novartis accounting principles for this investment in 2021 and 2020 are as follows:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of Roche's  estimated current-year  consolidated net income</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            815
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            913
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prior-year adjustment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            40
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-64</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of fair value adjustments relating to intangible assets, net of taxes of 2021: USD 10 million; 2020: USD 26 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-70</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-172</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on divestment of the  investment in Roche<sup style="white-space: nowrap"> &#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 556
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income effect</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            677
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> The gain on divestment of the investment in Roche includes the recycling of currency translation effects (see Note 8.1) and other comprehensive income effects totaling USD 3.2 billion.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859476000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest expense and other financial income and expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract', window );"><strong>Disclosure of Interest Expense and Other Financial Income and Expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInterestExpenseExplanatory', window );">Interest expense and other financial income and expense</a></td>
<td class="text">
          <div>
            <div id="anchorId001530570"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">5. Interest expense and&#160;other&#160;financial&#160;income&#160;and&#160;expense</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest expense</span>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-669</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-651</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-708</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense on lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-60</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-67</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense arising from  discounting long-term liabilities and capitalized borrowing costs</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-108</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-98</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-94</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total interest expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-837</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-811</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-869</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other financial income and expense</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            379
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            71
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            91
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-194</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-94</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-52</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency result, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-184</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-69</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-135</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other financial income  and expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-80</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-78</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInterestExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of interest expense. [Refer: Interest expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInterestExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859385296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfIncomeTaxAbstract', window );"><strong>Disclosure of Income Tax [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income taxes</a></td>
<td class="text">
          <div>
            <div id="anchorId001530822"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">6. Income taxes</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Income before taxes</span>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 986
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22 028
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 786
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 385
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 109
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            92
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 371
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 878
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> The 2021 income before taxes in Switzerland includes a USD 14.6  billion non-taxable gain on the divestment of the Group&#8217;s investment in Roche Holding AG (see Note 2 and Note 4).</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Current and deferred income tax expense</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The significant components of the provision for income taxes are as follows:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-617</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-958</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-932</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 454</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 470</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 168</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current income tax expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2 071</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 428</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 100</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-142</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-137</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            797
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            286
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            430
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Deferred tax income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            655
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            309
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            293
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income tax expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 416</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 119</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 807</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Analysis of tax rate</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has a substantial business presence in many countries and is therefore subject to income taxes in different tax jurisdictions. This leads to differences in income and expense items that are non-taxable or non-deductible (permanent differences) or are taxed at different statutory tax rates in those tax jurisdictions. As a result, there is a difference between our applicable tax rate and effective tax rate.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The applicable tax rate changes from year to year due to changes in the mix of the Group&#8217;s pre-tax income and changes in statutory tax rates since it is calculated as the weighted average tax rate based on the pre-tax income of each subsidiary. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The main elements contributing to the difference between the Group&#8217;s overall applicable tax rate and the effective tax rate are shown in the following table:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(As a percentage)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Applicable tax rate</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            16.8
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14.8
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of disallowed expenditures</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4.6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of utilization of previously unrecognized tax losses brought forward from prior periods</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of income taxed at reduced rates</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-0.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of income not subject to tax<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-0.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax credits and allowances</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3.8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of release of  contingent consideration liability</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-0.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax rate change  on current and deferred  tax assets and liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-0.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of derecognition and reversals of derecognition  of deferred tax assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of write-down and reversal of  write-down of investments in subsidiaries</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.8</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of prior-year items</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-0.4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of changes in uncertain tax positions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of other items</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Effective tax rate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            16.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            18.3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <b/>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> 2021 includes the effect of income not subject to tax (<span>-7.3</span>%) arising from the non-taxable gain on the divestment of our investment in Roche. See Notes 2 and 4 for further details.</span>
                            <b/>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our effective tax rate fluctuates based primarily on, among other factors, changes in pre-tax income between countries with varying statutory tax rates, income taxed at reduced tax rates, effect of disallowed expenditures, effect of income not subject to tax, effect of tax credits and allowances, effect of prior-year items, changes in the measurement of deferred tax assets, changes in uncertain tax positions and changes in tax laws. The table above provides the details of the significant items </div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">that impact the comparability of the effective tax rate between years.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The utilization of tax-loss carry-forwards lowered the tax charge by USD&#160;1 million in 2022, by USD&#160;5 million in 2021, and by USD&#160;29 million in 2020.</div>
              </div>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88__IAS12_g79-88_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfIncomeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfIncomeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859432592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Earnings per share</a></td>
<td class="text">
          <div>
            <div id="anchorId001531519"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">7. Earnings per share</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income attributable to shareholders of Novartis AG (USD millions)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 955
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            24 021
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 072
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Number of shares (in millions)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Weighted average number of shares outstanding used in basic earnings per share</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 181
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 243
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 277
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average number of shares in diluted earnings per share</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 260
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 296
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share (USD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3.19
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10.71
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3.55
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Diluted earnings per share (USD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3.17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10.63
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3.52
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Basic earnings per share (EPS) is calculated by dividing net income attributable to shareholders of Novartis AG by the weighted average number of shares outstanding in a reporting period. This calculation excludes the average number of issued shares purchased by the Group and held as treasury shares.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For diluted EPS, the weighted average number of shares outstanding is adjusted to assume the vesting of all restricted shares, restricted share units, and the conversion of all potentially dilutive shares arising from options on Novartis shares that have been issued.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">
                  No options were excluded from the calculation of diluted EPS in 2022, 2021 or 2020, as all options were dilutive in all years.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div/>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862557760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Changes in consolidated statements of comprehensive income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAbstract', window );"><strong>Comprehensive income [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock', window );">Changes in consolidated statements of comprehensive income</a></td>
<td class="text">
          <div>
            <div id="anchorId001531738"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">8. Changes in consolidated statements of&#160;comprehensive income</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated statements of comprehensive income include the Group&#8217;s net income for the year as well as all other valuation adjustments recorded in the Group&#8217;s consolidated balance sheet, which under IFRS are not recorded in the consolidated income statement. These include fair value adjustments on financial instruments, actuarial gains or losses on defined benefit pension plans, and currency translation effects, net of taxes.</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Fair value<br/> adjustments <br/> on financial<br/> instruments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Actuarial<br/> gains/(losses)<br/> from defined<br/> benefit plans</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Cumulative<br/> currency <br/> translation<br/> effects</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total value<br/> adjustments<br/> attributable to <br/> Novartis AG <br/> shareholders</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Non-<br/> controlling<br/> interest</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Total value<br/> adjustments</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2019</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            120
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-5 919</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 142
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-4 657</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-29</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-4 686</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, net of taxes of USD <span>-36</span> million<sup style="white-space: nowrap"> &#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            250
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            250
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            250
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-201</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-201</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-201</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes of USD <span>-3</span> million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            143
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects, net of taxes of USD 10 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   8.1</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 193
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 193
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 194
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2020</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            250
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 992
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 387
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 386
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities  sold, reclassified to retained earnings</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-150</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-150</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-150</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2020</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            220
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-5 773</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 134
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 419</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-29</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 448</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, net of taxes of USD <span>-44</span> million<sup style="white-space: nowrap"> &#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge, net of taxes of USD 33 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            216
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            216
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            216
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes of USD <span>-323</span> million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 808
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 808
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 809
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects, net of taxes of USD 17 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   8.1</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4 757</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4 757</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4 762</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 808
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-4 541</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 539</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 543</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities sold, reclassified to retained earnings net of taxes of USD 48 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-164</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-164</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-164</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            188
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 968</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-407</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 187</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-33</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 220</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, net of taxes of USD 81 million<sup style="white-space: nowrap"> &#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-382</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-382</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-382</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge, net of taxes of USD <span>-30</span> million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            91
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            91
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            91
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes of USD <span>-104</span> million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-104</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-104</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-103</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects, net of taxes of USD 18 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   8.1</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-444</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-444</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-450</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-382</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-104</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-353</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-839</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-844</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities sold, reclassified to retained earnings net of taxes of nil</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments, net of taxes of USD <span>-4</span> million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-198</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 038</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-760</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 996</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-38</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-5 034</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Includes fair value adjustments on equity securities designated as financial assets valued at fair value through other comprehensive income with no subsequent recycling into the consolidated income statement</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div/>

            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">8.1) In 2022, net cumulative currency translation gains of USD 13 million were recycled through the income statement as a result of the divestments of subsidiaries. In 2021, net cumulative currency translation gains of USD 3.2 billion were recycled through the income statement as a result of the divestment of the investment in Roche. See Notes 2 and 4. In 2020, there were no currency translation losses or gains recycled through the income statement.</div>
              </div>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862692896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text">
          <div>
            <div id="anchorId001533390"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">9. Property, plant and equipment</div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of property, plant and equipment during 2022:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Land</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Buildings</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Construction <br/> in progress</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Machinery <br/> and other <br/> equipment</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            492
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 819
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 508
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13 328
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            27 147
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 744</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9 786</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-15 602</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 075
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 443
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            11 545
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 075
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 443
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            11 545
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            297
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-964</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            667
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            124
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            780
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            312
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 219
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-49</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-33</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-45</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-155</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-437</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-726</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 163</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-351</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-414</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-166</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-57</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-53</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-288</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            442
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 493
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 157
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 672
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            10 764
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            451
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 396
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 184
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 842
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24 873
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 903</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-8 170</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-14 109</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            442
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 493
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 157
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 672
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            10 764
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for purchases of property, plant and equipment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            549
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Capitalized borrowing costs</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of property, plant and equipment during 2021:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Land</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Buildings</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Construction <br/> in progress</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Machinery <br/> and other <br/> equipment</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            555
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12 377
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 248
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 038
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28 218
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 807</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-66</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-10 063</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 955</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 570
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 182
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 975
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12 263
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 570
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 182
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 975
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12 263
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-610</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            413
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            109
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 027
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            293
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 430
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-78</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-150</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-453</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-755</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 208</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-137</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-76</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-167</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-384</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            70
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            103
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-23</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-203</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-84</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-199</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-509</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 075
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 443
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 545
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            492
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11 819
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 508
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13 328
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            27 147
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 744</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9 786</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 602</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 075
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 443
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 545
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for purchases of property, plant and equipment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Capitalized borrowing costs</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>

                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the property, plant and equipment impairment charges and reversals by reporting segment:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment charges</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment reversals</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-411</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-315</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-326</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            44
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-121</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            59
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-414</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-384</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-447</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            103
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79__IAS16_g73-79_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864083824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-use assets and lease liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract', window );"><strong>Lease liabilities and Right of use assets Disclosure Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Disclosure of leases [text block]</a></td>
<td class="text">
          <div/>

          <div>
            <div id="anchorId001534918"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">10. Right-of-use assets and lease liabilities</div>
            <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of the right-of-use assets:</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Right-of-use assets at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 676
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            247
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            321
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-300</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-318</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease contract terminations<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-34</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-66</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-52</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-52</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total right-of-use assets at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 431
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Impairment charges in 2022 were recorded in the Innovative Medicines segment.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Lease contract terminations also includes modifications to existing leases that result in reductions to the right-of-use assets, and reductions due to sub-leasing.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the right-of-use assets carrying value and depreciation charge at December 31, 2022 and 2021, by underlying class of asset: </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> December 31,<br/> 2022<br/> carrying value</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Depreciation <br/> charge<br/> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31,<br/> 2021<br/> carrying value</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Depreciation <br/> charge<br/> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Land</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            505
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            16
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            522
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            745
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            866
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vehicles</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            117
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            96
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            136
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and equipment, and other assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            64
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 431
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            300
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            318
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the lease liabilities by maturity at December 31, 2022 and 2021:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Lease liabilities<br/> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Lease liabilities<br/> undiscounted<br/> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Lease liabilities<br/> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Lease liabilities<br/> undiscounted<br/> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less than one year</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            251
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            297
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            275
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            324
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between one and two years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            190
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            232
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            216
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            258
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between two and three years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            167
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            201
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            162
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            198
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between three and four years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            172
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            139
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            172
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between four and five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            122
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            154
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            122
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            154
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            922
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 149
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            982
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 243
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 789
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 896
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 349
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion of lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-251</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-297</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-275</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-324</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current portion of lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 538
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 908
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 621
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 025
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for leases not yet commenced</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            83
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            134
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At December 31, 2022, and December 31, 2021, there were no material future cash outflows, including extension options, excluded from the measurement of lease liabilities. The Group&#8217;s most material lease with a lease term extension, representing a lease liability value of USD 0.7 billion (2021: USD 0.6 billion), has a determined lease term end date of 2071 (2021: 2071). Non-enforceable extension options of up to 10 years have not been included within the measurement of this lease liability, and do not have a material impact to the carrying value of the lease for both 2022 and 2021. Should the landlord agree to a lease extension, rent will be referenced to the market rates as at the commencement of the extension period. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2022, the Group completed three sale and leaseback transactions for certain property, plant and equipment as part of the Groups plans to focus on key operating locations. The transactions resulted in net cash inflows of USD 49 million and the recognition of USD 23 million of lease liabilities, and USD 13 million of right-of-use assets. The right-of-use assets value reflects the proportion of the property, plant and equipment retained. Extension options have been included where management believe that such options will be exercised. The liabilities reflect the net present value of future lease payments. The net gain on the sale and leaseback transactions amounted to USD 17 million. There were no significant sale and leaseback transactions in 2021 or 2020.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table provides additional disclosures related to right-of-use assets and lease liabilities for 2022, 2021 and 2020:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense on lease liabilities<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            62
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            67
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense on short-term leases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense on low-value leases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total cash outflows for leases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            355
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            381
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            379
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Thereof:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Cash outflows for short-term leases and low-value leases<sup style="white-space: nowrap"> &#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Payments of interest<sup style="white-space: nowrap">&#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            51
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            52
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Payments of lease liabilities<sup style="white-space: nowrap">&#160;4</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            295
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            316
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            312
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> The weighted average interest rate is 3.3% (2021: 3.2%, 2020: 3.4%).</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Cash flows from short-term and low-value leases are included within total net cash flows from operating activities. The portfolio of short-term leases to which the Group is committed to at December 31, 2022, 2021 and 2020, is similar to the portfolio of short-term leases the Group entered into during 2022, 2021 and 2020.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup> Included within total net cash flows from operating activities</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;4&#160;</sup> Reported as cash outflows in financing activities net of lease incentives received, if any.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The net investment held and income from subleasing right-of-use assets were not significant for 2022, 2021, and 2020. Income from leasing Novartis property, plant and equipment to third parties for 2022, 2021 and 2020 was not significant. </div>
              </div>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50__IFRS16_g47-50_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60__IFRS16_g51-60_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864232464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and intangible assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract', window );"><strong>Disclosure of detailed information about intangible assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory', window );">Goodwill and intangible assets</a></td>
<td class="text">
          <div>
            <div id="anchorId001535868"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">11. Goodwill and intangible assets</div>
            <div>

                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of goodwill and intangible assets in 2022:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill</div>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible assets other than goodwill</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> In-process<br/> research and<br/> development</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Technologies</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently<br/> marketed <br/> products</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other<br/> intangible<br/> assets</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            29 900
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 080
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            56 213
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 905
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            68 211
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-305</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 514</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-903</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-29 107</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 505</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-34 029</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            29 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 499
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            27 106
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            34 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            29 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 499
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            27 106
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            34 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            161
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 209
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 209
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 429</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 403
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            330
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 175
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            588
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 093
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-95</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-100</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-37</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 603</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-342</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 982</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-917</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-15</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-322</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-72</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 326</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-427</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-176</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-243</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-432</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            29 301
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 421
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            121
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            25 513
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 589
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 644
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            29 596
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 092
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 038
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            58 249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 305
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            69 684
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-295</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 671</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-917</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-32 736</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 716</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-38 040</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            29 301
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 421
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            121
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            25 513
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 589
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 644
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of goodwill and intangible assets in 2021:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Goodwill</div>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Intangible assets other than goodwill</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> In-process<br/> research and<br/> development</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Technologies</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Currently<br/> marketed <br/> products</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other<br/> intangible<br/> assets</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            30 321
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 893
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 115
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            57 333
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 384
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            67 725
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-322</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 193</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-885</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-26 566</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 272</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30 916</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 999
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 700
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            230
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            30 767
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 112
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            36 809
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 999
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 700
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            230
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            30 767
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 112
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            36 809
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            238
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            262
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            292
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            98
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            652
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-20</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            958
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            270
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            508
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 736
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-36</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-37</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-41</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 607</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-255</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 903</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-350</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-17</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-35</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-403</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-642</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-51</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-584</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-672</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 499
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            27 106
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            34 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            29 900
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 080
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            56 213
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 905
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            68 211
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-305</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 514</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-903</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-29 107</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 505</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-34 029</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 499
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            27 106
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            34 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2022:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible assets other than goodwill</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> In-process<br/> research and<br/> development</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Technologies</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently<br/> marketed <br/> products</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other<br/> intangible<br/> assets</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21 531
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 186
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            14
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24 487
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 139
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            29 826
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 770
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            235
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            107
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 026
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            92
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 460
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            358
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            358
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            29 301
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 421
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            121
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            25 513
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 589
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 644
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> The Innovative Medicines and Sandoz Divisions&#8217; represent the grouping of cash-generating units, to which goodwill is allocated.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2021:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Goodwill<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Intangible assets other than goodwill</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> In-process<br/> research and<br/> development</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Technologies</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Currently<br/> marketed <br/> products</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other<br/> intangible<br/> assets</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21 562
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 313
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25 938
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 091
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            32 357
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 026
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            186
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            162
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            61
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 577
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            248
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            248
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 499
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            27 106
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            34 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> The Innovative Medicines and Sandoz Divisions&#8217; and Corporate represent the grouping of cash-generating units, to which goodwill is allocated.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As at December 31, 2022, the most significant intangible assets within currently marketed products category are <i>Leqvio</i> (Innovative Medicines: acquisition of The Medicines Company) and <i>Zolgensma</i> (Innovative Medicines: acquisition of Avexis Inc.). As at December 31, 2022, the carrying value and remaining amortization period for <i>Leqvio</i> is USD 7.4 billion and 13 years, respectively (2021: USD 7.9 billion and 14 years, respectively), and for <i>Zolgensma</i> USD 5.9 billion and 8 years, respectively (2021: USD 6.6 billion and 9 years, respectively). </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Innovative Medicines and Sandoz Divisions&#8217; cash-generating units, to which goodwill is allocated, </div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">each comprise a group of smaller cash-generating units. The valuation method of the recoverable amount of the group of cash-generating units, to which goodwill is allocated, is based on the fair value less costs of disposal. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following assumptions are used in the calculations:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(As a percentage)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative <br/> Medicines</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Sandoz</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Terminal growth rate</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.5
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discount rate (post-tax)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The discount rates for all divisions consider the Group&#8217;s weighted average cost of capital, adjusted to approximate the weighted average cost of capital of a comparable market participant.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value less costs of disposal, for all cash-generating units containing goodwill, is reviewed for the impact of reasonably possible changes in key assumptions. In particular, we considered an increase in the discount rate, a decrease in the terminal growth rate, and certain negative impacts on the forecasted cash flows. These reasonably possible changes in key assumptions did not indicate an impairment.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">&#8220;Note 1. Significant accounting policies&#8212;Impairment of goodwill and intangible assets&#8221; provides additional disclosures on how the Group performs goodwill and intangible asset impairment testing.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the intangible asset impairment charges and reversals by reporting segment: </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment charges</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment reversals</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 299</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-367</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-768</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-25</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-141</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 326</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-403</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-914</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> 2022 includes an impairment of USD 0.6 billion related to the write-down of IPR&amp;D related to cessation of clinical development program UNR844.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <span> 2021 includes an impairment of USD 0.2 billion related to the write-down of IPR&amp;D related to cessation of clinical development program GTX312.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <span> 2020 includes an impairment of USD 0.5 billion related to the write-down of IPR&amp;D related to cessation of clinical development program ZPL389 for atopic dermatitis and USD 0.2 billion related to a partial write-down of the <i>Votrient</i> currently marketed product (<i>Votrient</i> carrying value was USD 0.9 billion in 2022 and USD 1.3 billion in 2021).</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>
              <div/>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864232464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred tax assets and liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Disclosure of Deferred Tax Assets and Liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDeferredTaxesExplanatory', window );">Deferred tax assets and liablities</a></td>
<td class="text">
          <div>
            <div id="anchorId001538357"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">12. Deferred tax assets and liabilities </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Property, <br/> plant and<br/> equipment</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Intangible<br/> assets</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pensions and<br/> other benefit <br/> obligations <br/> of employees</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Inventories</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Tax loss<br/> carry-<br/> forwards</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Other assets,<br/> provisions<br/> and accruals</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax assets at January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            125
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 307
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 026
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 273
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            374
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 727
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            7 832
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax liabilities at January 1, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-381</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 704</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-591</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-148</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 335</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-7 159</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at January 1, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-256</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            435
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 125
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            374
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 392
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-256</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            435
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 125
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            374
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 392
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            69
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            628
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            655
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to equity</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to other comprehensive income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-104</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            63
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-300</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            55
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-244</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-185</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 059</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            319
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 076
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            425
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 477
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 053
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax assets at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            158
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 726
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            739
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 214
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            425
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 789
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 051
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax liabilities at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-343</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4 785</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-420</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-138</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 312</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6 998</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-185</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 059</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            319
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 076
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            425
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 477
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 053
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After offsetting the following amount of deferred tax  assets and liabilities within the same tax jurisdiction,  the balance amounts to:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 312
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 739
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 686</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 053
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax assets at January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            189
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 351
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 502
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            507
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 658
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 344
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax liabilities at January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-430</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-5 269</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-340</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-159</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 344</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-7 552</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-241</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 918</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            797
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 343
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            497
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 314
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            792
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-241</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 918</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            797
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 343
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            497
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 314
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            792
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            567
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-22</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-215</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-121</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            127
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            309
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to equity</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-35</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-35</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to other comprehensive income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-323</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-317</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-58</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-46</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-17</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-20</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-256</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            435
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 125
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            374
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 392
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax assets at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            125
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 307
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 026
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 273
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            374
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 727
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 832
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax liabilities at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-381</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4 704</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-591</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-148</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 335</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7 159</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-256</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            435
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 125
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            374
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 392
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After offsetting the following amount of deferred tax  assets and liabilities within the same tax jurisdiction,  the balance amounts to:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 089
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 743
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 070</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <b/>
                            <b/>
                            <b/>
                            <b/>
                            <b/>
                            <b/>
                            <b/>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <b/>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Deferred tax liabilities have not been recognized for the withholding tax and other taxes that would be payable on the remittance of earnings of foreign subsidiaries, insofar as the Group has the ability to control any future reversal and the unremitted earnings are retained in the foreign subsidiaries for reinvestment. The total unremitted earnings retained for reinvestment in the Group&#8217;s foreign subsidiaries that would be subject to withholding tax or other taxes if remitted to the Group are estimated at approximately USD 32 billion in 2022, (2021: USD 29 billion).</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The gross value of tax-loss carry-forwards that have or have not been recognized as deferred tax assets, with their expiry dates, is as follows:</div>
                </div>

            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Unrecognized</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Recognized</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022 total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One year</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Two years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            42
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Three years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Four years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            138
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            138
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            79
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            688
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            767
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">More than five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 880
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 380
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 260
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not subject to expiry</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            433
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            452
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            885
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 610
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 530
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 140
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Unrecognized</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rcognized</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021 total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One year</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Two years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Three years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            47
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Four years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            26
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            146
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            166
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">More than five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 872
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 408
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not subject to expiry</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            418
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            684
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 102
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 192
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 607
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 799
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tax losses carried forward  that expired</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Deferred tax assets related to carry-forwards of taxable losses and tax credits of relevant Group entities are recognized to the extent it is considered probable that future taxable profits will be available in the respective tax jurisdictions against which such losses and credits can be utilized.</div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDeferredTaxesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDeferredTaxesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862246512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial and other non-current assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract', window );"><strong>Disclosure of financial and other non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock', window );">Financial and other non-current assets</a></td>
<td class="text">
          <div>
            <div id="anchorId001540616"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">13. Financial and other non-current assets</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Financial assets</span>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity securities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 145
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 663
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            281
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            366
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 463
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 063
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term receivables from finance subleases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            59
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            70
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other long-term receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            184
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            607
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            641
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances and security deposits</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            85
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            78
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 411
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 036
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other non-current assets</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred compensation plans</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            419
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            520
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid post-employment benefit plans<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            491
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 415
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            200
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            275
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other non-current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 110
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 210
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 25 provides additional disclosures related to post-emplyment benefits.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571863922832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InventoriesDisclosureAbstract', window );"><strong>Inventories Disclosure [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">Inventories</a></td>
<td class="text">
          <div>
            <div id="anchorId001540869"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">14. Inventories</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Raw material, consumables</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            934
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            870
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Work in progress</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 673
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 160
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Finished products</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 568
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 636
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total inventories</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            7 175
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 666
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the amount of inventory recognized as an expense in &#8220;Cost of goods sold&#8221; in the consolidated income statements: </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-8.6</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8.8</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8.5</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the recognized amount of inventory provision and reversals of inventory provision recorded in the consolidated income statements:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventory provisions</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-633</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-573</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-702</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversals of inventory provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            161
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            158
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            255
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The reversals mainly result from the release of products initially requiring additional quality control inspections and from the reassessment of inventory values manufactured prior to regulatory approval but for which approval was subsequently received.</div>
              </div>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39__IAS02_g36-39_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InventoriesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InventoriesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864224240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfTradeReceivablesAbstract', window );"><strong>Disclosure of trade receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfTradeReceivablesExplanatoryTextBlock', window );">Trade receivables</a></td>
<td class="text">
          <div>
            <div id="anchorId001541050"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">15. Trade receivables</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total gross trade receivables</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 128
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 088
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-83</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 066
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 005
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movement in the provision for doubtful trade receivables:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-83</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-93</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-95</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables charged to the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-47</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-39</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-59</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Utilization of provisions for doubtful trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of provisions for doubtful trade receivables credited to the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-83</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-93</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the trade receivables that are not overdue as specified in the payment terms and conditions established with Novartis customers, as well as an analysis of overdue amounts and related provisions for doubtful trade receivables:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not overdue</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 664
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 639
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for not more than one month</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            190
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            162
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one month  but less than three months</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            110
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            99
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than three months  but less than six months</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            62
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            63
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than six months  but less than one year</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one year</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            79
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            97
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-83</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 066
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 005
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Trade receivable balances represent amounts due from our customers, which are mainly drug wholesalers, retailers, private health systems, government agencies, managed care providers, pharmacy benefit managers and government-supported healthcare systems. We particularly monitor the level of trade receivables in countries deemed to have an elevated credit risk. We consider macroeconomic environment, historical experience, country and political risk, in addition to other relevant information when assessing risk. These risk factors are monitored regularly to determine any adjustments in risk classification. The majority of the past due trade receivables from elevated credit risk countries are due from local governments or from government-funded entities. Deteriorating credit and economic conditions as well as other factors in these elevated credit risk countries have resulted in, and may continue to result in, an increase in the average length of time that it takes to collect these </div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">trade receivables, and may require the Group to re-evaluate the expected credit loss amount of these trade receivables in future periods. At December 31, 2022, amounts past due for more than one year are not significant in elevated credit risk countries.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total trade receivables include amounts denominated in the following major currencies:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 709
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 344
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 426
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 408
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Russian ruble (RUB)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            430
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            473
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            383
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">British pound (GBP)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            176
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            200
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chinese yuan (CNY)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            155
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            197
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canadian dollar (CAD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            151
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            139
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Brazilian real (BRL)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            129
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Australian dollar (AUD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            139
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            108
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            106
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other currencies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 452
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 487
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 066
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 005
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfTradeReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfTradeReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfTradeReceivablesExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfTradeReceivablesExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862246512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract', window );"><strong>Disclosure of marketable securities commodities deposits derivative instruments and cash [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock', window );">Disclosure of marketable securities commodities deposits derivative instruments and cash</a></td>
<td class="text">
          <div>
            <div id="anchorId001541600"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">16. Marketable securities, commodities, time&#160;deposits, derivative financial instruments, and&#160;cash and cash equivalents</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Marketable securities, commodities, time&#160;deposits and derivative financial instruments</span>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            111
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            111
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 741
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 089
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12 965
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities, commodities, time deposits and derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            11 413
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 922
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The vast majority of debt securities, time deposits and short-term investments with an original maturity of more than 90 days was denominated in USD as of December 31, 2022, and 2021.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Cash and cash equivalents</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current accounts</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 877
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 396
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity less than 90 days</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 640
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 011
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total cash and cash equivalents</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            7 517
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12 407
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862152272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherCurrentAssetsAbstract', window );"><strong>Other current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory', window );">Other current assets</a></td>
<td class="text">
          <div>
            <div id="anchorId001541756"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">17. Other current assets</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">VAT receivable</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            509
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            487
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Withholding tax recoverable</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            50
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            58
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid expenses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            911
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 102
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivable<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            958
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            793
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 471
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 440
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other current assets. [Refer: Other current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862152272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfEquityAbstract', window );"><strong>Disclosure of equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfEquityTextBlock', window );">Equity</a></td>
<td class="text">
          <div>
            <div id="anchorId001541870"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">18. Equity</div>
            <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movement in the share capital:</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Jan 1, 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Movement<br/> in year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Dec 31, 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Movement<br/> in year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Dec 31, 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Movement<br/> in year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/> Dec 31, 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Share capital<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            936
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-23</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            913
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            901
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-11</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            890
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Treasury shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-80</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            27
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-53</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-48</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-92</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding share capital</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            856
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            860
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            853
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            798
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> The Novartis AG share capital consists of registered shares with a nominal value of CHF 0.50 each. No authorized and conditional capital exists.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movement in the shares:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>Number of outstanding shares <br/>(in millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br/> Novartis <br/> shares</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br/> treasury <br/> shares<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br/> outstanding <br/> shares</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> Novartis <br/> shares</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> treasury <br/> shares<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> outstanding <br/> shares</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> Novartis <br/> shares</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> treasury <br/> shares<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> outstanding <br/> shares</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at beginning of year</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 434.4
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-199.5</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 234.9
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 467.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-210.2</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 256.8
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 527.3
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-262.3</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 265.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares canceled for capital  reduction<sup style="white-space: nowrap"> &#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-30.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            32.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-60.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            60.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be  canceled<sup style="white-space: nowrap"> &#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-126.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-126.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases<sup style="white-space: nowrap">&#160;4</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1.4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1.4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options  and employee transactions<sup style="white-space: nowrap"> &#160;5</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.9</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14.7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation<sup style="white-space: nowrap">&#160;5</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total movements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-30.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-84.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-115.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-32.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-21.9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-60.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            52.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-8.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at end of year</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 403.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-284.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 119.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 434.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-199.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 234.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 467.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-210.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 256.8
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Approximately 99.0 million treasury shares (2021: 102.5 million; 2020: 103.0 million) are held in Novartis entities that restrict their availability for use.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Novartis reduced its share capital by canceling shares that were repurchased on the SIX Swiss Exchange second trading line during previous years.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup>
                            <span> Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2019 Annual General Meeting (AGM) for transactions after February 28, 2019, until March 2, 2021. Transactions after March 2, 2021, were executed under the CHF 10 billion share buyback authority approved at the 2021 AGM and the additional CHF 10 billion authority approved at the 2022 AGM.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;4&#160;</sup> Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;5&#160;</sup> Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">18.1) The amount available for distribution as a dividend to shareholders is based on the available distributable retained earnings of Novartis AG determined in accordance with the legal provisions of the Swiss Code of Obligations.</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend per share (in CHF)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.10
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3.00
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.95
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total dividend payment  (in USD billion)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">18.2) The following table summarizes the treasury shares movements:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Number of <br/> outstanding <br/> shares<br/> (in millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Equity impact<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Number of <br/> outstanding <br/> shares<br/> (in millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Equity impact<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Number of <br/> outstanding <br/> shares<br/> (in millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Equity impact<br/> USD m</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be canceled<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-126.2</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-10 787</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30.7</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 775</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32.6</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 897</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1.4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-123</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-145</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-159</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-127.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-10 910</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 920</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-34.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 056</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions<sup style="white-space: nowrap">&#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.9</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            88
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            806
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation<sup style="white-space: nowrap">&#160;4</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            854
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            745
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            730
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            30
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-115.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-9 963</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-21.9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 119</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-8.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 490</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2019 Annual General Meeting (AGM) for transactions after February 28, 2019, until March 2, 2021. Transactions after March 2, 2021, were executed under the CHF 10 billion share buyback authority approved at the 2021 AGM and the additional CHF 10 billion authority approved at the 2022 AGM.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup> Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price, reflecting the strike price of the options exercised.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;4&#160;</sup> Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax-deductible amounts exceeding the expense recognized in the income statement are credited to equity.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.3) In December 2021, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD 15.0 billion share buyback. The arrangement was updated in July 2022. Novartis is able to cancel this arrangement at any time but could be subject to a 90-day waiting period. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of December 31, 2022, these waiting period conditions were not applicable and as a result, there was no requirement to record a liability under this arrangement as of December 31, 2022. The liability under this arrangement amounted to USD 2.8 billion as of December 31, 2021.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In June 2021, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares to mitigate dilution related to participation plans of employees. Novartis would have been able to cancel this arrangement at any time but would have been subject to a 90-day waiting period.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">This trading plan commitment was fully executed and expired in June 2021, and as a consequence, there is <span>no</span> liability related to this plan recognized as of December 31, 2021.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In November 2020, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD 2.5 billion share buyback. Novartis would have been able to cancel this arrangement at any time, but would have been subject to a 90-day waiting period. The commitment under this arrangement therefore reflected the obligated purchases by the bank under such trading plan over a rolling 90-day period, or if shorter, until the maturity date of such trading plan.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The commitment under this arrangement amounted to USD 1.8 billion as of December 31, 2020. This trading plan commitment was fully executed and expired in March 2021, and as a consequence, there is no liability related to this plan recognized as of December 31, 2021.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In August 2020, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares to mitigate dilution related to participation plans of associates. Novartis would have been able to cancel this arrangement at any time but would have been subjected to a 90-day waiting period. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">This trading plan commitment was fully executed and expired, and as a consequence, there is no liability related to this plan recognized as of December 31, 2020.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.4) In October 2020, Novartis entered into an agreement with the market maker for its employee options to repurchase a portion of the outstanding written call options. A total of 3.7 million options were repurchased under this agreement. This agreement was terminated in November 2020.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.5) The impact of change in ownership of consolidated entities represents the excess of the amount paid to non-controlling interest over their carrying value and equity allocation to non-controlling interest due to change in ownership percentage. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.6) Changes in non-controlling interests represent the impact on the non-controlling interest of transactions with minority shareholders, such as change in ownership percentage, dividend payments and other equity transactions. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.7) Other movements include, for subsidiaries in hyperinflationary economies, the impact of the restatement of the equity balances of the current year as well as restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period. See Note 29 for additional disclosures.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.8) In 2021, transaction costs that were directly attributable to the distribution (spin-off) of Alcon Inc. to Novartis AG shareholders and that would otherwise have been avoided, were recorded to equity.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">18.9) At December 31, 2022, the market maker held 3 million (2021: 3 million; 2020: 1 million) written call options, originally issued as part of the share-based compensation for employees, that have not yet been exercised. The weighted average exercise price of these options is USD 66.07 (2021: USD 61.45; 2020: USD 60.09), and they have contractual lives of 10 years, with remaining lives less than one year (2021: two years; 2020: three years). </div>
              </div>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571863925520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-current financial debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract', window );"><strong>Disclosure of financial liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Disclosure of financial liabilities [text block]</a></td>
<td class="text">
          <div>
            <div id="anchorId001543765"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">19. Non-current financial debt</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            22 341
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25 296
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities to banks and other financial institutions<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            144
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            227
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total, including current portion of non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 523
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion of non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 241</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 621</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            20 244
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            22 902
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Average interest rate 2.3% (2021: 0.9%)</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All bonds are initially recorded at the amount of proceeds received, net of transaction costs. They are subsequently carried at amortized cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognized as a charge to the consolidated income statement over the period of the relevant bond. Financial debts, including current financial debts, contain only general default covenants. The Group is in compliance with these covenants.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The percentage of fixed-rate financial debt to total financial debt was <span>86%</span> at December 31, 2022, and <span>87%</span> at December 31, 2021.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The average interest rate on total financial debt in 2022 was <span>2.4%</span> (2021: <span>1.9%</span>).</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 29 contains a maturity table of the Group&#8217;s future contractual interest payments commitments.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides a breakdown of straight bonds:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>Coupon</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Currency</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Notional <br/> amount<br/> (millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Issuance <br/> year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Maturity <br/> year</div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Issuer</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Issue price</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022<br/> (USD<br/> millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021<br/> (USD<br/> millions)</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.400%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 500
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2012
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2022
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.225%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 498
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              3.700%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            500
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2012
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2042
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              98.325%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            490
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            490
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              3.400%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 150
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2014
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2024
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.287%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 147
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 144
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              4.400%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 850
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2014
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2044
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.196%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 827
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 826
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.625%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            600
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2014
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2026
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.697%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            638
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            676
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.250%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            CHF
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            500
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2015
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2025
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis AG, Basel, Switzerland
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100.640%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            541
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            547
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.625%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            CHF
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            550
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2015
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2029
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis AG, Basel, Switzerland
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100.502%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            602
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.050%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            CHF
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            325
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2015
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2035
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis AG, Basel, Switzerland
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100.479%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            352
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            356
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              3.000%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 750
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2015
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2025
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.010%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 742
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 740
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              4.000%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 250
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2015
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2045
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              98.029%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 221
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 220
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.125%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 250
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2016
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2023
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.127%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 330
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 409
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.625%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            500
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2016
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2028
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              98.480%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            528
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            559
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.400%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2017
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2022
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.449%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 000
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              3.100%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2017
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2027
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.109%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            994
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            993
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.125%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            600
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2017
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2027
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.874%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            638
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            677
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.500%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            750
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2023
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.655%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            798
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            846
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.375%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            750
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2030
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.957%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            797
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            846
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.700%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            750
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2038
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.217%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            792
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            840
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.750%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2025
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.852%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            998
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            998
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.000%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 250
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2027
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.909%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 246
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 246
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.200%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 500
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2030
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.869%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 494
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 493
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.750%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 250
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2050
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              97.712%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 215
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 214
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.000%</span>
                            <sup style="white-space: nowrap">&#160;1</sup>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 850
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2028
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.354%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 958
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 076
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total straight bonds</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 296
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> The EUR 1 850 million bond issued in 2020 features a coupon step-up of <span>0.25%</span> commencing with the first interest payment date after December 31, 2025, if one or both of the 2025 Patient Access Targets are not met. These 2025 Patient Access Targets are the 2025 Flagship Programs Patient Reach Target and the 2025 Strategic Innovative Therapies Patient Reach Target, as defined in the bond prospectus. As of December 31, 2022, there is no indication that these 2025 Patient Access Targets will not be met.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables provide a breakdown of total non-current financial debt, including current portion by maturity and currency:</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Breakdown by maturity:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 621
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 342
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 147
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 144
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 281
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 284
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            638
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            693
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2027</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 909
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 916
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After 2027</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 269
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11 523
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 523
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Breakdown by currency:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13 376
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 862
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 478
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 930
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            76
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            174
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 488
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 505
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            67
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            52
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 523
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The following table shows the comparison of balance sheet carrying value and fair value of total non-current financial debt, including current portion:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022<br/> Balance<br/> sheet</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022<br/> Fair<br/> values</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021<br/> Balance<br/> sheet</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021<br/> Fair<br/> values</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            22 341
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20 277
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25 296
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            27 079
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            144
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            144
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            227
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            227
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            20 421
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 523
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            27 306
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The fair values of straight bonds are determined by quoted market prices. Other financial debts are recorded at notional amounts, which are a reasonable approximation of the fair values.</div>
              </div>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859714544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions and other non-current liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract', window );"><strong>Disclosure of detailed information about provisions and non-current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory', window );">Provisions and other non-current liabilities</a></td>
<td class="text">
          <div>
            <div id="anchorId001545467"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">20. Provisions and other non-current liabilities</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued liability for employee benefits:</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Defined benefit pension plans<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 723
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 640
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Other long-term employee benefits and deferred compensation</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            554
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            662
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Other post-employment benefits<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            362
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            487
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Environmental remediation provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            535
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            567
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for product liabilities, governmental investigations and other legal matters</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            154
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            341
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            704
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            956
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            874
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            519
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total provisions and other non-current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 906
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 172
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 25 provides additional disclosures related to post-employment benefits.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis believes that its total provisions are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities in this area, Novartis may incur additional costs beyond the amounts provided. Management believes that such additional amounts, if any, would not be material to the Group&#8217;s financial condition but could be material to the results of operations or cash flows in a given period.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Environmental remediation provisions</span>
                </div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movements in the environmental liability provisions:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            616
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            809
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            714
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-169</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-18</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-  105</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            82
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-24</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            50
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            588
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            616
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            809
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current provision</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-53</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-49</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-167</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current environmental remediation provisions at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            535
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            567
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            642
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The significant components of the environmental remediation provisions consist of costs to sufficiently clean and refurbish contaminated sites to the extent necessary, and to continue surveillance at sites where the environmental remediation exposure is less significant. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A substantial portion of the environmental remediation provisions relate to the remediation of Basel regional landfills in the adjacent border areas in Switzerland, Germany and France. The provisions are reassessed on an annual basis and adjusted as necessary.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the United States, Novartis has been named under federal legislation (the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended) as a potentially responsible party (PRP) in respect of certain sites. Novartis actively participates in, or monitors, the cleanup activities at the sites in which it is a PRP. The provision takes into consideration the number of other PRPs at each site as well as the identity and financial position of such parties in light of the joint and several nature of the liability. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The expected timing of the related cash outflows as of December 31, 2022, is currently projected as follows:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Expected <br/> cash outflows</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due within two years</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:20%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            128
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due later than two years, but within five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            163
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due later than five years, but within 10 years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            251
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due after 10 years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            46
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total environmental remediation provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            588
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Provisions for product liabilities, governmental investigations and other legal matters </span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has established provisions for certain product liabilities, governmental investigations and other legal matters where a potential cash outflow is probable and Novartis can make a reliable estimate of the amount of the outflow. These provisions represent the Group&#8217;s current best estimate of the total financial effect for the matters described below and for other less significant matters. Potential cash outflows reflected in a provision might be fully or partially offset by insurance in certain circumstances.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis has not established provisions for potential damage awards for certain additional legal claims against its subsidiaries if Novartis currently believes that a payment is either not probable or cannot be reliably estimated. These not-provisioned-for matters include individual product liability cases and certain other legal matters. Plaintiffs&#8217; have alleged claims in these matters and the Group does not believe that information about the amount sought by plaintiffs, if that is known, would be meaningful with respect to those legal proceedings. This is due to a number of factors, including, but not limited to, the stage of proceedings, the entitlement of parties to appeal a decision and clarity as to theories of liability, damages and governing law. Therefore, it is not practicable to provide information about the potential financial impact of these matters. In addition, in some of </div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">these matters there are claims for punitive or multiple (treble) damages, civil penalties and disgorgement of profits that in the view of Novartis are either wholly or partially unspecified, or wholly or partially unquantifiable at present; the Group believes that information about these amounts claimed by plaintiffs generally is not meaningful for purposes of determining a reliable estimate of a loss that is probable or more than remote.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A number of other legal matters are in such early stages or the issues presented are such that the Group has not made any provisions since it cannot currently estimate either a potential outcome or the amount of any potential losses. For these reasons, among others, the Group generally is unable to make a reliable estimate of possible loss with respect to such cases. It is therefore not practicable to provide information about the potential financial impact of those cases.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There might also be cases for which the Group was able to make a reliable estimate of the possible loss or the range of possible loss, but the Group believes that publication of such information on a case-by-case basis would seriously prejudice the Group&#8217;s position in ongoing legal proceedings or in any related settlement discussions. Accordingly, in such cases, information has been disclosed with respect to the nature of the contingency, but no disclosure is provided as to an estimate of the possible loss or range of possible loss.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 28 contains additional information on contingent liabilities.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Summary of significant legal proceedings</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following is a summary of significant legal proceedings to which Novartis or its subsidiaries are currently a party, or were a party and that concluded in 2022.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Investigations and related litigations</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Southern District of New York (S.D.N.Y.) Gilenya marketing practices investigation and litigation</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2013, Novartis Pharmaceuticals Corporation (NPC) received a civil investigative demand from the United States Attorney&#8217;s Office (USAO) for the S.D.N.Y. requesting the production of documents and information relating to marketing practices for <i>Gilenya</i>, including the remuneration of healthcare providers in connection therewith. In 2017, the S.D.N.Y. and New York State declined to intervene in claims raised by an individual relator in a qui tam complaint. In 2022, NPC&#8217;s motion to dismiss this complaint was granted, which was appealed. The claims are being vigorously contested. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Government generic pricing antitrust investigations, antitrust class actions</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since 2016, Sandoz Inc. has received a grand jury subpoena and a civil investigative demand and interrogatories from the Antitrust and Civil Divisions of the US Department of Justice (DOJ) into alleged price fixing and market allocation of generic drugs in the United States as well as alleged federal False Claims Act (FCA) violations. Sandoz Inc. also received a subpoena and interrogatories from the Attorney General of the State of Connecticut in connection with a similar States&#8217; investigation. In 2020, Sandoz Inc. reached a resolution with the DOJ Antitrust Division, pursuant to which Sandoz Inc. paid USD 195 million and entered into a deferred prosecution agreement. The Sandoz Inc. resolution related to instances of misconduct at the Company between 2013 and 2015 with regard to certain generic drugs sold in the United States. Under the terms of that agreement, Sandoz Inc. will continue to take steps to enhance its compliance program, employee training and monitoring, and will continue to cooperate with the US government&#8217;s ongoing investigation into the generic pharmaceutical industry. Sandoz Inc. also finalized a resolution with the DOJ Civil Division and in 2021 paid USD 185 million, which includes interest from the date of the agreement in principle, to settle related claims arising under the FCA, and entered into a corporate integrity agreement with the Office of Inspector General (OIG) of the US Department of Health and Human Services (HHS). This resolution with the DOJ resolves all federal government matters related to price fixing allegations.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Since the third quarter of 2016, Sandoz Inc. and Fougera Pharmaceuticals Inc. have been sued alongside other generic pharmaceutical companies in numerous individual and putative class action complaints by direct and indirect private purchasers and by over  50 US states and territories, represented by their respective Attorneys General. Plaintiffs claim that defendants, including Sandoz Inc., engaged in price fixing and market allocation of generic drugs in the United States, and seek damages and injunctive relief. The litigation includes complaints alleging product-specific conspiracies, as well as complaints alleging the existence of an overarching industry conspiracy, and assert claims for damages and penalties under federal and state antitrust and consumer protection acts. The cases have been consolidated for pretrial purposes in the United States District Court (USDC) for the Eastern District of Pennsylvania, and the claims are being vigorously contested.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Lucentis/Avastin&#174; matters</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In connection with an investigation into whether Novartis entities, F. Hoffmann-La Roche AG, Genentech Inc. and Roche S.p.A. colluded to artificially preserve the market positions of Avastin<sup>&#174;</sup> and <i>Lucentis</i>, in 2014 the Italian Competition Authority (ICA) imposed a fine equivalent to USD 125 million on the Novartis entities. Novartis paid the fine, subject to the right to later claim recoupment, and appealed before the Consiglio di Stato (CdS). In 2014 and 2015, the Italian Ministry of Health and the Lombardia region sent letters with payment requests for a total equivalent of approximately USD&#160;1.3 billion in damages from Novartis and Roche entities based on these allegations. In 2019, the CdS upheld the ICA decision and fine. Following that CdS decision, several additional Italian regions and hospitals sent letters claiming damages for an aggregate amount of approximately USD 330 million. None of these claims have been asserted in legal proceedings and no further letters have been sent since. Novartis continues to appeal the CdS decision. In 2019, the French Competition Authority (FCA) issued a Statement of Objections against Novartis entities, alleging anti-competitive practices on the French market for anti-vascular endothelial growth factor treatments for wet age-related macular degeneration from 2008 to </div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">2013. In 2020, the FCA issued a decision finding that the Novartis entities had infringed competition law by abusing a dominant position and imposing a fine equivalent to approximately USD 452 million. Novartis paid the fine, again subject to recoupment, and is appealing the FCA&#8217;s decision. Novartis is the subject of similar investigations and proceedings involving competition authorities in Belgium and Greece and is currently in the appeal process in Turkey. Novartis continues to vigorously contest all claims in all those countries.  Novartis is also challenging policies and regulations allowing off-label/unlicensed use and reimbursement for economic reasons in Turkey.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Greece investigation</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Greek authorities are investigating legacy allegations of potentially inappropriate economic benefits to HCPs, government officials and others in Greece. These authorities include the Greek Coordinating Body for Inspection and Control, and the Greek Body of Prosecution of Financial Crime (SDOE), from which the Company received a summons in 2018 and 2020. Novartis has cooperated in these investigations. In 2021, SDOE imposed on Novartis Hellas a fine equivalent to approximately USD 1.2 million, which Novartis Hellas has appealed. In 2022, the Greek State served a civil lawsuit on Novartis Hellas, seeking approximately USD 225 million for moral damages allegedly arising from the conduct that was the subject of the Company&#8217;s 2020 settlement with the DOJ regarding allegations of inappropriate economic benefits in Greece that was disclosed in the 2020 Annual Report and the 2020 Form 20-F. The claims are being vigorously contested.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">340B Drug Pricing Program investigations</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2021, NPC received a notification from the US Health Resources and Services Administration (HRSA) which stated that HRSA believes NPC&#8217;s contract pharmacy policy violates the 340B statute, and threatened potential enforcement action. NPC subsequently sued HRSA in the USDC for the District of Columbia to challenge HRSA&#8217;s determination and to enjoin HRSA from taking action with respect to NPC&#8217;s contract pharmacy policy. HRSA then referred the matter regarding NPC&#8217;s contract pharmacy policy to OIG, which could result in the imposition of civil monetary penalties on NPC. The USDC issued a decision rejecting HRSA&#8217;s interpretation of the 340B statute, vacating the violation notification and remanding the matter to HRSA. HRSA appealed, and the United States Court of Appeals for the DC Circuit heard argument on the case in 2022. In addition, in 2021, Emory University Hospital Midtown filed an Administrative Dispute Resolution (ADR) proceeding against NPC, seeking the return of alleged overcharges resulting from NPC&#8217;s contract pharmacy policy. NPC has moved to dismiss the proceeding pending resolution of the HRSA litigation. Finally, also in 2021, NPC received a civil investigative subpoena from the Office of the Attorney General of the State of Vermont requesting the production of documents and information concerning NPC&#8217;s participation in the 340B Drug Pricing Program in Vermont; NPC provided documents and information to the Office of the Attorney General.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Swiss and EU investigation</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In September 2022, the Swiss Competition Commission (COMCO) initiated an investigation of Novartis acquisition of certain patents from Genentech in April 2020 and their subsequent enforcement against Eli Lilly and other parties, allegedly in an attempt to protect <i>Cosentyx</i> from competing products. COMCO is investigating whether enforcement of the patents violates the Swiss Cartel Act. The European Commission also requested information from Novartis regarding this matter. Novartis is cooperating with the authorities and will vigorously contest any allegations. </div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Antitrust class actions</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Exforge</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since 2018, Novartis Group companies as well as other pharmaceutical companies have been sued by various direct and indirect purchasers of <i>Exforge</i> in multiple US individual and putative class action complaints. They claim that Novartis made a reverse payment in the form of an agreement not to launch an authorized generic, alleging violations of federal antitrust law and state antitrust, consumer protection and common laws, and seeking damages as well as injunctive relief. The cases have been consolidated in the S.D.N.Y. In 2022, Novartis agreed to a settlement in principle to pay USD 245 million to resolve these cases. These settlements are subject to mutually agreeable terms, finalization of documentation and, in some cases, court approval.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Product liability litigation</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Reclast </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">NPC is a defendant in more than 20 US product liability actions involving <i>Reclast</i> and alleging atypical femur fracture injuries, all of which are in New Jersey state or federal court and in California state court, coordinated with claims against other bisphosphonate manufacturers. The claims are being vigorously contested.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Taxotere&#174; (docetaxel)</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sandoz is a defendant in more than 3 100 US product liability actions involving Taxotere&#174; (docetaxel), an oncology product, many of which have been transferred to a multidistrict litigation in the Eastern District of Louisiana. The complaints allege misleading marketing and that Sanofi, as innovator, and several 505(b)(2) NDA holders (including Sandoz) failed to warn of the risk of permanent alopecia/hair loss. In 2022, actions involving claims related to alleged eye injuries caused by the use of Taxotere&#174; were coordinated in a separate multidistrict litigation in the Eastern District of Louisiana. The claims are being vigorously contested.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Amiodarone</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sandoz entities are named in two multi-plaintiff US product liability cases involving amiodarone, a cardiac drug indicated to treat life-threatening arrhythmias that have not responded to other treatment. The complaints allege failure to warn, off-label promotion, and failure to include medication guides to pharmacies. The claims are being vigorously contested.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Sartans and ranitidine</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since 2018, claims have been brought against Sandoz and other pharmaceutical companies alleging injury from carcinogenic impurities found in valsartan and valsartan/HCT film-coated tablets and/or losartan marketed or manufactured by Sandoz. These claims include several putative class actions in Canada. Claims have also been brought alleging injury from carcinogenic impurities in ranitidine-containing medicines. These claims also include several putative class actions in Canada and a multidistrict litigation in Florida. All of these claims are being vigorously contested.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Tasigna</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">NPC is a defendant in more than 400 US product liability actions involving <i>Tasigna</i>, alleging that the product caused various cardiovascular effects and that NPC failed to provide adequate warnings about those alleged side effects. State court actions are pending in a multicounty litigation in Bergen County, New Jersey, and federal cases are pending in a multidistrict litigation in the Middle District of Florida. The claims are being vigorously contested.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Other matters</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Shareholder derivative lawsuit</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2021, NPC, Sandoz Inc., Novartis Capital Corporation and certain present and former directors and officers of Novartis were named as defendants, and Novartis was named as a nominal defendant, in a purported shareholder derivative lawsuit filed in New York state court. The plaintiffs, derivatively as purported Novartis shareholders on behalf of Novartis, seek damages and other remedies based on alleged conduct by the corporate and individual defendants. In 2022, the court granted Novartis motion to dismiss the lawsuit, which the plaintiffs have appealed.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Concluded legal matters</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Average Wholesale Price (AWP) litigation &#8211; Concluded matter </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Lawsuits were brought, the latest in February 2016, by various US state governmental entities and private parties against various pharmaceutical companies, including NPC, alleging that they fraudulently overstated the AWP that is or has been used by payers, including state Medicaid agencies, to calculate reimbursements to healthcare providers. In 2022, NPC settled a putative class action brought by private payers in New Jersey, which resolved the last AWP lawsuit. This matter is now concluded.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">Entresto matter&#8211; Concluded matter</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2021, NPC received a civil investigative demand from the DOJ seeking information from 2016 to the present regarding the marketing and pricing of Entresto, including remuneration provided to HCPs.  In December 2022, the DOJ advised that it has no additional requests and that the matter is considered closed. This matter is now concluded.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;">South Korea investigation &#8211; Concluded matter</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2016, the Seoul Western District Prosecutor initiated a criminal investigation into, among other things, allegations that Novartis Korea utilized medical journals to provide inappropriate economic benefits to healthcare professionals (HCPs). This resulted in a non-material fine, which the prosecutor appealed. In 2021, the appellate court upheld the fine, and the prosecutor appealed that decision. In January 2023, the Supreme Court dismissed the appeal. This matter is now concluded.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Summary of product liability, governmental investigations and other legal matters provision movements</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            397
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            487
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 369
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-105</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-292</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 863</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases of provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-52</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-31</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            466
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            251
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 018
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-17</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            702
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            397
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            487
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-548</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-56</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-306</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current product  liabilities, governmental  investigations and other  legal matters provisions  at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            154
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            181
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis believes that its total provisions for investigations, product liability, arbitration and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, there can be no assurance that additional liabilities and costs will not be incurred beyond the amounts provided.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div/>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other provisions, contingent liabilities and contingent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS37_g84-92__IAS37_g84-92_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571871566032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current financial debt and derivative financial instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract', window );"><strong>Disclosure of current financial debt and derivative instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock', window );">Current financial debt and derivative financial instruments</a></td>
<td class="text">
          <div>
            <div id="anchorId001546335"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">21. Current financial debt and&#160;derivative&#160;financial&#160;instruments</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of employees  payable on demand<sup style="white-space: nowrap"> &#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 814
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other financial debt<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            863
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            899
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 772
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            893
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current portion of non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 621
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            55
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            68
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt and derivative  financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 931
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 295
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Weighted average interest rate 0.25% through September 30, 2022 (2021: 0.25%)</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup>
                            <span> Weighted average interest rate 9.7% (2021: 6.1%)</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During the third quarter of 2022, Novartis closed the interest-bearing accounts of employees payable on demand, and paid out USD 0.9 billion to the respective beneficiaries on October 3, 2022. The net cash outflows from interest-bearing accounts of employees payable on demand were reported within the line change in current financial debts in the consolidated statements of cash flows. See Note 23.6.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The carrying amounts of current financial debt, other than the current portion of non-current financial debt, approximate the estimated fair value due to the short-term nature of these instruments.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Details on commercial papers and short-term borrowings are provided under &#8220;Liquidity risk&#8221; in Note&#160;29. </div>
              </div>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571871569552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions and other current liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract', window );"><strong>Disclosure of provisions and other current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock', window );">Provisions and other current liabilities</a></td>
<td class="text">
          <div>
            <div id="anchorId001546511"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">22. Provisions and other current liabilities</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes other than income taxes</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            836
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            619
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Restructuring provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 131
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            345
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued expenses for goods and services received but not invoiced</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 059
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 089
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accruals for royalties</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            767
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            752
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued interests on financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            116
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            127
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for deductions from revenue</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 732
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 481
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accruals for compensation and benefits, including social security</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 321
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 260
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Environmental remediation provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            123
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            123
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for product liabilities, governmental investigations and other legal matters<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            548
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued share-based payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            235
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            253
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            131
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            119
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares<sup style="white-space: nowrap">&#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 809
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            743
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            588
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total provisions and other current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            14 795
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 670
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 20 provides additional disclosures related to legal provisions.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup> Note 18.3 provides additional disclosures related to commitment for repurchase of own shares.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Provisions are based upon management&#8217;s best estimate and adjusted for actual experience. Such adjustments to historic estimates have not been material.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Provisions for deductions from revenue</span>
                </div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movement of the provisions for deductions from revenue:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 481
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 256
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 595
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of currency translation, business combinations</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-210</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-218</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            234
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments/utilizations</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-22 261</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-19 838</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-19 294</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustments of prior years charged to income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-322</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-245</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-151</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current year income statement charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23 072
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20 413
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19 773
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions offset against gross trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            113
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            99
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 732
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 481
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 256
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The provisions for deductions from revenue include specific healthcare plans and program rebates as well as non-healthcare plans and program-related rebates, returns and other deductions. The provisions for deductions from revenue are adjusted to reflect experience and to reflect actual amounts as rebates, refunds, discounts and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these deductions from revenue.</div>
                </div>

            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Restructuring provisions movements</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            345
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            459
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            438
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 368
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            328
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            354
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-468</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-344</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-268</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-42</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-54</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-87</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transfers</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-53</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-17</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 131
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            345
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            459
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, additions to provisions of USD&#160;1.4 billion were mainly related to the following reorganizations:</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Initiative announced in April 2022 to implement a new streamlined organizational model designed to support innovation, growth and productivity.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  The continuation of the Innovative Medicines Division and the Operation unit (formerly Novartis Technical Operations and the Customer &amp; Technology Solutions) 2021 restructuring initiatives.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2021, additions to provisions of USD 328 million were mainly related to the following reorganizations:</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  The Innovative Medicines Division commenced a plan to restructure its field force and supporting functions in response to changes in its go-to-market structure with increased utilization of digital technology.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Group-wide initiatives to streamline manufacturing platforms and manufacturing functions and implement new technologies continued. In addition, the Operations unit (formerly Customer &amp; Technology Solutions) continued the phased implementation of the new operating model to transition activities to service centers.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, additions to provisions of USD&#160;354 million were mainly related to the following reorganizations:</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  The Innovative Medicines Division restructured its field force and supporting functions in Region Europe.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  The Sandoz Division initiatives to realign its organizational structures to improve competitiveness that commenced in 2019 continued. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Group-wide initiatives to streamline manufacturing platforms and manufacturing functions through the setup of operations centers and implementation of new technologies, in the Innovative Medicines Division and the Sandoz Division, continued. In addition, the Operations unit (formerly Customer &amp; Technology Solutions) continued the phased implementation of the new operating model to change outsourcing structures and transition activities to service centers.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div/>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859602304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated statements of cash flows<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract', window );"><strong>Disclosure of details to the consolidated statements of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory', window );">Details to the consolidated statements of cash flows</a></td>
<td class="text">
          <div>
            <div id="anchorId001547161"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">
              <b>23. Details to the consolidated statements of cash flows</b>
            </div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.1) Non-cash items and other adjustments</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the reversal of non-cash items and other adjustments in the consolidated statements of</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">cash flows.</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments on:</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Property, plant and equipment</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 570
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 489
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 758
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            303
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            318
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            330
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Intangible assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 308
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 306
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 376
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Financial assets<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            260
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-38</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-335</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 403
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            896
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 411
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gains on disposal and other adjustments on property, plant and equipment; intangible assets;  financial assets; and other non-current assets, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-333</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-677</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-478</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-settled compensation expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            823
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            736
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            738
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Loss/(income) from associated companies<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 339</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-673</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 416
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 119
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 807
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net financial expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            817
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            891
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            947
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            11 546
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-5 299</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 881
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Includes fair value changes</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup>
                            <span> 2021 included the gain of USD 14.6 billion recognized from the divestment of the Group's investment in Roche (see Notes 2 and 4).</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, other than through business combinations, there were USD 635 million additions to intangible assets with deferred payments. In 2022, there were USD 247 million (2021: USD 321 million, 2020: USD 346 million) additions to right-of-use assets recognized.</div>
                </div>

            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.2) Total amount of income taxes paid </span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, the total amount of income taxes paid was USD&#160;2.0 billion (2021: USD&#160;2.3 billion), which was included within &#8220;Net cash flows from operating activities.&#8221;</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2020, the total amount of income taxes paid was USD&#160;1.9 billion, of which USD&#160;1.8 billion was included within &#8220;Net cash flows from operating activities,&#8221; and USD&#160;88 million was included within &#8220;Net cash flows used in investing activities from discontinued operations.&#8221;</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.3) Cash flows from changes in working capital and other operating items included in the net cash flows from operating activities</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Increase)/decrease in inventories</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-830</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            81
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-543</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Increase)/decrease in trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-589</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-389</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            137
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Decrease in trade payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-48</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-21</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-324</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other current and non-current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-194</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-202</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            229
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            658
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            772
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            211
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other adjustments, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 003</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-291</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.4) Cash flows arising from acquisitions and divestments of interests in associated companies, net</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2021, acquisitions and divestments of interests in associated companies, net included USD 20.7 billion proceeds from the divestment of the Group&#8217;s investment in Roche (see Notes 2 and 4).</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.5) Cash flows arising from acquisitions and divestments of businesses, net</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table is a summary of the cash flow impact of acquisitions and divestments of businesses. The most significant transactions are described in Note 2.</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of acquisitions of businesses</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 077</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-735</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-10 173</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value of previously held equity interests</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            42
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            59
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            98
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments, deferred consideration and other adjustments, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            62
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-864</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-633</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-10 006</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows (used for)/from divestments of businesses, net<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-15</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            66
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions and divestments of businesses, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-879</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-567</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-9 957</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> In 2022, USD 15 million net cash outflows from divestments of businesses included USD 20 million reduction to cash and cash equivalents due to the derecognized cash and cash equivalents following a loss of control of a company upon expiry of an option to purchase the company, partly offset by USD 5 million net cash inflows from business divestments in 2022 and in prior years.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <span> In 2022, the net identifiable assets of divested businesses amounted to USD 173 million, comprised of non-current assets of USD 132 million, current assets of USD 113 million, including USD 71 million cash and cash equivalents and of non-current and current liabilities of USD 72 million. Deferred sales price receivables and other adjustments amounted to USD 41 million.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <span> In 2021, USD 66 million included USD 52 million net cash inflows from divestments in previous years, and a USD 14 million net cash inflow from a business divestment in 2021, comprised of intangible assets.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <span> In 2020, USD 49 million represented the net cash inflows from divestments in previous years.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Notes 2 and 24 provide further information regarding acquisitions and divestments of businesses. All acquisitions were for cash.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.6) Reconciliation of liabilities arising from financing activities</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Non-current <br/> financial <br/> debts</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Current <br/> financial <br/> debts and <br/> derivative <br/> financial <br/> instruments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Non-current <br/> lease liabilities</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Current lease <br/> liabilities</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 902
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 295
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 621
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            275
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of the current portion of non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 575</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            295
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-295</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-51</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New, modified and terminated leases, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            173
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions and divestments of businesses, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, lease interest and other changes, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-366</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-401</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-41</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 325</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 325
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-224</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            224
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            20 244
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 931
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 538
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            251
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Change in current financial debts included net cash outflows from interest-bearing accounts of employees payable on demand amounting to USD 1.7 billion. See Note 21.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Non-current <br/> financial <br/> debts</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Current <br/> financial <br/> debts and <br/> derivative <br/> financial <br/> instruments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Non-current <br/> lease liabilities</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Current lease <br/> liabilities</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2021</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 259
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 785
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 719
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            286
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of the current portion of non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 162</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 524</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-316</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-52</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New, modified and terminated leases, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            61
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, lease interest and other changes, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-124</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            62
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-774</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-309</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 624</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 624
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-247</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            247
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            22 902
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 295
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 621
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            275
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Non-current <br/> financial <br/> debts</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Current <br/> financial <br/> debts and <br/> derivative <br/> financial <br/> instruments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Non-current <br/> lease liabilities</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Current lease <br/> liabilities</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2020</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            20 353
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            7 031
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 703
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            246
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 126
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of the current portion of non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 003</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 261
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-312</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-56</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New, modified and terminated leases, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            221
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            32
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            36
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, lease interest and other changes, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            65
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            832
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            392
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 067</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 067
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-250</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            250
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2020</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 259
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 785
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 719
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            286
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">23.7) Supplemental disclosures related to the Alcon business distributed to Novartis AG shareholders</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2020, net cash flows used in investing activities from discontinued operations of USD 127 million included the investing activities of the Alcon business, which was spun-off to Novartis AG shareholders on April 8, 2019, and cash outflows for transaction-related expenditures attributable to the series of portfolio transformation transactions completed in 2015. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2020, net cash flows used in financing activities from discontinued operations of USD 50 million were for transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders on April 8, 2019.</div>
              </div>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Section Presentation of a statement of cash flows<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS07_g10-17__IAS07_g10-17_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashFlowStatementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859576368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions of businesses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfAcquisitionOfBusinessesAbstract', window );"><strong>Disclosure of acquisition of businesses [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsExplanatory', window );">Acquisition of businesses</a></td>
<td class="text">
          <div>
            <div id="anchorId001549265"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">24. Acquisitions of businesses</div>
            <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Fair value of assets and liabilities arising from acquisitions of businesses:</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            26
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            32
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            292
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            196
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired research and development</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 209
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            262
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 600
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other intangible assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            98
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            218
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            476
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current financial and other assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            84
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables and financial and other current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            109
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            89
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            76
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-300</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-74</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 977</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables and other liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-67</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-144</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net identifiable assets acquired</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 005
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            612
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            7 669
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired cash and cash equivalents</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-89</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-76</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-controlling interests</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-105</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            161
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            238
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 580
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 077
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            735
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10 173
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Note 2 details significant acquisitions of businesses, specifically of Gyroscope in 2022, the cephalosporin antibiotics business from GSK in 2021; and of the The Medicines Company and the Japanese business of AGI in 2020. The goodwill arising out of these acquisitions is attributable to the buyer-specific synergies, the assembled workforce, and the accounting for deferred tax liabilities on the acquired assets. In 2022, no goodwill (2021: USD 107 million; 2020: USD 74 million) is tax deductible. </div>
              </div>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS03_g59-63__IFRS03_g59-63_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfAcquisitionOfBusinessesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfAcquisitionOfBusinessesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862258768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-employment benefits for employees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract', window );"><strong>Disclosure of defined benefit plans [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory', window );">Post-employment benefits for employees</a></td>
<td class="text">
          <div>
            <div id="anchorId001549649"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">25. Post-employment benefits for employees</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined benefit plans</span>
            </div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition to the legally required social security schemes, the Group has numerous independent pension and other post-employment benefit plans. In most cases, these plans are externally funded in entities that are legally separate from the Group. For certain Group companies, however, no independent plan assets exist for the pension and other post-employment benefit obligations of employees. In these cases, the related unfunded liability is included in the balance sheet. The defined benefit obligations (DBOs) of all major pension and other post-employment benefit plans are reappraised annually by independent actuaries. Plan assets are recognized at fair value. The major plans are based in Switzerland, the United States, the United Kingdom, Germany and Japan, which represent <span>95%</span> of the Group&#8217;s total DBO for pension plans. Details of the plans in the two most significant countries, Switzerland and the United States, which represent <span>83%</span> of the Group&#8217;s total DBO for post-employment benefit plans, are provided below.</div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Swiss-based pension plans represent the most significant portion of the Group&#8217;s total DBO and plan assets. For the active insured members the benefits are linked to contributions paid into the plan, interest credits granted and conversion rates applied. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">All benefits granted under Swiss-based pension plans are vested, and Swiss legislation prescribes that the employer has to contribute a fixed percentage of an employee&#8217;s pay to an external pension fund. Additional employer contributions may be required whenever the plan&#8217;s statutory funding ratio falls below a certain level. The employee also contributes to the plan. The pension plans are run by separate legal entities, each governed by a board of trustees that &#8211; for the principal plans &#8211; consists of representatives nominated by Novartis and the active insured employees. The boards of trustees are responsible for the plan design and asset investment strategy.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In December 2020, the Board of Trustees of the Novartis Swiss Pension Fund agreed to adjust the annuity conversion rate at retirement with effect from January 1, 2022. This amendment did not affect existing pensioners, and its impact on existing plan participants will be mitigated by way of defined compensatory measures. This amendment resulted in a net pre-tax curtailment gain of USD 101 million (CHF 90 million) recognized in 2020.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The United States pension plans represent the second-largest component of the Group&#8217;s total DBO and plan assets. The principal plans (Qualified Plans) are funded, whereas plans providing additional benefits for executives (Restoration Plans) are unfunded. Employer contributions are required for Qualified Plans whenever the statutory funding ratio falls below a certain level. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Furthermore, in certain countries, employees are covered under other post-employment benefit plans and post-retirement medical plans.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the US, other post-employment benefit plans consist primarily of post-employment healthcare benefits, which have been closed to new members since 2015. Part of the costs of these plans is reimbursable under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. There is no statutory funding requirement for these plans. The Group is funding these plans to the extent that it is tax efficient.</div>
                <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables are a summary of the funded and unfunded defined benefit obligation for pension and other post-employment benefit plans of employees at December 31, 2022 and 2021:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment  benefit plans</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            23 583
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 602
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            560
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            632
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current service cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            348
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            415
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            151
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past service costs and settlements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-40</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            63
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Administrative expenses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurement gains arising from changes in financial assumptions<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 046</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-713</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-94</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-20</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurement (gains)/losses arising from changes in demographic assumptions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-53</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-377</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Experience-related remeasurement losses/(gains)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            199
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            531
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-47</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-650</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-865</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 253</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 450</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions of employees</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            174
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            179
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            17 533
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            23 583
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            422
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            560
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at January 1</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 420
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            22 317
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            89
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            220
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Return on plan assets excluding interest income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 500</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 512
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-539</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-726</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Group contributions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            424
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            490
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            41
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions of employees</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            174
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            179
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Settlements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 253</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 450</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            18 945
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            22 420
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 412
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 163</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-362</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Limitation on recognition of fund surplus at January 1</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-51</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in limitation on recognition of fund surplus</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 504</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-76</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income on limitation of fund surplus</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Limitation on recognition of fund surplus at December 31<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2 644</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability in the balance sheet at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 232</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 225</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-362</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> The remeasurement gains arising from changes in financial assumptions is driven mainly by changes in the actuarial discount rates used to determine the benefit obligation.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup>
                            <span> As of December 31, 2022, the most significant pension plans where the asset ceiling was required to be applied were in Switzerland and amounted to USD 2 587 million.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The reconciliation of the net liability from January 1 to December 31 is as follows:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment  benefit plans</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 225</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 336</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-543</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current service cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-348</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-415</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-11</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net interest expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-31</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-47</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-15</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Administrative expenses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-23</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-24</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past service costs and settlements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-70</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 071
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            110
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            70
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Group contributions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            424
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            490
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            41
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-23</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in limitation on recognition of fund surplus</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 504</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 232</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 225</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-362</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Amounts recognized in the consolidated balance sheet</div>
                        </td>
                        <td align="right"/>
                        <td align="right"/>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right"/>
                        <td align="right"/>
                        <td align="right"/>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid benefit cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            491
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 415
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued benefit liability</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 723</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 640</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-362</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows a breakdown of the DBO for pension plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Switzerland</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> United<br/> States</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of<br/> the world</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Switzerland</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> United<br/> States</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of<br/> the world</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            11 824
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 746
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 963
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            17 533
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 268
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 645
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 670
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            23 583
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof unfunded</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            556
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            363
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            919
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            688
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            439
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            1 127
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">By type of member</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Active</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 799
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            431
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            931
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 161
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 478
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            620
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 412
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 510
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Deferred pensioners</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            830
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            861
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 691
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 208
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 730
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 938
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Pensioners</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 025
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 171
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9 681
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 790
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 817
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 528
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12 135
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            14 701
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 978
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 266
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            18 945
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            16 436
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 551
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 433
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            22 420
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 877
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-768</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-697</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 412
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 094</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 237</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 163</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows a breakdown of the DBO for other post-employment benefit plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> United<br/> States</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of<br/> the world</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> United<br/> States</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of<br/> the world</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            346
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            76
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            422
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            473
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            87
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            560
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof unfunded</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            286
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            76
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            362
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            87
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            487
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">By type of member</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Active</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            48
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            83
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Deferred pensioners</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Pensioners</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            308
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            58
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            366
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            64
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            464
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-286</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-76</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-362</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-400</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-87</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the principal weighted average actuarial assumptions used for calculating defined benefit plans and other post-employment benefits of employees:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment  benefit plans</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average assumptions used to determine  benefit obligations at December 31</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discount rate</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              3.0%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.9%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.6%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              6.3%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              3.3%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              2.9%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected rate of pension increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.4%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.5%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.3%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected rate of salary increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.9%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              2.7%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              2.7%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest on savings account</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.2%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.5%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.1%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current average life expectancy  for a 65-year-old male in years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current average life expectancy  for a 65-year-old female in years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Changes in the aforementioned actuarial assumptions can result in significant volatility in the accounting for the Group&#8217;s pension plans in the consolidated financial statements. This can result in substantial changes in the Group&#8217;s other comprehensive income, long-term liabilities and prepaid pension assets.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The DBO is significantly impacted by assumptions regarding the rate that is used to discount the actuarially determined post-employment benefit liability. This rate is based on yields of high-quality corporate bonds in the country of the plan. Decreasing corporate bond yields decrease the discount rate, so that the DBO increases and the funded status decreases.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In Switzerland, an increase in the DBO due to lower discount rates is slightly offset by lower future benefits expected to be paid on the employee&#8217;s savings account where the assumption on interest accrued often changes broadly in line with the discount rate.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The impact of decreasing interest rates on a plan&#8217;s assets is more difficult to predict. A significant part of the plan assets is invested in bonds. Bond values usually rise when interest rates decrease and may therefore partially compensate for the decrease in the funded status. Furthermore, pension assets also include significant holdings of equity instruments. Share prices usually tend to rise when interest rates decrease and therefore often counteract the negative impact of the rising defined benefit obligation on the funded status (although the correlation of interest rates with equities is not as strong as with bonds, especially in the short term).</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The expected rate for pension increases significantly affects the DBO of most plans in Switzerland, Germany and the United Kingdom. Such pension increases also decrease the funded status, although there is no strong correlation between the value of the plan assets and pension/inflation increases.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Assumptions regarding life expectancy significantly impact the DBO. An increase in longevity increases the DBO. There is no offsetting impact from the plan assets, as no longevity bonds or swaps are held by the pension funds. The Group&#8217;s actuaries use mortality tables which take into account historic patterns and expected changes, such as further increases in longevity. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2022 the mortality assumptions used for the pension plans in Switzerland were based on BVG 2020 tables with future improvements based on the BVG generational model. In US for the Pension and Postretirement Medical Benefit Plans, the Society of Actuaries Pri-2012 mortality tables with generational improvements based on Scale MP-2021 are used.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the sensitivity of the defined benefit pension obligation to the principal actuarial assumptions for the major plans in Switzerland, the United States, the United Kingdom, Germany and Japan on an aggregated basis:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in 2022 <br/> year-end defined <br/> benefit pension <br/> obligation</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change in 2021 <br/> year-end defined <br/> benefit pension <br/> obligation</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in discount rate</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-466</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-790</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in discount rate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            491
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            839
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One-year increase in life expectancy</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            535
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            869
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in rate of pension increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            316
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            512
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in rate of pension increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-63</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-136</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase of interest on savings account</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            58
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease of interest on savings account</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-37</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-58</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in rate of salary increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            54
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in rate of salary increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-37</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-54</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div/>

            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The healthcare cost trend rate assumptions used for other post-employment benefits are as follows:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Healthcare cost trend rate assumed for next year</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              6.5%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              6.0%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              6.3%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rate to which the cost trend rate is assumed to decline</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              4.5%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              4.5%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              4.5%</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Year that the rate reaches the ultimate trend rate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2031
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2028
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2028
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the weighted average plan asset allocation of funded defined benefit pension plans at December 31, 2022 and&#160;2021:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(as a percentage)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-term <br/> target <br/> minimum</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-term <br/> target <br/> maximum</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity securities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            40
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            27
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            31
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            33
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Real estate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alternative investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and other investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash and most of the equity and debt securities have a quoted market price in an active market. Real estate and alternative investments, which include hedge fund, private equity, infrastructure and commodity investments, usually have a quoted market price or a regularly updated net asset value.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The strategic allocation of assets of the different pension plans is determined with the objective of achieving an investment return that, together with the contributions paid by the Group and its employees, is sufficient to maintain reasonable control over the various funding risks of the plans. Based upon the market and economic environments, actual asset allocations may temporarily be permitted to deviate from policy targets. The asset allocation currently includes investments in shares of Novartis AG as per the below table: </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31, <br/> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31, <br/> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investment in shares of Novartis AG</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Number of shares (in millions)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Market value (in USD billions)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The weighted average duration of the defined benefit pension obligation is 11.8 years (2021: 14.9 years).</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#8217;s ordinary contribution to the various pension plans is based on the rules of each plan. Additional contributions are made whenever this is required by statute or law (i.e., usually when statutory funding levels fall below predetermined thresholds). The only significant plans that require additional funding are those in the United Kingdom and Germany.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The expected future cash flows in respect of pension and other post-employment benefit plans at December 31, 2022, were as follows:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Pension plans</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-<br/> employment<br/> benefit plans</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis Group contributions</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023 (estimated)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            397
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Expected future benefit payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 268
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 441
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 128
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 114
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2027</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 099
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2028&#8211;2032</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 310
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            171
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined contribution plans</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In many subsidiaries, employees are covered by defined contribution plans. Contributions charged to the consolidated income statement for the defined contribution plans were: </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions for defined contribution plans</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            520
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            523
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            501
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#8217;s total personnel costs amounted to USD 14.9 billion in 2022.</div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div/>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS19_g2-7__IAS19_g2-7_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859409520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based participation plans for employees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Equity-based participation plans for employees</a></td>
<td class="text">
          <div>
            <div id="anchorId001552812"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">26. Equity-based participation plans for employees</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The expense related to all equity-based participation plans and the liabilities arising from equity-based payment transactions were as follows:</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense related to equity-based  participation plans</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 048
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            979
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            958
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities arising from equity-based  payment transactions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            235
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            253
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            269
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Equity-based participation plans can be separated into the following plans:</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Annual Incentive</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Annual Incentive for the Novartis Group CEO and other Executive Committee members (ECN) is paid 50% in cash and 50% in Novartis restricted shares (RSs) or restricted share units (RSUs). For the Novartis Top Leaders (NTLs), the Annual Incentive is paid 70% in cash and 30% in RSs or RSUs. Both the ECN and NTLs can opt to invest up to the maximum cash portion of their Annual Incentive to receive further RSs or RSUs. Any cash is paid out during March in the year following the end of the performance period, and the shares are granted during January in the year following the end of the performance period. </div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Employee share savings plan</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis operates employee share savings and purchase plans in certain countries. The most significant is described below.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Employee Share Ownership Plan (ESOP) in Switzerland offers participants to choose to receive their Annual Incentive (i) 100% in shares, (ii) 50% in shares and 50% in cash, or (iii) 100% in cash. After expiration of a three-year holding period for Novartis shares invested under the ESOP, participants will receive one matching share for every two invested shares. Employees eligible for the equity plan &#8220;Select&#8221; are not eligible to receive ESOP matching shares. The Novartis Group CEO, the other Executive Committee members and the NTLs are not eligible to participate in this plan.</div>
                </div>

            </div>
            <div>

                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis Employee share purchase plan</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022 Novartis started to grant shares under the Employee Share Purchase Plan. The plan enables employees to voluntarily purchase Novartis shares through payroll deductions at a discounted price. While the plan is global in scope, the first phase covers: North America (the US, Puerto Rico and Canada). The shares are not subject to a vesting period.</div>
                </div>

            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis equity plan &#8220;Select&#8221;</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The equity plan &#8220;Select&#8221; is a global equity incentive plan under which eligible employees may annually be awarded a grant subject to a three-year, and for selected units a four-year, staggered vesting period. No awards are granted for performance ratings below a certain threshold. Executive Committee members and NTLs are not eligible to participate in the equity plan &#8220;Select.&#8221;</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The equity plan &#8220;Select&#8221; currently allows participants employed and living in Switzerland to choose the form of their equity compensation in RSs or RSUs. In all other jurisdictions, RSs or RSUs are granted unilaterally. Until 2013, participants could also choose to receive part or the entire grant in the form of tradable share options.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Tradable share options expire on their 10<sup>th</sup> anniversary from the grant date, meaning all outstanding options exercisable at December 31, 2022, will expire in January 2023. Each tradable share option entitles the holder to purchase after vesting (and before the 10<sup>th</sup> anniversary from the grant date) one Novartis share at a stated exercise price that equals the closing market price of the underlying share at the grant date. As the exercise price does not reflect the decrease in the Novartis share due to the Alcon spin, one-fifth of an Alcon share will also be awarded to the option holder upon exercise.</div>
                </div>

            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Options under Novartis equity plan &#8220;Select&#8221; outside North America</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the activity associated with the share options during the period. The weighted average prices in the table below are translated from Swiss francs into USD at historical rates.</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Options<br/> (millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted<br/> average <br/> exercise <br/> price<br/> (USD)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Options<br/> (millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted<br/> average <br/> exercise <br/> price<br/> (USD)</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Options outstanding  at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1.7
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            63.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            62.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sold or exercised</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            62.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            58.9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            0.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            66.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            63.6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            0.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            66.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            63.6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All share options were granted at an exercise price that was equal to the closing market price of the Group&#8217;s shares at the grant date. The weighted average share price at the dates of sale or exercise was USD&#160;86.1. </div>
              </div>
            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Options under Novartis equity plan &#8220;Select&#8221; for North America</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the activity associated with the ADR options during the period:</div>
              </div>
            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> ADR<br/> options<br/> (millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted<br/> average <br/> exercise <br/> price<br/> (USD)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> ADR<br/> options<br/> (millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted<br/> average <br/> exercise <br/> price<br/> (USD)</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Options outstanding  at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            64.4
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6.7
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            62.9
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sold or exercised</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2.9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            63.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            60.7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            66.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            64.4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            66.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            64.4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All ADR options were granted at an exercise price that was equal to the closing market price of the ADRs at the grant date. The weighted average ADR price at the dates of sale or exercise was USD&#160;89.1. </div>
              </div>
            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Long-Term Performance Plan</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Long-Term Performance Plan (LTPP) is an equity plan for the ECN, the NTLs and employees of Group units with specific targets.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Participants are granted a target number of performance share units (PSUs) at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. The actual payout depends on the achievement of the performance measures and ranges between 0% and 200% of the granted amount. PSUs granted under the LTPP do not carry voting rights, but do carry dividend equivalents that are paid in unrestricted Novartis shares at the end of the performance period.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The LTPP awards are subject to a three-year performance and vesting period. Until 2018, the performance criteria were based on Novartis internal performance metrics. For LTPP awards starting in 2019, following the combination of the two LTPP and Long-Term Relative Performance Plan (LTRPP), the performance criteria are based on both Novartis internal performance metrics and variables that can be observed in the market, which is the ranking of the Novartis total shareholder return (TSR) relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">TSR for Novartis and the peer companies is calculated as the change in the company share price, which is translated to USD at the relevant exchange rate, including the reinvestment return of dividends, over the three-year performance period. The calculation is based on Bloomberg standard published TSR data, which is publicly available. The position of Novartis in the peer group determines the payout range based on a payout matrix. </div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Long-Term Relative Performance Plan</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The LTRPP was an equity plan for the Novartis ECN and NTLs and the awards were subject to a three-year performance and vesting period. The last grant under this plan was made in 2018. The LTRPP performance criteria were based on variables that could be observed in the market, which was the ranking of the Novartis TSR relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. The TSR for Novartis and the peer companies was calculated as described in the LTPP section above.</div>
                </div>

            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Other share awards</span>
                </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Selected employees may exceptionally receive Special Share Awards of RSs or RSUs. These Special Share Awards provide an opportunity to reward outstanding achievements or exceptional performance, and aim to retain key contributors. They are based on a formal internal selection process, through which the individual performance of each candidate is thoroughly assessed at several management levels. Special Share Awards had a minimum three-year vesting period before 2021 and mainly three years thereafter. In exceptional circumstances, Special Share Awards may be awarded to attract special expertise and new talents to the organization. Externally recruited ECN members are eligible only for special awards that are &#8220;buyouts&#8221; in the case that it is to replace equity forfeited with their former employer. The equity is provided on a like-for-like basis as the forfeited equity, at the same value with the same vesting period, and with or without a performance condition.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Worldwide, employees at different levels in the organization were awarded RSs and RSUs in 2022, 2021 and 2020.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, in 2022, 2021 and 2020, Board members received unrestricted shares as part of their regular compensation.</div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div/>

            </div>
          </div>

          <div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Summary of share grants</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The table below provides a summary of share grants (shares, RSs, RSUs and PSUs) for all plans:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Number<br/> of shares<br/> in millions</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br/> average fair<br/> value at grant<br/> date in USD</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Number<br/> of shares<br/> in millions</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted <br/> average fair<br/> value at grant<br/> date in USD</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Annual Incentive</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; RSU</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            74.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            87.5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; Restricted shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            85.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            97.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Share savings plans</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; RSU</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            75.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            86.9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; Shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            85.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            97.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis Employee Share Purchase Plan</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            82.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Select North America (RSU)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            74.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            86.9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Select outside North America</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; RSU</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            75.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            86.9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; Restricted shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            85.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            97.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Long-Term Performance Plan (PSU)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            82.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            89.5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Other share awards</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; RSU</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            76.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            78.4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; Restricted shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            86.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; Shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            86.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            91.9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859576368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with related parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Disclosure of transactions between related parties [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Transactions with related parties</a></td>
<td class="text">
          <div/>

          <div>
            <div id="anchorId001553909"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">27. Transactions with related parties</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Roche Holding AG</span>
            </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has two agreements with Genentech, Inc., United States (Genentech), and one agreement with Spark Therapeutics, Inc., United States (Spark). Both companies are subsidiaries of Roche Holding AG (Roche), which were indirectly included in the consolidated financial statements using equity accounting until November 3, 2021, when Novartis entered into an agreement with Roche to divest its <span>33.3%</span> of Roche voting shares. On December 6, 2021, Novartis divested its investment in Roche, on which date Roche ceased to be a related party (see Notes 2 and 4).</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                <i>Lucentis</i>
              </span>
            </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has licensed from Genentech/Roche the exclusive rights to develop and market <i>Lucentis</i> outside the United States for indications related to diseases of the eye. Novartis pays royalties on the net sales to third parties of <i>Lucentis</i> products outside the United States. From January 1, 2021 until December 6, 2021, <i>Lucentis</i> sales of USD&#160;2.0 billion (2020: USD&#160;1.9 billion) were recognized by Novartis.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                <i>Xolair</i>
              </span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis and Genentech/Roche are co-promoting <i>Xolair</i> in the United States, where Genentech/Roche records all sales. Novartis records sales outside the United States.</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis markets <i>Xolair</i> and records all sales and related costs outside the United States as well as co-promotion costs in the US. Genentech/Roche and Novartis share the resulting profits from sales in the United States, Europe and other countries, according to agreed profit-sharing percentages. From January 1, 2021 until December 6, 2021, Novartis recognized total sales of <i>Xolair</i> of USD&#160;1.3 billion (2020: USD&#160;1.3 billion), including sales to Genentech/Roche for the United States market.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                <i>Luxturna</i>
              </span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2018, Novartis entered into an exclusive licensing and commercialization agreement and a supply agreement with Spark for <i>Luxturna</i> outside the United States. The agreements include regulatory and sales milestones as well as royalties payable to Spark on ex-US sales. On December 17, 2019, Roche acquired Spark.</div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The net income for royalties, cost sharing and profit sharing arising out of the <i>Lucentis</i>, <i>Xolair</i> and <i>Luxturna</i> agreements with Roche totaled USD&#160;188 million from January 1, 2021 until December 6, 2021 (net income in 2020: USD&#160;217 million).</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Furthermore, Novartis has several patent license, supply and distribution agreements with Roche.</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Novartis Pension Fund</span>
            </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2018, a Group subsidiary provided an uncommitted overnight credit facility to the Novartis Pension Fund, Switzerland, for up to USD 500 million with interest at the US Federal Funds Rate. This credit facility was not utilized during the current and past years.</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Executive Officers and Non-Executive Directors compensation</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At December 31, 2022, there were 11 Executive Committee members (&#8220;Executive Officers&#8221;). During 2022, 5 Executive Officers stepped down. At December 31, 2021, there were 12 Executive Officers. During 2021, 3 Executive Officers stepped down. At December 31, 2020, there were 13 Executive Officers. </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The total compensation for Executive Committee members and the 15 Non-Executive Directors (14 in 2021 and 14 in 2020) using the Group&#8217;s accounting policies for equity-based compensation and pension benefits was as follows:</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Executive Officers</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-Executive Directors</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and other compensation</div>
                        </td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20.3
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4.7
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            29.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            30.2
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Post-employment benefits</div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            42.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            41.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            47.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            42.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            46.3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            70.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            60.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            69.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            79.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            70.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            79.2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022, there was an increase in the IFRS compensation expense for executive officers compared to 2021, driven by accelerated expenses (cash and other compensation and equity-based compensation) required under IFRS for the executive members who stepped down in 2022, in accordance with their employment contracts and the relevant incentive plan terms, compared to the accelerated expenses due to executive officers who stepped down in 2021.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">During 2021, the IFRS compensation expense decreased due to one role less at the ECN, and lower cash and equity compensation attributable to former ECN members, partially offset by the net increase of the IFRS compensation expense of current ECN members.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Annual Incentive award, which is fully included in equity-based compensation even when paid out in cash, is granted in January in the year following the reporting period.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The disclosures on Board and executive compensation required by the Swiss Code of Obligations and in accordance with the Swiss Ordinance against Excessive Compensation in Stock Exchange Listed Companies are shown in the Compensation Report of the Group.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Transactions with former members of the Board of Directors</span>
                </div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022, 2021 and 2020, the following payments (or waivers of claims) were made to former Board members or to &#8220;persons closely&#8221; linked to them:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currency</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dr. Krauer</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            60 000
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            60 000
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Dr. Alex Krauer, was an Honorary Chairman of Novartis and was entitled to an amount of CHF 60 000 for annual periods from one AGM to the next. This amount was fixed in 1998 upon his departure from the Board in 1999. The last payment under this arrangement was in 2021. </div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24__IAS24_g13-24_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571871569552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and contingencies [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfCommitmentsAndContingenciesTextBlock', window );">Commitments and contingencies</a></td>
<td class="text">
          <div>
            <div id="anchorId001554354"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">28. Commitments and contingent liabilities</div>
            <div style=" padding-bottom: 10px;">
              <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Research and development commitments</span>
            </div>
            <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has entered into long-term research and development agreements with various institutions related to intangible assets. These agreements provide for potential milestone payments by Novartis, which are dependent on successful clinical development, or meeting specified sales targets, or other conditions which are specified in the agreements. </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of December 31, 2022, the amount and estimated timing of the Group&#8217;s commitments to make payments under those agreements, which are shown without risk adjustment and on an undiscounted basis, were as follows:</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:20%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            420
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            808
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            448
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            282
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2027</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            687
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Thereafter</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 169
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 814
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Commitments for capital calls</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group holds investments in funds in which it has committed to invest further upon future capital calls. As of December 31, 2022, the total uncalled capital commitments for the Group&#8217;s investments in funds amounts to USD 83 million. Note 29 contains further information on the Group&#8217;s investments in funds.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Other commitments</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has entered into various purchase commitments for services and materials as well as for equipment in the ordinary course of business. These commitments are generally entered into at current market prices and reflect normal business operations. For disclosure of property, plant and equipment purchase commitments, see Note 9.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Guarantees issued</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has issued guarantees to third parties in the ordinary course of business, mostly for tax, customs or other governmental agencies. </div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Contingent liabilities</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Group companies have to observe the laws, government orders and regulations of the country in which they operate.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A number of Novartis companies are, and will likely continue to be, subject to various legal proceedings and investigations that arise from time to time, including proceedings regarding product liability; sales and marketing practices; commercial disputes; employment and wrongful discharge; and antitrust, securities, health and safety, environmental, tax, international trade, privacy and intellectual property matters. As a result, the Group may become subject to substantial liabilities that may not be covered by insurance and that could affect our business, financial position and reputation. While Novartis does not believe that any of these legal proceedings will have a material adverse effect on its financial position, litigation is inherently unpredictable and large judgments sometimes occur. As a consequence, Novartis may in the future incur judgments or enter into settlements of </div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">claims that could have a material adverse effect on its results of operations or cash flow.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Governments and regulatory authorities around the world have been stepping up their compliance and law enforcement activities in recent years in key areas, including marketing practices, pricing, corruption, trade restrictions, embargo legislation, insider trading, antitrust, cyber security and data privacy. Further, when one government or regulatory authority undertakes an investigation, it is not uncommon for other governments or regulators to undertake investigations regarding the same or similar matters. Responding to such investigations is costly and requires an increasing amount of management&#8217;s time and attention. In addition, such investigations may affect our reputation, create a risk of potential exclusion from government reimbursement programs in the United States and other countries, and lead to (or arise from) litigation. These factors have contributed to decisions by Novartis and other companies in the healthcare industry, when deemed in their interest, to enter into settlement agreements with governmental authorities around the world prior to any formal decision by the authorities or a court. These government settlements have involved and may in the future involve large cash payments, sometimes in the hundreds of millions of dollars or more, including the potential repayment of amounts allegedly obtained improperly and other penalties, including treble damages. In addition, settlements of government healthcare fraud cases and antitrust cases often require companies to enter into corporate integrity agreements, which are intended to regulate company behavior for a period of years. Our affiliates Novartis Corporation and Sandoz Inc. are parties to such agreements, which will expire in 2025 and 2026, respectively. Also, matters underlying governmental investigations and settlements may be the subject of separate private litigation.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">While provisions have been made for probable outflows of economic resources, which management deems to be reasonable or appropriate, there are uncertainties connected with these estimates.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 20 contains additional information on these matters.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A number of Group companies are involved in legal proceedings concerning intellectual property rights. The inherent unpredictability of such proceedings means that there can be no assurances as to their ultimate outcome. A negative result in any such proceeding could potentially adversely affect the ability of certain Novartis companies to sell their products, or require the payment of substantial damages or royalties. The timing and the outcome of legal proceedings and their potential financial effect are not predictable.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the opinion of management, however, the outcome of these actions will not materially affect the Group&#8217;s financial position but could be material to the results of operations or cash flow in a given period.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#8217;s potential environmental remediation liability is assessed based on a risk assessment and investigation of the various sites identified by the Group as at risk for environmental remediation exposure. The Group&#8217;s future remediation expenses are affected by a number of uncertainties. These uncertainties include, but are not limited to, the method and extent of remediation, the percentage of material attributable to the Group at the remediation sites relative to that attributable to other parties, and the financial capabilities of the other potentially responsible parties.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 20 contains additional information on environmental liabilities.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div/>
            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfCommitmentsAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfCommitmentsAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859602304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - additional disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsAdditionalDisclosureAbstract', window );"><strong>Financial Instruments - additional disclosure [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">Disclosure of detailed information about financial instruments [text block]</a></td>
<td class="text">
          <div>
            <div id="anchorId001554504"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">29. Financial instruments&#160;&#8211;&#160;additional disclosures</div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables show the carrying values of financial instruments by measurement category as of December 31, 2022 and 2021. Except for straight bonds (see Note 19), the carrying values are equal to, or a reasonable approximation of, the fair values.</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                            <br/>
                            <br/>
                            <br/> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Financial<br/> instruments at<br/> amortized<br/> costs</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/> Financial<br/> instruments at<br/> fair value<br/> through other<br/> comprehensive<br/> income</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Financial<br/> instruments at<br/> fair value<br/> through the<br/> consolidated<br/> income<br/> statement</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> Other<br/> financial<br/> liabilities at<br/> amortized<br/> costs</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 517
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 089
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 066
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            958
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities - debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            828
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            317
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - fund investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            281
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances, security deposits and other long-term receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            129
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13/17</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            650
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            27 971
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            874
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 581
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other short-term financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            863
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 772
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            22 341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term liabilities to banks and other financial institutions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            144
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 146
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities (see Note 20/22) and other financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 067
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            55
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 789
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 266
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 122
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 789
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                            <br/>
                            <br/>
                            <br/> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Financial<br/> instruments at<br/> amortized<br/> costs</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Financial<br/> instruments at<br/> fair value<br/> through other<br/> comprehensive<br/> income</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Financial<br/> instruments at<br/> fair value<br/> through the<br/> consolidated<br/> income<br/> statement</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Other<br/> financial<br/> liabilities at<br/> amortized<br/> costs</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 397
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 010
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12 965
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 005
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            793
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities - debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 741
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 195
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            468
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - fund investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            366
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances, security deposits and other long-term receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            332
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            641
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            32 492
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 980
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 772
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of employees payable on demand</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 814
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other short-term financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            899
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            893
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25 296
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term liabilities to banks and other financial institutions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            227
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 553
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18/22</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 809
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities (see Note 20/22) and other financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 094
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            68
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 896
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            37 491
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 162
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 896
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Includes short-term highly rated government-backed debt securities, with an original maturity of three months or less</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Derivative financial instruments</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables show the contract or underlying principal amounts and fair values of derivative financial instruments analyzed by type of contract at December&#160;31, 2022 and 2021. Contract or underlying principal amounts indicate the gross volume of business outstanding at the consolidated balance sheet date and do not represent amounts at risk. The fair values are determined by reference to market prices or standard pricing models that use observable market inputs at December 31,&#160;2022 and 2021. </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Contract or underlying  principal amount</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Positive fair values  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Negative fair values  </div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 907
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13 248
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            189
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            92
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-41</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-35</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            97
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            82
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-33</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments included in  marketable securities and in current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 043
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            13 347
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows a breakdown by currency of the contract or underlying principal amount of derivative financial instruments at December&#160;31,&#160;2022 and 2021:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> EUR</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            687
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 659
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 907
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            80
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            97
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            767
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 715
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 043
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> EUR</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 485
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 158
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 605
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13 248
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            82
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            82
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 257
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 605
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            13 347
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Derivative financial instruments effective for hedge accounting purposes</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At the end of 2022 and 2021, there were no open hedging instruments for anticipated transactions.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Fair value by hierarchy</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As required by IFRS, financial assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. There are three hierarchical levels, based on increasing subjectivity associated with the inputs to derive fair valuation for these assets and liabilities, which are as follows:</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The assets carried at Level 1 fair value are equity and debt securities as well as fund investments listed in active markets.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The assets generally included in Level 2 fair value hierarchy are derivatives, and certain debt securities. The liabilities generally included in this fair value hierarchy consist of derivatives. These are valued using corroborated market data.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Level 3 inputs are unobservable for the asset or liability. The assets generally included in Level 3 fair value hierarchy are various investments in funds and unquoted equity security investments. Contingent consideration and other financial liabilities carried at fair value are included in this category.</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 1</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 2</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 3</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Marketable securities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities and derivative financial instruments at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            213
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            213
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current contingent consideration receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Long-term financial investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt and equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            473
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            699
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            261
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            281
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current contingent consideration receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            607
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            607
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total long-term financial investments at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            493
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 567
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 070
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            129
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            129
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current contingent consideration liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-131</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-131</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial liabilities at fair values</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-131</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-186</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current contingent consideration liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-704</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-704</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-232</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-232</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial liabilities at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-936</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-936</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 1</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 2</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 3</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 010
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 010
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total cash and cash equivalents at fair value</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 010
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 010
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Marketable securities and derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 719
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 741
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities and derivative financial instruments at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 719
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            127
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 846
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Long-term financial investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt and equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 080
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            617
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 697
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            338
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            366
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            641
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            641
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total long-term financial investments at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 108
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 596
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 704
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 075</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 075</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 094</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 162</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Includes short-term highly rated government-backed debt securities, with an original maturity of three months or less</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The change in carrying values associated with Level 3 financial instruments, using significant unobservable inputs during the year ended December 31, is set forth below:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Associated <br/> companies at <br/> fair value  through<br/> profit and loss</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Fund<br/> investments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Long-term <br/> financial <br/> investments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Contingent <br/> consideration <br/> receivables</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Contingent <br/> consideration <br/> liabilities</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Other<br/> financial<br/> liabiltiies</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            192
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            338
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            617
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            641
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 075</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value gains and other adjustments, including from divestments  recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            530
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value losses (including impairments and amortizations) and  other adjustments recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-63</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-78</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-84</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-114</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-18</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments recognized in the consolidated statement   of comprehensive income, including currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            160
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-231</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-238</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash receipts and payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            44
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-40</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            129
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            261
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            699
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            650
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-835</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-232</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of fair value gains and losses recognized   in the consolidated income statement for assets   and liabilities held at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-63</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-74</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-49</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            416
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Associated <br/> companies at <br/> fair value  through<br/> profit and loss</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Fund<br/> investments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Long-term <br/> financial <br/> investments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Contingent <br/> consideration <br/> receivables</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Contingent <br/> consideration <br/> payables</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            211
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            366
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            460
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            625
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 046</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value gains and other adjustments, including from divestments  recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            70
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            69
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            124
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value losses (including impairments and amortizations) and  other adjustments recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-26</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-189</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments recognized in the consolidated statement   of comprehensive income, including currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            51
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-22</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-88</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash receipts and payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-42</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            44
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-71</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            338
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            617
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            641
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 075</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of fair value gains and losses recognized   in the consolidated income statement for assets   and liabilities held at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-24</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            62
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            80
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div/>
            </div>
            <div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022, there was one transfer of equity securities from Level 3 to Level 1 for USD&#160;44 million (2021: USD&#160;73 million), due to Initial Public Offering of the invested company. During 2022, there were no transfers of equity securities from Level 1 to Level 3 due to de-listing (2021: USD 29 million).</div>
                </div>

            </div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Realized gains and losses associated with Level 3 long-term financial investments measured at fair value through the consolidated income statement are recorded in the consolidated income statement under &#8220;Other income&#8221; or &#8220;Other expense,&#8221; respectively. Realized gains and losses associated with Level 3 long-term financial investments measured at fair value through other comprehensive income are not recycled through the consolidated income statement but are instead reclassified to retained earnings.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">During the year, the net loss and net gain recorded on associated companies, fund investments and long-term financial investments at fair value through profit and loss were USD 316 million and USD 55 million, respectively.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">To determine the fair value of a contingent consideration, various unobservable inputs are used. A change in these inputs might result in a significantly higher or lower fair value measurement. The inputs used are, among others, the probability of success, sales forecast and assumptions regarding the discount rate and timing and different scenarios of triggering events. The inputs are interrelated. The significance and usage of these inputs to each contingent consideration may vary due to differences in the timing and triggering events for payments or in the nature of the asset related to the contingent consideration. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If the most significant parameters for the Level&#160;3 input were to change by 10% positively or negatively, or where the probability of success (POS) is the most significant input parameter, 10% were added or deducted from the applied probability of success, for contingent consideration payables and contingent consideration receivables, this would change the amounts recorded in the 2022 consolidated income statement by USD&#160;154 million and USD&#160;140 million, respectively.</div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Equity securities measured at fair value through other comprehensive income</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Equity securities held as strategic investments, typically held outside the Novartis Venture Fund, are generally designated at date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. These are made up of individually non-significant investments. At December 31, 2022, the Group holds 65 non-listed equity securities (December 31, 2021: 60) and 46 listed equity securities (December 31, 2021: 40) in this category with the following fair values:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Listed equity securities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            438
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            888
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-listed equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            390
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            307
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            828
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 195
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2022 and 2021, dividends received from these equity securities were insignificant. In 2022, in accordance with the consolidated foundations Alcon Inc. shares divestment plans, Alcon Inc. shares with a fair value of USD&#160;22 million were sold (2021: USD 9 million), and the USD&#160;7 million gain on disposal (2021: USD 1 million gain) was transferred from other comprehensive income to retained earnings during 2022. In addition, in 2022, equity securities that were no longer considered strategic, with a fair value of USD&#160;3 million (2021: USD&#160;254 million), were sold, and the USD&#160;3 million loss on disposal (2021: USD&#160;211 million gain) was transferred from other comprehensive income to retained earnings (see Note 8).</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Nature and extent of risks arising from financial instruments</span>
                </div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Market risk</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Market risk in general comprises currency risk, interest rate risk and price risk, such as commodity and equity prices. Novartis is exposed to market risk, primarily related to foreign currency exchange rates, interest rates and the market value of the investments. The Group actively monitors and seeks to reduce, where it deems it appropriate to do so, fluctuations in these exposures. It is the Group&#8217;s policy and practice to enter into a variety of derivative financial instruments to manage the volatility of these exposures. It does not enter into any financial transactions containing a risk that cannot be quantified at the time the transaction is concluded. In addition, it does not sell short assets it does not have, or does not know it will have, in the future. The Group only sells existing assets or enters into transactions and future transactions (in the case of anticipatory hedges) that it confidently expects it will have in the future, based on past experience. </div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Foreign currency exchange rate risk</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group uses the US dollar as its reporting currency. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Japanese and emerging market currencies. Fluctuations in the exchange rates between the US dollar and other currencies can have a significant effect on both the Group&#8217;s results of operations, including reported sales and earnings, as well as on the reported value of our assets, liabilities and cash flows. This, in turn, may significantly affect the comparability of period-to-period results of operations.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Because our expenditures in Swiss francs are significantly higher than our revenues in Swiss francs, volatility in the value of the Swiss franc can have a significant impact on the reported value of our earnings, assets and liabilities, and the timing and extent of such volatility can be difficult to predict.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There is also a risk that certain countries could experience a devaluation of their currency. If this occurs, it could impact the effective prices we would be able to charge for our products and also have an adverse impact on both our consolidated income statement and balance sheet.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Subsidiaries whose functional currencies have experienced a cumulative inflation rate of more than 100% over the past three years apply the principles of IAS 29 &#8220;Financial reporting in Hyperinflationary Economies.&#8221; The hyperinflationary economies in which Novartis operates are Argentina, Venezuela and Turkey. Venezuela and Argentina were hyperinflationary for all periods presented, and Turkey became hyperinflationary effective May 1, 2022, requiring retroactive implementation of hyperinflation accounting as of January 1, 2022. The impacts of applying IAS 29 were not significant in all years presented.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group manages its global currency exposure by engaging in hedging transactions where management deems appropriate. Novartis may enter into various contracts that reflect the changes in the value of foreign currency exchange rates to preserve the value of assets, commitments and anticipated transactions. Novartis also uses forward contracts and may enter into foreign currency option contracts to hedge.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net investments in subsidiaries in foreign countries are long-term investments. Their fair value changes through movements of foreign currency exchange rates. The Group has designated a certain portion of its long-term euro-denominated straight bonds, maturing in 2028, as hedges of the translation risk arising on certain of these net investments in foreign operations with euro functional currency. As of December 31, 2022, long-term financial debt with a carrying amount of EUR&#160;1.8 billion (USD&#160;2.0 billion; December 31, 2021: USD 2.1 billion), has been designated as a hedge instrument. During 2022, USD&#160;91 million of net of taxes unrealized income (2021: USD 216 million) was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge. The hedge remained effective since inception, and no amount was recognized in the consolidated income statement in 2022, 2021 and 2020.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Commodity price risk</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has only a very limited exposure to price risk related to anticipated purchases of certain commodities used as raw materials by the Group&#8217;s businesses. A change in those prices may alter the gross margin of a specific business, but generally by not more than <span>10%</span> of the margin and thus below the Group&#8217;s risk management tolerance levels. Accordingly, the Group does not enter into significant commodity futures, forward or option contracts to manage fluctuations in prices of anticipated purchases.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest rate risk</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group addresses its net exposure to interest rate risk mainly through the ratio of its fixed-rate financial debt to variable-rate financial debt contained in its total financial debt portfolio. To manage this mix, Novartis may enter into interest rate swap agreements, in which it exchanges periodic payments based on a notional amount and agreed-upon fixed and variable interest rates.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Equity risk</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group may purchase equities as investments of its liquid funds. As a policy, it limits its holdings in an unrelated company to less than <span>5%</span> of its liquid funds. Potential investments are thoroughly analyzed. Call options are written on equities that the Group owns, and put options are written on equities that the Group wants to buy and for which cash is available.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Credit risk</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Credit risks arise from the possibility that customers may not be able to settle their obligations as agreed. To manage this risk, the Group periodically assesses country and customer credit risk, assigns individual credit limits, and takes actions to mitigate credit risk where appropriate (for example payment guarantees, credit insurance and factoring).</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The provisions for expected credit losses for customers are based on a forward-looking expected credit loss, which includes possible default events on the trade </div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">receivables over the entire holding period of the trade receivables.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In measuring the expected credit losses, trade receivables are grouped based on shared credit risk characteristics (such as private versus public receivables) and days past due. In determining the expected credit loss rates, the Group considers current and forward-looking macroeconomic factors that may affect the ability of the customers to settle the receivables, and historical loss rates for each category of customers.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#8217;s largest customer accounted for approximately <span>16%</span> of net sales to third parties, and the second largest and third largest customers accounted for <span>11%</span> and <span>7%</span> of net sales to third parties, respectively (2021: <span>17%</span>, <span>11%</span> and <span>6%</span>, respectively; 2020: <span>17%</span>, <span>11%</span> and <span>6%</span>, respectively).</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The highest amounts of trade receivables outstanding were for these same three customers and amounted to <span>16%</span>, <span>14%</span> and <span>7%</span>, respectively, of the Group&#8217;s trade receivables at December 31, 2022 (2021: <span>16%</span>, <span>12%</span> and <span>7%</span>, respectively). There is no other significant concentration of customer credit risk.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Counterparty risk</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Counterparty risk encompasses issuer risk on marketable securities and money market instruments; credit risk on cash, time deposits and derivatives; as well as settlement risk for different instruments. Issuer risk is reduced by only buying securities that are at least A- rated. Counterparty credit risk and settlement risk are reduced by a policy of entering into transactions with counterparties (banks or financial institutions) that feature a strong credit rating. Exposure to these risks is closely monitored and kept within predetermined parameters. The limits are regularly assessed and determined based upon credit analysis, including financial statement and capital adequacy ratio reviews. In addition, reverse repurchasing agreements are contracted, and Novartis has entered into credit support agreements with various banks for derivative transactions. To further reduce the settlement risk, the Group has implemented a multi-currency payment system, Continuous Linked Settlement (CLS), providing multilateral netting (payment-versus-payment settlement) of cash flows from foreign exchange transactions.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#8217;s cash and cash equivalents are held with major regulated financial institutions; the three largest ones hold approximately <span>13.2%</span>, <span>9.2%</span> and <span>6.8%</span>, respectively (2021: <span>9.7%</span>, <span>9.7%</span> and <span>7.6%</span>, respectively). As of December 31, 2021, the Group&#8217;s cash and cash equivalents also included short-term highly rated government-backed debt securities, with an original maturity of three months or less, for approximately <span>16%</span> (2022: nil).</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Liquidity risk</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Liquidity risk is defined as the risk that the Group could not be able to settle or meet its obligations associated with financial liabilities that are settled by delivering cash or another financial asset. Group Treasury is responsible for liquidity, funding and settlement management. In addition, liquidity and funding risks, and related processes and policies, are overseen by management. Novartis manages its liquidity risk on a consolidated basis according to business needs and tax, capital or regulatory considerations, if applicable, through numerous sources of financing in order to maintain flexibility. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain countries have legal or economic restrictions on the ability of subsidiaries to transfer funds to the Group in the form of cash dividends, loans or advances, but these restrictions do not have an impact on the ability of the Group to meet its cash obligations.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Management monitors the Group&#8217;s net debt or liquidity position through rolling forecasts on the basis of expected cash flows.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis has two US commercial paper programs under which it can issue up to USD&#160;9.0 billion in the aggregate of unsecured commercial paper notes. Novartis also has one Japanese commercial paper program under which it can issue up to JPY&#160;150 billion (approximately USD&#160;1.1 billion) of unsecured commercial paper notes. Commercial paper notes totaling USD&#160;2.8 billion under these three programs were outstanding as per December 31, 2022 (2021: USD&#160;0.9 billion). Novartis further has a committed credit facility of USD&#160;6.0 billion, which was extended in September 2022. This credit facility is provided by a syndicate of banks and is intended to be used as a backstop for the US commercial paper programs. The facility matures in September 2025 and was undrawn as per December 31, 2022, and December 31, 2021.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table sets forth how management monitors net debt or liquidity based on details of the remaining contractual maturities of current financial assets and liabilities, excluding trade receivables and payables as well as liabilities for contingent consideration at December 31, 2022, and December 31, 2021:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Due within <br/> one month</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br/> one month <br/> but less than <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br/> one year <br/> but less than <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Due after <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, time deposits and short-term investments with original maturity more than 90 days and accrued interest</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 142
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 911
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            36
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 098
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            111
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            111
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            147
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 011
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 506
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 517
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 176
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            10 564
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            55
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            135
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            18 930
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-8 975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-11 269</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-20 244</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-9 002</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-11 394</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-20 396</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-8 975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-11 269</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-20 244</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 215</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-146</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 515</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 876</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-3 215</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-146</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-2 517</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-5 878</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-38</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 253</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-159</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2 519</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-5 931</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 923
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            10 405
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2 464</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-8 975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-11 134</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-7 245</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Due within <br/> one month</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br/> one month <br/> but less than <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br/> one year <br/> but less than <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Due after <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, time deposits and short-term investments with original maturity more than 90 days and accrued interest</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 585
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 088
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 706
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            111
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            111
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            64
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 406
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 001
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12 407
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            7 438
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            19 650
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 095
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            142
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            28 329
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8 464</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14 438</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-22 902</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-8 490</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-14 587</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-23 077</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-8 464</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-14 438</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-22 902</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 780</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-521</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 926</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-6 227</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-2 780</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-521</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-2 928</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-6 229</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-50</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 830</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-537</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 928</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-6 295</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 608
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            19 113
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 833</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-8 460</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-14 296</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-868</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The carrying amounts of financial liabilities included in the above analysis are not materially different to the contractual amounts due on maturity. The positive and negative fair values on derivative financial instruments represent the net contractual amounts to be exchanged at maturity.</div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#8217;s contractual undiscounted potential cash flows from derivative financial instruments to be settled on a gross basis are as follows:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Due within <br/> one month</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br/> one month <br/> but less than <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Derivative financial instruments and accrued interest on derivative  financial instruments</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential outflows in various currencies - from financial derivative liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 029</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4 598</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-316</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6 943</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential inflows in various currencies - from financial derivative assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 029
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 712
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            321
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 062
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Due within <br/> one month</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br/> one month <br/> but less than <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Derivative financial instruments and accrued interest on derivative  financial instruments</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential outflows in various currencies - from financial derivative liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-843</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 482</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-461</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-6 786</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential inflows in various currencies - from financial derivative assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            847
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 516
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            457
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 820
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Other contractual liabilities that are not part of management&#8217;s monitoring of the net debt or liquidity consist of the following items:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Due within <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br/> one year <br/> but less than <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Due after <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contractual interest on non-current liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-64</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-412</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 432</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 624</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 532</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-71</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-180</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-616</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-922</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 789</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 020</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-126</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 146</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-115</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-437</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-267</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-835</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 10 provides additional disclosures related to lease liabilities.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Due within <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br/> one year <br/> but less than <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Due after <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contractual interest on non-current liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-82</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-445</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 628</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 908</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-6 063</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-78</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-197</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-639</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-982</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 896</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 373</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-180</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 553</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 809</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 809</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-54</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-517</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-439</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 075</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 10 provides additional disclosures related to lease liabilities.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Capital risk management</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis strives to maintain a strong credit rating. In managing its capital, Novartis focuses on maintaining a strong balance sheet. As of December 31, 2022, Moody&#8217;s Investors Service rated the Company A1 for long-term maturities and P-1 for short-term maturities, and S&amp;P Global Ratings rated the Company AA- for long-term maturities and A-1+ for short-term maturities. </div>
                <div style=" padding-bottom: 10px;">
                  <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Sensitivity analysis</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group uses sensitivity analysis disclosures to provide quantitative information about market risks to which it is exposed. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The sensitivity analysis disclosures are in line with the Group&#8217;s financial risk management policy, and are based on a one-parameter risk model that considers a one-factor linear relationship between risk factors and </div>
              </div>
            </div>
          </div>

          <div>
            <div>
              <div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">exposures. They consider aggregated risk exposures arising from the most significant risk factors (currency risk, interest rate risk and equity price risk) and include all financial assets and financial liabilities as set forth in the table on page F-64. </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The disclosures below illustrate the potential impact on the Group&#8217;s consolidated financial statements as a result of hypothetical market movements in foreign currency exchange rates, interest rates and equity prices. The range of variables chosen reflects management&#8217;s view of changes that are reasonably possible over a one-year period. </div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Foreign currency exchange rate sensitivity</span>
                </div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group uses the US dollar as its reporting currency. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Japanese and emerging market currencies, as well as in the Swiss franc. A strengthening (weakening) of the US dollar against these currencies as of December 31, 2022 and 2021 would have affected the measurement of financial instruments denominated in these foreign currencies. This analysis assumes that all other variables, in particular interest rates, remain constant. A hypothetical <span>5%</span> increase or decrease in the foreign currency exchange rates against the US dollar would have impacted the Group&#8217;s consolidated income statement as presented below: </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% increase in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% decrease in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As of December 31, 2022, the Group designated EUR 1.8 billion (December 31, 2021: EUR 1.8 billion) of its long-term euro-denominated straight bonds as hedges of the translation risk arising on certain net investments in foreign operations with euro functional currency. This analysis assumes that all other variables, in particular interest rates, remain constant. A hypothetical <span>5%</span> increase, or decrease, in the foreign currency exchange rates against the US dollar, without considering the translation effect of these net investments, would have impacted the Group&#8217;s consolidated equity as presented below: </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% increase in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            93
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            99
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% decrease in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-98</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-104</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest rate sensitivity</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Our portfolio of fixed-income instruments as of December 31, 2022, was mainly composed of time deposits and debt securities. </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis uses duration models to approximate the possible change in the value of fixed-income instruments. Based on these models, management believes that a 100-basis point change in interest is deemed a reasonable possible change over a one-year period.</div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Based on exposures in 2022 and 2021, a hypothetical 100-basis point increase (decrease) in interest rates would not have resulted in a significant increase (decrease) in the fair values of the fixed-income instruments. In addition, a hypothetical 100-basis point increase (decrease) in interest rates would not have resulted in a material increase (decrease) of cash flows attributable to such fixed-income instruments.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The vast majority of our outstanding financial debts are straight bonds with fixed interest rates and are therefore not affected by movements in interest rates.</div>
                <div>
                  <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Equity price sensitivity</span>
                </div>
                <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Fund investments and equity securities held by the Novartis Venture Fund are valued at fair value through profit and loss. Equity securities held as strategic investments, typically held outside the Novartis Venture Fund, are generally designated at date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss.</div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of these fund investments and equity securities was USD 1.6 billion as of December 31, 2022 (December 31, 2021: USD 2.2 billion). The fair values of these investments are impacted by the volatility of the stock market, valuation parameters applied (for non-listed equities) and changes in general economic factors. This analysis assumes that all other variables, in particular interest rates, remain constant. A hypothetical increase or decrease of <span>15%</span> in the risk factors would have impacted the Group&#8217;s consolidated income statement as presented below: </div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% increase in equity prices</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            109
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            154
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% decrease in equity prices</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-109</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-154</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
            <div>
              <div>
                <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">A hypothetical increase or decrease of <span>15%</span> in the risk factors would have impacted the Group&#8217;s consolidated equity as presented below:</div>
              </div>
            </div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% increase in equity prices</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            124
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            179
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% decrease in equity prices</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-124</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-179</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35K<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialInstrumentsAdditionalDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialInstrumentsAdditionalDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571871569552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events subsequent to the December 31 consolidated balance sheet date<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Disclosure of non-adjusting events after reporting period [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Events subsequent to the December 31 consolidated balance sheet date</a></td>
<td class="text">
          <div>
            <div id="anchorId001561678"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">30. Events subsequent to the December 31, 2022, consolidated balance sheet date</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">South Korea investigation &#8211; Concluded matter</span>
            </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In January 2023, the Supreme Court dismissed the appeal by the Seoul Western District Prosecutor on the criminal investigation on, among other things, allegations that Novartis Korea utilized medical journals to provide inappropriate economic benefits to healthcare professionals (HCPs). This matter is now concluded. For additional information see Note 20.</div>
            <div>
              <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Dividend proposal for 2022 and approval of&#160;the Group&#8217;s 2022 consolidated financial statements  </span>
            </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On January 31, 2023, the Novartis AG Board of Directors proposed the acceptance of the 2022 consolidated financial statements of the Novartis Group for approval by the Annual General Meeting on March 7, 2023. Furthermore, also on January 31, 2023, the Board proposed a dividend of CHF 3.20 per share to be approved at the Annual General Meeting on March 7, 2023. If approved, total dividend payments would amount to approximately USD 7.3 billion (2021: USD&#160;7.5  billion), using the CHF/USD December 31, 2022, exchange rate.</div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_IAS10_g17-22_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859602304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Group subsidiaries and associated companies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract', window );"><strong>Disclosure of subsidiaries [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory', window );">Principal Group subsidiaries and associated companies</a></td>
<td class="text">
          <div>
            <div id="anchorId001561713"/>
            <div id="anchorNote31"/>
            <div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">31. Principal Group subsidiaries and&#160;associated&#160;companies </div>
            <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table lists the principal subsidiaries controlled by Novartis, associated companies in which &#173;Novartis is deemed to have significant influence, and foundations required to be consolidated under IFRS. It includes all subsidiaries, associated companies and consolidated foundations with total assets or net sales to third parties in excess of USD&#160;25&#160;million. The equity interest percentage shown in the table also represents the share in voting rights in those entities.</div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>As at December 31, 2022</div>
                        </td>
                        <td/>
                        <td/>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br/> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br/> interest</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Algeria</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Soci&#233;t&#233; par actions SANDOZ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Algiers
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DZD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            650.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Argentina</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Argentina S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Buenos Aires
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ARS</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            906.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Australia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Australia Pty Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Macquarie Park, NSW
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharmaceuticals
Australia Pty Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Macquarie Park, NSW
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.8
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Pty Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Macquarie Park, NSW
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Austria</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Austria GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Vienna
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Vienna
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Kundl
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            32.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EBEWE Pharma Ges.m.b.H Nfg. KG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Unterach am Attersee
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Bangladesh</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis (Bangladesh) Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Gazipur
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BDT</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            162.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              60%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Belgium</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma NV
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Vilvoorde
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            72.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz NV
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Vilvoorde
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            19.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Alcon - Couvreur NV
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Puurs
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            110.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Bermuda</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Investment Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hamilton
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Securities Investment Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hamilton
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance Services Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hamilton
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Triangle International Reinsurance Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hamilton
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Trinity River Insurance Co Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hamilton
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            370 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Brazil</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Bioci&#234;ncias S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            S&#227;o Paulo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRL</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            507.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz do Brasil Ind&#250;stria Farmac&#234;utica Ltda.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Camb&#233;, PR
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRL</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            190.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Canada</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharmaceuticals Canada Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Dorval, Quebec
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Canada Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Boucherville, Quebec
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            80.8
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Chile</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Chile S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Santiago de Chile
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CLP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">China</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Beijing Novartis Pharma Co., Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Beijing
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharmaceuticals (HK) Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hong Kong
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HKD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            200
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            China Novartis Institutes for
BioMedical Research Co., Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Shanghai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            320.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Suzhou Novartis Technical
Development Co., Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Changshu
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Shanghai Novartis Trading Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Shanghai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz (China) Pharmaceutical
Co., Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Zhongshan
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            57.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Colombia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis de Colombia S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Santaf&#233; de Bogot&#225;
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> COP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.9
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Croatia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz d.o.o. farmaceutska industrija
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Zagreb
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HRK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Czech Republic</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis s.r.o.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Prague
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            51.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz s.r.o.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Prague
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            44.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Denmark</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Healthcare A/S
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Copenhagen
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            14.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz A/S
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Copenhagen
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ecuador</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Ecuador S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Quito
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Egypt</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma S.A.E.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cairo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EGP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.3
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.96%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Egypt Pharma S.A.E.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            New Cairo City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EGP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            250 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Finland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finland Oy
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Espoo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            459 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>As at December 31, 2022</div>
                        </td>
                        <td/>
                        <td/>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br/> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br/> interest</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">France</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Groupe France S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Rueil-Malmaison
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            903.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma S.A.S.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Rueil-Malmaison
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            43.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Gene Therapies France SAS
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Rueil-Malmaison
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Rueil-Malmaison
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications
Molecular Imaging France
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Saint-Genis-Pouilly
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            CELLforCURE
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Les Ulis
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz S.A.S.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Levallois-Perret
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Germany</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Deutschland GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Nuremberg
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            155.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Business Services GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Wehr
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Nuremberg
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Produktions GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Wehr
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz International GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Holzkirchen
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 A Pharma GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Holzkirchen
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            26 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            HEXAL AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Holzkirchen
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            93.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Salutas Pharma GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Barleben
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            42.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Aeropharm GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Rudolstadt
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            26 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Greece</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis (Hellas) S.A.C.I.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Metamorphosis / Athens
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            233.9
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Hungary</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Hungary Healthcare Limited Liability
Company
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Budapest
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HUF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            545.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Hungary Limited Liability Company
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Budapest
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HUF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            883.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">India</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis India Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Mumbai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            123.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              70.68%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Healthcare Private Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Mumbai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            60.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Private Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Mumbai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            32.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Indonesia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            PT. Novartis Indonesia
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Jakarta
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IDR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ireland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Ireland Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Dublin
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Integrated Services Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cork City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Gene Therapies EU Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Dublin
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Israel</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Israel Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Tel Aviv
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ILS</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Italy</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Farma S.p.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Milan
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications (Italy) S.r.l.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Pozzilli
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            119 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz S.p.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Origgio
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Japan</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma K.K.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Tokyo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Ciba-Geigy Japan Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Tokyo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz K.K.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Tokyo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Latvia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Baltics SIA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Riga
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Luxembourg</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Investments S.&#224; r.l.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Luxembourg City
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Luxembourg City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Malaysia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Corporation (Malaysia) Sdn. Bhd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Petaling Jaya
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MYR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.3
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Mexico</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Farmac&#233;utica, S.A. de C.V.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Mexico City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            205.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz, S.A. de C.V.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Mexico City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            468.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Morocco</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Maroc SA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Casablanca
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MAD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            80.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Netherlands</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Netherlands B.V.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Amsterdam
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma B.V.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Amsterdam
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            IDB Holland BV
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Baarle-Nassau
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz B.V.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Almere
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            907 560
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">New Zealand</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis New Zealand Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Auckland
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NZD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            820 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>As at December 31, 2022</div>
                        </td>
                        <td/>
                        <td/>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br/> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br/> interest</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Norway</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Norge AS
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Oslo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NOK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Pakistan</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma (Pakistan) Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Karachi
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PKR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.99%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Panama</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma (Logistics), Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Panama City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Philippines</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Healthcare Philippines, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Makati City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PHP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            298.8
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Philippines Corporation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Makati City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PHP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Poland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Poland Sp. z o.o.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Warsaw
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            44.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Polska Sp. z o.o.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Warsaw
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Lek S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Strykow
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Portugal</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Portugal, S.G.P.S., Lda.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Porto Salvo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            500 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Farma - Produtos Farmac&#234;uticos, S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Porto Salvo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Farmac&#234;utica, Lda.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Porto Salvo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            499 900
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Romania</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Services Romania S.R.L.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Bucharest
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz S.R.L.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Targu-Mures
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            119.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Russian Federation</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma LLC
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Moscow
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Neva LLC
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            St. Petersburg
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            500.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            JSC Sandoz
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Moscow
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            57.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Saudi Arabia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Saudi Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Riyadh
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SAR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Singapore</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis (Singapore) Pte Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Singapore
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Singapore Pharmaceutical
Manufacturing Pte Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Singapore
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            45.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Asia Pacific Pharmaceuticals
Pte Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Singapore
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            39.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Slovakia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Slovakia s.r.o.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Bratislava
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Slovenia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Lek Pharmaceuticals d.d.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Ljubljana
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            48.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Pharmaceuticals d.d.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Ljubljana
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">South Africa</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis South Africa (Pty) Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Midrand
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            86.3
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz South Africa (Pty) Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Midrand
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">South Korea</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Korea Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Seoul
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> KRW</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Spain</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Farmac&#233;utica, S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Barcelona
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            63.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications
Iberica, S.L.U.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Esplugues de Llobregat
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            22.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Farmac&#233;utica S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Madrid
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            270 450
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Industrial Products
S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Les Franqueses del Vall&#233;s / Barcelona
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9.3
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Abadia Retuerta S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sard&#243;n de Duero / Valladolid
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sweden</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Sverige AB
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Stockholm
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SEK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis International AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Holding AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis International Pharmaceutical Investment AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Bioventures AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Forschungsstiftung
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Stiftung f&#252;r Kaderausbildung
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis-Mitarbeiterbeteiligungsstiftung
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Stiftung f&#252;r Mensch und Umwelt
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Stiftung der Novartis AG f&#252;r Erziehung,
Ausbildung und Bildung
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Overseas Investments AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Japat AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            50 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            350.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Services AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Schweizerhalle AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Muttenz
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18.9
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Stein AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Stein
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            251 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Schweiz AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Risch
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cellerys AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Schlieren
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            129 630
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              20%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Arctos Medical AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Bern
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            360 020
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Innovative Therapies AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Risch
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications International SA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Geneva
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9.3
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Pharmaceuticals AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Risch
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>As at December 31, 2022</div>
                        </td>
                        <td/>
                        <td/>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br/> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br/> interest</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Taiwan</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis (Taiwan) Co., Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Taipei
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TWD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            170.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Thailand</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis (Thailand) Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Bangkok
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> THB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            302.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Turkey</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Saglik, Gida ve Tarim &#220;r&#252;nleri Sanayi
ve Ticaret A.S.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Istanbul
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            448.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Farmanova Saglik Hizmetleri Ltd. Sti.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Istanbul
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Ila&#231; Sanayi ve Ticaret A.S.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Istanbul
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            880.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.99%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Grup Saglik &#220;r&#252;nleri
Ila&#231;lari Sanayi ve Ticaret A.S.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Gebze - Kocaeli
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            96.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ukraine</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Ukraine LLC
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Kyiv
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> UAH</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United Arab Emirates</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Middle East FZE
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Dubai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AED</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United Kingdom</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis UK Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharmaceuticals UK Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Grimsby Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            250.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications (UK &amp; Ireland)
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Neutec Pharma Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Gyroscope Therapeutics Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 492
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Frimley / Camberley
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United States of America</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Corporation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            72.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance Corporation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Services, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis US Foundation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharmaceuticals Corporation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            650
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications USA, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Millburn, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Gene Therapies, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Bannockburn, IL
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Technology LLC
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Institutes for BioMedical
Research, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cambridge, MA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cadent Therapeutics
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cambridge, MA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Endocyte, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Navigate BioPharma Services, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Carlsbad, CA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            The Medicines Company
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Princeton, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Oriel Therapeutics, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Durham, NC
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            50.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Fougera Pharmaceuticals Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Melville, NY
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Eon Labs, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Princeton, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Venezuela</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis de Venezuela, S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Caracas
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VES</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Vietnam</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Vietnam Company Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Ho Chi Minh City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VND</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            70
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">In addition, the Group is represented by subsidiaries and associated companies with total assets or net sales to third parties below USD 25 million in the following countries: Bosnia and Herzegovina, Bulgaria, Cameroon, Dominican Republic, Ghana, Guatemala, Ivory Coast, Kazakhstan, Kenya, Kuwait, North Macedonia, Nigeria, Peru, Senegal and Uruguay.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Share capital may not reflect the taxable share capital and does not include any paid-in surplus.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Significant subsidiary under SEC Regulation S-X Rule 1-02(w)</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup> Fully consolidated Foundation</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">m = million; bn = billion</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

            </div>
          </div>

          <div>
            <div>

                <div/>

            </div>
          </div>
        <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of subsidiaries. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B4<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B4_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864286256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory', window );">Scope of consolidation</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Scope of consolidation </span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated financial statements include all entities, including structured entities, over which Novartis AG, Basel, Switzerland, directly or indirectly has control (generally as a result of owning more than 50% of the entity&#8217;s voting interest). Consolidated entities are also referred to as &#8220;subsidiaries.&#8221; </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In cases where Novartis does not fully own a subsidiary, it has elected to value any remaining outstanding non-controlling interest at the time of acquiring control of the subsidiary at its proportionate share of the fair value of the net identified assets.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Investments in associated companies (generally defined as investments in entities in which Novartis holds between 20% and 50% of voting shares or over which it otherwise has significant influence) and joint ventures are accounted for using the equity method, except for selected venture fund investments for which the Group has elected to apply the method of fair value through the consolidated income statement.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currencies</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Foreign currencies</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated financial statements of Novartis are presented in US dollars (USD). The functional currency of a subsidiary is generally the local currency of that respective entity. The functional currency used for the reporting of certain Swiss and foreign finance entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in this currency.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For subsidiaries not operating in hyperinflationary economies, the subsidiary&#8217;s results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates:</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Income, expense and cash flows for each month using the average exchange rate, with the US dollar values for each month being aggregated during the year</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Balance sheet using year-end exchange rates</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Resulting exchange rate differences are recognized in other comprehensive income</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For subsidiaries operating in hyperinflationary economies, the impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period is recorded in retained earnings in equity. The subsequent gains or losses resulting from the restatement of non-monetary assets are recorded in &#8220;Other financial income and expense&#8221; in the consolidated income statement. </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory', window );">Non-current assets held for sale or held for distribution to owners</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Non-current assets held for sale or held for distribution to owners</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Non-current assets are accounted for as assets held for sale or as related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell and any resulting impairment is recognized. Assets related to discontinued operations and assets of a disposal group held for sale are not depreciated or amortized. The prior year consolidated balance sheet is not restated.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If in a subsequent period, the criteria for classification as held for sale are no longer met, the recoverable amount of assets and liabilities are reclassified out of assets held for sale into the respective balance sheet lines and the prior year consolidated balance sheet is not restated. The cumulative amount of depreciation and amortization not recorded since the date of their classification as assets held for sale, and any required </div>
                </div>

                <div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">adjustments to the recoverable amounts of assets are recognized in the consolidated income statement.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory', window );">Acquisition of assets</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Acquisition of assets and businesses</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Assets separately acquired are recorded at cost, which includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment and restore the site when it is no longer used are included in their cost.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Acquired businesses are accounted for by applying the acquisition method, unless the optional concentration test is applied. The optional concentration test allows for an election on a transaction-by-transaction basis to account for the acquired business as an asset separately acquired when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The acquisition method requires that the assets acquired and liabilities assumed be recorded at their respective fair values on the date the Group obtains control. The excess of the fair value of the total purchase consideration transferred over the fair value of the acquired assets and assumed liabilities is recognized as goodwill. The valuations are based on information available at the acquisition date. Acquisition related costs are expensed as incurred.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The application of the acquisition method requires certain estimates and assumptions to be made, especially concerning the fair values of the acquired intangible assets, inventories, property, plant and equipment and the liabilities assumed at the acquisition date, and the useful lives of the intangible assets and property, plant and equipment. Estimates of fair value require the use of valuation techniques. These valuations require the use of management assumptions and estimates, including the value of comparable assets in the market, amount and timing of future cash flows, outcomes and costs of research and development activities, probability of obtaining regulatory approval, long-term sales forecasts, actions of competitors, discount rates and terminal growth rates. The section &#8220;&#8212;Impairment of goodwill and intangible assets&#8221; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property plant and equipment</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Property, plant and equipment</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Property, plant and equipment is depreciated on a straight-line basis in the consolidated income statement over the estimated useful life of the individual asset. Freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Property, plant and equipment is assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections over the useful life.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the estimated useful life by major categories for property, plant and equipment:</div>
                  <div>

                      <div>
                        <div style="padding-top:10px; padding-bottom:30px;">
                          <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                            <tr valign="bottom">
                              <td style=";height:12;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                              </td>
                              <td/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Useful life</div>
                              </td>
                              <td/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 2px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                              <td align="right" style=";width:20%;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20 to 40 years</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and other equipment</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Machinery and equipment</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7 to 20 years</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Furniture and vehicles</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 10 years</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Computer hardware</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                          </table>
                        </div>
                      </div>

                  </div>
                  <div>
                    <div>
                      <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Government grants obtained for construction activities, including any related equipment, are deducted from the gross acquisition cost to arrive at the balance sheet carrying value of the related assets.</div>
                    </div>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases and right-of-use assets</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Leases and right-of-use assets</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As lessee, at inception and upon the modification of a contract, the Group assesses whether the contract contains a lease. The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative standalone price of each component. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases. For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease to the end of the lease term. The lease term includes the period of any lease extension that management assess as reasonably certain to be exercised by the Group. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the Novartis incremental borrowing rate for the asset subject to the lease in the relevant market.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The portion of the lease payments attributable to the repayment of lease liabilities is recognized in cash flows used in financing activities, and the portion attributable to the payment of interest is included in cash flows from operating activities.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease incentive received, and any initial direct costs incurred by Novartis, and expected costs for obligations to dismantle and remove right-of-use assets when they are no longer used.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over </div>
                </div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">the shorter of the useful life of the right-of-use asset or the end of the lease term. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In arrangements where the Group is the lessor, it determines at lease inception whether the lease is a finance lease or an operating lease. Leases that transfer substantially all of the risk and rewards incidental to ownership of the underlying asset to the counterparty (the lessee) are accounted for as finance leases. Leases that do not transfer substantially all of the risks and rewards of ownership are accounted for as operating leases. Operating lease payments received are recognized on a straight-line basis over the lease term in the consolidated income statement in &#8220;Other income.&#8221; </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory', window );">Goodwill</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Goodwill and intangible assets</span>
                  </div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Goodwill</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Goodwill arises on applying the acquisition method on the acquisition of a business and is the excess of the fair value of the consideration transferred to acquire the business over the underlying fair value of the net identified assets acquired. It is allocated to groups of cash-generating units (CGUs), that are expected to benefit from the synergies of the combination, and which are usually represented by the reported segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under &#8220;Other expense&#8221; in the consolidated income statement.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock', window );">Intangible assets available-for-use</a></td>
<td class="text">
                <div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intangible assets available for use</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has the following classes of available for use intangible assets: currently marketed products; technologies and other intangible assets (including software).</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Currently marketed products represent the composite value of acquired intellectual property (IP), patents, distribution rights and product trade names.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Technologies represent identified and separable acquired know-how used in the research, development and production processes.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Significant investments in internally developed and acquired computer software are capitalized and included in the &#8220;Other&#8221; category, and amortized once available for use.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Intangible assets available for use with a definite useful life are amortized over their estimated useful lives on a straight-line basis and are evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the estimated useful life by major categories for intangible assets available for use and the line in the consolidated income statement in which the amortization and any potential impairment charge is recognized:</div>
                  <div>

                      <div>
                        <div style="padding-top:10px; padding-bottom:30px;">
                          <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                            <tr valign="bottom">
                              <td style=";height:12;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                              </td>
                              <td/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                                  <br/>
                                  <br/> Useful life</div>
                              </td>
                              <td/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement line<br/> for amortization and<br/> impairment charges</div>
                              </td>
                              <td/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 20 years</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Technologies</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10 to 20 years    </div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"   or "Research   and development"</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other (including software)</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 12 years  </div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> In the relevant   functional expense</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                          </table>
                        </div>
                      </div>

                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock', window );">Intangible assets not yet available-for-use</a></td>
<td class="text">
                <div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Intangible assets not yet available for use</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Acquired research and development intangible assets that have not yet obtained marketing approval are recognized as in-process research and development (IPR&amp;D).</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">IPR&amp;D is not amortized, but is evaluated for potential impairment on an annual basis or when facts and circumstances warrant. Any impairment charge is recorded in the consolidated income statement under &#8220;Research and development.&#8221; Once a project included in IPR&amp;D has received marketing approval from a regulatory authority, it is transferred to the &#8220;Currently marketed products&#8221; category.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock', window );">Impairment of goodwill and intangible assets</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impairment of goodwill and intangible assets</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">An asset, a CGU or a grouping of CGUs is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value-in-use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGU, and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset. These valuations are classified as &#8220;Level 3&#8221; in the fair value hierarchy.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group&#8217;s activities with regard to:</div>
                </div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Amount and timing of projected future cash flows</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Sales forecasts </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Actions of competitors (launch of competing products, marketing initiatives, etc.)</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Sales erosion rates after the end of patent or other intellectual property rights protection, and timing of the entry of generic competition</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Outcome of research and development activities (compound efficacy, results of clinical trials, etc.)</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Amount and timing of projected costs to develop IPR&amp;D into commercially viable products</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Profit margins</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Probability of obtaining regulatory approval</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Future tax rate</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Appropriate terminal growth rate</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Appropriate discount rate</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Generally, for intangible assets with a definite useful life, Novartis uses cash flow projections for the whole useful life of these assets. For goodwill, Novartis generally utilizes cash flow projections for a three-year period based on management forecasts, with a terminal value based on cash flow projections usually in line with inflation rates for later periods. </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Probability-weighted scenarios are typically used.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Discount rates used consider the Group&#8217;s estimated weighted average cost of capital, adjusted for specific asset, country and currency risks associated with cash flow projections, to approximate the discount rate that market participants would use to value the asset.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Due to the above factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques. </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Cash and cash equivalents</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash and cash equivalents include highly liquid investments with original maturities of three months or less, which are readily convertible to known amounts of cash. Bank overdrafts are presented within current financial debts on the consolidated balance sheet.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock', window );">Marketable securities, commodities and non-current financial assets</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Marketable securities, commodities and non-current financial assets </span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Commodities, which include gold bullion or coins, are valued at the lower of cost or fair value using current market prices. The changes in fair value below cost are immediately recorded in &#8220;Other financial income and expense.&#8221;</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities are financial assets held for short-term purposes which are principally traded in liquid markets and are classified within current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#8220;Other financial income and expense&#8221; in the consolidated income statement. Non-current financial assets held for long-term strategic purposes are classified within non-current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#8220;Other income&#8221; and &#8220;Other expense&#8221; in the consolidated income statement.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities and non-current financial assets are initially recorded at fair value on their trade date, which is different from the settlement date when the transaction is ultimately effected. Quoted securities are remeasured at each reporting date to fair value based on current market prices. If the market for a financial asset is not active or no market is available, fair values are established using valuation techniques. The majority of non-quoted investments are initially valued at fair value through the purchase price established between a willing buyer and seller. Non-quoted investments are subsequently adjusted based on values derived from discounted cash flow analysis or other pricing models. These investment values are classified as &#8220;Level 3&#8221; in the fair value hierarchy.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group classifies and accounts for its marketable securities and non-current financial assets in the following categories:</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Debt securities are valued at fair value through other comprehensive income with subsequent recycling into the consolidated income statement, as they meet both the &#8220;solely payment of principal and interest&#8221; and the business model criteria. Unrealized gains and losses, except exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are recognized in the consolidated income statement when the debt instrument is sold, at which time the gain is transferred to &#8220;Other financial income and expense.&#8221; Exchange gains and losses related to debt instruments are immediately recognized in the consolidated income statement in &#8220;Other financial income and expense.&#8221;</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Fund investments and equity securities of the Novartis Venture Fund are valued at fair value through profit and loss (FVPL). Unrealized gains and losses, including exchange gains and losses, are recognized in the consolidated income statement in &#8220;Other income&#8221; for gains and &#8220;Other expense&#8221; for losses.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Equity securities held as strategic investments, typically held outside of the Novartis Venture Fund, are generally designated at the date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. Unrealized gains and losses, including exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are reclassified to retained earnings when the equity security is sold. If these equity securities are not designated at the date of acquisition as financial assets valued at fair value through other comprehensive income, they are valued at FVPL, as described above.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Other non-current financial assets, such as loans and long-term receivables from customers, advances and other deposits, are valued at amortized cost, which reflects the time value of money less any allowances for expected credit losses.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group assesses on a forward-looking basis the expected credit losses associated with its debt securities valued at fair value through other comprehensive </div>
                </div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">income. Impairments on debt securities are recorded in &#8220;Other financial income and expense.&#8221;</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For other financial assets valued at amortized cost, impairments, which are based on their expected credit losses, and exchange rate losses are included in &#8220;Other expense&#8221; in the consolidated income statement. Exchange rate gains and interest income, using the effective interest rate method, are included in &#8220;Other income&#8221; or &#8220;Other financial income&#8221; in the consolidated income statement, depending on the nature of the item.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory', window );">Description of accounting policy for financial assets [text block]</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Derivative financial instruments</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Derivative financial instruments are initially recognized in the balance sheet at fair value and are remeasured to their current fair value at the end of each subsequent reporting period. The valuation of a forward exchange rate contract is based on the discounted cash flow model, using interest rate curves and forward rates at the reporting date as observable inputs.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Options are valued based on a modified Black-Scholes model using volatility and exercise prices as major observable inputs.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group enters into certain derivative financial instruments for the purpose of hedging to reduce the volatility in the Group&#8217;s performance due to the exposure to various business-related risks. The risk mitigation is obtained because the derivative&#8217;s value or cash flows are expected, wholly or partly, to offset changes in the value or cash flows of the recognized assets or liabilities. The overall strategy is aiming to mitigate the currency and interest rate risk of positions that are contractually agreed, and to partially mitigate the exposure risk of selected anticipated transactions.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain derivative financial instruments meet the criteria for hedge accounting treatment. A prerequisite for obtaining this accounting-hedge relationship is extensive documentation on inception and proving on a regular basis that the economic hedge is effective for accounting purposes. Other derivative financial instruments do not meet the criteria to qualify for hedge accounting or are not designated in a hedge relationship. Changes in the fair value of these derivative instruments are recognized immediately in &#8220;Other financial income and expense&#8221; in the consolidated income statement.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, the Group has designated certain long-term debt components as hedges of the translation risk arising on certain net investments in foreign operations. On consolidation, foreign currency differences arising on long-term debt designated as net investment hedges of a foreign operation are recognized in other comprehensive income and accumulated in currency translation effects, to the extent that the hedge is effective. The foreign currency differences arising from hedge ineffectiveness are recognized in the income statement in &#8220;Other financial income and expense.&#8221;</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">When a hedged net investment is disposed of, the proportionate portion of the cumulative amount recognized in equity in relation to the hedged net investment is transferred to the consolidated income statement as an adjustment to the gain or loss on disposal.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories', window );">Inventories</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Inventories</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inventory is valued at the lower of acquisition or production cost determined on a first-in, first-out basis and net realizable value. This value is used for the &#8220;Cost of goods sold&#8221; in the consolidated income statement. Unsaleable inventory is fully written off in the consolidated income statement under &#8220;Cost of goods sold.&#8221;</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory', window );">Trade receivables</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Trade receivables</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as rebates, chargebacks and cash discounts.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions for doubtful trade receivables are established using a forward-looking expected credit loss model (ECL), which includes possible default events on the trade receivables over the entire holding period of the trade receivable. These provisions represent the difference between the trade receivable&#8217;s carrying amount in the consolidated balance sheet and the estimated collectible amount. Charges for doubtful trade receivables are recorded as marketing and selling costs recognized in the consolidated income statement within &#8220;Selling, general and administration&#8221; expenses.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Legal and environmental liabilities</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Legal and environmental liabilities</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis and its subsidiaries are subject to contingencies arising in the ordinary course of business, such as patent litigation, environmental remediation liabilities and other product-related and commercial litigation, and governmental investigations and proceedings. A provision is recorded when there is a probable outflow of resources for which a reliable estimate can be made of the outcome of the legal or other disputes against the subsidiary.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory', window );">Contingent consideration</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Contingent consideration</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In the acquisition or divestment of a business, it is necessary to recognize contingent future amounts due to previous owners, representing contractually defined potential amounts as a liability or an asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at fair value, which is then remeasured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance, and are adjusted for the probability of their likelihood of payment, and are appropriately discounted to reflect the impact of time.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in &#8220;Cost of goods sold&#8221; for currently marketed products and in &#8220;Research and development&#8221; for IPR&amp;D. Changes in contingent consideration assets are recognized in &#8220;Other income&#8221; or &#8220;Other expense,&#8221; depending on their nature. </div>
                </div>

                <div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The effect of unwinding the discount over time is recognized for contingent consideration liabilities in &#8220;Interest expense&#8221; and for contingent consideration assets as interest income recognized in the consolidated income statement within &#8220;Other financial income and expense.&#8221;</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Defined benefit pension plans and other post retirement benefits</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Defined benefit pension plans and&#160;other&#160;post-employment benefits</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The liability in respect of defined benefit pension plans and other post-employment benefits is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions in which employees are employed, while the net interest on the net defined benefit liability or asset is recognized as &#8220;Other expense&#8221; or &#8220;Other income.&#8221;</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory', window );">Treasury Shares</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Treasury shares</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Treasury shares are initially recorded at fair value on their trade date, which is different from the settlement date, when the transaction is ultimately effected. Treasury shares are deducted from consolidated equity at their nominal value of CHF&#160;0.50 per share. Differences between the nominal amount and the transaction price on purchases or sales of treasury shares with third parties, or the value of services received for the shares allocated to employees as part of share-based compensation arrangements, are recorded in &#8220;Retained earnings&#8221; in the consolidated statement of changes in equity.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue recognition</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Revenue recognition</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Revenue on the sale of Novartis Group products and services, which is recorded as &#8220;Net sales to third parties&#8221; in the consolidated income statement, is recognized when a contractual promise to a customer (performance obligation) has been fulfilled by transferring control over the promised goods and services to the customer, substantially all of which is at the point in time of shipment to or receipt of the products by the customer or when the services are performed. If contracts contain customer acceptance provisions, revenue is recognized upon the satisfaction of the acceptance criteria. If a contract contains more than one performance obligation, the consideration is allocated based on the standalone selling price of each performance obligation. The amount of revenue recognized is based on the consideration Novartis expects to receive in exchange for its goods and services, when it is highly probable that a significant reversal will not occur.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consideration Novartis receives in exchange for its goods or services may be fixed or variable. Variable consideration is recognized when it is highly probable that a significant reversal will not occur. The most common elements of variable consideration are listed below.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Rebates and discounts granted to wholesalers, retailers, government agencies (including US Medicaid and US Federal Medicare programs), government supported healthcare systems, private health systems, pharmacy benefit managers, managed healthcare organizations, purchasing organizations and other direct and indirect customers, as well as chargebacks are provisioned and recorded as revenue deductions at the time the related revenues are recorded, or when the incentives are offered. These rebates and discounts, applied using provision rates, are estimated based on the terms and conditions in the individual states, plans and customer agreements, historical experience, product sales and growth rate, population growth, product pricing including inflation impacts, the mix of contracts and products, the level of inventory in the distribution channel, regulations, contracts, channels and payers, as appropriate to the individual rebate and discount arrangements.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Refunds granted to healthcare providers under innovative pay-for-performance agreements (i.e. outcome based arrangements) are provisioned and recorded as a revenue deduction at the time the related sales are recorded. They are calculated on the basis of historical experience and clinical data available for the product, as well as specific terms of the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until the uncertainty is resolved, until such history is available or the period when the refund right has expired. The provisions for revenue deductions under the innovative pay-for-performance agreements are adjusted periodically based on established processes and actual experience, including the products actual outcomes achieved compared with the anticipated predefined targets.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Cash discounts are offered to customers to encourage prompt payment and are provisioned and recorded as revenue deductions at the time the related sales are recorded.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Shelf stock adjustments are generally granted to customers, primarily of the Sandoz Division, to cover the inventory held by them at the time a price decline becomes effective. Revenue deduction provisions for shelf stock adjustments are recorded when the price decline is anticipated, based on the impact of the price decline on the customer&#8217;s estimated inventory levels. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#8226;  Sales returns provisions are recognized and recorded as revenue deductions when there is historical experience of Novartis agreeing to customer returns and Novartis can reasonably estimate expected future returns. In doing so, the estimated rate of return is applied, determined on the basis of historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a resale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Net sales to third parties and provisions for revenue deductions are adjusted periodically to reflect experience and to reflect actual amounts as rebates, refunds, </div>
                </div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">discounts and returns are processed. There is often a time lag between recording of revenue deductions and the final accounting for them. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these revenue deductions.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">&#8220;Other revenue&#8221; includes income from profit-sharing arrangements with our collaboration partners, and royalty and milestone income from the out-licensing of intellectual property when Novartis retains an interest in the intellectual property through a license. Royalty income earned from a license is recognized when the underlying sales have occurred. Milestone income is recognized at the point in time when it is highly probable that the relevant milestone event criteria are met, and the risk of reversal of revenue recognition is remote. &#8220;Other revenue&#8221; also includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties, and is recognized when control transfers to the third party and our performance obligations are satisfied. </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Research and development</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Internal research and development (R&amp;D) costs are fully charged to &#8220;Research and development&#8221; in the consolidated income statement in the period in which they are incurred. The Group considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland or Japan.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&amp;D, that are deemed not to transfer intellectual property to Novartis are expensed as internal R&amp;D expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been received from a regulatory authority in a major market.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are capitalized, as are payments for other assets, such as technologies to be used in R&amp;D activities. If additional payments are made to the originator company to continue performing R&amp;D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&amp;D services not resulting in an additional transfer of intellectual property rights to Novartis. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Novartis of additional intellectual property developed at the risk of the originator company. Subsequent internal R&amp;D costs in relation to IPR&amp;D and other assets are expensed, since the technical feasibility of the internal R&amp;D activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval in a major market are capitalized and recognized as currently marketed products.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Inventory produced ahead of regulatory approval is fully provisioned, and the charge is included in &#8220;Other expense&#8221; in the consolidated income statement, as its ultimate use cannot be assured. If this inventory can subsequently be sold, the provision is released to &#8220;Other income&#8221; in the consolidated income statement, either on approval by the appropriate regulatory authority or, exceptionally in Europe, on recommendation by the Committee for Medicinal Products for Human Use (CHMP), if approval is virtually certain.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share based compensation</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Share-based compensation</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Vested Novartis shares and American Depositary Receipts (ADRs) that are granted as compensation are valued at their market value on the grant date and are immediately expensed in the consolidated income statement.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair values of unvested restricted shares (RSs), restricted share units (RSUs) and performance share units (PSUs) in Novartis shares and ADRs granted to employees as compensation are recognized as an expense over the related vesting period. The expense recorded in the consolidated income statement is included in the personnel expenses of the various functions in which the employees are employed.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Unvested restricted shares, restricted ADRs and RSUs are only conditional on the provision of services by the plan participant during the vesting period. They are valued at fair value on the grant date. As RSUs do not entitle the holder to dividends, the fair value is based on the Novartis share price at the grant date adjusted for the net present value of the dividends expected to be paid during the holding period. The fair value of these grants, after making adjustments for assumptions related to forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">PSUs are subject to the achievement of certain performance criteria during the vesting period and require plan participants to provide services during this period. The following paragraphs provide an overview of the accounting policies for the share-based compensation plan that grant PSUs. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs that are subject to performance criteria based on Novartis internal performance metrics and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on assumptions concerning the expected performance against the internal performance metrics throughout the vesting period. The assumptions are based on the Group&#8217;s targets for those performance metrics, and the expected forfeitures due to plan participants not meeting their service conditions. The </div>
                </div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">assumptions are periodically adjusted over the vesting period. Any change in estimates for past services is recorded immediately as an expense or income in the consolidated income statement, and amounts for the remaining vesting period are expensed on a straight-line basis. As a result, at the end of the vesting period, the charge during the entire vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs that are subject to performance criteria based on variables that can be observed in the market, which for Novartis plans is the Novartis total shareholder return (TSR) relative to a specific peer group of companies over the vesting period, and that are conditional on the provision of services by the plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on the total fair value of the grant over the vesting period. IFRS requires that these variables that can be observed in the market are taken into account in determining the fair value of the PSUs at the grant date. Novartis determined the fair value of these PSUs at the date of grant using a Monte Carlo simulation model. Adjustments to the number of equity instruments granted are only made if a plan participant does not fulfill the service conditions.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For PSUs granted under plans that are subject to both performance criteria based on Novartis internal performance metrics and Novartis TSR relative to a specific  peer group of companies over the vesting period and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on a bifurcation into the components based on the performance criteria related to Novartis internal performance metrics and TSR, as described in the paragraphs above.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Measuring the fair values of PSUs granted that include TSR performance criteria requires use of estimates. The Monte Carlo simulation used to determine the fair value of the PSUs TSR performance criteria requires the probability of factors related to uncertain future events; the term of the award; the grant price of underlying shares or ADRs; expected volatilities; the expected correlation matrix of the underlying equity instruments with those of the peer group of companies; and the risk-free interest rate as input parameters.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If a plan participant leaves Novartis for reasons other than retirement, disability or death, then unvested restricted shares, restricted ADRs, RSUs and PSUs are forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Novartis Board of Directors, for example, in connection with a reorganization or divestment.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants', window );">Government grants</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Government grants</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Grants from governments or similar organizations are recognized at their fair value when there is reasonable assurance that the grant will be received and the Group will comply with all attached conditions.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Government grants received to compensate costs are deferred and recognized in the consolidated income statement over the period necessary to match them against the related costs that they are intended to compensate.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The accounting policy for property, plant and equipment describes the treatment of any related grants.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory', window );">Restructuring charges</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Restructuring charges</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Restructuring provisions are recognized for the direct expenditure arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made.</div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Charges to increase restructuring provisions are included in &#8220;Other expense&#8221; in the consolidated income statements. </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock', window );">Healthcare contributions</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Healthcare contributions</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Healthcare cost contribution levies and fees under governmental programs that require the Group to contribute to a country&#8217;s healthcare costs, other than programs described in &#8220;Revenue recognition&#8221; in this Note 1, are recognized in &#8220;Other expense&#8221; in the consolidated income statement. Provisions for healthcare cost contributions are adjusted to the actual amounts levied. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these healthcare cost contributions. </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Taxes</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Income taxes</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Income taxes comprise current income taxes and deferred income taxes and are recognized in the same periods as the revenues and expenses to which they relate. Income taxes include interest and penalties incurred during the period, insofar as they are considered an income tax. Income taxes related to items recognized directly to other comprehensive income or to equity are recognized together with the corresponding item, to which the income tax is attributable, directly in other comprehensive income or in equity.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Deferred income taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax base of an asset or liability and its carrying value for financial reporting purposes, except for those temporary differences related to investments in subsidiaries and associated companies, where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary&#8217;s retained earnings are only recognized when a dividend is declared or has been planned. Furthermore, deferred income taxes are recognized for the net tax effects of net operating loss carryforwards and tax credits. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The carrying amount of deferred tax assets is reduced to the extent that it is not probable that sufficient taxable profits will be available to enable all or part of the asset to be recovered. In evaluating our ability to recover our deferred tax assets in the jurisdiction from </div>
                </div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations.</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimated amounts for current and deferred tax assets or liabilities, including amounts related to any uncertain tax positions, are based on applicable tax law and regulations in the various tax jurisdictions, in which the Group operates, which are subject to interpretations based on currently known facts and circumstances.  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Tax returns are based on an interpretation of tax laws and regulations, and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made requiring payments of additional tax, interest or penalties. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The calculation of income tax assets and liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions across our global operations. As a result, inherent uncertainties exist in the estimates of the tax positions. Tax liabilities for uncertain tax provisions are recognized on the consolidated balance sheets within current income tax liabilities.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations', window );">Impact of adopting significant new IFRS standards</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of new IFRS standards, amendments and interpretations in 2022</span>
                  </div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">There were no new IFRS standards adopted by the Group in 2022. In addition, new IFRS amendments or interpretations that became effective in 2022 did not have a material impact to the Group&#8217;s consolidated financial statements. </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Based on the Group&#8217;s assessment, there are no IFRS standards, amendments or interpretations not yet effective in 2022 that would be expected to have a material impact on the Group&#8217;s consolidated financial statements.</div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of adopting significant new IFRS standard in 2021</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following new IFRS standard has been adopted by Novartis from January 1, 2021:</div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Interest Rate Benchmark Reform &#8211; Phase 2, Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 (Interest Benchmark Reform Amendments)</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Interest Benchmark Reform Amendments became effective from January 1, 2021. These amendments address issues that might affect financial reporting when an existing interest rate benchmark (i.e. Interbank offered rate &#8211; IBOR) is replaced with an alternative benchmark interest rate. The effects of interest rate benchmark reform on the Group&#8217;s financial instruments and risk management strategies did not have a material impact on the Group&#8217;s consolidated financial statements.</div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Impact of adopting significant new IFRS standard in 2020</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following new IFRS standard has been adopted by Novartis from January 1, 2020:</div>
                  <div>
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">IFRS 3 Business Combinations amendments</span>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The IASB issued amendments to IFRS 3 Business Combinations that revised the definition of a business, which assist entities with the evaluation of when an asset or group of assets acquired should be considered a business. This amended standard has been applied to transactions entered into on or after January 1, 2020. The amended standard allows an entity to apply an optional concentration test, on a transaction-by-transaction basis, to evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this optional concentration test is met, the set of activities and assets is determined not to be a business. The adoption of this amended standard on January 1, 2020, did not have a significant impact on our consolidated financial statements and is not expected to have a significant impact in future periods. However, this will depend on the facts and circumstances of future transactions and if the Group decides to apply the optional concentration test in the assessment of whether an acquired set of activities and assets is or is not a business.</div>
                </div>

                <div/>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for business combinations. [Refer: Business combinations [member]]
Effective 2023-01-01: The description of the entity's material accounting policy information for business combinations. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for contingent liabilities and contingent assets. [Refer: Contingent liabilities [member]; Description of nature of contingent assets]
Effective 2023-01-01: The description of the entity's material accounting policy information for contingent liabilities and contingent assets. [Refer: Contingent liabilities [member]; Description of nature of contingent assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for decommissioning, restoration and rehabilitation provisions. [Refer: Provision for decommissioning, restoration and rehabilitation costs]
Effective 2023-01-01: The description of the entity's material accounting policy information for decommissioning, restoration and rehabilitation provisions. [Refer: Provision for decommissioning, restoration and rehabilitation costs]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.
Effective 2023-01-01: The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for financial assets. [Refer: Financial assets]
Effective 2023-01-01: The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for foreign currency translation.
Effective 2023-01-01: The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for goodwill. [Refer: Goodwill]
Effective 2023-01-01: The description of the entity's material accounting policy information for goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2022-03-24<br> -Paragraph 39<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for income tax.
Effective 2023-01-01: The description of the entity's material accounting policy information for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.
Effective 2023-01-01: The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for non-current assets or disposal groups classified as held for sale. [Refer: Non-current assets or disposal groups classified as held for sale]
Effective 2023-01-01: The description of the entity's material accounting policy information for non-current assets or disposal groups classified as held for sale. [Refer: Non-current assets or disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]
Effective 2023-01-01: The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for provisions. [Refer: Provisions]
Effective 2023-01-01: The description of the entity's material accounting policy information for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]
Effective 2023-01-01: The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]
Effective 2023-01-01: The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]
Effective 2023-01-01: The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for subsidiaries. [Refer: Subsidiaries [member]]
Effective 2023-01-01: The description of the entity's material accounting policy information for subsidiaries. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for trade and other receivables. [Refer: Trade and other receivables]
Effective 2023-01-01: The description of the entity's material accounting policy information for trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for treasury shares. [Refer: Treasury shares]
Effective 2023-01-01: The description of the entity's material accounting policy information for treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 30<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_30_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859475872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock', window );">Respective Useful Lives of property, plant and equipment</a></td>
<td class="text">
                      <div>
                        <div style="padding-top:10px; padding-bottom:30px;">
                          <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                            <tr valign="bottom">
                              <td style=";height:12;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                              </td>
                              <td/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Useful life</div>
                              </td>
                              <td/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 2px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                              <td align="right" style=";width:20%;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20 to 40 years</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and other equipment</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Machinery and equipment</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7 to 20 years</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Furniture and vehicles</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 10 years</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Computer hardware</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                          </table>
                        </div>
                      </div>
                    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock', window );">Respective Useful Lives of Available-for-Use Intangible Assets</a></td>
<td class="text">
                      <div>
                        <div style="padding-top:10px; padding-bottom:30px;">
                          <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                            <tr valign="bottom">
                              <td style=";height:12;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                              </td>
                              <td/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                                  <br/>
                                  <br/> Useful life</div>
                              </td>
                              <td/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement line<br/> for amortization and<br/> impairment charges</div>
                              </td>
                              <td/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 20 years</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div>
                              </td>
                              <td align="right" style=";width:1%;"/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Technologies</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10 to 20 years    </div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"   or "Research   and development"</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                            <tr valign="bottom">
                              <td style=";height:16;">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other (including software)</div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 12 years  </div>
                              </td>
                              <td align="right"/>
                              <td align="right">
                                <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> In the relevant   functional expense</div>
                              </td>
                              <td align="right"/>
                            </tr>
                            <tr>
                              <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                            </tr>
                          </table>
                        </div>
                      </div>
                    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864551776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">Segmentation - Consolidated income statements</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#8211; consolidated income statements</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Sandoz  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Corporate  (including eliminations)<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Group  </div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            41 296
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            41 995
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 249
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 631
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            50 545
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to other segments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            825
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            795
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            180
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 030</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            42 121
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            42 790
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 454
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 811
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 030</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            50 545
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 179
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            61
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 283
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-11 569</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-11 751</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4 978</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 147</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 061
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 031
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-15 486</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 867</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 801
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            32 218
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 504
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 725
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            67
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            36 342
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            37 010
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-11 679</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-12 306</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 062</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 062</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-512</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-518</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-14 253</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14 886</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9 172</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8 641</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-824</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-899</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9 996</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9 540</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            531
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 149
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            103
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            233
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            171
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            470
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            805
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 852
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 695</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 732</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-273</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-733</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-618</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 701</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 747</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 786
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10 688
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 448
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 600
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 037</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-599</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 689
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Loss)/income from associated companies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 332
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 339
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-837</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-811</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-80</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 371
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 137
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 416</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 119</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 955
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            24 018
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Shareholders of Novartis AG</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            6 955
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            24 021
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Non-controlling interests</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net income are:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Interest income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            379
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            71
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Depreciation of property, plant and equipment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-837</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-859</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-204</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-210</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-122</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-139</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 163</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 208</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Depreciation of right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-252</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-265</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-33</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-39</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-15</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-300</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-318</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Amortization of intangible assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 728</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 638</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-222</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-238</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-32</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 982</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 903</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges on property, plant and equipment, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-407</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-271</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-407</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-281</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment of right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges on intangible assets, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 299</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-367</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-25</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 326</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-403</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges and fair value changes on financial assets, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-134</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-126</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-260</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to restructuring provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 069</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-240</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-40</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-259</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-26</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 368</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-328</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Equity-based compensation of Novartis equity plans</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-706</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-721</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-280</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-193</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 048</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-979</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate  (including eliminations)<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group  </div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            41 995
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            39 013
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 631
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 646
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            48 659
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to other segments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            795
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            792
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            180
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            189
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-981</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            42 790
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            39 805
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 811
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 835
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-981</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            48 659
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 179
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            61
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 239
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-11 751</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-10 927</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 147</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 252</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 031
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 058
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 867</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 121</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            32 218
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 896
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 725
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 636
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            67
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            245
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            37 010
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            34 777
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Selling, general and administration</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-12 306</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-11 657</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 062</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 076</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-518</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-464</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14 886</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14 197</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research and development</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8 641</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8 118</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-899</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-862</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9 540</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8 980</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 149
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            922
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            233
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            176
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            470
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            644
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 852
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 742
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 732</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 871</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-831</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-618</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-488</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 747</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 190</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10 688
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 172
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 600
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 043
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-599</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-63</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 689
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10 152
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 332
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            670
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 339
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-811</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-869</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-80</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-78</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 878
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 119</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 807</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            24 018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 071
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Shareholders of Novartis AG</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            24 021
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            8 072
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Non-controlling interests</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net income are:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Interest income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            71
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            91
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Depreciation of property, plant and equipment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-859</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-912</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-210</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-282</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-139</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-124</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 208</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 318</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Depreciation of right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-265</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-273</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-39</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-41</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-318</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-330</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Amortization of intangible assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 638</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 080</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-238</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-370</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 903</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 462</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges on property, plant and equipment, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-271</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-324</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-116</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-281</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-440</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges on intangible assets, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-367</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-768</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-141</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-403</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-914</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Impairment charges and fair value changes on financial assets, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            153
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            182
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            335
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to restructuring provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-240</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-217</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-98</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-26</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-39</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-328</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-354</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Equity-based compensation of Novartis equity plans</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-721</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-714</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-64</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-193</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-180</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-979</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-958</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock', window );">Segmentation - Consolidated balance sheets</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#8211; consolidated balance sheets</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate  (including eliminations)<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group  </div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total assets</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            75 510
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            79 220
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            16 078
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            16 192
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            25 865
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            36 383
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            117 453
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            131 795
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-16 966</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-15 929</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 710</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 632</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-37 354</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-44 412</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-58 030</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-63 973</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            59 423
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            67 822
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net debt<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 245
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            868
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 245
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            868
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net operating assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            58 544
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            63 291
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            12 368
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12 560
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 244</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-7 161</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            66 668
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            68 690
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in assets and liabilities are:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Total property, plant and equipment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 488
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 861
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 901
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            415
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            476
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 764
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11 545
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to property, plant and equipment<sup style="white-space: nowrap"> &#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            842
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            991
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            292
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            349
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            85
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            90
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 219
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 430
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Total right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 233
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 349
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            90
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            104
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            108
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            108
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 431
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to right-of-use assets<sup style="white-space: nowrap">&#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            196
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            222
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            31
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            26
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            247
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            321
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Total goodwill and intangible assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            51 357
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            53 919
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9 230
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 603
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            358
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            255
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            60 945
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            63 777
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to goodwill and intangible assets<sup style="white-space: nowrap"> &#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 791
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 491
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            163
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            102
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            139
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            143
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 093
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 736
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Total investment in associated companies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            107
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            170
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            27
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            143
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            205
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Additions to investment in associated companies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18 930
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28 329
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18 930
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28 329
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Financial debts and derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            26 175
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            29 197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            26 175
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            29 197
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Current income tax liabilities and deferred tax liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 219
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 219
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 485
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Eliminations mainly relate to the elimination of intercompany receivables and payables to other segments and inventories</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Note 29 provides additional disclosures related to net debt</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup> Excluding the impact of business acquisitions</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock', window );">Net sales and total of selected non-current assets, by countries and regions</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net sales to third parties<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total of selected non-current assets<sup>2</sup></div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Country</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            970
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            800
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23 708
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            32
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25 770
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            33
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United States</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            17 653
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16 818
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            33
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16 484
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35 353
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            48
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37 054
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            48
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">France</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 257
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 522
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 442
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 188
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 615
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Germany</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 278
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 870
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 518
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 229
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 378
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">China</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 128
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 052
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 573
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            599
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            703
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japan</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 683
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 804
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            165
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            217
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20 054
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            41
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20 808
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            40
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19 038
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 351
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            50 545
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            48 659
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            73 483
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            77 088
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Region</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18 467
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20 197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18 715
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35 896
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37 525
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Americas</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21 536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            42
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20 463
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            40
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19 725
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            41
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35 806
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37 522
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 966
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 219
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 781
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 041
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            50 545
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            48 659
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            73 483
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            77 088
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Net sales to third parties by location of customer</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Total of property, plant and equipment; right-of-use assets; goodwill; intangible assets; investment in associated companies and other non-current assets excluding post-employment benefit assets</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock', window );">Net sales by region</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#8211; net sales to third parties</span>
                  </div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties by region<sup>1</sup></span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> 2022<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2021<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br/> (2021<br/> to 2022)<br/> USD %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2020<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br/> (2020<br/> to 2021)<br/> USD %</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13 554
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 919
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13 484
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15 899
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 999
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 342
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 929
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 304
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 718
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 914
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 773
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 469
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            41 296
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            41 995
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            39 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Established Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30 548
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            31 459
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            29 643
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Emerging Growth Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 748
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 370
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 913
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 278
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 231
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 754
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 819
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 142
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 613
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 662
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 501
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            969
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            872
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            772
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 631
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 646
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Established Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 460
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 855
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 089
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Emerging Growth Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 789
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 776
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 557
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18 467
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20 197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18 715
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            17 653
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16 818
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16 484
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 966
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 219
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canada and Latin America</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 883
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 645
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            50 545
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            51 626
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            48 659
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Established Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37 008
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            38 314
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            36 732
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Of which in Emerging Growth Markets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13 537
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13 312
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11 927
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Net sales to third parties by location of customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

                <div/>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock', window );">Other revenue</a></td>
<td class="text">
                <div>
                  <div style=" padding-bottom: 10px;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;">Segmentation &#8211; other revenue</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate   (including eliminations)</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group  </div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Profit-sharing income</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            921
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            835
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            921
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            835
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Royalty income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            74
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            107
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            52
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            109
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            300
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Milestone income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            127
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            148
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            155
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            50
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            155
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            162
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            114
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            54
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other revenues</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 179
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            61
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 283
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 239
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="26" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="26" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="26">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsNetSalesTableTextBlock', window );">Net sales</a></td>
<td class="text">
                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Innovative Medicines Division net sales to third parties by core therapeutic area; other promoted brands; and established brands</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> 2022<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2021<br/> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br/> (2021 to<br/> 2022)<br/> USD %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2020<br/> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br/> (2020 to<br/> 2021)<br/> USD %</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cardiovascular</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 644
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 548
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            31
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 497
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            42
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Leqvio</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            112
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Cardiovascular</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 756
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 560
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 497
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Immunology</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 788
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 718
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 995
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 365
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 428
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 133
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 059
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Immunology</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            7 287
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            7 205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 119
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Neuroscience</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 787
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 003
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 370
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 351
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            920
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            47
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            372
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Mayzent</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            357
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            281
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            27
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            170
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            65
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Aimovig</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            218
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            215
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            164
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            31
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Neuroscience</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 051
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 007
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 272
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Solid Tumors</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 770
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 693
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 231
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            937
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            31
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            687
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            36
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            474
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            577
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-18</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            635
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lutathera</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            471
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            475
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            445
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Piqray</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            373
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            329
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            320
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Pluvicto</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            271
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tabrecta</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            133
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            90
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            48
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            35
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            157
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Solid Tumors</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 723
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 101
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 666
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Hematology</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 088
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 016
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 738
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 923
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 060
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 958
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 339
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            587
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            474
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Adakveo</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            164
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Scemblix</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            149
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-67</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Hematology</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 452
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 430
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 617
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            14
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> 2022<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2021<br/> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br/> (2021 to<br/> 2022)<br/> USD %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2020<br/> USD m<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br/> (2020 to<br/> 2021)<br/> USD %</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Other Promoted Brands</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 874
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 160
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 933
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xiidra</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            487
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            468
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            376
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Ultibro</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            479
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            584
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-18</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            623
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Beovu</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            203
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            186
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            190
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other respiratory</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            84
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            58
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            26
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            104
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Other Promoted  Brands</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 127
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 451
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 148
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Promoted  Brands</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 396
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 754
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 319
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 238
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 413
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 439
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            859
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-21</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 199
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            745
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 024
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 188
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            743
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            901
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-18</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            980
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            652
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            773
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 003
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-23</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            512
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            938
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-45</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 083
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <i>Voltaren/Cataflam</i>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            334
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            373
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            360
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            329
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            431
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-24</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            452
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            323
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            563
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            653
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Neoral/Sandimmun(e)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            310
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            368
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            393
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contract manufacturing</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            214
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            108
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            98
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 641
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 257
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 944
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Established  Brands</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 900
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12 241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            13 694
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-11</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            41 296
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            41 995
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            39 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Reclassified to reflect the new Innovative Medicines divisional structures announced on April 4, 2022</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock', window );">Net sales of Top 20 products</a></td>
<td class="text">
                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties of the top 20 Innovative Medicines Division brands in 2022</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>Brands</div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by<br/> therapeutic area, other<br/> promoted brands or<br/> established brands</div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Key indications</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> US<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Rest of <br/> world<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> Total<br/> USD m</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO),   ankylosing spondylitis  (AS), psoriatic arthritis   (PsA), non-radiographic   axial spondyloarthritis   (nr-axSPA)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 770
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 018
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 788
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure,  hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 354
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 290
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 644
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune   thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 083
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 005
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 088
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis  (RMS)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 153
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            860
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 013
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia  (CML)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            877
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 046
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 923
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related   macular degeneration (AMD),   diabetic macular edema (DME),  retinal vein occlusion (RVO)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 874
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 874
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic   adjuvant melanoma,  advanced non-small cell   lung cancer (NSCLC),   tumor agnostic with   BRAF mutation indication</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            678
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 770
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology      </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycytomia vera (PV),   graft-versus-host disease  (GvHD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy  (SMA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            434
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            936
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 370
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA),   chronic spontaneous urticaria   (CSU), nasal polyps</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 365
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 365
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors,  acromegaly</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            800
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            438
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 238
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2-   metastatic breast cancer</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            472
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            759
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 231
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,  TRAPS, HIDS/MKD, FMF,  SJIA, AOSD, gout)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            570
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            563
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 133
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kesimpta</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing-remitting   multiple sclerosis (RRMS)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            921
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            171
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            859
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            859
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands      </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid  leukemia (CML),   gastrointestinal stromal  tumors (GIST)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            540
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            745
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            14
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            729
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            743
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            55
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            597
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            652
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology        </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> r/r pediatric and young   adults acute lymphoblastic   leukemia (ALL), diffuse large   B-cell lymphoma (DLBCL),   follicular lymphoma (FL)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            196
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            340
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            536
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/  tuberous sclerosis complex   (TSC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            171
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            512
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 brands total</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            12 753
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            19 384
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            32 137
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 146
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9 159
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            15 899
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            25 397
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            41 296
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="top">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties of the top 20 Innovative Medicines Division brands in 2021</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>Brands</div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by<br/> therapeutic area, other<br/> promoted brands or<br/> established brands<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Key indications</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> US<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Rest of <br/> world<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;">
                            <br/>
                            <br/> Total<br/> USD m</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology        </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO), ankylosing   spondylitis (AS),   psoriatic arthritis (PsA),  non-radiographic axial   spondyloarthritis (nr-axSPA)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 883
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 835
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 718
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 712
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 836
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 548
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis (RMS)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 427
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 360
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 787
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular   degeneration (AMD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 160
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 160
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia (CML)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            882
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 178
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 060
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            947
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 069
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 016
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors      </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic   adjuvant melanoma,  advanced non-small cell   lung cancer (NSCLC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            606
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 087
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 693
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycythemia vera (PV)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 595
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA),   chronic spontaneous urticaria   (CSU), nasal polyps</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 428
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 428
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors, acromegaly</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            843
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            570
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 413
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy (SMA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            469
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            882
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 351
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 092
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF,   SJIA, AOSD, gout)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            501
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            558
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 059
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia   (CML), gastrointestinal   stromal tumors (GIST)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            263
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            761
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 024
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/  tuberous sclerosis complex (TSC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            521
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            417
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            938
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2-   metastatic breast cancer</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            339
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            598
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            937
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            887
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            901
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            51
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            722
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            773
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kymriah</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology      </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> r/r pediatric and young   adults acute lymphoblastic   leukemia (ALL), diffuse large   B-cell lymphoma (DLBCL)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            230
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            357
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            587
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Ultibro</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cronic obstructive  pulmonary disease  (COPD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            584
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            584
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 688
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            20 976
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            32 664
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 311
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 331
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            14 999
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 996
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            41 995
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="top">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.</div>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Net sales to third parties of the top 20 Innovative Medicines Division brands in 2020</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>Brands</div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Brand classification by<br/> therapeutic area, other<br/> promoted brands or<br/> established brands<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Key indications</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> US<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Rest of <br/> world<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;">
                            <br/>
                            <br/> Total<br/> USD m</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology  </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:21%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Psoriasis (PsO), ankylosing   spondylitis (AS), psoriatic arthritis (PsA)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 516
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 479
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 995
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Relapsing multiple sclerosis (RMS)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 562
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 441
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 003
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cardiovascular</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic heart failure</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 277
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 220
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 497
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia (CML)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            859
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 099
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 958
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Other Promoted  Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Age-related macular   degeneration (AMD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 933
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 933
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immune   thrombocytopenia (ITP),   severe aplastic anemia (SAA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            833
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            905
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 738
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Tafinlar</i> + <i>Mekinist</i></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors      </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRAF V600+ metastatic  adjuvant melanoma,   advanced non-small cell   lung cancer (NSCLC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            569
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            973
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 542
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Carcinoid tumors,  acromegaly</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            837
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            602
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 439
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hematology  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Myelofibrosis (MF),   polycythemia vera (PV)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 339
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 339
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Severe allergic asthma (SAA),  chronic spontaneous urticaria   (CSU)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 251
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Galvus</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Type 2 diabetes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 199
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 199
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic myeloid leukemia (CML),  gastrointestinal stromal tumors (GIST)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            315
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 188
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Breast cancer/  tuberous sclerosis complex (TSC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            644
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            439
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 083
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Diovan</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            124
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            879
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 003
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <i>Exforge</i> Group</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Hypertension</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            964
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            980
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zolgensma</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Neuroscience  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Spinal muscular atrophy  (SMA)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            459
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            461
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            920
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Immunology    </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF,   SJIA, AOSD gout)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            473
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            873
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors  </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HR+/HER2-   metastatic breast cancer</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            318
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            369
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            687
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Established Brands</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Chronic iron overload</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            138
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            515
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            653
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Solid Tumors</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Renal cell carcinoma (RCC)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            259
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            376
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            635
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Top 20 products total</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 126
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            18 790
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 916
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rest of portfolio</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 216
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 881
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 097
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="top">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net  sales to third parties</div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            14 342
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            24 671
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            39 013
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="top">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.</div>
                        </td>
                      </tr>
                      <tr valign="top">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Net sales to third parties reflect <i>Xolair</i> sales for all indications.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfOperatingSegmentsNetSalesTableTextBlock', window );">Net sales</a></td>
<td class="text">
                <div>
                  <div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">
                    <span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;">Sandoz Division net sales to third parties by business franchise</span>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> 2022<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2021<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change<br/> (2021 to<br/> 2022)<br/> USD %</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2020<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change<br/> (2020 to<br/> 2021)<br/> USD %</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Retail Generics<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 776
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 092
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 244
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Biopharmaceuticals</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 093
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 116
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 928
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Anti-Infectives<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            380
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            423
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            474
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-11</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales to third parties</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9 249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 631
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 646
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Sandoz total anti-infectives net sales to third parties amounted to USD 1.2 billion (2021: USD 1.1 billion; 2020: USD 1.2 billion), of which USD 777 million (2021: USD 707 million; 2020: USD 694 million) is sold through the Retail Generics business franchise and USD 380 million (2021: USD 423 million; 2020: USD 474 million) is sold to other third-party companies through the Anti-Infectives business franchise.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOperatingSegmentsNetSalesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOperatingSegmentsNetSalesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864124688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associated companies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory', window );">Schedule disclosing information related to associates</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net income statement effect</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other comprehensive income effect<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total comprehensive income effect</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Roche Holding AG, Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 341
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            677
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            46
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-56</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 387
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            621
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 339
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            46
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-56</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 385
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            617
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="20" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="20">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> In 2021, Novartis share of other comprehensive income recognized by associated companies, net of taxes of USD 3 million was recycled into the consolidated income statement as a result of the divestment of the investment in Roche Holding AG. No Novartis share of other comprehensive income recognized by associated companies was recycled to the consolidated income statement in 2022 and 2020.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember', window );">Roche Holding AG, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock', window );">Schedule disclosing information related to associates, net income effect</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of Roche's  estimated current-year  consolidated net income</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            815
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            913
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prior-year adjustment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            40
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-64</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of fair value adjustments relating to intangible assets, net of taxes of 2021: USD 10 million; 2020: USD 26 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-70</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-172</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gain on divestment of the  investment in Roche<sup style="white-space: nowrap"> &#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 556
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income effect</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            677
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> The gain on divestment of the investment in Roche includes the recycling of currency translation effects (see Note 8.1) and other comprehensive income effects totaling USD 3.2 billion.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of associates. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B4<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B4_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859580736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest expense and other financial income and expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract', window );"><strong>Disclosure of Interest Expense and Other Financial Income and Expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InterestExpenseTableTextBlock', window );">Interest expense</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-669</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-651</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-708</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense on lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-60</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-67</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense arising from  discounting long-term liabilities and capitalized borrowing costs</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-108</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-98</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-94</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total interest expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-837</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-811</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-869</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherFinancialIncomeAndExpenseTableTextBlock', window );">Other financial income and expense</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            379
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            71
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            91
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-194</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-94</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-52</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency result, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-184</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-69</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-135</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other financial income  and expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-80</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-78</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InterestExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InterestExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherFinancialIncomeAndExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherFinancialIncomeAndExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571855196800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfIncomeTaxAbstract', window );"><strong>Disclosure of Income Tax [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncomeBeforeTaxesTableTextBlock', window );">Income before taxes</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 986
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22 028
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 786
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 385
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 109
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            92
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 371
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 878
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> The 2021 income before taxes in Switzerland includes a USD 14.6  billion non-taxable gain on the divestment of the Group&#8217;s investment in Roche Holding AG (see Note 2 and Note 4).</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrentAndDeferredIncomeTaxExpenseTableTextBlock', window );">Current and deferred income tax expense</a></td>
<td class="text">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The significant components of the provision for income taxes are as follows:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-617</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-958</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-932</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 454</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 470</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 168</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current income tax expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2 071</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 428</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 100</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-142</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-137</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            797
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            286
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            430
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Deferred tax income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            655
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            309
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            293
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income tax expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 416</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 119</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 807</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AnalysisOfTaxRateTableTextBlock', window );">Analysis of tax rate</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(As a percentage)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Applicable tax rate</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            16.8
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14.8
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of disallowed expenditures</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4.6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of utilization of previously unrecognized tax losses brought forward from prior periods</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of income taxed at reduced rates</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-0.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of income not subject to tax<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-0.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax credits and allowances</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3.8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of release of  contingent consideration liability</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-0.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax rate change  on current and deferred  tax assets and liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-0.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of derecognition and reversals of derecognition  of deferred tax assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of write-down and reversal of  write-down of investments in subsidiaries</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.8</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of prior-year items</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-0.4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of changes in uncertain tax positions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of other items</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Effective tax rate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            16.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            18.3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <b/>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> 2021 includes the effect of income not subject to tax (<span>-7.3</span>%) arising from the non-taxable gain on the divestment of our investment in Roche. See Notes 2 and 4 for further details.</span>
                            <b/>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AnalysisOfTaxRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AnalysisOfTaxRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrentAndDeferredIncomeTaxExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrentAndDeferredIncomeTaxExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfIncomeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfIncomeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncomeBeforeTaxesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncomeBeforeTaxesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859679712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Earnings per share</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income attributable to shareholders of Novartis AG (USD millions)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 955
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            24 021
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 072
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Number of shares (in millions)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Weighted average number of shares outstanding used in basic earnings per share</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 181
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 243
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 277
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average number of shares in diluted earnings per share</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 260
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 296
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share (USD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3.19
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10.71
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3.55
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Diluted earnings per share (USD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3.17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10.63
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3.52
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859537072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Changes in consolidated statements of comprehensive income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAbstract', window );"><strong>Comprehensive income [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfComprehensiveIncomeTableTextBlock', window );">Comprehensive income</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Fair value<br/> adjustments <br/> on financial<br/> instruments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Actuarial<br/> gains/(losses)<br/> from defined<br/> benefit plans</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Cumulative<br/> currency <br/> translation<br/> effects</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total value<br/> adjustments<br/> attributable to <br/> Novartis AG <br/> shareholders</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Non-<br/> controlling<br/> interest</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Total value<br/> adjustments</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2019</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            120
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-5 919</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 142
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-4 657</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-29</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-4 686</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, net of taxes of USD <span>-36</span> million<sup style="white-space: nowrap"> &#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            250
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            250
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            250
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-201</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-201</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-201</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes of USD <span>-3</span> million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            143
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects, net of taxes of USD 10 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   8.1</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 193
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 193
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 194
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2020</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            250
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 992
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 387
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 386
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities  sold, reclassified to retained earnings</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-150</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-150</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-150</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of change in ownership of consolidated entities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2020</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            220
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-5 773</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 134
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 419</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-29</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 448</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, net of taxes of USD <span>-44</span> million<sup style="white-space: nowrap"> &#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge, net of taxes of USD 33 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            216
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            216
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            216
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes of USD <span>-323</span> million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 808
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 808
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 809
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects, net of taxes of USD 17 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   8.1</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4 757</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4 757</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4 762</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            194
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 808
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-4 541</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 539</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 543</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities sold, reclassified to retained earnings net of taxes of USD 48 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-164</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-164</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-164</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            188
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 968</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-407</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 187</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-33</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 220</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities, net of taxes of USD 81 million<sup style="white-space: nowrap"> &#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-382</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-382</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-382</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge, net of taxes of USD <span>-30</span> million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            91
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            91
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            91
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit plans, net of taxes of USD <span>-104</span> million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-104</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-104</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-103</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects, net of taxes of USD 18 million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   8.1</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-444</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-444</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-450</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-382</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-104</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-353</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-839</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-844</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on equity securities sold, reclassified to retained earnings net of taxes of nil</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Value adjustments related to divestments, net of taxes of USD <span>-4</span> million</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-198</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 038</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-760</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 996</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-38</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-5 034</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Includes fair value adjustments on equity securities designated as financial assets valued at fair value through other comprehensive income with no subsequent recycling into the consolidated income statement</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

                <div/>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571863484064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PropertyPlantAndEquipmentTableTextBlock', window );">Property, plant and equipment [table text block]</a></td>
<td class="text">
                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of property, plant and equipment during 2022:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Land</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Buildings</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Construction <br/> in progress</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Machinery <br/> and other <br/> equipment</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            492
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 819
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 508
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13 328
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            27 147
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 744</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9 786</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-15 602</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 075
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 443
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            11 545
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 075
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 443
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            11 545
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            297
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-964</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            667
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            124
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            780
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            312
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 219
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-49</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-33</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-45</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-155</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-437</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-726</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 163</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-351</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-414</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-166</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-57</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-53</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-288</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            442
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 493
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 157
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 672
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            10 764
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            451
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 396
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 184
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 842
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24 873
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 903</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-8 170</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-14 109</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            442
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 493
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 157
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 672
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            10 764
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for purchases of property, plant and equipment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            549
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Capitalized borrowing costs</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of property, plant and equipment during 2021:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Land</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Buildings</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Construction <br/> in progress</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Machinery <br/> and other <br/> equipment</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            555
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12 377
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 248
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 038
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28 218
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 807</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-66</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-10 063</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 955</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 570
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 182
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 975
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12 263
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 570
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 182
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 975
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12 263
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-610</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            413
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            109
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 027
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            293
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 430
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-78</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-150</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-453</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-755</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 208</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-137</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-76</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-167</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-384</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            70
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            103
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-23</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-203</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-84</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-199</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-509</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 075
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 443
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 545
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            492
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11 819
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 508
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13 328
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            27 147
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 744</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-9 786</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 602</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 075
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 443
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 542
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            11 545
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for purchases of property, plant and equipment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Capitalized borrowing costs</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock', window );">Property, plant and equipment impairment charges and reversals [table text block]</a></td>
<td class="text">
                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the property, plant and equipment impairment charges and reversals by reporting segment:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment charges</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment reversals</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-411</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-315</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-326</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            44
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-121</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            59
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-414</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-384</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-447</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            103
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571863956848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-use assets and lease liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract', window );"><strong>Right of use assets Disclosure and Lease liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfRightofuseAssetsRollForwardTableTextBlock', window );">Disclosure of Right-of-use assets roll forward</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Right-of-use assets at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 676
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            247
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            321
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-300</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-318</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease contract terminations<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-34</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-66</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-52</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-52</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total right-of-use assets at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 431
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Impairment charges in 2022 were recorded in the Innovative Medicines segment.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Lease contract terminations also includes modifications to existing leases that result in reductions to the right-of-use assets, and reductions due to sub-leasing.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock', window );">Disclosure of right-of-use assets carrying value and depreciation charge</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> December 31,<br/> 2022<br/> carrying value</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Depreciation <br/> charge<br/> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31,<br/> 2021<br/> carrying value</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Depreciation <br/> charge<br/> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Land</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            505
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            16
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            522
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            745
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            866
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vehicles</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            117
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            96
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            136
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and equipment, and other assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            64
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 431
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            300
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            318
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock', window );">Disclosure of maturity analysis of lease liability</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Lease liabilities<br/> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Lease liabilities<br/> undiscounted<br/> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Lease liabilities<br/> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Lease liabilities<br/> undiscounted<br/> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less than one year</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            251
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            297
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            275
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            324
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between one and two years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            190
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            232
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            216
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            258
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between two and three years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            167
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            201
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            162
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            198
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between three and four years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            172
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            139
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            172
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between four and five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            122
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            154
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            122
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            154
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            922
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 149
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            982
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 243
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 789
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 896
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 349
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion of lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-251</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-297</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-275</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-324</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current portion of lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 538
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 908
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 621
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 025
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for leases not yet commenced</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            83
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            134
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock', window );">Additional disclosures related to right-of-use assets and lease liabilities</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense on lease liabilities<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            62
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            67
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense on short-term leases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense on low-value leases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total cash outflows for leases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            355
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            381
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            379
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Thereof:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Cash outflows for short-term leases and low-value leases<sup style="white-space: nowrap"> &#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Payments of interest<sup style="white-space: nowrap">&#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            51
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            52
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">&#160;&#160;&#160;Payments of lease liabilities<sup style="white-space: nowrap">&#160;4</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            295
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            316
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            312
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> The weighted average interest rate is 3.3% (2021: 3.2%, 2020: 3.4%).</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Cash flows from short-term and low-value leases are included within total net cash flows from operating activities. The portfolio of short-term leases to which the Group is committed to at December 31, 2022, 2021 and 2020, is similar to the portfolio of short-term leases the Group entered into during 2022, 2021 and 2020.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup> Included within total net cash flows from operating activities</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;4&#160;</sup> Reported as cash outflows in financing activities net of lease incentives received, if any.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfRightofuseAssetsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfRightofuseAssetsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862169904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and intangible assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract', window );"><strong>Disclosure of detailed information about intangible assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock', window );">Movements of goodwill and intangible assets</a></td>
<td class="text">
                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of goodwill and intangible assets in 2022:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill</div>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible assets other than goodwill</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> In-process<br/> research and<br/> development</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Technologies</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently<br/> marketed <br/> products</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other<br/> intangible<br/> assets</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            29 900
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 080
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            56 213
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 905
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            68 211
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-305</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 514</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-903</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-29 107</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 505</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-34 029</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            29 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 499
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            27 106
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            34 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            29 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 499
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            27 106
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            34 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            161
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 209
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 209
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 429</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 403
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            330
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 175
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            588
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 093
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-95</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-100</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-37</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 603</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-342</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 982</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-917</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-15</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-322</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-72</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 326</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-427</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-176</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-243</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-432</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            29 301
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 421
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            121
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            25 513
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 589
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 644
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            29 596
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 092
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 038
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            58 249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 305
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            69 684
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-295</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 671</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-917</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-32 736</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 716</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-38 040</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            29 301
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 421
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            121
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            25 513
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 589
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 644
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

                <div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of goodwill and intangible assets in 2021:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Goodwill</div>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Intangible assets other than goodwill</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> In-process<br/> research and<br/> development</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Technologies</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Currently<br/> marketed <br/> products</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other<br/> intangible<br/> assets</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            30 321
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 893
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 115
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            57 333
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 384
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            67 725
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-322</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 193</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-885</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-26 566</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 272</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30 916</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 999
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 700
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            230
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            30 767
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 112
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            36 809
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 999
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 700
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            230
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            30 767
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 112
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            36 809
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            238
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            262
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            292
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            98
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            652
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-20</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            958
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            270
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            508
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 736
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-36</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-37</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-41</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 607</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-255</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 903</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-350</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-17</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-35</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-403</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-642</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-51</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-584</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-672</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 499
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            27 106
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            34 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            29 900
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 013
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 080
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            56 213
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 905
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            68 211
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated amortization and impairment</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-305</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 514</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-903</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-29 107</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 505</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-34 029</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 499
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            27 106
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            34 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock', window );">Allocation of net book values of goodwill and intangible assets by reporting segment</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible assets other than goodwill</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> In-process<br/> research and<br/> development</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Technologies</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently<br/> marketed <br/> products</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other<br/> intangible<br/> assets</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21 531
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 186
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            14
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24 487
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 139
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            29 826
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 770
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            235
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            107
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 026
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            92
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 460
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            358
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            358
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            29 301
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 421
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            121
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            25 513
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 589
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 644
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> The Innovative Medicines and Sandoz Divisions&#8217; represent the grouping of cash-generating units, to which goodwill is allocated.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2021:</div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="1" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Goodwill<sup>1</sup></div>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Intangible assets other than goodwill</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="1" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> In-process<br/> research and<br/> development</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Technologies</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Currently<br/> marketed <br/> products</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other<br/> intangible<br/> assets</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21 562
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 313
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25 938
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 091
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            32 357
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 026
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            186
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            162
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            61
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 577
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            248
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            248
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            29 595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 499
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            27 106
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            34 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> The Innovative Medicines and Sandoz Divisions&#8217; and Corporate represent the grouping of cash-generating units, to which goodwill is allocated.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AssumptionsUsedInTheCalculationOfValuationTextBlock', window );">Assumptions used in the calculation of valuation</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(As a percentage)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative <br/> Medicines</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Sandoz</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Terminal growth rate</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.5
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discount rate (post-tax)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IntangibleAssetImpairmentChargesTextBlock', window );">Intangible asset impairment charges and reversals</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment charges</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Impairment reversals</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 299</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-367</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-768</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-25</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-141</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 326</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-403</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-914</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> 2022 includes an impairment of USD 0.6 billion related to the write-down of IPR&amp;D related to cessation of clinical development program UNR844.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <span> 2021 includes an impairment of USD 0.2 billion related to the write-down of IPR&amp;D related to cessation of clinical development program GTX312.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="14">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <span> 2020 includes an impairment of USD 0.5 billion related to the write-down of IPR&amp;D related to cessation of clinical development program ZPL389 for atopic dermatitis and USD 0.2 billion related to a partial write-down of the <i>Votrient</i> currently marketed product (<i>Votrient</i> carrying value was USD 0.9 billion in 2022 and USD 1.3 billion in 2021).</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AssumptionsUsedInTheCalculationOfValuationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AssumptionsUsedInTheCalculationOfValuationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IntangibleAssetImpairmentChargesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IntangibleAssetImpairmentChargesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862143440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred tax assets and liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Disclosure of Deferred Tax Assets and Liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Property, <br/> plant and<br/> equipment</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Intangible<br/> assets</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pensions and<br/> other benefit <br/> obligations <br/> of employees</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Inventories</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Tax loss<br/> carry-<br/> forwards</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Other assets,<br/> provisions<br/> and accruals</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax assets at January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            125
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 307
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 026
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 273
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            374
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 727
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            7 832
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax liabilities at January 1, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-381</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-4 704</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-591</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-148</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 335</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-7 159</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at January 1, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-256</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            435
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 125
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            374
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 392
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-256</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            435
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 125
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            374
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 392
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            69
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            628
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            655
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to equity</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to other comprehensive income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-104</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            63
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-300</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            55
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-244</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-185</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 059</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            319
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 076
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            425
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 477
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 053
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax assets at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            158
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 726
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            739
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 214
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            425
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 789
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 051
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax liabilities at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-343</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4 785</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-420</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-138</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 312</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6 998</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-185</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 059</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            319
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 076
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            425
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 477
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 053
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After offsetting the following amount of deferred tax  assets and liabilities within the same tax jurisdiction,  the balance amounts to:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 312
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 739
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 686</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 053
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax assets at January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            189
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 351
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 502
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            507
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 658
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 344
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax liabilities at January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-430</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-5 269</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-340</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-159</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 344</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-7 552</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-241</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 918</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            797
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 343
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            497
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 314
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            792
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-241</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 918</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            797
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 343
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            497
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 314
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            792
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            567
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-22</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-215</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-121</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            127
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            309
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to equity</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-35</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-35</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to other comprehensive income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-323</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-317</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-58</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-46</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-17</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-20</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-256</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            435
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 125
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            374
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 392
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax assets at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            125
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 307
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 026
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 273
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            374
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 727
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 832
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax liabilities at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-381</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4 704</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-591</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-148</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 335</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7 159</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-256</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 397</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            435
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 125
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            374
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 392
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After offsetting the following amount of deferred tax  assets and liabilities within the same tax jurisdiction,  the balance amounts to:</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 089
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 743
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 070</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            673
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <b/>
                            <b/>
                            <b/>
                            <b/>
                            <b/>
                            <b/>
                            <b/>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <b/>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

                <div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Deferred tax liabilities have not been recognized for the withholding tax and other taxes that would be payable on the remittance of earnings of foreign subsidiaries, insofar as the Group has the ability to control any future reversal and the unremitted earnings are retained in the foreign subsidiaries for reinvestment. The total unremitted earnings retained for reinvestment in the Group&#8217;s foreign subsidiaries that would be subject to withholding tax or other taxes if remitted to the Group are estimated at approximately USD 32 billion in 2022, (2021: USD 29 billion).</div>
                  <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">The gross value of tax-loss carry-forwards that have or have not been recognized as deferred tax assets, with their expiry dates, is as follows:</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory', window );">Gross value of tax-loss carry-forwards</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Unrecognized</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Recognized</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022 total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One year</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Two years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            42
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Three years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Four years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            138
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            138
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            79
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            688
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            767
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">More than five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 880
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 380
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 260
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not subject to expiry</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            433
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            452
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            885
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 610
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            3 530
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 140
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Unrecognized</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rcognized</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021 total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One year</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Two years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Three years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            47
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Four years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            26
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            146
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            166
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">More than five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 536
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 872
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 408
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not subject to expiry</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            418
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            684
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 102
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 192
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 607
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 799
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tax losses carried forward  that expired</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Deferred tax assets related to carry-forwards of taxable losses and tax credits of relevant Group entities are recognized to the extent it is considered probable that future taxable profits will be available in the respective tax jurisdictions against which such losses and credits can be utilized.</div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571863916656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial and other non-current assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract', window );"><strong>Disclosure of financial and other non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfFinancialAssetsTableTextBlock', window );">Financial assets</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity securities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 145
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 663
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            281
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            366
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 463
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 063
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term receivables from finance subleases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            59
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            70
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other long-term receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            197
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            184
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            607
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            641
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances and security deposits</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            85
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            78
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 411
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 036
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfOtherNoncurrentAssetsTableTextBlock', window );">Other non-current assets</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred compensation plans</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            419
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            520
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid post-employment benefit plans<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            491
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 415
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            200
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            275
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other non-current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 110
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 210
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 25 provides additional disclosures related to post-emplyment benefits.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfFinancialAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfFinancialAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOtherNoncurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOtherNoncurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571863970032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InventoriesDisclosureAbstract', window );"><strong>Inventories Disclosure [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories by class</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Raw material, consumables</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            934
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            870
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Work in progress</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 673
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 160
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Finished products</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 568
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 636
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total inventories</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            7 175
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 666
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock', window );">Amount of inventory recognized as an expense in cost of goods sold</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-8.6</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8.8</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8.5</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock', window );">Recognized amount of inventory provisions and reversals of inventory provision</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventory provisions</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-633</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-573</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-702</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversals of inventory provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            161
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            158
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            255
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InventoriesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InventoriesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571863697952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfTradeReceivablesAbstract', window );"><strong>Disclosure of trade receivables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProvisionsForTradeReceivablesTableTextBlock', window );">Provisions for trade receivables</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total gross trade receivables</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 128
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 088
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-83</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 066
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 005
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TradeReceivablesProvisionMovementsTableTextBlock', window );">Trade receivables provision movements</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-83</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-93</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-95</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables charged to the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-47</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-39</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-59</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Utilization of provisions for doubtful trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of provisions for doubtful trade receivables credited to the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-83</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-93</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OverdueAmountsAndRelatedProvisionsTableTextBlock', window );">Overdue amounts and related provision</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not overdue</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 664
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 639
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for not more than one month</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            190
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            162
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one month  but less than three months</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            110
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            99
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than three months  but less than six months</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            62
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            63
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than six months  but less than one year</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one year</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            79
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            97
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-83</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 066
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 005
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock', window );">Trade receivables denominated in other currencies</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 709
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 344
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 426
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 408
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Russian ruble (RUB)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            430
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            473
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            177
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            383
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">British pound (GBP)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            176
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            200
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chinese yuan (CNY)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            155
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            197
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canadian dollar (CAD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            151
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            139
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Brazilian real (BRL)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            129
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Australian dollar (AUD)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            139
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            108
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            106
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other currencies</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 452
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 487
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 066
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            8 005
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfTradeReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfTradeReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OverdueAmountsAndRelatedProvisionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OverdueAmountsAndRelatedProvisionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProvisionsForTradeReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProvisionsForTradeReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TradeReceivablesProvisionMovementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TradeReceivablesProvisionMovementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864566672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract', window );"><strong>Disclosure of marketable securities commodities deposits derivative instruments and cash [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock', window );">Marketable securities, commodities, timedeposits, and derivative financial instruments</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            111
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            111
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 741
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 089
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12 965
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities, commodities, time deposits and derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            11 413
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 922
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsTableTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current accounts</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 877
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 396
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity less than 90 days</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 640
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9 011
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total cash and cash equivalents</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            7 517
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            12 407
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859649024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other current assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherCurrentAssetsAbstract', window );"><strong>Other current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherCurrentAssetsTableTextBlock', window );">Other current assets</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">VAT receivable</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            509
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            487
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Withholding tax recoverable</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            50
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            58
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid expenses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            911
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 102
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivable<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            958
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            793
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 471
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 440
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862437264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfEquityAbstract', window );"><strong>Disclosure of equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementInTheShareCapitalTableTextBlock', window );">Schedule disclosing information related to movement in the share capital</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Jan 1, 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Movement<br/> in year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Dec 31, 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Movement<br/> in year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Dec 31, 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Movement<br/> in year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/> Dec 31, 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Share capital<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            936
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-23</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            913
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            901
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-11</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            890
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Treasury shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-80</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            27
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-53</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-48</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-92</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding share capital</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            856
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            860
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            853
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            798
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> The Novartis AG share capital consists of registered shares with a nominal value of CHF 0.50 each. No authorized and conditional capital exists.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementInTheShareslTableTextBlock', window );">Schedule disclosing information related to movement in the shares</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>Number of outstanding shares <br/>(in millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br/> Novartis <br/> shares</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br/> treasury <br/> shares<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br/> outstanding <br/> shares</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> Novartis <br/> shares</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> treasury <br/> shares<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> outstanding <br/> shares</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> Novartis <br/> shares</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> treasury <br/> shares<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br/> outstanding <br/> shares</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at beginning of year</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 434.4
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-199.5</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 234.9
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 467.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-210.2</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 256.8
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 527.3
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-262.3</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:4%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 265.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares canceled for capital  reduction<sup style="white-space: nowrap"> &#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-30.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            32.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-60.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            60.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be  canceled<sup style="white-space: nowrap"> &#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-126.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-126.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases<sup style="white-space: nowrap">&#160;4</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1.4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1.4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options  and employee transactions<sup style="white-space: nowrap"> &#160;5</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">   18.9</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14.7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation<sup style="white-space: nowrap">&#160;5</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total movements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-30.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-84.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-115.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-32.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-21.9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-60.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            52.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-8.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at end of year</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 403.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-284.1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 119.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 434.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-199.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 234.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 467.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-210.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 256.8
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="22" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Approximately 99.0 million treasury shares (2021: 102.5 million; 2020: 103.0 million) are held in Novartis entities that restrict their availability for use.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Novartis reduced its share capital by canceling shares that were repurchased on the SIX Swiss Exchange second trading line during previous years.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup>
                            <span> Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2019 Annual General Meeting (AGM) for transactions after February 28, 2019, until March 2, 2021. Transactions after March 2, 2021, were executed under the CHF 10 billion share buyback authority approved at the 2021 AGM and the additional CHF 10 billion authority approved at the 2022 AGM.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;4&#160;</sup> Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;5&#160;</sup> Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="22">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DividendTableTextBlock', window );">Schedule disclosing information related to Dividend</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend per share (in CHF)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.10
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3.00
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.95
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total dividend payment  (in USD billion)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SummaryOfTreasurySharesMovementsTableTextBlock', window );">Schedule disclosing information related treasury shares movements</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Number of <br/> outstanding <br/> shares<br/> (in millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Equity impact<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Number of <br/> outstanding <br/> shares<br/> (in millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Equity impact<br/> USD m</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Number of <br/> outstanding <br/> shares<br/> (in millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Equity impact<br/> USD m</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be canceled<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-126.2</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-10 787</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30.7</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 775</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32.6</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:6%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 897</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1.4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-123</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-145</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-159</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-127.6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-10 910</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 920</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-34.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 056</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions<sup style="white-space: nowrap">&#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.9</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            88
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            806
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation<sup style="white-space: nowrap">&#160;4</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            854
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            9.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            745
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            730
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares delivered to Alcon employees</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            30
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-115.3</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-9 963</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-21.9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 119</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-8.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 490</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="16" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2019 Annual General Meeting (AGM) for transactions after February 28, 2019, until March 2, 2021. Transactions after March 2, 2021, were executed under the CHF 10 billion share buyback authority approved at the 2021 AGM and the additional CHF 10 billion authority approved at the 2022 AGM.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup> Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price, reflecting the strike price of the options exercised.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;4&#160;</sup> Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax-deductible amounts exceeding the expense recognized in the income statement are credited to equity.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="16">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DividendTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DividendTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MovementInTheShareCapitalTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MovementInTheShareCapitalTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MovementInTheShareslTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MovementInTheShareslTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SummaryOfTreasurySharesMovementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SummaryOfTreasurySharesMovementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864129616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-current financial debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract', window );"><strong>Disclosure of financial liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock', window );">Disclosure of non-current portion of non-current borrowings by type</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            22 341
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25 296
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities to banks and other financial institutions<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            144
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            227
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total, including current portion of non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 523
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion of non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 241</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 621</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            20 244
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            22 902
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Average interest rate 2.3% (2021: 0.9%)</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock', window );">Disclosure of detailed information about borrowings</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>Coupon</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Currency</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Notional <br/> amount<br/> (millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Issuance <br/> year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Maturity <br/> year</div>
                        </td>
                        <td/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Issuer</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Issue price</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022<br/> (USD<br/> millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021<br/> (USD<br/> millions)</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.400%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 500
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2012
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2022
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.225%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 498
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              3.700%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            500
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2012
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2042
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              98.325%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            490
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            490
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              3.400%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 150
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2014
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2024
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.287%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 147
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 144
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              4.400%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 850
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2014
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2044
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.196%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 827
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 826
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.625%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            600
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2014
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2026
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.697%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            638
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            676
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.250%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            CHF
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            500
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2015
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2025
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis AG, Basel, Switzerland
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100.640%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            541
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            547
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.625%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            CHF
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            550
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2015
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2029
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis AG, Basel, Switzerland
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100.502%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            595
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            602
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.050%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            CHF
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            325
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2015
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2035
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis AG, Basel, Switzerland
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100.479%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            352
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            356
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              3.000%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 750
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2015
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2025
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.010%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 742
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 740
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              4.000%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 250
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2015
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2045
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              98.029%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 221
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 220
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.125%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 250
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2016
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2023
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.127%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 330
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 409
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.625%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            500
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2016
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2028
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              98.480%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            528
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            559
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.400%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2017
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2022
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.449%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 000
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              3.100%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2017
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2027
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.109%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            994
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            993
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.125%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            600
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2017
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2027
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.874%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            638
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            677
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.500%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            750
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2023
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.655%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            798
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            846
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.375%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            750
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2030
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.957%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            797
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            846
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.700%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            750
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2018
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2038
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.217%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            792
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            840
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              1.750%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2025
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.852%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            998
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            998
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.000%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 250
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2027
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.909%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 246
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 246
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.200%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 500
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2030
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.869%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 494
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 493
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.750%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            USD
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 250
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2050
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation, New York, United States
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              97.712%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 215
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 214
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.000%</span>
                            <sup style="white-space: nowrap">&#160;1</sup>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EUR
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 850
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2020
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2028
                          </div>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.354%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 958
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 076
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total straight bonds</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td>
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 296
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="18">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> The EUR 1 850 million bond issued in 2020 features a coupon step-up of <span>0.25%</span> commencing with the first interest payment date after December 31, 2025, if one or both of the 2025 Patient Access Targets are not met. These 2025 Patient Access Targets are the 2025 Flagship Programs Patient Reach Target and the 2025 Strategic Innovative Therapies Patient Reach Target, as defined in the bond prospectus. As of December 31, 2022, there is no indication that these 2025 Patient Access Targets will not be met.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock', window );">Non-current financial debt including current portion by maturity</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 621
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 342
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 147
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 144
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 281
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3 284
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            638
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            693
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2027</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 909
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 916
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After 2027</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 269
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11 523
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 523
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock', window );">Non-current financial debt including current portion by currency</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13 376
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 862
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 478
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 930
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            76
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            174
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 488
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 505
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            67
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            52
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 523
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock', window );">Comparison of balance sheet and fair value of total non-current financial debt including current portion</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022<br/> Balance<br/> sheet</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022<br/> Fair<br/> values</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021<br/> Balance<br/> sheet</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021<br/> Fair<br/> values</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            22 341
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20 277
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25 296
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            27 079
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            144
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            144
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            227
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            227
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            20 421
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 523
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            27 306
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571858800304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions and other non-current liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract', window );"><strong>Disclosure of detailed information about provisions and non-current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsExplanatory', window );">Disclosure of other provisions [text block]</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued liability for employee benefits:</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Defined benefit pension plans<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 723
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 640
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Other long-term employee benefits and deferred compensation</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            554
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            662
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Other post-employment benefits<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            362
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            487
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Environmental remediation provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            535
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            567
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for product liabilities, governmental investigations and other legal matters</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            154
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            341
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            704
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            956
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            874
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            519
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total provisions and other non-current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 906
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 172
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 25 provides additional disclosures related to post-employment benefits.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AccrualForEnvironmentalLossContingenciesTableTextBlock', window );">Accrual for environmental loss contingencies [table text block]</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            616
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            809
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            714
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-169</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-18</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-  105</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            82
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-24</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            50
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            588
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            616
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            809
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current provision</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-53</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-49</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-167</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current environmental remediation provisions at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            535
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            567
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            642
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock', window );">Accrual for environmental loss contingencies, fiscal year maturity [table text block]</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Expected <br/> cash outflows</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due within two years</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:20%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            128
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due later than two years, but within five years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            163
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due later than five years, but within 10 years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            251
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due after 10 years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            46
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total environmental remediation provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            588
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock', window );">Accrual for product liabilities government investigations other legal matters loss contingencies [table text block]</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            397
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            487
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 369
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-105</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-292</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 863</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases of provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-52</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-31</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            466
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            251
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 018
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-17</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            702
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            397
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            487
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-548</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-56</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-306</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current product  liabilities, governmental  investigations and other  legal matters provisions  at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            154
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            181
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AccrualForEnvironmentalLossContingenciesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AccrualForEnvironmentalLossContingenciesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859581792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current financial debt and derivative financial instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract', window );"><strong>Disclosure of current financial debt and derivative instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock', window );">Current financial debt and derivative instruments</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of employees  payable on demand<sup style="white-space: nowrap"> &#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 814
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other financial debt<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            863
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            899
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 772
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            893
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current portion of non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 621
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            55
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            68
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt and derivative  financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 931
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 295
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Weighted average interest rate 0.25% through September 30, 2022 (2021: 0.25%)</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup>
                            <span> Weighted average interest rate 9.7% (2021: 6.1%)</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859391248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions and other current liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract', window );"><strong>Disclosure of provisions and other current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock', window );">Provisions and other current liabilities</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes other than income taxes</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            836
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            619
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Restructuring provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 131
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            345
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued expenses for goods and services received but not invoiced</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 059
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 089
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accruals for royalties</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            767
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            752
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued interests on financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            116
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            127
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for deductions from revenue</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 732
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 481
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accruals for compensation and benefits, including social security</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 321
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 260
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Environmental remediation provisions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            123
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            123
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for product liabilities, governmental investigations and other legal matters<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            548
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued share-based payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            235
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            253
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            131
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            119
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares<sup style="white-space: nowrap">&#160;3</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 809
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            743
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            588
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total provisions and other current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            14 795
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 670
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 20 provides additional disclosures related to legal provisions.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Note 29 provides additional disclosures related to contingent consideration.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup> Note 18.3 provides additional disclosures related to commitment for repurchase of own shares.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProvisionsForReductionOfRevenueTableTextBlock', window );">Provisions for reduction of revenue</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 481
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 256
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 595
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of currency translation, business combinations</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-210</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-218</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            234
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments/utilizations</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-22 261</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-19 838</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-19 294</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustments of prior years charged to income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-322</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-245</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-151</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current year income statement charge</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23 072
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20 413
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19 773
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions offset against gross trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            113
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            99
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 732
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 481
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 256
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The provisions for deductions from revenue include specific healthcare plans and program rebates as well as non-healthcare plans and program-related rebates, returns and other deductions. The provisions for deductions from revenue are adjusted to reflect experience and to reflect actual amounts as rebates, refunds, discounts and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these deductions from revenue.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RestructuringProvisionsMovementsTableTextBlock', window );">Restructuring provisions movements</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            345
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            459
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            438
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 368
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            328
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            354
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-468</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-344</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-268</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-42</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-54</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-87</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transfers</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-53</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-17</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 131
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            345
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            459
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProvisionsForReductionOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProvisionsForReductionOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RestructuringProvisionsMovementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RestructuringProvisionsMovementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862120624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated statements of cash flows (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract', window );"><strong>Disclosure of details to the consolidated statements of cash flows [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock', window );">Adjustments for non-cash items from continuing operations</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments on:</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Property, plant and equipment</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 570
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 489
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 758
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            303
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            318
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            330
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Intangible assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 308
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 306
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4 376
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Financial assets<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            260
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-38</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-335</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 403
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            896
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 411
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gains on disposal and other adjustments on property, plant and equipment; intangible assets;  financial assets; and other non-current assets, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-333</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-677</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-478</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-settled compensation expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            823
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            736
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            738
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Loss/(income) from associated companies<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-15 339</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-673</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income taxes</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 416
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 119
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 807
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net financial expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            817
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            891
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            947
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            11 546
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-5 299</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 881
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Includes fair value changes</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup>
                            <span> 2021 included the gain of USD 14.6 billion recognized from the divestment of the Group's investment in Roche (see Notes 2 and 4).</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2022, other than through business combinations, there were USD 635 million additions to intangible assets with deferred payments. In 2022, there were USD 247 million (2021: USD 321 million, 2020: USD 346 million) additions to right-of-use assets recognized.</div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock', window );">Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Increase)/decrease in inventories</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-830</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            81
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-543</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Increase)/decrease in trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-589</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-389</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            137
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Decrease in trade payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-48</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-21</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-324</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other current and non-current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-194</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-202</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            229
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            658
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            772
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            211
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other adjustments, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 003</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            241
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-291</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock', window );">Cash flows arising from acquisitions and divestments of businesses</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of acquisitions of businesses</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 077</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-735</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-10 173</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value of previously held equity interests</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            42
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            205
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            59
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            98
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments, deferred consideration and other adjustments, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            62
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-864</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-633</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-10 006</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows (used for)/from divestments of businesses, net<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-15</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            66
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used for acquisitions and divestments of businesses, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-879</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-567</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-9 957</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> In 2022, USD 15 million net cash outflows from divestments of businesses included USD 20 million reduction to cash and cash equivalents due to the derecognized cash and cash equivalents following a loss of control of a company upon expiry of an option to purchase the company, partly offset by USD 5 million net cash inflows from business divestments in 2022 and in prior years.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <span> In 2022, the net identifiable assets of divested businesses amounted to USD 173 million, comprised of non-current assets of USD 132 million, current assets of USD 113 million, including USD 71 million cash and cash equivalents and of non-current and current liabilities of USD 72 million. Deferred sales price receivables and other adjustments amounted to USD 41 million.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <span> In 2021, USD 66 million included USD 52 million net cash inflows from divestments in previous years, and a USD 14 million net cash inflow from a business divestment in 2021, comprised of intangible assets.</span>
                          </div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                            <span> In 2020, USD 49 million represented the net cash inflows from divestments in previous years.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock', window );">Reconciliation of liabilities arising from financing activities</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Non-current <br/> financial <br/> debts</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Current <br/> financial <br/> debts and <br/> derivative <br/> financial <br/> instruments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Non-current <br/> lease liabilities</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Current lease <br/> liabilities</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2022</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 902
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            6 295
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 621
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            275
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of the current portion of non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 575</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            295
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-295</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-51</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New, modified and terminated leases, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            173
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions and divestments of businesses, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, lease interest and other changes, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-366</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-401</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-41</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 325</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 325
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-224</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            224
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            20 244
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 931
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 538
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            251
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup>
                            <span> Change in current financial debts included net cash outflows from interest-bearing accounts of employees payable on demand amounting to USD 1.7 billion. See Note 21.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Non-current <br/> financial <br/> debts</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Current <br/> financial <br/> debts and <br/> derivative <br/> financial <br/> instruments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Non-current <br/> lease liabilities</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Current lease <br/> liabilities</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2021</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 259
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 785
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 719
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            286
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of the current portion of non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 162</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 524</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-316</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-52</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New, modified and terminated leases, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            61
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, lease interest and other changes, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-124</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            62
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-774</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-309</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 624</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 624
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-247</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            247
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            22 902
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 295
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 621
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            275
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Non-current <br/> financial <br/> debts</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Current <br/> financial <br/> debts and <br/> derivative <br/> financial <br/> instruments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Non-current <br/> lease liabilities</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/>
                            <br/> Current lease <br/> liabilities</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2020</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            20 353
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            7 031
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 703
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            246
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 126
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayments of the current portion of non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 003</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 261
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments of lease liabilities, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-312</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-56</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New, modified and terminated leases, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            221
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            32
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            36
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values, lease interest and other changes, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            65
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            832
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            392
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification from non-current to current, net</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 067</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 067
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-250</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            250
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2020</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            26 259
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9 785
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 719
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            286
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571858507456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions of businesses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfAcquisitionOfBusinessesAbstract', window );"><strong>Disclosure of acquisition of businesses [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock', window );">Fair value of assets and liabilities arising from acquisitions</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant and equipment</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            13
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            26
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Right-of-use assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            32
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            292
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            196
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired research and development</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 209
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            262
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 600
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other intangible assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            98
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            218
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            476
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current financial and other assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            49
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            84
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables and financial and other current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            109
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            89
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            76
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-300</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-74</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 977</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables and other liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-67</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-144</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net identifiable assets acquired</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 005
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            612
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            7 669
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired cash and cash equivalents</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-89</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-10</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-76</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-controlling interests</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-105</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            161
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            238
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 580
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of acquisitions of businesses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 077
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            735
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            10 173
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="8" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfAcquisitionOfBusinessesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfAcquisitionOfBusinessesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571863817840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-employment benefits for employees (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDefinedBenefitPlansTableTextBlock', window );">Summary of the funded and unfunded defined benefit obligation for pension and other post retirement benefit plans table</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment  benefit plans</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            23 583
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            25 602
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            560
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            632
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current service cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            348
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            415
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            249
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            151
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            16
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past service costs and settlements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-40</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            63
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Administrative expenses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurement gains arising from changes in financial assumptions<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 046</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-713</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-94</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-20</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurement (gains)/losses arising from changes in demographic assumptions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-53</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-377</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Experience-related remeasurement losses/(gains)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            199
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            531
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-28</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-47</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-650</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-865</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 253</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 450</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions of employees</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            174
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            179
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            17 533
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            23 583
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            422
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            560
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at January 1</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            22 420
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            22 317
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            89
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            220
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Return on plan assets excluding interest income</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 500</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 512
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-539</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-726</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Group contributions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            424
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            490
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            41
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions of employees</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            174
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            179
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Settlements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 253</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 450</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-32</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            18 945
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            22 420
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 412
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 163</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-362</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Limitation on recognition of fund surplus at January 1</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-51</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in limitation on recognition of fund surplus</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 504</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-76</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income on limitation of fund surplus</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Limitation on recognition of fund surplus at December 31<sup style="white-space: nowrap">&#160;2</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2 644</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-62</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability in the balance sheet at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 232</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 225</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-362</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> The remeasurement gains arising from changes in financial assumptions is driven mainly by changes in the actuarial discount rates used to determine the benefit obligation.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup>
                            <span> As of December 31, 2022, the most significant pension plans where the asset ceiling was required to be applied were in Switzerland and amounted to USD 2 587 million.</span>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock', window );">Reconciliation of the net liability table</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment  benefit plans</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 225</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-3 336</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-543</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current service cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-348</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-415</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-11</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net interest expense</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-31</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-47</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-15</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Administrative expenses</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-23</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-24</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past service costs and settlements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-70</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurements</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 071
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            110
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            70
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            145
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Group contributions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            424
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            490
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            41
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-23</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in limitation on recognition of fund surplus</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 504</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 232</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 225</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-362</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Amounts recognized in the consolidated balance sheet</div>
                        </td>
                        <td align="right"/>
                        <td align="right"/>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right"/>
                        <td align="right"/>
                        <td align="right"/>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid benefit cost</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            491
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 415
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued benefit liability</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 723</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 640</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-362</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfAssumptionsUsedTableTextBlock', window );">Principal weighted average actuarial assumptions</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment  benefit plans</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average assumptions used to determine  benefit obligations at December 31</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discount rate</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              3.0%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.9%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.6%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              6.3%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              3.3%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              2.9%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected rate of pension increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              0.4%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.5%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.3%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected rate of salary increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.9%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              2.7%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              2.7%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest on savings account</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              2.2%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.5%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              0.1%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current average life expectancy  for a 65-year-old male in years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current average life expectancy  for a 65-year-old female in years</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock', window );">The sensitivity of the defined benefit pension obligation to the principal actuarial assumptions</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in 2022 <br/> year-end defined <br/> benefit pension <br/> obligation</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change in 2021 <br/> year-end defined <br/> benefit pension <br/> obligation</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in discount rate</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-466</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-790</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in discount rate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            491
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            839
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One-year increase in life expectancy</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            535
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            869
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in rate of pension increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            316
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            512
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in rate of pension increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-63</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-136</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase of interest on savings account</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            58
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease of interest on savings account</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-37</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-58</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in rate of salary increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            54
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in rate of salary increase</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-37</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-54</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

                <div/>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock', window );">The healthcare cost trend rate assumptions used for other post-employment benefits</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Healthcare cost trend rate assumed for next year</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              6.5%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              6.0%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              6.3%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rate to which the cost trend rate is assumed to decline</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              4.5%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              4.5%</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>
                              4.5%</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Year that the rate reaches the ultimate trend rate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2031
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2028
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2028
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">The weighted average plan asset allocation of funded defined benefit pension plans</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(as a percentage)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-term <br/> target <br/> minimum</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-term <br/> target <br/> maximum</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity securities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            40
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            27
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            31
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            33
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Real estate</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alternative investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and other investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            100
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock', window );">Asset allocation, investments in shares of Novartis AG</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31, <br/> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31, <br/> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investment in shares of Novartis AG</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Number of shares (in millions)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Market value (in USD billions)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">The expected future cash flows in respect of pension and other post- employment benefit plans</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Pension plans</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-<br/> employment<br/> benefit plans</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis Group contributions</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023 (estimated)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            397
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Expected future benefit payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 268
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 441
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 128
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 114
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2027</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 099
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            38
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2028&#8211;2032</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 310
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            171
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfDefinedContributionPlansTableTextBlock', window );">Defined contribution plans</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions for defined contribution plans</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            520
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            523
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            501
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#8217;s total personnel costs amounted to USD 14.9 billion in 2022.</div>
                </div>

                <div/>
              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock', window );">Breakdown of defined benefit obligation for pension plans and other post-employment benefit</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Switzerland</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> United<br/> States</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of<br/> the world</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Switzerland</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> United<br/> States</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of<br/> the world</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            11 824
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 746
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 963
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            17 533
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            15 268
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 645
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 670
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            23 583
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof unfunded</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            556
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            363
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            919
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            688
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            439
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            1 127
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">By type of member</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Active</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 799
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            431
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            931
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 161
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 478
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            620
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 412
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 510
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Deferred pensioners</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            830
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            861
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 691
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 208
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 730
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 938
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Pensioners</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 025
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 171
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9 681
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 790
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 817
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 528
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12 135
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            14 701
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 978
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 266
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            18 945
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            16 436
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 551
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            3 433
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            22 420
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 877
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-768</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-697</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 412
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 168
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 094</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 237</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 163</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="18" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock', window );">Breakdown of defined benefit obligation for pension plans and other post-employment benefit</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> United<br/> States</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of<br/> the world</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Total</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> United<br/> States</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Rest of<br/> the world</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            346
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            76
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            422
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            473
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            87
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            560
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof unfunded</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            286
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            76
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            362
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            87
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            487
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">By type of member</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Active</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            48
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            83
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Deferred pensioners</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;&#160;&#160;Pensioners</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            308
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            58
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            366
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            400
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            64
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            464
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            60
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            73
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-286</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-76</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-362</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-400</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-87</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-487</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDefinedBenefitPlansTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDefinedBenefitPlansTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfDefinedContributionPlansTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfDefinedContributionPlansTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571858080816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based participation plans for employees (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock', window );">Expense related to all equity-based participation and liabilities arising from equity-based payment transactions</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense related to equity-based  participation plans</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 048
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            979
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:11%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            958
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities arising from equity-based  payment transactions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            235
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            253
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            269
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="8" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Schedule of unvested restricted stock units roll forward</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Number<br/> of shares<br/> in millions</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br/> average fair<br/> value at grant<br/> date in USD</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Number<br/> of shares<br/> in millions</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted <br/> average fair<br/> value at grant<br/> date in USD</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Annual Incentive</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; RSU</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            74.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            87.5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; Restricted shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            85.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            97.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Share savings plans</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; RSU</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            75.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            86.9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; Shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            85.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            97.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis Employee Share Purchase Plan</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            82.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Select North America (RSU)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            74.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            86.9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Select outside North America</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; RSU</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            75.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            86.9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; Restricted shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            85.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            97.0
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Long-Term Performance Plan (PSU)</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            82.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            89.5
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Other share awards</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; RSU</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            76.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            78.4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; Restricted shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            86.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#8211; Shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            86.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            0.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            91.9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember', window );">Select outside North America</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Disclosure of number and weighted average remaining contractual life of outstanding share options</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Options<br/> (millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted<br/> average <br/> exercise <br/> price<br/> (USD)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Options<br/> (millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted<br/> average <br/> exercise <br/> price<br/> (USD)</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Options outstanding  at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1.7
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            63.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            62.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sold or exercised</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1.2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            62.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-0.9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            58.9
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            0.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            66.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            63.6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            0.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            66.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            63.6
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember', window );">Select North America</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Disclosure of number and weighted average remaining contractual life of outstanding share options</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> ADR<br/> options<br/> (millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted<br/> average <br/> exercise <br/> price<br/> (USD)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> ADR<br/> options<br/> (millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted<br/> average <br/> exercise <br/> price<br/> (USD)</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Options outstanding  at January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            64.4
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6.7
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            62.9
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sold or exercised</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2.9</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            63.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2.7</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            60.7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            66.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            64.4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            66.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            64.4
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571855197760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with related parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Disclosure of transactions between related parties [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OfficerAndDirectorCompensationTableTextBlock', window );">Executive Officers and Non-Executive Directors Compensation</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Executive Officers</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-Executive Directors</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="center" colspan="5" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="5" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and other compensation</div>
                        </td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            20.3
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4.7
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            29.6
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25.0
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            30.2
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Post-employment benefits</div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2.7
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            42.6
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            37.3
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            41.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5.2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            47.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            42.5
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            46.3
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            70.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            60.1
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            69.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            9.4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9.9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            9.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            79.8
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            70.0
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            79.2
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="20" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock', window );">Transactions with former members of the Board of Directors</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currency</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2020</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dr. Krauer</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            60 000
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            60 000
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Dr. Alex Krauer, was an Honorary Chairman of Novartis and was entitled to an amount of CHF 60 000 for annual periods from one AGM to the next. This amount was fixed in 1998 upon his departure from the Board in 1999. The last payment under this arrangement was in 2021. </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OfficerAndDirectorCompensationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OfficerAndDirectorCompensationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859576896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentsAndContingenciesAbstract', window );"><strong>Commitments and contingencies [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfLeasingCommitmentsTableTextBlock', window );">Leasing commitments</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:20%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            420
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2024</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            808
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2025</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            448
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2026</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            282
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2027</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            687
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Thereafter</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 169
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 814
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="4" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfLeasingCommitmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfLeasingCommitmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571858518048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsAdditionalDisclosureAbstract', window );"><strong>Financial Instruments - additional disclosure [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock', window );">Disclosure of financial assets and financial liabilities</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                            <br/>
                            <br/>
                            <br/> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Financial<br/> instruments at<br/> amortized<br/> costs</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/> Financial<br/> instruments at<br/> fair value<br/> through other<br/> comprehensive<br/> income</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> Financial<br/> instruments at<br/> fair value<br/> through the<br/> consolidated<br/> income<br/> statement</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>
                            <br/> Other<br/> financial<br/> liabilities at<br/> amortized<br/> costs</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 517
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 089
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8 066
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            958
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities - debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            828
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            317
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            37
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - fund investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            281
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances, security deposits and other long-term receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            129
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13/17</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            650
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            27 971
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            874
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 581
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other short-term financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            863
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 772
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            22 341
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term liabilities to banks and other financial institutions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            144
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 146
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities (see Note 20/22) and other financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 067
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            55
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 789
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            31 266
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 122
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 789
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                            <br/>
                            <br/>
                            <br/> Note</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Financial<br/> instruments at<br/> amortized<br/> costs</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Financial<br/> instruments at<br/> fair value<br/> through other<br/> comprehensive<br/> income</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Financial<br/> instruments at<br/> fair value<br/> through the<br/> consolidated<br/> income<br/> statement</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Other<br/> financial<br/> liabilities at<br/> amortized<br/> costs</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            10 397
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 010
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity more than 90 days</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12 965
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            8 005
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            793
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities - debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 741
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 195
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            468
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term financial investments - fund investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            366
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances, security deposits and other long-term receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            332
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            641
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            32 492
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 980
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 772
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of employees payable on demand</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 814
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other short-term financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            899
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            893
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            25 296
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term liabilities to banks and other financial institutions</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            227
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 553
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18/22</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 809
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities (see Note 20/22) and other financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 094
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            68
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 896
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            37 491
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 162
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 896
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Includes short-term highly rated government-backed debt securities, with an original maturity of three months or less</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory', window );">Derivative financial instruments</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Contract or underlying  principal amount</div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Positive fair values  </div>
                        </td>
                        <td/>
                        <td align="center" colspan="3" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Negative fair values  </div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="3" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 907
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13 248
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            189
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            92
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-41</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-35</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            97
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            82
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-14</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-33</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments included in  marketable securities and in current financial debts</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 043
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            13 347
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock', window );">Contract or underlying principal amount the derivative financial instruments, by currency</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> EUR</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            687
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5 659
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 907
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            80
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            97
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            39
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            767
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            5 715
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 561
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 043
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> EUR</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> USD</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Other</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 485
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 158
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 605
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13 248
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodity purchase contract</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            17
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Options on equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            82
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            82
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 485
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            5 257
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            6 605
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            13 347
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory', window );">Fair value by hierarchy</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 1</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 2</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Level 3</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Marketable securities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities and derivative financial instruments at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            213
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            213
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current contingent consideration receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            43
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Long-term financial investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt and equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            473
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            699
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            261
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            281
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current contingent consideration receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            607
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            607
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total long-term financial investments at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            493
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            10
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            1 567
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            2 070
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            129
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            129
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current contingent consideration liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-131</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-131</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial liabilities at fair values</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-131</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-186</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-current contingent consideration liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-704</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-704</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-232</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-232</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial liabilities at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-936</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-936</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 1</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 2</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Level 3</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 010
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 010
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total cash and cash equivalents at fair value</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 010
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 010
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Marketable securities and derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 719
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2 741
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities and derivative financial instruments at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 719
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            127
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 846
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Long-term financial investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt and equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 080
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            617
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 697
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            338
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            366
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            641
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            641
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total long-term financial investments at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 108
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 596
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            2 704
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit and loss</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 075</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 075</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities at fair value</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 094</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 162</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td>
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Includes short-term highly rated government-backed debt securities, with an original maturity of three months or less</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock', window );">Reconciliation of changes in fair value measurement</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Associated <br/> companies at <br/> fair value  through<br/> profit and loss</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Fund<br/> investments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Long-term <br/> financial <br/> investments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Contingent <br/> consideration <br/> receivables</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Contingent <br/> consideration <br/> liabilities</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/> Other<br/> financial<br/> liabiltiies</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            192
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            338
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            617
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            641
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-1 075</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-19</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value gains and other adjustments, including from divestments  recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            35
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            530
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value losses (including impairments and amortizations) and  other adjustments recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-63</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-78</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-84</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-114</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-18</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments recognized in the consolidated statement   of comprehensive income, including currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            160
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-231</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-238</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash receipts and payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            44
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            28
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-12</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-40</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            129
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            261
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            699
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            650
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-835</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-232</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of fair value gains and losses recognized   in the consolidated income statement for assets   and liabilities held at December 31, 2022</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-63</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-74</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-49</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            53
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            416
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Associated <br/> companies at <br/> fair value  through<br/> profit and loss</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Fund<br/> investments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Long-term <br/> financial <br/> investments</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Contingent <br/> consideration <br/> receivables</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/> Contingent <br/> consideration <br/> payables</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            211
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            366
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            460
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            625
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 046</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value gains and other adjustments, including from divestments  recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            2
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            70
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            69
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            124
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            182
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value losses (including impairments and amortizations) and  other adjustments recognized in the consolidated income statement</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-26</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-189</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments recognized in the consolidated statement   of comprehensive income, including currency translation effects</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            51
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-22</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            22
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            34
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            137
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-88</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash receipts and payments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-42</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            44
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-27</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-71</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-43</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-30</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-44</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            192
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            338
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            617
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            641
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 075</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of fair value gains and losses recognized   in the consolidated income statement for assets   and liabilities held at December 31, 2021</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-24</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            62
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            56
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            80
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-7</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory', window );">Equity securities measured at fair value through other comprehensive income</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Listed equity securities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            438
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            888
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Non-listed equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            390
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            307
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity securities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            828
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 195
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="6">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;&#160;&#160;&#160;</sup>
                          </div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock', window );">Monitoring of net debt or liquidity based on contractual maturities</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Due within <br/> one month</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br/> one month <br/> but less than <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br/> one year <br/> but less than <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Due after <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, time deposits and short-term investments with original maturity more than 90 days and accrued interest</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 142
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6 911
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            36
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11 098
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            111
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            111
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            23
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            147
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            19
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            15
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            204
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 011
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3 506
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 517
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            8 176
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            10 564
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            55
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            135
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            18 930
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-8 975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-11 269</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-20 244</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-9 002</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-11 394</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-20 396</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-8 975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-11 269</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-20 244</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 215</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-146</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 515</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 876</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-3 215</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-146</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-2 517</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">
                            <span>-5 878</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-38</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-13</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-55</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-3 253</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-159</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2 519</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-5 931</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            4 923
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            10 405
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-2 464</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-8 975</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-11 134</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">
                            <span>-7 245</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="11" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="11" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Due within <br/> one month</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br/> one month <br/> but less than <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br/> one year <br/> but less than <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Due after <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities, time deposits and short-term investments with original maturity more than 90 days and accrued interest</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            11
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            14 585
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            1 088
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            18
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:7%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            15 706
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            111
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            111
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            21
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            64
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            13
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            105
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            7 406
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 001
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            12 407
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            7 438
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            19 650
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            1 095
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            142
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            28 329
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-8 464</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-14 438</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-22 902</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-8 490</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-14 587</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-23 077</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-8 464</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-14 438</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-22 902</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 780</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-521</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 926</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-6 227</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-2 780</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-521</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-2 928</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;">
                            <span>-6 229</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-50</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-68</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 830</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-537</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-2 928</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-6 295</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#160;</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            4 608
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            19 113
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-1 833</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-8 460</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-14 296</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;">
                            <span>-868</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="14" style="border-bottom: solid #000000 3px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock', window );">Derivative financial instruments and accrued interest on derivative financial instruments</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Due within <br/> one month</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br/> one month <br/> but less than <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Derivative financial instruments and accrued interest on derivative  financial instruments</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential outflows in various currencies - from financial derivative liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-2 029</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-4 598</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-316</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6 943</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential inflows in various currencies - from financial derivative assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2 029
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4 712
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            321
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7 062
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="7" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="7" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Due within <br/> one month</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br/> one month <br/> but less than <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/>
                          </div>
                        </td>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Derivative financial instruments and accrued interest on derivative  financial instruments</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential outflows in various currencies - from financial derivative liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-843</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 482</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-461</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:9%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-6 786</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential inflows in various currencies - from financial derivative assets</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            847
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            5 516
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            457
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            6 820
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock', window );">Other contractual liabilities of the net debt or liquidity</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Due within <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br/> one year <br/> but less than <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/> Due after <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contractual interest on non-current liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-64</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-412</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 432</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-3 624</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 532</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-71</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-180</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-616</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-922</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-1 789</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 020</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-126</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-5 146</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-16</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-115</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-437</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-267</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-835</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 10 provides additional disclosures related to lease liabilities.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:10px;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td/>
                        <td align="center" colspan="9" style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:1;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style="border-bottom: solid #000000 1px;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr>
                        <td style=";height:3;"/>
                        <td style=";height:1;"/>
                        <td colspan="9" style=";height:3;"/>
                        <td style=";height:1;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">
                            <br/>(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Due within <br/> three months</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than<br/>  three months <br/> but less than <br/> one year</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Due later than <br/> one year <br/> but less than <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/> Due after <br/> five years</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;">
                            <br/>
                            <br/>
                            <br/> Total</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contractual interest on non-current liabilities</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-82</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-445</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 628</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3 908</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:8%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-6 063</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lease liabilities<sup style="white-space: nowrap">&#160;1</sup></div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-78</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-197</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-639</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-982</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 896</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 373</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-180</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-5 553</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commitment for repurchase of own shares</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 809</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-2 809</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration liabilities</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-54</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-65</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-517</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-439</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-1 075</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="12">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Note 10 provides additional disclosures related to lease liabilities.</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock', window );">Potential impact on the consolidated income statement due to increase (decrease) in currency exchange rates</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% increase in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-6</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            3
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% decrease in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-3</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock', window );">Potential impact on the consolidated equity due to increase (decrease) in currency exchange rates</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% increase in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            93
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            99
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5% decrease in foreign currency exchange rates  against USD</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-98</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-104</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock', window );">Potential impact on the consolidated income statement due to increase (decrease) in equity prices</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% increase in equity prices</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            109
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            154
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% decrease in equity prices</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-109</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-154</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock', window );">Potential impact on the consolidated equity due to increase (decrease) in equity prices</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2022</div>
                        </td>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2021</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% increase in equity prices</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            124
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:14%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            179
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">15% decrease in equity prices</div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>-124</span>
                          </div>
                        </td>
                        <td align="right"/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">
                            <span>-179</span>
                          </div>
                        </td>
                        <td align="right"/>
                      </tr>
                      <tr>
                        <td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of derivative financial instruments. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for fair value measurement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS13_g91-99__IFRS13_g91-99_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: Investments in equity instruments designated at fair value through other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 11A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_11A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialInstrumentsAdditionalDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialInstrumentsAdditionalDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859640928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Principal Group subsidiaries and associated companies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract', window );"><strong>Disclosure of subsidiaries [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock', window );">Principal Group subsidiaries and associated companies</a></td>
<td class="text">
                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>As at December 31, 2022</div>
                        </td>
                        <td/>
                        <td/>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br/> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br/> interest</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Algeria</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Soci&#233;t&#233; par actions SANDOZ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Algiers
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DZD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            650.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Argentina</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Argentina S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Buenos Aires
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ARS</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            906.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Australia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Australia Pty Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Macquarie Park, NSW
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharmaceuticals
Australia Pty Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Macquarie Park, NSW
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.8
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Pty Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Macquarie Park, NSW
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Austria</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Austria GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Vienna
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Vienna
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Kundl
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            32.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            EBEWE Pharma Ges.m.b.H Nfg. KG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Unterach am Attersee
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Bangladesh</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis (Bangladesh) Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Gazipur
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BDT</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            162.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              60%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Belgium</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma NV
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Vilvoorde
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            72.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz NV
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Vilvoorde
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            19.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Alcon - Couvreur NV
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Puurs
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            110.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Bermuda</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Investment Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hamilton
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Securities Investment Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hamilton
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance Services Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hamilton
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Triangle International Reinsurance Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hamilton
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Trinity River Insurance Co Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hamilton
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            370 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Brazil</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Bioci&#234;ncias S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            S&#227;o Paulo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRL</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            507.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz do Brasil Ind&#250;stria Farmac&#234;utica Ltda.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Camb&#233;, PR
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRL</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            190.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Canada</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharmaceuticals Canada Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Dorval, Quebec
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Canada Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Boucherville, Quebec
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            80.8
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Chile</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Chile S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Santiago de Chile
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CLP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">China</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Beijing Novartis Pharma Co., Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Beijing
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharmaceuticals (HK) Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Hong Kong
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HKD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            200
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            China Novartis Institutes for
BioMedical Research Co., Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Shanghai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            320.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Suzhou Novartis Technical
Development Co., Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Changshu
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Shanghai Novartis Trading Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Shanghai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz (China) Pharmaceutical
Co., Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Zhongshan
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            57.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Colombia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis de Colombia S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Santaf&#233; de Bogot&#225;
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> COP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.9
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Croatia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz d.o.o. farmaceutska industrija
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Zagreb
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HRK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Czech Republic</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis s.r.o.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Prague
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            51.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz s.r.o.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Prague
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            44.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Denmark</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Healthcare A/S
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Copenhagen
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            14.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz A/S
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Copenhagen
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            12.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ecuador</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Ecuador S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Quito
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Egypt</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma S.A.E.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cairo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EGP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.3
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.96%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Egypt Pharma S.A.E.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            New Cairo City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EGP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            250 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Finland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finland Oy
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Espoo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            459 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>As at December 31, 2022</div>
                        </td>
                        <td/>
                        <td/>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br/> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br/> interest</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">France</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Groupe France S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Rueil-Malmaison
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            903.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma S.A.S.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Rueil-Malmaison
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            43.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Gene Therapies France SAS
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Rueil-Malmaison
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Rueil-Malmaison
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications
Molecular Imaging France
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Saint-Genis-Pouilly
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            CELLforCURE
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Les Ulis
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz S.A.S.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Levallois-Perret
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Germany</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Deutschland GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Nuremberg
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            155.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Business Services GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Wehr
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Nuremberg
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Produktions GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Wehr
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz International GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Holzkirchen
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 A Pharma GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Holzkirchen
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            26 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            HEXAL AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Holzkirchen
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            93.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Salutas Pharma GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Barleben
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            42.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Aeropharm GmbH
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Rudolstadt
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            26 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Greece</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis (Hellas) S.A.C.I.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Metamorphosis / Athens
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            233.9
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Hungary</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Hungary Healthcare Limited Liability
Company
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Budapest
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HUF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            545.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Hungary Limited Liability Company
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Budapest
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HUF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            883.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">India</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis India Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Mumbai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            123.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              70.68%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Healthcare Private Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Mumbai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            60.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Private Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Mumbai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            32.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Indonesia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            PT. Novartis Indonesia
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Jakarta
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IDR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ireland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Ireland Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Dublin
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Integrated Services Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cork City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Gene Therapies EU Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Dublin
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Israel</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Israel Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Tel Aviv
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ILS</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Italy</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Farma S.p.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Milan
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications (Italy) S.r.l.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Pozzilli
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            119 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz S.p.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Origgio
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Japan</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma K.K.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Tokyo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Ciba-Geigy Japan Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Tokyo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz K.K.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Tokyo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Latvia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Baltics SIA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Riga
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Luxembourg</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Investments S.&#224; r.l.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Luxembourg City
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Luxembourg City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Malaysia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Corporation (Malaysia) Sdn. Bhd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Petaling Jaya
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MYR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.3
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Mexico</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Farmac&#233;utica, S.A. de C.V.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Mexico City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            205.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz, S.A. de C.V.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Mexico City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            468.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Morocco</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Maroc SA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Casablanca
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MAD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            80.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Netherlands</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Netherlands B.V.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Amsterdam
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma B.V.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Amsterdam
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            4.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            IDB Holland BV
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Baarle-Nassau
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz B.V.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Almere
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            907 560
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">New Zealand</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis New Zealand Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Auckland
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NZD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            820 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                </div>

                <div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>As at December 31, 2022</div>
                        </td>
                        <td/>
                        <td/>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br/> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br/> interest</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Norway</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Norge AS
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Oslo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NOK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Pakistan</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma (Pakistan) Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Karachi
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PKR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.99%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Panama</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma (Logistics), Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Panama City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Philippines</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Healthcare Philippines, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Makati City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PHP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            298.8
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Philippines Corporation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Makati City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PHP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Poland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Poland Sp. z o.o.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Warsaw
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            44.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Polska Sp. z o.o.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Warsaw
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Lek S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Strykow
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            11.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Portugal</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Portugal, S.G.P.S., Lda.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Porto Salvo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            500 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Farma - Produtos Farmac&#234;uticos, S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Porto Salvo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Farmac&#234;utica, Lda.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Porto Salvo
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            499 900
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Romania</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Services Romania S.R.L.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Bucharest
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz S.R.L.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Targu-Mures
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            119.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Russian Federation</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma LLC
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Moscow
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Neva LLC
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            St. Petersburg
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            500.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            JSC Sandoz
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Moscow
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            57.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Saudi Arabia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Saudi Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Riyadh
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SAR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            30.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Singapore</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis (Singapore) Pte Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Singapore
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Singapore Pharmaceutical
Manufacturing Pte Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Singapore
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            45.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Asia Pacific Pharmaceuticals
Pte Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Singapore
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            39.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Slovakia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Slovakia s.r.o.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Bratislava
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Slovenia</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Lek Pharmaceuticals d.d.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Ljubljana
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            48.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Pharmaceuticals d.d.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Ljubljana
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">South Africa</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis South Africa (Pty) Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Midrand
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            86.3
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz South Africa (Pty) Ltd
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Midrand
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            3.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">South Korea</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Korea Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Seoul
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> KRW</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            24.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Spain</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Farmac&#233;utica, S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Barcelona
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            63.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications
Iberica, S.L.U.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Esplugues de Llobregat
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            22.6
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Farmac&#233;utica S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Madrid
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            270 450
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Industrial Products
S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Les Franqueses del Vall&#233;s / Barcelona
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9.3
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Abadia Retuerta S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sard&#243;n de Duero / Valladolid
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sweden</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Sverige AB
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Stockholm
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SEK</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Switzerland</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis International AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            10.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Holding AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis International Pharmaceutical Investment AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Bioventures AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Forschungsstiftung
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Stiftung f&#252;r Kaderausbildung
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis-Mitarbeiterbeteiligungsstiftung
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Stiftung f&#252;r Mensch und Umwelt
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Stiftung der Novartis AG f&#252;r Erziehung,
Ausbildung und Bildung
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Overseas Investments AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Japat AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            50 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            350.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Services AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            20.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Schweizerhalle AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Muttenz
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            18.9
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Stein AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Stein
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            251 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharma Schweiz AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Risch
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cellerys AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Schlieren
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            129 630
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              20%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Arctos Medical AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Bern
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            360 020
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Innovative Therapies AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Risch
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications International SA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Geneva
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            9.3
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Basel
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Pharmaceuticals AG
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Risch
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                    </table>
                  </div>
                  <div style="padding-top:10px; padding-bottom:30px;">
                    <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%">
                      <tr valign="bottom">
                        <td style=";height:12;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;">
                            <br/>As at December 31, 2022</div>
                        </td>
                        <td/>
                        <td/>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share<br/> capital<sup style="white-space: nowrap">1</sup></div>
                        </td>
                        <td/>
                        <td/>
                        <td align="right">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br/> interest</div>
                        </td>
                        <td/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 2px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Taiwan</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis (Taiwan) Co., Ltd.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Taipei
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TWD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            170.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Thailand</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis (Thailand) Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Bangkok
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> THB</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            302.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Turkey</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Saglik, Gida ve Tarim &#220;r&#252;nleri Sanayi
ve Ticaret A.S.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Istanbul
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            448.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Farmanova Saglik Hizmetleri Ltd. Sti.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Istanbul
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            6.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Ila&#231; Sanayi ve Ticaret A.S.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Istanbul
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            880.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.99%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Grup Saglik &#220;r&#252;nleri
Ila&#231;lari Sanayi ve Ticaret A.S.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Gebze - Kocaeli
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            96.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ukraine</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Ukraine LLC
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Kyiv
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> UAH</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            8.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United Arab Emirates</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Middle East FZE
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Dubai
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AED</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United Kingdom</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis UK Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25.5
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharmaceuticals UK Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            5.4
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Grimsby Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            250.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications (UK &amp; Ireland)
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            100
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Neutec Pharma Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            7.7
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Gyroscope Therapeutics Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            London
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 492
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Frimley / Camberley
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            2.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United States of America</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Corporation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            72.2
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Finance Corporation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Capital Corporation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Services, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis US Foundation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                            <sup style="white-space: nowrap">&#160;3</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Pharmaceuticals Corporation
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                            <sup style="white-space: nowrap">&#160;2</sup>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            650
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Advanced Accelerator Applications USA, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Millburn, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              99.23%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Gene Therapies, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Bannockburn, IL
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Technology LLC
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Institutes for BioMedical
Research, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cambridge, MA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cadent Therapeutics
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Cambridge, MA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0.1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Endocyte, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Navigate BioPharma Services, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Carlsbad, CA
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            The Medicines Company
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            East Hanover, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Sandoz Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Princeton, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            25 000
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Oriel Therapeutics, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Durham, NC
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            50.0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Fougera Pharmaceuticals Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Melville, NY
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Eon Labs, Inc.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Princeton, NJ
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            1
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Venezuela</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis de Venezuela, S.A.
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Caracas
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VES</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            0
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Vietnam</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr valign="bottom">
                        <td style=";height:16;width:40%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Novartis Vietnam Company Limited
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td style=";width:30%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            Ho Chi Minh City
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VND</div>
                        </td>
                        <td align="right" style=";width:10%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            70
                          </div>
                        </td>
                        <td style=";width:5%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                        <td align="right" style=";width:1%;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">
                            <span>
                              100%</span>
                          </div>
                        </td>
                        <td align="right" style=";width:1%;"/>
                      </tr>
                      <tr>
                        <td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">In addition, the Group is represented by subsidiaries and associated companies with total assets or net sales to third parties below USD 25 million in the following countries: Bosnia and Herzegovina, Bulgaria, Cameroon, Dominican Republic, Ghana, Guatemala, Ivory Coast, Kazakhstan, Kenya, Kuwait, North Macedonia, Nigeria, Peru, Senegal and Uruguay.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;1&#160;</sup> Share capital may not reflect the taxable share capital and does not include any paid-in surplus.</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;2&#160;</sup> Significant subsidiary under SEC Regulation S-X Rule 1-02(w)</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;">
                            <sup>&#160;3&#160;</sup> Fully consolidated Foundation</div>
                        </td>
                      </tr>
                      <tr valign="bottom">
                        <td colspan="10" style=";height:10px;">
                          <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">m = million; bn = billion</div>
                        </td>
                      </tr>
                    </table>
                  </div>
                </div>

                <div/>
              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859610896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant accounting policies (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>SFr / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share</a></td>
<td class="nump">SFr 0.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571853429904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant transactions (Details)<br> &#8364; in Millions, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 17, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 22, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 08, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 06, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 23, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>SFr / shares</div>
</th>
<th class="th"><div>Feb. 10, 2021</div></th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 06, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,077,000,000<span></span>
</td>
<td class="nump">$ 735,000,000<span></span>
</td>
<td class="nump">$ 10,173,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,053,000,000)<span></span>
</td>
<td class="num">(673,000,000)<span></span>
</td>
<td class="num">(792,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,644,000,000<span></span>
</td>
<td class="nump">34,182,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Revenue from sale of goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,545,000,000<span></span>
</td>
<td class="nump">51,626,000,000<span></span>
</td>
<td class="nump">48,659,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,485,000,000<span></span>
</td>
<td class="nump">25,523,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation, property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,163,000,000<span></span>
</td>
<td class="nump">1,208,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Revenue from sale of goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,121,000,000<span></span>
</td>
<td class="nump">42,790,000,000<span></span>
</td>
<td class="nump">39,805,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Revenue from sale of goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,454,000,000<span></span>
</td>
<td class="nump">9,811,000,000<span></span>
</td>
<td class="nump">9,835,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Revenue from sale of goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,030,000,000)<span></span>
</td>
<td class="num">(975,000,000)<span></span>
</td>
<td class="num">$ (981,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember', window );">Roche Holding AG, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations', window );">Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfBearerShares', window );">Number of bearer shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainOnDivestmentOfInterestsInAssociatedCompanies', window );">Gain on divestment of interests in associated companies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,556,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SandozMember', window );">Sandoz | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DivestmentDateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, divestment-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation, property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation, intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment loss recognised in profit or loss, intangible assets and goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (42,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_AspenGlobalIncorporatedMember', window );">Aspen Global Incorporated | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 324,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 294.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment', window );">Portion of consideration paid consisting of cash and cash equivalents upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(303,000,000)<span></span>
</td>
<td class="num">&#8364; (274.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherNetAssets', window );">Other net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialMilestoneMaximumPayments', window );">Potential milestone maximum payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,000,000<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CustomaryPurchasePriceAdjustment', window );">Customary purchase price adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">&#8364; 27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Contingent consideration recognised as of acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 47.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_TheMedicinesCompanyMember', window );">The Medicines Company | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents', window );">Portion of consideration paid (received) consisting of cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,600,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashOfferPerOrdinaryShare', window );">Cash offer per ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_GlaxoSmithKlinePlcGSKMember', window );">GlaxoSmithKline plc (GSK) | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment', window );">Portion of consideration paid consisting of cash and cash equivalents upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(350,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfBrandsInPortfolioToAcquire', window );">Number of brands in portfolio to acquire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfMarketsForTheAcquiredBrands', window );">Number of markets for the acquired brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialMilestoneMaximumPayments', window );">Potential milestone maximum payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashTransferred', window );">Cash transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Contingent consideration recognised as of acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=nvs_GyroscopeTherapeuticsHoldingsPlcMember', window );">Gyroscope Therapeutics Holdings plc. | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Consideration transferred, acquisition-date fair value</a></td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment', window );">Portion of consideration paid consisting of cash and cash equivalents upfront payment</a></td>
<td class="num">(800,000,000)<span></span>
</td>
<td class="num">$ (800,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Identifiable assets acquired (liabilities assumed)</a></td>
<td class="nump">900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalRecognitionGoodwill', window );">Additional recognition, goodwill</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Deferred tax liability (asset)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets other than goodwill</a></td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialMilestoneMaximumPayments', window );">Potential milestone maximum payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate', window );">Contingent consideration recognised as of acquisition date</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | The Medicines Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalRecognitionGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional goodwill recognised, except goodwill included in a disposal group that, on acquisition, meets the criteria to be classified as held for sale in accordance with IFRS 5. [Refer: Goodwill; Disposal groups classified as held for sale [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B67<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B67_d_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalRecognitionGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph f<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_f_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_g_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets and goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of consideration paid or received, consisting of cash and cash equivalents, in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]; Cash and cash equivalents; Consideration paid (received)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 40<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_40_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the disposal of non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer: Discontinued operations [member]; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashOfferPerOrdinaryShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This expresses the amount of cash Novartis paid to the owners of AAA per ordinary share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashOfferPerOrdinaryShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CustomaryPurchasePriceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CustomaryPurchasePriceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DivestmentDateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DivestmentDateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GainOnDivestmentOfInterestsInAssociatedCompanies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GainOnDivestmentOfInterestsInAssociatedCompanies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfBearerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfBearerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfBrandsInPortfolioToAcquire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfBrandsInPortfolioToAcquire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfMarketsForTheAcquiredBrands">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfMarketsForTheAcquiredBrands</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PotentialMilestoneMaximumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PotentialMilestoneMaximumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AspenGlobalIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AspenGlobalIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_TheMedicinesCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_TheMedicinesCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_GlaxoSmithKlinePlcGSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_GlaxoSmithKlinePlcGSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_GyroscopeTherapeuticsHoldingsPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_GyroscopeTherapeuticsHoldingsPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862672784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfBusinessUnits', window );">Number of Business Units</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfCommercialOrganizationalUnits', window );">Number of commercial organizational units</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfFranchises', window );">Number of Franchises</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfBusinessUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfBusinessUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfCommercialOrganizationalUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfCommercialOrganizationalUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfFranchises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfFranchises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571855756240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 50,545<span></span>
</td>
<td class="nump">$ 51,626<span></span>
</td>
<td class="nump">$ 48,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">50,545<span></span>
</td>
<td class="nump">51,626<span></span>
</td>
<td class="nump">48,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,283<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
<td class="nump">1,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="num">(15,486)<span></span>
</td>
<td class="num">(15,867)<span></span>
</td>
<td class="num">(15,121)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="nump">36,342<span></span>
</td>
<td class="nump">37,010<span></span>
</td>
<td class="nump">34,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="num">(14,253)<span></span>
</td>
<td class="num">(14,886)<span></span>
</td>
<td class="num">(14,197)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(9,996)<span></span>
</td>
<td class="num">(9,540)<span></span>
</td>
<td class="num">(8,980)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">1,852<span></span>
</td>
<td class="nump">1,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expense</a></td>
<td class="num">(3,701)<span></span>
</td>
<td class="num">(2,747)<span></span>
</td>
<td class="num">(3,190)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income</a></td>
<td class="nump">9,197<span></span>
</td>
<td class="nump">11,689<span></span>
</td>
<td class="nump">10,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">(Loss)/income from associated companies</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">15,339<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="num">(837)<span></span>
</td>
<td class="num">(811)<span></span>
</td>
<td class="num">(869)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other financial income and expense</a></td>
<td class="nump">20<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income before taxes</a></td>
<td class="nump">8,371<span></span>
</td>
<td class="nump">26,137<span></span>
</td>
<td class="nump">9,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income taxes</a></td>
<td class="num">(1,416)<span></span>
</td>
<td class="num">(2,119)<span></span>
</td>
<td class="num">(1,807)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net income</a></td>
<td class="nump">6,955<span></span>
</td>
<td class="nump">24,018<span></span>
</td>
<td class="nump">8,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>Attributable to</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Shareholders of Novartis AG</a></td>
<td class="nump">6,955<span></span>
</td>
<td class="nump">24,021<span></span>
</td>
<td class="nump">8,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Non-controlling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">41,296<span></span>
</td>
<td class="nump">41,995<span></span>
</td>
<td class="nump">39,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments', window );">Sales to other segments</a></td>
<td class="nump">825<span></span>
</td>
<td class="nump">795<span></span>
</td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">42,121<span></span>
</td>
<td class="nump">42,790<span></span>
</td>
<td class="nump">39,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,249<span></span>
</td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="num">(11,569)<span></span>
</td>
<td class="num">(11,751)<span></span>
</td>
<td class="num">(10,927)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="nump">31,801<span></span>
</td>
<td class="nump">32,218<span></span>
</td>
<td class="nump">29,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="num">(11,679)<span></span>
</td>
<td class="num">(12,306)<span></span>
</td>
<td class="num">(11,657)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(9,172)<span></span>
</td>
<td class="num">(8,641)<span></span>
</td>
<td class="num">(8,118)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">1,149<span></span>
</td>
<td class="nump">922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expense</a></td>
<td class="num">(2,695)<span></span>
</td>
<td class="num">(1,732)<span></span>
</td>
<td class="num">(1,871)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income</a></td>
<td class="nump">8,786<span></span>
</td>
<td class="nump">10,688<span></span>
</td>
<td class="nump">9,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">(Loss)/income from associated companies</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">9,249<span></span>
</td>
<td class="nump">9,631<span></span>
</td>
<td class="nump">9,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments', window );">Sales to other segments</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="nump">9,454<span></span>
</td>
<td class="nump">9,811<span></span>
</td>
<td class="nump">9,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="num">(4,978)<span></span>
</td>
<td class="num">(5,147)<span></span>
</td>
<td class="num">(5,252)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="nump">4,504<span></span>
</td>
<td class="nump">4,725<span></span>
</td>
<td class="nump">4,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="num">(2,062)<span></span>
</td>
<td class="num">(2,062)<span></span>
</td>
<td class="num">(2,076)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(824)<span></span>
</td>
<td class="num">(899)<span></span>
</td>
<td class="num">(862)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expense</a></td>
<td class="num">(273)<span></span>
</td>
<td class="num">(397)<span></span>
</td>
<td class="num">(831)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income</a></td>
<td class="nump">1,448<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">(Loss)/income from associated companies</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments', window );">Sales to other segments</a></td>
<td class="num">(1,030)<span></span>
</td>
<td class="num">(975)<span></span>
</td>
<td class="num">(981)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Net sales</a></td>
<td class="num">(1,030)<span></span>
</td>
<td class="num">(975)<span></span>
</td>
<td class="num">(981)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of goods sold</a></td>
<td class="nump">1,061<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
<td class="nump">1,058<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administration</a></td>
<td class="num">(512)<span></span>
</td>
<td class="num">(518)<span></span>
</td>
<td class="num">(464)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">470<span></span>
</td>
<td class="nump">644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expense</a></td>
<td class="num">(733)<span></span>
</td>
<td class="num">(618)<span></span>
</td>
<td class="num">(488)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating income</a></td>
<td class="num">(1,037)<span></span>
</td>
<td class="num">(599)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">(Loss)/income from associated companies</a></td>
<td class="num">$ (9)<span></span>
</td>
<td class="nump">$ 15,332<span></span>
</td>
<td class="nump">$ 670<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByFunction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByFunction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2022-03-24<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39M<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsSalesToOtherSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsSalesToOtherSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571842371840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income</a></td>
<td class="nump">$ 379<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet', window );">Impairment charges and fair value gains on financial assets, net</a></td>
<td class="num">(260)<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Equity-based compensation of Novartis equity plans</a></td>
<td class="num">(1,048)<span></span>
</td>
<td class="num">(979)<span></span>
</td>
<td class="num">(958)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_RestructuringProvisionMember', window );">Restructuring provision [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Additions to restructuring provisions</a></td>
<td class="num">(1,368)<span></span>
</td>
<td class="num">(328)<span></span>
</td>
<td class="num">(354)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember', window );">Right-of-use assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(318)<span></span>
</td>
<td class="num">(330)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsAndGoodwillMember', window );">Intangible assets and goodwill [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(3,982)<span></span>
</td>
<td class="num">(3,903)<span></span>
</td>
<td class="num">(3,462)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">(1,326)<span></span>
</td>
<td class="num">(403)<span></span>
</td>
<td class="num">(914)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember', window );">Property, plant and equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(1,163)<span></span>
</td>
<td class="num">(1,208)<span></span>
</td>
<td class="num">(1,318)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">(407)<span></span>
</td>
<td class="num">(281)<span></span>
</td>
<td class="num">(440)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet', window );">Impairment charges and fair value gains on financial assets, net</a></td>
<td class="num">(134)<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Equity-based compensation of Novartis equity plans</a></td>
<td class="num">(706)<span></span>
</td>
<td class="num">(721)<span></span>
</td>
<td class="num">(714)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Restructuring provision [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Additions to restructuring provisions</a></td>
<td class="num">(1,069)<span></span>
</td>
<td class="num">(240)<span></span>
</td>
<td class="num">(217)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Right-of-use assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(252)<span></span>
</td>
<td class="num">(265)<span></span>
</td>
<td class="num">(273)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Intangible assets and goodwill [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(3,728)<span></span>
</td>
<td class="num">(3,638)<span></span>
</td>
<td class="num">(3,080)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">(1,299)<span></span>
</td>
<td class="num">(367)<span></span>
</td>
<td class="num">(768)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Property, plant and equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(837)<span></span>
</td>
<td class="num">(859)<span></span>
</td>
<td class="num">(912)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">(407)<span></span>
</td>
<td class="num">(271)<span></span>
</td>
<td class="num">(324)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Equity-based compensation of Novartis equity plans</a></td>
<td class="num">(62)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Restructuring provision [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Additions to restructuring provisions</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Right-of-use assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Intangible assets and goodwill [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(222)<span></span>
</td>
<td class="num">(238)<span></span>
</td>
<td class="num">(370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(141)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Property, plant and equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(204)<span></span>
</td>
<td class="num">(210)<span></span>
</td>
<td class="num">(282)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet', window );">Impairment charges and fair value gains on financial assets, net</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Equity-based compensation of Novartis equity plans</a></td>
<td class="num">(280)<span></span>
</td>
<td class="num">(193)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate | Restructuring provision [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Additions to restructuring provisions</a></td>
<td class="num">(259)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate | Right-of-use assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate | Intangible assets and goodwill [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate | Property, plant and equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation and amortisation expense</a></td>
<td class="num">$ (122)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
<td class="num">$ (124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional other provisions made. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss or reversal of impairment loss recognised in profit or loss. [Refer: Impairment loss recognised in profit or loss; Reversal of impairment loss recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_RestructuringProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=ifrs-full_RestructuringProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsAndGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsAndGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864823968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">$ 117,453<span></span>
</td>
<td class="nump">$ 131,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="num">(58,030)<span></span>
</td>
<td class="num">(63,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">59,423<span></span>
</td>
<td class="nump">67,822<span></span>
</td>
<td class="nump">$ 56,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt</a></td>
<td class="nump">7,245<span></span>
</td>
<td class="nump">868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NetOperatingAssets', window );">Net operating assets</a></td>
<td class="nump">66,668<span></span>
</td>
<td class="nump">68,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">10,764<span></span>
</td>
<td class="nump">11,545<span></span>
</td>
<td class="nump">12,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="nump">1,219<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1,431<span></span>
</td>
<td class="nump">1,561<span></span>
</td>
<td class="nump">$ 1,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill</a></td>
<td class="nump">60,945<span></span>
</td>
<td class="nump">63,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions to intangible assets and goodwill</a></td>
<td class="nump">2,093<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investment in associated companies</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AdditionsToInvestmentInAssociatedCompanies', window );">Additions to investment in associated companies</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments</a></td>
<td class="nump">18,930<span></span>
</td>
<td class="nump">28,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments</a></td>
<td class="nump">26,175<span></span>
</td>
<td class="nump">29,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrentIncomeTaxAndDeferredTaxLiabilities', window );">Current income tax liabilities and deferred tax liabilities</a></td>
<td class="nump">5,219<span></span>
</td>
<td class="nump">5,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">75,510<span></span>
</td>
<td class="nump">79,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="num">(16,966)<span></span>
</td>
<td class="num">(15,929)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NetOperatingAssets', window );">Net operating assets</a></td>
<td class="nump">58,544<span></span>
</td>
<td class="nump">63,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">8,488<span></span>
</td>
<td class="nump">9,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="nump">842<span></span>
</td>
<td class="nump">991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1,233<span></span>
</td>
<td class="nump">1,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill</a></td>
<td class="nump">51,357<span></span>
</td>
<td class="nump">53,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions to intangible assets and goodwill</a></td>
<td class="nump">1,791<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investment in associated companies</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AdditionsToInvestmentInAssociatedCompanies', window );">Additions to investment in associated companies</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">16,078<span></span>
</td>
<td class="nump">16,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="num">(3,710)<span></span>
</td>
<td class="num">(3,632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NetOperatingAssets', window );">Net operating assets</a></td>
<td class="nump">12,368<span></span>
</td>
<td class="nump">12,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">1,861<span></span>
</td>
<td class="nump">1,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill</a></td>
<td class="nump">9,230<span></span>
</td>
<td class="nump">9,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions to intangible assets and goodwill</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investment in associated companies</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">25,865<span></span>
</td>
<td class="nump">36,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="num">(37,354)<span></span>
</td>
<td class="num">(44,412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt</a></td>
<td class="nump">7,245<span></span>
</td>
<td class="nump">868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NetOperatingAssets', window );">Net operating assets</a></td>
<td class="num">(4,244)<span></span>
</td>
<td class="num">(7,161)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">415<span></span>
</td>
<td class="nump">476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions to intangible assets and goodwill</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investment in associated companies</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AdditionsToInvestmentInAssociatedCompanies', window );">Additions to investment in associated companies</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments</a></td>
<td class="nump">18,930<span></span>
</td>
<td class="nump">28,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments</a></td>
<td class="nump">26,175<span></span>
</td>
<td class="nump">29,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrentIncomeTaxAndDeferredTaxLiabilities', window );">Current income tax liabilities and deferred tax liabilities</a></td>
<td class="nump">$ 5,219<span></span>
</td>
<td class="nump">$ 5,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net debt of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AdditionsToInvestmentInAssociatedCompanies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AdditionsToInvestmentInAssociatedCompanies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrentIncomeTaxAndDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrentIncomeTaxAndDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialDebtsAndDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialDebtsAndDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864066224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 4) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 50,545<span></span>
</td>
<td class="nump">$ 51,626<span></span>
</td>
<td class="nump">$ 48,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 73,483<span></span>
</td>
<td class="nump">$ 77,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember', window );">Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 970<span></span>
</td>
<td class="nump">$ 873<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 23,708<span></span>
</td>
<td class="nump">$ 25,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 17,653<span></span>
</td>
<td class="nump">$ 16,818<span></span>
</td>
<td class="nump">$ 16,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 35,353<span></span>
</td>
<td class="nump">$ 37,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">48.00%<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 2,257<span></span>
</td>
<td class="nump">$ 2,522<span></span>
</td>
<td class="nump">$ 2,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 3,188<span></span>
</td>
<td class="nump">$ 3,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 4,278<span></span>
</td>
<td class="nump">$ 4,870<span></span>
</td>
<td class="nump">$ 4,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 2,229<span></span>
</td>
<td class="nump">$ 2,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 2,205<span></span>
</td>
<td class="nump">$ 2,683<span></span>
</td>
<td class="nump">$ 2,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 165<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 3,128<span></span>
</td>
<td class="nump">$ 3,052<span></span>
</td>
<td class="nump">$ 2,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 599<span></span>
</td>
<td class="nump">$ 703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 20,054<span></span>
</td>
<td class="nump">$ 20,808<span></span>
</td>
<td class="nump">$ 19,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 8,241<span></span>
</td>
<td class="nump">$ 7,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SelectedNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SelectedNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies. As percent of total selected non-current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571855770976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 5) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 50,545<span></span>
</td>
<td class="nump">$ 51,626<span></span>
</td>
<td class="nump">$ 48,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 73,483<span></span>
</td>
<td class="nump">$ 77,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 18,467<span></span>
</td>
<td class="nump">$ 20,197<span></span>
</td>
<td class="nump">$ 18,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 35,896<span></span>
</td>
<td class="nump">$ 37,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_AmericasMember', window );">Americas [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 21,536<span></span>
</td>
<td class="nump">$ 20,463<span></span>
</td>
<td class="nump">$ 19,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">42.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 35,806<span></span>
</td>
<td class="nump">$ 37,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember', window );">Asia/Africa/Australasia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 10,542<span></span>
</td>
<td class="nump">$ 10,966<span></span>
</td>
<td class="nump">$ 10,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales', window );">Net sales (in % of total net sales)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssets', window );">Total of selected non-current assets</a></td>
<td class="nump">$ 1,781<span></span>
</td>
<td class="nump">$ 2,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets', window );">Selected non-current assets (in % of total selected non-current assets)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SelectedNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SelectedNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies. As percent of total selected non-current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_AmericasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_AmericasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571861657456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 6)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CustomersWithNetSalesOverFivePercent', window );">Customers with net sales over five percent</a></td>
<td class="text">

                  The Group&#8217;s largest, second-largest and third-largest customers account for approximately 16%, 11% and 7% of net sales to third parties, respectively (2021: 17%, 11% and 6%, respectively; 2020: 17%, 11% and 6%, respectively). All segments had sales to these customers in 2022, 2021 and 2020.
                  The highest amounts of trade receivables outstanding were for these same three customers and amounted to approximately 16%, 14% and 7%, respectively, of the trade receivables at December 31, 2022 (2021: 16%, 12% and 7%, respectively).

              <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=nvs_LargestCustomerMember', window );">Largest customer [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PercentageOfEntitysTradeReceivable', window );">Percentage of entitys trade receivable</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=nvs_SecondLargestCustomerMember', window );">Second largest customer [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PercentageOfEntitysTradeReceivable', window );">Percentage of entitys trade receivable</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=nvs_ThirdLargestCustomerMember', window );">Third largest customer [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PercentageOfEntitysTradeReceivable', window );">Percentage of entitys trade receivable</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMajorCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMajorCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfEntitysRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of the entity's revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfEntitysRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CustomersWithNetSalesOverFivePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CustomersWithNetSalesOverFivePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PercentageOfEntitysTradeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PercentageOfEntitysTradeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=nvs_LargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=nvs_LargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=nvs_SecondLargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=nvs_SecondLargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=nvs_ThirdLargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=nvs_ThirdLargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571852847616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures - Net sales by region (Details 7) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 50,545<span></span>
</td>
<td class="nump">$ 51,626<span></span>
</td>
<td class="nump">$ 48,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember', window );">Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 18,467<span></span>
</td>
<td class="nump">$ 20,197<span></span>
</td>
<td class="nump">18,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 17,653<span></span>
</td>
<td class="nump">$ 16,818<span></span>
</td>
<td class="nump">16,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember', window );">Asia/Africa/Australasia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 10,542<span></span>
</td>
<td class="nump">$ 10,966<span></span>
</td>
<td class="nump">10,219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember', window );">Asia/Africa/Australasia [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_CanadaAndLatinAmericaMember', window );">Canada and Latin America [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 3,883<span></span>
</td>
<td class="nump">$ 3,645<span></span>
</td>
<td class="nump">3,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_CanadaAndLatinAmericaMember', window );">Canada and Latin America [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_EstablishedMarketsMember', window );">Established Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 37,008<span></span>
</td>
<td class="nump">$ 38,314<span></span>
</td>
<td class="nump">36,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_EstablishedMarketsMember', window );">Established Markets [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_EmergingGrowthMarketsMember', window );">Emerging Growth Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 13,537<span></span>
</td>
<td class="nump">$ 13,312<span></span>
</td>
<td class="nump">11,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=nvs_EmergingGrowthMarketsMember', window );">Emerging Growth Markets [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 41,296<span></span>
</td>
<td class="nump">$ 41,995<span></span>
</td>
<td class="nump">39,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Europe [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 13,554<span></span>
</td>
<td class="nump">$ 14,919<span></span>
</td>
<td class="nump">13,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Europe [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 15,899<span></span>
</td>
<td class="nump">$ 14,999<span></span>
</td>
<td class="nump">14,342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Asia/Africa/Australasia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 8,929<span></span>
</td>
<td class="nump">$ 9,304<span></span>
</td>
<td class="nump">8,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Asia/Africa/Australasia [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Canada and Latin America [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 2,914<span></span>
</td>
<td class="nump">$ 2,773<span></span>
</td>
<td class="nump">2,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Canada and Latin America [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 30,548<span></span>
</td>
<td class="nump">$ 31,459<span></span>
</td>
<td class="nump">29,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Markets [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Emerging Growth Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 10,748<span></span>
</td>
<td class="nump">$ 10,536<span></span>
</td>
<td class="nump">9,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Emerging Growth Markets [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 9,249<span></span>
</td>
<td class="nump">$ 9,631<span></span>
</td>
<td class="nump">9,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Europe [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 4,913<span></span>
</td>
<td class="nump">$ 5,278<span></span>
</td>
<td class="nump">5,231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Europe [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(7.00%)<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,754<span></span>
</td>
<td class="nump">$ 1,819<span></span>
</td>
<td class="nump">2,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | US | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="num">(15.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Asia/Africa/Australasia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,613<span></span>
</td>
<td class="nump">$ 1,662<span></span>
</td>
<td class="nump">1,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Asia/Africa/Australasia [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Canada and Latin America [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 969<span></span>
</td>
<td class="nump">$ 872<span></span>
</td>
<td class="nump">772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Canada and Latin America [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Established Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 6,460<span></span>
</td>
<td class="nump">$ 6,855<span></span>
</td>
<td class="nump">7,089<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Established Markets [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="num">(3.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Emerging Growth Markets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 2,789<span></span>
</td>
<td class="nump">$ 2,776<span></span>
</td>
<td class="nump">$ 2,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Emerging Growth Markets [member] | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_AsiaAfricaAustralasiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_CanadaAndLatinAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_CanadaAndLatinAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_EstablishedMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_EstablishedMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_EmergingGrowthMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_EmergingGrowthMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571854264016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 8) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 50,545<span></span>
</td>
<td class="nump">$ 51,626<span></span>
</td>
<td class="nump">$ 48,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember', window );">Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 41,296<span></span>
</td>
<td class="nump">$ 41,995<span></span>
</td>
<td class="nump">39,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 31,396<span></span>
</td>
<td class="nump">$ 29,754<span></span>
</td>
<td class="nump">25,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Cardiovascular [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 4,756<span></span>
</td>
<td class="nump">$ 3,560<span></span>
</td>
<td class="nump">2,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] | Entresto [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 4,644<span></span>
</td>
<td class="nump">$ 3,548<span></span>
</td>
<td class="nump">2,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] | Leqvio [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 112<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 7,287<span></span>
</td>
<td class="nump">$ 7,205<span></span>
</td>
<td class="nump">6,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Cosentyx [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 4,788<span></span>
</td>
<td class="nump">$ 4,718<span></span>
</td>
<td class="nump">3,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Xolair [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,365<span></span>
</td>
<td class="nump">$ 1,428<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Ilaris [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,133<span></span>
</td>
<td class="nump">$ 1,059<span></span>
</td>
<td class="nump">873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 5,051<span></span>
</td>
<td class="nump">$ 5,007<span></span>
</td>
<td class="nump">4,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Gilenya [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 2,013<span></span>
</td>
<td class="nump">$ 2,787<span></span>
</td>
<td class="nump">3,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(28.00%)<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Zolgensma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,370<span></span>
</td>
<td class="nump">$ 1,351<span></span>
</td>
<td class="nump">920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Kesimpta [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,092<span></span>
</td>
<td class="nump">$ 372<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">194.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Mayzent [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">$ 281<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Aimovig [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 218<span></span>
</td>
<td class="nump">$ 215<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 4,723<span></span>
</td>
<td class="nump">$ 4,101<span></span>
</td>
<td class="nump">3,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Tafinlar + Mekinist [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,770<span></span>
</td>
<td class="nump">$ 1,693<span></span>
</td>
<td class="nump">1,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Kisqali [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,231<span></span>
</td>
<td class="nump">$ 937<span></span>
</td>
<td class="nump">687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Votrient [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 474<span></span>
</td>
<td class="nump">$ 577<span></span>
</td>
<td class="nump">635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(18.00%)<span></span>
</td>
<td class="num">(9.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Lutathera [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 471<span></span>
</td>
<td class="nump">$ 475<span></span>
</td>
<td class="nump">445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Piqray [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">$ 329<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Pluvicto [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Tabrecta [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">48.00%<span></span>
</td>
<td class="nump">157.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 6,452<span></span>
</td>
<td class="nump">$ 6,430<span></span>
</td>
<td class="nump">5,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Promacta/Revolade [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 2,088<span></span>
</td>
<td class="nump">$ 2,016<span></span>
</td>
<td class="nump">1,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Tasigna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,923<span></span>
</td>
<td class="nump">$ 2,060<span></span>
</td>
<td class="nump">1,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(7.00%)<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Jakavi [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,561<span></span>
</td>
<td class="nump">$ 1,595<span></span>
</td>
<td class="nump">1,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Kymriah [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 536<span></span>
</td>
<td class="nump">$ 587<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Adakveo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 164<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">56.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Scemblix [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(67.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 3,127<span></span>
</td>
<td class="nump">$ 3,451<span></span>
</td>
<td class="nump">3,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,874<span></span>
</td>
<td class="nump">$ 2,160<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(13.00%)<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Xiidra [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 487<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Ultibro Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 479<span></span>
</td>
<td class="nump">$ 584<span></span>
</td>
<td class="nump">623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(18.00%)<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Beovu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Other Respiratory [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">104.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 9,900<span></span>
</td>
<td class="nump">$ 12,241<span></span>
</td>
<td class="nump">13,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(19.00%)<span></span>
</td>
<td class="num">(11.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Sandostatin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,238<span></span>
</td>
<td class="nump">$ 1,413<span></span>
</td>
<td class="nump">1,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(12.00%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Galvus Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 859<span></span>
</td>
<td class="nump">$ 1,092<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(9.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Gleevec/Glivec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 745<span></span>
</td>
<td class="nump">$ 1,024<span></span>
</td>
<td class="nump">1,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(27.00%)<span></span>
</td>
<td class="num">(14.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Exforge Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 743<span></span>
</td>
<td class="nump">$ 901<span></span>
</td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(18.00%)<span></span>
</td>
<td class="num">(8.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Diovan Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 652<span></span>
</td>
<td class="nump">$ 773<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(16.00%)<span></span>
</td>
<td class="num">(23.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Afinitor/Votubia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 512<span></span>
</td>
<td class="nump">$ 938<span></span>
</td>
<td class="nump">1,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(45.00%)<span></span>
</td>
<td class="num">(13.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Voltaren/Cataflam [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(10.00%)<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Zortress/Certican [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 329<span></span>
</td>
<td class="nump">$ 431<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(24.00%)<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Exjade/Jadenu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">$ 563<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(43.00%)<span></span>
</td>
<td class="num">(14.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Neoral/Sandimmun(e) [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 310<span></span>
</td>
<td class="nump">$ 368<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(16.00%)<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Contract manufacturing [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Other [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 3,641<span></span>
</td>
<td class="nump">$ 4,257<span></span>
</td>
<td class="nump">$ 4,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(14.00%)<span></span>
</td>
<td class="num">(14.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BrandsAxis=nvs_PromotedBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BrandsAxis=nvs_PromotedBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_CardiovascularMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_CardiovascularMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_EntrestoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_EntrestoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_LeqvioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_LeqvioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_CosentyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_CosentyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_XolairMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_XolairMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_IlarisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_IlarisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GilenyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GilenyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_KesimptaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_KesimptaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_MayzentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_MayzentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_AimovigMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_AimovigMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_SolidTumorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_SolidTumorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TafinlarMekinistMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TafinlarMekinistMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_KisqaliMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_KisqaliMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_LutatheraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_LutatheraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_PiqrayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_PiqrayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_PluvictoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_PluvictoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TabrectaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TabrectaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_HematologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_HematologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_PromactaRevoladeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_PromactaRevoladeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_JakaviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_JakaviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_KymriahMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_KymriahMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_AdakveoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_AdakveoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ScemblixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ScemblixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_OtherPromotedBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_OtherPromotedBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_XiidraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_XiidraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_UltibroGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_UltibroGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_BeovuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_BeovuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_OtherRespiratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_OtherRespiratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BrandsAxis=nvs_EstablishedBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BrandsAxis=nvs_EstablishedBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_EstablishedBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_EstablishedBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_SandostatinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_SandostatinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GalvusGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GalvusGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GleevecGlivecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GleevecGlivecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_DiovanGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_DiovanGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_AfinitorVotubiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_AfinitorVotubiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_VoltarenCataflamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_VoltarenCataflamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ZortressCerticanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ZortressCerticanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ExjadeJadenuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ExjadeJadenuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_NeoralSandimmunEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_NeoralSandimmunEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ContractManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ContractManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571849917392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures - Top 20 (Details 9) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 50,545<span></span>
</td>
<td class="nump">$ 51,626<span></span>
</td>
<td class="nump">$ 48,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">17,653<span></span>
</td>
<td class="nump">16,818<span></span>
</td>
<td class="nump">16,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">41,296<span></span>
</td>
<td class="nump">41,995<span></span>
</td>
<td class="nump">39,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Top 20 products [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">32,137<span></span>
</td>
<td class="nump">32,664<span></span>
</td>
<td class="nump">29,916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of portfolio [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">9,159<span></span>
</td>
<td class="nump">9,331<span></span>
</td>
<td class="nump">9,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] | Top 20 products [member] | Entresto [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">4,644<span></span>
</td>
<td class="nump">3,548<span></span>
</td>
<td class="nump">2,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Cosentyx [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">4,788<span></span>
</td>
<td class="nump">4,718<span></span>
</td>
<td class="nump">3,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Xolair [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,365<span></span>
</td>
<td class="nump">1,428<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Ilaris [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,133<span></span>
</td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">2,013<span></span>
</td>
<td class="nump">2,787<span></span>
</td>
<td class="nump">3,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,370<span></span>
</td>
<td class="nump">1,351<span></span>
</td>
<td class="nump">920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Kesimpta [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Tafinlar + Mekinist [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,770<span></span>
</td>
<td class="nump">1,693<span></span>
</td>
<td class="nump">1,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Kisqali [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,231<span></span>
</td>
<td class="nump">937<span></span>
</td>
<td class="nump">687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Votrient [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Promacta/Revolade [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">2,088<span></span>
</td>
<td class="nump">2,016<span></span>
</td>
<td class="nump">1,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Tasigna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,923<span></span>
</td>
<td class="nump">2,060<span></span>
</td>
<td class="nump">1,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Jakavi [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,561<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
<td class="nump">1,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Top 20 products [member] | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,874<span></span>
</td>
<td class="nump">2,160<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Top 20 products [member] | Ultibro Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Sandostatin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,238<span></span>
</td>
<td class="nump">1,413<span></span>
</td>
<td class="nump">1,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Galvus Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">859<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Gleevec/Glivec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">1,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exforge Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">743<span></span>
</td>
<td class="nump">901<span></span>
</td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Diovan Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">652<span></span>
</td>
<td class="nump">773<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Afinitor/Votubia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">512<span></span>
</td>
<td class="nump">938<span></span>
</td>
<td class="nump">1,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exjade/Jadenu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">15,899<span></span>
</td>
<td class="nump">14,999<span></span>
</td>
<td class="nump">14,342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Top 20 products [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">12,753<span></span>
</td>
<td class="nump">11,688<span></span>
</td>
<td class="nump">11,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Rest of portfolio [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">3,146<span></span>
</td>
<td class="nump">3,311<span></span>
</td>
<td class="nump">3,216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Cardiovascular [member] | Top 20 products [member] | Entresto [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">2,354<span></span>
</td>
<td class="nump">1,712<span></span>
</td>
<td class="nump">1,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Cosentyx [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">2,770<span></span>
</td>
<td class="nump">2,883<span></span>
</td>
<td class="nump">2,516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Ilaris [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">501<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,153<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">1,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">434<span></span>
</td>
<td class="nump">469<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Kesimpta [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Tafinlar + Mekinist [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">678<span></span>
</td>
<td class="nump">606<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Kisqali [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">472<span></span>
</td>
<td class="nump">339<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Votrient [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Promacta/Revolade [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,083<span></span>
</td>
<td class="nump">947<span></span>
</td>
<td class="nump">833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Tasigna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">877<span></span>
</td>
<td class="nump">882<span></span>
</td>
<td class="nump">859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Established Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Sandostatin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">843<span></span>
</td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Gleevec/Glivec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exforge Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Diovan Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Afinitor/Votubia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">521<span></span>
</td>
<td class="nump">644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exjade/Jadenu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">25,397<span></span>
</td>
<td class="nump">26,996<span></span>
</td>
<td class="nump">24,671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Top 20 products [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">19,384<span></span>
</td>
<td class="nump">20,976<span></span>
</td>
<td class="nump">18,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Rest of portfolio [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">6,013<span></span>
</td>
<td class="nump">6,020<span></span>
</td>
<td class="nump">5,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Cardiovascular [member] | Top 20 products [member] | Entresto [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">2,290<span></span>
</td>
<td class="nump">1,836<span></span>
</td>
<td class="nump">1,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Cosentyx [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">2,018<span></span>
</td>
<td class="nump">1,835<span></span>
</td>
<td class="nump">1,479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Xolair [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,365<span></span>
</td>
<td class="nump">1,428<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Ilaris [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">563<span></span>
</td>
<td class="nump">558<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">860<span></span>
</td>
<td class="nump">1,360<span></span>
</td>
<td class="nump">1,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">936<span></span>
</td>
<td class="nump">882<span></span>
</td>
<td class="nump">461<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Kesimpta [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Tafinlar + Mekinist [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">1,087<span></span>
</td>
<td class="nump">973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Kisqali [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">759<span></span>
</td>
<td class="nump">598<span></span>
</td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Votrient [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Promacta/Revolade [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">1,069<span></span>
</td>
<td class="nump">905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Tasigna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,046<span></span>
</td>
<td class="nump">1,178<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Jakavi [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,561<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
<td class="nump">1,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Other Promoted Brands [member] | Top 20 products [member] | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,874<span></span>
</td>
<td class="nump">2,160<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Other Promoted Brands [member] | Top 20 products [member] | Ultibro Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Established Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Sandostatin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">438<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Galvus Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">859<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Gleevec/Glivec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">761<span></span>
</td>
<td class="nump">873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exforge Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">729<span></span>
</td>
<td class="nump">887<span></span>
</td>
<td class="nump">964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Diovan Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">597<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="nump">879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Afinitor/Votubia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">341<span></span>
</td>
<td class="nump">417<span></span>
</td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exjade/Jadenu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">31,396<span></span>
</td>
<td class="nump">29,754<span></span>
</td>
<td class="nump">25,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Cardiovascular [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">4,756<span></span>
</td>
<td class="nump">3,560<span></span>
</td>
<td class="nump">2,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] | Entresto [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">4,644<span></span>
</td>
<td class="nump">3,548<span></span>
</td>
<td class="nump">2,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">7,287<span></span>
</td>
<td class="nump">7,205<span></span>
</td>
<td class="nump">6,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Cosentyx [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">4,788<span></span>
</td>
<td class="nump">4,718<span></span>
</td>
<td class="nump">3,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Xolair [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,365<span></span>
</td>
<td class="nump">1,428<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Ilaris [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,133<span></span>
</td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">5,051<span></span>
</td>
<td class="nump">5,007<span></span>
</td>
<td class="nump">4,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Gilenya [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">2,013<span></span>
</td>
<td class="nump">2,787<span></span>
</td>
<td class="nump">3,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Zolgensma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,370<span></span>
</td>
<td class="nump">1,351<span></span>
</td>
<td class="nump">920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Kesimpta [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">372<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">4,723<span></span>
</td>
<td class="nump">4,101<span></span>
</td>
<td class="nump">3,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Tafinlar + Mekinist [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,770<span></span>
</td>
<td class="nump">1,693<span></span>
</td>
<td class="nump">1,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Kisqali [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,231<span></span>
</td>
<td class="nump">937<span></span>
</td>
<td class="nump">687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Votrient [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">474<span></span>
</td>
<td class="nump">577<span></span>
</td>
<td class="nump">635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">6,452<span></span>
</td>
<td class="nump">6,430<span></span>
</td>
<td class="nump">5,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Promacta/Revolade [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">2,088<span></span>
</td>
<td class="nump">2,016<span></span>
</td>
<td class="nump">1,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Tasigna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,923<span></span>
</td>
<td class="nump">2,060<span></span>
</td>
<td class="nump">1,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Jakavi [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,561<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
<td class="nump">1,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Kymriah [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">536<span></span>
</td>
<td class="nump">587<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Adakveo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">3,127<span></span>
</td>
<td class="nump">3,451<span></span>
</td>
<td class="nump">3,148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,874<span></span>
</td>
<td class="nump">2,160<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Ultibro Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="nump">623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">9,900<span></span>
</td>
<td class="nump">12,241<span></span>
</td>
<td class="nump">13,694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Sandostatin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">1,238<span></span>
</td>
<td class="nump">1,413<span></span>
</td>
<td class="nump">1,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Galvus Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">859<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Gleevec/Glivec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">1,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Exforge Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">743<span></span>
</td>
<td class="nump">901<span></span>
</td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Diovan Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">652<span></span>
</td>
<td class="nump">773<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Afinitor/Votubia [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">512<span></span>
</td>
<td class="nump">938<span></span>
</td>
<td class="nump">1,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Exjade/Jadenu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">563<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Zortress/Certican [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Neoral/Sandimmun(e) [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">310<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Voltaren/Cataflam [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductPortfolioAxis=nvs_Top20ProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductPortfolioAxis=nvs_Top20ProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductPortfolioAxis=nvs_RestOfPortfolioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductPortfolioAxis=nvs_RestOfPortfolioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BrandsAxis=nvs_PromotedBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BrandsAxis=nvs_PromotedBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_CardiovascularMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_CardiovascularMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_EntrestoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_EntrestoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_CosentyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_CosentyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_XolairMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_XolairMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_IlarisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_IlarisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GilenyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GilenyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_KesimptaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_KesimptaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_SolidTumorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_SolidTumorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TafinlarMekinistMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TafinlarMekinistMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_KisqaliMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_KisqaliMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_HematologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_HematologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_PromactaRevoladeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_PromactaRevoladeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_JakaviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_JakaviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_KymriahMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_KymriahMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_OtherPromotedBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_OtherPromotedBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_UltibroGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_UltibroGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BrandsAxis=nvs_EstablishedBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BrandsAxis=nvs_EstablishedBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_EstablishedBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_EstablishedBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_SandostatinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_SandostatinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GalvusGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GalvusGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_GleevecGlivecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_GleevecGlivecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_DiovanGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_DiovanGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_AfinitorVotubiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_AfinitorVotubiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ExjadeJadenuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ExjadeJadenuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=nvs_RestOfTheWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=nvs_RestOfTheWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_AdakveoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_AdakveoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ZortressCerticanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ZortressCerticanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_NeoralSandimmunEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_NeoralSandimmunEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_VoltarenCataflamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_VoltarenCataflamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571861547456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 10) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 50,545<span></span>
</td>
<td class="nump">$ 51,626<span></span>
</td>
<td class="nump">$ 48,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember', window );">Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 9,249<span></span>
</td>
<td class="nump">$ 9,631<span></span>
</td>
<td class="nump">9,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Change to prior year-end [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Retail Generics [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 6,776<span></span>
</td>
<td class="nump">$ 7,092<span></span>
</td>
<td class="nump">7,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Biopharmaceuticals [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 2,093<span></span>
</td>
<td class="nump">$ 2,116<span></span>
</td>
<td class="nump">1,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Anti Infectives [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 380<span></span>
</td>
<td class="nump">$ 423<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent', window );">Net sales, change in %</a></td>
<td class="num">(10.00%)<span></span>
</td>
<td class="num">(11.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Anti Infectives [member] | Anti Infectives sold under Sandoz name [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 777<span></span>
</td>
<td class="nump">$ 707<span></span>
</td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz | Anti Infectives [member] | Total anti-infectives net sales [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_RetailGenericsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_RetailGenericsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_BiopharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_BiopharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FranchiseAxis=nvs_AntiInfectivesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FranchiseAxis=nvs_AntiInfectivesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductPortfolioAxis=nvs_AntiInfectivesSoldUnderSandozNameMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductPortfolioAxis=nvs_AntiInfectivesSoldUnderSandozNameMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductPortfolioAxis=nvs_TotalAntiinfectivesNetSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductPortfolioAxis=nvs_TotalAntiinfectivesNetSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862608976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segmentation of key figures (Details 11) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProfitSharingIncome', window );">Profit sharing income</a></td>
<td class="nump">$ 921<span></span>
</td>
<td class="nump">$ 873<span></span>
</td>
<td class="nump">$ 835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Royalty income</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MilestoneIncome', window );">Milestone income</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherRevenueOther', window );">Other</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,283<span></span>
</td>
<td class="nump">1,251<span></span>
</td>
<td class="nump">1,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProfitSharingIncome', window );">Profit sharing income</a></td>
<td class="nump">921<span></span>
</td>
<td class="nump">873<span></span>
</td>
<td class="nump">835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Royalty income</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MilestoneIncome', window );">Milestone income</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherRevenueOther', window );">Other</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">1,249<span></span>
</td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Royalty income</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MilestoneIncome', window );">Milestone income</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherRevenueOther', window );">Other</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRoyalties', window );">Royalty income</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenues</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MilestoneIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MilestoneIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherRevenueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherRevenueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProfitSharingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProfitSharingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864825392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associated companies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Net income statement effect</a></td>
<td class="num">$ (9)<span></span>
</td>
<td class="nump">$ 15,339<span></span>
</td>
<td class="nump">$ 673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Total comprehensive income effect</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">15,385<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies', window );">Recycling of the Novartis share of other comprehensive income from associated companies</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember', window );">Roche Holding AG, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Net income statement effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,341<span></span>
</td>
<td class="nump">677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Total comprehensive income effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,387<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_OthersAssociatesMember', window );">Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Net income statement effect</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Total comprehensive income effect</a></td>
<td class="num">$ (9)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share of the other comprehensive income of associates and joint ventures accounted for using the equity method that will be reclassified to profit or loss, net of tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39M<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the total comprehensive income of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Joint ventures [member]; Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B16<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B16_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_OthersAssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_OthersAssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571858719424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associated companies (Details 1) - Roche Holding AG, Switzerland - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInAssociate', window );">Proportion of voting rights held in associate</a></td>
<td class="nump">33.30%<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Proportion of ownership interest in associate</a></td>
<td class="nump">6.20%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsReceived', window );">Dividends received</a></td>
<td class="nump">$ 522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainOnDivestmentOfInterestsInAssociatedCompanies', window );">Gain on divestment of interests in associated companies</a></td>
<td class="nump">14,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations', window );">Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations</a></td>
<td class="nump">$ 20,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the disposal of non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer: Discontinued operations [member]; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfVotingPowerHeldInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of the voting rights in an associate held by the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfVotingPowerHeldInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GainOnDivestmentOfInterestsInAssociatedCompanies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GainOnDivestmentOfInterestsInAssociatedCompanies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862767136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Associated companies (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Net income statement effect</a></td>
<td class="num">$ (9)<span></span>
</td>
<td class="nump">$ 15,339<span></span>
</td>
<td class="nump">$ 673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_CumulativeCurrencyTranslationEffectsMember', window );">Cumulative currency translation effects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement', window );">Cumulative currency translation gains/losses recycled through income statement</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember', window );">Roche Holding AG, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ShareOfCurrentYearNetIncome', window );">Novartis share of current year consolidated net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">815<span></span>
</td>
<td class="nump">913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PriorYearAdjustment', window );">Prior year adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets', window );">Amortization of fair value adjustments relating to intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainOnDivestmentOfInterestsInAssociatedCompanies', window );">Gain on divestment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Net income statement effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,341<span></span>
</td>
<td class="nump">677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax', window );">Amortization of fair value adjustments relating to intangible assets tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39M<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GainOnDivestmentOfInterestsInAssociatedCompanies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GainOnDivestmentOfInterestsInAssociatedCompanies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PriorYearAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PriorYearAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ShareOfCurrentYearNetIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ShareOfCurrentYearNetIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_CumulativeCurrencyTranslationEffectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_CumulativeCurrencyTranslationEffectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862301360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest expense and other financial income and expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InterestExpenseAbstract', window );"><strong>Interest expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions', window );">Interest expense</a></td>
<td class="num">$ (669)<span></span>
</td>
<td class="num">$ (651)<span></span>
</td>
<td class="num">$ (708)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions', window );">Expense arising from discounting long-term liabilities and capitalized borrowing costs</a></td>
<td class="num">(108)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Total interest expense</a></td>
<td class="num">$ (837)<span></span>
</td>
<td class="num">$ (811)<span></span>
</td>
<td class="num">$ (869)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised due to the unwinding of the discount on provisions other than provisions from employee benefits, resulting from the effect of the passage of time. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InterestExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InterestExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862480128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest expense and other financial income and expense (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherFinancialIncomeAndExpenseAbstract', window );"><strong>Other financial income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income</a></td>
<td class="nump">$ 379<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromDividends', window );">Other financial income</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceCost', window );">Financial expense</a></td>
<td class="num">(194)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Currency result, net</a></td>
<td class="num">(184)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Total other financial income and expense</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="num">$ (80)<span></span>
</td>
<td class="num">$ (78)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2022-03-24<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends recognised as income. Dividends are distributions of profits to holders of equity investments in proportion to their holdings of a particular class of capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherFinancialIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherFinancialIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571861676112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income before taxes</a></td>
<td class="nump">$ 8,371<span></span>
</td>
<td class="nump">$ 26,137<span></span>
</td>
<td class="nump">$ 9,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember', window );">Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income before taxes</a></td>
<td class="nump">5,986<span></span>
</td>
<td class="nump">22,028<span></span>
</td>
<td class="nump">9,786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Income before taxes</a></td>
<td class="nump">$ 2,385<span></span>
</td>
<td class="nump">$ 4,109<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864825520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax expense (income)</a></td>
<td class="num">$ (2,071)<span></span>
</td>
<td class="num">$ (2,428)<span></span>
</td>
<td class="num">$ (2,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred tax expense (income)</a></td>
<td class="nump">655<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="num">(1,416)<span></span>
</td>
<td class="num">(2,119)<span></span>
</td>
<td class="num">(1,807)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember', window );">Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax expense (income)</a></td>
<td class="num">(617)<span></span>
</td>
<td class="num">(958)<span></span>
</td>
<td class="num">(932)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred tax expense (income)</a></td>
<td class="num">(142)<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="num">(137)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current tax expense (income)</a></td>
<td class="num">(1,454)<span></span>
</td>
<td class="num">(1,470)<span></span>
</td>
<td class="num">(1,168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred tax expense (income)</a></td>
<td class="nump">$ 797<span></span>
</td>
<td class="nump">$ 286<span></span>
</td>
<td class="nump">$ 430<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571855607312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Applicable tax rate</a></td>
<td class="nump">16.80%<span></span>
</td>
<td class="nump">14.80%<span></span>
</td>
<td class="nump">13.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss', window );">Effect of disallowed expenditures</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfTaxLosses', window );">Effect of utilization of tax losses brought forward from prior periods</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TaxRateEffectOfIncomeTaxedAtReducedRates', window );">Effect of income taxed at reduced rates</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfRevenuesExemptFromTaxation', window );">Tax rate effect of revenues exempt from taxation</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(7.50%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TaxRateEffectOfCreditsAndAllowances', window );">Effect of tax credits and allowances</a></td>
<td class="num">(3.80%)<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(2.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability', window );">Effect of release of contingent consideration liability</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectFromChangeInTaxRate', window );">Effect of tax rate change on current and deferred tax assets and liabilities</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EffectOfWriteoffOfDeferredTaxAssets', window );">Effect of derecognition and reversals of derecognition of deferred tax assets</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries', window );">Effect of write down and reversal of write down of investments in subsidiaries</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods', window );">Effect of prior year items</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions', window );">Effective income tax rate reconciliation change in uncertain tax positions</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Effect of other items</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageEffectiveTaxRate', window );">Effective tax rate</a></td>
<td class="nump">16.90%<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
<td class="nump">18.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain', window );">Effect of income not subject to tax on divestment gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense', window );">Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax rate effects, in aggregate, on the reconciliation between the average effective tax rate and the applicable tax rate that the entity does not separately disclose in the reconciliation. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce current tax expense. [Refer: Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 80<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_80_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectFromChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from a change in tax rate. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectFromChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from adjustments for the current tax of prior periods. [Refer: Average effective tax rate; Applicable tax rate; Adjustments for current tax of prior periods]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the expenses not deductible in determining taxable profit. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfRevenuesExemptFromTaxation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from revenue that is exempt from taxation. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfRevenuesExemptFromTaxation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from tax losses. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EffectOfWriteoffOfDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EffectOfWriteoffOfDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TaxRateEffectOfCreditsAndAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TaxRateEffectOfCreditsAndAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TaxRateEffectOfIncomeTaxedAtReducedRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TaxRateEffectOfIncomeTaxedAtReducedRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571855769488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Details)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareLineItems', window );"><strong>Earnings per share [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Profit/loss attributable to shareholders of Novartis AG | $</a></td>
<td class="nump">$ 6,955<span></span>
</td>
<td class="nump">$ 24,021<span></span>
</td>
<td class="nump">$ 8,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares outstanding used in the basic earnings per share</a></td>
<td class="nump">2,181<span></span>
</td>
<td class="nump">2,243<span></span>
</td>
<td class="nump">2,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares', window );">Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of shares in diluted earnings per share</a></td>
<td class="nump">2,197<span></span>
</td>
<td class="nump">2,260<span></span>
</td>
<td class="nump">2,296<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Total basic earnings per share | $ / shares</a></td>
<td class="nump">$ 3.19<span></span>
</td>
<td class="nump">$ 10.71<span></span>
</td>
<td class="nump">$ 3.55<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Total diluted earnings per share | $ / shares</a></td>
<td class="nump">$ 3.17<span></span>
</td>
<td class="nump">$ 10.63<span></span>
</td>
<td class="nump">$ 3.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OptionsExcludedFromTheCalculation', window );">Options excluded from the calculation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of dilutive potential ordinary shares that relate to the assumed exercise of the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OptionsExcludedFromTheCalculation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OptionsExcludedFromTheCalculation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571853236336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Changes in consolidated statements of comprehensive income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations', window );">Net investment hedge</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="num">$ (201)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Net actuarial gains/losses from defined benefit plans, net of taxes</a></td>
<td class="num">(103)<span></span>
</td>
<td class="nump">1,809<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation effects</a></td>
<td class="num">(450)<span></span>
</td>
<td class="num">(4,762)<span></span>
</td>
<td class="nump">3,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Income tax relating to components of other comprehensive income</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnFinancialInstrumentsMember', window );">Fair value adjustments on financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome', window );">Total value adjustments</a></td>
<td class="num">(382)<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRelatedToDivestments', window );">Fair value adjustments related to divestments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at end of period</a></td>
<td class="num">(198)<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnEquitySecuritiesMember', window );">Fair value adjustments on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes', window );">Fair value adjustments on equity securities, net of taxes</a></td>
<td class="num">(382)<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold', window );">Fair value adjustments on equity securities sold, reclassified to retained earnings</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Income tax relating to components of other comprehensive income</a></td>
<td class="nump">81<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnEquitySecuritiesSoldMember', window );">Fair value adjustments on equity securities sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Income tax relating to components of other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_ValueAdjustmentsRelatedToDivestmentsMember', window );">Value adjustments related to divestments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Income tax relating to components of other comprehensive income</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_NetInvestmentHedgeMember', window );">Net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Income tax relating to components of other comprehensive income</a></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_ActuarialLossesFromDefinedBenefitPlansMember', window );">Actuarial gains/losses from defined benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="num">(3,968)<span></span>
</td>
<td class="num">(5,773)<span></span>
</td>
<td class="num">(5,919)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Net actuarial gains/losses from defined benefit plans, net of taxes</a></td>
<td class="num">(104)<span></span>
</td>
<td class="nump">1,808<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome', window );">Total value adjustments</a></td>
<td class="num">(104)<span></span>
</td>
<td class="nump">1,808<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRelatedToDivestments', window );">Fair value adjustments related to divestments</a></td>
<td class="nump">34<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at end of period</a></td>
<td class="num">(4,038)<span></span>
</td>
<td class="num">(3,968)<span></span>
</td>
<td class="num">(5,773)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Income tax relating to components of other comprehensive income</a></td>
<td class="num">(104)<span></span>
</td>
<td class="num">(323)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_CumulativeCurrencyTranslationEffectsMember', window );">Cumulative currency translation effects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="num">(407)<span></span>
</td>
<td class="nump">4,134<span></span>
</td>
<td class="nump">1,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations', window );">Net investment hedge</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="num">(201)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation effects</a></td>
<td class="num">(444)<span></span>
</td>
<td class="num">(4,757)<span></span>
</td>
<td class="nump">3,193<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome', window );">Total value adjustments</a></td>
<td class="num">(353)<span></span>
</td>
<td class="num">(4,541)<span></span>
</td>
<td class="nump">2,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at end of period</a></td>
<td class="num">(760)<span></span>
</td>
<td class="num">(407)<span></span>
</td>
<td class="nump">4,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Income tax relating to components of other comprehensive income</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement', window );">Cumulative currency translation gains/losses recycled through income statement</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember', window );">Total value adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="num">(4,187)<span></span>
</td>
<td class="num">(1,419)<span></span>
</td>
<td class="num">(4,657)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes', window );">Fair value adjustments on equity securities, net of taxes</a></td>
<td class="num">(382)<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations', window );">Net investment hedge</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="num">(201)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Net actuarial gains/losses from defined benefit plans, net of taxes</a></td>
<td class="num">(104)<span></span>
</td>
<td class="nump">1,808<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation effects</a></td>
<td class="num">(444)<span></span>
</td>
<td class="num">(4,757)<span></span>
</td>
<td class="nump">3,193<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome', window );">Total value adjustments</a></td>
<td class="num">(839)<span></span>
</td>
<td class="num">(2,539)<span></span>
</td>
<td class="nump">3,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold', window );">Fair value adjustments on equity securities sold, reclassified to retained earnings</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRelatedToDivestments', window );">Fair value adjustments related to divestments</a></td>
<td class="nump">34<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at end of period</a></td>
<td class="num">(4,996)<span></span>
</td>
<td class="num">(4,187)<span></span>
</td>
<td class="num">(1,419)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember', window );">Non-controlling interests [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Net actuarial gains/losses from defined benefit plans, net of taxes</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation effects</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome', window );">Total value adjustments</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl', window );">Impact of change in ownership of consolidated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at end of period</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=nvs_TotalFairValueAdjustmentsMember', window );">Total fair value adjustments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems', window );"><strong>Changes in consolidated statements of comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at beginning of period</a></td>
<td class="num">(4,220)<span></span>
</td>
<td class="num">(1,448)<span></span>
</td>
<td class="num">(4,686)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes', window );">Fair value adjustments on equity securities, net of taxes</a></td>
<td class="num">(382)<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations', window );">Net investment hedge</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="num">(201)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Net actuarial gains/losses from defined benefit plans, net of taxes</a></td>
<td class="num">(103)<span></span>
</td>
<td class="nump">1,809<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation effects</a></td>
<td class="num">(450)<span></span>
</td>
<td class="num">(4,762)<span></span>
</td>
<td class="nump">3,194<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome', window );">Total value adjustments</a></td>
<td class="num">(844)<span></span>
</td>
<td class="num">(2,543)<span></span>
</td>
<td class="nump">3,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold', window );">Fair value adjustments on equity securities sold, reclassified to retained earnings</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRelatedToDivestments', window );">Fair value adjustments related to divestments</a></td>
<td class="nump">34<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueAdjustmentOnComprehensiveIncome', window );">Value adjustments on comprehensive income at end of period</a></td>
<td class="num">$ (5,034)<span></span>
</td>
<td class="num">$ (4,220)<span></span>
</td>
<td class="num">$ (1,448)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph ab<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_ab&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 90<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_90&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to hedges of net investments in foreign operations. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 39<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=39&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 9<br> -IssueDate 2022-03-24<br> -Paragraph 6.5.13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=9&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_6.5.13_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueAdjustmentsOnFinancialAssetsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueAdjustmentsOnFinancialAssetsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueAdjustmentsRelatedToDivestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueAdjustmentsRelatedToDivestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ValueAdjustmentOnComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ValueAdjustmentOnComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnEquitySecuritiesSoldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_FairValueAdjustmentsOnEquitySecuritiesSoldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_ValueAdjustmentsRelatedToDivestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_ValueAdjustmentsRelatedToDivestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_NetInvestmentHedgeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_NetInvestmentHedgeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_ActuarialLossesFromDefinedBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_ActuarialLossesFromDefinedBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_CumulativeCurrencyTranslationEffectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_CumulativeCurrencyTranslationEffectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_TotalFairValueAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_TotalFairValueAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571842033680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">$ 11,545<span></span>
</td>
<td class="nump">$ 12,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Impact of business combinations</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">1,219<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and derecognitions</a></td>
<td class="num">(155)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge</a></td>
<td class="num">(1,163)<span></span>
</td>
<td class="num">(1,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="num">(414)<span></span>
</td>
<td class="num">(384)<span></span>
</td>
<td class="num">$ (447)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairment charge</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation effects</a></td>
<td class="num">(288)<span></span>
</td>
<td class="num">(509)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">10,764<span></span>
</td>
<td class="nump">11,545<span></span>
</td>
<td class="nump">12,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment', window );">Commitments for purchases of property, plant and equipment</a></td>
<td class="nump">549<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingCostsCapitalised', window );">Capitalized borrowing costs</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">27,147<span></span>
</td>
<td class="nump">28,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">24,873<span></span>
</td>
<td class="nump">27,147<span></span>
</td>
<td class="nump">28,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(15,602)<span></span>
</td>
<td class="num">(15,955)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(14,109)<span></span>
</td>
<td class="num">(15,602)<span></span>
</td>
<td class="num">(15,955)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">485<span></span>
</td>
<td class="nump">536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and derecognitions</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairment charge</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation effects</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">442<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="nump">536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember', window );">Land | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">451<span></span>
</td>
<td class="nump">492<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember', window );">Land | Accumulated depreciation, amortisation and impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">6,075<span></span>
</td>
<td class="nump">6,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="nump">297<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and derecognitions</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge</a></td>
<td class="num">(437)<span></span>
</td>
<td class="num">(453)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="num">(351)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation effects</a></td>
<td class="num">(166)<span></span>
</td>
<td class="num">(203)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">5,493<span></span>
</td>
<td class="nump">6,075<span></span>
</td>
<td class="nump">6,570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember', window );">Buildings | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">11,819<span></span>
</td>
<td class="nump">12,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">11,396<span></span>
</td>
<td class="nump">11,819<span></span>
</td>
<td class="nump">12,377<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember', window );">Buildings | Accumulated depreciation, amortisation and impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(5,744)<span></span>
</td>
<td class="num">(5,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(5,903)<span></span>
</td>
<td class="num">(5,744)<span></span>
</td>
<td class="num">(5,807)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">1,443<span></span>
</td>
<td class="nump">1,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="num">(964)<span></span>
</td>
<td class="num">(610)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">780<span></span>
</td>
<td class="nump">1,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and derecognitions</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairment charge</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation effects</a></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">1,157<span></span>
</td>
<td class="nump">1,443<span></span>
</td>
<td class="nump">1,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember', window );">Construction in progress | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">1,508<span></span>
</td>
<td class="nump">1,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">1,508<span></span>
</td>
<td class="nump">1,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember', window );">Construction in progress | Accumulated depreciation, amortisation and impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(65)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember', window );">Machinery and other equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">3,542<span></span>
</td>
<td class="nump">3,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Impact of business combinations</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment', window );">Reclassifications</a></td>
<td class="nump">667<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">312<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment', window );">Disposals and derecognitions</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge</a></td>
<td class="num">(726)<span></span>
</td>
<td class="num">(755)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairment charge</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Currency translation effects</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(199)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">3,672<span></span>
</td>
<td class="nump">3,542<span></span>
</td>
<td class="nump">3,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember', window );">Machinery and other equipment | Gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="nump">13,328<span></span>
</td>
<td class="nump">14,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="nump">11,842<span></span>
</td>
<td class="nump">13,328<span></span>
</td>
<td class="nump">14,038<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember', window );">Machinery and other equipment | Accumulated depreciation, amortisation and impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward', window );"><strong>Movements of property, plant and equipment [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at beginning of period</a></td>
<td class="num">(9,786)<span></span>
</td>
<td class="num">(10,063)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment at end of period</a></td>
<td class="num">$ (8,170)<span></span>
</td>
<td class="num">$ (9,786)<span></span>
</td>
<td class="num">$ (10,063)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in property, plant and equipment resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingCostsCapitalised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest and other costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 23<br> -IssueDate 2022-03-24<br> -Paragraph 26<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=23&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_26_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingCostsCapitalised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual commitments for the acquisition of property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 74<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_74_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals and retirements. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from transfers from construction in progress. [Refer: Property, plant and equipment; Construction in progress]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reversal of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Reversal of impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MovementsOfPropertyPlantAndEquipmentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MovementsOfPropertyPlantAndEquipmentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_MachineryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571861522080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="num">$ (414)<span></span>
</td>
<td class="num">$ (384)<span></span>
</td>
<td class="num">$ (447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairment charge</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="num">(411)<span></span>
</td>
<td class="num">(315)<span></span>
</td>
<td class="num">(326)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairment charge</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_SandozMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Reversal of impairment charge</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_CorporateMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reversal of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Reversal of impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864879760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease liability and Right-of-use assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementsOfTheRightofuseAssetsRollForward', window );"><strong>Movements of the right-of-use assets [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets at beginning of period</a></td>
<td class="nump">$ 1,561<span></span>
</td>
<td class="nump">$ 1,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets', window );">Impact of business combinations</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(318)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LeaseContractTerminationsRightofuseAssets', window );">Lease contract terminations, right-of-use assets</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets', window );">Impairment loss recognised in profit or loss, right of use assets</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets', window );">Increase decrease through net exchange differences, right-of-use assets</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets at end of period</a></td>
<td class="nump">$ 1,431<span></span>
</td>
<td class="nump">$ 1,561<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LeaseContractTerminationsRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LeaseContractTerminationsRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MovementsOfTheRightofuseAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MovementsOfTheRightofuseAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571858741600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease liability and Right-of-use assets (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">$ 1,431<span></span>
</td>
<td class="nump">$ 1,561<span></span>
</td>
<td class="nump">$ 1,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(318)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandMember', window );">Land [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">505<span></span>
</td>
<td class="nump">522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember', window );">Buildings [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="num">(177)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember', window );">Vehicles [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="num">(96)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember', window );">Machinery &amp; equipment and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="num">$ (11)<span></span>
</td>
<td class="num">$ (10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571855643760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease liability and Right-of-use assets (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis of total lease liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">$ 1,789<span></span>
</td>
<td class="nump">$ 1,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LeaseLiabilitiesUndiscounted', window );">Lease liabilities undiscounted</a></td>
<td class="nump">3,205<span></span>
</td>
<td class="nump">3,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Less current lease liabilities</a></td>
<td class="num">(251)<span></span>
</td>
<td class="num">(275)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrentLeaseLiabilitiesUndiscounted', window );">Less current lease liabilities undiscounted</a></td>
<td class="num">(297)<span></span>
</td>
<td class="num">(324)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current lease liabilities</a></td>
<td class="nump">1,538<span></span>
</td>
<td class="nump">1,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NoncurrentLeaseLiabilitiesUndiscounted', window );">Non-current lease liabilities undiscounted</a></td>
<td class="nump">2,908<span></span>
</td>
<td class="nump">3,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentsForLeasesNotYetCommenced', window );">Commitments for leases not yet commenced</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MostMaterialLeaseWithLeaseTermExtension', window );">Most material lease with lease term extension</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LeaseTermEndDate', window );">Lease term end date</a></td>
<td class="text">2071<span></span>
</td>
<td class="text">2071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Not later than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis of total lease liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">$ 251<span></span>
</td>
<td class="nump">$ 275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LeaseLiabilitiesUndiscounted', window );">Lease liabilities undiscounted</a></td>
<td class="nump">297<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Later than one year and not later than two years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis of total lease liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LeaseLiabilitiesUndiscounted', window );">Lease liabilities undiscounted</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">Later than two years and not later than three years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis of total lease liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LeaseLiabilitiesUndiscounted', window );">Lease liabilities undiscounted</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember', window );">Later than three years and not later than four years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis of total lease liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LeaseLiabilitiesUndiscounted', window );">Lease liabilities undiscounted</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember', window );">Later than four years and not later than five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis of total lease liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LeaseLiabilitiesUndiscounted', window );">Lease liabilities undiscounted</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis of total lease liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">922<span></span>
</td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LeaseLiabilitiesUndiscounted', window );">Lease liabilities undiscounted</a></td>
<td class="nump">$ 2,149<span></span>
</td>
<td class="nump">$ 2,243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CommitmentsForLeasesNotYetCommenced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CommitmentsForLeasesNotYetCommenced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrentLeaseLiabilitiesUndiscounted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrentLeaseLiabilitiesUndiscounted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LeaseLiabilitiesUndiscounted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LeaseLiabilitiesUndiscounted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LeaseTermEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LeaseTermEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MostMaterialLeaseWithLeaseTermExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MostMaterialLeaseWithLeaseTermExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NoncurrentLeaseLiabilitiesUndiscounted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NoncurrentLeaseLiabilitiesUndiscounted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571861738432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease liability and Right-of-use assets (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">$ 1,789<span></span>
</td>
<td class="nump">$ 1,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1,431<span></span>
</td>
<td class="nump">$ 1,561<span></span>
</td>
<td class="nump">$ 1,676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=nvs_SaleAndLeaseBackMember', window );">Sale and lease back [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashInflowForSaleAndLeaseback', window );">Cash inflow for sale and leaseback</a></td>
<td class="num">(49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions', window );">Gains or losses from sales leaseback</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) arising from sale and leaseback transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashInflowForSaleAndLeaseback">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashInflowForSaleAndLeaseback</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=nvs_SaleAndLeaseBackMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=nvs_SaleAndLeaseBackMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862462032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease liability and Right-of-use assets (Details 4) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed', window );">Expense relating to short-term leases for which recognition exemption has been used</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed', window );">Expense relating to leases of low-value assets for which recognition exemption has been used</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Cash outflow</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="nump">379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashOutflowsForShortTermAndLowValueLeases', window );">Cash outflows for short term and low value leases</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashOutflowsForPaymentsOfLeasesInterest', window );">Cash outflows for payments of leases interest</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayment of lease liability</a></td>
<td class="nump">$ 295<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
<td class="nump">$ 312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_WeightedAverageInterestRateLeaseLiabilities', window );">Weighted average interest rate lease liabilities</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashOutflowsForPaymentsOfLeasesInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashOutflowsForPaymentsOfLeasesInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashOutflowsForShortTermAndLowValueLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashOutflowsForShortTermAndLowValueLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_WeightedAverageInterestRateLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_WeightedAverageInterestRateLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571842184480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and intangible assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">$ 63,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">2,093<span></span>
</td>
<td class="nump">$ 1,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">60,945<span></span>
</td>
<td class="nump">63,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">29,595<span></span>
</td>
<td class="nump">29,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill', window );">Impact of business combinations</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill', window );">Disposals and derecognitions</a></td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation effects</a></td>
<td class="num">(427)<span></span>
</td>
<td class="num">(642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">29,301<span></span>
</td>
<td class="nump">29,595<span></span>
</td>
<td class="nump">$ 29,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember', window );">Intangible Assets other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">34,182<span></span>
</td>
<td class="nump">36,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill', window );">Impact of business combinations</a></td>
<td class="nump">1,209<span></span>
</td>
<td class="nump">652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">2,093<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill', window );">Disposals and derecognitions</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization charge</a></td>
<td class="num">(3,982)<span></span>
</td>
<td class="num">(3,903)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(1,326)<span></span>
</td>
<td class="num">(403)<span></span>
</td>
<td class="num">(914)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation effects</a></td>
<td class="num">(432)<span></span>
</td>
<td class="num">(672)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">31,644<span></span>
</td>
<td class="nump">34,182<span></span>
</td>
<td class="nump">36,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember', window );">Acquired research and development [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">5,499<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill', window );">Impact of business combinations</a></td>
<td class="nump">1,209<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill', window );">Reclassifications</a></td>
<td class="num">(1,429)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">330<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill', window );">Disposals and derecognitions</a></td>
<td class="num">(95)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(917)<span></span>
</td>
<td class="num">(350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation effects</a></td>
<td class="num">(176)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">4,421<span></span>
</td>
<td class="nump">5,499<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember', window );">Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill', window );">Reclassifications</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization charge</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation effects</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember', window );">Currently marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">27,106<span></span>
</td>
<td class="nump">30,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill', window );">Impact of business combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill', window );">Reclassifications</a></td>
<td class="nump">1,403<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">1,175<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill', window );">Disposals and derecognitions</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization charge</a></td>
<td class="num">(3,603)<span></span>
</td>
<td class="num">(3,607)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(322)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation effects</a></td>
<td class="num">(243)<span></span>
</td>
<td class="num">(584)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">25,513<span></span>
</td>
<td class="nump">27,106<span></span>
</td>
<td class="nump">30,767<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill', window );">Impact of business combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill', window );">Reclassifications</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">588<span></span>
</td>
<td class="nump">508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill', window );">Disposals and derecognitions</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization charge</a></td>
<td class="num">(342)<span></span>
</td>
<td class="num">(255)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(72)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Currency translation effects</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">1,589<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount | Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">29,900<span></span>
</td>
<td class="nump">30,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">29,596<span></span>
</td>
<td class="nump">29,900<span></span>
</td>
<td class="nump">30,321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount | Intangible Assets other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">68,211<span></span>
</td>
<td class="nump">67,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">69,684<span></span>
</td>
<td class="nump">68,211<span></span>
</td>
<td class="nump">67,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount | Acquired research and development [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">8,013<span></span>
</td>
<td class="nump">6,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">7,092<span></span>
</td>
<td class="nump">8,013<span></span>
</td>
<td class="nump">6,893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount | Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">1,080<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">1,038<span></span>
</td>
<td class="nump">1,080<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount | Currently marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">56,213<span></span>
</td>
<td class="nump">57,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">58,249<span></span>
</td>
<td class="nump">56,213<span></span>
</td>
<td class="nump">57,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount | Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="nump">2,905<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="nump">3,305<span></span>
</td>
<td class="nump">2,905<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment | Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="num">(305)<span></span>
</td>
<td class="num">(322)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="num">(295)<span></span>
</td>
<td class="num">(305)<span></span>
</td>
<td class="num">(322)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment | Intangible Assets other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="num">(34,029)<span></span>
</td>
<td class="num">(30,916)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="num">(38,040)<span></span>
</td>
<td class="num">(34,029)<span></span>
</td>
<td class="num">(30,916)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment | Acquired research and development [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="num">(2,514)<span></span>
</td>
<td class="num">(2,193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="num">(2,671)<span></span>
</td>
<td class="num">(2,514)<span></span>
</td>
<td class="num">(2,193)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment | Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="num">(903)<span></span>
</td>
<td class="num">(885)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="num">(917)<span></span>
</td>
<td class="num">(903)<span></span>
</td>
<td class="num">(885)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment | Currently marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="num">(29,107)<span></span>
</td>
<td class="num">(26,566)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="num">(32,736)<span></span>
</td>
<td class="num">(29,107)<span></span>
</td>
<td class="num">(26,566)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment | Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at beginning of period</a></td>
<td class="num">(1,505)<span></span>
</td>
<td class="num">(1,272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill at end of period</a></td>
<td class="num">$ (1,716)<span></span>
</td>
<td class="num">$ (1,505)<span></span>
</td>
<td class="num">$ (1,272)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in intangible assets and goodwill resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in intangible assets and goodwill resulting from disposals and retirements. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets and goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets and goodwill resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets and goodwill resulting from transfers. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571842137264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and intangible assets (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">$ 60,945<span></span>
</td>
<td class="nump">$ 63,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">51,357<span></span>
</td>
<td class="nump">53,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">9,230<span></span>
</td>
<td class="nump">9,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">29,301<span></span>
</td>
<td class="nump">29,595<span></span>
</td>
<td class="nump">$ 29,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember', window );">Goodwill | Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">21,531<span></span>
</td>
<td class="nump">21,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember', window );">Goodwill | Operating segments [member] | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">7,770<span></span>
</td>
<td class="nump">8,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember', window );">Goodwill | Operating segments [member] | Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember', window );">Intangible Assets other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">31,644<span></span>
</td>
<td class="nump">34,182<span></span>
</td>
<td class="nump">36,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember', window );">Intangible Assets other than Goodwill | Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">29,826<span></span>
</td>
<td class="nump">32,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember', window );">Intangible Assets other than Goodwill | Operating segments [member] | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">1,460<span></span>
</td>
<td class="nump">1,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember', window );">Intangible Assets other than Goodwill | Operating segments [member] | Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember', window );">Acquired research and development [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">4,421<span></span>
</td>
<td class="nump">5,499<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember', window );">Acquired research and development [member] | Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">4,186<span></span>
</td>
<td class="nump">5,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember', window );">Acquired research and development [member] | Operating segments [member] | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember', window );">Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember', window );">Technologies | Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember', window );">Technologies | Operating segments [member] | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember', window );">Currently marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">25,513<span></span>
</td>
<td class="nump">27,106<span></span>
</td>
<td class="nump">30,767<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember', window );">Currently marketed products | Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">24,487<span></span>
</td>
<td class="nump">25,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember', window );">Currently marketed products | Operating segments [member] | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">1,026<span></span>
</td>
<td class="nump">1,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">1,589<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">$ 1,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets | Operating segments [member] | Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">1,139<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets | Operating segments [member] | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets | Operating segments [member] | Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Net book value</a></td>
<td class="nump">$ 358<span></span>
</td>
<td class="nump">$ 248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862254496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and intangible assets (Details 2) - Operating segments [member]<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Innovative Medicines</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections', window );">Terminal Growth Rate</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal', window );">Discount Rate (post-tax)</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections', window );">Terminal Growth Rate</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal', window );">Discount Rate (post-tax)</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The growth rate used to extrapolate cash flow projections beyond the period covered by the most recent budgets/forecasts for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph d<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_d_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 134<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_134_e_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The discount rate used in the current measurement of fair value less costs of disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2022-03-24<br> -Paragraph 130<br> -Subparagraph f<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_130_f_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571858793136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and intangible assets (Details 3) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=nvs_LeqvioMember', window );">Leqvio [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsMaterialToEntity', window );">Carrying value</a></td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019', window );">Remaining amortisation period</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">14 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember', window );">Zolgensma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsMaterialToEntity', window );">Carrying value</a></td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019', window );">Remaining amortisation period</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsMaterialToEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets that are material to the entity&#8217;s financial statements. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 122<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_122_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsMaterialToEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining amortisation period of individual intangible assets that are material to the entity&#8217;s financial statements. [Refer: Depreciation and amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 122<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_122_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_LeqvioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_LeqvioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571853303120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and intangible assets (Details 4) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember', window );">Intangible Assets other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">$ (1,326.0)<span></span>
</td>
<td class="num">$ (403.0)<span></span>
</td>
<td class="num">$ (914.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember', window );">Acquired research and development [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(917.0)<span></span>
</td>
<td class="num">(350.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember', window );">Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(15.0)<span></span>
</td>
<td class="num">(17.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember', window );">Currently marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(322.0)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(72.0)<span></span>
</td>
<td class="num">(35.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember', window );">Innovative Medicines | Votrient [member] | Currently marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(900.0)<span></span>
</td>
<td class="num">(1,300.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Innovative Medicines | Intangible Assets other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(1,299.0)<span></span>
</td>
<td class="num">(367.0)<span></span>
</td>
<td class="num">(768.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Sandoz | Intangible Assets other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(25.0)<span></span>
</td>
<td class="num">(28.0)<span></span>
</td>
<td class="num">(141.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember', window );">Operating segments [member] | Corporate | Intangible Assets other than Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">(2.0)<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
<td class="num">(5.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment | Innovative Medicines | Acquired research and development [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment | Innovative Medicines | Votrient [member] | Acquired research and development [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for intangible assets and goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_AcquiredResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_TechnologybasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=nvs_CurrentlyMarketedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=nvs_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=nvs_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571842719456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred tax assets and liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxAssets', window );">Gross deferred tax assets</a></td>
<td class="nump">$ 8,051<span></span>
</td>
<td class="nump">$ 7,832<span></span>
</td>
<td class="nump">$ 8,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">3,739<span></span>
</td>
<td class="nump">3,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(6,998)<span></span>
</td>
<td class="num">(7,159)<span></span>
</td>
<td class="num">(7,552)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(2,686)<span></span>
</td>
<td class="num">(3,070)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance</a></td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">673<span></span>
</td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementInDeferredTaxBalanceRollForward', window );"><strong>Movement in deferred tax balance [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at beginning of period</a></td>
<td class="nump">673<span></span>
</td>
<td class="nump">792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credited/(charged) to income</a></td>
<td class="nump">655<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Charged to equity</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Credited/(charged) to other comprehensive income</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(317)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Impact of business combinations</a></td>
<td class="num">(244)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset', window );">Other movements</a></td>
<td class="nump">11<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at end of period</a></td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">673<span></span>
</td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction', window );">Offsetting of deferred tax assets and liabilities within the same tax jurisdiction</a></td>
<td class="nump">4,312<span></span>
</td>
<td class="nump">4,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">3,739<span></span>
</td>
<td class="nump">3,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(2,686)<span></span>
</td>
<td class="num">(3,070)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_PropertyPlantAndEquipmentMember', window );">Property, plant and equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxAssets', window );">Gross deferred tax assets</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(343)<span></span>
</td>
<td class="num">(381)<span></span>
</td>
<td class="num">(430)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance</a></td>
<td class="num">(185)<span></span>
</td>
<td class="num">(256)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementInDeferredTaxBalanceRollForward', window );"><strong>Movement in deferred tax balance [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at beginning of period</a></td>
<td class="num">(256)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credited/(charged) to income</a></td>
<td class="nump">69<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Credited/(charged) to other comprehensive income</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset', window );">Other movements</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at end of period</a></td>
<td class="num">(185)<span></span>
</td>
<td class="num">(256)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_IntangibleAssetsAndGoodwillMember', window );">Intangible assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxAssets', window );">Gross deferred tax assets</a></td>
<td class="nump">1,726<span></span>
</td>
<td class="nump">1,307<span></span>
</td>
<td class="nump">1,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(4,785)<span></span>
</td>
<td class="num">(4,704)<span></span>
</td>
<td class="num">(5,269)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance</a></td>
<td class="num">(3,059)<span></span>
</td>
<td class="num">(3,397)<span></span>
</td>
<td class="num">(3,918)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementInDeferredTaxBalanceRollForward', window );"><strong>Movement in deferred tax balance [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at beginning of period</a></td>
<td class="num">(3,397)<span></span>
</td>
<td class="num">(3,918)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credited/(charged) to income</a></td>
<td class="nump">628<span></span>
</td>
<td class="nump">567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Impact of business combinations</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset', window );">Other movements</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at end of period</a></td>
<td class="num">(3,059)<span></span>
</td>
<td class="num">(3,397)<span></span>
</td>
<td class="num">(3,918)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_PensionsAndOtherBenefitObligationsOfAssociatesMember', window );">Pensions and other benefit obligations of associates [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxAssets', window );">Gross deferred tax assets</a></td>
<td class="nump">739<span></span>
</td>
<td class="nump">1,026<span></span>
</td>
<td class="nump">1,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(420)<span></span>
</td>
<td class="num">(591)<span></span>
</td>
<td class="num">(340)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance</a></td>
<td class="nump">319<span></span>
</td>
<td class="nump">435<span></span>
</td>
<td class="nump">797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementInDeferredTaxBalanceRollForward', window );"><strong>Movement in deferred tax balance [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at beginning of period</a></td>
<td class="nump">435<span></span>
</td>
<td class="nump">797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credited/(charged) to income</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Credited/(charged) to other comprehensive income</a></td>
<td class="num">(104)<span></span>
</td>
<td class="num">(323)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset', window );">Other movements</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at end of period</a></td>
<td class="nump">319<span></span>
</td>
<td class="nump">435<span></span>
</td>
<td class="nump">797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_InventoriesMember', window );">Inventories [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxAssets', window );">Gross deferred tax assets</a></td>
<td class="nump">2,214<span></span>
</td>
<td class="nump">2,273<span></span>
</td>
<td class="nump">2,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(138)<span></span>
</td>
<td class="num">(148)<span></span>
</td>
<td class="num">(159)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance</a></td>
<td class="nump">2,076<span></span>
</td>
<td class="nump">2,125<span></span>
</td>
<td class="nump">2,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementInDeferredTaxBalanceRollForward', window );"><strong>Movement in deferred tax balance [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at beginning of period</a></td>
<td class="nump">2,125<span></span>
</td>
<td class="nump">2,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credited/(charged) to income</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset', window );">Other movements</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at end of period</a></td>
<td class="nump">2,076<span></span>
</td>
<td class="nump">2,125<span></span>
</td>
<td class="nump">2,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_TaxLossCarryforwardsMember', window );">Tax loss carryforwards [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxAssets', window );">Gross deferred tax assets</a></td>
<td class="nump">425<span></span>
</td>
<td class="nump">374<span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance</a></td>
<td class="nump">425<span></span>
</td>
<td class="nump">374<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementInDeferredTaxBalanceRollForward', window );"><strong>Movement in deferred tax balance [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at beginning of period</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credited/(charged) to income</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(121)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Impact of business combinations</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset', window );">Other movements</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at end of period</a></td>
<td class="nump">425<span></span>
</td>
<td class="nump">374<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_OtherAssetsProvisionsAccrualsMember', window );">Other assets, provisions and accruals [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxAssets', window );">Gross deferred tax assets</a></td>
<td class="nump">2,789<span></span>
</td>
<td class="nump">2,727<span></span>
</td>
<td class="nump">2,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossDeferredTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(1,312)<span></span>
</td>
<td class="num">(1,335)<span></span>
</td>
<td class="num">(1,344)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance</a></td>
<td class="nump">1,477<span></span>
</td>
<td class="nump">1,392<span></span>
</td>
<td class="nump">1,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MovementInDeferredTaxBalanceRollForward', window );"><strong>Movement in deferred tax balance [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at beginning of period</a></td>
<td class="nump">1,392<span></span>
</td>
<td class="nump">1,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Credited/(charged) to income</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Charged to equity</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Credited/(charged) to other comprehensive income</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset', window );">Impact of business combinations</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset', window );">Other movements</a></td>
<td class="nump">19<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax balance at end of period</a></td>
<td class="nump">$ 1,477<span></span>
</td>
<td class="nump">$ 1,392<span></span>
</td>
<td class="nump">$ 1,314<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax related to items credited (charged) directly to equity. [Refer: Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph ab<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_ab&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 90<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_90&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in deferred tax liability (asset) resulting from business combinations. [Refer: Deferred tax liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GrossDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GrossDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GrossDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GrossDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MovementInDeferredTaxBalanceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MovementInDeferredTaxBalanceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_IntangibleAssetsAndGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_IntangibleAssetsAndGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_PensionsAndOtherBenefitObligationsOfAssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=nvs_PensionsAndOtherBenefitObligationsOfAssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=nvs_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_TaxLossCarryforwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=nvs_TaxLossCarryforwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_OtherAssetsProvisionsAccrualsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=nvs_OtherAssetsProvisionsAccrualsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571842172576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred tax assets and liabilities (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">$ 8,140<span></span>
</td>
<td class="nump">$ 6,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueOfTaxLossCarryforwardsExpired', window );">Tax loss carryforwards expired</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_YearOfExpiryAxis=nvs_OneYearMember', window );">One year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_YearOfExpiryAxis=nvs_TwoYearsMember', window );">Two years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_YearOfExpiryAxis=nvs_ThreeYearsMember', window );">Three years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_YearOfExpiryAxis=nvs_FourYearsMember', window );">Four years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_YearOfExpiryAxis=nvs_FiveYearsMember', window );">Five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">767<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_YearOfExpiryAxis=nvs_MoreThanFiveYearsMember', window );">More than five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">6,260<span></span>
</td>
<td class="nump">5,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_YearOfExpiryAxis=nvs_NotSubjectToExpiryMember', window );">Not subject to expiry [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">885<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_CapitalizedMember', window );">Capitalized [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">3,530<span></span>
</td>
<td class="nump">2,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_CapitalizedMember', window );">Capitalized [member] | One year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_CapitalizedMember', window );">Capitalized [member] | Two years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_CapitalizedMember', window );">Capitalized [member] | Three years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_CapitalizedMember', window );">Capitalized [member] | Four years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_CapitalizedMember', window );">Capitalized [member] | Five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">688<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_CapitalizedMember', window );">Capitalized [member] | More than five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">2,380<span></span>
</td>
<td class="nump">1,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_CapitalizedMember', window );">Capitalized [member] | Not subject to expiry [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_NotCapitalizedMember', window );">Not capitalized [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">4,610<span></span>
</td>
<td class="nump">4,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_NotCapitalizedMember', window );">Not capitalized [member] | One year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_NotCapitalizedMember', window );">Not capitalized [member] | Two years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_NotCapitalizedMember', window );">Not capitalized [member] | Three years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_NotCapitalizedMember', window );">Not capitalized [member] | Four years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_NotCapitalizedMember', window );">Not capitalized [member] | Five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_NotCapitalizedMember', window );">Not capitalized [member] | More than five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">3,880<span></span>
</td>
<td class="nump">3,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BalanceSheetTreatmentAxis=nvs_NotCapitalizedMember', window );">Not capitalized [member] | Not subject to expiry [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets', window );">Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets</a></td>
<td class="nump">$ 433<span></span>
</td>
<td class="nump">$ 418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ValueOfTaxLossCarryforwardsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ValueOfTaxLossCarryforwardsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_YearOfExpiryAxis=nvs_OneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_YearOfExpiryAxis=nvs_OneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_YearOfExpiryAxis=nvs_TwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_YearOfExpiryAxis=nvs_TwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_YearOfExpiryAxis=nvs_ThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_YearOfExpiryAxis=nvs_ThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_YearOfExpiryAxis=nvs_FourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_YearOfExpiryAxis=nvs_FourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_YearOfExpiryAxis=nvs_FiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_YearOfExpiryAxis=nvs_FiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_YearOfExpiryAxis=nvs_MoreThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_YearOfExpiryAxis=nvs_MoreThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_YearOfExpiryAxis=nvs_NotSubjectToExpiryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_YearOfExpiryAxis=nvs_NotSubjectToExpiryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetTreatmentAxis=nvs_CapitalizedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetTreatmentAxis=nvs_CapitalizedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetTreatmentAxis=nvs_NotCapitalizedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetTreatmentAxis=nvs_NotCapitalizedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859642784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred tax assets and liabilities (Details 2) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment', window );">Unremitted earnings retained by consolidated entities for reinvestment</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862624576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial and other non-current assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsAbstract', window );"><strong>Disclosure of financial assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NoncurrentFinancialAssetsEquityInvestments', window );">Non-current financial assets, equity securities</a></td>
<td class="nump">$ 1,145<span></span>
</td>
<td class="nump">$ 1,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NoncurrentFinancialAsstetsDebtSecurities', window );">Non-current financial asstets debt securities</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NoncurrentFinancialAssetsFundInvestments', window );">Non-current financial assets, fund investments</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NoncurrentFinancialAssetsTotalFinancialInvestments', window );">Non-current financial assets, total financial investments</a></td>
<td class="nump">1,463<span></span>
</td>
<td class="nump">2,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LongTermReceivablesFromFinanceSubleases', window );">Long term receivables from finance subleases</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentReceivables', window );">Other long-term receivables</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContingentConsiderationReceivable', window );">Contingent consideration receivables</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLoansAndReceivables', window );">Long-term loans, advances and security deposits</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Total financial assets</a></td>
<td class="nump">$ 2,411<span></span>
</td>
<td class="nump">$ 3,036<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLoansAndReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current loans and receivables. [Refer: Loans and receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 8<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_8_c&amp;doctype=Standard&amp;book=b<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLoansAndReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ContingentConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ContingentConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LongTermReceivablesFromFinanceSubleases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LongTermReceivablesFromFinanceSubleases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NoncurrentFinancialAssetsEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NoncurrentFinancialAssetsEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NoncurrentFinancialAssetsFundInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NoncurrentFinancialAssetsFundInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NoncurrentFinancialAssetsTotalFinancialInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NoncurrentFinancialAssetsTotalFinancialInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NoncurrentFinancialAsstetsDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NoncurrentFinancialAsstetsDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571858511616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial and other non-current assets (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfOtherNoncurrentAssetsAbstract', window );"><strong>Disclosure of other non-current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DeferredCompensationPlansAssets', window );">Deferred compensation plans assets</a></td>
<td class="nump">$ 419<span></span>
</td>
<td class="nump">$ 520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PrepaidPostemploymentBenefitPlansAssets', window );">Prepaid post-employment benefit plans assets</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">1,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentNonfinancialAssets', window );">Other non-current assets</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Total other non-current assets</a></td>
<td class="nump">$ 1,110<span></span>
</td>
<td class="nump">$ 2,210<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DeferredCompensationPlansAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DeferredCompensationPlansAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfOtherNoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfOtherNoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PrepaidPostemploymentBenefitPlansAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PrepaidPostemploymentBenefitPlansAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571855955632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InventoryLineItems', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventory</a></td>
<td class="nump">$ 7,175<span></span>
</td>
<td class="nump">$ 6,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod', window );">Amount of inventory recognized as expense</a></td>
<td class="num">(8,600)<span></span>
</td>
<td class="num">(8,800)<span></span>
</td>
<td class="num">$ (8,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoryWritedown2011', window );">Inventory provisions</a></td>
<td class="num">(633)<span></span>
</td>
<td class="num">(573)<span></span>
</td>
<td class="num">(702)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfInventoryWritedown', window );">Reversals of inventory provisions</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="nump">$ 255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InventoryAxis=nvs_InventoryRawMaterialsGrossMember', window );">Raw material, consumables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InventoryLineItems', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventory</a></td>
<td class="nump">934<span></span>
</td>
<td class="nump">870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InventoryAxis=nvs_InventoryWorkInProgressGrossMember', window );">Work in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InventoryLineItems', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventory</a></td>
<td class="nump">3,673<span></span>
</td>
<td class="nump">3,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InventoryAxis=nvs_InventoryFinishedGoodsGrossMember', window );">Finished products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InventoryLineItems', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventory</a></td>
<td class="nump">$ 2,568<span></span>
</td>
<td class="nump">$ 2,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventories recognised as an expense during the period. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoryWritedown2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoryWritedown2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReversalOfInventoryWritedown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a reduction in the amount of inventories recognised as an expense due to the reversal of any write-down of inventories resulting from an increase in net realisable value. [Refer: Inventories; Inventory write-down]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReversalOfInventoryWritedown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InventoryAxis=nvs_InventoryRawMaterialsGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InventoryAxis=nvs_InventoryRawMaterialsGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InventoryAxis=nvs_InventoryWorkInProgressGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InventoryAxis=nvs_InventoryWorkInProgressGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InventoryAxis=nvs_InventoryFinishedGoodsGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InventoryAxis=nvs_InventoryFinishedGoodsGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571861340048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade receivables (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">$ 8,066<span></span>
</td>
<td class="nump">$ 8,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">8,066<span></span>
</td>
<td class="nump">8,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | Gross carrying amount [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">8,128<span></span>
</td>
<td class="nump">8,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | Provision for doubtful receivable [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProvisionForDoubtfulReceivable', window );">Provision for doubtful receivable</a></td>
<td class="num">$ (62)<span></span>
</td>
<td class="num">$ (83)<span></span>
</td>
<td class="num">$ (93)<span></span>
</td>
<td class="num">$ (95)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfProvisionMatrixLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfProvisionMatrixLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProvisionForDoubtfulReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProvisionForDoubtfulReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=nvs_ProvisionForDoubtfulReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=nvs_ProvisionForDoubtfulReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571855739984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade receivables (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Utilization of provisions for doubtful trade receivables</a></td>
<td class="nump">$ 22,261<span></span>
</td>
<td class="nump">$ 19,838<span></span>
</td>
<td class="nump">$ 19,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | Provision for doubtful receivable [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProvisionForDoubtfulReceivable', window );">Provision for doubtful receivable at beginning of period</a></td>
<td class="num">(83)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Provisions for doubtful trade receivables charged to the consolidated income statement</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Utilization of provisions for doubtful trade receivables</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedProvisionReversedOtherProvisions', window );">Reversal of provisions for doubtful trade receivables</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation effects</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProvisionForDoubtfulReceivable', window );">Provision for doubtful receivable at end of period</a></td>
<td class="num">$ (62)<span></span>
</td>
<td class="num">$ (83)<span></span>
</td>
<td class="num">$ (93)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional other provisions made. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfProvisionMatrixLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfProvisionMatrixLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionUsedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionUsedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedProvisionReversedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount reversed for unused other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedProvisionReversedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProvisionForDoubtfulReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProvisionForDoubtfulReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=nvs_ProvisionForDoubtfulReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=nvs_ProvisionForDoubtfulReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571853217072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade receivables (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AnalysisOfOverdueAmountsLineItems', window );"><strong>Analysis of overdue amounts [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">$ 8,066<span></span>
</td>
<td class="nump">$ 8,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AnalysisOfOverdueAmountsLineItems', window );"><strong>Analysis of overdue amounts [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">8,066<span></span>
</td>
<td class="nump">8,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | Current [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AnalysisOfOverdueAmountsLineItems', window );"><strong>Analysis of overdue amounts [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">7,664<span></span>
</td>
<td class="nump">7,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | Not later than one month [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AnalysisOfOverdueAmountsLineItems', window );"><strong>Analysis of overdue amounts [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | Later than one month and not later than three months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AnalysisOfOverdueAmountsLineItems', window );"><strong>Analysis of overdue amounts [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | Later than three months and not later than six months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AnalysisOfOverdueAmountsLineItems', window );"><strong>Analysis of overdue amounts [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | Later than six months and not later than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AnalysisOfOverdueAmountsLineItems', window );"><strong>Analysis of overdue amounts [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | Later than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AnalysisOfOverdueAmountsLineItems', window );"><strong>Analysis of overdue amounts [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | Provision for doubtful receivable [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AnalysisOfOverdueAmountsLineItems', window );"><strong>Analysis of overdue amounts [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProvisionForDoubtfulReceivable', window );">Provision for doubtful receivable</a></td>
<td class="num">$ (62)<span></span>
</td>
<td class="num">$ (83)<span></span>
</td>
<td class="num">$ (93)<span></span>
</td>
<td class="num">$ (95)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AnalysisOfOverdueAmountsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AnalysisOfOverdueAmountsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProvisionForDoubtfulReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProvisionForDoubtfulReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=ifrs-full_CurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=ifrs-full_CurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=ifrs-full_NotLaterThanOneMonthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=ifrs-full_NotLaterThanOneMonthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastDueStatusAxis=ifrs-full_LaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=nvs_ProvisionForDoubtfulReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=nvs_ProvisionForDoubtfulReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>186
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571842037504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade receivables (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">$ 8,066<span></span>
</td>
<td class="nump">$ 8,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">8,066<span></span>
</td>
<td class="nump">8,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">3,709<span></span>
</td>
<td class="nump">3,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">1,426<span></span>
</td>
<td class="nump">1,408<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | RUB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">430<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | JPY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | GBP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | CNY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | CAD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | BRL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | AUD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | CHF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member] | Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionMatrixLineItems', window );"><strong>Disclosure of provision matrix [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Total trade receivables, net</a></td>
<td class="nump">$ 1,452<span></span>
</td>
<td class="nump">$ 1,487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfProvisionMatrixLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfProvisionMatrixLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_RUB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_RUB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CNY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CNY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_BRL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_BRL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=nvs_CurrencyOthersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=nvs_CurrencyOthersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862132896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract', window );"><strong>Disclosure of marketable securities commodities deposits derivative instruments and cash [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_Commodities', window );">Commodities</a></td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DebtInstrumentsHeld', window );">Debt securities</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">2,741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents', window );">Time deposits and short-term investments with original maturity more than 90 days</a></td>
<td class="nump">11,089<span></span>
</td>
<td class="nump">12,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialAssets', window );">Derivative financial instruments</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Total marketable securities, commodities, time deposits and derivative financial instruments</a></td>
<td class="nump">$ 11,413<span></span>
</td>
<td class="nump">$ 15,922<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DebtInstrumentsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of instruments representing indebtedness held by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DebtInstrumentsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_Commodities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_Commodities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864086224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Current accounts</a></td>
<td class="nump">$ 2,877<span></span>
</td>
<td class="nump">$ 3,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Time deposits and short term investments with original maturity less than 90 days</a></td>
<td class="nump">4,640<span></span>
</td>
<td class="nump">9,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Total cash and cash equivalents</a></td>
<td class="nump">$ 7,517<span></span>
</td>
<td class="nump">$ 12,407<span></span>
</td>
<td class="nump">$ 9,658<span></span>
</td>
<td class="nump">$ 11,112<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>189
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571842925600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherCurrentAssetsAbstract', window );"><strong>Other current assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentValueAddedTaxReceivables', window );">VAT Receivable</a></td>
<td class="nump">$ 509<span></span>
</td>
<td class="nump">$ 487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_WithholdingTaxRecoverable', window );">Withholding tax recoverable</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrentPrepaidExpensesThirdParty', window );">Prepaid expenses - third party</a></td>
<td class="nump">911<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContingentConsiderationReceivableCurrent', window );">Contingent consideration receivable</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherReceivablesAndCurrentAssets', window );">Other receivables and current assets</a></td>
<td class="nump">958<span></span>
</td>
<td class="nump">793<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialAssets', window );">Total other current assets</a></td>
<td class="nump">$ 2,471<span></span>
</td>
<td class="nump">$ 2,440<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentValueAddedTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current value added tax receivables. [Refer: Value added tax receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentValueAddedTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ContingentConsiderationReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ContingentConsiderationReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrentPrepaidExpensesThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrentPrepaidExpensesThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherReceivablesAndCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherReceivablesAndCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_WithholdingTaxRecoverable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_WithholdingTaxRecoverable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>190
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862645952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>SFr / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital at beginning of period</a></td>
<td class="nump">$ 901<span></span>
</td>
<td class="nump">$ 913<span></span>
</td>
<td class="nump">$ 936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury shares at beginning of period</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OutstandingShareCapital', window );">Total outstanding share capital at beginning of period</a></td>
<td class="nump">853<span></span>
</td>
<td class="nump">860<span></span>
</td>
<td class="nump">856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IssuedCapitalMovement', window );">Share capital movement of period</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TreasurySharesMovementOfPeriod', window );">Treasury shares movement of period</a></td>
<td class="num">(44)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OutstandingShareCapitalMovement', window );">Total shares outstanding movement of period</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital at end of period</a></td>
<td class="nump">890<span></span>
</td>
<td class="nump">901<span></span>
</td>
<td class="nump">913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury shares at end of period</a></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OutstandingShareCapital', window );">Total outstanding share capital at end of period</a></td>
<td class="nump">$ 798<span></span>
</td>
<td class="nump">$ 853<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 0.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2022-03-24<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IssuedCapitalMovement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IssuedCapitalMovement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OutstandingShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OutstandingShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OutstandingShareCapitalMovement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OutstandingShareCapitalMovement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TreasurySharesMovementOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TreasurySharesMovementOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>191
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571853226656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details 1) - CHF (SFr)<br> shares in Millions, SFr in Billions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at beginning of period</a></td>
<td class="nump">2,234.9<span></span>
</td>
<td class="nump">2,256.8<span></span>
</td>
<td class="nump">2,265.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TreasurySharesAcquiredToBeCancelled', window );">Treasury shares acquired to be cancelled</a></td>
<td class="num">(126.2)<span></span>
</td>
<td class="num">(30.7)<span></span>
</td>
<td class="num">(32.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherSharePurchases', window );">Other share purchases</a></td>
<td class="num">(1.4)<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ExerciseOfOptionsAndEmployeeTransactionsShares', window );">Exercise of options and employee transactions shares</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EquityBasedCompensationShares', window );">Equity based compensation shares</a></td>
<td class="nump">10.4<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployees', window );">Shares delivered to divested business employees</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ShareMovements', window );">Total movements</a></td>
<td class="num">(115.3)<span></span>
</td>
<td class="num">(21.9)<span></span>
</td>
<td class="num">(8.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at end of period</a></td>
<td class="nump">2,119.6<span></span>
</td>
<td class="nump">2,234.9<span></span>
</td>
<td class="nump">2,256.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StockRepurchaseProgramAuthorizedAmount1', window );">Shares repurchased on the SIX Swiss Exchange second trading line under the share buyback authority approved</a></td>
<td class="nump">SFr 10<span></span>
</td>
<td class="nump">SFr 10<span></span>
</td>
<td class="nump">SFr 10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Total Novartis shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued at beginning of period</a></td>
<td class="nump">2,434.4<span></span>
</td>
<td class="nump">2,467.0<span></span>
</td>
<td class="nump">2,527.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharesCancelledForCapitalReduction', window );">Shares cancelled for capital reduction</a></td>
<td class="num">(30.7)<span></span>
</td>
<td class="num">(32.6)<span></span>
</td>
<td class="num">(60.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ShareMovements', window );">Total movements</a></td>
<td class="num">(30.7)<span></span>
</td>
<td class="num">(32.6)<span></span>
</td>
<td class="num">(60.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued at end of period</a></td>
<td class="nump">2,403.7<span></span>
</td>
<td class="nump">2,434.4<span></span>
</td>
<td class="nump">2,467.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_TreasurySharesMember', window );">Total treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfTreasuryShares', window );">Number of treasury shares at beginning of period</a></td>
<td class="num">(199.5)<span></span>
</td>
<td class="num">(210.2)<span></span>
</td>
<td class="num">(262.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharesCancelledForCapitalReduction', window );">Shares cancelled for capital reduction</a></td>
<td class="nump">30.7<span></span>
</td>
<td class="nump">32.6<span></span>
</td>
<td class="nump">60.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TreasurySharesAcquiredToBeCancelled', window );">Treasury shares acquired to be cancelled</a></td>
<td class="num">(126.2)<span></span>
</td>
<td class="num">(30.7)<span></span>
</td>
<td class="num">(32.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherSharePurchases', window );">Other share purchases</a></td>
<td class="num">(1.4)<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ExerciseOfOptionsAndEmployeeTransactionsShares', window );">Exercise of options and employee transactions shares</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EquityBasedCompensationShares', window );">Equity based compensation shares</a></td>
<td class="nump">10.4<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployees', window );">Shares delivered to divested business employees</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ShareMovements', window );">Total movements</a></td>
<td class="num">(84.6)<span></span>
</td>
<td class="nump">10.7<span></span>
</td>
<td class="nump">52.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfTreasuryShares', window );">Number of treasury shares at end of period</a></td>
<td class="num">(284.1)<span></span>
</td>
<td class="num">(199.5)<span></span>
</td>
<td class="num">(210.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TreasurySharesWithRestrictedUse', window );">Treasury shares with restricted use</a></td>
<td class="nump">99.0<span></span>
</td>
<td class="nump">102.5<span></span>
</td>
<td class="nump">103.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EquityBasedCompensationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EquityBasedCompensationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ExerciseOfOptionsAndEmployeeTransactionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ExerciseOfOptionsAndEmployeeTransactionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherSharePurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherSharePurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ShareMovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ShareMovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SharesCancelledForCapitalReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SharesCancelledForCapitalReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SharesDeliveredToDivestedBusinessEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SharesDeliveredToDivestedBusinessEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TreasurySharesAcquiredToBeCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TreasurySharesAcquiredToBeCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TreasurySharesWithRestrictedUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TreasurySharesWithRestrictedUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_TreasurySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_TreasurySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>192
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571861575984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details 2)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>SFr / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DividendsPayableAmountPerShare', window );">Dividends payable, amount per share | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 3.10<span></span>
</td>
<td class="nump">SFr 3.00<span></span>
</td>
<td class="nump">SFr 2.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaid', window );">Dividends recognised as distributions to owners | $</a></td>
<td class="nump">$ 7,506<span></span>
</td>
<td class="nump">$ 7,368<span></span>
</td>
<td class="nump">$ 6,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends recognised as distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 107<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_107&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DividendsPayableAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DividendsPayableAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>193
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571863862880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details 3) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TreasurySharesAcquiredToBeCancelled', window );">Treasury shares acquired to be cancelled</a></td>
<td class="num">(126.2)<span></span>
</td>
<td class="num">(30.7)<span></span>
</td>
<td class="num">(32.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TreasurySharesAcquiredForCancellationValue', window );">Shares acquired for cancellation, equity impact</a></td>
<td class="num">$ (10,787)<span></span>
</td>
<td class="num">$ (2,775)<span></span>
</td>
<td class="num">$ (2,897)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherSharePurchases', window );">Other share purchases</a></td>
<td class="num">(1.4)<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherSharePurchasesValue', window );">Other share purchases, equity impact</a></td>
<td class="num">$ (123)<span></span>
</td>
<td class="num">$ (145)<span></span>
</td>
<td class="num">$ (159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharepurchaseOfTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="num">(127.6)<span></span>
</td>
<td class="num">(32.2)<span></span>
</td>
<td class="num">(34.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Purchase of treasury shares, equity impact</a></td>
<td class="num">$ (10,910)<span></span>
</td>
<td class="num">$ (2,920)<span></span>
</td>
<td class="num">$ (3,056)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ExerciseOfOptionsAndEmployeeTransactionsShares', window );">Exercise of options and employee transactions shares</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options and employee transactions, equity impact</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EquityBasedCompensationShares', window );">Equity based compensation shares</a></td>
<td class="nump">10.4<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-based compensation, equity impact</a></td>
<td class="nump">$ 854<span></span>
</td>
<td class="nump">$ 745<span></span>
</td>
<td class="nump">$ 730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployees', window );">Shares delivered to divested business employees</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff', window );">Shares delivered to divested business employees, equity impact</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TreasurySharesMovement', window );">Total number of outstanding treasury shares</a></td>
<td class="num">(115.3)<span></span>
</td>
<td class="num">(21.9)<span></span>
</td>
<td class="num">(8.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EquityImpactOfTreasuryShareMovements', window );">Total equity impact of treasury share movements</a></td>
<td class="num">$ (9,963)<span></span>
</td>
<td class="num">$ (2,119)<span></span>
</td>
<td class="num">$ (1,490)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EquityBasedCompensationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EquityBasedCompensationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EquityImpactOfTreasuryShareMovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EquityImpactOfTreasuryShareMovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ExerciseOfOptionsAndEmployeeTransactionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ExerciseOfOptionsAndEmployeeTransactionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherSharePurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherSharePurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherSharePurchasesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherSharePurchasesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SharepurchaseOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SharepurchaseOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SharesDeliveredToDivestedBusinessEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SharesDeliveredToDivestedBusinessEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TreasurySharesAcquiredForCancellationValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TreasurySharesAcquiredForCancellationValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TreasurySharesAcquiredToBeCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TreasurySharesAcquiredToBeCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TreasurySharesMovement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TreasurySharesMovement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>194
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864758720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details 4)<br> $ / shares in Units, Pure in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>year </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>year </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>year </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentForRepurchaseOwnShares', window );">Commitment for repurchase own shares | $</a></td>
<td class="nump">$ 2,809<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaximalAmountOfShareBuybackProgramm', window );">Maximal amount of share buyback programm | $</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_WrittenCallOptionsHeldByMarketMaker', window );">Written call options held by market maker</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_WrittenCallOptionsContractualLive', window );">Written call options, contractual live | year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_WrittenCallOptionsContractualLiveRemaining', window );">Written call options, contractual live, remaining | year</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_WrittenCallOptionsWeightedAverageExercisePrice', window );">Written call options, weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 61.45<span></span>
</td>
<td class="nump">$ 60.09<span></span>
</td>
<td class="nump">$ 66.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfOptionsRepurchased', window );">Number of options repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CommitmentForRepurchaseOwnShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CommitmentForRepurchaseOwnShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MaximalAmountOfShareBuybackProgramm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MaximalAmountOfShareBuybackProgramm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfOptionsRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfOptionsRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_WrittenCallOptionsContractualLive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_WrittenCallOptionsContractualLive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_WrittenCallOptionsContractualLiveRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_WrittenCallOptionsContractualLiveRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_WrittenCallOptionsHeldByMarketMaker">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_WrittenCallOptionsHeldByMarketMaker</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_WrittenCallOptionsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_WrittenCallOptionsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>195
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864092128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-current financial debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract', window );"><strong>Disclosure of components of non-current financial debts [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 22,341<span></span>
</td>
<td class="nump">$ 25,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LiabilitiesToBanksAndOtherInstitutions', window );">Liabilities to banks and other institutions</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total including current portion of non-current financial debt</a></td>
<td class="nump">22,485<span></span>
</td>
<td class="nump">25,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPortionOfLongtermBorrowings', window );">Less current portion of non-current financial debt</a></td>
<td class="num">(2,241)<span></span>
</td>
<td class="num">(2,621)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Total non-current financial debts</a></td>
<td class="nump">$ 20,244<span></span>
</td>
<td class="nump">$ 22,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AverageInterestRateOnLoansReceived', window );">Average interest rate on loans received</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RatioFixedRateFinancialDebtToTotalFinancialDebt', window );">Ratio fixed rate financial debt to total financial debt</a></td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AverageInterestRateOnBorrowings', window );">Average interest rate on borrowings</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BondsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of bonds issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BondsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPortionOfLongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPortionOfLongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AverageInterestRateOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AverageInterestRateOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AverageInterestRateOnLoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AverageInterestRateOnLoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LiabilitiesToBanksAndOtherInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LiabilitiesToBanksAndOtherInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RatioFixedRateFinancialDebtToTotalFinancialDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RatioFixedRateFinancialDebtToTotalFinancialDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>196
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571850458720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-current financial debt (Details 1)<br> &#8364; in Millions, SFr in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 22,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member', window );">2.4% USD 1 500 million bond 2012/2022 of Novartis Capital Corporation, New York United States, issued at 99.225% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.225%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member', window );">3.7% USD 500 million bond 2012/2042 of Novartis Capital Corporation, New York United States, issued at 98.325% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">98.325%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member', window );">3.4% USD 2 150 million bond 2014/2024 of Novartis Capital Corporation, New York United States, issued at 99.287% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 2,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.287%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 2,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member', window );">4.4% USD 1 850 million bond 2014/2044 of Novartis Capital Corporation, New York United States, issued at 99.196% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.196%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 1,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member', window );">1.625% EUR 600 million bond 2014/2026 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.697% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">1.625%<span></span>
</td>
<td class="nump">1.625%<span></span>
</td>
<td class="nump">1.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Finance S.A., Luxembourg, Luxembourg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.697%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member', window );">0.25% CHF 500 million bond 2015/2025 of Novartis AG Basel Switzerland, issued at 100.64% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">CHF<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis AG, Basel, Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">100.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member', window );">0.625% CHF 550 million bond 2015/2029 of Novartis AG Basel Switzerland, issued at 100.502% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">0.625%<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">CHF<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis AG, Basel, Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">100.502%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member', window );">1.050% CHF 325 million bond 2015/2035 of Novartis AG Basel Switzerland, issued at 100.479% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">1.05%<span></span>
</td>
<td class="nump">1.05%<span></span>
</td>
<td class="nump">1.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">CHF<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis AG, Basel, Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">100.479%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member', window );">3.0% USD 1 750 million bond 2015/2025 of Novartis Capital Corporation, New York United States, issued at 99.010% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 1,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member', window );">4.0% USD 1 250 million bond 2015/2045 of Novartis Capital Corporation, New York United States, issued at 98.029% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">98.029%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 1,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member', window );">0.125% EUR 1 250 million bond 2016/2023 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.127% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">0.125%<span></span>
</td>
<td class="nump">0.125%<span></span>
</td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Finance S.A., Luxembourg, Luxembourg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.127%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 1,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member', window );">0.625% EUR 500 million bond 2016/2028 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 98.48% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">0.625%<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Finance S.A., Luxembourg, Luxembourg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">98.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member', window );">2.400% USD 1'000 million 2017/2022 of Novartis Capital Corporation, New York, United States, issued at 99.449% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.449%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member', window );">3.100% USD 1'000 million 2017/2027 of Novartis Capital Corporation, New York, United States, issued at 99.109% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.109%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member', window );">1.125% EUR 600 million 2017/2027 of Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.874% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">1.125%<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Finance S.A., Luxembourg, Luxembourg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.874%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member', window );">0.500% EUR 750 million 2018/2023 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.655% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Finance S.A., Luxembourg, Luxembourg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.655%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member', window );">1.375% EUR 750 million 2018/2030 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.957% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">1.375%<span></span>
</td>
<td class="nump">1.375%<span></span>
</td>
<td class="nump">1.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Finance S.A., Luxembourg, Luxembourg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.957%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member', window );">1.700% EUR 750 million 2018/2038 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.217% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Finance S.A., Luxembourg, Luxembourg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.217%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member', window );">1.750% USD 1 000 million 2020/2025 Novartis Capital Corporation, New York, United States, issued at 99.852% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.852%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member', window );">2.000% USD 1 250 million 2020/2027 Novartis Capital Corporation, New York, United States, issued at 99.909% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.909%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 1,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member', window );">2.200% USD 1 500 million 2020/2030 Novartis Capital Corporation, New York, United States, issued at 99.869% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.869%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 1,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member', window );">2.750% USD 1 250 million 2020/2050 Novartis Capital Corporation, New York, United States, issued at 97.712% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Capital Corporation, New York, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">97.712%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 1,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member', window );">0.000% 1 EUR 1 850 million 2020/2028 Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.354% [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, coupon</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsOriginalCurrency', window );">Borrowings, original currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsIssuanceDate', window );">Borrowings, issuance year</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity year</a></td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsLender', window );">Borrowings, issuer</a></td>
<td class="text">Novartis Finance S.A., Luxembourg, Luxembourg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsPremiumDiscount', window );">Borrowings, issue price</a></td>
<td class="nump">99.354%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 1,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsInterestRateStepUp', window );">Borrowings interest rate step up</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BondsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of bonds issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BondsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maturity of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsOriginalCurrency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The currency in which the borrowings are denominated. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsOriginalCurrency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BorrowingsInterestRateStepUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BorrowingsInterestRateStepUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BorrowingsIssuanceDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BorrowingsIssuanceDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BorrowingsLender">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BorrowingsLender</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BorrowingsPremiumDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BorrowingsPremiumDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>197
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571860901920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Non-current financial debt (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">$ 22,485<span></span>
</td>
<td class="nump">$ 25,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Not later than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">2,241<span></span>
</td>
<td class="nump">2,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Later than one year and not later than two years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">2,147<span></span>
</td>
<td class="nump">2,342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">Later than two years and not later than three years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">3,281<span></span>
</td>
<td class="nump">2,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember', window );">Later than three years and not later than four years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">638<span></span>
</td>
<td class="nump">3,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember', window );">Later than four years and not later than five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">2,909<span></span>
</td>
<td class="nump">693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=nvs_LaterThanFiveYearsAndNotLaterThanSixYearsMember', window );">Later than five years and not later than six years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">$ 11,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=nvs_LaterThanSixYearsMember', window );">Later than six years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,523<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=nvs_LaterThanFiveYearsAndNotLaterThanSixYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=nvs_LaterThanFiveYearsAndNotLaterThanSixYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=nvs_LaterThanSixYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=nvs_LaterThanSixYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>198
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571863861312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Non-current financial debt (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">$ 22,485<span></span>
</td>
<td class="nump">$ 25,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">13,376<span></span>
</td>
<td class="nump">15,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">7,478<span></span>
</td>
<td class="nump">7,930<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">JPY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">CHF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">1,488<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=nvs_CurrencyOthersMember', window );">Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems', window );"><strong>Disclosure of maturity analysis for non-derivative financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=nvs_CurrencyOthersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=nvs_CurrencyOthersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>199
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571861616992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Non-current financial debt (Details 4) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">$ 22,341<span></span>
</td>
<td class="nump">$ 25,296<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total</a></td>
<td class="nump">22,485<span></span>
</td>
<td class="nump">25,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueByMeasurementBasisAxis=nvs_CarryingReportedAmountFairValueDisclosureMember', window );">Balance sheet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">22,341<span></span>
</td>
<td class="nump">25,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherNoncurrentFinancialDebt', window );">Others</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total</a></td>
<td class="nump">22,485<span></span>
</td>
<td class="nump">25,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueByMeasurementBasisAxis=nvs_FairValueDisclosureItemAmountsMember', window );">Fair values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BondsIssued', window );">Straight bonds</a></td>
<td class="nump">20,277<span></span>
</td>
<td class="nump">27,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherNoncurrentFinancialDebt', window );">Others</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total</a></td>
<td class="nump">$ 20,421<span></span>
</td>
<td class="nump">$ 27,306<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BondsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of bonds issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BondsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherNoncurrentFinancialDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherNoncurrentFinancialDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueByMeasurementBasisAxis=nvs_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueByMeasurementBasisAxis=nvs_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueByMeasurementBasisAxis=nvs_FairValueDisclosureItemAmountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueByMeasurementBasisAxis=nvs_FairValueDisclosureItemAmountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>200
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864628800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provisions and other non-current liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan', window );">Defined benefit pension plans</a></td>
<td class="nump">$ 1,723<span></span>
</td>
<td class="nump">$ 2,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation', window );">Other long-term employee benefits and deferred compensation</a></td>
<td class="nump">554<span></span>
</td>
<td class="nump">662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherPostemploymentBenefits', window );">Other post-employment benefits</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalRemediationProvisionNoncurrent', window );">Environmental remediation provisions</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">567<span></span>
</td>
<td class="nump">$ 642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent', window );">Product liability, government investigations, other legal matters provisions</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">341<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContingentConsiderationNonCurrent', window );">Contingent consideration</a></td>
<td class="nump">704<span></span>
</td>
<td class="nump">956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">874<span></span>
</td>
<td class="nump">519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentNonfinancialLiabilities', window );">Total provisions and other non-current liabilities</a></td>
<td class="nump">$ 4,906<span></span>
</td>
<td class="nump">$ 6,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current net defined benefit liability. [Refer: Net defined benefit liability]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentNonfinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentNonfinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ContingentConsiderationNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ContingentConsiderationNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalRemediationProvisionNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalRemediationProvisionNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>201
<FILENAME>R128.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571860897968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions and other non-current liabilities (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionRollForward', window );"><strong>Environmental provision [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvision', window );">Environmental liabilities provision at beginning of period</a></td>
<td class="nump">$ 616<span></span>
</td>
<td class="nump">$ 809<span></span>
</td>
<td class="nump">$ 714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionPayments', window );">Cash payments</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionReleases', window );">Releases</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionAdditions', window );">Additions</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionForeignCurrencyTranslationGainLoss', window );">Currency translation effects</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvision', window );">Environmental liabilities provision at end of period</a></td>
<td class="nump">588<span></span>
</td>
<td class="nump">616<span></span>
</td>
<td class="nump">809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionCurrent', window );">Less current provision</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalRemediationProvisionNoncurrent', window );">Non-current environmental remediation provisions at end of period</a></td>
<td class="nump">$ 535<span></span>
</td>
<td class="nump">$ 567<span></span>
</td>
<td class="nump">$ 642<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionReleases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionReleases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalRemediationProvisionNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalRemediationProvisionNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>202
<FILENAME>R129.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571861692336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provisions and other non-current liabilities (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionFiscalYearMaturityAbstract', window );"><strong>Environmental provision, fiscal year maturity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionExpectedCashOutflowNextTwoYears', window );">Due within two years</a></td>
<td class="nump">$ 128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears', window );">Due later than two years, but within five years</a></td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears', window );">Due later than five years, but within ten years</a></td>
<td class="nump">251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionExpectedCashOutflowAfterTenYears', window );">Due after ten years</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvision', window );">Total environmental remediation liability provisions</a></td>
<td class="nump">$ 588<span></span>
</td>
<td class="nump">$ 616<span></span>
</td>
<td class="nump">$ 809<span></span>
</td>
<td class="nump">$ 714<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionExpectedCashOutflowAfterTenYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionExpectedCashOutflowAfterTenYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionExpectedCashOutflowNextTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionExpectedCashOutflowNextTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>203
<FILENAME>R130.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571861417184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provisions and other non-current liabilities (Details 3)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent', window );">Product liability, government investigations, other legal matters provisions</a></td>
<td class="nump">$ 154.0<span></span>
</td>
<td class="nump">$ 341.0<span></span>
</td>
<td class="nump">$ 181.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_IT', window );">Italy | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine', window );">Estimated financial effect of contingent liabilities, maximum fine</a></td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed', window );">Estimated financial effect of contingent liabilities, damages claimed</a></td>
<td class="nump">330.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_IT', window );">Italy | NAG and Novartis Pharma SpA [member] | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities', window );">Estimated financial effect of contingent liabilities</a></td>
<td class="nump">125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | Exforge Group [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmountOfSettlementInPrinciple', window );">Amount of settlement in principle</a></td>
<td class="nump">$ 245.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | Sandoz [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations', window );">Description of nature of obligation contingent liabilities, number of states with alleged violations</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmountOfSettlementInPrinciple', window );">Amount of settlement in principle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185.0<span></span>
</td>
<td class="nump">195.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | Sandoz [member] | Taxotere [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases', window );">Product liability contingency, loss exposure not accrued, number of cases</a></td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | Sandoz [member] | Amiodarone [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases', window );">Product liability contingency, loss exposure not accrued, number of cases</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | NPC and others [member] | Reclast/Aclasta [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases', window );">Product liability contingency, loss exposure not accrued, number of cases</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">US | NPC and others [member] | Tasigna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases', window );">Product liability contingency, loss exposure not accrued, number of cases</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">France | F Hoffman La Roche AG and Roche SpA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine', window );">Estimated financial effect of contingent liabilities, maximum fine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 452.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_GR', window );">Greece | Novartis (Hellas) S.A.C.I., Metamorphosis/Athens [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine', window );">Estimated financial effect of contingent liabilities, maximum fine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages', window );">Estimated financial effect of contingent liabilities, compensation for moral damages</a></td>
<td class="nump">$ 225.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the estimated financial effect of contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 86<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_86_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EstimatedFinancialEffectOfContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AmountOfSettlementInPrinciple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AmountOfSettlementInPrinciple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This expresses a maximal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NAGAndNovartisPharmaSpAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NAGAndNovartisPharmaSpAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TaxotereMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TaxotereMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_AmiodaroneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_AmiodaroneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NPCAndOthersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NPCAndOthersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_ReclastAclastaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_ReclastAclastaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_FHoffmanLaRocheAGAndRocheSpAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_FHoffmanLaRocheAGAndRocheSpAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>204
<FILENAME>R131.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862769664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions and other non-current liabilities (Details 4) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward', window );"><strong>Product liability, government investigations, other legal matters provisions [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions', window );">Product liabilities government investigations other legal matters provisions at beginning of period</a></td>
<td class="nump">$ 397<span></span>
</td>
<td class="nump">$ 487<span></span>
</td>
<td class="nump">$ 1,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations', window );">Impact of business combinations</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments', window );">Cash payments</a></td>
<td class="num">(105)<span></span>
</td>
<td class="num">(292)<span></span>
</td>
<td class="num">(1,863)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases', window );">Releases</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions', window );">Additions</a></td>
<td class="nump">466<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss', window );">Currency translation effects</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions', window );">Product liabilities government investigations other legal matters provisions at end of period</a></td>
<td class="nump">702<span></span>
</td>
<td class="nump">397<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent', window );">Less current provision</a></td>
<td class="num">(548)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="num">(306)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent', window );">Non-current product liabilities, governmental investigations and other legal matters provisions at end of period</a></td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">$ 341<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>205
<FILENAME>R132.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571842357440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current financial debt and derivative financial instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract', window );"><strong>Disclosure of current financial debt and derivative instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InterestBearningAccountsOfAssociatesPayableOnDemand', window );">Interest bearning accounts of associates payable on demand</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermBorrowings', window );">Bank and other financial debt</a></td>
<td class="nump">$ 863<span></span>
</td>
<td class="nump">899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommercialPapersIssued', window );">Commercial Papers</a></td>
<td class="nump">2,772<span></span>
</td>
<td class="nump">893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPortionOfLongtermBorrowings', window );">Current portion of non-current financial debt</a></td>
<td class="nump">2,241<span></span>
</td>
<td class="nump">2,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Fair value of derivative financial instruments</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Total current financial debt and derivative financial instruments</a></td>
<td class="nump">$ 5,931<span></span>
</td>
<td class="nump">$ 6,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_WeightedAverageInterestRateAssociates', window );">Weighted average interest rate, associates</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_WeightedAverageInterestRateOnBankAndOtherFinancialDebt', window );">Weighted average interest rate on Bank and other financial debt</a></td>
<td class="nump">9.70%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PaymentOfInterestBearingAccountsToBeneficiaries', window );">Payment of interest bearing accounts to beneficiaries</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommercialPapersIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of commercial paper issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommercialPapersIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPortionOfLongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPortionOfLongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InterestBearningAccountsOfAssociatesPayableOnDemand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InterestBearningAccountsOfAssociatesPayableOnDemand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PaymentOfInterestBearingAccountsToBeneficiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PaymentOfInterestBearingAccountsToBeneficiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_WeightedAverageInterestRateAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate on interest bearning accounts of associates payable on demand.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_WeightedAverageInterestRateAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_WeightedAverageInterestRateOnBankAndOtherFinancialDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate on Bank and other financial debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_WeightedAverageInterestRateOnBankAndOtherFinancialDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>206
<FILENAME>R133.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571861313936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Provisions and other current liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract', window );"><strong>Disclosure of provisions and other current liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Taxes other than income taxes</a></td>
<td class="nump">$ 836<span></span>
</td>
<td class="nump">$ 619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermRestructuringProvision', window );">Restructuring provisions</a></td>
<td class="nump">1,131<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccrualsClassifiedAsCurrent', window );">Accrued expenses for goods and services received but not invoiced</a></td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">1,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AccruedRoyaltiesPayableClassifiedAsCurrent', window );">Accruals for royalties</a></td>
<td class="nump">767<span></span>
</td>
<td class="nump">752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentInterestPayable', window );">Accrued interests on financial debt</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRefundsProvision', window );">Provisions for deductions from revenue</a></td>
<td class="nump">6,732<span></span>
</td>
<td class="nump">6,481<span></span>
</td>
<td class="nump">$ 6,256<span></span>
</td>
<td class="nump">$ 5,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsAccruals', window );">Accruals for compensation and benefits including social security</a></td>
<td class="nump">2,321<span></span>
</td>
<td class="nump">2,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EnvironmentalProvisionCurrent', window );">Environmental remediation liabilities</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities', window );">Current deferred income other than current contract liabilities</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent', window );">Provisions for product liabilities, governmental investigations and other legal matters</a></td>
<td class="nump">548<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011', window );">Accrued share-based payments</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContingentConsiderationCurrentPortion', window );">Contingent consideration</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentForRepurchaseOwnShares', window );">Commitment for repurchase own shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,809<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentPayables', window );">Other payables</a></td>
<td class="nump">743<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialLiabilities', window );">Total provisions and other current liabilities</a></td>
<td class="nump">$ 14,795<span></span>
</td>
<td class="nump">$ 15,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccrualsClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals classified as current. [Refer: Accruals]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccrualsClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current deferred income other than current contract liabilities. [Refer: Deferred income other than contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInterestPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current interest payable. [Refer: Interest payable]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInterestPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRefundsProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provision for refunds. [Refer: Refunds provision]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Section Example 4 Refunds policy<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS37_IE_C_ex4__IAS37_IE_C_ex4_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 87<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_87&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRefundsProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities arising from share-based payment transactions. Share-based payment transactions are transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 51<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_51_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentNonfinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentNonfinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermRestructuringProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provision for restructuring. [Refer: Restructuring provision]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermRestructuringProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AccruedRoyaltiesPayableClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AccruedRoyaltiesPayableClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CommitmentForRepurchaseOwnShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CommitmentForRepurchaseOwnShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ContingentConsiderationCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ContingentConsiderationCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EnvironmentalProvisionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EnvironmentalProvisionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>207
<FILENAME>R134.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862216464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions and other current liabilities (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ProvisionsForDeductionsFromRevenueRollForward', window );"><strong>Provisions for deductions from revenue [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRefundsProvision', window );">Provisions for deductions from revenue, at beginning of period</a></td>
<td class="nump">$ 6,481<span></span>
</td>
<td class="nump">$ 6,256<span></span>
</td>
<td class="nump">$ 5,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Effects of currency translation and business combinations</a></td>
<td class="num">(210)<span></span>
</td>
<td class="num">(218)<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Payments/utilizations</a></td>
<td class="num">(22,261)<span></span>
</td>
<td class="num">(19,838)<span></span>
</td>
<td class="num">(19,294)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncomeStatementAdjustmentsOfPriorYear', window );">Additions prior year</a></td>
<td class="num">(322)<span></span>
</td>
<td class="num">(245)<span></span>
</td>
<td class="num">(151)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncomeStatementAdjustmentsOfCurrentYear', window );">Additions current year</a></td>
<td class="nump">23,072<span></span>
</td>
<td class="nump">20,413<span></span>
</td>
<td class="nump">19,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangesInOffsetAgainstGrossTradeReceivables', window );">Changes in offset against gross trade receivables</a></td>
<td class="num">(28)<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRefundsProvision', window );">Provisions for deductions from revenue, at end of period</a></td>
<td class="nump">$ 6,732<span></span>
</td>
<td class="nump">$ 6,481<span></span>
</td>
<td class="nump">$ 6,256<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRefundsProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provision for refunds. [Refer: Refunds provision]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Section Example 4 Refunds policy<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS37_IE_C_ex4__IAS37_IE_C_ex4_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 87<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_87&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRefundsProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionUsedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionUsedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangesInOffsetAgainstGrossTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangesInOffsetAgainstGrossTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncomeStatementAdjustmentsOfCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncomeStatementAdjustmentsOfCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncomeStatementAdjustmentsOfPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncomeStatementAdjustmentsOfPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ProvisionsForDeductionsFromRevenueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ProvisionsForDeductionsFromRevenueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>208
<FILENAME>R135.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571861356768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provisions and other current liabilities (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RestructuringProvisionsMovementsRollForward', window );"><strong>Restructuring provisions movements [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Cash payments</a></td>
<td class="num">$ (22,261)<span></span>
</td>
<td class="num">$ (19,838)<span></span>
</td>
<td class="num">$ (19,294)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_RestructuringProvisionMember', window );">Restructuring provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RestructuringProvisionsMovementsRollForward', window );"><strong>Restructuring provisions movements [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Provision at beginning of period</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Additions</a></td>
<td class="nump">1,368<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Cash payments</a></td>
<td class="num">(468)<span></span>
</td>
<td class="num">(344)<span></span>
</td>
<td class="num">(268)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedProvisionReversedOtherProvisions', window );">Releases</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions', window );">Transfers</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions', window );">Currency translation effects</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Provision at end of period</a></td>
<td class="nump">$ 1,131<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 459<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional other provisions made. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of provisions other than provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionUsedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionUsedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedProvisionReversedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount reversed for unused other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedProvisionReversedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RestructuringProvisionsMovementsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RestructuringProvisionsMovementsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=ifrs-full_RestructuringProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=ifrs-full_RestructuringProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>209
<FILENAME>R136.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571842223680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated cash flow statements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract', window );"><strong>Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities', window );">Change in provisions and other non-current liabilities</a></td>
<td class="nump">$ 1,403<span></span>
</td>
<td class="nump">$ 896<span></span>
</td>
<td class="nump">$ 1,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets', window );">Gains on disposal and other adjustments on property, plant and equipment; intangible assets;financial assets; and other non-current assets, net</a></td>
<td class="num">(333)<span></span>
</td>
<td class="num">(677)<span></span>
</td>
<td class="num">(478)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Equity-settled compensation expense</a></td>
<td class="nump">823<span></span>
</td>
<td class="nump">736<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod', window );">Loss/(income) from associated companies</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(15,339)<span></span>
</td>
<td class="num">(673)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income taxes</a></td>
<td class="nump">1,416<span></span>
</td>
<td class="nump">2,119<span></span>
</td>
<td class="nump">1,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncomeCost', window );">Net financial expense</a></td>
<td class="nump">817<span></span>
</td>
<td class="nump">891<span></span>
</td>
<td class="nump">947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsForNoncashItems', window );">Other</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLoss', window );">Total</a></td>
<td class="nump">11,546<span></span>
</td>
<td class="num">(5,299)<span></span>
</td>
<td class="nump">9,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember', window );">Property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract', window );"><strong>Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="nump">1,570<span></span>
</td>
<td class="nump">1,489<span></span>
</td>
<td class="nump">1,758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember', window );">Right-of-use assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract', window );"><strong>Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing', window );">Acquisition of assets (right of use assets) through leasing</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">321<span></span>
</td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsAndGoodwillMember', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract', window );"><strong>Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="nump">5,308<span></span>
</td>
<td class="nump">4,306<span></span>
</td>
<td class="nump">4,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_FinancialAssetsImpairedMember', window );">Financial assets impaired [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract', window );"><strong>Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss</a></td>
<td class="nump">260<span></span>
</td>
<td class="num">$ (38)<span></span>
</td>
<td class="num">$ (335)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember', window );">Intangible assets other than goodwill [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract', window );"><strong>Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities', window );">Acquisition of assets (other than through business combinations) by assuming directly related liabilities</a></td>
<td class="nump">$ 635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss; Depreciation and amortisation expense; Impairment loss (reversal of impairment loss) recognised in profit or loss; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 14<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_14&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAdjustmentsForNoncashItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAdjustmentsForNoncashItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39M<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39M_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_RightofuseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsAndGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsAndGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_FinancialAssetsImpairedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_FinancialAssetsImpairedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>210
<FILENAME>R137.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862185344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated cash flow statements (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefund', window );">Income taxes paid (refund)</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Income taxes paid (refund), classified as operating activities</a></td>
<td class="nump">$ 1,975<span></span>
</td>
<td class="nump">$ 2,342<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember', window );">Discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities', window );">Income taxes paid (refund), classified as investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as investing activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 14<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 14<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_DiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>211
<FILENAME>R138.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571861122000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated cash flow statements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">(Increase)/decrease in inventories</a></td>
<td class="num">$ (830)<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="num">$ (543)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">(Increase)/decrease in trade receivables</a></td>
<td class="num">(589)<span></span>
</td>
<td class="num">(389)<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Decrease in trade payables</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(324)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets', window );">Change in other current and non-current assets</a></td>
<td class="num">(194)<span></span>
</td>
<td class="num">(202)<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities', window );">Change in other current liabilities</a></td>
<td class="nump">658<span></span>
</td>
<td class="nump">772<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsToReconcileProfitLoss', window );">Other adjustments, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems', window );">Total</a></td>
<td class="num">$ (1,003)<span></span>
</td>
<td class="nump">$ 241<span></span>
</td>
<td class="num">$ (291)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAdjustmentsToReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Adjustments to reconcile profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAdjustmentsToReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>212
<FILENAME>R139.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571860975760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated cash flow statements (Details 5) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities', window );">Net cash flows</a></td>
<td class="num">$ (879)<span></span>
</td>
<td class="num">$ (567)<span></span>
</td>
<td class="num">$ (9,957)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AcquisitionsAndDivestmentsAxis=nvs_AcquisitionsMember', window );">Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashFlowFromNetIdentifiableAssets', window );">Net assets recognized as a result of acquistions of businesses</a></td>
<td class="num">(1,077)<span></span>
</td>
<td class="num">(735)<span></span>
</td>
<td class="num">(10,173)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate', window );">Fair value of previously held equity interests</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ReceivablesAndPayablesContingentConsiderationNet', window );">Contingent consideration payables, net</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherPaymentsAndDeferredConsiderationNet', window );">Payments, deferred consideration and other adjustments, net</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities', window );">Net cash flows</a></td>
<td class="num">(864)<span></span>
</td>
<td class="num">(633)<span></span>
</td>
<td class="num">(10,006)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AcquisitionsAndDivestmentsAxis=nvs_DivestmentsMember', window );">Divestments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities', window );">Net cash flows</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NoncurrentAssetsDivested', window );">Non-current assets divested</a></td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Net cash inflows from divestment</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrentAssetsDivested', window );">Current assets divested</a></td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013', window );">Cash and cash equivalents in subsidiary or businesses acquired or disposed</a></td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DeferredSalePriceAndOtherAdjustments', window );">Deferred sale price and other adjustments</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashOutflowsDueToDerecognizedCashAndCashEquivalents', window );">Cash outflows due to derecognized cash and cash equivalents</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NoncurrentAndCurrentLiabilitiesDivested', window );">Non-current and current liabilities divested</a></td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NetIdentifiableAssetsOfDivestedBusiness', window );">Net identifiable assets of divested business</a></td>
<td class="nump">$ 173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AcquisitionsAndDivestmentsAxis=nvs_DivestmentsMember', window );">Divestments | Intangible assets and goodwill [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Net cash inflows from divestment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The acquisition-date fair value of equity interest in the acquiree held by the acquirer immediately before the acquisition date in a business combination achieved in stages. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph p<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_p_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents in subsidiaries or other businesses over which control is obtained or lost. [Refer: Subsidiaries [member]; Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 40<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_40_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsiderationPaidReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 40<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_40_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsiderationPaidReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashFlowFromNetIdentifiableAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash inflow (outflow) from Net identifiable assets (acquired) or divested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashFlowFromNetIdentifiableAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashOutflowsDueToDerecognizedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashOutflowsDueToDerecognizedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrentAssetsDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrentAssetsDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DeferredSalePriceAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DeferredSalePriceAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetIdentifiableAssetsOfDivestedBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetIdentifiableAssetsOfDivestedBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NoncurrentAndCurrentLiabilitiesDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NoncurrentAndCurrentLiabilitiesDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NoncurrentAssetsDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NoncurrentAssetsDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherPaymentsAndDeferredConsiderationNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherPaymentsAndDeferredConsiderationNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ReceivablesAndPayablesContingentConsiderationNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ReceivablesAndPayablesContingentConsiderationNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AcquisitionsAndDivestmentsAxis=nvs_AcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AcquisitionsAndDivestmentsAxis=nvs_AcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AcquisitionsAndDivestmentsAxis=nvs_DivestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AcquisitionsAndDivestmentsAxis=nvs_DivestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_IntangibleAssetsAndGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_IntangibleAssetsAndGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>213
<FILENAME>R140.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571855716256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated cash flow statements (Details 6) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments at beginning of period</a></td>
<td class="nump">$ 29,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Increase in non-current financial debts</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 7,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfNoncurrentBorrowings', window );">Repayments of the current portion of non-current financial debts</a></td>
<td class="num">(2,575)<span></span>
</td>
<td class="num">(2,162)<span></span>
</td>
<td class="num">(2,003)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings', window );">Change in current financial debts</a></td>
<td class="nump">295<span></span>
</td>
<td class="num">(3,524)<span></span>
</td>
<td class="nump">2,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payments of lease liabilities</a></td>
<td class="num">(295)<span></span>
</td>
<td class="num">(316)<span></span>
</td>
<td class="num">(312)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments at end of period</a></td>
<td class="nump">26,175<span></span>
</td>
<td class="nump">29,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand', window );">Cash outflows from interest bearing accounts of employees payable on demand</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_NonCurrentFinancialDebtsMember', window );">Non-current financial debts [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments at beginning of period</a></td>
<td class="nump">22,902<span></span>
</td>
<td class="nump">26,259<span></span>
</td>
<td class="nump">20,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromNoncurrentBorrowings', window );">Increase in non-current financial debts</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">7,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges', window );">Changes in fair values, lease interest and other changes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmortizationOfBondsDiscount', window );">Amortization of bonds discount</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Currency translation effects</a></td>
<td class="num">(366)<span></span>
</td>
<td class="num">(774)<span></span>
</td>
<td class="nump">832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ReclassificationFromNoncurrentToCurrentNet', window );">Reclassification from non-current to current, net</a></td>
<td class="num">(2,325)<span></span>
</td>
<td class="num">(2,624)<span></span>
</td>
<td class="num">(2,067)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments at end of period</a></td>
<td class="nump">20,244<span></span>
</td>
<td class="nump">22,902<span></span>
</td>
<td class="nump">26,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember', window );">Current financial debts and derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments at beginning of period</a></td>
<td class="nump">6,295<span></span>
</td>
<td class="nump">9,785<span></span>
</td>
<td class="nump">7,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfNoncurrentBorrowings', window );">Repayments of the current portion of non-current financial debts</a></td>
<td class="num">(2,575)<span></span>
</td>
<td class="num">(2,162)<span></span>
</td>
<td class="num">(2,003)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings', window );">Change in current financial debts</a></td>
<td class="nump">295<span></span>
</td>
<td class="num">(3,524)<span></span>
</td>
<td class="nump">2,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities', window );">Impact of acquisitions and divestments of businesses, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges', window );">Changes in fair values, lease interest and other changes, net</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmortizationOfBondsDiscount', window );">Amortization of bonds discount</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Currency translation effects</a></td>
<td class="num">(401)<span></span>
</td>
<td class="num">(309)<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ReclassificationFromNoncurrentToCurrentNet', window );">Reclassification from non-current to current, net</a></td>
<td class="nump">2,325<span></span>
</td>
<td class="nump">2,624<span></span>
</td>
<td class="nump">2,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments at end of period</a></td>
<td class="nump">5,931<span></span>
</td>
<td class="nump">6,295<span></span>
</td>
<td class="nump">9,785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_NoncurrentLeaseLiabilitiesMember', window );">Non-current lease liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments at beginning of period</a></td>
<td class="nump">1,621<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
<td class="nump">1,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities', window );">New, modified and terminated leases, net</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities', window );">Impact of acquisitions and divestments of businesses, net</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges', window );">Changes in fair values, lease interest and other changes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Currency translation effects</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ReclassificationFromNoncurrentToCurrentNet', window );">Reclassification from non-current to current, net</a></td>
<td class="num">(224)<span></span>
</td>
<td class="num">(247)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments at end of period</a></td>
<td class="nump">1,538<span></span>
</td>
<td class="nump">1,621<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_CurrentLeaseLiabilitiesMember', window );">Current lease liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments at beginning of period</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">286<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payments of lease liabilities</a></td>
<td class="num">(295)<span></span>
</td>
<td class="num">(316)<span></span>
</td>
<td class="num">(312)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities', window );">Interest payments for amounts included in lease liabilities classified as cash flows from operating activities</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities', window );">New, modified and terminated leases, net</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities', window );">Impact of acquisitions and divestments of businesses, net</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges', window );">Changes in fair values, lease interest and other changes, net</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Currency translation effects</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ReclassificationFromNoncurrentToCurrentNet', window );">Reclassification from non-current to current, net</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialDebtsAndDerivativeInstruments', window );">Financial debts and derivative instruments at end of period</a></td>
<td class="nump">$ 251<span></span>
</td>
<td class="nump">$ 275<span></span>
</td>
<td class="nump">$ 286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to an increase (decrease) in current borrowings. [Refer: Current borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 44B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_44B_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from obtaining or losing control of subsidiaries or other businesses. [Refer: Liabilities arising from financing activities; Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 44B<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_44B_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from non-current borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AmortizationOfBondsDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AmortizationOfBondsDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialDebtsAndDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialDebtsAndDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ReclassificationFromNoncurrentToCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ReclassificationFromNoncurrentToCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_NonCurrentFinancialDebtsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=nvs_NonCurrentFinancialDebtsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=nvs_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_NoncurrentLeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=nvs_NoncurrentLeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=nvs_CurrentLeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=nvs_CurrentLeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>214
<FILENAME>R141.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571859618352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Details to the consolidated cash flow statements (Details 7)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash flows used in investing activities from discontinued operations</a></td>
<td class="num">$ (127)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash flows used in financing activities from discontinued operations</a></td>
<td class="num">$ (50)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's financing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) the entity's investing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) investing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>215
<FILENAME>R142.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864869216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions of businesses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems', window );"><strong>Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate', window );">Property, plant and equipment</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RightOfUseAssetsAsOfAcquisitionDate', window );">Right-of-use assets</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Currently marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 292<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Acquired research and development</a></td>
<td class="nump">1,209<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate', window );">Deferred tax assets</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialAndOtherAssets', window );">Non-current financial and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoryRecognisedAsOfAcquisitionDate', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate', window );">Trade receivables and financial and other current assets</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate', window );">Cash and cash equivalents</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate', window );">Deferred tax liabilities</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="num">(1,977)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate', window );">Current and non-current financial debts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate', window );">Current and non-current lease liabilities</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_TradePayablesAndOtherLiabilities', window );">Trade payables and other liabilities</a></td>
<td class="num">(67)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IdentifiableAssetsAcquired', window );">Net identifiable assets acquired</a></td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">612<span></span>
</td>
<td class="nump">7,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AcquiredCashAndCashEquivalents', window );">Acquired cash and cash equivalents</a></td>
<td class="num">(89)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate', window );">Non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate', window );">Goodwill</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="nump">2,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Net assets recognized as a result of acquisitions of business</a></td>
<td class="nump">1,077<span></span>
</td>
<td class="nump">735<span></span>
</td>
<td class="nump">10,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GoodwillExpectedDeductibleForTaxPurposes', window );">Goodwill expected to be deductible for tax purposes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for deferred tax assets acquired in a business combination. [Refer: Deferred tax assets; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for deferred tax liabilities assumed in a business combination. [Refer: Deferred tax liabilities; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for financial liabilities assumed in a business combination. [Refer: Financial liabilities; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GoodwillExpectedDeductibleForTaxPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill in a business combination that is expected to be deductible for tax purposes. [Refer: Goodwill; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_k&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GoodwillExpectedDeductibleForTaxPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GoodwillRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoryRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for inventory acquired in a business combination. [Refer: Inventories; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoryRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-controlling interest in the acquiree recognised at the acquisition date for business combinations in which the acquirer holds less than 100 per cent of the equity interests in the acquiree at the acquisition date. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph o<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_o_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for plant, property and equipment acquired in a business combination. [Refer: Property, plant and equipment; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2022-03-24<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AcquiredCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AcquiredCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IdentifiableAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IdentifiableAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RightOfUseAssetsAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RightOfUseAssetsAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TradePayablesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TradePayablesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>216
<FILENAME>R143.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571861549424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-employment benefits for employees (Details)<br> SFr in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ConcentrationOfMajorPlansGeographic', window );">Concentration of major plans, geographic</a></td>
<td class="text">

                  In addition to the legally required social security schemes, the Group has numerous independent pension and other post-employment benefit plans. In most cases, these plans are externally funded in entities that are legally separate from the Group. For certain Group companies, however, no independent plan assets exist for the pension and other post-employment benefit obligations of employees. In these cases, the related unfunded liability is included in the balance sheet. The defined benefit obligations (DBOs) of all major pension and other post-employment benefit plans are reappraised annually by independent actuaries. Plan assets are recognized at fair value. The major plans are based in Switzerland, the United States, the United Kingdom, Germany and Japan, which represent 95% of the Group&#8217;s total DBO for pension plans. Details of the plans in the two most significant countries, Switzerland and the United States, which represent 83% of the Group&#8217;s total DBO for post-employment benefit plans, are provided below.

              <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MajorPlansPercentageInGroupDBOPensions', window );">Major plans percentage in group DBO pensions</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans', window );">Most signigicant countries percentage on group DBO post employment benefit plans</a></td>
<td class="nump">83.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Net Pre-tax curtailment gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
<td class="nump">SFr 90<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ConcentrationOfMajorPlansGeographic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the major plans and the concentration of the Group's DBO by geography.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ConcentrationOfMajorPlansGeographic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MajorPlansPercentageInGroupDBOPensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MajorPlansPercentageInGroupDBOPensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>217
<FILENAME>R144.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571842304704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-employment benefits for employees (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Defined benefit plan, change in benefit obligation [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Benefit obligation at beginning of period</a></td>
<td class="nump">$ 23,583<span></span>
</td>
<td class="nump">$ 25,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset', window );">Past service cost and settlements</a></td>
<td class="num">(40)<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset', window );">Administrative expenses</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Remeasurement losses/(gains) arising from changes in financial assumptions</a></td>
<td class="num">(5,046)<span></span>
</td>
<td class="num">(713)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset', window );">Remeasurement (gains) arising from changes in demographic assumptions</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(377)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset', window );">Experience-related remeasurement losses/(gains)</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability', window );">Currency translation effects</a></td>
<td class="num">(650)<span></span>
</td>
<td class="num">(865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefit payments</a></td>
<td class="num">(1,253)<span></span>
</td>
<td class="num">(1,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation', window );">Contributions of associates</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1', window );">Effect of acquisitions, divestments or transfers</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Benefit obligation at end of period</a></td>
<td class="nump">17,533<span></span>
</td>
<td class="nump">23,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined benefit plan, change in fair value of plan assets [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets at beginning of period</a></td>
<td class="nump">22,420<span></span>
</td>
<td class="nump">22,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset', window );">Interest income</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset', window );">Return on plan assets excluding interest income</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="nump">1,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset', window );">Currency translation effects</a></td>
<td class="num">(539)<span></span>
</td>
<td class="num">(726)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Novartis Group contributions</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset', window );">Contributions of associates</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefit payments</a></td>
<td class="num">(1,253)<span></span>
</td>
<td class="num">(1,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets at end of period</a></td>
<td class="nump">18,945<span></span>
</td>
<td class="nump">22,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Funded status</a></td>
<td class="nump">1,412<span></span>
</td>
<td class="num">(1,163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward', window );"><strong>Defined benefit plan, change in limitation on recognition of fund surplus [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LimitationOnRecognitionOfFundSurplus', window );">Limitation on recognition of fund surplus at beginning of period</a></td>
<td class="num">(62)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling', window );">Change in limitation on recognition of fund surplus</a></td>
<td class="num">(2,504)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus', window );">Currency translation effects</a></td>
<td class="num">(76)<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InterestIncomeOnLimitationOfFundSurplus', window );">Interest income on limitation of fund surplus</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LimitationOnRecognitionOfFundSurplus', window );">Limitation on recognition of fund surplus at end of period</a></td>
<td class="num">(2,644)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net liability in the balance sheet at end of period</a></td>
<td class="num">(1,232)<span></span>
</td>
<td class="num">(1,225)<span></span>
</td>
<td class="num">$ (3,336)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Defined benefit plan, change in benefit obligation [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Benefit obligation at beginning of period</a></td>
<td class="nump">15,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Benefit obligation at end of period</a></td>
<td class="nump">11,824<span></span>
</td>
<td class="nump">15,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined benefit plan, change in fair value of plan assets [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets at beginning of period</a></td>
<td class="nump">16,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets at end of period</a></td>
<td class="nump">14,701<span></span>
</td>
<td class="nump">16,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Funded status</a></td>
<td class="nump">2,877<span></span>
</td>
<td class="nump">1,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward', window );"><strong>Defined benefit plan, change in limitation on recognition of fund surplus [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LimitationOnRecognitionOfFundSurplus', window );">Limitation on recognition of fund surplus at end of period</a></td>
<td class="nump">2,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Defined benefit plan, change in benefit obligation [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Benefit obligation at beginning of period</a></td>
<td class="nump">560<span></span>
</td>
<td class="nump">632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset', window );">Past service cost and settlements</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset', window );">Remeasurement losses/(gains) arising from changes in financial assumptions</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset', window );">Remeasurement (gains) arising from changes in demographic assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset', window );">Experience-related remeasurement losses/(gains)</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability', window );">Currency translation effects</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefit payments</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Benefit obligation at end of period</a></td>
<td class="nump">422<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined benefit plan, change in fair value of plan assets [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets at beginning of period</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset', window );">Interest income</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset', window );">Return on plan assets excluding interest income</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset', window );">Novartis Group contributions</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset', window );">Benefit payments</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Fair value of plan assets at end of period</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Funded status</a></td>
<td class="num">(362)<span></span>
</td>
<td class="num">(487)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward', window );"><strong>Defined benefit plan, change in limitation on recognition of fund surplus [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net liability in the balance sheet at end of period</a></td>
<td class="num">$ (362)<span></span>
</td>
<td class="num">$ (487)<span></span>
</td>
<td class="num">$ (543)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions that result in remeasurements of the net defined benefit liability (asset). Demographic assumptions deal with matters such as: (a) mortality; (b) rates of employee turnover, disability and early retirement; (c) the proportion of plan members with dependants who will be eligible for benefits; (d) the proportion of plan members who will select each form of payment option available under the plan terms; and (e) claim rates under medical plans. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in net defined benefit liability (asset) resulting from contributions to a defined benefit plan by the employer. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from contributions to a defined benefit plan by plan participants. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitObligationAtPresentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitObligationAtPresentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from the gain (loss) on changes in the effect of limiting a net defined benefit asset to the asset ceiling, excluding amounts included in interest income or expense. [Refer: Interest income (expense); Net defined benefit liability (asset); Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 140<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilityAssetOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PlanAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of defined benefit plan assets. Plan assets comprise assets held by a long-term employee benefit fund and qualifying insurance policies. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PlanAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from the return on plan assets, excluding amounts included in interest income or expense. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Plan assets [member]; Net defined benefit liability (asset); Actuarial assumptions [member]; Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SurplusDeficitInPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of any plan assets, less the present value of the defined benefit obligation. [Refer: Plan assets [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SurplusDeficitInPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in a defined benefit pension plan's projected benefit obligation or a defined benefit postretirement plan's accumulated postretirement benefit obligation due to the passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanSettlementsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanSettlementsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_InterestIncomeOnLimitationOfFundSurplus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_InterestIncomeOnLimitationOfFundSurplus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LimitationOnRecognitionOfFundSurplus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LimitationOnRecognitionOfFundSurplus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>218
<FILENAME>R145.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571853398784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-employment benefits for employees (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract', window );"><strong>Amounts recognized in the consolidated balance sheet [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PrepaidPostemploymentBenefitPlansAssets', window );">Prepaid benefit cost</a></td>
<td class="nump">$ 491<span></span>
</td>
<td class="nump">$ 1,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward', window );"><strong>Defined benefit plan, change in net liability [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net liability at beginning of period</a></td>
<td class="num">(1,225)<span></span>
</td>
<td class="num">(3,336)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="num">(348)<span></span>
</td>
<td class="num">(415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Net interest expense</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets', window );">Administrative expenses</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Past service cost and settlements</a></td>
<td class="nump">39<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurements</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">2,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset', window );">Currency translation effects</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset', window );">Novartis Group contributions</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1', window );">Effect of acquisitions, divestments or transfers</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling', window );">Change in limitation on recognition of fund surplus</a></td>
<td class="num">(2,504)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net liability at end of period</a></td>
<td class="num">(1,232)<span></span>
</td>
<td class="num">(1,225)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract', window );"><strong>Amounts recognized in the consolidated balance sheet [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PrepaidPostemploymentBenefitPlansAssets', window );">Prepaid benefit cost</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">1,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities', window );">Accrued benefit liability</a></td>
<td class="num">(1,723)<span></span>
</td>
<td class="num">(2,640)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward', window );"><strong>Defined benefit plan, change in net liability [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net liability at beginning of period</a></td>
<td class="num">(487)<span></span>
</td>
<td class="num">(543)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset', window );">Current service cost</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset', window );">Net interest expense</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset', window );">Past service cost and settlements</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurements</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset', window );">Currency translation effects</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset', window );">Novartis Group contributions</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Net liability at end of period</a></td>
<td class="num">(362)<span></span>
</td>
<td class="num">(487)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract', window );"><strong>Amounts recognized in the consolidated balance sheet [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities', window );">Accrued benefit liability</a></td>
<td class="num">$ (362)<span></span>
</td>
<td class="num">$ (487)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in net defined benefit liability (asset) resulting from contributions to a defined benefit plan by the employer. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in the net defined benefit liability (asset) resulting from the gain (loss) on changes in the effect of limiting a net defined benefit asset to the asset ceiling, excluding amounts included in interest income or expense. [Refer: Interest income (expense); Net defined benefit liability (asset); Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from administration costs in the current period, that are not reflected in return on plan assets. [Refer: Administrative expenses; Net defined benefit liability (asset)] [Contrast: Administration costs not reflected in return on plan assets, defined benefit plans; Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from changes in foreign exchange rates. [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from the passage of time. [Refer: Interest expense; Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 140<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilityAssetOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from past service cost and losses (gains) arising from settlements. [Refer: Decrease (increase) in net defined benefit liability (asset) resulting from gains (losses) arising from settlements; Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PrepaidPostemploymentBenefitPlansAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PrepaidPostemploymentBenefitPlansAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>219
<FILENAME>R146.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571840354480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Post-employment benefits for employees (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">$ 17,533<span></span>
</td>
<td class="nump">$ 23,583<span></span>
</td>
<td class="nump">$ 25,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Plan assets, at fair value</a></td>
<td class="nump">18,945<span></span>
</td>
<td class="nump">22,420<span></span>
</td>
<td class="nump">22,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Funded status</a></td>
<td class="nump">1,412<span></span>
</td>
<td class="num">(1,163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Unfunded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">919<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Active</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">6,161<span></span>
</td>
<td class="nump">8,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Deferred pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">1,691<span></span>
</td>
<td class="nump">2,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">9,681<span></span>
</td>
<td class="nump">12,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">11,824<span></span>
</td>
<td class="nump">15,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Plan assets, at fair value</a></td>
<td class="nump">14,701<span></span>
</td>
<td class="nump">16,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Funded status</a></td>
<td class="nump">2,877<span></span>
</td>
<td class="nump">1,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Switzerland | Active</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">4,799<span></span>
</td>
<td class="nump">6,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Switzerland | Pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">7,025<span></span>
</td>
<td class="nump">8,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">2,746<span></span>
</td>
<td class="nump">3,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Plan assets, at fair value</a></td>
<td class="nump">1,978<span></span>
</td>
<td class="nump">2,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Funded status</a></td>
<td class="num">(768)<span></span>
</td>
<td class="num">(1,094)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | US | Unfunded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">556<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | US | Active</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | US | Deferred pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">830<span></span>
</td>
<td class="nump">1,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | US | Pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">1,485<span></span>
</td>
<td class="nump">1,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Rest of the world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">2,963<span></span>
</td>
<td class="nump">4,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Plan assets, at fair value</a></td>
<td class="nump">2,266<span></span>
</td>
<td class="nump">3,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Funded status</a></td>
<td class="num">(697)<span></span>
</td>
<td class="num">(1,237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Rest of the world | Unfunded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">363<span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Rest of the world | Active</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">931<span></span>
</td>
<td class="nump">1,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Rest of the world | Deferred pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">861<span></span>
</td>
<td class="nump">1,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Rest of the world | Pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">1,171<span></span>
</td>
<td class="nump">1,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">422<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="nump">632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Plan assets, at fair value</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Funded status</a></td>
<td class="num">(362)<span></span>
</td>
<td class="num">(487)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Unfunded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Active</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Deferred pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">366<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Plan assets, at fair value</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Funded status</a></td>
<td class="num">(286)<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | US | Unfunded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | US | Active</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | US | Deferred pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | US | Pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Rest of the world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PlanAssetsAtFairValue', window );">Plan assets, at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SurplusDeficitInPlan', window );">Funded status</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Rest of the world | Unfunded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Rest of the world | Active</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Rest of the world | Deferred pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Rest of the world | Pensioners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems', window );"><strong>Disclosure of net defined benefit liability (asset) [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Defined benefit obligation, at present value</a></td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitObligationAtPresentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitObligationAtPresentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PlanAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of defined benefit plan assets. Plan assets comprise assets held by a long-term employee benefit fund and qualifying insurance policies. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PlanAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SurplusDeficitInPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of any plan assets, less the present value of the defined benefit obligation. [Refer: Plan assets [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SurplusDeficitInPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ObligationByTypeAxis=nvs_UnfundedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ObligationByTypeAxis=nvs_UnfundedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ObligationByTypeAxis=nvs_ActiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ObligationByTypeAxis=nvs_ActiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ObligationByTypeAxis=nvs_DeferredPensionersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ObligationByTypeAxis=nvs_DeferredPensionersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ObligationByTypeAxis=nvs_PensionersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ObligationByTypeAxis=nvs_PensionersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_ForeignCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>220
<FILENAME>R147.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571849906192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-employment benefits for employees (Details 4)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfDiscountRates', window );">Discount rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases', window );">Expected rate of pension increase</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases', window );">Expected rate of salary increase</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount', window );">Interest on savings account</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitAssumptionLifeExpectancyMale', window );">Current life expectancy for a 65-year-old male</a></td>
<td class="text">22 years<span></span>
</td>
<td class="text">22 years<span></span>
</td>
<td class="text">22 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitAssumptionLifeExpectancyFemale', window );">Current life expectancy for a 65-year-old female</a></td>
<td class="text">24 years<span></span>
</td>
<td class="text">24 years<span></span>
</td>
<td class="text">24 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionOfDiscountRates', window );">Discount rate</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitAssumptionLifeExpectancyMale', window );">Current life expectancy for a 65-year-old male</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">21 years<span></span>
</td>
<td class="text">21 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitAssumptionLifeExpectancyFemale', window );">Current life expectancy for a 65-year-old female</a></td>
<td class="text">23 years<span></span>
</td>
<td class="text">23 years<span></span>
</td>
<td class="text">23 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfDiscountRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 144<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfDiscountRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected rate of increases in pension that is used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 144<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 144<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_144&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitAssumptionLifeExpectancyFemale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitAssumptionLifeExpectancyFemale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitAssumptionLifeExpectancyMale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitAssumptionLifeExpectancyMale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>221
<FILENAME>R148.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571860673680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Post-employment benefits for employees (Details 5) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember', window );">Discount rate | 25 basis point change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption</a></td>
<td class="num">$ (466)<span></span>
</td>
<td class="num">$ (790)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption', window );">Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=nvs_LifeExpectancyMember', window );">Life expectancy | 1 year increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember', window );">Rate of pension increase | 25 basis point change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption', window );">Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember', window );">Interest on savings account | 25 basis point change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption', window );">Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember', window );">Salary increase | 25 basis point change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems', window );"><strong>Disclosure of sensitivity analysis for actuarial assumptions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption', window );">Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption', window );">Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption</a></td>
<td class="num">$ (37)<span></span>
</td>
<td class="num">$ (54)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a defined benefit obligation that would have been caused by a decrease in a significant actuarial assumption that was reasonably possible at the end of the reporting period. [Refer: Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 145<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a defined benefit obligation that would have been caused by an increase in a significant actuarial assumption that was reasonably possible at the end of the reporting period. [Refer: Actuarial assumptions [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 145<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_145_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfDiscountRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeInActuarialAssumptionAxis=nvs_Change25BasisPointMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeInActuarialAssumptionAxis=nvs_Change25BasisPointMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=nvs_LifeExpectancyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=nvs_LifeExpectancyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ChangeInActuarialAssumptionAxis=nvs_Increase1YearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ChangeInActuarialAssumptionAxis=nvs_Increase1YearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ActuarialAssumptionsAxis=ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>222
<FILENAME>R149.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864218352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-employment benefits for employees (Details 6) - Other post-employment benefit plans<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear', window );">Healthcare cost trend rate assumed for next year</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline', window );">Rate to which the cost trend rate is assumed to decline</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate', window );">Year that the rate reaches the ultimate trend rate</a></td>
<td class="text">2031<span></span>
</td>
<td class="text">2028<span></span>
</td>
<td class="text">2028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>223
<FILENAME>R150.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571860946064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-employment benefits for employees (Details 7) - Pension plans - USD ($)<br> shares in Millions, $ in Billions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanPlanAssetAllocations', window );">Defined benefit plan, plan asset allocations</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EmployerSharesHeldByDefinedBenefitPlan', window );">Shares held by defined benefit plan</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ValueOfEmployerSharesHeldByDefinedBenefitPlan', window );">Value of shares held by defined benefit plan</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_WeightedAverageDurationOfDefinedBenefitObligationYears', window );">Weighted average duration of defined benefit obligation years</a></td>
<td class="text">11 years 9 months 18 days<span></span>
</td>
<td class="text">14 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum', window );">Defined benefit plan, target plan asset allocations range minimum</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum', window );">Defined benefit plan, target plan asset allocations range maximum</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanPlanAssetAllocations', window );">Defined benefit plan, plan asset allocations</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum', window );">Defined benefit plan, target plan asset allocations range minimum</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum', window );">Defined benefit plan, target plan asset allocations range maximum</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanPlanAssetAllocations', window );">Defined benefit plan, plan asset allocations</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum', window );">Defined benefit plan, target plan asset allocations range minimum</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum', window );">Defined benefit plan, target plan asset allocations range maximum</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanPlanAssetAllocations', window );">Defined benefit plan, plan asset allocations</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Alternative investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum', window );">Defined benefit plan, target plan asset allocations range minimum</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum', window );">Defined benefit plan, target plan asset allocations range maximum</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanPlanAssetAllocations', window );">Defined benefit plan, plan asset allocations</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Cash and other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems', window );"><strong>Disclosure of defined benefit plans [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum', window );">Defined benefit plan, target plan asset allocations range minimum</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum', window );">Defined benefit plan, target plan asset allocations range maximum</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanPlanAssetAllocations', window );">Defined benefit plan, plan asset allocations</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDefinedBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDefinedBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanPlanAssetAllocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanPlanAssetAllocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EmployerSharesHeldByDefinedBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EmployerSharesHeldByDefinedBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ValueOfEmployerSharesHeldByDefinedBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ValueOfEmployerSharesHeldByDefinedBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_WeightedAverageDurationOfDefinedBenefitObligationYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_WeightedAverageDurationOfDefinedBenefitObligationYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_EquityInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_EquityInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=nvs_RealEstateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=nvs_RealEstateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=nvs_AlternativeInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=nvs_AlternativeInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=nvs_CashAndOtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=nvs_CashAndOtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>224
<FILENAME>R151.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864436528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Post-employment benefits for employees (Details 8)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract', window );"><strong>Novartis Group contributions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Contributions, next fiscal year (estimated)</a></td>
<td class="nump">$ 397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Not later than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">1,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Later than one year and not later than two years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">1,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Later than two years and not later than three years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">1,128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Later than three years and not later than four years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">1,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Later than four years and not later than five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">1,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember', window );">Pension plans | Later than five years and not later than ten years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">5,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract', window );"><strong>Novartis Group contributions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Contributions, next fiscal year (estimated)</a></td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Not later than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Later than one year and not later than two years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Later than two years and not later than three years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Later than three years and not later than four years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Later than four years and not later than five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember', window );">Other post-employment benefit plans | Later than five years and not later than ten years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract', window );"><strong>Expected future benefit payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment', window );">Expected future benefit payment</a></td>
<td class="nump">$ 171<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanExpectedFutureBenefitPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_PensionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RetirementPlanTypeAxis=nvs_OtherPostemploymentBenefitPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>225
<FILENAME>R152.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862409040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post-employment benefits for employees (Details 9) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems', window );"><strong>Defined contribution pension and other post-retirement plans disclosure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Personnel costs</a></td>
<td class="nump">$ 14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember', window );">Continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems', window );"><strong>Defined contribution pension and other post-retirement plans disclosure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans', window );">Post-employment benefit expense, defined contribution plans</a></td>
<td class="nump">$ 520<span></span>
</td>
<td class="nump">$ 523<span></span>
</td>
<td class="nump">$ 501<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContinuingAndDiscontinuedOperationsAxis=ifrs-full_ContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>226
<FILENAME>R153.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571855758672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based participation plans for employees (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expense from share-based payment transactions with employees</a></td>
<td class="nump">$ 1,048<span></span>
</td>
<td class="nump">$ 979<span></span>
</td>
<td class="nump">$ 958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011', window );">Liabilities from share-based payment transactions</a></td>
<td class="nump">$ 235<span></span>
</td>
<td class="nump">$ 253<span></span>
</td>
<td class="nump">$ 269<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities arising from share-based payment transactions. Share-based payment transactions are transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 51<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_51_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>227
<FILENAME>R154.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862643040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based participation plans for employees (Details 1)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationAnnualIncentivePlanMember', window );">Annual incentive</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement', window );">Description of share-based payment arrangement</a></td>
<td class="text">

                  The Annual Incentive for the Novartis Group CEO and other Executive Committee members (ECN) is paid 50% in cash and 50% in Novartis restricted shares (RSs) or restricted share units (RSUs). For the Novartis Top Leaders (NTLs), the Annual Incentive is paid 70% in cash and 30% in RSs or RSUs. Both the ECN and NTLs can opt to invest up to the maximum cash portion of their Annual Incentive to receive further RSs or RSUs. Any cash is paid out during March in the year following the end of the performance period, and the shares are granted during January in the year following the end of the performance period.

              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationEmployeeShareOwnershipPlanMember', window );">Employee Share Ownership Plan (ESOP)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement', window );">Description of share-based payment arrangement</a></td>
<td class="text">


                    Employee share savings plan

                  Novartis operates employee share savings and purchase plans in certain countries. The most significant is described below.
                  The Employee Share Ownership Plan (ESOP) in Switzerland offers participants to choose to receive their Annual Incentive (i) 100% in shares, (ii) 50% in shares and 50% in cash, or (iii) 100% in cash. After expiration of a three-year holding period for Novartis shares invested under the ESOP, participants will receive one matching share for every two invested shares. Employees eligible for the equity plan &#8220;Select&#8221; are not eligible to receive ESOP matching shares. The Novartis Group CEO, the other Executive Committee members and the NTLs are not eligible to participate in this plan.

              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember', window );">Share purchase plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement', window );">Description of share-based payment arrangement</a></td>
<td class="text">


                    Novartis Employee share purchase plan

                  In 2022 Novartis started to grant shares under the Employee Share Purchase Plan. The plan enables employees to voluntarily purchase Novartis shares through payroll deductions at a discounted price. While the plan is global in scope, the first phase covers: North America (the US, Puerto Rico and Canada). The shares are not subject to a vesting period.

              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectMember', window );">Select</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement', window );">Description of share-based payment arrangement</a></td>
<td class="text">

                  The equity plan &#8220;Select&#8221; is a global equity incentive plan under which eligible employees may annually be awarded a grant subject to a three-year, and for selected units a four-year, staggered vesting period. No awards are granted for performance ratings below a certain threshold. Executive Committee members and NTLs are not eligible to participate in the equity plan &#8220;Select.&#8221;
                  The equity plan &#8220;Select&#8221; currently allows participants employed and living in Switzerland to choose the form of their equity compensation in RSs or RSUs. In all other jurisdictions, RSs or RSUs are granted unilaterally. Until 2013, participants could also choose to receive part or the entire grant in the form of tradable share options.
                  Tradable share options expire on their 10th anniversary from the grant date, meaning all outstanding options exercisable at December 31, 2022, will expire in January 2023. Each tradable share option entitles the holder to purchase after vesting (and before the 10th anniversary from the grant date) one Novartis share at a stated exercise price that equals the closing market price of the underlying share at the grant date. As the exercise price does not reflect the decrease in the Novartis share due to the Alcon spin, one-fifth of an Alcon share will also be awarded to the option holder upon exercise.

              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationLongTermPerformancePlanMember', window );">Long-Term Performance Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement', window );">Description of share-based payment arrangement</a></td>
<td class="text">

                  The Long-Term Performance Plan (LTPP) is an equity plan for the ECN, the NTLs and employees of Group units with specific targets.
                  Participants are granted a target number of performance share units (PSUs) at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. The actual payout depends on the achievement of the performance measures and ranges between 0% and 200% of the granted amount. PSUs granted under the LTPP do not carry voting rights, but do carry dividend equivalents that are paid in unrestricted Novartis shares at the end of the performance period.
                  The LTPP awards are subject to a three-year performance and vesting period. Until 2018, the performance criteria were based on Novartis internal performance metrics. For LTPP awards starting in 2019, following the combination of the two LTPP and Long-Term Relative Performance Plan (LTRPP), the performance criteria are based on both Novartis internal performance metrics and variables that can be observed in the market, which is the ranking of the Novartis total shareholder return (TSR) relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods.
                  TSR for Novartis and the peer companies is calculated as the change in the company share price, which is translated to USD at the relevant exchange rate, including the reinvestment return of dividends, over the three-year performance period. The calculation is based on Bloomberg standard published TSR data, which is publicly available. The position of Novartis in the peer group determines the payout range based on a payout matrix.

                    Long-Term Relative Performance Plan

                  The LTRPP was an equity plan for the Novartis ECN and NTLs and the awards were subject to a three-year performance and vesting period. The last grant under this plan was made in 2018. The LTRPP performance criteria were based on variables that could be observed in the market, which was the ranking of the Novartis TSR relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. The TSR for Novartis and the peer companies was calculated as described in the LTPP section above.

              <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationSpecialShareAwardsMember', window );">Special share awards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement', window );">Description of share-based payment arrangement</a></td>
<td class="text">

                  Selected employees may exceptionally receive Special Share Awards of RSs or RSUs. These Special Share Awards provide an opportunity to reward outstanding achievements or exceptional performance, and aim to retain key contributors. They are based on a formal internal selection process, through which the individual performance of each candidate is thoroughly assessed at several management levels. Special Share Awards had a minimum three-year vesting period before 2021 and mainly three years thereafter. In exceptional circumstances, Special Share Awards may be awarded to attract special expertise and new talents to the organization. Externally recruited ECN members are eligible only for special awards that are &#8220;buyouts&#8221; in the case that it is to replace equity forfeited with their former employer. The equity is provided on a like-for-like basis as the forfeited equity, at the same value with the same vesting period, and with or without a performance condition.
                  Worldwide, employees at different levels in the organization were awarded RSs and RSUs in 2022, 2021 and 2020.
                  In addition, in 2022, 2021 and 2020, Board members received unrestricted shares as part of their regular compensation.



              <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of a share-based payment arrangement that existed at any time during the reporting period. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationAnnualIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationAnnualIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationEmployeeShareOwnershipPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationEmployeeShareOwnershipPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationLongTermPerformancePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationLongTermPerformancePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationSpecialShareAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationSpecialShareAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>228
<FILENAME>R155.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571842533504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based participation plans for employees (Details 2) - Select outside North America<br> Pure in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward', window );"><strong>Disclosure of number and weighted average exercise prices of share options [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding at beginning of period</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options outstanding in share-based payment arrangement at beginning of period</a></td>
<td class="nump">$ 63.6<span></span>
</td>
<td class="nump">$ 62.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of share options exercised or sold</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options exercised in share-based payment arrangement</a></td>
<td class="nump">$ 62.6<span></span>
</td>
<td class="nump">$ 58.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding at end of period</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options outstanding in share-based payment arrangement at end of period</a></td>
<td class="nump">$ 66.0<span></span>
</td>
<td class="nump">$ 63.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of share options exercisable</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options exercisable in share-based payment arrangement</a></td>
<td class="nump">$ 66.0<span></span>
</td>
<td class="nump">$ 63.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019', window );">Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise</a></td>
<td class="nump">$ 86.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price at the date of exercise for share options that are exercised in a share-based payment arrangement. [Refer: Share-based payment arrangements [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>229
<FILENAME>R156.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571861048368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based participation plans for employees (Details 3) - Select North America<br> Pure in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward', window );"><strong>Disclosure of number and weighted average exercise prices of share options [roll forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding at beginning of period</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options outstanding in share-based payment arrangement at beginning of period</a></td>
<td class="nump">$ 64.4<span></span>
</td>
<td class="nump">$ 62.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of share options exercised or sold</a></td>
<td class="num">(2.9)<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options exercised in share-based payment arrangement</a></td>
<td class="nump">$ 63.7<span></span>
</td>
<td class="nump">$ 60.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding at end of period</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options outstanding in share-based payment arrangement at end of period</a></td>
<td class="nump">$ 66.1<span></span>
</td>
<td class="nump">$ 64.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of share options exercisable</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options exercisable in share-based payment arrangement</a></td>
<td class="nump">$ 66.1<span></span>
</td>
<td class="nump">$ 64.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019', window );">Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise</a></td>
<td class="nump">$ 89.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price at the date of exercise for share options that are exercised in a share-based payment arrangement. [Refer: Share-based payment arrangements [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>230
<FILENAME>R157.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571861511520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-based participation plans for employees (Details 4)<br> Pure in Millions, $ / shares in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationAnnualIncentiveRSUMember', window );">Equity-Based Participation Annual Incentive RSU [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 74.7<span></span>
</td>
<td class="nump">$ 87.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember', window );">Equity Based Participation Annual Incentive Restricted Shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 85.0<span></span>
</td>
<td class="nump">$ 97.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationShareSavingsPlansRSUMember', window );">Equity Based Participation Share savings plans RSU [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="nump">$ 86.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationShareSavingsPlansSharesMember', window );">Equity Based Participation Share savings plans Shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 85.0<span></span>
</td>
<td class="nump">$ 97.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember', window );">Equity-Based Participation Employee share purchase plan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 82.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember', window );">Equity Based Participation Novartis Equity Plan Select North America RSU [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 74.5<span></span>
</td>
<td class="nump">$ 86.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember', window );">Based Participation Novartis Equity Plan Select outside North America RSU [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 75.1<span></span>
</td>
<td class="nump">$ 86.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember', window );">Equity Based Participation Novartis Equity Plan Select outside North America Restricted Shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 85.0<span></span>
</td>
<td class="nump">$ 97.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationLongTermPerformancePSUPlanMember', window );">Equity Based Participation Long Term Performance PSU Plan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 82.0<span></span>
</td>
<td class="nump">$ 89.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationOtherShareAwardsRSUMember', window );">Equity Based Participation Other share awards RSU [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 76.3<span></span>
</td>
<td class="nump">$ 78.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember', window );">Equity Based Participation Other share awards Restricted Shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 86.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationOtherShareAwardsSharesMember', window );">Equity Based Participation Other share awards Shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted, number of shares</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</a></td>
<td class="nump">$ 86.1<span></span>
</td>
<td class="nump">$ 91.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationAnnualIncentiveRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationAnnualIncentiveRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationShareSavingsPlansRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationShareSavingsPlansRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationShareSavingsPlansSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationShareSavingsPlansSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationLongTermPerformancePSUPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationLongTermPerformancePSUPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationOtherShareAwardsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationOtherShareAwardsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationOtherShareAwardsSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nvs_EquityBasedParticipationOtherShareAwardsSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>231
<FILENAME>R158.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571841965552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transaction with related parties (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="nump">$ 50,545<span></span>
</td>
<td class="nump">$ 51,626<span></span>
</td>
<td class="nump">$ 48,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RelatedPartiesNumberOfExecutiveCommitteeMembers', window );">Executive Committee members</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown', window );">Related parties, number of executive committee members who stepped down</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RelatedPartiesNumberOfNonexecutiveDirectors', window );">Non-executive directors</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember', window );">Roche Holding AG [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInAssociate', window );">Proportion of voting rights held in associate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_GenentechRocheMember', window );">Genentech / Roche [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NetExpenseRoyaltiesCostSharingAndProfitSharing', window );">Net expense, royalties cost sharing and profit sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (188)<span></span>
</td>
<td class="num">$ (217)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfContractsWithRelatedParties', window );">Number of contracts with related parties</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_GenentechRocheMember', window );">Genentech / Roche [member] | Lucentis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_GenentechRocheMember', window );">Genentech / Roche [member] | Xolair [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_RevenueFromSaleOfGoodsThirdParties', window );">Net sales to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SparkTherapeuticsInc.Member', window );">Spark Therapeutics, Inc. [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfContractsWithRelatedParties', window );">Number of contracts with related parties</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfVotingPowerHeldInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of the voting rights in an associate held by the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfVotingPowerHeldInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetExpenseRoyaltiesCostSharingAndProfitSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetExpenseRoyaltiesCostSharingAndProfitSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfContractsWithRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfContractsWithRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RelatedPartiesNumberOfExecutiveCommitteeMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RelatedPartiesNumberOfExecutiveCommitteeMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RelatedPartiesNumberOfNonexecutiveDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RelatedPartiesNumberOfNonexecutiveDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_RevenueFromSaleOfGoodsThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_RevenueFromSaleOfGoodsThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_GenentechRocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_GenentechRocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=nvs_XolairMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=nvs_XolairMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SparkTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SparkTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>232
<FILENAME>R159.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571860616224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with related parties (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Benefits other than equity-based compensation</a></td>
<td class="nump">$ 29.6<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="nump">$ 30.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Post-employment benefits</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Equity-based compensation</a></td>
<td class="nump">47.4<span></span>
</td>
<td class="nump">42.5<span></span>
</td>
<td class="nump">46.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total</a></td>
<td class="nump">79.8<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="nump">79.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember', window );">Key management personnel of entity or parent [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Benefits other than equity-based compensation</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="nump">20.3<span></span>
</td>
<td class="nump">25.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Post-employment benefits</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Equity-based compensation</a></td>
<td class="nump">42.6<span></span>
</td>
<td class="nump">37.3<span></span>
</td>
<td class="nump">41.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total</a></td>
<td class="nump">70.4<span></span>
</td>
<td class="nump">60.1<span></span>
</td>
<td class="nump">69.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=nvs_NonExecutiveDirectorMember', window );">Non-Executive Director [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Benefits other than equity-based compensation</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Equity-based compensation</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total</a></td>
<td class="nump">$ 9.4<span></span>
</td>
<td class="nump">$ 9.9<span></span>
</td>
<td class="nump">$ 9.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=nvs_NonExecutiveDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=nvs_NonExecutiveDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>233
<FILENAME>R160.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571862633744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with related parties (Details 2)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Key management personnel compensation</a></td>
<td class="nump">$ 79.8<span></span>
</td>
<td class="nump">$ 70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NovartisPensionFundMember', window );">Novartis Pension Fund [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsCreditFacilityUncommitted', window );">Borrowings credit facility uncommitted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember', window );">Key management personnel of entity or parent [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Key management personnel compensation</a></td>
<td class="nump">$ 70.4<span></span>
</td>
<td class="nump">$ 60.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=nvs_DrAlexKrauerMember', window );">Dr. Alex Krauer [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Key management personnel compensation | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BorrowingsCreditFacilityUncommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BorrowingsCreditFacilityUncommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NovartisPensionFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_NovartisPensionFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=nvs_DrAlexKrauerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=nvs_DrAlexKrauerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>234
<FILENAME>R161.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571861583040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and contingencies (Details 1)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems', window );"><strong>Schedule for commitments under research and development and other intangible asset purchase [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentsUnderLongtermResearchAgreements', window );">Commitments under long-term research and development agreements</a></td>
<td class="nump">$ 5,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_UncalledCapitalCommitmentsForInvestmentsInFunds', window );">Uncalled capital commitments for investments in funds</a></td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Not later than one year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems', window );"><strong>Schedule for commitments under research and development and other intangible asset purchase [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentsUnderLongtermResearchAgreements', window );">Commitments under long-term research and development agreements</a></td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember', window );">Later than one year and not later than two years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems', window );"><strong>Schedule for commitments under research and development and other intangible asset purchase [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentsUnderLongtermResearchAgreements', window );">Commitments under long-term research and development agreements</a></td>
<td class="nump">808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember', window );">Later than two years and not later than three years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems', window );"><strong>Schedule for commitments under research and development and other intangible asset purchase [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentsUnderLongtermResearchAgreements', window );">Commitments under long-term research and development agreements</a></td>
<td class="nump">448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember', window );">Later than three years and not later than four years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems', window );"><strong>Schedule for commitments under research and development and other intangible asset purchase [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentsUnderLongtermResearchAgreements', window );">Commitments under long-term research and development agreements</a></td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember', window );">Later than four years and not later than five years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems', window );"><strong>Schedule for commitments under research and development and other intangible asset purchase [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentsUnderLongtermResearchAgreements', window );">Commitments under long-term research and development agreements</a></td>
<td class="nump">687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than five years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems', window );"><strong>Schedule for commitments under research and development and other intangible asset purchase [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentsUnderLongtermResearchAgreements', window );">Commitments under long-term research and development agreements</a></td>
<td class="nump">$ 3,169<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CommitmentsUnderLongtermResearchAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CommitmentsUnderLongtermResearchAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_UncalledCapitalCommitmentsForInvestmentsInFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_UncalledCapitalCommitmentsForInvestmentsInFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>235
<FILENAME>R162.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571861480112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=nvs_CashAndCashEquivalentsMember', window );">Cash and cash equivalents [member] | Financial assets at amortised cost, category [member] | Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">$ 7,517<span></span>
</td>
<td class="nump">$ 10,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=nvs_CashAndCashEquivalentsMember', window );">Cash and cash equivalents [member] | Financial assets at fair value through other comprehensive income, category [member] | Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember', window );">Financial assets at fair value, class [member] | Financial assets at fair value through other comprehensive income, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">874<span></span>
</td>
<td class="nump">5,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember', window );">Financial assets at fair value, class [member] | Financial assets at fair value through other comprehensive income, category [member] | Available-for-sale marketable securities [member] | Debt securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">2,741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember', window );">Financial assets at fair value, class [member] | Financial assets at fair value through other comprehensive income, category [member] | Available-for-sale long-term financial investments [member] | Debt securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember', window );">Financial assets at fair value, class [member] | Financial assets at fair value through other comprehensive income, category [member] | Available-for-sale long-term financial investments [member] | Equity securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">828<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember', window );">Financial assets at fair value, class [member] | Financial assets at fair value through profit or loss, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">1,581<span></span>
</td>
<td class="nump">1,772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember', window );">Financial assets at fair value, class [member] | Financial assets at fair value through profit or loss, category [member] | Contingent consideration receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember', window );">Financial assets at fair value, class [member] | Financial assets at fair value through profit or loss, category [member] | Associated companies at fair value through profit and loss [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember', window );">Financial assets at fair value, class [member] | Financial assets at fair value through profit or loss, category [member] | Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember', window );">Financial assets at fair value, class [member] | Financial assets at fair value through profit or loss, category [member] | Available-for-sale long-term financial investments [member] | Equity securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember', window );">Financial assets at fair value, class [member] | Financial assets at fair value through profit or loss, category [member] | Available-for-sale long-term financial investments [member] | Fund investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember', window );">Financial assets at amortised cost, class [member] | Financial assets at amortised cost, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">27,971<span></span>
</td>
<td class="nump">32,492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember', window );">Financial assets at amortised cost, class [member] | Financial assets at amortised cost, category [member] | Trade receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">8,066<span></span>
</td>
<td class="nump">8,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember', window );">Financial assets at amortised cost, class [member] | Financial assets at amortised cost, category [member] | Other current assets [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">958<span></span>
</td>
<td class="nump">793<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember', window );">Financial assets at amortised cost, class [member] | Financial assets at amortised cost, category [member] | Time deposits with original maturity more than 90 days [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">11,089<span></span>
</td>
<td class="nump">12,965<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember', window );">Financial assets at amortised cost, class [member] | Financial assets at amortised cost, category [member] | Long-term loans and receivables from customers and finance lease, advances, security deposits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">$ 341<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=nvs_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=nvs_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_AvailableForSaleMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_AvailableForSaleMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=ifrs-full_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=ifrs-full_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_AvailableforsaleLongtermFinancialInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_AvailableforsaleLongtermFinancialInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_ContingentConsiderationReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_ContingentConsiderationReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_DerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_DerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_FundInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_FundInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>236
<FILENAME>R163.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571842058256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">$ 31,266<span></span>
</td>
<td class="nump">$ 37,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Current financial debt [member] | Interest bearning accounts of associates payable on demand [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Current financial debt [member] | Bank and other financial debt [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">863<span></span>
</td>
<td class="nump">899<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Current financial debt [member] | Commercial paper [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">2,772<span></span>
</td>
<td class="nump">893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Non-current financial debt [member] | Straight bonds [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">22,341<span></span>
</td>
<td class="nump">25,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Non-current financial debt [member] | Liabilities to banks and other financial institutions [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Trade payables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">5,146<span></span>
</td>
<td class="nump">5,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Commitment for repurchase of own shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member] | Other financial liabilities, category [member] | Lease liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">1,789<span></span>
</td>
<td class="nump">1,896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member] | Other financial liabilities, category [member] | Other financial liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">1,789<span></span>
</td>
<td class="nump">1,896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueMember', window );">Financial liabilities at fair value, class [member] | Financial liabilities at fair value through profit or loss, category [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">1,122<span></span>
</td>
<td class="nump">1,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueMember', window );">Financial liabilities at fair value, class [member] | Financial liabilities at fair value through profit or loss, category [member] | Contingent consideration and other financial liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">1,067<span></span>
</td>
<td class="nump">1,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueMember', window );">Financial liabilities at fair value, class [member] | Financial liabilities at fair value through profit or loss, category [member] | Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Disclosure of financial liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CurrentFinancialDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CurrentFinancialDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_InterestBearningAccountsOfAssociatesPayableOnDemandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_InterestBearningAccountsOfAssociatesPayableOnDemandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_BankAndOtherFinancialDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_BankAndOtherFinancialDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_NoncurrentFinancialDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_NoncurrentFinancialDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_StraightBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_StraightBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_LiabilitiesToBanksAndOtherFinancialInstitutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_LiabilitiesToBanksAndOtherFinancialInstitutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_TradePayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_TradePayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CommitmentForRepurchaseOfOwnSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CommitmentForRepurchaseOfOwnSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=nvs_OtherFinancialLiabilitiesCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=nvs_OtherFinancialLiabilitiesCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_OtherFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_OtherFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_ContingentConsiderationAndOtherFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_ContingentConsiderationAndOtherFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BalanceSheetItemAxis=nvs_DerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BalanceSheetItemAxis=nvs_DerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>237
<FILENAME>R164.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571842251424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_ContractOrUnderlyingPrincipalAmoutMember', window );">Contract or underlying principal amout [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstruments', window );">Derivative financial instruments</a></td>
<td class="nump">$ 8,043<span></span>
</td>
<td class="nump">$ 13,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_PositiveFairValuesMember', window );">Positive fair values [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstruments', window );">Derivative financial instruments</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_NegativeFairValuesMember', window );">Negative fair values [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstruments', window );">Derivative financial instruments</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis=nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember', window );">Derivative financial instruments, at fair value currency related [member] | Contract or underlying principal amout [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts', window );">Derivative financial instruments, forward foreign exchange rate contracts</a></td>
<td class="nump">7,907<span></span>
</td>
<td class="nump">13,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract', window );">Derivative financial instruments, commodity purchase contract</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities', window );">Derivative financial instruments, options on equity securities</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis=nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember', window );">Derivative financial instruments, at fair value currency related [member] | Positive fair values [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts', window );">Derivative financial instruments, forward foreign exchange rate contracts</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract', window );">Derivative financial instruments, commodity purchase contract</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis=nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember', window );">Derivative financial instruments, at fair value currency related [member] | Negative fair values [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts', window );">Derivative financial instruments, forward foreign exchange rate contracts</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities', window );">Derivative financial instruments, options on equity securities</a></td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (33)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_ContractOrUnderlyingPrincipalAmoutMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_ContractOrUnderlyingPrincipalAmoutMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_PositiveFairValuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_PositiveFairValuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_NegativeFairValuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_NegativeFairValuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis=nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis=nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>238
<FILENAME>R165.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571861544736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 3) - Contract or underlying principal amout [member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstruments', window );">Derivative financial instruments</a></td>
<td class="nump">$ 8,043<span></span>
</td>
<td class="nump">$ 13,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_ContractOrUnderlyingPrincipalAmoutMember', window );">EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstruments', window );">Derivative financial instruments</a></td>
<td class="nump">767<span></span>
</td>
<td class="nump">1,485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_ContractOrUnderlyingPrincipalAmoutMember', window );">USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstruments', window );">Derivative financial instruments</a></td>
<td class="nump">5,715<span></span>
</td>
<td class="nump">5,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_ContractOrUnderlyingPrincipalAmoutMember', window );">Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstruments', window );">Derivative financial instruments</a></td>
<td class="nump">1,561<span></span>
</td>
<td class="nump">6,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis=nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember', window );">Derivative financial instruments, at fair value currency related [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts', window );">Derivative financial instruments, forward foreign exchange rate contracts</a></td>
<td class="nump">7,907<span></span>
</td>
<td class="nump">13,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract', window );">Derivative financial instruments, commodity purchase contract</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities', window );">Derivative financial instruments, options on equity securities</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis=nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember', window );">Derivative financial instruments, at fair value currency related [member] | EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts', window );">Derivative financial instruments, forward foreign exchange rate contracts</a></td>
<td class="nump">687<span></span>
</td>
<td class="nump">1,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract', window );">Derivative financial instruments, commodity purchase contract</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis=nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember', window );">Derivative financial instruments, at fair value currency related [member] | USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts', window );">Derivative financial instruments, forward foreign exchange rate contracts</a></td>
<td class="nump">5,659<span></span>
</td>
<td class="nump">5,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract', window );">Derivative financial instruments, commodity purchase contract</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities', window );">Derivative financial instruments, options on equity securities</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis=nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember', window );">Derivative financial instruments, at fair value currency related [member] | Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts', window );">Derivative financial instruments, forward foreign exchange rate contracts</a></td>
<td class="nump">$ 1,561<span></span>
</td>
<td class="nump">$ 6,605<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_ContractOrUnderlyingPrincipalAmoutMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialInstrumentsPrincipalAmountsAxis=nvs_ContractOrUnderlyingPrincipalAmoutMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=nvs_CurrencyOthersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=nvs_CurrencyOthersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis=nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis=nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>239
<FILENAME>R166.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571842821408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 4) - Recurring fair value measurement [member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Cash and cash equivalents [member] | Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Marketable securities, time deposits and derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">$ 213<span></span>
</td>
<td class="nump">2,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Marketable securities, time deposits and derivative financial instruments [member] | Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Marketable securities, time deposits and derivative financial instruments [member] | Total available-for-sale marketable securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Marketable securities, time deposits and derivative financial instruments [member] | Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Financial investments and long-term loans [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">2,070<span></span>
</td>
<td class="nump">2,704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Financial investments and long-term loans [member] | Fund investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Financial investments and long-term loans [member] | Available-for-sale financial investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">1,182<span></span>
</td>
<td class="nump">1,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Financial investments and long-term loans [member] | Contingent consideration receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Associated companies at fair value through profit and loss [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Contingent consideration receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 1 of fair value hierarchy [member] | Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 1 of fair value hierarchy [member] | Cash and cash equivalents [member] | Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 1 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 1 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Total available-for-sale marketable securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 1 of fair value hierarchy [member] | Financial investments and long-term loans [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">493<span></span>
</td>
<td class="nump">1,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 1 of fair value hierarchy [member] | Financial investments and long-term loans [member] | Fund investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 1 of fair value hierarchy [member] | Financial investments and long-term loans [member] | Available-for-sale financial investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">1,080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 2 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 2 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 2 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Total available-for-sale marketable securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 2 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 2 of fair value hierarchy [member] | Financial investments and long-term loans [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 2 of fair value hierarchy [member] | Financial investments and long-term loans [member] | Available-for-sale financial investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Financial investments and long-term loans [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">1,567<span></span>
</td>
<td class="nump">1,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Financial investments and long-term loans [member] | Fund investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Financial investments and long-term loans [member] | Available-for-sale financial investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">699<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Financial investments and long-term loans [member] | Contingent consideration receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Associated companies at fair value through profit and loss [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Contingent consideration receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">$ 43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial assets. [Refer: At fair value [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=nvs_TotalAvailableforsaleMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=nvs_TotalAvailableforsaleMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=nvs_DerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=nvs_DerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_FinancialInvestmentsAndLongtermLoansGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_FinancialInvestmentsAndLongtermLoansGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=nvs_FundInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=nvs_FundInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=nvs_AvailableforsaleFinancialInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=nvs_AvailableforsaleFinancialInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=nvs_ContingentConsiderationReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=nvs_ContingentConsiderationReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_ContingentConsiderationReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_ContingentConsiderationReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>240
<FILENAME>R167.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571842060160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 5) - Recurring fair value measurement [member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Contingent consideration payables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">$ (131)<span></span>
</td>
<td class="num">$ (1,075)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Other financial liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(232)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Non-current contingent consideration liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Current financial liabilities at fair value [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Non-current financial liabilities at fair value [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(936)<span></span>
</td>
<td class="num">(1,162)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 2 of fair value hierarchy [member] | Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 2 of fair value hierarchy [member] | Current financial liabilities at fair value [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 2 of fair value hierarchy [member] | Non-current financial liabilities at fair value [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Contingent consideration payables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(131)<span></span>
</td>
<td class="num">(1,075)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Other financial liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(232)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Non-current contingent consideration liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Current financial liabilities at fair value [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">(131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember', window );">Level 3 of fair value hierarchy [member] | Non-current financial liabilities at fair value [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="num">$ (936)<span></span>
</td>
<td class="num">$ (1,094)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_RecurringFairValueMeasurementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=nvs_ContingentConsiderationPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=nvs_ContingentConsiderationPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=nvs_OtherFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=nvs_OtherFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=nvs_DerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=nvs_DerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=nvs_NoncurrentContingentConsiderationLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=nvs_NoncurrentContingentConsiderationLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CurrentFinancialLiabilitiesAtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CurrentFinancialLiabilitiesAtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_NoncurrentFinancialLiabilitiesAtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_NoncurrentFinancialLiabilitiesAtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>241
<FILENAME>R168.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571842294784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 6) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember', window );">Associated companies at fair value through profit and loss [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at beginning of period</a></td>
<td class="nump">$ 192<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value gains and other adjustments including from divestments recognized in the consolidated income statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome', window );">Fair value adjustments recognized in the consolidated statement of comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PurchaseFairValueMeasurementAssets', window );">Purchases fair value measurement assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisposalsFairValueMeasurementAssets', window );">Disposals fair value measurement assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ReclassificationFairValueMeasurementAssets', window );">Reclassification fair value measurement assets</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at end of period</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld', window );">Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_FundInvestmentsMember', window );">Fund investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at beginning of period</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value gains and other adjustments including from divestments recognized in the consolidated income statement</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</a></td>
<td class="num">(78)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome', window );">Fair value adjustments recognized in the consolidated statement of comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PurchaseFairValueMeasurementAssets', window );">Purchases fair value measurement assets</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisposalsFairValueMeasurementAssets', window );">Disposals fair value measurement assets</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ReclassificationFairValueMeasurementAssets', window );">Reclassification fair value measurement assets</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at end of period</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld', window );">Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end</a></td>
<td class="num">(74)<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_LongTermFinancialInvestmentsMember', window );">Long term financial investments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at beginning of period</a></td>
<td class="nump">617<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value gains and other adjustments including from divestments recognized in the consolidated income statement</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome', window );">Fair value adjustments recognized in the consolidated statement of comprehensive income</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PurchaseFairValueMeasurementAssets', window );">Purchases fair value measurement assets</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisposalsFairValueMeasurementAssets', window );">Disposals fair value measurement assets</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ReclassificationFairValueMeasurementAssets', window );">Reclassification fair value measurement assets</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at end of period</a></td>
<td class="nump">699<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld', window );">Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end</a></td>
<td class="num">(49)<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_ContingentConsiderationReceivablesMember', window );">Contingent consideration receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at beginning of period</a></td>
<td class="nump">641<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value gains and other adjustments including from divestments recognized in the consolidated income statement</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome', window );">Fair value adjustments recognized in the consolidated statement of comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets', window );">Cash receipts and payments fair value measurement assets</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at end of period</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld', window );">Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_ContingentConsiderationPayablesMember', window );">Contingent consideration payables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at beginning of period</a></td>
<td class="num">(1,075)<span></span>
</td>
<td class="num">(1,046)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value gains and other adjustments including from divestments recognized in the consolidated income statement</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</a></td>
<td class="num">(114)<span></span>
</td>
<td class="num">(189)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome', window );">Fair value adjustments recognized in the consolidated statement of comprehensive income</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PurchaseFairValueMeasurementAssets', window );">Purchases fair value measurement assets</a></td>
<td class="num">(231)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets', window );">Cash receipts and payments fair value measurement assets</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at end of period</a></td>
<td class="num">(835)<span></span>
</td>
<td class="num">(1,075)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld', window );">Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end</a></td>
<td class="nump">416<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_OtherFinancialLiabilitiesMember', window );">Other financial liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at beginning of period</a></td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value gains and other adjustments including from divestments recognized in the consolidated income statement</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets', window );">Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement</a></td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PurchaseFairValueMeasurementAssets', window );">Purchases fair value measurement assets</a></td>
<td class="num">(238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets', window );">Cash receipts and payments fair value measurement assets</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FinancialInstrumentsCarryingValueLevel3', window );">Fair value measurement, carrying value, level 3, at end of period</a></td>
<td class="num">(232)<span></span>
</td>
<td class="num">$ (19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld', window );">Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisposalsFairValueMeasurementAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisposalsFairValueMeasurementAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This amount can be a debit or a credit as the table discloses the fair value gain and loses on assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This amount can be a debit or a credit as the table discloses the fair value gain and loses on assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FinancialInstrumentsCarryingValueLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FinancialInstrumentsCarryingValueLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PurchaseFairValueMeasurementAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PurchaseFairValueMeasurementAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ReclassificationFairValueMeasurementAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is a reclassification that can be debit or credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ReclassificationFairValueMeasurementAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_FundInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_FundInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_LongTermFinancialInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_LongTermFinancialInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_ContingentConsiderationReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_ContingentConsiderationReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_ContingentConsiderationPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_ContingentConsiderationPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_OtherFinancialLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_OtherFinancialLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>242
<FILENAME>R169.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571842467984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 7) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">$ 18,930<span></span>
</td>
<td class="nump">$ 28,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Non-current financial debts</a></td>
<td class="num">(20,244)<span></span>
</td>
<td class="num">(22,902)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(5,931)<span></span>
</td>
<td class="num">(6,295)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt</a></td>
<td class="num">(7,245)<span></span>
</td>
<td class="num">(868)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_MarketableSecuritiesAndTimeDepositsMember', window );">Marketable securities and time deposits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">11,098<span></span>
</td>
<td class="nump">15,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CommoditiesMember', window );">Commodities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_DeriviativeFinancialInstrumentsAndAccruedInterestMember', window );">Deriviative financial instruments and accrued interest [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CashAndCashEquivalentsMember', window );">Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">7,517<span></span>
</td>
<td class="nump">12,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_FinancialDebtMember', window );">Financial debt [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Non-current financial debts</a></td>
<td class="num">(20,244)<span></span>
</td>
<td class="num">(22,902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(5,876)<span></span>
</td>
<td class="num">(6,227)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_FinancialDebtUndiscountedMember', window );">Financial debt - undiscounted [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Non-current financial debts</a></td>
<td class="num">(20,396)<span></span>
</td>
<td class="num">(23,077)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(5,878)<span></span>
</td>
<td class="num">(6,229)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_DerivativeFinancialInstrumentsMember', window );">Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember', window );">Not later than one month [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">8,176<span></span>
</td>
<td class="nump">7,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(3,253)<span></span>
</td>
<td class="num">(2,830)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt</a></td>
<td class="nump">4,923<span></span>
</td>
<td class="nump">4,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember', window );">Not later than one month [member] | Marketable securities and time deposits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">4,142<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember', window );">Not later than one month [member] | Deriviative financial instruments and accrued interest [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember', window );">Not later than one month [member] | Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">4,011<span></span>
</td>
<td class="nump">7,406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember', window );">Not later than one month [member] | Financial debt [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(3,215)<span></span>
</td>
<td class="num">(2,780)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember', window );">Not later than one month [member] | Financial debt - undiscounted [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(3,215)<span></span>
</td>
<td class="num">(2,780)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember', window );">Not later than one month [member] | Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember', window );">Later than one month and not later than three months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">10,564<span></span>
</td>
<td class="nump">19,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(159)<span></span>
</td>
<td class="num">(537)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt</a></td>
<td class="nump">10,405<span></span>
</td>
<td class="nump">19,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember', window );">Later than one month and not later than three months [member] | Marketable securities and time deposits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">6,911<span></span>
</td>
<td class="nump">14,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember', window );">Later than one month and not later than three months [member] | Deriviative financial instruments and accrued interest [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember', window );">Later than one month and not later than three months [member] | Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">3,506<span></span>
</td>
<td class="nump">5,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember', window );">Later than one month and not later than three months [member] | Financial debt [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(521)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember', window );">Later than one month and not later than three months [member] | Financial debt - undiscounted [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(521)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember', window );">Later than one month and not later than three months [member] | Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember', window );">Later than three month and not later than twelve months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(2,519)<span></span>
</td>
<td class="num">(2,928)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt</a></td>
<td class="num">(2,464)<span></span>
</td>
<td class="num">(1,833)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember', window );">Later than three month and not later than twelve months [member] | Marketable securities and time deposits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember', window );">Later than three month and not later than twelve months [member] | Deriviative financial instruments and accrued interest [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember', window );">Later than three month and not later than twelve months [member] | Financial debt [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(2,515)<span></span>
</td>
<td class="num">(2,926)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember', window );">Later than three month and not later than twelve months [member] | Financial debt - undiscounted [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(2,517)<span></span>
</td>
<td class="num">(2,928)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember', window );">Later than three month and not later than twelve months [member] | Derivative financial instruments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Current financial debt</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">Between one and five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Non-current financial debts</a></td>
<td class="num">(8,975)<span></span>
</td>
<td class="num">(8,464)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt</a></td>
<td class="num">(8,975)<span></span>
</td>
<td class="num">(8,460)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">Between one and five years | Marketable securities and time deposits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">Between one and five years | Financial debt [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Non-current financial debts</a></td>
<td class="num">(8,975)<span></span>
</td>
<td class="num">(8,464)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">Between one and five years | Financial debt - undiscounted [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Non-current financial debts</a></td>
<td class="num">(9,002)<span></span>
</td>
<td class="num">(8,490)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Non-current financial debts</a></td>
<td class="num">(11,269)<span></span>
</td>
<td class="num">(14,438)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt</a></td>
<td class="num">(11,134)<span></span>
</td>
<td class="num">(14,296)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than five years | Marketable securities and time deposits [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than five years | Commodities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than five years | Deriviative financial instruments and accrued interest [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments', window );">Current financial assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than five years | Financial debt [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Non-current financial debts</a></td>
<td class="num">(11,269)<span></span>
</td>
<td class="num">(14,438)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than five years | Financial debt - undiscounted [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaturityOfNetDebtLineItems', window );"><strong>Maturity of net debt [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialLiabilities', window );">Non-current financial debts</a></td>
<td class="num">$ (11,394)<span></span>
</td>
<td class="num">$ (14,587)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net debt of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MaturityOfNetDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MaturityOfNetDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_MarketableSecuritiesAndTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_MarketableSecuritiesAndTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CommoditiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CommoditiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_DeriviativeFinancialInstrumentsAndAccruedInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_DeriviativeFinancialInstrumentsAndAccruedInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_FinancialDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_FinancialDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_FinancialDebtUndiscountedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_FinancialDebtUndiscountedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_DerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GroupsOfFinancialAssetsLiabilitiesAxis=nvs_DerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>243
<FILENAME>R170.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571860928176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 8) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems', window );"><strong>Derivative financial instruments and accrued interest on derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities', window );">Potential outflows in various currencies - from financial derivative liabilities</a></td>
<td class="num">$ (6,943)<span></span>
</td>
<td class="num">$ (6,786)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets', window );">Potential inflows in various currencies - from financial derivative assets</a></td>
<td class="nump">7,062<span></span>
</td>
<td class="nump">6,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember', window );">Not later than one month [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems', window );"><strong>Derivative financial instruments and accrued interest on derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities', window );">Potential outflows in various currencies - from financial derivative liabilities</a></td>
<td class="num">(2,029)<span></span>
</td>
<td class="num">(843)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets', window );">Potential inflows in various currencies - from financial derivative assets</a></td>
<td class="nump">2,029<span></span>
</td>
<td class="nump">847<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember', window );">Later than one month and not later than three months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems', window );"><strong>Derivative financial instruments and accrued interest on derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities', window );">Potential outflows in various currencies - from financial derivative liabilities</a></td>
<td class="num">(4,598)<span></span>
</td>
<td class="num">(5,482)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets', window );">Potential inflows in various currencies - from financial derivative assets</a></td>
<td class="nump">4,712<span></span>
</td>
<td class="nump">5,516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember', window );">Later than three month and not later than twelve months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems', window );"><strong>Derivative financial instruments and accrued interest on derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities', window );">Potential outflows in various currencies - from financial derivative liabilities</a></td>
<td class="num">(316)<span></span>
</td>
<td class="num">(461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets', window );">Potential inflows in various currencies - from financial derivative assets</a></td>
<td class="nump">$ 321<span></span>
</td>
<td class="nump">$ 457<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>244
<FILENAME>R171.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571860562864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 9) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems', window );"><strong>Derivative financial instruments and accrued interest on derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContractualInterestOnNoncurrentLiabilities', window );">Contractual interest on non-current liabilities</a></td>
<td class="num">$ (5,532)<span></span>
</td>
<td class="num">$ (6,063)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="num">(1,789)<span></span>
</td>
<td class="num">(1,896)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="num">(5,146)<span></span>
</td>
<td class="num">(5,553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentForRepurchaseOwnShares', window );">Commitment for repurchase own shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,809)<span></span>
</td>
<td class="num">$ (1,800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContingentConsiderationLiabilities', window );">Contingent consideration liabilities</a></td>
<td class="num">(835)<span></span>
</td>
<td class="num">(1,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember', window );">Later than one month and not later than three months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems', window );"><strong>Derivative financial instruments and accrued interest on derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContractualInterestOnNoncurrentLiabilities', window );">Contractual interest on non-current liabilities</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="num">(5,020)<span></span>
</td>
<td class="num">(5,373)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CommitmentForRepurchaseOwnShares', window );">Commitment for repurchase own shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContingentConsiderationLiabilities', window );">Contingent consideration liabilities</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember', window );">Later than three month and not later than twelve months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems', window );"><strong>Derivative financial instruments and accrued interest on derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContractualInterestOnNoncurrentLiabilities', window );">Contractual interest on non-current liabilities</a></td>
<td class="num">(412)<span></span>
</td>
<td class="num">(445)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="num">(180)<span></span>
</td>
<td class="num">(197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContingentConsiderationLiabilities', window );">Contingent consideration liabilities</a></td>
<td class="num">(115)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">Between one and five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems', window );"><strong>Derivative financial instruments and accrued interest on derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContractualInterestOnNoncurrentLiabilities', window );">Contractual interest on non-current liabilities</a></td>
<td class="num">(1,432)<span></span>
</td>
<td class="num">(1,628)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="num">(616)<span></span>
</td>
<td class="num">(639)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContingentConsiderationLiabilities', window );">Contingent consideration liabilities</a></td>
<td class="num">(437)<span></span>
</td>
<td class="num">(517)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">Later than five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems', window );"><strong>Derivative financial instruments and accrued interest on derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContractualInterestOnNoncurrentLiabilities', window );">Contractual interest on non-current liabilities</a></td>
<td class="num">(3,624)<span></span>
</td>
<td class="num">(3,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liability</a></td>
<td class="num">(922)<span></span>
</td>
<td class="num">(982)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_ContingentConsiderationLiabilities', window );">Contingent consideration liabilities</a></td>
<td class="num">$ (267)<span></span>
</td>
<td class="num">$ (439)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CommitmentForRepurchaseOwnShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CommitmentForRepurchaseOwnShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ContingentConsiderationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ContingentConsiderationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_ContractualInterestOnNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_ContractualInterestOnNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>245
<FILENAME>R172.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571864764848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 10)<br> $ in Millions, &#8364; in Billions, &#165; in Billions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets', window );">Transfers out of Level 3 of fair value hierarchy, assets</a></td>
<td class="num">$ (44)<span></span>
</td>
<td class="num">$ (73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets', window );">Transfers into Level 3 of fair value hierarchy, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets', window );">Description of reasons for transfers out of Level 3 of fair value hierarchy, assets</a></td>
<td class="text">

                  During 2022, there was one transfer of equity securities from Level 3 to Level 1 for USD&#160;44 million (2021: USD&#160;73 million), due to Initial Public Offering of the invested company. During 2022, there were no transfers of equity securities from Level 1 to Level 3 due to de-listing (2021: USD 29 million).

              <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10', window );">Amount of change in OCI when most significant parameters for level 3 change more than 10%</a></td>
<td class="nump">$ 154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10', window );">Amount of change in OCI when POS for level 3 change more than 10%</a></td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueOfOtherFinancialAssetsSold', window );">Fair value of other financial assets sold</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_LongtermFinancialDebtWithACarryingAmount', window );">Long-term financial debt with a carrying amount</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">&#8364; 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaximumMarginPercentageImpactOfCommodityPriceChange', window );">Maximum margin percentage impact of commodity price change</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_MaximumHoldingInUnrelatedCompany', window );">Maximum holding in unrelated company</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge', window );">Unrealized income was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsCommercialPaperMaximumBorrowingAmount', window );">Borrowings commercial paper maximum borrowing amount</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsCommercialPaperNumberOfPrograms', window );">Borrowings commercial paper, number of programs</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsCreditFacilityCommitted', window );">Borrowings credit facility committed</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement', window );">Net loss/gain recorded on equity securities and fund investments at fair value through the consolidated income statement</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueOfFundInvestmentsAndEquitySecurities', window );">Fair value of fund investments and equity securities</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_USCommercialPaperProgramsMember', window );">US commercial paper programs [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsCommercialPaperMaximumBorrowingAmount', window );">Borrowings commercial paper maximum borrowing amount</a></td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsCommercialPaperNumberOfPrograms', window );">Borrowings commercial paper, number of programs</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=nvs_JPCommercialPaperProgramsMember', window );">JP commercial paper programs [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems', window );"><strong>Disclosure of derivative financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsCommercialPaperMaximumBorrowingAmount', window );">Borrowings commercial paper maximum borrowing amount</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_BorrowingsCommercialPaperNumberOfPrograms', window );">Borrowings commercial paper, number of programs</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_VendorAxis=nvs_LargestFinancialInstitutionMember', window );">Largest financial institution [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CounterpartyRiskAbstract', window );"><strong>Counterparty risk [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsHeldWithFinancialInstitution', window );">Percentage of entity's cash and cash equivalents held with financial institution</a></td>
<td class="nump">13.20%<span></span>
</td>
<td class="nump">9.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_VendorAxis=nvs_SecondLargestFinancialInstitutionMember', window );">Second largest financial institution [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CounterpartyRiskAbstract', window );"><strong>Counterparty risk [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsHeldWithFinancialInstitution', window );">Percentage of entity's cash and cash equivalents held with financial institution</a></td>
<td class="nump">9.20%<span></span>
</td>
<td class="nump">9.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_VendorAxis=nvs_ThirdLargestFinancialInstitutionMember', window );">Third largest financial institution [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CounterpartyRiskAbstract', window );"><strong>Counterparty risk [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CashAndCashEquivalentsHeldWithFinancialInstitution', window );">Percentage of entity's cash and cash equivalents held with financial institution</a></td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">7.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the reasons for transfers of assets out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers of assets into Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers of assets out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BorrowingsCommercialPaperMaximumBorrowingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BorrowingsCommercialPaperMaximumBorrowingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BorrowingsCommercialPaperNumberOfPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BorrowingsCommercialPaperNumberOfPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_BorrowingsCreditFacilityCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_BorrowingsCreditFacilityCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CashAndCashEquivalentsHeldWithFinancialInstitution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CashAndCashEquivalentsHeldWithFinancialInstitution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CounterpartyRiskAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CounterpartyRiskAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueOfFundInvestmentsAndEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueOfFundInvestmentsAndEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueOfOtherFinancialAssetsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueOfOtherFinancialAssetsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_LongtermFinancialDebtWithACarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_LongtermFinancialDebtWithACarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MaximumHoldingInUnrelatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MaximumHoldingInUnrelatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_MaximumMarginPercentageImpactOfCommodityPriceChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_MaximumMarginPercentageImpactOfCommodityPriceChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_USCommercialPaperProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_USCommercialPaperProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=nvs_JPCommercialPaperProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=nvs_JPCommercialPaperProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_VendorAxis=nvs_LargestFinancialInstitutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_VendorAxis=nvs_LargestFinancialInstitutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_VendorAxis=nvs_SecondLargestFinancialInstitutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_VendorAxis=nvs_SecondLargestFinancialInstitutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_VendorAxis=nvs_ThirdLargestFinancialInstitutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_VendorAxis=nvs_ThirdLargestFinancialInstitutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>246
<FILENAME>R173.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571861139600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 11)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CustomersWithNetSalesOverFivePercent', window );">Customers with net sales over five percent</a></td>
<td class="text">

                  The Group&#8217;s largest, second-largest and third-largest customers account for approximately 16%, 11% and 7% of net sales to third parties, respectively (2021: 17%, 11% and 6%, respectively; 2020: 17%, 11% and 6%, respectively). All segments had sales to these customers in 2022, 2021 and 2020.
                  The highest amounts of trade receivables outstanding were for these same three customers and amounted to approximately 16%, 14% and 7%, respectively, of the trade receivables at December 31, 2022 (2021: 16%, 12% and 7%, respectively).

              <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PercentageOfGovernmentBackedDebtSecurities', window );">Percentage of government backed debt securities</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=nvs_LargestCustomerMember', window );">Largest customer [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PercentageOfEntitysTradeReceivable', window );">Percentage of entitys trade receivable</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=nvs_SecondLargestCustomerMember', window );">Second largest customer [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PercentageOfEntitysTradeReceivable', window );">Percentage of entitys trade receivable</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=nvs_ThirdLargestCustomerMember', window );">Third largest customer [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PercentageOfEntitysTradeReceivable', window );">Percentage of entitys trade receivable</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMajorCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMajorCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfEntitysRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of the entity's revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfEntitysRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CustomersWithNetSalesOverFivePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CustomersWithNetSalesOverFivePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PercentageOfEntitysTradeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PercentageOfEntitysTradeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PercentageOfGovernmentBackedDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PercentageOfGovernmentBackedDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=nvs_LargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=nvs_LargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=nvs_SecondLargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=nvs_SecondLargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=nvs_ThirdLargestCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=nvs_ThirdLargestCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>247
<FILENAME>R174.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571842293120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 12)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems', window );"><strong>Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome', window );">Equity securities</a></td>
<td class="nump">$ 828<span></span>
</td>
<td class="nump">$ 1,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueOfOtherFinancialAssetsSold', window );">Fair value of other financial assets sold</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=nvs_ListedEquitySecuritiesMember', window );">Listed equity securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems', window );"><strong>Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome', window );">Equity securities</a></td>
<td class="nump">$ 438<span></span>
</td>
<td class="nump">$ 888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome', window );">Number of investments in equity instruments designated at fair value through other comprehensive income</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=nvs_NonlistedEquitySecuritiesMember', window );">Non-listed equity securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems', window );"><strong>Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome', window );">Equity securities</a></td>
<td class="nump">$ 390<span></span>
</td>
<td class="nump">$ 307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome', window );">Number of investments in equity instruments designated at fair value through other comprehensive income</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_AlconMember', window );">Alcon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems', window );"><strong>Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_FairValueOfOtherFinancialAssetsSold', window );">Fair value of other financial assets sold</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_AlconMember', window );">Alcon | Total fair value adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems', window );"><strong>Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainLossOnSaleOfOtherFinancialAssets', window );">Gain (loss) on sale of other financial assets</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_OthersAssociatesMember', window );">Others | Total fair value adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems', window );"><strong>Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_GainLossOnSaleOfOtherFinancialAssets', window );">Gain (loss) on sale of other financial assets</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: At fair value [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 11A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_11A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 8<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_8_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_FairValueOfOtherFinancialAssetsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_FairValueOfOtherFinancialAssetsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_GainLossOnSaleOfOtherFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_GainLossOnSaleOfOtherFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=nvs_ListedEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=nvs_ListedEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=nvs_NonlistedEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis=nvs_NonlistedEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_AlconMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_AlconMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=nvs_TotalFairValueAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=nvs_TotalFairValueAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_OthersAssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_OthersAssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>248
<FILENAME>R175.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571861553568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 13) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity', window );">Hypothetical increase decrease percentage in currency rate sensitivity</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=nvs_Hypothetical5IncreaseMember', window );">Hypothetical 5% increase [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement', window );">Currency exchange rate sensitivity impact against USD in the income statement</a></td>
<td class="num">$ (6)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity', window );">Currency exchange rate sensitivity impact against USD in the equity</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=nvs_Hypothetical5DecreaseMember', window );">Hypothetical 5% decrease [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement', window );">Currency exchange rate sensitivity impact against USD in the income statement</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity', window );">Currency exchange rate sensitivity impact against USD in the equity</a></td>
<td class="num">$ (98)<span></span>
</td>
<td class="num">$ (104)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=nvs_Hypothetical5IncreaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=nvs_Hypothetical5IncreaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=nvs_Hypothetical5DecreaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=nvs_Hypothetical5DecreaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>249
<FILENAME>R176.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571863994544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments - additional disclosures (Details 15) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity', window );">Hypothetical increase decrease percentage in equity price sensitivity</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=nvs_Hypothetical15IncreaseMember', window );">Hypothetical 15% increase [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement', window );">Equity price sensitivity impact of the risk factors in the income statement</a></td>
<td class="nump">$ 109<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity', window );">Equity price sensitivity impact of the risk factors in the equity</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=nvs_Hypothetical15DecreaseMember', window );">Hypothetical 15% decrease [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement', window );">Equity price sensitivity impact of the risk factors in the income statement</a></td>
<td class="num">(109)<span></span>
</td>
<td class="num">(154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity', window );">Equity price sensitivity impact of the risk factors in the equity</a></td>
<td class="num">$ (124)<span></span>
</td>
<td class="num">$ (179)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=nvs_Hypothetical15IncreaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=nvs_Hypothetical15IncreaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=nvs_Hypothetical15DecreaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=nvs_Hypothetical15DecreaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>250
<FILENAME>R177.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571863636720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events subsequent to the December 31 consolidated balance sheet date (Details)<br> $ in Billions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>SFr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners', window );">Dividends proposed | $</a></td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SubsequentEventTypAxis=nvs_SubsequentEventMember', window );">Subsequent Event [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_StatementLineItems', window );"><strong>Statement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare', window );">Dividends proposed, cash per share | SFr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 3.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends proposed or declared after the reporting period but before financial statements are authorised for issue. Such dividends are not recognised as a liability at the end of the reporting period because no obligation exists at that time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2022-03-24<br> -Paragraph 13<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_13&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 137<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_137_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount, per share, of dividends proposed or declared before financial statements were authorised for issue but not recognised as distribution to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 137<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_137_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SubsequentEventTypAxis=nvs_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SubsequentEventTypAxis=nvs_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>251
<FILENAME>R178.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140571591717856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Principal Group subsidiaries and associated companies (Details) - 12 months ended Dec. 31, 2022<br> &#8381; in Millions, &#8378; in Millions, &#8372; in Millions, &#8369; in Millions, &#8360; in Millions, &#3647; in Millions, &#2547; in Millions, &#1585;.&#1587; in Millions, &#1583;&#1580; in Millions, &#1583;.&#1605;. in Millions, &#1583;.&#1573; in Millions, &#165; in Millions, z&#322; in Millions, kr in Millions, kr in Millions, kr in Millions, kn in Millions, RON in Millions, RM in Millions, R$ in Millions, R in Millions, K&#269; in Millions, Ft in Millions, $ in Millions, $ in Millions, $ in Millions, $ in Millions, &#8363; in Billions, &#8361; in Billions, &#8360; in Billions, Rp in Billions, $ in Billions, $ in Billions</strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>EUR (&#8364;)</div></th>
<th class="th"><div>CHF (SFr)</div></th>
<th class="th"><div>JPY (&#165;)</div></th>
<th class="th"><div>DZD (&#1583;&#1580;)</div></th>
<th class="th"><div>ARS ($)</div></th>
<th class="th"><div>AUD ($)</div></th>
<th class="th"><div>BDT (&#2547;)</div></th>
<th class="th"><div>BRL (R$)</div></th>
<th class="th"><div>CAD ($)</div></th>
<th class="th"><div>CLP ($)</div></th>
<th class="th"><div>HKD ($)</div></th>
<th class="th"><div>COP ($)</div></th>
<th class="th"><div>HRK (kn)</div></th>
<th class="th"><div>CZK (K&#269;)</div></th>
<th class="th"><div>DKK (kr)</div></th>
<th class="th"><div>EGP (&#1580;.&#1605;.)</div></th>
<th class="th"><div>HUF (Ft)</div></th>
<th class="th"><div>INR (&#8360;)</div></th>
<th class="th"><div>IDR (Rp)</div></th>
<th class="th"><div>ILS (&#8362;)</div></th>
<th class="th"><div>MYR (RM)</div></th>
<th class="th"><div>MXN ($)</div></th>
<th class="th"><div>MAD (&#1583;.&#1605;.)</div></th>
<th class="th"><div>NZD ($)</div></th>
<th class="th"><div>NOK (kr)</div></th>
<th class="th"><div>PKR (&#8360;)</div></th>
<th class="th"><div>PHP (&#8369;)</div></th>
<th class="th"><div>PLN (z&#322;)</div></th>
<th class="th"><div>RON</div></th>
<th class="th"><div>RUB (&#8381;)</div></th>
<th class="th"><div>SAR (&#1585;.&#1587;)</div></th>
<th class="th"><div>SGD ($)</div></th>
<th class="th"><div>ZAR (R)</div></th>
<th class="th"><div>KRW (&#8361;)</div></th>
<th class="th"><div>SEK (kr)</div></th>
<th class="th"><div>TWD ($)</div></th>
<th class="th"><div>THB (&#3647;)</div></th>
<th class="th"><div>TRY (&#8378;)</div></th>
<th class="th"><div>UAH (&#8372;)</div></th>
<th class="th"><div>AED (&#1583;.&#1573;)</div></th>
<th class="th"><div>GBP (&#163;)</div></th>
<th class="th"><div>VEF</div></th>
<th class="th"><div>VND (&#8363;)</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties', window );">Principal group companies materiality of assets or sales to third parties | $</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Societe par actions SANDOZ, Algiers [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Soci&#233;t&#233; par actions SANDOZ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Algiers<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Algeria<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#1583;&#1580;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#1583;&#1580; 650.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Argentina S.A., Buenos Aires [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Argentina S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Buenos Aires<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Argentina<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 906.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Australia Pty Ltd, Macquarie Park, NSW [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Australia Pty Ltd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Macquarie Park, NSW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Australia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharmaceuticals Australia Pty Ltd, Macquarie Park, NSW [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharmaceuticals
Australia Pty Ltd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Macquarie Park, NSW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Australia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Pty Ltd, Macquarie Park, NSW [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Pty Ltd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Macquarie Park, NSW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Australia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Austria GmbH, Vienna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Austria GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Vienna<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Austria<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma GmbH, Vienna [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Vienna<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Austria<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz GmbH, Kundl [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Kundl<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Austria<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | EBEWE Pharma Ges.m.b.H Nfg. KG, Unterach am Attersee [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">EBEWE Pharma Ges.m.b.H Nfg. KG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Unterach am Attersee<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Austria<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis (Bangladesh) Limited, Gazipur [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis (Bangladesh) Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Gazipur<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Bangladesh<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#2547;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#2547; 162.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma NV, Vilvoorde [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Vilvoorde<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Belgium<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz NV, Vilvoorde [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Vilvoorde<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Belgium<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Alcon - Couvreur NV, Puurs [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Alcon - Couvreur NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Puurs<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Belgium<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Investment Ltd., Hamilton [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Investment Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Hamilton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Bermuda<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Securities Investment Ltd., Hamilton [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Securities Investment Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Hamilton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Bermuda<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Finance Services Ltd., Hamilton [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Finance Services Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Hamilton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Bermuda<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Triangle International Reinsurance Limited, Hamilton [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Triangle International Reinsurance Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Hamilton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Bermuda<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Trinity River Insurance Co Ltd., Hamilton [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Trinity River Insurance Co Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Hamilton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Bermuda<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Biociencias S.A., Sao Paulo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Bioci&#234;ncias S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">S&#227;o Paulo<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Brazil<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | R$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">R$ 507.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz do Brasil Industria Farmaceutica Ltda., Cambe, PR [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz do Brasil Ind&#250;stria Farmac&#234;utica Ltda.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Camb&#233;, PR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Brazil<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | R$</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">R$ 190.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharmaceuticals Canada Inc., Dorval, Quebec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharmaceuticals Canada Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Dorval, Quebec<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Canada<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Canada Inc., Boucherville, Quebec [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Canada Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Boucherville, Quebec<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Canada<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Chile S.A., Santiago de Chile [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Chile S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Santiago de Chile<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Chile<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Beijing Novartis Pharma Co., Ltd., Beijing [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Beijing Novartis Pharma Co., Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Beijing<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">China<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharmaceuticals (HK) Limited, Hong Kong [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharmaceuticals (HK) Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Hong Kong<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">China<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | China Novartis Institutes for BioMedical Research Co., Ltd., Shanghai [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">China Novartis Institutes for
BioMedical Research Co., Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Shanghai<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">China<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 320,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Suzhou Novartis Technical Development Co., Ltd., Changshu [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Suzhou Novartis Technical
Development Co., Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Changshu<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">China<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Shanghai Novartis Trading Ltd., Shanghai [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Shanghai Novartis Trading Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Shanghai<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">China<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz (China) Pharmaceutical Co., Ltd., Zhongshan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz (China) Pharmaceutical
Co., Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Zhongshan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">China<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 57,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis de Colombia S.A., Santafe de Bogota [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis de Colombia S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Santaf&#233; de Bogot&#225;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Colombia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz d.o.o. farmaceutska industrija, Zagreb [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz d.o.o. farmaceutska industrija<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Zagreb<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Croatia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | kn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kn 25.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis s.r.o., Prague [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis s.r.o.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Prague<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Czech Republic<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | K&#269;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">K&#269; 51.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz s.r.o., Prague [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz s.r.o.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Prague<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Czech Republic<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | K&#269;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">K&#269; 44.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Healthcare A/S, Copenhagen [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Healthcare A/S<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Copenhagen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Denmark<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | kr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz A/S, Copenhagen [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz A/S<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Copenhagen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Denmark<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | kr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Ecuador S.A., Quito [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Ecuador S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Quito<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Ecuador<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma S.A.E., Cairo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma S.A.E.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Cairo<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Egypt<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#1580;.&#1605;.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#1580;.&#1605;. 1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">99.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Egypt Pharma S.A.E., New Cairo City [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Egypt Pharma S.A.E.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">New Cairo City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Egypt<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#1580;.&#1605;.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#1580;.&#1605;. 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Finland Oy, Espoo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Finland Oy<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Espoo<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Finland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">459,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Groupe France S.A., Rueil-Malmaison [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Groupe France S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Rueil-Malmaison<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">France<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">903,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma S.A.S., Rueil-Malmaison [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma S.A.S.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Rueil-Malmaison<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">France<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Gene Therapies France S.A.S., Rueil-Malmaison [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Gene Therapies France SAS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Rueil-Malmaison<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">France<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Advanced Accelerator Applications S.A., Rueil-Malmaison [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Advanced Accelerator Applications S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Rueil-Malmaison<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">France<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Advanced Accelerator Applications Molecular Imaging France, Saint Genis Pouilly [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Advanced Accelerator Applications
Molecular Imaging France<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Saint-Genis-Pouilly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">France<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | CELLforCURE, Les Ulis [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">CELLforCURE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Les Ulis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">France<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz S.A.S., Levallois-Perret [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz S.A.S.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Levallois-Perret<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">France<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Deutschland GmbH, Nuremberg [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Deutschland GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Nuremberg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Business Services GmbH, Wehr [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Business Services GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Wehr<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma GmbH, Nuremberg [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Nuremberg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma Produktions GmbH, Wehr [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma Produktions GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Wehr<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz International GmbH, Holzkirchen [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz International GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Holzkirchen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | 1 A Pharma GmbH, Holzkirchen [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">1 A Pharma GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Holzkirchen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | HEXAL AG, Holzkirchen [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">HEXAL AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Holzkirchen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Salutas Pharma GmbH, Barleben [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Salutas Pharma GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Barleben<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Aeropharm GmbH, Rudolstadt [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Aeropharm GmbH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Rudolstadt<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis (Hellas) S.A.C.I., Metamorphosis/Athens [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis (Hellas) S.A.C.I.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Metamorphosis / Athens<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Greece<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Hungary Healthcare Limited Liability Company, Budapest [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Hungary Healthcare Limited Liability
Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Budapest<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Hungary<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | Ft</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">Ft 545.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Hungary Limited Liability Company, Budapest [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Hungary Limited Liability Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Budapest<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Hungary<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | Ft</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">Ft 883.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis India Limited, Mumbai [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis India Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Mumbai<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">India<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8360;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8360; 123.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">70.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">70.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Healthcare Private Limited, Mumbai [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Healthcare Private Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Mumbai<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">India<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8360;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Private Limited, Mumbai [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Private Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Mumbai<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">India<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8360;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8360; 32.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | PT. Novartis Indonesia, Jakarta [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">PT. Novartis Indonesia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Jakarta<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Indonesia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | Rp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">Rp 7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Ireland Limited, Dublin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Ireland Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Dublin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Ireland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Integrated Services Limited, Ringaskiddy, County Cork [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Integrated Services Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Cork City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Ireland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Gene Therapies EU Limited, Dublin [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Gene Therapies EU Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Dublin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Ireland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Israel Ltd., Tel Aviv [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Israel Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Tel Aviv<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Israel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Farma S.p.A., Milan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Farma S.p.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Milan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Italy<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Advanced Accelerator Applications (Italy) S.r.l., Pozzilli [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Advanced Accelerator Applications (Italy) S.r.l.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Pozzilli<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Italy<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz S.p.A., Origgio [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz S.p.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Origgio<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Italy<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma K.K., Tokyo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma K.K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Tokyo<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Japan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Ciba-Geigy Japan Limited, Tokyo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Ciba-Geigy Japan Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Tokyo<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Japan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz K.K., Tokyo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz K.K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Tokyo<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Japan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#165;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Baltics SIA, Riga [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Baltics SIA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Riga<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Latvia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Investments S.a r.l., Luxembourg City [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Investments S.&#224; r.l.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Luxembourg City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Luxembourg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Finance S.A., Luxembourg City [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Finance S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Luxembourg City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Luxembourg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Corporation (Malaysia) Sdn. Bhd., Petaling Jaya [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Corporation (Malaysia) Sdn. Bhd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Petaling Jaya<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Malaysia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | RM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">RM 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Farmaceutica, S.A. de C.V., Mexico City [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Farmac&#233;utica, S.A. de C.V.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Mexico City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Mexico<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz, S.A. de C.V., Mexico City [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz, S.A. de C.V.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Mexico City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Mexico<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma Maroc SA, Casablanca [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma Maroc SA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Casablanca<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Morocco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#1583;.&#1605;.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#1583;.&#1605;. 80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Netherlands B.V., Amsterdam [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Netherlands B.V.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Amsterdam<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Netherlands<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma B.V., Amsterdam [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma B.V.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Amsterdam<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Netherlands<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | IDB Holland BV, Baarle-Nassau [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">IDB Holland BV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Baarle-Nassau<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Netherlands<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz B.V., Almere [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz B.V.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Almere<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Netherlands<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">907,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis New Zealand Ltd, Auckland [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis New Zealand Ltd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Auckland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">New Zealand<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 820,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Norge AS, Oslo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Norge AS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Oslo<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Norway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | kr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma (Pakistan) Limited, Karachi [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma (Pakistan) Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Karachi<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Pakistan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8360;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8360; 6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">99.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma (Logistics), Inc., Panama City [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma (Logistics), Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Panama City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Panama<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Healthcare Philippines, Inc., Makati City [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Healthcare Philippines, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Makati City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Philippines<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8369;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8369; 298.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Philippines Corporation, Makati City [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Philippines Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Makati City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Philippines<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8369;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8369; 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Poland Sp. z o.o., Warsaw [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Poland Sp. z o.o.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Warsaw<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Poland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | z&#322;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">z&#322; 44.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Polska Sp. z o.o., Warsaw [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Polska Sp. z o.o.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Warsaw<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Poland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | z&#322;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Lek S.A., Strykow [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Lek S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Strykow<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Poland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | z&#322;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">z&#322; 11.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Portugal SGPS Lda., Porto Salvo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Portugal, S.G.P.S., Lda.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Porto Salvo<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Portugal<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Farma - Produtos Farmaceuticos S.A., Porto Salvo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Farma - Produtos Farmac&#234;uticos, S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Porto Salvo<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Portugal<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Farmaceutica Lda., Porto Salvo [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Farmac&#234;utica, Lda.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Porto Salvo<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Portugal<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma Services Romania S.R.L., Bucharest [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma Services Romania S.R.L.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Bucharest<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Romania<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | RON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">RON 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz S.R.L., Targu-Mures [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz S.R.L.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Targu-Mures<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Romania<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | RON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">RON 119.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma LLC, Moscow [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma LLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Moscow<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Russian Federation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8381;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8381; 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Neva LLC, St. Petersburg [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Neva LLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">St. Petersburg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Russian Federation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8381;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | JSC Sandoz, Moscow [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">JSC Sandoz<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Moscow<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Russian Federation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8381;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8381; 57.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Saudi Ltd., Riyadh [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Saudi Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Riyadh<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Saudi Arabia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#1585;.&#1587;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#1585;.&#1587; 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis (Singapore) Pte Ltd., Singapore [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis (Singapore) Pte Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Singapore Pharmaceutical Manufacturing Pte Ltd, Singapore [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Singapore Pharmaceutical
Manufacturing Pte Ltd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Asia Pacific Pharmaceuticals Pte Ltd, Singapore [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Asia Pacific Pharmaceuticals
Pte Ltd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Singapore<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Slovakia s.r.o., Bratislava [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Slovakia s.r.o.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Bratislava<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Slovakia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Lek Pharmaceuticals d.d., Ljubjana [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Lek Pharmaceuticals d.d.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Ljubljana<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Slovenia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Pharmaceuticals d.d., Ljubjana [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Pharmaceuticals d.d.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Ljubljana<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Slovenia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis South Africa (Pty) Ltd, Midrand [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis South Africa (Pty) Ltd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Midrand<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">South Africa<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | R</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">R 86.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz South Africa (Pty) Ltd, Midrand [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz South Africa (Pty) Ltd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Midrand<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">South Africa<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | R</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">R 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Korea Ltd., Seoul [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Korea Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Seoul<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">South Korea<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8361;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 24.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Farmaceutica, S.A., Barcelona [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Farmac&#233;utica, S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Barcelona<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Spain<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Advanced Accelerator Applications Iberica, S.L.U., Barcelona [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Advanced Accelerator Applications
Iberica, S.L.U.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Esplugues de Llobregat<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Spain<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Farmaceutica S.A., Madrid [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Farmac&#233;utica S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Madrid<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Spain<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Industrial Products S.A., Les Franqueses del Vall?s / Barcelona [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Industrial Products
S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Les Franqueses del Vall&#233;s / Barcelona<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Spain<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Abadia Retuerta S.A., Sardon de Duero/Valladolid [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Abadia Retuerta S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Sard&#243;n de Duero / Valladolid<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Spain<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Sverige AB, Stockholm [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Sverige AB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Stockholm<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Sweden<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | kr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Holding AG, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Holding AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis International Pharmaceutical Investment AG, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis International Pharmaceutical Investment AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Bioventures AG, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Bioventures AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Forschungsstiftung, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Forschungsstiftung<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Stiftung fuer Kaderausbildung, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Stiftung f&#252;r Kaderausbildung<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Mitarbeiterbeteiligungsstiftung, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis-Mitarbeiterbeteiligungsstiftung<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Stiftung fuer Mensch und Umwelt, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Stiftung f&#252;r Mensch und Umwelt<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Stiftung der Novartis AG fuer Erziehung, Ausbildung und Bildung, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Stiftung der Novartis AG f&#252;r Erziehung,
Ausbildung und Bildung<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Overseas Investments AG, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Overseas Investments AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Japat AG, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Japat AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma AG, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma Services AG, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma Services AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma Schweizerhalle AG, Muttenz [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma Schweizerhalle AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Muttenz<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma Stein AG, Stein [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma Stein AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Stein<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharma Schweiz AG, Risch [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharma Schweiz AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Risch<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Cellerys AG, Schlieren [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Cellerys AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Schlieren<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Arctos Medical AG, Bern [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Arctos Medical AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Bern<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Innovative Therapies AG, Risch [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Innovative Therapies AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Risch<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Advanced Accelerator Applications International SA, Geneve [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Advanced Accelerator Applications International SA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Geneva<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz AG, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Pharmaceuticals AG, Risch [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Pharmaceuticals AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Risch<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis (Taiwan) Co., Ltd., Taipei [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis (Taiwan) Co., Ltd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Taipei<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Taiwan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis (Thailand) Limited, Bangkok [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis (Thailand) Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Bangkok<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Thailand<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#3647;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#3647; 302.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Saglik, Gida ve Tarim Urunleri Sanayi ve Ticaret A.S., Istanbul [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Saglik, Gida ve Tarim &#220;r&#252;nleri Sanayi
ve Ticaret A.S.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Istanbul<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Turkey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8378;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8378; 448.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Farmanova Saglik Hizmetleri Ltd. Sti., Istanbul [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Farmanova Saglik Hizmetleri Ltd. Sti.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Istanbul<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Turkey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8378;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Ilac Sanayi ve Ticaret A.S., Istanbul [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Ila&#231; Sanayi ve Ticaret A.S.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Istanbul<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Turkey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8378;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">880.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">99.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Grup Saglik Urunleri Ilaclari Sanayi ve Ticaret A.S., Gebze - Kocaeli [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Grup Saglik &#220;r&#252;nleri
Ila&#231;lari Sanayi ve Ticaret A.S.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Gebze - Kocaeli<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Turkey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8378;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8378; 96.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Ukraine LLC, Kyiv [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Ukraine LLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Kyiv<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Ukraine<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8372;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8372; 8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Middle East FZE, Dubai [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Middle East FZE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Dubai<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">United Arab Emirates<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#1583;.&#1573;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#1583;.&#1573; 7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis UK Limited, London [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis UK Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">United Kingdom<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharmaceuticals UK Limited, London [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharmaceuticals UK Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">United Kingdom<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Grimsby Limited, London [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Grimsby Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">United Kingdom<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Advanced Accelerator Applications (UK &amp; Ireland), London [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Advanced Accelerator Applications (UK & Ireland)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">United Kingdom<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Neutec Pharma Limited, London [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Neutec Pharma Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">United Kingdom<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Gyroscope Therapeutics Limited, London [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Gyroscope Therapeutics Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">United Kingdom<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Limited, Frimley/Camberley [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Frimley / Camberley<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">United Kingdom<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Corporation, East Hanover, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">East Hanover, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 72,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Capital Corporation, East Hanover, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Capital Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">East Hanover, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Services, Inc., East Hanover, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Services, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">East Hanover, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis US Foundation, East Hanover, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis US Foundation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">East Hanover, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Pharmaceuticals Corporation, East Hanover, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Pharmaceuticals Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">East Hanover, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Advanced Accelerator Applications USA, Inc., Millburn, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Advanced Accelerator Applications USA, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Millburn, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">99.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Gene Therapies, Inc., Bannockburn, IL [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Gene Therapies, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Bannockburn, IL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Technology LLC, Inc., East Hanover, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Technology LLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">East Hanover, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Institutes for BioMedical Research, Inc., Cambridge, MA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Institutes for BioMedical
Research, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Cambridge, MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Cadent Therapeutics, Cambridge, MA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Cadent Therapeutics<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Cambridge, MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Endocyte, Inc., East Hanover, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Endocyte, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">East Hanover, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Navigate BioPharma Services, Inc., Carlsbad, CA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Navigate BioPharma Services, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Carlsbad, CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | The Medicines Company, East Hanover, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">The Medicines Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">East Hanover, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Sandoz Inc., Princeton, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Sandoz Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Princeton, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Oriel Therapeutics, Inc., Durham, NC [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Oriel Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Durham, NC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Fougera Pharmaceuticals Inc., Melville, NY [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Fougera Pharmaceuticals Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Melville, NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Eon Labs, Inc., Princeton, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Eon Labs, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Princeton, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis de Venezuela, S.A., Caracas [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis de Venezuela, S.A.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Caracas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Venezuela<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | VEF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">VEF 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Vietnam Company Limited, Ho Chi Minh City [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Vietnam Company Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Ho Chi Minh City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Vietnam<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | &#8363;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8363; 70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis International AG, Basel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis International AG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">Basel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">Switzerland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember', window );">Subsidiaries [member] | Novartis Finance Corporation, East Hanover, NJ [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NameOfSubsidiary', window );">Name of subsidiary</a></td>
<td class="text">Novartis Finance Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary', window );">Principal place of business of subsidiary</a></td>
<td class="text">East Hanover, NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary', window );">Country of incorporation of subsidiary</a></td>
<td class="text">USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nvs_SharePaidinCapital', window );">Share/paid-in capital | $</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Proportion of ownership interest in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary', window );">Proportion of voting rights held in subsidiary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The country in which a subsidiary of the entity is incorporated. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 19B<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_19B_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NameOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The name of a subsidiary. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 19B<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_19B_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NameOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The principal place of business of a subsidiary. [Refer: Principal place of business; Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 12<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_12_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 19B<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_19B_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfVotingPowerHeldInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of the voting rights in a subsidiary held by the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfVotingPowerHeldInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This expresses a limit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nvs_SharePaidinCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nvs_SharePaidinCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SocieteParActionsSANDOZAlgiersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SocieteParActionsSANDOZAlgiersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisArgentinaS.A.BuenosAiresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisArgentinaS.A.BuenosAiresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisAustraliaPtyLtdMacquarieParkNSWMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisAustraliaPtyLtdMacquarieParkNSWMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozPtyLtdMacquarieParkNSWMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozPtyLtdMacquarieParkNSWMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisAustriaGmbHViennaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisAustriaGmbHViennaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaGmbHViennaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaGmbHViennaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozGmbHViennaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozGmbHViennaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_EBEWEPharmaGes.m.b.HNfg.KGViennaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_EBEWEPharmaGes.m.b.HNfg.KGViennaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisBangladeshLimitedGazipurMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisBangladeshLimitedGazipurMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaNVVilvoordeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaNVVilvoordeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozNVVilvoordeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozNVVilvoordeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AlconCouvreurNVPuursMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AlconCouvreurNVPuursMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisInvestmentLtd.HamiltonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisInvestmentLtd.HamiltonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisSecuritiesInvestmentLtd.HamiltonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisSecuritiesInvestmentLtd.HamiltonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisFinanceServicesLtd.HamiltonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisFinanceServicesLtd.HamiltonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_TriangleInternationalReinsuranceLimitedHamiltonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_TriangleInternationalReinsuranceLimitedHamiltonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_TrinityRiverInsuranceCoLtd.HamiltonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_TrinityRiverInsuranceCoLtd.HamiltonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisBiocienciasS.A.SaoPauloMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisBiocienciasS.A.SaoPauloMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozCanadaInc.BouchervilleQuebecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozCanadaInc.BouchervilleQuebecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisChileS.A.SantiagoDeChileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisChileS.A.SantiagoDeChileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_BeijingNovartisPharmaCo.Ltd.BeijingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_BeijingNovartisPharmaCo.Ltd.BeijingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaceuticalsHKLimitedHongKongMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaceuticalsHKLimitedHongKongMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_ShanghaiNovartisTradingLtd.ShanghaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_ShanghaiNovartisTradingLtd.ShanghaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisDeColombiaS.A.SantafeDeBobotaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisDeColombiaS.A.SantafeDeBobotaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisS.r.o.PragueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisS.r.o.PragueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozS.r.o.PragueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozS.r.o.PragueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisHealthcareASCopenhagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisHealthcareASCopenhagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozASCopenhagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozASCopenhagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisEcuadorS.A.QuitoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisEcuadorS.A.QuitoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaS.A.E.CairoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaS.A.E.CairoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozEgyptPharmaS.A.E.NewCairoCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozEgyptPharmaS.A.E.NewCairoCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisFinlandOyEspooMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisFinlandOyEspooMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisGroupeFranceS.A.RueilMalmaisonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisGroupeFranceS.A.RueilMalmaisonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaS.A.S.RueilMalmaisonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaS.A.S.RueilMalmaisonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_CELLforCURELesUlisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_CELLforCURELesUlisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozS.A.S.LevalloisPerretMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozS.A.S.LevalloisPerretMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisDeutschlandGmbHNurembergMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisDeutschlandGmbHNurembergMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisBusinessServicesGmbHWehrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisBusinessServicesGmbHWehrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaGmbHNurembergMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaGmbHNurembergMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaProduktionsGmbHWehrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaProduktionsGmbHWehrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozInternationalGmbHHolzkirchenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozInternationalGmbHHolzkirchenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_A1APharmaGmbHHolzkirchenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_A1APharmaGmbHHolzkirchenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_HEXALAGHolzkirchenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_HEXALAGHolzkirchenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SalutasPharmaGmbHBarlebenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SalutasPharmaGmbHBarlebenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AeropharmGmbHRudolstadtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AeropharmGmbHRudolstadtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozHungaryLimitedLiabilityCompanyBudapestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozHungaryLimitedLiabilityCompanyBudapestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisIndiaLimitedMumbaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisIndiaLimitedMumbaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisHealthcarePrivateLimitedMumbaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisHealthcarePrivateLimitedMumbaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozPrivateLimitedMumbaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozPrivateLimitedMumbaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_PT.NovartisIndonesiaJakartaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_PT.NovartisIndonesiaJakartaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisIrelandLimitedDublinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisIrelandLimitedDublinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisGeneTherapiesEULimitedDublinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisGeneTherapiesEULimitedDublinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisIsraelLtd.TelAvivMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisIsraelLtd.TelAvivMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisFarmaS.p.A.MilanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisFarmaS.p.A.MilanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozS.p.A.OriggioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozS.p.A.OriggioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaK.K.TokyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaK.K.TokyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_CibaGeigyJapanLimitedTokyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_CibaGeigyJapanLimitedTokyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozK.K.TokyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozK.K.TokyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisBalticsSIARigaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisBalticsSIARigaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisInvestmentsS.aR.l.LuxembourgCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisInvestmentsS.aR.l.LuxembourgCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisFinanceS.A.LuxembourgCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisFinanceS.A.LuxembourgCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozS.A.DeC.V.MexicoCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozS.A.DeC.V.MexicoCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaMarocSACasablancaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaMarocSACasablancaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisNetherlandsB.V.AmsterdamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisNetherlandsB.V.AmsterdamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaB.V.AmsterdamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaB.V.AmsterdamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_IDBHollandBVBaarleNassauMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_IDBHollandBVBaarleNassauMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozB.V.AlmereMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozB.V.AlmereMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisNewZealandLtdAucklandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisNewZealandLtdAucklandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisNorgeASOsloMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisNorgeASOsloMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaPakistanLimitedKarachiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaPakistanLimitedKarachiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaLogisticsInc.PanamaCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaLogisticsInc.PanamaCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisHealthcarePhilippinesInc.MakatiCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisHealthcarePhilippinesInc.MakatiCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozPhilippinesCorporationMakatiCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozPhilippinesCorporationMakatiCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPolandSp.ZO.o.WarsawMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPolandSp.ZO.o.WarsawMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozPolskaSp.ZO.o.WarsawMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozPolskaSp.ZO.o.WarsawMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_LekS.A.StrykowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_LekS.A.StrykowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPortugalSGPSLda.PortoSalvoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPortugalSGPSLda.PortoSalvoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozFarmaceuticaLda.PortoSalvoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozFarmaceuticaLda.PortoSalvoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaServicesRomaniaS.R.L.BucharestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaServicesRomaniaS.R.L.BucharestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozS.R.L.TarguMuresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozS.R.L.TarguMuresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaLLCMoscowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaLLCMoscowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisNevaLLCSt.PetersburgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisNevaLLCSt.PetersburgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_JSCSandozMoscowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_JSCSandozMoscowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisSaudiLtd.RiyadhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisSaudiLtd.RiyadhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisSingaporePteLtd.SingaporeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisSingaporePteLtd.SingaporeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisSlovakiaS.r.o.BratislavaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisSlovakiaS.r.o.BratislavaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_LekPharmaceuticalsD.d.LjubjanaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_LekPharmaceuticalsD.d.LjubjanaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozPharmaceuticalsD.d.LjubjanaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozPharmaceuticalsD.d.LjubjanaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisSouthAfricaPtyLtdMidrandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisSouthAfricaPtyLtdMidrandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozSouthAfricaPtyLtdMidrandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozSouthAfricaPtyLtdMidrandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisKoreaLtd.SeoulMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisKoreaLtd.SeoulMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisFarmaceuticaS.A.BarcelonaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisFarmaceuticaS.A.BarcelonaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozFarmaceuticaS.A.MadridMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozFarmaceuticaS.A.MadridMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AbadiaRetuertaS.A.SardonDeDueroValladolidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AbadiaRetuertaS.A.SardonDeDueroValladolidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisSverigeABStockholmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisSverigeABStockholmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisHoldingAGBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisHoldingAGBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisInternationalPharmaceuticalInvestmentAGBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisInternationalPharmaceuticalInvestmentAGBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisBioventuresAGBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisBioventuresAGBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisForschungsstiftungBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisForschungsstiftungBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisStiftungFuerKaderausbildungBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisStiftungFuerKaderausbildungBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisMitarbeiterbeteiligungsstiftungBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisMitarbeiterbeteiligungsstiftungBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisStiftungFuerMenschUndUmweltBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisStiftungFuerMenschUndUmweltBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisOverseasInvestmentsAGBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisOverseasInvestmentsAGBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_JapatAGBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_JapatAGBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaAGBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaAGBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaServicesAGBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaServicesAGBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaSchweizerhalleAGMuttenzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaSchweizerhalleAGMuttenzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaSteinAGSteinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaSteinAGSteinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaSchweizAGRischMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaSchweizAGRischMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_CellerysAGSchlierenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_CellerysAGSchlierenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_ArctosMedicalAGBernMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_ArctosMedicalAGBernMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisInnovativeTherapiesAGRischMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisInnovativeTherapiesAGRischMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsInternationalSAGeneveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsInternationalSAGeneveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozAGBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozAGBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozPharmaceuticalsAGRischMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozPharmaceuticalsAGRischMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisTaiwanCo.Ltd.TaipeiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisTaiwanCo.Ltd.TaipeiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisThailandLimitedBangkokMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisThailandLimitedBangkokMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozIlacSanayiVeTicaretA.S.IstanbulMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozIlacSanayiVeTicaretA.S.IstanbulMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozUkraineLLCKievMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozUkraineLLCKievMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisMiddleEastFZEDubaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisMiddleEastFZEDubaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisUKLimitedLondonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisUKLimitedLondonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaceuticalsUKLimitedLondonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaceuticalsUKLimitedLondonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisGrimsbyLimitedLondonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisGrimsbyLimitedLondonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsUKIrelandLondonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsUKIrelandLondonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NeutecPharmaLimitedLondonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NeutecPharmaLimitedLondonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_GyroscopeTherapeuticsLimitedLondonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_GyroscopeTherapeuticsLimitedLondonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozLimitedFrimleyCamberleyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozLimitedFrimleyCamberleyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisCorporationEastHanoverNYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisCorporationEastHanoverNYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisCapitalCorporationEastHanoverNJMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisCapitalCorporationEastHanoverNJMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisServicesInc.EastHanoverNYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisServicesInc.EastHanoverNYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisUSFoundationEastHanoverNJMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisUSFoundationEastHanoverNJMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisPharmaceuticalsCorporationEastHanoverNYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisPharmaceuticalsCorporationEastHanoverNYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisGeneTherapiesInc.BannockburnILMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisGeneTherapiesInc.BannockburnILMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisTechnologyLLCInc.EastHanoverNJMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisTechnologyLLCInc.EastHanoverNJMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_CadentTherapeuticsCambridgeMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_CadentTherapeuticsCambridgeMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_EndocyteInc.EastHanoverNJMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_EndocyteInc.EastHanoverNJMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NavigateBioPharmaServicesInc.CarlsbadCAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NavigateBioPharmaServicesInc.CarlsbadCAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_TheMedicinesCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_TheMedicinesCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_SandozInc.PrincetonNJMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_SandozInc.PrincetonNJMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_OrielTherapeuticsInc.DurhamNCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_OrielTherapeuticsInc.DurhamNCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_FougeraPharmaceuticalsInc.MelvilleNYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_FougeraPharmaceuticalsInc.MelvilleNYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_EonLabsInc.PrincetonNJMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_EonLabsInc.PrincetonNJMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisDeVenezuelaS.A.CaracasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisDeVenezuelaS.A.CaracasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisVietnamCompanyLimitedHoChiMinhCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisVietnamCompanyLimitedHoChiMinhCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisInternationalAGBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisInternationalAGBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nvs_NovartisFinanceCorporationEastHanoverNJMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nvs_NovartisFinanceCorporationEastHanoverNJMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>252
<FILENAME>nvs-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:currency="http://xbrl.sec.gov/currency/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ns0="http://www.novartis.com/custom-units"
  xmlns:nvs="http://novartis.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nvs-20221231.xsd" xlink:type="simple"/>
    <context id="AR_I-CurrentYearEnd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">nvs:RestatedValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_D-December-22-2021_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GyroscopeTherapeuticsHoldingsPlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-22</startDate>
            <endDate>2021-12-22</endDate>
        </period>
    </context>
    <context id="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GyroscopeTherapeuticsHoldingsPlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-17</instant>
        </period>
    </context>
    <context id="AR_D-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GyroscopeTherapeuticsHoldingsPlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-17</startDate>
            <endDate>2022-02-17</endDate>
        </period>
    </context>
    <context id="AR_I-February-10-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GlaxoSmithKlinePlcGSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-10</instant>
        </period>
    </context>
    <context id="AR_D-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GlaxoSmithKlinePlcGSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-08</startDate>
            <endDate>2021-10-08</endDate>
        </period>
    </context>
    <context id="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GlaxoSmithKlinePlcGSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-08</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-Transaction-TheMedicinesCompany_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-23</instant>
        </period>
    </context>
    <context id="AR_D-Transaction-TheMedicinesCompany_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-23</startDate>
            <endDate>2019-11-23</endDate>
        </period>
    </context>
    <context id="AR_I-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-06</instant>
        </period>
    </context>
    <context id="AR_D-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-06</startDate>
            <endDate>2020-01-06</endDate>
        </period>
    </context>
    <context id="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenGlobalIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-31</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AspenGlobalIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="AR_I-Transaction-Sandoz-Divestment_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-06</instant>
        </period>
    </context>
    <context id="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022FR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022FR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022FR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022DE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022DE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022DE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:LargestCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:SecondLargestCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:ThirdLargestCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:LargestCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:SecondLargestCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:ThirdLargestCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:LargestCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:SecondLargestCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">nvs:ThirdLargestCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:AsiaAfricaAustralasiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:CanadaAndLatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EstablishedMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeOverPeriodAxis">nvs:PoPYEChangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:EmergingGrowthMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:MayzentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:MayzentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:MayzentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AimovigMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LutatheraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PiqrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PiqrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PiqrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PluvictoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PluvictoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PluvictoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PluvictoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TabrectaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TabrectaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TabrectaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AdakveoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AdakveoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AdakveoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ScemblixMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ScemblixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ScemblixMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ScemblixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XiidraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XiidraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XiidraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:BeovuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:BeovuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:BeovuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VoltarenCataflamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZortressCerticanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:NeoralSandimmunEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ContractManufacturingMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ContractManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ContractManufacturingMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ContractManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KesimptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KymriahMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:UltibroGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:CosentyxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GilenyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:EntrestoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:OtherPromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:PromactaRevoladeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TafinlarMekinistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:SandostatinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:JakaviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GalvusGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:GleevecGlivecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AfinitorVotubiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:DiovanGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:NeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:ImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:IlarisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:KisqaliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:EstablishedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExjadeJadenuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BrandsAxis">nvs:PromotedBrandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis">nvs:SolidTumorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:Top20ProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:RestOfPortfolioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">nvs:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:RetailGenericsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:BiopharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:TotalAntiinfectivesNetSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:TotalAntiinfectivesNetSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:TotalAntiinfectivesNetSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:AntiInfectivesSoldUnderSandozNameMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:AntiInfectivesSoldUnderSandozNameMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FranchiseAxis">nvs:AntiInfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:ProductPortfolioAxis">nvs:AntiInfectivesSoldUnderSandozNameMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4NetInvestmentHedgeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:NetInvestmentHedgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesSoldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4NetInvestmentHedgeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:NetInvestmentHedgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesSoldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnEquitySecuritiesSoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ValueAdjustmentsRelatedToDivestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ValueAdjustmentsRelatedToDivestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:FairValueAdjustmentsOnFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:ActuarialLossesFromDefinedBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:CumulativeCurrencyTranslationEffectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:MachineryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nvs:SaleAndLeaseBackMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nvs:SaleAndLeaseBackMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:TechnologybasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LeqvioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ZolgensmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentConsolidationItemsAxis">ifrs-full:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">nvs:CurrentlyMarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:VotrientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">nvs:InnovativeMedicinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:TaxLossCarryforwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:OtherAssetsProvisionsAccrualsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:TwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:ThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:FiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:MoreThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:YearOfExpiryAxis">nvs:NotSubjectToExpiryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:NotCapitalizedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetTreatmentAxis">nvs:CapitalizedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryRawMaterialsGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryRawMaterialsGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryRawMaterialsGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryRawMaterialsGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryWorkInProgressGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryWorkInProgressGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryWorkInProgressGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryWorkInProgressGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryFinishedGoodsGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryFinishedGoodsGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryFinishedGoodsGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:InventoryAxis">nvs:InventoryFinishedGoodsGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">nvs:ProvisionForDoubtfulReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022CurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:CurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022CurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:CurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022NotLaterThanOneMonthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022NotLaterThanOneMonthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanThreeMonthsAndNotLaterThanSixMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanThreeMonthsAndNotLaterThanSixMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanSixMonthsAndNotLaterThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanSixMonthsAndNotLaterThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PastDueStatusAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022USD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022USD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022EUR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022EUR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022RUB">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:RUB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022RUB">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:RUB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022JPY">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022JPY">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022GBP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022GBP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CNY">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CNY">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CAD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CAD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022BRL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:BRL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022BRL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:BRL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CHF">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CHF">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanFiveYearsAndNotLaterThanSixYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanFiveYearsAndNotLaterThanSixYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanSixYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanSixYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022USD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022USD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022EUR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022EUR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022JPY">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022JPY">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022CHF">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022CHF">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:FairValueDisclosureItemAmountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FairValueByMeasurementBasisAxis">nvs:FairValueDisclosureItemAmountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022IT_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NAGAndNovartisPharmaSpAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NAGAndNovartisPharmaSpAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022IT_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:IT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022GeographicalAreasAxis_country-2022FR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4FHoffmanLaRocheAGAndRocheSpAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:FHoffmanLaRocheAGAndRocheSpAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022GR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022GR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ExforgeGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ReclastAclastaMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NPCAndOthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:ReclastAclastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NPCAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TaxotereMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TaxotereMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AmiodaroneMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:AmiodaroneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NPCAndOthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:TasignaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NPCAndOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RestructuringProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:FinancialAssetsImpairedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:FinancialAssetsImpairedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:FinancialAssetsImpairedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022DiscontinuedOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:DiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:AcquisitionsAndDivestmentsAxis">nvs:DivestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsAndGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NonCurrentFinancialDebtsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:CurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">nvs:NoncurrentLeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:UnfundedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:ActiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:DeferredPensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ObligationByTypeAxis">nvs:PensionersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfDiscountRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4LifeExpectancyMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Increase1YearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Increase1YearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">nvs:LifeExpectancyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4LifeExpectancyMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Increase1YearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Increase1YearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">nvs:LifeExpectancyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:ChangeInActuarialAssumptionAxis">nvs:Change25BasisPointMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:EquityInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:EquityInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:EquityInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:RealEstateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:RealEstateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:RealEstateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AlternativeInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AlternativeInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AlternativeInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:CashAndOtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:CashAndOtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:CashAndOtherInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:PensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:RetirementPlanTypeAxis">nvs:OtherPostemploymentBenefitPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingAndDiscontinuedOperationsAxis">ifrs-full:ContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentiveRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentiveRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentiveRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentiveRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationShareSavingsPlansRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationShareSavingsPlansRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationShareSavingsPlansSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationShareSavingsPlansSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeSharePurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermPerformancePSUPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermPerformancePSUPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRestrictedSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationOtherShareAwardsSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SparkTherapeuticsInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:SparkTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:LucentisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">nvs:XolairMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:GenentechRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-4_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisPensionFundMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:NovartisPensionFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:NonExecutiveDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:NonExecutiveDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:NonExecutiveDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4DrAlexKrauerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:DrAlexKrauerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4DrAlexKrauerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">nvs:DrAlexKrauerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:TimeDepositsWithOriginalMaturityMoreThan90DaysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4OtherCurrentAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableForSaleMarketableSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableForSaleMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4FundInvestmentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4BankAndOtherFinancialDebtMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:BankAndOtherFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4CommercialPaperMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4StraightBondsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:StraightBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LiabilitiesToBanksAndOtherFinancialInstitutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TradePayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TradePayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationAndOtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2022LeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:TimeDepositsWithOriginalMaturityMoreThan90DaysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022TradeReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4OtherCurrentAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableForSaleMarketableSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableForSaleMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4FundInvestmentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AvailableforsaleLongtermFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4InterestBearningAccountsOfAssociatesPayableOnDemandMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:InterestBearningAccountsOfAssociatesPayableOnDemandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4BankAndOtherFinancialDebtMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:BankAndOtherFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4CommercialPaperMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4StraightBondsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:StraightBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:LiabilitiesToBanksAndOtherFinancialInstitutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TradePayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TradePayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommitmentForRepurchaseOfOwnSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommitmentForRepurchaseOfOwnSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:ContingentConsiderationAndOtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:BalanceSheetItemAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2022LeaseLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">nvs:OtherFinancialLiabilitiesCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:PositiveFairValuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:NegativeFairValuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:DerivativeFinancialInstrumentNatureOfInstrumentAxis">nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">nvs:CurrencyOthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nvs:FinancialInstrumentsPrincipalAmountsAxis">nvs:ContractOrUnderlyingPrincipalAmoutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4NoncurrentContingentConsiderationLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:NoncurrentContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4NoncurrentContingentConsiderationLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:NoncurrentContingentConsiderationLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:TotalAvailableforsaleMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:AvailableforsaleFinancialInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialInvestmentsAndLongtermLoansGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:NoncurrentFinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:OtherFinancialLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FundInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:LongTermFinancialInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:ContingentConsiderationPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:NonlistedEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:NonlistedEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:ListedEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:ListedEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:ListedEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:ListedEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:NonlistedEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis">nvs:NonlistedEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:AlconMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">nvs:TotalFairValueAdjustmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:OthersAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4LargestFinancialInstitutionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:LargestFinancialInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4SecondLargestFinancialInstitutionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:SecondLargestFinancialInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4ThirdLargestFinancialInstitutionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:ThirdLargestFinancialInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4LargestFinancialInstitutionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:LargestFinancialInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4SecondLargestFinancialInstitutionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:SecondLargestFinancialInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4ThirdLargestFinancialInstitutionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:VendorAxis">nvs:ThirdLargestFinancialInstitutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4USCommercialPaperProgramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:USCommercialPaperProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4JPCommercialPaperProgramsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">nvs:JPCommercialPaperProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:MarketableSecuritiesAndTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CommoditiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:FinancialDebtUndiscountedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:GroupsOfFinancialAssetsLiabilitiesAxis">nvs:DerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical5IncreaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical5IncreaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical5DecreaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical5DecreaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical15IncreaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical15IncreaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical15DecreaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nvs:Hypothetical15DecreaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_nvs-2022Q4SubsequentEventTypAxis_nvs-2022Q4SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nvs:SubsequentEventTypAxis">nvs:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SocieteParActionsSANDOZAlgiersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SocieteParActionsSANDOZAlgiersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisArgentinaS.A.BuenosAiresMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisArgentinaS.A.BuenosAiresMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPtyLtdMacquarieParkNSWMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustriaGmbHViennaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAustriaGmbHViennaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHViennaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHViennaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGmbHViennaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGmbHViennaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EBEWEPharmaGes.m.b.HNfg.KGViennaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EBEWEPharmaGes.m.b.HNfg.KGViennaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBangladeshLimitedGazipurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBangladeshLimitedGazipurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaNVVilvoordeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaNVVilvoordeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozNVVilvoordeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozNVVilvoordeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AlconCouvreurNVPuursMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AlconCouvreurNVPuursMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSecuritiesInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSecuritiesInvestmentLtd.HamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceServicesLtd.HamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceServicesLtd.HamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TriangleInternationalReinsuranceLimitedHamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TriangleInternationalReinsuranceLimitedHamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TrinityRiverInsuranceCoLtd.HamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TrinityRiverInsuranceCoLtd.HamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBiocienciasS.A.SaoPauloMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBiocienciasS.A.SaoPauloMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozCanadaInc.BouchervilleQuebecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozCanadaInc.BouchervilleQuebecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisChileS.A.SantiagoDeChileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisChileS.A.SantiagoDeChileMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:BeijingNovartisPharmaCo.Ltd.BeijingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:BeijingNovartisPharmaCo.Ltd.BeijingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsHKLimitedHongKongMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsHKLimitedHongKongMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ShanghaiNovartisTradingLtd.ShanghaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ShanghaiNovartisTradingLtd.ShanghaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeColombiaS.A.SantafeDeBobotaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeColombiaS.A.SantafeDeBobotaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozD.o.o.FarmaceutskaIndustrijaZagrebMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozD.o.o.FarmaceutskaIndustrijaZagrebMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisS.r.o.PragueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisS.r.o.PragueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.r.o.PragueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.r.o.PragueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcareASCopenhagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcareASCopenhagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozASCopenhagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozASCopenhagenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisEcuadorS.A.QuitoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisEcuadorS.A.QuitoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.E.CairoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.E.CairoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozEgyptPharmaS.A.E.NewCairoCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozEgyptPharmaS.A.E.NewCairoCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinlandOyEspooMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinlandOyEspooMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGroupeFranceS.A.RueilMalmaisonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGroupeFranceS.A.RueilMalmaisonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.S.RueilMalmaisonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaS.A.S.RueilMalmaisonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CELLforCURELesUlisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CELLforCURELesUlisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.S.LevalloisPerretMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.S.LevalloisPerretMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeutschlandGmbHNurembergMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeutschlandGmbHNurembergMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBusinessServicesGmbHWehrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBusinessServicesGmbHWehrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHNurembergMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaGmbHNurembergMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaProduktionsGmbHWehrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaProduktionsGmbHWehrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInternationalGmbHHolzkirchenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInternationalGmbHHolzkirchenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:A1APharmaGmbHHolzkirchenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:A1APharmaGmbHHolzkirchenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:HEXALAGHolzkirchenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:HEXALAGHolzkirchenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SalutasPharmaGmbHBarlebenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SalutasPharmaGmbHBarlebenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AeropharmGmbHRudolstadtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AeropharmGmbHRudolstadtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozHungaryLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozHungaryLimitedLiabilityCompanyBudapestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIndiaLimitedMumbaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIndiaLimitedMumbaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePrivateLimitedMumbaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePrivateLimitedMumbaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPrivateLimitedMumbaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPrivateLimitedMumbaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:PT.NovartisIndonesiaJakartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:PT.NovartisIndonesiaJakartaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIrelandLimitedDublinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIrelandLimitedDublinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesEULimitedDublinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesEULimitedDublinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIsraelLtd.TelAvivMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisIsraelLtd.TelAvivMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaS.p.A.MilanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaS.p.A.MilanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.p.A.OriggioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.p.A.OriggioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaK.K.TokyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaK.K.TokyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CibaGeigyJapanLimitedTokyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CibaGeigyJapanLimitedTokyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozK.K.TokyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozK.K.TokyoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBalticsSIARigaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBalticsSIARigaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentsS.aR.l.LuxembourgCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInvestmentsS.aR.l.LuxembourgCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceS.A.LuxembourgCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceS.A.LuxembourgCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.A.DeC.V.MexicoCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaMarocSACasablancaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaMarocSACasablancaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNetherlandsB.V.AmsterdamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNetherlandsB.V.AmsterdamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaB.V.AmsterdamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaB.V.AmsterdamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:IDBHollandBVBaarleNassauMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:IDBHollandBVBaarleNassauMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozB.V.AlmereMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozB.V.AlmereMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNewZealandLtdAucklandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNewZealandLtdAucklandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNorgeASOsloMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNorgeASOsloMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaPakistanLimitedKarachiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaPakistanLimitedKarachiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLogisticsInc.PanamaCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLogisticsInc.PanamaCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePhilippinesInc.MakatiCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHealthcarePhilippinesInc.MakatiCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPhilippinesCorporationMakatiCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPhilippinesCorporationMakatiCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPolandSp.ZO.o.WarsawMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPolandSp.ZO.o.WarsawMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPolskaSp.ZO.o.WarsawMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPolskaSp.ZO.o.WarsawMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekS.A.StrykowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekS.A.StrykowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPortugalSGPSLda.PortoSalvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPortugalSGPSLda.PortoSalvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaLda.PortoSalvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaLda.PortoSalvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesRomaniaS.R.L.BucharestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesRomaniaS.R.L.BucharestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.R.L.TarguMuresMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozS.R.L.TarguMuresMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLLCMoscowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaLLCMoscowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNevaLLCSt.PetersburgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisNevaLLCSt.PetersburgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:JSCSandozMoscowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:JSCSandozMoscowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaudiLtd.RiyadhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaudiLtd.RiyadhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePteLtd.SingaporeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePteLtd.SingaporeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSlovakiaS.r.o.BratislavaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSlovakiaS.r.o.BratislavaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:LekPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsD.d.LjubjanaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSouthAfricaPtyLtdMidrandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSouthAfricaPtyLtdMidrandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozSouthAfricaPtyLtdMidrandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozSouthAfricaPtyLtdMidrandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisKoreaLtd.SeoulMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisKoreaLtd.SeoulMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.BarcelonaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFarmaceuticaS.A.BarcelonaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaS.A.MadridMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozFarmaceuticaS.A.MadridMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AbadiaRetuertaS.A.SardonDeDueroValladolidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AbadiaRetuertaS.A.SardonDeDueroValladolidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSverigeABStockholmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSverigeABStockholmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHoldingAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisHoldingAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalPharmaceuticalInvestmentAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInternationalPharmaceuticalInvestmentAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBioventuresAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisBioventuresAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisOverseasInvestmentsAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisOverseasInvestmentsAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:JapatAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:JapatAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaServicesAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizerhalleAGMuttenzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizerhalleAGMuttenzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSteinAGSteinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSteinAGSteinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizAGRischMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaSchweizAGRischMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CellerysAGSchlierenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CellerysAGSchlierenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ArctosMedicalAGBernMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:ArctosMedicalAGBernMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInnovativeTherapiesAGRischMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInnovativeTherapiesAGRischMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsInternationalSAGeneveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsInternationalSAGeneveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozAGBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsAGRischMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozPharmaceuticalsAGRischMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisTaiwanCo.Ltd.TaipeiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisTaiwanCo.Ltd.TaipeiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisThailandLimitedBangkokMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisThailandLimitedBangkokMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIlacSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozIlacSanayiVeTicaretA.S.IstanbulMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozUkraineLLCKievMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozUkraineLLCKievMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisMiddleEastFZEDubaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisMiddleEastFZEDubaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisUKLimitedLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisUKLimitedLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsUKLimitedLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsUKLimitedLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGrimsbyLimitedLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGrimsbyLimitedLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUKIrelandLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUKIrelandLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NeutecPharmaLimitedLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NeutecPharmaLimitedLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GyroscopeTherapeuticsLimitedLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:GyroscopeTherapeuticsLimitedLondonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozLimitedFrimleyCamberleyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozLimitedFrimleyCamberleyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationEastHanoverNYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCorporationEastHanoverNYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceCorporationEastHanoverNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisFinanceCorporationEastHanoverNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCapitalCorporationEastHanoverNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisCapitalCorporationEastHanoverNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisServicesInc.EastHanoverNYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisServicesInc.EastHanoverNYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCorporationEastHanoverNYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisPharmaceuticalsCorporationEastHanoverNYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesInc.BannockburnILMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisGeneTherapiesInc.BannockburnILMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CadentTherapeuticsCambridgeMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:CadentTherapeuticsCambridgeMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EndocyteInc.EastHanoverNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EndocyteInc.EastHanoverNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NavigateBioPharmaServicesInc.CarlsbadCAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NavigateBioPharmaServicesInc.CarlsbadCAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:TheMedicinesCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInc.PrincetonNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:SandozInc.PrincetonNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:OrielTherapeuticsInc.DurhamNCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:OrielTherapeuticsInc.DurhamNCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FougeraPharmaceuticalsInc.MelvilleNYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:FougeraPharmaceuticalsInc.MelvilleNYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EonLabsInc.PrincetonNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:EonLabsInc.PrincetonNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeVenezuelaS.A.CaracasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisDeVenezuelaS.A.CaracasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisVietnamCompanyLimitedHoChiMinhCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisVietnamCompanyLimitedHoChiMinhCityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4AmericanDepositarySharesEachRepresenting1ShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nvs:AmericanDepositarySharesEachRepresenting1ShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4OrdinarySharesNominalValueCHF0.50PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">nvs:OrdinarySharesNominalValueCHF0.50PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisForschungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisForschungsstiftungBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisStiftungFuerKaderausbildungBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisMitarbeiterbeteiligungsstiftungBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisStiftungFuerMenschUndUmweltBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisUSFoundationEastHanoverNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nvs:NovartisTechnologyLLCInc.EastHanoverNJMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ifrs-full:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">nvs:RocheHoldingAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationAnnualIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeShareOwnershipPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationEmployeeShareOwnershipPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationNovartisEquityPlanSelectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationLongTermPerformancePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationSpecialShareAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001114448</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">nvs:EquityBasedParticipationSpecialShareAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USDPerShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="CHFPerShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:CHF</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Year">
        <measure>ns0:year</measure>
    </unit>
    <unit id="CHF">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="JPY">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="DZD">
        <measure>iso4217:DZD</measure>
    </unit>
    <unit id="ARS">
        <measure>iso4217:ARS</measure>
    </unit>
    <unit id="AUD">
        <measure>iso4217:AUD</measure>
    </unit>
    <unit id="BDT">
        <measure>iso4217:BDT</measure>
    </unit>
    <unit id="BRL">
        <measure>iso4217:BRL</measure>
    </unit>
    <unit id="CAD">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="CLP">
        <measure>iso4217:CLP</measure>
    </unit>
    <unit id="HKD">
        <measure>iso4217:HKD</measure>
    </unit>
    <unit id="COP">
        <measure>iso4217:COP</measure>
    </unit>
    <unit id="HRK">
        <measure>iso4217:HRK</measure>
    </unit>
    <unit id="CZK">
        <measure>iso4217:CZK</measure>
    </unit>
    <unit id="DKK">
        <measure>iso4217:DKK</measure>
    </unit>
    <unit id="EGP">
        <measure>iso4217:EGP</measure>
    </unit>
    <unit id="HUF">
        <measure>iso4217:HUF</measure>
    </unit>
    <unit id="INR">
        <measure>iso4217:INR</measure>
    </unit>
    <unit id="IDR">
        <measure>iso4217:IDR</measure>
    </unit>
    <unit id="ILS">
        <measure>iso4217:ILS</measure>
    </unit>
    <unit id="MYR">
        <measure>iso4217:MYR</measure>
    </unit>
    <unit id="MXN">
        <measure>iso4217:MXN</measure>
    </unit>
    <unit id="MAD">
        <measure>iso4217:MAD</measure>
    </unit>
    <unit id="NZD">
        <measure>iso4217:NZD</measure>
    </unit>
    <unit id="NOK">
        <measure>iso4217:NOK</measure>
    </unit>
    <unit id="PKR">
        <measure>iso4217:PKR</measure>
    </unit>
    <unit id="PHP">
        <measure>iso4217:PHP</measure>
    </unit>
    <unit id="PLN">
        <measure>iso4217:PLN</measure>
    </unit>
    <unit id="RON">
        <measure>iso4217:RON</measure>
    </unit>
    <unit id="RUB">
        <measure>iso4217:RUB</measure>
    </unit>
    <unit id="SAR">
        <measure>iso4217:SAR</measure>
    </unit>
    <unit id="SGD">
        <measure>iso4217:SGD</measure>
    </unit>
    <unit id="ZAR">
        <measure>iso4217:ZAR</measure>
    </unit>
    <unit id="KRW">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="SEK">
        <measure>iso4217:SEK</measure>
    </unit>
    <unit id="TWD">
        <measure>iso4217:TWD</measure>
    </unit>
    <unit id="THB">
        <measure>iso4217:THB</measure>
    </unit>
    <unit id="TRY">
        <measure>iso4217:TRY</measure>
    </unit>
    <unit id="UAH">
        <measure>iso4217:UAH</measure>
    </unit>
    <unit id="AED">
        <measure>iso4217:AED</measure>
    </unit>
    <unit id="GBP">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="VEF">
        <measure>iso4217:VEF</measure>
    </unit>
    <unit id="VND">
        <measure>iso4217:VND</measure>
    </unit>
    <nvs:OptionsExcludedFromTheCalculation contextRef="AR_D-CurrentYear-1" decimals="0" unitRef="Pure">0</nvs:OptionsExcludedFromTheCalculation>
    <nvs:OptionsExcludedFromTheCalculation contextRef="AR_D-CurrentYear-2" decimals="0" unitRef="Pure">0</nvs:OptionsExcludedFromTheCalculation>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">0.60</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9996</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.7068</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9999</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9999</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">0.20</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <ifrs-full:ProportionOfVotingPowerHeldInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1.00</ifrs-full:ProportionOfVotingPowerHeldInSubsidiary>
    <dei:EntityCentralIndexKey contextRef="AR_D-CurrentYear">0001114448</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="AR_D-CurrentYear">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="AR_D-CurrentYear">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="AR_D-CurrentYear">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="AR_D-CurrentYear">FY</dei:DocumentFiscalPeriodFocus>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Italy</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Malaysia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Russian Federation</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">South Africa</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <dei:EntityIncorporationStateCountryCode contextRef="AR_D-CurrentYear">V8</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">Lichtstrasse 35</dei:EntityAddressAddressLine1>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Algeria</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Argentina</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Australia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Australia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Australia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Austria</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Austria</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Austria</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Austria</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Bangladesh</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Belgium</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Belgium</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Belgium</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Bermuda</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Bermuda</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Bermuda</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Bermuda</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Bermuda</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Brazil</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Brazil</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Canada</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Canada</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Chile</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Colombia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Croatia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Czech Republic</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Czech Republic</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Denmark</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Denmark</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Ecuador</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Egypt</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Egypt</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Finland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Greece</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Hungary</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Hungary</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Indonesia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Ireland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Ireland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Ireland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Israel</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Italy</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Italy</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Japan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Japan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Japan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Latvia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Luxembourg</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Luxembourg</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Mexico</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Mexico</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Morocco</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Netherlands</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Netherlands</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Netherlands</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Netherlands</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">New Zealand</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Norway</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Pakistan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Panama</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Philippines</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Philippines</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Poland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Poland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Poland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Portugal</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Portugal</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Portugal</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Romania</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Romania</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Russian Federation</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Russian Federation</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Saudi Arabia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Singapore</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Singapore</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Singapore</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Slovakia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Slovenia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Slovenia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">South Africa</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">South Korea</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sweden</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisForschungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Taiwan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Thailand</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Turkey</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Turkey</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Turkey</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Turkey</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Ukraine</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">United Arab Emirates</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">USA</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Venezuela</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Vietnam</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <dei:DocumentType contextRef="AR_D-CurrentYear">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="AR_D-CurrentYear">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="AR_D-CurrentYear">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="AR_D-CurrentYear">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="AR_D-CurrentYear">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="AR_D-CurrentYear">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="AR_D-CurrentYear">1-15024</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="AR_D-CurrentYear">Novartis AG</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1 contextRef="AR_D-CurrentYear">Lichtstrasse 35</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="AR_D-CurrentYear">4056</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="AR_D-CurrentYear">Basel</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="AR_D-CurrentYear">CH</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">Karen L. Hale</dei:ContactPersonnelName>
    <dei:EntityAddressPostalZipCode contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">4056</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">Basel</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">CH</dei:EntityAddressCountry>
    <dei:CountryRegion contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">41</dei:CountryRegion>
    <dei:CityAreaCode contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">61</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">324-1111</dei:LocalPhoneNumber>
    <dei:CountryRegion contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">41</dei:CountryRegion>
    <dei:CityAreaCode contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">61</dei:CityAreaCode>
    <dei:ContactPersonnelFaxNumber contextRef="AR_D-CurrentYear_dei-2022EntityAddressesAddressTypeAxis_dei-2022BusinessContactMember">324-7826</dei:ContactPersonnelFaxNumber>
    <dei:Security12bTitle contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4AmericanDepositarySharesEachRepresenting1ShareMember">American Depositary Shares each representing 1 share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4AmericanDepositarySharesEachRepresenting1ShareMember">NVS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4AmericanDepositarySharesEachRepresenting1ShareMember">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4OrdinarySharesNominalValueCHF0.50PerShareMember">Ordinary shares, nominal value CHF 0.50 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4OrdinarySharesNominalValueCHF0.50PerShareMember">NOVN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_nvs-2022Q4OrdinarySharesNominalValueCHF0.50PerShareMember">NYSE</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AR_I-CurrentYearEnd"
      decimals="0"
      unitRef="Shares">2119609057</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="AR_D-CurrentYear">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="AR_D-CurrentYear">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="AR_D-CurrentYear">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="AR_D-CurrentYear">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="AR_D-CurrentYear">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="AR_D-CurrentYear">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="AR_D-CurrentYear">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentAccountingStandard contextRef="AR_D-CurrentYear">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="AR_D-CurrentYear">false</dei:EntityShellCompany>
    <dei:AuditorFirmId contextRef="AR_D-CurrentYear">3240</dei:AuditorFirmId>
    <dei:AuditorFirmId contextRef="AR_D-CurrentYear-1">1358</dei:AuditorFirmId>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">50545000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">51626000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">48659000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1283000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1251000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1239000000</ifrs-full:OtherRevenue>
    <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">15486000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">15867000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">15121000000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">36342000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">37010000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">34777000000</ifrs-full:GrossProfit>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">14253000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">14886000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">14197000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">9996000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">9540000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">8980000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">805000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1852000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1742000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">3701000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2747000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">3190000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">9197000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">11689000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">10152000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-9000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">15339000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">673000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">837000000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">811000000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">869000000</ifrs-full:InterestExpense>
    <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">20000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-80000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-78000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">8371000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">26137000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">9878000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1416000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2119000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1807000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6955000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">24018000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">8071000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6955000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">24021000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">8072000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">0</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-3000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-1000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="AR_D-CurrentYear"
      decimals="2"
      unitRef="USDPerShares">3.19</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="AR_D-CurrentYear-1"
      decimals="2"
      unitRef="USDPerShares">10.71</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="AR_D-CurrentYear-2"
      decimals="2"
      unitRef="USDPerShares">3.55</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="AR_D-CurrentYear"
      decimals="2"
      unitRef="USDPerShares">3.17</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="AR_D-CurrentYear-1"
      decimals="2"
      unitRef="USDPerShares">10.63</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="AR_D-CurrentYear-2"
      decimals="2"
      unitRef="USDPerShares">3.52</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6955000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">24018000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">8071000000</ifrs-full:ProfitLoss>
    <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">46000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-56000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">91000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">216000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-201000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-450000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-4762000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">3194000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-359000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-4500000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">2937000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-103000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1809000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">143000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-382000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">194000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">250000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-485000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2003000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">393000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6111000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">21521000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">11401000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6116000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">21528000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">11403000000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-5000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-7000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-2000000</ifrs-full:ComprehensiveIncomeAttributableToNoncontrollingInterests>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">10764000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">11545000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1431000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1561000000</ifrs-full:RightofuseAssets>
    <ifrs-full:Goodwill
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">29301000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">29595000000</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">31644000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">34182000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">143000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">205000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:DeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">3739000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      id="fact_188392"
      unitRef="USD">3743000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2411000000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">3036000000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1110000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2210000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">80543000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">86077000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Inventories
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">7175000000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">6666000000</ifrs-full:Inventories>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">8066000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">8005000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTaxAssetsCurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">268000000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CurrentTaxAssetsCurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">278000000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">11413000000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">15922000000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">7517000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">12407000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:OtherCurrentNonfinancialAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2471000000</ifrs-full:OtherCurrentNonfinancialAssets>
    <ifrs-full:OtherCurrentNonfinancialAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2440000000</ifrs-full:OtherCurrentNonfinancialAssets>
    <ifrs-full:CurrentAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">36910000000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">45718000000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">117453000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">131795000000</ifrs-full:Assets>
    <ifrs-full:IssuedCapital
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">890000000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">901000000</ifrs-full:IssuedCapital>
    <ifrs-full:TreasuryShares
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">92000000</ifrs-full:TreasuryShares>
    <ifrs-full:TreasuryShares
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">48000000</ifrs-full:TreasuryShares>
    <ifrs-full:OtherReserves
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">58544000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">66802000000</ifrs-full:OtherReserves>
    <ifrs-full:EquityAttributableToOwnersOfParent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">59342000000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">67655000000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:NoncontrollingInterests
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">81000000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">167000000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">59423000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">67822000000</ifrs-full:Equity>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">20244000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">22902000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1538000000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1621000000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2686000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      id="fact_188393"
      unitRef="USD">3070000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:OtherNoncurrentNonfinancialLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">4906000000</ifrs-full:OtherNoncurrentNonfinancialLiabilities>
    <ifrs-full:OtherNoncurrentNonfinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">6172000000</ifrs-full:OtherNoncurrentNonfinancialLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">29374000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">33765000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">5146000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">5553000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">5931000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">6295000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">251000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">275000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentTaxLiabilitiesCurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2533000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentTaxLiabilitiesCurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2415000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:OtherCurrentNonfinancialLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">14795000000</ifrs-full:OtherCurrentNonfinancialLiabilities>
    <ifrs-full:OtherCurrentNonfinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">15670000000</ifrs-full:OtherCurrentNonfinancialLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">28656000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">30208000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">58030000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">63973000000</ifrs-full:Liabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">117453000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">131795000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">936000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-80000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">59275000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-4657000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">55474000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">77000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">55551000000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">8072000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">8072000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-1000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">8071000000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-56000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">3387000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">3331000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-1000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">3330000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">8016000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">3387000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">11403000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-2000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">11401000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DividendsPaid
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">6987000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">6987000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">6987000000</ifrs-full:DividendsPaid>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">18000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">3038000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">3056000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">3056000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:ReductionOfIssuedCapital
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember"
      decimals="-6"
      unitRef="USD">23000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">-31000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">8000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">8000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">798000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">806000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">806000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <nvs:RepurchaseOfOptions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">89000000</nvs:RepurchaseOfOptions>
    <nvs:RepurchaseOfOptions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">89000000</nvs:RepurchaseOfOptions>
    <nvs:RepurchaseOfOptions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">89000000</nvs:RepurchaseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">6000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">724000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">730000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">730000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">0</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">30000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">30000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">30000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:TaxesOnTreasuryShares
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-32000000</nvs:TaxesOnTreasuryShares>
    <nvs:TaxesOnTreasuryShares
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-32000000</nvs:TaxesOnTreasuryShares>
    <nvs:TaxesOnTreasuryShares contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-32000000</nvs:TaxesOnTreasuryShares>
    <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-1769000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
    <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-1769000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
    <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-1769000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">150000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-150000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-2000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">2000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">7000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-1000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">6000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-7000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-1000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">18000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">18000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">18000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember"
      decimals="-6"
      unitRef="USD">-23000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">27000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-10134000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-149000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-10279000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-7000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-10286000000</ifrs-full:ChangesInEquity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember"
      decimals="-6"
      unitRef="USD">913000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">-53000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">57157000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-1419000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">56598000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">68000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">56666000000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">24021000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">24021000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-3000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">24018000000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">46000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-2539000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-2493000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-4000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-2497000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">24067000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-2539000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">21528000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-7000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">21521000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DividendsPaid
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">7368000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">7368000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">7368000000</ifrs-full:DividendsPaid>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">18000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">2902000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">2920000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2920000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:ReductionOfIssuedCapital
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember"
      decimals="-6"
      unitRef="USD">12000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">-18000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">6000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">39000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">39000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">39000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">740000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">745000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">745000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">0</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">17000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">17000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">17000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:TaxesOnTreasuryShares
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-1000000</nvs:TaxesOnTreasuryShares>
    <nvs:TaxesOnTreasuryShares
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-1000000</nvs:TaxesOnTreasuryShares>
    <nvs:TaxesOnTreasuryShares contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-1000000</nvs:TaxesOnTreasuryShares>
    <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-1040000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
    <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-1040000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
    <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-1040000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
    <nvs:TransactionCostsRecordedInEquity
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-12000000</nvs:TransactionCostsRecordedInEquity>
    <nvs:TransactionCostsRecordedInEquity
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-12000000</nvs:TransactionCostsRecordedInEquity>
    <nvs:TransactionCostsRecordedInEquity contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-12000000</nvs:TransactionCostsRecordedInEquity>
    <nvs:IncreaseDecreaseInNoncontrolingInterests
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-1000000</nvs:IncreaseDecreaseInNoncontrolingInterests>
    <nvs:IncreaseDecreaseInNoncontrolingInterests contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-1000000</nvs:IncreaseDecreaseInNoncontrolingInterests>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">164000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-164000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">65000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-65000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-5000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">0</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-5000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">107000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">102000000</ifrs-full:IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">48000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">48000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">48000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember"
      decimals="-6"
      unitRef="USD">-12000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-10235000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-229000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-10471000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">106000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-10365000000</ifrs-full:ChangesInEquity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember"
      decimals="-6"
      unitRef="USD">901000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">-48000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">70989000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-4187000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">67655000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">167000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">67822000000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">6955000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">6955000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6955000000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-839000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-839000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-5000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-844000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">6955000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-839000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">6116000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-5000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6111000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DividendsPaid
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">7506000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">7506000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">7506000000</ifrs-full:DividendsPaid>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">66000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">10844000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">10910000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">10910000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:ReductionOfIssuedCapital
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember"
      decimals="-6"
      unitRef="USD">11000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">-15000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:ReductionOfIssuedCapital
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">4000000</ifrs-full:ReductionOfIssuedCapital>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">87000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">88000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">88000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">6000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">848000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">854000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">854000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">0</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">5000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">5000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">5000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:TaxesOnTreasuryShares
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-14000000</nvs:TaxesOnTreasuryShares>
    <nvs:TaxesOnTreasuryShares
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-14000000</nvs:TaxesOnTreasuryShares>
    <nvs:TaxesOnTreasuryShares contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-14000000</nvs:TaxesOnTreasuryShares>
    <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">2809000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
    <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">2809000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
    <nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">2809000000</nvs:IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan>
    <nvs:IncreaseDecreaseInNoncontrolingInterests
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-81000000</nvs:IncreaseDecreaseInNoncontrolingInterests>
    <nvs:IncreaseDecreaseInNoncontrolingInterests contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-81000000</nvs:IncreaseDecreaseInNoncontrolingInterests>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">4000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-4000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-34000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">34000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">217000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">217000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">217000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember"
      decimals="-6"
      unitRef="USD">-11000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">-44000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">-14404000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">30000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">-14429000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-81000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-14510000000</ifrs-full:ChangesInEquity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022IssuedCapitalMember"
      decimals="-6"
      unitRef="USD">890000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-6"
      unitRef="USD">-92000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022RetainedEarningsMember"
      decimals="-6"
      unitRef="USD">63540000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-4996000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember"
      decimals="-6"
      unitRef="USD">59342000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">81000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">59423000000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6955000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">24018000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">8071000000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">11546000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-5299000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">9881000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:DividendsReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1000000</ifrs-full:DividendsReceivedClassifiedAsOperatingActivities>
    <ifrs-full:DividendsReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">525000000</ifrs-full:DividendsReceivedClassifiedAsOperatingActivities>
    <ifrs-full:DividendsReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">490000000</ifrs-full:DividendsReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">254000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">13000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">47000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">696000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">664000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">703000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">71000000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
    <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">464000000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
    <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">32000000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
    <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">302000000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
    <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">39000000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1975000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2342000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1833000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">16124000000</nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges>
    <nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">15949000000</nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges>
    <nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">16378000000</nvs:CashFlowsBeforeWorkingCapitalAndProvisionChanges>
    <nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">885000000</nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities>
    <nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1119000000</nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities>
    <nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">2437000000</nvs:PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities>
    <nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-1003000000</nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems>
    <nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">241000000</nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems>
    <nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-291000000</nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">14236000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">15071000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">13650000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1198000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1378000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1275000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">167000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">240000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">88000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1473000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1593000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1310000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">202000000</ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">748000000</ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">380000000</ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">121000000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">191000000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">230000000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">133000000</ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">442000000</ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">723000000</ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1000000</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">61000000</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">61000000</ifrs-full:PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">4000000</ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">2000000</ifrs-full:ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities>
    <nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-24000000</nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies>
    <nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">20669000000</nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies>
    <nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-7000000</nvs:DivestmentsAquisitionsOfInterestsInAssociatedCompanies>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-879000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-567000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-9957000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">34695000000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">16403000000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1900000000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">39357000000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2298000000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">492000000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1468000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">4208000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-13055000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-127000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1468000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">4208000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-13182000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">7506000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">7368000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">6987000000</ifrs-full:DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">10652000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">3057000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">2842000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">100000000</nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions>
    <nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">53000000</nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions>
    <nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">748000000</nvs:ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions>
    <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">16000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">16000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:ProceedsFromNoncurrentBorrowings contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">7126000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">2575000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2162000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">2003000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">295000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
    <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-3524000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
    <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">2261000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">295000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">316000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">312000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">3000000</ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries>
    <ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">2000000</ifrs-full:PaymentsFromChangesInOwnershipInterestsInSubsidiaries>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">55000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">97000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-147000000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-20562000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-16264000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-2158000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesContinuingOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-50000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-20562000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-16264000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-2208000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-4858000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">3015000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-1740000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-32000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-266000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">286000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-4890000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2749000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-1454000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">12407000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">9658000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd-3"
      decimals="-6"
      unitRef="USD">11112000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">7517000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">12407000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">9658000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_cca394f9-d866-4256-84df-c075ace106fa_0">
          &lt;div&gt;
            &lt;div id="anchorId001516732"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;1. Significant accounting policies&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Novartis Group (Novartis or Group) is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of innovative pharmaceuticals and cost-saving generic medicines. The Group is headquartered in Basel, Switzerland.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The consolidated financial statements of the Group are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). They are prepared in accordance with the historical cost convention, except for items that are required to be accounted for at fair value.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&#x2019;s financial year-end is December 31, which is also the annual closing date of the individual entities&#x2019; financial statements incorporated into the Group&#x2019;s consolidated financial statements.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The preparation of financial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the year, which affect the reported amounts of revenues, expenses, assets, liabilities and contingent amounts.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Estimates are based on historical experience and other assumptions that are considered reasonable under the given circumstances and are regularly monitored. Actual outcomes and results could differ from those estimates and assumptions. Revisions to estimates are recognized in the period in which the estimate is revised.&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;Listed below are accounting policies of significance to Novartis or, in cases where IFRS provides alternatives, the option adopted by Novartis.&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Scope of consolidation &lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated financial statements include all entities, including structured entities, over which Novartis AG, Basel, Switzerland, directly or indirectly has control (generally as a result of owning more than 50% of the entity&#x2019;s voting interest). Consolidated entities are also referred to as &#x201c;subsidiaries.&#x201d; &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In cases where Novartis does not fully own a subsidiary, it has elected to value any remaining outstanding non-controlling interest at the time of acquiring control of the subsidiary at its proportionate share of the fair value of the net identified assets.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Investments in associated companies (generally defined as investments in entities in which Novartis holds between 20% and 50% of voting shares or over which it otherwise has significant influence) and joint ventures are accounted for using the equity method, except for selected venture fund investments for which the Group has elected to apply the method of fair value through the consolidated income statement.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Foreign currencies&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated financial statements of Novartis are presented in US dollars (USD). The functional currency of a subsidiary is generally the local currency of that respective entity. The functional currency used for the reporting of certain Swiss and foreign finance entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in this currency.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For subsidiaries not operating in hyperinflationary economies, the subsidiary&#x2019;s results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates:&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Income, expense and cash flows for each month using the average exchange rate, with the US dollar values for each month being aggregated during the year&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Balance sheet using year-end exchange rates&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Resulting exchange rate differences are recognized in other comprehensive income&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;For subsidiaries operating in hyperinflationary economies, the impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period is recorded in retained earnings in equity. The subsequent gains or losses resulting from the restatement of non-monetary assets are recorded in &#x201c;Other financial income and expense&#x201d; in the consolidated income statement. &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Non-current assets held for sale or held for distribution to owners&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Non-current assets are accounted for as assets held for sale or as related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell and any resulting impairment is recognized. Assets related to discontinued operations and assets of a disposal group held for sale are not depreciated or amortized. The prior year consolidated balance sheet is not restated.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If in a subsequent period, the criteria for classification as held for sale are no longer met, the recoverable amount of assets and liabilities are reclassified out of assets held for sale into the respective balance sheet lines and the prior year consolidated balance sheet is not restated. The cumulative amount of depreciation and amortization not recorded since the date of their classification as assets held for sale, and any required &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;adjustments to the recoverable amounts of assets are recognized in the consolidated income statement.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Acquisition of assets and businesses&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Assets separately acquired are recorded at cost, which includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment and restore the site when it is no longer used are included in their cost.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Acquired businesses are accounted for by applying the acquisition method, unless the optional concentration test is applied. The optional concentration test allows for an election on a transaction-by-transaction basis to account for the acquired business as an asset separately acquired when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The acquisition method requires that the assets acquired and liabilities assumed be recorded at their respective fair values on the date the Group obtains control. The excess of the fair value of the total purchase consideration transferred over the fair value of the acquired assets and assumed liabilities is recognized as goodwill. The valuations are based on information available at the acquisition date. Acquisition related costs are expensed as incurred.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The application of the acquisition method requires certain estimates and assumptions to be made, especially concerning the fair values of the acquired intangible assets, inventories, property, plant and equipment and the liabilities assumed at the acquisition date, and the useful lives of the intangible assets and property, plant and equipment. Estimates of fair value require the use of valuation techniques. These valuations require the use of management assumptions and estimates, including the value of comparable assets in the market, amount and timing of future cash flows, outcomes and costs of research and development activities, probability of obtaining regulatory approval, long-term sales forecasts, actions of competitors, discount rates and terminal growth rates. The section &#x201c;&#x2014;Impairment of goodwill and intangible assets&#x201d; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Property, plant and equipment&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Property, plant and equipment is depreciated on a straight-line basis in the consolidated income statement over the estimated useful life of the individual asset. Freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Property, plant and equipment is assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections over the useful life.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the estimated useful life by major categories for property, plant and equipment:&lt;/div&gt;
                  &lt;div&gt;

                      &lt;div&gt;
                        &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                          &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:12;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Useful life&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 2px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buildings&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                              &lt;td align="right" style=";width:20%;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20 to 40 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and other equipment&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Machinery and equipment&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7 to 20 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Furniture and vehicles&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 10 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Computer hardware&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 7 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                          &lt;/table&gt;
                        &lt;/div&gt;
                      &lt;/div&gt;

                  &lt;/div&gt;
                  &lt;div&gt;
                    &lt;div&gt;
                      &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Government grants obtained for construction activities, including any related equipment, are deducted from the gross acquisition cost to arrive at the balance sheet carrying value of the related assets.&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Leases and right-of-use assets&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;As lessee, at inception and upon the modification of a contract, the Group assesses whether the contract contains a lease. The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative standalone price of each component. &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases. For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease. &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease to the end of the lease term. The lease term includes the period of any lease extension that management assess as reasonably certain to be exercised by the Group. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the Novartis incremental borrowing rate for the asset subject to the lease in the relevant market.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The portion of the lease payments attributable to the repayment of lease liabilities is recognized in cash flows used in financing activities, and the portion attributable to the payment of interest is included in cash flows from operating activities.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease incentive received, and any initial direct costs incurred by Novartis, and expected costs for obligations to dismantle and remove right-of-use assets when they are no longer used.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;the shorter of the useful life of the right-of-use asset or the end of the lease term. &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In arrangements where the Group is the lessor, it determines at lease inception whether the lease is a finance lease or an operating lease. Leases that transfer substantially all of the risk and rewards incidental to ownership of the underlying asset to the counterparty (the lessee) are accounted for as finance leases. Leases that do not transfer substantially all of the risks and rewards of ownership are accounted for as operating leases. Operating lease payments received are recognized on a straight-line basis over the lease term in the consolidated income statement in &#x201c;Other income.&#x201d; &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Goodwill and intangible assets&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Goodwill&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Goodwill arises on applying the acquisition method on the acquisition of a business and is the excess of the fair value of the consideration transferred to acquire the business over the underlying fair value of the net identified assets acquired. It is allocated to groups of cash-generating units (CGUs), that are expected to benefit from the synergies of the combination, and which are usually represented by the reported segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under &#x201c;Other expense&#x201d; in the consolidated income statement.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Intangible assets available for use&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has the following classes of available for use intangible assets: currently marketed products; technologies and other intangible assets (including software).&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Currently marketed products represent the composite value of acquired intellectual property (IP), patents, distribution rights and product trade names.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Technologies represent identified and separable acquired know-how used in the research, development and production processes.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Significant investments in internally developed and acquired computer software are capitalized and included in the &#x201c;Other&#x201d; category, and amortized once available for use.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Intangible assets available for use with a definite useful life are amortized over their estimated useful lives on a straight-line basis and are evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the estimated useful life by major categories for intangible assets available for use and the line in the consolidated income statement in which the amortization and any potential impairment charge is recognized:&lt;/div&gt;
                  &lt;div&gt;

                      &lt;div&gt;
                        &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                          &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:12;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                                  &lt;br/&gt;
                                  &lt;br/&gt; Useful life&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Income statement line&lt;br/&gt; for amortization and&lt;br/&gt; impairment charges&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currently marketed products&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 20 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Technologies&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10 to 20 years    &lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"   or "Research   and development"&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other (including software)&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 12 years  &lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; In the relevant   functional expense&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                          &lt;/table&gt;
                        &lt;/div&gt;
                      &lt;/div&gt;

                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Intangible assets not yet available for use&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Acquired research and development intangible assets that have not yet obtained marketing approval are recognized as in-process research and development (IPR&amp;amp;D).&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;IPR&amp;amp;D is not amortized, but is evaluated for potential impairment on an annual basis or when facts and circumstances warrant. Any impairment charge is recorded in the consolidated income statement under &#x201c;Research and development.&#x201d; Once a project included in IPR&amp;amp;D has received marketing approval from a regulatory authority, it is transferred to the &#x201c;Currently marketed products&#x201d; category.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impairment of goodwill and intangible assets&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;An asset, a CGU or a grouping of CGUs is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value-in-use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGU, and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset. These valuations are classified as &#x201c;Level 3&#x201d; in the fair value hierarchy.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group&#x2019;s activities with regard to:&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Amount and timing of projected future cash flows&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Sales forecasts &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Actions of competitors (launch of competing products, marketing initiatives, etc.)&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Sales erosion rates after the end of patent or other intellectual property rights protection, and timing of the entry of generic competition&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Outcome of research and development activities (compound efficacy, results of clinical trials, etc.)&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Amount and timing of projected costs to develop IPR&amp;amp;D into commercially viable products&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Profit margins&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Probability of obtaining regulatory approval&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Future tax rate&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Appropriate terminal growth rate&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Appropriate discount rate&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Generally, for intangible assets with a definite useful life, Novartis uses cash flow projections for the whole useful life of these assets. For goodwill, Novartis generally utilizes cash flow projections for a three-year period based on management forecasts, with a terminal value based on cash flow projections usually in line with inflation rates for later periods. &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Probability-weighted scenarios are typically used.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Discount rates used consider the Group&#x2019;s estimated weighted average cost of capital, adjusted for specific asset, country and currency risks associated with cash flow projections, to approximate the discount rate that market participants would use to value the asset.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Due to the above factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques. &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Cash and cash equivalents&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Cash and cash equivalents include highly liquid investments with original maturities of three months or less, which are readily convertible to known amounts of cash. Bank overdrafts are presented within current financial debts on the consolidated balance sheet.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Marketable securities, commodities and non-current financial assets &lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Commodities, which include gold bullion or coins, are valued at the lower of cost or fair value using current market prices. The changes in fair value below cost are immediately recorded in &#x201c;Other financial income and expense.&#x201d;&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Marketable securities are financial assets held for short-term purposes which are principally traded in liquid markets and are classified within current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#x201c;Other financial income and expense&#x201d; in the consolidated income statement. Non-current financial assets held for long-term strategic purposes are classified within non-current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#x201c;Other income&#x201d; and &#x201c;Other expense&#x201d; in the consolidated income statement.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Marketable securities and non-current financial assets are initially recorded at fair value on their trade date, which is different from the settlement date when the transaction is ultimately effected. Quoted securities are remeasured at each reporting date to fair value based on current market prices. If the market for a financial asset is not active or no market is available, fair values are established using valuation techniques. The majority of non-quoted investments are initially valued at fair value through the purchase price established between a willing buyer and seller. Non-quoted investments are subsequently adjusted based on values derived from discounted cash flow analysis or other pricing models. These investment values are classified as &#x201c;Level 3&#x201d; in the fair value hierarchy.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group classifies and accounts for its marketable securities and non-current financial assets in the following categories:&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Debt securities are valued at fair value through other comprehensive income with subsequent recycling into the consolidated income statement, as they meet both the &#x201c;solely payment of principal and interest&#x201d; and the business model criteria. Unrealized gains and losses, except exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are recognized in the consolidated income statement when the debt instrument is sold, at which time the gain is transferred to &#x201c;Other financial income and expense.&#x201d; Exchange gains and losses related to debt instruments are immediately recognized in the consolidated income statement in &#x201c;Other financial income and expense.&#x201d;&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Fund investments and equity securities of the Novartis Venture Fund are valued at fair value through profit and loss (FVPL). Unrealized gains and losses, including exchange gains and losses, are recognized in the consolidated income statement in &#x201c;Other income&#x201d; for gains and &#x201c;Other expense&#x201d; for losses.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Equity securities held as strategic investments, typically held outside of the Novartis Venture Fund, are generally designated at the date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. Unrealized gains and losses, including exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are reclassified to retained earnings when the equity security is sold. If these equity securities are not designated at the date of acquisition as financial assets valued at fair value through other comprehensive income, they are valued at FVPL, as described above.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Other non-current financial assets, such as loans and long-term receivables from customers, advances and other deposits, are valued at amortized cost, which reflects the time value of money less any allowances for expected credit losses.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group assesses on a forward-looking basis the expected credit losses associated with its debt securities valued at fair value through other comprehensive &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;income. Impairments on debt securities are recorded in &#x201c;Other financial income and expense.&#x201d;&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For other financial assets valued at amortized cost, impairments, which are based on their expected credit losses, and exchange rate losses are included in &#x201c;Other expense&#x201d; in the consolidated income statement. Exchange rate gains and interest income, using the effective interest rate method, are included in &#x201c;Other income&#x201d; or &#x201c;Other financial income&#x201d; in the consolidated income statement, depending on the nature of the item.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Derivative financial instruments&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Derivative financial instruments are initially recognized in the balance sheet at fair value and are remeasured to their current fair value at the end of each subsequent reporting period. The valuation of a forward exchange rate contract is based on the discounted cash flow model, using interest rate curves and forward rates at the reporting date as observable inputs.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Options are valued based on a modified Black-Scholes model using volatility and exercise prices as major observable inputs.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group enters into certain derivative financial instruments for the purpose of hedging to reduce the volatility in the Group&#x2019;s performance due to the exposure to various business-related risks. The risk mitigation is obtained because the derivative&#x2019;s value or cash flows are expected, wholly or partly, to offset changes in the value or cash flows of the recognized assets or liabilities. The overall strategy is aiming to mitigate the currency and interest rate risk of positions that are contractually agreed, and to partially mitigate the exposure risk of selected anticipated transactions.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Certain derivative financial instruments meet the criteria for hedge accounting treatment. A prerequisite for obtaining this accounting-hedge relationship is extensive documentation on inception and proving on a regular basis that the economic hedge is effective for accounting purposes. Other derivative financial instruments do not meet the criteria to qualify for hedge accounting or are not designated in a hedge relationship. Changes in the fair value of these derivative instruments are recognized immediately in &#x201c;Other financial income and expense&#x201d; in the consolidated income statement.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In addition, the Group has designated certain long-term debt components as hedges of the translation risk arising on certain net investments in foreign operations. On consolidation, foreign currency differences arising on long-term debt designated as net investment hedges of a foreign operation are recognized in other comprehensive income and accumulated in currency translation effects, to the extent that the hedge is effective. The foreign currency differences arising from hedge ineffectiveness are recognized in the income statement in &#x201c;Other financial income and expense.&#x201d;&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;When a hedged net investment is disposed of, the proportionate portion of the cumulative amount recognized in equity in relation to the hedged net investment is transferred to the consolidated income statement as an adjustment to the gain or loss on disposal.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Inventories&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Inventory is valued at the lower of acquisition or production cost determined on a first-in, first-out basis and net realizable value. This value is used for the &#x201c;Cost of goods sold&#x201d; in the consolidated income statement. Unsaleable inventory is fully written off in the consolidated income statement under &#x201c;Cost of goods sold.&#x201d;&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Trade receivables&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as rebates, chargebacks and cash discounts.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Provisions for doubtful trade receivables are established using a forward-looking expected credit loss model (ECL), which includes possible default events on the trade receivables over the entire holding period of the trade receivable. These provisions represent the difference between the trade receivable&#x2019;s carrying amount in the consolidated balance sheet and the estimated collectible amount. Charges for doubtful trade receivables are recorded as marketing and selling costs recognized in the consolidated income statement within &#x201c;Selling, general and administration&#x201d; expenses.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Legal and environmental liabilities&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis and its subsidiaries are subject to contingencies arising in the ordinary course of business, such as patent litigation, environmental remediation liabilities and other product-related and commercial litigation, and governmental investigations and proceedings. A provision is recorded when there is a probable outflow of resources for which a reliable estimate can be made of the outcome of the legal or other disputes against the subsidiary.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Contingent consideration&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In the acquisition or divestment of a business, it is necessary to recognize contingent future amounts due to previous owners, representing contractually defined potential amounts as a liability or an asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at fair value, which is then remeasured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance, and are adjusted for the probability of their likelihood of payment, and are appropriately discounted to reflect the impact of time.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in &#x201c;Cost of goods sold&#x201d; for currently marketed products and in &#x201c;Research and development&#x201d; for IPR&amp;amp;D. Changes in contingent consideration assets are recognized in &#x201c;Other income&#x201d; or &#x201c;Other expense,&#x201d; depending on their nature. &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The effect of unwinding the discount over time is recognized for contingent consideration liabilities in &#x201c;Interest expense&#x201d; and for contingent consideration assets as interest income recognized in the consolidated income statement within &#x201c;Other financial income and expense.&#x201d;&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Defined benefit pension plans and&#160;other&#160;post-employment benefits&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The liability in respect of defined benefit pension plans and other post-employment benefits is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions in which employees are employed, while the net interest on the net defined benefit liability or asset is recognized as &#x201c;Other expense&#x201d; or &#x201c;Other income.&#x201d;&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Treasury shares&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Treasury shares are initially recorded at fair value on their trade date, which is different from the settlement date, when the transaction is ultimately effected. Treasury shares are deducted from consolidated equity at their nominal value of CHF&#160;0.50 per share. Differences between the nominal amount and the transaction price on purchases or sales of treasury shares with third parties, or the value of services received for the shares allocated to employees as part of share-based compensation arrangements, are recorded in &#x201c;Retained earnings&#x201d; in the consolidated statement of changes in equity.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Revenue recognition&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Revenue on the sale of Novartis Group products and services, which is recorded as &#x201c;Net sales to third parties&#x201d; in the consolidated income statement, is recognized when a contractual promise to a customer (performance obligation) has been fulfilled by transferring control over the promised goods and services to the customer, substantially all of which is at the point in time of shipment to or receipt of the products by the customer or when the services are performed. If contracts contain customer acceptance provisions, revenue is recognized upon the satisfaction of the acceptance criteria. If a contract contains more than one performance obligation, the consideration is allocated based on the standalone selling price of each performance obligation. The amount of revenue recognized is based on the consideration Novartis expects to receive in exchange for its goods and services, when it is highly probable that a significant reversal will not occur.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The consideration Novartis receives in exchange for its goods or services may be fixed or variable. Variable consideration is recognized when it is highly probable that a significant reversal will not occur. The most common elements of variable consideration are listed below.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Rebates and discounts granted to wholesalers, retailers, government agencies (including US Medicaid and US Federal Medicare programs), government supported healthcare systems, private health systems, pharmacy benefit managers, managed healthcare organizations, purchasing organizations and other direct and indirect customers, as well as chargebacks are provisioned and recorded as revenue deductions at the time the related revenues are recorded, or when the incentives are offered. These rebates and discounts, applied using provision rates, are estimated based on the terms and conditions in the individual states, plans and customer agreements, historical experience, product sales and growth rate, population growth, product pricing including inflation impacts, the mix of contracts and products, the level of inventory in the distribution channel, regulations, contracts, channels and payers, as appropriate to the individual rebate and discount arrangements.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Refunds granted to healthcare providers under innovative pay-for-performance agreements (i.e. outcome based arrangements) are provisioned and recorded as a revenue deduction at the time the related sales are recorded. They are calculated on the basis of historical experience and clinical data available for the product, as well as specific terms of the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until the uncertainty is resolved, until such history is available or the period when the refund right has expired. The provisions for revenue deductions under the innovative pay-for-performance agreements are adjusted periodically based on established processes and actual experience, including the products actual outcomes achieved compared with the anticipated predefined targets.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Cash discounts are offered to customers to encourage prompt payment and are provisioned and recorded as revenue deductions at the time the related sales are recorded.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Shelf stock adjustments are generally granted to customers, primarily of the Sandoz Division, to cover the inventory held by them at the time a price decline becomes effective. Revenue deduction provisions for shelf stock adjustments are recorded when the price decline is anticipated, based on the impact of the price decline on the customer&#x2019;s estimated inventory levels. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Sales returns provisions are recognized and recorded as revenue deductions when there is historical experience of Novartis agreeing to customer returns and Novartis can reasonably estimate expected future returns. In doing so, the estimated rate of return is applied, determined on the basis of historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a resale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Net sales to third parties and provisions for revenue deductions are adjusted periodically to reflect experience and to reflect actual amounts as rebates, refunds, &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;discounts and returns are processed. There is often a time lag between recording of revenue deductions and the final accounting for them. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these revenue deductions.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;&#x201c;Other revenue&#x201d; includes income from profit-sharing arrangements with our collaboration partners, and royalty and milestone income from the out-licensing of intellectual property when Novartis retains an interest in the intellectual property through a license. Royalty income earned from a license is recognized when the underlying sales have occurred. Milestone income is recognized at the point in time when it is highly probable that the relevant milestone event criteria are met, and the risk of reversal of revenue recognition is remote. &#x201c;Other revenue&#x201d; also includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties, and is recognized when control transfers to the third party and our performance obligations are satisfied. &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Research and development&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Internal research and development (R&amp;amp;D) costs are fully charged to &#x201c;Research and development&#x201d; in the consolidated income statement in the period in which they are incurred. The Group considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland or Japan.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&amp;amp;D, that are deemed not to transfer intellectual property to Novartis are expensed as internal R&amp;amp;D expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been received from a regulatory authority in a major market.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are capitalized, as are payments for other assets, such as technologies to be used in R&amp;amp;D activities. If additional payments are made to the originator company to continue performing R&amp;amp;D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&amp;amp;D services not resulting in an additional transfer of intellectual property rights to Novartis. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Novartis of additional intellectual property developed at the risk of the originator company. Subsequent internal R&amp;amp;D costs in relation to IPR&amp;amp;D and other assets are expensed, since the technical feasibility of the internal R&amp;amp;D activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval in a major market are capitalized and recognized as currently marketed products.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Inventory produced ahead of regulatory approval is fully provisioned, and the charge is included in &#x201c;Other expense&#x201d; in the consolidated income statement, as its ultimate use cannot be assured. If this inventory can subsequently be sold, the provision is released to &#x201c;Other income&#x201d; in the consolidated income statement, either on approval by the appropriate regulatory authority or, exceptionally in Europe, on recommendation by the Committee for Medicinal Products for Human Use (CHMP), if approval is virtually certain.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Share-based compensation&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Vested Novartis shares and American Depositary Receipts (ADRs) that are granted as compensation are valued at their market value on the grant date and are immediately expensed in the consolidated income statement.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair values of unvested restricted shares (RSs), restricted share units (RSUs) and performance share units (PSUs) in Novartis shares and ADRs granted to employees as compensation are recognized as an expense over the related vesting period. The expense recorded in the consolidated income statement is included in the personnel expenses of the various functions in which the employees are employed.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Unvested restricted shares, restricted ADRs and RSUs are only conditional on the provision of services by the plan participant during the vesting period. They are valued at fair value on the grant date. As RSUs do not entitle the holder to dividends, the fair value is based on the Novartis share price at the grant date adjusted for the net present value of the dividends expected to be paid during the holding period. The fair value of these grants, after making adjustments for assumptions related to forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;PSUs are subject to the achievement of certain performance criteria during the vesting period and require plan participants to provide services during this period. The following paragraphs provide an overview of the accounting policies for the share-based compensation plan that grant PSUs. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs that are subject to performance criteria based on Novartis internal performance metrics and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on assumptions concerning the expected performance against the internal performance metrics throughout the vesting period. The assumptions are based on the Group&#x2019;s targets for those performance metrics, and the expected forfeitures due to plan participants not meeting their service conditions. The &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;assumptions are periodically adjusted over the vesting period. Any change in estimates for past services is recorded immediately as an expense or income in the consolidated income statement, and amounts for the remaining vesting period are expensed on a straight-line basis. As a result, at the end of the vesting period, the charge during the entire vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs that are subject to performance criteria based on variables that can be observed in the market, which for Novartis plans is the Novartis total shareholder return (TSR) relative to a specific peer group of companies over the vesting period, and that are conditional on the provision of services by the plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on the total fair value of the grant over the vesting period. IFRS requires that these variables that can be observed in the market are taken into account in determining the fair value of the PSUs at the grant date. Novartis determined the fair value of these PSUs at the date of grant using a Monte Carlo simulation model. Adjustments to the number of equity instruments granted are only made if a plan participant does not fulfill the service conditions.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs granted under plans that are subject to both performance criteria based on Novartis internal performance metrics and Novartis TSR relative to a specific  peer group of companies over the vesting period and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on a bifurcation into the components based on the performance criteria related to Novartis internal performance metrics and TSR, as described in the paragraphs above.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Measuring the fair values of PSUs granted that include TSR performance criteria requires use of estimates. The Monte Carlo simulation used to determine the fair value of the PSUs TSR performance criteria requires the probability of factors related to uncertain future events; the term of the award; the grant price of underlying shares or ADRs; expected volatilities; the expected correlation matrix of the underlying equity instruments with those of the peer group of companies; and the risk-free interest rate as input parameters.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If a plan participant leaves Novartis for reasons other than retirement, disability or death, then unvested restricted shares, restricted ADRs, RSUs and PSUs are forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Novartis Board of Directors, for example, in connection with a reorganization or divestment.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Government grants&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Grants from governments or similar organizations are recognized at their fair value when there is reasonable assurance that the grant will be received and the Group will comply with all attached conditions.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Government grants received to compensate costs are deferred and recognized in the consolidated income statement over the period necessary to match them against the related costs that they are intended to compensate.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The accounting policy for property, plant and equipment describes the treatment of any related grants.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Restructuring charges&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Restructuring provisions are recognized for the direct expenditure arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Charges to increase restructuring provisions are included in &#x201c;Other expense&#x201d; in the consolidated income statements. &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Healthcare contributions&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Healthcare cost contribution levies and fees under governmental programs that require the Group to contribute to a country&#x2019;s healthcare costs, other than programs described in &#x201c;Revenue recognition&#x201d; in this Note 1, are recognized in &#x201c;Other expense&#x201d; in the consolidated income statement. Provisions for healthcare cost contributions are adjusted to the actual amounts levied. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these healthcare cost contributions. &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Income taxes&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Income taxes comprise current income taxes and deferred income taxes and are recognized in the same periods as the revenues and expenses to which they relate. Income taxes include interest and penalties incurred during the period, insofar as they are considered an income tax. Income taxes related to items recognized directly to other comprehensive income or to equity are recognized together with the corresponding item, to which the income tax is attributable, directly in other comprehensive income or in equity.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Deferred income taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax base of an asset or liability and its carrying value for financial reporting purposes, except for those temporary differences related to investments in subsidiaries and associated companies, where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary&#x2019;s retained earnings are only recognized when a dividend is declared or has been planned. Furthermore, deferred income taxes are recognized for the net tax effects of net operating loss carryforwards and tax credits. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The carrying amount of deferred tax assets is reduced to the extent that it is not probable that sufficient taxable profits will be available to enable all or part of the asset to be recovered. In evaluating our ability to recover our deferred tax assets in the jurisdiction from &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The estimated amounts for current and deferred tax assets or liabilities, including amounts related to any uncertain tax positions, are based on applicable tax law and regulations in the various tax jurisdictions, in which the Group operates, which are subject to interpretations based on currently known facts and circumstances.  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Tax returns are based on an interpretation of tax laws and regulations, and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made requiring payments of additional tax, interest or penalties. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The calculation of income tax assets and liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions across our global operations. As a result, inherent uncertainties exist in the estimates of the tax positions. Tax liabilities for uncertain tax provisions are recognized on the consolidated balance sheets within current income tax liabilities.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impact of new IFRS standards, amendments and interpretations in 2022&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;There were no new IFRS standards adopted by the Group in 2022. In addition, new IFRS amendments or interpretations that became effective in 2022 did not have a material impact to the Group&#x2019;s consolidated financial statements. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Based on the Group&#x2019;s assessment, there are no IFRS standards, amendments or interpretations not yet effective in 2022 that would be expected to have a material impact on the Group&#x2019;s consolidated financial statements.&lt;/div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impact of adopting significant new IFRS standard in 2021&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following new IFRS standard has been adopted by Novartis from January 1, 2021:&lt;/div&gt;
                  &lt;div&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Interest Rate Benchmark Reform &#x2013; Phase 2, Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 (Interest Benchmark Reform Amendments)&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Interest Benchmark Reform Amendments became effective from January 1, 2021. These amendments address issues that might affect financial reporting when an existing interest rate benchmark (i.e. Interbank offered rate &#x2013; IBOR) is replaced with an alternative benchmark interest rate. The effects of interest rate benchmark reform on the Group&#x2019;s financial instruments and risk management strategies did not have a material impact on the Group&#x2019;s consolidated financial statements.&lt;/div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impact of adopting significant new IFRS standard in 2020&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following new IFRS standard has been adopted by Novartis from January 1, 2020:&lt;/div&gt;
                  &lt;div&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;IFRS 3 Business Combinations amendments&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The IASB issued amendments to IFRS 3 Business Combinations that revised the definition of a business, which assist entities with the evaluation of when an asset or group of assets acquired should be considered a business. This amended standard has been applied to transactions entered into on or after January 1, 2020. The amended standard allows an entity to apply an optional concentration test, on a transaction-by-transaction basis, to evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this optional concentration test is met, the set of activities and assets is determined not to be a business. The adoption of this amended standard on January 1, 2020, did not have a significant impact on our consolidated financial statements and is not expected to have a significant impact in future periods. However, this will depend on the facts and circumstances of future transactions and if the Group decides to apply the optional concentration test in the assessment of whether an acquired set of activities and assets is or is not a business.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div/&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSubsidiariesExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_6dcd87da-4dde-4680-9ad2-2cc8d27330db_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Scope of consolidation &lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated financial statements include all entities, including structured entities, over which Novartis AG, Basel, Switzerland, directly or indirectly has control (generally as a result of owning more than 50% of the entity&#x2019;s voting interest). Consolidated entities are also referred to as &#x201c;subsidiaries.&#x201d; &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In cases where Novartis does not fully own a subsidiary, it has elected to value any remaining outstanding non-controlling interest at the time of acquiring control of the subsidiary at its proportionate share of the fair value of the net identified assets.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Investments in associated companies (generally defined as investments in entities in which Novartis holds between 20% and 50% of voting shares or over which it otherwise has significant influence) and joint ventures are accounted for using the equity method, except for selected venture fund investments for which the Group has elected to apply the method of fair value through the consolidated income statement.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForSubsidiariesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_3770ca29-199e-4a05-8636-4e47bcdaf8ea_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Foreign currencies&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated financial statements of Novartis are presented in US dollars (USD). The functional currency of a subsidiary is generally the local currency of that respective entity. The functional currency used for the reporting of certain Swiss and foreign finance entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in this currency.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For subsidiaries not operating in hyperinflationary economies, the subsidiary&#x2019;s results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates:&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Income, expense and cash flows for each month using the average exchange rate, with the US dollar values for each month being aggregated during the year&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Balance sheet using year-end exchange rates&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Resulting exchange rate differences are recognized in other comprehensive income&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;For subsidiaries operating in hyperinflationary economies, the impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period is recorded in retained earnings in equity. The subsequent gains or losses resulting from the restatement of non-monetary assets are recorded in &#x201c;Other financial income and expense&#x201d; in the consolidated income statement. &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_cb4e7fd9-b54b-43ec-b1eb-9daf52a97f20_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Non-current assets held for sale or held for distribution to owners&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Non-current assets are accounted for as assets held for sale or as related to discontinued operations when their carrying amount is to be recovered principally through a sale transaction or distribution to owners and a sale or distribution to owners is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell and any resulting impairment is recognized. Assets related to discontinued operations and assets of a disposal group held for sale are not depreciated or amortized. The prior year consolidated balance sheet is not restated.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If in a subsequent period, the criteria for classification as held for sale are no longer met, the recoverable amount of assets and liabilities are reclassified out of assets held for sale into the respective balance sheet lines and the prior year consolidated balance sheet is not restated. The cumulative amount of depreciation and amortization not recorded since the date of their classification as assets held for sale, and any required &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;adjustments to the recoverable amounts of assets are recognized in the consolidated income statement.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_74be47e5-6c1d-4bea-97e1-e2335b8d53b6_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Acquisition of assets and businesses&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Assets separately acquired are recorded at cost, which includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment and restore the site when it is no longer used are included in their cost.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Acquired businesses are accounted for by applying the acquisition method, unless the optional concentration test is applied. The optional concentration test allows for an election on a transaction-by-transaction basis to account for the acquired business as an asset separately acquired when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The acquisition method requires that the assets acquired and liabilities assumed be recorded at their respective fair values on the date the Group obtains control. The excess of the fair value of the total purchase consideration transferred over the fair value of the acquired assets and assumed liabilities is recognized as goodwill. The valuations are based on information available at the acquisition date. Acquisition related costs are expensed as incurred.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The application of the acquisition method requires certain estimates and assumptions to be made, especially concerning the fair values of the acquired intangible assets, inventories, property, plant and equipment and the liabilities assumed at the acquisition date, and the useful lives of the intangible assets and property, plant and equipment. Estimates of fair value require the use of valuation techniques. These valuations require the use of management assumptions and estimates, including the value of comparable assets in the market, amount and timing of future cash flows, outcomes and costs of research and development activities, probability of obtaining regulatory approval, long-term sales forecasts, actions of competitors, discount rates and terminal growth rates. The section &#x201c;&#x2014;Impairment of goodwill and intangible assets&#x201d; in this Note 1 provides additional information on key assumptions that are highly sensitive in the estimation of fair values using valuation techniques.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_672c4e86-5604-47fe-95df-c7d502808904_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Property, plant and equipment&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Property, plant and equipment is depreciated on a straight-line basis in the consolidated income statement over the estimated useful life of the individual asset. Freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Property, plant and equipment is assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections over the useful life.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the estimated useful life by major categories for property, plant and equipment:&lt;/div&gt;
                  &lt;div&gt;

                      &lt;div&gt;
                        &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                          &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:12;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Useful life&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 2px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buildings&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                              &lt;td align="right" style=";width:20%;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20 to 40 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and other equipment&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Machinery and equipment&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7 to 20 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Furniture and vehicles&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 10 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Computer hardware&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 7 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                          &lt;/table&gt;
                        &lt;/div&gt;
                      &lt;/div&gt;

                  &lt;/div&gt;
                  &lt;div&gt;
                    &lt;div&gt;
                      &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Government grants obtained for construction activities, including any related equipment, are deducted from the gross acquisition cost to arrive at the balance sheet carrying value of the related assets.&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <nvs:RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_a9318f85-a40c-4431-8b4c-6eed14a4f1ea_0">
                      &lt;div&gt;
                        &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                          &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:12;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Useful life&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 2px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buildings&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                              &lt;td align="right" style=";width:20%;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 20 to 40 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and other equipment&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Machinery and equipment&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 7 to 20 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Furniture and vehicles&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 10 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Computer hardware&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 7 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                          &lt;/table&gt;
                        &lt;/div&gt;
                      &lt;/div&gt;
                    </nvs:RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_f6eb3138-3723-4a27-a629-e69937de64c5_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Leases and right-of-use assets&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;As lessee, at inception and upon the modification of a contract, the Group assesses whether the contract contains a lease. The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative standalone price of each component. &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases. For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease. &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease to the end of the lease term. The lease term includes the period of any lease extension that management assess as reasonably certain to be exercised by the Group. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the Novartis incremental borrowing rate for the asset subject to the lease in the relevant market.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The portion of the lease payments attributable to the repayment of lease liabilities is recognized in cash flows used in financing activities, and the portion attributable to the payment of interest is included in cash flows from operating activities.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease incentive received, and any initial direct costs incurred by Novartis, and expected costs for obligations to dismantle and remove right-of-use assets when they are no longer used.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;the shorter of the useful life of the right-of-use asset or the end of the lease term. &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In arrangements where the Group is the lessor, it determines at lease inception whether the lease is a finance lease or an operating lease. Leases that transfer substantially all of the risk and rewards incidental to ownership of the underlying asset to the counterparty (the lessee) are accounted for as finance leases. Leases that do not transfer substantially all of the risks and rewards of ownership are accounted for as operating leases. Operating lease payments received are recognized on a straight-line basis over the lease term in the consolidated income statement in &#x201c;Other income.&#x201d; &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_32ac2f12-f284-4cf4-9292-a621b9d9cb3e_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Goodwill and intangible assets&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Goodwill&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Goodwill arises on applying the acquisition method on the acquisition of a business and is the excess of the fair value of the consideration transferred to acquire the business over the underlying fair value of the net identified assets acquired. It is allocated to groups of cash-generating units (CGUs), that are expected to benefit from the synergies of the combination, and which are usually represented by the reported segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under &#x201c;Other expense&#x201d; in the consolidated income statement.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory>
    <nvs:DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_b22ee7ac-1b62-4d32-8247-7e01baf52145_0">
                &lt;div&gt;
                  &lt;div&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Intangible assets available for use&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has the following classes of available for use intangible assets: currently marketed products; technologies and other intangible assets (including software).&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Currently marketed products represent the composite value of acquired intellectual property (IP), patents, distribution rights and product trade names.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Technologies represent identified and separable acquired know-how used in the research, development and production processes.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Significant investments in internally developed and acquired computer software are capitalized and included in the &#x201c;Other&#x201d; category, and amortized once available for use.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Intangible assets available for use with a definite useful life are amortized over their estimated useful lives on a straight-line basis and are evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the estimated useful life by major categories for intangible assets available for use and the line in the consolidated income statement in which the amortization and any potential impairment charge is recognized:&lt;/div&gt;
                  &lt;div&gt;

                      &lt;div&gt;
                        &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                          &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:12;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                                  &lt;br/&gt;
                                  &lt;br/&gt; Useful life&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Income statement line&lt;br/&gt; for amortization and&lt;br/&gt; impairment charges&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currently marketed products&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 20 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Technologies&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10 to 20 years    &lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"   or "Research   and development"&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other (including software)&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 12 years  &lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; In the relevant   functional expense&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                          &lt;/table&gt;
                        &lt;/div&gt;
                      &lt;/div&gt;

                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock>
    <nvs:RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_fa2cd3f0-cdac-4210-a9ca-d6cdf24c2fba_0">
                      &lt;div&gt;
                        &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                          &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:12;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                                  &lt;br/&gt;
                                  &lt;br/&gt; Useful life&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Income statement line&lt;br/&gt; for amortization and&lt;br/&gt; impairment charges&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currently marketed products&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 5 to 20 years&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right" style=";width:1%;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Technologies&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10 to 20 years    &lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; "Cost of goods sold"   or "Research   and development"&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                            &lt;tr valign="bottom"&gt;
                              &lt;td style=";height:16;"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other (including software)&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 3 to 12 years  &lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                              &lt;td align="right"&gt;
                                &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; In the relevant   functional expense&lt;/div&gt;
                              &lt;/td&gt;
                              &lt;td align="right"/&gt;
                            &lt;/tr&gt;
                            &lt;tr&gt;
                              &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                            &lt;/tr&gt;
                          &lt;/table&gt;
                        &lt;/div&gt;
                      &lt;/div&gt;
                    </nvs:RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock>
    <nvs:DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_c90aef21-1ee7-44f3-b187-84a18c91c751_0">
                &lt;div&gt;
                  &lt;div&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Intangible assets not yet available for use&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Acquired research and development intangible assets that have not yet obtained marketing approval are recognized as in-process research and development (IPR&amp;amp;D).&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;IPR&amp;amp;D is not amortized, but is evaluated for potential impairment on an annual basis or when facts and circumstances warrant. Any impairment charge is recorded in the consolidated income statement under &#x201c;Research and development.&#x201d; Once a project included in IPR&amp;amp;D has received marketing approval from a regulatory authority, it is transferred to the &#x201c;Currently marketed products&#x201d; category.&lt;/div&gt;
                &lt;/div&gt;
              </nvs:DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock>
    <nvs:DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_9f835e18-b383-405c-9e1a-bfd7b0533326_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impairment of goodwill and intangible assets&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;An asset, a CGU or a grouping of CGUs is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value-in-use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGU, and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset. These valuations are classified as &#x201c;Level 3&#x201d; in the fair value hierarchy.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group&#x2019;s activities with regard to:&lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Amount and timing of projected future cash flows&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Sales forecasts &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Actions of competitors (launch of competing products, marketing initiatives, etc.)&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Sales erosion rates after the end of patent or other intellectual property rights protection, and timing of the entry of generic competition&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Outcome of research and development activities (compound efficacy, results of clinical trials, etc.)&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Amount and timing of projected costs to develop IPR&amp;amp;D into commercially viable products&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Profit margins&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Probability of obtaining regulatory approval&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Future tax rate&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Appropriate terminal growth rate&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Appropriate discount rate&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Generally, for intangible assets with a definite useful life, Novartis uses cash flow projections for the whole useful life of these assets. For goodwill, Novartis generally utilizes cash flow projections for a three-year period based on management forecasts, with a terminal value based on cash flow projections usually in line with inflation rates for later periods. &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Probability-weighted scenarios are typically used.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Discount rates used consider the Group&#x2019;s estimated weighted average cost of capital, adjusted for specific asset, country and currency risks associated with cash flow projections, to approximate the discount rate that market participants would use to value the asset.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Due to the above factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques. &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock>
    <nvs:DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_bc16bacf-a29d-46d3-84bc-304adf1fc279_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Cash and cash equivalents&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Cash and cash equivalents include highly liquid investments with original maturities of three months or less, which are readily convertible to known amounts of cash. Bank overdrafts are presented within current financial debts on the consolidated balance sheet.&lt;/div&gt;
                &lt;/div&gt;
              </nvs:DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock>
    <nvs:DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_87bf163b-b6e9-4add-98c9-7d767794532f_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Marketable securities, commodities and non-current financial assets &lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Commodities, which include gold bullion or coins, are valued at the lower of cost or fair value using current market prices. The changes in fair value below cost are immediately recorded in &#x201c;Other financial income and expense.&#x201d;&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Marketable securities are financial assets held for short-term purposes which are principally traded in liquid markets and are classified within current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#x201c;Other financial income and expense&#x201d; in the consolidated income statement. Non-current financial assets held for long-term strategic purposes are classified within non-current assets on the consolidated balance sheet. The financial impacts related to these financial assets are recorded in &#x201c;Other income&#x201d; and &#x201c;Other expense&#x201d; in the consolidated income statement.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Marketable securities and non-current financial assets are initially recorded at fair value on their trade date, which is different from the settlement date when the transaction is ultimately effected. Quoted securities are remeasured at each reporting date to fair value based on current market prices. If the market for a financial asset is not active or no market is available, fair values are established using valuation techniques. The majority of non-quoted investments are initially valued at fair value through the purchase price established between a willing buyer and seller. Non-quoted investments are subsequently adjusted based on values derived from discounted cash flow analysis or other pricing models. These investment values are classified as &#x201c;Level 3&#x201d; in the fair value hierarchy.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group classifies and accounts for its marketable securities and non-current financial assets in the following categories:&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Debt securities are valued at fair value through other comprehensive income with subsequent recycling into the consolidated income statement, as they meet both the &#x201c;solely payment of principal and interest&#x201d; and the business model criteria. Unrealized gains and losses, except exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are recognized in the consolidated income statement when the debt instrument is sold, at which time the gain is transferred to &#x201c;Other financial income and expense.&#x201d; Exchange gains and losses related to debt instruments are immediately recognized in the consolidated income statement in &#x201c;Other financial income and expense.&#x201d;&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Fund investments and equity securities of the Novartis Venture Fund are valued at fair value through profit and loss (FVPL). Unrealized gains and losses, including exchange gains and losses, are recognized in the consolidated income statement in &#x201c;Other income&#x201d; for gains and &#x201c;Other expense&#x201d; for losses.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Equity securities held as strategic investments, typically held outside of the Novartis Venture Fund, are generally designated at the date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. Unrealized gains and losses, including exchange gains and losses, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are reclassified to retained earnings when the equity security is sold. If these equity securities are not designated at the date of acquisition as financial assets valued at fair value through other comprehensive income, they are valued at FVPL, as described above.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Other non-current financial assets, such as loans and long-term receivables from customers, advances and other deposits, are valued at amortized cost, which reflects the time value of money less any allowances for expected credit losses.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group assesses on a forward-looking basis the expected credit losses associated with its debt securities valued at fair value through other comprehensive &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;income. Impairments on debt securities are recorded in &#x201c;Other financial income and expense.&#x201d;&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For other financial assets valued at amortized cost, impairments, which are based on their expected credit losses, and exchange rate losses are included in &#x201c;Other expense&#x201d; in the consolidated income statement. Exchange rate gains and interest income, using the effective interest rate method, are included in &#x201c;Other income&#x201d; or &#x201c;Other financial income&#x201d; in the consolidated income statement, depending on the nature of the item.&lt;/div&gt;
                &lt;/div&gt;
              </nvs:DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_3987dd88-a459-48a0-b2cf-ee01026a1dfe_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Derivative financial instruments&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Derivative financial instruments are initially recognized in the balance sheet at fair value and are remeasured to their current fair value at the end of each subsequent reporting period. The valuation of a forward exchange rate contract is based on the discounted cash flow model, using interest rate curves and forward rates at the reporting date as observable inputs.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Options are valued based on a modified Black-Scholes model using volatility and exercise prices as major observable inputs.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group enters into certain derivative financial instruments for the purpose of hedging to reduce the volatility in the Group&#x2019;s performance due to the exposure to various business-related risks. The risk mitigation is obtained because the derivative&#x2019;s value or cash flows are expected, wholly or partly, to offset changes in the value or cash flows of the recognized assets or liabilities. The overall strategy is aiming to mitigate the currency and interest rate risk of positions that are contractually agreed, and to partially mitigate the exposure risk of selected anticipated transactions.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Certain derivative financial instruments meet the criteria for hedge accounting treatment. A prerequisite for obtaining this accounting-hedge relationship is extensive documentation on inception and proving on a regular basis that the economic hedge is effective for accounting purposes. Other derivative financial instruments do not meet the criteria to qualify for hedge accounting or are not designated in a hedge relationship. Changes in the fair value of these derivative instruments are recognized immediately in &#x201c;Other financial income and expense&#x201d; in the consolidated income statement.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In addition, the Group has designated certain long-term debt components as hedges of the translation risk arising on certain net investments in foreign operations. On consolidation, foreign currency differences arising on long-term debt designated as net investment hedges of a foreign operation are recognized in other comprehensive income and accumulated in currency translation effects, to the extent that the hedge is effective. The foreign currency differences arising from hedge ineffectiveness are recognized in the income statement in &#x201c;Other financial income and expense.&#x201d;&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;When a hedged net investment is disposed of, the proportionate portion of the cumulative amount recognized in equity in relation to the hedged net investment is transferred to the consolidated income statement as an adjustment to the gain or loss on disposal.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_543e782b-168c-4cf3-a290-332e32fd8c02_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Inventories&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Inventory is valued at the lower of acquisition or production cost determined on a first-in, first-out basis and net realizable value. This value is used for the &#x201c;Cost of goods sold&#x201d; in the consolidated income statement. Unsaleable inventory is fully written off in the consolidated income statement under &#x201c;Cost of goods sold.&#x201d;&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories>
    <ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_a58653db-a25b-4885-bc0c-b319786c0d35_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Trade receivables&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as rebates, chargebacks and cash discounts.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Provisions for doubtful trade receivables are established using a forward-looking expected credit loss model (ECL), which includes possible default events on the trade receivables over the entire holding period of the trade receivable. These provisions represent the difference between the trade receivable&#x2019;s carrying amount in the consolidated balance sheet and the estimated collectible amount. Charges for doubtful trade receivables are recorded as marketing and selling costs recognized in the consolidated income statement within &#x201c;Selling, general and administration&#x201d; expenses.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_d4e7128d-a9cf-4198-a8f1-7b0eec3ca7e0_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Legal and environmental liabilities&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis and its subsidiaries are subject to contingencies arising in the ordinary course of business, such as patent litigation, environmental remediation liabilities and other product-related and commercial litigation, and governmental investigations and proceedings. A provision is recorded when there is a probable outflow of resources for which a reliable estimate can be made of the outcome of the legal or other disputes against the subsidiary.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_c150c585-9975-4cd9-8bb9-2d48c8a9a348_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Contingent consideration&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In the acquisition or divestment of a business, it is necessary to recognize contingent future amounts due to previous owners, representing contractually defined potential amounts as a liability or an asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at fair value, which is then remeasured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance, and are adjusted for the probability of their likelihood of payment, and are appropriately discounted to reflect the impact of time.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in &#x201c;Cost of goods sold&#x201d; for currently marketed products and in &#x201c;Research and development&#x201d; for IPR&amp;amp;D. Changes in contingent consideration assets are recognized in &#x201c;Other income&#x201d; or &#x201c;Other expense,&#x201d; depending on their nature. &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The effect of unwinding the discount over time is recognized for contingent consideration liabilities in &#x201c;Interest expense&#x201d; and for contingent consideration assets as interest income recognized in the consolidated income statement within &#x201c;Other financial income and expense.&#x201d;&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_68f9a85b-acce-4131-b8a1-cb6998552239_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Defined benefit pension plans and&#160;other&#160;post-employment benefits&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The liability in respect of defined benefit pension plans and other post-employment benefits is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions in which employees are employed, while the net interest on the net defined benefit liability or asset is recognized as &#x201c;Other expense&#x201d; or &#x201c;Other income.&#x201d;&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_4c994d9a-4d13-4ea2-b0af-3259a4010d8b_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Treasury shares&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Treasury shares are initially recorded at fair value on their trade date, which is different from the settlement date, when the transaction is ultimately effected. Treasury shares are deducted from consolidated equity at their nominal value of CHF&#160;0.50 per share. Differences between the nominal amount and the transaction price on purchases or sales of treasury shares with third parties, or the value of services received for the shares allocated to employees as part of share-based compensation arrangements, are recorded in &#x201c;Retained earnings&#x201d; in the consolidated statement of changes in equity.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory>
    <ifrs-full:ParValuePerShare
      contextRef="AR_I-CurrentYearEnd"
      decimals="2"
      unitRef="CHFPerShares">0.50</ifrs-full:ParValuePerShare>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_a26c3984-c8d7-4c60-a0d5-3f48808c4ccc_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Revenue recognition&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Revenue on the sale of Novartis Group products and services, which is recorded as &#x201c;Net sales to third parties&#x201d; in the consolidated income statement, is recognized when a contractual promise to a customer (performance obligation) has been fulfilled by transferring control over the promised goods and services to the customer, substantially all of which is at the point in time of shipment to or receipt of the products by the customer or when the services are performed. If contracts contain customer acceptance provisions, revenue is recognized upon the satisfaction of the acceptance criteria. If a contract contains more than one performance obligation, the consideration is allocated based on the standalone selling price of each performance obligation. The amount of revenue recognized is based on the consideration Novartis expects to receive in exchange for its goods and services, when it is highly probable that a significant reversal will not occur.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The consideration Novartis receives in exchange for its goods or services may be fixed or variable. Variable consideration is recognized when it is highly probable that a significant reversal will not occur. The most common elements of variable consideration are listed below.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Rebates and discounts granted to wholesalers, retailers, government agencies (including US Medicaid and US Federal Medicare programs), government supported healthcare systems, private health systems, pharmacy benefit managers, managed healthcare organizations, purchasing organizations and other direct and indirect customers, as well as chargebacks are provisioned and recorded as revenue deductions at the time the related revenues are recorded, or when the incentives are offered. These rebates and discounts, applied using provision rates, are estimated based on the terms and conditions in the individual states, plans and customer agreements, historical experience, product sales and growth rate, population growth, product pricing including inflation impacts, the mix of contracts and products, the level of inventory in the distribution channel, regulations, contracts, channels and payers, as appropriate to the individual rebate and discount arrangements.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Refunds granted to healthcare providers under innovative pay-for-performance agreements (i.e. outcome based arrangements) are provisioned and recorded as a revenue deduction at the time the related sales are recorded. They are calculated on the basis of historical experience and clinical data available for the product, as well as specific terms of the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until the uncertainty is resolved, until such history is available or the period when the refund right has expired. The provisions for revenue deductions under the innovative pay-for-performance agreements are adjusted periodically based on established processes and actual experience, including the products actual outcomes achieved compared with the anticipated predefined targets.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Cash discounts are offered to customers to encourage prompt payment and are provisioned and recorded as revenue deductions at the time the related sales are recorded.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Shelf stock adjustments are generally granted to customers, primarily of the Sandoz Division, to cover the inventory held by them at the time a price decline becomes effective. Revenue deduction provisions for shelf stock adjustments are recorded when the price decline is anticipated, based on the impact of the price decline on the customer&#x2019;s estimated inventory levels. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Sales returns provisions are recognized and recorded as revenue deductions when there is historical experience of Novartis agreeing to customer returns and Novartis can reasonably estimate expected future returns. In doing so, the estimated rate of return is applied, determined on the basis of historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a resale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Net sales to third parties and provisions for revenue deductions are adjusted periodically to reflect experience and to reflect actual amounts as rebates, refunds, &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;discounts and returns are processed. There is often a time lag between recording of revenue deductions and the final accounting for them. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these revenue deductions.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;&#x201c;Other revenue&#x201d; includes income from profit-sharing arrangements with our collaboration partners, and royalty and milestone income from the out-licensing of intellectual property when Novartis retains an interest in the intellectual property through a license. Royalty income earned from a license is recognized when the underlying sales have occurred. Milestone income is recognized at the point in time when it is highly probable that the relevant milestone event criteria are met, and the risk of reversal of revenue recognition is remote. &#x201c;Other revenue&#x201d; also includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties, and is recognized when control transfers to the third party and our performance obligations are satisfied. &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_f078b42e-edbb-4178-95f6-5b5f36ae1db7_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Research and development&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Internal research and development (R&amp;amp;D) costs are fully charged to &#x201c;Research and development&#x201d; in the consolidated income statement in the period in which they are incurred. The Group considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland or Japan.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&amp;amp;D, that are deemed not to transfer intellectual property to Novartis are expensed as internal R&amp;amp;D expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been received from a regulatory authority in a major market.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are capitalized, as are payments for other assets, such as technologies to be used in R&amp;amp;D activities. If additional payments are made to the originator company to continue performing R&amp;amp;D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&amp;amp;D services not resulting in an additional transfer of intellectual property rights to Novartis. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Novartis of additional intellectual property developed at the risk of the originator company. Subsequent internal R&amp;amp;D costs in relation to IPR&amp;amp;D and other assets are expensed, since the technical feasibility of the internal R&amp;amp;D activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval in a major market are capitalized and recognized as currently marketed products.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Inventory produced ahead of regulatory approval is fully provisioned, and the charge is included in &#x201c;Other expense&#x201d; in the consolidated income statement, as its ultimate use cannot be assured. If this inventory can subsequently be sold, the provision is released to &#x201c;Other income&#x201d; in the consolidated income statement, either on approval by the appropriate regulatory authority or, exceptionally in Europe, on recommendation by the Committee for Medicinal Products for Human Use (CHMP), if approval is virtually certain.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_0b2f7514-a089-4fec-bd00-da1c9263a0d8_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Share-based compensation&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Vested Novartis shares and American Depositary Receipts (ADRs) that are granted as compensation are valued at their market value on the grant date and are immediately expensed in the consolidated income statement.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair values of unvested restricted shares (RSs), restricted share units (RSUs) and performance share units (PSUs) in Novartis shares and ADRs granted to employees as compensation are recognized as an expense over the related vesting period. The expense recorded in the consolidated income statement is included in the personnel expenses of the various functions in which the employees are employed.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Unvested restricted shares, restricted ADRs and RSUs are only conditional on the provision of services by the plan participant during the vesting period. They are valued at fair value on the grant date. As RSUs do not entitle the holder to dividends, the fair value is based on the Novartis share price at the grant date adjusted for the net present value of the dividends expected to be paid during the holding period. The fair value of these grants, after making adjustments for assumptions related to forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;PSUs are subject to the achievement of certain performance criteria during the vesting period and require plan participants to provide services during this period. The following paragraphs provide an overview of the accounting policies for the share-based compensation plan that grant PSUs. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs that are subject to performance criteria based on Novartis internal performance metrics and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on assumptions concerning the expected performance against the internal performance metrics throughout the vesting period. The assumptions are based on the Group&#x2019;s targets for those performance metrics, and the expected forfeitures due to plan participants not meeting their service conditions. The &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;assumptions are periodically adjusted over the vesting period. Any change in estimates for past services is recorded immediately as an expense or income in the consolidated income statement, and amounts for the remaining vesting period are expensed on a straight-line basis. As a result, at the end of the vesting period, the charge during the entire vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs that are subject to performance criteria based on variables that can be observed in the market, which for Novartis plans is the Novartis total shareholder return (TSR) relative to a specific peer group of companies over the vesting period, and that are conditional on the provision of services by the plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on the total fair value of the grant over the vesting period. IFRS requires that these variables that can be observed in the market are taken into account in determining the fair value of the PSUs at the grant date. Novartis determined the fair value of these PSUs at the date of grant using a Monte Carlo simulation model. Adjustments to the number of equity instruments granted are only made if a plan participant does not fulfill the service conditions.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For PSUs granted under plans that are subject to both performance criteria based on Novartis internal performance metrics and Novartis TSR relative to a specific  peer group of companies over the vesting period and that are conditional on the provision of service by plan participants during the vesting period, the expense is recognized on a straight-line basis over the vesting period, and is determined based on a bifurcation into the components based on the performance criteria related to Novartis internal performance metrics and TSR, as described in the paragraphs above.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Measuring the fair values of PSUs granted that include TSR performance criteria requires use of estimates. The Monte Carlo simulation used to determine the fair value of the PSUs TSR performance criteria requires the probability of factors related to uncertain future events; the term of the award; the grant price of underlying shares or ADRs; expected volatilities; the expected correlation matrix of the underlying equity instruments with those of the peer group of companies; and the risk-free interest rate as input parameters.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If a plan participant leaves Novartis for reasons other than retirement, disability or death, then unvested restricted shares, restricted ADRs, RSUs and PSUs are forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Novartis Board of Directors, for example, in connection with a reorganization or divestment.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_036bff7f-aa1e-4f43-9b4b-d7f18b81e8de_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Government grants&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Grants from governments or similar organizations are recognized at their fair value when there is reasonable assurance that the grant will be received and the Group will comply with all attached conditions.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Government grants received to compensate costs are deferred and recognized in the consolidated income statement over the period necessary to match them against the related costs that they are intended to compensate.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The accounting policy for property, plant and equipment describes the treatment of any related grants.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants>
    <ifrs-full:DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_ff13d9b8-5e85-42fd-a343-29f17cbf1847_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Restructuring charges&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Restructuring provisions are recognized for the direct expenditure arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Charges to increase restructuring provisions are included in &#x201c;Other expense&#x201d; in the consolidated income statements. &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory>
    <nvs:DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_96a1979d-3a9c-48e6-b9a7-71bea5b7405b_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Healthcare contributions&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Healthcare cost contribution levies and fees under governmental programs that require the Group to contribute to a country&#x2019;s healthcare costs, other than programs described in &#x201c;Revenue recognition&#x201d; in this Note 1, are recognized in &#x201c;Other expense&#x201d; in the consolidated income statement. Provisions for healthcare cost contributions are adjusted to the actual amounts levied. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these healthcare cost contributions. &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_055b6e76-eb92-4c11-bb03-41901fca69be_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Income taxes&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Income taxes comprise current income taxes and deferred income taxes and are recognized in the same periods as the revenues and expenses to which they relate. Income taxes include interest and penalties incurred during the period, insofar as they are considered an income tax. Income taxes related to items recognized directly to other comprehensive income or to equity are recognized together with the corresponding item, to which the income tax is attributable, directly in other comprehensive income or in equity.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Deferred income taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax base of an asset or liability and its carrying value for financial reporting purposes, except for those temporary differences related to investments in subsidiaries and associated companies, where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary&#x2019;s retained earnings are only recognized when a dividend is declared or has been planned. Furthermore, deferred income taxes are recognized for the net tax effects of net operating loss carryforwards and tax credits. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The carrying amount of deferred tax assets is reduced to the extent that it is not probable that sufficient taxable profits will be available to enable all or part of the asset to be recovered. In evaluating our ability to recover our deferred tax assets in the jurisdiction from &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The estimated amounts for current and deferred tax assets or liabilities, including amounts related to any uncertain tax positions, are based on applicable tax law and regulations in the various tax jurisdictions, in which the Group operates, which are subject to interpretations based on currently known facts and circumstances.  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Tax returns are based on an interpretation of tax laws and regulations, and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made requiring payments of additional tax, interest or penalties. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The calculation of income tax assets and liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions across our global operations. As a result, inherent uncertainties exist in the estimates of the tax positions. Tax liabilities for uncertain tax provisions are recognized on the consolidated balance sheets within current income tax liabilities.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_3b79c294-3afb-418a-98ac-18fbd95eb241_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impact of new IFRS standards, amendments and interpretations in 2022&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;There were no new IFRS standards adopted by the Group in 2022. In addition, new IFRS amendments or interpretations that became effective in 2022 did not have a material impact to the Group&#x2019;s consolidated financial statements. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Based on the Group&#x2019;s assessment, there are no IFRS standards, amendments or interpretations not yet effective in 2022 that would be expected to have a material impact on the Group&#x2019;s consolidated financial statements.&lt;/div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impact of adopting significant new IFRS standard in 2021&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following new IFRS standard has been adopted by Novartis from January 1, 2021:&lt;/div&gt;
                  &lt;div&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Interest Rate Benchmark Reform &#x2013; Phase 2, Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 (Interest Benchmark Reform Amendments)&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Interest Benchmark Reform Amendments became effective from January 1, 2021. These amendments address issues that might affect financial reporting when an existing interest rate benchmark (i.e. Interbank offered rate &#x2013; IBOR) is replaced with an alternative benchmark interest rate. The effects of interest rate benchmark reform on the Group&#x2019;s financial instruments and risk management strategies did not have a material impact on the Group&#x2019;s consolidated financial statements.&lt;/div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Impact of adopting significant new IFRS standard in 2020&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following new IFRS standard has been adopted by Novartis from January 1, 2020:&lt;/div&gt;
                  &lt;div&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;IFRS 3 Business Combinations amendments&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The IASB issued amendments to IFRS 3 Business Combinations that revised the definition of a business, which assist entities with the evaluation of when an asset or group of assets acquired should be considered a business. This amended standard has been applied to transactions entered into on or after January 1, 2020. The amended standard allows an entity to apply an optional concentration test, on a transaction-by-transaction basis, to evaluate whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If this optional concentration test is met, the set of activities and assets is determined not to be a business. The adoption of this amended standard on January 1, 2020, did not have a significant impact on our consolidated financial statements and is not expected to have a significant impact in future periods. However, this will depend on the facts and circumstances of future transactions and if the Group decides to apply the optional concentration test in the assessment of whether an acquired set of activities and assets is or is not a business.&lt;/div&gt;
                &lt;/div&gt;

                &lt;div/&gt;
              </ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
    <nvs:DisclosureOfSignificantTransactionsTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_ebe58e15-af12-421e-b9f5-a20b8d01a03f_0">
          &lt;div&gt;
            &lt;div id="anchorId001517396"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;2. Significant transactions&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group applied the acquisition method of accounting for businesses acquired, and did not elect to apply the optional concentration test to account for acquired business as an asset separately acquired.&lt;/div&gt;
            &lt;div style=" padding-bottom: 10px;"&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Significant transactions in 2022&lt;/span&gt;
            &lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines &#x2013; acquisition of Gyroscope Therapeutics Holdings plc&lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On December 22, 2021, Novartis entered into an agreement to acquire all outstanding shares of Gyroscope Therapeutics Holdings plc (Gyroscope), a UK-based ocular gene therapy company. Gyroscope focuses on the discovery and development of gene therapy treatments for retinal indications. The purchase price consisted of a cash payment of USD 0.8 billion, subject to certain customary purchase price adjustments, and potential additional milestone payments of up to USD 0.7 billion, which Gyroscope shareholders are eligible to receive upon achievement of specified milestones. The acquisition closed on February 17, 2022. &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration was USD 1.0 billion. The amount consisted of an upfront cash payment of USD 0.8 billion (including customary purchase price adjustments) and the fair value of contingent consideration of USD 0.2 billion, which Gyroscope shareholders are eligible to receive upon achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD 0.9 billion, consisting primarily of intangible assets of USD 1.1 billion and net deferred tax liabilities of USD 0.2 billion. Goodwill amounted to USD 0.1 billion.&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The results of operations since the date of acquisition are not material.&lt;/div&gt;
            &lt;div style=" padding-bottom: 10px;"&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Significant transactions in 2021&lt;/span&gt;
            &lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Sandoz &#x2013; acquisition of GSK&#x2019;s cephalosporin antibiotics business&lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On February 10, 2021, Sandoz entered into an agreement with certain subsidiaries of GlaxoSmithKline plc (GSK) for the acquisition of the GSK&#x2019;s cephalosporin antibiotics business. &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Under the agreement, Sandoz acquired the global rights to three established brands (Zinnat&#xae;, Zinacef&#xae; and Fortum&#xae;) in more than 100 markets. It excluded the rights in the US, Australia and Germany to certain of those brands, which were previously divested by GSK, and the rights in India, Pakistan, Egypt, Japan (to certain of the brands) and China, which will be retained by GSK. The transaction closed on October 8, 2021.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The purchase price consisted of a USD 350 million upfront payment paid at closing and potential milestone payments up to USD 150 million, which GSK will be eligible to receive upon the achievement of certain annual sales milestones for the portfolio.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration was USD 415 million. The amount consisted of a payment of USD 351 million, including purchase price adjustments, and the fair value of contingent consideration of USD 64 million, which GSK is eligible to receive upon the achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD 308 million, consisting of USD 292 million intangible assets and USD 16 million deferred tax assets. Goodwill amounted to USD 107 million. &lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The 2021 results of operations since the date of acquisition were not material.&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Corporate &#x2013; divestment of the investment in Roche Holding AG &lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On November 3, 2021, Novartis entered into a Share Repurchase Agreement with Roche Holding AG under which Novartis agreed to sell 53.3 million (approximately &lt;span&gt;33.3%&lt;/span&gt;) bearer shares of Roche Holding AG voting shares in a bilateral transaction to Roche Holding AG for a total consideration of USD 20.7 billion. As a result, Novartis discontinued the use of equity method accounting starting from November 3, 2021.&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The transaction closed on December 6, 2021. Novartis realized a gain of USD 14.6 billion, recorded in income from associated companies.&lt;/div&gt;
            &lt;div style=" padding-bottom: 10px;"&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Significant transactions in 2020&lt;/span&gt;
            &lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines &#x2013; acquisition of The&#160;Medicines Company&lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On November 23, 2019, Novartis entered into an agreement and plan of merger (&#x201c;the Merger Agreement&#x201d;) with The Medicines Company, a US-based pharmaceutical company headquartered in Parsippany, New Jersey, USA. Pursuant to the Merger Agreement, on December 5, 2019, Novartis, through a subsidiary, commenced a tender offer to acquire all outstanding shares of The Medicines Company for USD 85 per share, or a total consideration of approximately USD 9.6 billion in cash on a fully diluted basis, including the equivalent share value related to The Medicines Company&#x2019;s convertible notes, in accordance with their terms. The tender offer expired on January 3, 2020, and on January 6, 2020, the acquiring subsidiary merged with and into The Medicines Company, resulting in The Medicines Company becoming an indirect wholly owned subsidiary of Novartis. Novartis financed the transaction through available cash, and short- and long-term borrowings. &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Medicines Company is focused on the development of inclisiran, a potentially first-in-class, twice yearly therapy that allows administration during patients&#x2019; routine visits to their healthcare professionals and will potentially contribute to improved patient adherence and sustained lower LDL-C levels.&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration was USD 9.6 billion. The purchase price allocation resulted in net identifiable assets of approximately USD 7.1 billion, consisting of USD 8.5 billion intangible assets, USD 1.4&lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt; billion net deferred tax liabilities and goodwill of approximately USD 2.5 billion. &lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The 2020 results of operations since the date of acquisition were not material.&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Sandoz &#x2013; acquisition of the Japanese business of Aspen Global Incorporated &lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On November 11, 2019, Sandoz entered into an agreement for the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Under the agreement, Sandoz acquired the shares in Aspen Japan K.K. and associated assets held by AGI. The transaction closed on January 31, 2020.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Aspen&#x2019;s portfolio in Japan consisted of off-patent medicines with a focus on anesthetics and specialty brands. The acquisition will enable Sandoz to expand its presence in the third-largest worldwide generics marketplace.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The purchase price consisted of EUR 274 million (USD 303 million) upfront payment, less customary purchase price adjustment of EUR 27 million (USD 30 million), plus potential milestone payments of up to EUR 70 million (USD 77 million), which AGI is eligible to receive upon the achievement of specified milestones.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of the total purchase consideration was EUR 294 million (USD 324 million). The amount consisted of a cash payment of EUR 247 million (USD 273 million) and the fair value of contingent consideration of EUR 47 million (USD 51 million), which AGI is eligible to receive upon the achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD 238 million, consisting of USD 196 million intangible assets, USD 26 million other net assets and USD 16 million net deferred tax assets. Goodwill amounted to USD 86 million. &lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The 2020 results of operations since the date of acquisition were not material.&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Sandoz &#x2013; retention of US dermatology business and generic US oral solids portfolio, previously planned to be divested&lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On September 6, 2018, Novartis announced that it entered into a stock and asset purchase agreement (SAPA) with Aurobindo Pharma USA Inc. (Aurobindo) for the sale of selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, for USD 0.8 billion in cash and potential earnouts. The closing was conditional on obtaining regulatory approval.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In March 2020, Novartis took the decision to retain the Sandoz US generic oral solids and dermatology businesses and on April 2, 2020 entered into a mutual agreement with Aurobindo to terminate the transaction. The decision was taken as approval from the US Federal Trade Commission for the transaction was not obtained within the agreed timelines.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The cumulative amount of the depreciation on property, plant and equipment (USD 38 million) and amortization on intangible assets (USD 102 million) not recorded in the consolidated income statement since the date of classification as held for sale was recognized in the consolidated income statement in the first quarter of 2020. In addition, an impairment of currently marketed products of USD 42 million was recognized in the first quarter of 2020 consolidated income statement.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As at March 31, 2020, the assets and liabilities of the Sandoz US generic oral solids and dermatology businesses were reclassified out of assets and liabilities of disposal group held for sale. The prior year balance sheet was not required to be restated.&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;There were no cumulative income or expenses included in the other comprehensive income relating to the disposal group.&lt;/div&gt;
          &lt;/div&gt;

          &lt;div/&gt;
        </nvs:DisclosureOfSignificantTransactionsTextBlock>
    <nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment
      contextRef="AR_D-December-22-2021_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">800000000</nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment>
    <nvs:PotentialMilestoneMaximumPayments
      contextRef="AR_D-December-22-2021_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">700000000</nvs:PotentialMilestoneMaximumPayments>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">1000000000.0</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment
      contextRef="AR_D-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">800000000</nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate
      contextRef="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">200000000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">900000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">1100000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">200000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:AdditionalRecognitionGoodwill
      contextRef="AR_D-February-17-2022_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsHoldingsPlcMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">100000000</ifrs-full:AdditionalRecognitionGoodwill>
    <nvs:NumberOfBrandsInPortfolioToAcquire
      contextRef="AR_I-February-10-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="0"
      unitRef="Pure">3</nvs:NumberOfBrandsInPortfolioToAcquire>
    <nvs:NumberOfMarketsForTheAcquiredBrands
      contextRef="AR_I-February-10-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="0"
      unitRef="Pure">100</nvs:NumberOfMarketsForTheAcquiredBrands>
    <nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment
      contextRef="AR_D-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">350000000</nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment>
    <nvs:PotentialMilestoneMaximumPayments
      contextRef="AR_D-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">150000000</nvs:PotentialMilestoneMaximumPayments>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">415000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:CashTransferred
      contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">351000000</ifrs-full:CashTransferred>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate
      contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">64000000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">308000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">292000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">16000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:AdditionalRecognitionGoodwill
      contextRef="AR_D-October-8-2021_dei-2022LegalEntityAxis_nvs-2022Q4GlaxoSmithKlinePlcGSKMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">107000000</ifrs-full:AdditionalRecognitionGoodwill>
    <nvs:NumberOfBearerShares
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-5"
      unitRef="Shares">53300000</nvs:NumberOfBearerShares>
    <ifrs-full:ProportionOfVotingPowerHeldInAssociate
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="3"
      unitRef="Pure">0.333</ifrs-full:ProportionOfVotingPowerHeldInAssociate>
    <ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-8"
      unitRef="USD">20700000000</ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations>
    <nvs:GainOnDivestmentOfInterestsInAssociatedCompanies
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-8"
      unitRef="USD">14600000000</nvs:GainOnDivestmentOfInterestsInAssociatedCompanies>
    <nvs:CashOfferPerOrdinaryShare
      contextRef="AR_I-Transaction-TheMedicinesCompany_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="1"
      unitRef="USD">85</nvs:CashOfferPerOrdinaryShare>
    <ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents
      contextRef="AR_D-Transaction-TheMedicinesCompany_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">9600000000</ifrs-full:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">9600000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">7100000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">8500000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">1400000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:AdditionalRecognitionGoodwill
      contextRef="AR_D-Transaction-TheMedicinesCompany-2_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">2500000000</ifrs-full:AdditionalRecognitionGoodwill>
    <nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment
      contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="EUR">274000000</nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment>
    <nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment
      contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">303000000</nvs:PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment>
    <nvs:CustomaryPurchasePriceAdjustment
      contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="EUR">27000000</nvs:CustomaryPurchasePriceAdjustment>
    <nvs:CustomaryPurchasePriceAdjustment
      contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">30000000</nvs:CustomaryPurchasePriceAdjustment>
    <nvs:PotentialMilestoneMaximumPayments
      contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="EUR">70000000</nvs:PotentialMilestoneMaximumPayments>
    <nvs:PotentialMilestoneMaximumPayments
      contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">77000000</nvs:PotentialMilestoneMaximumPayments>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="EUR">294000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">324000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:CashTransferred
      contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="EUR">247000000</ifrs-full:CashTransferred>
    <ifrs-full:CashTransferred
      contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">273000000</ifrs-full:CashTransferred>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate
      contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="EUR">47000000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate
      contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">51000000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">238000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">196000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <nvs:OtherNetAssets
      contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">26000000</nvs:OtherNetAssets>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">16000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:AdditionalRecognitionGoodwill
      contextRef="AR_D-Transaction-AspenGlobalIncorporation-2_dei-2022LegalEntityAxis_nvs-2022Q4AspenGlobalIncorporatedMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">86000000</ifrs-full:AdditionalRecognitionGoodwill>
    <nvs:DivestmentDateFairValueOfTotalConsiderationTransferred
      contextRef="AR_I-Transaction-Sandoz-Divestment_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember"
      decimals="-8"
      unitRef="USD">800000000</nvs:DivestmentDateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">38000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">102000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-Transaction-SandozUsAurobindo_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember"
      decimals="-5"
      unitRef="USD">42000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_7bfa1369-9560-4f78-86fb-8737ce2f53f4_0">
          &lt;div&gt;
            &lt;div id="anchorId001517643"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;3. Segmentation of key figures 2022, 2021 and 2020&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The businesses of Novartis are divided operationally on a worldwide basis into two identified reporting segments: Innovative Medicines and Sandoz. In addition, we separately report Corporate activities.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Reporting segments are presented in a manner consistent with the internal reporting to the chief operating decision-maker, which is the Executive Committee of Novartis. The reporting segments are managed separately because they each research, develop, manufacture, distribute and sell distinct products that require differing marketing strategies. &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Executive Committee of Novartis is responsible for allocating resources and assessing the performance of the reporting segments.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The reporting segments are as follows:&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Innovative Medicines researches, develops, manufactures, distributes and sells patented pharmaceuticals. Effective as of April 4, 2022, the Innovative Medicines Division is organized in two commercial organizational units: Innovative Medicines International and Innovative Medicines US, and is focused on the core therapeutic areas: cardiovascular; immunology; neuroscience; solid tumors and hematology; as well as other promoted brands (in the therapeutic areas of ophthalmology and respiratory) and established brands. Prior to the announcement on April 4, 2022, the Innovative Medicines Division was organized into two global business units: Novartis Oncology and Novartis Pharmaceuticals.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Sandoz develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. Sandoz is organized globally into three franchises: Retail Generics, Anti-Infectives and Biopharmaceuticals. In Retail Generics, Sandoz develops, manufactures and markets finished dosage forms of small molecule pharmaceuticals for sale to third parties across a broad range of therapeutic areas, including finished dosage form of anti-infectives sold to third parties. In Anti-Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by Retail Generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products, including biosimilars, and provides biotechnology manufacturing services to other companies.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Income and expenses relating to Corporate include the costs of the Group headquarters and those of corporate coordination functions in major countries. In addition, Corporate includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights, certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships. Usually, no allocation of Corporate items is made to the segments. As a result, Corporate assets and liabilities principally consist of net debt (cash and cash equivalents, marketable securities less financial debts), investments in associated companies, and current and deferred taxes and non-segment-specific environmental remediation and post-employment benefit liabilities. &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Our divisions are supported by Novartis Institutes for BioMedical Research, Global Drug Development, and the Operations unit. &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  The Novartis Institutes for BioMedical Research (NIBR) conducts research activities for the Innovative Medicines Division and also collaborates with Sandoz. &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  The Global Drug Development organization oversees all drug development activities for our Innovative Medicines Division and collaborates with our Sandoz Division on the development of its biosimilars portfolio.&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  The Operations unit, combines the Novartis Technical Operations (NTO) and Customer &amp;amp; Technology Solutions (CTS), following the internal reorganization announced on April 4, 2022. The Operations unit manages our manufacturing operations across our Innovative Medicines and Sandoz Divisions, and delivers business support services across the Group, such as information technology, real estate and facility services and procurement.&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The accounting policies mentioned in Note 1 are used in the reporting of segment results. Inter-segmental sales are made at amounts that are considered to approximate arm&#x2019;s length transactions. The Executive Committee of Novartis evaluates segmental performance and allocates resources among the segments based on a number of measures, including net sales to third parties, operating income and net operating assets. Segment net operating assets consist primarily of property, plant and equipment; right-of-use assets; intangible assets; goodwill; inventories; and trade and other operating receivables less operating liabilities.&lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Segmentation &#x2013; consolidated income statements&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Innovative Medicines  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Sandoz  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Corporate  (including eliminations)&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Group  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            41 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            41 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 631
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            50 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to other segments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            825
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            795
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            180
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 030&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            42 121
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            42 790
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 454
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 811
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 030&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            50 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other revenues&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            61
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 283
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-11 569&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-11 751&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4 978&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 147&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 061
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 031
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-15 486&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 867&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 801
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            32 218
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 504
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 725
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            67
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            36 342
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            37 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-11 679&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-12 306&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 062&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 062&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-512&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-518&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-14 253&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14 886&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9 172&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8 641&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-824&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-899&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9 996&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9 540&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            531
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 149
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            103
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            233
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            171
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            470
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            805
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 852
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 695&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 732&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-273&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-733&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-618&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 701&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 747&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 786
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10 688
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 448
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 600
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 037&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-599&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 689
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;(Loss)/income from associated companies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 332
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-837&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-811&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-80&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 371
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 416&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 119&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 955
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            24 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Attributable to:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Shareholders of Novartis AG&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            6 955
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            24 021
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Non-controlling interests&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in net income are:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Interest income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            379
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            71
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Depreciation of property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-837&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-859&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-204&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-210&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-122&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-139&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 163&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 208&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Depreciation of right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-252&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-265&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-33&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-39&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-15&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-300&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-318&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Amortization of intangible assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 728&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 638&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-222&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-238&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-32&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 982&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges on property, plant and equipment, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-407&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-271&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-407&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-281&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment of right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges on intangible assets, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 299&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-367&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-25&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 326&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-403&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges and fair value changes on financial assets, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-134&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-126&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-260&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to restructuring provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 069&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-240&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-40&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-259&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-26&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 368&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-328&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Equity-based compensation of Novartis equity plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-706&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-721&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-280&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-193&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 048&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-979&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate  (including eliminations)&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            41 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            39 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 631
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 646
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            48 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to other segments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            795
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            792
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            180
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            189
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-981&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            42 790
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            39 805
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 811
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 835
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-981&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            48 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other revenues&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            61
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 239
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-11 751&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-10 927&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 147&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 252&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 031
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 058
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 867&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 121&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            32 218
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 725
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 636
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            67
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            245
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            37 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            34 777
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-12 306&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-11 657&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 062&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 076&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-518&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-464&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14 886&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14 197&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8 641&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8 118&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-899&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-862&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9 540&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8 980&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 149
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            922
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            233
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            176
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            470
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 852
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 742
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 732&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 871&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-831&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-618&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-488&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 747&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 190&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10 688
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 172
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 600
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 043
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-599&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-63&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 689
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10 152
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 332
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            670
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-811&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-869&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-80&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-78&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 878
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 119&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 807&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            24 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 071
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Attributable to:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Shareholders of Novartis AG&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            24 021
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            8 072
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Non-controlling interests&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in net income are:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Interest income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            71
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            91
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Depreciation of property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-859&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-912&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-210&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-282&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-139&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-124&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 208&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 318&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Depreciation of right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-265&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-273&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-39&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-41&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-318&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-330&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Amortization of intangible assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 638&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 080&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-238&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-370&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 462&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges on property, plant and equipment, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-271&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-324&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-116&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-281&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-440&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges on intangible assets, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-367&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-768&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-141&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-403&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-914&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges and fair value changes on financial assets, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            153
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            335
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to restructuring provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-240&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-217&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-98&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-26&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-39&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-328&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-354&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Equity-based compensation of Novartis equity plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-721&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-714&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-64&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-193&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-180&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-979&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-958&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Segmentation &#x2013; consolidated balance sheets&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate  (including eliminations)&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            75 510
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            79 220
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            16 078
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            16 192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            25 865
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            36 383
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            117 453
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            131 795
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-16 966&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-15 929&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 710&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 632&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-37 354&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-44 412&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-58 030&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-63 973&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total equity&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            59 423
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            67 822
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net debt&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 245
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            868
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 245
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            868
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net operating assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            58 544
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            63 291
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            12 368
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12 560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 244&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-7 161&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            66 668
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            68 690
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in assets and liabilities are:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Total property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 488
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 861
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 901
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            415
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            476
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 764
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to property, plant and equipment&lt;sup style="white-space: nowrap"&gt; &#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            842
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            991
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            292
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            349
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            85
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            90
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 430
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Total right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 233
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 349
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            90
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            104
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            108
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            108
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 431
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to right-of-use assets&lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            196
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            222
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            31
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            26
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            247
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            321
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Total goodwill and intangible assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            51 357
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            53 919
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9 230
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 603
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            358
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            255
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            60 945
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            63 777
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to goodwill and intangible assets&lt;sup style="white-space: nowrap"&gt; &#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 791
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 491
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            163
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            102
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            139
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            143
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 093
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 736
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Total investment in associated companies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            107
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            170
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            27
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            143
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to investment in associated companies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18 930
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28 329
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18 930
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28 329
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Financial debts and derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            26 175
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            29 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            26 175
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            29 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Current income tax liabilities and deferred tax liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Eliminations mainly relate to the elimination of intercompany receivables and payables to other segments and inventories&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Note 29 provides additional disclosures related to net debt&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt; Excluding the impact of business acquisitions&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows countries that accounted for more than 5% of at least one of the respective Group totals, as well as regional information for net sales to third parties for the years ended December 31, 2022, 2021 and 2020, and for selected non-current assets for the years ended December 31, 2022 and 2021:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="11" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Net sales to third parties&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total of selected non-current assets&lt;sup&gt;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Country&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            970
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            800
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23 708
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            32
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25 770
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            33
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;United States&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            17 653
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16 818
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            33
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16 484
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35 353
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            48
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37 054
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            48
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;France&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 257
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 522
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 442
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 188
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 615
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Germany&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 278
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 870
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 518
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 229
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 378
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;China&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 128
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 052
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 573
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            599
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            703
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japan&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 683
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 804
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            165
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            217
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20 054
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            41
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20 808
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            40
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19 038
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 351
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            50 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            48 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            73 483
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            77 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Region&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18 467
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18 715
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35 896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37 525
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Americas&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21 536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            42
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20 463
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            40
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19 725
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            41
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35 806
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37 522
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 966
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 781
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 041
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            50 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            48 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            73 483
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            77 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Net sales to third parties by location of customer&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Total of property, plant and equipment; right-of-use assets; goodwill; intangible assets; investment in associated companies and other non-current assets excluding post-employment benefit assets&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div/&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group&#x2019;s largest, second-largest and third-largest customers account for approximately &lt;span&gt;16%&lt;/span&gt;, &lt;span&gt;11%&lt;/span&gt; and &lt;span&gt;7%&lt;/span&gt; of net sales to third parties, respectively (2021: &lt;span&gt;17%&lt;/span&gt;, &lt;span&gt;11%&lt;/span&gt; and &lt;span&gt;6%&lt;/span&gt;, respectively; 2020: &lt;span&gt;17%&lt;/span&gt;, &lt;span&gt;11%&lt;/span&gt; and &lt;span&gt;6%&lt;/span&gt;, respectively). All segments had sales to these customers in 2022, 2021 and 2020.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The highest amounts of trade receivables outstanding were for these same three customers and amounted to approximately &lt;span&gt;16%&lt;/span&gt;, &lt;span&gt;14%&lt;/span&gt; and &lt;span&gt;7%&lt;/span&gt;, respectively, of the trade receivables at December 31, 2022 (2021: &lt;span&gt;16%&lt;/span&gt;, &lt;span&gt;12%&lt;/span&gt; and &lt;span&gt;7%&lt;/span&gt;, respectively).&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Segmentation &#x2013; net sales to third parties&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Net sales to third parties by region&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2022&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2021&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change&lt;br/&gt; (2021&lt;br/&gt; to 2022)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2020&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change&lt;br/&gt; (2020&lt;br/&gt; to 2021)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Innovative Medicines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13 554
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 919
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13 484
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15 899
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 999
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 342
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 929
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 304
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 718
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 914
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 773
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 469
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            41 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            41 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            39 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Established Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30 548
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            31 459
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            29 643
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Emerging Growth Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 748
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 370
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 913
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 278
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 231
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 754
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 819
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 142
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 613
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 662
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 501
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            969
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            872
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            772
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 631
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 646
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Established Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 460
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 855
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 089
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Emerging Growth Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 789
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 776
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 557
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18 467
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18 715
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            17 653
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16 818
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16 484
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 966
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 883
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 645
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            50 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            48 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Established Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37 008
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            38 314
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            36 732
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Emerging Growth Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13 537
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13 312
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11 927
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Net sales to third parties by location of customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div/&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines Division net sales to third parties by core therapeutic area; other promoted brands; and established brands&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2022&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2021&lt;br/&gt; USD m&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change&lt;br/&gt; (2021 to&lt;br/&gt; 2022)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2020&lt;br/&gt; USD m&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change&lt;br/&gt; (2020 to&lt;br/&gt; 2021)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cardiovascular&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 548
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            31
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 497
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            42
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Leqvio&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            112
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Cardiovascular&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 756
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 497
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Immunology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 788
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 718
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 365
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 428
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 133
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 059
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Immunology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            7 287
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            7 205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 119
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Neuroscience&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 787
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 003
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 370
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 351
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            920
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            47
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kesimpta&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            372
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Mayzent&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            357
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            281
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            27
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            170
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            65
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Aimovig&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            218
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            215
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            164
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            31
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Neuroscience&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 051
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 007
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 272
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Solid Tumors&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 770
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 693
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 231
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            937
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            31
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            687
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            36
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            474
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            577
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-18&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            635
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lutathera&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            471
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            475
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            445
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Piqray&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            373
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            329
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            320
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Pluvicto&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            271
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tabrecta&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            133
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            90
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            48
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            35
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            157
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Solid Tumors&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 723
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 101
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 666
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Hematology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 016
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 738
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 923
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 060
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kymriah&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            587
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            474
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Adakveo&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            164
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Scemblix&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            149
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-67&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Hematology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 452
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 430
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 617
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2022&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2021&lt;br/&gt; USD m&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change&lt;br/&gt; (2021 to&lt;br/&gt; 2022)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2020&lt;br/&gt; USD m&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change&lt;br/&gt; (2020 to&lt;br/&gt; 2021)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Other Promoted Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 874
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 160
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 933
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xiidra&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            468
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            376
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Ultibro&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            479
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            584
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-18&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            623
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Beovu&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            203
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            186
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            190
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other respiratory&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            84
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            58
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            26
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            104
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Other Promoted  Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 451
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 148
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Promoted  Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 396
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 754
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 319
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 238
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 413
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 439
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            859
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-21&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 199
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            745
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 024
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 188
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            743
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            901
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-18&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            980
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            652
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            773
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 003
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-23&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            512
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            938
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-45&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 083
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;i&gt;Voltaren/Cataflam&lt;/i&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            334
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            373
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            360
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zortress/Certican&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            329
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            431
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-24&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            452
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            323
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            563
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            653
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Neoral/Sandimmun(e)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            310
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            368
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            393
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contract manufacturing&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            214
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            108
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            98
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 257
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 944
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Established  Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 900
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12 241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            13 694
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-11&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net  sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            41 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            41 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            39 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Reclassified to reflect the new Innovative Medicines divisional structures announced on April 4, 2022&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Net sales to third parties reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Net sales to third parties of the top 20 Innovative Medicines Division brands in 2022&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Brand classification by&lt;br/&gt; therapeutic area, other&lt;br/&gt; promoted brands or&lt;br/&gt; established brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Key indications&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; US&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Rest of &lt;br/&gt; world&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis (PsO),   ankylosing spondylitis  (AS), psoriatic arthritis   (PsA), non-radiographic   axial spondyloarthritis   (nr-axSPA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 770
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 788
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic heart failure,  hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 354
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 290
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune   thrombocytopenia (ITP),   severe aplastic anemia (SAA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 083
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis  (RMS)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 153
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            860
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia  (CML)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            877
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 046
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 923
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Other Promoted  Brands    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related   macular degeneration (AMD),   diabetic macular edema (DME),  retinal vein occlusion (RVO)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 874
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 874
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic   adjuvant melanoma,  advanced non-small cell   lung cancer (NSCLC),   tumor agnostic with   BRAF mutation indication&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            678
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 770
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology      &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF),   polycytomia vera (PV),   graft-versus-host disease  (GvHD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Spinal muscular atrophy  (SMA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            434
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            936
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 370
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA),   chronic spontaneous urticaria   (CSU), nasal polyps&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 365
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 365
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors,  acromegaly&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            800
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            438
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 238
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2-   metastatic breast cancer&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            472
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            759
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 231
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS,  TRAPS, HIDS/MKD, FMF,  SJIA, AOSD, gout)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            570
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            563
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 133
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kesimpta&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing-remitting   multiple sclerosis (RRMS)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            921
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            171
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            859
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            859
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands      &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid  leukemia (CML),   gastrointestinal stromal  tumors (GIST)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            540
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            745
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            729
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            743
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            597
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            652
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kymriah&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology        &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; r/r pediatric and young   adults acute lymphoblastic   leukemia (ALL), diffuse large   B-cell lymphoma (DLBCL),   follicular lymphoma (FL)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            196
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            340
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/  tuberous sclerosis complex   (TSC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            171
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            512
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 brands total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            12 753
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            19 384
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            32 137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 146
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9 159
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net  sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            15 899
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            25 397
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            41 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Net sales to third parties reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Net sales to third parties of the top 20 Innovative Medicines Division brands in 2021&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Brand classification by&lt;br/&gt; therapeutic area, other&lt;br/&gt; promoted brands or&lt;br/&gt; established brands&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Key indications&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; US&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Rest of &lt;br/&gt; world&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology        &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis (PsO), ankylosing   spondylitis (AS),   psoriatic arthritis (PsA),  non-radiographic axial   spondyloarthritis (nr-axSPA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 883
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 835
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 718
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic heart failure&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 712
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 836
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 548
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis (RMS)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 427
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 360
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 787
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Other Promoted  Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related macular   degeneration (AMD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 160
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 160
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia (CML)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            882
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 178
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 060
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune thrombocytopenia (ITP),   severe aplastic anemia (SAA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            947
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 069
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 016
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors      &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic   adjuvant melanoma,  advanced non-small cell   lung cancer (NSCLC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            606
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 087
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 693
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF),   polycythemia vera (PV)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA),   chronic spontaneous urticaria   (CSU), nasal polyps&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 428
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 428
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors, acromegaly&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            843
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            570
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 413
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Spinal muscular atrophy (SMA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            469
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            882
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 351
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF,   SJIA, AOSD, gout)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            501
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            558
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 059
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia   (CML), gastrointestinal   stromal tumors (GIST)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            263
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            761
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 024
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/  tuberous sclerosis complex (TSC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            521
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            417
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            938
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2-   metastatic breast cancer&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            598
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            937
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            887
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            901
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            51
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            722
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            773
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kymriah&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology      &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; r/r pediatric and young   adults acute lymphoblastic   leukemia (ALL), diffuse large   B-cell lymphoma (DLBCL)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            230
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            357
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            587
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Ultibro&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Other Promoted  Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cronic obstructive  pulmonary disease  (COPD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            584
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            584
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 688
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            20 976
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            32 664
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 311
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 331
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net  sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            14 999
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 996
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            41 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Net sales to third parties reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Net sales to third parties of the top 20 Innovative Medicines Division brands in 2020&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Brand classification by&lt;br/&gt; therapeutic area, other&lt;br/&gt; promoted brands or&lt;br/&gt; established brands&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Key indications&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; US&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Rest of &lt;br/&gt; world&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis (PsO), ankylosing   spondylitis (AS), psoriatic arthritis (PsA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 516
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 479
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis (RMS)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 562
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 441
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 003
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic heart failure&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 277
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 220
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 497
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia (CML)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            859
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 099
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Other Promoted  Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related macular   degeneration (AMD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 933
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 933
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune   thrombocytopenia (ITP),   severe aplastic anemia (SAA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            833
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            905
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 738
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors      &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic  adjuvant melanoma,   advanced non-small cell   lung cancer (NSCLC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            569
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            973
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors,  acromegaly&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            837
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            602
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 439
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF),   polycythemia vera (PV)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA),  chronic spontaneous urticaria   (CSU)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 199
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 199
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia (CML),  gastrointestinal stromal tumors (GIST)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            315
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 188
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/  tuberous sclerosis complex (TSC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            439
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 083
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            124
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            879
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 003
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            964
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            980
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Spinal muscular atrophy  (SMA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            459
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            461
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            920
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF,   SJIA, AOSD gout)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            473
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2-   metastatic breast cancer&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            318
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            369
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            687
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic iron overload&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            138
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            515
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            653
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Renal cell carcinoma (RCC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            259
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            376
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            635
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 126
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            18 790
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 916
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 216
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 881
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 097
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net  sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            14 342
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            24 671
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            39 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Net sales to third parties reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Sandoz Division net sales to third parties by business franchise&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2022&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2021&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change&lt;br/&gt; (2021 to&lt;br/&gt; 2022)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2020&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change&lt;br/&gt; (2020 to&lt;br/&gt; 2021)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Retail Generics&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 776
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 244
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Biopharmaceuticals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 093
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 116
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 928
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Anti-Infectives&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            380
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            423
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            474
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-11&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 631
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 646
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Sandoz total anti-infectives net sales to third parties amounted to USD 1.2 billion (2021: USD 1.1 billion; 2020: USD 1.2 billion), of which USD 777 million (2021: USD 707 million; 2020: USD 694 million) is sold through the Retail Generics business franchise and USD 380 million (2021: USD 423 million; 2020: USD 474 million) is sold to other third-party companies through the Anti-Infectives business franchise.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The product portfolio of Sandoz is widely spread in 2022, 2021 and 2020.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Segmentation &#x2013; other revenue&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate   (including eliminations)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Profit-sharing income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            921
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            835
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            921
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            835
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Royalty income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            74
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            107
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            52
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            109
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            300
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Milestone income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            148
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            155
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            50
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            155
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            162
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            114
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            54
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other revenues&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            61
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 283
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 239
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="26" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="26"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <nvs:NumberOfReportableSegments contextRef="AR_D-CurrentYear" decimals="0" unitRef="Pure">2</nvs:NumberOfReportableSegments>
    <nvs:NumberOfCommercialOrganizationalUnits
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="0"
      unitRef="Pure">2</nvs:NumberOfCommercialOrganizationalUnits>
    <nvs:NumberOfBusinessUnits
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="0"
      unitRef="Pure">2</nvs:NumberOfBusinessUnits>
    <nvs:NumberOfFranchises
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="0"
      unitRef="Pure">3</nvs:NumberOfFranchises>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_224e37ff-36d4-4efc-a4cb-a6ae43da48c3_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Segmentation &#x2013; consolidated income statements&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Innovative Medicines  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Sandoz  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Corporate  (including eliminations)&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Group  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            41 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            41 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 631
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            50 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to other segments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            825
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            795
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            180
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 030&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            42 121
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            42 790
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 454
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 811
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 030&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            50 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other revenues&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            61
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 283
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-11 569&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-11 751&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4 978&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 147&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 061
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 031
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-15 486&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 867&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 801
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            32 218
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 504
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 725
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            67
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            36 342
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            37 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-11 679&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-12 306&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 062&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 062&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-512&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-518&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-14 253&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14 886&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9 172&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8 641&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-824&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-899&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9 996&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9 540&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            531
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 149
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            103
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            233
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            171
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            470
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            805
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 852
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 695&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 732&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-273&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-733&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-618&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 701&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 747&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 786
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10 688
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 448
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 600
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 037&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-599&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 689
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;(Loss)/income from associated companies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 332
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-837&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-811&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-80&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 371
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 416&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 119&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 955
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            24 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Attributable to:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Shareholders of Novartis AG&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            6 955
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            24 021
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Non-controlling interests&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in net income are:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Interest income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            379
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            71
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Depreciation of property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-837&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-859&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-204&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-210&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-122&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-139&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 163&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 208&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Depreciation of right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-252&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-265&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-33&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-39&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-15&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-300&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-318&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Amortization of intangible assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 728&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 638&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-222&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-238&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-32&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 982&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges on property, plant and equipment, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-407&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-271&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-407&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-281&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment of right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges on intangible assets, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 299&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-367&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-25&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 326&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-403&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges and fair value changes on financial assets, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-134&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-126&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-260&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to restructuring provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 069&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-240&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-40&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-259&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-26&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 368&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-328&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Equity-based compensation of Novartis equity plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-706&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-721&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-280&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-193&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 048&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-979&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate  (including eliminations)&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            41 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            39 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 631
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 646
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            48 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sales to other segments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            795
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            792
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            180
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            189
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-981&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net sales&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            42 790
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            39 805
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 811
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 835
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-981&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            48 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other revenues&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            61
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 239
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-11 751&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-10 927&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 147&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 252&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 031
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 058
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 867&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 121&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross profit&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            32 218
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 725
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 636
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            67
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            245
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            37 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            34 777
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Selling, general and administration&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-12 306&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-11 657&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 062&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 076&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-518&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-464&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14 886&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14 197&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Research and development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8 641&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8 118&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-899&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-862&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9 540&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8 980&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 149
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            922
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            233
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            176
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            470
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 852
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 742
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 732&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 871&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-831&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-618&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-488&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 747&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 190&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Operating income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10 688
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 172
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 600
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 043
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-599&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-63&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 689
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10 152
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income from associated companies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 332
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            670
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-811&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-869&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income and expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-80&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-78&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 878
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 119&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 807&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            24 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 071
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Attributable to:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Shareholders of Novartis AG&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            24 021
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            8 072
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Non-controlling interests&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in net income are:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Interest income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            71
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            91
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Depreciation of property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-859&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-912&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-210&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-282&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-139&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-124&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 208&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 318&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Depreciation of right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-265&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-273&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-39&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-41&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-318&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-330&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Amortization of intangible assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 638&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 080&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-238&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-370&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 462&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges on property, plant and equipment, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-271&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-324&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-116&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-281&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-440&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges on intangible assets, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-367&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-768&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-141&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-403&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-914&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Impairment charges and fair value changes on financial assets, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            153
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            335
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to restructuring provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-240&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-217&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-98&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-26&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-39&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-328&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-354&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Equity-based compensation of Novartis equity plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-721&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-714&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-64&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-193&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-180&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-979&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-958&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Eliminations mainly relate to the elimination of sales to other segments and the corresponding cost of goods sold.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">41296000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">41995000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9249000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9631000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">50545000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">51626000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">825000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">795000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">205000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">180000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-1030000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-975000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">42121000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">42790000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9454000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9811000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-1030000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-975000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">50545000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">51626000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1249000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1179000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">61000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">6000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">11000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1283000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1251000000</ifrs-full:OtherRevenue>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">11569000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">11751000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">4978000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">5147000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-1061000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-1031000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">15486000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">15867000000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">31801000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">32218000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">4504000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">4725000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">37000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">67000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">36342000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">37010000000</ifrs-full:GrossProfit>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">11679000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">12306000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2062000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2062000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">512000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">518000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">14253000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">14886000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">9172000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">8641000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">824000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">899000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">9996000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">9540000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">531000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1149000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">103000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">233000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">171000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">470000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">805000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1852000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">2695000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1732000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">273000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">397000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">733000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">618000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">3701000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2747000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">8786000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">10688000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1448000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1600000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-1037000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-599000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">9197000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">11689000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">-2000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-9000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">15332000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-9000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">15339000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">837000000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">811000000</ifrs-full:InterestExpense>
    <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">20000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-80000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">8371000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">26137000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1416000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2119000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6955000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">24018000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6955000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">24021000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">0</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-3000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:RevenueFromInterest contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">379000000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">71000000</ifrs-full:RevenueFromInterest>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">837000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">859000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">204000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">210000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">122000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">139000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">1163000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">1208000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">252000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">265000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">33000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">39000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">15000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">14000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember"
      decimals="-6"
      unitRef="USD">300000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember"
      decimals="-6"
      unitRef="USD">318000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">3728000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">3638000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">222000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">238000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">32000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">27000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3982000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3903000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">407000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">271000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">407000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">281000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">3000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember"
      decimals="-6"
      unitRef="USD">3000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1299000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">367000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">25000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">2000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">8000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">1326000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">403000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">-134000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">43000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-126000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-5000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-260000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">38000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1069000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">240000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">40000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">62000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">259000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">26000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">1368000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">328000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">706000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">721000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">62000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">65000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">280000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">193000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1048000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">979000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">41995000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">39013000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9631000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9646000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">51626000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">48659000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">795000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">792000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">180000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">189000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-975000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <nvs:RevenueFromSaleOfGoodsSalesToOtherSegments
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-981000000</nvs:RevenueFromSaleOfGoodsSalesToOtherSegments>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">42790000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">39805000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9811000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9835000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-975000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-981000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">51626000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">48659000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1179000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1018000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">61000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">53000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">11000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">168000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1251000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1239000000</ifrs-full:OtherRevenue>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">11751000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">10927000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">5147000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">5252000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-1031000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-1058000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">15867000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">15121000000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">32218000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">29896000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">4725000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">4636000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">67000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">245000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">37010000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">34777000000</ifrs-full:GrossProfit>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">12306000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">11657000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2062000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2076000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">518000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">464000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">14886000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">14197000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">8641000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">8118000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">899000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">862000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">9540000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">8980000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1149000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">922000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">233000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">176000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">470000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">644000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1852000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1742000000</ifrs-full:OtherIncome>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1732000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1871000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">397000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">831000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">618000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">488000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2747000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">3190000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">10688000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">9172000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1600000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1043000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-599000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-63000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">11689000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">10152000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">15332000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">670000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">15339000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">673000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">811000000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">869000000</ifrs-full:InterestExpense>
    <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-80000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-78000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">26137000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">9878000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2119000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1807000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">24018000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">8071000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">24021000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">8072000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-3000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-1000000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:RevenueFromInterest contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">71000000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">91000000</ifrs-full:RevenueFromInterest>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">859000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">912000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">210000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">282000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">139000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">124000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">1208000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">1318000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">265000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">273000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">39000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">41000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">14000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">16000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember"
      decimals="-6"
      unitRef="USD">318000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember"
      decimals="-6"
      unitRef="USD">330000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">3638000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">3080000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">238000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">370000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">27000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">12000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3903000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3462000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">271000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">324000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">116000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">281000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">440000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">367000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">768000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">141000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">8000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">403000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">914000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">43000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">153000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-5000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">182000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">38000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">335000000</nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">240000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">217000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">62000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">98000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">26000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">39000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">328000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">354000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">721000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">714000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">65000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">64000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">193000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">180000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">979000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">958000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <nvs:DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_23793b69-49b6-423e-86b6-1a8b9caa3ae5_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Segmentation &#x2013; consolidated balance sheets&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate  (including eliminations)&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            75 510
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            79 220
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            16 078
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            16 192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            25 865
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            36 383
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            117 453
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            131 795
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-16 966&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-15 929&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 710&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 632&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-37 354&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-44 412&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-58 030&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-63 973&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total equity&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            59 423
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            67 822
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net debt&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 245
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            868
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 245
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            868
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net operating assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            58 544
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            63 291
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            12 368
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12 560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 244&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-7 161&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            66 668
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            68 690
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Included in assets and liabilities are:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Total property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 488
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 861
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 901
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            415
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            476
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 764
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to property, plant and equipment&lt;sup style="white-space: nowrap"&gt; &#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            842
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            991
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            292
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            349
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            85
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            90
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 430
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Total right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 233
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 349
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            90
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            104
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            108
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            108
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 431
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to right-of-use assets&lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            196
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            222
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            31
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            26
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            247
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            321
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Total goodwill and intangible assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            51 357
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            53 919
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9 230
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 603
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            358
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            255
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            60 945
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            63 777
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to goodwill and intangible assets&lt;sup style="white-space: nowrap"&gt; &#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 791
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 491
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            163
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            102
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            139
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            143
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 093
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 736
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Total investment in associated companies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            107
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            170
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            27
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            143
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Additions to investment in associated companies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18 930
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28 329
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18 930
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28 329
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Financial debts and derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            26 175
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            29 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            26 175
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            29 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Current income tax liabilities and deferred tax liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Eliminations mainly relate to the elimination of intercompany receivables and payables to other segments and inventories&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Note 29 provides additional disclosures related to net debt&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt; Excluding the impact of business acquisitions&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock>
    <ifrs-full:Assets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">75510000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">79220000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">16078000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">16192000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">25865000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">36383000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">117453000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">131795000000</ifrs-full:Assets>
    <ifrs-full:Liabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">16966000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">15929000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">3710000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">3632000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">37354000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">44412000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">58030000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">63973000000</ifrs-full:Liabilities>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">59423000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">67822000000</ifrs-full:Equity>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">7245000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">868000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">7245000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">868000000</ifrs-full:NetDebt>
    <nvs:NetOperatingAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">58544000000</nvs:NetOperatingAssets>
    <nvs:NetOperatingAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">63291000000</nvs:NetOperatingAssets>
    <nvs:NetOperatingAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">12368000000</nvs:NetOperatingAssets>
    <nvs:NetOperatingAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">12560000000</nvs:NetOperatingAssets>
    <nvs:NetOperatingAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-4244000000</nvs:NetOperatingAssets>
    <nvs:NetOperatingAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-7161000000</nvs:NetOperatingAssets>
    <nvs:NetOperatingAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">66668000000</nvs:NetOperatingAssets>
    <nvs:NetOperatingAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">68690000000</nvs:NetOperatingAssets>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">8488000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">9168000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1861000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1901000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">415000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">476000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">10764000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">11545000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">842000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">991000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">292000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">349000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">85000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">90000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1219000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1430000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1233000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1349000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">90000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">104000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">108000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">108000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1431000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1561000000</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">196000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">222000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">31000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">26000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">20000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">73000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">247000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">321000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">51357000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">53919000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9230000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9603000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">358000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">255000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">60945000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">63777000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1791000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1491000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">163000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">102000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">139000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">143000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">2093000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1736000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">107000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">170000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">7000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">27000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">143000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">205000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <nvs:AdditionsToInvestmentInAssociatedCompanies
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">-25000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
    <nvs:AdditionsToInvestmentInAssociatedCompanies
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">-24000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
    <nvs:AdditionsToInvestmentInAssociatedCompanies
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-13000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
    <nvs:AdditionsToInvestmentInAssociatedCompanies
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">-19000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
    <nvs:AdditionsToInvestmentInAssociatedCompanies contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-38000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
    <nvs:AdditionsToInvestmentInAssociatedCompanies contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-43000000</nvs:AdditionsToInvestmentInAssociatedCompanies>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">18930000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">28329000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">18930000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">28329000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">26175000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">29197000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">26175000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">29197000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:CurrentIncomeTaxAndDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">5219000000</nvs:CurrentIncomeTaxAndDeferredTaxLiabilities>
    <nvs:CurrentIncomeTaxAndDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">5485000000</nvs:CurrentIncomeTaxAndDeferredTaxLiabilities>
    <nvs:CurrentIncomeTaxAndDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">5219000000</nvs:CurrentIncomeTaxAndDeferredTaxLiabilities>
    <nvs:CurrentIncomeTaxAndDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">5485000000</nvs:CurrentIncomeTaxAndDeferredTaxLiabilities>
    <nvs:DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_96977b05-dd26-4cf8-a1e2-38aff63aab2f_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="11" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Net sales to third parties&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total of selected non-current assets&lt;sup&gt;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Country&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            970
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            800
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23 708
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            32
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25 770
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            33
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;United States&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            17 653
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16 818
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            33
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16 484
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35 353
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            48
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37 054
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            48
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;France&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 257
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 522
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 442
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 188
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 615
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Germany&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 278
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 870
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 518
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 229
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 378
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;China&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 128
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 052
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 573
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            599
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            703
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japan&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 683
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 804
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            165
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            217
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20 054
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            41
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20 808
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            40
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19 038
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 351
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            50 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            48 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            73 483
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            77 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Region&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18 467
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18 715
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35 896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37 525
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Americas&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21 536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            42
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20 463
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            40
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19 725
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            41
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35 806
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37 522
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 966
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 781
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 041
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            50 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            48 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            73 483
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            77 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Net sales to third parties by location of customer&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Total of property, plant and equipment; right-of-use assets; goodwill; intangible assets; investment in associated companies and other non-current assets excluding post-employment benefit assets&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">970000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="2"
      unitRef="Pure">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">873000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="2"
      unitRef="Pure">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">800000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="2"
      unitRef="Pure">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">23708000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="2"
      unitRef="Pure">0.32</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">25770000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="2"
      unitRef="Pure">0.33</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="-6"
      unitRef="USD">17653000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="2"
      unitRef="Pure">0.35</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="-6"
      unitRef="USD">16818000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="2"
      unitRef="Pure">0.33</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="-6"
      unitRef="USD">16484000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="2"
      unitRef="Pure">0.34</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="-6"
      unitRef="USD">35353000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="2"
      unitRef="Pure">0.48</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="-6"
      unitRef="USD">37054000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="2"
      unitRef="Pure">0.48</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022FR"
      decimals="-6"
      unitRef="USD">2257000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022FR"
      decimals="2"
      unitRef="Pure">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR"
      decimals="-6"
      unitRef="USD">2522000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR"
      decimals="2"
      unitRef="Pure">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022FR"
      decimals="-6"
      unitRef="USD">2442000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022FR"
      decimals="2"
      unitRef="Pure">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022FR"
      decimals="-6"
      unitRef="USD">3188000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022FR"
      decimals="2"
      unitRef="Pure">0.04</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR"
      decimals="-6"
      unitRef="USD">3615000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022FR"
      decimals="2"
      unitRef="Pure">0.05</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022DE"
      decimals="-6"
      unitRef="USD">4278000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022DE"
      decimals="2"
      unitRef="Pure">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE"
      decimals="-6"
      unitRef="USD">4870000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE"
      decimals="2"
      unitRef="Pure">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022DE"
      decimals="-6"
      unitRef="USD">4518000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022DE"
      decimals="2"
      unitRef="Pure">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022DE"
      decimals="-6"
      unitRef="USD">2229000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022DE"
      decimals="2"
      unitRef="Pure">0.03</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE"
      decimals="-6"
      unitRef="USD">2378000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022DE"
      decimals="2"
      unitRef="Pure">0.03</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022CN"
      decimals="-6"
      unitRef="USD">3128000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022CN"
      decimals="2"
      unitRef="Pure">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN"
      decimals="-6"
      unitRef="USD">3052000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN"
      decimals="2"
      unitRef="Pure">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022CN"
      decimals="-6"
      unitRef="USD">2573000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022CN"
      decimals="2"
      unitRef="Pure">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022CN"
      decimals="-6"
      unitRef="USD">599000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022CN"
      decimals="2"
      unitRef="Pure">0.01</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN"
      decimals="-6"
      unitRef="USD">703000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022CN"
      decimals="2"
      unitRef="Pure">0.01</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022JP"
      decimals="-6"
      unitRef="USD">2205000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022JP"
      decimals="2"
      unitRef="Pure">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022JP"
      decimals="-6"
      unitRef="USD">2683000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022JP"
      decimals="2"
      unitRef="Pure">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022JP"
      decimals="-6"
      unitRef="USD">2804000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022JP"
      decimals="2"
      unitRef="Pure">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022JP"
      decimals="-6"
      unitRef="USD">165000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022JP"
      decimals="-6"
      unitRef="USD">217000000</nvs:SelectedNoncurrentAssets>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember"
      decimals="-6"
      unitRef="USD">20054000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember"
      decimals="2"
      unitRef="Pure">0.41</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember"
      decimals="-6"
      unitRef="USD">20808000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember"
      decimals="2"
      unitRef="Pure">0.40</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember"
      decimals="-6"
      unitRef="USD">19038000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember"
      decimals="2"
      unitRef="Pure">0.39</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember"
      decimals="-6"
      unitRef="USD">8241000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember"
      decimals="2"
      unitRef="Pure">0.12</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember"
      decimals="-6"
      unitRef="USD">7351000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4OtherCountriesMember"
      decimals="2"
      unitRef="Pure">0.10</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">50545000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear" decimals="2" unitRef="Pure">1</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">51626000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1" decimals="2" unitRef="Pure">1</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">48659000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2" decimals="2" unitRef="Pure">1</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">73483000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="2"
      unitRef="Pure">1</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">77088000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="2"
      unitRef="Pure">1</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="-6"
      unitRef="USD">18467000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="2"
      unitRef="Pure">0.37</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="-6"
      unitRef="USD">20197000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="2"
      unitRef="Pure">0.39</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="-6"
      unitRef="USD">18715000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="2"
      unitRef="Pure">0.38</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="-6"
      unitRef="USD">35896000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="2"
      unitRef="Pure">0.49</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="-6"
      unitRef="USD">37525000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="2"
      unitRef="Pure">0.49</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember"
      decimals="-6"
      unitRef="USD">21536000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember"
      decimals="2"
      unitRef="Pure">0.42</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember"
      decimals="-6"
      unitRef="USD">20463000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember"
      decimals="2"
      unitRef="Pure">0.40</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember"
      decimals="-6"
      unitRef="USD">19725000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember"
      decimals="2"
      unitRef="Pure">0.41</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember"
      decimals="-6"
      unitRef="USD">35806000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember"
      decimals="2"
      unitRef="Pure">0.49</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember"
      decimals="-6"
      unitRef="USD">37522000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_srt-2022AmericasMember"
      decimals="2"
      unitRef="Pure">0.49</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="-6"
      unitRef="USD">10542000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="2"
      unitRef="Pure">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="-6"
      unitRef="USD">10966000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="2"
      unitRef="Pure">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="-6"
      unitRef="USD">10219000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="2"
      unitRef="Pure">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="-6"
      unitRef="USD">1781000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="2"
      unitRef="Pure">0.02</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="-6"
      unitRef="USD">2041000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="2"
      unitRef="Pure">0.02</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">50545000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear" decimals="2" unitRef="Pure">1</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">51626000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-1" decimals="2" unitRef="Pure">1</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">48659000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales contextRef="AR_D-CurrentYear-2" decimals="2" unitRef="Pure">1</nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">73483000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="2"
      unitRef="Pure">1</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">77088000000</nvs:SelectedNoncurrentAssets>
    <nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="2"
      unitRef="Pure">1</nvs:SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets>
    <nvs:CustomersWithNetSalesOverFivePercent
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_23ebcf1b-3f34-49bc-b005-fb2ee017161e_0">

                  The Group&#x2019;s largest, second-largest and third-largest customers account for approximately 16%, 11% and 7% of net sales to third parties, respectively (2021: 17%, 11% and 6%, respectively; 2020: 17%, 11% and 6%, respectively). All segments had sales to these customers in 2022, 2021 and 2020.
                  The highest amounts of trade receivables outstanding were for these same three customers and amounted to approximately 16%, 14% and 7%, respectively, of the trade receivables at December 31, 2022 (2021: 16%, 12% and 7%, respectively).

              </nvs:CustomersWithNetSalesOverFivePercent>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.16</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.11</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.07</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.17</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.11</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.06</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.17</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.11</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.06</ifrs-full:PercentageOfEntitysRevenue>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.16</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.14</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.07</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.16</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.12</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.07</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_3f761a23-e3d9-40f5-8297-fe0a94e23b83_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Segmentation &#x2013; net sales to third parties&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Net sales to third parties by region&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2022&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2021&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change&lt;br/&gt; (2021&lt;br/&gt; to 2022)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2020&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change&lt;br/&gt; (2020&lt;br/&gt; to 2021)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Innovative Medicines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13 554
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 919
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13 484
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15 899
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 999
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 342
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 929
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 304
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 718
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 914
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 773
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 469
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            41 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            41 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            39 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Established Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30 548
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            31 459
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            29 643
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Emerging Growth Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 748
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 370
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 913
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 278
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 231
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 754
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 819
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 142
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 613
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 662
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 501
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            969
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            872
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            772
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 631
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 646
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Established Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 460
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 855
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 089
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Emerging Growth Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 789
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 776
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 557
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Europe&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18 467
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18 715
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            17 653
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16 818
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16 484
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Asia/Africa/Australasia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 966
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canada and Latin America&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 883
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 645
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            50 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            51 626
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            48 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Established Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37 008
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            38 314
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            36 732
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Of which in Emerging Growth Markets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13 537
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13 312
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11 927
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Net sales to third parties by location of customer. Emerging Growth Markets comprise all markets other than the Established Markets of the US, Canada, Western Europe, Japan, Australia and New Zealand.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div/&gt;
              </nvs:DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">13554000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">14919000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">13484000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">15899000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">14999000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">14342000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">8929000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">9304000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">8718000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">2914000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">2773000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">2469000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">41296000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">41995000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">39013000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">30548000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">31459000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">29643000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">10748000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">10536000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">9370000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">4913000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">5278000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">5231000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1754000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1819000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2142000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1613000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1662000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1501000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">969000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">872000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">772000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9249000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9631000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9646000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">6460000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">6855000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">7089000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2789000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2776000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">2557000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="-6"
      unitRef="USD">18467000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="-6"
      unitRef="USD">20197000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember"
      decimals="-6"
      unitRef="USD">18715000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="-6"
      unitRef="USD">17653000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="-6"
      unitRef="USD">16818000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US"
      decimals="-6"
      unitRef="USD">16484000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="-6"
      unitRef="USD">10542000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="-6"
      unitRef="USD">10966000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember"
      decimals="-6"
      unitRef="USD">10219000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4AsiaAfricaAustralasiaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember"
      decimals="-6"
      unitRef="USD">3883000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember"
      decimals="-6"
      unitRef="USD">3645000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember"
      decimals="-6"
      unitRef="USD">3241000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4CanadaAndLatinAmericaMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">50545000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">51626000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">48659000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember"
      decimals="-6"
      unitRef="USD">37008000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember"
      decimals="-6"
      unitRef="USD">38314000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">-0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember"
      decimals="-6"
      unitRef="USD">36732000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EstablishedMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember"
      decimals="-6"
      unitRef="USD">13537000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember"
      decimals="-6"
      unitRef="USD">13312000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember"
      decimals="-6"
      unitRef="USD">11927000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4EmergingGrowthMarketsMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember"
      decimals="2"
      unitRef="Pure">0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:DisclosureOfOperatingSegmentsNetSalesTableTextBlock
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      id="SectionBlock_b9e69e43-43ee-4011-a29b-3703ba2e2dea_0">
                &lt;div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Innovative Medicines Division net sales to third parties by core therapeutic area; other promoted brands; and established brands&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2022&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2021&lt;br/&gt; USD m&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change&lt;br/&gt; (2021 to&lt;br/&gt; 2022)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2020&lt;br/&gt; USD m&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change&lt;br/&gt; (2020 to&lt;br/&gt; 2021)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cardiovascular&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 548
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            31
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 497
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            42
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Leqvio&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            112
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Cardiovascular&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 756
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 497
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Immunology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 788
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 718
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 365
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 428
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 133
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 059
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Immunology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            7 287
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            7 205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 119
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Neuroscience&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 787
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 003
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 370
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 351
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            920
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            47
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kesimpta&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            372
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Mayzent&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            357
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            281
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            27
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            170
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            65
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Aimovig&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            218
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            215
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            164
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            31
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Neuroscience&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 051
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 007
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 272
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Solid Tumors&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 770
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 693
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 231
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            937
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            31
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            687
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            36
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            474
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            577
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-18&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            635
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lutathera&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            471
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            475
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            445
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Piqray&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            373
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            329
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            320
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Pluvicto&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            271
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tabrecta&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            133
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            90
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            48
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            35
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            157
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Solid Tumors&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 723
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 101
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 666
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Hematology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 016
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 738
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 923
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 060
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kymriah&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            587
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            474
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Adakveo&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            164
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Scemblix&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            149
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-67&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Hematology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 452
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 430
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 617
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2022&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2021&lt;br/&gt; USD m&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change&lt;br/&gt; (2021 to&lt;br/&gt; 2022)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2020&lt;br/&gt; USD m&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change&lt;br/&gt; (2020 to&lt;br/&gt; 2021)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Other Promoted Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 874
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 160
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 933
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xiidra&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            468
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            376
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Ultibro&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            479
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            584
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-18&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            623
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Beovu&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            203
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            186
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            190
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other respiratory&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            84
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            58
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            26
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            104
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Other Promoted  Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 451
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 148
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Promoted  Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 396
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 754
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 319
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 238
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 413
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 439
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            859
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-21&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 199
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            745
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 024
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 188
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            743
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            901
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-18&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            980
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            652
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            773
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 003
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-23&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            512
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            938
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-45&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 083
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;i&gt;Voltaren/Cataflam&lt;/i&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            334
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            373
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            360
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zortress/Certican&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            329
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            431
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-24&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            452
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            323
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            563
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            653
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Neoral/Sandimmun(e)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            310
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            368
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            393
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contract manufacturing&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            214
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            108
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            98
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt; nm&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 257
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 944
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total Established  Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 900
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12 241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            13 694
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-11&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net  sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            41 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            41 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            39 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Reclassified to reflect the new Innovative Medicines divisional structures announced on April 4, 2022&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Net sales to third parties reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfOperatingSegmentsNetSalesTableTextBlock>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="-6"
      unitRef="USD">4644000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="-6"
      unitRef="USD">3548000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="2"
      unitRef="Pure">0.31</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="-6"
      unitRef="USD">2497000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="2"
      unitRef="Pure">0.42</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="-6"
      unitRef="USD">112000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="-6"
      unitRef="USD">12000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="-6"
      unitRef="USD">4756000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="-6"
      unitRef="USD">3560000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="2"
      unitRef="Pure">0.34</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="-6"
      unitRef="USD">2497000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember"
      decimals="2"
      unitRef="Pure">0.43</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">4788000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">4718000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="2"
      unitRef="Pure">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">3995000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="2"
      unitRef="Pure">0.18</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">1365000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">1428000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="2"
      unitRef="Pure">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">1251000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="2"
      unitRef="Pure">0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">1133000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">1059000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="2"
      unitRef="Pure">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">873000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="2"
      unitRef="Pure">0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">7287000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">7205000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="2"
      unitRef="Pure">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="-6"
      unitRef="USD">6119000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember"
      decimals="2"
      unitRef="Pure">0.18</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">2013000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">2787000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">-0.28</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">3003000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">-0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">1370000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">1351000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">920000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">0.47</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">1092000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">372000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">1.94</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">15000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">357000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">281000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">0.27</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">170000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4MayzentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">0.65</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">218000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">215000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">164000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AimovigMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">0.31</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">0</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">5051000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">5007000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="-6"
      unitRef="USD">4272000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember"
      decimals="2"
      unitRef="Pure">0.17</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">1770000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">1693000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">1542000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">1231000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">937000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">0.31</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">687000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">0.36</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">474000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">577000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">-0.18</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">635000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">471000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">475000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">445000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LutatheraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">373000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">329000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">320000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PiqrayMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">0.03</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PluvictoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">271000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PluvictoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">2000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">133000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">90000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">0.48</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">35000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TabrectaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">1.57</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">4723000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">4101000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">0.15</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="-6"
      unitRef="USD">3666000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember"
      decimals="2"
      unitRef="Pure">0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">2088000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">2016000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">1738000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">1923000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">2060000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">-0.07</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">1958000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">1561000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">1595000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">1339000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">0.19</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">536000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">587000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">474000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">0.24</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">194000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">164000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">0.18</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">105000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AdakveoMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">0.56</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ScemblixMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">149000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ScemblixMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">7000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">0</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">3000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">-0.67</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">6452000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">6430000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">0</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="-6"
      unitRef="USD">5617000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember"
      decimals="2"
      unitRef="Pure">0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">1874000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">2160000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">1933000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">487000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">468000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">376000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XiidraMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">0.24</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">479000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">584000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.18</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">623000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">203000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">186000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">190000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4BeovuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">84000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">53000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">0.58</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">26000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherRespiratoryMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">1.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">3127000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">3451000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="-6"
      unitRef="USD">3148000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember"
      decimals="2"
      unitRef="Pure">0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember"
      decimals="-6"
      unitRef="USD">31396000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember"
      decimals="-6"
      unitRef="USD">29754000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember"
      decimals="2"
      unitRef="Pure">0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember"
      decimals="-6"
      unitRef="USD">25319000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember"
      decimals="2"
      unitRef="Pure">0.18</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">1238000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">1413000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.12</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">1439000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">859000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">1092000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.21</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">1199000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.09</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">745000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">1024000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.27</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">1188000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">743000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">901000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.18</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">980000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">652000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">773000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">1003000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.23</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">512000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">938000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.45</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">1083000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.13</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">334000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">373000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">360000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VoltarenCataflamMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">329000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">431000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.24</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">452000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZortressCerticanMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.05</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">323000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">563000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.43</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">653000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">310000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">368000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.16</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">393000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4NeoralSandimmunEMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.06</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ContractManufacturingMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">214000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ContractManufacturingMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">108000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ContractManufacturingMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">0.98</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">3641000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">4257000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">4944000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4OtherProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.14</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">9900000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">12241000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.19</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="-6"
      unitRef="USD">13694000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember"
      decimals="2"
      unitRef="Pure">-0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">41296000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">41995000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="2"
      unitRef="Pure">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">39013000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="2"
      unitRef="Pure">0.08</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      id="SectionBlock_a17653c9-3732-4d05-ad56-80349f74a7a9_0">
                &lt;div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Net sales to third parties of the top 20 Innovative Medicines Division brands in 2022&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Brand classification by&lt;br/&gt; therapeutic area, other&lt;br/&gt; promoted brands or&lt;br/&gt; established brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Key indications&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; US&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Rest of &lt;br/&gt; world&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis (PsO),   ankylosing spondylitis  (AS), psoriatic arthritis   (PsA), non-radiographic   axial spondyloarthritis   (nr-axSPA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 770
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 788
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic heart failure,  hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 354
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 290
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune   thrombocytopenia (ITP),   severe aplastic anemia (SAA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 083
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis  (RMS)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 153
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            860
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia  (CML)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            877
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 046
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 923
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Other Promoted  Brands    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related   macular degeneration (AMD),   diabetic macular edema (DME),  retinal vein occlusion (RVO)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 874
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 874
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic   adjuvant melanoma,  advanced non-small cell   lung cancer (NSCLC),   tumor agnostic with   BRAF mutation indication&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            678
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 770
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology      &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF),   polycytomia vera (PV),   graft-versus-host disease  (GvHD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Spinal muscular atrophy  (SMA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            434
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            936
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 370
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA),   chronic spontaneous urticaria   (CSU), nasal polyps&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 365
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 365
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors,  acromegaly&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            800
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            438
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 238
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2-   metastatic breast cancer&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            472
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            759
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 231
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS,  TRAPS, HIDS/MKD, FMF,  SJIA, AOSD, gout)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            570
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            563
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 133
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kesimpta&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing-remitting   multiple sclerosis (RRMS)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            921
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            171
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            859
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            859
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands      &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid  leukemia (CML),   gastrointestinal stromal  tumors (GIST)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            540
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            745
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            729
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            743
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            597
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            652
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kymriah&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology        &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; r/r pediatric and young   adults acute lymphoblastic   leukemia (ALL), diffuse large   B-cell lymphoma (DLBCL),   follicular lymphoma (FL)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            196
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            340
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/  tuberous sclerosis complex   (TSC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            171
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            512
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 brands total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            12 753
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            19 384
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            32 137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 146
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9 159
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net  sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            15 899
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            25 397
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            41 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Net sales to third parties reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Net sales to third parties of the top 20 Innovative Medicines Division brands in 2021&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Brand classification by&lt;br/&gt; therapeutic area, other&lt;br/&gt; promoted brands or&lt;br/&gt; established brands&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Key indications&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; US&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Rest of &lt;br/&gt; world&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology        &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis (PsO), ankylosing   spondylitis (AS),   psoriatic arthritis (PsA),  non-radiographic axial   spondyloarthritis (nr-axSPA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 883
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 835
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 718
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic heart failure&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 712
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 836
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 548
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis (RMS)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 427
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 360
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 787
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Other Promoted  Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related macular   degeneration (AMD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 160
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 160
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia (CML)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            882
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 178
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 060
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune thrombocytopenia (ITP),   severe aplastic anemia (SAA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            947
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 069
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 016
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors      &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic   adjuvant melanoma,  advanced non-small cell   lung cancer (NSCLC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            606
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 087
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 693
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF),   polycythemia vera (PV)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA),   chronic spontaneous urticaria   (CSU), nasal polyps&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 428
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 428
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors, acromegaly&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            843
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            570
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 413
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Spinal muscular atrophy (SMA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            469
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            882
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 351
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF,   SJIA, AOSD, gout)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            501
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            558
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 059
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia   (CML), gastrointestinal   stromal tumors (GIST)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            263
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            761
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 024
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/  tuberous sclerosis complex (TSC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            521
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            417
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            938
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2-   metastatic breast cancer&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            598
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            937
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            887
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            901
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            51
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            722
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            773
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kymriah&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology      &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; r/r pediatric and young   adults acute lymphoblastic   leukemia (ALL), diffuse large   B-cell lymphoma (DLBCL)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            230
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            357
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            587
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Ultibro&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Other Promoted  Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cronic obstructive  pulmonary disease  (COPD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            584
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            584
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 688
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            20 976
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            32 664
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 311
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 331
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net  sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            14 999
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 996
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            41 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Net sales to third parties reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Net sales to third parties of the top 20 Innovative Medicines Division brands in 2020&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Brand classification by&lt;br/&gt; therapeutic area, other&lt;br/&gt; promoted brands or&lt;br/&gt; established brands&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Key indications&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; US&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Rest of &lt;br/&gt; world&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Cosentyx&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:21%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Psoriasis (PsO), ankylosing   spondylitis (AS), psoriatic arthritis (PsA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 516
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 479
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 995
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gilenya&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Relapsing multiple sclerosis (RMS)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 562
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 441
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 003
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Entresto&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Cardiovascular&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic heart failure&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 277
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 220
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 497
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Tasigna&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia (CML)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            859
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 099
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Lucentis&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Other Promoted  Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Age-related macular   degeneration (AMD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 933
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 933
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Promacta/Revolade&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immune   thrombocytopenia (ITP),   severe aplastic anemia (SAA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            833
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            905
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 738
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Tafinlar&lt;/i&gt; + &lt;i&gt;Mekinist&lt;/i&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors      &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRAF V600+ metastatic  adjuvant melanoma,   advanced non-small cell   lung cancer (NSCLC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            569
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            973
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Sandostatin&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Carcinoid tumors,  acromegaly&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            837
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            602
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 439
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Jakavi&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hematology  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Myelofibrosis (MF),   polycythemia vera (PV)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Xolair&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Severe allergic asthma (SAA),  chronic spontaneous urticaria   (CSU)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Galvus&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Type 2 diabetes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 199
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 199
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Gleevec/Glivec&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic myeloid leukemia (CML),  gastrointestinal stromal tumors (GIST)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            315
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 188
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Afinitor/Votubia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Breast cancer/  tuberous sclerosis complex (TSC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            439
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 083
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Diovan&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            124
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            879
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 003
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;i&gt;Exforge&lt;/i&gt; Group&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Hypertension&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            964
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            980
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Zolgensma&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Neuroscience  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Spinal muscular atrophy  (SMA)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            459
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            461
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            920
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Ilaris&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Immunology    &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Auto-inflammatory (CAPS,   TRAPS, HIDS/MKD, FMF,   SJIA, AOSD gout)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            473
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Kisqali&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HR+/HER2-   metastatic breast cancer&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            318
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            369
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            687
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Exjade/Jadenu&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Established Brands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Chronic iron overload&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            138
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            515
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            653
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Votrient&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Solid Tumors&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; Renal cell carcinoma (RCC)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            259
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            376
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            635
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Top 20 products total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 126
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            18 790
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 916
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rest of portfolio&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 216
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 881
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 097
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net  sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            14 342
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            24 671
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            39 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Brand classifications have been changed to reflect the new Innovative Medicines divisional structures announced on April 4, 2022.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="top"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Net sales to third parties reflect &lt;i&gt;Xolair&lt;/i&gt; sales for all indications.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2770000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2018000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">4788000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2354000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2290000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">4644000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1083000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1005000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2088000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1153000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">860000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2013000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">877000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1046000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1923000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1874000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1874000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">678000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1092000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1770000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1561000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1561000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">434000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">936000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1370000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1365000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1365000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">800000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">438000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1238000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">472000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">759000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1231000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">570000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">563000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1133000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">921000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">171000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KesimptaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1092000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">859000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">859000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">205000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">540000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">745000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">14000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">729000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">743000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">55000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">597000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">652000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">196000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">340000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">536000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">171000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">341000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">512000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">12753000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">19384000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">32137000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember"
      decimals="-6"
      unitRef="USD">3146000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember"
      decimals="-6"
      unitRef="USD">6013000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember"
      decimals="-6"
      unitRef="USD">9159000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">15899000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">25397000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">41296000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2883000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1835000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">4718000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1712000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1836000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">3548000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1427000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1360000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2787000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2160000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2160000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">882000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1178000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2060000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">947000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1069000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2016000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">606000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1087000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1693000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1595000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1595000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1428000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1428000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">843000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">570000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1413000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">469000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">882000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1351000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1092000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1092000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">501000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">558000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1059000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">263000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">761000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1024000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">521000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">417000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">938000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">339000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">598000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">937000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">14000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">887000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">901000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">51000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">722000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">773000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">230000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">357000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KymriahMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">587000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">584000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4UltibroGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">584000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">11688000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">20976000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">32664000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember"
      decimals="-6"
      unitRef="USD">3311000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember"
      decimals="-6"
      unitRef="USD">6020000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember"
      decimals="-6"
      unitRef="USD">9331000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">14999000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">26996000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">41995000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2516000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1479000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4CosentyxMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">3995000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1562000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1441000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GilenyaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">3003000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1277000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1220000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4EntrestoMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4CardiovascularMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">2497000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">859000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1099000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1958000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1933000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4OtherPromotedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1933000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">833000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">905000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4PromactaRevoladeMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1738000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">569000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">973000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TafinlarMekinistMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1542000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">837000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">602000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4SandostatinMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1439000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1339000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4JakaviMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4HematologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1339000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1251000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1251000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1199000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GalvusGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1199000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">315000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">873000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4GleevecGlivecMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1188000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">644000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">439000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AfinitorVotubiaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1083000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">124000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">879000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4DiovanGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">1003000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">16000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">964000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">980000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">459000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">461000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4NeuroscienceMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">920000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">400000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">473000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4IlarisMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4ImmunologyMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">873000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">318000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">369000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4KisqaliMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">687000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">138000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">515000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExjadeJadenuMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4EstablishedBrandsMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">653000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">259000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">376000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember_nvs-2022Q4CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis_nvs-2022Q4SolidTumorMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">635000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">11126000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">18790000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember"
      decimals="-6"
      unitRef="USD">29916000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember"
      decimals="-6"
      unitRef="USD">3216000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember"
      decimals="-6"
      unitRef="USD">5881000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4RestOfPortfolioMember"
      decimals="-6"
      unitRef="USD">9097000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">14342000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_nvs-2022Q4RestOfTheWorldMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">24671000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">39013000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:DisclosureOfOperatingSegmentsNetSalesTableTextBlock
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      id="SectionBlock_5bd63dcf-303e-47d1-bc15-2a943b7c6f18_0">
                &lt;div&gt;
                  &lt;div style="padding-bottom:0px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Sandoz Division net sales to third parties by business franchise&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2022&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2021&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change&lt;br/&gt; (2021 to&lt;br/&gt; 2022)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2020&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change&lt;br/&gt; (2020 to&lt;br/&gt; 2021)&lt;br/&gt; USD %&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Retail Generics&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 776
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 244
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Biopharmaceuticals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 093
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 116
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 928
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Anti-Infectives&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            380
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            423
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            474
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-11&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total division net sales to third parties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 631
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 646
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Sandoz total anti-infectives net sales to third parties amounted to USD 1.2 billion (2021: USD 1.1 billion; 2020: USD 1.2 billion), of which USD 777 million (2021: USD 707 million; 2020: USD 694 million) is sold through the Retail Generics business franchise and USD 380 million (2021: USD 423 million; 2020: USD 474 million) is sold to other third-party companies through the Anti-Infectives business franchise.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfOperatingSegmentsNetSalesTableTextBlock>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember"
      decimals="-6"
      unitRef="USD">6776000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember"
      decimals="-6"
      unitRef="USD">7092000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember"
      decimals="2"
      unitRef="Pure">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember"
      decimals="-6"
      unitRef="USD">7244000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember"
      decimals="2"
      unitRef="Pure">-0.02</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember"
      decimals="-6"
      unitRef="USD">2093000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember"
      decimals="-6"
      unitRef="USD">2116000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember"
      decimals="2"
      unitRef="Pure">-0.01</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember"
      decimals="-6"
      unitRef="USD">1928000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4BiopharmaceuticalsMember"
      decimals="2"
      unitRef="Pure">0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember"
      decimals="-6"
      unitRef="USD">380000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember"
      decimals="-6"
      unitRef="USD">423000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember"
      decimals="2"
      unitRef="Pure">-0.10</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember"
      decimals="-6"
      unitRef="USD">474000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember"
      decimals="2"
      unitRef="Pure">-0.11</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9249000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9631000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="2"
      unitRef="Pure">-0.04</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9646000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="2"
      unitRef="Pure">0</nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember"
      decimals="-8"
      unitRef="USD">1200000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember"
      decimals="-8"
      unitRef="USD">1100000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4TotalAntiinfectivesNetSalesMember"
      decimals="-8"
      unitRef="USD">1200000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember"
      decimals="-6"
      unitRef="USD">777000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember"
      decimals="-6"
      unitRef="USD">707000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4AntiInfectivesSoldUnderSandozNameMember"
      decimals="-6"
      unitRef="USD">694000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember"
      decimals="-6"
      unitRef="USD">380000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember"
      decimals="-6"
      unitRef="USD">423000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4AntiInfectivesMember"
      decimals="-6"
      unitRef="USD">474000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_0e5efc5d-a44e-40ad-8e18-33f25c057ecb_0">
                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Segmentation &#x2013; other revenue&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative Medicines  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Sandoz  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Corporate   (including eliminations)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Group  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Profit-sharing income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            921
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            835
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            921
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            835
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Royalty income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            74
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            107
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            52
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            109
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            300
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Milestone income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            148
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            155
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            50
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            155
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            162
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            114
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            54
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other revenues&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            61
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 283
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 239
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="26" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="26" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="26"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock>
    <nvs:ProfitSharingIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">921000000</nvs:ProfitSharingIncome>
    <nvs:ProfitSharingIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">873000000</nvs:ProfitSharingIncome>
    <nvs:ProfitSharingIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">835000000</nvs:ProfitSharingIncome>
    <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">921000000</nvs:ProfitSharingIncome>
    <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">873000000</nvs:ProfitSharingIncome>
    <nvs:ProfitSharingIncome contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">835000000</nvs:ProfitSharingIncome>
    <ifrs-full:RevenueFromRoyalties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">74000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">107000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">18000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">24000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">25000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">6000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">11000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">168000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">52000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">109000000</ifrs-full:RevenueFromRoyalties>
    <ifrs-full:RevenueFromRoyalties contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">300000000</ifrs-full:RevenueFromRoyalties>
    <nvs:MilestoneIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">145000000</nvs:MilestoneIncome>
    <nvs:MilestoneIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">127000000</nvs:MilestoneIncome>
    <nvs:MilestoneIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">39000000</nvs:MilestoneIncome>
    <nvs:MilestoneIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">3000000</nvs:MilestoneIncome>
    <nvs:MilestoneIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">28000000</nvs:MilestoneIncome>
    <nvs:MilestoneIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">11000000</nvs:MilestoneIncome>
    <nvs:MilestoneIncome contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">148000000</nvs:MilestoneIncome>
    <nvs:MilestoneIncome contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">155000000</nvs:MilestoneIncome>
    <nvs:MilestoneIncome contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">50000000</nvs:MilestoneIncome>
    <nvs:OtherRevenueOther
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">155000000</nvs:OtherRevenueOther>
    <nvs:OtherRevenueOther
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">105000000</nvs:OtherRevenueOther>
    <nvs:OtherRevenueOther
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">37000000</nvs:OtherRevenueOther>
    <nvs:OtherRevenueOther
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">7000000</nvs:OtherRevenueOther>
    <nvs:OtherRevenueOther
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">9000000</nvs:OtherRevenueOther>
    <nvs:OtherRevenueOther
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">17000000</nvs:OtherRevenueOther>
    <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">162000000</nvs:OtherRevenueOther>
    <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">114000000</nvs:OtherRevenueOther>
    <nvs:OtherRevenueOther contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">54000000</nvs:OtherRevenueOther>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1249000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1179000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1018000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">61000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">53000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">6000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">11000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">168000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1283000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1251000000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1239000000</ifrs-full:OtherRevenue>
    <ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_3a3abd27-8c36-475e-b9b5-b53fb3aa8b68_0">
          &lt;div&gt;
            &lt;div id="anchorId001530097"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;4. Associated companies&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Net income statement effect&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other comprehensive income effect&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total comprehensive income effect&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Roche Holding AG, Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            677
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            46
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-56&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 387
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            46
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-56&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 385
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            617
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="20" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="20"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; In 2021, Novartis share of other comprehensive income recognized by associated companies, net of taxes of USD 3 million was recycled into the consolidated income statement as a result of the divestment of the investment in Roche Holding AG. No Novartis share of other comprehensive income recognized by associated companies was recycled to the consolidated income statement in 2022 and 2020.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has certain non-significant investments and had a significant investment in Roche Holding AG, Basel (Roche), which was divested to Roche on December 6, 2021, that are accounted for as associated companies. &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Roche Holding AG &lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On November 3, 2021, Novartis entered into an agreement with Roche Holding AG to divest its &lt;span&gt;33.3%&lt;/span&gt; of Roche Holding AG (Roche) voting shares, representing approximately &lt;span&gt;6.2%&lt;/span&gt; of Roche&#x2019;s total outstanding voting and non-voting equity instruments, to Roche for USD 20.7 billion in cash. As a result, Novartis discontinued the use of equity method accounting starting from November 3, 2021.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The divestment transaction closed on December 6, 2021, and Novartis realized a gain of USD 14.6 billion, recorded in income from associated companies. See Note 2.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&#x2019;s holding in Roche voting shares was &lt;span&gt;33.3%&lt;/span&gt; at December 31, 2020. This investment represented approximately &lt;span&gt;6.2%&lt;/span&gt; of Roche&#x2019;s total outstanding voting and non-voting equity instruments at December 31, 2020.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Since full-year financial data for Roche is not available when Novartis produces its consolidated financial results, a survey of analyst estimates is used to estimate the Group&#x2019;s share of Roche&#x2019;s net income. Any differences between these estimates and actual results were adjusted in the Group&#x2019;s consolidated financial statements when available. As Novartis discontinued the use of equity method accounting starting from November 3, 2021, and the divestment closed on December 6, 2021, no such adjustment has been made to the 2022 Group&#x2019;s consolidated financial statements.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2021, dividends received from Roche in relation to the distribution of its 2020 net income amounted to USD&#160;522 million.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The consolidated income statement effects from applying Novartis accounting principles for this investment in 2021 and 2020 are as follows:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis share of Roche's  estimated current-year  consolidated net income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            815
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            913
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prior-year adjustment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            40
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-64&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of fair value adjustments relating to intangible assets, net of taxes of 2021: USD 10 million; 2020: USD 26 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-70&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-172&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gain on divestment of the  investment in Roche&lt;sup style="white-space: nowrap"&gt; &#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 556
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income effect&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            677
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; The gain on divestment of the investment in Roche includes the recycling of currency translation effects (see Note 8.1) and other comprehensive income effects totaling USD 3.2 billion.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory>
    <ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_55a5dac0-0c58-44e0-ba76-245074a558f8_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Net income statement effect&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other comprehensive income effect&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total comprehensive income effect&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Roche Holding AG, Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            677
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            46
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-56&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 387
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 339
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            46
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-56&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 385
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            617
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="20" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="20"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; In 2021, Novartis share of other comprehensive income recognized by associated companies, net of taxes of USD 3 million was recycled into the consolidated income statement as a result of the divestment of the investment in Roche Holding AG. No Novartis share of other comprehensive income recognized by associated companies was recycled to the consolidated income statement in 2022 and 2020.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">15341000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">677000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">46000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">-56000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">15387000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">621000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember"
      decimals="-6"
      unitRef="USD">-9000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember"
      decimals="-6"
      unitRef="USD">-2000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember"
      decimals="-6"
      unitRef="USD">-4000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember"
      decimals="-6"
      unitRef="USD">-9000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember"
      decimals="-6"
      unitRef="USD">-2000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember"
      decimals="-6"
      unitRef="USD">-4000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-9000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">15339000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">673000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">46000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-56000000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-9000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">15385000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">617000000</ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <nvs:RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">3000000</nvs:RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies>
    <nvs:RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">0</nvs:RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies>
    <ifrs-full:ProportionOfVotingPowerHeldInAssociate
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="3"
      unitRef="Pure">0.333</ifrs-full:ProportionOfVotingPowerHeldInAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="3"
      unitRef="Pure">0.062</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-8"
      unitRef="USD">20700000000</ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations>
    <nvs:GainOnDivestmentOfInterestsInAssociatedCompanies
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-8"
      unitRef="USD">14600000000</nvs:GainOnDivestmentOfInterestsInAssociatedCompanies>
    <ifrs-full:ProportionOfVotingPowerHeldInAssociate
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="3"
      unitRef="Pure">0.333</ifrs-full:ProportionOfVotingPowerHeldInAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="3"
      unitRef="Pure">0.062</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:DividendsReceived
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">522000000</ifrs-full:DividendsReceived>
    <nvs:DisclosureOfAssociatesNetIncomeEffectTableTextBlock
      contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      id="SectionBlock_0cdc6c60-b2f5-45d0-bbda-3be63da68b49_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis share of Roche's  estimated current-year  consolidated net income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            815
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            913
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prior-year adjustment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            40
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-64&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of fair value adjustments relating to intangible assets, net of taxes of 2021: USD 10 million; 2020: USD 26 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-70&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-172&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gain on divestment of the  investment in Roche&lt;sup style="white-space: nowrap"&gt; &#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 556
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income effect&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            677
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; The gain on divestment of the investment in Roche includes the recycling of currency translation effects (see Note 8.1) and other comprehensive income effects totaling USD 3.2 billion.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfAssociatesNetIncomeEffectTableTextBlock>
    <nvs:ShareOfCurrentYearNetIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">815000000</nvs:ShareOfCurrentYearNetIncome>
    <nvs:ShareOfCurrentYearNetIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">913000000</nvs:ShareOfCurrentYearNetIncome>
    <nvs:PriorYearAdjustment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">40000000</nvs:PriorYearAdjustment>
    <nvs:PriorYearAdjustment
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">-64000000</nvs:PriorYearAdjustment>
    <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">10000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax>
    <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">26000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax>
    <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">-70000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets>
    <nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">-172000000</nvs:AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets>
    <nvs:GainOnDivestmentOfInterestsInAssociatedCompanies
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">14556000000</nvs:GainOnDivestmentOfInterestsInAssociatedCompanies>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">15341000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-6"
      unitRef="USD">677000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-8"
      unitRef="USD">3200000000</nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement>
    <ifrs-full:DisclosureOfInterestExpenseExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_3de967de-4f83-4eca-b632-79663a2799aa_0">
          &lt;div&gt;
            &lt;div id="anchorId001530570"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;5. Interest expense and&#160;other&#160;financial&#160;income&#160;and&#160;expense&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Interest expense&lt;/span&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-669&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-651&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-708&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense on lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-60&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-67&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense arising from  discounting long-term liabilities and capitalized borrowing costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-108&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-98&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-94&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total interest expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-837&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-811&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-869&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Other financial income and expense&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            379
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            71
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            91
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-194&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-94&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-52&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency result, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-184&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-69&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-135&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other financial income  and expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-80&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-78&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfInterestExpenseExplanatory>
    <nvs:InterestExpenseTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_5dd2e4e6-1bb2-4f35-8425-e6ca87e052be_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-669&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-651&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-708&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense on lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-60&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-67&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense arising from  discounting long-term liabilities and capitalized borrowing costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-108&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-98&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-94&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total interest expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-837&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-811&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-869&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:InterestExpenseTableTextBlock>
    <nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">669000000</nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions>
    <nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">651000000</nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions>
    <nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">708000000</nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">60000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">62000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">67000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">108000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
    <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">98000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
    <ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">94000000</ifrs-full:ExpenseDueToUnwindingOfDiscountOnProvisions>
    <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">837000000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">811000000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">869000000</ifrs-full:InterestExpense>
    <nvs:OtherFinancialIncomeAndExpenseTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_08b62cd3-ec10-4822-aaac-f55b7a0cb47d_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            379
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            71
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            91
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-194&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-94&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-52&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency result, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-184&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-69&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-135&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other financial income  and expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-80&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-78&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:OtherFinancialIncomeAndExpenseTableTextBlock>
    <ifrs-full:RevenueFromInterest contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">379000000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">71000000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">91000000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromDividends contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">19000000</ifrs-full:RevenueFromDividends>
    <ifrs-full:RevenueFromDividends contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">12000000</ifrs-full:RevenueFromDividends>
    <ifrs-full:RevenueFromDividends contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">18000000</ifrs-full:RevenueFromDividends>
    <ifrs-full:OtherFinanceCost contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">194000000</ifrs-full:OtherFinanceCost>
    <ifrs-full:OtherFinanceCost contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">94000000</ifrs-full:OtherFinanceCost>
    <ifrs-full:OtherFinanceCost contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">52000000</ifrs-full:OtherFinanceCost>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-184000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-69000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-135000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">20000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-80000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-78000000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_a6c2d24e-fed8-43e6-b56b-06189a0bea97_0">
          &lt;div&gt;
            &lt;div id="anchorId001530822"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;6. Income taxes&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Income before taxes&lt;/span&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 986
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22 028
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 786
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 385
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 109
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            92
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 371
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 878
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; The 2021 income before taxes in Switzerland includes a USD 14.6  billion non-taxable gain on the divestment of the Group&#x2019;s investment in Roche Holding AG (see Note 2 and Note 4).&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Current and deferred income tax expense&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;The significant components of the provision for income taxes are as follows:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-617&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-958&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-932&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 454&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 470&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 168&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current income tax expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2 071&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 428&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 100&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-142&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-137&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            797
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            286
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            430
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Deferred tax income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            655
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            309
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            293
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income tax expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 416&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 119&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 807&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Analysis of tax rate&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has a substantial business presence in many countries and is therefore subject to income taxes in different tax jurisdictions. This leads to differences in income and expense items that are non-taxable or non-deductible (permanent differences) or are taxed at different statutory tax rates in those tax jurisdictions. As a result, there is a difference between our applicable tax rate and effective tax rate.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The applicable tax rate changes from year to year due to changes in the mix of the Group&#x2019;s pre-tax income and changes in statutory tax rates since it is calculated as the weighted average tax rate based on the pre-tax income of each subsidiary. &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The main elements contributing to the difference between the Group&#x2019;s overall applicable tax rate and the effective tax rate are shown in the following table:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(As a percentage)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Applicable tax rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            16.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of disallowed expenditures&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of utilization of previously unrecognized tax losses brought forward from prior periods&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of income taxed at reduced rates&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-0.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of income not subject to tax&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-0.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of tax credits and allowances&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3.8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of release of  contingent consideration liability&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-0.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of tax rate change  on current and deferred  tax assets and liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-0.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of derecognition and reversals of derecognition  of deferred tax assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of write-down and reversal of  write-down of investments in subsidiaries&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of prior-year items&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-0.4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of changes in uncertain tax positions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of other items&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Effective tax rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            16.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            18.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;b/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; 2021 includes the effect of income not subject to tax (&lt;span&gt;-7.3&lt;/span&gt;%) arising from the non-taxable gain on the divestment of our investment in Roche. See Notes 2 and 4 for further details.&lt;/span&gt;
                            &lt;b/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Our effective tax rate fluctuates based primarily on, among other factors, changes in pre-tax income between countries with varying statutory tax rates, income taxed at reduced tax rates, effect of disallowed expenditures, effect of income not subject to tax, effect of tax credits and allowances, effect of prior-year items, changes in the measurement of deferred tax assets, changes in uncertain tax positions and changes in tax laws. The table above provides the details of the significant items &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;that impact the comparability of the effective tax rate between years.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The utilization of tax-loss carry-forwards lowered the tax charge by USD&#160;1 million in 2022, by USD&#160;5 million in 2021, and by USD&#160;29 million in 2020.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <nvs:IncomeBeforeTaxesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_2e9c6764-3b65-478c-94c7-1a975843e011_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 986
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22 028
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 786
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 385
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 109
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            92
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income before taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 371
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 878
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; The 2021 income before taxes in Switzerland includes a USD 14.6  billion non-taxable gain on the divestment of the Group&#x2019;s investment in Roche Holding AG (see Note 2 and Note 4).&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:IncomeBeforeTaxesTableTextBlock>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">5986000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">22028000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">9786000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember"
      decimals="-6"
      unitRef="USD">2385000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember"
      decimals="-6"
      unitRef="USD">4109000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember"
      decimals="-6"
      unitRef="USD">92000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">8371000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">26137000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">9878000000</ifrs-full:ProfitLossBeforeTax>
    <nvs:GainOnDivestmentOfInterestsInAssociatedCompanies
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-8"
      unitRef="USD">14600000000</nvs:GainOnDivestmentOfInterestsInAssociatedCompanies>
    <nvs:CurrentAndDeferredIncomeTaxExpenseTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_25722d4e-1832-4386-8464-0bfb5a531092_0">
                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;The significant components of the provision for income taxes are as follows:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-617&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-958&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-932&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 454&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 470&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 168&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current income tax expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2 071&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 428&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 100&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-142&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-137&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Foreign&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            797
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            286
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            430
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Deferred tax income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            655
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            309
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            293
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Income tax expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 416&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 119&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 807&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:CurrentAndDeferredIncomeTaxExpenseTableTextBlock>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">617000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">958000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">932000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember"
      decimals="-6"
      unitRef="USD">1454000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember"
      decimals="-6"
      unitRef="USD">1470000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember"
      decimals="-6"
      unitRef="USD">1168000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">2071000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2428000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">2100000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">142000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">-23000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember"
      decimals="-6"
      unitRef="USD">137000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember"
      decimals="-6"
      unitRef="USD">-797000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember"
      decimals="-6"
      unitRef="USD">-286000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember"
      decimals="-6"
      unitRef="USD">-430000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-655000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-309000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-293000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1416000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2119000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1807000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <nvs:AnalysisOfTaxRateTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_cb2544ab-2d86-47cf-9783-40a2c5c3a23c_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(As a percentage)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Applicable tax rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            16.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of disallowed expenditures&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of utilization of previously unrecognized tax losses brought forward from prior periods&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of income taxed at reduced rates&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-0.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of income not subject to tax&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-0.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of tax credits and allowances&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3.8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of release of  contingent consideration liability&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-0.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of tax rate change  on current and deferred  tax assets and liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-0.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of derecognition and reversals of derecognition  of deferred tax assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of write-down and reversal of  write-down of investments in subsidiaries&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of prior-year items&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-0.4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of changes in uncertain tax positions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of other items&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Effective tax rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            16.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            18.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;b/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; 2021 includes the effect of income not subject to tax (&lt;span&gt;-7.3&lt;/span&gt;%) arising from the non-taxable gain on the divestment of our investment in Roche. See Notes 2 and 4 for further details.&lt;/span&gt;
                            &lt;b/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:AnalysisOfTaxRateTableTextBlock>
    <ifrs-full:ApplicableTaxRate contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.168</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.148</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">0.136</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.026</ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.010</ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">0.046</ifrs-full:TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxRateEffectOfTaxLosses contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.0</ifrs-full:TaxRateEffectOfTaxLosses>
    <ifrs-full:TaxRateEffectOfTaxLosses contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.0</ifrs-full:TaxRateEffectOfTaxLosses>
    <ifrs-full:TaxRateEffectOfTaxLosses contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">-0.003</ifrs-full:TaxRateEffectOfTaxLosses>
    <nvs:TaxRateEffectOfIncomeTaxedAtReducedRates contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">-0.003</nvs:TaxRateEffectOfIncomeTaxedAtReducedRates>
    <nvs:TaxRateEffectOfIncomeTaxedAtReducedRates contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">-0.001</nvs:TaxRateEffectOfIncomeTaxedAtReducedRates>
    <nvs:TaxRateEffectOfIncomeTaxedAtReducedRates contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">-0.003</nvs:TaxRateEffectOfIncomeTaxedAtReducedRates>
    <ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">-0.001</ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation>
    <ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">-0.075</ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation>
    <ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">-0.007</ifrs-full:TaxRateEffectOfRevenuesExemptFromTaxation>
    <nvs:TaxRateEffectOfCreditsAndAllowances contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">-0.038</nvs:TaxRateEffectOfCreditsAndAllowances>
    <nvs:TaxRateEffectOfCreditsAndAllowances contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">-0.014</nvs:TaxRateEffectOfCreditsAndAllowances>
    <nvs:TaxRateEffectOfCreditsAndAllowances contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">-0.023</nvs:TaxRateEffectOfCreditsAndAllowances>
    <nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">-0.005</nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability>
    <nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">-0.001</nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability>
    <nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">-0.002</nvs:TaxRateEffectOfReleaseOfContingentConsiderationLiability>
    <ifrs-full:TaxRateEffectFromChangeInTaxRate contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">-0.001</ifrs-full:TaxRateEffectFromChangeInTaxRate>
    <ifrs-full:TaxRateEffectFromChangeInTaxRate contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.0</ifrs-full:TaxRateEffectFromChangeInTaxRate>
    <ifrs-full:TaxRateEffectFromChangeInTaxRate contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">0.003</ifrs-full:TaxRateEffectFromChangeInTaxRate>
    <nvs:EffectOfWriteoffOfDeferredTaxAssets contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.012</nvs:EffectOfWriteoffOfDeferredTaxAssets>
    <nvs:EffectOfWriteoffOfDeferredTaxAssets contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.0</nvs:EffectOfWriteoffOfDeferredTaxAssets>
    <nvs:EffectOfWriteoffOfDeferredTaxAssets contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">0.002</nvs:EffectOfWriteoffOfDeferredTaxAssets>
    <nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.0</nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries>
    <nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.0</nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries>
    <nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">-0.008</nvs:TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries>
    <ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">-0.004</ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.001</ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">0.023</ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods>
    <nvs:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.014</nvs:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <nvs:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.013</nvs:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <nvs:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">0.020</nvs:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.001</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.0</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">-0.001</ifrs-full:OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:AverageEffectiveTaxRate contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.169</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.081</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">0.183</ifrs-full:AverageEffectiveTaxRate>
    <nvs:EffectOfIncomeNotSubjectToTaxOnDivestmentGain
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="3"
      unitRef="Pure">-0.073</nvs:EffectOfIncomeNotSubjectToTaxOnDivestmentGain>
    <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1000000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense>
    <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">5000000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense>
    <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">29000000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense>
    <ifrs-full:EarningsPerShareExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_fc4b2fa0-5650-4499-8258-8a1d50e13f3b_0">
          &lt;div&gt;
            &lt;div id="anchorId001531519"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;7. Earnings per share&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income attributable to shareholders of Novartis AG (USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 955
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            24 021
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 072
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Number of shares (in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Weighted average number of shares outstanding used in basic earnings per share&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 181
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 243
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 277
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Weighted average number of shares in diluted earnings per share&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 260
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Basic earnings per share (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3.19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10.71
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3.55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Diluted earnings per share (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3.17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10.63
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3.52
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Basic earnings per share (EPS) is calculated by dividing net income attributable to shareholders of Novartis AG by the weighted average number of shares outstanding in a reporting period. This calculation excludes the average number of issued shares purchased by the Group and held as treasury shares.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;For diluted EPS, the weighted average number of shares outstanding is adjusted to assume the vesting of all restricted shares, restricted share units, and the conversion of all potentially dilutive shares arising from options on Novartis shares that have been issued.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;
                  No options were excluded from the calculation of diluted EPS in 2022, 2021 or 2020, as all options were dilutive in all years.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div/&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:EarningsPerShareExplanatory>
    <nvs:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_f27b9465-464d-48bc-8fed-b46b0c20679d_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net income attributable to shareholders of Novartis AG (USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 955
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            24 021
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 072
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Number of shares (in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Weighted average number of shares outstanding used in basic earnings per share&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 181
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 243
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 277
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Weighted average number of shares in diluted earnings per share&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 260
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Basic earnings per share (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3.19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10.71
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3.55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Diluted earnings per share (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3.17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10.63
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3.52
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6955000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">24021000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">8072000000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:WeightedAverageShares
      contextRef="AR_D-CurrentYear"
      decimals="-6"
      unitRef="Shares">2181000000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="AR_D-CurrentYear-1"
      decimals="-6"
      unitRef="Shares">2243000000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="AR_D-CurrentYear-2"
      decimals="-6"
      unitRef="Shares">2277000000</ifrs-full:WeightedAverageShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="AR_D-CurrentYear"
      decimals="-6"
      unitRef="Shares">16000000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="AR_D-CurrentYear-1"
      decimals="-6"
      unitRef="Shares">17000000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="AR_D-CurrentYear-2"
      decimals="-6"
      unitRef="Shares">19000000</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="AR_D-CurrentYear"
      decimals="-6"
      unitRef="Shares">2197000000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="AR_D-CurrentYear-1"
      decimals="-6"
      unitRef="Shares">2260000000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="AR_D-CurrentYear-2"
      decimals="-6"
      unitRef="Shares">2296000000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="AR_D-CurrentYear"
      decimals="2"
      unitRef="USDPerShares">3.19</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="AR_D-CurrentYear-1"
      decimals="2"
      unitRef="USDPerShares">10.71</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="AR_D-CurrentYear-2"
      decimals="2"
      unitRef="USDPerShares">3.55</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="AR_D-CurrentYear"
      decimals="2"
      unitRef="USDPerShares">3.17</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="AR_D-CurrentYear-1"
      decimals="2"
      unitRef="USDPerShares">10.63</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="AR_D-CurrentYear-2"
      decimals="2"
      unitRef="USDPerShares">3.52</ifrs-full:DilutedEarningsLossPerShare>
    <nvs:OptionsExcludedFromTheCalculation contextRef="AR_D-CurrentYear" decimals="0" unitRef="Pure">0</nvs:OptionsExcludedFromTheCalculation>
    <nvs:ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_907e971b-ca25-482e-8a99-ce890ffdd23d_0">
          &lt;div&gt;
            &lt;div id="anchorId001531738"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;8. Changes in consolidated statements of&#160;comprehensive income&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The consolidated statements of comprehensive income include the Group&#x2019;s net income for the year as well as all other valuation adjustments recorded in the Group&#x2019;s consolidated balance sheet, which under IFRS are not recorded in the consolidated income statement. These include fair value adjustments on financial instruments, actuarial gains or losses on defined benefit pension plans, and currency translation effects, net of taxes.&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Fair value&lt;br/&gt; adjustments &lt;br/&gt; on financial&lt;br/&gt; instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Actuarial&lt;br/&gt; gains/(losses)&lt;br/&gt; from defined&lt;br/&gt; benefit plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Cumulative&lt;br/&gt; currency &lt;br/&gt; translation&lt;br/&gt; effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total value&lt;br/&gt; adjustments&lt;br/&gt; attributable to &lt;br/&gt; Novartis AG &lt;br/&gt; shareholders&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-&lt;br/&gt; controlling&lt;br/&gt; interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total value&lt;br/&gt; adjustments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2019&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            120
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-5 919&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 142
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-4 657&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-29&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-4 686&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, net of taxes of USD &lt;span&gt;-36&lt;/span&gt; million&lt;sup style="white-space: nowrap"&gt; &#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-201&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-201&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-201&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes of USD &lt;span&gt;-3&lt;/span&gt; million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            143
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects, net of taxes of USD 10 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;   8.1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 193
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 193
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 992
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 387
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 386
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities  sold, reclassified to retained earnings&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-150&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-150&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-150&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Value adjustments related to divestments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of change in ownership of consolidated entities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            220
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-5 773&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 134
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 419&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-29&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 448&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, net of taxes of USD &lt;span&gt;-44&lt;/span&gt; million&lt;sup style="white-space: nowrap"&gt; &#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge, net of taxes of USD 33 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            216
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            216
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            216
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes of USD &lt;span&gt;-323&lt;/span&gt; million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 808
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 808
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects, net of taxes of USD 17 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;   8.1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4 757&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4 757&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4 762&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 808
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-4 541&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 539&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 543&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities sold, reclassified to retained earnings net of taxes of USD 48 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-164&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-164&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-164&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Value adjustments related to divestments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            188
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 968&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-407&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 187&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-33&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 220&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, net of taxes of USD 81 million&lt;sup style="white-space: nowrap"&gt; &#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-382&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-382&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-382&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge, net of taxes of USD &lt;span&gt;-30&lt;/span&gt; million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            91
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            91
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            91
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes of USD &lt;span&gt;-104&lt;/span&gt; million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-104&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-104&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-103&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects, net of taxes of USD 18 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;   8.1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-444&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-444&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-450&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-382&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-104&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-353&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-839&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-844&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities sold, reclassified to retained earnings net of taxes of nil&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Value adjustments related to divestments, net of taxes of USD &lt;span&gt;-4&lt;/span&gt; million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-198&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 038&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-760&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 996&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-38&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-5 034&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Includes fair value adjustments on equity securities designated as financial assets valued at fair value through other comprehensive income with no subsequent recycling into the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div/&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;8.1) In 2022, net cumulative currency translation gains of USD 13 million were recycled through the income statement as a result of the divestments of subsidiaries. In 2021, net cumulative currency translation gains of USD 3.2 billion were recycled through the income statement as a result of the divestment of the investment in Roche. See Notes 2 and 4. In 2020, there were no currency translation losses or gains recycled through the income statement.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </nvs:ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock>
    <nvs:ScheduleOfComprehensiveIncomeTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_143b27a6-3fa7-40e4-a8b3-7de95319364a_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Fair value&lt;br/&gt; adjustments &lt;br/&gt; on financial&lt;br/&gt; instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Actuarial&lt;br/&gt; gains/(losses)&lt;br/&gt; from defined&lt;br/&gt; benefit plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Cumulative&lt;br/&gt; currency &lt;br/&gt; translation&lt;br/&gt; effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total value&lt;br/&gt; adjustments&lt;br/&gt; attributable to &lt;br/&gt; Novartis AG &lt;br/&gt; shareholders&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-&lt;br/&gt; controlling&lt;br/&gt; interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total value&lt;br/&gt; adjustments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2019&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            120
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-5 919&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 142
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-4 657&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-29&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-4 686&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, net of taxes of USD &lt;span&gt;-36&lt;/span&gt; million&lt;sup style="white-space: nowrap"&gt; &#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-201&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-201&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-201&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes of USD &lt;span&gt;-3&lt;/span&gt; million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            143
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects, net of taxes of USD 10 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;   8.1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 193
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 193
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 992
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 387
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 386
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities  sold, reclassified to retained earnings&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-150&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-150&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-150&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Value adjustments related to divestments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of change in ownership of consolidated entities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            220
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-5 773&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 134
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 419&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-29&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 448&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, net of taxes of USD &lt;span&gt;-44&lt;/span&gt; million&lt;sup style="white-space: nowrap"&gt; &#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge, net of taxes of USD 33 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            216
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            216
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            216
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes of USD &lt;span&gt;-323&lt;/span&gt; million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 808
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 808
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects, net of taxes of USD 17 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;   8.1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4 757&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4 757&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4 762&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            194
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 808
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-4 541&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 539&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 543&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities sold, reclassified to retained earnings net of taxes of USD 48 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-164&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-164&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-164&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Value adjustments related to divestments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            188
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 968&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-407&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 187&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-33&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 220&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities, net of taxes of USD 81 million&lt;sup style="white-space: nowrap"&gt; &#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-382&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-382&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-382&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net investment hedge, net of taxes of USD &lt;span&gt;-30&lt;/span&gt; million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            91
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            91
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            91
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Defined benefit plans, net of taxes of USD &lt;span&gt;-104&lt;/span&gt; million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-104&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-104&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-103&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects, net of taxes of USD 18 million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;   8.1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-444&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-444&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-450&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total value adjustments in 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-382&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-104&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-353&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-839&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-844&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments on equity securities sold, reclassified to retained earnings net of taxes of nil&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Value adjustments related to divestments, net of taxes of USD &lt;span&gt;-4&lt;/span&gt; million&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Value adjustments at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-198&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 038&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-760&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 996&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-38&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-5 034&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Includes fair value adjustments on equity securities designated as financial assets valued at fair value through other comprehensive income with no subsequent recycling into the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div/&gt;
              </nvs:ScheduleOfComprehensiveIncomeTableTextBlock>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">120000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-5919000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">1142000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-4657000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-29000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-4686000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">-36000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">250000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
    <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">250000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
    <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">250000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">-201000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-201000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-201000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-3000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">145000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">145000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-2000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">143000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">10000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">3193000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">3193000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">3194000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">250000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">145000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">2992000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">3387000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-1000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">3386000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">-150000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-150000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-150000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">2000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">2000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">2000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-1000000</nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-1000000</nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">220000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-5773000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">4134000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-1419000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-29000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-1448000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">-44000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">194000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
    <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">194000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
    <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">194000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4NetInvestmentHedgeMember"
      decimals="-6"
      unitRef="USD">33000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">216000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">216000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">216000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-323000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">1808000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">1808000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">1809000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">17000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">-4757000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-4757000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-5000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-4762000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">194000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">1808000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">-4541000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-2539000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-4000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-2543000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesSoldMember"
      decimals="-6"
      unitRef="USD">48000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">-164000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-164000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-164000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">-62000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-3000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-65000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-65000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">188000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-3968000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">-407000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-4187000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-33000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-4220000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">81000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">-382000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
    <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-382000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
    <nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-382000000</nvs:OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4NetInvestmentHedgeMember"
      decimals="-6"
      unitRef="USD">-30000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">91000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">91000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">91000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-104000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-104000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-104000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-103000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">18000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">-444000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-444000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-6000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-450000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">-382000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-104000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">-353000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-839000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-5000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-844000000</nvs:GainsLossesOnValueAdjustmentOnComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesSoldMember"
      decimals="-6"
      unitRef="USD">0</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">-4000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-4000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <nvs:FairValueAdjustmentsOnFinancialAssetsSold
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-4000000</nvs:FairValueAdjustmentsOnFinancialAssetsSold>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ValueAdjustmentsRelatedToDivestmentsMember"
      decimals="-6"
      unitRef="USD">-4000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">34000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">34000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:FairValueAdjustmentsRelatedToDivestments
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">34000000</nvs:FairValueAdjustmentsRelatedToDivestments>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">-198000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4ActuarialLossesFromDefinedBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-4038000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">-760000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalValueAdjustmentsAttributableToNovartisShareholdersMember"
      decimals="-6"
      unitRef="USD">-4996000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022NoncontrollingInterestsMember"
      decimals="-6"
      unitRef="USD">-38000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:ValueAdjustmentOnComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember"
      decimals="-6"
      unitRef="USD">-5034000000</nvs:ValueAdjustmentOnComprehensiveIncome>
    <nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">13000000</nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement>
    <nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-8"
      unitRef="USD">3200000000</nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement>
    <nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4CumulativeCurrencyTranslationEffectsMember"
      decimals="-6"
      unitRef="USD">0</nvs:CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_3d3470b3-35bd-46aa-a7c8-353f9eb5aa88_0">
          &lt;div&gt;
            &lt;div id="anchorId001533390"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;9. Property, plant and equipment&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of property, plant and equipment during 2022:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Land&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Buildings&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Construction &lt;br/&gt; in progress&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Machinery &lt;br/&gt; and other &lt;br/&gt; equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            492
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 819
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 508
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13 328
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            27 147
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 744&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9 786&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-15 602&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 075
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 443
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            11 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 075
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 443
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            11 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            297
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-964&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            667
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            124
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            780
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            312
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-49&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-33&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-45&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-155&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-437&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-726&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 163&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-351&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-414&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-166&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-57&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-53&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-288&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            442
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 493
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 157
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 672
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            10 764
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            451
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 396
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 184
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 842
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24 873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-8 170&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-14 109&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            442
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 493
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 157
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 672
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            10 764
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Commitments for purchases of property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            549
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Capitalized borrowing costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of property, plant and equipment during 2021:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Land&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Buildings&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Construction &lt;br/&gt; in progress&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Machinery &lt;br/&gt; and other &lt;br/&gt; equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            555
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12 377
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 248
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 038
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28 218
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 807&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-66&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-10 063&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 955&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 570
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 975
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12 263
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 570
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 975
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12 263
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-610&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            413
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            109
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 027
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            293
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 430
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-78&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-150&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-453&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-755&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 208&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-137&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-76&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-167&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-384&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            70
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            103
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-23&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-203&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-84&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-199&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-509&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 075
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 443
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            492
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11 819
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 508
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13 328
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            27 147
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 744&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9 786&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 602&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 075
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 443
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Commitments for purchases of property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Capitalized borrowing costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the property, plant and equipment impairment charges and reversals by reporting segment:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Impairment charges&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Impairment reversals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-411&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-315&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-326&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            44
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-121&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            59
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-414&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-384&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-447&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            103
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <nvs:PropertyPlantAndEquipmentTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_685cb82a-be82-4971-b240-7e665d376acc_0">
                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of property, plant and equipment during 2022:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Land&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Buildings&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Construction &lt;br/&gt; in progress&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Machinery &lt;br/&gt; and other &lt;br/&gt; equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            492
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 819
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 508
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13 328
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            27 147
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 744&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9 786&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-15 602&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 075
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 443
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            11 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 075
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 443
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            11 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            297
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-964&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            667
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            124
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            780
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            312
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 219
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-49&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-33&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-45&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-155&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-437&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-726&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 163&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-351&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-414&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-166&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-57&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-53&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-288&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            442
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 493
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 157
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 672
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            10 764
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            451
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 396
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 184
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 842
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24 873
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-8 170&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-14 109&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            442
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 493
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 157
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 672
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            10 764
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Commitments for purchases of property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            549
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Capitalized borrowing costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of property, plant and equipment during 2021:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Land&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Buildings&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Construction &lt;br/&gt; in progress&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Machinery &lt;br/&gt; and other &lt;br/&gt; equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            555
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12 377
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 248
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 038
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28 218
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 807&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-66&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-10 063&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 955&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 570
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 975
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12 263
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 570
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 975
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12 263
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-610&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            413
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            109
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 027
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            293
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 430
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-78&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-150&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-453&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-755&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 208&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-137&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-76&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-167&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-384&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            70
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            103
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-23&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-203&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-84&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-199&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-509&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 075
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 443
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            492
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11 819
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 508
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13 328
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            27 147
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated depreciation and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 744&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-9 786&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 602&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 075
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 443
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 542
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            11 545
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Commitments for purchases of property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Capitalized borrowing costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:PropertyPlantAndEquipmentTableTextBlock>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">492000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">11819000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1508000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">13328000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember"
      decimals="-6"
      unitRef="USD">27147000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">-7000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">-5744000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">-65000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">-9786000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember"
      decimals="-6"
      unitRef="USD">-15602000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">485000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">6075000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1443000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">3542000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">11545000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">485000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">6075000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1443000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">3542000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">11545000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">13000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">13000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">297000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">-964000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">667000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">3000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">124000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">780000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">312000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1219000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">49000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">33000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">45000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">155000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">437000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">726000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1163000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">7000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">351000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">13000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">43000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">414000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">7000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">-12000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">-166000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">-57000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">-53000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-288000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">442000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">5493000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1157000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">3672000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">10764000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">451000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">11396000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1184000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">11842000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember"
      decimals="-6"
      unitRef="USD">24873000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">-9000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">-5903000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">-27000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">-8170000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember"
      decimals="-6"
      unitRef="USD">-14109000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">442000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">5493000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1157000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">3672000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">10764000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">549000000</ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment>
    <ifrs-full:BorrowingCostsCapitalised contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">5000000</ifrs-full:BorrowingCostsCapitalised>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">555000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">12377000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1248000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">14038000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember"
      decimals="-6"
      unitRef="USD">28218000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">-19000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">-5807000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">-66000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">-10063000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember"
      decimals="-6"
      unitRef="USD">-15955000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">536000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">6570000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1182000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">3975000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">12263000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">536000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">6570000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1182000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">3975000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">12263000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">197000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">-610000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">413000000</ifrs-full:IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">109000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1027000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">293000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1430000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">30000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">78000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">12000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">30000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">150000000</ifrs-full:DisposalsAndRetirementsPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">453000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">755000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">1208000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">4000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">137000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">76000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">167000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">384000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">70000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">16000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">12000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">103000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">-23000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">-203000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">-84000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">-199000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-509000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">485000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">6075000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1443000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">3542000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">11545000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">492000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">11819000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1508000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">13328000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember"
      decimals="-6"
      unitRef="USD">27147000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">-7000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">-5744000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">-65000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">-9786000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember"
      decimals="-6"
      unitRef="USD">-15602000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">485000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">6075000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022ConstructionInProgressMember"
      decimals="-6"
      unitRef="USD">1443000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfPropertyPlantAndEquipmentAxis_ifrsfull-2022MachineryMember"
      decimals="-6"
      unitRef="USD">3542000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">11545000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">204000000</ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment>
    <ifrs-full:BorrowingCostsCapitalised contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">4000000</ifrs-full:BorrowingCostsCapitalised>
    <nvs:PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_55c2e1f6-fd15-488f-9c09-728086ad5978_0">
                &lt;div&gt;
                  &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the property, plant and equipment impairment charges and reversals by reporting segment:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Impairment charges&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Impairment reversals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-411&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-315&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-326&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            44
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-121&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            59
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-414&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-384&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-447&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            103
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">411000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">315000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">326000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">4000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">44000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">2000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">3000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">68000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">121000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">3000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">59000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">414000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">384000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">447000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">7000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">103000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">7000000</ifrs-full:ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfLeasesExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_d7184423-5d62-4ca4-85f7-c68e3d487ded_0">
          &lt;div/&gt;

          &lt;div&gt;
            &lt;div id="anchorId001534918"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;10. Right-of-use assets and lease liabilities&lt;/div&gt;
            &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of the right-of-use assets:&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Right-of-use assets at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 676
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            247
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            321
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-300&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-318&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease contract terminations&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-34&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-66&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-52&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-52&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total right-of-use assets at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 431
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Impairment charges in 2022 were recorded in the Innovative Medicines segment.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Lease contract terminations also includes modifications to existing leases that result in reductions to the right-of-use assets, and reductions due to sub-leasing.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the right-of-use assets carrying value and depreciation charge at December 31, 2022 and 2021, by underlying class of asset: &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; December 31,&lt;br/&gt; 2022&lt;br/&gt; carrying value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Depreciation &lt;br/&gt; charge&lt;br/&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31,&lt;br/&gt; 2021&lt;br/&gt; carrying value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Depreciation &lt;br/&gt; charge&lt;br/&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Land&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            505
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            522
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buildings&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            745
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            866
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vehicles&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            117
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            96
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            136
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and equipment, and other assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            64
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 431
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            300
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            318
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the lease liabilities by maturity at December 31, 2022 and 2021:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Lease liabilities&lt;br/&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Lease liabilities&lt;br/&gt; undiscounted&lt;br/&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Lease liabilities&lt;br/&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Lease liabilities&lt;br/&gt; undiscounted&lt;br/&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less than one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            297
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            275
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            324
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between one and two years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            190
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            232
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            216
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            258
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between two and three years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            167
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            201
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            162
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            198
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between three and four years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            172
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            139
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            172
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between four and five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            122
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            154
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            122
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            154
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            922
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 149
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            982
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 243
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 789
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 349
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion of lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-251&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-297&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-275&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-324&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current portion of lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 538
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 908
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 025
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Commitments for leases not yet commenced&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            83
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            134
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;At December 31, 2022, and December 31, 2021, there were no material future cash outflows, including extension options, excluded from the measurement of lease liabilities. The Group&#x2019;s most material lease with a lease term extension, representing a lease liability value of USD 0.7 billion (2021: USD 0.6 billion), has a determined lease term end date of 2071 (2021: 2071). Non-enforceable extension options of up to 10 years have not been included within the measurement of this lease liability, and do not have a material impact to the carrying value of the lease for both 2022 and 2021. Should the landlord agree to a lease extension, rent will be referenced to the market rates as at the commencement of the extension period. &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2022, the Group completed three sale and leaseback transactions for certain property, plant and equipment as part of the Groups plans to focus on key operating locations. The transactions resulted in net cash inflows of USD 49 million and the recognition of USD 23 million of lease liabilities, and USD 13 million of right-of-use assets. The right-of-use assets value reflects the proportion of the property, plant and equipment retained. Extension options have been included where management believe that such options will be exercised. The liabilities reflect the net present value of future lease payments. The net gain on the sale and leaseback transactions amounted to USD 17 million. There were no significant sale and leaseback transactions in 2021 or 2020.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table provides additional disclosures related to right-of-use assets and lease liabilities for 2022, 2021 and 2020:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense on lease liabilities&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            62
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            67
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense on short-term leases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense on low-value leases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total cash outflows for leases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            355
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            381
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            379
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Thereof:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Cash outflows for short-term leases and low-value leases&lt;sup style="white-space: nowrap"&gt; &#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Payments of interest&lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            51
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            52
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Payments of lease liabilities&lt;sup style="white-space: nowrap"&gt;&#160;4&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            295
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            316
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            312
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; The weighted average interest rate is 3.3% (2021: 3.2%, 2020: 3.4%).&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Cash flows from short-term and low-value leases are included within total net cash flows from operating activities. The portfolio of short-term leases to which the Group is committed to at December 31, 2022, 2021 and 2020, is similar to the portfolio of short-term leases the Group entered into during 2022, 2021 and 2020.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt; Included within total net cash flows from operating activities&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;4&#160;&lt;/sup&gt; Reported as cash outflows in financing activities net of lease incentives received, if any.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The net investment held and income from subleasing right-of-use assets were not significant for 2022, 2021, and 2020. Income from leasing Novartis property, plant and equipment to third parties for 2022, 2021 and 2020 was not significant. &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfLeasesExplanatory>
    <nvs:DisclosureOfRightofuseAssetsRollForwardTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_18a3572f-571c-4536-ba92-1b1cc73e5af5_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Right-of-use assets at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 676
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            247
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            321
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-300&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-318&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease contract terminations&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-34&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-66&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-52&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-52&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total right-of-use assets at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 431
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Impairment charges in 2022 were recorded in the Innovative Medicines segment.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Lease contract terminations also includes modifications to existing leases that result in reductions to the right-of-use assets, and reductions due to sub-leasing.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfRightofuseAssetsRollForwardTableTextBlock>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1561000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">1676000000</ifrs-full:RightofuseAssets>
    <nvs:AcquisitionsThroughBusinessCombinationsRightofuseAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">12000000</nvs:AcquisitionsThroughBusinessCombinationsRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">247000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">321000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">300000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">318000000</ifrs-full:DepreciationRightofuseAssets>
    <nvs:ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-3000000</nvs:ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets>
    <nvs:LeaseContractTerminationsRightofuseAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">34000000</nvs:LeaseContractTerminationsRightofuseAssets>
    <nvs:LeaseContractTerminationsRightofuseAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">66000000</nvs:LeaseContractTerminationsRightofuseAssets>
    <nvs:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-52000000</nvs:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <nvs:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-52000000</nvs:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1431000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1561000000</ifrs-full:RightofuseAssets>
    <nvs:DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_8ad36aeb-2695-4aca-9fb4-3e148a2ff005_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; December 31,&lt;br/&gt; 2022&lt;br/&gt; carrying value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Depreciation &lt;br/&gt; charge&lt;br/&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31,&lt;br/&gt; 2021&lt;br/&gt; carrying value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Depreciation &lt;br/&gt; charge&lt;br/&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Land&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            505
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            522
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Buildings&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            745
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            866
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Vehicles&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            117
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            96
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            136
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Machinery and equipment, and other assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            64
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 431
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            300
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            318
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">505000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">16000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">522000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember"
      decimals="-6"
      unitRef="USD">11000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">745000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">177000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">866000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022BuildingsMember"
      decimals="-6"
      unitRef="USD">192000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember"
      decimals="-6"
      unitRef="USD">117000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember"
      decimals="-6"
      unitRef="USD">96000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember"
      decimals="-6"
      unitRef="USD">136000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022VehiclesMember"
      decimals="-6"
      unitRef="USD">105000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember"
      decimals="-6"
      unitRef="USD">64000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember"
      decimals="-6"
      unitRef="USD">11000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember"
      decimals="-6"
      unitRef="USD">37000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022OtherAssetsMember"
      decimals="-6"
      unitRef="USD">10000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1431000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">300000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1561000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">318000000</ifrs-full:DepreciationRightofuseAssets>
    <nvs:DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_64e2c148-b3d5-4e05-8930-ffab01beba5a_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Lease liabilities&lt;br/&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Lease liabilities&lt;br/&gt; undiscounted&lt;br/&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Lease liabilities&lt;br/&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Lease liabilities&lt;br/&gt; undiscounted&lt;br/&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less than one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            297
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            275
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            324
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between one and two years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            190
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            232
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            216
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            258
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between two and three years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            167
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            201
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            162
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            198
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between three and four years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            172
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            139
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            172
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Between four and five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            122
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            154
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            122
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            154
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            922
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 149
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            982
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 243
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 789
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 349
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion of lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-251&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-297&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-275&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-324&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current portion of lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 538
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 908
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 025
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Commitments for leases not yet commenced&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            83
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            134
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember"
      decimals="-6"
      unitRef="USD">251000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember"
      decimals="-6"
      unitRef="USD">297000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember"
      decimals="-6"
      unitRef="USD">275000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember"
      decimals="-6"
      unitRef="USD">324000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember"
      decimals="-6"
      unitRef="USD">190000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember"
      decimals="-6"
      unitRef="USD">232000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember"
      decimals="-6"
      unitRef="USD">216000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember"
      decimals="-6"
      unitRef="USD">258000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember"
      decimals="-6"
      unitRef="USD">167000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember"
      decimals="-6"
      unitRef="USD">201000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember"
      decimals="-6"
      unitRef="USD">162000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember"
      decimals="-6"
      unitRef="USD">198000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember"
      decimals="-6"
      unitRef="USD">137000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember"
      decimals="-6"
      unitRef="USD">172000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember"
      decimals="-6"
      unitRef="USD">139000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember"
      decimals="-6"
      unitRef="USD">172000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">122000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">154000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">122000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">154000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">922000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">2149000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">982000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">2243000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1789000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">3205000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1896000000</ifrs-full:LeaseLiabilities>
    <nvs:LeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">3349000000</nvs:LeaseLiabilitiesUndiscounted>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">251000000</ifrs-full:CurrentLeaseLiabilities>
    <nvs:CurrentLeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">297000000</nvs:CurrentLeaseLiabilitiesUndiscounted>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">275000000</ifrs-full:CurrentLeaseLiabilities>
    <nvs:CurrentLeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">324000000</nvs:CurrentLeaseLiabilitiesUndiscounted>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1538000000</ifrs-full:NoncurrentLeaseLiabilities>
    <nvs:NoncurrentLeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2908000000</nvs:NoncurrentLeaseLiabilitiesUndiscounted>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1621000000</ifrs-full:NoncurrentLeaseLiabilities>
    <nvs:NoncurrentLeaseLiabilitiesUndiscounted
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">3025000000</nvs:NoncurrentLeaseLiabilitiesUndiscounted>
    <nvs:CommitmentsForLeasesNotYetCommenced
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">83000000</nvs:CommitmentsForLeasesNotYetCommenced>
    <nvs:CommitmentsForLeasesNotYetCommenced
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">134000000</nvs:CommitmentsForLeasesNotYetCommenced>
    <nvs:MostMaterialLeaseWithLeaseTermExtension
      contextRef="AR_I-CurrentYearEnd"
      decimals="-8"
      unitRef="USD">700000000</nvs:MostMaterialLeaseWithLeaseTermExtension>
    <nvs:MostMaterialLeaseWithLeaseTermExtension
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-8"
      unitRef="USD">600000000</nvs:MostMaterialLeaseWithLeaseTermExtension>
    <nvs:LeaseTermEndDate contextRef="AR_D-CurrentYear">2071</nvs:LeaseTermEndDate>
    <nvs:LeaseTermEndDate contextRef="AR_D-CurrentYear-1">2071</nvs:LeaseTermEndDate>
    <nvs:CashInflowForSaleAndLeaseback
      contextRef="AR_D-CurrentYear_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember"
      decimals="-6"
      unitRef="USD">-49000000</nvs:CashInflowForSaleAndLeaseback>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember"
      decimals="-6"
      unitRef="USD">23000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:RightofuseAssets
      contextRef="AR_I-CurrentYearEnd_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember"
      decimals="-6"
      unitRef="USD">13000000</ifrs-full:RightofuseAssets>
    <ifrs-full:GainsLossesArisingFromSaleAndLeasebackTransactions
      contextRef="AR_D-CurrentYear_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember"
      decimals="-6"
      unitRef="USD">17000000</ifrs-full:GainsLossesArisingFromSaleAndLeasebackTransactions>
    <nvs:AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_777a9ce6-dd1c-4571-8437-11241c88dd8a_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest expense on lease liabilities&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            62
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            67
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense on short-term leases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense on low-value leases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total cash outflows for leases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            355
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            381
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            379
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Thereof:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Cash outflows for short-term leases and low-value leases&lt;sup style="white-space: nowrap"&gt; &#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Payments of interest&lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            51
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            52
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;&#160;&#160;&#160;Payments of lease liabilities&lt;sup style="white-space: nowrap"&gt;&#160;4&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            295
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            316
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            312
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; The weighted average interest rate is 3.3% (2021: 3.2%, 2020: 3.4%).&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Cash flows from short-term and low-value leases are included within total net cash flows from operating activities. The portfolio of short-term leases to which the Group is committed to at December 31, 2022, 2021 and 2020, is similar to the portfolio of short-term leases the Group entered into during 2022, 2021 and 2020.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt; Included within total net cash flows from operating activities&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;4&#160;&lt;/sup&gt; Reported as cash outflows in financing activities net of lease incentives received, if any.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">60000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">62000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">67000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">3000000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">6000000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">4000000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6000000</ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">7000000</ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">7000000</ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:CashOutflowForLeases contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">355000000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">381000000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">379000000</ifrs-full:CashOutflowForLeases>
    <nvs:CashOutflowsForShortTermAndLowValueLeases contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">9000000</nvs:CashOutflowsForShortTermAndLowValueLeases>
    <nvs:CashOutflowsForShortTermAndLowValueLeases contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">13000000</nvs:CashOutflowsForShortTermAndLowValueLeases>
    <nvs:CashOutflowsForShortTermAndLowValueLeases contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">11000000</nvs:CashOutflowsForShortTermAndLowValueLeases>
    <nvs:CashOutflowsForPaymentsOfLeasesInterest contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">51000000</nvs:CashOutflowsForPaymentsOfLeasesInterest>
    <nvs:CashOutflowsForPaymentsOfLeasesInterest contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">52000000</nvs:CashOutflowsForPaymentsOfLeasesInterest>
    <nvs:CashOutflowsForPaymentsOfLeasesInterest contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">56000000</nvs:CashOutflowsForPaymentsOfLeasesInterest>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">295000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">316000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">312000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <nvs:WeightedAverageInterestRateLeaseLiabilities contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.033</nvs:WeightedAverageInterestRateLeaseLiabilities>
    <nvs:WeightedAverageInterestRateLeaseLiabilities contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.032</nvs:WeightedAverageInterestRateLeaseLiabilities>
    <nvs:WeightedAverageInterestRateLeaseLiabilities contextRef="AR_D-CurrentYear-2" decimals="3" unitRef="Pure">0.034</nvs:WeightedAverageInterestRateLeaseLiabilities>
    <ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_692bb3d0-d3f7-4285-8381-30c3440ba114_0">
          &lt;div&gt;
            &lt;div id="anchorId001535868"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;11. Goodwill and intangible assets&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of goodwill and intangible assets in 2022:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="1" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Intangible assets other than goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; In-process&lt;br/&gt; research and&lt;br/&gt; development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Technologies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currently&lt;br/&gt; marketed &lt;br/&gt; products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other&lt;br/&gt; intangible&lt;br/&gt; assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            29 900
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 080
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            56 213
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 905
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            68 211
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-305&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 514&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-29 107&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 505&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-34 029&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            29 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 499
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            27 106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            34 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            29 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 499
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            27 106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            34 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            161
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 209
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 209
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 429&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 403
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            330
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 175
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            588
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 093
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-95&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-100&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-37&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 603&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-342&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 982&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-917&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-15&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-322&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-72&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 326&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-427&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-176&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-243&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-432&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            29 301
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 421
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            121
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            25 513
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 589
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            29 596
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 038
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            58 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 305
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            69 684
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-295&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 671&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-917&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-32 736&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 716&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-38 040&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            29 301
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 421
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            121
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            25 513
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 589
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of goodwill and intangible assets in 2021:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="1" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Intangible assets other than goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; In-process&lt;br/&gt; research and&lt;br/&gt; development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Technologies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Currently&lt;br/&gt; marketed &lt;br/&gt; products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other&lt;br/&gt; intangible&lt;br/&gt; assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            30 321
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 893
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 115
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            57 333
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 384
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            67 725
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-322&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 193&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-885&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-26 566&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 272&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30 916&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 999
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 700
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            230
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            30 767
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 112
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            36 809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 999
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 700
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            230
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            30 767
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 112
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            36 809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            238
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            262
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            292
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            98
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            652
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-20&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            270
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            508
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 736
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-36&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-37&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-41&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 607&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-255&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-350&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-17&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-35&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-403&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-642&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-51&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-584&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-672&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 499
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            27 106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            34 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            29 900
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 080
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            56 213
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 905
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            68 211
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-305&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 514&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-29 107&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 505&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-34 029&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 499
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            27 106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            34 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2022:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="1" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Goodwill&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Intangible assets other than goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; In-process&lt;br/&gt; research and&lt;br/&gt; development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Technologies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currently&lt;br/&gt; marketed &lt;br/&gt; products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other&lt;br/&gt; intangible&lt;br/&gt; assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21 531
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 186
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24 487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 139
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            29 826
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 770
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            235
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            107
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 026
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            92
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 460
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            358
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            358
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            29 301
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 421
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            121
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            25 513
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 589
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; The Innovative Medicines and Sandoz Divisions&#x2019; represent the grouping of cash-generating units, to which goodwill is allocated.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2021:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="1" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Goodwill&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Intangible assets other than goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; In-process&lt;br/&gt; research and&lt;br/&gt; development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Technologies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Currently&lt;br/&gt; marketed &lt;br/&gt; products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other&lt;br/&gt; intangible&lt;br/&gt; assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21 562
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 313
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25 938
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 091
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            32 357
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 026
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            186
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            162
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            61
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 577
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            248
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            248
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 499
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            27 106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            34 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; The Innovative Medicines and Sandoz Divisions&#x2019; and Corporate represent the grouping of cash-generating units, to which goodwill is allocated.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;As at December 31, 2022, the most significant intangible assets within currently marketed products category are &lt;i&gt;Leqvio&lt;/i&gt; (Innovative Medicines: acquisition of The Medicines Company) and &lt;i&gt;Zolgensma&lt;/i&gt; (Innovative Medicines: acquisition of Avexis Inc.). As at December 31, 2022, the carrying value and remaining amortization period for &lt;i&gt;Leqvio&lt;/i&gt; is USD 7.4 billion and 13 years, respectively (2021: USD 7.9 billion and 14 years, respectively), and for &lt;i&gt;Zolgensma&lt;/i&gt; USD 5.9 billion and 8 years, respectively (2021: USD 6.6 billion and 9 years, respectively). &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Innovative Medicines and Sandoz Divisions&#x2019; cash-generating units, to which goodwill is allocated, &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;each comprise a group of smaller cash-generating units. The valuation method of the recoverable amount of the group of cash-generating units, to which goodwill is allocated, is based on the fair value less costs of disposal. &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following assumptions are used in the calculations:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(As a percentage)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative &lt;br/&gt; Medicines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Terminal growth rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Discount rate (post-tax)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The discount rates for all divisions consider the Group&#x2019;s weighted average cost of capital, adjusted to approximate the weighted average cost of capital of a comparable market participant.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value less costs of disposal, for all cash-generating units containing goodwill, is reviewed for the impact of reasonably possible changes in key assumptions. In particular, we considered an increase in the discount rate, a decrease in the terminal growth rate, and certain negative impacts on the forecasted cash flows. These reasonably possible changes in key assumptions did not indicate an impairment.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;&#x201c;Note 1. Significant accounting policies&#x2014;Impairment of goodwill and intangible assets&#x201d; provides additional disclosures on how the Group performs goodwill and intangible asset impairment testing.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the intangible asset impairment charges and reversals by reporting segment: &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Impairment charges&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Impairment reversals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 299&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-367&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-768&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-25&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-141&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 326&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-403&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-914&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; 2022 includes an impairment of USD 0.6 billion related to the write-down of IPR&amp;amp;D related to cessation of clinical development program UNR844.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;span&gt; 2021 includes an impairment of USD 0.2 billion related to the write-down of IPR&amp;amp;D related to cessation of clinical development program GTX312.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;span&gt; 2020 includes an impairment of USD 0.5 billion related to the write-down of IPR&amp;amp;D related to cessation of clinical development program ZPL389 for atopic dermatitis and USD 0.2 billion related to a partial write-down of the &lt;i&gt;Votrient&lt;/i&gt; currently marketed product (&lt;i&gt;Votrient&lt;/i&gt; carrying value was USD 0.9 billion in 2022 and USD 1.3 billion in 2021).&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div/&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory>
    <nvs:DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_6c2ac4c1-82bb-46fe-afc8-e160edb283e5_0">
                &lt;div&gt;
                  &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of goodwill and intangible assets in 2022:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="1" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Intangible assets other than goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; In-process&lt;br/&gt; research and&lt;br/&gt; development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Technologies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currently&lt;br/&gt; marketed &lt;br/&gt; products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other&lt;br/&gt; intangible&lt;br/&gt; assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            29 900
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 080
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            56 213
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 905
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            68 211
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-305&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 514&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-29 107&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 505&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-34 029&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            29 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 499
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            27 106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            34 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            29 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 499
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            27 106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            34 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            161
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 209
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 209
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 429&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 403
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            330
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 175
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            588
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 093
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-95&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-100&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-37&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 603&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-342&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 982&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-917&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-15&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-322&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-72&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 326&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-427&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-176&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-243&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-432&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            29 301
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 421
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            121
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            25 513
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 589
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            29 596
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 092
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 038
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            58 249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 305
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            69 684
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-295&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 671&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-917&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-32 736&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 716&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-38 040&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            29 301
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 421
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            121
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            25 513
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 589
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movements of goodwill and intangible assets in 2021:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="1" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Intangible assets other than goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; In-process&lt;br/&gt; research and&lt;br/&gt; development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Technologies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Currently&lt;br/&gt; marketed &lt;br/&gt; products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other&lt;br/&gt; intangible&lt;br/&gt; assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            30 321
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 893
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 115
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            57 333
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 384
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            67 725
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-322&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 193&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-885&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-26 566&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 272&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30 916&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 999
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 700
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            230
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            30 767
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 112
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            36 809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 999
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 700
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            230
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            30 767
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 112
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            36 809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            238
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            262
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            292
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            98
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            652
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassifications&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-20&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            270
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            508
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 736
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals and derecognitions&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-36&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-37&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-41&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 607&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-255&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impairment charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-350&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-17&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-35&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-403&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-642&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-51&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-584&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-672&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 499
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            27 106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            34 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            29 900
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 013
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 080
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            56 213
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 905
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            68 211
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accumulated amortization and impairment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-305&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 514&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-903&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-29 107&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 505&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-34 029&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 499
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            27 106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            34 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Reclassifications between various asset categories as a result of product launches of acquired in-process research and development and completion of software development&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Derecognition of assets that are no longer being used or developed and are not considered to have a significant disposal value or other alternative use&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29900000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">8013000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1080000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">56213000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">2905000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">68211000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">-305000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">-2514000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-903000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">-29107000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-1505000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">-34029000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29595000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">5499000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">177000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">27106000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1400000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">34182000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29595000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">5499000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">177000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">27106000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1400000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">34182000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">161000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">1209000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">1209000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">-1429000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">2000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">1403000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">24000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">330000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">1175000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">588000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">2093000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">95000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">3000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">2000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">100000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">37000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">3603000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">342000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">3982000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">917000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">15000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">322000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">72000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">1326000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">-427000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">-176000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-6000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">-243000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-7000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">-432000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29301000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">4421000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">121000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">25513000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1589000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">31644000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29596000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">7092000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1038000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">58249000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">3305000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">69684000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">-295000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">-2671000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-917000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">-32736000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-1716000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">-38040000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29301000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">4421000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">121000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">25513000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1589000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">31644000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">30321000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">6893000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1115000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">57333000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">2384000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">67725000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">-322000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">-2193000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-885000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">-26566000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-1272000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">-30916000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29999000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">4700000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">230000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">30767000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1112000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">36809000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29999000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">4700000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">230000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">30767000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1112000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">36809000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">238000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">262000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">292000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">98000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">652000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">-20000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">15000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">958000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">270000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">508000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">1736000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">36000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">37000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsAndGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">41000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">3607000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">255000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">3903000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">350000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">17000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">35000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">403000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">-642000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">-51000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-10000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">-584000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-27000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">-672000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29595000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">5499000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">177000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">27106000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1400000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">34182000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29900000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">8013000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1080000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">56213000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">2905000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">68211000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">-305000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">-2514000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-903000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">-29107000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">-1505000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">-34029000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29595000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">5499000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">177000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">27106000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1400000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">34182000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <nvs:AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_5f122fc4-96e9-42f7-8040-8feae55a3a2f_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="1" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Goodwill&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Intangible assets other than goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; In-process&lt;br/&gt; research and&lt;br/&gt; development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Technologies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currently&lt;br/&gt; marketed &lt;br/&gt; products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other&lt;br/&gt; intangible&lt;br/&gt; assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21 531
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 186
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24 487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 139
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            29 826
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 770
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            235
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            107
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 026
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            92
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 460
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            358
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            358
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            29 301
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 421
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            121
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            25 513
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 589
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 644
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; The Innovative Medicines and Sandoz Divisions&#x2019; represent the grouping of cash-generating units, to which goodwill is allocated.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2021:&lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="1" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Goodwill&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Intangible assets other than goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="1" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; In-process&lt;br/&gt; research and&lt;br/&gt; development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Technologies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Currently&lt;br/&gt; marketed &lt;br/&gt; products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other&lt;br/&gt; intangible&lt;br/&gt; assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21 562
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 313
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25 938
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 091
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            32 357
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 026
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            186
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            162
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            61
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 577
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            248
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            248
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net book value at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            29 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 499
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            27 106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            34 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; The Innovative Medicines and Sandoz Divisions&#x2019; and Corporate represent the grouping of cash-generating units, to which goodwill is allocated.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">21531000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">4186000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">14000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">24487000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1139000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">29826000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">7770000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">235000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">107000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1026000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">92000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1460000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">358000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">358000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29301000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">4421000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">121000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">25513000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1589000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">31644000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">21562000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">5313000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">15000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">25938000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1091000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">32357000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">8026000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">186000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">162000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1168000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">61000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">1577000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">7000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">248000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">248000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember"
      decimals="-6"
      unitRef="USD">29595000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember"
      decimals="-6"
      unitRef="USD">5499000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022TechnologybasedIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">177000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember"
      decimals="-6"
      unitRef="USD">27106000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022OtherIntangibleAssetsMember"
      decimals="-6"
      unitRef="USD">1400000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">34182000000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsMaterialToEntity
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember"
      decimals="-8"
      unitRef="USD">7400000000</ifrs-full:IntangibleAssetsMaterialToEntity>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember">P13Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:IntangibleAssetsMaterialToEntity
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember"
      decimals="-8"
      unitRef="USD">7900000000</ifrs-full:IntangibleAssetsMaterialToEntity>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember">P14Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:IntangibleAssetsMaterialToEntity
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember"
      decimals="-8"
      unitRef="USD">5900000000</ifrs-full:IntangibleAssetsMaterialToEntity>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="AR_D-CurrentYear_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember">P8Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <ifrs-full:IntangibleAssetsMaterialToEntity
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember"
      decimals="-8"
      unitRef="USD">6600000000</ifrs-full:IntangibleAssetsMaterialToEntity>
    <ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019 contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ZolgensmaMember">P9Y</ifrs-full:RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019>
    <nvs:AssumptionsUsedInTheCalculationOfValuationTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_90835707-17a9-4670-ac39-d2cc3710f9ad_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(As a percentage)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Innovative &lt;br/&gt; Medicines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Terminal growth rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Discount rate (post-tax)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:AssumptionsUsedInTheCalculationOfValuationTextBlock>
    <ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="3"
      unitRef="Pure">0.015</ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections>
    <ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="3"
      unitRef="Pure">0.010</ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections>
    <ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="3"
      unitRef="Pure">0.080</ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal>
    <ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="3"
      unitRef="Pure">0.080</ifrs-full:DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal>
    <nvs:IntangibleAssetImpairmentChargesTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_f92d8281-9963-4ab9-a5f6-8e20241de9ad_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Impairment charges&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Impairment reversals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Innovative Medicines&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 299&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-367&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-768&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sandoz&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-25&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-141&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Corporate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 326&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-403&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-914&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; 2022 includes an impairment of USD 0.6 billion related to the write-down of IPR&amp;amp;D related to cessation of clinical development program UNR844.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;span&gt; 2021 includes an impairment of USD 0.2 billion related to the write-down of IPR&amp;amp;D related to cessation of clinical development program GTX312.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="14"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;span&gt; 2020 includes an impairment of USD 0.5 billion related to the write-down of IPR&amp;amp;D related to cessation of clinical development program ZPL389 for atopic dermatitis and USD 0.2 billion related to a partial write-down of the &lt;i&gt;Votrient&lt;/i&gt; currently marketed product (&lt;i&gt;Votrient&lt;/i&gt; carrying value was USD 0.9 billion in 2022 and USD 1.3 billion in 2021).&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:IntangibleAssetImpairmentChargesTextBlock>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">1299000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">367000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-6"
      unitRef="USD">768000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">25000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">141000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">2000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">8000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4CorporateMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">1326000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">403000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">914000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-5"
      unitRef="USD">600000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-5"
      unitRef="USD">200000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-5"
      unitRef="USD">500000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022AccumulatedDepreciationAmortisationAndImpairmentMember_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4AcquiredResearchAndDevelopmentMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-5"
      unitRef="USD">200000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">900000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember"
      decimals="-8"
      unitRef="USD">1300000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill>
    <ifrs-full:DisclosureOfDeferredTaxesExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_213338fa-2acc-4dd4-9e0e-836ea6b11693_0">
          &lt;div&gt;
            &lt;div id="anchorId001538357"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;12. Deferred tax assets and liabilities &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Property, &lt;br/&gt; plant and&lt;br/&gt; equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Intangible&lt;br/&gt; assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pensions and&lt;br/&gt; other benefit &lt;br/&gt; obligations &lt;br/&gt; of employees&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Inventories&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Tax loss&lt;br/&gt; carry-&lt;br/&gt; forwards&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Other assets,&lt;br/&gt; provisions&lt;br/&gt; and accruals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax assets at January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 307
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 026
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 273
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 727
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            7 832
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax liabilities at January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-381&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 704&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-591&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-148&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 335&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-7 159&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-256&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            435
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 392
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-256&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            435
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 392
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            69
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            628
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            655
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to equity&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to other comprehensive income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-104&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            63
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-300&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-244&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other movements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-185&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 059&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            319
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 076
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            425
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 477
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 053
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax assets at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            158
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 726
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            739
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 214
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            425
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 789
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 051
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax liabilities at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-343&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4 785&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-420&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-138&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 312&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6 998&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-185&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 059&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            319
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 076
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            425
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 477
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 053
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After offsetting the following amount of deferred tax  assets and liabilities within the same tax jurisdiction,  the balance amounts to:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 312
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 739
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 686&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 053
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax assets at January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            189
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 351
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 502
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            507
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 658
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 344
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax liabilities at January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-430&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-5 269&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-340&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-159&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 344&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-7 552&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-241&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 918&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            797
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 343
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            497
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 314
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            792
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-241&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 918&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            797
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 343
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            497
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 314
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            792
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            567
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-22&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-215&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-121&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            309
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to equity&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-35&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-35&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to other comprehensive income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-323&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-317&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-58&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-46&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other movements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-17&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-20&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-256&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            435
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 392
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax assets at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 307
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 026
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 273
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 727
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 832
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax liabilities at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-381&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4 704&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-591&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-148&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 335&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7 159&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-256&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            435
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 392
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After offsetting the following amount of deferred tax  assets and liabilities within the same tax jurisdiction,  the balance amounts to:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 089
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 743
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 070&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;b/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Deferred tax liabilities have not been recognized for the withholding tax and other taxes that would be payable on the remittance of earnings of foreign subsidiaries, insofar as the Group has the ability to control any future reversal and the unremitted earnings are retained in the foreign subsidiaries for reinvestment. The total unremitted earnings retained for reinvestment in the Group&#x2019;s foreign subsidiaries that would be subject to withholding tax or other taxes if remitted to the Group are estimated at approximately USD 32 billion in 2022, (2021: USD 29 billion).&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;The gross value of tax-loss carry-forwards that have or have not been recognized as deferred tax assets, with their expiry dates, is as follows:&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Unrecognized&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Recognized&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022 total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Two years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            42
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Three years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Four years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            138
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            138
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            79
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            688
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            767
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;More than five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 880
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 380
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 260
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not subject to expiry&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            433
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            452
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            885
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 610
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 530
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 140
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Unrecognized&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rcognized&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021 total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Two years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Three years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            47
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Four years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            26
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            146
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            166
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;More than five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 872
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 408
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not subject to expiry&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            418
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            684
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 102
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 607
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 799
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tax losses carried forward  that expired&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Deferred tax assets related to carry-forwards of taxable losses and tax credits of relevant Group entities are recognized to the extent it is considered probable that future taxable profits will be available in the respective tax jurisdictions against which such losses and credits can be utilized.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfDeferredTaxesExplanatory>
    <nvs:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_ff893456-4a80-4fee-a6c3-39116d238e39_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Property, &lt;br/&gt; plant and&lt;br/&gt; equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Intangible&lt;br/&gt; assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pensions and&lt;br/&gt; other benefit &lt;br/&gt; obligations &lt;br/&gt; of employees&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Inventories&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Tax loss&lt;br/&gt; carry-&lt;br/&gt; forwards&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Other assets,&lt;br/&gt; provisions&lt;br/&gt; and accruals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax assets at January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 307
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 026
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 273
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 727
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            7 832
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax liabilities at January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-381&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-4 704&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-591&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-148&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 335&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-7 159&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-256&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            435
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 392
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-256&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            435
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 392
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            69
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            628
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            655
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to equity&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to other comprehensive income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-104&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            63
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-300&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-244&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other movements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-185&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 059&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            319
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 076
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            425
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 477
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 053
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax assets at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            158
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 726
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            739
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 214
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            425
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 789
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 051
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax liabilities at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-343&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4 785&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-420&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-138&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 312&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6 998&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-185&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 059&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            319
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 076
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            425
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 477
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 053
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After offsetting the following amount of deferred tax  assets and liabilities within the same tax jurisdiction,  the balance amounts to:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 312
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 739
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 686&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 053
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax assets at January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            189
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 351
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 502
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            507
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 658
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 344
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Gross deferred tax liabilities at January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-430&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-5 269&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-340&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-159&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 344&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-7 552&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-241&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 918&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            797
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 343
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            497
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 314
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            792
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;At January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-241&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 918&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            797
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 343
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            497
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 314
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            792
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            567
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-22&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-215&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-121&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            309
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Charged to equity&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-35&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-35&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Credited/(charged) to other comprehensive income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-323&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-317&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-58&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-46&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other movements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-17&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-20&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-256&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            435
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 392
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax assets at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 307
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 026
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 273
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 727
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 832
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gross deferred tax liabilities at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-381&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4 704&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-591&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-148&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 335&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7 159&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-256&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 397&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            435
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 125
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            374
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 392
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After offsetting the following amount of deferred tax  assets and liabilities within the same tax jurisdiction,  the balance amounts to:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 089
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 743
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 070&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net deferred tax balance at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                            &lt;b/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;b/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Deferred tax liabilities have not been recognized for the withholding tax and other taxes that would be payable on the remittance of earnings of foreign subsidiaries, insofar as the Group has the ability to control any future reversal and the unremitted earnings are retained in the foreign subsidiaries for reinvestment. The total unremitted earnings retained for reinvestment in the Group&#x2019;s foreign subsidiaries that would be subject to withholding tax or other taxes if remitted to the Group are estimated at approximately USD 32 billion in 2022, (2021: USD 29 billion).&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;The gross value of tax-loss carry-forwards that have or have not been recognized as deferred tax assets, with their expiry dates, is as follows:&lt;/div&gt;
                &lt;/div&gt;
              </nvs:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">125000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">1307000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">1026000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">2273000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">374000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">2727000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">7832000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">381000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">4704000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">591000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">148000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">1335000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">7159000000</nvs:GrossDeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">256000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3397000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-435000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">-2125000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">-374000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">-1392000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">-673000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">256000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3397000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-435000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">-2125000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">-374000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">-1392000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">-673000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">69000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">628000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-5000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">-43000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">655000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">-2000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-104000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">63000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-43000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">300000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">-55000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">-1000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">244000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">-4000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">-10000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">7000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">6000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">9000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">-19000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-11000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">185000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3059000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-319000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">-2076000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">-425000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">-1477000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">-1053000000</ifrs-full:DeferredTaxLiabilityAsset>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">158000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">1726000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">739000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">2214000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">425000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">2789000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">8051000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">343000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">4785000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">420000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">138000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">1312000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">6998000000</nvs:GrossDeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">185000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3059000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-319000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">-2076000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">-425000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">-1477000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">-1053000000</ifrs-full:DeferredTaxLiabilityAsset>
    <nvs:OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">4312000000</nvs:OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction>
    <ifrs-full:DeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">3739000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2686000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">-1053000000</ifrs-full:DeferredTaxLiabilityAsset>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">189000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">1351000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">1137000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">2502000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">507000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">2658000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">8344000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">430000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">5269000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">340000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">159000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">10000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">1344000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">7552000000</nvs:GrossDeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">241000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3918000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-797000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">-2343000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">-497000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">-1314000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">-792000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">241000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3918000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-797000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">-2343000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">-497000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">-1314000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">-792000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">-27000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">567000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-22000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">-215000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">-121000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">127000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">309000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">-35000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-35000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-323000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">6000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-317000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">58000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">-12000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">46000000</ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">-12000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">-12000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">17000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">3000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">14000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">20000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">30000000</nvs:IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">256000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3397000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-435000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">-2125000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">-374000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">-1392000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">-673000000</ifrs-full:DeferredTaxLiabilityAsset>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">125000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">1307000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">1026000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">2273000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">374000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">2727000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">7832000000</nvs:GrossDeferredTaxAssets>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">381000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">4704000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">591000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">148000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">1335000000</nvs:GrossDeferredTaxLiabilities>
    <nvs:GrossDeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">7159000000</nvs:GrossDeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">256000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">3397000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4PensionsAndOtherBenefitObligationsOfAssociatesMember"
      decimals="-6"
      unitRef="USD">-435000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4InventoriesMember"
      decimals="-6"
      unitRef="USD">-2125000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4TaxLossCarryforwardsMember"
      decimals="-6"
      unitRef="USD">-374000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4OtherAssetsProvisionsAccrualsMember"
      decimals="-6"
      unitRef="USD">-1392000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">-673000000</ifrs-full:DeferredTaxLiabilityAsset>
    <nvs:OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">4089000000</nvs:OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction>
    <ifrs-full:DeferredTaxAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      id="fact_188392_1"
      unitRef="USD">3743000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      id="fact_188393_1"
      unitRef="USD">3070000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">-673000000</ifrs-full:DeferredTaxLiabilityAsset>
    <nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment contextRef="AR_D-CurrentYear" decimals="-9" unitRef="USD">32000000000</nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment>
    <nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment contextRef="AR_D-CurrentYear-1" decimals="-9" unitRef="USD">29000000000</nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment>
    <ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_fef8869f-0f3a-4e52-8a6c-79ebf75d0d16_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Unrecognized&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Recognized&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022 total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Two years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            42
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Three years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Four years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            138
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            138
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            79
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            688
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            767
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;More than five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 880
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 380
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 260
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not subject to expiry&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            433
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            452
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            885
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 610
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            3 530
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 140
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Unrecognized&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rcognized&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021 total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Two years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Three years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            47
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Four years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            26
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            146
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            166
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;More than five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 536
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 872
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 408
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not subject to expiry&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            418
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            684
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 102
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 607
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 799
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Tax losses carried forward  that expired&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Deferred tax assets related to carry-forwards of taxable losses and tax credits of relevant Group entities are recognized to the extent it is considered probable that future taxable profits will be available in the respective tax jurisdictions against which such losses and credits can be utilized.&lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember"
      decimals="-6"
      unitRef="USD">18000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember"
      decimals="-6"
      unitRef="USD">0</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember"
      decimals="-6"
      unitRef="USD">18000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember"
      decimals="-6"
      unitRef="USD">37000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember"
      decimals="-6"
      unitRef="USD">5000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember"
      decimals="-6"
      unitRef="USD">42000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember"
      decimals="-6"
      unitRef="USD">25000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember"
      decimals="-6"
      unitRef="USD">5000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember"
      decimals="-6"
      unitRef="USD">30000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember"
      decimals="-6"
      unitRef="USD">138000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember"
      decimals="-6"
      unitRef="USD">0</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember"
      decimals="-6"
      unitRef="USD">138000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember"
      decimals="-6"
      unitRef="USD">79000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember"
      decimals="-6"
      unitRef="USD">688000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember"
      decimals="-6"
      unitRef="USD">767000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">3880000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">2380000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">6260000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember"
      decimals="-6"
      unitRef="USD">433000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember"
      decimals="-6"
      unitRef="USD">452000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember"
      decimals="-6"
      unitRef="USD">885000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember"
      decimals="-6"
      unitRef="USD">4610000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember"
      decimals="-6"
      unitRef="USD">3530000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">8140000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember"
      decimals="-6"
      unitRef="USD">15000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember"
      decimals="-6"
      unitRef="USD">4000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4OneYearMember"
      decimals="-6"
      unitRef="USD">19000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember"
      decimals="-6"
      unitRef="USD">14000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember"
      decimals="-6"
      unitRef="USD">6000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4TwoYearsMember"
      decimals="-6"
      unitRef="USD">20000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember"
      decimals="-6"
      unitRef="USD">37000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember"
      decimals="-6"
      unitRef="USD">10000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4ThreeYearsMember"
      decimals="-6"
      unitRef="USD">47000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember"
      decimals="-6"
      unitRef="USD">26000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember"
      decimals="-6"
      unitRef="USD">11000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FourYearsMember"
      decimals="-6"
      unitRef="USD">37000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember"
      decimals="-6"
      unitRef="USD">146000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember"
      decimals="-6"
      unitRef="USD">20000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4FiveYearsMember"
      decimals="-6"
      unitRef="USD">166000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">3536000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">1872000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4MoreThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">5408000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember"
      decimals="-6"
      unitRef="USD">418000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember"
      decimals="-6"
      unitRef="USD">684000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4YearOfExpiryAxis_nvs-2022Q4NotSubjectToExpiryMember"
      decimals="-6"
      unitRef="USD">1102000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4NotCapitalizedMember"
      decimals="-6"
      unitRef="USD">4192000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4BalanceSheetTreatmentAxis_nvs-2022Q4CapitalizedMember"
      decimals="-6"
      unitRef="USD">2607000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">6799000000</nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets>
    <nvs:ValueOfTaxLossCarryforwardsExpired contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6000000</nvs:ValueOfTaxLossCarryforwardsExpired>
    <nvs:ValueOfTaxLossCarryforwardsExpired contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">18000000</nvs:ValueOfTaxLossCarryforwardsExpired>
    <nvs:ValueOfTaxLossCarryforwardsExpired contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">14000000</nvs:ValueOfTaxLossCarryforwardsExpired>
    <nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_da3e00ae-1a4e-44d3-a58b-8e0992f9a90a_0">
          &lt;div&gt;
            &lt;div id="anchorId001540616"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;13. Financial and other non-current assets&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Financial assets&lt;/span&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 663
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            281
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            366
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 463
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 063
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term receivables from finance subleases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            59
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            70
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other long-term receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            184
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            607
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances and security deposits&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            85
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            78
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 411
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 036
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent consideration.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Other non-current assets&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred compensation plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            419
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            520
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid post-employment benefit plans&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            491
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 415
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other non-current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            200
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            275
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other non-current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 110
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 210
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 25 provides additional disclosures related to post-emplyment benefits.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock>
    <nvs:DisclosureOfFinancialAssetsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_96ec1835-1b4c-4401-b9ac-13346ec5d9b3_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 663
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            281
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            366
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 463
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 063
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term receivables from finance subleases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            59
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            70
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other long-term receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            184
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            607
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances and security deposits&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            85
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            78
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 411
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 036
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent consideration.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfFinancialAssetsTableTextBlock>
    <nvs:NoncurrentFinancialAssetsEquityInvestments
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1145000000</nvs:NoncurrentFinancialAssetsEquityInvestments>
    <nvs:NoncurrentFinancialAssetsEquityInvestments
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1663000000</nvs:NoncurrentFinancialAssetsEquityInvestments>
    <nvs:NoncurrentFinancialAsstetsDebtSecurities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">37000000</nvs:NoncurrentFinancialAsstetsDebtSecurities>
    <nvs:NoncurrentFinancialAsstetsDebtSecurities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">34000000</nvs:NoncurrentFinancialAsstetsDebtSecurities>
    <nvs:NoncurrentFinancialAssetsFundInvestments
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">281000000</nvs:NoncurrentFinancialAssetsFundInvestments>
    <nvs:NoncurrentFinancialAssetsFundInvestments
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">366000000</nvs:NoncurrentFinancialAssetsFundInvestments>
    <nvs:NoncurrentFinancialAssetsTotalFinancialInvestments
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1463000000</nvs:NoncurrentFinancialAssetsTotalFinancialInvestments>
    <nvs:NoncurrentFinancialAssetsTotalFinancialInvestments
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2063000000</nvs:NoncurrentFinancialAssetsTotalFinancialInvestments>
    <nvs:LongTermReceivablesFromFinanceSubleases
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">59000000</nvs:LongTermReceivablesFromFinanceSubleases>
    <nvs:LongTermReceivablesFromFinanceSubleases
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">70000000</nvs:LongTermReceivablesFromFinanceSubleases>
    <ifrs-full:OtherNoncurrentReceivables
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">197000000</ifrs-full:OtherNoncurrentReceivables>
    <ifrs-full:OtherNoncurrentReceivables
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">184000000</ifrs-full:OtherNoncurrentReceivables>
    <nvs:ContingentConsiderationReceivable
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">607000000</nvs:ContingentConsiderationReceivable>
    <nvs:ContingentConsiderationReceivable
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">641000000</nvs:ContingentConsiderationReceivable>
    <ifrs-full:NoncurrentLoansAndReceivables
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">85000000</ifrs-full:NoncurrentLoansAndReceivables>
    <ifrs-full:NoncurrentLoansAndReceivables
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">78000000</ifrs-full:NoncurrentLoansAndReceivables>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2411000000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">3036000000</ifrs-full:NoncurrentFinancialAssets>
    <nvs:DisclosureOfOtherNoncurrentAssetsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_d7b430c9-9886-4b81-b4d2-31ef5f94ab42_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred compensation plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            419
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            520
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid post-employment benefit plans&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            491
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 415
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other non-current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            200
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            275
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other non-current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 110
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 210
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 25 provides additional disclosures related to post-emplyment benefits.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfOtherNoncurrentAssetsTableTextBlock>
    <nvs:DeferredCompensationPlansAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">419000000</nvs:DeferredCompensationPlansAssets>
    <nvs:DeferredCompensationPlansAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">520000000</nvs:DeferredCompensationPlansAssets>
    <nvs:PrepaidPostemploymentBenefitPlansAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">491000000</nvs:PrepaidPostemploymentBenefitPlansAssets>
    <nvs:PrepaidPostemploymentBenefitPlansAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1415000000</nvs:PrepaidPostemploymentBenefitPlansAssets>
    <ifrs-full:OtherNoncurrentNonfinancialAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">200000000</ifrs-full:OtherNoncurrentNonfinancialAssets>
    <ifrs-full:OtherNoncurrentNonfinancialAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">275000000</ifrs-full:OtherNoncurrentNonfinancialAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1110000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2210000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:DisclosureOfInventoriesExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_5032009a-6aa4-4062-a7b9-d621a3480d37_0">
          &lt;div&gt;
            &lt;div id="anchorId001540869"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;14. Inventories&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Raw material, consumables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            934
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            870
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Work in progress&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 160
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Finished products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 568
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 636
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total inventories&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            7 175
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 666
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the amount of inventory recognized as an expense in &#x201c;Cost of goods sold&#x201d; in the consolidated income statements: &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD billions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-8.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8.8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the recognized amount of inventory provision and reversals of inventory provision recorded in the consolidated income statements:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventory provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-633&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-573&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-702&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversals of inventory provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            161
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            158
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            255
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The reversals mainly result from the release of products initially requiring additional quality control inspections and from the reassessment of inventory values manufactured prior to regulatory approval but for which approval was subsequently received.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfInventoriesExplanatory>
    <nvs:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_f6e7fa3c-88fa-4413-8727-cf0fcb316ece_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Raw material, consumables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            934
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            870
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Work in progress&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 673
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 160
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Finished products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 568
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 636
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total inventories&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            7 175
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 666
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ScheduleOfInventoryCurrentTableTextBlock>
    <ifrs-full:Inventories
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryRawMaterialsGrossMember"
      decimals="-6"
      unitRef="USD">934000000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryRawMaterialsGrossMember"
      decimals="-6"
      unitRef="USD">870000000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryWorkInProgressGrossMember"
      decimals="-6"
      unitRef="USD">3673000000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryWorkInProgressGrossMember"
      decimals="-6"
      unitRef="USD">3160000000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryFinishedGoodsGrossMember"
      decimals="-6"
      unitRef="USD">2568000000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4InventoryAxis_nvs-2022Q4InventoryFinishedGoodsGrossMember"
      decimals="-6"
      unitRef="USD">2636000000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">7175000000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">6666000000</ifrs-full:Inventories>
    <nvs:DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_df57547a-230d-496c-9cd5-296704619480_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD billions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cost of goods sold&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-8.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8.8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock>
    <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod contextRef="AR_D-CurrentYear" decimals="-8" unitRef="USD">8600000000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
    <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod contextRef="AR_D-CurrentYear-1" decimals="-8" unitRef="USD">8800000000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
    <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod contextRef="AR_D-CurrentYear-2" decimals="-8" unitRef="USD">8500000000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
    <nvs:DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_7fd1661e-2922-450e-b4de-f2a31c3b1a5b_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventory provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-633&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-573&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-702&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversals of inventory provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            161
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            158
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            255
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock>
    <ifrs-full:InventoryWritedown2011 contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">633000000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:InventoryWritedown2011 contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">573000000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:InventoryWritedown2011 contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">702000000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:ReversalOfInventoryWritedown contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">161000000</ifrs-full:ReversalOfInventoryWritedown>
    <ifrs-full:ReversalOfInventoryWritedown contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">158000000</ifrs-full:ReversalOfInventoryWritedown>
    <ifrs-full:ReversalOfInventoryWritedown contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">255000000</ifrs-full:ReversalOfInventoryWritedown>
    <nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_f73ea36a-c75c-4818-a468-1dfad9f0c0d2_0">
          &lt;div&gt;
            &lt;div id="anchorId001541050"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;15. Trade receivables&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total gross trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 128
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-83&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 066
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table summarizes the movement in the provision for doubtful trade receivables:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-83&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-93&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-95&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables charged to the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-47&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-39&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-59&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Utilization of provisions for doubtful trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of provisions for doubtful trade receivables credited to the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-83&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-93&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the trade receivables that are not overdue as specified in the payment terms and conditions established with Novartis customers, as well as an analysis of overdue amounts and related provisions for doubtful trade receivables:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not overdue&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 664
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 639
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for not more than one month&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            190
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            162
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than one month  but less than three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            110
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            99
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than three months  but less than six months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            62
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            63
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than six months  but less than one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            79
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            97
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-83&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 066
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Trade receivable balances represent amounts due from our customers, which are mainly drug wholesalers, retailers, private health systems, government agencies, managed care providers, pharmacy benefit managers and government-supported healthcare systems. We particularly monitor the level of trade receivables in countries deemed to have an elevated credit risk. We consider macroeconomic environment, historical experience, country and political risk, in addition to other relevant information when assessing risk. These risk factors are monitored regularly to determine any adjustments in risk classification. The majority of the past due trade receivables from elevated credit risk countries are due from local governments or from government-funded entities. Deteriorating credit and economic conditions as well as other factors in these elevated credit risk countries have resulted in, and may continue to result in, an increase in the average length of time that it takes to collect these &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;trade receivables, and may require the Group to re-evaluate the expected credit loss amount of these trade receivables in future periods. At December 31, 2022, amounts past due for more than one year are not significant in elevated credit risk countries.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Total trade receivables include amounts denominated in the following major currencies:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US dollar (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 709
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 344
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Euro (EUR)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 426
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 408
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Russian ruble (RUB)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            430
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            473
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japanese yen (JPY)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            383
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;British pound (GBP)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            176
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            200
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Chinese yuan (CNY)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            155
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canadian dollar (CAD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            151
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            139
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Brazilian real (BRL)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            129
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Australian dollar (AUD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            139
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Swiss franc (CHF)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            108
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other currencies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 452
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 066
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock>
    <nvs:ProvisionsForTradeReceivablesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_27283273-9f6e-461b-848e-dbcf49fd4433_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total gross trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 128
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-83&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 066
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ProvisionsForTradeReceivablesTableTextBlock>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">8128000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">8088000000</ifrs-full:CurrentTradeReceivables>
    <nvs:ProvisionForDoubtfulReceivable
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-62000000</nvs:ProvisionForDoubtfulReceivable>
    <nvs:ProvisionForDoubtfulReceivable
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-83000000</nvs:ProvisionForDoubtfulReceivable>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">8066000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">8005000000</ifrs-full:CurrentTradeReceivables>
    <nvs:TradeReceivablesProvisionMovementsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_a4cf83ab-8b48-4784-905d-00ee1c71a054_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-83&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-93&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-95&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables charged to the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-47&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-39&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-59&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Utilization of provisions for doubtful trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reversal of provisions for doubtful trade receivables credited to the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-83&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-93&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:TradeReceivablesProvisionMovementsTableTextBlock>
    <nvs:ProvisionForDoubtfulReceivable
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-83000000</nvs:ProvisionForDoubtfulReceivable>
    <nvs:ProvisionForDoubtfulReceivable
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-93000000</nvs:ProvisionForDoubtfulReceivable>
    <nvs:ProvisionForDoubtfulReceivable
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-95000000</nvs:ProvisionForDoubtfulReceivable>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">47000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">39000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">59000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">9000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">9000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">13000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">56000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">34000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">53000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-3000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-6000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">5000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <nvs:ProvisionForDoubtfulReceivable
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-62000000</nvs:ProvisionForDoubtfulReceivable>
    <nvs:ProvisionForDoubtfulReceivable
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-83000000</nvs:ProvisionForDoubtfulReceivable>
    <nvs:ProvisionForDoubtfulReceivable
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-93000000</nvs:ProvisionForDoubtfulReceivable>
    <nvs:OverdueAmountsAndRelatedProvisionsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_42fac49b-73e1-4115-9e94-319208dd20ab_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Not overdue&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 664
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 639
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for not more than one month&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            190
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            162
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than one month  but less than three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            110
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            99
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than three months  but less than six months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            62
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            63
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than six months  but less than one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past due for more than one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            79
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            97
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for doubtful trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-83&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 066
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:OverdueAmountsAndRelatedProvisionsTableTextBlock>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022CurrentMember"
      decimals="-6"
      unitRef="USD">7664000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022CurrentMember"
      decimals="-6"
      unitRef="USD">7639000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">190000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">162000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">110000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">99000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanThreeMonthsAndNotLaterThanSixMonthsMember"
      decimals="-6"
      unitRef="USD">62000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanThreeMonthsAndNotLaterThanSixMonthsMember"
      decimals="-6"
      unitRef="USD">63000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanSixMonthsAndNotLaterThanOneYearMember"
      decimals="-6"
      unitRef="USD">23000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanSixMonthsAndNotLaterThanOneYearMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneYearMember"
      decimals="-6"
      unitRef="USD">79000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022LaterThanOneYearMember"
      decimals="-6"
      unitRef="USD">97000000</ifrs-full:CurrentTradeReceivables>
    <nvs:ProvisionForDoubtfulReceivable
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-62000000</nvs:ProvisionForDoubtfulReceivable>
    <nvs:ProvisionForDoubtfulReceivable
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">-83000000</nvs:ProvisionForDoubtfulReceivable>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">8066000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">8005000000</ifrs-full:CurrentTradeReceivables>
    <nvs:TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_4ed1c8a4-a4f0-4aaf-8bc0-1123b55cb042_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US dollar (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 709
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 344
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Euro (EUR)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 426
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 408
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Russian ruble (RUB)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            430
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            473
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japanese yen (JPY)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            177
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            383
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;British pound (GBP)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            176
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            200
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Chinese yuan (CNY)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            155
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            197
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Canadian dollar (CAD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            151
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            139
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Brazilian real (BRL)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            129
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Australian dollar (AUD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            139
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Swiss franc (CHF)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            108
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            106
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other currencies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 452
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total trade receivables, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 066
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            8 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">3709000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">3344000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022EUR"
      decimals="-6"
      unitRef="USD">1426000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022EUR"
      decimals="-6"
      unitRef="USD">1408000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022RUB"
      decimals="-6"
      unitRef="USD">430000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022RUB"
      decimals="-6"
      unitRef="USD">473000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022JPY"
      decimals="-6"
      unitRef="USD">177000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022JPY"
      decimals="-6"
      unitRef="USD">383000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022GBP"
      decimals="-6"
      unitRef="USD">176000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022GBP"
      decimals="-6"
      unitRef="USD">200000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CNY"
      decimals="-6"
      unitRef="USD">155000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CNY"
      decimals="-6"
      unitRef="USD">197000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CAD"
      decimals="-6"
      unitRef="USD">151000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CAD"
      decimals="-6"
      unitRef="USD">139000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022BRL"
      decimals="-6"
      unitRef="USD">145000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022BRL"
      decimals="-6"
      unitRef="USD">129000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022AUD"
      decimals="-6"
      unitRef="USD">137000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022AUD"
      decimals="-6"
      unitRef="USD">139000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CHF"
      decimals="-6"
      unitRef="USD">108000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022CHF"
      decimals="-6"
      unitRef="USD">106000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember"
      decimals="-6"
      unitRef="USD">1452000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember"
      decimals="-6"
      unitRef="USD">1487000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">8066000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">8005000000</ifrs-full:CurrentTradeReceivables>
    <nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_fbde2a37-0b03-4c19-8afb-4b1a02a898d4_0">
          &lt;div&gt;
            &lt;div id="anchorId001541600"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;16. Marketable securities, commodities, time&#160;deposits, derivative financial instruments, and&#160;cash and cash equivalents&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Marketable securities, commodities, time&#160;deposits and derivative financial instruments&lt;/span&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 741
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 089
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12 965
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities, commodities, time deposits and derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            11 413
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 922
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The vast majority of debt securities, time deposits and short-term investments with an original maturity of more than 90 days was denominated in USD as of December 31, 2022, and 2021.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Cash and cash equivalents&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current accounts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 877
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 396
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity less than 90 days&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 640
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 011
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            7 517
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12 407
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock>
    <nvs:MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_b41d913b-b489-40a7-83fa-36416ec482f8_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 741
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 089
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12 965
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities, commodities, time deposits and derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            11 413
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 922
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock>
    <nvs:Commodities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">111000000</nvs:Commodities>
    <nvs:Commodities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">111000000</nvs:Commodities>
    <ifrs-full:DebtInstrumentsHeld
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">9000000</ifrs-full:DebtInstrumentsHeld>
    <ifrs-full:DebtInstrumentsHeld
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2741000000</ifrs-full:DebtInstrumentsHeld>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">11089000000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">12965000000</ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents>
    <ifrs-full:DerivativeFinancialAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">204000000</ifrs-full:DerivativeFinancialAssets>
    <ifrs-full:DerivativeFinancialAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">105000000</ifrs-full:DerivativeFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">11413000000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">15922000000</ifrs-full:OtherCurrentFinancialAssets>
    <nvs:CashAndCashEquivalentsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_c88db9cb-b5c8-4320-a87f-b61288c27692_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current accounts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 877
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 396
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity less than 90 days&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 640
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9 011
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            7 517
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            12 407
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:CashAndCashEquivalentsTableTextBlock>
    <ifrs-full:Cash
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2877000000</ifrs-full:Cash>
    <ifrs-full:Cash
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">3396000000</ifrs-full:Cash>
    <ifrs-full:CashEquivalents
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">4640000000</ifrs-full:CashEquivalents>
    <ifrs-full:CashEquivalents
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">9011000000</ifrs-full:CashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">7517000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">12407000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_c32ba237-8240-447b-8878-1cd938c97e0c_0">
          &lt;div&gt;
            &lt;div id="anchorId001541756"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;17. Other current assets&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;VAT receivable&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            509
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Withholding tax recoverable&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            50
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            58
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid expenses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            911
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 102
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivable&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other receivables and current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            793
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 471
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 440
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent consideration.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory>
    <nvs:OtherCurrentAssetsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_1e96bbe9-d118-4208-9bf8-9c979a6e352c_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;VAT receivable&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            509
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Withholding tax recoverable&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            50
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            58
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid expenses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            911
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 102
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivable&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other receivables and current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            793
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total other current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 471
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 440
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent consideration.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:OtherCurrentAssetsTableTextBlock>
    <ifrs-full:CurrentValueAddedTaxReceivables
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">509000000</ifrs-full:CurrentValueAddedTaxReceivables>
    <ifrs-full:CurrentValueAddedTaxReceivables
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">487000000</ifrs-full:CurrentValueAddedTaxReceivables>
    <nvs:WithholdingTaxRecoverable
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">50000000</nvs:WithholdingTaxRecoverable>
    <nvs:WithholdingTaxRecoverable
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">58000000</nvs:WithholdingTaxRecoverable>
    <nvs:CurrentPrepaidExpensesThirdParty
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">911000000</nvs:CurrentPrepaidExpensesThirdParty>
    <nvs:CurrentPrepaidExpensesThirdParty
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1102000000</nvs:CurrentPrepaidExpensesThirdParty>
    <nvs:ContingentConsiderationReceivableCurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">43000000</nvs:ContingentConsiderationReceivableCurrent>
    <nvs:OtherReceivablesAndCurrentAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">958000000</nvs:OtherReceivablesAndCurrentAssets>
    <nvs:OtherReceivablesAndCurrentAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">793000000</nvs:OtherReceivablesAndCurrentAssets>
    <ifrs-full:OtherCurrentNonfinancialAssets
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2471000000</ifrs-full:OtherCurrentNonfinancialAssets>
    <ifrs-full:OtherCurrentNonfinancialAssets
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2440000000</ifrs-full:OtherCurrentNonfinancialAssets>
    <nvs:DisclosureOfEquityTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_65b76240-e213-4420-b104-9b747734330c_0">
          &lt;div&gt;
            &lt;div id="anchorId001541870"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;18. Equity&lt;/div&gt;
            &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the movement in the share capital:&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Jan 1, 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Movement&lt;br/&gt; in year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Dec 31, 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Movement&lt;br/&gt; in year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Dec 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Movement&lt;br/&gt; in year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt; Dec 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Share capital&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            936
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-23&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            913
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            901
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-11&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            890
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Treasury shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-80&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            27
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-53&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-48&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-92&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding share capital&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            856
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            860
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            853
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            798
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; The Novartis AG share capital consists of registered shares with a nominal value of CHF 0.50 each. No authorized and conditional capital exists.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the movement in the shares:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;Number of outstanding shares &lt;br/&gt;(in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br/&gt; Novartis &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br/&gt; treasury &lt;br/&gt; shares&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; Novartis &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; treasury &lt;br/&gt; shares&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; Novartis &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; treasury &lt;br/&gt; shares&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance at beginning of year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 434.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-199.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 234.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 467.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-210.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 256.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 527.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-262.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 265.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares canceled for capital  reduction&lt;sup style="white-space: nowrap"&gt; &#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-30.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            32.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-60.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            60.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares acquired to be  canceled&lt;sup style="white-space: nowrap"&gt; &#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-126.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-126.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share purchases&lt;sup style="white-space: nowrap"&gt;&#160;4&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1.4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1.4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise of options  and employee transactions&lt;sup style="white-space: nowrap"&gt; &#160;5&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;   18.9&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation&lt;sup style="white-space: nowrap"&gt;&#160;5&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares delivered to Alcon employees&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total movements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-30.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-84.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-115.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-32.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-21.9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-60.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            52.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-8.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance at end of year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 403.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-284.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 119.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 434.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-199.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 234.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 467.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-210.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 256.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Approximately 99.0 million treasury shares (2021: 102.5 million; 2020: 103.0 million) are held in Novartis entities that restrict their availability for use.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Novartis reduced its share capital by canceling shares that were repurchased on the SIX Swiss Exchange second trading line during previous years.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt;
                            &lt;span&gt; Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2019 Annual General Meeting (AGM) for transactions after February 28, 2019, until March 2, 2021. Transactions after March 2, 2021, were executed under the CHF 10 billion share buyback authority approved at the 2021 AGM and the additional CHF 10 billion authority approved at the 2022 AGM.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;4&#160;&lt;/sup&gt; Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;5&#160;&lt;/sup&gt; Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;18.1) The amount available for distribution as a dividend to shareholders is based on the available distributable retained earnings of Novartis AG determined in accordance with the legal provisions of the Swiss Code of Obligations.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dividend per share (in CHF)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3.00
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.95
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total dividend payment  (in USD billion)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;18.2) The following table summarizes the treasury shares movements:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Number of &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;br/&gt; (in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Equity impact&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Number of &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;br/&gt; (in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Equity impact&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Number of &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;br/&gt; (in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Equity impact&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares acquired to be canceled&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-126.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-10 787&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 775&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 897&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share purchases&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1.4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-123&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-145&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-159&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchase of treasury shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-127.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-10 910&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 920&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-34.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 056&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise of options and employee transactions&lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18.9&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            88
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            806
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation&lt;sup style="white-space: nowrap"&gt;&#160;4&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            854
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            745
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            730
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares delivered to Alcon employees&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            30
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-115.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-9 963&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-21.9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 119&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-8.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 490&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2019 Annual General Meeting (AGM) for transactions after February 28, 2019, until March 2, 2021. Transactions after March 2, 2021, were executed under the CHF 10 billion share buyback authority approved at the 2021 AGM and the additional CHF 10 billion authority approved at the 2022 AGM.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt; Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price, reflecting the strike price of the options exercised.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;4&#160;&lt;/sup&gt; Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax-deductible amounts exceeding the expense recognized in the income statement are credited to equity.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.3) In December 2021, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD 15.0 billion share buyback. The arrangement was updated in July 2022. Novartis is able to cancel this arrangement at any time but could be subject to a 90-day waiting period. &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As of December 31, 2022, these waiting period conditions were not applicable and as a result, there was no requirement to record a liability under this arrangement as of December 31, 2022. The liability under this arrangement amounted to USD 2.8 billion as of December 31, 2021.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In June 2021, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares to mitigate dilution related to participation plans of employees. Novartis would have been able to cancel this arrangement at any time but would have been subject to a 90-day waiting period.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;This trading plan commitment was fully executed and expired in June 2021, and as a consequence, there is &lt;span&gt;no&lt;/span&gt; liability related to this plan recognized as of December 31, 2021.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In November 2020, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD 2.5 billion share buyback. Novartis would have been able to cancel this arrangement at any time, but would have been subject to a 90-day waiting period. The commitment under this arrangement therefore reflected the obligated purchases by the bank under such trading plan over a rolling 90-day period, or if shorter, until the maturity date of such trading plan.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The commitment under this arrangement amounted to USD 1.8 billion as of December 31, 2020. This trading plan commitment was fully executed and expired in March 2021, and as a consequence, there is no liability related to this plan recognized as of December 31, 2021.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In August 2020, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares to mitigate dilution related to participation plans of associates. Novartis would have been able to cancel this arrangement at any time but would have been subjected to a 90-day waiting period. &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;This trading plan commitment was fully executed and expired, and as a consequence, there is no liability related to this plan recognized as of December 31, 2020.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.4) In October 2020, Novartis entered into an agreement with the market maker for its employee options to repurchase a portion of the outstanding written call options. A total of 3.7 million options were repurchased under this agreement. This agreement was terminated in November 2020.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.5) The impact of change in ownership of consolidated entities represents the excess of the amount paid to non-controlling interest over their carrying value and equity allocation to non-controlling interest due to change in ownership percentage. &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.6) Changes in non-controlling interests represent the impact on the non-controlling interest of transactions with minority shareholders, such as change in ownership percentage, dividend payments and other equity transactions. &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.7) Other movements include, for subsidiaries in hyperinflationary economies, the impact of the restatement of the equity balances of the current year as well as restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period. See Note 29 for additional disclosures.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.8) In 2021, transaction costs that were directly attributable to the distribution (spin-off) of Alcon Inc. to Novartis AG shareholders and that would otherwise have been avoided, were recorded to equity.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;18.9) At December 31, 2022, the market maker held 3 million (2021: 3 million; 2020: 1 million) written call options, originally issued as part of the share-based compensation for employees, that have not yet been exercised. The weighted average exercise price of these options is USD 66.07 (2021: USD 61.45; 2020: USD 60.09), and they have contractual lives of 10 years, with remaining lives less than one year (2021: two years; 2020: three years). &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </nvs:DisclosureOfEquityTextBlock>
    <nvs:MovementInTheShareCapitalTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_d25e93f2-0c04-4397-8626-86f2242c460a_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Jan 1, 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Movement&lt;br/&gt; in year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Dec 31, 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Movement&lt;br/&gt; in year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Dec 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Movement&lt;br/&gt; in year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt; Dec 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Share capital&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            936
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-23&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            913
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            901
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-11&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            890
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Treasury shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-80&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            27
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-53&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-48&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-92&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding share capital&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            856
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            860
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            853
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            798
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; The Novartis AG share capital consists of registered shares with a nominal value of CHF 0.50 each. No authorized and conditional capital exists.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:MovementInTheShareCapitalTableTextBlock>
    <ifrs-full:IssuedCapital
      contextRef="AR_I-CurrentYearEnd-3"
      decimals="-6"
      unitRef="USD">936000000</ifrs-full:IssuedCapital>
    <nvs:IssuedCapitalMovement contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-23000000</nvs:IssuedCapitalMovement>
    <ifrs-full:IssuedCapital
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">913000000</ifrs-full:IssuedCapital>
    <nvs:IssuedCapitalMovement contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-12000000</nvs:IssuedCapitalMovement>
    <ifrs-full:IssuedCapital
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">901000000</ifrs-full:IssuedCapital>
    <nvs:IssuedCapitalMovement contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-11000000</nvs:IssuedCapitalMovement>
    <ifrs-full:IssuedCapital
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">890000000</ifrs-full:IssuedCapital>
    <ifrs-full:TreasuryShares
      contextRef="AR_I-CurrentYearEnd-3"
      decimals="-6"
      unitRef="USD">80000000</ifrs-full:TreasuryShares>
    <nvs:TreasurySharesMovementOfPeriod contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">27000000</nvs:TreasurySharesMovementOfPeriod>
    <ifrs-full:TreasuryShares
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">53000000</ifrs-full:TreasuryShares>
    <nvs:TreasurySharesMovementOfPeriod contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">5000000</nvs:TreasurySharesMovementOfPeriod>
    <ifrs-full:TreasuryShares
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">48000000</ifrs-full:TreasuryShares>
    <nvs:TreasurySharesMovementOfPeriod contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-44000000</nvs:TreasurySharesMovementOfPeriod>
    <ifrs-full:TreasuryShares
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">92000000</ifrs-full:TreasuryShares>
    <nvs:OutstandingShareCapital
      contextRef="AR_I-CurrentYearEnd-3"
      decimals="-6"
      unitRef="USD">856000000</nvs:OutstandingShareCapital>
    <nvs:OutstandingShareCapitalMovement contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">4000000</nvs:OutstandingShareCapitalMovement>
    <nvs:OutstandingShareCapital
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">860000000</nvs:OutstandingShareCapital>
    <nvs:OutstandingShareCapitalMovement contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-7000000</nvs:OutstandingShareCapitalMovement>
    <nvs:OutstandingShareCapital
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">853000000</nvs:OutstandingShareCapital>
    <nvs:OutstandingShareCapitalMovement contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-55000000</nvs:OutstandingShareCapitalMovement>
    <nvs:OutstandingShareCapital
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">798000000</nvs:OutstandingShareCapital>
    <ifrs-full:ParValuePerShare
      contextRef="AR_I-CurrentYearEnd"
      decimals="2"
      unitRef="CHFPerShares">0.50</ifrs-full:ParValuePerShare>
    <nvs:MovementInTheShareslTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_1d1ab5f2-9907-4658-a900-7ccd59ec7514_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;Number of outstanding shares &lt;br/&gt;(in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br/&gt; Novartis &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br/&gt; treasury &lt;br/&gt; shares&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; Novartis &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; treasury &lt;br/&gt; shares&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; Novartis &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; treasury &lt;br/&gt; shares&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance at beginning of year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 434.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-199.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 234.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 467.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-210.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 256.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 527.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-262.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:4%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 265.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares canceled for capital  reduction&lt;sup style="white-space: nowrap"&gt; &#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-30.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            32.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-60.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            60.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares acquired to be  canceled&lt;sup style="white-space: nowrap"&gt; &#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-126.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-126.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share purchases&lt;sup style="white-space: nowrap"&gt;&#160;4&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1.4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1.4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise of options  and employee transactions&lt;sup style="white-space: nowrap"&gt; &#160;5&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;   18.9&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation&lt;sup style="white-space: nowrap"&gt;&#160;5&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares delivered to Alcon employees&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total movements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-30.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-84.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-115.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-32.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-21.9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-60.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            52.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-8.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Balance at end of year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 403.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-284.1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 119.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 434.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-199.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 234.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 467.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-210.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 256.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="22" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Approximately 99.0 million treasury shares (2021: 102.5 million; 2020: 103.0 million) are held in Novartis entities that restrict their availability for use.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Novartis reduced its share capital by canceling shares that were repurchased on the SIX Swiss Exchange second trading line during previous years.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt;
                            &lt;span&gt; Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2019 Annual General Meeting (AGM) for transactions after February 28, 2019, until March 2, 2021. Transactions after March 2, 2021, were executed under the CHF 10 billion share buyback authority approved at the 2021 AGM and the additional CHF 10 billion authority approved at the 2022 AGM.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;4&#160;&lt;/sup&gt; Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;5&#160;&lt;/sup&gt; Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="22"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:MovementInTheShareslTableTextBlock>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">2434400000</ifrs-full:NumberOfSharesIssued>
    <nvs:NumberOfTreasuryShares
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-199500000</nvs:NumberOfTreasuryShares>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-5"
      unitRef="Shares">2234900000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">2467000000.0</ifrs-full:NumberOfSharesIssued>
    <nvs:NumberOfTreasuryShares
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-210200000</nvs:NumberOfTreasuryShares>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-5"
      unitRef="Shares">2256800000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">2527300000</ifrs-full:NumberOfSharesIssued>
    <nvs:NumberOfTreasuryShares
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-262300000</nvs:NumberOfTreasuryShares>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AR_I-CurrentYearEnd-3"
      decimals="-5"
      unitRef="Shares">2265000000.0</ifrs-full:NumberOfSharesOutstanding>
    <nvs:SharesCancelledForCapitalReduction
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">-30700000</nvs:SharesCancelledForCapitalReduction>
    <nvs:SharesCancelledForCapitalReduction
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">30700000</nvs:SharesCancelledForCapitalReduction>
    <nvs:SharesCancelledForCapitalReduction
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">-32600000</nvs:SharesCancelledForCapitalReduction>
    <nvs:SharesCancelledForCapitalReduction
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">32600000</nvs:SharesCancelledForCapitalReduction>
    <nvs:SharesCancelledForCapitalReduction
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">-60300000</nvs:SharesCancelledForCapitalReduction>
    <nvs:SharesCancelledForCapitalReduction
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">60300000</nvs:SharesCancelledForCapitalReduction>
    <nvs:TreasurySharesAcquiredToBeCancelled
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-126200000</nvs:TreasurySharesAcquiredToBeCancelled>
    <nvs:TreasurySharesAcquiredToBeCancelled
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">-126200000</nvs:TreasurySharesAcquiredToBeCancelled>
    <nvs:TreasurySharesAcquiredToBeCancelled
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-30700000</nvs:TreasurySharesAcquiredToBeCancelled>
    <nvs:TreasurySharesAcquiredToBeCancelled
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">-30700000</nvs:TreasurySharesAcquiredToBeCancelled>
    <nvs:TreasurySharesAcquiredToBeCancelled
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-32600000</nvs:TreasurySharesAcquiredToBeCancelled>
    <nvs:TreasurySharesAcquiredToBeCancelled
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">-32600000</nvs:TreasurySharesAcquiredToBeCancelled>
    <nvs:OtherSharePurchases
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-1400000</nvs:OtherSharePurchases>
    <nvs:OtherSharePurchases
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">-1400000</nvs:OtherSharePurchases>
    <nvs:OtherSharePurchases
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-1500000</nvs:OtherSharePurchases>
    <nvs:OtherSharePurchases
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">-1500000</nvs:OtherSharePurchases>
    <nvs:OtherSharePurchases
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-1700000</nvs:OtherSharePurchases>
    <nvs:OtherSharePurchases
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">-1700000</nvs:OtherSharePurchases>
    <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">1900000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
    <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">1900000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
    <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">600000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
    <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">600000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
    <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">14700000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
    <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">14700000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
    <nvs:EquityBasedCompensationShares
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">10400000</nvs:EquityBasedCompensationShares>
    <nvs:EquityBasedCompensationShares
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">10400000</nvs:EquityBasedCompensationShares>
    <nvs:EquityBasedCompensationShares
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">9600000</nvs:EquityBasedCompensationShares>
    <nvs:EquityBasedCompensationShares
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">9600000</nvs:EquityBasedCompensationShares>
    <nvs:EquityBasedCompensationShares
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">11000000.0</nvs:EquityBasedCompensationShares>
    <nvs:EquityBasedCompensationShares
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">11000000.0</nvs:EquityBasedCompensationShares>
    <nvs:SharesDeliveredToDivestedBusinessEmployees
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">0.0</nvs:SharesDeliveredToDivestedBusinessEmployees>
    <nvs:SharesDeliveredToDivestedBusinessEmployees
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">0.0</nvs:SharesDeliveredToDivestedBusinessEmployees>
    <nvs:SharesDeliveredToDivestedBusinessEmployees
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">100000</nvs:SharesDeliveredToDivestedBusinessEmployees>
    <nvs:SharesDeliveredToDivestedBusinessEmployees
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">100000</nvs:SharesDeliveredToDivestedBusinessEmployees>
    <nvs:SharesDeliveredToDivestedBusinessEmployees
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">400000</nvs:SharesDeliveredToDivestedBusinessEmployees>
    <nvs:SharesDeliveredToDivestedBusinessEmployees
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">400000</nvs:SharesDeliveredToDivestedBusinessEmployees>
    <nvs:ShareMovements
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">-30700000</nvs:ShareMovements>
    <nvs:ShareMovements
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-84600000</nvs:ShareMovements>
    <nvs:ShareMovements
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">-115300000</nvs:ShareMovements>
    <nvs:ShareMovements
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">-32600000</nvs:ShareMovements>
    <nvs:ShareMovements
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">10700000</nvs:ShareMovements>
    <nvs:ShareMovements
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">-21900000</nvs:ShareMovements>
    <nvs:ShareMovements
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">-60300000</nvs:ShareMovements>
    <nvs:ShareMovements
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">52100000</nvs:ShareMovements>
    <nvs:ShareMovements
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">-8200000</nvs:ShareMovements>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">2403700000</ifrs-full:NumberOfSharesIssued>
    <nvs:NumberOfTreasuryShares
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-284100000</nvs:NumberOfTreasuryShares>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AR_I-CurrentYearEnd"
      decimals="-5"
      unitRef="Shares">2119600000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">2434400000</ifrs-full:NumberOfSharesIssued>
    <nvs:NumberOfTreasuryShares
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-199500000</nvs:NumberOfTreasuryShares>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-5"
      unitRef="Shares">2234900000</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022OrdinarySharesMember"
      decimals="-5"
      unitRef="Shares">2467000000.0</ifrs-full:NumberOfSharesIssued>
    <nvs:NumberOfTreasuryShares
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">-210200000</nvs:NumberOfTreasuryShares>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-5"
      unitRef="Shares">2256800000</ifrs-full:NumberOfSharesOutstanding>
    <nvs:TreasurySharesWithRestrictedUse
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">99000000.0</nvs:TreasurySharesWithRestrictedUse>
    <nvs:TreasurySharesWithRestrictedUse
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">102500000</nvs:TreasurySharesWithRestrictedUse>
    <nvs:TreasurySharesWithRestrictedUse
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfShareCapitalAxis_ifrsfull-2022TreasurySharesMember"
      decimals="-5"
      unitRef="Shares">103000000.0</nvs:TreasurySharesWithRestrictedUse>
    <nvs:StockRepurchaseProgramAuthorizedAmount1
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-9"
      unitRef="CHF">10000000000</nvs:StockRepurchaseProgramAuthorizedAmount1>
    <nvs:StockRepurchaseProgramAuthorizedAmount1
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-9"
      unitRef="CHF">10000000000</nvs:StockRepurchaseProgramAuthorizedAmount1>
    <nvs:StockRepurchaseProgramAuthorizedAmount1
      contextRef="AR_I-CurrentYearEnd"
      decimals="-9"
      unitRef="CHF">10000000000</nvs:StockRepurchaseProgramAuthorizedAmount1>
    <nvs:DividendTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_e216b00c-07fd-49f5-8c14-87888746560c_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dividend per share (in CHF)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3.00
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.95
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total dividend payment  (in USD billion)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DividendTableTextBlock>
    <nvs:DividendsPayableAmountPerShare
      contextRef="AR_I-CurrentYearEnd"
      decimals="2"
      unitRef="CHFPerShares">3.10</nvs:DividendsPayableAmountPerShare>
    <nvs:DividendsPayableAmountPerShare
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="2"
      unitRef="CHFPerShares">3.00</nvs:DividendsPayableAmountPerShare>
    <nvs:DividendsPayableAmountPerShare
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="2"
      unitRef="CHFPerShares">2.95</nvs:DividendsPayableAmountPerShare>
    <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear" decimals="-8" unitRef="USD">7500000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear-1" decimals="-8" unitRef="USD">7400000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid contextRef="AR_D-CurrentYear-2" decimals="-8" unitRef="USD">7000000000.0</ifrs-full:DividendsPaid>
    <nvs:SummaryOfTreasurySharesMovementsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_02eb7cbf-331a-4c27-83f1-344a6ae8754e_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Number of &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;br/&gt; (in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Equity impact&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Number of &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;br/&gt; (in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Equity impact&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Number of &lt;br/&gt; outstanding &lt;br/&gt; shares&lt;br/&gt; (in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Equity impact&lt;br/&gt; USD m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares acquired to be canceled&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-126.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-10 787&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 775&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:6%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 897&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other share purchases&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1.4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-123&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-145&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-159&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchase of treasury shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-127.6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-10 910&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 920&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-34.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 056&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Exercise of options and employee transactions&lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18.9&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            88
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            806
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation&lt;sup style="white-space: nowrap"&gt;&#160;4&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            854
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            9.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            745
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            730
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Shares delivered to Alcon employees&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            30
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-115.3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-9 963&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-21.9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 119&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-8.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 490&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="16" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2019 Annual General Meeting (AGM) for transactions after February 28, 2019, until March 2, 2021. Transactions after March 2, 2021, were executed under the CHF 10 billion share buyback authority approved at the 2021 AGM and the additional CHF 10 billion authority approved at the 2022 AGM.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt; Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price, reflecting the strike price of the options exercised.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;4&#160;&lt;/sup&gt; Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax-deductible amounts exceeding the expense recognized in the income statement are credited to equity.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="16"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:SummaryOfTreasurySharesMovementsTableTextBlock>
    <nvs:TreasurySharesAcquiredToBeCancelled
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">-126200000</nvs:TreasurySharesAcquiredToBeCancelled>
    <nvs:TreasurySharesAcquiredForCancellationValue contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">10787000000</nvs:TreasurySharesAcquiredForCancellationValue>
    <nvs:TreasurySharesAcquiredToBeCancelled
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">-30700000</nvs:TreasurySharesAcquiredToBeCancelled>
    <nvs:TreasurySharesAcquiredForCancellationValue contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2775000000</nvs:TreasurySharesAcquiredForCancellationValue>
    <nvs:TreasurySharesAcquiredToBeCancelled
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">-32600000</nvs:TreasurySharesAcquiredToBeCancelled>
    <nvs:TreasurySharesAcquiredForCancellationValue contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">2897000000</nvs:TreasurySharesAcquiredForCancellationValue>
    <nvs:OtherSharePurchases
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">-1400000</nvs:OtherSharePurchases>
    <nvs:OtherSharePurchasesValue contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">123000000</nvs:OtherSharePurchasesValue>
    <nvs:OtherSharePurchases
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">-1500000</nvs:OtherSharePurchases>
    <nvs:OtherSharePurchasesValue contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">145000000</nvs:OtherSharePurchasesValue>
    <nvs:OtherSharePurchases
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">-1700000</nvs:OtherSharePurchases>
    <nvs:OtherSharePurchasesValue contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">159000000</nvs:OtherSharePurchasesValue>
    <nvs:SharepurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">-127600000</nvs:SharepurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">10910000000</ifrs-full:PurchaseOfTreasuryShares>
    <nvs:SharepurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">-32200000</nvs:SharepurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2920000000</ifrs-full:PurchaseOfTreasuryShares>
    <nvs:SharepurchaseOfTreasuryShares
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">-34300000</nvs:SharepurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">3056000000</ifrs-full:PurchaseOfTreasuryShares>
    <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">1900000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">88000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">600000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">39000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <nvs:ExerciseOfOptionsAndEmployeeTransactionsShares
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">14700000</nvs:ExerciseOfOptionsAndEmployeeTransactionsShares>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">806000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <nvs:EquityBasedCompensationShares
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">10400000</nvs:EquityBasedCompensationShares>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">854000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <nvs:EquityBasedCompensationShares
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">9600000</nvs:EquityBasedCompensationShares>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">745000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <nvs:EquityBasedCompensationShares
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">11000000.0</nvs:EquityBasedCompensationShares>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">730000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <nvs:SharesDeliveredToDivestedBusinessEmployees
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">0.0</nvs:SharesDeliveredToDivestedBusinessEmployees>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">5000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:SharesDeliveredToDivestedBusinessEmployees
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">100000</nvs:SharesDeliveredToDivestedBusinessEmployees>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">17000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:SharesDeliveredToDivestedBusinessEmployees
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">400000</nvs:SharesDeliveredToDivestedBusinessEmployees>
    <nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">30000000</nvs:SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff>
    <nvs:TreasurySharesMovement
      contextRef="AR_D-CurrentYear"
      decimals="-5"
      unitRef="Shares">-115300000</nvs:TreasurySharesMovement>
    <nvs:EquityImpactOfTreasuryShareMovements contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">9963000000</nvs:EquityImpactOfTreasuryShareMovements>
    <nvs:TreasurySharesMovement
      contextRef="AR_D-CurrentYear-1"
      decimals="-5"
      unitRef="Shares">-21900000</nvs:TreasurySharesMovement>
    <nvs:EquityImpactOfTreasuryShareMovements contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2119000000</nvs:EquityImpactOfTreasuryShareMovements>
    <nvs:TreasurySharesMovement
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Shares">-8200000</nvs:TreasurySharesMovement>
    <nvs:EquityImpactOfTreasuryShareMovements contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1490000000</nvs:EquityImpactOfTreasuryShareMovements>
    <nvs:StockRepurchaseProgramAuthorizedAmount1
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-9"
      unitRef="CHF">10000000000</nvs:StockRepurchaseProgramAuthorizedAmount1>
    <nvs:StockRepurchaseProgramAuthorizedAmount1
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-9"
      unitRef="CHF">10000000000</nvs:StockRepurchaseProgramAuthorizedAmount1>
    <nvs:StockRepurchaseProgramAuthorizedAmount1
      contextRef="AR_I-CurrentYearEnd"
      decimals="-9"
      unitRef="CHF">10000000000</nvs:StockRepurchaseProgramAuthorizedAmount1>
    <nvs:MaximalAmountOfShareBuybackProgramm contextRef="AR_D-CurrentYear-1" decimals="-8" unitRef="USD">15000000000.0</nvs:MaximalAmountOfShareBuybackProgramm>
    <nvs:CommitmentForRepurchaseOwnShares
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-8"
      unitRef="USD">2800000000</nvs:CommitmentForRepurchaseOwnShares>
    <nvs:MaximalAmountOfShareBuybackProgramm contextRef="AR_D-CurrentYear-2" decimals="-8" unitRef="USD">2500000000</nvs:MaximalAmountOfShareBuybackProgramm>
    <nvs:CommitmentForRepurchaseOwnShares
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-8"
      unitRef="USD">1800000000</nvs:CommitmentForRepurchaseOwnShares>
    <nvs:NumberOfOptionsRepurchased
      contextRef="AR_D-CurrentYear-2"
      decimals="-5"
      unitRef="Pure">-3700000</nvs:NumberOfOptionsRepurchased>
    <nvs:WrittenCallOptionsHeldByMarketMaker
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="Pure">3000000</nvs:WrittenCallOptionsHeldByMarketMaker>
    <nvs:WrittenCallOptionsHeldByMarketMaker
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="Pure">3000000</nvs:WrittenCallOptionsHeldByMarketMaker>
    <nvs:WrittenCallOptionsHeldByMarketMaker
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="Pure">1000000</nvs:WrittenCallOptionsHeldByMarketMaker>
    <nvs:WrittenCallOptionsWeightedAverageExercisePrice
      contextRef="AR_I-CurrentYearEnd"
      decimals="2"
      unitRef="USDPerShares">66.07</nvs:WrittenCallOptionsWeightedAverageExercisePrice>
    <nvs:WrittenCallOptionsWeightedAverageExercisePrice
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="2"
      unitRef="USDPerShares">61.45</nvs:WrittenCallOptionsWeightedAverageExercisePrice>
    <nvs:WrittenCallOptionsWeightedAverageExercisePrice
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="2"
      unitRef="USDPerShares">60.09</nvs:WrittenCallOptionsWeightedAverageExercisePrice>
    <nvs:WrittenCallOptionsContractualLive
      contextRef="AR_I-CurrentYearEnd"
      decimals="0"
      unitRef="Year">10</nvs:WrittenCallOptionsContractualLive>
    <nvs:WrittenCallOptionsContractualLiveRemaining
      contextRef="AR_I-CurrentYearEnd"
      decimals="0"
      unitRef="Year">1</nvs:WrittenCallOptionsContractualLiveRemaining>
    <nvs:WrittenCallOptionsContractualLiveRemaining
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="0"
      unitRef="Year">2</nvs:WrittenCallOptionsContractualLiveRemaining>
    <nvs:WrittenCallOptionsContractualLiveRemaining
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="0"
      unitRef="Year">3</nvs:WrittenCallOptionsContractualLiveRemaining>
    <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_9f7c9745-fccb-433d-bffe-01272e47b67a_0">
          &lt;div&gt;
            &lt;div id="anchorId001543765"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;19. Non-current financial debt&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            22 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Liabilities to banks and other financial institutions&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            227
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total, including current portion of non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion of non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 241&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 621&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            20 244
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            22 902
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Average interest rate 2.3% (2021: 0.9%)&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;All bonds are initially recorded at the amount of proceeds received, net of transaction costs. They are subsequently carried at amortized cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognized as a charge to the consolidated income statement over the period of the relevant bond. Financial debts, including current financial debts, contain only general default covenants. The Group is in compliance with these covenants.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The percentage of fixed-rate financial debt to total financial debt was &lt;span&gt;86%&lt;/span&gt; at December 31, 2022, and &lt;span&gt;87%&lt;/span&gt; at December 31, 2021.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The average interest rate on total financial debt in 2022 was &lt;span&gt;2.4%&lt;/span&gt; (2021: &lt;span&gt;1.9%&lt;/span&gt;).&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Note 29 contains a maturity table of the Group&#x2019;s future contractual interest payments commitments.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table provides a breakdown of straight bonds:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;Coupon&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Currency&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Notional &lt;br/&gt; amount&lt;br/&gt; (millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Issuance &lt;br/&gt; year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Maturity &lt;br/&gt; year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Issuer&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Issue price&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;br/&gt; (USD&lt;br/&gt; millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;br/&gt; (USD&lt;br/&gt; millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.400%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 500
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2012
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2022
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.225%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 498
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              3.700%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            500
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2012
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2042
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              98.325%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            490
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            490
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              3.400%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 150
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2014
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2024
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.287%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 147
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              4.400%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 850
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2014
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2044
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.196%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 827
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 826
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.625%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            600
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2014
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2026
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.697%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            638
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            676
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.250%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            CHF
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            500
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2015
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2025
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis AG, Basel, Switzerland
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100.640%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            541
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            547
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.625%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            CHF
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            550
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2015
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2029
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis AG, Basel, Switzerland
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100.502%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            602
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.050%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            CHF
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            325
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2015
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2035
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis AG, Basel, Switzerland
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100.479%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            352
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            356
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              3.000%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 750
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2015
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2025
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.010%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 742
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 740
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              4.000%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2015
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2045
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              98.029%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 221
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 220
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.125%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2016
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2023
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.127%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 330
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 409
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.625%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            500
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2016
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2028
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              98.480%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            528
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            559
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.400%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2017
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2022
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.449%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              3.100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2017
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2027
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.109%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            994
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            993
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.125%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            600
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2017
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2027
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.874%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            638
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            677
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.500%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            750
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2023
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.655%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            798
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            846
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.375%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            750
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2030
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.957%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            797
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            846
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.700%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            750
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2038
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.217%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            792
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            840
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.750%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2025
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.852%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            998
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            998
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.000%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2027
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.909%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 246
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 246
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.200%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 500
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2030
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.869%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 494
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 493
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.750%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2050
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              97.712%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 215
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 214
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.000%&lt;/span&gt;
                            &lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 850
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2028
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.354%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 076
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total straight bonds&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; The EUR 1 850 million bond issued in 2020 features a coupon step-up of &lt;span&gt;0.25%&lt;/span&gt; commencing with the first interest payment date after December 31, 2025, if one or both of the 2025 Patient Access Targets are not met. These 2025 Patient Access Targets are the 2025 Flagship Programs Patient Reach Target and the 2025 Strategic Innovative Therapies Patient Reach Target, as defined in the bond prospectus. As of December 31, 2022, there is no indication that these 2025 Patient Access Targets will not be met.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following tables provide a breakdown of total non-current financial debt, including current portion by maturity and currency:&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;Breakdown by maturity:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 342
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 147
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 281
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 284
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2026&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            638
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            693
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2027&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 909
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 916
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After 2027&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 269
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11 523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Breakdown by currency:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US dollar (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13 376
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 862
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Euro (EUR)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 478
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 930
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japanese yen (JPY)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            76
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            174
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Swiss franc (CHF)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 488
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 505
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            67
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            52
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;The following table shows the comparison of balance sheet carrying value and fair value of total non-current financial debt, including current portion:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;br/&gt; Balance&lt;br/&gt; sheet&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;br/&gt; Fair&lt;br/&gt; values&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;br/&gt; Balance&lt;br/&gt; sheet&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;br/&gt; Fair&lt;br/&gt; values&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            22 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20 277
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            27 079
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            227
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            227
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            20 421
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            27 306
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The fair values of straight bonds are determined by quoted market prices. Other financial debts are recorded at notional amounts, which are a reasonable approximation of the fair values.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
    <nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_089a0f0d-4105-446d-925c-f53642b5ba05_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            22 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Liabilities to banks and other financial institutions&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            227
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total, including current portion of non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion of non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 241&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 621&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            20 244
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            22 902
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Average interest rate 2.3% (2021: 0.9%)&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">22341000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">25296000000</ifrs-full:BondsIssued>
    <nvs:LiabilitiesToBanksAndOtherInstitutions
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">144000000</nvs:LiabilitiesToBanksAndOtherInstitutions>
    <nvs:LiabilitiesToBanksAndOtherInstitutions
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">227000000</nvs:LiabilitiesToBanksAndOtherInstitutions>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">22485000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">25523000000</ifrs-full:Borrowings>
    <ifrs-full:CurrentPortionOfLongtermBorrowings
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2241000000</ifrs-full:CurrentPortionOfLongtermBorrowings>
    <ifrs-full:CurrentPortionOfLongtermBorrowings
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2621000000</ifrs-full:CurrentPortionOfLongtermBorrowings>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">20244000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">22902000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <nvs:AverageInterestRateOnLoansReceived contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.023</nvs:AverageInterestRateOnLoansReceived>
    <nvs:AverageInterestRateOnLoansReceived contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.009</nvs:AverageInterestRateOnLoansReceived>
    <nvs:RatioFixedRateFinancialDebtToTotalFinancialDebt
      contextRef="AR_I-CurrentYearEnd"
      decimals="2"
      unitRef="Pure">0.86</nvs:RatioFixedRateFinancialDebtToTotalFinancialDebt>
    <nvs:RatioFixedRateFinancialDebtToTotalFinancialDebt
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="2"
      unitRef="Pure">0.87</nvs:RatioFixedRateFinancialDebtToTotalFinancialDebt>
    <nvs:AverageInterestRateOnBorrowings contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.024</nvs:AverageInterestRateOnBorrowings>
    <nvs:AverageInterestRateOnBorrowings contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.019</nvs:AverageInterestRateOnBorrowings>
    <nvs:DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_2d5c4bde-c17d-418d-a097-4126333e576c_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;Coupon&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Currency&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Notional &lt;br/&gt; amount&lt;br/&gt; (millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Issuance &lt;br/&gt; year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Maturity &lt;br/&gt; year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Issuer&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Issue price&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;br/&gt; (USD&lt;br/&gt; millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;br/&gt; (USD&lt;br/&gt; millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.400%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 500
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2012
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2022
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.225%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 498
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              3.700%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            500
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2012
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2042
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              98.325%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            490
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            490
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              3.400%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 150
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2014
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2024
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.287%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 147
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              4.400%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 850
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2014
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2044
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.196%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 827
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 826
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.625%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            600
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2014
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2026
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.697%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            638
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            676
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.250%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            CHF
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            500
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2015
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2025
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis AG, Basel, Switzerland
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100.640%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            541
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            547
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.625%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            CHF
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            550
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2015
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2029
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis AG, Basel, Switzerland
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100.502%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            602
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.050%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            CHF
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            325
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2015
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2035
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis AG, Basel, Switzerland
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100.479%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            352
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            356
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              3.000%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 750
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2015
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2025
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.010%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 742
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 740
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              4.000%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2015
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2045
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              98.029%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 221
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 220
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.125%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2016
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2023
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.127%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 330
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 409
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.625%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            500
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2016
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2028
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              98.480%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            528
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            559
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.400%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2017
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2022
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.449%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              3.100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2017
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2027
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.109%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            994
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            993
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.125%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            600
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2017
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2027
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.874%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            638
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            677
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.500%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            750
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2023
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.655%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            798
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            846
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.375%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            750
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2030
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.957%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            797
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            846
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.700%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            750
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2038
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.217%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            792
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            840
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              1.750%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2025
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.852%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            998
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            998
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.000%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2027
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.909%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 246
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 246
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.200%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 500
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2030
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.869%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 494
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 493
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.750%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            USD
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2050
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation, New York, United States
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              97.712%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 215
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 214
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.000%&lt;/span&gt;
                            &lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EUR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 850
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2028
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A., Luxembourg, Luxembourg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.354%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 076
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total straight bonds&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="18"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; The EUR 1 850 million bond issued in 2020 features a coupon step-up of &lt;span&gt;0.25%&lt;/span&gt; commencing with the first interest payment date after December 31, 2025, if one or both of the 2025 Patient Access Targets are not met. These 2025 Patient Access Targets are the 2025 Flagship Programs Patient Reach Target and the 2025 Strategic Innovative Therapies Patient Reach Target, as defined in the bond prospectus. As of December 31, 2022, there is no indication that these 2025 Patient Access Targets will not be met.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member"
      decimals="5"
      unitRef="Pure">0.02400</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member"
      decimals="-6"
      unitRef="USD">1500000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">2012</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">2022</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member"
      decimals="5"
      unitRef="Pure">0.99225</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member"
      decimals="-6"
      unitRef="USD">1498000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member"
      decimals="5"
      unitRef="Pure">0.03700</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member"
      decimals="-6"
      unitRef="USD">500000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">2012</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">2042</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member"
      decimals="5"
      unitRef="Pure">0.98325</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member"
      decimals="-6"
      unitRef="USD">490000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member"
      decimals="-6"
      unitRef="USD">490000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member"
      decimals="5"
      unitRef="Pure">0.03400</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member"
      decimals="-6"
      unitRef="USD">2150000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">2014</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">2024</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member"
      decimals="5"
      unitRef="Pure">0.99287</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member"
      decimals="-6"
      unitRef="USD">2147000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member"
      decimals="-6"
      unitRef="USD">2144000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member"
      decimals="5"
      unitRef="Pure">0.04400</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member"
      decimals="-6"
      unitRef="USD">1850000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">2014</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">2044</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member"
      decimals="5"
      unitRef="Pure">0.99196</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member"
      decimals="-6"
      unitRef="USD">1827000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member"
      decimals="-6"
      unitRef="USD">1826000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member"
      decimals="5"
      unitRef="Pure">0.01625</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member"
      decimals="-6"
      unitRef="EUR">600000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">2014</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">2026</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member"
      decimals="5"
      unitRef="Pure">0.99697</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member"
      decimals="-6"
      unitRef="USD">638000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member"
      decimals="-6"
      unitRef="USD">676000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member"
      decimals="5"
      unitRef="Pure">0.00250</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">CHF</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member"
      decimals="-6"
      unitRef="CHF">500000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">2015</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">2025</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member">Novartis AG, Basel, Switzerland</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member"
      decimals="5"
      unitRef="Pure">1.00640</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member"
      decimals="-6"
      unitRef="USD">541000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member"
      decimals="-6"
      unitRef="USD">547000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member"
      decimals="5"
      unitRef="Pure">0.00625</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">CHF</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member"
      decimals="-6"
      unitRef="CHF">550000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">2015</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">2029</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member">Novartis AG, Basel, Switzerland</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member"
      decimals="5"
      unitRef="Pure">1.00502</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member"
      decimals="-6"
      unitRef="USD">595000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member"
      decimals="-6"
      unitRef="USD">602000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member"
      decimals="5"
      unitRef="Pure">0.01050</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">CHF</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member"
      decimals="-6"
      unitRef="CHF">325000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">2015</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">2035</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member">Novartis AG, Basel, Switzerland</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member"
      decimals="5"
      unitRef="Pure">1.00479</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member"
      decimals="-6"
      unitRef="USD">352000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member"
      decimals="-6"
      unitRef="USD">356000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member"
      decimals="5"
      unitRef="Pure">0.03000</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member"
      decimals="-6"
      unitRef="USD">1750000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">2015</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">2025</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member"
      decimals="5"
      unitRef="Pure">0.99010</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member"
      decimals="-6"
      unitRef="USD">1742000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member"
      decimals="-6"
      unitRef="USD">1740000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member"
      decimals="5"
      unitRef="Pure">0.04000</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member"
      decimals="-6"
      unitRef="USD">1250000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">2015</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">2045</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member"
      decimals="5"
      unitRef="Pure">0.98029</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member"
      decimals="-6"
      unitRef="USD">1221000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member"
      decimals="-6"
      unitRef="USD">1220000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member"
      decimals="5"
      unitRef="Pure">0.00125</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member"
      decimals="-6"
      unitRef="EUR">1250000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">2016</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">2023</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member"
      decimals="5"
      unitRef="Pure">0.99127</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member"
      decimals="-6"
      unitRef="USD">1330000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member"
      decimals="-6"
      unitRef="USD">1409000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member"
      decimals="5"
      unitRef="Pure">0.00625</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member"
      decimals="-6"
      unitRef="EUR">500000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">2016</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">2028</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member"
      decimals="5"
      unitRef="Pure">0.98480</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member"
      decimals="-6"
      unitRef="USD">528000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member"
      decimals="-6"
      unitRef="USD">559000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member"
      decimals="5"
      unitRef="Pure">0.02400</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member"
      decimals="-6"
      unitRef="USD">1000000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">2017</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">2022</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member"
      decimals="5"
      unitRef="Pure">0.99449</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member"
      decimals="-6"
      unitRef="USD">1000000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member"
      decimals="5"
      unitRef="Pure">0.03100</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member"
      decimals="-6"
      unitRef="USD">1000000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">2017</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">2027</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member"
      decimals="5"
      unitRef="Pure">0.99109</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member"
      decimals="-6"
      unitRef="USD">994000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member"
      decimals="-6"
      unitRef="USD">993000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member"
      decimals="5"
      unitRef="Pure">0.01125</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member"
      decimals="-6"
      unitRef="EUR">600000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">2017</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">2027</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member"
      decimals="5"
      unitRef="Pure">0.99874</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member"
      decimals="-6"
      unitRef="USD">638000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member"
      decimals="-6"
      unitRef="USD">677000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member"
      decimals="5"
      unitRef="Pure">0.00500</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member"
      decimals="-6"
      unitRef="EUR">750000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">2018</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">2023</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member"
      decimals="5"
      unitRef="Pure">0.99655</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member"
      decimals="-6"
      unitRef="USD">798000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member"
      decimals="-6"
      unitRef="USD">846000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member"
      decimals="5"
      unitRef="Pure">0.01375</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member"
      decimals="-6"
      unitRef="EUR">750000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">2018</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">2030</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member"
      decimals="5"
      unitRef="Pure">0.99957</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member"
      decimals="-6"
      unitRef="USD">797000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member"
      decimals="-6"
      unitRef="USD">846000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member"
      decimals="5"
      unitRef="Pure">0.01700</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member"
      decimals="-6"
      unitRef="EUR">750000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">2018</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">2038</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member"
      decimals="5"
      unitRef="Pure">0.99217</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member"
      decimals="-6"
      unitRef="USD">792000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member"
      decimals="-6"
      unitRef="USD">840000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member"
      decimals="5"
      unitRef="Pure">0.01750</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member"
      decimals="-6"
      unitRef="USD">1000000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">2020</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">2025</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member"
      decimals="5"
      unitRef="Pure">0.99852</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member"
      decimals="-6"
      unitRef="USD">998000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member"
      decimals="-6"
      unitRef="USD">998000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member"
      decimals="5"
      unitRef="Pure">0.02000</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member"
      decimals="-6"
      unitRef="USD">1250000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">2020</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">2027</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member"
      decimals="5"
      unitRef="Pure">0.99909</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member"
      decimals="-6"
      unitRef="USD">1246000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member"
      decimals="-6"
      unitRef="USD">1246000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member"
      decimals="5"
      unitRef="Pure">0.02200</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member"
      decimals="-6"
      unitRef="USD">1500000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">2020</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">2030</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member"
      decimals="5"
      unitRef="Pure">0.99869</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member"
      decimals="-6"
      unitRef="USD">1494000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member"
      decimals="-6"
      unitRef="USD">1493000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member"
      decimals="5"
      unitRef="Pure">0.02750</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">USD</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member"
      decimals="-6"
      unitRef="USD">1250000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">2020</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">2050</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member">Novartis Capital Corporation, New York, United States</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member"
      decimals="5"
      unitRef="Pure">0.97712</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member"
      decimals="-6"
      unitRef="USD">1215000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member"
      decimals="-6"
      unitRef="USD">1214000000</ifrs-full:BondsIssued>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member"
      decimals="5"
      unitRef="Pure">0.000</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">EUR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member"
      decimals="-6"
      unitRef="EUR">1850000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsIssuanceDate contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">2020</nvs:BorrowingsIssuanceDate>
    <ifrs-full:BorrowingsMaturity contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">2028</ifrs-full:BorrowingsMaturity>
    <nvs:BorrowingsLender contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member">Novartis Finance S.A., Luxembourg, Luxembourg</nvs:BorrowingsLender>
    <nvs:BorrowingsPremiumDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member"
      decimals="5"
      unitRef="Pure">0.99354</nvs:BorrowingsPremiumDiscount>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member"
      decimals="-6"
      unitRef="USD">1958000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member"
      decimals="-6"
      unitRef="USD">2076000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">22341000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">25296000000</ifrs-full:BondsIssued>
    <ifrs-full:NotionalAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member"
      decimals="-6"
      unitRef="EUR">1850000000</ifrs-full:NotionalAmount>
    <nvs:BorrowingsInterestRateStepUp
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member"
      decimals="4"
      unitRef="Pure">0.25</nvs:BorrowingsInterestRateStepUp>
    <nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_42b92e33-c1a0-42ed-9682-3fd3dede1b88_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 342
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 147
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 281
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3 284
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2026&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            638
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            693
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2027&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 909
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 916
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;After 2027&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 269
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11 523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember"
      decimals="-6"
      unitRef="USD">2621000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember"
      decimals="-6"
      unitRef="USD">2241000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember"
      decimals="-6"
      unitRef="USD">2342000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember"
      decimals="-6"
      unitRef="USD">2147000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember"
      decimals="-6"
      unitRef="USD">2144000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember"
      decimals="-6"
      unitRef="USD">3281000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember"
      decimals="-6"
      unitRef="USD">3284000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember"
      decimals="-6"
      unitRef="USD">638000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">693000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">2909000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanFiveYearsAndNotLaterThanSixYearsMember"
      decimals="-6"
      unitRef="USD">2916000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">11269000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanSixYearsMember"
      decimals="-6"
      unitRef="USD">11523000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">22485000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">25523000000</ifrs-full:Borrowings>
    <nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_e8099986-8ca7-45d0-b780-a828b37cbf28_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;US dollar (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13 376
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 862
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Euro (EUR)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 478
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 930
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Japanese yen (JPY)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            76
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            174
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Swiss franc (CHF)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 488
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 505
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            67
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            52
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">13376000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">15862000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022EUR"
      decimals="-6"
      unitRef="USD">7478000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022EUR"
      decimals="-6"
      unitRef="USD">7930000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022JPY"
      decimals="-6"
      unitRef="USD">76000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022JPY"
      decimals="-6"
      unitRef="USD">174000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022CHF"
      decimals="-6"
      unitRef="USD">1488000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_currency-2022CHF"
      decimals="-6"
      unitRef="USD">1505000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember"
      decimals="-6"
      unitRef="USD">67000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember"
      decimals="-6"
      unitRef="USD">52000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">22485000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">25523000000</ifrs-full:Borrowings>
    <nvs:DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_9b41517e-a496-4ec4-ab06-e0a79b5f8a38_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;br/&gt; Balance&lt;br/&gt; sheet&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;br/&gt; Fair&lt;br/&gt; values&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;br/&gt; Balance&lt;br/&gt; sheet&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;br/&gt; Fair&lt;br/&gt; values&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            22 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20 277
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            27 079
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Others&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            227
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            227
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            20 421
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            27 306
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember"
      decimals="-6"
      unitRef="USD">22341000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember"
      decimals="-6"
      unitRef="USD">20277000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember"
      decimals="-6"
      unitRef="USD">25296000000</ifrs-full:BondsIssued>
    <ifrs-full:BondsIssued
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember"
      decimals="-6"
      unitRef="USD">27079000000</ifrs-full:BondsIssued>
    <nvs:OtherNoncurrentFinancialDebt
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember"
      decimals="-6"
      unitRef="USD">144000000</nvs:OtherNoncurrentFinancialDebt>
    <nvs:OtherNoncurrentFinancialDebt
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember"
      decimals="-6"
      unitRef="USD">144000000</nvs:OtherNoncurrentFinancialDebt>
    <nvs:OtherNoncurrentFinancialDebt
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember"
      decimals="-6"
      unitRef="USD">227000000</nvs:OtherNoncurrentFinancialDebt>
    <nvs:OtherNoncurrentFinancialDebt
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember"
      decimals="-6"
      unitRef="USD">227000000</nvs:OtherNoncurrentFinancialDebt>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember"
      decimals="-6"
      unitRef="USD">22485000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember"
      decimals="-6"
      unitRef="USD">20421000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember"
      decimals="-6"
      unitRef="USD">25523000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4FairValueDisclosureItemAmountsMember"
      decimals="-6"
      unitRef="USD">27306000000</ifrs-full:Borrowings>
    <ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_62b40a60-48ad-4e8d-b0d9-00534a13e36e_0">
          &lt;div&gt;
            &lt;div id="anchorId001545467"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;20. Provisions and other non-current liabilities&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued liability for employee benefits:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Defined benefit pension plans&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 723
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 640
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Other long-term employee benefits and deferred compensation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            554
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            662
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Other post-employment benefits&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            362
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Environmental remediation provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            535
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            567
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for product liabilities, governmental investigations and other legal matters&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            154
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            704
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            956
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            874
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            519
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total provisions and other non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 906
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 172
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 25 provides additional disclosures related to post-employment benefits.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent consideration.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis believes that its total provisions are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities in this area, Novartis may incur additional costs beyond the amounts provided. Management believes that such additional amounts, if any, would not be material to the Group&#x2019;s financial condition but could be material to the results of operations or cash flows in a given period.&lt;/div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Environmental remediation provisions&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the movements in the environmental liability provisions:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            616
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            714
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-169&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-18&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-  105&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            82
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-24&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            50
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            588
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            616
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current provision&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-53&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-49&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-167&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current environmental remediation provisions at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            535
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            567
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            642
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The significant components of the environmental remediation provisions consist of costs to sufficiently clean and refurbish contaminated sites to the extent necessary, and to continue surveillance at sites where the environmental remediation exposure is less significant. &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;A substantial portion of the environmental remediation provisions relate to the remediation of Basel regional landfills in the adjacent border areas in Switzerland, Germany and France. The provisions are reassessed on an annual basis and adjusted as necessary.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In the United States, Novartis has been named under federal legislation (the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended) as a potentially responsible party (PRP) in respect of certain sites. Novartis actively participates in, or monitors, the cleanup activities at the sites in which it is a PRP. The provision takes into consideration the number of other PRPs at each site as well as the identity and financial position of such parties in light of the joint and several nature of the liability. &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The expected timing of the related cash outflows as of December 31, 2022, is currently projected as follows:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Expected &lt;br/&gt; cash outflows&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due within two years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:20%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            128
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due later than two years, but within five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            163
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due later than five years, but within 10 years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due after 10 years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            46
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total environmental remediation provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            588
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Provisions for product liabilities, governmental investigations and other legal matters &lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has established provisions for certain product liabilities, governmental investigations and other legal matters where a potential cash outflow is probable and Novartis can make a reliable estimate of the amount of the outflow. These provisions represent the Group&#x2019;s current best estimate of the total financial effect for the matters described below and for other less significant matters. Potential cash outflows reflected in a provision might be fully or partially offset by insurance in certain circumstances.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Novartis has not established provisions for potential damage awards for certain additional legal claims against its subsidiaries if Novartis currently believes that a payment is either not probable or cannot be reliably estimated. These not-provisioned-for matters include individual product liability cases and certain other legal matters. Plaintiffs&#x2019; have alleged claims in these matters and the Group does not believe that information about the amount sought by plaintiffs, if that is known, would be meaningful with respect to those legal proceedings. This is due to a number of factors, including, but not limited to, the stage of proceedings, the entitlement of parties to appeal a decision and clarity as to theories of liability, damages and governing law. Therefore, it is not practicable to provide information about the potential financial impact of these matters. In addition, in some of &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;these matters there are claims for punitive or multiple (treble) damages, civil penalties and disgorgement of profits that in the view of Novartis are either wholly or partially unspecified, or wholly or partially unquantifiable at present; the Group believes that information about these amounts claimed by plaintiffs generally is not meaningful for purposes of determining a reliable estimate of a loss that is probable or more than remote.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;A number of other legal matters are in such early stages or the issues presented are such that the Group has not made any provisions since it cannot currently estimate either a potential outcome or the amount of any potential losses. For these reasons, among others, the Group generally is unable to make a reliable estimate of possible loss with respect to such cases. It is therefore not practicable to provide information about the potential financial impact of those cases.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;There might also be cases for which the Group was able to make a reliable estimate of the possible loss or the range of possible loss, but the Group believes that publication of such information on a case-by-case basis would seriously prejudice the Group&#x2019;s position in ongoing legal proceedings or in any related settlement discussions. Accordingly, in such cases, information has been disclosed with respect to the nature of the contingency, but no disclosure is provided as to an estimate of the possible loss or range of possible loss.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Note 28 contains additional information on contingent liabilities.&lt;/div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Summary of significant legal proceedings&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following is a summary of significant legal proceedings to which Novartis or its subsidiaries are currently a party, or were a party and that concluded in 2022.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Investigations and related litigations&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Southern District of New York (S.D.N.Y.) Gilenya marketing practices investigation and litigation&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2013, Novartis Pharmaceuticals Corporation (NPC) received a civil investigative demand from the United States Attorney&#x2019;s Office (USAO) for the S.D.N.Y. requesting the production of documents and information relating to marketing practices for &lt;i&gt;Gilenya&lt;/i&gt;, including the remuneration of healthcare providers in connection therewith. In 2017, the S.D.N.Y. and New York State declined to intervene in claims raised by an individual relator in a qui tam complaint. In 2022, NPC&#x2019;s motion to dismiss this complaint was granted, which was appealed. The claims are being vigorously contested. &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Government generic pricing antitrust investigations, antitrust class actions&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Since 2016, Sandoz Inc. has received a grand jury subpoena and a civil investigative demand and interrogatories from the Antitrust and Civil Divisions of the US Department of Justice (DOJ) into alleged price fixing and market allocation of generic drugs in the United States as well as alleged federal False Claims Act (FCA) violations. Sandoz Inc. also received a subpoena and interrogatories from the Attorney General of the State of Connecticut in connection with a similar States&#x2019; investigation. In 2020, Sandoz Inc. reached a resolution with the DOJ Antitrust Division, pursuant to which Sandoz Inc. paid USD 195 million and entered into a deferred prosecution agreement. The Sandoz Inc. resolution related to instances of misconduct at the Company between 2013 and 2015 with regard to certain generic drugs sold in the United States. Under the terms of that agreement, Sandoz Inc. will continue to take steps to enhance its compliance program, employee training and monitoring, and will continue to cooperate with the US government&#x2019;s ongoing investigation into the generic pharmaceutical industry. Sandoz Inc. also finalized a resolution with the DOJ Civil Division and in 2021 paid USD 185 million, which includes interest from the date of the agreement in principle, to settle related claims arising under the FCA, and entered into a corporate integrity agreement with the Office of Inspector General (OIG) of the US Department of Health and Human Services (HHS). This resolution with the DOJ resolves all federal government matters related to price fixing allegations.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Since the third quarter of 2016, Sandoz Inc. and Fougera Pharmaceuticals Inc. have been sued alongside other generic pharmaceutical companies in numerous individual and putative class action complaints by direct and indirect private purchasers and by over  50 US states and territories, represented by their respective Attorneys General. Plaintiffs claim that defendants, including Sandoz Inc., engaged in price fixing and market allocation of generic drugs in the United States, and seek damages and injunctive relief. The litigation includes complaints alleging product-specific conspiracies, as well as complaints alleging the existence of an overarching industry conspiracy, and assert claims for damages and penalties under federal and state antitrust and consumer protection acts. The cases have been consolidated for pretrial purposes in the United States District Court (USDC) for the Eastern District of Pennsylvania, and the claims are being vigorously contested.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Lucentis/Avastin&#xae; matters&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In connection with an investigation into whether Novartis entities, F. Hoffmann-La Roche AG, Genentech Inc. and Roche S.p.A. colluded to artificially preserve the market positions of Avastin&lt;sup&gt;&#xae;&lt;/sup&gt; and &lt;i&gt;Lucentis&lt;/i&gt;, in 2014 the Italian Competition Authority (ICA) imposed a fine equivalent to USD 125 million on the Novartis entities. Novartis paid the fine, subject to the right to later claim recoupment, and appealed before the Consiglio di Stato (CdS). In 2014 and 2015, the Italian Ministry of Health and the Lombardia region sent letters with payment requests for a total equivalent of approximately USD&#160;1.3 billion in damages from Novartis and Roche entities based on these allegations. In 2019, the CdS upheld the ICA decision and fine. Following that CdS decision, several additional Italian regions and hospitals sent letters claiming damages for an aggregate amount of approximately USD 330 million. None of these claims have been asserted in legal proceedings and no further letters have been sent since. Novartis continues to appeal the CdS decision. In 2019, the French Competition Authority (FCA) issued a Statement of Objections against Novartis entities, alleging anti-competitive practices on the French market for anti-vascular endothelial growth factor treatments for wet age-related macular degeneration from 2008 to &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;2013. In 2020, the FCA issued a decision finding that the Novartis entities had infringed competition law by abusing a dominant position and imposing a fine equivalent to approximately USD 452 million. Novartis paid the fine, again subject to recoupment, and is appealing the FCA&#x2019;s decision. Novartis is the subject of similar investigations and proceedings involving competition authorities in Belgium and Greece and is currently in the appeal process in Turkey. Novartis continues to vigorously contest all claims in all those countries.  Novartis is also challenging policies and regulations allowing off-label/unlicensed use and reimbursement for economic reasons in Turkey.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Greece investigation&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Greek authorities are investigating legacy allegations of potentially inappropriate economic benefits to HCPs, government officials and others in Greece. These authorities include the Greek Coordinating Body for Inspection and Control, and the Greek Body of Prosecution of Financial Crime (SDOE), from which the Company received a summons in 2018 and 2020. Novartis has cooperated in these investigations. In 2021, SDOE imposed on Novartis Hellas a fine equivalent to approximately USD 1.2 million, which Novartis Hellas has appealed. In 2022, the Greek State served a civil lawsuit on Novartis Hellas, seeking approximately USD 225 million for moral damages allegedly arising from the conduct that was the subject of the Company&#x2019;s 2020 settlement with the DOJ regarding allegations of inappropriate economic benefits in Greece that was disclosed in the 2020 Annual Report and the 2020 Form 20-F. The claims are being vigorously contested.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;340B Drug Pricing Program investigations&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2021, NPC received a notification from the US Health Resources and Services Administration (HRSA) which stated that HRSA believes NPC&#x2019;s contract pharmacy policy violates the 340B statute, and threatened potential enforcement action. NPC subsequently sued HRSA in the USDC for the District of Columbia to challenge HRSA&#x2019;s determination and to enjoin HRSA from taking action with respect to NPC&#x2019;s contract pharmacy policy. HRSA then referred the matter regarding NPC&#x2019;s contract pharmacy policy to OIG, which could result in the imposition of civil monetary penalties on NPC. The USDC issued a decision rejecting HRSA&#x2019;s interpretation of the 340B statute, vacating the violation notification and remanding the matter to HRSA. HRSA appealed, and the United States Court of Appeals for the DC Circuit heard argument on the case in 2022. In addition, in 2021, Emory University Hospital Midtown filed an Administrative Dispute Resolution (ADR) proceeding against NPC, seeking the return of alleged overcharges resulting from NPC&#x2019;s contract pharmacy policy. NPC has moved to dismiss the proceeding pending resolution of the HRSA litigation. Finally, also in 2021, NPC received a civil investigative subpoena from the Office of the Attorney General of the State of Vermont requesting the production of documents and information concerning NPC&#x2019;s participation in the 340B Drug Pricing Program in Vermont; NPC provided documents and information to the Office of the Attorney General.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Swiss and EU investigation&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In September 2022, the Swiss Competition Commission (COMCO) initiated an investigation of Novartis acquisition of certain patents from Genentech in April 2020 and their subsequent enforcement against Eli Lilly and other parties, allegedly in an attempt to protect &lt;i&gt;Cosentyx&lt;/i&gt; from competing products. COMCO is investigating whether enforcement of the patents violates the Swiss Cartel Act. The European Commission also requested information from Novartis regarding this matter. Novartis is cooperating with the authorities and will vigorously contest any allegations. &lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Antitrust class actions&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Exforge&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Since 2018, Novartis Group companies as well as other pharmaceutical companies have been sued by various direct and indirect purchasers of &lt;i&gt;Exforge&lt;/i&gt; in multiple US individual and putative class action complaints. They claim that Novartis made a reverse payment in the form of an agreement not to launch an authorized generic, alleging violations of federal antitrust law and state antitrust, consumer protection and common laws, and seeking damages as well as injunctive relief. The cases have been consolidated in the S.D.N.Y. In 2022, Novartis agreed to a settlement in principle to pay USD 245 million to resolve these cases. These settlements are subject to mutually agreeable terms, finalization of documentation and, in some cases, court approval.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Product liability litigation&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Reclast &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;NPC is a defendant in more than 20 US product liability actions involving &lt;i&gt;Reclast&lt;/i&gt; and alleging atypical femur fracture injuries, all of which are in New Jersey state or federal court and in California state court, coordinated with claims against other bisphosphonate manufacturers. The claims are being vigorously contested.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Taxotere&#xae; (docetaxel)&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Sandoz is a defendant in more than 3 100 US product liability actions involving Taxotere&#xae; (docetaxel), an oncology product, many of which have been transferred to a multidistrict litigation in the Eastern District of Louisiana. The complaints allege misleading marketing and that Sanofi, as innovator, and several 505(b)(2) NDA holders (including Sandoz) failed to warn of the risk of permanent alopecia/hair loss. In 2022, actions involving claims related to alleged eye injuries caused by the use of Taxotere&#xae; were coordinated in a separate multidistrict litigation in the Eastern District of Louisiana. The claims are being vigorously contested.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Amiodarone&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Sandoz entities are named in two multi-plaintiff US product liability cases involving amiodarone, a cardiac drug indicated to treat life-threatening arrhythmias that have not responded to other treatment. The complaints allege failure to warn, off-label promotion, and failure to include medication guides to pharmacies. The claims are being vigorously contested.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Sartans and ranitidine&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Since 2018, claims have been brought against Sandoz and other pharmaceutical companies alleging injury from carcinogenic impurities found in valsartan and valsartan/HCT film-coated tablets and/or losartan marketed or manufactured by Sandoz. These claims include several putative class actions in Canada. Claims have also been brought alleging injury from carcinogenic impurities in ranitidine-containing medicines. These claims also include several putative class actions in Canada and a multidistrict litigation in Florida. All of these claims are being vigorously contested.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Tasigna&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;NPC is a defendant in more than 400 US product liability actions involving &lt;i&gt;Tasigna&lt;/i&gt;, alleging that the product caused various cardiovascular effects and that NPC failed to provide adequate warnings about those alleged side effects. State court actions are pending in a multicounty litigation in Bergen County, New Jersey, and federal cases are pending in a multidistrict litigation in the Middle District of Florida. The claims are being vigorously contested.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Other matters&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Shareholder derivative lawsuit&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2021, NPC, Sandoz Inc., Novartis Capital Corporation and certain present and former directors and officers of Novartis were named as defendants, and Novartis was named as a nominal defendant, in a purported shareholder derivative lawsuit filed in New York state court. The plaintiffs, derivatively as purported Novartis shareholders on behalf of Novartis, seek damages and other remedies based on alleged conduct by the corporate and individual defendants. In 2022, the court granted Novartis motion to dismiss the lawsuit, which the plaintiffs have appealed.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Concluded legal matters&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Average Wholesale Price (AWP) litigation &#x2013; Concluded matter &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Lawsuits were brought, the latest in February 2016, by various US state governmental entities and private parties against various pharmaceutical companies, including NPC, alleging that they fraudulently overstated the AWP that is or has been used by payers, including state Medicaid agencies, to calculate reimbursements to healthcare providers. In 2022, NPC settled a putative class action brought by private payers in New Jersey, which resolved the last AWP lawsuit. This matter is now concluded.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;Entresto matter&#x2013; Concluded matter&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2021, NPC received a civil investigative demand from the DOJ seeking information from 2016 to the present regarding the marketing and pricing of Entresto, including remuneration provided to HCPs.  In December 2022, the DOJ advised that it has no additional requests and that the matter is considered closed. This matter is now concluded.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000; font-weight:bold;font-style:italic;"&gt;South Korea investigation &#x2013; Concluded matter&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2016, the Seoul Western District Prosecutor initiated a criminal investigation into, among other things, allegations that Novartis Korea utilized medical journals to provide inappropriate economic benefits to healthcare professionals (HCPs). This resulted in a non-material fine, which the prosecutor appealed. In 2021, the appellate court upheld the fine, and the prosecutor appealed that decision. In January 2023, the Supreme Court dismissed the appeal. This matter is now concluded.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Summary of product liability, governmental investigations and other legal matters provision movements&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            397
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 369
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-105&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-292&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 863&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases of provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-52&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-31&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            466
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-17&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            702
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            397
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-548&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-56&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-306&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current product  liabilities, governmental  investigations and other  legal matters provisions  at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            154
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            181
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis believes that its total provisions for investigations, product liability, arbitration and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, there can be no assurance that additional liabilities and costs will not be incurred beyond the amounts provided.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div/&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory>
    <ifrs-full:DisclosureOfOtherProvisionsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_908ad470-ac09-4465-8073-37ecc00bff88_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued liability for employee benefits:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Defined benefit pension plans&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 723
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 640
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Other long-term employee benefits and deferred compensation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            554
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            662
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Other post-employment benefits&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            362
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Environmental remediation provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            535
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            567
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for product liabilities, governmental investigations and other legal matters&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            154
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            704
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            956
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            874
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            519
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total provisions and other non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 906
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 172
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 25 provides additional disclosures related to post-employment benefits.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent consideration.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DisclosureOfOtherProvisionsExplanatory>
    <ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1723000000</ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan>
    <ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2640000000</ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan>
    <nvs:OtherLongtermEmployeeBenefitsAndDeferredCompensation
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">554000000</nvs:OtherLongtermEmployeeBenefitsAndDeferredCompensation>
    <nvs:OtherLongtermEmployeeBenefitsAndDeferredCompensation
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">662000000</nvs:OtherLongtermEmployeeBenefitsAndDeferredCompensation>
    <nvs:OtherPostemploymentBenefits
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">362000000</nvs:OtherPostemploymentBenefits>
    <nvs:OtherPostemploymentBenefits
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">487000000</nvs:OtherPostemploymentBenefits>
    <nvs:EnvironmentalRemediationProvisionNoncurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">535000000</nvs:EnvironmentalRemediationProvisionNoncurrent>
    <nvs:EnvironmentalRemediationProvisionNoncurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">567000000</nvs:EnvironmentalRemediationProvisionNoncurrent>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">154000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">341000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent>
    <nvs:ContingentConsiderationNonCurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">704000000</nvs:ContingentConsiderationNonCurrent>
    <nvs:ContingentConsiderationNonCurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">956000000</nvs:ContingentConsiderationNonCurrent>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">874000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">519000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentNonfinancialLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">4906000000</ifrs-full:OtherNoncurrentNonfinancialLiabilities>
    <ifrs-full:OtherNoncurrentNonfinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">6172000000</ifrs-full:OtherNoncurrentNonfinancialLiabilities>
    <nvs:AccrualForEnvironmentalLossContingenciesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_cd416968-caec-4175-9310-50ad300e2c5a_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            616
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            714
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-169&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-18&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-  105&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            82
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-24&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            50
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            588
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            616
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current provision&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-53&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-49&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-167&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current environmental remediation provisions at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            535
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            567
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            642
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:AccrualForEnvironmentalLossContingenciesTableTextBlock>
    <nvs:EnvironmentalProvision
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">616000000</nvs:EnvironmentalProvision>
    <nvs:EnvironmentalProvision
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">809000000</nvs:EnvironmentalProvision>
    <nvs:EnvironmentalProvision
      contextRef="AR_I-CurrentYearEnd-3"
      decimals="-6"
      unitRef="USD">714000000</nvs:EnvironmentalProvision>
    <nvs:EnvironmentalProvisionPayments contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-6000000</nvs:EnvironmentalProvisionPayments>
    <nvs:EnvironmentalProvisionPayments contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-169000000</nvs:EnvironmentalProvisionPayments>
    <nvs:EnvironmentalProvisionPayments contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-10000000</nvs:EnvironmentalProvisionPayments>
    <nvs:EnvironmentalProvisionReleases contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">18000000</nvs:EnvironmentalProvisionReleases>
    <nvs:EnvironmentalProvisionReleases contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">105000000</nvs:EnvironmentalProvisionReleases>
    <nvs:EnvironmentalProvisionReleases contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">27000000</nvs:EnvironmentalProvisionReleases>
    <nvs:EnvironmentalProvisionAdditions contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6000000</nvs:EnvironmentalProvisionAdditions>
    <nvs:EnvironmentalProvisionAdditions contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">105000000</nvs:EnvironmentalProvisionAdditions>
    <nvs:EnvironmentalProvisionAdditions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">82000000</nvs:EnvironmentalProvisionAdditions>
    <nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-10000000</nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss>
    <nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-24000000</nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss>
    <nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">50000000</nvs:EnvironmentalProvisionForeignCurrencyTranslationGainLoss>
    <nvs:EnvironmentalProvision
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">588000000</nvs:EnvironmentalProvision>
    <nvs:EnvironmentalProvision
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">616000000</nvs:EnvironmentalProvision>
    <nvs:EnvironmentalProvision
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">809000000</nvs:EnvironmentalProvision>
    <nvs:EnvironmentalProvisionCurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">53000000</nvs:EnvironmentalProvisionCurrent>
    <nvs:EnvironmentalProvisionCurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">49000000</nvs:EnvironmentalProvisionCurrent>
    <nvs:EnvironmentalProvisionCurrent
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">167000000</nvs:EnvironmentalProvisionCurrent>
    <nvs:EnvironmentalRemediationProvisionNoncurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">535000000</nvs:EnvironmentalRemediationProvisionNoncurrent>
    <nvs:EnvironmentalRemediationProvisionNoncurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">567000000</nvs:EnvironmentalRemediationProvisionNoncurrent>
    <nvs:EnvironmentalRemediationProvisionNoncurrent
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">642000000</nvs:EnvironmentalRemediationProvisionNoncurrent>
    <nvs:AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_7fc3571b-36ae-44f5-8c11-163394c97132_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Expected &lt;br/&gt; cash outflows&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due within two years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:20%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            128
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due later than two years, but within five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            163
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due later than five years, but within 10 years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Due after 10 years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            46
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total environmental remediation provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            588
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock>
    <nvs:EnvironmentalProvisionExpectedCashOutflowNextTwoYears
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">128000000</nvs:EnvironmentalProvisionExpectedCashOutflowNextTwoYears>
    <nvs:EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">163000000</nvs:EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears>
    <nvs:EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">251000000</nvs:EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears>
    <nvs:EnvironmentalProvisionExpectedCashOutflowAfterTenYears
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">46000000</nvs:EnvironmentalProvisionExpectedCashOutflowAfterTenYears>
    <nvs:EnvironmentalProvision
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">588000000</nvs:EnvironmentalProvision>
    <nvs:AmountOfSettlementInPrinciple
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">195000000</nvs:AmountOfSettlementInPrinciple>
    <nvs:AmountOfSettlementInPrinciple
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember"
      decimals="-6"
      unitRef="USD">185000000</nvs:AmountOfSettlementInPrinciple>
    <nvs:DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember"
      decimals="0"
      unitRef="Pure">50</nvs:DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations>
    <ifrs-full:EstimatedFinancialEffectOfContingentLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022IT_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NAGAndNovartisPharmaSpAMember"
      decimals="-6"
      unitRef="USD">125000000</ifrs-full:EstimatedFinancialEffectOfContingentLiabilities>
    <nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022IT_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember"
      decimals="-8"
      unitRef="USD">1300000000</nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine>
    <nvs:EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022IT_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember"
      decimals="-6"
      unitRef="USD">330000000</nvs:EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed>
    <nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022GeographicalAreasAxis_country-2022FR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4FHoffmanLaRocheAGAndRocheSpAMember"
      decimals="-6"
      unitRef="USD">452000000</nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine>
    <nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022GR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember"
      decimals="-5"
      unitRef="USD">1200000</nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine>
    <nvs:EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022GR_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember"
      decimals="-6"
      unitRef="USD">225000000</nvs:EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages>
    <nvs:AmountOfSettlementInPrinciple
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ExforgeGroupMember"
      decimals="-6"
      unitRef="USD">245000000</nvs:AmountOfSettlementInPrinciple>
    <nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4ReclastAclastaMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NPCAndOthersMember"
      decimals="0"
      unitRef="Pure">20</nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases>
    <nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TaxotereMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember"
      decimals="0"
      unitRef="Pure">3100</nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases>
    <nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4AmiodaroneMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SandozMember"
      decimals="0"
      unitRef="Pure">2</nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases>
    <nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4TasignaMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NPCAndOthersMember"
      decimals="0"
      unitRef="Pure">400</nvs:ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases>
    <nvs:AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_d989c169-f695-4e42-a9e7-d4b161eb7171_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            397
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 369
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-105&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-292&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 863&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases of provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-52&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-31&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions to provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            466
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 018
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-17&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            702
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            397
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Less current portion&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-548&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-56&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-306&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current product  liabilities, governmental  investigations and other  legal matters provisions  at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            154
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            181
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">397000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">487000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions
      contextRef="AR_I-CurrentYearEnd-3"
      decimals="-6"
      unitRef="USD">1369000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">4000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">11000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-105000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-292000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-1863000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">52000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">44000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">31000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">466000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">251000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1018000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-8000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-5000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-17000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">702000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">397000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">487000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">548000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">56000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">306000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">154000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">341000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">181000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent>
    <nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_c04d4e4d-b7d0-43a4-bdb6-d1dde2e4654e_0">
          &lt;div&gt;
            &lt;div id="anchorId001546335"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;21. Current financial debt and&#160;derivative&#160;financial&#160;instruments&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest-bearing accounts of employees  payable on demand&lt;sup style="white-space: nowrap"&gt; &#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 814
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other financial debt&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            863
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            899
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 772
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            893
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current portion of non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            68
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt and derivative  financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 931
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 295
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Weighted average interest rate 0.25% through September 30, 2022 (2021: 0.25%)&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt;
                            &lt;span&gt; Weighted average interest rate 9.7% (2021: 6.1%)&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During the third quarter of 2022, Novartis closed the interest-bearing accounts of employees payable on demand, and paid out USD 0.9 billion to the respective beneficiaries on October 3, 2022. The net cash outflows from interest-bearing accounts of employees payable on demand were reported within the line change in current financial debts in the consolidated statements of cash flows. See Note 23.6.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The carrying amounts of current financial debt, other than the current portion of non-current financial debt, approximate the estimated fair value due to the short-term nature of these instruments.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Details on commercial papers and short-term borrowings are provided under &#x201c;Liquidity risk&#x201d; in Note&#160;29. &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock>
    <nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_f6bc1d5a-0b0c-46bb-a777-d357746e739e_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest-bearing accounts of employees  payable on demand&lt;sup style="white-space: nowrap"&gt; &#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 814
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other financial debt&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            863
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            899
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 772
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            893
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current portion of non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            68
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt and derivative  financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 931
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 295
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Weighted average interest rate 0.25% through September 30, 2022 (2021: 0.25%)&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt;
                            &lt;span&gt; Weighted average interest rate 9.7% (2021: 6.1%)&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock>
    <nvs:InterestBearningAccountsOfAssociatesPayableOnDemand
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1814000000</nvs:InterestBearningAccountsOfAssociatesPayableOnDemand>
    <ifrs-full:ShorttermBorrowings
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">863000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">899000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:CommercialPapersIssued
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2772000000</ifrs-full:CommercialPapersIssued>
    <ifrs-full:CommercialPapersIssued
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">893000000</ifrs-full:CommercialPapersIssued>
    <ifrs-full:CurrentPortionOfLongtermBorrowings
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2241000000</ifrs-full:CurrentPortionOfLongtermBorrowings>
    <ifrs-full:CurrentPortionOfLongtermBorrowings
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2621000000</ifrs-full:CurrentPortionOfLongtermBorrowings>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">55000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">68000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">5931000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">6295000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <nvs:WeightedAverageInterestRateAssociates contextRef="AR_D-CurrentYear" decimals="4" unitRef="Pure">0.0025</nvs:WeightedAverageInterestRateAssociates>
    <nvs:WeightedAverageInterestRateAssociates contextRef="AR_D-CurrentYear-1" decimals="4" unitRef="Pure">0.0025</nvs:WeightedAverageInterestRateAssociates>
    <nvs:WeightedAverageInterestRateOnBankAndOtherFinancialDebt contextRef="AR_D-CurrentYear" decimals="3" unitRef="Pure">0.097</nvs:WeightedAverageInterestRateOnBankAndOtherFinancialDebt>
    <nvs:WeightedAverageInterestRateOnBankAndOtherFinancialDebt contextRef="AR_D-CurrentYear-1" decimals="3" unitRef="Pure">0.061</nvs:WeightedAverageInterestRateOnBankAndOtherFinancialDebt>
    <nvs:PaymentOfInterestBearingAccountsToBeneficiaries contextRef="AR_D-CurrentYear" decimals="-8" unitRef="USD">900000000</nvs:PaymentOfInterestBearingAccountsToBeneficiaries>
    <nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_993e8eda-d1b7-4f4c-a345-cb3bd2bacc7b_0">
          &lt;div&gt;
            &lt;div id="anchorId001546511"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;22. Provisions and other current liabilities&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes other than income taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            836
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            619
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Restructuring provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 131
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            345
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued expenses for goods and services received but not invoiced&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 059
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 089
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accruals for royalties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            767
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            752
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued interests on financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            116
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for deductions from revenue&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 732
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 481
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accruals for compensation and benefits, including social security&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 321
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 260
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Environmental remediation provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            123
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            123
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for product liabilities, governmental investigations and other legal matters&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            548
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued share-based payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            235
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            253
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            131
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            119
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares&lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            743
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            588
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total provisions and other current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            14 795
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 670
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 20 provides additional disclosures related to legal provisions.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent consideration.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt; Note 18.3 provides additional disclosures related to commitment for repurchase of own shares.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Provisions are based upon management&#x2019;s best estimate and adjusted for actual experience. Such adjustments to historic estimates have not been material.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Provisions for deductions from revenue&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the movement of the provisions for deductions from revenue:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 481
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 256
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of currency translation, business combinations&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-210&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-218&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            234
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments/utilizations&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-22 261&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-19 838&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-19 294&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Adjustments of prior years charged to income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-322&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-245&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-151&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current year income statement charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23 072
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20 413
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19 773
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in provisions offset against gross trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            113
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            99
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 732
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 481
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 256
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The provisions for deductions from revenue include specific healthcare plans and program rebates as well as non-healthcare plans and program-related rebates, returns and other deductions. The provisions for deductions from revenue are adjusted to reflect experience and to reflect actual amounts as rebates, refunds, discounts and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these deductions from revenue.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Restructuring provisions movements&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            345
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            459
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            438
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 368
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            328
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            354
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-468&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-344&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-268&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-42&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-54&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-87&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Transfers&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-53&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-17&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 131
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            345
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            459
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2022, additions to provisions of USD&#160;1.4 billion were mainly related to the following reorganizations:&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Initiative announced in April 2022 to implement a new streamlined organizational model designed to support innovation, growth and productivity.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  The continuation of the Innovative Medicines Division and the Operation unit (formerly Novartis Technical Operations and the Customer &amp;amp; Technology Solutions) 2021 restructuring initiatives.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2021, additions to provisions of USD 328 million were mainly related to the following reorganizations:&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  The Innovative Medicines Division commenced a plan to restructure its field force and supporting functions in response to changes in its go-to-market structure with increased utilization of digital technology.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Group-wide initiatives to streamline manufacturing platforms and manufacturing functions and implement new technologies continued. In addition, the Operations unit (formerly Customer &amp;amp; Technology Solutions) continued the phased implementation of the new operating model to transition activities to service centers.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2020, additions to provisions of USD&#160;354 million were mainly related to the following reorganizations:&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  The Innovative Medicines Division restructured its field force and supporting functions in Region Europe.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  The Sandoz Division initiatives to realign its organizational structures to improve competitiveness that commenced in 2019 continued. &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;"&gt;&#x2022;  Group-wide initiatives to streamline manufacturing platforms and manufacturing functions through the setup of operations centers and implementation of new technologies, in the Innovative Medicines Division and the Sandoz Division, continued. In addition, the Operations unit (formerly Customer &amp;amp; Technology Solutions) continued the phased implementation of the new operating model to change outsourcing structures and transition activities to service centers.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div/&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock>
    <nvs:ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_ac665d93-2eaf-4204-a85b-d310dce364cf_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Taxes other than income taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            836
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            619
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Restructuring provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 131
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            345
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued expenses for goods and services received but not invoiced&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 059
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 089
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accruals for royalties&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            767
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            752
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued interests on financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            116
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for deductions from revenue&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 732
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 481
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accruals for compensation and benefits, including social security&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 321
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 260
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Environmental remediation provisions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            123
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            123
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Provisions for product liabilities, governmental investigations and other legal matters&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            548
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued share-based payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            235
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            253
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            131
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            119
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares&lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            743
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            588
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total provisions and other current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            14 795
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 670
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 20 provides additional disclosures related to legal provisions.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Note 29 provides additional disclosures related to contingent consideration.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt; Note 18.3 provides additional disclosures related to commitment for repurchase of own shares.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock>
    <nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">836000000</nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">619000000</nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <ifrs-full:ShorttermRestructuringProvision
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1131000000</ifrs-full:ShorttermRestructuringProvision>
    <ifrs-full:ShorttermRestructuringProvision
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">345000000</ifrs-full:ShorttermRestructuringProvision>
    <ifrs-full:AccrualsClassifiedAsCurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1059000000</ifrs-full:AccrualsClassifiedAsCurrent>
    <ifrs-full:AccrualsClassifiedAsCurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1089000000</ifrs-full:AccrualsClassifiedAsCurrent>
    <nvs:AccruedRoyaltiesPayableClassifiedAsCurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">767000000</nvs:AccruedRoyaltiesPayableClassifiedAsCurrent>
    <nvs:AccruedRoyaltiesPayableClassifiedAsCurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">752000000</nvs:AccruedRoyaltiesPayableClassifiedAsCurrent>
    <ifrs-full:CurrentInterestPayable
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">116000000</ifrs-full:CurrentInterestPayable>
    <ifrs-full:CurrentInterestPayable
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">127000000</ifrs-full:CurrentInterestPayable>
    <ifrs-full:CurrentRefundsProvision
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">6732000000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">6481000000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">2321000000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2260000000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <nvs:EnvironmentalProvisionCurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">53000000</nvs:EnvironmentalProvisionCurrent>
    <nvs:EnvironmentalProvisionCurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">49000000</nvs:EnvironmentalProvisionCurrent>
    <ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">123000000</ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">123000000</ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">548000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent>
    <nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">56000000</nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">235000000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">253000000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <nvs:ContingentConsiderationCurrentPortion
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">131000000</nvs:ContingentConsiderationCurrentPortion>
    <nvs:ContingentConsiderationCurrentPortion
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">119000000</nvs:ContingentConsiderationCurrentPortion>
    <nvs:CommitmentForRepurchaseOwnShares
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2809000000</nvs:CommitmentForRepurchaseOwnShares>
    <ifrs-full:OtherCurrentPayables
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">743000000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:OtherCurrentPayables
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">588000000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:OtherCurrentNonfinancialLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">14795000000</ifrs-full:OtherCurrentNonfinancialLiabilities>
    <ifrs-full:OtherCurrentNonfinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">15670000000</ifrs-full:OtherCurrentNonfinancialLiabilities>
    <nvs:ProvisionsForReductionOfRevenueTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_1a8d941e-8fbb-4d94-968b-b2f93a0838f5_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 481
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 256
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 595
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of currency translation, business combinations&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-210&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-218&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            234
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments/utilizations&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-22 261&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-19 838&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-19 294&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Adjustments of prior years charged to income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-322&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-245&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-151&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current year income statement charge&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23 072
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20 413
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19 773
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in provisions offset against gross trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            113
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            99
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 732
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 481
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 256
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The provisions for deductions from revenue include specific healthcare plans and program rebates as well as non-healthcare plans and program-related rebates, returns and other deductions. The provisions for deductions from revenue are adjusted to reflect experience and to reflect actual amounts as rebates, refunds, discounts and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these deductions from revenue.&lt;/div&gt;
                &lt;/div&gt;
              </nvs:ProvisionsForReductionOfRevenueTableTextBlock>
    <ifrs-full:CurrentRefundsProvision
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">6481000000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">6256000000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision
      contextRef="AR_I-CurrentYearEnd-3"
      decimals="-6"
      unitRef="USD">5595000000</ifrs-full:CurrentRefundsProvision>
    <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-210000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-218000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">234000000</nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">22261000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">19838000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">19294000000</ifrs-full:ProvisionUsedOtherProvisions>
    <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-322000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
    <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-245000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
    <nvs:IncomeStatementAdjustmentsOfPriorYear contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-151000000</nvs:IncomeStatementAdjustmentsOfPriorYear>
    <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">23072000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
    <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">20413000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
    <nvs:IncomeStatementAdjustmentsOfCurrentYear contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">19773000000</nvs:IncomeStatementAdjustmentsOfCurrentYear>
    <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">28000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
    <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-113000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
    <nvs:ChangesInOffsetAgainstGrossTradeReceivables contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-99000000</nvs:ChangesInOffsetAgainstGrossTradeReceivables>
    <ifrs-full:CurrentRefundsProvision
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">6732000000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">6481000000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">6256000000</ifrs-full:CurrentRefundsProvision>
    <nvs:RestructuringProvisionsMovementsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_8343cd2f-4cde-43cd-944b-e07ac310f492_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            345
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            459
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            438
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Additions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 368
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            328
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            354
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-468&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-344&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-268&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Releases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-42&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-54&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-87&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Transfers&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-53&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-17&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 131
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            345
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            459
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:RestructuringProvisionsMovementsTableTextBlock>
    <ifrs-full:OtherProvisions
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">345000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">459000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">438000000</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">1368000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">328000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">354000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">468000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">344000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">268000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">42000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">54000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:UnusedProvisionReversedOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">87000000</ifrs-full:UnusedProvisionReversedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">-53000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">-27000000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">-19000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">-17000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">22000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">1131000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">345000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">459000000</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-8"
      unitRef="USD">1400000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">328000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember"
      decimals="-6"
      unitRef="USD">354000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:DisclosureOfCashFlowStatementExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_47eaf5bd-dcef-4558-9051-0614a90b32c7_0">
          &lt;div&gt;
            &lt;div id="anchorId001547161"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;
              &lt;b&gt;23. Details to the consolidated statements of cash flows&lt;/b&gt;
            &lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.1) Non-cash items and other adjustments&lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the reversal of non-cash items and other adjustments in the consolidated statements of&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;cash flows.&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation, amortization and impairments on:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 570
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 489
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 758
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            303
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            318
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            330
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Intangible assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 308
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 306
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 376
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Financial assets&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            260
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-38&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-335&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in provisions and other non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 403
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 411
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gains on disposal and other adjustments on property, plant and equipment; intangible assets;  financial assets; and other non-current assets, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-333&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-677&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-478&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-settled compensation expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            823
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            736
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            738
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Loss/(income) from associated companies&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 339&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-673&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 416
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 119
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 807
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net financial expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            817
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            891
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            947
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            11 546
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-5 299&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 881
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Includes fair value changes&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt;
                            &lt;span&gt; 2021 included the gain of USD 14.6 billion recognized from the divestment of the Group's investment in Roche (see Notes 2 and 4).&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2022, other than through business combinations, there were USD 635 million additions to intangible assets with deferred payments. In 2022, there were USD 247 million (2021: USD 321 million, 2020: USD 346 million) additions to right-of-use assets recognized.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.2) Total amount of income taxes paid &lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2022, the total amount of income taxes paid was USD&#160;2.0 billion (2021: USD&#160;2.3 billion), which was included within &#x201c;Net cash flows from operating activities.&#x201d;&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2020, the total amount of income taxes paid was USD&#160;1.9 billion, of which USD&#160;1.8 billion was included within &#x201c;Net cash flows from operating activities,&#x201d; and USD&#160;88 million was included within &#x201c;Net cash flows used in investing activities from discontinued operations.&#x201d;&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.3) Cash flows from changes in working capital and other operating items included in the net cash flows from operating activities&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;(Increase)/decrease in inventories&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-830&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            81
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-543&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;(Increase)/decrease in trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-589&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-389&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Decrease in trade payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-48&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-21&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-324&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in other current and non-current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-194&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-202&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            229
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in other current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            658
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            772
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            211
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other adjustments, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 003&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-291&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.4) Cash flows arising from acquisitions and divestments of interests in associated companies, net&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2021, acquisitions and divestments of interests in associated companies, net included USD 20.7 billion proceeds from the divestment of the Group&#x2019;s investment in Roche (see Notes 2 and 4).&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.5) Cash flows arising from acquisitions and divestments of businesses, net&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table is a summary of the cash flow impact of acquisitions and divestments of businesses. The most significant transactions are described in Note 2.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets recognized as a result of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 077&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-735&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-10 173&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value of previously held equity interests&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            42
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration payables, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            59
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            98
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments, deferred consideration and other adjustments, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            62
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows used for acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-864&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-633&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-10 006&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows (used for)/from divestments of businesses, net&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-15&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            66
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows used for acquisitions and divestments of businesses, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-879&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-567&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-9 957&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; In 2022, USD 15 million net cash outflows from divestments of businesses included USD 20 million reduction to cash and cash equivalents due to the derecognized cash and cash equivalents following a loss of control of a company upon expiry of an option to purchase the company, partly offset by USD 5 million net cash inflows from business divestments in 2022 and in prior years.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;span&gt; In 2022, the net identifiable assets of divested businesses amounted to USD 173 million, comprised of non-current assets of USD 132 million, current assets of USD 113 million, including USD 71 million cash and cash equivalents and of non-current and current liabilities of USD 72 million. Deferred sales price receivables and other adjustments amounted to USD 41 million.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;span&gt; In 2021, USD 66 million included USD 52 million net cash inflows from divestments in previous years, and a USD 14 million net cash inflow from a business divestment in 2021, comprised of intangible assets.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;span&gt; In 2020, USD 49 million represented the net cash inflows from divestments in previous years.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Notes 2 and 24 provide further information regarding acquisitions and divestments of businesses. All acquisitions were for cash.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.6) Reconciliation of liabilities arising from financing activities&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; financial &lt;br/&gt; debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Current &lt;br/&gt; financial &lt;br/&gt; debts and &lt;br/&gt; derivative &lt;br/&gt; financial &lt;br/&gt; instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Current lease &lt;br/&gt; liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 902
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 295
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            275
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of the current portion of non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 575&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            295
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments of lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-295&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-51&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New, modified and terminated leases, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            173
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions and divestments of businesses, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, lease interest and other changes, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-366&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-401&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-41&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification from non-current to current, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 325&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 325
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-224&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            224
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            20 244
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 931
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 538
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Change in current financial debts included net cash outflows from interest-bearing accounts of employees payable on demand amounting to USD 1.7 billion. See Note 21.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; financial &lt;br/&gt; debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Current &lt;br/&gt; financial &lt;br/&gt; debts and &lt;br/&gt; derivative &lt;br/&gt; financial &lt;br/&gt; instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Current lease &lt;br/&gt; liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 259
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 785
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 719
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            286
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of the current portion of non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 162&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 524&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments of lease liabilities, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-316&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-52&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New, modified and terminated leases, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            61
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, lease interest and other changes, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-124&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            62
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-774&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-309&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification from non-current to current, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 624&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 624
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-247&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            247
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            22 902
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 295
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            275
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; financial &lt;br/&gt; debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Current &lt;br/&gt; financial &lt;br/&gt; debts and &lt;br/&gt; derivative &lt;br/&gt; financial &lt;br/&gt; instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Current lease &lt;br/&gt; liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            20 353
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            7 031
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 703
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            246
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 126
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of the current portion of non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 003&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 261
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments of lease liabilities, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-312&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-56&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New, modified and terminated leases, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            221
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            32
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            36
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, lease interest and other changes, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            65
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            832
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            392
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification from non-current to current, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 067&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 067
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-250&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 259
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 785
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 719
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            286
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;23.7) Supplemental disclosures related to the Alcon business distributed to Novartis AG shareholders&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2020, net cash flows used in investing activities from discontinued operations of USD 127 million included the investing activities of the Alcon business, which was spun-off to Novartis AG shareholders on April 8, 2019, and cash outflows for transaction-related expenditures attributable to the series of portfolio transformation transactions completed in 2015. &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2020, net cash flows used in financing activities from discontinued operations of USD 50 million were for transaction cost payments directly attributable to the distribution (spin-off) of the Alcon business to Novartis AG shareholders on April 8, 2019.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfCashFlowStatementExplanatory>
    <nvs:AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_80b672d8-83aa-4a43-99fb-4335d458992f_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Depreciation, amortization and impairments on:&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 570
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 489
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 758
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            303
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            318
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            330
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Intangible assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 308
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 306
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4 376
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Financial assets&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            260
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-38&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-335&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in provisions and other non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 403
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 411
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Gains on disposal and other adjustments on property, plant and equipment; intangible assets;  financial assets; and other non-current assets, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-333&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-677&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-478&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-settled compensation expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            823
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            736
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            738
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Loss/(income) from associated companies&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-15 339&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-673&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Income taxes&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 416
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 119
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 807
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net financial expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            817
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            891
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            947
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            11 546
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-5 299&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 881
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Includes fair value changes&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt;
                            &lt;span&gt; 2021 included the gain of USD 14.6 billion recognized from the divestment of the Group's investment in Roche (see Notes 2 and 4).&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2022, other than through business combinations, there were USD 635 million additions to intangible assets with deferred payments. In 2022, there were USD 247 million (2021: USD 321 million, 2020: USD 346 million) additions to right-of-use assets recognized.&lt;/div&gt;
                &lt;/div&gt;
              </nvs:AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">1570000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">1489000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022PropertyPlantAndEquipmentMember"
      decimals="-6"
      unitRef="USD">1758000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember"
      decimals="-6"
      unitRef="USD">303000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember"
      decimals="-6"
      unitRef="USD">318000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember"
      decimals="-6"
      unitRef="USD">330000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">5308000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">4306000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember"
      decimals="-6"
      unitRef="USD">4376000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember"
      decimals="-6"
      unitRef="USD">260000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember"
      decimals="-6"
      unitRef="USD">-38000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022FinancialAssetsImpairedMember"
      decimals="-6"
      unitRef="USD">-335000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1403000000</nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities>
    <nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">896000000</nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities>
    <nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1411000000</nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-333000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-677000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-478000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">823000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">736000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">738000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-9000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">15339000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">673000000</ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1416000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">2119000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">1807000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-817000000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-891000000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-947000000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-30000000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">11546000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-5299000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">9881000000</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <nvs:GainOnDivestmentOfInterestsInAssociatedCompanies
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-8"
      unitRef="USD">14600000000</nvs:GainOnDivestmentOfInterestsInAssociatedCompanies>
    <nvs:AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember"
      decimals="-6"
      unitRef="USD">635000000</nvs:AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities>
    <nvs:AcquisitionOfAssetsRightOfUseAssetsThroughLeasing
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember"
      decimals="-6"
      unitRef="USD">247000000</nvs:AcquisitionOfAssetsRightOfUseAssetsThroughLeasing>
    <nvs:AcquisitionOfAssetsRightOfUseAssetsThroughLeasing
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember"
      decimals="-6"
      unitRef="USD">321000000</nvs:AcquisitionOfAssetsRightOfUseAssetsThroughLeasing>
    <nvs:AcquisitionOfAssetsRightOfUseAssetsThroughLeasing
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022RightofuseAssetsMember"
      decimals="-6"
      unitRef="USD">346000000</nvs:AcquisitionOfAssetsRightOfUseAssetsThroughLeasing>
    <ifrs-full:IncomeTaxesPaidRefund contextRef="AR_D-CurrentYear" decimals="-8" unitRef="USD">2000000000.0</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:IncomeTaxesPaidRefund contextRef="AR_D-CurrentYear-1" decimals="-8" unitRef="USD">2300000000</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:IncomeTaxesPaidRefund contextRef="AR_D-CurrentYear-2" decimals="-8" unitRef="USD">1900000000</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="AR_D-CurrentYear-2" decimals="-8" unitRef="USD">1800000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsInvestingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022DiscontinuedOperationsMember"
      decimals="-6"
      unitRef="USD">88000000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsInvestingActivities>
    <nvs:CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_93d9a48a-3929-4034-8865-bb163e5fa7b1_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;(Increase)/decrease in inventories&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-830&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            81
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-543&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;(Increase)/decrease in trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-589&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-389&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Decrease in trade payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-48&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-21&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-324&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in other current and non-current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-194&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-202&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            229
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in other current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            658
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            772
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            211
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other adjustments, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 003&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            241
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-291&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-830000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">81000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-543000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-589000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-389000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">137000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-48000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-21000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-324000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-194000000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-202000000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">229000000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">658000000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">772000000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">211000000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities>
    <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">0</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
    <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-1000000</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
    <nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-1003000000</nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems>
    <nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">241000000</nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems>
    <nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-291000000</nvs:ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems>
    <ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="-8"
      unitRef="USD">20700000000</ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations>
    <nvs:CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_eea59c31-11f7-4069-be1e-8cb92d410063_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets recognized as a result of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 24&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 077&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-735&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-10 173&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value of previously held equity interests&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            42
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration payables, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            205
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            59
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            98
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments, deferred consideration and other adjustments, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            62
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows used for acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-864&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-633&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-10 006&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows (used for)/from divestments of businesses, net&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-15&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            66
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash flows used for acquisitions and divestments of businesses, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-879&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-567&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-9 957&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; In 2022, USD 15 million net cash outflows from divestments of businesses included USD 20 million reduction to cash and cash equivalents due to the derecognized cash and cash equivalents following a loss of control of a company upon expiry of an option to purchase the company, partly offset by USD 5 million net cash inflows from business divestments in 2022 and in prior years.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;span&gt; In 2022, the net identifiable assets of divested businesses amounted to USD 173 million, comprised of non-current assets of USD 132 million, current assets of USD 113 million, including USD 71 million cash and cash equivalents and of non-current and current liabilities of USD 72 million. Deferred sales price receivables and other adjustments amounted to USD 41 million.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;span&gt; In 2021, USD 66 million included USD 52 million net cash inflows from divestments in previous years, and a USD 14 million net cash inflow from a business divestment in 2021, comprised of intangible assets.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                            &lt;span&gt; In 2020, USD 49 million represented the net cash inflows from divestments in previous years.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock>
    <nvs:CashFlowFromNetIdentifiableAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">1077000000</nvs:CashFlowFromNetIdentifiableAssets>
    <nvs:CashFlowFromNetIdentifiableAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">735000000</nvs:CashFlowFromNetIdentifiableAssets>
    <nvs:CashFlowFromNetIdentifiableAssets
      contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">10173000000</nvs:CashFlowFromNetIdentifiableAssets>
    <ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">21000000</ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate>
    <ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">42000000</ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate>
    <ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">7000000</ifrs-full:AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate>
    <nvs:ReceivablesAndPayablesContingentConsiderationNet
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">205000000</nvs:ReceivablesAndPayablesContingentConsiderationNet>
    <nvs:ReceivablesAndPayablesContingentConsiderationNet
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">59000000</nvs:ReceivablesAndPayablesContingentConsiderationNet>
    <nvs:ReceivablesAndPayablesContingentConsiderationNet
      contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">98000000</nvs:ReceivablesAndPayablesContingentConsiderationNet>
    <nvs:OtherPaymentsAndDeferredConsiderationNet
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">-13000000</nvs:OtherPaymentsAndDeferredConsiderationNet>
    <nvs:OtherPaymentsAndDeferredConsiderationNet
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:OtherPaymentsAndDeferredConsiderationNet>
    <nvs:OtherPaymentsAndDeferredConsiderationNet
      contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">62000000</nvs:OtherPaymentsAndDeferredConsiderationNet>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">-864000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">-633000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities
      contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember"
      decimals="-6"
      unitRef="USD">-10006000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">-15000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">66000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities
      contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">49000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-879000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">-567000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-9957000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">-15000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:CashOutflowsDueToDerecognizedCashAndCashEquivalents
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">20000000</nvs:CashOutflowsDueToDerecognizedCashAndCashEquivalents>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">-5000000</ifrs-full:ConsiderationPaidReceived>
    <nvs:NetIdentifiableAssetsOfDivestedBusiness
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">173000000</nvs:NetIdentifiableAssetsOfDivestedBusiness>
    <nvs:NoncurrentAssetsDivested
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">132000000</nvs:NoncurrentAssetsDivested>
    <nvs:CurrentAssetsDivested
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">113000000</nvs:CurrentAssetsDivested>
    <ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">71000000</ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013>
    <nvs:NoncurrentAndCurrentLiabilitiesDivested
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">72000000</nvs:NoncurrentAndCurrentLiabilitiesDivested>
    <nvs:DeferredSalePriceAndOtherAdjustments
      contextRef="AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">41000000</nvs:DeferredSalePriceAndOtherAdjustments>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">66000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">-52000000</ifrs-full:ConsiderationPaidReceived>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_ifrsfull-2022IntangibleAssetsAndGoodwillMember_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">-14000000</ifrs-full:ConsiderationPaidReceived>
    <nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities
      contextRef="AR_D-CurrentYear-2_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4DivestmentsMember"
      decimals="-6"
      unitRef="USD">49000000</nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities>
    <nvs:ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_e36c5d0b-3d14-4eb2-bef1-a17160d7f914_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; financial &lt;br/&gt; debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Current &lt;br/&gt; financial &lt;br/&gt; debts and &lt;br/&gt; derivative &lt;br/&gt; financial &lt;br/&gt; instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Current lease &lt;br/&gt; liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 902
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            6 295
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            275
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of the current portion of non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 575&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            295
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments of lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-295&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-51&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New, modified and terminated leases, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            173
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions and divestments of businesses, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, lease interest and other changes, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-366&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-401&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-41&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification from non-current to current, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 325&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 325
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-224&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            224
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            20 244
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 931
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 538
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            251
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt;
                            &lt;span&gt; Change in current financial debts included net cash outflows from interest-bearing accounts of employees payable on demand amounting to USD 1.7 billion. See Note 21.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; financial &lt;br/&gt; debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Current &lt;br/&gt; financial &lt;br/&gt; debts and &lt;br/&gt; derivative &lt;br/&gt; financial &lt;br/&gt; instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Current lease &lt;br/&gt; liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 259
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 785
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 719
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            286
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of the current portion of non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 162&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 524&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments of lease liabilities, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-316&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-52&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New, modified and terminated leases, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            61
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, lease interest and other changes, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-124&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            62
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-774&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-309&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification from non-current to current, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 624&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 624
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-247&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            247
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            22 902
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 295
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 621
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            275
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; financial &lt;br/&gt; debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Current &lt;br/&gt; financial &lt;br/&gt; debts and &lt;br/&gt; derivative &lt;br/&gt; financial &lt;br/&gt; instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Non-current &lt;br/&gt; lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Current lease &lt;br/&gt; liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1, 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            20 353
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            7 031
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 703
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            246
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Increase in non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 126
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Repayments of the current portion of non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 003&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 261
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Payments of lease liabilities, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-312&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest payments for amounts included in lease liabilities  classified as cash flows from operating activities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-56&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;New, modified and terminated leases, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            221
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Impact of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            32
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            36
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Changes in fair values, lease interest and other changes, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            65
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Amortization of bonds discount&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            832
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            392
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification from non-current to current, net&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 067&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 067
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-250&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            250
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31, 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            26 259
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9 785
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 719
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            286
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">22902000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">6295000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1621000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">275000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">16000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">2575000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">295000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">295000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-51000000</nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities>
    <nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">173000000</nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities>
    <nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">49000000</nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">9000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">3000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
    <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">13000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
    <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-60000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
    <nvs:AmortizationOfBondsDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">-17000000</nvs:AmortizationOfBondsDiscount>
    <nvs:AmortizationOfBondsDiscount
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">-5000000</nvs:AmortizationOfBondsDiscount>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">-366000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">-401000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-41000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-14000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">-2325000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">2325000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-224000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">224000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">20244000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">5931000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1538000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">251000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand contextRef="AR_D-CurrentYear" decimals="-8" unitRef="USD">1700000000</nvs:CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">26259000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">9785000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1719000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">286000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">16000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">2162000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">-3524000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">316000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-52000000</nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities>
    <nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">192000000</nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities>
    <nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">61000000</nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
    <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">124000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
    <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-62000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
    <nvs:AmortizationOfBondsDiscount
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">-25000000</nvs:AmortizationOfBondsDiscount>
    <nvs:AmortizationOfBondsDiscount
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">-4000000</nvs:AmortizationOfBondsDiscount>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">-774000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">-309000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-43000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-13000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">-2624000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">2624000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-247000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">247000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">22902000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">6295000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1621000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">275000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">20353000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">7031000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1703000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-3_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">246000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">7126000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">2003000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">2261000000</ifrs-full:CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">312000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-56000000</nvs:InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities>
    <nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">221000000</nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities>
    <nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">73000000</nvs:IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">32000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">36000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">8000000</ifrs-full:IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities>
    <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
    <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">30000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
    <nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-65000000</nvs:IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges>
    <nvs:AmortizationOfBondsDiscount
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">-16000000</nvs:AmortizationOfBondsDiscount>
    <nvs:AmortizationOfBondsDiscount
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">-5000000</nvs:AmortizationOfBondsDiscount>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">832000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">392000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">39000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">12000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">-2067000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">2067000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-250000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:ReclassificationFromNoncurrentToCurrentNet
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">250000000</nvs:ReclassificationFromNoncurrentToCurrentNet>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NonCurrentFinancialDebtsMember"
      decimals="-6"
      unitRef="USD">26259000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">9785000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4NoncurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1719000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <nvs:FinancialDebtsAndDerivativeInstruments
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022AssetsAndLiabilitiesAxis_nvs-2022Q4CurrentLeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">286000000</nvs:FinancialDebtsAndDerivativeInstruments>
    <ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-127000000</ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations>
    <ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">-50000000</ifrs-full:CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations>
    <ifrs-full:DisclosureOfBusinessCombinationsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_9f830ff0-f99f-4cc3-9ec6-f7f2b5774c64_0">
          &lt;div&gt;
            &lt;div id="anchorId001549265"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;24. Acquisitions of businesses&lt;/div&gt;
            &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Fair value of assets and liabilities arising from acquisitions of businesses:&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            26
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            32
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currently marketed products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            292
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            196
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Acquired research and development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 209
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            262
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 600
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other intangible assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            98
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            218
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            476
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-current financial and other assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventories&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            84
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables and financial and other current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            109
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            89
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            76
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-300&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-74&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 977&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables and other liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-67&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-144&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net identifiable assets acquired&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            612
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            7 669
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Acquired cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-89&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-76&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-controlling interests&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-105&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            161
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            238
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 580
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets recognized as a result of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 077
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            735
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10 173
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Note 2 details significant acquisitions of businesses, specifically of Gyroscope in 2022, the cephalosporin antibiotics business from GSK in 2021; and of the The Medicines Company and the Japanese business of AGI in 2020. The goodwill arising out of these acquisitions is attributable to the buyer-specific synergies, the assembled workforce, and the accounting for deferred tax liabilities on the acquired assets. In 2022, no goodwill (2021: USD 107 million; 2020: USD 74 million) is tax deductible. &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfBusinessCombinationsExplanatory>
    <nvs:FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_f2308544-9cb4-49c7-bced-9c9195b058de_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Property, plant and equipment&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            26
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Right-of-use assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            32
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currently marketed products&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            292
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            196
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Acquired research and development&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 209
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            262
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 600
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other intangible assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            98
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            218
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            476
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-current financial and other assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            49
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Inventories&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            84
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables and financial and other current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            109
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            89
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            76
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Deferred tax liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-300&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-74&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 977&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current and non-current lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables and other liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-67&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-144&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net identifiable assets acquired&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            612
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            7 669
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Acquired cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-89&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-10&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-76&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-controlling interests&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-105&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Goodwill&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            161
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            238
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 580
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net assets recognized as a result of acquisitions of businesses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 077
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            735
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            10 173
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="8" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock>
    <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">13000000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
    <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">26000000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
    <nvs:RightOfUseAssetsAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">12000000</nvs:RightOfUseAssetsAsOfAcquisitionDate>
    <nvs:RightOfUseAssetsAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">32000000</nvs:RightOfUseAssetsAsOfAcquisitionDate>
    <nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">292000000</nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">196000000</nvs:CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1209000000</nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">262000000</nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">8600000000</nvs:AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">98000000</nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">218000000</nvs:OtherIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">56000000</ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">476000000</ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate>
    <nvs:FinancialAndOtherAssets
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">49000000</nvs:FinancialAndOtherAssets>
    <ifrs-full:InventoryRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">84000000</ifrs-full:InventoryRecognisedAsOfAcquisitionDate>
    <nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">5000000</nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate>
    <nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1000000</nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate>
    <nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">109000000</nvs:TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">89000000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">10000000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">76000000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">300000000</ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">74000000</ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">1977000000</ifrs-full:DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">32000000</ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate>
    <nvs:CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">12000000</nvs:CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate>
    <nvs:CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">44000000</nvs:CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate>
    <nvs:TradePayablesAndOtherLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">67000000</nvs:TradePayablesAndOtherLiabilities>
    <nvs:TradePayablesAndOtherLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">4000000</nvs:TradePayablesAndOtherLiabilities>
    <nvs:TradePayablesAndOtherLiabilities
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">144000000</nvs:TradePayablesAndOtherLiabilities>
    <nvs:IdentifiableAssetsAcquired
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1005000000</nvs:IdentifiableAssetsAcquired>
    <nvs:IdentifiableAssetsAcquired
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">612000000</nvs:IdentifiableAssetsAcquired>
    <nvs:IdentifiableAssetsAcquired
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">7669000000</nvs:IdentifiableAssetsAcquired>
    <nvs:AcquiredCashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">89000000</nvs:AcquiredCashAndCashEquivalents>
    <nvs:AcquiredCashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">10000000</nvs:AcquiredCashAndCashEquivalents>
    <nvs:AcquiredCashAndCashEquivalents
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">76000000</nvs:AcquiredCashAndCashEquivalents>
    <ifrs-full:NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">105000000</ifrs-full:NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate>
    <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">161000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
    <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">238000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
    <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">2580000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1077000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">735000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">10173000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:GoodwillExpectedDeductibleForTaxPurposes
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">0</ifrs-full:GoodwillExpectedDeductibleForTaxPurposes>
    <ifrs-full:GoodwillExpectedDeductibleForTaxPurposes
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">107000000</ifrs-full:GoodwillExpectedDeductibleForTaxPurposes>
    <ifrs-full:GoodwillExpectedDeductibleForTaxPurposes
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">74000000</ifrs-full:GoodwillExpectedDeductibleForTaxPurposes>
    <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_448431e3-dfe5-4f27-9bb5-7ce10f2ca56e_0">
          &lt;div&gt;
            &lt;div id="anchorId001549649"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;25. Post-employment benefits for employees&lt;/div&gt;
            &lt;div style=" padding-bottom: 10px;"&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Defined benefit plans&lt;/span&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In addition to the legally required social security schemes, the Group has numerous independent pension and other post-employment benefit plans. In most cases, these plans are externally funded in entities that are legally separate from the Group. For certain Group companies, however, no independent plan assets exist for the pension and other post-employment benefit obligations of employees. In these cases, the related unfunded liability is included in the balance sheet. The defined benefit obligations (DBOs) of all major pension and other post-employment benefit plans are reappraised annually by independent actuaries. Plan assets are recognized at fair value. The major plans are based in Switzerland, the United States, the United Kingdom, Germany and Japan, which represent &lt;span&gt;95%&lt;/span&gt; of the Group&#x2019;s total DBO for pension plans. Details of the plans in the two most significant countries, Switzerland and the United States, which represent &lt;span&gt;83%&lt;/span&gt; of the Group&#x2019;s total DBO for post-employment benefit plans, are provided below.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Swiss-based pension plans represent the most significant portion of the Group&#x2019;s total DBO and plan assets. For the active insured members the benefits are linked to contributions paid into the plan, interest credits granted and conversion rates applied. &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;All benefits granted under Swiss-based pension plans are vested, and Swiss legislation prescribes that the employer has to contribute a fixed percentage of an employee&#x2019;s pay to an external pension fund. Additional employer contributions may be required whenever the plan&#x2019;s statutory funding ratio falls below a certain level. The employee also contributes to the plan. The pension plans are run by separate legal entities, each governed by a board of trustees that &#x2013; for the principal plans &#x2013; consists of representatives nominated by Novartis and the active insured employees. The boards of trustees are responsible for the plan design and asset investment strategy.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In December 2020, the Board of Trustees of the Novartis Swiss Pension Fund agreed to adjust the annuity conversion rate at retirement with effect from January 1, 2022. This amendment did not affect existing pensioners, and its impact on existing plan participants will be mitigated by way of defined compensatory measures. This amendment resulted in a net pre-tax curtailment gain of USD 101 million (CHF 90 million) recognized in 2020.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The United States pension plans represent the second-largest component of the Group&#x2019;s total DBO and plan assets. The principal plans (Qualified Plans) are funded, whereas plans providing additional benefits for executives (Restoration Plans) are unfunded. Employer contributions are required for Qualified Plans whenever the statutory funding ratio falls below a certain level. &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Furthermore, in certain countries, employees are covered under other post-employment benefit plans and post-retirement medical plans.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In the US, other post-employment benefit plans consist primarily of post-employment healthcare benefits, which have been closed to new members since 2015. Part of the costs of these plans is reimbursable under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. There is no statutory funding requirement for these plans. The Group is funding these plans to the extent that it is tax efficient.&lt;/div&gt;
                &lt;div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following tables are a summary of the funded and unfunded defined benefit obligation for pension and other post-employment benefit plans of employees at December 31, 2022 and 2021:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment  benefit plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            23 583
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 602
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            632
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current service cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            348
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            415
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            151
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past service costs and settlements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-40&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            63
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Administrative expenses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurement gains arising from changes in financial assumptions&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 046&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-713&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-94&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-20&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurement (gains)/losses arising from changes in demographic assumptions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-53&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-377&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Experience-related remeasurement losses/(gains)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            199
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            531
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-47&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-650&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-865&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Benefit payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 253&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 450&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions of employees&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            174
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            17 533
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            23 583
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            422
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 420
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            22 317
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            89
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            220
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Return on plan assets excluding interest income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 500&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 512
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-539&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-726&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            424
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            490
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            41
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions of employees&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            174
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Settlements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Benefit payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 253&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 450&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            18 945
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            22 420
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 412
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 163&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-362&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Limitation on recognition of fund surplus at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-51&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in limitation on recognition of fund surplus&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 504&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-76&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income on limitation of fund surplus&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Limitation on recognition of fund surplus at December 31&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2 644&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability in the balance sheet at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 232&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 225&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-362&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; The remeasurement gains arising from changes in financial assumptions is driven mainly by changes in the actuarial discount rates used to determine the benefit obligation.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt;
                            &lt;span&gt; As of December 31, 2022, the most significant pension plans where the asset ceiling was required to be applied were in Switzerland and amounted to USD 2 587 million.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The reconciliation of the net liability from January 1 to December 31 is as follows:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment  benefit plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 225&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 336&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-543&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current service cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-348&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-415&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-11&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net interest expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-31&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-47&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-15&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Administrative expenses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-23&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-24&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past service costs and settlements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-70&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 071
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            110
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            70
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            424
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            490
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            41
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-23&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in limitation on recognition of fund surplus&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 504&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 232&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 225&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-362&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Amounts recognized in the consolidated balance sheet&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid benefit cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            491
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 415
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued benefit liability&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 723&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 640&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-362&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows a breakdown of the DBO for pension plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; United&lt;br/&gt; States&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of&lt;br/&gt; the world&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; United&lt;br/&gt; States&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of&lt;br/&gt; the world&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            11 824
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 746
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 963
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            17 533
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 268
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 645
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 670
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            23 583
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Thereof unfunded&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            556
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            363
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            919
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            688
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            439
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            1 127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;By type of member&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Active&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 799
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            431
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            931
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 161
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 478
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            620
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 412
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 510
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Deferred pensioners&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            830
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            861
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 691
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 208
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 730
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 938
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Pensioners&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 025
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 171
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9 681
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 790
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 817
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 528
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12 135
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            14 701
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 978
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 266
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            18 945
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            16 436
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 551
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 433
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            22 420
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 877
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-768&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-697&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 412
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 094&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 237&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 163&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows a breakdown of the DBO for other post-employment benefit plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; United&lt;br/&gt; States&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of&lt;br/&gt; the world&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; United&lt;br/&gt; States&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of&lt;br/&gt; the world&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            346
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            76
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            422
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            473
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            87
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Thereof unfunded&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            286
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            76
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            362
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            87
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;By type of member&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Active&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            48
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            83
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Deferred pensioners&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Pensioners&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            308
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            58
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            366
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            64
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            464
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-286&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-76&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-362&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-400&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-87&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the principal weighted average actuarial assumptions used for calculating defined benefit plans and other post-employment benefits of employees:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment  benefit plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Weighted average assumptions used to determine  benefit obligations at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Discount rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              3.0%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.9%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.6%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              6.3%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              3.3%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              2.9%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expected rate of pension increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.4%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.3%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expected rate of salary increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.9%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              2.7%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              2.7%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest on savings account&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.2%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.1%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current average life expectancy  for a 65-year-old male in years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current average life expectancy  for a 65-year-old female in years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Changes in the aforementioned actuarial assumptions can result in significant volatility in the accounting for the Group&#x2019;s pension plans in the consolidated financial statements. This can result in substantial changes in the Group&#x2019;s other comprehensive income, long-term liabilities and prepaid pension assets.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The DBO is significantly impacted by assumptions regarding the rate that is used to discount the actuarially determined post-employment benefit liability. This rate is based on yields of high-quality corporate bonds in the country of the plan. Decreasing corporate bond yields decrease the discount rate, so that the DBO increases and the funded status decreases.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In Switzerland, an increase in the DBO due to lower discount rates is slightly offset by lower future benefits expected to be paid on the employee&#x2019;s savings account where the assumption on interest accrued often changes broadly in line with the discount rate.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The impact of decreasing interest rates on a plan&#x2019;s assets is more difficult to predict. A significant part of the plan assets is invested in bonds. Bond values usually rise when interest rates decrease and may therefore partially compensate for the decrease in the funded status. Furthermore, pension assets also include significant holdings of equity instruments. Share prices usually tend to rise when interest rates decrease and therefore often counteract the negative impact of the rising defined benefit obligation on the funded status (although the correlation of interest rates with equities is not as strong as with bonds, especially in the short term).&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The expected rate for pension increases significantly affects the DBO of most plans in Switzerland, Germany and the United Kingdom. Such pension increases also decrease the funded status, although there is no strong correlation between the value of the plan assets and pension/inflation increases.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Assumptions regarding life expectancy significantly impact the DBO. An increase in longevity increases the DBO. There is no offsetting impact from the plan assets, as no longevity bonds or swaps are held by the pension funds. The Group&#x2019;s actuaries use mortality tables which take into account historic patterns and expected changes, such as further increases in longevity. &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In 2022 the mortality assumptions used for the pension plans in Switzerland were based on BVG 2020 tables with future improvements based on the BVG generational model. In US for the Pension and Postretirement Medical Benefit Plans, the Society of Actuaries Pri-2012 mortality tables with generational improvements based on Scale MP-2021 are used.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table shows the sensitivity of the defined benefit pension obligation to the principal actuarial assumptions for the major plans in Switzerland, the United States, the United Kingdom, Germany and Japan on an aggregated basis:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change in 2022 &lt;br/&gt; year-end defined &lt;br/&gt; benefit pension &lt;br/&gt; obligation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change in 2021 &lt;br/&gt; year-end defined &lt;br/&gt; benefit pension &lt;br/&gt; obligation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in discount rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-466&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-790&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in discount rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            491
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            839
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One-year increase in life expectancy&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            535
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            869
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in rate of pension increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            316
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            512
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in rate of pension increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-63&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-136&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase of interest on savings account&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            58
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease of interest on savings account&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-37&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-58&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in rate of salary increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            54
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in rate of salary increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-37&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-54&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div/&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The healthcare cost trend rate assumptions used for other post-employment benefits are as follows:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Healthcare cost trend rate assumed for next year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              6.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              6.0%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              6.3%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rate to which the cost trend rate is assumed to decline&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              4.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              4.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              4.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Year that the rate reaches the ultimate trend rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2031
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2028
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2028
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the weighted average plan asset allocation of funded defined benefit pension plans at December 31, 2022 and&#160;2021:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(as a percentage)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Long-term &lt;br/&gt; target &lt;br/&gt; minimum&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Long-term &lt;br/&gt; target &lt;br/&gt; maximum&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            40
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            27
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            31
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            33
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Real estate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Alternative investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and other investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Cash and most of the equity and debt securities have a quoted market price in an active market. Real estate and alternative investments, which include hedge fund, private equity, infrastructure and commodity investments, usually have a quoted market price or a regularly updated net asset value.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The strategic allocation of assets of the different pension plans is determined with the objective of achieving an investment return that, together with the contributions paid by the Group and its employees, is sufficient to maintain reasonable control over the various funding risks of the plans. Based upon the market and economic environments, actual asset allocations may temporarily be permitted to deviate from policy targets. The asset allocation currently includes investments in shares of Novartis AG as per the below table: &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; December 31, &lt;br/&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br/&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Investment in shares of Novartis AG&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Number of shares (in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Market value (in USD billions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The weighted average duration of the defined benefit pension obligation is 11.8 years (2021: 14.9 years).&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&#x2019;s ordinary contribution to the various pension plans is based on the rules of each plan. Additional contributions are made whenever this is required by statute or law (i.e., usually when statutory funding levels fall below predetermined thresholds). The only significant plans that require additional funding are those in the United Kingdom and Germany.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The expected future cash flows in respect of pension and other post-employment benefit plans at December 31, 2022, were as follows:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Pension plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-&lt;br/&gt; employment&lt;br/&gt; benefit plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023 (estimated)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            397
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Expected future benefit payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 268
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 441
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 128
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2026&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 114
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2027&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 099
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2028&#x2013;2032&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 310
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            171
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Defined contribution plans&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In many subsidiaries, employees are covered by defined contribution plans. Contributions charged to the consolidated income statement for the defined contribution plans were: &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions for defined contribution plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            520
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            501
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group&#x2019;s total personnel costs amounted to USD 14.9 billion in 2022.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div/&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
    <nvs:ConcentrationOfMajorPlansGeographic
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_77f8ca46-8d50-4d9e-93e4-19bcf18d3935_0">

                  In addition to the legally required social security schemes, the Group has numerous independent pension and other post-employment benefit plans. In most cases, these plans are externally funded in entities that are legally separate from the Group. For certain Group companies, however, no independent plan assets exist for the pension and other post-employment benefit obligations of employees. In these cases, the related unfunded liability is included in the balance sheet. The defined benefit obligations (DBOs) of all major pension and other post-employment benefit plans are reappraised annually by independent actuaries. Plan assets are recognized at fair value. The major plans are based in Switzerland, the United States, the United Kingdom, Germany and Japan, which represent 95% of the Group&#x2019;s total DBO for pension plans. Details of the plans in the two most significant countries, Switzerland and the United States, which represent 83% of the Group&#x2019;s total DBO for post-employment benefit plans, are provided below.

              </nvs:ConcentrationOfMajorPlansGeographic>
    <nvs:MajorPlansPercentageInGroupDBOPensions
      contextRef="AR_I-CurrentYearEnd"
      decimals="2"
      unitRef="Pure">0.95</nvs:MajorPlansPercentageInGroupDBOPensions>
    <nvs:MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans
      contextRef="AR_I-CurrentYearEnd"
      decimals="2"
      unitRef="Pure">0.83</nvs:MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans>
    <nvs:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">101000000</nvs:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <nvs:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="CHF">90000000</nvs:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <nvs:DisclosureOfDefinedBenefitPlansTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_433d337a-3850-4a58-9c0d-8570d31a8d9e_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment  benefit plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            23 583
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            25 602
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            632
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current service cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            348
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            415
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            249
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            151
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            16
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past service costs and settlements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-40&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            63
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Administrative expenses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurement gains arising from changes in financial assumptions&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 046&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-713&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-94&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-20&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurement (gains)/losses arising from changes in demographic assumptions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-53&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-377&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Experience-related remeasurement losses/(gains)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            199
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            531
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-28&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-47&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-650&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-865&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Benefit payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 253&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 450&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions of employees&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            174
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            17 533
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            23 583
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            422
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            22 420
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            22 317
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            89
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            220
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Return on plan assets excluding interest income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 500&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 512
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-539&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-726&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            424
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            490
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            41
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions of employees&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            174
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Settlements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Benefit payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 253&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 450&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-32&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            18 945
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            22 420
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 412
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 163&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-362&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Limitation on recognition of fund surplus at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-51&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in limitation on recognition of fund surplus&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 504&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-76&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest income on limitation of fund surplus&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Limitation on recognition of fund surplus at December 31&lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2 644&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-62&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability in the balance sheet at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 232&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 225&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-362&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; The remeasurement gains arising from changes in financial assumptions is driven mainly by changes in the actuarial discount rates used to determine the benefit obligation.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt;
                            &lt;span&gt; As of December 31, 2022, the most significant pension plans where the asset ceiling was required to be applied were in Switzerland and amounted to USD 2 587 million.&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfDefinedBenefitPlansTableTextBlock>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">23583000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">25602000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">560000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">632000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">348000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">415000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">12000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">11000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <nvs:DefinedBenefitPlanInterestCost
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">249000000</nvs:DefinedBenefitPlanInterestCost>
    <nvs:DefinedBenefitPlanInterestCost
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">151000000</nvs:DefinedBenefitPlanInterestCost>
    <nvs:DefinedBenefitPlanInterestCost
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">17000000</nvs:DefinedBenefitPlanInterestCost>
    <nvs:DefinedBenefitPlanInterestCost
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">16000000</nvs:DefinedBenefitPlanInterestCost>
    <nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-40000000</nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset>
    <nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">63000000</nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset>
    <nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset>
    <nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-3000000</nvs:PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset>
    <nvs:AdministrativeExpenseNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">23000000</nvs:AdministrativeExpenseNetDefinedBenefitLiabilityAsset>
    <nvs:AdministrativeExpenseNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">24000000</nvs:AdministrativeExpenseNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">5046000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">713000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">94000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">20000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">53000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">377000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-4000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-199000000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-531000000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">47000000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-650000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability>
    <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-865000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability>
    <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-2000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability>
    <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-1000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1253000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1450000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">44000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">32000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <nvs:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">174000000</nvs:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation>
    <nvs:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">179000000</nvs:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation>
    <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-1000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1>
    <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">23000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">17533000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">23583000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">422000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">560000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">22420000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">22317000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">73000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">89000000</ifrs-full:PlanAssetsAtFairValue>
    <nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-220000000</nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset>
    <nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-105000000</nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset>
    <nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-2000000</nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset>
    <nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-2000000</nvs:InterestExpenseIncomeDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2500000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-1512000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">12000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-7000000</ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset>
    <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">539000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset>
    <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">726000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">424000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">490000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">41000000</nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset>
    <nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">7000000</nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">174000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">179000000</ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset>
    <nvs:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:DefinedBenefitPlanSettlementsPlanAssets>
    <nvs:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">7000000</nvs:DefinedBenefitPlanSettlementsPlanAssets>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1253000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1450000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">44000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">32000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">18945000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">22420000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">60000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">73000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1412000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-1163000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-362000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-487000000</ifrs-full:SurplusDeficitInPlan>
    <nvs:LimitationOnRecognitionOfFundSurplus
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-62000000</nvs:LimitationOnRecognitionOfFundSurplus>
    <nvs:LimitationOnRecognitionOfFundSurplus
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-51000000</nvs:LimitationOnRecognitionOfFundSurplus>
    <ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-2504000000</ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling>
    <ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-16000000</ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling>
    <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">76000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus>
    <nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-6000000</nvs:IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus>
    <nvs:InterestIncomeOnLimitationOfFundSurplus
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2000000</nvs:InterestIncomeOnLimitationOfFundSurplus>
    <nvs:InterestIncomeOnLimitationOfFundSurplus
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:InterestIncomeOnLimitationOfFundSurplus>
    <nvs:LimitationOnRecognitionOfFundSurplus
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-2644000000</nvs:LimitationOnRecognitionOfFundSurplus>
    <nvs:LimitationOnRecognitionOfFundSurplus
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-62000000</nvs:LimitationOnRecognitionOfFundSurplus>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1232000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1225000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">362000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">487000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <nvs:LimitationOnRecognitionOfFundSurplus
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2587000000</nvs:LimitationOnRecognitionOfFundSurplus>
    <nvs:DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_c1d0dc55-6f78-451b-b265-96c22462babc_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment  benefit plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 225&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-3 336&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-543&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current service cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-348&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-415&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-11&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Net interest expense&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-31&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-47&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-15&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Administrative expenses&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-23&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-24&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Past service costs and settlements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-70&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Remeasurements&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 071
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            110
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            70
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            145
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            424
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            490
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            41
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Effect of acquisitions, divestments or transfers&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-23&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Change in limitation on recognition of fund surplus&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 504&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net liability at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 232&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 225&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-362&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Amounts recognized in the consolidated balance sheet&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Prepaid benefit cost&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            491
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 415
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Accrued benefit liability&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 723&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 640&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-362&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1225000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">3336000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">487000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">543000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">348000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">415000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">12000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">11000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">31000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">47000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">15000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">14000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-23000000</ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets>
    <ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-24000000</ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets>
    <ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-39000000</ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">70000000</ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">1000000</ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-3000000</ifrs-full:PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2400000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2071000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">110000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">70000000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-35000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-145000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-2000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-1000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">424000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">490000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">41000000</nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset>
    <nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">7000000</nvs:ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset>
    <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-1000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1>
    <nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">23000000</nvs:IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1>
    <ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-2504000000</ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling>
    <ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-16000000</ifrs-full:GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1232000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1225000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">362000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">487000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <nvs:PrepaidPostemploymentBenefitPlansAssets
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">491000000</nvs:PrepaidPostemploymentBenefitPlansAssets>
    <nvs:PrepaidPostemploymentBenefitPlansAssets
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1415000000</nvs:PrepaidPostemploymentBenefitPlansAssets>
    <nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1723000000</nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities>
    <nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2640000000</nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities>
    <nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">362000000</nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities>
    <nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">487000000</nvs:DefinedBenefitPensionPlanAccruedBenefitLiabilities>
    <nvs:BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      id="SectionBlock_87184e57-05cb-43f4-85ae-09cfd21bd203_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; United&lt;br/&gt; States&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of&lt;br/&gt; the world&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; United&lt;br/&gt; States&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of&lt;br/&gt; the world&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            11 824
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 746
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 963
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            17 533
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            15 268
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 645
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 670
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            23 583
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Thereof unfunded&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            556
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            363
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            919
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            688
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            439
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            1 127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;By type of member&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Active&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 799
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            431
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            931
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 161
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 478
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            620
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 412
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 510
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Deferred pensioners&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            830
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            861
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 691
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 208
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 730
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 938
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Pensioners&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 025
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 171
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9 681
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 790
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 817
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 528
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12 135
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            14 701
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 978
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 266
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            18 945
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            16 436
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 551
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            3 433
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            22 420
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 877
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-768&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-697&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 412
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 168
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 094&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 237&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 163&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="18" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">11824000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2746000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2963000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">17533000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">15268000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">3645000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">4670000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">23583000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">556000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">363000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">919000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">688000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">439000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1127000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">4799000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">431000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">931000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">6161000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">6478000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">620000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1412000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">8510000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">830000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">861000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1691000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1208000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1730000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2938000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">7025000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1485000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1171000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">9681000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">8790000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1817000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1528000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">12135000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">14701000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1978000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2266000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">18945000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">16436000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2551000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">3433000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">22420000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">2877000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-768000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-697000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1412000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1168000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-1094000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-1237000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">-1163000000</ifrs-full:SurplusDeficitInPlan>
    <nvs:BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      id="SectionBlock_624671d2-8652-4078-8166-89bb19fbbd6c_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; United&lt;br/&gt; States&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Rest of&lt;br/&gt; the world&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; United&lt;br/&gt; States&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Rest of&lt;br/&gt; the world&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Benefit obligation at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            346
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            76
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            422
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            473
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            87
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Thereof unfunded&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            286
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            76
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            362
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            87
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            487
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;By type of member&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Active&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            48
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            83
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Deferred pensioners&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Pensioners&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            308
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            58
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            366
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            400
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            64
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            464
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Fair value of plan assets at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            73
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Funded status&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-286&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-76&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-362&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-400&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-87&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-487&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">346000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">76000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">422000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">473000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">87000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">560000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">286000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">76000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">362000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">400000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">87000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">487000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">30000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">18000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">48000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">60000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">23000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4ActiveMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">83000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">8000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">0</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">8000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">13000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">0</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4DeferredPensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">13000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">308000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">58000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">366000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">400000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">64000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4PensionersMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">464000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">60000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">0</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">60000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">73000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">0</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">73000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-286000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-76000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-362000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_country-2022US_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-400000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022ForeignCountriesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-87000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">-487000000</ifrs-full:SurplusDeficitInPlan>
    <nvs:ScheduleOfAssumptionsUsedTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_1e83a3ec-23cd-4ff1-ae04-0dbf0adbb7fa_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-employment  benefit plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Weighted average assumptions used to determine  benefit obligations at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Discount rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              3.0%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.9%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.6%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              6.3%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              3.3%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              2.9%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expected rate of pension increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              0.4%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.3%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expected rate of salary increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.9%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              2.7%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              2.7%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest on savings account&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              2.2%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              0.1%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current average life expectancy  for a 65-year-old male in years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current average life expectancy  for a 65-year-old female in years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ScheduleOfAssumptionsUsedTableTextBlock>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.030</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.009</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.006</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="3"
      unitRef="Pure">0.063</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="3"
      unitRef="Pure">0.033</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="3"
      unitRef="Pure">0.029</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.004</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.005</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.003</ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.029</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.027</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.027</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.022</nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount>
    <nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.005</nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount>
    <nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="3"
      unitRef="Pure">0.001</nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount>
    <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">P22Y</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
    <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">P22Y</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
    <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">P22Y</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
    <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">P21Y</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
    <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">P21Y</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
    <nvs:DefinedBenefitAssumptionLifeExpectancyMale contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">P21Y</nvs:DefinedBenefitAssumptionLifeExpectancyMale>
    <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">P24Y</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
    <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">P24Y</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
    <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">P24Y</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
    <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">P23Y</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
    <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">P23Y</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
    <nvs:DefinedBenefitAssumptionLifeExpectancyFemale contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">P23Y</nvs:DefinedBenefitAssumptionLifeExpectancyFemale>
    <nvs:ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_babfaf05-061e-49a1-a421-1e1ce9f09a4d_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Change in 2022 &lt;br/&gt; year-end defined &lt;br/&gt; benefit pension &lt;br/&gt; obligation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Change in 2021 &lt;br/&gt; year-end defined &lt;br/&gt; benefit pension &lt;br/&gt; obligation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in discount rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-466&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-790&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in discount rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            491
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            839
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;One-year increase in life expectancy&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            535
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            869
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in rate of pension increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            316
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            512
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in rate of pension increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-63&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-136&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase of interest on savings account&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            58
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease of interest on savings account&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-37&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-58&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point increase in rate of salary increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            54
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;25 basis point decrease in rate of salary increase&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-37&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-54&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div/&gt;
              </nvs:ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">-466000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">-790000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">491000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">839000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4LifeExpectancyMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Increase1YearMember"
      decimals="-6"
      unitRef="USD">535000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4LifeExpectancyMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Increase1YearMember"
      decimals="-6"
      unitRef="USD">869000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">316000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">512000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">-63000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">-136000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">38000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">58000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">-37000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_nvs-2022Q4ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">-58000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">37000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">54000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">-37000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember"
      decimals="-6"
      unitRef="USD">-54000000</ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption>
    <nvs:ScheduleOfHealthCareCostTrendRatesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_4dc1c8f0-5fff-40c8-afd9-cc30af559e84_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Healthcare cost trend rate assumed for next year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              6.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              6.0%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              6.3%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Rate to which the cost trend rate is assumed to decline&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              4.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              4.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;
                              4.5%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Year that the rate reaches the ultimate trend rate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2031
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2028
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2028
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ScheduleOfHealthCareCostTrendRatesTableTextBlock>
    <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="3"
      unitRef="Pure">0.065</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="3"
      unitRef="Pure">0.060</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
      contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="3"
      unitRef="Pure">0.063</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline
      contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="3"
      unitRef="Pure">0.045</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline>
    <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="3"
      unitRef="Pure">0.045</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline>
    <nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline
      contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="3"
      unitRef="Pure">0.045</nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline>
    <nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">2031</nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate>
    <nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">2028</nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate>
    <nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate contextRef="AR_D-CurrentYear-2_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember">2028</nvs:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate>
    <nvs:ScheduleOfAllocationOfPlanAssetsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_72b4173f-724b-418f-9d46-ff2f4d06224d_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Pension plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(as a percentage)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Long-term &lt;br/&gt; target &lt;br/&gt; minimum&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Long-term &lt;br/&gt; target &lt;br/&gt; maximum&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            40
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            27
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            60
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            31
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            33
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Real estate&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Alternative investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and other investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.15</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum>
    <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.40</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.24</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022EquityInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.27</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.20</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum>
    <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.60</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.31</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.33</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.05</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum>
    <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.30</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.21</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4RealEstateMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.19</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum>
    <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.20</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.18</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AlternativeInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.15</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum>
    <nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum
      contextRef="AR_D-CurrentYear_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.15</nvs:DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.06</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4CashAndOtherInvestmentsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">0.06</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">1</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:DefinedBenefitPlanPlanAssetAllocations
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="2"
      unitRef="Pure">1</nvs:DefinedBenefitPlanPlanAssetAllocations>
    <nvs:ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_e96ddc53-6ede-41e8-a590-5e80410d9f0e_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; December 31, &lt;br/&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; December 31, &lt;br/&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Investment in shares of Novartis AG&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&#160;&#160;Number of shares (in millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Market value (in USD billions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock>
    <nvs:EmployerSharesHeldByDefinedBenefitPlan
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-5"
      unitRef="Shares">2300000</nvs:EmployerSharesHeldByDefinedBenefitPlan>
    <nvs:EmployerSharesHeldByDefinedBenefitPlan
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-5"
      unitRef="Shares">2300000</nvs:EmployerSharesHeldByDefinedBenefitPlan>
    <nvs:ValueOfEmployerSharesHeldByDefinedBenefitPlan
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-8"
      unitRef="USD">200000000</nvs:ValueOfEmployerSharesHeldByDefinedBenefitPlan>
    <nvs:ValueOfEmployerSharesHeldByDefinedBenefitPlan
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-8"
      unitRef="USD">200000000</nvs:ValueOfEmployerSharesHeldByDefinedBenefitPlan>
    <nvs:WeightedAverageDurationOfDefinedBenefitObligationYears contextRef="AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">P11Y9M18D</nvs:WeightedAverageDurationOfDefinedBenefitObligationYears>
    <nvs:WeightedAverageDurationOfDefinedBenefitObligationYears contextRef="AR_D-CurrentYear-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember">P14Y10M24D</nvs:WeightedAverageDurationOfDefinedBenefitObligationYears>
    <nvs:ScheduleOfExpectedBenefitPaymentsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_52c7fbda-1ac5-4d45-a753-58114eef7455_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Pension plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other post-&lt;br/&gt; employment&lt;br/&gt; benefit plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Novartis Group contributions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023 (estimated)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            397
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Expected future benefit payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 268
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 441
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 128
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2026&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 114
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2027&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 099
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            38
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2028&#x2013;2032&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 310
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            171
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">397000000</nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">38000000</nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1268000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">38000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1441000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">38000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1128000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">38000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1114000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">38000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">1099000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">38000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember"
      decimals="-6"
      unitRef="USD">5310000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:DefinedBenefitPlanExpectedFutureBenefitPayment
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsAndNotLaterThanTenYearsMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember"
      decimals="-6"
      unitRef="USD">171000000</nvs:DefinedBenefitPlanExpectedFutureBenefitPayment>
    <nvs:ScheduleOfDefinedContributionPlansTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_3ceb567a-385a-4455-a995-e2c0a85441ee_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contributions for defined contribution plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            520
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            523
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            501
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group&#x2019;s total personnel costs amounted to USD 14.9 billion in 2022.&lt;/div&gt;
                &lt;/div&gt;

                &lt;div/&gt;
              </nvs:ScheduleOfDefinedContributionPlansTableTextBlock>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="AR_D-CurrentYear_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember"
      decimals="-6"
      unitRef="USD">520000000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember"
      decimals="-6"
      unitRef="USD">523000000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ContinuingAndDiscontinuedOperationsAxis_ifrsfull-2022ContinuingOperationsMember"
      decimals="-6"
      unitRef="USD">501000000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:EmployeeBenefitsExpense contextRef="AR_D-CurrentYear" decimals="-8" unitRef="USD">14900000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_f2d5a265-6acb-4c4a-a466-dfdd06d9709a_0">
          &lt;div&gt;
            &lt;div id="anchorId001552812"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;26. Equity-based participation plans for employees&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The expense related to all equity-based participation plans and the liabilities arising from equity-based payment transactions were as follows:&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense related to equity-based  participation plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 048
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            979
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Liabilities arising from equity-based  payment transactions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            235
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            253
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            269
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Equity-based participation plans can be separated into the following plans:&lt;/div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Annual Incentive&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Annual Incentive for the Novartis Group CEO and other Executive Committee members (ECN) is paid 50% in cash and 50% in Novartis restricted shares (RSs) or restricted share units (RSUs). For the Novartis Top Leaders (NTLs), the Annual Incentive is paid 70% in cash and 30% in RSs or RSUs. Both the ECN and NTLs can opt to invest up to the maximum cash portion of their Annual Incentive to receive further RSs or RSUs. Any cash is paid out during March in the year following the end of the performance period, and the shares are granted during January in the year following the end of the performance period. &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Employee share savings plan&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis operates employee share savings and purchase plans in certain countries. The most significant is described below.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Employee Share Ownership Plan (ESOP) in Switzerland offers participants to choose to receive their Annual Incentive (i) 100% in shares, (ii) 50% in shares and 50% in cash, or (iii) 100% in cash. After expiration of a three-year holding period for Novartis shares invested under the ESOP, participants will receive one matching share for every two invested shares. Employees eligible for the equity plan &#x201c;Select&#x201d; are not eligible to receive ESOP matching shares. The Novartis Group CEO, the other Executive Committee members and the NTLs are not eligible to participate in this plan.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Novartis Employee share purchase plan&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2022 Novartis started to grant shares under the Employee Share Purchase Plan. The plan enables employees to voluntarily purchase Novartis shares through payroll deductions at a discounted price. While the plan is global in scope, the first phase covers: North America (the US, Puerto Rico and Canada). The shares are not subject to a vesting period.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Novartis equity plan &#x201c;Select&#x201d;&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The equity plan &#x201c;Select&#x201d; is a global equity incentive plan under which eligible employees may annually be awarded a grant subject to a three-year, and for selected units a four-year, staggered vesting period. No awards are granted for performance ratings below a certain threshold. Executive Committee members and NTLs are not eligible to participate in the equity plan &#x201c;Select.&#x201d;&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The equity plan &#x201c;Select&#x201d; currently allows participants employed and living in Switzerland to choose the form of their equity compensation in RSs or RSUs. In all other jurisdictions, RSs or RSUs are granted unilaterally. Until 2013, participants could also choose to receive part or the entire grant in the form of tradable share options.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Tradable share options expire on their 10&lt;sup&gt;th&lt;/sup&gt; anniversary from the grant date, meaning all outstanding options exercisable at December 31, 2022, will expire in January 2023. Each tradable share option entitles the holder to purchase after vesting (and before the 10&lt;sup&gt;th&lt;/sup&gt; anniversary from the grant date) one Novartis share at a stated exercise price that equals the closing market price of the underlying share at the grant date. As the exercise price does not reflect the decrease in the Novartis share due to the Alcon spin, one-fifth of an Alcon share will also be awarded to the option holder upon exercise.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Options under Novartis equity plan &#x201c;Select&#x201d; outside North America&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the activity associated with the share options during the period. The weighted average prices in the table below are translated from Swiss francs into USD at historical rates.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Options&lt;br/&gt; (millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted&lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Options&lt;br/&gt; (millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted&lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Options outstanding  at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            63.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            62.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sold or exercised&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            62.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            58.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            0.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            66.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            63.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Exercisable at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            0.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            66.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            63.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;All share options were granted at an exercise price that was equal to the closing market price of the Group&#x2019;s shares at the grant date. The weighted average share price at the dates of sale or exercise was USD&#160;86.1. &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Options under Novartis equity plan &#x201c;Select&#x201d; for North America&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows the activity associated with the ADR options during the period:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; ADR&lt;br/&gt; options&lt;br/&gt; (millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted&lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; ADR&lt;br/&gt; options&lt;br/&gt; (millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted&lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Options outstanding  at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            64.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            62.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sold or exercised&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2.9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            63.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            60.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            66.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            64.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Exercisable at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            66.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            64.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;All ADR options were granted at an exercise price that was equal to the closing market price of the ADRs at the grant date. The weighted average ADR price at the dates of sale or exercise was USD&#160;89.1. &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Long-Term Performance Plan&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Long-Term Performance Plan (LTPP) is an equity plan for the ECN, the NTLs and employees of Group units with specific targets.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Participants are granted a target number of performance share units (PSUs) at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. The actual payout depends on the achievement of the performance measures and ranges between 0% and 200% of the granted amount. PSUs granted under the LTPP do not carry voting rights, but do carry dividend equivalents that are paid in unrestricted Novartis shares at the end of the performance period.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The LTPP awards are subject to a three-year performance and vesting period. Until 2018, the performance criteria were based on Novartis internal performance metrics. For LTPP awards starting in 2019, following the combination of the two LTPP and Long-Term Relative Performance Plan (LTRPP), the performance criteria are based on both Novartis internal performance metrics and variables that can be observed in the market, which is the ranking of the Novartis total shareholder return (TSR) relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;TSR for Novartis and the peer companies is calculated as the change in the company share price, which is translated to USD at the relevant exchange rate, including the reinvestment return of dividends, over the three-year performance period. The calculation is based on Bloomberg standard published TSR data, which is publicly available. The position of Novartis in the peer group determines the payout range based on a payout matrix. &lt;/div&gt;
                  &lt;div style=" padding-bottom: 10px;"&gt;
                    &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Long-Term Relative Performance Plan&lt;/span&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The LTRPP was an equity plan for the Novartis ECN and NTLs and the awards were subject to a three-year performance and vesting period. The last grant under this plan was made in 2018. The LTRPP performance criteria were based on variables that could be observed in the market, which was the ranking of the Novartis TSR relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. The TSR for Novartis and the peer companies was calculated as described in the LTPP section above.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Other share awards&lt;/span&gt;
                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Selected employees may exceptionally receive Special Share Awards of RSs or RSUs. These Special Share Awards provide an opportunity to reward outstanding achievements or exceptional performance, and aim to retain key contributors. They are based on a formal internal selection process, through which the individual performance of each candidate is thoroughly assessed at several management levels. Special Share Awards had a minimum three-year vesting period before 2021 and mainly three years thereafter. In exceptional circumstances, Special Share Awards may be awarded to attract special expertise and new talents to the organization. Externally recruited ECN members are eligible only for special awards that are &#x201c;buyouts&#x201d; in the case that it is to replace equity forfeited with their former employer. The equity is provided on a like-for-like basis as the forfeited equity, at the same value with the same vesting period, and with or without a performance condition.&lt;/div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Worldwide, employees at different levels in the organization were awarded RSs and RSUs in 2022, 2021 and 2020.&lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In addition, in 2022, 2021 and 2020, Board members received unrestricted shares as part of their regular compensation.&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div/&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Summary of share grants&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The table below provides a summary of share grants (shares, RSs, RSUs and PSUs) for all plans:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Number&lt;br/&gt; of shares&lt;br/&gt; in millions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted &lt;br/&gt; average fair&lt;br/&gt; value at grant&lt;br/&gt; date in USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Number&lt;br/&gt; of shares&lt;br/&gt; in millions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted &lt;br/&gt; average fair&lt;br/&gt; value at grant&lt;br/&gt; date in USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Annual Incentive&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; RSU&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            74.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            87.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; Restricted shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            85.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            97.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Share savings plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; RSU&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            75.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            86.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; Shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            85.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            97.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Novartis Employee Share Purchase Plan&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            82.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Select North America (RSU)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            74.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            86.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Select outside North America&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; RSU&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            75.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            86.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; Restricted shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            85.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            97.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Long-Term Performance Plan (PSU)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            82.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            89.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Other share awards&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; RSU&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            76.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            78.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; Restricted shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            86.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; Shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            86.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            91.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <nvs:ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_538ab274-2ab8-4671-b568-ef8e6d7bf570_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Expense related to equity-based  participation plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 048
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            979
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:11%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Liabilities arising from equity-based  payment transactions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            235
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            253
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            269
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="8" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">1048000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">979000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="AR_D-CurrentYear-2" decimals="-6" unitRef="USD">958000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">235000000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">253000000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011
      contextRef="AR_I-CurrentYearEnd-2"
      decimals="-6"
      unitRef="USD">269000000</ifrs-full:LiabilitiesFromSharebasedPaymentTransactions2011>
    <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentivePlanMember"
      id="SectionBlock_c8430cd3-3a4e-4475-a07d-233db9e6e560_0">

                  The Annual Incentive for the Novartis Group CEO and other Executive Committee members (ECN) is paid 50% in cash and 50% in Novartis restricted shares (RSs) or restricted share units (RSUs). For the Novartis Top Leaders (NTLs), the Annual Incentive is paid 70% in cash and 30% in RSs or RSUs. Both the ECN and NTLs can opt to invest up to the maximum cash portion of their Annual Incentive to receive further RSs or RSUs. Any cash is paid out during March in the year following the end of the performance period, and the shares are granted during January in the year following the end of the performance period.

              </ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
    <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeShareOwnershipPlanMember"
      id="SectionBlock_47540b15-2a5a-457a-b1c1-320cf844d0bc_0">


                    Employee share savings plan

                  Novartis operates employee share savings and purchase plans in certain countries. The most significant is described below.
                  The Employee Share Ownership Plan (ESOP) in Switzerland offers participants to choose to receive their Annual Incentive (i) 100% in shares, (ii) 50% in shares and 50% in cash, or (iii) 100% in cash. After expiration of a three-year holding period for Novartis shares invested under the ESOP, participants will receive one matching share for every two invested shares. Employees eligible for the equity plan &#x201c;Select&#x201d; are not eligible to receive ESOP matching shares. The Novartis Group CEO, the other Executive Committee members and the NTLs are not eligible to participate in this plan.

              </ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
    <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeSharePurchasePlanMember"
      id="SectionBlock_36e09eae-8950-4e91-8ddc-4834307aac7e_0">


                    Novartis Employee share purchase plan

                  In 2022 Novartis started to grant shares under the Employee Share Purchase Plan. The plan enables employees to voluntarily purchase Novartis shares through payroll deductions at a discounted price. While the plan is global in scope, the first phase covers: North America (the US, Puerto Rico and Canada). The shares are not subject to a vesting period.

              </ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
    <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectMember"
      id="SectionBlock_d205e2d1-642b-4834-9171-c26b78e56b54_0">

                  The equity plan &#x201c;Select&#x201d; is a global equity incentive plan under which eligible employees may annually be awarded a grant subject to a three-year, and for selected units a four-year, staggered vesting period. No awards are granted for performance ratings below a certain threshold. Executive Committee members and NTLs are not eligible to participate in the equity plan &#x201c;Select.&#x201d;
                  The equity plan &#x201c;Select&#x201d; currently allows participants employed and living in Switzerland to choose the form of their equity compensation in RSs or RSUs. In all other jurisdictions, RSs or RSUs are granted unilaterally. Until 2013, participants could also choose to receive part or the entire grant in the form of tradable share options.
                  Tradable share options expire on their 10th anniversary from the grant date, meaning all outstanding options exercisable at December 31, 2022, will expire in January 2023. Each tradable share option entitles the holder to purchase after vesting (and before the 10th anniversary from the grant date) one Novartis share at a stated exercise price that equals the closing market price of the underlying share at the grant date. As the exercise price does not reflect the decrease in the Novartis share due to the Alcon spin, one-fifth of an Alcon share will also be awarded to the option holder upon exercise.

              </ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      id="SectionBlock_b2a288f2-ef7e-4ccb-9e9e-3f4a1bf27fc0_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Options&lt;br/&gt; (millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted&lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Options&lt;br/&gt; (millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted&lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Options outstanding  at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            63.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            62.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sold or exercised&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1.2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            62.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-0.9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            58.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            0.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            66.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            63.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Exercisable at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            0.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            66.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            63.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">1700000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">63.6</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">2600000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">62.0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">1200000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">62.6</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">900000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">58.9</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">66.0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">1700000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">63.6</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">500000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">66.0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">1700000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">63.6</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">86.1</ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      id="SectionBlock_9f4af6bb-79d8-44c8-a9da-d63643a8f013_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; ADR&lt;br/&gt; options&lt;br/&gt; (millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted&lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; ADR&lt;br/&gt; options&lt;br/&gt; (millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted&lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;br/&gt; (USD)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Options outstanding  at January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            64.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            62.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Sold or exercised&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2.9&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            63.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2.7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            60.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Outstanding at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            66.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            64.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Exercisable at December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            66.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            64.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">4000000.0</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">64.4</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">6700000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">62.9</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">2900000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">63.7</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">2700000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">60.7</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">1100000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">66.1</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">4000000.0</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">64.4</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">1100000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">66.1</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="-5"
      unitRef="Pure">4000000.0</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">64.4</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember"
      decimals="1"
      unitRef="USDPerShares">89.1</ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019>
    <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePlanMember"
      id="SectionBlock_d71a92c0-423e-4e0c-94aa-e1d9a69021e3_0">

                  The Long-Term Performance Plan (LTPP) is an equity plan for the ECN, the NTLs and employees of Group units with specific targets.
                  Participants are granted a target number of performance share units (PSUs) at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. The actual payout depends on the achievement of the performance measures and ranges between 0% and 200% of the granted amount. PSUs granted under the LTPP do not carry voting rights, but do carry dividend equivalents that are paid in unrestricted Novartis shares at the end of the performance period.
                  The LTPP awards are subject to a three-year performance and vesting period. Until 2018, the performance criteria were based on Novartis internal performance metrics. For LTPP awards starting in 2019, following the combination of the two LTPP and Long-Term Relative Performance Plan (LTRPP), the performance criteria are based on both Novartis internal performance metrics and variables that can be observed in the market, which is the ranking of the Novartis total shareholder return (TSR) relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods.
                  TSR for Novartis and the peer companies is calculated as the change in the company share price, which is translated to USD at the relevant exchange rate, including the reinvestment return of dividends, over the three-year performance period. The calculation is based on Bloomberg standard published TSR data, which is publicly available. The position of Novartis in the peer group determines the payout range based on a payout matrix.

                    Long-Term Relative Performance Plan

                  The LTRPP was an equity plan for the Novartis ECN and NTLs and the awards were subject to a three-year performance and vesting period. The last grant under this plan was made in 2018. The LTRPP performance criteria were based on variables that could be observed in the market, which was the ranking of the Novartis TSR relative to a global healthcare peer group of 14 other companies, over rolling three-year performance periods. The TSR for Novartis and the peer companies was calculated as described in the LTPP section above.

              </ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
    <ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationSpecialShareAwardsMember"
      id="SectionBlock_78352555-d93e-4072-b292-1fdc19ae2af1_0">

                  Selected employees may exceptionally receive Special Share Awards of RSs or RSUs. These Special Share Awards provide an opportunity to reward outstanding achievements or exceptional performance, and aim to retain key contributors. They are based on a formal internal selection process, through which the individual performance of each candidate is thoroughly assessed at several management levels. Special Share Awards had a minimum three-year vesting period before 2021 and mainly three years thereafter. In exceptional circumstances, Special Share Awards may be awarded to attract special expertise and new talents to the organization. Externally recruited ECN members are eligible only for special awards that are &#x201c;buyouts&#x201d; in the case that it is to replace equity forfeited with their former employer. The equity is provided on a like-for-like basis as the forfeited equity, at the same value with the same vesting period, and with or without a performance condition.
                  Worldwide, employees at different levels in the organization were awarded RSs and RSUs in 2022, 2021 and 2020.
                  In addition, in 2022, 2021 and 2020, Board members received unrestricted shares as part of their regular compensation.



              </ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement>
    <nvs:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_4ed1e050-966c-4244-a7dc-b8b0c147e444_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Number&lt;br/&gt; of shares&lt;br/&gt; in millions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Weighted &lt;br/&gt; average fair&lt;br/&gt; value at grant&lt;br/&gt; date in USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Number&lt;br/&gt; of shares&lt;br/&gt; in millions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Weighted &lt;br/&gt; average fair&lt;br/&gt; value at grant&lt;br/&gt; date in USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Annual Incentive&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; RSU&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            74.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            87.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; Restricted shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            85.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            97.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Share savings plans&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; RSU&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            75.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            86.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; Shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            85.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            97.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Novartis Employee Share Purchase Plan&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            82.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Select North America (RSU)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            74.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            86.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Select outside North America&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; RSU&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            75.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            86.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; Restricted shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            85.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            97.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Long-Term Performance Plan (PSU)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            82.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            89.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Other share awards&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; RSU&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            76.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            78.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; Restricted shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            86.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#x2013; Shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            86.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            91.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember"
      decimals="-5"
      unitRef="Pure">200000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember"
      decimals="-5"
      unitRef="USDPerShares">74700000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember"
      decimals="-5"
      unitRef="Pure">200000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember"
      decimals="-5"
      unitRef="USDPerShares">87500000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember"
      decimals="-5"
      unitRef="Pure">100000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember"
      decimals="-5"
      unitRef="USDPerShares">85000000.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember"
      decimals="-5"
      unitRef="Pure">100000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRestrictedSharesMember"
      decimals="-5"
      unitRef="USDPerShares">97000000.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember"
      decimals="-5"
      unitRef="Pure">400000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember"
      decimals="-5"
      unitRef="USDPerShares">75000000.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember"
      decimals="-5"
      unitRef="Pure">400000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansRSUMember"
      decimals="-5"
      unitRef="USDPerShares">86900000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember"
      decimals="-5"
      unitRef="Pure">1200000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember"
      decimals="-5"
      unitRef="USDPerShares">85000000.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember"
      decimals="-5"
      unitRef="Pure">1100000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationShareSavingsPlansSharesMember"
      decimals="-5"
      unitRef="USDPerShares">97000000.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeSharePurchasePlanMember"
      decimals="-5"
      unitRef="Pure">800000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationEmployeeSharePurchasePlanMember"
      decimals="-5"
      unitRef="USDPerShares">82800000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember"
      decimals="-5"
      unitRef="Pure">4900000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember"
      decimals="-5"
      unitRef="USDPerShares">74500000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember"
      decimals="-5"
      unitRef="Pure">4300000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember"
      decimals="-5"
      unitRef="USDPerShares">86900000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember"
      decimals="-5"
      unitRef="Pure">2000000.0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember"
      decimals="-5"
      unitRef="USDPerShares">75100000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember"
      decimals="-5"
      unitRef="Pure">1800000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember"
      decimals="-5"
      unitRef="USDPerShares">86900000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember"
      decimals="-5"
      unitRef="Pure">700000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember"
      decimals="-5"
      unitRef="USDPerShares">85000000.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember"
      decimals="-5"
      unitRef="Pure">600000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember"
      decimals="-5"
      unitRef="USDPerShares">97000000.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember"
      decimals="-5"
      unitRef="Pure">1700000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember"
      decimals="-5"
      unitRef="USDPerShares">82000000.0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember"
      decimals="-5"
      unitRef="Pure">1800000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationLongTermPerformancePSUPlanMember"
      decimals="-5"
      unitRef="USDPerShares">89500000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember"
      decimals="-5"
      unitRef="Pure">500000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember"
      decimals="-5"
      unitRef="USDPerShares">76300000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember"
      decimals="-5"
      unitRef="Pure">600000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRSUMember"
      decimals="-5"
      unitRef="USDPerShares">78400000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRestrictedSharesMember"
      decimals="-5"
      unitRef="Pure">100000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsRestrictedSharesMember"
      decimals="-5"
      unitRef="USDPerShares">86900000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember"
      decimals="-5"
      unitRef="Pure">100000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember"
      decimals="-5"
      unitRef="USDPerShares">86100000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember"
      decimals="-5"
      unitRef="Pure">100000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationOtherShareAwardsSharesMember"
      decimals="-5"
      unitRef="USDPerShares">91900000</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_c2cf8709-c703-4cbe-867a-d935e86cf837_0">
          &lt;div/&gt;

          &lt;div&gt;
            &lt;div id="anchorId001553909"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;27. Transactions with related parties&lt;/div&gt;
            &lt;div style=" padding-bottom: 10px;"&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Roche Holding AG&lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has two agreements with Genentech, Inc., United States (Genentech), and one agreement with Spark Therapeutics, Inc., United States (Spark). Both companies are subsidiaries of Roche Holding AG (Roche), which were indirectly included in the consolidated financial statements using equity accounting until November 3, 2021, when Novartis entered into an agreement with Roche to divest its &lt;span&gt;33.3%&lt;/span&gt; of Roche voting shares. On December 6, 2021, Novartis divested its investment in Roche, on which date Roche ceased to be a related party (see Notes 2 and 4).&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                &lt;i&gt;Lucentis&lt;/i&gt;
              &lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis has licensed from Genentech/Roche the exclusive rights to develop and market &lt;i&gt;Lucentis&lt;/i&gt; outside the United States for indications related to diseases of the eye. Novartis pays royalties on the net sales to third parties of &lt;i&gt;Lucentis&lt;/i&gt; products outside the United States. From January 1, 2021 until December 6, 2021, &lt;i&gt;Lucentis&lt;/i&gt; sales of USD&#160;2.0 billion (2020: USD&#160;1.9 billion) were recognized by Novartis.&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                &lt;i&gt;Xolair&lt;/i&gt;
              &lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis and Genentech/Roche are co-promoting &lt;i&gt;Xolair&lt;/i&gt; in the United States, where Genentech/Roche records all sales. Novartis records sales outside the United States.&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Novartis markets &lt;i&gt;Xolair&lt;/i&gt; and records all sales and related costs outside the United States as well as co-promotion costs in the US. Genentech/Roche and Novartis share the resulting profits from sales in the United States, Europe and other countries, according to agreed profit-sharing percentages. From January 1, 2021 until December 6, 2021, Novartis recognized total sales of &lt;i&gt;Xolair&lt;/i&gt; of USD&#160;1.3 billion (2020: USD&#160;1.3 billion), including sales to Genentech/Roche for the United States market.&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;
                &lt;i&gt;Luxturna&lt;/i&gt;
              &lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2018, Novartis entered into an exclusive licensing and commercialization agreement and a supply agreement with Spark for &lt;i&gt;Luxturna&lt;/i&gt; outside the United States. The agreements include regulatory and sales milestones as well as royalties payable to Spark on ex-US sales. On December 17, 2019, Roche acquired Spark.&lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;"&gt;The net income for royalties, cost sharing and profit sharing arising out of the &lt;i&gt;Lucentis&lt;/i&gt;, &lt;i&gt;Xolair&lt;/i&gt; and &lt;i&gt;Luxturna&lt;/i&gt; agreements with Roche totaled USD&#160;188 million from January 1, 2021 until December 6, 2021 (net income in 2020: USD&#160;217 million).&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Furthermore, Novartis has several patent license, supply and distribution agreements with Roche.&lt;/div&gt;
            &lt;div style=" padding-bottom: 10px;"&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Novartis Pension Fund&lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In 2018, a Group subsidiary provided an uncommitted overnight credit facility to the Novartis Pension Fund, Switzerland, for up to USD 500 million with interest at the US Federal Funds Rate. This credit facility was not utilized during the current and past years.&lt;/div&gt;
            &lt;div style=" padding-bottom: 10px;"&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Executive Officers and Non-Executive Directors compensation&lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;At December 31, 2022, there were 11 Executive Committee members (&#x201c;Executive Officers&#x201d;). During 2022, 5 Executive Officers stepped down. At December 31, 2021, there were 12 Executive Officers. During 2021, 3 Executive Officers stepped down. At December 31, 2020, there were 13 Executive Officers. &lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The total compensation for Executive Committee members and the 15 Non-Executive Directors (14 in 2021 and 14 in 2020) using the Group&#x2019;s accounting policies for equity-based compensation and pension benefits was as follows:&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Executive Officers&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Non-Executive Directors&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and other compensation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            29.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            30.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Post-employment benefits&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            42.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            41.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            47.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            42.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            46.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            70.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            60.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            69.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            79.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            70.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            79.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During 2022, there was an increase in the IFRS compensation expense for executive officers compared to 2021, driven by accelerated expenses (cash and other compensation and equity-based compensation) required under IFRS for the executive members who stepped down in 2022, in accordance with their employment contracts and the relevant incentive plan terms, compared to the accelerated expenses due to executive officers who stepped down in 2021.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;During 2021, the IFRS compensation expense decreased due to one role less at the ECN, and lower cash and equity compensation attributable to former ECN members, partially offset by the net increase of the IFRS compensation expense of current ECN members.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Annual Incentive award, which is fully included in equity-based compensation even when paid out in cash, is granted in January in the year following the reporting period.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The disclosures on Board and executive compensation required by the Swiss Code of Obligations and in accordance with the Swiss Ordinance against Excessive Compensation in Stock Exchange Listed Companies are shown in the Compensation Report of the Group.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Transactions with former members of the Board of Directors&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During 2022, 2021 and 2020, the following payments (or waivers of claims) were made to former Board members or to &#x201c;persons closely&#x201d; linked to them:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currency&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dr. Krauer&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            60 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            60 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Dr. Alex Krauer, was an Honorary Chairman of Novartis and was entitled to an amount of CHF 60 000 for annual periods from one AGM to the next. This amount was fixed in 1998 upon his departure from the Board in 1999. The last payment under this arrangement was in 2021. &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <nvs:NumberOfContractsWithRelatedParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember"
      decimals="0"
      unitRef="Pure">2</nvs:NumberOfContractsWithRelatedParties>
    <nvs:NumberOfContractsWithRelatedParties
      contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4SparkTherapeuticsInc.Member"
      decimals="0"
      unitRef="Pure">1</nvs:NumberOfContractsWithRelatedParties>
    <ifrs-full:ProportionOfVotingPowerHeldInAssociate
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember"
      decimals="3"
      unitRef="Pure">0.333</ifrs-full:ProportionOfVotingPowerHeldInAssociate>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember"
      decimals="-8"
      unitRef="USD">2000000000.0</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember"
      decimals="-8"
      unitRef="USD">1900000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember"
      decimals="-8"
      unitRef="USD">1300000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:RevenueFromSaleOfGoodsThirdParties
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4XolairMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember"
      decimals="-8"
      unitRef="USD">1300000000</nvs:RevenueFromSaleOfGoodsThirdParties>
    <nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember"
      decimals="-6"
      unitRef="USD">188000000</nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing>
    <nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4GenentechRocheMember"
      decimals="-6"
      unitRef="USD">217000000</nvs:NetExpenseRoyaltiesCostSharingAndProfitSharing>
    <nvs:BorrowingsCreditFacilityUncommitted
      contextRef="AR_I-CurrentYearEnd-4_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisPensionFundMember"
      decimals="-6"
      unitRef="USD">500000000</nvs:BorrowingsCreditFacilityUncommitted>
    <nvs:RelatedPartiesNumberOfExecutiveCommitteeMembers contextRef="AR_D-CurrentYear" decimals="0" unitRef="Pure">11</nvs:RelatedPartiesNumberOfExecutiveCommitteeMembers>
    <nvs:RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown contextRef="AR_D-CurrentYear" decimals="0" unitRef="Pure">5</nvs:RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown>
    <nvs:RelatedPartiesNumberOfExecutiveCommitteeMembers contextRef="AR_D-CurrentYear-1" decimals="0" unitRef="Pure">12</nvs:RelatedPartiesNumberOfExecutiveCommitteeMembers>
    <nvs:RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown contextRef="AR_D-CurrentYear-1" decimals="0" unitRef="Pure">3</nvs:RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown>
    <nvs:RelatedPartiesNumberOfExecutiveCommitteeMembers contextRef="AR_D-CurrentYear-2" decimals="0" unitRef="Pure">13</nvs:RelatedPartiesNumberOfExecutiveCommitteeMembers>
    <nvs:RelatedPartiesNumberOfNonexecutiveDirectors contextRef="AR_D-CurrentYear" decimals="0" unitRef="Pure">15</nvs:RelatedPartiesNumberOfNonexecutiveDirectors>
    <nvs:RelatedPartiesNumberOfNonexecutiveDirectors contextRef="AR_D-CurrentYear-1" decimals="0" unitRef="Pure">14</nvs:RelatedPartiesNumberOfNonexecutiveDirectors>
    <nvs:RelatedPartiesNumberOfNonexecutiveDirectors contextRef="AR_D-CurrentYear-2" decimals="0" unitRef="Pure">14</nvs:RelatedPartiesNumberOfNonexecutiveDirectors>
    <nvs:OfficerAndDirectorCompensationTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_9450489b-cf34-4d12-8af0-77d1b5f07ff8_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Executive Officers&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Non-Executive Directors&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="center" colspan="5" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="5" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and other compensation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            20.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            29.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            30.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Post-employment benefits&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Equity-based compensation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            42.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            37.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            41.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            47.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            42.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            46.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            70.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            60.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            69.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            9.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            9.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            79.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            70.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            79.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="20" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:OfficerAndDirectorCompensationTableTextBlock>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">25000000.0</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">20300000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">25600000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember"
      decimals="-5"
      unitRef="USD">4600000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember"
      decimals="-5"
      unitRef="USD">4700000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember"
      decimals="-5"
      unitRef="USD">4600000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear" decimals="-5" unitRef="USD">29600000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear-1" decimals="-5" unitRef="USD">25000000.0</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="AR_D-CurrentYear-2" decimals="-5" unitRef="USD">30200000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">2800000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">2500000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">2700000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="AR_D-CurrentYear" decimals="-5" unitRef="USD">2800000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="AR_D-CurrentYear-1" decimals="-5" unitRef="USD">2500000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits contextRef="AR_D-CurrentYear-2" decimals="-5" unitRef="USD">2700000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">42600000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">37300000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">41100000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember"
      decimals="-5"
      unitRef="USD">4800000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember"
      decimals="-5"
      unitRef="USD">5200000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember"
      decimals="-5"
      unitRef="USD">5200000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear" decimals="-5" unitRef="USD">47400000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear-1" decimals="-5" unitRef="USD">42500000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="AR_D-CurrentYear-2" decimals="-5" unitRef="USD">46300000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">70400000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">60100000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_ifrsfull-2022KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-5"
      unitRef="USD">69400000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="AR_D-CurrentYear_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember"
      decimals="-5"
      unitRef="USD">9400000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember"
      decimals="-5"
      unitRef="USD">9900000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4NonExecutiveDirectorMember"
      decimals="-5"
      unitRef="USD">9800000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear" decimals="-5" unitRef="USD">79800000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear-1" decimals="-5" unitRef="USD">70000000.0</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="AR_D-CurrentYear-2" decimals="-5" unitRef="USD">79200000</ifrs-full:KeyManagementPersonnelCompensation>
    <nvs:TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_c0eed6ed-0178-4c02-9ea0-6d3f0967f172_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Currency&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2020&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Dr. Krauer&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            60 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            60 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Dr. Alex Krauer, was an Honorary Chairman of Novartis and was entitled to an amount of CHF 60 000 for annual periods from one AGM to the next. This amount was fixed in 1998 upon his departure from the Board in 1999. The last payment under this arrangement was in 2021. &lt;/div&gt;
                &lt;/div&gt;
              </nvs:TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4DrAlexKrauerMember"
      decimals="0"
      unitRef="CHF">60000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022CategoriesOfRelatedPartiesAxis_nvs-2022Q4DrAlexKrauerMember"
      decimals="0"
      unitRef="CHF">60000</ifrs-full:KeyManagementPersonnelCompensation>
    <nvs:DisclosureOfCommitmentsAndContingenciesTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_e24ce4d5-4d63-4dbc-9529-0ee39d5ad29f_0">
          &lt;div&gt;
            &lt;div id="anchorId001554354"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;28. Commitments and contingent liabilities&lt;/div&gt;
            &lt;div style=" padding-bottom: 10px;"&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Research and development commitments&lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group has entered into long-term research and development agreements with various institutions related to intangible assets. These agreements provide for potential milestone payments by Novartis, which are dependent on successful clinical development, or meeting specified sales targets, or other conditions which are specified in the agreements. &lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;As of December 31, 2022, the amount and estimated timing of the Group&#x2019;s commitments to make payments under those agreements, which are shown without risk adjustment and on an undiscounted basis, were as follows:&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:20%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            420
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            808
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            448
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2026&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            282
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2027&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            687
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Thereafter&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 169
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 814
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Commitments for capital calls&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group holds investments in funds in which it has committed to invest further upon future capital calls. As of December 31, 2022, the total uncalled capital commitments for the Group&#x2019;s investments in funds amounts to USD 83 million. Note 29 contains further information on the Group&#x2019;s investments in funds.&lt;/div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Other commitments&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group has entered into various purchase commitments for services and materials as well as for equipment in the ordinary course of business. These commitments are generally entered into at current market prices and reflect normal business operations. For disclosure of property, plant and equipment purchase commitments, see Note 9.&lt;/div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Guarantees issued&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group has issued guarantees to third parties in the ordinary course of business, mostly for tax, customs or other governmental agencies. &lt;/div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Contingent liabilities&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Group companies have to observe the laws, government orders and regulations of the country in which they operate.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;A number of Novartis companies are, and will likely continue to be, subject to various legal proceedings and investigations that arise from time to time, including proceedings regarding product liability; sales and marketing practices; commercial disputes; employment and wrongful discharge; and antitrust, securities, health and safety, environmental, tax, international trade, privacy and intellectual property matters. As a result, the Group may become subject to substantial liabilities that may not be covered by insurance and that could affect our business, financial position and reputation. While Novartis does not believe that any of these legal proceedings will have a material adverse effect on its financial position, litigation is inherently unpredictable and large judgments sometimes occur. As a consequence, Novartis may in the future incur judgments or enter into settlements of &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;claims that could have a material adverse effect on its results of operations or cash flow.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Governments and regulatory authorities around the world have been stepping up their compliance and law enforcement activities in recent years in key areas, including marketing practices, pricing, corruption, trade restrictions, embargo legislation, insider trading, antitrust, cyber security and data privacy. Further, when one government or regulatory authority undertakes an investigation, it is not uncommon for other governments or regulators to undertake investigations regarding the same or similar matters. Responding to such investigations is costly and requires an increasing amount of management&#x2019;s time and attention. In addition, such investigations may affect our reputation, create a risk of potential exclusion from government reimbursement programs in the United States and other countries, and lead to (or arise from) litigation. These factors have contributed to decisions by Novartis and other companies in the healthcare industry, when deemed in their interest, to enter into settlement agreements with governmental authorities around the world prior to any formal decision by the authorities or a court. These government settlements have involved and may in the future involve large cash payments, sometimes in the hundreds of millions of dollars or more, including the potential repayment of amounts allegedly obtained improperly and other penalties, including treble damages. In addition, settlements of government healthcare fraud cases and antitrust cases often require companies to enter into corporate integrity agreements, which are intended to regulate company behavior for a period of years. Our affiliates Novartis Corporation and Sandoz Inc. are parties to such agreements, which will expire in 2025 and 2026, respectively. Also, matters underlying governmental investigations and settlements may be the subject of separate private litigation.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;While provisions have been made for probable outflows of economic resources, which management deems to be reasonable or appropriate, there are uncertainties connected with these estimates.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Note 20 contains additional information on these matters.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;A number of Group companies are involved in legal proceedings concerning intellectual property rights. The inherent unpredictability of such proceedings means that there can be no assurances as to their ultimate outcome. A negative result in any such proceeding could potentially adversely affect the ability of certain Novartis companies to sell their products, or require the payment of substantial damages or royalties. The timing and the outcome of legal proceedings and their potential financial effect are not predictable.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In the opinion of management, however, the outcome of these actions will not materially affect the Group&#x2019;s financial position but could be material to the results of operations or cash flow in a given period.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&#x2019;s potential environmental remediation liability is assessed based on a risk assessment and investigation of the various sites identified by the Group as at risk for environmental remediation exposure. The Group&#x2019;s future remediation expenses are affected by a number of uncertainties. These uncertainties include, but are not limited to, the method and extent of remediation, the percentage of material attributable to the Group at the remediation sites relative to that attributable to other parties, and the financial capabilities of the other potentially responsible parties.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Note 20 contains additional information on environmental liabilities.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div/&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        </nvs:DisclosureOfCommitmentsAndContingenciesTextBlock>
    <nvs:DisclosureOfLeasingCommitmentsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_d24f4754-2136-4713-b0c0-535e2cfd988a_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2023&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:20%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            420
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2024&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            808
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2025&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            448
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2026&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            282
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;2027&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            687
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Thereafter&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 169
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 814
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="4" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfLeasingCommitmentsTableTextBlock>
    <nvs:CommitmentsUnderLongtermResearchAgreements
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember"
      decimals="-6"
      unitRef="USD">420000000</nvs:CommitmentsUnderLongtermResearchAgreements>
    <nvs:CommitmentsUnderLongtermResearchAgreements
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanTwoYearsMember"
      decimals="-6"
      unitRef="USD">808000000</nvs:CommitmentsUnderLongtermResearchAgreements>
    <nvs:CommitmentsUnderLongtermResearchAgreements
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanTwoYearsAndNotLaterThanThreeYearsMember"
      decimals="-6"
      unitRef="USD">448000000</nvs:CommitmentsUnderLongtermResearchAgreements>
    <nvs:CommitmentsUnderLongtermResearchAgreements
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanThreeYearsAndNotLaterThanFourYearsMember"
      decimals="-6"
      unitRef="USD">282000000</nvs:CommitmentsUnderLongtermResearchAgreements>
    <nvs:CommitmentsUnderLongtermResearchAgreements
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFourYearsAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">687000000</nvs:CommitmentsUnderLongtermResearchAgreements>
    <nvs:CommitmentsUnderLongtermResearchAgreements
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">3169000000</nvs:CommitmentsUnderLongtermResearchAgreements>
    <nvs:CommitmentsUnderLongtermResearchAgreements
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">5814000000</nvs:CommitmentsUnderLongtermResearchAgreements>
    <nvs:UncalledCapitalCommitmentsForInvestmentsInFunds
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">83000000</nvs:UncalledCapitalCommitmentsForInvestmentsInFunds>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_9657e382-a398-47d8-820b-6fe42150461f_0">
          &lt;div&gt;
            &lt;div id="anchorId001554504"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;29. Financial instruments&#160;&#x2013;&#160;additional disclosures&lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following tables show the carrying values of financial instruments by measurement category as of December 31, 2022 and 2021. Except for straight bonds (see Note 19), the carrying values are equal to, or a reasonable approximation of, the fair values.&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; amortized&lt;br/&gt; costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; fair value&lt;br/&gt; through other&lt;br/&gt; comprehensive&lt;br/&gt; income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; fair value&lt;br/&gt; through the&lt;br/&gt; consolidated&lt;br/&gt; income&lt;br/&gt; statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Other&lt;br/&gt; financial&lt;br/&gt; liabilities at&lt;br/&gt; amortized&lt;br/&gt; costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 517
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 089
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 066
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other receivables and current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities - debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            828
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            317
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - fund investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            281
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances, security deposits and other long-term receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            129
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13/17&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            650
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            27 971
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            874
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 581
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other short-term financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            863
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 772
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            22 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term liabilities to banks and other financial institutions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 146
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities (see Note 20/22) and other financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 067
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 789
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 266
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 122
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 789
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; amortized&lt;br/&gt; costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; fair value&lt;br/&gt; through other&lt;br/&gt; comprehensive&lt;br/&gt; income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; fair value&lt;br/&gt; through the&lt;br/&gt; consolidated&lt;br/&gt; income&lt;br/&gt; statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Other&lt;br/&gt; financial&lt;br/&gt; liabilities at&lt;br/&gt; amortized&lt;br/&gt; costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 397
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12 965
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other receivables and current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            793
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities - debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 741
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 195
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            468
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - fund investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            366
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances, security deposits and other long-term receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            332
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            32 492
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 980
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 772
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest-bearing accounts of employees payable on demand&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 814
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other short-term financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            899
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            893
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term liabilities to banks and other financial institutions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            227
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 553
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18/22&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities (see Note 20/22) and other financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 094
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            68
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            37 491
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 162
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Includes short-term highly rated government-backed debt securities, with an original maturity of three months or less&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Derivative financial instruments&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following tables show the contract or underlying principal amounts and fair values of derivative financial instruments analyzed by type of contract at December&#160;31, 2022 and 2021. Contract or underlying principal amounts indicate the gross volume of business outstanding at the consolidated balance sheet date and do not represent amounts at risk. The fair values are determined by reference to market prices or standard pricing models that use observable market inputs at December 31,&#160;2022 and 2021. &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Contract or underlying  principal amount&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Positive fair values  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Negative fair values  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 907
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13 248
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            189
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            92
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-41&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-35&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            97
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            82
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-33&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments included in  marketable securities and in current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 043
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            13 347
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table shows a breakdown by currency of the contract or underlying principal amount of derivative financial instruments at December&#160;31,&#160;2022 and 2021:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            687
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 907
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            80
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            97
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            767
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 715
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 043
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 158
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 605
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13 248
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            82
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            82
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 257
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 605
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            13 347
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Derivative financial instruments effective for hedge accounting purposes&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;At the end of 2022 and 2021, there were no open hedging instruments for anticipated transactions.&lt;/div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Fair value by hierarchy&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;As required by IFRS, financial assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. There are three hierarchical levels, based on increasing subjectivity associated with the inputs to derive fair valuation for these assets and liabilities, which are as follows:&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The assets carried at Level 1 fair value are equity and debt securities as well as fund investments listed in active markets.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The assets generally included in Level 2 fair value hierarchy are derivatives, and certain debt securities. The liabilities generally included in this fair value hierarchy consist of derivatives. These are valued using corroborated market data.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Level 3 inputs are unobservable for the asset or liability. The assets generally included in Level 3 fair value hierarchy are various investments in funds and unquoted equity security investments. Contingent consideration and other financial liabilities carried at fair value are included in this category.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 2&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 3&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Marketable securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities and derivative financial instruments at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            213
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            213
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current contingent consideration receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Long-term financial investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt and equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            473
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            699
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            261
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            281
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-current contingent consideration receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            607
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            607
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total long-term financial investments at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            493
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 567
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 070
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            129
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            129
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current contingent consideration liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-131&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-131&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial liabilities at fair values&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-131&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-186&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-current contingent consideration liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-704&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-704&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-232&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-232&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial liabilities at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-936&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-936&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 2&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 3&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total cash and cash equivalents at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Marketable securities and derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 719
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 741
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities and derivative financial instruments at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 719
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 846
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Long-term financial investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt and equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 080
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            617
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 697
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            338
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            366
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total long-term financial investments at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 108
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 596
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 704
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 075&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 075&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 094&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 162&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Includes short-term highly rated government-backed debt securities, with an original maturity of three months or less&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The change in carrying values associated with Level 3 financial instruments, using significant unobservable inputs during the year ended December 31, is set forth below:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="11" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Associated &lt;br/&gt; companies at &lt;br/&gt; fair value  through&lt;br/&gt; profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Fund&lt;br/&gt; investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Long-term &lt;br/&gt; financial &lt;br/&gt; investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Contingent &lt;br/&gt; consideration &lt;br/&gt; receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Contingent &lt;br/&gt; consideration &lt;br/&gt; liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Other&lt;br/&gt; financial&lt;br/&gt; liabiltiies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            338
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            617
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 075&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value gains and other adjustments, including from divestments  recognized in the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            530
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value losses (including impairments and amortizations) and  other adjustments recognized in the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-63&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-78&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-84&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-114&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-18&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments recognized in the consolidated statement   of comprehensive income, including currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            160
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-231&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-238&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash receipts and payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            44
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-40&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            129
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            261
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            699
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            650
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-835&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-232&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total of fair value gains and losses recognized   in the consolidated income statement for assets   and liabilities held at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-63&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-74&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-49&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            416
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Associated &lt;br/&gt; companies at &lt;br/&gt; fair value  through&lt;br/&gt; profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Fund&lt;br/&gt; investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Long-term &lt;br/&gt; financial &lt;br/&gt; investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Contingent &lt;br/&gt; consideration &lt;br/&gt; receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Contingent &lt;br/&gt; consideration &lt;br/&gt; payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            211
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            366
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            460
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            625
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 046&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value gains and other adjustments, including from divestments  recognized in the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            70
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            69
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            124
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value losses (including impairments and amortizations) and  other adjustments recognized in the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-26&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-189&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments recognized in the consolidated statement   of comprehensive income, including currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            51
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-22&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-88&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash receipts and payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-42&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            44
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-71&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            338
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            617
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 075&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total of fair value gains and losses recognized   in the consolidated income statement for assets   and liabilities held at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-24&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            62
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            80
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div/&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During 2022, there was one transfer of equity securities from Level 3 to Level 1 for USD&#160;44 million (2021: USD&#160;73 million), due to Initial Public Offering of the invested company. During 2022, there were no transfers of equity securities from Level 1 to Level 3 due to de-listing (2021: USD 29 million).&lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Realized gains and losses associated with Level 3 long-term financial investments measured at fair value through the consolidated income statement are recorded in the consolidated income statement under &#x201c;Other income&#x201d; or &#x201c;Other expense,&#x201d; respectively. Realized gains and losses associated with Level 3 long-term financial investments measured at fair value through other comprehensive income are not recycled through the consolidated income statement but are instead reclassified to retained earnings.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;During the year, the net loss and net gain recorded on associated companies, fund investments and long-term financial investments at fair value through profit and loss were USD 316 million and USD 55 million, respectively.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;To determine the fair value of a contingent consideration, various unobservable inputs are used. A change in these inputs might result in a significantly higher or lower fair value measurement. The inputs used are, among others, the probability of success, sales forecast and assumptions regarding the discount rate and timing and different scenarios of triggering events. The inputs are interrelated. The significance and usage of these inputs to each contingent consideration may vary due to differences in the timing and triggering events for payments or in the nature of the asset related to the contingent consideration. &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;If the most significant parameters for the Level&#160;3 input were to change by 10% positively or negatively, or where the probability of success (POS) is the most significant input parameter, 10% were added or deducted from the applied probability of success, for contingent consideration payables and contingent consideration receivables, this would change the amounts recorded in the 2022 consolidated income statement by USD&#160;154 million and USD&#160;140 million, respectively.&lt;/div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Equity securities measured at fair value through other comprehensive income&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Equity securities held as strategic investments, typically held outside the Novartis Venture Fund, are generally designated at date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss. These are made up of individually non-significant investments. At December 31, 2022, the Group holds 65 non-listed equity securities (December 31, 2021: 60) and 46 listed equity securities (December 31, 2021: 40) in this category with the following fair values:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Listed equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            438
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            888
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-listed equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            390
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            307
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            828
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 195
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;During 2022 and 2021, dividends received from these equity securities were insignificant. In 2022, in accordance with the consolidated foundations Alcon Inc. shares divestment plans, Alcon Inc. shares with a fair value of USD&#160;22 million were sold (2021: USD 9 million), and the USD&#160;7 million gain on disposal (2021: USD 1 million gain) was transferred from other comprehensive income to retained earnings during 2022. In addition, in 2022, equity securities that were no longer considered strategic, with a fair value of USD&#160;3 million (2021: USD&#160;254 million), were sold, and the USD&#160;3 million loss on disposal (2021: USD&#160;211 million gain) was transferred from other comprehensive income to retained earnings (see Note 8).&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Nature and extent of risks arising from financial instruments&lt;/span&gt;
                &lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Market risk&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Market risk in general comprises currency risk, interest rate risk and price risk, such as commodity and equity prices. Novartis is exposed to market risk, primarily related to foreign currency exchange rates, interest rates and the market value of the investments. The Group actively monitors and seeks to reduce, where it deems it appropriate to do so, fluctuations in these exposures. It is the Group&#x2019;s policy and practice to enter into a variety of derivative financial instruments to manage the volatility of these exposures. It does not enter into any financial transactions containing a risk that cannot be quantified at the time the transaction is concluded. In addition, it does not sell short assets it does not have, or does not know it will have, in the future. The Group only sells existing assets or enters into transactions and future transactions (in the case of anticipatory hedges) that it confidently expects it will have in the future, based on past experience. &lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Foreign currency exchange rate risk&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group uses the US dollar as its reporting currency. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Japanese and emerging market currencies. Fluctuations in the exchange rates between the US dollar and other currencies can have a significant effect on both the Group&#x2019;s results of operations, including reported sales and earnings, as well as on the reported value of our assets, liabilities and cash flows. This, in turn, may significantly affect the comparability of period-to-period results of operations.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Because our expenditures in Swiss francs are significantly higher than our revenues in Swiss francs, volatility in the value of the Swiss franc can have a significant impact on the reported value of our earnings, assets and liabilities, and the timing and extent of such volatility can be difficult to predict.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;There is also a risk that certain countries could experience a devaluation of their currency. If this occurs, it could impact the effective prices we would be able to charge for our products and also have an adverse impact on both our consolidated income statement and balance sheet.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Subsidiaries whose functional currencies have experienced a cumulative inflation rate of more than 100% over the past three years apply the principles of IAS 29 &#x201c;Financial reporting in Hyperinflationary Economies.&#x201d; The hyperinflationary economies in which Novartis operates are Argentina, Venezuela and Turkey. Venezuela and Argentina were hyperinflationary for all periods presented, and Turkey became hyperinflationary effective May 1, 2022, requiring retroactive implementation of hyperinflation accounting as of January 1, 2022. The impacts of applying IAS 29 were not significant in all years presented.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group manages its global currency exposure by engaging in hedging transactions where management deems appropriate. Novartis may enter into various contracts that reflect the changes in the value of foreign currency exchange rates to preserve the value of assets, commitments and anticipated transactions. Novartis also uses forward contracts and may enter into foreign currency option contracts to hedge.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Net investments in subsidiaries in foreign countries are long-term investments. Their fair value changes through movements of foreign currency exchange rates. The Group has designated a certain portion of its long-term euro-denominated straight bonds, maturing in 2028, as hedges of the translation risk arising on certain of these net investments in foreign operations with euro functional currency. As of December 31, 2022, long-term financial debt with a carrying amount of EUR&#160;1.8 billion (USD&#160;2.0 billion; December 31, 2021: USD 2.1 billion), has been designated as a hedge instrument. During 2022, USD&#160;91 million of net of taxes unrealized income (2021: USD 216 million) was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge. The hedge remained effective since inception, and no amount was recognized in the consolidated income statement in 2022, 2021 and 2020.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Commodity price risk&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group has only a very limited exposure to price risk related to anticipated purchases of certain commodities used as raw materials by the Group&#x2019;s businesses. A change in those prices may alter the gross margin of a specific business, but generally by not more than &lt;span&gt;10%&lt;/span&gt; of the margin and thus below the Group&#x2019;s risk management tolerance levels. Accordingly, the Group does not enter into significant commodity futures, forward or option contracts to manage fluctuations in prices of anticipated purchases.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Interest rate risk&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group addresses its net exposure to interest rate risk mainly through the ratio of its fixed-rate financial debt to variable-rate financial debt contained in its total financial debt portfolio. To manage this mix, Novartis may enter into interest rate swap agreements, in which it exchanges periodic payments based on a notional amount and agreed-upon fixed and variable interest rates.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Equity risk&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group may purchase equities as investments of its liquid funds. As a policy, it limits its holdings in an unrelated company to less than &lt;span&gt;5%&lt;/span&gt; of its liquid funds. Potential investments are thoroughly analyzed. Call options are written on equities that the Group owns, and put options are written on equities that the Group wants to buy and for which cash is available.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Credit risk&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Credit risks arise from the possibility that customers may not be able to settle their obligations as agreed. To manage this risk, the Group periodically assesses country and customer credit risk, assigns individual credit limits, and takes actions to mitigate credit risk where appropriate (for example payment guarantees, credit insurance and factoring).&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The provisions for expected credit losses for customers are based on a forward-looking expected credit loss, which includes possible default events on the trade &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;receivables over the entire holding period of the trade receivables.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;In measuring the expected credit losses, trade receivables are grouped based on shared credit risk characteristics (such as private versus public receivables) and days past due. In determining the expected credit loss rates, the Group considers current and forward-looking macroeconomic factors that may affect the ability of the customers to settle the receivables, and historical loss rates for each category of customers.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&#x2019;s largest customer accounted for approximately &lt;span&gt;16%&lt;/span&gt; of net sales to third parties, and the second largest and third largest customers accounted for &lt;span&gt;11%&lt;/span&gt; and &lt;span&gt;7%&lt;/span&gt; of net sales to third parties, respectively (2021: &lt;span&gt;17%&lt;/span&gt;, &lt;span&gt;11%&lt;/span&gt; and &lt;span&gt;6%&lt;/span&gt;, respectively; 2020: &lt;span&gt;17%&lt;/span&gt;, &lt;span&gt;11%&lt;/span&gt; and &lt;span&gt;6%&lt;/span&gt;, respectively).&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The highest amounts of trade receivables outstanding were for these same three customers and amounted to &lt;span&gt;16%&lt;/span&gt;, &lt;span&gt;14%&lt;/span&gt; and &lt;span&gt;7%&lt;/span&gt;, respectively, of the Group&#x2019;s trade receivables at December 31, 2022 (2021: &lt;span&gt;16%&lt;/span&gt;, &lt;span&gt;12%&lt;/span&gt; and &lt;span&gt;7%&lt;/span&gt;, respectively). There is no other significant concentration of customer credit risk.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Counterparty risk&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Counterparty risk encompasses issuer risk on marketable securities and money market instruments; credit risk on cash, time deposits and derivatives; as well as settlement risk for different instruments. Issuer risk is reduced by only buying securities that are at least A- rated. Counterparty credit risk and settlement risk are reduced by a policy of entering into transactions with counterparties (banks or financial institutions) that feature a strong credit rating. Exposure to these risks is closely monitored and kept within predetermined parameters. The limits are regularly assessed and determined based upon credit analysis, including financial statement and capital adequacy ratio reviews. In addition, reverse repurchasing agreements are contracted, and Novartis has entered into credit support agreements with various banks for derivative transactions. To further reduce the settlement risk, the Group has implemented a multi-currency payment system, Continuous Linked Settlement (CLS), providing multilateral netting (payment-versus-payment settlement) of cash flows from foreign exchange transactions.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&#x2019;s cash and cash equivalents are held with major regulated financial institutions; the three largest ones hold approximately &lt;span&gt;13.2%&lt;/span&gt;, &lt;span&gt;9.2%&lt;/span&gt; and &lt;span&gt;6.8%&lt;/span&gt;, respectively (2021: &lt;span&gt;9.7%&lt;/span&gt;, &lt;span&gt;9.7%&lt;/span&gt; and &lt;span&gt;7.6%&lt;/span&gt;, respectively). As of December 31, 2021, the Group&#x2019;s cash and cash equivalents also included short-term highly rated government-backed debt securities, with an original maturity of three months or less, for approximately &lt;span&gt;16%&lt;/span&gt; (2022: nil).&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Liquidity risk&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Liquidity risk is defined as the risk that the Group could not be able to settle or meet its obligations associated with financial liabilities that are settled by delivering cash or another financial asset. Group Treasury is responsible for liquidity, funding and settlement management. In addition, liquidity and funding risks, and related processes and policies, are overseen by management. Novartis manages its liquidity risk on a consolidated basis according to business needs and tax, capital or regulatory considerations, if applicable, through numerous sources of financing in order to maintain flexibility. &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Certain countries have legal or economic restrictions on the ability of subsidiaries to transfer funds to the Group in the form of cash dividends, loans or advances, but these restrictions do not have an impact on the ability of the Group to meet its cash obligations.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Management monitors the Group&#x2019;s net debt or liquidity position through rolling forecasts on the basis of expected cash flows.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Novartis has two US commercial paper programs under which it can issue up to USD&#160;9.0 billion in the aggregate of unsecured commercial paper notes. Novartis also has one Japanese commercial paper program under which it can issue up to JPY&#160;150 billion (approximately USD&#160;1.1 billion) of unsecured commercial paper notes. Commercial paper notes totaling USD&#160;2.8 billion under these three programs were outstanding as per December 31, 2022 (2021: USD&#160;0.9 billion). Novartis further has a committed credit facility of USD&#160;6.0 billion, which was extended in September 2022. This credit facility is provided by a syndicate of banks and is intended to be used as a backstop for the US commercial paper programs. The facility matures in September 2025 and was undrawn as per December 31, 2022, and December 31, 2021.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The following table sets forth how management monitors net debt or liquidity based on details of the remaining contractual maturities of current financial assets and liabilities, excluding trade receivables and payables as well as liabilities for contingent consideration at December 31, 2022, and December 31, 2021:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="11" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; one month&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br/&gt; one month &lt;br/&gt; but less than &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br/&gt; one year &lt;br/&gt; but less than &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due after &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities, time deposits and short-term investments with original maturity more than 90 days and accrued interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 142
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 911
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            36
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 098
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            147
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 011
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 506
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 517
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 176
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            10 564
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            135
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            18 930
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-8 975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-11 269&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-20 244&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-9 002&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-11 394&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-20 396&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-8 975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-11 269&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-20 244&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 215&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-146&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 515&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 876&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-3 215&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-146&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-2 517&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-5 878&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-38&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 253&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-159&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2 519&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-5 931&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 923
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            10 405
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2 464&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-8 975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-11 134&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-7 245&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="11" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; one month&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br/&gt; one month &lt;br/&gt; but less than &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br/&gt; one year &lt;br/&gt; but less than &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due after &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities, time deposits and short-term investments with original maturity more than 90 days and accrued interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 585
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 706
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            64
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 406
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 001
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12 407
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            7 438
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            19 650
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 095
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            142
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            28 329
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8 464&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14 438&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-22 902&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-8 490&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-14 587&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-23 077&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-8 464&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-14 438&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-22 902&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 780&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-521&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 926&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-6 227&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-2 780&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-521&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-2 928&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-6 229&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-50&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 830&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-537&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 928&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-6 295&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 608
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            19 113
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 833&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-8 460&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-14 296&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-868&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The carrying amounts of financial liabilities included in the above analysis are not materially different to the contractual amounts due on maturity. The positive and negative fair values on derivative financial instruments represent the net contractual amounts to be exchanged at maturity.&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The Group&#x2019;s contractual undiscounted potential cash flows from derivative financial instruments to be settled on a gross basis are as follows:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; one month&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br/&gt; one month &lt;br/&gt; but less than &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Derivative financial instruments and accrued interest on derivative  financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential outflows in various currencies - from financial derivative liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 029&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4 598&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-316&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6 943&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential inflows in various currencies - from financial derivative assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 029
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 712
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            321
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 062
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; one month&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br/&gt; one month &lt;br/&gt; but less than &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Derivative financial instruments and accrued interest on derivative  financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential outflows in various currencies - from financial derivative liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-843&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 482&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-461&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-6 786&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential inflows in various currencies - from financial derivative assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            847
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 516
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            457
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 820
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:10px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Other contractual liabilities that are not part of management&#x2019;s monitoring of the net debt or liquidity consist of the following items:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br/&gt; one year &lt;br/&gt; but less than &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due after &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contractual interest on non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-64&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-412&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 432&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 624&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 532&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-71&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-180&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-616&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-922&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 789&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 020&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-126&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 146&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-115&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-437&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-267&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-835&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 10 provides additional disclosures related to lease liabilities.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br/&gt; one year &lt;br/&gt; but less than &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due after &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contractual interest on non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-82&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-445&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 628&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 908&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-6 063&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-78&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-197&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-639&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-982&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 896&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 373&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-180&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 553&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 809&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 809&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-54&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-517&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-439&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 075&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 10 provides additional disclosures related to lease liabilities.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Capital risk management&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Novartis strives to maintain a strong credit rating. In managing its capital, Novartis focuses on maintaining a strong balance sheet. As of December 31, 2022, Moody&#x2019;s Investors Service rated the Company A1 for long-term maturities and P-1 for short-term maturities, and S&amp;amp;P Global Ratings rated the Company AA- for long-term maturities and A-1+ for short-term maturities. &lt;/div&gt;
                &lt;div style=" padding-bottom: 10px;"&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:14pt; color:#000000; font-weight:bold;"&gt;Sensitivity analysis&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group uses sensitivity analysis disclosures to provide quantitative information about market risks to which it is exposed. &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The sensitivity analysis disclosures are in line with the Group&#x2019;s financial risk management policy, and are based on a one-parameter risk model that considers a one-factor linear relationship between risk factors and &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;exposures. They consider aggregated risk exposures arising from the most significant risk factors (currency risk, interest rate risk and equity price risk) and include all financial assets and financial liabilities as set forth in the table on page F-64. &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The disclosures below illustrate the potential impact on the Group&#x2019;s consolidated financial statements as a result of hypothetical market movements in foreign currency exchange rates, interest rates and equity prices. The range of variables chosen reflects management&#x2019;s view of changes that are reasonably possible over a one-year period. &lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Foreign currency exchange rate sensitivity&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The Group uses the US dollar as its reporting currency. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Japanese and emerging market currencies, as well as in the Swiss franc. A strengthening (weakening) of the US dollar against these currencies as of December 31, 2022 and 2021 would have affected the measurement of financial instruments denominated in these foreign currencies. This analysis assumes that all other variables, in particular interest rates, remain constant. A hypothetical &lt;span&gt;5%&lt;/span&gt; increase or decrease in the foreign currency exchange rates against the US dollar would have impacted the Group&#x2019;s consolidated income statement as presented below: &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;5% increase in foreign currency exchange rates  against USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;5% decrease in foreign currency exchange rates  against USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;As of December 31, 2022, the Group designated EUR 1.8 billion (December 31, 2021: EUR 1.8 billion) of its long-term euro-denominated straight bonds as hedges of the translation risk arising on certain net investments in foreign operations with euro functional currency. This analysis assumes that all other variables, in particular interest rates, remain constant. A hypothetical &lt;span&gt;5%&lt;/span&gt; increase, or decrease, in the foreign currency exchange rates against the US dollar, without considering the translation effect of these net investments, would have impacted the Group&#x2019;s consolidated equity as presented below: &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;5% increase in foreign currency exchange rates  against USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            93
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            99
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;5% decrease in foreign currency exchange rates  against USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-98&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-104&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Interest rate sensitivity&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Our portfolio of fixed-income instruments as of December 31, 2022, was mainly composed of time deposits and debt securities. &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Novartis uses duration models to approximate the possible change in the value of fixed-income instruments. Based on these models, management believes that a 100-basis point change in interest is deemed a reasonable possible change over a one-year period.&lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;Based on exposures in 2022 and 2021, a hypothetical 100-basis point increase (decrease) in interest rates would not have resulted in a significant increase (decrease) in the fair values of the fixed-income instruments. In addition, a hypothetical 100-basis point increase (decrease) in interest rates would not have resulted in a material increase (decrease) of cash flows attributable to such fixed-income instruments.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The vast majority of our outstanding financial debts are straight bonds with fixed interest rates and are therefore not affected by movements in interest rates.&lt;/div&gt;
                &lt;div&gt;
                  &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Equity price sensitivity&lt;/span&gt;
                &lt;/div&gt;
                &lt;div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;Fund investments and equity securities held by the Novartis Venture Fund are valued at fair value through profit and loss. Equity securities held as strategic investments, typically held outside the Novartis Venture Fund, are generally designated at date of acquisition as financial assets valued at fair value through other comprehensive income with no subsequent recycling through profit and loss.&lt;/div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;"&gt;The fair value of these fund investments and equity securities was USD 1.6 billion as of December 31, 2022 (December 31, 2021: USD 2.2 billion). The fair values of these investments are impacted by the volatility of the stock market, valuation parameters applied (for non-listed equities) and changes in general economic factors. This analysis assumes that all other variables, in particular interest rates, remain constant. A hypothetical increase or decrease of &lt;span&gt;15%&lt;/span&gt; in the risk factors would have impacted the Group&#x2019;s consolidated income statement as presented below: &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;15% increase in equity prices&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            109
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            154
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;15% decrease in equity prices&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-109&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-154&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
            &lt;div&gt;
              &lt;div&gt;
                &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;A hypothetical increase or decrease of &lt;span&gt;15%&lt;/span&gt; in the risk factors would have impacted the Group&#x2019;s consolidated equity as presented below:&lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;15% increase in equity prices&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            124
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;15% decrease in equity prices&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-124&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-179&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <nvs:DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_cbafe3ff-2c53-4d80-a7bf-e74ec1451300_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; amortized&lt;br/&gt; costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; fair value&lt;br/&gt; through other&lt;br/&gt; comprehensive&lt;br/&gt; income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; fair value&lt;br/&gt; through the&lt;br/&gt; consolidated&lt;br/&gt; income&lt;br/&gt; statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Other&lt;br/&gt; financial&lt;br/&gt; liabilities at&lt;br/&gt; amortized&lt;br/&gt; costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 517
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 089
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8 066
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other receivables and current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            958
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities - debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            828
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            317
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            37
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - fund investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            281
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances, security deposits and other long-term receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            129
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13/17&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            650
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            27 971
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            874
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 581
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other short-term financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            863
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 772
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            22 341
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term liabilities to banks and other financial institutions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            144
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 146
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities (see Note 20/22) and other financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 067
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 789
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            31 266
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 122
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 789
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style="border-bottom: solid #FFFFFF 1px;height:1;width:3;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Note&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; amortized&lt;br/&gt; costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; fair value&lt;br/&gt; through other&lt;br/&gt; comprehensive&lt;br/&gt; income&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Financial&lt;br/&gt; instruments at&lt;br/&gt; fair value&lt;br/&gt; through the&lt;br/&gt; consolidated&lt;br/&gt; income&lt;br/&gt; statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Other&lt;br/&gt; financial&lt;br/&gt; liabilities at&lt;br/&gt; amortized&lt;br/&gt; costs&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            10 397
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Time deposits and short-term investments with original maturity more than 90 days&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12 965
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 15&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            8 005
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other receivables and current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 17&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            793
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities - debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 741
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 195
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            468
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term financial investments - fund investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            366
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term loans, advances, security deposits and other long-term receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            332
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 16&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 13&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            32 492
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 980
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 772
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Interest-bearing accounts of employees payable on demand&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 814
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Bank and other short-term financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            899
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commercial paper&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            893
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Straight bonds&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            25 296
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Long-term liabilities to banks and other financial institutions&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 19&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            227
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 553
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 18/22&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 809
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities (see Note 20/22) and other financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 094
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 21&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            68
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; 10&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            37 491
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 162
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 896
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Includes short-term highly rated government-backed debt securities, with an original maturity of three months or less&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">7517000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember"
      decimals="-6"
      unitRef="USD">11089000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">8066000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4OtherCurrentAssetsMember"
      decimals="-6"
      unitRef="USD">958000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableForSaleMarketableSecuritiesMember"
      decimals="-6"
      unitRef="USD">9000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">828000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">317000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">37000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4FundInvestmentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">281000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember"
      decimals="-6"
      unitRef="USD">341000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">129000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">204000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">650000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember"
      decimals="-6"
      unitRef="USD">27971000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember"
      decimals="-6"
      unitRef="USD">874000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember"
      decimals="-6"
      unitRef="USD">1581000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4BankAndOtherFinancialDebtMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember"
      decimals="-6"
      unitRef="USD">863000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4CommercialPaperMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember"
      decimals="-6"
      unitRef="USD">2772000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4StraightBondsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember"
      decimals="-6"
      unitRef="USD">22341000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember"
      decimals="-6"
      unitRef="USD">144000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TradePayablesMember"
      decimals="-6"
      unitRef="USD">5146000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1067000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">55000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2022LeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1789000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember"
      decimals="-6"
      unitRef="USD">31266000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember"
      decimals="-6"
      unitRef="USD">1122000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1789000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">10397000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">2010000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4TimeDepositsWithOriginalMaturityMoreThan90DaysMember"
      decimals="-6"
      unitRef="USD">12965000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022TradeReceivablesMember"
      decimals="-6"
      unitRef="USD">8005000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4OtherCurrentAssetsMember"
      decimals="-6"
      unitRef="USD">793000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableForSaleMarketableSecuritiesMember"
      decimals="-6"
      unitRef="USD">2741000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">1195000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4EquitySecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">468000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_ifrsfull-2022DebtSecuritiesMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">34000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4FundInvestmentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AvailableforsaleLongtermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">366000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember"
      decimals="-6"
      unitRef="USD">332000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">192000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">105000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">641000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostMember"
      decimals="-6"
      unitRef="USD">32492000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember"
      decimals="-6"
      unitRef="USD">5980000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtFairValueMember"
      decimals="-6"
      unitRef="USD">1772000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4InterestBearningAccountsOfAssociatesPayableOnDemandMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember"
      decimals="-6"
      unitRef="USD">1814000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4BankAndOtherFinancialDebtMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember"
      decimals="-6"
      unitRef="USD">899000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4CommercialPaperMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialDebtMember"
      decimals="-6"
      unitRef="USD">893000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4StraightBondsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember"
      decimals="-6"
      unitRef="USD">25296000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4LiabilitiesToBanksAndOtherFinancialInstitutionsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialDebtMember"
      decimals="-6"
      unitRef="USD">227000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TradePayablesMember"
      decimals="-6"
      unitRef="USD">5553000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommitmentForRepurchaseOfOwnSharesMember"
      decimals="-6"
      unitRef="USD">2809000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4ContingentConsiderationAndOtherFinancialLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1094000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember_nvs-2022Q4BalanceSheetItemAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">68000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_ifrsfull-2022LeaseLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1896000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember"
      decimals="-6"
      unitRef="USD">37491000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtFairValueMember"
      decimals="-6"
      unitRef="USD">1162000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember"
      decimals="-6"
      unitRef="USD">1896000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_0966d48d-a793-44c7-a455-cd616c60f156_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Contract or underlying  principal amount&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Positive fair values  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="3" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Negative fair values  &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="3" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 907
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13 248
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            189
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            92
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-41&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-35&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            97
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            82
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-14&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-33&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments included in  marketable securities and in current financial debts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 043
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            13 347
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">7907000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">13248000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember"
      decimals="-6"
      unitRef="USD">189000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember"
      decimals="-6"
      unitRef="USD">92000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember"
      decimals="-6"
      unitRef="USD">-41000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember"
      decimals="-6"
      unitRef="USD">-35000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">97000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
    <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">17000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
    <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember"
      decimals="-6"
      unitRef="USD">15000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
    <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember"
      decimals="-6"
      unitRef="USD">13000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
    <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">39000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
    <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">82000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
    <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember"
      decimals="-6"
      unitRef="USD">-14000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
    <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember"
      decimals="-6"
      unitRef="USD">-33000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">8043000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">13347000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember"
      decimals="-6"
      unitRef="USD">204000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember"
      decimals="-6"
      unitRef="USD">105000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember"
      decimals="-6"
      unitRef="USD">-55000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4NegativeFairValuesMember"
      decimals="-6"
      unitRef="USD">-68000000</nvs:DerivativeFinancialInstruments>
    <nvs:DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_8dd542d6-c2de-4094-9d5e-93318eef01f0_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            687
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5 659
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 907
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            80
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            97
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            39
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            767
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            5 715
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 561
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 043
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Other&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Forward foreign exchange rate contracts&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 158
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 605
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13 248
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodity purchase contract&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            17
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Options on equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            82
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            82
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 485
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            5 257
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            6 605
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            13 347
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR"
      decimals="-6"
      unitRef="USD">687000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">5659000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember"
      decimals="-6"
      unitRef="USD">1561000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">7907000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR"
      decimals="-6"
      unitRef="USD">80000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
    <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">17000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
    <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">97000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
    <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">39000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
    <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">39000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR"
      decimals="-6"
      unitRef="USD">767000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">5715000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember"
      decimals="-6"
      unitRef="USD">1561000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">8043000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR"
      decimals="-6"
      unitRef="USD">1485000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">5158000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember"
      decimals="-6"
      unitRef="USD">6605000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">13248000000</nvs:DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts>
    <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">17000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
    <nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">17000000</nvs:DerivativeFinancialInstrumentsCommodityPurchaseContract>
    <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">82000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
    <nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4DerivativeFinancialInstrumentNatureOfInstrumentAxis_nvs-2022Q4DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">82000000</nvs:DerivativeFinancialInstrumentsOptionsOnEquitySecurities>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR"
      decimals="-6"
      unitRef="USD">1485000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022USD"
      decimals="-6"
      unitRef="USD">5257000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_nvs-2022Q4CurrencyOthersMember"
      decimals="-6"
      unitRef="USD">6605000000</nvs:DerivativeFinancialInstruments>
    <nvs:DerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember"
      decimals="-6"
      unitRef="USD">13347000000</nvs:DerivativeFinancialInstruments>
    <ifrs-full:DisclosureOfFairValueMeasurementExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_93d5d178-10e5-47a9-911e-ac685569bc4f_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 2&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Level 3&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Marketable securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities and derivative financial instruments at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            213
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            213
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current contingent consideration receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            43
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Long-term financial investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt and equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            473
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            699
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            261
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            281
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-current contingent consideration receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            607
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            607
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total long-term financial investments at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            493
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            10
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            1 567
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            2 070
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            129
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            129
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Current contingent consideration liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-131&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-131&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial liabilities at fair values&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-131&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-186&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-current contingent consideration liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-704&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-704&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-232&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-232&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial liabilities at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-936&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-936&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 2&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Level 3&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total cash and cash equivalents at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 010
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Marketable securities and derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 719
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2 741
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total marketable securities and derivative financial instruments at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 719
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            127
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 846
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Long-term financial investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Debt and equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 080
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            617
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 697
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fund investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            338
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            366
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total long-term financial investments at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 108
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 596
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            2 704
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Associated companies at fair value through profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 075&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 075&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Other financial liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total financial liabilities at fair value&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 094&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 162&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Includes short-term highly rated government-backed debt securities, with an original maturity of three months or less&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DisclosureOfFairValueMeasurementExplanatory>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">9000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">9000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">204000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">204000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">213000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">213000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">43000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">43000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">473000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">10000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">699000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">1182000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">20000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">261000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">281000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">607000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">607000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">493000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">10000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">1567000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">2070000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">129000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">129000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">131000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">131000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">55000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">55000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember"
      decimals="-6"
      unitRef="USD">55000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember"
      decimals="-6"
      unitRef="USD">131000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CurrentFinancialLiabilitiesAtFairValueMember"
      decimals="-6"
      unitRef="USD">186000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4NoncurrentContingentConsiderationLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">704000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4NoncurrentContingentConsiderationLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">704000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">232000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">232000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember"
      decimals="-6"
      unitRef="USD">936000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember"
      decimals="-6"
      unitRef="USD">936000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">2010000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022DebtSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">2010000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">2010000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">2010000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">2719000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">22000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4TotalAvailableforsaleMarketableSecuritiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">2741000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">105000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">105000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">2719000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">127000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember"
      decimals="-6"
      unitRef="USD">2846000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">1080000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">617000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4AvailableforsaleFinancialInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">1697000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">28000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">338000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4FundInvestmentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">366000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">641000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfAssetsAxis_nvs-2022Q4ContingentConsiderationReceivablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">641000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level1OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">1108000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">1596000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialInvestmentsAndLongtermLoansGroupMember"
      decimals="-6"
      unitRef="USD">2704000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">192000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">192000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">1075000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">1075000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">68000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">68000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">19000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember"
      decimals="-6"
      unitRef="USD">19000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level2OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember"
      decimals="-6"
      unitRef="USD">68000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022LevelsOfFairValueHierarchyAxis_ifrsfull-2022Level3OfFairValueHierarchyMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember"
      decimals="-6"
      unitRef="USD">1094000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4NoncurrentFinancialLiabilitiesAtFairValueMember"
      decimals="-6"
      unitRef="USD">1162000000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <nvs:DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_e07d3e8d-9265-49c0-90e7-f9c5dc37e973_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="11" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Associated &lt;br/&gt; companies at &lt;br/&gt; fair value  through&lt;br/&gt; profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Fund&lt;br/&gt; investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Long-term &lt;br/&gt; financial &lt;br/&gt; investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Contingent &lt;br/&gt; consideration &lt;br/&gt; receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Contingent &lt;br/&gt; consideration &lt;br/&gt; liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt; Other&lt;br/&gt; financial&lt;br/&gt; liabiltiies&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            338
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            617
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-1 075&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-19&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value gains and other adjustments, including from divestments  recognized in the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            35
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            530
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value losses (including impairments and amortizations) and  other adjustments recognized in the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-63&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-78&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-84&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-114&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-18&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments recognized in the consolidated statement   of comprehensive income, including currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            160
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-231&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-238&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash receipts and payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            44
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            28
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-12&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-40&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            129
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            261
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            699
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            650
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-835&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-232&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total of fair value gains and losses recognized   in the consolidated income statement for assets   and liabilities held at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-63&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-74&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-49&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            53
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            416
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Associated &lt;br/&gt; companies at &lt;br/&gt; fair value  through&lt;br/&gt; profit and loss&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Fund&lt;br/&gt; investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Long-term &lt;br/&gt; financial &lt;br/&gt; investments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Contingent &lt;br/&gt; consideration &lt;br/&gt; receivables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt; Contingent &lt;br/&gt; consideration &lt;br/&gt; payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;January 1&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            211
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            366
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            460
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            625
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 046&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value gains and other adjustments, including from divestments  recognized in the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            70
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            69
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            124
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            182
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value losses (including impairments and amortizations) and  other adjustments recognized in the consolidated income statement&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-26&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-189&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Fair value adjustments recognized in the consolidated statement   of comprehensive income, including currency translation effects&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            51
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-22&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            22
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Purchases&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            34
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            137
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-88&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash receipts and payments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-42&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            44
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Disposals&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-27&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-71&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-43&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Reclassification&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-30&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-44&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;December 31&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            192
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            338
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            617
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            641
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 075&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Total of fair value gains and losses recognized   in the consolidated income statement for assets   and liabilities held at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-24&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            62
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            56
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            80
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-7&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">192000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">338000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">617000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">641000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">-1075000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-19000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">4000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">35000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">53000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">530000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember"
      decimals="-6"
      unitRef="USD">15000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">63000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">78000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">84000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">114000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember"
      decimals="-6"
      unitRef="USD">18000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">24000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
    <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">11000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
    <nvs:PurchaseFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">4000000</nvs:PurchaseFairValueMeasurementAssets>
    <nvs:PurchaseFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">11000000</nvs:PurchaseFairValueMeasurementAssets>
    <nvs:PurchaseFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">160000000</nvs:PurchaseFairValueMeasurementAssets>
    <nvs:PurchaseFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">-231000000</nvs:PurchaseFairValueMeasurementAssets>
    <nvs:PurchaseFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-238000000</nvs:PurchaseFairValueMeasurementAssets>
    <nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">-44000000</nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets>
    <nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">44000000</nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets>
    <nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember"
      decimals="-6"
      unitRef="USD">28000000</nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets>
    <nvs:DisposalsFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">12000000</nvs:DisposalsFairValueMeasurementAssets>
    <nvs:DisposalsFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">13000000</nvs:DisposalsFairValueMeasurementAssets>
    <nvs:ReclassificationFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">-4000000</nvs:ReclassificationFairValueMeasurementAssets>
    <nvs:ReclassificationFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">-2000000</nvs:ReclassificationFairValueMeasurementAssets>
    <nvs:ReclassificationFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">-40000000</nvs:ReclassificationFairValueMeasurementAssets>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">129000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">261000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">699000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">650000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">-835000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-232000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">-63000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
    <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">-74000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
    <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">-49000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
    <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">53000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
    <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">416000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
    <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4OtherFinancialLiabilitiesMember"
      decimals="-6"
      unitRef="USD">-3000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">211000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">366000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">460000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">625000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">-1046000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">2000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">70000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">69000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">124000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">182000000</nvs:GainsRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">26000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">8000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">13000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">44000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">189000000</nvs:LossesRecognisedInProfitOrLossFairValueMeasurementAssets>
    <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">-2000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
    <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">-1000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
    <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">51000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
    <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">-22000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
    <nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">22000000</nvs:FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome>
    <nvs:PurchaseFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">34000000</nvs:PurchaseFairValueMeasurementAssets>
    <nvs:PurchaseFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">12000000</nvs:PurchaseFairValueMeasurementAssets>
    <nvs:PurchaseFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">137000000</nvs:PurchaseFairValueMeasurementAssets>
    <nvs:PurchaseFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">-88000000</nvs:PurchaseFairValueMeasurementAssets>
    <nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">-42000000</nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets>
    <nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">44000000</nvs:CashReceiptsAndPaymentsFairValueMeasurementAssets>
    <nvs:DisposalsFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">27000000</nvs:DisposalsFairValueMeasurementAssets>
    <nvs:DisposalsFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">71000000</nvs:DisposalsFairValueMeasurementAssets>
    <nvs:DisposalsFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">43000000</nvs:DisposalsFairValueMeasurementAssets>
    <nvs:ReclassificationFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">-30000000</nvs:ReclassificationFairValueMeasurementAssets>
    <nvs:ReclassificationFairValueMeasurementAssets
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">-44000000</nvs:ReclassificationFairValueMeasurementAssets>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">192000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">338000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">617000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">641000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FinancialInstrumentsCarryingValueLevel3
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">-1075000000</nvs:FinancialInstrumentsCarryingValueLevel3>
    <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember"
      decimals="-6"
      unitRef="USD">-24000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
    <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FundInvestmentsMember"
      decimals="-6"
      unitRef="USD">62000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
    <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4LongTermFinancialInvestmentsMember"
      decimals="-6"
      unitRef="USD">56000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
    <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationReceivablesMember"
      decimals="-6"
      unitRef="USD">80000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
    <nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember"
      decimals="-6"
      unitRef="USD">-7000000</nvs:FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld>
    <ifrs-full:DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_ef047e1e-0090-4067-aaad-f959928bff50_0">

                  During 2022, there was one transfer of equity securities from Level 3 to Level 1 for USD&#160;44 million (2021: USD&#160;73 million), due to Initial Public Offering of the invested company. During 2022, there were no transfers of equity securities from Level 1 to Level 3 due to de-listing (2021: USD 29 million).

              </ifrs-full:DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets>
    <ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">44000000</ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets>
    <ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">73000000</ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets>
    <ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">29000000</ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets>
    <nvs:NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">316000000</nvs:NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement>
    <nvs:NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">55000000</nvs:NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement>
    <nvs:AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10 contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">154000000</nvs:AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10>
    <nvs:AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10 contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">-140000000</nvs:AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10>
    <nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember"
      decimals="0"
      unitRef="Pure">65</nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome>
    <nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember"
      decimals="0"
      unitRef="Pure">60</nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome>
    <nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember"
      decimals="0"
      unitRef="Pure">46</nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome>
    <nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember"
      decimals="0"
      unitRef="Pure">40</nvs:NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_556822de-8efa-4919-9221-94a3ace6c5bc_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Listed equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            438
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            888
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Non-listed equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            390
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            307
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total equity securities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            828
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 195
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="6"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory>
    <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">438000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4ListedEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">888000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">390000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis_nvs-2022Q4NonlistedEquitySecuritiesMember"
      decimals="-6"
      unitRef="USD">307000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">828000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1195000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <nvs:FairValueOfOtherFinancialAssetsSold
      contextRef="AR_D-CurrentYear_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember"
      decimals="-6"
      unitRef="USD">22000000</nvs:FairValueOfOtherFinancialAssetsSold>
    <nvs:FairValueOfOtherFinancialAssetsSold
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember"
      decimals="-6"
      unitRef="USD">9000000</nvs:FairValueOfOtherFinancialAssetsSold>
    <nvs:GainLossOnSaleOfOtherFinancialAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember"
      decimals="-6"
      unitRef="USD">7000000</nvs:GainLossOnSaleOfOtherFinancialAssets>
    <nvs:GainLossOnSaleOfOtherFinancialAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4AlconMember"
      decimals="-6"
      unitRef="USD">1000000</nvs:GainLossOnSaleOfOtherFinancialAssets>
    <nvs:FairValueOfOtherFinancialAssetsSold contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">3000000</nvs:FairValueOfOtherFinancialAssetsSold>
    <nvs:FairValueOfOtherFinancialAssetsSold contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">254000000</nvs:FairValueOfOtherFinancialAssetsSold>
    <nvs:GainLossOnSaleOfOtherFinancialAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember"
      decimals="-6"
      unitRef="USD">3000000</nvs:GainLossOnSaleOfOtherFinancialAssets>
    <nvs:GainLossOnSaleOfOtherFinancialAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4TotalFairValueAdjustmentsMember_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4OthersAssociatesMember"
      decimals="-6"
      unitRef="USD">211000000</nvs:GainLossOnSaleOfOtherFinancialAssets>
    <nvs:LongtermFinancialDebtWithACarryingAmount
      contextRef="AR_I-CurrentYearEnd"
      decimals="-8"
      unitRef="EUR">1800000000</nvs:LongtermFinancialDebtWithACarryingAmount>
    <nvs:LongtermFinancialDebtWithACarryingAmount
      contextRef="AR_I-CurrentYearEnd"
      decimals="-8"
      unitRef="USD">2000000000.0</nvs:LongtermFinancialDebtWithACarryingAmount>
    <nvs:LongtermFinancialDebtWithACarryingAmount
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-8"
      unitRef="USD">2100000000</nvs:LongtermFinancialDebtWithACarryingAmount>
    <nvs:UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">91000000</nvs:UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge>
    <nvs:UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">216000000</nvs:UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge>
    <nvs:MaximumMarginPercentageImpactOfCommodityPriceChange contextRef="AR_D-CurrentYear" decimals="2" unitRef="Pure">0.10</nvs:MaximumMarginPercentageImpactOfCommodityPriceChange>
    <nvs:MaximumHoldingInUnrelatedCompany contextRef="AR_D-CurrentYear" decimals="2" unitRef="Pure">0.05</nvs:MaximumHoldingInUnrelatedCompany>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.16</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.11</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.07</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.17</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.11</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.06</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.17</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.11</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="AR_D-CurrentYear-2_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.06</ifrs-full:PercentageOfEntitysRevenue>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.16</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.14</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.07</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4LargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.16</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4SecondLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.12</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:PercentageOfEntitysTradeReceivable
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MajorCustomersAxis_nvs-2022Q4ThirdLargestCustomerMember"
      decimals="2"
      unitRef="Pure">0.07</nvs:PercentageOfEntitysTradeReceivable>
    <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution
      contextRef="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4LargestFinancialInstitutionMember"
      decimals="3"
      unitRef="Pure">0.132</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
    <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution
      contextRef="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4SecondLargestFinancialInstitutionMember"
      decimals="3"
      unitRef="Pure">0.092</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
    <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution
      contextRef="AR_D-CurrentYear_nvs-2022Q4VendorAxis_nvs-2022Q4ThirdLargestFinancialInstitutionMember"
      decimals="3"
      unitRef="Pure">0.068</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
    <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4LargestFinancialInstitutionMember"
      decimals="3"
      unitRef="Pure">0.097</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
    <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4SecondLargestFinancialInstitutionMember"
      decimals="3"
      unitRef="Pure">0.097</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
    <nvs:CashAndCashEquivalentsHeldWithFinancialInstitution
      contextRef="AR_D-CurrentYear-1_nvs-2022Q4VendorAxis_nvs-2022Q4ThirdLargestFinancialInstitutionMember"
      decimals="3"
      unitRef="Pure">0.076</nvs:CashAndCashEquivalentsHeldWithFinancialInstitution>
    <nvs:PercentageOfGovernmentBackedDebtSecurities contextRef="AR_D-CurrentYear-1" decimals="2" unitRef="Pure">0.16</nvs:PercentageOfGovernmentBackedDebtSecurities>
    <nvs:PercentageOfGovernmentBackedDebtSecurities contextRef="AR_D-CurrentYear" decimals="2" unitRef="Pure">0</nvs:PercentageOfGovernmentBackedDebtSecurities>
    <nvs:BorrowingsCommercialPaperNumberOfPrograms
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4USCommercialPaperProgramsMember"
      decimals="0"
      unitRef="Pure">2</nvs:BorrowingsCommercialPaperNumberOfPrograms>
    <nvs:BorrowingsCommercialPaperMaximumBorrowingAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4USCommercialPaperProgramsMember"
      decimals="-9"
      unitRef="USD">9000000000.0</nvs:BorrowingsCommercialPaperMaximumBorrowingAmount>
    <nvs:BorrowingsCommercialPaperNumberOfPrograms
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4JPCommercialPaperProgramsMember"
      decimals="0"
      unitRef="Pure">1</nvs:BorrowingsCommercialPaperNumberOfPrograms>
    <nvs:BorrowingsCommercialPaperMaximumBorrowingAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4JPCommercialPaperProgramsMember"
      decimals="-9"
      unitRef="JPY">150000000000</nvs:BorrowingsCommercialPaperMaximumBorrowingAmount>
    <nvs:BorrowingsCommercialPaperMaximumBorrowingAmount
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4JPCommercialPaperProgramsMember"
      decimals="-8"
      unitRef="USD">1100000000</nvs:BorrowingsCommercialPaperMaximumBorrowingAmount>
    <nvs:BorrowingsCommercialPaperMaximumBorrowingAmount
      contextRef="AR_I-CurrentYearEnd"
      decimals="-8"
      unitRef="USD">2800000000</nvs:BorrowingsCommercialPaperMaximumBorrowingAmount>
    <nvs:BorrowingsCommercialPaperNumberOfPrograms
      contextRef="AR_I-CurrentYearEnd"
      decimals="0"
      unitRef="Pure">3</nvs:BorrowingsCommercialPaperNumberOfPrograms>
    <nvs:BorrowingsCommercialPaperMaximumBorrowingAmount
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-8"
      unitRef="USD">900000000</nvs:BorrowingsCommercialPaperMaximumBorrowingAmount>
    <nvs:BorrowingsCreditFacilityCommitted
      contextRef="AR_I-CurrentYearEnd"
      decimals="-9"
      unitRef="USD">6000000000.0</nvs:BorrowingsCreditFacilityCommitted>
    <nvs:DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_5d7581bc-0f65-4708-8690-162a3212588d_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="11" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; one month&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br/&gt; one month &lt;br/&gt; but less than &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br/&gt; one year &lt;br/&gt; but less than &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due after &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities, time deposits and short-term investments with original maturity more than 90 days and accrued interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 142
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6 911
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            36
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11 098
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            23
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            147
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            19
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            15
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            204
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 011
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3 506
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 517
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            8 176
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            10 564
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            55
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            135
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            18 930
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-8 975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-11 269&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-20 244&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-9 002&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-11 394&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-20 396&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-8 975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-11 269&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-20 244&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 215&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-146&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 515&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 876&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-3 215&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-146&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-2 517&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;
                            &lt;span&gt;-5 878&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-38&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-13&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-55&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-3 253&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-159&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2 519&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-5 931&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            4 923
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            10 405
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-2 464&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-8 975&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-11 134&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;
                            &lt;span&gt;-7 245&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="11" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="11" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; one month&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br/&gt; one month &lt;br/&gt; but less than &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br/&gt; one year &lt;br/&gt; but less than &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due after &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Marketable securities, time deposits and short-term investments with original maturity more than 90 days and accrued interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            11
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            14 585
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            1 088
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            18
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:7%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            15 706
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commodities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            111
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            21
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            64
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            13
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            105
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Cash and cash equivalents&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            7 406
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 001
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            12 407
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            7 438
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            19 650
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            1 095
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            142
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            28 329
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-8 464&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-14 438&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-22 902&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-8 490&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-14 587&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-23 077&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total non-current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-8 464&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-14 438&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-22 902&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 780&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-521&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 926&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-6 227&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"&gt;Financial debt - undiscounted&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-2 780&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-521&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-2 928&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"&gt;
                            &lt;span&gt;-6 229&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Derivative financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-50&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-68&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Total current financial debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 830&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-537&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-2 928&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-6 295&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;&#160;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Net debt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            4 608
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            19 113
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-1 833&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-8 460&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-14 296&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"&gt;
                            &lt;span&gt;-868&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="14" style="border-bottom: solid #000000 3px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember"
      decimals="-6"
      unitRef="USD">4142000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember"
      decimals="-6"
      unitRef="USD">6911000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember"
      decimals="-6"
      unitRef="USD">36000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember"
      decimals="-6"
      unitRef="USD">9000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember"
      decimals="-6"
      unitRef="USD">11098000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember"
      decimals="-6"
      unitRef="USD">111000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember"
      decimals="-6"
      unitRef="USD">111000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember"
      decimals="-6"
      unitRef="USD">23000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember"
      decimals="-6"
      unitRef="USD">147000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember"
      decimals="-6"
      unitRef="USD">19000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember"
      decimals="-6"
      unitRef="USD">15000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember"
      decimals="-6"
      unitRef="USD">204000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">4011000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">3506000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">7517000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">8176000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">10564000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">55000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">135000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">18930000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">8975000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">11269000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">20244000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">9002000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">11394000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">20396000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">8975000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">11269000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">20244000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">3215000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">146000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">2515000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">5876000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">3215000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">146000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">2517000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">5878000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">38000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">13000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">4000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">55000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">3253000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">159000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">2519000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">5931000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">-4923000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">-10405000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">2464000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">8975000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">11134000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">7245000000</ifrs-full:NetDebt>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember"
      decimals="-6"
      unitRef="USD">11000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember"
      decimals="-6"
      unitRef="USD">14585000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember"
      decimals="-6"
      unitRef="USD">1088000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember"
      decimals="-6"
      unitRef="USD">4000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember"
      decimals="-6"
      unitRef="USD">18000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember"
      decimals="-6"
      unitRef="USD">15706000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember"
      decimals="-6"
      unitRef="USD">111000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CommoditiesMember"
      decimals="-6"
      unitRef="USD">111000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember"
      decimals="-6"
      unitRef="USD">21000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember"
      decimals="-6"
      unitRef="USD">64000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember"
      decimals="-6"
      unitRef="USD">7000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember"
      decimals="-6"
      unitRef="USD">13000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DeriviativeFinancialInstrumentsAndAccruedInterestMember"
      decimals="-6"
      unitRef="USD">105000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">7406000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">5001000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember"
      decimals="-6"
      unitRef="USD">12407000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">7438000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">19650000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">1095000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">4000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">142000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">28329000000</nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">8464000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">14438000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">22902000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">8490000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">14587000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">23077000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">8464000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">14438000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherNoncurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">22902000000</ifrs-full:OtherNoncurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">2780000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">521000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">2926000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtMember"
      decimals="-6"
      unitRef="USD">6227000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">2780000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">521000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">2928000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4FinancialDebtUndiscountedMember"
      decimals="-6"
      unitRef="USD">6229000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">50000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">16000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">2000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4DerivativeFinancialInstrumentsMember"
      decimals="-6"
      unitRef="USD">68000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">2830000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">537000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">2928000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">6295000000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">-4608000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">-19113000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">1833000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">8460000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">14296000000</ifrs-full:NetDebt>
    <ifrs-full:NetDebt
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">868000000</ifrs-full:NetDebt>
    <nvs:DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_04b824e3-8f23-43e2-9c3a-5c8c866d1028_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; one month&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br/&gt; one month &lt;br/&gt; but less than &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Derivative financial instruments and accrued interest on derivative  financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential outflows in various currencies - from financial derivative liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-2 029&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-4 598&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-316&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6 943&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential inflows in various currencies - from financial derivative assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2 029
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4 712
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            321
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7 062
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="7" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="7" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; one month&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br/&gt; one month &lt;br/&gt; but less than &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Derivative financial instruments and accrued interest on derivative  financial instruments&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential outflows in various currencies - from financial derivative liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-843&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 482&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-461&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:9%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-6 786&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Potential inflows in various currencies - from financial derivative assets&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            847
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            5 516
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            457
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            6 820
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock>
    <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities
      contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">2029000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
    <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities
      contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">4598000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
    <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities
      contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">316000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
    <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">6943000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
    <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">2029000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
    <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">4712000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
    <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets
      contextRef="AR_D-CurrentYear_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">321000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
    <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">7062000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
    <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">843000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
    <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">5482000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
    <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">461000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
    <nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">6786000000</nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities>
    <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneMonthMember"
      decimals="-6"
      unitRef="USD">847000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
    <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">5516000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
    <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets
      contextRef="AR_D-CurrentYear-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">457000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
    <nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets contextRef="AR_D-CurrentYear-1" decimals="-6" unitRef="USD">6820000000</nvs:PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets>
    <nvs:DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_fa7d235f-5c9b-42a1-aefb-f0dc9087bdfc_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Due later than &lt;br/&gt; one year &lt;br/&gt; but less than &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due after &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contractual interest on non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-64&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-412&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 432&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-3 624&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 532&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-71&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-180&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-616&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-922&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-1 789&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 020&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-126&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-5 146&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-16&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-115&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-437&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-267&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-835&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 10 provides additional disclosures related to lease liabilities.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:10px;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="center" colspan="9" style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style="border-bottom: solid #000000 1px;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                        &lt;td colspan="9" style=";height:3;"/&gt;
                        &lt;td style=";height:1;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;
                            &lt;br/&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due within &lt;br/&gt; three months&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than&lt;br/&gt;  three months &lt;br/&gt; but less than &lt;br/&gt; one year&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; Due later than &lt;br/&gt; one year &lt;br/&gt; but less than &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Due after &lt;br/&gt; five years&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt;
                            &lt;br/&gt;
                            &lt;br/&gt;
                            &lt;br/&gt; Total&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contractual interest on non-current liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-82&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-445&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 628&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3 908&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:8%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-6 063&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Lease liabilities&lt;sup style="white-space: nowrap"&gt;&#160;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-78&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-197&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-639&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-982&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 896&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Trade payables&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 373&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-180&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-5 553&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Commitment for repurchase of own shares&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 809&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-2 809&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;Contingent consideration liabilities&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-54&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-65&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-517&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-439&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-1 075&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="12" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="12"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Note 10 provides additional disclosures related to lease liabilities.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock>
    <nvs:ContractualInterestOnNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">-64000000</nvs:ContractualInterestOnNoncurrentLiabilities>
    <nvs:ContractualInterestOnNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">-412000000</nvs:ContractualInterestOnNoncurrentLiabilities>
    <nvs:ContractualInterestOnNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">-1432000000</nvs:ContractualInterestOnNoncurrentLiabilities>
    <nvs:ContractualInterestOnNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">-3624000000</nvs:ContractualInterestOnNoncurrentLiabilities>
    <nvs:ContractualInterestOnNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">-5532000000</nvs:ContractualInterestOnNoncurrentLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">71000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">180000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">616000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">922000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">1789000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">5020000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">126000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">5146000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <nvs:ContingentConsiderationLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">16000000</nvs:ContingentConsiderationLiabilities>
    <nvs:ContingentConsiderationLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">115000000</nvs:ContingentConsiderationLiabilities>
    <nvs:ContingentConsiderationLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">437000000</nvs:ContingentConsiderationLiabilities>
    <nvs:ContingentConsiderationLiabilities
      contextRef="AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">267000000</nvs:ContingentConsiderationLiabilities>
    <nvs:ContingentConsiderationLiabilities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-6"
      unitRef="USD">835000000</nvs:ContingentConsiderationLiabilities>
    <nvs:ContractualInterestOnNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">-82000000</nvs:ContractualInterestOnNoncurrentLiabilities>
    <nvs:ContractualInterestOnNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">-445000000</nvs:ContractualInterestOnNoncurrentLiabilities>
    <nvs:ContractualInterestOnNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">-1628000000</nvs:ContractualInterestOnNoncurrentLiabilities>
    <nvs:ContractualInterestOnNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">-3908000000</nvs:ContractualInterestOnNoncurrentLiabilities>
    <nvs:ContractualInterestOnNoncurrentLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">-6063000000</nvs:ContractualInterestOnNoncurrentLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">78000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">197000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">639000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">982000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1896000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">5373000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">180000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">5553000000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <nvs:CommitmentForRepurchaseOwnShares
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">2809000000</nvs:CommitmentForRepurchaseOwnShares>
    <nvs:CommitmentForRepurchaseOwnShares
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">2809000000</nvs:CommitmentForRepurchaseOwnShares>
    <nvs:ContingentConsiderationLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneMonthAndNotLaterThanThreeMonthsMember"
      decimals="-6"
      unitRef="USD">54000000</nvs:ContingentConsiderationLiabilities>
    <nvs:ContingentConsiderationLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_nvs-2022Q4LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember"
      decimals="-6"
      unitRef="USD">65000000</nvs:ContingentConsiderationLiabilities>
    <nvs:ContingentConsiderationLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanOneYearAndNotLaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">517000000</nvs:ContingentConsiderationLiabilities>
    <nvs:ContingentConsiderationLiabilities
      contextRef="AR_I-CurrentYearEnd-1_ifrsfull-2022MaturityAxis_ifrsfull-2022LaterThanFiveYearsMember"
      decimals="-6"
      unitRef="USD">439000000</nvs:ContingentConsiderationLiabilities>
    <nvs:ContingentConsiderationLiabilities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-6"
      unitRef="USD">1075000000</nvs:ContingentConsiderationLiabilities>
    <nvs:HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity contextRef="AR_D-CurrentYear" decimals="2" unitRef="Pure">0.05</nvs:HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity>
    <nvs:PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_8ceefaad-86bb-44fe-84eb-91ccd9091b6f_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;5% increase in foreign currency exchange rates  against USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-6&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;5% decrease in foreign currency exchange rates  against USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-3&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock>
    <nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement
      contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember"
      decimals="-6"
      unitRef="USD">-6000000</nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement>
    <nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement
      contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember"
      decimals="-6"
      unitRef="USD">3000000</nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement>
    <nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement
      contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember"
      decimals="-6"
      unitRef="USD">7000000</nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement>
    <nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement
      contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember"
      decimals="-6"
      unitRef="USD">-3000000</nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement>
    <nvs:LongtermFinancialDebtWithACarryingAmount
      contextRef="AR_I-CurrentYearEnd"
      decimals="-8"
      unitRef="EUR">1800000000</nvs:LongtermFinancialDebtWithACarryingAmount>
    <nvs:LongtermFinancialDebtWithACarryingAmount
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-8"
      unitRef="EUR">1800000000</nvs:LongtermFinancialDebtWithACarryingAmount>
    <nvs:HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity contextRef="AR_D-CurrentYear" decimals="2" unitRef="Pure">0.05</nvs:HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity>
    <nvs:PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_7761cc88-8064-401e-b23a-519d70b147d7_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;5% increase in foreign currency exchange rates  against USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            93
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            99
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;5% decrease in foreign currency exchange rates  against USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-98&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-104&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock>
    <nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity
      contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember"
      decimals="-6"
      unitRef="USD">93000000</nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity>
    <nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity
      contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5IncreaseMember"
      decimals="-6"
      unitRef="USD">99000000</nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity>
    <nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity
      contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember"
      decimals="-6"
      unitRef="USD">-98000000</nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity>
    <nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity
      contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical5DecreaseMember"
      decimals="-6"
      unitRef="USD">-104000000</nvs:CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity>
    <nvs:FairValueOfFundInvestmentsAndEquitySecurities
      contextRef="AR_I-CurrentYearEnd"
      decimals="-8"
      unitRef="USD">1600000000</nvs:FairValueOfFundInvestmentsAndEquitySecurities>
    <nvs:FairValueOfFundInvestmentsAndEquitySecurities
      contextRef="AR_I-CurrentYearEnd-1"
      decimals="-8"
      unitRef="USD">2200000000</nvs:FairValueOfFundInvestmentsAndEquitySecurities>
    <nvs:HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity contextRef="AR_D-CurrentYear" decimals="2" unitRef="Pure">0.15</nvs:HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity>
    <nvs:PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_597cc3e0-2978-4af4-a86a-cf54a0c07f41_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;15% increase in equity prices&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            109
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            154
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;15% decrease in equity prices&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-109&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-154&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock>
    <nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement
      contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember"
      decimals="-6"
      unitRef="USD">109000000</nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement>
    <nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement
      contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember"
      decimals="-6"
      unitRef="USD">154000000</nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement>
    <nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement
      contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember"
      decimals="-6"
      unitRef="USD">-109000000</nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement>
    <nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement
      contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember"
      decimals="-6"
      unitRef="USD">-154000000</nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement>
    <nvs:HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity contextRef="AR_D-CurrentYear" decimals="2" unitRef="Pure">0.15</nvs:HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity>
    <nvs:PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_737ff923-d299-4ecc-b660-69ac6a14484a_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;(USD millions)&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt; 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"&gt; 2021&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;15% increase in equity prices&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            124
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:14%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            179
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;15% decrease in equity prices&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;-124&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"&gt;
                            &lt;span&gt;-179&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="6" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              </nvs:PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock>
    <nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity
      contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember"
      decimals="-6"
      unitRef="USD">124000000</nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity>
    <nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity
      contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15IncreaseMember"
      decimals="-6"
      unitRef="USD">179000000</nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity>
    <nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity
      contextRef="AR_D-CurrentYear_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember"
      decimals="-6"
      unitRef="USD">-124000000</nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity>
    <nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity
      contextRef="AR_D-CurrentYear-1_srt-2022StatementScenarioAxis_nvs-2022Q4Hypothetical15DecreaseMember"
      decimals="-6"
      unitRef="USD">-179000000</nvs:EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_48c0e011-3c62-4dfe-881e-6e0ae310b015_0">
          &lt;div&gt;
            &lt;div id="anchorId001561678"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;30. Events subsequent to the December 31, 2022, consolidated balance sheet date&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;South Korea investigation &#x2013; Concluded matter&lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;In January 2023, the Supreme Court dismissed the appeal by the Seoul Western District Prosecutor on the criminal investigation on, among other things, allegations that Novartis Korea utilized medical journals to provide inappropriate economic benefits to healthcare professionals (HCPs). This matter is now concluded. For additional information see Note 20.&lt;/div&gt;
            &lt;div&gt;
              &lt;span style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000; font-weight:bold;"&gt;Dividend proposal for 2022 and approval of&#160;the Group&#x2019;s 2022 consolidated financial statements  &lt;/span&gt;
            &lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;On January 31, 2023, the Novartis AG Board of Directors proposed the acceptance of the 2022 consolidated financial statements of the Novartis Group for approval by the Annual General Meeting on March 7, 2023. Furthermore, also on January 31, 2023, the Board proposed a dividend of CHF 3.20 per share to be approved at the Annual General Meeting on March 7, 2023. If approved, total dividend payments would amount to approximately USD 7.3 billion (2021: USD&#160;7.5  billion), using the CHF/USD December 31, 2022, exchange rate.&lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare
      contextRef="AR_D-CurrentYear_nvs-2022Q4SubsequentEventTypAxis_nvs-2022Q4SubsequentEventMember"
      decimals="2"
      unitRef="CHFPerShares">3.20</ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare>
    <ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners contextRef="AR_D-CurrentYear" decimals="-8" unitRef="USD">7300000000</ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners>
    <ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners contextRef="AR_D-CurrentYear-1" decimals="-8" unitRef="USD">7500000000</ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners>
    <ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_70183878-a85a-4760-afef-64a72f590faa_0">
          &lt;div&gt;
            &lt;div id="anchorId001561713"/&gt;
            &lt;div id="anchorNote31"/&gt;
            &lt;div style="font-family:arial,helvetica,sans-serif; font-size:18pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;"&gt;31. Principal Group subsidiaries and&#160;associated&#160;companies &lt;/div&gt;
            &lt;div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; "&gt;The following table lists the principal subsidiaries controlled by Novartis, associated companies in which &#173;Novartis is deemed to have significant influence, and foundations required to be consolidated under IFRS. It includes all subsidiaries, associated companies and consolidated foundations with total assets or net sales to third parties in excess of USD&#160;25&#160;million. The equity interest percentage shown in the table also represents the share in voting rights in those entities.&lt;/div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;As at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share&lt;br/&gt; capital&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br/&gt; interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Algeria&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Soci&#xe9;t&#xe9; par actions SANDOZ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Algiers
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DZD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            650.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Argentina&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Argentina S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Buenos Aires
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ARS&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            906.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Australia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Australia Pty Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Macquarie Park, NSW
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharmaceuticals
Australia Pty Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Macquarie Park, NSW
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Pty Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Macquarie Park, NSW
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Austria&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Austria GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Vienna
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Vienna
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Kundl
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            32.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EBEWE Pharma Ges.m.b.H Nfg. KG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Unterach am Attersee
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Bangladesh&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis (Bangladesh) Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Gazipur
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BDT&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            162.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              60%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Belgium&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma NV
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Vilvoorde
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            72.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz NV
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Vilvoorde
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            19.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Alcon - Couvreur NV
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Puurs
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            110.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Bermuda&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Investment Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hamilton
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Securities Investment Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hamilton
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance Services Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hamilton
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Triangle International Reinsurance Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hamilton
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Trinity River Insurance Co Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hamilton
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            370 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Brazil&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Bioci&#xea;ncias S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            S&#xe3;o Paulo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRL&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            507.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz do Brasil Ind&#xfa;stria Farmac&#xea;utica Ltda.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Camb&#xe9;, PR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRL&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            190.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Canada&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharmaceuticals Canada Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Dorval, Quebec
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CAD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Canada Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Boucherville, Quebec
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CAD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            80.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Chile&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Chile S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Santiago de Chile
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CLP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;China&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Beijing Novartis Pharma Co., Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Beijing
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharmaceuticals (HK) Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hong Kong
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HKD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            200
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            China Novartis Institutes for
BioMedical Research Co., Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Shanghai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            320.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Suzhou Novartis Technical
Development Co., Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Changshu
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Shanghai Novartis Trading Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Shanghai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz (China) Pharmaceutical
Co., Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Zhongshan
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            57.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Colombia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis de Colombia S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Santaf&#xe9; de Bogot&#xe1;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; COP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Croatia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz d.o.o. farmaceutska industrija
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Zagreb
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HRK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Czech Republic&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis s.r.o.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Prague
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CZK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            51.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz s.r.o.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Prague
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CZK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            44.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Denmark&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Healthcare A/S
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Copenhagen
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DKK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            14.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz A/S
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Copenhagen
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DKK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ecuador&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Ecuador S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Quito
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Egypt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma S.A.E.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cairo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EGP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.96%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Egypt Pharma S.A.E.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            New Cairo City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EGP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            250 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Finland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finland Oy
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Espoo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            459 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;As at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share&lt;br/&gt; capital&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br/&gt; interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;France&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Groupe France S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Rueil-Malmaison
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            903.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma S.A.S.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Rueil-Malmaison
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            43.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Gene Therapies France SAS
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Rueil-Malmaison
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Rueil-Malmaison
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications
Molecular Imaging France
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Saint-Genis-Pouilly
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            CELLforCURE
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Les Ulis
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz S.A.S.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Levallois-Perret
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Germany&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Deutschland GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Nuremberg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            155.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Business Services GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Wehr
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Nuremberg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Produktions GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Wehr
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz International GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Holzkirchen
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 A Pharma GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Holzkirchen
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            26 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            HEXAL AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Holzkirchen
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            93.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Salutas Pharma GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Barleben
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            42.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Aeropharm GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Rudolstadt
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            26 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Greece&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis (Hellas) S.A.C.I.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Metamorphosis / Athens
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            233.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Hungary&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Hungary Healthcare Limited Liability
Company
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Budapest
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HUF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            545.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Hungary Limited Liability Company
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Budapest
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HUF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            883.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;India&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis India Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Mumbai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            123.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              70.68%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Healthcare Private Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Mumbai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            60.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Private Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Mumbai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            32.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Indonesia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            PT. Novartis Indonesia
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Jakarta
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; IDR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ireland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Ireland Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Dublin
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Integrated Services Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cork City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Gene Therapies EU Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Dublin
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Israel&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Israel Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Tel Aviv
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ILS&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Italy&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Farma S.p.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Milan
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications (Italy) S.r.l.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Pozzilli
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            119 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz S.p.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Origgio
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Japan&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma K.K.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Tokyo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Ciba-Geigy Japan Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Tokyo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz K.K.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Tokyo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Latvia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Baltics SIA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Riga
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Luxembourg&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Investments S.&#xe0; r.l.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Luxembourg City
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Luxembourg City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Malaysia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Corporation (Malaysia) Sdn. Bhd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Petaling Jaya
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MYR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Mexico&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Farmac&#xe9;utica, S.A. de C.V.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Mexico City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MXN&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            205.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz, S.A. de C.V.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Mexico City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MXN&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            468.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Morocco&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Maroc SA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Casablanca
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MAD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            80.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Netherlands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Netherlands B.V.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Amsterdam
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma B.V.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Amsterdam
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            IDB Holland BV
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Baarle-Nassau
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz B.V.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Almere
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            907 560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;New Zealand&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis New Zealand Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Auckland
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; NZD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            820 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;As at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share&lt;br/&gt; capital&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br/&gt; interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Norway&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Norge AS
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Oslo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; NOK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Pakistan&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma (Pakistan) Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Karachi
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PKR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.99%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Panama&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma (Logistics), Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Panama City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Philippines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Healthcare Philippines, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Makati City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PHP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            298.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Philippines Corporation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Makati City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PHP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Poland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Poland Sp. z o.o.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Warsaw
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            44.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Polska Sp. z o.o.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Warsaw
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Lek S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Strykow
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Portugal&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Portugal, S.G.P.S., Lda.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Porto Salvo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            500 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Farma - Produtos Farmac&#xea;uticos, S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Porto Salvo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Farmac&#xea;utica, Lda.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Porto Salvo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            499 900
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Romania&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Services Romania S.R.L.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Bucharest
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RON&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz S.R.L.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Targu-Mures
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RON&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            119.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Russian Federation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma LLC
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Moscow
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Neva LLC
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            St. Petersburg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            500.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            JSC Sandoz
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Moscow
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            57.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Saudi Arabia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Saudi Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Riyadh
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SAR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Singapore&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis (Singapore) Pte Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Singapore
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Singapore Pharmaceutical
Manufacturing Pte Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Singapore
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            45.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Asia Pacific Pharmaceuticals
Pte Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Singapore
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            39.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Slovakia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Slovakia s.r.o.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Bratislava
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Slovenia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Lek Pharmaceuticals d.d.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Ljubljana
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            48.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Pharmaceuticals d.d.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Ljubljana
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;South Africa&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis South Africa (Pty) Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Midrand
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ZAR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            86.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz South Africa (Pty) Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Midrand
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ZAR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;South Korea&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Korea Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Seoul
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; KRW&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Spain&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Farmac&#xe9;utica, S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Barcelona
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            63.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications
Iberica, S.L.U.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Esplugues de Llobregat
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            22.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Farmac&#xe9;utica S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Madrid
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            270 450
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Industrial Products
S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Les Franqueses del Vall&#xe9;s / Barcelona
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Abadia Retuerta S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sard&#xf3;n de Duero / Valladolid
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Sweden&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Sverige AB
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Stockholm
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SEK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis International AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Holding AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis International Pharmaceutical Investment AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Bioventures AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Forschungsstiftung
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Stiftung f&#xfc;r Kaderausbildung
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis-Mitarbeiterbeteiligungsstiftung
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Stiftung f&#xfc;r Mensch und Umwelt
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Stiftung der Novartis AG f&#xfc;r Erziehung,
Ausbildung und Bildung
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Overseas Investments AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Japat AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            50 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            350.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Services AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Schweizerhalle AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Muttenz
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Stein AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Stein
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            251 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Schweiz AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Risch
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cellerys AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Schlieren
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            129 630
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              20%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Arctos Medical AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Bern
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            360 020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Innovative Therapies AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Risch
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications International SA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Geneva
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Pharmaceuticals AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Risch
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;As at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share&lt;br/&gt; capital&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br/&gt; interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Taiwan&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis (Taiwan) Co., Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Taipei
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TWD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            170.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Thailand&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis (Thailand) Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Bangkok
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; THB&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            302.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Turkey&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Saglik, Gida ve Tarim &#xdc;r&#xfc;nleri Sanayi
ve Ticaret A.S.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Istanbul
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            448.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Farmanova Saglik Hizmetleri Ltd. Sti.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Istanbul
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Ila&#xe7; Sanayi ve Ticaret A.S.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Istanbul
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            880.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.99%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Grup Saglik &#xdc;r&#xfc;nleri
Ila&#xe7;lari Sanayi ve Ticaret A.S.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Gebze - Kocaeli
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            96.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ukraine&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Ukraine LLC
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Kyiv
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; UAH&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United Arab Emirates&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Middle East FZE
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Dubai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AED&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United Kingdom&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis UK Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharmaceuticals UK Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Grimsby Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            250.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications (UK &amp;amp; Ireland)
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Neutec Pharma Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Gyroscope Therapeutics Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 492
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Frimley / Camberley
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United States of America&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Corporation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            72.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance Corporation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Services, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis US Foundation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharmaceuticals Corporation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            650
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications USA, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Millburn, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Gene Therapies, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Bannockburn, IL
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Technology LLC
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Institutes for BioMedical
Research, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cambridge, MA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cadent Therapeutics
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cambridge, MA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Endocyte, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Navigate BioPharma Services, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Carlsbad, CA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            The Medicines Company
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Princeton, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Oriel Therapeutics, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Durham, NC
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            50.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Fougera Pharmaceuticals Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Melville, NY
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Eon Labs, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Princeton, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Venezuela&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis de Venezuela, S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Caracas
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; VES&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Vietnam&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Vietnam Company Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Ho Chi Minh City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; VND&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            70
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;In addition, the Group is represented by subsidiaries and associated companies with total assets or net sales to third parties below USD 25 million in the following countries: Bosnia and Herzegovina, Bulgaria, Cameroon, Dominican Republic, Ghana, Guatemala, Ivory Coast, Kazakhstan, Kenya, Kuwait, North Macedonia, Nigeria, Peru, Senegal and Uruguay.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Share capital may not reflect the taxable share capital and does not include any paid-in surplus.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Significant subsidiary under SEC Regulation S-X Rule 1-02(w)&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt; Fully consolidated Foundation&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;m = million; bn = billion&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

            &lt;/div&gt;
          &lt;/div&gt;

          &lt;div&gt;
            &lt;div&gt;

                &lt;div/&gt;

            &lt;/div&gt;
          &lt;/div&gt;
        </ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory>
    <nvs:PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties contextRef="AR_D-CurrentYear" decimals="-6" unitRef="USD">25000000</nvs:PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties>
    <nvs:PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock
      contextRef="AR_D-CurrentYear"
      id="SectionBlock_c1fa9f5f-f4f8-4475-a7fc-98ba99290473_0">
                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;As at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share&lt;br/&gt; capital&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br/&gt; interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Algeria&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Soci&#xe9;t&#xe9; par actions SANDOZ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Algiers
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DZD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            650.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Argentina&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Argentina S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Buenos Aires
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ARS&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            906.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Australia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Australia Pty Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Macquarie Park, NSW
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharmaceuticals
Australia Pty Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Macquarie Park, NSW
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Pty Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Macquarie Park, NSW
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AUD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Austria&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Austria GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Vienna
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Vienna
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Kundl
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            32.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            EBEWE Pharma Ges.m.b.H Nfg. KG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Unterach am Attersee
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Bangladesh&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis (Bangladesh) Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Gazipur
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BDT&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            162.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              60%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Belgium&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma NV
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Vilvoorde
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            72.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz NV
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Vilvoorde
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            19.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Alcon - Couvreur NV
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Puurs
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            110.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Bermuda&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Investment Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hamilton
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Securities Investment Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hamilton
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance Services Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hamilton
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Triangle International Reinsurance Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hamilton
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Trinity River Insurance Co Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hamilton
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            370 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Brazil&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Bioci&#xea;ncias S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            S&#xe3;o Paulo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRL&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            507.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz do Brasil Ind&#xfa;stria Farmac&#xea;utica Ltda.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Camb&#xe9;, PR
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; BRL&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            190.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Canada&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharmaceuticals Canada Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Dorval, Quebec
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CAD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Canada Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Boucherville, Quebec
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CAD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            80.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Chile&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Chile S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Santiago de Chile
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CLP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;China&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Beijing Novartis Pharma Co., Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Beijing
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharmaceuticals (HK) Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Hong Kong
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HKD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            200
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            China Novartis Institutes for
BioMedical Research Co., Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Shanghai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            320.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Suzhou Novartis Technical
Development Co., Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Changshu
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Shanghai Novartis Trading Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Shanghai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz (China) Pharmaceutical
Co., Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Zhongshan
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            57.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Colombia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis de Colombia S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Santaf&#xe9; de Bogot&#xe1;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; COP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Croatia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz d.o.o. farmaceutska industrija
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Zagreb
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HRK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Czech Republic&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis s.r.o.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Prague
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CZK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            51.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz s.r.o.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Prague
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CZK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            44.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Denmark&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Healthcare A/S
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Copenhagen
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DKK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            14.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz A/S
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Copenhagen
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; DKK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            12.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ecuador&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Ecuador S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Quito
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Egypt&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma S.A.E.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cairo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EGP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.96%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Egypt Pharma S.A.E.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            New Cairo City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EGP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            250 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Finland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finland Oy
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Espoo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            459 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;As at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share&lt;br/&gt; capital&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br/&gt; interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;France&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Groupe France S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Rueil-Malmaison
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            903.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma S.A.S.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Rueil-Malmaison
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            43.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Gene Therapies France SAS
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Rueil-Malmaison
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Rueil-Malmaison
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications
Molecular Imaging France
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Saint-Genis-Pouilly
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            CELLforCURE
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Les Ulis
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz S.A.S.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Levallois-Perret
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Germany&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Deutschland GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Nuremberg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            155.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Business Services GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Wehr
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Nuremberg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Produktions GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Wehr
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz International GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Holzkirchen
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 A Pharma GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Holzkirchen
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            26 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            HEXAL AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Holzkirchen
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            93.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Salutas Pharma GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Barleben
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            42.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Aeropharm GmbH
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Rudolstadt
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            26 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Greece&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis (Hellas) S.A.C.I.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Metamorphosis / Athens
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            233.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Hungary&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Hungary Healthcare Limited Liability
Company
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Budapest
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HUF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            545.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Hungary Limited Liability Company
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Budapest
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; HUF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            883.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;India&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis India Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Mumbai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            123.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              70.68%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Healthcare Private Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Mumbai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            60.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Private Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Mumbai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; INR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            32.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Indonesia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            PT. Novartis Indonesia
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Jakarta
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; IDR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ireland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Ireland Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Dublin
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Integrated Services Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cork City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Gene Therapies EU Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Dublin
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Israel&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Israel Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Tel Aviv
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ILS&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Italy&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Farma S.p.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Milan
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications (Italy) S.r.l.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Pozzilli
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            119 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz S.p.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Origgio
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Japan&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma K.K.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Tokyo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Ciba-Geigy Japan Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Tokyo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz K.K.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Tokyo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; JPY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Latvia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Baltics SIA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Riga
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Luxembourg&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Investments S.&#xe0; r.l.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Luxembourg City
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Luxembourg City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Malaysia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Corporation (Malaysia) Sdn. Bhd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Petaling Jaya
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MYR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Mexico&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Farmac&#xe9;utica, S.A. de C.V.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Mexico City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MXN&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            205.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz, S.A. de C.V.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Mexico City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MXN&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            468.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Morocco&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Maroc SA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Casablanca
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; MAD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            80.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Netherlands&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Netherlands B.V.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Amsterdam
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma B.V.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Amsterdam
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            4.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            IDB Holland BV
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Baarle-Nassau
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz B.V.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Almere
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            907 560
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;New Zealand&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis New Zealand Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Auckland
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; NZD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            820 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;As at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share&lt;br/&gt; capital&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br/&gt; interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Norway&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Norge AS
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Oslo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; NOK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Pakistan&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma (Pakistan) Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Karachi
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PKR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.99%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Panama&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma (Logistics), Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Panama City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Philippines&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Healthcare Philippines, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Makati City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PHP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            298.8
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Philippines Corporation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Makati City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PHP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Poland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Poland Sp. z o.o.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Warsaw
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            44.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Polska Sp. z o.o.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Warsaw
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Lek S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Strykow
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; PLN&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            11.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Portugal&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Portugal, S.G.P.S., Lda.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Porto Salvo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            500 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Farma - Produtos Farmac&#xea;uticos, S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Porto Salvo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Farmac&#xea;utica, Lda.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Porto Salvo
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            499 900
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Romania&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Services Romania S.R.L.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Bucharest
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RON&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz S.R.L.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Targu-Mures
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RON&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            119.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Russian Federation&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma LLC
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Moscow
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Neva LLC
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            St. Petersburg
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            500.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            JSC Sandoz
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Moscow
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; RUB&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            57.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Saudi Arabia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Saudi Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Riyadh
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SAR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            30.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Singapore&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis (Singapore) Pte Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Singapore
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Singapore Pharmaceutical
Manufacturing Pte Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Singapore
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            45.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Asia Pacific Pharmaceuticals
Pte Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Singapore
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SGD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            39.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Slovakia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Slovakia s.r.o.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Bratislava
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Slovenia&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Lek Pharmaceuticals d.d.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Ljubljana
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            48.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Pharmaceuticals d.d.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Ljubljana
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;South Africa&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis South Africa (Pty) Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Midrand
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ZAR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            86.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz South Africa (Pty) Ltd
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Midrand
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; ZAR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            3.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;South Korea&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Korea Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Seoul
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; KRW&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            24.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Spain&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Farmac&#xe9;utica, S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Barcelona
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            63.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications
Iberica, S.L.U.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Esplugues de Llobregat
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            22.6
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Farmac&#xe9;utica S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Madrid
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            270 450
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Industrial Products
S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Les Franqueses del Vall&#xe9;s / Barcelona
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Abadia Retuerta S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sard&#xf3;n de Duero / Valladolid
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; EUR&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Sweden&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Sverige AB
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Stockholm
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; SEK&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Switzerland&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis International AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            10.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Holding AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis International Pharmaceutical Investment AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Bioventures AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Forschungsstiftung
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Stiftung f&#xfc;r Kaderausbildung
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis-Mitarbeiterbeteiligungsstiftung
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Stiftung f&#xfc;r Mensch und Umwelt
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Stiftung der Novartis AG f&#xfc;r Erziehung,
Ausbildung und Bildung
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Overseas Investments AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Japat AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            50 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            350.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Services AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            20.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Schweizerhalle AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Muttenz
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            18.9
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Stein AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Stein
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            251 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharma Schweiz AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Risch
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cellerys AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Schlieren
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            129 630
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              20%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Arctos Medical AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Bern
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            360 020
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Innovative Therapies AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Risch
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications International SA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Geneva
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            9.3
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Basel
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Pharmaceuticals AG
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Risch
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; CHF&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                  &lt;div style="padding-top:10px; padding-bottom:30px;"&gt;
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse" width="100%"&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:12;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"&gt;
                            &lt;br/&gt;As at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Share&lt;br/&gt; capital&lt;sup style="white-space: nowrap"&gt;1&lt;/sup&gt;&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                        &lt;td/&gt;
                        &lt;td align="right"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt; Equity &lt;br/&gt; interest&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 2px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Taiwan&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis (Taiwan) Co., Ltd.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Taipei
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TWD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            170.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Thailand&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis (Thailand) Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Bangkok
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; THB&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            302.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Turkey&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Saglik, Gida ve Tarim &#xdc;r&#xfc;nleri Sanayi
ve Ticaret A.S.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Istanbul
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            448.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Farmanova Saglik Hizmetleri Ltd. Sti.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Istanbul
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            6.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Ila&#xe7; Sanayi ve Ticaret A.S.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Istanbul
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            880.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.99%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Grup Saglik &#xdc;r&#xfc;nleri
Ila&#xe7;lari Sanayi ve Ticaret A.S.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Gebze - Kocaeli
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; TRY&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            96.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Ukraine&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Ukraine LLC
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Kyiv
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; UAH&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            8.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United Arab Emirates&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Middle East FZE
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Dubai
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; AED&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United Kingdom&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis UK Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25.5
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharmaceuticals UK Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            5.4
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Grimsby Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            250.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications (UK &amp;amp; Ireland)
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            100
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Neutec Pharma Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            7.7
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Gyroscope Therapeutics Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            London
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 492
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Frimley / Camberley
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; GBP&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            2.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;United States of America&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Corporation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            72.2
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Finance Corporation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Capital Corporation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Services, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis US Foundation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                            &lt;sup style="white-space: nowrap"&gt;&#160;3&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Pharmaceuticals Corporation
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                            &lt;sup style="white-space: nowrap"&gt;&#160;2&lt;/sup&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            650
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Advanced Accelerator Applications USA, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Millburn, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              99.23%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Gene Therapies, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Bannockburn, IL
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Technology LLC
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; --&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Institutes for BioMedical
Research, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cambridge, MA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cadent Therapeutics
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Cambridge, MA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0.1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Endocyte, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Navigate BioPharma Services, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Carlsbad, CA
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            The Medicines Company
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            East Hanover, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Sandoz Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Princeton, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            25 000
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Oriel Therapeutics, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Durham, NC
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            50.0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; m&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Fougera Pharmaceuticals Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Melville, NY
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Eon Labs, Inc.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Princeton, NJ
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; USD&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            1
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Venezuela&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis de Venezuela, S.A.
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Caracas
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; VES&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            0
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"&gt;Vietnam&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td style=";height:16;width:40%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Novartis Vietnam Company Limited
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td style=";width:30%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            Ho Chi Minh City
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; VND&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:10%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            70
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td style=";width:5%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt; bn&lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                        &lt;td align="right" style=";width:1%;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"&gt;
                            &lt;span&gt;
                              100%&lt;/span&gt;
                          &lt;/div&gt;
                        &lt;/td&gt;
                        &lt;td align="right" style=";width:1%;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr&gt;
                        &lt;td colspan="10" style="border-bottom: solid #000000 1px;height:1px;"/&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"/&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;In addition, the Group is represented by subsidiaries and associated companies with total assets or net sales to third parties below USD 25 million in the following countries: Bosnia and Herzegovina, Bulgaria, Cameroon, Dominican Republic, Ghana, Guatemala, Ivory Coast, Kazakhstan, Kenya, Kuwait, North Macedonia, Nigeria, Peru, Senegal and Uruguay.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;1&#160;&lt;/sup&gt; Share capital may not reflect the taxable share capital and does not include any paid-in surplus.&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;2&#160;&lt;/sup&gt; Significant subsidiary under SEC Regulation S-X Rule 1-02(w)&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:10pt; text-indent:-10pt;"&gt;
                            &lt;sup&gt;&#160;3&#160;&lt;/sup&gt; Fully consolidated Foundation&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                      &lt;tr valign="bottom"&gt;
                        &lt;td colspan="10" style=";height:10px;"&gt;
                          &lt;div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"&gt;m = million; bn = billion&lt;/div&gt;
                        &lt;/td&gt;
                      &lt;/tr&gt;
                    &lt;/table&gt;
                  &lt;/div&gt;
                &lt;/div&gt;

                &lt;div/&gt;
              </nvs:PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Soci&#xe9;t&#xe9; par actions SANDOZ</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Algiers</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="DZD">650000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SocieteParActionsSANDOZAlgiersMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Argentina S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Buenos Aires</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="ARS">906100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisArgentinaS.A.BuenosAiresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Australia Pty Ltd</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Macquarie Park, NSW</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="AUD">2</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharmaceuticals
Australia Pty Ltd</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Macquarie Park, NSW</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="AUD">3800000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Pty Ltd</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Macquarie Park, NSW</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="AUD">11600000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPtyLtdMacquarieParkNSWMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Austria GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Vienna</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">1000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAustriaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Vienna</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">1100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Kundl</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">32700000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGmbHViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">EBEWE Pharma Ges.m.b.H Nfg. KG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Unterach am Attersee</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">1000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EBEWEPharmaGes.m.b.HNfg.KGViennaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis (Bangladesh) Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Gazipur</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="BDT">162500000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBangladeshLimitedGazipurMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">0.60</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma NV</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Vilvoorde</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">72100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz NV</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Vilvoorde</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">19200000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozNVVilvoordeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Alcon - Couvreur NV</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Puurs</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">110600000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AlconCouvreurNVPuursMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Investment Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Hamilton</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">12000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Securities Investment Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Hamilton</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="CHF">30000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSecuritiesInvestmentLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Finance Services Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Hamilton</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="CHF">20000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceServicesLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Triangle International Reinsurance Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Hamilton</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CHF">1000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TriangleInternationalReinsuranceLimitedHamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Trinity River Insurance Co Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Hamilton</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">370000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TrinityRiverInsuranceCoLtd.HamiltonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Bioci&#xea;ncias S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">S&#xe3;o Paulo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="BRL">507100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBiocienciasS.A.SaoPauloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz do Brasil Ind&#xfa;stria Farmac&#xea;utica Ltda.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Camb&#xe9;, PR</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="BRL">190000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharmaceuticals Canada Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Dorval, Quebec</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CAD">1200000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Canada Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Boucherville, Quebec</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CAD">80800000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozCanadaInc.BouchervilleQuebecMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Chile S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Santiago de Chile</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-8"
      unitRef="CLP">2000000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisChileS.A.SantiagoDeChileMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Beijing Novartis Pharma Co., Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Beijing</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="USD">30000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4BeijingNovartisPharmaCo.Ltd.BeijingMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharmaceuticals (HK) Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Hong Kong</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="HKD">200</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsHKLimitedHongKongMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">China Novartis Institutes for
BioMedical Research Co., Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Shanghai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="USD">320000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Suzhou Novartis Technical
Development Co., Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Changshu</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="USD">12000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Shanghai Novartis Trading Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Shanghai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="USD">3200000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ShanghaiNovartisTradingLtd.ShanghaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz (China) Pharmaceutical
Co., Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Zhongshan</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="USD">57600000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis de Colombia S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Santaf&#xe9; de Bogot&#xe1;</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-8"
      unitRef="COP">7900000000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeColombiaS.A.SantafeDeBobotaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz d.o.o. farmaceutska industrija</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Zagreb</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="HRK">25600000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozD.o.o.FarmaceutskaIndustrijaZagrebMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis s.r.o.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Prague</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CZK">51500000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz s.r.o.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Prague</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CZK">44700000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.r.o.PragueMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Healthcare A/S</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Copenhagen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="DKK">14000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcareASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz A/S</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Copenhagen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="DKK">12000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozASCopenhagenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Ecuador S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Quito</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="USD">4000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisEcuadorS.A.QuitoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma S.A.E.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Cairo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-8"
      unitRef="EGP">1300000000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.E.CairoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9996</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Egypt Pharma S.A.E.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">New Cairo City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EGP">250000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozEgyptPharmaS.A.E.NewCairoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Finland Oy</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Espoo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">459000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinlandOyEspooMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Groupe France S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Rueil-Malmaison</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">903000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGroupeFranceS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma S.A.S.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Rueil-Malmaison</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">43400000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Gene Therapies France SAS</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Rueil-Malmaison</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-6"
      unitRef="EUR">10000000000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Advanced Accelerator Applications S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Rueil-Malmaison</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">9600000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Advanced Accelerator Applications
Molecular Imaging France</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Saint-Genis-Pouilly</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">7500000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">CELLforCURE</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Les Ulis</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">4200000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CELLforCURELesUlisMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz S.A.S.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Levallois-Perret</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">5400000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.S.LevalloisPerretMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Deutschland GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Nuremberg</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">155500000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeutschlandGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Business Services GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Wehr</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">25000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBusinessServicesGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Nuremberg</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">25600000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaGmbHNurembergMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma Produktions GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Wehr</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">2000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaProduktionsGmbHWehrMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz International GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Holzkirchen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInternationalGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">1 A Pharma GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Holzkirchen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">26000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4A1APharmaGmbHHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">HEXAL AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Holzkirchen</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">93700000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4HEXALAGHolzkirchenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Salutas Pharma GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Barleben</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">42100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SalutasPharmaGmbHBarlebenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Aeropharm GmbH</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Rudolstadt</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">26000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AeropharmGmbHRudolstadtMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis (Hellas) S.A.C.I.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Metamorphosis / Athens</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">233900000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHellasS.A.C.I.MetamorphosisAthensMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Hungary Healthcare Limited Liability
Company</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Budapest</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="HUF">545600000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Hungary Limited Liability Company</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Budapest</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="HUF">883000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozHungaryLimitedLiabilityCompanyBudapestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis India Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Mumbai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="INR">123500000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIndiaLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.7068</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Healthcare Private Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Mumbai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="INR">60000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Private Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Mumbai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="INR">32000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPrivateLimitedMumbaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">PT. Novartis Indonesia</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Jakarta</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-8"
      unitRef="IDR">7700000000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4PT.NovartisIndonesiaJakartaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Ireland Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Dublin</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">25000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIrelandLimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Integrated Services Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Cork City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">100</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Gene Therapies EU Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Dublin</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">100</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesEULimitedDublinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Israel Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Tel Aviv</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="ILS">1000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisIsraelLtd.TelAvivMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Farma S.p.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Milan</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">18200000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaS.p.A.MilanMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Advanced Accelerator Applications (Italy) S.r.l.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Pozzilli</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">119000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz S.p.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Origgio</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">1700000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.p.A.OriggioMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma K.K.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Tokyo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="JPY">100000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Ciba-Geigy Japan Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Tokyo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="JPY">100000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CibaGeigyJapanLimitedTokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz K.K.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Tokyo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="JPY">100000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozK.K.TokyoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Baltics SIA</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Riga</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">3000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBalticsSIARigaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Investments S.&#xe0; r.l.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Luxembourg City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="USD">100000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInvestmentsS.aR.l.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Finance S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Luxembourg City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceS.A.LuxembourgCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Corporation (Malaysia) Sdn. Bhd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Petaling Jaya</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="MYR">3300000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Farmac&#xe9;utica, S.A. de C.V.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Mexico City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="MXN">205000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz, S.A. de C.V.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Mexico City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="MXN">468200000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.A.DeC.V.MexicoCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma Maroc SA</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Casablanca</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="MAD">80000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaMarocSACasablancaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Netherlands B.V.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Amsterdam</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">1400000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNetherlandsB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma B.V.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Amsterdam</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">4500000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaB.V.AmsterdamMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">IDB Holland BV</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Baarle-Nassau</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">18000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4IDBHollandBVBaarleNassauMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz B.V.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Almere</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">907560</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozB.V.AlmereMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis New Zealand Ltd</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Auckland</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="NZD">820000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNewZealandLtdAucklandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Norge AS</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Oslo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="NOK">1500000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNorgeASOsloMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma (Pakistan) Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Karachi</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-8"
      unitRef="PKR">6700000000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaPakistanLimitedKarachiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9999</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma (Logistics), Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Panama City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">10000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLogisticsInc.PanamaCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Healthcare Philippines, Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Makati City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="PHP">298800000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHealthcarePhilippinesInc.MakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Philippines Corporation</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Makati City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="PHP">30000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPhilippinesCorporationMakatiCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Poland Sp. z o.o.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Warsaw</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="PLN">44200000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPolandSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Polska Sp. z o.o.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Warsaw</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="PLN">25600000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPolskaSp.ZO.o.WarsawMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Lek S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Strykow</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="PLN">11400000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekS.A.StrykowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Portugal, S.G.P.S., Lda.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Porto Salvo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">500000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPortugalSGPSLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Farma - Produtos Farmac&#xea;uticos, S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Porto Salvo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">2400000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Farmac&#xea;utica, Lda.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Porto Salvo</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">499900</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaLda.PortoSalvoMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma Services Romania S.R.L.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Bucharest</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="RON">3000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesRomaniaS.R.L.BucharestMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz S.R.L.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Targu-Mures</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="RON">119500000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozS.R.L.TarguMuresMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma LLC</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Moscow</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="RUB">20000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaLLCMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Neva LLC</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">St. Petersburg</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="RUB">500000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisNevaLLCSt.PetersburgMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">JSC Sandoz</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Moscow</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="RUB">57400000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JSCSandozMoscowMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Saudi Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Riyadh</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="SAR">30000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaudiLtd.RiyadhMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis (Singapore) Pte Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Singapore</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="SGD">100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePteLtd.SingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Singapore Pharmaceutical
Manufacturing Pte Ltd</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Singapore</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="SGD">45000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Asia Pacific Pharmaceuticals
Pte Ltd</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Singapore</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="SGD">39000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Slovakia s.r.o.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Bratislava</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">2000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSlovakiaS.r.o.BratislavaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Lek Pharmaceuticals d.d.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Ljubljana</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">48400000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4LekPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Pharmaceuticals d.d.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Ljubljana</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">1500000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsD.d.LjubjanaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis South Africa (Pty) Ltd</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Midrand</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="ZAR">86300000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz South Africa (Pty) Ltd</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Midrand</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="ZAR">3000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozSouthAfricaPtyLtdMidrandMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Korea Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Seoul</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-8"
      unitRef="KRW">24500000000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisKoreaLtd.SeoulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Farmac&#xe9;utica, S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Barcelona</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">63000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFarmaceuticaS.A.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Advanced Accelerator Applications
Iberica, S.L.U.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Esplugues de Llobregat</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">22600000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Farmac&#xe9;utica S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Madrid</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="EUR">270450</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozFarmaceuticaS.A.MadridMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Industrial Products
S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Les Franqueses del Vall&#xe9;s / Barcelona</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">9300000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Abadia Retuerta S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sard&#xf3;n de Duero / Valladolid</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="EUR">6000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AbadiaRetuertaS.A.SardonDeDueroValladolidMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Sverige AB</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Stockholm</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="SEK">5000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSverigeABStockholmMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis International AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CHF">10000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Holding AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CHF">100200000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisHoldingAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis International Pharmaceutical Investment AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="CHF">100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInternationalPharmaceuticalInvestmentAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Bioventures AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="CHF">100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisBioventuresAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisForschungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Forschungsstiftung</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisForschungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Stiftung f&#xfc;r Kaderausbildung</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerKaderausbildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis-Mitarbeiterbeteiligungsstiftung</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMitarbeiterbeteiligungsstiftungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Stiftung f&#xfc;r Mensch und Umwelt</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisStiftungFuerMenschUndUmweltBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Stiftung der Novartis AG f&#xfc;r Erziehung,
Ausbildung und Bildung</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Overseas Investments AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CHF">1000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisOverseasInvestmentsAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Japat AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="CHF">50000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4JapatAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CHF">350000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma Services AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CHF">20000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaServicesAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma Schweizerhalle AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Muttenz</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CHF">18900000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizerhalleAGMuttenzMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma Stein AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Stein</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="CHF">251000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSteinAGSteinMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharma Schweiz AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Risch</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CHF">5000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaSchweizAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Cellerys AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Schlieren</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="CHF">129630</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CellerysAGSchlierenMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">0.20</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Arctos Medical AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Bern</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="CHF">360020</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4ArctosMedicalAGBernMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Innovative Therapies AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Risch</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="CHF">100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInnovativeTherapiesAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Advanced Accelerator Applications International SA</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Geneva</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CHF">9300000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsInternationalSAGeneveMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Basel</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="CHF">5000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozAGBaselMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Pharmaceuticals AG</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Risch</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="CHF">100000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozPharmaceuticalsAGRischMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis (Taiwan) Co., Ltd.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Taipei</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="TWD">170000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTaiwanCo.Ltd.TaipeiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis (Thailand) Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Bangkok</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="THB">302000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisThailandLimitedBangkokMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Saglik, Gida ve Tarim &#xdc;r&#xfc;nleri Sanayi
ve Ticaret A.S.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Istanbul</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="TRY">448000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Farmanova Saglik Hizmetleri Ltd. Sti.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Istanbul</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="TRY">6700000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Ila&#xe7; Sanayi ve Ticaret A.S.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Istanbul</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="TRY">880000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozIlacSanayiVeTicaretA.S.IstanbulMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9999</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Grup Saglik &#xdc;r&#xfc;nleri
Ila&#xe7;lari Sanayi ve Ticaret A.S.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Gebze - Kocaeli</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="TRY">96000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Ukraine LLC</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Kyiv</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="UAH">8000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozUkraineLLCKievMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Middle East FZE</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Dubai</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="AED">7000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisMiddleEastFZEDubaiMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis UK Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="GBP">25500000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharmaceuticals UK Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="GBP">5400000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsUKLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Grimsby Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="GBP">250000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGrimsbyLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Advanced Accelerator Applications (UK &amp; Ireland)</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="GBP">100</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUKIrelandLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Neutec Pharma Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="1"
      unitRef="GBP">7.7</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NeutecPharmaLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Gyroscope Therapeutics Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">London</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="GBP">1492</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4GyroscopeTherapeuticsLimitedLondonMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Frimley / Camberley</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="GBP">2000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozLimitedFrimleyCamberleyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Corporation</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="USD">72200000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Finance Corporation</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">1000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisFinanceCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Capital Corporation</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">1</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisCapitalCorporationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Services, Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">1</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisServicesInc.EastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis US Foundation</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisUSFoundationEastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Pharmaceuticals Corporation</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">650</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisPharmaceuticalsCorporationEastHanoverNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Advanced Accelerator Applications USA, Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Millburn, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">1</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="4"
      unitRef="Pure">0.9923</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Gene Therapies, Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Bannockburn, IL</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">1</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisGeneTherapiesInc.BannockburnILMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Technology LLC</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisTechnologyLLCInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Institutes for BioMedical
Research, Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Cambridge, MA</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">1</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Cadent Therapeutics</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Cambridge, MA</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="1"
      unitRef="USD">0.1</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4CadentTherapeuticsCambridgeMAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Endocyte, Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">1</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EndocyteInc.EastHanoverNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Navigate BioPharma Services, Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Carlsbad, CA</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">1</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NavigateBioPharmaServicesInc.CarlsbadCAMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">The Medicines Company</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">East Hanover, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">1000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4TheMedicinesCompanyMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Sandoz Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Princeton, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">25000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4SandozInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Oriel Therapeutics, Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Durham, NC</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-5"
      unitRef="USD">50000000.0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4OrielTherapeuticsInc.DurhamNCMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Fougera Pharmaceuticals Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Melville, NY</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">1</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4FougeraPharmaceuticalsInc.MelvilleNYMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Eon Labs, Inc.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Princeton, NJ</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="USD">1</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4EonLabsInc.PrincetonNJMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis de Venezuela, S.A.</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Caracas</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="0"
      unitRef="VEF">0</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisDeVenezuelaS.A.CaracasMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NameOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Novartis Vietnam Company Limited</ifrs-full:NameOfSubsidiary>
    <ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember">Ho Chi Minh City</ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary>
    <nvs:SharePaidinCapital
      contextRef="AR_I-CurrentYearEnd_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="-9"
      unitRef="VND">70000000000</nvs:SharePaidinCapital>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="AR_D-CurrentYear_dei-2022LegalEntityAxis_nvs-2022Q4NovartisVietnamCompanyLimitedHoChiMinhCityMember_ifrsfull-2022SignificantInvestmentsInSubsidiariesAxis_ifrsfull-2022SubsidiariesMember"
      decimals="2"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <dei:AuditorName contextRef="AR_D-CurrentYear">KPMG AG</dei:AuditorName>
    <dei:AuditorLocation contextRef="AR_D-CurrentYear">Basel, Switzerland</dei:AuditorLocation>
    <dei:AuditorName contextRef="AR_D-CurrentYear-1">PricewaterhouseCoopers AG</dei:AuditorName>
    <dei:AuditorLocation contextRef="AR_D-CurrentYear-1">Basel, Switzerland</dei:AuditorLocation>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>253
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M8@#Z_9IS]7QC!NC_.['\'U!+ P04    " #(/4%67&1$6,\$  "9$P  &
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ME- -*9CZQ(^_T)I0H/7%G,GR%QUKK&.AN)"*9[4PK"!+\^J?O-2&: G@\(*
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MZPPLC8'^?B&$>KPQ[XP/_R,P^0]02P,$%     @ R#U!5JDC3(%9#0  474
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M/J?BL$%!R[<LUW7WO_5\P-H7UG)7-^7F,%AFL,F+_=?LTV$B3@8XWL  ]S#
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M&#3,A3T>^E3&'C-8V6*S34A8@Z9$T$MO0%%E8[EZ&VM<!X]+M!"Y_ARV'0S
M8%N(/K71"K/:6<0F^+ OA-S,P$-[(@'S!W13[I.K=Y_&-?.XV$]QG0#6ZV(
MAI8\5N>(E2VF-L&W0[2($@83)1T!&SHA4$:/JS=ZM'T]+N$@3+T0K:%&L$B?
MR6BE6 T5LTU(6(.F7&Q]Z97UXNJMEY$-/BYE&,Q=>$/(#!;I<QM=#$10U.1#
M9V9#TX,ULY2+K:^Q\D=<O3\RKM-'3S;62V-EBUS*F7#AJ2T&X3(@B-#!E+75
MBXNM7P/*6G'UU@IWPX]+M%3!VSX&F$B?]N@E $=$CX><3RIA32KE8NL_;Z+,
M%>],J]>89@^/:(;RP1,:"Q-0I,]JK+!$2! P)K."MT-8LTJYV/K**A_'T_LX
M_,T>'O8]''@I98")](F/%A]'1(\6G4\J84TJY6+K:Z_,)$]O)HUI]O"P\8(>
M!#L+B?0)C=:4DRT^GW["&C#E8NNK?_(0H=[U>OE.#X^P>AP;KJ\+,UBDW[S1
MM<3JI)EM0L(:-.5BZ]>3\MR\,ZUCZN1/GB+4W;WW95FMY''D^/PY61782(*G
MXPL#3*1/;W0]L/IN!ODGK!%3+K9^,2@CS],;>2_4]J//8NQU)BM;Q,IVR\H6
M>]@!=$)X=Y$ 72)4RI58O]"4[>CI;<>%>L5%,?2V [)RJ)XFN.JPMH&QLMVR
MLL6L; DK6ZI7JE\VRK+T_N)N,3W_Z)6'M5N,E>V6E2WVL'<:HK<W4 _(!G#=
M^2O\4$_YH=Y+]8MYA-4(O>0% ;I$;@EKQQ@K6VR0?T)@8(\I.5=#;U-1OJ;W
MS2UC'G;\?'CWR@ 3Z3,9K1%KRYA!_@EKQ)2+K?^N%N5J^NPM8S[9F>7!U6E!
MXWSXMI>(Q,&;$00(&I=T/->#^QB%<UUX@YA .2</V?:G6UF-/DO+F$/..]%,
M-9VY<)DD86$ 5TH"-H<O ;DE0)=P?X@)T-2>HR<_22X'O6V#@#GAT"N)E,WG
M?VW/F$]T4U&S2L&(625ZQO"L$GU>>%:)9RZI6:6XB%DEC+W!657VF?\M36,^
M-H#".9RQA1$JTB<R^FU/K$:7T18DK#%3(J8]H.;)>[LX&\9\HO=IYOM070J%
M;E[J$QNM+JMMQ<J6&,U'2J&" 7F5'>5S]I7YV/@('0>]J(U$P<<X](F-EI?5
M!:*V@-AY"1N(D(U #<FFS!W_&WK*?*K3*D O##&#1?I,1NO$ZLZ8;4+"&C3E
M8NM+KPP:G[6GS*?ZMNRY ^\M&>(B?7:CRX$R-."+)NC4T&$E84TMY6+KRZQL
M%)^SK4Q/-M9T8V6+?*JM#)W]$OX%NI0CB% -L+:5<;'U:T#9+_[+MI7YV,>8
M0:_& !/ITQZ]!A /Y$'EB:1@ PIK4BD76_\UJ\J "1C;R@+B-5P!/.<V 47Z
MK,8*2X2$2SN5%;+66+-*N=CZRBJO)WCIMK* >#@/BG\6$NG3'BW]^::R\SDE
MK#FE7&Q]X979%/#UE 6$,8-VZ/.82)_2:%%9N\H,\D]8(Z9<;/T"4+Y8\/_6
M5A80CRW.;-A(;H2*]!LWNI18O3:C+4A88Z9<;/UB4K9<H+?E7JB-2)_%V.L*
M5K:(E>V6E2T.L%>'UC;"SH,M1%Q)]8OLY&W_>G/P:UN( LH8@RZA/O;H8F!U
M$UG98E:VA)4M/2-5OW"4/1E\U;O-S)N(]/RCUQW6=C56MEM6MC@@#%'T<A0"
M!#$I5UK] E(F9Z W.0T:3P+BS5GH<1H34*3/9;2@K%UA)AN0L(9,N=CZTBOC
M,] ;GU_1>Q)0#J,?((^;QOFPRR,B<="QI$#0DHX'(MIHE\0X^#K=E.(:7*J5
MQQB<\1C->D]<<MZQ+1?,??ABIP4)\WSXF (!F\UM..O$)PG,73CK&!1Z 7K(
MA.+RY_,0SCN1U]!'\RB#+S0Q^*A)/0P,STPJ"<.32L#PI!(@/*D$B)I4BHN8
M5"HO.*F3DX]^;#]L].>L>LB+VEJ+>SG(_F$J):GVG]^Y_Z$IM]VG0=Z535-N
MNF\?12:OG%N _/M]639??F@_8/+X*:K7_P-02P,$%     @ R#U!5E<\:C=*
M"0  72X  !@   !X;"]W;W)K<VAE971S+W-H965T-BYX;6RMFFMOVS@6AO^*
MX!TL9H"F%B^Z=9, ;32SVP^=#5K,[H?%?E D.M96%CT2[;3_?DE)$67RD(Z+
M## SL?V2XGMX1#Z\7#_Q[FN_94P$WW9-V]^LMD+LWZW7?;EENZ)_R_>LE;]L
M>+<KA/S8/:[[?<>*:BBT:]8X#./UKJC;U>WU\-U]=WO-#Z*I6W;?!?UAMRNZ
M[Q]8PY]N5FCU_,7G^G$KU!?KV^M]\<B^,/''_KZ3G]9S+56]8VU?\S;HV.9F
M]1Z]RVFB"@R*?]7LJ5_\'2@K#YQ_51\^5C>K4+6(-:P4JHI"_N_([EC3J)ID
M._Z<*EW-SU0%EW\_U_[;8%Z:>2AZ=L>;?]>5V-ZLTE50L4UQ:,1G_O0/-AF*
M5'TE;_KAO\'3I U707GH!=]-A64+=G4[_K_X-@5B40#%C@)X*H#- M11@$P%
MR$L+T*D '2(S6AGBD!>BN+WN^%/0*;6L3?TQ!',H+>W7K>KW+Z*3O]:RG+B]
MXVW/F[HJ!*N"LNBWP4:F0M +^87L7M$'5\$?7_+@YY]^"7X*ZC;X5#>-[+#^
M>BWDXU4EZW)ZU(?Q4=CQ*(2#3[P5VS[XM:U8=5K!6K9[;CQ^;OP'[*TQ9^7;
M@* W 0XQ!AIT]_+B""B>O[QXZ'%#YJX@0WW$4=^7YY@'_U$_!;7\U/\7BO-8
M#X7K42/%NWY?E.QF)8>"GG5'MKK]ZU]0'/X-BM%K5I:_4F4G\:-S_*BO]MO?
MY2A9MR7?,2AF8]EX**L&P^-MG$71]?JXC(4MPC1$Z:DJMU5IF*!9=-+X:&Y\
MY&W\9W9D75\T =\$+6^OAE=QR("@:*N BRWK@J+ZGQP1AM<2LC@^(5JT"Z&(
MQH9'6W45X2PS/-JJ+$T='N/98^SUF-?'NF)MU<L)HV1RN*^"3<=W0='WO*S'
M$8CO]D5;LX5KT&IL6S5LVHH(&]V=VQJ:A;#'9/:8>#U^; 63J2UFBU#K$^NY
M.*)&^VT-(D;S;0E-X-:G<^O3E[5^7]1@RU,[>>+,S#!(%!O^<D"4A 1N?C8W
M/_,V_Y_#6[*IVZ*5^=2,?;"'7Y;,>GYBII#W89>.C/;SZ"(F)W91J"?O\"+#
M^^*[<W28JCJ).,&&95 4&JH<5&4.,PL206>23XW=@2B^R=??E8!3'2>/1EEB
M#N20#!-J&8%J2XDC#1'65O#9J6B&J7X<Y22J=X6HV\>1=6NA1KD')M&=#6RL
M?BF+?2UD/ZK!;]_Q8SW@=;DMVD<&=RJVAXD887,P@6111LU!'ZR-)*DC'!IL
MD'?>O[V?TC*0"P\UP<W6EI-;^QRS'3].Z"EQ<Y@+#UVGL*BIBX>Z&0('QH+8
MG9FF5F8 *H20%0I ABEQC*](,PKR0\K=T)>#,^5W<B9G0":6P=#)HIE\H '0
M. 4LA2$QG=LR3)'I&Z@+9XZ)'VFZ07Z\>>D+ =H#N(9B8LXZD"P*S4$]AV0D
MCAS3/M)L@_QP<W_HY'O:RW=Z3'!I3GQ_$^R;0O6O[%CVYZ'>J[P&/=HH(K,R
M2TV/D&SY@DX>(1E>#)*G'C7;(#_<W'>\9*R:^D_2*OLQLP#;Q(EI%8 D&II&
M;5'J&JTT R$_!)WT9-T*^<+6#]+J^)*"A@"8032Q7D!(%F4FUH$R@EP9JN$(
M^>D([KV7&;3I!9M4< >($FJEIBTBJ<,:UAR$_1QTTF4:A]R&,$ P")L "*HR
M<T2!5)BX/&D<PGX<@KOK1>9LJD'$3$9 1"T^ D0)=M 1UG2$_71TTEO3Y+^8
MYCW&;#ZYLOH,T,16E_E%I[XTYN SF /VV$4&7W5G!]L,8Z["  EVA$$C#O8C
MSOM2#OY]+6:^J^0Z>-JVF$:<89$Y\!VT]G^CV @,#P0G)NL"(AS&L0EX4%T.
MNL,:<[ ?<\Y9?SCTLH3L?H]'8'\F33+3)+2+8\ZA.:3*LLAE4[,.OH!U=D7W
ME8E"32 ]DRD^<-P;U9L[7HVK'!4)4<NU7<7V7(8'SGT 6@B-,Q/@(1V*J8F[
M.:C+0M>XK"$(_P@$O5H4;*(A&8E,.@)D&)NXF ,JFKG>;\U'V,]' ,NO?S[T
M\@VNVU_DORKCC67N$*J2M_+[@_II0G_',0*V 0C1V&1A0$5Q:(4 A*DP<K P
MUC2%_31E1&'R[[%?U?T4 :D\$X#7W'FZ>]7:<FP#G%I;P.$DFN"(G^ N3RKP
M8,1&,2!S !60.8!*87CJ>'^(!COB!SN]#:XVN0+!@WY;=&S+FXIUPY#Z.S\6
MG:C[X/W?09? KE42A>:"&)01,QHY)(NSU-6CFO*(G_).YD)I2G2LZ _=]]$M
MW'T0WX5Q9*XT()U\I\WI#Y+AE+HZ<'%.=PGGL6^L*^M^>*F%L:=UZEE^+-J^
M& Z\W0! ;"1#86A&P!9%Y@0(:);KL5/SFNZ(G^X^MJ4RQ<S-.;TPJ=@#/+<1
M&[F0E;3G-3F@21".'<XTO)%S1W#[>9]2INN6S=MS>]X-EQ2>S^8NL P0&(ZL
M[6I0AF)S.0;*0M>I"=$\1_P\IS<E+[%F\Q6V8 T079'(9/8<J@N[%F1$HQHY
M@VJ+_FR&I#VSA4QL8+H"3 $J8F<IJ'(-/IJ^R)DC.KE(*H==]'+N-?[4RIEC
M6^^'KY<W.J1[MUGO@RZ^1@" EC4B 1I70#2(D0L._98;YIXAUF88ZRH H,FL
M"09B(=<9+-4L1"]BH6>TU!9_F*PIM%451N9 <P?IY'!D'>*"]:'(,<E0C4C4
MCT@71^ "N/8_^M*T?]7:<@JPF.MH@FH2HQ>=1OJB"08,PB@H:2!Z@Y(&JF_)
MWZ<V-991/Y8--O5,I@PK$AO^4.<11[E45Y/!=.;*-ALV#J3LVU1,9@WSG;92
MX%"0II&YO@!D)$3FY1.H,I105V\O;D'Y >U7OZ^ >V(#F@8VRJQ[ Y (Q^:4
M"*APZN VJKF-ON!L\7R_@]X H*)I9M(V(,.)=7H.589HY+CD036=T3-TYLSD
M0LAD?JS;=ACY-X$<]VH.7IN@P(4I3$-S6PF09;&9WSE4F?S',9-3C6O4CVM>
MHTPMJKP6Q\J7U_*2"%D.;140B!R0G01B=+A>W+O=L>YQN+_<R^GXT(KQ%NO\
M[7Q'^OUP,]CX_@-ZEX\WG74UX\7K3T4G.[B7^+J1589O$QGU;KS+/'X0?#_<
M[GW@0O#=\.>6%17KE$#^ON%</']0#YAOE-_^'U!+ P04    " #(/4%6W@%C
M7Q<G  !DAP  &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;,T]VX[;1I;O
M_15$#W9@ ^RVW4DF \<QX$N<,9!,O':<>5CL T66),84J;#(;BM?O^=:=8JD
MU&TG.[O 3-R2R.*I4^=^XY.;KO_@M\X-V<==T_IOS[?#L'_\X($OMVY7^,MN
M[UKX9=WUNV* C_WF@=_WKJCHIEWSX.KAP[\]V!5U>_[T"7WWIG_ZI!N'IF[=
MFS[SXVY7](?GKNENOCU_=*Y?O*TWVP&_>/#TR;[8N'=N>+]_T\.G!V&5JMZY
MUM==F_5N_>WYLT>/GW^)U],%O]3NQIN_,]S)JNL^X(?7U;?G#Q$@U[ARP!4*
M^.?:O7!-@PL!&+_)FN?AD7BC_5M7?T5[A[VL"N]>=,V_ZFK8?GO^]_.L<NMB
M;(:WW<T_G.SG*URO[!I/_\UN^-HOOSC/RM$/W4YN!@AV=<O_%A\%#^:&OS\\
M<L.5W'!%</.#",J7Q5 \?=)W-UF/5\-J^ =ME>X&X.H6#^7=T,.O-=PW/'U7
M;]IZ79=%.P"&RFYLA[K=9/NNJ<O:^2</!G@(7OJ@E 6?\X)71Q9\=)7]V+7#
MUF??M96KT@4> '0!Q"L%\?G5R15?NO(R^^)1GET]O+HZL=X78<M?T'I?W&'+
MS^*6W\B6L_\J5G[H@5S^>VGWO/:7RVLC"SWV^Z)TWYX#CWC77[OSIW_]RZ._
M/?SF!.1?!LB_/+7ZYQS6Z04?76:WK)G]O'79/[OKHA]JGWW?=^,^NQ<^=SU_
M=3^##T6V U:HVP+9K6BR#5W<K;.RV^V+%A?S>U?615/_CH^HVVR Q1%-15]N
M<V"F:Q 2>V#Y(0<:;\<U',+8X[5%6\$W_0='P,&:1;;JNZ+*^J+=./RB;EN
M"ED\VV\+X-?2C0-LJ_%T<]GYX<(7UWC[QK6NK\MLYRK88^O\)>V2-P<;V8)P
M^VV$';K>50CF<V#[)L_>W=3#[ZYO8#V^H^Q:#WBJB@&N6\/.6]Q=Y@?X G?A
M$; A+%WT %OO]H4LB^CN*[C) =,/V^QU"T\,Z'L5UGOK]EU/&W\WP+.+OO+9
MO=>OWKZ[GQ4> /8CK+<ZT)/2-0QYQUN?=_ /+/#LW?/[M(_#K9#ARML:A%&/
M&"5DXN:O88_PH#QS'TNW'S+0$5D-6_=P0S'0JKW[;:QQU:'+5DXI#-$%U\(U
MZZ+NL^NB&9TYA+_^Y>]7C[[^QAN<'H!&+AP<))P/" 2W6[F>A,+-MBZW1'Z-
M[PC0HFU'!++I/&X<3T?/H6ZK^KJN\&<$?0":E&<M'U_= AX ^73 =3MT\30#
MC+<2 6^,T4L'@] L/DZ0Y9'X02/BEXBW7?$!:,WU ^C8S/FA!F7DF*P+./S=
M'A?U< IP5(ZPBE"NBH8.D'4[8Z'/*N8GO !1JO@KUFM0D\*/2&VPEV*'1T4T
MW -GMJ/#9WP$<\#C7_!H-\"_35VLZH9P*9Q&!(>PRPJ7V7<1Z-Z1%JTRP(,A
M*5RWKQT"C(MTO).XNTA1B.^Z(M8$*\0#G:\:EXV@;'J"?P,BH,W*NB_''> 6
M5A14$35NQJ;HFT.VZ]H:GNV DY^!D $(P&(!0247PR& +,/#'9LJJVI 3Y^M
M^VX'C^B\.WX*E\"MU[5GD#M['3V^[$#:_LY,AL#BICOZQ.> W^D]2-0]+H9
M_@"H0BY'*XK66I+5<%(^B'/ ) !@1'6.CRD!]QX>!OC+4(0 77; $0A@(Y+C
M&D\7 >GV;#A5\ =+&%WM\NQ="78A"W<E?[SV;E(1V*H9*]A#$_DPEV]Q0Z!^
M1Y3\<'_\N;N&(V LA4T]^SY?$,Z@28"+R@&.&052&SYM"V+7H0<SZQYI 8#@
M@$*TD!/''74W+0*Q ^I JFNSKQ[^APH0 N<0>/^Z&UB3H:KP XC3%W;S"CP?
M&,HG,#E=+^(0'HL+73W\QH\K(.FZ  ;PE_3=HV] DB>'%?9<=?!=VX'H'!%X
M@!:@#RL< (\#;90,7WX2R5>@U ,\'PUUTJ'C@-Q!^&Z[]D+PTMC]J"@!>J2S
M+DJ43WB%8E'0$A^/M]1PQ$!6I+2 /0>408@!N3B*?/VF!0$%- C86M>N$LER
M"1@ 4AR49/#K#B@)]Q0M"G.,8(N#,J]()Z9WAG,(?!:PN>T:4(DK-]PXD!I7
M<-+(T'+B<KP$/1D[A@8!RR2D;H _"=_>&%)UNX;M 0O>I^5^[0"C&6K+L5=J
M2!3AZ%4HHP880#PYD#-5HEB]'JBL ^>/ZM#L%*^*8H1MC@DE%/M]PX8"/X%4
M43R/80LW;?C^A(U1$0(-!!Z^/ .?"#P>H-$1Z+D-IN*=3** ?;$[O&OY(=G[
M=T#?#8AH.-GW[UZR?8([+<6BD<<=V 8T= >K15) ^)NNG%Q/*@2>MG?D"@HS
M'W_$Z.5XHEH4ZU.5,0@=SRI@+>C@+3M#<AXV]1+V!O*[J(3B >$&C@32FLU1
MDOUK/#@O3$/J61@2!,,V6X,JX(>#M]+ZHF1%R4_P+I4^^QYT2E\3F[3=#JUT
MU4+P*-WR9?8**<V((Y(T(.K1<F&;?7M I04$SD8FH!ZT&BZI:B,>2I"3HDYS
M0Q%[L,Y8O:#-$/=#>ZPZ>NZV .P@]@HO6%LZ)MP>8:")9AK>%)EJ#235W> G
MX*<M>0QHTOG'+(#_AL(6Z3N8-U.@D A< 8RU0]?6K P ]F"II>OFT6@.],P,
M-EMIY<B[V6S ,B'H)_99 /!Y8LTQ ,$F3G<5[GE+6)]M6\P9QY;1S"QATPLE
M;.^V&'VY=LK^,^+X-,*H06B7@PI]5# B%((> #T$>'$#*1+2 G02UL0,J!5N
M1\HNR;)W'X/IZS;@#@JO6C/+TU[[BG?:.V1BU--%CU>SKB !S$(!]PJ?$<(-
M7$DJ +P*5,I]P*U8A;,-+6Y&L*T0B/[_B5 >>4/07=#1$D&J42!FXRVR^9^H
MSXD]!GWRUC4LRWS1D",0OJC LNSKU4C,"*P#!H4#\;NPQEQOH>5T9/T"<<0<
M"8O"0]@O0%=5J :%%=@VK;!V6?3]@;B!O 8\+/89$6'79._#40."]B+B6545
M_$0C K/CFR)C/8!XY*+:6Q]C6V^V\#BP9U;H:!B'F1!>*<V!G( S1-TPV0=I
MAZAB&^<].="T/5#J#4-%QIG2%')*W1,E"<TR?X*SPNB^ VK%,7&L<@N\#F1N
MB,ND!X;[08E;.>!Z,;+P$'>H\^C![,/6\"7)I80"4U>S9J4A[ "WOEZ3^6;9
MB1F2Q4+9UV!NU@5!4S8 ,YE1K!RFE,6  K9!FO5HQ.3">T0CY H*WG'3RR)$
MN%">A#L=[>7I X/7;Q1VNE\,JHD>_GP<D>TT[L:&0UAQ#^%$5%?*F? 7O(@(
M%% *Z/3!2B;F42_A=&FGN:%#CMF<%=6OHQJ7 0M31'N+Z44G]Q9I]0R]"C$&
MTD-;H9YS)&^%[CT'41QZ;:5$EA*A6@S$7"$NQ)XFVU#[L0<UZ)VH#-UN< ^+
M@<4!;8Y9%)&S0HT<%#["$8D"ME;507X0\SEV0 :'X>_+[+N/>[:^XX+=JJDW
MPJ7,P#MP&AHGD8==AS','E<;P)W;-X5($3P6BHYJB&)@%Q6P"1S$LK06VE(.
M(1L6,228T$-!L@" ,/HA:#3(G@MZ\/W)=0AH,&>FOLK8DFR+D0.*% ))@JO(
ME#>@3XEF/RQ5*]6?NK9H@OD%?GA(Y2 16XE_L3I<6 6P*CQK#]E$,.*+Z6:)
M&5HYU27B(J2BX )?>:@Y7- TQUU9$*X^\%=8A56*[$Y"K,BN&Q0PXO@R2Q$@
M &T(GOMZ5Z/].+], HOSHXAQQ. P3 &:B42,8%%\*6&EF:L2-^SQ%(*LB0YG
MMQK(5)(( <.(;JSWQ[$V= -:<LJ?JGZ%$O!D)6Q"#OCR&G%O48#HMNQ6$X6*
MY[_INNJF;@147%,UJ(U5@F%+64"2H-<%G D=Q#!C!\2'L)5\H\J:)0"N*E:=
MQ"K(S!)N(-8H0YAXF=?B =\:%18;:E=4Z-U(_@6(F,B1K-X).OT,GR#+P'>H
M(]WE%'5H,72+IOWMHHKLHP5J.X*]/-P$TFL]-G#O=81K!@Y=?1((&X!. QZ"
M2'T8!7V4 $ $E=NV!H.%.<TGQ+%PIXG:VQ,@4/3Y-LPY"+FYD"3K#7>K]N2T
M5V[-25A+G)OU2*&@Z*KF:1R;28XB^)QEHV]-HHW3XA)B92,73XGB)<S*^"2.
MF\.!DQKH.X Z)PUS 9;;CLP'DM(. $'Z,+$(W)<;,-;N<[95<1=]H%5<H)9T
MX0VX=O2+N%\B[L5+HFC"U3>OHVT,RROSTEHSTDC<IAJ=&I!5CTS,NV+M33Y7
MY&_XWP=W6$X_B#_@T3,>V#>V47M-[QA^8F=]D:S.WISDG=._8BS8FNND4T!8
M8AW"!1JEH@?O8H5%P:J46D7F6R_ESPC!E]FKWCF,H69-P<FYB1?!)ZD2,#%F
M-=92^ZEQ$LEV,*$Y;^,N_/1;$837>0WC&:\*U;J3+?<$0M'2[D3T!L69FNU3
MWVY7'&C#J]0P9C@#4R*]_>J4)131!KT2@@Q1*K9 _9;C8<?.!&RR7?$K^DSP
MTX:$,6WSI"A\?/8^+G'V?*P;%$7^[.HA:HHO'Y+GXL]^+,HM4!#R>\C&A34F
MO\;OO\8UKG2-5R/H%Q)/>-6U X,<Q,395WC1([WH!8B'$61 MBWZZ@88[.P+
M_/UK^?E[1%=+1[8!,P")8B5!&_(6 :.4*PH%/K-<$CLT3'X!TIQ8&0AN)-,\
MA'#$>C/ZB%+=:$GV/?EE)ZDBL4?TH6*KG?W@*)M#ICNQ:+>^0,4ATOZ9I]"
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MS$T5/)7#^*GI?&15L<ZYU\XG]B YQ)SP!L&PHRX]CANWG>F)66%?*NV8SQ%
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M/6.&FMA)$BM8Q(#TAB:2!BX,9%8LV(CP>,,Q+&:,O,GY:UO3K<?.L:VX5VI
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MJRO6-<@R$V(9]!P*/V>R*( ^$!6B3[4D?@Q(KA7Z12MT-# 9"C1A)@V\PD$
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M_(T_-7IMQ;L0LBN85]M,%D4%MDZ";0?^FDA'"/NI <<O*C?'PY-:\!WE9KW
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MI&6<LG0 ]Z<&,!U_$(/F:[6+_P%02P,$%     @ R#U!5GXA^AH&'P  I%D
M !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6S-7&MSVT:R_8Y?,>6M;$FU
MHD6\ 3M)E2P_XHT?*DG)W;JW[@>0'(E8@P #@)*97W_/Z1F H$3)DA-O;B4F
M(!*8Z>GI[G.Z9X#OKZOZ4S/7NE6?%T79_/!DWK;+9X>'S72N%UGSM%KJ$K]<
M5/4B:_%G?7G8+&N=S>2F17'HC<?1X2++RR<_?B_?G=0_?E^MVB(O]4FMFM5B
MD=7K%[JHKG]XXC[IOCC-+^<MOSC\\?ME=JG/=/O+\J3&7X=]*[-\H<LFKTI5
MZXL?GARYSUX$O%XN^#77U\W@7'$DDZKZQ#_>SGYX,J9 NM#3EBUD.%SI8UT4
M; AB_&;;?-)WR1N'YUWKKV7L&,LD:_1Q5?Q7/FOG/SQ)GJB9OLA617M:7?^D
M[7A"MC>MBD8^U;6Y-@B>J.FJ::N%O1D2+/+2'+//5@^#&Y+Q'3=X]@9/Y#8=
MB90OLS;[\?NZNE8UKT9K/)&ARMT0+B\Y*6=MC5]SW-?^>*8OH>(V$Q55%^J3
M7JN+_')5Z^;[PQ8=\++#J6WLA6G,NZ,QUU/OJ[*=-^I5.=.S[08.(5DOGM>)
M]\*[M\67>OI4^>Z!\L:>=T][?C]<7]KS[VHO;Z9%U6!X'"Q,N\;(RTO5&#4T
MZG^R2=/6L)7_W35\TWBPNW'ZS[-FF4WU#T_@((VNK_23'__^-S<:/[]']* 7
M/;BO]<?.U+V-[1;5?ZKNZ42F0";"55DYX\E8G<^UFJP:M-XTN 1W?*BNLKK-
M&Y5!Q[/\*H<A=(JNRJPHUHK.2&<M9K!U3:?"Y7G95JJ]KA2^*MO\(L=MM5Y6
M]=;\/%-ORQ(]T)75>SW+I^Q:Y#G#1_7[4UR@LMDL9V\'ZEKCUF6&SC4Z-NVI
MXZK&$5^9F(!+=?-4G=[J3(8@ZBE;2)-3[$56EKI6TPIAJ6GQ _RUG:L6>L (
M=(T1#L3FD/#+=)[KH;7-]#1G5!LMLD^ZAI3S?#I74 (O?O593U<RON-JL<C;
M5NNA7I^*SF]K1H2%=(BDL^&8)WJ:K1K-IM=*9^B' \KJZ?P <EPA*B\/>-_J
M LK /.-;#*S.)ROJIV1;12'?Y>6TA3JJV6K:4M2L15._K7*9YXL+75,<1/9/
MV@C64H)+T>WYE\?%X4.R)14[*;0"WBA82S4U*L-/U:J>VKG.:&V-:!@M0Z^"
M3N546FQWZN=>O64-^D-GUW<96*<SW?1::[;4U@SUUO2*:]0R:XWY+.<99)QJ
MZ&":%9#G%70FF,3N(??1LLX+%1Q81^,P=LKR$B8KF B- 8VS,O_=6">]9PK=
MZGJ:PPSM;];OU*K,[_2?M\9T[944?N=EOYP=R(\YU05PHF>7QL*K6DRLSI8R
M0&HU0V_3K)[E:*B9KHJL?J[RQ6)55D5UN7ZN2KVJJV:::\S;<]5413Y3[6I1
MU49]9!^MO10*NJ894E'LA6:XJ*C528UK&[67&SENB6#"_!S66BRD,6F;AI;#
M/*MZO2]?Z*;-)D4.'.V:?*I.ZAPV:%T8;E^M("AMAH-^]&1=9]NS9:/=95%-
MH/(NAG:SU'O%QW*Z$;O_]N2F+9G@=X=IRKW&,3%Q>6F&.:L:Q KZV4(M-I%T
MHVF)9_P%9&WC]X@"Q6I&#S*$ZH9=X_?+&O<8E[-B;1FJ&3$BD]'!O$8<N(#*
M$23AU,\0A]L,JGVC$6?S*89R!#@8O2VMLYC1O,BK6_Z$P'_KWC^F%[&>9@%I
M%8P'X:NX.=Q&XE23X0<93%[#T3E';'T*\\8!!E5EL+FLO.SBT[:-'@R4NG-Z
M<%-&)>0;)<!=9K>Z%!W<4%>O@ULC;U;+96$$_<)$&J?OS:'5HDBPBK7(-<FK
M5K1-7?0H2-"9K&].B31U2V<C#F!M^:ZNS4!NS_%CYA,&V^J\','R;,R@F'HZ
M-^%G1"H_Z\UZ. 6XKLD7.>)58\(=+B*-:;9;&'1M\*2^RHE/&)/I#Z%X"9LW
MTX(_#)SJS\BG&H&4(NM(PH:1&#&T#:I-VW2(]J:N5DL$Q6SVVPK*TC9*MO.J
M$:N:]DU,JPI!UT1S=8&@Q1,Z+B3^=T6Y5B6 RIK+ABO=$J(+MGFKC2ODMX9A
M:  AM*QP; T 9A,SM\T21.<"9MZ![0&,#@P$P66J:]@%\[HK7:[0U04BNAA/
MP81M!0."VH'L,(N:F17N[>[95J$6/UA"5R.]6!;56D+T!/9VD?,N75[E=54*
MK24W,R9,W11Y-LD+H7]H'*:6&\DWK!"@7AE%6I<A/0% S?,EM/=+LV(@.\#8
M>ZIB:/- E:([!,!%-M,=F&PXR1'C TP7.>1P LAOK-L-A(1&, /Y4J*G9:#L
MK43N/M.35NU-LV8N=\D)R=D5W$P4;_Q"QM<@DM6FQ8*8@YB#\$O*P%::?3H#
M(D=K^!%I;]-4TUQ4W1NU<0TT5%/=/$<NK/$7IB/[;)VQ!,>U@QWUQG#WA(BS
M[9[(H1Z>JH^K6G*+QLP,S(_!#,R.\+W>X.3;$K2U%4;&F(.((LB,;D][$OS&
M(/#+>G6I7IJXPHX/K'MI];%+7@PZ/U5__UOB>=%S(92/Z$KM?7C[XG2?,V>@
MM".5 X.3>[],)H0#%PWI7E%D$S&:QF0B71HT%/*.(6XQ1%5=(:9H3ASY/B^=
M#2Z](2*X^ -$O"T=[[,QO+_24LAA;XPU;3.,Q(JS"XZ>5]M#NS$Y!S30B4C2
M#F?GG&%;9F-PP]Z'\X^&_AU;X%%_SQ;+Y^9J$^3/JF)EKSX^/]L_L'E"EWH,
M<KXM979T<7:+*S[=);9-W!K1SS:N5)LK+:&X4_>;++A7KG73F2YR3N^&9UI_
MV<"6;;R'FDVH!NN0^A?'M8&_ PP9XR9QMHDB9*:#K@=M&O!$D!#>;(:>306
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M(54G3\;LZ7THG9TD(KN?BBD<<RD#+K>]-1!!S53/TF1CYKZL<0628[('T+!
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MJQMV]8Z=&2'8[\I"2$8BN,_TQ3AX76M-2+2)Q!=8Y:T.D(.).Y1*(P+2S\!
M<BTS#G@ ;%4%3-/*L]7J5KJZ!LU[)$A/6((;[!>HE^;EK_LJ&,VB>3!:3A=X
M)''GI5'$TFGJ7O.07M%LT:ER0OH17 V?X97"XWA%X0&?*(4("=[P:<MEOIP'
M,6(C3<+@36L;(NLY!+/I-$@0)_$R"3Z<8 KIHIGC%BUIM0CGP57%B[V1WFH
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MF.-VSY5=@.\KB8BT$VN@__^"Q=]02P,$%     @ R#U!5D]N3?\?!0  ?0T
M !D   !X;"]W;W)K<VAE971S+W-H965T,34N>&ULS5==;]LV%'WGKR \8-B
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M;W$P7U*86,6HN4NIW%,)[^0/XOW7!>"RZ_2-I.,\?ZVJNB3B,P'D(BIP80Y
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M^Z_@_@7!N2_/U]I:W;K'A9((E@:@?Z91JX876F#[7Q'G_P%02P,$%     @
MR#U!5F*GW (Q!P  610  !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
MS5A;;^.X&7WGKR"\P&(&B&-1=V63 )E)I]UBISN8R;0/11]HF8ZY*XE>DK:3
M_OH]'V4[SL0VXFT+%$ADB9?SW<]'Z7)E[*]NII3G#VW3N:O!S/OYQ6CDZIEJ
MI3LW<]5A9FIL*ST>[?W(S:V2D["I;49Q%.6C5NIN<'T9QC[9ZTNS\(WNU"?+
MW:)MI7U\IQJSNAJ(P6;@L[Z?>1H875_.Y;WZHOS7^2>+I]$69:);U3EM.F[5
M]&IP(R[>I;0^+/B[5BNW<\_)DK$QO]+#CY.K040*J4;5GA D?I;JO6H: H(:
MOZTQ!UN1M''W?H/^(=@.6\;2J?>F^8>>^-G5H!SPB9K*1>,_F]5?U-J>C/!J
MT[APY:M^;0Z)]<)YTZXWX[G57?\K']9^V-E01@<VQ.L-<="[%Q2TO)5>7E]:
ML^*65@.-;H*I83>4TQT%Y8NWF-78YZ]OU519JR;<RP<NG5/><=E->*/E6#?:
M:^4N1QZ":/FH7H.^ZT'C Z BYA]-YV>._ZF;J,ES@!$TW*H9;]1\%Q]%O%7U
M.4_$&8^C.#Z"EVS-3@)><@A/N[HQ;F$5-U.^=<(=G'#SY(2?GIS _RG'SELD
MT;_V^:.7ENZ71H5UX>:R5E<#5(Y3=JD&U]]_)_+HAR.VI%M;TF/H1T-X.(+'
M,45\SE^1&NQ37YYA@OW9&N>H)%YN\_ROLEN@ZODZADS$&1,\B0I<HSAG,8^+
MA"5%BKLB+EC!RR3>![DC?A_N,"D%&Z:\B%(VS"K<B[3$A2=)QH8%%UG%_@:R
M>X8YEHWL:K47+\YR@/*D*E@*B)B3YJ0G(*N8Y=#ZYH]M>P_QVJO)Z$T]D_9>
M3=YR;[CN:M,JEE<LCZ$XE$X3!E^Q/,O8^WXAK5._+;1_Q+@X &3\3%D.,.3<
MC.*T5!OP(104<%">!/0?6R2GITJ0-5"=]B&F>!XO'#(#070P)HI81HH,XS1E
M/P?TUBP5*-H[!L,B^)<-87;%!/[$43^CHE4[!D2R=9DH,W)9A @E (AY5.0L
M#7F2%B%/LN1XDKT$%5F)C042K$@(,A9I@$22E14K 2E>D61[E$W2)*09Z9S&
M,%TD?9H)3.:\JLK_B?DW4X]-9CJ%R5YW]QQAX%/3H+G2DVS-H@N1W.NAY]6+
M5N-GN@L03K8J+/UE8;6;Z- SS\+45NN [9!:%RP-=NYEB'VV)9R\?WN:AV.>
ME_F)3GQ%CCRO5)0/\@!A0QX(+I("?L^BF&41W>7(GI(G2/=3B8@X*$%69#Q&
M)2-;*$,0V2%5B0B0(*,LBT\@HU!Y@G*D$B4K*M*0TC"M*#L29'8!9GE!1J_;
M=I2,AB#D+$=QA[@(Y*D@SV$TB:H]I#0DKL7_Z<24Q DCXA3%*UF)ZAM*I?D+
M1A)QF '2,*$N ,TC8K&34DJ\BLE/(B7Q7^M]>Y3]#[O?'S/__X:4HK)Z+2D)
M(B54P2FD%(HH*D[-('+103$SB>SOC.=CI>@UIS;WG?XW%N*%*UA*_IB99A+\
M2B;!7WT%X0D ?@:A*[-H)H#@<_F(4Q].M;T'K6JU]T$UN%])VP$FU!#@\<;2
MX6UL[/1$2PMESE"&SDREA=_"=J3@8@X5^Z=>Z4<JX1K'>XN7%=D]\NG"TSG:
MJJ6R3C9!05J^Z'KIL&4K6(:%'B^+&%U'>9\FP7H,=TOE/)7S.;_#4F\\!.P#
MWH)^NW$C)9CR_7=E+(H?W'Z9SSV)J5_PZDC6?AL"B-B-@)[RK4)8_>0XLA9J
M:+P\8@K@<CZWYB$\-X_\ZY=;GL0<7FWH!16*4@\[XV\H:R["=%QMIM_V'K@/
MI+"4S2)$% H,&QJII;6/0YBUDG:R-B6D%G0]F&)R+V>=!7O)#&VY>IAK=)()
M-*;T<+2GKVQWP=Z0BFVOGWO+OG9/V.SSTRU9U8>._=PI_HB@H>NRB"YW*Q,&
M'"@%I]PT9G<SJ]1Z#$P#KHG8![.PZR$Z9D7A^H'Z1C]8X+!<HK>A17U$9,G\
MCD^?YA->EA&U/5QS=&14,-RQ$^'>3! <VB)Z<HFCV%U0..4Y.G;",VA1<H$V
M?M3H79O%"YLS.B57.S:C*8']HV<VPP^0F!:[1J-'X#B-F1V;11JVBCP_9'.6
M8!LO"YQF>!J5AVQ&%/*2Z%S@W+.Q6H#:<?Y!B\IY457?6AT.6X'<<('^1&J&
M&G)(1-W7(:5BGXE!%+R24\AA]#Z.MJJ1ZPKZ)IG[/ ^TMA82* 9;ZW"^""NP
M72TEZKTO/53^FL8#XVQ3?EV?ZL$';O"4TB SD( B?5">XR HJ+UFMHUP3$Y)
MV@IN((:02ZF;,*,W;.OF*GQF>M&UH,@]",J!8&:ZGB$.N.Q8L[&D1A !O?"@
M6NA[ON_[P&CG<T^K<*RBCUID!CIA_^5G.[K];G;3?RYZ6MY_=/N(4QFTXHV:
M8FMT7F0#;OL/6?V#-_/P\6ALO#=MN)TI"6?1 LQ/C?&;!Q*P_9IX_3M02P,$
M%     @ R#U!5EG O=HT P  < <  !D   !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&ULI57?;]LV$'[G7W%0@6$#FDB49-G); --W& #5C1HUNUAV ,MG6RB
M%*F2E-W\]SM*BN-AME%@+_QY]]WW'<GC?&_L%[=%]/"M4=HMHJWW[6T<NW*+
MC7#7ID5-.[6QC? TM9O8M19%U3LU*DZ3I(@;(76TG/=KCW8Y-YU74N.C!=<U
MC;#/=ZC,?A'QZ&7AD]QL?5B(E_-6;/ )_>?VT=(L/J!4LD'MI-%@L5Y$[_CM
M71[L>X,_).[=T1B"DK4Q7\+DUVH1)8$0*BQ]0!#4[? >E0I 1./KB!D=0@;'
MX_$+^D.OG;2LA<-[H_Z4E=\NHED$%=:B4_Z3V?^"HYY)P"N-<GT+^\&VR",H
M.^=-,SH3@T;JH1??QCP<.<R2,P[IZ)#VO(= /<N5\&(YMV8/-E@36ACT4GMO
M(B=U.)0G;VE7DI]?/D@M="F% J$K,'Z+%K315V5G+6H/PCGT;AY[BA4\XG+$
MO1MPTS.X/(4/1ONM@_>ZPNK? #&1/#!-7YC>I1<15UA>0\;?0IJDZ06\[* \
MZ_&R<WC2E<JXSB*8&NKOR@/\)=;.6[I*?Y]*R1 P/QTP/*];UXH2%Q&]'X=V
MA]'RAS>\2'Z^("<_R,DOH?^/@[R(>YHUSZ[A^P*R([-AX<?/3RNZR4K1HW0_
ML7":H>'L_==.^F=P2 C22W2, \\GU!9%QE:X]L=[V91E.7OH*+;4.W2>*@6A
MIS/.LJ)@OQM/(5]/]=B&0TZ *234_F;TYLJC;:C"E"AW8JW006U-,SHCU2M:
MHX?OV.2&31/VL9>J3CDR?C-E?):S>[K[4F]"'DJ2*2NTP@]U[#4*9T4R947.
MCU@H([1["Z+:A=BNS^VH^IFJ36N<) 6S"9O._J-Q3' *.:<D0)(5C(]L3QS,
MV7-888UD61'SAFJ_&XBWBHBQG-^P29JP1XNMD!40'W^%3:O,<\@MK%%C+?U@
M30+S&Q[2S2?G>=#WP=+I9%1S]A[17>!D""FU'$X]F/BH"C9H-WVM=Z2BTWXH
MB(?5PW?R;JBBK^;#7_1!V(TD 0IK<DVNIY,([%#?AXDW;5]3U\93A>Z'6_H2
MT08#VJ^-\2^3$.#PR2[_ 5!+ P04    " #(/4%638ZM2X\#   )"   &0
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MT702,CLTGF'B3.N+_<HX;!W^M\9>+2P9X/[:&+>;T '[[K_\'U!+ P04
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M+/FS!8W;P.^76M/3Q#GH/H1F7P!02P,$%     @ R#U!5LZHJ<Z! @  L 4
M !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULE53;;MLP#'WW5P@>,&S
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M)34MP/.Y@I76%R1@\['W]']02P,$%     @ R#U!5K>]!F)7&@  \DH  !D
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M2F9MJZW7#/&:6LO3O'ZG* _22Y53F(P364061OK&(V$'IF%?[BSC( SU9FR
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M% 9-+J5*41 '[DC0QBED7=$T8M3#Y%:NKOCP(H:XK=]^ 8PS1OO4L=BF6&L
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M8$0XH0?P^<Q0641^H07"UUR]^!]02P,$%     @ R#U!5EK6.,L6!   _@D
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M)0*\7RK H>X#;3#\6N7Z_U!+ P04    " #(/4%6R07;P*0$  !9"@  &0
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MS;3/ORR3^ #\-0-!('Y7PONS(]C 6$=?J&?-8Y-FIWCQ4M6%)PMJ-/?=0S,
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M<4T7("NYPM9P/)N<(1SQET3-FU;M^(N92]6V:LO_(N\N9$,+\'RED W8-W1
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MJXMFC\#*5>\CMQ:$P.",+ <>[R@='?F<:2#=">!_=!7J$@@HN19'M#!"U1$
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M"7J.>O6:IE']?ZC_GQBQW_7#>CUMDJMM7Y<LF1O\ ;(,\"-"_;*E<8LV;W!
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M>DU/:[+@QI_Y1YVG)8JA49E.T*8GKJU\8,UQ^?C]Y^]__/ "[E,O2+*N!6S
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MX3YP"X5T#99]W JLO#:!Q4$[ 6:RNUL4+X&*DU)(NRX(C_ GVUYZ)'L1^^0
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MN! Z3N>\EGB?:E)91"QEHOTY<2RXNQ#B%=B(CL080Y\L@"HU=W;R=9KLM%*
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M;I[KW"B]YL$)^U<BIL)S.BV8MG"@3$(;H:T2M,XP$2K8#MIEI<@$G;D,1"&
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M !6?,(&D^U%* -GF#012?J"(J-!:Q :Z66S>'7H!'FZ*3;RAF/3FQOJFEWK
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M=,1]_CL:D_#3%0D'VN8B:_[^Y$,<XN1E7U;(&OW)Q1.47']X0B:=/_DUW^P
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M0.ZSEY7$RR@H4D^$QK")\:*3+#9M.U]NH/::&,0AY"P/^D-S]>$(6_Z[<Y]
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M/Q^OXGZ=@\5QR(TB)0%)5VKAPMC-86YF#QW7<0@]C,E L^7OL'VR;&2$.@S
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M0(P4IE?"0"390)FW'"*J,@P=<W)32O!C4J-?YUW^_(>]:Z_<*U=5GH,;/S[
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M;)J>7##YMA_+_89,&T;ARA /UK"L^25#ZQ587AI#^XUW,+R-L^]02P,$%
M  @ R#U!5GRQW\7D&   ]4H  !D   !X;"]W;W)K<VAE971S+W-H965T-# N
M>&ULS5QK<]M&LOV.7S'EK6Q)M6*(P1N.XRI9?B96K!)MWZV[=3] )"AB#0(,
M ,IF?OV>TS-\210M*?;F5F( Q&/0T]/=YW3/0$\^U\VG=I+GG?HR+:OVYT>3
MKIL][O?;X22?9NV/]2RO<&5<-].LP\_FLM_.FCP;R4/3LN^Y;M2?9D7UZ.D3
M.7?6/'U2S[NRJ/*S1K7SZ31K%L_RLO[\\R/]:'GBO+B<=#S1?_IDEEWF@[S[
M,#MK\*N_:F543/.J+>I*-?GXYT?'^O$S'?(!N>-CD7]N-XX5NW)1UY_XX\WH
MYT<N)<K+?-BQB0R[J_PD+TNV!#E^MXT^6KV3#VX>+UM_*9U'9RZR-C^IR_\I
M1MWDYT?)(S7*Q]F\[,[KSZ]SVR$1<%B7K6S59W-O'#]2PWG;U5/[,"28%I79
M9U^L(C8>2-Q;'O#L Y[(;5XD4C[/NNSIDZ;^K!K>C=9X(%V5IR%<47%4!EV#
MJP6>ZYX.\DOHN,M$1?58?<H7:EQ<SIN\50?OLXLR;P^?]#N\B??WA[;59Z95
M[Y96M:=.ZZJ;M.I%-<I'VPWT(>)*3F\IYS-O;XO/\^&/RM='RG,];T][_JK?
MOK3GW]9O=#EGS]6_>$D5^-7^WZZ>FG:"W>W0:1ZWLVR8__P(7M'FS57^Z.G?
M_Z8C]Z<]4@8K*8-]K6^/3D^=U%5;E\4(HH]440WK::[:94?:7<+?H_F__RWQ
MM/Y)#?>^Q'E35?551E=2I_FH&*+)UAEDU:C^PSFIFUG=X%9U@ ?+^:BH+E5>
M%K!;>4=[J+3SJJGG,^?@P^ Y[+DLY;3#4>5&?^7H-\2I-H-1JJY6W:1H1FJ6
M-5T!&0*MO#3B+DU#)U5>D&(;^=H)714&H1-J%7D19+6/U]TD1WPR.FB=Q N=
M&$]Z;NCHQ'5Z6KD^=FD<KE_K!)[2D .[.'71?A &V"9:;]V__<9W\J(FO\JK
M.9K0(II6.DX=+W$B[40.GL?IQ.<VU%!DV]$;+^MZU"H,QPC-:Q5&J>QCW-(+
M5!HG3B]4.HCQF!NQ"=>G(*$*DDCV2113X6VK9DT]+CK'URIQM>-[RM.)$ZC0
M#;"-T7<_=G"S'RD_\/!#N=IU!HB6&,,C=9E7>9.5"N.LLA'&LVB[1L94!(IB
M"N8IW\5K/<CBK7:AE@TDU0'ZYLL^@7CG\):L&4ZDS1&44]8SC@0T"-7@H41%
M 7J3> $V:<KS*088NS!PK5*-?3JAS\YKJM7U'<^''F,,4NPZ"4=3):%G'\B_
M ,_:G.)%&&P,6NQ3V!B"^6GL]&(\W(LHKZ]B: HWQE#PNUG._L*>[2L3%:,3
MVE51DN -0<!MY%J[04-A2OO3:),*2E+GX"W&X;!O76K<U%.5M6T]+,33<'*6
M533DGN? "O%?#]T)E>^OCU*X7Y<CSG3KCB1\&0W0=' ,7ZO09KGT7:IW>;,'
M\6#:;\R5BQRHGJLN^X*W)LJ'RKQ(:;1G;S!7T*% R[AJG8HK6!5$*@TA:0!3
M29SCKFN*BWE'R(!W/78&DZS))S#=O&EIR[\A;,!36W7\:N-)^G1=]1!TNJ86
M8T/KIHNM VE]RH)((K%(5:N7*S3^>*T-*Y$/.T0OGN>(Q=2K!378/H:O6QRI
M69DAY(M*?I\7UMZ,!D-8F =OZ'F:@XB(T],^S5KIB%8+Y$ENM-P0]'OUN#=O
M<XYFWG'\0EI4!.ORQ:KHB31['-,^?&IK6D,7?ZS:09^SZK*@[I:MP/P\L<+(
MQ\ZC/!Z/C+GR0IIXLH/)OX'Q%(W@V1!ZOT2$0\-[^WU$;2*,N#';T[2QGE[^
M3O1FD[=UU)?QV?GJ&QVRKV.0QHO\B&\)^2;:>X_A0?F(E7C_SB8I^A@GU556
MSG.>KNR;U@:__2(?@8WCQD;YHLAUH+[CT:@0*"("T'2:^;";-[0[:.NJ(-L4
MDW<9:ST$FA[_24 3"XE$TD@&(G%>0)O=HD=>:%P8;K8:U)7%YW*7# +:CADD
M8QB^M!J)$FAQJ5B9BT "#('#?S^H%41UOW*T'VJ)L7X*S_<MR&(;1$O$"Q"[
MH:W;H)8P&Z>>P*Q.4H.9O331VT!+A,4[&,(-Q&+KAQMW;[_M!LP28+4$)V C
MD(<@&R468K&%9]X"M *PB.TI'<T@+';T:P.QV(;)"F"Y)RG8!EJ#L!YD)BL1
MB V@J8@HZP7A$F)]7(KC.R*M15@"2AAO(FT<69 -HF"%L-P3?VY'VB7$(K(G
M%F03MF@@%N?3Y!K2&I1-R<<$92-!V2@(+,I"=\$-K+4@BSL89P1F$Q(5@=D@
M298@BV"F,>8WL-:BK.$%!F7I*+X!V5[D+R$6-VH(\>9K$ M.( AKX35"%RR^
M1K&_"V/)[Y(HO0O&$F![8&:[0-;"*VQB?8,%68.NU!$"\ ;(6GA-,,;Z?B!K
MX95/>GM EE%<WPME(4AZ?Y!E]$Q)!@5?O62%K^1W!ET96?5=058"9VP!EE9,
M@"5/\86\@8K?"60%77WE<M0,OL:N 5B]0E?L KC%PT%6\-5G1X7 1X*T!-E>
M #^['X(*=,8$($](M1;T# UR0L/!MX!/^)8F5V<JY!$W?03>.V*G@*:G8X-O
M:6) DZ/D"Z%!QO0@V"1BQAQDCKR$.4',Q#5XV4L1DO6>I#M<)=WA@Y/NBPS"
M#)$0L^"R,^/>V_;N<L'7T_#MU_[%.?C[NEM9BQ.'*H0_Q\BWP1ETA&"3<*<!
M[Q[A,924DIFMCI$M8X\4E 3 -%,6V451%D(KX+TJC4SBFGJI4&#&"CHI?3%6
MM!VX#/(1)I6)2;@C."GB@&G/V(P3(C/W?$1SE4!LAM-1?M$ISXD5L3>!^ZR/
M>+E>88[M&%H/@6IHW$.P(_*2.GC(P4D)\2PDB9$:('N/5(1K$< T=;<"J6E*
MG&^CGR:H&G'W!\U$!0;VA+4DDN&GR$D#Y!-!+-EG#$=@92"XYIY[&U:^DP"E
M4W3,PSCY0/0$'(NHZFERI@!Z-0+NBKVD3JQ4\#D^A*1)(WK+/SQ**4/(NATN
M;K8#*32H$3,;GYDGLU.,HP<BX*_,C,3L,TQ4.G S@(,!^F!"(4Q ,]WV?!9E
M(D1"']' 0Y(9@<5!.1A'TJPMF?:W3?%@J.Q-P"U9A@O*@$"F$1Y!NE*Y XS.
MB%I45XB)HE\S]C=YAP:V:^ +LE0'$(-P*$VYUP;O#BUY3)\A#%3(\(Q63K+6
M,+PA#SC6B/6DVT=JFC6?<D,:VGR(B$TS/&)KTWID?W0%X'Z4S^JVL"8+3E'8
M*+-)>!CV#8W7X(?0MY<@<TNO_7JY>H*.=\<&28_ [3U3-MG^=3)O&J.0)6O:
M]BEI?YSCIM'UBTXH9LVJ6+AU3!+HJSV0$:T@(]H+&>M<B7)T8@Y ,C/Y ($J
MLB_;@27,7BPP ',PLJ7X37Y) ]@%*GO?OAM4;D_?U-*W]DN(8+D+('XP(/"#
M21)_N';R1'JT< :?B^Z/O$'H&3DI#-YS$KJVD[@\]EA: Z<0B(AQ&>'D0U50
M#JG+P[1B9#AT8F))HLD_>!0D :(53L/K?>1]DD0!$W#TLB%"PBT]Q(, ^]"3
M.IH* NZ162"4XE$5(7B&SJN\F6;5 BF9!\!B)301OPP4TZB4[<"*Z>8^KL.[
M)K!8ML**+?8NTHR(;T&WT%[*?#U&V-'.+QE<E,_#JRE'E/@B1X(PB9 -0"0W
MDD0"6C/B$UYQ \1 .$563<*%F R4(?0X!#X<N!:W;7590Y<V ^:AS8)Y&(.O
M$G%Y" 6Q0(G#<[$OY\6<T$!W#5COC?EJ.I@O+AQ#.WQ[:-+6E!H.F;JFH-/P
M7P07R*]"1+V ? "-^%9JR7"U/.JN'_7DT;;(^L=C/MX_GC.A+3.<(H"%;(:=
M$^@W1_10'JDXD3P-N1[W?ZKW:&"?I\<K3X_OZ.GP7^.QNQQV?R,["5]U>[UE
MCR^OI(!7GPBK7^YVDL3EX/LJA-WI0&"3U65?? MI[H<!4V&6 G@5NX@'OCC1
M;<.8"%U+E<_R:<#2.'P((3NKLE$FL>TMN96R%H218)J"G#\VKA$@LX:92U2Z
M-H_3\Y9EIL1Y-U:?)\5P0E!\T1+/"A#BD3H5>&L=GY:1<(HC8++I$SHB(&.T
M_22$N"31@SE][B:KITFF6,1WQ;@]=H=E 6])K*WJJ#*?*,+)EY@')#RB-A6'
M4@:A2MD]'7A2^KW5^A&+2"$BYDD\",'M, 2WZBV%GA*60!!KN+.D=VNRJQ?8
M4IS[57TAGH+,(KZ&3*@<^HJH[2[:PN EJ0PAWX0XB*B;6@_=CC VO/16X241
M99D ;Z-[N SNWM="A8T3O6 9)_:8F:\2Q %$?(0+Q+=E-#4ZVYZB@YG9"!)]
MW<R@**(7B([4])G@L+X5W,W,X'H(NMCY6DI06JJ,.-Z7NR:K\)3LC2Q;-=!=
M@6GOX_=(3^O-%_W)A/0.Z:A[OY]G4H/MM9.LV2@CIJR&(>2PB+QY?%XOLK);
MK"INB%V!H>H)239@+5K6CEGA=(%L )33 @&YJ[EVP%8IB4J> *DOU!Z/,*"$
MG ^VE4,M/[4KTZWT&% !'=$* @?!P_*RV^>+33G;6U:THXV:]FKRV%2V]3ZT
M2U?FE.XUIUWCNLNJ]K;RP#42VETO87&_T5H.V] W%G1CK8V^&WG8*=O^9W<-
MA7I>F*K;'O)@\@Q6H&%4V2R?=\60%8ALZ<.SII[64F0"@QZU/YE2P4;<,^>=
M%;]8$XVL&140JAW.RZQQ7H#YTR,XS1&0:1LP)KXC_B-VO\U_ORIJF*S'<%=-
M^;^Q^&LM!4!2DFS66OQ@V0#G!:?SJB[KRP4G;C#@BR^\E\1>* ?(IY &'/ZS
M+EGNY'2!'W$)0,#:8[!TD<!Y@Q<5,DLDM0PW))1(DF)GTM':IH@;[X[A;#&W
M7%L _&3A7K.,!-QKAT7./.05HD.U(-4A=R%:RK0J,P>6:6/G?^OR,J_:*6F
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M4)8!W^<27=U=K()F&Y_\#5!+ P04    " #(/4%6_O6G2?\"  !,!P  &0
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M*]%U]WB6"TT;L+Y5N,RZ 2D8'OKK_P!02P,$%     @ R#U!5B"*' ?G @
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M^D[C+!I0*M&"-$))HF$Y"U_1J^O4K?<+/@K8FCV9.$\62GURDS?5+(R=0=!
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M6;RC>K'&/P6@W0+\OE3*[B9N@^%OQOP/4$L#!!0    ( ,@]05;'^$I50 4
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M\2(EDX7P4 R B(5Y%B0^3I+<QTD:'PZRYZ \+; P1X#E,4%&//&0"+*B# I
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MI?,IN\%4IQTV& +>@3Y=N-W%J_+M-T7$\^_L\)Z/+8FAWW!1)&V?N@!;['M
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MWRV.5#!> .]KK=W3QCL8A_3R7U!+ P04    " #(/4%6Z;0WI_D"  !3!P
M&0   'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6R-5=N.TS 0??=76$%"(+&;
MVR8M2UMI+R#V 6G5Y?* >'"3:6OAV,7CMKM\/6.G&XK(!EXFL3USYIRQ/9[L
MC?V.:P#'[QNE<1JMG=N<QS%6:V@$GIH-:%I9&ML(1T.[BG%C0=0AJ%%QEB1E
MW BIH]DDS-W:V<1LG9(:;BW';=,(^W )RNRG41H]3LSE:NW\1#R;;,0*[L!]
MVMQ:&L4=2BT;T"B-YA:6T^@B/;\LO7]P^"QACT?_W"M9&//=#V[J:91X0J"@
M<AY!T&<'5Z"4!R(:/PZ849?2!Q[_/Z*_"]I)RT(@7!GU1=9N/8W&$:]A*;;*
MS<W^/1ST%!ZO,@J#Y?O6=_0ZXM46G6D.P<2@D;K]BOM#'8X"QLD3 =DA( N\
MVT2!Y;5P8C:Q9L^M]R8T_Q.DAF@B)[7?E#MG:552G)O=Z!UH9ZP$Y"\^BH4"
M?#F)'2'[];@ZH%RV*-D3*&G&/QCMULC?ZAKJ/P%BHM3QRAYY76:#B-=0G?(\
M?<6S),L&\/).9Q[P\O_0>2VQ4@:W%OA7L4!GZ6A\ZQ/=0I[U0_KK<HX;4<$T
MHON 8'<0S9X_2\ODS0#ALX[PV1#Z'X07#[Q2 K&/XS#*BT]WUW1LE*(;@"^9
M+Z8W*9N+/1TC!U8*]8I7M+IMPNZSU_D9&X\2]H5N$Y>:;ZQ9D3QD.2]'.5D2
MR-Y)+>G0U7ZUWE8.6<:+<DRVS$OVT3BA*+93P$8\'16LY&59#M2FZ&I3#*JZ
M:,Q6.VZ678X':A"566GYDS@)Y$)SN*?&A> E5 :#]\J8&CD:5?=5<CAGJ.2B
MIY)D$G;U5P9V,CXMO1E[4PRH+CO5Y2"#^9'"G@+03NRD[Y5>?4WUV(%%H? )
MK[X*#.=_\BR%"MST$&$G99ZSDX*.S<DHR=C\'YR0I67*TH+.4=%;L?BHT35@
M5Z&=(^TO5:/M>=UL]V)<M(WRMWO[W'P0=B6I5@J6%)J<CFC[;=O"VX$SF] V
M%\91$PZ_:WKUP'H'6E\:XQX'/D'WCLY^ 5!+ P04    " #(/4%6F$7;;V@$
M  # "P  &0   'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6S%5FUOVS80_LY?
M06C X !UK!=+LC/;0.RDZXJU-9QXPS#L RV=(Z*4Z)*4G?37[RC9JIO80HI]
M& Q3?+E[^-SQ>+S13JK/.@,P]#$7A1X[F3&;JUY/)QGD3%_*#12XLI8J9P:'
MZJ&G-PI86BGEHN>[;M3+&2^<R:B:FZO)2)9&\ +FBNHRSYEZFH*0N['C.8>)
M!7_(C)WH348;]@!W8):;N<)1KT%)>0Z%YK*@"M9CY]J[FL96OA+X@\-.'_6I
MM60EY6<[^"T=.ZXE! (28Q$8?K8P R$L$-+XLL=TFBVMXG'_@/ZVLAUM63$-
M,RG^Y*G)QL[ H2FL62G,0N[>P=Z>T.(E4NBJI;M:-G0=FI3:R'ROC QR7M1?
M]KCWPY'"X)R"OU?P*][U1A7+&V;89*3DCBHKC6BV4YE::2,Y7MA#N3,*5SGJ
MF<F]8BF@=Q/@6[82H&GGOOI>C'H&\:U4+]EC36LL_PR6Y],/LC"9IK=%"NGW
M #TDUK#S#^RF?BOB#227-/#>4-_U_1:\H+$VJ/""<WA<)T+J4@&5:VI>V/XW
M6VF<3<P_IZROL?NGL>WMN=(;EL#8P>NA06W!F?S\DQ>YO[0P[S?,^VWHD[F2
M6VYO@J9X$U]2/\6W';&SO+O!B!+"@EX0ZV';>.1>&B;H@Y):O]R'#*CG#[!U
M!P/RC%0JRY59E^*$5C?R27<0[+%?K+^A!1@+&D6V=<,6CX6-Q\)6^UY&]N9
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M&>,;H^IZL1X8N:EJM)4T6/%5W0Q+;%!6 -?74IK#P&[0%.V3?P%02P,$%
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M.3W5H.T!VE\HA;N)O:!Y_,=_ %!+ P04    " #(/4%6KQSEBH0"  "@!0
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M0]@/L1M>W\LZ*[1-.+5"E;7-+;E<E6HK)85V5&F1N2<A80DXBK67#\?BQ<:
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M^<0?^"2#%:VXN9?;[[#CT[5XJ>3:C61;V_:[/DDK;62Q<\8,"B;J+WW9U>'
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MEO9T(05V>#0 S^<*Q:.YH 6Z#X#7_P-02P,$%     @ R#U!5ML2);"X P
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MPQ[@_OB .*T4A?IJ+ @ ,D/"3;<%SP^T$I&X0?.\;%/D+AGHNJ-DL3LEB5A
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MR2U1* UH.+"N6FT@QPO,RMPHF.6@9Z:7WRMN[D_0L8R45!F>\I+:@)6"%II
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M&'C/T/S".R/4O9@&>)T(\.#25Q<#];6HN;H.C"B[(;!3J+Y78.?032I)GD2
MEVI4\I 3$L7X=](1L3I_4@+TF7QA"[%!?CLCG3180#;\@A-C]E/JW(B0JVLE
MT>Y2!#J3)57@=RD$#ZG:XON-D.I;&[SL#&/+"UTM51> WRS:XOT@?:8<K\9"
M0K<17 #I7C$:<WWM\8Q,F$QA*EAMH?16PX?$9$VW+NQ<0]8*R>=<N6LRC_ T
MSYZ.7?D\MV[Q0I.%OJL<9WN07>C=K>ZN0[>S6\ %>':7>D3E@B.+!>P)J!7W
MHGE"9'8_.7M(Q%K?"9Z+)!&A_KED:G)3 'C_)$22/R@&NTOB7_X/4$L#!!0
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M:W]KP88$OUX:@Z<@=-+T'\A? 5!+ P04    " #(/4%6S^:HZ2L7   N?0$
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M@?KQNSRO'G]H!OB4%[_O7\[-OP%02P,$%     @ R#U!5A,X]@Z\ @  [0@
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MTH@[Y2O:@*; 07-T:B5<@N3$'F[(*+8Y$_?,5[GA3#&BPCDZL1(N3=KG2>:
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M@1Q'O^S",_<'QZ@C-6MCR7!N'*0*ZP6C%V%-<4B*0Z-4E9KV/-4(BXJAJM/
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M@ M_!<A!2#.@^^/#H28<'Q_N&-2X]82X!9][B"\6\X0)-0'Y=*CWFZNYR59
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M4=L= 3+8;M?3:+MF]*4T< 60F!7 V78GG%(R0\U>3=#P'84FT\C#]\1R^)Y
MPW<H&D.AR=SR\#V9&+Y/"ALZ,.E ;T+45SIJ6H5>I)XG[%J%4BM_X)6."0_,
MDRF!.>Y0DGFXV6L'&LZCT&2J>3B?6 [G$V@X#T5C*#296Q[.)Q/#^7$/:@:Z
MB(8]:*P5Y&I\;QY@*1-"$39S^'XV:/TQ)'/OV6L(6V7-3IDUL<Z:Y<,.KP.
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M1% S)PXY<]^ J+,GN7[JNL&J4&6TV-%*/NDDGFH@%*2_B5W_VBLBNDB2R2[
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M+T:9L==\2@)*Y>GVP:??$G;B[),G)%3.P^38Z!$F+'.;"4LLR$'E/$R.)9B
M7 DU$Y92KU:^.ZP898.*%Z*,&FF\KDJ"3N7I9L(GWR1VXN33YR-VT0LEQP:/
M(%V9VUI88B$,*N=A<BS!!,)*J+6P%#:*"\S#1P1Y,6CL%;^2,$]YN@OPJ7>-
MG3CW]+F(13&4'!L[@F)E;A]@B04FJ)R'R;$$$V JH3[ 4O#NA5_N0E#PQI\0
MI,C^\.R""*"4I[L ?PW;R$Z<?_J$Q"Y;H>2&XU<1&JMR^P(K+#!!Y3Q,CB68
M %,%]056P@YS=?#F@!!5\?<+O!1ER[&:KPBB5*?[ I]\9]F)DT^?C]AU+)0<
M&SP"8U5NEV"%!2:HG(?)L0038*J@+L&X6GHVL714A2Y!9<:LQ16!GNHDE^"+
MQXWU=F_;V8?U9GDS4>K8U2>HG(?)L203$JMRF_HJ+"Y!Y3Q,CB68X%(%-?55
MH0]/5\8%KA\ISCJ^$.C%N-*2NP5V8013JI.<?>/EF;A/[<3QTR<6=MD')<?R
M3ZBJRNW6J[#8 Y7S,+EA@BW!'@MUZUEASSMG>!/U*RE.%ZX.*E?2:VHWM@./
M);AA3_+L12OW1=)VMA-GD#RUH'(>)L=&@-"1S>W$LUB"@<IYF!Q+,"$8"W7B
MV= Z9PO>V/A*#M.!Q4X(JYIF["O7$FRP)UGGHH7[)+O>3EQ(^O3$$@M*C@TD
M01N;VU1GL5@#E?,P.99@@C46:JJSH:E.:Q>88H0PU9CPFUL(TWKTBYNPA#W)
M!7=J_6?:%3=^$>E3$[N\@Y)C@TBXR>;VPUDL&$'E/$R.)9B D87ZX6SH8=.%
M"C;2$,+VM5\%M2]MO%>/O6A3$QJI3[+$G:WV_[Y>SA>;>.7'+R%Y8D+E/$R.
M#2'AKCJW+Z[&8A54SL/D6(()5M507UPM-$PU-E@[E\)*S7O,B&&Z&KOKKPG+
MU"=9X\Y6^<?LDQV_A/2)B5WO0<FQ(23@5N<VR-58H(+*>9@<2S !JAIJD*N%
MGJS<ZWHE1E5AW8=193WVYGQ-$*8^R2-W:MGGVC\[?A7I$Q.[_(.28Z-(D*W.
M[9:KL3@%E?,P.99@@E,UU"U7AQZWQ@:@+T3M[PR"!WU26%F.?N43A*E/<LR=
ML?:/W%8[?AWIDQ.[A(22&XYC0Z"MR>V<:[!(!97S,#F68()4#=0YUX1N-\>?
MWUU)4<*.&D)4:<=JOR$0TYSDG#MC[1^WW7;\,M)G)G8%"B7'AI%06Y/;0]=@
MF0HJYV%R+,&$J1JHAZX17&JA:39^S/0D9>&BAG!1 _;0/?TVW/$K2I_VV)4M
ME!P;48*%36[#7H,E-JB<A\FQ!!-B:Z"&O4;:A<\%N_2*84VP#9\0YD8?)C2$
MDAJ\6>\)-NB.7T7ZU,2N;*'DV"@2+&QR6_X:+*]!Y3Q,;IA@1WC-02U_+K3H
MU97CI2]$52YXC"A$F=$M^!TA)(<W^SW%QMWQRTB>F5 Y#Y-CPTBHT.5V##HL
MKT'E/$R.)9CPFH,Z!N-JZ=G$PID+'8BF'GMOWQ'F<F<U(.;>T#M^->F#A(5#
ME!P;30*'+K<+T6%9#2KG87(LP835'-2%Z 3?8!%NU".&A6W_A#!7C.W4XP@?
MN;.:$//L]!V_AO2)B5TT0\FQ,20XZ')[$!V6U*!R'B;'$DQ(S4$]B$YP#19E
ML# AA2G>\\O+:FZ$)731X]'AS[_FTO_C_-W\??P1PL0EI$Y,K)R'R;$A5&0(
M,WL0NP/ $@P%-9@<2[ F"49Z$#LUUH&;KTO(88Z[C\4PV@R,794A5W56#V*6
MG;PGKB%]9D*9#";'QK D8YC9A-@= )9@*$_!Y%B"*Y)@I EQ0BT]FZ$/T51\
M@0%V4)8D2Y)T5EOC7_<?V,0"(K]4_GQ_O9_W$];FB>M)'R;H<AE,CHUG3<8S
ML\&Q.P LP5!6@\FQ!#<DP4B#8Z?&M@W@NQ!(85H%#D=1S8WU!=.%(U=U5H?C
MY_P:^&FY6[S:K(_8&G3BHM*G*G3Y#"8W'%1%^%!EMCMV!T E&"KG87(LP83>
M%-+N.*&6GDUA1T&^OXF''90EB1"8PALHGZ#QT,1EI(\.=$$.)L>&D2"GRFR@
M[ X 2S"6!U%R+,&$!Q720-FI#?BBY&].3!PS/4E9F$X1IE-X ^43-R2:N*3T
M>0]=E8/)L2$E!*HR.RB[ \ 2C$5"E!Q+,$%"A710=FJ#%RD,WW]!BJKJ@%>$
M*%OH$5Q1!,(4WC^9JU'1?/G^?GL,K<2O*7V:0M?H8')L3 F"JLQNRNX L 1C
M<1 E-TRP)CBHD6[*3FVL1?%CDH2HT&_MQ3 UN@:J"8)IO)_RZ5N635Q5\E2%
MRGF8'!M5PHPZL[VR.P LP5B:0\FQ!!.:TTA[9:<V^+8/84.(JOG:J9>BFK%W
M*K0F_*3Q9L@G;V4V<5'I\Q3+>R@Y-JB$]W1F3V1W %B"L?2%DF,))O2ED9[(
M3FU0XCJ\*0BCFN#E*BG*V9%>)UH3WM%X1^13=SF;N*;T:8I==4/)L3$EP*<S
M.R2[ \ 2C*4OE!Q+,*$OC71(=FK#EZAX5P0IJM8A&PA=B\>V:-2&\([!VR-_
M#?W/)JXK>:I"Y3Q,CHTK03Z3VS-IL/0%E?,P.99@0E\&ZIDT0@_B,K!,"E&E
M"NX)I*A1PZ0AO&/PALDG[XLV<5'I\Q2[8H:28X-*B,_D=E :+'U!Y3Q,CB68
MT)>!.BCC:NG9Q**6$;:/'&N5K@TA*!,GJ+\*\X[LUBK_XAFS1LEYQ:YO0>4\
M3(X- .$]D]OR:+#P!97S,#F68 )?!FIY-*%)T2C#>Z%=27':U57@8)+B*J-&
M[PH(])@X]$!+=[R#BYPE[&(55,[#Y(9#4Q)X*W-[%TLL14'E/$R.)9A05 GU
M+I;"]HIU%=2T$&:JT,<LA.F2/#]@5T70I8RCRYDJ^MC&2Q.GFSX)L<M0*#DV
M7 3+RMRFPA*+2% Y#Y-C"2:(5$)-A65H*BQI__$N2X+WL"KYB\]26*S*"9>4
M<2Y!5[G0@T%.#Q9PH'(>)L>&A9!0F=O)5V))!RKG87(LP81T2JB3KPS==[7F
MZW!7<AC?Y\1+85:-WH67!"_*.%Z<H9J/;98V<:KI$Q"[2H228T-%@*G,[=$K
ML=@#E?,PN6&"*X(]%=2C5X6VNK)N K.N&,9[JGDIS#@W]HBL(JQ1Q5GC/!5^
M1$NTB1--GGY0.0^38P-%\*G*[;NKL, #E?,P.99@ CP5U'=7A5XYH26:&!:V
M1!/#1ENBZ8I01A6GC//4]Q&-SR9.-'WZ81=T4')LH @X5;GM=!46@:!R'B;'
M$DP0J(+:Z2IA[T!E>.<S,:S@7GPOA8T[:RN"'54<.]#E+?9 D?.#79B!RGF8
M'!L80DY5;E=<A>4=J)R'R;$$$]ZIH*ZX2G#%%55@A1'#BL +(X25NAY[>\X2
MR+!QR#A+/1_9L'#B7)-G(%3.P^386!%TLKG-;A:+/% Y#Y-C"2;(8Z%F-QL:
MU'2A@F]L*:P.+?!"F"F*L:]L2SC#QCGC7"5^7%_"B;--GX/851J4'!LMPD\V
MMY'-8KD'*N=A<BS!A'LLU,AF0ZN8,OSM]BLYC'_=>RG,Z6*LQ@EKV#,:SR(U
M?E3_P8F339^!V*4;E!P;+,)0-K=)S6)9""KG87(LP82%+-2D9H6=],(^85*8
MJ8,W6"2QL<?FEM"'/:\]36P6)&<'NTH#E?,PN>' U 2@ZMSFM!I+/5 Y#Y-C
M"2;44T/-:;5D3M/!3;D4IHK@^UH(,]:.M.O9 SFYJO.:TT:;?R7V^)PX[_39
MB%VT0<FQ<2,P5>=VJ=58_H'*>9@<2S#AGQKJ4JM#7YFJP]MS*<PZ$Y2[$%:5
M8X_9:@(=]7E=:F/E?DPKSXES39^!V'4;E!P;*\)2=6[K6HWE'ZB<A\FQ!!/^
MJ:'6M5KHSZM-\"1="',F>,HF1-EFS(9:$^2HSVM<&ROPHSIV3IQL^@3$+N6@
MY-A@$9BJ<UO7:BP40>4\3&Z8X(9 40.UKC62)RUPF@M151T4N!!ES1B -P1#
MFO/ZUH2-J^7<8)=LH'(>)L>&A7!4D]NEUF"!!RKG87(LP01X&JA+K0E]9;:L
M@F=I8I@)W@T3PBJKQKZN&T(9S7E=:O(V]&D]<2?..7TF8A=N4')LS A#-;D-
M:PT6?*!R'B;'$DS IX$:UIK08J:+T' NABD;E+K@:ZO)7M/LJ@AM-.=UK(UT
MG#BB]>W$F:;//^RR#4J.C11AJ":WA:W!<@]4SL/D6(()]S10"ULC-*MUX:-T
M(4P7X7O>HEHU5N".P(8[KX5-+O!C&MS&3S1Y^D'E/$R.#11!*)?;O^:P, 25
M\S YEF "0P[J7W/'-;@5P\(&MU+8>(-;1PC$G=>_)M?W47VAXF>:/O^P:S<H
M.392A*I<;N^:PR(05,[#Y%B""0(YJ'?-"=N<F6"?%BDJM*<*4?09';LD AWN
MO,XUN;J_NIF_>]].;- 2/]/TR8==MD')L9$B(.5RV]8<EG^@<AXFQQ),^,=!
M;6M.:@ ;/#67HFRPKYH458P]-7>$.-QY;6OQ9K)RFK!+-5 Y#Y,;C) I>GHZ
M_#EK57<' "48*^=A<BS!BB08Z5_KU(8[)FJ^48L85@9^<UFM'(%N4VAR5>?U
MKTUVB3ZJ(_S$6:?/1>AB#DR.C9HAHY;9O=8= )9@* '!Y%B"2Y)@I'NM4YOH
M""^%"1WA1;71CO"FJ,A5G=>]-EGLQ_=]GSCU] D)7=.!R;&ALV3H,IO9N@/
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MDWQS28E^ V<!^OR<<_6^DUV@6F\W^1]02P,$%     @ R#U!5F_7^%&O!
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MV2*^C@_.;AH@1;L.@=Y,T:YC?,\S:P];[:%5NV@86'0S^>0.J@]U:9.I(M^
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MC:D$B.L;0OC+@;Q!^]UE^3]02P,$%     @ R#U!5O@@+R3H P  .Q,  !D
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M5$G,JTY-=2/9JNQ=/#$I65Y>ID!BX-I /4\8D[L;/4'3+UO\!%!+ P04
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M0T87E[P;3%?WNXZCNBV=3^2X$+?-DI]*:+P!SR^)W+;C%Q@>7]F_4$L#!!0
M   ( ,@]058&S->T.@0  ",3   9    >&PO=V]R:W-H965T<R]S:&5E=#@T
M+GAM;+58WV_;-A#^5PBM&%J@B4Q)EN/,-N!$:[N'%$&"=@_#'ACI;'.E1(^D
M[:1__8Z2+/^0+,28\A*+U-U'?I]XQ\N--E+]T L 0YY3D>FQLS!F>>VZ.EY
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M.Y@8-*@U.)-??Z%A[[<FR;H$BSH".Y SJ.0,VM G7S%G\@S/-!!M4$?,58;
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MZ3O1-DO]S %A 'I^QKE:=\P"W<,I_0-02P,$%     @ R#U!5CT:3I7_ @
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MT;RN'NJ.9'/SGDZ85*^S:1:JX *N 6I^RIA<=_0";0F7_ =02P,$%     @
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M)Z%'?LN2LQ(JR7B%!"SGWF=\E^+( &S$7PQV\N@9&2G/G/\T@Z_YW O,CJ"
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M]/D8_8,%CV#63,%21'_P4.\>!K,!"6'#LDA_$8=?H0!T8^(%(E+VEQP*6V]
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M4FY1/*KJCZN!D=NR8UQ*0_UG^;JA_Q2HK %]7TEI7@=V@>9?RNPS4$L#!!0
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MS53;/NJW?:?L0&^:5XO9EUG1SA)6=;5=KI[O_6&4 ^4#>Y"M1FYC"([-_7$
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M?6Y?@/!FC"U34W6$4_50YS1RJ?<F<$YH(,A>*2;QAHTM7&-V=/K!#1?T$2/
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MDA1R(L[9!@IU9\UX3J0ZY7>^V' @JS(IS_PP""(_)[3P%K/RV@U?S-A69K2
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M8_F9'7XCI4/C#&_%8I'_!(?"=A)Z8+47DB7E8,4@H6GQ.WHI W$T +8-0.4
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MU#>R'7OJVR0+6R*KN-@O7>S_WV;3;]/V-LG"EL@JM@]*VP>-A_<*BX4V6'V
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M;Y+*FZEZ9RWLJ1;#!F[SBIGO=%NNF?#CR&FL8Q!PH DXP)>Z#I@!PSWV?L:
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M- 2XU$$Y:#[5#GL,<(TTN$8D:T0C"%WM[U*FD%6#-O:7F&/ :Z3A-2)(SD<
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MH/GW^Z*H7WYH"W@NRB^;:M_\'U!+ P04    " #(/4%6J.#\G0@)   D8
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M.$YKK:GILT[;;:BK,)C/]&/>7,VB^0/3K+UK89=2.U"X8,C>V<5Y!+99)8U
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MNF6%7 GT;Y%"VB6P5:Y-PNYSPM?N(&,,R3GR\ ?D.JYK2.CF>#@VP./CX<Z
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M^LV2BPHK/10K7VX$X-(&5=2/@B#U*TR8ETWMW)W(IGRK*&%P)Y#<5A467V^
M\OW,"[WGB7NR6BLSX6?3#5[! ZC'S9W0([]E*4D%3!+.D(#ES/L87N=A9 (L
MXG<">]EY1D;*@O,O9O!K.?,"LR*@4"A#@?7/#N9 J6'2Z_BS(?7:G":P^_S,
M_K,5K\4LL(0YIW^04JUGWMA#)2SQEJI[OO\%&D$CPU=P*NU?M&^P@8>*K52\
M:H+U"BK"ZE_\U!C1"0C3$P%1$Q#U Y(3 7$3$+\U(&D"$NM,+<7ZD&.%LZG@
M>R0,6K.9!VNFC=;R"3/?_4$)_9;H.)7])G )^@,60'9X04&B]SDH3*A$X0=T
M@1X?<O3^W0?T#A&&;@FE^F/)J:]T:D/@%TV:FSI-=")-&*%;SM1:HI]8">4A
M@:_7W"X\>E[X333(F$-QB>+P!Q0%4>18T/SMX:$C/'][>#"@)FX_0VSYXE-\
M1!:4RZT Q)=H(_B.V).E-[8@3^B3P2.BH)*?7>;7Y(F;W)2.:[G!!<P\71LD
MB!UXV???A6GPH\NX<Y+E9R([,#5I34V&V+-'12CY"]OZTG55(ETO4<FW"[7<
M4J3Z1\#E<)TIM9E,+=UE412E>N?LNM8=H\+).!X?HG(7*IHD+>I [*@5.QH4
M>WR0/U50+4!\1G^CNW9#'2A_0;=@E_;!Q/]V=YV3+#\3V8'A:6MX^E\>V?2<
MIIZ3+#\3V8&I5ZVI5X.[^/6-BA5:P(HP1MC*&@^"\-+E<)UIU#EF%^.X=V =
MF$D/D[LP(_=A';<RQV^3^5HI0L4:BQ642'&DUH *'<(I*;'2<X05O (DE1[I
MJYARF3 ^7GQRU3/!@8DG/1,<F-'$;<*D-6'ROY7GR='R>@+FKR+R8T08NQ6&
MP<OM*AC4> \[$!+3;Q;8Y.FN;I3V)#HP<=(3Z>(YI;)SAPP'5<ZW0@ KOAHI
M3-+ZD\)RJ>_V;C'A\4+[6HXA:5_*,>3BQ+D,HQ<IT;<7(&#E<.EIDG3_Q5^D
M45^B ]0O4+D+-.E_,+]S_Z] UPO31^G:P;=,U3?J=K;MU3[:#J4W?V-Z.-M7
MO-#4#>"M+D-$[UP*2TT97%YIVT7=4]4#Q3>VRUAPI7L6^[C6?2@( ]#OEYRK
MYX%)T':VV3]02P,$%     @ R#U!5AM%\=82!0  "BP  !H   !X;"]W;W)K
M<VAE971S+W-H965T,3$R+GAM;+6:T8Z;.!2&7\5BJU4KM0,X"4EFDTAMS&I7
M:E>C3KM[4>V%DS@35,!9VTEFI'WX F$  ^.$ZG S@7#.9W,._,H_]NS$Q7>Y
M8TRAQRB,Y=S:*;6_M6VYWK&(RAN^9W%R9<M%1%5R*AYLN1>,;K*D*+2QXWAV
M1(/86LRR[^[$8L8/*@QB=B>0/$01%4\?6,A/<\NUGK_X'#SL5/J%O9CMZ0.[
M9^KK_DXD9W9!V001BV7 8R38=FZ]=V]]/$X3LHB_ W:2E6.4WLJ*\^_IR9^;
MN>6D,V(A6ZL409./(UNR,$Q)R3S^RZ%6,6::6#U^IO^>W7QR,RLJV9*'_P0;
MM9M;$PMMV)8>0O69G_Y@^0V-4MZ:AS+[BTYYK&.A]4$J'N7)R0RB(#Y_TL>\
M$)4$=_A" LX3\+4)@SQA<&W",$\87ILPRA.R6[?/]YX5CE!%%S/!3TBDT0DM
M/<BJGV4G]0KB]$&Y5R*Y&B1Y:O%%T U+.KYFP9&N0B;1:\(4#4*)\!OT#GV]
M)^CUJS?H%0IB]"D(PZ2[<F:K9.@48*_S83Z<A\$O#$/8^@8-W+<(.QBWI"^O
M3W=;TLGUZ4Y+NG]UNCO5T^VDW$7-<5%SG/$&+_#>QS1\DH%$?(OXD8G-@2$:
M\4.L)/J6!J- L4C^VU;F,WG83DY5Y5;NZ9K-K40V)!-'9BU^_<7UG-_:B@X)
M(Y P'PBFM6=0M&=@HB^^<$5#I.HOQEL4,]76DC/-RVBI+A\7$\?S9O:Q6NJV
M(&>D!Q'CO+J6$ BFE7!8E'!H+F%#5;Y%+%HQT?I,&UE=GVE(&(&$^4 PK2&C
MHB&CWB1G!-D>2!B!A/E ,*T]7M$>#U1RSK2167+:@AJ28YQ7UQ("P;02CHL2
MCG]2<M#_:'D0@L7*J$)&?-?''!)&(&$^$$SKT:3HT:0W%9I M@<21B!A/A!,
M:\^T:,\45(6F#8$9>]ZPID)M08-I386,\^I:0B"85D+7*?V4\_,Z]!=7**2*
M":1V-$8\>>(C'JN=49C, W9]]$%I!)3F0]'TUE6LL-N;/.5HJ"9!T@@HS8>B
MZ4TJO;-K]'Z=12K'507(G3HUD6H+\G!-I,P3ZUS&/BRN6WI<]X+)-<G4QS:)
MHO$&Q;I^J9U@^66SPS-/IO/; 4DCH#0?BJ:WM?3=[K _"0/UX: T DKSH6AZ
MDTHO[AJ]9'<)&S75R6U(6#-H6O^999Y7YRKVX9C=TC*[%SSSE0JFB52+B,G@
M\2H)@W3*2U : :7Y4#2]KZ6/=\?]21BHB0>E$5":#T73FU0:>==H1+M+V*2A
M3O7?5\NVF$%=P4#--A1-+V)IM]T+?OM*!:LH5(M^I;_0GA@59O6"=-A+4!H!
MI?E0-'UEK[3_V.EO;0_4Z(/2""C-AZ+I32J-/C9ZU,[JE>.JRH1KRK1LBYG4
MU,L\K<Y%[,.(X\HB]@4CWL%!7M0G\UB='WW8A6W8E>T^?#\N?3\>]*=/H"X>
ME$9 :3X436]2Z>+QA>7SKOHT;/Z3?5K7IV;,=%S7)U"7#473BUBZ;'S!99OT
MZ4[P8Y!M=MMR@3;\L%+;0UB)-JL5Z)(X*(V TGPHFM[#TN-CKS^U C7LH#0"
M2O.A:'J32L..S2OO%]^EUNZ,&QNBWC4<85O0I&X)VX*FM2"_-:C<"W&^<[NR
MC3+=)?N)BH<@EBADVR3+N1DG+X,X;SP]GRB^SW96KKA2/,H.=RQ1'9$&)->W
MG*OGDW2S9K']=_$#4$L#!!0    ( ,@]05;>2N+0\ 0  *$E   :    >&PO
M=V]R:W-H965T<R]S:&5E=#$Q,RYX;6RU6FMOVS84_2N$5@PMT$42Z6=F&\AC
M73>L6Y T&X9B'Q2;CH5*HD?1=@KTQX^4%=&4*;K*KKXDDGWOT7T<T\>7G.P8
M_YRO*!7H*4VR?.JMA%B?^WX^7]$TRL_8FF;RG27C:23D+7_T\S6GT:)P2A,?
M!\' 3Z,X\V:3XK4;/INPC4CBC-YPE&_2-.)?+FG"=E,O])Y?N(T?5T*]X,\F
MZ^B1WE%QO[[A\LZO4!9Q2K,\9AGB=#GU+L+S*S)6#H7%GS'=Y0?72*7RP-AG
M=?/+8NH%*B*:T+E0$)'\MZ57-$D4DHSCWQ+4JYZI' ^OG]'?%<G+9!ZBG%ZQ
MY*]X(593;^2A!5U&FT3<LMU[6B;45WASEN3%7[3;V_9['IIO<L'2TEE&D,;9
M_G_T5!;BP"%L<L"E _Y6!U(ZD"+1?61%6M>1B&83SG:(*VN)IBZ*VA3>,ILX
M4VV\$UR^&TL_,?O(HP65_9C3>!L])#1'KZ^IB.(D1^0-^@'=WUVCUZ_>H%<H
MSM"'.$ED[?.)+^2C%8 _+Q]SN7\,;GC,-9V?(1*^13C V.)^]>WNH>GNRX2K
MK'&5-2[P2!->G,\3EF\X16R)UIQMXX*7DA8\?D*?E#V*!4WS?VRY[L%[=G#U
MP3O/U]&<3CWYR<HIWU)O]OUWX2#XT98Y$)A1!U+5@;C09Q^9B!(DZAQXBS(J
M;(GOT08%FEH@MK-1,!A,_.UA0C:CH%\9&8'VJD![[D"/:/HII>D#Y=;^.+':
M]@<(S$B[7Z7=[Y*G?<@Z ($9=1A4=1B \G2/UG?SU&;4Q--A%>CPA3Q%7]5:
M:@O6B=BV2T!@1O*C*OE1EVP=0=8!",RHP[BJPQB4K>,C(I)A,*ZQU6)$>CT[
M6\- ?_L'+^?K3_>WUF]Z)V3;1D&AF04XD#]AEYPMT:%J 81FUD*+HM"I-5KS
MMH0[Y&38P_5EUFH5C!J8JY5+>$*ZN)A[>W]I#=@)V;I;0&AF ;0B"GN=,A=4
M)$&AF;70,BETJH_VS.T?<;)'@CIQ+49#TL!;K63"$U+&Q=M?;_ZVANN$;-TK
M(#2S %HAA<-.>0LJEZ#0S%IHP10Z=4A[WHZ.U]+AL,[;8R,R:N*MUC3A"5'C
MXNW/ES?6<)V0K7L%A&9.#+14PD&G,P-0U02%9M9"JR;L5"*M>5O"F;RM"P6+
M$0X".V_QP:3GA*AQ\?;J=^MZZX9LW:LN)CQ8"R5,.N4MJ&:"0C-KH343/C%&
M:LO;WC%O^_TZ;RU&XV$#;[6DP2<DC9.W%]9)@ANR=:^ZF/A@+93PH%/>@FHF
M*#2S%EHSX1-CI;:\'5IX&]9Y:S$BXP;>:DF#3T@:%V\O;W^SA@LZ^H%",PN@
MA1(>=\I;4,T$A6;N+FC-1$Z,E]KN+P2664%]O;49X0;>$BUIR E)X^+MQ;UU
MO75#MNT5%)I9 "V42*=[8@14,T&AF;4XV!8#WA<CEJ6T_KO,:M3$6RUIR$MW
MQI1.>/_.&B[H[ <*S2R %DJDTSTR JJ9H-#,6FC-1&#WR<CQ'EAX,)HM<[(9
M#1IXJR4-^1\[97^(%>768P9NU-;MZF+\0[16(IUNF!%0V02%9M9"RR8"NVE6
MP@U,J8#KW+59C>H_SOR#\S/J\-*'B#_&68X2NI1NP=E0<I_OSP/M;P1;%T=J
M'I@0+"TN5U1&SI6!?'_)F'B^4:=TJE-9L_\ 4$L#!!0    ( ,@]05;IY._A
M^ (  *4(   :    >&PO=V]R:W-H965T<R]S:&5E=#$Q-"YX;6RM5MM.VT 0
M_965BRHJ ;[D1FABJ22JV@<D!*5]J/JPL2?QBK4W[$X2^/O.KHUQ@A.HU)=D
M+W/&YYP9[WJT4?K>9 #('G-9F+&7(2XO?-\D&>3<G*DE%+0S5SKG2%.]\,U2
M T\=*)=^% 1]/^>B\.*16[O6\4BM4(H"KC4SJSSG^ND2I-J,O=![7K@1BPSM
M@A^/EGP!MX!WRVM-,[_.DHH<"B-4P33,Q]Z7\&(RL/$NX*> C6F,F54R4^K>
M3KZG8R^PA$!"@C8#I[\U3$!*FXAH/%0YO?J1%M@</V?_ZK23EADW,%'RET@Q
M&WOG'DMASE<2;]3F&U1Z>C9?HJ1QOVQ3Q08>2U8&55Z!B4$NBO*?/U8^- !A
M=P\@J@#1>P&="M!Q0DMF3M:4(X]'6FV8MM&4S0Z<-PY-:D1AJWB+FG8%X3"^
MXOH>D,\D, /)2@L48$Y8HO)<I=4$J6QDS5(9@31-08LUM^ZSN2AXD0@NF2@,
MZA65%PWC1<H2;K*7 3RL""+=[O&4GB>D^<1.V=WME!T??6)'A&=70DJJK!GY
M2,(L/3^I1%R6(J(](J:0G+%.>,*B((I:X)/WP\-MN$]VUIY&M:>1R]?9ET^8
M1"JSTL#4G(K5XG#3X-K:IK.M?O[F,UJESO_3YE%)JMM.RIX&%V;)$QA[]+H;
MT&OPXH\?PG[PN<VQ_Y1LR[].[5_G4/9X\N)-F\X2W'=@>TBMXS"DLJV;] _'
M;+'JUJRZ!UE-88:-"K8Q*Q/T&D\=[O!Z'1$-NGN(]6IBO8/$?C1?3]<L)E,:
M3Q%T3GVT!H-E'VT$9DQIL:"W5E)?HI7RQ')%C8H9+]@P8"E_:I76>T4\#(/S
M77DM4=&PWVO7UZ_U]=\P_O!YTT:W_]KGH+M#]G5,&.RA.JBI#@Z70J%S]A_/
M5%>TMX[5-IF#EC;OAIT=H2U1O:$]*+>D^HU+Q%[@=#-0HQ@F84ZXX&Q 3NGR
M4BPGJ);N7IDII%O*#3/ZC@!M VA_KA0^3^Q557^9Q'\!4$L#!!0    ( ,@]
M059%>;*) P,  .0)   :    >&PO=V]R:W-H965T<R]S:&5E=#$Q-2YX;6RM
M5FUOVC 0_BM65DV=U#4O)% ZB+02INU#I:I=MP_3/ICD(%:=.+4=:/_]SDF:
M\1(0E> #^.)[GMP]=YP]6@GYI%( 35XRGJNQE6I=7-NVBE/(J+H4!>2X,Q<R
MHQI-N;!5(8$F%2CCMN<X?3NC++?"4?7L3H8C46K.<KB31)591N7K#7"Q&ENN
M]?;@GBU2;1[8X:B@"W@ _5C<2;3LEB5A&>2*B9Q(F(^MK^[U-##^E<,O!BNU
MMB8FDYD03\;XD8PMQP0$'&)M&"C^+&$"G!LB#..YX;3:5QK@^OJ-_5N5.^8R
MHPHF@O]FB4['UI5%$IC3DNM[L?H.33Y5@+'@JOHFJ\;7L4A<*BVR!HP19"RO
M?^E+H\,:P/7W +P&X!T+Z#6 WK$ OP'XQP*"!E"E;M>Y5\)%5--P),6*2..-
M;&91J5^A42^6FSYYT!)W&>)T>$OE$V@ZXT 4Q*5DFH&Z(+'(,I$TAL;&0/$+
MH9A&,P')EM34E\Q93O.844Y8KK0LL8&T(C1/2$Q5^G\!SR5">+5['N'[&%?$
M_40^D\>'B)R??2)GR$!N&>?8/6ID:TS-!&C'31HW=1K>GC0BB"])S[T@GN-Y
M'?#)\7"W QX=#W<ZX-.CX>YP$VYC.=N:>FU-O8JOMX=OLE?[/W2&9<(_Y]\N
MB6M6OYO5#*QK5= 8QA9.) 5R"5;X\8/;=[YT"7Y*LNB49-,3D6V4IM>6IG>(
M/9R44F(E<#[&HL2*=)6A9NA7#&;,+T/O:C 8V<MU>7>=>KUA?],I.AC+>V4[
M$=F&;'XKFW]0MI_K$ZAJ;94*J8D&F>'@6(+2]>A9,9T2(=D"!Q/'.:G-1'LE
M')0B.J4Y&3HDH:^=NM<A!&N2^GW?V=)]UVGHN.Z6[@>3>:_N)R+;T#UH=0\.
MZRXTRKAWEG>I&.PTYB!PM[MWU\GU?&?+*]KU&O:#JTVG:0<5?KS6J\[;7CLA
MS?T'CSUL$86-,4><<SE &EG?*6I#BZ(Z-&="XQ%<+5.\AH$T#K@_%T*_&>8<
M;B]VX3]02P,$%     @ R#U!5G]J+U[0 @  <@@  !H   !X;"]W;W)K<VAE
M971S+W-H965T,3$V+GAM;*U66V^;,!3^*Q:KID[:RCVD78+4)IJVAVI1KP_3
M'APX"58-9O;)I?]^-E"6"T7=M!>PS?F^\WVVC\UH(^23R@"0;'->J+&5(987
MMJV2#'*JSD0)A?ZR$#*GJ+MR::M2 DTK4,YMSW$&=DY98<6C:FPFXY%8(6<%
MS"11JSRG\OD*N-B,+==Z&;AARPS-@!V/2KJ$6\#[<B9USVY94I9#H9@HB(3%
MV+IT+R9#$U\%/##8J)TV,4[F0CR9SK=T;#E&$'!(T#!0_5K#!#@W1%K&KX;3
M:E,:X&[[A?U+Y5U[F5,%$\$?68K9V!I:)(4%77&\$9NOT/@)#5\BN*J>9%/'
MAJ%%DI5"D3=@K2!G1?VFVV8>=@!N\ K :P#>6P%^ _ KH[6RRM:4(HU'4FR(
M--&:S32JN:G0V@TKS"K>HM1?F<9A_!TSD#J1E% @H4H!*G(Z!:2,JP_D$[F_
MG9+3DP_DA+""7#/.]>2KD8TZMV&PDR;/59W'>R7/%)(SXKL?B>=X7@=\\G:X
MNP^WM>/6MM?:]BH^_V]L_Z!SA5)OK)]=_FK"H)O0%-N%*FD"8TM7DP*Y!BM^
M_\X=.)^[W/XGLCWO?NO=[V./'R[OR TDP-9TSJ'+:HT?5'AS#*SCT#D?V>M=
M!\<QP3!J8_:$!:VPH%?8(\,L$SQEQ9(@W>I#(A%KD*^IK,G"/94'(CM"AMT:
MPU9CV*MQ)J&D+"6PU>>H J4K!#,F4U)2B<]=,L,C#>>N>Z#S.,9U':];Z:!5
M.NA5.A$%ZIDT^SO1)<M2/9-8G[U]:S\XDA+X!VI[\_[CYHU:5U&OJ[IP_UA0
MA!;I02%WV8J.5V%G*]2^CF.B<[][$8:MW&&OW#N!E!/1<=ITB1P>U9071(=[
MI2LH< YDVCLW@KF-KZE<LD(1#@L-<\XB[5+6-US=05%6E\1<H+YRJF:F?PI
MF@#]?2$$OG3,O=/^9L2_ 5!+ P04    " #(/4%6OHK3KNT#  !9$@  &@
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M."93^H8PCS%D0%>'FU/$/#C<W'.PF39S,BW]38?\Q3I,I,Z5(/*6A G7&N8
M+LO9("'?QH8GY-_"CL1&I/H_;!*JC_CX1XI\<J:W/!07(T@86JA[,5K]^@N=
M>[]A 3RFL^!(SCK!]9O@^B[OJT]YNA:JB2;$-3?:\"R*LSO"#5F+NSC+BAN
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MZLH 6-$N%A-!<]VMS*F0O8\>QK+#!J8,Y/L%I6([41M4/;O_#U!+ P04
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MS0B_9T : WR_$D(?.V:"\@MI]C]02P,$%     @ R#U!5OOR\R*! P  !PL
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MY1N7I;+8!OGA!CM5T,X OZ^4LH>)VZ#M?1>? 5!+ P04    " #(/4%6LY\
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M[Y.ZOI0R_VWRU_OV_N=V.SF O;L:.X!)6$/"% G3$,SJ/,5+YRF^^$6\(/L
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MN(;%*1:G,9S3(PRY)!&Y)*<7KI;N:V]+-VR6;J@"!Q!_QL^BE:2AE22ME0+
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M>2BZ#JTCK^[/%UJ3M=K](:=/.J-U=W#K4J%EY<#4OBC0WG::VXK9%X5+]V[
MUF7]C*TQ5-L]%%^)[KW:0%]H3=9J&XC<.W=G=)\<[19"B-+#C[Q[CO];0VW*
MD-N4C=M^[]UXK3OX,[;24&W\4'HENO?J"'VA-5FK'2%R[_6=T;U7&U>B-5?1
M\9Y[N'>29([Q/F"QH+D$C,QU7'33U3H3NY.QW8WBJ^)P:<*5XEEQN218]]D,
MT._GG*O7&W->59U/COX#4$L#!!0    ( ,@]05;R@-0B>P,  *82   :
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MG2G0YT><JZ<=LU11+4VE_P%02P,$%     @ R#U!5FS$%:HS P  7@T  !H
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M2Y27^;*C^+RX#X^XTK?KHCG3'T @3(">GW"NGCKFBEU_4B7_ %!+ P04
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MM+:YU=\I((R!?K_A7!T[IK!MOWP6_P%02P,$%     @ R#U!5O:(:7"0 P
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M.3RNLUSJO0(B-WC ET2_'?/O;(43O/Q_^X);[3WT[VTKPK4N60:S %->@SI
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MKL:8X*IJ7:N)D:7K_E;28"_IACML]T%9 _R^D=(\3>P&S3\0\W\!4$L#!!0
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M]^:ERM68K7,J5'Q5T+:<K:@$C)>JG_%22*YR\5]3%$LK [.5ND!=BRV.R>U
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M"R$(N]8;D*9>:+9^5EL_LUK_AVH6FX2RK*Q9?V7!3B(L##(SV"'1EYD%)SA
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M)<N*PPW!">%:0-U?,28/)_H!]>Z9^?]02P,$%     @ R#U!5NA"IMX) P
M40L  !H   !X;"]W;W)K<VAE971S+W-H965T,3,W+GAM;*U6VVZ;0!#]E1&-
MJD1*@P'?FMI(=6C5/$2*8J5]J/JP@;%9!7;=W;6=_GUG 5/;P993\6+V,N<P
MYZQWF-%:JF>=(AIXR3.AQTYJS.+:=76<8L[TE5R@H)V95#DS-%5S5R\4LJ0
MY9GK=SI]-V=<..&H6+M7X4@N3<8%WBO0RSQGZL\$,[D>.YZS67C@\]38!3<<
M+=@<IV@>%_>*9F[-DO <A>92@,+9V/GL74=#&U\$?.>XUEMCL$J>I'RVD]MD
M['1L0IAA;"P#H\<*;S#++!&E\;OB=.I76N#V>,/^M=!.6IZ8QAN9_>")2<?.
MT($$9VR9F0>Y_H:5GI[EBV6FBU]85[$=!^*E-C*OP)1!SD7Y9"^5#UL KW\
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M4)_OZKH]O>DZ.#^GM?X_4$L#!!0    ( ,@]059%+VN): (  *$%   :
M>&PO=V]R:W-H965T<R]S:&5E=#$T,2YX;6RE5%%OTS 0_BNG,*%-@B5-UPV-
M--*Z@N!A:%HU>$ \>,FEL>;8P;ZTX]]S=MI08.T#O"2^\]UWW_GT7;8V]M'5
MB 1/C=)N&M5$[64<NZ+&1KA3TZ+FF\K81A";=AF[UJ(H0U*CXC1)SN-&2!WE
M6?#=VCPS'2FI\=:"ZYI&V!\S5&8]C4;1UG$GES5Y1YQGK5CB NF^O;5LQ0-*
M*1O43AH-%JMI=#6ZG$U\? CX+''M=L[@.WDPYM$;'\MIE'A"J+ @CR#XM\)K
M5,H#,8WO&\QH*.D3=\];]/>A=^[E03B\-NJ++*F>1F\B*+$2G:([L_Z FWX"
MP<(H%[ZP[F,O)A$4G2/3;)*902-U_Q=/FW?824C3/0GI)B$-O/M"@>5<D,@S
M:]9@?32C^4-H-60S.:G]4!9D^59R'N5S)"&5 S) -4)AM#-*EH*PA$*X&BH>
M&SAB!X^"'!QO,RY.X BDAANI%+^ORV)B/AXU+C:U9WWM=$_M40HW1E/MX)TN
ML?P=(.9&AF[2;3>S]"#B'(M3&(]>09JD"=POYG!\='( =SR\TCC@CO?@+K;]
MPU=_!9(M]^VYCGN<L^=QO,(N72L*G$8L(8=VA5'^\L7H/'E[@.79P/+L$'K^
MB34\S,Q!YWB&/""I5^A(ZF4O 4D2'536-%!*QP/GJXXC6>=6T+Y)]I7/0V4O
M]%7^>I1>9/'J&;Z3@>_D7_A64@M=_"??R=]\)\D?=.,=V31HEV$Y.-9 IZE7
MT. =]L]5+[M?X?WRNA%V*;4#A16G)J=>[K9?"+U!I@TB?##$D@['FG<H6A_
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M@^D )'B#"BJ_LL-ON"8TT?EB1D7Y%QQJK#< <2$D2^M@-8.49-5_]%P+<1(
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M$%4!7)0!A(\$, CA6DF;&O@@8XRW 0)B4U,*-Y0NPKV(,XQZ,!QT(>R'84M
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MKJB= 7U?*&4W+VZ"^C8\_0=02P,$%     @ R#U!5@+V4N(("@  /TL  !H
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MPZJC7;5]J/K@@4MBK<'4=I*9OZ]M" DL,+,1G8<)AGO.]3DV]L7+(Q=?Y0Y
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MP.JN4;YJ2JV:M20LW#YBX489JRFUZM<%)621,T 6L4*67X<LM[53HY>01<X
M6<0*6?4_?=W.3DU>0A9I%[*(G9[J!<O>#%_9"Q8I(8NX(>N&*1 )-5^1HBC9
MZ-)EOMVS.VT4MII2J^8N88NT#UND4=AJ2JTZ("5LD3/ %K'!5GUEMX%:I$0M
M<@;4(E;4JD.FV]FIR4O4(NVB%K$R%+ZLI[0WZQ^I7"5J$3=J3:E<(IJ$B*LE
MB#>+5Z/DU91:-7I)7J1]\B*-DE=3:M6=D9*\@C.05V CK]KB=OLZ-7>)7<$9
ML"NP8M>KK_7<UDZ-7G)7T"YW!5:@\NM_#K_9++/?/=A8C4$/O]EOEFC.UXG*
M=AR+L\6>]DVZDUL[?XNOI]G.="F3;93?ZUF-]/PQ6&A)OS/4[TV1[3UG!XJO
MTNW;&5>*Q^G')= 0A&F@KR\X5_L#<X/B/P F_P)02P,$%     @ R#U!5DYA
M-;ZO!   5B   !H   !X;"]W;W)K<VAE971S+W-H965T,34Q+GAM;+6:VV[C
M-A"&7X50%T4";".1E$^I;:!)>@*ZVV"#;2^*7M#V.!96$E62MA.@#U]*5D2E
MD5B9E6X2Z\#ASYG?^C)4YD<NOL@=@$)/29S*A;=3*KOV?;G>0<+D%<\@U5>V
M7"1,Z4/QZ,M, -L4@Y+8)T$P]A,6I=YR7IR[%\LYWZLX2N%>(+E/$B:>;R#F
MQX6'O9<3GZ+'G<I/^,MYQA[A =3G[%[H([^*LHD22&7$4R1@N_"^P]<W(<T'
M%'?\%L%1UCZC?"DKSK_D!S]O%EZ0*X(8UBH/P?2O ]Q"'.>1M(Z_RJ!>-6<^
ML/[Y)?H/Q>+U8E9,PBV/?X\V:K?PIA[:P);M8_6)'W^"<D&C/-Z:Q[+XB8[E
MO8&'UGNI>%(.U@J2*#W]9D]E(FH#"&D90,H!I-!]FJA0><<46\X%/R*1WZVC
MY1^*I1:CM;@HS:ORH(2^&NEQ:GG/I?H&DBSFSSK7"JT@A6VD)-(%1Z?S !)=
MW(%B42S1]!*]0U&*/D1QK+,JY[[2*O)8_KJ<\>8T(VF9\0[65XCB]X@$A*#/
M#W?HXMWEZS"^7D2U$E*MA!1QP[:5E%;)8M8LRSH\=_^US-@:%IZVMP1Q &_Y
M]5=X''QK$4<K<;2(3EO$?>0')E0DT8^"[S.TYJD2T6JOVE)(!] :5EI#:R)O
MZ^+>HQ2>%-I&<LUB] Q,H N0*M+?!]A<-DD_!1\7P?-GPF%)9Y.Y?VA0-*H4
MC;J7%OV-/G*%8BU (+5C*>(IG)3]D4"R O%GDRSK#(X9'5?ZQ];J?_^4Z8<0
M;-!VK_8"7KYD*&/%EZ[1 >,!]$XJO1-KOO]#;Y/<4\!1K>J8C*?-99]6,J9G
ME?V7AI*S=(/2UW901UY<DU8_6*=VS.^L6MBL=S_,!M"+ T.)H&]'E!%?62(,
M<;,E<(U7V-44IO!-KM@)@ Z^L$_OFF@#,4QZMP8>@FS8H U;:>3D#?K6&YBT
M/"ZP 1>VD\OFC5KY&]RQY7O1Q1S6^5TS;3"(1_V;8PCP84,^; 65DSG&#>;
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M2?%Q!VP#(K]!7]]RKEX.\G?1U;\2+/\!4$L#!!0    ( ,@]059U2A!B^@(
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MMW)L5-@8J[!P-<U=R?E^-_?Z<#;8U9.QVV@QCJH81]88/^5SJ[A3>$>H6"L
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M.]NGPA*;*\O_?AYHBL2^Z>A D^Y7U<S4%G@J-[&YWKS,0OO%H]\_#_J@<:/
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M!IJ , /T^27GZKEA'-1[L?-_ 5!+ P04    " #(/4%6N#1?MJH#  "-$P
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M;!:-([*$%=](]T7O_H**T,#[2[6TY2_956N3B*0;ZW1>&2."7*C]/_]9)>+
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MG,[+RPPX(O8+<'ZEM7L<^".<^@1N_A]02P,$%     @ R#U!5AEL9*T:!P
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M$NHW9G+-0/1[(A;Z*(*<SG52=#'4$A3;&>/MA>*K:DQWQI7B1?5R28F^0Y@
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MSV!A.:8B%C)?&P@*'WNV8F%HD*".'SFH53S3)%:_/Z-_RL@#F0>JV$J$__!
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MY>"Z>G!9*V&DH[F0BO]'3:DNGP;4[$&RL9/E\Q1WIHO'!J5^+29;+2;[:G%
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M6)9;J#]75(F[J=(KTMA#AW6?W+M/0TA$7-$U'D BXJAD"PO-C( B6QQ+(N*
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M5M]QJ&ZTV)3?';@56HN\O$P939@T&>#WE1#Z\<94L/N:QL7_ 5!+ P04
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M XI0)I&/S]$K/0?=4<9TG9R[2M,QH&Y0O/HZ?S5^YM4^1G<\49%$;Y(0PB:
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MV <D!&+[@/;!)-?&(HF#[5#X]SL[:9IV:053)KXT?KE[?,_Y[GH>+[AXE#&
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M6UJNL]S*<FO+;2RWM=S.<GO+'2R78 ]W0' (!)= < H$MT!P# 370' .!/=
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M+-=8;FFYUG(KRW66ZRVWMMS&<EO+[2RWM]S!<D?+9>RUOV+O40^'0' )!*=
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MSH'@'@@.@N B"$Z"X"8(CH+@*@C.@N NB N#LRWX^F0+#MZ9_Z(+@,/RT 7
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M' /!-1"< \$]$!P$P440G 3!31 <!<%5$)P%P5T0%P9GB^_IR>(;O"K_R0N
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MWG)KRVTLM[7<SG)[RQTL=[1<QE[_*_8?]7 (!)= < H$MT!P# 370' .!/=
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M6*ZQW-)RK>56ENLLUUMN;;F-Y;:6VUEN;[F#Y8Z6R]C3?L6XH]X-]G )!*=
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MVG(+RS666UJNM=S*<IWE>LNM+;>QW-9R.\OM+7>PW-%R&<N$*X8B]7 (!)=
M< H$MT!P# 370' .!/= <! $%T%P$@0W07 4!%=!<!8$=T%<&)P-Q5<G0_'#
M*?JO<?SO&;IR?S\*)7=KN8GEII8K+%=:KK+<S')SR]666UBNL=S2<JWE5I;K
M+-=;;FVYC>6VEMM9;F^Y@^6.EDNPASL@. 2"2R X!8);(#@&@FL@. >">R X
M"(*+(#@)@IL@. J"JR X"X*[("X,SD;AZY-1.'AS_K./_PTK'_^N\>')-RA<
M/ODD-['<U'*%Y4K+59:;66YNN=IR"\LUEEM:KK7<RG*=Y7K+K2VWL=S6<CO+
M[2UWL-S1<AE[\*^8?-3#(1!< L$I$-P"P3$07 /!.1#< \%!$%P$P4D0W 3!
M41!<!<%9$-P%<6%P-OG>G$R^P8OR7WKW;QC_ZV^9/KP"T;'[^Q4HN8GEII8K
M+%=:KK+<S')SR]666UBNL=S2<JWE5I;K+-=;;FVYC>6VEMM9;F^Y@^6.ELM8
M URQ JF'0R"X!()3(+@%@F,@N :"<R"X!X*#(+@(@I,@N F"HR"X"H*S(+@+
MXL+@XQ7X_/%?*_#YX'WY+[G\-R(/7?X;_M*+]Q_E)I:;6JZP7&FYRG(SR\TM
M5UMN8;G&<DO+M99;6:ZS7&^YM>4VEMM:;F>YO>4.ECM:+F.O_^7[SWHX!()+
M(#@%@EL@. :":R X!X)[(#@(@HL@. F"FR X"H*K(#@+@KL@+@S.]M^3D_TW
M>%O^@LM_P]"%?_2;>^[T\M_3EP^<_:,?.['<U'*%Y4K+59:;66YNN=IR"\LU
MEEM:KK7<RG*=Y7K+K2VWL=S6<CO+[2UWL-S1<AE[V:_8=M2[P1XN@> 4"&Z!
MX!@(KH'@' CN@> @""Z"X"0(;H+@* BN@N L".Z"N# XVW9/3[;=X-UX<?;O
M[A.&CT ,?QN7_S9/<A/+32U76*ZT7&6YF>7FEJLMM[!<8[FEY5K+K2S76:ZW
MW-IR&\MM+;>SW-YR!\L=+9>Q]_Z*Q4<]' +!)1"< L$M$!P#P340G /!/1 <
M!,%%$)P$P4T0' 7!51"<!<%=$!<&9XOOV<GB&SPE+\[^W7W"R.)#%^WO%Y_D
M)I:;6JZP7&FYRG(SR\TM5UMN8;G&<DO+M99;6:ZS7&^YM>4VEMM:;F>YO>4.
MECM:+F/O_16+CWHX!()+(#@%@EL@. :":R X!X)[(#@(@HL@. F"FR X"H*K
M(#@+@KL@+@S.%M_SD\7W?'#Q?>KL7_/S/]_^/@1_>?1_E>]^^.'M+__WH_Z;
M?'/S3?7-WQXMWOWZ]L>?W__CNY]_^?Z7_YU?OWOWTR_#QP"'OXD+?VPWEKNU
MW,1R4\L5EBLM5UEN9KFYY6K++2S76&YIN=9R*\MUENLMM[;<QG);R^TLM[?<
MP7)'RV4L'JZ8C]3#(1!< L$I$-P"P3$07 /!.1#< \%!$%P$P4D0W 3!41!<
M!<%9$-P%<6%P-A]?G,S'#W?IO\8QP.?HY/W]*)3<K>4FEIM:KK!<:;G*<C/+
MS2U76VYAN<9R2\NUEEM9KK-<;[FUY3:6VUIN9[F]Y0Z6.UHNP1[N@. 0""Z!
MX!0(;H'@& BN@> <".Z!X" (+H+@) AN@N H"*Z"X"P([H*X,#@;A2]/1N'@
M#?K//08XIGSR-Y /S[]![?+Y)[F)Y::6*RQ76JZRW,QR<\O5EEM8KK'<TG*M
MY5:6ZRS76VYMN8WEMI;;66YON8/ECI;+V.-_Q?RC'@Z!X!((3H'@%@B.@> :
M",Z!X!X(#H+@(@A.@N F"(Z"X"H(SH+@+H@+@[/Y]^ID_@U>F__"PX C^$=_
M]_31_W[TX6^?/KP(!Z7+%Z'D)I:;6JZP7&FYRG(SR\TM5UMN8;G&<DO+M99;
M6:ZS7&^YM>4VEMM:;F>YO>4.ECM:+F,]<,4BI!X.@> 2"$Z!X!8(CH'@&@C.
M@> >" Z"X"((3H+@)@B.@N J",Z"X"Z("X.S1?CZ9!$.'J/_HB.!PW+Q_MV[
MO[][>/X-?N7E\T]R$\M-+5=8KK1<9;F9Y>:6JRVWL%QCN:7E6LNM+-=9KK?<
MVG(;RVTMM[/<WG('RQTME[''_XKY1ST< L$E$)P"P2T0' /!-1"< \$]$!P$
MP440G 3!31 <!<%5$)P%P5T0%P9G\^_-R?P;O$)_R8U =,[^?@)^X#ZZ$?CL
MV9O'CQ^Z$R@_>F*YJ>4*RY66JRPWL]S<<K7E%I9K++>T7&NYE>4ZR_666UMN
M8[FMY7:6VUON8+FCY3+VNE^Q[ZAW@SU< L$I$-P"P3$07 /!.1#< \%!$%P$
MP4D0W 3!41!<!<%9$-P%<6'P\;Y[\?BO??=B\,J\N!-X]PG#5R.&OXV+?Z-'
MN8GEII8K+%=:KK+<S')SR]666UBNL=S2<JWE5I;K+-=;;FVYC>6VEMM9;F^Y
M@^6.ELO8>W_YXK,>#H'@$@A.@> 6"(Z!X!H(SH'@'@@.@N B"$Z"X"8(CH+@
M*@C.@N NB N#L\7WY&3Q#=Z>%W<"[SYA9/$-?AN7+S[)32PWM5QAN=)RE>5F
MEIM;KK;<PG*-Y9:6:RVWLEQGN=YR:\MM++>UW,YR>\L=+'>T7,;>^RL6'_5P
M" 270' *!+= < P$UT!P#@3W0' 0!!=!<!($-T%P% 1707 6!'=!7!B<+;ZG
M)XMO\/;\^)W \K>?_O/WK?>H?/?VAU^_^_O;]^\>U=__^/VO[[[]_?]_^Q_?
M__#]K__]Z.;G'__Q]J?__MNC?__MV[?_^.-7@X-G X>_IPM_BC>6N[7<Q')3
MRQ66*RU766YFN;GE:LLM+-=8;FFYUG(KRW66ZRVWMMS&<EO+[2RWM]S!<D?+
M9:PEKEB3U,,A$%P"P2D0W +!,1!< \$Y$-P#P4$07 3!21#<!,%1$%P%P5D0
MW 5Q87"V)I^=K,D/=^V_QMG .YJ-0LG=6FYBN:GE"LN5EJLL-[/<W'*UY1:6
M:RRWM%QKN97E.LOUEEM;;F.YK>5VEMM;[F"YH^42[.$." Z!X!((3H'@%@B.
M@> :",Z!X!X(#H+@(@A.@N F"(Z"X"H(SH+@+H@+@[-1^/QD%#X?_!7C9YX-
M'%,N^H7D_[K[C>3#TW#PDRZ?AI*;6&YJN<)RI>4JR\TL-[=<;;F%Y1K++2W7
M6FYEN<YRO>76EMM8;FNYG>7VECM8[FBYC(7!%=.0>C@$@DL@. 6"6R X!H)K
M(#@'@GL@. B"BR X"8*;(#@*@JL@. N"NR N#,ZFX8N3:3AXL_X+3PJ.X/=_
M%_7A#3CXM9=O0,E-+#>U7&&YTG*5Y6:6FUNNMMS"<HWEEI9K+;>R7&>YWG)K
MRVTLM[7<SG)[RQTL=[1<Q@K@B@U(/1P"P240G +!+1 < \$U$)P#P3T0' 3!
M11"<!,%-$!P%P540G 7!71 7!F<;\.7)!AP\7/\E1P1'Y+O?%#Z\_P:_]/+]
M)[F)Y::6*RQ76JZRW,QR<\O5EEM8KK'<TG*MY5:6ZRS76VYMN8WEMI;;66YO
MN8/ECI;+V.M_Q?ZC'@Z!X!((3H'@%@B.@> :",Z!X!X(#H+@(@A.@N F"(Z"
MX"H(SH+@+H@+@[/]]^ID_PV>J7_XBN"C__?1]*%?W/W[B';AG__&<K>6FUAN
M:KG"<J7E*LO-+#>W7&VYA>4:RRTMUUIN9;G.<OT]]_2#]^&?9W[Q_,4W+S_^
M)YK7]G,WEMM:;F>YO>4.ECM:+F/O^Q4+CWKXB0]^XX,?^>!7/OB9#W[G@Q_Z
MX)<^^*D/?NN#'_O@US[XN0]^[X,?_. 7/SWSSA;>ZY.%-WB)GMP1_/ )(U<E
M!K^-R[><Y":6FUJNL%QIN<IR,\O-+5=;;F&YQG)+R[666UFNLUQON;7E-I;;
M6FYGN;WE#I8[6BYC[_T5BX]Z. 2"2R X!8);(#@&@FL@. >">R X"(*+(#@)
M@IL@. J"JR X"X*[("X,SA;?FY/%-WB;GMP1?/,YBV_PV[A\\4EN8KFIY0K+
ME9:K+#>SW-QRM>46EFLLM[1<:[F5Y3K+]99;6VYCN:WE=I;;6^Y@N:/E,O;>
M7['XJ(=#(+@$@E,@N 6"8R"X!H)S(+@'@H,@N B"DR"X"8*C(+@*@K,@N OB
MPN#CQ??R\5^+[^7@;?I/WA'LW_[T[<__\Z]_M/.+3P<.?QL7_N!N+'=KN8GE
MII8K+%=:KK+<S')SR]666UBNL=S2<JWE5I;K+-=;;FVYC>6VEMM9;F^Y@^6.
MELM8/EP^(*V'0R"X!()3(+@%@F,@N :"<R"X!X*#(+@(@I,@N F"HR"X"H*S
M(+@+XL+@;$ ^.1F0'T[=?XW3@7<T&X62N[7<Q')3RQ66*RU766YFN;GE:LLM
M+-=8;FFYUG(KRW66ZRVWMMS&<EO+[2RWM]S!<D?+)=C#'1 < L$E$)P"P2T0
M' /!-1"< \$]$!P$P440G 3!31 <!<%5$)P%P5T0%P9GH_#IR2@<O%C_N:<#
M1Y3/_1WDPV-PT+Y\#$IN8KFIY0K+E9:K+#>SW-QRM>46EFLLM[1<:[F5Y3K+
M]99;6VYCN:WE=I;;6^Y@N:/E,I8"5XQ!ZN$0""Z!X!0(;H'@& BN@> <".Z!
MX" (+H+@) AN@N H"*Z"X"P([H*X,#@;@\].QN#@I?HO/!8X@@\>"QS^VLLW
MH.0FEIM:KK!<:;G*<C/+S2U76VYAN<9R2\NUEEM9KK-<;[FUY3:6VUIN9[F]
MY0Z6.UHN8P5PQ0:D'@Z!X!((3H'@%@B.@> :",Z!X!X(#H+@(@A.@N F"(Z"
MX"H(SH+@+H@+@[,-^/QD SX?G&E?<"QP1!XZ%CC\I9?O/\E-+#>U7&&YTG*5
MY6:6FUNNMMS"<HWEEI9K+;>R7&>YWG)KRVTLM[7<SG)[RQTL=[1<QE[_*_8?
M]7 (!)= < H$MT!P# 370' .!/= <! $%T%P$@0W07 4!%=!<!8$=T%<&)SM
MOQ<G^V_P'/VEQP*'M0O__#>6N[7<Q')3RQ66*RU766YFN;GE:LLM+-=8;FFY
MUG(KRW66Z^^YIR_^]#[\&\RO7S\[/Q5(/W5CN:WE=I;;6^Y@N:/E,O:Z7['O
MJ(<?^. 7/OB)#W[C@Q_YX%<^^)D/?N>#'_K@ES[XJ0]^ZX,?^^#7/OBY#W[O
MTS/O;-^]/-EW@^?FQ:G NT\8/APQ_&U<ON0D-['<U'*%Y4K+59:;66YNN=IR
M"\LUEEM:KK7<RG*=Y7K+K2VWL=S6<CO+[2UWL-S1<AE[[Z]8?-3#(1!< L$I
M$-P"P3$07 /!.1#< \%!$%P$P4D0W 3!41!<!<%9$-P%<6%PMOA>G2R^P?/S
MXE3@W2>,++[!;^/RQ2>YB>6FEBLL5UJNLMS,<G/+U99;6*ZQW-)RK>56ENLL
MUUMN;;F-Y;:6VUEN;[F#Y8Z6R]A[?\7BHQX.@> 2"$Z!X!8(CH'@&@C.@> >
M" Z"X"((3H+@)@B.@N J",Z"X"Z("X.SQ??Z9/$-GI__Y*G YN=_OOU]"/[R
MJ/KI]__K_3_3^;='B]]^_(^WWX^<!407[^_'HN1N+3>QW-1RA>5*RU66FUEN
M;KG:<@O+-99;6JZUW,IRG>5ZRZTMM['<UG([R^TM=[#<T7(92X4KQB+U< @$
MET!P"@2W0' ,!-= < X$]T!P$ 0707 2!#=!<!0$5T%P%@1W05P8G(W%-R=C
M\</E^J]R%O"-'862N[7<Q')3RQ66*RU766YFN;GE:LLM+-=8;FFYUG(KRW66
MZRVWMMS&<EO+[2RWM]S!<D?+)=C#'1 < L$E$)P"P2T0' /!-1"< \$]$!P$
MP440G 3!31 <!<%5$)P%P5T0%P8?C\)7C_\:A:\&K]%_[EG ,>7!WS<^./V&
MI8NG'^4FEIM:KK!<:;G*<C/+S2U76VYAN<9R2\NUEEM9KK-<;[FUY3:6VUIN
M9[F]Y0Z6.UHN8P__Y=//>C@$@DL@. 6"6R X!H)K(#@'@GL@. B"BR X"8*;
M(#@*@JL@. N"NR N#,ZFWY.3Z3=X<_X+CP".X!_^ING#"W#P*R]?@)*;6&YJ
MN<)RI>4JR\TL-[=<;;F%Y1K++2W76FYEN<YRO>76EMM8;FNYG>7VECM8[FBY
MC+W_5RQ ZN$0""Z!X!0(;H'@& BN@> <".Z!X" (+H+@) AN@N H"*Z"X"P(
M[H*X,#A;@$]/%N#@H?DO.0$X(O_Y>\"'U]_@%UZ^_B0WL=S4<H7E2LM5EIM9
M;FZYVG(+RS666UJNM=S*<IWE>LNM+;>QW-9R.\OM+7>PW-%R&7O[KUA_U,,A
M$%P"P2D0W +!,1!< \$Y$-P#P4$07 3!21#<!,%1$%P%P5D0W 5Q87"V_IZ=
MK+_!$_.?/ #X?_X?KY\]_%W_^PAYX0_AQG*WEIM8;FJYPG*EY2K+S2PWMUQM
MN87E&LLM+==:;F6YSG*]Y=;WW-.7?WIW_UKSTV??O/CX7VS>V,_=6FYGN;WE
M#I8[6BYCC_P5,X]Z^(D/?N.#'_G@5S[XF0]^YX,?^N"7/OBI#W[K@Q_[X-<^
M^+D/?N^#'_S@%S_NR3^;><]/9M[SP9D'[@#>?<*3IR>=\?B;5X]?OCX_#3'\
MO5P^Z"0WL=S4<H7E2LM5EIM9;FZYVG(+RS666UJNM=S*<IWE>LNM+;>QW-9R
M.\OM+7>PW-%R&7OTKYA]U,,A$%P"P2D0W +!,1!< \$Y$-P#P4$07 3!21#<
M!,%1$%P%P5D0W 5Q87 V^UZ<S+[! _/B&.#=)WS.[$/'[N]GG^0FEIM:KK!<
M:;G*<C/+S2U76VYAN<9R2\NUEEM9KK-<;[FUY3:6VUIN9[F]Y0Z6.UHN8X_^
M%;./>C@$@DL@. 6"6R X!H)K(#@'@GL@. B"BR X"8*;(#@*@JL@. N"NR N
M#,YFW\N3V3=X97[\(F#Y[NT/OW[W][?OWSUJWW__S[>_OKOL/.#PYU_X$[NQ
MW*WE)I:;6JZP7&FYRG(SR\TM5UMN8;G&<DO+M99;6:ZS7&^YM>4VEMM:;F>Y
MO>4.ECM:+F/=<,5RI!X.@> 2"$Z!X!8(CH'@&@C.@> >" Z"X"((3H+@)@B.
M@N J",Z"X"Z("X.SY?CJ9#E^N%;_-<X#WM%L%$KNUG(3RTTM5UBNM%QEN9GE
MYI:K+;>P7&.YI>5:RZTLUUFNM]S:<AO+;2VWL]S><@?+'2V78 ]W0' (!)=
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M,1!< \$Y$-P#P4$07 3!21#<!,%1$%P%P5D0W 5Q87 V%E^<C,4/Q^J_QD'
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M6UFNM=S:<AO+=9;;6FYGN;WE#I;+T,M^P;:CW@WV< D$IT!P"P3'0' -!.=
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MI>4JR]666UBNL=S2<BO+M99;6VYCN<YR6\OM++>WW,%R"?9P!P2'0' )!*=
M< L$QT!P#03G0' /! =!<!$$)T%P$P1'07 5!&=!<!?$A<')*+P^&H77O;\_
M_,(K@$/*8[]M?'SY]4+G+S_)C2PWMMS$<E/+%9:;66YNN=)RE>5JRRTLUUAN
M:;F5Y5K+K2VWL5QGN:WE=I;;6^Y@N0R]^Q<L/^KA$ @N@> 4"&Z!X!@(KH'@
M' CN@> @""Z"X"0(;H+@* BN@N L".Z"N# X67XOCY9?[X7YKSP#.(!_^'.F
MCP] =/?^80!*;F2YL>4FEIM:KK#<S')SRY66JRQ76VYAN<9R2\NM+-=:;FVY
MC>4ZRVTMM[/<WG('RV7H^;]@ %(/AT!P"02G0' +!,= < T$YT!P#P0'07 1
M!"=!<!,$1T%P%01G07 7Q(7!R0!\=30 >R_-?\T-P &Y^.7N^\>^\&;@"\]?
M?Y(;66YLN8GEII8K+#>SW-QRI>4JR]666UBNL=S2<BO+M99;6VYCN<YR6\OM
M++>WW,%R&7K[+UA_U,,A$%P"P2D0W +!,1!< \$Y$-P#P4$07 3!21#<!,%1
M$%P%P5D0W 5Q87"R_EX?K;_>&_./GP!\?.RA8_4/$_ C]_(#=__WB[YY_O3I
MOYR'NK6?/++<V'(3RTTM5UAN9KFYY4K+59:K+;>P7&.YI>56EFLMM[;<QG*=
MY;:6VUEN;[F#Y3+TN%\P[ZAW@SU< L$I$-P"P3$07 /!.1#< \%!$%P$P4D0
MW 3!41!<!<%9$-P%<6%P,N_>',V[WAORY/;?QT\8N 2!3MD_+#[)C2PWMMS$
M<E/+%9:;66YNN=)RE>5JRRTLUUAN:;F5Y5K+K2VWL5QGN:WE=I;;6^Y@N0R]
M]Q<L/NKA$ @N@> 4"&Z!X!@(KH'@' CN@> @""Z"X"0(;H+@* BN@N L".Z"
MN# X67QOCQ9?[SUY<OOO[9<L/G36_F'Q26YDN;'E)I:;6JZPW,QR<\N5EJLL
M5UMN8;G&<DO+K2S76FYMN8WE.LMM+;>SW-YR!\MEZ+V_8/%1#X= < D$IT!P
M"P3'0' -!.= < \$!T%P$00G07 3!$=!<!4$9T%P%\2%P:>+[_KI;XOONO>>
M_&=O_^6[O]W]\.V[[Z[R[;?OOG_WT]TO/_YTE;_\Y?OWWW[X%_Q^OOK?'_X-
MO?]SU3[YZ<GW3[ZY:G[\QS_>?__]^_[+@/W?SID_P!O+W5IN9+FQY2:6FUJN
ML-S,<G/+E9:K+%=;;F&YQG)+RZTLUUIN;;F-Y3K+;2VWL]S><@?+92@CSA^2
MUL,A$%P"P2D0W +!,1!< \$Y$-P#P4$07 3!21#<!,%1$%P%P5D0W 5Q87 R
M))\=#<F/9^I_C\N ]S0;A9*[M=S(<F/+32PWM5QAN9GEYI8K+5=9KK;<PG*-
MY9:66UFNM=S:<AO+=9;;6FYGN;WE#I9+L(<[(#@$@DL@. 6"6R X!H)K(#@'
M@GL@. B"BR X"8*;(#@*@JL@. N"NR N#$Y&X?.C4=A[D/Y++P,.*.?^+O+Q
M4=C[&>>/0LF-+#>VW,1R4\L5EIM9;FZYTG*5Y6K++2S76&YIN97E6LNM+;>Q
M7&>YK>5VEMM;[F"Y#"7!!:.0>C@$@DL@. 6"6R X!H)K(#@'@GL@. B"BR X
M"8*;(#@*@JL@. N"NR N#$Y&X8NC4=A[D/XKCP8.X?=_"O7Q#=C[M>=O0,F-
M+#>VW,1R4\L5EIM9;FZYTG*5Y6K++2S76&YIN97E6LNM+;>Q7&>YK>5VEMM;
M[F"Y#!7 !1N0>C@$@DL@. 6"6R X!H)K(#@'@GL@. B"BR X"8*;(#@*@JL@
M. N"NR N#$XVX/71!KSNG6E?<3=P0/[\W<#^+SQ__4EN9+FQY2:6FUJNL-S,
M<G/+E9:K+%=;;F&YQG)+RZTLUUIN;;F-Y3K+;2VWL]S><@?+9>CMOV#]40^'
M0' )!*= < L$QT!P#03G0' /! =!<!$$)T%P$P1'07 5!&=!<!?$A<')^GMY
MM/YZ[]*?<3>P'SKS'_WF@?OD;N"SMX]<#:2?.[+<V'(3RTTM5UAN9KFYY4K+
M59:K+;>P7&.YI>56EFLMM[;<QG*=Y;:6VUEN;[F#Y3+TM%\P[JAW@SU< L$I
M$-P"P3$07 /!.1#< \%!$%P$P4D0W 3!41!<!<%9$-P%<6%P,NY>'8V[WK/S
MXFK@_2<\>WZTTYX^>?OV^8O30Q+]W\OYO].3W,AR8\M-+#>U7&&YF>7FEBLM
M5UFNMMS"<HWEEI9;6:ZUW-IR&\MUEMM:;F>YO>4.ELO0HW_![*,>#H'@$@A.
M@> 6"(Z!X!H(SH'@'@@.@N B"$Z"X"8(CH+@*@C.@N NB N#D]GW^FCV]9ZC
M%Z<#[S_A2V9?[_=R_NR3W,AR8\M-+#>U7&&YF>7FEBLM5UFNMMS"<HWEEI9;
M6:ZUW-IR&\MUEMM:;F>YO>4.ELO0HW_![*,>#H'@$@A.@> 6"(Z!X!H(SH'@
M'@@.@N B"$Z"X"8(CH+@*@C.@N NB N#D]GWYFCV]=ZD_^S]P/;NA^]^_,=5
M^^0O3_+DFZO%KTOPC^]_'+@-V/M19_YP;BQW:[F1Y<:6FUAN:KG"<C/+S2U7
M6JZR7&VYA>4:RRTMM[)<:[FUY3:6ZRRWM=S.<GO+'2R7H42X8"12#X= < D$
MIT!P"P3'0' -!.= < \$!T%P$00G07 3!$=!<!4$9T%P%\2%P<E(?'LT$C^>
ML?]=;@.^M:-0<K>6&UEN;+F)Y::6*RPWL]S<<J7E*LO5EEM8KK'<TG(KR[66
M6UMN8[G.<EO+[2RWM]S!<@GV< <$AT!P"02G0' +!,= < T$YT!P#P0'07 1
M!"=!<!,$1T%P%01G07 7Q(7!IZ/PY=/?1N'+WI/T7WH;<$#YY/>,CRZ^?N#L
MQ4>YD>7&EIM8;FJYPG(SR\TM5UJNLEQMN87E&LLM+;>R7&NYM>4VENLLM[7<
MSG)[RQTLEZ'W_OS%9ST< L$E$)P"P2T0' /!-1"< \$]$!P$P440G 3!31 <
M!<%5$)P%P5T0%P8GB^_9T>+KO3?_E8?_!O#[/V'Z^ 3L_=+S)Z#D1I8;6VYB
MN:GE"LO-+#>W7&FYRG*UY1:6:RRWM-S*<JWEUI;;6*ZSW-9R.\OM+7>P7(8"
MX(()2#T< L$E$)P"P2T0' /!-1"< \$]$!P$P440G 3!31 <!<%5$)P%P5T0
M%P8G$_#YT03LO2[_-7?_!N3/W_WK_\+SUY_D1I8;6VYBN:GE"LO-+#>W7&FY
MRG*UY1:6:RRWM-S*<JWEUI;;6*ZSW-9R.\OM+7>P7(;>_@O6'_5P" 270' *
M!+= < P$UT!P#@3W0' 0!!=!<!($-T%P% 1707 6!'=!7!B<K+\71^NO]Z[\
M&7?_^J$S_]%O'KA/[OZ]?OKTD<-_](-'EAM;;F*YJ>4*R\TL-[=<:;G*<K7E
M%I9K++>TW,IRK>76EMM8KK/<UG([R^TM=[!<AM[V"]8=]6ZPATL@. 6"6R X
M!H)K(#@'@GL@. B"BR X"8*;(#@*@JL@. N"NR N#$[6W?71NKON77?@\-_]
M)SQ[=CS43H\_]'\;Y_\^3W(CRXTM-['<U'*%Y6:6FUNNM%QEN=IR"\LUEEM:
M;F6YUG)KRVTLUUEN:[F=Y?:6.U@N0^_]!8N/>C@$@DL@. 6"6R X!H)K(#@'
M@GL@. B"BR X"8*;(#@*@JL@. N"NR N#$X6W\NCQ==[3%[<_+O_A('%AV[:
M/RP^R8TL-[;<Q')3RQ66FUEN;KG2<I7E:LLM+-=8;FFYE>5:RZTMM[%<9[FM
MY7:6VUON8+D,O?<7+#[JX1 (+H'@% AN@> 8"*Z!X!P([H'@( @N@N D"&Z"
MX"@(KH+@+ CN@K@P.%E\KXX67^\=^<^>^ZM__-O=KT/PYZOF3W<__?GN:OYD
M_N2;J_6/__7W@9M__9]WYD_HQG*WEAM9;FRYB>6FEBLL-[/<W'*EY2K+U99;
M6*ZQW-)R*\NUEEM;;F.YSG);R^TLM[?<P7(9ZH0+EB+U< @$ET!P"@2W0' ,
M!-= < X$]T!P$ 0707 2!#=!<!0$5T%P%@1W05P8G"S%UT=+\>/I^=_CYM]+
M=-7^811*[M9R(\N-+3>QW-1RA>5FEIM;KK1<9;G:<@O+-99;6FYEN=9R:\MM
M+-=9;FNYG>7VECM8+L$>[H#@$ @N@> 4"&Z!X!@(KH'@' CN@> @""Z"X"0(
M;H+@* BN@N L".Z"N# X&85OCD9A[ZGY+[[Y-Z \\LO&QX<?.GS_,/PD-[+<
MV'(3RTTM5UAN9KFYY4K+59:K+;>P7&.YI>56EFLMM[;<QG*=Y;:6VUEN;[F#
MY3+T[%\P_*B'0R"X!()3(+@%@F,@N :"<R"X!X*#(+@(@I,@N F"HR"X"H*S
M(+@+XL+@9/B]/1I^O>?DO_;T7S_^X8^9/CX T9'[AP$HN9'EQI:;6&YJN<)R
M,\O-+5=:KK)<;;F%Y1K++2VWLEQKN;7E-I;K++>UW,YR>\L=+)>AY_^" 4@]
M' +!)1"< L$M$!P#P340G /!/1 <!,%%$)P$P4T0' 7!51"<!<%=$!<&GP[
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M+2VWLEQKN;7E-I;K++>UW,YR>\L=+)>A!_Z"B4<]_+X'/_ 980^W0' ,!-=
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MS2U76JZR7&VYA>4:RRTMM[)<:[FUY3:6ZRRWM=S.<GO+'2R7H5RX8#!2#X=
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M$ 0707 2!#=!<!0$5T%P%@1W05P8'&W %P<;L/,:_5EW KO)$W\(5Y:[MMS
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MUG)+RZTLM[;<QG);R^TLM[=<^M[[,Q8?]7 (!)= < H$MT!P# 370' .!/=
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MY>:6JRVWL%QCN=9R2\NM++>VW,9R6\OM++>W7/J>_S,&(/5P" 270' *!+=
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M:RS76FYIN97EUI;;6&YKN9WE]I9+W]-^QKBCWA7V< D$IT!P"P3'0' -!.=
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M< @$ET!P"@2W0/IBX'\=I=W%BZ=/GGYA#=)O#'= < @$ET!P"@2W0' ,!-=
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M/1 <!,%%$)P$P4T0' 7!51"<!<%=$!<&1Z/PWL$H[#Q%_ZTW ?N4[D\>;]Z
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M6JZVW,QRC>7FEEM8KK7<TG(KRZTMM['<UG([R^TME[Y4.&,L4@^'0' )!*=
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M< @$ET!P"@2W0' ,!-= < X$]T!P$ 0707 2!#=!<!0$5T%P%@1W05P8' W
M>P<#L//8_&TN ?;(?9< NU]^^@:4W,!RA>6&EAM9KK3<V'(3RU66FUJNMMS,
M<HWEYI9;6*ZUW-)R*\NM+;>QW-9R.\OM+9>^ CAC U(/AT!P"02G0' +!,=
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M$%P$P4D0W 3!41!<!<%9$-P%<6%P- :?'HS!IYTS[I9?,M.-=WS)3.<+3Q^
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M< @$ET!P"@2W0' ,!-= < X$]T!P$ 0707 2!#=!<!0$5T%P%@1W05P8?#D
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MKK'<W'(+R[666UIN9;FUY3:6VUIN9[F]Y=+WO#]C\5$/AT!P"02G0' +!,=
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M#.>+\;J]&*\[-]V7'&;LH;L.,W:_=,!8E-X(>V/L%=B;8&^*O1GVYM@KL;?
MWA)[*^RML;?!WA9[%?9J[#78VV%OC[T#]H[8.V$OO5DP9"Q24"="="-$1T)T
M)41G0G0G1(="="E$IT)T*T3'0G0M1.="="]$!T-T,00FP_E8?-D>BR\[%]V@
MPXS=YC,_B'OL/6!OA+TQ]@KL3; WQ=X,>W/LE=A;8&^)O17VUMC;8&^+O0I[
M-?8:[.VPM\?> 7M'[)VPE]Y(&#(=*:@3(;H1HB,ANA*B,R&Z$Z)#(;H4HE,A
MNA6B8R'_JH6[3^#/-Q1>??7ZUW<9[8-U!D1W0'0(!); ^2*\:2_"F\Y%*.XR
M/CZBY^Y&]QL9,/ND-\+>&'L%]B;8FV)OAKTY]DKL+;"WQ-X*>VOL;;"WQ5Z%
MO1I[#?9VV-MC[X"](_9.V$MO"0R9?134B1#="-&1$%T)T9D0W0G1H1!="M&I
M$-T*T;$070O1N1#="]'!$%T,@<EPO@]?M??AJV?LPV%W&1\?T;</.]_(@'TH
MO1'VQM@KL#?!WA1[,^S-L5=B;X&])?96V%MC;X.]+?8J[-78:["WP]X>>P?L
M';%WPEYZ2V#(/J2@3H3H1HB.A.A*B,Z$Z$Z(#H7H4HA.A>A6B(Z%Z%J(SH7H
M7H@.ANAB"$R&\WWXNKT/7W?NPZ?N,E9OOOWFNW]>3-^_^?JGOW_SCW<7/[Z]
MJ-]]_>;#VQ\N\E7U^4<9N]_!,S^V>^P]8&^$O3'V"NQ-L#?%W@Q[<^R5V%M@
M;XF]%?;6V-M@;XN]"GLU]AKL[;"WQ]X!>T?LG;"7WJ08,C0IJ!,ANA&B(R&Z
M$J(S(;H3HD,ANA2B4R&Z%:)C(;H6HG,ANA>B@R&Z& *3X7QHWK:'YNVG9_P^
M1QEO\824W@/V1M@;8Z_ W@1[4^S-L#?'7HF]!?:6V%MA;XV]#?:VV*NP5V.O
MP=X.>WOL';!WQ-X)>XD&=2%$)T)T(T1'0G0E1&="="=$AT)T*42G0G0K1,="
M="U$YT)T+T0'0W0Q!";#^82\:T_(N\[O*C_[*&,W\Z^O-O_]WZZN+__XQ/>;
M3RS'3GO <I3>"'MC[!78FV!OBKT9]N;8*[&WP-X2>ROLK;&WP=X6>Q7V:NPU
MV-MA;X^] _:.V#MA+[V-,&0Y4E G0G0C1$="="5$9T)T)T2'0G0I1*="="M$
MQT)T+43G0G0O1 =#=#$$)L/9<KQZT5J.'W_HFGQ?>):Q1^\^R]C]XN<O1NJ-
ML#?&7H&]"?:FV)MA;XZ]$GL+["VQM\+>&GL;[&VQ5V&OQEZ#O1WV]M@[8.^(
MO1/VTML& Q:C!74B1#="="1$5T)T)D1W0G0H1)="="I$MT)T+$370G0N1/="
M=#!$%T-@,IPOQLOV8KSLW'1?<I:QA^XZR]C]T@%C47HC[(VQ5V!O@KTI]F;8
MFV.OQ-X">TOLK;"WQMX&>UOL5=BKL==@;X>]/?8.V#MB[X2]]&;!D+%(09T(
MT8T0'0G1E1"="=&=$!T*T:40G0K1K1 ="]&U$)T+T;T0'0S1Q1"8#.=C\:H]
M%J\Z%]V@LXS=YC,_B'OL/6!OA+TQ]@KL3; WQ=X,>W/LE=A;8&^)O17VUMC;
M8&^+O0I[-?8:[.VPM\?> 7M'[)VPE]Y(&#(=*:@3(;H1HB,ANA*B,R&Z$Z)#
M(;H4HE,ANA6B8R'_JH6;3^#/)Q1N;U_\^BRC?;#.@.@.B Z!P!(X7X37[45X
MW;D(Q5G&QT=<7K7^,_/BJ[N/?_WJ]D;WNQFP_:0WPMX8>P7V)MB;8F^&O3GV
M2NPML+?$W@I[:^QML+?%7H6]&GL-]G;8VV/O@+TC]D[82V\.#-E^%-2)$-T(
MT9$070G1F1#="=&A$%T*T:D0W0K1L1!="]&Y$-T+T<$070R!R7 ^$E^V1^++
M9XS$8;<9'Q_Q62.Q\]T,&(G2&V%OC+T">Q/L3;$WP]X<>R7V%MA;8F^%O37V
M-MC;8J_"7HV]!GL[[.VQ=\#>$7LG[*4W!X:,1 KJ1(ANA.A(B*Z$Z$R([H3H
M4(@NA>A4B&Z%Z%B(KH7H7(CNA>A@B"Z&P&0X'XDW[9%XTSD2>PXT%A_^_K>/
M?_]?[]_]Y:+Y\/=OW[_]\.[3U<;W'U_QY.7&XNU__O/MQ?][,?_NZS=OW[_K
M.>#8_0Z?^;'>8^\!>R/LC;%78&^"O2GV9MB;8Z_$W@)[2^RML+?&W@9[6^Q5
MV*NQUV!OA[T]]@[8.V+OA+WT)L>0(4I!G0C1C1 ="=&5$)T)T9T0'0K1I1"=
M"M&M$!T+T;40G0O1O1 =#-'%$)@,YT/T57N(OOKTC-_E@..C[2:D]!ZP-\+>
M&'L%]B;8FV)OAKTY]DKL+;"WQ-X*>VOL;;"WQ5Z%O1I[#?9VV-MC[X"](_9.
MV$LTJ LA.A&B&R$Z$J(K(3H3HCLA.A2B2R$Z%:);(3H6HFLA.A>B>R$Z&**+
M(3 9SB?DZ_:$?-WY7>;G'G#L87[CJ\]__[>KJQ=__/#Q7VZN_OCI2]#_\\M]
MQXYO0I\8EYV/'S NI3?"WAA[!?8FV)MB;X:].?9*["VPM\3>"GMK[&VPM\5>
MA;T:>PWV=MC;8^^ O2/V3MA+;T8,&9<4U(D0W0C1D1!="=&9$-T)T:$070K1
MJ1#="M&Q$%T+T;D0W0O1P1!=#(')<#XN;]OC\K9S%7[IC<=N_>Q/S#XQ'#N-
M <-1>B/LC;%78&^"O2GV9MB;8Z_$W@)[2^RML+?&W@9[6^Q5V*NQUV!OA[T]
M]@[8.V+OA+WT)L*0X4A!G0C1C1 ="=&5$)T)T9T0'0K1I1"="M&M$!T+T;40
MG0O1O1 =#-'%$)@,Y\/QKCT<[SJGW1>=>NRF.T\]=KYTP%B4W@A[8^P5V)M@
M;XJ]&?;FV"NQM\#>$GLK[*VQM\'>%GL5]FKL-=C;86^/O0/VCM@[82^]63!D
M+%)0)T)T(T1'0G0E1&="="=$AT)T*42G0G0K1,="="U$YT)T+T0'0W0Q!";#
MV5B\?M$:BQ]_Z%IT@TX]=IO/_"#NL?> O1'VQM@KL#?!WA1[,^S-L5=B;X&]
M)?96V%MC;X.]+?8J[-78:["WP]X>>P?L';%WPEYZ(V' =+2@3H3H1HB.A.A*
MB,Z$Z$Z(#H7H4HA.A>A6B(Z%M&KAYW^0RL\G&>Y>_?K4HWVPSH#H#H@.@< 2
M.%^$E^U%>-FY",6IQ\='7%ZV_B-S^:L#'MUO9,#LD]X(>V/L%=B;8&^*O1GV
MYM@KL;? WA)[*^RML;?!WA9[%?9J[#78VV%OC[T#]H[8.V$OO24P9/914"="
M="-$1T)T)41G0G0G1(="="E$IT)T*T3'0G0M1.="="]$!T-T,00FP_D^O&KO
MPZMG[,-A5QX?']&W#SO?R(!]*+T1]L;8*[ WP=X4>S/LS;%78F^!O27V5MA;
M8V^#O2WV*NS5V&NPM\/>'GL'[!VQ=\)>>DM@R#ZDH$Z$Z$:(CH3H2HC.A.A.
MB Z%Z%*(3H7H5HB.A>A:B,Z%Z%Z(#H;H8@A,AO-]>-W>A]>=^[#GP&/SEP]O
M/K[BHBSO_W Q_\>['WN.-78_[9D?T3WV'K WPMX8>P7V)MB;8F^&O3GV2NPM
ML+?$W@I[:^QML+?%7H6]&GL-]G;8VV/O@+TC]D[82V\^#!F5%-2)$-T(T9$0
M70G1F1#="=&A$%T*T:D0W0K1L1!="]&Y$-T+T<$070R!R7 ^*E^V1^7+3\_X
M78XU/MIN0DKO 7LC[(VQ5V!O@KTI]F;8FV.OQ-X">TOLK;"WQMX&>UOL5=BK
ML==@;X>]/?8.V#MB[X2]1(.Z$*(3(;H1HB,ANA*B,R&Z$Z)#(;H4HE,ANA6B
M8R&Z%J)S(;H7HH,ANA@"D^%\0MZT)^1-Y_>2GWNLL8?Y]=>83XS$3F; 2)3>
M"'MC[!78FV!OBKT9]N;8*[&WP-X2>ROLK;&WP=X6>Q7V:NPUV-MA;X^] _:.
MV#MA+[TY,&0D4E G0G0C1$="="5$9T)T)T2'0G0I1*="="M$QT)T+43G0G0O
M1 =#=#$$)L/Y2'S5'HFO.M?=%QY=[-%_^N.N3ZS%SA<.6(O2&V%OC+T">Q/L
M3;$WP]X<>R7V%MA;8F^%O37V-MC;8J_"7HV]!GL[[.VQ=\#>$7LG[*6W"X:L
M10KJ1(ANA.A(B*Z$Z$R([H3H4(@NA>A4B&Z%Z%B(KH7H7(CNA>A@B"Z&P&0X
M7XNOVVOQ=>>>^Y)+BSWTX_>+3ZS%SM<.6(O2&V%OC+T">Q/L3;$WP]X<>R7V
M%MA;8F^%O37V-MC;8J_"7HV]!GL[[.VQ=\#>$7LG[*6W"X:L10KJ1(ANA.A(
MB*Z$Z$R([H3H4(@NA>A4B&Z%Z%B(KH7H7(CNA>A@B"Z&P&0X7XNW[;5XVSGI
M.D\M7OW6&_]3G_G,#^(>>P_8&V%OC+T">Q/L3;$WP]X<>R7V%MA;8F^%O37V
M-MC;8J_"7HV]!GL[[.VQ=\#>$7LG[*4W$H9,1PKJ1(ANA.A(B*Z$Z$R([H3H
M4(@NA>A4B&Z%Z%B(KH6T<N%G\>=#"[=GIQMU!41G0'0'!(; ^2"\:P_"N\Y!
M2"XM_OR(ODL:G6]DP.J3W@A[8^P5V)M@;XJ]&?;FV"NQM\#>$GLK[*VQM\'>
M%GL5]FKL-=C;86^/O0/VCM@[82^])3!D]5%0)T)T(T1'0G0E1&="="=$AT)T
M*42G0G0K1,="="U$YT)T+T0'0W0Q!";#V3Y\^:*U#S_^\/G[<-BEQ<='].S#
M[C?R_'U(O1'VQM@KL#?!WA1[,^S-L5=B;X&])?96V%MC;X.]+?8J[-78:["W
MP]X>>P?L';%WPEYZ2V# /K2@3H3H1HB.A.A*B,Z$Z$Z(#H7H4HA.A>A6B(Z%
MZ%J(SH7H7H@.ANAB"$R&\WUXV=Z'EYW[\*E+B\OO?GSS<39^?[%X]\TW[]]>
MC-Y\_\/%^#3ZP\7#W__SS;N>@XO=#WWF)W6/O0?LC; WQEZ!O0GVIMB;86^.
MO1)["^PML;?"WAI[&^QML5=AK\9>@[T=]O;8.V#OB+T3]M);$4.V)05U(D0W
M0G0D1%="="9$=T)T*$270G0J1+="="Q$UT)T+D3W0G0P1!=#8#*<;\NK]K:\
M^O2,W^7@XJ/M)J3T'K WPMX8>P7V)MB;8F^&O3GV2NPML+?$W@I[:^QML+?%
M7H6]&GL-]G;8VV/O@+TC]D[82S2H"R$Z$:(;(3H2HBLA.A.B.R$Z%*)+(3H5
MHELA.A:B:R$Z%Z)[(3H8HHLA,!G.)^1U>T)>=WX]^;D'%_N8)[[-?&(J=F(#
MIJ+T1M@;8Z_ W@1[4^S-L#?'7HF]!?:6V%MA;XV]#?:VV*NP5V.OP=X.>WOL
M';!WQ-X)>^F-@B%3D8(Z$:(;(3H2HBLA.A.B.R$Z%*)+(3H5HELA.A:B:R$Z
M%Z)[(3H8HHLA,!G.I^++]E1\V;GQOO#L8H_^Z4^]/C$7.U\Y8"Y*;X2],?8*
M[$VP-\7>#'MS[)786V!OB;T5]M;8VV!OB[T*>S7V&NSML+?'W@%[1^R=L)?>
M,!@R%RFH$R&Z$:(C(;H2HC,ANA.B0R&Z%*)3(;H5HF,ANA:B<R&Z%Z*#(;H8
M I/A?"[>M.?B3>>@^Y*[BSUT\^V[']Y^<Y$/;_[S8O37=Q_=M]\_,1T[H0'3
M47HC[(VQ5V!O@KTI]F;8FV.OQ-X">TOLK;"WQMX&>UOL5=BKL==@;X>]/?8.
MV#MB[X2]]$;"D.E(09T(T8T0'0G1E1"="=&=$!T*T:40G0K1K1 ="]&U$)T+
MT;T0'0S1Q1"8#.?3\55[.K[JW'=/'V&\O+F]_N-7/_WKZ^O?^G_@3WWV,S^0
M>^P]8&^$O3'V"NQ-L#?%W@Q[<^R5V%M@;XF]%?;6V-M@;XN]"GLU]AKL[;"W
MQ]X!>T?LG;"7WE@8,B$IJ!,ANA&B(R&Z$J(S(;H3HD,ANA2B4R&Z%:)C(;H6
MHG,AO;WP_YUMFHO77[UX:CK2=Z9+(3 5SJ?CZ_9T?-WY<8ISC8^/Z#O'T?E&
M!NQ"Z8VP-\9>@;T)]J;8FV%OCKT2>POL+;&WPMX:>QOL;;%78:_&7H.]'?;V
MV#M@[XB]$_;26P)#=B$%=2)$-T)T)$170G0F1'="="A$ET)T*D2W0G0L1-="
M="Y$]T)T,$070V RG._#V_8^O'W&/AQXKO'VL_9AYQL9L ^E-\+>&'L%]B;8
MFV)OAKTY]DKL+;"WQ-X*>VOL;;"WQ5Z%O1I[#?9VV-MC[X"](_9.V$MO"0S9
MAQ34B1#="-&1$%T)T9D0W0G1H1!="M&I$-T*T;$070O1N1#="]'!$%T,@<EP
MO@_OVOOPKG,?]IYK;.87Y;N__O3?/_S#1?G=M]]\')(]IQH['_C,3^D>>P_8
M&V%OC+T">Q/L3;$WP]X<>R7V%MA;8F^%O37V-MC;8J_"7HV]!GL[[.VQ=\#>
M$7LG[*6W((;L2@KJ1(ANA.A(B*Z$Z$R([H3H4(@NA>A4B&Z%Z%B(KH7H7(CN
MA>A@B"Z&P&0XVY4W+UJ[\N,//SWC=SG5^&BS"4F]!^R-L#?&7H&]"?:FV)MA
M;XZ]$GL+["VQM\+>&GL;[&VQ5V&OQEZ#O1WV]M@[8.^(O1/V$@WJ0HA.A.A&
MB(Z$Z$J(SH3H3H@.A>A2B$Z%Z%:(CH7H6HC.A>A>B Z&Z&((3(;S"7G9GI"7
MG5]-?NZIQC[FU]]D/K$2.YT!*U%Z(^R-L5=@;X*]*?9FV)MCK\3> GM+[*VP
MM\;>!GM;[%78J['78&^'O3WV#M@[8N^$O?3VP)"52$&="-&-$!T)T940G0G1
MG1 ="M&E$)T*T:T0'0O1M1"="]&]$!T,T<40F SG*_&JO1*O.N?=%UYI[-%_
M_A.O3^S%SI<.V(O2&V%OC+T">Q/L3;$WP]X<>R7V%MA;8F^%O37V-MC;8J_"
M7HV]!GL[[.VQ=\#>$7LG[*6W#(;L10KJ1(ANA.A(B*Z$Z$R([H3H4(@NA>A4
MB&Z%Z%B(KH7H7(CNA>A@B"Z&P&0XWXO7[;UXW;GHON1,8P_]>*9Q_N[;__KF
MN[\^,1H[B0&C47HC[(VQ5V!O@KTI]F;8FV.OQ-X">TOLK;"WQMX&>UOL5=BK
ML==@;X>]/?8.V#MB[X2]].;!D-%(09T(T8T0'0G1E1"="=&=$!T*T:40G0K1
MK1 ="]&U$)T+T;T0'0S1Q1"8#.>C\65[-+[L7'8=!QI?/767L9M\YN=PC[T'
M[(VP-\9>@;T)]J;8FV%OCKT2>POL+;&WPMX:>QOL;;%78:_&7H.]'?;VV#M@
M[XB]$_;2VPA#EB,%=2)$-T)T)$170G0F1'="="A$ET)T*D2W0G0L1-="="Y$
M]T):P7#S2?SY+,35S<V+G_[ZW]<AHG,@L ?.9^%->Q;>=,Y"<7SQ\1$]QS6Z
MW\B \2>]$?;&V"NP-\'>%'LS[,VQ5V)O@;TE]E;86V-O@[TM]BKLU=AKL+?#
MWAY[!^P=L7?"7GI+8,CXHZ!.A.A&B(Z$Z$J(SH3H3H@.A>A2B$Z%Z%:(CH7H
M6HC.A>A>B Z&Z&((3(;S??BJO0]?/6,?#CN^^/B(OGW8^48&[$/IC; WQEZ!
MO0GVIMB;86^.O1)["^PML;?"WAI[&^QML5=AK\9>@[T=]O;8.V#OB+T3]M);
M D/V(05U(D0W0G0D1%="="9$=T)T*$270G0J1+="="Q$UT)T+D3W0G0P1!=#
M8#*<[\/7[7WXNG,?]AY?7/_YS8>_?GP/?__AW==OW@\XQMC]!I[YJ=UC[P%[
M(^R-L5=@;X*]*?9FV)MCK\3> GM+[*VPM\;>!GM;[%78J['78&^'O3WV#M@[
M8N^$O?06Q9"=24&="-&-$!T)T940G0G1G1 ="M&E$)T*T:T0'0O1M1"="]&]
M$!T,T<40F SG._.VO3-O/SWC]SG&>(LGI/0>L#?"WAA[!?8FV)MB;X:].?9*
M["VPM\3>"GMK[&VPM\5>A;T:>PWV=MC;8^^ O2/V3MA+-*@+(3H1HALA.A*B
M*R$Z$Z([(3H4HDLA.A6B6R$Z%J)K(3H7HGLA.ABBBR$P&<XGY%U[0MYU?E7Y
MV<<8>YC^;S:?6(V=[H#5*+T1]L;8*[ WP=X4>S/LS;%78F^!O27V5MA;8V^#
MO2WV*NS5V&NPM\/>'GL'[!VQ=\)>>OM@R&JDH$Z$Z$:(CH3H2HC.A.A.B Z%
MZ%*(3H7H5HB.A>A:B,Z%Z%Z(#H;H8@A,AK/5^.I%:S5^_*%K[GWA<<8>O>LX
M8_=+G[\7J3?"WAA[!?8FV)MB;X:].?9*["VPM\3>"GMK[&VPM\5>A;T:>PWV
M=MC;8^^ O2/V3MA+;QD,V(L6U(D0W0C1D1!="=&9$-T)T:$070K1J1#="M&Q
M$%T+T;D0W0O1P1!=#(')<+X7+]M[\;)ST7W)<<8>^G..,W83 T:C]$;8&V.O
MP-X$>U/LS; WQUZ)O07VEMA;86^-O0WVMMBKL%=CK\'>#GM[[!VP=\3>"7OI
MS8,AHY&".A&B&R$Z$J(K(3H3HCLA.A2B2R$Z%:);(3H6HFLA.A>B>R$Z&**+
M(3 9SD?C57LT7G4NNR''&;O)9WX.]]A[P-X(>V/L%=B;8&^*O1GVYM@KL;?
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MHE,ANA6B8R&Z%J)S(;H7HH,ANA@"DZ&]&E\V5^/+SEWWF!.-/?2=)QJ[OV_
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MOAJI5V!OA+TQ]B;8FV)OAKTY]A;86V*OQ-X*>VOL;;"WQ5Z%O1I[.^SML7?
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M1& (M,?@97,,7G:.07%_\?81/?<UNE_(@-4GO0)[(^R-L3?!WA1[,^S-L;?
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MB[<??_KY^L/?+Q;O?WK_Y>;[[RXF'R_>_O#^8OG^PP\7;]]_^7O/-<;NU_'
M']Y;[%UAK\#>"'MC[$VP-\7>#'MS["VPM\1>B;T5]M;8VV!OB[T*>S7V=MC;
M8^^ O2/V3M@[8R^]83%D;E)0)T)T(T1'0G0E1&="="=$AT)T*42G0G0K1,="
M="U$YT)T+T0'0W0Q!"9#>VX^;\[-Y]^>\:=<8[RUW824WA7V"NR-L#?&W@1[
M4^S-L#?'W@)[2^R5V%MA;XV]#?:VV*NP5V-OA[T]]@[8.V+OA+TS]A(-ZD*(
M3H3H1HB.A.A*B,Z$Z$Z(#H7H4HA.A>A6B(Z%Z%J(SH7H7H@.ANAB"$R&]H1\
MT9R0+SK?L;SO-<8^IN<-SCLF8R<Z8#)*K\#>"'MC[$VP-\7>#'MS["VPM\1>
MB;T5]M;8VV!OB[T*>S7V=MC;8^^ O2/V3M@[8R^]<3!D,E)0)T)T(T1'0G0E
M1&="="=$AT)T*42G0G0K1,="="U$YT)T+T0'0W0Q!"9#>S*^;$[&EYU;[Y$G
M&7OT]A_"WK$<.Y$!RU%Z!?9&V!MC;X*]*?9FV)MC;X&])?9*[*VPM\;>!GM;
M[%78J[&WP]X>>P?L';%WPMX9>^EMA"'+D8(Z$:(;(3H2HBLA.A.B.R$Z%*)+
M(3H5HELA.A:B:R$Z%Z)[(3H8HHLA,!G:R_%5<SF^ZMQVC[G-V$/?ON]XQUKL
M_-X!:U%Z!?9&V!MC;X*]*?9FV)MC;X&])?9*[*VPM\;>!GM;[%78J[&WP]X>
M>P?L'?__VNYMMXWS@,+HJPAMT2NCL2U;EH$BP([%X?DX/-^QC9(8=:5 %A*@
M3U]94FJ6+6>L\8JO3-A<,^ -OPU*_+&WP=X6>ZGM@B9KD8(Z$:(;(3H2HBLA
M.A.B.R$Z%*)+(3H5HELA.A:B:R$Z%Z)[(3H8HHLA,!D.U^+Y_EH\KYQTQTYF
M_/,?ST_/3O_?C7]79S[QA7B'O0OLM;!78*^-O0[VNMCK8:^/O0'VAM@;86^,
MO0GVIMB;8:_$WAQ["^PML;?"WAI[&^QML9?:2&@R'2FH$R&Z$:(C(;H2HC,A
MNA.B0R&Z%*)3(;H5HF,ANA:B<R&Z%Z*#(;H8LI<,;^[%AP,NWGP^[_%P$;[=
M7X1O*Q<A.9[QX1)UQV]4WDB#V2>]%O8*[+6QU\%>%WL][/6Q-\#>$'LC[(VQ
M-\'>%'LS[)78FV-O@;TE]E;86V-O@[TM]E); DUF'P5U(D0W0G0D1%="="9$
M=T)T*$270G0J1+="="Q$UT)T+D3W0G0P1!=#8#(<[,/7S_?VX=V#+]^'S8YG
M?+Q$S3ZLOI&G[T/JM;!78*^-O0[VNMCK8:^/O0'VAM@;86^,O0GVIMB;8:_$
MWAQ["^PML;?"WAI[&^QML9?:$FBP#RVH$R&Z$:(C(;H2HC,ANA.B0R&Z%*)3
M(;H5HF,ANA:B<R&Z%Z*#(;H8 I/A<!^^V-^'+RKW8>WQC-U/'R1>W?].XN[#
M2=K/3K[;?;S\4',88_55G_A2O</>!?9:V"NPU\9>!WM=[/6PU\?> 'M#[(VP
M-\;>!'M3[,VP5V)OCKT%]I;86V%OC;T-]K;82VU&-!F7%-2)$-T(T9$070G1
MF1#="=&A$%T*T:D0W0K1L1!="]&Y$-T+T<$070R!R7 X+E_NC\N7]]?X70YC
M?+3=A)3>!?9:V"NPU\9>!WM=[/6PU\?> 'M#[(VP-\;>!'M3[,VP5V)OCKT%
M]I;86V%OC;T-]K;82S2H"R$Z$:(;(3H2HBLA.A.B.R$Z%*)+(3H5HELA.A:B
M:R$Z%Z)[(3H8HHLA,!D.)^3I_H0\K?Q\\DL/8ZQCCGV<>60K5FH-MJ+T6M@K
ML-?&7@=[7>SUL-?'W@![0^R-L#?&W@1[4^S-L%=B;XZ]!?:6V%MA;XV]#?:V
MV$MM%339BA34B1#="-&1$%T)T9D0W0G1H1!="M&I$-T*T;$070O1N1#="]'!
M$%T,@<EPN!5?[6_%5Y4C[RM/8:S1[W_L]<A<K'QF@[DHO1;V"NRUL=?!7A=[
M/>SUL3? WA![(^R-L3?!WA1[,^R5V)MC;X&])?96V%MC;X.]+?92&P9-YB(%
M=2)$-T)T)$170G0F1'="="A$ET)T*D2W0G0L1-="="Y$]T)T,$070V R',[%
MU_MS\77EH/N:HQ=KZ/+7][?_NKSYL+OZ_LABK'Q^@\4HO1;V"NRUL=?!7A=[
M/>SUL3? WA![(^R-L3?!WA1[,^R5V)MC;X&])?96V%MC;X.]+?92VP9-%B,%
M=2)$-T)T)$170G0F1'="="A$ET)T*D2W0G0L1-="="Y$]T)T,$070V R'"[&
ML_W%>%8]ZXX<OU@6-T=F8J7WQ!?A'?8N_N.]>  ?O]GU^<.?__Z"UQ:^>(&]
M-O8ZV.MBKX>]/O8&V!MB;X2],?8FV)MB;X:]$GMS["VPM\3>"GMK[&VPM\5>
M:M_]FVQ""NKW_UQH4$="="5$9T)T)T2'0G0I1*="="M$QT)T+43G0G0O1 =#
M=#$$)L/A)GRSOPG?5&Y"<0#CXR7J#MBHO)$&XT]Z+>P5V&MCKX.]+O9ZV.MC
M;X"](?9&V!MC;X*]*?9FV"NQ-\?> GM+[*VPM\;>!GM;[*6V!)KL0PKJ1(AN
MA.A(B*Z$Z$R([H3H4(@NA>A4B&Z%Z%B(KH7H7(CNA>A@B"Z&P&0XW(?G^_OP
M_ G[L.$!C.=?M \K;Z3!/I1>"WL%]MK8ZV"OB[T>]OK8&V!OB+T1]L;8FV!O
MBKT9]DKLS;&WP-X2>ROLK;&WP=X6>ZDM@2;[D((Z$:(;(3H2HBLA.A.B.R$Z
M%*)+(3H5HELA.A:B:R$Z%Z)[(3H8HHLA,!D.]^';_7WXMG(?UA[ 6+R_VEW]
M_?+DW>??4'QVTMI]O#WI[*ZN?[F\>78RZM4=QUAY#T]\X=YA[P)[+>P5V&MC
MKX.]+O9ZV.MC;X"](?9&V!MC;X*]*?9FV"NQ-\?> GM+[*VPM\;>!GM;[*4V
M*II,30KJ1(ANA.A(B*Z$Z$R([H3H4(@NA>A4B&Z%Z%B(KH7H7(CNA>A@B"Z&
MP&0XF)IGS_>FYMV#3]?X78YC?+39A*3>!?9:V"NPU\9>!WM=[/6PU\?> 'M#
M[(VP-\;>!'M3[,VP5V)OCKT%]I;86V%OC;T-]K;82S2H"R$Z$:(;(3H2HBLA
M.A.B.R$Z%*)+(3H5HELA.A:B:R$Z%Z)[(3H8HHLA,!D.)^2+_0GYHO+3RB\]
MCK&.J?AP\\A<K 0;S$7IM;!78*^-O0[VNMCK8:^/O0'VAM@;86^,O0GVIMB;
M8:_$WAQ["^PML;?"WAI[&^QML9?:,&@R%RFH$R&Z$:(C(;H2HC,ANA.B0R&Z
M%*)3(;H5HF,ANA:B<R&Z%Z*#(;H8 I/A<"Z^W)^++RMWWE>>R%BC'_X0[)'E
M6(DT6([2:V&OP%X;>QWL=;'7PUX?>P/L#;$WPMX8>Q/L3;$WPUZ)O3GV%MA;
M8F^%O37V-MC;8B^UC=!D.5)0)T)T(T1'0G0E1&="="=$AT)T*42G0G0K1,="
M="U$YT)T+T0'0W0Q!";#X7(\W5^.IY7;[FL.9ZRA%V6.+,7*YS58BM)K8:_
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M=;TK0._J>E> WM7UK@"]F^O= 'HWU[L!]&ZN=P/HW>+#$H#>S?5N +V;Z]T
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M9X#>L^L] _2>XV9O@-ZSZST#]%Y<[P6@]^)Z+P"]%]=[ >B]N-X+0._%]5X
M>B^N]P+0>W&]%X#>B^N] /1>7.\%H/<2L0Y ;Y7,=0!^JT2P4P""JT2R4P"&
MJT2T4P"*JT2V4P".JT2X4P"2JT2Z4P"6JT2\4P":JT2^4P">JT3 4PBB9X#)
M*# SP22(GA$FHL+,#!/186:(B2@Q,\5$M)@98R)JS,PQ$3UF!IF((C.33$*3
MJ8@R1:@R%5FF"%VF:F;U!-$CS12AS53$F2+4F8H\4X0^4Q%HBE!H*A)-$1I-
M1:0I0J6IR#1%Z#05H:8(I:8BU12AU53$FB+4FFKYJ!2"Z!%LBE!L*I)-$9I-
M1;0I0K6IR#9%Z#85X:8(Y:8BW12AW53$FR+4FXI\4X1^4Q%PBE!P*A).$1I.
M#?GX*X+HD7&*T'$J0DX12DY%RBE"RZF(.46H.14YIP@]IR+H%*'H5"2=(C2=
MBJA3A*I3D76*T'4JPDX1RDZ-^4A#@N@1=XI0=RKR3A'Z3D7@*4+AJ4@\16@\
M%9&G")6G(O,4H?-4A)XBE)Z*U%.$UE,1>XI0>RIR3Q%Z3_5\3"U!]$@^16@^
M%=&G"-6G(OL4H?M4A)\BE)^*]%.$]E,1?XI0?RKR3Q'Z3T4 *D(!JDA 16A
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M4$L! A0#%     @ R#U!5@=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #(/4%63&@!R.\    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" #(/4%6F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,@]05:+)F O)P@  &@T   8
M      " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" #(/4%6:_Z2:Y4%  "I&   &               @(%K$   >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ R#U!5EQD1%C/!   F1,  !@
M             ("!-A8  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( ,@]059-IGPGO08  "\@   8              " @3L;  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #(/4%6J2-,@5D-  !1
M=0  &               @($N(@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ R#U!5E<\:C=*"0  72X  !@              ("!O2\
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( ,@]05;> 6-?
M%R<  &2'   8              " @3TY  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    " #(/4%6\MC;6-<,  "Y)@  &
M@(&*8   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ R#U!
M5GXA^AH&'P  I%D  !@              ("!EVT  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( ,@]05:9QGR!Z 4  !0/   9
M      " @=.,  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ R#U!5OU=.=CQ @  0P<  !D              ("!\I(  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #(/4%6\^K+3.$&   R$0
M&0              @($:E@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( ,@]05:RUAG-R@,  &8)   9              " @3*=  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ R#U!5LT(_2E.
M!0  .Q   !D              ("!,Z$  'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    " #(/4%63VY-_Q\%  !]#0  &0
M@(&XI@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( ,@]
M05:\KY24Q@<  %83   9              " @0ZL  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ R#U!5M*TD&9^"   EA@  !D
M         ("!"[0  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    " #(/4%68J?< C$'  !9%   &0              @(' O   >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( ,@]0599P+W:- ,  ' '
M   9              " @2C$  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ R#U!5DV.K4N/ P  "0@  !D              ("!D\<
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #(/4%6Z5\>
M3L8&  !W$   &0              @(%9RP  >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( ,@]058]HSQ?1P,  !0)   9
M  " @5;2  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
MR#U!5LZHJ<Z! @  L 4  !D              ("!U-4  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    " #(/4%6,CHT_.X*  !T(   &0
M            @(&,V   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( ,@]058C(.)NX@<  /@5   9              " @;'C  !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ R#U!5K>]!F)7&@
M\DH  !D              ("!RNL  'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    " #(/4%66M8XRQ8$  #^"0  &0              @(%8
M!@$ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( ,@]058/
MHI2_&@@  #05   9              " @:4* 0!X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ R#U!5@1WL? /"P  N2(  !D
M     ("!]A(! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,@]05;GS76'9PL  #,=   9              "
M@;Q- 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ R#U!
M5A=U%/1Z)   U'T  !D              ("!6ED! 'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    " #(/4%6.!GT42X$  !R"0  &0
M        @($+?@$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   ( ,@]0591TB95Y!$  $DP   9              " @7"" 0!X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ R#U!5O-P4I87.   4M(
M !D              ("!BY0! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    " #(/4%6FY#[Z28#   G!P  &0              @('9S $
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( ,@]059\L=_%
MY!@  /5*   9              " @3;0 0!X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL4$L! A0#%     @ R#U!5BP[C;<@!   F0L  !D
M ("!4>D! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #(
M/4%6_O6G2?\"  !,!P  &0              @(&H[0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( ,@]05:L!6!D"@4  /0+   9
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M970T-RYX;6Q02P$"% ,4    " #(/4%632;LD<(&  " %   &0
M    @(&(" ( >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (
M ,@]059D\GMC3 <  .$4   9              " @8$/ @!X;"]W;W)K<VAE
M971S+W-H965T-#DN>&UL4$L! A0#%     @ R#U!5G0R8'-# P  L <  !D
M             ("!!!<" 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"
M% ,4    " #(/4%6Z;0WI_D"  !3!P  &0              @(%^&@( >&PO
M=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( ,@]05:81=MO: 0
M , +   9              " @:X= @!X;"]W;W)K<VAE971S+W-H965T-3(N
M>&UL4$L! A0#%     @ R#U!5I[IIA@- P  " @  !D              ("!
M32(" 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " #(/4%6
MKQSEBH0"  "@!0  &0              @(&1)0( >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;%!+ 0(4 Q0    ( ,@]059#R*N;( 8  !H1   9
M      " @4PH @!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%
M  @ R#U!5G ^*"U/!@  MA,  !D              ("!HRX" 'AL+W=O<FMS
M:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " #(/4%6=4VP,,X$   0#0
M&0              @($I-0( >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+
M 0(4 Q0    ( ,@]05;V7-)=]0(  -P&   9              " @2XZ @!X
M;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ R#U!5OFFIL>N
M!0  9@T  !D              ("!6CT" 'AL+W=O<FMS:&5E=',O<VAE970U
M.2YX;6Q02P$"% ,4    " #(/4%6+J9>^5()   ,'   &0
M@($_0P( >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( ,@]
M05;;$B6PN ,   \(   9              " @<A, @!X;"]W;W)K<VAE971S
M+W-H965T-C$N>&UL4$L! A0#%     @ R#U!5H*!I>D3"P  HR,  !D
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M=#8V+GAM;%!+ 0(4 Q0    ( ,@]05:6Z/D3+!$  # N   9
M  " @<-T @!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @
MR#U!5HU"#*K^ 0  $P0  !D              ("!)H8" 'AL+W=O<FMS:&5E
M=',O<VAE970V."YX;6Q02P$"% ,4    " #(/4%6S^:HZ2L7   N?0$ &0
M            @(%;B ( >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4
M Q0    ( ,@]0583./8.O (  .T(   9              " @;V? @!X;"]W
M;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ R#U!5GSSX@MR"0
M^C<  !D              ("!L*(" 'AL+W=O<FMS:&5E=',O<VAE970W,2YX
M;6Q02P$"% ,4    " #(/4%6!;05M<\)   360  &0              @(%9
MK ( >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( ,@]05;L
M&TS!0@D  $]!   9              " @5^V @!X;"]W;W)K<VAE971S+W-H
M965T-S,N>&UL4$L! A0#%     @ R#U!5O0>(IO[!@  2#4  !D
M     ("!V+\" 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,@]05;&.TIUM"    N^ 0 9              "
M@6#W @!X;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ R#U!
M5B\+PB6A!0  >R<  !D              ("!2Q@# 'AL+W=O<FMS:&5E=',O
M<VAE970X,"YX;6Q02P$"% ,4    " #(/4%6;]?X4:\$  "#&0  &0
M        @($C'@, >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0
M   ( ,@]05;X("\DZ ,  #L3   9              " @0DC P!X;"]W;W)K
M<VAE971S+W-H965T.#(N>&UL4$L! A0#%     @ R#U!5F(08Y)/ P  B D
M !D              ("!*"<# 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q0
M2P$"% ,4    " #(/4%6!LS7M#H$   C$P  &0              @(&N*@,
M>&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    ( ,@]05:@0'S1
M! ,  $0)   9              " @1\O P!X;"]W;W)K<VAE971S+W-H965T
M.#4N>&UL4$L! A0#%     @ R#U!5CT:3I7_ @  S@D  !D
M ("!6C(# 'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6Q02P$"% ,4    " #(
M/4%6C.1@70D#  #K#   &0              @(&0-0, >&PO=V]R:W-H965T
M<R]S:&5E=#@W+GAM;%!+ 0(4 Q0    ( ,@]058HH@L*CP,  $X0   9
M          " @= X P!X;"]W;W)K<VAE971S+W-H965T.#@N>&UL4$L! A0#
M%     @ R#U!5EME+OAW!0  +18  !D              ("!ECP# 'AL+W=O
M<FMS:&5E=',O<VAE970X.2YX;6Q02P$"% ,4    " #(/4%6<H^> LP#  "Q
M#   &0              @(%$0@, >&PO=V]R:W-H965T<R]S:&5E=#DP+GAM
M;%!+ 0(4 Q0    ( ,@]05:CRVTS20H   E4   9              " @4=&
M P!X;"]W;W)K<VAE971S+W-H965T.3$N>&UL4$L! A0#%     @ R#U!5G@Y
M3R\)#   GVP  !D              ("!QU # 'AL+W=O<FMS:&5E=',O<VAE
M970Y,BYX;6Q02P$"% ,4    " #(/4%6*?B,FN<#  #1%   &0
M    @($'70, >&PO=V]R:W-H965T<R]S:&5E=#DS+GAM;%!+ 0(4 Q0    (
M ,@]05;WJ@MV@P,  #H+   9              " @25A P!X;"]W;W)K<VAE
M971S+W-H965T.30N>&UL4$L! A0#%     @ R#U!5NG2Y_=@!   *AH  !D
M             ("!WV0# 'AL+W=O<FMS:&5E=',O<VAE970Y-2YX;6Q02P$"
M% ,4    " #(/4%6 J92Y8D%  "Y(   &0              @(%V:0, >&PO
M=V]R:W-H965T<R]S:&5E=#DV+GAM;%!+ 0(4 Q0    ( ,@]05;X(._\90,
M ,\.   9              " @39O P!X;"]W;W)K<VAE971S+W-H965T.3<N
M>&UL4$L! A0#%     @ R#U!5D3(6#G. P  ! T  !D              ("!
MTG(# 'AL+W=O<FMS:&5E=',O<VAE970Y."YX;6Q02P$"% ,4    " #(/4%6
MQM1JV5\-  !9@   &0              @('7=@, >&PO=V]R:W-H965T<R]S
M:&5E=#DY+GAM;%!+ 0(4 Q0    ( ,@]05:HX/R=" D  "1@   :
M      " @6V$ P!X;"]W;W)K<VAE971S+W-H965T,3 P+GAM;%!+ 0(4 Q0
M   ( ,@]058%$O09E@(  .H'   :              " @:V- P!X;"]W;W)K
M<VAE971S+W-H965T,3 Q+GAM;%!+ 0(4 Q0    ( ,@]05:<P53-"P,  !@+
M   :              " @7N0 P!X;"]W;W)K<VAE971S+W-H965T,3 R+GAM
M;%!+ 0(4 Q0    ( ,@]05;]:C\YXP4  .\M   :              " @;Z3
M P!X;"]W;W)K<VAE971S+W-H965T,3 S+GAM;%!+ 0(4 Q0    ( ,@]058G
MI\SM&PL  $E:   :              " @=F9 P!X;"]W;W)K<VAE971S+W-H
M965T,3 T+GAM;%!+ 0(4 Q0    ( ,@]059P4.$NUP@  "=@   :
M      " @2RE P!X;"]W;W)K<VAE971S+W-H965T,3 U+GAM;%!+ 0(4 Q0
M   ( ,@]058_8J2B>P(  -L%   :              " @3NN P!X;"]W;W)K
M<VAE971S+W-H965T,3 V+GAM;%!+ 0(4 Q0    ( ,@]05:)TZW(6P,  -H*
M   :              " @>ZP P!X;"]W;W)K<VAE971S+W-H965T,3 W+GAM
M;%!+ 0(4 Q0    ( ,@]058XP&WZH (  #@'   :              " @8&T
M P!X;"]W;W)K<VAE971S+W-H965T,3 X+GAM;%!+ 0(4 Q0    ( ,@]058D
MK4SHRP,  !43   :              " @5FW P!X;"]W;W)K<VAE971S+W-H
M965T,3 Y+GAM;%!+ 0(4 Q0    ( ,@]05::1-.6< ,  )D4   :
M      " @5R[ P!X;"]W;W)K<VAE971S+W-H965T,3$P+GAM;%!+ 0(4 Q0
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M965T,3$T+GAM;%!+ 0(4 Q0    ( ,@]059%>;*) P,  .0)   :
M      " @9C0 P!X;"]W;W)K<VAE971S+W-H965T,3$U+GAM;%!+ 0(4 Q0
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M965T,3$Y+GAM;%!+ 0(4 Q0    ( ,@]05;(V^"1C 0  !<2   :
M      " @=/D P!X;"]W;W)K<VAE971S+W-H965T,3(P+GAM;%!+ 0(4 Q0
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M965T,3(T+GAM;%!+ 0(4 Q0    ( ,@]05;R@-0B>P,  *82   :
M      " @7$2! !X;"]W;W)K<VAE971S+W-H965T,3(U+GAM;%!+ 0(4 Q0
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M965T,3(Y+GAM;%!+ 0(4 Q0    ( ,@]05:@YCN_?P8  , Q   :
M      " @8$D! !X;"]W;W)K<VAE971S+W-H965T,3,P+GAM;%!+ 0(4 Q0
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M965T,3,T+GAM;%!+ 0(4 Q0    ( ,@]059=41Y_MP,  -(.   :
M      " @8\\! !X;"]W;W)K<VAE971S+W-H965T,3,U+GAM;%!+ 0(4 Q0
M   ( ,@]05;XRV57)08  $DC   :              " @7Y ! !X;"]W;W)K
M<VAE971S+W-H965T,3,V+GAM;%!+ 0(4 Q0    ( ,@]05;H0J;>"0,  %$+
M   :              " @=M&! !X;"]W;W)K<VAE971S+W-H965T,3,W+GAM
M;%!+ 0(4 Q0    ( ,@]05:Z0QDP;P,  *0+   :              " @1Q*
M! !X;"]W;W)K<VAE971S+W-H965T,3,X+GAM;%!+ 0(4 Q0    ( ,@]05:H
M.6YEI 4  ,@=   :              " @<--! !X;"]W;W)K<VAE971S+W-H
M965T,3,Y+GAM;%!+ 0(4 Q0    ( ,@]05:JZ -+00@  +,U   :
M      " @9]3! !X;"]W;W)K<VAE971S+W-H965T,30P+GAM;%!+ 0(4 Q0
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M965T,30T+GAM;%!+ 0(4 Q0    ( ,@]05;'!;[5F@4  .<:   :
M      " @;9S! !X;"]W;W)K<VAE971S+W-H965T,30U+GAM;%!+ 0(4 Q0
M   ( ,@]05;']T>6@@P  +".   :              " @8AY! !X;"]W;W)K
M<VAE971S+W-H965T,30V+GAM;%!+ 0(4 Q0    ( ,@]05;W 5=LT@,  &<2
M   :              " @4*&! !X;"]W;W)K<VAE971S+W-H965T,30W+GAM
M;%!+ 0(4 Q0    ( ,@]05;CW2D>( 0  #H7   :              " @4R*
M! !X;"]W;W)K<VAE971S+W-H965T,30X+GAM;%!+ 0(4 Q0    ( ,@]058
MUK)B\@(  .$(   :              " @:2.! !X;"]W;W)K<VAE971S+W-H
M965T,30Y+GAM;%!+ 0(4 Q0    ( ,@]058RQQA> P4   T@   :
M      " @<Z1! !X;"]W;W)K<VAE971S+W-H965T,34P+GAM;%!+ 0(4 Q0
M   ( ,@]059.836^KP0  %8@   :              " @0F7! !X;"]W;W)K
M<VAE971S+W-H965T,34Q+GAM;%!+ 0(4 Q0    ( ,@]059U2A!B^@(  ,,*
M   :              " @?";! !X;"]W;W)K<VAE971S+W-H965T,34R+GAM
M;%!+ 0(4 Q0    ( ,@]05: N,4RT0(  -H'   :              " @2*?
M! !X;"]W;W)K<VAE971S+W-H965T,34S+GAM;%!+ 0(4 Q0    ( ,@]05;S
M!?#INPP  ,<M   :              " @2NB! !X;"]W;W)K<VAE971S+W-H
M965T,34T+GAM;%!+ 0(4 Q0    ( ,@]058ZNB7R[@,  -\.   :
M      " @1ZO! !X;"]W;W)K<VAE971S+W-H965T,34U+GAM;%!+ 0(4 Q0
M   ( ,@]05;<8V/%[ ,  !L/   :              " @42S! !X;"]W;W)K
M<VAE971S+W-H965T,34V+GAM;%!+ 0(4 Q0    ( ,@]059F5/^PL08  -PT
M   :              " @6BW! !X;"]W;W)K<VAE971S+W-H965T,34W+GAM
M;%!+ 0(4 Q0    ( ,@]0588$[W%! 4  )0=   :              " @5&^
M! !X;"]W;W)K<VAE971S+W-H965T,34X+GAM;%!+ 0(4 Q0    ( ,@]05;K
M]MZ.3@0  &<4   :              " @8W#! !X;"]W;W)K<VAE971S+W-H
M965T,34Y+GAM;%!+ 0(4 Q0    ( ,@]0594+U6#400  )<=   :
M      " @1/(! !X;"]W;W)K<VAE971S+W-H965T,38P+GAM;%!+ 0(4 Q0
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M965T,38T+GAM;%!+ 0(4 Q0    ( ,@]05:62L26R 0  "@>   :
M      " @8KB! !X;"]W;W)K<VAE971S+W-H965T,38U+GAM;%!+ 0(4 Q0
M   ( ,@]05;?0=O*?PD  *UE   :              " @8KG! !X;"]W;W)K
M<VAE971S+W-H965T,38V+GAM;%!+ 0(4 Q0    ( ,@]059O!U=X@@4  '8N
M   :              " @4'Q! !X;"]W;W)K<VAE971S+W-H965T,38W+GAM
M;%!+ 0(4 Q0    ( ,@]05:]'7E610@  %4^   :              " @?OV
M! !X;"]W;W)K<VAE971S+W-H965T,38X+GAM;%!+ 0(4 Q0    ( ,@]05:$
M UYI(0P  .!W   :              " @7C_! !X;"]W;W)K<VAE971S+W-H
M965T,38Y+GAM;%!+ 0(4 Q0    ( ,@]058*"-%!\P,  %@3   :
M      " @=$+!0!X;"]W;W)K<VAE971S+W-H965T,3<P+GAM;%!+ 0(4 Q0
M   ( ,@]05;_'Z)1@@4  !(E   :              " @?P/!0!X;"]W;W)K
M<VAE971S+W-H965T,3<Q+GAM;%!+ 0(4 Q0    ( ,@]0596G;/],0D  %E#
M   :              " @;85!0!X;"]W;W)K<VAE971S+W-H965T,3<R+GAM
M;%!+ 0(4 Q0    ( ,@]05;!M\6CU00  #@8   :              " @1\?
M!0!X;"]W;W)K<VAE971S+W-H965T,3<S+GAM;%!+ 0(4 Q0    ( ,@]0599
M04TH300  !D8   :              " @2PD!0!X;"]W;W)K<VAE971S+W-H
M965T,3<T+GAM;%!+ 0(4 Q0    ( ,@]0598];/J7 ,  $@-   :
M      " @;$H!0!X;"]W;W)K<VAE971S+W-H965T,3<U+GAM;%!+ 0(4 Q0
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M96QS+RYR96QS4$L! A0#%     @ R#U!5@Y!=H8I"@  #'4   \
M     ( !?_8' 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ,@]05;N$,CL
MHP0  "UH   :              "  =4 " !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( ,@]05;(?KH'2@,  ,]B   3
M  "  ; %" !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    "Z +H G#,  "L)
$"     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>254
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>255
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>256
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1959</ContextCount>
  <ElementCount>778</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>518</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>49</UnitCount>
  <MyReports>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated income statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/StatementOfIncome</Role>
      <ShortName>Consolidated income statements</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated statements of comprehensive income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/StatementOfComprehensiveIncome</Role>
      <ShortName>Consolidated statements of comprehensive income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated balance sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/BalanceSheet</Role>
      <ShortName>Consolidated balance sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated statements of changes in equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/StatementOfChangesInEquity</Role>
      <ShortName>Consolidated statements of changes in equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005000 - Statement - Consolidated cash flow statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/StatementsOfCashFlow</Role>
      <ShortName>Consolidated cash flow statements</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2100100 - Disclosure - Significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2100200 - Disclosure - Significant transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSignificantTransactions</Role>
      <ShortName>Significant transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2100300 - Disclosure - Segmentation of key figures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFigures</Role>
      <ShortName>Segmentation of key figures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2100400 - Disclosure - Associated companies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureAssociatedCompanies</Role>
      <ShortName>Associated companies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2100500 - Disclosure - Interest expense and other financial income and expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpense</Role>
      <ShortName>Interest expense and other financial income and expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2100600 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2100700 - Disclosure - Earnings per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEarningsPerShare</Role>
      <ShortName>Earnings per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2100800 - Disclosure - Changes in consolidated statements of comprehensive income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncome</Role>
      <ShortName>Changes in consolidated statements of comprehensive income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2100900 - Disclosure - Property, plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipment</Role>
      <ShortName>Property, plant and equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2101000 - Disclosure - Right-of-use assets and lease liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiability</Role>
      <ShortName>Right-of-use assets and lease liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Goodwill and intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2101200 - Disclosure - Deferred tax assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilities</Role>
      <ShortName>Deferred tax assets and liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2101300 - Disclosure - Financial and other non-current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssets</Role>
      <ShortName>Financial and other non-current assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2101400 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureInventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2101500 - Disclosure - Trade receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTradeReceivables</Role>
      <ShortName>Trade receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2101600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureMarketableSecurities</Role>
      <ShortName>Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2101700 - Disclosure - Other current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureOtherCurrentAssets</Role>
      <ShortName>Other current assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2101800 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2101900 - Disclosure - Non-current financial debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebt</Role>
      <ShortName>Non-current financial debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2102000 - Disclosure - Provisions and other non-current liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilities</Role>
      <ShortName>Provisions and other non-current liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Current financial debt and derivative financial instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstruments</Role>
      <ShortName>Current financial debt and derivative financial instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2102200 - Disclosure - Provisions and other current liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilities</Role>
      <ShortName>Provisions and other current liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2102300 - Disclosure - Details to the consolidated statements of cash flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatements</Role>
      <ShortName>Details to the consolidated statements of cash flows</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2102400 - Disclosure - Acquisitions of businesses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinesses</Role>
      <ShortName>Acquisitions of businesses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2102500 - Disclosure - Post-employment benefits for employees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociates</Role>
      <ShortName>Post-employment benefits for employees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2102600 - Disclosure - Equity-based participation plans for employees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociates</Role>
      <ShortName>Equity-based participation plans for employees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2102700 - Disclosure - Transactions with related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedParties</Role>
      <ShortName>Transactions with related parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2102800 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2102900 - Disclosure - Financial instruments - additional disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosures</Role>
      <ShortName>Financial instruments - additional disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2103000 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSubsequentEvents</Role>
      <ShortName>Events subsequent to the December 31 consolidated balance sheet date</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Principal Group subsidiaries and associated companies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompanies</Role>
      <ShortName>Principal Group subsidiaries and associated companies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2200100 - Disclosure - Significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2300100 - Disclosure - Significant accounting policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Significant accounting policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2300300 - Disclosure - Segmentation of key figures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables</Role>
      <ShortName>Segmentation of key figures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFigures</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2300400 - Disclosure - Associated companies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables</Role>
      <ShortName>Associated companies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureAssociatedCompanies</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2300500 - Disclosure - Interest expense and other financial income and expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables</Role>
      <ShortName>Interest expense and other financial income and expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpense</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2300600 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTaxes</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2300700 - Disclosure - Earnings per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEarningsPerShareTables</Role>
      <ShortName>Earnings per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEarningsPerShare</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2300800 - Disclosure - Changes in consolidated statements of comprehensive income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables</Role>
      <ShortName>Changes in consolidated statements of comprehensive income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncome</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2300900 - Disclosure - Property, plant and equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, plant and equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipment</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2301000 - Disclosure - Right-of-use assets and lease liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables</Role>
      <ShortName>Right-of-use assets and lease liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiability</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2301100 - Disclosure - Goodwill and intangible assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and intangible assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssets</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2301200 - Disclosure - Deferred tax assets and liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables</Role>
      <ShortName>Deferred tax assets and liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilities</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2301300 - Disclosure - Financial and other non-current assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables</Role>
      <ShortName>Financial and other non-current assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssets</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2301400 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureInventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureInventories</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2301500 - Disclosure - Trade receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTradeReceivablesTables</Role>
      <ShortName>Trade receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTradeReceivables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2301600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureMarketableSecurities</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2301700 - Disclosure - Other current assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsTables</Role>
      <ShortName>Other current assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureOtherCurrentAssets</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2301800 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquity</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2301900 - Disclosure - Non-current financial debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables</Role>
      <ShortName>Non-current financial debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebt</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2302000 - Disclosure - Provisions and other non-current liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables</Role>
      <ShortName>Provisions and other non-current liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilities</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2302100 - Disclosure - Current financial debt and derivative financial instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables</Role>
      <ShortName>Current financial debt and derivative financial instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstruments</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2302200 - Disclosure - Provisions and other current liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Provisions and other current liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilities</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2302300 - Disclosure - Details to the consolidated statements of cash flows (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables</Role>
      <ShortName>Details to the consolidated statements of cash flows (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatements</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2302400 - Disclosure - Acquisitions of businesses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesTables</Role>
      <ShortName>Acquisitions of businesses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinesses</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2302500 - Disclosure - Post-employment benefits for employees (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables</Role>
      <ShortName>Post-employment benefits for employees (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociates</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2302600 - Disclosure - Equity-based participation plans for employees (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables</Role>
      <ShortName>Equity-based participation plans for employees (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociates</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2302700 - Disclosure - Transactions with related parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesTables</Role>
      <ShortName>Transactions with related parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedParties</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2302800 - Disclosure - Commitments and contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2302900 - Disclosure - Financial instruments - additional disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</Role>
      <ShortName>Financial instruments - additional disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosures</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2303100 - Disclosure - Principal Group subsidiaries and associated companies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables</Role>
      <ShortName>Principal Group subsidiaries and associated companies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompanies</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2400100 - Disclosure - Significant accounting policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant accounting policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2400200 - Disclosure - Significant transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails</Role>
      <ShortName>Significant transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSignificantTransactions</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2400300 - Disclosure - Segmentation of key figures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails</Role>
      <ShortName>Segmentation of key figures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2400301 - Disclosure - Segmentation of key figures (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1</Role>
      <ShortName>Segmentation of key figures (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2400302 - Disclosure - Segmentation of key figures (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2</Role>
      <ShortName>Segmentation of key figures (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2400303 - Disclosure - Segmentation of key figures (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3</Role>
      <ShortName>Segmentation of key figures (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2400304 - Disclosure - Segmentation of key figures (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4</Role>
      <ShortName>Segmentation of key figures (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2400305 - Disclosure - Segmentation of key figures (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5</Role>
      <ShortName>Segmentation of key figures (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2400306 - Disclosure - Segmentation of key figures (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6</Role>
      <ShortName>Segmentation of key figures (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2400307 - Disclosure - Segmentation of key figures - Net sales by region (Details 7)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12</Role>
      <ShortName>Segmentation of key figures - Net sales by region (Details 7)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2400308 - Disclosure - Segmentation of key figures (Details 8)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7</Role>
      <ShortName>Segmentation of key figures (Details 8)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2400309 - Disclosure - Segmentation of key figures - Top 20 (Details 9)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11</Role>
      <ShortName>Segmentation of key figures - Top 20 (Details 9)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2400310 - Disclosure - Segmentation of key figures (Details 10)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8</Role>
      <ShortName>Segmentation of key figures (Details 10)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2400311 - Disclosure - Segmentation of key figures (Details 11)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10</Role>
      <ShortName>Segmentation of key figures (Details 11)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2400400 - Disclosure - Associated companies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails</Role>
      <ShortName>Associated companies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2400401 - Disclosure - Associated companies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3</Role>
      <ShortName>Associated companies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2400402 - Disclosure - Associated companies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6</Role>
      <ShortName>Associated companies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2400500 - Disclosure - Interest expense and other financial income and expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails</Role>
      <ShortName>Interest expense and other financial income and expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2400501 - Disclosure - Interest expense and other financial income and expense (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2</Role>
      <ShortName>Interest expense and other financial income and expense (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2400600 - Disclosure - Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTaxesDetails</Role>
      <ShortName>Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTaxesTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2400601 - Disclosure - Income taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTaxesDetails2</Role>
      <ShortName>Income taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTaxesTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2400602 - Disclosure - Income taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTaxesDetails3</Role>
      <ShortName>Income taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTaxesTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2400700 - Disclosure - Earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails</Role>
      <ShortName>Earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEarningsPerShareTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2400800 - Disclosure - Changes in consolidated statements of comprehensive income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails</Role>
      <ShortName>Changes in consolidated statements of comprehensive income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2400900 - Disclosure - Property, plant and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, plant and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2400901 - Disclosure - Property, plant and equipment (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2</Role>
      <ShortName>Property, plant and equipment (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>2401000 - Disclosure - Lease liability and Right-of-use assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3</Role>
      <ShortName>Lease liability and Right-of-use assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>2401001 - Disclosure - Lease liability and Right-of-use assets (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2</Role>
      <ShortName>Lease liability and Right-of-use assets (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>2401002 - Disclosure - Lease liability and Right-of-use assets (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4</Role>
      <ShortName>Lease liability and Right-of-use assets (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>2401003 - Disclosure - Lease liability and Right-of-use assets (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5</Role>
      <ShortName>Lease liability and Right-of-use assets (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>2401004 - Disclosure - Lease liability and Right-of-use assets (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6</Role>
      <ShortName>Lease liability and Right-of-use assets (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>2401100 - Disclosure - Goodwill and intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>2401101 - Disclosure - Goodwill and intangible assets (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2</Role>
      <ShortName>Goodwill and intangible assets (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>2401102 - Disclosure - Goodwill and intangible assets (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3</Role>
      <ShortName>Goodwill and intangible assets (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>2401103 - Disclosure - Goodwill and intangible assets (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5</Role>
      <ShortName>Goodwill and intangible assets (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>2401104 - Disclosure - Goodwill and intangible assets (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4</Role>
      <ShortName>Goodwill and intangible assets (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>2401200 - Disclosure - Deferred tax assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Deferred tax assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables</ParentRole>
      <Position>104</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>2401201 - Disclosure - Deferred tax assets and liabilities (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3</Role>
      <ShortName>Deferred tax assets and liabilities (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables</ParentRole>
      <Position>105</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>2401202 - Disclosure - Deferred tax assets and liabilities (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4</Role>
      <ShortName>Deferred tax assets and liabilities (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables</ParentRole>
      <Position>106</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>2401300 - Disclosure - Financial and other non-current assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails</Role>
      <ShortName>Financial and other non-current assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables</ParentRole>
      <Position>107</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>2401301 - Disclosure - Financial and other non-current assets (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2</Role>
      <ShortName>Financial and other non-current assets (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables</ParentRole>
      <Position>108</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>2401400 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureInventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureInventoriesTables</ParentRole>
      <Position>109</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>2401500 - Disclosure - Trade receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails</Role>
      <ShortName>Trade receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTradeReceivablesTables</ParentRole>
      <Position>110</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>2401501 - Disclosure - Trade receivables (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2</Role>
      <ShortName>Trade receivables (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTradeReceivablesTables</ParentRole>
      <Position>111</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>2401502 - Disclosure - Trade receivables (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3</Role>
      <ShortName>Trade receivables (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTradeReceivablesTables</ParentRole>
      <Position>112</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>2401503 - Disclosure - Trade receivables (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4</Role>
      <ShortName>Trade receivables (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTradeReceivablesTables</ParentRole>
      <Position>113</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>2401600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails</Role>
      <ShortName>Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureMarketableSecuritiesTables</ParentRole>
      <Position>114</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>2401601 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails3</Role>
      <ShortName>Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureMarketableSecuritiesTables</ParentRole>
      <Position>115</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>2401700 - Disclosure - Other current assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails</Role>
      <ShortName>Other current assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsTables</ParentRole>
      <Position>116</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>2401800 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquityTables</ParentRole>
      <Position>117</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>2401801 - Disclosure - Equity (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityDetails2</Role>
      <ShortName>Equity (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquityTables</ParentRole>
      <Position>118</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>2401802 - Disclosure - Equity (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityDetails3</Role>
      <ShortName>Equity (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquityTables</ParentRole>
      <Position>119</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>2401803 - Disclosure - Equity (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityDetails4</Role>
      <ShortName>Equity (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquityTables</ParentRole>
      <Position>120</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>2401804 - Disclosure - Equity (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityDetails5</Role>
      <ShortName>Equity (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquityTables</ParentRole>
      <Position>121</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>2401900 - Disclosure - Non-current financial debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails</Role>
      <ShortName>Non-current financial debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables</ParentRole>
      <Position>122</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>2401901 - Disclosure - Non-current financial debt (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2</Role>
      <ShortName>Non-current financial debt (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables</ParentRole>
      <Position>123</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>2401902 - Disclosure - Non-current financial debt (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3</Role>
      <ShortName>Non-current financial debt (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables</ParentRole>
      <Position>124</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>2401903 - Disclosure - Non-current financial debt (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4</Role>
      <ShortName>Non-current financial debt (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables</ParentRole>
      <Position>125</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>2401904 - Disclosure - Non-current financial debt (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5</Role>
      <ShortName>Non-current financial debt (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables</ParentRole>
      <Position>126</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>2402000 - Disclosure - Provisions and other non-current liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails</Role>
      <ShortName>Provisions and other non-current liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables</ParentRole>
      <Position>127</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R128.htm</HtmlFileName>
      <LongName>2402001 - Disclosure - Provisions and other non-current liabilities (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2</Role>
      <ShortName>Provisions and other non-current liabilities (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables</ParentRole>
      <Position>128</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R129.htm</HtmlFileName>
      <LongName>2402002 - Disclosure - Provisions and other non-current liabilities (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3</Role>
      <ShortName>Provisions and other non-current liabilities (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables</ParentRole>
      <Position>129</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R130.htm</HtmlFileName>
      <LongName>2402003 - Disclosure - Provisions and other non-current liabilities (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4</Role>
      <ShortName>Provisions and other non-current liabilities (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables</ParentRole>
      <Position>130</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R131.htm</HtmlFileName>
      <LongName>2402004 - Disclosure - Provisions and other non-current liabilities (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5</Role>
      <ShortName>Provisions and other non-current liabilities (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables</ParentRole>
      <Position>131</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R132.htm</HtmlFileName>
      <LongName>2402100 - Disclosure - Current financial debt and derivative financial instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails</Role>
      <ShortName>Current financial debt and derivative financial instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables</ParentRole>
      <Position>132</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R133.htm</HtmlFileName>
      <LongName>2402200 - Disclosure - Provisions and other current liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Provisions and other current liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>133</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R134.htm</HtmlFileName>
      <LongName>2402201 - Disclosure - Provisions and other current liabilities (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2</Role>
      <ShortName>Provisions and other current liabilities (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>134</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R135.htm</HtmlFileName>
      <LongName>2402202 - Disclosure - Provisions and other current liabilities (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3</Role>
      <ShortName>Provisions and other current liabilities (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>135</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R136.htm</HtmlFileName>
      <LongName>2402300 - Disclosure - Details to the consolidated cash flow statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails</Role>
      <ShortName>Details to the consolidated cash flow statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>136</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R137.htm</HtmlFileName>
      <LongName>2402301 - Disclosure - Details to the consolidated cash flow statements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2</Role>
      <ShortName>Details to the consolidated cash flow statements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>137</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R138.htm</HtmlFileName>
      <LongName>2402302 - Disclosure - Details to the consolidated cash flow statements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6</Role>
      <ShortName>Details to the consolidated cash flow statements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>138</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R139.htm</HtmlFileName>
      <LongName>2402305 - Disclosure - Details to the consolidated cash flow statements (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5</Role>
      <ShortName>Details to the consolidated cash flow statements (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>139</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R140.htm</HtmlFileName>
      <LongName>2402306 - Disclosure - Details to the consolidated cash flow statements (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7</Role>
      <ShortName>Details to the consolidated cash flow statements (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>140</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R141.htm</HtmlFileName>
      <LongName>2402307 - Disclosure - Details to the consolidated cash flow statements (Details 7)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8</Role>
      <ShortName>Details to the consolidated cash flow statements (Details 7)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>141</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R142.htm</HtmlFileName>
      <LongName>2402400 - Disclosure - Acquisitions of businesses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails</Role>
      <ShortName>Acquisitions of businesses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesTables</ParentRole>
      <Position>142</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R143.htm</HtmlFileName>
      <LongName>2402500 - Disclosure - Post-employment benefits for employees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails</Role>
      <ShortName>Post-employment benefits for employees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables</ParentRole>
      <Position>143</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R144.htm</HtmlFileName>
      <LongName>2402501 - Disclosure - Post-employment benefits for employees (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2</Role>
      <ShortName>Post-employment benefits for employees (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables</ParentRole>
      <Position>144</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R145.htm</HtmlFileName>
      <LongName>2402502 - Disclosure - Post-employment benefits for employees (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3</Role>
      <ShortName>Post-employment benefits for employees (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables</ParentRole>
      <Position>145</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R146.htm</HtmlFileName>
      <LongName>2402503 - Disclosure - Post-employment benefits for employees (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4</Role>
      <ShortName>Post-employment benefits for employees (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables</ParentRole>
      <Position>146</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R147.htm</HtmlFileName>
      <LongName>2402504 - Disclosure - Post-employment benefits for employees (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5</Role>
      <ShortName>Post-employment benefits for employees (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables</ParentRole>
      <Position>147</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R148.htm</HtmlFileName>
      <LongName>2402505 - Disclosure - Post-employment benefits for employees (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6</Role>
      <ShortName>Post-employment benefits for employees (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables</ParentRole>
      <Position>148</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R149.htm</HtmlFileName>
      <LongName>2402506 - Disclosure - Post-employment benefits for employees (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7</Role>
      <ShortName>Post-employment benefits for employees (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables</ParentRole>
      <Position>149</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R150.htm</HtmlFileName>
      <LongName>2402507 - Disclosure - Post-employment benefits for employees (Details 7)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8</Role>
      <ShortName>Post-employment benefits for employees (Details 7)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables</ParentRole>
      <Position>150</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R151.htm</HtmlFileName>
      <LongName>2402508 - Disclosure - Post-employment benefits for employees (Details 8)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9</Role>
      <ShortName>Post-employment benefits for employees (Details 8)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables</ParentRole>
      <Position>151</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R152.htm</HtmlFileName>
      <LongName>2402509 - Disclosure - Post-employment benefits for employees (Details 9)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10</Role>
      <ShortName>Post-employment benefits for employees (Details 9)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables</ParentRole>
      <Position>152</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R153.htm</HtmlFileName>
      <LongName>2402600 - Disclosure - Equity-based participation plans for employees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails</Role>
      <ShortName>Equity-based participation plans for employees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables</ParentRole>
      <Position>153</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R154.htm</HtmlFileName>
      <LongName>2402601 - Disclosure - Equity-based participation plans for employees (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2</Role>
      <ShortName>Equity-based participation plans for employees (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables</ParentRole>
      <Position>154</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R155.htm</HtmlFileName>
      <LongName>2402602 - Disclosure - Equity-based participation plans for employees (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3</Role>
      <ShortName>Equity-based participation plans for employees (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables</ParentRole>
      <Position>155</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R156.htm</HtmlFileName>
      <LongName>2402603 - Disclosure - Equity-based participation plans for employees (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4</Role>
      <ShortName>Equity-based participation plans for employees (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables</ParentRole>
      <Position>156</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R157.htm</HtmlFileName>
      <LongName>2402604 - Disclosure - Equity-based participation plans for employees (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5</Role>
      <ShortName>Equity-based participation plans for employees (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables</ParentRole>
      <Position>157</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R158.htm</HtmlFileName>
      <LongName>2402700 - Disclosure - Transaction with related parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1</Role>
      <ShortName>Transaction with related parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>158</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R159.htm</HtmlFileName>
      <LongName>2402701 - Disclosure - Transactions with related parties (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2</Role>
      <ShortName>Transactions with related parties (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesTables</ParentRole>
      <Position>159</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R160.htm</HtmlFileName>
      <LongName>2402702 - Disclosure - Transactions with related parties (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3</Role>
      <ShortName>Transactions with related parties (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesTables</ParentRole>
      <Position>160</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R161.htm</HtmlFileName>
      <LongName>2402801 - Disclosure - Commitments and contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2</Role>
      <ShortName>Commitments and contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>161</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R162.htm</HtmlFileName>
      <LongName>2402900 - Disclosure - Financial instruments - additional disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails</Role>
      <ShortName>Financial instruments - additional disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>162</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R163.htm</HtmlFileName>
      <LongName>2402901 - Disclosure - Financial instruments - additional disclosures (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2</Role>
      <ShortName>Financial instruments - additional disclosures (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>163</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R164.htm</HtmlFileName>
      <LongName>2402902 - Disclosure - Financial instruments - additional disclosures (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3</Role>
      <ShortName>Financial instruments - additional disclosures (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>164</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R165.htm</HtmlFileName>
      <LongName>2402903 - Disclosure - Financial instruments - additional disclosures (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4</Role>
      <ShortName>Financial instruments - additional disclosures (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>165</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R166.htm</HtmlFileName>
      <LongName>2402904 - Disclosure - Financial instruments - additional disclosures (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5</Role>
      <ShortName>Financial instruments - additional disclosures (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>166</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R167.htm</HtmlFileName>
      <LongName>2402905 - Disclosure - Financial instruments - additional disclosures (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6</Role>
      <ShortName>Financial instruments - additional disclosures (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>167</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R168.htm</HtmlFileName>
      <LongName>2402906 - Disclosure - Financial instruments - additional disclosures (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7</Role>
      <ShortName>Financial instruments - additional disclosures (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>168</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R169.htm</HtmlFileName>
      <LongName>2402907 - Disclosure - Financial instruments - additional disclosures (Details 7)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8</Role>
      <ShortName>Financial instruments - additional disclosures (Details 7)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>169</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R170.htm</HtmlFileName>
      <LongName>2402908 - Disclosure - Financial instruments - additional disclosures (Details 8)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9</Role>
      <ShortName>Financial instruments - additional disclosures (Details 8)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>170</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R171.htm</HtmlFileName>
      <LongName>2402909 - Disclosure - Financial instruments - additional disclosures (Details 9)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10</Role>
      <ShortName>Financial instruments - additional disclosures (Details 9)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>171</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R172.htm</HtmlFileName>
      <LongName>2402910 - Disclosure - Financial instruments - additional disclosures (Details 10)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12</Role>
      <ShortName>Financial instruments - additional disclosures (Details 10)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>172</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R173.htm</HtmlFileName>
      <LongName>2402911 - Disclosure - Financial instruments - additional disclosures (Details 11)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13</Role>
      <ShortName>Financial instruments - additional disclosures (Details 11)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>173</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R174.htm</HtmlFileName>
      <LongName>2402912 - Disclosure - Financial instruments - additional disclosures (Details 12)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14</Role>
      <ShortName>Financial instruments - additional disclosures (Details 12)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>174</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R175.htm</HtmlFileName>
      <LongName>2402913 - Disclosure - Financial instruments - additional disclosures (Details 13)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15</Role>
      <ShortName>Financial instruments - additional disclosures (Details 13)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>175</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R176.htm</HtmlFileName>
      <LongName>2402915 - Disclosure - Financial instruments - additional disclosures (Details 15)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16</Role>
      <ShortName>Financial instruments - additional disclosures (Details 15)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables</ParentRole>
      <Position>176</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R177.htm</HtmlFileName>
      <LongName>2403000 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Events subsequent to the December 31 consolidated balance sheet date (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosureSubsequentEvents</ParentRole>
      <Position>177</Position>
    </Report>
    <Report instance="nvs-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R178.htm</HtmlFileName>
      <LongName>2403100 - Disclosure - Principal Group subsidiaries and associated companies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails</Role>
      <ShortName>Principal Group subsidiaries and associated companies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables</ParentRole>
      <Position>178</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 344 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, dei:EntityAddressAddressLine1, dei:EntityIncorporationStateCountryCode, ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary, ifrs-full:ProportionOfVotingPowerHeldInSubsidiary, nvs:OptionsExcludedFromTheCalculation -  nvs-20221231.htm 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 181, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358</Log>
  </Logs>
  <InputFiles>
    <File doctype="20-F" original="nvs-20221231.htm">nvs-20221231.htm</File>
    <File>a23020120f-ex12_1.htm</File>
    <File>a23020120f-ex12_2.htm</File>
    <File>a23020120f-ex13_1.htm</File>
    <File>a23020120f-ex13_2.htm</File>
    <File>a23020120f-ex15_1.htm</File>
    <File>a23020120f-ex15_2.htm</File>
    <File>a23020120f-ex2_4.htm</File>
    <File>nvs-20221231.xsd</File>
    <File>nvs-20221231_cal.xml</File>
    <File>nvs-20221231_def.xml</File>
    <File>nvs-20221231_lab.xml</File>
    <File>nvs-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cogo_0002.gif</File>
    <File>cogo_0005.gif</File>
    <File>cogo_0021.gif</File>
    <File>cogo_0025.jpg</File>
    <File>cogo_0026.gif</File>
    <File>cogo_0027.gif</File>
    <File>cogo_0028.jpg</File>
    <File>cogo_0030.jpg</File>
    <File>cogo_0032.jpg</File>
    <File>cogo_0033.jpg</File>
    <File>cogo_0035.jpg</File>
    <File>cogo_0036.jpg</File>
    <File>cogo_0037.jpg</File>
    <File>cogo_0038.jpg</File>
    <File>cogo_0039.gif</File>
    <File>cogo_0043.jpg</File>
    <File>cogo_0044.jpg</File>
    <File>cogo_0045.jpg</File>
    <File>cogo_0047.jpg</File>
    <File>cogo_0049.jpg</File>
    <File>cogo_0059.gif</File>
    <File>cogo_0060.gif</File>
    <File>cogo_0061.gif</File>
    <File>cogo_0062.gif</File>
    <File>cogo_0063.gif</File>
    <File>cogo_0064.gif</File>
    <File>cogo_0065.gif</File>
    <File>cogo_0066.gif</File>
    <File>cogo_0067.gif</File>
    <File>cogo_0068.gif</File>
    <File>cogo_0069.gif</File>
    <File>cogo_0070.gif</File>
    <File>cogo_0071.gif</File>
    <File>comp_0003.gif</File>
    <File>comp_0005.gif</File>
    <File>comp_0006.gif</File>
    <File>comp_0007.gif</File>
    <File>comp_0008.gif</File>
    <File>comp_0009.gif</File>
    <File>comp_0010.gif</File>
    <File>comp_0012.gif</File>
    <File>comp_0014.gif</File>
    <File>comp_0016.gif</File>
    <File>comp_0023.gif</File>
    <File>comp_0026.gif</File>
    <File>comp_0028.gif</File>
    <File>comp_0029.gif</File>
    <File>comp_0030.gif</File>
    <File>comp_0031.gif</File>
    <File>sign-full.jpg</File>
    <File>sign-half.jpg</File>
    <File>skill-g.jpg</File>
    <File>skill-l.jpg</File>
    <File>skill-m.jpg</File>
    <File>skill-x.jpg</File>
    <File>skill-y.jpg</File>
    <File>skill-z.jpg</File>
    <File>x_coverback.jpg</File>
    <File>x_coverfront.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="51">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
    <BaseTaxonomy items="3575">https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>259
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nvs-20221231.htm": {
   "axisCustom": 19,
   "axisStandard": 37,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 51,
    "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 3575
   },
   "contextCount": 1959,
   "dts": {
    "calculationLink": {
     "local": [
      "nvs-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nvs-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nvs-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nvs-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nvs-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nvs-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 2141,
   "entityCount": 1,
   "hidden": {
    "http://novartis.com/20221231": 2,
    "http://xbrl.sec.gov/dei/2022": 7,
    "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 339,
    "total": 348
   },
   "keyCustom": 385,
   "keyStandard": 393,
   "memberCustom": 410,
   "memberStandard": 84,
   "nsprefix": "nvs",
   "nsuri": "http://novartis.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://novartis.com/20221231/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2100400 - Disclosure - Associated companies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://novartis.com/20221231/role/DisclosureAssociatedCompanies",
     "shortName": "Associated companies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401101 - Disclosure - Goodwill and intangible assets (Details 1)",
     "menuCat": "Details",
     "order": "100",
     "role": "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
     "shortName": "Goodwill and intangible assets (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AssumptionsUsedInTheCalculationOfValuationTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401102 - Disclosure - Goodwill and intangible assets (Details 2)",
     "menuCat": "Details",
     "order": "101",
     "role": "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
     "shortName": "Goodwill and intangible assets (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AssumptionsUsedInTheCalculationOfValuationTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsMaterialToEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401103 - Disclosure - Goodwill and intangible assets (Details 3)",
     "menuCat": "Details",
     "order": "102",
     "role": "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5",
     "shortName": "Goodwill and intangible assets (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LeqvioMember",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsMaterialToEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022IntangibleAssetsOtherThanGoodwillMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401104 - Disclosure - Goodwill and intangible assets (Details 4)",
     "menuCat": "Details",
     "order": "103",
     "role": "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
     "shortName": "Goodwill and intangible assets (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:IntangibleAssetImpairmentChargesTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_nvs-2022Q4CurrentlyMarketedProductsMember_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4VotrientMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember",
      "decimals": "-8",
      "lang": null,
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:GrossDeferredTaxAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401200 - Disclosure - Deferred tax assets and liabilities (Details)",
     "menuCat": "Details",
     "order": "104",
     "role": "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Deferred tax assets and liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:GrossDeferredTaxAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401201 - Disclosure - Deferred tax assets and liabilities (Details 1)",
     "menuCat": "Details",
     "order": "105",
     "role": "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3",
     "shortName": "Deferred tax assets and liabilities (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-9",
      "first": true,
      "lang": null,
      "name": "nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401202 - Disclosure - Deferred tax assets and liabilities (Details 2)",
     "menuCat": "Details",
     "order": "106",
     "role": "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4",
     "shortName": "Deferred tax assets and liabilities (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-9",
      "first": true,
      "lang": null,
      "name": "nvs:UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfFinancialAssetsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:NoncurrentFinancialAssetsEquityInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401300 - Disclosure - Financial and other non-current assets (Details)",
     "menuCat": "Details",
     "order": "107",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails",
     "shortName": "Financial and other non-current assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfFinancialAssetsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:NoncurrentFinancialAssetsEquityInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOtherNoncurrentAssetsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:DeferredCompensationPlansAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401301 - Disclosure - Financial and other non-current assets (Details 1)",
     "menuCat": "Details",
     "order": "108",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2",
     "shortName": "Financial and other non-current assets (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOtherNoncurrentAssetsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:DeferredCompensationPlansAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Inventories",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401400 - Disclosure - Inventories (Details)",
     "menuCat": "Details",
     "order": "109",
     "role": "http://novartis.com/20221231/role/DisclosureInventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-8",
      "lang": null,
      "name": "ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInterestExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2100500 - Disclosure - Interest expense and other financial income and expense",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpense",
     "shortName": "Interest expense and other financial income and expense",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInterestExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401500 - Disclosure - Trade receivables (Details)",
     "menuCat": "Details",
     "order": "110",
     "role": "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails",
     "shortName": "Trade receivables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ProvisionsForTradeReceivablesTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfull-2022GrossCarryingAmountMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ProvisionsForReductionOfRevenueTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProvisionUsedOtherProvisions",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401501 - Disclosure - Trade receivables (Details 1)",
     "menuCat": "Details",
     "order": "111",
     "role": "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
     "shortName": "Trade receivables (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:TradeReceivablesProvisionMovementsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_nvs-2022Q4ProvisionForDoubtfulReceivableMember_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:AdditionalProvisionsOtherProvisions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401502 - Disclosure - Trade receivables (Details 2)",
     "menuCat": "Details",
     "order": "112",
     "role": "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3",
     "shortName": "Trade receivables (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:OverdueAmountsAndRelatedProvisionsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_ifrsfull-2022PastDueStatusAxis_ifrsfull-2022CurrentMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401503 - Disclosure - Trade receivables (Details 3)",
     "menuCat": "Details",
     "order": "113",
     "role": "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4",
     "shortName": "Trade receivables (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfFinancialInstrumentsAxis_ifrsfull-2022TradeReceivablesMember_srt-2022CurrencyAxis_currency-2022USD",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:Commodities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details)",
     "menuCat": "Details",
     "order": "114",
     "role": "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails",
     "shortName": "Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:Commodities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:CashAndCashEquivalentsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401601 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 1)",
     "menuCat": "Details",
     "order": "115",
     "role": "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails3",
     "shortName": "Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:CashAndCashEquivalentsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:OtherCurrentAssetsTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentValueAddedTaxReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401700 - Disclosure - Other current assets (Details)",
     "menuCat": "Details",
     "order": "116",
     "role": "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails",
     "shortName": "Other current assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:OtherCurrentAssetsTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentValueAddedTaxReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R117": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IssuedCapital",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401800 - Disclosure - Equity (Details)",
     "menuCat": "Details",
     "order": "117",
     "role": "http://novartis.com/20221231/role/DisclosureEquityDetails",
     "shortName": "Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:MovementInTheShareCapitalTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfEquityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-3",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:IssuedCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R118": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:MovementInTheShareslTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfEquityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfSharesOutstanding",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401801 - Disclosure - Equity (Details 1)",
     "menuCat": "Details",
     "order": "118",
     "role": "http://novartis.com/20221231/role/DisclosureEquityDetails2",
     "shortName": "Equity (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:MovementInTheShareslTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfEquityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-3",
      "decimals": "-5",
      "lang": null,
      "name": "ifrs-full:NumberOfSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R119": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DividendTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfEquityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nvs:DividendsPayableAmountPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CHFPerShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401802 - Disclosure - Equity (Details 2)",
     "menuCat": "Details",
     "order": "119",
     "role": "http://novartis.com/20221231/role/DisclosureEquityDetails3",
     "shortName": "Equity (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DividendTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfEquityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nvs:DividendsPayableAmountPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "CHFPerShares",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2100600 - Disclosure - Income taxes",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://novartis.com/20221231/role/DisclosureTaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R120": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:MovementInTheShareslTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfEquityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "nvs:TreasurySharesAcquiredToBeCancelled",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401803 - Disclosure - Equity (Details 3)",
     "menuCat": "Details",
     "order": "120",
     "role": "http://novartis.com/20221231/role/DisclosureEquityDetails4",
     "shortName": "Equity (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:SummaryOfTreasurySharesMovementsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:TreasurySharesAcquiredForCancellationValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R121": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:CommitmentForRepurchaseOwnShares",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401804 - Disclosure - Equity (Details 4)",
     "menuCat": "Details",
     "order": "121",
     "role": "http://novartis.com/20221231/role/DisclosureEquityDetails5",
     "shortName": "Equity (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear-1",
      "decimals": "-8",
      "lang": null,
      "name": "nvs:MaximalAmountOfShareBuybackProgramm",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R122": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:BondsIssued",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401900 - Disclosure - Non-current financial debt (Details)",
     "menuCat": "Details",
     "order": "122",
     "role": "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails",
     "shortName": "Non-current financial debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:LiabilitiesToBanksAndOtherInstitutions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R123": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:BondsIssued",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401901 - Disclosure - Non-current financial debt (Details 1)",
     "menuCat": "Details",
     "order": "123",
     "role": "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2",
     "shortName": "Non-current financial debt (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022BorrowingsByNameAxis_nvs-2022Q4A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member",
      "decimals": null,
      "lang": "en-US",
      "name": "ifrs-full:BorrowingsOriginalCurrency",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R124": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Borrowings",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401902 - Disclosure - Non-current financial debt (Details 2)",
     "menuCat": "Details",
     "order": "124",
     "role": "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3",
     "shortName": "Non-current financial debt (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022MaturityAxis_ifrsfull-2022NotLaterThanOneYearMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:Borrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R125": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Borrowings",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401903 - Disclosure - Non-current financial debt (Details 3)",
     "menuCat": "Details",
     "order": "125",
     "role": "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4",
     "shortName": "Non-current financial debt (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_srt-2022CurrencyAxis_currency-2022USD",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:Borrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R126": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:BondsIssued",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401904 - Disclosure - Non-current financial debt (Details 4)",
     "menuCat": "Details",
     "order": "126",
     "role": "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5",
     "shortName": "Non-current financial debt (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4FairValueByMeasurementBasisAxis_nvs-2022Q4CarryingReportedAmountFairValueDisclosureMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:BondsIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R127": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402000 - Disclosure - Provisions and other non-current liabilities (Details)",
     "menuCat": "Details",
     "order": "127",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails",
     "shortName": "Provisions and other non-current liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R128": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AccrualForEnvironmentalLossContingenciesTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:EnvironmentalProvision",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402001 - Disclosure - Provisions and other non-current liabilities (Details 1)",
     "menuCat": "Details",
     "order": "128",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2",
     "shortName": "Provisions and other non-current liabilities (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AccrualForEnvironmentalLossContingenciesTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:EnvironmentalProvisionPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R129": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:EnvironmentalProvisionExpectedCashOutflowNextTwoYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402002 - Disclosure - Provisions and other non-current liabilities (Details 2)",
     "menuCat": "Details",
     "order": "129",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3",
     "shortName": "Provisions and other non-current liabilities (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:EnvironmentalProvisionExpectedCashOutflowNextTwoYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2100700 - Disclosure - Earnings per share",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://novartis.com/20221231/role/DisclosureEarningsPerShare",
     "shortName": "Earnings per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R130": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402003 - Disclosure - Provisions and other non-current liabilities (Details 3)",
     "menuCat": "Details",
     "order": "130",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
     "shortName": "Provisions and other non-current liabilities (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022GeographicalAreasAxis_country-2022IT_ifrsfull-2022ProductsAndServicesAxis_nvs-2022Q4LucentisMember",
      "decimals": "-8",
      "lang": null,
      "name": "nvs:EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R131": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402004 - Disclosure - Provisions and other non-current liabilities (Details 4)",
     "menuCat": "Details",
     "order": "131",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5",
     "shortName": "Provisions and other non-current liabilities (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-3",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R132": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:InterestBearningAccountsOfAssociatesPayableOnDemand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402100 - Disclosure - Current financial debt and derivative financial instruments (Details)",
     "menuCat": "Details",
     "order": "132",
     "role": "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails",
     "shortName": "Current financial debt and derivative financial instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:InterestBearningAccountsOfAssociatesPayableOnDemand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R133": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402200 - Disclosure - Provisions and other current liabilities (Details)",
     "menuCat": "Details",
     "order": "133",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails",
     "shortName": "Provisions and other current liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:AccrualForTaxesOtherThanIncomeTaxesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R134": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentRefundsProvision",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402201 - Disclosure - Provisions and other current liabilities (Details 1)",
     "menuCat": "Details",
     "order": "134",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2",
     "shortName": "Provisions and other current liabilities (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ProvisionsForReductionOfRevenueTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R135": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ProvisionsForReductionOfRevenueTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProvisionUsedOtherProvisions",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402202 - Disclosure - Provisions and other current liabilities (Details 2)",
     "menuCat": "Details",
     "order": "135",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
     "shortName": "Provisions and other current liabilities (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:RestructuringProvisionsMovementsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-3_ifrsfull-2022ClassesOfProvisionsAxis_ifrsfull-2022RestructuringProvisionMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:OtherProvisions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R136": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402300 - Disclosure - Details to the consolidated cash flow statements (Details)",
     "menuCat": "Details",
     "order": "136",
     "role": "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
     "shortName": "Details to the consolidated cash flow statements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R137": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IncomeTaxesPaidRefund",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402301 - Disclosure - Details to the consolidated cash flow statements (Details 1)",
     "menuCat": "Details",
     "order": "137",
     "role": "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2",
     "shortName": "Details to the consolidated cash flow statements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IncomeTaxesPaidRefund",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R138": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AdjustmentsForDecreaseIncreaseInInventories",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402302 - Disclosure - Details to the consolidated cash flow statements (Details 2)",
     "menuCat": "Details",
     "order": "138",
     "role": "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6",
     "shortName": "Details to the consolidated cash flow statements (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AdjustmentsForDecreaseIncreaseInInventories",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R139": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402305 - Disclosure - Details to the consolidated cash flow statements (Details 5)",
     "menuCat": "Details",
     "order": "139",
     "role": "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
     "shortName": "Details to the consolidated cash flow statements (Details 5)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_nvs-2022Q4AcquisitionsAndDivestmentsAxis_nvs-2022Q4AcquisitionsMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:CashFlowFromNetIdentifiableAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2100800 - Disclosure - Changes in consolidated statements of comprehensive income",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncome",
     "shortName": "Changes in consolidated statements of comprehensive income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R140": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:FinancialDebtsAndDerivativeInstruments",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402306 - Disclosure - Details to the consolidated cash flow statements (Details 6)",
     "menuCat": "Details",
     "order": "140",
     "role": "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
     "shortName": "Details to the consolidated cash flow statements (Details 6)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-8",
      "lang": null,
      "name": "nvs:CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R141": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear-2",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402307 - Disclosure - Details to the consolidated cash flow statements (Details 7)",
     "menuCat": "Details",
     "order": "141",
     "role": "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8",
     "shortName": "Details to the consolidated cash flow statements (Details 7)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R142": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402400 - Disclosure - Acquisitions of businesses (Details)",
     "menuCat": "Details",
     "order": "142",
     "role": "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails",
     "shortName": "Acquisitions of businesses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R143": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ConcentrationOfMajorPlansGeographic",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402500 - Disclosure - Post-employment benefits for employees (Details)",
     "menuCat": "Details",
     "order": "143",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails",
     "shortName": "Post-employment benefits for employees (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ConcentrationOfMajorPlansGeographic",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R144": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfDefinedBenefitPlansTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DefinedBenefitObligationAtPresentValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402501 - Disclosure - Post-employment benefits for employees (Details 1)",
     "menuCat": "Details",
     "order": "144",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
     "shortName": "Post-employment benefits for employees (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfDefinedBenefitPlansTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:DefinedBenefitPlanInterestCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R145": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOtherNoncurrentAssetsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:PrepaidPostemploymentBenefitPlansAssets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402502 - Disclosure - Post-employment benefits for employees (Details 2)",
     "menuCat": "Details",
     "order": "145",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3",
     "shortName": "Post-employment benefits for employees (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R146": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfDefinedBenefitPlansTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DefinedBenefitObligationAtPresentValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402503 - Disclosure - Post-employment benefits for employees (Details 3)",
     "menuCat": "Details",
     "order": "146",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4",
     "shortName": "Post-employment benefits for employees (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4ObligationByTypeAxis_nvs-2022Q4UnfundedMember_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:DefinedBenefitObligationAtPresentValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R147": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfAssumptionsUsedTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ActuarialAssumptionOfDiscountRates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402504 - Disclosure - Post-employment benefits for employees (Details 4)",
     "menuCat": "Details",
     "order": "147",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5",
     "shortName": "Post-employment benefits for employees (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfAssumptionsUsedTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ActuarialAssumptionOfDiscountRates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R148": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402505 - Disclosure - Post-employment benefits for employees (Details 5)",
     "menuCat": "Details",
     "order": "148",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6",
     "shortName": "Post-employment benefits for employees (Details 5)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022ActuarialAssumptionsAxis_ifrsfull-2022ActuarialAssumptionOfDiscountRatesMember_nvs-2022Q4ChangeInActuarialAssumptionAxis_nvs-2022Q4Change25BasisPointMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R149": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402506 - Disclosure - Post-employment benefits for employees (Details 6)",
     "menuCat": "Details",
     "order": "149",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7",
     "shortName": "Post-employment benefits for employees (Details 6)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4OtherPostemploymentBenefitPlansMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "nvs:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2100900 - Disclosure - Property, plant and equipment",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipment",
     "shortName": "Property, plant and equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R150": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nvs:DefinedBenefitPlanPlanAssetAllocations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402507 - Disclosure - Post-employment benefits for employees (Details 7)",
     "menuCat": "Details",
     "order": "150",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8",
     "shortName": "Post-employment benefits for employees (Details 7)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nvs:DefinedBenefitPlanPlanAssetAllocations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R151": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402508 - Disclosure - Post-employment benefits for employees (Details 8)",
     "menuCat": "Details",
     "order": "151",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9",
     "shortName": "Post-employment benefits for employees (Details 8)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4RetirementPlanTypeAxis_nvs-2022Q4PensionPlanMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R152": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:ScheduleOfDefinedContributionPlansTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402509 - Disclosure - Post-employment benefits for employees (Details 9)",
     "menuCat": "Details",
     "order": "152",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10",
     "shortName": "Post-employment benefits for employees (Details 9)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:ScheduleOfDefinedContributionPlansTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "ifrs-full:EmployeeBenefitsExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R153": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402600 - Disclosure - Equity-based participation plans for employees (Details)",
     "menuCat": "Details",
     "order": "153",
     "role": "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails",
     "shortName": "Equity-based participation plans for employees (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R154": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentivePlanMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402601 - Disclosure - Equity-based participation plans for employees (Details 1)",
     "menuCat": "Details",
     "order": "154",
     "role": "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
     "shortName": "Equity-based participation plans for employees (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentivePlanMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExplanationOfShareOptionsInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R155": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402602 - Disclosure - Equity-based participation plans for employees (Details 2)",
     "menuCat": "Details",
     "order": "155",
     "role": "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
     "shortName": "Equity-based participation plans for employees (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember",
      "decimals": "-5",
      "lang": null,
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R156": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402603 - Disclosure - Equity-based participation plans for employees (Details 3)",
     "menuCat": "Details",
     "order": "156",
     "role": "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
     "shortName": "Equity-based participation plans for employees (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-2_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember",
      "decimals": "-5",
      "lang": null,
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R157": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402604 - Disclosure - Equity-based participation plans for employees (Details 4)",
     "menuCat": "Details",
     "order": "157",
     "role": "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5",
     "shortName": "Equity-based participation plans for employees (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022TypesOfSharebasedPaymentArrangementsAxis_nvs-2022Q4EquityBasedParticipationAnnualIncentiveRSUMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R158": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdParties",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402700 - Disclosure - Transaction with related parties (Details)",
     "menuCat": "Details",
     "order": "158",
     "role": "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1",
     "shortName": "Transaction with related parties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "0",
      "lang": null,
      "name": "nvs:RelatedPartiesNumberOfExecutiveCommitteeMembers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R159": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:OfficerAndDirectorCompensationTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402701 - Disclosure - Transactions with related parties (Details 1)",
     "menuCat": "Details",
     "order": "159",
     "role": "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2",
     "shortName": "Transactions with related parties (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:OfficerAndDirectorCompensationTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101000 - Disclosure - Right-of-use assets and lease liabilities",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiability",
     "shortName": "Right-of-use assets and lease liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R160": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:OfficerAndDirectorCompensationTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:KeyManagementPersonnelCompensation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402702 - Disclosure - Transactions with related parties (Details 2)",
     "menuCat": "Details",
     "order": "160",
     "role": "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3",
     "shortName": "Transactions with related parties (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-4_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4NovartisPensionFundMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:BorrowingsCreditFacilityUncommitted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R161": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfLeasingCommitmentsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfCommitmentsAndContingenciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:CommitmentsUnderLongtermResearchAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402801 - Disclosure - Commitments and contingencies (Details 1)",
     "menuCat": "Details",
     "order": "161",
     "role": "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2",
     "shortName": "Commitments and contingencies (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfLeasingCommitmentsTableTextBlock",
       "div",
       "div",
       "nvs:DisclosureOfCommitmentsAndContingenciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:CommitmentsUnderLongtermResearchAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R162": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402900 - Disclosure - Financial instruments - additional disclosures (Details)",
     "menuCat": "Details",
     "order": "162",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
     "shortName": "Financial instruments - additional disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialAssetsAxis_ifrsfull-2022FinancialAssetsAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialAssetsAxis_nvs-2022Q4CashAndCashEquivalentsMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R163": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402901 - Disclosure - Financial instruments - additional disclosures (Details 1)",
     "menuCat": "Details",
     "order": "163",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2",
     "shortName": "Financial instruments - additional disclosures (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022CategoriesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrsfull-2022ClassesOfFinancialLiabilitiesAxis_ifrsfull-2022FinancialLiabilitiesAtAmortisedCostMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R164": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:DerivativeFinancialInstruments",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402902 - Disclosure - Financial instruments - additional disclosures (Details 2)",
     "menuCat": "Details",
     "order": "164",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
     "shortName": "Financial instruments - additional disclosures (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4PositiveFairValuesMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:DerivativeFinancialInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R165": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:DerivativeFinancialInstruments",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402903 - Disclosure - Financial instruments - additional disclosures (Details 3)",
     "menuCat": "Details",
     "order": "165",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4",
     "shortName": "Financial instruments - additional disclosures (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4FinancialInstrumentsPrincipalAmountsAxis_nvs-2022Q4ContractOrUnderlyingPrincipalAmoutMember_srt-2022CurrencyAxis_currency-2022EUR",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:DerivativeFinancialInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R166": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402904 - Disclosure - Financial instruments - additional disclosures (Details 4)",
     "menuCat": "Details",
     "order": "166",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
     "shortName": "Financial instruments - additional disclosures (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4CashAndCashEquivalentsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R167": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialLiabilitiesAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402905 - Disclosure - Financial instruments - additional disclosures (Details 5)",
     "menuCat": "Details",
     "order": "167",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6",
     "shortName": "Financial instruments - additional disclosures (Details 5)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfLiabilitiesAxis_nvs-2022Q4ContingentConsiderationPayablesMember_ifrsfull-2022MeasurementAxis_ifrsfull-2022RecurringFairValueMeasurementMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialLiabilitiesAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R168": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:FinancialInstrumentsCarryingValueLevel3",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402906 - Disclosure - Financial instruments - additional disclosures (Details 6)",
     "menuCat": "Details",
     "order": "168",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7",
     "shortName": "Financial instruments - additional disclosures (Details 6)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-2_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4AssociatedCompaniesAtFairValueThroughProfitAndLossMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:FinancialInstrumentsCarryingValueLevel3",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R169": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402907 - Disclosure - Financial instruments - additional disclosures (Details 7)",
     "menuCat": "Details",
     "order": "169",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8",
     "shortName": "Financial instruments - additional disclosures (Details 7)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_nvs-2022Q4GroupsOfFinancialAssetsLiabilitiesAxis_nvs-2022Q4MarketableSecuritiesAndTimeDepositsMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Goodwill and intangible assets",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssets",
     "shortName": "Goodwill and intangible assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R170": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402908 - Disclosure - Financial instruments - additional disclosures (Details 8)",
     "menuCat": "Details",
     "order": "170",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9",
     "shortName": "Financial instruments - additional disclosures (Details 8)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R171": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:ContractualInterestOnNoncurrentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402909 - Disclosure - Financial instruments - additional disclosures (Details 9)",
     "menuCat": "Details",
     "order": "171",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10",
     "shortName": "Financial instruments - additional disclosures (Details 9)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:ContractualInterestOnNoncurrentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R172": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402910 - Disclosure - Financial instruments - additional disclosures (Details 10)",
     "menuCat": "Details",
     "order": "172",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12",
     "shortName": "Financial instruments - additional disclosures (Details 10)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TransfersOutOfLevel3OfFairValueHierarchyAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R173": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:CustomersWithNetSalesOverFivePercent",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402911 - Disclosure - Financial instruments - additional disclosures (Details 11)",
     "menuCat": "Details",
     "order": "173",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13",
     "shortName": "Financial instruments - additional disclosures (Details 11)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "2",
      "lang": null,
      "name": "nvs:PercentageOfGovernmentBackedDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R174": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402912 - Disclosure - Financial instruments - additional disclosures (Details 12)",
     "menuCat": "Details",
     "order": "174",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14",
     "shortName": "Financial instruments - additional disclosures (Details 12)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R175": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nvs:HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402913 - Disclosure - Financial instruments - additional disclosures (Details 13)",
     "menuCat": "Details",
     "order": "175",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15",
     "shortName": "Financial instruments - additional disclosures (Details 13)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nvs:HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R176": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nvs:HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402915 - Disclosure - Financial instruments - additional disclosures (Details 15)",
     "menuCat": "Details",
     "order": "176",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16",
     "shortName": "Financial instruments - additional disclosures (Details 15)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nvs:HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R177": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403000 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date (Details)",
     "menuCat": "Details",
     "order": "177",
     "role": "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails",
     "shortName": "Events subsequent to the December 31 consolidated balance sheet date (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R178": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403100 - Disclosure - Principal Group subsidiaries and associated companies (Details)",
     "menuCat": "Details",
     "order": "178",
     "role": "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails",
     "shortName": "Principal Group subsidiaries and associated companies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101200 - Disclosure - Deferred tax assets and liabilities",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilities",
     "shortName": "Deferred tax assets and liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101300 - Disclosure - Financial and other non-current assets",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssets",
     "shortName": "Financial and other non-current assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Consolidated income statements",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://novartis.com/20221231/role/StatementOfIncome",
     "shortName": "Consolidated income statements",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101400 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://novartis.com/20221231/role/DisclosureInventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101500 - Disclosure - Trade receivables",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://novartis.com/20221231/role/DisclosureTradeReceivables",
     "shortName": "Trade receivables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://novartis.com/20221231/role/DisclosureMarketableSecurities",
     "shortName": "Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101700 - Disclosure - Other current assets",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://novartis.com/20221231/role/DisclosureOtherCurrentAssets",
     "shortName": "Other current assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101800 - Disclosure - Equity",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://novartis.com/20221231/role/DisclosureEquity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfEquityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101900 - Disclosure - Non-current financial debt",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebt",
     "shortName": "Non-current financial debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102000 - Disclosure - Provisions and other non-current liabilities",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilities",
     "shortName": "Provisions and other non-current liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - Current financial debt and derivative financial instruments",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstruments",
     "shortName": "Current financial debt and derivative financial instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102200 - Disclosure - Provisions and other current liabilities",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilities",
     "shortName": "Provisions and other current liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102300 - Disclosure - Details to the consolidated statements of cash flows",
     "menuCat": "Notes",
     "order": "29",
     "role": "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatements",
     "shortName": "Details to the consolidated statements of cash flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Consolidated statements of comprehensive income",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://novartis.com/20221231/role/StatementOfComprehensiveIncome",
     "shortName": "Consolidated statements of comprehensive income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102400 - Disclosure - Acquisitions of businesses",
     "menuCat": "Notes",
     "order": "30",
     "role": "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinesses",
     "shortName": "Acquisitions of businesses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102500 - Disclosure - Post-employment benefits for employees",
     "menuCat": "Notes",
     "order": "31",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociates",
     "shortName": "Post-employment benefits for employees",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102600 - Disclosure - Equity-based participation plans for employees",
     "menuCat": "Notes",
     "order": "32",
     "role": "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociates",
     "shortName": "Equity-based participation plans for employees",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102700 - Disclosure - Transactions with related parties",
     "menuCat": "Notes",
     "order": "33",
     "role": "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedParties",
     "shortName": "Transactions with related parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfCommitmentsAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102800 - Disclosure - Commitments and contingencies",
     "menuCat": "Notes",
     "order": "34",
     "role": "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfCommitmentsAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102900 - Disclosure - Financial instruments - additional disclosures",
     "menuCat": "Notes",
     "order": "35",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosures",
     "shortName": "Financial instruments - additional disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103000 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date",
     "menuCat": "Notes",
     "order": "36",
     "role": "http://novartis.com/20221231/role/DisclosureSubsequentEvents",
     "shortName": "Events subsequent to the December 31 consolidated balance sheet date",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103100 - Disclosure - Principal Group subsidiaries and associated companies",
     "menuCat": "Notes",
     "order": "37",
     "role": "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompanies",
     "shortName": "Principal Group subsidiaries and associated companies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfAccountingPolicyForSubsidiariesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2200100 - Disclosure - Significant accounting policies (Policies)",
     "menuCat": "Policies",
     "order": "38",
     "role": "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Significant accounting policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DescriptionOfAccountingPolicyForSubsidiariesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2300100 - Disclosure - Significant accounting policies (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Significant accounting policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Consolidated balance sheets",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://novartis.com/20221231/role/BalanceSheet",
     "shortName": "Consolidated balance sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2300300 - Disclosure - Segmentation of key figures (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables",
     "shortName": "Segmentation of key figures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2300400 - Disclosure - Associated companies (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables",
     "shortName": "Associated companies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfInterestExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:InterestExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2300500 - Disclosure - Interest expense and other financial income and expense (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables",
     "shortName": "Interest expense and other financial income and expense (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfInterestExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:InterestExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:IncomeBeforeTaxesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2300600 - Disclosure - Income taxes (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://novartis.com/20221231/role/DisclosureTaxesTables",
     "shortName": "Income taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:IncomeBeforeTaxesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2300700 - Disclosure - Earnings per share (Tables)",
     "menuCat": "Tables",
     "order": "44",
     "role": "http://novartis.com/20221231/role/DisclosureEarningsPerShareTables",
     "shortName": "Earnings per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfComprehensiveIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2300800 - Disclosure - Changes in consolidated statements of comprehensive income (Tables)",
     "menuCat": "Tables",
     "order": "45",
     "role": "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables",
     "shortName": "Changes in consolidated statements of comprehensive income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfComprehensiveIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:PropertyPlantAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2300900 - Disclosure - Property, plant and equipment (Tables)",
     "menuCat": "Tables",
     "order": "46",
     "role": "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentTables",
     "shortName": "Property, plant and equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:PropertyPlantAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfRightofuseAssetsRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301000 - Disclosure - Right-of-use assets and lease liabilities (Tables)",
     "menuCat": "Tables",
     "order": "47",
     "role": "http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables",
     "shortName": "Right-of-use assets and lease liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfRightofuseAssetsRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301100 - Disclosure - Goodwill and intangible assets (Tables)",
     "menuCat": "Tables",
     "order": "48",
     "role": "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables",
     "shortName": "Goodwill and intangible assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301200 - Disclosure - Deferred tax assets and liabilities (Tables)",
     "menuCat": "Tables",
     "order": "49",
     "role": "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables",
     "shortName": "Deferred tax assets and liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-3_ifrsfull-2022RetrospectiveApplicationAndRetrospectiveRestatementAxis_nvs-2022Q4RestatedValueAdjustmentsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - Consolidated statements of changes in equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://novartis.com/20221231/role/StatementOfChangesInEquity",
     "shortName": "Consolidated statements of changes in equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear-2_ifrsfull-2022ComponentsOfEquityAxis_ifrsfull-2022EquityAttributableToOwnersOfParentMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfFinancialAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301300 - Disclosure - Financial and other non-current assets (Tables)",
     "menuCat": "Tables",
     "order": "50",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables",
     "shortName": "Financial and other non-current assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfFinancialAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301400 - Disclosure - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "51",
     "role": "http://novartis.com/20221231/role/DisclosureInventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ProvisionsForTradeReceivablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301500 - Disclosure - Trade receivables (Tables)",
     "menuCat": "Tables",
     "order": "52",
     "role": "http://novartis.com/20221231/role/DisclosureTradeReceivablesTables",
     "shortName": "Trade receivables (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfTradeReceivablesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ProvisionsForTradeReceivablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301600 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Tables)",
     "menuCat": "Tables",
     "order": "53",
     "role": "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesTables",
     "shortName": "Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:OtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301700 - Disclosure - Other current assets (Tables)",
     "menuCat": "Tables",
     "order": "54",
     "role": "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsTables",
     "shortName": "Other current assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:OtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfEquityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:MovementInTheShareCapitalTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301800 - Disclosure - Equity (Tables)",
     "menuCat": "Tables",
     "order": "55",
     "role": "http://novartis.com/20221231/role/DisclosureEquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfEquityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:MovementInTheShareCapitalTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301900 - Disclosure - Non-current financial debt (Tables)",
     "menuCat": "Tables",
     "order": "56",
     "role": "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables",
     "shortName": "Non-current financial debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302000 - Disclosure - Provisions and other non-current liabilities (Tables)",
     "menuCat": "Tables",
     "order": "57",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables",
     "shortName": "Provisions and other non-current liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherProvisionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302100 - Disclosure - Current financial debt and derivative financial instruments (Tables)",
     "menuCat": "Tables",
     "order": "58",
     "role": "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables",
     "shortName": "Current financial debt and derivative financial instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302200 - Disclosure - Provisions and other current liabilities (Tables)",
     "menuCat": "Tables",
     "order": "59",
     "role": "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables",
     "shortName": "Provisions and other current liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - Consolidated cash flow statements",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://novartis.com/20221231/role/StatementsOfCashFlow",
     "shortName": "Consolidated cash flow statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:DividendsReceivedClassifiedAsOperatingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302300 - Disclosure - Details to the consolidated statements of cash flows (Tables)",
     "menuCat": "Tables",
     "order": "60",
     "role": "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables",
     "shortName": "Details to the consolidated statements of cash flows (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302400 - Disclosure - Acquisitions of businesses (Tables)",
     "menuCat": "Tables",
     "order": "61",
     "role": "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesTables",
     "shortName": "Acquisitions of businesses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfDefinedBenefitPlansTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302500 - Disclosure - Post-employment benefits for employees (Tables)",
     "menuCat": "Tables",
     "order": "62",
     "role": "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables",
     "shortName": "Post-employment benefits for employees (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfDefinedBenefitPlansTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302600 - Disclosure - Equity-based participation plans for employees (Tables)",
     "menuCat": "Tables",
     "order": "63",
     "role": "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables",
     "shortName": "Equity-based participation plans for employees (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:OfficerAndDirectorCompensationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302700 - Disclosure - Transactions with related parties (Tables)",
     "menuCat": "Tables",
     "order": "64",
     "role": "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesTables",
     "shortName": "Transactions with related parties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:OfficerAndDirectorCompensationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfCommitmentsAndContingenciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfLeasingCommitmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302800 - Disclosure - Commitments and contingencies (Tables)",
     "menuCat": "Tables",
     "order": "65",
     "role": "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfCommitmentsAndContingenciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfLeasingCommitmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302900 - Disclosure - Financial instruments - additional disclosures (Tables)",
     "menuCat": "Tables",
     "order": "66",
     "role": "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables",
     "shortName": "Financial instruments - additional disclosures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303100 - Disclosure - Principal Group subsidiaries and associated companies (Tables)",
     "menuCat": "Tables",
     "order": "67",
     "role": "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables",
     "shortName": "Principal Group subsidiaries and associated companies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ParValuePerShare",
      "reportCount": 1,
      "unitRef": "CHFPerShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400100 - Disclosure - Significant accounting policies (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
     "shortName": "Significant accounting policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400200 - Disclosure - Significant transactions (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
     "shortName": "Significant transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "nvs:DisclosureOfSignificantTransactionsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember",
      "decimals": "-5",
      "lang": null,
      "name": "nvs:NumberOfBearerShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2100100 - Disclosure - Significant accounting policies",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nvs:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400300 - Disclosure - Segmentation of key figures (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails",
     "shortName": "Segmentation of key figures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nvs:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdParties",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400301 - Disclosure - Segmentation of key figures (Details 1)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
     "shortName": "Segmentation of key figures (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsSalesToOtherSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromInterest",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400302 - Disclosure - Segmentation of key figures (Details 2)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
     "shortName": "Segmentation of key figures (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Assets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400303 - Disclosure - Segmentation of key figures (Details 3)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
     "shortName": "Segmentation of key figures (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:NetOperatingAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdParties",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400304 - Disclosure - Segmentation of key figures (Details 4)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4",
     "shortName": "Segmentation of key figures (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdParties",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400305 - Disclosure - Segmentation of key figures (Details 5)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5",
     "shortName": "Segmentation of key figures (Details 5)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember",
      "decimals": "2",
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:CustomersWithNetSalesOverFivePercent",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400306 - Disclosure - Segmentation of key figures (Details 6)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6",
     "shortName": "Segmentation of key figures (Details 6)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdParties",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400307 - Disclosure - Segmentation of key figures - Net sales by region (Details 7)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
     "shortName": "Segmentation of key figures - Net sales by region (Details 7)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_srt-2022EuropeMember_nvs-2022Q4ChangeOverPeriodAxis_nvs-2022Q4PoPYEChangeMember",
      "decimals": "2",
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdParties",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400308 - Disclosure - Segmentation of key figures (Details 8)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
     "shortName": "Segmentation of key figures (Details 8)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsNetSalesTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022SegmentConsolidationItemsAxis_ifrsfull-2022OperatingSegmentsMember_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4BrandsAxis_nvs-2022Q4PromotedBrandsMember",
      "decimals": "2",
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdPartiesChangeInPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdParties",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400309 - Disclosure - Segmentation of key figures - Top 20 (Details 9)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
     "shortName": "Segmentation of key figures - Top 20 (Details 9)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember_nvs-2022Q4ProductPortfolioAxis_nvs-2022Q4Top20ProductsMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfSignificantTransactionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2100200 - Disclosure - Significant transactions",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://novartis.com/20221231/role/DisclosureSignificantTransactions",
     "shortName": "Significant transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nvs:DisclosureOfSignificantTransactionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdParties",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400310 - Disclosure - Segmentation of key figures (Details 10)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8",
     "shortName": "Segmentation of key figures (Details 10)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsNetSalesTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4SandozMember_nvs-2022Q4FranchiseAxis_nvs-2022Q4RetailGenericsMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:RevenueFromSaleOfGoodsThirdParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:ProfitSharingIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400311 - Disclosure - Segmentation of key figures (Details 11)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
     "shortName": "Segmentation of key figures (Details 11)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:ProfitSharingIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400400 - Disclosure - Associated companies (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails",
     "shortName": "Associated companies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
       "div",
       "div",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "nvs:DisclosureOfSignificantTransactionsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProportionOfVotingPowerHeldInAssociate",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400401 - Disclosure - Associated companies (Details 1)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
     "shortName": "Associated companies (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "div",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember",
      "decimals": "3",
      "lang": null,
      "name": "ifrs-full:ProportionOfOwnershipInterestInAssociate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400402 - Disclosure - Associated companies (Details 2)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
     "shortName": "Associated companies (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfAssociatesNetIncomeEffectTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear-1_ifrsfull-2022SignificantInvestmentsInAssociatesAxis_nvs-2022Q4RocheHoldingAGMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:ShareOfCurrentYearNetIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:InterestExpenseTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfInterestExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400500 - Disclosure - Interest expense and other financial income and expense (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails",
     "shortName": "Interest expense and other financial income and expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:InterestExpenseTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfInterestExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nvs:InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromInterest",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400501 - Disclosure - Interest expense and other financial income and expense (Details 1)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2",
     "shortName": "Interest expense and other financial income and expense (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:OtherFinancialIncomeAndExpenseTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfInterestExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:RevenueFromDividends",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossBeforeTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400600 - Disclosure - Income taxes (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://novartis.com/20221231/role/DisclosureTaxesDetails",
     "shortName": "Income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:IncomeBeforeTaxesTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022GeographicalAreasAxis_ifrsfull-2022CountryOfDomicileMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:ProfitLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:CurrentAndDeferredIncomeTaxExpenseTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400601 - Disclosure - Income taxes (Details 1)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://novartis.com/20221231/role/DisclosureTaxesDetails2",
     "shortName": "Income taxes (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:CurrentAndDeferredIncomeTaxExpenseTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AnalysisOfTaxRateTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ApplicableTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400602 - Disclosure - Income taxes (Details 2)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://novartis.com/20221231/role/DisclosureTaxesDetails3",
     "shortName": "Income taxes (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AnalysisOfTaxRateTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ApplicableTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2100300 - Disclosure - Segmentation of key figures",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFigures",
     "shortName": "Segmentation of key figures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400700 - Disclosure - Earnings per share (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails",
     "shortName": "Earnings per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "div",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:WeightedAverageShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400800 - Disclosure - Changes in consolidated statements of comprehensive income (Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
     "shortName": "Changes in consolidated statements of comprehensive income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:ScheduleOfComprehensiveIncomeTableTextBlock",
       "div",
       "div",
       "nvs:ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-3_ifrsfull-2022ComponentsOfEquityAxis_nvs-2022Q4FairValueAdjustmentsOnFinancialInstrumentsMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:ValueAdjustmentOnComprehensiveIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400900 - Disclosure - Property, plant and equipment (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
     "shortName": "Property, plant and equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:PropertyPlantAndEquipmentTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:PropertyPlantAndEquipmentTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2400901 - Disclosure - Property, plant and equipment (Details 1)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2",
     "shortName": "Property, plant and equipment (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022SegmentsAxis_nvs-2022Q4InnovativeMedicinesMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RightofuseAssets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401000 - Disclosure - Lease liability and Right-of-use assets (Details)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3",
     "shortName": "Lease liability and Right-of-use assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfRightofuseAssetsRollForwardTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:AcquisitionsThroughBusinessCombinationsRightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RightofuseAssets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401001 - Disclosure - Lease liability and Right-of-use assets (Details 1)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2",
     "shortName": "Lease liability and Right-of-use assets (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd_ifrsfull-2022ClassesOfAssetsAxis_ifrsfull-2022LandMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:RightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:LeaseLiabilities",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401002 - Disclosure - Lease liability and Right-of-use assets (Details 2)",
     "menuCat": "Details",
     "order": "96",
     "role": "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4",
     "shortName": "Lease liability and Right-of-use assets (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:LeaseLiabilitiesUndiscounted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:LeaseLiabilities",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401003 - Disclosure - Lease liability and Right-of-use assets (Details 3)",
     "menuCat": "Details",
     "order": "97",
     "role": "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5",
     "shortName": "Lease liability and Right-of-use assets (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_srt-2022RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_nvs-2022Q4SaleAndLeaseBackMember",
      "decimals": "-6",
      "lang": null,
      "name": "nvs:CashInflowForSaleAndLeaseback",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:InterestExpenseTableTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfInterestExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:InterestExpenseOnLeaseLiabilities",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401004 - Disclosure - Lease liability and Right-of-use assets (Details 4)",
     "menuCat": "Details",
     "order": "98",
     "role": "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6",
     "shortName": "Lease liability and Right-of-use assets (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_I-CurrentYearEnd-1",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401100 - Disclosure - Goodwill and intangible assets (Details)",
     "menuCat": "Details",
     "order": "99",
     "role": "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
     "shortName": "Goodwill and intangible assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "nvs:DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock",
       "div",
       "div",
       "ifrs-full:DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nvs-20221231.htm",
      "contextRef": "AR_D-CurrentYear_ifrsfull-2022ClassesOfIntangibleAssetsAndGoodwillAxis_ifrsfull-2022GoodwillMember",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 518,
   "tag": {
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY",
        "terseLabel": "Germany"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "country_FR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FRANCE",
        "terseLabel": "France"
       }
      }
     },
     "localname": "FR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "country_GB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "UK"
       }
      }
     },
     "localname": "GB",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "country_GR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GREECE",
        "terseLabel": "Greece"
       }
      }
     },
     "localname": "GR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ITALY",
        "terseLabel": "Italy"
       }
      }
     },
     "localname": "IT",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "country_KR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KOREA, REPUBLIC OF",
        "terseLabel": "South Korea"
       }
      }
     },
     "localname": "KR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "US"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AUD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Australia, Dollars",
        "terseLabel": "AUD"
       }
      }
     },
     "localname": "AUD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_BRL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brazil, Brazil Real",
        "terseLabel": "BRL"
       }
      }
     },
     "localname": "BRL",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CAD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada, Dollars",
        "terseLabel": "CAD"
       }
      }
     },
     "localname": "CAD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Switzerland, Francs",
        "terseLabel": "CHF"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CNY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "China, Yuan Renminbi",
        "terseLabel": "CNY"
       }
      }
     },
     "localname": "CNY",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "terseLabel": "EUR"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "GBP"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_JPY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Japan, Yen",
        "terseLabel": "JPY"
       }
      }
     },
     "localname": "JPY",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_RUB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Russia, Rubles",
        "terseLabel": "RUB"
       }
      }
     },
     "localname": "RUB",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States of America, Dollars",
        "terseLabel": "USD"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelFaxNumber": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fax Number of contact personnel.",
        "label": "Contact Personnel Fax Number"
       }
      }
     },
     "localname": "ContactPersonnelFaxNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ifrs-full_AccountingProfit": {
     "auth_ref": [
      "r59",
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accounting profit",
        "totalLabel": "Total Income before taxes"
       }
      }
     },
     "localname": "AccountingProfit",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccrualsClassifiedAsCurrent": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of accruals classified as current. [Refer: Accruals]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accruals classified as current",
        "terseLabel": "Accrued expenses for goods and services received but not invoiced"
       }
      }
     },
     "localname": "AccrualsClassifiedAsCurrent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": {
     "auth_ref": [
      "r65",
      "r77",
      "r149",
      "r160",
      "r163"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated depreciation, amortisation and impairment [member]",
        "terseLabel": "Accumulated depreciation, amortisation and impairment"
       }
      }
     },
     "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The acquisition-date fair value of equity interest in the acquiree held by the acquirer immediately before the acquisition date in a business combination achieved in stages. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Acquisition-date fair value of equity interest in acquiree held by acquirer immediately before acquisition date",
        "negatedTerseLabel": "Fair value of previously held equity interests",
        "terseLabel": "Fair value of previously held equity interests"
       }
      }
     },
     "localname": "AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Consideration transferred, acquisition-date fair value"
       }
      }
     },
     "localname": "AcquisitiondateFairValueOfTotalConsiderationTransferred",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill": {
     "auth_ref": [
      "r452"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in intangible assets and goodwill resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Intangible assets and goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Acquisitions through business combinations, intangible assets and goodwill",
        "terseLabel": "Impact of business combinations"
       }
      }
     },
     "localname": "AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsOtherProvisions": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in other provisions resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Acquisitions through business combinations, other provisions",
        "negatedTerseLabel": "Impact of business combinations",
        "terseLabel": "Impact of business combinations"
       }
      }
     },
     "localname": "AcquisitionsThroughBusinessCombinationsOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in property, plant and equipment resulting from acquisitions through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Acquisitions through business combinations, property, plant and equipment",
        "terseLabel": "Impact of business combinations"
       }
      }
     },
     "localname": "AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ActuarialAssumptionOfDiscountRates": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of discount rates",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "ActuarialAssumptionOfDiscountRates",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ActuarialAssumptionOfDiscountRatesMember": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the discount rates used as actuarial assumptions. [Refer: Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of discount rates [member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "ActuarialAssumptionOfDiscountRatesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreases": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The expected rate of increases in pension that is used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of expected rates of pension increases",
        "terseLabel": "Expected rate of pension increase"
       }
      }
     },
     "localname": "ActuarialAssumptionOfExpectedRatesOfPensionIncreases",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the expected rates of pension increases used as actuarial assumptions. [Refer: Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of expected rates of pension increases [member]",
        "terseLabel": "Rate of pension increase"
       }
      }
     },
     "localname": "ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of expected rates of salary increases",
        "terseLabel": "Expected rate of salary increase"
       }
      }
     },
     "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreases",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the expected rates of salary increases used as actuarial assumptions. [Refer: Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumption of expected rates of salary increases [member]",
        "terseLabel": "Salary increase"
       }
      }
     },
     "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ActuarialAssumptionsAxis": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumptions [axis]"
       }
      }
     },
     "localname": "ActuarialAssumptionsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ActuarialAssumptionsMember": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all actuarial assumptions. Actuarial assumptions are the entity\u2019s unbiased and mutually compatible best estimates of the demographic and financial variables that will determine the ultimate cost of providing post-employment benefits. It also represents the standard value for the 'Actuarial assumptions' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial assumptions [member]"
       }
      }
     },
     "localname": "ActuarialAssumptionsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions that result in remeasurements of the net defined benefit liability (asset). Demographic assumptions deal with matters such as: (a) mortality; (b) rates of employee turnover, disability and early retirement; (c) the proportion of plan members with dependants who will be eligible for benefits; (d) the proportion of plan members who will select each form of payment option available under the plan terms; and (e) claim rates under medical plans. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial gains (losses) arising from changes in demographic assumptions, net defined benefit liability (asset)",
        "negatedTerseLabel": "Remeasurement (gains) arising from changes in demographic assumptions"
       }
      }
     },
     "localname": "ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Actuarial gains (losses) arising from changes in financial assumptions, net defined benefit liability (asset)",
        "negatedTerseLabel": "Remeasurement losses/(gains) arising from changes in financial assumptions"
       }
      }
     },
     "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r445"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments",
        "negatedTerseLabel": "Experience-related remeasurement losses/(gains)"
       }
      }
     },
     "localname": "ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionalProvisionsOtherProvisions": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additional other provisions made. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additional provisions, other provisions",
        "negatedLabel": "Provisions for doubtful trade receivables charged to the consolidated income statement",
        "negatedTerseLabel": "Additions to restructuring provisions",
        "terseLabel": "Additions",
        "verboseLabel": "Provisions for doubtful trade receivables charged to the consolidated income statement"
       }
      }
     },
     "localname": "AdditionalProvisionsOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionalRecognitionGoodwill": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additional goodwill recognised, except goodwill included in a disposal group that, on acquisition, meets the criteria to be classified as held for sale in accordance with IFRS 5. [Refer: Goodwill; Disposal groups classified as held for sale [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additional recognition, goodwill",
        "terseLabel": "Implicit Novartis goodwill"
       }
      }
     },
     "localname": "AdditionalRecognitionGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, intangible assets other than goodwill",
        "terseLabel": "Additions",
        "verboseLabel": "Additions to intangible assets and goodwill"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, property, plant and equipment",
        "terseLabel": "Additions",
        "verboseLabel": "Additions to property, plant and equipment"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions to right-of-use assets"
       }
      }
     },
     "localname": "AdditionsToRightofuseAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjusted weighted average number of ordinary shares outstanding",
        "terseLabel": "Weighted average number of shares in diluted earnings per share"
       }
      }
     },
     "localname": "AdjustedWeightedAverageShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in inventories",
        "terseLabel": "(Increase)/decrease in inventories"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in other assets",
        "terseLabel": "Change in other current and non-current assets"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInOtherAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in trade accounts receivable",
        "terseLabel": "(Increase)/decrease in trade receivables"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss; Depreciation and amortisation expense; Impairment loss (reversal of impairment loss) recognised in profit or loss; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss"
       }
      }
     },
     "localname": "AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForFinanceIncomeCost": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for finance income (cost)",
        "negatedTerseLabel": "Net financial expense",
        "terseLabel": "Net financial expense"
       }
      }
     },
     "localname": "AdjustmentsForFinanceIncomeCost",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other current liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current liabilities; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in other current liabilities",
        "terseLabel": "Change in other current liabilities"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in trade accounts payable",
        "terseLabel": "Decrease in trade payables"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets": {
     "auth_ref": [
      "r458"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for losses (gains) on disposal of non-current assets",
        "terseLabel": "Gains on disposal and other adjustments on property, plant and equipment; intangible assets;financial assets; and other non-current assets, net"
       }
      }
     },
     "localname": "AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForReconcileProfitLoss": {
     "auth_ref": [
      "r167"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss)",
        "terseLabel": "Reversal of non-cash items and other adjustments",
        "totalLabel": "Total reversal of non-cash items",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AdjustmentsForReconcileProfitLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "auth_ref": [
      "r462"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustment for share based payments",
        "terseLabel": "Equity-settled compensation expense"
       }
      }
     },
     "localname": "AdjustmentsForSharebasedPayments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdministrativeExpense": {
     "auth_ref": [
      "r53",
      "r116",
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenses that the entity classifies as being administrative."
       }
      },
      "en-us": {
       "role": {
        "label": "Administrative expenses",
        "negatedTerseLabel": "General and Administration",
        "verboseLabel": "Need new ITEM here"
       }
      }
     },
     "localname": "AdministrativeExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AggregateContinuingAndDiscontinuedOperationsMember": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the aggregate of continuing and discontinued operations. [Refer: Discontinued operations [member]; Continuing operations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregate continuing and discontinued operations [member]"
       }
      }
     },
     "localname": "AggregateContinuingAndDiscontinuedOperationsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8",
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2",
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AggregatedMeasurementMember": {
     "auth_ref": [
      "r158",
      "r162",
      "r227"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated measurement [member]"
       }
      }
     },
     "localname": "AggregatedMeasurementMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "auth_ref": [
      "r29",
      "r235",
      "r249",
      "r250",
      "r288",
      "r330",
      "r331",
      "r333",
      "r334",
      "r361",
      "r396",
      "r403"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated time bands [member]"
       }
      }
     },
     "localname": "AggregatedTimeBandsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "auth_ref": [
      "r93",
      "r228"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "All levels of fair value hierarchy [member]"
       }
      }
     },
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Amortisation, intangible assets other than goodwill",
        "negatedTerseLabel": "Amortization charge",
        "terseLabel": "Amortization charge"
       }
      }
     },
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract]"
       }
      }
     },
     "localname": "AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ApplicableTaxRate": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      },
      "en-us": {
       "role": {
        "label": "Applicable tax rate",
        "terseLabel": "Applicable tax rate"
       }
      }
     },
     "localname": "ApplicableTaxRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_Assets": {
     "auth_ref": [
      "r25",
      "r227",
      "r228",
      "r230",
      "r315",
      "r318"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AssetsAndLiabilitiesAxis": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets and liabilities [axis]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets and liabilities classified as held for sale [axis]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for assets and liabilities that are classified as held for sale. [Refer: Non-current assets held for sale [member]; Liabilities included in disposal groups classified as held for sale; Disposal groups classified as held for sale [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Assets and liabilities classified as held for sale [member]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesClassifiedAsHeldForSaleMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AssetsAndLiabilitiesMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for assets and liabilities. It also represents the standard value for the 'Assets and liabilities' axis if no other member is used. [Refer: Assets; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Assets and liabilities [member]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for assets and liabilities that are not classified as held for sale. It also represents the standard value for the 'Assets and liabilities classified as held for sale' axis if no other member is used. [Refer: Non-current assets held for sale [member]; Liabilities included in disposal groups classified as held for sale; Disposal groups classified as held for sale [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Assets and liabilities not classified as held for sale [member]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets, other than cash or cash equivalents, in subsidiaries or other businesses over which control is obtained or lost. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Assets other than cash or cash equivalents in subsidiary or businesses acquired or disposed",
        "terseLabel": "Non-current assets divested"
       }
      }
     },
     "localname": "AssetsOtherThanCashOrCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AverageEffectiveTaxRate": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]"
       }
      },
      "en-us": {
       "role": {
        "label": "Average effective tax rate",
        "terseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "AverageEffectiveTaxRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "auth_ref": [
      "r130",
      "r131"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "terseLabel": "Basic earnings per share",
        "totalLabel": "Total basic earnings per share"
       }
      }
     },
     "localname": "BasicEarningsLossPerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_BasicEarningsLossPerShareFromContinuingOperations": {
     "auth_ref": [
      "r130",
      "r131"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_BasicEarningsLossPerShare",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share from continuing operation",
        "terseLabel": "Basic earnings per share, Continuing operations",
        "verboseLabel": "Continuing operations"
       }
      }
     },
     "localname": "BasicEarningsLossPerShareFromContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations": {
     "auth_ref": [
      "r131",
      "r132"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_BasicEarningsLossPerShare",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "Basic earnings (loss) per share from discontinued operations. [Refer: Basic earnings (loss) per share; Discontinued operations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share from discontinued operations",
        "terseLabel": "Basic earnings per share, Discontinued operations",
        "verboseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "BasicEarningsLossPerShareFromDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_BasicEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic earnings per share [abstract]"
       }
      }
     },
     "localname": "BasicEarningsPerShareAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BondsIssued": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of bonds issued by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Bonds issued",
        "terseLabel": "Straight bonds"
       }
      }
     },
     "localname": "BondsIssued",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_BorrowingCostsCapitalised": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest and other costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset."
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowing costs capitalised",
        "terseLabel": "Capitalized borrowing costs"
       }
      }
     },
     "localname": "BorrowingCostsCapitalised",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Borrowings": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings",
        "terseLabel": "Total including current portion of non-current financial debt",
        "totalLabel": "Total",
        "verboseLabel": "The amount of outstanding funds that the entity is obligated to repay"
       }
      }
     },
     "localname": "Borrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_BorrowingsByNameAxis": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings by name [axis]"
       }
      }
     },
     "localname": "BorrowingsByNameAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BorrowingsByNameMember": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings by name [member]"
       }
      }
     },
     "localname": "BorrowingsByNameMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BorrowingsInterestRate": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings, interest rate",
        "terseLabel": "Interest rate on borrowings for new additions",
        "verboseLabel": "Borrowings, coupon"
       }
      }
     },
     "localname": "BorrowingsInterestRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_BorrowingsMaturity": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The maturity of borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings, maturity",
        "terseLabel": "Borrowings, maturity year"
       }
      }
     },
     "localname": "BorrowingsMaturity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BorrowingsOriginalCurrency": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The currency in which the borrowings are denominated. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings, original currency"
       }
      }
     },
     "localname": "BorrowingsOriginalCurrency",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BottomOfRangeMember": {
     "auth_ref": [
      "r233",
      "r262",
      "r333",
      "r382",
      "r384",
      "r470"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Bottom of range [member]",
        "terseLabel": "Low"
       }
      }
     },
     "localname": "BottomOfRangeMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BuildingsMember": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Buildings [member]",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Business combinations [axis]"
       }
      }
     },
     "localname": "BusinessCombinationsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "auth_ref": [
      "r65",
      "r72",
      "r149",
      "r153",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r278",
      "r292",
      "r293",
      "r475",
      "r477"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      }
     },
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CarryingAmountMember": {
     "auth_ref": [
      "r72",
      "r153",
      "r159",
      "r161",
      "r162",
      "r278",
      "r292",
      "r293",
      "r416",
      "r420"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Carrying amount [member]"
       }
      }
     },
     "localname": "CarryingAmountMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Cash": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails2": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash",
        "terseLabel": "Current accounts"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalents": {
     "auth_ref": [
      "r18",
      "r182",
      "r216"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 5.0,
       "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "totalLabel": "Total cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails3",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents [abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013": {
     "auth_ref": [
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash and cash equivalents in subsidiaries or other businesses over which control is obtained or lost. [Refer: Subsidiaries [member]; Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents in subsidiary or businesses acquired or disposed"
       }
      }
     },
     "localname": "CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 9.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer: Cash and cash equivalents; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents recognised as of acquisition date",
        "negatedTerseLabel": "Acquired cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashEquivalents": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails2": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash equivalents",
        "terseLabel": "Time deposits and short term investments with original maturity less than 90 days"
       }
      }
     },
     "localname": "CashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate cash flows arising from losing control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from losing control of subsidiaries or other businesses, classified as investing activities",
        "terseLabel": "Divested business"
       }
      }
     },
     "localname": "CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "auth_ref": [
      "r164",
      "r183"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Net cash flows used in financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 14.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's financing activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) financing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities, continuing operations",
        "terseLabel": "Net cash flows used in financing activities from continuing operations"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 15.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's financing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) financing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities, discontinued operations",
        "terseLabel": "Net cash flows used in financing activities from discontinued operations"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) due to an increase (decrease) in current borrowings. [Refer: Current borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) increase (decrease) in current borrowings",
        "negatedTerseLabel": "Change in current financial debts",
        "terseLabel": "Change in current financial debts",
        "totalLabel": "Financial debts cash flows from continuing operations"
       }
      }
     },
     "localname": "CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "auth_ref": [
      "r164",
      "r183"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "terseLabel": "Net cash flows from/(used in) investing activities",
        "totalLabel": "Total cash flows used in investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's investing activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) investing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities, continuing operations",
        "terseLabel": "Net cash flows from/(used in) investing activities from continuing operations",
        "totalLabel": "Cash flows used in investing activities from continuing operations"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's investing activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) investing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities, discontinued operations",
        "terseLabel": "Cash flows used in/from investing activities from discontinued operations",
        "totalLabel": "Cash flows used in/from investing activities from discontinued operations",
        "verboseLabel": "Net cash flows used in investing activities from discontinued operations"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "auth_ref": [
      "r164",
      "r183"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Net cash flows from operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 2.5,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's operating activities, related to continuing operations. [Refer: Continuing operations [member]; Cash flows from (used in) operating activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities, continuing operations",
        "totalLabel": "Net cash flows from operating activities from continuing operations"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) the entity's operating activities, related to discontinued operations. [Refer: Discontinued operations [member]; Cash flows from (used in) operating activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities, discontinued operations",
        "terseLabel": "Net cash flows from operating activities from discontinued operations"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashOutflowForLeases": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash outflow"
       }
      }
     },
     "localname": "CashOutflowForLeases",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashTransferred": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash transferred"
       }
      }
     },
     "localname": "CashTransferred",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CategoriesOfFinancialAssetsAxis": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of financial assets [axis]"
       }
      }
     },
     "localname": "CategoriesOfFinancialAssetsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of financial liabilities [axis]"
       }
      }
     },
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      }
     },
     "localname": "CategoriesOfRelatedPartiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ChangesInEquity": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in equity",
        "terseLabel": "Movement in the year",
        "totalLabel": "Total of other equity movements"
       }
      }
     },
     "localname": "ChangesInEquity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "auth_ref": [
      "r134",
      "r136",
      "r231",
      "r247"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of assets [axis]"
       }
      }
     },
     "localname": "ClassesOfAssetsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfAssetsMember": {
     "auth_ref": [
      "r134",
      "r231",
      "r247"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets [member]"
       }
      }
     },
     "localname": "ClassesOfAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "auth_ref": [
      "r300",
      "r301",
      "r329",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial assets [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialAssetsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "auth_ref": [
      "r292",
      "r294",
      "r296",
      "r297"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "auth_ref": [
      "r292",
      "r294",
      "r296",
      "r297"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial instruments, class [member]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
     "auth_ref": [
      "r300",
      "r301",
      "r329",
      "r336"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial liabilities [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialLiabilitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of intangible assets and goodwill [axis]"
       }
      }
     },
     "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of liabilities [axis]"
       }
      }
     },
     "localname": "ClassesOfLiabilitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      }
     },
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of other provisions [axis]"
       }
      }
     },
     "localname": "ClassesOfProvisionsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2",
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share capital [member]",
        "terseLabel": "Total outstanding shares"
       }
      }
     },
     "localname": "ClassesOfShareCapitalMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2",
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CommercialPapersIssued": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherCurrentFinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of commercial paper issued by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Commercial papers issued",
        "terseLabel": "Commercial Papers"
       }
      }
     },
     "localname": "CommercialPapersIssued",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      }
     },
     "localname": "ComponentsOfEquityAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]",
        "terseLabel": "Other comprehensive income to be eventually recycled into the consolidated income statement"
       }
      }
     },
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]",
        "terseLabel": "Other comprehensive income never to be recycled into the consolidated income statement"
       }
      }
     },
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncome": {
     "auth_ref": [
      "r2",
      "r40",
      "r195",
      "r197",
      "r212",
      "r380"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncomeCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "totalLabel": "Total comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income [abstract]"
       }
      }
     },
     "localname": "ComprehensiveIncomeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncomeAttributableToAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income attributable to [abstract]",
        "terseLabel": "Attributable to"
       }
      }
     },
     "localname": "ComprehensiveIncomeAttributableToAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r2",
      "r43"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncomeCalc2": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]"
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income, attributable to non-controlling interests",
        "terseLabel": "Non-controlling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": {
     "auth_ref": [
      "r2",
      "r44"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncomeCalc2": {
       "order": 2.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income, attributable to owners of parent",
        "terseLabel": "Shareholders of Novartis AG"
       }
      }
     },
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ConsiderationPaidReceived": {
     "auth_ref": [
      "r174"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Consideration paid (received)",
        "terseLabel": "Net cash inflows from divestment"
       }
      }
     },
     "localname": "ConsiderationPaidReceived",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ConstructionInProgressMember": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Construction in progress [member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Contingent consideration recognised as of acquisition date"
       }
      }
     },
     "localname": "ContingentConsiderationRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ContingentLiabilitiesRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r388",
      "r390"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contingent liabilities recognised as of the acquisition date in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Contingent liabilities recognised as of acquisition date"
       }
      }
     },
     "localname": "ContingentLiabilitiesRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ContinuingAndDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Continuing and discontinued operations [axis]"
       }
      }
     },
     "localname": "ContinuingAndDiscontinuedOperationsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8",
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2",
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ContinuingOperationsMember": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for components of the entity that are not discontinued operations. A component of an entity comprises operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity. This member also represents the standard value for the 'Continuing and discontinued operations' axis if no other member is used. [Refer: Discontinued operations [member]; Aggregate continuing and discontinued operations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Continuing operations [member]",
        "terseLabel": "Continuing operations"
       }
      }
     },
     "localname": "ContinuingOperationsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual commitments for the acquisition of property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Contractual commitments for acquisition of property, plant and equipment",
        "terseLabel": "Commitments for purchases of property, plant and equipment"
       }
      }
     },
     "localname": "ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in net defined benefit liability (asset) resulting from contributions to a defined benefit plan by the employer. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Contributions to plan by employer, net defined benefit liability (asset)",
        "terseLabel": "Novartis Group contributions"
       }
      }
     },
     "localname": "ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from contributions to a defined benefit plan by plan participants. [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Contributions to plan by plan participants, net defined benefit liability (asset)",
        "negatedTerseLabel": "Contributions of associates",
        "terseLabel": "Contributions of associates"
       }
      }
     },
     "localname": "ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CostOfInventoriesRecognisedAsExpenseDuringPeriod": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of inventories recognised as an expense during the period. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cost of inventories recognised as expense during period",
        "negatedTerseLabel": "Amount of inventory recognized as expense"
       }
      }
     },
     "localname": "CostOfInventoriesRecognisedAsExpenseDuringPeriod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CostOfSales": {
     "auth_ref": [
      "r0",
      "r53"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      },
      "en-us": {
       "role": {
        "label": "Cost of sales",
        "negatedTerseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSales",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CountryOfDomicileMember": {
     "auth_ref": [
      "r323",
      "r324"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the country in which the entity is registered and where it has its legal address or registered office."
       }
      },
      "en-us": {
       "role": {
        "label": "Country of domicile [member]",
        "terseLabel": "Switzerland"
       }
      }
     },
     "localname": "CountryOfDomicileMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary": {
     "auth_ref": [
      "r121",
      "r125",
      "r200",
      "r204"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The country in which a subsidiary of the entity is incorporated. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Country of incorporation of subsidiary"
       }
      }
     },
     "localname": "CountryOfIncorporationOrResidenceOfSubsidiary",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentAssets": {
     "auth_ref": [
      "r30",
      "r208",
      "r380"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "CurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets [abstract]"
       }
      }
     },
     "localname": "CurrentAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 17.2,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Current assets; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale; Non-current assets or disposal groups classified as held for distribution to owners]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners",
        "totalLabel": "Total current assets without disposal group"
       }
      }
     },
     "localname": "CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities": {
     "auth_ref": [
      "r435",
      "r437"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current deferred income other than current contract liabilities. [Refer: Deferred income other than contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current deferred income other than current contract liabilities"
       }
      }
     },
     "localname": "CurrentDeferredIncomeOtherThanCurrentContractLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentInterestPayable": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current interest payable. [Refer: Interest payable]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current interest payable",
        "terseLabel": "Accrued interests on financial debt"
       }
      }
     },
     "localname": "CurrentInterestPayable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 5.0,
       "parentTag": "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "negatedTerseLabel": "Less current lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "CurrentLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilities": {
     "auth_ref": [
      "r31",
      "r210",
      "r380"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "localname": "CurrentLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 6.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current liabilities other than liabilities included in disposal groups classified as held for sale. [Refer: Current liabilities; Disposal groups classified as held for sale [member]; Liabilities included in disposal groups classified as held for sale]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities other than liabilities included in disposal groups classified as held for sale",
        "totalLabel": "Total current liabilities without disposal group"
       }
      }
     },
     "localname": "CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentMember": {
     "auth_ref": [
      "r391",
      "r404",
      "r476"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a current time band."
       }
      },
      "en-us": {
       "role": {
        "label": "Current [member]"
       }
      }
     },
     "localname": "CurrentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrentPortionOfLongtermBorrowings": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherCurrentFinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current portion of non-current borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current portion of non-current borrowings",
        "negatedTerseLabel": "Less current portion of non-current financial debt",
        "terseLabel": "Current portion of non-current financial debt",
        "verboseLabel": "Less current portion of non-current financial debt"
       }
      }
     },
     "localname": "CurrentPortionOfLongtermBorrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentRefundsProvision": {
     "auth_ref": [
      "r365",
      "r367"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 15.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current provision for refunds. [Refer: Refunds provision]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current refunds provision",
        "periodEndLabel": "Provisions for deductions from revenue, at end of period",
        "periodStartLabel": "Provisions for deductions from revenue, at beginning of period",
        "terseLabel": "Provisions for deductions from revenue"
       }
      }
     },
     "localname": "CurrentRefundsProvision",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current service cost, net defined benefit liability (asset)",
        "negatedTerseLabel": "Current service cost",
        "terseLabel": "Current service cost"
       }
      }
     },
     "localname": "CurrentServiceCostNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxAssetsCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 7.0,
       "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current amount of current tax assets. [Refer: Current tax assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax assets, current",
        "terseLabel": "Income tax receivable"
       }
      }
     },
     "localname": "CurrentTaxAssetsCurrent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax expense (income)",
        "negatedTerseLabel": "Current tax expense (income)",
        "terseLabel": "Current income tax expense"
       }
      }
     },
     "localname": "CurrentTaxExpenseIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxLiabilitiesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax liabilities, current",
        "terseLabel": "Current income tax liabilities"
       }
      }
     },
     "localname": "CurrentTaxLiabilitiesCurrent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTradeReceivables": {
     "auth_ref": [
      "r350",
      "r351"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current trade receivables",
        "periodEndLabel": "Provisions at end of period",
        "periodStartLabel": "Provisions at beginning of period",
        "terseLabel": "Total trade receivables, net",
        "verboseLabel": "Trade receivables"
       }
      }
     },
     "localname": "CurrentTradeReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentValueAddedTaxReceivables": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current value added tax receivables",
        "terseLabel": "VAT Receivable"
       }
      }
     },
     "localname": "CurrentValueAddedTaxReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DebtInstrumentsHeld": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "nvs_MarketableSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of instruments representing indebtedness held by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Debt instruments held",
        "terseLabel": "Debt securities",
        "verboseLabel": "Debt securities held"
       }
      }
     },
     "localname": "DebtInstrumentsHeld",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DebtSecuritiesMember": {
     "auth_ref": [
      "r381",
      "r383"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for instruments held by the entity that represent indebtedness."
       }
      },
      "en-us": {
       "role": {
        "label": "Debt securities [member]",
        "terseLabel": "Debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in other provisions resulting from the loss of control of a subsidiary. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease through loss of control of subsidiary, other provisions",
        "negatedTerseLabel": "Provisions related to discontinued operations",
        "terseLabel": "Provisions for doubtful trade receivables related to discontinued operations"
       }
      }
     },
     "localname": "DecreaseThroughLossOfControlOfSubsidiaryOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxAssets": {
     "auth_ref": [
      "r21",
      "r26",
      "r61"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 8.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax assets",
        "negatedTerseLabel": "Deferred tax assets",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets and liabilities [abstract]"
       }
      }
     },
     "localname": "DeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DeferredTaxAssetsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 5.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for deferred tax assets acquired in a business combination. [Refer: Deferred tax assets; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax assets recognised as of acquisition date",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxExpenseIncome": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax expense (income)",
        "negatedTerseLabel": "Deferred tax expense (income)",
        "terseLabel": "Deferred tax income"
       }
      }
     },
     "localname": "DeferredTaxExpenseIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax expense (income) recognised in profit or loss",
        "terseLabel": "Credited/(charged) to income"
       }
      }
     },
     "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxLiabilities": {
     "auth_ref": [
      "r21",
      "r26",
      "r61"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 4.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities",
        "negatedLabel": "Deferred tax liabilities",
        "negatedTerseLabel": "Deferred tax liabilities",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 10.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for deferred tax liabilities assumed in a business combination. [Refer: Deferred tax liabilities; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities recognised as of acquisition date",
        "negatedTerseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxLiabilityAsset": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax liability (asset)",
        "negatedPeriodEndLabel": "Net deferred tax balance at end of period",
        "negatedPeriodStartLabel": "Net deferred tax balance at beginning of period",
        "negatedTerseLabel": "Net deferred tax balance at beginning of period continuing operations",
        "negatedTotalLabel": "Net deferred tax balance",
        "totalLabel": "Net deferred tax balance"
       }
      }
     },
     "localname": "DeferredTaxLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deferred tax related to items credited (charged) directly to equity. [Refer: Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Deferred tax relating to items credited (charged) directly to equity",
        "terseLabel": "Charged to equity"
       }
      }
     },
     "localname": "DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DefinedBenefitObligationAtPresentValue": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]"
       }
      },
      "en-us": {
       "role": {
        "label": "Defined benefit obligation, at present value",
        "periodEndLabel": "Benefit obligation at end of period",
        "periodStartLabel": "Benefit obligation at beginning of period"
       }
      }
     },
     "localname": "DefinedBenefitObligationAtPresentValue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DefinedBenefitPlansAxis": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Defined benefit plans [axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DefinedBenefitPlansMember": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for post-employment benefit plans other than defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods. It also represents the standard value for the 'Defined benefit plans' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Defined benefit plans [member]"
       }
      }
     },
     "localname": "DefinedBenefitPlansMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]",
        "terseLabel": "Depreciation, amortization and impairments on:"
       }
      }
     },
     "localname": "DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DepreciationAndAmortisationExpense": {
     "auth_ref": [
      "r1",
      "r53",
      "r219",
      "r312",
      "r320",
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives."
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation and amortisation expense",
        "negatedTerseLabel": "Depreciation and amortisation expense"
       }
      }
     },
     "localname": "DepreciationAndAmortisationExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r70",
      "r76"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, property, plant and equipment",
        "negatedTerseLabel": "Depreciation charge",
        "terseLabel": "Depreciation charge"
       }
      }
     },
     "localname": "DepreciationPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, right-of-use assets",
        "negatedTerseLabel": "Depreciation charge",
        "terseLabel": "Depreciation charge"
       }
      }
     },
     "localname": "DepreciationRightofuseAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DerivativeFinancialAssets": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails": {
       "order": 7.0,
       "parentTag": "ifrs-full_OtherCurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of financial assets classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Derivative financial assets",
        "terseLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "DerivativeFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DerivativeFinancialLiabilities": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_OtherCurrentFinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Derivative financial liabilities",
        "terseLabel": "Fair value of derivative financial instruments"
       }
      }
     },
     "localname": "DerivativeFinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for available-for-sale financial assets. [Refer: Financial assets available-for-sale]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for available-for-sale financial assets [text block]"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForAvailableforsaleFinancialAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for business combinations. [Refer: Business combinations [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for business combinations. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for business combinations [text block]",
        "terseLabel": "Acquisition of assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for contingent liabilities and contingent assets. [Refer: Contingent liabilities [member]; Description of nature of contingent assets]\nEffective 2023-01-01: The description of the entity's material accounting policy information for contingent liabilities and contingent assets. [Refer: Contingent liabilities [member]; Description of nature of contingent assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for contingent liabilities and contingent assets [text block]",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForContingentLiabilitiesAndContingentAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for decommissioning, restoration and rehabilitation provisions. [Refer: Provision for decommissioning, restoration and rehabilitation costs]\nEffective 2023-01-01: The description of the entity's material accounting policy information for decommissioning, restoration and rehabilitation provisions. [Refer: Provision for decommissioning, restoration and rehabilitation costs]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for decommissioning, restoration and rehabilitation provisions [text block]",
        "terseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForDecommissioningRestorationAndRehabilitationProvisionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.\nEffective 2023-01-01: The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for employee benefits [text block]",
        "terseLabel": "Defined benefit pension plans and other post retirement benefits"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for financial assets. [Refer: Financial assets]\nEffective 2023-01-01: The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial assets [text block]"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for financial instruments. [Refer: Financial instruments, class [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial instruments [text block]"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for foreign currency translation.\nEffective 2023-01-01: The description of the entity's material accounting policy information for foreign currency translation."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for foreign currency translation [text block]",
        "terseLabel": "Foreign currencies"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for goodwill. [Refer: Goodwill]\nEffective 2023-01-01: The description of the entity's material accounting policy information for goodwill. [Refer: Goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for goodwill [text block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForGoodwillExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for government grants [text block]",
        "terseLabel": "Government grants"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForGovernmentGrants",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for income tax.\nEffective 2023-01-01: The description of the entity's material accounting policy information for income tax."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for income tax [text block]",
        "terseLabel": "Taxes"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.\nEffective 2023-01-01: The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for leases",
        "terseLabel": "Leases and right-of-use assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for measuring inventories [text block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForMeasuringInventories",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for non-current assets or disposal groups classified as held for sale. [Refer: Non-current assets or disposal groups classified as held for sale]\nEffective 2023-01-01: The description of the entity's material accounting policy information for non-current assets or disposal groups classified as held for sale. [Refer: Non-current assets or disposal groups classified as held for sale]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for non-current assets or disposal groups classified as held for sale [text block]",
        "terseLabel": "Non-current assets held for sale or held for distribution to owners"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]\nEffective 2023-01-01: The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for property, plant and equipment [text block]",
        "terseLabel": "Property plant and equipment"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for provisions. [Refer: Provisions]\nEffective 2023-01-01: The description of the entity's material accounting policy information for provisions. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for provisions [text block]",
        "terseLabel": "Legal and environmental liabilities"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]\nEffective 2023-01-01: The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for recognition of revenue [text block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]\nEffective 2023-01-01: The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for research and development expense [text block]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for share-based payment transactions [text block]",
        "terseLabel": "Share based compensation"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSubsidiariesExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for subsidiaries. [Refer: Subsidiaries [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for subsidiaries. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for subsidiaries [text block]",
        "terseLabel": "Scope of consolidation"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSubsidiariesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for trade and other receivables. [Refer: Trade and other receivables]\nEffective 2023-01-01: The description of the entity's material accounting policy information for trade and other receivables. [Refer: Trade and other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for trade and other receivables [text block]",
        "terseLabel": "Trade receivables"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory": {
     "auth_ref": [
      "r472",
      "r474"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for treasury shares. [Refer: Treasury shares]\nEffective 2023-01-01: The description of the entity's material accounting policy information for treasury shares. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for treasury shares [text block]",
        "terseLabel": "Treasury Shares"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForTreasurySharesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the contingent consideration arrangements and the arrangements for indemnification assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of arrangement for contingent consideration arrangements and indemnification assets"
       }
      }
     },
     "localname": "DescriptionOfArrangementForContingentConsiderationArrangementsAndIndemnificationAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]",
        "terseLabel": "Impact of adopting significant new IFRS standards"
       }
      }
     },
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections": {
     "auth_ref": [
      "r139",
      "r140"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The growth rate used to extrapolate cash flow projections beyond the period covered by the most recent budgets/forecasts for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Growth rate used to extrapolate cash flow projections",
        "terseLabel": "Terminal Growth Rate"
       }
      }
     },
     "localname": "DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the justification for using any growth rate to extrapolate cash flow projections that exceeds the long-term average growth rate for the products, industries or country (countries) in which the entity operates, or for the market to which a cash-generating unit (group of units) is dedicated. [Refer: Cash-generating units [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of justification for using growth rate that exceeds long-term average growth rate",
        "terseLabel": "Description of growth rate"
       }
      }
     },
     "localname": "DescriptionOfJustificationForUsingGrowthRateThatExceedsLongtermAverageGrowthRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DescriptionOfNatureOfChangeInAccountingPolicy": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the nature of a change in accounting policy related to an initial application of an IFRS. [Refer: IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of nature of change in accounting policy"
       }
      }
     },
     "localname": "DescriptionOfNatureOfChangeInAccountingPolicy",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DescriptionOfPlanAmendmentsCurtailmentsAndSettlements": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of defined benefit plan amendments, curtailments and settlements. [Refer: Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of plan amendments, curtailments and settlements"
       }
      }
     },
     "localname": "DescriptionOfPlanAmendmentsCurtailmentsAndSettlements",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the reasons for transfers of assets out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of reasons for transfers out of Level 3 of fair value hierarchy, assets"
       }
      }
     },
     "localname": "DescriptionOfReasonsForTransfersOutOfLevel3OfFairValueHierarchyAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of difference between the carrying amount of dividends payable and the carrying amount of non-cash assets distributed when settling the dividends payable. [Refer: Carrying amount [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed",
        "terseLabel": "Gain on distribution",
        "verboseLabel": "Difference between net assets and distribution liability"
       }
      }
     },
     "localname": "DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributed",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "auth_ref": [
      "r130",
      "r131"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "terseLabel": "Diluted earnings per share",
        "totalLabel": "Total diluted earnings per share"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations": {
     "auth_ref": [
      "r130",
      "r131"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_DilutedEarningsLossPerShare",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations [member]; Diluted earnings (loss) per share]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share from continuing operations",
        "terseLabel": "Diluted earnings per share, Continuing operations",
        "verboseLabel": "Continuing operations"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShareFromContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShareFromDiscontinuedOperations": {
     "auth_ref": [
      "r131",
      "r132"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_DilutedEarningsLossPerShare",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "Diluted earnings (loss) per share from discontinued operations. [Refer: Diluted earnings (loss) per share; Discontinued operations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share from discontinued operations",
        "terseLabel": "Diluted earnings per share, Discontinued operations",
        "verboseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShareFromDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DilutedEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted earnings per share [abstract]"
       }
      }
     },
     "localname": "DilutedEarningsPerShareAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of dilutive potential ordinary shares that relate to the assumed exercise of the entity's share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Dilutive effect of share options on number of ordinary shares",
        "terseLabel": "Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options"
       }
      }
     },
     "localname": "DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [abstract]"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsExplanatory": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for business combinations."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of business combinations [text block]",
        "terseLabel": "Acquisition of businesses"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinesses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [line items]"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsTable": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of business combinations."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [table]"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfCashFlowStatementExplanatory": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for a statement of cash flows."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of cash flow statement [text block]",
        "terseLabel": "Details to the consolidated statements of cash flows"
       }
      }
     },
     "localname": "DisclosureOfCashFlowStatementExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [abstract]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [line items]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails",
      "http://novartis.com/20221231/role/DisclosureEquityDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [table]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails",
      "http://novartis.com/20221231/role/DisclosureEquityDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDeferredTaxesExplanatory": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of deferred taxes [text block]",
        "terseLabel": "Deferred tax assets and liablities"
       }
      }
     },
     "localname": "DisclosureOfDeferredTaxesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of defined benefit plans [abstract]"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPlansAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of defined benefit plans [line items]"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPlansLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansTable": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to defined benefit plans."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of defined benefit plans [table]"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPlansTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of derivative financial instruments. [Refer: Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of derivative financial instruments [text block]",
        "terseLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "DisclosureOfDerivativeFinancialInstrumentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [abstract]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [line items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of borrowings."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r290",
      "r294",
      "r302"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [text block]",
        "terseLabel": "Financial instruments"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for employee benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of employee benefits [text block]",
        "terseLabel": "Post-employment benefits for employees"
       }
      }
     },
     "localname": "DisclosureOfEmployeeBenefitsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociates"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of entity's operating segments [text block]",
        "terseLabel": "Segmentation of key figures"
       }
      }
     },
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFigures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "terseLabel": "Events subsequent to the December 31 consolidated balance sheet date"
       }
      }
     },
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementExplanatory": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for fair value measurement."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement [text block]",
        "terseLabel": "Fair value by hierarchy"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfAssetsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of assets [table]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfAssetsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [line items]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [table]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: Investments in equity instruments designated at fair value through other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [text block]",
        "terseLabel": "Equity securities measured at fair value through other comprehensive income"
       }
      }
     },
     "localname": "DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items]"
       }
      }
     },
     "localname": "DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value of investments in equity instruments designated at fair value through other comprehensive income."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [table]"
       }
      }
     },
     "localname": "DisclosureOfFairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialAssetsTable": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinancialLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [text block]",
        "terseLabel": "Non-current financial debt"
       }
      }
     },
     "localname": "DisclosureOfFinancialLiabilitiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [line items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialLiabilitiesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesTable": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialLiabilitiesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [abstract]",
        "terseLabel": "Goodwill and intangible assets"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsAndGoodwillExplanatory": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of intangible assets and goodwill [text block]",
        "terseLabel": "Goodwill and intangible assets"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsAndGoodwillExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfInterestExpenseExplanatory": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of interest expense. [Refer: Interest expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of interest expense [text block]",
        "terseLabel": "Interest expense and other financial income and expense"
       }
      }
     },
     "localname": "DisclosureOfInterestExpenseExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of inventories [text block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "DisclosureOfInventoriesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of investments accounted for using equity method [text block]",
        "terseLabel": "Associated companies"
       }
      }
     },
     "localname": "DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompanies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "auth_ref": [
      "r252",
      "r253"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of leases [text block]"
       }
      }
     },
     "localname": "DisclosureOfLeasesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfMajorCustomersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of major customers [abstract]"
       }
      }
     },
     "localname": "DisclosureOfMajorCustomersAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfMajorCustomersLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of major customers [line items]"
       }
      }
     },
     "localname": "DisclosureOfMajorCustomersLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfMajorCustomersTable": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the entity's major customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of major customers [table]"
       }
      }
     },
     "localname": "DisclosureOfMajorCustomersTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [line items]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis for non-derivative financial liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [table]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisForNonderivativeFinancialLiabilitiesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of net defined benefit liability (asset) [line items]"
       }
      }
     },
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the net defined benefit liability (asset)."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of net defined benefit liability (asset) [table]"
       }
      }
     },
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [abstract]"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]",
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of outstanding share options"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the number and weighted average remaining contractual life of outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [abstract]"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [text block]",
        "terseLabel": "Segmentation - Consolidated income statements"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOperatingSegmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [line items]"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOperatingSegmentsTable": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to operating segments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [table]"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other current assets. [Refer: Other current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other current assets [text block]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "DisclosureOfOtherCurrentAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for other provisions, contingent liabilities and contingent assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions, contingent liabilities and contingent assets [text block]",
        "terseLabel": "Provisions and other non-current liabilities"
       }
      }
     },
     "localname": "DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherProvisionsExplanatory": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other provisions. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [text block]"
       }
      }
     },
     "localname": "DisclosureOfOtherProvisionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherProvisionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [line items]"
       }
      }
     },
     "localname": "DisclosureOfOtherProvisionsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOtherProvisionsTable": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to other provisions."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [table]"
       }
      }
     },
     "localname": "DisclosureOfOtherProvisionsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [abstract]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of property, plant and equipment [text block]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfProvisionMatrixAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of provision matrix [abstract]"
       }
      }
     },
     "localname": "DisclosureOfProvisionMatrixAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfProvisionMatrixLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of provision matrix [line items]"
       }
      }
     },
     "localname": "DisclosureOfProvisionMatrixLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfProvisionMatrixTable": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the provision matrix."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of provision matrix [table]"
       }
      }
     },
     "localname": "DisclosureOfProvisionMatrixTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about leases for lessee [abstract]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutLeasesForLesseeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [abstract]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [text block]",
        "terseLabel": "Disclosure of quantitative information about right-of-use assets"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to right-of-use assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [table]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the range of exercise prices for outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of range of exercise prices of outstanding share options [text block]",
        "terseLabel": "Disclosure of range of exercise prices of outstanding share options"
       }
      }
     },
     "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of changes in intangible assets and goodwill."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [table]"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "Transactions with related parties"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of sensitivity analysis for actuarial assumptions [line items]"
       }
      }
     },
     "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the sensitivity analysis for actuarial assumptions."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of sensitivity analysis for actuarial assumptions [table]"
       }
      }
     },
     "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "Equity-based participation plans for employees"
       }
      }
     },
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociates"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of associates [abstract]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesExplanatory": {
     "auth_ref": [
      "r123",
      "r127",
      "r226"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of associates. [Refer: Associates [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of associates [text block]",
        "terseLabel": "Schedule disclosing information related to associates"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of associates [line items]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable": {
     "auth_ref": [
      "r123",
      "r127",
      "r226"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to associates."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of associates [table]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [abstract]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory": {
     "auth_ref": [
      "r123",
      "r127",
      "r225"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of subsidiaries. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [text block]",
        "terseLabel": "Principal Group subsidiaries and associated companies"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompanies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [line items]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": {
     "auth_ref": [
      "r123",
      "r127",
      "r225"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to subsidiaries."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [table]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for significant accounting policies applied by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of significant accounting policies [text block]",
        "terseLabel": "Significant accounting policies",
        "verboseLabel": "Selected critical accounting policies"
       }
      }
     },
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [abstract]"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]",
        "terseLabel": "Gross value of tax-loss carry-forwards"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]"
       }
      }
     },
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [abstract]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [abstract]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [line items]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [table]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DiscontinuedOperationsMember": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of an entity that either has been disposed of or is classified as held for sale, and that: (a) represents a separate major line of business or geographical area of operations; (b) is part of a single co-ordinated plan to dispose of a separate major line of business or geographical area of operations; or (c) is a subsidiary acquired exclusively with a view to resale. A component of an entity comprises operations and cash flows that can be clearly distinguished, operationally and for financial reporting purposes, from the rest of the entity. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Discontinued operations [member]",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "DiscontinuedOperationsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8",
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2",
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The discount rate used in the current measurement of fair value less costs of disposal."
       }
      },
      "en-us": {
       "role": {
        "label": "Discount rate used in current measurement of fair value less costs of disposal",
        "terseLabel": "Discount Rate (post-tax)"
       }
      }
     },
     "localname": "DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember": {
     "auth_ref": [
      "r285",
      "r469"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for groups of assets, which are to be disposed of together as a group in a single transaction, and the liabilities directly associated with those assets that will be transferred in the transaction."
       }
      },
      "en-us": {
       "role": {
        "label": "Disposal groups classified as held for sale [member]"
       }
      }
     },
     "localname": "DisposalGroupsClassifiedAsHeldForSaleMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_DisposalsAndRetirementsIntangibleAssetsAndGoodwill": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in intangible assets and goodwill resulting from disposals and retirements. [Refer: Intangible assets and goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disposals and retirements, intangible assets and goodwill",
        "negatedLabel": "Disposals and derecognitions"
       }
      }
     },
     "localname": "DisposalsAndRetirementsIntangibleAssetsAndGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DisposalsAndRetirementsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals and retirements. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disposals and retirements, property, plant and equipment",
        "negatedTerseLabel": "Disposals and derecognitions",
        "terseLabel": "Disposals and derecognitions"
       }
      }
     },
     "localname": "DisposalsAndRetirementsPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendsPaid": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of dividends recognised as distributions to owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends recognised as distributions to owners",
        "negatedTerseLabel": "Dividends"
       }
      }
     },
     "localname": "DividendsPaid",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails3",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for dividends paid to equity holders of the parent, classified as financing activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends paid to equity holders of parent, classified as financing activities",
        "negatedTerseLabel": "Dividends paid to shareholders of Novartis AG"
       }
      }
     },
     "localname": "DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendsPayable": {
     "auth_ref": [
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of dividends payable by means of the distribution of non-cash assets to owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends payable, non-cash assets distributions",
        "terseLabel": "Dividend in kind distribution liability",
        "verboseLabel": "Derecognition of distribution liability"
       }
      }
     },
     "localname": "DividendsPayable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners": {
     "auth_ref": [
      "r11",
      "r54"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of dividends proposed or declared after the reporting period but before financial statements are authorised for issue. Such dividends are not recognised as a liability at the end of the reporting period because no obligation exists at that time."
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners",
        "terseLabel": "Dividends proposed"
       }
      }
     },
     "localname": "DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount, per share, of dividends proposed or declared before financial statements were authorised for issue but not recognised as distribution to owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners per share",
        "terseLabel": "Dividends proposed, cash per share"
       }
      }
     },
     "localname": "DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DividendsReceived": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of dividends received."
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends received"
       }
      }
     },
     "localname": "DividendsReceived",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendsReceivedClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from dividends received, classified as operating activities. [Refer: Dividends received]"
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends received, classified as operating activities",
        "terseLabel": "Dividends received from associated companies and others"
       }
      }
     },
     "localname": "DividendsReceivedClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of dividends related to investments in equity instruments that the entity has designated at fair value through other comprehensive income, held at the end of the reporting period. [Refer: Investments in equity instruments designated at fair value through other comprehensive income [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Dividends recognised for investments in equity instruments designated at fair value through other comprehensive income, held at end of reporting period"
       }
      }
     },
     "localname": "DividendsRecognisedForInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeHeldAtEndOfReportingPeriod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share [abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Earnings per share [text block]",
        "terseLabel": "Earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_EarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Earnings per share [line items]"
       }
      }
     },
     "localname": "EarningsPerShareLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EarningsPerShareTable": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Earnings per share [table]"
       }
      }
     },
     "localname": "EarningsPerShareTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "auth_ref": [
      "r169",
      "r170"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 4.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "auth_ref": [
      "r1",
      "r53",
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      },
      "en-us": {
       "role": {
        "label": "Employee benefits expense",
        "terseLabel": "Personnel costs"
       }
      }
     },
     "localname": "EmployeeBenefitsExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EntitysTotalForAssociatesMember": {
     "auth_ref": [
      "r123",
      "r127",
      "r226",
      "r339",
      "r343"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for associates [member]"
       }
      }
     },
     "localname": "EntitysTotalForAssociatesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForBusinessCombinationsMember": {
     "auth_ref": [
      "r276",
      "r279"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for business combinations [member]"
       }
      }
     },
     "localname": "EntitysTotalForBusinessCombinationsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]"
       }
      }
     },
     "localname": "EntitysTotalForRelatedPartiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForSegmentConsolidationItemsMember": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Segment consolidation items' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for segment consolidation items [member]"
       }
      }
     },
     "localname": "EntitysTotalForSegmentConsolidationItemsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForSubsidiariesMember": {
     "auth_ref": [
      "r123",
      "r127",
      "r225"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for subsidiaries [member]"
       }
      }
     },
     "localname": "EntitysTotalForSubsidiariesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Equity": {
     "auth_ref": [
      "r25",
      "r34",
      "r194",
      "r196",
      "r227",
      "r228",
      "r230"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity",
        "periodEndLabel": "Equity at end of period",
        "periodStartLabel": "Equity at beginning of period",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "Equity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityAndLiabilities": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "Total equity and liabilities"
       }
      }
     },
     "localname": "EquityAndLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities [abstract]"
       }
      }
     },
     "localname": "EquityAndLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity attributable to owners of parent",
        "totalLabel": "Equity attributable to Novartis AG shareholders"
       }
      }
     },
     "localname": "EquityAttributableToOwnersOfParent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAttributableToOwnersOfParentMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity attributable to the owners of the parent."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity attributable to owners of parent [member]"
       }
      }
     },
     "localname": "EquityAttributableToOwnersOfParentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EquityInstrumentsHeld": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "nvs_MarketableSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of instruments held by the entity that provide evidence of a residual interest in the assets of another entity after deducting all of its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity instruments held",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquityInstrumentsHeld",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityInvestmentsMember": {
     "auth_ref": [
      "r392",
      "r406"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for investments in equity instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity investments [member]",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquityInvestmentsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EquityMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity [member]"
       }
      }
     },
     "localname": "EquityMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EstimatedFinancialEffectOfContingentLiabilities": {
     "auth_ref": [
      "r147"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the estimated financial effect of contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Estimated financial effect of contingent liabilities"
       }
      }
     },
     "localname": "EstimatedFinancialEffectOfContingentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Exercise price of outstanding share options"
       }
      }
     },
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_ExpenseDueToUnwindingOfDiscountOnProvisions": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense recognised due to the unwinding of the discount on provisions other than provisions from employee benefits, resulting from the effect of the passage of time. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense due to unwinding of discount on provisions",
        "negatedTerseLabel": "Expense arising from discounting long-term liabilities and capitalized borrowing costs"
       }
      }
     },
     "localname": "ExpenseDueToUnwindingOfDiscountOnProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions with employees",
        "negatedTerseLabel": "Equity-based compensation of Novartis equity plans",
        "terseLabel": "Equity-based compensation of Novartis equity plans"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Expense relating to leases of low-value assets for which recognition exemption has been used",
        "negatedTerseLabel": "Recognition exception for low value leases",
        "terseLabel": "Recognition exception for low value leases"
       }
      }
     },
     "localname": "ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease."
       }
      },
      "en-us": {
       "role": {
        "label": "Expense relating to short-term leases for which recognition exemption has been used",
        "negatedTerseLabel": "Recognition exemption for short term leases",
        "terseLabel": "Recognition exemption for short term leases"
       }
      }
     },
     "localname": "ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to variable lease payments not included in the measurement of lease liabilities. Variable lease payments are the portion of payments made by a lessee to a lessor for the right to use an underlying asset during the lease term that varies because of changes in facts or circumstances occurring after the commencement date, other than the passage of time. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense relating to variable lease payments not included in measurement of lease liabilities"
       }
      }
     },
     "localname": "ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of a share-based payment arrangement that existed at any time during the reporting period. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of share-based payment arrangement"
       }
      }
     },
     "localname": "ExplanationOfShareOptionsInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome": {
     "auth_ref": [
      "r286",
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: At fair value [member]; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Investments in equity instruments designated at fair value through other comprehensive income",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r464"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": 10.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for finance costs paid, classified as operating activities. [Refer: Finance costs]"
       }
      },
      "en-us": {
       "role": {
        "label": "Finance costs paid, classified as operating activities",
        "negatedTerseLabel": "Other financial payments"
       }
      }
     },
     "localname": "FinanceCostsPaidClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r464"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": 9.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from finance income received, classified as operating activities. [Refer: Finance income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Finance income received, classified as operating activities",
        "terseLabel": "Other financial receipts"
       }
      }
     },
     "localname": "FinanceIncomeReceivedClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssets": {
     "auth_ref": [
      "r289",
      "r292",
      "r293",
      "r296",
      "r391"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets"
       }
      }
     },
     "localname": "FinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets at amortised cost, category [member]"
       }
      }
     },
     "localname": "FinancialAssetsAtAmortisedCostCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsAtAmortisedCostMember": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets measured at amortised cost class. [Refer: Financial assets at amortised cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets at amortised cost, class [member]"
       }
      }
     },
     "localname": "FinancialAssetsAtAmortisedCostMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsAtFairValue": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets, at fair value"
       }
      }
     },
     "localname": "FinancialAssetsAtFairValue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssetsAtFairValueMember": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets measured at fair value class. [Refer: Financial assets; At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets at fair value, class [member]"
       }
      }
     },
     "localname": "FinancialAssetsAtFairValueMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at fair value through other comprehensive income category. [Refer: Financial assets at fair value through other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets at fair value through other comprehensive income, category [member]"
       }
      }
     },
     "localname": "FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets at fair value through profit or loss, category [member]"
       }
      }
     },
     "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsCategoryMember": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets, category [member]"
       }
      }
     },
     "localname": "FinancialAssetsCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsImpairedMember": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for financial assets that have been impaired. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets impaired [member]",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "FinancialAssetsImpairedMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialAssetsMember": {
     "auth_ref": [
      "r300",
      "r301",
      "r329",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets, class [member]"
       }
      }
     },
     "localname": "FinancialAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember": {
     "auth_ref": [
      "r186",
      "r188"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial effect of changes in accounting policy."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) due to changes in accounting policy [member]"
       }
      }
     },
     "localname": "FinancialEffectOfChangesInAccountingPolicyMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilities": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities"
       }
      }
     },
     "localname": "FinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": {
     "auth_ref": [
      "r306",
      "r346"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities at amortised cost, category [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostMember": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities measured at amortised cost class. [Refer: Financial liabilities at amortised cost]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities at amortised cost, class [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtAmortisedCostMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesAtFairValue": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities, at fair value",
        "negatedTerseLabel": "Financial liabilities, at fair value"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtFairValue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueMember": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities measured at fair value class. [Refer: Financial liabilities; At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities at fair value, class [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtFairValueMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities at fair value through profit or loss, category [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesCategoryMember": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities, category [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesCategoryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesMember": {
     "auth_ref": [
      "r300",
      "r301",
      "r329",
      "r336"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities, class [member]"
       }
      }
     },
     "localname": "FinancialLiabilitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r388",
      "r390"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 11.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for financial liabilities assumed in a business combination. [Refer: Financial liabilities; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities recognised as of acquisition date",
        "negatedTerseLabel": "Current and non-current financial debts"
       }
      }
     },
     "localname": "FinancialLiabilitiesRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ForeignCountriesMember": {
     "auth_ref": [
      "r323",
      "r324"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for countries outside the entity's country of domicile. [Refer: Country of domicile [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Foreign countries [member]",
        "terseLabel": "Foreign",
        "verboseLabel": "Rest of the world"
       }
      }
     },
     "localname": "ForeignCountriesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from the gain (loss) on changes in the effect of limiting a net defined benefit asset to the asset ceiling, excluding amounts included in interest income or expense. [Refer: Interest income (expense); Net defined benefit liability (asset); Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on changes in effect of limiting net defined benefit asset to asset ceiling excluding interest income or expense",
        "terseLabel": "Change in limitation on recognition of fund surplus"
       }
      }
     },
     "localname": "GainLossOnChangesInEffectOfLimitingNetDefinedBenefitAssetToAssetCeiling",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gain (loss) on remeasurement, net defined benefit liability (asset)",
        "terseLabel": "Remeasurements"
       }
      }
     },
     "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gain (loss) recognised as result of remeasuring to fair value the equity interest in the acquiree held by the acquirer before the business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gain (loss) recognised as result of remeasuring to fair value equity interest in acquiree held by acquirer before business combination"
       }
      }
     },
     "localname": "GainLossRecognisedAsResultOfRemeasuringToFairValueEquityInterestInAcquireeHeldByAcquirerBeforeBusinessCombination",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesArisingFromSaleAndLeasebackTransactions": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) arising from sale and leaseback transactions."
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) arising from sale and leaseback transactions",
        "terseLabel": "Gains or losses from sales leaseback"
       }
      }
     },
     "localname": "GainsLossesArisingFromSaleAndLeasebackTransactions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnAvailableforsaleFinancialAssets": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherFinanceIncomeCost",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) on available-for-sale financial assets. [Refer: Financial assets available-for-sale]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) on available-for-sale financial assets",
        "terseLabel": "Net capital losses on available-for-sale securities"
       }
      }
     },
     "localname": "GainsLossesOnAvailableforsaleFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r12",
      "r105"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2": {
       "order": 8.0,
       "parentTag": "ifrs-full_OtherFinanceIncomeCost",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Foreign exchange gain (loss)",
        "terseLabel": "Currency result, net"
       }
      }
     },
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnNetMonetaryPosition": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2": {
       "order": 7.0,
       "parentTag": "ifrs-full_OtherFinanceIncomeCost",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) representing the difference resulting from the restatement of non-monetary assets, owners' equity and items in the statement of comprehensive income and the adjustment of index linked assets and liabilities in hyperinflationary reporting."
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) on net monetary position",
        "terseLabel": "Monetary loss from hyperinflation"
       }
      }
     },
     "localname": "GainsLossesOnNetMonetaryPosition",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GeographicalAreasAxis": {
     "auth_ref": [
      "r325",
      "r359",
      "r386",
      "r412"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Geographical areas [axis]"
       }
      }
     },
     "localname": "GeographicalAreasAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_GeographicalAreasMember": {
     "auth_ref": [
      "r325",
      "r359",
      "r386",
      "r412"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Geographical areas [member]"
       }
      }
     },
     "localname": "GeographicalAreasMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Goodwill": {
     "auth_ref": [
      "r14",
      "r138",
      "r141",
      "r278"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GoodwillExpectedDeductibleForTaxPurposes": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of goodwill in a business combination that is expected to be deductible for tax purposes. [Refer: Goodwill; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Goodwill expected to be deductible for tax purposes"
       }
      }
     },
     "localname": "GoodwillExpectedDeductibleForTaxPurposes",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GoodwillMember": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for goodwill. [Refer: Goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Goodwill [member]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GoodwillRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r389",
      "r390"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Goodwill recognised as of acquisition date",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "auth_ref": [
      "r65",
      "r149",
      "r160",
      "r163",
      "r278",
      "r293",
      "r296",
      "r391",
      "r475",
      "r477"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross carrying amount [member]",
        "terseLabel": "Gross carrying amount"
       }
      }
     },
     "localname": "GrossCarryingAmountMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GrossLeaseLiabilities": {
     "auth_ref": [
      "r248",
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross lease liabilities",
        "terseLabel": "Operating lease commitments"
       }
      }
     },
     "localname": "GrossLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GrossProfit": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 6.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed": {
     "auth_ref": [
      "r388",
      "r390"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Identifiable assets acquired (liabilities assumed)",
        "terseLabel": "Net assets recognized as a result of acquisitions of business"
       }
      }
     },
     "localname": "IdentifiableAssetsAcquiredLiabilitiesAssumed",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ImpairmentLoss": {
     "auth_ref": [
      "r135",
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Impairment loss"
       }
      }
     },
     "localname": "ImpairmentLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for intangible assets and goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets and goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Impairment loss recognised in profit or loss, intangible assets and goodwill",
        "negatedLabel": "Impairment loss recognised in profit or loss, intangible assets and goodwill",
        "negatedTerseLabel": "Impairment charge",
        "terseLabel": "Impairment charge"
       }
      }
     },
     "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "auth_ref": [
      "r51",
      "r68"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Impairment loss recognised in profit or loss, property, plant and equipment",
        "negatedTerseLabel": "Impairment loss recognised in profit or loss, property, plant and equipment",
        "terseLabel": "Impairment charge"
       }
      }
     },
     "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of impairment loss or reversal of impairment loss recognised in profit or loss. [Refer: Impairment loss recognised in profit or loss; Reversal of impairment loss recognised in profit or loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Impairment loss (reversal of impairment loss) recognised in profit or loss",
        "negatedLabel": "Impairment (loss) reversal of impairment loss recognised in profit or loss",
        "negatedTerseLabel": "Impairment loss (reversal of impairment loss) recognised in profit or loss"
       }
      }
     },
     "localname": "ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]",
        "terseLabel": "Consolidated income statements [abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "auth_ref": [
      "r46",
      "r56",
      "r59",
      "r60",
      "r118",
      "r222",
      "r314"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income), continuing operations",
        "negatedLabel": "Income tax expense",
        "negatedTerseLabel": "Income taxes",
        "terseLabel": "Income tax expense",
        "verboseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome": {
     "auth_ref": [
      "r49",
      "r58"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Income tax relating to components of other comprehensive income",
        "terseLabel": "Credited/(charged) to other comprehensive income",
        "verboseLabel": "Deferred tax on above items"
       }
      }
     },
     "localname": "IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxesPaidRefund": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded."
       }
      },
      "en-us": {
       "role": {
        "label": "Income taxes paid (refund)",
        "negatedTerseLabel": "Income taxes (paid)/refund"
       }
      }
     },
     "localname": "IncomeTaxesPaidRefund",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxesPaidRefundClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r172",
      "r368"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded, classified as investing activities. [Refer: Income taxes paid (refund)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Income taxes paid (refund), classified as investing activities",
        "negatedTerseLabel": "Income taxes (paid)/refund, classified as investing activities"
       }
      }
     },
     "localname": "IncomeTaxesPaidRefundClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r172",
      "r368"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": 11.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Income taxes paid (refund), classified as operating activities",
        "negatedLabel": "Income taxes refund/(paid), classified as operating activities",
        "negatedTerseLabel": "Income taxes paid",
        "terseLabel": "Taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember": {
     "auth_ref": [
      "r3",
      "r186",
      "r188",
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial effect of changes in accounting policy and corrections of prior period errors."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) due to changes in accounting policy and corrections of prior period errors [member]"
       }
      }
     },
     "localname": "IncreaseDecreaseDueToChangesInAccountingPolicyAndCorrectionsOfPriorPeriodErrorsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember": {
     "auth_ref": [
      "r186",
      "r187"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the financial effect of changes in accounting policy required by IFRSs. [Refer: IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) due to changes in accounting policy required by IFRSs [member]"
       }
      }
     },
     "localname": "IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "auth_ref": [
      "r182"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "auth_ref": [
      "r182"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 5.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "terseLabel": "Net change in cash and cash equivalents before effect of exchange rate changes"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents from discontinued operations. [Refer: Cash and cash equivalents; Discontinued operations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents, discontinued operations",
        "terseLabel": "Net cash flows used in discontinued operations",
        "verboseLabel": "Cash and cash equivalents of discontinued operations"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in a defined benefit obligation that would have been caused by a decrease in a significant actuarial assumption that was reasonably possible at the end of the reporting period. [Refer: Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption"
       }
      }
     },
     "localname": "IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in a defined benefit obligation that would have been caused by an increase in a significant actuarial assumption that was reasonably possible at the end of the reporting period. [Refer: Actuarial assumptions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption"
       }
      }
     },
     "localname": "IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners": {
     "auth_ref": [
      "r193"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in dividends payable through a change in the fair value of non-cash assets held for distribution to owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in dividends payable through change in fair value of non-cash assets held for distribution to owners",
        "terseLabel": "Decrease of distribution liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInDividendsPayableThroughChangeInFairValueOfNoncashAssetsHeldForDistributionToOwners",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets": {
     "auth_ref": [
      "r446"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from administration costs in the current period, that are not reflected in return on plan assets. [Refer: Administrative expenses; Net defined benefit liability (asset)] [Contrast: Administration costs not reflected in return on plan assets, defined benefit plans; Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in net defined benefit liability (asset) resulting from administration costs not reflected in return on plan assets",
        "terseLabel": "Administrative expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset": {
     "auth_ref": [
      "r441"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in deferred tax liability (asset) resulting from business combinations. [Refer: Deferred tax liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through business combinations, deferred tax liability (asset)",
        "negatedTerseLabel": "Impact of business combinations",
        "terseLabel": "Impact of business combinations"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from changes in foreign exchange rates. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through changes in foreign exchange rates, net defined benefit liability (asset)",
        "negatedTerseLabel": "Currency translation effects",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity through changes in ownership interests in subsidiaries that do not result in loss of control. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity",
        "negatedTerseLabel": "Impact of change in ownership of consolidated entities",
        "terseLabel": "Impact of change in ownership of consolidated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through exercise of options, equity",
        "terseLabel": "Exercise of options and employee transactions, equity impact"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails4",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill": {
     "auth_ref": [
      "r454"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets and goodwill resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets and goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, intangible assets and goodwill",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, other provisions",
        "negatedTerseLabel": "Currency translation effects",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, property, plant and equipment",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from obtaining or losing control of subsidiaries or other businesses. [Refer: Liabilities arising from financing activities; Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through obtaining or losing control of subsidiaries or other businesses, liabilities arising from financing activities",
        "terseLabel": "Impact of acquisitions and divestments of businesses, net"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Equity-based compensation, equity impact",
        "verboseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails4",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through other changes, equity",
        "terseLabel": "Other movements"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesEquity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions resulting from transfers and changes that the entity does not separately disclose in the same statement or note. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers and other changes, other provisions",
        "terseLabel": "Transfers"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers from construction in progress. [Refer: Property, plant and equipment; Construction in progress]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers from construction in progress, property, plant and equipment",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets and goodwill resulting from transfers. [Refer: Intangible assets and goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers, intangible assets and goodwill",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": {
     "auth_ref": [
      "r375",
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase through new leases, liabilities arising from financing activities",
        "terseLabel": "New leases"
       }
      }
     },
     "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsAndGoodwill": {
     "auth_ref": [
      "r435"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets and goodwill",
        "periodEndLabel": "Intangible assets and goodwill at end of period",
        "periodStartLabel": "Intangible assets and goodwill at beginning of period",
        "terseLabel": "Net book value"
       }
      }
     },
     "localname": "IntangibleAssetsAndGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsAndGoodwillMember": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets and goodwill [member]",
        "terseLabel": "Intangible assets",
        "verboseLabel": "Intangible assets [member]"
       }
      }
     },
     "localname": "IntangibleAssetsAndGoodwillMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IntangibleAssetsMaterialToEntity": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of intangible assets that are material to the entity\u2019s financial statements. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets material to entity",
        "terseLabel": "Carrying value"
       }
      }
     },
     "localname": "IntangibleAssetsMaterialToEntity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r14",
      "r153"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": {
     "auth_ref": [
      "r154",
      "r363",
      "r387"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill [member]",
        "terseLabel": "Intangible Assets other than Goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwillMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InterestExpense": {
     "auth_ref": [
      "r221",
      "r311",
      "r320"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense",
        "negatedTerseLabel": "Interest expense",
        "negatedTotalLabel": "Total interest expense",
        "totalLabel": "Total Interest Expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from the passage of time. [Refer: Interest expense; Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense (income), net defined benefit liability (asset)",
        "negatedTerseLabel": "Net interest expense",
        "terseLabel": "Net interest expense"
       }
      }
     },
     "localname": "InterestExpenseIncomeNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense on lease liabilities",
        "negatedTerseLabel": "Interest expense on lease liabilities"
       }
      }
     },
     "localname": "InterestExpenseOnLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest paid, classified as operating activities",
        "negatedTerseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestReceivable": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails": {
       "order": 8.0,
       "parentTag": "ifrs-full_OtherCurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest recognised as a receivable."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest receivable",
        "terseLabel": "Accrued interest on debt securities and time deposits"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest received, classified as operating activities",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceivedClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Inventories": {
     "auth_ref": [
      "r17",
      "r99",
      "r350"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current inventories",
        "terseLabel": "Inventories",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "Inventories",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InventoryRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r388",
      "r390"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 7.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for inventory acquired in a business combination. [Refer: Inventories; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Inventory recognised as of acquisition date",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InventoryWritedown2011": {
     "auth_ref": [
      "r51",
      "r101"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Inventory write-down",
        "negatedTerseLabel": "Inventory provisions",
        "terseLabel": "Inventory provisions"
       }
      }
     },
     "localname": "InventoryWritedown2011",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InvestmentAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r16",
      "r224",
      "r316"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 4.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Investments accounted for using equity method",
        "terseLabel": "Investment in associated companies",
        "verboseLabel": "Balance sheet value"
       }
      }
     },
     "localname": "InvestmentAccountedForUsingEquityMethod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Investments in equity instruments designated at fair value through other comprehensive income [axis]"
       }
      }
     },
     "localname": "InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r286",
      "r307"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for investments in equity instruments that the entity has designated at fair value through other comprehensive income. It also represents the standard value for the 'Investments in equity instruments designated at fair value through other comprehensive income' axis if no other member is used. [Refer: At fair value [member]; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Investments in equity instruments designated at fair value through other comprehensive income [member]"
       }
      }
     },
     "localname": "InvestmentsInEquityInstrumentsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of investments in subsidiaries, joint ventures and associates in an entity's separate financial statements. [Refer: Associates [member]; Joint ventures [member]; Subsidiaries [member]; Investments in subsidiaries reported in separate financial statements]"
       }
      },
      "en-us": {
       "role": {
        "label": "Investments in subsidiaries, joint ventures and associates"
       }
      }
     },
     "localname": "InvestmentsInSubsidiariesJointVenturesAndAssociates",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapital": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureEquityDetails": {
       "order": 1.0,
       "parentTag": "nvs_OutstandingShareCapital",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital",
        "periodEndLabel": "Share capital at end of period",
        "periodStartLabel": "Share capital at beginning of period",
        "terseLabel": "Share capital"
       }
      }
     },
     "localname": "IssuedCapital",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapitalMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital [member]",
        "terseLabel": "Share capital"
       }
      }
     },
     "localname": "IssuedCapitalMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensation",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2": {
       "order": 2.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, post-employment benefits",
        "terseLabel": "Post-employment benefits"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2": {
       "order": 3.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, share-based payment",
        "terseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2": {
       "order": 1.5,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, short-term employee benefits",
        "terseLabel": "Benefits other than equity-based compensation"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel of entity or parent [member]"
       }
      }
     },
     "localname": "KeyManagementPersonnelOfEntityOrParentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LandMember": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing land held by the entity for use in operations. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Land [member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanFiveYearsAndNotLaterThanTenYearsMember": {
     "auth_ref": [
      "r396",
      "r405",
      "r433"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years and not later than ten years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than five years and not later than ten years [member]"
       }
      }
     },
     "localname": "LaterThanFiveYearsAndNotLaterThanTenYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "auth_ref": [
      "r249",
      "r250",
      "r334",
      "r396",
      "r402",
      "r405"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than five years [member]",
        "terseLabel": "Later than five years"
       }
      }
     },
     "localname": "LaterThanFiveYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember": {
     "auth_ref": [
      "r249",
      "r250",
      "r334",
      "r396",
      "r405",
      "r433"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than four years and not later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than four years and not later than five years [member]"
       }
      }
     },
     "localname": "LaterThanFourYearsAndNotLaterThanFiveYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneMonthAndNotLaterThanThreeMonthsMember": {
     "auth_ref": [
      "r394",
      "r399",
      "r405"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one month and not later than three months."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one month and not later than three months [member]"
       }
      }
     },
     "localname": "LaterThanOneMonthAndNotLaterThanThreeMonthsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": {
     "auth_ref": [
      "r395",
      "r405"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than five years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one year and not later than five years [member]",
        "terseLabel": "Between one and five years"
       }
      }
     },
     "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": {
     "auth_ref": [
      "r249",
      "r250",
      "r334",
      "r396",
      "r405",
      "r433"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than two years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one year and not later than two years [member]"
       }
      }
     },
     "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearMember": {
     "auth_ref": [
      "r28",
      "r415",
      "r419"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than one year [member]"
       }
      }
     },
     "localname": "LaterThanOneYearMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanSixMonthsAndNotLaterThanOneYearMember": {
     "auth_ref": [
      "r396",
      "r401",
      "r405",
      "r415",
      "r418"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than six months and not later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than six months and not later than one year [member]"
       }
      }
     },
     "localname": "LaterThanSixMonthsAndNotLaterThanOneYearMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember": {
     "auth_ref": [
      "r396",
      "r400",
      "r405",
      "r415",
      "r417"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three months and not later than six months."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than three months and not later than six months [member]"
       }
      }
     },
     "localname": "LaterThanThreeMonthsAndNotLaterThanSixMonthsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": {
     "auth_ref": [
      "r249",
      "r250",
      "r334",
      "r396",
      "r405",
      "r433"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three years and not later than four years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than three years and not later than four years [member]"
       }
      }
     },
     "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": {
     "auth_ref": [
      "r249",
      "r250",
      "r334",
      "r396",
      "r405",
      "r433"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than two years and not later than three years."
       }
      },
      "en-us": {
       "role": {
        "label": "Later than two years and not later than three years [member]"
       }
      }
     },
     "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LeaseLiabilities": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Lease liabilities",
        "negatedLabel": "Lease liability",
        "negatedTerseLabel": "Current and non-current lease liabilities",
        "terseLabel": "Lease liability",
        "totalLabel": "Impact of adoption of IFRS 16 Leases"
       }
      }
     },
     "localname": "LeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LeaseLiabilitiesMember": {
     "auth_ref": [
      "r376",
      "r378"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Lease liabilities [member]"
       }
      }
     },
     "localname": "LeaseLiabilitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LegalProceedingsProvisionMember": {
     "auth_ref": [
      "r365",
      "r366"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a provision for legal proceedings. [Refer: Other provisions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Legal proceedings provision [member]"
       }
      }
     },
     "localname": "LegalProceedingsProvisionMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Level1OfFairValueHierarchyMember": {
     "auth_ref": [
      "r93",
      "r228"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
       }
      },
      "en-us": {
       "role": {
        "label": "Level 1 of fair value hierarchy [member]"
       }
      }
     },
     "localname": "Level1OfFairValueHierarchyMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      },
      "en-us": {
       "role": {
        "label": "Level 2 of fair value hierarchy [member]"
       }
      }
     },
     "localname": "Level2OfFairValueHierarchyMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      },
      "en-us": {
       "role": {
        "label": "Level 3 of fair value hierarchy [member]"
       }
      }
     },
     "localname": "Level3OfFairValueHierarchyMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "auth_ref": [
      "r93",
      "r228"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]"
       }
      }
     },
     "localname": "LevelsOfFairValueHierarchyAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_Liabilities": {
     "auth_ref": [
      "r25",
      "r227",
      "r228",
      "r230",
      "r315",
      "r319"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities",
        "negatedLabel": "Total liabilities",
        "negatedTotalLabel": "Total liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [abstract]"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_LiabilitiesFromSharebasedPaymentTransactions2011": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 11.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities arising from share-based payment transactions. Share-based payment transactions are transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities from share-based payment transactions",
        "terseLabel": "Accrued share-based payments"
       }
      }
     },
     "localname": "LiabilitiesFromSharebasedPaymentTransactions2011",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities in subsidiaries or other businesses over which control is obtained or lost. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities in subsidiary or businesses acquired or disposed"
       }
      }
     },
     "localname": "LiabilitiesInSubsidiaryOrBusinessesAcquiredOrDisposed2013",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale": {
     "auth_ref": [
      "r22",
      "r284"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 7.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities included in disposal groups classified as held for sale. [Refer: Liabilities; Disposal groups classified as held for sale [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities included in disposal groups classified as held for sale",
        "terseLabel": "Liabilities of disposal group held for sale"
       }
      }
     },
     "localname": "LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LiabilitiesMember": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities [member]"
       }
      }
     },
     "localname": "LiabilitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net defined benefit liability (asset)",
        "negatedPeriodEndLabel": "Net liability at end of period",
        "negatedPeriodStartLabel": "Net liability at beginning of period",
        "negatedTerseLabel": "Net liability in the balance sheet at end of period"
       }
      }
     },
     "localname": "LiabilityAssetOfDefinedBenefitPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_MachineryMember": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing long-lived, depreciable machinery used in operations. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Machinery [member]",
        "terseLabel": "Machinery and other equipment"
       }
      }
     },
     "localname": "MachineryMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major components of tax expense (income) [abstract]"
       }
      }
     },
     "localname": "MajorComponentsOfTaxExpenseIncomeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MajorCustomersAxis": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Major customers [axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MajorCustomersMember": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Customers [member]"
       }
      }
     },
     "localname": "MajorCustomersMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for material adjustments used to reconcile items in the entity's financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Material reconciling items [member]"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MaturityAxis": {
     "auth_ref": [
      "r29",
      "r235",
      "r249",
      "r250",
      "r288",
      "r299",
      "r330",
      "r331",
      "r333",
      "r334",
      "r361",
      "r396"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Maturity [axis]"
       }
      }
     },
     "localname": "MaturityAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MeasurementAxis": {
     "auth_ref": [
      "r158",
      "r162",
      "r227"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Measurement [axis]"
       }
      }
     },
     "localname": "MeasurementAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NameOfSubsidiary": {
     "auth_ref": [
      "r120",
      "r124",
      "r199",
      "r203"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The name of a subsidiary. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Name of subsidiary"
       }
      }
     },
     "localname": "NameOfSubsidiary",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NetAssetsLiabilities": {
     "auth_ref": [
      "r379",
      "r433"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets less the amount of liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Net assets liabilities",
        "verboseLabel": "Net assets"
       }
      }
     },
     "localname": "NetAssetsLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NetDebt": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of net debt of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Net debt",
        "negatedTerseLabel": "Net debt",
        "terseLabel": "Net debt"
       }
      }
     },
     "localname": "NetDebt",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-controlling interest in the acquiree recognised at the acquisition date for business combinations in which the acquirer holds less than 100 per cent of the equity interests in the acquiree at the acquisition date. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-controlling interest in acquiree recognised at acquisition date",
        "negatedTerseLabel": "Non-controlling interests",
        "terseLabel": "Non-controlling interests"
       }
      }
     },
     "localname": "NoncontrollingInterestInAcquireeRecognisedAtAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncontrollingInterests": {
     "auth_ref": [
      "r23",
      "r198",
      "r202"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-controlling interests"
       }
      }
     },
     "localname": "NoncontrollingInterests",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncontrollingInterestsMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-controlling interests [member]"
       }
      }
     },
     "localname": "NoncontrollingInterestsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NoncurrentAssets": {
     "auth_ref": [
      "r30",
      "r209",
      "r380"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets [abstract]"
       }
      }
     },
     "localname": "NoncurrentAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 10.2,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current assets or disposal groups classified as held for sale. [Refer: Disposal groups classified as held for sale [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets or disposal groups classified as held for sale",
        "terseLabel": "Assets of disposal group held for sale"
       }
      }
     },
     "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentFinanceLeaseReceivables": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails": {
       "order": 6.0,
       "parentTag": "ifrs-full_NoncurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current finance lease receivables. [Refer: Finance lease receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current finance lease receivables",
        "terseLabel": "Minimum lease payments from finance lease agreements"
       }
      }
     },
     "localname": "NoncurrentFinanceLeaseReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentFinancialAssets": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 6.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current financial assets",
        "terseLabel": "Financial assets",
        "totalLabel": "Total financial assets"
       }
      }
     },
     "localname": "NoncurrentFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 5.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "NoncurrentLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilities": {
     "auth_ref": [
      "r31",
      "r211",
      "r380"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities [abstract]"
       }
      }
     },
     "localname": "NoncurrentLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentLoansAndReceivables": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails": {
       "order": 8.0,
       "parentTag": "ifrs-full_NoncurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current loans and receivables. [Refer: Loans and receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current loans and receivables",
        "terseLabel": "Long-term loans, advances and security deposits"
       }
      }
     },
     "localname": "NoncurrentLoansAndReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherNoncurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current net defined benefit liability. [Refer: Net defined benefit liability]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current net defined benefit liability",
        "terseLabel": "Defined benefit pension plans"
       }
      }
     },
     "localname": "NoncurrentRecognisedLiabilitiesDefinedBenefitPlan",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentTradeReceivables": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_NoncurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current trade receivables. [Refer: Trade receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current trade receivables",
        "terseLabel": "Long-term receivables from customers"
       }
      }
     },
     "localname": "NoncurrentTradeReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NotLaterThanOneMonthMember": {
     "auth_ref": [
      "r393",
      "r398",
      "r405"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one month."
       }
      },
      "en-us": {
       "role": {
        "label": "Not later than one month [member]"
       }
      }
     },
     "localname": "NotLaterThanOneMonthMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "auth_ref": [
      "r27",
      "r249",
      "r250",
      "r334",
      "r396",
      "r405"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Not later than one year [member]",
        "terseLabel": "Not later than one year"
       }
      }
     },
     "localname": "NotLaterThanOneYearMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NotionalAmount": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument."
       }
      },
      "en-us": {
       "role": {
        "label": "Notional amount"
       }
      }
     },
     "localname": "NotionalAmount",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "auth_ref": [
      "r264",
      "r466"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Granted, Number of Shares",
        "terseLabel": "Granted, number of shares"
       }
      }
     },
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "auth_ref": [
      "r256",
      "r259",
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Number of share options outstanding at end of period",
        "periodStartLabel": "Number of share options outstanding at beginning of period"
       }
      }
     },
     "localname": "NumberOfOutstandingShareOptions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercisable in share-based payment arrangement",
        "terseLabel": "Number of share options exercisable"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercised in share-based payment arrangement",
        "negatedLabel": "Number of share options exercised or sold",
        "negatedTerseLabel": "Number of share options exercised",
        "terseLabel": "Number of share options exercised or sold",
        "verboseLabel": "Number of share options exercised"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options forfeited in share-based payment arrangement",
        "terseLabel": "Number of share options forfeited or expired"
       }
      }
     },
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfSharesIssued": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "periodEndLabel": "Number of shares issued at end of period",
        "periodStartLabel": "Number of shares issued at beginning of period"
       }
      }
     },
     "localname": "NumberOfSharesIssued",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "periodEndLabel": "Number of shares outstanding at end of period",
        "periodStartLabel": "Number of shares outstanding at beginning of period"
       }
      }
     },
     "localname": "NumberOfSharesOutstanding",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_OperatingSegmentsMember": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for operating segments. An operating segment is a component of an entity: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity); (b) whose operating results are regularly reviewed by the entity\u2019s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance; and (c) for which discrete financial information is available. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Operating segments [member]"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OrdinarySharesMember": {
     "auth_ref": [
      "r130",
      "r438"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ordinary shares [member]",
        "terseLabel": "Total Novartis shares"
       }
      }
     },
     "localname": "OrdinarySharesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherAdjustmentsForNoncashItems": {
     "auth_ref": [
      "r462"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other adjustments for non-cash items",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAdjustmentsForNoncashItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherAdjustmentsToReconcileProfitLoss": {
     "auth_ref": [
      "r167"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Adjustments to reconcile profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other adjustments to reconcile profit (loss)",
        "terseLabel": "Other adjustments, net"
       }
      }
     },
     "localname": "OtherAdjustmentsToReconcileProfitLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherAssetsMember": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for assets that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other assets [member]",
        "terseLabel": "Financial and other assets including deferred tax assets",
        "verboseLabel": "Machinery &amp; equipment and other assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherBorrowings": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other borrowings"
       }
      }
     },
     "localname": "OtherBorrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r371"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow to acquire equity or debt instruments of other entities (other than payments for those instruments considered to be cash equivalents or those held for dealing or trading purposes), classified as investing activities."
       }
      }
     },
     "localname": "OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of equity or debt instruments of other entities (other than receipts for those instruments considered to be cash equivalents and those held for dealing or trading purposes), classified as investing activities."
       }
      }
     },
     "localname": "OtherCashReceiptsFromSalesOfEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "auth_ref": [
      "r5",
      "r39",
      "r50",
      "r215"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets": {
     "auth_ref": [
      "r341",
      "r342"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to available-for-sale financial assets. [Refer: Financial assets available-for-sale; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, available-for-sale financial assets",
        "terseLabel": "Fair value adjustments on marketable securities, net of taxes",
        "verboseLabel": "Available-for-sale marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxCashFlowHedges": {
     "auth_ref": [
      "r32",
      "r50"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails": {
       "order": 7.0,
       "parentTag": "nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to cash flow hedges. [Refer: Cash flow hedges [member]; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, fair value adjustments on deferred cash flow hedges",
        "terseLabel": "Fair value adjustments on deferred cash flow hedges, net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxCashFlowHedges",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "auth_ref": [
      "r32",
      "r50"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails": {
       "order": 11.0,
       "parentTag": "nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, exchange differences on translation",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments": {
     "auth_ref": [
      "r32",
      "r50"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) from changes in the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income applying paragraph 5.7.5 of IFRS 9. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, gains (losses) from investments in equity instruments",
        "terseLabel": "Fair value adjustments on equity securities, net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": {
     "auth_ref": [
      "r32",
      "r50",
      "r444"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails": {
       "order": 10.0,
       "parentTag": "nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans",
        "terseLabel": "Actuarial gains/losses from defined benefit plans, net of taxes",
        "totalLabel": "Remeasurements from defined benefit plans, total after tax",
        "verboseLabel": "Net actuarial gains/losses from defined benefit plans, net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations": {
     "auth_ref": [
      "r50",
      "r157",
      "r328"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails": {
       "order": 9.0,
       "parentTag": "nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to hedges of net investments in foreign operations. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, hedges of net investments in foreign operations",
        "terseLabel": "Net investment hedge"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxHedgesOfNetInvestmentsInForeignOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "auth_ref": [
      "r353",
      "r354"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax",
        "totalLabel": "Total of items to eventually recycle"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": {
     "auth_ref": [
      "r353",
      "r354"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 2.8,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax",
        "terseLabel": "Total of items never to be recycled"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentFinancialAssets": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current financial assets",
        "terseLabel": "Marketable securities, commodities, time deposits and derivative financial instruments",
        "totalLabel": "Total marketable securities, commodities, time deposits and derivative financial instruments"
       }
      }
     },
     "localname": "OtherCurrentFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentFinancialLiabilities": {
     "auth_ref": [
      "r19",
      "r217"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current financial liabilities",
        "negatedTerseLabel": "Current financial debt",
        "terseLabel": "Financial debts and derivative financial instruments",
        "totalLabel": "Total current financial debt and derivative financial instruments"
       }
      }
     },
     "localname": "OtherCurrentFinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentNonfinancialAssets": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 6.0,
       "parentTag": "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current non-financial assets",
        "terseLabel": "Other current assets",
        "totalLabel": "Total other current assets"
       }
      }
     },
     "localname": "OtherCurrentNonfinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentNonfinancialLiabilities": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current non-financial liabilities",
        "terseLabel": "Provisions and other current liabilities",
        "totalLabel": "Total provisions and other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentNonfinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentPayables": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 14.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other current payables",
        "terseLabel": "Other payables"
       }
      }
     },
     "localname": "OtherCurrentPayables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherExpenseByFunction": {
     "auth_ref": [
      "r53",
      "r117",
      "r348"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 1.5,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses."
       }
      },
      "en-us": {
       "role": {
        "label": "Other expense, by function",
        "negatedTerseLabel": "Other expense"
       }
      }
     },
     "localname": "OtherExpenseByFunction",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherFinanceCost": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2": {
       "order": 11.0,
       "parentTag": "ifrs-full_OtherFinanceIncomeCost",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other finance cost",
        "negatedTerseLabel": "Financial expense"
       }
      }
     },
     "localname": "OtherFinanceCost",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherFinanceIncomeCost": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 4.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other financial income and expense",
        "negatedTerseLabel": "Other financial income and expense",
        "terseLabel": "Other financial income and expense",
        "totalLabel": "Total other financial income and expense"
       }
      }
     },
     "localname": "OtherFinanceIncomeCost",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherIncome": {
     "auth_ref": [
      "r115",
      "r347",
      "r348"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r168"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Inflows (outflows) of cash, classified as financing activities, that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other inflows (outflows) of cash, classified as financing activities",
        "negatedTerseLabel": "Dividends paid to non-controlling interests and other financing cash flows",
        "terseLabel": "Other financing cash flows, net",
        "verboseLabel": "Transaction cost payments"
       }
      }
     },
     "localname": "OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Inflows (outflows) of cash, classified as investing activities, that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other inflows (outflows) of cash, classified as investing activities",
        "terseLabel": "Other cash flows used in investing activities, net"
       }
      }
     },
     "localname": "OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Inflows (outflows) of cash, classified as operating activities, that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other inflows (outflows) of cash",
        "terseLabel": "Change in other net current assets and other operating cash flow items"
       }
      }
     },
     "localname": "OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherIntangibleAssetsMember": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other intangible assets [member]",
        "terseLabel": "Other intangible assets"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherNoncurrentAssets": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 7.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current assets",
        "totalLabel": "Total other non-current assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentFinancialLiabilities": {
     "auth_ref": [
      "r19",
      "r218"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current financial liabilities",
        "negatedTerseLabel": "Non-current financial debts",
        "terseLabel": "Financial debts",
        "totalLabel": "Total non-current financial debts"
       }
      }
     },
     "localname": "OtherNoncurrentFinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentLiabilities": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "ifrs-full_OtherNoncurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentNonfinancialAssets": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current non-financial assets",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherNoncurrentNonfinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentNonfinancialLiabilities": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 6.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current non-financial liabilities",
        "terseLabel": "Provisions and other non-current liabilities",
        "totalLabel": "Total provisions and other non-current liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentNonfinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentReceivables": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails": {
       "order": 10.0,
       "parentTag": "ifrs-full_NoncurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current other receivables. [Refer: Other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current receivables",
        "terseLabel": "Other long-term receivables"
       }
      }
     },
     "localname": "OtherNoncurrentReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherProvisions": {
     "auth_ref": [
      "r33",
      "r142"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of provisions other than provisions for employee benefits. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other provisions",
        "periodEndLabel": "Provision at end of period",
        "periodStartLabel": "Provision at beginning of period"
       }
      }
     },
     "localname": "OtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherProvisionsMember": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other provisions [member]"
       }
      }
     },
     "localname": "OtherProvisionsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherReserves": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other reserves",
        "terseLabel": "Reserves"
       }
      }
     },
     "localname": "OtherReserves",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherRevenue": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other revenue",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherRevenue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Tax rate effects, in aggregate, on the reconciliation between the average effective tax rate and the applicable tax rate that the entity does not separately disclose in the reconciliation. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other tax rate effects for reconciliation between accounting profit and tax expense (income)",
        "terseLabel": "Effect of other items"
       }
      }
     },
     "localname": "OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ParValuePerShare": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Par value per share"
       }
      }
     },
     "localname": "ParValuePerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_PastDueStatusAxis": {
     "auth_ref": [
      "r391",
      "r476"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Past due status [axis]"
       }
      }
     },
     "localname": "PastDueStatusAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_PastDueStatusMember": {
     "auth_ref": [
      "r391",
      "r476"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all past-due statuses. It also represents the standard value for the 'Past due status' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Past due status [member]"
       }
      }
     },
     "localname": "PastDueStatusMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from past service cost and losses (gains) arising from settlements. [Refer: Decrease (increase) in net defined benefit liability (asset) resulting from gains (losses) arising from settlements; Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Past service cost and gains losses arising from settlements, net defined benefit liability (asset)",
        "negatedTerseLabel": "Past service cost and settlements",
        "terseLabel": "Past service cost and settlements"
       }
      }
     },
     "localname": "PastServiceCostAndGainsLossesArisingFromSettlementsNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsFromChangesInOwnershipInterestsInSubsidiaries": {
     "auth_ref": [
      "r178",
      "r179"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 9.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for changes in ownership interests in subsidiaries that do not result in a loss of control. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Payments from changes in ownership interests in subsidiaries that do not result in loss of control",
        "negatedTerseLabel": "Impact of change in ownership of consolidated entities"
       }
      }
     },
     "localname": "PaymentsFromChangesInOwnershipInterestsInSubsidiaries",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Payments from plan, net defined benefit liability (asset)",
        "negatedTerseLabel": "Benefit payments",
        "terseLabel": "Benefit payments"
       }
      }
     },
     "localname": "PaymentsFromPlanNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 10.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Payments of lease liabilities, classified as financing activities",
        "negatedTerseLabel": "Payments of lease liabilities",
        "terseLabel": "Repayment of lease liability",
        "verboseLabel": "Payments of lease liabilities, net"
       }
      }
     },
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsToAcquireOrRedeemEntitysShares": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow to acquire or redeem entity's shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Payments to acquire or redeem entity's shares",
        "negatedTerseLabel": "Acquisitions of treasury shares"
       }
      }
     },
     "localname": "PaymentsToAcquireOrRedeemEntitysShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PercentageOfEntitysRevenue": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The percentage of the entity's revenue. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Percentage of entity's revenue"
       }
      }
     },
     "localname": "PercentageOfEntitysRevenue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_PercentageOfVotingEquityInterestsAcquired": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Percentage of voting equity interests acquired"
       }
      }
     },
     "localname": "PercentageOfVotingEquityInterestsAcquired",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_PlanAssetsAtFairValue": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value of defined benefit plan assets. Plan assets comprise assets held by a long-term employee benefit fund and qualifying insurance policies. [Refer: At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Plan assets, at fair value",
        "periodEndLabel": "Fair value of plan assets at end of period",
        "periodStartLabel": "Fair value of plan assets at beginning of period"
       }
      }
     },
     "localname": "PlanAssetsAtFairValue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The portion of consideration paid or received, consisting of cash and cash equivalents, in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]; Cash and cash equivalents; Consideration paid (received)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Portion of consideration paid (received) consisting of cash and cash equivalents",
        "negatedTerseLabel": "Portion of consideration paid (received) consisting of cash and cash equivalents"
       }
      }
     },
     "localname": "PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods."
       }
      },
      "en-us": {
       "role": {
        "label": "Post-employment benefit expense, defined contribution plans"
       }
      }
     },
     "localname": "PostemploymentBenefitExpenseDefinedContributionPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PreviouslyStatedMember": {
     "auth_ref": [
      "r3",
      "r186",
      "r188",
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the information previously stated in the financial statements (ie before retrospective application or retrospective restatement)."
       }
      },
      "en-us": {
       "role": {
        "label": "Previously stated [member]"
       }
      }
     },
     "localname": "PreviouslyStatedMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary": {
     "auth_ref": [
      "r121",
      "r125",
      "r200",
      "r204"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The principal place of business of a subsidiary. [Refer: Principal place of business; Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Principal place of business of subsidiary"
       }
      }
     },
     "localname": "PrincipalPlaceOfBusinessOfSubsidiary",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations": {
     "auth_ref": [
      "r459"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the disposal of non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer: Discontinued operations [member]; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations"
       }
      }
     },
     "localname": "ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails3",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails4",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromNoncurrentBorrowings": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from non-current borrowings obtained. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from non-current borrowings",
        "negatedTerseLabel": "Proceeds from non-current financial debts",
        "terseLabel": "Proceeds from non-current financial debts",
        "verboseLabel": "Increase in non-current financial debts"
       }
      }
     },
     "localname": "ProceedsFromNoncurrentBorrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from sales of other long-term assets, classified as investing activities",
        "terseLabel": "Proceeds from sale of other non-current assets"
       }
      }
     },
     "localname": "ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from sales of intangible assets, classified as investing activities",
        "terseLabel": "Proceeds from sale of intangible assets"
       }
      }
     },
     "localname": "ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromSalesOfInterestsInAssociates": {
     "auth_ref": [
      "r459"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of interests in associates. [Refer: Associates [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from sales of interests in associates",
        "terseLabel": "Acquisitions and divestments of interests in associated companies, net"
       }
      }
     },
     "localname": "ProceedsFromSalesOfInterestsInAssociates",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 17.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from sales of investments other than investments accounted for using equity method",
        "terseLabel": "Proceeds from sale of financial assets"
       }
      }
     },
     "localname": "ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 9.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from sales of property, plant and equipment",
        "terseLabel": "Proceeds from sale of property, plant and equipment"
       }
      }
     },
     "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 15.7,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from sales or maturity of financial instruments, classified as investing activities",
        "terseLabel": "Proceeds from sale of marketable securities, commodities and time deposits"
       }
      }
     },
     "localname": "ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "auth_ref": [
      "r322",
      "r385"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Products and services [axis]"
       }
      }
     },
     "localname": "ProductsAndServicesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProductsAndServicesMember": {
     "auth_ref": [
      "r322",
      "r385"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Products and services [member]"
       }
      }
     },
     "localname": "ProductsAndServicesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ProfitLoss": {
     "auth_ref": [
      "r4",
      "r38",
      "r166",
      "r195",
      "r197",
      "r315",
      "r317",
      "r380",
      "r411",
      "r414"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://novartis.com/20221231/role/StatementOfIncomeCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": 4.5,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome",
      "http://novartis.com/20221231/role/StatementOfIncome",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossAttributableToAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to [abstract]",
        "terseLabel": "Attributable to"
       }
      }
     },
     "localname": "ProfitLossAttributableToAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r41",
      "r201"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncomeCalc2": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to non-controlling interests",
        "terseLabel": "Non-controlling interests"
       }
      }
     },
     "localname": "ProfitLossAttributableToNoncontrollingInterests",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncomeCalc2": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to owners of parent",
        "terseLabel": "Profit/loss attributable to shareholders of Novartis AG",
        "verboseLabel": "Shareholders of Novartis AG"
       }
      }
     },
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "auth_ref": [
      "r282",
      "r347",
      "r348",
      "r407",
      "r408"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "terseLabel": "Income before taxes",
        "totalLabel": "Income before taxes"
       }
      }
     },
     "localname": "ProfitLossBeforeTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromContinuingOperations": {
     "auth_ref": [
      "r38",
      "r213",
      "r315",
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing operations. [Refer: Continuing operations [member]; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from continuing operations",
        "terseLabel": "Net income",
        "verboseLabel": "Net income from continuing operations"
       }
      }
     },
     "localname": "ProfitLossFromContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromDiscontinuedOperations": {
     "auth_ref": [
      "r47",
      "r52",
      "r214",
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from discontinued operations. [Refer: Discontinued operations [member]; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from discontinued operations",
        "terseLabel": "Net income from discontinued operations",
        "totalLabel": "Net income from discontinued operations"
       }
      }
     },
     "localname": "ProfitLossFromDiscontinuedOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "auth_ref": [
      "r362",
      "r439"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "terseLabel": "Operating income of discontinued operations",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "ProfitLossFromOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "auth_ref": [
      "r13",
      "r72"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period."
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment",
        "periodEndLabel": "Property, plant and equipment at end of period",
        "periodStartLabel": "Property, plant and equipment at beginning of period"
       }
      }
     },
     "localname": "PropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "auth_ref": [
      "r73",
      "r363",
      "r387"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [member]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentPledgedAsSecurity": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of property, plant and equipment pledged as security for liabilities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment, pledged as security",
        "terseLabel": "Total net book value of property, plant and equipment pledged as collateral for non-current financial debts"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPledgedAsSecurity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate": {
     "auth_ref": [
      "r388",
      "r390"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 1.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for plant, property and equipment acquired in a business combination. [Refer: Property, plant and equipment; Business combinations [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment recognised as of acquisition date",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProportionOfOwnershipInterestInAssociate": {
     "auth_ref": [
      "r122",
      "r126",
      "r206"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in associate"
       }
      }
     },
     "localname": "ProportionOfOwnershipInterestInAssociate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "auth_ref": [
      "r122",
      "r126",
      "r205"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in subsidiary"
       }
      }
     },
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ProportionOfVotingPowerHeldInAssociate": {
     "auth_ref": [
      "r122",
      "r126",
      "r206"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of the voting rights in an associate held by the entity. [Refer: Associates [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proportion of voting rights held in associate"
       }
      }
     },
     "localname": "ProportionOfVotingPowerHeldInAssociate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ProportionOfVotingPowerHeldInSubsidiary": {
     "auth_ref": [
      "r122",
      "r126",
      "r205"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of the voting rights in a subsidiary held by the entity. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proportion of voting rights held in subsidiary"
       }
      }
     },
     "localname": "ProportionOfVotingPowerHeldInSubsidiary",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ProvisionUsedOtherProvisions": {
     "auth_ref": [
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Provision used, other provisions",
        "negatedLabel": "Payments/utilizations",
        "negatedTerseLabel": "Cash payments",
        "terseLabel": "Utilization of provisions for doubtful trade receivables"
       }
      }
     },
     "localname": "ProvisionUsedOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 15.5,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of financial instruments, classified as investing activities",
        "negatedTerseLabel": "Purchases of marketable securities, commodities and time deposits"
       }
      }
     },
     "localname": "PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 11.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of intangible assets, classified as investing activities",
        "negatedTerseLabel": "Purchases of intangible assets"
       }
      }
     },
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 16.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of investments other than investments accounted for using equity method",
        "negatedTerseLabel": "Purchases of financial assets"
       }
      }
     },
     "localname": "PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 12.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of long-term assets that the entity does not separately disclose in the same statement or note, classified as investing activities. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of other long-term assets, classified as investing activities",
        "negatedTerseLabel": "Purchases of other non-current assets"
       }
      }
     },
     "localname": "PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 13.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedTerseLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfTreasuryShares": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of treasury shares",
        "negatedLabel": "Purchase of treasury shares, equity impact",
        "negatedTerseLabel": "Purchase of treasury shares",
        "terseLabel": "Purchase of treasury shares, equity impact"
       }
      }
     },
     "localname": "PurchaseOfTreasuryShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails4",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RangeAxis": {
     "auth_ref": [
      "r233",
      "r262",
      "r333",
      "r382",
      "r384",
      "r470"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesMember": {
     "auth_ref": [
      "r233",
      "r262",
      "r333",
      "r382",
      "r384",
      "r470"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges [member]"
       }
      }
     },
     "localname": "RangesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges of exercise prices for outstanding share options [axis]"
       }
      }
     },
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Ranges [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges of exercise prices for outstanding share options [member]",
        "terseLabel": "Exercise prices for outstanding share options [member]"
       }
      }
     },
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of average effective tax rate and applicable tax rate [abstract]"
       }
      }
     },
     "localname": "ReconciliationOfAverageEffectiveTaxRateAndApplicableTaxRateAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RecurringFairValueMeasurementMember": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for fair value measurements which other IFRSs require or permit in the statement of financial position at the end of each reporting period. [Refer: IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Recurring fair value measurement [member]"
       }
      }
     },
     "localname": "RecurringFairValueMeasurementMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ReductionOfIssuedCapital": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in equity resulting from a reduction in issued capital. [Refer: Issued capital]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reduction of issued capital",
        "negatedTerseLabel": "Reduction of share capital"
       }
      }
     },
     "localname": "ReductionOfIssuedCapital",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RefundsProvision": {
     "auth_ref": [
      "r365",
      "r367"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of provision for refunds to be made by the entity to its customers. [Refer: Other provisions]"
       }
      }
     },
     "localname": "RefundsProvision",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The remaining amortisation period of individual intangible assets that are material to the entity\u2019s financial statements. [Refer: Depreciation and amortisation expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Remaining amortisation period of intangible assets material to entity",
        "terseLabel": "Remaining amortisation period"
       }
      }
     },
     "localname": "RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_RepaymentsOfNoncurrentBorrowings": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Repayments of non-current borrowings",
        "negatedTerseLabel": "Repayments of the current portion of non-current financial debts",
        "terseLabel": "Repayments of non-current financial debts"
       }
      }
     },
     "localname": "RepaymentsOfNoncurrentBorrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "negatedTerseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RestatedMember": {
     "auth_ref": [
      "r3",
      "r186",
      "r188",
      "r190",
      "r332",
      "r434"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Currently stated [member]"
       }
      }
     },
     "localname": "RestatedMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RestructuringProvisionMember": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a provision for restructuring, such as the sale or termination of a line of business; closure of business locations in a country or region or relocation of activities from one country or region to another; changes in management structure; and fundamental reorganisations that have a material effect on the nature and focus of the entity's operations. [Refer: Other provisions [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Restructuring provision [member]",
        "terseLabel": "Restructuring provision"
       }
      }
     },
     "localname": "RestructuringProvisionMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetainedEarningsMember": {
     "auth_ref": [
      "r8",
      "r349"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings [member]",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": {
     "auth_ref": [
      "r3",
      "r186",
      "r188",
      "r190"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Retrospective application and retrospective restatement [axis]"
       }
      }
     },
     "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from the return on plan assets, excluding amounts included in interest income or expense. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Plan assets [member]; Net defined benefit liability (asset); Actuarial assumptions [member]; Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense",
        "negatedTerseLabel": "Return on plan assets excluding interest income"
       }
      }
     },
     "localname": "ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueFromDividends": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2": {
       "order": 10.0,
       "parentTag": "ifrs-full_OtherFinanceIncomeCost",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of dividends recognised as income. Dividends are distributions of profits to holders of equity investments in proportion to their holdings of a particular class of capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Other financial income"
       }
      }
     },
     "localname": "RevenueFromDividends",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueFromInterest": {
     "auth_ref": [
      "r220",
      "r310",
      "r320",
      "r433"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2": {
       "order": 9.0,
       "parentTag": "ifrs-full_OtherFinanceIncomeCost",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income arising from interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest income"
       }
      }
     },
     "localname": "RevenueFromInterest",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueFromRoyalties": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income arising from royalties."
       }
      },
      "en-us": {
       "role": {
        "label": "Royalty income"
       }
      }
     },
     "localname": "RevenueFromRoyalties",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueFromSaleOfGoods": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 3.0,
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from the sale of goods. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue from sale of goods",
        "terseLabel": "Net sales",
        "verboseLabel": "Net sales"
       }
      }
     },
     "localname": "RevenueFromSaleOfGoods",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueOfAcquiree": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue of the acquiree since the acquisition date included in the consolidated statement of comprehensive income. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue of acquiree since acquisition date"
       }
      }
     },
     "localname": "RevenueOfAcquiree",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReversalOfImpairmentLoss": {
     "auth_ref": [
      "r135",
      "r136"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as an increase of the carrying amount of an asset or cash-generating unit to its recoverable amount when an impairment loss had been previously recognised. [Refer: Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reversal of impairment loss"
       }
      }
     },
     "localname": "ReversalOfImpairmentLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of reversal of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Reversal of impairment loss recognised in profit or loss; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill",
        "terseLabel": "Reversal of impairment charge"
       }
      }
     },
     "localname": "ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "auth_ref": [
      "r51",
      "r69"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of reversal of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Reversal of impairment loss recognised in profit or loss; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reversal of impairment loss recognised in profit or loss, property, plant and equipment",
        "terseLabel": "Reversal of impairment charge"
       }
      }
     },
     "localname": "ReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReversalOfInventoryWritedown": {
     "auth_ref": [
      "r51",
      "r102"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as a reduction in the amount of inventories recognised as an expense due to the reversal of any write-down of inventories resulting from an increase in net realisable value. [Refer: Inventories; Inventory write-down]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reversal of inventory write-down",
        "terseLabel": "Reversals of inventory provisions"
       }
      }
     },
     "localname": "ReversalOfInventoryWritedown",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RightofuseAssets": {
     "auth_ref": [
      "r246"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 9.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      },
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "periodEndLabel": "Right-of-use assets at end of period",
        "periodStartLabel": "Right-of-use assets at beginning of period"
       }
      }
     },
     "localname": "RightofuseAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RightofuseAssetsMember": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Right-of-use assets [member]",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "RightofuseAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SaleOrIssueOfTreasuryShares": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Sale or issue of treasury shares",
        "terseLabel": "Treasury shares movement of period",
        "verboseLabel": "Sale of treasury shares"
       }
      }
     },
     "localname": "SaleOrIssueOfTreasuryShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SegmentConsolidationItemsAxis": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Segment consolidation items [axis]"
       }
      }
     },
     "localname": "SegmentConsolidationItemsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_SegmentsAxis": {
     "auth_ref": [
      "r136",
      "r234",
      "r315",
      "r360",
      "r413"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Segments [axis]"
       }
      }
     },
     "localname": "SegmentsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_SegmentsMember": {
     "auth_ref": [
      "r136",
      "r234",
      "r321",
      "r360",
      "r413"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Segments [member]"
       }
      }
     },
     "localname": "SegmentsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 7.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling, general and administrative activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Selling, general and administrative expense",
        "negatedTerseLabel": "Selling, general and administration"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 5.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Share of the other comprehensive income of associates and joint ventures accounted for using the equity method that will be reclassified to profit or loss, net of tax."
       }
      },
      "en-us": {
       "role": {
        "label": "Share of other comprehensive income of associates and joint ventures accounted for using equity method that will be reclassified to profit or loss, net of tax",
        "terseLabel": "Associated companies' movements in comprehensive income",
        "verboseLabel": "Other comprehensive income effect"
       }
      }
     },
     "localname": "ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r45",
      "r313",
      "r320",
      "r338"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Share of profit (loss) of associates and joint ventures accounted for using equity method",
        "negatedTerseLabel": "Loss/(income) from associated companies",
        "terseLabel": "(Loss)/income from associated companies",
        "verboseLabel": "Net income statement effect"
       }
      }
     },
     "localname": "ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/StatementOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The entity's share of the total comprehensive income of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Joint ventures [member]; Investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Share of total comprehensive income of associates and joint ventures accounted for using equity method",
        "terseLabel": "Total comprehensive income effect"
       }
      }
     },
     "localname": "ShareOfTotalComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share-based payment arrangements [member]"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ShorttermBorrowings": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherCurrentFinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current borrowings",
        "terseLabel": "Bank and other financial debt"
       }
      }
     },
     "localname": "ShorttermBorrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails": {
       "order": 6.0,
       "parentTag": "ifrs-full_OtherCurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Short-term deposits, not classified as cash equivalents",
        "terseLabel": "Time deposits and short-term investments with original maturity more than 90 days"
       }
      }
     },
     "localname": "ShorttermDepositsNotClassifiedAsCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShorttermEmployeeBenefitsAccruals": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]"
       }
      },
      "en-us": {
       "role": {
        "label": "Short-term employee benefits accruals",
        "terseLabel": "Accruals for compensation and benefits including social security"
       }
      }
     },
     "localname": "ShorttermEmployeeBenefitsAccruals",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShorttermRestructuringProvision": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current provision for restructuring. [Refer: Restructuring provision]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current restructuring provision",
        "terseLabel": "Restructuring provisions"
       }
      }
     },
     "localname": "ShorttermRestructuringProvision",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SignificantInvestmentsInAssociatesAxis": {
     "auth_ref": [
      "r123",
      "r127",
      "r226",
      "r339",
      "r343"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Associates [axis]"
       }
      }
     },
     "localname": "SignificantInvestmentsInAssociatesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "auth_ref": [
      "r123",
      "r127",
      "r225"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Subsidiaries [axis]"
       }
      }
     },
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of comprehensive income [abstract]"
       }
      }
     },
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_SubsidiariesMember": {
     "auth_ref": [
      "r111",
      "r123",
      "r127",
      "r225"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for entities that are controlled by another entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Subsidiaries [member]"
       }
      }
     },
     "localname": "SubsidiariesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SurplusDeficitInPlan": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value of any plan assets, less the present value of the defined benefit obligation. [Refer: Plan assets [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Surplus (deficit) in plan",
        "negatedTerseLabel": "Funded status",
        "terseLabel": "Funded status"
       }
      }
     },
     "localname": "SurplusDeficitInPlan",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce current tax expense. [Refer: Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense"
       }
      }
     },
     "localname": "TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TaxRateEffectFromChangeInTaxRate": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from a change in tax rate. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax rate, effect from change in tax rate",
        "terseLabel": "Effect of tax rate change on current and deferred tax assets and liabilities"
       }
      }
     },
     "localname": "TaxRateEffectFromChangeInTaxRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from adjustments for the current tax of prior periods. [Refer: Average effective tax rate; Applicable tax rate; Adjustments for current tax of prior periods]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax rate effect of adjustments for current tax of prior periods",
        "terseLabel": "Effect of prior year items"
       }
      }
     },
     "localname": "TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the expenses not deductible in determining taxable profit. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax rate, effect of expense not deductible in determining taxable profit tax loss",
        "terseLabel": "Effect of disallowed expenditures"
       }
      }
     },
     "localname": "TaxRateEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_TaxRateEffectOfRevenuesExemptFromTaxation": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from revenue that is exempt from taxation. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax rate effect of revenues exempt from taxation"
       }
      }
     },
     "localname": "TaxRateEffectOfRevenuesExemptFromTaxation",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_TaxRateEffectOfTaxLosses": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from tax losses. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax rate, effect of tax losses",
        "terseLabel": "Effect of utilization of tax losses brought forward from prior periods"
       }
      }
     },
     "localname": "TaxRateEffectOfTaxLosses",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_TechnologybasedIntangibleAssetsMember": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing assets based on technology. Such assets may include patented and unpatented technology, databases as well as trade secrets. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Technology-based intangible assets [member]",
        "terseLabel": "Technologies"
       }
      }
     },
     "localname": "TechnologybasedIntangibleAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TopOfRangeMember": {
     "auth_ref": [
      "r233",
      "r262",
      "r333",
      "r382",
      "r384",
      "r470"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Top of range [member]",
        "terseLabel": "High"
       }
      }
     },
     "localname": "TopOfRangeMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
       }
      },
      "en-us": {
       "role": {
        "label": "Trade payables",
        "negatedTerseLabel": "Trade payables"
       }
      }
     },
     "localname": "TradeAndOtherPayablesToTradeSuppliers",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeReceivablesMember": {
     "auth_ref": [
      "r291",
      "r295",
      "r391",
      "r433"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for trade receivables. [Refer: Trade receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade receivables [member]"
       }
      }
     },
     "localname": "TradeReceivablesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers of assets into Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers into Level 3 of fair value hierarchy, assets"
       }
      }
     },
     "localname": "TransfersIntoLevel3OfFairValueHierarchyAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers of assets out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers out of Level 3 of fair value hierarchy, assets",
        "negatedTerseLabel": "Transfers out of Level 3 of fair value hierarchy, assets"
       }
      }
     },
     "localname": "TransfersOutOfLevel3OfFairValueHierarchyAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TreasuryShares": {
     "auth_ref": [
      "r129",
      "r352"
     ],
     "calculation": {
      "http://novartis.com/20221231/role/BalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": -1.0
      },
      "http://novartis.com/20221231/role/DisclosureEquityDetails": {
       "order": 2.0,
       "parentTag": "nvs_OutstandingShareCapital",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      },
      "en-us": {
       "role": {
        "label": "Treasury shares",
        "negatedPeriodEndLabel": "Treasury shares at end of period",
        "negatedPeriodStartLabel": "Treasury shares at beginning of period",
        "negatedTerseLabel": "Treasury shares"
       }
      }
     },
     "localname": "TreasuryShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TreasurySharesMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      },
      "en-us": {
       "role": {
        "label": "Treasury shares [member]",
        "terseLabel": "Treasury shares",
        "verboseLabel": "Total treasury shares"
       }
      }
     },
     "localname": "TreasurySharesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]"
       }
      }
     },
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_UnallocatedAmountsMember": {
     "auth_ref": [
      "r409",
      "r410"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for items that have not been allocated to operating segments."
       }
      },
      "en-us": {
       "role": {
        "label": "Unallocated amounts [member]"
       }
      }
     },
     "localname": "UnallocatedAmountsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_UnusedProvisionReversedOtherProvisions": {
     "auth_ref": [
      "r145"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount reversed for unused other provisions. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Unused provision reversed, other provisions",
        "negatedTerseLabel": "Releases",
        "terseLabel": "Reversal of provisions for doubtful trade receivables"
       }
      }
     },
     "localname": "UnusedProvisionReversedOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_VehiclesMember": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing vehicles used in the entity's operations, specifically to include aircraft, motor vehicles and ships. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Vehicles [member]"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options exercised in share-based payment arrangement"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average share price at the date of exercise for share options that are exercised in a share-based payment arrangement. [Refer: Share-based payment arrangements [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r256",
      "r259"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Weighted average exercise price of share options outstanding in share-based payment arrangement at end of period",
        "periodStartLabel": "Weighted average exercise price of share options outstanding in share-based payment arrangement at beginning of period"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16",
        "terseLabel": "Weighted average incremental borrowing rate"
       }
      }
     },
     "localname": "WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_WeightedAverageMember": {
     "auth_ref": [
      "r233",
      "r333",
      "r382",
      "r384",
      "r470"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an average in which each quantity to be averaged is assigned a weight that determines the relative effect of each quantity on the average."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average [member]",
        "terseLabel": "Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life of outstanding share options"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_WeightedAverageShares": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares outstanding",
        "terseLabel": "Weighted average number of shares outstanding used in the basic earnings per share"
       }
      }
     },
     "localname": "WeightedAverageShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "0.000% 1 EUR 1 850 million 2020/2028 Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.354% [member]"
       }
      }
     },
     "localname": "A0.0001EUR1850Million20202028NovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.354Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "0.000% EUR 1'250 million 2017/2021 of Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.133% [member]"
       }
      }
     },
     "localname": "A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "0.125% EUR 1 250 million bond 2016/2023 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.127% [member]"
       }
      }
     },
     "localname": "A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "0.25% CHF 500 million bond 2015/2025 of Novartis AG Basel Switzerland, issued at 100.64% [member]"
       }
      }
     },
     "localname": "A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "0.500% EUR 750 million 2018/2023 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.655% [member]"
       }
      }
     },
     "localname": "A0.500EUR750Million20182023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.655Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "0.625% CHF 550 million bond 2015/2029 of Novartis AG Basel Switzerland, issued at 100.502% [member]"
       }
      }
     },
     "localname": "A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "0.625% EUR 500 million bond 2016/2028 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 98.48% [member]"
       }
      }
     },
     "localname": "A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "0.75% EUR 600 million bond 2014/2021 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.134% [member]"
       }
      }
     },
     "localname": "A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.050% CHF 325 million bond 2015/2035 of Novartis AG Basel Switzerland, issued at 100.479% [member]"
       }
      }
     },
     "localname": "A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.125% EUR 600 million 2017/2027 of Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.874% [member]"
       }
      }
     },
     "localname": "A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.375% EUR 750 million 2018/2030 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.957% [member]"
       }
      }
     },
     "localname": "A1.375EUR750Million20182030OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.957Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.625% EUR 600 million bond 2014/2026 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.697% [member]"
       }
      }
     },
     "localname": "A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.700% EUR 750 million 2018/2038 of Novartis Finance S.A., Luxembourg, Luxembourg issued at 99.217% [member]"
       }
      }
     },
     "localname": "A1.700EUR750Million20182038OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.217Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.750% USD 1 000 million 2020/2025 Novartis Capital Corporation, New York, United States, issued at 99.852% [member]"
       }
      }
     },
     "localname": "A1.750USD1000Million20202025NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.852Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.800% USD 1'000 million 2017/2020 of Novartis Capital Corporation, New York, United States, issued at 99.609% [member]"
       }
      }
     },
     "localname": "A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A1APharmaGmbHHolzkirchenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "1 A Pharma GmbH, Holzkirchen [member]"
       }
      }
     },
     "localname": "A1APharmaGmbHHolzkirchenMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2.000% USD 1 250 million 2020/2027 Novartis Capital Corporation, New York, United States, issued at 99.909% [member]"
       }
      }
     },
     "localname": "A2.000USD1250Million20202027NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.909Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2.200% USD 1 500 million 2020/2030 Novartis Capital Corporation, New York, United States, issued at 99.869% [member]"
       }
      }
     },
     "localname": "A2.200USD1500Million20202030NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.869Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2.400% USD 1'000 million 2017/2022 of Novartis Capital Corporation, New York, United States, issued at 99.449% [member]"
       }
      }
     },
     "localname": "A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2.4% USD 1 500 million bond 2012/2022 of Novartis Capital Corporation, New York United States, issued at 99.225% [member]"
       }
      }
     },
     "localname": "A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2.750% USD 1 250 million 2020/2050 Novartis Capital Corporation, New York, United States, issued at 97.712% [member]"
       }
      }
     },
     "localname": "A2.750USD1250Million20202050NovartisCapitalCorporationNewYorkUnitedStatesIssuedAt97.712Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "3.0% USD 1 750 million bond 2015/2025 of Novartis Capital Corporation, New York United States, issued at 99.010% [member]"
       }
      }
     },
     "localname": "A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "3.100% USD 1'000 million 2017/2027 of Novartis Capital Corporation, New York, United States, issued at 99.109% [member]"
       }
      }
     },
     "localname": "A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "3.4% USD 2 150 million bond 2014/2024 of Novartis Capital Corporation, New York United States, issued at 99.287% [member]"
       }
      }
     },
     "localname": "A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "3.7% USD 500 million bond 2012/2042 of Novartis Capital Corporation, New York United States, issued at 98.325% [member]"
       }
      }
     },
     "localname": "A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "4.0% USD 1 250 million bond 2015/2045 of Novartis Capital Corporation, New York United States, issued at 98.029% [member]"
       }
      }
     },
     "localname": "A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "4.25% EUR 1 500 million bond 2009/2016 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.757% [member]"
       }
      }
     },
     "localname": "A4.25EUR1500MillionBond20092016OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.757Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "4.4% USD 1 000 million bond 2010/2020 of Novartis Capital Corporation, New York United States, issued at 99.237% [member]"
       }
      }
     },
     "localname": "A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "4.4% USD 1 850 million bond 2014/2044 of Novartis Capital Corporation, New York United States, issued at 99.196% [member]"
       }
      }
     },
     "localname": "A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "5.125% USD 3 000 million bond 2009/2019 of Novaritis Securities Investment Ltd., Hamilton, Bermuda issued at 99.822% [member]"
       }
      }
     },
     "localname": "A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AbadiaRetuertaS.A.SardonDeDueroValladolidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Abadia Retuerta S.A., Sardon de Duero/Valladolid [member]"
       }
      }
     },
     "localname": "AbadiaRetuertaS.A.SardonDeDueroValladolidMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual for environmental loss contingencies, fiscal year maturity [table text block]"
       }
      }
     },
     "localname": "AccrualForEnvironmentalLossContingenciesFiscalYearMaturityTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_AccrualForEnvironmentalLossContingenciesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual for environmental loss contingencies [table text block]"
       }
      }
     },
     "localname": "AccrualForEnvironmentalLossContingenciesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual for product liabilities government investigations other legal matters loss contingencies [table text block]"
       }
      }
     },
     "localname": "AccrualForProductLiabilitiesGovernmentInvestigationsOtherLegalMattersLossContingenciesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_AccrualForTaxesOtherThanIncomeTaxesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual for taxes other than income taxes, current",
        "terseLabel": "Taxes other than income taxes"
       }
      }
     },
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AccruedInterestOnDebtSecuritiesAndTimeDepositsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest on debt securities and time deposits [member]"
       }
      }
     },
     "localname": "AccruedInterestOnDebtSecuritiesAndTimeDepositsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AccruedRoyaltiesPayableClassifiedAsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued royalties payable classified as current",
        "terseLabel": "Accruals for royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesPayableClassifiedAsCurrent",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated amortization/impairments on assets held for sale intangible assets and goodwill",
        "terseLabel": "Accumulated amortization/impairments on assets reclassified out of assets of disposal group held for sale"
       }
      }
     },
     "localname": "AccumulatedAmortizationImpairmentsOnAssetsHeldForSaleIntangibleAssetsAndGoodwill",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated amortization/impairments on assets held for sale property plant and equipment",
        "terseLabel": "Accumulated depreciation on assets reclassified out of assets of disposal group held for sale"
       }
      }
     },
     "localname": "AccumulatedAmortizationImpairmentsOnAssetsHeldForSalePropertyPlantAndEquipment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated amortization/impairments on assets related to discontinued operations"
       }
      }
     },
     "localname": "AccumulatedAmortizationImpairmentsOnAssetsRelatedToDiscontinuedOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated depreciation on disposals, property plant and equipment",
        "terseLabel": "Accumulated depreciation on disposals and derecognitions"
       }
      }
     },
     "localname": "AccumulatedDepreciationOnDisposalsPropertyPlantAndEquipment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AccumulatedImpairmentsOnDisposalsAndDerecognitions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated impairments on disposals and derecognition"
       }
      }
     },
     "localname": "AccumulatedImpairmentsOnDisposalsAndDerecognitions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AcquiredCashAndCashEquivalents": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired cash and cash equivalents",
        "negatedTerseLabel": "Acquired cash and cash equivalents"
       }
      }
     },
     "localname": "AcquiredCashAndCashEquivalents",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 3.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired research and development intangible assets recognised as of acquisition date",
        "terseLabel": "Acquired research and development"
       }
      }
     },
     "localname": "AcquiredResearchAndDevelopmentIntangibleAssetsRecognisedAsOfAcquisitionDate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AcquiredResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired research and development [member]",
        "terseLabel": "Acquired research and development"
       }
      }
     },
     "localname": "AcquiredResearchAndDevelopmentMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AcquisitionFairValuePotentiallyRefundableContingentConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of potentially refundable contingent consideration"
       }
      }
     },
     "localname": "AcquisitionFairValuePotentiallyRefundableContingentConsideration",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition of assets (other than through business combinations) by assuming directly related liabilities"
       }
      }
     },
     "localname": "AcquisitionOfAssetsIntangibleAssetsOtherThanGoodwillByAssumingDirectlyRelatedLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AcquisitionOfAssetsRightOfUseAssetsThroughLeasing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition of assets (right of use assets) through leasing"
       }
      }
     },
     "localname": "AcquisitionOfAssetsRightOfUseAssetsThroughLeasing",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AcquisitionsAndDivestmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions and divestments [axis]"
       }
      }
     },
     "localname": "AcquisitionsAndDivestmentsAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_AcquisitionsAndDivestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions and divestments [member]"
       }
      }
     },
     "localname": "AcquisitionsAndDivestmentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions [member]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "AcquisitionsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions through business combinations, other provisions and increase (decrease) through net exchange differences, other provisions",
        "terseLabel": "Effects of currency translation and business combinations"
       }
      }
     },
     "localname": "AcquisitionsThroughBusinessCombinationsOtherProvisionsAndIncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AcquisitionsThroughBusinessCombinationsRightofuseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions through business combinations right-of-use assets",
        "terseLabel": "Impact of business combinations"
       }
      }
     },
     "localname": "AcquisitionsThroughBusinessCombinationsRightofuseAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisitions through finance lease contracts property plant and equipment"
       }
      }
     },
     "localname": "AcquisitionsThroughFinanceLeaseContractsPropertyPlantAndEquipment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ActiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Active [member]",
        "terseLabel": "Active"
       }
      }
     },
     "localname": "ActiveMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Actuarial assumption of expected rates of interest on savings account",
        "terseLabel": "Interest on savings account"
       }
      }
     },
     "localname": "ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccount",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Actuarial assumption of expected rates of interest on savings account [member]",
        "terseLabel": "Interest on savings account"
       }
      }
     },
     "localname": "ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ActuarialLossesFromDefinedBenefitPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Actuarial gains/losses from defined benefit plans [member]",
        "terseLabel": "Actuarial gains/losses from defined benefit plans"
       }
      }
     },
     "localname": "ActuarialLossesFromDefinedBenefitPlansMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdakveoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adakveo [member]"
       }
      }
     },
     "localname": "AdakveoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdditionalAmountOfSettlementInPrinciple": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional amount of settlement in principle"
       }
      }
     },
     "localname": "AdditionalAmountOfSettlementInPrinciple",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AdditionalBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional borrowings"
       }
      }
     },
     "localname": "AdditionalBorrowings",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional disclosures related to right-of-use assets and lease liabilities [table text block]",
        "terseLabel": "Additional disclosures related to right-of-use assets and lease liabilities"
       }
      }
     },
     "localname": "AdditionalDisclosuresRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions included in disposal group prior to classification to assets held for sale"
       }
      }
     },
     "localname": "AdditionsIncludedInDisposalGroupPriorToClassificationToAssetsHeldForSale",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AdditionsIncludedInDisposalGroupToTheDateOfReclassification": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions included in disposal group to the date of reclassification"
       }
      }
     },
     "localname": "AdditionsIncludedInDisposalGroupToTheDateOfReclassification",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AdditionsToInvestmentInAssociatedCompanies": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions to investment in associated companies",
        "negatedTerseLabel": "Additions to investment in associated companies"
       }
      }
     },
     "localname": "AdditionsToInvestmentInAssociatedCompanies",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment for change in provisions and other non-current liabilities",
        "terseLabel": "Change in provisions and other non-current liabilities"
       }
      }
     },
     "localname": "AdjustmentForChangeInProvisionsAndOtherNoncurrentLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for non-cash items from continuing operations [table text block]",
        "terseLabel": "Adjustments for non-cash items from continuing operations"
       }
      }
     },
     "localname": "AdjustmentsForNoncashItemsFromContinuingOperationsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_AdjustmentsForPrepaymentsAndAccruedLeasePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for prepayments and accrued lease payments"
       }
      }
     },
     "localname": "AdjustmentsForPrepaymentsAndAccruedLeasePayments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AdministrativeExpenseNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Administration costs not reflected in return on plan assets, defined benefit plans",
        "negatedTerseLabel": "Administrative expenses",
        "terseLabel": "Administrative expenses"
       }
      }
     },
     "localname": "AdministrativeExpenseNetDefinedBenefitLiabilityAsset",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AdmuneTheraputicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Admune Theraputics [member]",
        "terseLabel": "Admune Theraputics"
       }
      }
     },
     "localname": "AdmuneTheraputicsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvacedAcceleratorApplicationsIbericaS.L.U.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advaced Accelerator Applications Iberica, S.L.U. [member]"
       }
      }
     },
     "localname": "AdvacedAcceleratorApplicationsIbericaS.L.U.Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvacedAcceleratorApplicationsItalyS.r.l.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advaced Accelerator Applications (Italy) S.r.l. [member]"
       }
      }
     },
     "localname": "AdvacedAcceleratorApplicationsItalyS.r.l.Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvancedAcceleratorApplicationsAAAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanced Accelerator Applications (AAA) [member]",
        "terseLabel": "Advanced Accelerator Applications (AAA)"
       }
      }
     },
     "localname": "AdvancedAcceleratorApplicationsAAAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanced Accelerator Applications Iberica, S.L.U., Barcelona [member]"
       }
      }
     },
     "localname": "AdvancedAcceleratorApplicationsIbericaS.L.U.BarcelonaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvancedAcceleratorApplicationsInternationalSAGeneveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanced Accelerator Applications International SA, Geneve [member]"
       }
      }
     },
     "localname": "AdvancedAcceleratorApplicationsInternationalSAGeneveMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanced Accelerator Applications (Italy) S.r.l., Pozzilli [member]"
       }
      }
     },
     "localname": "AdvancedAcceleratorApplicationsItalyS.r.l.PozzilliMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanced Accelerator Applications Molecular Imaging France, Saint Genis Pouilly [member]"
       }
      }
     },
     "localname": "AdvancedAcceleratorApplicationsMolecularImagingFranceSaintGenisPouillyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanced Accelerator Applications S.A., Rueil-Malmaison [member]"
       }
      }
     },
     "localname": "AdvancedAcceleratorApplicationsS.A.RueilMalmaisonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanced Accelerator Applications Switzerland SA, Geneve [member]"
       }
      }
     },
     "localname": "AdvancedAcceleratorApplicationsSwitzerlandSAGeneveMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvancedAcceleratorApplicationsUKIrelandLondonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanced Accelerator Applications (UK &amp; Ireland), London [member]"
       }
      }
     },
     "localname": "AdvancedAcceleratorApplicationsUKIrelandLondonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanced Accelerator Applications USA, Inc., Millburn, NJ [member]"
       }
      }
     },
     "localname": "AdvancedAcceleratorApplicationsUSAInc.MillburnNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advanced Accelerator Applications USA, Inc., New York, NY [member]"
       }
      }
     },
     "localname": "AdvancedAcceleratorApplicationsUSAInc.NewYorkNYMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AeropharmGmbHRudolstadtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aeropharm GmbH, Rudolstadt [member]"
       }
      }
     },
     "localname": "AeropharmGmbHRudolstadtMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AfinitorVotubiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Afinitor/Votubia [member]"
       }
      }
     },
     "localname": "AfinitorVotubiaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AimovigMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aimovig [member]"
       }
      }
     },
     "localname": "AimovigMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconAGFribourgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon AG, Fribourg [member]"
       }
      }
     },
     "localname": "AlconAGFribourgMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconBrandNameMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon brand name [member]",
        "verboseLabel": "Alcon brand name"
       }
      }
     },
     "localname": "AlconBrandNameMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconCanadaInc.MississaugaOntarioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Canada Inc., Mississauga, Ontario [member]"
       }
      }
     },
     "localname": "AlconCanadaInc.MississaugaOntarioMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconCentroamericaS.A.PanamaCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Centroamerica S.A., Panama City [member]"
       }
      }
     },
     "localname": "AlconCentroamericaS.A.PanamaCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconChinaOphthalmicProductCo.Ltd.BeijingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon (China) Ophthalmic Product Co., Ltd., Beijing [member]"
       }
      }
     },
     "localname": "AlconChinaOphthalmicProductCo.Ltd.BeijingMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconCouvreurNVPuursMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon - Couvreur NV, Puurs [member]"
       }
      }
     },
     "localname": "AlconCouvreurNVPuursMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconCusiS.A.BarcelonaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Cusi S.A., Barcelona [member]"
       }
      }
     },
     "localname": "AlconCusiS.A.BarcelonaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconEyeCareUKLimitedFrimleyCamberleyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Eye Care UK Limited, Frimley/Camberley [member]"
       }
      }
     },
     "localname": "AlconEyeCareUKLimitedFrimleyCamberleyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconFarmacevtikaLLCMoscowMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Farmacevtika LLC, Moscow [member]"
       }
      }
     },
     "localname": "AlconFarmacevtikaLLCMoscowMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconHealthcareS.A.BarcelonaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Healthcare, S.A., Barcelona [member]"
       }
      }
     },
     "localname": "AlconHealthcareS.A.BarcelonaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconHongKongLimitedHongKongMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Hong Kong Limited, Hong Kong [member]"
       }
      }
     },
     "localname": "AlconHongKongLimitedHongKongMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconInc.EquityPlanConvertedNovartisShareOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon, Inc., equity plan, converted, Novartis share options [member]"
       }
      }
     },
     "localname": "AlconInc.EquityPlanConvertedNovartisShareOptionsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon, Inc., equity plan, converted, Share-settled appreciation rights (SSAR) [member]"
       }
      }
     },
     "localname": "AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon, Inc., equity plans, granted to associates prior merger [member]",
        "terseLabel": "Alcon equity plans granted to associates prior merger"
       }
      }
     },
     "localname": "AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconItaliaS.p.A.MilanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Italia S.p.A., Milan [member]"
       }
      }
     },
     "localname": "AlconItaliaS.p.A.MilanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconJapanLtd.TokyoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Japan Ltd., Tokyo [member]"
       }
      }
     },
     "localname": "AlconJapanLtd.TokyoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconKoreaLtd.SeoulMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Korea Ltd., Seoul [member]"
       }
      }
     },
     "localname": "AlconKoreaLtd.SeoulMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratories (Australia) Pty Ltd, Macquarie Park, NSW [member]"
       }
      }
     },
     "localname": "AlconLaboratoriesAustraliaPtyLtdMacquarieParkNSWMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriesBelgiumBVBAPuursMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratories Belgium BVBA, Puurs [member]"
       }
      }
     },
     "localname": "AlconLaboratoriesBelgiumBVBAPuursMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratories Hellas Commercial and Industrial S.A., Maroussi, Athens [member]"
       }
      }
     },
     "localname": "AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriesHoldingCorporationFortWorthTXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratories Holding Corporation, Fort Worth, TX [member]"
       }
      }
     },
     "localname": "AlconLaboratoriesHoldingCorporationFortWorthTXMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriesInc.FortWorthTXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratories, Inc., Fort Worth, TX [member]"
       }
      }
     },
     "localname": "AlconLaboratoriesInc.FortWorthTXMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriesIndiaPrivateLimitedBangaloreMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratories (India) Private Limited, Bangalore [member]"
       }
      }
     },
     "localname": "AlconLaboratoriesIndiaPrivateLimitedBangaloreMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriesIrelandLimitedCorkCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratories Ireland Limited, Cork City [member]"
       }
      }
     },
     "localname": "AlconLaboratoriesIrelandLimitedCorkCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratories (Malaysia) Sdn. Bhd., Petaling Jaya [member]"
       }
      }
     },
     "localname": "AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratories (South Africa) (Pty) Ltd., Midrand [member]"
       }
      }
     },
     "localname": "AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriesThailandLimitedBangkokMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratories (Thailand) Limited, Bangkok [member]"
       }
      }
     },
     "localname": "AlconLaboratoriesThailandLimitedBangkokMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriosChileLtd.SantiagoDeChileMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratorios Chile Ltd., Santiago de Chile [member]"
       }
      }
     },
     "localname": "AlconLaboratoriosChileLtd.SantiagoDeChileMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriosS.A.BuenosAiresMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratorios S.A., Buenos Aires [member]"
       }
      }
     },
     "localname": "AlconLaboratoriosS.A.BuenosAiresMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratoriosS.A.DeC.V.MexicoCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratorios, S.A. de C.V., Mexico City [member]"
       }
      }
     },
     "localname": "AlconLaboratoriosS.A.DeC.V.MexicoCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLaboratuvarlariTicaretA.S.IstanbulMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Laboratuvarlari Ticaret A.S., Istanbul [member]"
       }
      }
     },
     "localname": "AlconLaboratuvarlariTicaretA.S.IstanbulMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconLensxInc.AlisoViejoCAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Lensx, Inc., Aliso Viejo, CA [member]"
       }
      }
     },
     "localname": "AlconLensxInc.AlisoViejoCAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconManagementSAGenevaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Management SA, Geneva [member]"
       }
      }
     },
     "localname": "AlconManagementSAGenevaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon [member]",
        "terseLabel": "Alcon"
       }
      }
     },
     "localname": "AlconMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconNVVilvoordeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon NV, Vilvoorde [member]"
       }
      }
     },
     "localname": "AlconNVVilvoordeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconNederlandB.V.ArnhemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Nederland B.V., Arnhem [member]"
       }
      }
     },
     "localname": "AlconNederlandB.V.ArnhemMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconNordicASCopenhagenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Nordic A/S, Copenhagen [member]"
       }
      }
     },
     "localname": "AlconNordicASCopenhagenMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconOphthalmikaGmbHViennaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Ophthalmika GmbH, Vienna [member]"
       }
      }
     },
     "localname": "AlconOphthalmikaGmbHViennaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconPharmaGmbHFreiburgImBreisgauMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Pharma GmbH, Freiburg im Breisgau [member]"
       }
      }
     },
     "localname": "AlconPharmaGmbHFreiburgImBreisgauMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconPharmaceuticalC.A.CaracasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Pharmaceutical, C.A., Caracas [member]"
       }
      }
     },
     "localname": "AlconPharmaceuticalC.A.CaracasMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Pharmaceuticals (Czech Republic) s.r.o., Prague [member]"
       }
      }
     },
     "localname": "AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconPharmaceuticalsLtd.FribourgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Pharmaceuticals Ltd., Fribourg [member]"
       }
      }
     },
     "localname": "AlconPharmaceuticalsLtd.FribourgMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconPolskaSp.ZO.o.WarsawMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Polska Sp. z o.o., Warsaw [member]"
       }
      }
     },
     "localname": "AlconPolskaSp.ZO.o.WarsawMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Portugal-Produtos e Equipamentos Oftalmologicos Lda., Porto Salvo [member]"
       }
      }
     },
     "localname": "AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconPteLtdSingaporeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Pte Ltd, Singapore [member]"
       }
      }
     },
     "localname": "AlconPteLtdSingaporeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconRefractivehorizonsLLCFortWorthTXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Refractivehorizons, LLC, Fort Worth, TX [member]"
       }
      }
     },
     "localname": "AlconRefractivehorizonsLLCFortWorthTXMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconResearchLtd.FortWorthTXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Research, Ltd., Fort Worth, TX [member]"
       }
      }
     },
     "localname": "AlconResearchLtd.FortWorthTXMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconRomaniaS.R.L.BucharestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Romania S.R.L., Bucharest [member]"
       }
      }
     },
     "localname": "AlconRomaniaS.R.L.BucharestMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconSingaporeManufacturingPteLtdSingaporeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Singapore Manufacturing Pte. Ltd., Singapore [member]"
       }
      }
     },
     "localname": "AlconSingaporeManufacturingPteLtdSingaporeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AlconSwitzerlandSARischMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alcon Switzerland SA, Risch [member]"
       }
      }
     },
     "localname": "AlconSwitzerlandSARischMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocation of net book values of goodwill and intangible assets by reporting segment [text block]",
        "terseLabel": "Allocation of net book values of goodwill and intangible assets by reporting segment"
       }
      }
     },
     "localname": "AllocationNetBookValuesIntangibleAssetsandGoodwillTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_AlternativeInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alternative investments [member]",
        "terseLabel": "Alternative investments"
       }
      }
     },
     "localname": "AlternativeInvestmentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AmblyotechInc.EastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amblyotech Inc., East Hanover, NJ [member]"
       }
      }
     },
     "localname": "AmblyotechInc.EastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AmericanDepositarySharesEachRepresenting1ShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "American Depositary Shares each representing 1 share [member]",
        "terseLabel": "American Depositary Shares each representing 1 share"
       }
      }
     },
     "localname": "AmericanDepositarySharesEachRepresenting1ShareMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AmiodaroneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amiodarone [member]"
       }
      }
     },
     "localname": "AmiodaroneMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AmortizationOfBondsDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of bonds discount",
        "negatedTerseLabel": "Amortization of bonds discount",
        "terseLabel": "Amortization of bonds discount"
       }
      }
     },
     "localname": "AmortizationOfBondsDiscount",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of fair value adjustments relating to intangible assets"
       }
      }
     },
     "localname": "AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of fair value adjustments relating to intangible assets tax"
       }
      }
     },
     "localname": "AmortizationOfFairValueAdjustmentsRelatingToIntangibleAssetsTax",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AmortizationPriorToClassificationToAssetsHeldForSale": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization prior to classification to assets held for sale"
       }
      }
     },
     "localname": "AmortizationPriorToClassificationToAssetsHeldForSale",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AmountBorrowedUnderTheCreditFacility": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount borrowed under the credit facility"
       }
      }
     },
     "localname": "AmountBorrowedUnderTheCreditFacility",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of change in OCI when most significant parameters for level 3 change more than 10%"
       }
      }
     },
     "localname": "AmountOfChangeInOCIWhenMostSignificantParametersForLevel3ChangeMoreThan10",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of change in OCI when POS for level 3 change more than 10%",
        "negatedTerseLabel": "Amount of change in OCI when POS for level 3 change more than 10%"
       }
      }
     },
     "localname": "AmountOfChangeInOCIWhenPOSForLevel3ChangeMoreThan10",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of change in OCI when pricing parameters for level 3 change more than 10%"
       }
      }
     },
     "localname": "AmountOfChangeInOCIWhenPricingParametersForLevel3ChangeMoreThan10",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AmountOfResolvedAction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of resolved action"
       }
      }
     },
     "localname": "AmountOfResolvedAction",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AmountOfSettlementInPrinciple": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of settlement in principle"
       }
      }
     },
     "localname": "AmountOfSettlementInPrinciple",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AmountRecordedInEquityRelatedToHyperinflation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount recorded in equity related to hyperinflation"
       }
      }
     },
     "localname": "AmountRecordedInEquityRelatedToHyperinflation",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]"
       }
      }
     },
     "localname": "AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [table]"
       }
      }
     },
     "localname": "AmountsRecognisedAsOfAcquisitionDateForEachMajorClassOfAssetsAcquiredAndLiabilitiesAssumedTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_AmountsRecognizedInTheConsolidatedBalanceSheetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amounts recognized in the consolidated balance sheet [abstract]"
       }
      }
     },
     "localname": "AmountsRecognizedInTheConsolidatedBalanceSheetAbstract",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_AnalysisOfOverdueAmountsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Analysis of overdue amounts [line items]"
       }
      }
     },
     "localname": "AnalysisOfOverdueAmountsLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_AnalysisOfOverdueAmountsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Analysis of overdue amounts [table]"
       }
      }
     },
     "localname": "AnalysisOfOverdueAmountsTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_AnalysisOfTaxRateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Analysis of Tax Rate [table text block]",
        "terseLabel": "Analysis of tax rate"
       }
      }
     },
     "localname": "AnalysisOfTaxRateTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_AntiInfectivesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti Infectives [member]"
       }
      }
     },
     "localname": "AntiInfectivesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AntiInfectivesSoldUnderSandozNameMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti Infectives sold under Sandoz name [member]"
       }
      }
     },
     "localname": "AntiInfectivesSoldUnderSandozNameMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ArctosMedicalAGBernMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arctos Medical AG, Bern [member]"
       }
      }
     },
     "localname": "ArctosMedicalAGBernMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AsiaAfricaAustralasiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia/Africa/Australasia [member]"
       }
      }
     },
     "localname": "AsiaAfricaAustralasiaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AspenGlobalIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aspen Global Incorporated [member]",
        "terseLabel": "Aspen Global Incorporated"
       }
      }
     },
     "localname": "AspenGlobalIncorporatedMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AspenJapanK.K.TokyoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aspen Japan K.K., Tokyo [member]"
       }
      }
     },
     "localname": "AspenJapanK.K.TokyoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AssociatedCompaniesAtFairValueThroughProfitAndLossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Associated companies at fair value through profit and loss [member]"
       }
      }
     },
     "localname": "AssociatedCompaniesAtFairValueThroughProfitAndLossMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AssociatesSummarizedFinancialInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Associates summarized financial information [table text block]",
        "terseLabel": "Associates summarized financial information"
       }
      }
     },
     "localname": "AssociatesSummarizedFinancialInformationTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_AssumptionsUsedInTheCalculationOfValuationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assumptions used in the calculation of valuation [text block]",
        "terseLabel": "Assumptions used in the calculation of valuation"
       }
      }
     },
     "localname": "AssumptionsUsedInTheCalculationOfValuationTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_AvailableForSaleMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale marketable securities [member]"
       }
      }
     },
     "localname": "AvailableForSaleMarketableSecuritiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AvailableforsaleFinancialInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale financial investments [member]"
       }
      }
     },
     "localname": "AvailableforsaleFinancialInvestmentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AvailableforsaleLongtermFinancialInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale long-term financial investments [member]"
       }
      }
     },
     "localname": "AvailableforsaleLongtermFinancialInvestmentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AveXisIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AveXis, Inc. [member]",
        "terseLabel": "AveXis, Inc."
       }
      }
     },
     "localname": "AveXisIncMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_AverageEffectiveTaxRateContinuingOperations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average effective tax rate continuing operations",
        "terseLabel": "Effective tax rate for continuing operations"
       }
      }
     },
     "localname": "AverageEffectiveTaxRateContinuingOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_AverageEffectiveTaxRateDiscontinuedOperations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average effective tax rate discontinued operations",
        "terseLabel": "Effective tax rate for discontinued operations"
       }
      }
     },
     "localname": "AverageEffectiveTaxRateDiscontinuedOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_AverageInterestRateOnBorrowings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average interest rate on borrowings"
       }
      }
     },
     "localname": "AverageInterestRateOnBorrowings",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_AverageInterestRateOnLoansReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average interest rate on loans received"
       }
      }
     },
     "localname": "AverageInterestRateOnLoansReceived",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_BalanceSheetItemAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance sheet item [axis]"
       }
      }
     },
     "localname": "BalanceSheetItemAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_BalanceSheetItemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance sheet item [member]"
       }
      }
     },
     "localname": "BalanceSheetItemMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_BalanceSheetTreatmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance sheet treatment [axis]"
       }
      }
     },
     "localname": "BalanceSheetTreatmentAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_BalanceSheetTreatmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance sheet treatment [member]"
       }
      }
     },
     "localname": "BalanceSheetTreatmentMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_BankAndOtherFinancialDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank and other financial debt [member]"
       }
      }
     },
     "localname": "BankAndOtherFinancialDebtMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Based Participation Novartis Equity Plan Select outside North America RSU [member]",
        "terseLabel": "dup_7_Annual incentive"
       }
      }
     },
     "localname": "BasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRSUMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_BeijingNovartisPharmaCo.Ltd.BeijingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beijing Novartis Pharma Co., Ltd., Beijing [member]"
       }
      }
     },
     "localname": "BeijingNovartisPharmaCo.Ltd.BeijingMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_BeovuMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beovu [member]"
       }
      }
     },
     "localname": "BeovuMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_BiopharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Biopharmaceuticals [member]"
       }
      }
     },
     "localname": "BiopharmaceuticalsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_BorrowingsCommercialPaperMaximumAmountOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings commercial paper maximum amount outstanding"
       }
      }
     },
     "localname": "BorrowingsCommercialPaperMaximumAmountOutstanding",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_BorrowingsCommercialPaperMaximumBorrowingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings commercial paper maximum borrowing amount"
       }
      }
     },
     "localname": "BorrowingsCommercialPaperMaximumBorrowingAmount",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_BorrowingsCommercialPaperNumberOfPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings commercial paper, number of programs"
       }
      }
     },
     "localname": "BorrowingsCommercialPaperNumberOfPrograms",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_BorrowingsCreditFacilityCommitted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings credit facility committed"
       }
      }
     },
     "localname": "BorrowingsCreditFacilityCommitted",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_BorrowingsCreditFacilityShortTerm": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings credit facility short term"
       }
      }
     },
     "localname": "BorrowingsCreditFacilityShortTerm",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_BorrowingsCreditFacilityUncommitted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings credit facility uncommitted"
       }
      }
     },
     "localname": "BorrowingsCreditFacilityUncommitted",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_BorrowingsEURMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings, EUR [member]"
       }
      }
     },
     "localname": "BorrowingsEURMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_BorrowingsInterestRateStepUp": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings interest rate step up",
        "terseLabel": "dup_1_Straight bonds"
       }
      }
     },
     "localname": "BorrowingsInterestRateStepUp",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_BorrowingsIssuanceDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings, issuance date",
        "terseLabel": "Borrowings, issuance year"
       }
      }
     },
     "localname": "BorrowingsIssuanceDate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_BorrowingsLender": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings, lender",
        "terseLabel": "Borrowings, issuer"
       }
      }
     },
     "localname": "BorrowingsLender",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_BorrowingsPremiumDiscount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings, premium discount",
        "terseLabel": "Borrowings, issue price"
       }
      }
     },
     "localname": "BorrowingsPremiumDiscount",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_BorrowingsUSDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings, USD [member]"
       }
      }
     },
     "localname": "BorrowingsUSDMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_BrandsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brands [axis]"
       }
      }
     },
     "localname": "BrandsAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_BrandsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brands [member]"
       }
      }
     },
     "localname": "BrandsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Breakdown of defined benefit obligation for pension plans [table]"
       }
      }
     },
     "localname": "BreakdownOfDefinedBenefitObligationForPensionPlansTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Breakdown of defined benefit obligation for pension plans and other post-employment benefit [table text block]",
        "terseLabel": "Breakdown of defined benefit obligation for pension plans and other post-employment benefit"
       }
      }
     },
     "localname": "BreakdownOfDefinedBenefitObligationForPensionPlansTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage",
        "terseLabel": "Divested interest in associate"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_CELLforCURELesUlisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CELLforCURE, Les Ulis [member]"
       }
      }
     },
     "localname": "CELLforCURELesUlisMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CELLforCUREMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CELLforCURE [member]"
       }
      }
     },
     "localname": "CELLforCUREMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CH Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities [text block]",
        "terseLabel": "CH Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities"
       }
      }
     },
     "localname": "CHCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxLiabilitiesTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CIBA Vision Asian Manufacturing and Logistics Pte Ltd., Singapore [member]"
       }
      }
     },
     "localname": "CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CIBAVisionCanadaInc.MississaugaOntarioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CIBA Vision Canada Inc., Mississauga, Ontario [member]"
       }
      }
     },
     "localname": "CIBAVisionCanadaInc.MississaugaOntarioMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CIBAVisionCorporationLLCDuluthGAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CIBA Vision Corporation LLC, Duluth, GA [member]"
       }
      }
     },
     "localname": "CIBAVisionCorporationLLCDuluthGAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CIBAVisionGmbHGrosswallstadtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CIBA Vision GmbH, Grosswallstadt [member]"
       }
      }
     },
     "localname": "CIBAVisionGmbHGrosswallstadtMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CIBAVisionJohorSdn.Bhd.KualaLumpurMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CIBA Vision Johor Sdn. Bhd., Kuala Lumpur [member]"
       }
      }
     },
     "localname": "CIBAVisionJohorSdn.Bhd.KualaLumpurMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_COPDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COPD [member]"
       }
      }
     },
     "localname": "COPDMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CSLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CSL [member]",
        "terseLabel": "CSL"
       }
      }
     },
     "localname": "CSLMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CadentTherapeuticsCambridgeMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cadent Therapeutics, Cambridge, MA [member]"
       }
      }
     },
     "localname": "CadentTherapeuticsCambridgeMAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CanadaAndLatinAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada and Latin America [member]"
       }
      }
     },
     "localname": "CanadaAndLatinAmericaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CapitalizedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized [member]"
       }
      }
     },
     "localname": "CapitalizedMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CardiovascularMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cardiovascular [member]"
       }
      }
     },
     "localname": "CardiovascularMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying reported amount fair value disclosure [member]",
        "terseLabel": "Balance sheet"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CarryingValueOfTheDivestedBusiness": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying value of the divested business"
       }
      }
     },
     "localname": "CarryingValueOfTheDivestedBusiness",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashAndCashEquivalentsHeldWithFinancialInstitution": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of entity's cash and cash equivalents held with financial institution"
       }
      }
     },
     "localname": "CashAndCashEquivalentsHeldWithFinancialInstitution",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments",
        "terseLabel": "Current financial assets"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMarketableSecuritiesCommoditiesTimeDepositsAndDerivativeFinancialInstruments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents [member]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents [table text block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_CashAndOtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and other investments [member]",
        "terseLabel": "Cash and other investments"
       }
      }
     },
     "localname": "CashAndOtherInvestmentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CashFlowFromNetIdentifiableAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash inflow (outflow) from Net identifiable assets (acquired) or divested",
        "label": "Net identifiable assets (acquired) or divested",
        "negatedTerseLabel": "Net assets recognized as a result of acquistions of businesses"
       }
      }
     },
     "localname": "CashFlowFromNetIdentifiableAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows arising from acquisitions and divestments of businesses [table text block]",
        "terseLabel": "Cash flows arising from acquisitions and divestments of businesses"
       }
      }
     },
     "localname": "CashFlowsArisingFromAcquisitionsAndDivestmentsOfBusinessesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_CashFlowsAttributableToDivestedBusiness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows attributable to divested business",
        "terseLabel": "Cash flows attributable to the spin-off of the Alcon business"
       }
      }
     },
     "localname": "CashFlowsAttributableToDivestedBusiness",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows Attributable to divested business before divested cash and cash equivalents",
        "terseLabel": "Payments out of provisions for transaction costs attributable to the divested business",
        "verboseLabel": "Payments attributable to the spin-off of the Alcon business"
       }
      }
     },
     "localname": "CashFlowsAttributableToDivestedBusinessBeforeDivestedCashAndCashEquivalents",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashFlowsBeforeWorkingCapitalAndProvisionChanges": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows before working capital and provision changes",
        "totalLabel": "Net cash flows from operating activities before working capital and provision changes"
       }
      }
     },
     "localname": "CashFlowsBeforeWorkingCapitalAndProvisionChanges",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations [table text block]",
        "terseLabel": "Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations"
       }
      }
     },
     "localname": "CashFlowsFromChangesInWorkingCapitalAndOtherOperatingItemsIncludedInOperatingCashFlowFromContinuingOperationsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_CashFlowsFromDiscontinuedOperationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from discontinued operations [table text block]",
        "terseLabel": "Cash flows from discontinued operations"
       }
      }
     },
     "localname": "CashFlowsFromDiscontinuedOperationsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_CashInflowForSaleAndLeaseback": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash inflow for sale and leaseback",
        "negatedTerseLabel": "Cash inflow for sale and leaseback"
       }
      }
     },
     "localname": "CashInflowForSaleAndLeaseback",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash inflow outflow from net identifiable assets divested acquired"
       }
      }
     },
     "localname": "CashInflowOutflowFromNetIdentifiableAssetsDivestedAcquired",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashOfferPerADS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This expresses the amount of cash Novartis paid to the owners of AAA per ADS.",
        "label": "Cash offer per ADS"
       }
      }
     },
     "localname": "CashOfferPerADS",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashOfferPerOrdinaryShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This expresses the amount of cash Novartis paid to the owners of AAA per ordinary share.",
        "label": "Cash offer per ordinary share"
       }
      }
     },
     "localname": "CashOfferPerOrdinaryShare",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashOutflowsDueToDerecognizedCashAndCashEquivalents": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash outflows due to derecognized cash and cash equivalents",
        "terseLabel": "dup_3_Divested business"
       }
      }
     },
     "localname": "CashOutflowsDueToDerecognizedCashAndCashEquivalents",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashOutflowsForPaymentsOfLeasesInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash outflows for payments of leases interest"
       }
      }
     },
     "localname": "CashOutflowsForPaymentsOfLeasesInterest",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashOutflowsForShortTermAndLowValueLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash outflows for short term and low value leases"
       }
      }
     },
     "localname": "CashOutflowsForShortTermAndLowValueLeases",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash outflows from interest bearing accounts of employees payable on demand"
       }
      }
     },
     "localname": "CashOutflowsFromInterestBearingAccountsOfEmployeesPayableOnDemand",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CashReceiptsAndPaymentsFairValueMeasurementAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash receipts and payments fair value measurement assets"
       }
      }
     },
     "localname": "CashReceiptsAndPaymentsFairValueMeasurementAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Catalana de Dispensacion sau (Cadisa), Esplugues de Llobregat [member]"
       }
      }
     },
     "localname": "CatalanaDeDispensacionSauCadisaEspluguesDeLlobregatMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CellerysAGSchlierenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cellerys AG, Schlieren [member]"
       }
      }
     },
     "localname": "CellerysAGSchlierenMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_Change25BasisPointMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change, 25 basis point [member]",
        "terseLabel": "25 basis point change"
       }
      }
     },
     "localname": "Change25BasisPointMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ChangeInActuarialAssumptionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in actuarial assumption [axis]"
       }
      }
     },
     "localname": "ChangeInActuarialAssumptionAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ChangeInActuarialAssumptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in actuarial assumption [member]"
       }
      }
     },
     "localname": "ChangeInActuarialAssumptionMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ChangeInCashSettledShareBasedPaymentsLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in cash settled share based payments liabilities"
       }
      }
     },
     "localname": "ChangeInCashSettledShareBasedPaymentsLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in net current assets and other operating cash flow items",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "ChangeInNetCurrentAssetsAndOtherOperatingCashFlowItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ChangeOverPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change over period [axis]"
       }
      }
     },
     "localname": "ChangeOverPeriodAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in consolidated statements of comprehensive income [line items]"
       }
      }
     },
     "localname": "ChangesInConsolidatedStatementsOfComprehensiveIncomeLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in consolidated statements of comprehensive income [table]"
       }
      }
     },
     "localname": "ChangesInConsolidatedStatementsOfComprehensiveIncomeTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in consolidated statements of comprehensive income [text block]",
        "terseLabel": "Changes in consolidated statements of comprehensive income"
       }
      }
     },
     "localname": "ChangesInConsolidatedStatementsOfComprehensiveIncomeTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ChangesInOffsetAgainstGrossTradeReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in offset against gross trade receivables",
        "negatedTerseLabel": "Changes in offset against gross trade receivables"
       }
      }
     },
     "localname": "ChangesInOffsetAgainstGrossTradeReceivables",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "China Novartis Institute for BioMedical Research Co.,Ltd. [member]"
       }
      }
     },
     "localname": "ChinaNovartisInstituteForBioMedicalResearchCo.Ltd.Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "China Novartis Institutes for BioMedical Research Co., Ltd., Shanghai [member]"
       }
      }
     },
     "localname": "ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CibaGeigyJapanLimitedTokyoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ciba-Geigy Japan Limited, Tokyo [member]"
       }
      }
     },
     "localname": "CibaGeigyJapanLimitedTokyoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ClarVistaMedicalInc.AlisoViejoCAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ClarVista Medical, Inc., Aliso Viejo, CA [member]"
       }
      }
     },
     "localname": "ClarVistaMedicalInc.AlisoViejoCAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CoStimPharmaceuticalsInc.CambridgeMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CoStim Pharmaceuticals Inc., Cambridge, MA [member]"
       }
      }
     },
     "localname": "CoStimPharmaceuticalsInc.CambridgeMAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CoalesceProductDevelopmentLimitedCambridgeCambsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Coalesce Product Development Limited, Cambridge, Cambs [member]"
       }
      }
     },
     "localname": "CoalesceProductDevelopmentLimitedCambridgeCambsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CommercialPaperMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial paper [member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CommitmentForRepurchaseOfOwnSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment for repurchase of own shares [member]"
       }
      }
     },
     "localname": "CommitmentForRepurchaseOfOwnSharesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CommitmentForRepurchaseOwnShares": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 13.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment for repurchase own shares",
        "negatedTerseLabel": "Commitment for repurchase own shares"
       }
      }
     },
     "localname": "CommitmentForRepurchaseOwnShares",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CommitmentsAndContingenciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies [abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_CommitmentsForLeasesNotYetCommenced": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments for leases not yet commenced"
       }
      }
     },
     "localname": "CommitmentsForLeasesNotYetCommenced",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CommitmentsUnderLongtermResearchAgreements": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2": {
       "order": 1.0,
       "parentTag": "nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments under long-term research and development agreements"
       }
      }
     },
     "localname": "CommitmentsUnderLongtermResearchAgreements",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_Commodities": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_OtherCurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commodities"
       }
      }
     },
     "localname": "Commodities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CommoditiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commodities [member]"
       }
      }
     },
     "localname": "CommoditiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ConcentrationOfMajorPlansGeographic": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the major plans and the concentration of the Group's DBO by geography.",
        "label": "Concentration of major plans, geographic"
       }
      }
     },
     "localname": "ConcentrationOfMajorPlansGeographic",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consideration paid for share capital tendered at the subsequent offering period of the tender offer"
       }
      }
     },
     "localname": "ConsiderationPaidForShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ConsolidatedIncomeStatementEffectsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated income statement effects [table]"
       }
      }
     },
     "localname": "ConsolidatedIncomeStatementEffectsTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ConsumerHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consumer Health [member]",
        "terseLabel": "Consumer Health"
       }
      }
     },
     "localname": "ConsumerHealthMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ContactLensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Lenses [member]"
       }
      }
     },
     "localname": "ContactLensesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ContingentConsiderationAndOtherFinancialLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration and other financial liabilities [member]"
       }
      }
     },
     "localname": "ContingentConsiderationAndOtherFinancialLiabilitiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ContingentConsiderationCurrentPortion": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 12.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration, current portion",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationCurrentPortion",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ContingentConsiderationLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration liabilities",
        "negatedTerseLabel": "Contingent consideration liabilities"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ContingentConsiderationNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "ifrs-full_OtherNoncurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationNonCurrent",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ContingentConsiderationPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration paid"
       }
      }
     },
     "localname": "ContingentConsiderationPaid",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ContingentConsiderationPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration payables [member]"
       }
      }
     },
     "localname": "ContingentConsiderationPayablesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ContingentConsiderationReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails": {
       "order": 7.0,
       "parentTag": "ifrs-full_NoncurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration Receivable",
        "terseLabel": "Contingent consideration receivables"
       }
      }
     },
     "localname": "ContingentConsiderationReceivable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ContingentConsiderationReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails": {
       "order": 7.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration receivable, current",
        "terseLabel": "Contingent consideration receivable"
       }
      }
     },
     "localname": "ContingentConsiderationReceivableCurrent",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ContingentConsiderationReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration receivables [member]"
       }
      }
     },
     "localname": "ContingentConsiderationReceivablesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ContingentConsiderationReceivablesShorttermMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration receivables short-term [member]"
       }
      }
     },
     "localname": "ContingentConsiderationReceivablesShorttermMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ContractManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract manufacturing [member]"
       }
      }
     },
     "localname": "ContractManufacturingMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ContractOrUnderlyingPrincipalAmoutMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract or underlying principal amout [member]"
       }
      }
     },
     "localname": "ContractOrUnderlyingPrincipalAmoutMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ContractRightOfFirstNegotiationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract right of first negotiation term"
       }
      }
     },
     "localname": "ContractRightOfFirstNegotiationTerm",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nvs_ContractualInterestOnNoncurrentLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual interest on non-current liabilities",
        "terseLabel": "Contractual interest on non-current liabilities"
       }
      }
     },
     "localname": "ContractualInterestOnNoncurrentLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ContributionOfBusinessToJointVenture": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution of business to joint venture"
       }
      }
     },
     "localname": "ContributionOfBusinessToJointVenture",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contributions to plan by plan participants, net defined benefit liability (asset), benefit obligation",
        "terseLabel": "Contributions of associates"
       }
      }
     },
     "localname": "ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAssetBenefitObligation",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Core therapeutic area; other promoted brands; and established brands [axis]"
       }
      }
     },
     "localname": "CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Core therapeutic area; other promoted brands; and established brands [member]"
       }
      }
     },
     "localname": "CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CorporateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate [member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CortheraInc.SanMateoCAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corthera, Inc., San Mateo, CA [member]"
       }
      }
     },
     "localname": "CortheraInc.SanMateoCAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CosentyxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cosentyx [member]"
       }
      }
     },
     "localname": "CosentyxMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CounterpartyRiskAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty risk [abstract]"
       }
      }
     },
     "localname": "CounterpartyRiskAbstract",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_CumulativeCurrencyTranslationEffectsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative currency translation effects [member]",
        "terseLabel": "Cumulative currency translation effects"
       }
      }
     },
     "localname": "CumulativeCurrencyTranslationEffectsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative currency translation gains/losses recycled through income statement"
       }
      }
     },
     "localname": "CumulativeCurrencyTranslationLossesRecycledThroughtIncomeStatement",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails3",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.",
        "label": "Currency exchange rate sensitivity impact against USD in the equity"
       }
      }
     },
     "localname": "CurrencyExchangeRateSensitivityImpactAgainstUSDInTheEquity",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.",
        "label": "Currency exchange rate sensitivity impact against USD in the income statement"
       }
      }
     },
     "localname": "CurrencyExchangeRateSensitivityImpactAgainstUSDInTheIncomeStatement",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrencyOthersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency, others [member]",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "CurrencyOthersMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency translation reserve for net investment hedge, net of taxes"
       }
      }
     },
     "localname": "CurrencyTranslationReserveForNetInvestmentHedgeNetOfTaxes",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrentAndDeferredIncomeTaxExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current and deferred Income Tax Expense [table text block]",
        "terseLabel": "Current and deferred income tax expense"
       }
      }
     },
     "localname": "CurrentAndDeferredIncomeTaxExpenseTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 14.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current and non current lease liabilities as of acquisition date",
        "negatedTerseLabel": "Current and non-current lease liabilities"
       }
      }
     },
     "localname": "CurrentAndNonCurrentLeaseLiabilitiesAsOfAcquisitionDate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrentAssetsDivested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets divested"
       }
      }
     },
     "localname": "CurrentAssetsDivested",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrentFinancialDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current financial debt [member]"
       }
      }
     },
     "localname": "CurrentFinancialDebtMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current financial debts and derivative financial instruments [member]"
       }
      }
     },
     "localname": "CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CurrentFinancialLiabilitiesAtFairValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current financial liabilities at fair value [member]"
       }
      }
     },
     "localname": "CurrentFinancialLiabilitiesAtFairValueMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CurrentIncomeTaxAndDeferredTaxLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current income tax liabilities and deferred tax liabilities"
       }
      }
     },
     "localname": "CurrentIncomeTaxAndDeferredTaxLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrentLeaseLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current lease liabilities [member]"
       }
      }
     },
     "localname": "CurrentLeaseLiabilitiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CurrentLeaseLiabilitiesUndiscounted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current lease liabilities undiscounted",
        "negatedTerseLabel": "Less current lease liabilities undiscounted",
        "verboseLabel": "Less current lease liabilities undiscounted"
       }
      }
     },
     "localname": "CurrentLeaseLiabilitiesUndiscounted",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrentLiabilitiesDivested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities divested"
       }
      }
     },
     "localname": "CurrentLiabilitiesDivested",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [member]"
       }
      }
     },
     "localname": "CurrentLiabilitiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CurrentPortionOfNoncurrentDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of non-current debt [member]"
       }
      }
     },
     "localname": "CurrentPortionOfNoncurrentDebtMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CurrentPortionOfNoncurrentFinancialDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of non-current financial debt"
       }
      }
     },
     "localname": "CurrentPortionOfNoncurrentFinancialDebt",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrentPrepaidExpensesAssociatedCompanies": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current prepaid expenses associated companies",
        "terseLabel": "Prepaid expenses - associated companies"
       }
      }
     },
     "localname": "CurrentPrepaidExpensesAssociatedCompanies",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrentPrepaidExpensesThirdParty": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current prepaid expenses, third party",
        "terseLabel": "Prepaid expenses - third party"
       }
      }
     },
     "localname": "CurrentPrepaidExpensesThirdParty",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrentRefundsProvisionDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Current refunds provision, Discontinued operations",
        "periodEndLabel": "Provisions for deductions from revenue, discontinued operations, at end of period",
        "periodStartLabel": "Provisions for deductions from revenue, discontinued operations, at beginning of period",
        "terseLabel": "Provisions for deductions from revenue, discontinued operations"
       }
      }
     },
     "localname": "CurrentRefundsProvisionDiscontinuedOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 2.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Currently marketed products intangible assets recognised as of acquisition date",
        "terseLabel": "Currently marketed products"
       }
      }
     },
     "localname": "CurrentlyMarketedProductsIntangibleAssetsRecognisedAsOfAcquisitionDate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CurrentlyMarketedProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currently marketed products [member]",
        "terseLabel": "Currently marketed products"
       }
      }
     },
     "localname": "CurrentlyMarketedProductsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_CustomaryPurchasePriceAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Customary purchase price adjustment"
       }
      }
     },
     "localname": "CustomaryPurchasePriceAdjustment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_CustomersWithNetSalesOverFivePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customers with net sales over five percent"
       }
      }
     },
     "localname": "CustomersWithNetSalesOverFivePercent",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_CyPassMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CyPass [member]"
       }
      }
     },
     "localname": "CyPassMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_DebtEquityRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt/equity ratio"
       }
      }
     },
     "localname": "DebtEquityRatio",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DebtSecuritiesBreakdownByCurrencyTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt securities, breakdown by currency [table text block]",
        "terseLabel": "Debt securities, breakdown by currency"
       }
      }
     },
     "localname": "DebtSecuritiesBreakdownByCurrencyTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_Decrease25BasisPointMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease, 25 basis point [member]",
        "terseLabel": "25 basis point decrease"
       }
      }
     },
     "localname": "Decrease25BasisPointMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease through assets related to discontinued operations, intangible assets and goodwill",
        "negatedTerseLabel": "Cost of assets related to discontinued operations"
       }
      }
     },
     "localname": "DecreaseThroughAssetsRelatedToDiscontinuedOperationsIntangibleAssetsAndGoodwill",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease through assets related to discontinued operations",
        "negatedTerseLabel": "Costs of assets related to discontinued operations",
        "terseLabel": "Costs of assets related to discontinued operations"
       }
      }
     },
     "localname": "DecreaseThroughAssetsRelatedToDiscontinuedOperationsPropertyPlantAndEquipment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease through liabilities related to discontinued operations",
        "terseLabel": "Financial debts and lease liabilities related to discontinued operations"
       }
      }
     },
     "localname": "DecreaseThroughLiabilitiesRelatedToDiscontinuedOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease through reclassification to right-of-use assets",
        "negatedTerseLabel": "Decrease through reclassification to right-of-use assets"
       }
      }
     },
     "localname": "DecreaseThroughReclassificationToRightofuseAssetsPropertyPlantAndEquipment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DeferredCompensationPlansAssets": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred compensation plans assets"
       }
      }
     },
     "localname": "DeferredCompensationPlansAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DeferredPensionersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred pensioners [member]",
        "terseLabel": "Deferred pensioners"
       }
      }
     },
     "localname": "DeferredPensionersMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_DeferredSalePriceAndOtherAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred sale price and other adjustments",
        "terseLabel": "dup_1_Divested business"
       }
      }
     },
     "localname": "DeferredSalePriceAndOtherAdjustments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DeferredTaxAssetAndLiabilityValuationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax asset and liability valuation [abstract]"
       }
      }
     },
     "localname": "DeferredTaxAssetAndLiabilityValuationAbstract",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DefinedBenefitAssumptionLifeExpectancyFemale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit assumption life expectancy, female",
        "terseLabel": "Current life expectancy for a 65-year-old female"
       }
      }
     },
     "localname": "DefinedBenefitAssumptionLifeExpectancyFemale",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5"
     ],
     "xbrltype": "durationItemType"
    },
    "nvs_DefinedBenefitAssumptionLifeExpectancyMale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit assumption life expectancy, male",
        "terseLabel": "Current life expectancy for a 65-year-old male"
       }
      }
     },
     "localname": "DefinedBenefitAssumptionLifeExpectancyMale",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5"
     ],
     "xbrltype": "durationItemType"
    },
    "nvs_DefinedBenefitObligationDiscontinuedOperationsAtPresentValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit obligation, Discontinued operations, at present value",
        "periodEndLabel": "Benefit obligation, Discontinued operations at end of period",
        "periodStartLabel": "Benefit obligation, Discontinued operations at beginning of period"
       }
      }
     },
     "localname": "DefinedBenefitObligationDiscontinuedOperationsAtPresentValue",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DefinedBenefitPensionPlanAccruedBenefitLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit pension plan, accrued benefit liability",
        "negatedTerseLabel": "Accrued benefit liability",
        "terseLabel": "Accrued benefit liability"
       }
      }
     },
     "localname": "DefinedBenefitPensionPlanAccruedBenefitLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, change in benefit obligation [roll forward]"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, change in fair value of plan assets [roll forward]"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, change in limitation on recognition of fund surplus [roll forward]"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInLimitationOnRecognitionOfFundSurplusRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DefinedBenefitPlanChangeInNetLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, change in net liability [roll forward]"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInNetLiabilityRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DefinedBenefitPlanExpectedFutureBenefitPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, expected future benefit payment",
        "terseLabel": "Expected future benefit payment"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPayment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, expected future benefit payment [abstract]",
        "terseLabel": "Expected future benefit payments"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentAbstract",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, expected future employer contributions [abstract]",
        "terseLabel": "Novartis Group contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, expected future employer contributions, next fiscal year",
        "terseLabel": "Contributions, next fiscal year (estimated)"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year",
        "terseLabel": "Healthcare cost trend rate assumed for next year"
       }
      }
     },
     "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed to Decline",
        "terseLabel": "Rate to which the cost trend rate is assumed to decline"
       }
      }
     },
     "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedToDecline",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_DefinedBenefitPlanInterestCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase in a defined benefit pension plan's projected benefit obligation or a defined benefit postretirement plan's accumulated postretirement benefit obligation due to the passage of time.",
        "label": "Defined benefit plan, interest cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DefinedBenefitPlanPlanAssetAllocations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, plan asset allocations"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetAllocations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, recognized net gain (loss) due to curtailments",
        "terseLabel": "Net Pre-tax curtailment gain (loss)"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DefinedBenefitPlanSettlementsPlanAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Settlements, Plan Assets",
        "negatedTerseLabel": "Settlements",
        "terseLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsPlanAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, target plan asset allocations range maximum"
       }
      }
     },
     "localname": "DefinedBenefitPlanTargetPlanAssetAllocationsRangeMaximum",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, target plan asset allocations range minimum"
       }
      }
     },
     "localname": "DefinedBenefitPlanTargetPlanAssetAllocationsRangeMinimum",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Year that Rate Reaches Ultimate Trend Rate",
        "terseLabel": "Year that the rate reaches the ultimate trend rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7"
     ],
     "xbrltype": "gYearItemType"
    },
    "nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined contribution pension and other post-retirement plans disclosure [abstract]"
       }
      }
     },
     "localname": "DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined contribution pension and other post-retirement plans disclosure [line items]"
       }
      }
     },
     "localname": "DefinedContributionPensionAndOtherPostretirementPlansDisclosureLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined contribution pension and other post-retirement plans disclosure [table]"
       }
      }
     },
     "localname": "DefinedContributionPensionAndOtherPostretirementPlansDisclosureTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DepreciationChargePriorToClassificationToAssetsHeldForSale": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation charge prior to classification to assets held for sale",
        "negatedTerseLabel": "Depreciation charge prior to classification to assets held for sale"
       }
      }
     },
     "localname": "DepreciationChargePriorToClassificationToAssetsHeldForSale",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DerivativeFinancialInstrumentNatureOfInstrumentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instrument, nature of instrument [axis]"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentNatureOfInstrumentAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DerivativeFinancialInstrumentNatureOfInstrumentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instrument, nature of instrument [member]"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentNatureOfInstrumentMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_DerivativeFinancialInstruments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instruments"
       }
      }
     },
     "localname": "DerivativeFinancialInstruments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instruments and accrued interest on derivative financial instruments [line items]"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instruments and accrued interest on derivative financial instruments [table]"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instruments, at fair value currency related [member]"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_DerivativeFinancialInstrumentsCommodityPurchaseContract": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instruments, commodity purchase contract"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsCommodityPurchaseContract",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instruments, forward foreign exchange rate contracts"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsForwardForeignExchangeRateContracts",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DerivativeFinancialInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instruments [member]"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_DerivativeFinancialInstrumentsOptionsOnEquitySecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instruments, options on equity securities"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsOptionsOnEquitySecurities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DerivativeFinancialInstrumentsOverthecounterCurrencyOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative financial instruments, over-the-counter currency options"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsOverthecounterCurrencyOptions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DeriviativeFinancialInstrumentsAndAccruedInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deriviative financial instruments and accrued interest [member]"
       }
      }
     },
     "localname": "DeriviativeFinancialInstrumentsAndAccruedInterestMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial assets, cash and cash equivalents [text block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialAssetsCashAndCashEquivalentsTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial assets, marketable securities, commodities and non-current financial assets [text block]",
        "terseLabel": "Marketable securities, commodities and non-current financial assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialAssetsMarketableSecuritiesCommoditiesAndNoncurrentFinancialAssetsTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for healthcare contributions [text block]",
        "terseLabel": "Healthcare contributions"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForHealthcareContributionsTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for Impairment of associated companies accounted for at equity [text block]",
        "terseLabel": "Impairment of associated companies accounted for at equity"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfAssociatedCompaniesAccountedForAtEquityTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for Impairment of goodwill and intangible assets [text block]",
        "terseLabel": "Impairment of goodwill and intangible assets"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfGoodwillAndIntangibleAssetsTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for Intangible assets available-for-use [text block]",
        "terseLabel": "Intangible assets available-for-use"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsAvailableforuseTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for Intangible assets not yet available-for-use [text block]",
        "terseLabel": "Intangible assets not yet available-for-use"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsNotYetAvailableforuseTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DescriptionOfAccountingPolicyForOtherRevenueTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for other revenue [text block]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForOtherRevenueTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for Revenue from Contracts with Customers [text block]"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForRevenueFromContractsWithCustomersTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DescriptionOfAnnualIncentive": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Annual Incentive"
       }
      }
     },
     "localname": "DescriptionOfAnnualIncentive",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of nature of obligation contingent liabilities, number of cases still pending"
       }
      }
     },
     "localname": "DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfCasesStillPending",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of nature of obligation contingent liabilities, number of legal questions referred to court"
       }
      }
     },
     "localname": "DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfLegalQuestionsReferredToCourt",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of nature of obligation contingent liabilities, number of other cases referred to court"
       }
      }
     },
     "localname": "DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfOtherCasesReferredToCourt",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of nature of obligation contingent liabilities, number of putative cases referred to court"
       }
      }
     },
     "localname": "DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfPutativeCasesReferredToCourt",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of nature of obligation contingent liabilities, number of states with alleged violations"
       }
      }
     },
     "localname": "DescriptionOfNatureOfObligationContingentLiabilitiesNumberOfStatesWithAllegedViolations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_DetailedInformationAboutSignificantTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Detailed information about significant transaction"
       }
      }
     },
     "localname": "DetailedInformationAboutSignificantTransaction",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed, Net",
        "terseLabel": "Gain on distribution of Alcon Inc. to Novartis AG shareholders"
       }
      }
     },
     "localname": "DifferenceBetweenCarryingAmountOfDividendsPayableAndCarryingAmountOfNoncashAssetsDistributedNet",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Difference between fair value of distribution liability and net assets at the date of distribution"
       }
      }
     },
     "localname": "DifferenceBetweenFairValueOfDistributionLiabilityAndNetAssetsAtTheDateOfDistribution",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DiovanGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diovan Group [member]"
       }
      }
     },
     "localname": "DiovanGroupMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_DisclosureOfAcquisitionOfBusinessesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of acquisition of businesses [abstract]"
       }
      }
     },
     "localname": "DisclosureOfAcquisitionOfBusinessesAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of amount of inventory recognized as an expense in cost of goods sold [table text block]",
        "terseLabel": "Amount of inventory recognized as an expense in cost of goods sold"
       }
      }
     },
     "localname": "DisclosureOfAmountOfInventoryRecognizedAsAnExpenseInCostOfGoodsSoldTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of assets and liabilities of disposal group classified as held for sale [table text block]",
        "terseLabel": "Assets and liabilities of disposal group classified as held for sale"
       }
      }
     },
     "localname": "DisclosureOfAssetsAndLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of assets of disposal group classified as held for sale [table text block]",
        "terseLabel": "Assets of disposal group classified as held for sale"
       }
      }
     },
     "localname": "DisclosureOfAssetsOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfAssociatesBalanceSheetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of associates balance sheet [table text block]",
        "terseLabel": "Schedule disclosing information related to associates, balance sheet value"
       }
      }
     },
     "localname": "DisclosureOfAssociatesBalanceSheetTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfAssociatesNetIncomeEffectTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of associates, net income effect [table text block]",
        "terseLabel": "Schedule disclosing information related to associates, net income effect"
       }
      }
     },
     "localname": "DisclosureOfAssociatesNetIncomeEffectTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of collaerallized non-current financial debt and pledged assets [table text block]",
        "terseLabel": "Collaerallized non-current financial debt and pledged assets"
       }
      }
     },
     "localname": "DisclosureOfCollaerallizedNoncurrentFinancialDebtAndPledgedAssetsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfCommitmentsAndContingenciesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of commitments and contingencies [text block]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "DisclosureOfCommitmentsAndContingenciesTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of comparison of balance sheet and fair value of total non-current financial debt including current portion [table text block]",
        "terseLabel": "Comparison of balance sheet and fair value of total non-current financial debt including current portion"
       }
      }
     },
     "localname": "DisclosureOfComparisonOfBalanceSheetAndFairValueOfTotalNoncurrentFinancialDebtIncludingCurrentPortionTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of components of non-current financial debts [abstract]"
       }
      }
     },
     "localname": "DisclosureOfComponentsOfNoncurrentFinancialDebtsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of current financial debt and derivative instruments [abstract]"
       }
      }
     },
     "localname": "DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of current financial debt and derivative instruments [table text block]",
        "terseLabel": "Current financial debt and derivative instruments"
       }
      }
     },
     "localname": "DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of current financial debt and derivative instruments [text block]",
        "terseLabel": "Current financial debt and derivative financial instruments"
       }
      }
     },
     "localname": "DisclosureOfCurrentFinancialDebtAndDerivativeInstrumentsTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Deferred Tax Assets and Liabilities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of deferred tax assets and liabilities, expected to have impact on current taxes payable [table text block]",
        "terseLabel": "Deferred tax assets/liabilities, expected to have impact on current taxes payable"
       }
      }
     },
     "localname": "DisclosureOfDeferredTaxAssetsAndLiabilitiesExpectedToHaveImpactOnCurrentTaxesPayableTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfDefinedBenefitPlansTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of defined benefit plans [table text block]",
        "terseLabel": "Summary of the funded and unfunded defined benefit obligation for pension and other post retirement benefit plans table"
       }
      }
     },
     "localname": "DisclosureOfDefinedBenefitPlansTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of derivative financial instruments and accrued interest on derivative financial instruments [table text block]",
        "terseLabel": "Derivative financial instruments and accrued interest on derivative financial instruments"
       }
      }
     },
     "localname": "DisclosureOfDerivativeFinancialInstrumentsAndAccruedInterestOnDerivativeFinancialInstrumentsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of derivative financial instruments, by currency contract [table]"
       }
      }
     },
     "localname": "DisclosureOfDerivativeFinancialInstrumentsByCurrencyContractTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of derivative financial instruments, by type of contract [table]"
       }
      }
     },
     "localname": "DisclosureOfDerivativeFinancialInstrumentsByTypeOfContractTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of derivative financial instruments, contract or underlying principal amount the derivative financial instruments, by currency [table text block]",
        "terseLabel": "Contract or underlying principal amount the derivative financial instruments, by currency"
       }
      }
     },
     "localname": "DisclosureOfDerivativeFinancialInstrumentsContractOrUnderlyingPrincipalAmountTheDerivativeFinancialInstrumentsByCurrencyTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfDerivativeFinancialInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of derivative financial instruments [line items]"
       }
      }
     },
     "localname": "DisclosureOfDerivativeFinancialInstrumentsLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [table text block]",
        "terseLabel": "Disclosure of detailed information about borrowings"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about provisions and non-current liabilities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutProvisionsAndNoncurrentLiabilitiesAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of details to the consolidated statements of cash flows [abstract]"
       }
      }
     },
     "localname": "DisclosureOfDetailsToTheConsolidatedCashFlowStatementsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfDiscontinuedOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of discontinued operations [abstract]"
       }
      }
     },
     "localname": "DisclosureOfDiscontinuedOperationsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of equity [abstract]"
       }
      }
     },
     "localname": "DisclosureOfEquityAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfEquityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of equity [text block]",
        "terseLabel": "Equity",
        "verboseLabel": "Summary of equity attributable to Novartis AG shareholders"
       }
      }
     },
     "localname": "DisclosureOfEquityTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial and other non-current assets [abstract]"
       }
      }
     },
     "localname": "DisclosureOfFinancialAndOtherNoncurrentAssetsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial and other non-current assets [text block]",
        "terseLabel": "Financial and other non-current assets"
       }
      }
     },
     "localname": "DisclosureOfFinancialAndOtherNoncurrentAssetsTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets and financial liabilities [table text block]",
        "terseLabel": "Disclosure of financial assets and financial liabilities"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfFinancialAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial assets [table text block]",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "DisclosureOfFinancialAssetsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfFinancialInstrumentsNarrativeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments - narrative [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsNarrativeTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of impact on adoption of IFRS 16 [table text block]",
        "terseLabel": "Disclosure of impact on adoption of IFRS 16"
       }
      }
     },
     "localname": "DisclosureOfImpactOnAdoptionOfIFRS16TableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfIncomeTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Income Tax [abstract]"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Interest Expense and Other Financial Income and Expense [abstract]"
       }
      }
     },
     "localname": "DisclosureOfInterestExpenseAndOtherFinancialIncomeAndExpenseAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfLeasingCommitmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Leasing commitments [table text block]",
        "terseLabel": "Leasing commitments"
       }
      }
     },
     "localname": "DisclosureOfLeasingCommitmentsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of liabilities of disposal group classified as held for sale [table text block]",
        "terseLabel": "Liabilities of disposal group classified as held for sale"
       }
      }
     },
     "localname": "DisclosureOfLiabilitiesOfDisposalGroupClassifiedAsHeldForSaleTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of marketable securities commodities deposits derivative instruments and cash [abstract]"
       }
      }
     },
     "localname": "DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of marketable securities commodities deposits derivative instruments and cash [text block]",
        "terseLabel": "Disclosure of marketable securities commodities deposits derivative instruments and cash"
       }
      }
     },
     "localname": "DisclosureOfMarketableSecuritiesCommoditiesDepositsDerivativeInstrumentsAndCashTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis of lease liability [table text block]",
        "terseLabel": "Disclosure of maturity analysis of lease liability"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisOfLeaseLiabilityTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis of total lease liabilities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis of total lease liabilities [line items]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis of total lease liabilities [table]"
       }
      }
     },
     "localname": "DisclosureOfMaturityAnalysisOfTotalLeaseLiabilitiesTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of minimum finance lease payments [table text block]",
        "terseLabel": "Minimum finance lease payments"
       }
      }
     },
     "localname": "DisclosureOfMinimumFinanceLeasePaymentsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of monitoring of net debt or liquidity based on contractual maturities [table text block]",
        "terseLabel": "Monitoring of net debt or liquidity based on contractual maturities"
       }
      }
     },
     "localname": "DisclosureOfMonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Movements of goodwill and intangible assets [text block]",
        "terseLabel": "Movements of goodwill and intangible assets"
       }
      }
     },
     "localname": "DisclosureOfMovementsOfGoodwillAndIntangibleAssetsTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of net defined benefit liability (asset) [table text block]",
        "terseLabel": "Reconciliation of the net liability table"
       }
      }
     },
     "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of net gain at completion of spin-off [table text block]",
        "terseLabel": "Net gain at completion of spin-off"
       }
      }
     },
     "localname": "DisclosureOfNetGainAtCompletionOfSpinoffTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of net sales and selected non-current assets, by countries and regions [table text block]",
        "terseLabel": "Net sales and selected non-current assets, by countries and regions"
       }
      }
     },
     "localname": "DisclosureOfNetSalesAndSelectedNoncurrentAssetsByCountriesAndRegionsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of net sales, by segements and regions [table text block]",
        "terseLabel": "Net sales by region"
       }
      }
     },
     "localname": "DisclosureOfNetSalesBySegementsAndRegionsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-current financial debt including current portion by currency [table text block]",
        "terseLabel": "Non-current financial debt including current portion by currency"
       }
      }
     },
     "localname": "DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByCurrencyTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-current financial debt including current portion by maturity [table text block]",
        "terseLabel": "Non-current financial debt including current portion by maturity"
       }
      }
     },
     "localname": "DisclosureOfNoncurrentFinancialDebtIncludingCurrentPortionByMaturityTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-current portion of non-current borrowings by type [table text block]",
        "terseLabel": "Disclosure of non-current portion of non-current borrowings by type"
       }
      }
     },
     "localname": "DisclosureOfNoncurrentPortionOfNoncurrentBorrowingsByTypeTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of share options [roll forward]"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments, balance sheet and income statement [table text block]",
        "terseLabel": "Segmentation - Consolidated balance sheets and income statement"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsBalanceSheetAndIncomeStatementTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments, balance sheet [table text block]",
        "terseLabel": "Segmentation - Consolidated balance sheets"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsBalanceSheetTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments, by countries and regions [table text block]",
        "terseLabel": "Net sales and total of selected non-current assets, by countries and regions",
        "verboseLabel": "Net sales by region"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsByCountriesAndRegionsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments, net sales of Top 20 products [table text block]",
        "terseLabel": "Net sales of Top 20 products"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsNetSalesOfTop20ProductsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfOperatingSegmentsNetSalesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments, net sales [table text block]",
        "terseLabel": "Net sales"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsNetSalesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments, other revenue [table text block]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsOtherRevenueTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other contractual liabilities of the net debt or liquidity [table text block]",
        "terseLabel": "Other contractual liabilities of the net debt or liquidity"
       }
      }
     },
     "localname": "DisclosureOfOtherContractualLiabilitiesOfTheNetDebtOrLiquidityTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfOtherNoncurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other non-current assets [abstract]"
       }
      }
     },
     "localname": "DisclosureOfOtherNoncurrentAssetsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfOtherNoncurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other non-current assets [table text block]",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "DisclosureOfOtherNoncurrentAssetsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of provisions and other current liabilities [abstract]"
       }
      }
     },
     "localname": "DisclosureOfProvisionsAndOtherCurrentLiabilitiesAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of provisions and other current liabilities explanatory [text block]",
        "terseLabel": "Provisions and other current liabilities"
       }
      }
     },
     "localname": "DisclosureOfProvisionsAndOtherCurrentLiabilitiesExplanatoryTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfReceivablesDenominatedInVariousCurrenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of receivables denominated in various currencies [table]"
       }
      }
     },
     "localname": "DisclosureOfReceivablesDenominatedInVariousCurrenciesTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of recognized amount of inventory provisions and reversals of inventory provision [table text block]",
        "terseLabel": "Recognized amount of inventory provisions and reversals of inventory provision"
       }
      }
     },
     "localname": "DisclosureOfRecognizedAmountOfInventoryProvisionsAndReversalsOfInventoryProvisionTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of changes in fair value measurement [table text block]",
        "terseLabel": "Reconciliation of changes in fair value measurement"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfChangesInFairValueMeasurementTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of research and development commitments [table text block]",
        "terseLabel": "Research and Development and other intangible purchase commitments"
       }
      }
     },
     "localname": "DisclosureOfResearchAndDevelopmentCommitmentsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of right-of-use assets carrying value and depreciation charge [table text block]",
        "terseLabel": "Disclosure of right-of-use assets carrying value and depreciation charge"
       }
      }
     },
     "localname": "DisclosureOfRightofuseAssetsCarryingValueAndDepreciationChargeTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfRightofuseAssetsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Right-of-use assets roll forward [table text block]",
        "terseLabel": "Disclosure of Right-of-use assets roll forward"
       }
      }
     },
     "localname": "DisclosureOfRightofuseAssetsRollForwardTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfSignificantTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of significant transactions [abstract]"
       }
      }
     },
     "localname": "DisclosureOfSignificantTransactionsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfSignificantTransactionsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Significant transactions [text block]",
        "terseLabel": "Significant transactions"
       }
      }
     },
     "localname": "DisclosureOfSignificantTransactionsTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of ten day loss fair value VAR model, average, high, and low VAR amounts [table text block]",
        "terseLabel": "Ten day loss fair value VAR model, average, high, and low VAR amounts"
       }
      }
     },
     "localname": "DisclosureOfTenDayLossFairValueVARModelAverageHighAndLowVARAmountsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfTenDayLossFairValueVARModelTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of ten day loss fair value VAR model [table text block]",
        "terseLabel": "Ten day loss fair value VAR model"
       }
      }
     },
     "localname": "DisclosureOfTenDayLossFairValueVARModelTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of ten day loss fair value VAR model, worst case loss scenario [table text block]",
        "terseLabel": "Ten day loss fair value VAR model, worst case loss scenario"
       }
      }
     },
     "localname": "DisclosureOfTenDayLossFairValueVARModelWorstCaseLossScenarioTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of the collateralized non-current financial debt and pledged assets [abstract]"
       }
      }
     },
     "localname": "DisclosureOfTheCollateralizedNoncurrentFinancialDebtAndPledgedAssetsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfTradeReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of trade receivables [abstract]"
       }
      }
     },
     "localname": "DisclosureOfTradeReceivablesAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DisclosureOfTradeReceivablesExplanatoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of trade receivables explanatory [text block]",
        "terseLabel": "Trade receivables"
       }
      }
     },
     "localname": "DisclosureOfTradeReceivablesExplanatoryTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of unremitted earnings retained by consolidated entities for reinvestment [table text block]",
        "terseLabel": "Unremitted earnings retained by consolidated entities for reinvestment"
       }
      }
     },
     "localname": "DisclosureOfUnremittedEarningsRetainedByConsolidatedEntitiesForReinvestmentTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DisposalsAndRetirementsRightofuseAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposals and retirements, right-of-use assets",
        "negatedTerseLabel": "Impact of divestments"
       }
      }
     },
     "localname": "DisposalsAndRetirementsRightofuseAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DisposalsFairValueMeasurementAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposals fair value measurement assets",
        "negatedTerseLabel": "Disposals fair value measurement assets",
        "terseLabel": "Disposals fair value measurement assets"
       }
      }
     },
     "localname": "DisposalsFairValueMeasurementAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DistributionByWayOfDivindendInKindToShareholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for distribution by way of divindend in kind to shareholders",
        "terseLabel": "Distribution by way of dividend in kind to shareholders"
       }
      }
     },
     "localname": "DistributionByWayOfDivindendInKindToShareholders",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DistributionOfDividendBearingSharesToConsolidatedFoundations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Distribution of dividend to dividend bearing shares to consolidated foundations",
        "terseLabel": "Shares obtained through consolidated foundation"
       }
      }
     },
     "localname": "DistributionOfDividendBearingSharesToConsolidatedFoundations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DistributionOfDividendToDividendBearingShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Distribution of dividend to dividend bearing shares"
       }
      }
     },
     "localname": "DistributionOfDividendToDividendBearingShares",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DivestedCashAndCashEquivalents": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Divested cash and cash equivalents",
        "negatedTerseLabel": "Divested cash and cash equivalents"
       }
      }
     },
     "localname": "DivestedCashAndCashEquivalents",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DivestmentCostToSell": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Divestment cost to sell"
       }
      }
     },
     "localname": "DivestmentCostToSell",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DivestmentDateFairValueOfTotalConsiderationTransferred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consideration transferred, divestment-date fair value"
       }
      }
     },
     "localname": "DivestmentDateFairValueOfTotalConsiderationTransferred",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DivestmentFairValueOfContingentConsiderationReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of contingent consideration received"
       }
      }
     },
     "localname": "DivestmentFairValueOfContingentConsiderationReceived",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DivestmentsAquisitionsOfInterestsInAssociatedCompanies": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 15.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Divestments aquisitions of interests in associated companies",
        "terseLabel": "Acquisitions and divestments of interests in associated companies, net"
       }
      }
     },
     "localname": "DivestmentsAquisitionsOfInterestsInAssociatedCompanies",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DivestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Divestments [member]",
        "terseLabel": "Divestments"
       }
      }
     },
     "localname": "DivestmentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_DividendPaidNoncashAssetsDistribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend paid, non-cash assets distribution",
        "negatedTerseLabel": "Dividend in kind"
       }
      }
     },
     "localname": "DividendPaidNoncashAssetsDistribution",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_DividendTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend [table text block]",
        "terseLabel": "Schedule disclosing information related to Dividend"
       }
      }
     },
     "localname": "DividendTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_DividendsPayableAmountPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends payable, amount per share"
       }
      }
     },
     "localname": "DividendsPayableAmountPerShare",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "nvs_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_DrAlexKrauerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. Alex Krauer [member]"
       }
      }
     },
     "localname": "DrAlexKrauerMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_DrDanielVasellaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. Daniel Vasella [member]"
       }
      }
     },
     "localname": "DrDanielVasellaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_DrJamesBradnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. James Bradner [member]"
       }
      }
     },
     "localname": "DrJamesBradnerMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying value and remaining amortization period of the most significant assets within currently marketed products [text block]",
        "terseLabel": "Carrying value and remaining amortization period of the most significant assets within currently marketed products"
       }
      }
     },
     "localname": "Dup_1_CarryingValueAndRemainingAmortizationPeriodOfTheMostSignificantAssetsWithinCurrentlyMarketedProductsTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_EBEWEPharmaGes.m.b.HNfg.KGViennaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EBEWE Pharma Ges.m.b.H Nfg. KG, Unterach am Attersee [member]"
       }
      }
     },
     "localname": "EBEWEPharmaGes.m.b.HNfg.KGViennaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EffectOfDiscounting": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of discounting",
        "negatedTerseLabel": "Effect of discounting"
       }
      }
     },
     "localname": "EffectOfDiscounting",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EffectOfIncomeNotSubjectToTaxOnDivestmentGain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of income not subject to tax on divestment gain"
       }
      }
     },
     "localname": "EffectOfIncomeNotSubjectToTaxOnDivestmentGain",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_EffectOfUSTaxReformLegislation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of US tax reform legislation"
       }
      }
     },
     "localname": "EffectOfUSTaxReformLegislation",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_EffectOfWriteoffOfDeferredTaxAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax rate, effect of write-off of deferred tax assets",
        "terseLabel": "Effect of derecognition and reversals of derecognition of deferred tax assets"
       }
      }
     },
     "localname": "EffectOfWriteoffOfDeferredTaxAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective income tax rate reconciliation change in enacted tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective income tax rate reconciliation change in uncertain tax positions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_EliLillyAndCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eli Lilly and Company [member]",
        "terseLabel": "Eli Lilly and Company"
       }
      }
     },
     "localname": "EliLillyAndCompanyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EmergingGrowthMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Emerging Growth Markets [member]"
       }
      }
     },
     "localname": "EmergingGrowthMarketsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EmployerSharesHeldByDefinedBenefitPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares held by defined benefit plan"
       }
      }
     },
     "localname": "EmployerSharesHeldByDefinedBenefitPlan",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_EncoreVisionInc.EastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Encore Vision, Inc., East Hanover, NJ [member]"
       }
      }
     },
     "localname": "EncoreVisionInc.EastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EncoreVisionInc.NewYorkNYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Encore Vision, Inc., New York, NY [member]"
       }
      }
     },
     "localname": "EncoreVisionInc.NewYorkNYMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EncoreVisionIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Encore Vision, Inc [member]",
        "terseLabel": "Encore Vision, Inc."
       }
      }
     },
     "localname": "EncoreVisionIncMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EndocyteInc.EastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Endocyte, Inc., East Hanover, NJ [member]"
       }
      }
     },
     "localname": "EndocyteInc.EastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EndocyteInc.LafayetteINMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Endocyte, Inc., Lafayette, IN [member]"
       }
      }
     },
     "localname": "EndocyteInc.LafayetteINMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EndocyteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Endocyte [member]",
        "terseLabel": "Endocyte"
       }
      }
     },
     "localname": "EndocyteMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EnoxaparinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Enoxaparin [member]"
       }
      }
     },
     "localname": "EnoxaparinMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EntrestoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entresto [member]"
       }
      }
     },
     "localname": "EntrestoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EnvironmentalProvision": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual for environmental loss contingencies",
        "periodEndLabel": "Environmental liabilities provision at end of period",
        "periodStartLabel": "Environmental liabilities provision at beginning of period",
        "totalLabel": "Total environmental remediation liability provisions"
       }
      }
     },
     "localname": "EnvironmentalProvision",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EnvironmentalProvisionAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual for environmental loss contingencies, additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "EnvironmentalProvisionAdditions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EnvironmentalProvisionCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual for environmental loss contingencies, Current",
        "negatedTerseLabel": "Less current provision",
        "verboseLabel": "Environmental remediation liabilities"
       }
      }
     },
     "localname": "EnvironmentalProvisionCurrent",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EnvironmentalProvisionExpectedCashOutflowAfterTenYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Environmental provision, expected cash outflow, after ten years",
        "terseLabel": "Due after ten years"
       }
      }
     },
     "localname": "EnvironmentalProvisionExpectedCashOutflowAfterTenYears",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Environmental provision, expected cash outflow, later than five years, but within ten years",
        "terseLabel": "Due later than five years, but within ten years"
       }
      }
     },
     "localname": "EnvironmentalProvisionExpectedCashOutflowLaterThanFiveYearsButWithinTenYears",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Environmental provision, expected cash outflow, later than two years, but within five years",
        "terseLabel": "Due later than two years, but within five years"
       }
      }
     },
     "localname": "EnvironmentalProvisionExpectedCashOutflowLaterThanTwoYearsButWithinFiveYears",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EnvironmentalProvisionExpectedCashOutflowNextTwoYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Environmental provision, expected cash outflow, next two years",
        "terseLabel": "Due within two years"
       }
      }
     },
     "localname": "EnvironmentalProvisionExpectedCashOutflowNextTwoYears",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EnvironmentalProvisionFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Environmental provision, fiscal year maturity [abstract]"
       }
      }
     },
     "localname": "EnvironmentalProvisionFiscalYearMaturityAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_EnvironmentalProvisionForeignCurrencyTranslationGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual for environmental loss contingencies, foreign currency translation gain (loss)",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "EnvironmentalProvisionForeignCurrencyTranslationGainLoss",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EnvironmentalProvisionPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual for environmental loss contingencies, payments",
        "terseLabel": "Cash payments"
       }
      }
     },
     "localname": "EnvironmentalProvisionPayments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EnvironmentalProvisionReleases": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual for environmental loss contingencies, releases",
        "negatedTerseLabel": "Releases"
       }
      }
     },
     "localname": "EnvironmentalProvisionReleases",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EnvironmentalProvisionRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Environmental provision [roll forward]"
       }
      }
     },
     "localname": "EnvironmentalProvisionRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_EnvironmentalRemediationProvisionNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_OtherNoncurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Environmental remediation provisions, non-current",
        "periodEndLabel": "Non-current environmental remediation provisions at end of period",
        "terseLabel": "Environmental remediation provisions"
       }
      }
     },
     "localname": "EnvironmentalRemediationProvisionNoncurrent",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EonLabsInc.PrincetonNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eon Labs, Inc., Princeton, NJ [member]"
       }
      }
     },
     "localname": "EonLabsInc.PrincetonNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedCompensationShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity based compensation shares"
       }
      }
     },
     "localname": "EquityBasedCompensationShares",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_EquityBasedParticipationAnnualIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Annual Incentive Plan [member]",
        "terseLabel": "Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationAnnualIncentivePlanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationAnnualIncentiveRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Annual Incentive RSU [member]",
        "terseLabel": "dup_1_Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationAnnualIncentiveRSUMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationAnnualIncentiveRestrictedSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Based Participation Annual Incentive Restricted Shares [member]",
        "terseLabel": "dup_2_Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationAnnualIncentiveRestrictedSharesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationAnnualIncentiveSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Based Participation Annual Incentive Shares [member]",
        "terseLabel": "dup_3_Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationAnnualIncentiveSharesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationEmployeeShareOwnershipPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Employee Share Ownership Plan [member]",
        "terseLabel": "Employee Share Ownership Plan (ESOP)"
       }
      }
     },
     "localname": "EquityBasedParticipationEmployeeShareOwnershipPlanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationEmployeeSharePurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Employee share purchase plan [member]",
        "terseLabel": "Share purchase plans"
       }
      }
     },
     "localname": "EquityBasedParticipationEmployeeSharePurchasePlanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationLeveragedShareSavingsPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Leveraged Share Savings Plan [member]",
        "terseLabel": "Leveraged Share Savings Plan (LSSP)"
       }
      }
     },
     "localname": "EquityBasedParticipationLeveragedShareSavingsPlanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationLongTermPerformancePSUPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Based Participation Long Term Performance PSU Plan [member]",
        "terseLabel": "dup_9_Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationLongTermPerformancePSUPlanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationLongTermPerformancePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Long-Term Performance Plan [member]",
        "terseLabel": "Long-Term Performance Plan"
       }
      }
     },
     "localname": "EquityBasedParticipationLongTermPerformancePlanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationLongTermRelativePerformancePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Long Term Relative Performance Plan [member]",
        "terseLabel": "Long-Term Relative Performance Plan"
       }
      }
     },
     "localname": "EquityBasedParticipationLongTermRelativePerformancePlanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationLongTermRelativePerformancePlanPSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Based Participation Long Term Relative Performance Plan PSU [member]"
       }
      }
     },
     "localname": "EquityBasedParticipationLongTermRelativePerformancePlanPSUMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationNovartisEquityPlanSelectMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Novartis Equity Plan \"Select\" [member]",
        "terseLabel": "Select"
       }
      }
     },
     "localname": "EquityBasedParticipationNovartisEquityPlanSelectMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Novartis Equity Plan \"Select\", North America [member]",
        "terseLabel": "Select North America"
       }
      }
     },
     "localname": "EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Based Participation Novartis Equity Plan Select North America RSU [member]",
        "terseLabel": "dup_6_Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaRSUMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Novartis Equity Plan \"Select\", outside North America [member]",
        "terseLabel": "Select outside North America"
       }
      }
     },
     "localname": "EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Based Participation Novartis Equity Plan Select outside North America Restricted Shares [member]",
        "terseLabel": "dup_8_Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaRestrictedSharesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationOtherShareAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Other Share Awards [member]",
        "terseLabel": "Other share awards"
       }
      }
     },
     "localname": "EquityBasedParticipationOtherShareAwardsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationOtherShareAwardsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Based Participation Other share awards RSU [member]",
        "terseLabel": "dup_11_Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationOtherShareAwardsRSUMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationOtherShareAwardsRestrictedSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Based Participation Other share awards Restricted Shares [member]",
        "terseLabel": "dup_12_Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationOtherShareAwardsRestrictedSharesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationOtherShareAwardsSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Based Participation Other share awards Shares [member]",
        "terseLabel": "dup_13_Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationOtherShareAwardsSharesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationRestrictedSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Restricted Shares [member]",
        "terseLabel": "Restricted Shares"
       }
      }
     },
     "localname": "EquityBasedParticipationRestrictedSharesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationShareSavingsPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Share Savings Plan [member]",
        "terseLabel": "Share savings plans"
       }
      }
     },
     "localname": "EquityBasedParticipationShareSavingsPlanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationShareSavingsPlansRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Based Participation Share savings plans RSU [member]",
        "terseLabel": "dup_4_Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationShareSavingsPlansRSUMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationShareSavingsPlansSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Based Participation Share savings plans Shares [member]",
        "terseLabel": "dup_5_Annual incentive"
       }
      }
     },
     "localname": "EquityBasedParticipationShareSavingsPlansSharesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationSpecialShareAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation Special Share Awards [member]",
        "terseLabel": "Special share awards"
       }
      }
     },
     "localname": "EquityBasedParticipationSpecialShareAwardsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityBasedParticipationUKShareSavingsPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-Based Participation UK Share Savings Plan [member]",
        "terseLabel": "UK Share Savings Plan"
       }
      }
     },
     "localname": "EquityBasedParticipationUKShareSavingsPlanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EquityImpactOfTreasuryShareMovements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity impact of treasury share movements",
        "negatedTotalLabel": "Total equity impact of treasury share movements",
        "totalLabel": "Total equity impact of treasury share movements"
       }
      }
     },
     "localname": "EquityImpactOfTreasuryShareMovements",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.",
        "label": "Equity price sensitivity impact of the risk factors in the equity"
       }
      }
     },
     "localname": "EquityPriceSensitivityImpactOfTheRiskFactorsInTheEquity",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.",
        "label": "Equity price sensitivity impact of the risk factors in the income statement"
       }
      }
     },
     "localname": "EquityPriceSensitivityImpactOfTheRiskFactorsInTheIncomeStatement",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity securities [member]"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EstablishedBrandsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Established Brands [member]"
       }
      }
     },
     "localname": "EstablishedBrandsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EstablishedMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Established Markets [member]"
       }
      }
     },
     "localname": "EstablishedMarketsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_EstimatedAcquisitionFairValueOfTotalConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated acquisition fair value of total consideration",
        "terseLabel": "Estimated fair value purchase price"
       }
      }
     },
     "localname": "EstimatedAcquisitionFairValueOfTotalConsideration",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated financial effect of contingent liabilities, compensation for moral damages"
       }
      }
     },
     "localname": "EstimatedFinancialEffectOfContingentLiabilitiesCompensationForMoralDamages",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated financial effect of contingent liabilities, damages claimed"
       }
      }
     },
     "localname": "EstimatedFinancialEffectOfContingentLiabilitiesDamagesClaimed",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This expresses a maximal amount.",
        "label": "Estimated financial effect of contingent liabilities, maximum fine"
       }
      }
     },
     "localname": "EstimatedFinancialEffectOfContingentLiabilitiesMaximumFine",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ExelonExelonPatchMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exelon/Exelon Patch [member]"
       }
      }
     },
     "localname": "ExelonExelonPatchMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExerciseOfOptionsAndEmployeeTransactionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of options and employee transactions shares"
       }
      }
     },
     "localname": "ExerciseOfOptionsAndEmployeeTransactionsShares",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_ExercisePrice46.4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, 46.4 [member]",
        "terseLabel": "46.4"
       }
      }
     },
     "localname": "ExercisePrice46.4Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExercisePrice46.7Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, 46.7 [member]",
        "terseLabel": "46.7"
       }
      }
     },
     "localname": "ExercisePrice46.7Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExercisePrice53.7Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, 53.7 [member]",
        "terseLabel": "53.7"
       }
      }
     },
     "localname": "ExercisePrice53.7Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExercisePrice54.5Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, 54.5 [member]",
        "terseLabel": "54.5"
       }
      }
     },
     "localname": "ExercisePrice54.5Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExercisePrice57.0Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, 57.0 [member]",
        "terseLabel": "57.0"
       }
      }
     },
     "localname": "ExercisePrice57.0Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExercisePrice57.1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, 57.1 [member]",
        "terseLabel": "57.1"
       }
      }
     },
     "localname": "ExercisePrice57.1Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExercisePrice57.6Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, 57.6 [member]",
        "terseLabel": "57.6"
       }
      }
     },
     "localname": "ExercisePrice57.6Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExercisePrice58.3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, 58.3 [member]",
        "terseLabel": "58.3"
       }
      }
     },
     "localname": "ExercisePrice58.3Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExercisePrice65.9Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, 65.9 [member]",
        "terseLabel": "65.9"
       }
      }
     },
     "localname": "ExercisePrice65.9Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExercisePrice66.0Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, 66.0 [member]",
        "terseLabel": "66.0"
       }
      }
     },
     "localname": "ExercisePrice66.0Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExercisePrice66.1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price, 66.1 [member]",
        "terseLabel": "66.1"
       }
      }
     },
     "localname": "ExercisePrice66.1Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExforgeGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exforge Group [member]"
       }
      }
     },
     "localname": "ExforgeGroupMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ExjadeJadenuMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exjade/Jadenu [member]"
       }
      }
     },
     "localname": "ExjadeJadenuMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FHoffmanLaRocheAGAndRocheSpAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "F Hoffman La Roche AG and Roche SpA [member]"
       }
      }
     },
     "localname": "FHoffmanLaRocheAGAndRocheSpAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustments financial instruments reconciliation [table text block]",
        "terseLabel": "Fair value adjustments financial instruments reconciliation"
       }
      }
     },
     "localname": "FairValueAdjustmentsFinancialInstrumentsReconciliationTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_FairValueAdjustmentsOnDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustments on debt securities [member]",
        "terseLabel": "Fair value adjustments on debt securities"
       }
      }
     },
     "localname": "FairValueAdjustmentsOnDebtSecuritiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FairValueAdjustmentsOnDeferredCashFlowHedgesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustments on deferred cash flow hedges [member]",
        "terseLabel": "Fair value adjustments on deferred cash flow hedges"
       }
      }
     },
     "localname": "FairValueAdjustmentsOnDeferredCashFlowHedgesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FairValueAdjustmentsOnEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustments on equity securities [member]",
        "terseLabel": "Fair value adjustments on equity securities"
       }
      }
     },
     "localname": "FairValueAdjustmentsOnEquitySecuritiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FairValueAdjustmentsOnEquitySecuritiesSoldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustments on equity securities sold [member]",
        "terseLabel": "Fair value adjustments on equity securities sold"
       }
      }
     },
     "localname": "FairValueAdjustmentsOnEquitySecuritiesSoldMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FairValueAdjustmentsOnFinancialAssetsSold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustments on financial assets sold",
        "negatedTerseLabel": "Fair value adjustments on financial assets sold",
        "terseLabel": "Fair value adjustments on equity securities sold, reclassified to retained earnings"
       }
      }
     },
     "localname": "FairValueAdjustmentsOnFinancialAssetsSold",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FairValueAdjustmentsOnFinancialInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustments on financial instruments [member]",
        "terseLabel": "dup_1_Fair value adjustments on marketable securities"
       }
      }
     },
     "localname": "FairValueAdjustmentsOnFinancialInstrumentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FairValueAdjustmentsOnMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustments on marketable securities [member]",
        "terseLabel": "Fair value adjustments on marketable securities"
       }
      }
     },
     "localname": "FairValueAdjustmentsOnMarketableSecuritiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This amount can be a debit or a credit as the table discloses the fair value gain and loses on assets and liabilities.",
        "label": "Fair value adjustments recognized in the consolidated statement of comprehensive income"
       }
      }
     },
     "localname": "FairValueAdjustmentsRecognizedInTheConsolidatedStatementOfComprehensiveIncome",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FairValueAdjustmentsRelatedToDivestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustments related to divestments"
       }
      }
     },
     "localname": "FairValueAdjustmentsRelatedToDivestments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FairValueByMeasurementBasisAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value by measurement basis [axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_FairValueByMeasurementBasisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value by measurement basis [member]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FairValueDisclosureItemAmountsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value disclosure item amounts [member]",
        "terseLabel": "Fair values"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This amount can be a debit or a credit as the table discloses the fair value gain and loses on assets and liabilities.",
        "label": "Fair value gains and losses recognized in the consolidated income statement for assets and liabilities held",
        "terseLabel": "Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end"
       }
      }
     },
     "localname": "FairValueGainsAndLossesRecognizedInTheConsolidatedIncomeStatementForAssetsAndLiabilitiesHeld",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of assets and liabilities arising from acquisitions [table text block]",
        "terseLabel": "Fair value of assets and liabilities arising from acquisitions"
       }
      }
     },
     "localname": "FairValueOfAssetsAndLiabilitiesArisingFromAcquisitionsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_FairValueOfFundInvestmentsAndEquitySecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of fund investments and equity securities"
       }
      }
     },
     "localname": "FairValueOfFundInvestmentsAndEquitySecurities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FairValueOfOtherFinancialAssetsSold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of other financial assets sold"
       }
      }
     },
     "localname": "FairValueOfOtherFinancialAssetsSold",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Farmanova Saglik Hizmetleri Ltd. Sti., Istanbul [member]"
       }
      }
     },
     "localname": "FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FinanceLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease liabilities",
        "terseLabel": "Finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeaseLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FinanceLeaseObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligations [member]"
       }
      }
     },
     "localname": "FinanceLeaseObligationsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FinancialAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 6.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current financial and other assets"
       }
      }
     },
     "localname": "FinancialAndOtherAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FinancialDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial debt [member]"
       }
      }
     },
     "localname": "FinancialDebtMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FinancialDebtUndiscountedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial debt - undiscounted [member]"
       }
      }
     },
     "localname": "FinancialDebtUndiscountedMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FinancialDebtsAndDerivativeInstruments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial debts and derivative instruments",
        "periodEndLabel": "Financial debts and derivative instruments at end of period",
        "periodStartLabel": "Financial debts and derivative instruments at beginning of period"
       }
      }
     },
     "localname": "FinancialDebtsAndDerivativeInstruments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FinancialInstrumentsAdditionalDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments - additional disclosure [abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsAdditionalDisclosureAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_FinancialInstrumentsCarryingValueLevel3": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value measurement, carrying value, level 3",
        "periodEndLabel": "Fair value measurement, carrying value, level 3, at end of period",
        "periodStartLabel": "Fair value measurement, carrying value, level 3, at beginning of period"
       }
      }
     },
     "localname": "FinancialInstrumentsCarryingValueLevel3",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FinancialInstrumentsPrincipalAmountsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments, principal amounts [axis]"
       }
      }
     },
     "localname": "FinancialInstrumentsPrincipalAmountsAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_FinancialInstrumentsPrincipalAmountsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments, principal amounts [member]"
       }
      }
     },
     "localname": "FinancialInstrumentsPrincipalAmountsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FinancialInstrumentsValueAtRiskComputation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments, value at risk computation",
        "terseLabel": "All financial instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsValueAtRiskComputation",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments, value at risk computation, sensitive to equity market movements",
        "terseLabel": "Instruments sensitive to equity market movements"
       }
      }
     },
     "localname": "FinancialInstrumentsValueAtRiskComputationSensitiveToEquityMarketMovements",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments, value at risk computation, sensitive to foreign currency exchange rates",
        "terseLabel": "Instruments sensitive to foreign currency exchange rates"
       }
      }
     },
     "localname": "FinancialInstrumentsValueAtRiskComputationSensitiveToForeignCurrencyExchangeRates",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments, value at risk computation, sensitive to interest rates",
        "terseLabel": "Instruments sensitive to interest rates"
       }
      }
     },
     "localname": "FinancialInstrumentsValueAtRiskComputationSensitiveToInterestRates",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FinancialInvestmentsAndLongtermLoansGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial investments and long-term loans [member]"
       }
      }
     },
     "localname": "FinancialInvestmentsAndLongtermLoansGroupMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FiveYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Five years [member]"
       }
      }
     },
     "localname": "FiveYearsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FougeraPharmaceuticalsInc.MelvilleNYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fougera Pharmaceuticals Inc., Melville, NY [member]"
       }
      }
     },
     "localname": "FougeraPharmaceuticalsInc.MelvilleNYMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FourYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four years [member]"
       }
      }
     },
     "localname": "FourYearsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FranchiseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Franchise [axis]"
       }
      }
     },
     "localname": "FranchiseAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_FranchiseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Franchise [member]"
       }
      }
     },
     "localname": "FranchiseMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FundInstrumentsHeld": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "nvs_MarketableSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fund instruments held",
        "terseLabel": "Fund investments"
       }
      }
     },
     "localname": "FundInstrumentsHeld",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_FundInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fund investments [member]"
       }
      }
     },
     "localname": "FundInvestmentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_FuturePutOptionToSellBusiness": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Future put option to sell business"
       }
      }
     },
     "localname": "FuturePutOptionToSellBusiness",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_GSKConsumerHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GSK Consumer Healthcare [member]",
        "terseLabel": "GSK Consumer Healthcare"
       }
      }
     },
     "localname": "GSKConsumerHealthcareMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GSKOncologyProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GSK Oncology Products [member]",
        "terseLabel": "GSK Oncology Products"
       }
      }
     },
     "localname": "GSKOncologyProductsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GSKTotalTransactionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GSK Total Transaction [member]",
        "terseLabel": "GSK Total Transaction"
       }
      }
     },
     "localname": "GSKTotalTransactionMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GSKVaccinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GSK Vaccines [member]",
        "terseLabel": "GSK Vaccines"
       }
      }
     },
     "localname": "GSKVaccinesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GainLossOnSaleOfOtherFinancialAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (loss) on sale of other financial assets",
        "terseLabel": "Other financial assets sold"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherFinancialAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_GainOnDivestmentOfInterestsInAssociatedCompanies": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on divestment of interests in associated companies",
        "terseLabel": "Gain on divestment"
       }
      }
     },
     "localname": "GainOnDivestmentOfInterestsInAssociatedCompanies",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gains (losses) on value adjustment on comprehensive income",
        "totalLabel": "Total value adjustments"
       }
      }
     },
     "localname": "GainsLossesOnValueAdjustmentOnComprehensiveIncome",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_GainsRecognisedInProfitOrLossFairValueMeasurementAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value gains and other adjustments including from divestments recognized in the consolidated income statement"
       }
      }
     },
     "localname": "GainsRecognisedInProfitOrLossFairValueMeasurementAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_GalvusGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Galvus Group [member]"
       }
      }
     },
     "localname": "GalvusGroupMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GenentechInc.USAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Genentech, Inc., USA [member]"
       }
      }
     },
     "localname": "GenentechInc.USAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GenentechRocheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Genentech / Roche [member]"
       }
      }
     },
     "localname": "GenentechRocheMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GilenyaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gilenya [member]"
       }
      }
     },
     "localname": "GilenyaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GlaxoSmithKline Consumer Healthcare Holdings Ltd. [member]",
        "terseLabel": "GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK"
       }
      }
     },
     "localname": "GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GlaxoSmithKlinePlcGSKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GlaxoSmithKline plc (GSK) [member]",
        "terseLabel": "GlaxoSmithKline plc (GSK)"
       }
      }
     },
     "localname": "GlaxoSmithKlinePlcGSKMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Glaxosmithkline Consumer Healthcare Holdings Limited, Brentford, Middlesex [member]",
        "terseLabel": "Glaxosmithkline Consumer Healthcare Holdings Limited, Brentford, Middlesex"
       }
      }
     },
     "localname": "GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GleevecGlivecMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gleevec/Glivec [member]"
       }
      }
     },
     "localname": "GleevecGlivecMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GleevecMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gleevec [member]"
       }
      }
     },
     "localname": "GleevecMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GrossDeferredTaxAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross deferred tax assets"
       }
      }
     },
     "localname": "GrossDeferredTaxAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_GrossDeferredTaxLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross deferred tax liabilities",
        "negatedTerseLabel": "Gross deferred tax liabilities"
       }
      }
     },
     "localname": "GrossDeferredTaxLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_GrossLeaseLiabilitiesDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross lease liabilities, Discontinued operations",
        "terseLabel": "Operating lease commitments, discontinued operations"
       }
      }
     },
     "localname": "GrossLeaseLiabilitiesDiscontinuedOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross trade receivable from closely monitored countries [table text block]",
        "terseLabel": "Gross trade receivable from closely monitored countries"
       }
      }
     },
     "localname": "GrossTradeReceivableFromCloselyMonitoredCountriesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross value of tax loss carry forwards expiring in future years",
        "terseLabel": "Gross Value of tax loss carryforwards that have or have not been capitalized as deferred tax assets"
       }
      }
     },
     "localname": "GrossValueOfTaxLossCarryForwardsThatHaveOrHaveNotBeenCapitalizedAsDeferredTaxAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_GroupsOfFinancialAssetsLiabilitiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Groups of financial assets/liabilities [axis]"
       }
      }
     },
     "localname": "GroupsOfFinancialAssetsLiabilitiesAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_GroupsOfFinancialAssetsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Groups of financial assets/liabilities [member]"
       }
      }
     },
     "localname": "GroupsOfFinancialAssetsLiabilitiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GyroscopeTherapeuticsHoldingsPlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gyroscope Therapeutics Holdings plc. [member]",
        "terseLabel": "Gyroscope Therapeutics Holdings plc."
       }
      }
     },
     "localname": "GyroscopeTherapeuticsHoldingsPlcMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_GyroscopeTherapeuticsLimitedLondonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gyroscope Therapeutics Limited, London [member]"
       }
      }
     },
     "localname": "GyroscopeTherapeuticsLimitedLondonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_HEXALAGHolzkirchenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "HEXAL AG, Holzkirchen [member]"
       }
      }
     },
     "localname": "HEXALAGHolzkirchenMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_HematologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hematology [member]"
       }
      }
     },
     "localname": "HematologyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_Hypothetical100basisPointDecreaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hypothetical 100-basis point decrease [member]"
       }
      }
     },
     "localname": "Hypothetical100basisPointDecreaseMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_Hypothetical100basisPointIncreaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hypothetical 100-basis point increase [member]"
       }
      }
     },
     "localname": "Hypothetical100basisPointIncreaseMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_Hypothetical15DecreaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hypothetical 15% decrease [member]"
       }
      }
     },
     "localname": "Hypothetical15DecreaseMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_Hypothetical15IncreaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hypothetical 15% increase [member]"
       }
      }
     },
     "localname": "Hypothetical15IncreaseMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_Hypothetical5DecreaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hypothetical 5% decrease [member]"
       }
      }
     },
     "localname": "Hypothetical5DecreaseMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_Hypothetical5IncreaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hypothetical 5% increase [member]"
       }
      }
     },
     "localname": "Hypothetical5IncreaseMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hypothetical increase decrease basis point in interest rate sensitivity"
       }
      }
     },
     "localname": "HypotheticalIncreaseDecreaseBasisPointInInterestRateSensitivity",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17"
     ],
     "xbrltype": "decimalItemType"
    },
    "nvs_HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hypothetical increase decrease percentage in currency rate sensitivity"
       }
      }
     },
     "localname": "HypotheticalIncreaseDecreasePercentageInCurrencyRateSensitivity",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hypothetical increase decrease percentage in equity price sensitivity"
       }
      }
     },
     "localname": "HypotheticalIncreaseDecreasePercentageInEquityPriceSensitivity",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_IDBHollandBVBaarleNassauMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IDB Holland BV, Baarle-Nassau [member]"
       }
      }
     },
     "localname": "IDBHollandBVBaarleNassauMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_IDBHollandBVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IDB Holland BV [member]"
       }
      }
     },
     "localname": "IDBHollandBVMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_IFMTreInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IFM Tre, Inc. [member]",
        "terseLabel": "IFM Tre, Inc."
       }
      }
     },
     "localname": "IFMTreInc.Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_IdentifiableAssetsAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Identifiable assets acquired",
        "totalLabel": "Net identifiable assets acquired"
       }
      }
     },
     "localname": "IdentifiableAssetsAcquired",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IlarisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ilaris [member]"
       }
      }
     },
     "localname": "IlarisMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ImagingEquipmentLtdLondonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Imaging Equipment Ltd, London [member]"
       }
      }
     },
     "localname": "ImagingEquipmentLtdLondonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ImagingEquipmentLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Imaging Equipment Ltd [member]"
       }
      }
     },
     "localname": "ImagingEquipmentLtdMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Immunology [member]"
       }
      }
     },
     "localname": "ImmunologyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ImpactLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact location [axis]"
       }
      }
     },
     "localname": "ImpactLocationAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ImpactLocationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact location [member]"
       }
      }
     },
     "localname": "ImpactLocationMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ImpactOfDivestmentsOtherProvisions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of divestments, other provisions",
        "terseLabel": "Impact of divestments"
       }
      }
     },
     "localname": "ImpactOfDivestmentsOtherProvisions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax law change in deferred tax assets and liabilities and current tax liabilities",
        "negatedTerseLabel": "Total revaluation of deferred tax assets and liabilities and current income tax liabilities"
       }
      }
     },
     "localname": "ImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax law deferred tax expense income recognised in profit or loss",
        "negatedTerseLabel": "Items previously recognized in consolidated income statement"
       }
      }
     },
     "localname": "ImpactOfNewTaxLawDeferredTaxExpenseIncomeRecognisedInProfitOrLoss",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax law deferred tax relating to components of other comprehensive income",
        "negatedTerseLabel": "Items previously recognized in other comprehensive income"
       }
      }
     },
     "localname": "ImpactOfNewTaxLawDeferredTaxRelatingToComponentsOfOtherComprehensiveIncome",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax law effective tax rate after implemetation of new law changes"
       }
      }
     },
     "localname": "ImpactOfNewTaxLawEffectiveTaxRateAfterImplemetationOfNewLawChanges",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax law income tax relating to deferred tax assets on Swiss post retirement previously recognized through OCI",
        "negatedTerseLabel": "Impact of new tax law income tax relating to deferred tax assets on Swiss post retirement previously recognized through OCI"
       }
      }
     },
     "localname": "ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnSwissPostRetirementPreviouslyRecognizedThroughOCI",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax law income tax relating to deferred tax assets on unremitted earnings"
       }
      }
     },
     "localname": "ImpactOfNewTaxLawIncomeTaxRelatingToDeferredTaxAssetsOnUnremittedEarnings",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax law income tax relating to revaluation of deferred tax assets on equity based compensation that were previously recognized through retained earnings",
        "negatedTerseLabel": "Impact of new tax law income tax relating to revaluation of deferred tax assets on equity based compensation that were previously recognized through retained earnings"
       }
      }
     },
     "localname": "ImpactOfNewTaxLawIncomeTaxRelatingToRevaluationOfDeferredTaxAssetsOnEquityBasedCompensationThatWerePreviouslyRecognizedThroughRetainedEarnings",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax law increase decrease in current income tax liability",
        "negatedTerseLabel": "Total revaluation of current income tax liabilities"
       }
      }
     },
     "localname": "ImpactOfNewTaxLawIncreaseDecreaseInCurrentIncomeTaxLiability",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax law increase decrease in deferred tax liability asset",
        "negatedTerseLabel": "Total revaluation of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ImpactOfNewTaxLawIncreaseDecreaseInDeferredTaxLiabilityAsset",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax law tax on unremitted earnings period allowed for payment"
       }
      }
     },
     "localname": "ImpactOfNewTaxLawTaxOnUnremittedEarningsPeriodAllowedForPayment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "durationItemType"
    },
    "nvs_ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax reform applicable blended tax rate after implemetation of new reform changes"
       }
      }
     },
     "localname": "ImpactOfNewTaxReformEffectiveBlendedTaxRateAfterImplemetationOfNewReformChanges",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of new tax reform applicable tax rate after implemetation of new reform changes"
       }
      }
     },
     "localname": "ImpactOfNewTaxReformEffectiveTaxRateAfterImplemetationOfNewReformChanges",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_ImpairmentChargePriorToClassificationToAssetsHeldForSale": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment charge prior to classification to assets held for sale",
        "negatedTerseLabel": "Impairment charge prior to classification to assets held for sale"
       }
      }
     },
     "localname": "ImpairmentChargePriorToClassificationToAssetsHeldForSale",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment charges and fair value gains on financial assets, net",
        "negatedTerseLabel": "Impairment charges and fair value gains on financial assets, net",
        "terseLabel": "Impairment charges and fair value gains on financial assets, net"
       }
      }
     },
     "localname": "ImpairmentChargesAndFairValueGainsOnFinancialAssetsNet",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment charges related to disposal group held for sale"
       }
      }
     },
     "localname": "ImpairmentChargesRelatedToDisposalGroupHeldForSale",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment charges related to disposal group held for sale to the date of reclassification"
       }
      }
     },
     "localname": "ImpairmentChargesRelatedToDisposalGroupHeldForSaleToTheDateOfReclassification",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2": {
       "order": 5.5,
       "parentTag": "ifrs-full_OtherFinanceIncomeCost",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment loss on commodities and available-for-sale securities, net",
        "negatedTerseLabel": "Impairment of commodities and available-for-sale securities, net"
       }
      }
     },
     "localname": "ImpairmentLossOnCommoditiesAndAvailableforsaleSecuritiesNet",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment loss recognised in profit or loss, right of use assets",
        "negatedTerseLabel": "Impairment loss recognised in profit or loss, right of use assets"
       }
      }
     },
     "localname": "ImpairmentLossRecognisedInProfitOrLossRightOfUseAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncomeBeforeTaxesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Before Taxes [table text block]",
        "terseLabel": "Income before taxes"
       }
      }
     },
     "localname": "IncomeBeforeTaxesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_IncomeOnForwardContractsAndOptions": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2": {
       "order": 4.0,
       "parentTag": "ifrs-full_OtherFinanceIncomeCost",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income on forward contracts and options"
       }
      }
     },
     "localname": "IncomeOnForwardContractsAndOptions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncomeStatementAdjustmentsOfCurrentYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income statement adjustments of current year",
        "terseLabel": "Additions current year"
       }
      }
     },
     "localname": "IncomeStatementAdjustmentsOfCurrentYear",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncomeStatementAdjustmentsOfPriorYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income statement adjustments of prior year",
        "terseLabel": "Additions prior year"
       }
      }
     },
     "localname": "IncomeStatementAdjustmentsOfPriorYear",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncomeStatementLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income statement location [axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_IncomeStatementLocationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income statement location [member]"
       }
      }
     },
     "localname": "IncomeStatementLocationMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_IncomeStatementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income statement [member]"
       }
      }
     },
     "localname": "IncomeStatementMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_IncomeTaxExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax expense",
        "negatedTerseLabel": "Total Income Tax Expense",
        "totalLabel": "Total Income Tax Expense"
       }
      }
     },
     "localname": "IncomeTaxExpense",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_Increase1YearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase, 1 year [member]",
        "terseLabel": "1 year increase"
       }
      }
     },
     "localname": "Increase1YearMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_Increase25BasisPointMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase, 25 basis point [member]",
        "terseLabel": "25 basis point increase"
       }
      }
     },
     "localname": "Increase25BasisPointMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) due to changes in accounting policy, IFRS 16 [member]"
       }
      }
     },
     "localname": "IncreaseDecreaseDueToChangesInAccountingPolicyIFRS16Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) due to changes in accounting policy, IFRS 9 [member]",
        "terseLabel": "Adjustment, IFRS 9"
       }
      }
     },
     "localname": "IncreaseDecreaseDueToChangesInAccountingPolicyIFRS9Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase/decrease due to revision of prior year amounts [member]"
       }
      }
     },
     "localname": "IncreaseDecreaseDueToRevisionOfPriorYearAmountsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase/decrease in fair value measurement liabilities",
        "negatedTerseLabel": "Changes in fair values, lease interest and other changes, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInFairValueMeasurementLiabilitiesAndOtherChanges",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseInNoncontrolingInterests": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in non-controling interests",
        "terseLabel": "Changes in non-controlling interests"
       }
      }
     },
     "localname": "IncreaseDecreaseInNoncontrolingInterests",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase/decrease of treasury share repurchase obligation under a share buyback trading plan",
        "negatedTerseLabel": "Increase/decrease of treasury share repurchase obligation under a share buyback trading plan",
        "terseLabel": "(Increase)/decrease of treasury share repurchase obligation under a share buyback trading plan"
       }
      }
     },
     "localname": "IncreaseDecreaseOfTreasuryShareRepurchaseObligationUnderAShareBuybackTradingPlan",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through acquisitions, divestments or transfers, benefit obligation",
        "terseLabel": "Effect of acquisitions, divestments or transfers"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersBenefitObligation1",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through acquisitions, divestments or transfers, defined benefit liability (asset)",
        "negatedTerseLabel": "Effect of acquisitions, divestments or transfers",
        "terseLabel": "Effect of acquisitions, divestments or transfers"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersDefinedBenefitLiabilityAsset1",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through acquisitions, divestments or transfers, net defined benefit liability (asset)",
        "negatedTerseLabel": "Effect of acquisitions, divestments or transfers",
        "terseLabel": "Effect of acquisitions, divestments or transfers"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughAcquisitionsDivestmentsTransfersNetDefinedBenefitLiabilityAsset1",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase/Decrease through changes in foreign exchange rates fund surplus",
        "negatedTerseLabel": "Currency translation effects",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughChangesInForeignExchangeRatesFundSurplus",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through changes in foreign exchange rates, defined benefit liability (asset)",
        "negatedTerseLabel": "Currency translation effects",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitAsset",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, foreign currency exchange rate gain (loss)",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiability",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase/Decrease through classified as held for sale, intangible assets and goodwill",
        "negatedTerseLabel": "Cost of assets related to disposal group held for sale"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsAndGoodwill",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase decrease through classified as held for sale property plant and equipment",
        "negatedTerseLabel": "Cost of assets reclassified out of assets of disposal group held for sale"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase decrease through net exchange differences, right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase/(Decrease) through new, modified, terminated leases, arising from financing activities",
        "terseLabel": "New, modified and terminated leases, net"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNewModifiedTerminatedLeasesArisingFromFinancingActivities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through other movements deferred tax liability (asset)",
        "negatedTerseLabel": "Other movements",
        "terseLabel": "Other movements"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughOtherMovementsDeferredTaxLiabilityAsset",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase to retained earnings arising from first application of IFRS 9"
       }
      }
     },
     "localname": "IncreaseToRetainedEarningsArisingFromFirstApplicationOfIFRS9",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_InnovativeMedicinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Innovative Medicines [member]",
        "terseLabel": "Innovative Medicines"
       }
      }
     },
     "localname": "InnovativeMedicinesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_IntangibleAssetImpairmentChargesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible asset impairment charges [text block]",
        "terseLabel": "Intangible asset impairment charges and reversals"
       }
      }
     },
     "localname": "IntangibleAssetImpairmentChargesTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_InterestBearningAccountsOfAssociatesPayableOnDemand": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_OtherCurrentFinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest bearning accounts of associates payable on demand"
       }
      }
     },
     "localname": "InterestBearningAccountsOfAssociatesPayableOnDemand",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_InterestBearningAccountsOfAssociatesPayableOnDemandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest bearning accounts of associates payable on demand [member]"
       }
      }
     },
     "localname": "InterestBearningAccountsOfAssociatesPayableOnDemandMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_InterestExchanged": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest exchanged"
       }
      }
     },
     "localname": "InterestExchanged",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_InterestExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense [abstract]"
       }
      }
     },
     "localname": "InterestExpenseAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense, gross",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseExcludingExpenseDueToUnwindingOfDiscountOnProvisions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_InterestExpenseIncomeDefinedBenefitLiabilityAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income, defined benefit plans",
        "negatedTerseLabel": "Interest income",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestExpenseIncomeDefinedBenefitLiabilityAsset",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_InterestExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense [table text block]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_InterestIncomeOnLimitationOfFundSurplus": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income on limitation of fund surplus",
        "negatedTerseLabel": "Interest income on limitation of fund surplus",
        "terseLabel": "Interest income on limitation of fund surplus"
       }
      }
     },
     "localname": "InterestIncomeOnLimitationOfFundSurplus",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest payments for amounts included in lease liabilities",
        "negatedTerseLabel": "Interest payments for amounts included in lease liabilities classified as cash flows from operating activities",
        "terseLabel": "Interest payments for amounts included in lease liabilities classified as cash flows from operating activities"
       }
      }
     },
     "localname": "InterestPaymentsForAmountsIncludedInLeaseLiabilitiesClassifiedAsCashFlowsFromOperatingActivities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_InterestRateSensitivityImpactInTheIncomeStatement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In the sensitivity disclosure, no amounts have been recorded in the accounts, as it is a hypothetical scenario if interest rates would increase/decrease.",
        "label": "Interest rate sensitivity impact in the income statement"
       }
      }
     },
     "localname": "InterestRateSensitivityImpactInTheIncomeStatement",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_InventoriesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories Disclosure [abstract]"
       }
      }
     },
     "localname": "InventoriesDisclosureAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories [member]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_InventoryAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Axis]"
       }
      }
     },
     "localname": "InventoryAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Current [table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_InventoryFinishedGoodsGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished goods, Gross [member]",
        "terseLabel": "Finished products"
       }
      }
     },
     "localname": "InventoryFinishedGoodsGrossMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [line items]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_InventoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [member]"
       }
      }
     },
     "localname": "InventoryMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_InventoryRawMaterialsGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Gross [member]",
        "terseLabel": "Raw material, consumables"
       }
      }
     },
     "localname": "InventoryRawMaterialsGrossMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_InventoryWorkInProgressGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in progress, Gross [member]",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProgressGrossMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_IssuedCapitalMovement": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureEquityDetails": {
       "order": 2.0,
       "parentTag": "nvs_OutstandingShareCapitalMovement",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued capital, movement",
        "terseLabel": "Share capital movement of period"
       }
      }
     },
     "localname": "IssuedCapitalMovement",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_JPCommercialPaperProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JP commercial paper programs [member]"
       }
      }
     },
     "localname": "JPCommercialPaperProgramsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_JSCSandozMoscowMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JSC Sandoz, Moscow [member]"
       }
      }
     },
     "localname": "JSCSandozMoscowMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_JakaviMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jakavi [member]"
       }
      }
     },
     "localname": "JakaviMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_JapatAGBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Japat AG, Basel [member]"
       }
      }
     },
     "localname": "JapatAGBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_KedalionTherapeuticsInc.MenloParkCAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Kedalion Therapeutics, Inc., Menlo Park, CA [member]"
       }
      }
     },
     "localname": "KedalionTherapeuticsInc.MenloParkCAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_KesimptaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Kesimpta [member]"
       }
      }
     },
     "localname": "KesimptaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_KeyManagementPersonnelCompensationAnnualGuaranteedMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, annual guaranteed minimum"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationAnnualGuaranteedMinimum",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_KeyManagementPersonnelCompensationDailyRate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, daily rate"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationDailyRate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_KeyManagementPersonnelCompensationOwnershipInterestAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, ownership interest acquired"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationOwnershipInterestAcquired",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_KeyManagementPersonnelCompensationSharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, shares acquired"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationSharesAcquired",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_KeyManagementPersonnelCompensationSharesAcquiredPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, shares acquired, price"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationSharesAcquiredPrice",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_KisqaliMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Kisqali [member]"
       }
      }
     },
     "localname": "KisqaliMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_KymriahMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Kymriah [member]"
       }
      }
     },
     "localname": "KymriahMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LaboratoiresAlconS.A.S.RueilMalmaisonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratoires Alcon S.A.S., Rueil-Malmaison [member]"
       }
      }
     },
     "localname": "LaboratoiresAlconS.A.S.RueilMalmaisonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratorios Alcon de Colombia S.A., Santafe de Bogota [member]"
       }
      }
     },
     "localname": "LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LargestCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Largest customer [member]"
       }
      }
     },
     "localname": "LargestCustomerMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LargestFinancialInstitutionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Largest financial institution [member]"
       }
      }
     },
     "localname": "LargestFinancialInstitutionMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LaterThanFiveYearsAndNotLaterThanSixYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Later than five years and not later than six years [member]"
       }
      }
     },
     "localname": "LaterThanFiveYearsAndNotLaterThanSixYearsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LaterThanSixYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Later than six years [member]",
        "terseLabel": "Later than six years"
       }
      }
     },
     "localname": "LaterThanSixYearsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Later than three month and not later than twelve months [member]"
       }
      }
     },
     "localname": "LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LeaseContractTerminationsRightofuseAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease contract terminations, right-of-use assets",
        "negatedTerseLabel": "Lease contract terminations, right-of-use assets"
       }
      }
     },
     "localname": "LeaseContractTerminationsRightofuseAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_LeaseIncentives": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease incentives"
       }
      }
     },
     "localname": "LeaseIncentives",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities and Right of use assets Disclosure Abstract"
       }
      }
     },
     "localname": "LeaseLiabilitiesAndRightOfUseAssetsDisclosureAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_LeaseLiabilitiesToBeRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities to be recognized"
       }
      }
     },
     "localname": "LeaseLiabilitiesToBeRecognized",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_LeaseLiabilitiesUndiscounted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities undiscounted"
       }
      }
     },
     "localname": "LeaseLiabilitiesUndiscounted",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_LeaseTermEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease term end date"
       }
      }
     },
     "localname": "LeaseTermEndDate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4"
     ],
     "xbrltype": "gYearItemType"
    },
    "nvs_LeasingCommitmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasing commitments [abstract]"
       }
      }
     },
     "localname": "LeasingCommitmentsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_LekPharmaceuticalsD.d.LjubjanaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lek Pharmaceuticals d.d., Ljubjana [member]"
       }
      }
     },
     "localname": "LekPharmaceuticalsD.d.LjubjanaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LekS.A.StrykowMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lek S.A., Strykow [member]"
       }
      }
     },
     "localname": "LekS.A.StrykowMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LeqvioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leqvio [member]"
       }
      }
     },
     "localname": "LeqvioMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LiabilitiesToBanksAndOtherFinancialInstitutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities to banks and other financial institutions [member]"
       }
      }
     },
     "localname": "LiabilitiesToBanksAndOtherFinancialInstitutionsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LiabilitiesToBanksAndOtherInstitutions": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities to banks and other institutions",
        "negatedTerseLabel": "Liabilities to banks and other financial institutions"
       }
      }
     },
     "localname": "LiabilitiesToBanksAndOtherInstitutions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_LifeExpectancyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Life expectancy [member]",
        "terseLabel": "Life expectancy"
       }
      }
     },
     "localname": "LifeExpectancyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LimitationOnRecognitionOfFundSurplus": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Limitation on recognition of fund surplus",
        "periodEndLabel": "Limitation on recognition of fund surplus at end of period",
        "periodStartLabel": "Limitation on recognition of fund surplus at beginning of period"
       }
      }
     },
     "localname": "LimitationOnRecognitionOfFundSurplus",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ListedEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Listed equity securities [member]"
       }
      }
     },
     "localname": "ListedEquitySecuritiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LitigationCaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [member]"
       }
      }
     },
     "localname": "LitigationCaseMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LongTermFinancialInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long term financial investments [member]"
       }
      }
     },
     "localname": "LongTermFinancialInvestmentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LongTermReceivablesFromFinanceSubleases": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails": {
       "order": 9.0,
       "parentTag": "ifrs-full_NoncurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Long term receivables from finance subleases"
       }
      }
     },
     "localname": "LongTermReceivablesFromFinanceSubleases",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_LongtermFinancialDebtWithACarryingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term financial debt with a carrying amount"
       }
      }
     },
     "localname": "LongtermFinancialDebtWithACarryingAmount",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term financial investments, fair value through other comprehensive income [member]"
       }
      }
     },
     "localname": "LongtermFinancialInvestmentsFairValueThroughOtherComprehensiveIncomeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term loans and receivables from customers and finance lease, advances, security deposits [member]"
       }
      }
     },
     "localname": "LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LossesRecognisedInProfitOrLossFairValueMeasurementAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement",
        "negatedTerseLabel": "Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement",
        "terseLabel": "Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement"
       }
      }
     },
     "localname": "LossesRecognisedInProfitOrLossFairValueMeasurementAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_LucentisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lucentis [member]"
       }
      }
     },
     "localname": "LucentisMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_LutatheraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lutathera [member]"
       }
      }
     },
     "localname": "LutatheraMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_MajorPlansPercentageInGroupDBOPensions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major plans percentage in group DBO pensions"
       }
      }
     },
     "localname": "MajorPlansPercentageInGroupDBOPensions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_MarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_OtherCurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_MarketableSecuritiesAndTimeDepositsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities and time deposits [member]"
       }
      }
     },
     "localname": "MarketableSecuritiesAndTimeDepositsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities, commodities, timedeposits, and derivative financial instruments [table text block]",
        "terseLabel": "Marketable securities, commodities, timedeposits, and derivative financial instruments"
       }
      }
     },
     "localname": "MarketableSecuritiesCommoditiesTimedepositsAndDerivativeFinancialInstrumentsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities, fair value through other comprehensive income [member]"
       }
      }
     },
     "localname": "MarketableSecuritiesFairValueThroughOtherComprehensiveIncomeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_MarketingRelatedIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketing related intangible assets [member]",
        "terseLabel": "Marketing know-how"
       }
      }
     },
     "localname": "MarketingRelatedIntangibleAssetsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_MassachusettsCaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Massachusetts case [member]"
       }
      }
     },
     "localname": "MassachusettsCaseMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_MatureOphthaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mature Ophtha [member]"
       }
      }
     },
     "localname": "MatureOphthaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_MaturityOfNetDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity of net debt [line items]"
       }
      }
     },
     "localname": "MaturityOfNetDebtLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_MaximalAmountOfShareBuybackProgramm": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximal amount of share buyback programm"
       }
      }
     },
     "localname": "MaximalAmountOfShareBuybackProgramm",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_MaximumHoldingInUnrelatedCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum holding in unrelated company"
       }
      }
     },
     "localname": "MaximumHoldingInUnrelatedCompany",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_MaximumMarginPercentageImpactOfCommodityPriceChange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum margin percentage impact of commodity price change"
       }
      }
     },
     "localname": "MaximumMarginPercentageImpactOfCommodityPriceChange",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_MayzentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mayzent [member]"
       }
      }
     },
     "localname": "MayzentMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_MilestoneIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone income"
       }
      }
     },
     "localname": "MilestoneIncome",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_MilestonePaymentAlreadyReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone payment already received"
       }
      }
     },
     "localname": "MilestonePaymentAlreadyReceived",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monitoring of net debt or liquidity based on contractual maturities [table]"
       }
      }
     },
     "localname": "MonitoringOfNetDebtOrLiquidityBasedOnContractualMaturitiesTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_MoreThanFiveYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "More than five years [member]"
       }
      }
     },
     "localname": "MoreThanFiveYearsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_MostMaterialLeaseWithLeaseTermExtension": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Most material lease with lease term extension"
       }
      }
     },
     "localname": "MostMaterialLeaseWithLeaseTermExtension",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_MostSignificantForeignExchangeLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Most significant foreign exchange losses"
       }
      }
     },
     "localname": "MostSignificantForeignExchangeLosses",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Most signigicant countries percentage on group DBO post employment benefit plans"
       }
      }
     },
     "localname": "MostSignigicantCountriesPercentageOnGroupDBOPostEmploymentBenefitPlans",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_MovementInDeferredTaxBalanceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Movement in deferred tax balance [roll forward]"
       }
      }
     },
     "localname": "MovementInDeferredTaxBalanceRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_MovementInTheShareCapitalTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Movement in the share capital [table text block]",
        "terseLabel": "Schedule disclosing information related to movement in the share capital"
       }
      }
     },
     "localname": "MovementInTheShareCapitalTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_MovementInTheShareslTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Movement in the shares [table text block]",
        "terseLabel": "Schedule disclosing information related to movement in the shares"
       }
      }
     },
     "localname": "MovementInTheShareslTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_MovementsOfPropertyPlantAndEquipmentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Movements of property, plant and equipment [roll forward]"
       }
      }
     },
     "localname": "MovementsOfPropertyPlantAndEquipmentRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_MovementsOfTheRightofuseAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Movements of the right-of-use assets [roll forward]"
       }
      }
     },
     "localname": "MovementsOfTheRightofuseAssetsRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_MyforticMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Myfortic [member]"
       }
      }
     },
     "localname": "MyforticMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NAGAndNovartisPharmaSpAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NAG and Novartis Pharma SpA [member]"
       }
      }
     },
     "localname": "NAGAndNovartisPharmaSpAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NAG [member]"
       }
      }
     },
     "localname": "NAGMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NPCAndOthersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NPC and others [member]"
       }
      }
     },
     "localname": "NPCAndOthersMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NavigateBioPharmaServicesInc.CarlsbadCAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Navigate BioPharma Services, Inc., Carlsbad, CA [member]"
       }
      }
     },
     "localname": "NavigateBioPharmaServicesInc.CarlsbadCAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NegativeFairValuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Negative fair values [member]"
       }
      }
     },
     "localname": "NegativeFairValuesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NeoralSandimmunEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Neoral/Sandimmun(e) [member]"
       }
      }
     },
     "localname": "NeoralSandimmunEMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NetAssetsDerecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net assets derecognized",
        "negatedTerseLabel": "Net assets derecognized"
       }
      }
     },
     "localname": "NetAssetsDerecognized",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net book value of Property, plant and equipment under finance lease contracts"
       }
      }
     },
     "localname": "NetBookValueOfPropertyPlantEquipmentUnderFinanceLeaseContracts",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash flows used in acquisitions and divestments of businesses, classified as investing activities",
        "terseLabel": "Acquisitions and divestments of businesses, net",
        "totalLabel": "Net cash flows"
       }
      }
     },
     "localname": "NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash flows used in acquisitions and divestments of businesses classified as investing activities from continuing operations"
       }
      }
     },
     "localname": "NetCashFlowsUsedInAcquisitionsAndDivestmentsOfBusinessesClassifiedAsInvestingActivitiesFromContinuingOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash flows used in from divestments of businesses classified as investing activities"
       }
      }
     },
     "localname": "NetCashFlowsUsedInFromDivestmentsOfBusinessesClassifiedAsInvestingActivities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetCashOutflowsFromDivestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash outflows from divestments"
       }
      }
     },
     "localname": "NetCashOutflowsFromDivestments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetDeferredTaxBalanceRelatedToDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net deferred tax balance related to discontinued operations"
       }
      }
     },
     "localname": "NetDeferredTaxBalanceRelatedToDiscontinuedOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets or deferred tax liabilities related to disposal group held for sale",
        "label": "Net deferred tax balance related to disposal group held for sale"
       }
      }
     },
     "localname": "NetDeferredTaxBalanceRelatedToDisposalGroupHeldForSale",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetExpenseRoyaltiesCostSharingAndProfitSharing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net expense, royalties cost sharing and profit sharing",
        "negatedTerseLabel": "Net expense, royalties cost sharing and profit sharing"
       }
      }
     },
     "localname": "NetExpenseRoyaltiesCostSharingAndProfitSharing",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetIdentifiableAssetsOfDivestedBusiness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net identifiable assets of divested business"
       }
      }
     },
     "localname": "NetIdentifiableAssetsOfDivestedBusiness",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss from discontinued operations before gain on distribution"
       }
      }
     },
     "localname": "NetIncomeLossFromDiscontinuedOperationsBeforeGainOnDistribution",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetInvestmentHedgeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net investment hedge [member]",
        "terseLabel": "Net investment hedge"
       }
      }
     },
     "localname": "NetInvestmentHedgeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NetInvestmentHedgeRecognizedInTheIncomeStatement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net investment hedge recognized in the income statement"
       }
      }
     },
     "localname": "NetInvestmentHedgeRecognizedInTheIncomeStatement",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss/gain recorded on equity securities and fund investments at fair value through the consolidated income statement"
       }
      }
     },
     "localname": "NetLossGainRecordedOnEquitySecuritiesAndFundInvestmentsAtFairValueThroughTheConsolidatedIncomeStatement",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NetOperatingAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating assets",
        "totalLabel": "Net operating assets"
       }
      }
     },
     "localname": "NetOperatingAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Neuroscience [member]"
       }
      }
     },
     "localname": "NeuroscienceMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NeutecPharmaLimitedLondonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Neutec Pharma Limited, London [member]"
       }
      }
     },
     "localname": "NeutecPharmaLimitedLondonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NewLeaseArrangements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "New lease arrangements"
       }
      }
     },
     "localname": "NewLeaseArrangements",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NonCurrentFinancialDebtsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current financial debts [member]"
       }
      }
     },
     "localname": "NonCurrentFinancialDebtsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NonExecutiveDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Executive Director [member]"
       }
      }
     },
     "localname": "NonExecutiveDirectorMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NonUSspecificHealthcarePlansAndProgramRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-US-specific healthcare plans and program rebates [member]"
       }
      }
     },
     "localname": "NonUSspecificHealthcarePlansAndProgramRebatesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NoncurrentAndCurrentLiabilitiesDivested": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current and current liabilities divested"
       }
      }
     },
     "localname": "NoncurrentAndCurrentLiabilitiesDivested",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NoncurrentAssetsDivested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets divested"
       }
      }
     },
     "localname": "NoncurrentAssetsDivested",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets [member]"
       }
      }
     },
     "localname": "NoncurrentAssetsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NoncurrentContingentConsiderationLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current contingent consideration liabilities [member]"
       }
      }
     },
     "localname": "NoncurrentContingentConsiderationLiabilitiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NoncurrentFinancialAssetsEquityInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "nvs_NoncurrentFinancialAssetsTotalFinancialInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current financial assets, equity securities"
       }
      }
     },
     "localname": "NoncurrentFinancialAssetsEquityInvestments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NoncurrentFinancialAssetsFundInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "nvs_NoncurrentFinancialAssetsTotalFinancialInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current financial assets, fund investments"
       }
      }
     },
     "localname": "NoncurrentFinancialAssetsFundInvestments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NoncurrentFinancialAssetsTotalFinancialInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_NoncurrentFinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current financial assets, total financial investments",
        "totalLabel": "Non-current financial assets, total financial investments"
       }
      }
     },
     "localname": "NoncurrentFinancialAssetsTotalFinancialInvestments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NoncurrentFinancialAsstetsDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "nvs_NoncurrentFinancialAssetsTotalFinancialInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current financial asstets debt securities"
       }
      }
     },
     "localname": "NoncurrentFinancialAsstetsDebtSecurities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NoncurrentFinancialDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current financial debt [member]"
       }
      }
     },
     "localname": "NoncurrentFinancialDebtMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NoncurrentFinancialDebtsCoveredByCollateral": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current financial debts covered by collateral",
        "terseLabel": "Total amount of collateralized non-current financial debts"
       }
      }
     },
     "localname": "NoncurrentFinancialDebtsCoveredByCollateral",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NoncurrentFinancialLiabilitiesAtFairValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current financial liabilities at fair value [member]"
       }
      }
     },
     "localname": "NoncurrentFinancialLiabilitiesAtFairValueMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NoncurrentLeaseLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities [member]"
       }
      }
     },
     "localname": "NoncurrentLeaseLiabilitiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NoncurrentLeaseLiabilitiesUndiscounted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities undiscounted"
       }
      }
     },
     "localname": "NoncurrentLeaseLiabilitiesUndiscounted",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_NoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities [member]"
       }
      }
     },
     "localname": "NoncurrentLiabilitiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-healthcare plans and program-related rebates, returns and other deductions [member]"
       }
      }
     },
     "localname": "NonhealthcarePlansAndProgramrelatedRebatesReturnsAndOtherDeductionsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NonlistedEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-listed equity securities [member]"
       }
      }
     },
     "localname": "NonlistedEquitySecuritiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NotCapitalizedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Not capitalized [member]"
       }
      }
     },
     "localname": "NotCapitalizedMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NotSubjectToExpiryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Not subject to expiry [member]"
       }
      }
     },
     "localname": "NotSubjectToExpiryMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisArgentinaS.A.BuenosAiresMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Argentina S.A., Buenos Aires [member]"
       }
      }
     },
     "localname": "NovartisArgentinaS.A.BuenosAiresMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Asia Pacific Pharmaceuticals Pte Ltd, Singapore [member]"
       }
      }
     },
     "localname": "NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisAustraliaPtyLtdMacquarieParkNSWMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Australia Pty Ltd, Macquarie Park, NSW [member]"
       }
      }
     },
     "localname": "NovartisAustraliaPtyLtdMacquarieParkNSWMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisAustriaGmbHViennaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Austria GmbH, Vienna [member]"
       }
      }
     },
     "localname": "NovartisAustriaGmbHViennaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisB2Ltd.HamiltonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis B2 Ltd., Hamilton [member]"
       }
      }
     },
     "localname": "NovartisB2Ltd.HamiltonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisB3Ltd.HamiltonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis B3 Ltd., Hamilton [member]"
       }
      }
     },
     "localname": "NovartisB3Ltd.HamiltonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisBalticsSIARigaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Baltics SIA, Riga [member]"
       }
      }
     },
     "localname": "NovartisBalticsSIARigaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisBangladeshLimitedGazipurMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis (Bangladesh) Limited, Gazipur [member]"
       }
      }
     },
     "localname": "NovartisBangladeshLimitedGazipurMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisBiocienciasS.A.SaoPauloMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Biociencias S.A., Sao Paulo [member]"
       }
      }
     },
     "localname": "NovartisBiocienciasS.A.SaoPauloMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisBiosciencesPeruS.A.LimaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Biosciences Peru S.A., Lima [member]"
       }
      }
     },
     "localname": "NovartisBiosciencesPeruS.A.LimaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisBioventuresAGBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Bioventures AG, Basel [member]"
       }
      }
     },
     "localname": "NovartisBioventuresAGBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisBusinessServicesGmbHWehrMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Business Services GmbH, Wehr [member]"
       }
      }
     },
     "localname": "NovartisBusinessServicesGmbHWehrMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisCapitalCorporationEastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Capital Corporation, East Hanover, NJ [member]"
       }
      }
     },
     "localname": "NovartisCapitalCorporationEastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisCapitalCorporationNewYorkNYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Capital Corporation, New York, NY [member]"
       }
      }
     },
     "localname": "NovartisCapitalCorporationNewYorkNYMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisCapitalCorporationNewYorkUnitedStates1.752025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Capital Corporation, New York, United States, 1.75%, 2025 [member]"
       }
      }
     },
     "localname": "NovartisCapitalCorporationNewYorkUnitedStates1.752025Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisCapitalCorporationNewYorkUnitedStates2.002027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Capital Corporation, New York, United States, 2.00%, 2027 [member]"
       }
      }
     },
     "localname": "NovartisCapitalCorporationNewYorkUnitedStates2.002027Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisCapitalCorporationNewYorkUnitedStates2.202030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Capital Corporation, New York, United States, 2.20%, 2030 [member]"
       }
      }
     },
     "localname": "NovartisCapitalCorporationNewYorkUnitedStates2.202030Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisCapitalCorporationNewYorkUnitedStates2.752050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Capital Corporation, New York, United States, 2.75%, 2050 [member]"
       }
      }
     },
     "localname": "NovartisCapitalCorporationNewYorkUnitedStates2.752050Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisChileS.A.SantiagoDeChileMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Chile S.A., Santiago de Chile [member]"
       }
      }
     },
     "localname": "NovartisChileS.A.SantiagoDeChileMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisCorporationEastHanoverNYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Corporation, East Hanover, NJ [member]"
       }
      }
     },
     "localname": "NovartisCorporationEastHanoverNYMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Corporation (Malaysia) Sdn. Bhd., Petaling Jaya [member]"
       }
      }
     },
     "localname": "NovartisCorporationMalaysiaSdn.Bhd.PetalingJayaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisDeColombiaS.A.SantafeDeBobotaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis de Colombia S.A., Santafe de Bogota [member]"
       }
      }
     },
     "localname": "NovartisDeColombiaS.A.SantafeDeBobotaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisDeVenezuelaS.A.CaracasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis de Venezuela, S.A., Caracas [member]"
       }
      }
     },
     "localname": "NovartisDeVenezuelaS.A.CaracasMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisDeutschlandGmbHNurembergMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Deutschland GmbH, Nuremberg [member]"
       }
      }
     },
     "localname": "NovartisDeutschlandGmbHNurembergMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisDeutschlandGmbHWehrMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Deutschland GmbH, Wehr [member]"
       }
      }
     },
     "localname": "NovartisDeutschlandGmbHWehrMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisEcuadorS.A.QuitoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Ecuador S.A., Quito [member]"
       }
      }
     },
     "localname": "NovartisEcuadorS.A.QuitoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Farma - Produtos Farmaceuticos S.A., Porto Salvo [member]"
       }
      }
     },
     "localname": "NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisFarmaS.p.A.MilanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Farma S.p.A., Milan [member]"
       }
      }
     },
     "localname": "NovartisFarmaS.p.A.MilanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisFarmaceuticaS.A.BarcelonaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Farmaceutica, S.A., Barcelona [member]"
       }
      }
     },
     "localname": "NovartisFarmaceuticaS.A.BarcelonaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Farmaceutica, S.A. de C.V., Mexico City [member]"
       }
      }
     },
     "localname": "NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisFinanceCorporationEastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Finance Corporation, East Hanover, NJ [member]"
       }
      }
     },
     "localname": "NovartisFinanceCorporationEastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisFinanceCorporationNewYorkNYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Finance Corporation, New York, NY [member]"
       }
      }
     },
     "localname": "NovartisFinanceCorporationNewYorkNYMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisFinanceS.A.LuxembourgCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Finance S.A., Luxembourg City [member]"
       }
      }
     },
     "localname": "NovartisFinanceS.A.LuxembourgCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisFinanceServicesLtd.HamiltonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Finance Services Ltd., Hamilton [member]"
       }
      }
     },
     "localname": "NovartisFinanceServicesLtd.HamiltonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisFinlandOyEspooMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Finland Oy, Espoo [member]"
       }
      }
     },
     "localname": "NovartisFinlandOyEspooMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisForschungsstiftungBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Forschungsstiftung, Basel [member]"
       }
      }
     },
     "localname": "NovartisForschungsstiftungBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisGeneTherapiesEULimitedDublinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Gene Therapies EU Limited, Dublin [member]"
       }
      }
     },
     "localname": "NovartisGeneTherapiesEULimitedDublinMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Gene Therapies France S.A.S., Rueil-Malmaison [member]"
       }
      }
     },
     "localname": "NovartisGeneTherapiesFranceS.A.S.RueilMalmaisonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisGeneTherapiesInc.BannockburnILMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Gene Therapies, Inc., Bannockburn, IL [member]"
       }
      }
     },
     "localname": "NovartisGeneTherapiesInc.BannockburnILMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisGrimsbyLimitedFrimleyCamberleyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Grimsby Limited, Frimley/Camberley [member]"
       }
      }
     },
     "localname": "NovartisGrimsbyLimitedFrimleyCamberleyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisGrimsbyLimitedLondonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Grimsby Limited, London [member]"
       }
      }
     },
     "localname": "NovartisGrimsbyLimitedLondonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisGroupeFranceS.A.RueilMalmaisonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Groupe France S.A., Rueil-Malmaison [member]"
       }
      }
     },
     "localname": "NovartisGroupeFranceS.A.RueilMalmaisonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisHealthcareASCopenhagenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Healthcare A/S, Copenhagen [member]"
       }
      }
     },
     "localname": "NovartisHealthcareASCopenhagenMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisHealthcarePhilippinesInc.MakatiCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Healthcare Philippines, Inc., Makati City [member]"
       }
      }
     },
     "localname": "NovartisHealthcarePhilippinesInc.MakatiCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisHealthcarePrivateLimitedMumbaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Healthcare Private Limited, Mumbai [member]"
       }
      }
     },
     "localname": "NovartisHealthcarePrivateLimitedMumbaiMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisHellasS.A.C.I.MetamorphosisAthensMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis (Hellas) S.A.C.I., Metamorphosis/Athens [member]"
       }
      }
     },
     "localname": "NovartisHellasS.A.C.I.MetamorphosisAthensMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisHoldingAGBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Holding AG, Basel [member]"
       }
      }
     },
     "localname": "NovartisHoldingAGBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisHoldingJapanK.K.TokyoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Holding Japan K.K., Tokyo [member]"
       }
      }
     },
     "localname": "NovartisHoldingJapanK.K.TokyoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Hungary Healthcare Limited Liability Company, Budapest [member]"
       }
      }
     },
     "localname": "NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisHungaryHealthcareLimitedLiabilityCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Hungary Healthcare Limited Liability Company [member]"
       }
      }
     },
     "localname": "NovartisHungaryHealthcareLimitedLiabilityCompanyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisIndiaLimitedMumbaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis India Limited, Mumbai [member]"
       }
      }
     },
     "localname": "NovartisIndiaLimitedMumbaiMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisInflammasomeResearchInc.EastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Inflammasome Research, Inc., East Hanover, NJ [member]"
       }
      }
     },
     "localname": "NovartisInflammasomeResearchInc.EastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisInflammasomeResearchInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Inflammasome Research, Inc. [member]"
       }
      }
     },
     "localname": "NovartisInflammasomeResearchInc.Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisInnovativeTherapiesAGRischMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Innovative Therapies AG, Risch [member]"
       }
      }
     },
     "localname": "NovartisInnovativeTherapiesAGRischMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Institute for Functional Genomics, Inc., San Diego, CA [member]"
       }
      }
     },
     "localname": "NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Institute for Tropical Diseases Pte Ltd, Singapore [member]"
       }
      }
     },
     "localname": "NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Institutes for BioMedical Research, Inc., Cambridge, MA [member]"
       }
      }
     },
     "localname": "NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Integrated Services Limited, Ringaskiddy, County Cork [member]"
       }
      }
     },
     "localname": "NovartisIntegratedServicesLimitedRingaskiddyCountyCorkMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisInternationalAGBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis International AG, Basel [member]"
       }
      }
     },
     "localname": "NovartisInternationalAGBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisInternationalPharmaceuticalAGBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis International Pharmaceutical AG, Basel [member]"
       }
      }
     },
     "localname": "NovartisInternationalPharmaceuticalAGBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisInternationalPharmaceuticalInvestmentAGBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis International Pharmaceutical Investment AG, Basel [member]"
       }
      }
     },
     "localname": "NovartisInternationalPharmaceuticalInvestmentAGBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisInvestmentLtd.HamiltonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Investment Ltd., Hamilton [member]"
       }
      }
     },
     "localname": "NovartisInvestmentLtd.HamiltonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisInvestmentsS.aR.l.LuxembourgCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Investments S.a r.l., Luxembourg City [member]"
       }
      }
     },
     "localname": "NovartisInvestmentsS.aR.l.LuxembourgCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisIrelandLimitedDublinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Ireland Limited, Dublin [member]"
       }
      }
     },
     "localname": "NovartisIrelandLimitedDublinMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisIsraelLtd.TelAvivMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Israel Ltd., Tel Aviv [member]"
       }
      }
     },
     "localname": "NovartisIsraelLtd.TelAvivMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisKoreaLtd.SeoulMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Korea Ltd., Seoul [member]"
       }
      }
     },
     "localname": "NovartisKoreaLtd.SeoulMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisManufacturingGmbHMarburgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Manufacturing GmbH, Marburg [member]"
       }
      }
     },
     "localname": "NovartisManufacturingGmbHMarburgMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisManufacturingGmbHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Manufacturing GmbH [member]"
       }
      }
     },
     "localname": "NovartisManufacturingGmbHMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisMiddleEastFZEDubaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Middle East FZE, Dubai [member]"
       }
      }
     },
     "localname": "NovartisMiddleEastFZEDubaiMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisMitarbeiterbeteiligungsstiftungBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Mitarbeiterbeteiligungsstiftung, Basel [member]"
       }
      }
     },
     "localname": "NovartisMitarbeiterbeteiligungsstiftungBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisNCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis NC [member]"
       }
      }
     },
     "localname": "NovartisNCMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisNetherlandsB.V.AmsterdamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Netherlands B.V., Amsterdam [member]"
       }
      }
     },
     "localname": "NovartisNetherlandsB.V.AmsterdamMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisNetherlandsB.V.ArnhemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Netherlands B.V., Arnhem [member]"
       }
      }
     },
     "localname": "NovartisNetherlandsB.V.ArnhemMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisNevaLLCSt.PetersburgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Neva LLC, St. Petersburg [member]"
       }
      }
     },
     "localname": "NovartisNevaLLCSt.PetersburgMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisNewZealandLtdAucklandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis New Zealand Ltd, Auckland [member]"
       }
      }
     },
     "localname": "NovartisNewZealandLtdAucklandMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisNorgeASOsloMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Norge AS, Oslo [member]"
       }
      }
     },
     "localname": "NovartisNorgeASOsloMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisOptogeneticsResearchInc.EastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Optogenetics Research, Inc., East Hanover, NJ [member]"
       }
      }
     },
     "localname": "NovartisOptogeneticsResearchInc.EastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisOverseasInvestmentsAGBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Overseas Investments AG, Basel [member]"
       }
      }
     },
     "localname": "NovartisOverseasInvestmentsAGBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPensionFundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pension Fund [member]"
       }
      }
     },
     "localname": "NovartisPensionFundMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaAGBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma AG, Basel [member]"
       }
      }
     },
     "localname": "NovartisPharmaAGBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaB.V.AmsterdamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma B.V., Amsterdam [member]"
       }
      }
     },
     "localname": "NovartisPharmaB.V.AmsterdamMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaB.V.ArnhemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma B.V., Arnhem [member]"
       }
      }
     },
     "localname": "NovartisPharmaB.V.ArnhemMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaGmbHNurembergMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma GmbH, Nuremberg [member]"
       }
      }
     },
     "localname": "NovartisPharmaGmbHNurembergMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaGmbHViennaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma GmbH, Vienna [member]"
       }
      }
     },
     "localname": "NovartisPharmaGmbHViennaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaK.K.TokyoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma K.K., Tokyo [member]"
       }
      }
     },
     "localname": "NovartisPharmaK.K.TokyoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaKKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma K.K. [member]"
       }
      }
     },
     "localname": "NovartisPharmaKKMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaLLCMoscowMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma LLC, Moscow [member]"
       }
      }
     },
     "localname": "NovartisPharmaLLCMoscowMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaLogisticsInc.PanamaCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma (Logistics), Inc., Panama City [member]"
       }
      }
     },
     "localname": "NovartisPharmaLogisticsInc.PanamaCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaMarocSACasablancaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma Maroc SA, Casablanca [member]"
       }
      }
     },
     "localname": "NovartisPharmaMarocSACasablancaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaNVVilvoordeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma NV, Vilvoorde [member]"
       }
      }
     },
     "localname": "NovartisPharmaNVVilvoordeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaPakistanLimitedKarachiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma (Pakistan) Limited, Karachi [member]"
       }
      }
     },
     "localname": "NovartisPharmaPakistanLimitedKarachiMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaProduktionsGmbHWehrMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma Produktions GmbH, Wehr [member]"
       }
      }
     },
     "localname": "NovartisPharmaProduktionsGmbHWehrMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaS.A.E.CairoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma S.A.E., Cairo [member]"
       }
      }
     },
     "localname": "NovartisPharmaS.A.E.CairoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaS.A.S.RueilMalmaisonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma S.A.S., Rueil-Malmaison [member]"
       }
      }
     },
     "localname": "NovartisPharmaS.A.S.RueilMalmaisonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaSchweizAGRischMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma Schweiz AG, Risch [member]"
       }
      }
     },
     "localname": "NovartisPharmaSchweizAGRischMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaSchweizerhalleAGMuttenzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma Schweizerhalle AG, Muttenz [member]"
       }
      }
     },
     "localname": "NovartisPharmaSchweizerhalleAGMuttenzMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaServicesAGBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma Services AG, Basel [member]"
       }
      }
     },
     "localname": "NovartisPharmaServicesAGBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaServicesRomaniaS.R.L.BucharestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma Services Romania S.R.L., Bucharest [member]"
       }
      }
     },
     "localname": "NovartisPharmaServicesRomaniaS.R.L.BucharestMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaSteinAGSteinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharma Stein AG, Stein [member]"
       }
      }
     },
     "localname": "NovartisPharmaSteinAGSteinMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharmaceuticals Australia Pty Ltd, Macquarie Park, NSW [member]"
       }
      }
     },
     "localname": "NovartisPharmaceuticalsAustraliaPtyLtdMacquarieParkNSWMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharmaceuticals Canada Inc., Dorval, Quebec [member]"
       }
      }
     },
     "localname": "NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaceuticalsCorporationEastHanoverNYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharmaceuticals Corporation, East Hanover, NJ [member]"
       }
      }
     },
     "localname": "NovartisPharmaceuticalsCorporationEastHanoverNYMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaceuticalsHKLimitedHongKongMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharmaceuticals (HK) Limited, Hong Kong [member]"
       }
      }
     },
     "localname": "NovartisPharmaceuticalsHKLimitedHongKongMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharmaceuticals UK Limited, Frimley/Camberley [member]"
       }
      }
     },
     "localname": "NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPharmaceuticalsUKLimitedLondonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Pharmaceuticals UK Limited, London [member]"
       }
      }
     },
     "localname": "NovartisPharmaceuticalsUKLimitedLondonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPolandSp.ZO.o.WarsawMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Poland Sp. z o.o., Warsaw [member]"
       }
      }
     },
     "localname": "NovartisPolandSp.ZO.o.WarsawMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisPortugalSGPSLda.PortoSalvoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Portugal SGPS Lda., Porto Salvo [member]"
       }
      }
     },
     "localname": "NovartisPortugalSGPSLda.PortoSalvoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Ringaskiddy Limited, Ringaskiddy, County Cork [member]"
       }
      }
     },
     "localname": "NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisS.r.o.PragueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis s.r.o., Prague [member]"
       }
      }
     },
     "localname": "NovartisS.r.o.PragueMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Saglik, Gida ve Tarim Urunleri Sanayi ve Ticaret A.S., Istanbul [member]"
       }
      }
     },
     "localname": "NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisSaudiLtd.RiyadhMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Saudi Ltd., Riyadh [member]"
       }
      }
     },
     "localname": "NovartisSaudiLtd.RiyadhMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisSecuritiesInvestmentLtd.HamiltonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Securities Investment Ltd., Hamilton [member]"
       }
      }
     },
     "localname": "NovartisSecuritiesInvestmentLtd.HamiltonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisServicesInc.EastHanoverNYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Services, Inc., East Hanover, NJ [member]"
       }
      }
     },
     "localname": "NovartisServicesInc.EastHanoverNYMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Singapore Pharmaceutical Manufacturing Pte Ltd, Singapore [member]"
       }
      }
     },
     "localname": "NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisSingaporePteLtd.SingaporeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis (Singapore) Pte Ltd., Singapore [member]"
       }
      }
     },
     "localname": "NovartisSingaporePteLtd.SingaporeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisSlovakiaS.r.o.BratislavaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Slovakia s.r.o., Bratislava [member]"
       }
      }
     },
     "localname": "NovartisSlovakiaS.r.o.BratislavaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisSouthAfricaPtyLtdMidrandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis South Africa (Pty) Ltd, Midrand [member]"
       }
      }
     },
     "localname": "NovartisSouthAfricaPtyLtdMidrandMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisStiftungFuerKaderausbildungBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Stiftung fuer Kaderausbildung, Basel [member]"
       }
      }
     },
     "localname": "NovartisStiftungFuerKaderausbildungBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisStiftungFuerMenschUndUmweltBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Stiftung fuer Mensch und Umwelt, Basel [member]"
       }
      }
     },
     "localname": "NovartisStiftungFuerMenschUndUmweltBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisSverigeABStockholmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Sverige AB, Stockholm [member]"
       }
      }
     },
     "localname": "NovartisSverigeABStockholmMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisTaiwanCo.Ltd.TaipeiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis (Taiwan) Co., Ltd., Taipei [member]"
       }
      }
     },
     "localname": "NovartisTaiwanCo.Ltd.TaipeiMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisTechnologyLLCInc.EastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Technology LLC, Inc., East Hanover, NJ [member]"
       }
      }
     },
     "localname": "NovartisTechnologyLLCInc.EastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisTechnologyLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Technology LLC [member]"
       }
      }
     },
     "localname": "NovartisTechnologyLLCMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisThailandLimitedBangkokMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis (Thailand) Limited, Bangkok [member]"
       }
      }
     },
     "localname": "NovartisThailandLimitedBangkokMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisUKLimitedFrimleyCamberleyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis UK Limited, Frimley/Camberley [member]"
       }
      }
     },
     "localname": "NovartisUKLimitedFrimleyCamberleyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisUKLimitedLondonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis UK Limited, London [member]"
       }
      }
     },
     "localname": "NovartisUKLimitedLondonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisUSFoundationEastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis US Foundation, East Hanover, NJ [member]"
       }
      }
     },
     "localname": "NovartisUSFoundationEastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisUSFoundationNewYorkNYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis US Foundation, New York, NY [member]"
       }
      }
     },
     "localname": "NovartisUSFoundationNewYorkNYMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Vaccines and Diagnostics, Inc., Cambridge, MA [member]"
       }
      }
     },
     "localname": "NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Vaccines and Diagnostics, Inc., East Hanover, NJ [member]"
       }
      }
     },
     "localname": "NovartisVaccinesAndDiagnosticsInc.EastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovartisVietnamCompanyLimitedHoChiMinhCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis Vietnam Company Limited, Ho Chi Minh City [member]"
       }
      }
     },
     "localname": "NovartisVietnamCompanyLimitedHoChiMinhCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NovistaInsuranceLimitedGibraltarCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Novista Insurance Limited, Gibraltar City [member]"
       }
      }
     },
     "localname": "NovistaInsuranceLimitedGibraltarCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_NumberOfBearerShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of bearer shares"
       }
      }
     },
     "localname": "NumberOfBearerShares",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_NumberOfBrandsInPortfolioToAcquire": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of brands in portfolio to acquire"
       }
      }
     },
     "localname": "NumberOfBrandsInPortfolioToAcquire",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nvs_NumberOfBusinessUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Business Units"
       }
      }
     },
     "localname": "NumberOfBusinessUnits",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_NumberOfCommercialOrganizationalUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of commercial organizational units"
       }
      }
     },
     "localname": "NumberOfCommercialOrganizationalUnits",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_NumberOfContractsWithRelatedParties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of contracts with related parties"
       }
      }
     },
     "localname": "NumberOfContractsWithRelatedParties",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_NumberOfEmployeesAssociatedWithTheProductTransfer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of employees associated with the product transfer"
       }
      }
     },
     "localname": "NumberOfEmployeesAssociatedWithTheProductTransfer",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nvs_NumberOfFranchises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Franchises"
       }
      }
     },
     "localname": "NumberOfFranchises",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of investments in equity instruments designated at fair value through other comprehensive income"
       }
      }
     },
     "localname": "NumberOfInvestmentsInEquityInstrumentsDesignatedAtFairValueThroughOtherComprehensiveIncome",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_NumberOfMarketsForTheAcquiredBrands": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of markets for the acquired brands"
       }
      }
     },
     "localname": "NumberOfMarketsForTheAcquiredBrands",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nvs_NumberOfOptionsRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options repurchased"
       }
      }
     },
     "localname": "NumberOfOptionsRepurchased",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails5"
     ],
     "xbrltype": "pureItemType"
    },
    "nvs_NumberOfOrdinarySharePerADS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of ordinary share per ADS"
       }
      }
     },
     "localname": "NumberOfOrdinarySharePerADS",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nvs_NumberOfOtherShareSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of other share sales",
        "terseLabel": "Other share sales"
       }
      }
     },
     "localname": "NumberOfOtherShareSales",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_NumberOfProductsInPortfolioToBeSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of products in portfolio to be sold"
       }
      }
     },
     "localname": "NumberOfProductsInPortfolioToBeSold",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nvs_NumberOfReportableSegments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_NumberOfTreasuryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of treasury shares",
        "periodEndLabel": "Number of treasury shares at end of period",
        "periodStartLabel": "Number of treasury shares at beginning of period"
       }
      }
     },
     "localname": "NumberOfTreasuryShares",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_ObligationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obligation by type [axis]"
       }
      }
     },
     "localname": "ObligationByTypeAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ObligationByTypeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Obligation by type [member]",
        "terseLabel": "Obligation by type"
       }
      }
     },
     "localname": "ObligationByTypeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OfficerAndDirectorCompensationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer and director compensation [table text block]",
        "terseLabel": "Executive Officers and Non-Executive Directors Compensation"
       }
      }
     },
     "localname": "OfficerAndDirectorCompensationTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting of deferred tax assets and liabilities within the same tax jurisdiction"
       }
      }
     },
     "localname": "OffsettingOfDeferredTaxAssetsAndLiabilitiesWithinTheSameTaxJurisdiction",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OnbrezBreezhalerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Onbrez Breezhaler [member]"
       }
      }
     },
     "localname": "OnbrezBreezhalerMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OneYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "One year [member]"
       }
      }
     },
     "localname": "OneYearMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OpenHedgesForAnticipatedTransactions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Open hedges for anticipated transactions"
       }
      }
     },
     "localname": "OpenHedgesForAnticipatedTransactions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OperatingIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating income [member]"
       }
      }
     },
     "localname": "OperatingIncomeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OptionsExcludedFromTheCalculation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options excluded from the calculation"
       }
      }
     },
     "localname": "OptionsExcludedFromTheCalculation",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_OptonolLtd.NeveIlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Optonol Ltd., Neve-Ilan [member]"
       }
      }
     },
     "localname": "OptonolLtd.NeveIlanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OrdinarySharesNominalValueCHF0.50PerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares, nominal value CHF 0.50 per share [member]",
        "terseLabel": "Ordinary shares, nominal value CHF 0.50 per share*"
       }
      }
     },
     "localname": "OrdinarySharesNominalValueCHF0.50PerShareMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OrielTherapeuticsInc.DurhamNCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Oriel Therapeutics, Inc., Durham, NC [member]"
       }
      }
     },
     "localname": "OrielTherapeuticsInc.DurhamNCMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OtherAssetsProvisionsAccrualsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets, provisions and accruals [member]"
       }
      }
     },
     "localname": "OtherAssetsProvisionsAccrualsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, before taxes, gains (losses) on remeasurements of defined benefit plans",
        "terseLabel": "Defined benefit pension plans before tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, before taxes, gains (losses) on remeasurements of other post-employment benefit plans",
        "terseLabel": "Other post-employment benefit plans before tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeBeforeTaxesGainsLossesOnRemeasurementsOfOtherPostemploymentBenefitPlans",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherComprehensiveIncomeDebtSecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDebtSecurities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails": {
       "order": 8.0,
       "parentTag": "nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, equity securities",
        "terseLabel": "Fair value adjustments on equity securities, net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeEquitySecuritiesNetOfTaxes",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, gains (losses) on remeasurements of defined and other post-employment benefit plans, taxation",
        "terseLabel": "Taxation on above items"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeGainsLossesOnRemeasurementsOfDefinedAndOtherPostemploymentBenefitPlansTaxation",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherComprehensiveIncomeMaketableSecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, maketable securities",
        "terseLabel": "Available-for-sale marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeMaketableSecurities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherComprehensiveIncomeNetOfTaxDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails": {
       "order": 6.0,
       "parentTag": "nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, debt securities",
        "terseLabel": "Fair value adjustments on debt securities, net of taxes",
        "verboseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxDebtSecurities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income net of tax exchange differences on translation related to discontinued operations"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationRelatedToDiscontinuedOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherComprehensiveIncomeNetOfTaxFinancialInstruments": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails": {
       "order": 5.0,
       "parentTag": "nvs_GainsLossesOnValueAdjustmentOnComprehensiveIncome",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, financial instruments",
        "terseLabel": "Fair value adjustments on financial instruments",
        "totalLabel": "Total fair value adjustments on financial instruments, net of taxes",
        "verboseLabel": "Fair value adjustments during the year"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxFinancialInstruments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income net of tax gains/losses on remeasurements of defined benefit plans related to discontinued operations"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansRelatedToDiscontinuedOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income recycled into the consolidated income statement"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeRecycledIntoTheConsolidatedIncomeStatement",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other countries [member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OtherCurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets [abstract]"
       }
      }
     },
     "localname": "OtherCurrentAssetsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_OtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets [member]"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets [table text block]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_OtherFinancialIncomeAndExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other financial income and expense [abstract]"
       }
      }
     },
     "localname": "OtherFinancialIncomeAndExpenseAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_OtherFinancialIncomeAndExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Financial Income and Expense [table text block]",
        "terseLabel": "Other financial income and expense"
       }
      }
     },
     "localname": "OtherFinancialIncomeAndExpenseTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_OtherFinancialLiabilitiesCategoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other financial liabilities, category [member]"
       }
      }
     },
     "localname": "OtherFinancialLiabilitiesCategoryMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OtherFinancialLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other financial liabilities [member]"
       }
      }
     },
     "localname": "OtherFinancialLiabilitiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OtherHematologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Hematology [member]"
       }
      }
     },
     "localname": "OtherHematologyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OtherIntangibleAssetsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 4.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible assets recognised as of acquisition date",
        "terseLabel": "Other intangible assets"
       }
      }
     },
     "localname": "OtherIntangibleAssetsRecognisedAsOfAcquisitionDate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherIntangiblePurchaseCommitments": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2": {
       "order": 2.0,
       "parentTag": "nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other intangible asset purchase commitments"
       }
      }
     },
     "localname": "OtherIntangiblePurchaseCommitments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherLongtermEmployeeBenefitsAndDeferredCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherNoncurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other long-term employee benefits and deferred compensation"
       }
      }
     },
     "localname": "OtherLongtermEmployeeBenefitsAndDeferredCompensation",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherNetAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other net assets"
       }
      }
     },
     "localname": "OtherNetAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherNetCashInflowsFromDivestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other net cash inflows from divestments",
        "terseLabel": "dup_2_Divested business"
       }
      }
     },
     "localname": "OtherNetCashInflowsFromDivestments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherNoncurrentFinancialDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-current financial debt",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OtherNoncurrentFinancialDebt",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherPaymentsAndDeferredConsiderationNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other payments and deferred consideration, net",
        "terseLabel": "Payments, deferred consideration and other adjustments, net"
       }
      }
     },
     "localname": "OtherPaymentsAndDeferredConsiderationNet",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherPostemploymentBenefitPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other post-employment benefit plans [member]",
        "terseLabel": "Other post-employment benefit plans"
       }
      }
     },
     "localname": "OtherPostemploymentBenefitPlansMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OtherPostemploymentBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherNoncurrentNonfinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other post-employment benefits"
       }
      }
     },
     "localname": "OtherPostemploymentBenefits",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other [member]"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OtherPromotedBrandsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Promoted Brands [member]"
       }
      }
     },
     "localname": "OtherPromotedBrandsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OtherReceivablesAndCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables and current assets"
       }
      }
     },
     "localname": "OtherReceivablesAndCurrentAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherRespiratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Respiratory [member]"
       }
      }
     },
     "localname": "OtherRespiratoryMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OtherRevenueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other revenue, other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherRevenueOther",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherSharePurchases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other share purchases"
       }
      }
     },
     "localname": "OtherSharePurchases",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_OtherSharePurchasesValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other share purchases, equity impact",
        "negatedTerseLabel": "Other share purchases, equity impact"
       }
      }
     },
     "localname": "OtherSharePurchasesValue",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherShareSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other share sales",
        "negativeLabel": "Other share sales"
       }
      }
     },
     "localname": "OtherShareSales",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherShareSalesEquityImpact": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other share sales, equity impact"
       }
      }
     },
     "localname": "OtherShareSalesEquityImpact",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OtherSolidTumorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Solid Tumor [member]"
       }
      }
     },
     "localname": "OtherSolidTumorMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OthersAssociatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Others associates [member]",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OthersAssociatesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_OutstandingShareCapital": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureEquityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding share capital",
        "periodEndLabel": "Total outstanding share capital at end of period",
        "periodStartLabel": "Total outstanding share capital at beginning of period"
       }
      }
     },
     "localname": "OutstandingShareCapital",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OutstandingShareCapitalMovement": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureEquityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding share capital, movement",
        "terseLabel": "Total shares outstanding movement of period"
       }
      }
     },
     "localname": "OutstandingShareCapitalMovement",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_OverdueAmountsAndRelatedProvisionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Overdue amounts and related provisions [table text block]",
        "terseLabel": "Overdue amounts and related provision"
       }
      }
     },
     "localname": "OverdueAmountsAndRelatedProvisionsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_PT.CIBAVisionBatamBatamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PT. CIBA Vision Batam, Batam [member]"
       }
      }
     },
     "localname": "PT.CIBAVisionBatamBatamMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PT.NovartisIndonesiaJakartaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PT. Novartis Indonesia, Jakarta [member]"
       }
      }
     },
     "localname": "PT.NovartisIndonesiaJakartaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PartialReleaseOfDeferredTaxLiabilityRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Partial release of deferred tax liability recognized"
       }
      }
     },
     "localname": "PartialReleaseOfDeferredTaxLiabilityRecognized",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Past service cost and gains losses arising from settlements, defined benefit liability (asset)",
        "terseLabel": "Past service cost and settlements"
       }
      }
     },
     "localname": "PastServiceCostAndGainsLossesArisingFromSettlementsDefinedBenefitLiabilityAsset",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PaymentOfInterestBearingAccountsToBeneficiaries": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of interest bearing accounts to beneficiaries"
       }
      }
     },
     "localname": "PaymentOfInterestBearingAccountsToBeneficiaries",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PaymentPutOption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment put option"
       }
      }
     },
     "localname": "PaymentPutOption",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      },
      "http://novartis.com/20221231/role/StatementsOfCashFlowParenthetical": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments out of provisions and other net cash movements in non-current liabilities",
        "negatedTerseLabel": "Payments out of provisions and other net cash movements in non-current liabilities"
       }
      }
     },
     "localname": "PaymentsOutOfProvisionsAndOtherNetCashMovementsInNoncurrentLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PensionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension plan [member]",
        "terseLabel": "Pension plans"
       }
      }
     },
     "localname": "PensionPlanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PensionersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pensioners [member]",
        "terseLabel": "Pensioners"
       }
      }
     },
     "localname": "PensionersMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PensionsAndOtherBenefitObligationsOfAssociatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pensions and other benefit obligations of associates [member]"
       }
      }
     },
     "localname": "PensionsAndOtherBenefitObligationsOfAssociatesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of income not subject to tax on the divestment gain on GSK investment"
       }
      }
     },
     "localname": "PercentageImpactOfNewTaxLawChangeInDeferredTaxAssetsAndLiabilitiesAndCurrentTaxLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_PercentageOfEntitysTradeReceivable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of entitys trade receivable"
       }
      }
     },
     "localname": "PercentageOfEntitysTradeReceivable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_PercentageOfEquityInterestSharesReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of equity interest shares received"
       }
      }
     },
     "localname": "PercentageOfEquityInterestSharesReceived",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_PercentageOfGovernmentBackedDebtSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of government backed debt securities"
       }
      }
     },
     "localname": "PercentageOfGovernmentBackedDebtSecurities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_PercentageOfShareCapitalInTenderOffer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Share capital in tender offer"
       }
      }
     },
     "localname": "PercentageOfShareCapitalInTenderOffer",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of share capital tendered at the expiration of the tender offer"
       }
      }
     },
     "localname": "PercentageOfShareCapitalTenderedAtTheExpirationOfTheTenderOffer",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of share capital tendered at the subsequent offering period of the tender offer"
       }
      }
     },
     "localname": "PercentageOfShareCapitalTenderedAtTheSubsequentOfferingPeriodOfTheTenderOffer",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_PercentageOfVotingEquityInterestsContributed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of voting equity interests contributed"
       }
      }
     },
     "localname": "PercentageOfVotingEquityInterestsContributed",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_PiqrayMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Piqray [member]"
       }
      }
     },
     "localname": "PiqrayMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PlansAndProgramRebatesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plans and program rebates [axis]"
       }
      }
     },
     "localname": "PlansAndProgramRebatesAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_PlansAndProgramRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plans and program rebates [member]"
       }
      }
     },
     "localname": "PlansAndProgramRebatesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PluvictoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pluvicto [member]"
       }
      }
     },
     "localname": "PluvictoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PoPChangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change over period [member]"
       }
      }
     },
     "localname": "PoPChangeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PoPYEChangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change to prior year-end [member]"
       }
      }
     },
     "localname": "PoPYEChangeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Portion of consideration paid (received) consisting of cash and cash equivalents upfront payment",
        "negatedTerseLabel": "Portion of consideration paid consisting of cash and cash equivalents upfront payment"
       }
      }
     },
     "localname": "PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PositiveFairValuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Positive fair values [member]"
       }
      }
     },
     "localname": "PositiveFairValuesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential impact on the consolidated income statement due to increase (decrease) in currency exchange rates [table text block]",
        "terseLabel": "Potential impact on the consolidated income statement due to increase (decrease) in currency exchange rates"
       }
      }
     },
     "localname": "PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential impact on the consolidated income statement due to increase (decrease) in equity prices [table text block]",
        "terseLabel": "Potential impact on the consolidated income statement due to increase (decrease) in equity prices"
       }
      }
     },
     "localname": "PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInEquityPricesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential impact on the consolidated income statement due to increase (decrease) in interest rates [table text block]",
        "terseLabel": "Potential impact on the consolidated income statement due to increase (decrease) in interest rates"
       }
      }
     },
     "localname": "PotentialImpactOnTheConsolidatedIncomeStatementDueToIncreaseDecreaseInInterestRatesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential impact on the consolidated statements of comprehensive income due to increase (decrease) in equity prices [table text block]",
        "terseLabel": "Potential impact on the consolidated statements of comprehensive income due to increase (decrease) in equity prices"
       }
      }
     },
     "localname": "PotentialImpactOnTheConsolidatedStatementsOfComprehensiveIncomeDueToIncreaseDecreaseInEquityPricesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential impact on the consolidated equity due to increase (decrease) in currency exchange rates [table text block]",
        "terseLabel": "Potential impact on the consolidated equity due to increase (decrease) in currency exchange rates"
       }
      }
     },
     "localname": "PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInCurrencyExchangeRatesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential impact on the consolidated equity due to increase (decrease) in equity prices [table text block]",
        "terseLabel": "Potential impact on the consolidated equity due to increase (decrease) in equity prices"
       }
      }
     },
     "localname": "PotentialImpactOnTheConsolidatedequityDueToIncreaseDecreaseInEquityPricesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential inflows in various currencies - from financial derivative assets"
       }
      }
     },
     "localname": "PotentialInflowsInVariousCurrenciesFromFinancialDerivativeAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PotentialMilestoneMaximumPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential milestone maximum payments"
       }
      }
     },
     "localname": "PotentialMilestoneMaximumPayments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential outflows in various currencies - from financial derivative liabilities",
        "negatedTerseLabel": "Potential outflows in various currencies - from financial derivative liabilities"
       }
      }
     },
     "localname": "PotentialOutflowsInVariousCurrenciesFromFinancialDerivativeLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PotentialReceivableFromDivestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential receivable from divestment"
       }
      }
     },
     "localname": "PotentialReceivableFromDivestment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PotentiallyRefundableConsiderationFromAcquisition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Potentially refundable consideration from acquisition"
       }
      }
     },
     "localname": "PotentiallyRefundableConsiderationFromAcquisition",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PowerVisionInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PowerVision, Inc. [member]",
        "terseLabel": "PowerVision, Inc."
       }
      }
     },
     "localname": "PowerVisionInc.Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PreTaxProfitLossFromDivestmentOfBusiness": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre tax profit (loss) from divestment of business"
       }
      }
     },
     "localname": "PreTaxProfitLossFromDivestmentOfBusiness",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PrepaidPostemploymentBenefitPlansAssets": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2": {
       "order": 3.0,
       "parentTag": "ifrs-full_OtherNoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid post-employment benefit plans assets",
        "terseLabel": "Prepaid benefit cost"
       }
      }
     },
     "localname": "PrepaidPostemploymentBenefitPlansAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PrepaymentsAndAccruedLeasePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayments and accrued lease payments"
       }
      }
     },
     "localname": "PrepaymentsAndAccruedLeasePayments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously reported finance lease obligation of divested business"
       }
      }
     },
     "localname": "PreviouslyReportedFinanceLeaseObligationOfDivestedBusiness",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This expresses a limit.",
        "label": "Principal group companies materiality of assets or sales to third parties"
       }
      }
     },
     "localname": "PrincipalGroupCompaniesMaterialityOfAssetsOrSalesToThirdParties",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal Group subsidiaries and associated companies [table text block]",
        "terseLabel": "Principal Group subsidiaries and associated companies"
       }
      }
     },
     "localname": "PrincipalGroupSubsidiariesAndAssociatedCompaniesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_PriorYearAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior year adjustment"
       }
      }
     },
     "localname": "PriorYearAdjustment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProceedsFromCurrentAndNoncurrentBorrowings": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from current and non-current borrowings",
        "terseLabel": "Transaction costs payment",
        "verboseLabel": "Cash inflow from borrowings"
       }
      }
     },
     "localname": "ProceedsFromCurrentAndNoncurrentBorrowings",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of options and other treasury share transactions",
        "terseLabel": "Proceeds from exercised options and other treasury share transactions, net"
       }
      }
     },
     "localname": "ProceedsFromExerciseOptionsAndOtherTreasuryShareTransactions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProductLiabilityContingencyLossExposureNotAccruedBestEstimate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability contingency, loss exposure not accrued, best estimate"
       }
      }
     },
     "localname": "ProductLiabilityContingencyLossExposureNotAccruedBestEstimate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability contingency, loss exposure not accrued, number of cases"
       }
      }
     },
     "localname": "ProductLiabilityContingencyLossExposureNotAccruedNumberOfCases",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability, government investigations, other legal matters provisions",
        "periodEndLabel": "Product liabilities government investigations other legal matters provisions at end of period",
        "periodStartLabel": "Product liabilities government investigations other legal matters provisions at beginning of period"
       }
      }
     },
     "localname": "ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability, government investigations, other legal matters provisions, additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsAdditions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialLiabilities",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5": {
       "order": 1.0,
       "parentTag": "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability, government investigations, other legal matters provisions, current",
        "negatedTerseLabel": "Less current provision",
        "terseLabel": "Provisions for product liabilities, governmental investigations and other legal matters"
       }
      }
     },
     "localname": "ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsCurrent",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability, government investigations, other legal matters provisions, discontinued operations",
        "terseLabel": "Provisions related to discontinued operations"
       }
      }
     },
     "localname": "ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsDiscontinuedOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability, government investigations, other legal matters provisions, foreign currency translation gain (loss)",
        "terseLabel": "Currency translation effects"
       }
      }
     },
     "localname": "ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsForeignCurrencyTranslationGainLoss",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability, government investigations, other legal matters provisions, impact of business combinations",
        "terseLabel": "Impact of business combinations"
       }
      }
     },
     "localname": "ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsImpactOfBusinessCombinations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_OtherNoncurrentNonfinancialLiabilities",
       "weight": 1.0
      },
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5": {
       "order": 2.0,
       "parentTag": "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisions",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability, government investigations, other legal matters provisions, non-current",
        "periodEndLabel": "Non-current product liabilities, governmental investigations and other legal matters provisions at end of period",
        "terseLabel": "Product liability, government investigations, other legal matters provisions"
       }
      }
     },
     "localname": "ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsNoncurrent",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability, government investigations, other legal matters provisions, payments",
        "terseLabel": "Cash payments"
       }
      }
     },
     "localname": "ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsPayments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability, government investigations, other legal matters provisions, releases",
        "negatedTerseLabel": "Releases"
       }
      }
     },
     "localname": "ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsReleases",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product liability, government investigations, other legal matters provisions [roll forward]"
       }
      }
     },
     "localname": "ProductLiabilityGovernmentInvestigationsOtherLegalMattersProvisionsRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ProductPortfolioAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product portfolio [axis]"
       }
      }
     },
     "localname": "ProductPortfolioAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ProductPortfolioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product portfolio [member]"
       }
      }
     },
     "localname": "ProductPortfolioMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ProfDrBrodyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prof. Dr. Brody [member]"
       }
      }
     },
     "localname": "ProfDrBrodyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ProfDrZinkernagelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prof. Dr. Zinkernagel [member]"
       }
      }
     },
     "localname": "ProfDrZinkernagelMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities, as a percentage from net sales",
        "terseLabel": "Operating income as % of net sales"
       }
      }
     },
     "localname": "ProfitLossFromOperatingActivitiesAsAPercentageFromNetSales",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_ProfitSharingIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit sharing income"
       }
      }
     },
     "localname": "ProfitSharingIncome",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProformaNetSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proforma net sales"
       }
      }
     },
     "localname": "ProformaNetSales",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PromactaRevoladeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promacta/Revolade [member]"
       }
      }
     },
     "localname": "PromactaRevoladeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PromotedBrandsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promoted Brands [member]"
       }
      }
     },
     "localname": "PromotedBrandsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment impairment charges and reversals [table text block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentImpairmentChargesAndReversalsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_PropertyPlantAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [table text block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ProvisionForDeductionFromRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for deduction from revenue [table]"
       }
      }
     },
     "localname": "ProvisionForDeductionFromRevenueTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ProvisionForDoubtfulReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for doubtful receivable",
        "periodEndLabel": "Provision for doubtful receivable at end of period",
        "periodStartLabel": "Provision for doubtful receivable at beginning of period"
       }
      }
     },
     "localname": "ProvisionForDoubtfulReceivable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ProvisionForDoubtfulReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for doubtful receivable [member]"
       }
      }
     },
     "localname": "ProvisionForDoubtfulReceivableMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails2",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ProvisionsAndOtherCurrentLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provisions and other current liabilities [line items]"
       }
      }
     },
     "localname": "ProvisionsAndOtherCurrentLiabilitiesLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ProvisionsForDeductionsFromRevenueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provisions for deductions from revenue [roll forward]"
       }
      }
     },
     "localname": "ProvisionsForDeductionsFromRevenueRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ProvisionsForReductionOfRevenueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provisions for reduction of revenue [table text block]",
        "terseLabel": "Provisions for reduction of revenue"
       }
      }
     },
     "localname": "ProvisionsForReductionOfRevenueTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ProvisionsForTradeReceivablesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provisions for trade receivables [table text block]",
        "terseLabel": "Provisions for trade receivables"
       }
      }
     },
     "localname": "ProvisionsForTradeReceivablesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_PurchaseFairValueMeasurementAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchases fair value measurement assets"
       }
      }
     },
     "localname": "PurchaseFairValueMeasurementAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_PurchasePriceAllocationAssociatesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price allocation associates [table text block]",
        "terseLabel": "Purchase price allocation associates"
       }
      }
     },
     "localname": "PurchasePriceAllocationAssociatesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_RatioFixedRateFinancialDebtToTotalFinancialDebt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ratio fixed rate financial debt to total financial debt"
       }
      }
     },
     "localname": "RatioFixedRateFinancialDebtToTotalFinancialDebt",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_RealEstateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real estate [member]",
        "terseLabel": "Real estate"
       }
      }
     },
     "localname": "RealEstateMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ReceivablesAndPayablesContingentConsiderationNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables and payables contingent consideration, net",
        "terseLabel": "Contingent consideration payables, net"
       }
      }
     },
     "localname": "ReceivablesAndPayablesContingentConsiderationNet",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ReceivablesAssociatedCompanies": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables associated companies"
       }
      }
     },
     "localname": "ReceivablesAssociatedCompanies",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ReclassificationFairValueMeasurementAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is a reclassification that can be debit or credit.",
        "label": "Reclassification fair value measurement assets"
       }
      }
     },
     "localname": "ReclassificationFairValueMeasurementAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ReclassificationFromNoncurrentToCurrentNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification from non-current to current, net"
       }
      }
     },
     "localname": "ReclassificationFromNoncurrentToCurrentNet",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ReclassificationToPresentationRequiredUnderIFRS9Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification to presentation required under IFRS 9 [member]"
       }
      }
     },
     "localname": "ReclassificationToPresentationRequiredUnderIFRS9Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ReclastAclastaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclast/Aclasta [member]"
       }
      }
     },
     "localname": "ReclastAclastaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ReconciliationOfChangesInFairValueMeasurementAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of changes in fair value measurement [table]"
       }
      }
     },
     "localname": "ReconciliationOfChangesInFairValueMeasurementAssetsTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of lease commitment and lease liability [table text block]",
        "terseLabel": "Reconciliation of lease commitment and lease liability"
       }
      }
     },
     "localname": "ReconciliationOfLeaseCommitmentAndLeaseLiabilityTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureRightOfUseAssetsAndLeaseLiabilityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of liabilities arising from financing activities [table text block]",
        "terseLabel": "Reconciliation of liabilities arising from financing activities"
       }
      }
     },
     "localname": "ReconciliationOfLiabilitiesArisingFromFinancingActivitiesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recycling of the Novartis share of other comprehensive income from associated companies"
       }
      }
     },
     "localname": "RecyclingOfTheNovartisShareOfOtherComprehensiveIncomeFromAssociatedCompanies",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursements from plan to employer net defined benefit liability (asset)",
        "terseLabel": "Novartis Group contributions"
       }
      }
     },
     "localname": "ReimbursementsFromPlanToEmployerNetDefinedBenefitLiabilityAsset",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_RelatedPartiesNumberOfExecutiveCommitteeMembers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related parties, number of executive committee members",
        "terseLabel": "Executive Committee members"
       }
      }
     },
     "localname": "RelatedPartiesNumberOfExecutiveCommitteeMembers",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related parties, number of executive committee members who stepped down",
        "terseLabel": "Executive Committee members who stepped down"
       }
      }
     },
     "localname": "RelatedPartiesNumberOfExecutiveCommitteeMembersWhoSteppedDown",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_RelatedPartiesNumberOfNonexecutiveDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related parties, number of non-executive directors",
        "terseLabel": "Non-executive directors"
       }
      }
     },
     "localname": "RelatedPartiesNumberOfNonexecutiveDirectors",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_RemainingLeaseCommitments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining lease commitments"
       }
      }
     },
     "localname": "RemainingLeaseCommitments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_RepaymentOfIntercompanyBalances": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of intercompany balances",
        "negatedTerseLabel": "Repayment of intercompany balances"
       }
      }
     },
     "localname": "RepaymentOfIntercompanyBalances",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_RepaymentOfLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of lease liability"
       }
      }
     },
     "localname": "RepaymentOfLeaseLiability",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ReportedValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reported value [member]"
       }
      }
     },
     "localname": "ReportedValueMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ReprixysPharmaceuticalsCorporationEastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reprixys Pharmaceuticals Corporation, East Hanover, NJ [member]"
       }
      }
     },
     "localname": "ReprixysPharmaceuticalsCorporationEastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ReprixysPharmaceuticalsCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reprixys Pharmaceuticals Corporation [member]",
        "terseLabel": "Reprixys Pharmaceuticals Corporation"
       }
      }
     },
     "localname": "ReprixysPharmaceuticalsCorporationMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_RepurchaseOfOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase of options",
        "negatedTerseLabel": "Repurchase of options"
       }
      }
     },
     "localname": "RepurchaseOfOptions",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development and other intangible asset purchase commitments",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAndOtherIntangiblePurchaseCommitments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ResearchAndDevelopmentCommitmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development and other intangible asset purchase commitments [abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCommitmentsAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development commitments for transactions entered into current year, closed after current year end"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCommitmentsForTransactionsEnteredIntoCurrentYearClosedAfterCurrentYearEnd",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Respective Useful Lives of Available-for-Use Intangible Assets [table text block]",
        "terseLabel": "Respective Useful Lives of Available-for-Use Intangible Assets"
       }
      }
     },
     "localname": "RespectiveUsefulLivesOfAvailableforUseIntangibleAssetsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Respective Useful Lives of property, plant and equipment [table text block]",
        "terseLabel": "Respective Useful Lives of property, plant and equipment"
       }
      }
     },
     "localname": "RespectiveUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_RestOfPortfolioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rest of portfolio [member]"
       }
      }
     },
     "localname": "RestOfPortfolioMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_RestOfTheWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rest of the world [member]"
       }
      }
     },
     "localname": "RestOfTheWorldMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_RestatedValueAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restated Value Adjustments [member]"
       }
      }
     },
     "localname": "RestatedValueAdjustmentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_RestructuringProvisionsMovementsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring provisions movements [roll forward]"
       }
      }
     },
     "localname": "RestructuringProvisionsMovementsRollForward",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_RestructuringProvisionsMovementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring provisions movements [table]"
       }
      }
     },
     "localname": "RestructuringProvisionsMovementsTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_RestructuringProvisionsMovementsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring provisions movements [table text block]",
        "terseLabel": "Restructuring provisions movements"
       }
      }
     },
     "localname": "RestructuringProvisionsMovementsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_RetailGenericsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retail Generics [member]"
       }
      }
     },
     "localname": "RetailGenericsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_RetirementPlanTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement plan type [axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_RetirementPlanTypeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement plan type [member]"
       }
      }
     },
     "localname": "RetirementPlanTypeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_RevenueFromSaleOfGoodsSalesToOtherSegments": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 3.0,
       "parentTag": "ifrs-full_RevenueFromSaleOfGoods",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from sale of goods, sales to other segments",
        "terseLabel": "Sales to discontinued segment",
        "verboseLabel": "Sales to other segments"
       }
      }
     },
     "localname": "RevenueFromSaleOfGoodsSalesToOtherSegments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_RevenueFromSaleOfGoodsThirdParties": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/StatementOfIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_RevenueFromSaleOfGoods",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from sale of goods, third parties and other segments",
        "terseLabel": "Net sales to third parties",
        "verboseLabel": "Net sales to third parties of discontinued operations"
       }
      }
     },
     "localname": "RevenueFromSaleOfGoodsThirdParties",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from sale of goods, third parties and other segments, as percent of total net sales",
        "terseLabel": "Net sales (in % of total net sales)"
       }
      }
     },
     "localname": "RevenueFromSaleOfGoodsThirdPartiesAsPercentOfTotalNetSales",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from sale of goods, third parties, change in percent",
        "terseLabel": "Net sales, change in %"
       }
      }
     },
     "localname": "RevenueFromSaleOfGoodsThirdPartiesChangeInPercent",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from sale of goods, third parties, change in percent, cc",
        "terseLabel": "Net sales, change in %, cc"
       }
      }
     },
     "localname": "RevenueFromSaleOfGoodsThirdPartiesChangeInPercentCc",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_RevenueOfAcquireeFullYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue of acquiree full year"
       }
      }
     },
     "localname": "RevenueOfAcquireeFullYear",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Reversal impairment loss recognised in profit or loss, right of use assets"
       }
      }
     },
     "localname": "ReversalImpairmentLossRecognisedInProfitOrLossRightOfUseAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_RightOfUseAssetsAsOfAcquisitionDate": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 13.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use assets as of acquisition date",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetsAsOfAcquisitionDate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use assets Disclosure and Lease liabilities [abstract]"
       }
      }
     },
     "localname": "RightOfUseAssetsDisclosureAndLeaseLiabilitiesAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_RightOfUseAssetsToBeRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use assets to be recognized"
       }
      }
     },
     "localname": "RightOfUseAssetsToBeRecognized",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_RitalinFocalinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ritalin/Focalin [member]"
       }
      }
     },
     "localname": "RitalinFocalinMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_RocheHoldingAGBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Roche Holding AG, Basel [member]"
       }
      }
     },
     "localname": "RocheHoldingAGBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_RocheHoldingAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Roche Holding AG [member]",
        "terseLabel": "Roche Holding AG, Switzerland"
       }
      }
     },
     "localname": "RocheHoldingAGMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails3",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SaleAndLeaseBackMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale and lease back [member]",
        "terseLabel": "Sale and leaseback"
       }
      }
     },
     "localname": "SaleAndLeaseBackMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of business assets arising from contingencies amount recognized"
       }
      }
     },
     "localname": "SaleOfBusinessAssetsArisingFromContingenciesAmountRecognized",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of business assets arising from contingencies amount recognized other than at fair value"
       }
      }
     },
     "localname": "SaleOfBusinessAssetsArisingFromContingenciesAmountRecognizedOtherThanAtFairValue",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of business, contingent consideration arrangements, range of outcomes, value, high"
       }
      }
     },
     "localname": "SaleOfBusinessContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_SaleOfBusinessContingentOptionArrangementsFeePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of business, contingent option arrangements, fee paid"
       }
      }
     },
     "localname": "SaleOfBusinessContingentOptionArrangementsFeePaid",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of business, contingent option arrangements, range of outcomes, value, high"
       }
      }
     },
     "localname": "SaleOfBusinessContingentOptionArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_SalutasPharmaGmbHBarlebenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salutas Pharma GmbH, Barleben [member]"
       }
      }
     },
     "localname": "SalutasPharmaGmbHBarlebenMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandostatinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandostatin [member]"
       }
      }
     },
     "localname": "SandostatinMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozAGBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz AG, Basel [member]"
       }
      }
     },
     "localname": "SandozAGBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozASCopenhagenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz A/S, Copenhagen [member]"
       }
      }
     },
     "localname": "SandozASCopenhagenMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozB.V.AlmereMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz B.V., Almere [member]"
       }
      }
     },
     "localname": "SandozB.V.AlmereMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozCanadaInc.BouchervilleQuebecMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Canada Inc., Boucherville, Quebec [member]"
       }
      }
     },
     "localname": "SandozCanadaInc.BouchervilleQuebecMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz (China) Pharmaceutical Co., Ltd., Zhongshan [member]"
       }
      }
     },
     "localname": "SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozD.o.o.FarmaceutskaIndustrijaZagrebMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz d.o.o. farmaceutska industrija, Zagreb [member]"
       }
      }
     },
     "localname": "SandozD.o.o.FarmaceutskaIndustrijaZagrebMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz do Brasil Industria Farmaceutica Ltda., Cambe, PR [member]"
       }
      }
     },
     "localname": "SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozEgyptPharmaS.A.E.NewCairoCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Egypt Pharma S.A.E., New Cairo City [member]"
       }
      }
     },
     "localname": "SandozEgyptPharmaS.A.E.NewCairoCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozFarmaceuticaLda.PortoSalvoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Farmaceutica Lda., Porto Salvo [member]"
       }
      }
     },
     "localname": "SandozFarmaceuticaLda.PortoSalvoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozFarmaceuticaS.A.MadridMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Farmaceutica S.A., Madrid [member]"
       }
      }
     },
     "localname": "SandozFarmaceuticaS.A.MadridMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozGmbHViennaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz GmbH, Kundl [member]"
       }
      }
     },
     "localname": "SandozGmbHViennaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Grup Saglik Urunleri Ilaclari Sanayi ve Ticaret A.S., Gebze - Kocaeli [member]"
       }
      }
     },
     "localname": "SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozHungaryLimitedLiabilityCompanyBudapestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Hungary Limited Liability Company, Budapest [member]"
       }
      }
     },
     "localname": "SandozHungaryLimitedLiabilityCompanyBudapestMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozIlacSanayiVeTicaretA.S.IstanbulMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Ilac Sanayi ve Ticaret A.S., Istanbul [member]"
       }
      }
     },
     "localname": "SandozIlacSanayiVeTicaretA.S.IstanbulMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozInc.PrincetonNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Inc., Princeton, NJ [member]"
       }
      }
     },
     "localname": "SandozInc.PrincetonNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Industrial Products S.A., Les Franqueses del Vall?s / Barcelona [member]"
       }
      }
     },
     "localname": "SandozIndustrialProductsS.A.LesFranquesesDelVallesBarcelonaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozIndustrialProductsS.p.A.RoveretoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Industrial Products S.p.A., Rovereto [member]"
       }
      }
     },
     "localname": "SandozIndustrialProductsS.p.A.RoveretoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozInternationalGmbHHolzkirchenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz International GmbH, Holzkirchen [member]"
       }
      }
     },
     "localname": "SandozInternationalGmbHHolzkirchenMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozK.K.TokyoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz K.K., Tokyo [member]"
       }
      }
     },
     "localname": "SandozK.K.TokyoMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozKoreaLtd.SeoulMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Korea Ltd., Seoul [member]"
       }
      }
     },
     "localname": "SandozKoreaLtd.SeoulMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozLimitedFrimleyCamberleyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Limited, Frimley/Camberley [member]"
       }
      }
     },
     "localname": "SandozLimitedFrimleyCamberleyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozManufacturingInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Manufacturing Inc. [member]"
       }
      }
     },
     "localname": "SandozManufacturingInc.Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz [member]",
        "terseLabel": "Sandoz"
       }
      }
     },
     "localname": "SandozMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails2",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails3",
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosurePropertyPlantAndEquipmentDetails2",
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails1",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails10",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails2",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails3",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozNVVilvoordeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz NV, Vilvoorde [member]"
       }
      }
     },
     "localname": "SandozNVVilvoordeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozPharmaceuticalsAGRischMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Pharmaceuticals AG, Risch [member]"
       }
      }
     },
     "localname": "SandozPharmaceuticalsAGRischMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozPharmaceuticalsD.d.LjubjanaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Pharmaceuticals d.d., Ljubjana [member]"
       }
      }
     },
     "localname": "SandozPharmaceuticalsD.d.LjubjanaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozPhilippinesCorporationMakatiCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Philippines Corporation, Makati City [member]"
       }
      }
     },
     "localname": "SandozPhilippinesCorporationMakatiCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozPolskaSp.ZO.o.WarsawMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Polska Sp. z o.o., Warsaw [member]"
       }
      }
     },
     "localname": "SandozPolskaSp.ZO.o.WarsawMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozPrivateLimitedMumbaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Private Limited, Mumbai [member]"
       }
      }
     },
     "localname": "SandozPrivateLimitedMumbaiMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozPtyLtdMacquarieParkNSWMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Pty Ltd, Macquarie Park, NSW [member]"
       }
      }
     },
     "localname": "SandozPtyLtdMacquarieParkNSWMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozS.A.DeC.V.MexicoCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz, S.A. de C.V., Mexico City [member]"
       }
      }
     },
     "localname": "SandozS.A.DeC.V.MexicoCityMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozS.A.S.LevalloisPerretMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz S.A.S., Levallois-Perret [member]"
       }
      }
     },
     "localname": "SandozS.A.S.LevalloisPerretMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozS.R.L.TarguMuresMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz S.R.L., Targu-Mures [member]"
       }
      }
     },
     "localname": "SandozS.R.L.TarguMuresMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozS.p.A.OriggioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz S.p.A., Origgio [member]"
       }
      }
     },
     "localname": "SandozS.p.A.OriggioMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozS.r.o.PragueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz s.r.o., Prague [member]"
       }
      }
     },
     "localname": "SandozS.r.o.PragueMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozSouthAfricaPtyLtdMidrandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz South Africa (Pty) Ltd, Midrand [member]"
       }
      }
     },
     "localname": "SandozSouthAfricaPtyLtdMidrandMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Syntek Ilac Hammaddeleri Sanayi ve Ticaret A.S., Istanbul [member]"
       }
      }
     },
     "localname": "SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SandozUkraineLLCKievMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sandoz Ukraine LLC, Kyiv [member]"
       }
      }
     },
     "localname": "SandozUkraineLLCKievMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Saudi Pharmaceutical Distribution Co. Ltd., Riyadh [member]"
       }
      }
     },
     "localname": "SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ScemblixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scemblix [member]"
       }
      }
     },
     "localname": "ScemblixMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule for commitments under fixed term operating leases [line items]"
       }
      }
     },
     "localname": "ScheduleForCommitmentsUnderFixedTermOperatingLeasesLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule for commitments under fixed term operating leases [table]"
       }
      }
     },
     "localname": "ScheduleForCommitmentsUnderFixedTermOperatingLeasesTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule for commitments under research and development and other intangible asset purchase [line items]"
       }
      }
     },
     "localname": "ScheduleForCommitmentsUnderResearchAndDevelopmentAgreementsLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ScheduleForCommitmentsUnderResearchAndDevelopmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule for commitments under research and development and other intangible asset purchase [table]"
       }
      }
     },
     "localname": "ScheduleForCommitmentsUnderResearchAndDevelopmentTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ScheduleOfAllocationOfPlanAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of allocation of plan assets [table]"
       }
      }
     },
     "localname": "ScheduleOfAllocationOfPlanAssetsTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of allocation of plan assets [table text block]",
        "terseLabel": "The weighted average plan asset allocation of funded defined benefit pension plans"
       }
      }
     },
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of asset allocation, investments in shares of Novartis AG [table text block]",
        "terseLabel": "Asset allocation, investments in shares of Novartis AG"
       }
      }
     },
     "localname": "ScheduleOfAssetAllocationInvestmentsInSharesOfNovartisAGTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of assumptions used [table text block]",
        "terseLabel": "Principal weighted average actuarial assumptions"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of comprehensive income [table text block]",
        "terseLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ScheduleOfComprehensiveIncomeTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [table text block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of defined benefit plan amounts recognized in other comprehensive income [table text block]",
        "terseLabel": "Schedule of defined benefit plan amounts recognized in other comprehensive income"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of defined benefit plans disclosures [table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ScheduleOfDefinedContributionPlansTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of defined contribution plans [table text block]",
        "terseLabel": "Defined contribution plans"
       }
      }
     },
     "localname": "ScheduleOfDefinedContributionPlansTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [table text block]",
        "terseLabel": "Earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfExpectedBenefitPaymentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of expected benefit payments [table]"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of expected benefit payments [table text block]",
        "terseLabel": "The expected future cash flows in respect of pension and other post- employment benefit plans"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of expense related to all equity-based participation and liabilities arising from equity-based payment transactions [table text block]",
        "terseLabel": "Expense related to all equity-based participation and liabilities arising from equity-based payment transactions"
       }
      }
     },
     "localname": "ScheduleOfExpenseRelatedToAllEquitybasedParticipationAndLiabilitiesArisingFromEquitybasedPaymentTransactionsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfHealthCareCostTrendRatesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of health care cost trend rates [table]"
       }
      }
     },
     "localname": "ScheduleOfHealthCareCostTrendRatesTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ScheduleOfHealthCareCostTrendRatesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of health care cost trend rates [table text block]",
        "terseLabel": "The healthcare cost trend rate assumptions used for other post-employment benefits"
       }
      }
     },
     "localname": "ScheduleOfHealthCareCostTrendRatesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [table text block]",
        "terseLabel": "Inventories by class"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureInventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of provisions and other current liabilities [table text block]",
        "terseLabel": "Provisions and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfProvisionsAndOtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of sensitivity analysis for actuarial assumptions [table text block]",
        "terseLabel": "The sensitivity of the defined benefit pension obligation to the principal actuarial assumptions"
       }
      }
     },
     "localname": "ScheduleOfSensitivityAnalysisForActuarialAssumptionsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of share value adjustments currency translation effects [table text block]",
        "terseLabel": "Schedule of share value adjustments currency translation effects"
       }
      }
     },
     "localname": "ScheduleOfShareValueAdjustmentsCurrencyTranslationEffectsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfSharebasedCompensationActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of share-based compensation, activity [table text block]",
        "terseLabel": "Schedule of share-based compensation, activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationActivityTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of unvested restricted stock units roll forward [table]"
       }
      }
     },
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of unvested restricted stock units roll forward [table text block]",
        "terseLabel": "Schedule of unvested restricted stock units roll forward"
       }
      }
     },
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_SecondLargestCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second largest customer [member]"
       }
      }
     },
     "localname": "SecondLargestCustomerMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SecondLargestFinancialInstitutionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second largest financial institution [member]"
       }
      }
     },
     "localname": "SecondLargestFinancialInstitutionMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SeebriBreezhalerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Seebri Breezhaler [member]"
       }
      }
     },
     "localname": "SeebriBreezhalerMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SelectedNoncurrentAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies",
        "label": "Total of selected non-current assets"
       }
      }
     },
     "localname": "SelectedNoncurrentAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies. As percent of total selected non-current assets.",
        "label": "Selected non-current assets, as percent",
        "terseLabel": "Selected non-current assets (in % of total selected non-current assets)"
       }
      }
     },
     "localname": "SelectedNoncurrentAssetsAsPercentOfTotalSelectedNoncurrentAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_SelexysPharmaceuticalsCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selexys Pharmaceuticals Corporation [member]",
        "terseLabel": "Selexys Pharmaceuticals Corporation"
       }
      }
     },
     "localname": "SelexysPharmaceuticalsCorporationMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SerelaxinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Serelaxin [member]"
       }
      }
     },
     "localname": "SerelaxinMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ShanghaiNovartisTradingLtd.ShanghaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shanghai Novartis Trading Ltd., Shanghai [member]"
       }
      }
     },
     "localname": "ShanghaiNovartisTradingLtd.ShanghaiMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ShareMovements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share movements in period",
        "terseLabel": "Total movements"
       }
      }
     },
     "localname": "ShareMovements",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_ShareOfCurrentYearNetIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Novartis share of current year consolidated net income"
       }
      }
     },
     "localname": "ShareOfCurrentYearNetIncome",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_SharePaidinCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share/paid-in capital"
       }
      }
     },
     "localname": "SharePaidinCapital",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_SharepurchaseOfTreasuryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-purchase of treasury shares",
        "terseLabel": "Purchase of treasury shares"
       }
      }
     },
     "localname": "SharepurchaseOfTreasuryShares",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_SharesCancelledForCapitalReduction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares cancelled for capital reduction"
       }
      }
     },
     "localname": "SharesCancelledForCapitalReduction",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_SharesDeliveredToDivestedBusinessEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares delivered to divested business employees"
       }
      }
     },
     "localname": "SharesDeliveredToDivestedBusinessEmployees",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares delivered to divested business employees, equity impact"
       }
      }
     },
     "localname": "SharesDeliveredToDivestedBusinessEmployeesAsAResultOfSpinoff",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails4",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ShortTermLeasesAndLowValueLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Short term leases and low value leases"
       }
      }
     },
     "localname": "ShortTermLeasesAndLowValueLeases",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_SignificantAccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [abstract]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesAbstract",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nvs_SocieteParActionsSANDOZAlgiersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Societe par actions SANDOZ, Algiers [member]"
       }
      }
     },
     "localname": "SocieteParActionsSANDOZAlgiersMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SolidTumorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Solid Tumors [member]"
       }
      }
     },
     "localname": "SolidTumorMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SolodynMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Solodyn [member]"
       }
      }
     },
     "localname": "SolodynMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SparkTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Spark Therapeutics, Inc. [member]"
       }
      }
     },
     "localname": "SparkTherapeuticsInc.Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SpinifexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Spinifex [member]",
        "terseLabel": "Spinifex"
       }
      }
     },
     "localname": "SpinifexMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SpinifexPharmaceuticalsInc.EastHanoverNJMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Spinifex Pharmaceuticals, Inc., East Hanover, NJ [member]"
       }
      }
     },
     "localname": "SpinifexPharmaceuticalsInc.EastHanoverNJMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SpinifexPharmaceuticalsInc.WilmingtonNCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Spinifex Pharmaceuticals, Inc., Wilmington, NC [member]"
       }
      }
     },
     "localname": "SpinifexPharmaceuticalsInc.WilmingtonNCMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [line items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails",
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails2",
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome",
      "http://novartis.com/20221231/role/StatementOfIncome",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/BalanceSheet",
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesTables",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails6",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails7",
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails8",
      "http://novartis.com/20221231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17",
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesTables",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresTables",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails",
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails2",
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2",
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3",
      "http://novartis.com/20221231/role/StatementOfComprehensiveIncome",
      "http://novartis.com/20221231/role/StatementOfIncome",
      "http://novartis.com/20221231/role/StatementsOfCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stiftung der Novartis AG fuer Erziehung, Ausbildung und Bildung, Basel [member]"
       }
      }
     },
     "localname": "StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock repurchase program, authorized amount",
        "negatedTerseLabel": "Increase of treasury share repurchase obligation under a share buyback trading plan",
        "terseLabel": "Shares repurchased on the SIX Swiss Exchange second trading line under the share buyback authority approved"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_StraightBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Straight bonds [member]"
       }
      }
     },
     "localname": "StraightBondsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails",
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SubsequentEventTypAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Typ [axis]"
       }
      }
     },
     "localname": "SubsequentEventTypAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails",
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_SubsequentEventTypeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [member]"
       }
      }
     },
     "localname": "SubsequentEventTypeMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails",
      "http://novartis.com/20221231/role/DisclosureSubsequentEventsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SummaryOfTreasurySharesMovementsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of treasury shares movements [table text block]",
        "terseLabel": "Schedule disclosing information related treasury shares movements"
       }
      }
     },
     "localname": "SummaryOfTreasurySharesMovementsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Suzhou Novartis Pharma Technology Co., Ltd., Changshu [member]"
       }
      }
     },
     "localname": "SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Suzhou Novartis Technical Development Co., Ltd., Changshu [member]"
       }
      }
     },
     "localname": "SuzhouNovartisTechnicalDevelopmentCo.Ltd.ChangshuMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Suzhou Novartis Technical Development Co., Ltd. [member]"
       }
      }
     },
     "localname": "SuzhouNovartisTechnicalDevelopmentCo.Ltd.Member",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_SystaneGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Systane Group [member]"
       }
      }
     },
     "localname": "SystaneGroupMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TabrectaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabrecta [member]"
       }
      }
     },
     "localname": "TabrectaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TafinlarMekinistMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tafinlar + Mekinist [member]"
       }
      }
     },
     "localname": "TafinlarMekinistMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TakedaPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Takeda Pharmaceutical Company Limited [member]",
        "terseLabel": "Takeda Pharmaceutical Company Limited"
       }
      }
     },
     "localname": "TakedaPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TasignaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tasigna [member]"
       }
      }
     },
     "localname": "TasignaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TaxExpenseIncomeDiscontinuingOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax expense (income), discontinuing operations",
        "negatedTerseLabel": "Income tax expense from discontinued operations",
        "terseLabel": "Income tax expense from discontinued operations"
       }
      }
     },
     "localname": "TaxExpenseIncomeDiscontinuingOperations",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TaxLossCarryForwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax loss carry forwards",
        "terseLabel": "dup_1_Tax loss carryforwards expired"
       }
      }
     },
     "localname": "TaxLossCarryForwards",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TaxLossCarryforwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax loss carryforwards [member]"
       }
      }
     },
     "localname": "TaxLossCarryforwardsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TaxOnTransactionCostsRecordedInEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax on transaction costs recorded in equity"
       }
      }
     },
     "localname": "TaxOnTransactionCostsRecordedInEquity",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails5"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TaxRateEffectFromBenefitsExpiring": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax rate, effect from benefits expiring",
        "terseLabel": "Effect of tax benefits expiring in 2017"
       }
      }
     },
     "localname": "TaxRateEffectFromBenefitsExpiring",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_TaxRateEffectFromNondeductibleLossesInRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax rate, effect from non-deductible losses",
        "terseLabel": "Effect of non-deductible losses in Venezuela"
       }
      }
     },
     "localname": "TaxRateEffectFromNondeductibleLossesInRegion",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax rate, effect from write down and reversal of write down of invest subsidiaries",
        "terseLabel": "Effect of write down and reversal of write down of investments in subsidiaries"
       }
      }
     },
     "localname": "TaxRateEffectFromWritedownAndReversalOfWritedownOfInvestSubsidiaries",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_TaxRateEffectOfCreditsAndAllowances": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax rate, effect of credits and allowances",
        "terseLabel": "Effect of tax credits and allowances"
       }
      }
     },
     "localname": "TaxRateEffectOfCreditsAndAllowances",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_TaxRateEffectOfIncomeTaxedAtReducedRates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax rate, effect of income taxed at reduced rates",
        "terseLabel": "Effect of income taxed at reduced rates"
       }
      }
     },
     "localname": "TaxRateEffectOfIncomeTaxedAtReducedRates",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_TaxRateEffectOfReleaseOfContingentConsiderationLiability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax rate, effect of release of contingent consideration liability",
        "terseLabel": "Effect of release of contingent consideration liability"
       }
      }
     },
     "localname": "TaxRateEffectOfReleaseOfContingentConsiderationLiability",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTaxesDetails3"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_TaxReformImpactOnDeferredTaxOnTreasuryShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax reform impact on deferred tax on treasury shares"
       }
      }
     },
     "localname": "TaxReformImpactOnDeferredTaxOnTreasuryShares",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Amortization of fair value adjustments relating to intangible assets"
       }
      }
     },
     "localname": "TaxesOnAmortizationOfFairValueAdjustmentsRelatingToIntangibleAssets",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAssociatedCompaniesDetails6"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TaxesOnTreasuryShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on treasury shares",
        "negatedTerseLabel": "Taxes on treasury shares"
       }
      }
     },
     "localname": "TaxesOnTreasuryShares",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TaxotereMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxotere [member]"
       }
      }
     },
     "localname": "TaxotereMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TearFilmInnovationsInc.FortWorthTXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tear Film Innovations, Inc., Fort Worth, TX [member]"
       }
      }
     },
     "localname": "TearFilmInnovationsInc.FortWorthTXMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TekturnaRasilezValturnaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tekturna/Rasilez/Valturna [member]"
       }
      }
     },
     "localname": "TekturnaRasilezValturnaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Differences On Which No Deferred Tax Assets Have Been Provided [table text block]",
        "terseLabel": "Temporary differences on which no deferred tax assets have been provided"
       }
      }
     },
     "localname": "TemporaryDifferencesOnWhichNoDeferredTaxAssetsHaveBeenProvidedTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_TenDayLossFairValueVARModelLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ten day loss fair value VAR model [line items]"
       }
      }
     },
     "localname": "TenDayLossFairValueVARModelLineItems",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_TenDayLossFairValueVARModelTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ten day loss fair value VAR model [table]"
       }
      }
     },
     "localname": "TenDayLossFairValueVARModelTable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_TennesseeClassActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tennessee class action [member]"
       }
      }
     },
     "localname": "TennesseeClassActionMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TheMedicinesCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Medicines Company, East Hanover, NJ [member]",
        "terseLabel": "The Medicines Company"
       }
      }
     },
     "localname": "TheMedicinesCompanyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ThirdLargestCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third largest customer [member]"
       }
      }
     },
     "localname": "ThirdLargestCustomerMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ThirdLargestFinancialInstitutionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third largest financial institution [member]"
       }
      }
     },
     "localname": "ThirdLargestFinancialInstitutionMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ThreeYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Three years [member]"
       }
      }
     },
     "localname": "ThreeYearsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TimeDepositsWithOriginalMaturityMoreThan90DaysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Time deposits with original maturity more than 90 days [member]"
       }
      }
     },
     "localname": "TimeDepositsWithOriginalMaturityMoreThan90DaysMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_Top20ProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Top 20 products [member]"
       }
      }
     },
     "localname": "Top20ProductsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TopicalOlopatadineGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Topical Olopatadine Group [member]"
       }
      }
     },
     "localname": "TopicalOlopatadineGroupMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TotalAntiinfectivesNetSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total anti-infectives net sales [member]"
       }
      }
     },
     "localname": "TotalAntiinfectivesNetSalesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails8"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TotalAvailableforsaleMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total available-for-sale marketable securities [member]"
       }
      }
     },
     "localname": "TotalAvailableforsaleMarketableSecuritiesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TotalFairValueAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total fair value adjustments [member]",
        "terseLabel": "Total fair value adjustments"
       }
      }
     },
     "localname": "TotalFairValueAdjustmentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails14"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities, time deposits and derivative financial instruments [member]"
       }
      }
     },
     "localname": "TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total percentage of share capital tendered after the subsequent offering period of the tender offer"
       }
      }
     },
     "localname": "TotalPercentageOfShareCapitalTenderedAfterTheSubsequentOfferingPeriodOfTheTenderOffer",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_TotalValueAdjustmentsAttributableToNovartisShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total value adjustments attributable to Novartis shareholders [Member]",
        "terseLabel": "Total value adjustments"
       }
      }
     },
     "localname": "TotalValueAdjustmentsAttributableToNovartisShareholdersMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails",
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TradePayablesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 12.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables and other liabilities",
        "negatedTerseLabel": "Trade payables and other liabilities"
       }
      }
     },
     "localname": "TradePayablesAndOtherLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TradePayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables [member]"
       }
      }
     },
     "localname": "TradePayablesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade receivables and other current assets excluding pre-payments [member]"
       }
      }
     },
     "localname": "TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails": {
       "order": 8.0,
       "parentTag": "nvs_IdentifiableAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade receivables and other current assets recognised as of acquisition date",
        "terseLabel": "Trade receivables and financial and other current assets"
       }
      }
     },
     "localname": "TradeReceivablesAndOtherCurrentAssetsRecognisedAsOfAcquisitionDate",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureAcquisitionsOfBusinessesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade receivables denominated in other currencies [table text block]",
        "terseLabel": "Trade receivables denominated in other currencies"
       }
      }
     },
     "localname": "TradeReceivablesDenominatedInOtherCurrenciesTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_TradeReceivablesProvisionMovementsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade receivables provision movements [table text block]",
        "terseLabel": "Trade receivables provision movements"
       }
      }
     },
     "localname": "TradeReceivablesProvisionMovementsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_TransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction costs",
        "negatedTerseLabel": "Transaction costs recognized in the consolidated income statement",
        "terseLabel": "Transaction costs recognized in the consolidated income statement"
       }
      }
     },
     "localname": "TransactionCosts",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TransactionCostsRecordedInEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction costs recorded in equity",
        "negatedTerseLabel": "Transaction costs recorded in equity"
       }
      }
     },
     "localname": "TransactionCostsRecordedInEquity",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/StatementOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TransactionCostsRecordedInEquityPaid": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/StatementsOfCashFlow": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction costs recorded in equity paid",
        "negatedTerseLabel": "Transaction costs payments",
        "terseLabel": "Transaction costs payments"
       }
      }
     },
     "localname": "TransactionCostsRecordedInEquityPaid",
     "nsuri": "http://novartis.com/20221231",
     "xbrltype": "monetaryItemType"
    },
    "nvs_TransactionCostsRecordedInEquityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction costs recorded in Equity [text block]",
        "terseLabel": "Transaction costs recorded in Equity"
       }
      }
     },
     "localname": "TransactionCostsRecordedInEquityTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_TransactionRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction related costs",
        "negatedTerseLabel": "Transaction related costs"
       }
      }
     },
     "localname": "TransactionRelatedCosts",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TransactionRelatedCostsPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction related costs paid",
        "negatedTerseLabel": "Transaction related costs paid"
       }
      }
     },
     "localname": "TransactionRelatedCostsPaid",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions with former members of the Board of Directors [table text block]",
        "terseLabel": "Transactions with former members of the Board of Directors"
       }
      }
     },
     "localname": "TransactionsWithFormerMembersOfTheBoardOfDirectorsTableTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_TranscendMedicalInc.LakeForestILMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transcend Medical, Inc., Lake Forest, IL [member]"
       }
      }
     },
     "localname": "TranscendMedicalInc.LakeForestILMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TranscendMedicalIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transcend Medical Inc [member]",
        "terseLabel": "Transcend Medical Inc."
       }
      }
     },
     "localname": "TranscendMedicalIncMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5",
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TravoprostGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Travoprost Group [member]"
       }
      }
     },
     "localname": "TravoprostGroupMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TreasurySharesAcquiredForCancellationValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury shares acquired for cancellation, equity impact",
        "negatedTerseLabel": "Shares acquired for cancellation, equity impact",
        "terseLabel": "Shares acquired for cancellation, equity impact"
       }
      }
     },
     "localname": "TreasurySharesAcquiredForCancellationValue",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TreasurySharesAcquiredToBeCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury shares acquired to be cancelled",
        "terseLabel": "Shares acquired to be cancelled"
       }
      }
     },
     "localname": "TreasurySharesAcquiredToBeCancelled",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_TreasurySharesAcquiredToBeHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury shares acquired to be held"
       }
      }
     },
     "localname": "TreasurySharesAcquiredToBeHeld",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2",
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_TreasurySharesAcquiredToBeHeldValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury shares acquired to be held, equity impact"
       }
      }
     },
     "localname": "TreasurySharesAcquiredToBeHeldValue",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TreasurySharesMovement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury shares, movement",
        "totalLabel": "Total number of outstanding treasury shares"
       }
      }
     },
     "localname": "TreasurySharesMovement",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails4"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_TreasurySharesMovementOfPeriod": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureEquityDetails": {
       "order": 3.0,
       "parentTag": "nvs_OutstandingShareCapitalMovement",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury shares movement of period",
        "terseLabel": "Treasury shares movement of period"
       }
      }
     },
     "localname": "TreasurySharesMovementOfPeriod",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_TreasurySharesWithRestrictedUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury shares with restricted use"
       }
      }
     },
     "localname": "TreasurySharesWithRestrictedUse",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "nvs_TriangleInternationalReinsuranceLimitedHamiltonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Triangle International Reinsurance Limited, Hamilton [member]"
       }
      }
     },
     "localname": "TriangleInternationalReinsuranceLimitedHamiltonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TrinityRiverInsuranceCoLtd.HamiltonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trinity River Insurance Co Ltd., Hamilton [member]"
       }
      }
     },
     "localname": "TrinityRiverInsuranceCoLtd.HamiltonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TrueVisionSystemsInc.FortWorthTXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TrueVision Systems, Inc., Fort Worth, TX [member]"
       }
      }
     },
     "localname": "TrueVisionSystemsInc.FortWorthTXMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_TwoYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two years [member]"
       }
      }
     },
     "localname": "TwoYearsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_USCommercialPaperProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "US commercial paper programs [member]"
       }
      }
     },
     "localname": "USCommercialPaperProgramsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities [text block]",
        "terseLabel": "US Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities"
       }
      }
     },
     "localname": "USCorporateTaxRateImpactOnTheRevaluationOfDeferredAssetsAndLiabilitiesAndCurrentIncomeTaxliabilitiesTextBlock",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nvs_USspecificHealthcarePlansAndProgramRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "US-specific healthcare plans and program rebates [member]"
       }
      }
     },
     "localname": "USspecificHealthcarePlansAndProgramRebatesMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_UltibroBreezhalerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ultibro Breezhaler [member]"
       }
      }
     },
     "localname": "UltibroBreezhalerMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_UltibroGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ultibro Group [member]"
       }
      }
     },
     "localname": "UltibroGroupMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_UncalledCapitalCommitmentsForInvestmentsInFunds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Uncalled capital commitments for investments in funds"
       }
      }
     },
     "localname": "UncalledCapitalCommitmentsForInvestmentsInFunds",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_UndiscountedFutureLeasePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Undiscounted future lease payments"
       }
      }
     },
     "localname": "UndiscountedFutureLeasePayments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_UndiscountedOperatingLeaseCommitments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Undiscounted operating lease commitments"
       }
      }
     },
     "localname": "UndiscountedOperatingLeaseCommitments",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_UnfundedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unfunded [member]",
        "terseLabel": "Unfunded"
       }
      }
     },
     "localname": "UnfundedMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized income was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge"
       }
      }
     },
     "localname": "UnrealizedIncomeWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized loss was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge"
       }
      }
     },
     "localname": "UnrealizedLossWasRecognizedInOtherComprehensiveIncomeAndAccumulatedInCurrencyTranslationEffectsInRelationWithThisNetInvestmentHedge",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unremitted earnings retained by consolidated entities for reinvestment"
       }
      }
     },
     "localname": "UnremittedEarningsRetainedByConsolidatedEntitiesForReinvestment",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_UpperLimitOnHoldingsOnUnrelatedCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upper limit on holdings on unrelated company"
       }
      }
     },
     "localname": "UpperLimitOnHoldingsOnUnrelatedCompany",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_VAREstimateConfidenceInterval": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "VAR estimate confidence interval"
       }
      }
     },
     "localname": "VAREstimateConfidenceInterval",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Value Adjustment Increase Decrease Through Changes In Ownership Interests In Subsidiaries That Do Not Result In Loss Of Control",
        "terseLabel": "Impact of change in ownership of consolidated entities"
       }
      }
     },
     "localname": "ValueAdjustmentIncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ValueAdjustmentOnComprehensiveIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Value adjustment on comprehensive income",
        "periodEndLabel": "Value adjustments on comprehensive income at end of period",
        "periodStartLabel": "Value adjustments on comprehensive income at beginning of period"
       }
      }
     },
     "localname": "ValueAdjustmentOnComprehensiveIncome",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ValueAdjustmentsRelatedToDivestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value adjustments related to divestments [member]",
        "terseLabel": "Value adjustments related to divestments"
       }
      }
     },
     "localname": "ValueAdjustmentsRelatedToDivestmentsMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ValueOfEmployerSharesHeldByDefinedBenefitPlan": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of shares held by defined benefit plan"
       }
      }
     },
     "localname": "ValueOfEmployerSharesHeldByDefinedBenefitPlan",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ValueOfEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of equity"
       }
      }
     },
     "localname": "ValueOfEquity",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ValueOfTaxLossCarryforwardsExpired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of tax loss carryforwards expired",
        "terseLabel": "Tax loss carryforwards expired"
       }
      }
     },
     "localname": "ValueOfTaxLossCarryforwardsExpired",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_ValuedAtAmortizedCostMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valued at amortized cost [member]"
       }
      }
     },
     "localname": "ValuedAtAmortizedCostMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_VendorAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor [axis]"
       }
      }
     },
     "localname": "VendorAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_VendorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor [member]"
       }
      }
     },
     "localname": "VendorMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_VivactaLimitedFrimleyCamberleySurreyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vivacta Limited, Frimley/Camberley, Surrey [member]"
       }
      }
     },
     "localname": "VivactaLimitedFrimleyCamberleySurreyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_VoltarenCataflamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voltaren/Cataflam [member]"
       }
      }
     },
     "localname": "VoltarenCataflamMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_VotrientMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Votrient [member]"
       }
      }
     },
     "localname": "VotrientMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails4",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_WaveLightGmbHErlangenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WaveLight GmbH, Erlangen [member]"
       }
      }
     },
     "localname": "WaveLightGmbHErlangenMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_WaveLightInc.SterlingVAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WaveLight, Inc., Sterling, VA [member]"
       }
      }
     },
     "localname": "WaveLightInc.SterlingVAMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_WeightedAverageDurationOfDefinedBenefitObligationYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average duration of defined benefit obligation years"
       }
      }
     },
     "localname": "WeightedAverageDurationOfDefinedBenefitObligationYears",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8"
     ],
     "xbrltype": "durationItemType"
    },
    "nvs_WeightedAverageInterestRateAssociates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate on interest bearning accounts of associates payable on demand.",
        "label": "Weighted average interest rate, associates"
       }
      }
     },
     "localname": "WeightedAverageInterestRateAssociates",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_WeightedAverageInterestRateLeaseLiabilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average interest rate lease liabilities"
       }
      }
     },
     "localname": "WeightedAverageInterestRateLeaseLiabilities",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails6"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_WeightedAverageInterestRateOnBankAndOtherFinancialDebt": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate on Bank and other financial debt",
        "label": "Weighted average interest rate on Bank and other financial debt"
       }
      }
     },
     "localname": "WeightedAverageInterestRateOnBankAndOtherFinancialDebt",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nvs_WithholdingTaxRecoverable": {
     "auth_ref": [],
     "calculation": {
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails": {
       "order": 6.0,
       "parentTag": "ifrs-full_OtherCurrentNonfinancialAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Withholding tax recoverable"
       }
      }
     },
     "localname": "WithholdingTaxRecoverable",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nvs_WorstCaseLossScenarioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Worst case loss scenario [member]",
        "terseLabel": "Worst case loss scenario"
       }
      }
     },
     "localname": "WorstCaseLossScenarioMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_WrittenCallOptionsContractualLive": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written call options, contractual live"
       }
      }
     },
     "localname": "WrittenCallOptionsContractualLive",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails5"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_WrittenCallOptionsContractualLiveRemaining": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written call options, contractual live, remaining"
       }
      }
     },
     "localname": "WrittenCallOptionsContractualLiveRemaining",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails5"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_WrittenCallOptionsHeldByMarketMaker": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written call options held by market maker"
       }
      }
     },
     "localname": "WrittenCallOptionsHeldByMarketMaker",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails5"
     ],
     "xbrltype": "integerItemType"
    },
    "nvs_WrittenCallOptionsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written call options, weighted average exercise price"
       }
      }
     },
     "localname": "WrittenCallOptionsWeightedAverageExercisePrice",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureEquityDetails5"
     ],
     "xbrltype": "perShareItemType"
    },
    "nvs_XiidraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Xiidra [member]"
       }
      }
     },
     "localname": "XiidraMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_XolairMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Xolair [member]"
       }
      }
     },
     "localname": "XolairMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7",
      "http://novartis.com/20221231/role/DisclosureTransactionsWithRelatedPartiesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_YearOfExpiryAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year of expiry [axis]"
       }
      }
     },
     "localname": "YearOfExpiryAxis",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "nvs_YearOfExpiryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year of expiry [member]"
       }
      }
     },
     "localname": "YearOfExpiryMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ZiarcoGroupLimitedFrimleyCamberleySurreyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ziarco Group Limited, Frimley/Camberley [member]"
       }
      }
     },
     "localname": "ZiarcoGroupLimitedFrimleyCamberleySurreyMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ZiarcoGroupLimitedLondonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ziarco Group Limited, London [member]"
       }
      }
     },
     "localname": "ZiarcoGroupLimitedLondonMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ZiarcoGroupLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ziarco Group Limited [member]",
        "terseLabel": "Ziarco Group Limited"
       }
      }
     },
     "localname": "ZiarcoGroupLimitedMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSignificantTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ZolgensmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Zolgensma [member]"
       }
      }
     },
     "localname": "ZolgensmaMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureGoodwillAndIntangibleAssetsDetails5",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "nvs_ZortressCerticanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Zortress/Certican [member]"
       }
      }
     },
     "localname": "ZortressCerticanMember",
     "nsuri": "http://novartis.com/20221231",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails11",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails7"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AmericasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Americas [member]"
       }
      }
     },
     "localname": "AmericasMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4",
      "http://novartis.com/20221231/role/DisclosureNonCurrentFinancialDebtDetails4",
      "http://novartis.com/20221231/role/DisclosureTradeReceivablesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [member]"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails12",
      "http://novartis.com/20221231/role/DisclosureSegmentationOfKeyFiguresDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation case [axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureLeaseLiabilityAndRightOfUseAssetsDetails5"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails15",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails16",
      "http://novartis.com/20221231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails17"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 49
  }
 },
 "std_ref": {
  "r0": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r10": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r100": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS02_g36-39__IAS02_g36-39_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "20",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2022-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "23",
   "Paragraph": "26",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=23&code=ifrs-tx-2022-en-r&anchor=para_26_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "137",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_137_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r110": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS24_g13-24__IAS24_g13-24_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_vi&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Clause": "viii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r120": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "29",
   "Paragraph": "9",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=29&code=ifrs-tx-2022-en-r&anchor=para_9&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r130": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "130",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "130",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "130",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_f_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "134",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "134",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_d_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r140": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "134",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_134_e_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "135",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_135_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "86",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_86_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS37_g84-92__IAS37_g84-92_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r150": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Clause": "v",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_v&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vi&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "122",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_122_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "39",
   "Paragraph": "102",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=39&code=ifrs-tx-2022-en-r&anchor=para_102_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "32A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r160": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "14",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_14&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r170": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "40",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_40_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "40",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_40_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "40",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_40_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "40",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_40_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "42A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42A&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "42B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42B&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r180": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44B",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44B_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44B_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Section": "Presentation of a statement of cash flows",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS07_g10-17__IAS07_g10-17_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "29",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "30",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_30_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "m",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_m&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r190": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "49",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "IssueDate": "2022-03-24",
   "Name": "IFRIC",
   "Number": "17",
   "Paragraph": "15",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRIC&num=17&code=ifrs-tx-2022-en-r&anchor=para_15&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "IssueDate": "2022-03-24",
   "Name": "IFRIC",
   "Number": "17",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRIC&num=17&code=ifrs-tx-2022-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "IssueDate": "2022-03-24",
   "Name": "IFRIC",
   "Number": "17",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRIC&num=17&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "10",
   "Paragraph": "22",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2022-en-r&anchor=para_22&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "12",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_12_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r20": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r200": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_12_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "12",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_12_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "12",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_12_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "19B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_19B_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "19B",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_19B_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "21",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r210": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Clause": "ix",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_vi&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_vii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Clause": "viii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_c&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "p",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_p&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r220": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B16",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B16_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B16&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B4",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "q",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_q&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r230": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS13_g91-99__IFRS13_g91-99_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "14",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "120",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_r&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r240": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "58",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_58&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r250": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "C12",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_C12_a&doctype=Appendix&subtype=C",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS16_g51-60__IFRS16_g51-60_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS16_g47-50__IFRS16_g47-50_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r260": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "51",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_51_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_g_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r270": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_g_ii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_k&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_o_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "p",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_p_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "p",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_p_ii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "q",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_q_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d_ii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r280": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS03_g59-63__IFRS03_g59-63_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "38",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_38&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Section": "Presentation and disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS05_g30-42__IFRS05_g30-42_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "11A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_11A_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "11A",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_11A_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r290": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r30": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r300": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B2",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B2_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r310": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r320": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS08_g20-24__IFRS08_g20-24_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "9",
   "Paragraph": "6.5.13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_6.5.13_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "9",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r330": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "C32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "9",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39M",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39M_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39M&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r340": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Expiry date 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Expiry date 2023-01-01",
   "Number": "1",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2017-en-b&anchor=para_7&doctype=Standard&forcepdf=true",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Expiry date 2023-01-01",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2017-en-b&anchor=para_91_a&doctype=Standard&forcepdf=true",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "4",
   "Paragraph": "39J",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39J&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_20_a_ii&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_c&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_f&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r348": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r349": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r35": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r350": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r351": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r352": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r353": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82A&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r354": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r355": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r356": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r357": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r358": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r359": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r36": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r360": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r361": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r362": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r363": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r364": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r365": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "87",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_87&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r366": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Section": "Example 10 A court case",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS37_IE_C_ex10__IAS37_IE_C_ex10_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r367": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Section": "Example 4 Refunds policy",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS37_IE_C_ex4__IAS37_IE_C_ex4_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r368": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "14",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_14_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r369": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r37": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r370": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r371": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r372": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r373": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r374": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r375": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44B&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r376": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "44C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44C&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r377": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r378": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Section": "C Reconciliation of liabilities arising from financing activities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C__IAS07_IE_C_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r379": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "IG63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG63&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r38": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r380": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r381": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r382": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r383": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE60",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE60&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r384": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r385": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r386": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r387": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r388": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r389": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r39": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r390": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "IE72",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_IE72&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r391": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r392": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r393": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r394": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r395": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r396": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r397": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11D",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r398": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r399": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r4": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r40": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r400": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_c&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r401": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r402": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r403": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r404": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG20D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG20D&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r405": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r406": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG40B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r407": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r408": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r409": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r41": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r410": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "IG4",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_IG4&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r411": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r412": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r413": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "96",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_96_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r414": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r415": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_a&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r416": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r417": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_b&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r418": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_c&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r419": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_d&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r42": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r420": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r421": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r422": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r423": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r424": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r425": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r426": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r427": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r428": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r429": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r43": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r430": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r431": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r432": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r433": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r434": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "20",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_20_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r435": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r436": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r437": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r438": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r439": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_b_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r440": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "135",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_135_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "144",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_144&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "145",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_145&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "57",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_57_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r450": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "14",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_14&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r460": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "38",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_38&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "ea",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_ea&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r470": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Effective 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Expiry date 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2017-en-b&anchor=para_117_b&doctype=Standard&forcepdf=true",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Expiry date 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-b&anchor=para_117_b&doctype=Standard&forcepdf=true",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82A&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "90",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_90&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r50": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "98",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_98_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "98",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_98_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "13",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_13&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "10",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS10_g17-22_IAS10_g17-22_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "ab",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_ab&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r60": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS12_g79-88__IAS12_g79-88_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Clause": "v",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_v&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_vi&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r70": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Clause": "viii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_viii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "74",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_74_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "74",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_74_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS16_g73-79__IAS16_g73-79_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r80": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "139",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_139_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "140",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_140_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "107",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_107&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r90": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "145",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_145_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "145",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_145&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS19_g2-7__IAS19_g2-7_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>260
<FILENAME>0001370368-23-000006-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001370368-23-000006-xbrl.zip
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M@32+]CLD8SX)"HXY3%\;<]FNF>,>G[38[*EFW+-GGTES&&K/3G\#4$L#!!0
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ME=M86CJ0(SF;GLL<*&3QR#5#A8-HD:H\OJ'X4:J _7)72FS;0UC[G#^7=#?
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MN&C/U:4X&+NY[XS+;8ELH][L*K=%V1NT1UP\N%B)KFX+0X%QV,5>856P%_Y
MM0$WA)167T&%B8-DJD4&T6%H+6*5-06*=I<8/$,:PQV^-?Z=IVOIAI43G>,Q
M'#L;+9-=-8=C92P-DZ)Q<#L,CA70+08S11X%T6*]6!9_RA2/5: E5J=\/?$^
MY??@/!_B(:#W(*<S& B@M3674B5GS>APW$V*E$!:]!1W,,@FUJPD/4\Z?%&
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M\4FK.O!9JDM%7[K=)J-D%2DQ5G1?8PC7NGSY50Y$ZWBU:6639]IVGE'T%K$
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M^-8MA!*B1%?93$BKSOY0P+5VO2(?XIT=PO)H"2$VT9F327Z?D_9MFYI0Y,F
M^?8TH2]Q6<84@S'\W75G!FHHM3YW>_;F!U/[\5-\?5\W=K^G[R,LBYG2 (P
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M\V I"/HW_-]WWV!_G#?XRV4SS^&7_P-02P,$%     @ R3U!5GB$0^31W
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M*H7BVI%@GDDTEZ\'=1#JJU&E 1":P"#S"98'9N=.2[+-$UV*Y+% ?=Z-21F
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M%9&-;S%$W7+DWV,1-#*B2D_D.!6[^_"R7=905$J;3_RF"]<5#M0IWP_'_S,
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M%0:W!"P+>>T4@H2]C.G;$.@XDAD=$1NX@)SDS-U')F>D@/V("/&9T1 !R#%
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MXJ>$3R(M'M^)BVC@^>IC1PP5B]6&HB^EE2A5.:!.!]OA,EPSHB7R<Z3R-2J
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M13^)T?#?9UO+BE6=TWFR0H+^MMH>B3_Z[=O(OL2MSBO&VE'MLBW,I5@4OF&
MC7IHBQ*_F_/(*0>(91ZP=@6(&A#NO,Z.NM>5KN%"]) Z^2,6Z^HWKG HZI 1
MT0O%L1HTEVMZ(P\M6 YQ47$!%1"-ZRR[G*TM9AM/@YN."72JV7]$3D^TALV!
M2DJZ3F\5-"YS872S:5(^K8UOC&]PKG8SJV8?% ;JGI<J-A0[.,R R7_G&TVC
MS4=DOD]EQ'BW(R[_0Z%U!S6Y?.VWID((D& HPDLU%#54Z0:D1)JA%Q4#@F*]
ML8/U34*HBJ%W#(A*4P,VQ!:*7D!1]%I U!NQH:(W=FSY?7[_[)R9/?/LGK//
M:3,+&79SCST(.2S9&E$EUIV==W9.:<)%R'19X-E^ZT_<75;=N*%+4.NOG>/D
MNEN-7J!Q\:E%N^)G?ORJALY[[3+,:[]US]-D0!3A<<%X-*8ZS-.$91\^ IED
M%%EB$[I^BW>H*+:#7E3N!=.TGV>7^N<&0=1N$>_\CY.5T.:O/Y+.%/S&MS;W
MBV97E6](^,&ZZA=5!IF$7<R*N6CM,/L S^O,R1^_.G>V5XE6C?E9<<6V+3O'
MBSMNA5^X$.])]6[..)?3*;D^<.O6J<*[/>=Z=/-W7_]GV]&8OAS)SS!WL>9J
M3_L%KLEE_PZ)5[*?IN^TY>HC*W:YI5R\%>M_SOE6F7S/HW.$\U[B\\8G/"=V
M^6?X?-J]J^.4RG#@PKF):Z!GGS6RJW?,[^KJX7^(<=3I76<\:YM67W[Y[ZS=
ME_KD&_86?8ZSRIA(#V<E[KD\[> ^51B_ZWAOZ7'?Z1T39X\O/WZO9GUQ7,:[
M\;.;:M]]BBN>TFSZOK?>K_:=_I6_.A^M[:Q9O_CA1YW__6?\OS&?RGV.^]Y1
M__?>\L$[LRN*WY.ASWT;/VS])_%_TZ7^_Q/-7OE:<^S\\G=SXOE9"_%-#]:3
M$[[N,%9?O_SE\)7&JY<U_RW\W[<K.ZM]N8-Z[C*!GX2H:Q/3+4M9E*MC'E3F
M7IP:6#C+<=7=;DWQX8%$YL)ARGAQVF*93>31,-;FM($*.^W+C]A;+,*K%FQZ
M>?=\Z>HEAQ:*"$S/LHS(P\'%-K$]96L"H^S#\LM"U,^J>5#ZS;759U3!(6F*
M:W4[;=MB>-:\YGIGH?U$;N+$39%S;%MX:'I_U+:)>_9C)W;]+P2:F+0[$K_S
MTXF[/]L"$X_O0R^W9;N_O%^1:UM^VZMK;F\"-,)ONNM_WY[)#FL5.MQ7M>ME
M:4(T8Y.1"2=K] M/CW_4([G"GV9&PA=\"[Y)65'DL&UQG-6LLMP%Y;[U.[_4
M=+%GL\_(^AX]F_6.)QQ\^DWI1GYXVJ-4Z:4J,8N5)8R5]!M-ZO5'WUCR\HT&
M#OEFZR0%H[ MUW7)Z_N67"RT4?3KW;DOPQG11KM"#3RT@*=R&)U<<O*77D!$
M!9V7]\;9U6"ZY93$UVY1?W"V_6B/X9J.V]="C-B!3J'#BI68]PTL77(F;,TB
M;6A%8_.@F[JF7VMQ0$ESF>M#]["*J)O*?IH6LKDY6#3/_*JNSMQ> 'WINU9R
M_>!=I9P1Q?Z@6^XVJ@@PB#I1<K7$I]I^;DDQ+W*1]LNPU@$]Y]T,MIZ3W1H0
M;:N[&!(F^FKU F*27/6&>,G5STI"0B(/AXB@V3$5<ZE]SZZ_')[\/.P0>>EY
MN;<5W[(M=%00917Q=.R$/.KG[JL'W!RJ<>ZR;9JYGTN<I^CD0*_DZO0B9Q/;
M*:;[C>ZU!B'^L[_<=)[FNCIMO*=<5.%]$^,;1#_B'KX5?1V32LZD6??"H:O.
M/W<.O8GW#X?<%,(G18/]V!+K3\)F;;*\7OC8[8XB>MG>W\R6DF7$"G2\Q:%3
M+GWGN[D?.C#_@].2-==;XC#>L/S98<ZS&(-'HGF+%SV(SWP<$6NVPCP%COAY
M,>!N"\7')=*X.")I39-=BHKIH^<NVD]4>HH@IP !=C">G2#:3[;+N@K2DP"1
MN)]+2CGP?E4*ACAQ5, %8DQ"(Z2=9OY,[.:>>1HE)@G\P.#I# #VN&&<*.^Z
M526 G<(:N6M)FH\)4C!XU8<EX:*7<@$68NI^^$.B/B]EK>()KI3JFV)SF^EW
MCW*+XN?=JA,2.566FT_V[GTATG$;M(3HPWE+#1;[+WPV[6V'M61K/\]<5D$(
M+,'THDRYO1LOSL47:1.\Y0&93OPJ;C#)5XF75%AMXFZEG+T.(+/<,Y6,I*%#
M2H8/"WNZ3C\9%!/K5$PV )J8"@BM%YN@.7@_\G'T+)UQ"^YJ01['<47:6@,,
M&LF/:D.'&'D = I#43Z70)HAH0RVA$0XEDN):8+TW"7XUSF@2QT&CS7B1E&
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MLI*'"",Q';6NK>"3;A0[VL"^^^6+]\]=DN>=R((< ^&V6((D"--C=Q]UF!*
MH]5ZY7%E5PT#%"=(LB9(X7?40;N N.T,NSV3DT%PMZ/R6*?K;#/M3$95>2_]
MZ(<$3)[I76MJ#CD-31PYEN7] $I]^ \M\,@ F?T46)&HI+$]]YLRZ-%V2?+$
MKKPEP:\^4K)WTMJ/3=Y)GELHYF4[U0<^?KXFLC:)ZKHAKN"4A#@YVM_/O06;
M< N);@+*TKT#J-W,0W( 5TP.$$..![BV&M:N>!T&K7L.CIO>4+,3%:HJTYEP
MWA,U[JX$:3<215MM5;%_/2371-F"AJM20L^>]D/F<-LLE]6"T]7B<P?%!Y\'
M<<6D,$*->><)!P>5:.*E 52?4+DS% 2ASL9+_[FV7.4+Q-KKU9#OV@PKCN#$
ME@,..[IPH 6WI7HO4^[@;<XN1_J2O_G[H\%U4EL'KOV/!KO,934;3!S\1J+]
M<,AJ\.UYGE#L>=._-RGP1,XG;NAQO2FMC\6!'LXR-NN"0))[F^N7GI)#7[8&
M(EKTDB($X(X< %KCD(=ZQT%P3'M_EV(RA2,@:JNU:@W9@3!O--GQ( DRK*(>
M\=>LCTM+7G"UX9/MBB$E-&L?0NNJWTB]*;P1[?$0ME<H]W\2B.(9XV)VINF3
MT]ZOOZ=^&BXP[EP;6;\V-E1ZIOK:R\W,;VE>6W'MD]T#MF%/P[>URM&$Z_$G
M]/?G;R-WCFR9XOX)KH+0BXN;2H[.<\JJ.4KMEJ)WS@"3[V,"0K;*X353>L2Q
MM]ZTL)=P%AX0^6)] 7'FS:C:O/<DV8KLLW.I@1G?!FT+,%@6BO/[3+:#"SB&
M.E7.]RL$^!63V_T4SE:HA*7G%EPA\IRZIW<R ^])#4V#C9N19T%'3>/FR**T
M=K1#(ICXW%-&6=JWY52>@74,CI4NE">M<D\MOK1&4^ V87Z_)SUB-3A-HOVJ
M+J[5Y^U_L/->1Y&W'CTOVY876;#LWR$:C?\R.&B=E?MZ_'#NTL3(9UI+HP(M
M= SY@; 5N&U9<#LC]M4:6U/Y/(_]-Y[T% <:0_;+3Q;W(L7YV29AH6+G:?HD
M/(0;L4>/E5YN>AZ^R+W2LW8CL85*,\5/<B,NK1WYR[2TG*?LL,%'* F[)[>3
M<,LG M'!S..'F\VO_DD7AX<&S)'@ ZW_%,37:+<D0YL4\J-+9?>9@ZMA!]9B
M8_^_ZAJ^UI>O+D7)9[W!QXZ GH5YRAG_5)&S@ AN5XVV^I\$=R3Y@P\&?L#3
MC%Q*R/\.=8WA7O?D/S0-3=\FW[;]+W+;">5TY@IOLR$8]K7(2_LS>*VD$02)
MZ]?#WL>@^TW@?0O$?9C1PS-@*95AC:F^_C\5SX WF!Z+.[9,#B2;=Z>!3!N
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ML"+=^OZJ:+=5B[>O<CV[6K,F;G6*P6K)=DL+$: % %45E"$ < F@ 7^8*0(
M)4!3KH7U  H 0 #@K]0K^[J.+!>7G 5V6^D! @DBA@ 5;/$,U.)RPS<")*Z.
MC 2T764PE$"<"(&4:XE*05J*-J#2:MC^!PJX[*9GYP=!V.;<PG)(L 96 7&O
M8UUW;)F;JD?#.Z<$M#>802H($P":@Q+0P+330T 20+, :1".J'&:8('7/ %M
M"H<!I3;/'-03I+$; ;N[NG0<-%!&-.6!W*,8%P-IJE:N /CZ%:Q[B1#DZ#0@
MO K3 $&Q2N#30Z1Q1!!!J06L @;Z-=JK=E#-<:!IFR7+G'H6HTZ?V_MNP;YS
M\KW?*BD*G JP\',8CE;AYP4XF272<<>9"2*JN\C076R6(+;-%)N/X;-8DMG=
M8H\QL4>FQ*]*;#R&+\H4!\^(%[(DSE79L=W9T6/9*Q*RTUG2E*J<^)GL^#')
M)E;NMLR<+3.Y.\9REW?GB+JE!Q(DB6,YDN[<R,S\E6.2QIG<ZIF<TFYJEUR'
M86$0U;C(MA=P43(B&AG^?;H,^5\KF_\XM_TA "2IF$TTK^$X;!@ 'N(,FAPD
MR;7GI0 U?+1I![#W&=-* $X9Z-, Q$$)-DW"$;<T#!4S CN 0@B@P71> L O
M"S1_#0T"#&W'=>=E,;/._?!L8F9CA%58>3I6GNA1O@XK7ZDDTQOI6HT5&\8K
MUE17_)55J>U7N:VZ<E]UY5_GZ>*L*NEXU<'O584>U;NJJW=D59=Z5-:/5Y:/
M5Z^KKFJOKFY,K#UN6%E;77O%L.J"8:TTJ_;2]YICAO77L^K.C=?=.U\_GE7_
M(JOF\7C-V_&JM]4UKQ)KGQK674BL?Y9U*#=1E^%/T0 6%F FS 6F$NQX2F!R
MG@,0W_\06&>Y )C7JT=3@?X PA+ )=D'%\A!M1*P&]SAH-+34UXC5/O\@P X
M M1<A8V^MYR8=12=U)KJIG$2(S4D?,.VG3]IS]:DVP(.7,0= Q^U6BTS)ZU5
M$N2>;8T[B4T]A I\2V=-> I(2170,7\]+;F72JD]';#$% "UE+[^T(%[[D
M=]XCP=+W+-@*![I"]*8]URS P.?7/C]: Y-4"ZVXX)3;_W\M_,@%GO?#B."O
MV:J=,+=_&0"H<-K.'YE[D["[^('0E3WLI;2["V C)4 Z8,5]2FA(:HO=11 K
MF6]<4W(K5B\\+ @U6)D5=W;E_55K)LYN<<M(\3HGW;YRW<3J0+?NW(ES.^ZG
MIQBLV.%U?MW759%N/9_.G,^O."NI[=EF?&Z7UP7ISW/%M1EG?IX)O'^A?*+G
MR$]-=[GQI4.U%_^Y@/D_)455ZV!-A;4RS%\ +%/NO!U@,.9Y]?(.NR@%C$S"
M *#',2\*E0-Z<G$(#N +0!+@8(5G42>/F)J 1DH&\"!8BP98&KK-2X$07*_9
MK50;K\)$P+QP;1W%P'_/03VEMVNJKI![YD@/(9/+Z-KY]_7/SBZ-Q%4"XBJ@
M<&F<0TD%R,8A&SST8F5H@UO 8N 8=0& *2$[ (J1ZT'RW+24+I_T#:Y'040)
MAYF#IDKMBW\#2C;45W.B<F=7+'[!&P FE7\RURX' /!V1B !- \# :[O_9F&
MFI5 ]S*#, !@"YH ^7_W,\LY&ARP>19H/.E,,3^SX1'!2?2WQYXP7;^V7!,+
M.W#$ACOT&$&L +>0%-B*FZX)2G_._0,W]/JEGA5V?!('V<Z[HCK )*6N$=>=
M)[\7B W9XAL#+!"]_T[(EFO;X&#7'+L$ >0@@-X\X[R4@\.6?]\)L8IA@YA<
M2U$/3A\^5A=A/< EK-]-T&K\Y_'OT/\)"-SZP;EB^S"+6.NMSAOU+?FE=Q9,
M.G=QGQQ.(CR_,/CO;]6ATP&7! 3.8X*_SY_"N"@?HB!["=W 4\<G(2M%?^0G
MKQ@&^U7EA[%GBY-#%J60/9\\>^7"V*@D"1J?ISQ93#0G.#U^2MT;X0PR-*E[
M7U5_I@OE3QM_/,W:.Y7?X,D2$:/V$M<"A8677]?[V@: EWV>J Y=?G/<U,97
MPN3[MDDU;RYIWOZ5^NS>XY>]EZ='3*T-D@=?[PEWWA:=^"QZ(G5!WN%W3QMB
M"@_/^SKIKI[]W^/4_W[_GO;80T^N?OWZ\W^!#+7NBC6,%,+&Y/!0D=8P]G%"
MZ?()\[VK=/&Z@P[_^&!Y1>O-3 AV1>L&)K:KTUD.^+]2HC<$7Y8+G.XL_N)S
M98F%'VK2R\#^U1I4?3('OV[:-U<AT3%\L4RPXO,0SK5H1'ER$K;UVPCV\94R
M!/%#@W"M8<\/*S7.%S&ML<L>B!P@"( ?WG9Q<LUF)@:8*K]$FP -=GIVE8#R
MW[WLQM^6WV"^%DU+ + $?\KA)O;X[^-ND< ?1D,P8)5G&:H-.%5"=(R#X7#T
M!H!.XH]*.MP)B!5)AD<5BE!32)Y&M)" 1/I14"#@!AP0>ON2<$%)1[WWKA^_
MR"XMHXT!A48^!2ZM=XZ$U7KNH;BVW6V-:4^ZE.12T<'9H]CYFV+0W@P;)U^R
M )7%E@#38<A?7] ?84 TY7&M"TM$VLUA]8 \AR'2JK#( D93Y]B@%/5@7RFW
MMUT?GJSJ27M][Z8>\J@L2<)U,@$R>._>_3QW8/; 2=Z7N5?'BAS< (=E9R5<
MB;7FQOY/WD6_*!& P4F'%!*=/ #X=*DX?,MU<6.O[[8OO5+D<^'KNT>M6V(]
M"^^^#ZTIO>GTXA_&C[:CS?];]N_RMF2MM8Z\S'((J*L_:6,B_ D0[!%LJ14J
MY,P"-I-L*AV*3;BBK8?KZ?4.-H @ET*YO)F\VQI1U4I9-T&E8;T6+G=P /C$
M?,LQ\UP38Y#;Z-#YO#AW58E)]S_9WN6<2?_;*1RE=<8&.<'JQ=6_TTHC?,GI
M95$10W=W),U.)\.,95P_I"B&5;;+J_@C8"LXBT-50>?GO(QXG\@A5MTIAD35
M&WH6WZW?$3=GN56CM1 '+ 8A,; BY)4?4!;@;Z2Q!LM4 DC+>Y0+V@Q:D$'M
MFCM<>*H^LLFAIACD&MNQ1G4!H\7!_D#1$-1F;-7@-PR6N@F Y@T,G N @-IP
MS>TS:P02>8-YFT-ZF2<1U/96*L'U@ZED(@)PE$@Q?VC#N2=[J1N[)S]:!<4'
M+XXGPY6\X!R$^VXHVM9[S37_FCNO#5_RCS@,_>/PL8?\WX4E(<'Y1T_>\&]K
M_7%^C0BLTFH),M7FJ$.L"3P^0B8+.*'6->_3%D/?AJ***<RU[+\I4(L\Q[!K
M V$R@OV/WT/K61?DCH2NBZ"24GD^-I+B':B7OZI,S7,";$*_5<[>,A"80R2,
M>15:;\K$-9/=27^-;'N0O&]V65R*.L4RJMQ%_9<U+>%.GPDC(+6 9+Q>-9@X
M=:G)WVINU<<0LH&"*QZJ&GS7>W:G<-2/M.IC (6\Y2<AU\B!3Q=?G!OCE&M8
M6BJHN-5U6B8B;!A,':9L6,_OO;[QK-R/</CM@1S4**9KMC51*!\/G:L"@?<C
MVKC(E@XDX1 Z:EX5U 6TYHX85_E39*[)F[EPF?N8$CS20M]RQ8"&_6V_S87+
MM=TLJ_BU:LWM:>CU[A5B+BSS7J6$@XQE%E]HO)+XKT<'0-QI$&+J\[G6#AQ1
MZ&"?+C)J.&9*ZB6%",5/'"O'6:J\4)>;T$F>DOA1H*%0RU(,MF< MAP5(?%Y
M"G14@-ORZ.+XY^9@?B>7\DD@2N1C$7/ELEUVW)Q$56_T*@Y@FNP(G0]3T=;R
M@4<V0#U2Y8^:LB.0M*W 9'<C6%-<1.;BE%"NDE8,_.L0-BJ?+KL-D/]T*EHJ
M8UV &^K0./ ]3)@?&C, EPFN1_#0W!R6"GC0I)Q\HH?#"2H Q"-('*LY_J *
MV&\%=#%2<T(!I:BYI#^#QAD$TC!SZ ^M4KO,B!NZ_->2_O2[MH"+%0(XC"TF
M $HW@ W 6B2E$9MT0T#94C7P:&A'250^&@/ 3#6092+T\0K#YUBYPR;TK9#&
M:= ?*I;A4.4K,<\=TQ/+$?@E%](9>[K"J[??98<%Y"(7(2LG+1[?$-HRJ\.@
MDCQ\:<TI42*7*^I;6F=KJAY9D*G498[ESW90U$?4 2C;W8]ZF3%[028&VW8G
M&_LKYD:VXF@Y!^R*(4'T&B[*YO<:QSTM]<X#8 O2[>"3KTK=.AAH&JG5DBO(
MG=7P^5A67H J0B[6XP9+K90 V=^J\%K]UCE.5Y4D_^=Y]-&4.1LPT5(5 &GA
M6,15A_;$6P5Q[/P1<:#?K(<[4RE_N06O_AS2:V\EH&C%3)[(4K9O3>)G>WOC
M6G8)?H8GXG.T.=Q:/:,CJ^)&Q<X:!VTF73E ^"C(,3HN.+1G^:U%*T!1A.Q$
M&";!5\^G1B:./86>I$8GK:!.C UO/SO>63)NHI[_>B!65)P))*<5@U.X ,6P
M>L2A=Z0^4XE6*LQB+1L)(S'^X%O=5SLY&-&UF:VG#9RPO,FW-.@0U#97<?.6
MT:'$NT/=N?NY>4E\,:_938=V]Z;#^_+YHM;%X7?.ERP90%2[G\Y:\I,9[4 P
M&6I0M2LI-L+Q#.I34FA"W]\!!<FTQ9X$AWDHBSN'X (K?U?Y.ZW% 9-E,J"T
M7@D),3\T.06DCS8BMB6)!&\'JC-;C@IEN)NUC.@T&FU@U\W8]@H0N<DT3\'J
MR/B<=W?K2.SS87NVM5RPV?_"85W6]65/BC8<3"WP4*\SV)9PQX1/?UQ?!=%V
M'):LFA*(/0*@PYNYGQ[?Q2$7Y>HYJR-.97X0B(^WG664*=FWT\Q?HB=PK2IZ
M;/7A3QD-W-3;%*NKUQT>OPA;M_.?NO>G^==>NKYNP1LT1T)JH9>O8]IWWNN8
M]S;II%C0^.C;%>V<!QVS!NM^NU5= 2NVM>_3GA90?XJ8IF<[#QZ83K.OM5MQ
M]K]M$9>F,T)W/;Q[+>1\VX%WZ]?MFM#?NZWUP6F!]Y>'O>7<.,.SV]8E_6<D
MN/PDW]CN;WVGP1Q!=/BW"U]C7$?J)GH?O3]WY7]SP_A>$QK:^QYVILR?0QCS
M"Z-SE9,[.]XV/_JRT\&=H9Q?]&'_CN-CO"&)D7^!K>O%M<P+D1+H%4!\G=#'
MR!)(JM7R4WN*3VAOD#U(Y^DZ7CL#TEZ0(XR_AMUSD>_2UI<%9*WJ%6DUS[I-
ML[IZ<UM,0ZC+0]T,TNWDV9TMQ%]U?]$*6&VNM*^*PDN>)^,*'CV4=CCS<2T3
MWE^F+!S2XZL0VQ8E*:T3U*[#$>WN;$LV5DBYT<B0S(70Y,9<-.$NN(IOC@#!
MX)<$ )TK!]X]LCSGQ/W -,L R+3%(F;11IKV._O=*Z;!1(*ISEPEU]@)4VIO
MQ2$A&X;=N62ML5Z:AID@N?,W[9>*^C_[$=."K8]&1R]FWLOV:@0,?:RIEZY/
MKL]<4.T0QQ5?N0[!F7G9^],VB;QY?=(N&:RRYL8QGS<JO"(7;;(NVQW%43%*
M@=U+;/@9J$S1./7O$#E.0/1<1-974];BIMN!3$-.VN]-/BPYT=[:[JGS;GV>
MB%G%,(EG6,E8Q'],BK;ML:>3.P+9A[>0Z1RJL=HI2P9F*I,6W#>Q$D*LYZ36
M=*(1-W/JJ2E+!<X10*;\%495#CWQ9/U1&X;:VIP/@9F2=UO!OD^4U4+;"@64
M837+4+UGQYFY/?')9?!F@RGIBBGIU6"&'=_RI""8_B+0)WV?QDP=NG6S."V=
M6'DUB24CRD_--6.0O\["B6?<+XC =0)*&9<R/1#%U-M9H8[P]@,_K:3H"R$S
M 86F<-\,1)JK(XM&_?$IDN<S<9-XG]+:\A27O%H!G(9SCN45*.<(UW5QM54&
M <0D4O&\"A4I_AHXNHE,4U-,Z/S;P80SW3N-<8<*'-BN(OUG%=ZE M=\I.@(
MB!N4B_/-9Q>I"D8^ +3-Z1LM0%8Z$?XS,PSN-\ =MF"@F=Q?"YMMKYHW=M7L
M)IMJP"6: ;,A-+8UX^"WP0WIE0PA%S3!P0D]LJ$2=,N.TIPS:Z;S,0S"Z"NI
M:47F*E(6"9K'UQ!LSVQ=&.B)R4 #&>M!,&BL ED$HH'JX*>5K V3X*]G@5?3
M*4;YX!DK.R;GX!Q5S#%GXARYYUPU4*:.(3X']TD.^MF6C>>(@GK-@2#3P-LI
MD4S&2?7\7Y/Z>\!XEMO\?T\SH@P9RQ90^8F"V4YE*\@5PS8YK[H8YIR_(CH%
M+5^W_3A3\?+V[/B/&W3.,C:-NV[-9R2E5/I^V+#I]8HC%943?I5"6\:N+$;6
MXJJ%'RHC/E;F>RS=?UX_-[]J<Z);T;AK*M?M?LI?*:VN9:W5]6O6/[G&V."Q
MH56&2A3ZC7RT4&"YG$_J4A"7*M!D)<DKDK0,H^[AH\M'T:4XVJ@9U:^6U7CU
M4HZ<UY>HT"X^23&$YBFK__(@1=+KO#Z0DP T147QZB4FR,AN%H18&?FXHC9!
MA=9@U/U [<4UM;DR]+(AY:$M52Y#(U1HJU)?V4KJPB@)"G2Y$HWY XBC^0K]
M UPTBD]*<JP[:DN5T GW1:08 "7^J)( :*SPT'$YFJ/0+^2CC:/$I3)T*1<M
M !HNCJ/?;*FI:E2!40ME:(?B#W)-ETSN%D5:H=!O5:,12K0)H[8J4:P'C04H
MCR<I3\=1J(8"_FA8BAVZ[%$74H-65L<=IQ,B5/7>Q:1H#,V1,\_84G.%#3&C
M3+OA)LV\AQ0W_\;;WVL4B]$\=6VL@CCB81V8)9PXRMP#P)["^EHUM!RD+E A
M773$204OH,/:(:@C1HT3P@LPV%L('QK5CU-#DA\-SASX^6O$ Z/&TF%O)>P(
MH/_J49?0X3 5[#A:D\>!?0#4F8Y\MD4X0K3:"-XGHS@*82X..ZG)N738EX[X
M"I$N(3J?CW;)R!UV5'<5',N%78##71RT<KAC@1)VPN$%"K05@$48-9D.!RD0
M1SI:W=/:-=IZ[P/J2$?" 'B)P#*"#H?2$4>NFP\=\=)%748I_EB[GP*6*-J]
MY8@/!A\W1.8#I!.&&MCW80L';Y5CL#.W]5T-Q8<#A^*P*YW2B,$+A,A")3RQ
M^-A]D-+8AG#I<)Z2\M2.ZJ&"$[BP^^@?G5.+./#$]Z0(#AS+;X="3OC)$4=A
M>^&/5K41XJWH\ /@?1AU-[USNJ:MO:W1CZ/P&F4FZ5+<.2A7@0I6'@M,(:<A
M\T[BIMQ<"K>2\:9W-D^%+!#4%,K:NP"J%X9VJ>!0A3[_SXT5J*NRZ5 !++VN
MWR@_MX#??$@(.W-:^$JX"T>SW]9PA*1'3<P<54>G$GG]!O:5,T<>HMG#L#]&
MW:>$W3FDXQQ8VXCBK$(/_/'U!?WRB5,6F@G280!>;DY9P6\NL$?=L<[."\1C
MMO >)<51T7&.#.?+*&Y\N/@M?->\*T:AGP.@G5C'\37'G8$_(73&58;N?GLN
MWPO^>^*/22W!?-@3H$HXL*\190&&[O_9X#7:V06@7'6KLN"0]RCQA+KG:>K%
MS*5PG)(R=/W"9:]#K;++,1PX\$>2@@/OHE)W*4@7'EY<CO4D\N$NH"_/F!JN
MOOS!N/M/BWC4D!K":=E#931QX$(%\KJF*[SI(.]V"5T%ZN%@C.&F_YVI>/;2
M9^'M=?ON02.D]$.G7)ZL)%X)&/"Z#=VOG'V( ^?AR-Z)CN7MY[J4<)A"/Y\.
M:_)'T0I[:HS@6OHGHK.2A&I17'$T/@PM77K>H8;B.GKQD?C:FF%]@\+#2;K(
M[Q_P$DYKM )9-D%Q&D45?)*C@IB'P<%RQ!<[$R5$0CE(-08GMRFX,I1Q\5JU
M[+*7^1]-^8PMO \G.>)-]$<HW>1OG3=7!!^..,IKY #%-PEU5O[=KG7)$2"-
M[#SD)X##A$.=] M1<M(N(6ST!N:/PAT>5UJ7PAL>R0\!?V_V/L_]<]R':[Y*
MQ$^./K'H'[Y(=,=))^0GD]>W)');Y0+X\$/Y BTWOK(]"I-G"ZYO3D3-ZU!G
M.1)"1YY_OW'[T6#'Z*W=OZH&.C1(Y?YN!89\:QLU?G!F\5/P$H^=/[.^HQMB
MI);?Z85\FVW2U'M_53C,GCV0\A1UI5-3Z-T-PG-92]NXP+6Y/[K2EW5OF];G
M =>@ \-2(>K/136UHUVJGJPPZV@^O&:G=8U@.'TE\OLAO$R K* C]CZD#C[L
M*F\-45YR M"E'%3HB<[Q@I<K>X(>$T/YL!,F#QK]YW?!(=2!:O&3V-=#]MAY
M_X1"X6]\]JXCZ6?'72=54ZB/W%%VW@] DX4P?A%>Y'FVB0][J6!G(;)F&-;8
M7G#E-_-&1WAXC],RDG\HVE2H>+(,#L?NQX18_Q4VWE5PPPD_?%QQWUG#':/O
M'G+%.A7;2%$R^))]1UM^Y2%/N,SX= (']:T9SU:,G^#?];E]>M$PFC<QZJ="
M4G!DQ98-BW7)=Z_J'\4LA:,$>\!6* ,-.<E'9="4'\5F)6'NV>T;)DDF<O#0
MK%@K.6BBMBY606MQT)CKM9&S8+$#]0C^KXG2I';;GMU;(.8H)"J=9:X";S+(
M^AB8?]O=&( >/)ME0G[ZT%SAJSB>3:<XJHA!R^%HP64OL*U1B:Y:AN9.Z)?L
M@7.'QUO_Y(6)X[^-GJUY.!@5>NON!^+\G^="Z=1C!X:O#\,I:M27@^1S8%PV
MN%Q%:5*</S.A'ZN N]23KCA)4RA +[\F.]%)Q_^\R5[855'OM/OBMOJ+JIUU
M70)25>U@5!'L)43\BAB'Z/!96^J/.O*/1Z1S]G#@&]2;CHQ=F)PJ/+Q]@NG-
M;^,)83=ZU^J]+?I:O<=_MOSMB3H#1WQ5:/ZCE]Z-KP2Z%R;7GHMJ&"[DH)^_
MD],:!O>H>E[5QC5AZ 29ZJU"FD9?>742/;!N3=VUW<:O2]]3?F@=ZZ*C JU^
MWT:RHX!T7*Y8?\95_K+J3B>A-9U2S"=_]"<0N/9".E@NH)C*H;G9IH_093,[
MR'J<V H5L!U?X'EJ^TD!<5Y,D'<PA(WZ?^P#?T;^]VTC)0USB3K]7PN@,70]
M;;8.Q]BC8#.'>N)PDO:9_T[*U ^+21PZH5!.\L%[DFI1'C[6I>P,5;2]"$6=
M^-VV![N?4=X5C@XNIY]*ZR=R\![YPU%'')F[T%HA0)QP-!2 _[:_'*) /;@7
M;[U!#ZFA2/FI?:,4IZ5N.  'K3O=B5\+FHO,%Y(NFB(KA">J%<3Y_PZ>HU"B
M;KUU[VD9M86#\$-OEWUJ"9U=2$$3%,<A.T6"X-9>WY<!IM2D0B2(.Z3RG' 2
MMGMP6@HQV$E)$7&_.JJ'%RT\XS:?&E<'+Y6=K,&ZO$<1\4)*"M837?(U:"Z<
M-$J9KR(V ;!\[XG]P*LN@#1?@Q^.;8.=.,V.PKH$;ENA9TL(M2T(1_P4'7G_
M-LU:VBQ-0B, ^"=E-%P%O^S[D\^1W8JV39==/=8S5JNXV]4 0\59Q5\V41DR
MZ(I/.>*9E?XO<G/LNO!BV7XO/^C5JGT.,Q1=_J:I3G]O<VBMD+#& BP#Z'KS
MADIB_:4.T4<M.A78VS!2XG93_N: UR(C2@6IAF>^SL!/9AY89)7HE.:0F--R
MVH*7$=(>DUCD[A$P2BVWC:4W(C'HD8Z&A>2]'Z [A94Q,7I#:X\<:0FMVY-0
MTYQT[TUL\?&+2$H4R:K)VJ\%MV@Y8E,>I.AP6,M$(P?#8X01C7J%,H,RS0%Y
M6DFY;8&.S5_Y1K,M[>^5G<O1O5YP[]B0[GR'TGG2%XRWZ:4'#K 6?Y;.;S\>
MHL'WO["^?K<VKL7=L?EL<<?PGK0UQ7.OWQKF!)*W?^@K*+ 8BX@4-^DAPQ;]
M\2\]#<^P@^UNW#Z2Z_W+S>!=7*'SXJ<_W,K+'QQI#ZM/?O(KJ]A18M(Z^^W!
M$LN4A*]EL7GSF.S "S/F8[F4K:/=%@,VY^.,9=@5L>JPCKU\T7]^G_I:WCGE
M^_Z8*B?,,X?1@S:#$GF4C3!;')76&  E.BDD<F\;(#_;("WKA:6[DRS2P" N
MKQD23V=,E>AS,C ]#T[W)JG!S2F>V-N*\\)REKLF (1G+1M5FM/31,]$[%CW
M1;0YC<_I_D[7TVZ$N?P3LR7<;6)KM.>B[LPM$9YO3W^*\+9\OJB'.*CFA8)A
MML\0,5<=76$P/TL^X(WQ/FB)[XZI@A:3>YJ18"Q3BFFI\IK-$]5CF)Z[Q8BJ
MA. 6'EGD3"M1ZI$MS =A)XM(E:77?@<)DFB1SXT-YHBX<8G<A*>WO!=;\MCI
MU=LJV@YEE[B-?ZH:Z;!:=^ON]J7I2X8K)DI;KKY9NO'P[&]))5VN"YB;K[[;
M/K[A^(8'R[U&I/%66X;J#?[=]?W(K$N<K_OGE:">7$N$;M,R@":'[Y;OGQMZ
M%4#<W03<"ATK_F%M@L;W(EVB-Z7 ^?I.59+LG&FNHP5E7J02]7(3^%7H.\GA
M],08ME\%$A.Y"/(8=)>CT2P^7$1G* **D(=R0XE'&/>#EGR(IY)G_>_>SG4G
M+GS]L4[1;[!KVLL:>= 6-<KQ.Q"/10[JRAPV^:'=Z1Y2+2>[Q$[8_:Y[XT99
MLM^S["ARR3/D;+IY>N#5^(O-4OU',[R*?OV#R$8/-Y_QZ&[+-:(-'JJ-AX7N
M$>XKF>*7;)#& Y;$/=G<_V[6I3WO?&J3QKZ4/_[WX;\''NQ01#[\]JTX^]#R
MB=6B!4_^W?%NQ.C;XSWG?L\\:OWOVW?O0[$+'K=5W%K_<^J2VX61H< FN5#3
M]4_\OCU?)W;\;\_,LTJSY@]'3G&:/Y*']WT\^'*4O>\7JM@-(T.:]_'<W^94
M$?77/QI&U;$ U8 ] EXUD"MR6]7FU-W%J)E"EA^WM9&ZE"2QT3HL/4+/9B[C
MI;#/"N5E&>:,G'',CV'N)YY.H7IU]*T;2)_%CA'I8J#48-Y@2<),8TZG6F C
M,/>?:NZC+LVX.J>-7K!0X)>]?!"R[V+WS<YITO%Z)(YJ&)3.3O5CI.JCLSXZ
M]_-)Q8[)+"3Z*SW@\F>_0LM'?5I4D=30":46X%<-;$AY'#R;GDAJMKDS)5TR
M*&8F)02D1PV6.7 LF+%CXED]N-3?H8FB69<MG643<)P4T4O'OF?K.O+HVA^E
M^<:[4V<UL?WC$HJ9A?(^@W99OE\,N'_/-&QTCB\-N.MT8-VO2K9"@>J*N\J]
M;OC/$J14<;B-5.<; \Q58Y1Y%P.U5G3;6)Y64JYI6>0-OK[.7-17X+5=5-TE
M#'0[1Q_RW2JR;ASLLWXM+<%'ELC_(2_2$@NR66E^!GE5H(Z<(\&XP21.M]@A
MR%'" L1,QVZ0OHHC"6N&""+W4K9 +=4HN<3HUCYJV^@LEM8@E1#88I"FB^01
M4HC';N@S4I6(V8#27NM=[R*)BI(8=KJIJ<5/2R.C[*?ET1UE(C;] Q0>TTA8
MH,F8T@YHC#WQ445HH/=I[15F&VM9,)VZ_>B[E3!M[W&FMPID9G E"6F3:)?H
MJG8=1IUS Z?H,ZUIPM'1V9G^!KYXKRDI-6KA:0N"<UZS_F:N+"ZLK)DK\J/7
M""7&IRT8'!5LGRPW3LQ+/=FD!'7&"B2^US#*ERQ0J_0+6M/';=3:Q@ZP#HE,
MQ%,)' ")D=H5ML9]H0< *+96)LFY+Z<G^3CH;)?E=YD^)2Y@SUNZ3PUWKYVK
MOT#X3GOMJ'31@)*XT=7?(:I78LAYJNAP'Z#*2@M88S$DPW<"K?M3V:QL:T+1
MW.P]MQB4&7\_HC,W@KV3([%^CA$:6C0GU[?1X2[AR/JQZ_H <5@YE>=/F%\?
MKK/LZ?UUJRP(RV57=3,Q)/&7B'AGPU4M/<,"PZEH0M&>::U,[U+C,#K5%5C#
M3A/FQ>VOPI9-@?9B1?:^HU:$;?M1O09%@EES L'!MV_GRANP,:./^?R(V.&H
M"C;.AG2=QA"_TSO#93&]!.%7L,Q/O-+TX ;=B/"Y42Z.Z=>FN92NJEYYBCG!
M+ XD"H,":'7T;-/@^P17O(NQ&]<+4*MN(X[96C.I)%:&F.DL&RX*??/,M/!I
MV H9R"Z2(SL,JP>6JD'[;-F+RX/*HQNEG\UN+,V+D8W?\.$Y6Z0J>_T'!7D+
M>_LT=>2/L)<^<DM0NSW$>W:)W2!6(N_N-3/2E;A=:"($DOVUMZH:#$]/TCE5
M<D8:0%UY/<I@O.CYLI3=J"';S0N72?7$6(&A?/NZ5-7K7.V;)_T&\'I&&;A6
M KPV<W]*D"L@_>TU:?.4?73'&?\2_7P]W<.?]9VXB-ZTMQ1S[R758.<[9]VL
MPL8$Y* $J*XT4&HDF]/MQ+4-,;V<D+\OE1*J\#.+$DFN*/J(D2VBV(/O7AJ-
M+3-PS]URHYK[*2&[B8"3Q?[]]PM,!P!28EYSP7>[C,29SX0H@';WJ0EJR=J5
M9_%RD?U:7&J(B2E<C,28-)68V^PBQW3W,C1I*<\'A[GW#I;[642O6RF[L8WD
MFK'KJZQ=+</%KU9[0OOWT#\W_G>7R?OF9U_QY'.F?C-=11N2/=V-&'.>DD+S
MT.CS[[\<-QS_,.0+\;^/P#9YS73G3%<]:!X5XXJ(RWEN]FI?9N6Q!HQ+\@TY
MRY'P$9 <]B& O:H[SY E(DX],N)2-Y8G*LUUC@KK8SMB?8/+>%9',O[7:^N7
M_]KJUPO+_V46IMR YW'$\_']1E-P7 MH05UX>^W%DE3N_"HP<0::KO7$!K/Q
M=C" -_\YG5(_#-F-0JW]^K:#YV6J*\[?/3"2<CX)FM\B6L@ZXS,%+E2+B#&G
MCM4NT-NO.66"G'2*8A]=*YY;)?:&:^.F8)L6< DL9;E[L;&\13+Q;)7[N94%
MAG1)0A58>^?B0.T\<W?GHRV@?0<H#7&SG8+FC('\!/O6/)%&OW/DCD_F:PD+
M<]ST';[QDZP?D&^)NYB-06!:+^2M]%&+##O\5JX[]:.[U_9BZ^RIWG[J%8Q1
M=5RW\W$MR!Z#;#.IIKA3(\]MCES,=K_<8Y%-?=1L\LLM<,8M8+\T/%L[424V
MI*-F^)D/-:)WM9Z^SQ2>Y);K,R0#' BF,YW&<>;30WE"W9*9//T\23$_:-5G
MQ<<94H@:('TG,57,C.:")0F=)I,@?PI,V'6Q4C,I>J06F?,1HXFN&+IT78U;
M695;W4[[J-H>X\Q BT79?-4UVJ2(7^5SO+-_ (<>7A<)D>Y-#L&6_&Q#5K91
M*#*'#K'=$4.%7T",B_LBLD."B[CEE QP_]O8^)*DJ)B:O?N1_H5V<0PN-A>C
MIMV!'BOSTYZ!9F,]_:6B*/BL\1C(>^M2W3QT8)VS)37;JI02LRLX9I?WWWW]
M67<#7<>##":"(X&_38V#'=70EK!L0W9VSFX>>\K%^+D\HG2!2?.IC%T#YG>-
M#C_J.%!HGZ@0D\-0,Z[+_2W29[#8;Y'86 '&5[4QAL4L ?HZ](*14(9-@<[K
M/,>JKFKD'9J3XYP;8\ QD33\.RET*EO6DATR>BBQ"@WA2)7YR*VRXJ'.[!M:
MY=2J*SQ^N397LM!<>M<J3QMGA-J.+.Q$;KE([_S*"Y6'#UNA!IM*QC]S'L24
M/W' %LND!E-YKY5B%JF)-6/OY2*>-PB:8%030+(D4S1G\.^%0FGI&Y[AE$@Q
M9<E22R(S1?,3L@.F0-YAR"1/&D>")FO.O;RHL/DL,N2+;6; <4&(LTB*L1SG
MX** KD5653??E$G??LZ>I1#?_B&)PT7A4[#%C*0]ZM0L;H!=YCF97,SJ/IK
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MNE@.4*LEY)RR@VIFSQK1RBS@NI:N#Q!!,"TUB<B0)F?D;,S(M=$7EQ;IC+[
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MZ<.D!;)6\A$@TV>K'N,O;TU.W9[YZ(<6?^+*-].TR;IE&0M>G/UU:62N<&]
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M[MV<N2JK -"U*H8,YFO$Z';5S=6U#P^NN9I;:J.$77;7"D:KN[K%N+2%&_?
ME&W7!;N\+/\MLBD#60N FP$+DVZH![*?.CXQ,^U0(=M55LVBH6>[AOYVZ'/*
MM.(!IIYJJ%[-3P$P.;%HP;YM(C%.$F3:IMJ!Y^;."D)?AZ#./&[Q+\>5?*=$
MI<T?BU/_U!W=I&Q?93:?T4YSIZ]=KC[Z9^WS$P!-)H;R2_@\@*_1*U:^ACJ[
M\T)VJC9M#IC=B'Y123LN"K*>F5XV=G51.PY6XC0 (C 2BWWDQ /"2\2G3U0U
MG 3R5$HCR>9+A!9!CE)_6H<L<Z@I"-=WJ=_/+%N+KC\]'%]0FVA4 4JPYB1V
M%[NPH@,YITF@*QR3M@JBN)VR.)(:E676%)82+\MK1[LY<FI9J\6E]>8\DTO*
MADE")I4&5S7O,%L3=&S!CF_3/\V29!4^N=0YZ92U(=4!A^=N^T5)#CL=>CHB
MP:KF0'VDQ$FOVM)ESV]H<CQ<-.=,D611\I1TE^^I):*CYQV/=<Q^;<Z7-@4^
M*LG*+:[WY&V<GSSRI"@J*G?CS2,C]@K_1>MXU?&!\\:JE^V86[9\A,<]K2M.
MO-N=<3FL*N182*G5@BN;_?W7345>W&V]?<,_UW9\__;'.DTQ=*616F+YHN#5
MBU1[PO89>OK6-P]/+[L\L^=/^N>SD@.8#QN^[.S^.*0J^D1[Z144BGJX[[^?
M-V[<6W:^X<GEOVW_WO/GWY\NQFU[;_WXA:@CFPA;E,B.OK?GR/WM 9]:T/]8
MW[/WIWL9G7H@[%V-G$RM/& \)V9(2_G.N+ZX$BOJ\<DT6^CNXGOTA48[-[>/
MJ;</%<L"?<R"O8B=>]^RVP@6V_+NMUD$1\M*0^;S3!<_I+QW/?7QDOK >>3?
M@60?V]V2I@#NE< NBFEOI5NGZ_[?Y(5SUNC;!*;)]>2;WW3QY.MS;U1MZ2$T
MELO8L_,"/R\]2F_,[)G+CVY>&OJL*"'3DT\X^ !<_ZRNI;K3;/+&A$?'?L@M
MD,]%$F;JBK/RCWB4\![Y+^2,()9M:9(4!"THJC;^==WG$:(I>4ER*>:]XA,2
M>(9=HNK4=,LKO)(O?"B9MW5]O:K;^VM7,?KV\(:ZE!+4QY+D!!4B^)]SU8XF
M"[L/)F1D]8T]+L2$%)V,#CC8/7TEJN;BO+H02\N>8FI$5#W*''^U7><9WX7(
MHKY=V+/?K*^S!UX0TYA!L="%M"'=$_5()('BUY%O1@GJ(I(-BDQR.'W@Y-#Z
MT,H,Y()(66SL0^?8=;&4Z)S>XME!"NQ!$V'#20K&1J3*NBKM:C,UL[_-)^;>
M349 ;I<6JI X$G=,I1.L!;.>36G.%,5^\-"C N-S.>29!<-'F)E2P>G\HJ,G
M.MZ4S DB;8H-\$!_>"/E/-[VONE>G?$&3VFM><'_]%BS,:5/1DJX%)6QDT@.
M<JY&4>F'#<^K'2SJV[.,U&U(W="EDU'F]$OO$Z_<G@4J0GMA?07=#ML;==,_
M(O+ C?A-]=>T2V+>+UL$GXE'9:R/^[,Y2NAM]*9S18ODXKOP0]PXW9V+RT])
MPV2@>V!?Z1%O+T?:[[3\+KCXU\]QCPW$T!C^8:);C^&/_=(>']S49!Z[GKDM
M=9(6Z6AJ[:'YM,VHD/"/P1XW>&-6>F;&\CL3H3AJO2&JBMDV%1)R:UF#EG,^
M)W.P\UN]EVR88 _<%3 B%^Z9>2I9\.)M'UZ@.U(LQ9JSE0^*-D_A+0*5$-4R
MHC*ZZA3.]'.NI)A<E4SA$FX8\3ER)0U?1EXLU1IO*5/:^3>"^$&6B5E_AI45
MR3*WN )1C.WB>L JC^)*T)H)\F$FY'E.1[&N!>@Q*M+">"VA29:!-"C0B"I6
M3$L13._5*:\.2J'-"A74*=R'+&M%4 "5W2@,>FE54$T9"ATDQQAIM?EKRA%(
M#@WC[F$@%S !HW$8++>Y@[2.M$;'W,]&EQN*FK BZVZY8XB'CE*L!*Q&)Y7S
MF_5AW>X^UAQ2[NQ(F.HL![#/ %.B+ [%U60A7\HQ:,',9WL;2Q5]GEJ%TXJ,
M\8H8,!# $)-@:E%9#=WR3=>R8A:8G(1 C )[5Z/W(PIYHKFOI.!&]4,4;GT&
M]!&C,O]Q8;_E< U]P^(\4C.32U8@C;Q)%X\TR\N=CL*, 9WRIE1G'%>_!.>W
M0TWJ;$4XY2!1$4I6J)>.LB5-R8UXJO:Y)"+>U8>CQN,Z"54B*K'S%22(Q96_
MW<IN=0=1\:ZJV+L05*"8P$F#5<458513A<3(RY!C-I!),#V6%#0]V3=?RER+
MMK3"S&7N([R8?6)]K)*QN **/0X@%ITUYM)AO'$#T\3* R'+\A\PIFE1R6E*
MS#,F%%H8.P.]="_!+P^#8BN5=?$MG58I11A<>>@E9B0-\5:^%\LY"UPOU^$3
M]=+MQ'?@FAPDFDXN*H[241S38%JB2.6Y=1A,RD%8)JA O$Y%P*6AK*:/W+7N
M%A.B1'D2]GWE0&.=_4N\/T;(Q(7H],"67TM:'+^4#/6RB<PR #'WG4K2K38V
MN+<MO;*6>KLJ$SGK2 <G7I5-/3Q\[,Z[.'["INP3QU6(OU*4_$1\[-B1MR Q
MN8V\2J0I5BA134HE7RXPBJR:PV7*$'2\DU&(=IHPJPGQ/U: )DO8$+D1$1Y*
MSL5,U*U\-[U/(FZ(PNA$YL9IOMA.)@VG@:"9JK(.I*!1'!4]W)4H_(2A-D'4
M,C:(VK0D^RH64\=VXZX!1#O?F D\4W^RR$(4,E&4?:(.B7I7GX_E!%KYH,;)
MQ)RLBM!*R*V%U=ZDS(1>[EL=5J@SC=\F09?7G\%(V<9/RPNCWD(0?#X64:I0
MGF-J,03!J'GCT#Z4+(H]U9W83@'NHE\J6>[3+61"FA3MK:@GTB.-Z?"%<YUP
M'L' XE+#MVZOL$\.^<N3>\I/OW3-T,11=^'S-0^G/C-(.!/@UV!3I^)T:"7H
M40PNBO_!:Z)-XK/H+H<OE6 QT0UE44=I=R]@5U95$#!SHN6+;;7KC9IR-T2%
M&5(R9RXQT-)&I3KG-N5M40<N4IF[[>1;2A'S3.P7&((7J$NM/*@^4UJUS]'G
M,67=W:GJ.+S[])<TWM:,N+S4YA#LOQF%78CG-^?LW?,<:>R*;ACHA>8]7CE,
M=I@<[/!J@92XLW];^#@8O<!B>OB)ZV?)]ULS==!'U.W7\"I+PA+Y@KK\;OM4
M(<R9VP":9AH0LZ84_M$D$-?,W,'2 *B"B_*;,'-;&@#B8%GDG1-*B(,58=G^
MH&M/)2HQTGFP;ZM9 #.<[:Q[>G">MN'A?RN1M-KH_%6;Z'>>LQ#W)/^BIS1+
MEL5AB30/QL2\!W>/:K32U"28 ZP#4[Z@3K-R9MIJN\0_R3"3ZBQUW^W5/[Y?
M%PN1 3UIW3NPVV(N(J#7YU?6TA/&S:*R-:Z^\[CR=DK5:**;<TX!1ZAZ^4?V
M)1" \K%K/,2O\I*I4H%;?Z#KI Y*'+HL=C&Q4DY)=1!;12 O82^'(>+&$@_#
M)R\8Q5[TQ0] 3.G( A@2&L2!>O#Z&6?ATB]QG\SQX^9O37Q"F%_$,#)N"16&
M00Z$\("_2!J,,\\O*IX0A*P[AA?'QQ.VMN1 .TB(23D5EG^F#R\(C$5Y :@'
MW::!'7^@P#^..LH>S+)G2ZG>G>0C&:A]<LC=!>FFI3B"B(A)<;: *WW7RX3-
M!3.B+^=<J,NUV&F-=X06E9D=<G4I]^,!EZM"% ,FT<'R>DRY 8;83*0_YUF0
M%NJ#379R!B;L$./,&:V+)F@\Z9P0^OWI>LCP7SG#YD( ]5Z.D,FI,OE52AOY
M+998\':36%GW3 L%\4N$F4@9VX\SC/S?9NATO/Y8B6+""?;:'HJRN2J@1*A%
M/=[((C&1HTQD9QUA&C_<J:OLTX4]-I1)AR#Z,+1\+6*@ZYKNW:KZ5N)HA[T]
M3.SD<V- P08)E:<72&.AO%$!_:XIV4 >-+3V"\D4+;.UH6UY/$KQORFP&@K*
M1@2]-R_%)QP?J[T]C,Q["X:I$#/)8[7=U9+EP**"-2Q!RHAW4_0S[3EF$'52
M%\9IO902A\0'07$^;#_Y!;\-"&>F)K&/;&5(C9"SK R1O\_VN\NHWDKC,#$*
MF$J3,MO3G-D.#\+*G+C#<H3?'7L>T^1WH8!I(-L;S/VP_RG\H+=QY 'QB7:$
MXX$[LX9"N#FCW$:G;1%NW(:U[#X#0@"R4]1SENM,:6W,1]JG?</F,M;^E$J*
M% S.>S-:T$T94-9% G;W4ICS#(3:S<8^9H(I \(?6"/0&<]LFEV%WR4=2IIN
M8MIKW=RT$?XZH6DH)+C@XM]F:FD0?VM <EH1?7YS[T\A8D*IHTQ$##AC_,$P
MCU5O< .(0!UJ_JA JJ>X'30."C+Y6W/I61.%R71T@(>6*W^FL)$#@/%<R&$P
MQ=BH_W=():(ONTMQCZ)KI4B5R CC\$[M0LR6A8XPVPV>4_( '!R+=X>)_BIO
M^I#S/:-5\[G&Z?GV?-'<]<A%3=5N_D.@LZ@Z9+A*V(XPO+6?V+^2?L[>NVEN
M4^A+>B8BE?#4CP*)MSX.TOI";UG,#Z _<MZU'M,7L,^A;D32F6M!V8YU3D@>
M:-8-@_01$#N%R'M+0,YB<=P1_8"/4(<$0E:T\%T_WC>E*BG^(J35UD+GH>E)
M-2'3Q3;\/#@ C,>S4%(.V6TFOULLGTUDWJ;H*.V;1[T,-5/,%9/0I?F$AO?*
MTC EXO$(J*V9?WC$ON6S^3"SJGW,PQOHW] /O!P&[5D:\EF*O1P*.PV^EU/[
MM("SGAL\?:IO+YFH94; 2(Y^)6-X5?<HF%B!X&G)NGICG@J02(RMPD[S*BCN
MRA8RDPI?>""K!*^[_P]#YO,/MJ].AQL#$:O<4&%*"@4V"1Q"XN4YS/"0$7FL
M,YLKT*)B*HC8)<O;UD(<"N(9TZ1N@.(-5/-TJ)=LWI<'P=M0;9$GH5YF\*NF
M.\U2<N GT. >$AI(M6*:3!4R0\.H/&;,$'S=_OQLC)995\*:H;--*%I[2[;\
MC1R89T F#DTS1<8D7_9<YNWI/F/V4.0JU?YX5N3>BYS$(<8UIY@YYL%]!H"\
M^+%A*R)&!,9<D ?[U95U&'0UQ*N/R,T'6,/AQ%]+EF>T(_:\98?&(?*ZB42
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ME=I<#S:)(7AX&.>LS:4N*\;@(J583@ R=DQ(?IS;&7'*PN$)K<: 0-YO,(=
MU_0-B _[U*6=)_PR?Y++F(DK?20QAB1-.-J1S-R2)% 2:&QT(*V>K)3U1?N)
M55YUMU!V=LH1<(U1=IDKQ:5R\L J?8:C18I[+#6Y>/E9: >JQ_-#WI"G+X;0
MAP/P9)FZ?CYZ:=9:CZG=.BDTC;XX8$(@N.!:+D2RF$+>B^LB0X@HOTG3L)$V
ME/.P++*=-0U.2@&;"F92@YH1G%".HI8<\'/V)"Z-2211TX_3EZO?A:1K!R^<
M! [ML2*.,WDHUXYZXKF41^['F9L=62?A<?)>.)E/<:>MW#1&T)RU^NQ#IH,V
MT;Q.@E_"J F3F5R6/#!Y?A'30DND5-(P#I]'#=DK, 4V:4SC>/+27:__6'RJ
M#%[>?_K4!\,SS7B@T>?KCSUAG?7S&&4P=_YGA=Q.;=Q*&MR-F\ O*XQ=O>IP
M3BN&%^71N\XJ]Z?M>9XJ(J5;E\1&O#<H4U9YW]!-6!D<;GDE[$S9<T>N\A]E
M_PK8L!N]G=/#>KFL/&.4[?A\6F&%MA?FL-,B!''E\BS>^$D+R^%FQ0FZ7HWJ
M^I)74V@C$SJ7HU#WD,C1X!2RU.QASM"RN'GH61+%*LI93@2;=VFULMU_"J#,
M9-'EA((O8?DNTX0YM8U8=N_UA8^4=:>EJ IQ+^A \["G\E"D8IY#\C,0PQ8X
M$9H#'0.'%V$%K[;0A#P4S[ KLN :PTG;BZ;S0%PR HZCJZ%4Z>99KC"9F*5@
M!O) 3+B="ZG](=@) #]>V8IRE"*!^>;Y&(LL@J0' NL:[LR=!:#&W@(<6'R%
MHWP="B]7>%'8"ISQ#+A37M[&- #<]"UWR%)D66;,\J+6*_5K%\=C'XAQH3D-
MY$ ,OX.:J'3I\_.;L@J6WS5.GMS\D"(SP+2";^616P/)^WVR@[*16UZ'^?!X
M3*)O3'R[TJJ  XR3I1+2"IW@V.Q DMDZK[Z4%%Y#7VDHF!AO5&K[\XAT<?QX
MO&L9BBV%O$VF@>< 0JA#H6 6%B8@BB=2P+6:@X!"DA)@T:D% -(E,RL DQ_L
M*3>!(5)%6!8#H+'0*!KO" , [$YZ.G)MQX<<914 4,0@#/ <),U^0/._/&#7
M="SD09_3_O8L,YF'@%TP$:+SIOD:D$2$!SES '2GO10G!>YQQD[#HJ2*W2*Z
M<_1VT[6):<L'=IY+GQG>+='T?'>B"V#89 *&II =.'JZ'V!*FJ-%8CI X-LO
M!& M5P)L 74'F]<?1P=*<VQ HU$ -A62-DJ0V<+' ,/5$'BJ]QGY^!03DS%I
M*9R#0F/%)HSL,X@.L(7;UK2\WC8F >HX]^'"9(TW("Z]_?WI?UOYW6=8?A[*
M>K(7#]5GA (F4?QY9TQL$KF>$N>'B>?U:F&X "!8@&R&'3-Y$I+I6H85 OA!
MWI]_(F@#<4!Q)AL"1W>@K^WG)+$0O4)U.@R-TM0*2='$EZ8S$,) MM]$8-I7
M)RZ N';"T# "(5"$$'!B(2*. FT!WBU!B&*D7(.@Y2%DT_EKM?Q/= 7*@!",
M%48_ &M"\";D\__.3R[I[>8T<L+Q/G\ Q*V!2B-L.8(H7/GD#4T2*;)>:0K3
M<.>ZG!L)FY)(CTOE =4_N[/-/(()B:E"QU?MO%T$@X![@T4%T$&1!^+*\76V
M(&0/("@=H8J1,"$0RD/*M<"$=(''KA)V (;,1D()GN'IO1%_Q',I%W.3*Q5V
MFV^OY6A*XD6W5/T=?V0^%T/R. -R:C.!R0]O_6;*G.\'LE$ ]0_^J; I2?2>
MV:D 00@8<P4C81@N!EG]IYH*<- (X!@F"*6K =(QF >$B16 -@[NA!SE *83
M@HJG9F_@NP=@II=<5#^:OCY*D'? 4AZ.:6\72H187(&JKKT\"@"<V3A(O$T2
MHZK86N-U "A;#P!R. $ \,@D!\SYDPNF*'E3"@HA2(B\W54"&X#(+"B"U4FB
M(50][ 8@F^D@0%<@"P"H$Q:1@% +!'$ H5@!FF *&Q#9 ) $BNC(]P7 )<:4
M2C/QW BS@07:45E@50 +Q"@J!"K^%4O7UZE/!^@+!1J)&#JSE'?G'U&[?LQS
MS].]M6.4N]4QALY>&:TPH-]L<X< !   V  [>  +4E1Z@7I?;W*_#.-N[ ?8
MP,==:E<Z F 0"#.VP11;O@7>ZZ\1B1%@N.%*7S+  1SGG+QY &AEJZE]R0[-
M.Q[$*#)^RTF+=@$0D3QZS=789 #A+P8@><BC:&]E\[7G6C65!@ DY.D1\ZV<
MI.[T&_:E;;UT'*<8B,FZZ$K>FOH#N!R#2<L"-EP1G"DNN=>Y9<%+? [WF!"!
MD^CJ(#\<BEB'BA#?TJDX@\&?ZJ!HO;CFBAUR[&W\=M@MP6K=N;6$1)QX\3(T
MV0)=V IS]-"EGL9@14EE,YQ0C!:12AHLUDRK*K@,3C 115:H\)%5J4EQ^29.
MLT N:OBUY :3>6K5D2V9''6F 7):EKP8%[3X9DN.I#O*8U^J7GW%3!-I T\_
MMR9I5=_:#PB- [L&FI6:$K=K-QK8:A&2IK&H4K6(=M#[]P ]6!UE2Y%H(&PS
MW$!'1XE=-<$'&XPJ37+U_V0#PNK;#["\X\9&L@>( 7HR;0B)Y4T[@9"&"+.O
MEKN9 (H62&!X8_50A &@-",DL8(D!=;[0_C.C"-#P,T> )_EXY25<<<N5A#$
MBNJ7KMN-B"N@<!!O(QD!,@".'AZ_HQ.@(,A.(X25*YS$8-H@X@" :9I);B:D
MQ:(2/P:2+ AEV OSM\B5X>>BZN\)3\:.7C7?KL6$;%E0DKYNO&E#OBG1;5!]
M^':[&!-[!J[.4AQ@U5+HEY;%J')T$):.JQ &.1O&6Y* A%351S$XK0>[I]/O
MY!+%Y2CHR(9M&ML.2><=>5M2LU(%&2;$&@8GEGN&2S6I0SN$%FJJ%(C=A;ZQ
M0% J5CW/4N%]!@]D/,#OZCUKJ-F,\>4,>E"E8,5EU<JRK&-DXAXC1)(?^#.Q
M7#*P/ZH8D\:#GNA=N_H!>[05.>Z'HW02QJ=XON"43_73N-$A*J>V08-(Y*![
M@6('WYMC:7?DJ856#0=IN2,%]_K0" :$7+"_L?'1E3WTL8WX&"1;HJ<XL:%$
M3FJ:?MPG2W;+<,5R4+'LV2%2^C:.#<DL!MR;2V*&G+A^F.,NOCJV6K)G;O#]
MW2],6Z_0H:^A3A@$[<Y2VF;0C&_38^GJ*54EA;6J>BV:0M^Q4H?F<U1H#Z^K
MWYY\>C5FZP9&Y6TATU_UZ6]A-1.W^G.UHZ%Z?BWZX5PBN^UBI38[00H<M5 )
M@S7+^:JW7(6K!AX]7'V+75&T4I$;5>;GM2V2CD@E8&Y#=936?O1W8,8*@<51
MN/U23)IT=O6>G=US3R/HI^3(9Z^?B;HLF()JX$BQNOTS@&>A$XIKSX1)M5@0
M)\4YF42AEO),(]*&=O\P[(G3J[3^FNNVP\?,P&Z6"HL!M^9Z9;%4W1&U?Q,]
MR49$PE*UL""<YOG AKLK)&-_F_]%> '.=KY,IQ9U DXVA(!I<&UZP?WH!Y)-
MNP==$_0O0K_0+\34-0R('VD-J(=ISW-\XCZFG _"\*=H;K)DMU*(PB>[&[+5
M2ODI[8!,9WOAE)J<*)5%4U^EG-M-.;?E5:IA(_-5QL)7G?_S 2.21_LRX=17
MLT^^FD-U8V$@_.'\'/N_K^;/],@R*#U,"Z21KQ?,2YTM57KJP07]6S9&A)S5
M+,3Y;Y75W1AN@S,^YLM>OUY^#'^)I*;K%3YZ,+T'SQUR0M.B=@.*C_V9S\W(
MWB+_=7_5.VQ AQNQ! .EQ(3P4Y-5)A76%(67[ETW??=&:EN)_,"R?U^7VE]-
MZP0':Q5Q5GR:S=J&-%8:D:VK> 0VT*:'RJ0%MS6-<W>\XG 7Y[G@0^D-9[2-
M;@S5.L_%FYO>9DR :8B/=S-8?ATO$E9%&E6N%J25B7$O!DB&D@^,>ZU'8;(-
MV#102RA02.[OOY>EVI:+"\MJC93#Z>+9<].@! [(X4'R/; ]BI7N]@,Y&*Z)
M[(0]E:J]BT\WB!%!=;#$!)%830U9H!,=-"Z&8MM5SL- 0CE,T"/A;"C"?'S7
MFO<+GJB0FY3RTE=N[2J,C3ID_-URQ0OCH(T]0,2,A SIG4P66,K48 TPV:-J
M+HZ:/U*MVO_445-R<(*GW Q@K'_'%",W[N:&-F,B /&T-B@1 T1TPLY9[DJZ
M"L* X5D3%UY1)0V6?>* J3S5Z)U<H1: +P#K714$;<_EMV/)>_L[:Q<_3OIT
M:<*I\=KWE^_B8Y\]:CWQ&)VQ;,^/;((%BAA$,NEJH>'0[7]W?UA%7I/=NC,^
MN&NC1M19%S:X@S!L;]!9_7\%JJP;U:()F%]K'NWV^#AWI ;NK*Y^/C':0E5J
M59F#2 P AG;2(JP8_O]PHW$'JQ9^\IJ<.UNN_%ZZXK*!8%>7?9Q!7'9Z[@I%
M]$"J@OXW62+]O>1+,XJ,EZ7N(C'X,525%JO07P9T2]WW !6XM4 K T=\TZCM
MGF%.S'H0ZYW6B3!^-&9*G;DW/5SI"K+A;,LOIRG9R[NT-3MO0\QO51*K?RIF
M.F_^1?\9;NG#_W0UPU[G?8)6QXOT5HE'BIFNCCJYTO>GRL-"\=8//6U7Q=92
M#M=7Z8#=(>?GQHQ,2'Q*QR/PW#:G-:D[PC2U;E+06?\,[4%,MT=^(]WV)VI5
MT6Y8!_UY@D7U7\NAV'HJS*G#&%4NS2=^I]'[PUMGVI 84] +\;;7G"@7$KC)
MC!?Q &(_XN!!G97"W,66-@ ,\@250]:09$WVIO%^'$-T.]. MPWUW'Z]]L26
M\M5.2(1F2VW-$0[P8%CBSOUTGG#A[\?'14_K^7I%7>FG*],UA7]5M.87[5$
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M]C+44ZD  ":M   -    8V]G;U\P,# U+F=I9M1WAU=3RQ?N.>D5$B#T$GJ
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M- $A?2PB5OSPRK)5@O!X56*Z- .AKP0^X((O^5T=)^,:H/9))U\<A_XF]-8
M*DIXT,O*6T^_H,R,(180^A=CF 8*F5USIH%F3R.*!OE_<)V#W646R)5K@AY8
M)_Z/G DC?NY$8YUX(+7N+N+FHQ'3^8>7TGF0N>:P-N.M[ DK @@R70@WIFP3
MQ-RW1[;V.^]*A*RHF5H6!2((9:K&+.%2M?74AY(6Q%<"9E\C=67P^)H:/*&
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M6<<T <'2$\! -_+F522H*DI7P]U''4@44EM648D?.+R\XK8*]A:C=W_6JIE
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MX&\<^I]+#;YBN$R&? >"%%B\0MHU[%/R>W>10%QR^S<*N0\9\ Y=*IF:M,L
M5SQ6M2PB/JA*S.L$*1RT:*K$5BP(H8M<58*(<(V&9ESMFK<-,^ ?FT47O0CX
M:/=(8%,')DJJS:2"-,KFAFJ$/@.=U')5Q >B(H,[YU !)O\"<P"1A6]7P[@2
MJ@8DZ)A:JE$'YXR@*,,P!F[1Z@;RIDJ\%48R]GQ"*_"C%T?@-EWD &,=@(84
MZ*,2M;L!; $^NL6'XXS3X( XR $] ?C)-@HGX-6/MVW+-8JQ'BGK3JX?*PZ
M =T%<3/@]_Q_:_^$!M>-M#[Y\EV^ZW$.;"8 4BQ M!HH%0/:64A\0=G[MU_;
MLGQ\*6#1"W3)Y8UH12Y!ZGS#_/2*Q?"NY!4"*@3'%,&R"4W<PM$JH$U3GZBC
MAKVX@,+N^TJ3]F0Q/9[S,4VL<;\:)Q@#356@"4X>FH4*JT,_%!>(.,4&+0L5
MI\''O!*#%N'^>U4/6D#O_0(&'Q78+;#L+C'G@Y[8?_'=0SH\7Y&ZF" K*NR$
M];'H&$A7WR _&H"]O?LQ0'/*' K!*O.FU'KP''4AP8D3S#66FW3 X7\[X>MG
M1!:[1(_,':[6%H4=+=)[A<Y\@<;#E>EU0&P!&A%CEOMV)?!#._&;8THMTC3:
MT6-"5/ /32B)3?Y\#E,0T/<W_#QPXUR[D9_HY&\!&J6/N__FZ-F0D8TAQQ=]
M)47:L1(N!T@&=G HM;Y!"MRKHL&= )<K /$E5S(N E6WP<<&*WHMD/J=Z=(*
MH?ANZW[<2JG BJ+?V*QG,XLV[093I1NHM:"56,B A2F,$CT8]%E/7IFUR*X3
MF/$0-I+LQ_HH_:SB%*C#\Z^M]=_J#7AOV6IA;!<>%IXN@XZ/+GN ;ZE8P1,H
M:X[Y>S.S0!&^!W,.FK+KA:*T"M92S+'59>@>OZXI6L8]6:6A5][[V3E+A=@B
MK):9/6\56:7'^35\!GL@C+BEX.L+&@%D:O)=70L\2OMD7G3(#NY<%X/T;#><
M-EP@!#+3\YEJGW8+ZX<73$SXG$6W!H!QS&CI$M5:870+9O6[3&E=-@]59["$
M+[G7K,$\NVGG@ $[$/R;JW%L7YZ2>!@9A_R?F#7%:VZ..KYAPT4_L="$O,5V
MX2CET!D\S6%<_8)3BC0]OB%:JL\-1#O3+ JR5W("4>6X[#P/Q:UE,4BB?6&*
MT^9?WO,OXW-([6/E>F?_\-ZC9BY+<L:F5E?.Z-OX"%I98>@Q_K7?YYM-C;&<
MXB:-JF3?7T_*7KT&8Y<>L.']2ITS1.>:"5F?H_':O,10JH*='"HY>&@PJ]%.
M/4*P$>6#IEAR,1:]NBE#N*_GE[D8;:<RQYIN^= .VB18?[>H=!FIBT=O%27(
M8Q:1S^J!H#S1*XBQ#1BX9611T"$SV7I?CF6>@J!D!F7ZT#+4":YJN-+EXYC,
M:$._B\#0="T<AJF'QX&UFP"T(%5;X<'!Y.2XEV*T<V5X9_U,(7>YQ ]/1+51
M?L!F[36'7T78%RC9RRT+ <1:TGQ#&,:XYRL&:Q#\-3*905\P='8X*+MU]!2,
M&+&3]ELT<:_R$(&EHA$?AXNF+JY]I%A2\0AIF7I<1/+7:0BGL"0=(E*T:"Y$
MKR0'E:.YCT)$VE5U>2GU62S76Z2 <'.TMFMA_2KR-?YK4^=EH[(1O;#[M36V
M@,X(D4E4RRLDY$#><K1N\26(L?=@R+E%A#2G@^+<SH2MG2G35 L;7#VK%SHZ
M>I^(U5_@.@R9['X?APZ8J26N_;&N^"5TBD%99[A[KE[7V 3U"G0F9[DJ#>N#
MC\:MO-D.@P-F&P?8A-7R^L.V>W)TL*C.N=5RPR\!'*SS'W4+6A@F0RNC/88%
M[-L)&^,A&\+WJ[(,@LRJ-^>J-Z^8&SATN\(,(6%Q3,#WT\,W#!\8G;=%PRP.
MP^\PQ]W9<K)*.-J32EF772>+ET83/]>6!>=MO/DCHG.67E2HM/95TCT50!%Y
MGFP11'8=!9"&SX?O+'OS]]]WEIFSQ(*+Q K2B\#9BZ/J/L>EHSPG$H]D54)J
M*O[?8FKH=I9,CM,4TQ_<5/N(CV#R8_:Z$;1; 'G4WLS]_@3=T6_8P&V?CA,Q
MA@>5T/,MQG3BZQ_O5J5B<,$ B-+B.Z,F*UT-PF4H"R4<]+47:<"2([]!C>8W
MZF-V\&&\*^ 9J[^.?K4.0 >R[1'3&7]9"=!H@H(8%ZRB\25'0U%;L;W9=*2.
MMPZ6%6]HHH%"+1E1F&!*2_$%0* 9#HW!'1 TBU1@?4$)VIN/\"[F_W45AE$1
M:- O46QI&@ZN94K;N:FP7K98VYE+\8CR5FUN4,K0_4>DQ(49LK8*1JW+ZO7_
MN(5V3CD ;:\G)&4VZAX0HYPP><3$KD4A[7S6 --'2(P(?Y'6PVUTU'E3GC+Z
M8G_'QA+[7?+RUY.].D>G!YBI]14IE#Q+Z420B?YA(G5=HUY&_9$M 6R#Z/M3
MAV](K*?>JG6/*5WUKDRCS=ZJCTYX5^V_4V@3ECY5EKTK4'LG6-+8N"3Z!:E?
M<\08QYRGQ?Q]?TH3^6/M)*^F[%C.:I:R,,XY6!Z]/_R<Y=6%*'^/\8,"4</&
MPDQ.@*/E6<ZHVQ]O?\#SL\H2U_MK&E0 4GU?61:_+=2!(S-"K!S;G[WMC.EO
M1O@2["FQL%%OM[=-Q'*?,^G;MED"UA'+7&H\#HUW-7O>L(N)>#)^8EXGSO%9
M=FR1_?WZ)]L6&PT-WCA5^EROM,H_&[;6/J'^7(*:XR%^[O(VX:)A8O.Z0Y9I
MY,;XMK<)CS.^GEWY[%S2\9_41E-L2_ >A]27]H^NCGLLR;CHD/[YW*,;\XFM
M1704'>M:X8I"4 2XX%F)Y;Z0S&*=-=[OZ9SV&C:P6J\1*++$!)8[5[[0+2:C
MS&UJ:L(J!128WJ\?54]PH5A0A!)4@7'<OH<-AW6NZ??1@;(*%Y90KYJQB:Y#
MC4B7O&@O<0Q:1XS;EZ012+E,#S8 ,B9<W5?3NUG,K!!?<9A(0#O'N&B  /&0
MSS>I0#]HW<ZQ<M?4>M+=C('U;-]]D:D=E!6XHNU;J/]"=?64Q;Y7.)HS'R1.
M9%FVJV#842DXGH]"6_O9IL5!(+A*IF&Z$SDI&P8/(MJS["5/)G_:OZ >F+"Z
MKI"3%GT)!M*%;4L8%.=S0!&=I8=Q\WY&4GX]::K@Z5T](V=D/4*PI0T#S+V!
M@D9*D>YU">7A-9<*L#'3@/D8'5S-+A09(:W5JT<NKWE/SR$A#;JA%?XPFU90
M7V&JA&@#O0_>;1NH2.BN'G'E!0JD*F&$%#MRQJVX+G;H55C=QT$/^@!CL-+!
M%?E"-T $'NQCK5]Z"\8JSUL[1_+!&%ZO!KJ 'YJ>"V2L0Z!)N"S,7N]'QZ(D
MJ&-0OS%);5,E42$-%LL&P 1<AE=7"3*+Z2(M<GQ_9E&%J4%IMAUF$9,JM?PZ
MNT'-=12?$(6$>(&/VF])59A-0'J5+>S6@GJ</DF8$A8>8ETG\4WGLC$5O+4,
M _,BNRX++4@L9UZC(T,G7]1<XY20,=N(4RX"O16 B0/.!6D\VTMU52(<CMX@
MFD^&:?4PMMNFN*"5EQIH'F WA>-"R%_VD^#2TF^YFE\28\K&-!;T]R7CAU.^
M\# 5:A?2/CXQ7BQ\6A,^X-BH-$WK:GA5TX+>0W]<LE'0?/3*8X6#/K0LM0BA
MNPLU0%HBE:3+,E#9C!;.0!V5\.L8VZXN.II'C4N?%I(USB[BC>% :D^9ZMV7
M\2);#O MX_.-3W[/2C1SU*O2S3.T:@KZ^6?]]QE%A4U&K7I&NWS;;"<R U.X
M3T#O?K PBY.K7/61UJ;F3W(W9M"G+$+T _;G15(>84Z_^SC[Y.*FHCY :S_D
M-F()AF]^KL)=DW@[8E;/O\L,IKF%][9N4"/3^2"&L5\P7R OUN\2^B]OZ9_:
M63-OAYJG5NN?I6R PI,F !QKIEIW]/<IF[L-V&)E.![C)<9W#9YNX\J,?ZE*
MR^8:-#5E1H%9LI@"&186$@KAE ?WT76 S0)HG%6^;& 0S>LU79!7\R(P$IE-
MH:R%-Q*L*"-D0C:-;(/%G;T@'_[WQTE"*ST&/$6VTBH0!\JJD@\<32>C3MZ:
MTKAW2$A2&*CFL#O$ @J)74<]2EH8L9Z#R5]Z:4Q#TC3</0Q3N.QN-2R?(I#\
MS)U;A*1@ 6T4M@@O?4U=54<66C*?O)G&4@"YO@(P]Q:091/JV]5S2P06()O\
M)5!?!LT.PQH+L,8HO*-XZMV)._96O9=:$NGF;+(?UJ[R#I00J%E[FKP =86
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M>CC)P8F->UA(M]1DS!#VF)C<Q\O$N$1T+6MVH*7:CA/C^.5YKC,H[P,,><Z
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MWB/JXXL/W.S;=R:4$<H5Z];N[VV=>*O;OS9A1UX&(RD[KWHRY]3%W P1\GQ
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M-H".O,5O-D([">U.-AX?^B%J9Q(VPOCN-M*E2L:A*CSW =YG&K_(CWA0XU[
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M2J0(P,U,%$[9M T!\4.D;4(5640PU'CO4H(62H#"1)GI""['(*SPPAP%\*"
MHH^TNNRA^,QI5;%!0Q7*4@AD:4C;D:O4:8*1MM[$$ZP2>E7S >4@?(P-F.M
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M[0M,43^>*ZL1(&@0,M*"ALJFS4+06@!2%+75"M!<"-K!#:8J%(S@S)2 F8;
MT)QG,G&31-0/$HDH;-(^)U4"H*T2G)]V@\Y!,9A=E0+U5MU5-@GWUQ:OG0I@
ME:E&/T%%XUR^AH#_#I(N*D%3!)RG):G9*'LVN$5#LA& 9H)9L,P390&C#!5@
M>@'!2 <:"NKIP#4U'Y6.G+<6JCI4P"+2C40R:*,"26R<6DN@,U$FRNO'@<O;
M 92YIF\G&_P2;&&5!AO/O92+7,2*VC8\OZE60)J/0-Q1Z.WO-CTN2'M.P.N(
MBPOP:C;.B(]BC "*=IPA'V6D;%AT8L2& PZ2[T\]4)HH(;@$2HN%;80J2W[7
M/%6CAQ[J1BR\F0UVD*\Y_0?" $IX'+11@'K\1]<4%TQUH-X'T$$+'/.L3NVX
MA0<T6M(M0R%*=N[<!07(5(*B_XAOVG'F3-2;CS@]^!J)2=2O)I#XW41VPV;.
M'Z6,?)YM@CH$H*T6U%.=V<T$;?FCDNA[7;^O[=& 5LC5G0!HRD;!.MRQ$4"?
MK1XY"Z07H+X\5]:,U)G"* L -!]19G# _KEG'%1GC(4WPYO OQT<K50 L!6<
MI^R **@SCF=("L*Y3_7[E8!:!3D,D\R5UTWX%]4*,",'L-76'X/!._;JKF=
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MT'0, +$E!&<#G%C_"RWFC>W'YGV*-D^#&UL5J/,G")3C$(O34*EX.^#;DR8
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M)H29K?GB$B_4;-+J*P_]=%,L_JJW/"M1TSJ?C)(O.O;2/M\74"V&<8(L:Z8
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MOI==W:TOF\&\UCMW=Z^,9 O^KV2]\4?9!^6%M0):H%53;/:$IS&\RE;+M:F
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MFDGM'ZI[]2JSME,G[>]!F]Y4]#@2:!ZB,\([!.6[GD\'/[QT,TQ!>ZCRW>6
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MS)_?W#94V^>29+L/W3<=7CJH5I3N.ZXG-?</@1K0O=@?141T;*F'H1>3M%(
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MT0'6U'I:332>;.1C["<L1?8!)6-3+#E-44QKG[6)5905WMI11S'5Y-I"S6
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MW%<H673?FHT2JQ$\<D30"$#-*/F_.2?)HOVVHP2SL/DB6^RO/0KHHV&HX]A
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M>O9AYO'^O/./ME]\'":^+LG/+RHH+"XL*BLIE>[>4[Y'6E5165M=LZ^FMN[
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M=<4N"@'&88U*]V,''O?Y!W;J;1Z#\D=-^ DSBA8CIV'X+W,K>,",U#>Z(!.
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M^]H.E+ZPL&W.G*^[]5V4L>FT11]FU0!>TR&3K;H-?0<->GQU::)8 2NTPA.
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M@')83:D>IUR9(<2-4-ARPE9-*E&&JV11&G.+G^I;M DSM%2FS>J=B;$[M=3
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M J&2[#QGA( '$BR$Q$PF,0LA;OUJ3E:#AS64-.$"G/5^V4TP!]U_\J1).)3
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M?I6*-$<P**'A5R[#EX7C@^14+Q2_ 'S!W_D?YQ4I2D# 15#X'*@0(*3(J>7
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M C/9UK]%DCSJ2--;\*0U,8Q5O.&Z3,5_*7G!RH2T>S05 8'M-@V-H)'*/"W
M_5G4JEJ0SK0JH >F&'L!HCBC"+RYUXC=DR:8)A*&Q<@N*UT"?9TO(93J,1'!
M[D208<D"TIQ!V6.GM9W:F^=0Z%J=KSI\;^3[BF;4F=D^FW$2I!&LBNSZ$"UN
MO4C'O4EBXEI/6X5\/QSC(S&C,=Q/*[AZF\L))M$CC_.?2&:N%B36C/_^T,:"
MM3GM%;P^Y2.*_M:+MA'DI9,(.9\I,AH_ W.=1BEM[A*# N:_%:[+R;Z<_*AK
M:(%?_+25=3S0J6^127/.?4$YQ<+/N*TVM@>LJ&ZI10Z75$5S>;FTPXOP2]/
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M Z=@H_LVW\O?ISYK8[M!W3U@3BFP!/J?>H!&D-4"G)L/&DM).Q7KCPBOS],
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M5F*_APB4L<5D\9VWQRR735_UP:&%&V/Z D9T66,=1$'%ZU21. 4)H8O-F6B
M$VK',0XH0\P0 5GQTBR:%SH)KK.QI"@-9^>B>EO1@PUB%@=MF<#AH9)C'"1Q
MHM.,INSV6$95/I1,]OU!E98HCB1$[@4! 57H$:<J;C:*FT? CY4ZAB \]3"[
M2FF67<$5(W8\9=U*T5WUT^M%I*^9(P/:$&40>M4%T@G=:U3)0X.#4GJ7J=?R
M$ &P@I/ T/B\G=R?WNO/[>O ^PA^<!)%*E'J1Q_*&9#E=8ARY1&25[ZBCTPN
MJ%4Q>99U V0!8EZK3#P(9"E J!U'E985J3K(--2":3I-+I/^;D3^6:*5N!>!
M<OO@H5'V$+CJ"Y$T'O"EZ*EY'0*K.VUI"%G%)4FEE%2EN1R$I( S1[FY80E8
MAI+2 'P7M-RVA]V,0ET8Q0"([>J TA!RJN$ #255]2Z<5T 0(VD84@XK4US+
M>%E/%Q%**$5$2BY];3GJ&1M"5=ZU2_&SS*VT<$<8"A"?ZF.'/K3E0^_V25YR
ME>]SQ02MD9,(0E6!D*+#T0FE3 YW04.M5S!&/+)[ EQ\#<3+C%ZE\)YJK2+S
M!@\J>-!8J<YRB'H3^];"_:% X"&,P@?"E#ZX;*4$ <R&03)+>3D5(.3B7(JG
MJ?CXHED(0%5A$/38N37:T@8AG0&)[@C/YA'2L&NENQA2<:GNB*A9_U<1 +-6
MP1#EJ.3OMP]<:0>ST#<$G@%^&)R=!Q '.SP)>^/$*''<?RD-J**+R7PEM Z
MBIX@O\"4ZOM$V:H5R8&PP2I8>H?"0%L"4<.,-XYE:%I/2+ "!X^%'*W:Y^B$
MW'NRR_IY$"G5@B3E,X;+J4/:3BSDV,- QY"WIG5*<*B#7810%"^[O! H0DD>
MQ&#(2E/4A;$**.T^<!VZ':IG):+[4X\$-"G=[5#+1F67LNS$&4 O'D@HL!H^
MMFOC[_C'SS%2X&X[=T0X[8Z8JSNO0*N+MG=Z/_33]B=0%-CKL8[=H7")JS^C
M5FGK'KZB':2@Q*L/"6O:.U=S##I-Q-EU:'(B;K8Z-;8.+3UTVS+5IS0+.M^B
MM%7Z,%2=%EJZ+!7&Z.$Z2;09*9#Y&=2.U.\HH'WR1M:FK:T9Y:Y5^S#JT&TZ
M$$O&K#NB=%N%$ZST*Z5TV:8J;2=/[EG.LU2+D[0@N_;'T0H?[1^Q5:XG+W_G
M-M&[+$,<,NN5E_DWMSHDQY(@^V9K^T&9'<O!/V_6[+QWM@I6*D/<L/D]0@NT
MSPX\L]"2(N>NG> >S\/ID8Y9=G79I_:MUH:VFX@=F2#E3&-Q:]4T2]Y![@+#
M\WI.KXLMG/R[VU%7ENPS@5$: ,KQO1ZK@V,3"76XO8PNZ'P]<&('[L)@H:%I
MO4_9T=)UHHQU8K-:Y7MQV0<ZY*3H.$]Y^6;B3=I61SNDUQ8]K>WY]&TZ(R M
MT2F/=[QLA?VGXVW] 1O,DW)H2RG,LG]7!7=$6MP,KJK]J.7#[&1DKV744MB<
MT[5S"L7.!JPS'::NY18K<78VT%'Z6O^Z4U6=_67'32B)SY%<G[_=_!I6V@6+
M])]+UEZV:@IO]N%_PKK@U=\YS@]OAUOFE=Z,;7J4T?3RKB26'L'S5OZ$_1YE
M-3TI&2(+E19G0&CJU9-KZ7P#J'SMM%[/IJYDJWT!LH1[84>>OT@/GD@?$K[X
M+7MJ,YH^-)Y^+RO E[G$48&)[,3#=EVCZ_2>L[O&6D6&<\0^//:OL8\O[_;L
M-\QX^=7YG45&N/AL4/8G&R/QXG'1:.S9@&;V(770DT[GX)!/'TVAMT?$'XZ?
M'1O-&#_49=D3?[=$B[+N[&N=LW9DMGJT6.V3L;C*N3QT0U'0N>>1[,DW'X.&
M0:IBE*OHZG?^]*WZ[*?C&1^?LG\>/_?S[.S_+IW[[]KL7]WG?MW;(# JG'=A
M'57.;6KO/+1ZZ+?>R8NF77:R1]RICK1@MO\O</;DBW<%NS2UD$4S:N;U< K6
M6-:^P;M [U_H_IXNB+_?6?QH[).C +:+CO=)%)%O-=VM]@_;9]FGLY9X2UZT
MY:S68XZR[ISV?TF^9S""'(6C3=EI2N@,0+91QDY8'Q("E>H@1R\T=%X7&0"
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M@#@:71^C76&!&40\@+]J83TM(T.">Z%E^ !B&S1J0P*K=R]\NA3Q10RTVO"
MS+W+I^K^0]:7JL$93Z8IQN&)\#Y3\%(1I_D3[#;%L$9A-[[!3B-H$F'R5"4!
M/#CO0<(G5)^![-S_27]KHH&YXF"Z*2<)P*U.S3EQ'W1I^RDK>'_)U>^J$]SX
M:ZZ9T&93RT>*-1(F%,KI_!_*= $XIJC!G.IR,%824X(XB.#[VEN>'\&R3)IU
M*>>^=GA5&WM.A+]T%R]\^$>BB&DM0AJ:H;<L#CRW7U,*QK1U,XT5Z_ XEA'
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M;_&2.7?@J2M"JA!/'A,][%-0_5#\?P/40 U4QZ/L LCG 1CE/;NS'XI34+P
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M6U_<$X>>6&8SXL[#C#W94W>IU+A?LME(;JB@B^;#64,(DNI:>+7#TMQ"(,^
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MQI'[WUY1$KN^+1"1-D_Y3,(]C26SHF/'6C_ >=_%OSYA8==6TK6DQ'EJA8A
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M$[>P$8=*HL*3@-LQ278$&@_S,QJ;:J]%$SB($[KR.2@\7KB2"L< B=%);%4
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M">*L^3V6.F?^3\OB\9;A.\(4SWPNQ0@?QA((C_I?4X $0+A5?% TL#,*:$0
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M*F @$7@@6*P1ELX"@([ABA!BN/,\..E\B!9!^K^R_XDU 3Q;:PP_@:/IVP.
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M[:H?VN,U!IQ*SLU:=6UT/,1O=,L_L:(GV;VY*+>U(CK^TC_!H=5UX/UI\^S
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MPS'-&7^F5+C?R,+\A;RKR:GLXB=('5GYO$!#D^:3OO'O,@#43)PR&HT:A$G
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M86-WPFH^R";35?OF\>Y:J!$' -=>1Z34*;2RC-654A;>6%A?!XF/HC(=D"Y
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M^T#P7_5] #TVE)N*<JQ'II\FMD<*2J+6L J]DF3"7:8X, @4^<L\"J#%1D%
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M-1R'$$ /?1VQ0QVP]-69EL^T9,G$%W<N?_O&^&+?6$OS]LA?HTAL(<"E09K
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ME)%_)MPXC!J0Q$Z_X@BP?]L?4N55/EXOV9X!%)]&;R>$(;BT"2!64J;,8AM
MLTRVE\2=R,N91<+F'U8[<H 8KV BLG.)4&0XEFXC)Q&* ?3D<2 9V(DY'%?$
M%LD145:H0<?$ >>D@LN%:%<0N(7&&3>KF?)DG(A-U@1 6AV)TS![CP7(5- 1
M'=JD SAK(SEC9"T"RA4$#GZ6#08'E6%Y9,'Z5]QN"1(C1"31(-9='(M04(\U
M1AW2F$*@;MX%0)=M&!!U)GYBZ'IL]5-2HT=<)(#TF8$".# 7!@!>8G1I^.9
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MBV]PK.]5B]CKTQUBA7_NCJ_SB=+*#K 5ICA)F=\<T,^K]?PL;%^8<N=IH([
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M$JZ'T)!V6^23P,=>WQP=^*XI^T.?:&G^/;]Y1;7A\[_;2PGEBT9Q/ZW:?E9
M^0F\>ISS2.^"=82:6L1^3=UZ2N*(^Z+KDUVU"^_%9*=UT>&WGQ]C%R>W)UE2
M!4\?]6Q].[OS_315N&] \IZWP""6^HVWH4-@TM7>K#SO)\YK/2N* \01YV<G
M$Y=IJ8.-\:E26O<9H[ZOC.[J\T*5^!HD-=C/EDP4&*WBKDS51'!C69 :GX%V
M6G8G;,TE:S)'(#>GJ\Z3Y'B2[1"G8[:D,9'G)/-<*BV8<0')ZE)<]JHJ6I>F
M=YET [^KC_^QWI^=Z21$A9OT+7KHHWW\TL 2.=N*QU;PNZ8^COQ;S+@6C%2K
M7/Q:0,,;_M)5AZ639B;5;DW>LN<U3?+.].H.ZX=#6WR-QQ7>WD$FCQS6Q33)
MZ,_9LOPZX7A&NR04(H)^ _:L=)CWI=TKCI7F0-3@/4Z]QRQH74O-?C2<(Y/!
M'NVG_6(V:YU[AYFT7?P?P+K+Z/ 7OCZ M6#1SJ62Z^..9F.YU\]D;^@4/"<$
MRSQXX@0R6;+Q +) )O+D^0 Q,&=_S^TZZ@VS:.[QY1L@\\LO]]C%FF&]_Z:K
MCO$I<:Q0US0EF$:][-Q'I!6OM/GH(3?74?_/&N>&P%EF9YN_+ OQ1JAKA9/"
M+)%'9>F?+GCS%:FO/\UI;0(U:A2OPQ=I@Y-L/;"$XG7"B'9E/Q=](%GDZLOV
MXN*M)'JSX@W/]>BEXO4LV?5K,=IOMKGA,['^60N;LYJ5Q>;]Q;FR(9SWYJ_P
MMN;^X!Q"QZ)=INU5CJ(]C.>/^>U2?R]*A^F>%Q>+5_-OVPIU2X$D7J^_#RXU
M]TF,Z]D:I\JXPKCE]9A6;!:?BN>F[:53J\O-B<O3CBXQ1.3V12>(LIG+9'VJ
M-2ZT)6U7M9917VS9%.E<\W."3%[&V?K90+MA*JM"\N@!]3 6G0 H=VO$1MJ+
MGZ4&$5:O+U\.!,RO[O6ST8IK"B9%\$2_TO,SG*TLL%SH1[^UWL[:)-0,*GB1
M \AEK;;N?5NSY;]>:3-Y.FM:9<<A=%<]=*=M#6EQSZWT8$^W/%6R#D"@(1\S
MV,7:)M'^1KOE &L)SSQ[,WI5@E6XY)X>"P!:R-K\<FC_S!/FI^YA^E#7\8^
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M>U(F\SHF5+8F%;XK^JD[QP_W5=:FGS\X53XBO6Z^29@S%$&>!:MIY9YJX'D
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MJ__HT5-2EMPXJXPOHD3X79R:4)7UH)NS<:4_"T4P-=AU=]B5K220U6<H'7*
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M\V0S]*-J%^50&J,0RS8TT+MP:EAQ:##"^I)GO*8THA-)JE8FC73,5T<I=>3
M/O*7 DI(-?F+D#)/EV<[N_M?<:GUX=BP!:7\=^2/XW>J1N[:'1ZV#8SY+5+C
M#WEH=G6$.-?>1CF]/J]B-44,[H9E%LY@QN@K;F[R9QJ3"QEWRR07E4N\*<:"
MF!/K$,N0_'D2Y*.,$B+/7?4A[^LX^9\/2)C=\/,/N5:3_Z*1ZJ@%N\JJ.O-"
MA?GQPOSK_>1F55Z\>*'I]O(D<>XH5%C5RI2ML0B\U4H[--R7<?;5*C/CKKP
M&19T[](_?69O]V%1WKG"+,HO9HR+YLZ>8,J\OKQENKSEPORU\^F'I8N<C,I3
M0-M:LF!75*Y!?.F:PWG+QO/F9]YEST=DA93\#[F##*KI@3TF'QKVZ,@A^"+I
M!/E<'Y*DRF,[1C7.CS^\-/[(FB(/)GOJ4*E=X2.]#T8'QC$W^[*6[<JC^LSF
M X5OQQ\=.Q-_;->C134&4$U\JJ:PXQ:UDZ#,_A!_;@%6V\?J^O<1JVU)Z_Q*
M8UYAYX'22Q>7=#L_/N*<<,5XE_#R[(1K2Q.N!"?T;D_HVY70?R!AX$3"C8L)
M-V\EW/HCX?:[A,%_$[3Z2X?,E]YQ7JI"4>#S_P!02P,$%     @ R3U!5BB-
M.HW/+P  ]R\   T   !C;V=O7S P,C@N:G!GE7=E4!M<T&XH4*2X%7?7X@1W
M"1[<6K2XNY:BQ2$$#^X.(<&AA19OH;A3M#C%G7+[WCMWOM_?<V;.G)F=W6=W
M?YQ]]GGA>1U  %)64P:@H+P L/P[@.=E@ ( ]<5_^.]&_0>TEVC_ ?/E2_27
M6)C8V%B86%C8./@XV*_P7F%AX1+BXN$3$! 28.,0$1,1$/][$_P7!.4_3U0T
MS'^.!*^P7A'\K_'\!4"("6@"-*.B$ )>$**@$J(\?P/0   HZ"C_ /C_>(F*
MAHZ!^0(%@/7/K$0 ^$?\ A4=_24JZBOT?V:4%ZAH '3"EPP81/S$C'*Z5I@D
M IX?29GDP6G%9,V3S'I]6((*BH9>&253&Z="UO80^+\P5"C_EP7P/T#[%P?]
M)0#CGU'D7SHO_BOO!1KZOQ(!_X^$$(V( 9V8_Q\#B=4_@K27X.:^4U*F24%Y
MZV(]K[/G)0 .*LJ_.E ) 3( IM T6'R7IQVK<JT*GZQ_A2MM&7V3]U2[.8R4
MG1K@G#QRXMW1(,&H;L@5!?Q]9T3-NKZ2NQ5S^,>%0P=BHH(]BK*4)<,D0M-&
MYAQW3!F#K/S^(3:?56>O+P1++ ?3N\6,E\7X5A^"ZZ=SG+"N.;<C^LL,CX6M
MF)T>S$8=AVS$=-/7NCNK=+N5( K3]MZ(-X\;V<.0XHJR+S<O%?ZJF/].P#->
MG_?E.!'>3%0:(9>.\)!@_\9Y@]@-@M:Z*SVY2^\9$-.5GL"SF>CB$$L0^E6%
MI/"'AB=U610)B@RI(&I;Z?@PG;@RG'7;RV0M_<6VTJ#!G3-D=3VX_]S#E-X>
M.B_$BT<BT>-92.E&ER:0_D6W3,RBQK>0<7/P)L!D)'!RE']3;U=GT:O:-I=$
MXNVK/(U3/5G'TUA>[82H\."Q4#/[2=1'!RYALV[T^?+E[3:?OQ$_7RNK8[9\
M,P4I TU4CN.37X^M1HE;=M.[&WA4RLOVL%R[LN.6PS'IDZ]#'>$S0H\0Y6SD
M>AKR=%=IS4S#2.B(?LE/#2R@/0ZK=X<.BI<44'(VB#V(#2#,2*L12>TDK5B9
MT_9^L1$0&:*0(5VE^:JE%GIUGZ["HN\0*B_!'LA/^9:IA.%7QANPC(];H ["
M.NKJ']5?/3S*[81Z)6&IB_, X ]1YCA<V%M-KT )#$YOEWB])K9E8E#.@M2Q
ME!+OQBNE$]?A/?9P_LA:'8EI%<PX-"Y:DL'D+TTAA$A&4DG:UVVWM<DK[,MQ
M)FL95@$T7?YI.DLP#@7-C&H5 +-M^LY%>7_$RM!]Y3=U48737E0>T;"96W!*
M8%7V$]9%S:IR/<L77TK#7RR1GEW5%03]L!OVVYVC97)=[>^^-3DF'-W#B$0F
M]"@&]^R,]ICCZY^;X#"6_%[;*6Q3<:7:E4]#R P\"3FQKY[7&+M:*1_%T(41
MM3 *=75X< A!D;SGJG0&]<A&(E$N]H6W$]CP @T!%]".5L/HH_G4:JY'S%2/
M%%I.ZDQ6:BU.;0J:5/\"C TM#C#/)PTV/S3CS?,^Y'3@ &YC/[*\I0_070HF
MN>5"D@J/:+Z<4?94;-^(; 0#S11Q-J%N:-1HS.'B4](J2I:VSP 1*251U!@M
M'L=#\V@"\ A%WQIT:[M:%FR[$6;SNW$.YNG:B\$P0#8'H.PC>0:8/W&TD_(W
M4T5J6I=NJI9]2?+R_NZ(UW= UE0$C5 36Y[X8J14/@9\9%R:S+7*(Q%IR%*.
MS.(0PVGZ,)DB7C/G+"K5S'MIZJYE2]K@$K'QG@%OF'QT\+$@CC:,U +Z=<8O
M;1S]8?2]EOH%<V,73<Q$X$ 8_0=.O<W&H@KA%*;F4XH%^NIR^/:^8CT@=)IC
MQQ9UJY".NY#3[Z7H^"NL'K,*'H*OW@VN+,83;-)?+RMNF&C)]^;9ULEFV]BS
M''XMK%*//7+JT-N$]2J7PK;.";&W@3]U2D=8%GE[R LNW.&]MK8!0:%.IMNY
MBB*59)-.$0AHO^]YI2F%0FGIU_M)SG?,=%[$[_8.#3NFIWB()\_HH]B? :6&
M(I5Z]JXE7*4]5N2O#?=S*,%GK-,<K^2W.LN\V"V3KN^M$<)*QIG8P535W:D[
MU"/EOMU;J.F:MFHND3-Z-!J:7XV*HWU)AO1>>RQZO.2/MTG&8$OKK-\ZGW<5
M4],!?<!E19>^L0LTLMR<]^W=7TNR%& L*P7$.VTK"F.QO<C]N34K4KR1*T<>
M_Q&#?&@\=QSW-K@BAZ>CE@_W0C'*:U1?!/SXY/39J%K'6"DF!?3[CN6]DR-V
M:B58WG9XD*RT1?7\LD9J7)N[=ZDVF4"EHD+PVA."/;-5[,1V7N::?C$N;>\4
MYL'OY3>S2,3G@%PJ;>'=%V+F">!4Q]VU5-T#G#XY-L[VL?J="\P_JAJFI_I<
M);$'R>N-,9I]A;7O:ND7N0"J>&;8N=$F2_VEOF.U"%?Y:@Z\2GV3 ;O^I"8[
MD>(S:WY%$<CK_-.*3'6:V.54WD8M%"21/-G?B+^CX2\2%Y;$R!33V6*PAZOX
M /D=Y[GF_8>)&NJUZQ/N-XY+53YC569X*.2Z/2>R.-G09*T9?^B4PL/6[,DY
M[');*2/> <U(,P/10!HT^;=5ILHS5P$$);&$,]L??H?IWTHUNR9!QE0G_LY1
M2Q/QN#ISA>AH^%Y[D:1EH"27W<8C]G,S"YA1&DMYQ')4)5(*0;TIU;9U@>:T
MT=$T^PU 4I'DCE05D&9<0IHP&AV*9@9P^_A6[ BB=QJ?-/TQ."*"$B2W,[YF
M0%47E/9G<?BQ$"EJM;S@5H2MY>3RH@TBKF<9:5X2RRP$DJ4'6^%"<T^!Z@QJ
MRQ1EGL8,?I(0<6]-JJ>-*C6F#)7>$A%5&@<+Q0?^8>5,/EVIWKX3>#KM(D4"
M"6L$@[REY#K&YJFJ3(4SO\\JW#5WU$E_@-F@A5>K=XF,FL&K8!O[#&L<?RH[
M==_+V _9Y3SMMFJ^MR6WD7+2'V\F>P<KK)<ZA:N0CF/A,OBX:ZID^*26->C5
MM<.+9SI5SBD&%-82B=W7!3I9G%5?-9L:B6^Z71 OB=_?=61TU%W==#'_""O4
MI"Q)"-9<,DT,5P].AT(DG:A%1V1>?=%E9;1PI2^RQ397=5;[V)FGP>%1SBO0
M0::[\F65F=:U%W%K?&AY/5.Y#MW@[4G#:;'/O)'D2J]UE1RB_<,@0Z2=*D&X
M;]3)HQ7PWKO*T1RH5).O6C9&E)F^]&;=6A7#^Q;<6'BK.Z?62V@0%;>(*S?S
MAGFIHC7+9LP%450,VW7?!0^.R%4/C3)"2=(3;M[0$5UZW[\R67'A1(,OPXZ(
MGY;:5.\-\[1MH"%0D?J6;4K0Q70]49GB<IA6__#"3+P\+9=-&GA@^P0#E]D5
M*=7'WZX8B:7-NU6.+_:J)\%.!CHM0M,1]9LKBJY+F(A^164X>7W"(W$Z]8I1
M#(%HW&@@/6>'=HV_2?\<[6UN&Z$^>Y?9FMQ6JFT2NC,3R0H&S:;U2F*4VP?%
ME(:TEJI,(T:SW2QY6SH^OVF=PDY,@":#41Z9[K!K>#'%FLS;G1Q:JWYL\%2U
MICP#@$]:CCJ#QD&3KF;'1WU#3&[BT'4?W"$M&5_JQP,)NV0, ^IADDB>95AY
M$Z1A LI\CT]9.K/RR*17/-U Q>/*5K$4BON:"(J#)[>_JR!?L95ILFR=@MFD
M5%U!!8J1/JR0="CXA4EH,L;,],WU)[5'N,%G'M:^U3Y'LLRW[EDMJH=CK=Z%
MXLD^';QH?]A[0:7F#AQ^.;QKW#6F\AWFOCRX>9Y29!@%(D((S9^G@P=65%M0
M#5-D>*=9\1H)2.J2W)OH UI90-J,K1OG2;[R53I'];3?-NF^E&7OHLXV%YZR
M(7;+60JJHO)**DC, ?.Z>O*S^_Z>Z?72L%X:? 62UJ'EA75G,*\]X]F<07DL
M(S$?R=4244Z@G<FY(U6+;NCO!51'5R3>TM)C@C4!"0P!2X6OW@RW%<0D.%'I
M.@6RI##%0.4&_<KM^><,[AQ+/<R/'(G6^Z1)J9VY\NM2.O8VPSWC/S@8A$FF
M'N^C\Q@O3 <K_"TRWO<KDHZE X3+AS-]TPFZ\ZOI#XEU(.K]CDQ[=5)MALZ?
M7F#'A@4XPLBW81'9R?R1X:EF2=5"Z-<EX>N?H]D'@D1\($1]U!3@2;'"P#[&
MSJ^6GO-$,4\PS9.CBDI*OX<5EDOCK]AF!LB;![;SO^\VN7P&N([QJE/07^Z
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M7O6I1B2'V59UN5Y;,#)E*8T-$CJ&-M'1=2?C%/ ]V59P]5[?&$,3]?5[+#6
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M)T3:]<+4J MO)SJI;^&R[H_>]%%S6;N(!97>2@VO=KH&T 6:X<W)U>7#@/P
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M>G\VR3"XW\-AQ2Y*T^>>&U2HSFRKK [Y#^RU'K*!CS9M@VJ&%3YBKP,?FSV
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M6Q.2^-2W%QT*XYU))4"M?,#S=*0U6^-/N)1&X6/P3XX6;J2RQ*6D_MO:P8M
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MK4;4K^4@"=JC>;22/I55(+*P(BF9"3?[VHBJ\MVU,X]U<M/E%+1,P\Q _>\
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M$Q>^UUJ6Y"[0ZH&X2+%P2>[W9-@<D?=NIF:N"E?M[GH^;3P*51[,C"O^"8]
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MQIRNM"\@3A.T+;BM9ELV/W(I_U0CV\B1JK3LR$_]5S:,UV+"QM?J5!G^G&>
M.B>?3X&WFNRT.H1NX2R\O<#P!<L51R/'NS5!^;43X]*-)S)4,A];H^I%HZ*N
M9Z;N3\DWL71UJ![DSX_?U):,5#NM@.W*#D=(:H+!+B(EN^@LBB;/;N+@!Y/R
M!_(\G1U3IVBD*"65YZ+\#;^W?52@_ZTT1I3UAO\@5#:_M^3*0C5'-(5L8#*(
MRU/J\Z[M7S/Z9RP&[XZY-/K+HCY?_F/YGHTOR$7=5D3=BI2,O,V=(IT*'KSA
M_W]O_T9!_JE@HA3]OU';MG<  ["V(1G\#@!AJ>C8Y4&Q-8TD*E3A$+@M6V%%
M+&+?-4Q29]!@6B<\.TDD0C>B^&/"+'Z;ZUOQ8^6:FEQYZK9'JJ23<E(B05_]
M(OJ5RPI]=/66LP_5.VV$G7D/!=Q8SZN,N3+X"Y;4'YE?"N"LO3LMXJ<#=/^8
M5=K5#[<:MU)H 4VB8)' O^77$GO2@ZF;Z8MZC CD^ZIM*J+HN=)2K[$M \C;
MCZ-*H+*]6I$?MSER0L9K_?[CVP9TFTP%8NLB O\:JGK:$%61*.JD?M%E,&,#
M]Y1J-_Q?BXN>J<UQ@.9\^RNB1OZ57;2F?G*8%[57A_$TP6"_OK[^%Y(;6290
MA+#^(+:GT]#UHCAUU(HM>>WR+WO\HR41<\?8ZI[1KCM !_0.</STM#8\=3GQ
M;N'_ 5!+ P04    " #)/4%648#.Q/HG   B*   #0   &-O9V]?,# S,BYJ
M<&>5EF50'#[4[A=WE^(.RZ+%'8JSBR\N+5"<XM9"D4)QE\5=EL5="Q27!8J[
MM+BW!0H4Y_9_[]SW^_MDDLG,2<XOF3DY)\_+SYL 8H@*6 6 @H(*8/_7 ,]K
M $4 &NI_^F]$^R=T3/3_A(V)B8&)@XV+BX.-@X.+3X2/BT>(AX-#0$) 2$1,
M3$*,BT]*1DI,]F]._)\3E/]VHJ%C_]M(C(>#1_R_UG,O@ 0;4 ]H0$,A :"2
MH*"1H#P/ N@! !0,E'\"_'^AH:)C8&)AH^  _IG!Q  45 Q4=#0,#'1T?*Q_
M9A14-,"_!22DS%@"\KID+%;8Y((>(124K-!DA:*^63;AMPTX[$*B>H;6GFDS
M<V<O%&U#4V'%_US1H?P_TO^  *@ %+3_R_IG%?YW)E04]'\=%0,-]3_0/Q()
M&CHILP"&/!F++KD'IJ!5<@-KR!ETAHU=Z!]JZWD5@(^&\N\J:"0 .< ,V:2D
M4!P=*XR9H9_DYB*,Z8-,'#-1:3Y(_.5$"D\^;&RN/2I[-P^2M(F>ZW\1KIE0
MUAUS!I-%)_V(@IM]ZKL0J#U%/B:*.*",H'TU!CL.!3 :VVV'QMD,0C1'YXWU
M4H1XOK'1SX]'OY%31 N^#%LS%T:Y]?@J#Z;K6^XSPY19H3I!X>9"RR5B:_V0
M4M2:>J= Q>RC6(IM_YO">)))J9-DN^K-FD)]/Q:]C!!AQ-LUZ&1 &1UQ"&1R
M<^".^#Q%34OII8-@"')YH/ 1M^_4,FJ,1I:SWCH<C#-IA2-%*;U>I)-H,$X<
M;O_9$EWR;3-%DD);1/<&4<M(HQ/4\L8F]*/_H&]U/JC%5BQ:VKYTV=-M##J_
M >VJR4E1S>*U<38?X;L1T-:M3N CVYV9<X#GI+=+"$4%30<X5TZ"&M[3L*I?
MW @B!IBNQU3YJW72F]@>L]VGK1/5BK7U^7'_U&@MN'Y)>]4<1R;TLH6M_,\H
M\.\@/T\.'Z\T2]30V/?+# Q(K)=DD@%"74_=33;'VH/H DDBK2-22W>OX!$Q
MKR=X57E7J=\7)AX3J_P#/^")^4\T<PU,)EE;/I%+,F)DQ[;H0[)VCI_P6"+L
MT,<B;%,NV;ZG^LU 983!^.[DM^)\K/[-F32.R6-6M5-_Y2^@'PW<" 0UVDL>
M*91?JM1S*!K>MZB[]>!E-]S/#2[-DOV&^'GH$%*F<H*1(A!7&*FOE$MWA)(
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MI3TL;]DZ[-5U*ES&A%%1T[X.M'Y4>:O99* =NL&L0>07(<9$0FF-:>0)43B
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M+C/!I"BQT=@1D5I<Y/@Z8XJ!_]B"T(&LVE1X-7:U[(#:.V,E3>L72.N"UAE
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M/6YVSL>)"(U3S^8QIZS.%$?\P3;NY5@D%!.^4Z;$(WI/Z90H(/O1"^AL<^
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MK3K!.4F;CL!ULMS^;[=6]&2BICR),-4J=W,)UK9ZRA:9"1G;1D3;QKZ*.RB
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MQJ(.O\E4I+7&Z6QC[T5[1_$04WP%E=E!+5MLL3=HEKTQ ^,#V263 Y6^VR(
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M\AH_CMQ(-A@QER8I[_"WSOH;X-\\>0-H?N]L7%6+_3X0P/2V^G\ 4$L#!!0
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M7Z:L&3!V1WPX.#'LRNJ&ESG;7_@G[S9ZEG5,2R$EE 9>%V27]]<FC6H<L?.
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M[@-/ 5,P+MZO6L#T.J3/H)I&,2,8M1(JH%]ACH5.KHQO1+EL\@SH $T+<<^
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M MP=?DNI;IMJ81<N>/<$"/#I]%@V(33;9E,5QAT,7A['HKBC869PP7)YG1Q
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M^B4S-=JH7M>KHU7*C R"!5U3FDQ8\A*G@8=+4TM#7VL7<@=_(X7Y?<DZ#<S
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MXI*E])QE^YU=_&RE!E%WX63)T':'RZ9DA %N@U'R+3]+\:F33'L245+.%R'
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MUV,R\*F''I_U*AB<X1OBCUM[-F!K.W_TE_J5FE2JR2K1:'7 [M[Z_&LY\*=
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M6A&U&FQ^)?+?:/3.[R"EW:S-Z<FP>8(BX&H\_&,")T]'H'T;GIJZ!A5[DZO
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MDJP*.CSGW@?_4JRM98U(EN%AR]'^-5'![T3!4 J"DJ/$1K(]+/Z&T?/E),L
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M/6(&FB,A_?T>HO>0<R>4P(D813JQ$ OD^J.T1CB;?6ZR\E%/;"/C/LC/&(/
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MW5LRCH6!8 W1#Z'^D@)*E>HIFFN4WSR(VC]O4.;<?D@IJ1H. :> QTZ4IZJ
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M/U TKH>]8,9&QLX?6,Z\#/U[&=I^EYY?+P=E.Q]IU2CF\/K!SL#2ZJG+Q+.
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MGYR]%\NB.H&GL4_+MUV9J9+?UN^FQEZ.X>)-WC]>D_4(F8ND,SBSSWQK3KO
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MA%--D*AC(KX'0"W<]]#@-]7PRW6K-[D.U$Q?VT/ BR7(L4B8*F>!994H'"*
M09N@XM$3/ C0:S+Y7!1N%VAQ :B2E>"-=Q"W#'B-CDC7Z5C?;<:V;F$(_ZIP
MY_>*,:IJXJWLK0@RDD+X1M,<O)N,4'^P>X:]J9)EW4ED)^,OAJPII4UIEKAQ
M-?;VV,LXI0!8(A#$;81W?/+&4Y3=%%)C=J@((Q0 ='J*72H'Z) "$A :0MB"
MN)60K1Q 9G]QX@-DA%Y/0*E6T#;_)6,3OJ7"L#!E78SHZ:+L2:UOR-NF1YT
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M8)(OL=2!N+=";N$MT8O;VQWYR&];YAJ_TSSP@;9:5M>>GZH3JF&@P7/#&4
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M$>HUD+WZG^%8CC4XIC%ZP5<;U8XB5EA6$,J='0G/.5:Z53-<O9Y7&TFL_T8
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M6&@ECU)01%O/9:GN_O@9)C"Q=[@%F@.B48K!4Z!Q/( ?WQ@W9(W5NUGBU2A
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M7Y8N><1LM.R5/[REGXFX20GMJI,F/)P;(%TM'/:4$F*+AZQ4Y(4<$H:]Q4W
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M0G$*E%*\N!4[N#L%BO?V_!_NW-?[[9D]>^:;;_W6S'K9Z\_//^L 4K &2 .
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M3=8XX"K!I$T**P;J_XJ I>KF5AOPEMN9:#']0(<5!01\ZPPT*M4=_[K<_N6
MIQ!.CR<2_V&&X(OD'*$P'[A6%#],00O$<9+":U\EX :42.78M7!^G.5" 84(
MR9+::](RYYP,@,-3MBX,G!]JJ.=;N^5M<%BZ/*_-LYB3U;>NXES3*FYU^QAL
M2T2W6Y;Q@^K>'UF[&U=F@J!'33FF=HF<UO-)M#]-7T?V.Q=\]:N9RK_Q@0GA
M96;.9.8:K1_2*OLJVB=VS">8D3=%[GQM\P'M+ MZ6P@JSO 1T+U*][TJU[-(
M(0V_!5H#SZN6V;*86S00VKRL)1@X)V;4 7:%&.6ED5L^'LDT;69>,S3JHY*#
MBS9@6M-5H&*AJG7AH.L[==T"CM';-14]_9?!K%^J]>"C"N,O(<\&ZWWQ(UK?
MQ!*>OR\X,6:4!>3]7$Y(4RPURTQOI)P.1S9%H:P_GBJA?/C&\1^LV%;Q^?1T
M#5Z:*HQI?GV8F])=I ZZ+0P,?>%4907 XEBGU#*DVTD6N9]!KEOFXWH79E"A
MM25*'J$L*N:]42JAU3*5ZHKH2 APS%22\_2%7Y%#B=8ZE3&A%:&\'H)_8Z!2
M.\G?[KS\\3D;\A3'^$79C]F+8Z^YBLS+VUVV4&C9[N9A@1_*]V%UJL]/M4C:
MLXQN!.#.M2;YW+PC\4^A9L?DAKZFSKZVR@Q9>NE[PE"_,\N6NQ:_"Y4IK\6:
M"; S)3_^&:RD;7+GTX]XU09N+CY?4QYOM>)UX+8A<_'B+&J/#M/GU%57,K+2
MD.&:"X4/V?V<_' 'TVDH<91QX\M_6RK^7!QZ7;P[ HO!%AM%9@3.3N\4R)A3
MU XF"_@-;75S[)N(1W\DVQ)OV6HK\$E/;"R<)2D?Z4J*@1ZIW2VD3]]3//-,
M"C%-&#VQV+53D5?";BA1;SD_OI_NHI;RT(P;:7'(.M6U0^J+J0&B9APOEHIT
MXKL>(5W*IF)SD$^T')58#''B@HEB](JVP(M]G4[L\_U0#EP00YK9V$-VIUQU
M8-1@01\YMBQ^I#/H*NE;!:>M'#X/*Y138VB0EN;TRXO9NMHZ^_B@2M8KF:4(
M*-$G+X;2@N.IF%./J,H8A>L6#Q)6?!DF(@\)T8V"$E7\U-D\SF1TAP:*LA6Z
MA/0*CG_@.VM,7:XC<$^PUS)E4"*WJ0J^H4_\&NC?IE();CG93/31525YGO3'
MSV:B&Z.)WM0^5TM?B#IR!!F(RR-G]?=3EK.E#9 OEQ?@N-OZ/F,C_.Q-,TQU
M- ]<O8PU'05NEFE)5W<.AN ?!?$);33-1P2T;S0#7;4,L/',O@[.)]&Q_Y2Q
MX1HIRC*_8(B>]V,(W*O:*!)BY,)[F[VW+_6Q ,\1^?,?T^M/,_WWM:1 FBY@
MU:-=63TNLF7:$KA"CC-?N3X<#AKVP)A_/=M?H0AVC_=S*J]:5F!K!6L/F5/C
M",E(L3[Q-V]UST\[9?ZBWLP5#B%-QHBY#Y3Q5"NFQWXX60Z\R;;>Y[M5=*\T
M1II<FNE0;"30BSB#=Y[K"_,-A-1LSC99:DT)Z4XSG'4Z 1X%UF6YE!@8J1UO
MRXJ$/X6\U"<7B+Y[6[-[X1AMK,\;%4F*/8>N$<_J*^$<?F[EPH%?8H0'>]"!
M$Z0S4?9'S__2:7UG40OF8JT<2$'_\@*B<SWF_9A9K ^-VS^ZM6+T)<];<WEO
MB&33 'F*AD<3!%<!F2A)GD0L+2]7DFZ0) Q^,LN^'!?Y1@%O!501#BU+>J*;
MR?H4*_<%LZAD^"K5,,K!*XC[EO%4QYF_;\A1KSYP0KS)RMEF$-KJ90# V-<E
MM';QYK+;(Q)%T6BT=$&^(^A_-0@LC=@=L#*B%^/C#LE7H8&6@\G,/F_U*XUS
M?R$?C<GS6C^!. X*K:A.1I\$9&/T9Y3RIV<XR-G';3CU$WK#>:JF' HLP88R
MK?&_B7PI8):U7F[3/Z/[#EVBFM-1RF]QYEM=C"R-D#(=V[\EN-5]MI^ Q*<"
M2ZD/VP]+A2Z9[ ^-&3^V(C%)1+ L4O,"%]2WAO4\7#CB=J(@,SF(/P#TD5;7
MZLS<N1\_\UMZG)%]MX)MT[D$O=]RV5[A#?X(EYNF3[]H64TTCF?7-[(T#Q<W
MFUKB#4AO.K0&&QFF)),QEA:F@,3IS8[CT[@[&1M'7G#+\WQI]@C=YH7]WEP^
M<6-G=%!H+$1CJ,?9H&/BG[P-OAREXY[@N<_53-9%$A,T]52ZJW*L#FQV:N;$
M9HP^6;Z#!T6QO_@]"!.,E0VO/9S\QP^_+%JJK$@''XRM5<:F _E6_?'O9S &
M/N1+EAG"SC>%D79._^DE"TCF:P59C9>!\Y1.35=)TZ^%)RK$NX08UE5R<,RE
M(!9W>XBCA4?_(]/9S)?=G+OG/1%_(A&O#'P>J<B^;A;9@7'&UZF66%*\W('
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M"[D<R\#B-:>*. E6;XP5QLG1)*W8HIQ<:I1OEG'LY;CF1V/GQ6YJZB,UU83
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MZ9#@&:S>^U8"4S=\ %"4W8#K.L3_V%2;SNYR/;<WP=9S\UX3R-*/#G@"@#P
M\LZ>&P:-@Q,:*LCX^#:BJ3Z>3/0^09D_ !X3ZJBO61'@!Y ,&=""W23-Y@^I
MT\C5"&6#-08[\+R7G',$^85.1[>$RKBYL#>,.8-]/UO6U*:U(2:6I$BM16R5
M>SS=%RVM=#5 &%_\WJR=\S[;:=A1J\)S^I7;7&HH9DOE1&_FM2C;^_*K^%*=
MXS]\8*Z(KHAE?IFC9R:-ERD?TR)H=?%T%"Q5S_+4%F.(F>7IXI]EJ> ^%8]'
MSM6O" ]FZA]&VQ+TY6!.7+0*_"W%FQ)'X-I$CU*R"1W-%Q,'9_U@ZPH3"@1
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M9Y'_E$"5RUK3>?RP "#^)_5/@AP@ QC;;_%5^(K19=KS^S>E::WD#$OG"3#
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M[:1WF%-"P<$A3\Y1[D=E*8?Y45;_1.ZX^.AD&.&!U]=GU&%D\VIVYFQ8$M!
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MY[= '!U])K0DZS>DF[FKS=^:P4!+# )K4R1MU[@^EOK_6K,,7'[H91XX876
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MZ2<[[LE CL':"6Y2_"2%JRI-V8$:)P]B5@VFGG1W*&9/AG5G='XM_'3_95T
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M1C%BHT[AVOLQMDVUC>@7<#]!JHQBJ+WF#"':IYC2J&QS#VT'L<J9G@3[-]Y
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M3$,"I8^ +U@];@0Y)M&QVDSD8[ER,<YL1<_9ZY8 X*=JW[)^&EWW/:V+[NW
M5,"XDBZ-%,20N&9TNZMY3N'ZRTC;6SM D=Z U,?-S6Y#FNL893M9>9-N%/G;
M^Q-\Z\3FO+0+<TZ(0HC/X&VQI[10(R$LC1GN;3/'<;*LB@">4:O'4KGZO<4U
M(X'O),^)MK]TY)>1=RAC6=PZMJ>+3GK=:ELL(?RMB-5:(,D#QWV:(:W-@OQM
M4?1:1/R:4*PCZ#-#%.,E>0_:61A G[>R\#5O1DC/T["*"!T&V'B@& FW#R+A
M%A47=_,++A:I_Y&=_4O_86&<O$Y/QOOY@]/%;[^'A4WMG8^/:_\/4$L#!!0
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MD)[L5@>>N=<HT579WNE,_'HKRZN&@&H09V8;?VBAZMDDC(#(44^) /@W9_\
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MUJ2BR()+62':1>8. C31IP<2RS4'M:H0<%>2"R0XPY*)6W$@S!*%*Q>5 C#
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M7ERERH1+!Y2?\S83MV_[R.UBY L1'9RJQ=&SUY4O+34P@X/9BCD@F@T#6XQ
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M27F+A6ZQQX8WKUA2(+)1*RGI;4@Q(*X/^SP]GW%FK"<&,WZU>0QCP9ELXV_
MV#/8LA5VU<K.W 1/AH97<P=GCZL0<K57.Z6;;TICYMK5"/6V-\J<QJ(DO)U+
M 8F&_U4S=-UF"*QX5WI)Y(A@5 J5D()QA[TZVH-'BY0\!OIFIYSF?X2KA6QB
M1 B'S&/B::->T0"P&6]OB' $%SD)HCU1I8W_RJ2E@/"-2&4#6QY^X]]VJTX%
MC8$=,,9MV/"W\+<GHU8.IBL2>J@0!DZ,[7QF=(6;@G,9P%.C@ 5+S.Y"K$YL
MO5)DU IS&#,NQM;9GT,9G3&FG.<I%U("DW9?>LX\.WI?M_0.E6M%?%1HO,5F
M_(Z>U:=-.::X,@"#0[ ,16KO6^L.$GZR<2#O1WSB"G1>+@ :Q99%<>R"ARN*
M8&< *#@\]0KDB.#D8@A)10UNU7;/((R*K(#DP7</!_\3_+1A)PS%3/,48T=/
MH%TPFYH>#%:@GMUKZ==K;33XQ#D8K)ZS"W[#C=R9R!9Q#X.;L='<4Q@Y@54>
M@]F6*T$U- >?9^39)D+:M\<$F^/MRK1"U*R=,4KF,-M_T>1[[J/0GQB[;3:K
MK>,'/[]]&K"(]RAE<='+O.^ASFF DH:1Y1AEA8A2C6]:BBXK@"G=T9M3 *]5
M<>Q7-W42F.!SD,3(LDT!CND0N3R7) ZU3L4V'FW3;,,:5"CMYSV)IHU8BDZ?
M@M)+ :T3II:B'LV (.;STO'#T1X[(G""!BTL;J<-CTHP0W"]C9(H1JW2<'9G
M4]9\8[LT.;''.6H%F-6"JWDPS3/36HQ%7LO]_N$VYRC\[TW<+J7L!!/BEO_O
M><]=J[R8Y%9%$82N4VV]?<C9]>"3H3X[BP5.L\OS&QD!:V8*W\^QY-Y_%#&<
MI##?/KI_&JXQ2J\C3K^F2>_=Q**MGAU"G=DI)[>(GP#C<RECK),<QM[;_$XF
M]BYYXG[0-9!:7^V<$#V\<6'+7-*-XRG1FXI%MII%*USO;MY?9)K.K1D_HZFY
MY61G2_JMP&VW HWO!FZ_',@81>V?5/SS)] >_F9_;,:%4I]!RK!*[[31MO55
M0AMKDC!SVK>,B8K,^+3,V:U9AB6MV=.$YC$BUXADU_36G']:53FM.8>$N1EI
M><=;\ZJ$>;N%^9?3\J\)"W:UYE\6OA9\F^6P\+\8V!J?_7A$N(W?CG0&VQ4'
MV_"^6Z_7\=60E3JX&!>Y50=?;@CW6(%'W:U\Q[RQQVE7_?K3HEC>KL7C-QV)
M/#XB3.N *7:HAPP%W]ZD'K1;[8@"/K:>#_^]/2$$ASCF- ;ZY^VWL6$PZQ+%
MXI6"\L[9#@&G?H3R."+/N[F)OA^V?7PY&VSV8(_L[.Y>$3+>+)1:9_5CEYU(
M0\_EJD?X"9=DGTZ;[*N?N _R+%5 *98D"D9OSH;8V L(96M:--?F>*0! T19
M8=TL*@]'.^Z'?'($) :ZYU'\+7N0K%+ E&5T?"G)27ER=SO"!+$']AURP:DR
M#(E!@0!,BG(GV/U? "8#V?Q &(3N!)A[=,#"&"3 <+H +,A! Q@  8S D C4
M4&B  :R!(B "(YDS"*!!).P)(E 5=S#1@1Y +_\Z'T;"!JS!*"3=*#1&&:P<
M&,0<"" ""'!LGAB !21"17%!ERV2-KL!"@0 *?17(Z1N)( F"T ">J" 'BS'
M&+CNM7/ &9!"!#  MQN &$0;"U3" &1 )"3)(4Q !)COOQIV@-7% /@K<L"%
M    <4:"]I8 +)!""4@K),1" UB Q-/B&H0 !BS^  54 @-$+A&/@<S%08_.
M'"71B0!XP9=96'NM0+65P09(P"D\@ -PP 8<  7( 0&X;P. :"4(0&'+UP4P
M  3PL,Z.PN>*V5L&T@1H0 9 U4+<,B@!O!D8 ARDJ(I^009\LQL(0"^/@L^Y
M<MF??? EDD51 KE?/%H90@"$P9>EAIA)12((@ ><PI=] 8]V;LS)1MDK0*$Y
M@'S$01JP@>(CQF_XL !P =V+@)TVP"A\:"Q$@JUK[Q@P7H4A@*Z\01KD-8!U
M+L#S95^H/8^,P@) 0"0TAJR$P # 02P(,>U[&T#$@L4%@!@T!2!4,E !EB$
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M*S'GLVKDJ2KBE4O!,YR^<,QT;NX&O,MT-U;*O2)^T=JC/"/+_'+'?GC%FF]
M6;]+1]4E^OB3,)OGH;71U_WK7_/;#X=TGOWS6+_DG(7(9(-[BG3//3[K3X5M
M7A1+\:;FI2^4!QJNQE;/XA%Q/Y=/"VX&'^PXZ"LJ9]V3\W/NMFJ$WM44G<2!
MS B[;VDO%-MP'T*YCC>883$G>,5=SUW__%/-[=BVWJ: M>FD<LO+D-L?#RS0
M)&,T^#_-O3LL__Y;E<5\3X=C-J=P\?%MC2[S^J#5N,L"5=KE2C4"JUG780*V
MOXW"SN[R8DIZ*+)U]V9O7'Q'C+G^CC6?5PB*X<<BE2>[QL5"/X27+&P+3&LD
M/1_#F5VM2FN_*>XJW^S'RM*Q(?1D:HD_O)QH/K]O<YII'7FWT5SJLX#)!CL#
M]]?HZ\PQ6XRC=@]42T'2.5!6?&.T_?E@PTH1\UM&D=4>W*?X2&-]SX"OC.BG
M+?=7%O&GY6M5CUA&/3&^OEQ'E1>WO?%B^DVR?M/ -8%_!0KNX0S6<#J"O>90
MK%Y.)!2K=NS'U"2[2]RFC^;[Q_IM6$/T-V+?T17QSXT16>?P?,95G_9;.@J\
MOQ_F>&?KF5_3=^&WV'0ZGCR5<.@"</H'JF[6QN'\A3&!5PFW363IR&/>PS@&
M_&+D[AN961I33>HZ]KR=@]T?.;\[>265TI1(K]DYGSQ._8V_8DWI@%R^=U5"
MVS6UC80C$_[%Z9R,DREJY_:_9OA.$N84_G1%1_];E)^P47K)O5,^.360-WNW
M,5-V@\;;Z %1KM&$R2--$"H3]-5X(#=,;3Q5/!,N6K=:$$$.%'@V.*[=KM^*
M6PJ->"<XNY<B+Q$J_BYBCI'K;=G2=7"/FR >6=L?OV'6>ZDKL;M!YD] G-[S
M=\&BO<X!+P,TT<.[,4+U[.JR0CS:H)F,M",.X]8',]?:\#S*LR9O\P"TK-JP
MC'2FI6XIY:+>%U#DX-HX00K9=TX\RW$]8T'ZOI*$Y 4%\CU>7T_U];9#VUS2
MN&SU@=3%4<M/(RQW)_O)1R&]=GIKV?]&>G^*T;_NT)RC:$<!!<MV^ [B5F44
M]K,5! NY#&'\<&TO%503"<T\OQ(O&?,;85I;-Q4997;F<0K<HI #;0I6*9C_
M!<'TS/%R")$%X!*V:4FKZ7%3_=F:D>:6^(DYJ9IZ&_8OQ7BO9+37O4\B5P<W
M3RC?>/+>Y?+E.JL79MNE_!=@T8S>E7I>%R),KI$-4\,SG!MR,E&F@;PJ'E6F
M/^E3UD:! G\)&\=<ZG(P?H<R^!7&9@9(.;4*)N$>PS#%[GK'@C/%QX_M"$9=
MOM=H<[#.*<NG, XSZ90S,!^H<;CR^;@!^O*[W1Y,^#;)6@]MXU4J=UTL*_!]
MR"UGHPQ>O^ 1%?'C#(%6,H\"@2YZ0A4FB*?+O*#MC^,RN;/G=^=DBH@,G/T1
MV*%%H$0XG:"_-@&3P]-Y'V<S53)+2VXR>-1&P-F^.V 78\A5+:/>1;;K75N)
M@![+,$S9%MN"/L[\());;1'XK'+@P4W]EK*CWFDO<CVGW+Z+W&BH53/L@7FI
MQ,29>@RCG&QAPAR@1)D=S)LW.Q[FTB!JV<K,Y(^ "GF(\0SI@OQYN.5(L@O.
MVI=Q<MV3O U1NOE@N:IO4%_MCMN#J\+3LGRA1GXR&WCD6YY3?'>M17WG344W
ML%]PH9>>C#<?%KD:J[%D4SK@37C>6ZP@_C(6DBN#-$$J4[>.):F" JU AYD'
M'5E*GA7F@ITHX?O[\O-(-V&?Q6G+[-,F3Y#8&!=B_BP^2Z48KX=4CA9\%^CB
M^S,A$Y"5#5!\N!'9G>LK799?SQ2^*HM]#Y64C+F]^G)8>5Q$%@^]$53'O5ID
MX'F=\E N>6M,V=Z@?,#MM?N=BU@>%=,X5$Z"W".(WF$T)0T043.!G50?UAX8
MSD6A33KA7<Q3CC0(?YG>(SW<APHES0L148&2R]PDJ5I(<]B]-^(SE!'"A8;C
M$7\>IS_YXWRJ<"<LVG&^8CFJ;17C/IAZ<BG6>/OS[R3'W@?UOX3M,>W<2WEK
MCD=^]EB=ZTR33$/M!LP]T.-N0<SQ#.'6%4#! \+KAELY\&GAS4 6,WJ_(PZ
M2JT MKY-[M6L<=*1 LGGQA^JWY;Y]#=/"=I'VC2>T1&)L.Z8#:CS48%G3<Q:
M5["^UR0/??SHM/ R6+1EY?K+G=P<YQ<?M]QE+.S-NOR<W/4F 8?X]LC/)SS5
M('GNZI QY9@5*)6,;!,>,7.D+EFON%WY2Z%#D,2X_+\99^['!FIH(=T.X44E
M%NT;S*['86/$,GE%9+.5)MX07TEAL^R_%ND4T*S^L??:;*,.SQ75A!^D1?KH
M)+Y4L^>/[ P\>'>K^N9+\%S$-U!*9.OLIH8])!>_1D6V-I'4^&F@"(X,\Y?6
M?G,1#TKN9<@\W3NN$X5G# 56M<779.HM[&.PFX[>N ,#IWF&NRY>.5Z<VDAH
M4GMUIA@OVZ1_ FTK@/S^)GGJQ9P!TE2EV/A,VC_G?GR!)M;A$_=T]:^MGW$/
M341F)PX@4(2>,Y065'5LL"D>%'0'+YK%(6@ @@C;[8.9LK%_:?Y1:WPYAT 8
M#8!1 3D:J$>%4H4=BV*C'Y.CBV@^SYLME^$Q?[FPY0'2Z7M&8T6"IG18%T2X
M^_&A3%,\S]SA2R)^^I9G OJ@ <6H(U32ZUTT&[0V'3_3PCR)'J2AK-+J*&CS
MI @P#E7//>E?"B;\L$EH8?R4!Y4Y)N9$7A&1T,D0**(0@'$8,>\9_L*A>BD9
M1TFP_:+"Z-JG&9^#;.TXY)#C#GI*:-L,\9XXR3:RT*26".R)2-TUWS?OTOYU
M)WVSS HP]]-J\KB.2ZRWM'8+1?F+,1%[*/8*BAH:<?,MF2(<K5883+ "H.M1
M$\<=>-RB'_^P%"L$'I  '  1F(40:%"-;&A\$E2C[.SD-U>3TR1K71-_78>5
M[QBZH[3I)50;'E5%S2]OA;5Q\\_K)IC]N!!69U83D+72!"T=3[@R'EA@KO=;
M!/T["84-C4"(Y09X%#8#J*0GUG4)22W%T(@?+IP^N@(>_9<3^:<)U"N$/%=$
M/RWUAA4"4&[>-!(BR($0GD-(-"@!!U4W@))P^U!]*DR/X 4?  M2O$Z.PY@_
MLFVYE 8N;WWA!5-9E.6%?//'^=L3,76!^39SAREA!5K-4 /.>5;)J?U!C[U$
M%*]8+H\X"G6#QL:C_#T%7"8<K&9AMYET.7+ZU3ZR<B&)L)+T@LLW2R[2) )R
MX<"T&(3P\XKD+(1A4'9X%B+!ACQ.@:KBHO7P5#TRS  ?\K,8-,=[2;>B'F2A
M3%+S+:U1]2OE5N7YFXNPK<4+&?>4_PTM42NI*!]WJDQ"[6\4'- W[R"A3X;K
M^X<7NNM'(C9XK<@@<C;W!$]R0K87,M;&G S*XV$EJ2"<"$UZSV=)@T !X.'&
M%<D="&U?N8QN4/;RPF4)?)D2#AH3XG57N#SBBH,>$6J.P_8TN4%)Q<>5:\T-
MBDT-BM=)A"K]A*C/\H:%%6YA65D-%6JZSN^:T)5)HMCK.>6NB;Z3M#HJ"J)4
MZHRP.<(%Y:F@YSCH0/EO#L'SR<#5H#CI")BHJ'_RIO>A<.#\3XCT"N1@8;7R
MSWK-K7J9V 9]E0;)0HCX"J.E!%0%;.&EH"(9-K-2,U,(;>"@:[CEII[_8<%K
MJ5QL^IFWBMJTM2@">1N6[U;Q5YQM$%10OI[ 255XVUC9UUK("=,_>4&@'R@M
M''9P*(2:DEL<8M-MV4EZ.ZR[%H R%Q:3!,2+>N];$J&2W+SGF_6RG-;<K7J-
M+8@LT$"*:%@2AYQ[WB!Q(=ASW$6XS.O=9LVQ-E14<''3#B_%L+:VL-U=I7@+
M26SRK/CE;MA[Q@D246"/L,9>]T.*Q0JB4/9K;.0B+VJ2UY0&FVR(,V##I&Y6
M04/ -!9$U!-,8D)@1-[?.WSS(E Q $*?;,W-@;[Z5:^) QD_ZXN\V@CE$ D:
MA+!CXZX'<PN*4V/76:*P!8NP61S6\@*JB8:JQ:-^JZ":*MKK=ZZZG\F_BNJX
M:MC1I)W3/FJHHVM_G;>N>:#C4EQB/0Y=3^V4VHI2Q%-/FB<_34[7 ] \ZT8/
MX=AG-T'MV?T\R9TN5?%KYX!N567HB@2H+PG*L*_)T*JG)QK$:! %X.IX,(S5
M *I2RD]0BT[@%=MC\UMQ_10O%.77U;:(_LJ=JVW4?MX7_4W/.4VS@:MS@8Z(
M1 RJ$TVJZR&@9'IT#+EUR)4Z,QK(38H2'F0HT(()%%N[)ML>8:@ $:).AJ;/
M(IA3B/05Q#G:8"H7D4J&:N%N7)9LTUFZ5KIU9;8,DM=6E) 3;/V!]'>V3(7:
MV&C3WQ)QLT6%TYY;VY+#J5WI]_V7]YB+PDI]5LB3,\BPQ(;8B%NY*/LD&J>L
MIV9G8,@*/#P(_B7"VH+CA"?H;18L[G6;FR[8HD*(X#X>FB6)7.H8RN0.L7('
M5VXA=%6AN5L0_:TK_-PNR17&1<_TG_(P-6+?G)+_)/K<,_95T!L%7KC9G(L"
MT:4_*U$NMK7OPYJN_LO;[54!0'L\RTJ<X,Q>)JVRD>9VI1+5"/J6@O*QZ;F>
MH!C[DK B.%WJ^I>&M:3=?D&%Z<=")7&0-,X0G8)DDGF+\:-,(O+%BR$Z&9F=
M"TTOO+:>=D<2@)R;[-;>:>#LNB1DDXH*78Y76#[FW/TU=?>W3;^3)*HULGB]
MK-W[]TWOR'S@JT8MT/,S1 ]]IK*_-+%)9+@?5^IO;63&!:,O &G/TB.2O3A$
MF-HBX]$3VYWVJ/T7$A 2>R@+/UI,^:\\-L>'=XZ#TK$;S>(,G2T<U$>#)LO7
M:.40,5ST+1Y;,6*<G07,K##T!!FFC<,NQ=YM(8[]1C?M1[1W1=UT]^;\M9ER
M3YL*0*M7ZCEW[C7CTM&(UEM"JG7V?<Q[9C!%*EUM;U+T?9U&&"A^)6ZF\'YO
M%L2H B*)AYZE3.@\G'BR,_V$@GW=.3%''LT )I<^#*ZA09($1&1V1"G57R,,
M*O'3Q4S5RXYMJ<<;(]V,<KK]P"T*Y?:;UW7YP5^O=FC:E)LWJ@Z/PGDKR%Y#
M]Y.U;H<G?GIW*V'TS%4:JAM "58?:>/']K+CU&AUT^O#,,[^];\T")P&0IM!
M#@5K@HN>-P T/B!>1/&R.B=6C+ O=Z;GR=@GN/GYG8EB'+*H"B'+??01,R,Y
M"VIRHT3T378B:NRD'$\ Z0*SL+SC_4#T33 :!1Z<^AW9[N[=WM1QT__?65SU
M*4'LL)M^X<FPB&9J98]HA)JLMP,GCF=]6(\"P@NIZ2D - GXRT6;[C (5 "*
M@\BP$23?B3PU[.ME[$L*=AEX]$8-:_%G@DY$GBU$: &@75=UB2%$D UQC/:W
M$]:QMYA)WL,0?V!,:1!Y*NP9&Q7DBPJ<?G'KXNSORKO[DOW D5N()<.@'PN=
MHFB?\$0GD8B0,'3W_@IJ*XO?IA *$;Y[2[%/(=?K8!Y$D3-IR44_!= F4XLX
M*N0,\%PSBK?HXY.GU.>EA_VO8.<+I";/%2+.<.:W;T/^B;HAR)X\O,DPP[G=
M5H!)EY'$YV%*U,;'A2_ VR_8N"DR=?9/Q$U@JM(Q#;6P,K/ 7=7@>4QA24'%
M(\0^!G$[_0:HS/XKSB')5&,K%&(E^([%V<,3Z2L?HSI<L/<YB]#8R[*<5V=Q
MR-*55R4''[V:Q2ZSU]ZL8&V-L3EVO,S"1[^&YJ_803SL(9!'#4KXZZ'W77:-
M',RI4)Y]OMQPZ,_??6#ZE MZJK62]^[%FQVW'SA*]A_\BI8QQK13L?NK\6<$
M?+6N,=]<=D4_CD8/$-$A)%0?#CNXH^UI"6O5F8YE 7*%BS%7XCGX344*H#?=
M6GAT[9,O;PG^]97JM2]#SR_Z\#J_0OP<>J3W +)T R+$:<B>?.D^X%^Q1:_C
M\>I*! ADU,\*5%EL?\4.;P7U9AGN?<_MNXEW5M,.O!D%*B^N%0@>+JRWC%0P
MVUB*V7!SMYDI!-6(T!W5%XU$F.PO&P5<=DP(-"<#%*"UFG0/DLY.O"1NE40_
M?\O!OIG%O@+>K1DAL[BC6W8WKE1-^KSJKH_"G>@'"1Q_'LMR,SPD+O?J4BPJ
MLJ8]-J9]T@\5V[T=_^IJ"PTE^X]9"WO__<$8;.#7\\A?:$%L8G_LN+P9NH_]
M\08YJ:P15IL%.'#(MCCLUR!_Q??>(HN,5H6H)0YXZ&>OR?YF%F6MP8^7<NZ?
M+]A'.>FC5D.#:;@;>.H[QB3D_.2[HS;KN4^,%CBP!"43.]K*B95.Z6Q8GM)V
MJ&^[9.TVO_3JK:/OP?(?G)^K"]P?8.I[L"<MZ%GL@R'T15=T'Q5]8P6]8AYL
M/NM0:02344,[\2PJT$!%E;Y9([#LKHTE=_'(K5<Y+Q#V#M]6[+9>DA^]\QF%
M\-WQ^@=2BFG0K.CV,89JA\-L*;+B0;#FQ)2BG6>*9.^96#??JO8F//?@^=\/
M3N5/?7J:NL^7Z'@]3>:363L1<_#01TXYLR/LXUL7M.X_?UX5H-M,4*(_8(:Q
M(\@:\/2'I*!S/T_?N#X1 IM&MI& YU^[GZS]?G+L*+:3L[9,Q@*R%R44&'3P
MF^P])8<:G"R9M@/T0%E823R5&SLRCCUD5C8!AA^6N"2DD&E4F< %X,(,%PR]
M6<6UW4'7-EC%%>5L7W/T[+I18KL+I?Z6_9]?3:C-N9/'D_^TNW[8;/-VB9R^
MV:_:<=BG/_[G@Y+<)_D*,V74E%Y&-COTQ'P "5^?B>4G4*1PX!1<+<S2#K.X
M(PO+'S[W"U;O8KW4%_[TIJ:?49>D;L1<([^:S@15QA@5;+2?OF&B@\"*:%<-
M^ =F8Q4;J9=&>"Y.HD0L%365X[CW<F052LFY>D7K#YW:$KX_+(Y0>E1CPA+(
M.E?<IMO8WOIW[NGNL^[6_G:_;WZY;H=/^HV>6;ID=I97^*]+@MVPW)COC3;'
MA[6GXGG@2)R>CA0&,0KV-%ZV$2M2&QYK]1_38A#$&PNG25-0^*SYORM0K-4+
MVC&,#MFD__S^!86*L(<V)K#+;JJK,,%LZIOR4!=9BT$'FQO\2G9YVI^49!K0
M6\K-I1+-RI&,N4]"#>US6R)M]PY=%?&+I_/P'O0@L3/Y3Y"':;"U$2[ ;^4Q
M#!\D"CQA"F"(5!K&;':T@/2'L]]H#^V ($R."DMNF$R#LIDC,^2I'>@!Q:T=
M.4'[LKILL=H+BJ4*F51_?6$70IVZL!/%)/M\-^\G9$72+_DBNPA3UR+)LS#4
M1$/"Y"?1K7KKK>)#T;Y;Q5X)']55E,+CYCJ\2@D?:FV>RK,!/5=3+@ S]Y"]
M#MT;19<*[&6LG"#]V8$BCJBV-5= V_P[!>)5#[7.'/L7UU?'TEHF9_ 9MEI!
ML?9D?[AP10JS6($YX9\EQ"2:9DMA2%2>0Q3",%+.;LU\WL'J3U!1A4O79+&#
M'22"4.!],::-VFW6;N59.>?JWI#^[5/K3OKG=R*>#YU,NK6BB0&K4"1^A3;H
MLD\<!OZZ_;J/Y%_$=,H>W<7-<D"9#OF9\%9-C@!#[<,UG V&-[/ ^,LL%(XV
MV>-FF/)U$:!"]BG^<*4RJBF/R/R4[-5Z%KY._1!,KSY3UKXXN-G!R>#I&V<'
MUZ=")\XE?#*H#_NC4"9[VC?G5JM:P5:K<]AP56ED$/\(#.:GXAP*31'1SA*^
MJ<.5P\3[/:$AC<*0+(,/?:<KH.(-9_#MRH[ZA2;,?S!1XLN')5]A2<O4C^G5
M%.U_[#[XK2K(4O 0J*QBG$:6D-7S=8E5+<W;\[DG(!9Q-55'QH3J?'P?5%#E
M_P:7.>?<?KWOE_:T2FPCJIQ'Q^J2,C_2'ZG(];RRCZ0!-1?(/'I4W_/J]: 0
M-0C\*XLY  O"V<HW)\/KF8-GGBDAL0ZF58[( _F(2Y@X;M;!#3)ZYVFK8!4
ME:?2D6_D&)J7 /I?/ BG@EA)'!WY%_F:/Y\BF/L4)E1!<OWELXJJ8X/"S=R
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M7P;)F7G>%X+J(!Y/><56]0JANE'08]D9*A.  @;$L]]A*:,R8EQ>P@JP%@P
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MZ#A:#LX@F-1X63$X#<J@"O:29)$PO<;7TG,<0E_1-L5 *YM\#=B R<N9#M3
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MMP1NGABS[4G+R;P3=@@O Y0HT,CLM@2P @[8)T\S0MJ&@?JOZO09&VS_TR0
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MVVMAG@C>10OVM]84M7U05"D26Z@="G%<TTR^(;A8KYSW"F/')GWASBEED7U
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M_892_^)N6MGN;K6+$DV^ NY9C '-$+IZIB95+ #SH]Q-AT:%BGE5:A-"(6/
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MR;9 5L"S<4'?'JYD6OSR\(+.?I-QIM4^_>:"MO*4:$G86,8+FW,;FF]G,7<
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M-Y8%HU;=.]2 &>L[+$@#  0P3+;;(_\F<JYC_7X2.?=WV!/V_'\R."<9W0I
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MFYV:"A$4(5 BJ(!5'I\0_RZI#P @4#XR)F6]=KA 0E@<<*$#3# 4  A(PAD
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MVL.O*="82_KJK'&,2YB^]*%4E4TI:,)65L%,)1>N13J"4!D2E^*]3_!S>ZN
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MJ-O77F9Z]7 A;P>ATI7SS7&WRJ<B%HM_+0M+O]WMG/'9*:Z\XPC:9A1>-('
M,%Q P,TEE5+(ABHT;O ;1#"%%PW?)'SNO*$3 :J?]6J":'3QK1]R,=DPA&![
M^L07.P>(*@E/7((X]3DKWE0CJV2![JZ&H^>^7]I,Z]]FF?$9:(-%M).@F+-Z
M?+H19XY\[1UO*+]W(_014V!E#YSWF=J"%5[Q@^.F'XOP \;_!U!+ P04
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MB=M'28B+/Y)\Z."!Q!/'CY\ZF9YU^O3I](S4E*.TL^< _@V L*N B&9 ="N
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M]B;ZFT_IL0!+#/Z!7LE$U-%)@_FZ0Q,OV(=EO5H^C?Z::LA68.UXX:XRCEH
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M),L[6?S%N?0GC%YMEOV67#"R66KK<_8]OVSG9H$N  !'(<9Q<C JX 86>0D
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MA?.:+?4PMKX6%S".!H$!B E.W;G'<.FI!B!7%NHB"Q#+R/ZZ"!K@-F)11T0
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MOAJ1AX:&2Z[K[$&H9B+VH:#)%-YK,H*,AK)QW<)^N&FF%-8S>\T\2?T&!52
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MB&4S!"1PY\T>=T]"& ]QD' MB-,F.#L6$I)QSY,KCTR .-&*70["NEOO_:#
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MT@R./8YAOPDRJJXVDRS:4"!&/"AF?<&>#<*@.1@VZ$0%PZ19RS\)9(G+QG!
M812FG@!D0\E^0V$1  P;37!*04,(AVE$@5KPE^RK0;&>V;K5(.^GX0YDAJ6
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M#I_>C1/OV742A.'>L<7&&//MPOA0"PDHC'@X2NF..2X.0\S>BV-NZ;SC1W+
M;/8M-+ZXOG2@& =28#&,B"Z3U5&=?$C:21@!M;BUF2F[@Z5- H?/G)>&@H]7
M,+X0GX41KPZ<B'+,6'^&V""5W"Z=8^#,7D?QE$P!V7O9[WX?.62IN?_-3O"
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MCYZDR,'&9"]3>\^M*1VD^]G1_1#%4+J,F2!NFFT&5KUJNM-1\PWRSK>WC\C
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M(SBT@YBTB0'8/ANK=N8#%>!D*:\*8"F)/5F07.4__K3G=YL/NFU4% $4IR4
M'3@?J"W(D=&F:]7.V/GG:>U],[EQ<*[DE<,$K:@(GC!BOOT^[N*7GZ<^!W:N
M &;GT&DKWH1);?-YVG:(KA"<_5XAO$T1((:DUBG* X"]"@ R4TU1#'1@@37%
MH"3@6P\QT [P[>C>^37Q]P\,7.'' 6\6P(8%M@$ EQ@X2RD Z0_.!N*,6,"D
M81!&B&-M!V43P+DT    SF9CY%G@QV(@&0_Z@ ?8H*'- @!1J&@^\U=ES3%V
M&>C^GK52*U8;225=G,O>N!R>[Z4(Z[VQVH),^_)2,/=N5G&KF0)!:27K5A95
M"; B5(2(P;)4W.@M<$Z-HNBCX@I9D36\JBO^_R/^5VEHP!)>"296WBP"RP,P
M6RB ;@NY8P40. -$) /1PL7L-84/#$5-_U\0L0):"NZD 0W(N-K;:NF?["SQ
M()(8O ;X=VR O-GW9V(PU5*]8+E&,ZTHD)*^TUL_>GE,4:!\'(]:358> JM6
M,KQWRD\0MS]<,_A<;J!<ZIH92E%8ISD>3<'>Q:/D83?D19]_?OP$N*OSY2(
MX=ZK;0YP&?X-4 +*D\&$KA^I;@O:@9.*8CB?#08(5;\ROF4/@]!"P&.Q>KPR
MT+-D/>OC>EK<KS76G>ATG(T8P#AE_UT,T!,#/DO5C?%(E/BV8"_NL10@CX?N
M! (Q )",5:-J)X7UG=+?;^I@<S*>F(@>![N]C/4ICW/[P#-K;</0):C\%=XD
M"YFZJ%*R0I2O$[>7.$;77OI,=93NCH:#=!V75/")S>^HIE.U\KTL$E'^4OD*
MT=<7_0>M\#=MA3;S-];O1G@JCLP".08J=?N]<:"I[)X!DEBJ[G@,1 SRG%(
MX)7LNB'93*-AVH*'5,4J0_&[])$E &P@GO642D^N 759:O!4$ D QK.43EJ"
MX"Q@\B)2"0#B">0M5$$_&38H,B!5!?2/+MG#JC-[(+YB($0\ZY'B$*S8:T)!
M3(KO>WC8P8 *:LS8P[#-=_%IY_65[PJ=/3BR'28U_MX$5&@>R8>@/"LV5C14
MGB%W7)EJ(B7&+IVV,ZCQEQIL+:Z_V0V!DW+L'G VGX8E?DW'XA:5YO"F_C5<
M XK"0A#>O5/!]N,HLD=I8)^!_%V(+@/S70I<V8.CB8&/4W$_I< %Z1L#%LB(
M =)F0'920$)5N0VL55T\/*<&PBB%:)-G8F\#:0PE/19(CPS2%L\^E@(U3^*<
M6*"=!$C:5X^.KW:/ :"3%]6(#' V 9+QU6L#WG$7 6Q$GA%D&FZS!F.D ".I
MD?I%]#<EA4P& LTD;)%#=+(4*LD;GH)1W5(48Y<HD(FLPC=62C$J0'@IWCH8
MJ,N62=LJ63LP6(76MT@AOK%1*)X1(N;%J-^)6 %>.;X94T+%-@*0,T)DJ[2H
M7GHD61P8CD6(A,A),J)3K-9X4VT6@&@V0:"'U>H!R /U'2MC0.N/2A<^;_AF
M<[^_QY&67=.];Z#??/0G3RU6Q='[W:>4X2,'F&BA6*U2*)^R2"S%H_W9L'F>
M'H<<?=S5*718K9^,/,"4GV1L]6]V(AO(_7SMJ;<L7R]6H]?P;^S:LIJA+A,B
M_WDB^"Z#4C'&VY832D"RR&$-*HC/>G:ITLA^"%R%HM )A9NPL3.VR-1AQ/HK
MHN\9@,[M&\W[T9LQU/<&:$2 4LXVT%7;)!G_C/V\2*EG"@%B-E8AX?'ZU-DR
M X$/7F *G_SB_E(?.\I*>Q./G10CD_401PM)VVL0,*#JDBI:P+"%I)P2B:FA
M^TU/BS&5Y(Z7"<IZRZ&_MFT>6%)9B3/NQZ,[$XC?DU"DD2/)KM@J?!-:54'N
M,_!B5^*?@+\/9D>R^S/X:G\A/0!E=70* :T+0=@5ALYTD<NIR<2=R7:%!IZY
M:6K+AUM96$N"5SB79$5 U#-"&@U1@SZ41KP^9W](GR1D(G#SXDCH(XAW^P,$
M2RZX'9!0D81L!*#J5]6$4B7>4DK&FP>AG4D:]E900;K]#-7LX%&W=DO[';LL
MV+MZ4++S..Y.WX-6 G)E,G=7SQE2=NWN3]X'E."(R/OF?6\#BUI(=[.QK '_
M$G=$R4XBG(N]LFU3?KO=/_OM"DGXRT"5QBMCZ%M;?QQ6_='CY*\DU[T3?&_G
MWM"=R#'\A#W_EN<15 +VC!2-HR+QK]"2;6%3+*MHZKYP=92(4;#4A$@=1M%_
M\&3\ XD#ELCQG/L,%-Q5OI6A?F/Y7[FI9>.5,78A@014"A'+P<%3@7O98I50
M-[M4LD)R><I?LCP(B#S +N@A<\%L[G8DKZX,_^N3V[[^\*80*G-Y)'C]5!3L
MK[=#U@T#)(Z)KA2K&6$5T(O(2ORQ++)8K4FK3,9 H6OD?[_:I-N$$;7*@0C'
M;BVSYNLP'#P*S58P<-^E]NHBLHV,CT-[&WAXNLJK4.1+\)N$^%UE0M3<::L'
MMLKMTJ*=]9@L5O%U,O*X5*56FO.2XSQD^ 5P!UU3H5A@FN$W?0KH>.XO55!D
M5VO)5@"]+@ZDJ%P1>\W486"+MI:+:(Z<X2AK[V+=V;!EI7DQ1L2+G3]D-8]'
M7<&;"@J4X3LS?^[# H"HKT1E2\J6:U+DM7R!"B&;Q%90H]A%AJ@T-IUWC%4F
MVNP&$; S>&50_9#_(IK$7BD\H'C!EQ<RA*[(4:71SS&'MF\I/QD7YS/#[3P:
M6_C*58'I%B>;*MC9]ODZ<CK^Z- AN,3D^MOF"NKPR:7KZ)=Z\4D&A\4J^>&[
M7KX@/GB[\A+4H)K6.+P#OUGIU&5'!741(,:I\4ZEPV 8<+/->/*[T06GA_D^
M6U"&.F\K-\3$(:?==)Q3_.V4,D8&P@T''FXZ6.DWW7#/J:MHV?*_\A%6>**<
M\ZEM\UU@4==3JP;]RXG;>BNOV_=<VF$GNF1/'#;\'8_BB.4Q6D5;(D0-&J*0
M=^E7SS;&G6NTCFBW5@?N>-+M^"3<V*CW4!PJF*7RDX<.ET*%^+Y;21UCE1TQ
M$=T*E].O._'^&Q2%7>Y[/SA('VRSOCV07H>(%JL,]3D$,F'Q>%@S0':I;%O1
MH/I0QR^ A7/EH3T/+#]<?'VD_:U6);CD_E>(0V@C-EX*Y470!'B8[->5.\Z'
M.FV'6IZ(U+5/F7U,KWARS5GKVG!XS^4=UP\>Z39TL=.C.0CQ,,!O639!(5H*
MRY)"Y7^+8SPNG?UU=4+SZ ]<CX7+B,Z3H;:(H5T+_;LBKAD_M#]*415*H6GX
MT0&L@\TB-%R([A5# R/'HHPNUVD-#?RXL3FUY_[G,<.'DPU/VC;NG22\&8$S
M4<U"N6B6^*^S.&]$??SW8 MKHOIWU@-G4<]"95>5Q.K*L%MYXD,!SR\K,2IB
MH#KBU)%S]IEB:+1P.@%_Q^V*0Z]P-(Z)JY<)H96_;P'Y8YLQ$GVER8M:W?8Z
M-U_]OK?YS^>,R_W.42\._[:+)F C:[#!FU5GCCJ$[E11U%%)U;^[L?JNUW2Z
MX:FNB-]MJ"-SE*OWN-7]X*B9J-^W+QRY.J#>R]=7V\FX<VZS7#09E<9%&N@\
MC/"8,HW\&^\R-^ R>3KJIM?3&\O:LU^R#%C?^[,7L='''-JKY8XRW[;_>= 5
M%?EIX<F.G_,OCDAN/KYZY-C"6^UPQ)$AVU,T)Q>'Z,5'_,OCZ75HQ<VJ62,/
MWFZF?;\Z=.C/V"/14I[.?,[3V_I:_6%#_5]^74O\[5:AL_A$QR%\\5& \]+%
M8TO_2 L-6+8_*MEU?OYO-57VT>$F^-J\X['*OJC[,Y7V55>ALY$)V4!$. #1
MO_\9<\M##<$*);/_UM67;>=?7;QVV_U9GT6T].HA;.6?^QKG1Q/QV+FHI0OG
MMY=&/+RL/$9:6/[/Y<W![STQOD,+X2,=SV[<C H?KI[:7I3#XSZMN6I_\C<4
M0KBR=^2UQI;WU2J/*L!M74[#G"US1X\MKQ;LQ%_X>S)J3NJS4#3E&%W_Y;]C
M3QJ>7=O.5!T\\C3G]VIZG?J#!?O0&Z\UMF[W,6M]!%>%410R8W[($6X>W?QB
MM0WCY'FYZQD-S<Z:?>2Z_V]Q:G1/W6,55M.A4/\RZYNVR1QE5X-7P]77'CU[
M>#PN0>7X6KJ;#!6.E]/]8S][_+OZ+Q-'S&EYZ)94X8YVAJR'<8-8>?$UC_K*
MVF+V6\^'Z!N VM(6-L0'89#T1GK*N\4_:LCJ13Z6Y%U9[A22AK_!ABEGN#1W
M!;=2X_P[*FMWEHE/PBG1U.;\ %6B=RLC.,1C F.0$'PHWFMM;K@(D;/S:SFZ
MQ:>>$B'1A-FVSNW8%$W3-/)]4Z]N@??Z8]( +;L8/U6YN<"NXW%?4IY1I.'+
ML9H0N'VL[Y@GHNWJD1T5!N6332TAO&//$MRSA":U!2%_!E?4ZSPEF18P\W<!
MV!>7SX8UZ'F6WS?&R^M\=^!G84T-8U:3HPT'N][<!ANCMI29E+V14?Q3HUSV
M>Y>ESK,2Y3PFW?Q2-^Y(A8(X7B'&>*[).>^R\$]K(;UR;798+2M3WB/UF(7"
MN3U10=MO7ZMD?MO=KFW6*VS0.],A^_/[5QVV\9E)XA4T6-/$BK\#[:HQ%X '
M5<=.X =;V'SU0D_UT^IA0N "X:SG 4_CY+4UJ'Z#@4JD831C&)951I2,Y^<P
M,E7U3%O96OJ%)- -M<*C9Y#\%,9=B+Z8>9=KT,C@Y+$"TM0]U=3L>..&.<%T
M1#8WOABJ)WF=A= JC 2.;F@@!B*,\NB?Q[#9C.9QM2UO/.=,4GS340>8W2IC
M&]HC)9,:.T1ZLR96L9^VI3IM L%D:GE'&Y%X;'2)YYF<[@!D6J.0[:Y1CM=3
M,4IA6'DT6MB.!1M?%'Y#*G[RXE]0O 8_C0VEW==\0!_X>7/WQ6O>4.&VME)E
MMY#8=7ZPKQ>^T;N''94.3?$6#N=C@@P^RZ$+VTO@Z&2##+YJ"Z!K//8L^<=-
MQ=A(CJ=J.^GNB$8>@\TSR9MC$?%;<;4E)DGR5G"]@/CT*77'+*MQ#9?@C!),
MGHC@KM00=9=KW/(4Q%<?B 1"]5BTG'1T!%X"4RH1=;NKYLA+[IDE_,;S^?32
MEGS,[LA-7&RRMLJH1G\SY>D9QV9F :/-P2K7F"W/J38^P^#HF/K5!^>;Y *4
M99YZ@9',J0VV*<#Q#4X&G Q,SN]T=T6G,XX7,1=LTZ%ZB0XU(R6>6<7CZM[Q
M0W,M?EV25GFS2"R68#;-\@Y??_US]_+)+Z]"C4>NL;AM=#S12S&03.!C @!Z
MD>C\*G:39L""9-(LC]R%1.?.<ZHQ!9C_-(R\;2H@1NUX$-24(@_Z919:6L[U
M&OA]Y\C](,N,*;.ZKL_\RZWP4S?TR*+:R0]61Y,F#0UJTV&:.P:K<U6:GP<B
M5-K)B]2U!%^"EU*E\B38*#IB>I(0.-_MC65'!H+)CT#*W@YC2B1V>? < UU(
MFW&O%,,VIM0@R0*J6VP)%$\U#6HB<PQF7LF&*>-[#\>).8:'A5JAEK&PL^L@
M/"VQ )\+1PX'N2F&WFF):H]5CUYS31:,84[VWB1]S-L>&@O<8"QT5:U*JE6]
M,,]3<V&K5M*76G5SQD@>AO0FS="N>$NN6M6P$WC81PF=GFNC*U%YV )!5^(O
M&:^OHG/1BWJ84HP4LKA-D0(R:MRWZ1D3!-?6R%-56>0=AW+V]UE!]16+*:%?
M!;1VL41C-*U=#CK,49Q@8[M9?#, )8Y.C]94#@#[>M8X593P5+M%T+)2#C8(
MSM-L%><;_:%$;D10?P825)Z5;7<J:>,0^E=.!QL X3V]4,U*?+D/9*GBE&1*
M"=/5+;LBI)QH2[JKT2_,5N T(?+7Y/71 =G:Y2!#N2&JBF\Q;ZM!+#H_-]I0
M<A#VH2897S6HISSB.<@4+D$W-2-W1,^".@V^"J&VJZA($=3,&U-0?"Z2$B.%
M?F/E*'NR_'H@8%U=8DW8^2\2-=]\&$C%T))"'TTT3W?..O\.O>8F\5A;XKD5
M!F>,OWVXH93%MVBN0;19&AN:5?"MDD<15?4XF4L0V*O^'2IBM1@7: 6U2'BC
M4A7TAB%B96^ELVEM<(A%DR7<1QJ S6%)"%52U7]).K 7X:J1<4CYKH&!PPS"
ME8&NX>IRANM+X#S,T$3^II1%^3 '@8E0J&\HBQQ&L9- 1D)+^$AD+>)5JT#]
M<#S<7?X!JFRVV8-TPV0]TM#THI2B=!C >SCYO:_KF)EB/ O\^#%>0?7]^XL@
M*DEC%&^H.3:%+BDI#0L'*I@^'L/,B@HP3D4"A->87OSG.M[Z'<R1A6J,]R>N
MKVU+1P'...LPDJ";XF-#O3\;<(\&VY AL!'7T'<I=".GSU/B;NF98D!W_*Z0
M:^2Y/^/Z%&NRN[Q3BX<^73!D 7S;'(>+7A97:D*LITQ$P(N-9)"^D(6H*6],
MUDXXDQ3\2<Z8UBT?EO4V*^T>V..WHET[W=6X?XT?X6E^O&D^_DZWNLZG3+D0
MUT^)8<V?6R/NR)(G)'#8Z7.DPDBS1Q/7.C).#&8I3W0M0NW+"UI<2O")+V#.
M7'RK<>]8[E#"QZ; +QH'2W@V<T\_3K.2V\QJ_TG!#E?$B?$"[U#V%8MO>)N$
MV6&S0J<I?R^.7#.3K]F_X[GN:D]XHIBJB!_)3WUA#^<]FE?SK@&36VARK0PN
M!^@W$D(?1B?S@_6<3"B+D%A8Q1@OMG-GR07C837OM463E$4^-=0/L4L<;7)<
MG$MIIF<DBES?RD3E5M,LY=E'4_A4M*K.;\\R>VVWC]T;;Z9^+S)V<\D("9W:
M8#+(2@]-_7%<]%N-NV=*WS2!JGA&Q#-:>8+(GVTS:4_,M\8ORE!A\_4F)#;/
MM!"(B&.,X5GX;+-(($)0 5(^L,*+M*.,3$]LL#EDDM+NNBA/&7O<C(ZHX1BS
M%7:4@W9ING;Y'-UY)D(D,9L%\"RR"/#X<R!,8]I&AS-8^">HA)#*3"Z30N%V
MES@6[#35ZI]4I'\::!16 R/B.N3EKTMT0X#WB%D4)%D$*3)0YOE_^YEX]=[3
MZA0F8F.*OX(W _+PMAAJ80-$70YR?;5JKG+A^03B.&II+^VM[OV?B>D?4G\?
MGQMY<$A+UZ&@]:@AB7(NV!.TJ83LAJ_55PEB_'$->>NBAZ<*3,HX16(-ZC>U
MH/R[T1#5A;<"35R-JWNDZP799:49O5E\C4^:"..-1!J5UN=[-R\J;8KA/S('
M'IVE+RE-_Y@PG%;4=KLUKG(V3;,H] 328[X6<W8>>C<W9J-'/0$M[9HFS.!K
M/JS'?WWY1N9^X,3OK15ZV27TL8_6/L9EEC[R^Q"[R^"):7 %9I8WT"%A.#Q_
MA^G/X:R3V]A_ R+?,,,'/P7$P78FE)+A%-S3&JT)*AH?PEE0QAR@Z.<#M?2Z
M<-0:XX=W2#D[/)I"N*\6U7ML;!\%>/)J./!T[4H5KO@3/4)T)$$ T;.*-X<?
MV>CIH:7,:?K&);-@EQ.A@2S"J!6N< V<EX8H$4+BTO#Z@ZS7=[8G*:->O=P@
MNQ3(WI.DUMBW/7U<^6VQR?YY%0J$NQR:_;H&DS:.T4I'MPI@6^\JFS;G9,[G
ME -@U5SHIILY1[#<A*Q<<P[4,"3+L!P>-.N89!E_!$=56-_NU;\A936[ 8<]
MGIM[/C?_Q&K>D<'\SB3UCG*-B\2<4Y[ZQ8L:*%S>Z9R<KR_5AYA<QDO->(,"
M"Z!V RTUGDVM);(M:-#&I'QZ/Z<#5S!&+[2D%SR8QUQN+CI5GO^HN6#\6U$O
M[J0W(>_Q?-YU*Y_VS[33#--?GR"F .@L/7_M0=&/W%/_-9_ZE17ND9YWD%AP
M5)4;<^/47WKV"EU]B*MV700-$SC\(<"CR/"O=%D^;CS_.5UPOER+4L\R6BVZ
MNIXCJ5%^L)@3/L]].:P\O%@\\[F8!30^4.S[%,@E&A<87<I_/5Y@P8S'3)P^
M.>*ND7M2HX)DJJ]3P?;XA^#&V.*A\2)-*X-OA@04_, )@8WUP;03#/A@ /'>
M69N[;*UYO4.G<]1/B)"[6,?*TV#ZZ837P["=3?D/V3"/DE,._]EOWG7VE%L!
M_!+KV+ZP,FE>B7[Z\AT5]S)HBQ1"V)E#R43W-^HVH.,<]:"L<E(B !)A"3V'
MP7'1D# :M+P%F2BJB%K;?\X0&B&$1$B+MW8ADX6Q7N)M)6O@-H"_.X(W[G'V
M#SVJDTM(XC./R!SB,_,*#QI770/EV+\F2=*U'U#4YX<U.A=56P$0 <%1 4CM
M^Z0Q@$Z/=Z_FUNP[HJQM67QL,$!#0M&V)I:\4M9N854\M-+=D*!B/P9WL?09
ML(1]*/FG]Y%;P9#L;O!0'"J%L250 /V]#YFX4DQ<56?9A?;N0Y;,0HSNX"2?
MJIMH!^\.ZX0LJQ)QY^?9D#RI:K\TE..H*\X]A2LN',FK3?YT&O?:7K_K:/!-
M>(DEU%\*3;"!50?!I$!XYT:HC\ F0@!^V(U,FG4,6TL@JD&/;8*%X3439AUC
M&5:Q4FBK):S,$L9*_Y=<Z/E]S"9! ^156G40=$,&LIR6)PNB19< M,MF]5*$
M<&UKZ(9-/K%"AF+7A4!7(G>Q,LD2>BF^29I \=,SE*O%44V@(:P+ _$HW5*M
MUW7(Y+2H8*_]NQ[%>717SI7D/2B):I)" _#.J2]4D5]B&#N\ ])@ VS\Z1WQ
MQI.MNYFG.@:1+#2XS [N+'(YUV"E/'PLB 4=8$%MT? S(OBXQQXO5;@W#7%6
M!$T;2_$4M"?0P)K66RX?_!>T.N@QN!P-R6&83\]!WBX)$]-0?FAZR5I:(0N1
M+."UL""Q+$0A'FK+./#@Q0Y[ '1(/25ZXIAKE_-#+J2B#%UF &M*BVF?W5MY
M%G/EC(JP*VU7QK][DC$"1[Q>CR"#1=8]D_!4#/Q:'=PS!](@Y@L_I\$-H$7C
M\.N547![V%,YB&D$PD\*':47#C]JM3VBYE-1U-6Z1:VG(Y<2Q,AU.J(,:<2G
M7V.BIL:0"7(I.T2HW!I88ZU9YO#N:*D_Y7+S671,JW3'+AI4U!5CT^#F]""@
MZ1"JC04Y0^N_(H &/X+T,ZQ*Q*Z.M?O''W!F*?IBJV2NH/>1+2[:,C1K"NXL
M"+/O0H8Q@LA9L*2"S6@U^+'P@PJ4KG!+>(YP2RL#E4B#6L4CD@#0^3M63J.H
M7^Y[CG?A[*4U:JI0+OE"UMWC"8E%75FU=KM[+B8+\.6Q0!CTE*P6R6$1W5BP
M&#$LD0:VTLL>RVP-0 7YK$'S157:4'["&E0I!Y8@AB4)P'D"6+,&I-<>$A)D
M$(&&)HMA<T? #=+0; DX07CMM@T]!E_>2#.(^2R\DZ?\BE->L]%[P4ESMZ-/
M--KL$A V%Z"1O0D2Q"B$#"-+\->"UL M^-# ?02%5H@#M2QH+;&Q7W.')?CX
M)L]HRVOUUE".JWK),B2\ >F_)C? DG1GVMQ/+\[(56[#7[8F_2-K4>&=H.7Z
MRQRAM7>:W=S-CC \+#X$&E=O-L0N=5:O^'M@</H&C"6$T'_();/@+9:P(,WJ
M;4&&;X*@27U'G]<BM[2ZRA)<CP6'(4,M/>2 8;?T5)<YAPY,;F[%(\ABZ/#B
M5>$7M1!!XEPV-$0?W8J'>23JF%J1/,6P;#&<IPZO^#4(N4RBBVQR#!T3!)<V
M6T++Q> SECJ):#A[38Z5AHC]QV("-'H3SA\-[V=->H"A\8YY*'B^#>GR_/I9
MUG>#D-.7*W9!\V8A [,QYF50A;-,#WF-OVX:+@/(L^AH'!.%+5%/V'W)HZ3/
M"T#\U0"+H%E&B%!?EFL\W=1Y$.>TG+Y(U<-.PD8'6_/XP^;Q3CJM1PJB!9?X
MM6:P>/C,/EU0DX9JI6]YNW-M#;Y ?EC0ML6_*<6DF![*0#W.0&7>E"%USVSD
M!2)8 A<C($0W?\HBF+ LI]OYGT9;4G@7::H#N7<E-WFJ!:+;BN3..E-8L$J"
M:UL:U,W%)Y &:T/']=.@]&8D-]Z@5=PFZG*-$#5O9MHZ"I"Q:-BL\;YS+Y@3
M[>#H6F0,"W(%YN3NGN5\"YS#0CR&:44 =CUH^-<O5C]^X+A=T)RQ?_U_\:P
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MNF;SI#(\XB5!IP2M0^C"E3 0Q->JA_?8X&67G7V$5?B"%U)@]Z$3NG@M7(O
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M0,DL.4"V,X %7V.! 2P77/:XD5W8R9)-N4#M+*!Q6O_6[/$LHW8\'.*K H[
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MR=;6H6M^LD$U*2FCKJRP;KZWQ9GB1WTPA FK X&]R]ID]S'Y;@4>I#86;T]
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MO(<% F8L\X.UQ=B:3Q*S*.D#S>&]L'ZWLYS3X;I@ND2S< -L2:0 7-+F )J
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MK%<-'CRJ ?W"EG,-F#1H)?X9TZJ<"7+B\,H]J#H." S%P[3<S?Y<C&8^[-D
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MA^$M3#2H[N7!-=6J]2/*F$CR-+ T2^@+B)N=37(_L7I>YY7DUHM-KU4G7#C
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MHZ7M8 <55VB!=\^<%[7XE^A=]$.K#-8'E"J=(<G[/7+*)J+Y[>2M+@RRG4?
M,JNNLK?%W'X\^!88//:8&!GXL&Y_;JW+P6VAQ(_"IY<M0T4UZ%*H(UP*#D$V
M- AUNJX9/SXN"X,&6;(C<[?&)1B(@KKAX:4!3*ESCF=L>T0QHS/%U,SL:4\$
M(BA NG@^H"^QJ0@GDUD@ N5<OGG@?:P3\I).6&:V$S:!C]Z3__8S2E>[PP5B
M8U;Y+=LOCC:'#/+J=<FW(J_7W&7 $^:0F^E]F0BO@2E0%Z,%.U^HY]7A<I9$
M\_+=DA7@"T(X7F$I"G\%:H,A01[[ZU7=Q:SYDH!D7P4U?Y%;/H01L,TP[W?
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MW^7TSL'V?MX:B;;:7@S*(8TRO0/?6:B&-5K;%/.#S;I[2@_*_ZR!\M#GVE*
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M]W[FTZ>I#W_/?)IY/?/C_=>?TY]_?/OV;?;'C\]__YK],?O]Y^\_?_X _[\
M@/H3\?_Z'[WP3:GK,Z)2UV]8NU%_?>JF3:F+&*Y>WE[>WH#S_S;^]S  9@YH
MU2@#58IN$<;$*4FC:N@5>]E$U,<S:/T2,[>L<8W1I&&,DEV"#T>'A@DMEIU*
M&KBP-J+&8DU[/?9\T?%*VW?XII,Q]LN*%_^%L\YWIX=8,ITFDP:)*X@D'[&E
M2T3;J?NGEY_TKVYH<G1RYIXKV2Z_G_7H_(KE1\[D-8V.+%>VR8.77OK8*P]^
M>- %9U?]\'I$>O#%W=Q/$;UT[-JXR';;,KI2Y[KGPO[Y4R4F;G]&ASH\0TC1
M78F5E;W;EK4TO]EZ9.#[N8>QH4XG-@?L_O[>LGU#CZJ7Z&K2?<GDDWXT^>L*
M*T9;WO%(3U]V[YU2M]H(4F&-YNP!X2_JH;S<-ZCK<YZ_76T:\$NBEAJ],;A&
M_?EWT3OV,Y'UZY-VZLEG>_^ZE/'SJ.9^I?7R S.*HTO1%3L3A;@)('R/;?$4
MN+O-G30O=7'-CS42"6PDCL[B,@]+>KN#&[D^];ZZV/TZ_A17>S6/8GC$:T6Q
MP>3MOD>%'BD:2NP!KY<#8L:77(M]BUR9M?J&$>TT)X%4J:T8I2H/5KJAYO<:
M[77_KN'MFO_H: ;V2R:HOR2WDSC?=4>A76%:X2,9?O'H;!.GX(7YZR/Q@^'-
M>&[>=[0^K^>'_>;E7TZN*8E@%B^G($P3K>KG<G+IC>GM=J!QA0'F0'1)X5N'
MYM;YZ%0._P-U/A<]):D]/5?HL6[B).WG^5/*M)Z#CJ>#8/FO.:O'$VG!)<F7
M$^H]M _CK%/+,UKVE1W^WA(/^[MPT#K?;,/CMC#'@X?P2;^=1DSS8XM/5]4,
MKF\,=<P?BS/;-G_@S&ZKVT_(44X^&6%=7;'Y'\\ZA-8XGP']N[?4^>\X-'/=
M+T(<)(L*J?S0\^^-_+.%Y*@I4[,>CQ;5S:;'VYLI4XVQ.&.3)>@OQ7^7S ]:
MD^(]_'F0LGKT0O!Z5*K#<J[7E8]R+_1$E0'A#VYJZ!O.P4MK1FM/+(GLVH$8
M.3(QY*%.&Y8%G[!%KCM^R&GWC[>E;J=WO9;%_964L>[QC0W>@1Y)-[V=*.N4
M?X]L^M19.X=?1LC>FGWS5.G!L;3FL> !9=Q6^TE<>,FEFPS,6)S T7-Z-OB
M;_7/YQ'GQ$D=[*V^[1MB-E7LY'X=A)!3PG%M&W[#-M>UUR)CTO(;#W<;!#WV
M>F\'IET_L7UF!'PB79NZ:@2Y\'V9^2TY?B=E\[L/)X=98C-N_?:?'YJ77]]S
M3QSRG;=<T)5\SF3[:$S_U$[J^1!#_['48'V?ZG7<-]\,;X#684-VCOIA*I%
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MA/T4,)2+&[I0177'+*2 WY#S:P%,XGI<<,82IH[:S,7MSD5X;\560KMW:DO
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M,M1B 1=QW"AXR-V$D!0K0.)1?:.G_KR'!XE&1Z65<)REMP1IZ_;\+:S(_P.
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MIXWVB6U+8KU<V[YR1610E$6L#![$9X/6I"!2Q *T23 %)&P0'Z=M$NI#5K2
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M'Z2^9O(.*Z6)*9Y*7A<[!@SLQBR/!U/(U;Y\7=%MMAD7Q-'+^-_@;BQ@0XQ
MCR0R4@--,0#K.8"'!D8'ZH/H4$0Q8#@M-*#+'[:XC=(%J*E@IU^*#]2L:B6T
M-A&X/;#^93#2+1,PF(5S<J4^G'HS-21;:XRA/YC<_:+<18!7R>NH8,E[B)QN
MCI8=/ABN7U("#<)@1IEV<Z=( GV2 ,<H/24383&PAO_&:9FAQZ$EG=#D#*3*
MG321;S)3?CA.;0M5 &@*+/QS=%\I<.8:_F95!.4.@O WI"VNJZF#1"2DI[L
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MX=1#W0!]$$$/"<NF5>8V_1SJMN"IY\6JK1AW' X&PJN/'%*QG*@LRUSTO_)
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MI/9?\FN).SSW^QD6GY4VW+!P*R>IJ]I#7A]2-E3ZJ'K]O2,1I]9N/W'>(U(
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M"1PIT+ +4(Q+*W!+9@"9Z4K(U",CA(SHL=O6D;EF[(.N=K2@V1ERDZ\7SHD
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M+W:FC %8!*6,&.FCJ.K=WBU/MKJ-()%.IM8""*(]Y@\_8(U)KAYOQ%K^7!/
M8X9W\JX.>@3EQ[ LK>MZ,< F2C\ [GC9LMA"\#U&@]M)]1CJ?>6BG[]RNHV;
M$I PGUYR>#$H 3A+3=_.?/9+Y,QXT3&)/B!2109>8T4:G "-LNTACP 8LY'.
M;PUV<%X::0+C$&:O$8R9.2;+=O/_@X*%K7;AK=L6K_!1KUUE,I*>^#&[C;C?
M(KN_*4X];/,(P5%[BI#&J.6(#_$XO<M$XJ8;[TLN_>$.)5H^?.'B\+%[UC_]
M[NPPKULY5Z2ZOR$E903%Q3SVH/8 C]PI?W(>CR'?JO&66U8X@.))(+E\-[9>
M1U,8R:O6O+R0LC\1I0S]PZD[Q$N%J J4O'[ZS2#P9?-[6J*D)_/I?54C??,L
MSSN\IY[YY,W9#<L0RA?OW)<F<NJ_O'$4]_5:V2"*.]T*77E7GAHZ6BB1/D=Q
MMY1/&7=))B/^6/3-[6L#@QH.[Q^DE1YD&8Y&"AM(79*4222'U<F;<>C!?')E
M&B^33)9DL3/9*V2^1+)E6^KKG8]?6VLF;^>SR$YN?BX=FGX>K0&GG>&UN?W/
M7_7]562U]FKYPF2I4 .J^S(73 !CJ'?U1 *LJGE:QYQ:V)41C0N5,.O8JXNY
MI*C4F)B'2D>$*7L!R)34(*7+,V,R10H,2JB(Y4"WR>=/&^<QTVXG@.S0H)AG
MC0EHNF&G4CS,*]"3+A\+HCP+7F>+!K!13",AVG;%=R,2J/%E5H\)RU#Z)2JA
M]0M QP"0YDQA&S%D%=G][8>?T0(A!C*AN#VKSQV\3QM5@BLLI/7KTC@HN=MX
M0/EMY@]  @PY.8WJ:)HAC:^/#I7X"95P>B.IX%991MQ?*Q%0\1*22::6-O41
M7#$!://!86[=&!D8QUHM:148E'D@F2^F=)_+ 2";$NIZ@4Z27XR4$#?$A/?#
MPF9S!7=1W?SEE11[+8?PPS6TF,4/("ER,HW#<JQ Y>HUI"^6XXAI\MHI=4L8
M,;%>T"P(<Z;P \E=VS06\%X^*44A$.M.D/+]/8*,#MLU_35PBCP6J2[2).XO
MY)#!LT#Y'7*Z9)O@*$$*"^QO[% )&N,)S%9^LEDBBP-MO3CH=*7SR4:"<C &
MF/6JYP"+U WPMJD@^U@*?L.PB15*\F=.LAWX>.[ZF7MUCN1GP-;$ N9:?@W!
M/C2\,2S;QRS=YZJM&5K0$R/O@UX=Q,Z.-'(^ C%$O#?:.']OR+^M,<T.&N4-
M+7;0I]1>U"L>QP['TX4-E>HC1#N:D.CFO$;MR*_MSC)CD#+Y8<Q?M> LOJVY
M089E:Z9Q2ZC__SRQ5<3A1(8T=$A)]1FID=AF,;#0M1Z5]+J3#'?,[DW-5]/V
MALS Z8;0U-%( +J!JW0E??UDVMHZWPC+2VC:._BUZ@Y4TRHV#+HM3_UDRJ*C
M21KGUM+WFI7KE>F#N-8])BAR-FN (;.5!T;BV!4](#]-U1Q*>$7O->FMV;*"
MY3:R_*$9^TQ:HRJ&+-9&NP4YO$PYQ,YO'SVH,G;@(],VHD28^)8[HFP66(XL
MS:QA_+:S.3*_@O!]=CY]'W)&:N!8FT7I[?,90@"(.*\CJGP;&@NP[*,:D ^G
M?HJHDVP_4^U8T=B!NJK2\XN=J:QPO%$0J_8BV9TYD^9"X2[Z3;](I1S,YVPR
M#L>DNR>X1]I,=YF^KQ>TIV'Q=30W7%;CA\AF]KE[YL[9D[,*EI/#C]_KQ>;W
MU%1"P>V'5T7^:H5/P]*YD5=)@M[$ACVIYV"S9)_1M)2:+BCVL)X:"@W?Q*ZY
M5JA#C->64]$D ['79S;#S37=J$UH;36-C7J4CLR@FI9J,L/-.CTU&KNV<7P
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MFT7OT7A:Z)9"]Q8/5_41BB/)IC#GSF)Y0]%,C*@WZO#?S?-^(<15T5(U4:G
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M(43.(,$I3GH3^"DP_1=S&. '7,L_CA8=15$2$S,%S,@U0[LQ#-M?(I1>V;$
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M8*;_A$YF)';:-*[<V/#WTVW?G3Y;BF9F*^%>L6L!8TR5K)ONQY/2F!TX*5*
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MZO;;]O#(MKG-6C;@>G#EIF\(C6RP&>/!V+/4J_-QYI6;Z2=MN*A[U_+M5U]
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MP[A'!%H@"Q*I#3&<T<AP"^R'4BB0'/_F@')-"E%Z\Q<-6.:)*")I9X7(9Z?
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M3"=L6EP2S^<?W7<XG$^TWC9W-IM4J(6#U4CPH,93"UIHVVT R)H)'B75Y/!
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M1V8[:M"",CYF5^4GF<9(#JE9''J)N&N;JVOFI?>[:V8R/N]_2@<-5J.]%N4
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MBH_>]O>?=#2GV,B,:%06\;IQN?>)TW2!^:A#X.4I2T\IE#!%<!$KG*0-%FK
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M80?%=15E?NO.HCOC6S,7SX[,'&0J9L.9,$1JGR*+$ _--)$7W[*94X<<VO
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MLO4L7[9K^OH_YB')X_M:IF]-E+>(V*NW&*E\_;2][.XU"Y+1?PM>$T'X\W.
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M<+$$/O&-VUX_'>>]!?C",^89%0;E@\!'E4%)N+20P_L$U%&MY>R._=%;Z0J
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M\PL,=!1T=8(R\(ZC578R#(HB0'?\?R+_/@"5D*5D#X)]_RQ%&=S]NMIMU,L
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M2ZH/WF=_47+WF)\JO4A^FYZC=?.SK>1EZJA$X^DT>0:V'OY]TL\J?]BMIKO
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MO/I]A];RJM9;"*3>>P%.[:P9+_B#RBJ571PN#XOHA 760@.YL)C:XN@.6+<
M@ID 5WZ&R"?#EW:;<FI'IP.69I\.?L[VZX>N40]^9A'=9$O68NTK[Z;F(O8S
M$2]R$91F/K&M2(E0YZP5D!EYG'YNO/)H^=_=AW^X3S[+OVA'KEO>JUGD(+DF
M#>4:MZ9Y KVQLPZDD"H;.]$X!,K\>E#M:G742!P']BSR:2"FY#Q@XZP@WY6]
MN7S48 ZO*;46,7L13B$-WA;8W/TJJ/]-<!,5M,$1DC!<8P-42HU-NVN'LKB"
M-P&L?:/I?SO/GND.9X=%$DA)#BBDGB;RO>;,Q]R6IIJ9Z]HOK@7<7V;U/Z+<
M?\2K'^*^J'R''$$A7??^._.39K^ZOP$(R#@]16WD7YM^VO8.VOH.SODWA_Z(
MR"<]8%+@(N<?!&KT'@CN/AV>A[W ". ^ZB?."CUG^1&4%E[ZRVW7/-NE+.RK
M3S]W.DN31!1:\;U:<=/C@H[6#@]SRNUG^PH$[E<???%U_LDJ7M#5__7O^7[X
M?%FYS*VB=P(!0M#WJJ'#%_PD'9^&#Q5?:VV[/IT?PX6= VPPN0@6#\'"/T[>
M>)"ZBY"_U#Z"W)2M@?=]%NRAO'S*?JD=O_- 8X%_ K]6_<C^B6 6V^M@ZE7I
M3?Y2C$^U/M@(GW+J#5_ S=:HUH>.Q^X[!][_]NS)8[+@_VZ^*S>;*%T7^/?T
MQ30/^9"-Y'!?CZ"VM0D)+0E"W0FKD[%S&]@."0?8O<[B/W8(9NVNS#4$DWNP
M.SJ$X,I]N,B!QW)AT7N\6(( ]MA7C4/9VV\\<P\\HV!>0\F.,:67_4RF>UOY
MJ1A^9K5%#C/$@@VYEC [S=JR-W_7Z-SO++]2Z2#8&+!R^^^+?X+(6?:>T$-(
MYS.(/I?O?Q2A-Q0^'\#(L2=07]E=^4_01"Y<P?&QRJD'*7N;#_\B<ED;9[AP
MHLD][5W8'9+ FSW!'?:'38)0G*%7H 0F9Z<DLNS9N797>=7(W+AJ*HN_AF24
M\12D5QOEJ("<!B#SVY<;-[8 \J_;'%_[7$<.)=PY^2^G?&#O(>FWT*?3.L60
M*HK0!P)_[*V>'[\66TWOG3WU4SG@"Y/2F\I!I![D#:9QX1>YUT?D.AA'ON*>
MAV^R!5\G7")\N0BJRXI\/65^:XUP?>S9AV<U+N8?FKSM]OB<_H=<!"#M/_2Y
M76_YE_>NX[C@,O[U7Y=UP*+ $QW:1-HOXHYF97?$;+VV $P+7:+J4+1FF^A\
M"J?M>YNL(S8V-U48NLKV:5![>.U8\JZ6[];4HKP9DU]DH!OQL.$$7F(S^]4#
M006C\VM]09;O-XR:7_0RQ:0\:^[ZW&E;&,V)EKS;R>Y-?+4JJ+5V,NQ4J=OW
M' E-SUAP]FVK5IB-O3[EPI<MG+<N>9;Q+UERK1(_,E]E$N/EU&4P^0>M=RT\
M;ET_>J9"<2S/47HD9$SHRX'I3OLGO:41QS<]WLIVVA=O]T8"I66W; UZ8F[E
MA:B_J3<;$EA1]+B1.F>=<^[56S "=?UH/.MVI6INF7O2T_I+U0/:DEZ^+8.C
M(.$#"2-O\@3MZG?^U?8[;>O#1 :V$^>7&--H1U2>*G(9H !C(O$C$"VMKG')
M\UHC#]2JMV_/Z9M-HA^FC4 K0O=!^*H(VA-N\:E8.R4KCV]U4$/M/N/"W"=S
M)+JUP=J4LA!QEQLG\FP7HU)@FK([+_+JDIN5R?8/S!>L;X'Y;5SK^!.;>][7
M\J#F/J&NM[1.KJ4W57^=>RDJLC_LP2SS-;9[.8PR\QD5^Q]KTZ&"#(-HX<'M
M)@>DKIB.UHPN\Z^A>Q;SAIK-Z(<9G\,J@LL4\_4!3G\FQ'3-NICC1TCZ(KW:
MWJ&%2-TU\K2J3/I3G0(3&XD%=;-W  9*L1P\;F+8:+F$.\..69I6;X*<+KV]
M>G:BE#U.9'3<ML?-.AQYU@Z]ZH2M4^%S-N6KO_^_WZ#M(SB8%E)GHK=SNRIF
M "JE.X/]XZX7HH1,0B=GVL$6(]H6]Z3),G'+9<XV5ID"XM\GZI6+8MWI2)/0
M"]G-9BGC(1ZF]J\_D(E9'O$F]6NV_--Q)1W?[7SJ2Z"#;L<.0\OV>0(I6D=F
M$V^5[&^==2GU?=>P]<29^"W4UU J1^QI7$_ 7!?D[L&'K[IA!U92^BDK<495
MIZ]GVXR1+_UJ*CMU;--*(6F8 Q*PMU@"/5J'/ ]Y4"[)9R#DFAK;=]?T-R91
M>'N?]-%$Y4;,.]G3O9^;)7R\*D4E6<>%5!)*18+@A?&BF^%A5K"38:\G'2PR
MB_6-ZVJ*<^)_J2J%EA5..8W6I.OA304M\2-FG74V.C#UL^R1NBMVL*AAEFO5
MG30[NMK/<J>N@;Q+KKOU KJ^&Z.&AK!KA9/N[_%/8^^<?]\IW/ML&_SQ;F'5
M4USSX*_P,FRJH/0>YX&1U9FOKP1"]_:1KF'BG@N;XQD.X?%>\UE:_K ('%&!
M+1W5Y\0*^5%H&FW;[")<-<D]**G+6_O\DOB!N/Q!]'O>QI-ZR0Z+$S)]"3BI
M]'F56 Q=]B4%7H6]DAY>3;\126M[^WK$Q++UVMEEELI W!6-)^BR%P1)?N-O
M[$PJ *(D>F:8@%%"96/K%9$B"$_V$8E$"\M*XC>!;';N$0&^C",W7^=%&[^Z
M/&N,!'0J<J;$$V06R2PZRR(_B@PC]4U-@)]:RZ3J?)!>X\#T+P$%8VL:Y$^3
M7.WTK6%2\M9DTWJ^)\25(O$J%BKVO-!$<):XT1V@G8/)TD3X9LZG3N+)E^_K
M9'D8>P)R$95->"U2&&FE6B8L8H]DJA;59N>J !%VM?61J$3%(%L+_F&.Y*.#
M RETK/ED1&P-[#IK$0,I>D\=SGIU&:\_$N$/EGV\=N+0D98K*9P@PP7I0[+#
M-EU'\U@,_?5%9;^7K:_MC@B+GW>5#5S+,"0YXI)#^$_&>Y9Y<I0N4G<V99_O
MC6;5+=7:0H*5 $$( F0458=F*A[6,=&?PU@Y[%UABA<=-X*&7*:F9Y 'LO(Y
M5N%Y?/97#>JICG/?:$U&].W#B84"CP!85YD!-<//B'S?_45!C*NEJWZ8;0DE
M@?PF]L:W=Z0L]YZSPNGL>9E5PL-SO76&=KXY[H=[!7UBQR3> 7UXQ%]$(ZRZ
MK051252YN4;95%^\;HTA6!6VJ++U6O*_8"28#QP<)QO3CX@%@<0A E"7#9KE
MHC=*MW!ZSL Y0V9JAWFDA@-1<^SE<^S3-/B4-7]QQU*AI<7:J >S4(_",:I
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M9CFDR /*30%.SU)A<AD<6]BI-69 'S. "[TV<]6LK3LB2_SB#G')FX[R!2>
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MPD.^=U3S2H1*::?UWM$\R\W!Q&SNI$YP8T^_W!=1XR%C)E1(:\*!]5R&2@8
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M:2'\&(P\^(N=ZSC+@=DK$=3V\,#:5HFQ094O83TL5-PL%"Z_S4'4TN<N!(#
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MVU("-#\I=B6I!PH(5D1V06W3<==RA+<'<0KE X5"3>:A1\@(,C4!_6$<UFE
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M*_T$ ?Y_E/Y#V)T-B@AS#(J(#(D6B @Z>S;H.$;/R-C(V!B@\W^/_PL& #L
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MH.HYC=*"!D^ZPO?<*\[0]7L55)+ /DHH4QI11TJJ(E39D$".&+ ['NS)!0<
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MN,!D&J;\]!LX4!:J'(E].W>+>N8@^7-U?>(8=*%G2F@#2D$);$M/3V"*FNS
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ML]$3X<6QG^*('W0OA*0,.94*0GE&GY_?V=1%*__0I ZZ A5^^6BQ_Q7P1-$
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MU,K12*48YAVY<O"3<^1=XHNYC(_)OH+HRK3X((W7Q%G!8W^_3YRK^?NJT.G
MH:28()LS33PU??>%NTJ>IH<.'7'&P<%@N,4)/$=M"&B[,"3LO1"/T//!*KT6
MMO'"D!&2G5P*"&F+Z@<IV#J3D=8-852)DUB<A,CYK1AP6;T[F:J7H:MR4N31
MUVJ$X7,8FG"$==%JN^*VPP?&4?\CS+DC\GPU+L<JO(<^]NX?7M=_4]A2*-C?
M)"V7;_S*G3=_H'/1:.KP(SO1'#D7U?!AI /LM56+2^CNG?N*BHM#8[X$#[&$
M!TV8_@>'(K8'X/[&NYVB;H0@< -*T>6UJ$?EHSM:%/%6?L-S3UHFS;<S$YPZ
M%Y-G!$P*PXY/:50F'T][S4?]NSV[*XA>Z_WA8WLP=>>LO;G3@JYWR$[6A<]#
MHCF73G^0U3IMUBPF:G?)R;-E*^M1,?(DU]A#+_=<%577FF^19U64M?#S:;!\
MA99D.3;C.YG_5$C_@*;7!7@HQT)ZE)$NY^S2?3[14DY/^/41=K- ;&'TZ7<E
MD-W,&TT?O(?DGAR2[:6<R7?R8OK%V$./X6</%[<-R2VR%OL'JGHCF+;GV!,"
M@]4&<)<2B@33%BB:[PQ2FPF[],1BH* :8[C_MM:T<W8XK8*M#:P0NA0MK/BK
M!<-NDMKA\T*#\YQXI [WADAP.FG&?=3!;'>./[3YQBNDR$#3)165=>0-'.-(
M!^R6P-G7W!'CRH>"4N,'.X$,BN_12:4GLJXM5F^9-*<3M0_[KO%J])%I1C6X
M'#557)8U%IA<P=91=1_E"V2#G[0!Y5%V:CKX-(HXDPMJJ3SMZ\05]J=XRFL)
M+[I[H*V!+S+XO3E+\CNV6:;89WD;>3DR;U'T(_/?^H7J/_@-V=-MMMTKL06M
MLM+DUR&;'OH2L>G&>3&R"R-!EG(%@W*O"'RF RXWN[WO:)C,31D9+>:&F_ >
M>8:?%RUT!C&VGO-=?2$H_.Z(N"[[W(DT/ON_IZY)^:*C=:> (:(2,D:>'0]*
M'%$R9<]5<X(XRK(;F-%.LWZ!:.<[H@I\4-S,LR.+EY3] WCOVNR7X++08P<J
M&87.1S>^\5DEI<L8%48<!4!84@-G"[X;04U'KIT6?6GC]K)S*K9BD=^10*D,
M*1I!%P JJ!4B?%<M!\!Z#.K/135;BP&J>R5OT:JJNJ3"WZ7V>G:&:B*8[V[#
MM+#@C>>''N5+S'M!WS8$N46A,V5>P22S^[[SG=^Y=S/@&/TH-E7C'('54E0T
MYO+)6M^,4BWZAC5BWZYD1ZA;K2UHBS ]E>AA%W":_G3MKCITG,^)&"7ZE$G]
MB4WJ5#8BPR2)BI(=R,=W.S]>^E)ZM:1^K$'A295W??( TG-'=54"![.M!.I=
MBZQS+PG&/!^#/&0_<Q^GU,@8O?6OD*"@(%2D]0%LWD:9Q^]%-(MX[T/!6&=A
MV>'Q5U-R';U;9Q5CGG9Y\])%:0W;&.\CCO#$RBD"1./P(K_7F%+6P*ZB?_UU
ML!ZQ'^[$LE[R$5=?S8PT/4T"CE6R[#VRPV"_?'E$ZC"N_L6:DI'!G[5H2@+=
M>>V#"DF0,''5:PV[GQZ_ ="/LA:.@1S39<K8DN0OY_,P]C]%9W9 \WHU62F'
MO09$BD--T693IF^NRTGTY*F;%V4)"15*3\Z"#E7N^E?QA]UPY^2+MF"I7*8A
M?#P+*(82H*HY=CVW\.H'JQ/-A<;47AP>+ )GLM:L4\GPG)M/K[DI(8*M/LC
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M_?;MC:(+-K#7W4.0G70DBRUXARD8+"3YFX&/N(A? L>F^''L)K7^,%SL,$X
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M54LOK\MI9)]GG@.:9@42CCW4"7R@YVW2$E]_:-^Q<%)M)+C9 G:ZK=! ?@
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MR=7:(*')0"PHXT5#7-(;)1'Z,-O6VD)G1COZ(5*$VO^TGQ^-K?,'0) 'A=A
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M[O[GZ32Y/A:?0]:/N[QK_2YY-</E0*S>2\5=DVP 7@J+!W0PCD[4SET'06V
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MR^QGROW^XU#\8PN[YX0\Y2%,^PV(;Y;-%\(UPIQ\[?E5KQ[4<-1#4I-4I(4
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M#/^_=2U8JZ%*_X[\_L8??]Q3,'2DCH9U2CR< @ D(<H-N.2EA.H=EQ45CYG
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MK(;Z*.;@#KC9-Z6M(EAO[33<9-R0%78Z%]JL ^Q^ - $B8U."'W01HT%)8$
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MRIT3AZ0_%W/MD[PWQXLR8W2<'D=H[*28%-^X6GC#?A/J2H6Z8DJJ)XI=J;
MU/UJTY(P#'.MP/WZI4Q /LN!X9'>>?W,VVRP)*YNV&P)%?V"AERDI_D7(Y\*
ME#TQ02*OART1V=?_<UI^'H@D@80!,(8&QA K,>CR^1^@!=/R%_4YE!0*10X
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M4 +' B PR0=)!4GAP):;\,/^-\<QL+!L9C(*'H>"%_YA_A;<8-GP7-NBQI4
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M3E_%F[$(N.>)C?+?R?VT].IVBCNLU!];LVL4-$@.E4D*-9<?#>T+-01!J/(
M"7V>5#$NWCGY34GZ_?6TL\XD'M[)[X?ZG5,V^+M9TP-N,5).I[5P:%^H(AT-
MD86?-"FP,ZL'9KM4\$T//=)<)4EDJ,JZ0)"J##B$[5\RV;FKLH65D_+.GN,K
M)D$6:X)<4S43!0)JW4,% UXF.C_@YQL=%:Q*;CM?&AI^=U,. D=O CRZP.ND
M]ZFT%WF2X1V-IMT.+!H.'HV2G8IM@TYO6LX.S4_EG;5F42U0]:V/><J.QA!
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M)6R1:'1(8J_+0M('97[/R?PVR(JE5'T;/SW"SX[#L2JPI86?XN8<F)+23X\
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M&F%(KX,PI$ &B( &9( )#,$BK-NE7[IZRR*2AT &O#L)</J$$C (7%,(^#,
MIB4Q >9?KB0MI/HY\%-6PR2L%_PP4*./G?5=L2S,TD%F'ED>.]3,AH'OL'EP
M]S5G]AZ+?S0XS'4,G04UE/A)6]Q';3,;$/M?HQ3X!8BA(#KV7(\Z-/KU9 ,\
M0$,)8, %B( )T,#3)8$SE0+0 WWK-EN1C_M[OS>G$_ER55, :Y6IH[&_ISHZ
M0,.!EZ=Y\A,AZ)X%B10R+_R."F[$4Z8OF(EG4KSO2%(($;N<</ZFD$;"(W@W
M.(0##DO-63C[Q.U0#Y[\R<.Y=>O%BQ,Z-Z!S$3*Z9Q4A.;2#(:B !(C & V!
MT .]*9A"T+OS#VAZ"*B "FB !FPZD9= /(= "NBJ#:# V\JRE:/Z'T$#'EQ0
M7/ 3/_V*M,J:'10M9TIJ"^<Z9=X$<)]:(WR!'R\B7@7_AC.B=\]UE6V+F.7Y
M??18UPE%)&@X)NC%-F-"+EQ"+\CO,A &HA<^5W*_.JA#.^3#,YR !*1 ^1B!
MSR=!T*NWXP^]<A5Y"&A^_&]^!L0ND3L5%9N #2!;2D;]+  20/@1J&>7GCY]
M_/ )!(B7GSYV_JRA,VG-I$>X'F7$M?ZQ3L<Z<$#":20F3"-'AKX8*CE2#!LS
M;-;$E"G&(CAPX[)EPT:-)[-CS'KUXN5KXQ\VDR)-4DIQ::0_E70% X8L6;-F
MU[!V\[;5FSJN7M6I*]=NWC-'*&3<  )DB*E2I=R^+36D%)$?=V> "!%" P05
M%RY T* A@X80'3)DZ!#"1 U%B1;!HC49';ISO_;XV6.',\2$ AW^N<,&YAHQ
M8AZ5R?@(3D:/(5N3_/*%"^W9M\>(,?.2-)O3IQ_9!)>3)S5FS(0="^HKU\:8
M2B,='8-TZ:1*4($)N^8,*U9O6KF.\]I5W3AR]<J5RW?N[A CI9+(?;OH[9 A
M=N_^R+L70OY_%8(%&^R##Q8SP0=%3H%%LEG,,0<=<W39I8[-Z+CCCC_^X(,/
M/_[8XXXU2'LDC9)46RTUUD(J XXRJ "#"R^PX *+&&.L[44OPAACC"YTU/$+
M1[89;AML=EKF.&*"ZJ6Y.F3J+9*DH%L**EVR$T899[C+:JMNQMFRJWC$4:^=
M<N99;Q&VY"LE%;F&6&0(3.[+[P<08. /P/X&,VRQ&0Z,#)99&'3P'T@ @</"
M->Z8P\(Y.K2P#3+8Z"(,+L((XXF,GJB44C7*X)0++LJ0@D8LGL B"AEGG%$+
M+5[LPHLNLOAB54/ P4:GG8P[3AIA>M$E%U\H,HV-I&BBB3HHL?ZS4IEEN^O&
MV6[&2T>=>.(1:TQXU,N''3CI2E.^^X@(%[_\]-H+@W,'_" $$$#XH<]7)@/4
M05 ,&08.2-,@@XPVXIB#C#D>U=?53PGFXHF"N5!#886M6/@*+*YXPHHG2HW"
M8BL@SGC5AU?E8ILA=]KI..5X]86H8->8;CJDHHMR$EVH5-;*:ZRYQMEQQ/ON
MRW?2R8><=GPFYYGUYNJ6EC73M,]-^\+-;P88V%UWKW7;/3"1!<UAL+(:HN"%
MC"[ !EO?L;_N0HTKSK["X"C4H)@+*:* VV*XY:;8[B<LCL+4**SHN^\KK  <
MBRVLB()((JMA)E>?B/'U9-).,RV2F/[$>++R23!Y61=CDN%<&6JJP2H;9[VY
MYLMXX($']=15G\?U?,SY)!$U4S'BE-KG2T3W(1()%Q%W\4(A+Q#RFF&&']I<
M9+(&LZZLB2B4*>,)*29](M1.'59#BHGKOKM[BIT(7_PHG&CB^>?S=B)O@]VF
M>,;#16:&&/F15+*YR4W[S;1)AHU\\NM@9@QC'$,8U%!&Z+IC.F^L(W7N8!T\
MZE$/>+0#'O/ !S[RT8E2'"$5J3C%[>0"&2+<!Q'B\H$/G&8\O+BK39.AS(,L
MDP)$>.,1IY)"&:2'!2E<00IW U_ZPA<%BN5-B. 37_C,E\3R/4]\/APB%PR'
MC6HL(U?'(/[&%8'1*UQ0I"6Y.8UO)E$Y,3YI$I<(X#$&*(P"=B<=W% ' U6W
MN@C68QX33-T\^('!3]"G@VKZ%K@PX;L3GA O,) 3$19Q"A?2HC+F\,<B*!"&
M:SQB>NR+V/2,Z(0G+-%\2SBB)O'6!"A X8A-0&(2S<?)(-[M"D(4XN$6=T6@
M],(7NM@B&WKT&UV*L7))J<0ES+BY7B1'&=UQ1CK6(4%XD -U<Z1C':&)1WV@
M@Q:)H O29L>[1 0R7+T+%R$/>1=$TJ(3M#C'.6#H#Q10 !%J'&(1>_A)3W*R
M"9Y<0BHUN412.L&328P"*DUIRB""<H@Q.E4U$'H<QLTR*+G(2/Z/NJ %'FFA
M1V.@:!;$:)U@<@)FO<B.,[B!3'G4XQWN0-T\)%@/?-#Q@2B]8#YH01^YT&<1
M;EK$"$U(A!/:!3_B&L(B'60+1])"!9'$RB:OD$\HF/*>3 6H^4[@SX ^-8E+
M!>@__:F^NQ4Q"LLPTLB4,TQ=T+(2%HGHJM":UE5E00NQ>M(O81;,8 0#&>EX
MQSSD <%WM",>=%3I!27H4GQ4,!_PP&!,2P'"$(+K/H%4A$[%^0-Q$:$4RC/G
M.9J'CA\40 20$,8Z&M&$)\S3JDWEYU-'0%753I6JY?NG5MUVJAAY51G'X55V
M>F7+2CRB$6B]@A9^^UNUKO5R903F)?XJ$8QEV+6"[X@@//9:0<!>,)H2)$OJ
M#DL+;RG-FN B0A FB\)PM9 6T&C0+&@Q"TU<( %.\,4UUA&,$X2OGYU,8E/-
M1X+5VO>IG%Q":@&J/DV>RF*DBD(R?'*,+(XUM[G8[2-D!5S@7D&X$M9"JK*0
M!3+^\I?&>(9=]]J.=XSTF:Z[X(GQ44?6H6ZE=#33(I F4][1A0B/#5<0P-NT
M$5K6G(":#"(*4 $X].(:ZC@'5IE@U7HN ;^H52V 4:EDU2ZQB':SV!..@4:8
M;5D7UU%*(R)<A2HX0<QEQH*8^Z:J+!@B*91(KC! 7(YTK*Z"9;+@B?\ZQP<:
M=A[,K,=ZM/X+0ON40G>)>*R-@^"#1.. !D)(Q"<4] KTTN(4BN@  43@"VE8
M8QWR$,8CDMJ$$8R R?<%Z CT"]"FCN $36VRJ)^Z5 '#%HJ?&J QMGP=75ND
M$3 2,YG'7.8R;T',6\""6R,A"5TT8QUP;,>8Z$P6%-^YQ1>$X!WK2$$,GH,6
M0T :78:@"*9]][LXO@L.@J (/\$+%HM ! HN4  F#*-FWKC'.JY!C5Y$ HI+
M( &3 7[/_[Z:JJW>;W^7>N6M B,8QCAN69OBB"Q@P0I5&"4_Q2=F* B["EM8
MLR,BL6QWD!2Z[D@/.<J1.FFC6*5_!:PR#;M2UO$CIN\I!2:*!OZN0]\8O.E6
MMX)@<8I%*,('*9!  MPPC&%<0QG-OL8XQ.$-9>B"?*-.0:G]_=]1 U2_I&YU
M5)\<8%&&;X@%G2LP+<&R1D0"$F">N,6A\'4GS-=\&Q^VJB(!#&_$PQWJZ+LZ
MVO$SE*>NQ-1M.8H!"\%\N$Z9%S3'3>LC;D6(&\?EQC&.)Z_N3XQBZ(@P@082
M(($Z6,,:XTB'//#=#7&L(RS7D(8O'!&%_Y* U*2NYY.7T&J"KY9\!"4P%(][
M"4FPK)<2']PF3_#UY-]SE':/0A6>D(5*),/OZ1"'.M+A#G*8-![D8!U*_=KB
MPZ.8=<^V(.LP: Z<5Y9I0[C\^WON\_ZA*P(1-9!!"C!P@ K06SPB]8ZTRB,G
MK(%7'H$+^ G5:,_5_"VUP&[WH R@]HE\%.Y4T.XZGB02&"$2LL#XMH!\DN_K
MFF^4+"[YK* 1@ $<PN(;N$$<M(\<7+#[)B@]VD&9G"F"$&^P^.R.GDO:M,L^
MK$G<A@ 1$FT(?0#=T@T1J(#H:@ %4B #*.  F* 7LF$KD.G>3*?9U*$;2D\+
MNZ1T?*$1N(#)1"#K\.N_3H#57NV>'K#N9(U\GB@*+,'-)$$2,# 2)"[#WB[N
MOB[W/G"4D@\*#.&SY '[_$[[Q(%:5*?\QH*O($C\7"Z/J,MUZBS%S@]U\B$?
M3N$^VD1<X/[O\G  $>BO!FS@_C(  RC  ** ]+ B'=+A'N1A%<=#];1B'%A/
M':YO' ;P$0[AGTB@%[=NX +N##NIR9I/ K<*"RK!S2XP"QB!&0\APXCM Y=O
M#T^ ! #Q%])A'MIA'=XA'KJ16KK/^\ QVE;GQ 0+S_#,@O+AI2[1L"BH': !
M%$8HW"8/QWQ "%&H!D[(!J( !4J@"35  1H #J2AF*SA^O;A'M3A&N@-^Y"I
MV2"R%COM'B@R'80!$DP%U48MX)@@]["NGJ ,"O+F;M9&U^B0$9K1$%02&OVP
M&J61!$X "APA&+Z!I+SA$*F%F5R0F;C/&]]!Y40,N_#!'FQPVOY>SL0HT<3J
MZ(+TX1P6H0:"(!'L$850R 9L0!1MP 1*P 12( 4V0 ,D@ (TS1H6*%2$P1_N
M+2BL01W8(2+=<B+E(1_>82[3H1DN(?9H;R/-,."H2N%B:T:N@PXC00Q2TA"@
ML>.DL1I[L0HJ01D<R!V@KAS$01R@[@5STJ1,JAOK*![:8<YB[@97RBA=9S0C
M""GK@1[Z@1W^01%PX ;TT0:.YRY@4P;\,03^,04T@ (HH 2$0>G4X1\L8 (L
MH!<2\AIZ8>GRJMGD83F5$R)'["=';![>81W2(1,,0=1(3>NR\]7(SLK*#A,J
M03";<<U4<@N(;00_L!>U(!B<RQW$P?X%RR$GN*0RP=$=[-,=YO(G5:<SRR$>
MT!'/7"X2ZZ@T1S/%%J^PW.$3:N!XK-)X7$ &9L $)-0#M+(K2Y$"H*<72L\3
M@G,"RD >[.$:?&$8J$%:.HTY40_UJ).!0NQ$[\$>["$=)"$*>C'Y1(TOS:?W
M" IOH.@)!!,#&6$E#3,+B"T*DJ]&MV 3QJ*D[),RQ^'D=I(<KH\G\1,_[RIU
MMJ\<1@[Q I2.4FR.!C3% (OQJ@$-UH =8,$'C"=")=0%)/1-*U0#\(\"GH#T
M2J\2+" XI> :]L$B 4%#5P\NEY,Y:W&O!K79\H$BU^$<9K0$8!([":X[?8@+
M,$$P"1,/B?Z42+?@ Z-@"W3A&5(.'OHN2LG!/*+4/:]O+GUR+E.G6K[!/B'(
M!B4(-%5*Q2"H3!:OK^(A&J; #8@!&\ !&NK/!$! 0F5 !N 4!)IP PHCTQ9R
M*]X@3RU "?) '>K!&D94&L1#4 \U+-ZHTZ93'NY!'^2!'>2!'^CA'""A&K.S
M(^^I?. 5E%II1IX@V8 4#X?4/#?U! PA&.;,^\;D&YPT',)!2J%42JL%/ZDE
M/[^1[]SA57^R!N=HVBQ(SPR4@L@A%]Q@"N9@&K1!&\0A'3[!!T  64W 9(VU
M*Q%C YJ@%Q;2=*1@ I3  J;@#3@-'JR!%X:A&T2*'I:3'5R1]?ZL3SGAP17-
MU14IDA[LP=.B8 P#SK2:R(>BX (9X1"><<V(M..V@!&,8<Z^06##!!S"H1O"
MH1QP!NHFDYD2UCZGDQM_4AY4E4F_(1UB=6)#TQR3$J4N$6C*00^F0 G>8!K"
M07##(1W8X1-H\UB+M5C?- ,^H"LA@2RO@1V$00ED=EK?8!C4 1[D(2AX-IG$
ME2++E16M[XTX=U#O 6A#]Q[H@1_880L2$. $:I.\TV H%2FL5B4-<T:R0!*@
M8>3:@1M,+CT.EF#-=C)9T#[Y+BP8]CGGH3[EC()B-59!$X/6T74H*!_*X0ZD
M ' !(1S& 7RCSG!!X621M5B/E2L[H/XK9< 7:L8KI"!/E4 )I@ .&O(>M#"D
M&"ATQ94ZK2]53W0Y17=UZ8$>4M<11,!=F2QJMPIO+*=JH='C,"$9'.C9M)3O
M2+54P5<\KL];L=#OXH$;U6'$EC-N[=,S4VK\0M,><)42(P@<V&!^IP /0#8L
MW*$=OF$<W($;$(%"9:!D32 O3, V2^ 0-'0M?6%F9;AF]T!#1XH5N1'U7)$Y
MP:(K1JQH*3*+*7)I[4$?\B$U#>'J9#='=W1OJ'8\LP 3L"'P E9+[5-M=_(]
MSQ9YO;6."['9&)9SN]$^IZ69G(EBKS=7XZ$:W&!:I> -I$$;N@2*Q38;O@$6
M4L #BM5X)/X4!$J@ U#@$HYX&.:WDPNA9M]@%X9A'#BW+5'/E%64%<,B'I:S
M'K*X@.UAB[-8'_2!'](!"_ZMU)AH).T&"Y(-C3%A&P*O/OFN'%[U/NM82M$6
M>3NXCO]N.DGXBGU2^Z@EA578@LI$>GN!">;WD(=!&FSF<]>A&K1A;-G!!CX
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M$N[IPS_I;AQV'/DN8>VXSVV8;??X':9[,KMDT+-]VEG5N4AJ0%L5'L3ATYB
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M.J !#6. 4QC0<(8SGA$0 #M02P,$%     @ R3U!5MEIB'^L7P  \5\   T
M  !C;V=O7S P-CDN9VEF%%=U5!..]UT!VX QNG%T(R =.E(Z)*0=(4Q I$1
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MYBE,!%2@GBG<[#WYP![%@%:BB^%S\2=,J#K&MVHIZ9;0P%,/ !33)(P#2J#
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M-@DED1LPI08<Z)V:_ZV%3)60HJ)TIROMZ?F&UY3-+MUR9);0 ^Y\Z3:#G6$
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MI;YV#G)0U7"/(,Z'W.EH/QYJ6/QKJ&YS\T$#1UC3QS#S.HL$O^8I[#&;Z._
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M3Q EPK_M#1])I/:N:+]%U2<]&SH/+0@^)+FTDC79Y5XX;(7C'HUKOS CX$Q
MI)*=FZ.1UPD5*6Q^VWG<];;0X(>ZY6SD":X>6A"Z.1?&)AQR0B)++DAMTR['
M5@0?ZWZ..&=S+!(T^O O]/GA?A!YKKFK?E%>PKO[[#ND\1[;NX1/.>"+P>/J
MK\34/FOV$[Y8?@8Y6VF U%WWNZ)[_2)UY+>Q9F<%>EH IG\59@&"A1AHI_$Q
MTM%A9ZXII!!PW>2+<,O_.-*O@="UC>/Y#L+X7LPELE0R$]G9W;5*4W%X\&BM
MZ?F5N/FD2;3?1=#WC@ABJ],BJ41:*,.3/H2[QWO&Q-^NX-2W/CM20F/V3A63
MI02D5@. VZ4=#0?.H9P,9N>+GNFX7VO?V2B+&<G(@\E0\0>N#/-G%=/X.!?Z
M:\R$24OT"A#1Q.VU+EP-A0BAJWL!]SE5+QJRP;=%#-6ZIA"SU@1SA%/_57]0
MFIV&0B._OT(64X'>7LX>%X0.JN;=V>'-RF'\WA8%K8GN/"RR=RC<V7A; -JU
MO 8ZOJ!XE8VV(  +945E^I^&G\\V2]ZODE_LG\?T60#)H/G&'YBV2H4G9"R'
M0 OW/;L//3->H[O)&&F;^SK$0F[.H?=,%],(U6O<RZ"=949WK5/SX\L@D!)*
MR:,,JR?&H]3CSEW_%FWDJF'\E/T*OF (B(],/=-IV]H%3 #9&STI/^("C]O@
M)A'.IW,AOC\IB4GN3ZY_5^H)&]S##>R9C!Y^'?GX9PL!UWBX:2GZ[G@: $V1
M&M. ZO4++3#0\V; )&KSA_:7;PS1[S(KF?JMKV>[''W_^A!UFT@7"9?W.)PO
M(4IG*\_2T>>JU>68.HZ'_2Z8[/W>5I!:7X(O:1%=TB8 G+I>5W(O6N!FJ2YM
M@(&!;DIB6MWJ9;6A*,WCG-/2-[S^6JUA.L)F.P+[51TJ#<-Z.>$2WX@XHZ"G
MU0=GP<5.^^%(@7]3][]=;3Z5E"2G$62??^U@])+0RY3I<I>3=I>1&E_OSK3<
M>'P)9)H>AM'+G'X8#A9%^3QLX=>UN-2HH[1]/L_,G_N25>QCW5NFY5H[QFKU
M3RB%N];%:K1&IA(/:U2OSNK1P>WA2D/ C![M7M))X72H)R4#*NIQVYB(U,^>
MT0Q=JM.ZW9:/,$V>K<VM,O3K\>E[E_+#3GC/PJBPP^)/-EKG=MRJ[$M_>^-S
M-3TY1R]B2R-;&K@E@2H'PLK]7].>)=]"'?OY=JUE[MRYVUD1ON%O57\-GHG'
MW ^<*2,H5_^L:,N>T8UHT[&W?0=%8'3!F "TKK0P@D:Y4F/AJ5YKFP#040[%
MN49O E)X1OCYUSS#=U$DS+X'/WN? HIUR27R29-GG\K'0X01\H9OF7BJW:'!
M3ZY''M\9TW&70T"),P6R8W%O8ZS+C.=RKF8;?ZJ(OZZ49^-ZPS>Q]_3KPC<Y
M;1])+\R*3Y7CB^*4XZ9B!ECD")GHUWJ6%LIC[E6'P.R0\U;^@!_N:\;'"EQ6
MG21I0#JZ2N["-#]M3U=KHJY.KE UZQ;19'/FEIZ98WNQ;M34'<F4F>$A:+$_
M4RFOY,SWHF.)48_F;4I/=5C;%]X8>>!LMTLN'M<''$EOZ>@O\8#E+-$S0"-#
MI S36G44H.N?=]P=+Y>/,%YJ#[@T\$%OH%SM@'WLNS91N<()YM,K"3:AHJX]
M9EO%^2L.L3DZB?^FRGW?VA?[LF>2XJ=,^+?_!&@[]_P.+76/2 @H3!MR5S-X
M$_.BL'F2MB#)Z7%$3%GO$],8,SI5,^3Y;#T$F9.\1<Z<:4M8#"&DX^(\/2_C
M!E5QQIG7RZ$Z>I5G_">S5!M$=7I\CJYTV^I(VNOT:?;+VX#\^L>>O(_YM"?7
M, V\4_=IX(9^Z=M7J _U?,=0PAF<8D;'-N.>:/VZ\<:&!-?OI8+=ZU2DE&_0
MO(]#"*/:_3GE&;A=KU^9IPSZ1?<9_X1/RQ6AT3&=%^:F;Q:(.*2-325=O-Z6
M/--FO:_5+9(BZ<7W ;\R> CD<-3%L^^-&]F.#%W/G/:1@\V^SQ';T@?.#O.L
M8YS>PXUFI(,5@C94 O;3$4@K0GO2^H&@L3[W[%-;V:2];&*!4OM3ZE'VA9TO
M_41KZ6^>CX]XQ?XR[$^<MI:Q@9*.-5R+76G*R"C;2!VWZU$LLPDH-@OU 9_A
M<]\:,MJUYD!V.#Q_)MEJ"SE-KDU<(U=LB.S?NY?-S7'JFRTOM]QFEVN)X<<A
MPN>2^"1;^!<KDEYE30X_IUXVU2;QS4A940>Z2X&"6<*(32?SLEP,^HE^.XZ+
M+FG9ZRR5L%Q(5?,F(B=D8,C@#6MHV7&J*R+ 7_^RWG@[E03M<@B(;^8-Z2K,
M9YOP1#'H[R_FM/ONA(KEZ_($/HBM!,-#91LPCL4C1+73MTQL)H*MB[-J\]@*
M/>:?==I'<JJ7^U3^Y#0=4A2STOE,@;8SA0U/K?G)\FYRU&4X'K7\80_J?.'=
MLY2RV07I#OMBC>8D?X#%%,%93Q]TNN)(V-=6<'0]>*BO9#4?Q1P*[M/7$G.F
MF%))LH:9S@?WS&P<I=S?C+BMZB''\/V'O<6&C!_H#P3J*QW^C?$U?2Q\APZ9
M"OMU>^A$T-FR1]!). 8GV6RQ84<47 KU^%%,MVBUA=,SR.OO?(U*'I1^A2.4
M7I#4_/[4/3T5;G]BZEP01\0HFY[SXG!_ M0YTR_#5.B.(TI,A*9047&N!XYI
M5[31;;SE&!@C=LRZR.I[6%I-.Q$<>;]<6'OURLA%D^32.V*\3-K!.B^7,'NM
M:YF7W']-AI=\Q?1QJO17#4=/]*PEIY'JFA]NY9KUY.I>PE<?5[IY@P[88ALA
M(J1MW0R3V]E5CKLYE#UQ($,3<F>DW"GI:\I,'+;!O9^6OE?]4#)H#W(+.1UU
M5.#T:16]G0S3L%]VUL:*Q[*<P?KN_Q91A]9S>$)UVK,)=1X6%F_[*EI23[__
M)/]&W<P/,Z3O_N6GKL5\N;O +2#)$RV7M9E]PME28\;<ZG*;XD"C>3PY]IE+
M]-U$SQU=_Z+<P:'E@9:NH(="Z%93J2 Y<FUV:G#)R9TBC3>&Q% ;"H"I&&:I
MN1]K2E:]VEPZA!/+@!]9+,P?L=382C6Z]T!;36ET.XN<1&_"8-8CI=_41+,E
MRK>-![1CV4ZB]4'H_HF,VIUBC0_<L[E/NS6 4ZXS2YE'55\'%%!]WQ4$[QL>
M+0NU]#N]JQDIE2+Y>D1$&5E?QX%%OP+=W_O-?;Q>0*RO\9^$?@H[D!)EE\M$
MWIO,57[.^D034?HO8+)F\B?+GY*DUX5O:$FW.YY5NM9TO^1U=\M(([T#409'
M+CZ0I[Q/_XI3&"IX1FRJP5U#I9*^:$62NPR"O/:%4^&+SQH^TB#7%12=(H#;
M0#R#Q_OZV67QE3#'RSG344YO0O)TX&&OO&4B["CT=*J+77*,5=1ZXDF-1"7_
M]ZOIBVX/N"=)D[CYX+FA.F+NW1T3O."OH9>&M4M1VY6L)Z,SLWH=/V*6SL^^
MG; RJ>7G1D9>F.UIC6OF2#ZXD@:FO#6VTNE6#LMJUU*1@_L_SO;H?MZ!8A'.
MJ9A?V[[F=M06AG\B-_3#AZ_^\*$=$@02,/T_4$L#!!0    ( ,D]058\9'<Y
M5UT  )I=   -    8V]G;U\P,#<P+F=I9A17=SS4C_]_WW3&<?;F["-[SYR]
M.2.;[.PN(:2ZP]ED.[.S9Y(MZG-F=F8AR4ZAT%+?/OI]?J_'Z\_7'Z_7Z_E\
MOH:)F;&ZAO=3H!WX"0 (#FX4.P>7J#BSI")&4D)2155-74U)]@J:E\]84]5.
M22900]%(B/>:@=8=8^T;1II7M W4C4SX;8.<S(W-')UQ-E9!%D8Q%H9QU\QC
M71V"G'!1OBZ6+GZVGH'7?,)=_(,<_6\Y!]QV#8KV"(UU#(KTN'7/._RN;VBT
M?T0\/CPLR,/+2%<WS4(GQ=D\U=V^T.-:EH-IIJ]#>H!+OI]#0;!;>8@;.<"Y
M+,(CQQ=7&^+6<-NS,\J3'.)7?MNW)"JHY$Y,YLWPNC"_VDB?EDB?UEC_AIC@
MSGLAW7$!C7>C>N)OMX?Y9WM<I\8']26$MB3%#&;>[4V.'LB+;R&&EB3$#)-"
M1]/O3.7'C^;=6WL8Z1>9%!"?&12?=2.&%' O/_A^7N#]LHCX9-^[^5RA!:5W
MDVKBDX*)V0'$;/_$@I#$_.#$LI",\J!D<F0:.3(]/S2C*KR@/KJX(8K\.+:^
M/[*JTR:M,;Y[(JYM-&9X)?=A7F-R6D]Z\K/"U*:,_,ZL@J:"TIZBDN:\U-[:
MDHRRAI:RFNZRNL+:QZ2F_L+ZCL+FGL*V_M*V9Z7-/>4=SXN?#J8V=K;6M#37
M-W76/>ZK;VUMZ>IJZ1QHZ>YK[JGO?-[5.3#0.=C7U=??T5)653Z:GSA=1IHH
M21TK*Y@N2IZISARKSERLR9AL+%YZ7+;<6#3?4?&RL6&FNV%YH/5U3\-H:]?+
MGK[EYQVO^[M76NOFFYM?#_?-#?7O#S]+Z9TLZQU)&5S,Z)ZL[1FN?396^WRJ
M^<5DR[.QP9ZAP6>CO8,O!Y\,#3\;&WT^-=XWMC0PDCFR6C#UKF!\M6#R3?/0
M; -UMFMX[OGP[/.A\=:QQ;:)E>ZQA6?CBQV3KP<G5[IFUE[,KG6,KP[,ORN8
MW2'/[90L'V2/;PTN[XX.STZ-S+R>?#DZMC@UMC@Z]7IZZO7(W/KT[/JKEZN+
MLV^7IU?&%MY-+[Z;7%I=6GRWNKR^N3 YMKP]M;(SN[8_]_;CR]4/R\O;ZZ_W
M%MX=K:Y_F'G[>7OCX\KVEYW=L_VYF2A"K- O*/#_)O27WBS,^X:_E?>-(-\0
MY WOL#!O'7E9915E%15 ^O\C_E\P .(2*/[^:2R4N].BF$O&//(05Y6<(?OK
MDTK8NF;TN6)'!N?#"HW;*_5F].*/G>1#%VNOM?QX6F<1>313D1_;5C];MC=1
MN!1D?6,N:"<AEYXC=%%4+V8U!G1[V!"!XM?$;V&)4M?HKK58OYLJ3%QNO*X1
M<XJ*:EWK##!H]+@BG)3:B]]-OG5E.'&=6=AX"YE?A^Y,*"8KV*W.;X\8/8LW
M*_O![&L<R[M[C\%E84\YC]W%\_::XL',*\&;Z])WLMT_+FK<+AW@FREN,R%!
MGW)#Q*=IF=$3YB=3 W<<GG@NY+%G1S\^ZXO<[>EN49UQ>QZ[$N 2T+XE:_R&
M54-SKW%^>U1"][(M_X:-@$FVCJ0OO>JIGU%$F5O>[5_]E_W1'TP?V3LM=;U:
MWF'P9[1]8=F1BN[H!B732C1^'[KY/*J[S,F[<&7(68BMER,Y+ K!Z3$Y6^A^
M.WI(Q2DRBGF9/FK&O0$EG'RO@8P[:-\E9QU^%V4Q$W%1G37_>DO5/E!Q073]
MWM7NW4?J.D,F#*K/+R(FA1 [(.,P"67$ZR2J&>*U@TM,#HS&-X^]GBY8X0:?
MV\VF.KZ(X/L8B7"A+9+3]>63Q6G9 =$N1.8F>P+"1]Q;9-/WX"DKJRF[6>>F
M#WGV)=<-HU+[.9/Z[W>6K!M^%?,HO$$U9LAFL"6D\%JL]92'NR6HN--<^F>S
MUWL$K1627)%M^PYMH1U!/FDWDU')I=R:-,4TRV+3'Z(>1'S@%\X_].&VX"_D
M+/%#>RM9*0UA#1S,]QQ8!>N,UD>MK2["IIH:FKS72^4S<)*(,.>VJ6"7&_O)
M'&3>9&Y]FG 2WJVL[YE9^]"$6,.&??^OWX[7(;2C'[S2T8L>E%0K!]NLAU%)
MFRI"=:.;9IA_^UQR]!,"[.MK<HL^/OA:85@@FS_Q/Z/F7G_3<IK?JN5CY/;T
ML7*R3W:LNQNHQ7\X)73G>T#[[,JO )I)QBYI$7:(5.#XD.4GKNJS4<-L4TF]
MR=W:G3J=6@WSRI'LH(\[R]EYE3\,,S5&![7,+D-]M[9AG#U$RM<Y;7K989+/
ML&8(^3*=]LVBH.;^\M-QV4SWE!#-/WB]YZ<=,RM9^#Q3"LGP[73<"H75)M;K
M9616CTB6J%+\06C/G(9";'U'?<U*U]*7/8SDG+*&QE=+^>+E&3/>L#]?;6C%
M<JCX;?0RR1LAZ/7J]8^0=SP'2U/LR-,G"0/]]:G#/'>J$2.7T[&5K&IY".$$
M3<7&KB%"Z)P1]\=\V]7N$ >SU B6B\PKH1G"BS="(VM[?GW@V\&/J]GM9@;@
MI['3OI7<U2;@C4P25+#1TZ/#1#J%>?;Z39=2ND=?A5![!XYCYJX'R\-$)/=+
MB$C.=F1K9\/%@ASN,K4/=LDPIF"H%V"K)4RGW/5=TZ<O_$'OE6(VW9I'_Q:,
M^T>*I%1/+&3>4![A;-MF_+K>/O3 [Z&W(""$4(@<GU% >L=Z;P_K4_L8*:^\
M;$JVDZ<^7.G&6:%9;MN*H,X,OO#INXJ7O-)T3L&(YLVZ>6A-]KW6FX1:GYFJ
MGYE9;8Z3^[MWHP8I+-P53@E,?W:AP@Z[-.N+X]S#I%L"7&2^]Z+U#=0IB*F2
M=?AG<O]Y8;O,D@M<KE55P1C%DIK*;"S7]K0D!CWU (CW\%\U8 Z=;U,ZP)I8
MO$Z>M/+(#0?YN"D5T3RWNP]<.;24<!0F%#*V*Q:'6V;O&N++^#1/@EPN">S4
M;Q,V'L_.K\.933^(%ZDLWI+ARA)Z]5=>N"<])PNSSN(4[Z4_^:_54W=I-^Z\
MN C&^/8:E&0C%@1%$\!8*@!# UI74$0X&Q5@)F!! 5-SRN9,E0<#Y1&?U^K[
M#I7H;YX!<O]KXK@J\%(FAD5<#^&JJR?DXP!18+-T+,X]!^;YUO.X"Q1'N(&X
MY*LJS"GWIVRSHPL,6O?)6UIM1!JV>#18R4C2G0:[V.=( ,/EJ2"<IGU>D3*8
M;V*35D!4OB(6$7\K?D[G9<&K^^E"!CE157YBT^U3SVPH.I$+AY7=J4:629CE
MWZXZB@F&N2[U(3)#'&Q7N$M_4WQ;_<4N30A3ZXR6%#08:AH$$J:^+1DOK+^C
M@H5(S0-@!!4  UB/K^8@EIRM./G6NN%P2+_ZNF1CYG[#UAP+6,'RQX!1H30-
M^6EUW0_:$'E%!I](/;:=$YNJK U+\]KM3"]GO,*..6^('$MISXHH_Z^%AT$;
M"]F>?R!M\EG ]:]QA T6]!.X*1:2[ ;:,79^ I67-2N<MA[U!T'GV/5H="-Y
MN7YG9$M=2)8X:HLW4H,[?&]Y/Y:OM:E*"QJ$<YMFM"E-#/-5=Q[7(7S'11[&
MLOU*%61.@_6O9(Y!S;KMH%>>+>J51CXUX,NY(-P,6K=[KM\WQ%PI?RM%:QLJ
M"HP@3,,O(T  D)]G!O.-Y4GU*1$:__>XZ)>?= GV=/N+-4='2$(A'=<1Z,F%
M/_GN,YA('$-NILN!"#_QIHXJ2WZZ,]Z/W;O^OMJ[O-O[#;HG[<PZ!R!XGSZV
M'HS[2"/E1:!MCP/SKA+@XM)'SC:4&:@Z-C&+EX#L= $@&&H&<[T\,Q"EL:@A
ME.$2+Z1KX6@UKVKA<)]CAGC\$5W<Z.S-J,0L].8P)&>2>:UHD"P8QKJ8-?2N
MWTF<L7>%@X$M]6-X[%N +A +X375>UR'3W1]Z0KA(E.A O+;\,-2(&A.I@R$
M(@!=_<G<<1:)AGWMCTH^-NC][S1C#.JC:Q =^)?.?OYR=!CTR?D$S09A,S0>
M$R@Z9MK8]GRI,FXU:TG35,WQ>$'U?ZS:8B=/>"0P02 X0$#\201W7+YD,U8@
M/0@EO/\W.VKYBXYWPI6M+>ZK%Z5I<P&T?UKU>F^%TYQ=F&<>K07^.NY[].1&
M>3S+R<Y],XXI[G<NZ$=S&UR23$>J+%BQ]VI+.]P/+459'Y8,9H7=_FJJY;S(
MJ#VAO-IT";QHD(=)&A+/[2A_D(J"47P; ,U3\0L(8A-04D*_&3 FC*QE @@\
MH3*<6X_FMO.JV[OQXQAQ^V1W3/00]TIR8DVABV6;Q-6/.QSKT:D&U?L9;6%P
MD:_R'=J?B-22C-J$C=)DE<Y+(C:;_"%:52@O>-46&><.KD,A5$%7T;\DU;V9
M:E(3_LC)D7X[W8=4_OT#O_H0Q* .T'!A\;24D( B (H"$.UX0!X0:K\2'2&A
M86 2Z1>M!K?(9@7/&3FPQG"DYDO#A^@'*/2'^Z@SGSM#..37(<8?J'L\1 &-
M7)8]8^T> [/<;=6#'!%%/<8Y-*.Y':*WVRWG!I#/":M!/3":H/W*"2OJ3?K^
M)DD3#\$A2.KHN#HU;S@!".H)  !0I.@M"Q%^:I)'8I%Z>^05;H0-3;Y&0,0M
MW1&-D2[I7I3<5;C?BWF&S_Z&BS<8UZB8;V,R1WJ&[SZH*ILF"A!Y9AP0EV$4
MD+Z:/70>D)*'G4K0G7$BC$SIB@)ACO(/2M0?V&%A%:MI-NHD)@((=@//74\R
MHG$ WP9C5])-20Z/ T/'H_7U(/%/3$W"G<1]?7S%3/A'H D#J)0(!#/+-OV<
M5_@'>:9,0U<SU>O%'%(5"\P,=9@C N.Q/),&420F!\R&!E!8.\%Y+_MVVD9Y
MN@+G)*-4NB)3.D<L70TAS9:0YHAZX(B%??V09K?ZP/$EX)1"0O82F.7!S8OB
MD!HI2+Z]1$$.AY-%U!F;;^XM_25UJ=.KHY'T27N^NN(RU@&,U\82:L5N"XW(
MB-]"6D8@O6LT>:LPJN=A:X&,L]2LIA^76<-&  ^6OIE 5Y>37T>@TV[*/IK(
M/D8\/">G_7 NN$B%F&J0D*< '05 ],8!6!!\,GW<\3_QV&!5-/Q-E6/\U/N'
M;BR.J?/E^$0YHAXM&3C[YMZ.H4U[RC4;Z?>0>#MKT>]^*C*9157 (.L,8!6P
M17(2:<,H8%IC $5P^HNE;VRG58W-K\/2:?_*_XPH*":G%03!G+$P!]S#2@Q,
M"T4JDX!Q;15 V_$0*LB:.8,IL?"): :=B\7+@-#VBYQ+L/A-I\"%K8Q'(Q*W
M8G*SX,8>2H)S!<P"DMSH)<S1K01I6S/,&O.?,<83>>3MKPQIITP#A6 ZQYOE
M*,:N2RQ])X'<Z$57OY7? )20+_(-N&$.^!)R?^51/T2+6F*'ABK($YH_X%%>
MO"X1O,@=G?9?YBP7WM'UI4V_HK.,3)ACA0 C_MY^WPDUW8_=B'2TC 4T:)C[
MWE<<4P:+XK$"\HF!R!&5.?V_^I_J+FBHQ5#=[)A!//*P<BS]Z7S%YEJ^SJ_\
MW?YL9WQ:+0KFC'IXR/WPN!_BL%7YN0FBE0-AI!8TO\3SY3SJ\;ZU"<EP.:^-
M#K@2GJLT'FW1?BXG#??HG12>H=+WHE+ZJ66H=-/U7MT:%:;?Z'N"4Y;%VYB&
M1!RN5C,M ;MR:/85A13NMD:>,I7)TW<"3&_[*R[5)NF4/N7GQ-;H<3\LZJ\I
MG:PLYZXM[X<8HF&&: @''OB;"D2RU5&3,BIX,C9'E*(=G3N<.>-[;):+;G4O
M@^AYD-?I$KSC$!]74&FW[KRAWC-19?IVJJM9?0_Z301A9'8 XLXA:HUJJ"UC
M*YQSP?7?&D[1C82IBDYT3?9:=DY_=B6JX'RB46NJ<DNJ5A,-T\1">"A-/R;3
M'=(R-@T*VRZ4XCF>4"-#_R=YI9,EPB^"8VBO;BB&_MQ7MV8)X0Y)'>JO-TZ6
M*>KQF]UBD/U9Q;5M&</-JJK(5(RZ>?P3))E3L0TPK=,V=K;3M:(ZDN/H&G$U
M:5/9E<##$LF'6^F7)5;S4'(_Q*H=LFO>IC8/F$D!8H"ZBP_8JKG-2HHBO]?&
M\B8]%BZ>6&23KA0XW,'@\9MS!E5_;F^:1BVR7;'\GE._2(,5JFJ//F007& <
M*V4.9PU:46=*0($X+4"2IPQ;6]7K9O0MIT_1(8T/)>G6FA_7YG2<J!<8K'7H
M:S9I$B#?BX$6$Y";//CJVUK,::?5[[Z^P-#E'WUY6OU%+>J+3QGFM[KF3SGM
MM'211 2SE$QTD!;[LVXS5>3J&S^&LG*^7URJ'<SG.8D26) @#LR& \6T/^6[
MTAA!WQCU/W(#H3=V(/NDL>:$7.),*7FX7FF@6;O[#%2S%@".!6M?3O>U!O:O
M#SS/;U%_-]"\W-/_AR<S;8N"8JZZTY!REM.]\$$W79'[K7[X'$KT ZK<>(_Y
M",?TD,!>9PCZ.U^],%7Q]M?3[G:ZH>E\\;+')^2._,GL";>'L_2UKRPZ->7;
MD.T!;#A>%T!==ZEO;?HYFF\8W=J_\I3!^],3BD5+-;W 3AZR83IA= WSDGQO
M=+?=^)MNU3ACS#QHSG\@AD*6DWHL,$ 'V\C?*J&.#_16MC\N[AN4GNZ8NU*K
M/'TS20M6^HSD>:I$&(&YXW@]I(=Y^<9=&<;7+?@K_E=G^Q9A3R^2Z-/]'(=<
M.ZU:NE%E?*!Y.RCERU/=S3LC->Q,H5'@2PR6G7N EE?K,42[%SU IQA'IV(^
M6(2ALYAY_%6]8-H"=@WHF\\HL')V![  IAWFS0"_/C,D/#/FQC#E5PZC_(&Y
MX,<%&\OL>9]EH VC,+*"4R]&?C&W^Z9$IR;$,=R^U<3T'("'[_\3 ]"^PM+?
MTFJDNO4*N75D6M)5$WJS!T<K3[-?'O5*WYW4DQI3IB?98?L4<X"I,="#$9B;
MUY3[((RR,:>[._=Q9JXY=*JI=<H;.QQ .RWYQ_?P"O(U'AFQ\8+3_-Z]7C]&
M%3_5B)&#6\CO>(35]D@,"C$C36TY'4AWIR:[TF4=TRX/]N;$I]7@:]8ST\C:
MM4EN8W:GEP 8!5RASAVVPMS04U[H5^?'L);6J>/R);=YV,>9J?SIJ=89SN/0
M)3=*?YF%IU?S^'JN9QH54=S.()7;<H:OBI1F*O"[=Y;Q4N]<E\Z#:8%*:]+0
M\Y>>-IW[OT4V&'FEXWT0W8(EW:-3VIB!T1SWI'M7Z-;C)Z^=-I:[#-FL)E5*
M/ ?A +GG,'F=)4V=90VK93>O)4,D7+4"=GU^KC5^-47FQ8,A^HYGXU49_%$7
MKWYIW:N!C_SSC.OEJDH^2_FQO&NJ/M."%_RF_\!?%"Q=@YIBV0MU[S79F,#+
MS+YF*-C76&3^4_G%9>B1TP,U-(1Y/D2$ '?=@LT^9_-$O5N\Y'^7\7S5<'9U
M56=-^=U<:MC2=>RP!KP^P_%%*$.5S3N&'NT5#E<_/E#>_3<,ZWFLWT,$3E#W
MAC0$%D[7ZT=IR^3?=F6]AKM3T0.OPV3>F ^.UFR]%9F=/789RO\]BY. L,_C
M^0GP&WBX/P&^\'A[X5^8P.?5!>3.DM4[SZUM=?XU]8JQS.>K97?'R?R9I>_&
M;?A7CM ]"PWK7[ULKVSCK.M-4Q693E#E>M;(#Z,]?Z??IS;1I892+3?W7LV\
M+G*N>1TZ>_XF>TEZDCRQ]0C3%B]#LJ> :KA!YD]A_@#<'P=_?0+SE=_QI&RK
MB;SS(, #@:ELJR7QS]NY61_FVS]<7DE8>S2-2DI"($ K/>Y5)N/,C[IVO\%D
MT]G*%]XP?@<^WAZA;3$&A5%II9_1PBU[K3;WND]GQ+1FJ]'[]INT]^@+&M$/
M8Y]7RA^EV6WL5VJ :FA!YD+O E[ >!CA-Z_N7,^!=WL>^5-6XT%K B]@,9O;
M;O/T=^?HK]/M_IT:KW9#+0,O#0]R?SQ/T=KTDQRJ4KO@P@I\Y#1G.@%H/A2
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M:/#0>@X,TWJR&MR2)KX1/"S[_/-ZQI-?RO(  ;2^^C!+;N.BVE+YN=?(4_"
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M0,YX=,/<S#QM^68:ST+JH>JRD&1"(/]W+]>E:@[L7?]F@F=ML?:&4%EH:)A
MCOK!+511^5Y[LT;;(;.4\5,[NZYOX4T8TGG!#9@TOH'5H3%!( ]=-!"UU!"'
M8;I#\1(00559'&H7B03EM"*5MP!$*I9?7(.FV=4.&4*5>J4\:39#.D_=!2-9
MU>RZ#/EV4*9W_6O<=W0;S1Z+RP0G6T5&4+/G1@0ZJEYJ#1,O:8K8_1-:L&/B
MYD]G')Z#Z\J )*9R2@KFN,JL#C,F@.A/L7'7*]^19L*5.?7VG82%6RO:L"RF
MS5U0;M,IYH"1/&@R8F*(XQ:EX6(]Q^">3Q2R;#3,*39@],GG)G>">6,0:IL9
MHUC#O4"!VZ!+'W:O*_+V3#IDU'IC;_M!Q,]3.:^>,S,Z_0$TC'^]A)H\;<Y[
MIH#*0XP*E+=[2EY@X<H71-9X%%145(]ISQ+,UIB3=$*^(1VZ'2IQGO$>O>P%
METUE@K-I"_+-8^&*JP0F:1P!;(A%];>/B>[C)BT\HZQU:Q/#E]J3E0O.;XA;
M^P3**BMWY'UFJ?=ELWC]J?$R%K=<?4LG34-3S/CA^BY_MQ<,;7>:&:<.-IGD
M-D*_[IMQJ@776]O*(97G"5 ,!<24.G0W%I6$YA*B-58?MLZ7WY+2%OH'*_,?
MC;&)7%Y4,!*'+=^-]V>H984T5NC?D\I,,.$:9G38/^7]9I:B<H'KO8$^2WT%
M52*:CXY>Q[SIIS@[[H@W<RM$3VJY"AO+[-C9ES]+UABTE:0,BDC570RQ1><B
MC?'"H;88(^6*<D_L,@_*'DA@Z&@]^OGB#JWR(9$Y4SX)?5K,8':JQSSH#A6#
M;L/"/0G@YAD SH<&(:D_(#Q>((8M &*?"F*LIQ"''+S %J?#?)?NDVJ7"%=D
MRKB[(^OLX:;^;^$9ZIUD2U],\N^=PK6)<=<WGY E6"?[(?*ZRB>%X/I)<;XJ
M>9)4^/.T&\XB/-'JB3R'V!0V'!K,'HB%"1-.:$6!/=9Y*ERQG<@&>#-@ 3!+
MCA=4#%.E;8K_0>^)2N);IL#$;+!@1B\"Y8D76&J5 %>F@&^'H"%,]_'V]*=,
MW)84F*3ZJ,/-P\^91ZJCW/_(5+'*Y%;V?Z$OL3#@V?"J\O?RX\P\-*UB(39Z
MM,.+E,=-1MR&\TO\I+@6R>,J[<R?;'_>%+@ 3-A7Z^E<J;N\9%-CM0,LC0*#
M%R!HZBN$/DS1NQABJC<?@I,]08M.EU@(UY8>>S0I2>8?"NQ)+P'<&@9 ^*@_
M>GMU3D)NW@WU=3L4Q!G2<7@E<OIA4<F4O=??^^,K/W;^<H)I.2Y5]G<^^I<A
M/-7T0'IGJD?)X'W$P^J/M=Y9H1,Q12&%M%;MVYE>EI#M*L8#\QT]ION--?6S
ML7!M:E6:F?HP TL. 11(L"*D'&!)SDHD9PO%*1X2)A4LFD-DF <6W8AT.**T
M.E$!2%38 NK=B%#*\\4E@,Y4@W:&H%8&A"[IK%\!IB& DG,2!$?@(_^'=*(A
M6=0B6.W#=-^3_SUK-1_XF)@Z,\F'T]02R4OV[U/[,@ S-N5,7B<Y?1);32U^
MGG&9TL1-">BC31HI32G-BINGN=?^CS69I$:7XK^>I!\(86P?9#/-#E0DV>;(
M-S3W0-H![D.BA'P"8IG 1DU44 < ! % $R!<AB!G$)),H#,EMO\"H2<27:<3
MM2^(R/;1.GN092L :A]$I +@0("3 &+@2G(G)YJQ"*Z[7OW0^7C=%>(4^0C'
MHG#R]FJ\+WPQ$(I4*,"DZW-*_A/KU382PI,PHO]S@#9T-:O2*T6^-262FF!#
M)CDA4O QR?6K4"<"E(6+@%0GNP12;RT1F%+_&X9"4/0S>""1;P+$UT>@QX,=
MYPF ,S'6$H!R&;)3"33S!.D1$$T@@?;2V;# _ADR%0NS;U?;-00N^J Q )<7
MB.LTT9 BA9VNXG<?&[,=&',IW[=(=%86?DNG+[)^-3!0:]$+*B'=DA.8Y$%0
M",;H?@U17S'[!S1,^Q;1_?AIBC_4X'^LI$9"BE)D>F$I29U D,20K+A@DH'-
M\%6") [$I0@@38'@NP!?()%^ A!$0.6Y(25N8/K_%(,CTK?_EZ+JE2OE["B"
MGJ@A!">/1$_3.QL&I &%90 ] 90B"M$MF]@+Z?V'33F+;6;($J)BJC6B/)/E
M#KE+CW2;07FX)QGCV/)C)D=&4@9#>%XDR@9=# 0UTMX^;8P&#.YYT4BC2"Y8
MTJ4+0*,VG-Z*@D).00Z()$D\F"8SH=V,*#DPS3!AHCD-<)Z"L*N0@J4F45R"
MF!< O9BEG^^1*@/H"$#$GJ&-* #N4V7(H=)J$^ Y(,$M$*<S.,6/*#Q!TM4R
MBJN6HCK8J,4D#D7:J&%FAC(AB<)F+S,'),S9IB(+_IW1^FNF2\V'ATX4!*-H
M;GO16(70W#R%W\?37%$GN: %8K"2&N>)4'*"6T;"&5T2,@HK009+;H$\,H@,
M@42N+9#HH3;:E" (P$!:8 $< ,4,Q2M;A%_IAZ !"& :VJE*CP?1<PU!<"!5
M2((87I7+&1#$V$35-#25FGX/53M+NX1H7DS_7)[X89@?2(#+D. !AR0WKV1W
MMC:#V*=&_<GGK.E%,2F7>P.]'6F@?63T(>>]4W@<CF9"GX13)[GBZ1HP)"R0
M!._#22"2=+MG=0*E,;AE8028)Q"D'0F^B@.Q'P*P>0B.2\*GDP!IQ'(&@O[#
MEIX*<)*)".6A)7M-W"R!9A6@DP<2RD%HYV8^O.EY%T0K<-$]RD[R'L0\;_'Z
MOV"[=#NUBY5?M? @YV'QP5?] TD8AD'KJJRBPU=%IO]8+@QG@$56JNRSXF#V
M"!@& 4/;DJ!_(%@<41)8_J:_C'%^LNXGC9%/$,: A;!@B8LD;76"41?@<HF
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M<L-HY.ZG'(XZ0_.2*&[O.VU,B?H!]NE03%>Z9H?ZY9G>+?4?F<H(4\973[P
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M'T*?#Y& EJ^]>7D0WN;OVK//V[5O\&+_UG =]TS=[45_(U>_Z_!=P&>%2]9
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M/?2S_F#BE78*2SL5; E:O*HL%3HLL]0QC)G!'.NQ60[)R=%P:F0SL=UF^D9
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M&4A)"S-1 0-=P#]B]Z_P"0>D?4DJ#'UQ+J=!9$,(W_X)>-YU@?]580P%I,U
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M8CKK!N2V]AI0DC=KOI%BBP*/UQZI+R;!KIC S(E9TO3Y.W>[5>,@&#H%B 7
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M2*KA E_0P?FAT8@H.BR2].9K\%^U:K08CKCY."P^/S=\^LV!;M;G'R>;ZZM
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MBCZ.>C'?7C=,\H9\C2+&OT?K6LW C :_"WJ +>,#%&( ]IL B#TQF P+)@
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M9G>RIQYYE??;N--"OOI@BE2P<] G%I,=<4MUUYN,9XV2U\J5(N(ZF?QCV -
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M&;J*X";(7D_I@KV)![ .CN8AII0$B??._5%*O.1JN?\([]^+/6D &J:=>Z8
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MWK'YCOZQ@ZZMFTT4MB\P@!Z#M(<"3'EX%@#!(I(5 *MY"HH\4"_>N8M",&:
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M.4F8Z!S#4G?'F#76%]QH.23!^OS(:03MC2!)T1-7:KUU=G<,>\=,G2K5,#@
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MK7("7[7-?+5>0^LUD7JX3>Z_YF'(-P2+9WU$D,U6G.RD)XX.95-QTGK5 /<
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MP'R*K;W7+O3QT#8H?$^&F^YD7"R['9QAISJ*/=1ZF5B[B+94 U<F*/;YJ$2
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M*9A@!I9R&!M*%3SS.;TM/L6#TA$5BETOZ8MR\BLU677#%?N6=WL]/54+0M,
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MOZ( <9F+O!E([B0?0'F>.YV9CPEJB$K44:6AU(/=X]C[;K./IUF_J2<#!IB
MX=26J^_A"PH"8$C$LDC[]L1\3S$*S?0R=2JZ3? 2 6*/%QD&R=H4P!,ZK89-
MI-"'V"35150FWJ'HI&Y&!=S]4)#JVI:"7DO#X.D>IOX.R8 N:EU 2STLRAD(
M=BT"8J=8H+0$P#R:JC(5P1HQ 3745[5L_#JLP0'0#$V"XB"8)8<B%WX< LYI
M:-2_>(#QH0?]>OIZ>;35M):EB6B@WR)KWT#Y.9/<!%W!0]N]MA@5DJ%&/R/5
MLDN6O![ ^-KX+H,"4F;(/,"L[\'D7BK(8"V*5O>C=2B'B!1X>M%D"RY$R_],
ML!(;:EUG)^F?R<YPJV=BXB0A.1MJ,]R=#FL5,Y)4,K*))FG@/OVA;7%/IU!I
M+$HSEP;KQ]N&+,>U*1VCPZ8']R@8"8S4O!H]&38>Z.7H:46;<@=EB]ITASP:
MX5@:JVSY?]YCE$F5FPMIL/9S)\S2]RS-73Y\HER<OE$:13 5>BQ*-'SK\HWU
MX)@<0R^1)K,EAH0;4HQU"?.1][8GZ"4^2_2FZ4]<G%.?NMVK9@G/&02Z&BGH
MB]HU]LMQ 0)(8?\X6G.O*&W^+8):6PZK&@5C]!A&*A?BO<C.;(R%PV3S6KJ'
M0NJ%9A\NB\20(>I?WN$_KH8\\\M9^$ I)H YA0^:LZ$&2B$SZE/9NAX/U?W"
M9.TT0U7U$Q[X*ODFYQD$OTRX+%.W5B!<8QA_#+U:8[]HO^&,Z-4%BB=A;^!G
MJ_GYUTZ4>Z:Z1<DJ$AG1ILOL,]?J1^W/K]UI[BX30>UGHOQW&SZ<7J#99D&9
MMW<O^SB:EVI[3ID=-?L?M<.GZVD15+F%>>^3SJ\C#CBES#QJ[,>32]<ZE"L?
MXEK="QY*ZYHB7OT9,P_+CSUJEF7:_MQN9?PAM1>WOEF;%"&I';XGZ[1)-0R)
M($UK-,0?/1*SF;@9;4QM>9%BG;#X#V>6I=E&J1Q,\$B</E^FT<:]^^7T]<+G
MJ_YJ='=WVF0%I;]7W?QK^;NCT;N&B2];&YZ^VGHZ[G!#X?=/5O^8<(CUP(WB
M&P?O9*MDFWVI/!DPL]2G,/Z,U</+3.K3OQ7GK5:T__W/P)V,SITW,*.UHTPD
M:%?6L>!P2!$],;L9MN' IIS"Q$<+.]M/SUU66(#Q$ZXG3;ZIN&]OIYO0_MIR
M4*]6HA9>T''H_W:VFR;JN;=1'W\7*45X.=#N95[05]:89-U$E\Q15SKY%<VW
M*VL0U#0(5?-PHU>1MX_AROJ.Q5Z&*WF&53UH!@5K&U>D&FC(\C54TX_0UC;T
MHT^P&-K1LJ0_MM[O'K+>M2DG/"C2^VAH\"-2^M0P<38RNF<R\8&AM638<(FW
MD46Q7L-SW6&-!-?BQN\9B5*-:,F+53TOX!]G"/J;CDUVF[&2Z'NCS'X'NU>(
MZ G%YEE&)KPDXQF$0FM_M*<XK61J^,*4:=8H/37*HI1F><IH\;GBQ7IZEBH=
M%E-K;*?6I/T3QB^R!25W8X=SZ<Q:0\?"2U=,BIY$JMO%&8<<%CS6B]!L)S@=
M]'IZ=-+#>E+]&+J1U^%\SDLKQ-BW,3+SDH';V!6WY]%#:INC!X+U;UX>RMMH
M\GLZ<28XKLV Q36R-RTQP L8%C-,DLCSE$__I*K9_&:,MXFW=\Q?Z*0!YK0<
M-S0_J>IC9^RUM<3W(\>AM,3/ NW:$)/E>YIUN\1?9:W",K3NB'%"J)&[XDSC
MAYCEV/M!'V>6OYUA-W3_>;QRQ"O&8B'*3N6*]:M17].9-84S'5MF?+P7A6R]
MZN-WU;ZF9'W6)H>!DM!8X2JO/DK6HC"+OI#',]*9$JG8@'GWY2_E+>'/H]F$
MA9*=-[<$K9YJ]# Z2KMJN[6=:$>;D(E6#,IR*%O_6[35$COH%;LE)&)+C W-
MYYR)]P3'1_M*R!+6^-&KVY*N4@JWA&5M]1-[G=YRA7NF-#;?Z^F>LQO;Q]S[
MQC;=/:'W\JJTQ"#PB\GMLYL'98MV_3;^LRXJZ%6)]3AKF';51#9HB.-KSJPT
MC?%0=874?+:INK(T'?CJ>074_4F29?S>#6V&_V(D@W6*61H3MFA%Z;:MK-*M
M9V9B\F..[7^Y;7#;8^6NV.=FOI)-3\R]_&5EQ\\)7$V]'$*--C5<_HU?M+.]
M=/,/TZ17IK<[0Q9IO-ZL'S RKZR.9KY,U%2@() )\X0*T%N@^)Y01!['MR<O
M8L(4!-X/&7DAZ-!2+QO.NM5;O0JWK4V:\9F@9YK.'"8H99PRR=)&'U5\LSSE
MY7']-RL90]N_O%YJ5)$S%G.;4<YT+]?]L"6I^$5NUI--@Z_B]+AN-O2XPN[@
MU>4&VUD:\^14']A("JG3F3A=6(_D"\\RC1+;4&F9V%FRD2L$KP4F3E"!^+7/
M MU[HCS+(B9+X]H1ENDVE8HKIJ>SG=_D1$3[^UW+J=F2VW[U[/.MNV+?+A\<
M,XDR9]MY+V>5[TK=6+[US<8L<P/')&8<2X,B(:&S3&+:Z26]YO6*V3R^A=,(
MB/=0H /C<E:F%3!#()O:L@7/8S,A%I9>O^G%=U_7C7%->EY?B:C\$GKMZKFK
MIZ^6-M1L18PZHGJVY#TO+=,HOXW9<G8)O:QK;%/2&S>_<@^_Y/D+VP]=?7/H
M++D0]XA$8A)"VT@Q5.,X #] U+F!INO:4 -T>SNKT^VO??>V%UE4QOR@AX19
M-FRM\J(F'SUF>6SOCB4)[[.CWA8_CF;NBDWR*S__7/E\X?NS=97\L:W-#2<V
MWBWM^SBP9S67D,!2WZ_9^_V,*>(!%TA,YX-)5 2F(; 74S,./FU2#?,0*SM8
MS\G*.VSGC=4[QI[/CGWDLE1BCZPVS;!C;8NM>KS:RSO-ZIA1T89KUL=2*QV>
MSE24+E0&-NUP[WH76&QY[=3%BK#MB^IB=ZTKOW.0FCM>(%7Y8/#]'<.P_="*
M) P=H3JUCW][ =E9C<56UWE7KEN8[8C:Y17U_G&J#8OBM[1I9UA[S*U\F\:F
MTH1QT[+!1?V_33>W*YS'OARBE$CG3?CG=NS\_$'0$'LLCJ5>'DJ2(/B8-GI\
M&Y"='%8!ZAGPVA $TF4M&$9[1KT$?J5;3-_6>YN,N\?\/&AMKV\Q>VK7K'[D
MJOC*MR'&3RPF?Q?NLA6^UTF]]J&]BG?W8_^779\^[O[05Q,15;$(WM6TZ.H%
M&^!ES81D$G.$#[/S>)-,:""'L#=I NE]6+,M(^OZF'OEHX6#/ 6=37.G=K^.
MXIDX7/M5*-<Y%OG[[G7__%?'3+V^B^6A=>BG=MIY4S4F4Z7/S[S]U1L7UW#Y
MP]4JM[>[PD=>#@U4FK)@8P9L0E7U8"89"WSD]#WC[K#J-IN.K1]Q.UZN.W:=
MM<#]5<QHF C]?>TZZ6*A/\<X)_^SEDXDM;3P/\7[06\'%(VY>G_D98,?=WS\
MI-1MJF*VR,-+T\RG:L2DS,<O[E[4AY=;8WZ<6ARS:S%^L87&CH_PN6KJ989"
M;8=#@ZU.?JGV/=Z;O7:N?9]<BZV:$][^O;NK_XRE0=E;\W0+RXLG0+<!+:C.
M^F)9\42YY@GKD!"KGUNKA1%V! 5#G72[!>U6!NM;F6US#/G1](>FO99E;^/V
M;E\_;*Q_^9K2B]T[OT</PI^LG]05'?R@<='$Y.M>DR.\Q>LK&>E[)FSL79/>
M:S?;NRZQO__#MGSLY?N)&[GM=2_>+@I>O6]YD'E3E-&=L2^,A!I6X%.C;;::
M1VQNQ#)81W8:K[(KQGYU3K<IZK'_8V-.WU'GK6.8>R[N_>\2\\JWE//UOR8_
ME2^9U>_^:&!)=CYNKW&:8;3RFV_L=>,3/%:^?,6)7<RC^\WN[5L9;<@NTS,G
MTA?@^GZ;V=4Y%P?!?JM'5Q.9-\.;/NY>F+8RB+$^L8^UK_;?#^+>?0E84^=_
MA.%_8D_0T#;ORBW+&GBV[Q9"WR3L+1&8%E?I^3KY=;."Z*=-GV95;BJMMT<=
M=/CTU?Y>E>/Y'7I_IPW..T8O;8BV7Q)6]GW;W>]^^]&J'P_X<GYXCSM&Y:*W
M&40>.]6_;;?Q,F>"W2I/?R?"EO2.;2>\7*YTQ![Q<KEV)6YYD.W0P96";_/Z
M/Y[EOUC^>@_GR9[-/QK<'\7IJR]9_H47M_6 QR>[D(C%[I'6^R]^C5ZS_X!E
MC)E_D$/YYV_,4X<>Y3GX)Q_LMB[)^'GPM$W"B4-/LPX]-?(Z;&9XI-7+07PK
MH7)IXNBMQ%N'#M^ZE7AQ:6+9H</=MXY<^:&A<6_QOU9QW)!!CU=;$I\<E)*\
MNRBYK$C5M)&_>(ZZH-W(7]FH"GNF'"\2&,PE'7<Z&12ONM>0D=&8ZC(I\'12
M\VL\Z3EI7[_T^*J(]!USF1L;TY8:)G<WGCPT=VHZOBB^\=1Q)]OX^.3K<XO5
M;I\Y/IG=ZI1U?C+M:WQJ3N,I352.F5/2(?:QZ[<<YFX::DSI&TWI&1D9$XHO
M&!@U].XU+EQV<;%1P="DWILBFMU4WHO;>A,LHY&DPK\#A:.3E^XI-PRW[\E?
M>L=OU/9<5-I^(^L%(UOGE_2W4<:,ET[6SC:[BEE+9NR>&ZVU^Q\.OCP>RL7[
M_WEF7QG&,C/$,PC9&E))U&.?BAJ2+?18HW6X)4F:&3.,M2%$2D,J11JETB(S
M=E$-E;3>T:INR[3<TC:?W_W^_C^O<U[GO-[GG/=YG?,ZST\L3YE7\#,\WG-!
M4^+)Y\].+A?-7;7H(N[I,^_\UN7Y;:,_6V]?.7/GYP+WOM;[GFW??[8M[FN[
M/4?7-M^B@[SGK-F>]CM7.NA7GU&7=N!_==SW5#@N/3N4TQ'YZXS?TK8U2]OH
M#6VW6]V#?SUV]NM,^K7 _>KY7U>N_.WI/I-S=>/5L\OW7+OZ\SS^:<?_?EYH
MO7KMH^?EYSD7K/></;"G0__JN5][KHS^3+?#S-?V?CD3W_=%]-GG]Y>R#7UK
M<C^660XN]AI<>^WS5J^A];_[=UT;W/5[<,/O6=??O=\M^O;DCES*'=[H-;3/
M:_3VM8&K7B/;<WL_^@840'JOH-O?<_50W?@LC9K^YW\[1>-T;[W3]W4+_TS,
M[[ZSO/LN?N]=_)^[D7L)ITW5WW,GUW;?7^5]>_.?R>VH>3/"!T>]'Y[L?GA6
MY_WH4O>C'N_'0]V/;WL_:=UKIO QNP::O?/^^_O>O__N_AM_7?/%6_-Q[_0E
MGZ=?_I@9+7MJ??VIODZS0/?\N??3^<M>!%W_>T&>9L'U5]N7/5JOF]ZP;!JO
M>U&R[&7]=<W??Y[_M>S%KNO31Y>]W:C[9[_NW:5E[]!YCQZ!K'?+/GY?]O&J
MZN/'ZV; /NVOO(_TY5KZ_S[-WZ>U7O[%M.?3K[S/JWJTCCU?UB[7G@0_;NXQ
M:_9A47JT0<M9@O]].Z8R;_MCD::B\\!?EWI^]2S_O1[\O59H/-SSZ_Z^/Y=Z
M?K_>I[OSO]__6P[S#+@#-^!\/-[$OXLW[5NHSW:YVUN\SK'8>%Y,9[;.(*FU
MS&Q!YC7".>N@_58KRL>XGYM'*JW7GC-:<N?XRAK7@'9#&RGO=D-^+FJN.\%^
MO&EYH2$UQST]]'@^QL#XY8&WO-:U!V(6QER8=[\]J"CPSQNC=%[KQJ%%3^J^
MS0MK@'SR8D;7_C/1%%H7AGU40XL['O(_G%XPP;$13BV<>'_:5+OV6'8CRSAF
M7>;+,P<,\B\XM#R[&5%E/PV&C-R>43>O^A5ZAK7C[=T3T0<"XW+<M]Z]%#DT
MN?7GU[3Q[O67GKZ_\G6[IGW[EX@&\\Y/+^4!.UV*@BB,?Q)/EWS*[/[Y[2UR
M+7NH?$[PMW<OK]Y1?0CH9GB^&[H:=/O)S]^?)B\=O+W]>J[NSY]?O\C:JS\(
M7OK>GZ^OXBM_O1LMUTN'2GF]Q'EMZEZRZQBOC[KDG=J/=&IW:EU*@T%&/WV5
MS:=^>GWT"28](#>CWVAC;$> 26BS:YWA;O%XOUF(S:>ZY/!WK@'6:Z^%!D ;
MC2J&C.M_CP_8Q-EDWH!6>;WJ=93TA_E;I3A-K&"$FH<.;HRAA VXW3-R"[)L
MS*T<LQAHRUAI7V=^8-"ER.O<Z/*C[S[7I7->#*C]J.]?JN.-4JH.QF<EA(\'
MS0TP"EUAMM-H[0KKEW/#N,['P^_R])\,J%<OEH2/QP5W=X:%FNWM7+=NS9^J
M\=6K]KJ/KY];-N@;YS'N/Y50^#*9GEBANV=#7^,UXC^54OBO>"KEU-:+T2'-
MQQ<]V'KY_>2C[:J]->LW#KQ<%)6XA#W7=P,[>;&O[_T+ZKCLXQGWXPAOME[R
M]9V^^?UISOPQ4X3XNFP7(J+F[>K==_S-049B<1&#(;5NSTZ46KH4,))ENZ>>
M[U_0,)58MN26QW/I/O#$LZI0EU>F93Z++C]+#-_&9"3%9T5OK-ZWN^MYK=_D
M[,'#\RQV)]5Z?ZA-:A;F%?2F-?SH>M7@C(M^?MI[\-";,N__)I@#W;>NI![<
ML&BP]E#)B27/VG9M^_'R<+KNRC]U.VU_OCRT.SYZ8_W0]:N,Y'?5M$,QA/F'
M36)(=N:?8DP6'_XT8+;]\*<1G?[)QYDC]/WFGX?(0W,_W7:\]/NOOL7Z>S/5
M:R(/9\0Y[(_-Z%]_\GC=R6.NQRNX_-MQWY_LWH^I?+SO?T]V36?H/_W^G+W"
MXL?S/=L;=CT[@H__'M1P,'[7S+']\95/EZ9[3.NK]#?\_C3R7;8M,2?O05*2
M=,DK1N+8:I:N[N:)JXRDO$6#>;^>+T_]W^STT/4_.[?LP[Y@_98U7NI^L#U-
MYZA!?\<O3^0$LT);:W7O!I>=3Z>)EB^U[#>,*OV^A"8R/C;55S[N^J=:EOQM
MZ4/@\D5?DRO\ IS_H*3)U?->PK8=5]33^D%#?M!;M<D%+7LZU[Z?[9(A#4A.
M=#[,[;(/-"@^6J^+DVRYU/WNW]4EZ]_-L=GV.L!U6T=)DOMSYL[(P?<[S^9N
MW?'<;'JJ,:W9F:E6')NSZIOKMSEHUHC'H-LMNSZR5=_^N?T,T+I+Y6U2EKAJ
M?3WQ?610XFR&)#4?!QUE^Z;Y.QT8$ 3:/5I\GC>IS7MW3(ZU3BU->6S THUN
M .[8WF ?W\K\N/[12-34,MC0SW_9'N2A^8H>6C$_==]ARWD; VT2K<XGQE3>
M?VUE7(IP2$5'CSTS.,,,V&+582IY9$N_4.0?X[_)=$WRL\4W'_A;O54;13;S
M3#),G=:4)M+K-1C6@+W3ZQ6^]*N.SYG5DC7[/KO(*V=?+Q^P+PK<(3)V5JAT
MY'B^.#)[S0;CN5,]C*SY>0,5Q^8,3-^H4>&,6F"L/0,]E/>J(ZG3%Y,DE>@O
MDBX[.I>39+X>Z_C[>T?/D\P39/\'?5.%KD8U;1OM.EFCQ16E/E,:9M)4GUOQ
ME5+KF6GF<GZ XQ9>:2S-RG24@[)LJ+A>VJU_:@'EM!)*5GU[*<([1($D@;8X
MV<:Y968S\T9#!F:IN_5F&!F(+0)+-\CXF[GT!!=<1<FUZ\*SZ4OK)H(+N(U'
MG%*2=@Y -5F^I]E;S_NN'[2L KBI$>\*/A<_<VE"4/1F)2;=_N1;45J738[+
M7^>H ?JIJBLW&M<6-C@F_I.5033YJBSL/-/T3%?>XC^%ZLA8O<7%XWC:S9BN
MOWRU+_K9JS7@^P:!WI_^.?^>'KHV_7YU]LBC?GJ;HFC:8#Y]OT!H_>&4U^>"
M@[L2N/ZF+Q\MU9(^'NV](S9ND!-?LK^6_-J"F?>-!F"]!"#(!UR]6 G$-5&^
MPU$)[EE\H7>GD*JG];E;8U"69O/<=&+*AUP.2O'O0OO_6M<H/5A!3N]"*!,,
MI]+IQ;W)-M:LC^M3]EMG4<RMC]5879SKFFI:5OZG8LBZ8&J!OY-O1"F;9=V2
MX5XS?GTAS8I)I4D<!Q642"\D:'T>CB,WH*;];AOYZTBCQ"ZJ<37*FMD.*XW?
M:7&T7&1H"%[[RU]W>$5*9B9S_2VW4DM8F@*LOMGY]:^[THK4M-]63$6V$G,?
MD*;8]!WXRSC3?2HHF>V''HD:9+@[U"J7^6P5Y0X+W&O:7%><O[UR4_PCA^.A
M!?KBG9T^@PG/1.,@?5A%3><)C')<;R5@^@H;FB0N.=-^:?<33?L8N/F$2^0T
MNSVF*MK@7 :/E+;JK_H3I[,XUYBEF_>X/!PS"33R%7BL;S%[=%=7U7TFKB2>
M\OS"!5GJXO?='_.^)#X(NCO0<WQ]@%U8!S^TZHA$<XK(@33$=5.^)(92^G[K
M,Z.W+^T^')8L3?$11=\L]E?4#!"Y6WKIIP0^%"^#HLK7+O1B1&GE9J K"BWM
MO?JZR>[F&V;FDR.]Z'"/ 6L;5<9'AU51KST#EK_^L6;+5I3A2:F*R,MH>QRR
M=\\A3?^Y*Q^(_[[Z</0(H1_(XI1MA$!@*S_ DG"<GCZ,H@W1^AUC#:1)"N%I
M Y0_$S!@)W>J**U2M>.DNF BK/;3B[6?!_,,J!9:F#4B&[1@"4HWMCTC) D&
MW"(JA',4(IH)Y.8TR!>O2U["/,O] \D[2+0N>!Q9U@N=\UH11>LU3LT>6+!,
M*'8<_I>A4/8:8 P6PLI>"E<:4',PE&!=E5#9 _D[#0HPD>;6S%R/7J9]V51:
M&T+=PQ"Q-ST@13*24$WV!6QI0H$.?WC:N$V*K?B&B!>VY!CW;I2D14OWJD^+
M[%\Q8E5@E ]KT0HP:GKTJT!?/FU\0TD 0%9BH[['>].?&M-WV]MO: A1;+31
MUH^EL+Y'2%(5R606UE]41EW)&;VE 6_(=1?U:9D)5 J;%0,2JY3&KT@TQ4=*
M#?M__/FG8M68 XT@$22\D_^;*T!]E;.J3OPZ<995V6@<(:05*/5^;V12$@A?
MX6;/],Y%K^Z3"DU]85)5@FFM#\E)R7-ADYHTAB)0WR'!-*U1+S7!U+=1+Y=M
MU P3M()U]HWZTW)37S:I66!H+S?*:=03PZ1OG$<NH+L(H-Y(-^6#Y&(=H'^%
MJ+^2325E8((%AEH:6:#1RYTV<6DT=/ A[1 :NB20FA%3+43 C9ML85/%@%Y+
MB,EK.1[789*MTA<CI)4^C]*F2<5*_;=;C[ ^%!9+K]C8/%,*0):PP4L%GD;H
M;HVD5#G)76C0!1FZ3]/Z!70/E;>7D+Q)3F0(Z2P?"J.12%/1KT,XI1R'M!LT
MR'']!B_,V2B3QJ,-"*X+CC9D4WH17(O\'ST0WP 93+CNFNQ (1#%#334=9#=
MV/1WH^33 H->@)((43P2B#LT!A_F-9R6X]KD;S?]IPW"79<?7=1(YB-$<S;=
M)-/@D-S /8$,5-)U!"?#L=5 'N ["0"32CP*Z'6"P>9&*B#  (A^'@PX:0 4
MC#F1P(I  "<$X"(L:2/H!&,!#:&Y4=\00+$0,+;QT[NP7*>QJFP$GQ/,*M>@
MFX3ZM@A5ID'E)>C;:M"S",T>'G,!B),("IAF)@I1!7**N8#Z\S_=2KWB1G25
M@,H0G,YK9&*$8+@2*VNDV0LX\P&3XFFT3$!ER8F6 $:AP5M )DW3)!>8FB5'
MY[P">7)*N  E;Z2ZP?I;-*@&(8VA86Y1HBH1"D.@WSR-'@-8-@+C"!68ET#P
M*F7XP\0F'Z*G@)H%8Q.W<X;D.C!F&K-JN.H%)<FA[#^H]Q/ _T3Q3C!F2F/J
MI,3?0C@;$L!$D+7H+]:-!2P8QI8> /W9K%@$.X5@9(*[>2 K1HGB(M03C;X/
M (P,8@J48!YD&@$0FQ)0,(Q9IJ)!<LJ@ /5A.RI027$#, *(R$",/79@WR&8
M4I@UJ0'*!10&0D6$&%N '#^]5PX2O 3Z64ILJ=&*FW)P#&;-RL%A#0%28@?Y
MG28?TXM;I#F-Z+N*AU$"G%BE;P.33B H6$@(AAD."8 &9H:5F)A#)(T2]0%F
M) -!=Q 3&SF^68ZVD9N\5:)$H:A4889(1372(?C'/%Q.H]$R"*]6HC00PTF)
M#E3J.2M1$P(3#Q@WH41)8<9C.1BLQ&7YH#T!LA>"SH'^;QLI8F.BY'J^ D*M
M#XZ%D)H0D+20VM")MX&,-C6B7<91:NB!R8>NYHKI%E=?*Q<* W[MQ38P@2B!
M;%SQ+70B3&<HR:M!G 7TVD*@=PA&=2$X#X1.4X&><@QCFFBA)"8BX";(V!,R
MMY;CO$!#MP0#"^#U(@VF18Y*U1B=TP"I2J(Y@%\-4A9%X*V@#=8)>]S89 L!
MNNN_% -P+4I4 V"<JDD^*B?3Y#B^!EP)XSLWO]D!I'C#Z-5LO,X"QN] P'.0
M,9Q%3E6B%TV3&4ITF(#.1]#G@$V_1NQ'6^A (V KQW*5  DP$2B!;6D8"YCU
M% 9<H!_R<Y3/) "7H \(J&H3P.3.O/?;C!L:P67 I!Z"_>#&?SE3<T*%9R#8
M6#DZ?@'35JX/]>-R85:,G-(,TFPAUC:$ /7KN< LR-27H'+>*E\5+027^;!B
M5;3<8".&XK,]L-1[%T'F U+ G<NG&>9*/2@96ZXQ90$F$ 8[]@5$G1U%$@CA
M<#^@8E"F,]<)/I=^134U>ER^8VTC8,4+4=G!V+L:4W.DJ4F(^@G0+()937[+
M]JT _J'KL DJ,!#!1LA!&3(8#OCF(7BHV9@%,:'PSY4P*QRZXQ+)B@)!%QDJ
M=V#7Q^VB>&CW<1]]F@<K][ZQU >U33K8Y(.Z8L3RU%"A?D(\S+*"]:_=!0^_
M0C]%:%8(RZ86C!=2702\20"#^@O3#*:6^^AOFZ%;0,U. MY=9<%\P3;O2(SM
MF?O^PQ1BH6D8C(J"L0X()HT]-0$SJX2$9,C(0F[Z&,(4PPQ/2&^ECUZM#R,*
M)I0OQ(A\F"(!MM:'^0P!<]@D3[FI2*7?O[5X6@-F^3!2?4#?!%*PO/2/!N16
M$ZH:3<1"0@[$$D-K)&PC!F+R0H> J6Q&KBKF&*C/@DUK59AF35B^D#DA1]<V
MXI-A1JT0)X88++FAV(<A%A@V:S!5/HS_YO$=T]()(VG.DHR'Q&>]7'HO#':.
MHLTUQ-4^% N8WE .&B;@^#!]M0"M)]2S5=)/ X9AH(&%P, B 3P-&$,)X QD
M[.6#WH30^Y<80SZ43!>ZN0JT4A$]-$;EY:!1(_D0T_B<'!6F0O,!X[!&XN<+
M!@RA 8LM;X6-=WPS"INF,1!ZIASESC;N@N)#A6@^;&RH F4NAHL:,8C\^16$
MOND_((/&B?+F\TH#7D(#$Z3H(08\-F7F\G,+F#+XR4 G#]I,!E">$#H"H7F9
M@C<N@F]KQ"&E6XXW&A^>(."0IN1&($O##(0!'(2F@"84 <I)@S("4#@>_V9.
MG(V4<6(:'PC09@546T0_4P7&*K$Q ,;J/O:5*8U%Q\!R[+4(3#G[O^+/C$]@
M-C<R8V#B(3;S(8!R4N+BA7MKA#072#+8UKX!P.1!+(MZ5+S&6"9$V<\R;RBQ
M !M-,6.5?F':(,;<+:@((8,'H]P$U*8$FLM]WX/"W7,!5H2<(@=1#HFH=AXJ
M-B'GD9+&4.)BY4ON0ZQ2 &4/$#^\%3[;"-P[?8LEI^A@?63/[\??&+" FEBJ
M^Q.CTN-JF$ZP$=!%'53BFGS:703&+V[C(C18%\&HU7[LXRQF%8S*@GKFRUO9
MT&77;)1:WP2"%JY',%D(TUY :Q92_05<?UA_4@,>_H6SEQM/(=WD$(R#.:;<
MB1DQW1@+[WF$=-<G4'D:1GP]HT:EQ]-(]]RL<[ IO,7'I&GT7@!D&[GA#A]4
ML"9$4AWNV(C7"' N0A2L,IU0_F<%U814'X,8V0D8!?3 -P&ULM$D"C@75\(7
M@=0PA+%2:+I(H[=-@XK2%,V7&ST\;'K"@[ -9G9Y,29_H[2PGB?$2%.9NLOU
M"D"U?CFV"69\@!;Z06M2='("(P#W2@M:;&14";%. MRS7+2+\%)G]70;MW9O
M82U33KJN)'MI,*NGB0P )\]"]6O(7@(]1$YLDQ,1)5T/Q*W68*[7&5@H#=R%
M>A9 J9?0<NTTV5V.\M30GNTVF/F!V8'0&0ET=P&Y'T8?EI =-$8. K*;C^$5
M);JM'64K)TFW$9_N1"%RS$H$Q6K$I6JB+L)H]P2ZEX88*-2S@I^/N1IX0"AW
M3=I&)&XAB%_I:9 [9XK92-;&T5L$8!@T>0DQ<)"CO(!K,D,:#LJ<VX^CP*M<
M )2%AR-;C,?(77X!P%<!!8!,FMDF&"6A7&CU%4#I3.2"=8!)^VGC6YXSN[SF
MVZ7A[6]_SD.P+2IP&<C,9)O2K@T20&&0G$+Y91H[S801JH.^R3N(96NZ<U\"
M,U&%"X3:&H2N=NGM5)_63- $:6Q-G,8&(LPK=])ER%<;>4VSBI E6#J^GV&O
MI)U;9JJ#08+0V 9B=5T2$1(^L8U8MLJE9?7&]H@H7$Z- KWVX$P43_=%3*/*
M@4V;9JJZ3LS2>*Q%9UCV.R@-("MX)>LW'OQK&KWE6KF3T>!V#Z859#(I_Q"P
M],/2 M\1N?^8_$,"R$#.NZ50\N<AM"8<ZJ>&D3EMBK"9+I#V'8#)$F.^:JBS
M3C_BIG4#]W\Q)P7]SK\_.9P!'\H9\:HESKG5DP*,?!JDJ-+O"G09154WM'4D
MNRC0EW0^KM?7R #76'XF[+@OE6XH#G0V\T\CT$73E1PK_]IQ>T.GJ&+[WNRX
M8M[;"9>8;/,N8J CXQ"M=\>_E;PW@?N1QDV2ASL;5\^/T=_.^8OM/^4<K\\9
M^:%N->$MZ7W!5R]TDM2M)&EG>[\TUE'8[*UPW3VDYFS\3I<',^.M1F<:KFQZ
MT%UR:9MS=_;F)TWW@@]I5**0A<5&*^@,7,6B(Y[-4%@U\9!Y0(S12 7>?,V,
MTGY\[IU\6YE5"/+"'F6UIM#"Z\8.A\'2X))%<WL_ :YVNH#+2?W<>QZ^C/G&
M;EN?A4V'$\U;PIRG%2/C5D'[%^V6-Y%PI3<J#+<>,D@Z8.O"\(C>]]G#UWJ%
MM'O!C28D5(]1?_TVXR5"; XVMMBI@D9LH_V5(PGEG,P'PG<!$X1Y>P&U"!GW
MMPXQ!-JTO0"5VX<#<@B#?8!EU2<E<$YI!>.VYT* DP#@X!R9]IP0Z=9KXTJ&
M^/UPTOYE.D*RS%>/:.,Z3/,K=7=NTXXYJI$$H?MR&4QQ@CK9920N]\X0>GR*
M#3H.S"KRW7.\%"17FR[H)LGEFN\PJLG++Q!_FW:>PC8T1U/<89FVI#I'T21@
MCU9]4KGI3<G(.D?JC$$(+HCF1T#GVSP7L&__GH"=7*;X8_-I1A,KT>,M6L"Q
M1Z#)=X=D(!7=UC8!N[4Y:8?<K4H-0O KS*U)V/865^$!%Z!CC''9J&_+^5MN
MJR@2KZ=%%+>AKDR!_<AOT8M3D?[GQRSUFD?0I!&O+_FH+4[H,D+RBR:8W1_+
MAAW/>F@'7;?O0)([[>T-0EP5_LB0:U8RK]21K/U46C/N 0^[W83 7L?+4A[.
M70^P"C$S59![F0/NLH^JT1;7W@5JR*%L3II5>BNJS3R_'^QI^P2ZJUO&A556
MM+X;:"LXZ<7Y0,NX,=?E@?F1\\UD"U=Q7!1*BH'9<(JNUZB7)X)I8]P$P'QL
M6.[+J?9 JD@^F+X2<VIL6#$9K[7*)^Z)EN&"NX=#E>87N)^ ^7E>FB'GT&9.
M*2:3LC!8WYV3'X3.NVO5C^UMSE#QK@;#Z\SIR$*421Z'1W:>%\RA4#=_]\VG
MWJB%#"*KD'/ W*O^":+YG5\']GS<=<]XJMR(-=B0B+>W*K(IL8?Q=@9>[!%3
M^ET3-+JP]H2/;:D3%&@;8B\8_B;E-Q'QKOQG$M #;@),&W*G@<0Z^U[ NI"C
MP=IY!&M&!(<(#'"-6 5ZJ'VP*Q7$%<DB[TFACTVO8/EJ+SMC5_E^V]^7B'KN
MTT8[6C9\<N#HT"$<$7AIB<HVT"#?*,T7C%>+Z129U,4?IK^K4QJZ34N(-HG"
MPUR+1*OQHHAKFX+ZTWS0I8C8F&M-LV2(D2RYP-I+B=I#*V4O4PKT";Z<S;6P
MR9'94FMW.;@,QE7<D@ZZGZ[@@OF3"P8Y!4N=T31GSJ!KKAJDV4\S;L,HLQ/L
MXCE&24P/M(H:GT'Q%0&815"@&R$#=/-/HNXV5SE43@^O(YR+]IM5XF6R8=]B
MQ'AH&#;DRL %-L]C' $5_JN"DOA88%S;Z>,4WR$RV $0;Z=)J T9$M=.".TU
MBW4OEQ>F7H-,.KK \Z5J8:3]-%7-#W!<KBS0;31Z3K $5/4R-EA@@$Y75TZ6
M?PBG))JC#W:&VW%^SA:$>.=3G^2JSKWR0$49H5EYI046GUO$EE(K5CX#) 3R
MY]EX^Q&W" ;GU[!)^<6:L &N+QYQ+2AX*#?N\,(M]N&+D\R3\ 6U@6R!K#0%
M6L RF*,B$ RHR\P3F*.R>>[(-,H4LCXRHJPC?]7FN]$2":/9!<&++^13N@ R
M5VFSY&@,9<%/ BM[.H#VF%,5+V_$7YW"&GBHA=#=7I,+B-"\P(=(KTHT;>0*
M"6).(6W,E[2[%3N_F2^D!?O@.CE8ZC(EV%'CPMA&$-(6:84K=QCKS9D5$%VF
MR4P=3V3:.1/ :E:3X_M5:$O$QUX46@AI?1V\M7V<WWQTG-:*E$8(I/G"Z"6U
M@'XZUV]^#AOK3$DR<9M1XB84)=T[(<S^)]B/L\^N7@<&@_I74>:LU!)60R<P
M\5.8.5Y*(377AWYHUI<(31>Q. GTP_)>W&I8PKH+&=HA&+NTM2)2OV#!28T(
MY\$7O@_TW6/74K9W"4_T,)N-JU/W"T9>2\W#$\@64_WZ]#X)4?ZZQ\*C?]YA
M!>:#2*@\5.MCXM4AI7N)O ]S,5F.\ORU7NR^^JA/\UKD0D,>B/?0ENY8D/",
MFA9)U\_CVPF25_?R6K @UW#_B8P7"QUTNT>"XS/-&B^L3&18IW>X#[H;;:)X
MS?$[,LH]N>@OL,R9CF8- E]JT@^5)GHE'1GE.QP\8DS=YG.,L3?QBUO>M"!J
M2TG:6W&@2[F/>[+3<\;8V\^7,UU?)3+\ZE][!KI,OAM.)AQ2QT6<;[R4F[:L
M_$[CY;2_7 O4JUNL=L>$+1JLJE>U.2]P9*9_.W>L[_#;)6=SUN?K!A;45*0<
M>F5U_*VXKG[MPS=1IY<P!]/.RX\$N"=9I:MC+396E?PD'=)9581ZXVSI*][E
M->8<S;^XZ C]P>OER]$'GHL=)IH?6I^83C'=R=X<^=ZP5%5YP>0ZI]VYR:JZ
M42LR'=R[./IY60G"N*^S[6QIBT_^#"94B?[.>C.PTCR>+'WT\DG6DX!YF')R
M\:/JMBN<]O!2,CV.$.N0\T R_W-(B>9#N^F56FQ_1?WC:U_G9GM96>RQ427U
M8UJRK5ZT;\NF$(_:%= U-R_;NK&7AWB)KM81KA!&OOL=7G7P:JE'CHT\;^=S
M+S;N\;]P]LHO?B?L L7U:3G"G=MVO'GFM7O@$4:4W49\$S_GPX3QFL^9US=<
M2NH>DOYPE>WU+S"XYLOU,8D_H+]_UG9Y]#AWDTGE":_W3GZMCZO6Q#R_D_YV
MT#K]<*#A@B6KO%>/M!YB.*8%')KW]S\W_!R/W,F:G#]19..Z:MF1UC6O*Q+7
ME*87%D?KSEAN=/G:=NND8=+=UT[?7QS=N?OAQZ>?3DU>>^EX].5HT(:QKC7>
MKQ=_=%);'OVF^+CLO9GEWJF#K)BUN,%_ZRSW/*K_]67E%X,[K[P_OAC\GTOR
MD[BQC]M+?GQITG-C.']\M=WT"W[?]R !-DW0?8R<X[KOBB+6>R(V=V@7&25$
MOOL9$80&V<+0@\)*#8&C!,T!M P2FGJ(F&DB1K9(/T+D0/ O>BV:3\AWM6<,
M*M;>=$L)7) R6.A>'Y06^F]VT(%<[H(]%^X[>4MS/;OR@FK%J]*V^F2[#\.Y
MX@R[Q5WBH]^=@L(D8WAQ4*+8OU82/NQ4AR]8,;Q[8:TDH,O]\RZ!;G.V@#-4
ML)U0./*R@)@M<+]DK5\KVMU2N*>V$!0QB/V%9@QI/E=4IMGE)I46M4@#$@M>
MN!?TWM]<NJO@ &'=K4OY#^Q2#A6*-Q(H*QB2?%?)L%U>X/FB"&Y1[Z[BUN_2
M%R>+UDDE#R(E@[("#$&0P2A,7E>R/:KD<II@V_#22[3"+"XCFT%</%1HPI6.
MM)3F=(ELITH]+Q52STGO<,N*&-35M<6W+ZW-NBMYX%&TW20W\/G6@*G0VLZ5
MT5'%KTR<O46K;XO25__K=";5_?5,V;_VN6VO]A8O2HG.*L^/D 0\=]+5BF<&
MK3^>+.A,*QG:*;N6M"_;)Z)+L_1R;<GU6IWL?T-+>ST8!9_\]AP4>M]-BKA4
MJE]#Y)I6WN!6SKTLM".6O<N0WINIG#^27%RS-SIU4].P4Y"($IU%N?<Y_](N
M2AM ?C(;'I2XJ?+^_%3N7F!D[X'7::W\/0<BG4<TI 4+5H?,J^[L)+6K)?61
MSF7#3@_%-I<N%2^J33EJSUAKGU+^_4#,Y:H!!6E4)-[^H*8XL&KA#Z< 9LW9
MV>*M=47N*R1_#&L>?*?L0_ -J7O2Z]P[-*01B+2O9G_HA8/U^-I[YTC2SKRW
M507HX9+/0858Z?;K:TUIE^NN66?L\B%?YV<:GSKDNE@ 1I$9T8Q_,G:6JKUN
MU1**^$F_A 2I8,=M75=A'8POU]0[22LWFA)W\$IM&)65</U-^S(.\<CX2.#C
MQ7MW,FLJIG97ICO[O\G/=T=MU?!N#U4]/KEZ/.A P^+=Y9TI2U-LWA&=A]04
M$0=\N6)/[5?R. ?GP"_[&$Z@"X[:0%0;!'=_V$D)A=V/IJ1_(X_0R*56J:&X
M=4&)-1.TXK'[%'N9*_G&7D,.H7?2J0<&FVBK5+OV#M'R6H:J$_]C%NF[U8G.
M[G5[\#>RK5Y6]\-@ 4!=3G/=?RGEX@G4-3=0P&DZ.53EU9626$"I# 1]#Y5'
M>I10'IC2TO?1HCVS$L!L.#IK7';B%/DXA#TNB+VZEM]NC/6;/J1+?+CTH@Q7
M?&%;)@T_&'#\1LJA6=._<J<+NF8.?3I8HIA'O7F!N(X'NO?OFL 2[8W0QVA$
MJQDBAX9N (B_?*0VIX@F,JS>B<.T&;_^NL/UAQA%5XCA,O0Q-:L$VN784JG_
MJL)0NLO3#A+F")WG'>EP:#4,.^#Y@Z+0IMT3;1X4K,CZ2KFL3;O^BC3,M[.Z
M1WG^E=PCH-Q$*.WJU.=W4TO>A"^N;NW74F[>V!3PG#NJ(5T^Y![RF3>6N79(
M33*2Y738G!E'<(X M;6Y[;+@J --CF;M&16T)F1MF3A$.:,!]J5N;9=O"3F4
M(ME5X]F2WMB;HM#8U/J#8O[FD2&=\V3JV>S>E';DS./:3;8W@AI[@\YJ2&.'
MFGM86T>SG#6I%+66M/K<%J$O==N)=AL:=00!<V'W74T;6ZO(Y(>*K;;5^-'-
MCS9UY&;9*6A44X#PGK#N_<%M20.=%VF4ZYS,KR:&:U9%7*-1NFG;+VCPFW>N
MCUK*WT*GS DBZ_&B.Y49D687^S2H.2KRT:*+NM?\/CFY%P$S($KJ>L\;$":P
M(A-9FG&5?^%[UGK4K@NZ^Z9&*_8%_W-(+UIP0GFR'TU$]8+'% 2/[X7[>685
M2$N#X"\IG[10W5(T3:@H8?S/3_CQN!GW$G&_C)!QDLCBG3JULE+O(@&:M[Q>
M0;BG:S2KN1%7O7E'&>_JH1+T7#ZI0@"593"A%<MJ.TX_KB;X7+HZMOY*N9R8
MJ#E-([2>/]VMKJNIZT);:\$D#O4O-6I7$ZH)H2SFX*QA,"3%T0I"62KQF'_1
M24A[$(*?4.(M(92-FC2NQ"T#,*9:4'D)W9Z,T5[&_W9$O7_!G6Q&3:^B]BC0
M43#*D(-K2\68R%&!,K#^($6@!0T>XS_=F&NE);5I4&\=SCK(7 .>HZT %*PE
MWU3C*6/_,2845:U4P"@;+;@1V+^4JS Z5/3K"CJ5 _9H@D9I?=9:])@OF$^C
M+N7@JB,HSDI20Q/&D@/F\$(<:#TZ]!7<BO^@A> R.M%Q_N>#U#UE8LI2.<8!
M J-D86(MB#-V'=2@VU]<WPS\YX;RQ3<*I'1,W %N 936T""Z&K.51EW%H@H5
M7$M>;Q:"@3FHL'F#EEI<VPF\*1!FHFS^YV0G]HVL$\(X*5'5ZHQL".4$X*-@
M\C4^W@E!A<D$Z<#B*&B]+8]XG4;REJ.\^<0K:K0>C-Z20Y:KT;80FN5JLE8-
M7KEF&H:@G#3&%P38*AB]$\#K<5"9"L-YA7@3!(S2D*L%HVOE,7P^/I2&W4>/
M].6,64+X K) >K6KZ-'MXM:39T=B"\<9T7)P"0^DTW!!A3KT]VK4?IJ9*Y]4
MI 196N9"/JF4CYHC!]=HE[GRT"S>E5BY;W$"ZI#6W(*'*E<0&0KL?@VX*@AO
M)V.$"T +&JH8KCRL)=@I0(8<W:#&?ED'5M)PYAK03(U]7#WA^AZKKP46*@G@
M*^(Z_@9S&NXDA)LG0!.I.)MY1-L(%$,S'J>\Q^" B<HD5S[LJ@ SAW8]N-K]
MEW?9N.S F_ !/X@Z O7<YH!9 HPSA]JC!);"E ZMO9H/6O:23&3D5@[ 59,D
MUW#M$-@!4;=KP'$8YW: 8J-%3R!HSVHR78E3 &#M&3P$I0]680(A:K\6R!D$
M_'1:+@FFQ&':;#C@DBZ*D197]P<U^P/=06L>APAZRMXO.66WY7A#Q7T'#J$=
M -L06TLMUU#;LUR+FE"2;)"ZHY']:9<IK3P@2$%ZWX03:>;>5J""5H%M?(P+
ME'[J&W"41B8J7%* )\N4MAT<E/MYU!V FFQ%U>.$]@.$-F>JE0(W 0>.( 22
MAJ10 WMDE"U:X#:"60Q1WU?.)PL>!-&">C@I^O#YL[+A$2V)J29-<' KQ:@5
M$)7.(5S6 'MH+A0M.8L#;**1ASBH31#U+.WO=B4@X5-2>8#5P^;R(%EOTB&5
M$N4N(*?+P6X>D0K@TR\ NFO\1=D<LID&UZ<!LGDD-(2I5J.-.!0G&J8+PK U
M9+X62*>1*-R7&?&8.1#%6T;+5@#;Y!0W#JJ:AA<OH- 1,)1'K.:!/GSB-85)
M[Q:4E7;F,)WD!&&2C@&^&GPC#_#1X,V42](4P'+V7^1HP;%Y:CW[^N<9@+,1
MVEQ&(E")AQ&4G8!4FD-B\=#W6H&%,M)<.?H40#3D$^)E0 B?<%Q%+-$ )J_,
MRGE@F8!D)T.?XH&Q"@)%32B>!HH-P/TRTAHU<OP?D",CEFN > "'EJ.+E 2Z
M!GN*AJ/3B(5JRP="=,<T>%4%E ,^Y#\8?;F.&,<#XK1SU)\*.7+T:07A\C@6
MI\7^W0B>$J 9,B:#W^UD?W^'\V?IU/Q_O@(I2MP>=<^$AJ1/TP2Y@6T*RH0
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M2-C5\R36YL$3YTJ/;? X9SWWP@:/.^A&U[\SJRX_-C2ONF-=MLI]H<S#855
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M!!V!D#N<P&YZ+G?,I1K7NT >\\PIW!4("+J$:L,"@;VW.U%[\-FRQ 3N"J@
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M"Y!B"TJH!)PHT;9_NRB^?77D].\)E\5LY:(P;/&Z[:CV\PO5CB]?GGTH/#U
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M5OXURF\U>^LR?-+O'_C!+D3H9/OTI\YSD_L*-HQ7^(I QM(UTV<3_]!<26'
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MM2YV=?.%#+MA&\)?R79*)1RAA/<P$=J<S05JX#0+XT/*UP'0GKPD;2KBSG+
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M=+O_ *YP]Z/&D"81AA-H'4QM5*]A:*C_K*T4AHQ*5P^,)P@>6$F=-W;MWJG
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ML/W;HQU+$4(O<HR&M3R* >-Q+Y%J5(#%W@!TPCU7:)=N 69AQBK>B!7!+W
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M0*%& *R^PT*061^,KG;$0G_^]A\0*83Y 4";%ZN%(7@K%J\?MR!2=O0!GO[
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MXJ?6<Z54V\=)>3]M')(KHN(WG)+_S%[7H7HS)-5+4U*E!HS)=Y4;^ U0\*I
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M%\&[ISVCTOIP+1/!L.-8."PXT"A%HQ8+%,5P8LWE$B2$S-FN9U;()5S_ZG)
M]_CRPOXG->(WZ84+%\7^5P:Q]Y_W>9_J$(=E&0!OK>%0S((8P@1,5(!0?U.L
MK1<[" 92?@#<!1BXGQ9IV7*8201:LN@ >-P; K 4($"5!@.K N!PQ1U:%[>7
M:$  SCV=-$]C 8?U &0I("JJSD*D+HUX^+F+$/PFVA^'+:%$M0Z"<-*2]=JW
M_YRRNU%%LK);^_/#X8:>PURWH69.1WBT8&J<ONWGJ7N?HYDYN':#!"$RL%#?
M3+HH,B6FZ.DI^FU(JH/TGMOZ6':?BP4'L5G39F!<);),8QWW]@8,\H0 R9H
M7L7F =O*4LV)6GA$*4MNJ119[N:*DA^FZ^U7,3T2-!*>-L68JMZ"?4C60P7W
M&9HK0/6G6*C',8&\ZXIHF%CX 301Z=MT?8-%1^JS1.2>+K>L]M?]9U&N#,#_
MV$@@D*TH,8U4HM<J$QW\M")&&AA_3"."]%+@&!LQ*&E)C"!KY.0FP,B[5FC<
M9BYCF*GU> L AKFV6_=YJK+G];OT \-G_R3MDQ-59,@_*?UZEBU<_9!G V3I
M;HR[^A Y@M-GY!Y6Z@9,V;21(8Y-BX)U=3QUVP3(,#Y QF*GZF\IO&4"=RI;
MV:.$W4K*7!:OEL0/0K'8S!6KY=MAN,L!,)_?PRT3A=)UI9-Q>_@@U&/EF80E
M -F^M.0QK$'40I-A82W#8^N!G>O\;X_>/%I<?>7X]_]PDE&W*UEKIT\77 GC
MM&RN+W?1<J#4I H\$3V4^J?V +T*C X^#M8?%Q13I"G+K[6$F#(FT8E8$2RP
MMLAY[W:$L8IE(&B'X8(5\!4SNYRNMT $S8RY1%8?-(!>Y%*PO7B93CA&NBX?
M,"\4H9,C-\$"@"&7E-<0QFR_<94BP) !.C!XNF_Q2H<(-2V$1WIO.M1R?4]V
MZY<+ZT1A/<6%X /N'5(7?B A?D&-2K$O#FH2HCO-/J'\6$61?#':3BVBY6M@
M;FFB?]9Z_^[T" +WHR HDZ_SLEX7%+_&8GN@T37P<ST6#83*'+"]"NR\ '9C
M0#RQD+'<3WZ:WYOOK!_]! D7;.C!.#FTE.^EDF4-L-8UQF)01R&5G _RR:'"
M!QS(V?<O]I>0N"ICONIKBN9++@/^(\<G7@ /VX*,0L-3!4Z%?8M- ZB= J<"
M$>K-*/)#^H5\W@^O@YOZ9\NENO9,U3;?$GU;J4S@W7"-$5[MQ2.&!E2[4PU\
MTPAS"OUY =&=1V#R=$>W$OP""!00GLDCOM( YIK7=SZ"?MH&?[?5K@P&/W>Q
MS3YC\^P3_H=T77\@884;H4X\RG(C\%+POHN$Y6Y$_P[[I$9VY")QW7;PQE/0
M].T;^!'0S$72CE,;Z/2_LP,N7I+(A=N=]G9@]FSWX8.,!7V9,EQ7=0<Y[JR)
M9"QS=P6II4(>>5"^NXS\14Z^DOIWOZ3'*]C/:S!HN"+(*PT[EHJ]7Q'<$XH?
MQ)D38G#?,BR,&"&]:'R8M-JZ 6<M@/R[: ERI\ JP3488WV\8Z!"&+I T9G@
M[6<-G)0B3,<V3-C!95>V+W,>+\^SM;JF0N_*L'+KQ-Q4T/9-8VZ\6?9A.VY9
M3 UV#!<GK4D:W!;?"?J[W58_;)NIB C/L]O5:;</#UOF3C^<TNR L]5CTRLJ
MZ1:Q1AYYONQ.>YM.S')WAV-YUJUC/O6??1SR',^>=[S>N4P"MX'<W#):$60Z
M&71ON]EKG/E_^A8O.X!;'2 ;D,O\V#5LC VUP\6XP_+W3M=_/[LZ,SY5YC'V
MT:AGVR@H#WO).VB=>U<GWF'U[2\M$F.EE=5.VV6_P=TM'SR9I7M<J207;?T1
M&6M:7O9Z6D.8P?[C%1"B97C^U^*93/AGK<?K%VXZ@KN(P SP>ZPQ7__6>8VU
MS9<\6Q.5Q3=W"\@!5Y#'BB-?7#>>LL5_6;$EAGK"PTV2;C^0XF1!</]C\1/Y
M/N)TJH=6^-=1O$?,P8N!>-^N1<=U:WS[.@_UNO5PT@@&/'@D!6X08$!H0)&I
MP>Z3N*/:5\_N;[O*1>4K67VL:HT5H1^ 6P<0B%3T(&7Y#S=<OQ:+%V$)5/1,
M'JZW&76<\CHW+X3<X1V^UMM8%40.L*O9$;*ARBXKQ0>U8W_)N#T)'RJI=#O6
M;__AW:=^AF^.")W5$'9-)3\J<!(WX"=2)G:+C'5#^FE"XZ;4"PZ?]9)G[&]Y
M=#7G^;G&.E)W,#?JT*% .(BK17%9(-I%G%<#'*K6JY1=HJDA1RD(LA(^<A]B
MP85S4*"E;6:>?9 VBE&G%A2M!/LIGQ\7_F++')N^5U -9R>7:,W#T=2XZ.#E
M?Y>%?*KTQC&\4YM"_+_%>:K681^$FG0ZLF-,7Y6OE<0:'QC-;&8;_"-,R:8N
MG];BE2>)?"KQ+86]J/PS![0^,\ @QS.=+\?'VIZ+"#"@BXS;!A"WW^&GA"6C
M-.*4%L]O(-[;X7B!:'6!X+_J@L>ISK\Z'ZP>RJM^]F:-)\AHW)9 F\0Q6 @_
M%O9O)BR61XBE8D@4C$H?P0GX)6]]R\"8*9,-N>A8$4%'TZ)46]%_?<.%@N#Y
M@)$?"W-NVHD*JK#H<L)A<9,>P5OPH0K"VI""M'7;;<4V0A_.NE78]$SBNKCX
M]%4+<^ 1<ML.HN]AX]TCL)5"6(81VHF+<* DDT\B5E*@4@K,@L5W%<+7JD'8
MN_KW^J$N >!/4V#Y8ZBX3W\ERV0W ,VE0&E:O"S P)8%XPO!*BZY_TY8^R&'
M-1\W7L%[7#[B?TN<E/5Y2PL%W#UO-J!\WJD$TQH"O:@X(@4WL9,8'8"U+][\
MP'/K530^E(KPXQ+QDWX6O,WV]NAJM9[+=^A1UI9^ /%*\CR4A_(3/E^2Q6W]
MG.MQ)#BO,HVW7%=P"G0JVDO(+2 5QT+#OA6\R\U8X]5"EU^TIAA(><8KU88N
M(E!@ #FB >028/!/.IE"01Z?-+#@DK4 J+H&3U22IM4 /:#33&TL54./\\B-
M0I*6"ZD-@ <"7$T(F0+<77#29_6!-[EZ7,!/3,1;]1U9_=^3K6??.-[7V$0\
M,"N676.E>2YOJ%Q+A0DH1KUJ$(5*<+@,%[ V$SRC,UF02^U/*<6B]PH]O1J!
M/X!@"*_U A#KY9AH "\0ZIDRT33A\C5,VZW%J5'Y<;[K"O8MQ1TKVE]0\]N>
MFOG\&OGJA=].@L.V7C+>)<);<W],99.;*3!9 U$F@C?I6 :A%'+I>@,_/E@,
MTH_4ENSAG9VB0&633 MUDH,2DJO$2T'Z*X4F?&V[^)=3==^%SR.+67K9 7I\
MWC)7#^%KKZ0/CQW#/I>/>%K>'7L^M=.,RL.-!($R*.BD+():"*IJSMO. E6S
M4API".O+8*(HA++\2&A %HD:,T#)4E,(T3P"XRVQA_4+%*&)M_)K  ["*V[C
MC^  J.7/NQ56 2&_>]<=N; NTBM!D4 J2Z >6*H[V58 :<G84.14[UUR8!Z?
M$Z WVDVT#D+/:B']HQ#-'4.:VCE10BJ<3'ZK/KZ5E_W[^72ILE,KA#S[H?KL
MK9??  H$<6-9>CJ2XT9TG8?A%0^T29)QHM!NG&A:M^UA$,@B("B4=_B_ =!"
M/KQ%1B!JT=&3"DX#N(V5LIUE-&=4%=J0@R\DN(,P9ES4'"/6O&&56PV!(T)G
M*"]Q C#$MR@'%C8N;Z<AIW8K'A\87W?D+[NM*4=;5\PW_F2<\"G>\.C3UQ;P
M..L7@%]DB4!OO7>Y]I56YT,TI7@+X04#[2^E&Y*TI!=*"!_KF1]PJ*[/Q _0
M?ZL%S]6>R*(@YY8@#GWZ!A3]W$F#RIB&-UX-DU[6N-TTT$0YV[W1YAF$(8PU
MX:V*I8(CGFV:-#3*IVR^XHS :]<0L@AD'M$BC>@U^-2:I2/<VTD@\G#,2;3>
M;P)C2B!B#$(*B/TC*H <W/6CW2;\[?+B1)P-K[7B;[N3H$_-5Z$G+XP>?7ZE
MSOM85QW>20AS4L.];NO3A3!;%EK:IR\X^7":16[S)1-E, X%W)G8,S"+=U*2
M+ :@+"WD,1U:.PE?2+@A$1DW:R$J-4Q%(9*U/_ ;-OH3K'9D6$5MT0NX@+&Y
MYN+\#6H&0,RT4/> 5?0-6;T4\-4H!!F T+CP?#7*^A(\?C=!%U?]W0U,7PL*
MW@LVHZ!I/Z+,60CB#Y2%44!G%":4"KX*!!,$(QMJ>A@[@V^^V7EXSRV$N^G>
MY5?W/&&\/!?:T'-4I+N\KNL*:4&)K_5D!X$, QO<LV;6(ZZ0GM'T([G&GP"B
M4D+B\YTBJ.<NFAGN_YIXUVQ9:\P]EX!4)[6^F'H/5OO[^:\7'U_:ZA_7X1S;
MN24K6$\@.)OA:3F)RTG 6_"Z+!NR\RZ(%YNK:2(<MA 5S2*0^W#L/W#Q&W$]
M7%S\#K_O._P>6N&B^_Z;T(RL9FJ1!QZ4/>BI.GYKU[^64=_3S[XXG;?>1Y(\
M?Q5\;&-_>?57WP$'DZZ3?0>1V==K_\JA,F^EA+4+)G:W&ZN4X"0UA"]4##%\
MR,MR42_=J<N8U&?+QL9Q.Q^<&L ]N1EDMIVPT]C\E^.,[U1O>U%!D._1U\6L
M#W[@MGR%"(U9;@;K#:[HZ=Y97+O"NG6/_Y0]PW03+/V/JQ-4]FA9Y:A;[VG2
M#N,K'2;;;-=?>_17_O1]>^K&SVQC4]^-AE<:#'L<UMU>YK$N]9MM[4<!Z':>
MBZ^UV8XON0>?VF85VZPWGK+1S:RWD:^Y].;W,_'U>T;K]M\^0WA[PMS]K(4P
M^97]2<;T3V.' _G^M\P[#%\JBCJ$X1>2#ERMR7G58L5[_V9,%A*<&F3MK:_Z
M]$#W*8985['_SQN1HY%>L_Z;0@^1%QKND%OJ-_I^_GC+8K7)[ZMQ&ZR6+7/8
MQRDI:O_X^OML1]S?_?A/X4UF6U?:SF_?QKI1,]?;S1MW616LV_ES>.;G_C]K
MKK7^4;>P>;1@C>>Z]%7-9TQAQ6-W;Q9ME+5_-O2[<RGF[8,_,/<)TU8WT+^!
M-"?'?;CU/K3CKY<6#F&K;"5/J_^/HO,,:K+YVOA]IY$&":'WT%N   $CHB80
M(#0-5:09BA0+352*)0E!JH@"4H70)"("(B B8!****B@J(CH/Q05.]8'&[Z^
M'W<_[,PY>\UU?F=G=LX1]Z]T@P?_)2T$E"SX')>Z\G5";OP>7OQ^/'_W?OD_
M1]%/S)'ZF72$M@BR\A>RAW[*=K@H]X9:LJYJ*!$-1*JV!_<D3:,1.=E6/.S>
M:3UJY\+P";QI\$#0A/)P3K]FPKN#S6Y6A;)V,09Q]QLL@^\T73OR^KY_(Y.B
M[]Z:;GOF/$G=C#W>=>N\ ;,X[J5!1DF<=PVEP#(@P_;" V;QB4=\- K;Z+TK
M,KHUGV+\L*6J/Z9AXX$+<U7QC]==][RU;P_V);^=&RS8T/%\\,BOGW\P%1W6
MT:-HC2V%U,N+HX4:FXYA-W8MWRH\+5]]Z#\UZ]LUFS+7L0Z4R*B1HA<G8Y+U
MQ.%:_-)6_NLS[1Y=1W^@'^V-OO1T*/6+1&M?Q*4P\;&/55H>49_8_;SZUX+K
M@5:+DUS;D<WGV <6K^_9C^O%J'1\Z!$]5J_;?#@AN/O0A?)P4[?2<)Q?;??V
M^Y$3UVWJ' :OW2+(1,N[*LM0+M_2KRRT01M3=NO=,JKV[[EEHK (N\63O=^$
M,L8Z,,N,L*[->0:R3KX166>2%D5Z+9P%AI%6(#*2WQCGJY<3X:B;9U3IGZ;L
MK838K9A5Y;B^UFB,#P[R,ZHU4=OAO]'NOCL[,#QO]]G@A-<$:WX>(J8BLDA-
M+7XZVK70.KK]5DRUX$+\9#PV?D8C_7ZV](3M,+(D1//PFEZVI@V?>-/R^KR8
MA_*=C<0H'\0&KU@*OK)Y6 $6>K/N/#Z"ARE%9KDB]:WSLS4MFP"TLA9S^IRE
M7VIP7GWY>+$3KIF9X8S>$$KP4C]8F).M,\BDHV0/?(7DH(U$ER<LRFK472S*
MO[+<%;7J9Z9ZE!=:=,+_J!E&^-48I-!46YAG;BMK,_IRY:C\RRCC"-)]%^4J
MQ\41;)AF98E1A%0 U=?*J!]7L./7H_+9,YTC^C6.>F/ZGNL&$B4Y3ZK$75EN
MI7-</R):SU5O^\!$GD$ERSI+E6V0$FU4>$3SLX+M5/+R-EM'GRZCHCX-A'$E
M/YFI3*4N(N7\J<(\O8U2FJU?RO3H[AG?[=X]X=/X*Y75P8EW>B)':N)WV.X\
M['WH2;2Z;44-]OT95V3IN\\L*Z.*8H2RKW]#(8J.A'*?QINLJD./37:!ZA)'
M,L3P^*ZN"3C=G\" B3NGH+:D3DZ!AC)LZ800]MZ&CBP;[P0N8\9U)V4M^80<
M>#VG"&ZYN8^=CNM#?N*2=1G<IS*^2%LNW"=4STVFS/\,76O02SI&TL+J,!3'
MGKJ?<3=-#BDP^_7$L*1T?5NTCXU!(\5'G&U/UTN$*;L5NYA9,Z1BPIDTP%E9
M*<A:-]^?49P(4]S!XC9; ]A&@03&.L]E4AM [57.R.P&*"Y)3T:6*M;KDW+\
MV #4.Y=>8'\:@G4$$<A5GI'Z0A[I'XFJ"FDR&IVYWI,TJ/^J"$&ARWRS6P#?
M7P2A*<4\9 T;)3<N-I'@:<9>0(1/ZRW]5O\>$X_D_!UF)ZHF3XR2>"_WQO4W
M*-] CMVL0%@)I\<M+;D<(-<LP50 R(:R>=NGB>AAH4B++X_%S-<KUQ<'(G.)
M6/1\LJJR@*%%$K6$"^@J-D0)V=*G8&?? G@]:5@F]0H&LSXC5DLKIEF5BB&F
M4SRP% FW<&#QPVDVBGT*"$US>@$+FP7W,Y%[QH_@4DP:552*):08.E^6M!U9
M+A@ES4/1E"FW3:K7GM?T!A2\?]B\U218 F [.]P*(3+:JR.^C&502Z"G%)HF
M,HWA<+V;G&2TF:.F$CRWV1' MM!<L-LX^<!YB-+\/!\ZF9V_MML)#*6.;E/E
MYC,<:?+5JSH;[9+RT8Z@DOP+)SU5?)Y?DA[$J'#$J(_#]8L3H10OB50LJWR\
M11QY8Q'=S/=3ME**@E(-FZ;B3X=C81297]U.&UYT*9KX)@L9%JV4!I_"R]G)
M%[R\'^R>&ID1NJ[;>;=<KK4(8G.L"_G*@VLT]8IIS$ML%L(%::!]I!Z#D7*5
M2:J@_!9\-NTY5Z5'2#-L*N:Q2WG*$CQ"%JA$R(W3D J=+J_(Z5P'I+Z<UE3V
M_/VD//@X!U&:G665.\75GA+!!J=<\!0I0+O?I3) !I63TG/")AL@)$$;]B44
MK1P$0"8SF!<%%RZ="67HFY\^[WEW9O,I7UT0+5 S<)R&8>8+C$Y))?IZJ]9P
M!R+!MD)\TI?%5:@1P)28_$+)*M 0Q\.\>,!1L3F=9QDGQ6-G/Z H BC3D2-_
M>GQ$[T,Z#YF*[6_IK&->E>IC4^F##D_Y,D/%G=ZSB>N*ZD"=$<PK6W9?I-&%
M*9C;J9'<UXM$1 M[!+;"HJ%VB*#&<0(9CIERO?K!4=)+7\J4J_J%VZH%>Q8;
MPBA+HVIO*_8EZT7U-O5@3B;UP(*08\YQUH6N! +N7 ^P[$7$QGXEMF<L9UN@
MTW/0V"C5@170(H/&#S81$"8%+O",Y*"G";3+HWOE,/=9&,24D]IMD_.:Z@),
M[(P85H,Y0:8E<SRG:.A)O*O,?8[GBQ]ZT.3_?\SVR6.-<]5N]WUQ/50P^'NE
M09_T*5 _Y4R>5:YNQ+?-,,A*4KY7DQX&/34"ZV5/.5-I)VR+\5AV)\J-$?F/
M<$?T-$6Y7C42]+HZTP6.KG*2=92 >0*T?NW[&YF;V:B5BT#'G\?_0^=VHZNG
M^ A2_K0_4P(:,>29;I>Y9E(F-&S5">XXW4BB+AHCPAA0*A>J6M@@__MD$N."
MX(JK"43H>9I1@"M:-6^^E;\IH>_1Y(Q+CN>\]^8AS!X3IT'';1&J;LHGGO,7
M@(U>-\'28@G<9 &!JF"KX%C:$V_)A;AQ$<YFJ@O-[RQ P"[*(&D_7FZ1X5*1
M4#G"["C9B06+@=$OQ<?1#$VF <?Q"!@.<$%Z264HCASEH#2.9A,+8&1NWI"2
MQ-%X W ILY$@8S4+[T ;_,T:R9@T0&8Z+#XMAY4[NZVWWC)*$G%(!I$8F30G
ML[-D+H/"@Y)IHZC(J?UD*@U;$\23X77G$6J(A)PT0(G1RG4AZT$<F-DO]4_G
MHE-! I:MIJ],W@-JZ1&PG9)M>DGY2&&(@I+ R<R7#1K_Z_@B*SIYR<=%"<9;
M(9[CLZ >/5O&8%%>FPF:L8MY<G\/S"HQ1Q6^:N2=);A;,KC!DGNGCA7HZ]]4
M2#P>-_5]1L/\X9^O_V'CQ^*2GT5JRB:&5-?QN/#"*$SQ;HP?#1J<A*+CT?$<
M%/T$O&(*TX>'9_BAD<DR8MJ!F45$0A(JGJ9]M1A1)L64"0Y=!V2.L4WBIX)+
MR5K)9+=Z/'P]+0G#$$ HJ_:]G!U)@$RI"(-#;ACDR%B*(,G2?QJ$EGYQ2&F1
MO]MT'#LM/_@B/G)!N6H5ID0&"0&V#@)0G0S5?@A#0E!+V:"F%"1%*9X&H"%K
M,*H$M!6%V8E0-0 J7@AZ=J)(H\@: <I? !K1X':LO9XL, >/Z%.&_FI Y>3J
MAY*A>5(PE*Q;!2!.Y.;FK*!RV,X:G59E5[.M\:C:5=BA6:1I$C+4&IK1!U/M
M!,D"XM[3"G(I"B_+CUVI.!8N.?8MI^!TA%J%[O&K%04W5E258E5VE^H\F<8O
MZ6H93>]\(8^56F.+7+0G3\M/T(V':)@A,E9Z>EWCPS3^"5T3YL._*!^X?%IC
M+F[WDSCMR5E,7(#VLCC@3J[[K/SA@U=#M@GCSXWIU+DF/3M/7'(S8"SJVTWK
MAL@;'-NA2!=G%N?J#9XE:H_J0DQSGAU2IA)0&4(%^J+^C JBD8C =B([9_4=
M0+V-G_5/TDYK&Z).T@Q61G4W1)R6^X%<?<1PI1MVQY6\RO$7"4N*P>3!OI*M
MMU37-A0>*%>_DRJ/DY>'B_'NIH>U%TI=?I0><I-O79#W5RO;-JZM*"[].EO*
MN$!8&]_\,TX!MD$YVC0[88'H4H\R[K2*?GUV]P7ERF*X;#<8.G4X(?WLF6*%
MV!__$+VD*ZV$N]-_XSJJ-#M/U3Y0A1I34> >L.6$Q;V9LM-YA,JS.J6FE6=-
M#U]S(53=*C.N)SP[<RK1M*KQ!Y'H5-64IV^47M[R.K\-Y6]F5'%YHPO_6D7V
MDY*\:TD]/TKV\+!['O!-(\IJU"H#7U>.FM8\_%*A1J^LN&#Q?5J^ N4]E7?8
M9Z5\^T+5X[QSC3O/)7S*;[]5?GZG0J=I]9*[759]=;;:\;[TVFS3TH/)R2E7
M,1(ZIMK^<+)QS7Q09=]#_FAEW9UN_IF=IZZ-6OS-DV=O](Y$^>MU5>$N*%<1
M=>&F^M0N 2ZE/,,]"7Y-D51Y[FE>9.QXN6:P0B%0L>S>$+IH^/9:R5640GY>
MP[IHMN)'2XUJLFM;)&:0A6[&:WV51T\(,;&IFFJ7"4,LF=LP03_\W/JMNI\Y
M.I7V@G)W0KJ* O*-<J4(M:L3%BI0&/R.9+.2JO&(;31X09)!31(R4@H/)R+4
MNA1K!$@'UB[W*\5*[LTD]^;(X"H'.GQ_Y;FH"\K$C'.^)K6&9L+ %+LOCQN^
M7BU@'12*9JN+4)6S-AM]!3M(G: R$:9U&>/'!C78D.8I^0UDB T'<YV#HAJ;
M*HBHWRIJ/-:$M;>:O'^TGLK;G!JKLW8ZA&4FFVF<O2%BUXXTR XA4OX)#,)A
M#P9"Y-@031$ ])[%B,#-GP OAE(U *4FK:-35]N:C/4#R."]C,A"%D2; ZU9
M]?'DZ$>RP)2%%NG.I*-S>[5:VQ-\2K(\.G8X51<$'S?[22#E=WQ[7$O^5-OU
M<V/9*G"%O)$B""8 ,I)B!$Y$M9D"G3= TAL]*7B903)F> JZF1W]RUW^SFNM
M7^Z'IPPZB].;_EQK;6]MFEZ.IY6A%(!T)5^(.LU 4Q"&LD%;D\%E!W0@&\@C
MHW59T$:!0OSLX:IBI.@\"L>!4IN $ [:D$Q)!1#5+*AF(+BZ"*:N*E6+P.U2
MU-^%]JBWY[8]J&K8V/"MM3?P0<>-BEKS/<+];Y.:Z^TKE;$^>,@I ["?A>Y0
M0*>O+R,D GE9/-JW&#I-A 6Q4"0!%C.-26&E7OI99^PI<)TKF\BSZ/;HVA9,
M.,^YF'E3,6(<CJ4UKPPC_:4^8<5I%@VV:,#*(?E2$1FMS8)2LM'_.VQ@XIM=
MG81$*:*$;(A=$EH3CTBE6;<D0?P%:&T X<^!"E>5&HNA6UV2=/+/O5/OH%XN
M3Y07[GT[^.%U0<KUJ*#A@CZUH<5-49*5VI)*]1)]J(0E(YP!E:>@0V0,;M7^
M?3V8S$(IL)#&-R'E-)0)E8<MYKM7=8T_:?W>)[I'N7CQ38W[[9!O?4VP3]=\
M^Q7O3X OEXJ)%.C$16B+%"XG)1>*X*$ 8KV C*Y2082+X)29PXT U(C634E&
MYPB L-4,V:^ 9"]<$T HT60,\:A044\5"R[/'MS;7Q^[UKYMLBK^UZ#?O.'*
MTV-[(/8O]XXJ/!:2/0CBU>0T-M#FB]$@PS>JF-]/CG,NAQSF(/RDB /Z%TZ7
MM6K_JD:^*SM<(ZJ[(*JNOOE48H) *V3>;'_:+=[KH"BW"BLB0^?L):<XSNI2
M$,%.,Y8"CFV@^6?EQJ0K:@TH!\%X=2=2X0"Z@.T'^D)R6-  #M18!,(#MMEQ
M!^<W]CY]VMYP;>3J;X;_Y,3!RVI-R4,A;2ZK.X:2S"<)_W58R7?V[T9'N4 E
MP$&8_#HV!0\1 ^#Q%"\E8LJ->HPN"]U^ *4RA2F5 @)@P^E;?-?T&MG0BZ[7
M;IZMO.MI-IZQ0>&(:;]<DK+:_>N5(C@:#]$0@9@DY"EI/[(2K4[VZ0Z)J":#
M#GC%106H(1E]1H14$H&Y2;H7QI#C>R]5)0T;%R/[6BR%;+@\K3DFO>J*U\2>
M^OM1E0K/GD[LR;2[.9^4]Z:$LCDJ?+':5 /KF^3>0P8/-V&=:)ML1)"CV3*R
MY#H975B\"$-8]52>PB330(E85/GV;EE(DW7PYN!G_+>3=5>J".DRH:IMRO)D
M:$LG:CQDGR;[TO(;T%::IK2JWRB"0]EP,&"OQOK1[7^#LK<T@!MI/MM\X4K2
MZ4HI,/\=6:F"R".#%Z;@FART[3_;&&BQ^-.2 CZP#NNP4YZD[K?_^8;P&SWG
M4S9Y UY7@0>IP3+R+-AF&E@^A1&PP8P'0 )-YSH+920-HA.A-GC8)#G(%?$H
MK5#^9KJ%\=N;LK^%]]*;C!:N^<3UXNZG*P%0)?*N/ &0@S_MWPE0%D < -5F
M08PZ84(1:$U&6^=!7SS8>Z.W&24%-45@:PM*FP7:L4##J9X SMX:/&0^.DU)
MM+^ILIQUI'?;4LN1?N63Q-$:[XZ-/YXTA]GGHJXJ;%N(/C#GUMP*L\9:LCR;
M'.!!25[KPW1,/!Y>QG$O+V[MY2#BI9AZ(BASY"&^ID9_8M[\>I?WGGFSBZWO
M)X=4)NMC?> ;67"'>F1D9_FI*?A)HGZ8 +I=0,N16LV'G2X0-7LGHZTYT#-3
M<.,CDN>C]S:*X/0SJ%01TES/&OXBP5BV(^[:?91<!V;H"=Y2&%2RX%<VJE+[
MRNOAJ#.JKIQM,3Q=>$T)&_H(?T*"?Z,K$T_3&?TGYUH+ZE"E@YR@XL)#==WE
MZ NH6KQ58JMR]905H:&<.6RE=*WJ3"<R[(. VH6J>(6Z>*&^+E=_.ZN-9/$J
M\^=(HK9*,>O5H6VU.YQ559^_VO^Y]Y?ZU=$$>XWUVM(GZXT$Z[+3KX/L:F^^
MGS1IVU,ZE7?M/]W7UOTUT^=.Q6Z<\ /+^[7/+,OX;[-^.[?Q673(('+][)#<
M.S]'5>OS[^HMYN[3YOX+7S@^-/3<LA(RM_38J88SOW1;JROD_=*1WU%'WY55
M63[##DFQ[6^5[GU0Q'W\4/1)'>>/V_)17%O].\'>_E*M7IW+NEQGV,Y5=-UJ
MR/MWQS5?9[;=_''M;FD"1JI]5KGC2^/.8H]DI1?M@UTU@P_"SMG=9\SN3=*Y
MT7LKX;-B[,+XMG?>.D:3M4N](LVGGS86/V\TTJV9.Z/AHJY5IX#5^L#O/UWD
M,J<UEW!S?NAUBGSQ)JOB ;.2=ULR.S&&W]9[4+7KIQH2%)*9"H%;OCK=&TDS
M_;!PX:O-G:^^VXVJD]\UGEO+WVJ4^E88=)*PZQ&H18.Z!WG,.95!(S "&JK<
M7AYV3WL0#[^=&@UWP/?CT9O)&&WKAW1ID7_ESS:=GSU$Z!^9,HV($ $1MIUE
M BEX[98N[NQ3KDQ"FJXBMW8H3_SOMP;NZ\GW>XV+7[K0/_@G_ZFC0CT%!H5"
M:#XG/(\&7SJ^?&85MK$X)SICQ)0&9T1^O5I8WH9":1]?NZSVK?BO6M/TVD_M
MSVL?C4QP^/LPURL!$U(Z?S"H0LAW1\"")9;C:N?WEG>P$3FR&->]0>?0$NSW
MQ;CBL^WLX2-AZPR_FSLNE:K)/UKLF7[4[HF)*?OZPOB.9?!U^S<.J@I&VABE
M9G]T[X2T/9SN![G48Q[T(#R%SVH(Z)1.=B"&M;%O>P)MN?$/JO8HWMIOP$PP
M=+D/>\G1\ZZR.3>W;%]RWKN%,OB0\L;?J#]7_T_8NULEYUU;[%GN/4RWD&V-
MKKOSJU]W2*\6X#:G+9NZ\8V-M0T< H;I^00R98%3W\AXCH^@QJ,5=._/3XFS
M)Y3D?O^WNIAH>&'W\_D?!U:FF[>WA#_[>?#U=/[^5\^?_3J\NC!ZRGC7\]_I
M7U_?U+ -)%5]B1V9N]BRZW_K1W__&-3)TMY_GM6PY[)+.<(D.:8B/*-O!+>.
MRA MG_$P.QVI$M8-2$Z&>: :(%1>BC.26C,'+S5IZ(/APBRO+9\-DR(76X#X
M!@;2U /UDH"QS'/*WWD(U4P(R2! "DI:><ZY=7%/IF2#S2I'3WD<>M),V)I
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MHN ;(MMND3P2HK8"MJQSPFJYJ0FP9 4H//7P?^H]_OK#VMTB=1:'A.4ZN&[
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MO)/A;&N Y"Y_$5NW(2V',KDTW;%;H;QO)ZR%#ZWN+A4YO'Q#%2OO>T2JF=C
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MG,_:VB4A(387T\</*(R!;N<S^ELLQ?#T;E.MT%P-M6VDK;'[0A1_.Y2/4R#
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M8U). C$RV;_HUOC1>ZQC65OIS>=Z5YYMF@=#NTTBN]<.P!O+&-Q)":$4)KU
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M++M4N;?,B @92, $)MQT'Q9*@4XVI,(\:DB$A#3P6?CAW4*PNA?D.L%*1*P
MP"=*"@N)H(DMF,*H,'$'V1*XG 9&B3+F<LMC)=4S:=S.'*)5'ZZ(BH\2<TJ)
MH/)H=H\&V$0M[)!@%-G%(7F9)>;UT&!3X2N,,A%?3,,;4*$3N*-D41&1G<D6
ME3OU HT2>#^CH$, /J\F-FAF"ZEPS!:.D%EL+:DX@_#5Q=P3<Y@CM7BG\&.<
M%$R+.1$OPY12 !L!7GLT/R;^I)(LDT($]E.([4!VXQ:,4 3ECQTTH?('L3!*
MANMRSC)$H)Y>8+F$#VH+("TQITA:5"D#;\V"%G.P'@-MZ<QZIJZ5R@ Z)1"9
MBK_W ],A J(E\%Z@+$4$F,Z!"F+8DPC$,C$[&9B'-9 &%9\B 0J(IS9= IH!
MF"#$].8=9TN PQ2\$AM3*@ $1+R^K':;5LX9A!@GP=32,-_P4*D$%M PB4*0
M(N/C2O-MQF ;!J>, FFSH2;)P2@1+D8-D\*$K8D9B0)AIQA:%X?5L 2A+IR>
M"+2A9L7+3G90184G84MVYN!KV(*8NT,$:C,QT#Q&%X!+A75R[\!_F[%D8O?3
MH'G-!F-J5HP(U).=;!9#LNISLMEEG &[5<,9JRL".7T8+7F\E2#O96Z&* RK
M3L4WRT#=C8UN"8>BNLZWG$I[F4NDUQT$>F,39*">&%)>B#OWO3MCMOO7J2-^
MA[K_ZU5W]<WP=.V)B>S9Y1H_DMX3?[EG=V1C$_:@T.N@X.*%S[F'%4@]=;GI
M*9%MJ5G=AV;CXGPO%IK%OPX[[.O;FQ-[48!%#F9=3)4_6+_$RK5*+T\X7*S=
M=^+4A<-U%Q(?]C58D6.)EYI<+[5$7CIYZ%)KW:66!$S[PTN=OR^=\,6DLM4K
M:!C1H<L=MRZUG;[<^_#R%==_GD\]YL?EX<C^ZX?Z3]1A&D7]C0 \?KG_]JW^
M2?F!.P_[[RXG#-QYUS_E._! >^!AP<!LW<#$PP&A;.!!Y,"K@BO/$@9>1E[8
M677EG?:5V<@KSWVO?I6_,JU]]>>M@5\%5Q_*7WU_^LJ;AP,35K$#EC JX\J2
MZ]6W5E>?:%^=^BW^<^CJ7^TK^/$KZ,*KRY%7?'_UZ?T9I!2J1Q18&>E<TPJZ
M9EI_S7+<PYR0ZO&057COVF&#(>:A@P[]UTP?=:_<RAJ X4J SWY[I>O>4*4T
M+]5J.-, =FJ&A91AOT*K<@:VY(>Z61OLM;L@;*O;P%%\K71(.9S321EN1H81
MYZJ\N;*T1KA 5FXX#Q<QL+O_Q&M* 14&J"1H4A<?+N[I^Y]V[^,9<)G  %6E
MP)O1V&C!D=S+.$76814&HM"% YGE)O,@ 1@^8A!K3 $-J* ^,NS_[@B1B$\2
MGFIT[]KD 66Y@2GOL3YMQ6NU,O2HY2:-A\]0L:ZU4(C+M4[J>64QSI"$5Z6"
M&B+ (OX"5PVLH,,"8O%"WO!93-8A9[R\0*@P>3JE"U.>KDYB\E[&8O'(\>$Y
M@"08X5Y6WX,@4"!X)8T[&W8\\MUMUWX#'5I;,PV653><E,+['H'-$>1.<;,;
M"UK)BMTG%MA0H,Q5,('85HL #S7N;#4%\?G$=[-PC+3S[BG04'C"N W,O@^]
M.SII"AS9Q\1$21IN/UK>K"KFX@Q ]3$HF0T62W$/G;'$ JB3@E>7 >9"N!WY
MQPO@WK<PF<G+BIU2%]=[2D!U(;R+-E$D@M9? K48Z,%4#)L!/?<NT!;6X;HP
M"7#>Q_9B569.100&[8HY+(&/T;M83%"?G9D@ >,8X+Y$-QW*+7PIGH7'AVMJ
MZ2*53[WA$$UL?AP41<&C)D0&K4(5 5Z3EJ=@BW&K(1Y@GGB<#Y8>9*E*P6AQ
M]1]^Z1XI3)!BVHD8 AZ>JC^'$K>0*,51THP8-I!"A EO;]S@@CI43+04O'4#
M5A#<.,/ <.C59:O+K=G@_0>@"15.83XB24?QR[8WHYC-G6PP7H0D,.YOML 3
M$;XA9<9( ,0*\ 52(-3Z^-7>6_)$*(:!_^\H4$##:XF #L$L% 7ZT:M3J$ <
M%;82Y;,9P-\.J-+?C8* ,42,M11Y<Q]FB_*?WKBC4(J')7 246(MAO$R_LM6
MD@$%X(S%ZC(J=[S"-!)@+:HD)Q34EF0;"$&>#S:6FFDS@(N75,>\@7<B8*T,
M5\  6A@814N,4_Q.#0%HXPQIR/A*XOI=@B,D 50DN&,245"$/($&(:=?@( )
M[Y%AC%Q:RME-R4*P7%QV!@#WX<!&!F0LP)?*,$A>\? H,/J@NY"(6=9F TX;
M*R&2L(-9 G6![\W ,@![_SV\01-;^0%N#'>C,$!K 60FR%9:@5UK25393@YX
M"R=1:Z&)HA!-J/E7IC41"GX(FTFO:(KN*T2!P@=PJ11@^;'(NEK&5+XZ#6LM
MS%5N!?>S,3_5F]K%D(H(,A5 H"_&>_OCWD0_55K>8&ZK06U'!P-S&PN;,O\A
MKCV1<2Q%+ A;PU<BX@4B4)<RLU_,T6!@+=B8)D#@W7;/U>6\)442;@$I:F2L
ML ))Q%S('=MV'][-GN=V"@EXJ&#W0@?[(YO*5S8'!41LRYDG+ARBKG!V35K3
MFE\7!/$%APXV[:<NUYK)LE,88#M0U3B/LVZ#B<"TWZVW?)V,%.KALPIY2N))
M7H[P*@OBU(#),DSJS85;EP!'#2R6(?*X"3\SQ_CCOX6%GKC:"UW0D$'[,$8
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MJ$MVHX'3SN0QRTAWNUL&)>A@NDYI_4TOD_W)/-ZGZ"2ROVE7\C+^INVG8?N
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MUJ=LU%NW=M.FM0M9[CZ^/KZ^ /-_+_XW, !Q#D@A67%52HV,:.22.*1JZB^
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MW(?-':R&]PI[0H:K I<Z,,T+LFQO^HS\W=:D08;;NC57H#\C%7TZSIEPOWU
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M#7U1+\FV^HDOG;IF)\65]ZX%Q$AK-?C>@?WKV6&:\*!@R#;<#'UR',[.?ZL
MN/9@!7:NVGK!*TE =Z&\BJ=NH91&)IWD)Z4]0T##U^\QA/7!.P(+S$=6N&]U
M-X[6"3Y]P2&$M!NI, ?W_P1E5DP,58VD!0DE<&D3E$'+6^%'DQR&7V/F%?Y!
M<)@A4Z)0##Q494$;E9!8#,=R,8#?O$Y%_"BG6.X,)3#5$@-!I@-%U;PI1!$D
M[\(:;"LLWWLLKE@WD88QX3[A.%P%"($T$,_AF)RDEK"U<S'ZXD ,?I3F8WF5
M&-W-&@R=K?/3F1VN<%]%=ARBF_@F(DA[L":"S@'UXVE81HP$ZS>%MBJG:8QV
M2QL**HU%E%ZM7+4YOX^<L%D(;8N9(*\9ZOMC@%_?+.$8*G;"B<M2#XQ)L5+]
MH*(SW2\658BQY\ZMB$X0=J:7J6T85EE12I4=)7Z%X3F52=%AX0=*F< XP-.>
M7*:-:WS3'<6 +$9#'WV-.RFXYQIE6.(UO@XJ;4I=9&A7]%O"JSC#2_0%.[)C
M,G'Z]!\?C_IBKI\5K\RGE"O2TQO6MZ;'%K5ZS)KQ4ESNWN!GM_E=ZKCT )!4
M]E".>A_O6"IS::TY=F:N_1]I!W_]@7NM7K[M?V);WJ*/[W7<,O9Q'WRX;-_[
MH);8LYU)_[@(^ET2;F2<[4I_/2ZX:Q'?<>SL\<VA;2M>#D?=[3JSU=_M[2KO
M8!-E5V''[IL?5H.N<1<H/UJWUSC]2,J27 1J*C.7N:Q2OA)4M[S26S.M/LP4
M-@Z\]S@5MFI==(==P=CZJMS&/S]6M66OO-]<>S;LAA/?HRF_.I.VM&FP5&]K
MYT-98K(>HUXOS7;!A;YLI\YA'_?UH[ON+O<!Q-)+I1:JX*)A']K!RA)TD\W?
M^;&\U_K6NUUQ+EC'<-AYP96_-C@,6Q;5ZIGZ#CF>2%RO7K;[THM,6Y$NSX9&
MX16J,7.,L0B;9RJ\CE+H7#Y4:)XY1#8);'67*/HM&QR*ZXS'O+*U *$VUM D
MAX;=9EYC-><E82MHF!Q$WR%(>- W5>ZT08C@/PKW._.F%E+Y'/,7,B]]MK)O
MW9B:,">%8]LG]*F+& [/6(]E+6LQ-C,ZC#L(@5/T FNJ\#P4JY(8MNS3TQM2
MQ[X9E>AB0HUM,M0DVA&\D0#IKR9J\)1,\P4B;5I.;+\]F[_?Z3?MX686A\#E
MD[V;+AAGM]^0>L/2,S5V>MNF4/R2 W<N]"WWO97[.??#]V*L4*N?S5:OL4"*
M&GLEQK9 C 5^"A^.H'9O?@_!7:RJ1*J":)_GS '2*WXQN66",EW,M+31LO8-
M%F+/[KUAD9XG.8LH_;8C2*,%#?0J3-8S[)$[6(F*/-I02K58;>VN 7U:-: P
M!26T!)%-C%^;. X!#J^40'$V:>D&!&"\@8'_M@F66OA3PC,$C%\U00;M_9;Z
MZK/D!AHEG7YW-0\A!3 K*$;*"![/,U]VNH]95B@#0[[  8E0$N)99CW4B4^
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MK^F:^K*WEOW]%I-F!4I-X!N@S M9ZF+^.N4W^*L**W],--IJ(JXSV;3;\&+
MOZ,MO^1H?V O\91DJ9;>_F,QE#T7R+$(%*/$LHU-%1"&/0!U]98<1PD"X$'U
M1U59B84%^LH9D%6K0'0WU! S,Z%K ?^/Q$-@ $=?B :-6!R(1PGPJIA6<$N
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MFO=]Z 712B>/B=DEB^8R#\@>P\9_T:[9G6%4,P2"IQ).HW<9H[K.-N)YI,Y
MYJ(YC"'ES'/^-_30)>SA?;N#IZ.;SC7+'4P#GC>\>G@M^TZ3:<X1Z]]!1QIF
M99VF>8<C#KQ9]6U;X;ZR'-'ZWV]2%OQ\^)S"Z;[:+O7^7WCUM6<N+X729YO^
MQHW>;OQVXM3+UR[+?\KL34TJUL'9\R+\/"\P2_HF_1OIJ\\]Y5SYW+7;Q%]R
MD+Q_?2^XH.&^U7%A],N/B54N#>\_709+?6!-_5*B!92IRFVG1FT[%MCXU6;?
MKW?!_E\;VYL@@W'E4F\^I(LH-AQ\!N 3^S8"TD.WR\H*#!WD$"E&],Q:\X3D
M#X$90:+S'V^L,@F$?Y-ZGM/9@BW$=A=;:K(B^,R6OPO$9G_/#7](9B;%@5.>
M8C#8&=&^>&F8C:B_0RA5_NQ(_3&J-OH^.1UV$U4Y(<*I8"8-.3D* W*_/8\5
M -=GD.P+75>P>!)@9 J8VQA=]OZW4&P[>>*#]L [AP^0&T+=EX^9S-C^2.9H
M^&+3':3B#@*]A;6G1(!#$[7WD*HW]7BB#]U4>82?0!T,:>2K.L<5Q/^4F-XC
M5K[*" J/FFB.NS3Z8E+']N0@[H!Y"UT4/96ZY[Z":844#<);'M^ AQ#H)DJ9
MZR51N=2LH&>^OKT-K^G78>! $9T/%H\C%6-*3(@$[!K=3W<$T]YI63J^>QO6
M;I$\MXE+?T%T8<Z)=EU,QTPIJ9=E%#5_BZ_US5_)U&+AG^*@VFD*\A)TD!2$
M#0+R/M#0_EB,[JE!Q7D*FKV92O?,I!?I>O:*9S:'?YO)9\)*S) "BD*+C$F8
M9"&8>@-SW8J*!%F$K,?Q .WYURFUQ]H#@QL3?7:Y()@X)88(7&C<>"XQ88.>
M)>;..R@. [FC%'O1@^)NLZW--W<\9Y=+/8>ZK.,GJ$/H$$\R/Z2%/MEF[\_I
MW="K/:2,?<3]2O;;^-7WMA!L'%'S1>V.#G?XCZ'8>EXGUL_E5Z:E5SXNSQ=>
MB&7\MQ&;^Q)CJ_X8GV69</+5Z0V+2F]&2M];?\A;E*&M,W<'2),Y6-<XZ6VN
M?$7.LFG*LC2?>HWXQW>4329C\<6P=03?UK("KW2R'\BROW;2_L:,_6VG>?>R
MYCT\:5^GM)N(LHE(<'AUTN'=C,-'I_E?LN9_/SG_@Q-K>H;Q/HK_.\LAFN.@
MZ^S(JK(6@![&GQPYSDZ6V4XVIYSF?7)R='9VS7;V..6\\).SC[.+>39#C^']
M'IE_!W:-S79==LIUU2?7!&>WE&RW]%-NZS^Y93HOR,E>L/74@ECG3A%'3QKM
M7N3LOONN.Q7R*'?V**ER/\#P*&!XUD5['J[R.!SML?>4QW%GK^Z['J&?O%3.
MMF_\+(:BPY[F"YXF!Q^=\KY7M?"V\YS%S>PE4(OW</2B6_W>SYT7W?VT\-6G
MB*>,Q3^S%_[^% :=7O2$L>C=*>1_T3X?JGR>G%IT ?:UW.1K<]IWWF=?1Q<_
MUTU^'J?_# 6MRPJ=WFS_+S=Q(K7_DL_^D3$!"7! ].F I6.XU3$!JZH#UGP.
M3' )2JH.2!CS3ZD.ROX<L.ITX-_5025CN%VH?\W8VTV=P2HZH3>+EZ8,5E6&
M[/\<<H 9>GA3:,Z&D.-CH7]+0R6]H2VG>4>981<^A]QR"7NX*30!)NTX:7<K
M/+SN=( L,2 BQB9L+&CYZ84KZ;=>NP@/E_$.(;[G4)(("9% 6CVBP$.;R!>!
M)=GA5MG-VB,*RO4YA"HZX>72X5V*=>AY]OR0K_97:UY5>(QK/W-Z+$#0SQ#W
M:M%=>8DY^!A0#_7%W\?8B&!?$8Q_ORDNA85?Z4J88P96WO:R$$&!),RZ .O\
MS-@#YI@A^/DV"!/F%"%_Y783L_S;L\=<@5^\2EW/Y(E@1F("*4U$$OFP4N'(
M.A$I"X[TF6 ^RL%7 JL+I 2Q"%^K)B3&XHM%)+$HKDY-'#I#J!7AF1R]+-$,
MCV5M)<IWL<Z.;]+.]Z.'7(<U"NUI7]A4M>I.L_:C$_;YYE]?*)G^RHJ99]J=
M9YBOU8[^/M!]FC6W25N6NF%UA ,-H_*\ Z\\NZ!A('7.[VRPV[4U'%_839AT
M@J43=FPJ4'G!WY<Y#7RHE'=2N$YJ;9=]M<QIV)G7-#@-Z72R7LM\&3==5R5,
MT$0 $5'!X3XDD<AAC9KPR$WO:1P^7,48N<]J!?!9@"[%E]6HQ!4K8Y,XC&T
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MQ^[BWQQF&*4&$$8M;<5 &T+:F1VK(_S_#87YF6"Y'TE7Q*3Q\6T*__0L*9T
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MEA#_\\(Q_$-&W!1_+9JSZ(RB3HY/[6+/0:FENBZ$^8VVF.FGLZ1[<3L]?G9
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M,?><3G (R:?+ZP\3GVZNO+(%SOK?;YGQY>%"\AJDF-&#,;405PHN-FOK;BW
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M$1#>?[B&1%I64&?JJ\TFFT76LC]*L8_I\\22)(8_-EN/)TO1)8G 7N*>R,7
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M"O@BO5\H^^OPPO\ 2IN(<PN@5%\:[M!28Y5V"&QS2VLD4]@4)U(B'O\5+ (
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ME.X'QRY0?V6BRORQ F2#.3S _@U$,*IAFX$9\L"\M8>O02GK)Y;ISC774\:
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MO7\5^?YUQ?NW(^\_L#Y\COSPK>+#SY$/_[%FT1MF\7]8@B"P_/\ 4$L#!!0
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M_*GG*5[>WB01P<$SU-K5J4=EN;3S5?\J]UGTD+4;M:U^D^_WF1<'47C!M#3
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MS7+8)1^*XA&3%<<?##57T,%]0Y0,2LM11771D'R3JO&F!#XU46;M0#J"@5%
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MP*\2H^T6E.KMRR$K>6\C'R)+0=>?O6L'P>.IQ&^/(2?@!$4)#0[?,I#73M"
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MK&*WB&:"MOHMJOK/%/OREG3U0J"[ "L6<[C]TCY-*)W!6FDQS7+V6#XHB%U
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M'8S$@W8Q3#]VI[0_-)&',U<KURGOY9"RU>E*?^4PQ #U(C&,&2%!W%#(:3U
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M#LF14\3[G 3"]X7'.RV(3.GD<CRE!8@EXV'EC0XBN2I*K#<#F'0".+,_(C3
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M.*#%+U[;M-"99CYC+':2;7&GZ0S<5P3[*'6)P((5E,I;PLHVLM,XI',*[P)
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M_QUBE'+.-HM=<I"-LX#Z%<O=SP;9\0 :<@N'CS0UTFAQE/;T2F8-5A%5SJ,
MM&'3H@6ZD.)!K2E R^[UBQ):.=V..Y*+9!_"MWLEO?E_&*[OAR;N-P[@=Y=+
MN"RX#$) Q$M8 1EA"HH80L PE("@X$P0,2A5<(*KEQ P+ D;*6(8*E:KP3IP
M-@PQ(BINU%H#+EPU.%JTEN^W?\'S>7YX?]ZO1\8^$D$<SISU</WR)TNF9$ P
M4#ZM1!UULQS^<;ZNN(=_O-]6*7+30N0:H[MFG+Q4Y1Q5FG8K#6I7-9[:/H-W
M/Y%K+(JLV#O/7NQ[$\A3%9GF7K#?#07[_*>Z'A8@_1Z%:=>YNY9@*WNLJ1M*
MY4:D/2U1TP-J#W5K-$18O$A!%+_*<$M=X:94$0._DS-*_"^F=RL5BW5- NA*
MX*EN8%,W7^1=6/'O;XUW?A8#RUJ/N39-@KELR8&ON3\8"R-KNU9]I^Y-@1"=
MR+[LOT+&[<N[?ZF/_F>'^N-)G'I4M.AB-M'Q[F^;(@Z&X=N=/#.U&M[FV"BI
M\-E2R$'$@2CY63O )VG#5CK WK(30D@?OO_I/%AHKU'9<XT\RT?@-#"Y3&L?
M)K)+=CQ91W-X_L@=-XK+!@5#M<ZU_7R_(_P&%2='L7 PPGZ9:KT&MQ/M>3\+
MYK4G!*AW>L\])QF^T/:;#3'GT5DOZ$^/50,)Q^% +WN=Z)M6S"OKILBH4T*,
M9)G/]GBC?=<D^/SO.:=,".(@:@+\8R%>!'U^S7A@":^7EAF]TW0;%;?Z"(2U
M(7Z3)IHVL952K@ 5R?8T&B,"N:S3E%:T<6(F @<**46V4'E/S4MJX?0VP5&%
MLDA,J&^+SQ,Z'RP%$U5>@1E2A<P!R>QI",4$9;NUF??#0JHWOVVLIGL\=TRY
MVBU@+$46IW<KLN[(O)*DJQH\Z V4.5'E)V %+PG[P;$LJ$ _[R<*W1M)8M4>
MX 3;88?L3WV$J2?5UHE*;NK0LT2.9L^ +KJF(&[M%/SJ&E64WBKUNH#K?(_
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MF5EXN=VI ^C% T@#R0"U=1BP6@RH]K/303YW/QS8"U$,QAT!/ +PYPLU6?>
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MZY5:0P[4+.W/TTK=C!FDH2H'YEUJ&#WU001'03K2I.],$U&7<&[A];9BL%E
MZ-A35TQ0]M.6N!9H^^6V 8%FFE('(#X+!KUD_5I"_B!W\G3A'DD?DS;6XR#&
MFB<\74Z[CUI3QUX"B4='P,:O:J(P%Q]H5QS)E'K%WI5?Z?I>1&0*GZ]D^]W]
MBHK09AF^[1C6W%,^V</T."TX?_#3A:"R"%";B*#AYN*W?VJN-BL)_WUUVOZ/
M[42FJ(Q$BZF-@ ^*GT9T;Q4SD,/;>D!F3&3^NW?#GAMVM^_X\]?]_\N^2!>X
MT])]7&&)A;QDV0OH#4@@AHA ?^#R+:<.0"KD':5AV]B*#J =#-:2=<!MY9;
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M>2E(*"CB[)NYIF!O8JU+*K,XJJ\CWMJ3')_\>LA!M=BKK*<GHJVCVK.HF=$
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M)EO_O#BL%BUTX$S7)32,T'+&8330L+!@Z0BTVZ(AWJCR466'^DY#"?R2B<B
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MY!!-H$'W,<"9@NV/U ,,/1Z;"E.Y(+,#>*O'P5L!M@;\F:JT7CZI8IJ!;=V
M#<*FHX4)PX U!EHCG ),13+C$FF!58@*E>.-4@)%!EKKJW1#Y/AA3;S()V -
M'C<!DQ$X$07_FV?O=9R*@$P]0*X$#AMAB@!FRP$WC6]\'EZ2"",3L(\!=\CF
MIE)4V5_AF5.HP7I . (HK@(V0A59:C^P!,[GJ= &H.,J3D,*YX;LF?D[$#D!
MD0R 'T)TEO06KZUG&G$Y"V&;@/$[];9&_,T"7;7^,FJX'&L$'K4!+T+ LR;
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MAT 0H["DRVOE/?6OB'7G9R<KA&@+0!_&;U!D 7&FLI,[D9\->.OPD[=2H;4
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MC<([!;B6NXC4T$CKW$,1E"QI!?S00I^Q%#"%Z94--@UKG7Q"-M:R?KS*B>L
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M94X!N'4E2'?\#4(]V(;;*,BU! BU 3:LE[F34<?#;*^O%9H]2EXF?KM13R%
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M'H1^,;FFD K'<D_8^ PYE>EM8M5_NGEO.'"/%BCC\4X%5?VF^N4*EHJ7=UE
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M*S"MF^)Y''QVR2(M3M J9-8'!7EK3=U/1O9;37MX<];7D=_<03_H7&0 Z I
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MI-VQ?&@9BD,TQ3 CU;Z /#6Z8)).#Z*CI;; <F7D7)'.#G"ASS&"=&(8MAP
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M3 QYGGS5!-(IC7+H2O]#LC!8=+0RV3FJW&;A',]9=E!X#HJ/Q??$>;_0"%L
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M6Y=9H<_7A!$HV#.E8N6\Q1=\,UC(N#Z?H?'&X>MBPE/3?C'7QC(")J&$M3G
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M[C;XW0OZ-].OWU3$.5\[F-?08P-9W"EV6;PE^CXGC56T%.DN>IUM7[(MN'_
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MH:4.WH6C6G!P]D:6O(2;VV:8':L>L5XT'I&\K)8LK-T7<I0LX_R8(#*OP]K
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M"27*[^R]?NC9E4.WGUM1]9KD'IVR1[<@%26ER?JO-+SC=)$Z<Z+H^@6M J5
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MFS^ET[_])J"$5K9_ZCM_XG^;CH6(0N,Z]ADTR:'-_#1TWP[\Y<=[9FW?"U-
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M*2+W"5!?#R/C,>X^K2IU]XWP;1N1G)C3[ WT]4*H 2+CEKLS7] K-]&\"="
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MW[U27W9-TM=D,^2XY)4:1FXX!^'T:"S5;(0FQ$%>ZAR5.H&2"*<=@A%G\Y@
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MP2XW"=1G9YO-"^FXK+KZ,XYFY([2*=82>;[A'/8V4#43ZA@)W2UO> %.HVG
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MK7'NQEC)N+!61REZ75HM.]R"->6#U/FXY^]K\RB! _=?[ ER<F_ 2?\\=>Y
M?ZM#V:[+EKS/)N6/C&2#%H'"D5A\0WT4>H'GCH>QA"V@I=R-UT]2^EAG\@%$
MP$J;JLR173\%7(N'U7_]"'TV0]AQ%BTN._ZLXN-1U(:78D;9U=6%VX@0E8,N
M?0.PH%=FM@ G*2KT*U'RQ#6/7CS=OVS5(MP0WT52H[]SY:0PC"R!3/K0J>?-
M=H<&S#F_E_";V4/38@AIIMRXWY(NN)&&O7[T\X^5&*GA)[_XU_JLTG_]^*D7
M$!-UB]8!"R9'#B2V8[U3KK&  ANVQ&S&%!JYW58AJV%N;SBQW$2%!SQ5.9=@
M)-[/A9WH7TN!1Z[WM?/6N:>#!XOEA?-U[1ER,7#)YN63N2SB0PEFVKN.$%8+
M:5 W#0JY[H9H F<B8 T(W0(IO$7;V3E,M5G[&0=:9DQI9:(5SF/ZOZ%4)*K9
MR4E!('4_GQIU8E3<=0OV:0]+%G5T#C0GMD8UU_$HRZ\GYCHR=45+,VP(<IH;
M.[&KK"S1R94[(T(3MX_J$[5R2/[Z8D7LWEY):%#EQ:;$K=P4G6OKM4Y_TS7E
M:A773.:;Y+9Q/*#2K"S155S-".9?ZTQHQR1H\QAE<B%5*;@FXUVI-_%=YIF\
M48@3[1.F<R1HJ>?J?8E>/RHEO,Y;Y8QV\RUM-/(R<C7+<7X;N^EB[+$3K>'/
M@3&QAMC\?Q2;=U03V?O_9R:%20$FA1"*.*$&! Q50,1)"!TE*$H1-10I FZP
M8OU,0D! P% %"R9@044-B(I8-B @]H"HV ,V;+M8EW5W^?[\_7_/<Y_SOO>\
M7^_GG'N)L07>9?VEEW6SA$AA!)$2XC_OLDW1Z_%"W4RTI&-$QRJM4ZRIM\!?
MIQ \ZSL1O_6#0GZL]?"K2V*1TK8R17 @7SMX.I:8C2'1DH0) DO@3U3\1*?4
MU:YTK*7:Z,YD.F[FDF(G#TX^86I\N"GI*I.1G@/X<EI_*@H;[=%7#%IGJSU"
M95KTDU@RYFN6@.\GKJ6)"I0(*? 0=L3;=;3\B#M?TE=-.P6'0+,%$2WR, $/
MV!49)---JVS-/O?ALUQ ,%K$;'V%4)">B68SDZEQ1&0I); X NGM\EC7UC]W
M%2U2A;/WAZO?,ZB(4"S'7'ACP-E:RU6[BDR,7QV)]>1>K:X,M1BCSA]"#BN"
M'K6B;%_8KX7)]D-6T2F!(Z4/DO(NFSU,WO"L[N&*[?^9C4J+9IQ[(+HVA0G@
M(U8D**I;BR&^#S##K/WV$S5+A>B@<UC&"^N6_N.W)/:*_9Z"M'(J,;&P G+]
M6W0N]A)6KZ3W)?BRHXF4E_+3(S-6J:B!H(E3])Z?D!/C#Y?:<DKN6=I1B8V.
M2$\/Z\&-\>_4L5.1MJ.YM$<8<E,IR5G=KIK[D#M-A 2WU%*5#^0O50'^-OW5
ML&=*N&^,[Z5Q1W(8Y95BO[A*C>R''_D:&\NZTY>%<*6%%4+[4:B&3+X7H2@/
M*W5'?'M+:HDU%O\>@D8#(\05#$QZ[DV%B3R[PJ?LXO&YK^Q3%S#8XI*-'V,C
M&W+9K"3N*M+QK-[L/)_P2> "I]=N#/%2?;]0X7K.)VU8L'^ HA"Z;\:+O 77
M2X]P[*EVA><<9]42S=?:BJN,SF7D-W>.-M02W8(V2\^</B\E*#:0A#CBD_3B
MV'?C(#2XL_&;PTNY3Y^;M3+K.F;XIG ZJ\NA]>[0%9#>MY1"'UX'I0V?/HN0
M% ?.).0U8^3I^H,[J'1049AU6X"Q7?6#?(EV#KZ\+:@QH<]2HN\6DO@Y&=)"
M5&!0N/*-,O?]DVRN.@R58BBCH0%8$)A?<B3V,+3$[N SMJ GXK8&:D'%]-(E
MP5;/D9W^(V,F<E)Q_&;1TA9N@X-6"IIK=:381DJ"R5^EH@T:FKQDS$G44W3^
M5_\M4R(C6;7<VU[D7$B1F^]?+S:7@:SE)7LXX_T]9+X1W<Q/V-V1 'XP5D"2
MK4J^B->YK_V5N[>S$MJXM#5&";"LT<)M4TL]]B?HMN1U1<".]QRC=-G.-<X]
M8Z%"LG%)L[%QEXB6I"(%Y\JAC(^]Z[-$UV/M1=/0GKX[6>XZA;M4ZL6%Q331
MDM9H7,)N#N][4_\7#&]+19K3A<[93J#3>V*&W]^8465!49D*H'_)-G$<>5UJ
MF@O07%7&L@)E#5C145M8("8NW ,=WR9*M#=@M%\(4M;ITE=9+5BY5E&*Y$IK
M56F%1K=411ZY(,DL@DJ[HC:7W596B$9JO]MH%/2G$4[7*2$<=Z<R%M]$];I6
M0YSB4[T^7J^<^^@>WZ^>0AD,8\^2R2U061\G=XR1F?"<6[^IR$0@=<ALQ2B]
MN/QGEI3N^@R8=W)SM^A3I2,'OB4F"N_-<CU#NY]Z&YTJJ7''*LMLZ$5'DU7S
MA07CX'0=$I*8+Y*+$KZ58),B?AQF5G_EMYS__ZM8S(.,@3'JPJWH I,AP%SU
MA:KPZS&;*J%<;ABK25):9_\8)WF6&^HLIG!.N!::?U;N%+]!SF&WS]W/S\YJ
M'1];G?@DZ>&5<\5%>_<@A?#=*)F[4Z::LF!8AEM1/, T'9'0_5;NJGTS*P5/
M7I)0A_\A1)'562L/CI34N&4I:YHD0+3TJNN0!-U5\&VQQ:7'W:9/5['1!.Y"
M@0"+=,9/$<1$@A@\'9;1%NIZ.<J6+^MV34Y/W\I[&CR+?<DG3F2\I:?4XHLE
MU,ZWK6_1]U($H"[>Q8\^<U+7(5L+>AB(],AI#\(R%QX8G9Z767"LSW9_Q EJ
M7P4IX$O4P5_P]G[:%^H+>G0()(QB^R/@L[3@/'MM8Q\E%*K3*;;^8V^SW[".
M[:1Z-CZ@=3N+?F!9-A7N\96H"!_;_ ^D[[+TK*/8G>4=>Y@X.%[YE#QK=RKD
MJ;EN5K\5%@?I$#]_^5J^JMV[+2[EX*C[UFMH)^E_J7U^SH5&[BF>P7S<)SUK
MEJC<<M]^Z2['G(1C<3.=2X(#4:>#%$F"S)9LSO9UXDAE9P2V+]=T_*1^.Z'C
M79&V[T6OG:KK+;5%C][$5,K-+>"[/W=8E8C7\Y(+$[ %9<7[32+3C5%$N'VA
MU,/,^@\HMW5Z^9IY/<49+4O+M&9_=5U?OL;F" ],F"02KG3\<5JF<[< A)JU
M:TFD6HQDT@6'\O5%S 24U2S%.!>UEQ8ML06M_\'(U->@R7HA0?75>:'C%3F]
M8(QH,?B%FVC K^:I(:4?,6)T$G=-EF];PGM*=CS3%1:N@URG,%I8BI79>A#:
M=!U:9JG<0\9?=]G]GDY#C236'BB])2$8,CE*@F5CQ*:?&>:^>G O^SA!$TDD
MN+]3F"IM(;?).83!N8*?K^T14QW$L5'5KQ]+9R3OD=V)F02B[%/!S?VE!"F+
M&B71$9>K=&/O=Q2Y>Z/'"+-SS;L,H!$[%3'M@J8YE@*CR'DS2-E+B#S2T?TQ
M C72J,8HQ)@Z4]D70MQU!>2RB"\*5-.63>D(JP<@8NX;8<N@F!2'YW^M2%GT
M]6_ 7(P!5;/4I!6MP):#K?C%6HQ@_2]P>8X"'(Y"XU:J,/,X57K&_;?T1L\U
M?(X!=%?AT#X>2/8K 1.&)/2H9@R^ D"/&J2$E5D@<?TKCD]!,Q2JBUB$.8V(
M295'@A*"'2,-4#= E#D[435'.M5@JQO!;V*)BQ 4!^^7C8,?PT#W8X2P,7 4
M9;MB*:^R9M<&LP-YA'!=A,E1X95@VDB6(0X+F\BCV_SR(S6(]/@LPM_GOF58
M3F.D_29KHZ4^02D0'W?,>D_K1 DWFJ'J]\3ZV407 TN/+N[]S94-D!;=>CJ@
MHM_4TX-YQC_MC1?E&G<[T1/P2ZN+D-"([3*%<6ZV0"PTWNC(Z-YE["I'!#ID
M4N#T7&#" 'DKG!G7<-(Y U/)IYH)&=7'F5>DC,"4XPBHK>\?O?7NO"23OH:*
MR2#6.36)V6[Z:;):P!- FF<CN!:Q19[WL?IT.</H[5'#D3X58WZT4^ "P;!4
M8 +R7#1D+QXR$@8=B71BCE%/&<[;].0$";GYS<9KWJ\_=6CI8X&3IYR6I,L)
ME])N8:1AT3N;?).;*/L6>G?_9^ITYVJ3!(S6D6^</'N76&YUKX0TDHD</SR3
ME$9_+V/3QZ@#&/L.FAUY0GJ\:%XW9A_>ET-LH248D'.Y;/;8<2;"OG^-GJ S
MW]#+<NPP(6D8%W>*5]_)*3_)=,417&HSNX*T+3=8ENH87*UI2*=K#8B[QE8P
M1NN88#DNLELGRHV[9=)RU&Y[M%-M&ZGS/3T!?:<,-R[V8#P1L(^L=3W^97VN
M)TCA9=N^H46^Y5\;I_;J6,.&>1WA3F1-K7NV75,LXFI8CXQ1;Z%FESNDW3GL
MQP;JU&JZ.P^I3&/K<=(EM22#Z4 CT[_=H5O=\YC)\LS+P@8K?MK6T._II@E/
M3].M3&#7>UXI.5\5;[W"[ITMCJ)'L'P6+_9)/.%)(&Y8>]C'CNP[ISE&4;K4
M95W^^F9)Z^D3R5Z^RVOB3U4NY1Y+*#CL,ZMFSNXS\05>V!L#M?O:TAUG$@ZQ
MXM>>,?[B.F>#E^\RK[D5B^-KUY6FG_&3?_6]=B9PY=>ENL7Q@3WTC1\"^[_.
MVY3N%QL6<*PF< /+;^N]P->L^(UGYK?4S-_%FK-,.^_O>T'_-0=M>HW%UPBM
M1H0SV2*[.)%3K6C6B&@V.]AKY&GW8B>_6KHY6R1D[PSL#-X>(K[V21SS;?[;
M=?YVBT,VEXC7.82ZK0OU&0G]C1VV+BYL4VW8UI&P_['#ET^S-R2C6_1>V,NO
M2Q^,A_Z[SC7!(%ZWCA&P+B2OR \L5@_6S#4;"?_3"S/3A.]F1X\M#KJ,6U0<
M"<E?);B"@O_[&N1W+/+VM_01SSF$B5 3,""MQA$2NK[/B]C4OW!G,>V/KPMR
M%I*^N$014CR[U;Y[.B2K%B.P4\"Q/V-S#C/C,&_6M[GK1$X7OB%!ZN]=W\*_
MLR+2U@EE$*W:,2HOA.>)$3O+HFK6Q?WU->C[/3M?$6E1>7">5_BF.N_Y=Y=L
MR.H:QKS708STL 1R#[AB9*FK@6J3[]72MF=M":&Y[FR@+KV,!7L:%JQ_S1I)
M2[ [0EI#K,9\G"ZI'_UPM]VPZO3TJ\/;UQ]F)N >.0Y]7)%C%LFYV(?^^/O2
M+-MI?AWIRO?B+7^D+,0$_16.?5'@Y3-$%*>/8B0F>K>V;B<UA.8^SDP  C8O
M29O)8M236!TPZY*4=N0EZVD?:YS,^A)=H@..OI+0;N#/J>!0_>&P[HS,QQA-
MD!=@TL-Z@\VF:+;:C,UBIM"N2#/[/C!V1#&SJVE7 .E#C':I.+ 6=OI8:]R)
MG2AYD$52/G<!&9&#W)P!>C?:'_1K/N0X(6/,!RAMC9@1@!$[!EF]4MJ.LXZ=
M.NMYXXA6]X7Z9L8"8)&Y*VU89"^SS<YO1MPIL==U>PKJZ0N=D.>?B94GICGG
ML56;3A+XUTS.H&#4(,MFSY$',K:[AM:6_E"L01:]"Q6-J8-B&1VX\8#T0L!M
MNC:TN-FH,6,GE*1F#J#$_>TF]P;75Y Q5R'#!-RX+I71@1D/JD-<4H1/JQ>X
M#\O.8L;,3TCS6^2IIW$';O=(L?3(2R:3Q[CTE^\UC#9>C"PJ1Q1'Z9V8F\<
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MQB^L=<&O,L%A<O,IKL&=V /^L$CTS:E/H-($0C!(CG@FD?A 8IN94_-OSH$
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MRUABQB_T<:(X%A?4X0!YL5SEN:RUS$'9F.9AL-MHQE\A")5073$*LR>7YV9
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M[(_!)&G0U_8%?\VJ *V30X/(!>"?N_ G9T&*%CNGDC@TX.0>JJL!)W?CJQK
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M"RL@NI0;B%,%O;88==4/0GA@7VJCT5Z I;6/\>+0J!E/C9L"2SZ.$;7JA;L
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M8&4PTOL_!41,JG1#DE;-0<..KHP7TVW.RTC?\D0PY'_D[3&#1)=V.-&]CRB
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M*#*NTTQ\E.:(9S;74KV14]1MS<7C3DC3J['BT ,+89D=F]5G-=;%:%*ABYL
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MAP-W(ZQ_<,Q1'6N4#5(TL>Y%J(Z8R@9I62 -,0_/!SP!'#%*&:#".C'LWUS
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M<S]_EVYC&<2LHH1Q7P]DZ?&%@&'@OGH3L/U#$JD#Q46I+J^5DT( INZW=4K
M&4;OY@ TVB%2EI HP&QE"EP^YB)YR<^6PP\2"%>)N.&C#ZG]+M^D-RA*)P?@
M<9#NB#,4OT&(DPG;@FM"%NT]\C "QS(C9@',9-W!3AZQ?@;"UW6Q]U.GUY84
M8R-@-)*,,<L ,U[<.M@!UB!F3\K,WA*"TM&VN[UNJX0$A\7SB:Z\KG76&W0M
MJX$-E%X;/H"H,9SJ,<L?(/;S"92JI_XZZPX=/")&Q#J'UON\(JR9+H)"B*P0
MW;##LK#\:>'SO]O4,2JB#&7*4,)J'2U&MSD?<'05U4U0.F@*7'\:SK@L+$\(
M9?YY>;GPDATTW(_<Z3K&SJHV+Y])CD))4@74^=>]TS=7E^NKE8#JPWH;J0$:
MCB90UG:M<L!GR8F9Z#'V45(GL$\45:H"5,J]MNP?XD8J\Q6W-M(=B[%;94#Q
MO3^) ATK:M6?+\)MT]2?:FZ2D+*U56#O\7CPO".NW\/LN9U0B^$SY029%3&-
MR.+IF#75)X@ D4:UU\W:?N_7P]$#A\_+[3P 6O:]U_Y*VQKBQV, #<6&)#,'
M U&V((TLML%1(+(#LYZH)/-U9UO&K/-1\^EU?.:\2&[V8J8_1DJ3XT)N$1'*
M?\\=MQ!A&A]8LPLRB^+B0XA/+F)DB>Z&T^N_MA:ST_2*AH']; 5><).3+63S
M% V[#*P\N5--2N@,_"(M>+)6_SI989/,Y?3?XJB%<\IOLF5R)Y)R6_!X5L.
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MQJB9A[;M?+3MY]DYOL?)T(^F]<)N;!KW(644@QD8[0&!'"(_<T]'<< 6SU=
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M6F]D?6_LD]YXAYM):3>7U-]<^N3F"H>^E6E]:^K[UJ=%X"!@[O\!4$L#!!0
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MFEX&Q#94#4:@/Y/W#T14LFK0;*SRXX'#_CYU9SPA<QVJ93,Q Q2+@87A* /
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M/$)2")!6(M")C[,GR^6I3XU0'6B'T 2U%?O#/\"(AP)C:5DR9#$2CQ2[7%:
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M<40+=N4^XID0(KW9VQH[I=;2-[FDZQBC#G-B :8E'YS;Z1%B*(QB!]XW%)E
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MAQG6QQ3_J5TT54;R@?-XQ:0YSB:T?Q:R_4]TV&I)J'"T->T\F4F)=\%L>'?
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M&QX8^I;E!9X@Q_>-ZD*R7QP4F^>\1Q$?)=+?*T@T0G;&)Q$-2,FQMFQGGHR
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MHYB1!6!MRS)US\ZR!5)>( 23Y0D-46?$ZN[RC<#@X/A7H!EYF+# 73JLS8^
MK#S7;TGU,]_8"7D_6 V9<XY=/>1T2R$C2SFDQ7A'+C?/)H+DI @ERA RUHC8
M1[4!(H.F0^JD#F(1)IT5[VU9+/NDA/0!%@]+8JK,W0]&M]AB4NQ9-*(+3H'W
MW&:$5ST* +W<SJJ<I$7^J:"URI'4,6'KR>%5Q1(6/;+P5)[;4G#)P\LBM*,A
MRZAALL&6^6KJT.I=*J9EF/IVM4>*V S9UX=)9TR35&B[D7Z(P)P@B5%.![5M
MUA90-GDY;[NZ$= 7& C"3<\VDC]TLQN@&6L_=H.,(HC2VK.'TYPMA<6P!2JE
M0U"]<"/-B9DN+;.H.:8BT::!CIYY#A4]X7#A/T%7)/N-VW^QM>8:^TJ9"NZ5
MU, CP[/FCT6Y=)N@+7< Y%(% &/E[(<-4*D> O9-1D"6UFSL)N#ZHNZ==HZK
M]-&CB#WW>3?8-\S0,+F845E@7^+7#1@+OMLPYP%3N(3OP)4S@&'X)<B1/-B!
MH <ZWTILN-1E!B0+>6M3Z$"];72\'XFY<\.X3&=DCS3&&<Y.N';R)MT8Z09_
MODS?W23YN)$AX!*&3/&*EUEN-ZIY]R*\,2IAJL%!%<YP<Q@@/?BR$"9J71($
MIKK5*I7KO,4J.^1C#,B86I!DTM#MU,7*J:5"58\D!Q@EV('*'KJU(S[P".4N
M$X;3RQS4OTO&XJ^C;<=_?C"+!25I&="X4U+@9)O^@&=KM7& F-5C.6W9[2N>
M9!H0EVBC8?&>\*B&ICP>F.JI/C(J/M649R+$\XNX>8OU%?[=R!/Z@%;O5O_A
M(9;\ZC,&B6;<K!YPI*6[6\/JQ9N8H*HZ]?)<FC28QJG(/,;<:>PWPVG3S2\]
M].B=C;"HXGDDX$V(I.]?@"\$C&DKK1,NS[GF@*5A,_G 9L'G<8,6[.$K 32^
MNH>@S:_5&#WF+&](E:S84'%-LL<*!M:ZK=[=?0X25=?N GVB$I\GE79++G\_
MUW,C+TP?65HXAD]PF\")YIG4F8YKC8[BJK]*-V[T(^@&B\8H#&YN$--3)#$7
MWQ7]X=^;I;K@J28%>DW8F.\*Y.O!2<"AD6^=$0N.?^J4IK#0^<9Y],G/1DD+
MX2+O4N,#2?'*<T^:#_)'!!IPBS2 9F)Y>LKU_KY+'D'2P[3YF#:2[T?NJ7J_
MQ&W/,TDH">(KU&#]8SWB8V.JAWX4)=5_L9/Z\[A%A6RJ%STYH>R:DQ8X#JFA
MDP]% B[ITO<$YAY^6:U2@ H>W/A@,DDJE*"269^(#M,DD2/OEY:TH'-EB:7!
M:YU3U[TI^Z5=9 C((W_DSK8S3X'MB:P(F3.DE"@>5$>@/8(-[S$DL+CG6MM4
M[]_\W"P\NYNV)!GAAF82Z5-O:O/*S*N7B1;RP4]3E>5<N/F!M/Q:Y\6N+6R/
M)F";G6MXF-$\WD%*N=T*8HY.ICT?[V";B!-?:;Y5S]C[1AJ'74TG.I,RA6X2
M,-4.US*;<V#+8:WLFFGZ"[\;&3:&E%,2:^;^AO <.M4[*XFB3QVG@-.VD71A
M!JE>A4-U?03<KJ)??)H#=C3/[A^68VSI9Q>FI!NI2#E=>^B>P-) ;3ZBHQV-
M,R..RN[E)BEI:,%!N:I"W)&I^>WS2[0T99935+CF?;45JTA,T<.X<$*X&_HD
ME&2,O/I9=N1/5I-, ^6EPH+6<+^<SG)P)1GR<)(#3TH/-1= %J=_AETF1OR9
M.@R8>5N+FY27?FL.#GZZBEC70/;/C']X(L$A$P1D#S*LS:61HXM)**V'0,HV
M:Q@2+<0WCF.F2'N*$LZXS!L"SK+B1U)G5S7C>TSOKK-!V97:D/EY""*_V_\<
M=1;ZX-<]+*5CDU:[<N&.Z8M:ADKIV<;\D+8G]$YQ69 01QQ' /.DN90K,2/N
M&.CL,T$T0-!:HOLD"E)L1?@*[67I;HG< ZCJ@YXY1$P=Z=W$]SS!@53[[$=_
M9%E-(3BAL2Y^N#-RKW)5?0HQGQ!J50;U>0E&V%I6=ZE09Z!Y4V8A*>SZ:^ $
MXHAK&+>XTE>5/0)N/;GI[R?5*Y+E*":9VT2>?&87VEO&J2*90R%,+F[F16<2
M;@[JGY[9C:JIL2I-F2[N=NZ'@_HTWBY$\SPZ'%-/F.NF0*MJT_\.!M?O1^O%
MCCTG8FK5Y?L<FL"9U%WT*H#"S=GKHOP\Y25U82TM#=L=2=?X]<^A'?:G_[UH
M(EFGU>>;\,_[)ZD8YY9GPZ(1/>K U>X[8)Q3'AH!E 3=7VA!:SU_1&\4@=QH
MR2%D8,S@+:/8G\+ 1L.7U(79I>4-L;M;_* #KI(]BC MFKX@1X(7G]M[Y3,:
M,B8RSI)TLD8)#GUFMTLIO;>,$1B-GCJXB3&P\_5RVJ/]8:3=136PN,E<"H;*
M3_H]@^ .#9=13WGTMQ_<L@>'F,J],?]-.CTMC!B%YZSJA5(85Q:OC@1Y6.0<
M8=N/%74?1?!X^PYFXM[F.M]ZY9>RGPA#2W+=['>A$1)+/VWG8O:"?52N<V>5
M^/"RE^.S3E%79ID85S(HJ'K:.XF7$<R8>UR6@]%^3VP*>UW4+;  T'/FR>V_
MMHM8_O_)83'E];NGF=O01UP0*XI9?<F^CM_UV:9B+$"I(,2?^B-2WHE@11',
MPR*[?AXNW>7P?-V8Q<37LA>;$CKP^>^]DF:?ES^]&!CYX=K?"E@_5'W-.OYE
M Q:!)^Z95K&W&ZWF''&6GU9>'W.[KVD0H)X9,#O(S6G.(PH2\IAC,WJX+8[\
MB@G_-)Y8<OGCZ#XUH7VXQ%FHAKL_>T/.CR>5^=VSN+3.:>'FF>Y@]M$R[D8"
M>]Y5A65^C8SE=3@8/"LG>JS#^W<6@RVT@53&-B*1Z9>&-?ZCH>EAE$;H/3RE
M4.SG#Q?7O^V?YU/J=^N.TI&W:'/QAK.Z2?L')()BG*A.G[$-HA-8.0$5O@R8
M4X59$]*U?'J#"58[QS5^8HQ7N<^ICMB0&#1YJ<.&<&S#!UH] 3NT6SM5!>S'
M5UQ(RK,:L)VT0KZHSG>'@!EJ&.,MA6FDJY/)KP"G/UPQEV&./R2'%E2!@&68
M!453A6_$C&$>*B!I IDD0\05_6\JMD -KM[FX55@]&$V&'*FT\T>J2".0<TT
MD,2;J$AA<8@R9\JR88"8IF$DUIRPZ/(+ANO 1H8J.2)K0JD1W)#3:4:)8!,C
MF[0?2T![,Z U*1#136?CP-H$60(^G0(N%+AI 2%&^D$GGHCK=^JE,D,!;"@]
M.)R(]X!JFHA'6?_S !Q93*>3?I;=PB,:F:!JX?([,QF?@*4QY48?#1X &*[9
MP04A"?(5_A6[=H05-F!6 ,P*@N'AS6=?S-K[V2//&MJ\=*U'%>-1,Y?!G<V7
M3KSL!UD'^1<0%?-5<]^[@G M5*_V/N "6N^(EB= &!>(U 8K%=A_2G(Y?#3Z
M4$*8P 2:I)CR!7A@L27+#P"I@T$'T88WS[HO[#\%\U&/4X*YW"JP/S@(ED)V
M56#S"ZZ^5JKECG6YQVMQ(B9_ '1S55!-MN-BB":59TH!IPH@ _1]PV#Z4HA_
M-J5_)GCH]/]^=-Q>'>HV.\R:!/L)#S& .%+#G'!L^ANQ)H&!S8!;(+RL@=9D
MJIMS3;%?K>^Y$PNX\.ISO@M?0;MQ*"F_KN];:.L.UZQM8/TCT2\!M5'6D= =
MYS$)] ]M@#$<8B<%[_0,S#A+N=)C,T&'JK;.6:40S5I-&V88S(!N!*C*O;H/
ML*4 N2_:5^RR)7QFRZ@FL>$SL# !?_^T0S*[_35@>L\RHGOK12=(/X/!Q,&>
M(&#@KIDV#LP2;0(#T%FGM(QE-6("XF='-YG=-23#$@<,Z;[^NZ)2 %FH=^<X
MVZ=N W_W%(FJH+M!S"_7QF[,'3=>#3VJP2+&;5G4+JGGSNYI<JLWDJPRQIQG
MQK'5BTK-.[_G8L%?&0W<!L?NP/3;#4Q)8+W*JUR+S3YH',N;/3Z7T3#<X-DI
MV4I@W[\N<F VG'O44,?U8\J8.Z7R?56,L=W+'3S]?CG=N+^8(5_:Z/BVIL@\
M8?FJ\HZ40(UY47-;FL&%KJ:(#,6",J.R?H#^_8#;?#--9_8936BI;GG!6##@
MLWF8EJT*VS] G_B8KI,Q-PZ4L?EBQV[AJ"+D;@!S!_?0F&<'JX-"4A,/-T@/
M9[Q<M+G?;YX1,Q0?W$PL4/<3&]XJRST/KWCL-3.#7KPKAC,, M]&C[B$S'K;
M7#="VV,]M<@<E%FP+,V\:/OCEC3YP;97A\A^ZZ.[L)87!R_/:-Y!TJ.<Q..O
M'+KTBL8Y[+;#PZLFHJET^)!+$F.NCK&0<*R7NLSL]U8/\F[U-T\Y1[/KW9%M
MINU)912HR:+B8[K'7O-P^G93:Y:+U^^AP0NDP7;!P7=7TR,^8H6/I[U/S=[$
MI?<_YFG-M)*5\JM_U7SL]%;CQ\M>C=*W]+86QF27DH>6J8[/7;U$8W)+=FW(
M'J;M.8)E#)O*>^C'/_&8NXTO^UO*AVG/RTZP[&,4U<KP3@^GS8>NO*!IOO$*
MJD(SB%A'Z-C,V_3=5<J:62)#Q#%NV\FYYL,?^UL;JNCQ/*=FZ(R>RTP9IC'K
M0?&])7,I4Z)G>U9L>T),^_SR]OSR]@]?H<DM[8M89Q=/%(VW.[N\\.S[!YMR
MUIR-S((LB+.9:0(VMWW-W^VYL1V;CR;6O&PW7.^H?->Q..'@EC7MEK>!Q<"B
MRY[G=AX]-[^P(S6H/?<=8\/YLP]S)[ [)7+!P0/7#8?+R_DQ@5NSVP_N3CS;
MIS^=%MC^1.0U6COSZ'BODQ//G[C>>>'H]O,'.^O?13>1&#B::'K2V75TYHTU
MY[O?=:7?/K=W3=>5-1?VKL'*T*Z?QE^X<+ZK_MWY0NC"+VLN'$V[:'X7?6;-
MQ2OOE =V7;A5WOFZ_,+E\5ZEQ?1\<_N#\^?^???3?RP*\J*0.(I61%E44(Q6
MBM5%_3.Q<_,[BNU \?ZA^*WGA$7=MJW=R\N[[=]W.S[M'NO5 Z<S]H3V>%3T
MC&OM&7^CQWMMCWT!YB!5O7S'<Y'#:?[EOT_\Z6IYB2->_7Y9RN_G,3W>>?G\
MI3OO&'J*."7&1.9%(7&-IM# M"5T!]/YK0=@"1[V)K;S!NO\7]>ZRY\S1M.,
MT)#_Q7>%%]U/-H9XB>=DT!U-!WV\KBZ-N[J\Z.K*][RR#]F'TR0^X*?LHX7[
M])#8V/G+J>E.<8%!34'EC70:N2GUH/AJ1D?2PPV*3^#4T@Y^YI453T3SMT/K
M&]OGA"]O9799^G645/2WM/8?O=%?67[,E!R7U4GCV](Q"OHDPM)(4URUN*P8
M:P^?WF2BIX$C^]RO76F2%'&7S#5*2H?]YIIW9E.TW+<-!>;K^W6,3!.-=U?4
MRZ-?CJ#C 3$/O&(&5_<5F&CK>^QH),S3,;),-^7O:#868+]+0T8536/#7-WG
M7<:/23,=&7^(7DIBZQ-+TXJ3QCRCSQX>O5EXVZZ\O%U/T3C',%P-YIIB5[I,
M7W;]1QW-XZJQS6;:Q3)]&A'P=W_KW;)U8S0S#C_M]^7<]?.^>RR=(5!OF7>2
M]CZR=FW;STP*Z"MF"*L<ZRR  P"YQJC/&FRV!F(4APSVBE)0^9Y(P-_LR#&!
MA2K&C'$0HLHI.^.$X/#4=O";U@>! Z</WF/B\$O=CR/X1H*[G_,6-P([LQ,,
M? 0YT\ 4$4:Y0B("&+ON[\T9H[R?A7+![80Q(NY^@Q&+B0!C50RN$?R6Z)ZJ
M D[</;JA'W.R/9T ///=D5A?QO#:-"G@/@+O%,[]'8&E!-@1#-!1;O3G1K!@
M0!C%6?+1UG6V?.G@Q+N7ICV]O."I;=SRV*$)<Q%0B)< $C/U>M;8+E[M!$04
M?1]5Y$1@.TC:K0O;RM2%Z4Z0L'@#@XL92$"TC=%)8*0XZ1>W$YO-=S-5#%>3
MG[U9)A@ 9=3U@TTIS(&@.G- J.O2=!549Y[Q>PXX+YR[G] INB 8]$];K%Y0
M%9JIY'_;.4WS(;0XP]8N&Z83CC\OW<!6-ZS:Y3W:VEY&M'*#W"[4A<YY]APW
M9@A)^C2>^ 9D<VU5Q0W_DJRE]%/3%HBJ4M?]S4@M3KYZ\^6T/U_&__E3B<*Q
MI FF2XU"*2B. :TPG::"1E<K?ZB2P^R>Z>H[/)=,B =\JM]'OUJ0OSJ(R:N:
M7OA9-^>V,'UC5W! _CD7_S^7T=GG@(>9H4KPVVS\_<TV^CS>U3T1P5:N_L,N
MB6G/0_!^Z,P<J&R);TV4XE."QN_,PM#NWPNFM_CM!![@A"O(S'\B4HV9NR;H
MQ:DO$\I[BM(?!CIQ\U? (L('Y/:_>,(/'9/AN%E:Z<-Y=7GA^ZM;WD=&P&;X
M789Q C)G4QT0/1V)>)(6?867M;HQU%7%V) PT#;]U[KVJ3T"Z/T<\.[E@IV;
M-V75+K<Q WW5NH4DHTR*%9FVS289;<NPMEJ?H3W2C0-PN>J7T-M 3V(UNE&&
MF )_N 3P2QF;"2R[V+.N*GEK0!4+0-QX[Z L>$[&;/K6X8SG_%0>DW)[FOEW
MZ/+HX-RFM,+JC^,?P L(EXN=7F_O>@FZ?1V>Y8\9#"Q&)77&Q]]VO8^(_QSY
MV\L\+K F9V$-&#P G5X\<2L T^=[61;3O2F@5>UK*N;NOK>P0+I/3PTE<""O
MG. F<M+"L]!(FD>&$3B_]+E1OVJ\V<UQF"&B@,8<,'<XC4G1KN[P7PO;(P0T
M#]^RG;  .%10[)>Y$)HA7XX;8;\W/Y?;)&[*W#KG-A":D\5F^C+^C#/;?#+7
M0PYFALW HLF?:&7A[_>7$QE PAAMVS9S]3>;O:+Y:@8=AS)!\"]C0 'OT0KY
M<EL2"_V5MUY'FRL%7W/ZH_[WS\]6_[:^IZUZ1<NYX<=<!)4E,NR,F:4 3DG:
M44!"QE::V#1]WX#8@:+9@0\O_A?MHH(;"'B< +ZQ#7.20OL%=/X <#(N*0-<
MN_8*9I!G!4IWP"IC/C=T(];[HM:UJ!L3Z=Y-46W=QMPD>S;;'[5[E7]9K[$0
M^'S6-T*;O<76UO]H!^2[$UR50M>$S%HQ@]]>C.FB(Z(J/47^Z ?5Y68K?N#T
M@ZGWC]R/<;%3FA.E[$T1:% RLRVHX@IA+TX93HE&MB<LM/!Q=M)8.K%'YP>N
M[_EHA)AQ=#_7SM3!X8S>4I%O[M/!#UE]U6[QA](??<RYL3-HT>NG.Q>''S6R
MRJ/B=IU\<WMF1$/4/V],^0_6C#]_J'.7$^AH&_ON^)C'GQ:9NS=:><Q].K+X
MY;4Z#QO.WZ>C?AT03=T?,^;D\C=' L9[ECWJ_'3-V.;K,>_7?U9]?G/_Q/S?
M?OUWS<B'5S\?GO?;Z+I_OG_Y-KIGTO+EHW\]643 K'^.A2""&T5A-'N'+>%_
M.-06RYGC3P_+V9RC^@/7^$ZN[?%8@KZ#8S]#PXZ#0WJK(CP;F+R@Q\6+A7'8
MSML"WC'G"!KF<I07$-_C^:? :<)$?? U0U=<-75<CEZ[I!T]P!3T-,=D7^F5
MAA\XXK&AZ:0TTE3QOHJ G?3<@*DABL9^SS;7"RK+-XO]G'\_S:SA>;@<B+8[
MVZJX<7.TU^J,%GY&;OEU,E#'HI=&U%&_^!-D/+!BD'I,D&7">=9?4-3W'V2X
M//("9@8P76FD:55B_#[:*W[%!OOLW+A *EI4&PY&Y*V_I?^R9,)16(-W76$Z
MNVJU*VXFW;OMF()1\UON//>2.Y+\E*MAF*@[WK7^FDEK>3NYU3>XOO\,UU^N
M.K],\V\V'-YQG\WF,%E.$X ?3Y-X*;D9UZ&>%*5;]:AD(;I^_%U.UZ_"Q4!]
MN4=LF!#I:!Q4;!WMZYOE+X>+PUL#/,6O4.'[Y143A--5.P<MCF4N30:?C_1S
MO*N$'!KXJ']PQE)HO->>P'4RM^S,<9EPDC"-H#4@RNCY)F&R!M<EM&,D+;C/
M"( <A7!]))Q!@?A!0-).H]*,7UJ"90]CV7)UT/4)+KTO!8H#=N5G8IKIUH+N
M!H03*W<'?]3$'F&NC2$ACIN)P6QA"DB/LV5HN^!P]>G#K"<33\<K! %O^AZ%
M*>#;%S&GXRT*L;+I]N$#WFPKH/CWXX+#/;VG'U_=-7/.U?A-A5Z//1>#V!OS
M:E8<86*,O9[$N6.C@L>36_:MD$0\VG>ES]=B<-LEM[P[:T9_B^DY29NS<7]H
M39SSH#B%&!_.U_D=^75=<:]*'(X$'WP&-Q'=3--)\=\Y_9'>IIGNKV=-NOOO
M%;:-)()VB\L42(W0[($^6_?A'U[\C&N9!Y">@4W,J@:X +M$3W])PP)Q=#>N
M@QT -"'[)L0>L8D(,Y(_O!^:UJ-G.)I)KJH4N& 0HN36!Z<8?ZR>2Y)[57+6
MIN>H7:\VSU2LH8PDTM370^\<!HRA@RQ'0L^UQ\]X*RC(1KQC4-9, R6NA:N2
M(HY')37%MV84YC'(^/8?^I5"NJ9BQ(70%R(K(0P?#[DML6[0\'9VD^/-P"+.
MO,NZ) ,9+<Z':&$FF-5[&7&@J-F'Y-96V6I\OZ0[7)BLY:A)W8P0!:-="L4E
M:1'[/G(N^FR"CUJ-N%9A7CFS@T1%:L2SF#/U0$@K,Y.B">J3[ZNJ-.Q6(YZ2
M%\YP)>"'0CW;TD!9<_T@+S4!K_X,TP.'%6\O?X1_ZC&'PVTT?^$TQ%H6S@B#
MM3&M#2A\"F3\(XKM:#T^F_Z,8'FI-1OUI*YNA*!_#=F>DHHG>3O0G&2$F)?4
MR&$=(VGM+TOY23CJ*7-4+K5515;A^_*]& Q/J99/@I32 8+6N+-:7FQ&; 9B
M9P>:N*(\ EEYOLS#@6I(R"9ICJ,DU;>P3L,)NU\V/@_Z85V8::%Q=W88R]:R
M7>-Y.?*PF"1O/CT"68X4"7=*-!;!Q1/DI !AVD?.#BC6WLF T=ZP<F><6W^B
M"*":D'!QHHSI542T[$M![/;+,0[W;G5Z,S5OW,"!F!)<NF\$N%M"R9PJ5."J
M=DMO'R 951KNHA<]S.GJ?@KM@6U2PK$'H:+X,)QW^1YF1V_6'B:C.'8C9%S8
M,\BF%)KA45.=F/:=)U0WP+\^(6C3AZ'V#*AUTIXRNV#5G&TE$"O4-M+I0,BV
M6T49@&68RV";Z(D;GPGHZA>,,*-!(";1C5@$&(DU\(&1GPU&*8;R#*10XY!/
MLT(,S+1@G&BVQRCK)!)4YJ,LH(ZPEQ33(W$UY#%(GI _(]E<9Q2BT(VV*@WA
M6K\1,LOO1_G!4(?R4I-!2D\N!G0U%VS&+D&A<HNG#HV(SZ>8FU'=?8(J:).8
MVH," C":2>FZ0/,QV C+LQ_5!-;4[16>TI")E$N:ZJ&MI7$'1Z_A]EXG;*.>
M:2Q:(8%%]QX+9X+8[]J#\&T/0\=>.]-+<&Z#*KP_J@&Z4%L(?&1\.GL.@Y'T
MG'LU%*$S3VJ%ZN!.N\)+;5$0;!^NOID;B2+P,X:WF)32PKLMPC2E98Y_P744
M.HJRYW#C#00M54[9ACVCM>SIAHTO_<.7V98I",K%:I Z-*FJFOFR@FN!Y2'\
MQ71$Z8LFWM4>=C)BD=)8KVPI83_Y]L:L:PN%UL6[LFY+F6R9-X^M0FT51L.J
M@E[(,!S@%!:N?=A"(ON:]30]<R]Q-P^>Y4R*PWB;++C%=[@;QBSSJCI%..!)
M3K+K;^^A&JNV>!='&:L@[#;8)M3#'L9M,+^:L?B7@J[Y8LKF>._-M 5I7BOL
M:8C78=KZF8T@8[@W=(K_!U5)1M?0X^,H\\,GUO$&:/\ O'-2@Z9Z,9Y4WTPY
M23^0*A2NGRWHEK@;E?%"&#G."[<>G;P8YJ?T\ 4XP^G*=;J%I$>0]O)N3MJD
M$U>V/F2E?%+,]=- /B6-;(%X(],1_\XL<1)R9)<\[A%@*MQWK&E8_F>49E-2
M(]Z)COLFZ3/ZL/K*4*MAO8?8S!"Q#_"Y6*0]W7PKH4A-<XJAK#UYKQ+JJ=PN
MCVA;TP/ME( UL&R<@O9ZZDZZO8IG,4C9]A6#[^-(R).K*_^K><?G0CW:<X7H
M+]]48RT&-BTD'4<6V)/!2G+[)=!P&PO[2'I3#(64?!B"0FI1)*8/&"0AB7[R
MZK(8&5"YZ%!J8J5,@Y3H$\PD73()2L%X4A"7HH%4>I6,/,L8U8-ZTMK4WC((
M@Q3DAB>@*P$L)4EG@U12_B.HD7D(Z+!/3X!BGX6/?>]R8*CBW0R='&@>:CI4
M>9 ?>V-2$R\80S 9Z]Q= UO9D_/A@D6>)DC*B53IGCA76&#E\26DCPP)'"']
M$JW3[/5T0N>O0BPPW2L=DZ_4!0QH:1)##('XYH&U.B# $9MG<+M4%X"3,</:
MK?8TC,L_VL*7RZRYQ6X\B7^;3(-+QOT4K9^*0'Q"%S (T]0"^?#NUE5C]MPU
MS"P*'L UIPSDIK]!):ZSQ TQ*L17#13-Z+J[!E_3A802,D8"^3:C_S5=J%U"
MSAI]Z\?,(\L_G%=(D"<N.K]MP-))]W"<8>[2*4%5P#NOO:T*Q"M#R_CE,W>7
MK7,RK"R$'G2CWVUI# J>XJ5).G+DZ"YFL_U&IE0?8""#9 I$B@:)\=]V>_QH
M$E6)'TJ@#H.;K]BZLF_"PQ3%WEW,E0<<@T9@NDR?O)L9275=2-%/50-_J6Y\
M 70T,21(IO/\I-]"' \6ZYCJ.NMB6W_NV8@P$*Z"3GR\0DDP7]45KD077 *"
M1OK0/$1>/V5LQ47R2+1PV',7'ZVYC7$HQMW!DW()0B_F/74Q!NLLY3C"IW9Y
M$X?Y,DVP&EG.H$7*=!<Q6G!>[.BB[!IXE\VN&H<?%_C2HZ)AQGAM3) *1#RI
M\,7 A90)K!'22@4EA^N?V9.EYZ;HAD_ND9(1]61[H+\(1.K7 NXP*1CJ1HIM
MF\6-+0#A(."=/=@1HH<HN.FE$[^D>[)_H%Q2;S4,[A[@"&0D909T'(<)E+TM
M7-0<'B<%OV4C5FH2#))W&B8!F2SL>6>$@71:@O@65\:G0("+I.<'C%EK'SP"
M/M\@54--B]ZP??I.FV+:.(2.KT3Y,IU?JHXA@P)&R'E.S,J^\OLR?3L;%363
MS.)J[:#V8!+"PE@,C!5; FP&M(7=1WK'&8Y_AFTXHXC"%&)9-<9K1,MZ#C/S
M(,$<0PP%_^&*WGFN]0*2.(F'RR7)XW,3M"-7N<67K8;@-X,WM^T"#X<N1[ T
MWGVPKPIYG(?<2>,\#>_+MXT2.-!XLO(U+LB3HY,>-P%K)5*1>G%9XZ2XQ1P&
MH>>/:"^V[%)A"-<4<OL'"WE%Z->>]?,W/,WHRDF*RLD'/LVW(XJ]2E/&Z#[?
M4LETN5ZU_FYXAU3#IK3^)A#?H<>:4?\BC=UEQN;>(TSR/D.&&LVPUP L]$.>
M?] RB$32KEHK@4ZDRNE&3P.+?;4SZ/Y2#DM5K^7J&"HHL(KAUS?F ]>F,01=
M>D_K/<H-7'2#@?7"OJ;V[CN8W CXN(ZOCHEK*?6A8-*YW%N"Q<F\=[-O,X="
MCRL3_7&V0G(TK.+B*9D."M4$!T#>Q5TM%$@YN(]>=6BLYV"2UJ>MP\?*#"<D
MUGR]! =16A$FTB3TK7N%51+H<WN/'5 PX$CR/I&69JTOM4MD$OD;2)_AAQW]
M%3_?8[T(&*]3ZV)PC<-'&&"HUS^H7_&T_X[H!1@9/J)G&TX.)]5S9>#O\4RZ
M\@R10@JOVR5_U],[2 5.G@V_Y3W41!9 8)@ 6//+ J6_$FF3_IASNK8P:R%.
MFB0:1,J U7SX$AHD@6QLH5'H'G:&(0J+Z1$ 4B%]+!_S&.]%89(,EJ+<DB>$
M!!*Y:L"P_J!;ZRTC>4NAG-WB@23^8-<Z%E$6G!X^RQ.*_UL[M5#C><U[2$7F
MSW;4G]ZCN=M$D->]ZGI+9T?-K&'^UKB7?#ZG])(^H*KN3@#D,ZU,I43N9&$T
MXMK_^NV6?R=5&<EJIVM>RSF[LQ+MHN5V^63&!]!AOLHUW6$6[QIB2[+U,PJ3
MHFAF[H)TE-%W]W"M@CZ"\H?*=CX]YQ-JCA"@RQTVBDR3&$HT-Z[,+U7#,<M8
M579K[E^Q9 K6>=FU#,U%/HU9>1=C2,J0JJM9^<&E V"6,[IU:'3,469HZ<NJ
MH>]3"__1^^..63N9QP6L>3UH6KA>&7?-ZM:$QRZ.D7G ZT-,Y< 911Z9ZW2*
M=-CX*Y/VZBVNH*X&:;><:@8];QF56)](N=-Q.C-^$'XR Z$;A3R9YJPMFA9@
MB =M>[/JNNI%IV(TYY^]N#\>>3@1;*_:<O/O[J0CT2*I42O367^>U)IQEY.B
M>W>'C.E#WZ?_5@D>3WK)G>.LGW/2JTW]PO+(8,J,FD7OM]PT:\_>QX*D@$[$
M$\<!5/^8,8PJE  ,P*G1/=RAG:^6OH*P.C\Q";B/+:2D1;.IE4'"P^71;W!
M C9.2E/TZ0DUDE8].JH&[&:RZ:!H5JH.J?H)- >,MR.A819-?;(]9X9C@&8<
M:R,+D.P4&2^,Y ).G HTI+;MRTH+PFA<+H!Q,G9QI;<40&( C8!+2232!]8Z
M;N2"6S<EM7.$Y=;X!<4/;OX+?O)>R^C3GGQ,J@;)8<X$H4G28M;2*5AD!/MY
MD"7Y!E/7T>NW$WE@J(!</<X0/A(E7J+A#LZ25V5V"B";$G*>K8;3!XN&CK0=
M&+?O2)R7"<QY ZR*(:X27.?U[N)<X=2/J:_:XJT$_H3^S/AQ!]K)=:O(X2]E
M>K:&7678\VN(98_^8Z*&+6/1E>BVQDFMW6ZC577 6O4NC(/0I)!-%4A>/$^G
M5/+P4_L-P$OR-GX$GL6B>1X)5=1?*"UY:26"_CK)\3-$\*1C(V47&Q]-GY!'
M6J= &)5L<?J]H/FBQN6:( ] Y2 FZI$P!:(/G[4P9E0.Z__=R[RQ+G./3//]
M)OGT.[-M1/5ER5!+H4;53%KVM2XLS\R9=#%^D%Q73<+>%_1I$+/*+JG,H^7-
M;J%:\WQ3A$US^93\K);E\QB&R]RW.$;!-F:@=D90,_[YEI=E_1XF#MD,DG39
M_@0)8GW74-/G53-9E^6FW":%+/)TJ[/]XP,T+[HDFFM.BP7EF*R\COTTJ(K)
MM1EE&0HUWPN 4]P0I7+7FLEUBTNE:ITJ,L2+@.AF$QV_=D_ *DC7B*U0=V_#
M%?<[K/8 3G5U2XE>JNK]"C?'#1@4*L2]^N-_2SEQ$IWOD+MXO2#^QRK:7T:
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MS)3BI)K.1.;QGC:;C7L&VBJJ5X!RVW7.:H:U&RLFC&DK&Q^^/S%P\^45+2=
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M U:@M/ 3GK(0T0<Y<^)T7=.U' J\'U_83X+#J<KI"%B)=JFT$F\JY.W:J'Q
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M?FPA.7N,O0%<L2![=Y5Q?ILI>,CPL.TS/07!6>=0V)O>AH+D-$GVO6D@L$(
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MHXR/YN[_"WV$O[=K5^.5A^+J;N ?J6B>U\1D8JKK)V#/6S&J;TB;)4ZA5KI
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MBA_RO3"+=I"9_1&GU22RV]P*(C+<>UQVY_KVNM>?:XJ^Y2V$H53M#=*ZG&6
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MC>BB-O"G+XTA3TLX$"L# \SND74H#M$5N,>&8 (Q]MVVB!A;AYWG:P3R4[Y
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M=?"L[9B&ZHW[9-0LKT<&<;I$*;_I<.QOIQF=($G$Z/_8Y.' V[+@3<0 WJP
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M"=0;:00X1^:Y9ZKA0HPBN'_NW\[7W+E/F#%XM34%[)UT#H6H* E#8'I:!RM
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M5_561Y8P"#Q0!,V+43,B/36,X?=O&;KOU:&\RA"DR>!D&[7$EL6KE(X-!US
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M[UF99,:E"$GOI_YTO9R3.R.<)Y[W3Z4,J'^FP\^LH?#!.AU"WG0)ML=T.P:
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MB(/I$E@G=1F?#/[824-PBBL HS2^%PYA@(3@]^H@. R'#6(';T!A@E_K":#
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M!OG!#"%FKU@89P<MS7NW@=,/@&99O1T<HEU4\3J9CP-/8J0)L'O1&7_^A $
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MCT?O[S#7SOJW7KWS>.PQU;WCB?\>C^\\ON!LQ[V3&^]50Q"8_7]02P,$%
M  @ R3U!5IK2&@R]]0  ;?L   T   !C;VUP7S P,#DN9VEFY+?Y.]2-]S_^
MG'G.;FC&H+$VC)TTF!A+-<:^Q-#0D#(D$6J(TOZ<Q9K*GBV-)5O4*)7V(:12
M35*H;@VA3=U#DKI+G]?[^OX9W_/+^>&<ZSK7.8]S'N<<;U\OAE,T#-P-^P$
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M26E]./!2X_FU-FP1DU+Z2]9)3FJSA]T4":8@D?N'U7OWR<0F;X!:=SZ+DZ@
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MH1 EKSZN]J[^?PE@3.^-V]K X[_'J#<&?GR_\?ER!Z-FR/)J\>P=XI>0%*>
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MHN?0\[/PKI[#A8Z< DBC611>5T3@0W8*NTLD& IH5U\"9IYU,F($2*GCR=>
M$Q-$21 <B+UEU]!:/C X^[]!$S&X4$*X"),#.O @$9;F0A;)+"\D3%?;'Z(
M0JV;+9<[$I#!HU4^/,B^0(0%;)'4$1,.\-<7IBH5T26A'#8TW@:$+B=>#F-:
M,.)%:HF9Z@60"_F6G51$H 7')G2M/P^1R*85A=Y#EN#!2N?%!! -_(^%"$'F
MT-\(X*+VL&T+I-X,$KL =R<!DBRBET-XA;JF#Z1.%JA3 O]$0ZMT0!04%-H"
MN-J!)/<R]27W?;W]Z=;@Y5=Z%K87RE(AQPQP#GO]D4B\6P.&,@H+,@?7;Q&A
MEZ#AGL$P+B1Z !&;102?&B<>T+P#R U6=^5!S@4A<E@FGGT%3PM6I8V5!XB
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MUHUXQ8T<1($[<R0KG[A4X<+6&^"*#(SSGWWZ]W(\+/<$_EFQD?%C$E%^QFY
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M -99Y$<X?H^Y!@PC$9J>_,PKTS81"Y&W$#UU<!5K#]0PUW$_0O. $-T;O$\
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MU-U74GHMF:#JX2<?L9EY1"K82\HJM1< FR\?B@L(HE?)L(HOEBRL >W%G'K
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M\GO1KNB7-5.'(NS[!;ABXLRCVOX%Q*M!]TLK-CI;VL05#$9G1N_9_W/ZM*+
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MG>)B"Y_5_CFS"#].J>TQQSX]+[(8*#L%D3"[EK-?A"Q0C0QR94+GK=4A)R+
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M,W4?]5:6Z7_I1HDA+>9_$J[Z3 [2G1QZ3&=X1+9:_TN7&EX=8'T^:7J"E^=
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MM'B73DH+,]42<B3F$1O%E0+N]EY+,BV+QR%I) GA1VB-=TDL%&_&8X0B)!?
MI4"PY48>WC5B<^+7)2P=[8.;K><$@ "0]0@8,D$O$*R^>9(D14F;1VQFU3W
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MB5\FDW.8SCD#6:TV@/9N\YASN&EA)<_P%1S/>7E:^;RF7[\N4EG,YE9R>ZJ
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MO9"YGO[X-HF@]]W=CNS%XE]70L8RDN(!*>_@W&PMB:(B%8B7ND9RK[D1>;0
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M37J DUY(U"AI__9WUQD?MPCAC@+Y/":CB-(JQ#(ULW.S71JT8HF'TT:T+S5
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MW:\BM/ML+%^V[]&"G^T4+X',3667WDI1"T!6 4:AA:,BX+]^U. %X!<WT!<
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M#)4JO&FR2\/#$:^NC^V"ZZ!BMZR:NF1,6+YW>7)%@U).U<EI@NA##4,-:DQ
MLH(NU22I%(^';YQ.<Z[7[2_S@9^TR??7]"9)%$P!N-= "?>1L73F4;3.N[K]
MB8*#+!W&)!GT 62\3KFQ;W\ODV B1.=SY#B.S$O+KZI$O55RHM;(2$JB%P!L
M"8SM=L7/H%X<&'(":=URUHA1@ ]J#%3"ORJ,.(<Z5:'&8W54CBQ, (Z9PE@U
M)4$%L&=N0@ V81 PT<HITA:V%'5/MJ,D*U1W=HLE(!Z!Q2A,0.7SI;/ FQ&4
MP 'SML)X'UFD6(Z-D'LG Z4%\J$T.=&@2!0"X@@8([Y61P IJ)SE _@78#[)
M4%]AH_&]JU5C+>M:@7;M[VM/689Q '8!3-;TO<LYB'>0"\N-[7??V*O$8")
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M9=:];35)N8=1<#!1.2\A AQ85W&E<;KT9NEY0C%C!F5*@9!E@4^26Q3)DW7
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M_MODL\">P3(2A2;$YR8A4'#\3KQ/$SFTA<Z5H=@B4Z3Z=\*?:EL%(7_V.MM
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MDHRZL<_IR6PIHBK62W_8MK'*2',D1.W'6V-J&_2'F5:Y\KRXAZ)9>W-_PU
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M@M0QNP1?$8@^D;_ZDE+)48/IE6"N'69GLSG&PY&5#5G#H(L(35<?V!6.(1I
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M!VW/P+P:+Q0U(@P?H>K8G4!F\<<GMRT^MT':)AI,AW05U*E+>S#]UE<52UQ
M="7FF XL O/"@D"OJ3L6 D^/603T:84Q3^96- U&SR<+ 1E9&QS,E%TZ#E([
MQ9YBQ9=;BI0,[5QN@3@F+\:I.& *H3#!$Q*%S_D!Y!&UJ5I)!5"^7/!\RND5
M;BCCR,HH%LI,@B)SP?28W1]]9;HTX@G1P!<"-S&\@-UP,Y(+&D\ +@4*. GU
M.%II\DEI.@$89XOCY,?=^($R>E7"*>0HU8\>C<*7'B5K'(-+ ?L*"[\)G0<,
MA8OFQ=FIK8* C]&([25?2K2"-+G'1W^.KD*LU8J@EF$KMYJ#"2C1;>09XA]4
MA.RT4'E) 9)*45]72&ALDTTJ*5*$8:Z )#*Z")@9+S/B*9;=,\\<0)XQP;^F
M[P'&9:#J;< %(^KR2XBO=&X$T+3B&,>=>E^>4/SX'/E\K&+\F-/+BX"2U+_Q
MY6415S&RF3F_%1%I,932&K1EQVU_#:7TXN<1DT MQGA$NWX)4:/%@*68:ZE8
M$F]W^01P6@(>.(!\;%R8>/Z,;2YAQ_D"7:,22\5VR G&QRA%0\-1&L4N,6&?
M3H&9<#R P?X]&^6N90_V]WFV.LYG59)%!6VZ>JR.&IC=2P=,3"2N#?VD8K96
MIL(<3,?>O@BJ<A1'M)P#DYY%(\//N(N.VQ;C]2ZW?0H?B!5&V<@%MHK0CRQN
M1F@LMA2[<KK;?2A%06I<^@&>S[8[--V^HWC!3V0RE<(.=L>O=S\SFUQS-9!F
M1_9!;ENT/'XB>@S]8^\!44]$]^6!Q90O2&BF$K^;\*+_EG&C!UFWA\&5W0LK
M-&YT.Z%%A,QY\E*%#FHWX:)@M\MZ<Y41X/VKU-Z/&7N<IY@G 19E O.C\R@(
M0N(MUG"/1TX"_Y4VS#*'_+2(S$#6 (<'/&2!IZ->_%4W5W5OWF9@D0[T)^:9
M 0*K0>22\WTTOUZF?OK2"U4.Q!U_U"HN5:#%31"WS)N'&H >3U4\_V'?%OZR
M4:/K<_BUI\K)8L,7VJ?YU8]JE>5!%?NUF%Z]VR "!+4J=-RE@RE*K H4ZZ;!
M6@0<R+HR7V<0-CJ.8(<?AU1.;*_P$3D=? CP+%#P 2"/N6K[J>7CLQ5^&H"Z
MB_FW$S<?S N>Q*AB.B-5B)D6$]&('#$ #66@:5DSI>2LU;/X-PA2E\T@:#OH
MR(TW 3'<(\]=S%9V96ETO]TZZC '8K$^5""H%/1WTJI+8SQTR"-IJ65AG5L_
M\@4\'"6643IOTTT:53Z@&@']W1?Z$_6RV#Q:ZZ5Y+&3^'QE:E3>?"P3L&PXP
M(RS8?/]3U0'Z9%U<FZE&!R3%8O2Q>9ZJ6WMTBMUC]8>9=091@:@3L/=$T;5D
M*#K9",J;UPA$I%AZ^"(;?D9$3"-#$96S*EC/13JD, :+TSR*@O:QMBBQXB:L
MQF1,$C'[R*MU':_B3/2>GY @O>)HM-*H'R"6^C$Z$<L;NN!W%T%SV<#D63,H
MC\(L]I:4DUG4>:.WMP?DA9FC?/J!!PT(O1/XM%MA!*-(U$7SUF.KB(W@.8 G
M9V ^/1IL[!6G@M)=ZL'LM:=XX(I9X'\2C.O#IR4G@D.. 0WG%4?%#XVC%;=N
MT? :A1"Y\9\*B""0IUF\(0,PTRC/1(L8:8 ;CY$^C>W&2Z]JI^W]&NG7O8I%
MDVWP^G7#(NQ7C;*/NR<H>GF=-],ZI-ABC5^96[%X<AUV\XK>Q!*CG173E^R-
MMK9H7G .M0G)9U^9WQ<[_B-]]U:UOKEW?06[W8ZO.$6K^M<:\NA<3;(,^R*A
M'>88=]UY]WS6!84Y-%\_O@=)^R?E_??&]]OBWO<]<S^O"8U0K9-#1@8 96>E
M$NO!3R(%+1HKU%O_!DO>II"CQ"")=49-W1,H4?Z7H'P8 2(6;$VITE\Y6YRM
MN#OT_H7PX_B)-8&= *T1F.L&7@H?/+ ;W*5"FJ2=)HV(2=C#[V?N^R5>>^^S
M[WL5@$=NF(K[S&"L\23 &3M-F$"(V83.JW\6A:Q_XQ!,+:..($<NI+W$30(S
MI*7C]63V?O>4\T]'U"<N'FV2Y+7\.VW<*P$QC?2J"P7 .80C\W_%+/0O!()&
MA)<^ T7; =[@DF")PH3U+#@(/+E2 ;P!XNL0O<VDQ=E/EJ]/U2,/CJB\-=H:
M2O2B+66*E;>N:$XT311:^?!J3!HK9!/21MU@D(_"C%LMDAQYF:+ BX"X+^$>
M+ 4]&A CB)]%U\5KG[Y/,C\TKO^NH^RJ5*KF_^/S7226*#3_*#__J[5&97!:
MB&&=R)Q8C'_PASW92#!W\Z6DEP_3%I?\!!)S0$A[!SXU.)_&_[[]/MD'-4^E
MN$?*P^OKQO;]TW::Z/?+.-G]GRO7BL4BV1&]I:YAS[U.!7:J8-:_&UV/O/_4
MF'5AFOSUK[G%)OTSZ@!2QF<MI=&-.D$.A)&Y841OPXA?IVJMK,"M$;@T6*?K
MCWO64N%YN9*7H?2&2M_5EZK3E$UZX,80L(BX;-6RK"OWR:;]Y0]8YF\:]YQL
M*'Z;?42M[5"9N[TI_6X;MV*<:3RA]?Y??_&$KOLU;^KDTJG/V1_D*[9F'5;@
M(13!LQ*:JB).D(VY:B\8B7H'9-EKYVH6L+X(:U#<8!8P-V<.;M*..O$N#P&:
MNA8-E2!43;-1OO _ $6"4&?09 A T71_?,Z]_.L\/PT='02Z^\@(4U=7_  F
MZHF#T>)2%D@7S3@1C?K]CF&X;$;FE2S_H9T^\*B4Q&/("C"!$\6YO727ASG4
M4N"&I2I (G.7JH,MS[=8%WM&@PMV:Z%)[>IMM+Q))1U1$'SZU[XQ0>?D!!'\
MT3$8!@LDZI#AG.<D_#+)*!+87_FZ-L(G&[0]5I[KP A*5):-( _89HFS3/VX
MC?,0(S/N'<[#>QQY ?$5DNZ=L\H8^WG3Z4':Z'-O]:M83  A_CUTXC6\-,.+
MO*RQ_)&F9#[/XWY3N_?, FD:]N[M[[XJZ !U^NG?%*(8ZCY#5$ST7KJ%T(&\
M^3Y(U%/Z+3[JGSV R7_[A5/^$4AW[ :5R0CM."UO*5H55<)NSOFBHSCYF,9N
MXZ*<!J=!WQ9V]N0XEU\?=3SV'FVR=[D%'FT7LNZ>P/\X'7H40DP>6[R$L%[P
M,,805(ZB;16'3AC>A,A\#]E<3/7J6NKL91E[FR#!1Q106A869>N!NTV$S;%/
MCR'!B3>Q:B9-,CH+HXJRC6K_[-D5YFR4%=LRP*MH.4AJ>1:1<N]MT5,B;1Q)
MV(NZYV2<&NO;.;0NA'BES''YB;0?[J_ZJN9N_OC^A\=$?VW@7M?TGYYOAV:9
MT$,__/1Z/W)J;:+0Z\8=Z()][Y07WX&N*&Z!Z:@E;_C'32_N/<T[KY^3)\QR
M%>'4:\*546D+VP4O9^VIQ*OLLO^O &ORY*,/X?H7W]&#Q=,9C?\6]ZL"\@.V
MCM%3&KJ524GE_<%67\ZPT>8M+D#A:H9/AU[0HND7;#U;J7V0N_,E(QBLF0HH
M<-SJIU-9%W%X#X2S6O.",>743I23D5YV_?\*(HGV6S0(WSG)OU3(L>R*7^&<
M*EW!7S^CO330QH7UH LW<\#;OB(R=IO]OIA##D_VE0>4J5/C$AR.[$NNVK9F
M*RL%[F6&J^%X9XZ&3\!(6N!1X2%5DF!S2SD\BBDQ9Q LPVVWR(G"4'>!50L]
MK(N8)J8&<SF5#[HXQFGM-ZV&PY (9[I/1YC5K@ZYS'I64C_:*+&YC4B\O>->
M-]2BC6\J;/3329P9?=-Y@=CF=G>T^7&DM(N9-'+OV.I-:;QAIX&?]W"8Q&8=
MNE320(UI,+\T@.*26GD;S+.U;/2IFS_M\9"QB!&(LVP9Y<=EID3P"2_*!E*<
MUV3J@.H4HA^O"VN9R^LF.%]L7;.1M?99.,=EA:#-J'/D)I;PJN )0;HTA6[3
M[V52(-H9"@0ZNV@,LJWX;(B8<3YGXKT316<_BE NSW4*M+\.F5RZ[8Z_SP3=
MQQ"IJ5Y&Q%SL?D"T,9L*$%@4N1@>6#'?7BO'>7F,/2!DA(1G.&=D=ZJ)!;O<
M96<MA^/"G7>'R*_?LWIS3YYCY)<0N+JE6?<4N_G,8%="^BCM9D;Y-$MK<[5X
M_K3/N'K)0M^7->F8 G!M]2<4J"ZB/I06=+"ZS&=9Z1X+RSF\M-IU]F^!1FI?
MI "7FFGH$JHAUGJL8WU\-SJMV42&.]331K5<= 1>Y7SJP8R9@5"YI!=KF[F6
M#Z6&  ;(,?/UV:\W_BK=A0_?=DJRP^3AITE\8G8W8IZ*M"*9)IX'K*V,JVNZ
MP0J12/;+5==I0N+2$P;N")X8 (]F!,7*@,W'SP+">@"=*NG""#Y=II>/HKX4
M E=$'6@/GI9+GT L8%:%26M#AFNN+2F1>]5\4.JA9H%68K?\H-P;<TJ Y=81
MTGR;GUB&Z$>-L8<<OVKVINF_G.'*I+?B0U$(FYP*7;-[95+@E>V8U)+B;W1'
MUS-K++X0\QFVB^JO^M@HPVH%M:O9 RKN"1TYH%TAO2D*F%/2S%!SKUH6,0O$
MV0.FJS+]C6[JG$O\@T-*$:5PR^"^UU ]=HVA@@.D]OC>EV&3-&.<7E;'R3<#
M<PYQKS(W=!1Z-\/DU3$]5NNYMV(&3^WKN&CONMRN'GIY:O_E7_8\Q:R^^#7"
MD*2RHG:7N96)X;V:??%KDC,P^]9LP555V0ZYS0T(36:?=G]H->3Y.R$TH>QT
M]2L_QWE#Q^YDG3I]\&.NH]^+67>W#9X^].VBX\)_CMW=\?GTX>E?CC#HU"\S
M:==.XQ9P!:9-_7GN[364'5Q_.Z>!@O#V6K-+7*%'TT!Q1GN=S6^N:+'3H+JL
MO=YK^)7/R3>AK1*/ZG]#C@4E.@U5#K8?\;YTC&>MWN5UL8N\OC/!SH!>OKRL
M"Y,,V%O>U^[RTLK*MKO)B/ UVG_;CC0<;GLE/G9#%1TE7-#J1W;J YJ:Q]J;
MU]B_%KZ?E)FX2-#VC1 !OFZ^R(6%29[4H0WAN#?%"&8FMW"E"P]GYJ.-6DY@
M5NG7F9L JI#&3GA;E!BW?U<OIK;V?8S'\9BL'!VI;!;* HYW37)%AY2YL2PY
MI^67RV7SR]\@ZR^ 5]BVUTK7N"1L=?4N"%#=H*V>GI\^:\4GAK#\NND5QL<9
MN_]=>:4OU&<U;?8+<;RK67M_1U\6L'&O^5S16,>> )?9R0(U:O[/E[1;OV\Z
MN78\_'IJ_ZY#O!:?E36H9[GV6(O.?DS<N(J( .".S[<L3YFVI-QN(X57%CE2
MQ3;CN$Z&:Q-XF<V+&6V58+P_/\;"$E2GMANTF-!A?VWUHX;H3A]J1 B>,,JC
M5#/_4"M<N"0D@9JFQ)J? .*B6V5&,>MH/99\+#<"1W=.CS;JA#G-+Z\;9?M@
MCF>W$>89D%=B-FBVQCQ:-&47D0N#-IUP4"\+32[57EJST.-E[Q:@*W0-^*5"
M_"!6+;N!6[=6TC6])WGP3P*+,Z 9P#6V!>N(D <O8$ZZ< W*#EQ2/;RSLD39
MG2]W0\80K12V$[>]*J<F,1(&OL2)$:ME*^0;+6J7$IU:U91)!_26YDRYO\%6
M5"= V[OQDQS$/N20+4/JZ+\L)H;07RFN9V9)9YM_Z4:W<<UNW]GIO>\C"P!2
M7"YOP!E=RZG38XMLU315WXK>5KJKFYYD)E'.-&N#(GBU_9_2S^:,&0#C:MDF
MD[>F'\3GY)C.E^N[XZ]VVBOG?O+KW2Y,]>>RX$+Y 1<3IT[ *4:*1#9JE\WB
M"KBEK_:W9^63$_L!?.S [%?:;M1;]6*<_R<@3/P)5:/MF<:XMZ([9<E@ND:_
M.:JK)K(9/M$_[=N/C9JW_=]DD/#SYN%?[O(E[EK*9BVXR7[QW'1OM.]T;4C1
MKP\S+.VR5]$D_<*I^DS:")^R>+S@2M8=W(7<9(&7L[$1+HD>6'[1;W;I_,?A
M@/S4"Y0K-Z6&P$W_7!SG3#<6R:S?2O8'!PD,]<R+3]\^VW<DU9_B*$9F_.Z6
M'0C4+8B@$XS80^^U>R]_::N<T_$IM 9"FK"W*C;C5[VZ'U7.!VN :Q\6^.\"
M,^J!0ZNOX1)\NX;!SHV4_:7QRTKEP?N5BXM*?ST-W9>*U_WUD88HK=GT GVU
M-N_IQ@#_\R\03Y?:#4G:I;W3'NC(NOH.AO#O?U^OB ^ZDJWU[7X(KUM6:O9H
M.1Y;.W<!@&.EP<OQ$8\W?,'E38VT92/Y"):;I@.3$!#1K9B(P?C!&!Z :/S!
M. #K UR9RK. @?-%L!,2<!W)(TS.P&A)W%P-/@+9W=J%4>HP')5C[L&Z-!:V
M_^D)OU[<4MUF#4P6PF&YJX,-UT Q%EO>E;@#.$S"+?9#')6'X!"DRD#A3D@H
MM0*.OPZ?BV#[GQB>Q'%A A0!"^OA=Y#6\K)M&H)^H93G],?3GJ)6A.WB/$'=
MWI;O^*O&T:4LY5-4<K:@0+G_4D#W\A"<G20O"9%;ZVX[31*GG3Q9W#2,?6RM
ME,L^J1)8Q];2WU0+>0+AKQIAB%SJ97 RH%;,+G-,(]H4W4_2UR3QY-K,0+"[
MQO7CV(LBFSG3;)Y\>*YL*%E7/F=PUQS*/3><G8=WG<=".\^.!^[?:BM"$CU7
MV7D7]KIO*/3JQ=F[A'OOJO-Q)>W7HBW[8EM29G@4W"#Z(X=C8(R2M%]RS]-W
M[TS# "?DIGO6D-L9/B8$N3 ^-J_WP<+>%863.!N$:']1)B6->WC5N_D.^156
MXY"_/'R7+RBI$]XL/[H-LIP4I:3 1'\T)Y<P4($S*C=WHM:N;4>A64K';!TF
MLR[)3R LDL6["0YJ@CJKI\>%T_6A-6BC;-WGAB*P'''4\_$]*'PSDM.,@LKA
M($1@Z=,-=>J%:3J+")Q%>:UY+C9B'Z#1"HRH]@H]ROY2U_X(!-N*<L*46830
MK')O6RMAZ$EM6GJ>3S&\+:2;D!GUL4=V^L]D*0R5*ZU'9.9I,,=%@&_4K6A-
MX$R96V9W0S!LE)T449),RP6,QMDKN Z)[G(\_*H][8C^#,HF&V@H.)#8B;4I
M!Z G)/OFD-$1ODTS:N.X#%("=)2]=!7=*4E'<!$8A< "%RIW&(6NYZ_(ODO,
M1NRX2IPUC'(MPR. 53O?LJ]+6(_BI\&;#-?MN!C%]),';)>[3ME'5@]3[-,0
MW!.4?4@<7JSB\A".H0LSCE+JZV">KCM,:.\'_,B+?TB"+?0R, VPCMZGY"!6
M]7QT.?!<B\16 _:9,.X)G]L*&]6BS=,0.ZMEVS)U1,Y#60.D#$XAP)KOJ@-V
M^B[,DQY4.Q?'K+&<7%F4BUC7RT*;0RW]T5!K'I&%$/I1]I+]=LK54N\W_O=0
M<Y+A,!C)U\F&RXMQ/2J[_GB<AN_$07+2,9 _ .7">&9<L 1 E+?V4=9:> JV
M3&%G5.B2R'<2BF3?Q6@^L/NI),1"BW8J1V6E86PT<<G-R!,WG+T!A9W*PS7R
MIU>JE$1F->A9M8H5O"?-L/.&67<-^J2:U, L_?N(#A?E),LD@SRT]19XLR>\
M+>[@YF:TYN<U/)=1I)3;L71.=+[>EPGVR*SD1_92C@O2_<W[1VI:=4Y^<-!%
ME#K7R-X%)BAU?Z[4*@ &TN'1S+UV %SG@P9#WD$(;-TL.\;]ZV .4,]>EU-P
M_91<3G#!!13I(!6\*1>ZDMJS]5">.>L!=@IETY^/HV-O<&P9,<&6$]@3#20"
M]6V($ V6 I?DB%4/'U2MA\:KN^1RC*C;Z0<&['_7B3-A+!16^N)WLW!WVW2;
MRA#H"\.I&:Y-\R_V1["Z&6VOIET$_&-)2<BD/W#+]_AJ'>I6Y\J5B(!"?(>#
MUWG\!7_.1DL]#3/?'DUJ1;@N!^LV-/1UY%%^"@.^%/I'Z),BD#B^'&"5Q)]!
M@TSV#O\@9Y%@2R.PLCDTJ%/VEZ2)(2#_= -.AJ177YZ=TZ!\U'J[08M^7F4R
M[&YL7IV&G;S_Z&=>5CU_"E(^5ZWB^'7?3R^^L^$$OT6 J]?M8*TM:M6M]'9"
M%]QEZV31B  -'<>%P$9QMPB=> B LC\_P?+D;W<65[G+]S9WF\,ZZ^8N(.TE
MTT]GS6$J7+J!-*V5)VP]\=H\9#EG.-)*E"+GI-[+!BY=Y"LCX'4!:/3TU TD
M(E;8W"4HTB&9_7$:T;HS -9%;L73;2XUMROM,OZ)114\00U(;O;\[]>) _(?
MH?U^0!0=P;N@+4=Z&BI1=DI=N 9Y,KL;I9/9*>'* <[K#:WS\KJ)F3 Q1&T5
M$<#AI=NE):LSX=YPM6DXSJH>(!HL_CQJ/O$Z,PGSHUFZ-;>5X,(TS]99MG8]
M0 3$SG"CHWU6#9&5)]1)V7)B&H)7&C@7&>:Y 1SZ'8L^&C?DOE5?@-9=3]A_
M.X[ZZ<L)M$4U$+WFZ$PZ;><7:>X]V8P#_&T^:.+=)9"2I,K16\,T"W&W4[W,
M&@&@7_?I6V%:;I[5A/VP$I[^_8.#7^3."3S%F5^W^ 2='[[7.WVYPVKW169)
M<V>;>GJ-.V[_[+C;W3%_R"?],W?17L>U>R,9=FM"3[G<=9_]X-3LY^ZNKT^Y
M_L]]SG([Y[WN:UL3YL[N?L<82M9WI4<REHLCN[0"*Q[%+N6IUXX\C_D9<U9[
M^(>.$UUP^Y6Z_XIW_5/4"[8^K(@>^N'"_'$B([E>]CU;<#G!P^_T$(<S9\-#
MH=6-L231C-S;Q3DLG%/_Z5FH3/>\;FM5]QF5J8UF7WX(VLOQ2Y)+4S5_C_&-
MVGS/5TD1 GT2$A&::=W1O>'@OIF^%?F:6KBY37^[9K7J?KH7NCL4"3BB8U(]
MO0)7+#H^C>!9Z3CLO:3QHU[73R\;"C>*@XGT&*(*$9]%$Y-@J'$TR0>-S48J
M:D)W60<\_'('Q]-%Z5&70X"-U7_XDX^1ZB#I&5@,0[DG%(0SH%C $0/GVRD6
M_C"^"$$MP>W/@@F\,\0]6?@(;=R0UUVM #)X+=^NZUR%8'FJ^.\K$CQZ"$Q;
M)SB(9&&RXXELE=5=2 RO:Q&L^AN&)B3%R0 !UMKY=(<46F'CBE1^.N*XA) +
MK-_XU]<0V.V_]O1;)D[EP#%N,^CY[OZP[-5G_[!FP<?[*#Y<K+WWAY@/K(K3
M?=G2>-CS.N@9W#!0J8U#SEGI5GR[F;5_X _X[[*I2*]0GO?L0-B7(-!'[LA%
M=O.Z@:*Y$ZJG&.8^/*#/'3K\O9JJT,)32FZB[MI@<G4^KYBK[]KT[N'#^C[0
M)<["TRGR<7JNFM^"R-$I:K34__E4%S9E,GUKML=J,:ZY/R.:::Y\EG%]8&E4
M_MKTGI4C*+4V[J$/C-?(\L5]#83KA%^]:+K,,0!X8['N*^4^TU]W>>2:,%HG
M7"XP;P74BA"%I\"*Z=O+^5$6"&SL.;G+Q?_%FFTGD6",>+ A2'0\#VT-ESK:
M C:Z]M41A>8-\.&D)S,WY^,\"Z4BGP<YJM$:.3$:+C@-H'FG\_$_C9)O$@TR
M*Y> Z4%R(.$)W[I\7XX_&@/E6\EUA<:%UOWY_1T!ENU&3N/9FJ.0N7+)V$.^
MW2_;E^J^1M,'%ABK)B3 VJ74KFAW&'(3 Y\K7]]^_&K.^V]$^Z?\N@W;G)-F
M]D(EU".>@P8^WB!;E3W'9KC+.NU83[-ORE%,-?/9AU"=7?:UI)%SCC"\R;9X
MVBU'\+U=N_]"=UJ/Y7N.T<0U2$=8/24V2NW!/+'2C_ QN=>L,?B+I)95*;!+
MV]9K;KU14I&<7OF<57WKQO:1$\"FATJ8CO0.KM]NAH_,O\EN_FXU _D[.&V[
M]_5O\(D=&R4?+/(,$X=7Y\9MS=3IYFE <21!U?UI:AIKR8+E)X&N'QN#Q?"9
M]!YF_35Q[@5:@)XS57UNQN\7B  'U^2[=A/IUX75@%EP39+&&XI#H'H5MI09
M[K/D] C6$H:AZ-_]PS(\*D;NV8V!LU9?" "K.AZ]>W;QHV,TKSMWZV%,MB#W
M,CY\2A6_#/F[]C>D^8/A%7O3@:1SSW&-_5B>?@C:?_.ZX5I1%[H1;P4#!6W7
MG)27UE[P'(BNQ/L!]E[=0*GML(N.V/JC2Q@U[-$V<';AU6:T72<TC'Z;Y(]>
M:+?\>6BOW_%\[EA"\*)_JQZ,6NMM__?ZLA!YX?2,M+G2Z,-A,SN>:F:^7"KZ
M+_^)3/IP)=?OBF)Z051J\JH7CZ93R57+4S$I<GGN4J%=+CF%O>O'Z2="YJYD
M32TK&&<O;7SW?-&XU"?_2J\G,= @QL%QC4.%$KX"3^N(K2BU%42PS%S6^:@-
M@L(9;FN&.]6)@7MF\G?1?<N2@O8ZAAV).%>6O&0_<W95467&J^!EC91G];YN
MK^R6S9'A&//*4\+J M4.D>?+4Y?7>!T\I+2H6!=Y?$7;FGOG*YQO'@N](BPV
M[U@?<WKMP)'("_M:!B+WPF>2H74F,<W'!4'W4E9L6'WE;Q3>K,_]MH) FS?>
MTMAOZ*O:8^RJC).^XG@3W<9CBJ1-1RDT![_.BP\34F\6SYA3[VD[W.2U:7KE
MM4V9%EZ)NSSL0ID#A8,IC]ME=;A-@:/=OA:BL\2&4<?G77=K O<OO/1.X$4P
MJ_D\7B/?K-W-IB;51]LU0?9PS?GE<$E0A,G*V<@.VSO_VV-T.Y<U,H$*(FXA
MH9.]E7 JX/B6&B+NPII;$2NP*CN(\26VH%Y)N1FM5\]]IH=+1$(@OBQJO/,%
MB=S7JJ=08:"5X3T)\\$90T \1@A]YF"IX?T4#!0%VY?0PN)K0-.=Q.1B!E^5
MY.;AP)L@>T )5Q54P_H7%%/!I)),'A1ON$$I!/*P9-7B:\5BO111BL:S$<4W
MER^&(OE'R2:M<AQ"*;]9M&GETUY^YJ,HL]C$+I QEL,IF2_T$5-FW&8.[)W?
M%<%7?',X=K+"#YXT%$?!E1(*=2&SM2LR)OW>O14SW*@U03;1"K4QG((M 48:
M%3+R>UZ7/"H$UI+]',2R/W2>JD2/L?7 'F\J9%]"Y*JOR@X[\*[N-0V!D_.@
M<1B+!CQX-31W-HREH\-U=GE<HT=:Z-_8>%M%P)@4""2XCF2@/#Z*#)0("!XM
M(;%5+XHQ, J+$K^5LLC++"IUF, HA9T)-3JE@;+&^L?=CKRQHG$:Q*X95Y ^
M2D['1_A)XDW<2T\G(K3[K:IB[BP"*Z1ZY0U@C0]ULH>"CXW)F2X)<%F5C#*=
ME-BB_[?J=NR[EG.7U]4TU 1W*>7,R?H2(^BFCOQ,@]NO%5F(7J*]!/&F'PCL
M:IW:YQ/<<";*Q=Y.$67&OU!!M$"=?.8E3F6=%-OHU]>0&OV@\E.$>76**"Y3
M18,@)UE1I(5J-^EW;+Q9A7YE =!!>;NR"PR#XS&H"'>?N@T>7%B_5RR^D5X2
M=9-Y@1%8&S>.$N]<K:4)-:OZXFP7^]14A/IN/%EA-"FIET?Q4A3:H%=PGJPS
MZK]C[[X^W/C\=SU;?;(SJ@_ *CVCNE+EPO?,W K26[!@6@.0CT=CN6RX@)@M
MP9 YX.M)F$KTYY%G2.%I2!J^*[-8LGF+5B?XTKOK=DT"8Y:DZ^V8@'"?YH])
M]) X6PS@@MIO(5E3J[#_OP;].,-.- #N[$;/^&C,H "K,-69"[R;$S",% .T
MU%!@Q&N5)<(JCE\_RBQ$P@H8N7W4H;70VT>+8;-DD)4,WWZ['LP2HVR$!A5Q
M_"5Z<[0(^[E5]2Q 0OMA!Z'_'B- C?_;D><Y;DLCE!&;M:PB*JP.%JM/W4/Y
M/CB^C .O1=,OWD8=;]0=DF_MA#(VT':LQSHYZ'!"%\ Q&UYJS8.I/6YL/\P
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MR";Y1DE:L-JL"^V*V/V:VL.B;5/-B>3AV@,$8,#A$WT>K:AEH@'43.@0CK>
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M&-D\<:-3_7GYDH#$%T)SA<E-@,)[Q7+H(C$=%U^?3K/]!PYBL.<+,DG2=GC
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M:LNFN5NSMF[==G;KCN];97.S\[9F%YS-+OZ>7<!F <#\_P=02P,$%     @
MR3U!5DJ^D_7[. $ 'D(!  T   !C;VUP7S P,3 N9VEF-'IW5!/;]_VTS"2!
MP(0:($+H$0$C(M*94 0L&!054#$4%44@%!$$<0@M%"$4Z6JP <K38,4>L(#M
M&:S8G@$+6)X&V\,6OW[6;_WV7FO^F#MKUCWWGGMFGUD[.'2.NT?L;V@$_ H
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MV,0WZXMIBF!W$K)N*\;'%D.)B6)KQHL$J$9&-=VK+DQT L U$O']OXWX?@F
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M477!#VN7=FV<,7.S^>3V8,N-J9R-"\?0- !+X32(<"P9P)(Y6$)H0U)90PJ
M)7S+S(QJ6/<M<X.Z(5F);NQJS/V6N6A @VZF-8E?H\G-3153F[9U-<9W-:X]
MU2CB-68W-S7E-&[W:&[J:LRA-:\[U4!^0].(I@R93N>WO*Z'>>R>EK\>MG1?
MS967Y1V:VGH=:WW-:SUY:DOO0^QX5\NKCM;NJ6V'3[5>7-=V^77NN6^M-TQ:
M%5&MU\O:3G2U71UHN^2Q0WFU]<S#MM[7;?>G[CA%VWE^ZLX')CO/O=[Q=_/.
MEQX[[^:T_1NZ8^CASJO-.WIR=G[MVO&EJ^7MJ5TO'N[ZKWG7O=+6^*AF)%J&
M?F](YV!4!VSM.EE65*/.7%G<:Y06W6[X2(:V-, .[?%E[5DFS12'C6FJ=DL'
MS,"T/;%L-W(MR^S ;@?-=]1Y?2/3LV%1HTR8L\?] '6JZ9[MZ]J-RG=;O]D]
MY5J#[_<&XD #V[.1;;IWWMS=>G/;TQ5[N(_:<8=]Z+6]BSWWI$IE*;(LC^_[
MA.OV^1R0^3KL9WKN]HUN=R[?-^/-WKD'=MNOW[_LS?YTAX[P\H9T8/]FT_UQ
M+?OG1'=03#'#T[)-F_=OH'=Z1W>2FSLEZ_?;T1MS3G?4GBXH:I%)HO;Y1'>5
M1\N2A=B.[UW)-(P6+2M<W[7_=->VE@,'3A_8:-JU4[IU[]CV8YR#=='+@CRQ
M7/)/?F4M6=^N5;Z;_J9KYX&#69P#Y2W[UUT[<.UT]XTWLI5T[;S@@ZWV?QV?
M&W[W$55SO@5;JX),9> T'IHM:-8JEVTU.9"2T_%\/;9:#OKAAUXZ'-KZNNO%
M@?TWHP]_+>\,?W-@NY1BSH%L!9"5'(S!*0_P)3TDZB1;[4-D2D1_-<A6=XW0
M[,F<G3)X@4I>*Z02./O2 WDY3CE\E)ZCHJ#3J$[2#5[*I;855"_>AC*5?QW9
M8YY$6T/T9&481HE":U6H'>%SR6W6Y8\PW8Z:HC(52VEI<JAP#,O#^5$"1P\!
M9?YUZH1B4XS:?8=@92D/L\6C7<RT/HQ1'/?1&AYUK>: ( \TY  Z2DJV^@2=
M7D<[C6W!#XG4)S)(+ -8TO<($Q(F.4I-UQ8YUC^W-UE1EU&!O=I\N/)Q;]EI
M6B* A,I 0RGB1V!>9.91U28&037#CQQ2 3?4QW/K8;?K-+Y"WJX"(Q_3"/7T
M@RJT= ]55SVE!D?,5]/\5:FE@E.=Q.E"&60GHQJK#/P%8+T:]9 ?*Q0@@],0
MMM?Q- &</X)J*Q=7DLA7$G+B'6^1G?MG.=U' &*(S@*>4RNQ/YW$K'' B\1R
MU? Q% N54C(XV$(EDL[#YBG@<-G).!&2K$96"B@+E%W+I<A:#K)$?CX.0/Q%
M:(Z4$JKL6BB@9(G04!4E0]Y;]:./<[9A)PDQ:FA>(BA!"6EKDE O (EIP8)4
M4*"Q8:@4S@QR2P40'X'Q2GOJ&MQBE0SV$QG&D!Y9+DB4"K(-=/.OG.+X$Q85
M(,[J*:52BH< L9I OXM=<O'@*XL0#R(SW8"R5(K.:Z/<&KGX2W@Y4&6<J+ZX
MS^YR8"/%*M8P?BHU6G39@#\@M?9>0[HDRN& GP'V\R ?$74NYV(ACGW70PLY
M)_@*(SY@X:0XL]6;NDAA%)>$U"@&/55>RV,I9\_8X!QD Q,CY-IB =BQG9^O
M0#?&&@;(85$LXB$W7M?MV/,.Y<OAP$K3O3U8H!3>-G91K&T<IH227Z(^"M@:
MHLSBN.?S^C0I&=$))!JF@CH^H>8JD//?H"$O(D0-)JH@]O4;/L!&[B<TGH>^
M\J:ND<)A0L2W'LW T>(:] 9ND:&&^6J*7]K-K(N&H>J_#^QF^I,N"Z3PO/LA
M*3+*?((Y1P5=V8<D3*#>"GCQ2<]UTDL1\V?X$=?%BCZS2E<+TF4S;RB"C<4K
M4,-12@H',?Q(\>!XYRH0[6W1]P.&"GGH?>5L7O>U4ND 7VK,>PK[*6>O$_;,
M!<XT"+M,G@"Z2C2#<R#R'D4'![,Y*$4-9JO!H_Z _YVIY@#@+UQHXP7J"B@P
M#\J7(QF;IJU5PP!'87\;\P& 4#G6::KISU]Y^'LY-41UI%1-M>= A3"BHX0\
M9,!%(XJ>&G8BP9=)H*T\/FP"U)?!7 6P: 0PEYY*O .YU[IY)2 Z L1)"B84
MGB_A0(9RR%D!C)-(UU/(M #5!Y"C"TQM5& 0"7H>=# 2(I:DVY&#,)\#<F%P
ME8IO(T58(L; 7V"("C&?.0N7K69(^88D8D6Z%<J&S3FNML 3R%X7=L$L#2%?
M"#'D_!F*TE<9$")@8SL80*)Z2MA9 ,XHB/,20-H"RPD1I/@+]!U%<2D<P $[
M/L$U"Z"F>(0AASP50-37&5W^;CMRSZY=L#!5#2SS!CLT05 +;)F[%V(04"*!
MZ0A&;W! WE]+3@<$Z,E!+S48&K%P9 Y$50TV ]#3UN=>.'3'"M%1@!L+01L
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MQF_MP' 2C2?/B]7@0P1)?([<D&.E 2_%P@MA0EV#YP"V%^I^CYG/0F^_ Q\
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MCP20N^*?\QWP"BZWBWVN?&'<7B')'>\#?2/$TS+)@A6:UWM (AV"'1K)AU+
MT(9E27/8 ^E(:=0'#@CZ.1RI#CS!-L516NT8YNJJ,C)F#<V(D%6Z1P#Z8Y]A
M$QL29,XZOD(;KZ%KJTJ-N %:2(B_$4M 92;2:.=:%';C2I+;K""CJ.]G4VL0
M>I[UX</*8#SE/H0&OD DPZ#7'QU#4Q[ 9XD"TV;TP_ZN_%.CSW?;2L<HR\[&
MZ4V5<.G]+PJ:_KI(NQVX[9]#,S"*<"\5(PIG!AE@Z+M8;*"I$#V4/4_ZL\8F
MMU.,L>0 (\)2-WD8/DS(#;W9L1!=2N#?147H**AC Q903BA+G2-DJ/DT$&;A
MXAF5&AMDBK20Y2B#Q$/I ][O9T2E-*B2J '8>"'"G,-%5KT805@*!6.;C9A1
M3XKC$T'IHID[=%=H(6J9#5W J[99(4OQ<"\PR2K#C8L4D#6G3L^1>)4A4T!7
MD,9.5QEX:F4APWR8I#@$E#"R990 I<(LD C0"XFBF:K]=?*NT5'WUZ8KJF#,
M553 _L>J=/<C /WL>+?CRM?YB6H2=93>F"X$5OCP6BP6*1,,AD>U.N84T#@+
M=+43 1CCPYB[7&S5O5G'PGV64ZV02"C<2Z-/2LWF.U7?T$13OEDSG*YPKB1U
M*Z(;T"S-/P14V7OMT:2".N^F#V)8!&I@ENT<G40FE%$!6 >2BLP288%VMJSG
MI7BF;K: X:3Z!FU.X7</](+>QE.I>B'K;V1*;[!=KVD9JBF'_>**ZM=8\O)%
MT "CJD O+\3JG@0:6*"IZ,^349XK"Y[.%2IFYY$ZSV0*=#U'['VC#S:<SD\1
MR$ ]FP(X7"4^>$[437\W9NHE;^5D_EL@D7F?R+3C'PJ+UOXW4@%O=!R@B,,R
M](JJ6?^:,._N>_]&CWU):WKNIO7BG8BN.Y]Z]6U?_BM"O-A^.LW(?2G+UZ5(
MJXB@^K^XB+WO^90;^!9VSEXK/3PQ\)>\2&AKR0I]1^;4&KS[: [;+'/>E:-,
MO1RO*5]L;/Y.:7CC1_:7[K$94@O=7,_*G]9'M^;]NS5MWG+?W5]SLGUZGWR<
M\^B.K6X2<M7\H[K 'M[U:LO/+>\?EQWR4#^W_ELW]$N:;JW'_!;GS8.%5/8J
M23G5SR;#O>_?PVF:Y:<M$:LCXJ/"552?\?R?%CE;IKS:^NOSQ:V3G[;ZOMNH
MHW=V65X*$U,&&Q\NS3]1C[\@<#TF^2O8&&_*I=GE?QDSBGJ^]<<RZJH9>LLG
MYEKHYTSABK/DAKO^F_&GM-<^*+"-%+_QC[/O-?S+OG FRR65@YE*"CV:A(\[
M"GV:A&DDR"9)WY"B(&INFCSI@7%"JB)U#A7Y7@*^B"M:'%*L69)8O'00N]E'
M_4=E!&<7KXHL9O<*G:CS&F>7K)P(CADI<)1LMEE:DCAH* HIS @IC;/$W*@E
M.9VERQ))CV$LM[-T"U6B[RXI3I242B1EG1*S1*.T2;$U7RQ_85@[7'#8!K/A
MEFSL+&N--)K=*]E%+6_GEN_I70P%E7=(RKLZRP.I+K:6XEKW,A&K;-U@V?'$
MBJ2>\E.=%6<&*\Z-5UR@5I917;3F5$X9+$B(K#S96=GJ7B3A6BWKQ-;)MV8H
M*TN:?/HBJ4.!QKMA2<QP</>=PL:9Y;<DVQ9/HB]8"3$"Q $NSU$6N4]6J6=7
MOOE8?HQ::AE27=5;^8-;N'-24Y8AL_IG?)O:WE0<8BR5P8E9\[9.,N&N@CDR
M8$5OX9Y)BIXR+$T$_:>:&C2)VG,*U/8(H[;0K+E0I\PY2I;W0,2Q6%=D5^;L
M'%HTSVX;5[9NRPN4I13IR\SORR6IKPJ[Q566-1@7KZYL,KH<61TGJ?\Z6+W@
M87RZ8-O)S'QXN/3UVGD#QGIH2)Y%P?842]/A4F?K1LRZ T,'\\:-26])PXKF
M_.*@K5L2R%]KR5Q%X>MEV/'9C?LIX+^?%UGI03_"<]?2])YN<KZARF-E.Z?E
M,"R;MV])E.Y1&4G7Y=5Y:,=P&Q\H$2JJ1US)C3VU964.X\XFAFR=#=.]"=6<
MRGW8T?+PY%(WI&'?U;H)I8LE$;-MZO8M$5BT"5FOC*H/U;$ "P"3^H89+4\"
MC#])JK6R*N>%ZH6];EO859 "0 /IN(><EH!#>03JH(:-!.#C[90!"'*-0+QD
M4)4(4N.(J1P<C]#)M@2GRK4MY4F;C^TT5>WD]%&,E+")>EJ^BL+<3A$499HK
MP-Q:Y+8(\A--OVJPTTRV.LL5:LRRZ]DNLKY$]U!!AG+P9GBB*2?IF<+&2[94
M']>*4NPT(YF/39!Y1Z&K)!@E@O3480EJ<+^;\0(YY*1HO\U:OF _-UKD:$X$
MC)="YE*PE8CXTR-_>8[Y$0Z:]9\L_QD#3%7HB1)(3PCURSW.G%CY0(Z;"?,/
M2\W"2"B7 S%DNWN*UUX-2 ZLI3C(VTT!W35JT$(>6/F-Z:S<?^TV; & K7A*
ML12*P9&UNZ&:EP$>\J39G^'5=F!6VCX? K2242R5L[Y>!,4EIF$R:!8O.D48
MGC>2.P-&/(3F-@ M0VW,(K3"E9 G2>UN$=TI6&RF *W61G<< 8.L#IJJ& N$
M\YF;&8M$#FR<>?UEPB5\ XM NF1)#@!MC0K<GX4G"/XRY10?5@*F0M29 SGP
M0(\Q;",^U52T.OPB$)>#ITFA(-QZ^9&DK R(U8?9JM$8F0;RXD6W^&^Q4H$L
M54#: 3>6>A,0#EHI($_#Y2K"QHEW*%+//LD4\1-"=G),A[/-%C"]N]F1-;$P
M)ZMM?4'E-9I12)3X5M<1KRNU8[6S\W%4GX<Y1*SO45% !9RGI/=9@ZP9R#4U
M;+<:S5-&APG!$P2QA.^A2@"_"W13A<=^$H2/"._GH2B'D;4=^Z^/_EL EC&1
M*AD]7P%P95BX%$A%V(EBZC05-8:DAO-HF^7@47X60DQSEMDV7]5U+=/5)I%J
M?;LC=68FQ@L0$LI_#A0,09B4 KH9FRNYO^.I56]GCBDA4]%6\_W8D32M,P*J
M[BB6J?G3Y$M1F-#RYO%-S3#2<]TBP9+EN\T[1'9F<FHB ;H&:H<38,(1*'8W
M4K=GY6?\C < %2O<C0V*Q01P=(;%I)RVXCD6P*E]*3K;+++3Y4"Y*@H-QWB-
M4:TO&W A&*; [B]ALGDZCPO03#4P1XHA/-T3!>CK?>ZLN\B %$%$^&/QXGF%
M=B=:HGJW0SH*-(<#;KL-QKJ@L8844 YW]C%3A$ZOTW0Y' 9;IKL L/ F'<P)
M+88(=R+;SZ?CVN4Z:?68RQ>?Y_V8()HTQ^VFD+[LL]Q9-^28_[3_>2_DF#Z'
M8:G2VEW,_-6N$RZCN!I@5 ZD.5ICDJ= F2([=$(+V4X! 5."7!Y#1BT7^R;@
M_N'DR7P2NL;S[@Y8:Q$+LF48(5B^XS'W=Q=_FQ>RGP.R<G3RA."=&HJA%+.]
MBZ!E;5\ZJT62RFD5@T=>H)K)[,N&E# 510=?0Q<2JUY'SL41(]6?.PBJ1OE*
MSF;!Z;/ME$5*^)""6QZ.K"'I7X]B'!&T[PG<NQ%:ZZ_-&+%Y.1,-"^ OCPM<
M2VIG]9R8Z$.=3E\-%P)K\+,^JMG[7P)...5H:7^U,KS(,HB0 B<AI_-RV*H+
MG*-&&;PM7A_]CZJU4G"*,T$]5;CX('[&A(GQ>>  .]+_OD8G4 DDJ%"F4"N!
M1[.4>O?F,=8IO!U?,JP4?MHJ1*"BZ,MTI4KC& Z%+P5.*&&:=/[U#%WK[91H
M(=3$ 5_T>Q43YZH5Z"+1E,1%YZQM*=%_5! !;G8#5RF5"]]0/2#KQ\5\P-3?
M3L:5DQBN.L.T!1-DR.;;2)0(:#VK97HL;%A.*Y:B=21D'0%YJ.;?\D=S9,@R
MUX4+%$KW-2:K5(BQ3!<W0V[R04\I)>V[KK@$X;^N"A= ZAG@8T.,&0OZ?MFQ
MJ9#NR0/Y:DHE/HR9M3#]KZ 1]Q):$6DE& O1*J.I(0H#5'YORG8F0YU;O*:_
M6NBT5)/)\*FET*<RERKAW?)%]2)M0^'!.<JEXW-U]0GM"I\'.P3:.9;19BK7
M,-[,,-%RHI\]YC)HF5@:TCPXL,"EDIT0!H">2LA9#;,F*!BQ8@"@67 0P6G8
M20I_4L'3]V!,$MUT )XF@]=:G3HK1*)5KDG'P"G]T%@R:1"L4]%SO5B&3!PU
MT\%G^JFH.&\XX#GJ38!>__MK'/ER$=099)< ).G*[?L3C*4\< 4./95#'H"I
M)4\WY*W6FHA#^0!$R+W_[K$WJJ<>DT$L ?QR[\S.T6<N^LRD2X=?_DI966IG
M*(7F",!5'+Y4Q+D605W# >M>3=E8Y*W9 2&W7SQQ4L,MZ7O^W@$'$78_'L_\
M9P+-(_8X*R$O8II7')4!70-B06?E[B1QOFN+1XR.]>8YX%&F)4?HZ^EBE@/8
M%I-HIP@J3X^J'CDC<'5-)!<^9CS-()'UHW>3-S*.S,3'ZRR\.%[*TM%8%3"+
MZ+]1B8IG(]:J\1 .I(-#N028>_Y/#9Z2JX1UKQ0G'J!YR.D[E^>==M'>V<J4
M6E)W53F$JE^GQYGT_=L"U\!IP.+&0U/GRJ,F]]GDJ &5"VH03ITO?X358/=O
M!TEEX!]5_?,1%*0\TW43:5+MO:5FL@1!RU[8.^[[LZQP<A+Q[?C[LG#DYB_-
M$S\"W9&4DC*CVG::44+3D<%_/ZQO?T)K&$L>0M;;F)D26M'J9<6")=]:MZT5
MVSP<]/8_IAUU?Z8B@?G@(Q@OASX@[CVTHW]=5D>I*3I]>_-5D*LQML[LA/'G
M33O>HF&DD-![ZBU&P@7M#J*S_:I1FQ?T"Q5.=YA0!8\X+T-VAB])%-9<%(R(
M97;FP-^82'=5%Z=8X'Z^EM6E?G&\#+'&PO8*4219BW\(FE.'X+QU",/92IYI
MS=-%;/T4E8PY&6[[+[-[#G[-%P:VSS!['G"[TP6QQ#$,<([ET:S/S3&5?HD7
M+9V^"!R![2P(NW_@5Z;"V7-DMLN>VGII5&. Y2Y>'-J0IW62'+^FJK.TY">\
M&\\UGS-]$=1V5JMZB"T@:ZSE5FL9SIL5\]DI?E%JM+PVQJ(VK9A )'+PJC[R
M7'"^6 GF=MAZJ"NMGL /;@,M>ICDW'#7B):.,"5<5NSR?'R< -;Q@E7]V(=N
MZ/H,XP4OT45*X(04>Z+;,,V"R8EPGOATERWU]E _REL!7@*H]CXQ]/S\$%;^
MM*DE&7A.44Y\=4EH6K[>FI+6-M'_]]KN2D]/[NP\<+ [??__\]J>D*=O:3M[
MKM5#CV^CEVOAD!]/2TR@6?+-34O,S0)8YOD>#_)SM5>GX?:$CF>^J9^FQ,P[
MWU/?W\HP/U7/GJ_CE6_.S\_+C\'^MG";O*H?BU33R]R%W$560U5)VF=9Y9+J
MEI(D3U-DB-FWP(CB(9[/&PVNWF5)%R#M<JN=B#Z?(WTLNB65Q.?[B[B[^8$7
MT%SM68.CP1)* .MS:*3EI4MBKO_N;]^83N7SIQCX)>)'^*TW=>9$NB?&EO"5
M,[1_RDP>PX6%WJVOW-4*^R*M (OUDR,3P""-FC*ZB,.<B=EM"3%]\7#FIBIC
MU".+ES@Z (;[\?5BPP+Y08LI896*Q_67^2^N;M_#VBQ[- ^XF$\<4U]\)#6F
MUDSIU)GAE:7CK?5JTB,\KG6UGPV/6J!Y53HX5*>F3O'B_RUM]K<5U;H;!4*X
M :ZS[<H[0%*.9DC=N;MA^*R^OJ2[4[[V1J0YHW:R6=TW6(JW2B<4.GYY2@5K
MC;?*7U>[TPY<G5\$\K6\W8DHFK[V# L+^Q!9+*5Q@TL!FM$I$EO:MG&+8+]N
M)6#2ECU"HAX;.&)*S(MVA5F) 5B0T\RUZM.U99%SC&A23B *&/6!]J;UO$LT
M;0-F,;)=V$R!/<<Y!6M*0HC:)27JAF#8$V!"\)IC@A7>&[X7^+LZ"#B!5"-D
M20'*^YY^?=?17JO$:8> ]>/M$KOO90[G7:_-,Y@&]+#T1-^8Q28Q0MX<+0T_
MXDTPTV%\##/1,]&C3)GXJ>Q?'94X&FR4R+(*TO*C-KXY4#*N;+5("QE:TU'2
MVQ[ 3.Q\5<J<]E-$V]_PZ$V1*->@!])K#1SRU]E2U7ZPA_^%$!M/%3P.T9TF
M?[/>+WZ#N(AN\RVMM.?F@<OKNQ/5P"5V5,A(C67PQU;XQ)M# F1Z+M(#FR:R
M:DKUMP7V59MYJ(7HV9)*RR[C+7$;0HR</N-Q*WR.R1Z9X=]' KOCD32:R>^O
M)D&27]][T/#4SZ)4H_"S:0_M$L>E :<;2B:/6"Y [NM6!OQX*SYH:I%\)#2^
MWK3XK]!N7J!@PXI7)8;[=0J:::WO^N3&1%VR1&,T997>IRL&]'_]#7(,TD+U
MG-X),TT]>X%,<[Z<4]2Q1Z<U6%]O7T^ %C%VEG8),.L/U/)D/45>S$F-NW(N
MOOY7<;+!TO.A;'\Y3VW<Z,XT&#-/782<T)D]TL=:BJU&T9\L/0SW.=M7K)_&
M^E'2LTJT_LK?#>C],\FO:WLNWBN:F40UX+^L00XLF-SR_>7.3;L3=Q?2'<:_
MJDJG:Z96-:1J#C+:#FN^G]=.<_ZA'KA TX6NIO[^-3EV^+?F9^JBW-__'=S!
MG$M10*9J$IT/-<39.".>RH7/?^BWG_V/'A&H%K/.4C2:!Q4>D@/&[#PA\,G8
M?Y6T(,YJ?CM]V6"_GL9*6>ST[O+KN$'_'Z= ?UYW^_3T[//:]_MS]5<4.^2%
M7+(2]R_UG+];KW'PDIWG1/'"RMT&'2%!7TQF&!G,+Y:]4Y9,VSPA3B;B# ="
MKKBT3%0FSM]C^F#PPO3:W>*H%<5F8RQ?MT<35=DW]IC_-QCL>WN& 9%9[! ]
M,>!O?J!Z8ES?ROCJX!S/CS52U[WVBRSI3OD+:YNT#:P*!7XAFS_6_<]K6R<)
MU8(62;H']SHLL,1^Y(PP"&'_09T3-/MQ8E;NH#CTIYIBWCZ";?UTD7U%>=29
M_3:F-5&L<ZP$G?Z"Y&X4@*C$OY2C)FKVW-CO=O+JS>2&V_4=,I7#@ E]]C&-
M2WX.J<!6$ 4X/@ V<OK0?"%H- E"!YHOPK?_B/=W1,LO 4F+X(!ZW4+XRS2^
MKZ.RL(M'4)P$A/X_9 'U!4?77-"GRY(5I6S^O(?#Z)IR(2ITWK6:-FY0\4]6
M@ FG:$#74-*_73N\%)598C:3]80CQUGO!8>AK0JGYGU$4<<-KNM$I 6I;F/G
MR;@+TPLA5R8Z6O;Y0.3- TN#)+=#3X@%*Q>\GFL+[.%X'V>'*_EIJB/ZKD7V
M2$P220T10%HRH;8^#Z&]G]CF]4YH;L4K@)\ R*YW%*3I-6F9KP*TCA&5R[=U
M)]C/BPHNGE41:SOF,=*(T?9>UW27* D#^C$:0UL;GJLDV)_5I..-/D8J>0F9
MY$/I[E:Z/BK27(F7ND[V8< C+7+G2*GGNUC=F$E%G</U)Z\\_SO0..LU/H#]
M?4.#Z[2N?F9N+G7FW+T%-0B!\%I@H=]G!5BI#J!I_RBP:>)W><RXP1:WE* A
M-O0A55^4A;CY;(,=+VAPFA[Y]0ED-JG85GGH/ZO(E6\U@OS-:M).2D(&,[II
M1L,DZER'TD+Z\)Q$*NK@77(T_9INIIH0M@@*&$)BEG_BU8ZJ E0;&.>PY4"X
MNVH6\F-R@ BS=I[O$!))3NS=38TSNN!9&N'Z<+"N\GFFR1/4.7W(4+,"27+L
MEQ"SWQT)3R,W?,L[<]Y[[\AU?MC1E@=/ E?<&+DZ]XJP?4[X"[I#CD!&O&2+
MN6NG+6L6+#D!U\[K6^UF]ETI\94['7(<Y.[RS_//LZ[Y\.Z%SRV3JM@5(EM#
MV\ Y6FE204-FEOZ"-XM:3?>>F/QDVV>R/DS7\U9:X$O93O9+VPN;:P\9[9WB
MO>7MW/)O=Q4Z)^0FI\8=#HLKCON^;CM<\72>7=2USF-'V*P=:_U]OMW^&TUP
M7U"6X/_-1'DNQ8U;LN!]>FONWN."6=/>J1)7GS1]D',_ZZA3V=/:^Q[*()T]
M!V)_K8MP/54QJI-][F+SAN"MXJ&M1L=L#9U?IXW5E(YIJGHO[7I\N?QB^ZC@
M?IR9V_F)"-&3YX7O)J],?U]6LRI/:HL='YP5DUY[L8^Q:LFI@5F:>\VWO%_-
MP$[]'53UM.H"--;U;O2FQ_N,FC,CXR%^FV]L=9I8.?_G:X$?Q_P=[\N!#RUO
M[NS\>N\_XDO7XE]OE^K^>#"0_^7(!U/=C/'3]S;M^'KDY+EW,0,!3\[D9YUZ
MSG\K.GGFX2V=K",?5NID[?KZ]*!.]I'K6Q[D*@+,)W7^.WIABTYZ:=Y=^X7?
MKKW]L,I#;?)JUH6<&[F^GWS?WK[@_CMG:.WY3VT?:E^%7BB\=2;FLV^2S_C"
M"]^5=S2?CQ[V>1]P*_?)C_S/7IQS8TM^__C[S/E)WT^:@CNY$[#RH.:;<FS+
MYXZ%6]Y4G_\^?.O\UY.W?KW/_?U#I7MA<F"AYF/K[Y__>]6#6YJO9W[_&GK&
M-[M+9%;=N:"9?#;YZ].MW]\_;-4DB]!?)]$D>1IE<.OOM5N3"1(9WZH]2*+4
M JU),HG8:CB8QAC>:NJ^%<LF)\<*OHP55-5B_S/;-F'EP>*-,K%]-I;#P^QZ
M_^>WM6T2Y\C%CMEB6TFA9V=V)E%H/U@XN[/0*[+0,;'0(Z0HH+/0/[+(=K)P
M>F>1;U-1R'"1IWMA:&>1O7OQ/(EX?E/Q2FJ)MZ0HNK-0P"H*S"XA0HJ61I8D
MAH@3QDM2QTO6CQ?91VI*A9$E\=S2O)#B+8,E6R>+12Q)!K<T>;@T-T22%5)T
M4+Y6O%^T<,UJ>H=(JX1>[UYV2D5_<%^2+DJN'_<YTT"__2J55KIZMZ0LLB3U
MSIQUJ6O*HC>5TSOH.SO+[N\O&VC8&!58-G]MSMGABG,A%<M.<+/LRI<L3?I+
MM<[N@>B>75*!0<6.3OK?W"3?!SYN6*"\(<-\=OD]]Y7#*#T@<%W6JXI1]ZJS
MU-7[N.7[W5/O%8M&T*0K(=M.-(A^GTC:VK"N  G>:+=RX9IU!O4BS7!5]]UJ
M<5SB]> J-$?ZYF)RMSR-^E\:T%AICZ4PLN9>+:DVM0]1=J8VGTA+/5%FU%S=
MHUF:\=]XM?:I#7XVM08108DE4L>'M9(7V]+EV!9>W6%>W19%4 : 98M69*MI
MV4ILX.7:;=SU1I_+3HW3LX4;8HLJF]?4<ZY67FFH$+OQ\[-65[.VVQI*;[_T
M<>X*GGEWN] DZ)]$+%0(67.0T*M!?CS(04G)4:+9@H:YD%:6@.* 0Y[X=JVI
MF<[+,CWM5[ICC?%"T%E:OT6$X"(D-&IU[M<TU]G<N4;IG<?2LE6V,7+,:EGU
MLOWXE_%T)TP4:!*RY!771VUK2H(L(9@AA[Y/;*^*0[EJT%/DF:> 399XA!.0
M)8^WWQ_B*%K;A'J'3OE2OFVWD(7(CC TOV:V)>Z'SGJTE<@Q4QR]EN,W[2$7
M[_!U!D"]D18+(9JJ CO@'6W$SMB<G:^.<G-4,*0$='!@FKJ!C0.&4@!3(Q=L
M 6WUSJE*;(D4H.(@* 57K<9<KFX4-6=[=]&WR.O*C.=L43>@I]=FB&1G7E%@
M#M1T"O,#@.^$6-NC+E=!S^'5;6JDN[U..,6IFQW:[/80S24A4$H1KZD[O'J%
M83EFK08]ULF8C^B.+?4?O@JWC:+1/-J\  ,S 'G['-W/I+B5&+.E%"X'[!]"
MM'E(J +P56&1<Y%0)3 FVH&^ .Z:&/Q<$C!%H/_R#G(F,BA% 6Q0:KA/[J$,
M8O]X<\?W3XE:"L#,'J1SL"D'C*.$ (N#T54=R4!G,@ !:F0+#X+D2-/5("\>
M-$U)R1509LDIGB(H7(ZM%L +"<2.0+(%J ?1%:."EI#-WF17"@W%",C, 8'4
ML+<06D)LC%- UM+&U 8D<SM"MT=L5-!J:?V7$PU3I93%)Z=:2^%D)3:5 **4
MV 7/O]9+L6 %+!3 <3R$ !IC9)"-"/G<V\!5'Y!]L]_S2LL0:+-0PSYJT/83
M;*6$+)YC3@*_=3)@H\#T^%&PI "<58!$BD%YN[R-7/[CFG6T"@D2'.8/(5%R
M^-^76(I&T;J&XQPM@FR4+3N/TWP$4)@*W&!ZQ#J)FL YHC!!SO99MW&T'50.
M*4K(2@GSPP_#(T[3<%8T3@GCF<T5T3*DL)4:[H@_.C:*^@L=\$5("T"Q$4+[
MXI U N>&]..(@:/G&5@4CGG@W=FXF[,*<,:G+1) -D)'?34E!0=%!:@#!PK_
M@7Y784L!R^@*AI443CW0$9M#3U;#P4JLX@V0K 8I*LJ9*R"FI/A+>RO>=(0*
MIN5SNMX[8/H\P%X%,(28+P#HJ@%$!JQ54F E@)- '1T%!.Q@ /!28KNF13*4
M:)P0L/F3MM$ 4PC218 F2H12E("=$"BW16 !9(T#A!*S(0!+T>G5BJ!L$J(H
M(18!K!2@J *P%P(+T_\:\3K_\CJX!8=@'(2E%-(!BR(!?14(JZ M)(0H()80
M4*[GIN*'SPG &'T#2P$8^D>3<9BV.!0OA1>-'#ED12E60;Z@L1\'/YQ ]9!2
MIYS5$8YB%APH104MO VC ")0 6]4("Y% D5 @L"T1"6O'D%B>6 @$[Q[5=<?
MT)M\J>]1N2S0$@SBH0%6]A8\U(O7']&'>JH7:5Z@.?S^-P!DJ49G'8F@\J#O
M!--4"24(H,M\PY( [6TRX.Y5,&>))B)-B>@K3]K^ +*VH^EME/2?Q_5D<*K"
M+)\#V:M02W7$\8N1GCQW7(;,!<"[5F#ZP8AU .@CI;"4>G0.TYRT35, :00[
MA0,]X*$)<WHWMZQ=^Y9BA .^<HPE ^)YR=8"8 FO3DB"H.)HE@I+%D  #TIM
MIA."ZW8XL%R @(+8:0 PCX-223#-!' 2H!21=JCT8(8:/IX'@0+*6B%@*V_G
M2V_DJQ%(!"6IX'@>=BD)FPH _AQTH1(-!W;ERA% "9578/HR8*&2LD1QQ@^_
M;B0%LN00K**LEOV=KKZ63D*P$*)$@DPA9D$"4LUC$%6B+"GPFTU97*(UO-'7
MY B-+=!G"Y$=;*NXVUK+K^VU%UF5<!!C!<U# 40+[QCTT!I?8W-)6S\9PYN,
M=)C&""+0/371;"WKS3)P/AU<ZVDXZV8/0XVF*NZ:XE=L9F"9)+HDF6HHT_TI
M@%DB6HH"DPJI3NH(<Y&.Q^B^2"LD9S55GT33-WC1<<Q;"'KWHS,-H/G+!VVL
M<7V.PS0R$E>T&G"<IXF6PN$.#U68&0E5C'BD<,!&P7")#%&KHNH<[5U^H0P!
M9B_2Y<CBPG &6P2)1I:;BXSW=W>0)9@_"= )I.(!B'%04==0C!+S_Y/\=-$L
M410%YP%.O(U_*2+T>"!%2@D$@!@8 94WF/]BRZ47XGG @!PY]03S(T%]'HB*
M7"C"@\F*V: (R1&A6G(P70D]_P7D1Z.F/ #"P24<!.6 . =D$%!H&;:0 X($
M8*9X_"X0_/P4=2" Y?@S X4J_]J%E;)>?0Z8+ "U.: N!QQ=0H'F J8 ^LZM
M)CK'%^UN8^/':[<AU1.*W4_"6]4H6P#N.P)Y4(S_V>BFAT/;[RSD2'T6R$$;
M @H>@DLNPT"M[IR_+FW'&1E2B"V#;!D@\LK)M@?3XS"Y<O!3N^[_D?'>04TM
M?]CX[CDG.0F!Y!!:#"U4$0$#(M*40R\"!@N"(#<4$00QB*A<$)/0$36 (BIZ
M@Z*HH 8$1$0-35!18^_>8"^HT>NURWW]_GXS[S_OG[NSLS,[NY^G[#SSF2>&
M;"$,[@>L<,1,->%4JD0F=.[/4L#)2NCQ+]2YB:U.0'XC2/D0B]#,(7A/CEE9
M$^#^+#\D4H!ZRC!N[ES_A2.E5Y_U6T,>#['4P%-)";4/88#![WT:"OGGLQ5X
MS+OV+21,4%-9:MQ$V?23!Q-5F 5!<5*@(W[,#3]?V5'=VTSKVN[@@228Q*.&
MGL0] 'C!IS)(N)[$,#$4\M5+E$!'A6V,/=*9,==;.#K2RO+A@0@^E2) ULLH
MF !=JNFMUP4!&@R(M.^;49:)P)CVONX_C1:"GAD !)/]6@KJ0A6V7([1Q3!"
MPUTG^CVD_/<9>Q3?T\D$ 82Q9.("@O&I3LKW^O^I0,%:_17X)"5HZZ4\^HE%
MR:GCZ4B]1U-,@+*7?VR7"LZZ!4,4ALU/J"&#EU\HZ&$$W$4@CM447=+[1.+"
M?<A%W9JG<QX]#:]D!8D7S:JAU1U=%!77_E.#7K0QRM$H%VR)+U6@J1.&?=*
M6!%]KRDE@O=YK5^_'XES9MGGO[NC*^/K55$+E)1^79RI?)ZFAC8$)58NV,F#
MYSXN_A%E7_PW;5LR]O+#E-E],XZY+-PX_;=%A]K)4_("8;*:.A:%N!R8F\['
M3<3MB^4"_L?$7S+P_OJ;%Z^VT%4]+!E@*;(OZR L/IBCHA[[&[#D8(+)PTT
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MXT&%C8M1R\+5>8TEYG0#/.$QDUB9_Z'0%W1K:D?FL&=Y >LI& 9D?FGL&&%
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MP4CP[?.UPSDAXAV!P+@<E6!KCFRC(LRJ['H,#$85NY74RP466;^9.A"+_S0
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MEV\+!#^]2ANQI.2;C&&KOR;<(X6N)X^C];NU=OUZ/7%@WS)Z"4QQ@GJR0]$
MJJ\A%R21$><A(QTZBD]?OPILAH!3.XH+L!O:="@J8\D1KR[70][07 W,B#$3
MD7$Z,S%3<MB)8)O(@C?/7G*[+;#M&FC2H#0-S9X/'?G0H!;W.8 <B=<RT##3
MA."<%+NZ>4LFU!H? ]?.P*B8N7NT97T":"&A4A1$"GA0_Q*DR7NF[9:9*\$W
M)>RCP*5C)]\/:>H$1](UX/KXV0?$#I9*]^^V8CWAT[ ?7A'-""&_K"-'2 E[
MH'".OI1G1R*&XF?Y/_HGHJY4\+#M[0<BG0K.@?BI&C 20YL$9JPP\]#Z'H%K
M)M!77&TT![]\L^+A&[:50B=<5AW59" <M; $;9,UP9]4'[:(_G5BP.5SX9IL
MQ/<#G)]]V$X-#44K+92;%^48,7F?'JB@B26<31R^@MW5WAIO(Q_8 ]\;$K;,
M_Q98*&$%"YN60>=JW+3>?G$B9%5*E*U C#1,-);6<Y!6Z[_%6H[H*(@MVZ_9
M:>"I@GAM/FL6^653+,U2#!W(<2_R0/?[D/WJ^[%JG08%,54&(@E*/:_O_ L@
M6?6ZTGX3H:R8U:.EF/@5M2IC]V[K-.&J! WE?ADU? A/(+32Y)?KU!0_WJ/,
M1*QWD8'1B84I8FX:B7%-TL3$PJ<3SQ;%T&8\C1YQ>W%B6?37 ^6&+VBO)K]:
MUO5B^_9_HU_FOC((2+,K3TVKIQX^'UL?I+^P._C !;>G38M#2K?N'#J_N'M2
M1<!7@R_1>8OUE]4MX@1NY4[9.B-X5N_PVD-K7QG-V.JFO:1^^]8;+U_>>+K=
M\/EP=''3N^#EKU]$WVA]'?TM_#+152 'R^V-G'99N%7&&WPTNG"+X_^WUE#U
MWA<14V<:YWRXN_0<S=I1U7 HK/O@-MOJPG95Z*(T5%86>._MQ^2E(6Y)I9\#
MTON'+PU6Y.GO/;1]^):"MWA!=>R!%R_,&O/L+U?73)Y_D1>;M;DMNIS9N:_$
M=N_(F"UMQDR=)S<6Y"(E\R>.'FZE1;TNJY+9;AH5W0ET.]:H_,ML1\M+/&*1
MZVJMQBG+2M]=.E^BCOF_8=L);<^.EU>;YNRJ*]K9_OIF:]RI0AVOKO$M[1GW
MSVSR.O'N86_>]7>G[U%*3,Q<MZ*;O4^.=Q_[Y2>(N3]GT;/S$7%G-\\Z]?GM
M@_DOWODO.;'G_).!73/_F/CY[N^9=ULVK+S_Z_>AJ@+R*&<[?_[<>I5<-*N,
M_=^'8-Y:JEFY4*JURA:7,&?3$HO9D2&))88)Y18EC*R1Q#*SK.=!19QWVQ,K
M;/>4/W;Z,;:,5C'E#"VYROQR2/*F>Q6<Y,V>[T:2M\R>H%EGNC%#4ZIWGHS:
MLN)5U/.)/1M+7!MIQ-27MQ\Y>83SJRT\0N1;M-IV"(KM/[ZUD,8E]*SUJR_H
MM4026DO$,=N.93]&V(4BV=)MSTX*L976!6/EYH$-PI&:YP7\:J.O^GY[&Y<>
M(J5.ASF)$NHDH0#=6+M# AM+[7;.I0UW/@^@3P[??D?+VCHQQ,13IAS(3KW3
MI,4U5'GNJ#W5^['T8*E=8A^5*Q3X^7<\M5TBNW N->7XY6OU*27$Z-XAAY[&
M/G&4-OFXI//8C.KFY3KUOJ5-IUSA%GNF0\].-,+B11]3ZC1P#_?$=NY"#Q8F
MODO)L5,MI*]Z^#P0]>+T*<-+;_!\.R-)M=3\Q_H./]JIA@FA7X).5<].@JE_
MM0@Y7C]&[B8>[ JFV+@V2O#-@VT2VLRW*D [WWB5M'KR%OB>B,T40]'4D=[,
MJZVS-JZ^1BM=MTO79EP5PRY^&A5@E=8AD)Z,?*\:,8Y<%R5E;.- J)4J3PPS
MM&L0ANDG_"01_5.*L?X+FY^"/M:1<<D7UIV"L=+=NSG5PV9>6\E!I_@FJ1/#
M+L6CC-$\CU]JG-#;=]@J9'PLT#Z[6RPU-*C*WIP<%E KU7H529;K'SKN=4YK
M<LC.8);-3V4V81EB(66I76L"7U]_!K^P&HIYQ\S#BF=%)CG*92?-0[;*!URJ
M_Y*74-[W7%]HV"039YCI3!1+J%3CCOGY=-\"UW-SK>*/^C%"_U3ZQR8N_R8Q
M?_)*V'?2ID-6Z9PB1A]QBZAN!&7Z G*%8]J0<;P0B?\F@3LR?/&?!#+M62 L
ML$,P+>>R%70!G'\OD%+#[_%;-Y=FX;[;O(%?:K)5/N4MHZ2S78X8B/I,V?)%
M+#=AN;,=T%\Y(J''OSQM62Z?VROHHS=IK%U?\AA91!UC4^G0$KL5&^-[F:>3
MCB.LE$0*Z2!%?ZJ0[3L@XB7H1U\W2YE5'Z8E\ &]BB>=F-0';=8-,,4A;E;8
M&#RN 5BII@A3#VBS51*V+>^8H3MP[!!)T,7J,M,"'DM+V#"!O=LJ=2B0%SN_
MZL,\9)@^*=;3=_=EDW*Q^T_E;QX%UF;/RW1&YBP-I?DB#Y0ET[];T/_21[!V
M :9%^B/+=M7IZLN.]O*5M%@9T \52)U%XC1S7TC=*I=BM$1I0@B*-6C"_3*G
M:YD!RX^J=5-[I_0CLU0(%KX#U4GIHW"_TJC1!@B%D.J1-"[=A,!XUJ"R1(&B
MYX2EC#2YJ;G[-AHM$$/'Y3CSJUC73=BV9;P1B4KKP_=^T35=H$PT%DKM5XFF
MFI)*G89^\M,9,=0F^W2TW27L>Q7TD""(^KI7>(;\EHDDJ&RH)_4>"[5<[[03
MQVKJ+2::-'V$\!IKLI DI#P7GQ" !J5!]"=1+/_61W&:XX?N)4=3O.5F7BJQ
MA90/?4;[$$\90BU4+J2\5%9]O"!%Q42(SP(Y8JGRXY8.#3J$W6(M:6U=ZO//
MT'-7X20]Q77Z;#44E,N+FY1W7:S56&:G'])JF6Y;:P]WT2S2S+JWFWL*;GR0
MD476UU&N-=]^>KA<UT?!P<-#I3RR$:D6*MUG?Y3L<+BI.SW0[S]VD7@F9K'A
MTS\H?94:9W'ZZ+>WV1N?D2WR<;5(V_V/O\F?!Q:XBBSB*AJ-[FE=E7Q/!+7Y
M(WI<$U4E?;1X1X)\&O>SJOC3<UAK"5IS&!/9R#1G]>IL33!Z,%%B'6!Q.HLX
M:%&L,=+-G(%]>8R9?GJ&&X1/H6N9);&=!.5:^IT[C]20U%) H=^X0ECH15,4
M-PYG_[X\FY /6V>[[#%8=UY;1X"=5[DC!EHY1O9I)/>K"A2DR0\VBI71OP0+
M%VX5AM%+-<J)%[@6+1))(*47$S)8<>.)2.S(0#RZ7\ 4R1&F(I#AD+KE^&%E
MJJ/'/JJ^8<G<Q63"ZH\W4FSR[X;,N>?B+MVDQQ4@A(Q$UX>AH"8XNB!0 JUI
M$AH?'.U=A6 ?=RH=UI#2V>YB;L+7)KR[(,._>/$&-@\UMI19NWQ2L6:-_$7$
MVTY(/#0 V6'81P4+RU]6;K.;?LEWWK]*7*M[[$XAK_\/6R'CPT<R]4FC>)+J
M1Y.\L1$S%]C([XR7F?]^33;NS+_=Q C,2$+9!\$1-Q,[=CW[T>SZM=4YO.D_
MQ3Q:\M>GP5(P:+> AW 5)H?\2>G*S\JD)VWD(G>8[5/.R[.:.6@J,$GT<=CU
MT%)%ADP\QA?<]T<ZS@^X^G\X3SX#SPL)/S2ACU+V(Y&V9F&?4CMQ=42(G+FS
M7+S6D92RBL6H/<2Q$$'%+)/KA.'+^69A:O%+B<>ACKM%J#T_%\6T>POYOH-V
MPB-7+>!SK_*/Q@(U7+@\D<ERO\RRUY1,.*1 ],N%Y!O^8/"X=_$.1L$(^EHL
MB271C"U[QINF_7$W[6008WY0S=HE0N@WN-'HW#JQA?Y8"<O0#ZW(\&[]I3CJ
MYWV-9:Y>]1;]5_)T*/%X9DR/??%]FGG,N$[<FATL<7?Y!W*MLEA=A'4P_O%T
M5^KXCYA_.&&\PDH?/L]9%WF$(2F61RB[..O6<N[LO:U#:'$GB_/HJ4F5MG9B
MG:79I(<GB*$76.CEW"$96^71!>)X4I'_6HU$N>D6),/_]C/E!+8F<,E7 G.:
MO^I19W*A$&<I_.WX-BQWSL//J2XO*/IR+4.UW]DANKFO22E)/?N4PU1H>ZI=
M/%(63I3(4_(LX!HYW7SKJLV-6I'R#8<5L,L UR:R@I<M3/RLZU!'R7H")^FY
M$=%HI<':/X08?]D*YV;?[P&X,I7F+2XH!-CHD,GL.T4I:I OAM(GE -E\+FE
MQS8\O3ZX+'1^ND*R<K4&8VFHR7=R(HTH.B(=KB"%*T9R"0I(I5+D: Z![7J&
MZXI#O31&,T0PC:3J\O6X(*90#HTXY7]IH,MTJO$3?6T!W4N3.ED&UGRD$@0V
MF+.D95F8ME"+9> 72N".!,@&V$@S0N.YNT3-^:3<F*JATE58JAR.4N!T78RJ
M8MZ7\F4:F.!B9B-TCE6"!&0">BCPTOULCAQ9+<00OEY0.1;4C4]J6M"]#UV6
M,JTC&,GA+T]04W$5<T/PEAQA3-, 6/@$@6(6Q2"AZU^H'J+GR,"2L8A,5<EL
M&>ZG"4U?2--3VI?NUPI1IJY4PH2]V)>DT% >%LB'Q=$T2P)9R:.L'%JXN2[%
MB)RO#7121=$4E)(G0NQ>X702B=(LC-"E:/UVHDIHB&*8' LDL""-EI.R]H>!
M7800% H0;@ RW\6Q1!2>P!,DJ('A?/A%BE&%6&#(-/NEM%#%[S65$3+<7F,T
ME>>2HX(N_M5GUD!=%'9<0PR$C*F$TZJO5KEI]9<F'INVZ^*3%=!$2(D^I#]5
MQ0Q50JX*4?'QR7*(W6!OR"6O5V.&JME>U-*XH(4U>]%?US!C&=R^@S5%:9DE
M1U0JS*N.8B'&EWZ 7##YL +MD2,WQ,@A@H)CF .!1\F\3QQB>JN80U/TP%,\
MB'3P)9P3U-!L!E;,;ABT=9@L,LDFD0]L"D^L4SXSJG/5<@\Y^E:.R#0H5PXG
MJSBI!,(%2)<2;9V'VZOJ:Q"*B0*: ;OL/-*MFF*B6>2HT1&(IOV(I?D0L_*%
MB(RD[@NF?J$C>I!R_CKB54SEIM ">0Z9B["46U"^,&Y?.SZ53[HY8Q/^@/UA
M;VV#:*V*H&S+0_[54/?7[>;R(PN5&%<([54T/X#(A^!S>N'N.W0;C4X>B:0)
ML/#BF"FI6E.!G9<03M6@XAG44'LL5!5L)S()(YP'!,@FV3ZN$)&K Z:*8>IB
M&M$,S2I9:3*9Y;!3\5VK,OI!-TM<),][_T$W5OAGX>&#&R\<?-%'3S[@L^G>
M04G8(==599W0K"N1NMGVD$W-H=U<BYY59F<M#E_X@,93#U<N/M1RSV+'ML/'
M7ALK[%N.A[74]AT^T</[%G6X\T++Z=<M9RLMNNU;J8\/*Y>W#E>VGE_L>KE?
M=_0[=< >W]/<>CWLR,WE1R8E3<H&$_B]GB/<1MV=C4<>[-1^5#EIE8IZ4'+T
MI1:^2GWD2MA1D>:(9N>DMY['/G"//0P[>A >>\\]>C?LV(ZKQ[[^>6R[KN*)
MI^)NSY&)[T>W.Q\<WWFLZ+#V;?LVO3EM!AM-\A5XGL"]I*AMTL8V[OTVWL4V
M\Q]M)G'NZQ5M9BWMMO?;ILYIM\IH=S!NM_8ZSF4<M]C5/GU7&W_7<5=&NTU+
M^^R+QWU/M7M<;/?9V';D@]:?,FF'S*Q!7N#0;KNTV2=BX[2.OHX9W7BIM#/Z
M5*=]N\YP3>=2O)-MU5G"[XJ\KU?=8YO$[I+4="WZT25XT[GT?I>CM"OA1T?F
MU,Z<N,[%&2>.B5/R)EHZ\XT[DS*ZDORZER[KKF"<&.['J^+LJE_3+C1W9<WI
MS-[54;9QVO<!O"[N9,;%DU6/3^R\:+<Q_V3MCQ,U&[O7>G5+V"</&7<?R>]J
MF7JJ8./)I+@3W1M/=!GW=.PZ)7K3V;3KY"FOGAD'3V[*/S'8<NKK-=3X)GK%
M^+3J/NJM1&]./7V]Y?35C-,WWZ#>:O3OC--/\D_?B#MS)__TS3EG[K><>7LJ
MZO:N,ZHYIQ]=1/^9<_JC\>FW^6?N9YS1[#I]]_[9._EGQ^^??OH&_95_VE-\
M>";$/!7HPU.H,>7TOW&G=1U.:^+._(@[PQX]K:O=9Q+?9S#>9]QP6C^\CQ7?
M?X71/[GJS,2_/Y36WGWO,_K>OSG#;>V?4M6O5S#@7-#WVJO?ZT&?Y8,!(G-@
MNLF@J_<9U\Q!B_%^_]%^SL^!.9G]0=I#7T[UNV3VDZ.#[/C!1>.#+C][;UT<
MB*@:G%0UL.AG_V+OH:CQH90'_6^F#KF,]@E^#J6;#/O%GTLL.&?C/3P[<WA%
M^-",WF'/AH$'+>?6.YS;,#J\[D'_G^$C[R^BD5RSOY:W;<L\O[WJ_([6\[M&
MS^\>/_^7]H5&APO[PB_LS[S07'7A4.N%EM$+1\8O'-.^V.9P\7CXQ<[,BR>J
M+IYLO7AJ].+I\8MGM4?['$8'PD>',D>'JT;/MXY>'!V]-#YZ1?O258=+U\,O
MW<R<N'2[ZM+=UDOW1R\]'+_TM_;E,8?+3\(O/\N\_*+J\JO6RV]&+[\=O_Q>
M^\H'ARO_A%_Y-_/*EZHKWUJO_!B]\FO\RG_:*NBH0B-4E!4J?).*?D3%N*32
M>:MBZ5S5=;RJ%W'58,55HTU7)QVY:GSIJNG;J^8ZURP<KUE%7+-9<6WRIFM3
MCER;NL2R0$DUR;ET7GG-/ )!K>7&JGHK&5J49\:O!1RAPY2/NH["V3QPO7VL
MVD0$S_B;9JM_XS0TLK-8J4*M%3#0$&/(@=;TZ\:S("8"N!C09( F!,)+:]ZW
MH8@:(+);_,<0%0'7*<;-T7#^2V:R*0@I-\F2 7R"  U:%BDJ@(EN';_UOR2D
MQY,E' %LNG%3;P6D*X&V\!8N!!LO_=[%.^,-=_,U9R '4'FS'=X;R_;.V5W4
MUHCK"0%*NJ:K@(X06![FGNIA9*F MN#^C'5FS8X(I@9:"F!"X&P28  ^B8(4
M$GSSG[23?9>Z M*40(M$'(2KV<*'#"7P76'F*88>HGNV; 27 T+%:4O\7X^1
M2;6L;0_O=^L89_+^+OCU?WAXSZ@FVNZ-=^[))),$ D-HH2=(5S @O4[HJ&C
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MZ6+SS6/5<+H(Z&'P>K)5(J,NJ@!>H:B]&I@+;SJ2JS!,WQ_J'-UVV$4%FXB
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MEM_3G1Z"!TZ(C^\0_#-8'CZL'HJZ*0J)HY\OY4^%RV^&0!-WG%#F8U;<DQ^
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MI:Q PK+2I*3,Z0A';M-WB!4C8S4/H&GFODJ99PX_LEP(.S_B210T7:[>[_=
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M*0;O'P!_A?><(31&#86)] HQ =6+F8@!+Q6\9HAF#@$_'#76K+8FLNW5((P
M]9H$:XTP>ARP4"&_/L>-:"BH1H\C0]H'T?%J$"F>:S(31.*,;W'PEGZ8I=$O
MEB$]!RR,%10_.;1@$?RNN_(#%.!& B/%XN-[*5?C8#<%-,*=+1"%M#9#;D[
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MX,^-:%IM&*+VD?#].>)BC1JJXU%U9;"_"JJ7(8;B1@N-;2X?@$R32!%HU7J
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M&5ZL1[M_6(9I@?_,8,&?\.5WP)O+5,:(UN:+>>')<(ZE ?O-&J4;L%!MVJS
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M3LB\=T2\+85&N%KT53$D-8<7:G(D>FF:%M@N *?O;!MWO(PP <F3(1Z N)*
M9M#G<DK&H2Q/2X!2 4#='.@T"+HHD"LRFE '3JT9^_/UG'J>"V8 RTP!E3CT
M4-).Z"!+H]5F0.JAG&._*.]A/[#:!10H$&<R5J+-]/JELH,.$@,0:80_S5X1
M 2 XOO*@.RF2([1-R&P9+5<)*()I-HIRD0&($:/),<D, OVL@7:V 2>-8]0$
M%393/8$)WVD3N.)@K@F)ZX#.U9$>.O"A=$*A 9A\& 8:D9H&!/"C8N1FEL+6
M0P%&89"QLLY9LY<!3.#)17C@"%BGW>LMU@6[T^QU<QR,L?5Q4)0.W%XMB'F$
ML,VP#P!&=:J7QAW('U2O,U$\4I&#.F2KB;H8]J\$*#[/-(__@')>HV$**(V$
MFJW0,#TD^#PZC>"G'H7^6[*'DH)XR46GQ-M/D0<7RX,VW8=F:BD+M2C(1Q=G
M4_/F4J?;4+Q-D N/0G>GI1FMRXV(%J!HC2049C,>.U2I/51A/%QA=HB4*T7&
M0W.43H9=T$]/6LZ2PT6S$$^,DF[6^NCA!?W42#TD5:*/>6,_>(XO,Y*I2YQ:
M'B$B@U<!YK<0IR3CQRM)ZMG&@)7&B BY1;$9]I93IE[WRAT!#C_E48[+\RH,
ME!PM$GR&)M'".1BEW4PEQ-0I&VFY^M';^BE%[4=/F6%/Q<HJXXEH/;U4'E0[
MG9:MGY.IJUDS/9/:9)VK*/ T+RP5(V/$U'PLIM34T;CX</CT.9NS4U8.4D+D
MR&(MDDU0$P>I$8;C_QY7_>>_LPI#<[]1,[5AB5J:[ R]JQ%FSV>4Z1":9$ZV
MCK]\\\I]AIBD 2B6H)Y-04(4WC%DYV&"ZO\/=?J)<Y(&56,7X@D@[<9S:Z##
M?7?/KEU/%)C/G;@."X_Y.6)43]/*QY_@P#Z*MP[>/I_VX)\+GKY.] ;XSG/K
M5ZJ#_:84@6_RPD7TD5 CX)EJX.QGQ5VLY;9B1_>R_MO79=OEL:S.8HD?'<^G
M92L-SF?Y?XI=CN#=#_7=[$FJ1F/W(Z#;UWL=9[1%F1YN_L H$[ "'+M&Y].L
MNPV'\&Z9$8Z#G,>WLM:V]7PP7<R1>3S6=TW*X#CE=SG?Z9FV_]+T&Y<$3R[U
M$Y>RPK%'WR[-9G(=(?Z<_9?7 3WS$[BSF%?>X>C4MY<7YU]96G_EF_92@>.5
MY?LM%8.,0B//QW!!DD^.=: O\*:5R^$T\.+(88LE+E<KM?!LR<4PHCDJG)4,
M2&9SZ<N\''J)',O0\4%%4)YX*CV:NN\8ZB.'A(;5+7ZT9!U,*$<LRG2C:]^B
MZ=I*E[/Z]]SB*B,2*N]^=1@ZU@?=M;>,,H4F,Z_=(ZEKSEY9]>/&$9QRWY_E
MVD>95=H]8H+LO"Q69M#"])DF8W=%_:WW8E9ED 53<7&=:>.F>I?+<>RKZ?C'
M'_26<,MP_99#9@H+OZU*T!&#H)4.22&@D:\S_SU"EVN!D0[ AXP,UUUL[89=
MC%&56K=0  P4C[<$%KFDT9RT!:[Z,>M#:.X'6J[):&$ L+Z!QL27_ZVG"PR_
MW\>[O; ]0PJ/8_4LF4[M_81U_SJKCMSW-)_]>O_]*P:/G"<"$0F>["F-45Q7
M&Y&!\+L9G3=!$2W6".>-8-1V,3H<Q:\:OB77PQ<\:#E&.,I(*Q53;U.Z5BF0
M<).F0$&=B><%MT/OUJ/O9B-3$H^$F9H/W:-E86@,AAPW4:R7=Z[DH"LDU!V?
MRTKE2 1NDZN#TXT[-8K'X[&&V[+U20'@9@R5&N%MW(>))'6=#VVQ/G.9%@E3
M'&6Z,>J G;A?LKTVI@ZCS"E&;^32EK[0\.5V@I6S1RM$_Y:/>E+>_>K1]%C%
MY$KW>]_6R76A]UZ?!KEB#RN#5[+N]JKK<*S>J53'?[%Z]HZ=<-$LZH[8/]_4
MCLXF[@C]J 4F^.)=)%)N4:;HV3:+6J"@O!^%BOP]_JQ'-INI(__-.-NHJE63
MO8ZNUME&6)N&9YDS_MR4'0'LKI"C0;X/(Y16_VVAA!*_%VJ+P^1!<7(RWPP3
M<JLR,\5V*V-H!M(<2(LG'_0/I<-O1!( F26Y?G5:[TF-/FGR2:F"<;L*66C2
MI.CA#!_:3'EZA'BE'49*"H[[-#_K? (_?VL?ICAW"HB\/U1_R9LV<?6+2Z;[
M503UX\9?5@*\Y>)YLS;#1AM99P+3[OL2ANU#BT<+?@&T619B@J>\L-5@P1%B
M\&%6OD0'G>NC,''H;O2&4R0H--QY^@EFFOT9VE'YN\&]H:@3O$BV!%HU%U1T
MTAWD=I@1Q#WV\; 1Q%G?1G^^>O_D\7WMH+L>GMZTTM( <1BMIXLAPKRK A\;
M"V14F"FQ;@4^9IC\-)-R,<#I,DR/1?\.V>LZ#6)A4%)G\>DL1JF19J^8.[-/
MG!]W_+\9M)8@-%,'?D.6/)T4) $J&D1WG8^!<C(AR%XA$-L',ES7%=#&Z*%1
MDP0'[CP:$_CV7QO$16L;>H*NICA:F>8QY:(<->1%#NYN<X@5@Y$XM./^MJN]
M02(S^-=ESY5_[>48(9$QH7\*N.9BLI _,];TS^N[S>D!^I?MD)MYK7/'%"$Y
M-K)I%H^,32- B<ZW@D0FY5!YAO1%>R!,G\X ;IUH=N". !,:3UZW-,*WI1:-
M(]X[FBA6 &*OMG$R@^$$N&8[Q-.!W;X6?",4:@"^"2$'@T.+[Z:.FJ1$;&7@
M''!'T\PN7W 7B/ )X>_+_+7Q2;U=\>7O(WU,P+1(;S<,2AAX(@'D;O)X[6=P
M^ ALH["WO7LA[^ W@_Y%E2D9N2R..Z;_*W;92<.,YX565@:*B\WJ(HSZ\P_P
M(Z\A@9R13\8F&NV5M=1<$EC!R6&NHWD!6Q-[IC;E3]F,95?*;8_*%SKSK>>$
MT!QMMQR,6KC0"$U=/RK=G)>HEVI=:*N"C][) CDP=-$]]W_S[,QE$O+WT/5[
MDQ!:;$6%(*)BQ#)4G8,55? 3*\HKQCBK,RV7+>06JM4\R98V)TM[OKT55K&4
MS>59\5NW)--'L=S4 AOW2)YGA<]Z=8)56^[F-)[:/K)B686G<,T-M:=+6]F%
MD]QJ=E:69:F:D[0EQ+&[+(=[*^6:Q\N*V#WOU4,5PI":S-_C2BVR;P<,/[Z'
MLS"VND-F+NJV%]A63.W@!_34.P=8_@A(-LS!5EI5M*?2I@B<+^9BG<P_Y#EK
M(7(.?[A/8/R-NYK_HX1\M8M6-5= K<N]D^ *)Q58GRU<U+76:E&%9_3CBPKG
M3=2*BH'B;^XI#P],^S" V_P^41V;=GX8O"NZ=K7-7YU.MD_H&CD_SB]N>&B[
MZZX:7L60J' <#3;-7#^&^'9'%G?$AF;W;1YAR;J_#/B;O-X(F/BQ:N%;BT#:
MFM?W=D_:EWGS]/$WC_39U[<FGCFQ($0YH/WKYI^_:2U5;JDWX+Z;EG11=!.)
M[;1"73/YK?Q"2-J(/_S\MHUT=UJ,QOP0.[^JN>23KQXRXY)VU6;?R"U5XM>B
M\'&T @WRZ5YVY"7631F@=<(Z^F!$5*^0QF\I-]23,#VXALI5$DDV.8&^C6IU
MB:Z++B05*@<L=<"!U@;TD13O@/[+#&&Y]@;_36]T-]T2Z*O)W9)/:GS;\H&5
M_NV7DC-$]F_%,N>*LR]K1JBAU7!,;&FPMLJY*.!NG9UE_8EUS@Z(50V\^*V<
M/B[NQWTZ-:HW1^+J('[&9)ST?L;;,K#>BC5W3@(1B]&J)D')O3U=*L3AR<<J
MI%<F2:#'C]MXA]YPVO>U98',HYMN]5:,YGH/=]=L\T@%VFD?6G*@9"]R8(+C
M&"TF]8RC">FV'''T-F>;C-<U7/N6.R1]<Y(NRHEM+$Q&B@?Z0&3\95<M<C[]
M&S.9.6J.%=FK &*L$[^>R(/3L)<NKF7A#@L\!,+*1$K:??TTT9A@LLOREE;R
MD@K,H[U(+'H'J@H6"O>!PB0P.);"+=?%B/C1OC+K'H7R'E_4HA]1$9YOCT.,
M"AR44-PZ.8Q1(5H<"G9A54;#K"DUR,(3#_(_W Q^N?_HK44?G_QY6XTDQSEQ
MM;Z8:UBQOL9N82<GJ2:VOH]P+)@\:I%?HA_>3/G>!# TZE=D?T]YOARR+\L@
MJT-O7:._""@*%D_ LO_3;Q/&&%Q5Z="901@M;9$$CNLMUV4C\[[Z=N7F6F=M
ML,UQNV--&U_<<O%NX5E)1G\$XH\YERH'01/;+*ZQ<UU^V9;RO=5L&M]K+>FV
M]&:ZU*$-#.]A][979. 8T2R ,2Y9_IJ\<R;O01WGFI9<,#D[NN$-'E+RU\M7
M=L%:B9-7,+)3((K>?B.@;6!$>=W?22&NY@1^'91TI'YKH'(9T:I83T'$/.Z&
MBA;]?SN*<DF[O2\"@J)U'!_E%.0&"5E[OV/EO7+^;2JOH>Z&  HIN>C0F+P/
MM\N"W8<T/<N.J()H6K(4;U@E%-<H=0+Z)W4EX0[P_'*B*;W2K@]:XWA&CH 1
MPE&A]9=5>PC2*C\8'W=7JZ'2I%RWED=_98@/?31G6:;I249CBB8\6H*7EB#4
M[D+0 [N:0_D T[B';8# ;F:DG*#YZ#22X,N<I!(U=+JEJK6XWOY\KL963C1+
MY I*04L4Y6QPX\Q$A65N[A_W9$>/QJ</-;;<&)C'I1_;!G9!I2.]ZE]D5%/9
MT0;.JX/(91W;Z60WBR_>1(G7(5R1(8V,@^&6.P#)E*9.<^F&:=(U(C[)S,6)
MDF/XE21KU5*?J]<L7?P3#PUGT7@M:M$$_WBKO=$,^Y8.U//1#E4PP'+MO8XT
MFJE(DPJ+' 38&9>[]S]Q05Q+UB,_GE6AQ5=\<F7$M"7X.E^%&X+[9KGLOU\7
MDJ^ !#_6PPG-ZH943QOU<!/M"8;BCKH0GO%.CPWI1AUN#,B4D3V?]:#5L,#"
M4E_+N<I514?/U6RA3;#B/T?][K_?Q#)I?KN6C!RX)*&UY:J&/Y,JL*2M25L+
MP:?]:QUXL;0RV0CQ*$4%H<553B(#.^H6:,L<V&YI;Y0ZWAIB;G"J9(H#'V/R
M@;-[H5@*K3 *\N8BB!FD3R_<"&<\H%N4$UR>3$.M;:QAY0C(U80ZH7M7O4!^
M@QUB(,N'["Y)6HC)2;YD3R-Q-RR>F) 93%K]@]W?#\YV,U^O!![YL;OO^CN&
MTB0V.=W8D6,FT+V-M-I=&4N](0@E^-T(-@N<4WMWVAH3<;+63R7*D8#JX"[I
M9-/>2#]3_)S2/QR/V;/A&P+&/)<_$F^0JC5O8]>95Q\J?WDF[FEQ8U"N'J!_
M-(&K7K7!-LF5E&"%BA/?C_@[J*D!"K!A+TJYJH1'_@DW0GBNB>44O"?66P\R
M,Z[1;  ).U4)^<H)BKV.*)%VP99EQ,&RT5#N3P.5B>RXT'#57$UG5LEWX^&.
M8GOG;V^H%6E 3OGCN18%;9!+<27*ZP50[\HLAVW$]!]V2M5/.<RL5= $IBZ'
M6UE45@E!D1@,#E)=EO6Q0U:1)C%Z^D.UI:(86PBH$'=\_=Y;^5@:('>J?+#9
M93(!\\2J(P=/'+ZC!6&;%B"E=!WE/U$69$-.\]A$YB66935D?@6C6QLH-"":
MP>\E*6/N"2W%G4BOZ9=L&BIU.A/L*EN,+$R$F$J\DM>\K<9;RPXJUEE6]((.
M(XL=-:+Y"N<Q+;&6+_90Z$ U:DL#ERQ14 9W>(!:G-F29%(Q6@EN 7]<\N4G
MM;XO!9;.HJI G0GCM50BJZ^J!.+YM( 9AIL\'#T7-:O7\94)+C !'I<S:D)Z
M_KQ\]=\>+'@_2+X"*K8H)'NSKV$L+;ZP;U"*E(^N]%J@XQ2: 0\^3>-"ZUB+
M_,5#X\W@S^HHA!NFNA+9J\%;-.A7<0#JB=<FE?LA1+#$XJSA]N3INL2 [8?^
MU]AV\[FN\U]N+A-]-% _?KR<IR9@>G<?0M/M\HKIN^GT!*_[F'N-/3VU]D7)
M)/38_)]SRQ7?GV[.61H9\&;N8G&:R#!R?G-X1]N[BA5A>?^6KPZ1Z5YU7(OZ
M&[P]?(Z=.0ASRD5_F3Y]/[@\:%FM[OG%OQQ8U2[L=3TU/T(%E>7RQ4$+#3]N
MIY1\"4UH#"@CNJ6R23,B$RK^)?Q_%KR0?WW*%WC,0'\.E+J6/YD_,K=(^1[O
M5Y8=L!"D")7SUXEG@C+O_Z8\^/NFTUWC5\E;R6<U>X7'WELCG\]$!G9V?7OU
M\C]_6X4!MM5"/Y<^JYJRA#OXW9:$@LDF*O@RBJ3UTH$6DMFYU$L>\L*6\^$^
MN?2*\,QAR)(4MY.3K&D!B2;G4?S*,WU4@6F>@*QXVSW/);?T_:/*,:+%XX]6
M+CV)_NVA'E<RHK:NK0SN5(?WJEG\^/%\C416_N4X*1W.'-NBB2^)&UJJ@7,U
MXVA52<%5DU.KII94I;94I0>OF-A;E9GKG]A9-2NX.B>U>DXMV;^D>EYG-7VX
MJF"X^A"G.NAJ2=O2F=&=)3D*:AY)G4/,7K5D:9H6N:IV*^^MF6U>DFM$)MVA
MWWY$9IRL"JQ5_W%?^!P->'FENGE:G7_PBCQML!I?%K)#G=A>X=);VU);I6Q9
MN3?7?I%(G:POVZ*C5'WT#S-%_$8%^4: JP"MQ:B+SC5%9O_V> 8+AWJU, /(
MLP7 O@;4S00XDB";%//ULQ :&=!8O=VVGLA6_6*D.2,>ZELX\K"7CNN$5L",
M<QS4TT"/Q.SF\.O3#58ABR$^"7ZW&9=5.5^(H>XFT!F#!(2ULS54N4'RA4)A
MBL=^L;+H%?_R!P[[EJAOF:D3BE=.[UQI_[5JFBW9Q:_?:*3W&BCZW$27C?DG
M2AI9+]"K+\"HRK*S(%AV&.4"W*8'WK]-@GA8H4P!L.]!05WH)KYJ^TE1FV&U
M^\:Z+XO+&F1-_7-+W<6<CCO2E=O7G&T8/6.P@)&J20MJ*MNU>KVH8$.L_>\-
M:*X8O&=$,XU(HHGBB+&234@R1F%C2$ <&J:TB%%,CSP*H;U"'6>E1YR]%;VY
MHVUU*;1LI":.+ZQ,[JAM&-_9T+A1,QBTK$P/E5JEJ Y#!0+?,7I%? K2P*6$
MFEW4!HOY]V5C3J;V:5&1T0(?\K<1AVN,GE;RL/,>4,K.%=R:R&:=JY&P!]UR
M'E=A7'^JDP$,G3K>8ERX%X"LW@E9$=:YYE9MK&6F85*<WE?OON3586A:(VRQ
MTW49T+36G",QC'8S!X2*MZJ-D-0?#/5#/0QC*TEJV6%XIX(;881;7=9O(5OM
M#6#=47B'(3;2 &L0;B( 6AGAL2G(6B$"9 ?Q=,(Y)L],@.]B!(J:*75BM. R
M]ST=<<;!>P;XAW1M4F$AD(*&G@0'M"-4'QSAR\$@R:8P/-=-[TN[!_^H],DQ
M@5FS.,E&Z/PDJ7X <-.Y;2*7))K#MNB0K1^V8GT4:!!9KP=WMJ"?=X*RYP@7
M!S^JJ#PSO'>)(%#)<28Z_MD-1A!07=5<(=&A-6UR\,]+,HSU4);ERBL=#9M#
MB([X60VMVB!'XZX+<J\X.7)/VZ;-4Z\+V?/^D?\!6D"Y :"^IE@0EDP]J-5#
M'B^I5F)DIA&X9<*[N>R1 >HN'>=Q,1M+AASEZ)E+&]K$FP<XOTJ5VDBA.RAH
MVNREATN;+N#@4#M$MB'W[M'C3)OY.M<E46,E#>CL 91)0&4ZR'/D$I6AI11@
MP!@Q^DMB5V%<2XQ:1A3T@_0<W JUY;_,&UMZG_ZNCV(%<1^X'EI\'Q 2:+(2
M*,,.90+Q[W^WM<700L54#0[FFJ@L\]Q4")1]@NT.P_3O5#[ $>".[D*:0+PD
M1P$(<5]<RZYUR6HZO#>IP2L9^!7^.:&%4)F2SGT&N(C1J5J@T$RYV(/:*^UB
M"2!4S\8!3HX8+#!383U49$*@!PBHA;^+M15&CP*,RB)9=KBO%4 G9ULAX@QG
MC'46DT8_FR@U L!NN_,:5FNS4WL;% 8@X3ITJMV14CQ0BWOQ=TP(TZ,V#NS!
M:.W(R$N:G8*:#X ZP-;4PK-3'N>9J0&S.!-M&,Z$M0S H_3Q99/<YHP&.<5K
MDGU!F1:=[4%_:K7'3[;GX/4*W\ZED+^]-\9BQCANY^Q(%OC6*YH<Q:Q9>ZU&
MBZD99GCZ_'GO-S:>"LT+]64YB9'3390TL]VMYZB;><,6([2E'_+1[XR5-]HW
M<-2_ $&+Z'J9]=<IV03T$@?9SQ:IS8Z4#P$.8N2A]+1W2.#[8#H.@H2)\L8"
MYY"3&L7.Y&<@C(NDBZD1IUW/IP3$FP")F-I+N%HR<_?@4+X0BJ]D24PKTK6H
ME6'SCB5LAU;VM!=HBI7%T:.NKI-'5N6)P4:C7P$.NF]WGL^S""-=7,-I5@9*
M=C^4AA6JY<AJH??#&*JU%EZ,!XV"D&0RL'%]CUMRO/0)[>\P:HJ)0M,W!X(7
M$K%4M1[&2"22$*RXBLD>TJ,?T5.(K&P<*BB=4]^;G@;B=&M&GK+AX5V)CQR,
ME+8L'G!06*.9.I>D.\!_JU@G8ZGI6B1\\[GHN2[+Q&@VUI6B&+-7057%6MLH
M5ML ]$V73[L,G]X9OGA#:)EEV:;U\H#&_LRT_XUEAY.5EOQ^6@P:HEATS-,$
MQ2@C)W^"'Y(M9Z6;G? 4)V 4"Q_KI8/9:E:$F+N,9*5CK*XT&^:(D5=N8GZV
M9;SO!3[TEX1V0('R"5P=-T8?[T@B^02SU] E'!+*W.CM66/LE6Z6XEMCE%:K
MGO$HWBG_*)OC=T$AAMOG_7XE"CE:"4X\2K^ZK]ON3K=&)[REA1\W.+$71'W!
M1MM[VWG>F%0AAEX%VTO-X&4BW+6-_I2#" SC8L*CT.5NV7)/MM*-37>L4-+'
MZ"%/'6SR!*6/(T.-R+X<&Q_#O5#="KMYX#DA@FGAX ZX2']J[+FL,WV(H^.E
M72BX7=5UMA!*UD$?)H/GD36_K4-"&J[4T^QS2<.HXD1G\J@PBZ(F'UZ; ]X.
M.2600%9BL%17-/D^-!)I7!J-/9)P+@G%A<G Z868.P'8@A.<0DEHIE'6X5BY
MJ_7QX'/JGA_^++'4!> ??(M:BZ^.Q[%T$^A&3C[I^$=,JY>;DE]@S.8"/#?3
M@C."<%;EC2AY_&%%Y!8SE0Z41G]C]KZA_;%K6LPT]W</$[:*KV;IV3];@P97
M(<LT2V;.)RY'T*B7Z&X*Z+MJ^Q.?IS-66QQL1"RRP*"V;O:'B]76U&BQ/4^,
MQ/;3Y$&%%3CT?1ST04CO6N7F)!;HC%8WU<OKE-#Q*-??[G5S];,\22B?I"-_
M";E&'EEY( >(L?+]W=I,29,7CU%:'H;9A=DNR?IC3(7+/^=&=ME-<:'W45.
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MORG+?_MRNG4$URUGJE?YI1JK>\LUL59OKW*MEZ<D76M='?;NC@3QT>E(B^1
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M302Y;> AVR>57#%E*K1;F%5089H]BFGJ$ %\BNS\>N2?*BI%<2A_[N/++8V
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M4FY :YYJEZ=?8=Z8YG[[9&XD.G9G;Z#E:)Y,,36E$&P H)86Y(8.FI&]?.4
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M5$ATCJ;TJP:S2&UL1: UKYGX#*/)APDY@X/[#!_;@@_V^T\Q9[RGN^'3?-3
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MMW;!,!HLE8<*HU@ 42X#G/#8=T4Y2TCBU>J<!@P& ""AFG[]+'??9Q);ZW%
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MY*2">'30)0%&<6I%'<;4%"+MI:.JB%#9IK#(\,^;HR*&B8%J"'EC3ET(#_'
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MAQ?+'GSQ1^S.G3.3DG*>(]JEATZ$@"6]ZF'J@Q@>J"H']P*0F>B)7K_AZ5K
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M:8,PJC'<-<NL0P<CKSIT2E->G/F;J<F>XC?_ 50UD-N\.V&T"W2CB&FO1,R
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M],NZUONA9O$G/H0LE-^XT_<T[N#AK1,+-CON3':;&7$%/>U+LC:7V+)C+T[
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MG8+=-!M%_Q-X5?E0#V@2[D QRP4]$]^MD.F0M'] 69I=<PHK!E,N%B\AZ>F
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M0,'E1_$L6J%VO4O;%BDUA,7_@VRI S+!A[?!P4,OO-(!DE._=KQ]64.WNA,
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M*/$_B!XL,:%Z I,?PZ@R#706VP6%?LB1O.K>YYYV^L[HV<Q[!\?&W_LU]_Q
M5WE(_+3R)W[+'Y\)VA-Z>//Z#X834UZ:T^P^O__?^<7W65=M?3[VMJ_Z.>9J
M\*:5KUNKG^U@!$K&SWE\:L'CJX>W;/SX])R2_=_AW$V?WLSM;CW]OTJ/+Q\O
MG5OU\<7OK\.G_SWZ^%KH5O.,__X#&5(<I'H8<)B?'U%&M$HWA$^PS96TDUV/
MR2,H8]>9(DB^'PP=;,_KI@CB)$)/%'-Z0G.'^*&D21/8JTJZ8;.TJ3G&+_L0
M]Z;]HN>[;CIN(?3>M-]>T=QE5WA^.-9VW\.D;I=MV1:Q[K4%:VZ-/QXU$N=Q
MRF5-O%?+G9';PD:/M0EN;;G)\6,ZT\_>]>O.\)WJ-R2Y?B_H8]1U3LCWA*CI
MD1;=EO?#/C)X]R.Y(173$=#5KR>2>6&/(<QYZY^1X,*YY&C/]0][$?Y?OH8H
M_[N?.%$\"U?>K+GS+OPU9T[YEUE)F95_S4Y)NS)K3GKDZK_FS)_+O#A'MM1A
M;]^\7>937^:@BT-F/UE8G?CH2>:>%Y5/EB\F'D^=W_*/]9SL:U\>I<D76>U[
MOE0?LC%];?GO6:D;CT9_F[VI=-Z&M,VS+GQ+71<]M_/O;7.2HBLQHEN.$>.2
M4F3Y?-*HL8CKE6(U>TQ13G^)YST!.OO7X:J!_(FLR2\5Q%#!J[)YX=+7E7-7
M/GF]3[9CD_/AE)K2-P?7/J6]/7CMZ?XWLU5KDMY4%WL]':S=13*\/;[T3?&[
M$]6/NM_M*YCV=*BQ^5[J^U.E)4^7'T9_I'YHGC/NN/?IGFEI_UQX$F-W?#=Q
MPV*W6>E<W?&3W??2/IZYO_+9QVL@.]UT?%JR:R%-C%PF)>?$+7>/FBG%&'/,
MS^.*>5?B6G^YW#TW-/?XK4L^QRWN?*(=/G[[\+\VZWJ_Q'0Z^;KI.C4O6.V%
MD(3UH[Q:'THI%*;[<SHG/Y>L9?"#\L ;9?QCE@>* DO8;A)I5+W'A.IYE\<(
M[ :ZMGY]<NXM8\*':ZO*"A+7M"3DHB;3UD!TOL2YQ4\:D/#C,_G^@FTJVDT
M9 0;,> ZLO*?79WCLM;@K7<CJ( *="+-/KJ[:0 C'Q,2Z6+Z[ 1#R%F,2GSP
M,OR,(3%$,I9(_&M&P-<40X@LLI\4;Q$A:*A1.O)$Q.GAX;;M+@5K?(G,%QVT
M^\6G5OTO,E82""A\>6S1<@PG[;ZY"PTP6FYO-A>"#;I=TR4 'Q\M<!LSLH]3
MH! =R$%B8["VA@FOP7U=7801-2<!@T0U\I=F4]7-8MX]F"BY[N'6\T<'%EHM
ME(0S[?MI4QXB[&RT0S1.C=GP(JR+JA2T+K1D%J^&5(1$B%YA!9'7$6H=&DGK
MDTB2A7J"KZ3 (V 3Q46+L*'E!18S,4)B:SMG@C3<CE,_=8J'C)4MU=N[<94V
MB-IJ.ZKWYNI*)A]#B(LXF4S6.\I<^YH]9ZLBF6[ZQ$@DG%7YV=4.RJ2)JX3$
M0LJ;>'E^RP'=#J=<(S#&!ZD*0 >(8N1HN#^ZG6V4"2]JE8YQ*)RF97/F<4!S
MN')7D=<(Q.QN*Z"GRLGZ*$W)MDM$.$I1&BB<2:)_<6+$ 2'Z*I X*:4^?.KF
M4O2Y$?37=;I[K::&,EY9&CJB67$<4H<:9RSA*.*4((G79[3"^ZX3S&NH @W.
M@D]VN&9(H00&@9\@#N?7]&VWU@DM"[ZW1\8+P_(_RXB>H_"<-@32LEZQ/;,4
MCJ1V<F*!K/BH&IQ%'2"W#<R2R!"0&0,R$DT*MC]0Y)DMA<*D:".!6LB(59/R
MKU<3)%TU#EXRV$+7S&*+%78K5L.\'-&F;<#+6<[O;TS_4,'>1NE(HBXB<8^)
MV.C#EZN^W9Q"L(^P5F4!L#FN&B+4:T"FL%-$0$'P#LZD20'"<Y0"^1D)L$3O
M4</!: 0-<RP%(0@D ", !R"YTL-)@@D"4+ >BP!LC0#D@G./U2-@L!"CU-=P
MB!J<2M 0;IT:X, HDFN#*$@4 -8&XPJB5#E7"P*V$F\+XS/ 18)#31P8N"$I
MM0%PCOV8,[:<<(Q6A0#Q5=$TBJ8@M'6MVTC%5"YWC]*^@$T, D@P+B@CE@&<
M(#G"(T,T$J&#[B)0N9'4RO@"A(!S0,*HE QG1W2W6Q9">=7%1&# TE+^$CX[
MVD?L<^+!N-XURO Z,0!@[JM"6)AYPE_2 M'1@UK?(VWV)+)ZF'YB/8YDX,',
M=>$\3RQ\4:H)\_NL!^-=0-K*_D*VV!J:-@]W1"8H6GR,\#83!.\^ =ID+23R
M@2('L;PX- $H$X_BKANDP%US9]F!41B^-6YYZK.G+#;Z 6Y(A4B7$>Y%%>;@
MWZQP]3_(WI0"A,=+\],*9# >&PFFJHM0*4[:EZ4'=S,82<$XHTH',+%P)1,=
M8,A)17"@:;NW!\#?EX,Q&E) ;V,-<8>58A?X[W9O%T"P7@-(4G$@V"@"@PKU
M)"]9$:@!!:N(_W:#-V_"B! B43 +&A>S[6IG@K'YSBRC&8M(B.B$8Z][!.,+
M%C2-<E8(,+*MOH3'0%AU* XE3"#O;\QG5&2$ XR>HG?W(LB@H:/XA;'4OTK#
M%<9BHIG]()2P$-T>@)$RN/,=@-_ 'D !,II+0HO6,AH""D!$4ESKF&]J0I7
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M,BNC<7B9)M47!30:$@3,^W3#W<V)1T-RS!"Q-1ML&.0+A/="RX51,B!*9BE
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MCU SI61Y^S:9D'--2L[$S]=P2$OKW<\@O&T Z>7!95E"KPT7J)LT)U3?.7D
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M@F=R.<E#=R);M1<AVQM@=$\!%*&@O^&2RG ,=\U[O'U/%AYB3KCT]U2:IM;
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M25R\08/3YP? NW0%\0'8?BS.NVOJ-0 .S$@7C!(2.8?_-I2.6?P\:'3W:8W
M5Z<J'J(]'6R7:IY#G,*@+&SB*.'B)F 9E9B$4,_*!;LEQ5UQE*=R^EDLM#&'
MF( HM@O!GGSWRU+N\&@!,\6W\UT^'3UTSUA&P>NO/B,$R[%G@OE%P(N T;GS
M.U2ENCCW8:\3/6G?46#/6)Y#:QFK7AE/L1'(%7ZZ0HI@G)V$(<T!@BSI9TTE
MQTHHEPY%I(\6!&<!B8+"$SELFOA(P63N_+[IB4;BW41:>14FZ2N8GL-$1QW_
M@*<./^?J*T(%A16#Z''<[+*Y)XG5=6A:,RVIZ^_=[:!67CJ-R-PWHJR[I'3(
MIR#U/0>["E :VIQ\F#X*<?\'4G'&R,O"G9NPHWV*(R(JJE40OE:%]3FCZ($"
MO# Q "93BO:7J^BF?''>D335#*MN)>U_E:@!\^H[X( !GWXY>#$54KP@1 RT
M)HRS&X02@-DEW0H.0-0'8=J%)=.E@%T?^ .N+7RW=WK.D5)]61CGB*H*RRF-
M?KY'FG;H6=ISMZN*"3.OMEJG+6ZSFG2Y4\\Q\'9.59$%A2RU8WT.D"0M8&H+
M-?V]C"ZPG%:JYRCRZS,0@\I! [AI%'84>%8M^,/TFJ$MO&6NX%IT@<OG*WTZ
M*WQS5!P=+ DX$IXV[[+N.3FGT$<%N&D5=@!\_25L@6%3DBK#^DL2B51?1.&S
MN(0/,)XT%TKKT3U9BDH1"-<H2H'GR<T,@2G_T7/?H!P?_BCEOI%W1?.2CYU^
MAC!O,!4.6H5] !R^2>.G4U7A1);JNDH,:A%AD*!\46YE:>S@30V R!7Q:L7;
M/JYM )6B/0=FMML5C7&3/+I-$9NO (ER>AU00)N=I<I2G./9#9Y4;BQ6[E1A
MY9,SOO<0W08Q8FS=0>2QSXM]5W'XGDK)S=KK_ZY,+=HSG</]8TP6 4H+@#'F
MGB!9Y-K6N\-<GFF7)A#Z^)548(K*2W[9*T'[^@SL5ZPJ9:=UK/)GE^)(/[TR
MQ6;H4H'D?]==+@.V];$30YT6+E.T]RG<[^Z.>M8;7HM9X:!MGZ+[!NX7JLVZ
MH; KR595#890YI[.Z<JZ!_KB0;]S?0@>NR.WC+''!9^KYNX9!$)E:<2YBTF+
MVZB'+QU:^^Q)K=O^4O6&-B"1"MKSP,2QN@(5EF;DJI#S_E303C"T_,*Y^'IC
MHG\Q5ZR*YRCXAL:)G$43S9R;(Z7>3N4GY8J;9PLC=]NH<A2E'#!H<$DCQ^HJ
MJ8BF>TX1%&)0>2B%Y)>UFVH8=V?4>\^O0B)>83&87\4QS\>EE*E/9DS[#@=I
MA>N+_I?4S$@8!7C&Q;^0NMM_B@>=LJ.(0A*\MBL"=U0K/'Y1^9B%S9-COUU!
M(:$ BKW*JC?ZF29U K,_&:JX6@9O%$C=_79/%9!I4WI;!]_34;WKKY%TI0.<
MPM^-[P:>C.6+N:0L"X&N("2'?WH,;1TT+RTK=C[5_?>,JO_N5NUJAI.:'?XW
MN%\ZBD7Z<\4;%;M'!LJ&H:0D@?8U?$]@\TNHD,512&*N +T:/4YXA4FLUHG_
M&)(]([H=*/6Y6S_M6N'TQZS@^MV0E)MD?/D!9[Y:4?I.7':N]=QO.NEI^^JD
M*A:3TWD54 J_%^:82_<YO,N?0XE2&6(<$E5OQ/LV@.53;QF-)F6%Z4VU":X
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M7<"V/C0$!ZO%%WN@SD7ZNM(CDQ9@R3!?8W"GX /[@O+MX[,;B0<5S_'*?%.
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M%LM?IM:HXWA+^X[[MR-"3Y0F6:IKDI$ZN"PJ'^&.B D5R!S=62'?>)P.8-'
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MZUQ=0K?)^[J"&]:_;*!PVXKB_42TI792.QJ;+@S;\5' VM#2/+/[\S6BMXV
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M!:,#P9;C68GU?7NLA/<^)0?O&$(I_]M ]5\-#WP\,'SR9@-_E*]56&B03\%
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MZ=CXTY,1=&N9#>C</EVTQ8]3N^W]B78C\5@VYFM,/4N\@>YL63:<.S_J'+H
MJY5 B6:SG_/_#']7.ZPP[ FXZ%V=KN^F%U5Y_J;V<494L[7'_8?3NTF::MM1
M:)5Q9:&KWK+/'VZS8@X1LV4O. &\AQV)%"]W@NO8FX)A[$UFNBK_^[D8@Z99
MG28V*8=O7'']\Q!POH??>S1AP.?ET*)&@_WE\&-:I6E+LEYS?OSHWGG(KFW
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M@X"+J,I?.K=!CB;&]__<3RK8(7J1OXMWU59[D9"[ER %C]W5MY_)*XNS;%S
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M!C'@0\JL]*9=.N3Q]P9R7MULZ-%[O;WCI:\*4H:95[";?4<MI>RUUVXS$;7
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MDKSSZMG'RV!8"\?U 'XE$0F-"OXBY?6?-FY=8!U$,%))MVS[RV]S6\C2[1D
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M_8#9*V@X\R\4 >1>GGF&V0PWS<S VRXX=^X(5F_[B5]W]FK4Y,&')PFQR5O
M*Q$]*+QD#=QPT:Q?[90]J[S6X_"R\J[[:F<$?$ (U",!'J=!IV;(" !(M0AD
MC]HU@@_NRZR=U?9L"$11.W:542T:Y_ZF]@SF["4S8D!.]"\V=9 M R!%0$^:
M4"<$]3\(X42HTU_1K@5(;(!0SG_VJ.K+PZX2(9"("$C/>1RODV%_3N@(A_Z%
M(1C7@]LV"+%)Z3SA6U*OE&.)A(WS-LYT+5>!3((<NOC<A8NZL,P$\4@QR >_
M1L/T+K-RQ_RC/ TDI^+>!FX"S-8@2 $:DYV5MPMZ48^[_)VG/P<Y ,'F/;C\
M0 &QZ,HZ6&[XY?N7IL\MN_G_)9U=Z(8#YL3EA(WP5;P6%R2BE@>B<7\N?VNY
M&LMJ=^,V>C<%'B-4VCA8 A)_S?1LUQ1?-'[J\[E-ZEQW 7+D="CK]PPO-/V%
M#)>5F!(H20]I>ALM,3PHNKH_"/YJ2V)JO$NQ;4 'K3<.A\KT <[ASLJC+0?Y
MG1IF=UH@$ A_T CY6>LOZ6Z"6;D.7J==*%=^^JV>^%L(-]J[3^? W GO574;
M:RH=[-&8^*W_^\ZZM09%_:OYY9=2?2=93U7EKH+,Y:WI+[)7'?UW.FZ[-6Z9
M[DUZL';K%AYR?9T%5P)D5TJG'#)UORQ=)5C%"H!]:.;\\7:\KQ_W.7!C4NV]
M"IO^1UIX^5IY:G-JET6,/; U_B\@9JTJ2[84GB043U S8G$90?I=F%L#$H9"
M&ZJ:K,0RCC/VQ G5[ S)[Y*1+4\XL]HA>PPG H9.@4"1^M35=I80H=0"H*7,
MJ1(#N!B0@DROE!%P +ZY;V8S"'6]!)5J9WL0X@ @%QB_A0(Z2\"V@4]0[;<A
MH4]\$,^#?'@)\,"9AW<&";%HP+'0HXE/2@3H[_](Q%X0O_KF\ODHLQ_%O^$B
MV=#WTU*$9=XB$$$-'68BYO(/Q0]5>\T,,10/G^!(*2*N;]9Y=_"6 ]%<^L)\
M/4C,\\4>^7=-)'6XB::SQ'HW@> ]I%T>4*&Q^B[5D(GFD^0E3W/ILRU;-5-.
M'7FNC!;@]"MV'HG:BE9+QF>(K6I\^.R^<H 0)DJE58)OV,;!Q"IT?=8O-C5X
MMXL#UO@0$%L=2%@//KYHT[$TJH8%S'D,'C.[0W--S6Y,ZX5$8D[X&X#"+"#/
MXJO42O=;BM,^.NXB[06_5WD&0JO!9O9DNYYH=N,B%5BD:3^X+.H."GY8/.)U
M+&G/)Z2FD$I,RW!OO.K97T=V2_&G3R&/CQ+[0H53WM*&1)'7PB>?BE^I%UDR
MV_J[M)!'[."TN@M#4D])$MN]2S90"YJG5+)S_@=9TO?C_B+VJ<3E*HQ@B $$
M2(4>  2[N8;L"Y:F/5VTVH!E*IPH :6RF)DD/9:9T>@Q3)/P\/X^DK!QC_/N
M78*D//(3H',/A&&ITCCNY$JHQ*>Y*Q<WSLZ$':S'(3LNAY/40?\"!(<Y>(BE
MEZVL)>#,.?P1NTJ2J!_,)7 GDJ&B297H4IQULTN.CBI3'P?CN$UX6]#SMQ9Z
M;3F.JYQGVPPJ]%7V2;-H^WYW@!9")<(09:A$1 :C<O?EI5+WFWTQ,:&"O:$1
MRVX:>KSAI#X)7;4TU803BV@J*(S*E(JE>H:!!C'9AU/V!"YQ/\Z(-C<++ J,
M/M5']WC.O6D2H^]8^R1TQ#>GG$^/>ET<&+_B:;E9.C?5".\Q];UOQ\2]IWWB
M;]Z*?W>!N[XEQD2JKVA1PP!%GV+9?_;N@WSU=):44!-;YBT@O]F;&' ^?W:Y
MJSOL)N)+%^V?,_('QX@//K[6.(@[>8P6+[F:LO+&]_$IF<>!.8$+3_Q!ON[S
MNP^D]A5ZZNQ842J-F6[WOAC]7 -/CPX2PW,7(7>_*NV:;WFH>K!VK,_5L"ZY
MZ#YMU5[/MA.[WX7?1_W*/;_WC.X+X+;?E,8P[,ZLC6\+^/T*MSC]][YS/\?7
MR?<_;]=0(J(W9BT]]4"5M6B..%IP+**N4YGVP'#% H: 3/1?)]VEMMM[?.*7
MX%B^]_#Q/=[6 3O*O'&_X/&\F#@;XN!47?:E>6/-"N9QET27;WU!#W'?B^*)
M;TR.KG?W&_,?%UE5+@@Q5N[-FU>\QOA_]GL'?Y8WW%*L%'8U3?_Z,.UQY><%
M"7MUS#F-<15,?T$"U;CU?EY)>*_:] 8@"-9QZT53O"R,$Y<:@!W*6]M.(6XR
MT%&WT NXPH@-@7:%#A[![M_^2X-JZCJLQM[NZSU>G6:IA=D]/5ZB?EOJ@,41
MLU^HD?F@.KG,0\ZQ[6SL&UUCTN0;:Y@:Y;1T*LSD>*S"DB)!<72$<I83="8^
MR2WFO&T<5*9P;E$&K5(7)/[=,IW*8T^[6A>:A+(02$^%\G,,DS9?/-9&V#)_
M+D0QX7]]-0TT"^'1C(+-2?*US_DA0:ZE);M38FT]FT C]%3PGG@3JBL]UU "
ME.[[.C+#XFH^W1]=I_*:?AJ%<XW$"//DIM=.\O8\X@<T2IHCG>\WNRN.R]Z$
M]I+PGX!PY/O[@G,S3[2U32?ZDO03;_4>\]3]X+BL\VZG;N":8I/*<QE/UA]\
MV/U4_15_?X<)Q>3JIN.SERGN\VJ,C=>,!]H^3%NX>9!SN.S+\1ERP\@=P1\-
MTM!#3MXEA("OW%T_GI_DOGMW*[[>F+F9%3379':DW./#EM.!8L$TQY#\LYVF
M6QH#W?['*KCLDG%,C6G\C4_E:Y#2XW07,?OZ ;?$J[(][I<<K2_T"Z0OO$0O
M1M*L;IHM6?QUHB;(>RRJI&K)<=>*4PLVCRVN-E]Z7%=>?X*^>NGYJJ7^Z=\.
M+OHV%I/XHV]_VX9C*[W?+WNXO;?IQ+>Z^,WOXWZ_?GRXO4_T;V^R4W]5S/5/
M%>=V?GN?"/Z.:4G_5B_WSKBAI[N[>&E#GYNK-F[9BT>+?MA[5?_<E-;++5R6
MM<5E6T%H@BLHY?BSWZI..RX@!O1(C;*_-WWM57+BV0.GFK6P#NRD"9])3221
MG$9>:,J*>O(3ZXME-U >\<_CT->7]S6=O=<P-[\7ZB3L:^F[]*G=B,"M;O<^
M'U_Q/NE"V/T@@AP\?/WLW*CQ.3_*M5O'BK",-KKZ_-DQ4P*W8YH.@(GT325Z
MI:L5[)X[?<B(47:S%.S:D.]LN,C.=7RM7:JCMI6?>^/MI7&%B^6]3[+]'9GW
M7N5>/Q!;8S3)9/0(=@7?S-MWG;^T^[;&.@'0B^L'*)R?<NJ6'H]YV3+R+/'
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M9QBIW=J"M]Q$G4Q1&!@Q84P9:#\!^_$=R,_ /OP.IA\CIS5:F'%UDTC@PCN
ML@;FQ0*O=:R&9@"K]Y<5 KB9[*^R/(VA&F HG/:20&T A8&/?67#]$""Y]\4
M"< -6? E@3 MA0$?>C2AY:F:>.21&,04O%"28-0OEU*L8)RS(#$*A@Z$>7TG
M>=''VGKP1@K 08Y%_P :9B)]>.;0)<!(CFUQ@)LQW3<R1QW4P#$!=JX>JZN&
MF0&C0=3S1ES %4#:T0%C+LY4CKA$@H,JC#<)*!!@0 #9! $&+%PZ"7!58V"R
M^Z\)R(LL&()T_<%:$*$&MZDP(C^\*PDHDJ-@,E *P$ Y.AT W%68LP]0AYF
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MQ.8%JVIM^[#(2XW\R?45#_T&1@\O\R#W;>0E<O?#^ULS%95N0?ROK80%H)^
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MQYI]5D&BU]I(+MZC'IR4[7^IDJPH?<6K7ON69,2<<?.Y(&4JQ"0:V+P4YR:
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M[C^#(4TBAN&K!\E,F78< _BH)7<=T_-AQ\6IX6"1>/:)-GI>_*T=3"P2WQP
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MFC_'( *.=S #DIT'NQ6'>2AL/1 HY5="QOA*RR0ZR2H*+W B8SDUMNF^!T*
M?;"Q=/5,IN:UY-OZ^S=[AI:(DI6'Y@V.?ZALY1 +XTPS7Z>ERJ*%^_S4Z8XJ
MD7PHE<&VXGP D)$@2CD50AQAAU/D+QEJA88"ZAU;E23BTE@P9WC$!R>$0) T
M>5X(/S3);(WN@&2$20@P%M266$&C$TIP.,$K&'TTZ:0W%1[2R-DTVK"EEW4/
M(1IG_HL> 60077CI,F>R(5''2),J==,/8,3\]_S_<>]]T+F=#]BCZYF>#>5:
MM6(38KF;"1MMQN:_OQ%7'!PAQ&^@X$;P3,?$JR6WY:4[WH?&I;GW?[_/.E^^
M)6'S\_(]/\I),L5;Q#R5K'48@<USI;O,H36?HP@/B:G<,[FH<8ZZ5#O?F^Y6
M)X$6S:F?Y5Z@"[3*_4!U=$3CQ[-+Q(;,2'7"\88NPA#$S4PLQ05Q,VBKY3C[
M]3E8(<.9W#1P1[FEBI% UW>TD)Y<BI^5:<GH,DKR2?=$=!UO83A+#MU1;/M\
M]/9^/D<E0V<'&KD@0U+KTRX2(H?MC6POAG2J1J_@!A5S>2$M*L$<3KHAXL&C
MR:?1OC4#,^V_MQ6^45'#=F5A7Y<^PQ.!=\@GXOLS/YM^M8K.'T8]5GK]^=6O
MMA/;B<9/_2FCWW^I'W*'G_W[D?\O**6=,_OE8(A,D5WE4 :2)N+TG&"/X@^U
MRUS^DHS"S]Z,F>0K2M9DJ&D&A<#RD[7'J6]B)!Z0\@7-Q[Y-L?:,R!ZA%:7^
MO?/?D.*]Q"]6G:3PV8MGO=BJP45]J2-?SV84"ZEZ+_LV6ZCGIZZ_T29/]EOU
MKA34+3-5G$\,.E>MY!%:6I7/OAS8HQIW.7=]5KKY]U,KXYKB2W.AY46BPNT2
MAT\?/[%?Y#&X)T:RGHOV7G12:E+7[LW!? S8O_ZS-D4IT4/OU;J,_?BLY+&^
M^KN?8M*M)V='KP_7WS,_+3[ >E$R7D1KN&MS^H#/O:MCE9^_JP1%'=Q><7*L
MSOYHE67K =;9DQ/M*(OJ=(-#@;A3DV47&AZD/UT.MUE[*;CPLVZ3P:>#62>?
MWTL[5G;GT\<@>//4TV'X'2GOS[\Z*7H7'AZ\I?=NCO#I7?[NK$<M[Z\W>(W[
MRUX3I+36/#Q\>FSMS=?/QVDK!!'T9DJ(_'*\LRY-(HF<^/KG\/%V%;$HTW]]
MCO*LL==R^.N%-9O7-_4>]<THO[5]:]ES\LS.TOL[@ID7U^<9%Q\/[5<M<#]^
M?$8[X%?F^\CW:S<ZYW]W'$DW799]'5I$<]MT,G6_R>=":I%VU)FF,07]_-M;
M[6C;M*TS"JM^B#''3_,W_8L9.[#E& X5IW<J_'?Z^(W/#8<:EF,N-D^_%X?_
M&: \2T OE/X01\B]GVFV_3"K;7%D)FL]E/327&*&?'@B4S_A:TZA5M/+SQT/
M;ZY]L?VW=F/PE $Z@@DG^&U._9''K9%JM3!CZ!V.8E)< T8^YI[]K661PY%,
M220HTSN.)>4F]_:*?SE-;7P3M67_X#^%"H.JR[L$H7G(E/P3CZ] J4=75LO;
M;_]!'+"E4ZA^;%&H'Y$[9*3H'ZYA(79XCVY+"RZ!:HI*P/;&;8P60:EII???
M5:/+7P_?_S9[Z/6_GSM(L$4YIQ_$I:]8\AC(BI481>./\$$5(:Q#)"$V(%+8
M?'>&P.JLFD)!+OIA'>VGC!()TKN8"Q7DDIN_@B4BG"8?4*-BTZ1ARA!Y(Q]0
M%*$?LO1LB"J2(#Y80)9FPI^-@!L$L+;"LZ_D*%9L*J!.+>E&_U@!I=)2?"F6
M:]IJ9:Q8W??'/TSH'TZ7512 OVK!4FVMJPRPG2MQBH.6 I*-6$9X)D6)X7K4
M7-_4W?T$#$^$T.%LDPX><$1F&[P&/.ZDU<C3AG." E: Q5I;VQ7L(P88T>&]
M402V0#@%(5&=X?V]&WUV4I5!M-@Q&:0&Z;FKPPU@X%41+)R%"A?IWJ)D86./
M_7L2IQ:?VI@1')P@J\@2FP;'P!49"7@NY@R34<K4W9"C&(\XRR#N7#3&[F/3
MGHT!W6424BS4=UD0/;+Q5@W<$&"<965+LM&'( T$QT0:TGR=)'%( '1]M7(U
M 3N$6NLNI@/NL/N.()V'3M7.VM8#WE>S$(,8#0'R&@_VSQGVZ_U%_,8='RZG
M7BD\ID/.[4-#]1ERN@5Z%DQ8(1\(A. V *I$I,'/ 8_6[I$281-S5,/9J @(
M-C/J+BG*O>=,:6> J:,;N_>BZ#D23\.LV52L#9NV&N(Z6X.2I<*/\G4O)"OM
M[]/HWGN>#UU$&,/NUZAOX $1(SG;7&$FLA3\.V8AR9$/N02(3URV&'$L.IX;
MN3LT?W_BFTN)5YZ0BN_)WBG0,V1OQ4,!,2YY#+;-%2'P>@7TN".A086=U\)*
M\@M)G(LV_!0"4Y//@UD)7&I@FQ(%T",1V!&3[9X'%'3@I 6JLH#6?@R>S',*
M9U)]-UXZQ',__-T]XK?O4<:F=B%0@<"?%FY0 SR+3:_Q3TB3-A8^3CAQQJ+X
MR?'C[C59%L:@%!.FS@6E1!MMB. A(8PN7731&+2 4%*\2P9\>@<7>+A=>JD
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MENRRE)4]. >&?0 &_L*D]9$S?[:IH>\45)%EO6VOI4U?%2\#VLI+1;#,O"(
M._&T.46T,:X9<&A,10#ZWA$._AD 2@]D "@TO8H08RJS:'',,VLB61^UDLE@
M THY'!D_0 "#O_!(7KX*50]PBO8"0P=M_2$G-@LQVISJA<]BAS'L10\D^E)8
M;.AE)U*:CPPBNJ&%#Q]];)1@.6F&-E?'<- (!+DQQ9S)65C#PM8SI^ HASZ(
M)RJ+Z'S0)<*2>&X*%)# YF&*>J4$>HPB UNVI>)B(\[*5%K8+;.85 TDE\5!
M<'B:1".C3U"3 Z=7Y?114G2C7VE'R9CDFU[TSM-1+<Z2ZFM3HD+538@D>!H5
MD28MT,./5:"!)DPCDLV'DW,X8A3%6?=[IA?5KIK(^7QU,R4&:(U]B(L!_2<[
MY;F;":M=+93FWCZ=IWE==9,I TV0'/\Q8S53\-%L5(-#@,#_EL ^RZB&WGW_
MK9UFO1,=:TR) !4@P+01^78-H=EBA/*T8],YUBZ=L_D@+QOB3=W:O:;# ^"8
M,KBI.]P"9U%DX\ 6)?V^!7@#J3/?,JTQG%V+KDS #9-ASJ9:6^#2S"9[D4"J
M6:/YYE.0/[TMMQ;^^RH$/Y1E3FU5'$CVX<%I&7 92BL&EX;I2ZGF(=^LP;?=
M?F!]4 J,Q),6@9-3' PEU8<-/"P B0@4BUM!$)B?1: @6^= N!C55%<IM0JQ
M$H @4:;RHI6Y;];%6T71M7V_$JO*H8Z,>BQER+VL\9E"@6;5[L<M&"0:@#.8
MR<2,IKR"QU@^P[B+9QSOY#/9:M@(U1[D?,9R]*:M\Q%IDH)Z";H>.:$F&(/R
MYG&0IP '=S/_C,UM$0/==)N&# \V@$!9F=L0>[S#&LFKF79=/&4^TAFA;TMQ
MX=$',3$/YKHV;IFN]>:Y^&"0/@FI;" UJ'C02M:-5,2TI7/,(L#B9HYJ0^IF
MO9X;?ZJK%Y/L$%E>?H!U5S)QD4'H2U[6;0N!HTRIX-#WS!%GTQ!$%GN]5H;(
MF9N#O"F#U8T(WS5/'W$,% %'F?498EGNFG/)/\=*I(1(DI!!@.IPR_4_UY+C
M$3C A7X"=O\G8*6)Y2AATI"3B*.G4H,;6\R$2&:.T:<6X->>Y'=K6+GM3W>M
M5J#X%DJ-O=T)[MVK-7\2=2YON\CCW/Y=7ZYHFYI]W[!%E*G29UC=F );17HO
M=N5'MDOZ61]&HE#\>H85@&_>Z.\'?9Z#_MMS;PK0-Y:"X"-E8JS\V1!9;\3*
M$PI>]8@*Z&]IK--*<GX$I-E' #9FFV7Z##EA!B@@V58().7;[HX'V67)&$'J
MPP1H*]/WM7_WMJQ^I1PC[&)5RUK*+JM)=G/WKF[/^LY422XD[FF"JR/3S,LF
M&3_N_XRX5\V&_4XJLYJ<D,^I5L -5 N@)%^&K2 503>D,#O]^WI"X@'4*2#!
M '!=347ZZ3-S=@7Z0;6O +EQI#$"Y:W2&P_G)25RDNJ;#JBXD#*L[8N>SJV7
M'7/!2R]:O<C;Q!8"<GB4-#^%\A>K*#15R.'4_DC>Y0[8L[R?*'>KT/MP3#T?
M=\@L$O_35F>ORL:_X].+3O?+!S152%E7!G#2Q"K,%.! 07Z91@0F/ZJ&P+X*
M.&854L9P=@X"TGS0U'V3(F1;/9DBS>-(%@&MHRDX[@N3/B@X9XI(W6VFX4"(
M 7_<-K (&_')H[M2Q'N"Z/]+1YT:2U'FL?QY'&5A,DZ4:=0(24X"^^J0[Z*R
MOM:G2HHR6:M =>,CR46 CT7^;07D2*EKGQA_YEO:ASAW/B:5(%$,+O#3_%$S
MT:OO(,UT<M1@V[!\63*!7V]/!R)/I1(7@?Z_F480(,/C_+[%=T)D%1JX-7V$
M$9)'\#%!OSQ"6),.DHU04C?O.=RTTJ6.'&,@M0;4CZHI"2!"SH-\DBO/[\DO
M+E4Y&=SR/=.<Z.J/ 96/6;&)K^3]DL?-DY/6]<T2(*D^",,W4VB$"!00M9:B
M$<V19XY:*$]T08;A*K6A!"6UNK<5PCZ599QC'BX(T\P6<WG62CA_C UCWML1
MEV7T-PL*Q'T+PQ%3LRPUM9H8'@TKR9"_T-:E;CB@HT:(9(6'U3AEM5^E(Y)P
MXYUJSENRKGMG>;D98"O9/.%S7H+;!47<CF]J/HRPS?"A&@&"D' K>+6VIA&)
M]:>_'3?T^6&Y"BR$Q#_(A554\Y'[JM2"SUR4'YI^%J63.?U,<7WAL Z=-WGS
M]E4I=]JD-1W 5$!:05GR6O@@/X[D*B )6%R=N_\D-DN*7VW-@$RWX_P,]0.A
MW2S#.YZ8<+E]"]L7_'R U+U!6;+.^U?]#',T=J[>?I:%WQ^&?']$_OWP_+,+
ME8NK?B.U7&@1#S KPL2-![,/W0W:FBFL%\$!IB,R**OO:E;)U8M%:7B62I89
MZZVT$-AR(\)6]T/"U;V=DQ'W5Z[F3;VM7(FH>IFY7M 1EJH[8DZ_Z+74Q=K?
MP.H%B_@IG3J%GY=Z&:X-BS P!C@W?*#*_F,[</"),#58F-H4E#65^;'7[V '
M=^GP5V-%_(>R8_?/S-UNC<[.IV5Y^_VGYKG+;MK=9XS8[H>>UG) -B 8H"=-
M2-V\@5N*FFL@+DE3#][:B<N\'-FQ^+$=<Z#C<T3.L:ALWY*[Y>X/Z.^KJ8&P
M)N2S8Q>KCV5)9 !* ,#9DG6O?I^.[[/@L1+2G8O!?HM-?O"-<KC,@9?U0G$R
MP.>@N-#Y4ECCL-3KUV7\QH>:5PNS8TN_7:97^Z6H)BS4\E/?_\R:B0Y[3<-Y
M?,8-M6I%77VV;S[@?INF6MV2:O,5\?1%HZO OEM?NEF1-8M)L[U(I%^OAZ%1
M,[27G0&7C."\Q**,8N9YKY*1C*6M19#D%\= ^5(S8H_H+E,.[V4<F!7@!]B;
MP@'!;'$;_8K&7,N6"IXHZ4U I(D\R%K%4@,YI!^P!=6L7720P&_=,P80,M[Z
M)W!P N#-GQ1I##CD 1]JXCP1CZ=MR79E'OQV$C U_[I#G$E@M5<+?+\%92NO
MUJ[A]CV=6UC?.7%QHJ^]]PX@%?-O0?&O>&/MC?#*\W95?T6?:C&I([6I6UF^
M#6SUYD4[)_G.E>O;TTUMANN^5T\B,(L5%NM8,]&PBG;6W*%X7M&!7^*4 +\6
MEXLXO[3JQ]?CN@9VS-;BRE)Y1J+6FIY4PXS'UGR?>J C>!(.!QXH%P&T5$"S
M)R9(E(R@ZTD*DSW9EFMV.'1/.!OSZ2<QKEDE:V(<.%*\7"T<-CH)V3/V-0J1
M*-;#7S2_!K^H=JN)5]$'.Z/_4\"]B9_R;/4/O_FIA'4@#IUF2N1(T9ERG^'2
M& X^F*WO"G<0A 3D@*L[8SZZXCU?:TS:V ?6)1M\@MAI"9*+4+5N0S\\R[L1
M,D3UB*O]DHEE@:\U.%)4S@(<_O?OBVH,_!0MU%_T"^Z<[+^6JD+D2 KT?"9!
M&P'@T\A9J$@F7P-FEXQ\DZ22Y%,),0 YYK,\915>EZHLW#0<R\$U<@Q7=8.X
MX-> 2D8$1#-2IS'&\&7)NP10N&R/)*_6YR;@^@G8,K2L'-7NR;!G]W%^#T([
MM>P4^/5UC=";ORN_6%^,-V5)^26G:8P;8I)Q&-#5/]FDD2,1X\)N!!&/0'X3
M_'(A^&)N"R\!DF[F[+X-0.TI4HN0?$;_?P5__^H&\#F[6X"XX#;)U13AJQ1]
M%+*G#CFOR4'3<.NOC5]5_>)/Q.7:[[1)$SN^+SR>>/9,W<;EZROK97!$TO84
M#.7A'F0:&DA]K:_7U<- E3W:Z@>]=((7IUU$DO$G4'47NKI]1"R0@(IYPJ"L
MIA+A&9Y\ET8><IE=!ML8\W(SWW,[(H!O,7Z%@O)3D.:WI6!Z/>$;V!U0X$G1
MQQ>I#O!FX*,IZ'=5BL_OZ_[!O_P -'!Z"!V)@=W@;)14558XMTFKU*/0)&J)
M1)%3]^Q@K2(JNP4.1INDF2-HRCGY=C&1$2>'YFV5=9DI%<V3#4TUI#)7U64H
MA)M2S)>K230OGO>6Y%G% WH=6CZ29U1:>@"RXI7LWRZ4QK2+&9YZT(%0?"7R
M_!WGV[9B@ZB3!ZBJ]SVF#D(?MZ7D)J*$OW>$(AA*.+.7F3&H(OBE=DIB[0\J
MR8_!IZ<H*PR!7#;BV+IU%^!'1R6>Z9\$EE/QR[+VFY]UX)X>]9;2'>!]U>/0
MV38>0#,/1;F)B[L6_GODHQGD?<6$^G\,EU=44PD7A>^]Z3V$$$(/ 4) 2@1$
M5-2$)@)*0$14P(!410U55,2;T!41$!"P)31I:FR(#.I- $5%![&A8PF(#=$_
M=G2<S#\OY^&L==8Z#_OL_1T9QC27(T<?J^84D-SJ%068@'9%H=&27.MBDWBO
M"9B4D:MU6+E\KA]LMR0Q )U=.FGNVL1W4^^F117M<VZL@35!VW=77O/;7C_[
M,MP_!&PIJ]71":LL5.@02ZL9Q7)28Y9.79WJG",V_JH6W(\^'DT8P5V=X-ZT
M,XZ^K\'FL=$AZ-0T+I'\?/_7Y:@-*6[&KOK>-,8UE&!Y\2W[71[B:-1%<[1!
MLF%YH8:TW<!H.6VY@8FV-/B34BW:D9]Q#:7N'X-%/5ZJ)%*R[BQB55]:K1:;
MHK_=P##VWU?[VTP(-UA9:54$XN$\#K2NMY ;Q%<&9M$M*0)1-2IS0H,X)PY[
MC%G1 1LBT:[P+,1S+17*_02C%U^D'*P+Q--4-4G%6'7Y&&R%:&4=_<9320,B
M#^TBF5 =PJEWZ8D>4XN-"_V865?+B>7MZJ=:0\'5Z#%3J\;2,? *Z<5GQ%GM
M)ZFES!9?.L([Y*6[87?<B5ZS:OUL\JE4TYN_%27N?^6YWS'NS/AR9X'[^-Y2
M?^2WC=[2QHMSS]ZT4AJ FRMGD D6,.A+0@H1FXW9I9);Z&,4BI;NF_]/354@
M8QZ#,-_I@<;..8*I;ESW;.CK=M]G%PB8[;5TK$O080.?DTEY"$*YZJ?54#RG
M)"7AA\]+U:A&X.409K[XE?U!X_,P%M,O4AW''LJ*FT^(=L1TM&R<;U3;:F*.
MOH;Q%'^[Q:?I,CZ@KO=)BYW)6KJ;H>,6Y'.XG=.M<9+R&6; RB/:0^:<F\"1
MXTVC!V_ACUKYO3G3XT0/L:BO*%SVW*_U[I"E=?2WOXA+/JQ!IW8N*G)Q;,W6
M(5AS)^V]_N'X)\]%"8H>0OO@AN/(T.D1N/:7QS);/2$35OI]:[ H3;!5I B'
MF3]PAPL=MUL:EE-\"HH9I=QMV;D(]<D]C%J0:/O/SP._:R;/F8R-,JVJ'U,V
M1RF.O9,F&1##5CD:#9PX BY <H568IAUR]S .)G_PKB3!WG0BXRM<F7OBL>9
MUJEA#K4ZL/H[JMP\9<HEK]T4-YD-=@FZP4\_R5=Z6IAB)PESZ<\"$B=2_@(6
M<7OA/W54:&\(O96VRZN4(H;W0>P$0R/@FJF'!O8N3? ^70IL#,@H_DM5!1DM
M,!-45/>YG#W%#]'4\,F291> C<SZWV7U;,0&R_[$&+X+V/UPK_:*"+"EI6CM
MWMI UXI..7#UXL/A7,1+XFVPB)B[D:#)I,=D >PD*1C;#Y IXC"'5].3,:,7
M3$_DR<'F^I'L6:V%9 9<Y1DUN>AQ2_7S9Y/87K"83,P15/D!]*M:]L!"N]X"
MR3YCFD0YE N"!4^Y7$N4R96T3^!0E:TG[K%VU:^7).EW5;/E V6!UZ O9?_7
M9MRF(G89UT_J^ I+ZT6=2/M41/HZ0:(+U:XL(0^K!2D__L9HS3%8"):WACCX
M&):O\VR3-*WR_PE+KHCE\[H-@YG( $6+)3.U7<$QEWQ)L5 Q01?7[?83P,U6
M%AR:E8%)7@,0=;DSJD:6Y[T3-M;I(%0TEUK/T(L(LRH4-E?$).F>+'TW(,"9
MO\]:K"@,:^48M49K@%AD")T#X]BVPA7$WIAU+HCL>L,KDD,\Y(SSD:THC(?V
M8^[AIE7@T)@_)YF=A TGDH6  C.GE\+3-0."7' U+DZ#>JB5X]F;;!?TEO*&
MUQD5G2SCOTAP^*?1C<&..,C'(@-6.\M*EKW^Q'%-N4]R$9<8DX7,W%S$<D0*
M_@.\2B/H!G;Y7( UT5I,GD*8.Z*%O9@_#'\FCD-DAHS^6X,=_TT%Q]]":RXI
M-IM0(/*%4H6Y8^F U>*B$NL:)?UP38L'FKLJ<E-$PKO@#'5I 05()[EKY33&
M)Y2>^E"WSZ.R;+_-<M_5:_(J5;),V^ 5J;@\=/GZ]BE.*B+*IFEP[%RUV+;*
M/$QZMV3%J()T_>P Y1>\SRW0EB*0:.90SY95QC7P#R,R<A1KKTN>FI4GOK=F
MLKI@15X\I1\I8+\GE;MXYSI4RIV"[6XQO7\',&-T<F=]98D$,+56"_"$D3&&
MB2!NQ6F=AI=_!CLW\@2F^4Y&/S4<9]:?[M 4-6#RW+1X_B9N0IKWL&7L*&9.
M\&/W0Y6R($2X_OTUVA_O=A*MHG+I2W6O)4U>4W8J\P^E1]781M7<@UMA7*SN
M#BWL2H%HD^'<]/?QFX*>.U-RZ,<W1#2.E3_VJ]4']UQ.[#3%YIF1!;'#86:F
MI;Z6W^<7>3Y5&+PH'[3+%R__F\+-7Q\HXG*K*E^5[!/H/";]TN7CR*6(-NZ]
M2<L33L2O-@SV^2<U31Z.1AQJ"ZM22XOI+6M><LJ?_;21K]OX+O#LG"]':2M>
MQ'CW(@7Y\0;;VB>$_TI+TM@>#?O271RR?X7GRE [UQ\9=CKI1].,^^2Y#BUH
ME>T,0TZM?]9X]EW0W5:'VL^XR./8[*JC:8_N+?F^\*E"E?YBX?,_3_TXX75]
M9L>;OE6G2"O3H;*9/%SBR ]J[I!K[!_ YTO%K@FZYK]5)0=/Y*E7A%WE=!YY
M<PQ7_6!>?LN?!Y_[;0W->A.L/_WK!/[*OHZP1],;_SQ^Z)^GS8#QSC%4[,"-
M#4N2";AWQ58N?T^X8E[Z8Z]=*]N6/E#P>:JL>%&57)WWZG#7MW6VWM\2:3^M
M[ZB2[/1BZJX7N[#_Y)=XF2V5BT7?@Y2+/Y3A_O[[V?]^?+]E\4E\XFJSCO;O
M3]J"ES%.A[\NCAFY:P5RGP.F$O#)<?#U"ZCQ*,IS0XO"?'#'T=_6DJ=V'-3S
M(OUJ#N[:"]!1\?>"O=\H!GWMP7]/',>ND^#B.:1.+2Z)@[EV_%$<^,'?<N#N
MR$_GZ-<.T7?8T8$-[#LU+RB_M&.)QV=,7CQ(/&IP[=@7V2H'9^7TLR-A[\R9
MU<=8]SD_*-;ZCW&6Q@\KZ9869<KQ<+&(+A49';$V;5.:GK(VZU&:7;$VOZ8T
MOQ-G))71F>N-PR!:(,@:55KIK3G8)DX&:*0#FA;$T>\K.2Y<&\]X3H:(+@;O
M@+Z;HF4F"[F\I";>,6MCIHP^H[FR)<ZXD5FZ?W(D3_EQN>75+9:KHD7T?J[3
MM2:G.USGATW.S[DNKYM</C8Y!4T^(/QWU+ 3T<:5U3S7TL9M>I(&O+3.J3)"
MR^BVS1XK;>;Q-GK$JO?.A3PB;>;G-,^_V40GBXH3XUZE#E^E1#NRGHTVQ--X
M^#DN_JZ#S=YW;!8_;%[\W&;)Z^8E'VV6?F]>?*K>=;992-7;BE@MHCLO TQ6
MN\YH1)XMODM:1*>B!&A;O\@6_]@$;U["A^P-"Y^0_V=R=)F\)?!L\[)(Y?)C
MMD%M+4&G;(-[I@Y4VH90\8Z-]T/V-JV@#B_J:UGYT3;T>TNHWE:\!&/\L,4X
M_'FAXKB,_HK2V<3&MJY:8A<1T!JQ,I'U_!CU.3V<&QUR=F.DS_#7,+NHXM:H
M"KNU3;:T:0[U#CW,T6[YV5;'SHVRJ82U=^QB'K;&/+<+OF G[TT,D;^(_"Q9
M-=DJH?+B6*\EOT+6Z%_)='8AL<>B37D) 6T)*WFAKRW7:>Q>S7U-S:E)>IY0
M(N:E%+>E5/ ^.;R^F\V[*[->AN6EZGO:-E_AI6G( W9MJ=4)#N//U[N\"C^;
ME/:];9L^*>V8W+%=+J6>2+>TS^"=R.C4.'+>.-;[9'J^<>B&LBV3,UU.9#J^
MR5YGGQG_1MJHR9"/2UDGMM>=V''L3:[+FVR((NTYL>N*?2)7EG?'?O?-9,;X
MF]T\4?ZT/>/MF_SO;W9/)L/?[7=_MH<9;_-Y[?)?]@6>[04+^?"OY,( ?F%0
M>Y$;O\@TI8#%SW]B+WMH7WKS!*,4?(SQ-85!=J%L;UO*WF)P7^?;O77JO5?:
M]SU,V3?V=N]K?GE3RGY-^_Y??/9P^[Z>]@.LCJKO_"IJZH&/;ZO[VBL_\ZL^
M\P_R4BOOI.@/7DFI=72H??+VX.3; TD.-="[ [$.^[>^J\AY5]OF<+"ZHS&\
MXU!%:OFZ=W6\U*KG_,J='4<_OCT\Z=!X)[6BL>-PS[NCG@Y'%G;46G8<(+YK
MQ#K6?N^H/]O>O+)#N>E=\\I-]4&;E'*'8YT=%:\[*N(W'>EK-ZF$.NHZ.^JF
M;2LW=;8Y.H1 73V.G9V;NOH<NTXY=O=-=Y_J[*K3G!J;MM5UGL9VJ:B;3X]-
M=]R</L-[W]78>?).9_<3QU-N7>=7;C[;U.G@/;0\H:MGZYR+.5T7\^?T%K^_
M^%FSO'+.);WF4EM7[ZDY?_1T_7%E3O^UKI[&KOZFKLL/YUS1=/4=VWSE>]=5
MO7[S'V/OKSR9<Q7J5EO._-'9U3OM<YEA7[HX+=W':8?I":G<?D?DS!VVO<S[
M3>XQR#%D9KNC?6YQVK4Z^QT5,\/<$])3:4-/*@<8)T+JTFZT.>6VI=TX-7-K
MTFDH:&;@2O>?DTZ[-"=&J<YWJQ,=>!9;'K:-?3RV=5U2>'[BW8"3]U>>7,O[
M,!:[)60)[\%6YT<Y'W3?_DIW_+#]8R6]Z?4#R]8%.S]$UZ7L\CD9].OH$ZA4
M5NECXR'OZI,_-AUV'-9D3H?(O#2V,W0'CB8P<<;62Y.T\.2#BJ:'$#X:C8^#
M[[UL+':N>?JXOXZ%*9!=LDW9;?&:=2PU=_^ETJT;CQS]2X\_K=]_>\K-/TY@
M\8XQ]/[:Z)J<CZDMI\+/;YW1D%U'MWYD##GGKIBZ-NIZY&/X3"6.+X3,80B&
M;69&MCQO<Q!N^\H:_F(YO.64C]F(\ NC].NZ_\$1 $9ZVJE%"+ UF4NV.?1J
MR.;PSY6NH\X?URYT7A5P/(\I[%*JEUB@]1"*-Q[\\I__!1:*'DS%6/*1ZM]L
MNU3Y\(+G+5XX0E[(I+,$[1Z+7ZDJJ[?P8\<>XA-7Y6GVUP@)W03+-"'V*1*=
M!>*<;O"C"\.%?O_+>!;8JVH^7_>H!O84.5,W[-N\_W;@?5E(;X/GEE4'"=H7
M:W43K:)Y[UB80=*75F:/ B!6PGJ#3R)<"D#.#6!+ 8QS0P;?GS]58?!B:,Z,
M8'P+@A7148>+'T\ Z\H+^<B1B15(4GEH99@JM5!S%O#%BL=(I.%K.X5@C9"2
M"P,P(NV#N$OMN;1A[G&(ZWK64>><>U;N, *1 -BF5QYRT^?:I'/6DHROZP!T
MMX9[6F/6@MCBW]ATR><,(H"Y3R;7S7[],>JK#[05@:-ZO$L:@GTJB%(5/JH"
M,&JL%^$PQI6(^7 =BI-?(.^?<"AVZ6WYX\@U>R\CODR$BX8LM3(_G1H*"<%I
M RUSES4"*')$H<O:K1./JXP/H\/&-6\@_)?+Z58EG\+O@S@^)O&I/FSPPW57
MOX;P<NC3P@8LW\=R7*:,UNR>@ CM![CCP?B(04J]_T)<:?K@.77TOM_EA5=2
M.(MHQ5@Z<.NI[%_J_AOF@W/NG[.ZU8*C(S:S&@<A#)%/$2)@W CHT XSZ,F4
M0<2A4D.6 +A>V1R.AE"N=F)"^!&9N0<"/?WJJ/*QS@7"S.:9#,O-<H48OAJ.
M K!"$-L"VPQKV*47G,SE1+&0R-$X#0*0N6;M<2&F-/MY8W-\IT9H6&21)\RU
MOH42"^??N+7AD0PZ(<-F 683(ER6D)[\F)0%$ *IELUJK+ V< K V-X!0@TI
M64+\X*U=,7 ;P1.C[U;SHH'$[4#=/,+&XQ:&3T%"-'  0+D, PG!.<;E4GZO
M$!4X-R +P*4TFFA%'=$0.TN$Z5;;28%X*S_;W<A9M*_Q?5':GG!^#8"K'!45
MJFOR&*)LF84NX^ .*8Z)%LRJ36 U<1PR+/<[)85WF0]:) C;8I#W?4(Q?&<;
M9]RU'KPR#)B60@1!D;/M.4H>@C-GA/T6F=2H,97"O,"+^#QD-W,V\*D:FV"*
M26"$% YF-0M378>L%$:460.R^(#PMX;"R17#T*;M"!:/7O54_E^3._/0N%!=
M<'JY<31,G@&V]G[Z!P%< U>0Q$C:QF#<>639P*#>8AQ^,BO#9P'4<G3W8P0]
MJ[9($>)=&\CE0GQ[83K*U_R(^K]GDU)>:%P(N4XAIA%S.6G;L>=ADY0G@>/(
M[MS;./1<%]MZBPB*89[:^;<J7 =EE]_%%2*7EC_&AAA\10;C__<#,QA,_>U#
ME9BP!TF,[7#;#M"J'-F=]BO_BYR< !B>1QB@[^%;MTPD/>2WX:ZH&HM1$J_T
M/[T +EHY9?@F)6(K(8^4D0"QNT7X0OG=;F$TO9KF>_$OUK#C^?/F]7)S6P15
M":$$0C,) E;*L61D@@@3AB$L$V'D"@$$Y ( :<3'#(#9YCYH-DPPAS(](3!7
MCSC9@L"PVAPO)-JJ@19X3@0"2H18-$P<@? UIVW8 *K[--BN(9,!;H@<S,M&
M10B--=L"\]M6"<[C!\_AHP=1@PM<L@!RA#%T&7!-\P&/R%R&X<N]?GDU<,Q(
M$3[E8&3**:!>YC(*7QY%L((&2#@BRH/);WW6/[MAU.$M H+ T7K*^+[(01P1
M^")R0G"%&CLG86 I$ SX/"K4 +U(CDZ&*AP,N>Q#B/$C.,$F4SZF9,0JQ0=2
M(,[C0%NTQF?+*K$30!SWL;0%7'[?,_DM-_Y*8 O&G4-^Q<!RX.M.<UOA]?O&
MST;^.98JAW2N*#[DT@L'Z,^OYA5J<%'GPL4(+@U&B2LUY]<NK;WAF@)P^@'>
M4Y^#>S2O[Z&75\X5W)<!+:+G5PM-<J]?&]?,2;O"S3O'+Q2>>WM;+  (XPV.
M!D4\#P3[SZ_5?I>B5M^S"P%<G_J T77&7\,_^>U(U,H :28^8H5Q"#(G08-Z
M>B\G%)Z:Z;5"KF=$#)I.?8D9AD$8%!;^8HH,!6P!V66VL$1(C;:@-ZE LA@M
MR>$!!]7"@^W85'CQ[)?-"#5:8@KX&EI'M!,L8 P*FS: I=)X4(&"SU.1<X7^
MLT.R _N7]/K=/I(:#*KFF<);&BNSDMHP>V)K Z5A*)=8\TF@62]P$PF,W>")
M> DI]-$&"V%L:27VT%%R[W.Y4QBTYA@J9N=SQS]LP+8U])&O9)Z(2688NP*D
M(0[ME+G8YJER%AC'5,8M ;[8(,7')9NYT9 G2#N%.9WRY%U'34_XJHO!'9_%
M')D,1 UVCV7B[Y:!):_1TB\\Q'HQ4#GKV(H46*/=D]0FP- C,E214.MF=VL0
M#.>8MVL4D@IK&IX>%E6Y"\2L=<!ZA#,D%:=]EH<TQ '+:N@2\K(D *:LW;IY
M5+W*W /C@[?IUGD2G?M7U)+G>&,&J&:_50-/4GQ1 '"'<Y=5 :>JBQK6S<9[
M2B)U4'TPMW*YX;Y E5Y4(QZ5"!U6F([Z'0PS;_=EXK..: _AB! 6Q]PY-@4V
MP&<FAEC X>4\8^"OL&7[@BI%-:$/H^">^TDWE9CU+$%&S:7(P41>6"%Q^;R[
MCD!;H7G20M_"!K[VY;5R^7^C(2Z!<Z&0I)W"FH5>NL^T6&X4JF:-!$YM"[4<
M36RC3@]O=+2AT5M/ACK[R,H:<E.U+)?D\*F;3W)WJ,5>/_#%LM":/@55<D4K
MH7AGO"U 43^_=6#NFY8"M##5$8<*2G\A@QWC]ZY9MB)MHKO((DDS)=NP<Y/Z
M&D%?GPH]2-@T@8WZZQNQQMT<>$W%S2A8]6&6JE4UN%SKNW,X"_0#S>&2:=@!
M6II$'%C5, L'.96NN=="J_/X:2O+291/%#4D\-5UH;->PN8=Z3L IF0,;^T<
MZ[/<9H.WJB@N=K^4_IX1:ZYR?RKQ8M=-B"[7@ ?.FP,WP%S9!&>N>\O' :S_
M0L[J#N7/%$6%6%6S_#_3_-DBV^ YZ\,,JQ]^*Z^Z<WN0ZRWI0_:)_3YIN!0A
M%%#@NNZS7+[!%-Y_[0A\Z=5-\^$>&;957B8Y*"$#A33BV;ST-OR2!2_GF@P/
M80Z%NAA2H%;!C5+>$GDZ7+9BU"XL![?F\18LOYH_:!04G@*@:-A1WUITN#@.
M7#N(A_>O#E%RY+ZGOOA30;VBW@X#D>.N,-<^9\/EF/@H#(05M",H&K4#D/_E
MI$!^@6LY@,&JZ ;_.C96./6+S/7:0%DS^%)!22^%,1Z*8FH]@C_JD[.]"< $
MB,P:6I2 Q3B"YH@%S*P.^SG B!V/8TB'FE$VO2 Y38)U^JD$[5M$5,^YE1EA
MPO2(N:C:A#'<R U;L@UP#9L\!67$-$$;H6*\G]3'K- Z[0@I@N"AALW**;A&
M/+'NV+=]&[PX3/<SU<<9*+*[=YL['>47X*,&&35*E(-<*)*#LC4P6.*FOD]*
M U#FPP&\XT+F?DUE,5YP![M ZV^:%^5Y!VFUKS83[87UZ4/8FU-89^#:/=.R
M,_6E0J8QO8CGIJB1*4@T;BZ"(WJJKP\7QC3T L01(;BBD,2VQML<BU_6G/WA
M7<QB U%\YVHL910@,U6&EH$ZF()&29IN<LM&I&!\TB#UV%[?%'-ZZZ+" (>\
MTO*H)Q<:5XQ/@(5/05729[G+!1@5=+Z*#"3NP]MB*,JR-C)26;7Z,B!&M&\V
M,97[%.!&B7H45L)5N(8' ;P-[/NH7Z,'2;IT'A<_A%THO]2*)K/S."*TAY34
M6J,([JF'G3TX!D=EMJC\\::C/(!H#!="CD.@Z>^D=DG_&-9-);(0%I$:M!*N
MVQG_*QF5>D,SYCP>8Q@]P!/CVA5PM-N"=N\=Z;(5":FH!<.B5L>'AO1UV:G'
MI6H,FWX'^Z1-U*45@HRXI:M[Y12 XRNH$\ +1KA8,O#"J;K PH^I19<)84)"
MF&(ZYG_T[EZQC6DEB!F.8UD& @Y)Z7BOFB:(T4M!"Z16D =$)'[&,)G24CN.
MA"'6'G UG\ N(XME-"AL2[I9TU,WZ4EU.VN+1R7[[F))JAW@NR52^O1^[1P;
MY[?V+KEN!\72KP']E7LK!,8RJ0:I=OM4ZIP4+M_10<IP/EO%\\&76X #F,7!
M)$[*%Z!<+<1>E<!'M[:0EL8O9QJJ##%UKVOTPY6<\F2^.N1Y#E]2#J?9(0ZB
MIW;$)>TKC?F(/_8[YQF_=@NH-2)9Z15A=]MMJ]SNCQUET<DFWJ>:+S;=ME\"
MMUI:I"<W1L%'$R:+!( -U)<[--_&Q$?!]9K[=F_!M/0NX&VR!=).DBET;F-F
MZ^9#A?(GE/:66)-R#;#\TTO_GB<-[F_C;^8ZLK?T'JE11!<>SL;O5R5I"D<E
M#MU'"2><TEN8PI8Q3HQ&9B?[1"I5P]$7ZXDC@?1R*,L@%$$:1,.M!AEAVF3S
MUE>4X5*HX<:4D15RFN3T&!+NFYRW>,% %T]'C/5*;;Z*#*Q:/NO8,,6Y=4@B
M%"P!;JS1M_-0>TJ; \L<Y?B>=(?.!6]#,A8?7)/ 95.$)_"=C:P[MMD\O]4C
MF*9".8%,)#\=+$+U!,G-O=MH#A_Y$=-Y-ONW(C1EY7ZV?W^D!%\)@?Q!QZ P
M8N1('& DEJ$@H&3$5 'LE& <PSD 3:  BL1%&+0*@)?A"! '-C/_XS(3X$!M
M4?[65!5 Q6O1G6( M;7Y/TC3H %!H8.C&/X/N5"G D69DEB ;JX S\U3E&[=
MI7P:4-ICPKA; N=;[Y@O-L0@9T3<C:C2G0[!H?LF0URJJL5>$ESN?^QX+DOF
M_52;YJ?IJ]05E0AL.;?<SXBPLW !'M:O>>K._8/KF;[Y&W$Y,_K/ 8[U?)!R
M'R03P6L4?F6)N8?PZNN**<BOKP37#5(H<!2N@D06Y$Z#Q;\**ONDX-)Z$+))
M\>R/^BICS%JCE8]1J+'*8HQ',$\9*"1\!PJ^YDO0ED5[351#<9)Q"%HTCL(,
M?R-@"Y54$_%!$SJNG):FH+I*X4,FE07S/"37+_P+] 7JBBPX+0<V?890.G$)
M3OB!BE.!5IY2B8%"2ULDAI\T<HG8/#75-$KH\OX4J+D!:C?SML95SG*@X5=@
M/TR+10"]@LP":,.I=5M#W.[;4H9=1QT5I%D 2Q8:Z(3-8QRW&1B<UB-D4V25
MZ@Z09@O1;X*<8O02F+9."R7X\"(Y]E)KZ/G_(*?EW.)M8%\[V=$?7$J'+I_R
MSVC"\'R ;&MP9LJ(*326QZ'=%&@_+5(C1[MPJ)Y05$40]OZ!@C09:F80DP%7
M]+0YW1&"TUHJE]-4?A/L@[<2M<9-?/(, IH793. _B5QP/"UA[.5H+D=(I#]
M/:T PVUQ/ FM[S_A!/#0-NPT28*'C^%&.<BQ2R<"F?D34 *@;^JF ARG&E=*
M92KHIZ:M?+.*#$=S[[*H6M)O!>I7ZCOT,$6A,$C9;/0:QE1KZ0K.+G(<R)7X
MK%12PA58NLA('Z&F)P$$,DBDQOF."PGD.#A236^24.N3C>A*;+AD1T0<>5SK
M>5]!B111\].->-:$2 XA2&WTFD/@@7 U!U.M8-0GOT5G< AG1>*X=PG)AM#,
MRH<<YRN ,@DROJ(-?[[?^:,M3@)P:S54!-WOY)8.I=$B 8J;Z& 2E]:+OJJ7
M#' 9Y%^P\7.*L0>*'0O:N),S7&!:CA [>N-N(;X_(=PA7TU5V1KF.8[\YHR(
MDW@ZCMSILT<*3-MJ3?X%7=4)6_(GR-'"HO[A$Y(M/,\)R$4VZN<X.J+ ]&8X
MW&OB-F@Q6]T<$P <D\'62^+Z$R@+PQW\E/IJ;I"#)_A0&H?KXQR:EL>_W1S*
M*]6/AO-63F(78BE9$]1?I5AS0UIGHIW%[0$=,D!6.:.<F!D*4IJ,EO 2%:>(
MR9+Q92!OVV!\RV9<O=9H%J;9AO31IVG1'+*'R,;B0Z_G00?U'/9Y!OE.=^3W
MA-D^!//\ X-CQYX!8I98#_A9>RQ3TSPS4P5? CB)[@5*:L*D<?\]5C[8_U!R
MIZ:)>E\@K^/BHB76-JFA^4I2B ]_]3U: H -"7>K"S+4 0N_\(_TGJ..MB[:
M]=E0G\E+656SLQ,P2<),:QD5]Q9L2PCEU'B>"G=PL4:D:E(TDC(&473!AG5X
M8TL]T_CI0=H5#GM6L4\X\>>8]N)#1Y]HM='>.R\31*Q($2M)B<TO(+.G/+=&
ML") GXB)@'U9<!2X+'49R_R]9\;7@&T; YKO&Z5E^;X.8J74Y)^MR5=Y<+9W
M<4I<WFUZSS$X&W+[:\A=CQ4/SGM&):QX]G7%(\?_29@K-P_0&HM6WHO@C2+S
M/IT/M2_C/KT7BLD6+T^0\Q0TG7 =/CO,Y$*8Q>KGCK:PF^W\KP!A2O$V4'1Q
M:W"X6>&J](WA-@]$7JN]O8U"]J]\:]H2L, OQ+EPM7W"BCB/-&+VN]<UTPDG
MUFVZT#^U9>6>S2OO"5OB5\MW;@ZX$Q%I[Q"U&67\D(,KNA"I3Z^-2JQ=LV/U
MBN,7/%\SUA75*E.^15ZXL+[LV_HM\Z+/94>67 CI,HJ^NWK-J]NTK0B6?;X_
M?MZ:RWZQF0^B[JV.&;H@KGJP_DMM])=O:]]E;[B5]3;COE'4@PB#[\%;YL29
MU/D.?PVS]HRWRXEWZ(EW_AX_UW/CO)R-"UBAI, 0]V\2LTB?)74<_TB?"I>+
M$?/B'%HVFJV.M7\8>]TH/JXG=//#Q/2<]7\_"-WV<,.NAR$-\Y*+OL?OZ?$,
MJ$L\P))5YZ3*7-ZM5*:4>&YJS=G44:?,Z-ATQG/SA;JD??="U%\3#GFF81AI
M:[)E4I*/99VXRS^LT(C"K?$<--S0L=+ .R+F-D?O]=/(^MWJYSYQN"?SBN*7
M&4;#Z'6<(!?EMC$-2=>5Y#_LNX=DO%48D%.W_L(#:D7FO&UPP:;(K"0-6;)Q
M6W)DLN_%D#5 !;IG0T&<[?U.V4?MMM!V^]NKGWO]8/4K8AON8)8HI';XK*L7
MUB':1*_YSKJNZ']6;_5_E/NE+NKE=^ISQB:3-0ZQRC6WYC'O*#+E,K17IN3Z
MP[1YM0G&D6F7C%<//=KUQ\6>8<_$ZX?RKC[:M>-]XM%X90H*][;2C[]EC4Q)
MJGP=^=?]> <LV*<@]4L@E?]/1,M .*"VJWZG#Q,/.WZ-_"+QV9FIA22'5OHC
M :H$^9RHY]I4GCFGKTV?0XD:79$=;G^H N7!(:/=<;'70DU*%.L4FPW.4LD(
M*E,+O+X8&J?M$&3PKKG&*[^OV&,-Q?+(4L?2NU^->9*"0Q^-QNULZH69_:R\
M =;N+J\\YX3$KMP5':\8\%GJSJ'@[PJJ-QGG 3#ELG5,D??&9<R' /T7'Q)Z
M\&8YU)L9LV,2YDV@I+^0-NS%JQM?F$F@CP)'8R>,EX 5OV<K:(?L;#Y3==J1
MOG'IPLY0[ME;(QSY/)KX#HR9L'78JJ9R+\FV6E/:#Y5/:]S6K$*G<:2D!=PM
M$RQMUSX;?FU7:Z;4^E)A.'IZ#N^WA-(.&<>O/9DODZJ#Z_3:!?I[\?67W]9>
M;J$]Y.Q*3=J,W-J_Y@=CE!,TZ%[UZ.R\307;;MI1/)W8^0W5*\XO[:B@+4%N
MUWU$W036C"Z_6N-,"<DP' ,>QH)7 T3M8B1!KEXIM,Z)%;4$Q%$^WV.1)?FW
MD7G@?\MI6%*186FUWP438S<9/UM)71+6+E=B5#^,O1?N;/8YDOJ2-@977TRB
M1%UWO2<)+7S,&@/ZDPSKML517!ZU/#!L^M#@F"N#2M8PQR2MKA/@1^&^.R.L
M:4DK(6AT1I);NZ)U=Y?]%M!S9D?HR"LJ\=J#QIV\@ GCI"?[_QAFW>0P*TC,
M]N!='5ZRZ'DG'R],_>M'2"T;@]?H[=(DF"LT-GX[C@48+GP';@6,8\LR@[1'
MWW,@J01EV4QB25!/6E%BX!-1$QFKP/ X-Y/DT@:M(RR"=DY!O65H/PX9& GU
M@R'&2Y3E+HBH(7ERR%<^#O'A/_@<A]BRF)UR6GR5@LQI(B&DT?'[CD7W&$)F
M@ %.H@7/7G2T1##1,.3TSI O#*[KH%E*H(0IMSX8"D=3^!)]3M"I1[E0B@+C
MB:P<U8()$LQO78\5!\HAEVWE0'4\2M_A\G5.4,5[*&H'RL>!.OUWOCOG*YR*
M'CQY:%JU+Q)ER!2!OL+,=0I4?&I4K +EPO&?KSAQ*M0A&A7%TB\D\Q3M@1(T
MI\I^X7)LK&).BF_[S>JUF6+>$D# ,;W.%7H*3C?S)#@_8!1MCVOZ*]3V(FH&
M";+DD .4('GZV?/$9=(\3+L+A6Z'H^ P6>DN9VW[Y@G1$@3#$GJF:0=.1R>P
MA.Y<X']/S,B.DQ?46LC']8L8>,)';/]%</X2%+&MW@5EW1> [1<'<P'GSUIP
MG;;W[X[_7&,+&8-;TH^9+"S,:@MD8R$-C(XMQ+(4*#]U[[O/ \' T+EKV(42
MJ5\95 ]@7!2X'[:H7PH:CT.&!<&.,8;YUJAH!.M=5KA0<2NF!9-O-WJ>SYMZ
M'YN*DIUGYSWJ.ZG??SENP[Q0$R3@]^MGD1QROC7(Q=.YCDD+SP3[ +8L2=>I
MBQP^;+]5F'ESE=.O8E3?YEDFQ\%%&6,J=,^2@7XRXSXA#]'.#52@DO;?,&D+
M;]JKF/8LVCU>8LH9JVFB,;3;'!3;?OVG(^#RA\)-3^C&>MC=?$M! >DQM1LE
MW90X3A+K.9=C9>XS"'#_W)'*+2\7Y=[= 1HD^V)?^]]1N=C-2'HW-Q?LZ+;>
M[<_\K@7Z\,O*IX-VIO"^PZ'!</1O &?M=.+C1<D8P&M<S],C(!];T=0T\/OU
MT2U*ZX(KS3[+T6[;]L)'_8)@T 79,?R6X0*0L789WQ-0*0?UH-\T2W<9XQ:*
M%D*XT7@)K"1C7S'X\(=D.8J_"=?;X7D'B5\B6I$F$4N5 '>:)(&P[!< N?6O
M)61V/IO]Q,T1'_!$:DWUMAM,04%;SV+TP$KO-'OFQ+\+-W)/W:&1 <]8$?&#
M)([U6]>;6J!%Q_P2SKNI[=#XM]>QV?R#UZ%NS&B39OZR$X/#\0^UQEO_P]N)
MK !.EI"; 0]=2IHDM4]!PQ@ZD>,0" CRYZ T^),+$A)O?(^@O<T[D_O/^EK8
M+V=\SRG],MO0HV]9Y@A&S&\5O "!)M_Z#<AH(?!]CL9>@BS1JCW *$$QV0&
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M';O-F4E&GQXUQKELKI_CLYHRK[V,?SKD*XDCH.]@'2;'84;0KK6#R]#,#V<
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M>!M.+^:>*L52"*M\-KD9= _K.W8CN4BPW*#%/:(<[?HWL%+![C J(D#!F>+
M\E6&DE)."&66[ ]SY]?;<M@I@<#Z/):#F*F@JK7^)&X\]B10@)TS6]86H+VT
M04!DSV%;"K:*:UE/$Q>8_/)+JIBJQ4GDUBY2T'>KT 3'%E=^;QPF:2)PG*UV
MW&3ID[6#S&7X<@:;VDO>?NQB9:CY%-6P'F^9D!7L(83W(@H@43Y7+I;>C6,Y
M@D\"_;S]W1*@?P\"QW*5\!K;<DYN.X%L2BBW\/A8K)X$'G@JR^Y?X(20D7N8
M3D8Y(UIN3!IE\<A:]\PB#4 _!RX_ACOL$8)$YRRT(>K%U14>-#V3['77TK*R
M;S_X$G-A?;#(J<9,4DAR2'D;A-9EH:J= KUZI,A8P"?9AED0RICT-3<Y"S[_
MK0%WX;$H#I&(*96O?-),]I=]PD%.%/JN+&K:+R'#1*?#Q,SZF@Z,RB1,B?4.
M/O /6VJPS$*08RPF8/2X<E+()JZ'J@7/2\#U:CVHC%1D+)](YGDYDT,"N]8R
M#61EA>=MG2_X"V:%])P[TC/E1M8D,]+CX:#O$?,23KSTU"V++I6@S(2@:*L0
M- A!:&.+0@2"6Y4LVV6&IG004_@0@ZUDG;<:17S\E&"V4K+[1#^"YP%AE(2W
MYR7OA?AH*;;@,1*B)S4)\1ZZZH4AVHL6A@Y3GJ.07 HDQ/[T/<BN;BK*LX;,
M>@'<M5J<K[\6E:;V)WB(UW?-T_K?FDPCZ'CA#&D=6G5)O0>6E1!Z/1=L%K1^
MIW[O??K9N,/PK9#DIQLQ^><BR;C]@\^T=-7>6643[O<(UN],28"I^WG#P(KE
M/+J</%YEW<L'4G>A-CA9^Z&M4F1L]S,HY3\01G?A@_-ER2GOD.W0F??07G=A
M_89N(<J<+II>,GQ\?6PG:%"*H)D([N&2UN6]_\#ELKLEI,+_8ID\A/'@H$HX
M%\!M8["+^"M0:I2"LN@%W(_&HW#1"+@]+I#-U[X*^[6FQ4R/+[,8*4*YTDT=
M<E*F<"Y->)SX$X.*7V45F.8JP-=#P<W#<]S&;(JC'ER@ORR0%G]9^E2? +G,
M"M$C4+D /PO1;X-/<A SX]*?T JE@'C3B&<BD# W>%7Q>[XD,OIST:[8:W-Z
M!F1TA,<F".9RDFX/>,_'8(W?"G&#<OL0J3WNW[M,_A_&7F9!.<\N[ISI>T'Y
M7_00W0@YF_8GG[$W_<RL85EM8!4ZMR[4S]69>0:SW8ZKVU6PW;#L04V;'WAX
MP_V_6(K1^ZX!QMU?P&AIXZ?Q"^CD??:K_)C'A21RY-/#J0>B7QS[-60_E76K
M_O1OG]^1N9;J]9_V;^;=G+M-__-6<,:^ZCV;&I-!_S[KBLJ=5WW>VJF',.,9
MG[)>RM^Q[EV\C+&_Z!WT=&/*S][K+_)876N/O"'^;T7?R<\$E7'1.RK.:]V3
MC[KB^=X3FT_/%Y2?,NG[T?TA-V6,=]\EO//BLRV'1^\[3QF6<^>9OY"9Y2WW
M^;0L: 'P&G^(YL__=^\P[<IST[?GGRU]T#GT<6^DLF0^X9GS@%'%\S."\NWD
MT-:]7;>NS)P[??G#M@-_/WU!3^[[M__C'EK>7OPB6/T_ZJN]!WY/S=GS<X3&
MLDI[_/M%: *.*)C[)?WN3-<?SXO:C\]\O[KAU]K;CK^F7*_^_/-JWHOF%\6]
M[-E?+VC_SMZZNNB?8U?UE].M,_[>_N9,)_]!9]\!G],_?)JN1_UK#Y\:V_./
M\5K[B+6_WL TO,R +S,,E!FER(Q[\[07X9/VVTR]8&X+?(:;SQN<PTZ1VY?*
MWY_(=QB6.[^5SS\O?W-=9C,ELV+GVT85S,?#%EX%I\=@5WRAB%_H&UCHGU+X
MZ<?N1?BU05[R!6\+;;)V94YLL=!NS-F>N?"'0[V.T2#=I(:<KKS)=<,5V%6A
M_OU2M&'6(67684_EUF^OB\T/%1N>P<9]+O:<\K:-LTO'ERP^5"Q]BTL^(;VJ
MA2P$TM- &/6+OT5RR2Y^HH1E<GQ[450I:P_,S)4L/U]2QE Z[*&#W[D&NP&]
MV1YAR5XO@^MM.=]>8VS%)5%OB\ZD)Y,8<551.5M[RP(_I7V\7KI4YA\_3+<;
M=4"TN$.]\F.3#L=' [CTQ95OC0X)O+OXF56!.1BO@@\/"RQ[=WH&%LR?+>Q^
MY'@"69DS'_2"";NUN-WB/9?F&]A*TK#W2S[/-[ 6QXS\ %J,"BZ=(.16[[H%
M^IM+\PVUHI/#.,#7(%<\EZYP_I:R*U47HUX&)BD)F[_M,A/'7$2 0 -<ZF!^
MX6"^L6##\'R#'/'<!6K?H1-@C8QDNB-; 4>*6>#Z(?K8@XHU\PUB..:?,RKF
M#^(,E'EF[3Z/\/E+R@J6OMOSO]?[>[9'/IM+Y.ES""4I.%<!_7D<UJ42:SB!
M>ZG!B;:#7 6^7TJX"N,$UW'E6)0$R,S*1.$&XO-@@DLE3JW%N-$9E]-1;D!8
M'N!V6G<@>1)*J:Q(@N-*\.0=PM6R@S@!XHS:B)HO65:'QW[<'B;0,1H!'O\Z
M[K0.LT)&\)"BJNSK2W;P7"7Q32K"13A2K:M5TVLS(AE[=.[J%D&JSLW.NL%3
M9Y(G(4E4P0B WW,7FFT_W/B3T4NOVS:)HTDSA(\PK@*'7BW$E.#*AHX8JK!7
MI?8;Z$N3T[&NBD;F&8*G$'7\$TFB@_)NT'=P4"%TQF8A=$BR\9B/V\/497D
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MY617[88@O'&/^%!NE L*O\+D>[=VB$1 \!QFH#NZ)Z!0._<".6L@]>,J;,)
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MYY)BZB00.DK5%7%MM!?"/H7=G-,96 ).A5\"R$EY>"XQ- P&%$JJK@))#^<
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MF$XZ%V> >C%$53_Q&IM5&A?O6R>RTIQ7Z//1BY]"#;3$0!(3W"\RF#NA&_&
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MC@"@I(M! *3<V>KA72=N*]*T=QR>0S5WSG W;L":+S=3I]BSR,[9WCQ=U[J
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M W%(B'G6I4@TZ;@*V'40R%/A<&*OC7I@EP)/4?@[>P%N8N)\SFJU!DC4X%G
M5I("OMSH5Z=OD]G#;D0<E9[GW 5XXBXWZ8$K!\#TEEWKKG'S#$"^ D]4$FHU
M *K!6VO<'/6"!L$9O\^ >+6#W=ET:P-4KX.L-?MGB<F96(J]7N" \/;004<=
M9*I(G-O HHIST@&0AT+#:_!;_E87* #;9I!=CHMQ8=@"\.U,(,- (NN8B\\N
M)JMPA2J0J.=E 5DY*N#+). @)9,5L7&75F7K@-W= );)S54@1MO@ZUSA#:8
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M3TR3*9&1>@MZZQ)GHZ&L+%*@/H,-Q5$SZ:;HU[FFANY$X179BOQNG*6I-C*
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M$1;S@..'4713<WP<&GH&)F:"-F*)J0I+&EC($@/1!OC17:.D]P@:VGF;R(X
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ME[;>-V-&/I5Y:"JK96I#QU2Y"0'P_W]02P,$%     @ R3U!5L PDV?QH (
M3+$"  T   !C;VUP7S P,30N9VEFY'KW6U/+]_4Y)\GA) 0(/10Q]!"*H2.B
MGH2 =$-30-2 H(BH$5'!>E* 4(0@($74B* 06U2N(K;0-")J1%3L ?6*/9:K
MZ-7<U\_S_3/>_<O^96:>9]:LV6OM>69>9'C0S(S_H&GX[P"  T$B =;70PR)
M)&,#0U,CBH6)J96YA8TEU<[:QGZ:G>-TFHN#HYNSB[LKW9/A[NWIY3N#Z>_C
M.],_8%9@T.S@6:S9<]AST3!V:&18>-2\B-BHZ/C8N(3YW.2$Q)3D!6D+4])3
MTS*6+,E<RLO.7):S?'GNBIS5N:OX:];FK^5OR%]?N''3YDV%V[9LP;;O &):
M@:1#0+H<6-@!+CL.K%#@<D_IKSY-6J$P67/:8-U?9AO.6F_LGE9TSG)CM_W6
M\XP=%P(W=0MV8!["2]ZBR[XERCE5 T&EO3-*E)R= V$U5Z)JK\;N5L4U7N/N
M5B4V#:7O'4[;=86W;WB)[";OP,V<@[=R#]_>>&QTZ\E[.[K&BD5B24EI6:ED
M9T6%M*JZIEI:7UO;U-#0U-#8LF>/;-_^ _ME;0</=AP^W'FXX^B1(X</=RA.
MG#AY0M%UZG3WV;/GSG9?.']>>?ER]<4GXC,/=EU\TG3YJ?*RLKGWV6[ETY:!
M\?9KSX_>>'G@ROC)6W^?5K^Z</=US^CD0'^_ZNI5U575\/7K?[+ZUI]0JV^I
M1^^,CMV_/W9_[/'CQW^RYMFSWOMO!AZ]N_;LP[-G&LTSS77-QUL3VM&7GQZ_
M^3KVZK-Z_..+%R\F7_V)R<E7DV_>O-5^_/C\P[>/'[7:C]J_M=\_:C^]_?+C
MZ]>O4]^___/]Q]3WJ7^F_OWOO_^FIOZPX/_?L/^!_[_\GW[DZHP5V;$9*U8N
M6V6P(F/UZHS93"\_?S]_?\#C?R/^=V$ 1 <D=PJSYLUG""#[\=<BIOV^$#W"
MKI%0O810<>=/[4FZ8L0Q@C9]&SLG\GE[1:?=MJU^;JV<>:[&IR[0UR>$UB,S
M9N871<Z?'@\EQJ817QMW"ACVJ:V=Y:/39U=Y;9_H=W7IZ]S*R$B:.?K&^?CB
M]6_&?4^-.\_UFFVXMR")YK*[>K?/WNBSQY^<+_SRYLGULR>>7<9P^G8QW8KQ
M?HFI^Y+AJ;7U5MZ94\HVQMU:E7=EW3;;T!*C/;5;.?LR7K;NF^;C,&MF^Y"J
M\KXW+\28_NK*),,@\K7LT^8KU;5Z)U0:XYHZ@VE>QKJBWQ&9U=1-^("RC-N?
M*T>#/_L]F8;SJ9R<S=/=24E8H'&\?<)?OW*9H_]*\;LG\V=.Y< ?[X>%,P33
M%D5F,_Q4-)QA(8U#,O))CV]BQ'ZUP!FN0[[B\GSI\4N649=WC)?8;IP<+Z65
MT"<DU#>@R+@ZQ5ZT(U^IX3CGJZ1BQM8+Z(!CWP]7/'GCE'W:>KT,GWZ#];]J
M!O3CN\+3;&-T!\JG^?S2)!HSZ?3;Z^8DV_?G09]D_>2'R;MQZ_QFK@LU2,3_
MDVWHZ#_VV(SI=%O/[O[*^E##&)].<R-_E?$\8Q^SVU)CGQ?QD>8SAG=?Y1=-
M?NK7-_8:"K7;[@3BS.6C\_#3B^B@R$SNX1UJOHEY36KN^EDP;XOM:V^1H2Z$
M]H)#SO_:^Y2<]@/M-U_G9-]O?*V&_DXQ8+'JW4F5RY%W)1N!7K6K+_G D)%_
MG;^]6Q'06\I0F]203*(1OV+R9H^@-8+8L/@T8]_TQB%QG7^VR&"UE>5;U$=S
M:&BZ=TJ&:$?L2W6HHG-4(S:>:=OVJ.&TIW&H<]LP4X$6H;=;E/1/O% .1Z71
M8[/5BJNLAA8.AWRC,Y]HMKXC/W^H\RN*<VL8H!P?\BFQ#KU@<A=K03>CXVV,
MR$EN&'GZD0DQ.<W-('1]SQD"/;37:]4_=U-6'/OG7OJF)UQ&G!(+ZYU;^L8[
M?+Z2VYP?\)C6P)BGZ:&QW[WAG37JW,H.U1TU=O8.'6I[P1,9S54S.8L2!OAE
MQOZVV2>B]5Z"H7:>/EDMQ@G,;0\6^@1YG^6<?ZW&&?I>R1/1>WLIXZQU2(3(
MV-/F^^EHP:V;,G+UZ%:\W3J:H/],Z\/5@6[5 TS'V-9A#=Z%V=990$[6K",8
M1MERCJ6O4])*[S_>]/'W=TWIC$LQ<[H;26YSYKW@CU3_ D)-O3H+<:'(X+'D
M_'<NXP,F"2\N;@J-1)LX^,!B-Z=QF.1STSC)6X^JMN>=,56!R1:X6U;SD-V-
MO2:'9$%S"ZI<>D[VFC2K\>Z?B'1Y3KR8 I4QD SX5.3@.J%SN>VDAJY7!'WP
M8HFLM7^+=&2??:;-&G$=]>-ZJ!=W+FF\_6!0!AP@8Y'SI'Z+K[4+'MGLMSBK
M&O3:_*EBVS71P%"RU<Z_G+-<'_0?Z1NM ^8<\$1NV_?4!=AL[#U9Z2^)',[!
MV,^G 'N?Q.(C^4S\;61HB>5)CME.RBE;*;OD9$\?>2OFGJ &UJ*A['-Y_!F5
M7WG+3.K WQ'&>CY+V/RV(&@#_C/1F3ZIYZTH0^ENY5'4&6MCI2S!;AKN"']5
M"?0#9T)ZT3R=W M[JV^._)366$O=<J%Q9YO>B!NY:5^:QT(LG'+Y.'?M 9J\
MF_W%PUO/BL8RK]<<"NQMFNGPPMZH,(6T+5.Z-S)FG*#39338:K%2NTZ'+?0^
MSAC37VGWM==HO;1QI.X5WE5[S:1383_W$_?XS $@7:^BURXI V>?M)SMEQ,W
MU@(0YTQJ5LK5+,,/ROFSWEV#?V4)R6)N"S#XQ<A_4L"HFQ+-#9F((+7VG_C%
M);IUTQ.] >KT+*YU_&+!_@(>TK*;6397JR%41>PSLF;(^3<8V1Q9;P3;0B]D
M4JJW:?A0VOVA>V=Z-LP(KG,@\Y2!2UE7]%P%M6;9 &YZRF=_:'-ON+&PU*8M
M' X/&J(8NHLLD2CS)$DEIBFEQ/]2^ 9-]KMF:G'B]'$"J<>#+/V"LZI[:>P:
M5<Q.OJVG\BLUBPK2O2,[9+7<;(.[W/YZ3Z[41,_6H+#T9.^9I R"JN#*>CVW
M#QFU?+/1.=^,F$C#8MS;VTDQAWU]E="ZI3P]\0L:W(I!Y)+E;D-?-8JFE0\7
MW;_^]%N/964]7SS]EQ:9QQ?_E8]%S--I].9-G77^\O[$CCL_RV8/9.3@FDY$
MV1Y8$E/'R#:H6;MC9]^Q.<"KK3L4JJW3XI<:A :9SXDEE&9/Z 7-R30L5#]W
MG%RT=&XEYY+NG^QLM[.E^LF0T7I,@7K%RSOP@T:V,\-*D@5ENI&&#I\FW+1F
MF-A%:S/9)GLP_6%^&7W%T&%FT8G=9X=?>FWY<9UG>+KQ:LSRO/"VW V1AKIF
M;Y\&_SN#-_P$CWGW/%9<2+IQ@Q\>N61T^._ AA^W,,,NF5[L)-OFIUH2U]5J
M>6,R?-;/V]*JKC;7V-<S]LVD-^H>L]YL?7UNP\,[2_N[6F;]?CU_5?"=!CO_
M/9$[W\P1;69MV.Y_9*GGVSF'']X]?7/#$=\;;U/>]MQ3AK>>6'WQ[=*&X-&+
M+@&*G>_?)+IN>3#X]"_%NF-YR_7VW+I5<N9,=>S[%8O^O7_GYK>S!]_GK5NX
MY['FRL9S5X^]YY^P>:+U^GZ^:/'KS8_^?3JU9-6^;S<^;O_WWV> 4;=2+TXK
MM/FE0>9W]UG>U);,^C5.J>X><(W[5+[HUP3U5O>5P)N?JA)#_!N)YU2Z>7&?
M=^W9^H(V]]S0PNV?ZT[_>LFL/C><_>%STZ-??P>M*+JQ_N:7?<^WOIICU*-.
M-OQZP.;WY%Y6STC]DJ_ML[;][=,H'CT<]X]\T>\W*;=Z1E-;_SF^Y??;]/]Z
MQJ[.^4=1^_O=XL!9#^^OV?#7Z=_O5PG./WX^Y_O9\Q<_9%V>]73P^/>+6RY^
MW'X_6(.K_J?7]-+[TEM;)@:W/]LZ2_=)6KWUOO;HJX!'SK>&EI-:7K];<=UQ
MT9>&9[X7W3_^"-ID]W5_X+;FL&K.R,$E_YPH_3V9./W?NV?W?3M^==OI]?.+
M'CT;'#UGI'NW:?Z_3_?/^7K6]=*'VKF_;MM<_JK:<>E=PZU?]Z)W_-Q[6??9
M6S?CQX<M__VK,;H\=76^[O.>_WY-SK_\\_XMW;?S__W65E_^]>K69#)M0/=U
M[ES=Q^K_?C^;/N-WH(>N80<^!?L:B,&-V%I_)$<)K]; JY1PGHPDPA#+>!*&
M8>7VR%YM6),6WA)/6L,E;3I)<I38MP#"M#O$M4RLC (W:RU;-/#VD\A2-92M
M%D#&B E=D*N&_WT%>TD)J[F60B6<J\8JN)8[ <0J0;!(A(BXU"8:7*;PJ. )
M'O<+#4Z2!*BP[!!D0 /U^8 Q )K*2#8R2,[;\4T/@:7$U72*=42IGS>&*X0R
M9:1V*9#-+-TX5EP@*+6,+\6H$EWQ&.60%HRC2RQK$%LE4<Z$#;0[RL8H%3R@
M0E.RB4YIP8#$[AVZ%9*2J1VK98"U!.LL+-L]5GY\JOP(@!"!$B@>(<E BY12
MG(IHRQ.L959(ILJAVP0]#+2G@61FL9P/(C30F%]BC@J;,5!?"TY7 N:TTA@!
M2,1 "R:(2 DQ&3N6TL#>L;*^R?(CO!WV*%0Z5GYDJJJTHUQ46-82 =G3JK]*
MJIJU@+E&#$Y*/D9(CM*EDV,4>P7X):7Z%;UZDEK]JJ.<#U1^.TS$ U+#5&E/
MD.74=YC&DS:H*J)5-1OBRR49.U(IX,9)T!,U#6ZD?FO0@8O4)?L4_OI83<%)
M!.&1Y%SX[P[+)B7@G6.Y5PVDJ:@"+=!5Z"]2 [R<'3D N"V>A-!*UVJ K0=@
MD"N&6!"10I+S0,](X>]2D"H3M4M!4T4=L@[T=*.L0(%S$::9/-"*#=$5_G1-
ME6@=0E1+!S))>>?\8\_5M?-VE6;L6,,MLY< CF7^J5K X!/HKB98*,%B&6F7
M$G*2P#8*D*[=!1V ]ULU0R<1!P5HSZ];JP&M4,A[#-+1JSRE3>UJR$H!+J-1
MFI30!@"B2@DZ/7@%#:8J0 &-PL/@'!DXC0[OOT98/T78WTF8:B Z*4":3E:<
MJH'=,=!)26SG0@92D"<CK=: -EPHU(TB4H &:I"< N8I0 MM*10/VTC!-+[Q
MSO_I-D150#P)0M. =LSB%C70](#H*MLWE0IGTF!+!;BSFY0F!?\NHRQ7@-:T
M%BB>Q,! 5TUM-%'/3@DZ,7>U\"$K)>A'I^SK!!EJP3X%).%"7C*29P]H)VTY
M>.X/E'_6;T;>B \H(0D?6G8.LN!"*R@@;^6.U5S02+%7+H-M9:";6M".'715
M0NN[$7LU8*V!15K@=2JX%*/D*4$;99.E/>@.2!P8I::T*LO;,$PK>]M!VHL!
M.X(PG;GB(#3^ARUM64K0EGM0SFV8)9$=>5#BJ87I:&NPI-E**K/O@:R58'JD
MP)8'9G A5T!R1$FX748YU@2^*VIVDH%S&90U2H)("EY[#=NA!W/*]MA@^^4\
M>)H2=%4+UO*.6&G$(LT?! E;'E"N_H39/:40B+Q)/2I7[RFG0!D*Q$H-V '"
M>W+0G4'QHB&IFBI.!V1&@UM0R(*V%^HE\$FM E3\C7AT6CGH@>UHYD(V6G!(
M0C&1DSI>'T2C%*9IX(%K! L>M"M"0%/L"W5KY9?O/_NCZ7PGJ9Y!64NK$DD)
M$@682SMI ^RQ#VYUX<,45%?1KH2:%21W0 ^*:K/L)=*E>\)R=LA[P,\_3_&Y
MD 4&.:604K5-JW_"5"U0F]LV/E3J">BY8"#G")&F!FPP>,L0:(4=RZ:=V*OI
M"&J&\B3V=+?Z]1$024VP<ZL7H4 [AI#4L$@-6O%*13(@3W&4*CUF("6(E 1#
M-2)7PD0*C*&0D9JXF@G:HR*2[*_]UT1D]7X)$[!3PCD\8#1WAQ,/<-? J3S
M@@Z1*-"$BD#1PA@7S N"#9F(  #SQJH]F<AB)1"-@$9<>*VF^P@7-I!!(@52
M,PMQ0,%_#Q/3U,!2&3&/![AJX*72#KF.UKV:@CCEEE8H@>\_8!,:]* <2)<B
M/%E=V,QB"\7>M6H@3@+A982U_#_[$=CSP+5*F,P]O%0-K*8AQQ^66&/@6@ V
M5NQ&#A#)7%C$@Q)2228HQ*?!L.RO# 6P@H+0N. 1)9'$!5UD<#L3=&4BF4I
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M*5Y:3'",E,%KF!I[G.U.\62"_N=(%I);2#S4I(8F;IS<M@A&F'4W=U*,*(A
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MDUZ6R#[F&&90V+:T*/$,_L"\-RJR%CMA*C)08='C"&$,&>'M1^B"LK$[9+[
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M#V?0B*  :-I<E:R"#KRWXM#]:W^4FZB!H0V!!3>PG4&IMC?B4%Y;LN+<#9I
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M>Q#S1BRX$$?LMA@!Q!!3 @!@ #W 3R4VY6/.3J)MQJ_L=-;MS"VX("E&4W<
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M US- >8,6>N/>:QP1EKZ/ABI4_[T)Z&38K*6;$X-^4KO.+JM$MSQ;%")G?5
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MP? KDNNCAZ71,[CW3MD5'887 (*&OY1 <&P3P4<!/0]Z!4[C@K"+9L9N,8U
MED59Y1,]X"YE.8D988%H:_72J]<NRE3^P02HZF03+H] N!0^]%(,&C+")"[W
MV)"96=L<4E [I)*13 N4P;:%J594;BI\5+!+% ^$=<@[< 69%&*0@!2#@I/<
M$SZZ^\F]Z;,!\$4="W1F"B"7SETSJ#)O\PX9C<(E5=?3+IN/*1GOWO8T*V1@
M[A8@/X("6J2LBUPD?<2PP!R?1A @&K<73SE"\J=K3I#X[Z+(LG+$YEV9I$RU
M07Q/ N?)\+0(-.K4]_L$*D<_<%8$[F$?#(]U>VZZ]F9!JED)7H;AJ5ST)<P+
MN0= @/ D,3'9'O)=SH8.U -(%-O8B(I!)A@*A=!J KE-)VM2!W!LA= T;X.Y
M_5099PC#7B^G@;:KAB+.7 <>IF.N?.L!@,8$B70>KEE?D(=*W>*2 )R[Y.1F
M16(JH6"&J:%$F1H%",SS4,A#%W4BZJD4HW3QH.4A3_ >/,BXT!QOE,(B4K5R
M3]%9S[5< $E3IHD!X2EZ4"\>U3@:^V&$:W/T_\ CB%/_#(#+@-4=;TPXZ2CD
M&"3X'240D(XJ(:KV/CZ.*I%OQX/F(<@"EB+-$)MT,&.)-M=_N5T>K.FO2"$X
MV*H%YB$:5\KX[>)9HWLM4C"<<V<U*//-QG9VN>SM5N(#NKV3NS"0@8!'CK!!
MN(L0U_66\SVWK\2C+D.,*5H"PJZNWQ_H;;I8 [5572WVT)QT^;)K^JVYQ\L.
MEKY/^0;AK9U:RV:H\N2Q?C<L+BDL6VJ9K^1!8HL>14-:O;W^VG1=F,T2YS-G
M+L>G5B!L:IN.X)GC:\I:F&EYTT3RH7>QMOGMP-/^!:2@.B>V7A'.\N9$YT#P
M15#"%.D/5\WQXH/9DJ#3L5^+C;T*P.QFYK_G?6"DW"E@[N+)F:Y1^.EW0X/U
M,W.>.@3=2K_7#<X['7CMC??G8I_&5M.<L?M6HXFFK"R0O'0%SM+I)<R]X459
M^I%[MN0FY:9HSL8GCN<3$_)_BK(<,M=9;W];?Y/0&W1I9?/U@:>LRU_V.691
M4FDB5R##'4W_;_N:J: W?H.OGMRB=N\MH@EMN@20<)]+(>O^-+&+F$4M@.I0
MVTE[X?LB-FVK+3[_R;M?3U]?8$%G6.ZZ _.CR+SU78OOK'YJV37BT"+X^P++
MHI(5F=/WK'>IA>WT505"ZN-]L]YS+0KV^:Q;XKYZL6'S/ ?R_@LM1NQN%N5O
M\<H6EL<V6@6^;VQ#M4M+JL78+58+R\(CO506XQH1G]S"&O KUI#9^HV&2-4^
MB@.'EL6B;EWL)F99J)X<PP3?7F:,-EVUX>QB^$'?'URWZE9:YMRL6MEKGWG?
MJDZ6--O!*;S5Z=Z )37=R8'=$MOJLL;!]6'%;B77M:25SJ:!!<_H^QP8AUH9
MQQW<S[2Z7W+PN-+J<=/!L[ET5Y?2IJ#7JWX>/4YY^>X$_:$MLR3!Z6$+\_.$
M][V!J\[+$ODTW2KJ,I^1.+\Y!UT3EOD[<*Q&6YAQ!SM2#A;Q';T?1KMVH_&+
M#SJ=2J&W+BN)>!X8YQADYQCB\#S XKGOI8,S2PX&SFD-+A\*Z<GT^ZF:O;MT
M5M3=.29.,]@.OMN7E?"?(X2VJ ''.8PVOV\'71R,$"E@M]&1?>J*Y84H5E3;
M&)HUQ_!%L'56A*%CU*&VJ.-.T6?:HB\YQ5QIB[GI%'NO+?:I4]S?;7$?G.9_
M:YNO<^+"V>ZZY^'"@R[6[5R7]@3(,<'N153 RX3P]J0XY^0%[<DZ)T)SJ>_3
M^>[YT%[TI<L:9_98<8*PG5[>OFS,*>W*A,/7Z7%#%:D/]5V196Y3U^<=USE[
M+'=VW9R==FDB[4UVW+UVNF&?S='%+3F0J],A%S^C<&:92[-P452F&_-OYB[G
M57DOQ>J)>7W$%FW:4I>1>1F:FO21>:>6T>M9D!^LAR>@PJQ5QY]?:HE9KR0N
MDMRPP)XNO[E\5L#5G_5.JW+8%GR>SRZ@X,*A-?N<_ ,(KEF"RXT"8-WR)[2*
M\."7;-@IY,JR;U,&B9*LP"6'V<>%1!JFY_\B(NYPT<^_BTQ>1HR]+/J\;+87
MA#^ZN-638$F_PA#WIF++.7$<G_+>1_&';<1@&/TZ(R^;99>>N[L/!\1M-ED6
MDC"00(2+SI3HV7/6MAX.MW:=,4<3&G4W_Z>^C>[QL"!\F:$_L"][PL$/*Y=/
MMM8\@ST ?$?'ZZTK2CE8\OM#15FLY2_^WFZW(J@OT@W%VOS:CF_H8VQEW<P
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M1:7[JBQA>C8KBO:4)!'X.D!%^+YF.6:Q=6__&663IU"_ WM<#UGSV5T^"#\
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M>C$BYAI3"'K(U=MK<C4O2RO;D N_YH45N2Y7P!1BWA'R)B*A(<Z6]IY 0.N
M;CJ&.&@IH00B(2C8-5BSUX,9,?E<[M+6.55OHI&%M.C]"9&IBHL.1 VI7;A)
M&ZQ+G*<\Q+::T]I]5L#&QSS' ^%4^#.N$QCC=L:JR<E:839AVJB:7V!DCW3
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M11&0O*W@)EX0JX0[KE ,/[VPA!%G##$'M'/H#B\YQ:K:.)?JDEO-=L"I;'D
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MK+9;8E[PX:R_.U86$Q?3L4W//A^.+P'&%^DPH-N*^*]2OJ^"0%^8>2U^L:G
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M]RYZC$$H*/]?+GIP>/Y"*KB=)"BWW#]V^ 0%OIK_8%9]:J/,XR8$7Z<_N6M
MW(L68"-0!L-[MJ2_\(_MMLP)5D:LO9&/?J(;6TX)&MOL783B=-:71IO+,0!>
M$_ 99%>_.>+*KO)($B/6TF]0TIZ]C7,X2BVMY1[QE/;QQ!(8K5;"L1KF89?J
M>Z237*2-1%W Y9@)Q=Q@H?MET]@9'XO*;L-7P,ZX52'L;@]@=WSJK69 F[S7
M#0VI/J-;H2]?'E.KZ4"<AGKT=U3 <_(."Z^W[8T3$]9$CE)>TX,L]&<N(7*N
M52!,JWGQ,)RG]5W:L9\-9PF=^).B  3I<7_-2>1[V F',>0CH652AHK=V?ZQ
MCA\T?FQ!3UT\G')T3^NB;'\6I=CUF2$P74#.&E$X9GB)P9J&.@04*^JO39._
M7[1B&M]]1J@A'I<I-O-QX1\W-HE\TSQ_PQ(.4/0";[R^H_BU C[V]L/!/ KJ
MK)!<=CVYYE,XR_417Q  ;(UBWG6VHHX5UC)G$%'7/EG^>'9FV7:A.;7WX]8-
M76?DDKM[>*ZZ\PY*XZK:^+31++NHU+\O*Z9^#;RQ_6_KZ7T/%^R61M;9??=B
M_0W7S%UTO8I.K'S0\7;=U3^5_ZE'JQL=:-UB_V=GM-VOQG\K<S'K_F)+[=X-
MOUGZL;/I[SN7*[^?OI%]*KRZ_/[#E>W7US!_OUFW^O?!OY5W&PY\^_U&]K!I
MY4RD[&DD(#NU%M@;Z?"D:7FR"49[*NN_"1(IRP8<4)$SNYWS>S5RI2=2[M0;
M9C9%;B1R48F"TA6C4CCH@TWH@V+$S)O_5-Y@'W$47D@5;A=24#!_[(CB-\X:
MV/2:OQ1_+!6G/*VD&*7T@Z-D&H6C32N9-./MHI0W4U4PS4IVS4HAS<0 *B%C
M6F7OM(H/5=63JK:[F?1#3&B)PLLXQ%/3JNU1^&-1Q.HHM98H K]9Y?PTB36]
MUCUJW0R56$]=%SU-E#6KOZ!J[HZBK6W1\*%2S#5I;T=IT R9%JT#B]8,H9$B
M6JB&5!W+F75[6RB;9V@'6PZGC6@?I*T['$W>W6)0'BW3OT1;/S)C-!)E?)-*
M+)>8_*!M.,S8 (NA8V9-9"UTHM9&Q=G_FZEIC!ETW'1SC+G[K+E/C$4Y8R-K
MUG3'\0TA,1M28BP.'C<OB-E4'F-=?WS3L5F+^EDKRUFY[%OU:6 ];W;S,:TM
M1;/F+[3,WL>8L8ZC.KG."-A$ZZS=9RV[1S&VF[44#=^R3&,=-K]M&)2B4B)1
M 1S#N2*G'TWR[5+8BS?..UI=/-\NN[7^RF_],>:$S6@%_S9!Y12'*FVW4QRW
M*ZT8#,<Q\:U' <7]\+I_C=I>9UN=(\0>FRG;:!SVY]:MY9"\^G:OB'5L0QT0
MLQVY>;M[1*3+M[?06LI'!5F;VPMMUY1W*$L=S_-2%^?M03+A]J!6K-W;D+/;
M0R^]"QW9'G;[7=BC=\*Z=^/8LI!R040((I+OB&#I^#S3.02^_V/<%*7X_NIT
M9'31A&'\V@0;W=LW4,X:\C$A[[>73Y&S 0A+B&YYS1K@0;V!SFPQBO;>,0,4
MJEVGN0;H4B9@$<Z<D79=T@T&821V;Y.V0-+_[NUU8\]4=02&_<+-T!&%A:*-
M6 _FIU1CF<)*V*X"%#P?%9;&AQQU=WBR==.8Q"3-&HD2$V 1TX9OXBI81B-9
MT1\0I6!]\YVNJLA=M]\Z:+]0!5AJV@RH5'"9$N'.8:29OWX=R]+\>#M 5LEO
M3>;68F&H<2R\:P23+:%-'%/M*PRPNR]A(LA)Z&BNY%A?A0>=NR=^!%'"E2>4
MGPT"2$%;F])4[O5RW[9U(*B.5!LNIE?R(U: #&,PA2 B%I2W84R7,>0K&= ]
M[\=#^B6Z)$C$(\4.[WWW!K'TQ%'_P>-IUYOI,%H:C'D#4MT_? <-8U6.5(2=
MV%T]O&V B1 P]8Q8NA185P.32#C&R!Y1+>E@"CYLR7!3??+I2"V/J!'W5<S$
MO0V1QN:[J0A)\3R?>%B8$2P2RW]/'2%Z'&88P6HLQQB53**&'FN0N:^2E\Z5
M5(SF[]X]K*;S\IE_X@G/,&)\@DSA*ZKFO08IC=E)8N^D?,Y,X9'&/1B?A+KF
M (_+93?S3E4R;@$CL.X15<XAC)'B2(_;,^G[,N5MT.@:4B4[+_'E*5=)%UA1
M'@MKC@7Y2VU]NBZHWJI]08\$XY]TMW-KS=><C%;*KPS3E>0WT?W(YEPYKL1P
M@(>(Y6%<&;K 0S4+QD]] -W+E>($1+I$C@)3=95 O4!7/M<XN:"N6W+RT^C)
M!! 5+S&,5:CY?'1!,)6B78M\ZP?G",7?QREA[KM6'I_.<@L5>.FM/*BO'(8+
MF/+=$S0-3UQG4C0'0)<PJ[[>J<MDR@/\8KX>8H ASV!0^WB(($;6#5G![NW#
M&5%?]A;<4>464++KY-.*%4XPID4@TX.[)W-D/'$83CE\M;TN.$ER3%\@1@O4
M8ZLB/KHC-- L;37U"2Q:S",E.4>+Y"\ZLY]8W2 UH-N% %D",=_ZT:1H+VT%
M6A)#]Z[*C"<;5<DX#F-!&C>>.-U'Z".A>4=Y;0R*"\G->9)17)__9\?=WEYB
M0IE<.2-#&.KA>0S""/GD0U@119^!L6 \*#T4$,]\M.!6L(,5T_A_%@DFU;(/
MG."CS3]W)4LFG8'];_._8!PAO['Z2H#/?H1N_4+Y>!L2\PRX#+E*&+GO%J-W
M."J[C!Q?FN0TNL7=PWEN!I)16"@CEKQ \BQ8,AE==+<!F,(XD@4/9^.=Z@RW
M?A2 \1P&P4*_>I14PTY0S%+YB^5CTOCP^7P,O0#5Z6:\_>/UC8Q1<P85BX!P
M3W;OEU $7-U*!CKI45?)^@^_D.I&@!?]A6$O;]8U')[$0'*XOJ-/H;YAS !3
M;3]7[@_]8?8]6!@723GCRV64+JI6;9PZ@')$]O+4>PJQ1]!A8OVV:MX!]QGC
M_L?'NV$:08">HT2MK>RNE=-AG9L(&S?YUGD,MAY5PK"ONFNREP$]^:JNXXJJ
ME<"S;Y%=&4@NUX=^3*%?R>RK(D4?#?4R$>?'5#L!2I\$ [!N_G"3Z<^3T#9<
M'S& T'9G#H+H2BY2(G(.T]R8SL.4*.T4/#W"O;^8H<CLE,"UB]#;UJ#TW10:
M)_^IWR+9,) -#,RJ:UFP6Y1Q?CFA'>7G4?VVDY')1[D"VX4$K-9U9+:+@082
M<]=TNKX*P4E365.JFPT@L<["+E"/"T)SX6K-1?(#GA0*G])[#C(/W7/[7&>2
M?W F##WA@<P$:!?D( FH_O&[81^ F<<KUH 8RHCQ#6>8P%5O_E1B[2NK$WSU
M6*Z>H]<67N!L]/VT'^3/1LI@#5\W<\3;35U/VG>=^NAZ A\3SYV3%9Z-9<8<
MD,RE29983X^QE:-44!@=&5^.L9%L%?\AF(N)=X(XGP241]^L\M7-)<\;P1Q;
MI%SW".3W_T5U8E@G?ES!-PV^"E3U(\6S=G6R2!-WX0M"W7GS%PHP='<O.?^N
MG'[19CDSHD$^E#W\N8>)H N1T@^DV01XMCMQ"NM3-7X$LX.UX5:?VQV7<]^0
M*/)3K/Z;3\I?XUGR<X<\LL['Z<EIN\D1-P)55:#7A[[489 B64";%UUL81B(
M)!@4T=,8&+_(D].0T%Q_,' _@K8QTNB >N8(IO,6A<!5N_X?S#6,H;*6;G#G
M>Q=?K>\6R4/2TPM\[7)%9C(-4##8^"Y(DP\3#']G0S0Z(V0Y#I(MZ5WZJJ@A
M.*QVU\= S/W""-9+&X'/;]MI+O'N!$$C6-'F?.+8J&K#H8N9W+ &!J'MZ DW
M(48#JQ<K80N!@WL#D+5.:"%]_VD^L60-27(3(]FP,BJ"Z>=/G1I#2T1P+5A
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MX8;1ZPB=WG.+ED%XY1?L3 7E*Z=4/@Z;\L3RCA,<3CS!U2I(91L):/VDZ^4
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MJ;\F.<84\)"MMYP\"E)0L&*BW,63PW[<E)/Z-W[@J.!D,G D^SCC4X '3'X
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MMAZ;]7X]Z[_V;7#$V_!C;\&#[QY.X'Q6VW<>4ZI>*G:;?I8U0%",@F,8  :
MCPX=ZPDL;":>1%KC?9JQ !=+:P;<)82NZN&OOXX]?":X,%&6%9QFO%S6G%U\
M=2T!8"*><4<OV!5H-<,A#IQ%S?&:5M#G  4R.(TY$I5]J^+"L=5G\;M(A!
M)(H545*8)_-4C67AA8A/,;5*".F\DBI!.PJT8EQWB)+WI"AG3%3<ZOG""QJ+
M&Y#WX/QL:L1K3[=OG88A&$\;?QTK;KSCE/V?K75!'9& C4*,,H8O'NNQ9B+#
M&,^>1LQ]"2]9/B^[/76@P(P)JC,*]H0]4_TGU7DEW38XV'BT]>%$/]-VRN)E
M4T_3D46;96OU<WIVKU5?WOYO[]G4R^?ND%8?1%Y\?'7UH;5,=9]L\M_JU)N5
M=_]DB_;_/N7^6UU'V8R>ZTMX+.$AF6H9;(IC)SM9F< I*\+K\9$./#4>JI+I
MIHKH#)IM80A<Q2S>S-L33SH\VUF'-COU^G7ZM%HVPJJ4GYPP!T8=#1DS?L/;
M6MVSSAZJ;/?BG<AVGEKH\S/(V[*E\?8?<S_#+KN<8R_&\">#^#XY?/<;$%?5
M7_7>WR=H.>XA5Z(]-9$CN:&N#%@)0O8^GC6HZG#T-N[W:7OA8YZ@.]<GX_";
MMS%'Y[']/YMO7 NQ?3W78+;PV+-.[OAG@N4COD(SIGV&S>U*J&]<&S*U,*[G
MV]1D%>?SM)G1/MR><12F(R+4$?VL*QXEBCAZ?@;A/E]+EJ=/2->G?UZP1DDP
M_N7'CIV?K-.#H[TW%@R-A6[I_&1GG9>?1/_\:EO 0VW?W&COITZJ=__$57JZ
M?[KUPANW]VU9%DQ%>USOJ;\>.\)O>WQC 92#B&)I^@@?YJ]5O#XM6%=/FA%J
M>Z*B\\WY\;.'4-/9+?G6/P:.%ZQ[_3%&A%(S;RUCP0[%EFU6#IXNM]7-P57:
M>YXXGN\2X=96X>\\%EMMXY,_"E.P2A,:&E'29(!3@RCK=IH.@COJWRBD2E!=
M@A9W#"!DWD1R6WUN(M.XY2-P)<J &\HP#22KX6UZ00T^Q+A)0U9R"'K-(N]A
MN)I$J8BZSI'"(XIC6U@(I<I>E'Z)0,I QNDO(I%*28"K02%7DHCKZ&X>5B6[
M]MY4+<>8!LEW[QC60.O&EGVA%GKT @A)2H8W3ME1Q-)[:H(;QIQH5W8$F)WE
M&,,8@5(1F53Y<#@TSVZ>1SDA*;YIN)U#1VFH90\/PXW]4+?E,%8X/E4+X7T;
MK9VDQ(.XG4_R$;_4,VZCM=*4F%!69ZO3!:-,FMNU-M<,V$F#I)D0.8.FEALP
MQ2 9PU7/H+>(I2L6T_DDU=CH46B-& ?#M#GZC,#Q^\LPJN:!#%==K=Y+(]YB
M!)6E%QN/NXDD"*@T_7(QITO51@TV B>*RMRUUW5+6 @*)>.V6"E,ZJRK:L1>
M,"@0S$M.=.#*056JHQBFKZ,ME4"G,[I^P57%5'TH3?P("94U- ^KD;K/(%$Q
M86G"9IRCU,F@3B#BR_\Z9C*&Z<Y0PNCIMDJ][W=UM-Y$YAQ7"BW6?>2**[A!
M;J+^"#0-/E[U2:TAIO3N.L?]1=MNHHXG/UM_@CHY]2!^=<%+$2&KG#D2.7CD
MPY:FP:IO%R*O?/^\+_6*]G2%_955V-B;P;]?9,MK9>,=5[_=\_*0'V# 7NT
M,?H<9*2U'V) A-DXG@1+&6A$(Q@%OJZT(-!UF Q(8?Y)8DM=?2[I+ [8T# "
MR@4QT)_97*7!*'#>(*^MP*?2HY)?H)66!Z>E%2EH XK,; EE .":-DR#D?HW
M$!K< B4L \=%42DF=+Y?IA3(FN KWP&X <8 2"+Q !LQ!H^3RH>B)$0?*@\6
M3T& 2Q)=YS2N8C>54&=U P/KA1DC*(A]YA+(O(*,0TD5VCB.FKB-*'8E$\"F
M2=0F<%Q% 0_$2A'JKUJ*C ! ,1$E@7GV@@!;%!?*YGY&1=WR"V( :B@9#S 1
M8TQ%:0K()88AJQQ4FC-5,4)QT0$<53<LMT:?!*@- @!BZ+VAF.. (/;R)]/G
MY8%1OJ$)&X 8IV 'OC, 4_9U1"L3";*OD<]/WB.@. K1:0SUUYE%\E@.OKT$
M0-^/1Z$/,  F"02NC*/EC #L9QNX'I'-5<P$  /2;3G@(4\A-AHI)P'4W)MY
MB%Z>5RIP'2#2^1CSC0HS,RQ=A#(:9<25)P(2BN10@26,H13.UD%\YMQ%IJ4@
MD)1K%Z\#F(),  %(*E"P<;ZRX!SAX!:DSPV<P"YY!B!3'%$FHK6412$K*/KP
MV),NFQE;+X>G^R)DA^VHAT#UL9S0$.5?(0AJ7V8GI3P;_7=ITU5X]"?]_'MK
M_^%>!MY0QITN5,!':18K:;O].G.HJGN[F?FD5OKN<W5?Y^+6[PS(H]) *I>+
M)J9SE6W8*C37SSZ@-P_1*A8W]$;+Z7@76;[Z1,@I1L \*6BG\V"[TD?'9+@.
MFO5D&OMR#L$>I1SR4&O#UP&.FG=[[VTCZ"&C*0+#^RK\#0/3A'B4!/T*N(^/
M_0X+8^2ML:8#\\HTE5C1<4-W.I?9.@*J!CG")KE0?59+ZN8H?\/7.&!C)S^N
MF,V%?!XZ@W1:<3ACS<ZBGY"_$ 10)(#ZC,+%E>3#44&.&V0@'8)RF2KIW7"]
M8#$&C ..'LW>9D@J ]:(:7",4&!(ZT>[/0%QQ&Z&?HG^6TP#0A(3!2='!& <
M)<V*.M;#>A%FM=LZ80AY *=U2D/@4=<+)+*1&A!C=INY!"X@,5"OZ!!L7AF!
MGC=%P]C\#0#+L>TCX]A%CH$Y6J)0XGT"[4<-9^W/QG8)'6&6X^/H5I8R9@G0
M\BC/-Z//$ I)#'EI!LH*:$' <-<H$!OF/P"&=W&!#6?NF ""YIO;A==5$:+W
M! )%.0K'P/@T^R=T1>-4;+^!NN/H@(T[0(V)/I0?B#$?C,*?=;X.6J6%(3P8
M XHHECI)=J;\R\,'^X4JPO ;>MI_O<>Z*=$[HZ:3&5?.ACIJE8M"M_":AR)<
ME2?6&[/^'OB6*Z?!O27_>.GCWC0@A2_]+V;@LI(L+3_4:\:DQ>KZUN+O"U]3
M9^7EEJYK?J-NU)3$$?6O@3?9@"JV#3YU6'(,TRO\DL$$S+\)#&NM/A.,)/*%
MEM=!?3$/6T)!E@LE"!^?0J]2"4S^XW4U(__P;=[YY]=D_X5]W@LKT)!D!-<R
M0,1XOBD!@).D7-39M(MPE!@N%CIB-.@ ?( ZY&G& W$/Q^6Q+!"O_Q<EW,>3
M([7"E!FI\K[I#0XD#J+!.E SHK%G6RL-:>R'U$(]E($P;(NQYTL!<BUN-'!7
ML\(!GWQ5&#V'&*@-(S#DM8ABGF_#,_BU)(:VN_=2XKG$!+R5$T3L%;+#&+!"
M-E?._6&[JR$7WC'!NN?.X>(%,_7H3Q(836D5"A(CY"05D+"IR.+#(+@N+0\T
M$O,4A!QD&V"FE;+I HP 8%,QR*)-S/A>>V73%#H@.4MHTP:2TC -.%"%@E84
M@<U2=0UI(E\7($K0Z>=A*"$,R\F$ U >PU5>%PAF8Y+.*==S,:LN^#81)AP
M4GKUB! $<*%")1B*BY+?#:B(0.<:[Z084\5Q4$!1=E92J6-89]$SU<6@%A<F
M$[/EUO4"<#JHF:Z5NCTXR=^6^-ON>%5PO'_JA]V!RY#V:(R6)HVJQ:(^A-LO
M!Z3NJ:*J,NVB@^Q3_:GI5NFPYP'1G<9)5H7+OH6(]$*UFL+(@4*^E98@*",^
M2QCW+HT[6N@.6X\4P6)[ 0H'Y'+9H^?S;$D8 S\V-(Q2Y *Q8A2R&OC]#L(
M-D[G ;5>DQV]D%B<&='.CN.#\@!F1Z\#)#8H%V&T<$!<.8B5H(REG#0<H,^
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M880<%X?=@$6<<<<X#$P#U;D #H=120-*V!B""!!+(13#3$,;?;DO%A*#JCA
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MT9DBBQ6A):T?-'?SJ[RXQ#W"EP%YZ 7G/#*"3PQDVT9N<<AX/5F;4^/$-<K
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M>X71>Z!?F3&HVJ\<VH^E^0,@H,TROJDA61_QV-4L8")D*O!W&'MF>R5)9$4
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M5JQ&: *I.IL.Y$7%,%9#Y'&OYQ1.^QZ"3*GB2W[LM8U6]*,SJA0#Q_/L 6P
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M3/Q\*5-E)U=]:K]-1 =O0KO#36HJBZ(9CFCVVM/JD"[#V<%*4)@0D%9+SC8
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M(;@6W#:YOLL$M3]CS?P%N#D>3?'=W-\*.A?DWQH!7%CH@7OKTMC?.7*%R;K
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M/4"85_H??[0FR-%JX"NWT?\.DE<9H812;/G=ERZ5:G.+RY%CJY<=?U9CLS)
M-VMIL4N^F+*?&WQKO6OV9$R+V6/)A<>5M U*/&>HNO#VC] ;%W_OS=\):[!
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MN&P>M:T]<E5.89*[4DB\.<?HJW/^\RY2YI=%RAD6#EWXB69%K0@KEQZ((V6
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M9:8]QI9F:UVF#[ J(&IS- LQL;ZCU\-+PUYFRO56^!P:R,U'@LW4^/'%@F:
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M@,@#71?;9!VRDW+.6,(!*Q6NHF@@2_EWOA]@><.$3[B!JW?ALD54>X/;N?#
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M._&O^Y#BI]2+3[P,D?Z&$Q)[9#P].\CZ^728;[+(7@]OWMI"=@7/DR%.#EN
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MG?ZK^][?78O^F'M^RX.1RY^V_-3UI/C!<;S C,$<I5E-=&LS:ZB!DV8M/4K
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M21):NXQ^.;E=I@:MZC*A-$ =95,JI4\=[LP 0,*Y++ UP.R>_[L&;Y1I"#J
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M53"+A2US,"9A>^5M'UBVIR"'S@,]EQ<AV*(X=8H0@\AF[FI5TA<YF8VZ'P1
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MZY;I<+I-8@1K82P81&?S4PO9A_"6:ZE;W83OX*KYMZ(I OG]YE;#XZ%^KF=
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M8XQ>&VZ9 5B<'?)3-R\FX]&(^E5Z:>*)ZMU?&0^ %5\U_^W"_&7XP$'-S!)
MOV@OJQO(5E<&2LH-:.I9\W)1R><J#/#MU\"".6^!Y'^OMXZ-+7@BP\IV \5]
M (N.8RNFL9FI>/Q0,$V@GLS#@NY@D24^7S=\\R;R*4#.[= *.H;UG$D)< ?]
M4D&"8<%8F&[[)\.STU32*!;,,!,D"4#T+!M 3\J4H&;_MAZAW(+5D1X 7MKM
M1>6TOP?"XK?2.V2K3'0!"V9G\D^:NW-<MGIUI(M0K5(M]&$-]G^@OP*-51T<
MWZ&65]NT/E[D^D37X_$>)/[%#,,4*_R2' G6?S$VU=XXDGYF[9M7?WN.=F9=
MW>&],O!U ]MSK" CP$V/)&3&'N^)O;=3N- G%<F_%2-OGRF\X1^11+BVVX_*
M[I*\BW*W9V=T7AP01?LERW,R@%<?2E?G7F^<HYY.8P=+V@,< G+2:I+8S?>.
MGUC]]FO.'8>*CL?(V!NHO3Y2O?'/HJD4MKNWL(\_49415R':)E\7ME,U]#]3
M&MV;J6V,^_"RL;M-\>MP57:"P_VV9=GS/O$HVF3EEP?E"WL3%LLZAP?<KFT0
M9C<Y*29H[\L6A7B/_+&Z#^]'5&2>3*RP)R5VIWI,;#E()A08%CAN.MR6F5*Z
MV+O+1K?!MXVD=:@;(?"\LFN,N<*'IW<Z='36#$2MRI;&\C:TA_6L?+&E25*A
M;5&65345%I4I//YI4U \X:[A H>]36$VJ3E9^X2K)T\G<83_1\&9!C5U=G'\
MWIN;D U(2 AATR2$+2"$54"T-R$@(&" L(H:-D$$#*ZX]B8LAD4- @H(&A"4
M31L0+5JU%P1$1 5%Q:T-B-8%6[36VFKQ]9UY/CR?GCDSYYS__W=FGCG,ZT.D
M#.HFVS1!#Y(D%U1U55"^-*!#0?,-BL9!GGJT)&C=L_3QW^K+%(TAAPMT>E5N
MRK'ED6*S$B5T=*=1J7I[L8OX05!]SR3IX&O3+6M7I;<>H5D>^N_Y^E.+SFSJ
MLSS]ZGPI>]/K*I+9Y:[87X(4-(/@C2V%[PA%B><19W9#CX@CWY!63* H 7&%
M[K_T._UF>]Y^J(DX!^6S>J=*E[A<>%ZWRZ5WHS_J\E-*B9LHY.W(C7M<X<U=
M?P09*\HV7FB1:R$+?J;0NM=$?]WU(NFTEMZ_9O7<V]ZZ8 W>PE(C_UU I3T0
M7K/>]<5M>+6M1!C ?R-1K+)??J[Z.G6]>%)PM_J)--;FP:C[3<<W]=VC/K]2
M@\S<K\V>G8];^B;[;&QP1WW/2$-]XX>;87\\84U$,RY[WF^O[WN6XG B^Z^X
M&..&K2/*Y#=IMWBG+M,M-(=R-MU?O7;UUB<)^/?L)VN=3F^/S_Y@US.^]K=!
M/*7T[:Q7W-W:B][/-NW;[_-LWXJ]6YZE[MOM^Z)VPQ7?WQIVS?N^;-SGW/NR
MY>A>O]?61\0V_0W#ITF/5G/[+R8<$U)^%_1LCAEYB[Y:D.NP\5*>55S]P-Y<
MQ_RN+[M>SVP3?[GW[(7!GI]TBXTGWT5N]%K2VW'PS7^7+AU_OK.W%O,EOGK0
M<?O=:&X2+?;?P W5??5E>=*O<0*?L84SJVM-[@[J]YT52>7KPCZK@K*+L9[!
M'YSF<U T< %ZZE@)2JFX2[*/1Y8.XT'QZCD M]U=.>MKY+RZTO+)T*$?N_D#
MX6C)L4<NK1[GAH79JY.O[O=&:BRR7+/^N_KTJ*Q/5>9[8$M'?-^\R^195]HZ
MFFFFW-C #=29CZD7?X:(S8=]L#! +!TUMV3K5 W!&.[AJH46=);%XGBL^,[=
MDK^BAI1NFG![^B0[@74"S\O**[.L2*&F]NO,5-RR%-\3 IY"Y\W7;K<$^RJB
MADF$0KN]#/D*^YIS[$ $J%#*&F/'7H1\=\#6TX%]XMZ57M-(LAM^ZVSCHU[Y
ML)'7@;5?_RRMY "-8:S9C?*?$H@R2.UXZ+U3P;QBQ F?[^&&THH3Q@L%T2<A
M6??4GO677ER.T/!<)I[#"R:!8T^D8(Q:2;5,3@E(U('66>FT=Z75@AXIP42F
MQ9/HA08^ %2:V6C4'EQHX*S%&XZ&,/C?1OJH9@;+$\'YCJ@([HKF&BT(KQXF
MVP=CH-&'Y13.L!@OT1Z3MNJ/;A9+6",*943AM-:Z-XKC/(>GRCF!IC<PDNX.
M?G]5"IZ%B,@2785SY]TE'7+04BA<9+Q%C\OW-X<O_7DMPEF,_[Y'0$K4JLA:
MP$G]"3'P1]51&BV8LG1Z<<LCR U%H5\>BG%"?;$H7L=T^63'GG=4CO)G*.?:
MYQ&2[A";H4.66PTCI.'M!*H"<6@G!IB'"8<"43GN\Y,08C^Y,:H5Q5G61,?*
M *Y$ SCM<QM9;$\NWGH1E1< RL"=FU5N5Y)/V.@C5WK-)9S>DH)/P5 B0:0B
MA7V@AGF!L7Z1*C(UKWSIZE,6N02B<1H"^V\Z9>:L _V-HJ'46902BH"4=LCH
MF!?XSH2W<N<CCV.9G["* 1UHV,H_]F?:[U_](J.V&?$HJ1CBR*)#QGR9J5,F
MFOY$..Z<AN 8SR%VJ%#)R1S$4X>!52.Z6V?:(4,ZO3UB% !_-!*?] RO*%Y,
M*WSEG'+:<T\YDP$5[SZ<9KKA/VP^;%NWRC4-LTE,/+4T+IE\_!B")TV46'AC
M2L:7%GPZ(,+;C:C",E/P\F$4OZFIQV4TCN*GPN!>'9&*<+HF_3TN!LNAF,(F
M\$&B!\_O'P*YM0FVSV^FR/(@1DT*W50>+1Y#1H6(+<Z$/<"S.TDF,6TI9AWH
M=CY6%*96 N/5+P5Z*?B2*X927L(4;_D5TDPUSIAXP-/U8['W7A&(#@_@R8^A
M1E4S0\W&2(]TI4:*9-.K/5Y0_]ATWODIL& 8)G4[K(C1(A-H)C:8!*CN)7"6
MFRT+</16\)VWX0VI.JS!&U)O?37L:(N%V,VWE%*3JA[GHECA_!6@/P)!>8;L
M/MX3#1KHS!NM!ZY^7M9+WKF8QS!61)%8&LNR>[Z@')%P+(!]@@S$5"E'.*Q(
M%?SRX93ZI03?>7:RM%5RM7U.19"G@@O&P^ S7U0@1Z+T;N7B3CK@89,N-:&*
M]YBQ)7(XYIUHJ=E'T#<*C W0E(@1O;Q!C% <'@.VMAP&IS&8>(D*F>QV!'><
M_U/PI5,ZZ8D:=IK_9DE0% =5:7'LM]D;J^K5(@?]Y,6D0%;A17: 3>*X>3[&
MML@C4# CF#6SZ^>8;I7)[(R^@(WLB.T"@>K&Z8;Y+93N5BC27C7QYCS 6]/M
M.IG_*'HH:!OKIWDIX$*<3JM]B9%8;D08/H7/R0[ [Y5 U<*9=P4"'"[;4/D^
MMRX@/PHA/:D$VHT ZM5?PO'>,:I#K1Q<?QX"_)F6':/!5(9Z@&>DLB=0Q0S<
M)[%--S+:J>B#O@QAY>>OM'T\:'WSH[$9YZ$.Q+:DT%)\?#AC#SUS8%*2; 6Q
MGY,/+'Q%E+7VLQ78Q?$*04\?LX]EP1\F? J'7Q;B.T&>9JTUI[^MQ1#_(0CW
M,LAR+"$U9_#;C,>3X\W02>C=+4Z5\BA7C/LR/@&*N?Z(N7,_X=":P+ JQ[DG
MT%(@+TT95/^H(+-*X \<U2"$[)MQLGUD?P1?!<V#C2.?TYXN-/R5)$?-=5;V
MLZ9?#2&+[%\;<P:.YQ%7%8+$:M7I1B6.J;+;$C4RN^#PC)84;_KW\X0K:>+4
M;(F=3V#%^A*8([:FBJ$/<?@O<NU2S$Q[,+:S3M"*D78/K3%,XK:"$8I^G-4*
MA\XH.T!,ECW);E,1"E&+3X5V/IA#.V0^NS!  <%?\&;E6% \EBJMMLQ&*%7B
MN9R!#^E42_]A0J=Y0"=6ES/0B._W:8,X$IN;NT5 .M;G,V&6B7 !E:45<",'
M%OTUS%R/K,F34*@JCD)DE(OZ%I5$#R<;>J,BS=$_ !5%DDJR&*QKD!]LY63N
M02-?S4OPR/#,!35=K(_=<GR0&WVJK=] B_H5@SCG(0X\=?$_;72GROY#$>)L
MD1<,_(R?XE'7$FM0OU+05@3D.1^-J%+AJ[!NG]12ZFJ>:B HN)_P[Z]LA CW
M'!-3?R4/K+!L?O*?=4MO$L#38N>5ENQL"ZNP2'(G(F;*'3TQS],(K4<MZ!3A
MZNH)+Q\)K.X&98(&0B0D#;#L!65R/%';=W;]/7*:TNQ<H%EU/T[1OS5;;C!&
M[].*B A@T F9P1H6\1Y;AI$*11^X_3!?8NF#)MU)/V4KX?C@"?'+Q0AB5Z@D
M=JJ.#HZRB?=PHX=1?0COM<2LOB5FGAYFY_-4@&!L?J)85R$H_':1\"2H? >"
M>V(>/$>T %BI:TK@I)* )!*!5LQ&](K#0.KAA0M>PZ3@Y;]WWB!-F!G,F,8R
M9\A DUU8!6DBCC)B>[RUO]P7(7VY;:E&X<ZD6(S/J<(X]8AY)OQ[!8#]=8U7
MV(@K7^-8@Q!Z$ JB=_0JI&0#N-VBD /4WY<R,BP"@1B DPF)\T1"98KC0!BK
M![%7CWNF*W?(TEDU0Q>M4SV[198MU&*[ 68N3+@DHL4CJ3K$3'>+H+9-R$4B
M.R%"(49N12GYRP\,41-*P=ZB/CA3Q0@L(LL!2B8HZX0J6E7SE'I,,--2X1=H
M$&P:DQE8'0OLS3YIMUOI,G+S]]-BCO_)P?"*=/RKQ*?_7PUHF1P(>O?/F?8?
MW-FWS>Z0V;U53<GX!!-V?:G(3H+Q!D8K6\)7I@.XL7&8+QZM[YM_RM_8/S3W
MU)XX>AW'SYH\?0/8%C_(M6VK*V+5 T0L J)=FPL_<:SQ#B&):9)"RN,76DAL
MS! Y07.$G884TU*@*I6!5F3'&0A"L ,S^J!+HC^8,TW/U6-O?SV2%6AFM>^*
M&E2;GA3P@:,(LMSD+L\'C1!VI,Z/,QNPAK<PKJ;?C!@#*VZ0B/=@1=FL[X!+
M19SC[..;3QX-Q:.ZBOE5YN4,4K.3I3_]B@#C54T%"=$=8<A&*2 ]SRU:QB*Z
M 05A&"^SO^5.>=VB-Q>KD#T7@*MA)JN?I(3-R+<=,W O"K%/F@AR0(_3EA/F
M%MSLQ);G+32@%1MW)W]Z2S/SU)X6.'VK?Q+<]T,_ 3>94JI#?SE=#'\J//%N
M=G5.(=HJQM'V&51)3N5*N!.O5\X>%S"3[;"^TO,BW!VJF?"7RFS)M]R:.\S
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M'=#LXP92J\2&)D(P^,J1>:NZ.S18$ _"8S3"*:4KM6,2(X3. 22ODY"5@])
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M=0M6\QA,.<X$:>%S<$P@U#T9EVV2B@R!+/G^6!$> M9XBJACB*$[2*=R0'?
MD  "8CE-#,P#1B)J_3@5D.-F1R$_+I$@QY]W!EDH)0P OA1M/W9]&1D8#$8A
M]RG3&R@#X.!?0L#)-(B X'OE0-@;'"Q' 3G>DPLR44H$ /R;"KX^20$ H_L:
MBD_RIF 8>C$HML@S97Y3;CE Q4;8>IC#H4B!9B24YXYI.]W]6A@F<6=UP1P&
M%<'3,+P,Q)4V&_:[,7P < !UFXAJ@9(!&@#<XC"(@$0V!1, 7_:4T#<98#-P
M JUAZ[N2R6A3(R40E$8WVAQLA![QE[M;V@B?H 5S9QGK(DU?<X!EC&H.@'-7
MVEXG)%"12)8(4 $TB /WS,OQ<]UL4[3Z=<82"[1A-^-XNQN#H 05:?0P/84@
M2F?KOT7C0.<,G_0(+OH >XD9W0R\'4(UT48H[@+N<DHW!DP'XXF<X1$.\**5
M&<\!'G$8,%(?C!G_V?\M)L@=@88 G*S;9DR^R+00R(;HY"U42*_;U%7TT0:,
MD'OFG45P?1Z+(<2;ARO-.U#<)?VS NC&# G:MMAOA9E%B\4@(B*UQ$%; GE!
M6KIO7RZ" 8FMN E]A[L=\6(E*$T)CMD:LW@L. 8S9.G;:5Q_FRB\9'-H% 9\
M6N?@@  [GU.8*#"!F!" 56O<*'XB"H"T)&+ O**9_STY+.IN$U&[;(:I<>=$
MO[T*+(BA*&1 $"S\"1!_5<$.GM+D#%]GS&^&"3_9C!@@L03Y6E8RG@#2A%J;
MT7NY_@CXOH/O.^7B):?=P@ [SHLG2%PP%+RW&6P^%,/U3N%*&488'-H'$O04
M=]#;XX5\!9<B&X$)6JJ,1'?F $-"BHEV*0Y8=><.P-0"$1R$( (.V%$!=,F?
M/&A3+(,@E\PP$]Y%+TFY Q#EWPY=@@(+]+R?Q3#T#3NUP!P/4J397$FC+<
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M9/"TRX0HV0DSG"U?%"=QY4W#PI-,8+K0/J9#EE<Q5FS()F3_(I<&JLH$,2S
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M$R3B\CTB/NGSZK\#[8G#0T&:Y+ XU??M>KNXNJPSU]<=S;U"RJC?="LDHR&
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MPQF.9KGFA],3OHO;X>5P@5P[MD!,JC:N/J2HK=Z<<C@^P3[WPN&L**&JY%#
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M!;TT_5*NRWT.=882]]>R;L'S+ZFSR#SJG/!C-!^8.T#EORRV&X=X*/!BP"F
M!4*#4VSC!NP-5"Q%:%9<5)15(M5/&\>?T@SB9/W-O_[K3GU@E7/JO><4&\(U
M5;H_HY(TN\KYP(F/T2\G]?9::'T^@ ,+9 /Z^BY@.C9\'0.I2F/(>-^@)H.'
M _,HN61^KH1_)$Z%YU&0B2V?#!3<65-2D)\/<'0!#EJ"JOWO LYI"2-^=??!
MG&263RYK $]@P24,.,LIX; 6"*_^B:D"9ZA F&^,'>3>&&C9G&+,F(PH;R@#
MU%KA&EP\/DJ$ZP_<>!FAP6^,.G"MO!O$[HZS<8XV/-!G3X(4)E%@L9M1PG*Q
MMU9^>DAECU: 0Z&Z=\ /P\Q@(!=1FTHNVC=-A256O,<]ZY?IQ:Q!/$"E!\=2
M*W0R]CA^6:HO#-/3^(<I8Z-V_\5;53(5WR?TA6?E4^/B#\DU^/)6H&NMT4X-
M!I0"8/=3A3KN)0GP2,LECQN.7N*0!W\JU^+^XP:R;8+.H<SE^0#0+>2V/TQ5
M4T+&GT_3X92;BH-F8''RT;N.3YM>&AEWD8@KQL0[#W\>&_B:O:?X7T,<!LLP
M8RB+FFB9?7A0F23)U4=P%#;H^*>BHY:I,Q<8#QYK]=]4N'()+'G'\1] %.9C
M<NG%*B"7DYT;8EX?9..6@IV)J7G3I.#ASW]6\8UN%]:5:^0*4RGI5]/F=-C)
M:E 5L0ZJ]1C?,NF*P<DT)2JEB+'/2M&O7^%Y_ ^U42S1%Y=0_WH+!0TCMW5W
M9BU9OW+1D1MNU #6AD^NU'F6TXYQE);X.8/Y:U?(X ()Z<.]<[/V)Y=)8:=!
M:.G6W/]"K7AK;NN$N[%9Z.WL29WODQN@R_$'F&L30/8*>!YEWL.QO;7M%SE=
M_<4:/7=P)B:I2,"2CV1S)O]JB)!V)'4!P4\1TU]R1?NZ_]DV#L4A3D N3]4:
MF>@=S$?BB#U8]IY 57_QN#=A5676OZBB(+,7%LX_,WT\N>)&S S7A6#Q%>/$
MBP+>^,85WT;_M0'F:0NF61&I^@AI&4DBT8?H<F7+<R6ZG%>.\*I[)1$JO?\
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MM_VX>/^/4]OG;VO]L;ELV[^[]VV]LON+==_V2[_4]>^LOW;\T/7?ME]UKDL
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MP&U[<9?'+L2)7YL4*3HFYQNY4(_"5X=1*)  *-88L=@R!?]9+8U25%*77_7
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M@^U^A)$C;\BWWW\B_8Y( U>.('C>4E.K^DHF:6(KO MAB8 ;$L :*X!8W:1
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M$MCQZKEH8L?*SE7^]_JF#Z&I^R,B]J\F)FL8YS3S-S4O9 4*H^?&8W*QS(8
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M5) ! .L5J:SG>(S6LH "[.-O*X:!*P((U#FNIP!8! "T7C09Z'20X!)#B:<
M10V-:34G3DT0"!2@P%(& D G?U/TZ]AM/""IBO@>[U8-,^73<SO:8,(O]13>
MJ(^,2=AJ7!Q?@PO:AY<U_.=93*'VY'9@53P,%$N#"0;@'1\R TQ0/7ZG#_!9
MP5.=I13R@$7-)]I_;5NN(9)Y($EK=ZP-^,F*M%V4*:=">%W#(TL ^QRPDH*@
M%%AM"1%U( 8&L/U$>RE E@(;#-R*SN#&S2!V&L!/X^8]!/ J'SP\/Q4%3*4
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MRD#+J^?:'U_,.$G$ZR!/>.EN7R#)(!P=!X^&K<)-2^BGO"BHWX77+#S,9*F
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M %0'FB>I=<E C&V@/<PLD(+F1O"4_O*%:&W$DY%C[:N?"B@<A/5!8%^M!PE
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M\,;S_0<T1W#.%U=+S[;M_QM8!]>O]\=7/-^*]CE?5\80D$(;BKTG#TR;9MH
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MR]-*-EW$A$7=/CSMLM/V:]T"]1))FE;M6^T>^:NMXM]H*;E8=1<>K,QK:-V
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M,QFQF;.=0*LA><P2K<G?:H?63C,$L_X6Y=^B)Q<17K7FX>%H[>;G=A]H=N\
MD) %4'I&R6D722CZ Z@TH5]?SU<Y_",43J!X@EPMTJAE]4< 2T^F97-68U>\
MTD<+=" 3WA32Y)=><^D]L]E#7W>A_YX%.">(Q5MJ<7%E"V%6LJ""-U5%X;GN
M(EI7_7.H<4*U>ILJDWGX(@\T+5@A=@E@Q&-YPZZ+]&^WUI5[44C4-)Y%RV$\
M4FO2\D*\ ;A"F8R18EXV]LVUT>]G2WY.;K,:/D$QOG3=8/Y%XT+2]9&3<[&
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MF;J"WU:'HYM2^CFGH"R9 -N#,FZ.)NQ[V<K((VCEIFQ]<C^3^T,,K.ROGY=
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M*F\8:&NHO=U_1<[@7_<<IQXNGU/J!:4#JQZ1H52LT,DG?@9=ZVWRXYDB?]C
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MCU3FJ_,V$D48U!)3\$,L(=R8NKT%%LD?@MTLS 1),;C&%C\+ZS02U[U["D<
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M]5Z[6;6A>VN\+\]*N>JUB;M?)-F?<5Y>6+:_>&[T-'7:1K\#>B7I4?P!47/
M@L(#V=#^A+<'LF[MIS[WTLVMVW7U0(YZ_\*R61J_ SO.UVKX^[?5UV7O)>\E
MUJV_6E_A7%]*;JA<45\^HZ%I1GV119/5T7#L:D.0\X&X?QJ.^QW,YAP\O>+@
MN;*#D^<[#OXXX^#NV^2.\UX5\NI<$3*,>*=\::@P*EMMI% 1DF,A+E:PBTVD
MNUOF=@)VJTVDU;S%]N=#,V^1)H?Q]24Q(?OJ_T]?VGR5H4)WU/,.+>@_? QH
M7-Q,_KM^EAJHR%7_L.@6.5^FS63J<J8M>#%#Z/? "^^F');_</&J,?N!T:&\
M]LS<^A61.:M>9)6FDA:<1C"SUYEIW$!3<<IYQ-W@_O) 74ZW^S_OEG=:B ZF
M[^CR650SB<3+_;\V#1D'_V\(".^ 0*%RVCLBS29ACLSBI+K3JO-R#>QB*\M>
MI)12G%";B,HGE;=Y.0!(@USP0[:'I]4Y'P^4;9WTBFF;Q9(I]!WLFOVQV[9
MY1)CVPNO9^%[ MZ"),;J?1V93C4!Z,C1'2^/+LC>;Y>FG;K.R^'\@<_-52%B
MUMZV@C5FXA33CCF;A;^=;Y]J*E:^!6^P^15X6NAF?V;-WG.(TV)LB9TFYQC*
MI)FSDCX$6-0K'57 ]\-DKG ]*PIJN$ IP]/:XNN;MPKGEFDUU>3+"IFPB0S:
M:03566 +NPAQJD=W$&XG3ZZ/T69I*_3@(=B)/Y=_<SFXZUG=^[U;+H8=];V=
M[(0B3GW'_?YA3!_T<+;MVC:6/"V_L6*$$:B<)M"7%L5/^[\7QRX/,X'+V/R%
M7HT&R?^=1ZHRA-&3S06/HDHU?,;W_J=8\T[]28#VJ!".C+'4"AU#H:DF\"D?
M<[&"KKS*(*S'6:EV5?I7V,(=39"S;?7SIK3F0:*39>MB(Y'ML7[?<\#5YL8L
M!5\379P,ZZV.)#JV0Y#KZ&0[U-@-THU@@RS05PYRY*C.<(1K=)G5&T\X G!"
MP;9^QCK$:24^1V-VWGL7DJU%W;J1*=.YHTZ@:Q/)J1ODH#%Z%,JVS5>N#>'+
MP=>;2 [+P%WAW&6"ODS=&C?#^MC,]>'+G?T-ZQQXT"$ (ISS= 5\"4_ 3^PB
MX5N0AQ>YB<&--N9**RM;!GG+P'<>3"8.[MBLFR3W-SMV@UP\7FU8Y2AS?2D
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M638,IK3?%)CW:;D$>Z/EV]3M^PY'8)4_=H^>5<X>/ +8A. ?+V%D6(NB%2@
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MV'B&['N ,G9,TB<F]3C1T<J7.7#G+RPB"HN[I[716B4*(,(".W*O6VK%9/U
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MU5?\^:GF!4P>UEY_MH;\!;#/"Z:8<#MYQ>CZV3JE"NYS/\A[T;Z"0,@ZV?U
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ME=V7_?/EQG+'E-7R(8&'..#@E<1"I?.BW\]:YKIR'MTM@XOKUJDIDYT%N:!
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M)%CIX.@N0ZLF">BFW2?)9AA>$#9@S>:DB_4ML:T7Z%O2A?]3@Y5UKE\)4-X
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MFE+I\JXIO3_J[>W]?7\?W__B>WXYYX?SPWF<<Y[G^3R; C=Z><?]"[L _Q\
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M<X(YW@5<J51J'9;B:EXHRA28DTQX03Z.RX:7T3#[?'!'V/#R3!Q7 W"9[5P
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MH"TC8*IFXT9O)L.XQ(P*N')&N(A!F/JA'4O(GW^H4+]Q;H6Y*OHMJ S',)N
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MEK44U^E9?=P=FNMYH5_VBN7)CRY'RSTK?Q;7TI\W.*8=?U96YR7E:'?0;4_
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M2,42A"J=)!1 W9+1VNDTU^E_%)[JK-?.!)$XB$^Z?6;]X(#<D4UK$(P+8&C
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M>J]N@A.A;:ECMW.$MX<4R58 N[*:(S9L+L8"Z!M;?29@.]F]SL/IVV7[;\@
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MW,16"T$:]" =P^4HL-F1-1QIBA.V&5/C4).=E(:C</ XCEPI>F2<YE/=JN
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MP/\403GY;MQ$^NYA,^.)APK<811ZEZM?QMDUAN\%=% 2>U=U]NWJ'(;HV[U
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M>#$'!VQB&LUB@BFFGO,X>^B7'[S)#W@Z8]'_^X+"M!!3]-J(]4Y;0LST+K)
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M9T5US4 )_SA]:D\E,:"W)5H6(@'XU:KM70F]*>4%:F2LF;GB&1<Y15'LLFH
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M/>,GEJV3/5ZCFQ3>57E._N-9YT?YK\5;L4^^?WZ\[..U]\N*RN2?OGW\[S]
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MCP%?1FO>[?2XNW_ T1-+X>E5^&H2=:4LG:F=4')HM)QO?WEQ6$E'_^)YZ@I
M]W;.<%FZFC7JE,_6\&<Y-N>7%-8AV$X>!EI4V$DB=/ (40 ZC$G80R*$L=!Y
M?$(]@JWG8M8S%=OYA(LP9@,?SR#C?JY$>P*X*TLX+Q+:GS?>P55<+_X;A% O
M0]?"Y!P9NIZ%92_B\GD/ZV',>AXF2!D?]4?<,;"SD 4\,J!Y&E'NTQ246"@S
M.\(R$8 G@4;QX)4DX#'!S09Y; T1FOFHU#:<(?+XQ@ >QZ>L/ VHD%#9QB!.
M+@865M$L^ IDF/ G%; D@18F(!8!U&P5L#) 48+3EP'X41!=I526OF.?/FB-
MI/Z< U?YX.A,L E[\@@?948"2V""J0PX6H,W@D$Z<]?Q.< IGF#% KN4U5;*
M7/H:CEA GFHD_P(#\,8<0 &>=BV"_S:#D*V2 6O26I"FP09-N>D*@IDV].Z*
M/,"[*N4XS*KDD5).D,E,4I=@;Z?LCFW5CK$[0B,NK9(/KH+ VR?(*[@HDT5?
MP3O08'0&6E*BBT-_M>$L9(J*57A#/JB_2$Y'*:GS0 /(X*@8[$.GA\:AU-_1
M5Y-FM]DJW-T!&H:C5$4S<@L>3H4^J\HTO"P"Z7]I1W2?,9O6P@-=<^=[]$$+
MV3-3+D@7FS[8IT!G@4=AD)Q#ADF@V0QKAG."^<A^!15[-WSJ<)R5R=P*IR6=
M6(%2?CS*ZZ;B2C[((F/[=, /XP%^(:C#+)(MTHN[OP4Q>DPCS?Z9IK;5Q*6V
M@K(3A$POL+68;#4P-75L4T0,ZA#@1@H!5<7Q72P76AXNAF5.(X$/$R3ZXAAW
MCJ8S"=<IQK 1=-LBU@,>\^ I;G^/\^-B.[G8<)B\"<9TYF$W+>(Z1.@P/N$<
MC/E*1Z?R"8%\S#FQH@N/T(B@TT7OM_,(;8N8#:SWY_AR3.'5O[K"-ZWYD$M"
MU_ )N_/>UR./KBA>[0P'2+RGS:UX($\/E(&KF4#$-B6E4:4R"$#'+F+7ZP)<
MI?T 8(?@ 2[5N0AW!  .P00E9+28B<JOI1E>4@(6R30NH,I7:!(#*J-*-JQ%
M2]N\6  XCB09'P>51CN2GRH!H];Q:PWNK+0K)&T^" '' #4UIF$EHN\\2Q>R
MZ&7<8YW0P:91L-X/]2LTY@Y-ST(&E(R&'R1Y#X>&:IX$]>[/QZ*P9)C,X@<:
MD?1CN53S/!I=K"=FY16-9J$>#JAPO#.\OZV-HW:L)1SA*Q&/&]))V&1$R41L
M<%A?J4_^/XK./*BI\^OC]][<A"2$$ ().X8M! B(B @(]29L834@8%C4@$@1
M$>..UMJ;$# LRBJBH@8$91,C+J!5>Q- 08."HD6+-" JXH96K;4TO]?WWS-S
M9LZ<YWF^G^<[<V8.!_R.-KQJ0?U6!ATPFS5<OQC9[SRWB#*\I!8#&H?)>#%N
MR_P*\OF$IS!(7&DP<M$ 1AWV8,#?N> XP:/Y_2Y_IY^[*PR8WRVK%^F"& ">
M&PRG;YLX7]*\E-0I!B#U?%%5, >QL!?:71!'#BZD7?VZP61]KB4/%/I",ZF!
M"1?I' <B?X"\%]_M/DE YPPVLR"R8MQ)9I"U!+? >0 PL7]P-MI,]%2SXS5\
M++4V9?SJASEFF6MWCN#:CM)$:&EWPB)E4UM?1^K"W'$W]=S]8%]W;XTXN\'Q
M#)ZRN&N/[N4CMD%MEFW+-G<:KLHR,4*Y_<Y->8%3WKB#O8$^7;'<\NR:_J.)
MKY,Z0J[M\?"6CWAP>0KN8_[I40_WM7DF$']ZM-WQ!\K3C*V_TXX(NF_X7'G(
M\:QD9><=BAQ]OC\U+/,=>=_G' '-I9OY3T^&OX*;S)/U.?1/,T\MX$4.?CN:
M\CGGT=G5OQ79IOI6VD?E;CJ>J>,I:&;>9]WF5!I<%9W#NCA]*PPRZ>;Z<?)X
M#)FIY9+6V4S=)#?RIS1BG>PU6M+NI/CSZ)(-*PRA)7FK_;R\A$!KAQE69R;N
MM_4%HL>MP*NI:404]F5_:"F2=F842O&;CS0=-&?WK#_X/ZLJ)8<QWU, !;UH
M>09$B8IURN5V^6!Y8T<74I&JMQ-5T(EY<6IV^PO$WM%FLQ0]$/ 1:?"O[HPO
ME)E.SSB=2M8K"^"/PKIGIP)>#..@I9)*G2#6.W*@W/)<Y, 52V]I00O!X&AH
MH:E9_B1SJ860AS>Q&_O8%C.7O]@TT8$546VY,M_Q5#1+9.+J[,X%&U+C*W!G
M"KRWB&\'.4D6-EB=E2'500)5)!25X<<K#YCP$S=&+GFRCDH*F'64EW&4<@:1
M.N44;-AV-;1\5M/!2B**KQ16$]-:633G'Q]/7TN=]>,]*LA%)Q_&7-,&4P/I
MPZ[V=.AZ25,#<-X)MI33)=7T> Z+0^0KJJ46*HUS18!0YU.T:[,:!^D#7V#!
MTB"SYF=2RZ^L5LAJ#GM6:/E8PHLKSQJ:P?\M>EQPD!Q+SA=7<>O 27,WX7-I
M05ZQE!#Z687$54ND".- RN4<)HEP-+VH+$N9SC28KEM73K,C5[LW[+\;><E!
M-A-E>'O-^?Z*\RVTWH478HN;20N85]87AX6M<S()5HDT70M*YF852Y KFVC=
MK/1,DV"M14:GHRQ?XZWU*7W.<"@!8GP$J"*5V?6CXS5)K_&/9R__H;M>2 >M
M+I>8OLUK0(6WRT\57%EJ([D$W7$E2JMQ:5?[&:E.NP8+X1PGUK61<T>KG1ZN
MDA0 U?L=229 0/QSP$)/P^3FXAY[/8<.UZ^GTLV(K);^XNUB5IJ0TT!='E];
M$"CCKE*4^W-;+A]<+O+/R8P9]SIWMXSK]44: Q^/P[?*:D]=39T63(8NG:T(
M+F\2^T4,BWC[&1SQ7K-LZ0)=Q6]FPSS3RJ.]-E^5I /:!CSEZZJP@ ;@U8:0
M@",BA!RKA BZ229=6=";0O.P?I.#^'?=MN;HBB(42KJ]8P3;05GAGRDW->7<
MYK(D)+G3M-$_CA&&$[J.U 1(1M\[7#D<?"7Z34, _AA,24 --H(9B*^)',YB
M$4O&-<;F^8?.9>/!-#FK(%^U-FQ/?U_*>1ET2#+F3#Q4$5B!)'FVJW]5;=>[
MD.3WC#VC!BCTPE*Y5NWL58$>#9/4'W!RCF9Z3>+2FBIAI^?L-W3&&:#.9)D0
M+=W^M>!.1T:QM0B#+O18_&\.9169N :3*J5&?B!H"6<0WFT8,/(4@J)'&/51
M5PA;45UA-<:UWV&A-MMRT_&P;>BAF4K 9./.Q=8],M#DS>,"A6]LHZ4'<=T(
M1&OT+;++?4O:V%-HP:XN2E5Y.$9)2BWV*O%\+_M<I5@S4>1%#+-I(%Z>"UEO
M!L(N9HW<,ZI^1I'0<@7'?G'I5QX7OM4=/X^9G)+V><0N\NL[--KDDAC#./'C
M(;E?9WH9I1:T*EIV.Q'=2L4*W<R&;?3W&-K33 '@$K(+2ARH84"L>PL C)#&
M0GZR-)%"W 8R-/W>&/0CQ:P/0RT4*. A_M[3+O+2'DY;#=9O>**+!&((P\&+
M^<EKI ^NRP[[NC*!F(,:\FP VJ$*M JZ=*= BY7>C9ATOLZ!\IZRXLKB$QS3
M_?;/*I3[N[_V_I9&0^*WEA(6#N,*\]1%LP@S+""^WR[W/G__61:<WB7%Y2W"
M?73J(PRU!@L7QQ=#/?LO.;4&W^[0 ,=[H+#PP4G-FQ\-0.=,>\L&T#I_:T5R
M(,NIUM3![O!Z4JC:_FA,)N;Q1>B)U_*IYE,ARC2Q*>-BA#WE,<YJ\Z)PA?[M
M1Z:D!?AG;,<A_Q*N2)JHCLA;5+@K2*?BB(-WG&1XN+E5._6(,J9I8OX!KG(_
M=;CS[C>O2LKZ$&/@Z^^XLD,5Y#HO^_Q\)&Q:YV8!K#QBH"ZTZ7PEPW_.K*%Y
M-QBMV6.*NS%KO 1-1S>/R*Q^B<2J!Z;3/;#D$RWQT,^TC"7.7MZ?$#3+]]C9
M(2?)6'+5@SO!J4/^FQL*%V3:,R]S^E,Z@7L+RSR(&9Q"!XOT4BZE86'W!_CQ
M#UL,X_.=B:M[0KFQ6TJ] >D)R^)^QCZ)>:I?.O&GHI"GS ^6HS1[9K.%QH2P
MI817,\5P"MW0$NIQS-XKO7E5 PP(7@8W3>@=(+\=G\LF6*B! @5]#P%Q&4]#
M#&QT0/SJ?F!@F^S_YRN@.C67"/3*53R ,!QB"(MSH1#WWT/C^BF>@('!]  5
M+T1!,S3\1U.$L0, 8%8%&OT5!*3DH[$C3A SFD?P;^@M]&F4E2:^9WHK,2/.
MG.>R(I2Q1X(8I0%=[4*E&UZJ-MQ[BI:7W+S/+3:![:2#S!&@?)L F[_\4F8E
M8-':4&SA:AT0>Q&UYYQ6D[AH:0RBQ/M6H+$9.V4&+1AT9CV22*\JQEV[1[#W
M 4G9M+-6$C?[O>B.L!P)Z*O%("]=WVZ?#T":JA%RJP-)7S,/Q0@Q/;ZB26GD
MAA61Q[C)H9.]N&P4,A3NWN.LDM[(JS0P@$40Y4@_25"QJ[4#P?;E ]8O8L%,
M#Q0O.@J[VR#M!CT9%QDB<),M6SJPX@?1L.M]\MG<,))V->S_>9[",@#A&![D
M2U2W+?YH8*! \-1\@2W4WL),VX*GBGEO5@\'X_,7V=OG1_)+8,P\9/,QTI8"
M.$^UMET%0DL%(&GKM\^6%GZK2*JX@5@$9QJRF/;[2379^U.1P1@2^X?!O[@V
M649A]Y_IDHI]1"OV/SD!0*6E)4@2%EI)SEEFFR*T.H82W?BMBW"-_$@B<Q=
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M'QN7#I]8*BDV$$@!3_!'>LE? D5R2R3=:U%M\JWY+=1U1^18I%0Y=B)9A+=
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M?T("WM1%X=$*W\$E,->^;;>IU'1\,#[TWF:A35?$VP@ E?7=UV06OIR" 4F
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M"C"T[IC4]Z!_CLE%E9B9" NKQX@=K.Y," <PK*<3B D'#47 \YJRHRI^%_Y
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M'9/8_,74(R#[ U.V:+&1ZB/G)ET%&:<@!!9J-,.";\CJ?8G(Z#IF&NM&IN[
M! N>5AI;('K("7\U2>E6WXC/4D)NK#-. )0F?A*&4NT +B1-G]=!T=^3O=+'
MH(P$9.D'G;#J+6PCAA/4A*W#O0*,=0!OFZ@C1(M]3CJ^Y"(N.1CHIOLO7NQA
M@\ )Z03!'?A_&.@ >,ZSX%@$?L-G1.K@^W]-J5;"\\_PC:_//WIF),!B":^-
M-GXP^JQSS@)YH6*_S>GD!!;,[X+#"N+X:%<2Z"'4J?WD16X9IM$H[(9R<EA(
MHLK!<*K0M]'08%WHMVKWA$E8J(/V%-SFO+Z0 .!#@)_\P!4L<94^%S'0$,(
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M7V&DCMDT9?5*94*1A-3_&=!VQM(XT<T$L%V!/(;(?OE*VXF5VZU$8CG^*R6
M(Q$R9_O3Z.#8#FPF9T<W"^G,1I,(1&, ]>"1]3%P8[<D1U6?3AN/P; --"1H
MRPL$FA+0)D!H<5PW&T:B^CNSP5,DXI7795P^]M=)C!I@V0U0-'+RRN<M*8KE
M%+;NQ1^$G00R<0'Y/!^[0XKFN94G'DKZ_@ R51&R9$3SF_L6M(F.8F*Y*/C/
M!#I/ZC*RD-4!P C $FBJ6/XSW]F,FJSO:-"MK"S7T?PSB,Z7&!5)(-Q!#V<J
M-\08 NDZ)U>B\UH<$Z,M"5SLVT7"'DXTB1U[D<7I$ -KP]#J'.Q/8CSF)^2V
M .A,E#OF&AAI@_5RO>(%I#I[S6MY?MPI<3'W@,=.K$@B+G*H;L\Y\&0LQF7&
M^!<#],AS:E<)K4W (PZZOG):(Q#E("925$AKL8?C3P*-$$SL1&I3R04[L59B
MXDJ"7J-XKPT1?$@D[F8'D*DH[3[:/E=LH6(#3^JBQ<VR5AA[K\*26*[;Y\H2
M+%!&L8D;TD$V N3),!IBX_-44#T?NYS*S>20L\60ZQ)!KXBX=SEK YGK]*'4
MY+#$Q$1&JW!,U0 ;'A"#MZS*24\1-IW9YD.']Y%7U[% "['QJ"-W1:/F*6TB
MC4/Z:+YV08WAQ/EO\:7-ES+M.H//IIB; "P5!;6BN]+&49=3C8X%8:XJ0!W<
M^?*@9F%+3F@^5ENF]J@:36$YK@3 :AJ,)'5HHH(%%Y#.4H-F*9JHLN^1'9E&
MP@;/D(?>$,CT+1;L/!VRX^<ST&-BF"L!MD("_(3  A+1FJ")2,I:VY4MF*']
M+C2XX@8VLBI7.I#:"JV;.#"$Q(JHU/;J<2%2EZVD0_H,4-<+;)1 1J]I6]#&
MAG>(Q)Q#2T5<9 \B_@#_0!X ABMK_CZ&E"MUR50K,@M]E@!N3\JR=*!\.DYP
M5*FURP[@(J$.U3$B"%//@44S1,4Y!RKZ:<PWVL9OD3<+L#3 LI&=503H=_A+
MGAPDNDCW[960!OUACAP84:FV6PF$*RLQ5-.5_A;U;-C54$<3*HA3D,-6P4;]
MJOU^ZJ[Y27!4&*_DD&\8-SM*EM4L((5W@'HQ<DW2:AN%CD8+NG8G=K<LGZS8
M[XE"_1I#'B.BR&+/&EE[$<^II>?@KRTP0S=="KO>A0MM2(?TK;;HY+>OB&F[
MG03;J]*]7%./Y9UUD9P-_'Q,H^48=:#Q/B9!<F7)C[A*MUX)['^-[$65;PWC
MFQ$@#0ZD#6O2<FTZ!*XF<[/&O?]+[UO20&1[#FQ;#V'@#5#OX%91O:'F:H*Q
M&"V5Y2@GM(.-D0V,W&Z6N8/4)819;LV&=NA"AUEY(<<;%!A8;LL_M5)+8\7R
MU\[_<2'V73@#QT4>[$2+V.@F0MKS*VO,?A$:V%F-=-$Q,M&)*M1R""IZ##E+
MT7PNNEE)J^= .QC0PQ^ >L5_Q'9Q.?F/:1Y6BVIK>O@$L?_"_THM65N#?H7"
M=(R-SOL4YCIT\EEH[$'HMC.V*A:\2SD>4IXX=PHB:Q(QQC!_3/MV#M0CB71X
M17#10TF7!G7KY<>Q$LSF.6U,J)&&,31&.S5BK&O*(>T_VV:ONS/ JJZDO_,B
M&TE6.-9)T=HG:D8*+:+)73ND5]XRE]72T>_Z*/O*.96[L*YTTL$9[>5481@1
M2LF#:F5(IR["Y:>TES\[UB[H:HDM+RI*]OX^<&RF??-XK_07@>* OM: +OER
M976 ?8T8O>'-CK-N6S22.MJ5 )>%;FRJ73)),;V:_9*/,BW1+NB+O>!U[LO9
M4,.N]4$UP-\^]/LN[3"W0\4BXXLR])D!S)L52(IX/5D:T"2U=U!4^=T^\$]A
MU5M3I-%MM8+3&!,V&-IR+HB$PA1"CO+";CK63FE7G7MQJ::]%2W=B)$2R$JU
M=X-H+5F<,UM3[6SM$O]0MPRH/XA&T8\2E;0\Z:9B%=!A!NX6:]D1R/+3Q \%
M6!=%E1IVT-3X7]T^M#4AK6BUKIVJW9FUWWEGS)XK^]8M$(B*+49OD).72>K*
M*&$?P'4"$;^!CIM$.UE<MU)M4@OL.T[XD29-> TUS:MUY6'Y#G7U )"=::[P
MT8Z-MOS0@_P5(W^09$UBH5UBK7+EE%\BY.@K*)S0U75"ML<*JF<AT82-\4G'
M:Q;4L 0R>+IVE^3 +F5"J/F6RG<)NZBZO;&$403,P D6G8.]MFC/'>36RC K
M)S$E]37YN[$5/Y8(VF)B76<V.1P\!8<9W:4D(&$UOT9"IZIF*[2@@^FW(RTQ
M8@<<7:=)"J#":PJXNL9BCZ_Z79-:*#4))O,78;>$Q".TOH,I@I/ LZC:/V1R
M!Y5?' IC!2')7S8V2;**0C=TJPJ+B,6.+#]UR0U-.^-N%FSGJS*WT#L[ST1+
MO6Y8G5OWT%UWAPP@ Z 6B[.3MT^#1(1'@R0 -)&4[69KIO'W$@EM33&P,R<K
M.*MT317GI<XPX_\82J<.SFO;-$!Y^5@;A?;YMSO:>4.[TF%9@RRTY#] P;1W
M@*8#2%!!<.-KB._M&@SLYRNV3JXG[>D7+[] KHMO)"WU3"B>]/>PH'RD=)7N
M9%8W(9\*1NX/[N% R^:UG260-1VBT"V*N #L52FG1[N*!*W-I5Q[(G*Q*2"I
M*@\I"[$BY(<AC.="BZX)I/OE27,Z>.VPH@-?F#:K]A05<Z' O%9<IG$0J<F%
MM C%OCY/$296)AQTRX16,XMVX0BTP;=JS[L'9QQU\U3G(_5V_L*MSOXO#%'!
M[NME9"XT_E1_H@ *:$9;CR'G#4Y9,V!N($I=86R\#I(D@Q8$R$YE7T0'(__R
M-<:@V%MHL@1RS=]NH>Q/'4+G]SQ?>H$LT'ZNP8!UW +:._,B#8J)+4@M!;3"
M :8O/Q7I*5G*ID^'G;6W(T(.G#H""Y*@W(/0J();&(HX;-46T$0V2=IB\.SJ
M6;*FOAT!,N/*\EG[LSC1JQJ@4[Q$+T/(1J&5Z3XU@X2IJTQME$KL0HF%M(0M
M'+?&SWD+A 1C5NJT=Z-B/?.F"=/<M]49*Z6F9![5NN[M;I.TMEGEINQZT"$9
M)N8=;\RTLF9K7U;9RXT+;1RQY^GK\XIMO^0%OG$*[7NSQ[4_AK,!7>NUOE'J
MV-]EK>/,"MDT?Y:%?HT>)^\Q'Z1M*CMOW*2^NEF\XG0RVNWV?'^?U9FLUR%C
M;Q"A&3HO'/+_==N=M7[_\42+9:M*/VIU9+UK.[XRDTXE2Y?*/8Q78VK\VF5O
MJ[/>O3WY=NPRQ9:_F9"$;IA^766X:OJXR84=Q\<N7_AR7^L2_?VS?TG_9)F7
MD(A_5F.YHY83Y]\O'+5]$C+WT5 __O['3X:%2]6VKX[6%"T@OR>O22^V79L1
M&'(!C3!R_&FR];/>G/9SYJ:J=0@SE 9U_$8_VKO$Z].+]NH-YT/A'AUTB*1L
M>&1*QT4$/W@0MRH4M&6#9U9@S1WNYWS]?"PBWMC%8^W_5G?Y0)8EK+^;6(]+
M%P*-UMA>7Q@;O;#>Z$.Z_==;>=?71GQSOK$:8_INIV,4,C)D_;%O81H!%_("
M-SU?'?3/]^E--U(^>:5_^IZS_$?>^A_Y&[VV+AWX<>9%8TCVCSW+O^3"?U1]
M\^TB+Q8_]Q!F+S*VN]O4_@A:;KY[[[N_HZLS/F)$1A\J3%]OJ_)L4[/[';%P
MX=3\6^'/RQ*,[['54T<7-;_^2,WV).]==_Y3(!#QNEK#X^*Q7]W_(^S_YW=B
M,GS9\G]+_Z@59L;%/<RF&X#?OV6?U?C^8,"G0!5BKZT?][,+>SN^9\ GC8]<
MNV?MSC,G<N@DH\H_Y/GB79.0&P,T.;#V,@QI;N,+#3"&EX=V&GW*5@0Z&86N
M[3]A223G2O[^>$Z\@2=TPV=)!15LAJ!Q#N<M<CB *47]7+3R4['[RR'RRMZ&
M,=.;E;M#IC+D<Y1SE8V6TB4GU#B5L<8J+JUU)FWN5HE!]D&4R\43HTWT[,L>
M*+\#@:W^=?:I3QZ\"6_S;@TY&3?Q-K(CMBOKU9.)=]'GO&15@^XI^^P.M>L[
M#-$4:@/'NE^*TOUF1FPCBPB7A.VU;(S>\NS@,-EGB@29\YPN"  )?I$:6@FD
MH;16(V2[2PUWB#M[+A9G_BS7--Q*N'9/Y#^4MG)>TL-EFY\=EKZN;P\.WKRP
MYVH9%,;?X8<S0[T89)WZ=U,)353VT3R2NG/YMA#MU@H9LR[*[WKS+[ME-N(B
MBXW3?\(OO)GX9_/SZ;]%%],961C'_E_[*1"LQ:W3H0:%GFP(EF!4EB*^I[7<
M2WU).^OQ@)"4P4&XZ(6P>*2_B_'S]>[?&XSAJ[(6O/B$]W0_")9=")8^3:.W
M""]3:K#]\<KT=PS-=!TQ-<"P81M%+X"[L)*X1FL(K^5=*9&L-62%]L;77C/3
M1+*OX=5(;)&Z.C*DH)+*>-_@!;?+1L,/N'\.1Y22$D6C#') VPM\E"7#>6U4
M0@+O@O^\N!_RM%T%"J<B"F<$VNY6Z10=_1A&G<=2F[\W.:3 B^KQ56HL",R6
M;U*XPZN]ZMP-J4G504%?OPHT(T:VWP^,O7*)Y#Z' M7ZYZF:&C#T[  <M3U%
M&*SMQABJ(L$/FR*TJC"M? RSM74\Q+2]=2E,CQ.*F-1-:SRIIA4A];[!T&[>
M%A>X-_>$0&M7WZ8>SUW5)0<H3+=R\JJTIR_@JQ"0TU1 UNU-/3Y;@4ZA'KWH
M!#PG.\G4]8KO_9()#_@%I6-D&B&L)MZZL?\*N;(K1=W=5FI:HQ4@\Z8&SFXO
MD7BJV*8"@16/4O4E]V'AYLKI+S\W2THH3]I-1&YWS4)H[,'S\9F$Y02,;9(0
M[I[%,X8'V+>S6V(A1VZ-.Z;!F!"-@8?U8CSKE)0 <_$O>'.PF%OM3VH0D(EQ
MW :J7A!@QQ\SZ156$;(.CO%9V0>Y)AB5;'!+Z9)6NC#K1QN;$F62/@C53(IO
M:Z!BDI92*61?M^%;\1%^.B[(=/B(?>2D!- .A"JK).YP\:::7:MH;#5Z6HL,
M'SG5L*<>-:T4X,$8^8N=Y2SQ3/UJ6Z646Z#KQZC1GK>6MU["]KT 81M8W/U!
M;<,I]01<P@S/WS*6*@XV9)F].:K?D**)SFPX6=4W)M]FO0_F_]5B+;W-!.Q6
ME  JV;[X9\GJI![O RG)1#T6FW2Q3:85L:"&'C9WZV_L?[42Y(4,\R.;AP1P
MB.%>DP#7KK@VB";M@&&^MB+P%Z9J=:1EP6UT4#W7^$V4A5B[@:M93*<GSA_G
MZTY!$&U(8$B2-"+>@E#MT ",.<!7^SGCNFO)80,CA@-)#91ACND\&XGOU653
M?'+C@A=BY=@^K,-'1XJ49_T2X,7_,0:R)@=PQ2^0R+ ^,*)#GEU-\=#VSE'#
M  -F^FR)V_Z*S4TO6W>6?O=GE8;51N\[$.A.9 ;2V)1,[A Z0U8>J>2!^LMN
M^_BJN(0$.H1HKFACRC 4$V"CEF1@/HO'U^UADB]XF(]F+/HT)0R0U&6#-',Z
M(9*=Q5]1C4:'"59X1  -C7Y ]J2#_K<<B*+9!K/?78M.^C>)MI=.M[>B0YMF
M(.A (9 *_\Q=<TF@?LK4[W=6$N^HOD =GN>3IF)[JH^=E!0O]B/^G+SD$2&A
M/DY9\C$ 8LM2GAV'+K<,/(G@0H$%6.-VUA.[* =/14J>IDG/ TQ0]7_O&:#Q
MF(9RS"9"Y0^2:*3Y$&J]0'K[-H\<LNL076 :]M1/[ @M>,VHV*&\2DF&W+_>
MVGL=&H6:I3B+9K%QW$-K<0<UN8!WEB6K)+CM4OLY>8)ALW?)BZ MVYQBP$2@
MA0OZS 7O'0J<26"3/J*\2ZZ@6A#'#Z,KDT(T0IZ4Y&=M6LMKYN)[V(!9V)!5
MX)]39\9(!GHN 4&,/Z74W,,#V4N%:#I].QP[)JC)%$.I:A"HW#=KETP8U'O9
M5=-O=C[<MS#AI?DASY-P__&HI!7D7H:'J25C"9>@@FI07<;QUT88T^)C\4J.
MFAU7CJM<H8UT:8-/F&7WL5A=R^P'3NGD5.)WV93%3\AV<>;G#. DOO\0 WIA
MEYV%^ES:!_:!SAQY/D*.07O?\LGM"9KWOB7^' (=EQ32F4WUQQY[1[<>L!+I
M#SCK85(@#7_,IWWAT4A/VMG3=X-('[-28?O'DVC(X&!_AE<)P4UFCEAULM-[
M=Y-6 Q=OVO/@H(^^2--/!EUI?,K8=N)%O =W^0;:;7&D).(4*>@:26?_:7M+
MPIH8#7_)E<&D^,\1 9R;!9Z-8$48%5K9)U'KX8RBF -H[0@EN.X-S'N!P-=6
M*C+.A@]F+[VMVZRG<XI$)!@S/M.UM6D=D"=QBZ.IU 6WX:4"U?3,$/7$$37,
MISI1#6%L!5M'Q2AOYS#:+"7\Z'X)E\Q2<-)@,%=XW_:+:+D1E&20'8(6+^^A
M']WB\'#S[Y7E*]/%.\J+/LQ:1S]].G<YLJ&"&!G$-7M_D7LDV[V"NT7;F.(7
M&C@M@WBVEZAU,J'A]%> /L#.ORA3%"'X?*%4&69P18X)<5B6ZWN+M*P.YNVM
M.(N.2-80;GK,]88/_=(UUSQ>H;++-(:P^IN]J:LN8]6*FX8OO6Q!5J]@ZC+=
M>-+9%3O8.88KW^M$VE+=Z]RX7V)Z]\$M \STDW,Z'R_MN.(Q[,O3-QVRBAWG
MAYR1,+9EY9Z.<R@+XKBK.2UL,42Z5D.A$V-1R"_MS6]=$[#>" [1+S5;CGRT
M="GZZ&<]>$0^;TP\T6T+!<NBEDVLM:5["\/9\6[&<8\>)M47?#OT_-4B(.KD
MD?;*7))7;>!=8P#:)GY3AI^[#L7KKPGH-QX*(T=Z-;G)8L*=*#AK+8.2Z5-V
M%(FWV</O&SU1L]\O%G#-@5!?39UTS<"^ S<<7$IDE2NJ5HK RT?^MYNW/?[7
M_;4?N_7Z]CU""4A NL+EE:K#;38)_##ZF6D[*S6X=WRJELV8293(/=-U?S__
MAZ[E0S@>[_ X8UFFGSF.O630)8,QTGGP2;B;3A7N%VS.?S^F  R8/\*/:;_,
M!8D- M<A7)1B53T(B"9+$(1R#)V[FZ13;H-R.B.@6)Y SJOSVDI@XEZ27[6;
MY8F1/)D63>0F!LCI/.1\FU-YI7N#0-ORM+M4?=EA.'+12DO54%^^2DUT7*OG
MC!6*%V!91V/PFMQY;FUPN P60. ]>(<F4GE5ULV+3V%KJ,>6!:P)3!(BQNL*
M3'L=$T!BV\J_?H"[#&'<(M!&\;Z4K")QP$!.R9><!O4*G&N#P%U?-+Z)JR<5
MZ.I4T?VX[C'6JQK@.G[<!UP>)H:GI6@;8I?XZ_#.:(JLV@#&DKBD3U'RG'O<
MUM01U:.'D GI'*Z'"J;6IK/\N$#'#=AWOXW?LPQ+XPKDG70)3 VE$T#ESJVN
M#,RH%G*Y#QQ <AO<RQT':^-M::GPX-@-+!@GL!$H*1C UJ[F6FFS#V);121+
MY_FB=4=;UA0VKY-TKA&PA:ND;AZ+E4%<'MGO8*RH).,*8K6BE2\1W!.?T&.!
MKCIB=S:/HKQ4_&<=#U5;KJ\=V<8[D2[ZM!4=P/&,E,+6MID(8WEK%267V8BH
MC*%2CF=)&XPLXDTU(-RE/1[2_<'<Y96JDH';'4<KK]3I$U;'>/(;2BB3VN";
MAC9HOP2.'XLU0K%;EO:_U_%\ ?>8A%73AIAG#D?&@3I*/&^Q)&NAQ*D)H78;
M%JDR6BLYZ*FSG\[AD1M@4_NJ@D1@X*1 JQ&N+?)S.7&PJQGQ/S]B8(]V0HR1
M.[N3+X'5-"!<6>!**8E\#:_'Y?E+X35LH9X#,:0!)$^*W[T8CLZ06S54ZTAX
MP9.PU3)A[#P\,MUXXTS0E4R1A^K.95'06L)9]YCK[BQ$0IO_Y1R0,E]UM9EW
M?S?U<S]B%9WGKH*%],.>Z*/T%H8H,;Q[LI+&A$J]@O/[%F!:/6"]*&B]_VV/
MS(.C--%:JN/EY#OMA3 1;]T/#XU=E>M_!FD4[5[_VQL3.6]SY/827,4O=[4\
M<2IFF;L";GOEWNLB&%$*'Y#BMQ:MEWZ&!5)Y:2ZL$(P%YCH+=V0]_IFBPY+_
M:_N^'CKJ"(")%V%U3=2)J>HMJ%")#*%9IU[J%MH,5)7'C$G24:MU#U3VB((D
MO/X+U3K[4<;/0N?H5<TZ8<<MQ_6Z+E,&:[4+0$K0V &5Z,O9,:M7(KW@\?H&
M^+OR$6IDV %8:&5;F%P1ZI3J;15\OXJ.Y0\)SD'W-;<I3 =9[MLPZM?#/<SX
M&N?"UWP(7_LWG(Z/8!A$N(^$>TTH3AA'^+QJ52/?]]T0T<8)97B&^^U_$' ]
M8L(M(OC(+6,.]%,6P<)'AAI$ABW918:349U^D=F:%6?8$U$G,='?5H95E\=,
MA,?88<^S(R,')^*")Q)/3L1/7([PY$>E\M<;W#\EOO^)'K7L&]:A;MRW;JQ5
M&IHV.)X1?'_KBON;KX_;=CW<\BPJ>UL4Y_KXNHF'F:^B'#VCC^E$[\!'Y^='
M:PFC\T]&%?I$%YZ,SO2)3LV/RE\![?T;S5T!F:BB3>A\/C[F#"J&__<1WP?B
M!L?P\R?WKI@LBXP11<94&L14^L30Q#%5GC&E=3$E)R?WITY63DR6/XNI'IRT
M=GL8OB>V87]LXY'8PZEX_9[8YI'8(\]BFU_Q])6QD@^/]96\IK^/):]BCWD^
M:0Y^(C%[LG1D1=P18=S)(W'ZXB<MSV*/C3S1[XD[.<&S;$,<\COV50[OM(N_
M0'YZT>#IA0WQ%U.?!OD][=X6W[TAON=(_+74^ OGGEZ+?'K]2/SU#_%7Z^+_
MQ2?(KL<'+3[M^?#TAC#^)B)A8$002$WH]GQZRR[A$GEJP">^9W_"W6=/[SR;
MDA])&#XW=9>\X?ZWJ5'/9\,;-EPS>_; Y]DX_MG#/<^"5%S\//#T&7?J&?!L
M9,/3;X 2GS@SN&&*G*BT2WSQC:M.GY[V3'R%3WRY)_&U7>++DXGS^8G*5X Z
M:GIZ?^+T]43EMNF9NL1W*Z8_UTV_-DM\\V'#PM\-SUYQ_\E'>TIA'CTP#^D2
M[/?)YZLESW]U;?S?J[J_".6?O\^!?S<FGMFX=!T&J2GAALI?/FQ@COQ'R/YU
M1 D\?/[;3/F_.O;_\MG_>[7Q;Y<2,\K&%"M_&R015[(U$MFHRQO5LV90YC/8
M^AEBJ1)U5$F@L'4O)VG/)5'LV8CI)&KQC/[').+H1KUBMG[(#&:)#?L^@]PQ
M8ZR>;*66!-\Q:VZ?I%^:C)U60E')-+59HRRV<8A2KSZ9-#JS9/=")RUY67&R
M8U6RVL,D[.49PLU9U]%9W1V;++\G.YU_ 9UGNU*25@^55'FF["4_]MXQ6;4M
MQG1^<MV:%-^JE(#2E,#ZEUY9,4'U+P/F7@:FI;"6IE-,V_A^#U/\5Z:N-WP<
M'/(J)/'5^N\OO>U3_=1CK#B/#U]/31A-W3"=RHB<,%Y,C7D6Z8F8BS& D@W^
M&VB.*HW<$)QF8KDL9<T<NSCR#(%_5LG;.CJ71JE(?1B9K!;%WI9F,I\67X?)
M+)[8.)V6K;Z9;7^8RH9J.0]$#?=-ZZ)V'7U=E/C(=F2S_[GQXH?C7UZ\+@P9
M+U)/Y_N&[UTYO^OA9E[BHV:'=+G?/"\MW?I(NO_)]#TWYX6&\[N.AN]72Q<M
MO3Y@^$88E5YV?O[ ]_G]]6.EI]+W7DZO/;6Y1OW-H;0M#3O>E!S=<DSQIO3C
MEJK1+:63BKA\#=ZS!Z_:(>FKU*63B1FGLC)./]0]7IAV9F5&N^&RBWX99L+Y
M+^PP#'[L].5'_WRORL5OG5WV[M"Y<JK?.^HBK^5\1G?B>3-9QH6C6Z^>WWIM
MS=;VF!(7-YB+)<PF9NXL=Z[3$NJ;QLB/EO?7EP\4OY,L*,P4ZFL/PVX?+7%G
M#S]09M &T:ZB<9^#)0(XOL)4HPYZY\YM"!*7E$S"[),5J:\>[1YY6"%V^RP=
MJ[SR/CWX4;-NZ'[V!\IN38,]'T[WB,9\,1J/B2<=3@4I/Z1,B$ZDARG:,@6+
MQQ045+0T59FF3AW)M*W[N#,8HWJ0-74S^C^I>I^U[1!W(C1=M!P%[<R*S*DO
MI^I Z6I+:9YV?*H#/+X DOFF;=B?O?U[]B)ESMAOZ\WOC9YX 6 )@%0NX'<3
MF.Q\M^-A","-RT!%Z@"H]4?N_MS6QN+A]T9A12=.@<#>7.[:-AAP73$W;W>Q
M%%.ZY=X1>>9I*JKA+$I+4DGICKIH#I8KJ@+8P.J&K%8'\*D4QLY\-.>6FY*/
MKW=#O;^;9?):]8D O_L6^RA=^,KA7MC7\ !+QA=NY/H>X?("R+%'&"[]9#8)
M6<?,6;.A3C;?3/K)1,%?L7?.6L4RX?!I.I!O#\)>@K&(X?]WT3DA>=:+KV@<
MOFD,9*M2&!,@&PG?I"?/,Q*R:^/_M>=\]WN@M;3!EYP^$C0)3YB$5:8@GL1Z
ME@P)DC/PX3?@$<N'OUT9NAEXYBD+L 3Q6#8@8KC&W<"';_0,\;/ZQVF-*$F8
M\!H;12<_*X7M.UYOY=^WBL.+G81%W,/N[6ONI7_C2^$9RT7^*EB_#"$0[.]U
M\(M4PO)>PVZ$6T5*A/Z H(2-6-L#'SXC&@/AMS;I<0ZLZIT4G'SL%X<[^M R
M:*P1$32_+U95\CT"45%[XMD\;%()I\9IT5'PH1"Q#QK.ZX:1&[YO6"L*F/R!
M=1:YH@O[=8[XHW0B)W?RW$8F](X$*V'U#M]W7Q'^U_=1:#V!U:7H#]BK:U#B
M\CTPUO& T>)2D$@]2E:P=VSQ\5")ID2X[\"J"UJB5L=*ND30GHUJ^1]Q+:%@
MVQ5$W+WONSX5BJ[ ,(1O D5)\NONM=(>_P9XO<F/C#YQWH\/UK,Z&T_;3%PJ
M+-;#1\Z7/"VL^<?(X'GXR%H@<-B_8+I!N#:]J%?T(\<TL(+P9WX(AJ;__L_)
M/>C?8].%EU$%QNM0#C<0EBJ>D0@1;\EGH.[[6D*Q=,3/8F'8(F^Y6,./"EGW
M"+T!OGV/<(5EWJ5Y2%8L#%7!8W7X3+=]\6P!E5H2+X)? H3'"^$E5&&\ XP:
M4U*0!0_./F#L$'5((@"E_8J\%0?;N204%^Y6'M(&P%A+@-H\.MW_?_"VAB I
M ', , J<6KJ8S@*X?F()9!.%CICJR[\["*IA(T+#J&+FZ7BR;:L;=VL5#Z+H
M4/]<5')![6ZV#D?%&8=02)I6Z\$WE)$ =<ZV9;S3 ^?<C;-&&@$O1 F]^P^K
M@<B_:>>NE=S&8=?.W2:Z6OZ)+4B^"6-T)V;N87]='T9TS@IM9WEYE\?764\2
M>,>W/,7:)$:XY6S5%&K9V\K\"FPTA=K6EO";$\?A.&S]O^UM,M\J/J8X1LAJ
M,1&TQYLD>C1H:?LFZ5BU?F^5I0GVMSL$^"FW8]63,5E99TAC3)]]L1&(%Z%V
MLVH?A\LVOSE(V+2$@*WMMF1=[6IPL5B[-OM#@A_D*[QE$G%)S-K4*1C-M1YN
MH[^N#],Q-VPK[Y?T&8:0T\5*_YIP%-(Z<R*4@:,0#JU+HUENOZN'8W]#PN^N
MDMZRH_52>4:"V])G=A>;%7PL03I[JV3X3<Y=FE8/BY_83E?J8:ZV />S+XZ<
M+K/6&I+J9)$CAM!F&AU*/IP#Y&]$Y+/G9)@.5JH7*C.">TM@V<OFH3#;+C,K
MS[)2(0QS7-F')@S-T6IW3"6O0Y3X.]PU6MO(@1J2F9)R:U)/;H69UE2?+\HQ
M0MJ'"_5O(\3:=ZADV[[+E7RT:Q13$_TM4M&'-E/F6M0T+B7(T.BE_%,$/4KE
MU6F\A0B V9MQ+9B;G<-\!!W>.,<[=J5B^9"=V'+AMC&=EGN7))SZ+"!W-X\-
MV!VS7!BT$]CF!)JLX? R"553XS[$"Y2%<CM)@5Q@40*TB*3)4V'E%/%4KE#[
MGCMXQVXK+0=KRFC(N:O-&'[RSXW_0?I2&4PS02J_F'5-8"<==_'WPKEQN&8=
M*$6?'86@4C-2B^$>033UY +K=6YT(F]I4NBW:8@!NB/3>=X,!>0J<V68B,YD
M'JQA*JP_H090W;33)E AHR8= M,B&ZZ [)#SKY# #N7QBSLQTFHTOOD]".CQ
M9S[3S0LZ'+#P)6S7RG5-GL]Q<C.74(<=%=V37#&S8UBII^]J0WUJ5#S<)S/O
M_F/< C_@>0BMAQHQV8ZOQ :7)6ITW,+ VCL43^R4Z,NW06[F$-<L?UYH@!X/
M53ZU,TY)Y<^MG$<PV-U2!VT+-9T5_2,KO0_??FQW*?\N*K\M]Z==<P+W+H;Y
MG%0R=Z-S[/=C:X?!:?V];L!=NRP5C6&^<[X;>2KY>1C?L+"Y^*ZAZ90)3U&H
M+WN)V"EM>'VD1\;:A>X6LF:U=LTPU5M,IM8[)7E$NU$UN0[ ;)L)WV.*J:'.
M'M<+60=2: (H',V@.LT SZ<8/!R;I!]BP2,]FX5G-0AAAY=RP<-#26#[;SRZ
MM;;,7=$*U30,@B\!5RO/=>H=!4!-# A&M[YRO=C V/R5"E7LMLL\).L_?)B_
MHETFY*BUH=""F][?-JP36LIF#!,;?.CZ])5FW'Y;49L%6O'!HH,.P&TL&Q"C
M*9J8& 1U=T&G_P.J0V-Z#8+3LTKOTD'_>A$0U^ZGF;![3&/K51[,7;/D8N:]
M9-PUGQM\U;[GN_D8!J=/5X=8$1\C1W?3O99EC77$5X*H9^Z#G:2%$GOJ7>1^
M2\H-$0L>JV2B&3J0E;8Q-L)]*\[3LM_N$ET43Y<CXWN$VC(.=KT#?\./)P_E
M5]^,9//SV R63H?6A:4+F"%):#-+"-I&\9"+I=#NJS[420X$]U@X\F^C#.&>
M PA0OEIJ,FIN.A6")F64E9J5FY57C#UU(H 5/3&0^Y<R8'B&TL'B8B$&@#E#
M!4[KR9&_70"U6GK Q<G^L^FY_%4R69GVXG]B_T.-VR='J%WBX2:57'>E<4%N
M S8R8J%T68PL.<&?8: 55H*L)-KAI S<I H  ZAPIP9_<W/)1".N:\\!.6*[
M+>'(T:D@8P$1AYT&8*0IKMIR-G=[EI<F-D6X._.P4'W+A=X7H3*/;8T^!AEB
MR.TRM]"Z#?9&QQV+[I6HN5J"OTG>FGWC2H<.L>PII]-A:74#UWS'?*)Y IN\
M3,8%RQ>2FN(<^%:2'7P*?2#T:$&%EC))0X-=@LL2_V=ARJU8XY#_?<\EZ@P+
MK*M[A?I?9YLH0R#AT<_]J%9!V=<-CTQBKPA@&82$A2D37QMER9MT?IDFIZ]E
MTDI.R%Z(GAI*]UW1BJ9F4&%J[U5@0C+11HM4\FZ54LVQAP=!"_6ZG;-MIJAS
M"/K.S@ 9O>>L^" S9MT][>)76]NY7GA?B5$TE5ZS9]$?U:PIJMJ3*J3N,BUJ
MZ"OO\5%MQRQXI7J:GJ07:-]H<M/32W/P-I^H)Q,GM?3O)\?NO].B1BLPR=A2
MK:LW245\28FY4:JZ;;>DQ4.O0_61LWB8Y1[A6(:;T&)-*(8JL:F_T?KJW"Z6
MG0N01.QMKK,-"87;/Y_5VDBM)S>;J5$=-+'GX"4:"GKP5GL^+IT TRXEC*[S
M<A^'F[ZNU&+N QL$UMT7=1!SYO?B%73 &06'%X>!Z^/I9"0JT<RV\\V$&5V]
MB #H9>QP1KI'P%'B%:!Y %@69@)LO@T'V001>$FIOEWF%;7F55,LP,>;J)9Y
M(9S+ D=:U6RH8,U+;O@1=RZ))X'?FZ-'K(*O7Z]1 +-X#[""IUH@G:E CO@W
M$(!*)C7.XRYMDW+]OEW+?KUM8^O08?2)L0'\%@/<,:T+T*J>):H:YM) T%)<
MDL(3R*FXY(,8_14=4KN.X7H6P%D?W+>B2W:^PJ"'Z3:#02M;2 8=0]GM:K
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M^MN$H%M*GG<S%R$]@%*DH?X(K,5<D+;_"$>KR,4;ZP:8+#G23S4>\N9 >CH
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MV4.#VRWU-"N/D-T=O7'CT[HN8F+C*$2#[])]HQO-("'?IU4V[)'*]24.JY:
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M^^9[!736[)T$(R]=_H?*=72H>!KA-H,D Y:Q= 3[CKI)\GA;+9$NN\4 &&9
MNP\]-5, 5OI!3>ML*E-PP(.H8C,P\9<Z7$+#15+B[-:%=6)-\,(NUZDY#07I
M$1JA!L ,F4WRHRPCV4.D>Z[?-%Q3Q)7#7V3*$-F^NB^.(LV +3YT;X6.7C@
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M;B+'R,E(U63,BE:)H#YYK6AC&TTU8HWLP]. 9KD#QWQHC =X7S-/(6+8;5+
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M\9KA?=ZO\ 4:O-&!J^?6B!]%$@L,[_L@JO<J-G^E%Q!D*F<$8U@[4B VR B
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M+T)?0H >]:^T"0:(GY&>$>P>']H0D'9(G9;U%%-72*WKQT!LF&D_1!%IB>D
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MW8"Q0*T?;BO;HCT);TIDH]YYVGQ;J?*"1:N15;KE\$;!WWYFRF+7^@7JRCS
M<'^K^]K_)<%G-<.%^WTB0<(K 1)'N[0B6Q=6M#@/9]&&8'QE61A7@-U)NV,G
MH(L)JBE==+<8BA/?*ZSC"('5TD(LT(]%@VY",4I51D.+/5CBIC$X-J_0E5Z:
M-\.QZQG2-9+GDRJ">2+#=@E*4;0NXKC95-']7K!-!!+P^FB%1)]+B2EKQ([9
MZ<DP[ULEJ,FNHG']UU"1E0"(26M,.0$,%##7<H'ANUZ#0K&!$F&L_]L[?3&%
M+PY* \,591\C$"AV/5DACA*?E<I%+X;1)I>TR'FE!J*Z^@N7]=75"6I8F5LI
MKT,4U@1_<:$HQ_=J@@@(F2SDB@O_X(A'94#MK[Q/)C%1_.:T7OC-[8VWOFM3
M2F'>G57X)GBPS(_VW&O0JC%X0$Q1H-4"+;\DA(R+52HD0W@M/P(6=##  F4<
M=@U52%S1YSW Q=#WHPG*<QYN(,6MT5!XHTPF-@G%$NBU<'XK5GD.C^_SN"PA
MX.N)$VMA\:!EEH'G<J.GMJ[V_E)]?E7M=O?G04!ED@0S3R#O12>?'MYII7-3
M"[1LUWYPN@%++\/*8>%Q%Y^T(/2:$.2Q6ZY"W\4%Y7\/3S& X5\KAH[W[I+!
M%^6EQ+'"^3R0(J@)4\$QW1?QJJ*I?-B:TK*)[6**FYBH*D+SQ)1Q'+H,B/7%
M:OKE0*U;,TE(M-E?BA9<H* O4?+$VU:#\=O*5@LJ*"S?8_746H'$(!T,9H%K
M1;"H'*\R.=J]M(S*[RM1W"D!X.U7@3;3J@2N^/Q]..EC(Y4G)BNK/=7,;9>J
M#/)$6"%,[*,;-8"F=,.\N+<..H0H'$=UKOKWPLHH8ZVHR3%JTQW/:/!3&N@J
M0/06%J)$8+5?N>E>],]",5E ",77E4P68=R:PTM%<4U^H<&KM]UIL_&N-RZ[
M7Z(LHGZ7)>;4NO)TNT[#)Z?'L/S*(HYGE@-6VN0UF"/&RBY2:^P'A&4)<E@1
MS>^+%99&)^FQ?+T%X(?2,D^_&Z^?:V#$<<Q,G\AM3&>]&_G7X-%\PW!6N;[<
M6N%)2->GF.\M;,T#&KM%.CW O*F+N$=$XHLOA-R2F/&L"L9@'TY9M' 'N0-2
MM'@M<#^F"=&NX&1Z@(9"6$R:F+I\F\"OC(F6F'3"X[M-8I62%L]RNK:8(T ,
M0V5Z7 IF[,P*0CD'#>?()P8FK@1F@6T !CLOW>9>_QDH\VH2Q\E'PTKKT6*1
M6@&Z>=?Q@GU7#^ +1:2I <H.?6SOHR!Q$R_F8U6M# CAU<8IX%I<APJ:YR!-
M[#4.NP3<?_.R#J^ 76(;O"#K>HX5[JSAM=-O7>%KK\63VJ2%.\$)-\WW, _V
MXY4-4>]6Z_N)$5]SR$5+TM<.SAA\^60;.B''YF6HX1&V.' "_BU;$M=]/-]=
M/'59JS<9P>&=P9\Y'C=?5-Y=YD@6I__4QBB;]N\7+]07AG(!XL?"/U0/CDW2
ML4NF48@(Z7V3T"_XKDB[+?T]MU;75-,:$CAB"KZ<R&[ *FE:W45K)]U6ITA^
M?'JXUGH\9X4E?,NS[(5NQ('28!IP\C,,,49"T0E>R]0P 8#97"BX)B$*8[V$
ML09J'&WY2!Q;7"VDQI(K_-LD,*"%PQ5=;"J\WR0A\77*K4#".)RC+GRI@"/D
M6JZRWRO^+*J\&'Q"$+3M3E%23+D&S_(-53Y+X(-O%<3L3EBOUMF=99=\Q8 !
M+YH4UV\,NA>*1"E7$ XW82_V@__@.U#X/L_Q?O=)]"?L.8.;9THV5'+H(@\E
M B77HD1'?Q36QN'%==M77E'#%GF@8YP$A7>A.%?A=X")^I'M='" %G.%5\%/
M :[PQ(ZAAHAN.D4V/'R@%%O6+*6#+3P)MKO(I$T?H2K:;U-*6VZ\%F9XYR@"
M1M?]Y: ONP'+?MBB %;QJ"'Z3LW!_,(U2Z5DY0T\K_R_/A/,F-^#&(067A\Y
M28L=J_R+MX&D+,MV0+^X)M&2QZZ8.:+K :37 %TM0)08^)GM\UH.?$[1@):G
M'7._O$Y(>S:1S6WTD#]Y%T-8OJM+%$^<T$F4<GYM/:*JS)5^+*&I4 O_RSQP
M^FBP^0N:,D](! 3]0O%%61%! >SZ\SX6( ;&F2?2M7YV 4871%B6>-7")2Q]
M3"KB#6+T*)&(2;2X:=BX7P[;<&T-421>FW?==5Y:KUB1>/4:/H_4+I D1Y=3
M6&@#61*9=7'"5'R?,5#"?KC#P6&-,J%1'XPK$U<WP0DTD,"O8%X'286%;K-M
M!#I(H-=8I_+LJ."!O3 M%K@ZZ-SSRY)8@=C\UCDWC+4AN_J_)*TS(:"KLNQX
MDB&"M^(53ZPQUW&EDSQ$TJL:HIB,+X_A_WKT\J=ND2%=W![5@ ;@P4K,DFQJ
MRT\=;^LI&AW44\-(:'AP+!;I#3K_?MP/!SY$)QV/!(],5.#[2U^"]PPKP:B/
M(VB"V \>JC>_8N-U20@+)*+! TF%&@E801<KOF^$=#8U&$"F-/FGF/*5#FU]
MYYGQ@*/YG9/W';'T"\Q$=>J.P9-#'^>FKC+3CU6L[?8UD$<)!YE1$N;VD[2H
M,'!3F];V6XB]C1W[&YFDHW/95*U#&F8"USR6+PX^II65:;9]H_]$*%%2S"P]
M]C;\_-D$]KHNUA/KVK1P:#X1;*[:. ?MF*NQ-]MFT7>ZP\9AQ%QD<$(3X]-]
M22;1IUV+_;OO[YYM70()@04>.&;>N-%L']:>"/2[14I(\_.%(TR*W-8N<FPG
M[MVI!Y:UC0NF^YXE%RP L'=[/LEZ72S.?ETX=_;4:>K[$H=WQXZ=*CB_3>ZR
M?2#V_>#N]T.-I_H;M^<4K \S2%/<>G_UZ?MKQ>_]DLNW-BY\//K^=/?[.+?V
ML#3]H.!%J_,FMB.2,,[B0M+1G\U%'+Y^HALC3+!"- </F72)4'3L*!P*[2["
M7BC2(G1X*@OWO*S;X;NCW2.].%(2NYP:)F.&EW[('5G,BXUG!<>]XI^PB33J
M7]YQ?>Y$G(QH]I@Y&UL>-CG#PJYA&RR^>X#==DP#AW$!""^"<6:"(Q$P$2DS
MX+"I%P505,UCR\+&_X;Q1#! A&&C$6@ 9 $MK%H8"_CQ>ETY48SB)Z/HQN=;
M:*OYHK_:S'L;3T66B[$* -$-:)5BTE[R4&DS1*'HFE2$Y;2></MGX/7;NK/O
MAHZNC.B*R3P&W]0&;''9;IOD4>][TBO.+A-YFW((7;JY0C]PFU4.+IAN?/ Q
M$_[;.VYZ.GV=T+K#:0V;0)._I:_'KJ$]2^ )PJ"-.6>8"X/9O7R>M D.T<5K
M)PM)@,@QYT0L%[ [6H'E 15YM@<L/GUK+R2R1311<YP 0'47A=%!0/TR[7.A
M/A[8IQFXX_(:?N. X;&GHV'3[X8(W;\5O#V$FS\\MZT,^2XUHN7G3!L<7QZ=
MJD6<G/PY7'7F04-?>LXKH+GR:V??W;>'-38'GS[.RIS_I'P4L?+FSV:STD9[
MDR]+>Y]NW1-[_)%MV<<[OCD/CM?=^</P/VVQQ=MTG"Y-6+V&<]5J2YIT[Y>X
MN^EEM][ZZ?[B5O1ZV<F*ZK3HPSDB9-D'&O9%3%K"UOG\O9_P<JWBKU;HO)49
MAQ=L3GT[Y2:_;"CRT(8#PM)P+HC$1\9P@:C'/%23=$<0@.*3/-W$H0K,X4G>
M \ROJEC6 WJM/PZ;Y,0JB_ '@$T[&SLX&5URD<MUQ'&G7LT7K]0E^0O791BJ
M:<W(^#3=F&I5AJ'E%9H?*_I?[^P_B7>,)];H245Z>.8D[_7+A+_T^+F&I<F!
M-[^3I(!WS5>Y%@9#UYT80(>AR@REA]5YX*M8D(0'O;$8%4NL@PP\M+=!6)-\
MF$\F+(<);4%R7@,V(S\Q[]_>OXJ(<L" +79[2:)-/L>'B>VH?:'JW O/&L/D
M(E2:.*Y4W)Z^V1U?;S"IY:C?AN*=+T//L>?<I_;M[\(7:<Z(J?/P&"6I4)1,
MGJ\I%!;RVZOB.).WYS&-OY!A"PPY\&''I?VZ >*W%77GM,2H)KO;4>*F_]Y,
M?-X_]HUJ&8&@C5\ND&O$U^BO?.-P!)G(9;!(@#P8$[>) CC<73L?-N)%%,!*
MW#XF/R@C\I,'S8V]\)XN?#6)L[[7+N#8?*%"H=IV4&RN"=,#T"%#PHN\F!)0
MXB6V?M7B]/9II:NUV:0BM^(PFF@=K=,9X3VJ3:3:-2KZ"T:T$X=2+]$)'0_.
MQ!#<?MSA%SRR);=E3F4E914?KQDJQ=NE+[$>=@8?<=RQL&3UN#OR5*2=8TJ9
M7;N/%8$^'/A'&:(N,R*/;14 !%_ =2N>C  R=T#-VZ=2_6Y' QPOHI7I),"P
M1[M-1DX&>VLNT"&5D_HI%H#H [35]^R/>3GA5;D">O\HWL4Q3M.RB_/$1*MB
MZWV%9&38I-HJ^=7TDNJ/,UZXS"<,7@G)'C6PPTA^L]R;GDAQ_//RQ/13C%8?
MWVM\USVH->$(50A%)SE4/;7>.<%RV/ZTU/#_%)UY(%2+^\;/.7-FQ1AC+8/!
MC&4L#96$ZLS8ES1I$E)W2)*DH4VE.C,D6X5DIR'9DL92)'7/2(4V2B6IQE(7
MJ:1NVW7G^[N_O]\_W^?YO,]?S]O.P#H\K4'ORD9&^&'&E"159Z_>V\4.VS:P
M):G*81]JW#B!TA['YT=RUM*[(]E8#[#7J2/!GZ3Y<;! X_%K/M^X79"4I?'R
M!-,[GM&$T(W;A3E;F(2!+P:6A!ZF@&S5P.=9-B#B++:^[8%N][TAV""N>"I"
MXJDC@+PW#RB6Y:G9*_GE^X\[8[E^//LT*)/SL/V>W6&2G+R_/2!OTBZ>.W02
MC'KTQ=QH]YB9!%'IP/,A)N3L=]WD=GFNU-/R00S(;N_5JE/3?;8>]-9K0_TM
MR%'2^SB[WPK,[L#P2@F[U4 I1?:PDK*.G6F.1#0Z0JI0=L=4O85[OD#>;T?G
MY:/&7ZZO,$MH7S#%#,OD9KRLLUR,8FP:\LV+?(,RE!?<'A7$B[2+^H%5[!F:
M,VA8,IK8:-2. +U^FL+$+-++7PJ:^GBPN-NVS"K'UX(N;HLI;:A/E+2:GZ))
M.:U"<25%]Z%T:GMC5#?6N3< '<NV=\;ZMY>2/'7O&1U9<.@US4K>&/RLX1 &
MD0UHP&X4GI,R$Z_*GV=>%D:2-2"A3C?N$AGS90(_>405T-"EA1F>?0!@V1.Y
M1"!^XE<S!$/PP#B.7,= 2!DWUP_ZL! !WZNC?*Z;A795 @WZ#9/2P_%P0Q[I
MF-+T":+3>.1@)?=A9)^)91N^QM-JR+0?-[%;FD4Y]Z\I$3<Q!BDZ8P-%66]P
M:P6_?+Y&F W9GNW@@3#C' "2V5Q:G4 GJHIM*'7>O7[JB "M(EDJF[4/Z3PP
M';"C=X&]+#MG5^FGKA=BU[GN_SGX^E_[<A+:RMD-\2(U?PS>8]'E"@J<U<SO
M,]957CU)6FOQ&^.\R%O>Q5P"-](U'$?Y]TAGUFNZ_'J_IL8;:SJ;\6NT:KU>
M\:C% @TA9WOJJJ3RVSB85["J'M:<GO!566&$<04*V1QZ3:GZ6YKY4^)KSR_,
MXHR=5,MF:8^KI1HQN!FA<7UF2R /9C37(:MN')3ME!A"(,BS@L%\N8)L,7;2
MU0#36QYSYFGT0,7FV2F]SRWIQB%U=%UL3#/I+*XR9%MNX$]Y6&L=;.(Q4:(U
MS-MF/AV1;#M5M>JA%'*6]AD7L;S4:+W061&.G)]^$B<W@Z,X&P '';.*=)&>
M.I9B8F$*):P$])?3-IWE2(BZRF[\DI_N3'MG>FYN2WZ-&YMSEM\26Y]*AT(4
MMD()! BZ-2$:CRQ00BOEXX M4POG0<-!R3;PF"HE'; _A^J7*;V7<E&RCQS2
M9\P[+*.5>#HYG'Q\+@,@'T:FH\<(0/*N R^*G_CXR:0KY&,:SWD*]S?!N8M_
M1ODD8;?KI>U-KLI3L!U_JU'<0(&VC.22)$^%J2%U^T>P\H6^(D^NJ<2% NO+
MGO0GH/<R%IU*A9)6#H)+V3IDUHRM+CKDPUG_'\DCRMO%)Q@"#.C*K\=KHA=A
MLT3<2F6TGJBLWO.[:$/9(TQ#XV(/R_Z'4[MU3-6G0X#KR___H#/N_2*69QR<
M4[X*SH;H0Z\-8T1-56]D692+O",!5_.@X&I_71'/N.WO(K?T)]#=0T##7(N!
MZ[RIX,A&563@]<RFT'J69M+$*]@L$K<2B-2S[,TU] C)'1JFG3C0X]XF=C!>
M)8./2H _4JR8N!6SRZS<RNK\HD6X-0B3ND)\FQ'R!:(G?]2P"_JX+<C?D&/1
M9J%7G.*CIXUS6AB3.CS,.MP$2\J=[;3U0D#CK7.70X<RP-U7@Q\+@[H_##CL
M91<-ZO[PD5$"J@CFJ+O[%XQ"D=%H&>I@?*,/ERBOO)4H2[6AK^B^FB;3;"!)
M3(*/I*3%LL\15G.EVHTZC44/5D$8R[CH;B;0EJ:[WX );<4H(,V/!@K.X-5A
M+8C44Z/>>]H($!FM'5!LTJOG 0&N9 !A"O<#@&KW7&O16@93D-C[R,<6T'[8
M !-NO.MQG3B4I1_W+&6Z/]6(=&Z%1*F ]4PEK\L>I"ETE^'WR>^DAV\C._U,
MS7S6=0=?HT/,5>[L-]@/[(UU1SWJJR$Q)BB*S^6*KW^Z5=GWE1QFSMZ(?ES=
M*N=%1E<"@46R\$^5L.707C5W\\-LRG /N<:#[#$@T'9Z\-6BC'++^1^)]NHG
M2RU^U)Y4R_NA=TC H]#9T.E@Z,2:G:=HO\PE,ELO?)$0W' FQ7"- 1:2=!3W
M89D"#5VHW"$<S8/YK$O-0D1ZXDZIL0=?*@VNHA_!;/9XM/R!#^N!CB1JL1W'
MT#LR;]W>(),8E6^0 +NI%?SN[NV_?SZM<I:?#FU/5^RWJVHL[X@ @[MD[+*U
M!6OB?N@YQMQ7KUJ^L^L1E; ^$32D7LX+L$+7O'=9H9[<\F&'6BK,]37W"-L+
M/DT3T9,--V4% E%.#\YL6:JI@[.#2/II5T+=4I=&^<F)P3(4?O"E0WJVZ=O%
M(P\XZL_];$ :&P%DJ^**LONSM5'X! ;@U) C!=^++[+[-?^+VGL-5J!D&A.2
M'<K>*JVB.^D@ )&$PNA9H"?[ [ F$0#?V$ND!TY#=CDX>"[QS=4&Y>9X4]"(
MSVQ:$7*(2?41&D%ZTM>O[PA7C[ZU\T/U5_J(J#8DQ3EUU1)BG32+3A.E:,1V
M57B\YF\QUWH*/K^8EX)A&F93(_\8/Y5>#X4?'1 !C'BFI.WM.FA?!X_D(\L\
M,R2!VT)Y^"FE]-O&;I#-#YP3"O[]L../8\AA5*,&*'VO;DP@UU5<?;Y;RX6E
MP@]/P+5SRF2G=/1$@0_BAP!&*X$W+(:&7/%[51J#A;EC"&D )"\\\5'RX 'P
M?_5W?0+X^%1,O>,TQ];0+A6C/)#,S<%0!\80(D<PE#3,T_!!.\KN;U.":E]@
M]_]43^!K7I=X. .67<BN+K\C/DBRUMB?Y$5D6J9Z.F(T@,$81I1Z62#(^I5
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M$$!O1FS!0DXCR1XUY-GV!NKOEOC[B/2?RR]#.B&SAO9,J7Z(1[/;>G /6-E
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M7.\Y!VCGOFS;]>K6*=<?LZ:=1_Y1:;AUS(WU9&BW9;E=GW_WH-3U./7FK\;
MDK4-O^LYM"TIK<*-YSTS#EN&-UXS%-[IZU0$'G<T97U!G[&^*FT&QP.M<]Y/
M/]N8T7F18J,B--/3C[3O:S]_:'#G,C7+-48]9'9K8U %@U@G'K ])T@\SRN.
MDV8=;%=V]W&(YXB5J8U%!LKT<AD;8I8Y,Z6\CI @7Y\['WNWG5FM(D7E\!CM
MHEPOXXRH/#_[C-&4!U<%O/T!@2O7^QQG,*62Q\UY$(Z2*F/S>:=]HXNC*XH-
M<X5-?=&E\;?(ENZ!G&4[//8^,GOGOC^L;4?9@??6.\X?=EJ6A9(^;J>5W%Y4
M&7/A-&&E@'>,ZK+S8L'6S)TU)8=9,>=,GOV:VM-UPB^V_I8N+[6$NK]SYZ6F
M6Y0/_,:[?I=.2:V&H]F$DOY=5VY]UYMVE^1@*&XI:6IQ0+I*)UT%G\TNHE4]
M;(!E^(25H7^E[ G!*'9)(8G^K5)DU[;KQ%7.?U7,>!VI:QR,S+*_T?K<[W/)
M7BY2:+>_(8BXK2! 3KP.M7^P+X?/JWVN7./K,M>5D*:3SRF6*].B%_1F(RAT
M@_0LX\<%_VSPF>;$31A+1N?O@OO^[9_??>%:=K1< \\'<$YM (IO%],!C=D9
M$#.A@A]/\LK4F<-=INN#C0&G4?Z^FT'KRJW_8!GT?V(!RH0L)C#@P'T6_Z@*
MV$ =%4A$2]Q>"WSLU07W#I++[FC9D\M$0=#R46COVV/W&AOXY@8BIC$W?Q/V
MM&&4QE?/GN8!1IPZI;']_FQ$!;TX N_^!BX?%4@'VJ-:I*2],7<I$U9NKBG]
MRUD"A<EQ$M=;+=_PVSTR&V9\(IO))5DVRTB1[L8QYQ#(A'0SXB3#%-.BVRP+
MX=X^<)QIPK593GN\WZ?Z?(ZW1MG"F!?37MF71EH2D^C/YG9L(AJV8^OO,1Z[
MVAY0/5@;=-M6,JP\J8V)7%L%/,A#0/8G*34<$1Y;74K4*E-N(W8JC WN7<4U
MCT%<G\=V9LX*W$NEYA[!<SNK!*G>5 2AM:A'PV)0.O\ @9?+LDQ.GW"4AXHI
M9KVB2P"((G'=0*OH-HEZ89'E1]Y!\-5M'$/@GM+% ^EHRN9@&L1XH\(T$Y-P
M0U[<%%=@'<O<6='W1JZ[I :S/+[K@N&1U ;,-%67(E>W7]V6\8FDW"F4N,-Z
M7+75K.T$2A)F-P,4+ :8VHB.D24E0WHU_R_^/B[Z."P'796C!-IEBO"01)#W
MT]3:BH;A/>BH3H=H5P,-4)\! &<YWZI8O0>(5QJ\6Y0*0<X*,J#T5$, 3?I
ML4E\1N&:!T] 2AWNH)D,6.P# /ER'L"@09ORE< >&0)%2XB/<IE@>QVRY/AT
MVF9NP/'9Y$"?80#8V 4"NC^W;Z8.07 ^H'V.B\)!(H DRP82Q!(0.]>NE@$
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M4;2-O@<(S1XDQXE=+FPC)R+$9Z6LY1B!(S Z+L!Y3MP*=CU=FTMFE5DFH2N
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M/JC6IT9RC?.REE&.,7'M"-2@DD'@T[N1V]A)[OO-$O224--](ER9,LP>(Q[
M=%J1QW$Y@?5@6X(9:?%[@E1"/!-NU2Z&AGW _RDHRA;B/NT#QF[$Q[N>S;/6
M2&1_F IH-C+BX;DNQ%1HD.3(*6/<S(+,$;!AKH>0"TDQ@M!3?X_2TQ*PMZ*U
M/TKMMY6YC0?8[\=TS%(L6Y41!W+NMJZ$SKD/ GE'"1%>#0*(*R/ND1'-F7?-
MG[S<6T74$ITJSQXYIR2<J=MIXP ]6R#NNTNQOUR:W<@P=<#1E) >=W$2YL15
M$E'DR<"_A"0QKM]]D#T +0%P5VV<G&2C>O+(_R7[2+76%- PIX$1E1D7QQ6O
M=J+I[]-X8/,%L,_1#A*">F+RBG)O,[G)4AFT.H;FQ%U<$H&;_1=:(MB^-97$
M14ET+LX>@PJX^*U"(XD *DYVC)=V6C$=2M;CC#:.M=-P^'3'Z2A(,Q4JD$$3
M_.<%S,=(PJ&!(.)CM4.Z D@7N&'> K'G.FI70DJ(M&^B-RT(>AR9#51#99N,
M]@I E@"<_ZIM+_:P,!U$RLE%1]6NF[_*GR/$R8B/UHY>F?[3VU%-'SM3)A@^
M-K>;C20ZW7QLNSIWA=T06T&9<EVNF#T5VT1!D8W[F08'1+A@.Z:>DK@?>,B)
MP'%-WY96;3Y])*A :9P$J#:QT%/FLD7/9_6$GF1]0&W C+CW!Q*G]#P[!Y4B
MYPPNOB0DX$IE&:Q;8X')ZTS73T ODO>!N 3:FB74L+-'F9L&(4MWXH:<EVL>
M&I5<S2..Q;2'CCC))UC,94T15KL*R<=FLWKMV8?2:6S!L@;Q9JDRS$E\R%0+
M5P;@"D2KM]F7#&:RD@7FII50(I=,5@XM?W)C[W^6T */[ 9?K@?])U]OP)'^
M/*!F!QS<P2/N7N]Z<1=X?[>;#O/18CU<</[3S?]:G 5B3+] <8+$XP-0X4%H
M?S)8TDPT5Q*YV#9+&KA4Y%J[#5RTQ7QY3N#-F]#>S2"5#B4@RA5;7M-5F-/N
M)V.3CFIF<^\*>#@6C61.N[[N++0C LJ7O4^20P'K(;;6S&3+G(8IA9BCM!*'
M-(2"RLCY 8BD+5[I^@GZE  ETC#UL>"B-"A\Z>.#"'0F:>>>N3,$D!2;=BU)
M]JF*_-3$(7O ,;M!1'X6H%\E_ADG,JO.W?.;MWBY>(-PPS9B,SF?*W7=>V<P
MAESBT.[Z]/;Y>/)3QHFBQ%^T1$<)@MLOSC#)(!$51((ZJ51 3A(0K_U!]WG0
M68RMGD]@!I;O:5 2_+)[CLDH9]]::&33+BD)>P1&N/!E6T%F0LJO"]MPBX3_
MEM(LRM"_* K*$3'Q()=H6%XR12*IYGS(2\4;E&.F?;-%1T3$ PB1=$[U80EQ
MQ9S9F]OI^[#EMP:?'->D>:2K:X4,*'FI9%U[-^>HC,N;M=B!U2&#XY[9BY;'
M3PX/3GCGF.XIEBNB>QHW=W@T1;U\\LZ_R&'[H^K0I^_7EMDO^C3Y\NE?ZV2\
M$U1VR8!I3YG9QH;\WF]Z09F!9P,_6IT;MUUU(&1MF]_^A@WU6Q0UK%?+(E^T
M[%!4_3WC:+OA6F"EUVM2^\?75PQ>/MGB_\/L:94$KVD1/BQ6F'D8CV\?'?ZR
MK3>7O:XF_&7BH]O%R_>\9SCWCM^O]-PQZCKR;>=0_<;SGT9'_M[U0K;I<<V6
M5]]WCU[?O709GW9ME^IM^9'_O3DD_)$PV7=NR8XWR68)4X,7ERY3Z3^WG1W>
M$K'CSJH;!SZW=AY_:[\Z^?O\Q+T+FG\:=QWZ.3MVX_RYU3>.9,\_.W[E;<6?
M__Y\\^K*GZIKKTZO!K2^?>K\I X_/O>AR4;@=JW+5<PG[<@=P$@FLW),<^70
MP&VM?PSWW/[-#VCVT%K_8.#.QSSH"H\6&C[HJ?L'2\O;<']CKC?S(.OQGY1?
MYF+DWT?:@C[SXH"Y-?]+*]/T^VI0)K@QW?)_%)Q[.!..]\>WV=B&F8TAEV:8
MVT@E1M0VE^36,'*MN:9"(PG=MAGFOMQ#-9=JKBG*DFJ&4B0)4=1(DB2%4FG?
MW^?WWWG.'^<Y?YSSG-?[><[S'MUA.VGRK#>/*$G6R[>66.QTW_E<JVUPYRM:
MT:#E2_>3SXG3*N@AJ^FZG2]LOG,<AJPG-U=?$.&J;?F/YI&)5/M_X#5/\E;I
M=)&7];]V](BM9I[ED,7+L\4'=EC?@RI;SQ%?O7(S;K8<.^#[?'3(+SSRU+B;
M_;FT@BI_C2+JGH/-)7[^K/5=$X=S#,:']K\L[LES=X:@7QVJ/K4K($*[.<G'
MX[ B+>CH1\MVGYV?)A*"$ZS_QIA_&O$]'9+T]E39M80/)1V"WLZSOVI'EL=.
M'S[_]\'3^A09C/#&XN:N#3H'[5=^G:69M($]HU::')9M:D7LE.B,EU>?-/NY
M$<YS<#:WU;.R"JA.?:FJ47?V1>"]VZ7H_,FFDA[7+_,-PI& VO$=>U)LKWXV
MVXC\U%JK;I"3BT_]_/9\4N! ]??%#VR4(S.T<<NF:#*R17KTRF >TA,ZH]CV
MDUY+*,$KK\]KC.?W%Z"BLZ(QJ#\36V)O&A0Z<)0/D3J/E_T3 LO42SO3"]N.
MG#?F(5V-ND&V#-8,1JTB#RKKVP_JS0C"=W3_R(XZV@T*-JSX")$W(6JNO,+#
MNL&-%S%?,$3DNMZJ&J%;H]G&+_G#MYS$R!Y95[OYB +NHG^W8IW9T=",YKAJ
MO8QF&I!3&[!"S2K$'..>+]$('/Y72NI]%(G92TM-/9>K=]WUFK5WOSY:)8K8
M531%<V7EN1M5DPIN.'+0)0(7^15FF[*_IT$R5*2/ W$!6-=XE>I>B#]+7M6]
MQ;)*!#:E2(KM!9(X2R\I3-N%#W-UIZ@VM0+,\<H/@F@D-,HKW<#?BQ54S$^V
M:I19HY"45=N9J@U\IN:QM$SE:!S:4- -/;']41"7=)K-K':.8[+=[0YLZYA(
M@ZY(9$&>PR$-)!9TDL%V[Z(G5/"8DXX,>5(7'U%T'_C#LL84:G<15*E'=G04
M9=B[D%1;++JWNC/D]S*6,4OA^C$U2676EM\QIXE W*E?<JI=))J0T0.;9PH"
MAB7@)&&ZR:*%' I W6':6BO?GR1G,TA6[>]Q@+?<S8+S^ %6))86COVXF& !
MSJXC0WYBH<W3LXI-"QQY&A+J^&<&TM#?"_=K=3#_^1W3-+Q%:GIH&+0;0$4T
M"B$Z.ZJS][3.@A.-NK60GT'$<A*2=BD\P'\[.VA.]^3YJ3DSJ^[,@"XO")O?
MXV<2+Y<%")-EDKH="63@=7]Q61M=!MZ?L<5.B,6Q%O0,_(9!H-MALD9\F=\F
M9!BTB:EZ1N)HXV.1-O@1J&12SIK"H62\0F<S4W*XFK3/VZVH6-D.+KF-D9*C
M$=P.+A$X:$=5@WRC$_62D=U*1[#=L[^K"SOH,II6U5XJ I#L1E"$WO/.2SB[
M'^<Z> [015$&$CG,=!SLU3$7C:,%8;(H89\\[C3(M94"3"GG8'5K"S$"/L(2
MRTI6Q\IX2D(KD"4]BM*X>'9;-U-V,?&&>8A5YI8J *:)RI)?H<+.1E' 0B(+
M[D3R@DE",?%W.- 782#X(#^Y(QJH2/1B8:9F0<^/=>N =,5R7<"RXE:PC!0)
MA2_M-$P6 +0RGL#]NRZ"P;DNT"D,)6@3":GX#V7"))[779@@WR8'AF+F:&,]
M,R9L[1G(RZ+WTRTVJ)BY;':,/MF5Y"ODXE@&(%V0;U=UH0&=9>)"]<[B*T%2
MAJ'RSM1=G[T)M4>^.\"1ONR4=_\O(, *F]0TXB99573?Q?#\!#L[GW3:( 4+
MCPIENZHC$6W]4P$0E.56M%/SH8L.D'>BC*2D9:4X830<+'T)<MQ8!3>WDK!6
MVV74P;0+']+<Y3U79#6YV%9=TE,=^#Z@333%P$(B8V[.1+FM?><4E\L CENG
MD:#+BA%ZJUIS]"RD/PY=;_=C6S@=)ID).ZE ES&GM*K:@3O ->SNK?COH* N
MO]3>MN:C)V^3X%TSLKO\9S1]1)'?"C\JF8OZ- ^TPO:ZQX%'+I,57$4P:\<"
MQ)93V:8ZY^0])*N69ZDBF".68N/R W)&Y "5MJKB#_N=]C]+_NPX//CE.>ND
M^Z4^34>J=PF#C3*,/>JXP+"W:N*'R2LL__XIFQF42^_H^; H;Y69B18"CC;Q
M'1_=6WJQM1 +:0. $;$,Z<O]:_%*1E".(L7H$1M@TX_^]917C]H/G-\N>YX/
M-/[;*:>F<@)M)/IX\3T5)K=O;K2Q/5S'4P3W2-O,.G.'H##RNSN(,9M7-)XF
M/R0KMSLF/SD&&Z2XR'^ZUY^$B.&EF<1)AE997\'NOWLVB&06N1:,W'*YO5!Y
MIJ/^/45I9WGO7!Q99DWJEKJMG&ORC@M:?H<;4_[M(*]U3EX%^P=\7K)N9O*]
MQ\Z?#G&1Z?4\\A"^H\S[54WHZ0"$SD5-GJ*2$9-ITF0:VQ44!AGN6C((YL4.
M7"E8M<Z]HN7,9RMO[#"S/7S:9O+\@]7FTY"G5< N+['L7@$=L],%;^#, TG1
MK8&X*N2)S\,N<G_CO3@FDS+:,199>T7,V>&+R?>FRLJLAYG+*@M56U.OH.3U
MB<*85N94D.UR\?NPCP5>67#:TPP,V!(7_H*S[::G#3Q3@NJ@'D*H]OL=1K%<
M&X"WZ\'*]/ONR+OV]'3-%0-?:AURHMD::>7!9S*/E2;FX*9U@6[ANZ#1I1I<
M&3=1=1 6.#2093ML5,NZ-Y!]?\;V:I#@_GT'UNPM%G)X2PF@G=L*>)L-A9-4
MWHT8*3.P]M&"5US+L@ AEV=M,W'-.KD1-:IMB;+P%0 4V/C8RDI8- ;74"-8
M(=@9 0LF+6##VO_$Z>]LKL);JSS*J_9(;[.N=D(]A:86N[<JTR'!E"S,BD%O
M!41=P"$ELSYK]E:W"@_<3[>A E!0%G1XBSH1JY+,0I>SN0(@JI7E.B(C7PZ$
M3W#6!N[WU%3)85FC7I .'Y@]$Q@L *B[ +_6ILE)..)*%C(:\T(,*>')W'Z*
MK<M.6^XTTL0"U9)KMS!M,42@.I'UZ"BP\7=WPFWFEE;FTY0TN  (@W(,@YS4
M2)<#C)HTB$","[RD/TU& ( S %O*S;IR=LO_OQ4HP,KHJ@;A"HD!D&0!E5V
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M^"9FZ;%MLO\)Q)TL#Q=@[9=U[]MI6_R;4</:';50/Q=;M15LB='.Z0;F]4Z
M73F'$0$AX%C'3\2K$*_),>],_>FX-'&E?]S2TPCH2\P*H@/=^&#EBG047R!/
M3[OG;C=^?R9K;>EISAYU;QBQO,K:]-J+TM/2[[KH1YH)FJV \T=TBQD6<@Y9
M+WI"+]$?RG%9JBM.P-WW;?E@V+!9"Z[R],,F ML>O7$LNB$M-D=WH"&A#L:Q
MIA9_\<IJ?<?Y^49R"@86]KC*6N)^?*YUI<9HMJ:I)5^_]WUG2%,-.)L[9GYE
M"S:5O*#G)F2YM[)RPUA[_=><1V)S-]+N9T/_]WF/:RN M"'SO4H&QK<X4*ME
MSTA+>)OFB@/ZO*@J$K#L_=>K7N$+?9H-4YF#DT)2.?#W[A_5>ZQ)U--5@)B=
MITT.:MZS 8!)1$/E:/&&*="< +Q>GC82 )'GMAU_ MF+O:^[)D,F796 ?H$)
MYS29K/TK:3EK4D,;X>,* *>MGO," ;R7\BOGT3=1U^G>G_>CV\$IWS@=)_G6
MK:E-9<R'13+P(AE?]PU/;DS*898[(_E, =1-\HG8N/$B?^GINR_><?%T3H='
M>1KR:C^:1_DT8Q>2 ,S7ST%+NGX5<.W+6<;EP-T5$*: OSC>C"R"XMP%#-V>
M#,162JZ1%ZXER&0%V?0]ZH4\.REPJH%XY(6"&RL*6149?BV/!=WOW_FQQJDO
MZ"0=V=N#J_,H+$'>P^(2C5[6.!?@/!H2C5]=][Q*R3,I^?\_5OP>!?*'4A,4
M*D(:&OX!4X7NP)=0G4+'MZ(ZB%XB2#B$K&[D$--I$$;G!DAWK@AN,X[[0-EX
MRTB3LSEY64';?@)2NUV_PSQC)JK.I9W:V;,7L6/Z33C@!:%;CW;K4D)2/E:Y
M@^ DW/4APP-JM^I(/^560$>?T7H!<VP3-P19T_YYQ>>40(,-?TRQ=6\4!OA9
M,FY!54).>@PIF'K^"7SR%99K'27IM/CB!W<K\B88=G_F+"-+ ^D1KRZ"KP6=
ML%!R[B9ABD5HS94[%GXI.=W,',B7.[_>!QA)"L?-]&BS%&V%=S\D9J: V<M<
MJ&]$9D(;S7$_5#A( 1INWXB75TP8)+^%7ICRIN!/,1WW0SJJD#5:NU;T,^4[
M@D=>.^C1V[-R]"@:UXIQ[P C4C/]N>UNX"J57CERTS!$!G=F>%S; 2.X+0=I
M2@15F*#G#,0G!EZJ.F#U/4IN7#GS8_+&52]5KS%?[X8P-@0C(6MJ7DB\P]8R
MC-DAD[_K79@#3'_3*D<>Q^6SX\P9D^PXL^';RKQ=K6&1"E4Q89'IE_[??C-F
ML.887EA'!67XA$7*052[2$]T[M@^AIF;5&$I!AWM5+&FV>CV')B!B*%/8?B3
M*-!_D=YBV#,()4('QV-Z"SM$LR#SRJJ59M/'%RU VAT G!AFO/"XD;*+1B=?
MJ"A?^4JH;[%VP)?R::;FB5PJR'7I?*.FPO:Q[7('3ODCQ9KFDN0!@C&-(163
MD+6B9P2"2M53;<U 5)H'KISYZNROBBEQZJZU&]O\SL>4(+7T>1;;#'Y66+CU
M6?E*7M^V6$BE*OR;T94[(.P%M"?I_^!0\?I5=):V;9IV4K%A$1:4>C\="8I2
M_<RZ:& DD'B[J%Y*D9=OZ"*SH*I<?J7.T3*-BK>,DS]NS&3J71'.T@*NW33Y
M8FRY,@4;&W5]>/B9MM?T>Z<UX03R>>%ORA5T.WQ:-TM,79A^B?MCUB+,'UZ$
MUB?\)CP^[XG\K%M_.\6AJ3_/[1OR5N&)T^*M6_]^ZU:Z^K>XKXB[^R/\ZS)U
M'3$CALT-G7QOOUZVK2SE]/ ^V.;:X98.X9\O;=+W#ZEL]M?[WP+"OS[XAWQ^
M^$+Q+L741_]3_'A"%[BY%6ASD,166&'"@^G%4Y]$<A2JR4HX%F(:W2T?9I'V
M/S>^[.Y^>X1T&QNGI0O+HH)QED-I)L&Z\D$+8C6Q188Y05?QN/ A[)E%INV4
MKM*9A9ZMAX8S*%HU5QG<!_61S?A$G[!_Y5QY/"X^P3,1AZH6.H+#OB8>Z)W%
ME)2+S$9>9!?)AZO>Z7<R\MN>=]!N>G0XVMFBY6+.1D^8YF?!8V.\5_:103VM
M ?4^TT*OG.2UFG]3"T]L$0D%R;1PG2_J+OL>*Q?F5NGIO9]P(>F<*,P9U-_:
MQ^VW]T,==]0R,*XMI$BQ-3M*&H(-3(,N]7B+=Y0ZPT:-U6[#;"4SB*36'NV$
M>C>[C=ME76L?S;^M#-!G0\N3^C_N./W4+03>5C[L?GU[_7YW^A:?\@>6\SOJ
MZP="\3X5SZ8,=!8M#(&+H9<F50RM&NO=HU)?54S%W+"Z^?EY&&CUT@^[**M?
MD\^/S.ZL N3-[_@L,LB@@<JFESY9?$HYP+ MJ@27"$C&6UX>76RKWDS\9%4
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MLB6^%T'G=&<,>BWEKZ<KEM/=WEH\M0*'Z: OM<,H;VD^K,.3O>!'">]U"-T
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ML0#98* :/@N\L8&UK88XDR T VK4)^PR'Q'-!QT3X?&ACE*AFH^+ ?I*'8)
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M-:'WS#,!<7R4OZ[TK:O3ESD1 -$+J@&Y)GH ^I_4;UL]"P:"HH'DF)-PF15
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M]F28-&K%]ZG'ASL/[\5$@,Q?_H!4!BCY3\^JD$]2_)2MIFO"@8\KX<(%JNR
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M0WX9OY %N(@CX+8\T(WC<$81JH9*A>NI(5 88S:\@0/*9P72?J&Y*W#99:
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MSQ=KGJT_?+8J%?0CX?GW7.*WW*!%9[ZBX/G?\2#\#DGIX>Y7[KUL3F7]U'/
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M?]=> ";5TCU",K&N?-'SD1U&-&!.%ET!:0Z *8O/3@_0U7G@%)7GP\-4K?V
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M:HFM:IBF),E90#)_BP0%C>:#:]CD/:%P,0M(PN!&#>")D#T4@%Q)HJ S<*,
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M.P'0.@ :476XZ0DG,[>UJ E4(23GPXB&D J MK.V>K+!11? A",0949'<$%
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M/S-A4'!80ML-0(Q/$"%2(#Z3? 3O*&*_"M=@5.:+<-=I3=B"DSX&HV7S-F(
M_L'P0A*;@3OU6$YV5TC(LAG@*95IMF[U+- BV1YR1#GX[BU5=<N4L38YPZ1
M-A+Y]V9\S-PPF,66& =CZ8=P(&E*)2XP3#Z5I1FP%^XSP?UU%%VM8+PDQV#G
MU8UNK8@,2G[_XAARC9G^^J9U;E]=!"7:$/](\[>KELCI;-EG@.%#*QOV>VG
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MO+V%1 O(+ESE(H>]69CM?]B?B6)%%HZL!P[Q@2NH#->%#V*74.5[N2RLGN*
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M9TNB6G<$@04V+6GU'5J^2QKKJN.! Y+NQWA"0\$YIP$6UP0M^.V4?9,'!+:
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M)FEH3T]D\),>&5FL!Z\RO96#[T++*+:*CB6 VZIW>\XI<#;_Y1Y(H7L9<L'
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M#?B"'%$]6OF_3\">9-*J-H7#7:[-1-8J!<+A0US%9CL:?$,"/?<ES QS:39
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M@FY&QJ.H*BJ8ORVHBXK^DS)!I[;A%0:@XPE@> 9H+YUU &D%+&^N0W\0+KC
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MM*1Q]0)(Q4"=\"(X.)X7CAZR%6)61!6-CS>AVNC]F"_:3,C'1>2 T[O-+>H
MD1'V56 6%4R?%L1I.AQNHMXCJII^W$ZXK95/ (VRLY?C^T>M-!,K-$?R-4R7
MWS H\)5KF<C1(TA!?J:J+$?E.?)WYWV'WT&%]2T\0@D^]+W%Y((0N>N\$?8'
M5+H87) )HHWO+5=J\K(MZFQA%A_L).(8\:J>#BV;KSH7K[7 ABVN%/4Q59Z
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MWES5C-ZO# 1_[+]]33!9.RJ*NK]JN/I/[SQR2ER6NW.$[#B!>37MJ9A%=2I
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M$89OQVQ XN^*?=I]<ECWR(<>:E,1V?1< 3%!PAVN=>AX@<673&#VCY=&CD3
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M?74;XQ:4U0R2Y83 R(:8];2]&T[OIXH<O=C!?(FW.0,=:Q>C\*;.M*5VL!N
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M33#&78$^.RB+8?K/RZG?[3XSW_\[DP2<3;%^+5J!Q2QW^'-H\24'T;-]J/R
M1W7UG,Q":#4_)$M./1*,!!6N"Q* H<ZP*$+LN2G"R39GX@M#7TOZLK,9R%'#
M5U%0I ^X'A682P*'#<Z4)W(J&/K#67WWRI26QC4I0(I7*)FB^5IB,A*(48'D
MN)F(T; X<M1LS$.  VMLD"7!K<'%9>#R_,'7\PPVXCH.E3KML^*U#TL#O4[_
MW%\3X&B&DKXHB0G;6=2FWMRV.-.'%0#,690@7?F(I97F$#A4>A$4Q.3^1<SC
M+8=V\\E^;TD^A93!%5#^EIT')I89WJKKPZ3+>XT'W^\R]V[)+"2):A;+'KEY
MFN/8U:3<"*BU;'Y@H0)P2:]$66OXH>M:D(WVZ$IG:GJ!2\!T+K-LUYGA+7"+
MX4'.W-++2QNY%9E:[G()>.3.LBS4N1S?WFK<Y'24E5\ ;=!XP//\!Y/=DBSS
MST]4/C7MO?[.13[*SI3&Y?%3*M.I.S70*?$,]3()$B#"4P;2^B**VUJDS$(*
M35CK@X.?=Y*9-DIPD+8>AQ)TXI)IT+N*Y(Q02SK(&_FQ)06@*\*LT$*>> CW
MUF;O#K*_&4HS@S^U(NGHOIUV0::-Y&F##FJXWQ[;N_!\#>MS,$!*]I5R;^J0
M_7^16!I/2R-Y=P;"Z?CJYN;4<BUI_RU(GT.2O0;GOP9XTZ3, N.<'*J\RJVQ
M0U+!CWLFV+(1!^_I%E?8T'Q@2;J4W+3233<-X'<VKS,'/1V%9F/DW"KQU<U0
MOAFTI).H@#J\SK1HURI7/C,3I>9TS%=_C+OE$<_NLMD:$F$E]X<6'^:T\^!,
M!O6];O^.,X)S!WQ+\)3]ETGGOJ"8JH *&U15PZ(_D^3)/>Z\<7X@!E<60IW"
M[.9I5\)\<2N_("3K<Q=;<<7YAO!H\:>_F*C>$<U(SJV_038 ]@I  0I-7LEB
M8UX^.+'<9CHDK_?6UD\?Y)5T4%*.*8)!4(P?]L;("#BO7@I.S^-$1U$]D?*_
M]."/C\(O?@X=/Q>R8CDTN0 ZGYF7H@G^^4H#<J)&IUD0QJ2&'.!Y/2&YF+^D
M%I(\E:! ,>=D1H@18>>]F3LWH=ZKHMXB9KVUD,X2W/PT7HQJS!CD[8>O#7!=
M=O .>_91Q!>!+>O$MPO70:-FD3Q^AMG7;.9214*R#S K'6&M!< \F[/.3*'8
MB$8;)-.3',VD#0#XRRBP4P@-/3/97H,!KW74UX#!3*':V-P.J+D*%/') ?;"
M\@[@[A#X*3<]U;YISAVBP0X^?C/W2A-4KX4^9AUE%.),DW)P8--FT_R(2,?@
MO>I[QR7<V<GG$^!QDA"!O,K(#YJAVE%2T_QOTCO\ ]#(XXF>ZS">ML-?"U#T
MA;-WXR'MK\%*OWA^Q^:1%8+7H,MN>US:]/R?GR9X;6FA!I$NG_"IMQ-G_WIB
MXNGQ>WTG#TI)C9TG[>ZG_NJI9!VHC&WS$NLT=]@:YYPXZ)==SV/2W_C-G'J7
M<OK/;:??YU;^W7?ZWWL?*^)I@-<!+>J 5W>0MG>0#W50+W30[W<X_M.!\#I9
MBSH=%Q4<>()P#G5R+W2ZWN^L[Z"XO^CTX'5Y+^IRO] IV=[INZA@SOHNX3]=
M(MJ90-X9V7V*SW==8=>Z%FP_X[_HS&+:&?X_9V1SNA<NZ@Y^T2G?WAVUJ#O@
M?O>B^UTQ_YQ)TT0GW">N6'\V^=#9E8O.KKA_=K_Q;-JAL]K8LUFQ/6LNG/UL
M=T_VG)[<?\[F'.I)N="3NKI'Q^O9''NN8'M/P9QSVZ_U?+G^W-;=YS;RSI7P
M>C)C>W>^(&*K>W=<Z-UUO]=PJ'?#HO-?WS^7O^A<Y?JS"8O\V/+[YX_\<][,
MZVM:U->\NJ]U>U_;H;X3%_K:[_>=^J>O@W>A:]&%[M47>K9?Z#UTH>_"A?[[
M%R[]<P'G]5L7]0^L[G_*18!%_P=02P,$%     @ R3U!5GT\6MD== ( F8$"
M  T   !C;VUP7S P,C8N9VEFU'?I7XSM&_=U7;,O33.M,ZW3JE(:;2;"S#3M
MBXDP63(E*7(;B;L(UVPU+3)13 M-"2%,A"3,M!D)DS4*4T+<89#[SO++X_D\
M?\5S'"_.%^?Q.5]\/\?Y72*BPIG!*;\A>^1_ (  03P*3<!@23@\"8NFF)#,
M3<E69N8T2RM;:ZJ#C:TEV=3)WL'%D>[N[.+IYCYSAH>/U\S9/K/\?1F!?O[!
M@4'SYC#GSYTW)Y#)GK]@P7P.9R$KC!,:%18>'1$9%QT3QHU.B(M?O(BW=/$2
M_M)E*Y;S5Z]8N7C)RMC8)2G)R:EK!&FIJ1GKTC>LS]BT86/*VDW"OS9G;Q9N
MR]Z:N_WO'7_G[MJQ<_V&;2M7K8-W[P'B&H"EQX%5IX#E3<#:<[CT<X@-Y_&;
M6Q'KU29;+IIOO627=X6VO<W\KU:W75?GY%_=OD,FV@-[BZ\'2*[GB\H6%'4%
M%&I]"S3<O=TQ!VY&';B96-6W\G#_XDK=XI*NC+INP9$[:QON99T8V-;\<%?+
MDV3579E$*B\H+"J4[RTN*2R4*\KVE>]35!PXH#QXJ.J0LK:FYM A94')(=61
MNLJ:$_5UJL:C1YN.GSAYHJGY].D3)YK4Y\ZUG%.W7KC0=OERV^6VCJM7+[==
M:3Y[H?;8)<V-&_NN#4LO/MU__7E+FTYS0Z/4OFSO'*CM-C3WOSZJ&[UTYW7'
MHW>7[H^?T[_I[NK2W;RINZGKOWV[5W=+?^_>W7MZ_;T_/?#@X:/!)T\>/1D<
M?#+X^.FSX:%AP\N7;PQ#G??&M7??W'SX0??H8]?0Q)VA3[T/WCQ_:>A_^O7)
M\)>!E]\-+PVW#9]>&$;T(Y\>CGT>?C_YY/7W>Z/&L5=CXV__U/CXV_'W[]^_
M>??>^.G3JX__?OID-'XR3GS]_N[SOY.3DU/__3?YWX^I_Z;^_?[K]^_?4U/_
M_;D&_C\LI^_(_W?^)D1M2EF_+BYE?>;:C2;K4S9M2IG/F!40&! 8"'C_WXG_
M^V$ [#0@09D'ZA2S1% 8&"UEI&@ET#8:5''*B;.ZF%C$F?*J:$H\R;G(&<0/
M."^S$LE6928L=ZZ EAZ'TF=3&?NP2PLX.B^+.%$ST;-=QDAL4C1P/MB,)Z3%
MU=!V!77(=.18Z66KI+#QVTT#I^?O.VX6:#;>4&^UDT.T^G=\L6CFX06':_2\
MAHO;++\[YRTWG.5>;G>?_SY@X+2@?>P%-X\@[.:ZK*2A:/AC8XK"=QM>]%^Y
M\/:>*K3$(:Z]]=V#IB6GD^^T7_SG2=WEB?&65[H4P=(=^G1.P*#5LXLSC\\]
MO_;?@[5:(L7SA00?-Z-]_3]-SD93\IN;F]!#@=S+'UT\,J>W/V6G^:;2PW8'
M)3Y\=3.^.VP[T2QRW<WX-<FP[6SD0OE?CB']R[M-V_]'[UD9(./8;8J??'-S
MVX4M(H5C..-0F/A#GG5/Y++<)Q+2$@!1:O7#LG-I_NJ,B##3Z0\"J2-D3UEM
MNF3R."WN,A<<IGQZ[A=F&C+!0^[1)FJ[+"!:0Y=C_;C>0327M^4V*1:Y1*[@
M/K_?9::=:FED%8X+5_TU\)EW+.N%?0LV*^O2NS<UPE[/M[4YCS/?9D8OH."M
M(]!?(RI._BIR=9X[_A0EUWC7=]'QST[8SYP_I=9;!*=1B#FKINI/.FN)#5T4
M3G"]1!KP3GS$J21K]NI8;DY$X\GI=X%<<\N%OU1AW+!) )FP>$)=;C67VZ*C
MLR<T> 8'^[GP^!Y5@.%\P]SZ(^;S[.[W607S3KA2"KW/<TD,!\X+IZ+8^JXS
M#9.:;N="Y<Z-YU8"HS<=-V;72\R[\/5=X;>^,9"4A8\B/DGFJW*XY#V_*#VD
M14UOU<T-.\IUCB' %D73"JD?5F19'KQ&N7KB_(39?.'GF[SY(2ENFQYFWCIV
M: _LF5X^+Z/^I&/AU*502U@Q'AKV-]IG4L^UWC0Y$'D;AS6KW9#TVFS!9/B7
M687TEN,/M%PG&6N%4>,8E^1MDV!IQEF_MG1AA*NTAP*RD:M"TJS[2*L T5A>
M2]#8[6G31.;L[N1V[(#]MF74TS&F>;;9LD7B$XE(<@#XM9M$[!GL<@IHR9X8
M^]22BBJM)8S=AMO5YQ&6K,_D,,8W\/DE"MDG&W5"$SM;FO7I$<;<<NY$3K?I
MFX2KQW<LNO,!R=G#WU+B,<_.5W'B\EFFE*(E>]6S'OZ+/MDGFV1Q3>N-^[,/
MS=50^YU"(IM0KZV>QKCV7#:KF_PU^63S[_]-O76L]NWX&^PW#96O.N>UWOS%
MZD7T(@ B]YD1]\M...DIP^0R0\G*7X9-V*3!G=!_$I=?93CR9W%+K5%R##EK
M\S/< :?I5O<E\T%^<Y.XY4W!7,KJ-%:8\L5[^'/;:OF)_.EGG[M(N4;)#& T
M9,^#^"$HH^M'8GJ,Q!AJ4:IV]YS:B WUX*1NAUV_VY?A3^I%Q_@1E]DY6JP3
MOO=3'^0O]8#(,@\N6SSE-GJQW/W,X.+R'<9"^QPGRMS(\C@5HO5#4F94*+_3
M)]]XWO>P[ZZ=_<Y6<13BSCLSJ.>H==-!MV[%[_AR0!6[5]R )*[^19]_852[
M,SP*]160$.89P7(D='$MQ73N$I78<L5VK1+Y*L)V58U5*QGEV.@A7/KE?GY\
MF_4W"W/J&:9]JE0M738EP/^S,<RYL6J_$Z#%)RHXQ;E3B-7ZL46,'T4>K:SS
M[Z8@;%26;I:!%OSX&VGQQ>D&D_?B@7H/WDC=G)&&.+LWGM-V('9G$D6T'4 6
M &OW!EQY=6R[P?'3_\86S;Z0LNU71FCDEJB"9J785*J3U;%F^!<0S>DAWPJY
M^WW3W]8D[:XEQWN6IA%"-*L87_C'>#\F3[!,3O%*MF,=B:)(#1TBO^"<+[?X
MUK0JB6_9+R%[&35<5",IQVA6^JD210WU2!EB4$N=D4[!\\B0>5I."#]IS(HU
M!9HKC8@2L&N3=IQCFE91O)H?$-7)6499W)!H.ZMTB=:(N@:?#UK-JL?\:I<Q
M'RF#;G_HS$F8ZO')7=^0/)M!M?(6YUE09+7LM]A8<N=K71MVC4<GIN7'M#T7
M?^C"XN<<ZZN#/>R,\W%OMWGBY^.L.-VRN2XMSOO\^N(92H&WJM0WEC%7/,<6
M]X!3ZD5=O=.4,\5M9!OAN5]L3^7>C'GQI?JR>T.3I75!3UUH9KTEG)',6/P9
MX2C4DF6&?=@ZH3P4$'M0;3J=%M>?.L-^:[K%#GEBNEMZU/B1>8RSS]EL!-/=
M<C;XM[?8=(7(VZE[]HW5&UXLG''(GVZG=??+WC?_)!T?9I&RQMZ!Z_2KQ.Q8
M7]N"B*DP[FZZXZ8C7Q0QD5R/!H7$ A1CV+MEU@T!9!NW=^WVHYWTX_V>@CBV
M11&=0ZHX_V3/-#8JW@)KL9M5\?)[/=G/VW1ZO6O$G 0[SIP%JR#3=DUQ&%&;
MX#>,L\X)/=5LV7]E*7Y)OU6];>6FK;APIRT,K@X5?)=R<"7CJ.D.EN;KBA_W
ME7<#IM-T:^W'#9NN*SNS-DC,!)8;,<%,\9IM1Q&);XE.,H!SNN9O\AM2.29X
ML#ZK>&O[Q8G4^ST#VMW'<U)%.?6ZWZ\ND@I4O?:3QZ/N_YBYT^X8(<$?$W[<
MBV2:PQL3),J?Q MEOM8)]::@*'+GFXM;D?L_CG)'Z/4&T5?@RD6/UO9'P0:S
MW[EW;D:_,<BA*_ZSFE62OJ=7G6\_99^N,FKNM*;BM.C.ZD$Q,CDFFHZ\<8^2
M'GY@QCAP[&++8M*TH&_>+'#MDYZ3G<VY9XS:[7N?A&E.'5\?_[5ZZ%?<\4CI
MW;V=OH+8?O*;%)E"-E%^=CQ_?-6U'J=I!7:;5^?,RI&BCE;; T=M7]/WXA9Y
MSDLHYTT,N]S(;=^>_R+GJ,4Q7P@G<T2#!VK(SSVXGW\L/])0<LQQ-*M9/KIS
M]_Z_%V8\L3X*//,U:Z'4[WSM%I8T+U8]''N)WI"3L;[GE63DVR*N?<""FT^?
MPBUR_Z'(<78$$M'2O+8&2VM54.Q'*/N+0XGB-5FTGB'"C:T)O&]OVNY=^_BW
M;ZOQQ7C'];?7_B?V_35J^WMJ[']%OP**[5Z:O_P>7?'H4WGHH1T+PKYO/+C@
MW\KIR%^BQZY3_?^Y?;M2MW^\9LV/)PL7OCEWX]>[DM\_C1$+OY[9]^O'T._I
MJ7LWIO^[]WOZY^_? !6&F#"2#Z-S8:P2QK?!-V<X?VO,?[P^=,@ZV'0*7ONW
MB*(4#9\0#4:(J%,BN_$8RS;1V%N15:[8%2ORI)I3F-L]IL3>;>(7)\3V3 E]
M2A2DE)A1)8%M$@95/!<K=9F26%.E?FT2:J34*D,:H),X9TBBQZ6Q'K+07$F,
M7,KWD,[*D#&5LHA!L;M.QF$6N&%EJ9&RM$%)@K(@@U^P(+=@";5P::24R"_<
MGEN8JRQ<M,4_?[!P]U0A3)6+F7^>D!?DRJ?E2GEQF[QT4%XV)5=0B_8SBRKX
M10=SBY3*HNJVHMK!HB/\(F_KX@9F<2._^'AN<9.R^%1;<?-@\=FI8C6UY#RS
MI)5?<BFWI$U9TMY6TC%8<GVJ1$,M[=25T!-*>W-+=<K2OK;2_L'2NU.E>NK>
M^\R]#_E['^?N'53N?=:V=WAP[XNIO09JV2BS;(Q?]B:W;'QP[P[EKG\&RSY.
ME74\D8[-V,V/W">@BB=G[)O/EW[C[XN8VOUC4/2?QTR/C'U?L9*Y2L5OZJX?
M&0KHBOA[I&Q1K@P1+#*[I;!^JDANDQ**%/\;%-M'[9IN*I^2E^/?E5M&[:-Y
M[J='[2=G[G?)FY;@: =FW-J/\2RW39(Z)2D<\PX$OE-X!1]P^\X(O'7 $[<O
MLJHB^DI%[-.*^.\5/%KEXN#*Q*3*97F5_*K*%5<J5]VB=>HK!;2#J;?@2@;Q
M> JNE7%PPY6#.#[&50VZD#%G$G"5=/(L/73\,]H5()Q-0,PB$[<PH&K UL\(
M9-*(ZWF'U ),K@*SG7?HF@"=(E16DG'0 $01*K.N5-469;9J(#<8#8&$F3Q(
MR+"N-F*OZ<EK (!D ,D X*^QL:*#D!:T55<W4A" $7LV!<23B0'ZFG,I.,B(
M@IS0@ *M%: !!H " &\RT5T .FI +9UH-JW'0"(<1$8?IAT9#4Y6PP#$ D]7
MH2$R$$ FMGN23WLB$*JJ,B%@I3G4J@<A#?8:"U.MP:8;:J!Z7+H0G4\CYAJQ
M+0(,M 63:D1GWL*:T<%L#6&[1J5E$;;PT&5T<HT TPICT/BZ+73T=G5U( _8
M5D2N%J(SX+IM>JP6(&0+<%H!80L+#=D0:W@JS#.00B:N80#0!DPJC#F*:\@3
MHB5/5>[%Y XC.DU?WXP#J@U8HA# &-%:#416X01XPB4>L(M!A%B$=!9DH@7-
MC$=>?3\N[(M2&P%K%6 ?#9EI@&B&*EV!SL_$.:D %QOB-!, UAN.P#B J<*]
M_0Z@>$ VF9@M!"P,@(G@*(D.4O3 -08$:$"B +RFAW &P%*%,S<"6A7. @8L
M&$ @F9@! -N\ #,6H=4(H#4@2@UI&0@$4(4M!LR, -& [5" ( _GS@"J 8*Y
M$&C!H;MLP-[W-7;DQC5T8%L4A!* *,;AS< ?E $( /,S(8@,0@S(/QK$&T\U
M%)'M5:>J68B9=&!5'T@SHMPTQSI@8#,/AR'C+,D$$PH"(3BZY9F:M'*A6@.X
M:(!4,I'$:&F9>[+R&:"&T1@C8*+ ?'P*(7@8>1\6-$#5AE-JP30.KP [C,!@
M, $G@+0"$,-#9!0AB"L0@+[>B@5";) S!$&&FEF"8]ETP!T@^ - GJ$UZ!F(
M!XB!:K61!EHKZDEDZ/1[X'4?6JLX5\JXY,@@6O! 6A^0?!LDTQLA%GX[ )PX
M67M0A8%XD-IP(1?& +R6]0*P&FB61$$XH?(:&;2"R5L H+P:P#,@&@#LB4)3
M #"%A0A48&AT1"8.#=+/F\YK;YP7\/HI9,> RGA JA#0W0+L&4>Q@@NS!$"<
M5^UM&K&#3-RZ$J&F TPZV<D(Y&D "P'X.AKLXH&7/,E2-63+ E'T\U8\\/1T
MU:5KK-:@V9>%FFM:  -H5$(&9&T$2'1B-+D9&CE_<R-8]>-*G1?9DM[J;7/.
MVG"=HB<XJ$X%TH'_=@!V< <$H_,45[<!0*[Z#'$FF:8':#S0G >(Z>39-2!6
MB\ZQ)1X4JNQ40/YW[#Z 8 UC5D:#>W#HD97M7AV=V1 !PT"DDD$F .[B 6EJ
M7$5Q!U%0X\<#+M=@4!KPJBW1%;BH9@ /:$1K.G@0!EQ9A_9JZBSII[1Z#*"&
M:@5HD'?IT;S6#;=!DKKZ53%FZ\Q+K_JPF0!P(!/"LIKX,Z\ZL0Z5\BZULD!3
M!4#L TW45W.,J(,:8-I1@*MDW-0"C<+;N#X:YJ 1FZM6%E0WQ> O:@2XP#][
M?AM;4HNI3JH)#3F[77@N\0>($:H>?D=OU@!2K];_73WJ/=QWML.F%0;\>+C>
MJU"I%[J5![C3=0EV1(80J*81_0# 7 ]9 4#03RQ>!00R^G.K()0"G64$=-\!
MBK$R&P "8<S-TD8:[P\]$2@&0 MK9RK0)"-P';C>4-6;1T;GS,0D]1$676W0
MLLZO-Z+]8KLA/<:2T?<T"TIG .SW$$)QCT(^;0GW=67BJH6  QVC?*=+-UX#
M6)A9L6 Z"P2,]0" R-:#CL8C#$,75-Z[Q3A]%<5 N,']V'+,I2H,MP\,^@F2
M&-WG:A_,G6\340MIZ6#9:=PS.Z(;#\A2H$U99[I"H'_MB.L,URWIZ-,T'$8!
M.6D ;\7!+IZ29( RJZ#KIZ[*OH.I!M"Y!&.O 1O?/= JT)5]#[5"#$VCVJX
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M+-CTYR59OOBY%JJNXWFBP\2Q!$\+*A;5OXES8YI8M>W?S&,%7BHR(_<X]+>
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MV&/3PI +2Q9V%0-,M8R)M1ZXY=R_5E>0HXNC@T5&6H2Q:M1(<_IYB*( S0T
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MD]3($H\^N1RL\F9ONJ#WY8><0)8D1X)J^L$#F>"K Z+SWMK;#T/UL7_\$_+
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M%RFNMP92ZB,=^"R,$,!(P[?S :<RX$?P$>O[(D(:X4;PD16Z,.QD#WJR-]L
M4+0JQ(XZFJ&;VJ?%2EF?0GI\[VAL+Y:UM26EZ6!RNP!QZ64XM],J@;PQ:PVW
M41NMKEN:A21.DO'5HLQ5JA\MAE-9>Q/S@3WJV,6-*OPLJ;T7??K:)LUCH<S"
M >_NBL7D$Y9.U1$-E-(0S3Y^6)I!PQ<"@N=U<1,#__FLM16_(BQ#G<OJ;E='
MV6=WTO2CB53;I!P-\A;==WSMW#<-2[M9!SY$%0E>+1QUXKB[.CQC [,+-Z"Z
M$.1PWX>:Q7PQQ.AT3X2(C7??)HJ)ND%.J86-G%W.#?\WML=%S_'E+7*)U409
M#,L\R,L[M AI-+(4Y<UB41D<7,43%&!)"H'?9R&I ,S>0(P,DPZER6C$.\LJ
M6"[G]]5L*W7)36%,W4L<%"/XZWI+XP/BS5R&PZ.C75 FFKXL)(W(.I461J1&
MNR0:.().IVD'1@#'_*_IHF7ZXL7]G<N\^U9M#TNXO^)Z(DS7@ B[8QSWXZDK
MZNVY,;Y<C?5L#>N\B)'&'7I>NKX-P(S+?@W>F0[DV>2S3++"W;!=&0&H9,#*
M3@'CNDU]:T7VS1IL_K%'SV]G;."X5&NUZX#&V6G%RG!J,.=K$NN.CHV5 H*$
M'IK:_4QF)RTW%1]+=I"R"!U:E$J%R]=:#YK^'!^JW6+"ZP =5 ^4>;U$NAQ'
M/4@+X> -"KMNZ,8WB,I<*<AULAL$2?FPVR ;^VNE^K TJT^+QKYYT,]"TI^:
MEP,$*=J[$5QTB;A[-\MM&"Q8YT2^A;8QB @P/D;COM&LRGZZ L -ASD.F\[@
M%[DS%A.-'&\EC-0#OAKP>8ZM"W6%FUJ#37O&:6,5Z8>VI);:*U@X!6X@!Z!Y
M.P]C&[*\M.%C8+%29*\$<-Q][H:,=*.XZ2+@SD5N$+$Q#/':-N &(V8GJ2PW
MJ.0[/=)&VCN4(3Z6L/YXTRU\)$PT'M,W Z0^$-5$#.EAX_O?L+$#\O!NQA^&
MG91>+T_UE8JB0CJ5/>S+/ER[_(;;JH'32G =TYR0]2)U^ZD3I'I[Z1TV2[/A
M$0PUPG]M<,I=772H4]"1EN+"U> 3 0RVGLJ  [<!]]3WL_0<EYQ>(A!&Y;.*
M6I8S:C<X2,%I)+&K4BE:_8V-;0:2:*7NC95KC"7$Q@>KL[BX?+9OJ6[.K@0W
MYLVDB3IJ&GPP"O9)% -\,UBZ.FY4B[:(7W?XH#T#.,,^]$89ON1(*4+#=HB$
M7PQ6X)3W074X,DUC/9R$F80FD;(E0H"6 9G(8].4&L2PB'>'=;!49O&YW.TB
M #4[VW)9B_MAG(#SAUU]A)W@Q$K?5A@Q*+K0QW)L>!7=5X#,9SFH07\M!Q1Z
M$YDR.^I2/KH&88 &+")0(4>*B:$F/, ^)'UO^%V,2E37+7)3PE'VR,3'&QC#
M6FP_<$\O0@5TNJ3!H:TL3$@U5!J&'!0MUDP_P0(]^/$HD*@,1L6C-"+W1M8I
MC_"8*\G7/6![-8CPX,.-.LQ4POHQ-MBH&<IG$9"5@$H'ZB$7(D!CS7S5K$=V
M@[Y-AUQJV5_LI2YIK/8J=\(82*5'\?$<-R%</]]DA[*(RH2('EP4U<;$%8X:
M6XX/QA06O.?$0OOS1?=KP?6[3WU=\&F"=@Z_G?;^S0FH&>G>N#1-"8Z0RB9E
M'[ !'&]8)/*1?G'HGISLQ#;W9\[ML1Z_A2 GV?U"[QCC9I"/82M,]Z<1!IJ1
MUNTP<E7\FJSNQO):I*X/\^MN3D*/^R0G;)74#4G&5['2#>S0(\0;Y1IBB[?W
M-'+0NY$]G?V!C17?"Y$Y;0&R(X&J6I#7JM$HX=S%\.%O1US>13,&H4W"N"UP
M@3V7Q.5P76#/I!RT#Y.5, CE?.8@.O $8G]#6K0-\[7,K_LR^1^/RK!"K.39
M]:2X'-::/RN >K%]-&R,OWRK<5F<-\FG&^IO??XCB"?LT%H;^]$5X.8B$ -0
M_FN,1C,YF=[(C8R5Y_PP^V$M5M_IS82@R<Z\N1Q?XVN.'O[=R^/!&+:>XQ "
M^'8[R /&T"KLYK&>V\R]:Y@]+@%C>'WDJDA"S"IN/ ]+,BZSJ6#X*N_0QC;O
M"8%LE>B@UR)WN5=,#L"M/;)#OF'Z7[3DG)WM*HZO_YROKE&?=&.@M_"]@0ZX
M:#B(5?A+S-?W\C\E4A]6/M2L^"+>&M*;Y9J]OF.S[X355F_*PUHT*NL=N['G
M6S"I9+(3CN]Q+,J,S/KG5BG*MU$C?(1M:IX@$EW;Y 12EL)MN/>_MIZD] AN
M]S-VJ<96>3:GF26!9&C?>S>,M^T?$E!).!3WG@\F#&/DH&+W(K'%VBPNOA55
MDH:G!1!V,&Y7"N'5!2Q,/F#S7V]M9+0EV,]6_]$F"-4$Y2;?LC _+2%O+%0B
M2_HY*&HIHUMG?@4VT+]&WDH?3&:EI<&WN:EU(^'HR,(>'VG8[R^_C.+H_&G%
MCJAB:NGI1 .\@GSZ'36RN#&:5(?QU;!4L?B%A'"DLC3.T/TKZ\6OAAP\U\<'
M*QX8>U!9"M\N[3VXVG:DX-B.U@/YT%NVD!"3I?]+R/&-BC:/004/=;ZI",.J
MV=YI&I<_5C!?2QO'G5/#N!XVBF=SS9OKRM6$6\0A5S7X6U_>\G?_(R/!![!V
MH;.XB2R[IGV)>C'43/QWJ1C%^(==R_;@P%G(.3OSI8SF3TN7(8]T?,K2*3@/
M-V-61Z?!X*P'4 RMT'^;XTN#JFE+558IT&O'M1GN#MK->N@CI9XT\0Z8#%>E
MO[!#OLRMPY72<,,G3#>_R)[^>IL;0YM^VC\DN"MAW,0\G$P_H5C5"%=F<5#Z
MG LPVKXM&8D=YG038N#NJ#3%Y$4@_LC4D?[E2%T!"OOFW?>BQ+][8PQA<1F=
MV'RV40=&CM?SA-Q?'6Q"FZ:OXUM-&/(!K9!HC"4V<R/T*]V:3*]7L8R36VCR
MTN\3D:=<7ZYTNK ^%%EE\?GB6$G](.=<CS;;+GV/03:0WQTO_6?I7^<?J$R_
MCA2%>7.W.T3CJ-5U0@6QAN717O50^H83"11/V-L0N_ *F#T]AZ@!4$IRTBU_
MVN =TS -[#CGU(D?RQ0LE' .2AV!XP-V!O#_4'"=84U>?_L9V0DA"2$D$.!A
MRB8L141-F $162HB8H)LT0:TB+-/!AB&$(8"SH"(H&B#JSC_3P I*&K 4;1J
M Z*B4D6E5JVEK^_W<W[W=<ZYKWM\.=3*4F<N:J,'&N+"G?Q1P5 (*?C"+*26
M6^\0;KVU"53?BT[&UK@(;]E%[:H0X1^+^,% N0"+'57XKBGCLH6\@?CLAR)0
ME1";(>0BM];T#=#B<@H&0&"'J,X@;(P7?IN1_W?"A#YC ?6!KZ_$6/XE@OM$
MIC>+R9G]Q.0H_ "* )_,_NVGA+7B(Y^3<BYQ2=\+6Q)O<L#"@^.-K+ -KD^Y
MJW;VZ-H:7G-[7&C3C0([G)8$8@=O80$C"?%H!AEG:KFFG!M'6(4 Y7$_XWUZ
MYD7]./2-F2BR)"-8[(P<G@!M*K'P>\LM24I<=V5"LG!5?@A.)4<TP)Z=PM6M
M(&#8[X['XX1N^,G^G<_U//:L<#IFY^ZI#!* ITZ2'P3?\=@\8$%2D%51I!WH
M+?QTU8>A26&?56 )3@,Z&# P,)?\/SE.:[7"-]'F<^4/;1JW,0)Y!N0>W)AY
MM;XWK?Q";\_<JR*;5%1Z>5_T,Q3I%&X]=DR_ WB;')X_=!8WH.<9OU"$SVR7
MAS@8&D_\MVBZ;A4E<%O8M^1Y=I9<1\J-E=<]V&K/>\*C)]:8II?Q&^7)^6&6
M0A5W6F%\+O_8!UX:MCSSOF(H_B?V=O=_-+>_UH C[7UCKU:;^D(X'RM:SL>B
M=WTQWBIG#*4^7L/M@X0:,H>VKTF^1=R-*=M^PR0RKLD.,Y\'-%9 #G[=S*QS
M<KGWVHC6@D#-RCT:AK),'F!@_BK9+YNV%-\<IZUV>#9#CEA2&1,A4S0-SYS!
MD^?GEE;1(GZ]?L//*3F0,G=)3*^D<!K7ZY35&-$ ]]+,@Z9IQ],R,D9"K#R6
ME;,+^9^8S^+H%=[[>R;($5D1 O]&Q_X"]2"^[*)#?#_KF7NR=7=^8B,CF#%$
M\BN<PBU(=!UUYCIB ^<VS3D6DY:Q<9OS^^LS%F:NFX/.U5UL:-I;%[:B<*RG
MQMKO *WVW+%?0K-\>OSQOVV.<+6R\-5KT*["5F<+V?6,X ,UPQ0S^\C:0=*2
M_M>5WGK_UH_WFW7R+(_Y.T+MP_ODZ3&-[68>([,6Q_X#:7$82/8P8# S)DZ/
MY^4;]$2[RK@>,F_B>I5IBI8A7$*_:\!,@V;B^IA1'L-AK.UCPLKH/HWQBIFT
M,KZ?E]LYW&_%S!^X"IT:']9;[PS6$2PV4G3--L2P0L>F>NC#8J?_-A4ZNBJC
ME/[,CGN")6:_)%%N@)?9@IO>9M]J8Z#F>QFE;(GXAA"I5C&XEKU]P[<7O!]*
MO+/PR]3=.XM!DR2#B.QYSQ#*7)HT',[;,-,79+TG:23*]=2]D24^MY+N+IW_
MY[V[RT0FR^_%1WG>O[=(KIJY%_$R]?[]E=(]RQ^LRCUU_\'J@EM[XU-&D=Z5
M@C/IRD'2=NG1D_]-S:I->^9ATV8<2QQ/?%_BUJ6\U%2[O)P97'I_LFJCT_[K
MMQ>T6G8T^#4JW^]9GSO4NXB[M6EN8]KM^OBZP15_AK>E/2U^+]SU[Z&"E!1T
MY*\[T8QDZ2]LH_8Y7&3;ZH13$V\ P<0_9>B>;1N^:551K,UZ!<M&LDX;Z(@T
M0[RL<4S)<-3<&*-'J!\^-@WL+<#Q^7EJ&MEF08&J<'VG79B94ZB!]CT:'%6M
M?([8<=,6Q7%$:2$#\^.66 Y<ERQVKS'^;^>S6[U+T][F9" [M^M[;TGX@^M^
ME=IV/;MB2MFWHBVXDTZH6W"[XI>&:)5>CG/><#'T3:5'<WA;M/UKI^KUL]NC
MMF]HFI[\AQF\K=5I]3%),W)2/C?;UR'E::D2'+(VXO<1["V=(?T*DA1Q\B65
MEI@2>NS^=E(R7[0-*KOZ%MWM=.IH/BCM<G MR$X_4[U%67:=GB;)>>"6MD)R
ML:'2[:%%=21_W*OV4/?R<HNT1['1:_..%[6SL-_2=CFF!-FV;RUZ;UC?UN!R
MP2SO^HO%>Z:/A#Y>OFB/IMIQ8G\4L4=V^-*A[. 9J])PERSRY9J^S;FN3[^V
M[3O[Q=S5T^I@V?@V9ZN6W DTNAEOPSE>8U[E*'\>.G9E8T)9:?';#0Y;PVP:
M^Q91NVXRCYHAKPD]Z@7\*!H_N>S5:,MYR6.I"U@W6R;XY'Q]9+[*HCCPC_\L
M];QDV6V[_>*T^KS/UX+%-<SJT3 \]E= \')[J*OQMQ@7C!H1A^$=#,F"Z3C0
M8@>:6\F8(-D@K+1Z(^RL0^FN@GJV"B!PU&KB:*^:VHW@F-/+!-<PN7D2XI[.
M!4MM1')2)\(M:A=2?+$S4AE 8!;C:!$81!Z2:"[<4^-3$6C%HA;(4^BXJ;@&
M,FW40LR+2OP*3+XLJ)5@^O\AHGF(G9RPQ5V'^2N91/] %7A! K^S9)4R<3#Q
MDS0,)^1Y[L$V.7)TN#F?)^6T'<TX<X%(,(K).9M',G(_ ^3B+01JJQ8B#**S
M_P4:2"G?2[LC(HJ81.3,=BT$-2_!.<;!2S,P/!,M<>"\EK.[7\(US0!]A5%.
MT2VA6W%S<(UFNS.+$"[?4$$-P@Q#D_=P_,EA#2&=2 ?N01XZP KU&>&T2G F
M/#G51=8EZ=,2]#FM\Q8;/%=7(CBG8L>?/"0*Y:YWD*>+')?<1I;O,L+9!4+\
M;0.550D0>,@?%D'8(#&GQ92E$=+J$Y341A02UHA6*H>AW0]\YQ]/$@GRD&AJ
MAA--_F=KTN1T-%77:7KQ;E]Z*!;]I$:"-VML=D_$P'WO[6$/@1SGFV1-%WR
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M \-)$#P?*;G:,#MDD$ SZ_=+QF!?% XQ@C*SC54;'(?0S" A8GF:%2+164S
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M%^XHRQ?#,::=8[3XZ0L6_<.X8&-*CD@;H852U\&OW;AYQVOM0VAB!#<;1?!
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MM[8>=)\F56J!;+'KUCAPZS2)/\TJ5,"':HE&"_*V498;LAW2^5LCL,ZX#B.
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MU3#LM F_L(D%O]9DYZ)Z XFNU;A+H")!T"_G((^'T&Q= \= NJ$/N%RX1&H
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MNF_E)K]-<D\;.G)R"YK3$F)(G!J%CS2.;V;Y(CY$_G$F,2[TO(LI\=RY#*U
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M@G' =C@H[;"/BCKGK9?'CY1Y>[D/_;\]W+XBHAV/!#_.GTZ4-_;-O9VS?V/
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MNE:W-YU]2M+G\D+*BA@0*U=+R!!=OI>S%:1)9,:26/^*5>XC&E[\_26]H+C
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MD\/XHUC(-'0X!*556]*#L8GA7=1IA;$_]GQS&<X/^ZT")+7@O?NKIGO,D62
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MD(T?M$A,LSFS(K*W6O2L$(P9795^R(%;1@59LQ,D6W_4CPCRE'4:H]E$4VI
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M+&70U-\[CR1;?2TA;<!%)D:""$9V59IF(\O24!E=B"N*8-GR0"6/1)?/IXV
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M_(8C2!X%]8IT(<Y9U'9.C@OLX_=%IA_TU"W.NUD\A<PF4RB#VH [^ZUCSQ&
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M8FKI 'IL!I/ZO :B:_VWUW)[AOZHZ][\_$_<(AVX!OYK;RWS&I8[@'Y/AZ;
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M3"_1SNPQ Z3Q7K3"T0$I"Y2QB:6%ZI9DH:R6C30 32[]PL"XEJ"(==ICZK>
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MSL_*"%]G(4!$)V,5E 5,8^))?N]Y(Z[EYY+PC](7"1BG-YPL??C/C\,[7X_
M^*TFL/<Q&&AWL&"X3:UXJ017RUK%.UHVNPZ7I:1PT6L3@15W#X2'\()?&8WO
M FE*.VXBGR!$:3EVX!& FQ+@G@CCNZEB&4:+ >3OX-4<T99W+QPP#!_@QO9
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M3!I(5O];X'VR/7)#PB7S3X>,OA%#=$)46*#IADJ_D1HK.[9]*6N9D9).\P@
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M*<<Y)LIF^]HLIY'8)4=F[+S @^/+FTV%N.0H]#F$G*Z:D[*<6)V#([ /BUX
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MQAQ?EHO+>N>O'4,5C8O*<;'P7-I3LYV+Y_+_CCE /^QL/ <5.$%@VZ+?/+8
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ML>[R$?.];?:!)2T?L_Y>^?SGZ\U7&])*ZUYH4,,-&U8ZT\P2&!BSZ<%JF6'
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MX,)OA%DD ,WZAK)0'^#R8*9:9L>1-+)G)!<FL3]#3-%-$@_A/Z$ZS,5'_W@
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M!MVB[<+%VX[H4WO3BM9&C3"@HA\_I/YLV34QL-$4W?6<L.J+FJ;\T3G6YKN
MP/;?CI]\IW_ZD?,6,!E_G^14$[W#T[LLD;@18_=27I)E._:^.*3'N:00L[-+
M[I<AWY)\<<=CQ4(%G%S?'=(T0X/V--H]PH1\([9.#LD4F$AV^&3A_X[HL; (
MX\+@2VN<=2U(^0-T)&;6',;8K6&>%)%JW@Z>"#@@;7 V?6_:\9"7JK%^U$<8
M.7Q8J?$^:2>X13LIG;W*K/45'*DQLPZY.!JD,?,@9TJ)QHN%=J=%W5FX\NZN
M.(-P;V<SC%F[0T>HC^1.;[PR"F+.):S/:JUGV^[2%.9RSYA-/DSF1-Z$-.3&
MOK#UZQZW".L"#Y[RV<*79MU+US1ZN!55QG;B*J[M#%Y^?/&MM8(08</"XTUK
M4,M#_@1P$OAZ/3^R2F(Q$Z8;>;?0Y/6AU?)+(O&^O=QY27OOO2;,<=)B#JMO
MS$0/G35YCK/]5++<]A&#B4TYT>TT)'V2B]N8__W57Z3<]SNL<DT<+8PU_K<^
M#CJ^"B=K?B7</;UST?]F9OZ'9JA@]%=\>* F!PC%SP[6C9)F54!]:S2*U#X2
M*X*WG.%:H;>V9E8H00:F*(I/<$V'H@AS8MD'L7;I.2:N5CMX 3&>VT52; WF
MWO5RIHI_J-1- ##Y:OD4@E=SISEX+N:,E.D1##QBNF&\ O$NZ;IHLF<\Q*FP
M:U/R8UFM(@DE93 7+.,_GB!XN+WIOA%-^I4A(3(5M J[64-4T#6%*SK@9B,7
MKHJ$M$J-N3J'C<9;-<U!81N^U/81G&8*(2'!O9X--FJ05 W!="HH7&[3"IE;
MFA*NDU>X(9E2J^X@*J7%5$N[3L*4T@(AVU$VG]57 8M/;*M)-YYMI=7Q<6N4
M/,WI_ HJQ="^&Y%@FWOC)'CS'7R;O29Z6H4]2XEH5EPZ "['&1;34'P;+BJ$
M41'$UE"V:Z  S*MSUT",[5!7)LFTGEUK95ZOY+-\AFLE'2QDBL.T"8(XUM8(
M(L'$W-'WA5LI=1K*$OX["3:C"5$+"G\5QL[2%4PA)WUWZ9;A7-HH0TPC8<XU
M6S+N7@">DZ/7D9:NI$K3,!=T&D+DO6E)[<[5ONMW^RR@MS_8(/R@(<S,&ILN
MV::)YWT=OI*)*G>X'*]'$>E-VU^%UV6%!4(.2IT4RXJPNGXA?3> Y]NU_N0C
M6\N\I13;>&% 3!7,>%,$AT'BEK*?#OP"C3J7WTU3O@HX6!$[I2G. WZ!F!AZ
M_*4/YU\>N/3QP3K>+GOSSQR&Q:,72A2?V[%"9VY R2_!:.0M\'K*)KF+;357
M6,?"?Y[6 O>& T"!YAX'W['BVFUX\9J!U'+,RQ@@W-9HM/X:F!AWB.I!'QNO
MQVS12M":PC]N_@'(G9)B,$39IR6OJ!"[4K#8<AEE,E!I5FB_\\>?Q#.&E!AN
M9S-,V>4$-TTIJ@ET9DX>)$;,-':G[-$7O0W@A>;+:;BA]%C[IA&DN0^(%/>!
MRBT#ZT0YC8ZT"O:6SB6YA!$)5W_<B=44S^PZ<C(E"L:@<S4W:QL'3HM1X.^U
M&HPWG39_[#J6"97B?]A)#F=+P:(T0/!>-]M0*V&S)E/PSZ#=1BS[R&Y(N,(Y
M1I:BD8);\N7HDE3C66]H,493%1@DN)PD&N3U3J)1K$/'_O/7+T"S;]F:\,H]
MFBK0_L02_"25@F4=P1F*R]#YMN"NJ0"HD@L(=*)9H=V.C# @Z4\'Z<)Q">IB
MP%X&9A)\B5V%.N4J\"(&E!@T!]GX2 8?7YDZ<8VMLL\19C!,"#,+&$.<^D8E
M;W7]5.2[(%&86@AX.)ONOXE9%3[<F8;5+J?^BUE%W_$3:/917L?;G485Y?&F
M76'6J@9\F6-LBQ4C1EE;],K B*&E= 5+:9%P]OPM_9"80?&?R-KLG.04OC++
M[\SD.DRNF,^4UDC,%'R*FZ!=D,7N.!\D8HB^95@-!2F9HPC%]=O?D$7N0K^A
MC^0,$6#9]Q_($J&<[(4QH=-3@)?@+)@']+=);20=6X/V;%$;\;7.%.+G-%PJ
MK GQ[L=!3[P9-G",E')H:&$0C$EOLN"_%_?_&N"HE_[L:V:)<%#3^ EU83+?
M4U=#Z#E"O^ )YAW*6SC#J'?9S1X>8%ZA2@I+J]FF[).^H;6WF!.?LWQ:^&N)
MM?0[S\(-NY6(:%J,V[@###>=1/,=V;)FZ^4^ 6\R ]Q2\> Y49 &< LDO4!=
MU8A0[MK##M94G'8YDFXM;(Z7II:8Z@YAO7IDK*[!-I>TH/PE>WBNV5W+I>GL
M),);65RXW[*=/TZ;%U)%^5J?1W5T!G\+@*9L'8<]8 EE2P.OZ-94I"$DI:44
M=W!FI<:&).KM_B:7L+54]!#N,&;N[4!%G(":',1;9FSYP/E+T_4:0M:%E)9@
MBZFRI>?D7']U6@/CM468H?<+@Q3Q??R/-</*",3MT]KJ%97U)2DS[;O8#BHK
M-4>-VHD:*?U=[LF_(_(@,=H7O'-5,*-S]#??/G0P;:N*; M6SAM;>^O2Z@KR
MB'JEE&#/=;?R;B'?CO:;T)YW)H "3UC&[1TW;+81&%P<(S^3IK9K"&QAEA#M
MT[1Q9Z\8L_(#&YR/\ U13"(K$8%GL/V&<PMAQK?5N[@#-D;=39KJX6QC@Q&*
M8YJC)/D1@HKO@&]6*V'*1R'N92E\VNO4P'=1;@G='Q%L&(>)>;<E3ZGI9H;(
MS6T<'C[Q;]#L^QDQ3K'27AK[8DO/Y>KM23F-O]?UC::(Y&]K P-(XC[*@!DQ
MRI%7PD7&#;F=@8[742?<_IXI.!_YAF=]BY<]^;O,UK8%9E /X*=,THU[#7 &
M4Z6O_W;XH' CH%TY*I,SZE=DDQS^YMS]:W=M!Y S8"MC6H@VGQK KHU&-3JL
M?'[C3I]#!?06]Q9."<'@[A^_1CJUM09_N(J=O%=[W\K,KM9A%Q]WN1"QS*G$
M1[Y_8&/*T6(9-?@9C8UA15,Q>\SB?2C&6)RI&,"Q#[^H>WQ]D'L42UR^9^-%
MPLQ(WJ7*D=_%^/WT ;L*D<N[:2>T+Z(Q=/N.,A0)B<SM.NFF%CC.W:K<JV=V
M()+%_B"@>NP+XE!85!'AUR/)#-C,SN2>6<E;0%Q]ZBZF+JD<^Q$PJ<MY/&/?
M[[+QP&VD'(^YCMEA?<'>@2T.7+7HY^-_[MJ[">O"_)'D>U;+K,5KZ'N,Y887
M^C1ME&XZ<51B1E'(',0JP-S*"55 "C$0?QHCW^39-]59Q0*G>H(-D "1R?+9
MFF?_4OK1NA585K!%/+)BB+>(&(-IAY,O/Z,D/C'W7TI&+(X#Q;:.O!^1",X7
M6*/ G.H8,!<'?'D4M./-?=JFV/S\Y3/>Q9<O%V.&I,1OE9$M9OM+J^W3ET+9
M <(]<+Y-<Z0N\@2W&"LB$INQ@4_*MJ_F6>\'?=XTW*#L;N3?.'J?P:AD&315
M0,VL_'96?1#O8N)>1KI!@C<OBC&K6!D\DU*$W2VZCL^_F7_RALW@0QY[?]'^
MNSCD,4X/!O*P*$YQC+=V%U5.8!4["& ("D"-+>8,HIP[;U?LD5QJM_)^91X8
M.T#1]4W0!HI\^_Z=0J$H<@?HKIH=JAY^L%]S<QS;C^^(7KIBV-(Q9F8HV$ N
MK!<15T%2S^+R<QV5MI]+=]$L6;$\ZNOK&'A@IOD ZC[2VW'HA@+X4('40\%W
MJ7*G&AY#)$=_OHO.?X"O)V/REQ/JPS'Y\LA.S92I'#O Y*<_BG--@53\ Y4"
M0@?L, :B)ANWG[SW9=WS ,_6KUL0:.^RZ?1*WDQUY)\HUL8C!2$#H[P5E<:[
M]3,Q]ML1?),$JR6MK"G#)"JVN>XKCD5L/_?A\WED(1*%2,(RD,>M +Z-1\F]
M[1K/PU%DK'@ROOL@WU#I]#04V\VC(+R:)N3=LB&"OV*/EH_IYA'SX;36:P0$
MH9A$[IC$%(Y*PMPC/0;^2DB$/V4&+/E8.N>5RB?IX<H(8';O?ETNT34>N5I3
MS(A%2(XF]"L*HM*:43J$#T((WEAK'D#L ?ZG#PO3 O.31_!M4:MC83:+J*"^
M;BT:3+^/,:@@(2V)9!;-Z)HD["B K1"0GM1C'37;!#R2'%D^/0L-&PJ;0;3W
M()X70^D@6CGR_A<5OSVR4EM,M9YYU+3H^ 2V?ADT)+W5&6^'N_'@BP 33\#&
MJVYP45AQ& [I@P3P_H[]D5^,+/6MGR+60!&S4_(!#P')/)7RV1%@ ?=6.I*Q
ML;OP\"/&=$!7AX/3G .A\MT4!,!VRR?V+WWU^]B[*2-^/&^U?-@_X?K*RP?/
MGJQDI .'12O>;7KP20B/_"+U-R"KOBX=[4#NCP;AY,@AVI*.%>'XGEVX%;OO
MF&!2J(V+$H87S53F#_)PCB Q(B4F=E;/W(D:SIN/_H.5\Z/Y>M#*,?V()H 5
M.U#[3,S**7$8:G*8>ZOR^-[-8Y+UID'6NH.[K^"V/087ZZ]E:.6LYLR0"LS]
M1^",(!WGYOU&H -SEV%<M?R]-W'6RF#7' /&!]S!6N%NZU+5([ C%>/>71+!
MPS;3)WBQTKW6I='Q 2Q7UN&;UVQUX!([/:1#;2X,*OHDM1JJ9-\9M/K6OJ.G
MN*%/"KTOCN$5-V2A6 C*8_3A-E'[Y@FG,>KRW0GM)^</I+P_&#D@C4.<0C#7
M';22-:B$9H>L;HZ%A]BY]4J3U<"*AH_MT1%.Y.5R]?R2ORH'PB*D["JG^B4N
M9VZ&S-)*5 ;'8\; ]'A47,G:3$5[A Y_8<7U+L,!-C9P#TY&)I!=@XX'9#@3
M;5JL7(-B%$MG<:VB8WGV$^"Q1B,B$7UUH30-F4$V;@T-'CJNP?5O'1L=^!7<
MZY!Y\WC'UV'XZ&^\6U,E6?[JYDCV[<?O;[]X_W$,#'N=???U$M90XL"4BT0
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MP=NT,"IS)ROGZIII5-A?_*X*5ZP6M.3Q7@IYK!X$/02PN+ E!HVVNX,7\IA
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MO/BHR,:.#AU)+MQ7>-)=:A!+_&)\WVU#DS6#A5M_F*$:(U&E.A77<7 JH",
M8W*%=8;XPQ[[+>J]2IX2,L/W1#5*@/G76[32$V^6X*90EW6(KG>9\]P_MN6R
ML^%GSUUIUJ5ZC;>9-H/G+CT?EI#/^#$I?@8#++,]9\W;5R7P2O+#$N,Y^ZQ
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MPE$M):N+%FF (A%VK@P3#M=.*A@\^P#BE^E @9E"1P.4C#.#=%ACGB,D/'9
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MNL0L$T9^!6-\:>RDB<7MK]MF'BXH&*&5FOCGB7XS628TKQ1:5BX8@>]N-W$
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M\EN&]9(;G?]\'7]X<LV#&]=W?Z^2-*3*&N1'X393G-=(LD9=<3#RK\=[H5O
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M=A7(YT'&FAC+$/KS/O?<2XJ <6#M\6J=!#>43Z]N$^P+AIJ$V.SY+%DV+=D
MS,NC9QM8Z3"H^I+G#9@U1Q^"[$10>P#T!>L: N8]! M^E2/?S\34S%Y+>N1'
M_=Q-(AO,NJEAC=^ Z\_ 3CN.3D,T <B9O,U9!=#MKW8Z*6Z:1K+7DV:]J)4T
ML@./=N)+B#7,X?'R/$P%T!>\8PQJ@ [FF52S)L)F\53' W@__!?,ML,X>C*V
M#&4^(P/00>"42?A_PSM^EEG2>4XZ-OB8@9T-+QA$65U' 'B+5VL0UD#S1NF
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MUBTV-QE!.0M(4M"W:@H\O/9QVS/W_?KZ:%/_OG7@GF=>>V&0U;:PLF\6-)6
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MK3)6SCT8)S..FP6]#>:B%L2X#;F9!5*&.TN98%A' K/&98&Z-=5E38U_F/<
MLN9KPU&P2D/.O]XS+SV^?\H_V.\CL,LUR+WK;&RTD,4&*3RPG <2R_$-/JZV
M>8<L\)#$[^:?)-GG$TMR]GCDP<]-]8=-6R#C=$>J;W>N]%5N#D0RO)PYFIMY
M%8F+2"H0*TALT ,!F2VY%;MRRT[*2#/(NX^=ILJ^N'B0Q)1MRL2O$LMN;@,+
ME8H7#DI__G.2Q+_3$_QK/8@4X1EM2,-%)>LYLN+D@55[<D4>3XRMZ<*^F":?
MN4PQ/CX.I'>$VKQ&[&UXU4F'OQKE>VD0BDI&-?".S3J,?:,N;W,BV :-E8^;
M/IVP_<PUX4V0HG(HQZ?LG(KPRU 'ZU5$^(3Q$_W(]]8Q#V%1U"+C1WC"2RGK
MQ%24MF-L22_Q-8&$U^$7M^05CZNOJ?"PQFS9QM22ECO=^MR[KPEQ4U%SG%5J
M95'Q5-/WYQJEDTN3_X.NN-0R=>GEC*)"95X54-2,Y$7?(,W?2:"6IU&##F0]
M(1W/ )>(BA:'IY5,%04=7(LNI(B8V@?PW=^VDA.=A!;M79U3?^RT*9G.4*Y@
MC#_30+%^XWXG;N5M'R]P+]R\CYP(K^UBCW>J2VL?<_8G4DI%#TJU1DK?C%<Y
M)67YXQ6BB<K8B:KTB=F#VR<.48JCM'3]^:,S^RU0.PES"XW^U(3_P:3\BEDK
MZKL"0%&W#^^1(6.VR')I"=H^Q:[*TDY>)ITE\Y@>[U0=MN"6S',2VOY +1G[
M=6>+>@RIW<I"SC.CK;'X7N?"XEEE58;1#+XX *X^JE'! NB'@/6T+*-6KZZ=
M>9/?=_C@%KP?C7PY?^+S+WR8LF[.*F$KLBI!]HNI?DW>^6UX(GZR34DPZ5N5
M)YA\!MQ,DLKN?2+@QM^5YRCF:4&T\JR7^GT^5>']N/[^>87F!7+R+:'ZAYPV
MCMQP+_P<1!SQ+=F?3%; )=[ZM<^9YXK%*]IZ,WS*Q 4YN1-NLP2>=)Z&5?.K
M4V2(CZZR(/MUE"U<0.4QDTK@QSV,C$0#\"??O-K)/I&M%O/,K.(VME8CWC/6
M&UGXI&'ZYI1";R=>L3+/.Z-VC5SV?B3OZDANH1,Q3N(? +#RV!9&K<6U'M7N
MK-5R)70M^RA5*G-CX1=-1<6UU*X40*=?/8Q@'C&2;RR("W[JI[B2C5_ 5OPW
MA/;*0/LZ@?_:*<-52G=G5E0;YO#@04/FT9#-UPN&<[TRK'^6*9PWAVRL(T3A
M"P^/Y[F=@!KZEN1)F:VMUA.;C9TXU8&%EK[,,C&,-$D>6\R'BIV((@TW40#=
MJ<.4,_/G2VWS\!:G"6R;V0504[ R"8:NW#H\<V]-R\^VO_]I^&_V:,O*]#B!
M@AQ^CS5>F:C_ZG*;X.5D.QENW#2.C_REL(9GE"4N\>I<6P_;1%CA);-I8%M,
M@(0XK< F"4JR(RSB0Z=G3Q7440_*\K#_?:M5U?,93E.?:H^QE(>9MITJ5I,)
MU/57N9&+;6+D@?1ZP!/)8YRU*L!;%#,+(ZB70N[8_R^:?;"E]IX&\Z?IYH(^
M)$PYW:%G_AA&U^@M#K-2_WI;&C$#^"I+$']FN7())@5=?W1C7HL,AY<%,$]8
M:&41_YS2%Z'C58U]GF:?EY<9&_+F*Q&/CQCJ;3!MKY+'?UZX149MF3O;_*Q1
M;-2\)3.(A#];=F+NG*6&Y5<4>X<&82WOC]T.OEIT^+/3K&<MS X+3_Z,/#]O
MBX]'.$M&9=+NTQVXM%Q\WV_":DS)7C21FD]GREK^"R2I96:2'WS _<^WF'=1
M,HL69+O=S_#!G!JB[.<H<E2?8(Z Q.&RGP.7GS54[N<Y^L457K5H+?S#-&O=
M.5C2F;P9N:=R9K)=PK<3X?5*^O@%XK@Y2U69Z:G^O<M;W7XH][]RR__)\:H2
MXG#)O#;$8@8Y%?'#5"E[L;G*"*\X%U',DB*T#+3=+9F%>LV-RTAC(V*F=,V*
M:=%65WGG_ J"S]_Z '/-"3</USN79EO/V!X-!"!KHHS6@;SL!T:. <0?*.\8
MKF@\#\\#S34 (T-VZY/2"_\G%5B%$W>JW^3-MA[/;:;7]43FJ674X8X90,ER
MDV-2HKEQ>/,(J[$3E4)Y">SCJ20(N<P&O"XR59W$D3?#?%<5P8.K9A'=$D)X
M)N02)<R]C]XM*2Q14/:F=K#%Z6@=?"%0K:;9+6XSM7%M##?A#!?A'+W[ZQ!%
M3Q%<92\=2QLM'J"ENG82+%R[\2Q;_C>B*#F72=KZ*8Z=\]9Y/R7"M]+CP_=Y
M!JT<9^*^?H8WVE-D?#,)Z2[),[4TGB:*W@;SF'.##&5E<TJ)8?OFYLX.< O@
M@H?DC/3[19[!/%(.OAFHJ&QVQ%Z0_W;GZZ'(W)6Z,2T%NRBE6*:[$QL$.\?-
MPU7]>&3D^T'(LW#$WYEX)H_D)=)ACU92L;S-6*RX^'\4G7E;4]?W]L\YF4D(
M28"00("3@7D*HR"H)S% 1-" 2 $1PR"#H@(BXM@DS*-A4D2T 4%148.B4D5[
M$D!140.BQ=;:@#A4K06E:FU_?!^?%["N:Z]AW^MS_[.WC!&I<HQB_)+?XN$N
M["$TEOPB^*(+$/4IRADR=J?(0!1@'^J4OFT"O"@K9*,JWW[^!<KO6YMZLU#W
M-#I)>%D"MT;*5\CBA'S\]@U$H%6G7.>)^ZCD#'!R6Q.N[TU18BVU]!J^6>S-
MN\2!MC%0=##0<)<BQ9L3<%M-OY3FB\8:5)"0-G&0[8U[*&WR 2QKH!N'E8=Q
M-3-A-'Y'$%J15]#VB.!^E2Y1VB[HA&JN.[5_AR'_,VXMZ*Z;K'^5L//U/VFB
MQ!LEZ;A]\&L&R?GK(TB3"0R#\;I8>,16N(GAT*PK,K23[SSQ%@DW!+H4'Z2.
M9I1A=[X45:MWQL548JY-T;L<+6E#80Y8W>=GV[%1"@NO7.G$&J'GWK%JJ'15
MQVL;D\3'C_G1A6_C)&0[Y[!U]1.[P[!/O^XJ4_E>M[J=T'%X'9NPZ_+:XLN%
M6G43 7L8G'"/_L  G;#K<]^"55MG8EC8+N\3O?=/?)%ZT?"-92J&Q:^@W3KZ
M_$ILJ6> SVV'(WM][I3.\9***.BT?L66M1*:[0$A#V-G;Q1ER:['(JD<MR7J
MS(61[K,_CQ NAZC;R.ST4-5PH 05#1KH!1M.,=8"&+)GB.:V(S->#K7M0HOL
M23DMWB!%O%E\_!'V+,#T,K=P$[EODS)U)FYY&OV>?S<JRAT?D0*J,;/3T=^M
M:VU=2Z)$F6''M4CO'F:;^@JJ3'<8R8*L#VHW,4FVG:T0[EJ*Q8NJ''F<J*Q7
M1SJ*O;VIHYZ$*8,)'I>FR\/ .OE JHS?/\%\YQ//N5O$EDV*B2V''2CN!])E
M<>O<<M1O3*QO*XKS.G&#-]=8S;@LQ]J.C-R<\'V7H>3GR>,.4^@KM+^Z,V9C
M2+AZ2YLF#^?998&"5^ N5LN; 'EY,K&8OL#7E&)B7JC(62[8GCDR(4S=1D=O
M8@(_R*N*4LIZB (6!XW&99@?(\Y"%(->M%J@)3455/S_C\LQ?IABX@B7\<CE
M0%P,P=:G3XZC$5?\J4HM)Z:CN-+3RORD7+57Y)9$'3+8(H_&6.72I-'6.F5J
M>IM'G<8SE25==[.XK'!, LTVF&YZ!Y!3<%V827($*3X-CTL1?U^;J\A($BI]
M4?U.&Z5,P#L$WL8.0[TK&^,L?CQJH1:%Z!"KGY, \/?.GL9C_PF<HQ\3ZZ^?
M9&2J[6+UI9IXU(@(T&CAWFAEJ@YQ&I"",767ZE<-*SW,Y"4.[F"U^+#"\?("
MK<IVL8%[<6_*!AY7Z>C:_@W2.GP."(LA5SII,4] 7<\+=8C55287 :$#BH<F
M\! 99,Y0/-3FV%E:9/R0F&6A^)F=!.-G3?'?#:=BWZJX97\^=3*C*C#NT]HK
MZ2EC@0&2!M'O #G(>03+='-TAVE-$:@>ZV<H$69*:0?^(3M;M-@*:D-Y*XU4
M4^R3]7_%+HH9_+.!NDHO]8HQG/J<)<8?=15XC##NI> =3)D7*1F_7&"H]3R!
ML)_HX4QCG,0^AW9FD=W?R$$/4K'5KGC1>A\#,1BM@#U0I?!F6MM<[$UZBARY
MH.>O_;178W9=*#HV\899?7T*,U"TH."[>]\3U\,U^V^C[)<)SF8]M^ITSJ!-
MC,;9V5.:RD;IYW;3\2]RZ G.8P=-[;G+=5M360@ES+YD+6EQO@9W@(8GJ%MZ
MDONZS(0&9U.]9;%U;!FS\ L@L\MH(U1P6[1YDB8IVDK73IT??H3-&3&V6@RG
MUF[-3NOU%%[SZU=0"/0FW!6LD_G\BXLZ5G-<G7/\6H.>89%U-VQ<1L)+FZ@F
M*J__WJ=7A@<:38]H,;)W<M6B]&&*K5'B(/6^+_/IUU'WSUK5;<2_F__#;Y=B
ML^Q^;L/3FV420R5RS <X]A1^L1F;5X*Y#Y13X%/8*7U79(:P9L.?+TUWU*<M
MR&X8VJ4AQJ!]0 3QM*,R)*<#R,\ON>LWEE83\L+4<K*6[(C%),[SH'__P.#$
MN9&6SB=Q&W<! UEC(+EDB)KW]UWW3Q(:N;_$'+YLG4XK89N4GL=F="E6CB+A
MYO(,+,!3;I&F<O"2::HX<GESB:C^$L\!NM@(M/W"*Z89#F(QT;I"NSP@&-'Z
M9)Q"30H_$O&3HNR+="RF2%E.')VE]#0H$S<:SK-KLO'A&[&0T:+:9/*$1Z'L
M#.?R0U7%/-7<:OGXBK]DRLLE4\J5+[?EO$/)Q DNJUY=-V[2'.U=3H=RKSX0
M3O_A<FB3&-RU6S'RU:CP0]NAU6Q0LQ ).YGM55H-QIN)],9.+XX \W8*27B-
M@(R^4GS"C\=^\M':7)(.^3>MO\#J<SC4=PS/M(?-WFIS_CS_M_A>4>ZJJ(;0
M:A)*8IIH1W&[=94$=3N#/FG:="X+3(0/PQO057P_!L3>IS#5(H (-3KY<>#E
M614-+,4'\) $7FY1M'Q=6:K2=Q#<ILMJB'2/*SN9)5Y\'<DI6@I/%ESW,UW+
MK2 =8UA(S070P8I_PH3\';\[)_@U?U%$VO=\OOYQB7=$-X+W$5X+B55@+!0O
MA(E:F_B!%[R,=M%#^Q20,0%3K,Q %_\QE==\C+/ "!"2A#53".K@.X(0X84G
MRN3CDN8\K8+@HSX9EFO$1 V-/%XL RVN[W>I^"K&+\W-6RX"Q/;"3ZK%_A1S
MQ7[<<:M@44?2)]20BKE]H636*S?V0;4&ES6"V)=UC#+;AI:''@\E+455?NDH
MW5]>2QGQ^"^4P*?H_@(&5!\"?OUN"[:7+'J'A),+ $(/LA&Q(AA^.5N@.(G#
M/4\ "+'(R1D=?J\"!U>QTQ6$ G0_BA([$4(!(IW7ORP 2#._O4W0D-%#/R4I
M"+E FP$9I(1*AT1Q-0I8LA*7@92U*7&=R0EJQ38B1!A*3AB"GI%""?,0/PDA
M)BF>XX8I69&[T%^MY,]FZ24++_?I;&"2>PU"\(M>-Z##=((>W0FR$04^]5D8
M'&$R23[RSY#(N%8V 1!:Y.T5H*9))ZHP?D&JT_>MF*UDA=54\@&<E_K_/^%9
M*XKZ=50JI4E,;G(]<M7D%L5* S*['LV)5WW$%E-RZTYTZGZ5D*OZD801A-")
MKN]4*K90!7E6>YJ&">E2UD!"GR9&IA#-[D.D_<#Q ='J>;T)K<JQ "4D ?%R
M^[T_*MQ.;;">")<!QI71D5_/;KC>=R?JB1)7@.*,ZWXO/1Y8QQ=-B@6MI0Y:
M6-Z65A<(B_S@G?$UX5B<DS92]D6L&+)DH>,;B)C@8X=&B"IMUH+XV=%#&PSZ
M9<R;CNKQ@T/ZJ=H:1_0X9G>K1C(CSU%)SJ4]XZ;+XSM3:,T)PDXYW*G!#A\N
MO15T3K&E+7W-CG31UA5B1MB>PSBOHLX-6:K%YXXON<POJ*B1W%#69(7)W#LW
M%*PE_\?WJ&BZ;1#KFFJB\&4GYU2K\64.G,;@5ESX!X%']ZI5"SCW;NK23=S4
M>3UGC@\,=V[0PB(&WKVO5-@DV%^4^%V50]#CKO7/'.Z@#B+AL=E>KE!05NYQ
MD_]Z^MD+)3:6E/J?0[)GQNU1Y)'0,7F3F"AY0*R8^9;7__Q:4L6.F0P\G_,R
MJ?!$5IUC]L$,::)CZNN-J:-=FQ8*&X0#@N+2$]F+XS<SPK;<?_G( B\5G\B9
M/K&^X\0V_,E<JE,>\V2>G5/^U8Q4@VJMX\GM2YT*PIR<2:I\=./F9"??N8<'
ML:%V6'@N<O763\]WQD%.IF&\8\=9;27"F73[&?N"IQGRILY-%XSKVS=&/W,J
M8F"%!M&:LLRG+<,9FZ".'"=Y@</>!1QYOR)K)&.S_M"FQ%??X\/X31S2I"KY
M@F-JH)@ZKB?MS[0M();<%Y,L!$D?5.1XA?3QB1RJX^O:U_+YEP='NYAL;"Y^
M>,O+]!5Z1<>7J9W,FWM5)]G=,:LN&$TTQ+JJ5\J(DPV>+G(#N*BKAC^Z*MAZ
M=4D#9<%:?E,9$2Z39,OC8YM]6-BB3*>C$R,C.ES-<<X0E/SL[HT"VQK7L'7.
MHK@"VY!-*CU0YA&H:#4I<YBY<[O'G&V W!6/CGC>'+D'V*$*_;[Q?;F*E<.B
ML!.1VU@W;=L$C<FN)UHIMC4 OP>@%EE[."L/;8G]=4;3'B)F=2HZ<RS:)L'3
MK8IM,[J9%R0/&>GX[$V3"8 ?:\,/4=E.EC$OH<HL%:\LVGJT]@TJGFFZM?T_
ML3!>?&:Q'G&IZJE3M&7I*3V*A,>;R"VB=4+(B2ZFWE$Z$"7O1D0.+6X%,H7#
MI.Y_.:JAK"F*%KCAK2+W(_S<6_STS;VH#JM=0/E&U>';Z-;^-:;O7)S2W6)0
ML4FL8B4JIO0!@1$\\@@BV!1=;UU>?P,<W;6I/58%"_6A1M!C%K+U@_ZII-AU
M RRA_BA^^;U HM>0DF2TL:4<Z1V#;.<G*$'BF:)7?)J&8U%W_8YB9$9W_>5F
MX82.OU=IXGQVA8EDX,/-Q"'0/1ZQ[P<HHS3WT3#[6#$'J7#L5V3&H\<8$MXE
M18<!HA@3GOTF(J-([R0T00I-R(+L0B!3]&=V X/U+NSL.<5*.M9N:,N[EH33
MI]7E%)O@F\K+G15-GN<H:+5C3[G#K"L?:[-9<NKEC28;UIW7N*TL?Q7_/]>X
M_3J3A9+HIO$>/_;05N3MQ0_8#*7HRO[-@C?W*!95WT94,+KY@A8\,9%U@NI5
M, UB4-2F!6@PB/%[178EBCV*VS:YQSLD1ANU$@HI[]Q2_G=JHR/-CJ1V/SD#
M#NR[C>ENP1'O6@D!MW'Q2C\50:-T;!I3HD#/-+H&:Z"DDS%M::9#0X20W]CI
M:RRO;L:J0=MXY-%_7:01@%^B2)\\_W0($0:BA$X12RZ-R@5L*D#,4U/WO;J6
M$47ZTW#[2M%:CH331OS7N0I3 W!& :Q!Q9$H-J= 4">.5(?PC7_MBD99L3@J
MQ16G47JD*]AR=A'QCF1$9_4ZFZL$%VQS@6W[<H4SRK"].L*,DI6.> V(H!;%
MEA"$;Q"#FM0_W/_$:,%_0[8*94A0/8K=*[)V1JCO*SC +3\'A!AY&.8<X\0"
M$Q>Z.?,KR*B2E(/F2@"[25V2Y3,;A?(NI>M;./_+.IFV^Y%8<4CYJ'&BBN*'
MF'Q)PNX%.7O1N[C0, W8I 4]T%;V2"Q;AG#:0&RLN+6R]8>]2:0)@'P9P$P@
MMMVK9/<4'.>'#F,7/ 8KIXZ*K .!F#;ENR[PP0"_(!9B_ADFBD;L!Y085']:
M,G)XOQ+*;<?-#UG!BJ#/0X2FT$^?Q 0C8J=&5TA]'#]%$B80N_Z%%H2+LBMT
MF)I\,*)D1:\RY:H%*5!+S+F%1Z0>8SJK2*0]4$$<4%+D!.M<A.\,XB2N<_L+
M\J>5W!]MUQZUPLQ#FJ#(]4+BIG@3*D5"H)PC<(BOX6;FL;Z3C!);-(S5=DKF
M[DPZ<$ 5J\=T4V___2CJAS16>B@Q/K+H+%#4 BS+TU,(.$O[A]O3:RF<$C!T
MPVJ)0B^YOT<NCAS&#SBO_2=;M3)6H1\"<]1_V S>Q4^N_]\%TM3CJL?O-PX^
M!3,H@Q@4W'(T;7_W?;8<,D7(YUJ<O_0CK%D51L(CH#K;+*P(I7H@Z&O;6RIA
M!+M_#I?<^Y?ZNX**">;"CJ?_RT%8"<^J^H:M)$..%I=D6K60A%L7?D3W] _W
M=[<\ABFB"I "+-]O4;7!QJ1F5#'_39GF#D7N S:'J,)BH:BH7_]'F1 ^/7")
M1.8'(F&_@/'>0+S@MV"5LFCH_F'WBF$)?V:\S#5[BEAT)6%(^2L.$_:+DN=%
MR% H&WLJ63!)F*M?<0!]]>R!35/S;38I:CU%>3+QT-,5Q[*>LD/#;0L>4:+G
M7I<.$7/?-=!*1)W$RI*:&Y:C:U1]%7PGVY#0=04*6R. ZU20.E'BNPTFG0B)
M@B7>J[CX]"Z2B^[N^YB\,0RG+3*1)Q.'P"LHGH(;/DR1KV[1K1G1+6!Z%*0>
ME+D]?EWDT4<*9?H\1]4_\=T0OFZR4?!Z S$6P8V0J(&-E"0LSKTEMSYLG?J!
M3>9(Z3)Q KVD[GRF KVUK]_*"[U_-:/BGUG\HOIM)EID?1%Z0"M_E2+!RP!"
MOQ/?4*^!KSZ*101$*"<>=9PU:3H)U XI#Q55\86K-_8?$G:N6#<!#@V5;9NT
M^*4^]6Q?*6<O<&IY.&ZOW$30ER![W/VN;*]T([ES6-V[6#1RK#8YY>&L^>9,
MG)-,D9OU:55FV,!:4X_8CS:^^GW]YSW\](V)JH6>BB=#>NR[,(%D13='X/)"
M!,9#% YV[V^K-OK)FHK0'&$*_ND"53U8VCSKX7$$QXY%4ZPC\N =IJ,*C0QP
M_U(HDP&.2)QP=-9*AIQ\?I05V/AH0C%T)?#E81%I\Z'REK%"H^CX3J07%1-E
MR.&=YC1O]?.LT:O,:G(LB@5&*G[^+R__N7Z9'OGC]XR/(6GTH0?!;^O_-U![
M=TCIK/,I+:'TA[$G0A^W@?H-D:N;=(5[7TI4HG)*S:?']FO*QXBY/ZXL017&
MJI%YJ')2!,WJZ\/OBB3H_S1;JP:NIS\U'PV856AL%:AX@Q2HI!T[.43%I4OQ
M"+1MX-"*P14R4>A)XDAC",X]A.!5(4*R(2S1Q"9>98'#85GK"%JERIF]=R'Z
MH4W)5?[1<,\VJS-J8-EMA8T])>_X;^S_FD^F[-JQ[D7F^8J8Y-]6S%_-TT8L
M_:EI&V55[\_7)+GHUKW@LM\(5-GLKNYL[M_BOEO(/[H[R2?R>\^7-Z24K"80
MKP:-8OZI^Q&+L9L(VBF_I9D$R[&E+,ZM/_5$](\^*_OHH(;QE[AA$PGVBKRY
M8KV/:$#TDS.(=!*9-8<PR:F1E'<O% <K%^D$!I_EJ7)AE$Y/[&%11BNJK(:S
M^E#G>#LR:YWA@D4.JXYRG8/#9(2+SC.VR9=T.P^&"DT:57^?EKED"%>:S>3$
M7FW*7G-R=7M8\^+F36O/?->;\<C5\H%">!"5$A<NNT V47Z!V./FW -=9KZJ
MM46L4?U@LBY#T(=FR,O\=-*:;@FS]H1U=G:"U+MX>;G<CX'W70/&\<FV15TI
M-N^*R5'Y/%3U"*YSL,)X4H>FO </*SFCV'5S[3''"#O=2[.BZZU*O(Z\>UWS
M43%FB_-7A;+F*NC%(;</?<ZS&]4=UW"=#;]\(W#;*VZJRM[9$3K.;Z)Z:46V
M#M<3@??PH:63RJ"H W83MX_*ZC A!RTJ,$SO@$EGG+E[^^#2E1S-8 .#=V9*
M\6,LK&L(MD-G:B%"%4J/9XT,.^-+QB0J9KH6&*CBH7Q6D"O+N<0KW69*3. <
M+E6FX%,7TJ PURF$4JK2M4/A 2E(<!3K=5>QM9\2 _XLT*;!)CT#9\JH\A2)
MRJ*(\[K:Q%HY#,:KP&@/$U5V^TFY79ZQ+B(F$+EV;5H-C%#4=Y?WU&9H[@6X
MV<//Z>8LXDUJP*(WI<7TK]V=^#)Y)6P:E2BM+J.ZI@A4G>)N0$H:0:N+5SEI
M8UKDK7N.,P(MLCIYWKR*]$;J?44H&,SZT3T$&^'++9&/ (\9*<5S;BR\7[N#
MRM?OGVD5;\DOW3%9/P7^4;UIT46^BK?&,*-8+-=Q2Y+MOJC,MP6Y[2BQ=*]_
MKHSHOKB5&[G,,,0@O2Q..?,]2(TW*DF>DT:EW0(=8VKFSNEF,!97;]0$BHE@
MC1*%2?S:XLKGY[W\J,6=X6&Y_)85D;,:G-]WS?P#R1M"O)P=I.A4O:4K&S\L
MSU).81A^]X]/^]U ML/!J>;/?YP]QO_'*SBL9>[<@9@O0(QW\)?IFDX?X?$2
MZKLWBU_\N$EXM=1RD3ZMQ$QM0ZQM)[1R_:T]KZ9AP[*4F^&@,+F2+BP;3?O3
M^GU'Z4GYU_A?2R8L3D\5TPYF8*?91>PLAF4?^<X<K6<T;42IF=E8=DW.7M*]
MB-4>V+*VNO,SW=KA[@?RF;^DC1^J)KO[8S='P<56;-=%3WGF6R^D7?'J(;\D
M:_",HUBA'>D*+WXA!CA^B)TSE5 FYT7S6 $O8R8V!6P:V?L7;>GD;PV7%YGP
M2^BO617U9C$*3+G<=2[9)9GS&2YM7A6GNI^^BG)@980P;+8T<A^5?Z"Z.$;P
M.=!JBX3R>E"W_ID!9'>F2.7Q.JO%1JARWU0Q5](X,JLZ$=&$8MR11D[ZY?JT
M?7)<5L?R'+N+C!4NK@&R?Q4F@2GUIVN-02FYT<_VG_#^<=B4^?/R'S9O+12Z
MK*JO6MLW;=G[Q2*P!/';=ING>]_51!#>3]35/[(:R[(T&Q>;6WX3[RG6K>\3
MC(JU/<HPU_SPH/?U!_;-/[<'L[7)%5RA5=.=">B/P[5$##Z=8G(F<,'8BL25
M[,C*(9'$VFM^O/P&Z(P W60H=_MF?8MVIW&4O4VQA0W-9PM>N*6P5R;<;SAX
MJ>^%1][AE>O?-QRZ/O_"2\F.3*$VM@S[O?2N/QRYT;/Q\+V"E[[M[*CL58VM
MC_I>^O<>CMJRM?'(;_,O%^G8J_+J&MM>^+T*&CN\:L>YQJ-_%KP*GF*OWG6_
M\=C??:^6S!U>O>]]XP__-_]J&6@M4U*;-#C_UR)ZJZS4LZG==,?KY5SKZ,I5
M31V6EUZ'>K=&UVYM.F[[]^MPD75,?5U3IX/_'RNB6V.:SS5U>>SX8V6*]9K#
M]YM.^%_Z(RJO=<UWXQWY"9VA+0N/R!_G,KKQ;J=CB\86'G9SUIZ,VG?*46QH
MH:;#7+=)!6&I44EY=Q/+N8@IDG-5"12!&:<;P,7(ER8Z;X:U,+CF[ALE-1?%
M_;*B^)D[ _ISI@S#@<%6N6Y8WFG<_\&<Z"$V@,-?+UD-Y.KP7R,8\L  S#[+
M%V&IJ-(L%\5TI&,S7[FVU*+  <T1!<YUUFHH/^ ,LS^>&/.\@MJV YO5,4RT
ML$G\LXV+L=.B+D>MGS;'J<"!5(E=S_.*"1<%M:9"(KSZ4>H7B3I_<B%!XP!Y
M98U1L*0*U>([2#AICDL.?#\O2*;B[9/O^+(<:'6?Q26B>ES.N 3RU"O!+(K9
M[^)2: :M6'C>(,%S)[$>SQ2*YA$CI@V9!8% VC>CA\IE@,<[% !].W#TUZ<<
MG6'E#&X0R_RBMM56!X95Z,":U\LO6JB3<!4@LS5>69ZM R;^;C<3Z#!8CH@<
M'H@TZ/U](MSF3G:A$/3R.'!K.I<1U7;;Z20%!(+A<JI[E#F=]3;FF>&WAD %
MWX(]$ITU1LY8.T,>&+D=6K!&>><%-RPHP23'585O,.Z"LXWQ%XPR^F(?530F
M!8F^ 6 <<LSR_$]5<)[%-HA]#R=S-+HPZ2RQP&4'G)I;\]]"?GKTH3[&#Q<&
M;=^A@7BVA^<&Y&_;=+52+E?%4.2'8^I4AWY;B)\!(VN78U=%E=/;,M=9<CU;
MTU&%M8&[/>-J1>4:0V/PQ#]@;N"EG<DE"LL!95Z^(>#*H0N'+KNB]/VG*Z[X
M?*<,:?KJZ2.\&/,^E4"*K&52NX?$K[N:XN/?4(NTF.M7GX*^_^V:P!&R'>P,
M8,_X7/V9<]*-48C*(A[V:,U2>#P;C.4H7M$9W6V.N^]9!#D;,4?.-GQPON Z
MW?#Y#%-V.9236T\V_@DT9V%WW.M\8I8D]SR@!@D<H6KT'\YK\>\C!,&LDBI!
M-^Q$D-N+-"DEWJ>AN!A1YR'>7U43-N9]60K^0PNE:=-_4$,GCB6F*>W9;7_:
M>?B?=-/#L;$+)9"J6\I)E;R-GVFIZ6HGX\*$$$: ,S=#S)V*P7+6;3.P#TX?
MM*61UVE;Z41TW6CCVF#?=-@LYP[I3+$^,"H2"*+CO9-.7 :/!/'\G^W&[HK4
MOK5V5F %<J!H$ZP*/^&R-]%>>MVC5QU.+/Y2=1KK=;/;(BZX<&[+SJ5AC4^;
MCFNOOL'^<ZS)U)Y"%;9F8EHDI]:/$JV*L.:T^#OKC<*S5<)JTWO?2SHZ+]:;
MMK7#5E/_(1TWGT7DM5I1 OGA(6(P$$\)D?-]8 ,^=>T[S3\LD=->_0,62+73
M6+F">E>(,"EXUE3#A-'%4M@'KP>(7=T#S@,LX/VQ!2\<]PV=:OPV[90AE%(T
MY>FJSK,>^CJ*.+FV YX\AH4&-VO\&3N]ON8L$*BTH!C)<MHN.Q?3$S.4404F
MO79%(DH5:)W:TN_RIL@6B)^)W$'A,4!!W(>Z\,DRBEYC=0,%IXWT:02T^W8.
M@^E4[F>>)O8]M)KQPI/3#A2U+PN8!LO2\19&R@> 0$6:7#-G3N"95-BQ90C[
M7D%UE<?+03##2-$IF*YFN[\BH;%""X?35M^T)S(OTT+\/9Y'B3_+*"NQN+(5
M+]5@Q6>S J;)<1WXR#%<G,;97>44.5?[X28V!MXK&,1&HK@ L "OI\3_2943
M" MRN=7O,V<BY;B#8=%Q1NN+O>QP]P'/$SS/>]0WTFCQG]08.381UH\+.&O3
M-DE[/SU[3>X>P[T7F\L!MG*EQ3_1[:B",FJD8#]0;AC)30!E5 -O1G$Z#=P,
M4T:,Y(4QN-E  9RXZX44DPOP/82/B3&]#Y@.R?GT?/B!AOL33+F/4.X ?(=\
MATL9@O5:^#9,R47AVQI*H ],R'=:;Z TR9W^-^9 SB>1/S@.H@[T&!(_GS^L
M<;FGH-#R!=M\',PON#;G.PPKX)WC IM\M^99RB:%\6NO.RF".@-3#3[4:075
M\,%C*H;Z=-SCUP\>O_EX3#50)V(6/'_.]WC2X#'VP?-AC,>C&.&_/IYSXU[F
MYM[_QQ":;_?ZO4'XML&+:^[I=M&'[2LD/_3QW>[-W^YEZ^LY!;P;O> 7]=$O
MVM>_-W7M4I*=U:GKR1_KXS,#4BX&V'1%[^6"ASNL D\UO.]H2&QLN+]MD=(W
M(.5C8\5,@+DP,*W1OW%-X(XU_EW;%Y^ZN/CLQ\6]OL&7M@?W9C7W;^]4?PP>
MOGCJ ^Q?I*,NK7''W&;<\#9;-$VOJF+>H*\*-)UK%5-[L'5^HKCX;:Y?M_._
M*D[UB&EE[5:>FUUF7[I.*BC8V*K=[3:'>(S).1=7[N^.)#-:;O#+Q@,?4"L2
M[U&'BBY76E$78ET^ +CCO)0)WZ@/'UT">W>-:QARW?(K6T-7^[W/LCAU;+EY
MZC1=:GXB#.'/ , F@E"K;=X$8-?R.7,:*$0!/:N@N&HPQW+@5"#5$V(F J'-
M8HJ=PE3_L<K$F16!^K_[&) I<>')0\_HE_OI()G6RD<1=42,#T-Q2XV1YU-Q
M5?,N)WI$ZX'"5I65_$R4]OV!=RBH1URRID!79+7IS3!-!V0-U#\% /&?+CXP
ME:=<SKH$[9]PL59"FQ007  G(D"^14%2,3T9$GH:Z:.:/M<.>O(.EXGG]:G
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MSST"C9N+10G_N[(E"!Y%M_)*BF YNF=8LTR 4%R5U[-0T-U(-<H7]<6?BU%
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M7T0\GJ213DQ:M$U!Z=R>QA1H\SQ@RZ<!#HX^>=_8#-PW>SMRRK59N(#9%G_
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M2ZAJ)T15G6PF+&I9:P3$ZT@8"#:J-71*F4$+346!I.>!R+?1-+)T9-+>@!!
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M,;%- -<',J *Q#PDGBKN@T^SW!MB_<L OU$9775)VL^>TP#X8[6P5T_5I@I
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M8A_M ZM1.*=CR"R/S%BXD;0',.ET#%XE%=)*9]4Z-I Y:@ X.)]5_E&L8^'
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M3?\"V'8+ =1TS[H:2#*I$Q@OB#![C*OZ&B#N>[J&S(J0X(@:36?EMH%PV:Z
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M.*+?EZ7(4DQX$/HPPB&K.4[= 0?&4N%5Z?#Y#W&.(&YG(EB)[L"L!)&@0[8
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M-BW[R17QT';6Z-%9_^O?9V[*TUUR_JG>TCY^R6]M(\&9LIK<E.1 W6BT=W>
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M\))WAW<*0!\!9 N0ZSB@UHCU77!\DK[84@7Y,,'E='"GBDC30SX >&>,8*V
M)O+!GI54;P%4N[!R&1]<8@2#J)0J1=?,^+]^"8I;:DR3$7 R0%LAZ';AU.Y4
M5QPGU]YH@/ST%=0,_,40B*4N92"0#P<Z\,_>!A_(^BC16@W9\'=9&[&NZG.9
M1L!.@,]5U]R^T66A:.2JVU^,%7_Y@0OQ@@FK( O.G@+D_W]]=E&7^E#;K/E5
MN4PP@ ,Q !@34JO6_.T=Y*AI5";7$HQ0K! "46@?^O=!GL($1 K,% 8!5&#V
M\P%'/7$-!XA%"+  /JS!PRK,82&,U^#5WO\<,O9:#FXU1A^5L[=5KZ*ZH"4G
M5U'M <4[.B1= /\OFWJ11'O\"YO- %?Z;NLP -'G*JV8H)T"7,V@V*OE%C03
M%*??EZL!HEN(% YEM1'$N1+D/K UL[A<75-G!+9EGR65 ?OHL/0AF<"OS$24
M&0;9&>!8G@%H4.(JCD ]WK@E -D_AVIID'VQ@^[0*?ERO#F'8O%8:4-M\>+#
M'8HN^9YN'[38 M@3?K2]]"A0Q:"P%-UKZ!3FHH:R!;#U#7"C\8H:H.Q17*-F
M0!.WX\N"S^! F+$ _H(_Y7\#.,$_4;8;W#<"V=B#)S2$?6.@C1?H]I: 5TO4
M5# S!MPIP._^I59K"':*3B=UYVP=;@Z)O/L:05#812BX@.-=T?XU(#;L6M_5
MLHH:.$@6ANY09M^N5P$MIO&V[;_:O335:_N /53*#OY?=>%$>[KJ%%V9?&A!
M9XTMO[C;*+5PO=NTNXOU0;;#6.W*/W,]0<EG@^%L:*4O>"(!"O<"9Z;VYVG(
M>,T^+1/7TG6[81!\J</A/T!>P= R@&S.W$_1[Q9R[L]QH+BKKM  A:>&D(MV
M:IF*;NKU!KGZ^J_J;]E4QR).81[)40@0-7_=!Q(92%,+(9H0$%$)84]:%BQH
M/0R0Z'_]:"5\X-REH-6 AGUYSF_QJ9*"!_,OK]."^>QMGFJYEQ!7KP<"#5 @
M$UQ)H0F9($==RC54?)G_MZW]EH:[.!%,$SR1C %F*RM-I_3'-JN(=XJD+IR3
M%AG]'\9Q;D:JK1Y?[@5/U$/W2? =]K;-:.<*SL$OKR&NGDQ#MDU477ET32$+
MW;:""G]PH&P2ZJ\6Z*V-\M$?."K_<:!!_=(79!B@EEC\[\5X%_7MT;S_:05@
M'8#+4D,=G'.;C0#F(Q"0>D'+H5@#U6GG03^TWH8C[>;T<9$3CB@^3UUS?%'5
M:#0DE^/E"^'A+>>LR62!X%K(;GR%/46L 3LTMS_$JKX7[IT$P!::XL6%AR\5
MX1EK']/XQ:[4'2_S\?E.>+P3-#L?MVXZ3*-"6U93O[\F$&)Q1Q;BO*D4"Z'T
MS^'SAQO.<8PF[,;*RXO:B)6KJ'4JI36?^.4JSF*<NL0(N""X[U,IF:JC93G$
M0PNAA]M/T)B4/"K857_+HK%D$A\J*R4B<7MM$+)I48,T9UL%JL E/;,1-@N-
MH-( &(H>9PC(X/1MRPRGK5&RS<U].4*]K['=CX_+,X ?QL$\KVUKBHYV?8 "
M_,!?T9"GUS9;#2%?H-L>W[ 3 =\K(8Y>&Q([R)Q/*G$B[$<)1$*K@P8?RP$*
M!8..*I!I(*WBMYXU$NDH*.(#4U3D0N"1/_/AT;A'&)>C'5-);5>%IW[:.O%Q
M'W*@F#50ENIZE8&P0T4L3(6M3=2\_Z@-"2J620#E#))=^)",3G'2].$RP(F_
M +>55 'Z  >2"?K=ZU0#5B;"\T7$"L[YLVD7OI3@*W;C!ITI/@#NHU_QF>ER
MG ,E1_W4#H#+ ;*]GKR9^C'7\&QTFKR>B;<1$"OYQ'H!F>I**># A;OQ0[/P
MS@B9"NQQFBWSXY Y ISTS3>!"[%>0YX(/._F@(QZ_&1 QP 49XS52S@W\_7X
M<&>*B^H>+@DZ5=[I-Z.?(QS._TC WR3D/\4["H?KS<GU>K(E0LX0@/>ZH6_O
MK_MO?Y#/!.L$G^G_ENX0XLP-\O!;!BT3FBW'O76B-/!/RLQI*YTIR_A7EAD5
MIHDSO]8;#QSV:0LP8A^;J,>=*&[3P2_1KVT!Q1*CXOO94K7AI:> ;(W E2BQ
M(H>X.QX*TGS=J29^R?HVD?_S60P8:"#4ZY5?SI?.7$FV$C8#6L\(=;K6+9:P
MT]BG(5597B&>(/:PRNJS<YH0'_IQ4@!S_2/5"<D>P;IIF*4BUA IH(;M3O'4
MTA*X$Q8.Q Q"E&,$SF1MVF?LBO!0AN76?*N^.YATVSNAN<VE5@FM<X^E7ZZ?
M^^Z^='_W5F]L#Z*:HYJV-\V*>6T"%1[K3*MA\FKFR!UB"+41?DV097TV53%\
M?[M&%%<464Y/R;Q2X32SF#%^-_/:$J_YFPM-P2=6]#9UKF"&<^BE'&)\;;LB
M2$F,TDJQVP]H[O@FUD^)BK%*N"N9ILU,56+?97'L-;)+3==' ,?T2Q>Y^C&D
M\F#<O7\>EAF@><?C;.;Q#VY0)7-"*>*'C1J?P;V??(6VW4M=Z;Z$8S[!+1'O
M1%<$?BLP!R*A>'$L2YI.E7O0IUGR.1+I<"=3Z8 C>6+I^04"S[089&*C^?.8
M$5'<%X6_<AIC%#F8SF5_H!$OQK\0Z3-+5:?-<K3A4(4.H1XR3_G'4!7(9;?@
M+,2[A\Y3AE671?<97AKSUBCJT@N[5@I<&^V7J7N[!1<1]HY=8MJ&('O+DX9R
M@>J7JL/3Q"O4G)'2[6OL2,WOEV-2^SBNA^V#,A"65?E/3;F@>/C@#A*I]<7!
M&2M$UVC27J:KZZ2HU)LR:0 WW(H@GG1)"\Q][J>,HPI82JY?J8II1RS75'+=
M4%Y'-)M>W$<*2F(V!C$XW^9P?=DQE8$^(RQ7/"[%6R0>!';._>8]'B2SG?(<
MF*/T_4L=I.2#R%U! ,"BDY,7?Z#]7-UO!FX>RD:FSR(&K<36B4_D/;%]WP*"
M):0ME[0VV3&Z"^OC7WB(0^FE3.V"C$!OI4MB$=)C:4DZ$-<^Y57GTF,7WS;7
M6CEPVFJN44$>2%F+&H[-8F:C5'["$"S!6.>[#IO<K;,-,L)]X4L+"C7[DG7-
MI!N4P%N*%>=R#C=,E/E8ZM$CV,F2]5I]S$2"JR0PHY4'D=E*)ESA< 2%27%D
M3PR)W<(46XMIC5 G:ZS2.]30KH',@A7H>Z(;G;J3ZB[_M:K_N5H@LV SW\23
MP]2 A?M#\T,6I _*;O$3P1!S/E'6)(,?/Q\Y54Q)4(UNG]%Q&KZ;/L^@DE"9
M%PY U\,E7A=I4_36%FL^T^4U%C,,R!,!E]-131CN"\\C!^W+R+7CCB@2R%$Z
MC>Q!^TSG8(Z))7+GLHTJF;EQ4>S-&3,(GN5_Q+07,VU"^5J*N4&-,0GHHF>^
M86CW*M,W-_B40(J-X<",C4Q;)\4<#F/H7T%09JXMOW1H-5YKXFLPOGR>+'DN
MD=BLL@O0(4^;!\#&[E>TJ.!+I\TW'3,K4,%%K=*D[,\B2@>*>1EV&Y^&UKZ\
M5QQSJ&S0*<:JN$O;O(75 L0N4HBL%4/P,F Q+YO31>EX97;N*#!+X"8Q:T8H
MKM1PVTU+K5,W:F#W&-&7A.4AYM35!5Z&?<1#=:+V>RNM&/S9G&SUN?BA"(J%
M1F*47YIB7^M#YW)$3M/T]?BY*W%AO&I^4,9Y2M]LRJ+5B4[>-N66:(Q5A&44
MB6L +5IZEAZ7>ERUO%MZH.B@M8H0H9L&DF8,F@S !.[E";>^E"+,)E^!UPK.
MA>2RI'SQI/A_TH(:[1-7SML0Z/IXT+_3K?1(BLRN>^3RU",!1--JS)ZA4=FJ
M6\1;1P>*O8>D63P!M/UW=R =(EYA0;NI6Y)?3N94986-$FNV>0[O_T)A^YX[
M4H4F1UJ] $=8U^W["3^M/.M:LN=)::6E:S,1,YOL2)>5LUL'G],6\MB(5< >
M89FG*WBY)6YJCV_Q/&SS#K1V-@.RFI6-H4],)&P33-*/O8PZ!)JU>'!X_/W6
MP_N[N4>RDW\F\V-+:W^(K_DZ:]NEJYO")[]\[=X"W7NO76;5$$,XKR!9E4+?
MFAX>0-P%6E]E F0ZEK+W]7Q)V8 8&EFE%B)1(F^*<J>-;>;TUH1-<'_JE/LG
MYF;T9;CY/)SS?C4LTO?YK2JX<8U]*.!NQXKL2!][?>:5P!V1:U8F.>+7'+'=
M.7/3FM7+0Q8^NK_9I[;#;SZ]RL^B5M#45>>'%S8L9"Q#,;/ M;EU9*N<G6$G
M#QQ;D1.[RGYDGEW.]N U*S/.+WI85GF^Z\.[O,LAZ5]R'^Q]&?EAW89X<OQ[
MJPN?BE[>15P7OYM2<?';Y75+;5F+^9H'__[!"E%LJ #"<[NQ4>HU7X\^P_H<
MN_CC0OOD$PV&S\[*'KLKPN+)W1GF>?23]V4<J9WO\P7USR>Y%U/*_JU>_.![
MF-KD_/WXEHPG9$6NS&[1W+:K*_<,/4NC[WSOJRY?\_9_4F.F;0<2X,?TF%59
M,/7TU.]TO^ND%Q:'.[7WYGZN.\5X9+J2>_4O;..E%$$P2@BM>C=8.14J]OJ'
MTK=F;9M'T$Z;1,&MJR77PZ\N4W$E:U^23S==+^'BR)R6P[!0'Y?_J>]$Y(&@
M_>9-)'K]X*"X!5UY9$W0O,+5I926\?VKZ1YS[S!%E&X_V!*]3&'D)!W5-)[.
MN5+&B$#G'^,D%*><N5ZWZ<*J]!!N0-+V8T[,"L,#'3('NU=T:.#]I SDZ@FB
MXU<?C]-UT:-2'Y?.T2L","N1_.6^SZ:3\WP_>SV-.*\Y:VHEK4E>"/W/+-7J
MV*.RV+8>LGL>@$^^\J#U;$]Q3><4<]J&4;N3TG='(Z8&+"QNE],^=L@6[KX\
M]R&&_EP8&K<V$^LJ%$49-<7TS.?K PPRSDJCB#;<92?(=V(-:XKM-TXR=TH5
M166#L*5"X+EG#&)4VMV#9(:5/1H>(48O;Y7G8KQ+_S>Z*'S?Q;KMM@%,+2'M
M+CZHNS&YGL/#]P'%!W/%6!<!F)L)@ T3A@^O8/((R9';_9%EU43M)<>' E'N
M15>SR9V(L_MNL;E(-+R1FCT0.&L[+08)69WX#UF1 !'9_Z,4Q/"2;U$WA7?Q
M((;N)BN!*K;'5)LQ4DV@8QC+)[X(P63/(CA%&<&$YRIL9HSS^5LJ5[J4B<VM
MCR#>R2(O5!HB.V+"/>;-..Q]9 :F.*".&*47OU\05IZ#V)D']6]_=%@0NI,)
M.\T O *D LP\&9%E), FI2O&-2:.%2"HMBB?8''DN8P2)H!*"D750J!J/)H:
MG-J!PLN88'C5A$3A'ANU62(5CKV^+UTI&@\Y$MII]XM5<^^H2&S .A!$EO+6
MQ!BP_(97<*=KD!KXII-T7'+_.038_T6:$VH+9>"?%I \)M[F$&RI<D<_N\3Q
M_AVGLA+Y8@$*3^$[,103&&,H56')-0:;&\ZW&L_3@.YFT]VS<9H#-FR?27*)
MK0[8N%MF2Q#9#&+2E&!%)WS&51+Z:^)O;S^;59TWY>KTD$G-]K*2 V5Q=, ^
M7[JD5'8H'T[C'A @$D@%AJJP'FHT-!ZTTDM#\M'[<I3,D9B.[IB* (Q\Z:PT
M,\4!>%PO!<?$L2TB$I-*4A&(G%H;'3>RZZA *26T8-*-P!145M]0*@!PLSBB
MDPM%Y!-P4KDDI!FN!"1Q;!C,QV3HT4 5-HA;S1#!PX"2K @ [8LAI2@.@*5R
MS-\,',T&L^+E= %0%X[2\Z547?6C4QB>' TA%)/DDHQ4T'Y$%J!"9Q#89!0V
MI66#]!%LH H-3:41F7"B"B:AV#05$&4(FJB5A^2?6U4@(61+XVLMZ"-6]B-H
MG "#%UY]H(:)5*GIB V'CW);,):=RG55RKURR2P)]HE>^HY6G'0>ALO@*$3>
M3X4[CF N)5G-*OVW&U0L)Q:;<<IB\]%TINB?QQ$MWJ@-$L31U\2I@2:R-U$#
MIV>+ L?%%*6TL@-.Y0(!<JG73\LQ>Y&#2I;^'LO0[Y1%2"R41\DQ.\V%HC@N
M# OA?GY,((*01K#Q;%3W^+"U F2<0%,-Q!#$(ET@Q:OA>/4%4FR"Y6YL>NK,
M-*9DP3L)7B>)'D/W=9KJHN0R:PV1HT9C=#!AQ*IM#,WU(MBEZJ*%:#,2F38"
MDT<.57-+ SF.J0HT42/-=ZW9]U?NA5*\SLR6#L9WPE@Z#9,OB1D+:S4VTD1H
M"(I]>312+"Q+'Q//&#],&D.CY;? _FF&D-(0K1V>,(%&.]XL"I_:=OM7\^V5
M ;(VH7-!6%EZ(3L> 1+E$D(L(81;G2<I]5<V$-6MUL)I*2&U<2)LNEJ:1"Y.
ME*/[+6^E<WOK,C&I^6A4BW1F<E6%2I::C;&@ECDH791\\?%K"0G*&"SM\E<V
M;<,1Z0P%6@)9\PC%Y2I2&ATWBXHACDBD21;[$$O$]+@B]]$IZ4C2X!B:+D3-
M=]]XF0-&T7'SKR599(!1U,/1;)IYI\-" S95955-%SUI$=$&,96A0#I=%'\>
M/M B"NQ*%I5YE_+L:&8XCTXZL"#.O4.*UV#*PYH#Z2G8_@K'I[QD2O*A-C!1
M+0T<JQU_!R_,9EO%2.XF@&D<F#Z(^:UA$^5P(F KEJ-O]%)K 4^LPM:DB3[)
M@=Y6:32S4:K&2-GPJ\![B2HT2%.9WMFK-+@D9H-6\E@7FB:\466FD*0*@1_3
M4A8_E9):JF/5@'D F.!0'#)HMO@>YG873)+?C8M!=W?O>OG>PE:=$BQ TUN
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M?X19@L*\):WYL(W2!'9LD;2T2O^RFKU ]&1&GKVB1C)UV9GZZ&BY1#R(<1"
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M9!6>PX"L=FC"FBY[867$(NDBAN04Q//R](BE1K>,/>@5>29ISHNAOZEXX$F
M:@UD71^1X,(+%-]P3"#TX8]A9(S)#S97+WR=%6$RTJN3IEF+9XO'16221-]*
MF^(<^P%#!N[_?YN[63?5MS*#<1MC%B7\/--FKN&_BO-\!HQWA(-CLX;A)Y/
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MQ+_2C/!;3F,BG]^'.6CJE8".8'(J7M?X+@67/\I6RRC%V,Z-5/R'&=3RFL*
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M:@"9FM!LL3D?R(")_5;7.L.NG8FX]D)0/86/6$"KV'YE-'"VZ(VD>%#W6$Y
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MT'D@D7)E1I.DMY!G!F#F?P%02P,$%     @ R3U!5BL616[J40  $54   T
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M[T"F5N(!/BQMRG_C4JN6E/A:,(\Y,/R?X2Y DQ499BS5(E14AG!'LZ(Q0+8
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M3<C'"BO,0*U(J*?2Z#YDLC>!."CVDJP%"*EF;0(G@L@,DA83BY \!\]1/13
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MV??!_MK=6T! KWFVP1$GLT+_P#[+G^,=^EX0#P.:%E9]T*,.6_W@4"<6"!0
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M[9ATN_$I[09M.08 ;O\'4$L#!!0    ( ,D]058?P@I/B58  -A9   -
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M,(6L_R,X"$0+6X- A!#.,_5D#4..OK3Z$.*4"[5O]L1NW"<G43ES+!'2=&^
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MB=-IX"NVPYF8R@6/AU%"> $%*#$"$ZL$8@"2^[G ,#(/%-7+"H0XPE;6G;+
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M,H576IZ0KI31"I3FA"HTF79@]F1TZ3I4+%_[XC>ZE>:^64WJW(B2*M"[,Q=
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M.JQ#D^C4NO(T@-X/JN79NJ&0@?A:0"VXE8WH_R 8WC1Y+B7H<B0ZZ 5XGI,
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M8C 3AQ&\4"@Q"P1K8=C9%T!L8,=JA9,PJK,I21=06-@3"0YSE(8B" S<IB+
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M)HR)B(" >.EP<4PEN8B*EVP;0P8BL F(H+3-"5A(F&BDA =$1=-4,D,SVY"
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M":06@%&3<QBYQ6ZD6UY!(I;00)F+OL!'7Q9..4&S1C@&1W8;8=GX@,C&3F%
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M'/6%1LG_?B! <FR]A8&_>G.\J6\AE^7)6'HAV74S@WDLT\]+UW>_;UI: :Y
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MJ\ \U'S,8 T/,(5OK1HEHEGJW1! Y:%U < )HBQE 5:S*/MD5">,QG/GR18
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MU0>B,//P#?Y-6BD+T-R)!J3#'=*12RP\"!&JN=<5:AP&HI0"0!47]3,0$O/
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MD-%5[$"K+]*+[]?BS=^U-V#]4V\VZOCRGUNHE2:YV@1EG26KI:0(T:S/6DX
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M_B9^U[V_*T@/V7@NL/[AD&6F=.<XFQ"*8#%3E@4 *465G4L[L'^21^!0^_B
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M"43* 6S\]4U?!03W;8XX(8,B#HJ)2Q\H7!CX %8+,!$BIJN<* .)@8#])/G
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MB8F01/)B!4O.LF/L>:8YGNU]E?]Z(F??A_I5.1>.RI;G?:C_"M)3@0$Y_*]
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M2=N-OU0R8)"2>Z@ )>3E@7J;/K[PBL- \:::B2?3JSS6I=P7U7_W)PGF<^C
M^(6Q41KL6W6E<.U5ANG\CI<_@F-?+(M DP+^F2*"V5LOL:&%J<8(QP#GLDF-
MR'/>$)&_A+UV_7+1![0OS-OE FK#\AEFE'R'M;Q_7?^!JKK79O7I2AU[R\L_
M&D>U3H)_R_[I"I>V_+E^&L^YYX8,/QK'N;SBK'P^<6L,_]:3EA69JK"MWN-G
M&A,*Y[J^3@\80UYJ4H=6T/F#\6X4(8LP %D\KOIK_I/C[5Y!A=<S2I<>VAD%
MI"F,)%S!J=8-&X.W)4'@JX2ZU[W%%:.1?5[/(AZZ\Y0_(F&(SN*OJ%7_^MGG
M75NK/?@KQ.Y2V^GSKZPORKB_C%9)Y^ZN7NXD8/S>LH7?;K3C@:5[Z"^_/T^M
M)FY@*7*J24^>9Y,-J+VPVQU+E*>>LC'YN8U!D!?0UN#;G= .*L2 EF]#Q_1B
M,XE.&)P*>9:.QI(312!PAYKZ8 W:0(L09;&;E4@L>1_TB(W[^4+D^QQ2/V./
MUGQRF_%[ZXC'25;"(A8^44*\GQG9GM];@K<2<#UZ; 9D^R+Z39VY2$=.#G06
MX2*'+ <%++9'HMTYKA'_B3PG*>4[PE4)2<F%;'K(@HY#4+,0%PZD8 9"X9LK
M[D.6:R![8$ ZB613R:MQ1G:/(TZN!Q;#<+O( -\W-M(WQ(H/S2BV$#V.\79!
M.F.A3F$8*S*X)B&*)H>D#*(,L/A4WS2'F7VI8HL";;&-+,N-"0$V -N?8*@R
M().HXXXM<TXWMP7%-Y/!.O=33V<NG7?>LQP$-1Q'.&ACJL>W+><B!P3%MGSS
M9B[$E@MUY2=N=T/^:HI.4R%LR3KUVK(_<PA+#M0:!-2V0?2P)FZ:F/,;,,X<
MZ!<>TDX&>;<-:BN %(I%VP&+-"W*BL=M8"QBVMY"V!;HG'D(>Q#A+H?HM6W=
MGIRQ@\->#,,TJF*=-!C[9IR;.U*'&POE(:E.(?Q!A(T2XC7!==1"5@A8B$#H
M ->?SN%RPW@2@8$.$[V<#J>2TY;PE^Z@H^MG_M\:+A^KLU.+<GUZ.)L/)?*7
MNJI,"F7B '](&GW;U @V2PZ1-^'HFICW81!73<Q9.F;* SWTSOR3U+R# IR*
MRI7,E%@JD71Z>5X'Y&GRQC0&Q*H2J8?-J'6'VLH@!W%0/6VQ!0]YEH.F'Z)F
M6J//,C"M,AQ^&U0*W[_*$XMZFF11G91&KKPUAOV+ $O/(HMN(.O.HMQ!F0Z+
M2LCV2:2]$@+WQ]<SH*]H.LY<V?OQI99\Z/*.E'HN].9-!NK"$7M.K,M@,ET%
M28E(_T,RR19 :&2#)BL9+#"VDZB3+Y<UW9<9>:Z6TZ&./<@F9LT13PZ='U21
M@SM!@KR-P"P<A30+,BWNHQ3:,KMG& >5E8O*0(^_&3J^S>$99B?_V"1.Q^L#
MQ.H^:F@]-']@10?.:%":*DPPMN?OM^%FV&B0K1P/.XJ.K2#^Q3#D>A&$N7%[
MBVRKP2,D7H/)8. R9'$N/<C.).@N>5"(]0&1P/@N2<>!#$AFL'VJ3&^BSA(&
M9DU=DS'/\PI(S/5'A\>D4_B86\\PBZ)'2QQ5DM=^Z $Y9#=9Y]E6*XDUEBC<
MZAB&M@4EM(PC/WKB\;($G?O(4WTRM0!2XXO>0486-N_/X!S\'8!/ET=3.086
M='0&&6]+!OJTH*W6?..+H"- @EJ+RB1*KW"A+QZ#5X#7[DE@+^.@_]_I[#Y$
MH$$%/R4U_JPQ7.G9+-AM,@[:1<?4R_?V!B&K'J+>G]_RLBG+4(EK56X>X)9?
M(GJX."$+W^RO;E)<D><,\$^Z'5I-HP#Z86 M<FV#RA.72*7,&+BD'T ->6+I
M*39RY  #W*C!T.195 $[W@.#(@.KD_EA">R;1)UF%:A5BT+3,0W_[X.XN*F0
M ;X"0M]KA]1?!+6"T&BYLA$7H%MI8@?V+P E7=R J3-D:N>;1%@/XLQ^.1.S
MA*QC1<:[8Y&-=(B:DQ\9@]MK#1AP,-E8,+,>XF^)3\,ZZPA.$Y5[J"!T=1B4
MV;']BM+3BX7GVZZJ>[=Q"1:Z[0WJ0=#J0BRR0;ZY6@@IXEG9_D0(TR'2YXC7
M*4@" ZG7LXXVY.FLVNK"1=9C378+++ JU/<(2S2E,^7[QN\9^T5*K)-,7*AT
M;50C\&3TSEN^K3G;$_TA*= MNVN!)2 +*IG'M40.EAEDM"F)'$Q'\L9D=MQV
M2_0*LL'3K4B/,YY'PH"B-J3+(BW*@+!D<.42$9#4,23H'5EAVV-AP\FL2S&6
MS'#579!GXX@<5_#:$Z<S:I*<L28]5AE;P@ =@6O#+>QRK+F+P'\Q)=&2X9Q&
M[M:?A'A'0CM/G&]5>69LQ%PPUBGD&+Q),3X[P]C_Y+^4I&S!&2+(7<*%T@3I
M2QCHT]4U=/4*5YFWU8P!U.2_FJ+=N'L[5J+=L WZY]*K>4A75K=:NV;M"*E(
M#I$%X7?*+R!O(TW3D&'VB6H&N%DE24#PJ"H$06O^($NI_&#\/ "YBP,N56'_
M?80BN0T<NXZ@<-BN&O,E1CK+O+#6,Q!2DOGU@#K_5.[#, \:WUQ,!R^F<: T
M.G('F>\TLX^6QBX:@Y W8"P8^(I2GGRMETXZQE# <Q9 SJH\;?R!.E?P^]J]
MK#>("#JD&^ 5!4 :\D9*=?!]9*@,A+X=@:;-X!*", -TR :OU>[8@\9,B)?B
M? LW,<(;6L6\;L^%OITG6O(A:3,@SZF-$"?,N5B/Y4K4Z0WI+WY =M;@/N!T
M(A>,NS<93&%X>]B].CVH,'M('P/21[CS]3ZB3P!I)X,3]VS:'HFQIZ-%##!]
M V0/&;!R KXX 0Y*T7,S]\"\'O_#"51!%$V#.LM)AE860]454*$RH ^EGXTI
MX-<(&!L# 5Y9+$;HA>PI6H0T-D&H3FCE;V5ZP6I+,A*> VD )=3+-ETAI]'D
MT04:L!TC+2)-806"DK*])SRP-R.@Z62=V;,X-1W^)1#\'H!^[MI7 %(9+V!_
M6%4UD6YD>$.R+J-VT9>XA&'<-T.+*B *#<J!@:&E-[ORH12E_Q4Y<C%9LY/,
M<6*L&M@0Z[8"*-0@7EB8-/_'AT0 ZY:U)J?0='RIOPZP];RW2';K61K47AX=
M;&2TT0NZ1X6DSNQCLP=^@9\,O!A!(-+T?T*26\Y;IB&_>6%U1I >W]2%H*UJ
M/F0'!Y/)19:JEM1ST/_^<WM]!+"#"^WHVT-+AO["0<#_* TKV-S%X']V<*"*
M"WM<&*O^'67X. !^77%^IM"H0+R+YLG*VTL<-DMUF-!F?F4KYV1Q<_21SR:&
MY+'TKKCH[&LO6B$?HV5P(^AR%:I L$LM>'F% Q5QDJYHD0PO[ =O[)N$&L*'
MI[I(?$!+Z[%FR(H>U U?S/)QQ-$.B!\;_VUSN^%TZL_+%KLUD(Y-]^SE&PLY
M_VT67*_@M/Y/'V>5B2&CDG07&_H,D\9?ZL+<=,3G<39]HL:B0VB!/E;%L),!
MMP<%ELDXZV*6(MAY$?VF  OM98!7KD"W" [M;&K>JT+N KTIKL:UR'#MLMN7
MNJ-[55L=-?&T,#3-"5/D^V TA;VX)Q.R?0-$:*I3R@$GGG-=XX)-9D,B!Q$G
MBR&O6RW0!15I6 \!!])1GA_@,5QHG(G7'&TEHZ-?)8T+1Y^LEYI4QU>G0XU"
M'D+\1DV:8J#@/=E\S^LCC")G V$$9*<*N9<!;B$#+UXB7[@BJ4'HTPG&NS20
M B7*@6/@P(">U2)WCJQY8L'[=N=9 ;?FJ!WO[DIHEB"U?>Y&D1%30:]3</9
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M0=[8845/B:XZ_;F]A(B?N6T]J32^QIMR_$Y=#/T4\Q#,FRXA%W!23?E=^'5
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M5.J?-*3C0:<VNBC:^JS[^Q3:W4RU.S)008.YVV)[+>J# AV<JQM2=B.T_Q6
M5FA6M[1.T#]/F$^U;@/C-6MZX*#@.5"P8R-CDK#]1D:@=/'1Q_O50Q"QOT-2
M=>P]#,XFH$ 'CW!K1'GF(\2Q'.Z:ZMSQ*-3=5T4NVFU/6_82.9BL'FQ%J8HM
M^G=!.=="1#I1MYGHZ*GNX:=F2=;Y^*X\V7>1CNX*6UT^4OP/'IHH8?$=XY-$
MCRM)VYP.6)N6DG@EFLV"<N6C39/[R!/FRTG$E71(=._Q/3&<3HU$)1?O; 1?
MTCV-^<O>^H,ONXT-7UL'/&%C^! 9*!&T#]>8EK*1A\(?XG=(>4:]&KFRWF9@
M_1;O6V7=]$U+3Y!YL)]$D2;%*%M^Z(7QD]<IYW<\B6USB]@\GW4=/M3U^OG6
MNLW/&VRNP60T.40%+%:7,*N>QTDP?(',_0+HUC0+SJP F>H2H:B\5H8%( 2V
M"-!C"\MOCEDBL@0D6R!]<EX,&+\\'I>$W:6#5BWY,%HR.*)(;I>U6I40 "B]
M#33E$1+X(R1_OQ 8RTEP972;[!?&UVM ]V6R%P]>; H%XJ?6.L^![J@)SVY6
M7M.:N <?,Z:6PJCSZ0S NE:!GW(P0T?CU H(GKL  ;Z=%"ALE?@A?$@5'JS9
M/1B61_X#*B?6&8>WDN:N@)< ET_5[F=#><Z$;345H.3605>5=;Y_N4JOT)Q*
MEBCP/$+7)THH]5U+"@AI+NC6@8(A15#[GK D[&<A.,8FB#94!QOXOH"G[YU4
MXFS+#RKX)W^OS)FCU;&IY><4@XV-^5VMXUME#+2$M\W$N FCK,#BII0D+,[>
M#,+UTZS\L5+TX?R!"DO^>3+OV(F3)2M']E*#8"+_?-Z371=.$N*+3BY>"Z:@
MA+&KE&]_0\]5BA\MEM F]/SVMZZ[8-I<=O$P2."_GV@M\)MY$GB:PA1Y)H]
M7?.2QENFC#ZW;K*N#& #[#KPU$$WR'T7D4Y8.7,[6:7X=Q\>WU+)J.I;S26\
M?T0C\L]X;,*G&)3/*BMCU27T=D_?-JS6*'PL!5[<0B!.X&.-NNJF>DM$9HU&
MD;X:PN)N[U/V^RRU&>61\^(-^'7.2\S5W-D%1< _N<![P\P]=  \!,Q<Z(SG
M$:K./,P2/$H#SEJ=2+8 '@NZS__W[MF%[G*!%",NDEW_2?;NP;UW;C*6ND3
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M#HI8'EL.RU[5[/<YVUQ!O.2JQ*?]L)$744>]5(9/;<,1NF2SH5ZHC)PB/IU
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M3&3GS--($;#.M\N.Y[BZ<E%<CP!X@$+?RM!I 3ZLZOJTS#$YW6B^LVTB4/U
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M31HS1/G.>!'20-:UL[GBVNK[CX]1)4*,;NU3O5,%UEED$!%6E(U>1SJSV@?
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MJ/I]JM-8A<7)#739]&0.%;BNVHZ&ML\;IDWB2ET,O%P0S<,Y#ZNR7&!UDWF
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MU2E;O&HY5+]S.U?0)WU6>$"ZWDCX,6[/[]&M/3Y8]M\K"P$:%X$!&@QK"?I
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MWWO3"^%"0H@4O0G%T$/OF 2$B (!$0&1O2 B(KJ(R&*_:11%#46-(FQH"MA
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M^PZMFLR$21>RC*.?HH(!'])7ZS"HMCE1D&(X$1>F,FK?]$@4V5?<ZM<C==B
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M1Q2"#+?'D/5CUPG8"L!42&<:0%-AN@-O&ST#F*;G%UOIP/!TC14":D*-88Q
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MF$76"7&+H5J'M)6(279*K#T;>"N<'A%R&%B/\0C^SW$@7,;":XU3K5[8 J3
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M1-V8MT!CNJ>^S,XQR?]6S*6\O6V-RUTCSLY/J;A7V36YW.6/EIOQNS[O/;+
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M"@&'9Z@<%2+$6LSELNXF0-,GG&:4&.$Z3QXE3*B*/'6+:-&"_;C&PTRB6B)
MD7+3+BUSPX<K?!9L&;P 9<K4&%K:^_/9SV>M-86BK$ 33D,K(@W>[Q %?BI*
MXJA9-9\50:3^EGNW4:*[6D9C!Q?ONUKW]')!J$.F='O:W6$\U8A('=*M*AD$
M]?HV_@_O<-Q_5)W@R5%9_>HK%2:Q"$[2U4;_$%N&20[ 0EK_YN#^^)4=I!_N
M-->V+043;M,^.C=&(ML+C>%[DUY]G>.B)O]E+N?YR6W]K'W44,APIEV7W'E
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MEE%O1V]3*Q'P_3#1=%I*^H!///W5:M_4ZZ9QZ#P--XOE[#%*D><N;C(  1^
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MG9I^5:<RFSA*XI4E\_&-K32[33BSMRHRAY!,;CK"!0(+F\D(X==Y71F?T'B
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MY">#O634D!/FP&!OKN( F0A?-*;FROQ*,,M"F]%6&4G3ZRO$@A'"XX/=+;G
M6-=-7^P_HRJ.S*U @>-2L&GZ',(I]&=*91H-<&,MX\6&+E8NMK5&Y@O+>@XN
MLY@*-8L#E[S%XS5@0CM(PF:3^(?,.3)_8>/=,"! HPI^JX*E,C\-]N8E[JVG
MW=MW!"HB2]+(/%1EMMM+HP& =!+$&:@O[Y4:2JU'SAH3FQ?>X^-]2A3%#:/9
MIT=771W->32Z>G1TS=?1-06*@(DJFQ^C>3ZOUX6_SJ\=+5Z&DT\]'VPFX&XK
M!#.4EBBNXT595);"?T2QN5HF;@:?I"NV,;*>&1Z5S7^8\NF_D>[R?ZM(FL#/
M/T<09YGZY.(Z.>J[8\K'D4F'.3;)S>KBGEV'M*KQ_=M7-=S8<ERUZ.;8])5E
MEG$8@UY7GO^"+E9;Y3N1H]7,O\Y=^U%ZNAHVW?F@Z^6 PA?CA8_BAK5C/@M-
M;M:96);@<$EO_RFA)#<_NILEFI%\(<":X(M$B>#RI+:QN+$SITSQ<5KCF"EC
MR77-F64*D5:VNJJ^OG/FG$3:X:L\R\0R@Y91N=7V&HPO;+T_SXHQBN2,#^!,
M]*L.;WU]U=5Y\8\ B]R&]6\4S$3D6N9.]E34[='QWEUF(0Y52Y+&K"%5Q3\!
M->O^.D5CS>$X/K6IO^MSZ?LZ,Y$_?VK'^\=$L\'H/>VKS)[UKC0!BQY;!O3F
MS#+_Y[>[X1]>)GQXE?EA=&_5"P8KD,MZ6/#A[>GI#^^NK@E4K7E@O_/](\O)
M:M]%KVZ//_/_M@DW-K&'-\)]FN#BS?XPMI?R?/7@EUUS8LG,1=8[4]O I/OT
M<QJ"MXTRO?O! Y]@RPF37\_*_GVT^L73LC"-]?-'@=#LCY3#$^ZE%/U_6ENB
MU&WY*S,SYP'PF/XM0%R(2?NRNFQO^ ZD]I=DW <(I,1V3>"C\4,@C2^#)3V\
M[:Y%;4@,OW<H$\=*O'IT.VC&R7MD\M\: F<YEASI?M:297<<6=4>.DN<*)LQ
MM?-(/7A[)<Y"G??X6&XO0%BUC#$G%V<&_G9W)>Z/>@)KBX+[O-G&]Y\9Z[I"
M!O"]@^5^6MQQM#%U3!$P/6]I7&*X9_&N[0O+/'GKQC4*/XGO[DHNN:9^_W6%
M[]1NX9Q5_0%=]1IP21DEIE!Q^JORA*0.<B#'_+XJ0=@0U[6KUK$D)%=!35,E
M"55<<T+EV)GCPOZX9AZ^6Z,96Q:7I;C2IC!+/+*:I?+5O)8#A".7WOC +IZD
M?[H#+^S(F+^W>M9+ SZHGK#&VLC1&4^5S%M\]KAX#'")MVYYJK0\1Z%PE#-T
M_, N4$5+W4Q$.5D[SE@K+=14LFJ5KA.,/T[;>&)"@X1:_;G$C&-7[3=KM<4<
M)NSY;+7,8C$WL'F8B?'?;,31VBAQ&#96.3=Z0^^W@T <5LF$P;-S/:<I?N"2
M9)!5@ELVKF+G8HEQ,ECWJ=[3B[(_QBU,=CU/0>2WW=E(HW"LHM\=6UAO\FAU
MAPD&7&I34%"<2='C[SU\T^LE+]-P9LBCHV[D&9I>,EQN,K4DI"9F_Y4A.4P@
MPT2:<!:S#2>2 I;_P5*C+&G7?.+$U4-_V9&T,@MX6>!$-QMVJWI[+$8IXZ#8
M1SZ8;>05Z"*+NW=(?^/'[%GX'HEQH%8UHQ (;"94<R*R_RXEV\IRMS6_A(^]
M4@38QB_[>&F?1B@[Q%=%A()_%+19CN&3,3!.<_Y;;4SN1KJD%=N7'$XZ_SJU
M$(P;&!=\I)OR>W>[E/PKHMQHF0[]E'^S!7W(X4<7AQR9RRQ*=BS9:'')/1WG
MFXX%=,XQ_X#[NU'UHI&P)+QD5Z6+*>*UHH!FLJ&UP"XX)BLH,'>8:E1D#I!]
M_O\;U.CKL+8D1J11D'M$6IL_7U[3?'\'>!EUD]Q)<U=?+4/AL"\G/7,9XD!Z
MMI$SGRH6A/!,Q?#IXFXA99U\M?SL-9$^B;SQ4WGNYS W4CVQM8U;$=,FHA,K
MVFR.]NJ";,F,\;=?G ;:TJ]5N*SZZCS8F?V8X=Q^^,$AU;H$]0%1J$:9I$+Q
MU<);NTOB:IWQH2;%#\AS.ECT05N970S+U[E/X-1/I"3G^*[[,#XC9[;)PC!X
MFLJNC]>SY;^&VOXINL./(5P[YVQR=/$)M(8_:2%JU=+FR',&UKX(KQJ_>W.?
MY^\??IU--,&(O5J#?.X.<F?T.,6>6K3#U)-VQ[FPF^%"8TI8U/!EW3O8+DB5
M*;=9^W\47'M<R_O__^RS^[6UK;7N6[>MF]9%I9+/UJJ59"6Z2-8]28IT4BZ?
MK95N&$)4K!M)6 I)L:4(80BY'&>2A#BAXW1\G<[/[_%X__M^O?YXOY^W?YXG
M"6LR%K?9A8_E](OXQ!ADY^L!R$L\ Q(7B"""PU[T&V;,U@Z@!"G+;OHC&QFI
M2\3M^,E]Z+SY=V8U>5LH%+94.];YF&U.\-A%:-4H:$'%"G>$H.M"YT ()U2'
M7^[2HY.%>#*G&B+[_:&EE@XBV]9UK7G)-1;0Y"H!=SO;MMK"L3HY6E"<O5!K
MKYWM/,AW'#0D<1?T4.4$W;.MW&/SN@:^ ,_)-P9E_0H=$>^9_=4*WU\>=9+K
M..).7^XTDKPZJ9G4C0=+= \'S%PV[!^V+YVP#W?ECT)8PJ>WEQU/)SU_+3S)
M5+M32?FH%8%D17=2",%CQ(O85E<X_MB^YH:M8-U),N-ZQ$*=!&?6=UMI=OIQ
M?/&9"];0EH^$[I'Q,WQ;G/L=L'C$.@RG90A9*[>J1;<M<35?,8173]RK^)S$
M]C^@4$,6B6.D'VJ*V=#-UY%YH_+;_=IJ=T&.7>U$(D[4J\,Z\-?X.AW65O,[
M^91184@#FO/DIBCQ4]+JY6LZOPPX>T?D"RU;_76/[;OZ9/HSG"# &%DR:CT\
M+Z)M>4L;U&IFRK*T.IERG5Q3D79;*^(3K&K*\ \BM[?BQR#>%*<2E.N$N-&Q
M]OZ+#;8MSS;BYO$V R[]Z@=:PD"U;BF7OM"Q<L. 8C_HP*T-R>6N7E2_R<59
MI1S 'VK';QG/7GV/Z6(D6:UM:6)TRZW6/):(&YRI)D9XQWJ)2<S0#A'H&"US
MEQ!?-/54U+CT;5_T9___+*O1+XK&->H=8^DRJV:2'8EL ,1"5@/4\X"+_4M(
MAZRK&0?V[<@V"D%?&MTDCTRXK!*ZON]_#V@3.B-/7J?DTJK9-CB;V\C+%=+U
M?%N?H$JP($KFS2,@KLMAB_*O'I.[V:SY#>(X0;(>?LAH81?PEN->YB[!9LL9
M%%RP^46AW#M.1>Z76#I41A$-GK!99%Y0I-PMX'^W.+EK#$N1FVP(>+:==66S
M)G^<1D=F-]E:=0<BUW0?I(Y!K!=$A?CY(VS!/LB@=$[J&LT&L_X]6Y4X7?DB
MOD:N$XRCVG+#^#RHDC9#YAR#*M&X48S9B#"/RZY5L9*Q5_.GG$HD]5^N\H83
MH^&@2TK(-8=*BY][&^7-CN8GJ/TZ<Y.=BN'HG&QJB93_=6V#&F&[5GDB@'"^
MYL1T-9&722660ZAOF[7LES9RYO1KU/;A^R2A1/:^7(ZR54/T]S?##*NC,,QY
M'QFY\(FK<3E<<4D@".Y)QIYDB*@=),%1L4S^<I"=KP6&<!$Z4\/1)H8=2X;N
MI1NFHM^0.6P! =>]BUF II+8K>PY6G54/82RX-_B40=V*4=4?C\9,G3XPRIF
M-(#A%ZZ8*-+*:7V0?0-KT+Z_Z>ZS< T9^3Y0+-?*/2N2K;=2!20AO*PD==1@
MVQ$TX>CE ](V:6RIWH2L>BBG]< &MN5V#LL=1E<>E-8@!4_K*5M HPX-^G43
MVL5VIFSA#1%J 0OA0C#V8AH-&G R$?BF9_L#Y!?0C-H)B4L&]B-)>6 FG!>3
M+G4P[=:C$QA5'Z/9",-H #W0-H_&2Z2(#D8JIJM+L.;/HT^&W)\X__<CS-4W
M&O>OKFEOEV0Z!2LD#A6D=:V_-1W+?G/P=J7=]J3W0\Y1T++SRB?.9SX=CA6M
M/I28.X!0D8E[<HB'GAX:6K+[7Y=CA4Z!R[;8&;8_)''QBH0H:I-\^.T&!XSV
MF;I0F*FY\-(9Q5DD)R5?J9^N;!NQ)MVM.<!H+4__+83XZGWBI?[/BTV7/\0<
M4ATKO;JV?LAOG].K"V-/K_9LT0QFT@\8^]^\]N=BOIS>H4=[]&@IZ93B?I\F
M[(JY2YBR<YL7)"3=R_2Y;C:O?IX>>)MRNO7:&ENW\A7;QKM5L4,+=KA5ISBG
M$"X5WO"ZZC:_9W-'BNO#9$83M71O:.N1._:IB_IYXS&9G:;_)NYA?O-;ZCKH
M2SQ4^,1IQ2IBED[N>@X7>(G[?5.%H.JY&EKI(K)?ZF ]\M;98&(U\L$0FW$@
MU>J_0@?N;-[TU?'T^_EM]UF3FZJ ?P\:$GMULANYDG^79@J>%H;NVM'=[#27
ML<3 ]&'%6<]M#OTM2_UZ'_D=RB,QJ2 Q7P5>4"-D0?I=+7S%HV__AKGXJIS/
MCB! GH\,V7)B'2+EN8''OQY;+'3R*XGQ5/\/E>CL('E#/@X]0KE3;L=W_E$@
MAD1' W\S]W#,#(QW=CEQL2I\'"\Z'S1(*0&69BM/+!XST/&AE,;Y+X'W"6*R
M<Y.T ?V!/'UO@<+)EBI>+E&#V+Y33@NH%]#.TJP EG34D(V0$1Y6]>_H'6=>
M\[D8KW=Z*:ZWLX'#THW,DA;LL0;7'D$B;;DXY%1,Y_E/#TX3Q^V[&;8&-WP?
MQ()N,GR,QO:"?MPE\\?Z<Z*+#Q]^)F1<GGIFW#US3KSK8MF!LX>:C L.O+%8
MJOM(/$*8Y;#BM5MC$MG4H8C8-3?/0D<9J\N_-EI,JRTV7#MEK3QFD,K JJ,%
MT<5UAG=E_)T;M/>PXXMCBGXX=TTIN+1S<T,>5[]4A/P<YUAM'5IZ[.N!C=O>
MNN[\YW;&_)<]?Z/&_3H9G0KYMT,W?[Y?,G_NQ^.28U\:#F][%^?ZOR=+$CM8
MR]6R)5SJN9DDKO54[YH@MQ+O6%7RI3P9.A$R/Y<@0?'%:_'FP%W9J!S1W,V6
M;0L#C=4M="Y/BS^Q ?EEQ)/R*U5&R%]CL'/!E%<,49J4OR1@%%AB!&N(-^[(
M5Y5%,!:JD>](*/;,'4BAB5#+1I5R?+2&K 16C4!6T0"G)FS),A)' >/Z!#=S
M!Q8M^R/W)82N 60:C3-)C@S7F(V :T?E1"6,:SL@FWOX'S667PBN)8%F:@%:
MJ8G"#3"FV/B1/5;3KRS[\.1903GN.JE6@^O#LR$8U8-P&81<>S13)K>=V_;,
M;\\=,N/5$)R'[$>A4[A <Q\ C9.SRR&S:78,NH2D@;9T YOZ$?AJ*&UT%[(#
M<JG1,*96FN4&.51KD%-)^#$-(3_Z]P8-KE8SG;GJFM'@-<3R?\DH!W\F(;\R
M1B?HS0_2>8HLZ]=F%()6LPBKFB:'8]:.)YH<SUH[G&UR:DIVNMKD<*/)><^X
M$RC?CA Z/FQR_)KL,F_-OY?,I]@X?T7$;PU^8!+7O+BAL9_%@>!S2C0I7$,:
MA(G=-TE Q54>X%(X\/^MBCI->#=,T,EY?$C,0%DEW#TQ6F$E!D+;;(YL"XHL
M%[JT ;)0Z+?IZH<*D6O]RK7=&N?L>3G8(4'ER_FC&FUX_>A+B%@(HO0-OU?#
MK0H->53(I1HXD#0D1N3"QA32H(;$AT.5T,EPP.QG$")_%W(LQ+5'JWTY@!P9
M<$;==0Z7(93"Z#,OPL<0AANP:_D 5P<&W)-SP]%FX:A>=@Q'(^HIMY2(2B.G
MM=[W0#,6VBK:SJSVI9FD4HBYCE3 [.KJ&IR8EQU&K!G@.4/\#HW%I(3X,XEK
MNXP_+=N1+4=,#Q)'(!?&A'.LQDPG9+,!SL@ H::Z.-8J$L3/J0<*1J#0: UO
MHJJY4 Y6)[I.R%*C3D0F3BX)(W-B@0L\T>F_##2+8%0;9*$T0L^/P"1QE"B[
MZ:6=B'*P_NCOECE':0V>S1:#47&,)[J%-JK=\G&&B%>>_OK!F * $6.6V_HA
M7-\-,A7?CBYIKT %?[UC'POS(4"K%OC&O[LX)4=."1W,ZV3#,4O%FA?5JVWC
MH*=H)( 7<A@@>@*1J!YTGJ[GYFL@TD!X'^*GH@I=G7A$77W+KIR4NRRF5F6A
M0UB,(>"WY;OS@_!CMY'^SPHWR"W'5EE$[][P.XI+%7)8&N?1J%7L0=3(<E+"
MWN*O,F0?0E@PQ/.!SN;_T8FNKF+=$7:$QA1FU+"K*VLP@M$!^Y^BH[!BV]&7
M]GJ4169%8H\ )5GJPMX_;QZ=PH^&%X?A\(H]1T@BTTVEITB*N]3][=D&R^<R
M#K57QEZD7(D&ZG:$?:>"@B=F+H,--Z>/S4[I;3"!Q'+X_ZM=27?,VQQL?8?,
M<_=@#=^GBX]>7A:+7O3AQ.Z5,G_'&'&\:G=YZU&SD3S'UG59)ZQ-3^P/>E;!
M.I'SH37J0_.Q]I8='TY=%)]N=^PXG]6^PW$S0QZV-:;]K,;JN;'Q!1B:^W!Z
MZRZ-^>[-A'?RQ6_6%*Y>G;@W)OKDU?*1,I(HLR#CV 5!89A^9_A+YVJ\\65$
M'0/%'H.B@P[-SE19*."UK!?D4<"L3^"0#UX!A+VUY=MN/$!E/W,6:>Y^:N-_
MFO_=O,6NB*#7F$KYM1K+:4Q,MR9"#/%&$P*?I3F8#Y='0PXC6E2XC/Q28ZZ3
M6T"['ZA//NS64=X&<P!+53[::8+VI3I4$'[H43=P"EA^>/36(?-UM_NJGVZ+
M#GPKP$F;2<[K4I=!#FV:_#$8_?,X6JW8.HL@E0N)"5*^"D1-W;<<4XQO6R?H
M@\Q1I2C^_NSJP]]LA9WQP+ZC+C'AJP2Q@"2OP@H"S,9@\K!L@H>ZRA#A:R5P
M7$9A$QR2UO0'&86"T'@Q[(I?O6GRQ'B!X?4GFJPC%?_I#%#1<++(QBJ_DM<"
M$U2:* V!_1RPJ('YI &\2D-4#YK/=R-(T7#(;C!M>Y*/+]FLX_-GHP%<#5#X
M*KUX72PQNJQ%-KZEZ44W!OF,></>[6'67Y^AU(E_)7!+J1!,'0R*+46RG^('
M!?4+46;#ZV/RUVA,<6L[@&'GQU:O,&C5LJ=W;]S\O.*OBT/F]2<OX^7?-@U)
M(Q66T5:I8L@2=?T!^CK81^XE@Q&V"G!$OF<'H[:%=&NV= BG*+Z'T-K6 44K
MR.+;6'2)Y=0NRQJ#^>\"^:N!,,5GJ =8"Z3R?>"-$1IU7]UU,:1[ )'F'CN;
M0SG3IV]+HODO@<^?#R@4D//V=>'J4/X@<-#SK8)ASIXI'UT5BFBGG66J-A9H
MYNVK!^Z21&RHC,_77,1=!SM,$7/I27,+EJ&=8D81+=UTI.C(AG^QW)8OXU?S
M''X'!WMR!"0YJAIT4<)FHR!A%/I%O)W/X)HVZ+<Q&5ZT/^1(-6(4YH[*<;%A
MQ,(:0NPTCP]OW4?_!>.E(IJ=!Q"JXKNHM9(1%B'6(D8'*,.AW]B 2[;0:,F;
M#340=CKZT9=<\FC\;Z-/UG0BD#J8[ ,'/(-P2I(P?*_9B P%XZ[' VM5T#^5
M<&@;C Y/MPU*<Q&=G,AY89YM;2;1F+/7NI(,MOVE1;\;K$M5/8R%S =A1"T*
M25K*;X$(.@'9!Z*7:@C# @)K7C.MTIS_)\K/@6+1*SFJEH'36AX/\END,>\1
M_&<O!\,%3>/O4!VPWQ><%1L@V3JNG9&!_*5HZECD$\C,!Y M@MNG&19C&F1V
ME#D/MJ@!D2@+'J#Y:TJ('M&8:P!D?HA )T?@%%: 1JT$D9EE!%4H*AV]B^2&
M'-.8AV=R(0VY8ZWS%A"<JT3-G4!-Q9/3%R9"AO]%W"3F:\Q;-*K<H+X.B#0C
MR9E%()UW$W2[KCW^"ND0B)?QV%SEPY<)U?8+S+$%%_*-4-LJ_S+"_.>S+SB_
MDJN !&JML'(\(BCJW,7<&-9[2P4,E6]<S1APCH91A8KK4[N(\^'AD8;R\5EP
MTVW6^/92'C74FCK,KGZ:=_"&6JW87_#$; SP?PHV%P1QP[7D\/U6H_"G<B%E
M8+/KB(P\=R+#0,3)++LY3WQ+03E.O8@M0"? QM'O;CR;>K;1&*S*UT$SLL9\
ML"KVZ0;&S:U;0ER'9>3J 7OV4\L)AMU5LD,+GI,9[#HM,#1<9ST&F%5;VIT7
MG.T^8C:87YQZR][\-:0(+;'ZFTP:6'^:N"GMA%GU@//T.?Z,@".^GUV]M*Y?
M:_ZS\RJ")'LIW_A]('OS?HNIEG92:DPAZ  ,=$V'4&B%G.D_-Y]>FFX'[OUO
MZ=X7<Z^>_&ZN1K#NO#.KK\Q>UCE_["^MY;1@L^#2;WD#;@2O0\CO\9[5L>(N
MPM1*L1*(G@C.Z8%#%A8(^+N/'X4MQK0BD7N,:JED),IJ;M/JKP9X"'1Q!JRZ
M&WC*[^'[ *XMV#(*KB%<Y/^I9?""'+;B?VJ^>%T_;)_^S\:OSS87+G6 C\3,
M/4G[9MQZ^*%[6:G+2ZVCHE3(CMD0A&I]J;$_!4QF51.&(1=S38DWM?X*ZK?>
M8>"<)OW-(MMM%P4LM /@NS)<KS\D7/PQI]KE: QUX,JDR>$U8VV6Y*[KYJ=N
M#)K//CB;5]>*7/TLTN_$P1>7BHNKJN6.D>.72ZZTDIW.E?KU?'G>$^-WJ?A%
MSTG'*W_.FW6\"B6PSJ+*\];9A3D41G,EM^*H0KSSBSBU5JU#^)^"GFSOW=RS
M C]"<>D!"+&W[0>Y\:.@Y4N9 QQD;KX)'0J7MU$"XRHM/#6/;XR2RB%Q"T 8
M"TIZ!%D7W[1O$N+Z +(&0.L&B/JM]S+OL>Z#$3V:\(/P:,W &;OV\X%]CY9L
MEQZ UDV_>Y&ZZJ"AF*,$3ODS,V\]<<Z'>?YA^TN&G'4:!.D.GBJ7*GQ'KQM;
M 9564R'F(]I$4=3_ZH?:_D!84@OK?E]YY,M@S8KQ:^%?'G]![0L_LJ!\U6%.
MP_,[[]9&+DUS"1"HRO(#=_Q@)'#%P(L_QDX_K.]_<>O2_.__V[&X]H1C?,^E
MQ<?TGZ8Z :M9<&3Y'V:S]&BEGDBM)WP(QJO@%0?EO\P66MEII8BVTNE;"W A
MF:?X'?"VYOE-]9H7X7UFV4(7C<;^YX;X6>'-CXO];6KY&@#/'ZWPN#;7M<RU
M+R$C\\?<QF#.#^V/QW+2SZ3:63"\KX5?/FD_=Y#K'%G,^K?A1-Q5"@HJI!DZ
MCY&,M K#Z!Y^+#ZRR[2/G]=D'%AE[)8^VK,O)62OE:",Y%;)KEY<%S^J3DFI
M:8ABKCMS=*C2WNE(XV?]Y0.;#]Q4&.]<0.K-RQ17M?JO].RM6?=H;Y"A>[A/
MY=V!Q&8:^)R^LBUHN6M"=^Y\8S(EIBOJRK&55RYFNK)VX.Q%BY8F/5 ,Y(PZ
MKK29NI_H(7E\H>I[,L<X[&.\PM?G[% B5]PH-RS(KI-NSG;N^$NH%,8O\ W:
MDO)LW;I')R-/KBH<0)%83?)252E?=([%&1LEV#<=YC*T_J=807)I;A07U\0.
MU6'P+#LI=7KAN[MFWOG-^Z=&3V>HZ=N>M#.7'.L31Z%2:GY/R=#5FWE%3R7V
MA$5O7W$B^/'?W9NYQX2:VT2)!H&?+:?BF*9!H#S3IZUY,4.=LF?1.+M%LSO=
M#9:K) !\8(81+ZV)RH;;C<W43LO02$U)V$)?I<T$X#M5&[@GP!0$+BJ^ _.J
M=L44F]VKR-S''B+N"]_D3Y-6+54\4VQU9XG3<8U,6M'["?:;<F+PG:AP]I3B
M;='[4OIR3,6"VL27TA(RP]B]D1Y?DT47V7T9^69-ZPUL])CU#^6P6(0OF;T-
M^CE%6W="@F=GJ^GC%5'5HJTV>RL5AJU,OVE)Y2&?G[P69&E18R (*9)*,,O'
M<+O9$:_F/!P#A&IQS3,YOC4\*NMUL_7R5QI#3F31LQ3*H)2<VACP:BJG)AZS
M]8U=:9A)HUQ88C@$$GN13&7I7&W*(8*T[M"A15/*/UN/B-8UGU2D'VE>\?ZK
MLOD6RD_=O%3^4UG :,6M.Z2*"S,<(F>7S"_Z;<\SKW_6,<<<@;U*O/,FK=RT
M*:Q1;I5RY[J<$5GXYEYHZ+%HA5 1NJB6U7ZTI#2NMT/U/![5=,3'T#E;\%(F
MYR1=SLNP09P5_T9/H^,SCZ2!XK"<HBB_,/U9>2(MN>!28FSNRL[![/?WZ2>U
M%#];/]M:9!E=<6H(892%D_E$L>%&#+$PHA:-36A+VX/-KA7([KU2ZW?31\/+
M#0BQ#JV,*,?S4"S>RW (P1!3T_?@Q\2-J*0BF0I58J]:OX?P"M*6+@S*E.TI
M[S^MP1B;UWK51HEJ96AY#LQ1"&-^LREE[K>1E=%94% -IJ\:+C,Q9U?(HKY+
MI5O1\YJ/J&\FOK6?%*Q7N4#?C3%)X^%W^&29PC3ZE[-[]Q*GW2V=5N[ 8+X"
M$:!I9F8BRF]_<?-A]+T5.!PO(L]HD8SLK*I;IM2@/7E[D H!Z"LJ)=M17Z"_
MH4K..;0PG?@(0N( AJ:$4K?2R_#/^57&P$F4?;F,+VX\8=*G".%0!>F]40PR
MIIG\@F:"D<5:)NG8*,Y41/O4?BPM>LCF@@9I^?D@:TTV"&E90VROJ8IS=]FV
M=6S4V8XI[/);>_BX3B0=:W]\GTM9=!<[GFHTL.OP[#BBFUJ&+'*_FNBI9&>K
MH!2QH%-:KA2XJ4J1->#EMCD.@MD&H6WG9RY0-78LHRF4 V5FX2H?P,^&1T1>
MC9%[S0X@OA[1V'L%*;W,6U ^YHC_]$&(Y>PS^^M4$#?G-9"P3$4OC:7FDOA$
M]%#93FTN\C]+?M7B:)C=2BQ#7_4NH7%4"152,;IH0&Z&"H11C6AD>I[G>_8F
M WE]"3I0<D@ZF&10TF;DPLZMBN3#2;C"%C1;RC'$6:-_;I:9'PI1FD@[#)"O
M][%?UTIL96ZL"U)>\![%OD3_;INTJ*F@R)20ZK9.FXL:I(G). CV36!0; T0
MJR,R%&QE@?)Q,].]BDK2 #C@/MN<+7\^7;:?M:\*V6%RT*0\F[>Q3^Q*K9R/
MO!G>B':!-<Y%22UEI@XHA3B.&]Q*_;AR$!.8?)WDI058'0#&<*SRM:.$>.&)
M-<>:>LCNE^U84MUNO=&G?!_-?1=3881QAF6HN1A<9[2TU*[M^&]2D^HX?XC%
MTY=PL]X"D;G"CF09;/4RMU<1#3.::P'_W^?H22(IL\"G_.TJ*@G; 3E;^^ L
MS*4RD]Q1.A;6DIRASD6X=FM.+=IBW)Z)5<H-KAF66: 6)AP\@P>[QZYO]'T
M].)RSUQH&\;A$+AQ$<R\E+8 GZZ3(^NYK.*YYJ@'3NSF$X?[/WTJ3^0_Q&+-
MX6/' )@@<D,"5#G&EC>$RM;#\^0L!1I)%3DX2N'X>FDI1C_(+D\Q#M"]MKO0
M)L-]7EE)ZU:%[JB]CCG^N.+<P61**9LE$$5RY+.O$<GYY_B.$#(*UXS,,9<&
M7O8#TY;= HE?1&C:II)'Z#<83VK0YDBWJKBV?:N8>"T;%X587BY45D"9,27[
M1@)Z]<-=XJ_..1P<EM3$+ 82\95;Y8/WA.# 3" Q6\)$[)4?6/LYR"QJ*15?
M,]"5GQ#A(/P6/4%+I6#SX(H, =$W+X?N.!4E3(= _-!&QG@"??&GF98HVT\]
MP[(_-EKJ6G+/3I,73(TXLZB:M0L4J.W48-Q7N)[IDTNEUG:C:X?+^/.7#S_M
M__[7.;N5.--\X!=BAHC2ZUB D4Q9@;LACY V2E5"E#5+=J$SL I5^-P H [&
M*O)@H73,^E(NQ<P6J(BK!\"\N5!K1_XM>J^&LM(B&BMFXY9#*HQW+)SVE2KW
M46EDB!,"T<'G1/2V,P98'MK!:01^'ZLR)C)3A?Z<9](QH-!LHXQOJ]KUK$+O
M7W8]A2.Q-)WYGDP%J4-76U?(%J42]FJE&E*1&Q&K20-_!I9N?*=[DU@-;+"5
MG'Q@U+3YXOAF+](4'GW;>D64,ADQ>/0Z8#GY2P%5XY)+_SA_D&JE?9QPOD1P
M.YI]<PQ]W>#T_-K?Y#)07S$O11?DRL":A&_+%!!KR]1#\V!J]?PA_%,M4(KB
MT=)ZJ')$A1AUN_C\->FH"O@C3)"O.$G]QQZ%/A3GJA98%3W8:VGCC#LAQ.0!
MHA\(L/C/(+PZB&@VLN-[#ZT4&.W& WV"33188"X%\+0Q8$5)WQH^2ALN*(SG
M!&Z8^CM5$V1<^!Q%)P437F$17\M^/+MZ,1 KX>\R&=$K\K=6FZV5RN@ZZ?##
M. %V3U7@2.K'Y_]DA7-X>K'XQ*K5'#6"()(Q=I2PRP)1T^>,':68,&D*3CU_
M6\Z,!GR_LU&B1LQ5+B87E1@A];I*X(3KUXME*)$&'+U%<=272>9AJ;+9.%'U
M?/B^7Z;6H*>MKZ<<787#.%I3G*6H'CM'+\2&)[8L=H?U)!OCWXB\6D;UU0!^
MS0;)TJ%C$E:.#4JJY[+XG.G;2RW?[[,'%OE<7UJ8\D94]M)1SN1)6,<J9T=S
MR<\DY%(!VCQG628 B*3QA6E>JC#?'RJ#GRJ#;:7LL$:@K(-:L+Q3\OX60VI@
M"Z=$2 VB3C"MX4_6SHY2:9U"@I:J9F(U/YP=.&-Z<OX"3#R $;$-<V17MIT9
M-T7:3*4ZO)RR\;EMG9BWS.=6(\O:8#%R86ZD+_5>':_2R,3QG6\R,\J1Y=58
MLW^/37;>,O<]"VA-QL'@POGG<%7 .;+KU((F8;=I8)K:T*SKB]F53K/+0O-;
MAN9W.\T??#&_&VG3%VEV^8O9XWWF=R(M;KI9QGQ9,.EF<=W0<GD@F@8OB)<"
MKS)LQ%H$Z2'[)/H4==T; /B<#9-Q" 3JO@I36B'FT/X%%JD-,:+@$?' 8KD@
M8[\-!=>$^AER&"?/R^2<&E.;NHI887#?V)<AGW&R4(6:OLNC#5#,H0:&G &U
M.UR\;EIQGK?[:U,X *C0  T"?X7I>XZV/]D CXT&]=WGT>#9 > '!+HCW["A
M/W)M6. "-^L-# I*QX.MH_6[_(F8KR&I\5)TL,S $8Y@20VH;^9Y_[B7*V1-
M"?LW_]C$=VVB^[SE&WJX&6UV,^ERL_CFQO%PMWM$F5-%SDG=W3P\%F[^=193
M3WA.0YBB1FJJ"I-S!ZU?8(M#H$6:G8PF [Q\5:;4U8R,[CA'W[9)F@"$3$'H
M,8@A96.(=ANRM 9A,LS%4\9C>M0J:<C(M/&#.W9N8;[/JGP]!GSQ'K/I2;=/
MD!@]W]XF4AB#*ZI$2?YW'M$'Z?[]W_SO>#"@UV][-R\>\EA\I2O@Q;?%#^A+
MGFU>?,UCR>-' 0+MXNLKEOSC4<D" [0'_-X=\+_[R._]YB575D FT0%_'! 2
M/9>\]0APS1>\Z0JP\@S\DRY8S&'XSS<:=VWF8"@N'&A]1'=0TNV@),_@M/S@
M%=<M0FY$EI?M-D\S:QV@#%HOO _Z:4\8G[\C>CHHMK!AQN6Y'DEFQM:P"8T&
M<MIRL19"BU@I8=[6'USKY,R)0):RQMBL,G01&+[T^M(&<-E":\!#^& 8&5XZ
M&_2G;0C=)BJAQ755I%N P?+K*?TL)"]]?\AVQ^6/FJH)6]:?[8I8YQF<4;'(
M0K^KMXE:U!&.WECZ*A/51(O\<U86R^9Y)8%B"&VNH7T:E9@DNU*-7.9@A,^D
M@W"<.ZGI80C1XDU!7%=/7P%8N3&$WH06!S+R'T<?Y+&V?0N^M7\GO-+[NZ>;
M%-@U#VR18-\Z79HDLU2UNF2,>>;EL#?<3%DW\Z_5VH6A?7GD4)Z=QWMKG.Q(
MOB<O.M*7!;IU5$5O:W*;AO^!D0B%76!J:>BM[K7-R0:#]VSB52MOC;I%75@P
M=]#YR#GK6"@U,0]T5BQ]ZXD[(^1@O!;LL4WZ'^P3_V#-&= L0RJ6/Y"&>K$2
M5(ZT[VM6,E>O7,513#I3 S'FPRE.%]/>KG1[R$_84I"QE6DC@C [Y(PI.28@
M-2TVZ<])57E1LL&8"F,K-<@L?3F WB$&?!EMJ#!H$>:4)+T1W7'&8WZ\WEX5
M1&U:%/]H*8^=LR-YCFK-035R1;)-X8!70(J"AY^7AK(QCG)JNA[CJ")@!: M
M1"7(*GJ_NQ8-&&2JLBREH'.)@8B_<>PS>4P*E,Z@(GXAK=E7*@43E3HU\]T3
MU*5?'YO2Q)!HP!P]2AR%">-06"HDJI&9.%Q[=C?YZP>R;\S&R_C- AYK%>R9
M_AI/?,UQ4J$RRW]ME"E3*)I 1@2$"M.O+VK$1*@2T C05D7.%.2C7S]/G'1_
M)<78Z]'4%+I]<OBJ&^CAO_ER@;%4JB@(-X@?WD9/1SL"VR\Z<"0Q*+'FZ(0&
MX:A73T.4=!48+?5*AJMZOZ."@05>,DQ1^<OI7V-A,![REES*$B0-O9PD.\ZS
MPXL+%*&Q9'1FWL(!NB4$KH(I.Y+!LDF$?Q*# "5\!>1CO_S %) L91YK9L=+
MMTT)T7,98.X@&;X)SF6D9'(,4;^,A5X/R(ZA/J!PP9,1"E1Z>"=3Q:AL8A3D
M^#(5&%3:GV,18=$:]U\.Q7( D?X4G%(9TUX?CM?CG\$++O_B?  3ACCI+V,F
M:^33,#"NHM.:F(7KWD1@T?924<$>=O;[WHO6&+$FU$)?X L$_=0 <]B]->E)
M(@&B^M:E= 'J8BC:5LJ0:!&YHGT#V,+0D@]RF0%),[@CXZM(ZL<!%DGT&-^;
ME,S797X;EHW5,N,A-",#,:^0T6?$WX/1&-OUS&R726=;BC(%8ZWGL*7R:+;'
M_-*\%D>TZ,:B=$$PQKW]8="(XB(RBL?)!!"TI%_2NH@YENHV.2R744G9S 2-
M/!-&A.6#XOU;'JYD^6O?1XL1JBZ%26_C=A>.& ""*WDX&=E1M37YS7(>Q-BT
MDJ,.I92%'_IZY,B8BK!].34W#2V6&J@#,T4<FHFBJGOZF;AI\XE6*N\&)?4O
MUJU9-+^,?2S+H(BVPE&SQNMUMEQP$P=>D2>!B<EVQ:^'^:6HE@ZW1)5CF(:[
M-'3MJX,,G !-L?Z):T*7.[)RM'24]J-GSO0JZ-VJ$EL[MF<!=WZU/;L] 7W\
MUE'VV:)E?;UHI4WA"IH *!@J#P0K#YU>>;.ANS(KJY$^<>=H%EREOY':L 7.
MA"M2H?CB1@;N-;K\.MHY#S.FWXD[3/?5R+($#!0'%;R.$TC;]5,:%7C>40QG
MW[Q?QX)FLI1,KR0*NYR:55I76Y'F_1GC?O:PKP#AE40XQD_Z)=>-?KT[/T$!
M?UO?=HY8-0RBDKJJT]F.UG_,9BVCF5!KWV/@7<P?Q)JC%87FF<=%:<L4K\E1
M1%#<Q(R*Z^P.9_ER:!\7.KJ?G2O_\KBC<O/#W'\H9-H&%<;R/+6ITK;W@C$8
MZN ,,:*E3K1@T'X?&_+S2I@_8_U]I%LN9TJ@&E/;SQ,P.PJVE=F@AL=1$R-5
M=TZC_67)464VQUT\G?6KVSK$:B%+XV,;FH+^R44?:L/L0*I+9 Q+5=_@V6N!
M+FD_?[%:[$F'0Y\.77KEK, T-3.HMC^C@V]GZD^NU="*!:W/]!CG*73N,/IL
M"8+V$O-<114+4%$0)5I#CD6 4<&L]+VZ5;GE_(U.CM:8YWI#0X?SNT,O3L-@
MN>=IL/%F3G$:>U/T.@WF%<R(\$JC2A2M5QXM7IS]JHU)@6)AXT)[X+;X5(#M
M'G:9$R4"B[@63"V:QJ1+&1U_YM8\JJ/IW7[HZVKDJ(CZJQ67)R(:V//CL$_;
M3Q,+O?JL08.BE*+\>U>X<L\.^0BUP]I+=N0[^P+-&K.*?9^:^\^P%^M[D3M.
MB?AQ3_#U0]\D^\+@T=C'Z_[=7[(38[QXE9[9UK/_MO6^3H?53!&*LOX(_/>N
M#PN*\?+;<5)V:)+@N_0IIFZ+_5Z?_.!-JTKN\D);L(ZW;#K)&-W3- W-R<WK
ML#_+Z]!+@>5OQXO#TK7LV?C4J VGCK31NQ?<OMATL30+2+O*=G\#C&R\963V
M3U9IS[YO-_%":E%2;F5)Y9O91T>NOO\KM7+G.33_!X:M(4MAP.<YD%^V$/4G
M6^R09ZC Q,-,IA3COMLUYR'%OZ[6*V(R037O=>/D"1/IHMS*3<=C*1_LCQOK
MVT-RO<"DN@V:4X]O3 >I'#.!/:OA\:]PQB'Z#I;*0]%H@ &\LAIG]BUW:A:B
MS<7KTJ64VV6[W'^RU@^BDK'HVG*4^ VYZ"S9$5CZ T9,PN1?63,M!T/1'RA*
M1O@U,J@0:\\#\DN]KN\Z;;G^8=).2H2T9Q6P*UA0\W$W>TIU\Z<*,:'Z=<M'
M J1$FSY_<.-<S#BBR89BG<IDJ,+G#U'L]349J[Y%=G!_JT*(9-OQR>A4-FM*
MCYAD[PQK-,B^:T\?)@/"@7I3;#:*SB25X?P<PF8)Z=I[6JDW:ZP6^7H9WY@O
M7PD+YKF8DH 26Q1Q$BM4&[M&#.3NTPW4&QD5/=[/3XG H[HB?OS$>[;I&D55
MIHLK/4\]; VO\]U.6-@^>BKZ='Q_UH51,]--F?],I 1&-\9W>\F:W-XUMD5@
ML8\)7E42?F2=/N?MYJA:"].\5TS'+?NISW<-O+RXO3"JANP%E^QK_U]7C9EI
M,?78R^@WNY]*N\?'9KX=++-0K%]>1-N2:S!AXE)Z%]P>I9N4UDNPI_\Z@9FX
M"2WJ?/VH:OFI1X=#_D$-8J)<_39ZWQWS(&PZ;E+J:V(UL>6)>52IX?YDCZ%"
M];)Q[\;/LU=BK*(&2_ZB,3JBFPY\75[0M"]C].=S[O_* RZ;F\TWCUCOXQ=3
MK:O9!G^Y8\F;T(\J-AA&, AFQ;/C-WE-A<E6O,./]3?2%6J9RB(1X5["5N5.
M';#ZKV'VJ<CC)7N89% TD)2Q<62\(MO@AA%ISXG.*6N+0P\&;I!;&'+6JH@
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M/_ F&^NH0Q@D88'<-"I@Y4(%_WV%N 3[H_1&1JI3"$7*M_VOPOX!3(:!]C/
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M_5DS0;RY1A.0B7-4Y'['C>R@N99J&?KE@%"-F6$*$1L7Q>(<]IG1[B3G8],
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M[-O//OC\->]*Y(&RF8BKYT1:J5#D<8AVH5*_ZO37FEG;:]>$/I@F>1X&.$&
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MC<%E15P;VQS#RYX30VBEEVXR&JO%( ^RYW(Z68))3&2P&H.[P=W-H8V2"*3
M^)"QZQU_H&YYU#_^V.MF_&5>CM1HD:=-"9( .$2C#M]Z>SY!M-G8@6>%7[;K
MW^A0I!(5!WQ[\6I>[5+M0-): 1>EY44^7?M7Q72KK00(]TP<J'T1"],:;=I4
MRZ3%4W7(2E3[RU7(LQX[> UC"-%S%S"W<O0':S%U0NR*E.VI5/!?JJ+7KHAZ
MOQT*PI!F,)(E>Z_6)OQPY6SC/%.$%!5&A3=A;N<P117ZZ,_''BQM6/]O @WA
M7)YL6S5&L>W+"W<+:M,]W@_$)XI+JA"M43LRH4.0#M:/$^N<@M8B! ?GZN"
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MR8\#X;=5G2=^G8??WXX#='WO+H&TC^, ](U/@HZ,PT0('9,9Z=/+JZL'A2X
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M'8=TWIR8-XEY^A:'EDKLI%9\KJ3A,:%M''/D&O:I,W[+9))#O/$.+N@\A,/
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MB-H()T16=8>Y$WKW8\9A74-MVE(7)0CIZMK"V':\0:;:JIY%L12VCAE5Y$D
M8KC ?0S#]MA$9YML81"Z#*B6,'[8N5E;B6F"L0CV?;(9>-UVFT(*_+J8=NBM
MBYXDOXB-1ZDQQS4"&KF 4-IIX8)?^'2Q0F9Y<:R@?#6V28;9P3.RM#![.K]S
MKCW[6%KL/I8<8\S O_6P'QK:64\[#4W")!A[IX-^U<5B 1M?S#5U6NR@SZ<*
MV7@KJ4E@VG,2UT4/<;I8?!2E+-KI"5GM8>B0M+>H#5S=(%R@:SH_[_:V]:LN
M N]#U?[!SB'A+F]":_6KMXF.+]@D!MA-/IH2,-\6O&GM=-7!Z\1\9.5472,
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MN;U.>'N9$'$C0-,I?:F@#KFG3G"^XO:FZ=N9J&44(@^F-(4VFQ-@Q!86+[Q
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M]<#;32>>>GU^>^/8>(F)<7_+F^O-R\^\&3TXO4%Y<6WG#_O"*Y^>G/]T<.5
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M-7=U!Q.'%\0?XVI(6+:T.(;$X"/4&8EG$60:>+KF L2:TT0)O3+6^=FS+@G
M0/35Q-U%JC50_2R3')F]YQA"U:]?7(O]#M+;N.U=".=[5(+][LO?$4EEH&T0
MU^J=R+A_.4,(JV-EL*8"*-R+;".?_(2;*U/(+8.$4?6T',7ZQ2\R'[((GB'4
M26;7(;@/T?<8A4213*([X)ARO;3XLM)B=DD@X-9@2FT%'@5P#\(*QB<$:H97
M^JX'DNB8"D=R]RFP[I&V-2"5N *=L1O=K(%#'23CV:>Z_# %0^]^!=JHH]V>
M&&M(Y=9GK5 9K/A:T':!S#J#/]=\&+B9(IX>YC(8L#('I&B"9J@&3B3 V![D
M0(,_A "V2N!,%( _NYHHG8=S??KF&F< C?P6TKR'#2M&@5%(H*'DHKME!,8
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MH%I?%;((WI8C!?9F);YQ)79Q$&YT#$T"RJJ2NN4@08G>)O5$UH*QH[HH&9$
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MK8BYSC?MPCCDKFA\QB_F"\]=PD0]0JP"T!N\4%&80=C_,B/JD A=:M5?NGA
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M;W4#"\Z*1_?.7=UUYO!J=WN3$S'>!7J^.X L/@+=?.WLN99K9S\@#)RD?)!
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M'E3FY1:K>RQ&VGL,F(X@O/2U'=\;UT\9%8)HOI2A$1<0>#0/\-PBMZV?="P
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M1&]  GC&>!E1;D))X%LFY*%PPQO3PTEJ\,\0L/PL.>B7@5&KP9'N+7LZ69]
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M;8BR+F:"P_GP .7J9^6/U.\-6UT"_@A=4]$K?^^<W?HH<<>WR@>T6]8NJL6
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M[!\,F84A"[+_IQV_SO.V3/M/5"OW-V)^!D[E3EO3 F$*N+RJ#<"FO=ATO7(
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MY4GZ-<F+:R4P 4P $[#2!*8R&2.80@W:05@!5O!X 5:P^ U@!=Y9@4]M(:P
M*\ *YKL!K, [*_"G/?0UB?2/D_&^R,5-)#HX 4Z $UCI!-.IC!5,X08-(LP
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M'%52*SP,8^\RS  SP Q64^4IA'+ DGPT 9]J VP &S"3\C@6CD4ML*%)9&P
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MDFQ7,0O^9Q*U]&AWG'JF@BT_F !WS&2,V&ED3"QP&K^<9KWM*9S'9^?! K
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MY!Q%0IO+E37%XX"N8TWQL$Q888=XC+&-+3S'5\]!_!%_;_IL.%!%S2O\ __
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M$SW$Q"TQ87K# 5(R]X%N\ 2&!:D'3V"0<" <3*DPI8*@C'_C9@2%60PC9C$
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M@!;08FQD\8K]AG,+/JPD16/NE2AX!;2 %GC%YDFQ=WD"*>HGA1X& TGAKU=
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MTD"46Y;M '$@3K8#22 )V<[/$PNK>O_S\[++JG[[V>?#7:H,J(%XMRWO >R
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M[X+CSIU0J0R]@=U37(8A-S,JIF#.W@-(1@#[;)T"9-V&[,[RD-VI&;+/U39
MUFW(;B\/V>UZ(;L@8(]CG;2TU'4D^U?TNGWE$05'21)^4U'D.73GC(^1(+8X
M51C777VMB@M=%C3TG:@LZ/^W#,_U=_<.!YT"[>G7.8_G^4(UC/%9@3(2V!:K
M\]"T>/!WH0O<_HB40_4X&S,^?SYTH9OH[4WGS@S'8,IW(A)&PM-BW=T!H!X
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MIF#/*CU&V"'L&(2=5NFMHX.C/XZT'<'CSK@SZ'R]N!UVOIT0%FL&- ^+JS&
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M/[J#'Z8"&(F06C.@N4A=1'I3\&BE3B0\$9X,Q5,K]=OE'1<Q9W&)B0B73LV
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M0+LB!Q TMP7-&^Z.PBB(AM.SLQZU6VXK/E=A P+I,QY +N*9;AQ'K@_O%<\
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MS\'\_1%&]_ >G,4@OCP-PAU$EL=O_5!5WERG 7?>[K[+ %92)2#_7[3T9.[
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ME(@MZA99M5F#L2R6<:96M2U0\F*%]&\QJ<+;3!$(0KO!;\#2JISGOD3]RXG
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M=#HUI4]4.B"/15BC)]"&::/E[UXLV0_&\!"PDX_$&];U$%0=D\7YEQ%Z ]R
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M< 3@H=R^$W04.I_Q;["F$#1Z?'@,>^5Q&?^99@ZWIBT\UPEO-_5E?*T/)N@
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M4NI'+83-JP.\DX/C"E&]DZ?[ +>D10,[M(-U*='5[#YXM$H X6BQJ<=>'P7
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M#0QV&O02H[!#SB"XIS"$ D;ZBB I*W,Q)5$I: N,-J7:1TV)*K>6O\6;6V&
MGJ4+;)25IFG' _;>_CV>+QX]85U'6# F4Z$@0LG&XQD!(0N2/8)SD!T^[=7
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M&L;YC'96+_* K[U"SKZ=.E\XWO$<3I5\&9/1$.V!$3 MLA0\9A^9#^[>#/^
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M/-D/@7/6Y093XX\&G3K?X1XCM]R8Y2C3A/@!^=RTO$6>ZXU/CXKQN&'Q<?P
M%9DA""R''4:A/>?SHQA'D6/#R2! LC@J=S#C=!&6>K+<TE(3&91G-TATR*6
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MID?,&8\/[BQP5V<O!W< \NDXX_- D56F!HKB?J]4E631T40CEVP ,0EC[&^
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MJ!9%,QHFB$P$)(WW1>0)7 <V)HC/ZWC!NR6Q,.#.K^@MB3.F?%(W5W:9R.?
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M&WE78.QH3A%R#!=WC,O/2E;E<&Q@@]EZ0X4P@)K*R,E,<H4)OH 0^Z-GBQW
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MRWF,4K)SFCQ/E8&0>$MA$]_0,>=,H?R^UADS3/-:V[D/G2B.69H6MEXS6;B
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MK("M3<($@5:CVH2>*)1E7'BC$9PA@;'+@G(WYO&K$S.,L,/<,[\?1 _ G<!
MF&U>3B9Z!PGMDBB(%7_%;2FN7X73@:Z&VJ_[)*('^B$V _7,J=]G<$%I+[J
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MV.!BJ]3-U[UY-.C_49##FV4Z!9/'K%*3-\00TK:('8>_,)1+S''HA+%+'7H
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MDQ^#I4R+1#-ML/F6!ZN3-0RR;'T$;HTY+7JXWQ.L/6 O, 0EH3Q6.%D%NU3
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MQ6M!\$ZI)Q\RS_;L*MKR/3@O^41=Q&.B!DJ]AD:P80>J W>4R3F%LL?B 8[
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M NEI=D_OA#=)P)#\)+=@AU7/@\6,P+)(''<24AL6=/^FPS=N6@Y_'%_Q)*E
M>L?8A\OFQ*HHD7 XB-$7A 8T$.$4@A?RC( J'Z@9JURC]Q5K6FH(Y"IKZ18S
M' 7_0B:MFH]# 3"@\)178>>D=J#&![AP=F2IV!.,QAGYM-["R?QB!4;FOG53
MW(>+O-0Q)^>$B0*Z$?^../"]B:5$;[%&1$=;'R[.W[_=QJD,8'TW2U]DL50W
MG:J$< VL!SC1P* LP]'Q(^N;YW1['Z(Q6N9S"_S<H#C:5ARS\ 03T$VL(,GO
M;%K\&AFDWN2K>8M\HCXEDWIB0"6\RW3 >BCA%CRDKV<(E+=_?XX*0CTK37UO
M<3V8>Y)G" Z)=2M"E6 +SQB&FPSZE>#KQ9KF^\07+S!5@/J$3E[.MF&%&7-7
M<,%O-@+9 0(]*3QGTEDY =K/&9M?H6/SVW;<'%$0@MKS3-S4-LZ*$S)7N6;C
M7!;-U2&S($N1C31@AI:$&<U&]@TE9Y,87A, ;(9B]-$=03QW%4.WK!AZN,$5
M0ZO+5RT0R"A\K$17UWA79,VOXZ;GA(FMJEE>?NP?..DQ)Y[;O+%;2Q=OBC$!
M_5,B@2N"N'QJS8_^O:?H DA@"3$9R%\38IQ2:H *N00M#50[Y5KAG G%OV<!
M*<D;:Y1@E\DGIR\R</^<]^X>W>*3RB@BBT!,(W0576$Z:XRQ9M>/BR=,?F)N
MV4E8&2L\YQCL#YD4]8[/HV7>$!V7A-58P;M*ZY*G0]WC.?!"E^&?YSWN)FZF
M"ZR&6V@['G+"R2S\-E&X;TNE;QV,0WAN)ICN@W"0<S!W0J8##@'#,!6HJD9@
MLPS (GJ4^20'S,& <%(JF '@X=@FI0OTM\?6;BU>+$70'SW<"A/_J2QVW.((
MD,4@HX@R!V.4<SZ%IF]1I+)A@9%O.^IF(R(C)@K@3S1)3(N@\5,Y'F*ZO,PA
MRU=-R.#T_.VV5.0L*M9I5'_!-VR= M5+>X#J#4.JKVU$T Y.^1!-T[HT4SH<
M+GQ0_6@2TA=72?6W+E+2<>]KX-69S7Y]^$W"P)4L2N"1E9<YM0C<9F2%/0]O
M)(0ME^:3X<EI5DC)KDT$R0:B&J%.7 "% QKEVE@C1R<-*[EC]&FN$][D_:2
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M*>I^[..>D_H)SRH.)\_#N2",,"2+_=L2% W$#0E*M"-'"_4.%C?:[>V*1*K
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M?.>?3,+4-]G*W'=&( N_F7DI\"%E&:<DJ$?^)!I,1&-+*/F1.A+2RA*>><-
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MH2[G:@95$=L*E((;W*%TJ:_V4:_ >!0KE%/BXHQ/HD"<<(V93!V2Y IAOJ?
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M&,?63(#RS19S-5@\%\%Y'$RG<MJIBYA_:5H0M+@E@6E28/U ,82E]%5?B53
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M5V1#97,[R11'O"=*0I,[5;8J^)P]5%WW"LH'/^.%NN*GE8-'L3NE0.<.3_0
M>QB(QT"GEKS*,K>T0(]%)^I?&A20"8)'G!%G1*];.0N$81+XA"J#?&[O*,4!
MS8;Z,[2#T2^$*1AH6N+8JSC)!UV(Q)0/J?()-"^5#61TB5(T5#DAD_)@2U2
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M"4H* S*N$L&K[RV]?5!Y:"N/\.'V\MG/R/72J606YLSCZ,K'E?)WG"MT'H;
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MK!:J?*?+<A)C_J9<.\\H>49I?&UV>X.L41EJE+ VC:,0G4&HJJ-P K!'D;L
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ML8^>!%=D"2O#B>]^"R2[DW3R@$Z@JH\18>M'%15:^4Y2*CKS3&5]JK1XR^-
M^Z;JEA(NF[D6G&SWN^V+ LH#1I6J-&<=-(,;P()P0LDT?/KQ TLWQF@@0W,^
M\UA>^5&6:"^4-O[Z!KW3!7)O4!B^ 8,DU41Y@!-RGIJ,WJ^#WOZY,5 J$@.
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M1G@*H"<4%YI *%B#[K",H3!Z?47^9\"@$U *[@/_$?Q-LN^E#M-*:!V4L"3
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MX-O\Y>$&EHO#$I)UUU\PFC(@,)U_EL 5\QEK:SR?<:TNC*#A^CCJD@_\!=R
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M9>U)%G])>'V@.T>7@N$H_ 6B0[P?EQS\VO=X\TVZDW@J<H"U"W39G*\G"P?
M46)T"H=X#XO8\3*;4GGO<?,<'KJ**\/D"@(]M4<?MWOK['H"/D*]>UB)QTN<
M0G)GNRSJ"%?PNO9<MU:'F4G3)Z^-Q@ &CZ-A%6N33<QW*R4])(1UFHRZ[\FO
MN0V>VQLGXG=&/H3Y-*F[@V_P2]Y4'JXJE3MY:XTNDTLUY+?O/W__>-,N,YX<
MO=,*R3N*&>3T-'B%\WJOT%H&V*"2ED3F:B3?<,K>LDZZ4E5FED3./67_(;OX
M<7;;T/&7'31H:>6=O)#J8WF^A+/.\;[B3=(Q.?_\&N=35K>$8EX,Q0:E2(PK
M. \6__JJ]PKB9A=11/!0G/XLGL)^SH>7<[P@WH3T.OG'*SAE+:(58I"4 NZC
MD/#Z+X):@L!V205C> #"W1G@Q*9UD2%[_0,@[<Y%2 FQCL,H'+_L0X'/QA<-
M\/U;0]C>*45,^Z^MUU7,JO&]X>MS<8+,! +:[.A1B<HR04++%0!PX^G1:+FU
MN' B+54=D+HHE!^W!C!5<81RF)@E'21$R)^%^%5J4I,I4TI-OW=&,'>C.DQU
MX/\JHFQ5A4Q6F4%/O?D'%;HRL(R2O+22W&P_S.JD(&+>YE0]B.\J/1'4]!KT
MD$9=:LG2YVU)G<.R.N6<SMZ1<$2OF7#LN2(XFB@X&[Q"+0D9-PFU;](8AQS>
MDTRW8F)4(RN13.X:3#2:W"7E&R:<O&FO0=]\(MTYT>B#L>9@Y&,E0/;S@P^^
MKVA R2-EI=O%NYPJM\Y158MHL?4X>C34^>5<9/)R-"=,*N1;<:=96E5 185$
M* $FVVL_1DQ<?H5>*-]CM0_)+UCC':\SX!U%R:7I%2]$J;AZ3^_(S:6@N12L
M$TY\I/,4;[;]!)7"!6GYYI+PV3RN/IO]@U6T)?4Y(CFDZY58.=Z>B4A@-#@Z
MJZH(T5(4/A.G#*MWVLM/DV>J)86(1BRPG5U^-R]:990[ I:G&C<XVO-<R1YK
M?+26&)5XCDI4UWJK*E"94O1[XIYXJ-ZPSG(!5S^YH&A_2D<W+?FPHQMB;].!
MJJ(GWRJ,A.P--' SA(BHK#]K<-RMT:0#3D&EOIY=C3W;.WMTTS+\OTY2*CBT
MM"C5XC0E]N.0[(C1N&9\U[8^.U6E*].8CKCE&ED-'AS.I2H=2P1XP^.3!28C
M]\S[[L+5@W)25>?F>S85=\,C]0I$ZEQ]SX15L(;M=S8GN_L^W:U!<W?#Y?_E
MU\2EI9LYUR^/I#'6&$E#Y_O^5W_[BI")<\<5-?H,<HAAU"0PPI&?Q\YN+9Y<
M?C@ 4^@P0SKVV+0,&=@[.)#R'4BV>HM(;E+QP6P[6%YT*I$XK(:,\'TCAX'W
M+I?UR\A(C4("[FE>9?'!H%P;=YK2CQKQZ&?/\T5FYQ_)^/'+H/P;:*#_YV70
MFH[?O0QR63W9"U32% @>;*^(*+)F^R=W,-0\_Z3//V[3=RSU643MS9*:U[;]
MM<:*7.#S&TK"GJ$6F,0>J\@6H'-4S#=X=$*J1YFPHN7!SRT+-OPW_#?\-_Q7
M!;O,FE[T+2C+_17Q'\]<M#\Z'X"9N"Z=3(^^+E65!]*E:B_!+SNZ75I5)D@W
MYZ(^8WAQ/) $0<C!\=A(JO) *CL23.@-S@UI>$9!Z(QFIX4R;"'UF0BT!M3R
MG*:@I9B6=:.W9FMO6A.][< >>Q[TF*H2FVFM@/@:38^N^U>5!YG6)CSH7UP0
M(QV##SE.ZD&\=)@^'A=,5>+3G;\TPM-=OS3"2S9_VKLXJ2_9_,GXZ#;8LP9J
M2J;9=F!<:BJ(%V)L+\2TFMW4D$RSFSJ1:793@>"E->W$<L,6'QW;D/25V[@^
M-Y5R.G=W;NGNIS_3  !C,%9VL(64PVD0N^-<&]%7MFU=V@=527BV6SDW 27C
MU.BDE[,9I^D9T0^,4]_NU'_?-6J5!-1E!;N1G^$I=QZQ3S.P^3AKZ4IJ;7OQ
MTIY'<< F.CO1(1U?[1+<3 D)Z1]?(71N,F3$GKYU]'WNN<F0=Z.COF>"IZH?
M(:A*@$;Q 9HF#1 P@8Q^@Q;6! ?-!0>_89_.[FGLJLJ?5 BLP9%SJ/[17U4"
M]'$HJA*@SPX86V1J#YY3%O.=S5#*!G"1^0J"!06/X?7;-L9C]0Z$-6I[Q@J>
MUNN4:*H'?ERG$$N]4UB=O=*'*'4CA ,,89,9]G-3)QG"T1D'=VL=3I0Z3.9P
MI@\=GLT/"+R AA&+(OPEN8M#1' +*9^.D=P+.!%=JQ==F(-/2P@P.W!N LP.
MG)L LP,FAW_*''Z'?'X6TL>YQ4L?_5#X[EJ?35"5@.R\UU$OVU#6A.-[ULY-
MA&X;8:[>6^JV;W]LJ!>J[[>)!N6KRK8'&,=];@+TV0&P>,I6PNIEC<XY2E#K
MG'C=*W9[5ZY\9[+\BGA4O:*Y&M=01$'-JG'_A&-N]:%+76=TF7>[1,5#9BVM
M:G**Y[GIDO=+U^UJT B:B&-'?,I+[LV]>BLB;54),#MP;@+,#IR; +,#)D%_
MR@3]Q^S,?V\[GOK>&@ZZ8_6.NE57B^J5SFMGLU0\MY850H-NK,Y$62)REDG9
MFP=Y*XY'9S>^_)2^_&?'L[VY@XE]!FQ'.F1I.XRHF!)[\9^8>WH-G+RE8+-2
MA7-1KX],.Q>O*@&2+C2).W(N7=# O??51:Z4;-+ ./=6.O>O<$P/X@26SG2O
MM84 ?1R)J@28'3@W 68'SDV R;*WVGEKT[T&\:&R9U8YR%6O;*<BFZA#"N3X
M>7_G)D+>"55ID.^;5*5!VH?C9Y^?FP@YO=Z@6AL?;EK9MF,MC2;*NL%,7Z;J
M!B32AHS50[TJ]_/,--B)H;IE%]E.Z!#>]KF-LJ8:^'1A;WLCDUMOI6O_E=[;
M;L?DT]M @,DEGIL LP/G)L#LP+D),/GT5CMLC?+I(_63AZH2H(^5(AU+63'2
M9Q=4)4 O:]2L+ABO;3+H%8HR4!?Y44I+390M6,UV8J3LQ:54_*Q^XEQ5 C1R
MWL.^LNJ<J4*_R=E*QGDWY[QO%@N'STHGCBYG[_%,V8LR.=P=*'ME*>^%JC3(
M.Z$J#;KM0Y--3&?;B4E/@S-&IS\QE]YM=^A4EV/Y6-F#E!0!-PE2>*Z-4-;^
M:G0>5%:,,EU0MZ [VP8=BFS[TP:/&*=RXDH"I[*?:T"U^PH#JNZG,:F0M&;J
M'3^V4B?5XT[5L\4U-JVOX*5SC=VR9NJ=NVKLUDC!*ZL:N]51$0JJOD6<3;34
ML:%!8C_W[!>%X>!JJ,^8J\]0P8*6.NHC&OCZZK6-U=B[X4@]-+ ZFZ:3 Y;C
M"O4.N'7B"@7O!FOLUD38Q;%ZF97Z=G$Z,^F*<T47'_R $G]# SM"H#I%:P7J
M!.@C+FS]@49.6#H%)^19&CGC\O&JI]Z-48W-$\W3/3TCCLY0033X.B''>*;1
M:472-7$8&X^UW+:$O%&34 4FZBAN GO$M1/!HN9E(;-#\AJGUGHT(J'M4D63
M&KN))(-Q=_9:(\JD*Y)QMZ\39=(M2:\[UHDR*<JPND.=*$OW3".:U*UGJ64/
M!]V>3A(HV<-^UVJ0,A-.["C1>?.K'X9O?^*I"K(,_#4.T/'G#H,#@E\"2QP%
M(XKRP4F]E*:6@T)4)4%R_:J2("F#LETSY23=0 ?$/[TV1($;B-9T/30D0>SJ
M0:IK()%/]CGU*Y8Q\)<DLG^H*G[JGEN4/Z28'6@) ?KL  YV$$YDJ%XUM-F.
M>M08GUY/?CY[$0UH&&G3HZ@J <9#G)L LP/G)D"?'2"=J8)E2V7?/#58?R_O
MDW]CO8C+=-J\.&/C3%KCI5NB&JH28';@W 28'3@W 7+MB*HTR#ZZ02*,BSX^
M%>X;M]U6 O0Q6:H28';@W 3HLP/$ZJM7QU^N0#,WV&?(=C.7'-D_\&::^V^Z
M($L_(/:=_T Y !!Y,T?W[D@??JNJO!FS=6X"S Z<FP"S ^<F0,J+B];)<4^]
M!OD*\%U!S*#!JEE32GYX/SS6F&G;":\/2>K:,;-+2I-D=DD%DJ0#_D"4A(W4
MJ[O?OV,DJ7CK-8F$:>*&Y\0-Q(ZBP+F+(_O.I9C-#U=V0%?P51J$6+_^Q7^P
M@\@)R<TG?432V$452#*[I ))9I=4(.D"8XP&ZQ!/%6,,-(XQ[NS0F9/;W[\1
M\N:?WSZ^_4L8;Y(W/ZZ<B': 5W-Z33S_,; WR2@AZR\_P0?5TSSEK:'RML_L
M0$L(,#O0/@>9^?]QU]+2\8^[?04J"YK-*E2]/G7_/?:J1C=C>K26-T#@R4F1
MAR1RL8OHCZCC> OJ1=<=]JOR*F =&+"(Z(7_A\<PY-8./,>[#\F&!CRQ0MY
M0/26."&9V^X\=AEH@.^1:$6)O?9C+TK !@]/SW2/V0CX$1^=_B;_#)G#&WNQ
M &(2N1;BM?WSO]]\NNV\_WI[\_?.S<_?;[]>@\H]VD_A._*OSQ^__X)C*'NO
M97;*7_Y^^^_OG9M?/W_Z<DWF%'LUMWX-^0\B<J @D-V^BVT\D\YKK)5QED]Y
M8>CWNEP:QG#*P-?G%W0@VXILSS]!V)/(WVP[/FS_;N'M@\I-J[WEH_IS0X_@
M[RYA*JSD@ &F>Q92]BPYD6Q>LJI>V._U^ZQ>&OYAD8#.?6_NN(Z-8U0YQ,CG
MG[]^@S^$L<MKKEFA5O(SV)Q^SQJ\(Y\"/]X4Y'$_3U&PF%B2:FF1V,'-$!?(
MO[[JO0+==-% S^%;Z<_B*>SGO @#)UQ[$]+KY!^OR*.SB%9@WLM*?=21M_\B
M'J_"!=P%Y">^CWC8)? "%S8O)+'GTC $:[Z 5S!CC]7RCTY(#RBM.T/8=1#=
MA_X^)\[ZL('<K'WPQ7]RO16_ Q_M>)'MW3NH.N*7=AA2H'Q?1N3@7$C;.72X
MH*PWMA/P:5+[N-57E5OD9O[?V G9U&SB!PGM\![*VVQ0B,0O[^+0\<"BT! =
MAOAE0'D@R<=X[N/30%4^'2P]O*%8_%"/.<-+8<Y6IGV00HOGL.'@$_3PHN_E
M(7:#.&$3^$LG.C:-D5+#HJIKZW45H_9_;_+Z7$P@@W&"B71TCDH#)HCJVN.G
ME&O @\'E$G^QA)/CYPJI3_NP)TS?\0,":S'A5'Y9]9ZY_5OTVP5,GYN)/':3
MU1/MH4YXUFE//0#,.I4](FZ8:KEW6HZ<TW$:NT3=*0:T&?]U['Z(+O [NL0C
M/NOOUE'JIB*.TE.GC M3ESHM75@R$U;/N>;)X(W9^)QH8Q?BPG;!EM0L'QYI
M4CY,.L(4#BWU#+TN=:"& $- NQ% S"7;0>[\B\YX&42<MF<C]6<9&@(, 9=&
M0)W3R"EZ-\UIY-C]>)^V.![2X3A6](A2)SG5M90=MJFNX3 $& )4ZQL\E=-I
MMJ.^ZO69V]&@OZXUKO3[BL*G7-=_Q/H*NSQEP X"YP'[X7CORWT#Y9+&7!@"
M# &&@+81H(9O/-.=$._I".@#]6(%ZQ>VW7CWIP/E:3$$& *>/S]4_>O.1*<;
M+:(U6;JZ$\I"UB]Y[_N+$&E=J"]/G:0*9:B#=CR_O:E%M!S?IM0:(I0G@%@C
M9>=9RDIN)9<["I2:G0K'RN39VI5G\U7O>=+.VAD"# &&@+;[1RUR;=^HZX+I
MOR+WU ,WX#*,,GNQ=CPGC (&<Z2\*$'<)1##^R.3@C,$7#P!9*R^&F1*;<T4
M.$SIEH/[2D-J!_,5\Q<+^D!=?X,'# WD2N CS&8:).*LD?K)*S(;J==5J9_/
MZ/1[ZF]#JMV]J0(M.KHY#7ZQKTF6B4Q[I@GG[ 20C@ZAK Z&=6AI0,5@>LZQ
MI1?M%NB/#?5"#?Q"1]Q^3WKJH=/HYQ\&,PU.0!J0(%KCAV/U,&0J*M@&#48=
MYO[>W-\_Y_[>T0#S33N_8P@P!!@"VNXBM;C"Y\>GI>/9WAP>DHX5]!;ZG*GZ
MZE=_&@(, <^^SNNKGU(@UK!!(C0X/.DUQ'=X>E(:'^*;&^J7G^;'Q_A=PPJ*
M/4?H9]UX0<-DLF_N$3;.>POH@C#!Y0,]XR" !;I/! CX@^(TMTW@+^)YQ :]
M\;&1R:_@,9UTYEMQ.>]P>%=E^<5ABX(#([!NOO* O?=.S6/CA4A(/R<ATI#"
M*EFXVKXAV<Z*8"S9(N*DSR3S%2P8-BW9<9"6BDWWI>O3'<]EHZ5W/AMD;$.#
MZ.F*;%Q;K)&":-2OX+D0(1CDS41^AN,B-[PQ/[4Q/Z_Q2NP-YG- 4*( %#P.
M6';'8^I-[WFI;;)9UW7W.@J &6Q%$/@#3QZ<.25+2N5O5@A MO226+FAGQF1
M0N()Y.8!&.![Z;<*ZP%MB.SUABSBR,F_T?:X]>&+-3*6R=@P)V.B1 *E)A&"
M! A!VA9Y?#P;'@WL]>/(A=T'<4"YN@\HQ7U[5VFMPOU5W]M-VE5=X<R+^FZ)
M1'=5_#R("BSE@3)SN-ZXE!M4(/X1]C"@]AJ(P'G+P;WM"3<'M*S]!76OV!._
MP=O\/PFCB=X[<^2E0Q_Y']DH[<ZC@RL5WY5\Y=KVXJ6=+ ;$ELI>&OF?7VY"
M4TGY3[ #.WB^56/K+4Q\:MMK)>, 7_:P:8RY&'@^L%'8,&D)M7W6$KP5ZG:<
MIX M(#.S][8C"'%]9FEQ=GJ:]^!NDO^9WMMNIT#M#CO''\PT"24C;]ES05KF
M.B&<BVS'+2S,END7AH]Z#T[@>_@;6&:Z)5MMJ,U4/@CAPQBTH>6<![&0$?X=
MW#G^PAQQNY) ^=!P[8,(V\$3XR3R,5% X%A"N <Q:/HY]AX6,8;Q'>RV R:3
MV22R>@*..-[2Y4H$G\7I]O[:$=K R(&MY=*!D<F</=Z6ENLZ]IWC.M$3KA+C
M9# **]#/^Q5;V(T+3X1M =5P[F+C0?(>9)3S(-_Q BC945F9[FCT2*G')[,S
M,RR- 2:1_0>*"$KL?.[':.9QLZD-=@!'VS\X"Q1!%(-$DC!T*;R%6];(_H$F
M%?ZQLB/RZ+@NVVH7CCYW\.G-!AR5C9&M,/SLH7=VB+:</_$_8%3#A</.0>01
M1)L67I1_ZLK&^S#V7BY?7?*)VU7W"9?DA"F=L.3<L8CI4!8M5YW^N!1GT4MJ
M6';'<EQC8&GLCV09PX+E%7YG9,'2XC!F5,@$("/\+!:X H,5K80^P%?@_WD^
M&N1'^XDK]!S8QW:,OQ;$D04"S*8Q<P@N)XJX#V5<F%.T7UZ.U6&7W$@2DSN.
M2,%&&/J@M?@7^"5H"M-T)DMSS*DLF'MDINLI>P:01I=+BI1_C).MQS4#M7[
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M9*X^#4F&)$.2*2/(O_Z\.$9;IYPI)UGE<%64@@\&ZE]&D/[Q</.M(4)Y B3
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M%[FIG_EQG_E!GU=B[_#V \0F"L#*Q&S>/=LK+Z+WO&$EV:SKO"RDFE^X-MF
MC5F"[_1)% !3P ZL^6/PL3?N'/X5;H %_A(-T#R(06AJBQE[)",6#C? [@=G
M3CM+2BL..CGA0IO#W[W 1AP<F0[/>%=X"ZS$WTY7X#\ HWWO(+.(+[ZW':^X
MF/P^^3'2GOX&/L[,8K*^7>>Y[%7%S^)K2TRH]5ZC;9FV#7/:)HHN47^J;/#5
M5@-\55?"/1I5J"/_;(75Q#W]%/CQIO/HH!FVN6Y(3GYM>_'23AX&RH-^O6KI
MX?[>M=I4\-_FZ9"^)'N%G%&J7MG13)45NJC/8 RP(YQY(U!JX!ZG\5T]1CQ[
MHW>8ET.HXEJ.'W)]9NB942JK>BZTS(P$=_/\E^"<48'C_-HPEBM\_*JX>.H]
M.('OX<_PH8P4OBYZ;[N=PC8?8MAL(2]%N5_[H"QV\,0H)PM8-_QA]011A.,M
M7:X 8-)N MQD>!-[^O^%/?TSA@?Q7<7 !4@6'P;S/6?<LJ6EN8Y]Y[A.](0K
MPI@=%K "E;M?;7$KQGQFYG.4,Y_?L6H")8J=1B09NJ/1(Z4>^?SSUV_<0DAC
MI$ED_X'B@#49\[D?HY+A\8+:H'ZP&.?!6<0H0R!:B=1@!%-XRQ7[.;)_H)6$
M?ZSLB#S":85MM0O'L#OX]&;C H<P !9"QAYZ9X?P1+'N_X Y"Q<..Y.11Q!C
M6GA1_JDK&XM(V'NY?'7))VY7W"=<DA.F=,*2<T>T0M!<=1+E4IS%@*F>[0[I
MF!;BTM@?R3*&!<LK_,[(@J7%8<RHD E 1OB9(P1KX$8KH0_P%?A_G@_QN_MH
M/_$ : [L8SO&7POB&.)[F:5BU@%,;A2YE,L"<&$.!P$,FF16AUUR(TE,[M2R
M)QJSF2S-,;^S8 X6-=Q[RIX!I-'EDB+E'^-DZW'-0*T?<"9SDPJ?8@SE'\?Z
MH$2@PD3BX+SK^'&87WPF?$**(A]-9<[0+MDA>M8=DCMQB,Y5(47).3D1EZP4
M"<4F%K88GS&RQLE!O$MN?R1A?AJ,BC74"@;KKWS4[3>Y\I3KH$"!?2^I;H4!
M>;1#Q)+NO>X:ZYM9WW'.^M[:@0=B$!+PD"(=\^;V]V]O46/GMCN/N38DW&4;
M@WOKI4,P8#.YETLL)'O*"H(T./SC1]-LS\VGHS8"?L1'I[_)/T/F\,9>H$PG
MZ5J1-=W^^=]O/MUVWG^]O?E[Y^;G[[=?KX6!>D?^]?GC]U^N07IZKV5VRE_^
M?OOO[YV;7S]_^@)1/W"?!EN_AOP'$3E0$,CNBSVV\4PZKU'DG>537ACZ(/E,
M&K"U$U^?7]"!;"NR/?\$D2:/_,VVTIOMWRV\?5"Y:;6W? 3?;H:_Y<JGG"0T
MOZ%5+^SW^GUF\^ ?%O-7$']"\,D<-G-N+#I*@R(_;U-!U?L]:_".?/8\T$+F
MF_Y!P?]@!J@@%?MYC-O+A(-4[YG$'6X,N%C\]57O%6B(BV827GR?_BR>PG[.
M"Q(PQK4W(;U._O&*L/GC8&3+JG74W7O_1:Y3*@SQ74!^8MO*_X4C'Q+G%KZM
M?^=UAJNZ@R@\]/<Y.=:'#;EK(_&K7,@N?L<#][VC/ZQ#AWZTG3^'BTEVX;&7
M6WU5N55,X O:\Z&Y^&4^G2]^F4NL[.730%4^'2P]/%4K?JC'G.&E,&<KTSY(
M$<5SV*!&&49K>I$^-3!2(J6&14_7UNLJ1NW_WN3UN9A !@D(1._H@B -F""N
MG?I']Z1JP(/CD;"5)_YB"2>=XX<\J4_\0%R4C*RCJ^9K,<$4TA^[1;_ICR%.
MI@EVOWJET?5=ZVBJ7M%T#>I$\#0>JX>@54<R=21*;)DUTU+=DA;/_J!!>!4U
MVH8-BL=S*3+#&PWD@"')D&1(:B=):OCALW9A8TN,%ZL+UE&*4_M#9;$ZU%5J
M0T#;"" =!=,C6\^>8X/288;[-J$4R>#/D;KC)4JIPF?<PK6(%G7GRFKD-$8:
M2%)G(NX'FAQXI4:IB,GH/9<B,]NW!<=V0Y(AR9!D2#)9/3/;=_<Q;CQ1_QAG
M"# $//O<IBS8:)52'U]B:;)]9K9O2:[$_$]KHE[-646YDGHU9B4B9J,&T_G&
M9QRK%_V>!C=$G6DR>E*!^CW=G(8.TWVE(&J@[+1KG<R2V82S$T Z TO];2!]
MRQPDS"3?YT9)XE Z4Z\?1S^[-%"P"46#+J&M;5PS#8[4G=%, 3=A1GL<3>#)
M23&C/4XTVL-(R)%C-K8C?^_ ^C[5U V&S&FF:N@P5:.$>AY&]GI#%G'DY'?4
M]F2\9PZ26S$5@^!4C J!R$@Q-J#>F <_U\TCP])+P+@<?!J$)8Y<X+[' *[M
M^X R4.MG#%QX]IR!O4,8"JCZ\/;(X?"A:)O6&X[+S<A]A%T+J+V&92-0<'!O
M>\+GP.K7_H*Z5\=-I)#67QZ <="TB-UCD'*C$[9-@,@5'/(]V3*JH6I)-;=E
MR[0%MN#,VI2F.U1,8]@W9"%92FZX#7]PG5D1F0>!J":R';>P,%OFES!06^9!
M%.?M2*J4S(_BT.S)8"!Y]@GLM!@C=>R8L+\<#"YM4' ;1,&UB-(PN.G RFTD
M'OI[-6%P][+APF%P3R F&L/@9E-@#0SN2:3J$F!PFU<Y X-[@O3P_D+V2X;!
MS2SA0.2C^M;1UQD:,$$<RX^_9U:>!X;P2R.<#(87!WPL$2_P F?3T\)_FW(3
M X&[70JMGKB GZI73%#?KX[Z6E(W;K(LK3UD*5BX64<4C[?S;28KA;VU&BQK
M.Y7/,K"W!Q'8&D]L8&_5+K\T)!F2#$GJD:2&'S:PAL\D20Z]1?WH9*1>M'J"
MK&IK:#$$G)N YV0KVT-$@FDX:S+?H\:]GSFN/9<B@VG8@IC,D&1(,B09DLR1
MS6 :;CG#B8J:@;JP//H<&PP!YR: - G??G:E[@\4N&=3O39$=TQ#2:X$ZMEX
MJ(&26#WU$WUD,%86@E4CG]%7%H^DK-M6DZ"^QF5<#J*A9%F%)*D[$E$CV]09
M*HL@)A&AA8%M<M;[V5S=V)PH#+CA<X^GHFQ@H+Y:*T\ &?0TN*G6X#PZ4;#D
MNZS:XV&#:60-2@4,JJ%!-32HAFV3D!VHAON9?RK P@3F*6126GX)PW<R@(8Z
M !KNE86MJ(72-\5W2B!U-^X<WKC 2VKG+JY]37TA6[\#S/ 00-/:$(-ER#X)
MMZT:9?!@A,!G0"C6I"+!>=P#EU@+A? HE-A"3> V>,)WSP..K+^ #.>PMGTO
MX17601BL!#3<@H]8@7]81!7, QU6 "-683IN02Q\(9Q!$<*+2'K[YW^_^73;
M>?_U]N;OG9N?O]]^O09B'^TG8,&_/G_\_LLU*8(%RE_^?OOO[YV;7S]_^@)F
M .BDP=:OH34!@W>@62.[<SS,C#%;>XVL=Y9/>=/6[W6Y;9OTP'+!Z_,+.I!M
M1;;GGR".3HCON*6L:_MWJZ$@"YM6=\OQR\VPMUQ4EQ.$YO>SZH7]7K_/U(OA
M/084#-?<<1UNV)DM8*"'S+IE$%L$_%6_9PW>D6_P7?_/PO8;G,X7Q>GL*PW3
MN9?"0W^O)DSG7C;D<P:7A]-Y CG1&*<SY5;#.)W*T7^P5!R!OZD:.&GSJF3P
M-T]PD;&_Z>*2\3<S"R>R)Z/C[PS5YT&_?UH,OG83?[D;?[&$D]G1@]/5IUU8
MO.GPZ%J56CPPI5 &>'.[$(H;[>%0(V3*1AQJJ\DZVFJVF"H-22)]!:>.US<:
MLUZ#<G@J-V6P-@\BL#7.UV!MZFX=#4F&)$-2VTA2PP\;K,VF2"(=D8>83=0[
M FIQX&LP$]H:&I0GX!F9R?;0D*CV>*A Y[U!V3R(0&4/:@9ETY!D2#(D&9*>
M3Y(YK%TFRJ84XHF&P]Y86<0#=57=$- V HBRP% 5*CU2X'I-]2H0W2$V);&:
MFKS2^0E0%T]&HSU0/U1";6Y0DHQWN!PT3<D4-5F_8XS1T>&>\C0H3P#I6.K'
M1F3:( JH\0@7!* I&Z.)\0F&@(LG@%@Z%))TK%&#P84&%_\&,]-@9AZ&F6EV
MLA:V9<6><<2VW9"7ST2\3,7"3B$NF4!XY><:,,MG@UGN131\%D!>;<# +="&
M',.*L!?1>V>.$N'0QZOC< ^E]Y=A%G=@$AZ(B5<%8L@>6X.5^_$#RPM\&5P]
M@PO6("Z8I30N6(K?OHW"0W^O)B[87C9<.B[8">1$8URP;"K"9>*"'2TMEX +
MUKPJ&5RP$R1K]I>)7C(N6&;A1 O+I'_T=##U>= ?'#WZ1GWBK:/;$I6G_6()
M)Y.C&];4IWTDRC^/'W):BP?FAM?@@NVPNJ)SM*?>%/#3.M0VDS50KXCE=$ZP
MQ201:Z;C3I&T%ZE!ZM1H<3/MYL^ER.""F?980Y(AR9#43I+4\,,&%ZRY@=LB
M#V$-&RPK/Q<Q*A[X&LR$MH8&Y0EX1F:R/30DN&#3)H'$U;C=,P>UYU)D<,%:
M$(T9D@Q)AB1#DCFL&8@7*:Z;SI3%/]+HB&#VX.P$D(ZR[9LY=388+P;CY9F)
M+V7[^76R1J.CJU=;0X3R!, N:. 4K+Y!>3$H+\]4A,%,_3L=Y0D@ZD(V:[0)
MUD2#F\&.-6KPT*G!38X!>C% +P;H11N@E^UH( GN2\ADK/P2_.;N=QLTF-.@
MP=3<P#*\2O;9+5 OST%SR;]*6MT.4)=]PAUNAV#9!EB$5-_;CA>29>"O&56+
M7-.^G1BMVII0 2_S,G OPMD+G[O]\[_??+KMO/]Z>_/WSLW/WV^_7D,<\F@_
M 8_^]?GC]U^N21&S1?[R]]M_?^_<_/KYTQ>0-N 1#;9^#846].I [2&[SX!,
M6YA*7^-6.\NGO ;U>UVN0A.$WH#7YQ=T(-N*;,\_0019"+.SY7YN^W>K$7D*
MFU9WR_'+S;"W?#N:$X3F][/JA?U>O\\4#&%W0.OGOC=W7(=;%J:G,O@,"S\D
M9 0"YK'?LP;O$"]AXR,,54$2#'+2BR(G]95&3MI+X:&_5Q,Y:2\;#D5.TH;P
MP_?_ $0DU?"C4FXUC(BD&W+4T5)U"<A)S:N<04XZ0?9S?R'=)2,G999P</0=
MC_*T&\(-X89PO0D_M7TSM1'/QT=RP0\K=[M:0_0ZXJZK=[P,MI@\#4E2<.1C
M'3'4"$4HHVK4)'Q0>\CJ#"<-%H&JT>%CNFV?2]'INVTU]=&&)$.2(<F09'IM
MSUDX_VW_'"/EA*L<V8TL]8X7RNNX(:!M!!#USFT5NMQK$&7+Y! OI^<VDR%K
MHFR?H3[&2'D"5,SNE6F8*@N&D1$Q,1[!=-P^4P\FZN(P:&12S3'M[ 20\?%S
MC=I#1&?:H"BI4=UG^FU;UH]G;>_2K.P0"P]MPC3,WM826R@RSU>7Y\O*\P7E
M5V(S\.*MW/4(.T#OQ71WL4'76QH(=P]]CP+@C,-;(PDPZ,&94[*D-'F,M.O9
MVLU^UVMV#??GM&MWO^YM1RVTOL([(FQ(>Z!,8]<;ES*QLXE''X&% ;77L#CX
M@A_<VYYHBX$UKOT%=:_8,[[!\_T_"5LKO7?FV$/MP+>S599[<G=TQ^ZAU'9#
M/R5W">8'A27.7T^SOMI,AWAC+/X2[Z;AK=A^YWBV-W>0VY4-XM);X*N("Q#9
MCIL^[F4Z84W[7H/M>Y;2[7LI-LLV"@_]O9KM>WO9H&O[W@GV7VK?4XX++]R6
MIUK[XM'2<DQ;GFH]B\VKDFG+.T&.9'_-S26WY4FH?Q?7EO=LM$!#N"'<$*X&
MX:>V;^8"U;3E;1.]SDC!^2>GLR6&I!>5OJ%ZM\MU=,H:J%>'5(>NL0K#54P[
MWD$$ML;7FG8\U>M6#$F&)$.2>B2IX8E-GT4#4R^&&LQB-P2<FP X":AWP*D8
MZ311#XJH1$5?@2DVJB<*M>RTD+79:K!=QQC5"R6 6#T-YH+UA\IV'4D:W1\K
MX!9,L\71!)Z<E.:'F[6N_M\/HB7(H\]+_Y=^L.:/P<?>N'/X5[@!%OA+'*,V
M#V+;K3]C:U\W 9N8Q;]3*ECG[UY@9;QS%^,SWNTH$-_1UV"$<5LS2JXY88NT
M>!)C6?H9%N5AOIGU @%[G045@A?0.74>L#R]MH T5]9_510 ZCTX@>_AS_"A
M0IO+X<.\S$2L^E+<V$2LOIF(I>A$K*_Y&5C@W-AHK-P8+-0QS_<Z[)=K:H<Q
M_(7D)F/A1Y8!.(RY':[(TO4?F6K_$.YEQ<=#XLQ.> /^R-Z2]ZI^')"O_ISU
M0"6_KSU?ZV02+XPY:_P9,<'YCC9K!48M62C$!S%H1!!&P :T4X)&-L60SPR;
MO0O)A@;,:_,OPIN!(X$3 M<?G6C%OK$)''C8$[6#*_*(/](0]7Z1L:R!C>&[
M@NN4]T7RZE4;<446,>](@\]*^P:$1.PF- Z AO_&=@!F*A&C;DLV+'=5RTQ]
MR!T-R*9=' ,G))%Q>Q/?N4ZX K8THQ#I-HJ/736Z&=W+ZE\[[)!$N)"16E*6
M"MER>>#EU9Y#-7?CK[)X=%(^_)VT+T_*'& #WNE;(PK4#;97NQ;YL/V3.[CW
MS.<?1]2.I3Z+J+U9ZC/0JN &*M<;F^N(A=@"_%4(YG\!3T>OP(YHCTY(+[A9
M]M#?DZ^)8PZ3WZ3.71\NDM_2:"%I&$R#AO0W/,80/Z7QA_@Y/Z=:_+)V?[T2
M3-K*O$] )O&]4N=JUK,,P5B)K^DO../5XU.J&D61*$A,\F,ZS[S<XIOCE.!'
MB5\OV8Y9"DLOJATSZP=Y7D%00RU+L_.U+%DBNS\^'JVRY4QH67N:(5,7D3Z5
MS=6MRN8SOYQ@WM$.0W_NL&"=I?D\AZI7\E^6N)% SAJHUX-7KCF83!L<UG4V
M*JPAWY/12(-BELXY(3<OUFQ%%&]9L]OZ]!(XN[JMJ -07]H(8I<KB^.O42$>
M;(2E@?4",F:]!DNTS6'WH,.NB+_NZ!+OX2+[AW(252/H[X]%L9I.8XD5#\KJ
MT)6&:1,M(02L'B=O,FVP7\M$< <=/,'BZ7#([(C21\M2_Y!I"#@W :<1)Q.9
M'129?:&1JAW)=4(RX=I["G:EF9!,VY!L*FX'QN?$0+ILN_?>#ITYH7;@.=X]
MJ_\EX0J1@K"^YX#:'76$SNIU%9R,6<=:]+H#/<W@N#M2#V.C!F&#[K3!G**Q
M?$7NLT=<.Q$L:EXV?;?+)9WS(3;V#X)C:/:"UHLX_5#H^C9)9"5/))?<M5XK
M1YAV1T+E"*@C6M:L.VE0MDSJK5[J+>G254RBE%<)0X"^!+3; NP_]7W(H[WJ
MF_BRQ%WD:*I>XLOHW[D).)> F="F7FC#S)BC?4WK;*8#?M9LIEYR2GD+9LI7
MY96<UTQ5U+!RU'U6R"I5LNI:R#I2[Q)+.P.@/ &-2Y))FQ]^='0NH8XU">TG
M3>)!MX<\)0.R_71I2%+:U#9I<@B6B=X./V1J5K\Z5K!>0'E]UXZ TXB3"<L.
M#\L\K8M8DV+(WDR]22DF'M.()&(-$DDT!?MG-7AW%U>].NYJ>AKM=8?&_"E!
M$AEUIPJ<0]6U>[O+5IGAH\?6KO8UKEVU0#!-\:HAX"2R-3;%JZ9X]6)4PA"@
M+P'&]AQ[YOPY-RRC9L0U4#GBJI<'Z4_5J^RH<R8=]76D2T.2B"6N("9C!<!]
M3C6DLU>>TZ+7D,[>Z4EI?$AGN<N4."$X$7<>\_E)=DAD="2$JG<6\/N[)U*"
MB^L:/F^;/[DE+5)F=ND^7^9X=7638;O$]D&.[6QN67Z&&!_%0 (J1L.%R< .
M8#*;A(F3/8'=.([B_['XK#%6O9^,$..CQ7#.F1A')@]NQ<$-.%(,OM:3+CR/
MVJ*_F)F:SYNI.;B F9IF'%W+QM&-%!E'USX"CG9C^T6KV9%K90[M>/ZAWSJ.
MP&;GYXWJIU1._;"+W&^UQ^V9F7JU?T_R.;ODMW .4'BT'ODH@NETWED:5+-
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MUM$6L$5$J-LQ)?NBL09$:"%-YYQ8>*'.0O$ZK@J[JH-ST,$BJ3<(]_B[&4-
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M*F =F,,6U5S)(1I_16Y_"-35%% IC\E!$/&GSIQ>&=J5@7/5AU)+X'D<1%R
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M@2+T>NT_4%&J'4'(#6Z;V1&P6FGP<?.):^$*GD&#^A=-"2MQ%YD,D.JMD;C
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M$NF($MM13]FK"*DN(AD,/C[C\-]+-51?<M@+F*AGH.+%-E2Y\10_*#6E*B>
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MW;FF#Y=N-U_:Y=I84T17!17Q]A^QTLN#+_(GEF+&>1@729%%A%$P^$;%B?;
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MNJ53,?:_$2@!/NH:9@Q,!&MO4JX8$IP!W&L7[R"#EZ<E5",LX@SS0M87IX6
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M/%Y*K]T&6[YE?-4LFR;Z9&$C;W)RI\HY7Z6#,Y](D=/">KUSHNX1>G*&M"F
M/$0%YE<^<6:,&<=PX1X*K2?5@>CM=V9>,IWX,/J4#83&'?+=C/S_VA!TW4TZ
MD$+Y JY5KMU1I2?=10>+83?SD3&9G7B: [S)W6\@ 3 QPFS$FX!G5W;6[0$N
MS6.IH7C@Y[Y.09Y)$71D,?\$&7"NT"=)JQKY*$3S&Z5BQ]ZV :>JY4[>\# N
MAR7%>SU>"-,7.__\"//W1\?G3V.C'MFFX^QGPY9FM#-?+RCVH]FQ(TT<0]AQ
MT&'T@05]A7,1ST<RP5[9S)"F0"LWY-QVE 5'%ZD\X['\KOGA+7XY46"#%J'9
M3HG3-/(]9_)&H3*)1$_)F[1KDSF3N"2M=N>>??;ZX4 Y9I&J(?JE=)S,#GZ>
M0\Q#686#?!K'R36KJA-_N@5CVX*%H P.VDAGLQ?"9P5*'#DJ4,]&XV?NT7L;
M81OV5N*A<A3<"S;+UI'+QOBD2Y]WYY"WP9 3BRA3)74 8\,^.O9UW#(P&0Y
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MA;D$%;7'H41[W=9?^B@[ $"8% G/<KT_D;IBF8\Y--CQ%EET@S;0<@ $V6?
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MT^PT\K3O !*QF;U\ALW\;,:OHI4WY0V($,]=L5QD\-)8/X6W%H LL^!/;M6
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M=<KO[K7WJJ1_V#ZLDGZW8R^#,92I_O A5$_O>PJJY]'6Z(KK^L26P6(IE6K
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MIFO!CJ-"69<-RQB#*KFA\Q0(%UW[LW)V0#8V_[W%0B-L>Q],P(!)Q!@@T%:
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ML!_+B-2MK?7YS4W$;K"1274)I&PU($L?K>Z#VU_S[M>;VU];V[:_'K2&.C7
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M"#N3&!'?OJX(+ZVSI8^Z!2$*)K!EA-H7*@)8D)-<D;%%EJ*][%2M),6M1"$
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M.OS:'3@M<C?UW"GN.6X9A1LQ$L'O26/A?N 7'\#SF"L=&2OU&?"D/TXG$R^
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ME.2"#?T4Z*=;K=1HL)#:!Y (4B'V$@:26\K<&(7%3WB-D.4>4$D44)0S(%O
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M?:9.3P/&L)78'3:V/WIA:[H:R%WED@]TD+O60"5E. >$Q@C>[=#_W@L#BEW
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M'A9AQ*OMU'$$]>.0UQ0!^+SD9 Q4Z8=S47@![RE!>\WB!!Z"E74NYB77AX0
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M\W%!F1P"$"/^"P\8QDO1NY6,\8*8D"]E*LHD91%<#POW7*&+_=#]R8>S <Z
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M^,<,+ .KL+"VRS]VQ3UKQD[K[-BS S%]Q/#W[;8&*^<%,7@:/+<1S\H=U#=
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M43M-0PS@#.5N/6J6->]N#2)T=>YA1\N*@VWQ,[6?:]$8  9 Y0$H/],VHV
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M>^S:Y5YDQ@66%6&#9[GP-/WURXAGY?JQ*R_5P4&G,A@W5)^@;G7RCJJ(L^I
MWSFLC)=JOW&@DZY>]S0;+Y6!96 96,9+96 96*7W4H&E&[@B9%_KK,>G,Q&$
MQAPL*<(&SW+A63D&KAS"53%N38=V@W,Y<:Y.4:#IT&Y@&5@&UEO#,OXI \O
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M8%^$ZY9!."G=NW5DF&G3S'3&/4>X[(MOC<(HX&%8!G[J-IY<@&08Z8E$_QS
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M6&/A; Q\\9%=??_]:I<(IIZ_$E.&(Y)9+_*MGQD@5__JG>]JY09'\R*-CL>
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M:2B=!K%G<_Q%]ICT8^P8.!X[$7T!/AGZ(),\X U!?0"IYQ]LC/ LU<,0!=5
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MZ&F2>2I$,!</XT1ZE5J!$M'(<RS\+3-J67A)4U9X%"X9F_)+5 #KUP3V /^
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M#_IU;CLOGC2A*WB'S-*J4*;.)5C!>Y*F?OE-#,?!FCN@'/FXAY+6'(0N5MZ
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M(\?M&X[>I^PU%D!1/-0#&]VY:75EZ&CYQQC93AI4:TO=XHTTR<(?1 2D7!T
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MLK_8S.S9^W<MEK2*/\/Z.)B#-V;%\X?JSEO/+\!<XB.K+L[X9[A"_TP;/6#
M3,M[7C_*=?3H!^:ZKZA3^,3+(YY.*S:=L7%RR7HBPMGCW([L'LBHT )'2?=!
M'R/?V2GF9J1\(K@1<^4L0M@49$,,BO!, "=&Q(1#(8?PP0C_5 (4^FK3\X($
MG3"SN;7(-XO,:(\B)7>%9)HQ#P_=@0SF0EO;&A4//,5=.;,QJ9A4A 3(16]_
M-XA^P!MH[^$+P@+CO#"J$HAT6"B9B8YA-L[0&4/E0%SI?$4PRD$FN+\N<'(Y
MSD>'S?CM6O$XQ;^L'[C:-#LP<]DQ,HUV=B*U@!,Z!F;+I;*DO%+PLCBKW9 0
M1[J#ZIT ]4 9_QM<63SC8(R0 \?T6$KX*L<?D6_LQ\U;G0%"8([3$^= _![>
M#=7,:A/U0D0"5H$T94761]_#<M)OEY9MC*XN%) PELJH'J BF)0B$>2M# V)
M@6%/TA2<%#KM9UYDXN^]7(6W0C4\%<I) ?.4II+Q& P6?P(]?RW20:@>QCW#
MBZ4V*JE$&L>0SMQXVA"Z&:)I\)GEF!TGL@=B[D 50W8@;D0B,_+VD'I?,^0Y
MC&.M^LJM!C#1."?:2CYP,3EN@W:*4BICH89@RA@/(PCJ=1:S5L+Q)\&=Q\8M
MD:RO\*!J-U4[<2=YM2F[+]-^01E,DY02GKZ&D#U9Y&%L"RAB_#:4[9= 1OEW
MQP1DC0?+<U05(N-F*^ 3V(HAZF/,[X!2AA>3@P&;R"+!P/\ B(VW[PF=8QJO
M$*A\,JG]L8Y3#+Y*V,8-7?2<6M(CL Q'8.G3_MH0T0-ZRH^KL^>R)H:8G?7=
M(>_,1J?+0V\Y&]UA> 8)6/R5@"TVVZ&M;P?_!\2+-5K<ANH1&-IX29-(6&01
M^LG#6K@ &1P,(C1KE!@6"2\C_3YJF,Z/6K A!MPHBM040B4R'6(6$C2D'=\]
M)P9 Q%$"1"@:CW#:!B J@-OL6<4+R $Q-QA3T2&FM_LQJ7?2SG-J)5YCK413
M"$G!:CB%?5*_UDWK MM$B8FXG*0N9FUM8\]M74P>,1":_G=*H&%.0G82:QU$
MNQ,^:0K%#%,%SIT-]5DV%,E@4Z!T^H9@^G;$Z1LQ'GSM^PKP/)?PUYD0*+"6
M3P*[U;["%V9F$#1[2Z__<+47BW9ID$B>_X+\YE_ES;:AY)>"A N<C+%=(FP4
MV!*W54L$CV;$M/"N] 3[AWW$CGU$O=3XVT1[.T.SD+>(K0R#]1(>73\H09NU
MP_BO>OSOQ_;V=;NW3[BW7335_S+U&AQ,*3X4K%]8E;@QDH72+^YSN]_]\KH]
MS$^YX58/69^$4OWWN+V['[;>_MS\_;WMPD?;^BLPT)Q]#Q:\ .\\'I>9M2UV
M-8JU+=Z@G".Z5JK4TG#=KQSL.P7>:S=3<=)AOQ:I@#^*(3REP[Y&N43!CV;A
M@8A(]EN'%FPJE].P87U_6PS-"/C A/VQ>B%R">$M^[Z1RZ7 U=,,,P<8"Q?"
M^"%]/@7O!,QM&SMT-[:6..:VS'UPA8X$9'+<Q"H'>[7#1M.>BHT]FXVFFG(3
M[CXV(8'&?1S%8(OEFOU;QN15 4DR>$\0?9,1T!-<*1WW$K&UK)G6! 'QZQ:[
M$'$Z JKF;,-0=W_$8W6O>J UZ9YTDR^WV)E4X'--V<;O<20VVQUNV Z?XVC)
MA+.-4P%"^ 1\_TQ0 ,"7=K>[W9S=+N=CWZLUU^[I$^YI,!RV/:F-V=5R,F*[
MJ8W95#\6K-W3QNSIG*$!_]QA\U$C?V"7/[2;_(2;7!EZU![>QNQK!?"\W=<F
M[>LLVF\KEINVS26297MV&[.I)8Q;&Z.XMVQ3B[K@"FP.9%10S66C8!:6KE=K
M7K.E23U=!!6A][Z52YW2R62RE5I*;T5R_-)70+^T_72;6(2*97,O?5G@YC*%
MJ?>S,Q\>9V/" XTVET7GNA=X+M/FSF]$4"KMLKQE EC'6*T OXN5N1$PQ=;R
MU&V!E A(Z<UV"Z3T\$!*W:(?FYZ?_1)3P_>0MJ!*=U;O:P&J=%EDJ$BT!5Z
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M-)#H!SSG88TQ_NBL1EUG;AJD=_]Y(+=LH?.I .U^$ ^IIGP?'L<V3@_V7SC
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MV:@!0V.\O,<HPR:*CJ"!JNI"AQ@A.!X,M2JH7EWA+^KJH;8JH,Z 73KW^^L
M-$$[!J = _!HO0%M ?ESV>"V-Z!16_OX8P#>MKT!;6_ :F]O$_C@"GL#,-8$
M@OT!^@-:J?ZD"GL+O*2^PB1:NZ<-V=/#+78@1Q0':/>T(7OZ8$T?[;8^\;;V
M!8;MV+%,_^:);+>V[1-H^P2^.[+9M@FT;0*KN-JV3:!M$WC -H$W;9O P[<)
M7$8QU7T9!$&JSH'?#*=MZT#;.G"[U7)F2IAT68FID9<0\CSJ4,9UT]:*=."$
M6[ZB\@Y;D2JXBD8L5X1[3B4W6A="N]KYGJ)4FX<@M+5B#1PZP$Y24SU?+FS>
M+ '>DT6.]:NFD+5?%A>6B( 6&L\5@)4U-PX@/MRCRJX8W//*U@0EVP%29@_D
MQ0B69ZKTP=!YL>+D[VJ@;AY2GVI4M,CSA;BK'OG6TQ1K(9'I [).JYS>8%I)
MJN*"&]**7>5P68@85(RZCV9)NH@S21P8]KP@-740<F8S1(#K"0D)9?NN,DGU
M5-S )MN*/*SOH;X9QWH+F>X;?2.KZC,[@OF9/-13!-0AG8.L!XIBR8.9CWCN
M $?=L <^13UDH9'E)*5"<"5,X5!?B#'\CXX5[R5B'J(M_JJN_;\I -H>GH;V
M\ 3]!.@,Q@BG/"QBDYZ6YD0'S%E1+OB=KYX_2<%ERHO<%"WOQ9)*=4%$7OCS
M_N5D[V+%*R KI;,S>@+6B0T"KE;8U1>O]I(7-EC@/B]H*?$0QX."VB@=VZPV
M)<X7'9!>$2?]S2)S!L2E.R7&=;5UYX,BM=6=L]T[,ZP4VYKW "Z_[!Z;?_]$
M<!!C./FE+0]MRT,?J3ST3?-S8BNRP6UY:*.V]K'+0]^UT-%-+@_=?=M6AZX$
M&_RZ!4Y&G(ZXZN</41[:*NSFE8>V>_J4>WJTQ6[ 3?DD"Q#<+2YM4[;U<HN=
M206^[[U6_;9'M7F8X&NPI[==^&C;W=9WM*6I;6EJ6YJZVJMM2U/;TM0'+$U]
MVY:F/GQIJM4]&)QYZ,+)I93(E==Q]$Z4"@PKH>!T@2 U4&3T,0U1$=H,GN9)
M B_)K\4(5D?XMU@IE3J,3G,8,X4@2:S'$Y?[S>1$*-83^42(-!S ;('@#O\2
M44&H75Y);[$3O#+63,E$=((?T7O_LMJ54C8_K(-,;,4 6>W5718$^&2X TU,
M++"EW/7AU]5>V:%E=5]LM7!,\T2J:R8& ZRGNA') ]8S/,J."ELNR8>8<>B8
M=S?G5Z9TQ@TE;*T"&LX=+!,:2\I41/!WK@JB!5S#$SDLS,\]B<"RB6+\X>:8
ML+-7FV".461* \V1!A8;SY0YIV)B*6;3L:;4 ^@$]"KP<M$O+) C7H]?Z@PH
M! +];U^5BN*X<I=F$,T?K++(Q<*(AS5%98'N:J_ZG$X)++L\"J[\$_6"A5P%
MR5*D#MK3:=)2^LS1H-_FB57UYQV?E 2KDL=7/\V69X/C[VR7CBV[G;%GJ'BM
MZ"5QM +VY>]Q)#:-*8?O?@KVA*DR/P'B87 #*&@^." D6+F\&5I;XOW%[.:M
MXZ'"7TL0[MG8Y<%>CK@1@P.9)')""/&U0NP5MX!/:WX'EI]S;6P"6'LBL;Y!
MU\U^1J#W$<]X%.<8!6F><"L),S5%P@B/'72A5/0].@U6#XI%/2H!^3I8%X3,
M-!G%T6@><5.9.R#JYQ/XK)T-GFCI2M UQ0!MGXDV?D<UE$N_V5I7*8?<Q )5
MP.ZL!1YT8Z7?,W"#_R0N1A,87'[@\&C$TUB/=6=^8)[)(B=,;H*2EXD( ./G
MKWF+7=WV]3)"=\7;7<UI,*NT<L6W6<8!299T*E9?QBY<M.M1$S<T*F. DY[,
MT!7I.K6 ._XL8@?''R-N,V4@B(<U""=;@@D_<+[MT]D6>$#\5M>,QEL/#:AE
M=#A,.7AORO*)K%$*KNGAN*>J;F(;8)3WX'SVZ=DOMAXGL?B]X? R+LI!(,4T
MY.PR'L/VN=(.$ XUNIWS7*'NV0.1A%\OI&&'P<I&=@]*KX73AIQ1R].;#K6B
MW4:E9^-S?)*I5 @-0*08B_19*)-N(OYBGQ4OA-F= ] >(F&_@U69P/Y,A!+!
MWLZLP;1=1G*(,/7>W,)3#<^AJ1K8K!2-8I (IEV='/$13P;A;)@M;(1G!R(R
MAP#V=*?#SD#UV#?+.'7R\ F?,AM#Q'IMN,/N]C,_(K@*1TUO*MH^)W*Y;0C0
MU168YB4IS*6F6-F+"--D<HM=]FRX_8RG=FI9D:-4KS8S'BM99,^#_Z-(FD@C
MV+_X<A&81*]!KJ!2HND);,<I@*[YFN3/2>J*!:A?8(DJ W9KF<&+3LV(2N)Q
MG#N;+<4Y#W:4$ Y)NLVB"NMM3.W3_*1@P!(Y]3*;O.,_?MK^B>%,,(WN8CKT
M?]N[T-_53"70.>&9%K^X?_QDBJ_^\=.<Y&VNV WM OX<WZ?Z/5[1=_?_:&ND
M=EY]K%_U71Q23='7^&,VL6JX,N_/ON _YW_,[,+(OGJ,-P8U^%<\+L8L-8U*
M_]53[.4_J5_)\LN/K D^4/7-F[-H>"D\R/_XZ4V=,9P0JF:Q7]F<]!)/^PY6
M>7??K#)/EI3R;7GZ5IG#O[>I[MOY>1Y)OOV[5]L_/\YZ09$\Z%(?B-=V@-<<
M9S2![;Y2\#V)-5IC1K,@N)0N,E\M.HI!L:#P%K^ "3$!%49.7'?[XXZI#_K>
M?7P"H;> %]_<WQ)6C>_FO(A_4%VOW\,&?+^>_/'U/?A*PNB(X;1*_&/'&/#U
MM[#E=O9(F?_8PKM/8/M2BR$-L02W1>K0+6(] _ U8'WKXE+ 1,X]T_"O@MP!
M3<$#I\^WOH?X\"=:>,_?U'[])*9V:5N#LXM>5U T2:YF#WZ[B=X9O #L46":
MMX9X:XBWAOAS,,0-%)<3GE1JAL?9)D8206%8'X#H'J^-X?Y%&H'5FN_/B%DI
M+V CF9@0 056F97=/6:8(0BM@9"/OW\WGX\1S]C;]37CGYK_0%BZP;RFZA0,
M5A4;\T.J(?#<W^X;,)0*!\$+EI,JM U2BW&6R*D0" \[0%D;7-@$]OS^B,?S
MY<_E/8''+E<QY8;['QV+FK\//K*QX(C]/)):N/0R.%M*C 4S-CV:\#W9GYI\
M,S9Z)3CG',?YDAF W1"4<S:CRWLH<8?H;>$']HX$-*VP4-A_B?*7&PELL#X'
M4@&I4W_!%@N/4S\>#.".:1Z^0<44@<,!=_TWIM)\O09^CI"B_M4P(6Q-QN7+
M;]KF+-N<]:Z)S5EQ_Q\_@=\ZDNJDO[V]L[WS=O?#^YG?9=]/]%=+YO3FE$O_
MU\OLV[XO@18&)(G'0Z95](^?(CF4_]K>?K6S-8P'/P%/YO_XZ8_+X\-_'9S_
MZQ@# O\Z\^/-<<'PP^^07._J7O8/:0L@%=9/;7JQZZMP!O3_$ 4!9(:+_&QP
M0G8N<]NO=TS-PHO?N<;D^ ;\]P7[ C)&Q^,13\U \I+4=B+YY4@)H?B8=17O
MCZ;B7 E,JZ9Y9Q%&J,&N-+=S6+'V9K_'5*.R5R2Y#&YT8C$Q;P1=#ZO4[+?+
M+E@&N) +F:;3%^R8)W9F^ER03/N$SR#84G:ZQ3[Q1)CK3TDLVN\_<:6F['.L
M=#0R7Q_%&)R)RTLN)) KQ^?V7K#/<L(3?1V;:\^%S!(WN.)K8*YX:N58+P(O
MP--AL,"OF:TNTD?P/YQ]0A&N](@G27#5',A=;"99#+G[.>&%9F=2ZC&?"F5W
M,!_%$1A,%[&^MF^*?)'$5&5JWQ.>'HO-(T6?70$M<&S]W!UAY9:<H A.:1WP
M+N$V[Y=:;/X@^^=?-[ /1V H_*R'N2+G\8$7EK)@+@NX ZCO2["ET1: _?-;
M67'NOJ:117N.<=^QRP)[PT26"2S]F*1LH.288528*C3+2.7<]@Q7)H<TPS*=
MH7)US>=P=,<\$@6-C3!6NW]XK]#(3AKLDMA:])$2^%-?D??;)7U<9;C 5*IX
M"M:^P>?.9=N-D[,7[""^H7?M! 5=W4S%25G*-?=,+")E?84A12=<!Z5+]WFJ
M;GG[4+1VV#RI4G_E_3*XW0&*=WY@#?CKA6_V25"I;@];H+@K-[3A]GF-4.8U
MSOB4[;A;6)'\ATAR<0/6LX W_H3E>W";?3@($N@T.T[H4B:%X9"-_:O+%_;&
M1Z*G"BPE,W??F7L";"/S74Z K9\LZ4UO8K2?%_\@N*^^OB#FAE?"4R.!)MA>
M&%R#Y^(6>H8ZQBMA1XW;G^YW^/TM.UQ>?\M+_"I'*1P2'I<;<1MD^%QKX%;*
MET\F3GCK5U^S1Q:O8]'[W&*?=.J/?><>.VN,U!Z\A&T2WOW7(H';?W"W/\*U
M5TC< 3;(X4]SX7OWX6F1_PT4!],41'XHG$H^2.")YO&@&'(.Y@W5PT^!W$+=
M"&K8X7V#%!"/EWEQ$-DY+9<J []]A.' QAC7Z;-+/DVQH':!<=F!"]*^_'L>
M)RP2#R4-OX+$HZK-MXXZY7%%/K*;8YA08SL[#= 8IJAB'*([/1^["L'U3= )
MMKD\)O[*X#G>/S8JROOM6H GW6>NGA0>_QH.!1^COOF5 X?L 7NFN,**_E@T
M6>%V.V_)@^+H\=K+S1EK<]%I^9%W*U\ ?FU8P[V 25)CL78OEI1IC<NR=NQ\
MPCDJKBY]L4:P->T4YG,;@**;=4V?\86@II2-C*,%M_/F/=N$_]V%=^,W/$XH
MB,*!@^L)7)"[^N48UL4WD[B']<4OW?>;IH5Y4]&M-_%I*U'L?1%TUOR(#?LX
MH":C"C<NVG['(52@7 (JP=48AD.NKC3^3'T+?CDBRE)$.M4&3#/V'GY%;QK[
M?]S!QL4$+<#ABK=N7HA(%3'6;W<<K:E4Q R&L8@/6J0Q=<HXFJSVFJGEW%EM
M G5-3/N<^28?PP]4#NZ;:H)V ;Q 9GD\IKBL!J-ZQ<$:SOU6(^Z/$=>Q\3S,
M<$3XL?FCTIRO62:3.*HCI:[:ZJWY1[@>N!X:+X@MJ,;JB2.6)1CL)U57P2DS
M0!_Q.$N(+PQ/84; 7'!;2_,J$ 9,Q!Y*67=6 G\G[,HE@6HI\@LS=4_4--)A
ML.#R#R!GJGGD4GN8:X"_#*VQ)7-HF8KZ3SBF*PLXGW]%0E!YUF^7!^SM]C8#
MDB5^GD[$LS@G>:VNA?$F3.$:; JH9@QE#DP(#]^Z\@+!!$G4$M6Y;7#"!Y@V
MQ%>'VY=]0^ AV<77VT96>:?/"7#127Y=;ON?!:%K)F9 G45N,69/;?+I+&[2
M:I/$C$!UK+_G:B215>[ )"Z<=1LU5K7S]@"\20(@H/,*3E'U")7&&'::?AL-
M[0F0")2PQ96!-')X//YX&P,@ANW/\ /$ \-?AG5;$UDDI?5)M/!QS,"21.A+
M.C6Z(,2&X)YM5O7.6=7W3<RJ/C>/D5#^GH%7^(>#@7(8$XN]V(Z#)S0E%M;W
M,Y422_IY""YAT&G R0O;O$$/UJP]'_=UYN(4I[$F<"VITX'/'UI'P9@M>L0S
M6Y+O2L%9!%_CU$1X#S$FE$T?(*UYL"!!@+(9ZRMCJ+N9@9V9:;V@J0M3$[[%
M7$_ XV_?W -\ IX&\+B;C&MT!ZF(3:Y1E6) JT#96&YH"7 Z=]_-R/:9/:<Y
MC<ZV&7-P;.#_6V>G#$\)?\=<\/$6NR>.6_'X@/>5O:YSP"H(W.0'"6.BPOC'
M9 ,BXM,FZ(YQX$-):EY ?V"U*1*ZBTJ"FL]#(6+'W2-3FX!4F5DHG4@+RN2G
M0C<$*K:,(MP*YA?B]@4.6PC=M]ITF#TSF THT+C$P^$M0ZQVM65Y%&/!T@RC
MDM*9$HD5(T%P1BI"5F'9B:LR'"CPG A;ER((X%AYT@1SO9OG-U4#D(-$3E"W
MQ.1OSLH$U"D\BG &)"J:>"RL,QZ!-KR%39Z-"7D04Z ]GS[;$IDK4VKKJ^,,
MEL],;5R'LDN@U>AK5Y1!N5-$4L9T'L*_4#A+I$,0=6@RB!2,N@[NHAYA?LYF
MJ,I8&N9"\^5;]KY5MOAZ=V'9HM^)?QWN?UFARD7_WIB3&,2)^%+2?B?KCN&6
M$4_?[/R<'0LT?G<^_)Q=3F*M\1]["C95CW;A(VQ:H7^=:,7!1G_[\S'M6W;&
M$_'^]<_9D1C#OUZ]_[D[%-E_)/G'-V_AZC=OWV[#?_YCF']\N_WAU<]7M*7T
M_:OIV[<_9Z_>3.$W=,&;*3QSYQR.IJ:F3>'@Q96X/7TUX@B;C=&UDK$P+L .
MP;"RMB?>,OR2Q;8?UZ;M3<+9,ABUAQKFJ@<7GK_,:!!.SZO[:1Z^3YB>MCFX
M;0YNFX.?OM]M;9I]W[5=OD_/=2U(#[+BJ^9U3R[+=RU(S[J ]%A$3X[FH.BW
MX#SW;E^WV#RM^=V:W[<^[?D:0BTV3XO-LWK,VF+SL!:;I\7F>=;LV6+SM-@\
M+3;/2E61?FAB%>D,-L^[G=WMI\#F.?MV^^:]8/6\>;WU[VQ82WJ?Q]&_2@2;
M%<IWKURZ=@%H4(>=;1UL/6"B=G>F=&?^<5W08%ZQGSWZP0?V?RPH,/B%N0(#
M^/S_"4Z_ZL4*'!NVL_O^W=)\U+!IA.=*#DRE(ZJNOS*XCP */L%$VL<MWJI!
M:MP%T"+PU3KL<A+G?PN5X/4;P';OC/GR^B.RX(OFTZTDV6(4FEDJO0FH]*YY
M5*H1:2^6V6U@22<I!IW1U-0.+*.*&-1AIB)J:HC7/((MQU:_\XB@B!#)B"CQ
M*F"C)E+EBP3]Y!07#EK%- C2:"Y1D*> ,/M82J:F<^&AW,5F&E_,AZD$NSKR
M%-W^$%#TU?(479FBW5\EC;_T! '_#5;]=FU'KI<U+,W6]\:#Z7B+D'4CWA=C
M"ATXB#,Z!(U;N1TDOF$,XW *YBN#4=:K3(B%S[=+&0#7=%AW8.SF<ZZN-?LB
M<BSV!T4E"Q1.]&7CJ%:O[.W,*G'L%-/L D.?)GRZL;>/4$E5K+\CT0_P2*J&
M$8:1B@&/L%\0O&N#RM4-HK-LX^3H_*S[HF) -8[69Q6H,5\A,1"8I@?5](FK
M&_S,&>*7T4C*!$]K\_1395PSM:PKP37R1Z?./!ZC"R^K<A)0SQD-&^>C"^*@
M.U"K83KNL%^8QK6F*[D#2?"@6'O@5=H]')Y56?X9Q^!\"-PYQ'8-,/&RHI<@
M_@_!''4,KN71%OLL4C &IY8F!&])>07C=CC*_9:ZOI6&BAP>P4O)N83KQ>BA
M$N/HB )#Z"IX@A T*[8[#N5RM%DJ"OQN7NL31H$M&F@; GZX$' =>?79Q'Y_
M#/,UQ!NV<*^WA(=M$==,E/C=JW55H>L:)2YS#;\#&P50JK?B"Q_@?U(^&P8U
M09;2P3HC^XW<K#6E77A^/?VZ?V&U*[<XQS[:MQOXI=L-)%@0 ^UXINH.!N"^
MZ]OR$3-LYJ);1#F+$ET+P+\/XGR[3:=ER&0$_3^*-6BV+Z)0TIHU/GHZ\XLJ
M.4VQ/]'4_+-.V-<!8=\WD+#EJ;8D!M4P1(/!LFV1Y#&.3[F,$@'4C2OL6"=6
M&+]_W4!B&9HX>R7@PI.T'_.0,O0!T63G^R+PJTF3?3"@29C-VG$U 4@!.!W#
MVKC2):1\D!?;#O3#SLYZY"YV=G=WV<CV'+E>(VUP2!#,7A.\405V;%U-V+6)
M ADKX<)96RAKKP3">@$K'%%,%3GGQ.%"E]F/+V*2RQ0'L"1")V+*/DE-L+R-
MC!9Y K7$8 %??!'92%%9 @C9G)T6UZ(,#%U(J5%0YUXZ[U-9:"-I<BN#L V,
MBV!R+$FL\O;3-'Q.D<*M+FI&%S5/*;GH89A()9D3?G%9J*%0T_NGUG+QQ \+
MXHDT1ZN-)CY@06DPK^QYQ1 73#BS<<+*D";V?[4,Y;SR9X,U%LPSJX<7+6K5
MW.+3#^MJDZUK6/$[)O=5(V"&01L:.)P;+J3*0"##"0*1FK))\\4!>H"Y^20(
M[EB*-3W.=2NMNDD$)NR"*'2E4KF)D2JB0ACC"]G#UE(>PK>9N"U$%<;S&EBI
M#+K98K5ZXLP2KD*?C(,]O [!NV4H\_+L$GD)/$.0U!(MW*\Z%Y(@3HJ$*TNO
M0,PCY;:_+\2W,CX!3B*\%@0A312[E4!S6*L2R7N<3,]SM(Y\D^E3(.X^6=4;
M!7KS<L#OB9^+4!W&OK%W\K4M:UN'@*:IZR*7R0.+]\<QN%.YLX\/+[L'AZ7$
M=D5N)%$:2H]YY5HC,Q@8Q];*<1R9K+&M6I;^TPX[E^-,%.R(]Q0/R[G6C5[1
M2(PI\"12N)N@62^@S_D8Y,MI4B1)I?CO;M19'>$[4_\')\V9S#5:P8F;WAN!
M6NP"@UVPVT3L@N\)U+[?7A"H/>9)&Z9]N##M[-Q[+"IZ'G6?RTRN-T';7XMD
MRG8^S ^_VE$!+V\# 7C7@@"L61SVTDS$YK#LJ<XI,M:KMWE1K<D !"C;$RH%
M2R).9PLY?RU2T=1P[!PBZ4P@8A).\IC3UV[]MUL(%\8>FUC*>6>2'?[&QG%_
M,^)9_>NY5(0;PDT_KT6 \BZTO(7EMM\T/%Q)F8"L3"SM\Q1T.BS^-!Z((+-N
MR1&PS?8=H!-6QJO9ERD.ZN1("IP$24,G,;IDIOS!/ZYH-)?&*A][,08L:2@-
MYH>CK0X=LTOXE&<2AS^!+9)RQC9V=G<# ;;].$+_.=H-/XH>L#+<1,<GQZG@
MC/=O8BVQ[!ZGO'Z2J9BR*Q>NC,T)6U=^6)N0)'E'&!4!6R<(C)QQK7DT*K3(
M<UTM<?(L,KT;S,3*')&]K<N(2+)?TN-P+-7TS@VTRQ5UO5D0*_C$D[9#] &#
M!9^Y$BD[W6)(Z&<3(#@EZ-7%@(!4F?668@,[=P$&?-?69JU93*!N1_=Q]OH4
M1X,*!93 08U:)!W6[?5^CX4W%&<Z%._0@;*RM(GH[-'$8^/'(FAR$M/<>NF[
M.><0*G1:&UB65:<3SOD<FK2U&2N+PJKT8F5F(8+T FHUCT+L( 8SV@B7FSI7
ME9#<)>&(,O R[)3W)-62Q($W^Z[A%35[P#$IT @':D<T&91/;/_7&V*I?YO>
M,$LC\\W[=55=:^.&[(&U8B</C^),_\).$K W96R$\>\QW@G[3!O8G?-KH6"9
M?4(\ZK _8E@X'[O640Y>QRF<D$8CA=T"VQ.4>AP4U^)A/+ W[Q> M7^.E8Y&
MK0_V<#[8)ZZ PPV=GXT+=A3CD+WX5C<,=73=_3(MW"]ITOM<%^SMNNJQ!2[8
M=]>#KHIL9[<P%#9@U5MEG"W)-E(Y8=?P/SCDB"Z=V^?EKG]Q%\CR[8;GCVZA
MN:'-3+/$-VE609-N8)JW!'AWA:?GL'0:2V2Q7"EI"90:2'4KY]Z%J&^#U-.'
M%PV,),_'Z'Z-1YH(;G@T *")QVCP[7-E87P0Q)'(/05=8D?N+0>.P8#6(WB>
M>\2Z:I[U:3U@%P)##U@A&K"<3*M8Q,<)_TM>CH$Y/J,Q:1+&8^ R U$6<4H%
M$@R+9J=Y?XM41G!2'VD6R'/DI1_VQE>&EP[B+)&@*$M'#*XL=(ZO&Y:8FR&*
MI8]6!53]S%6B53$2'MWHOE)F;Q>DS#[+"6B:Z[AUV1[.9;N0/:%RK+'MO6".
MX,_&=SL7$D';C-52:;-:[,M=BBPWN @[;5ZMS:M]-QPH"L/:^)\+,2P2ZA?U
M^)>H3S]4TFL5R$:CI.?C M<[2M_2#ZO@ '2_I;$8&K<[79R'FL-[C.=B4\S!
MH@""-9H,WV*J9>?#L9E PEU\ME4AG"W2G7.R%Q_I.YPWMM09;N2\O7NA[-Q)
MA:%WTD3\CYI.<6/1W'%=:G+A7!2>,!+81)Q18+.;6!8ZF9K0B2H9S!118[*1
M*9G@'+D<DVSDU6R>)[(8CD*2F8#LF5#1M9DU9<D;\]FKS@>P6O4XLO$YVH5K
M4TM=!5.SY=13$VLAX#_TF*>>572N*QY)6U^]!H4-Y20CV^$SK4=)_HAUA'';
M=/.,]X&#[L87*W-8*BB:MB<?!QI51X$MFLWS@T1J&_2I0?_M=MN@;TL^WBXH
M^3CEZ;"-'CY<]/ R%X,!EMUS!"AY+KWY0:C@JR]A70"A>K>2C[4M75S7Z&#-
M6?/^&+5-F?!*R6$;7ZZ^OIAU:'THH-'HJ+.SY6E"7TBJ>IRJ' Y*^$:W$G?M
MXP0E42H#5I<*%\P6:U1B5@V,%<R?2?+&UVH 07W!_A2_=42]KTJ-F8J:<I_6
M58>L3_%&#3<2?:6QJ\.8B7FN*SNL6=  .'^.AYP'[=?&[#2#V9/%7=K?Q3LK
M<W1N&9:\7&SADP#3/X&#-[SO.I7W.POJ5,Y 1XQXTF+!/:"G>82N!_NTQ1RQ
MGZ6[Z>T-?WI-C2U8PRZ_XZVWC2\G>Q<OK%L*/PQK5F8\TST%M@>-Z5@X!/C-
MNBJ2=?5-;0JVWJ8ZLO9M'X.L-S3>"+Z-W$1#5!NY@C4DEK_ 3G'#Q2@CYN;@
M2@LT1$45SETHBZL:ZL;66Z2'Q@MS1$TKXP?FT&LM^^T==7[[7'(=^D76HYHE
MT^=ZW503N^V#TK+J&360!%2DHTL )P],<"FUB,&.R7*NR+[Y_"-5VRMC^=FR
MI5F*$+D&LD@))\W1!7'2%,_('/1$JC3<KV]I^X_F[%?EA%53]@$86M=E[_=,
M]AZ^0KC!4]Y#_PD\K.:AR9M1F1UV(:<XL5 ",:BM^G/C5OI)IN!.P^;.73+5
M5)507^NP?N<<V)BC";PWG G<VD'N=R/>%^/I_(&==UCZRFC*A7QODBZ/MN'/
M4?6M353Q?'1@YB*'#DDU%+;/QST5]X>BF<=@[S*:A;JL4F"/YZ/E%K]<G<F;
M!74F9U+J,9\*U88 'RX$^#GAA6:>U,\G &@<ET."FP.I'.O2V?6P<[=BCWR8
M7XC2-JBU83[G%L]#,+R,Q5BDII_'ICHH4O#FT9W@IZ$((5X&E%E(D4JYPQU
M4E9&%8:2QJ(VIL-O,LIVT*2T_3@!N.<H6-8E6E*M2J!LL\.&Z)@ "B6@!Y2
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M&GNXT-@9W$YL&CJS*QV-P%!:_L@_2FG<7,13U)_*^Q'6<G2*UH'M5\>IWMK
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MVU?,%)B.<21*G_3VK&9Y6?BF@?MYWVTCLT>A9,;WVX/W5E031"V^^2] <*'
M_1!P9NK!PUE!^PM8'.*C%;KVI!BQ^RH0G@_;"S.[Q%N61(SN5]2X&A^4<EI8
MX[;.T,%QSC SK/4=0MJK0@$3,-)UIZDD0Z?T;N/<M;Z2Q(+_20R0AY%9G9**
M*(3 LH^ES1I&QEF.QS:\8014J'0;1M9SH? LH0X2&09O!7JVH'DP?$ DXCBA
MQ8+'8J&9QD@7*)]"D?NGX6E&/VSF_!HHT#@27;B(@LMD8^)YBB  6D0%M:T3
MI\'_H9-LHE7-B_EY,K@$9B6Q#UH8S(6RGD9.4F*5JGM]%X@OFT+"G_E9V.4/
M+N!YB46N>C9*R)@GQCSPZVFN4CH,RV-J-AI&=HQQ2 :QBZP[J6(3LO1+$UZK
MFW25]*2&!WFTB#@E:Q?OCM7PH37:.!*S/Z0"(SM*I!;)M,Q.T$D(:HLD5H#$
M8WA)-N09!2>1('"C[O9'0I('!=8XZGB1Q$$4CV,K?\.*GZ!B:'G1TV0ZV2!J
MK3"J3J9*60DSQW*H"( $ ?=O3+C26TDF*FK.H(6VXEX*F)..![\\N";[[Z6E
M1]%!^^L&K+<&VJ_GF.3., P0D?:DD@FB/1S>H)@ 2-@\V^$3MS(,<46H?3ZL
MT9K#<M045V24:*-P;:=^_0^>Y$>W#2HU-7>W"59FJY?76*:ZMK0!HI!"UJ?U
MF8$$34#\T5_HWV)90N!R4$C'Z+H%<9V]2DV3^[*R)T/4DG@,A?OZPFO0P-D&
M!Q-.*@B^LKC@_D%!?BBZ4Y;(12&.U)>OOW<OKDXN[S_8L[*L>N&#GQQC)AJ=
M&Q_HG.OM&H]X G8MUBQ3-A11<$HV]WFJWWE2V/:\/3'B-S&6W[E^ G_5ONQ;
MQI5.I#TO7K)25I52MG1M'IR35D6W'Y/HT+-;RY;8U15=\WDE]NZ;:0XOSH)6
MEPV7 X +(Q7WC-U83:=K09Y?\X 50JZP\\^"L !9U'SLRB =VS1/RKI>5%/1
M5,E.G8-HB*9A?@H%I*65#RCXUB?/5\]*1%X>?CGY>L%.#[L'AQ>7[.L1.SCY
M_>3RY.N7RP[[>G'<_7+RO]TK^+-[RG[[<G)UR;I?#HS,/[[X^MLY._KMR_Z5
MN;Q[Q;JGIW"OWP]/'UY1K\I!LJ+&5/@ YV#2LYX#L<?(E)ICR)JT=66F>./H
M<JASWDMP9!'O@Y?DR0*>_8WU+:E&!ASJH;6J;>45=IB,A(D18<96DB6. ][[
M9O:7J!0UP:\BLK/+,(#)-<&VV.I<6:C(3FF%NP')$^&R*0T4:60M,N \_,W0
M9Y449?&I'A@C;DE2TI8;Y]^GZ$%-VES=NA9NW%*E$ CZ9]!3@75JMT<;-@XO
M]E\L*DM88!J!+RM[.>)"<S8"&0Z/BZC9AT8.F9+)P!OIFU+\6S-O6^PWC\N-
M_C)HW%&<^::>Y<,FG=)CKV=;0!."T1+K4K8FPM=(.JX/N!L+[TT["E6Z4"@:
M'H^E>;'U[.-Q;"JI.VZ]%L[$)@U^N?]]?U1I<465S&Z*:]"JVD$%5@RP2%G!
M]N&?ZMKW3S'-$P/H;GIY\A7O[K3-']A&QO\2Y#OG(DF$*=%&S2X4HG$$-C)Y
MU0F?!)5*%D;195X[CCA K0$-Z1L5./+':R03?1X)GF CD;G(]!ND-[&2*55:
MT^-SXX>L-I$] HSL81&R"?H3C+-3_*%>1_TE;%B"1W\6V![93(U]Z+H6\;1A
M),9UHJ#8(FF3 "N!&,[]=&_A$-,#3GE"!52*U*" $ .B-Q*>@VXU+M7T.=TB
MN1'4NXA\FAY5D1[)3-NL=9+PGE1>]#*4YB;F54G!CF6*O9_(0T[K4:6V-1^G
M99X7^$I)76D$V&*'V,SA R74^"\-8#UFCH!&4:'K;\ALE#A0;+2@!.4IM0J
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M )EXG;4?-#A[07X45@3_^M/^3W!ZXABX[!#NLI_E*?2YJCI2)M,L-R_TCY^
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ME8HU"<,K2@N;)SQ; JGLO^"W ^%%"("5$K03OBMB2D-@@H1AZMDQ8?V1*WZ
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M,F52>'2Z/=S,&2:S2F3RSEG-3\^3/)B("FR"^(>H,"FC6&-FL6F8O#%BP%'
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M8>%1SBTK5X><Y!Q@=((G(4.=27$[GOMK<HS)J2?&02"C/#/Q'=]IACER$V_
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M7!D2K_))(DN/2Q+AN_QO;MM1._:/1;4KLR2/?.II3>5';VD?;96V!_GV/;T
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M+R)1\S(!)[B!#$;/B>.^>,8<A#"(X,7\'6A\HS]?8??-S\D0#'M<KS3W<*2
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MN'9NE(CH=]@0N2"Z HU4*NR92?Z*FPNUYT7IK )9 5*!S?<!)).L^6KXMDE
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M42(E0[:Y\]PY]8+74S8T+F#.(,YQF6<Q<[,NE+1F]@^.%?(-&8'WI )NDJF
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M)1,Z?=)16\HR0]'&*L&#D-3MDGY3XJZ>(RD4"=,80>#9HP5O! U<\L-]-KS
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MFFP:D=OM>.GZ_2S^H[3W*E5ZLIN?ER76$]/PCJ3@I,(\OZNGERG;5V#0NC*
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MEOV_!C+&PA^:']_Q_HP423J%K*",B1'""9'M 37I%"6O"=^,?A=W8K\ODRZ
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MJ9WM*0_*:"I@<0C]HC=)MWLDNPA*&0Q8!G.JL<%OO$7];831PK<="N:EQ,9
M1SJH"C &Q$AR-G.,SQM+DM+0L1("Z7;\-2*C')R46"#U>VI6?0YX7[8:*HGY
M3LKP!X7YC&V,2F)^0 :="N!>&2(9)O)GAO<G#0SL%/2IN? 8F9QB8&+F6GR?
M(MHJ@3VC0#MS%RA01? K#U )2?[KL&STQO$#;\$D4RYM2FW2'51@])F$&FAK
MJK\H_&I=TE8+*G+![]9\?V'X)8.FZAUXXRUJ8$2DYOR5-7%$UD2N_07>[T:
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M@6'I#=TT^Y;>:[6:UFC-'$_S^-,# <ND0E9HA6P)@1SN-N_HG3V8[IPN[QU
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MV%VC465K=04'$*%U(I5%$-().,T:@AAZXDS_C))"0>F3,S-8OZWB_=&+%&N
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M&-!KA\7F"GL"/_U#OANLP)6*,V;(<KUO^D8UNK:.7Y.KB+^=Z(D$Q0ZQH(X
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MH&$&WNP>YYG$FC'>[+"<L%._0?;0.W;L?8"2-&@'&H0+$2[OOB5?'\#)WVD
ME91<8[%8@>,&N;ZZ)5WX+_P]%/_MX?Z _VP/R$OUJ(VG)/=\53FX'#*J3;V?
MA1/9+EC?7UTWA.Q_+XI6,@:SP,94/*$K,X+"'?4^-V@Y[:M>NC%1[\E;L^(
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M@[)8/8=M&W\\!#"SP0]("-">S7 N]9=F?'&J#6&@I@X24L,IUG&0'1]S],!
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M"SP-6C5^C#Z\:?]RF!F\ZQ[]7TR8PETO0)[+V7*6PI9O/!OW4Q@L;IFL;V;
MFA+=@;2_<F&GZ%,&A]*GM$DG@[]VIT LJ':"2NG<<X&JV:X"K,;CS2:B%E95
MUU7;2J+.A*,QZ?3&%D87J)T*!]*@N]GTP (I!WUD)^K %6<GJN0=K@ ]TV^1
M?L\:/A7;L8H 1IL,,AI<& V,HOTY$-R5GI4ZN';6]=ZM=.+P#']9_I W#@SR
M56;/0U6],2B_NP#9D[,HUPY6%J-.N5N(J0@QY?!B D:&)?M73,6(&5KD><?;
MW$#1:5E0F*PX2H)%>[39M]S"XG!=@<5#S3.K#)637S0\2(0SWV0X(:WN)E)V
M%$\E@*@'8 [5(Z<"YD!U8@!DQL/-'<<"I@R_J7%3<&[_IUG."YN,DDY&N7AX
M&QZIW7M&30K:L_>*XP+_'=+NE!MHJPY03#F5E :5X=B>2ZJD4W8W ,L1&V/2
MZ_<L-"JE10H$QZAMMYA\]4:9'HYS@,3Z- K0*.5Z.<X+&^O7,,U".>N>8D#>
M3G5$76!&SGF$77XNCEF^J[HGWJ _7!'>7_S"-NI,^0SG XI)Z('CXJ"EEQ.8
MB@53#I'%HJ$]M&@P5S/L=BB<+/[.R,K>8$UP9ND/K ?)W)6_]\1_NOBM] U>
M^^>7OW4@E[/\SV/4C[I6FN4LY_/(LV_RZK3.F6)5T?N ]]*#WBB\UV==UJ]1
MP;MGG,Q!8C<SS#4]<G,F_<'FR=R&7TR-T!6+C6'&]F"Q8:;6V'V*/Q4,/3(>
M;GIQ+!9,U1/G14.?M'M#BX;*.W=.Q$$J]<>Z^:KMZ,D3"R430)F*A:+LA3/8
M@GW2&VUZ<JW&+V'_/XMT1X,*[.>VT&SC-T6D&7[&]M'+,)AY\<4O9\/K0IYQ
M_D>Q?46I':45NFTR:MF-W)A$3>/PT2&=MLWLJ)+VV.T5.!40/=)OV5*R:NF+
M<R-B:/G5*J4A]KH)3MXU-L\9%@\F:XBS(R+CY&D184C=U\FK?4"ZO8Z5KRDK
M_ASZG+3:)G-+V"2B8GW;MW0^]_S[!KFG/@V=.6$6)G'<A>=[41QBR_N+7^(F
MY@<\PS,@1/B9"_#*=Z\T\3W2CS^7U(^.S08F@XQ2(.-<S74()%0)-AW2;=GX
M4U5TS6ZOPAEQTB&MP::Y:6%BJG:Q0#$5*$;ID[T^B#,BI=^V.*F.0BD7*39#
MU@"-4JQAVB.=_F9-G!6[$8E1YQ7\J H9<=;]5:QR^T8C!L;I [J]7/I(Y\$2
M-JJZ+'>C[,9GT2USN3$E\2&1VBD:8DS:0VLZ&K$SF ^6$1GT;*U=5?3*/@+F
MW-'1V<RKLM@P59$4CHZQ#:@<HCGJ,N"2V@ 9(.'"/0OGL!K'XPH<*PU =PG^
MA'.(N]^K &>^]2(4J\@X3;+G3X,%K<O"-B,!^KFTN-<HH^/B!;9,VNB2^0*A
MT"9M2Y=ML%8X@"+W%.FW+*NBR8K@O-+O=*WTS5WYAQ'DGK+XA]8*,'GQGQT
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MFFU5+I#.J[0JYG<H.F.KL@24.>W\W]G"H"ZYC9VXAG219891>(WZ$U[Q_;:
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MI=&"S0@A5W//G;&ZL V(>A>^%X3?1J0O[L1HAS1:6-H';I6+X_DBVU.BR"N
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M ;LT94B:1@=;A$)V9B26-9#K5Z(;4ZR^QJ9EY?LV!_6[*$+KJ*2)/3<ANSR
M.*7;PM,ZX'=^#NND(Y'M@L4#@8BK['J$%2.N= WR&09Y.:78GE\22:ISR(D1
MZ&45:PM@!R]0;M8CC2$*T$8&Z71P8TD*+ZML1FDU<%\ [G;389UFT&8YF'F
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M/)I;>H3I+]>FEO=DF>1HOUO/JEBR'%(77#0J6BP4N*"L%HT8+;1:)(E%(8)
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M+@2FM^P/K*SMF.).AQ&U@TF6DB3](Y:@8TG#Z+T<^?\(I:*@E,DY $25',<
M$%:@-91&V@9:>[*<"$ PR:2C0)M^6'2B])#4@(K>1EAS8N>!!=:<".F/0A28
M1=+%0P2RQ)\00A AI!.UA64GI&I&B4"";]"O6U$F3_QB*TK(02A$%T0UQ2V]
M)L:>9(D](8;@:ZASR$?H,.)4>L3I5_J=WEMUD:+@ DX1^5&" K-"FBT\G"])
MO D1!!-!7<B&!WP-5'BX"7$$WI9?1YN21YLQV@0YVH3@ JFD# ,[)LL2;$((
M@==/YQID.&&PJ?1@TV^+*;_?I"YB%%RT*:8_"E%0=DC3@)P5*J\5DD.P"0$$
M$D =R/76X>N?PF--""/XQOPZV)0TZC'8!#G8A.B"J*0:;3R@*DNL"1$$7S^=
MZY#QA,&FTH--O1']?L_<NLA1<,&FF/XH1$&9(5H7LMB4UPS)(=B$  ()H!8"
M2([R38@?":QX#8_[2!)60CB!5$<JYMG*$E9"!$F@D)J0-^,QK%1Z6*EO<L:T
MK1]U$:3@XDK+!4 Q"LL0:4!._I37$,DAL(0( HD@3&)Z5/\09UJ7.=>WS4WA
MBXP6=;$H#J5Q7=@:G.V\U(7ASU#]@U+_6'%"$O,9080@VH,)H"""MS>+&((3
M$%<?1116#99D?Q8A!5<M8?7Z8T!T]/DTM/& @BG3<VHM"6IP%QUNTNL08PH_
M/T3/&[KV**6OCAM0FZQYM?(2]FF2%!.20C%9FLW1(HUFLDX<'%$("16%1YD0
M%V7BPD"GMAAM\=S $<("HSY2 :3P.! BI#3%T20M#7-TBL'%\V,Z" P@ 9ES
M#?(!2;D",/PKOM@L]=O]=-L$]HR.1IS3E<"="<S^>$>65^+W-=3P#?<\/WP\
MB688V@PFLP4%../?K3['=PP_;].$D\NF,Y^=+?\X(0_6*)AP^JGJJ_W2X?BP
MDYYGV*ESF-%\/&<#$O@'SOD)>3_TR-N#?D.$-(O_Y$82R2 M$!HQGZDJGT4Z
M;8MT_GRV?-6'B14P12"8G1''?> *)\R:X#^I(+\F<H@C_183YU00B@3N!L?]
MM$&W5Y6E1RXLIR++I68T)UA.W6(YK5"6D\O\J<S^4VC*DZ4M3R+#/6O#=S7U
MT,0ZTUX]1?FG[]%Y!8%Z2*@#G6TD%'(4<E0.A )'EHHHS<>/VG^:BQB4A8H2
M]J&BY3)AFMS^J&S*J +[G'5*KCTM-^  'D%"R,&&G$ZT5KE;Z')##FSG$@1>
M8<#+-#=<2Y[ *"$W7&Y0 CSSA'"$K0<UTC7*/?M4;\CE<30*,2>3"CS7RCT#
MD'ED*^L=JKH5Y#D@[O:798T\6OGD1:CQM(C\*%YAFC0-;#8J2Y0,@00:2"UL
M_2!'L1[$D43V/N3D^RIKIV?'KA!5D+63T8;<!T)>(.41D4(D2:2?L&UOC8-/
MSS5QSW^W VOHN9QESLFUY\YG=9&SX*)2\4J$BX"B%J;1TFAC#Q9)8E,()_AP
M:G8@VRKP=5/AV5D(*MG<@8T,K60T&%SUSBIKL&?'KQ!L\#582\?*TY)5GD98
MR:O#DB%C<"H,(UREIU>]9^[]O"Z2%EP<*Z0^"E:8]HJNHKTB20 +<0081UH'
M=Z_ER*U"&$ECYY_CYHHDH2D$%63=U,7B\I+%I!!/TBBI=3 J>>X/@U$U"T:E
MEZ'TF#^S.!9=K_I]T*!&H<*5N%TO! I7F,8*9H#($H]"1,F!J"9&>.6(3"&@
M9+3_SYMXJE:2*!4"3 Z-I>->BBPG 1%24NHL387L9F'/E,28(GHT#-R VF2G
M<TI.K5/ R=C<.C(_,Y*%PK)\^\,@FHXUIZ#T8\:VLP !TFAJ")!,]4?&9_<0
M)M",[O5&<3*M"=Q&,20$%1Y)0NQ 4#%: P.KQ0#D^8$A1 @T[7*N04[RPXA.
M8DSV&YG__M>/GOJN\F(P[]:B4"><6R],J!/&%<8)YS)AU$:),<7M+^#. NXL
M'&RS%^%H:L3H8L(!E%!,!1S-(C)DNJ3=A+R%#XEIB\[TK#[/9A&O0)$+1>16
M(/I=A,AM$D/# ^D8D999Z*;4_(3#P.B6)\9@D!A#B#)$U'"%<84K-F'Y1?_3
M#O'&]C9&8VLC2)ZVVNM+ N2"&G$!*IC<2R_WN5)QN9;A[G9=V E<Z9N--9#Q
M>&8B!R^_=+X]CRJB1A_1#<BQ&0#2N:@M1P14-0#5T+#PC53-Q!!6A<(JVV9B
M$A2_K+(.>W8M' 2;%#K,P!UGR4HW([#DU6(2*#&LX S*2+;.KZE]/_<YXYR3
ML(5@740PN#!7M!#2MG&43?"^K+IS$^T928)<""?X<-*(VDW:+ @HP$$NA)7$
M[D&RYA4X_Z#*.NS902X$FPPZ3.NB42A9D N!):\6DZ#Z' :Y2D_<NK899TOS
M[;7-X6761>3""VI%RQ"M HI:H#9,N]%$"T:2L!8"2@) :435L;R%7($M!);$
M3D%*OP-P7D&5]=CS0UL(-RGTF-;!M'[9@EL(+8DUF9:T&\%I,HQO@;*5K?.K
M'YRU[AAF<>TE45$!KW@E<&L!LEG3;N#1*DGB78@G"?#45;&;FE3!+D25S!Y"
MTB,'YR%468<].]:%:)-!AW4@-Z""CZ<2 EV(*XFUF 1*#,-<H*QDZ_S2XD!S
M,,JUET)%1;FBA4#!"]F@:37Q:)4D02Z$$WPXM=L8,Y8JQH6@DM<YT)+=E<!Y
M!U768,\.<2'8X&LPC:@JZC#)8EP(+'FUF)Y$&S@MAC&NTH\J]L86ER"N]_8/
M-Y@/+5H7J0LNJK5<B'@=4-X"-62:*=5ZX4A4^&9,@9$MA)0<D.IB]P:YHEL(
M++E]@Y03]^!\@RIKLF='N!!P<F@RC:@=C'))%N5"<,FMS5):%8'39ACI*CW2
M]62"UQ^N'5 N1MY>T(".;3H5N5YP6 B^'U)8K&RY4LN%0I$-U!XR#"Q$)$FP
M##$E"Z8P%TRN:!DB2W8'(WDX"YR#465=]NQP&2).%EW6PG./>6 JCS 9@DI*
M-78.V0/#L%CI8;'_<[W 8[[_]H)YXG9.760LN*C6<B66"X$"%JK5HF//'4FB
M6H@I23#5,+"*EU11+426E.[ Q@$1"6K]5EF7/3NJA8B319=A\0O9<L 06Y)K
M,PDRFC'857JPZ^K'/W3$WO[*_^?,ZR)VP06ZHE6(%@$%+5 CQD@Y0 Y'EL(W
M8@HM4X]X H^G9@OQ)%6 "U$EL3N0TF,%G#]091WV@C+UB#;P.JS51!TF66 +
M<26Q%L-VC!C5.B"J]86Y'K7?]CG/6M/IW#EE/]5%\H*+;45KL5J**Y2Y0&T9
M(^54!QRI"M^6*3"^A9B2!5,M+.0E58P+D26[AX"UZN6*<R'B9-%E78QU21;K
M0FQ)KLTD4&88[BK68N9 #00SD"EUYF/^Q]SCB*R+L 47WEHNQ^?-U4 Y"]2&
MT5,V$."(4O@V3($Q+@263,#25 QTY:&OLH]P(:[D=0S.NXBR1]57[29,G"FZ
M>X>_G7SN7BBPZL+6X+R[I;H(?X9*$JCQ:9!6 XME2.+7(:1D@%2#Z,TV0DJF
MU 4$EGP.G5R9S5768\_.6T"XR:''N@T,^4N6MH#00DV6_%[F*)9>A]!5^/DA
M>M[0M4=)DWG@!M0F&RQ+2,2TE1>Z3].FF) 72DX 1DF7=%4\:W,8/@J/8"%"
M "!$TXF.(=V,54C&$2D$"F0C/%F0'YP1#@E#A0>8$#T0U(Q!6ET,#V4+D<P#
M1@@5R(HF::6!4S08[4F,R7X[]-__^M%3WU5>/.Y.NRX3KEV*):XP3CB7":,V
M2HPI;N^!/\GRA3WJL( 0GYLZ/@E<$@CSB,PB^ZCR_ ]L,^)@0[R(? &-Z-WD
MJ6LXMBPD=BDK-@^,8;K=9*\59!B,5+^0#;/M:0??.X?$H&6%@2%)-*-+5 U+
M_13#,/)%0XL_] KYS&OUG;FT5UQY=FKX.KF!KY-Y/"9'XA1*ABGU[BQ'L=DX
MB$64$""*Y8PXRLZ4\-+39M9\%H=MM67T5EPBM\RTJ>];8XN-A'?LL;'-S(![
MR8S[S0]D+1O(2CBL/&ON9/N!-Q>%!?A5RG\Z=TQ^'R[U>C//LDGC-1$B!I<Q
M^V74MY;Q"POV1#A6*_JS=?Z7:U/+XR+V//XQE\1< MJ$OP2?BI"W_AM<K.P7
M*_G_:-UR4VZ/K /_B@YMEOKMOF>F7U_JZB_S*:>HN?-]<LSNE7"\L(<L9TZW
ME/WV+S<7=T9'(V[E+%5FK)7V__Y;[_I*>7][U?M-Z7T87-V><7Y_H O_'?GS
MYG+P\8QHJOIJ<R4W!P^N_AHHO4\WUU_.B#!IF+=W6.S)/I,'R>,;$B'/A8 Y
M^V?N!]9XL<V'NOHF8L0/BA"R"6?ON81+6:*-.\3&2N#.=BT5(_U>^Y]NI"Y;
M8A$W;[;#*L0:_7+29Z&-^-YVS>]_MX=CJAFMKM)MME2E,6YWE$YK/%0Z;:-M
M,GW<-,:-OSN1 <[OPD:]X"5WZ)XD2+S+^*E8V8)*08'32\LW;=?GVOGK..$@
M<)4A#'G_ZWC@SG1U>09G((3#@+];2).3))VIUFXU#;.K&&U#5QHCM:G04;.E
M=%2CT1VW&[1-NW^K)X1QBW_&7X0;".PQJA]T/RU-V*82^@G.$XR7#3B3CN(^
MA9"#9$A[^",V@#L.#3H.76Z/I=MTE\O=DF&8;,)-@MATVQM"VJ^@TN@OQ$8H
M=$BZ+-A#NE!7D4CT_'+"V<IDMK )^$O?K3['=PP_;PLK3C6;SGQVMOSCA#Q8
MHV#"+8J$ -]^[K$;87KNSM+1H=>A1]Z>9W4HYX X3NGTB$X@D:7'$UF\9+B(
M*"$@LDS;(M1C]#5QPXH\T;>S.(%K"1!W^07;..,TK!$U#^&NK'Y#?F.+32^E
M$ H7%7=,#7UD1KG?^ZL_+DD&%<2J0#ARRT$KM&+\\<'U[%&UR50<GDF8?E$D
M-66.S'*[Z/DY-J$-<Z9KKT"TX+MP?>Y0+'YD'8Y?33R:;CC; ^ZQ/:H0(B4,
MC1O1@X%?O%ML3A_)$Y/GF^_RT;[ED]-O_M>?7O/'4.?[@ONJW(PG_LQU1@O;
M"OCWY+37Y]_/P@&1819,O.@K,;C'O^1^M>+1D>7><?-MPG_#[_;#$L'IZ$;N
MUAC'4^B/_K=>YFTB7[@>C]VC7<+BY+4=OAW6N&;+U:*V.",1Q3=,=^X$WB+\
MQ>_]YY<[CN10$0=!MH]SY'<*9"U($L^("?+-]8(Q5T_NSLBMJ$YQ5?=)NUWN
M>7>$X=$P7#.1L)._CCDG_RDLY#1@(2SE@*6JE9M;@;#,N+0_@JIL4#5(NR,9
MJ"I2TOU%3C,$5_F*F[=<I;HE9%$6[N1=4(_[9/?4-^<V];)G?I!SGGBNPSW0
M"1?I 1E3RYY[C+NWD\6,>0%SQ Y;Y3-H(9FRQWF42[A62<MNPU(.3:L3HXFU
M.\""+%M_$4$'!71Z%TL7 @ =0D86R#1("W0)<G3_]HXIQ/T3(.!,0=]R_G-M
M.F)U\(D^,@Z7U5YH'68<!K(8OWG W<'IT#47G&.98U%R>C/X%FYW^EP >8S0
MF4W]<%O385/Q?;^7_<8DJM'<',0EH)=XKI("7N-6#N6K$;6#9YG! BU;)Q&!
M!PIX*I9% 0 \A(U,L-&YOL)Z!^@L[G,6KRV;.0M:!X?I"YM[KF]:S#%9/5S$
M6R:.HXELU^G<#JR9S;C0L!FG0ICT>ONYCV[@S@,!NX$Q5*ND33<A*8<^U8C6
M1/\/+,*R]?\0<0 0UVGA_B  O"%:I$"+#KS6(OI[>\<4XN\-J"CE6@M_;W-+
ML [S7::%3A?,=CD$;#;_'N[WD=.+SY_0T]MY(&!/+P9IE32I;''33KL-6(O6
M'%W9>GF(MM+1IA&U@4TR . -T2(%6KHZ^GCHX^WS\3[-11U9JXR^4X4[/2'B
MR1+R)"J^YT>SJ_[L>W=,\9A-PZF3*8T.08[8'7/"0JQ<$YSV/E^&R: CBP[%
M$U8_8R,N]\CIY><K\;W'OQ.UUN^9Y1#7-.UY6*CS]/:/K_5S'6LWX>I8\TOA
M5R4#)664+)9*IPWYJ$IMD(>X0=R@A1^_'7 +_[D2XGQ QY;#+;JPY\I_Q)7/
M[+OE6'X@KM3!#NZ'W#*83UW/WYQ9]6?^_K;W@?S14M7_D"D+*!>(052;<O3/
M_)XZ ;]J4\>=TM?B&K\B6B>)6I;^5/3D$87M^:_MN7-'3/&E1TZ_]"\^780N
M0R (2NB=XX;'QQZL8,*OAH^<SH.X1<:J7C:J[NT'@MY@BB3&4DY42>F'LB 4
M!7+H^E8;<GY^S6&6]4X3P@X*[#2B=I/-C!%X %U3A TDV)1=>AD]4\A[3[_2
M[_3>JH/GM5UQI![>YF>16CBVAM$)LM//'T(W<>;:"U%]1.0:WG.92$Z__1%^
MP0VJ<:#P2_[<5R;<B20CR^>F%2/D]/K^XR5N+%5^PM4QWB/)5B7;0[Z\EV9+
M VQ[U 9N"!8$RP&\CX8Z8$/]_US[CCG^M!9'@>I7^J$_"[.YIO.X,#X-/'<V
MX:[*:?\S%O_;?2#@K9H53JND3.4[5]LP(.=CU!QAV3IZB#@0B.L:>"(( .(0
M+Y+@12,&[LR@P[?7X?O+M:GE_>S/9\MG/4RL@"F<JB8[(X[[P%%S<O[O?_WH
MJ>^TG]_R']8B=W"[BW8=9MR/R\+;-O/N1%EX/YA,X[+P8MO&C M)B,[6 768
M._?)W!./\40U"7)ZT?]==,2F/O<PQ>;/K(RC9KB14^B$JV/?1X*P2L:*;#U-
MN:G2PEK> ."&8$&P',#[:-<#MNO[G,?=\-Q'&2<P"C=>-^"].NQ?AWE?4(\+
M4U'7+3R5XXOS/"87->R.V@M4C]L/!+R?LP'7(K1J0AOFIUB??A1(_=I1(4?-
M:HZU;#T_Q!XP[#4,//L& 'N('.F0HQ$=-';0*]P[IA"O\#?+_R__I@Z>T7;Q
MASK,^./M?]Y^O+K5%7[_C:H/0V$V!7$=!U25VP\$[!+&6*U2D%6V8ZV--IX%
M!XNN;)U 1%OI:&LWNXBV\M&&6)$ *\+1PW-<Z.CM<_1N;'Z_6I3ZKE^B7F\>
MN(KEC&TZ%8=/O04YO>A]Z[\F9' ;_OOQYK+_]O-OEZ_)A\\?^.7^KS>]UZ3W
MM<^OW+GS  ]Z[3P0L!<8 ;E*JE:V3)LFZ/SYFH,K6R<0P58ZV%J06]C4!FP(
M%?A0T8AF0 8+NH![QQ2SU\=\:SH+L))')6=\RVPZ\RWG3O'8U H"_A=_TG1N
M!];,9ER"V"PNQW=[^[F/'M_. P%[?$O<5DFWRG=NNJM##J_6'& 9;_TAX
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M53K@O!8#<IROT$E3*W?+%8&8 1"SK>6!P"P?F!IIM,M-OY$4F"5F3.@(-/F
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M-K<)ZS#?6R:.$)K,YO^C'A>J[I22T]L+[&>Q^T#0#N(2HAAK+4^)ZGAX$#+
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M_^N'KFK&NUB#>1$5L1+K"Y-]7A[X)M$BDX/$VVJ1Q^/BBZ]& OQD'>1N)C<
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MW29L^>I/&/$?/'>ZCIU?+-_T1=(L&2U95I\B#U14W1;OQ^G!16I4=IO/+90
M(942E4WY$,H'^7,[HAD?P!DMWN-:7K%6NU[\3[);R>!-1AWC"R"MND5:#A-3
MD/>!RTN?.2?G7]PD<3/FSNU%.FB)K! H.J'.*"P'\B9O\_@1$?=S:672R9ZZ
MV'N>F5)$.M:'H<IY037PE'R<4&*&XO[LG[D?6./%.R*X*.:8"5]JDWD!Y2O(
M9ZKXZWWD#4CYX<).*+<:2/HOTD#WFKRG/K/):?C%3Z_)P\0R)R%W1?B-N"L:
MQB%YR<QP$YJT7L=B-YA0#G_.TG1I<0ELA (AA6_?[%W&E(7*</%V"WZ31RR&
M4+$<4>^]\42]]]"N3E9R(7OQN!<1Q]6E/Y@3OSI"?$7K;KS>5;=A->2EIN"$
MHW<>BR3.@Q5,$APGV"EB+6)QIHVT^%[)_XW;\B#.YWWSW)GKB9?[.O[##?AO
MO[D/S/O([-'&O3?UA;%2%]RU.3>,-TF5^RI><J$.$G2*(4GNPZ=%>H-;)1[C
M^H*KF? BG<T\]P=_8,#LA92T_/K@,,^?6+.;D(W\X"!JMMXD,YP2Q.2FI*YJ
MW7>B_8<HC>W. ZX-G9"^,5&%R!0B-?[(0A^1<[(?>/-PKJ_7TD](M6--P*+(
M:S(V\H5-<VGY,]>G]M?Q%]<QHU?AMV>!_]5;?G?MN?.9?[$*[O9\P=7<;^YS
M>G._6K1]<,,^(FST=<:\L)O(MFG46:U.]^2<FQ9)3YD,8^N2*R&3^A/1QV)E
M,FY(D]'&PT*C9NZ'UE*\--/0?U_JFA 7@1C(_P@;S.S*J;V-7HJ1G9N^$"=+
MY P-MHWCP../B'E)M-?@\TY5M()75V3R&'^2L \IN1-V00;N28Z\*<SR:_Z:
M7YW+U;Q%AY@(\9MWW6-Z;_&7UGB3W"I8\M?K=1,@RUD:P5'OH51SI,\8IVK
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MI>_BRD-8^12S(/>5K]&Q<MQ_>$XF?MB+3AP8SW5? ASF 78AW7$-7E;GRI#
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M"^^^?OL)N;2)W-1>3"UJ5HS>:$M;EU44>*<U7B"WH.WG7H^J7G ]9*$ S_V
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MZHN1#R(ZNF#!35^P6/)#LK'F(%" O^3C+Y%FG4O&09#RSI=[CIA]SIF3A!R
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M!6!K[#CU/@Q3EQA_4HQ2EZ"M.@!,XD'J?1GBR1"&R5U3:ZNYD\>H"]8IB]\
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MQ-OOX=\A3TB_)VWHUG#N;MUH 5@P+!@6S%$_-4$95%]!*ARHI/<<(!"V_0+
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M(&!5\K4J5]TJVVI32J K=@7C5P3\[(?A8WRL$F*'1<;&;O00T,]+MKO$ER,
MK')*,6I EV9 5_V&X.O(ZHL:P-:#+O8-P=K^,HLZ9%D79)D0^!(##D9? M,)
M7#"^+M@C?L%!:$V1/\X,@ -WK/"!POIA*14?QG4(%NCP(2VH]OI@]2(+^EG)
M"ZWCW*]Z<:9!ZSUI<;;7]:H96M!"39B2E)J1H(I<G02.%U_'*X:J_88BVFEC
M&F=6X?$8VQ'4I&P\4(0(W\YCL.(>*E]P=/>=>-+>,[YU"64IO7%5S7ITR$9J
M"-).;5'&%VX%R@SP)B7>2NE2QA5\,@2R 7M5MB?C"C=MD.^+ G@3XQQ- 'AT
M"MKF" </WNX=S#U.1[X0:#+9A@P8^E)!T"?7XKQB7Z_D9,8^')XU"SO<A[ZH
M,&&A81"J=^B+:8H<I@8\23#TI6/"H9=($*I<:&B$Y")K(?!^<M? ]./2-J+U
M%<^P8%@P+/B,!;=!&;0R% 9\! N&!<."3U\PY.5QH>XJ+\\/H]9!FF< RPJ"
M-]=['L[\A1<-;7LQ6TRM"#O9[C/DRR!RP_C?GK/*UB5_? K\,-RX2R[D5?"C
M./@EU>'0 ,)H -N28,OY7$K34%^#<4( WY+@6^^96*>@>QE &: LPW&<9B!#
M!_@"?+F@3>\AS11YO!OXTWS]Z0S""9XR7<3I**95QQ$0.>L//"%96@S)<^Q]
MI7/+5XG?T%T+@,X?Z'P=^4R9 ^J94'<%B.>/^!I]_Q7\N]"V'K#/'_M\@P4K
MN ]0KP_=:0'QQR*>&T"U#NJJ$DP^A-3CW#4\LLV^X B-?/]/NI9%\QN92E^C
M B67VR\ [(CD$4/)90,A!"67@"<HN5S['B $)9>[*2B4WV. WQ.G+\]F;L3&
M@E/XH/DBL"<6$5]TP,,\@> [-*<@9$>P.(5A>R7"<O-@"V +8 M:O05U60?$
M 8GHS1;6-"/"/_K!T"8".G3I4W98H*?E:JGY\]SV&A!M2]0ZP):PYFY$EO$_
M[""R=8'_ZGK/Y%=A"SJ4@XR$+8 M@"W@;BSL;7G[(97$M%(U3&5TB)V2IFES
MM0!.H1R*28<*:8<VB+<$ZWA\/EBE-4G(5]9HB@N_W;8CQ9\SN%#(NM["*L!+
MT55_*[Q1#+LOBQFAF[V3"U(>\%["[5&T52+"#9M=&9(OTWD_X1-=_1.Y_X>I
M;_]Y@5SGEXMOF.&=??)'IV/K6!MWE;&C=12SWQ\K UL=*#V]K_:[EM,9]/I_
MJ!<($Z::DU>)@@4N0F_A4M,O4IK/+8<>5RF1/[_2.H2P!\JE36QO2&*Z?PIC
MKZO_+,+(';^]1Q?73Q-,KIM.8^.-P0"%$_\U1!'Y9F=$*#\0-&0_"-)M1:,W
M\L><)H20>X?XF?[T:CN+;=T$E6P"2C])>,%0&>2W #I>2,P]OUP0RMAX2KG+
M)G=8_IW<D?V]SF]DYZ;6/,17Z3\NT*OK1!/"FZKZPW:Y=+YEOVM5^5T20^ZQ
ME1RAEFT" WKHL11XG8O</NA5>CC]HDH4=)^#,^S*VJXL&;OJ?3E3D6[LFK%/
M,Q9SXF%7[:!6PYY;+E$.7&9IF[/7D&K#ZP!?"?C<BD.%_%7&C\1O1>0>4V(^
MAS]QU:%5._S]PT(>M'FAWKR%;X8U2NK1*,,RU>8M$V ,,"Y]F:6%P$PH9]C:
M,^'>\_P7*W)?,/H5.Z[M>F6XJNO@7*Z3Q3VNM!\.,WYVW:/W _^MVA-Y/W?F
MW'I6Y[<XPA6R?$_O)60?_I^Y(M>26EO'&=8P=]S4-!'*I.0&7(7E?CN':LH)
M.4,3HEH:('<0Y/1&0$X7HEQ9;L@=JE:%T:?I"=_#N!;-6NOAN=Q0XY [T3"P
M =I$1EOI2K1>M-5;378TV'B')=J6++QI'WRS/,?_7^,S_T2,-L1;+Y3I+8+A
M+2IV! L<B(>>;KXW-<!'U"" >/#1="&BFZ+B1PR/?C=LZK5TH?6&R.ZYR,CI
MP'P;D7UMH:$C,'+ E^:KF6_\8.X'5M3\+H6MJQP4TP=< DXH.QZL>.%FSX*(
M  HW;,&0OYB[AD>/@"<_LJ:-A_;^?:C8 !!#E9L:S(FII(_$^?:A&  Q^@ 0
M,0&BBP$0LV"$) "D! 53HF:I-X F\HA1D8!12XNB>J&AJ7"D(PHX"O0)R U1
M?-/S6F:7W%-JU0MJX_O\-9N?;.])M?[+C>9,)W2@6J'XU@WMJ1\N OPP_HQI
M@^V[[[2%DA7YP5M!@RFGI_5-4S>4CM/5%=.V3*7?&?<4N]O'AF/V>PYV<@VF
M4+(H[ RC4^ZGK7,V6W_AYA5L?G[K-CLW):!*.AIM__W7X:<[Y</CW?"?RO#C
MT]WC%>&)5^LM?(]^O[]]^OL5VFRYE+WXZ>[?3\KP\_VG+U<H;J"S];+$_CU2
M6)[05(M]YGH.;7:EJY?TJHOKCXJA%9BHQVY< ;HS=TC8F?;,VL++VZ\M;J^U
M0;9]_)+ELA-!KIT-:[T UALR@ZZ;OI[EV1,_N'=45>L8YD#K%\<;3U"R6=P4
M=,E84[HHUKHS*WAVO90 .B5 \A$E:$(03;U$C_0JQ1\KBQ C.GPDBANO3:F@
M05/7&KE3-W*+BX+W(8Y[L[G%C*R2W"?N.#?S7W \GL ?LP^"_&(+6\B5V44P
M*[W99OMC\O0A>_@C>?^/?O!J!<[>MH%:WS(Z/7VL='J:K9@=HZN,K(&N:"/-
MMGL&[ECC3C5M UO4,0\:W)2]7N@,PK,S2%EF?1=.G(X(A!7JT C]PR+62_"&
M2J!ZY?5QFLFA0(YK2/&021B;^OC$F7J=;CZCA*>KWS@\<)F,4A0O*@</W5Z^
M/X#0>."L-MJ>A4F#D79$G1)K-7&'.2FC14CK=,/R>S )9![Q+1K)^F*9 4?A
MTR3P%\^3#\F.W_BSD>NQ8$-8CAB (9D-S,4""7<0,P^):\]8J2VPKN%0?+G'
M3WXI DLO2(0 B573L7;9Q#4*2E?%(2Y(YVU75"*C;O$\(,"(3U;B\11M8>;Z
MLF.SFUX.2ZLJ)*Z)4 C%@]::!)TK0(IONZ*R*,+:B*&_A8MY^HS7B1MAA1ZY
MX2OD^:^!-;^X_NM?O@_5]S1U8#%O3?$/;XE/XPR'99LQR? P_NT<R8!"MJ,*
M=$:"J$/K)2)+CF-,2ED 13B8I2&] V6C#K*QZ(%ERD9&I'0$_5.&1.482E#M
M(Y1-7#W%NT+TX@8]D+ZL 'H@1J+]A@CBO' :QSGP>(SM" +2&P\LU>SU[(#R
M^BV._YL<L7W!T=UWXJ)XS_C6)52@M,&E,/_*^NWD3]N$DP)MD_L !Y&4 N3J
MK;I#%"6"TXP]@E36I@@9I>?L"2<::DW&JRSURC1$/N<2B<Q<<NR:FW/9<ME>
M\(9+.;^K-"2Y0^EE%&>1M[J]X;H+28'7%(^CA/FSU8.*%A</[C,!%_/TG"#^
M3QP10[G3AA"Y'BO=0*_$A$,!MBE"'?HI+;4JFBN)PKA)X"50JW1JZ6O4VA$)
M)6(L] F5[.G"(229^8X[)N\=?Q?Y"']WPXB6U+$*0%I(1PRC (>+:41I&V!G
M82]_O*6H[ATK(<S\U%E@^O-P,5+H;<GM*\- ?;7B:$O=X)9G[JB=[-11.SGQ
M7\-M!$6V%01O],>$N0@M*7F=?!;)A@W]+I8/],>T^.D=&KT1^X&HL2F[E3TE
M-V=9T/095UNI4+#/-=9LWB0[\2^Z$4//R9[UW[!=V%O*V;<<HVOAD:)W!QW%
MM&Q+&8Q'IF)@S>Q;^GBLJE#**5\IYQY9/0K0SXTO]\P5=V;%0;P%<;UG_,]U
ML=**[<@(S703XNR-S.8T=1]6Q;#%L-#:!8OL=NR'A33%PUI."XCBM0IP-O69
M6$.UU_OMO\= [D' FX&H]5[U-]3PQ.'#.+;H6,OZM1]0(FT=YE%&_*JCUCN5
M Q!SQ*"IL^!2>BJP)EEML5#(X1/T%D[:Z)*-V&T\9G:.4A%,WDC6VX*W%=OV
M9*L/"W=*@S^06;7Q0([VZI(&E:J1GBGR*+EF >(<<W0O&LK7$3TH'9?&W.0C
M+/H%>=D "1&MR1K$Q4#DWCA@0/+5FO_"$]>>0L>KS0=RM!]3$E2J$30-C 09
MS,=]8"A='0S 4I#&>.0C*0Q A!RV(W=9H=5\< :FX_)M!3 =?[7LB>OAX(WE
M&.)T6E.<?NI'$QPD^8MMD1 "VI8/E SQEY4JC6Z^\E\<P= L1)QC71X AZ8=
M88D*#2$-3%[BP@!G5 X3LQ:!D>^L* XX($TS=TVMA>.-%PU0*1Z3$<A<D4ZH
MJ5DN4!OZ @"A^?:UY](961QZRV6K-:%TNI:QL\O2Z=S47%KR3*"["-SH;7=U
M=.$@VBU[Q;'\^=?DY8>>-7T+W3 90?XY6>+;WF+GKHEU6S/[RLAP.HJ)U8[2
M'QBJ,AY;(U4;X9'5L:#8&8J=Y2WC/&I/DM8<V<':+2C\715 ;UO^PG.(U/$7
M1$(Y;=B10ZVOO:"IO"RX_BTZ$C10*)U_)?$C</EF[B%K/N0AW\/HC9@HM9<6
M[;^'Y$6PNX]ZEZ9@+D;_Q8\^6Q$.G@BY'CQ,K]X6JU^S'@DGGS:JKB-941H@
MYU3D+!O(9S#S6T;LGX:?0;VG?W+CIXYS8X%D3P]:-[0&.Y5('T.O-U4)2JIW
MO:T IN\''+UB'!N^-#P8O?K, &[^4;. %LJF@!AZ3E9L/+WZ]-.MN2FEZ!QM
M *>7C<1)-=:M(7)Y97UH$<OV$$&NZ#4WDP*D2"99.G#8#F;JIIE*S5-FIDX"
MC,%0+7H@5P,D%0B;<H*2AX.MVH7,^J9"I1JEHD+&GD1&2-W2!7R;YH*E$OFB
M#<!H!:,U9[0R8Y6:K6-_$8#56O1 OJ;(4B9L"(N/A#X<% L4A#87*]7HE1Z8
M(C*9(G7+EP&@I;EH::&$ <NU'LN5V:O,<*7#5<%P+7@@5V-D*1$V)04A#P>]
M4O-L#X!*=5"I1JETH%&61(8(2!< "\@7,%HE-5J'8P)!L%2W/I"O^<%%9PQ
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MX^;F'W;5#BCS>6X>-A4]MURB'+C,THBR]Y"-+ZWJ>1W@*PGY2KK! WLBA*,
M_=SXX02G[,DAOT&L(4GS]XO8(<H\\&T<ALG"Z90B*[ GU,E(/G+P"Y[Z+&C2
M_!TI#T'8GGCDYL_G'GM(L6THB29,WY+EQ\,2L9-N!T&9L["+PQ<-VXH':LDG
MRUZYZ<D'VX,XS=H%N21Q6=EFF@G#1O8//U^"9!BA?UC>P@K>4)(S4'N3^/WW
MZ-4P/ 2V!;8%M@6V!;:E/=O"VR:1MA*O)(+?^&$)_JW@%2\5%KYMCK)6M#]H
MN@'--F"S@&^L('BC92ML6/&6D<+D2YJZ$?_;<^YG<\L-:.2!YB0$?AANW(4.
M&UY[2L&/XI'#&R]#"VIHN^,=N0\%-T^^V3;$>,?-3BS?0P.UWKEK@&#9$;R:
MQ3VT_[MP ^P\)C$^\LO;56R/%ZC[2(5628#I\J3R,M+Z-K)"G$M/XH5K#:E]
MD-6 ZW)D]3*>_FL22/^:!-!YP;G313K(:<!S>7*:G8O4)9UU8DE#+PQ <VEH
MWOPQ0_?3Q/)X.XG=/A'4(O>.@T 67S[.L!.R& _]+RY18GGC2RX"^;;^0%:M
MID@HYHZ]K[3Q,%:!17Y^<6T4Z/*J&Q@ Y%L*><$":"LNT%%'R_?R #X /JA>
M](L1=%OQPD#-QRJ $X 3*M8(=8?I,LI@@#0U/U(5> !XH'IM4&=H;\4"&NJ
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MG%65#HU$!7X8;MPE?R:=_U$<[)+TP+LSR*>NBA,^ _R*CE_1SMI[2!W A%9
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M"2"2LINVB4P=8"4]K(3LI0W DA]8(G72[J".EA_4!Y"2#%(B]='N]&&41+,
M)4X7;0UUS7KKT\1R_Z&+-G315JONHDV[Y!8UM6#=;N-S<W3KOK@A[;Y%KM15
M;?">=KRE39:\B#7-?0[\Q9RVO_7'R+;"B?*,O23HR.19^([V47Z=N/9DU4W7
M#=/VN]BY%*E3\CH!U_K-=MK5LEC;TK)XYQY!3]XMNP0]><\6B,O9)-"3=\N^
M0$]>Z!VZY1KHR0L]>8&OH"<O].0]7J\>LB>'_*;A/7FS=@CTY*T(06WHR;L"
M4NM[\JZVHLT]>265Q) QEKL&>O+R[V@DSTQ7 9)>:^[*VZVW#!* SF'(NK"-
M0VK$?@<9-2>K /3YR'AQ^XW4V;2QWAXZ@'T.8E_$'B5U6CL=-##JK?<!V/,1
M^:)5:=;:G5<=P."--H!>Y,K.&AG T)'1D:PE.[1,X1O2:U=_7GE$F@"2BV\O
MISXTU9,1M!*$VCCW)*MYYA6@N+E1,\Y(KOF !)#<N!@8[_:06E?D+C< 8?GB
M67P1W(4^!7+#5^3(%&]AW.F)W/4? D]\ T^MZ]4KC] 20#9Q[X<HLF@2 +.P
M8%APPQ8LO!@6S?7A+I-U$[QWN2$LLOL#<-Z\&Q30K%\C1LMEK?%B;>LNR2/H
M:FBZW!G ,- &P$BTMLL=9 Z@\V0#@"5DXV6A0\  +0E;+_>0ID+&30- )5+S
M95,5>:PD0$KN]LLFTOHBIU9!^V5HOPSMEUG[9?KE,E#8Z&;,Q9^G4NK+8D;H
M9V]\7W3-WPIOL^69QP/HI&[/P[!PEMD[1L:9'T8H)%>X8_(L0MM\&^=7-YJX
M'K)38W?5&RMMBH4H09_]X U9 2;:[OHS_N^+ZY/MNT8_%L'N"EG4W0_=M,$T
MQ><*E#?^C+#@VT\,@.1V_\^?$G2%,^N(.PY?,%&"!/3VY4^7:.<>V%80O%'<
M)E%(\M  SRS7HY]9,]K ^G]Q*^PYH8+O4/6VL4KR)-JJL,0I"ZDK0?3M-QR\
MN#;>#.''CS]4;_]*2$2!]>3?>9$;O:TI[_Y2>0\NKGN7^>D(:!0W84PHDN6*
MS67=9I=5[IH>4ZH,&5%"1I2OC"9Y<VASP52DK5DFA*?L*V<1O)'W)&:OL<GM
MB'Y!Q!@1>G-L4[@1[/_(^I6?3^Q-JZY.<N<#7J>2N^Q554IP\Q""__2.[4'"
M\>N"B#O'+Q]?/@HZ):*@]&55"8.^X&Q?(<V[E_G0$3_.KY7J@X-X_W*[O5@P
MEB)Q[RJ>WI%U"G3U,O8*3C/O3S+;WVVUE0NLX=QGFY\P,E!<N=["6@L$K/]R
MUWZKB0.][?=?AY_NE ^/=\-_*L./3W>/Q%2<OEIOX7OT^_WMT]^OT.;\CNS%
M3W?_?E*&G^\_?;E"\2R&K9=1]XN8K=6;](40^*@81*'1%UA_I2,WKH!$F3LD
M@0PZ@&5+%&/[M<6S6C;(EB-B]F8;4$&N\\O%-\SDU@>"SC__Z [TT<AP5,4Q
MQCW%U/L=I6_T-<50;<,TU9&E:>8?>BRDR5VP,XQ.N8-QD=MB"=Q ;!&6MHEG
M%;@A<7)B!YYZ2D0$3Z?$*2H4!Y?,-:..4;SG,QQ-B >4S 0*L.V_D-\S;W'F
M+XC_F'RSO/N)0H;\Q<[J$'DFO=_8<H/$/YOBD'B<Q&]E,X@<-YS[H3652E:O
MAB\1'WLQF].M#9GSO*!K=KW$+YW:BRG;]W#+B*3#I.XV0!ZNWE/M3-3WU7#U
MRK^QTU2RHIO5JSZ,_Y6BY8G<CO'519Y7!VK?Z/34GJ+UK(%B=GNJ8MG&0'%T
MVS9ZFCH>6,X?Z@7"Q%Z9DR='P0(7A;^V<%4QV=LV.4K0J0XT&D-C*52A6L^X
MN8,=EMN2M<Z2QN E]I 6??6'@ *5U8N'S^E.%_(\MQ:W/>%@YGK6E!H!K]$$
M55'G5D%S.<WDUUWNW*F]7Q<!/C*\)%['MUNBVP-W'AL-GQA6'@E4J%%!W/CO
M46#-?6)3$.,BG'PD]M+7P/]/;$*$V:"&L8QI*/KNS(;+QC6_!<Q67PO.'Z;U
MIM_4UK7P0)W:]MKQ6S>TF:O-3N5_)-YOI$36]Q*L:,'3L!HOAX[1G0D(4DET
M[R7O_RNV0K) >ON'\4?+#:@WCC_C,+RA(9.'\6T2,#E)-O5KEDV 2<%T(\"P
M\&Y2ZD-(G%J/F--(K9-5MB'+ ["F4_)Q<IA&>39T'3;Z&J-/-.J=GJ^%*$X9
MQ@0\-$C^C%G4.@Z*S]V(#F:W'/H\\HO(1]9\'OC?"<")5J<WVW<U_:?%(OI6
M'(&/\[(0^9,LWR40BK;FV/'9PNWQ[WW1_'?+G2X\/V"2,DG02@\0V)E!@%]<
M_(KCA VZB2[9'9OM6D DDN^1C7I#Y!$ARW"S)Y;W3,CJ>NA/_)8-QE^B>R_9
MR<74"MX1:BQ)34GBD6ML>DN<1NO7D$(H2^7:V@^B@K!(G%UBXX"N!GGX.0X1
MQF\=+@\__ "3?:!8H-N!QL3+B$]F0GSDNLAK.LCS:9X?L3 HU.A2R./<@,IJ
M$0$3\]/-^R\^>5OM$GW+9"M:-MMSB@/BA!'4X^1XVWQ_OUP4I?[RF(GN=R['
M,;[F]CW-:'PA) X1#>;3#;.FC+!3GVHS1I")_[KB=1K%IGHJW/V S Z3-8;T
M?0_::;['59MG4_&Q1T@6',:\M&-5!''!<Y)P0)@0!X2)0S1ZHUG#-'N#W"Z,
M#8RKLQ((RCW*VL@B64'F)E[.K@.L\4!W^GI?4P:#KJ&8UFB@6)UQ5^EC8CB9
MFH/A .M\]_KT:@04\P8ZB#F6O#$>GU^0<.R13)Q6<K&R^SKYJ@S^!WGH/L?<
ML"MKN[(4<X*?66WLFG%8U'ESKP^[:@>U&O;<<HERX#)+VYR]#F4;7@?X2L#G
M5AROYZ\R?J1)X[,XJSIL8*K+_BY/K-2J>0O?K $OJ5V5#,M4F[=,@#' N/1E
M0EO!W#7E'[D5%;[00OCT,:\3-\(*C7;@*^3YKX$UOTB+Y./R^-HS*/;?@^/D
MTT//,EFMB7)4.=R.,L'FM5@]9O;I,JKPV0_#1VS[SY[+CE._!O[8C1X"^GGY
MG7[T@F9W!45$>7X ?CF^(?&Y_-+\IL3"<XS1S7?P WX1E5]TX)>:^:57,($.
M^.54>PRVA<OL#MB6<K:%M_/;]KSP=@VS!R^5RQS$6LP&/5^G58/5("KRP=]L
M-/:%L)A;C_W&^XXB8E\S\Q.? ?S5.X*B+KB]XQGE+%@"3PVF/X.S5NO4QGIL
M5M#: IBLC7?7!$4_.&PBH+_Q#IN@Z(=0'7ALM3LPK5LP));FKCF?I/M3P)_\
MR)HV'MK[]Z$Y;IPH:E1#AIZ?Q@"JM(3ABU(Y5J+@T50-0*.0:.3IZ(B"QH&6
M'TD&:#Q$4[=W"]KCBHBV!;R=$YB@"Q-TU8HGZ!ZBU5F!,.T+-UVP%F+9QFJT
M!]G1T^-V.47)S-(AF[HSM.W%C,Y?P<XMG=)KNRP*F1V<1E3P2G=3?1P0/;UQ
MEYR9<.Q]B\*9!QLHJU#GD(YR#;#SB$.R<'M"?GF+7_#4GV][B&@%$IT##1MU
MUPB^ +.=I[TA63_(@-:Q.OXKFV][__7QK]9L_OXV^S,;AS%56)O(J>L1]IF2
M]UKN'6UP]QQ8,_3;E\>^:5Y6;42!:,F\TTJTY/__."FC529E<LXNR)EFR)G\
M&3T7.?/IZ=^&IH.<D5/.J-7)F<TP!LB99LB9_'DP%SGS_[Y^-OJ#N&MTY,]=
MF_R*OJ4;N7%36H!KA7#=/^WY7WX4N(T#^V%*U8H;B1/DKD.>,L'?W.MT:]A,
M>3O&W/0MZ>9.[C"/-Q?]F/MM I^DD_JK%9;K8AZ/G)OT[7]-7CX%1O-!DYVL
MOALT^98K2]"X7AQ#*$%@G7IH!<0\@IC:9?Z4;(.8VD]U&K_UC?2 2>\53GKO
MP*3WBN>T'S:-X!R0;ZSWR.D%ZR.8XO$4#^-;/,;DI\Z3]1V'=]_G4\LCUG#P
M5C"^0-<,P^B/+46W;%LQ'<=4!EC%9!N[V.J.-*T[,'+C"U"R-NP,HU/NIQU$
M$?:REF=/_.#>456M8]!1X<6''&?.)2EPP=>.TU!\GI:XY0F@=0KHY"/*( G
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M%RQ[<)ZC^+CN"ARO%1]*53@I]2@/38)4*O!0^'HH][,Y@0+RQ\BRB1,<NLP
MHG^/%J'K82+6PM9)A-8M6!0C_=PD0B(F VR%^!;'_WV:!/[B>?(A@3(1J2/7
MBVW\<BM#"R;'"2=:!< 9++CI"Q;(+C\F ZLNP9'-R@(K'3BI=K>D'O5IYEU4
MX=0G>"9\/1/F!*.9_X)I,5+[G)#:->FI8S2W2!%&SU]3<H(6!5 =-TX38"4M
MK"0[Y*L';=<RA&<!:\<.VJP!2'!&+">.#ANZ68=D@CF*<B+JR!&<-4!+AY&O
M0D"K;I4E 0R@7U#NFKJG=1*$,B&&#&@'79VHR'40X]YGJ Q%TY$@Q@R DJL=
MM%'0*!- 57>#0P&:#)7:C;6@L@C0)1&ZZFP'K>D 'JG!(T [:*,'_7NEQI!@
M[:"%[@K</CAQ(WVW)_)H M[A'9C7V5R.;GWR(BP8%@P+A@7#@ENDW#\%Q%%=
M/ZNQF-/1SJ,:$7W"4W-Z&6DS;D'\@!,[QD)$2BZ<')6F6R92D*%"=V'AL5)>
MTFVIV%%UZ'LA$79V)M&6" P=Z4*'H0 8)V7%EH@0..Z0"A]'YKB6*DIZ,/V@
M1JA41-8>ZALBGU!!(7+M88WI2AI!;$/D',$S0AR9^YYF1O1AS)+,T#DKZG$N
M>$S44Z'H2C+X5!<(.1=.G0'((FG!=%1DY%RD:"9TLA/OK%" !0O)&F?Z_F<S
M"S)DF/K1$O142>D>TCKYL8?"41I*5'/70(FJ=.G,HD<+H$05  4EJFT'E40A
M!2A1!71!B>I6+ !XH$0U]SU@2-1(#I2HM@Y.4**:W@U*5->O@1)5.-" !<."
M8<&P8%@PE*CN4>[#<80#Y(_'Q%*D<U<1<3N(83B=^J_T+VOF+SPV#7/M.&=9
MQNHY:ZF?KVXT<3UVCY#8I^RW_UG\?_:^M;EM'$O[KZ"RU5M)E>GE33=G)E7R
M+>V9=.+7<6_/?NJ"2,AB1R(UO-C1_/KW "0E2J(L6>(%E,[N5,>2"!# ><X5
M!P>^$]B.,!W/B/AMOALD>@](Z%V<"G#G"U_XA''\.'X</XX?QX_CQ_'C^.4<
M?_4'X;[-;=MOP[7S<,LA^#^$^?HX8M^A-3SSCXSINN>I!;6[GB5WNO'34S\Y
M=XVE@"J29CAAG#!.&">,$Z[-9G-L>#'\_:?6[1H]_4^PRHK<Y3ZDH GIF+BM
MC699KEF&I0Q.5,SAA''".&&<<*,F?-B)GV43S2C:1#NX8@Q1.W@/*AXRQ4.F
M* !QPCAAG#!.N-D3QF,CFPA[S 9;]<=&LD,L#]/==1Z>4/_)<94Q&X8)Y#DB
M%<>U 8<7BOAJN[,239-3)^O_!>L??MW2P0 6>W#"#QW$3@C%S)@J@&)9Q(*?
MZ&#,<G_=],[\[U-1_C6:P+);*[^OMUG]9E/[Y>>R])]2VW;<IU2> JU^KID'
MV>?O^Y]OE,N'F_X_E?[MX\W#!:B#%SH+/I(_[JX??[T@FJK^DB5VMO'CS;\>
ME?Z7N\]?+X@%V&#^QF9)).6-,"6OVST"EH*G+OZ*@M 9SI:AJJOG,59O%:.=
M$_UXZ\+E$"C30Z+)0F^Z28UM;KOR=B.7;&M$S'8&0.%6C.-&=!ZA^LZ$ 7$Y
M]JP??^J:81C=(55T:EF*:=NFTF,J4[I&F]'V0-/:(HZUMD"KH,W%^=:W#X?=
MGF&VVHI)NZIB#AE3:-LR%*,'+[9UH\N,WNK;7WGAZOJ5AZ=7-KE&])D1UPO)
M@#&7^,SRGESHVN:&GCBNP4]UC,!8%<=#>.*2:Q./'T_GGZ"#<$1#\N)%8QNZ
M(%,ZXV*'>/$Y$)]-G# 4<1EO2, 0=:&;@/\-W8,A#+P4#0+'=BBOM7%&'#?P
MAM0G-!#-/_M>-(4AQI\2 Y6$GK!U?6\,@YF1811&/G_5,_,#.A8#Y(]';OQV
MF,O\Q50\&%+'A6^3LRIY(Q&SAZ_=9Q:$O.35.7F$1T,OA!?D=3SO=+5A^A8Q
M%= <NJKU/@;Y+UU>2OCI+T ?G^XJ#> =61(X0S(?$3R]6#D^71@'F.?\)^B<
M3J>^]U-\'L\(N UO\RFNLSY%-LWR]_F2W"0K\I LR.7LRG.%).%CN 'VXK"[
M]?R'S"(MN1N]N;O1>ST^O%Z4@ !"QH)U71[WT\_(>Q[^NSAPILLII77,55_/
M(TWG^N%\LPE1B71)+"VN,K26$/F<59[$-0%@+$:"]0&HRIA_8_&R*$I:%R6&
MO)!!@.F-LHCFWJ-X)OB"P]WQ"?LY=?P9X2O/Y4C V\0GV8*-Q\M>L7>RBF"K
MQ?.*0EG8/3OQ4L8U=P(+%@PDV[?A(YM,/9_ZLVMG"*O 0)S^[D9![+?#HC*>
MR3S_Y@I6R0F#FY_3,75IZ/FS=SFJC V[W79OJ*A#@RHF:^E*%W29TNFQP;#3
MLE5;:_^IO@/I8=$I#"ST([:W8DL- P$1;A60?%-A@R4K#%D26R9_?P>#LMB8
M>Q46]##_G/0H/B_;,@#@,9T&["+]XQW@Q@Y'X).LV7?+[SUTHT0O<Z,DQ^=Y
M]^D]%W236# $'PZ/JT@40LN=+^'".!43)S#=AR.>[/8]/Z'38R.L[.D7%23L
MXJ;NQGC_-Y>1&2B_HL._\[D),7^A_;)M:7?H0W12\?H4N!FP9&QDZHQ=QIOF
MWT>,A8\^H\)"7:E%]M4+K^C4 :;C<B<N/I;YF??X;7@CS*_5*F8NX[]NJ#S_
MO]PV!.,F4R[O-C$+'\$J_!6,P6\^_R\,X!(,PLP@^D5=B[I^NT.5^Q0(U$*!
MVER4JJ^B=#T)"D$J)4CE!MEQB<**#;13/R3Q^.()6RTX^B0-297;_E88D([_
MNND"( EDCX'7!C<!@D>+/RRX7C?\&@T?4^;JV&@G;6I1CITT\AE#2RGOA0VP
ME#CQ)!<V>#M((T!XQ A$ -8-P(8#R*@WH(GV4CI8">RE6R_RT5S*>Z'\YA*G
MG>2B1C/J#6LC"$LUEZ1 H,R;=X@_^?'39 F&UM*F%N582\XS!I=R7]@ :PEH
M)[FLZ<A<K1HQ>*BQ)#\ VUV9E=UI(+#9".JT9<XE0'-I4XM2N.4WSV?\A)E+
MAF@X;7BA_(83IR*(#[<!TL<@W2XZ_$V X_%C42<&8K%V+!X'EMI$;\N,);2K
M-K4HA6\ :-GJ%/'1>Y0>RR^4W[""EM]C*CYZ\0/R2B#3D+FD(*+Q0+NJ45!L
MR9SO>QI0/!(H=;LR)]-A#835-E44MG\LIKR%Y#)C^SI(HM#RS"L918E)VIK,
M+AIB[ U&DXP ,TA+ZL3=DP*8C #I$LV4&2 5FS/5EWU?-6=>*ZJ7M-K  R1F
M K)3A<@YYH?#@JYQV('1<5HXK3JG57#E]>55P'J9&]I@O<S]YCN_7^8TZF4N
MIOMP0G/EE:ZQ.&;^B.0/#&%QS#)OHW]+K7<LCSD_>U)O=!JA6C!4CQ6G)L*T
M*3!M,LRT>H_'8(G,5P8K@<5V<B4RY5-PQUPD4ZM7RR$(3[Y,9AL!6#L &PT@
M';<'T5I*K:73*Y0IGZHZ[E*96%:\(3 \8@QB3IX$&&PXADR9Y1B:39M:E&(V
MG5Z]3/G4U5%7S-31RV\&"H\7@IJ&$*P=@LV&D-2N'YI,FUJ48S*=7.TG^935
M49?-U$RTF9H!P^/%H-1;*Z<"P69#2&O++,;0:-K4HA2CZ91+9\JGMTZD>&;+
MD%D"(2!/J7RF1KH=K/-4/QJ/ TTM8JHRE[9'ZVI3BU*LJY,NH"F?-CN1$IJ:
MS!((\7A2133;73S.4#\8CP1,&M%4F6UUK)>PV@8+:9:^#O*IM>:4TM1Z,HL3
M1%GCBVGJI*W*G*)R8A"3$2)MTNG)?!_GT9?3S!EA :4U]Z]5=Q!YL5YASGNQ
M7J%$6J"[FU7/R]SIQS?QW&I^IS%-%<L5KHY(?O=[S=FF/\D83"46$ NL)8?9
MW+;A!A/A:21AO,=11!W.HRJ^56FA^!RC-J%1<!-3IX%E01H.@(J=FY(@4//.
M$F)@"P;T*C#0L"J,34UY*,Y=2P:JM6 \.R)XM>S^BA[C"%0$62[^BH+0&<X^
MDG>?TG@("<%(H"(B0GPVIB'_RA/VPDQ)(4B\(7].N(2)04'=N*D%?3BA> *:
MLV?JAN2S[T53 CAW0H<_ZC.R*'#.>P]'#&R/$)X@#OPOX(P2.$ G^'GJ>P/Q
M(F&A#*,PXDFOR<OAQR%_VPMX6V3 "'VFSEC\XKBB5Y\%4P9 ?Q9MR%^1[P2V
M(Y / WFBCAN$Y&7D6",21/"?S&S2F5C4Y5U'H2-"1^>;Z)?_?<IO7Z,)$,=:
M^7V]S>HWHCV7&XX;T26&77[R;RO-EMZZL_5Q[006+ $L\;?AK>-2UP*4]5W[
M&ZRE_]5SK;A9'#%[A!XOQY[UXQUQ[+^_^\[$LHIO_K2IP525,D6C)E-,TS84
MVNH.E"Y3>SU]V*,]E?ZIOB,,Q-847A[Z$5N6K7];7TW!'_Q5,*Z1Y]_9JJJU
M3+6MM?,#+WM(_RSOY#CW2[XOB9W?"?6?'#=E5)U'49*O>*@EB:IHQCF9+ZB
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MC;7-BBT1(9WW63J$U/6:8?) J&(==%CA!2PNL$-Q@17%1@9T3'GU._@.;,>
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M!C/XD]\=#Y90*A\$D5\8/.6S]+YOFW!!,F+D^]V_R/<7)PC(S4_XQ7UB)&#
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MD+T%A&]D6Y#\;.$30L1K"U Y_8NR_[0UV7_"_OK:'ENI5]"7D"G;.[(LZD6
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MF(*!T!@#ZV?=472=:^W.A-#9W'(6%)1^K%S$V" H3[PQRR]>, _'\C(U?=I
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MW*0G7;-DYHK-_B:.9;'&<H0WB_*FV%,1F^W-G&?&7D6/O:0?<,4"G&_#$XL
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M^.ADMP(PS+TY8&=BZF1*-<N?ZEA!96YIHI G/.S)U?"N,:MQHGGDA5H6_@L
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M,CZU>J3346V490!'CB*Q9W#T!S7P'"K-H^B.4F3F#=,YB*_]4&$(RR_<H<+
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MBK&7(]=\9\Z=Q&1)TG56>8Y_82X-POW@O[Z#0>G40F>?#D^(/HLGLL]ISSD
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M(Z? ,7O%R'D[$08)&#"."XBSKWYP!]>]YI?LAHVE2R>GAY-R#,@/Q=UFD-8
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MOY.)4[%S9K]-021H<4*16E[L:'_]VPV0%$51LJP+!8K8JIU8$@D2C:>['S2
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M\>2$/[NSKKR);=@.$\'H/1_H7A7$'H9??19 T_]'G8AM676.](^<=EP!]3!
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M7G8,\K\?C"WGFU 8DQ-CQ^#^"F,KKU;4OV),N'8=5M2_7/V]Q5/Y+ @)V/:
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M]_Q^G[Y&4N<5GXIA #\-&) _T>?"??%4G_" P#F_Z]XS;!9RBCI, ?'5MS5
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M&/P2_(OJ;R.[P(@<WU.!,A$"PIQ4YZ!/U$4X\,&+0M!JET\AYP]@OF$'_-%
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M=,V+4&Y\7,ZQJ4<?C+]HX_]1>*P_2[SF#/AC7 XYJ;SLLZGGBTK+T&G/W$B
MDI0V-^W <+P@\L%A@5@^>"!2@<S4;2W(+77+,>#NGVU ^4?/Y&BZ&\%C^87"
ME18[W_BF.Q\$P'^@C]1V P#A3P-T)BZH/G\FM'(?@A'"W\?4?63DLQW@Z.!5
MU,7*UN",23".72D^8J&!;WR $GW@A;+7CE$QP=R_!UJ> L&@ /(",4\(A,1B
M_4^H3MP+,5+P(5/-=<E%%9G^S>#8*).FIB79L;"',+AS#9N*/3S )H']/5-
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M(N>?2(T[0W)4M*<QB9+H%[P8T#046[="G^*8P)#@'L4WZ18F??#VO/!]D,W
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M1C$68]/]\.QX?\71[&6!0GQG@2)W@O-6\PSODD?;AW,P=,^SY-I_$@NEI3&
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M*1 *JR^AK+IPS+M04NU+878H2Z6NSN^K3?E2H)6'*(*2XE!ZA05?#HA:U39
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M \%R=@R[W=Z@U3)Y8\!'>J,SU(:-8:NE-88=O:T;O&=T'XWTCB&,:?L-P\C
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MR >/=_<74F-'[LPQ=9FT?F'#3W"[<<;\L>[!XV$XH29AN.OMG^9<(YZK+Q4
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M6DC3.9CZA4</Z\EWNUY#9-Q<Q(D"0\5MW"1.G7'4*%%KC?_R4GLA$<K5990
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MB[T^TS<_7/_GH7'QZ>;7S^=,]K-<>=ON,F,7U'UL]%LY@N.UA,M9HM030L<
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MIA*66%CR.6*V<TZ=&VH'GO9=U--JA#*3*#MQ$RITL4:K%-+"]=1$ UT-'"C
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M7X[;B)(JRFQ\-&J5V0!&6XVJV\XVGE-7M1MMA*\&J6X  Q-%."0G10TV<(9
M' *@'+_PJ(J$CCSF(,A T.N0=1B&SI%U-,$ZH$58C4QC;V\+S[RKV UD&@57
MK> L"SC!B.P"2_P+:X&7^#^XW &U>P06^)]U#T.+X6WLDW[D8H+#=G%8VI1'
M(-139::*X=UY=#.FMF[%+"WA2],2Q<Q U:)C^A@4CRKYXHNTS$"O I?NR8>/
M^*++@GSST:BS J\GFFI4OC8VMWH[J'Q5ZD8;$21\Y0M.(JN@<VV7U;EV^[TW
M>^U4NI #//<5KF05"<=.MS1D,/E 9BEO;">2 W0U) I5[H%$H6U$07]DU4@:
MWO2Q6EZQ&\@9"JY:T=OPNJ,0Z^3('HH:;& ]I'XW+UQSBR0!/0J)P3/O@<2@
M+<1 ;S352 :V-I$,5.P&DH&"JU:P=!9"'D,"D-\ +I2%LU#6X] *%\OB8EG]
MBP\-[9-^K&*"PW9Q6-J42W0*$Q>7O<RB$)6P_J#7_ .J6^OBII'LBMDDFQJG
M2G1,ZP+C4N7$KM@T _T*7,8G'PY1[<JH78>UJ%V:XZF$W+67$NO!]Q?F]78[
MJ':-71/F"WAA!4#N I3*4._*;P#U+BAZE\\<ZDZT^P2J7<^ZAZ'*4!O[I!^K
MF."P71R6-F42"&OUXUP5%S /H[%CN[KEKH74I8S#Q5WH5<TH7LHR _T*7-+'
MDQ";/ E15SP]K7CU4V;=__[9ASNDG\.M6Z]YF3!?P LK (*7[M!#Q0N90%&#
M#6WI$[*I3[F3CYA_:ULLB'W^L^U.:7!M3R;W!U[DBHU!_6LX'"$UFR1V(U]
MWULUDQ!VD0/>0P.=#ASH1C+1*)D %VSUT8P\-(,< \ T B_:('$,<!&)[ /9
M1U&#C2# $^:RRQGS^=3/@J,O,.L1PDB26LE1"C(-]#.L4#S_'D@JVD8J=,<5
M4@BD$%VF$+KC#PD#+M!=6 M]@6[@4^9H=PE<G_NL>QBZEK6-?4+ 4O8>71N6
M-B42"'J%2E5GX:1WR9SAK7T+1@Q3EA%AFH'R1$?E+\WN5$[SXJ8189N!;@4N
MV9,/9Z,V@IB*JA<?C5I+Z3K"J4:I"]?D5NQ$&[&C.6*7]BR&"E=^ ZAP05&X
M>$:XU^X1*' ]ZQZ&BD%M[!."E++WZ-JPM"F/0% DCBE'0J/>O#?LG=L.A;/8
M2QI&E&4&*A$=%;CTNE/)0T6$80:Z%+A$CTNZFES2I2.4ZCR3?*^WV3UM"T\4
M,5[=TIW"4-S*;P!A?PTX;3BYI:[%)D/+8@[S:>CYP_G<X18+7PBD;C7J^3VG
M=^%]^V8[CO:#!A.+2<9DDK69O)16OR+*;@.!7<>X G0?+,<B$ML,]#=P@!N)
M1!-$ F:<U5@^WQA@ ;UB)Y!B%%S5*,6 &9$_2#ZVRY*/P:"WN87TH\OT0YW:
MJ<CU)_XLIK:GFU_$!YECH0$]J$9V$)MFH#^! ]%(#IH@!YKBJ,X"0R?/<,+Z
M@JG@'T#FPM)"?@.X;A;(NMD_Z)Q".:0.U\V6O(>A:TS;V"?] ,4$A^WBL+0I
MCT!8Z'@Q$\M$3GNGO4OO^EZ[BI4NFU5V$6&8@>)#Q\0L$,Y4\J5P89B!'@4N
MRY,_+O[31O124<[BHU'GHED-D52GI-7O]SI8ST91RUA1"T@&0V$KOP&$_#6@
MM -[3$]XI^^E.A5O[0D"]0O+UJ5I1-J&^Z&C3R'X+WD/!/]M ?]Z@PGQ/^+_
MA@8&/OZ'D\>0 N0W@!2@ME6'8-3^>,TJBOSH.XCO(>%@Q/=-X'L-$82@'D%]
M0P,#']1KSEB(Y/,;P%6J0%:IGM'PUJ;:70*7J3[K'H8NZ6QCG_2C$Q,<MHO#
MTJ9$ F%EX3YUN)G!Z,/PLSVENG6K=)5J;!;A=ADH.W1,P(+@2^5T+&&7@?X$
M+L7C*]=-;NRZ^CBJ4<W:0BVK8C?:B!?A:UDPDA=*6OD-H*0%1=**OG+G]2)_
MJMTM4-9ZUCT,E8#:V"?]0,4$A^WBL+0IF4"0(C( ;=2CGWM.;Y' #OC/P A=
MF9;(J/?K+U^/^N\(;E..OM:L$+:PD @3G^-L@K9%\^2YW<WLD*USG&VQM\3U
M[GPZ?_$[=^-A_]TFYQC1W 3'!8<UR)?181LQ5$5]C8]&K:>" PA87#^&FEM#
M V..Y@8A$%&%0VI2U& S)V#:KMCC?]0;0N4DL85DA!N>HU^!XQ] O P<MD;.
MT"1GT!I=-1Z)U._CD4@5.X%<H>"JU9RZ"B6](4G(;P!+]4!*]>?4H?<!OG^"
MA7K]:='0/B%>*7N/K@U+FU()!-7BP/,YGI+'6R9Y:S1Q>_NS2>^"<9)CN],_
MZ#V<%U,R]I*7B<6OB+"9"*,-5#(ZJI>!]+R21XO']A%AH($>!PXRD//_X/LL
M"^+.1Z-.[0Q0I-7ZHLOCLXI;+Z-AT=UX(0U0-**LAK+:PEKHLAK[:EN>=I=
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M#SR?^YO<$Q,.J8A/,\V823)V&HCP.L8F('H9$@DD$BTA$G#"JT8.L=7O=;
MCQ3"6 H!)PJ1/6 -?F$M]!J\AT>D8OD=0CG3T#[I!RTF.&P7AZ5-B01",52E
MJM&\]_>GGM?[B_H!O=,MC2W>3I'&$6X=^48\;I^!>D7'9#$X?E5.#%.6&>A7
MX-(^N3C[V$8X4U4'._M8ZXLHFN*I1O5K>[NWB>I7I6ZT$4K"5[]TQQYJ7D@&
MBAILHI;I.<$UA44%DBJY- V) /H4TH!GW -I0%MH@-YHJG,9[4[O#9* 2MU
M$E!PU2I*X #R&%* _ :0 M0 U\[8]:@W[(U"__[:TP[[N35$F&,@(.L8S-?I
M-^6@?6R:@:X$#@,CMF\"VZ\^A.H\AG"CMXUXOE(W$,\77-4HGM>;L!##YS>
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MS?P=B0U_92#"ZQAS@.R#R"602YC/)>!%V-/LHI]BF/ZS(4SKJ84)TP>\* -
M+.!%X@I/BMK<0K+19;+QD44ALU2E#5;501H6+U/"D@/Z$W*$DO= CM 6CJ U
MF)ZF QLEZ<!N;[=[=  K#<82 C Y#,L,^0T@\J\!J9W<^UY@>7-V.>.D=RY7
MV06@*$!J(<F:B%P /0Q)P7/O@:2@+:0 1E356"P@VX/-[O$#$R8->+$%@!W
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M7C=7X":1U"82&V4@;.L8/]#N25@S0#[0)CZ@*:!JQ/ZDGP,O$/\#F"7@!1,
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M.Z5L^^!\< F=3&P12VLDG#%RXGO1G' VY+,YCUH^,[ )&=^3(!/^A+H\)(+
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M$T._]YQEGY:;D6A<6"]&.\C,*\)GF)!!2CWD'WB<B:@CT[?%['F<6SFCXIS
M#N736.ZO-'O,Q'UDOO-<YS[/!!KQ9^QG%;L,'58CG!'VEP94?/MRJ\R@+H*'
M#Q3/#&J<.,*U;\3#YL]?%<1$$Y&;F"1'@V/K(%X_QM/ZFOA5YID_L&GAZ[$/
MR"'C ^I,8OEUD>Q4GDK24&[R_GZ)$RO-SZXT[[:\TORX'ENA5@J##NTSB_*
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MM9)474(A">DU<P56H^1NYHESL*3&I01=WLZ:H/\9XV)47V"=])BUF!Y( JK
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MJ;QU&*D"NEC(!XD/7 @N%$BGN9)2CH!5ZD]!HJ7($['L/)D+"[^,XF5&$W+
MD]J:^DJDMPOJ<]@GQT-]9HO%*&-!NO@4.O7I35LY1%(HF2\/<5*^3H8A4# L
M'?GE@;^;,7=I!7/RA5S@9GD<,GUCDQ[Y'-\KYOSR)['TE9T8Q&,0*&Y1R2@$
M6*G9Q%=6QH4;^X8E1BR75'KDXN%/?('%KCC3X1-<NM11M*4L62AQB24\C#F@
MG(A@H4*-BP<U$W.B4N+;XH9K"0N(XU#<<>I[=V)-%6^>?^W-D_=!U>>+7W#
M94GY0\[+]E>E^G%,0*TPK8Y)AJ$N<40"5S5PH7IZBUHT]Y;0M\>1;$:HC"YS
MUK++K=86-XY7LJN+XF;H/?.# K(FZ-&\7(!*ZL5_*IC7&[*[M?FCQ*O^,"<O
MA?),KX0PE"X=/A?WC ,A74,,FK7%\9N)E*5.9!Y8#G?+!)4:'!DHWV=B@C(L
M:^;%=UJ0,,J#9CK+B-H+H2^'S_$ #!=Z8=+%&+=DW"0')"]F*LGEA [ DYR<
MXAPARF?5>YJ9QL9YRA@6YGZP,+>'A;G2A3DPM%_%.Y+_)LA_$?4/5(DS9T)[
M-)U+GO] *<AA]/DS<GN)?3P$<7W)NW.7UK8+G&:%)?,D1X91H-8KQ4\IP\6S
M8DHN$%3>X#/Y*@%U[L7J/H%[$](E'X;E4)MC$+%M2PS#4D9GR]R4RPZ36\2+
MAN)7*=OZ4(\Y)J <38L28/$(JH!8X'D9/FMBSEH.U?AZ.N7A%X0)?Y)(.(IW
MUKD12^_E]9(3I-*N;(_ZOJC92PH@)8IV#GHUA2)AD=\-K"+A0J[%BUTZ<W52
MN8Z?CQ+551&< \0,J!-!M/3TX>CKKX/7S]DT.-F:<,+LMT.%BL7&SR]^/[TX
M/Y$OO2_OL0NFG\DKX*(6J%8SANIEW@>KYV*D'XCS@27O@_.H'LA=/_30SCRE
MR,JW%@4!']W9X3?F.W+:*-XG69_0] =U(X']8CZ^A4RH9B8TZ  3>FI[EDW<
MGZ4-^[.T9&^69 %,WFXLH%XMS]M?I?26*NFF#(\W44E4SPSAC'=,R.P^D&2$
MC<>[ERS9H/9+6:H]?&?/E8*]5K[S@X)M6+[SBW03"O4*/:/B[2X%Z<,[3^Y(
MD0K]\8K,Y0TJ,EU?KI\O;]]"YW,6,S>Q4HG=D(V]Y3U=EC?N4-@H&?PG:S@+
M&1K0NMBZ=C1I<O^27,]]YM8E/^ T\/8S 34)/]K. ]24>UEN<XY4.GVP+T5^
M:6)!IU>SF47N[A-F;3^1M AR PIM#EI^"XIT#>+3WK*RW2H@;E8!1X;XE-T_
M!'>!:'@7B(>[ 1BW#40MFPT 6N#P3,%T?:-0,KW@OV5W(AAF'G]B!YY >P%D
M$;6R ID["N9ID,=L[$L1,EX3!.;!_%5:V):+H'@8.DPLU]P8;/?%3"B%;I+0
M>/$^VIB)]\A$0/*OT[=[5,)-U@+++1/O1'Q/!2#G!L1[ R:-Y:-,/I%,Y$X"
MGH]OFM<MX^[UVR;CCGWR>O&7?3,E@6_]Z\77_\KW6<;4NN[],Y^^$&]0\OO;
M5B@/ GM==(/,7XN&?GL]]B;W_)^_O9Z%-\[O_Q]02P,$%     @ R3U!5G^X
MOR?SE@  9A8( !    !N=G,M,C R,C$R,S$N>'-D[+WK<^,XDB_Z>3;B_@^.
M_K+G1)QVVZZJKJZ),WM"?E5YVK:\EJMZ=[YLP"0D84P1&I"TK?KK+Q)\@R\0
ME+I3;=YS=]HE @G\,O%()!*9__?_O:Z\@V<J L;]O_W[\>'1OQ]0W^$N\Q=_
M^_>O#Y<__O+O_^\__K]_^[^O@?O7P%G2%3F0-?S@K_*'O_VP#,/U7W_ZZ>7E
MY?#EW2$7BY].CHZ.?_JOF^N9*OM#4MBE+"O\^BB\PX ZAPO^_)/\(*N<G&0%
M0_%CN%G3H$1;50'J\O-/\!GJ'/UX=/SCR7%:TV/^4WTEV:5W/\'G1Q+0M+C/
M?3]:=;0B"_TH2U'!G*Q>=R6MPG..Q>?/1(0L.'3X2L$^/GF7 0A$F!6<D^!1
M494_EO@#S;EAF9<)Q@\_Q1^+15D+1Y@?A,1W,HZ\5CB8B/3XTZ=//ZFO/QR0
M,!3L,0KI)1>K<SHGD2=[$_G_BHC'YHRZ/QP\>MQYRC[]<$ ]NJ)^6*I0*#YG
M/O$*Q4,B%C2\)2L:K(E#.W@GA^;!P8$:G6RUYB(\\"LUNT=0/+"ON4-"F :J
M8F!04_T[.)2M__"324_JQ577>HW$T@H_PM_F;;8)WK#E=ZKE']-ZT(%W/QZ?
M_/CNV+(;]1/,I#?%FK=Q1>C.)^C.\<^#NV/7E6WU PC\)+@G2=(%"6%VF'3$
M$Z)4JW]'@G1LLKD(%,V0O'*?KS9JIOTHQ7WR_B?X^.,\\KSF"=--!.K_#Y3(
M__K1X>)_\B(]IU.ZDS@\\D.Q25;+U@[654G_\2/\P[(+0;@6?=K/RJN_AK3L
M1$+(;;L?^F*=[%]#>I%OYD8=2(O#'SV;K=D?6YNLE/^)>F$ _ZIOF/@^#Q6A
M^,?L]_6:^7/^'\EO\O]+O\+V^-=4R;BG\P.U8?Z5" >F9ONV^M-:\#65FQL-
MBGJ*(K 4=/ZW'Z02\6.ZY_W/6M!#N66G)2KTRTNW6AEDE4#NP0K1==[)E 0L
M8W_[(9#L]JCDP[_]Y?<%Y)''OH!D%>KA0^(0KR\26<6)/*22<>F\+QY9A?FL
M+QRH^B _'C!YJG"Y$X'*./'="S]DX>9*SCFQ4CSZX0"*?KV_:E<,X[Z<MQ'*
M9G9Q!N>]_X\C>9*1_W?PXT%*IO@G\=V#F.9!@>C__4FG4M=(%%!WZO^'^EL3
M?T(@*=%5N<SK?G7U):&Q=O(AE=!_U A,ZH6A4O*G\RMY>%S17E*:56IWB>8X
M$TU65_Y]QOV >\P%'>B *4H'6<^"431G?"4I+ZD?L&<Z3$YUI R$=M(AM%Q:
M!WQ^X!0;200Z2O%L2?P%#:[\BW]%<O6QEJ!&QD!Z[_M)+VY RNV JB;>J.@>
MB0>'YMF2TK"7L$Z+%0W$\ZY#/$E'#@(@^.:7PT!. 1(L+SW^8C>%B@0,I/.A
M0SJ.I'4PE\3&+<ME@>/Q(!+T+E96-W=RY"HE3BXD:V#-.0T)\X)^RJ YV2YY
MGLBE\%.L&F9$Y3]2NO_G8 V4E8Y(4]H'_RNA_K]'L7;P_V1'<CTQ%.RQG6 /
MCD?1-HI@VR+M%N5Q_SDZBJ^)W0_DT:-;7V\3JIVB?&>SW,;$QREYY3]+HEPP
M:_D5*1A,N^/W55D52(P"R7DQ:%I5Z1A,I [AC-.FAKO#M,T:0@9J2*><1FTR
M8<P%$3[S%\$=%;,E$?UL6N?-9$P4C(]5(:5T#N3>),_:DM(H(8VU@U:]!F(F
M.H21M,85L(G3PY;!)FHF1S)#P8U+8L*?6;1:$;&9SF=LX;,Y<T#O=I2'@^39
M'?>88Z\-&A(W63Z/JW(M$#T@&=6#=4+VS8OVR@^I)!Q>O*ZI'U!YFIJ&2RHN
MF4]\AQ$OOHQ)OEIK+'W:,!'TASIE)F[D@,9TU/&-0SO*)5 UE-[BJ9-=7.S-
M#X '\FH]=>.Z)@+[N4Y@2A8AT'CS4OC,N?O"/$_.#3F0B;]@4F>8! $-;673
M1M'DT%VSEJ8DU?QA&=$#HJB^>1F>TSD5@KIR5L1\EJR_9N21>2RTWQZ[J)K(
M\J0JRY0LS+]$@$JL7D[ZS0O43#/Y7=0?<S7HQ$8-.OA?:0.CLFLFD$%GSEY-
MF)Q$;20^'DLMM-.!!M;^+9E(?WO:\#@J#-2G06.@FZZ)T;VW<C8*UE"?&B1<
M,]HF K;3V$8I9SMLV\8ZS/!H1-K$"FFS:8\F29N]=.B%FT53)@-@F_OV.# &
M2,O60<RN+;.A47$:&SHT1G>RQ& Y:(LO4C#1S3L,G^..76+LL(6Z1,)DEG4*
M9UQ5:UAKNUJ6:9C)IV85K)'/N+25N?MN"Q)Z9RBA$S,)G8P2:CGZ#UOW# B;
M>(A9&!7&]=%8!+:KI@EE,^E6UE)#Z8ZK:Z=E9]C\-21N(F5;N]$XD7O)PG8R
MFU(W$W5E0O<1];@CFXK#5ILRI?Y["'M<P@W%\7ZGPGYO*.R*4CW.[.W;_VT7
M<3/:9C< E5EM>@,P"EG0S,Z:&EYON1_''0L'N<YUTS5QNGI75<4RP@7;+80L
M3(B/CG2&_!]DP36E;G)-:RWCT>YK+(YA9RMC\B8;\P!QCP>LG@*QW9W-Z9M)
MO+)#]Y3XJ'J;R\3VI&5.WTSF%?6[K\S?C3)7<CC;@C960\A$_:IYXZ<H'8S*
M5H><!FE7C>1,U"E#F8W*4S.WAVE+S?1,%DYC\8W*4,*A&R*>)"_D8)Y1R:0A
M[X1J29DLE#5.$#FM@R C]G\@@.:*N\D_0K:B!RY=\X"%\I\N%>Q9<N>9EKR1
M@E!$<0A'V#A54+KL#XBM\TR\,3)=@_0&K<,M!$U68@R#8ESFVX0Y;*%OHVBR
MU.,8'^,^TBU.VW-T*TFS(5(Y.O]Q0V0TE[=*U/;@W4IR_P;):*JAM]Q/]/_,
MYG%.'VW#;391,]%+:R(TWA9,+KF@74GQS<NM<&_X((@?$ ?H;^&-4XF:@=R.
M:ER0BI>:88'>FY=:W>28^.YYMIX5GI)DJYFE3.W:,I#X28WCZ%GM+%7+;]=B
M/0X*N=.Q4/%"RN>,*P\ Z@^(,=%&T43 O]0(."<9;ZI%HF]>A+/H,9 :AB1\
M 2$VA[XX;:!FH& E21S*H>X4D8,@HWH0\H-P20_.J4-7CU0<O#L&>3:D>CB
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M4XSUD VL833VAUFIF(-3.N>"_L;%DQ*^LEF KTLZJ>*!DX^C_O40,T4[C'\
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MUK?NWMQ?V>"[(T%X'M$;^2,<<J<^+=[L;)7BWO#Q3@Y=AZV)I[HUD_UD+B.
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MJ[$KNP'*KFUCNS0$<TK3<A6.=C?D%:) RL(9KP91V!]&G=/ $6P=F^YNP3
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MH1^$<O?<Q-W79=GX%1^0^)T@'%$A\E:IXVF_<V]KL[+[H\!/GJD@X 0=/]8
M!^BI5+>5LZZ6NL2D)#K/Z7NH<\E>Y>%;=KB4I/6!Q^_'B[]EIJS>U;"]Y*D5
MURD7@K] .JE6J9:*H1-I'K@(4L0P-W%EON5^HN;E"D]W0<1*@F[%+P3>SW33
M0CKWW+#?71#?V^[Z7K=CPBT^(X!W9%/>7[I*[9$&U# 09;UB'-7.4ONSE]9#
MF;BN]F*KL]C>"UFN-)0M_!I+'CP9 FM>.S.,ZN\]E[3MJJO0GJYU\"[,C2_'
M,E#Y2^A:\)U5$+/"9->NILG1([-8U-N7/1V>\L)SRS,2+.6)?^[QEUOZ&CZ\
M< #6L3!T5T8\-&S9<RV5<O&P)'X*\S0*(=H7DP/BF=IQS8SFGYF9&<X,^0/U
M!S*SE>:?D)F3.0"W99M>&S&#:E\]9C'NC;-V%>X4J@>WK5/%MR-L >(6N85[
MR&V?=>T/S7?9P!ZIZEM@@WZHWR[)M\5+W5RP79+[8UO8 NZ*(6++--_6P#0W
M<?Q>C;TM_FO&DZU2?%-:0=46LVVB^\/.W^0L6\I#2LVMV"0(./AXYUN1:6%T
M%V@M'9_ZI\1_2G/0U5Z-6M=&QX>&^\$T\#:\=<NOH$P+(Q[L+7Z$J:<)>,0E
MP3Y5P.%:1\*6PF;HW?"ORPV(-7JD5[L[?#;@#=(!>E;)<%^/V: "8MSW<G(*
M*; (J.>8,G>5$F;3PJCP5L+=UF%0.M.<YF:J[F+[<SI0CJWI*)5G1>7=6LB(
M#D\3\D%['S^Y">#YP72N'J?$L2#/"P$4MTL2\:JH^V*Z\C.;,^AN$LXW>;V3
M.62VE=@;MUJPPUYZ_ 46\5L:5D%E&Y]!P?TZ>M2_RFL>PBQ]-%&<'UN@LS_K
M2[+Q>9L;(IZH5/[2$#%2^R/^@F5CH2<3=T!W?YB:KAHQA*;7@0,YO.M&]H?=
M#]19^A"_JW6[JF6B7=7]88W:XP<.M($T]H=9V;$V58YBJ%=^$M^^\J"S)R-W
M2']_F R&)C_D8M.3>1;U]H<I^O,U[5AJ-=JV3'-_F EJK00+_P'5[9EX<+[M
MJ[\,)+)'[$K&@U_(8E(R\%FJ?ELAN$?'C]ICM<V<M:>!F5M:^ F?K8CWA1(O
MU$+FU'Y!^(Q9GF<<2MT@SYQT&@40T[UX.]A<8G_6A\D*+.#?XQ@X\U/NNT&:
MT2>366N1_8%:-OE#=MK:]4M;Z R*[\_$_$Q]^5F>BNZYL]1B#C1\0S@YT\QU
M<+4#!50*W21?AI82SJPHRJQWQ3ZF,.08I*_4B2#<2I8:.#>,]ZF"$',U\TSJ
M?'H9A9&@Z8?8IRJ%W;O6_MBT+U9KCV^HB!]C?Z&>>[JIPLW\=TU+[_(IMQ7.
M)!!3/[A]*^V-A5]/K9J$38JS7@57Z2.K-($07.!#)KDRZ,P))#]A;YDJYEUO
M%QQ51^JM<C.EB)F36GSMVG.S%FV[O0P&?:(,ZC1FUFQ)J7)6F;RR;$]M^&9\
MC>ZR%<2PXO[OYC:@][@LG,:O^,02A^S(@WUIL5>;ON(#<AGY;B& 6QE'TT=\
M,(PLCEFVV#M!UXGO>R7)PT R^%C3X&-60*DG)# NCP_LQ''DO]W4?W#JPRDX
MGXA2G@]RT3NG:TA4&N@!5:WJXF-"L9MPI)P*MF"^<JA5[WMOY/X/#PL_'9V3
MC3X#[.KB8\(U]Q=2D"L53$C*3H_0%P4A7U$!GV*3";T&76GB/L/?02+W3?U0
MV15Q?&S,G(Y=B'I)?)@(X25A0IUP$LWR3G#0&'T7'@UHD\J^/CYFG$L"SRJ<
M;"'X*3C\U6PEAF7Q@53-!M-Y?F6L=KV"7UY1!S4NC5@K[<:@&2/-R^,3KU)Q
MTON=&NVG\@D?A'2'/J5$^') R(T;[/UP0Y4]D4A@P":^(KZKI<H90  ?.QJ?
M1^BGJZYB^*!!=%DJH*-W9*UG2VGZB!!&XVU-54R&9?&!G,E?X1&/NH/3$O34
M?L('H?@&@\-\"2H3!O;PI).Z3FA9&1\;BBKK]-%+7^9IMH&.0OA@-1QL*U)J
MW/>'$,#'#K@F]W@0"3J=MRNKIQMH)K^G+#WN&4X&U;.?'@K_+1R))9[\EZ)B
M;%<5L9;<$U"/TU!+9833IG6,%\ZVZ;OZY.:[S^G0@ H^QM0!N9,CT6%K>4):
M*06[.$%ZE$<\*TQ0U&V<AC7PB3E=O:?BJR]W0&^C#.&%[NOZK'EY?&#OP#P'
MDS2=CIHL6[[C W-+%Z0-3,MW?&#,U8YKYBN%(>BOL12KXHM[UMYWLYUFGUQ/
MVI$D$>IJ?!LR]SHSEI@1^I-P;?I,A3R[*/-7>LWI;*9K=98SXU<7";R<LC\/
MI2@'GXB:""$^$ZE$%?'36NAB?D%:O#J,LW"V0%<H-//S#@CCV[CJTN:IFZ_"
MC6(-<_I7PP=="5A/(U@G\)IQT:L:/NA9]^6V,C-"W:L&8L")O-*!6C>.&X#W
MJ8F/ 6<USS%J+?W[<A?3\,1$.T-T%,('RR2M:?L W;.!J8YV[B1,7DZ!8T:@
M2;&]"#Y(#8;Y^EMNT\+X8!I>4^SC9<394O;WEC_#\Z @O2:C<!8[9?R&NLR!
M!!YQE)$S?G@=NH<S.)<M"=.DNP5"&-C3\4C@RL^L-#<J7:"J7_2Z23U78Z?_
MIJ<!%G00OZG4-ZQX%$PB. F1SZO'+]\8]7VB;UE=Q3",AWIH=TLB5IW(&DOA
M S;Q'.Y/U\MP2;P5>VJ$9E .'[@9\5W^O0E2XU=\0"Y.+WZ[2$85#0Y7AX^'
M7V[GB\-?/]<!,RZ-#V@Z@T[EXN<1EP;+:[:2S;N?R7>VCD3]?.LLC1=H?K;,
ME5G8([^0%?-"[M<#-JZ%%W@\/ATJ^R(U!$B<3%PB=\O#<RZ>B?>?$7VD3MOR
M:EH5'PO46IKW^H8%@?S_2;0@4U]NUZ V599>H^+XH)Y=G4Z^Q1GPC/'VK(,/
M=+RQY)T_Y9$C-;IGV5-:-ZY[E,<'-IV4\AS@T=GAY%"B"1E9\'.J?JJ?PIVE
M\0%5T_":/')9ETM:,09UGFE#W+\:/NBGE/U3GN#+ZV]RF$N^::[//2K@@]NP
MSWSY-=$NOG!_\2O7,?>NA0_X+/J^Y%$92!8U<Y/(3QU,@V6DK6%651&R(+%-
MI$C@B88<K<WVCSX5\,%5JU,Z,EN'MU%)I "5C2H[O#I)>.*V!:Q_-7S0$[4"
M0)37I 3!/Y8<9B/Q:[61'M6P0C\_Y/+_7:88@B>I7;G*Z/1/\@^R$/2Q#GF/
M6OB 9P?$0R%!W FRB!HTL-H2^ "IB:@?^+Y#7#*ZCAX]YC0CM:N*CP7QL&S&
MV?(='YAT^,5!'QTBZ&1VQM?47Y(%;;!V=)3%!U*-O%LN7.8TH^LJA ]6/-":
M$;5\QP<F'5P73D1<+N L^I\1"WG]$&PLA1=8O/)!CR\.SP@3#<B:B^&#%@^P
MB\5F'1:[?4M?5,_/(%Q&S8@TJX /;BJB2^9[$LAT<Q&L>8,8&\K@!:6:IY="
M!:"24KF/*/-NI*)-6-!D]C:L@Q=T/@AG1H -RN,#FQJ[F*"!VN2Z\?:K@@]R
MJH)!IZ_I,_$\+H4'"1[">EVMK2 ^>.EP/(?SD+.$A0:N37^CRX8+N;:">.'E
MU_:WX)<AN]MJXJLOB!V>LF(\J;<"[3+L+HX7:AI\?0:W* [M0-I9&A_0PMD6
M>GLI*'N,Q.)J=2K_"A8DJCEK&!7'!_4W\DRO(9@%]/Q">. 6I6T?[47P0<IO
M.*'#LA-!\"*W@B DKNZR;%(2'\!XFU-1?WQ5FWC0_R_<^_[$A+.L/SD:E<<'
M]LO%?TVN)Y\;P;5\QP=F1KPH)(4=[I0(CSY6!=95#!^T"15\#1V&_MY'+J^;
M<%V%\,&ZA9RW(;GR@T@=C%(7*/8HB!<243T5]ZJ!$G!B%I1="T"7/CN\.KRA
M(5EQL5[R@ 634,XR_;5U[VKXH&O.!#0!DP?FFD#\X/BV@GB \8;(G@8!J^/(
MUJCA8U0F[,A?$+')+<C)6,]"U\=!,C>GD4O65'^6,9@*/L;$.VT"J!<SK&KB
M8T#^5,%E)(%Q$ZT>]7M]@W)XP>4C]4X]W:4&0 WKX ,=#\QNH ;E\(&[>S@L
MC$0NCZF,_)T\R1\TIV^3@BCAY4><4R+W8O4_%6BMA?#!RB0A*-C DL%V#K?.
M#9;>UI)X =XSN1T$3\QUTRVA\,L91*B0_RN>ZC'WK8R/#14-JBQ&Z'U5_>Y;
M"1_LZ3KD/O? &^B6/M,K3_<A:BN #XX2R%5(/$9FAVM0<UD%44<9?*#2FP;H
M*^046.AN]FT%L,+)3R.),UX0]_^>/U-!]<O[GG7P@<Y4,^Z!3^G?B=2Q?SW\
M]?"!/VT:[H';B^*%&%N2.L U%<('2RT72@BP!M9 :BN #TX\DQJDT_01'XS*
MSGM#/+*1BO+,]0]/E^[A'845'J;/IN[]:^^J^%B0*])_YTLNTM[_&DDXU]&J
M\L2R1WE\8"MO;\"&=4[/#K\=WM!7YM1X#/6K@@]R[F#0CM.@'#YPY7T C)'.
M;')& ME-XCNMC_&;"^.%>4LA$ 0<#8)3*:*)\)=Z!C^SHG@AQL+I0M=8"A^P
MV*N7NK$PFH!UEL('+%XP5%>]E52<ZY:3FJ_X@.13YN4?E*B#=^A.(N?)JZ2M
M,2N*&"(7"SJ930.O0:&N*X 73N*11)[@]M)/S"6_$EEEV6#3-JJ!'? U7\CN
M,R> M^%W1"(DM7>Z/:K@@QP_N),E!)=X!'.4UVL36N/2^(!>TR?E_AF*S1-_
MT=Q@Z[_A Y&--B[":$&\V>>[V;5+#N'??$:\YZ8#?'=YQ&!C9^S$2?!>-N:#
M,?#^\/KP-')4POF&^^->-?$Q0,TV$[PF!?'!2X]"T-\'(A;1323T$'\=9?"!
MTO:#Z[,;'CCZ>M-5"!\L-<*2M[G/(7MJ0F90#A^X7-U\AO[.0C J41& JVZ3
M8MI2$A_ &8E<5GZ1>\[ -O^H>I4\,+]G&^(N]?EG41,? [+'UY[\XPD627BT
M>PJ4 H\\-U@P.DOC RHU&>WE]?FA>WC]S^CQGT0/5V=8%A_(Q*'$%*=Y<7Q0
MLZ'(HW YF8/&?1=NY)R[8:YH/#=WEL8'M&+GKV XK(5L40\?^%1NOW)!B8I@
M0WGDU<NVH0P^4$HR;8C:"N"#D]RVM>!I+8$/4'R6CP(&1]]3(ASJ\=KHL\UE
M$()Z)"XC]S2,J CC![Q$N-P_I^?R%_Z-R!Z[W&/Z*M*[&C[HV>+_+"DMZ.1T
M%G+G:<F]!N-^2SF\X$I/E2:?3TE &];)UI)X 29^)*W0&LK@!56215D1,Y=A
M>SV\X.-^M^*L+X(=4FI7,X#65!0]1&?Y0MEW*I9R!Z"3SS=1&%+_>RO4CBKH
M(8>4^9//ZC^M..O*H0<7"V?R^9X%SM) C'I)? #CL!TO+/P>7VK/)C78N@HA
MA:6=V4&KOA3LD5?L<L:E\0%-@G?5K:'UG[!"T-A?.\>,2N(#F,68)>R%I$9/
M^8\U;;C_;BN(&-X2\GUE#R(@N\,3;WA#TE$6'\B*H<@$;=]*N&%'4G0>$>R!
MP6O#$&(A78%_QF.M9:9')7RPTV%ZPUS7HQ<D""__<7$>-3[";"F'%]S7-,2Y
MW.96'MV<$>BR_*,>8W=QO%"U+:,G\MZU\3+BL^QR\+CI!=^P#C[0:AVZV- S
MN?(8BKQ?%7R08PW)"*I947P0/WODE0>RU\LGC_F0;#Z(5E3D[^ 3^U:0;K*0
M977.A1LOT@%]+?-AB_3P,2M+W,+%FL?U89?Z0GQX1G?[W_4SOK,T7J!Q/D]:
M0'!+7_Z;BZ<FK"85\,(](VL60HQ_4[@F%?#"U</"]QK5?2OC94-'OE;P'H:5
M7#!W06\F3<9Q*QI[P!2)YS+RG=CL_YGZ?)5X5,L=[YS1!3_K8DD?"G@9\HTX
M#@3(G/CN.2,+GV>NY9V#HU]5O"Q(+PZ@YP8K1'=Q?%"KT<!B=:6PO,GA'/XF
M_V_Y\%\=]@FSNGO !)"@.>RFTDB!WM,Y?&//="F[_UTJK-?79^UHC:N@A1QO
M2\HJWX&TO212@-?4#UYA'$X\%O!OC/ZSLDT9E,,'+@WFX1S>"2;U[% JG'^O
M.X@V%<$'Z4(M'D$KIHXR^$!=\FA!A98Z3/7_AGHJI:F^:?:J@0]P'O/^&_7I
M]XAZRG'K#%X9DH88I!UE\8&LN=@\:P)I6!8?R"P>/.,.H[[#XC"Q,\+O2-3T
MA+:K,#Z829H[?BI(P+PL/-)E06!RSR-*0Z]]YMVW*CX6Y//PC'M\]<A(FHN8
MS.DY/>6/7(^OV*\*/LC%F"9JAO; ;ED7'Q,R6UUAP';'2NE="SEP%0<MY$4\
M<9R;KN>[O6OC8T2\.27/D%,H%Q?_BMB:0$4>3.<A\5:0MAB M;UJWA(M?$R*
ME_G2JM["!N/2^( VS>R&9PCFQ?%!K4HI#NCN"OT1@E%)?  SVQM9>.SI,W/)
M-_I !%M]%9'O2>H2%]DP^6.7V\E6*.%C4'(\]HACS(E^5;!"_BRB=2S+5("
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M>2C_:$'851@OS!L6$O$(!A[YOR%E'EL88NY5$Q\#5"0F7V*)P\Y\8=]7-(3
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M('6_^@-Y/Z]?(YU^,7.%Z2P^'A7@8%[$T4;YELA@M8,9 =%@<(!\4== 97;
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M?,LBZS!_1@7TU-'&/?;Y-N#(S5K%0#BP+#TE/,"&BSN:P*>)*;-5C!ZTN<1
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M:4;YBJ%;DB.&>/[Q:8D(1Q<D'8DOLQM,A"APDMT*[5F@ZM=KE"<XXQJ2TB#
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M1\J1H ^#(VR,.MD$(4K:&B++(R3CB3"C)I<+0+8'0;^<[I/X2?P[7-,:XPY
M8#K97"8<3VMD/U&^0?A&"*9LLKH2/XV6B!5,46F?,PPP!Q&M%-A0"SOGJ$>;
M!I%F9!/:B;U<GB4!*'77Z&XH,!.18:1O0GGL<ER<K7*4>EHT#RA@;%H'#784
MP[9K)HC30%*%K=O&ULT+#DS[%DX++&W<<!&E>3M+ &&ES$6WY//!&<J(IQ$#
M'#5WXTS;Y!([_6$DC$!2&. <V%@*)@<XP]D<QW[ I@;HH,&L^,/F.I'LFXX(
M+XB0=_RY]KZ;9@88@Q/M@F7_YJ8;9>H@+[@I.5.YA3V^[-]8&<G0DD83*2JM
MP9BA98+3,>4"UV5&G^6E]TM$T SGW5;!<B;,TGHC63A1&L6?A&NF#R'&I8L%
M8A+9<2(V"KSLLJD*53H'PG)+_T[WUHRQI^9RC.RNOLXIRW/$%I>4,?HH-[@*
ML76, NR2+"2E)3#V]J8D92RP%$2/9I\H>=!*S7P28%]FL]PLZ8V=G3MT8KJ&
M$"838-:VVLK2AE;G6+'N/'Z)RMQ>U1N)CV8B *+BFSGBU4VQ$;E&BX2H&T@Y
M0X%94V,K*V\&#!A:MCY1!29*'#,JPG"995;N4?9_!!,-;E&[1#/*T"1YZB3@
M8!1 2F1^O\KI2[46YJC--AO/@1DO=8F%.E$8/:Y-&!K-MD@WC9'80?Z#8I+_
M+NR V&1RVY:!X8'##, ,M*(O5D#(XNTZB/U=K,I]P%W6NC5+-91!D$<9BU1/
MHEY1KBIN[1X(,S8V6&8F9$46T:],'HP7I"CDHO@59E6I]9)II0S"DKE#:T16
MK39L[V>81DS%8*HC(O:EI1(GJ4)%Z?E,-DU67EWJ' @S+.@0B DY*M'$TBT-
MOIU43>:8U0^+@U*^O0>A.U(6>R.\L^[]/,=DX!\["8IN"S@2*,R+<ZLURFCQ
MZ$"[<(S& WTYR]I[6A ;.P4O J[13*Y_9:[]\%>@JZG#>K<2 2&4J73B\OEF
M1::2OK:@IG6@FT#>@5LS)E0ZY\3-?9TVBFEWD*9)/@L,"ZV=T((W7]'#HJ4*
MT'XRS!C,)W#14QL[>8>*AV%_142L!5E*>)$N,)%W-HL3H7;7:3?1^Z8K$'O@
M0C6D(%QQJ'&0<VXY+8@>:<M4C,"JXK'A;2&;:> #O<-0W):X*)5E>SN&NEZY
M44\FR:A^!7MM8I"\Z)!)Q 23XH8-XB-RL19,EZ?&8NESX;/TK;]<IL/T[QIY
M45]Z8R>+FXA_0?EG2L028\]CRG%+;&\Z!6;_"@=Y:FF$),./3]-Y0A[0-9[-
MA%T55(H_3EA">,GL.S2E#R(FD3U82M\Q8BTU#D'APGS!R$$;PC#"O51JL4PP
MDUN%XI"7R-)6FA;AJ PX]TS/]L*A4&)5 .0/S:UTJO?-O)ED@]$?/;6YV5_6
M\53WGGM_%,P.;69"U)(%1SC78N>8BEA5DQ$Y&.;8.1V<?%H(@Y#6K,@P"-M]
M"QG.!D@NFTFFFRJ/<E[YP1&YH>PQ8:G<>+)DFDN3.EIV[\5-)L$L'C%T.)94
M1MF2?Z%$==\+ZG6NSKL7MG<L!L5;&,+6NV>*7V%>QE)PF&I(<+8LC>+W";U,
MR)^\SA?):X<X7[59%[N),"U,.Z-=J(M1Z\]',]DJX2:CC^"L2(U8D>S_5FS?
MS"K.[2:"L3YF:!NW)@H!#F;9FZ5\:6A^Q"ZW."2D?,1^AQ## Q=_8#"SQ 'H
MJKM9HWP#K 1T,?UKA<NTHS3K8@LEX%;6]'+%,4$R,=7LM:OX-"B5*N^U"2J+
M=TZ6.:_/Q05%Y4V$$9,!9Z.5P&A6%EL(!A:<-*/VX,+[ -^$>94PG((.S,C(
MJCIF=(I0VB3REN0)><#W6?4L@+TNA@,*\XPEG+*%YA0@;2J61'TS/H0FN0.$
M>3;3CQ;Y<@F0!E4+0OQ)4)X_RX9!LB>/-,)%\6X0P^0+'>;!0J\6*@S+CB+L
M=P[Q8:>T+&EHW_(Y;6Z.0O(^B0%K<$>3& BF)<>9&*B."^PM1,=$, FS6S)E
M\N&A:U3^]Y88]Q^VG0J&YH^S&9KF8F-7%;W<)3FZ*OZ?+)8P)=\#"LQ,O+4\
M:2!&0$G<C).B526?T"([Q5#O:9M^O^BM9OV<XO>0M1F"C['W2"LFEA='05(U
MOK"@%H@$W &%81$8I0F3F D SDEUSH]3=8X]+;,A)&0V)AA0)TT:X/)2'YHT
M7/9%6:'2\_E=\U'?(4X*O2X(-Q"XV&)6^(FB2E=\?M.CK'A3("$M#5>] #EI
M_S$=R85@#[QD@J)<PKW*P!*86\+IW1%7HH1)2RK-0+G#O97WJ'9>#ZYKU#;8
MU)C>"NJ5<O4"=#2I9EOIT'#<<99QO:T<K?+"!:^%%2J]4/D01NFK/M-U60<H
ML.QZ-+@9! 4%[)U('BP.<E2"/MCEOO!KLLJF 7]0]F>A?DN<%^T1-OA5.; N
M4VX)XFC*Q%P7NQ=?X#E[Q0& N[.W!.;D&/I/,EL>D[1[>R=V'(6*^!Q"6H,[
MGFU$,#4Y@E/(S8W"<8+3"2VSV;_13+!?EF(D;&_G;W9$&1 JT.YS >P$[8E7
ML7-Y^R<D(W:'4H06Q5G(,R\ZK7>%JF83CR<4==0+%W:X[S\:95@?G^1;7QQ5
M%RKKV'<BCVI7[+GX;M&P(9FV^8L0X(XF!'65;S >Q5[P#4*VVZ'.6Z6F4V"6
M+_2C WH^1._#L*QWQS-#.9M.\;[T =V8VS$"WN9!4;%C('X_0##?50BG$R&X
M Z&@Z9;,)!6C55[^M[BC;+]G\(9U-)=Y'/4E$(.<8\1& ");<W#9J4MP41!4
M[EGD_D4A5YMI1W.3QE&$]KR('=M57DM27J5";\GHD8B]Z1PO&P>D7U?W'*<X
M8=W'$$YPO._ 0(\. G 'B)Z,9I^DWVJ<A=@[ F]8_MV^CD5A/%D466E,R\#+
M,YJ.XF^%$@6'#?->NFLE?4_L42E4K,J \"1:Y?Y=&=/_O:LA&>-4*!@KMS<D
M8Z"_.]NL2M^6019)24%CXV^V;\Z&!>SDZO\6Q=4'N!X0BE^Q=4O5E2*LDO7S
M!2=M._I^(=^MUK'/22X;4C^/9HWG,C97N$+T?PCS"<?2B1^/6.]",BZVXFTL
M>" M"P'/4:5Z[SO?A^,,J4"#]?H<S>1- X;FB'"\1JJWS %T_2SOQ1XB^@4)
M B;)D_W3-X$@!KA^H\-$I58.!'6!@5ES[T41[4',$$[!.FBI;=IO*%4GJ]P
MP.SJ,H1R=/$#N"[HGK]QT Y3D&"ZHK01)+86^1\XRR[1'9IN_/.$-I\!JHFV
MX),+V.,RO$X4&JXU.^V"E,Z+P2V],X]=V],>5.Z\ JX)/:&MC"Z$-:)S-P_
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M$FBDH$&::KGK;C75GZ[[1IMS>']& *GOT-N!4><XH"[;D(DJR:LIC)PEV&D
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M=3'PYT=1%C5 5128AD!&5.P<[OZ>9"MTD?[OJKRR,")F_0&<8<#*!WR/=5F
M>/C_O6Z^JQON<*W+F8^#[W]/[D'/H&UGCOVJ6?\)!'>_%_:>&41+!JC+7?^)
ME=X5P;?%G=5:+LOCMGI7(V$E1CT0F*\[]29*4X:8)PS?PV.&M:L*V#O&Y"6?
M(^52^"L&+<SJ/QO6/[.<6Q0.E\ H22CS*64'V_#IB0K\F*%E@M./3_),$O%-
M'YOBF#(AZB#->BZP#=;A^8:FP;1N LS,LB'NU$NHSN&%^GN3.69%7X)G8[T[
MG (S<QM"'&VT1H[V*V0K>RU,DK"S=VB*\%HVY>XP(;H90"MF721I1JI?M-X
M*Q^B:GJ0-MMF, 5R*T-3(=C1ZBR%YA>,7*G9!)B9*CL)V%#JS'_9W&9.,UG+
M7JXR>90EOZE@O78LS*R2'=<-B73WXNIREZVPK<M=6Z?"S.U8^@(GFN.<HM+%
M E?/=@EC62,^]6X8U:)'FZ]]$T VA91WB"-!_OSB@2'4=D9J/SG V<4&N"SM
M7*.,+N47ZC*C6Y*+3286$JU?%FH@J?0#WM!@;D)"$$;]Q.P74]E*LE^!];]-
M"2@P6U9$L7,7T[]6F..RPF5VN>*8()E^@GH_;,SH$HD-H,SD2;'(Q'$AHFW=
M_84@I$'6M8BTU$53'H!"W"U.Q<?P#$N_5[K+XEL,J6Y8Z@?#M'\&>--P\O#-
MQF3/GQ/V)Y*](<NB,+Y=OB7VMEH6%C!,DVDNXSZXX2SS&DFUQ?<5? _086:#
MS*7?&TM"13ANDG8' C.S9"Y07\HCIVWK*VGR!44GR;L!@)G-,I>Z#]7.*W7[
MI&45B;>F=34C86:US+EO1%[DA25K%8A@[[/M@K*;"#,C9BY*%VJ=%]"$)2G:
M/0$X/&>WE5<XH##+G<QE&9H3L4\T$R[#,_D?N0];)YE,5UAO?MRAN.A#_Q5?
M%CL=7]+AQ$:-BZ(> 9(M%*=TQDXU6S]]N9SB)#?B(ZO C>+VLZT".,-P$O\9
M)/%[DN[GZ,?)\XX;ZF[;8CK%22@#],JS=-/&E+K704AJ1[-OO$;':+%8S'*2
M!*1<D#6MOJE=(>Q&[P.4<-00NU4NUQ62D\S>0EH]01@0Y93KL!%&X(Z(+1GF
M*5LEV0UEQ4V&XKN3>4*JI];DW]KK0^PG@R\S-F@>9C8+YEF7#0'43\B10\/-
MJS!W2%ZAG.8KALG#9I$IA&LX ^8!EX-@K>B-+,U*"?G5YK''"[U=ZAH-\Z#*
M?7GJ:?4XA!1?0.D=?4XRB4$5FUJ(PFHRS!,G5\DXD!X[KU;B=$N$:1"&H<*Z
M/=9L&0CS",E!C"9D1A;9'9JM2,J[G%O;$)AG30YBZB802C!RT'6TLMY=X8AN
M#LPS)I^ Q(QB9X>VTQATHS#M/LQH/,S3(0<I6%#K+('OJO5BM&OK#L*-V7>P
M1_O:H%B^V7[P5&SS=>WSUV=G"JUQ!>%_"@!%-_PX$/I^4GV[5K@$=41C-<__
M6 "*E!S(]A!-?0W@AK([M*QN!XP>2>L#1J93@)X.. G$AN+(AK))7WW&I,ES
M[@_S/R. (CD]E3"VX@;;.\U()YE!WHT;[_:&.[\YJ'K<=MP-T"%FD.>L;K3-
M5K1C UPZ:OW&A(H=2:,UXJ;;E VB6B P\X]ZQA^\\N)&>&23MT5_OURQ4\AM
M@V%F(1V$V4T@&*&5]*#BQ-U4=IHY,#.4SNM10V?H;=3V0^9;J,,Y,%.,QC*P
MI!/,:OI$DZ(:Q'0E=8R'F9YT6$5:&IU74"LR9>-/QWBC=3+, A&/\$$7@&@X
M$5AN>1%Q:WI9VTZ%6?O1E\QT? B_TF[$ILYQG;5,A5GGT>,JZ^2#L\1D(Y=)
M42JTL;HR1UR%-%]7X@\BJE$)S'(FS$LUQG[*B5H(.<&=QT$[@@W]8*"'9<8B
M-*4P2I*I;$HAL=D:9:AYI69V3Y]9,A@=(+>DXI\"F:YA,/-#)NRCIL1Y'1C1
MM(VKBE]AYF<LF-E*$Y2*HVNTI!SG_ O-=RH/=V]]=M4?V4& F:ZQD*@7W9&E
M?HV8P"O':Z0WN-JQ,),^%I(TI#"RS.K"TLY,7?L@F(D="RGI2(N^I.[SQBM<
MOZ%,U?NN8Q3,/$]G$$ -B8HLFCJAI!-.YSB8*1T3\1B0Y1S(E5D$'6,[1L',
MNYBP54O4@!N_S9.XHUEYW>Y*@'-LZMQOP],9SN6;0!=YSO#]JF#QA,I=-"6Y
M($7@\5 ;>E4PX@@!S'72+?Z=Q,'V"0H\:0#Q1/82;;B/'@EB?#0;)^UUY!83
M8?H1>Y%V41?'\BE>"H-I!A6(NMI#7U!@#*/9"\'.+XS',I4&STB&$6'L"E0=
M$5HKZ@@!ICD-(78@!G9[IE!K7O6"65V^VCB%+%X_+7\-WX%D[_,?GZ;92CZ&
M4W]P)7CVC3QB(O\XFDF\Z4H^-;F]DM21, D %8PMW:-)3S5L&]J&+.U)@D#R
M?!7^([+?ED@OS_8Y,,VEG81UU,7.-GG9H^!V)UHO_6Z9AEB=@^TMA!>NWV4O
MO?$<Y5C AK>SJ+ LBDF^<93>U@]KDX>+:8[7K4>N5A/!>+KMB]*\N%0GXN0I
MSE!GEL5X#LPS9TM)42>B8Y^E""I2L99X>=:#TN:YJIE"NX* >2SM)G0_'@ )
M@]Q5P!$"S.-L-PWP8D%D!:AJ(<M=I;L6^("!663JI@K^? !B$,8)]C &%K.]
M*R;ZZ7'K9PFLZ8=A!:XHS[F;Y!TA0&W:[[7ZW9@0?>%O&LA*U,LK_2X6P!T,
MU!;^KK; EQ/NA;_SA#P()_0%Y3O/R=3)Y,V7:\IN!=W*#:L7()AI,#=IAN!$
M[-,C(\*+W)"\H+M":?6S.H<6 IQW*AS2@@_'$.>%7_4&XZ-5/IH=MK"7RBN0
M_$S79<)-J//V)F]GZCLL8.]<*B2Q]\$:,$4ZO=5/O7WU#J2=-\C5M2;$JQ_D
M_\A.?>(O_P=02P,$%     @ R3U!5CC1?R4E)@$ T7H4 !0   !N=G,M,C R
M,C$R,S%?9&5F+GAM;.R]77/C.+(V>+\1^Q\F9B_.55>7J[JZNTZ\LV_(=KG:
M<UR6PU9U[^S-!$U"$J<I0@.2=GE^_0N0^K*$SP0HI+H9)^),NP0D,_-) (E$
M(O&__O>W1?&7)\*JG)9_^Z^S-V__ZR^D3&F6E[.__=?7R=5W/__7__Y__^__
MZW\5>?G[?XO_]YA4Y"^\4UFU?_[MK_.Z7O[W]]\_/S^_^?;(BC>4S;Y_]_;M
M^^_7K?^Z:BY^S>I-A]W&'[[O?MPT/2#]_+YM>_;QX\?OVU\W3:M<UI 3/?O^
M__MR\Y#.R2+Y+B^K.BE3P4N5_W?5_N,-39-:B&T6X2_*%N*O[];-OA/_]-W9
MN^_>G[WY5F5_Y8K[RU_^TNF.T8+<D^E?Q/]^O;_>?+2D3PFK\^I-2A><Y+MW
M9^_>GWTO6GU_F5=I0:N&D4LR)8R1;))\&U45J:M1F=WDR6->Y'5.JDM2)WE1
MO>?2M=^:,S+]VU_+I^J[-4'!SO^30>G5+TORM[]6^6)9D+]^'TRJ.UK5GSA-
M^K(@97U.2C+-Z^J*,LX33?.DWG#RSEHR ,V^I&-YF>;+I/C,:+-\:!ZK/,L3
MQM7+E;WA)KN@BV52;I5N+ZD?_9ZD7GWE@I85+?*LY2"IYE<%?7ZH^5\"E34K
M/SG8*X!J3Q).6)+QWBG)GY+'8J/7'ZR%,1'HB>\',A-J:J>\\?1_R,M5/N/_
MO/[\V9FU -:4XDAB;U:VA.+(\7,H.7[N68X;PM>^]?+QPF>?^WPVK\?3KQ7I
M5I<5'S]:"^1,,;)D'X)+]@&)9/;3FC/%R)+9^Q3.%*/[2_:>((!F;_X2?<K%
M-D3X+^-Z3M@M+2\:[J:6]:%O:F^70+I]>0_)-P!*TEX]<7@Q3\H9J:[+76]K
MZV6-I\*C9&1.RBI_(M=\L[@@KKYK@&]$GCWLL7.FB, S[\4Q[UF^J[SD._P\
M*:[Y7I\U[9='698+IR@IMNW<UVPPY9XD_?3OAEO2.3>K[$ZT%KM P<M=D932
MJ=M>5#AI+++:+^MPTM'7][.W/2SP6Z)8L+2?9.&D^]K;-8M%PE[&TX=\5N;3
M/$W*>I2FM"GKO)S=\<DRY4['^G_M=WH@LCW)^)G2[#DO"KZF7?/=9SG+'POH
MOLB!5F_KHTU,U-[O=*2'9%4\LX^>P$DC\'#L@RL@JG$B1O9KGRVAGN20A*<G
M;2S46@ CA7AKM*,DSA2CK\Z. D()(YD1[6=\,&4DDMK'9\&4D4AJ[UB"*2.1
MU'Y) %-&(FEO@O:]%J9\?JS:KU?CZ7E3Y27A_J*S6)9T$/A>]KL"$-5(YZ?V
M6W)K2I$D">9&GO4]1QB^;[^@V1**(X?]@+$E%$<.>U?*EE <.>S=!UM"D49Z
ML($>5XY08O0MQ39F-V%\[Y.D[6+MOGFWHQ-%BD!"'$^&P^BIAR1&8D<>'XX[
M=3LR866@:>N!C\KL$U=<_7)=3BE;M"R8^+;H&I37C<LYGG9'T@8&*U7[J!'L
MP 'L_K,M-W/#;WD]OR>%V 6T@23 .F9'[I]GV?3CVQ_?/R+;XI[U%XLZPQ:,
M.NLO1G.&+4CCL.."DT:P\;??CX&H8D&SOSCJ&3I9^\NB.>M[L^K*4'\GHWT?
MC#IG1]BO,W#2QSM:=)Y]+&@<G7O[Y=""QA&26T&YK?VZ[2*O=+6(V'KNDBY(
M9B.'>#.<]'&O4#GD0QL(]+7MDZ0EV^\!-9V#\GN>%.*JZ\.<D-K W:.D:7_I
M_4O"ZA>Q,+1;=KYP+(5BG,-?UI1ZDF1[?6 SL"[)H[L<EG1Z2U!\K,B_&_[U
M3T\[SK1#%-) X+A\^[(=/54R8*9DWQ=$Z&*1U]TJ4G(?HXUWDA(2.K4GU:MG
M#$P=/U9:N&&^"S9QQEGU[;5N(G ,&X&92/\6LG?%37F_S6F9=29Z7,OQ-9S>
MO<7U+;?.%AP\17G'J,<&+DD[3O107">UEPY(%T'TU7[H@ZBBP-%G>K.BBV7W
M;W_D!2>-1-:/O8GZ$9FD]I=2P)2C[0GL1Z8#K9B'SD[1*@=R,65R\L4=R&$Y
MU[ _ H"3QB)K?Z+VO>);WUBV7QD -*-+9[\: &A&E\[^-!5 ,[IT]A,-@&9T
MZ1QV2^XTHTOG4%K(G69TZ7H0#D]TRZ'N%8 HBAUN3QO<J&=F]O.))9TH4MC/
M&Y9THDAA/X0LZ1PW)FQO2B8"/?%]78IC1\H (UK=-=JII;W-.]"*)HV][3O0
MBB:-_6;>@59?N]N$E7DYJ^X(>Y@GS+F@H*'_$?+='$(GLEY'SR<,D$YXS'-7
MUU)@1QJ%KS[F6F8/A=<2:+F/*H/];MN23E]1<LFG^9Q[21CW0>K\21K6=\ZI
M"?"1OL]#=G8D:<<N<!UVIJB6+&'I6KC5?^[*MWGU(R_K[[-\\?VJC?AOD=%)
MR^\R,DV:8B_E4O%PR/K!$_%BR(>53 HZ?7),%TE>^C/\BDQP?N><($N;1_+=
MYI- EC64PFNY5<IW"[)X) RJ8AF-X)PF10'D;Z>GFBMNSGG9'DS>\#]7S<6'
ME1]ZW\T;HN%K\N1;3<J,K!_6V7RBH.F! -5:Y'S*JI9RG7RC)5V\M-/3=V_?
M?_?NA^^G35'\4[38_M=W*67_W#9I!6W_O6UQD3#VPCW-T4)<]/[R"IDB>23%
MW_Y:/.J;=;(4XO4ARM:ZBB_+*$V;1=.>XEV2)2/"Y^.@\1_%O-[]-]\?<!<P
M9ZMKUY\9K:H]*M_RRJB/\)_2ZW1K@B.6_H6RC+"__?7LS>::PVHD>$SV4T87
M1Y*4VEH89SJF=2FS396#QK('GO%3)*+ UGBJ9%PU&IPZ(K)M-[XI %8;HSWP
M!_D__',=''M1FI>BA9LYZ;^MP%OZ.QY8Y>Q1"ZU%GF+NVS19)>"RG]%,'BUS
M"GLY^ V/K1RR1DW*CFPD^Q'-=ILXF2?E.NJIF3"<>J(QK<TT;13 M#XY$<!C
MI$#^J0?LD8W\,Z$SEBSG>9H4(T82]:1H:(G&B _X5-BJMAT>D]2S21VPB6QI
MLBL=2F,S-T9C;S)6%29G:HK'ZHR<4C><P-[Y/TC"QM-/WY:YQD%7-PK@H^\2
M5^"J:H('3R6'U$Z#8/QV:PI,^,Q4:S?R%JT#("K]B@):8UL\&)M9I8Y:=EXQ
M*I*^F=&G[[N3E+2;6#=_M4BT**S_Y9^CHNB.G=I+&J^. W;G376K()MP45%C
M<S]M_;J[QKNW:-\?7\I0@;$U'E.U898Z:SNV@S.;,3(3$=L)U\!Y4F8:_\;4
M%HU[\R6I&R;>GY2;G>QG/'8FY8XZ01#9J#8[TC8[Z2)9YG6B#CQ8M$9C6%)>
M37$%55L\)F=FE3IB!?:]]BK63#@UI>48VP98T Z_H8!;WQ /U@8^J9-J(T\T
MYY0Q^BQ2(<]?;I.%VE+T#=%,+_MLJOQ[33,\AJ;EDMKC IY*KI*<_9H4#3GG
MV\-$)%"U=WN2*E?[.-9] DPMFF\I@+?L@<<&;!FF(.W']IV+XH8\D8(OAQO&
M?\D)XVS-U7$?AUYHYB4UPPI#M>N QTXM^:5 "",;:I> K;1(V<]H3$^DX=.R
M*T[;,:IRM[4-\9B:@4]JPB3VI+?>@7:E2AJ1E%5F(NNY^YMDXR4?"6VI#',D
MP9D((KLT<JXT5*>>F"S7C?']F 40;'! -R-Y%\OE_[$-X_(__OFI?4%'&;J5
M_>QA>&9^;KA^BNZKR@55V@*/<:@8I":5QEX;6\:J":V3XHHRL>_-LSQANH->
MZSYH9JN=5[M$BEO5%9RZ+G=95\4U'+OB,4EGSBD(WL@&W";L;,L?*(U6VPZ-
MH>XFW:X+.IC3BB4M\9BAB5%JC0^6L+[L3ITYO&_NA<\*I94'#?9HZH/0,HTL
M[X?_;;&,?2LCJ>K+ICV(;52X*=O@P4G-(I4T0(C#I5 6R59EE=I2>\KYPM@6
MS2PAX51A8X:6>"S-Q"AUP@@<N1\_%OFLW1&>OVA/ /4- \3H]S^@ %C7# ^Z
M6BZIO4;!N':EWJ_+45HWW)].BE%5-8NE-G/)ND\ M#7?4JWZ=CWPV( MPQ2D
M_=C!R4,N-4%(8V,T*XV,556ZMJ$I'DLT<DK=<,*R.^K2R\W[(5D[-!:WQZ5I
MSW/8"H^=Z9C<W]>H,0&O>?>DSKMS;.$G:;T94], *]SA)U2W,K4-\:!KX).Z
M:!:,\2C]=Y-7>;VJ/WJ9;Z*-FM7'KDL S-6?4JXA-AWPV( EOQ2B>5S'$^=-
MQ3=>575!%X]Y:3AE=>Z+9O61L:K*A3,TQ6.E1D[EQP^VL,5V?Y*:S-IJK>/I
MZ^<QE$5R;#K@@<^27SF(KSL@A,^!7_4,8Y82P=RRQ_.VOKNME*H>:"14G7MN
M&7<\ZI5WQ#,T'?F6#U$]K+$/,AC-FK2]M/Q V%.>:LS5V!:-H4HX51W2Z%OB
M,443H]0)(V3%9$2]-M<R,LH^:*Q063]EAW77TC&*KGCLU)ES1;D8 [RXO)H'
M,A,KP_:E3ZZBZYHL[#.][ B@,6TEORH'P*8]'B.V8U>1U>4"960S7O&J-E-Y
M VQF:+ ZW$8FM2F=WF/;C+B@^]@]<]B^:35B3!SE&0S)OA<:ZQ+1W/6-9!7K
M"LMS[8K'*ITYIT" (YMQ5VA15/DA+,TK<L>$K\SG[W%35]P5R?)RULHT-ISV
M^A%"8^RN8NAJ;@+)X!D$7E+0<'81.SB@SOY3Y3DBM>XOR;\HNVBJFBX(4XNB
M:X94%F4E&E4C/*-,PR.UQ0-\LKH*E-Q15D^YGTY-42]%PP"GJ/L?T$>JI,WP
M8*KEDMIK-/+,MTE#MRG/:6Z,9NXXS+,WU^FT[H/'"NU9IFX0(C3+U?&A^A:^
M?2<\9KIS).IBJ0[=$!FK"]<:>]5A"EXF/S/:+'<9ZZ*S-M.B:]< 2ZGYDZKR
MUTX=\=B.(]_4!QFP#>U66!614*N"MX<- ]C'_@<LRMSN-\.#O99+27%;E4:Q
MK&F=$=HO9[KVN%<R?>JS70\\=FC+\/[29<8/EV7:6B162SSPB>TR\$_#!FVX
ME1M@V,J DNO+=RSG_[3DWVO?F+.P(^O.(6H%6GQ45330L2L><W'F?-]T'!$"
MVY/VN>%;4<^9B$R+];]H[CY[T E@98[?5]YV!E/!8WL^0M!@:$9>6G>*<*H"
MV/(6>'!4,7A04'VG(4(D;';R)Q37= AGHM_<&SFE5O#$OCIM'@C2IR ,P\9K
M.1(O!:<6;YMHF@7G0O62B;(1'D/5\$AM-0EVD7XE94:9$D/9SP&PZ\@J,#O\
M$0]6$MZH25.>93G&3X3=<9>%9MI:%_)F>#2GY7)S'7A)&9^\VLK-""?C>U+5
MW>2JO"DN:X!FG;\G-:/5DJ3"^1TMET6>KE]_?_732@R-?^E)"8]9^@I"S<!'
MORVR<_6JJU_]JCI<ZR=DHWI3,GTR9[29S=O"AZ(J-B-SH<4GTCV?I;EBTN>'
MT RBT&*J/)<>/X-G^/4J)3V>7<;>)4B>3KVE=;L%RJ<YEZ[ZA129N%^1%.H1
M[$,&S?B4":&00%5G T8!SZB""J!YB-?-#.!YA6UIPS*[8^(1ZL4]>=1> ;=I
M'B+'4/H95::AL3$>0['@E;IJVGDJG";58RM Q>JN$#\IZDK\M:W&S__@/E92
M?&K=+,['*$V;1=/6-;@D?(865\2YJ.*QJK:B\Y(PS4L"OJ0\)KN0TEZ2*F5Y
MFP"_Y53IL0>@A\=RPXA#0YI#;X:_>J]8^<+.SL]G^)"2L[=]LDG_&C-X);GA
MXG4%4R^22NWRZ)H=892__KSJD1%E(SPH:WBDMIH&8ZV)&[V: 0W1)1#2YE=D
M1EG&2%6)JX'J5\E5;7KE;/4N3/=MONYOF5!8HET'/%9IR2^U J&W^?TA)67"
M<OJU%-&FUL-6&HJQ[1$FK<T#ZFMF5!?(=>WP&(F>3>JD=WB6+Q./AJLR:@]^
MQ*,]"6]T]Y>PN= 2D@=Z"E]^G#(RF1.6+$E3Y^F(D63]*LR"\@5EI8(R$S[D
M8Y%7\\V_*3RV( 3QV$ @>:@OM;"G;X'8"()[^,1%3C:=YQK/6-$BY+=5F9&R
MW_%8NYP]:J&U'5O\7]_O\7W#_US])/EE1>:5#"5]$A4=JS<I77R_5O+WK13B
M%<>"BKCV-EVWS%I;NZ5EVNZXZB[,=TGJ)"^J]Z\Y)=]J4F8D^VO,B]IUP]0O
M+\I^QA.#WN3A3+@]G6LG!6/;XUO^*\=F]\:Y1.4'"7M:*2*?D]S2^H;SR";S
MI!R7Y!\D4:>^&-L>"Y<6C>\6K[Z]$^LW*IXZR1,[H7*/13YM[3)^E3^U_ZS)
MM@01 &#Y+B*6/D)B =@!RG"@O<< FBT\Q_(1N@ALO7$5+LEC+2KPZ_+DUWX#
MS&V0.]P0-B;<3R;*H+@/L1 ;1P@3'$K25CP,)=4!0?#"Q4=(5O^WL!J2_>VO
MG#[9_B,M:X[^IZ*-I/SMKU57@L]YL"5%H3I"\!:;AC6-R!/IPYRRFL\HBW/*
M&'W.RYDT!J=NA6/-"XNM4=S(H%W0Q4(4-$N*NV1)6'5=50V?+F6A EU#'"M?
MX&%I(7%L]#J!1>FE]DSYAI8SXPBT[P1 ]0?TJ#I*'QEAB90[25 2=.TZ )#]
M@!U9%\DCH]IE<NY)K\?5M@L V1^Q(^LFNPQ;J=P_89?[-Y+/YGP?-WHB+!&O
MJ_*)BE3UO<@+VKQ"$NATP>E;.W8)X-%K"Z/YWKCDF]W?UW'E5QBX,6Y!"##,
M?GKS[F3-S5HC\$3;KLQT^]!$^]ESDC"^'(_2M*W#,*'=*^+\LTP^0P(I )#\
M^<T'W$AZJ0(,X>['RIVOM<^EKF8"SIG8N([+2[)(2ME&PX,*C@!X6"B]U1$A
M?G=+2YD25A&Z'P.&Z+;?'$\G<W)!"Y$GRY(B_P_)MB>+^UC<%22;B6L#XL!1
M%;$+3CM$X94 /.GB>;W0/[GP7C]:H+V:%7C65GRRNJ#<#2#9^<N60^FAI'-O
M'+-TKQB#M1)Y7[J^32 NUPAIQ>7$I1A7&[$?2-H>N<O\+^?.. *^O5H"5"GH
M5NV>%FUQG966I'5H5*/&9H%VIA-X,;;YONW""Z)UTHLL3&+)@@HT@\C3[CDM
M,_7)B^17?$NH%X)*":/CHCE&P7I<$A 5E"<B^,Z\>C@9"0;BB1UW[64$NYR-
MV/7"<3P2#%YGR<';1&E0^(8F975/4I(_29<N^TZ@>#I>7%P%A]\T%1=8K_)O
M)!/?>,7=A'9OV!K.08 40&%SO(!Y:2'LH-(N9)8] .A\1(R.D]0>-_0WD^:$
MBO.N:GW@)0+U>=VT#SM*0''K"(IZ!#]P"H8-1'@P1!U/Y(8D%='[!(:6H(2U
MX.>WP4"PDC9"3*FK;K8*(7UXS0Z"*UV;F]9<_6TYT$U!MM%C5;,DE2V8]IT"
MQ)B^)-_RQ?HQ@M4[SN?-RV.2_KZJ?+20L.C0"T?FIH-.*5!$>&8,RVMNJ1=)
M4:S>]A7%QLY?OB3L=U)_27Z7WA5QZ(4C;N .@;.( 2&XH&7+4R/V.D^RZ+!U
M'QP[_A#JUPK8G_+OB9",.V(0% XZX]BA]P"'0M* N.PE<+UZJMP*&QL".';J
M(?"QEQ:^P6N7)[[G%YK(UBS>D[::VX3^PJFSO)P6;1DJV78/TA_'UMP=(0]A
MP0!-DF_C<L*2LN(,B5)@M*JK?18DP#CUP['C<P<$("0<"  &?:H_^%X/H/[C
M:%[<<\K;<M17E-V39</2.=]&CI_+UJF6UPNRZP+2_%E\S;O)%WM?#2R5HLAI
M>,HSWGV=4]K-R7>$M8)+$Q=L.J IA!)UQW^L@WEW@W=!,?:-N"VKN>S,2?H[
M )>WR'#9%R;"K+/).,]$L#(I18E<G^RP/L=Y/BOS:9XF9?WJN85MTKRJ1J13
M1S3SVFXDV2R"34:=(Y4CS7QSL0E(FT?RW:8\E#ZL[BH&A9M!Y(FQJRU;=8>5
ME&TY5=:SL>R!IMZ7(R@4("7\()ZF<_(++3)Q1^>SNN:SIAD.Y\%67=16(+!*
M/Q=\6#QP1WS^/[PIN:!EU2P(^X4D13U/N5^R^FQU4ZM?0(,3P9&=[@B'K[A@
ML-H3W\IBTM$WQ'$<Y:AT&Y&B>\TN2^*-9:8Z@-))YZE#Y)5DJ8-<J\@&U&X$
MV_=&IGE]0ZM7%U!'9?9WRK7Y*Y>#2UBM+JD2\233UXI/-]TNYPNIYU2V9PM/
M',=:&LAV^E(/#I-2/6L'%G(R3^K?\J(X)_<DW;P1-J&=_L9,:/"6\$WX)/FF
M-D84;.'P0<*:,2+%XA@ K9L14B%JH^[M4SC\MK"&VK.RX%M-DKZDO-&LO:]Z
MNXK<&4;7%5>2)'XGVZ+V0!Y'BE,@\^A/01%BNGQ.W$1QW[WF!D$8]S,1J7S+
M.<>I$*]3J**VVG8!TC WD7M5Y%3> %-05,$AM59@Y,7R@$-UR$??$DTX4Z]S
M%3 (@PL78LEC+^/I)5WD::YYT-G0$L>NS:1RZB!+9&2X%T+X0M>QFFNB<OJ&
M.+8AEKC8B +VO3:SJ"Y$IFYT<M$OC2C4O/+%GI>Z.S3<Q?GT;<DGXY4K)IN7
M]"UQS$MF+*S$B!V))E/"N<PL4#$UQ3$MF6&QDR,R+AU+6Q9%]GI>-F*;P[W+
M1'7WT:4;CB"!&2]WF7SRCU^9A-B8V2G>L2>.';A9]R"QP.K?1]K"P#T4VN>U
M(6MC1C7I;$>6J)"Z@9ID6Z253Y8Z]423J+5YG<E" /,3?<Y$T&Q^7?';?]8/
M*#D:>[= V=P8AU_J@0EUDS2VZ^HV2GL:CWV^\P=&T&\$!DO #A )!2TL,:Z
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MN'4?/./=%1H*DC0RED;@XJ*D=\[M54W-PB ;5&U=B F?5YR'EJ$GCL-69^A
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MP>X,N3\1WE@^_F;L=W(%&=RDDSSL%BA-%EGJR@ZS%NDJDM8X1CT(76OI4%X
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M56LD/63$@NZ:QWW6.0?$$F!'$CC<4W>,06*B@7G#Y1[[5[1AMC@[TL 1:04
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M=V((R21&'>#[$1;@.^XBKLK)-35%66GI07A0=?XD0L=E4KQ4>0N,1!2; DQ
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M6%VJAX?1/0A?5[(X'/!CH W3#**H43 /Q#:<U-\'3SK.U*-:) &H/KUL>(*
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M?WOZ!(ZDH+ &$%0UX8SBTW1*TO9I!+X\\2W3:%H3QEN);7"]6I]XXXT 5F8
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M]Z3.6:<?)_<72 )'#I^OD^LE/-B5W0EQ=F'-_[1&MXUI5N.R<ZJ!'FT_'P!
M_A$=Y'VJ)H1![,:\Q^7&0('H0ZE!@E1O,6/MIXC8T_P.\VZA#8=^$,CQ!28!
M(L?>:&QF'G%GZYZD=%;F%<E:5W::UV,F_MUI4Q&&(L0@\,4S@RHCLJETUTV2
M8CP-;S3!:4/,!U\8M">UQ)YS7*ZQ!(AG  E#3.AD0JE>.@%[FORKYY3^WI8-
MWQ-G\ZFO)5=E5_V,W B.VVO$25K+4A7"$,1Q=.9WPAU2$['3!%=<-4EQ01>+
MO*LBP>U[)\2K49$LHS ,11Q':WYV$E05L:]B4,;H<U[.+FA55ZMZ^&)5E)B
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M,%N<'6G@./0"  V2$PO2&R;WF<^?; >T(PD<AVON.(/$1 .S YS!8.OA- X
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M;TSWJ"@6@)X_=22OI8?Y^2B*065HZGE<TPS/Q-TW8%+#"'H)YX[1IUP(*5X
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M.6])+1C[0I_(JDZB[?E06,*0\,+;**_0]2 V?-BUIL*_P;_:?:-[=6K-S6;
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M>:3/%;O]]_N DL=>T"6!(27*YL8X'IGQP.1@(*-&SW&4]C0>^WS"#XS@R8S
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MCQ*;ZO4[.")U/5K;$;2'< ;CRIB2O XT@SE2PQ&*//(,!M+1R<Q@EM)YSV"
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MK0(.XL RI?Y8X?%>FQWFR>!/KB]T<;[B!BC4J#\%QBOR7;TY<<M0B-I<$,?
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MEKE(A#2>BA&ASEEP\E<<UE"[Q+5=3RQP>3O;F=UTU]"'?\5A@W2\=E9U/;'
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MP47>T>TF=$59''ZD<+%K(0T@>+Z+%&4]>ULOWFFE$+;R[X,:=[J#^2N9R5"
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M$+DF/FH:D0PGVX>2+1Y5$>C*OT/DFO@T:< QZ"GR>:5Q -,5@<@6S?E1!65
M!2.G;$F[:$SI]GTKD@ P?H8J]%</3K4@)* X/GJ@&XR7WF^P_X_H\ ]:-@QE
M(1R@.$]:,0TM^5O^SS&;T*^JK=)2$B)U%"=,"Z*A9?Y"N899_;]R:5Q\3(4A
M3F0H#IEV4(,/^&Z-LX[VPV(0@:,X4YK@#.CDL;GEWFXM^_[,"D</8WF(\!.?
M*#UP#>FFNDU:_B;,PNJ7W^R%(?+'XK-J 36$#T 7X?!"6$/KFE2:H[VI&$3@
MB<^B=CB#B%JN:F*2*8_ZRK]#A)OX0&K ,814Q;;!2*;13E1_AL@T\4%4#V,
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MXR23=]Q6;FQ%(2QA,K6XX8/OX(Q,LF_'-\D;?6+75^55NU]5"!.83"$PO/#
MX&W3=V%AHF$-05C#9-"(@3[\,KN+,1/7=(>CQG1Y;:L#80:3[<$3:(2)M,>^
MQK*UB04T3B/_9B!483(PA&,'L_>YK/BG:4WZJ,M1Q4A6K U$.=: <(+IU.\%
M$RS^AY4P'KRL>EO2A+Z1JC(H!4[E(:+'=(;W  G?.CI6MQ]1[12:(A#Q8CJF
MFW&!);JQL-Q_R^?"(*H,QM25@<@4TUG< BRULV_6.S81]C;/F.HJ7E<$DI8
MTRG<C"N*95:V>YLMRU8\$CTA-9?">#I5O\#C4P\B>TQG:P!8N -=ULQE>_RC
M8U;POK&U;JQ;RT($C^DH[0@PBK!'=V\6$>^5@ @6TVG7" LLSN>5Z.9X>D"5
M5K0.I2%BQG1T=88(%OE!0*Q"R,J_0\2*Z9AI !5](^Q6>%*,VLF<W'];EMWI
M=3SE/\*V2,\6(61A.G]&%0.87NE-^$Q:;2B0N@!$^)A.H"94B77Y.]*94"?9
MMTTVE[7LILJF9BL+X0G34=818.H+4#Z-ZUFYS<:S==$UI+9QK@.A$-G)V0=H
M!#.UN"7O;$I&,_1I,4C&-TQG83LVN'.&N.VQ;EG35E!+A \5^>^5O-7C\[>L
M9[QF20L'Y6#0[T#XQ73>/H-PAM43 P;&(.U#!@0F.\" 0H';#H[S@XJT"0,,
MB$&_ QD8J.P8PPLGP+C$V)I_9.-',"?=OD4*P[V8>R4(=9AL([Y(@ZU2+XP6
MJUSX/HL<OU-:E71";\@;K50W/!ZU($Q@,J=X0T7@]5>OI!-(%]$@-&R=SY^^
M((0V3(85%W0!_GY4OICP3%K1N"Z%CJH(1*Z8;"9F7,'+T W+ZN)PCO6!SX95
MR%X)(G5,%A!?I,$\?,[8K_R8SA4&OO5LDJYU7S<0X5 +P@0F0X8WU,3;@32T
M[%Y@TMEV3TM TJ%C,H,88:6V[I8?7"_G0^4E6^^_@G1HH5(6@=""R7IAQI68
M%^,\B3-%,!D.D,Z.QSIG)&O('>G^^U@?#YK)G-'5;'XKG; >ZSUW6I'-4;PZ
M(HW,?;I&+I\N%E!Z&8Z_UH2I8U_/]UG(R,%D63B_K!*/R>TMX=[;"BI%R% ,
MPCDFDX0=6V*.'CB$.B^SJD^P8DQ*9"\,X0N3X<(587)=2%@529V3&])^):3>
MF+ZZ1#CCZ?'*(E^4.BQRL*1LUQ)- ,KPGX.,'$RVD_/)*.">=[@N/JN]+,[S
M1<C8P60?.JN8X@V?/?UD7Q?9N9O4Q7;_D]<E(@[RL*S+F(GX&<A P632&EXV
M<//N)J9R&QWV.?M6+E:+/J9&:>]UK0/A#9,!S!-HL"7R?K&LZ)K(I\RZO#O%
M+V4[Y_SW-S*;@&.#7=*[#<C3<)B,7X' P:3MGC$SFE),Q2"BQV3@LF.+XEUS
MF.](WNHWAG!>WZH0%C"9MF!X _2)W2:T4W%N2";\*+HO3JAPQZ!5*5[K*AZH
M2#@N,2CUAO#F( QB,C'%DT'B RY?:9>;9Y,[R]:\7.[>MMJFFE,%J'C7A;".
MR<@$! QW0UIQ%6;!VWM9L7R>-7Q?+',R*OZ]TJ86<:T"H0*3_<@/9VHK$EDR
MDG>O!(@Q1%B[?JFRNN6G!K'^+S5D>M6#,(K*KN,/-C&MHX58#!K98TA\!:@^
MA&9,)I@ T*EO_@Z2L^W>BWRLNX1A8R9^?XR)CUY3B$VL-B'# I/!);(@$@\5
M$:-MSMBF*0&A$9/]Q0@K-2G:9%;;AU_[ATR,3T"'- .@]V^8+#?AV,-],/D9
MJ\^C8G+V4Q6#2!^3\<:.#2Q=\0KRN-Y/=;E-5OU8[\QSO)O+K%9[%T";@+""
MR9@3AGN/L?_UAR/$_)._]G]2_*5OY@!\33\RH5U]E]/%'S8D_T'"W^%[*V?=
MPXYUNY>^N;DC;596S1\/^T>^M2*ZIO@?Z=;MO?X>I,'?I;H??2M5(]*OHGD<
MGM7GP#P2)UJG3(]Z@%D'60KG_#,L7[V3_\E_2_B6L;L&<Y]ZAQVG<'(3*R#W
M?/-LUXT,D7V@;-?3SP=KTAZECC7.1.:6PO_9K:6G3'J20@$HX;<_54YKK:05
M?SV75,W[DJMPJ 5'XK'_1F;=T\*:I5KQ9\C;"+B6*"TH)&1H9X.Z )YE1B58
M:N^Z2NSGFL>:?B&?MMV!;R7<G^I"_?R\9D9[UH0D7T4UV4%X4QNP9S-&9GPS
M<>B\?N<$-X)F/?'ECL9!GOI6RH]G3(R:E]H 7J@O5@0<>EDM/,Z+IQ8/*+L<
M=]'^?^)CI/C?_Z-ETLF__R47,_G6WE?R\<+__3^:;IOT'A+9[@8@CGN'[U$:
M;MC<N(W>$69ZJMA8#L?$"X_>T6-+/M'.&12+R;Z).B;V&I\#U80O,<0BTHJK
M=MZ;4*4;GWKC]*\/R9&)BE8PY@#WM\6JXOWZ(+<K)H;46MY75+*KPAU >LJN
M\XH4?4!O^UB+IZO?6J[\:1WD8C4*21:"B-'8@@#3O'<)Y?!H;>AKM9A<WLRP
MKN&'$<(/,;F^I8H^/-O%<G=VZW/!_T36#^5,/$O>WRSCNUB.?2>1Z.#?6RCX
M[MOWV.6&V%P)Z_6PI=?7BY?+N7AQ?-!-K#Q"2?E,BC(7:ZU6=M:R.(PDYHL@
M1Q!@@;YE=4%_TX\_Q9]QV"_,8M/W&[6_P  ']P'O&36YM-F2\C69:$6E*8'C
M0&P6E['K 2*KF]6"L!])5K5S@]STQ7"</6W"L_4_N?'0H%B<:/&N>M2I^G_)
MUR8.\!1W)B[*9; G^"L1P9BBX<U75+<FUL(XM *8S%W1A7O=]^?<+UP61K=[
M53D<"D28A W @H5[2Q=\F13)T,9LEM7E;UF7HL$F;*=Z.+22,.%[  TFXX%E
M=3XO&V-TR6DA'-I,F)AUJ/"9DG[ :DO:I7P0X:U"V&;CDKG\U=IT0=8F%RIQ
M!2!H.^X:C^#8 #;SE84I=52"%];$/)^,6RVAEI(X=&,@$]0#8F+"/F<M85R]
M$8&T=5[RC\[,$]&M @[%.XP^'Z1(K/N_@QB7ZST+AHWJ>L]RO6?YW=^SG/,"
MX>SW+<$7"%?S]]7\?3A?U&\'3N8E*UZ$845IN'*OA&/QAG'@BS(R!_+)P0F5
M6<P,5Q+^E7'L##$YL:--O#BF>Z@4C?4]UB.E0[\?V/=39=U0_/F2#?5Z/(EY
M$-[+XZGNM5G%7W'X+\!8T,))3,(G1INFRY:H($'Q5WS>\^XD:.$DMSQ4PD3U
MB=0<236JBU&QX&)L6B8/F_??EOSHKUJK_"KB\X1WIPZ"-+DVT!#>A;D((^?+
M;T5E,F(]F4[E(8GOL'#H 3 Q=:[S+_9T&S@KJSM5^&>75&NZV#*=$G?X5\@9
M=> TJIY*G H/!A;ZX7&S?EC5,BY-1XBV((0;- 8$%VB):>IT'A&?*0YF6V@C
MWM,/W<.OSG4@Y*&Q-'BB!!M_K-\9-:/="S^BS#-I=6>C\,9P&.S<A>_*EB/P
MU/J^"'@?3W=HQM.]9)=U\0_*!?DS!R&\UT9Y+J(XQ6M [$O#T7://WTF[9RJ
MTDW$;QPR6- 8I(821^(AM$D7K==--24@9**Q91DQ85"%NA>J2:>I"9N/3A72
M%H3P@\;*Y0(-C2IT0Z:4D4GVS;C#GI2"$(3& F;%E7Q9$X.&]ZJ?X;MD?+N,
M>LJUSKT:A#\T9C!_H&BFF]#&'.ETKP0A$XT]S!<F/$R%]%EX-M]2IZKLEH3-
MTQ3&9\ CM0BA#XV-+*H,P-Q>\_;L^2^@L=>ERMJ3?HE73P+K(F^N!AD+:.R#
M_D#1$&JD+80<A/8_I!2,VF[>BT5B0D?OXDXF5RW+KE4@=*&QYOB!1$IB]PKT
M>/J2,76Z2;^*V&RY%F8L3)HP(N53;-1\2>=2JD2@T>8A-P]B+2W@<.6,Q; 3
MV#VJD82/_^FP@]?P\6OX>/(@NFOX^#5\' G/U_#Q_7N0:_CX-7S\G#K -7P<
M#1/7\/%K^/@U?!QW^/@U32^Z*/O+2]-[C;+_#XZR'S+X1%[XJ=:E@S_@V/&
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M1*TD(^KY]"EC,]*TF\:UDC26PZ$H&Z5$G6$$[.O\+%:X"M2A- Y=UD6LSF#
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ME-E-1H&-QK3W99VJZE %2;1 *DW464)@[DZ],PP93>R%D?C[IS@^.LHF^/;
MV=?.K0*2\("$1OY8+GD#:E3"C:WS>:[D8W['R9+VQ-;:M]D(K2&).T@P:J()
M+_&0VN0@]%7,O>HA"3)(,$P 8DIM7]9N8*>PO70#?74D@0VHM 6;M) L&_??
MEB1O27%'A#N%N!KE$IIDWUY63(1NJ?01WZI(8C 2+AY^DDK@-KTU.3S63<M6
M74:SHI -9]6N7)@?]9 &<D$6X73M;@ [WC0O@CD4]_.#/M.CY4?]U;F*NU;!
M]'2E<Y^I+X=8S*@C<VY^8SDT;QXXB?WD.GZ ]/S*TYX^1;]#<1SNTV:A&6^E
M$*:0/QXE[39EL.L\T%;!X1;M1)<?)&R4<<U):! BLVG3NM-FJ(;#CQE&G156
M<E^!ELRHC*1WU8;<:IQIO@VC+/A Q#7_^JZO72>>NCP>_<&1"?7T,X'#1=O1
M0N'+HE-UE J+IJM.R^DET;O=PB=S1E>S>>=?1A=+1N9B#GR0QYJ?N8D_\V$M
MHU2+/ =%# E@'R\OC$[+=LR>:..]QD-:0ZES!8X+5]3@4^8G_IGEZ4YE?V'2
MK^*9N!E$M8(@'9 /[13RK8I&8_(4L#,M42=*%Y<IQL<;R5=,?L!U%==2%J]1
M')J2-R=T&#G ?5<^LK+*NOL+D1Q,U3']PZ[>E7&H,E#6H'C![#S1>M82MMB[
MS=EF#PN>B_$;QZ&00-D=2A[A<W-*6<.'FZF#]CGJW0B.&//@N0K$'>ITO?W.
M'7G7FUCMA7'$=T-9<,6GDO:Y@I'!V*+>V"C'TDU6\2Z1MSDAK?!'T!Q-3,7.
M-(L'.8C8<463K':&F@NB.5(81:41)T(;BU@?'!1/4S$<!P.+K*DK#O  [UYO
M=9"EN2 .A=U-FBY(P/)\6-6%B[YE+(=#07:3I@,0N(ZD?JQK+[Q;KS%Y5L6A
MQ;J)'(8M+#K,%E)__RVO5@7OU0LCR_YI5"TYD5K$H?.Z<185<N+=]QB+,\_!
M] V@UL/HBSK!3@>"5J*VHC@2 +G)U U+0+A=SE;B/<XNP&=<'VI1? ).N+I\
M1Y:T*4V&D8!F<*3B<6,C'"=\@]EK^)>RG8]9.>/'ONISUHJOKS]31L1+@G__
M_BY;&U:;@&9PY,MQ7(N"<08;FI]H)M^VW5L1Y8.UJZ:E"\+$G[J#.Y%![*/B
M0_R[Z8?3VCKI!OT.DI0V;F2?01+P%;9I:%YFK7#A62RS6BP3FIMZ$3Y#&\,J
M&]@4DEPSCDMM%+!@VNX(XR.H+3^4T3\&8XI[-20Y7%RM*[[ 4EN_]/;1)\,S
M"3[5+NZ= R]PU%H'WTL#1QU4F934)7 8.B'\& 'MT8$U6/*/ASU&&2UI=VAS
MKH,[;G*OTU[!D[IZZ",HM1W7AE$&>^Z=.26=W6D6OX^?.PN&)'$(=10E'-^
M,M>Z.+8X!V8,'.*/+U/WVB.LTZ4>CHO$4"HQ1WDJX[ <U "/:N@#!JU[HS=8
MA'/3/;;$6@G/=NE#C&&*7D+\D'YS #%[B8&%=L;<=]2+HSQ.W%A@DWCW8\B
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M'&E&;9<)76:)HG=E]]KNS:H1@=/-#9E2?ISI?RLJ\1U/_$>$9WQDE9AOJG-
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M;8;W@A\GEEE=DJ:O080=9M3:+2/G^!QD2*"TA<43QF##X^CA0W4:SY ! ?L
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M_(G6,V&]>B%L2MDBX\==F KET@Z.&+6(Z[8'ZL&8>R55)@T4D1AT:@]'_-<
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M\^O0.(X+HS.0[2R+)+OWRZK-1+)/>20<=O-V^12.>[!S[]WNDDDR1J0(SC!
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M0%S\>]5?<#Q0)NUFTE@F'BKI;2[2P/'2_UIE&@8V@4/7B4Y:F#@0&[#^C,Z
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M"5KI-\E-OX?PEM+,,(" F[HY>MEB_9+;^'L(<2FM"P,(>#!>)ENC1']BT5P
M0EU*Z\*$(BSPRR'*SE@.PF1*2\,!3("Y5K_7HC_0:"X H3"ES6%" 3\_(R0W
MV+E-OX;PEM+BT&, L_:1EF3.V35GU4;+G;X0A,&4=H<-"9C'$6;;2DM@PV\A
MS*6T,K00PE:/1RPVA"L.+,N'MB"$R)3&A@L:^&Y&Y9D5*L50H=_0Z,I HC!2
MVA\6(/#S<42WE3"K1&T9"(DIC1$+$#B)%.,MSJXID7_J:=27@A"9TCBQ0H$'
M\7U>R(YC\X#4%X(0F=)4L2$!\WBA;BD69AJU92 LIC13+$#@CH8:*.//K*SF
M1+_?-I:#D)G28'$ $W"\24O$<3%&)5I0M#8<<YH*0BA-:<NXH F(U.(J(EB,
M,5</G>CW0N:"$$[3!F[9T02L0K^C'/\L_U?H#1U](0B7*>T=&Q(PC_>8<435
MWI6HR]R76B[-!2%\IC1[7-" .1VSHN0H*^]042WD?RM."GW8ET-I2&1U2E/(
M&5*8M7[LC]E4;RX%H32E862% J;R#I7J#M=F5:[T^R=](0B1*0TC&Y)0W^6(
M8_QEA2C67YZPE(0PFM)"<H(3-M,=<E08RT$H37ZJTU(>BB>.MFS#F2C-MJ>Q
M'(30E":3 QBXEQ/C.2<.\]Y<$$)I2I/)!0U\UA=SCK\X<&HN".$TI<GD@@8^
M3G>B1(7%<:<O!.$RI<ED0P)7H&RCGBM]H&R#2I03&Z5.Y2'L)@U2<P<%WYGN
M%DRY#O2[TL8"D"N5*:TE$XH _PBFK-C_.45EI@]BLY2$L)GT]KT+'#"MCZ1$
MLLR5I(,:#C5-Q2"$IC28[%C@CI(D[U="%OCS^Y7IDI><WZ\\OU^9*'G)^?W*
M\_N5Y_<KS^]7GM^O/+]?>7Z_\KMZO_+'']_W\/R Y?D!RW2&WOD!R_,#EOVR
M#<X/6)[(\?R Y?D!R_,#EK:N@_?FYP<LX8F46QS'UY@M.=JLU$&>>F!!IUJ,
MY3HR>UK2,0[0^B8D[<RQE.R-^C%SKA-,E/DC<#98LNT/&:N*DN\%<_Q'K;9J
M\@\_^/?'60/+;S_LAR*R$<6:NQW@9Q'EP^)IA7]AG.:&@R5]L7ZXMQR)LP,!
M4]G^,\0]>B[S_ SQ^1GB\S/$/=![YV>(P_5JCU[>.C]#?'Z&^/P,<>_>&SP_
M0WQ^AK@/Y\'G9XC/SQ"?GR$^/T/<1^;/SQ#_1SQ#W+\71L_/$'\'SQ _L<U/
M?[:F<#"4ZH?AX/8PL15&H#_>/BR-Y?IA%[A1Z0 D\9%=RN>>>W2YZ?S<<V+=
MGOJYY^Z>WTUYX;25YW>[>RD[Y=725E[*3O?N3LHD/*T^N]/5$[TI4^ZT\41O
M5\\5)<VLT\)K1=T]/)$R@4XK[TZD>RLU[0-N+3Z5VLW;62E3Y;3P=%:7KY.G
MS(/3SNOD_Y)K.-$?A#3]&K)K3IGU1H\!?H34\7,325^';NNYB?/#T-!C>;G^
M&+8L3;^&T);2R-!C@ \W+,AZ8WAAMKD A+F4UH4)!=PLZ_AEF*0O0_\GO0R3
M]*'H_Z2789*^&OT?\S),TO>BVWH9IJNW>Y,^%=W*V[V)GM1)^GATFT_J=/]4
M2=+WI%M[JD3*AA-<Z%U:S04@_*6T34PH MPQJ9X@2OK.=*M/$*5*I)_TO>DV
M$^FG>XLHZ?O3K;Y%E.X]MZ1O4[?ZGEO*W-I)WZMN-[?V,$<O6ZP/>6C\/83"
ME.:. 028N 2OIJ<T>EI[-3U-.G+(:#RG(T]XC_.<COR<CCQ-8-TY'?DY'?DY
M'?DY'?GWD=WZ^TU)WH/LUD\<Y?@19YALU50^9K7^Z_N.]2"I]9@B(;!X6%R1
M A490?2V$%)WFG*5.M<QCSK'P[2W(?..3XE<?EVNIK?%,Y(;N4J,*\ZQ[ YV
M2E<-:ZPC;>=M( #1,)! $^]#C+W5[@P]:O7'5G&6BXL@>[BE_%I-FISPAH+]
MV(/XD,_<87F+:('$O.Z_X.4^12:FI5#_>LN1*?_Q[X-2V.FT?,.O.]I&=*W^
MM$B]N7_-4'IH\I"B]/"ODQREAY_\>TCI6^\NWNF!4]^IOE1_E%43B\RQ_^T3
M_7%VT>16??MI/Y2(B2FFZ7/[Y%U^?&PZ'GG[:3_L"P?RONES^^0]?APU&7-O
M/^W'744'\K[I<_OD_3S]M8&\DY_VXYZB WG?]+E]\JY'TP;R3G[:C\N*#N1]
MT^?VR1O?-XV\DY_VX[ZB WG?]+D#\H9-J^W)3_MQ0]&%O*_[W#YYH\=) WDG
M/^W'_40'\K[I<P<;ZH]-(^_DI_VXH>A WC=][F#:WEPU3=NWG_;DFJ++O/VZ
MT_"X@@,[=>8X@X/)4*PGMQ-=:+.BZ-$IY)2S+5%&Z1TJ.?D\<3R#M%7[KD\@
MK> :SA]#?.&IG<%UW\JO'6G:^:DMV0_S'R)))V )SL .9UYOC_CA?(S$ZHJR
M3[-2_JOVBQX*_;U_!V-RPI*B(L5R6.0*U/[?.#\<7$I4VF<-O&I&."1[I5-W
M\-5<H$^'69H>L@!*$VNFX7+)\5*B<NB\/F@6W$A__,*>LF-QD*=>EUY[[2!E
M>^%^K$X!,OEF(O=:>IZSM*7YV(:'/%B"W\T,' J!ZW#T"4%S0HD*%-*LV+:B
M?3KV-"^4;DAZ*!G]"F@MW)N5SDJ^04AQ;^*QXF 4O(8B7."Y(3C&K4)/%B$[
M>\P?5:!WZ*LO*)V*.=F_(>P7IA2AN9XL-<YRBH<Y9,;LG:#E!".!7123:Y6>
MG.[ZS!H/7*'SQIENI_(].0SV'?FM$OVZ83"Y1_6%OCMGJ $*,VZAPF@V:*\3
MI=5 O5_%?JS!=HXAJ,#<7^!,O0"-GU:<5<O5R4QZQ%3Y'9]8L]G29,N%MM6/
MU=<NH4A $]L24\XRC'.A;H>\K5PCQCG[)(U;S:L=3E7ZL7#;!>F')[&\'O$&
M[>JY_[!PE)=KE7XL_G9Y^>%)[<<\G-C4H^NC4*>"M\5><1P5R.W1RC)*,:RA
M?@2JV64; V5JC?HZ.+_>EM87',B"X'PH#NM[L1QF<DTGFFNDP6WU(\;.00?'
M 0K> =W*#;5ZB^78CRO&AVM6R;_)X4>K7 U$4\_>C=O7JYE&V7;UR7Y$"MJ'
M0+=\)%821Z5VV#S>XT\U-''J^>1$2  *C9NRB-9F/\(C749,5, !RN/]"O76
MGSN6UZ/S"?-#4-"^AV#9QOY$/X(YW47=#OZ>*(.OP#W,2TF:.NKE$Z:PJ#-'
M2>?#8E;-!<D)XA+) Z]##4>5+(%%)!62J"<]B8X%#\=N>8JFKVZ+*T3X(:L.
M4J%G>_!OO2KRNLO[/!$N P?:9$\"??U'0!A@L"CE#HF7Y$OM6'I8C%B1B]KI
M5+UY@T_/@NVE(0)(XGYSQM)/Y7ZY6."L?%@<AH,</HQCLBPN/V?U3QXE_C94
M>3O?A8R:)+Z^!*R Y_8CS@[F35:/\O?^R2=V<(/<XZ:I[E\9(L-$_C\8M-"C
M5O7F=JULWC[V[I1&?^CJ6A,B@C1N.@@N,/]3CK?J'@7='3, [K^"ZYW^PYR2
MY6$9N"!;+.3OCWNKQM.+T,8@4DKC5(L$%3YQD%@]5.7BZ)4YNGA&6&Z$E<:L
MEVOQL+A<;RC;82RF:*?.E!^*"[Q&1:[Q@T=I$R+&)(ZQR(@3W&29RGYF9(-H
MG;3XU!:2N^*A$$PJ#'6[A:TWJ""OV=[>][L'=UIF<DM0+SM%>5NH&5,[*F^+
M=XB:0V1]J_K=:NGHOJ +")?<<=[M].FF31@0%C(<$ILRET5)RIUX8B6B<H-\
MVE?]$P"N=7H3A>PM&@9"FEB63L)++RWSVNE..7,#Y"V48X: ')-]<@#YE[>\
M /(?_Y[@):+[CFJ6!DV)/EV:B*+SC#A;8'[_*6U.N*9?]T8)Z;ABMK[#PUSE
M)@R7>(JX<F2P0LR&]Q</OPWIDIBR-OA4ZY/2:,[>X(\F(&)^OW$>\B56(8)H
M-A@.1A4NF!@2;HR;]ZG8CVA*$^<0/.&L5Z+DB!(T+7>3,K]#V1^5TEQ2\B_W
MLU_LY/O4[T<@I),,_&$%BV*Z0GR-,ERI)^IHL&1"FNM'!*2+H,)1PA<*5.3L
MBZ=TW"OU(U+1N$AX8HFCK BZ7L]OG@DN"OVCM(XU^A$5Z*R0;$ BJ2 /?LT5
M^A%QYZY&6F)W/T\<6#47[$<TFETAM,3BY>CRE\N#G+ 8K ?SP<W]8CGX<&UA
MU:]B/P+!3"Q#\ 1KAA$JEA3E6*PF9$U*G%^C+V13<:N&<*O8DX G%U7A RB2
M0KY_?B9TRQ1P1XVLK=&3N")WG6Q!$JB479BUE.Q)H)!=+[?%Y)!FK!BS:LMQ
MQ>^?IU5E<)/8"_<DA,;$IRN(X.G_YE>46^S!#5H36C+]H^T^U7H2Y>*B"-SA
M!!,^PUG%Z]@E(/5^#?0DSL5%"!!@P>(XA&D<WP'VDH1SW9Z$L;@(P1,3F/\G
M:6K*70ZN(RR*.C8&T4=,"E'Q.FYFO_.QRB*HG9[$I9CD$@%?B(PD_MTCV6)^
M>_S@F#G-$>^Z$%ET;'P",85;1D2=E:A0/Z$<]C/$IJBB^N?KO>I!>._8' 7@
M"=RT7[ 11X+0VR+?>\6N3GS 4MYH,$;RHY8-/:@5R"E2QW9J,+K8!QEC5* <
MW1;9X(+Q+:+_5^$YSGS/+UQ:@4@GJ7$+0!<X=]X^-&)5ME(;"4JQ122^52%R
M2&(2^T(*GAKC%:%XKQYEY]"27>#Z1];9X%810GRB$U8?0&#:1YC\3HKE^TDW
M9@.U*3C\3LN\=UT(^1U;U$!,L5>$FP_'C3$KEA^800BP!B"22&160X#!KR&L
MI/WXYE41LGM5B56"";EYN\.YZL(C%EA^8'48%3-U[6N%B%9"T=J$"*UC,SPR
M5OA27GU9L>K8D2><K0KUZ0N\Q91ME&?F\/7Z&I]858; UJ"6(#+KV$2/@A N
MJ8/X7[_/42Z5K-/,\JX+D4;7)\0P3*&;7C5OWVO:@]!_6S$E=*1WE0!;@,BB
M8\,]"%GPED!N]QAEZSE!QTT@6N +/&)S5MKC3CQJ0X(.$QTM>Z,*=:0,F/R_
M5\^ >$%'=\'OZ#>TY'AN\Z%X-@"11=>1SP' PH^?!EQ^=LK1LK*;A/K"$)H3
M!3O;0 2.<"=";44A='9L5;M!"!Z?-QC1<I4ACH>S,=O@8H66V'X4YU(-0G*B
M\VAW.(&CUXED6U$(L4D"B5LC\RBWRZQ".>-J;?V_BI3V(QIS!0BQB<Z-78!$
M<O*H;UP.QHAP.[^6&A""D\8/6Y $:H/+Y6Y3GG[H'G^JOS66W;.H!X^Z$-:3
MQ!E[8XH1CD+EIQ]VEV+#[,/;5!S"<J*#73N,8&+K=!CXJCZR5[)\K#"A=XC*
M;@F'4!^?ZI"K38G,07]8$77XS%<(KE4A DAZ2.L**7P6X (_K3!'&X+%F]B]
M)0%J!R*61#9C +XF&35CZSJD.-\J'/DPRS!5*;L9'VXV])#93;0\_2U?OY/@
MLHHB?KM&RSK=7\VYA%%*6<AYPBI"J7X/TD;SD/':L;W8'FSX">#E9+)@?/SQ
M\7*"Q4=*#.^D68I"!-"Q7>D&(=C%I%3/!&\1I4Q*#7..2ZNOR5H'0F_'UJ4G
ME@A'!E4ILI7:C*H[AO<JM[#\BCUZP*TBA/%$YJ8/H/  UT,NQ&/4N?KB+WCE
M</7/J2*$]H[M30B@2%MQOX%NK0,A.Y'9Z8@E$L]3SO+JI5Z7G<>W8TU((H=$
M%J<7HL!U\]V="?6=&T:_O!">K:S.;O>J$.Z3'#CZ0G(V9/[6L9$V_''X-G,!
M()Q&T,WEOX:3X;7+B+$5A8R0CFU#-P@!TY%6)3K1MR/$*9X;9Z%3#0BU'9MH
M7DC@YC7F;*,^H;[P6.6,BA+E>B/!J3R$W8[M+P\<$8ZF*=W?/!H/;@=WN$1K
MQC<K)H@8EG+*V//(>;8 X3_1\1\(6;A$JF*)^.[MM/P0VGQ\/F*W3W.]&U4Y
MVF"AGPYQ&H3(*Y%Y%P-HX.[LT 6HR."-0,24Y/@1#BYX9MT6.4&'#]]5Z[DA
MB-BU"H3V1(:A&Y2(L4[3^L%Y[$>X3W5(&KI$%J(_K$!%Y$6^:Q4(X4G,PM9)
MGCX-3N85*[ @Z&?T(G^@#\)VK@.AN6-SU1-+N.KF6'EM#P*]J.:RHEUY6RM!
MF$YT\=,53(15LL1+KMY3><V7LO_F(Y$KMW@A>2Y7ZZI0:S9_<5A!X<U!Q),L
MV5(HS+AQ$)<?_>:*>V6(4!+=$O4%%3YW!$>8JEM 3Y@.MV1KGQ[F&A"R$UG+
M3DC"8PGWH44;:93?$6JX@.96 <)O(NO6!4A;D2RW):([=4V"#J;LRQ="J7XS
M&=H41"0=6[)Q( 8'4*BA\,#)<DGT0;76LA"ZD]RXM&*(=*3Y8?!A\,1>=JYQ
M^)KRD"3>28\OC3C@D5-DCJXQ6>Y^1AM4'%9@,[VN52 ,=VR-^D$)5 CV@6LL
M!Z$S2?:A=@;J6YYJ6I),S&Z'CV1IOU%M*@YA-)%U:8<1P:Y\?>QK-D"/<G&<
M5)_EAUC%E\:K.+ &(.0G3]3K#BQ\(WW(B2K75$\Y.-:$"""1G>B%*)CY,>,;
MQNNMXAVB:"<(FN7%8+3*!U,LMXZD6/Z,=G;5 VH'(I5$!F4 OCAFYB&QAQH6
M%W@\>![<X<\D,]\;A#4 D4I*,]036(10<6<!N%:!4)[DP+1UDM^; 7>(LVPV
M'".!YE1J1=?'C"SU('0GC:!UPA/,^3TN5Y@KQ[X820D/UZ+$/$=K*^EN%0&L
M_R.1$>H#*-)0]V/<6@="=M(;FNWQ?'LQNF%4"7/T/$(J-O >"8'T"?7<*D 8
M[MA$]0$2N"S6XJ-KS&TI>G0%(70F2=!C!A!!"7_Z#:/Z=+7,AU7VHO[JH(&M
MM2 $)[)!G=&$LRT1X.'L03@D^]>6A3";R+BT8(BTEDW1"Q'EJX_Q ^(H6]G#
MK=PK0QA/9#CZ@HHD@@E;R@^23*C$Z%-4H#5R,A4]:D.$D#2UCP>JF)&'*T+)
M9J,N':KOWJ$75!(G67BW 9%(HFN80&RA@8AOWWKGT+&*!%(=(HTDAYD06.%J
MBJE%?;89_/8P8(-?$!?HDUT[62L!2/]GJI-.1S"A8YY1\8(<B7:M J$Y3?"M
M(Q0PR1/\4F=/*/GNA>F)-16#D-FQ)6GO?@2%P,MJB>CL>CJ;Y&B@_LUFB&X=
M8A\<JT*(3G0&Z@<ISA%#?6>\9*=>=5;?./,0!:PAB& 2V:8A  ,U^;OGO]QF
MB%]%B!B2I)GU Q3)I#K&4C_*CA4JO?OC8#(859G\I<O-1_]&(.)(:N7Z@PL^
MC%-?>$)\6=U5\AO6@SA3<0C=73^$X@PCEAMA,KYC(C-L;)S*0ZA-9)@ZX(C@
MX]VJ+\Q*%3N N9A7#GF![)4@+"<ZUG0% Z;ZY]EX/UDLP]=8#D#HCW_NV)IT
M ! \7F>HRHFZ3/%(=BA?68>JL3R(U$1'DPY PLE5=[(VC.-IB>LWE([_MM/L
M5A-$>*JG1'P@1:3^W=M)=ZBH%B@K*RY_O^\(1"C -D'B2F2E1@(;+,BA(&B*
M,K(@V5>/,?J*#]@22&B)+-@@B.%SCLJ_O"CC0+US,U*^9D'1UA[9Y581)(A$
MA[$^B$+\DU])^6*0#R:_5_/?4:%GW:<:B/..#55_/,%'3?ZD>]8$\9[$8NV*
M^M>9Q:IR-5QP^;5IN9,Z[8[DW"6.QJTBB/A$]JP/HE!OC"_K/M5 G*>Y&]H%
MXT?Q?I#K-*IWRIA5U#J^3<4A#/^8Z.S4CB/.D<C)W8*1;!%39E#?GC5!?"<R
MA+T@@:FW76677ZJ_/QE\=!!'A-9 (NHZ66\LF!%/I]00N4,Y)S;=[U())(0D
MH<'N: *Y/CYDBVA]$IF5]>'C9/^2SA\5%EA<8/J,*,7"/E&BM0F25.?9@J."
MA>NZ.<H)>L1EA7EY>"N:YZRXP!?R)TQ]&N6,&F80L 60D+I..AP"+=QZV$J5
MN<3#T:QDV<N*4?M]'%L5$.F)SG+=L(1'R#*:DV(YO!XA@>T[5U-Q$+NI\@);
M<00S^^X=@O>F]]OM?E?>X8V!I)+(2@Y%&2RS$6%;^0EUG.\J&5L5$/^)SH/=
ML(3;=(R+;%452R%*LBCE7]RH=JH'X?NG1/:S!Z#PY?3PA2NY='] $C>JQ)S0
MW)E]OP9 8DAUO@Q %BR/.U(B/L=$:KPY+C&A9.D_(_P; <DET3$T%%W4N7*'
M"SE'/Q;YQ_4G3$O_N6)O "235&?- &1P,_OPL0O,7X]-K]67+_D7@I7B'+[.
M5-F-D8LZB]8F2&I=F]EQP09/K =IU B,3M-;N>ZS7*N"Q)+HZ-D/$SP*#VV0
MU=+0%P(QVK'5;.M]I$!<U\%J* UB,^F%W?9I/4:L^]%KK 6B.6FPLP.<6'1G
MJT^8?,%\I3RKP^N[JBQQ\<65=I?:(/J3)G?R@!5+#')+6PROZ_^X<J^M B'\
M+TF3"]NPQ!WLP^M'(C>K?F.\L1*(Z:1)G>QHP%R/L9PL?">5EOP()9@;WKJT
ME@4QV[%MZ@@"?B#%LY*).YPKIZ=<"C#7$VHM"R*T8\/2$40$=WPA_U:2[=OS
M'ZXZP;4JB.YD"89],+462W+J\)\-U>,L6WUT>'AC( EU?>H:"65@<(-M+VXH
M!6*Y8X/1VOU ^KZ*M;6I&O=*('+[$&[<AGHY:K,G1#ZA8LP&]5M#B&RP/<^9
MM0Z(Z40FI".8<*)7B)R\.3="Q?*%V5]\<ZD&HCN1R>B.)_PL BTI>;DF.7K&
M3XB3]4=>%7)=('*2H1V1/R0J?U<Y',P&MRJYW=PA #F\48BT_IK(WHR%%BS+
M.B)1[;?V/;DA7]:X5!VH8Z=+8A<<L 60E#JV58.@A49P4I1!YA&@-D@421[3
M < *%,,UKS9[Z1]GINH#18TS]!K/O^ /DD=L>'$N:KL@T24)?8X*.%"H'U^X
M[">>3,8?"-:_>FDO#*(_23RS'46$L)$\I_@2B?+JM\N+RN7]=%L5$+^)3DS=
ML 2S_/'#86<W8>HI:RO%QO(@?A-%'3L B>27?[4+?;GVJ0ZB/NEAJP^N8$E<
MR[VPF._\^+=7 K&>R'!V1=.6!_3CA^,K[F;V0YH!R:-CRSH<'WPVR"F'#TDX
M'*>"6PT([W_KVD;V@0*F^'K'55ZLS>&PH=9QPHUKWZH@TCLV>6&8 O?CA_:O
MI,*C>#=&Z@/R+Y:-N5,M$.=);%L/.,&KZTD6=[5AO5%.#LSO?[6NL&X50:0G
MBAKV013,^^'ISI-OWN-/OS+^XD"]<UT0^ZF2)?N!"A_X:$-*1#5"_]D^_GWJ
M@P21R'H%  L_/SB$%:I7/?S4D&--D !27:KU@13N19A=L:K( 3/ L2:(^D3F
MK1>DV#X&\%(,:@<DEJ2QQR" K9G$LV']!!&A=%[QPC!=PAH"B:EG9K$+PG W
M$2[>HL34]T:H*%CVHCYY.[$[C#RJ0V3RWXF.E?UQA8=?X&Q5,,J6N\ED_/4B
M9E]6?*J#))$HS-D?5X1P4B'[59587>(>$78(8'W$ LNV5ZH3RKKD)%_BNZ%#
MB"F\.9"D$EWI#<<)EMP8Y;@H3STN+@+RJ 620\<&N3<<,-V71<ZR78G=M91C
M#1#-'5O>7E#@N@AMR1*56,ZC]U?(]M.(4S%'^=B@?"#U0?1W;6_#@8&%(>=4
MK<SV[S>N-ZC0NU:M94$D=VQ3.X((C=!2C\1R(O? )3.9 @ZE0:0FB9QV@ &F
M]8$33$\7 /6QBXJOT/I^K*77HQ:(YHZM7V\X\-!/5BWE9[XRLVNC#=.MM-NP
MP0OA7QE$?L<V+105?"O"B@F:"U=5XE(<PO/?.[93W7$$6T,7^%D:PU\J3.LT
MD6/UL#K2OP/G4PW$="([U!U/,.//!)<%6A\6WL.QY@T;K\@=*59.#YO[-@&2
M1"([$X8M<*_R[L&=O3XS[E8LY4%\)PD[=@(")O<#SA&5.+]>K^]P0=D4\1>#
MB>-=%T1ZQ]8E$!3<<\)XJ3ZEOB$%?B<M*V;@W*4XB.:.K4AW' ',SDJR;M@)
M.;FFO"N#6._8K(2B"G!498SC9R(D</4=>["(8PT0VQW;FUY0HE'LZ@]TK@6B
MNF.;TQM.%-?K!"W0#I?R'_=.CE=M>1#%'5N6'D# Y#[B#2>?=XX'Y_K1'=0.
M1!C_Z-C\C  0OA_?2 (6^'/#,O(+H6NY2U6VL-[=!:H/$DK'EFH L#:$X395
M8 V Q-%U4'( LGA'V%>,7U5%MD\I<XT+MCX8%'+7>T'PTK39#V\,)*=$<<RA
M*%L.F;)O78/: 4FJ8]LX L ($VM!T7J-!%OCT\@&OV =0"L@ 26*A0;#"Q;/
MPZ9D2UQ@Y3:!BP?0"D@\B2*EP?#@*FX]ISM68A]A.-<!4=^Q+>X)!DXTS>J3
M(59KQT/LHES0RE^4P^OI7WJVO2J"*._8)H<@"N/]$2\XRE3>Q97\X!>Y)$TF
M8V?R_6J#)-!U@#,45J@8]BI-Y1CR8-^A$H3T?W9LFONB"50UN!"?U<0:4B+8
M,\&_FPP*URH@GCNVMOVPQ%/HA]?M3EPM(/7NT0Q(&ET_T1N,#RRA7] 63\AR
M5=8F8HFYK+!\UD\"I_(@SCLVG#V P",OI1J[(G1]3&E<)\EUV]'X5@51WK$%
M#,,$9Y]7AT.-V4Z4>.W.O5=%$/,=F[801/"CX]O1</^Q$_TEMTT7%:W*U;7A
MV-BK(HCWKH^, 8C" [!05H<^#XO\@J!EP<0Q#,/GW@^@%9!$$EWZ!<-K43Q^
M;AY0.R 1);H '  0KKLHXG+"ENAP_<O9./"K"!)#Q_8O!%' 6HT*D>$B/_G8
M!+VHTPPL2L-57K^* -Y_^G/')C $49B!]OZ,;^P0)NU3#<1Y"G/8"T];YV7#
MH<$!X5D5Q'S7IB\($UR_KTB!FLY,O[WQ>WBR0*_Q YL"2:?K2[E1,,+C,ZHO
M*U:]NTNO/GF!MYBRC7J5U"8D8 L@V72=V#D$6O N]EU@_?5Z?F/=KUIJ@"A/
ME>O9!4H+%",^K_@2P'1311#AB<Y\?1 %\_XN9X>5;$-I$,.)[&$KC-9B3\#A
M)A'(3F39^B *YOVF*I:([VXPHN5*/;%P3.=*T)Q0V5=;3H"PAD!R2?1X4@C"
M((/ \*A>B>AN-N #JI\HP!8@DOFQZ_/@$&AMB41^2/Y]-I@,/H*%HF\#)):N
M[>4P<&#!W*[14NX +O^H2+W#E=M;K0"L94%$=VP>.X* $WHQNF%4I:\?/>N9
MU!8"4=BQ#6OK/=R7<#F9+!@??WR\U#L)=&5 S'5L85HZ'RLJA F5DF!4X8*)
M(>'8XG9TK@BBN.LG=0&(XD7C#"M1<D0)FI8[I5E0]D>%Y"_43>W[V2_N\3A>
M#8'DTK'A&0-AF)P>-JMRA>B:O"!E\#X37!3(+!&'*B#NNXXV]L(2;S:,,%V2
M:CUZ'@VG5<6=U9"M)HCSU.'&+I#"J+]_?B9TRQ1B,]/:@B!B4T016Q $F_BC
MGY2?]P:M"2T=WLDR%8=P^E.B-,=V'.',_L6/64-Q$+.)TD79<83-_3$J4([V
M"<*%D/^/JB5Z*$JYHC*S,G"O">([1>"O+Z08@7D0_B'504+H^I 3C"N>!31>
M$8KK9Z61["E:L@M<_\C=%')K 22/KB_*AD"+=-:\CP5Y.Q0Y'*6.5ZA8BE7E
M>-[LU0I(-!V;J\'PPF;,#2N6'^3_7K/F[?]IGB1.E4#DI[!)/= $+M$J]./5
M"LNFG.55=@PI&&'R.[$1[]\"2 HIK%,H-+!(3M5AW0.I N6<6\])G<]3*4:T
MP!=XQ.:LU+L)0IH!":=C,S8<7\Q(2C'^(G7C(]Y4<THR=4[%!E..EI5E68>U
M I)/"FLX!%Z@RT'B)MEP-F8;7*S0$AM>-78I#Z'\+RENU+H!"=9.RF-=?Z^>
M;(/'"A-Z)S4D(L)@/ -J@XCOV)8&PPIV6ES(J26RE3KR4K[37_"*6ST7UCH@
MRA/E6'8$$T/7J_:O."8J&NUV/9)_$TNDMP\\:X)([]A\!D$"4_]Z;5=]ZY)+
M$9NTN$-I$,4=6\3.,"*XAM0GKCD3XA.B5)0H+QT<0K9*()*[3JKLB29$3:MK
M5;>%J+BZ^W PY:[)G"-:(FY+D>]9&<1]]W&^(%3Q#O]N,*5(O1:TQCPCB Z+
M_+;(U:&O_(=:N>\09Y409%BN<.%Q-AC4,$AV*0SBR(CCR55^F: I)UM4'D?5
M2*I/1!EW=J[ZM *26.K#7E]X8/%,GP9O:G:$2K2N_] *PJD\B/*.#5\/(,';
M_T<B12=>2)[O#L(\^<F8586*8^8O5I, U Y$&']-='X< #"B@N)8V2F'#JCO
M&==_4'V04))DI (! PM#I9(L&%5.VWN\Q;?R>UKBK65!)'=L(#N"@!^B'1X)
M/*[V!\>XF TV<MU_5 D;<*D_8894!]&>Y"TB"*XP/:/N1RC/M_K*'3&-;I?B
M(*93G!T[X0A>9@\YVGY&&U1\&'P8/+&7G7YH>]0"\9SH)JPS'/A %AM<.))L
M+0NBMNMC7C<089JA;E\M Q9";65!A*8P4.T@XFWI[A!%.R$U4%X,1JM\,,5*
M(:E9LK-$<,-: 0DAM<WI"R^":_-GMF+\^+T/E>S I%IO*OWAB&]5D""Z3NL$
MPA0OTDTY@"[P>/ \N,.?2<9\K!V7VA 9_"W%F2P$5O"FY1ZKAP.5725&\FM#
M7JRPWOWB40M$>Z+H9F<XP73OC\4\F#97 )&<Z S6!4E@- ?.]U)TX->M HC?
M%,>MCD@"(P!Q47*&UH?+W,/!%!5HC>P*V[DBB.\4%J4GHF"],9)K0D9PD6$Q
MQ;Q27YR0M7[SZ%4/Q'HB^](#4& T!Z/B!<TV@]\>!FSP"^("?;)$<5AK@(A.
M$53L"B648EY6RX/WJV3BLLYJ@%1: R8>%G+[OU9AY'+[(R8Y&JCB;(;HUF*>
M1FH6)*P4EFQ4O&$2?92]+)2G[7$P&8RJ3"[Y6.CC19SK@&21PJ!U!Q-&]-4^
M8G9;DA>D\G-)I<@LZLFA"HCF%!'#SE@"#BZJG+P/3+X@RED_K\HZ>WL=V?](
M=BA?&8XOH(U )/'?'1NMH>B"-T6G^4>?.-L<>H"1D)N#4ET0FZGCVXTILB.X
M+9"D$MFY@2 #5WM'B=@+@RA/<9&W=4[?FC[-A^G%-* )$/\IK&(PM@B^Y:$@
MJ'CWW6&13^0VK'ZT8-^'@5U&<1H$2:SKY%(1D<8[NIFQJEP-%\K,WR?Z&=R1
MG*-"GV8.V@1(1FFS4WEB"XPB^2"%C6K18U912\R(J3"(Z8[-<%<482/=D5)K
M61"C*6SE%@D=(VEIHP)=8+FEVN!"H$P]KX6J,<J)0)=B0ZMEA<4%GE VYWB)
M#!<I0ML"":1C@SD2R+ 9\);:MTZT)QO#E-GRJCE5 HD@A3'M@2;P_* 2Q(-E
M2W$(OW]/<:[KA".",5QB7M3Y=A$=7H^D3:=7Z.Z50"PG,V_=T,3E^KT'!,2\
M0Q,@.20ZZ85A@^L6\XM!LT^D_+(_')T-KW&!MP:+.+ ID)2ZMHRC8 Q;"8;7
M5YS,F>GM$F,Y$,\ISHG- ,)(E!8R6F)US',0E&4]M94'D9K" '4#$NA9.YT&
MCT1D>B^_4WD0N2F.?MV !+J"WR=\4?:8FSYPK@BB.\GAK1\B,.^/+%OA0W"^
M;8]B+0MBMV/KTA%$/$_ATPJ1D_MIZK[L"]-?J@35!Q&?PJ:$ 0MT$,YV<N/Y
M<DM1=J,>4\ISM;\A\G=H1Y[Q$U$F;JE2[CQ57RBZ%24JYE9'8HQ&(6+[1^>G
MN7'11IE8E30H*.+DY,-6L8'J@R24\$*L)[!@B_?CA\/LE8O3FN*=>A-=;A*P
M_9$PQYH@ 22R;[T@!5/_U0X!+@E80R#!=&S2QD 8+*=K^1$QWT&EXU,=))..
MS5\X+K D&M[&FC"YJNEO.3O6 /'=L67L!05,\3/9HJQ$&FG.*LX-0]V_,HCX
MCJUF*"JP#'XCLBJ[YJS:P.0 :P DBXY-ZA!D$>5AT3IN%4!\=VQD^R"!'ZPS
M1+'(\"%)QLE[YL=4,%*XG.1+K/ZBS\06U Y(&EW?Y T'&&:U7>YDRQS[;U$!
MM2$"^6>*XU\(++ 8KBGZS(3\SNI%%L5C5HAJC?G;$?_!(R:.SA@N1\="\G-'
M\EP.'OQ9*Z/838,$V+')W0[F8%/CBA3J"&_,^$8Y R1)ETB4-ZA0B8/N?[;:
M&E[U07)*9)D#@ 4+8XPVI$3TY)OW^-.OC+_<_VH5A'-=D! 26>&>H,)]4[,K
M5A6Y)_4.M4"D)S*SG>&XT*WZ*XX=)@LNZEZ74A<6;+W[04GB3W_^RY]^^NL/
MBXK2?ZL2;W_[4\;XO]^*U.*J?UZ7N" BHTQ4'#\L9F19D 7)4%'>%ELL2K55
M$;?%K)H+DA/UFJI4K 6^+?%:-(@RN"V @/<+D.0E+_^?^CC.__>_2E[AMQ^R
MHL2?RTM:'U#_[W\)O%1_\1X3B-)O1T(X8@9KZ G-*>[50+I':]7W8Q]W35-=
M4P0L]JBS.IHLS3 3BVG*29&1#:)3BC+9S5$E) XA+*+SJ091TST6IS_TQ"*N
M$^/RW</BMLC>UOP'_HAE;U6F!HNL0?4!0F]A.Q1-Z $<P _-U>7T*9)M%H<M
M6],AN+800 (M[(VB2< &-+D>97)4U(-B\?"IP%RLR*8.M)4X3R V*U//N@#1
MMG#:$5&C@O#W2.+/K%075]DGY7N@N8>\'6H"I-W"$4LKTG9&#U:BKZMU[00?
ML_4&%74R2SFZ"*+2;GM8#(7 I7C@,^6>?6)/*\+SJ;+:<)-5$ZE%@%1;.*R)
MORN*P4IK5PU4\FZW-^X"6S)+UPW+C\.W1[IN&/WR0GBV,KV Z%2AL6?_\\-7
MHT[*^>7PJX;?')IZ-P*+@Z-CD+'U#T<P/]1C\&V039DH+]<;RG9J;(UP(9LM
MQ97D5@B6$3E8Q 4N$:'BI_?]E18[+G*<_U?*;70AE56UO^VN(.W_C?.'#=YO
M!\7P,VG2&)XU_<9.1[Z@"S4 <'X0F31]BO<^!XW;QU:M(U-_)3_#LVJ._R1_
MB@N5Q,"L"ZW]9@&B3;QQ&2Z7]65=[-!YO;(!-]*5=^<HZ#_E[QRS;_+VE1V+
M@SRY-^#8:P<IVPOWPU<7()-O)G*OI><Y2UN:CRVXY\(E&'<&-E_2P27A];F!
M6A&>9&.:%=]<L"/&6UOT7-!%Y%A_#\I2M#<KC84P+:U1!^]TW\FIZ54A;9E^
MJ'DK0\P)!IC"!Y6&7MDP^&L;IIXL6EJ]ZO5#'[M2#8"6> F]QFS)T695ISO@
M&.FL-F.YCHXW6E/A#N#Z)B9]X)NY9&]6 3/G.L'T< :]'H9=L#7)"#5D1S27
M[,>J8J/\ZR- $Y8>F ='57"/R_?:8$+0G"A/;.V'_<:3J_'@^#;S7<?L>(-M
M"-=Q<WF!]R#?-C]>H6*);XO#CQ[FE"QKX^>147K%^"?$\R8A!S74CZD;1781
M>$@][=]!>.OOL)QR+.1,>4:T:G35>E7LB<S#Y-4H=3?DD>;LV\<T3D>HU'R:
MZX>5T:XL_?E(O;%2E]^*<H;YEJ@H>5%:E%K3E@O:1D\BMJ*,B$ 2FH9!9P%3
M+4P)U<HQGD:1$<NCA,0IQ<,BOY;(Q(1)1L60$T&*Y94$-L-EN=^Z"<_!W-(7
M>A(_%472K5+D/!':"#B*0L\P7\O>BE(I_RV^_*SR&.-@9=#E:6U65DB%T#2+
M=<^)N"WV5ZMD.0FA6F_JI<Y_]>C@:ST)?(HSNKJBZSL9A!=X??2E=#(,@[X'
M&(@M7-_O=B!&(*S?0U%I>%Z_/SG,?Z\.,8S1!V#(5P##KH4\!9T,NW":P'O3
MVR)3KEQ\@??_?5IQ5BU7;QJ9<4R6Q>7GK/[)HPH]U/>L882T\P&(BZ6%I EQ
M1D>;%*4._D?U4:=0HUS1XZ]A@"U !DAOG7!!'(!5@XHP.CZ"*)Z8^O!HI_ZL
M8]%5$+M=2WV#LO'PJ\7O0,9!;QUX'3 5>R$99G]4<IVK>WQ!7F]+/'%4B 7F
MXION_.B^AL#;AHR*WCKQ6F*GA9.W*T1X[4U^6*@?[^^Y0$_?7!OKB0>_U1,X
M/RY2[PE>>S@L7SO>M/*;RO7]C,U9(LP9K+.3L=/URQ?HT;]^<#&J>^)K_-U8
MU8^XK'CQ4+Q!]=_1@MOH^\F3[U ()"*MS:N3;OS&>Y*@(*(&:(>AU(?239OS
M_25.S 'GTQ&:Z_OYG>_(B<=)P+4+LIY77.!W!OD3@PLZ4HL]R7X0<7&(2$L?
M58.GW=Z2X^1[.6V,HBJ"N(EH#Y_$&+R!<3)^C37[?E#G*T,0_*X=6*8!%-&7
MY?29WI^*1-HJ1B0K\<HPJ_B&5G6',U+>UJ90PZ Q%>N)51C!OV5'V8)/LLYX
MO<]25SSBC"WW;#TLKJHB/_0(ZJ($MMT3@Z]5CV40->!AX/+5!@G[5.N[8Q)*
M/(-2D?I^I*1)!5P\%*\.ALO% F?EPZ+&0HIELW/AB=7_&6,YSHMEPZB(W')/
MSBG:&CBML-6I"]"L(R*UV)/5O*U1$)6E .D?<V:JPX>'4U"6E<"S9D]6\O:D
M"6 C\7KP?N?2> VU<0?@7*LG3M<(NS=OT!&WYTW7<(Q[;OV]G;#LD@'W(MZE
MR0R]7A&$ GSHVJ#Z@ >WB3)IR@YBSG'^A#X?CM?5 ][[;I+7+)I_>=]7URR:
MC5R/$%4946<K+/<N<I&K?1.:W"G6LKW,<?F$URJS.]]=$+F#XRIN^6-1B9KD
M0VQSD;_^9"S9)Z53%LSPAON:)S,",N8U9,"JN+%];>(2A]*]R2MC9\Y$<=RG
M(/>9^<D7G.MSPNC*],/#X$(2<T("9O&>E2Y$FHKUP^CVX-(.!DSGKQCQAX5<
MW@G?:=8K79&^9FJ,IW;-R*-PKAW ^D*]T:U:>AKHBYMJL,"J;7U*P:;?]T.#
M&CAAULZ#"7OZQ%2;^C1QS07ZH2CME)EZ#^=,_@Y;6-,4Z8<_SX$W8__!S%VQ
MBIN)TY3HA^?,SINQ^W#:R-8RWC0E^N%\<J#-U'TP;7>,XZ<5*NST64KV(YC.
M3J,3C)#]]:R:_XZS\HE9MBBVHOT(+[,3ZH8#S.BL1"7>/V2OSRJI+_3=Y8PT
M0&G("!G+_0,6SS677SG$)QV^.4:<[P[''T).M?(&;?$#5W_*L3+"N#@QQX;B
M&W=CT[EQ>U_IQ\;6+O76*0 /@89.+0Z=JO4!;HH <J_4CVVT74"^B.!;ZP;I
M-VVO#<7ZL<6V<VK'<,*B[GSD\'/UQQP)+'_R_P%02P,$%     @ R3U!5N8_
MLMLVG@( 3*(< !0   !N=G,M,C R,C$R,S%?;&%B+GAM;-R]?8_=NI$F_O\/
MV.\@9#&8&\"^5]2[!I-=M-OVC1>VV[#[)CL8_!!0$M6MW--B1])IN_/IEZ1T
MWBFI1+VQDQDDQZ=UQ(?%IXIDL5CUG__[Q\/&>")%F='\3_^.?C;_W2!Y3),L
MO_O3O_]V^_YU\.__^W_]C__O/S=9_OM_\/^*<$D,]J.\%/_\TQ_NJ^KQ/W[Y
MY?OW[S__B(K-S[2X^\4R3?N7W=-_:![_<?'\=UL\C<(P_$7\=?]HF<D>9*]%
MO_S?3Q^_Q??D ;_.\K+"><P;*+/_*,67'VF,*]Z7?EQ&ZQ/\7Z]WC[WF7[U&
MUFL;_?RC3/[ I&$81BV0@F[(5Y(:_']_^_JAM='P%_[$+SFYPQ5)OI BH\F[
M//F(([)AZ,6[[@N2RE^P*8J3WW-$(4>$/([H?W:^MGI^)'_Z0YD]/&[('WZ9
M"ORW"A?5'/ O7SQU!VYIA3?30K]\Y=2@I\4[KWR9,2$3R_?BE>V@-_RQC^Q3
M\R1_?8<Q$*TWIN?HS>1'1?*$[+3]].U&EOSI#UGR-]OV+)0$T>ZGXH]_^L,F
MVOSM^L_O_R;^6?YA"([++A:DI-LBKHTH:X&9Y3^0_/5OW_[PO[Y]SZI_DH)]
ME[PRWA?,$I;_^<L!R#ER&E\,1\F@"!@EB7^^HT^_Q-NB8.;_F6&RK/V_7O-_
MB?'8?</[)^_U*?H-M\:TV(W0J1BOBMB@14**/_V!S3N['^(B[A%5\\0O,66V
M_[%Z?2*UM* /EV!HVZC4,-D;Y1!W(VTA,TS-*)'T67QT7<<*0S= BXSVZ%&F
MV[PJ=H-<_^-HC.LOF+"D(ZS3 )^/KWPL@&-LFY;M(\=N&^/ ]#TK1)8]WQB_
MI?'V@>25<<N>'#O*"<GJ$68?#J/+_O&W73.\%4EO97]>?[2EJ&C7^ #'/8H<
M.X@=B2 ^,T3"X%5794FJ<G:+SAI\W;1H8-&D*@FRM"@%E K_H#E]J)7]-5O(
M6LXOZ7:S^1M_XO#I=4R+OQT>$501WXLGS@4!D)4^Q&E%1D&C#&21GR:)F23N
M/#2J6A:8'5P2:U(C'\2HXPZA(+*\))5UZ'I1I;C64"&N>[1!^O?U54$.B_:/
M*G29E#A10DQO!LXH:X :^TF0!'8<2SJR$.NO-&)[*\UUX[><V&,8C6(3L?_(
MK.#R5!YHP/W$MF)'MK"Y+0@NM\7SMWO,&IV=R[OFC%*TIP>I3V70*R1]2-Z"
MBP*&%K[;]5TGD5F_=__89M7S55456;2M<+0AM_3F>TZ*\B;]@KFAG9U--00#
M'V$P*FI0@<*@J?$H<.C!LGYY*0E9'S8.P$H5*01DK1N';H1DSKA92*M@Q5N8
M^YD^X:+*2N/JU]I"WM,-&R^PH?=P@IW83UM[OI!*ZJ1QK;+037/DVJ%JMWW7
ME+LRE(F@O%@AO9PX@6Y:01!@W+E]_E+0IXP?5"[KB7G<-ZL'PV4" <I-'_9W
MHKOPS+2./-BW&_L>BOWYZ#6)AP;&M!.WDXG9-A5;G1W[F.$HVV15IK36GZ1G
MFP,$W93H2#I0*>JH1C)X%WK4S@2@(CE>C/P R]8:4_%-W5 #279B&'PO#!Q7
M9ABNE^_,M:[:<BD+D,#TT9,.;!0XW% -L:S81(%L$38)HT8[0A6TQ,-6$'J!
M[/A[2?7XJ)M:=.N#EHK0H0&CJ6^[L6_[2+:(7XGS*ER/,&;_EG&]\2/DR9*D
MWSD-\D2_:4$F$*#<]-&(3G04//)0'?%#)TU#6=S%1/0:N6,?PK03]QN)$]=,
M91UC&ZM'4E3/7UBC%>L?[^CCPQ*^XEW+KXQ'WK;H&]FUKH<.M0IGB"#UT:9^
MB'08*:#>W]1//2)==HF/R#,M%'C!X8GIV?8KI<GW;+/1@U@[-!*)G/]I?=I<
M(**=8P<-R@E<+W0=LXT4%ENHAPX3X(RD^)!7[)\9]_77Y[<&K>Y)853W.#?N
MM&+, 6I]MGW#@=XRG!U4 O]F?8[!H=).C@#)YYEF&#I8MI!\2U+"-F/)+?ZQ
M4#C)KD6#$46K2*H+44#$I0^GVJ%1V%!#+9F'L>6X2"(=0>.#\XU]2K,<YW&&
M-PN12R X<??RSWL46O&M5UHJ$M:'CW"H5(T]X$C -,6Q+3-^'_(GUA MEG2H
M9H<V]:#AD1"Z1:0/M62@:-^00G?%D8^2,)0MU 1!FW%\OXIAVQDUC0V:7#[#
MI*D/TR @Z5!V0-WWOA\&J2=UW^/RGFU4^?_PS>H3WK!&%[!AK#WAN(CY!W)H
M60_^R:4"%I\^K.O!1P>0 ,BUV/'L()3.D66Y):R1QZS"F]D95K?&^"6:TX-6
M)Q+HDY ^))+#HOVC"KYF1) 9Q+(H1V$*OY*2%$\+K*SJJ;%HFM.#,R<2Z).0
M/IR1PZ+]HPIU1%@D\8-8YIEOW&MNZ-LFLKSYZ"+"-&A>L9^R']RQ!7E%V..Z
M3&)\ W1 ]V$'3B*QGB?79U,?0-HY\M!5DADG)@YE83/UB\W 1W[H'"[.S'&K
M!"=$+(SHA?_A$3_SZ&J-V-6$&#:X6H@E?T@/3K5@HYVC#MW^(0?[R)+=LCKR
MGRUYZG[B+]7NW%TN%+#T]"%6#[Y+'^KH\W?D(B?$TLGPS!6VWTXNR;M+5^K!
MZZ =#0$"4Q.S/@0= E;N4070"#KI!MA*D!<,\U"OR][3@P#=&=PB-V6!:\OC
M/KS]AP.CV>RY*6$K!5FN *E3;WD>OQ0+W"$I!>%JQED(TBY?\'BKFWK8#Q*9
MU6W:.EV6-%\N=K1UMD!]M:.M'@3M$M% B>I#3!!*.I@C4,-INV'@V;(K7\<:
ML.X:X"7-_]T"4Q.S/F0= E9B2">>\YV8)-+-U[BH@*HE06AG7!XH). DJ"$(
M$A*%,LT;>V"CT &1X0-R:'/<A<BS[(C(;FB,/3Y0Z,%7P.G!B9LH-FW?35HM
MW\1!4 H]NMP #<O9XQ*<AC[I3D8X[I[R\$X=VFOQMBK<%F![63:)2<.UYW'#
M*/1[W[+!M'Y WB7+BT/BR7SC,VQLQO=+#"J;?K(G7&5/Y&B[P_.K%R+I)GQ<
M4PO'EKO :EFAXX=HL)@^D"&NW9/QQ5'BV(G==O;A.(&'D!780WHST#N]RQ/+
MA^Y=7O%K.Q_RE!8/(O?]@+55_E2*W+#(JK/;_T_VQ3[5*K^5(5Y^].ZKB'$"
MQ[+%^Y"?K;\N&H26=HTO]) CP9:)_+;%3UD)-+%(OTR2][3XK<SRN_I2V"=2
MW=-D_D"0/0YF%79(#"868\NQ[&Z(/0@T>JS@@:)3%[H^C!T*F(XA%W1%']N)
M*5M.SD=IQ;5^#8;9?KXDHVQ^X]1F\\ CSH?<<G11;*;2%$OU$:AC^:%I.>:,
M-XHNLT0;_XT;B_7_ZZ&5YRF/.V:-OD?7U[M>A+23 ."\$8[MIT'8RBSV'Q^%
M ?+G8]:UWJRZ!E*J\[GU^=0-CW:..=0L$R_R"9$=KJCG?NTK\S)E'M@3S?"Q
M[=NV[.Y3+:7ZBAX*9UQQR[,P:*<ALA0"'8H">7Q]?0&AI)V$@ :'V"BQPZAU
M:V=;IA=8[,6S$TU38O5225?R=-'E8E3!L=BN8[66! ILQ_&L&0L"?=38#L',
MC]96!VILSL89')-M)2EJ)0\RK= )/'O&M5Y+XCSMJ"1-*PC:3VA-+QA,VL4)
MJ)F*L(M=(DO9*#Y:IN\XKNT$"VPL=";:97:^_BV&UA0#8*2=/  2+ B2!&-9
M\':S([9=OBN>D5YOLS+>4+:U(#S_?T(JG&U(8F0'CZZ!([H5"7;;\T%IQ\A#
MMV[2UG1)70YYE=^OSULUV+2+<O#+O[852;?-S7X\#'S;M-",WKVIN"S*"[PD
M(M]RP*HL/OGQ"Z'P*6;:R3,P@:/$MXFL<LMN9\RCQVPTXU6_ZPUW']:56'K,
M[8^LU(2A#>@N@\/ RA8"@WZX/C,'XJ6=Y &R,HHQ6U4,R@SYB3Q$I%@W/Z3Q
MWP\"A284[9'5<.GJ0THHT+[4D5+60!-(>GX4!;;,='YDM%B(D+PIS7AWZ'VG
M:/1ADP03[1E(J'_82UTG2*0)KL=P1.%(^V-/'?!CV-@G46C*<D:\V6:;),OO
MRH7HO6]/,XZ?R:%?4OJPO0T8A8PP=%F9>&$8!O,P2('\^T;!2=TM$N%86L_U
MFHHHQYCOK#[D;&JY8PTOI0_'C?/0E,>F><W4HTM& T6JC^* 4-+!)(%Z99W4
M<4QI==:)&:D2*-M"2_")O8M2WT6R$_M/.+[/<E(\+Z1A^_8T4ZDS.?1+2A_%
M:0-&(2,,78V;28+-0'82/YY!"AIQH-'A"@2HD,#)+)1: 7&E)4KK#7;@.:&+
M3.\%N,I9:\3(*O*@BP<'Y'+[R%!_X*!5_8P7+UA?'15QTT[B06>QV+$#>9K?
MYDPI< (3N>&<9XNX*)YY=#I^X''&KWCD^O9ANQ$!O@EY+ @/]F7$?L6?X(5V
M&YHS0F</CS@K]E<I[@K*UE[QZ0OU\E,VV*X$M*M#3]\>=?3JJ)N,!!_VG63_
M^)5W\>PM+9[-F9M:7W-F[R'M5 7H5$A,G'JD/7V?Z[/_>($?+*9CFJVE3D>@
M?5O2\9AN9)0OK5K&&WH!R7%3W[=E=_,D1%YH??ZKW.1JQ:]6Z0R1I#Y,ZX=(
MA[$"NECPDS2,(UF@R)05PMB+,II\JW!1#5OC=Q\&X<J(R%V6YYRF_&Q3- />
M$2/'=9$O6_I/W_=W>3)QSPG?] SM,TI=US-CV7A_R&-^%X"\)?7_WMX7='MW
M?UO@O$S9[NP](ZO<#;)>+;D=9N.GI$']1Z.J<1O5#KC!U<R(6_PGK[IW57I8
MNQG&9AD&Z&-AY^P<74J#X.&EV+:DRU,]M%PI,4G,PR2R-(O%NA^>H81$KIO8
MLDM\5TF2B7?MRXXUXGC#[U:S/E_3ARC+Z_;6LW)[F,=EZG9F+FJ@\GNS>ZPO
MPJA-(_W9AE4?TS5Q?^B,Y <GEW9-E,A67JNII())VF,%WU2W ]N.I+FVWF;E
M(RWQIF3=^$JJK" BY<-Z1F</2)B.X@#I1=B6H>*<8$3TL1?*R.DD7(1>MW*"
MV+8]:8+Y^95!0=U/-8*-'HGI73[0 @2F'=N>;#'2LC+[3*IW/V)F!^_(VRQE
M2S3"QGYM4=376.+G>I.UJ9WWA*&+=:D>,HTT9QLF?8S%Q/WIW@J-(S/4.>^D
M#DXCV>IB-1V;SJV1D\H@#5@C.: =,2T?"R\U_00%LD1YQP<P*RY+3@X/7\)*
M!"(V57'K8T:&P:7JE((: 3_U_,"1':S,1625)<41%(/I='%'P($KV#4C:=&Y
MPW'H1UJ67^M52DD2X<I)L^JFX-^OW/,#2$"_%UPVC)/=]*.ACX9/U1$Z!TNA
M0=-1'#AN(KM,NKS6#%P3'!1FPX]GBSW"YC2#863#+_XXT5K BV(S08ELL_*5
M/#&=QYN;5'>Y[9#RL[)L&1DN9ZXF&X8YAU@?$S9]E^B\Z@!UI\8QBA.LFZ(J
MG?)(M778TLB*_-1&MNQ*F/CH6Z'ONJ%GS6=UV([2B"C]W7C"FZT(Z^T^S]_F
MC/1-FF]B;,3F3Y0,Q<,\*M+<T0S,&X;E+QS*63SJ?GA_XP#J+.3D(V_^>M>Z
M1(K3O'!]>S!1/V@7MX J;'EFC"U7IL*[!K=X<TT?'K(Z&?1[6ES%#&0I') =
M8<9+7)C:X>.'D#N (D<U/D#L33Z@QY0Z4MK3CY\^ZC)51^@<O 8'7 8HL -9
MO9+E]4SI&MBI@CVRY^XQ)+<'^(B";9(B$LKN#[RA14&_9_G=-2VKLJFLP]<0
M\U]2WK7,+ QK>E=BA[>MA]EH%<T0,>JCZOT0Z3!*0-UVKAL'L32O\/[=PEOV
M%5=LRCYM_=TFN\NB#6$J>_KP_%/@27-&P<!Q?8S.6$L:@$)SXY/?Z,'B$3*>
M=L3TT80I.D&G9C#4W15;86"9LB/V?;OEAYQ-0Z2L.)[E['CYRLB:AH6ZZ,%_
MN53 XM.'M3WXSHUW%PF@7/,0(BB279Z?C&M*94:.2&8PV[RWR?7Z*2??#3PT
MCLN.,<8>ZB3&!$LDE>5AT^ _27(^^X#7?W'D8\N6Y:9==@H>T_VC>7C+W;L5
MY?>J2?' KTA7]V1WJ0DZ2?^S=Y(^7<5XL<_6T6T.*.38-O*1Y;OS6=IO%>N\
M8MI)J1=I_\*VI)#R!]:WA2VX:.> 0+-/^029:=1Z$92GL$<N>_TB [U12@#0
M/=H?.Z[GMS^DT:A?8J-= P3>J'C$PJYL>P>Z_/_N!]^B<^D\+Q'*>Y1?HB]'
M+?E1&1$;N=\UN>DY5)P3C(@^+%9&3B?A(KAR G'LB,B<UPLH@UKYW/&.,I_]
M(S6=UB3^?F AT[.M&1-3]^1*%1._H:;1TEFA.V_R+6OH#6]'(I&!OUQ?\X8"
MIETC#]4CA%PK2&7.Z7J9XEF![WM>:,Y'J:,:[,;1Q '+PW^B'BG;$II23_NQ
M43AJ;[TY,3OJM-XSH%Q<2C+61]<&8)7,:R &034P<4,KZEW6349:Q<*I3=MC
MS?G1JPZ]ZRA> 7I^?3K!8-).PPI.[D\<WTUEYQ7?XGN2;#=';'G>EUL_GD%F
M-W4[(-S0[:&\,G;U?Z9?)4![/D)H^I!M,&(ZBAY@OT3H^F$H\T#-R,MQULR(
MG@UQQQ]^4FWC(&G/=(<<9#-BVL&,M2%;%6JT%DE'I\,H2Y];7S^ZX='.X8*F
MNPA0')EF1\9#[N%QPSDS'NZ[:?SWU<#4A-VCWY()4/IWC4:[(^?>^6! *Y:8
MQ'))>TFSP'5\SPUFK.YY-,;#<Z%UCW)K[K*6)S0:Z:ZT>.=C IV](C>P22#/
M4M4T^Q5__X39A)/A32F2HBV4'._(X#,(QA[#*Z-.FS<Y-5HZJB ;#<G3AY0J
MC3HTYC:*@CBP9'<$9Z"92C0\(]A#T_HKD<%L^\"G3_ **4QB'"'I=:==!_]*
MB]\/29Y6TB0.XC0IVTS*U-I;)1%IJ%#]6,]5"DH J <E])+4,V59XF?AG():
MG;,-O-^(G-@.<?M^P[61SYCG#EIG*G3@?99G)=O%\1XDVYX;(B<6+W6],(U:
M>^"'CF5Z;"&^B-;ONW%':3*?SN^:^96W E3YOM]HI/&]4&G7 /=HM9:=N-0S
MJ+<N0&$4(5EVBSV2C[MP@>7FOTD#-RX[ NJMAL2^Q'8^=;6-%73]%Z:VA]/.
M;<88.HQPASV#DQA'5HA31QHP3\OJY*CB<.?SBA];D+PD;[=%EM]]$3F$%[@H
M5E;GIVU'5[!Q:9 :E9$(6(#<QDO>"QLFS0D&1!^=5$9.)Z$B>#_G(-N7E^^:
M3Q7"6A5R<L?+5-PJI)'<AZ)F^QFA48M_GJ@%.,DWBC'QI!EO#TOP@DTW"?V>
M6R9""TYUWWF[KWG#>JBU7"!@R>FCHCWX+G9]'>,/]=*EV,8HZ72?*--LM%8=
M*,<V24]9.22^WTO]R,'2+&A'^10N^KALBH3RU&+ >KE*:I(+00V4JSY*!D)Y
MF1.DCRG0F&./!"2R9>Z\B6DYS+J?).T8:.F/^V>')$9)U!K^%OK(]UT'S1C]
M]@X7N;@;Q):>1GF/P9%ORRG6#B);J7SC #OB=?H>75^A>A'2KO&'ZDV0Q(Z?
MR%R2Y^TO&8(HXYIVL8<= AHF3GTYUQ%F"*<'=(MBICAQ')F)FY:*"@N+2SZ"
M'>.$=<I*I)?"]M%&Y_U[@\LLOLJ3M]EFRY=XZP7%[3O.H!D"VRM#H!/Q] V^
M6>/D!LEF.BGKHY-C.W 15#>&;> 4LR@D*)4MQY9C_;)Z;B/3#J5WO&O'O!W:
MKF]9OK?PK#DTX&[!";,M;*_SN?45LAL>[1QTZ$EQ'(6N'<MVV?6+ \LQ X>]
M?5DV;70KHWT^%A\[3G9ZG]6/6I<0:2<+H.XIDA*4!#(OJ/CHHC#T313,R"Z>
M42S+MZ*(*B\9DI5Q_0U;3O#;9745([V*6>\ABTGJ /AFC[>M-O6P7Z[/PZ&
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M62+$NI$&H!$U"%^@">L0\K1#]G),$J030-,#IS#4J6,3/TI#:3+21=5)K;I
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M:*,'"GT7(=NU5F''1":F19@=W@_ \]IRI"L0X7PTH6LEQPD36YIT2'STS"!
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M[[/XWLBIE.CW^(DG:B=Y?3R<L+].5TA]#^FD-N5?.9[/]&+L_LR@O&%(OC1
M.N)\IWWQ^IR>N#^TDWI03GN)CU.OO;AA&-J!XWG6K)7:6[,%31KJU+3Q(3_.
MH=09^ 3XQ?JT@@*EG<,*C7=QW91XKLPE(S[:;N"9GF/-& KU*Z7)]VRSJ;,6
MX?@?VZPNJCT=6W9-\'PX5T<-M-<A!/U@?:X <=*N$04RQ7+LD/B)[,;MVWVV
M'9E)?$^+%IOXH3R<,RYP@+9/"51))UU^;;5CUC6R\NC\40]/U12"GVD\]=&1
M27M#9V,\=(*WS#1)//GQ]2IJJ+ )';CJO<?EV6J7?<%V=<^\VBU/7O6 ^3D!
M7VSDN-H68 <\"NV4W\=JF_T<BUE+/_1F7"SQ:\$;6C+0(B6A1#"OC&V^+7>>
MJCJ;&=_I'GV[R]VLW9W ?>=N4@DG?Q,]:$)["=\&[K_99<7NN#4X];LUL%23
M=XEVD1GJ\(J"P$DZMA2!Z9BA$UB#4DVLJ245+R7PKZ(BM[PS<^C'R8O_!93C
MM#^TD\'@+#1IFKI^JVJ$=NA:R YGO"K^IHZ -<I[PM:H54&PV#H.OY,KW3@U
M;__&7WZ[>W?+==K>9]?G4#]$VC5ZX)RHH1FFJ>QV0DTWQT1AX)ONC#>U6VDQ
MT8Y:*LG6[33@:4W)T>5SN1A&:!B,'<9FFLIV7O6+D>W8)S&JT_/C&C]F%=YD
M_^2NXXDX<?3.5B:T/K/^^+=#HYV# QWUU(JQ';7N-9!M!;;ENG->@OY,*R.>
M8>39>R&#W_78^N/?B8YVCA34A>:Y3NPEK8KO,6:%)G)FU/O_XOEMV1):Y(1_
MGFB5P%]ZDXH$X\\MBX.V1]8?]E9DM&MDH$J/D$EB5Q975%/)#)%G!0C-6*7R
M?,@GTOECN;5J?/M#>@U\E[9?#!%T&4@\TS=)>\(>-[!M/_"&5;P8&#.1DSJE
M]52CSE[(Y=8ZX-*_KS_6<EBT<S2@*HX3.XF=]GQA;*:PP\#Q9W0BWGZG8I@G
M3"#PG7*!=20-D#ZP_DBWX**=(P+5Z!"Y,98646YV!*'C,:SNC!/X+1LT,O5@
M\W?V#'?+(QH,>!LRVCDRT..6*/*M(&Y=LEFF[WIL.S LS^ZP(7_/_C#QB/-7
M=@]XRQ/KCW<;,-HY*M#A=BR2!'&[AH=.:%F^->=Z[3V_2#+Q<+-7]@RW_ D-
MAKL%&.T<%:C_UO%Q&K7OR8/ ='S7=&?TWWZB!3&J>YP;Z?3CSE]^R][=/_X]
M3Z[/@SZ M&O8P-H?.\@*6VO4A8[E>?[L*=5_+7ABJ+_@S9;LRM1)4D4QSE1U
M("@MZO_-:54?DQ^[>' YIF@H<E(?HU 6]"/PW:2RQ$QB3[5 2$^?B$B-8ZP6
M]?=423SZZ-8 K%1Q\*%GS=@E:1K*+E;/PC>5V!5EKIV8&C--D.VUQEVB('0]
MMB'U9HP]OTS )3)NQ%5])5[8%#8O9<VULORX=APIC4?\S$]4#9Q6XD;);AY#
M%OM'7MV/+HAP'J?TK@%W2WDL]55>WW>[R0\5Q$CYI09UQ3'MI@QD?1)X)+*>
MJXGU=7JVGM%.ED)WTI:5A"9J3SEL^X&/?'_.N..V;&W:*L'1'9EY56&&AK12
MB#GZ1SO9"ST@2OW \V71/.*C$_J^9[DS3@F_Y05YR"I.?K;&SK/\C@<]5SC+
MV3?1,Z]95-)-EF#Q1%[5"E.7)SL4B1[+^0.*=PV(KPV&-\_71PC>-0!$1;=#
M\Q+Q3?3&]5D\54=H!ZV@-CSQ"');]\ZA'WJ!X\WH*/FR2XTJ")CM$]S4H<3;
M2RJ/3N.]:Y!)=9^PA-_YNAP5B504?KT^WU1 TPX6='!KN9C+7YG"E'6<X$U^
M]82S#;?OC$0EWI#W68[S.,.;^MJ>9""'_!P-&,K]WB")3)R&LGQ]0YI>9CO$
M4W(V_H9=V"U3/KR#]IIA>\W!&25A*R=0.MRY[TPI#1\=/0#0-8!O>E9HRYQ0
M,X_^,.LKP!@_U6/^QY9!3W>@!OJ=?(3] $NK*C<>7],+3-<V9PRA/(TY/^K)
MOH $KS2_VPXT-[.GNX9]'.]\&-NF=L)G1O&ZX>8&/>R>Q.#WK#\!C8-/.SD#
MWJR&EB^-VAH$[I;\J-XP4?X^_U5')>96#)\1<8#+<G<OE\D$_$+9>XF?3D@S
M>)AJ% 589GD78[O",N0]B.3@/.$^\>T@D+FGY$*HNXS%U<O5M7RGS[B^ZSRS
M5DNZ/D9LNNMN%^1.=>VG"/2,Q':(907P^6@:<HY3RD'JY_J18P>H[U:;W.ZL
MJ80=D^N<R@@0Q'A1ZJF80X!+U',XA:!*&M@6B66QO_,S6#DKG/J$B=+ "R)+
MFASDJ+^?LCQ[V#[4=H%\Y#GRON!GD>IF5;U]J'$UDR@Q-B*+Y&,#;6;M!0ME
M*N'JJ<G#X4OT695@4-\,<:T@)K+K'$O17$&Y/W6R&[PFQHBX0=)^9.L'INW;
MLQ[9UF9J-I=+G64<Z%?I?WA]_0)@I)U#"/60^$YD>8&TKM+Y='<"Y]V/1S;
M7#X+5%"1+-6F\8$LE!ZB4WQC1*\/88=#;EO4 6D&/I@GKAU9?5Z1J0FNO))3
M6\59:4C2():9^,N>+;Q@DYO^R1=F??U4$(T^V@5&2I4&';HUBNW$MQQ9?OD9
M6+:T"EEAZGN1+/='TR\1QWJ5)$U=I)AD3[R/\Q_8->T;3R)J&G,$33F@/08]
MYKP>00T7K3X:" 5*52@#CMLAV#<#6=*BZ2FJH'Y_N;HU#HV"MR<!07['@;%I
M.5;HAW/>T^.)R^_I)A&EM6K%HD^DZ.L%9%HZ>G4])+L72_K;^^SZ:M /D7:.
M'?@^C^V3U&Z]O!F:KN=Z:%@>)@5&?RG((\Z273W+TGAM5/=9D; ]> $O.N=9
MR&2J*PL+:O2V::>IY%FR&93&&8\&Y)6S<*Y6!UMMDGD\[S+>@Q$ELP2:T0F'
MH-T>(S)]M&8X9#J.'M#-D66B"*<R9_><Q)Q&$8?R\D0C6;=)9+=G=_'LD/U_
MX,Z8^N%H>IY%QX[>#U,LV _6UR8@3MHYGM![QCCV"4I:5R=AX''?&YK==5H<
MLR5/!FQRP)OG8[GFR<EFKFW'!_C)^GP!(Z5= PN-PC%]R_:E-T&.]\B?:9Z.
M#ONL:(4WP^SH+?^)U(6JQPZR6T:#A:H9"?MQ2OPWO50!,I/82100F:=_<F*.
M<1#RHVS5X.,$!:YIR?Q3XJ.%0B_T4;A8Z/$#+GXGM:?S$$3/9_@'FM2?$_)(
MRTQ4-2R8>:KJ4K1E56SK VQAZG%Y/U-X\J<]P&][?-<'>&\;=&_WX#X<L'$S
MRI ! YAG:&E]I9Z[@[2+O%"G;6A:*#'[0K(F@+]:#,B$6C97I,B$TEUP(/]E
M-0T6DC*?2D 7DV'@)-B5G4EHI+L*V_FY%!A\V.-@,[(CV7EICS!OLP>R0\-D
M=Y#I/F3V2+@+G[1^DLGQU;$@7QG5$?Y70FY'(CVLNXZ%._U9[7PR7G1 ]3&/
M"_21+JP>4!/IV,BW(YDG3RM-5HG^FT6=P<7DG91XIO0FC5BKUO/&NW]L66N;
M%8P=;_VP<",''#/8*TB'%>6DCPT9A)8J,P&HUR@*4M\ALFW+3/13T-!6#D*5
M+# #9'G2O1F)JB/[\V>R6:+09E2=S/SWK%4]_((2<<"$IH]^=8&CT$&';OJ)
M:<98FMI\&F*IK/DYN^"Y) YGE-B+ BP+>N':7STOK25UJYKJB50D4-'IHRO=
M\"A\^*'Q)I83N"B5I>Z8BF0*&M,P;;C.."B,O=23G5J^W^;)TAK#VQRC+_+,
MV)<=@757'Y9W@:/0X8+&#MH^%Y^,X=-00N66<<V+78HS^)U%W_3#J+T*FQ^$
M;.,2VM9\E#[:1X)C3F+7#+ ONVGY[9X6%1/@P\Y5QRM:;7!99FE&DJOR;*D[
MN\(*/*\Y(..PN>1)JN,]*)Z>>LBJ=[DI<* PQP^'/@9%%3B=@H;0F#.'Q![Q
M9>?0\ZN!2M;H[($<_,]\LU<>M./(>!G?L^J>#6YVE^5X8SSP<N9\]CYDE@U-
M(\'/8'M!4A='\IMYEZZJ)1/'O1WA85IRQ]@BI"$"U4>U^R'28>0 'T&YCH^D
M2\DI:3C442%AX-!,)<3"V)(M(C[D3"F86A]"QF;OT*[)HS _/;3H4A8@@>FC
M-QW8*'"XP8$6H8=CJ<&>A%$*EOHJCHLMX6OLAEXT9U/9B1M&S&C5\1PWH!!"
MZOM$5@B!3]0+>6!W,8QQ3+?:S#V\_RUBT4<S3M#0UH&#[B]-"X>6M,*>(AN&
M'P>!W2,VVXNY87M!9V0CY-O6G"FP.XZO5"+]9B;SY7%+1]A?]P^&Y%5>Y<3K
M$BCMY 9TWV.:KIU*[VY*82P9#QZ//<=R_,BWXTBV2M1ITV9 -VT;4I;@3=NR
MJMCMNM#6-='C>IC$M8#\ 'NN-%QN:0_:M:(B62[V$]N4+2+%1\]&ONNZUHQU
M#<_.Z9@:,=XR]:@RFD^:)INU<PC,>7O<2E=,.?Q7ZY-^"%C:-<K@8U\>UYC*
M+AI/<^S[1(J(CCSX[3W].>Z1[;L!<;$T#(0^/&Z90>=J_<@[5=>57&C?T30N
M=/RQKW3.R509^&F4Q.V+3PMYMHVL.?,=?*)/A&-F4^%IC<D(;T2BN?]F+]T8
M38F\"8J9ULU]R(]*.;VIF_K*&GI?MR.1R,!?KJ_Q0P'3SI&'^NA0DOJNM/"$
MI';6LW#2#5&3L.983N[X3=LOI,AH\JW"135,9WC!$2G;,*]^RE9@O!@-CP=_
M%"V ITQB!9;9XJ&<J??O\F2ZOA.>]WQHKYT8^<@.V\M06K[G!KR:]HPKA9X\
MYIIM9#MR; ^NPJ%IVL@A8&DG6Z"!,[RJLBEW M*\8@K-C"$O;Y:Q/HN5SX)>
M]0,"XP0",$D1*#*XKY,J@M&'3W"H5&W0H3N[./2<1%K->@Z:*2T(]UR+3[@&
M3-)VVMO81'8LVP0>4HZO<O0[I"[ <H:]52A#!*B/TO5#I,/( %U&^K'IF5+W
MR92T&V;#/Q]EME<]Z[5,.R"1]([0I/JDZGY5KK6&'=.+D,PJ'OKUD>*<WV]:
M,F'E\:!M>/O"!:M=NLI.(0T5JH[VHPOFA0WI)PKX(#PE@25-1GQH[;; "5F+
MDQ5O7&<^GDMGD"AU9&(KQ@L:]A #>ASMQ6&* ]F^I-7DG]?E7'5ND]3DU(VD
M/>(;(WH=*0R%W+<XZZ$9=..=!A[V79G7:TZ"JP0A71:7W=#\K@Z@/0X@'7P/
MP$$>CE(BR_<TZ42CT.F/^QX>)^[CM#+B;5G1!_9*>+)*AYC$Z5Z^3K/,&]53
ML=)[9>#DB7LVFV/W^MCG>7!TF863&(6V+%Y"?/1Y45C?<68,T8%6B)LE,]>8
M8L$OL$#P\*+ %P2 9O3T+60[D6QE( 6Q4/J[817<%D[(>"X3J.STX5HW/ H?
M?RC+/!*XB2\[B9^*92.S?ZJ7#+23(#1Q(.N;^.B:MF.9OA7,:)IW1VD\6S+)
MR]K5R@OVE!-EQ-VU<'W4P!?^_HY+)*!?K*\+4*"T:TSA]<7LV)*68&]2>G^A
M944>'C=4%+5[0W*29M41G-GM[RZU.%N?5*\/2(RHAC(IJX!]5I>6/BP;"IB.
M804X2#V,@]"3Y;NOCT%MUW)LS_1F/#3_M(LQ_6_\(RLU.1K?@;IBD"3"D?UY
M?89)4='.X03/WA&)$VDXL_@8HL#Q'>3/F/7]ZNZNJ"-.ZMLY$=M-L;W&@XAQ
MTX0U!XP\WOH-1UC'X$GDUOOL^GSJATB[.  ]R@XC',O#E3[3ZB-KOKB]Q_E-
M3OZ+X$(YIG&H)[(R-KSI.NB=YL1X9JUKQK=6^0R1I3Y\ZX=(A_$"7*+ =I%E
MRM;OY\U<Y<EQX^^S)_%UN1 M/THHR;U*^2E=4WX1F/]1-P,Y3)RCQT,?:BOB
MIA.P$'H=RTMBS[=D3E4=Z*X_I0>05W^:0@DY"?4\/P@=JR4<9;H5@((OOV49
M #ZH<*.8$"+;7LT^L2CT]@VIOA-2=Y//*@>=@P<6.3:.I/D[U^V:U)+ PP^#
M,'"P-'N<.*XC'PDNR9>"/F5E1O/Y\\?5K1H;WJSQN&MW= 8Y66>@G=;'B'7#
MH_"!@RX?L>U[*)&%"8ZFQ^E=BUN5.H'#R;%@L$0M&FA@3\]OUJ<>'&I+4,3%
M#Q3]>CZRDB2%1*[VM;A$E,_.DBF$AMNQBTQ76H_P0Q[3!_*M8IK#?::[P],%
M_.>4N\EI86QHJ=^MGQ:QP 6HC[KU :1#B !UA::F';FI/*O15(13NV]1TDV6
M" ]I)I 8Y0X*E(4GBU<<)Z%CR@).OI(GDF_)>S80W_"&W*2_4IK,;SB:9NNH
M(1$W15/CCC>MAV;)Q0*6GSYZU8./#F !5*MPX%C2NLN3<4UE^T<JP3/X3L$U
M8ROR94F?FJ*KHC,+A= 4=6MZ*,=Q_WO$HX\B2%'1W@&%GGQ8?A*Z,M*/)(L"
MU4\8 ]_O^YX9)=(T\=>TK&Y2KK(+))>A/)5?VJ^K"V8F.G2_6SCZD%T&BO8-
M)M2[' 4F-J79UA6),GIGO".-6$ 8;.T$3C7@^K&++5,6P_-KP9;\]09@=M:+
MMKCWAS6F!^F/>M\M&WU(+P-%^\82N@NWO,A)0]ET-XXG"I&.4+*<+,K"Q/>(
M+3L7%>IZE2=U2;8LOWOW@X?.S;^R$0T+[_3#KFF#U&WKH0-MDAD@1'VTHQ<A
M'40'Z&018#,-H[EX-WKFV#<N>/AMT ;!3$POE-99_4I*PD1S+THO/I$-%5FT
MEM*K7>M-R<1]^WHI5Z>,ALI4'S6#P:3#>0(]@$VL-(DMV160R5@Y6NO:&#I@
MU>8E4=(:I8\<W_)<<]8\<_4NJ_;.Z:%1 E'MN&S;AY[^=7UMD8&BG0,)7:^E
M@8^C0":(>JGVD:VAN"/JYE$DL\GOKN(J>Q))')<Z5?B)GRG\L7:!TAT, ^]Q
MZ,&J7G&IB%@?!L*A4C7ZP//[FK8E+4D\!V$5MAW[A@%&[Z1G*3%C,Y;Y"[[=
M8WY!\M#!F_2J+&F<L7F%+PW_#\WRZB]L8M@R7%=U&022O*?%;R5?+XH2@I](
M=4_GK_,GH(I4AB?*R[[ >\1B.OL[QVP\-:!WQ1M(PC..&MM2;'+JVH</ KD>
M6C[=2,PZS/K8C1GZ1&=6"F@,3.#'?F+*DOBNJJ\*GO"?.,8__M(<H8J)=J^M
M]?U*G ^H<FA[EHN(-"?#J8VN$^9M69\;HTGS5585\1[';H'!@.AA</H%IB1E
M?0S$ *S2E06 0^ M86+YKB]3Z%EHJW@Z.VQ5X9N>X]I8EA^NWD_<XA_-UG9L
MMT9O=VM /#7R .\2X9G4<?]ZD&>:J#M(DG6M37*$1'-[(Q>:HJQUM3D]:*56
M!\0FZ):&$#-QB<Q+,Q.%1UD>91*?GK.8)+2DI9 .?5Y6.773OT[1Z*A+[1JC
M.!];)/ ]:9:>41Q1V-,/GW>]*$!QZG>#OZJJ(HNV%0__O:5+1^O6M']EX",4
M1D6UB][MDY>"B'54GQZD%TH%(@]T"DHM[,2.+(BOK4$>5,\F -9']HN[7773
MA6WV)7E%2J,#KGW94^V65R!ICA\/_9G>![R'^# >@JOH>*9CAK)(]_GU0.FR
MI@+;3Z:I 'M^(G75U =+ONOZ3"K^C-EPWN RBPV""U[[I^0U<(Q2>)%UFX@$
MT'<-SB^D$&Z^CED(]/SZB@F#23M9 =4O8MI>&,IVZR<HN)KMD$SH<5$J77<]
MU#EXW.$T]FPKEFWM.OL[V4Y/K5C?N+V=EWC$MY/6^I4HL-W0=9$;SF=3WF:;
M+?==OP"KTD =8%> OUC?LD"!TDYV0+-A!]@G#%R_P/YEK(OE!2Y)+&G9N^XN
MOV@#XYI>;'I6]_G2&Y[AG'NWEUF)-;[K2+0ZS(7MD!@EGC1/;*T1ML7^WYLU
M2NLTSW6\X:DN2W&_1-C,&#]F/&VL?K;SD#[ZN@9]DPJ27]>(@=FR0;_5P9X.
MA4P[>00/3L:N%<@.Q@ZU3F_OR3&26[$[(C^J-TQ@O\_N%3BN9EO=DW/:-NX!
M!L>(.)X)R]EV]EM=8OJ0;BA@.H894-<P2NW0E):$GH^1"K/"M_B>)%M&O:36
MW'J/SJ:(AUUAP$V=WI,:#UT,!B^]0[;=L(AL#70IEU(+)2T7T<[SOBH)2&>=
M;,7:JHX]PP^]Q1[Y2>#*CCEF(=P*.@A?C:,T-B-7%FHA/KJ^B3P/F?Y\&@9=
MQ@F->REKN-N6&KK#?KB^T@[$2[NH YTGPQ3Y*.EP[_J^8R/3=-;G)'L;,;**
M/.B2$+UWO#XRQ!\X8!5R7OSX!1#T$C/M)!.4I9YEA:G3FFJ=5[EW'5Y^8CZ6
M7K=O>?5)T2_?\\GS]?<^NS[?^B'23A: XTC<($YMV>&V%,%"F7Z_G=),JPR_
M'7(9)D7-R29/]0MG!?38R_4")T6RW(37]XP3I/R0UU'_L[/N0QX7(O'@3PFI
M/_V1KW;KJS::D.]4)/U"TXAD+< H9+"AWKB0^"CR97O\\612V%^=[^J'9(MV
M2.*2-)7-_+><G-OBN=XY+F23=XWN71-:66692("2TT=%.M%1\-B#KXOZH4-L
M6<#!39%D.5Z88+M&]2283"1 R>E#L$YT%#SV0()%_#:R+RUTO>5O;181Y8>R
MW)+D*D_>,T$_?\'9_%=Q:P#['4UI9 )#G>>>HS!XE34]F-<G+ 7YZL-(,%*J
MQ!RH*4Q\F_U?/U5OME59,9)D^=WR'*6'QG5DYI%LALA15R[*($I)V,X)\&UI
MRTV0U1X49B'3L?W0FM$[WK+WR;7GX [XVP;VAWP(*Q5^O3Y/54#33CZ!B1J@
M-'6DE7DF-)./I,AH\JW"135LN]5E,0W,2];>97DNXLE2HVX%O!LS31<15UJ6
M</*NO\N3:3M.V+)F<)?M*(YB+(V@FV']-MV@2Y=R(X??M^T0H41V?CF;+,:S
MH%422GSP+#LEC!$R,RH::KR!2P[^J:-XW!C;;A(B.Y8="$[3O\$#>M$[I7&S
M@B"U?%/6KU-G@GI"@R]J_3MW*:GV$#EF8#-RSMY#!89*^CB"H[%/?"R]@Z7L
MUE3D9MV>\I %*+(C2^9[&MD1A2$Z=&7$R"#32M(@DJ4H^\+:O6?KM)M4G8UJ
M]T&;AGEOJE,>ZK%X;Y/, "'JLRSO14@'T0'JNG!1$N) MC(1!5(*,7<M3KUO
MHAY/42]!M.5?AX2&R5,?%D) TJ'\@!Z_F<RH!Z:LA(GXZ#J!YP2A9\W'N].(
M*G[C'2=_WY9U8O@G4?L*IY6H;?)("_%U;>>UOK_QF>;[;KP3O;CBG?BZZT.]
M.@%>Z%![V?K,GJ /M(N,4">([;K((7U1E^VHWOUX9)3E8IP_I.%4'7H40"W*
M?"$5 ,ESBC'1D_##H--I^ @^2/9B)T5K:81"7$8-Q2BW44G^L>4!&A45 1IO
M22P./ T;\<R7AQ**$=Z(RJ3E/2&5P;\#NQ4<QS-#Z0TQ\3'P?>Y;#-SYK,"W
M0S]%SXW;Y\?AP9O2ZR2'5XLWLQ>WQ%QV/[B^LO7@HUTC!KV%;1&4D%B6V*WV
MRX>6[YBNY=K+4H&HA%H V4!:(R5ZG]61$^<0:>?P@4^?L87#6'912'QT0A^%
MH>O.F&?F@A8S,0+*!LV9T,&"B\&"&H>4F97(EWG$WF9/64+RA%<(>Z0E26X*
M-D]MV#XMJ6_RUZ6[,[S9%QLNK[;5/2VR4J3.%EN\-]OJ,ZV^DIC>Y?S[JY)-
MSG6VIHSFM_3F>\XFT@56I$UG>!9\T1ON)DB:_NR2!*2['AT7+<;[/HE$^+5K
M@<%GV[R*%PMO.F;@DM]GVW>-S^U4=$Z75>URP[DRF_11X%5Z35?77ZCQB>S
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MZ5M:2 J.Z#-3R[=Q>^"Y5U?.=&?T39^JW6'?O\EPE&U$;4*MCV;W>[>/!\#
MJ0/R4[WT%828=C((NB,E21)8MCQ]9S>@]<Y76]BK];EJCP3'R?_EL!AXBCJ,
M;V"NAT[BX>6YKII5?UL4_(S@0/>$1/#"VZ$3)T?IT2\F'2<,+-,/EHL2DO>G
M*2Q>9$^XRIZ(D>7,SFWKO=8\&Y'K&L=^G-\R%*+0^@[#AP,$:/+6$:_42VE'
M]81V\@NJILA+V.)01EQ5H*MYO88S?BY/F(JTYAB!E\]ZF/-L G9"O6DX<@*S
MY41S>7U1<:^!U.3PUR.% 4<')8&9IDY?[!2OI%.#^<(#IVA^_-4;6A3T.T]E
M_^:9QR@LG+KV,N1V9UX>:ZSG7T=[O$;T;%0B &7R/+<326^^<='3X$S1(8G9
MF8Z_0./C1G'DITZ?\5E6KQ1,T 3*!;Z2Y;BA3]JCT^S ]P,W')2$8'2/$U+A
M;$.2D[3$.*+;XYZ";_$R_&Y@M5:38+A=R_)=;[&C#E#W9K:.;QL,'PX0KCB"
M _T'F435U^EE!Y5[03OYU&.]7EH'+VP"-.UH$!+;#_N\[ =3?+(Z_)#'FRU/
M;7!]8KK?/'_"U;;(JF=M%D!G"\=L!]PX-^+,5#\TX!=;"XV1Z2(#IZ=EF+AO
MG8NE"6D/ST7D1#B0)0O00C,G=5G"%!*\N@C,T XC^)(3)KKZW_'+-&IQ UXS
MHR:7Z2(#]Z]AU'KZ-H%1 ]$>?&73XJ6+Y>4/-=#,!8W:3B'!1LU-S<B3%K$Y
M"XE[Q$56\@WTF_JJW#=^4XXG0L)9\1>\$7?,:84WPZ2\JM6+][WB_SJ] BB2
M*K&N&4^\;R+# >^=FJ6<USHN-#AZ4$1/^[ITY^5ALRNH*#3L*DA1&)/>LS5M
MS8Q:\.XBUF5 @3R+1-)KB*=CL-E@4N#-)OLG25K$S ;DRX8D=_R:2DFJ<F4S
M?HRX2X9<[(\U;@,+X+.;YM'"G'^X=#6ITW5,:BZGICG4%%J625(L2^BTOAHJ
MF3EU[0-G9\51C!UI;4_EH^95+99"?,:L9DI9<+.-B*9&:7Q_Q@9M3&&"TB"Q
MDK#/";BH.LT6OJ$0M!&@((BDU0*.Q?.18%Y0]>B.UJHVI8%S<N-Q7JO1)X"1
M\M/3 H!12_1\(&.@<8M^9+HIZO-+ST!7!9V5L!2\?_'8_B7LC<_\2DK"9'8O
M+-43V=!'WHHN6EHTZ!HKM<>WH-H.%-"TXM93J54[(='Q<?0#JKR=6H2X7M]]
M_/E50<$"?#W6@"-8XM^TNB<%F[(K]HN,Z\#C+L6Q@L&PL.=&@=-^\1DAFQ_I
MS1@-))V4)[M<<&G2.ZX-]#^\ODX",-*N 82N?Y%OIT[46JW>"JT H=";,T];
M?$^2+2,XSW1TS(YMSJ3+EK0_V":9:=>#01_9YEKD\=SP8C"E0@5[>>:N!L%[
M6AS)^S?>_'O>^BUK_&;7]D?1=%LU^K&O6I]XHWM N^@#C6D-(X0):@U?1*[I
M!(@M@^9,)3F"EQNE*O93D?-C1T7Z*5[W(DEZV0O:22@@4[&3^!C+3$']7M\*
MG# XE!Z=86+%/,=Q=8]S@^9UX5VQ@."IXC:'OU7?J?B;;M5&!?Q;AO F)__%
M\+$5VF=:[;^]_4[YM^UE2)5^OSZ#U6#3+FJ!+_?YB1-)#R#K]X:F8]K>4IP]
M\%)&6D8_HC=M=R-U/H <.9"Y U^A$7F'(J>=/(/&.#&+&UINZYH566$8^$PW
MYMS-R#DJH7#*7J$Y@_>C=3:,[QET*(4'OD,G#@^%3CNY!O5;1([ON&;KPB$,
M'=?R''\9(WQ$4AF%^>&!UA3>#]7Y$#+D0 8/?(5&!!Z*G';1#&J#HS#UW5"6
MR*/1"R_P'>3:YGS\_=KF0):ZS\0QN]2)-J$;JM?-V.&5&OS;]2DX'#+MY AX
M!>O@(,*R&(C=RL+TD1D<_ >+>P=:#S<@W)S?K24?. 6G%N!%Z]-T)'[:22WH
M?.^EV$JC5H,96I;MN4$P8RJ@62F[C,=+/EQ7=VP%)QY2]'P-?NT+Y'17;V@7
M$:$N6QPY"7%:*^)YMH5LQW)GM,G7%YS>T/SNM?#1MK-[+Y<)TZV+<?C(&N=M
M[\=CWY)$1L-_O#X'%3#3+D8 F6;%A*2>W\HTW[4#-T!S9E4;D2YGJMF]-R1M
M_Y?SV#09^T:_3 ,VCN\#[6(1^,)_XL4H;7>O^FX0FDY@Z4K/"6=RI2'IFL.G
M>>$+Y6KWO'W)*^AN*O2CR(YE(;#U&:YI!\@US7!&PG[(V;Q!2EZ6'!>B*CF.
M8[KE?*0I7VM2)HN*E,8C?A8!831G3'Y@A!Y+T5W+;YJ&KYIV;]*K?:M?ZD9O
M\K>B28F@1KQE?3*. 4\[B0*NR8-<UTJE6\][6E1\37%(UC)[F.+.>L*R+BU8
MPOM2%C")Z4.U+G 4.N+0#8EIF9X5RF+>IF&50L3?&YS_?K2?5DLKC&QBA[$I
MRV7/5^2DX&_\@A\9/%%.*YE?8_;-,@/-VZTKU@TQSC/JC5PH8.GIHST]^.@
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M(\%I9KSBS:[/F]D9$PH;)2L%OF\<WA\"W6TB7;JCJ3T<9J;BS[AOTD ?1TZ
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MS$ONE&6[MSU3P=UH*.:[8*2Z-)K551OR/+K+1P-WW"(6"1!5=M^I#>M7V06
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M%UNNJ@E1N7.;9N@X9N#-R-"[C/$YUYQD?V[Y^>\I?>%TY2=![FZ(K O=F'K
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MPU?+:=,@N4ZU/OKHSCCX;#J.0D.R'DWBP%0= I;2E"%I2O^S2XNW2D7XX4
MW?>UVU<GIO*W+C?S.))'1+R$JLX'-]N"0TBC#96%&L4K"9'X\6>ZV2QT7W%
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MZJ,[[= 8C!1 W4D(,3U75:%B"M8-B6]6%(/8T.,]+4S<,.J(Z!X_0UY2D^K
M[< 7R C;@><HTVX?:/RT91OV^":S;=><Y!Y*G]2Y"-DX-E5Y29\R;G5^Q\_+
MUN*5HQI;,2R8>,1!01BJ#F.-A(MEG[KWSJ]P34)"HHYB-AH+BZ9 A']WFJ1X
M3[+9[8(LOM<8MC81'V3O3;[Y?!1/0LL#*"53]95LG>\0&>FSL<"ALF'K#RY
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M47"?NXBX?D?U#V1[3F"9?C ?51Y$K9-=]E:R(M\GT8HC841E<M?HNXMJ""G
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M.$NV$/Z7=+N4+MB./G6IT;,V<&PP;0*<S$>UG6RE$KOL!!)HFKR68!#FL@"
M/9N.NQ68M?.#5&E1$U$KIYZA6A#N#_X#Z2AMB^C4[UGP!^^]+9[.4X2/7X[L
M_C02[DUO6)"0%,6R^C3;M[=O9=L%XH;]+Z-'A!$RY'XKF=5_0Y>\L,1W7&43
M/HBO.@J=:D.B4W,:V6_XU80-+TJ4<#*MOGL/VJKQ-W\^ C/60MZ\6H\!2F,7
M&O !]F3IUEMZMJ[Q73MZD3(CNVA>)I2-W0>DW0LK[Y'5$F=5(OKLRV@;/$?\
M#Z+_#>R/@)GID9!F:1QF,H?QR=!^9+S%8<@;AY&E 0C\3%:9\/3GXY&[TN>0
M-.[$X+MQ3*3=PZ>RY@>U<3C:I#?V=^(0^E%PZ*%U)@Z3H_?2@M?$>*<3Z (L
MC905/R+/#Y 7HM.%01F]XXJC>(:7PH.OET*]'?N"NS?(]*?W$;13'=1,#<\X
MSL*0J/O<>#!P \\++98/'8)A-C)QBH8\SJ7":"\^?F;4?^+$'POF-P.],T"_
MI9]JP6>*ZB3/ YPK%3/P4.!Z(0@M1MB<LV7>TZIH3_6WP33S*8Z[I73OH9N'
MB\A+Y)K]P?10-*23:I%A"CF @L#U97>:=F WYG78H&NQN)ZD8.X;W,VY5.X^
MCTR+Y.K^:GH,]B&6:O%B^OCAD2!TI;T"VH%A[*+0!S8+@OY!7IQ'=B?HHNR?
MF(U/RY+1R*\\8D-XLV"&23*L0*Y%2#+2OVPHOUX3SBZ6@NRKZEH0K<3FD#^?
M'J2#J*9:4)FB%02(Z5QE]7I>OS(,W2BP:'_*HQ5&*]S,AM^,OAY<B9_#'T^/
M%@,:J9:%IEU/4!#Z?J@,DV8T>Z)OA\7[]:*N:5HPE3TOD^VVN"^+O$AQV7PJ
M-ZU1/I5;<A6F6[\_G!YK/>FE6GB8XBYWF?T'E2>H!WC)>@2 Q1-48LKA'2C.
MZLA\9>)L66-JP:G^8GKXF1)*M? P?1;)@@![N2P6^8:F#^0O=,E]E8N/)VIH
M("9UNEF=Q<?13D39:@P7/1]H:*FCQFPSK<+D>BD @2PJM 4= M"#/NK5CKH?
M'*XKFJW2KL-A3:IG\6(QIU-Q3>&BS&X[^A3'X($OIT?7(0*ICO>FYQP&&7 3
M91JWY_H1\@)@\_U" :I9G6\27BAUUL%O9PDMW6GV!@3&/M@P0LK^\W[L@]BW
M6'OY\RKEGH9!6)(>6NL!E:R7?S ]OQ5T434W3#F<8>"YJ?)^QNP@SW<#:#./
M]?^C2U[I9RPFM\,I62S[]?0,EE)%M8PPY;#K1BY&:@Z[R/>8F$=V3XB=+J+/
ME#=5="K^T%^+"NJ\I,GF:C2; ^-IW8?U;X+@:_J=5+P^^<[-57YZ]/C#Z9'7
MDUZJA8YQJ"3)?2+U&'XES>4/'HI%;N@+7G(/^SFM&QZLP@WP,F/TYL7ZWZW?
MGWBK5]+2<^94:XJ<E)$DXDTXD$6W>T'5^C\=[6[LM0E'[^)\P#B0;CH"=DR=
MW5$8 A#+)%_N@=^-?.1)L=N<V'5NKG40*Y]R]J,>GQ0IN_-0R$-W=T1&S4=.
MCEX!'16RQJVA /1=*+M0'";D35&9N8B-I/32>Y&8-WLZ#F?>DYRHB3<6D4/(
M-#;48^ G4%;CX# -\Q"&]X+[05O\GE#='\0#-;J? D*PK+'2":VA$<N3&(>-
MLRL,@<DP,W",H^S80FBF8KMG^\:Q'\#H9!I*O)OV6Z-XY3-=#V8JA&BBK,(X
MBH!GT_7UD<&N;$CZ<.9\*M-?SYQOMXO1'&&;P?G0;&"E2TS_X?3Z[@!]5,<S
M\\8*)(U3Y=L<< .(((,_L@<&?CO]U;FH?G5^KVCV,AH.^+@7E1A3]^8A_V9Z
M[JM)HUH&F;:,<G&2Q]+J81VB/!!%T LL!OUN.?]_V?>DXHIT.3+_=T8^@ +E
MEW/!@II JF6<Z9NJB_($:_)IH@CY( ; XD,]Q\)B27XX?U1X1<9['+FH^*CM
MH$H8J#^:'@$:VJB61Z;^O1RD;IK);)QVX" .0@0C#]AE_@4N"T;5WYBQMESB
M$?G?#MR-JX& YKLYH$!''M7RRSBK#L1Q1F0YR^W GL>#I=GP=H'P5_Q(:F81
MX*P<50^(<;MA-3!0?S8'%&BHHUI>F89L>0#&S"Y4@0"ZT$,!""V^G1IZ(3-<
M+%^<JM_[J10:AZ]R%WRN&_GSYX"_GAY(0XBF.A@8NT]"/TIR981-A&+7Y8'W
MD\,+ER5/N[]?X0JSJQC)G,>B+!Y7C_;1MA!3?]S,_*6=>!#V#HSU'I!X: E4
MAQ_3LP\%:092=48/B)$7!C"P: 3U>7W9]DJW#\?]UM_#_7]OAG@/X%-03K78
M,+UV97X(@"L[5,2/'G !\F$439'TN \Z^IW9&_5#\>043 9YH9P3 O!J/?FG
M;NZCL'APM/< R\.+H%H@&>>'NR'(/5U^..\]Y$&+"#VJ47C?HC'C]0A75'TY
M>JSIT7G\$J@60L:)1Y&7 2#K"R#K^'E5?L'5GT0@XI:DJZK8YK)/U1V7EDSW
MKHERZ@U5HUUZ^V[$"'LY'YP.IES3R[8'BHS+"G+-/!6,QVM2J\*RZ=,D@" @
M22([:N3[<$%R4K$3[QS7#Q^6]/M?2'8_ X'..K*<E-'EY(PPYT%09EFH==LQ
MRI[.7;"-:->*=@]$F0IW3A(4!N;"/3*H1Q5O);*-BV+R\C#R3CX+7N2P*O#R
M,ZUK4G]@O'[;V?94PKTAQKG'15G_MA0T.1R TI:UXXEVGVTX<A?G(\Z#J*9'
MX\;TM3Q,F0BGLK=1RZ =(+R]D6L<_96EKH=]6=C;^>IQM<2\K,KYBJF',GT1
M!?26XIYZF><D;4XEN%M2G+2CI:W,V!+CD)::T<35?.E'[=M\1'4 S?1(E)B^
M6X4H\>)<=K98!>@ (35$J;%HPCR.$RQ;N?@Q=&$0NA&*+<K=$2Z:Y:":J*/Y
M:3YKBIJ.,MX,A':495 =I(RK_ 5YDF/EZU\<N;'O@EYO+$^D*FAV66;]A/!O
M,@M7BE#<.*3,.(#;J8QCAW,/9UXHD\NKYH%4DEW_2IJK_ [_^,@/[]:HN"IO
M&)LPKTS;<4MB8@S06\^D2FA?S<5S0W%?$^/,*=F?\1K)^(?Y78'CRR?*6KA^
M['&O2=0K1'%H=/7;ZY#QC2<'[%\]:5O$ QCX4)2X3-D^?RKKIEJ)::>^ >9K
MFIAL;(@R;XE <.R&2N$/F#(/40Q[198,L9&?<;'D3JI?<EK]4N,EV5O7IER;
ML>,*>1F"H:P5QB$>;TAAE'!"-CQ?,)D:Q.Y!8BW9D>-<>5F$$(AD.\(U&U=L
M5^4MYBU"ML[,G4)YUN\)G KG)ZZY?N:P%BMF"FIGT88X,$I*,%GRT*V:CY71
MCUPZ' ZF]W:4X,C+9%'NMD X0!E]D3[_,"O-V,Q@1D:2Q+Y,K;Y>IU!'Q^N8
M462-<EIV%"\6U(PM:[(5#]RH^4J:EEJ%H!E P=3%[:>Q!XG,,V0)?P/$[$J*
MMEYR!J$?Q4@:N7@B4V[0V:XPYK*5*.3""'=>"*Z,-R&$7I0099@<?\J//,^F
MKV'_.J1URH_H6MB?5>'IU?D2A@TPO;(92#?5@<+46Q!'"<A<=9Y:P+@4Q5;[
MH;SJ@$;X;A7+ J\K>Z5;SU=1-NSG@A_EG7KA99+N*<V^%\OE?!M8W>PMZBK?
MN(L^;1;4JNI%F7WL5F/2T^KH<:<'_[C+H5KLFD;D>3A/W$!9_A0 $$7 !;'%
MY,WS)18^'X;_0Z"?49W=CNJK7,,P5>N@GG\Z/7)[4TRU&#(%9Q3X)("R#++U
MI"=Z"?RX0>"LBO+N[\+!;9H/GA1T40/FFI[V.'+C!,M,R]<8%O;V'=._1X-J
MP%5B2XS34M-=91M&C[,FR-2>#O,TB5,L"RZ88FU]R4=1''L^@3*5*5XVF^5+
MZ^$@V;J \VE?6CLB.M<>$64K!1G&'$)A1' N@V6[,G:-ZMICO8;I*5>ZH<7Y
MLZ3??WF@WXV=M1&*LBA5)J'XP T0=%V+$?[[1G9&&EPL"2^1F]/JL36U<4)7
MC<3:F'=+S=>(T%T0>_W=] ="/W*I#E#&UT$/)8&T2(7&R+%N:7S26L#SP*1F
M?_KMYGSP9T(D[8L.T[R]U"49D+U-CPO$-M[@ML%5,]A&D=W*,*_^=E^4HL=X
M[[@&Y*,DC3+9#=3&\GM'=AQ>_*!P#I\0XN-('KS\SU51%Z)A\-U#15?W#[^O
M:J8$Z_J</B9%*<ZP>DHMM4LB,U4%C4[2$<GC7C94GAVXT\]#HQV_Y5;X.!_]
M..):J"64&WN\XB#TI4Z%201OR)WQ\0FG(@9**G*F*BC/H@1+7]H^E6E%<$TN
M2/O/;C-$G&O.Z)W60&II<G[*.NI^WFB@9DW@^] Z1VSSN$R;CYX98Q%T;!";
M/EW'*,A0+(O..ZU #5 I-R3E+E[19;27$H$H21!*9<%9BRQK=>G&P=9#J;YQ
MRMFW:=;D[GK@>MLV.W\[+V4S+C>LLWL^*LG2NN@)A,2TBA;(@B"2AA5/+L-#
M(G+7-!O?Q1+/]W-ILL]%43_1&B^Y1KXA3=$%+DQI &U($A9-M27J?1@]_7=T
M%+;,1Y\<03L="92&>B'U<H*D99'LBD7<BD5)[OD[2#_AWY<.QD22TONRGSX
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M<-EU5:1DL13[RNNI;J@[,<8WM?:>.$$.WE"T;Q2/#>Z>VW#\1LX'SD,)IV,
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M:]2F_M/U ZX>L7/[M!@-*&P.D<7>SM!.P,97 L7H^^F!8D8FU3+4N$!8#KR
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M)T'DHFE)5+Z+GVC&Z8%^JH52'=!-DS_8GP1$W1"/5^9QH54!\G[U]0+DC25
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ME5\4%4G9-K_J4&,]S&:7P/:I*!<D.JTXU%RVF@?B"#+YOVP(M=!8Z=C=LL"
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M#?/,5_>S<UTOBD,$;)99W@M#)_]<\<=+LXPDHQ*Z.V'AEV)PPXPR^<?3(\*
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MLF"[^]O?:+-*BO$D?#UP-ZZ2^=KOI@> GCRJ8Y;IV4Z(G_B^K*IG]Z[@13%
M06C117CYXQ\X([_]E?U/N1KO3B]&;0=5W^65'TW/? UM5,LAT_"-B  _BI4&
M>Q@%4>!%P"+G[S #./=(_6_G"_F38;UN1CSDV['7 VM.>]V'T^/@ 'U4QS+C
MN-<L2K&G/O^1[WFABVR^+O+'+9PV^+<;\DR7#/5CWN+%R.N!=;=XS8?3(^$
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M PSMR 98T'\X/10.T$=U##,%@AO#- -*)T\$_#CV0ILW^*LRJ<B_; "A'=D
M"/H/IP?" ?JHCF'&!E\29W&L?N0)81R$<62S*^9ER>\LS7B)*>L!U8%MT@^F
M9[B"+JIEB&D\*PZ27%>]+O"9Z8]\>WS^B)?/J[J'*W?/ 8%!E$6!FGY>]=SW
M/&@3J#^8/7[?QQF]9XL%&*4$J5TH,8(Q9/RUZ$*YX'FNY< %>,1U4:!..T8(
MH,@#-M.._T:7#:Y(^=LY;G"^Q(\C!O*T(Z\'U@3TZ#Z<7H<<H(_J&&::V I=
M'^-M=?@W2(:QQPZD$%A$PN4/LJ3E;^T_G&O<I \C!D?S0=O_%2-K(J2U7TZ/
MAD,$4BW;3.L1N!@$,%+&#'@H=MT(0(MGRTW18/;E;Q_87B]'S)'IQNV&5>)
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MT >AM'""6%_6\?-+-X-U]=?.NN;>V69I1Y>_D:W&=-7ST7QZ\J@YYTRU7A0
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M;+$Y43_\5T0DL]BR&+O1S<W%5W\P5_R_H9/JF#Q'^&M7X $?QFP!J*\W';K
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MP@04Z\!B&*HB%3H 0DQ\>5N'#C417>SH;(W<75&6%G;N'LVFAV$O;H4),+9
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MQ=J7 1' N,F7 6%$(Y>:WT (GB*]R?,5&);OY% _+PZ(9D^%)Y"Q/<0Q(A%
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M8Z'>UC7'Z+S@MF&WZPS1PJY'J^GAUX=9842+=2F1#(,XU?JG!2%"5"J*+@L
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M8P'F*='>51&D!"&"'%9UVQZ89<$D9W6&_6_RI_.'_*'WI91& &!&M XQP(<
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M9R4?9;S(QQEGAJ=2/_1]0$/B4%FJ->SM&)XA^/71.Q>S5.(S-:2% 5+5]/W
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M1KVX?6I9W%]M XSZ[-HWN4ARODQR5M9%7L056R_$P6UKU6[Z">_'[M[-EH(
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M"^^!+=;<N^-,382:(>]?*Q8ON'5B4$AA@ />Y675-?\7K"@>\^7-;XKN)_[
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M/?VO2HTI?]1LCQ/O@:$S.^(BS6<7'#T",2I<;?<-2D$<T"Y?W@VI\RW"OFX
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MPEA7%I5&J0J05."A?PJ,0.<8@?TP8OA\1A@Q<2E,:VGKA1@G&)!8F\$X #0
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MC;CVNJ-,U7WXWUU6OD2X(,DUJ(LX>Q))/H=GQ[T==O#""P_DA.*?8.+0695
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M(!>9*+\CSN#O=D6V)06S(!ZC;"MDAQ^U]H>OLYX#]L?LJ**,*9(]:<K:(V*
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M*$0Z4Y#732A'O-DET+8: MZAR&6,-_%.%  ]O9U&%=4BQH"-\NZ!7.X'D#!
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M\U42&O/+3\EYK<\X>\B@[-)3SDM]\IN(?20SK\;8]"[BA0N990//T.];*$H
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MG.K-%?$"-\2=\0\N,I'KHD"C]^,#V\#NP9SYE-/OY</TH*B^+SY_%!?'GUX
M-!2(I'VKJ&H!A&[B(=Q953/T+,=B.D7GK7CE'($ZF=]IOAF59]_C'+E[('_
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MH'=ZM!>WJD:OCY/8D9I#=SG>%ICWR;JD15G<D!AXE5QM/_"@ZO/U^6Y18L1
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M4EX2H$AJ:\KG+FS=!0EH96&?343E##B1?TL7TR-4]PJJ$F)4[\O\*";(DT4
M:8;KI,+Z!K/*NVD:>7Y".HL1N;9ENK:S]Z]-+XG[A@FB8;;H$4(*-C?Q[YQP
M!T-B[+8,I<;5QYM;(YQ,*%\/#ST;]H/?5&-_@Z%AY+!3/$_[T/R">B+]M \U
MJJF/R,%6TEG%&J' 9V<U2V/!J!MFC?+3$Y=\HUT 9CK B2%>ZY8>8*F\L 0
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MV@< 59<QMBUL=D?S.W;H6JZC,YC_+M^1*M/O]J4HR:-V5#4#5N,I8VK0BPM
MU#!Z:=^ZG[CEW>5X6\1DFWPA"62W 26?\9^$4<-VY:O//3P?\N(2>#Z(WL,P
M,SOP7"L<O-]9?ABA).U.'O<<Q_>1SAH"34[%.[PIL[@P;J]6D$=Q/UTJ3CU$
M-0(; #Y_U%3J>WQ^N"A12?O64O72FC!;RO%E%T.5PRIP_2 P+8V-_?8@R6@1
M9X1QIC"N2;ZKTK<^9X]J<&E/S+,2+TC<[BA=SPTL*S ]C5M8,['U,QP(,:06
M[:_'(:/H'2X8R5.+0CU<VWOYB0]U5"Q47UV.B"A33'M77U6GNDP;6[CS#.%9
M+@H@&4@?JOZ.GW"I 3W\N\=PTOW0_(CHH8WV+9%J+%2<V.S?W7E\5A"$CNDB
MC7E\(L/U"]YBT5#6@-HKG\B6/$^<V[H?XG8EOM^?UGKL^?G1H48F[5W0$ZW=
M^O OC+_JX'_UM9.S2L_/SUDU,E]5_WMUTZ*>+>FFIM>]J_NNY[N.:6L,,5OG
M&2-(9 ;SHAS-P?3]+G_ CQ?&U\O)A)$/UAX+1A+C?+WL!,Z M^:'SQ!B:>]:
MJX+()!@CN\<TM-R02;ZMT>;] S^3SQ";66/GMB0Y>_7^POA]NO)%S2@P1CW"
M[]VY@$K/SX\8-3)I[Y).=%??.K+ B85?9+/CRO'CI\I[\W-Z&+F'D8ZO#XZJ
M)](H23U?VH6N^K"#;,_WD,:0\SOH";C+7T3'B\+XGI4/!ES4Y%D,'KK=H/B$
MCILO,03W<!9_L %NFN]_*V2S5WQC?M"H$DI[5U6Y4F9D!D$D<\;S'RWD6);O
M^IY&97Z'?Q@Y+FN_-P3(Y>29;'<,.N0'>7PJ17!<B7_P"_QEQ+8PJF\8T1\X
MS>OTIJ+X R<8PA#O*G)E6!SZ[@)0.9ADV@LC56,#F0%FN) PL8I%J?O"7^,7
M')VA:>8^YDJ,:SR)@9>!2CE3E+FW'+P=H8\.P("JTRZ-79*$6J$V)K(ECO,=
M3YD1@_- _Y0[_C.\X3V7E"]U(S]VB"<-*&MR)3_2_(8\,6(><$'6W[=B&](O
M5@T!O+ULWI!@T._;RI X.9O^R"1'\&5! J-**1VUXLH.$0L\(MU5;FW3MP(O
MT-@B]2O=_A)72GHO)[@H2DA]G+A'&1NL&NMC/=1*C'2T2]G05^>'V&"*:=_*
M*ZOE(+#3I#.'-K \$_F.SJ:[JR3)1+'N;!MO=@G7QJ\[8S_E&=-;)37J@$A1
M61I^4V7=*O?.5BOK7=%T59%TM3WH(WX-Y-S1RP-B[JA(8VTU&9?=2$_\Z?F!
M._F,:!\ E7UA7F3:OLPA\IX\Y03"6:&@--/&]T25PC,D\>Q),V).V[FA/YX[
MD[)Z.?">8 YT8N"I.@4CC\"]A?+VR 9=/>-L _8WPU,Q#O*C O;O:,F4_=ZB
M:.7J*8?J1]"5I#/>%%EFR [)/M(85 $A^C1_Q#P5<9)&X/47OY*RJP-XUR/S
MBTXG9;1W7515?! $22)M\BU\Z8%INH%MZBQ=RPZ-&_R#V2N3U:JMO]A=H%;^
MQ/RKW448[5L3555&G#1T35D?ZLK^15!WW79T]O=XN69J>KKV'?QSW4TZ)'^>
M?XVE5-'>A5 ]VUI6@'PDB^I^5;QBM2_+ '41V0[Z/P3GVFVSJU=550[+0Z25
MG?;"2#D5&4KS'<NGY6!I&+ET/!:4XS="$WF.S(#0A< Q-Y;-<5D-< >G?2LU
M(^+*=LR^&587M(N0LOKN2;><M>8\GEL_AZS)"%:0MFY4J-X]F::)(DO61U ?
M&D^2.%7P'>QK[%#BIU:GE8H<TV>X='76T[UF_Q(EQ9YR>I_C1R,G$>0E&_]D
M]EIQLBG#O[_:)M?BZS?BXROV:=EQY>C#\XN+ HVT=PU5MQPGMHA+9!?ZJ_A_
M=UDA@%?5]*J+]E[2QX@=E/F?>/8Y(_.9YTP!S4QV(,:!O"?BO]7+[ SVX4?\
MP&!!WF=IRFQU")AY];IV]=Z>55/ KJ[G#$GDS<0N#,IS^)\:XCB LVIVQE^2
M:GY_;;X#AVY2S=%(]I-\^ZF3[X?G6)RE@&0Y8CKO].ER!%4UR=P-$Q=+G?!+
MF(6F_5M$U;2LQ_C%*"'E<2,NTD&M2%60ZA;OVVGLA4'4N<6'CAM:T&Y9H]W\
M^(2S7+3)X5?+A0&W,1 06-+7WK1)'0;[D<6==G$CQKVC!UZ@?D?!^(_,KX5.
MH)WVHD35B"#$CDV[,\H0!9[IH-!S%@D_^#OO[@ QBCPX\=#/=7YXWE%HE,">
M@4"\0V(F0:["]W]&4*M,B_;"4ODN.+&(G7;CW;8LQ[&U1M4J!2UH1O8QO_LP
M'$_PM?E1.\4D:"^45"._(X*0TUW\!C%=;_JNX^L,U6+'H1@7#T:ZH=\+R O@
M(.71WDFVS_5FT*S-'Z:V]Q7'#%Q4;ECHCH'C,GN>)JJ+E)>,K(] U;<"U@@B
MG/>][(IU^JZAY[(A9U5E43-B5@TM,M>VAL_/CVPMLZ*]B%0U/VQLHRCNM'XA
MI=FT YWE>-I!B55,3-TL:KH01!$?43=0D@'OR*,+ -$Q"E^GHA^LFW+2BQW'
MB=?IJO5<QPF1IS,,XU(/%BX5@=#[W/PHZ">/]BV5<F1&FIB)&7=!P#(]B^VJ
M0:"Q"V&-@78;GXF!T.IS<QP-/0\O!A)]--+>]5,%!O(9)W%W%Q8G<$P?^D:=
M9[-H1;!OD^J66"B-4R&R#ZO;)OS62XB;9.)'GIP?',<(I+T+J'HU&7EQ% :R
M0UVKL'D+H%6CH )LG'7:NKX$\_Z\U?;;*B9OR +SF9G6>$\9/PDN(Y-M!$^G
M69GEP/H4XM_6]A^)3-4K#X2P0SQ992?-TA$*Z=B2>W[[<V)C@):D*/?:"%"2
MN*C;?VZ988B<5B5W#;8$G**S+9RC#;HK^7_Y,1H\CEG"=A)VV(*@Z=<6IY#^
M? *+@U%PQ0E8B_'A]/?_<_>FW9';2-KH7^&7N=<^1W9S ;=S/VFILC535=(K
MJ=SO3'_H Y*@Q'$FD4UFJDK^]1<+MTR!3' !R>KNGG%:R20B@"<"@4 LY$QX
MVQC\V*"[+$86622C7[:\]$[ PVD0\C&*9"V:"$8ZTD5Y)D\9C%"1S9J7>V=#
M1I5O4HR ,H,Z;Y@XDF(H622UD\D!\[(>D$E3B@>MN&R<E&T;R+)$!^HI(39:
MTX^%VY%8^= &87OI3\?WR/\\E>[3WDI?>+F,BLOG34*T3T3[3;'.CG63.6(B
M5HVHBAST^3:+ZX+DIYKBXK;\4TDO;398]A:\B\N&7P6EHS:7J09?7D\LP#/N
M$@993YT9N:%IMID(S-=,.?F$:8N2:YSNR63<Q8^'(">4PHS(\UW&5(ZTZUE]
MI8/ZPH,)ZX;13ONC4N*IM.4-\@DH"AU5WX!<3'L%HK(<B:)%FA$/ZY)AI1SB
M625+]F#I^,@GYL6Z5<"0?G3E":P4;.E@+C\"<6RVNBA-'0!=-W5/X?W%QR/S
M@"NHHV(;U-S(\:;S6-ED*O8#X)BMU8%-Q_ L8+H*,R4_P^Q/M&?F4K.!KJ"=
M-6YOW=6WSKH5NX%CVK#5=Z [MF[KKLIR?9]P^OP+ ?!6G-RL8@ID;$1*%J6J
M<NXV2I2?]I)NZW#6FKLX_<N7WQ\4\(0[H3BR"&@M<'7IF-$+.]U+EU_0"7G!
M7;I4]@+$<JTX@JU=C3S',BW?]A0&M76D"4VD=<1Y-:UPDWE\>2!)48F[EE(Z
M13KV/=!1Y-_RB5U"8RK58>3KXR_Y#H4T;$Y[07"S?PEAAK2=<NA\?2S'_;T:
MMB><AKYB>8@-IAQWPD-6-4$C0%:[&>6[P-<=4V4G/WIIOQCTR. 3H&_$6Y8'
MX!CB<1=4I%6?9[@A:B^\;7G -%Q/918MQ6 7[GXI,QX*_%V0#_M#EC9=X1&*
M#B$/')\0G2]M"U)05*S+ R>GO">XJ6CIPNRT[UX%DB=F"7?B4!;@AA=8>B"Z
MY)FG7MT$%_U*:]<U)\LQC,!TA750&^$0?#J6"W8X'TAVM,G:1#<"3V3_/] L
MROPN_O =96&2T^4/R5D%9W>'?;XGRB5)GWDS\ET#GS,E5Q8TT:6FK?'H4N*:
M+%Y;6,,[>9UW-"D1='3+;0TD-71RU/)U'?1RX Q@$SB_NM(5'V@N:-P>$&\
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M@^LCO.!@DSSW3,JQK! "M[4/H>$XP#>\1KS=]*#G13<U7I@UQ%OJ\^'G659
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MK"1=9<4+CH@/6Y2QGGR_D5/@_F4N;)3#\E'/@:3SZ;6@I9M(W+F\TI6;O,B
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M^^&0*F0"=P%*%JAN%.D M19;8HEICC%+K:6^0"UV?WLQH-*MSIX,J**W_7!
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MYW J,VL*^VU2])291NS5W7#I>'0E^.BB$'>MG*R"L4$<1;;HDJI*N[Z,_O?
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M9#^T!V)/@ATBY,/\@C:.>C>:8<,&J+^?OKW1NI%X>GZLRQ")6]=1%NRZC;S
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M72>;9+>C[J]:G=:OX ?Y]S(IFC.*^GQ]?I[WHKJ^#(YM&J[N.C+*O].>G6<
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MWSNT >RN\D2.J0S?3N GJ5:ZHJ*^XH2&VQXNDJZO7+Y<2\\$M^%+4EQC$+M
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M*)AP=%Q%&.ZI4Y!M<M+X>N!%S7EX3I)JX%6&*54(29D8^G]R6J[J/WG::/4
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M\8J:9)VBJB]I%>UZH8%<2\BA+]> MJXWC<PA(LHYP5H2G_:'S+6?>+^)#K<
M?U8U)\]ZUH_BZ#EQ+.S?\8T @N7T%1_)5I#"!&QXB;H'7(#-X7?')NF]<B[I
MN[KM582NMR5A6EQ1<? ]LQ?6?I^D4HE.)P:H#P(4V"*>L(]$N&U;-TQ389CT
M%<IAENRJ['.ZJ%7?)99?&9,]GH91TS]^04^$>(MEJ8,D*_?L=8(R(G3KYXM%
ME02M3>PFON/3^HBSAVI2-WM:'I?.R+J)/Y+I,-/H<S69QC*?H[YW?G4[[G1P
M*WI?*>@Z4KZ03^2WU:_(?T*B7\AO_AM02P,$%     @ R3U!5N2AQP-&2P$
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M,\V=\/,T0^.B2O&1K$?WP6 <_!@[!U7$^O+S;J:!DT%Q(\YVG(B_&QR+VJ[
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M-N>",O$[OE\3FAA>]H(-%DN&M =*6DVB?BK7M\O%[OOMN]*G;!C+?3:-\F]
M0YSIZ#^2^60HAUCZ[*BV;2QK7R-O4JEL),<7M*:P]@72?;":484BVNJ!^4 2
MKB\('\J"*UW)D)W@<<K)3^H,H\T-[<VJRP=E,:.,Y%7N^GF>E_BH+*ZHJ.U
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M7CWG9E&99[#LP34BWVUOMAJ- !2L"*J00NB$1\WL^> 1[Q8\;O9XN^+ZHU\
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M-I_>QP^*N';+GX(E?X=S G0"1W"#9 W%[D-]2HNRJ6%7=[$?,+NCL1LJ>J#
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M,;;DN^(-7E!6X*3^1L,$I+P$CM!_)=&:K4Y(=>K9J1Q-]1Y_3.=\L!G.<O*
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M#!L-5H(>F@E1'TY\$*C0;]OZU*%[B"@6OV;[$%%?>V'3;MZ'>^710&RWK5K
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M1O-<Y.^+V\R8/(AY-AZ-]KU_F%0_)P<E&+C0QTJM*M[@22G>"UA#T"0:ZI;
M \4\0Z2C$DEN4F""D0>;KH/,"[<J_!]B*\(/I+T3ODI&;SXJS%>FNC]PO;[]
M.ZQ7$^0L%)&/?XO%8 E:I)ER'A/E>N-)-0S#CUF)A%#4*?/BP[=<Z:G3;JK?
MK>;1&#NW[=S_EPM\>8VAV 56+$<SR@J.[EQ4$V!\ARF9N#NL4# ->_3_Q0-?
MDF$%6&!Q6$EQ?IRB/"<3@I.!?K]0M>[LI;[HQ< 8+(<4+/X%G-S0)4K%3*[1
M4EBR%KRTZMSZTWW]8BT NSB<"NL;+ZM9RRT72</6/4N]D0,3G&(Y[]=WS(]P
MAB>DR-?;D^K$U_4!WE#] 27!$C+PEG^:/1!&,Y$_C]+-A.6[O%'[KDKOM%D/
MTA<C+0!S<1@*VWX]F^5GRI&I/GF>B<(0JTH_M4UQ@:<HO41"N+9&O>)<]S]X
M=V^\1K_,VP(W\"&Q0[EP-BDKHKY^=7C8(';0(3I[3#9^X7*#$.[FKKR#4_X!
M44*9)"L7X6K>U_Q<DP2>;/HY%(/YT=@,P,V!M_,YJ6[;G5&V<V'Z,9.6)#'M
M N/HVWC30.T(#[QC[]*V,COD)6N;F\$8^$/:\WJ8(F+W%<TFZTHJ.[1IN*_I
M!1,&B%$OG@SMC3 8H1:'5R=0JLB'F(H/>/;KN.<5M%I=5<MOSXR.]N3^V^=_
M?(BI6D3+BQ":!-+]CKRN&5E'A#<!XM5?JTI2:%RHCW#7H:#%OZ)=ZWX B3_A
MY<U+QDN[:U3$ZG#^A K)M21URV@HVJN2(+W"H&P7R_T3'>C4F);@:EI3#HCR
M11-=\_[G8*G91FVA &MXS9_(+^E#5:LJ5^=M WK'NEGHMPGW#2*N_&0(\YHW
MG:BVF[UZ.D^*E@XGFP*G2SW_'4=J?9/JZOJ1@Z!X@3!T@F"25.6==H+A)D6Y
MS'OU/V_404*L<0HL#;'4ZK-)&.W!1N&W7%^+_/^:E2(>O9Z<N)7"C"3!KF/K
MF:8]D D(8H&EPW-EQV %&@&W)*,\72(HLMB9A>664!3=54 0Y;[L$Q G977:
MK?K%4CK#7V3*FGB+"ZPM^-WL)KSVR9MX2.'9LI'4:6VA()J1'ZR#:I)_ZZIT
M()'_>U:E WL\XU1,JX1:?N1OH:BKQ8!54\L!@1>I(HKU^U=.01"&CO?'4?*P
M._4(IB6T56_KI;3C2VG'E]*.<9=V[#++9K^PFU,)F99+3SXS,B]1P<AWF3%M
MVB6:.+-BPK991LV]8EE5-E.F$&:&W@S7-O[F%=?S3"@!U7FORYS2]8E%KS'F
MR+[CPXS F%DH/]C,>\6R%LW98L+'"#63_1-.RCQUPU[PJUD%,2$L]')#C"V%
M<C6G958,QN-R7E;OAIQ@#BVGL@)V+NY[YO6_L^1\OD"$5>\D9DE5I79O%,E&
MV_*G8G'56>_/G> 2E9S)]W%%LV@V@K;YU2@7$>X=#71(&:MM&R=WF_=U0V)"
M9UG*]R%5F,2F&SP%)NR6:T]CZ.VS#G^8%.%7M^PJ,[KCFWLRWE$+4-P#DZ(@
M,BWO"LZR[5?D,6"+;K'H-B:[HSU=+2%OC7F/+'VIJ-M0&)?K\_6+[S,N&E]\
MGR^^S_XP\<7W^>+[C(:3+[[/'O@^8S60(_!)]LY [O>5TJAN"D*LCA_A$FDL
MUP;C+UYH:H+&?E'P[Q[\BB$YX27X]1+\ZF/PJT7ET?"6X(MO.A;?]-_V+GOL
M554UBLK+[?5@M]=C?,,;(D(1W%X7Q^NX&$Y.B'C<HW+)&##>N!-0LXSH_A>(
MKY;XA+X"-/ZSY-.J+CFL1/"HS#EQ7->B\SN2[;SXHJZ)Y#004%8^_A!;@0_H
M0ALJ4=\1[*K@K\I<?;D>^'(]\.5Z8'!F!KD>&,K-8+%,6UN0+;@*W7G8FU5H
MZR>3;\-. P$Y_RZ$I\8'I3](7N&;V,H2=YB7J$,GNIIH=@Y>3^#\[4OMPDNM
M1K- 7*KL1I"]Z_,ID $'89F3?#@9/F"6E+@^**35^XS:OV3<1I2L*<NXM>!D
MZ&P1E!<G)>:';%'*G"+2-M'(XI,9RJ.!\E:QR)H<:FI(0VA#O;ZB)+?-F_X>
M)?H2>UL^?[":+MLMGIVQ!F?%\W,Y%C/9:$O4[)\2ZN*0^9=;C3:,\WVE\6]V
M)<6[,\-J?;[<1XGR_'JYC_)R'\7.[W0H@M8!-Q*-:1%8W"Y043]U.LSP)<V*
MV2!+KFBQ^?4MGT']![DD6H_A]KA"&V[N1I67^B$O(@[_CA$S8N.VH1NOWK>P
MHYCR2DI#+ P9D>^UV.P)E#&CC 9P8V +)6#,& BA+1;&[NP(>[/?4*5GKO$@
M;@Q^&XK!4/H",WE/%JN)2IFI;PS4TSYTRC-3,D(;07_S2V*'!^_#FLPO-\1>
M;HBU=D.L5Y>F6O NOQ3TBL&7+_7R]K>:UUM8/L"/&W>/Q6_;KM\]%BI?O-,O
MWNDH^?52+4F1"@??6G(\/IC2AY_'E<4YKDG=_%0I&A4]Z]_\9Y"FM74Z)OS,
MHG-$LJ9L 7DK#Y?S5T/757$46Y:B6?\KS*@@IJ8 A#;?7A(9XBW/O#NC)WHJ
M9[NXE(F3\^P;8H26^5803>J[P@:+Q19QK(?J0KQ5G+55PH%4^,OFZ,Y_[H_L
M#HH#6A_G7T<G#:MUY[?]WUD-#LIG]+8/_.G7FP;@=WX+W^]Z!/PS>ML'_OC+
M69-^L?UMZQ=I8@#^&;WM W]T<]$ _,YO@06QWD=43<D ^6<$6R,_0?E=-;&<
M%37J."UR\=,6=?[#1OV7>:YV_NR: Q3QJ:L@,ZP^U3PQJA>DCM;KS=>C!JG9
M^2T\7ZQ'R_49O1V<4%>_-RW7[6_[7UK*Y(3:I[<#X =-RO#.;X$GU-M^ ;]/
M;_O _W+=)/$[OP5*_/M> ?^,WO:!_WQTW0#\SF^AP/=KDW]&</O(#[XV[34[
MOP7N-1_ZA?PS@@-%XZ\9X;-<H/0SH^5B4WB?SWN0)8,\IR(!!R?'=+Y &=E$
MZZ,.UH_(-",3,D99<9YMRC&>9[O4F?AKK<>))M1M2X5A/@-DJ%B"K,YT-#@S
M@0(2./AD1'VSZ6S;M:_,;S2H8<0'9O9I5I!BF=_2 J5GE.W.51H_-NX3"WNM
M.4-!A(9>MR:\BY]9YJ!3,Y(BRG,Q$<0+P^07T%C1:"!7:(YW'W)J(%;6)!9!
M=6<&-2$TL/AN#(#K%(WY--<EJ#7,L^D6HV_=B:'VQ(?.-Q)9XVPYG)QGO-V"
MUI5/A^P&\]F*IP8TW ;UC^6=%V]L=T A^"*G"W&!AL]V,GS,,,MG9'&>%9@S
MH=BAOGFE6_:-Y0*HQ^4.0B BGG^C!<FFU_01LR\X32PX;M SEAO=K?#;F'YP
MNN%HQJFZ1GS,[!@M"->*F]1Z:2/@+NN]>(4W]'6D@EW4"2:U=YK_8^N8YC_\
MYP)/45K;)1+'AZ1%7X^X1O^&DL9X<A'!]'DRKEJ0OQITZ:6"IC_'8B3)A(;J
MI@[>+Y]&+#:!B4M1&H"@E']N.!GD.2[R(1NAE L#O9T1EER+8$ACCKVG$6,I
M3>/?S/&!"_Q\I&.""WXBL,&X>J]A-+@Z&?Y[D$Z)ZA*,3;=8%E/C:J%0>L"(
M7ZT"AP,VQ>*U##0Z&!P<E3BC^8 PA?/1KF,L;@$5ZA"*W'$O1>@I)>BZ6%X4
MR24:_UF*E<IY?W\U^DT/OTW_6%08(R[8$^;,C&NNCL[1&)<%WT539]ZX#!>+
M86W"*G<ZX0<&RA+ZER5_S#O%8NXJ#PM+:OQL601]GM]]^49PEB&S34K>(Q9E
MRGA;TI'B:2.R0%C= 03PAY";24OXUFO% %=U0Q">'T-L"RWA>'IT^MOIBE,X
M/Y@?W!U\N9I,#W[]K,'5KB,(YT_=X@RAR'E_.$+9-$4)SF<79$X*G'Q&?Y%%
M*2_@:=<19B.U\ 2KR89A0Y*GC?GJVS>2/E!!N.'.+.T!@[IC>]2*%L?-V01;
M34L8IAU;FT8T@+$<I&.:'=/R@>&277V[+DN%^T3?&(9HQY:C*1G.F\#6N\95
M[H,O:$[2@F;:G<"D&PSH0':?.4'.D(_PN&1$>!J!X-L- &-#QX:?"VG.#*FK
M6N 19@]DC',K7ACWA;$AD&5H2168 [?<_.0:#ZZ2$C)4/PMY@TF6ETQ,8*4%
M:;GA- Z,,QV;E!XH=.%2QB=V0QXP.U]_\)@:K1/KOC!N=&R0 JERMY6(B*:(
M"CRY<.B/$+U&94KUII))/QCR'9NH (H<E?@3>L103M+S+*G]96<['F+.<71P
MC/A'-0H^:!18I*ECV]69/M^ACF.4H02=9^.#$\H>4/J_2WR'Q[81#I-18/P)
M:O "Z'-</]L/'=%R/!,J19IB#5-LN\(X$<1,MB7*>7D<\YGB>I/DDT-3>H*K
M7VE7A%E'&/2!(K$V)(&!/\+D#Y)-GRZ\8WH@U(/5WZ386_>%P=^QE0VDRO?)
M\.77M9I,L^FO5,$&V  P7@0RM2&D@1G"%UF&MKZ6G$^O+'!^1AE7Y"YQ(J9P
MP^'A'YBMY&(TXP;/#!%YN6!?8\+8UK%I[IE:^*%>_C6CY7HBMW@\R\2G3_ #
M3NE"^&M67S\67\]GI>+*I]-(,*YU;+9[H1'.JY4 ;+[/4,*W6J/59=T7QH^N
M(\DPJEQ58+%VG^ZW*[;_>T8%VY'<@0(< <:-CHUY)]J<E0.N^M&4SN\(6BN$
M:()/\!&]HX4^2\6B-RQ5,5 (VIHN5_?* >7_M_$6Y/=H[4+X _T;31F^TWE6
M+ > <:/KK&D'TMP#5 >,?_::H6FI-Q+EC6% !TJ4UI'A*.5&D.J:P@#MV-(V
M(\)91K]@E!:S,9_F8'1,%SB;H2G6A^M,NL%@#A2W-B?(48*-8-8UA4$;) FY
M-3C7G#L=ERBA3)RR_[LDA3Z(H^X @S90?-F$%$_.'_&-TX-C1)@>84T/&,1!
M<X\UM#CN":?3Y:+8_= 5?JR^=<RGI]DD+/K"< ^2HVQ-E8_DE91_>K@\S1=4
M+^*JYC"< P6 ]80X0UM='\5G57!?</.FQ"2]1"F?5FZ0&F33'79%*I"):$^8
MQ[U\9,L&TZXP%@0-YIH2Y;X2<(9O9YBA!<'YEO'6O "- V-,(#O2@<(F+LFH
MZSH=.7D0E"2#\1BGG#C.B,%BD9(QJJ]TM[L):+Y^R6D;EREBYW,T)=ETA3HG
MH^#<X&N%EB1-Y?I(&\/#9+9C&[(]PN%QPM.+BPEEQU]O3B]P_C4EBM="-4UA
M+.C8UC0CPMGY)#:@"_R TI1ROHE2\X76"Z7M P.X8XO3DAH/086RR,<SH9J*
M^XI7):N^HL\T,.L(PSR0"6I#DGMJ[*J6Y3IG77SQ-SPSN$9HU!$&?,<V*(0D
M3ZJYG;!K^\#@#F2*&E+C">EK1I/ROCJAC67<L">L1$0@*]2*)L<3],FM"_&=
M+S3]ZYZP\4SK##?O"D,_2&#2EB@+T^9=QX;;X'"P7;\ ,HRDZ,OI_QE<##Z;
M2(VN*4Q*.K87S8AP6)1I6:"=??<(L13?*=>B40\8N!V;;5:TP(UNS.A"?$)\
MX:9,:)H7*)&;#4;M8?AV;)-94.(AC)VF]0VFXX/S@TM<H#EEBQG-23XH^++1
MUZRS' '&@4!A0A!M[CPILREBRVUD?948?4'0'1'5(^N*DLNC,D$+G,N7A)\!
M81P+9/+Y(-515UM- <HT^" P1@4)4\+)<UY=YUE"T.K#E^7\3I&";-H%!GP@
M8]&,&(_Y4=>,/* "VT%NTQU6\BZ0U6A/F.-V9 6_:1<8Y$%,Q=9AOKX]V%E;
M-,,Y0;^@>_X+>1*W<1\8T!V;L);4N&_A# N?[HJE)^4=[ZC?Q+6=8%@'NDAJ
M2HZ'\[+ 4R;>LMU48ZF_>4/X&9[?DR195@_\\/]E]P9G*7PX&(."%71R)=1O
MUL3I5[OU8MX9QI9 MTYMR7)?/SE#.!6WB6YQ.G@@#_HEHNX!@SN0!6U$BWL.
M8IV,M."&^B5)%9?9S#K $ YD\9J0TE;FRWF!TJ6X:I$>7-.__B)I*E<M78>"
M,:5CZ]8/D<[I%D(8AHQ,IT2>D*MM"P,\R U.+16>0I^_'OQZ<$OOEZ:9_)+V
ML!+B0<.<2DK@V5;D#GW&9+K\!2U0MCJ+U0";=H%AW+&%:D>,X[:@%UYE.QB@
M02H<M2.LVQK9:4'&^>A\<$.F^GO:JN8P3 -9G'I"/-B:FZ>V1@?HAA^3%^5W
M_B%:LJGR2@]L !C\P0L$FY/FKEBOZK#RT]62$X8]82P(9#M:T>2,_?'VJ>1+
ME*)E3M HR0Z.9LG!->:*),FFOZ"E?@,"C0/C2R CTX%"/Z;GJFR($(P3?'SP
M[> 2?R=C]2U$V  POH0T32U)\Y!J;LP"TRXPT(,$5EN'^:E9<(D8'8\&QRA'
M=RG?&TT?5]+T@P$>-/O6B")GU*]P,<-,./[S(\[CP3PO,$O07 N[64<0[A\#
M&:8V)'D2=SO,M7U@< >]\=D>TN<G1U]H*MAY].T(B8S"*Y3G2%Z^SZP##...
MS58;4AP/R(J!Z1PS71D@64,8H$&* *E)\+ 9/_X;HRH*6R2#<GPO_FFP$VM[
MP2 .9)<:T^..-Y\]'HR&N<&# ]*V,&P#&9P:*CR=:M?HGN3%QO_X*V*(S]GT
M3H]!9QCF@8Q)6[(\,>&"3OD'R3@7A=FO48;FR,A\M.@-8T/0\D$6=/G,6.33
M)HN%N,(HOGN)[CDJ1MRP'@/&DT#7.H'4N28P;K_UQ-&C90JD.XP?08*>$,+<
M-RLJCO?1XN#?PP-Z\!MB.7K4[U':3B#8/X6*B!J2XRKW-,WOD2'4IEU@0(=)
MW#4D!@SS!;ZOZC(4;'E/Y="JFL'@[-BZU!/@85M@13E%Z>CS]>@B00?B9SI"
MZ8-!IH1A5QC4@6*E=D3Y"4)4-]$+NNMUI]7=-0MFP :"L2:0O>I"HN.._N1)
M,K-58M<1QH@@Y6WM2/)D9*TSL6_XQ#)18/[FX.+@J!SS/YK<H[0?!,:0H):O
M/7G.(3OQA5O$IN5ER;^A#=>IFL, [_I1%F-"?#D7+HXO:3Y6*#E&[6'@!C)6
M#2CQX %^$%\8%2+/ +/\KC2H/:3O!,,Y4/C3E!PPV+^,CNL%HQ%A93L0I(>O
M.K8P#4APEMD1*A,B+F3<D"5*9EIQ5;8'PAHHA&E BCN\XG;7@C)\7>#J5:?U
MSWJ@S7H"(0_UK(D-41[!?_*:TR7*R@D:%R7C?Z\G F$+<$P@PP)9KI[(=6;E
M("?H&HW)A(SW'HJT92!P)"#; EFU3D2ZK[N4_^->& OBU9TCX8G.4_2@SP8S
MZPAD1:"@K0U-+K[+/3Z?'"0'%W^4=W^@3(Z[33<@ZAT;K_84.8>C[&&W[ E$
M/H@5VQ7XF]5%RV(VF##^M>MBR7>V2Y(PD[P;LXY Z /9N#8TN7II;'&WZ09$
M/<Q=TRXP7S/X5WYBHTIOQK1,M3*N:@[#^#!0C%5/B9^@R<[MA",^(DZI8ANW
M[ E$/)!Q;$44&'S=!7G^I>K[%P=?#1CB830@D[HN$NR+4(\1+"$DERAA1'<&
MF'0"LB%(6K$Y/8YHKQ_;16D5KQP758CRHG[7Y\^28Y*?X/0;2E.<ZQ>+MS&!
MO.J\2K%7<N$[WAU*"+K!18E9L7K3FB4T.\$G_#=4?!HE-%6L(N (0#9U7>S8
MA3AW:^*!;YQ3/#@:%71\/Z.I_E:/K@L0]D Q7S-JW'-K:9J0;#KX?(1RK-=C
M5<V!^(:J1ZREQ!G;)V\A/#7'MS4#3)&'#P;D2R#+V95.9ZX=$?K /R$"_Z:\
MT74!<B!0W-B,&G<KC[)\/"NS:9X79%+P?YB!;=0/AOCK0#:U!4GN!^OJ"V?\
M$/\5<;I1F=_QF1OC;S< D!&AXM  VIPY<DD*Q.XPX?O>'2XP2<G4?E78#P+D
M3*!P-90^K^OE$F=\G7[-DJ_S1YP6]NM%/P"0*Z%BT@#:X*;WZF,GF&V"JY_%
MET_97P2+[7.P6:U\&D<FFYJW,8%\Z]KT]DNN\^(:<B,GQVBWA):ISF7:%<B8
M0"%J.ZK@F7MH@;26A[P1$-..+6G=_#VE\)H*K*(U$,^@%X#;!W:=[VX'L+(7
M$.B@B=(&!/D"?#Q[Q.0OS&;"ZSKX?%D6!<[^,@7>I#>0 4$+2%D0YHL17,'-
M!I^K_YBB+^T"@_Q-T*+&.FK\"OS@\PWAJJN=G#=V F(=M'"4GAXPVL>8+QBV
MY%L7_TA*,%.\PZEM"\2V8WO5D QXT(J-"YI?XD0X1/F1@)D<4FU;(*0=&YN&
M9'APUV?\7P5YV#Y#8KHSF'8% AZLL+$-5:UEGNP&!$8#\4S,@SRWW'TP((^Z
MCLYZHM,Q$4*GFRM: 7'NV(C4$N (X%Z6KF[#,>\$A#>&5.4V-IGUGG:+R"/*
MCNE!]?(1(@NLKZ>F[0/$.I!9:4B..]0S1'9>PCM"V?2>ZM^A,^D&!#R0&6E.
MD7NT DU3<O^9).@;OD6,S+^R,N/G ^$+#2T)_R415<**P<'HX%R4T;LS2%YV
M'Q3&K[>!;%!?](*Y6>4Q"MVKGLD7\M<<%V("5=YU0?2L XX Y%/']JL3<:Z9
MGRD:0]82H#>0&4$>]@$0YLB(SZQ<U/Q?KTXQAQ0UKM+/^.XO_"M'$BO>P?,Z
M+I!Y0=*FO9+LR-:O]XS/$U]<'/]*L/Q%3GUC( ."Y$+KZ?"09)(D*3Y%>7'V
M[].3TN2E=UT7(,*!(JMFU#CC_/77E99W0<6#VUJ0E>V!" ?*6#8@Q9/??F,I
MVJ)MTQT(?M"@K UESKSXS#7C_&YIQP%])R#N@8QI4WK:\HY^_77]WKP:?Y=A
M@!SIV-IVIQ"^(OBRPZOR'H;+P:P'#/EW7=O--L2 0?Z\9*+VUF(5C*AVNMP,
M;=NN0-@[-H-A5#GJYZOQS_BVE^+E,1(?X/_0*.I&O8"H![%W+0AR/F=W:L@+
M]?6+<'U@=O6[]JPUZPB$/5#&L0U-SLBOGA7=^>85?OR=LGL#\(W[ O$/5:39
MCBQWX4<+4J!4PO9?]&O IC^0%8$L6@!I[O&%53*B>%O$;C,R[ ED0:A+NC9$
MN?L61F>TS!+ *C#L"00_D,EK191OSP/X4 :- V1,T+QE$(FMF<FC0?4<$DG3
MNY)EBB7C-A"049&9RB8TNKN/<+;-*Q/?.T)91L?WXI/G%WI'DD5W&%?>!PH_
MVU/FGJJ!Q[.,IG2ZO+@XWC_,],>+37<@+P*E2-M3YB$-->?S*@LLKH4?$;I*
M?+WAP/"Q9V(2PMYD))GBRX%!:BI\.""O ET1=J<4S+MCE/#)[_IA3%ADT0O(
MB8Z-=&N"P("?9@D=+PMLOE<9]@ "W;$U;D4,?$="#V2*"LS7TM.K:/528FE^
MAY)CQ18$Z0]D0-<V.)PT,#OXNJJVM/I=R?D"97*WJ[8M$.:.[6Q#,EQSNL03
MMHQPC;B@*M/ H#40UB!9UP:$@($=,H+3W8- ?.RD9#,TOSJ6 FS1"PATQQ:Q
M-4'PE%%:3OEG]DSORHS#Z0.WY+#"-V'?&0A_QW8NE"ZX6D*S"W27FVXH)LUA
M2'_HV'8UI\39/CK!W[B!_%>)TZHHY;%X ![)WZ:SZ0;$.I!M:DZ1,^;?""XR
M-%\=P:O@YQ=Z/".7))L9/<!N.P20%X%L3QAUCGK+DZ=_ZEU-J;EHV@,1#Y*R
M;$0*&-Y?<8)23N?^R7V)LY1>(W:O,'JL^P)A[]CB!)(%]ZA05HA/B6]PEE]R
M6XLJ4#=I#@2Z8\O2G!(';$<%F3=H149.*^O.0-P[-C6A=#FXL,:4X6\DYX2+
M[^A32PQ[ /'NV :U(L8;R*:^0N->0+ [MD.M"?+BF+U $[3$!?_ARL@M*VT/
M!+EC:]."%#"\-WC!R/>E88A=+N%.X\#8\;%CD]0#B7#]?$$R,L'?&XZ3WT@Z
MYSJKL(_ECC!0?R!;.K9>'4AK@QUFRP4V ) A72<T.]#F+]A]1ME9F8WK@C6?
M<4;G*P.#Z\ G!$]5RK_[8$!.!<J!=J6SY20KO2+K- Z05QW;RQY(]+"X)BF:
MSU%.YW@W"\(NN0<P"I!%@?*HP00Z,VBX*.@49U@X4^ , HP"9%"@+&LP@?"-
M;GZ7+FF!;=AAW <(?L?VN24Y<*C3<14[HM4>N<IXY =;\9MPA-W^'SG>5AV!
MH'=LIT-H<D/^!D\8&HL:CS/^P;_XT71Q<6P,OUUO( ^Z3HZ&$N;*B'IC$S6,
M+/ WZ 2#_5/'YKHM/8X;#L[R[V)Q#5*2TV\$_Z$R,$R[ )'NV *WH\;?QKYZ
M<6_' 0/:YBV& ?*CZR>$G2D$\^@W]( OR'165$9C@1GO,/TF7PA&[8&H=VQ,
M6Y "S]CDF]D92>?K0LI585XS[<:V*Q#TCJUB&%5P_%FY"GJ,EGF!Y^;H6W4$
M8M^QN0NA"1YB/C\:U!_;V<6X"G52IF4Q^ZP(+UMU!"+?=6@90)-[RA8:5VG3
M@RPY(6B:T7R=LF%S>P@P"I G@2X1@PELD4%V[A_0.$ F!;I0[$ B? =+$>.+
MMD"K:V3&QH)=1R C.K:)(30YG-HHR\<X2W8^=H'N1;0#YX7B:K!=1Q#R',^N
M3VU[FMQ,MJ=QP&.#%&N;;D#40YC(5A2U%5,;#!1N"<NN0.R[-H=!5,'W^1G)
M4%-D]?D-XM63"?*=WW$H('^ZON3KA4IX+D?YUXR63^[GBT^>X ><TH5X,57'
M)N (0.YT75#:A3AGG?9)6O[G^=T7K?:JZ0$$/52-:1-B6@ 9L;N230%8-W4$
M0AXH-FQ#DS/R3ZJ!:.%6M 9B',A&UA+26J8*.#G%"]R!K%T;FIR1_U)F4\26
M7S!*BYEXY&%=0):@.Y+RN>HJ#;@-!.1,H(><7&AT,A 4#_T5*%V.#MA!*E\L
MP!%@O#GL.F[L0EQ;3.$?XO\>'5P<? 6S13X&D#%=V]!NY(%9<SY'4ZX+G/Y9
MDDK?Y<JNE 7:MD"H.S:9#<F 0WIR](6FHGC^T3<YEM)&0! [MFMU\X=[&$XO
M+B:4'7^].96[#F1M@-AU;'5JIN\KAX3FHM#!48DSF@\(I]TT:T33$0ARUT_^
M FCRE[TS*/."H92@ZV(I]A<T_K-$_ _B[O?5Z#?S_!VK@8"<Z=@8]4&C&Z>&
MBUDQ0^F<W"-A!'\C.,N0FB<&78#H=YVI;$6-OQ5QA-,I*>='WXX&UV7)C#<C
M74\@ZJ%3E4V(<@/_ZMLWDCY00;$::VE#(+0A,I U-#@;_D>OA1?X"YJ3M#!X
MMTO5'(;JZT#EE?64N&/[Q@Y;17,@MH%*4NDI<=L!CE&&$E07)\]S_O]0.45#
M#@ 3L2?5EF#>$XAXB*1A6Z)\I/-!. #I#F1#U\%0,&7^;*)C/FU</7V-^$S1
ME)[@ZE?FQI'9"$".='WQUH4X3U'I.G-D&S99A5R/9RB;YK/2,#)M-0J0.1V;
ML,X$NJV:+S2;_LK__Z8^7_VC>J$8=0+"'\).M:#'\; 6B2(;NVQ\S6A2CM?I
M!T>8_$%TT-N/ .1#"(L52AR8*;N;8C4#OA'R=3>_(U7]4+$]H@D^P4?TCA9R
MYX'+,$#V=&S:NE/H,P,S/_Z+[Y W>%'>I60L8EGTX)JA::DYX&&C #D4PD)V
M(=#1$<'I)N/!Z)@N<#9#4ZQX=]FD/0ST-R%NZ)J1XKQ'"7]V];UJP1W<E)BD
MEWR?1"17&-2 WD#H.[:OP80YNS).^/+*QS,1%A-^U=_PC&G]&=H^0- #U78V
M),?'GB_&/V.8B RV\_D1_U<^17)[P;(G$/:.36H046#P-]> Q;=.&6>R:C<W
M: T$N6,KV9@0#RXC\8G/C.;Y(TK3O$!)8> HTG4"PMQU,6=+>ERV:W$]ZSS+
M2R9N3ZR,N\_DCJ&T0$Q7HM^R,Q#][G.$073Y"Q%^P6F*Q,M%<\S&!*6#+#G/
M$A$<YC^(,_P2,5KF.1D4,YQ91!"=!@9R+X21[)EF?YSE7R;HFI$'5*SEZHAO
MHBBES-CQ:C,*D&>A@\*V!((9='U[L-ULCU"!YM7_2%EAU!X(>L?&L 4ISN;
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MNV8B4+/X*GTB956?%Z8%.Q$QEI0G=+\1K&;G8\-,DC/<53PAZS"+HM.3BJ6
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ME,V]C)KBOG^EU>)ZN<KH,R$B^;$:YQSD16JL.$ FL(SL^5-:J7C[^LT;@7A
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M8$);W>RZ6\=L JG<G2MN@$5+:>=;J,B I[*PPWA%"B+/71$VP+*F]9-5%&3
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MM2[B15221(!_>V/80O#P')4YZKK$6?B5E\NTXG.ZH<5N^/&/O%:'XF*;>EV
MLOXF/.IF% 8Z7]^D>93':93=YHR*=?/.=)*D?. HV[4KT1[!1UEV1YY(5HYG
M-U%:U(70?T^9)<3@EKLM#7J9'<(]4BJ?L*2@K5X'+)Y:S=E2( -UE)MOYKTQ
MDE'=+E@8:,(2"B$1 PO?FK-0HPN(A1Z>DX"R4)M$#"Q\9\Y"C2[P$IHX6*A-
M8F 6[A?Z?)GP5Q+QOS3VV:@LR5&)\X/,1D!_-#; WD0EF[ZD!99- @8_U: M
ML%R.YO."S+EK86^6<ONSO346CLE IX:4!.;/A,3K@B?ZB*1.RB>#7ECXI<,0
M"J1.Q,/NK!,KW6%R& HLJI=9Q.@HM^3(GBN1M\)BBU@QK)4^7%R2YZ2IVF%1
M&BJPQ?Q J.*OR/?JD:NTE%=NE]]M432#'\2P%,)7LXGJ0@#V!=>W;+B>W7H6
MFWG<I='W-*L_)]%G9AV!C'(>,+12<1"2/3)&?DW1L"L6K6:(KS97G"Z8*:VB
MK,DYXC*R6Y;3=$FNR(J6:9UZ?46*](F!]B1TVJNO\WG[!HC3'H)BQCRCG0 #
M%HJ]KSR1LFKB,GER1_,YVSJ6=S3*6U@.' '$T/=X&&I%-CPUHRPI^R@[<UW2
MY2K*N6:I7K:#Z8)]<+YX*.@LK>K)E')=:SL4B($?\##0#?WPA;?.DSW1D2\O
M53LLYR\M6U"#$KN];?04I1G7KC-:E%%&1.I6O7.9CX!E7]+B@!6-<-[L[7!_
MI=5B7*1SME:S^IVXM'K^6M\OB/+/KZ^B9P6#+(;!LMGH<<F:4#"KU-:'XJ"K
MWPW+MJ%Y?#4E#+ZSQW&QYKEIS'I@*G*<'QZ=V1:T+Q?R7=UB&& *5!C6V!,*
M9]61!A69@G(&&7?&<O%%CRU \BQ2 G/^ B,;E_U7F2;UBXPTGY"8L*7+)J)Z
MK]FL*Y8+,%J,@!$'9L/!N8<MOKWO\$<O+]=E19>DX#\U(D'N2%224?+$_[O<
M+-SG5OWF]3MH+M1H<;@#*$+[V35]GG?'SZX"TC!.QL!BV5LY?BVI!ZN#^CO)
MJ!HM:5&E__ SMN*!'XW66+@!R'K2IB[P:CMRH.PY0U1>/VEC+*F&\"5P[.EK
M(163LCR:LOR.N$$O+,$6DRD;JD%!+AY8!3:7-C0\3^J&6.*/6B:)#BD>+?W'
M!=.PW"2R,/DE8V Y&T.]W9:$PYD6E0MF@/+_X<+QQ(Z$JM.Q3G,L3F\P*[1I
M-,B"\W#>]R=JB.J^F-Y+.YPT@FMIBMU0*S-=T05-,OI@VFB:-JW,Q&NC:I_A
M6[JA$=H7@^F8D2U9MHKF6'8^;9D[SNALI0W7$;C]W-LC!:)[OL7,D/8DI%[D
M/JN6@9@I?7 7-?ZMLL779](-"^/4S)"YB5H)Z_VARD/16BVH[4Y07=H 447F
MM$@-S "]'E@26HPM 1/R#(Z_'A)$3$DS-U)Q*? -:^07U+7:8U'9NH(F5MXJ
MVL!:^R+*>.#U<4%(Q:5!H@%4S8#+WN]E%(VUT4Z3,U2EXJMNB$5NE4A)T$2X
M\86Z(=<!1SJ_Z!8VD!0(3Z^1I+/*O=?#$YA\WUUBA1X9'6>U38LH(7N#LT-'
M7?K^<EUP6IH=[_IGG*T3-JN'@JRB9[5(.1H1B_VOQS6G1/<_4_2L\\$]G,3T
MA"Q@0GA?;[AXR$_05 CAKKC\NHG*'E($]+B-)%'Y+"_4>KA>H*ENPUZ?Q7I3
MS<=M -T3J(^[:D'RC?6#1Y(NP&C&!QR!(R51:)EVL.3'!5_QIBYER&A8CN%Z
M'N16EAO2C4T:#F*>YNS7Z(XE']J.W]J$@C=(S.6QWKM_(L0T(C%4Q/+K-0]=
M$0L3I2TWI6]H\6A9AZ,[[[TUM9M[X=LSH<W]\!ZD^C<.SI=NW"7EIQ2!MA")
M2A$82J"=7Q,L"(HB"J;29$5!.U/W/<>:$F!\5D$CXR*I.39G&V\_73)J%B0O
MV1GU-H_ITNU3RRHA@$U(X,YS-SAPIW;^O#.4[[X0 ?/?G2 >/"WI5KH17$PX
MCL9IQRJ=A""='\1@(4BGDG<:S)1BVM84B.K',*CJ41,VL2#,-4U,+CF9?K)W
MSYF-#'3=.)=MMZXZ" 9[$H/YLNO;PUECO>VZMY2-KKS*^J'9J=MF;7KY5=$5
MB]_(>-ZJ['LU@T/?#3FY#=;NF]7NTQ=V:EX7M7;+=K']ZKASVQMCX9P^$XXW
M2@?O%W3,+N.[B[I]L3!3@S<*+CJZRM@Y4PWR"73ZH8LT YF).;U >&U+8U\T
MZ(;E'@1L:S0F%.'*U#]WMG;"HF"-^*)8G7W(]1 K$ZOT'\LAL4B! 4?U-+2'
M;*#>)8MT5;^F3?6ZRAC!E)F X%6R(3>FDVP"_!DB]S2/?:=+U%&@A^A9(^XE
M;H5%@X&?H6LC#0QMJ.H&OBNNZVX/0XD#C"4.A'ANKPA>D*C(TWP^BF.ZSJNF
MMG%SJ:7<K!%^BW 9Y8D4<NNQL')%K#\<D6NQ%/*_M[>']1*P-'M@\0KHL<&(
M*##8EW2Y) 4?^B%:D4)Q.UK1#LN.J5M?H)44.)R-=?/ 7:DT'\]V!H].!J%6
M-RP[J";8QI2!L7^LBBB=+ZH+FB=RPT_1JE\%%UH)@2=9[IE!E*NA\D0/\>2"
MM%IS+!37HVW&Z5=A @>D@MFU?Y]Z_#U+YY&:+5KM^U5KP( DBYU26!_DA,\Z
M7@WKL?I5', 1N6#68;U('NQB?X=OGJH_M><';RR%^'E",EYQ ,@5W0'/ZN*_
M&=&!8TQMGI<[TT<"5'VQF'0@=Q.06H0Q1,VX(#9_B3D#%"$_MR?,;FZF:<U(
MRZF_-RF#( ""_-S:IM2QZ=0-L90T -\$TZ#.[FX-*(O$L"<61Y5Y$@&(4/<,
M,6<$3N<5=!DX/Z^$S8(%9N_X*N'BP;QVE:[COY@+=TNG]=7:&UI,R&I=Q ON
MSIB-?^2/"T:DRIU@UA6H!M%L1C!Z>W(AZ]WAK'4O9(D/WWL&K/H(>?$\99\;
MS[BKAM^]T;ED93&B [-3^?5[7F24?7SW%TFN@L4H&$\I-BS1<37H(.+'573Z
M99B'J&T<-%RU8 .,DX/;#RUW<3@%%=&GPT\_%"G[TXKMY\LZ<T2B>TV[8LG?
M<*QP83!X95C[>4"[,Y859XRR 7><QQFYK(R+;\SN*[+G^KF$O0\JW'V&7?O$
M&WEDT9QB,&\>>'%ROM:WFE6^4MJ:8E%F<.SU* 1C?4_FD2;6;4W1N?V,L=:C
M$&ZM:>]H=YK1.<-1L'#(]5G*%A%/]O<-+7Y$1<+^AZ3S_/IGO(CR.9DPXW!+
MCO%9V61,++K/ACU:-K@Q)I[X;<S,_JY+(*<Z8</XB135@M3I]-N::O'S>%4G
MJQGS2&LT+'%'[PPT0,/IT4GDRE74;((.@=E4UYJ_\8ZHX3_VM4P;H1GGQP]4
MFB_1MI& R_-3_Y:G'A*>.,H#1I0)Z?/#)E2T%2ICCK:.!"V V#^-JPE%3\)N
MOP4*NVUW*I>!-^680^@MS'%1S90A^(:*KT/P;0B^#<&WO@??M%3N$'[#$N(9
MPF]X>8,B_(8\3/&+.N:#VM7 L^O@F.\+I\S9<)!27Y+XU9P^_4^\,05J?\'+
MOVIVU:S:_N5_1UFV,1M24E[1993F B8I6EG<7#*>[/6WB6!R>W^%6VWLMQEA
MGTGNFH&E<E(+246*DM0M70N8"FDJH=>_E/SKX=\"X/?^"E^?/0+^A%[+6XWQ
M<WV_1G'10=$,7K&B1XBW ^!?]K\]7@E8L_=7>,RQ1YPXH7>(*O8CJJCA'#=>
M0[.H_%[37!95LWY(5I7\7[OUP_[QLGQE)>[W?GYCQ2,/A9"<.UX4U(H8T&&A
M=^'$J*;E]\L&I?L7P1R"TFJ.ONT=1\UCTEH6(G)-ZC+-%'.,_@,L1M]5,:/=
MFSL1_PLG9SPS?;C0:! T55*,2-!]TM!T'"S6K!T1HN)/ *$PMF'="L3>3"7&
MKJ1%+YDHU,I* @.S9S2?%_Q*"8]'O\Q2ZG;1:(V%;3+0J2$E@?DSX:9HD>9S
MD>A)^630"PN_=!A"@=0%YN$=>2)9N:<]?D])P>:TD!W_]3I@3,2 *4@3>D/K
MRRR3SU:N-_5[85F/FCRA0 (Q+,DW1CS4[8*%@28LH1 2,;#PK3D+-;I@T:Q0
M%FJ3B(&%[\Q9J-$%2UH$E(7:)()]DO70R;:@W3\MKV%KM,92TA$ N39U@1>,
MD:EUXN*#NE<DOD($WJ:7=^LU7HUN:8I%>NVM:3U*#3S?OLN@@ZAT(<&AMS^=
M8M+8WS=ME;;3AW&Z>(VE]=U/HWY8P-8HB&I,%1AY7+6A/9C?W1>![M6C-1ZL
MY5;$S8D*K./%1:1?-BP!WS1[>$_H_=P$:?/&*3OUEF)GN9$KBW5+4 ,O1;-'
MUHU>+[>V13WG],.L- C='KDC59;G^[J\R!:#46N9TUVU+%'MMVMTNO>'/Q([
M#DPSF$N"UW@,&04< 8NY!^65%=D.V"6Q^774'GP0+.X2 ^[ 2.Q)1MS'PUE;
M5:U!>P_AE[D;+,QHC8J"7ZNN54D3(] $7M$3OD^:W=!9,0AI\E@QP?=^B #F
M$X.0@]NJ49J7$Q+3><X?$[K-'PHZ2ZMQ<4?+4F1K-YN1R'2U&PG+[NN @TZ0
M '/TY0.CY#_KLGZ4:#N9?_ADI@N>@U[2+$WX@9JMA6ISB+JD2X;S@K!-Z8G<
MYFQ;$/H%?(R/91MWL7[]X8,G5@+$9GL)POLB8(#S>$ Z2^,:&2--9MX9?M47
M'8N@Q,/=RJ'L)+L+C9^@QL=UGF Q/4[N$G9K>[R(5KUACA@NE(?P%,JR48HO
M*O.&%HTH\KZ[X]/O9(>/:./R^#F0*'W&=.??Y0[H'6B;_8&=Q]FX-2_8UEN7
MVREO%>I.=EG*=B@L+D+;*^]N<# P<3P8_]8T!']F W-DZ(W[&]FN&#;$AT+'
M'Q#$A]CHE'VEXFF7RU64'WK-IPLVF_FB.<MO-C7Y10O+H?K#-[&WVPW]<,MR
MG3.;XHELCM_R\J6J=E@\4E >:! '7RI/49IQ13JC11EE^UM;.^KFG;$D(H"7
M Y!BU]F(;+LDS!B!)"1*NV)QW<'?;H?0>X9YHAY<AHYY\@NDCWJHDP5E0C=9
MI9=1N:C7VJH^[C,6-_5P31RVX#& ZP1C82E+#,#\TW?I[[]%:Q@'0'#%1^20
MNMQXRDDRJIU3-[1X9+N[Y(0-' $U O>TDI"@.AJ!A\%R+(*RDKJ"(' VN0']
M1G+0>R'0YJ)"$OHC!FS;6E%VGFDL#%,! /3&S'HCOH-I-_"/OWGUT37=KMRM
M5ENA3:2Y!MW,N#3H!;?X$=^%@9;%-(4-S-:#Z*)=#IOM4-Z+[/=( -Q@:2$5
M^9SALS3R3.IW G+:^<D1>K@WI32PI=$XA-9I/F>;!A?.YM\D&:\VOB%IO06S
MGGA.6]LZ=!H$M-=)-!X$BZ5ERK[CLHI PM&(NP:3VQMC8:8%5Z@9K>$/1B;+
MU-N"]%$+S)J'=JM00NEKO+DEH!VH)]>]/AW.VNJZUU>:ITRV^=J>W9/JBGSG
MMF+ZWW7*Z^=?1,R&'.?;LO/K*/O*'\95UC%W-**GBU0HKK+U)[_0*3/!QXK-
MJ,\O<S@Y_^S+7VMC!Z+% S],L?#_X:^&/$59;<-'Q=]LB3+"=X^(;-^BX)"D
M2W)%V $]K=TPQF]"=O=1>'H!EHQJ#2F@85 ]RRQ3#S:/*]4S))LB25KTFVS:
M73Z:8\'4W:\L=L]35<9TUKX*DTJC<5\LV@/JH@,2;)&9]K*G*'P-DC9]S]!L
M(0P><^+;<2K=CQD_1W%<K+E[G%D@1%'YV'*DOJ=I.B'?*DM-8)E)EXE&\][G
M:&K3"$_CWTZ)[T7R)'YYJ[ZG8+:2Y@;:;WG"W5+KO'[U1@=F>0\L5^&=0-Y&
MIMVV@+"6ZB<\C.A=B=4Z7UI1,$_ 3]TN9Y-8HN\+,8,& ^O5]?=DW-?K!3<6
M^BT )N@$EH$M9;+7)04_8W&8>'(CX'LT[>5M/WZ(OHCR1"-U0M86#?-$:)^\
M+JDD(C!;[M@$B^DBRL<Y^3>)"G:JN*?5RU]OF G _ZQ(VP(-X+URN??(0CM[
MJ3U 6(3#0 Q<,MPD.Q,APS&S=E\$F6"R7:A:*$H$MS7&HI"UF:1+$I85N)WC
MD?:8LADT/^AI:*,QL!2: :E: *7P?.?3#QQ_^0?)GK09!1@&R"OGMU3,>04F
M-K0&;8QUD;IL?K&K<6A2F [? 5(,04\2ZSX?SOK7J*/>I]/Y<&S]U8^M@_DZ
MF*]>S%>?6?N#^>K6?/7Q5#<N\Q40OSQ-QACG%J6]?7_+01+V V7V655_9Y;1
M'^5M_F=4I'1=-A&L."7E#6/P7G!Y.T-YC1Q'0V)10?[92'T AV:)R"ZY>/T.
M%N&QO3S2 4@&F< >K#:_!((">_U5+>*:WMUL0V!]\Z+VQNO*4.^ITQ3<#NS]
MI:_.2F1TOI\YQ+\G7K WKP^G_6NXP09S8C G0GM->IS-A- 4&IS%O[JS>/!"
M#E[(P0LY>"&A7LCA,.WK,#TDMN(KF3$DMOI/;#6Y'8*0X9A9.RVBA#!1K*^P
M;!\MF=+ZSX_KU2I+&9 "/AOU.Y]:LUTYT@#PPB^,BU^P47M:]3MY5_%GQWQ3
M;*TXO[DGM9OT[AY;NP28=?;N3_?_XG"7(@ !-[2A0**R)40C:^+]BM.AFNBW
M>*A!M- 'RV5:;9ZUGI#5YNFC\8_\<<$(%VL!O2[P(N2_[BY@@FQ?HF1'*>Y6
M4;(IR:^BYX,2_7^.)E]I0C)9R$BWRU!'%4/LRHQ;8+6G^(S*S6;2#4V"_H07
MAI9$RDY^P^+GTY8#JB3$(//'@Y?:E AS\0IL_-6HRSU#HI^Q**I3@:%MDPX,
M]E\DG2^8H3-Z8J?#N?SE,F4[$/RO,1W(A/RAVJ2'=K[1U7A6DR#EGZP)D'7Z
M]G10UJFI#LRU"UI5=-G&.$6K_OM!5+QK)1QLI_U%B[*ZY"=?MBD^QB3GJ85R
MS=?>NO]E593Z3Q< ,$-$]GUMJ(RJ25K^S4ZPJW6#G^;A1MVY_^O&R*8[KO)H
MB%,'7'TD>9ERQ\:4WM"";;?Y)LWW^?IG7#]!,XDJH=O(VS?ZOZ3]R@@(SFY%
MB9?HK9Z;DN)?Z1.1/>SA?O#^5UWJ3'@T<.Q6:K;^5J<:1SAH_W-6.I,2!7Z!
M'-:-W-9U(A]XZSA=U8,^9%%>,HTX*DO*J*Q>/-;O#Z=MY;!^C!<D66=D//M6
M/V%*D@G[_T4:L_]ZK&C\][<\K<H)S3(VDQ]1D<C<V'8#H7%&[C_=RU]XY>&3
M2YHW#N)R/*L#'=\;7CW73]<5!=^BZO^4N\U=#HO%0^64)NI.BD)[4-@D6JB7
MO>]DVA5+MK,EUZ@-]8&YK9RMU!%@T O+:C?F#@62&IBA-EKMQ%)QM -(@BOA
MGZ-QL_ ]0 ,V]&7&V"C/Z\2GF'V3V9&3QV_2Q0T= DNQ3I,52UV0[)U9.YFL
MTU2L.:<<#TL=3X]LU*#?-T_=<-(A_S[UAW\=<JW^U&/TE.;SLC[/0A1G^R!
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M3@_/M#G XRLMJ\=TGJ>S-([R:O-0]_:!;AZQ<^82,/G4GA2;S]!*0_**@$P
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M)M&16=P"^H &1NB5)(*A_7,TN2ZK=-EXM&9IPK9 IAZ9H?8490*@M=I#W[S
M"+L!P=XTT^9$NJN! -!-TC& VLE]:-N_=FK!P 7_"I*DU4T4UT%8/HLZEU[-
M+W4?('_<1YN=\D>'9C _+CF;2<'H8<HR+?]6.(O;FL)4F>=*+4#X]6B%HQZ5
M"YY#Q_Z'[U-,/?+9_$ZRA!^;#F::5FL.F8@?X$&P.)5;4:9N*(5O^21/:"%)
M@#C]T8'#K!E4&O\3_8R%FP(\:-NLP9RYBXHY.[6*>"\%3[L/+D3%L5%#8L!
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M+YV;N_J/-',5"MVE1C:(XDN$13 O8"HLQO6($%?G:16/"UI4_!4<@[2*DS[
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M?R,$KSA_(=[$P P-[P%,;747_L15A]NZGX"X_6. X6XZE;5,(/'M&&YNI[B
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M@;_;Z0R?TVI^/_XUK^")N$2V"3!N'C+B<G_8UEK?</O=[+TBI*_Q:PPS)EN
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MNW"L6+?3V":4$94^,UJ"-EV.7P&#^2I8E/9(!N2=55<#T??&&O<S?MWN4J:
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M'_=3!X\$8?=!O5O7O&3,Q2SJ"_]9\9L_NH:3;$&_3$BL828,.@Z,PR&=P8\
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M,BN.BJX[J>L8-UU#9A<]D\7;K9/?^;!'G_MM=43-X3 P^0K)'S<\.G#_=/N
M=/L,[AZ]):MJU3P<$CJL=;^!<2XD[YTAJ=:.U.O5.B4;S&O5U8F/XM^3<DDE
MH+E6:E]8*]RJQGW JO^%Y+FS)!W,MEV=.J4O1]4,!GY(\4;]U#D)%]I/.<5#
M% K%^V733V%\",F[!J/8PK+8;48[8^<"(Q864H\X(RRZA*0)*ZH6WQ"6"9[3
M(+0@[+N#\3"D:!QW*'@^)5-]NV[+;-<NLF6RWI4@V^;\$[W!,?X6QO>0O%5
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MB.CZ&0T=;_$^]V$'MK+?UG#0F\5#N+/@.</?LU2VN8Y-STA&WYW LSD/(@:
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M MR$M$^.0R56=M"IJM,IXHI7A:=KT,VG@O,<X&-,GT*0"V[9;N=LW7C+_-'
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M_V\!'0,R JH#J(!Y >L#/@^XS0_B2_C]^%;^''X+_QC_3F!H8%I@36!CX)+
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ME_'+SBL7K^Z\MOSZ^!N:KPN_Z?:M_[<_W#QQ:]MW;WX_Z8?A/U;>[OE3_)W
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MP\.CA (&/(^6 0D*# P*#@H-#@Z-" X.CJ!OP1%N$>&S*'!M 4(># ,NAH@
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M9=%H*4#P:)0-[VX=G1@=H3LO$!LKVL_>'7.GU8 )-W8O9VA*AG:+IGLB&X!
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M$M6(>O9PG>$>@B?'H:7JDEZ%1?G,NS3N]SEYN?EH-@ 6*T72!\D! P?AW(,
M R@( %S01:-SV,'3 >JX=\#]MGR?6 O5S[>D?+AJ6?Z]",M[J_L)PBQ_(4L#
M7V<GZ7?A]"OG=^AC)50Y&I9K:R@[Q"/_HM_FD>5J%0 H#P#V6\8F96V3,@D-
MA_V93/,;W>5%=%GK+M,?Z"(HHI;YM*BRV4<P+\+QSJHNN%PJ3<>U(W#FM(V7
MV<Q.YJMO-SS';,:93X(.7$TX"!+FDTGP2*\CK X"U\,TRV1VX#J-%8=)GH'^
M_(';K$J\R?LU>#9G7H;!IX2P2MQ'=9C)T@YU]Y6! -\9WNN5 $  '3 !-2@
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MU?OF?[_XYPL/E \3'[5S!;E<_G6YOA: ?H^:K]7BF0#,@V7A$#].M N \#,
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MTCY#^=(TF!&?(55*%1E2&2,\T9?1<XA0PI=F*YR!IX>G!]N#Q?;T9;#\V*P
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M_OC A_WO'^_T/G*P.24P<.N#@H,#;8=]63VGYO(7^)[BS6WK'J5WVBH/689
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M40@B0&HB4)H(22/D&%)2@?"$K,0@8!AP$ 402#0&BU/"*ZL@?F1"$4+)F<,
M HU (=%(# ZKA$&I.D),313:1(N$\9Y"U2;.7>J U<G./^%C:J8;?BG.T4FP
MK(J",]\8T='T@29TUMM3M-S"=U,DW>]R@<AE>'54,^/CR157:L0MG_PM-^]=
M>2JGHK:U<U_QU;JVKNCXY/3<_277'KSH=@V(8::LVG*@]/K#EY\U 1()68N&
M;<)A,<ZP"28D+31DP5RB-L9A:;:.U()+X54=CF9Q38)E&RD1NC2ATP=SK-0
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M6H9V[F*1!Y$H=X'#5U3[TU@-$0P._GM1#D<A+13Y)8O^7EHH7;#LPAE"GEA
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MFV19?)$\%X#45- 9 $ '-,@6D# ,PGX :@LH! Y #M3.C ^"O)MU8.S&P^_
M%;NT$)_ [;%KQ@0Y(#?KK\*N,\#BXV@ O-J8GC%2=0["3L]3HVI=GEK#%HI"
MV-Z]Y"JINE#G _@!_ !! $_ #V'S0@6\,$$P'P#2,LCX7H,!@&6PN7S;920S
M[@*,0(5(S3Y26\<!N;;$ 7FVC@.&3&5 _K"Y;!*ON;RDYO*)IZ'6\!0PB0@&
M"E,Q^AFP)B@@'4W(KX%Q@$FGTQET)H/!9%E:6+(<;)A,&P=G.SL'.SMG%I.
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MUFZ-RN_S/B5ESOF'HU8VC0CN&C8I=F+=XOS/#S<LR)B>QDXH+5DSY?WU[0:
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M*9]+) 8P:^\[^=M13A\3#&#DJ#/UR7O[[3& $TX?*W[H,<X M@]\OO>]4\E
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M>0[1\\<TZO6:SS>[EFW<:SAW_?;U'6]^?/-L]^7='S;I#5?^"U!+ P04
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M)KT4A>0!3<S)!<;_A#FY ([+QJZ3?:5GB(#,X38E==:CWE?(K>A&.\BD GB
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MZT[YA>@FCY"&A_,BHU@2/C\&KK8(+BM&&BUGA<= 'P[GR_ABJ?PK1K;$7)Z
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MW[3O>-7=9QWN05,34U?D[B^]=.]YIQ[ 8!!K<:A-1 +>%37!G*J/0RR833;
M.RW.,I1;<"ZBILW9,OZ1<$FV']V(*7)I'TF0&T"T<CU?BQB1/Y@5$.4FAIM5
M)ORU!=;])LCN RTLVJ8>\ 9ONTNC7?E5%Z5P)K;5PY+'-6_R^2WQ$Z>AHM7-
MO>.U#"PG3NB^$,(]<?*Z].K%.<Q%C",75W1M$!V)A;W9]:UGCJ>EPQF2A<MN
M4EI,HJ>'MNJ<O.W<>*F"_]+N8,7>R?#'TIJ>J+B"0[W4>.:#FP0M>N@'UIC5
MU,V=;^# !?SBYL:7AY@+1CSG?;'._]RY-Z-EVF^^)D^U(<_I(UQ@&9A;6YUK
MYS2+.5Q;?81_?O=8[[N]<:\[*"TG-\%GFN@="PRC.95%YF4+[QQL&,$0--%C
M/]A>XK]**^@)*)&!Q3%QQ7P9.#$U+; G2+L[K5/W95IPY-S0MRU=A-=WW5/#
MS#-_U>7_&O@XYTAORZ\?'KP\FMN[8<2'J[,=%U>:G[?3/I-W6@8\U@>W3;0>
M\LARB@QH=J8]\Y;=_!A5)?&I34N*24H)YQ^LYSG/LF@UZ.8?'==9TG!F1<,7
M0EK^1QGP+S<?Z:9Y;$;LPG6ZCZON/2M*=[]0\;(][5I'T][>0[V_]Q"[W-/V
MEWW8>? M?>%=I*&6M'-S?]K95#/WI[R]W:[[SD2%Z+ZKV%_Q94IJUXB;#;T%
M,B"KE[5J=?<O.LX.CF",;T@H;B0ZS >!;P#ET5"TO8^OF!*: B&;)PZ3B 42
M,5*4KR@@7"2FQ_/Y'%0BA">&89Z$J\3E;S^.4%[6177I;*E<PI<MENOTUPD+
M)S.X<&3 M$A58PJ%<"&?GT"'Q1)!6/PL)D+6!^% "/C(7P*P!P& #7A !,0
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M>FUMV;9Y>^#VCSL*=D;FX?)*=B7N-ME]=<^"?&K^TX(M>R?OP^X[N5]PP/K
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M.C=Y4@BDL B<,U8.+ :C(PGW/SS]PL6"C'#Y_LH>545:1S(+,/F8=%= !A1
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ML'7PU\!4AQK'X/1;/B79#9B[J%A9V-X/HC=P;'R]MH5NL>\IIU. K[(AM3#
M,-*A@;%(N<-9A!%;@P@<];O"?LR)&%WRX0:<M@BM/2S$*P8PV)3?Q1"5+V(
M])?^C0&^84!4:+)]Q8W&OX86C08<TQ D#$)A[_*UXE+'0X-'F9+2% EK<D!
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M/D@?""&NUERA6[QC7=M"G^@N%;>6G)<O]X7E>F>[G')SB+J&,V8B?9E,8ZR
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M?^QU-(%!L/;*%FHFZ=?.N9AZ+%?LR0\_Y91IE4($1L"!RS&C(.?E>ND(ZJI
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M1B9U7RRWUP8_18P]?57!&,45^>@O8^=14(?TZNEI<XR4B=" IA'1K>2D(7H
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M4V^].(OO_>D][BMK6?TI6\A6L6.=K"7A/92<*_+1V\%_>A)X+&<S.T,W+I[
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MZ)Y.,;3#9%7H#X:G/Y2Y31O6X/_=BV-3"=9<DV#,OV4UG@7&QJ?#(:B(IT:
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MK88EYIY^Q[68CL,(P$_#D?\WC0G"H6,#,ONH8=3^OU.<M[;=3<[9>HXO@Q%
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M#%'@2UTZCFHADE%.359F=W)9-_K(Z4 U+Y0D.%G]Z-Z3>,WNQX'WMC1KZ<J
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MOYFNL'Y3=7,LBK_SGQ@!>!(Y20!2W$,)0!P;H&?LS]CKQ5>I?=MY.6\[KZY
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MYS7&<N7HRQR*%@7_@D:ZCZUZNJITW-[]/G@G6Z<6%0&S69L9N 3_=.V[);P
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MKK$,72)A!2CF)QU$=(-!.+ QBXN4S7W!]U9D)\W*[J]G/.4PS.RPC:1-W(@
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M/3D&SVMN[N-E+,@D-1L\I5[_ -T]:]E9'*HGE1QJ'+,K-5.O$^$T]A*6YI;
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M)N29XFN45A?)ZM4D)N8:0D@.A0Q[9/-?4<4CXZ+?(^@DK+>.$G H3-(M4/\
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MHRKD:UO+H*D]VRD]-K8)KYW/^*]=JI7#T_R_X/0AX+@A]1.TQ?.]DN&[W 8
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M4^(VVXDMJ4E06,8(_P##%>]#*G-'@:C%M5FYCP@A"<XX%=<I\G)%<$D,-XY
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METDH-;CKBH__ (V3V7(KB$M%U"<C)W'!K7%B2X,YJ:YH=E&U-LAD;773DI0
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M;(<KD'PJEJ\;J\>E:?DD_P!YB\^ND)7:H9(4MH*.>JC2_(Q^1/-.71(0VTD
M!I(QTP*TC@V<))BN7N+2IQ)P%9'O5[UCXFOY$33ET$XYCE2A6L9J72(;C'ZF
M(#H)^9/[TVE=-!OA\B^\\DX41Y \UE/$W]*0U*+&UR0TG+NU'U4 :F67%BC4
MY45&.2?TJRMGZJLUM;*YESB-?5S/^%<>3Q310X<_Z'3#0ZO)],#-73MNT9 &
M&9HE'_V=>9E_$>.*]*L[L7@F>?U<&1N/VA4.%0M5K4G )!42?\*\;/\ BC4.
MXX\:_FSU</X<Q5>3(_Y(R=S[:=;W+*(KJ&0H8PD8/Z&O/EXCXCGXEQ^G_P"C
MMCX9HL'3LS,YS7>J26E.7)\N\;&DK4#64<&KR2MR;^W]HZ%ETV)521.T]V#:
MIGRF'+G9WOAUN)4XX^O:0/IUKNTO@^;/.Y*CDU'BVGQQ<8L[5JB(C2>G8D33
M]L ('=DIR0./\:O\0:5:'2148=NK_@SSO"9QUVJEYLZ57_J8=-GU;+ <>?0E
M*QD#!R*^$\G-=PB?71U.EP>GL!T3=7G$JFS5*3_='2H_+9KO(J!>*XXVH)%M
M$T+9484]N6L'JK%=^'&E]4C@S>(Y)/TQ1;IMUKC-!"64!0\\>5=F[#"-=G$L
MN7)/>Q$BXQX["@A*,A!\.*VAJ<5<108\,\N3F3/)O:+JN$UKM]*6F0X!E2BW
MG)KU\#O"I(]9X:R4V0%W@ST!*'5=/(X'[>5<.>?)]!I,:BB\TO*>CW>"UOW)
M5*92<G^\*\Y9+S0R5[G=J<,/R\X_"/:FJ=.1M1V]-NEH[QM2M^S'3PXK]1UV
MEAJ\<,;XXO\ D?B.CU#TV2>1<^QY"[6^Q&;I6\&83(5 E+VM**^BO2O%EI_*
M6VCWL.I67E,YQ(TB_%)<:"\IZ*SR*XYZ;>NZ.V.=18PS=M7V5P)@SGFT@]02
M*Q\CR_N:>8LG9T#2?VA=9:7"8\N4Y);Q@A6216F+4Y,,KHRS:/%FC5G7K!]J
M^P.LA%ZC]V<#*MN,G]:]#%XBW]2/-R^%I<Q9KXG;;V1ZF2EDW"&7%<%"Q@@F
MNU:W&T<,]#G7TD][1>A]2QUN6\L#</"II:3S5PSXI]LAX\N/ZD8"\]CMRB(<
M>A)=6V"< I'-;I6JAR@\^,%<F7/8=IJ=9=6RGIT=397'(!4,8J,.GFLEF>?-
M">.TSNS6UQLJZ;:]M*47;9Y;VS5HP/:9I1[4U@DJ>NJ(*6 MQ"LC:2/)6>E>
M+XABCD=MGIZ'/+$]JC9YJ8N\]A19[QMS8=N[=P<<9KPI:+*N:/?CJ(2+2#J%
M2W=LH;$>J><UA+%.'L;*2?0^_<[9)>VA92?+BJCDE'LE[9%7/LTF>2(NU041
MU^M=VDU2EEC%G+JL26*37)TR/JS36BM-Q8-WMH&  X0UN!)\SYU];I,KR^E/
M@^,U<7BEOHQ>NYG9SJ. MRSS(7Q;A!Q&Z@>8.:CQ!RA';'DV\.AYN3?+@Q+&
MF!)0R$!PI3P<)!KQ)3?[T3Z&*BOWAW55M5<6&826'$);24GBL]D'RT;SRMI*
M+Z,]%T4W(>9C%DI2.2K'-<F330?)MCU$TN46^KF5V6W,0K8P$JP,JSS]:YUI
M4DT='YEOEF3B7K4(E-Q$%3BE'!R3YUR2TS@[3.B.>,N&C<O219X;?\95N4I/
M*3Y5K'59,<$1/!#)*R*SJ*QNX0TI(4>@K;#XG*_4CGRZ!/Z66K4=N0SWC;VQ
M9Y \J[UGQ2[1QO3Y(],<0U-C\L[%C^\<TGCPY/WJ&I98>Q(B:ANL%25Q9;S)
M20H%"B,4EAR1_>$Y8Y=HUEE[8M4VP@JN2I7/R.@'=[41SY\$E*N$3+2X,L:O
MDZ%9^W^W.M(3>K8XT1\RVTC;78O$ED_S(HXY>'N/T,N?^FW1/HY_W!5_F=-_
MX(S_ ">4T;:/%R*^KDSP%$>#8'(K'W+JD#:*8K$K&,4T-.Q!2#UIC &L],T"
ML/;MXH&+" 1GF@38-@]Z!6#NQ[U(6#8!SS0%A!9)QQ0.A2DA:2D]#0)=E+?]
M)VR])^)0EZ+<&Q]S+BH^];_0<*!Z$'RK*<=QTPR*)YO[6.Q-^2)$VX]GT34!
M4K[V=84ICS@#U4IH^%>/,# -<F7%-+TG9#+"7#.-0X6M>S60]<^PO7-PN,*/
MA=QTM/!1,8]5)CY)5S^3)QY8K!99PX9L]-CR<]G4>SW[8=BN,IC3O:%I*=9M
M1K4EM!*2B*_NX"BHC+?OD5M#4-]F$]-&/TG7)T6'?[<IR3*CW9_:Z5(8<!AI
M04] 205$>O2K<U(B"V2-3V5B/'T5:X%NA+8" II); QM"CY@UM@2VF6KDW-?
MH6[HW:B:;;4\ZY'8<X]RKT-:<6<R;KDXYV[W6.F9;T2&TEYB4M:&\8+:L>>.
M*\;Q?)%PV+L]WP;%/=O?3.1:,N?P%S8N[L5N6YLD+6X1RP$ @$GH>37E:62@
MO4>UJH.?$2JTTB(S"NER0WO"2IU;@'*EDY)'MFN+)ZLC.['Z,:(=AA/7%:F&
M(#RDN.EYTGY-V.I]JV6,P>2BWAMQK"I41(;E;N75-^%"?7'G59*+QVRCEWYI
MZ:[%;6>Z;!4 ?*N/)+TM'9BA4DSG<Q;-Q1)N"PGNXZE-!/YEGC/Z5$57!4Y7
MR<>[2[TQ:+8BWL**I+F4DCJ5'.-U>CI<=RMGG9\G&U'++C9''X]JMT10>F/I
M*G0!QUYKU82VV>9-<I(]&:'3 [)M!(O=S2E3K@"6$^:B>M>3J9>=DVH]?316
M+'N9BQ/NNH+B]?KEE;DQ9!*NG<CRK3B,:1DTY/<STAI5HW#LYB6EMP]]$BB1
M[!&\X'[5Y67C)9Z6'G'M(FE@I^PS&7%*"TON1@?/:2"#]:RRRVR-<2W1&FIA
M?TO<(!PJ3!G;D@^22.:B_6I&B7H:. ZAM;+NHYB04;G=Z5)<&0 !D*^M>SBG
M44>7DA<F<ZU1':CZ>^(1M5+@NE*]PR4H7T->MI'MES[GDZQ7"U[&*TM?K0FX
MRK:ZTJ$Z\C;O2=T=?/"O5*OWKT]1@N.Y'D:74/>XL[IH'2K#ZV;G<5I<0,%Q
M2CYUXVIDXJD>]I_7RSMEQAR+LQ"MT5?<1514*2KH%$G&:\R$;=L[LDJI>QL)
M+46VVN' :> 6RD?=9'!_-7)EC)-FT)JC(ZDO[D1PV:" V[(CN+"CQN4E.0,_
MO6VFP;Y;I$9]1MCM1S:SR[@B*;HY*?6W/:"VFG#E;8).0K]1Q[5V[(REM^#F
M@W6X>;M$B9W;ZD*QNRK'F/>NQ1451%MLL46Y*5C+8 'R@"J22*)S=O&TG)_6
MJ?(^Q7<*0-J5$>?%9M%+@2Y'4K8H$Y)Y]ZRDC1(U6D[E*M:GV""62CO6VQT\
M/S_^%>9J,2D:P;1T%^&C5UG0XVL_'1$*,=P'DMJZI/K7F[W"6TZ:35F,U0W_
M  5E4 ) "0E6!ZX'%:P@Y.Q[^*).A]1*M]T58[HAIZ(H$*)!)6DC&T^6.:Z(
MNU9AFQM\HUCVG%0=2VJP6]O-N8B]^P%=4KW;LDCJ<<?2E-?O>YEAFY+:_8U6
MDX+TS43CVX*;;3XT_A&T9']13VT<^6?)Y+^T-+<UQVMW"V,K<5&3 5 <(Y4D
MI5N"^>I%>QIO3!'#ECNE9PB[H;2&K>\X$-QWTL("!]X' !NW#_X,5VKDYG\$
MJ-)_M"[)MR$N)NMD;)AYX$EI."4@^:A_4426U%KU?J;O7<!0U:B>E"1_%K='
MN#3>/%N*0'4GW\\>U<,)>FCMV^J_DTD"X]PJTZRBNGO6%_!RB>NX<!9]B,?J
M*X<J;BT=49+S(L^G?9WK*'K3L*+C4HK7\&J,LJ()2ZE .3]<IK5ZF./314CR
M=3I)?G6X_J=(TYJ2"[IJWSY\QOO/AD)<"3^(#!XKTH^,8<.%6SRLOA>5YVDB
M="U5;;@Z$0B5C/4IP/WKEC^(,4Y4BY^'3Q1N2+!^>VRG>KD'TYK?+KU*.Z+,
M%BLBMW)R02&F".?Q#K7G_P"(:E/TE^4EV+4\^D$"&Z?UK:>++MLARC=&(O>H
M9L.2I+D?NG$*RE*N<BOA_$-?ETVHBF^+/IM#HX9\3:-M9;@S<X+,J/@@)&[_
M (J_1?!-3#5X+/F-?@E@RTRSR>.GO7KI)<(YG8,^U AMU12!C&2?,5,H[O>@
MN2^D:<<6V,K6T@>YJ/,QX_JD-0RY.D5TO4]AMR2N?>HC6.<%T9_:N/4^*:/#
M6^29U8-#JI<;69.[=N'9_ )2;G\0H#.$)S7E9OQ/@P?Y2O\ D=\/ ,V?Z^#'
M7/[35@CJ+=KM*W"!D%Q..?TKR\WXMRY)5"']_P STL/X9Q0CZY&8N?VB=5W/
M#=H8^"WG@H1G_&O/R>,>(Y^8NOY_\G=C\%T6/ODH)>J^T+4#BVY-WFO9/1 /
M^"17)>OSR]5N_P!3K4-%IU2K@D6WLQU[?' ZBWSQN\04_E*3GSYKHCX-J,_,
MK,)^+:?#]-&ZM?V?;C(2%721%C$==B2L_P"-=^'\-YD_4SCR_B'$UZ$:FT=@
M^DXZ@N:],F$GD =V/UQ7LX/P]BC3E['D9O',LN(FRMO9YH^SI3\'8HVY)RE3
MB>\(/U57J0\,P1]CAGKL\NY,N&XD9D;8\=MKW0@#_"NO'I,6+U)'+++DR.FQ
MX)4"#O6<>5.,XVZ0E#Y9G]4.MMQ&$*^5:B<'UKY#\5ZG]A%3ZW?[,];PK$O-
MEM^#*2;BWG*4C@8K\^GXBL7TH^BAI7+W(2[P\5A*$@)\^*Q_Q+\Q]:JC5:/9
MT$Y++BAM)!Q^E<^3.W])K'&H]C92ZI1+BST\JR\R;[*2C=H@3@@,NDGD)-=&
M%S:Y.C!%>8CR'V@(9?UW-=2@%2>#7U>E<EIHGK2@GF!#:6E1PG:/:N'.W9Z^
M!)&OTG:79FH[4WWA^\FM 8/]X5RXG<H+[FGB#\O!DE]CW.E:FIJ2I9.$]#TZ
M5^OM5/&G\,_!L;WK(_NC%=L^FYNIK+;[1#&]UZ25A1'RD#C]*QU>%(ZM'E:;
M9YJNECFVR:[;IS:DNLJ*5YZ$>U<"Q19Z7FOLK7K,TOQ%O-1+3)FD=0T5TK3;
M"_$AK"JYWHU+AF\=6UT4=YTNTY%4'6"O&<'TK"6BV],WCJW+LX1?Y]WL%^7'
M@+>V D\'IBM(:5T99-5M=(T^F>V/5]A*) N$AI((/#A'^=.>FE%<"6:&3ZCL
M^E_MAZI:92Q(;=N3J#X4%)62/3BL<6348GMB^#+4?D5#U]GJSL5[0YO:/;UW
M:XZ<-J?:1M2GS*3U)->MI=3EW<GB98X'']FSJB.Z;1X'4E)]Z]U.616SS]FS
M@Y5VLV"[:IN,33\2>\S;WA]\&5[2<]>:\;60D>IH\\(KU'"M<]A7:=89(>T9
M&%TMZ>#WJL.#'O6>/49&JG$Z9.'<&<X@]IRV+Q(TE>[!+C7&(H)6$M%8_<5T
MK'ADKD9>?F3I&PCS(4M"WTOI; !)RD@XKDGI<;Z.]9B;#GO- .0Y*5I3SRK-
M<<M$HO='LVCF3X9SSMA^T5'T^6[7(9*G-NTJ0C(^E>OX5JGAX9YOB.@696CS
M5(UUK;5.J6UZ/+C9<..Y'"2K/I7=J=1&3WLY])I7#TGH#0X[;XBHT>ZV=X[R
M 2V">:\'4ZO'[,]B&E^3L"AJ*"$FZP22I/1:>1ZUQ0U:9O\ EE'H>BW6#O"G
M8[C*QQR.*T\ZQ>704^!!O#B5-O%:@,#G@5I'+%+DRE!M\#$71QC24R%]VK:=
MP*>M9RG"0TI(KM;VR3<I2 &EJ0C ./3%:1T^+) 3S9(,K[!HYI=S3(=CGNTF
MN++H4NF=.+6M]D;6\N?'NR8]JPEE/' YXK..FG%<FKU,)/@7I"XWF\2BVX-K
M*>IP<\5SY/,QU1M&4)HO9-^M,22J,_A7NDUTY-=E@80T6.?0MARW7($P0HJ'
MJ>*Z,/B"R>F?N89M \?J@/KA/M[>X=2H#YD$UT-X9=,YTLL>T([N9_N4?O4>
M7#Y'OD>N D#H*^[MGQ@K/&*D&[#2 >M,02T)XXH&(*/2BQIBD92,46+L2I)4
M<T;AH6E/A&:6YE4A80*-S#:@;$^E*V&U V)]*+#:A'=I'K18Z09  H5O@322
M" 0KA0)'UQ5.$O8E2B-O1([R2@-$A7S *QQ0E*+ML'4^(GGO7W9LQV@3YMV$
M:/IJ9#5W$>X- LKX/&2D95D_TKS-3'))O:>MIG%)*3. ]H_9KK2VSEVK7G=0
M[@\@-0;T](4N#+)'@0F0!EISSV.>$],UYSE/"_7[G<H8\GTF%,CMZ['T]WJ_
M1[UUT].04(N:5%QDIQC<'&CA!]CQ6JGE:W)F3QX[JO\ 4Z'H'M=D2]&VVTV^
MW/1GX)46YT&]E@[RHG[Q"@01R.:UCJ]JKW,Y:1RE;Z.D6+M9[78TX-&[6.Y/
M?"J>6]*6=R6MP&T.(&%'/J*M:C+/Z63+2XH+E&5[4-;SY\=UZ1! E%2B3WFY
M6_: 2#Z9KR-6I2S/>^3VM"HPP)P1F-+*4+,PVVM9*&BEQ)5G.[Y@?45Y^6;Z
M/5PQB^34Z;AK_L[=)KJV8[2G@VV"@!/= <C'^=)5:(R2DN$5DB^-?V;D&P*,
M:$X2$22<J)'45KYCBZ,XXU-6S)3)3\33+%S65N.&0AM>#UR1S],5DYN4J9OM
M4$FABZ1V8$.=<1DJ=0$HY^4$<U@TI-)G7%U%LYXQ-CR "PI2(L>.M\Y.?%Z'
MUK7:TSF<K//>H;N]>;O*F,("$,K.XN\@X]/2O:PP44>1DFV[1K=%::N%PN-I
MML9#2C*&YQT#*D GR/E499J";'BQN<DC<=K4MG^T$+343:N%98Z4A2N05#YL
M^IKS\5RN3[9Z>1*+VQ]BFTNY_$BXUW)[E33BS@]$@CIZ5MD]-49I[CL/8IJ-
MG4,FY6!HE 7!.Q1Z$))P,UR:K'M@IF^FR.3<47^E' L3H2]@4U)0K"3GI\V:
M\[-SR=V!]HRJKNU9]>S[5)4$L7A>U"ST02,)/[TH)SA?P:6H2Y]S!ZUL[T+5
MD189Y"RPZ<<*R#FNW3Y7)4SAS0K(8*]:=3/C+0#W;^["T$?S$#IFO;P9>4>9
MJ,'#2.+ZGTZ;%<&I5N:?W/<L*2UD(YP4^U?08LWF1VR/F]1IG@ENQ]G5NS35
M<N=>(FDV$&2Z5)7+8W;=@3\RMWIFO-UF!;7(]'1ZAI[&>CKO?&++IR&^RZA^
M4ZM,-M"N$H3NSO\ <)'6O,TV/>VEV>AJ<SQ*Y]'.U]L-DN>L)-KLEP,A5I2%
M2G7-P2L@X4E)/!SGBM9^'Y)+DY\>MA?I+K4%R7K2_1+;;'$0G(J$2%/ [N\;
M/5)/X2!^]91QRTT;9U.<<\DD6+\-B5,2(C24M(3L0@#ICJ?UI8U3W>YLW7"-
M-"M334)6]K@BNARL%&N2H?89"BE(P$=.::93CP0WW^Y'B6,5LJHQ;HJ[AJ>R
M6IOOY]P2V.FS'/UJHX7-B\^,>R+"[1=(R"-]UCMXZ;UX-+)I)7P5'68DJ.@=
MGEVL][GIN46:R[%CJ6E:S\JBE/B ]1S7F:K#*"X-H:B,G:-MI6>TQ=%18K@Q
M##3JT@YV-JY"3ZUXN;'*/J?N=:RJ2I&/[:KQ%TGK=*)Q_P#-UP#3S>3T0L\\
M_6NG21>:'I[,Y98XY\E.R\R._<@2T*<#R4,/'D$@Y(]^*%&29N\MP:1W?3\X
MW.*J>HI4]$4EH*QTRGD5I&#DKD>?.?ESJ/N/Z,D.6NPWK4#P*BA2O/C&>?Z5
MIMNCGR/FSQMVVVT1M;76:EIPO7%9>A+;=*4EY &].1UR"E8'IGTKT<+I)&,U
M=V<Y[0I%NN#,*[VJ AMQ^.W)>2I7A$M"=CBL>I(KJQ-],RR)=HR3L_=.BRA'
M#4AZ(7 \TX0=P&#^F:Z'%./)C%ML[[JVT(NND=$7F3*3'N2X:4MJ/ DDIVE
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ML- D JW-I*TJ/0XYKA<&Y;))4?2XFU#=[G.]9Z>[/M+-3.T2? 91W385*6$
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MZ%=TJ@ TH*>M !.>5  1T- "MH/)%2S6*M!@ < &E8]H6!Z4!5!T "@!.30
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M?0"N+(XS5]'9Y>2"I<_<MY5TC/RG+4S:A5<4;O0F\%%0! EI:>D&Z0:E&7I
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MK%6NCO"F+BRH)^]&\=;/*= B--<JJNC,(\JC]-#R;/I>+>9&WDB3]29U$!S
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MCJKS;C7XYD8: 8<KOKE]W0.#>,)'<&:FCIZ;U!LD>64*EU&]BHG0<?CWXHY
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MA/,R>,6#\XU<%HF3SH;#Z([?WJ-7P@YW3+&Y>EK0\\FL3*QTZ;/R7R=455U
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M+CZ"BJ/)\[&9?EW*"%,@;4VY#]M&3T2K:N]2OZOVTLS,*3(6,:PU?7@(7ZC
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M,:*'#Y8<"/Z*!LP$%D3VC&T;>,Q+-!N,2S EQCH$\?$;-R>,UD1")W*!MJ/
M>SB5P]:%5/43H'<UA9I5)/#UMX5&W&PGJ7]0OWN9XXQ=(*5]0\IPE8,[SH=X
M?"?,.M\W9\^UW40D7BJ(MF]H/K"-]4SOJ @%Y/>43"CT)#(^9RBPY-B*IW/K
M4[HJ.KM"D6ZOI6<,#&P1SH@OE<V(</[EHY%Q)WQ;G;&9Z88XW]%MJ#*VLP\#
M+4FQ=+&ESAA5W$']+7]=E!W77@W]D/ J7#TIW$%5V3>M#?:O$OYM^:NW 3JJ
MX:B]>0)TE=35ZXC@3-MQR\*N0ZUUOK<GE24>W^?WP/1_S^Q8?VVUR)VP=X[C
MTY&1PF86*.O;I?UI01EGOC*YHH4'#=!-=/>>7FHBE/#\-M&P[E0NV='")P02
M/KRBHGA0&4RTM@O3.]#N#"OZ?7I:[L)+=B"]FM_4'1W_P@S%V)EIN13\Y7\>
M_D@%AP#D[]-?L@"47GR[$4_QC ?@WQO'3M!,G3X!0B^0,JO5J6IG.B?[PT.D
M(G-J+LJ]4QQYRT8H5MF4+P,.X+TM?8S5?Y$G1A,B^ *%"N7M&1/G(E:/)#&V
MSJG%^WM [<6+?(OD,)7>N.XJW8>?TR[KQ@9XO+6RTF(!)_KP:V[%=*%OL6)X
M"T\ 6._QIY-"=H1GB>>4SU=W "BW'X\80(Q3G7Q'5BZ9VN#B)F_=E]G&'ML\
M_\.O>=[WF6#F\TP /@N *#EA^YFL':8"JV %I4H1UC/!!PL$<L7)K!;UZ(54
M_-NP,">1:HP13Q/4Z$QNG+U#DQ]@86]Y\9I4AL<^S-56*"D1.QZ[/L@S=KIE
MV](X [RT*X:ULX&Y&EV^8J%U,#UF%W$\(VP<X%Y M5;D/B7*@.3R\7<6N F(
M92>?F6?;(&@TM+/6*R;KEG/HN$OWU@?,&#XL/#+^8;V55TZ^%D[1O?WYXD^Y
M6*EYX?F(D+N(@J@9UGV2*-MR5/7QF60(-4DXC@=3HR S0RLGYQ- 2KZFU5$G
M)HEZ]@M6C *>=0C_7/@A,-MK#6JP0!N7WV@M*"PN0%-;AI(2F-C7T-L/X?'T
MOE/RRFU6;;NLM0_.O^!=&S&K^ZOR.9Z\FPX(5> J+T23;*S/Q0@;CQ1W\<;(
MDO)*7X'G'.N$V\KV.Q>X515?-?',6D]1_=A<#M@J@Y_(P\(M0>^ZJPWBG@!F
M78K7#DBP]LJ9):'RX?ZY2_HDAQ[=NE#\&Z'<+=Y;UY5_?V;OX7*G_ -/@#!1
MX3].1!,;LU.D8Y"[DM+WQC&B\5><-FH\K4A.5G3#0U<R6J[#L450 ?^;4;$,
M>G&N[56CC+)?U6 XKZ/(/SIIL4MXU^CD6?7LE*1-$C4V)T-]*Y9]#Z(\/PQZ
MKGDVO+J;U=%7O.>7[QFBU#EYO.??S3P#0+@>8.0Y,^[IUG,4*)!Q:4BRVM.#
MS&+UWZ[=(HR'&C-RO"FG#+NS5L^.)0/S>1[2<.??D1- 7BU>+KM=]4+.T-BV
MRI!A5+HF/:AZK7W]KZX'W^1'766FKOR\?HNOT;4MS!GNTVYF;9?Q_OJ!DE9Y
M[I(5"R\F%,SKZ)96R:IT$+W$XTWA:)+S=.P\=QW.CTMS)QD_:S]-6[;TB<93
M-A<760<PUMAR"A A(1>I:6.K#++0BNKTD&>\14YT.'$)DX12CHIN2CFU*\3X
MG]6P5199P0[SD@WEQC#=4X-\8J_K'9VFN1L*!(S/P@_1:-A&0-1N6F?Y^L92
MMS7>-8:X=,$!_#/Y_I'0;I769=QN_0(_N/)W[2P&'D]"A_3[9^'VXZT/?"(-
M5W-G\R&'_741NED)JC]6J4'%4\?7ARZ(VW22=]A;Y^7JT,7M,_3OIFR_M+:/
M$'@"-8WUG:*<2CV'F/7V<QW/E9N5<-C6$R#$<7(7.2KVPK!UZ G@E>K:1)O<
M)CHR2L!77O<ZOJR72V+MJZ3P74SF#MA=U8Z/P4%QNCTGUH)VN,Z@S"MS,:]A
MP>%@14IQJ:$-&ZK('&6'C<8H?YDW_W)??DXYOYHZ:+-TDUK,:9Q:1E;' 2(^
M0F-\H[(?*RRF8N%JV/I\7@_Z(68B!DUOQ.9TKJ2O,OI@W\.R6!3%:R*5;%]@
MORG;<!09J6TH$5O="H/:.8"I\5B:]K4A7">Z4PMQ,A&U;T<HK=M4JU9VPM'Q
M9A/$)4[FB9S?ZOZ<FBC*U9N]8/V1X* I:L(F]OY6333@U94F;H_)0NW26^O2
M3X2G,6/*-"'OS_JWZ*=SLJ-5..EAI+'V<N_79@(;S@H9/HUM_].GB!-A(\_F
MAO4/>]H%DH2\6>AYH_<%I[?*'2"D;F6JOO(=;)?'Q27]OE0G.8K]G..WQ5QQ
M:A)N'MM$;3=K16ZAOJ)601.1U VVH7$P9WD\":/X\>ESCT9.FL(58USG4I4K
M.CS+R(E?8?!#C+=1KD9X5?C'/C@JH]]'MRQ#YQVOWA:4E]$E,GV8L'6*WW?V
M</!.SQ_/EG/Z9J0P9\QNFXQJ"XB14.ZTLX]=AP--&%CO>/,Q.0)8?W\*?@,.
MFZ&G@K(%U)*RO9DTU:1UP;8W=D1:/O>MQ%[,YA+=3@V,XE=B"A##%P3C?WSO
MQ$KVL%VI=-'2,F*GK147K)3;,.("D1[112/WOD5\&-^^$[>7Q+XV)7MF/A=%
MF+4UQ%12RT;V!!@B&+B&_VT/J!NV9\,Q8-/K+LXBZ^%RGW8,C<E&"YE5>H_P
M_VPZJ_ZS0Z8 ^5J,UV'-A]Z>1_?3_Q$_HS*&_;T.XL>V 8]N<]E&4+T^X#>(
M#$F9_9%(Z_=YM-;5E\/S]/,FF J6L]K?HHIXI&<X/?Q8(YJ-=-D/:Y'\M_?)
M&O_/;+IP/:7Z8X;6RI0A' 0;%*YIM%7XURG,$5S[BG!IM*DQ/P0_BV]'<K3!
MEUAQUU&'JW<W@;N-7.1SGPUO[LL+ZL;&S[0R%I,%+\P"<^(>[P(1@H;'ICG3
M_F<G6J#B^:F0FVG-TFZK6B'"]N38^]]")!YW,Z/F7-/F<ZO7"2+7-,O#+UX*
MY0I=)SRS8R@UF@*77\-F=&O!?>CS3HC4$$7"DLWHR([QAK6T%V&JA2XI M-'
M^0[&W=',D0*Z"(WVF.58@SI3L'\M[=$*JGF63M3.@/F AUAFSE=\+:+_:O)@
M(/::LW8YV S6X:-DP36?VZ$L-^L3YN!MPN"^XE2FRP0.8I7>F3:,1 A^64W\
MZ;68BK* JC^/:O_T><!G2U\\U-N,><BTEYTS8LMP*8M:A-VB^&]IA4DY;DGL
M%5P4//BR8FH%JD,3'+R;P-^_/_R7DVX]1:O1@TX^RHVEG$A4I B9/V&R.-12
MD"O8*M-1QK!]OCLP=TDB:]32CS5?&[ ]R"F\/2A?55IV\I'!%PNG!YYEINZ(
M< RU&H&$UGQLQD-)GXG@V53EL0S#JX25%J)P(! %SR*JJ92218I6D;R#>S%6
MFQ7F3/I8G4;4,1PWL3\G]O//DP -/!3YRHICZ.J&J#S_X7LR&U! 37CBNWZV
M;3;5&^Z8%6_>VKPWM5$+%B:,4!IG<19K^J(JSV)9A^VA;H]4M)I+4UZ*.V?X
MKSBP%2NG+K$XOM\DEXC(GKD%BM/887U2DG;\/[4;L-:J(IG^UC$(VJ**"W =
M%F-8R1A^Z5[@W.WTJ.AL(\!84FSWNIIS(K7A,B+_+BZNV]";VAOB*[LC(OPW
MG,%LH#X!2>$OM^%>$I.(I3!9/UB*K&5M2NCU\0TBX>7.;1C]8]*@$OQV&_%
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MVZUW.\=IKDB-#<4AN*VP" >1@D?UK\R_$.59LC<5R?IGX6RX]+B6]_WR8_\
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M<>>/*H&9INW*CD+0ONEGKY[??'45+ M+?.5'[I32^_CH<\<A22$J(\^>B?\
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MCIUILO/:BA)3UR7$CC]Z?^*Z;V8?D\_P1K9KS3-]N+EKLE]8ERVDA2VVEA6
M>AK73Z[!GR;41FT^;'CY*S7':YI'LS0E6K[D&$*("2!DJSY?UKS-9XM@TFHV
M(Z=)X?FU&.PW]1V?4UL@W"W/J5'DX>0LI^9"O4?2OSW\7^-Z;QC9IWTI)/\
MU/3TFCGHG)^X6H-0VW1UAFWF,4XC,+63GJE*"36VJ\5T'X<\/<O"E>7:OYNO
MU'ATV7Q'+MS='F3L;_T@,;6^G93FH]*3E7!MY:4*92GN5)"B!].!7V#U^;#%
M._9&4/#8Y7P6>I?MSO0E):@Z.E%2C@%1&,^]8OQ3-/FS=>&07#"C_:X[1;E%
M2_;M%P4I5_M''OE]\5A+QC,N'+^_Y&T? <,NO[_U(DS[3O;'(!0U#M<9)_$E
M&XC]*PEXMDFJMF\?!,6-[O[_ *E+,^T'VWK6-MVC,)/XD1L'^M0M?D^66_#\
M75%?/[8>VZY,C?K5]I&<_P"KH"59]SCI2EKIRX8UX=B]D9NY7KM"U T$7O5=
MUDI0=R4ETCG]*S>IE['1#28HE7_"K[<5D2+C<0!@%2Y*^?ZTO/FC1X,+),3L
MVN$U]*6X<V63YD.+S4.6;)T-1P0[-Q9^PG4+T8'^S,K85'_XF4/\:C\MDEZI
M)DRUFG@]J9G=9]C4VSSV_BK0Y%0H Y6@C=Q3B_+^I/\ U"\67F)EKKHIDQDL
M_##*1CS%%Y&]T>BW#'5494Z,++BOAWI$8Y.2VXI/^!KKQ99KLYGIHOH)V=V@
MZ?1NL&M;FSCT=*O\<UO',GVC/)IH5PR^M/:GV\06U/1=0M2T_,0ZP4@X]:K\
MQ!<&#T#?*-78_M:]KME6E-^TO%GA"@28JCG'M6BS17*D9RT<EW$V$?[=S*0E
MN_:"NK6/F6AI*\?IBM/S+:I-&$M-729<6?[:O9G(N#,B5WT-?(*7HY:(S_>Z
M54<LC%XVO8L^TCMOT3VJZ%FZ;M6J(H5<&RWW;;V5D>X]*,F3S-JE\CQPFW1P
MC0/V-=+/7^+J%,W<TR.\++!P%+SY^@^E? _C3QK4Z2/D8EW[GU7A&+"O7D]C
MTK9;[<K"&K!'#I;86AG"DDX3G Y-?BN262G"$N9--_S/=S:?3Y5++)='H*-:
M6)-G1'N;"5I60K8OD&OZ:\ \/F]+A>3X7]3\PSZAX<\IX2]A-"+&0PT$I0CA
M('0"OM-L8^F/1Y4YSR2<LG;'CR03Y4$G$>U_3 ONLXDV/O$B,VD%2?(9K;PW
M.H9YW_?!P^-::6?!BK^^1)M=Q@:BA/RV5%I,?8EU2>F!7FY[EK'(^UT^HQXO
M!UA]Z_V)4>8Q;;>_)GH=5'6LA1:Y6>?2O>UN3!'&M_PCXG00S9LK\GY9C+_J
MJ/99C(TY<)"6W!XMR2?\:^9S9(O_ "S]+\%T6';_ .K7)<P-42;S9&U2YS+Y
M0X1E?"L#/2O4\%E+):9\K^.--BTFUPXO_LT3NHKTW:D0HL9E3+B0-V[D5K%2
MGJ'?2/.S+'@T<-GU2_X0F-VD,Z7+<6ZN..NJ/BV)' ]*Y=7JHXY;3T_"/ \^
MJB\I8RM=+N,EIV$5(BD9.17=IU')BWGC^(;]/J?(D79U7&2RT6)2<D^-)(Z8
MKEW^MH[<V#9B4A^X7Z.Q%:D82I+F?E/I2C#SF_L8O]E%/Y)4*_M*B)?*=J/6
MIE@<1QRV3HLUMXAY#W>)/GZ5-.,;-;W,H>TVZM-Z+O(.X9B[05#PG)P0/>N#
MQ/)NP-'1H(_MTSS!V=7&+;-5,/R%]V$K  <'0?K7RFCCFEDVQQMKYI_\'T^J
M>+8]TN3TG,U-I9$=,R?J2V0VU)!'>3&T\?3=FOKGH]1*%K&_Y,^5D\-_45'_
M $[=C]HCEI_M$LH<0HA01([P_P!!7J:7PC7M)J+1SYM3C3*]W[5?86B08*NT
M&&'<?@;64?\ ?QBO3?@NO:NC"&IQ#3_VN>P: @MC6)>< _V$5:\G]!2P^ ^*
M9/K5?R%/4XT<^UC]OK0D%+L72=BE7-P)(#CZPP@'RSU.*];!^%-5)IY7Q_ Y
MLFLQJ+VOD\UZ_P#M<]K>J)OQ\:\P[ H82D6]M 6H#IE:@3G'IBO>TWX5\.Q>
MK/&W_?W.*7CF?$ML3%_^49VU?_;(O7_RXG_E7I?X'X1__;7^IR_X]K_C^_Y'
MEI^Y)AEFUVYQ3[AX90I)2-PY*N?PCK7P)[A7F6_%<,ER0VM]ESO-BD;E;O+Z
MJ_\ "F! >_B-W[R0W'^'=4H+2E9P5*]2 !P/2BV!/M]RM-DBO69LJ4Z$J=ES
M-I.]:NO3JGT%%@64B9*O$>':X45*TC: \GC*D\CPGI3NP**X6V7:Y[BI<EM#
M.[O%OE@!IUST _#Z8_6D^P['9"8(8^)A6>2V\\K<]WC^$$GJ-WIYX%( Y^G&
MT,&Y,AAI+J02ESC"1Y@>8_QJA%G'LMLEPVK@])DMX*4!;A)<5(]-B>K8]J=H
M5B+H;V_([MI]EV7D-JE$=VA#7FV KY3YD]:EE&=GR)R%/-!A*7"<J=;6,G'O
M68%5=)"9K*'6BXEP^!\]!@]34L!@NH=7\#]X^TI*4K0E6"H#RJH@;:V7RS_P
MIDQ+<9$GO2V6WE%2.F,E(YXK5- ,P7D!X)FQP!(<4VZ$%*>\3C@9/B2*; .(
MS;W"DPGG$M1=[;[1WXY_%N' ]*S92*B3(;CMO(0^E')"R$+(<2?E&3Z>U8LH
MBQY$-$=3#[:2H=3CDCRI6!%C2HK95'9;6$%6X%?KZ"@=$AU^3&:,@IW(40E*
M$MY(]S3"AA]^0J:VRZ@!!')2,"F)DIQ,CN$,QGBEA*_$GU]<4"*^4XE@]Z6.
M]!.U25#Y!ZT^&3R1'VP27&G-J5=0/.D#MD9F('7P&V L ]:4G[L()](V-EL-
M\E=XXAMV:ZKQ%6<J2/8^5<66<6^3OPXY^S-YH+2]T8,A*;6\PN0#O=<05';Y
MY.>M>=J,D3T<&*<3H5HM,'0]LDW2<IQ$=2,%Q1QCGA('UKCWSU3\N)T*6/3K
M<T6;^JY&HNR.5=X3G?+CN/QPI:O!M5P L^GE2CC\K4J+-<F7S<%H\FZNB.-7
M%"I49#?=L)96A*LI!'0#U !X-?3Z=-'R^=^HK+:_\'_JSJ-V3D$^5=!A9>Q7
MH5M5\0\VY(?=(##>,IW>I^E2RTZ)%SU!/F@,2GE.-H5@<\;O,BH<(MVT5O=5
M97@DNEMSEIT9.>AJN$05\R&V5*4A6,GK3$R-(B+[@.)4<)%"%2&XW>AE*&%J
M0M"PXA23@I4.A!\C0TF5&3CT=AT3]I?55A;;MFJ8R;W$:X+A^[E)/J3T77)/
M21]D>AB\2R)^IG7]/?:![-;Z^TR;XN!(5@=S.24)!/\ >Z']*XIZ1WP>KB\5
M@^&=#MNL;&^WWL:^1'TGHIJ2C']36$]')G7'Q&/R'<^USLVTQ&7*ONJH/@X[
MAMSO'2H],)'!-<TO#YOHO_%<<%;. =J_VN+YJ:%(L_9[ =L]H3EIV6ZO$E_V
M21PG/7%>EI?#X0YDK9XVM\7GEXBZ1YR5/67RX^GO"M1<)6=RRL]2I7F:]38D
MDHGB/*YVV2OB;>M*6Y#*FTG)!1_6EM:Z*4D."';4I)AS%J)Y(5ZTKDGR5MW+
M@-$,E"W'W$I2GR_%BFV)</DT M5@G6N$\R^\R'N\9=)X2%I\0)_2N9Y7YCBT
M=:QJ<%(OM"Q+(+U#0]N6ZTZE38924A1.-J23P5'KFB<N>2X8U%<G3;M=8Z>T
MIZ(EY CSGG(3\E*LI0I+> A7DHA7&1TZUSZK%"<>C739G&;5GK;L.[2(UZME
MKTC=)ZS?XS(;1WB\)+B#C82>=RD 8'0]0:^3U6G\N3:7!]+BU"R12?86M'';
MG<7H[;?<QX<HLK6/Q;CE(.?U_6N?,G)6=.FEY;IG!.T[4427J%G3NG)CC_P"
M@VZOO,I/FI0'MTI8<+C%RF;Y\RG+;C]C-ZD?9MMF>5/=*I!6$H"3D)!'D?7V
MJ\<;=HF4ML>>R7V<]G]PU.D/K:RTELNALKVE0').:,F;RWV1BP>9V=*LMLCV
M)"D1(X;[P[>1E21Z@^E83D\G;.B,5C7"-99DN/EV1C>\A!6VD_B(_%]17/.'
M1MCG1VOLAU-8G(>I+!<T(>CS6$]QOZ?%@9!'HH'G/M3W;4<NJQ3E)2B^F6W8
MU!BM]HLBVWV:B9.F0URW'Y)W*=:!QO)/EC(IX&YRV/W9EJO3B\R'%?!Q_MYT
M7<>R22+]I*UML:'O,YU]GN2=X0KE)'MO"B/8UV3QR4[?\",$U/%7==GK'L(U
MN.T_2-O96_MGPHJ%)6DY[UK&$Y_2IQZ>6KR4HVT>=K8K1K<I4F=I9CO&,AGO
M4J4E(2I2#YBOH\.GU.&&V?7P?/.>'*[B^20A@A"6TJ.Y(P3YYK=:;,ENAPG[
M&?YB*]$G89MH<6EY]S>E'0$\ UDM.HO<TK*<XR5!F5W;2G7MS2$@G<KBNS4S
MPX<3R*71CAEDS3VJ)F]+:TBZR9N!M\YESX!TQU]VO\7U\J\;2^)2URDL7LCT
M=3I8Z=Q4EV>9>U#[3W:[H+6]UTE;[!;Y#4-T(2^XX5JP>0<5P2UNHQRJ3/3Q
M>&PS0W11DU_:H[:[@T2EFW1UGIAKI7)GUFIO=N>T[\/A6)*MJLI9W;WV[3VE
M*>O4*.">/NPD?UK/\Y.7#;+_ ,-A'NBK;U_VOS\K?UH\C=_NB /\*)9I3XIC
MAI\>+G@;5([1KEGXC55W=].[41_@*S<I?!ILQE<_I77<IP)7.O<E*NOSD#]J
M+D_86S&B2[V;:^FQ>Z9M]Z?2>/D<./:JBI_!$O)^QV?[('9AJ;2VK;C=+S:I
MT9#S.Q#CJ5#D?\5>MX6[U"4HV>1XG&*PN4)4=?[<.PV%VT1VXYNOP3D1:2%X
MRD$<X%8^+^"3U.I\S&B?#_%(:73[)KW+"X:;U98-,P;3IB%_$)++:(Z7@0E"
M4@8W$5^>^-?_ $\\0U#?Y9[>;X;7^QTZ7Q;29<SR9[Y^R,UJ/LW[5]4:;E6"
M?=K3'3.;4RZXE9!2%C!S^G%8>$?_ $\\7P9-^>6Y?=WU_ ].7C/A.)7!2O\
M1?\ )SS2?V$&M'6<VNRZDBI2H[E$-* SYU^ER\'\1R5NV_S?_!Y</&--C513
M_O\ B3'/L6293[:GM81  H9PPKU^M)>!ZU/G;7ZO_@;\;PM=?W_,V\#[*EBA
M,L,OZ@?=+9\7=,@9'^5:K\.M]Y#!^.I?3C+1/V8]& A;L^Y+ ]DI/[U7_P#'
M8Q5[_P"79'^.S;KRR4U]F_L[2?OEW1T#\)= ']*TCX%C]Y2_T(?C6;VBO]2T
M@=@W9I&.U-HD+&/]JX2#6G^!X(\MM_K1E+QC4/K@N(G9%V<13]QI2&HD<]Z@
MJ_QKIAX/I/WDCGGXIJW[LL$=G^BFP C2MM '/\@5H_!]*VMD49?XGJ5]4F7D
M*VVR,V&XUO892GH$-@8KI7A^#&J4$9RU$\CN39(V!"CM) (Z9XK7%BC!;*,W
M;>ZS)Z\TO:=30C#F]T'D@J:WJ (./*O"\7C!.H\,]/PW4Y,4KJT>/NTY%NT0
M])_C3@9/>%#12-Y7[XKRM-&.5[;L^DGGDEOV</K@P3-WLEQC[Q+\1&>4J!_;
M'%=*P0C+HYEDS3=Q="'+?;5#PN(.>:4M*BUG2'6(;8CX">*YY:3G@UCJ*&%6
M7X@Y0T,GS K)Z3)\&GYN^P*T\$I(6PE1]QFL9:6<>6BEJ(WT1'-&V=\[Y-OC
MD^[8/-9N.1=&GF0E]2*>^631^F(3MX>;:@N1_$E2 $'-:X(:C)D43GU.HT^F
MAYLET=7^R/VB:-[1)\NW?QI3DZ$Z5"(04Y1T!]^:^(_%VAUFFUV/-G;EB_T(
MTWBNEU6&2PTIO^AZ[B6JR37(Q9CI!*AO2I(X(/!JO\%\,U.?%+%BBK^KCOJK
M_0\]:W/MG-R=/HYU]J'M&UKV;1[4YHEYC=*>#+B7#R3GJ/TK[C7>(2TOBF/2
M8).,%!\+J[(\/TRRZ>662M_<[38G[E.TQ;Y$@]U,=9;<?V'\12":^ITN6633
M+(^V>)G2\UHM8[BN[6EQ1*FQDD]:ZX2]#;,Z1R_57:_V?Z0U.(^J)K<1]P;4
M*=X2JO'CK7BSRH]*6B\W#$1<NUKL[O-J6J+>XC[F,@?$@8SZ>@K7+XE!\UR1
MCT&5<-\#6C]2Z1N2\1KG&SC! <!K9^)X,M+(K,H:#+I;\GC]#1)TQ9;U(#BV
M8RVD]$E23BKC/3R3VI(IZC50:W2;HH+WH")&>4U"A-!DD[0E. "?.N[PR2P+
MLX/&<N3Q-KS.4OD$[LXG1[,J1!G+5(V9:&[^6>.E4Y[-0I)^GW^YG+;/1O&U
MZTO2_=?I_ RK&B[^Y(9?O 2IOQ;W5')R,X_K7G:R"GF32X/L? O%_P OHI0G
M+U?_ ++MAJ-'BK0^A:PD?,VG<JNO/J9:'"G!?P/FL,(>,ZJ7F2I]V8C5EV#$
MEMJV,3#NQN&TI %>;/7O4_Y<-I]AX5X;I=-Z==-37M=?]%K8M0O2;.KO5+4
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M4&B+QP)S:5)QLW$'%<\\>++)2DUP"P:A<;'_ "+MBXL.N16(U\3W:5 !M"<
M&T#DOQN_6NBX?)QZC!DQ_NLU,23WTEUM39;">/$<Y]ZZ\3\Y'GS7EJB&NUP(
M[[]W=3EP C/L*PRXHP^IFT,LI<1,G=.S7L]UGNN5VM"9#RE<N)60I)]L5FM)
M&:W;N_N;_G<N/TI<+[&;G_9GT*Z"8"YT=77QOY%9RT#]I&D?%/\ R112OLM$
M\P-4+:] IHFAX)=46M?'LS%Y^SEKV!]] N46Y>J>Y*3C]:RE@FOW6;PUD)?O
M&2NO93VCV]"UOZ.<[M*25+;2%%(]>*Q6.56TSJ>6#ZDC/FVRH!+4ZS3@X./_
M $=0(/ZBG4&K;X$LG/ S?HFD=,Z:7J/63,COW]R8,#D2)+@\S^5L?FQ]*]KP
MG\/2\1FG)>DYM5KXXE2:L\[:_P"T:\7Z8&FG6F(S"@&(C0VM)''"?4CS/6OU
MWPWPK3^%XT\:5]'P^O\ $<FOE^73I+F_T.:*NP8NCJ'5%3Y9PH$XVDY'/MBJ
M<E'(]S,5F48[&K^YGY$M#S*5.2H[46.G"4J95@'/&".5$GUXKEGF<NWPB8X9
M0DY-W97JE-OELNJ"0%%L,(;V\]<8'XC_ $\ZYI3OLZ%&ADJ86ZDPI;NQQ6%;
M@-WN$YXXQU/ K%R5\,V2(4J2E9$9M3ZU.N[D[5 E?LA(ZDG\9K*4KX&H@0R&
MFW'& TE;*3M2%[MKA/*4_G<Z\^](H;7$>;8#(.Q9\:TN#<A)]73U)]!Y5#^
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M@^XTCG=*4-H!]QG/Z5QX6L>.Y/EG1)/)/T]+^I>3H4U,(W/NTNP(2?A5R=X
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M\CDE2>H]1Y >]>QARPTD=L8GE2RYM8O4RE-\M5[9+=QLD1"6]JG-N0%$G@!
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M./ZX\@ *EM(=6(=5)6E*R6V9<L80E1)*$=5''J.OIR!4W8*(T]([M)"@XB!
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M1&1.2!EFX2ENJVN%2<\9'G6WL8-^P,/J0IF2D-X5@.9Z_I30B9;E*80A>](
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MP7$J)(2L@YZ\U!5F0O,<6<?!OL.S4M3-C+: 4N-;>I/DH?K3B#-&TW\6E$J
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M@;CMEA"-I'=\\=*]E:*&/-O3+GJI;-J7!Z ^R_IYFQZ7*(^YOXES)!'H /\
M*O>TE?!\OXC*665V=*[57=O9_?R?^IK_ %R0/\ZCQQUHY'3^'L>[Q'#'Y?\
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M$N(*BIQY)\/MX1T'D*+ $2\6Y*$0'1W,I"E+=>6@K+@/0;>G'3BFF!:1;_<
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MVH=;17[:XN,FTW!R6^\VO8N45. K;< X*=F 0/.N['I5")SRU$IR1Z]_T?\
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M_.W,E01PA&,JK"-QX9U.,9\F/FO3&IA-L5W;2#P3YU;QJ1C*3CP=%T'VKQK
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MGV..#[$U.WW -1<4E0VI4U!'*>G>O$\<^8''ZFI? "%QI:\0-Q2^^.^F/(.
MVD=$#S'IZ\&IY*CV-*G.-AVZMK4XV?\ 58#/FM1X[SV]#[4ON57L,N1U-%NS
MNR E1^_FO)XW9_Y]/H*GWI]$R#^("N^N+F=SG^KP6N@7C@''D#_@*$[Y?\"1
MLM; FU)>Q'CH,J:]G@DG\1^HQ]*E\\?Q*7R,(?4\IRZ.[N]DX:BI/DGS7CW_
M ,!2W?O%"7.ZW.1PH"/%0AU:D]5N^0Q_4_I4_;V :*G6 XXILB7.^;U:1_D
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M8QFI;<2XQC[')>U3LBB2"J\6-@AT@J<"$GG]*>+52BZ9I+"IJSCC>E+O/EF
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MDX]@!UJ;^1%7,>A.S%3DSG6$(1W:7%C@N.<=/Q#'4TK&0W'(K##K4F6B1N&
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M\,CNUD4=_P"(9[-%-KX/3>J%?^9;BH'&([O^!K]7RWY$OT/QG1_YG\3CO86
MMMTE(SWAY(YZUY/AR3;/:U3J!V<@#H:]INSR:"=2,8. /2L91921&<91@C
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MY*=U_?V/0_PO2I[MR_F6VF.V]=\D-QX]P2AM*MO*AR*Z<NHUF-I-NC+_  K
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M$[SD=&QTS4V,;6\"/B8R2D('=L@CD9ZJ^GO2$+#RRVE#9REL89 _VSOFH^U
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MDJ3,2LN$K(:VH61T/OZT%(KV/O8 B- J4$* R.48]S0,DP5.2&F6U.+84T
M<C"U>@-% =6T/!B1=.7&]J4ONRVAM(D,DA+P5P3ZT@%ZFU!)TI8[UJQXK3<)
M++<9DI 2WN=RGP#R(3S2B9MNSDUH[K2]A<^&R_<Y^&4+0/''9ZJ4,_B55-#2
MLT&C8<=AUVY7!K,9*=V]?DKSXJ:99-OMZEW/[A@GNCX&@.@ '7]:0%; E(0A
MI]<=#[X6DA+H.%*!P"?[IZ&FN09W#L0:M-L[08&HKXRVW:(!5+>6M>$A2!E
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M/KBG%$,E:'ERK1KM\H>/=,J"@@#(6@GY/T/.35DE5J%@1M6WJ(I.U/Q!.!T
M6,C^M+W$)[,4O(UC$EB6ZT8LYOO4M+P5#/"0??I^M-C1WO3TVW.:[O-I3$<;
M8,QQV(RI VJW)R6U@X\1.>?:LWV49_M(LTBXVF=W2E/+:^Z ((4XE/('GG"3
MZ^57[$F2[-+!+5>VG;C;UG,EM32QR!D<N''3&.E1(#L?:D^DNH@.25.LL1VT
M+PW\A(\1'KD8XH&<-OJV65B)!=2VG=^(8.V@:*!GO&I"XK3KCRE+*]@0>$'J
M3Z"D!J+5I-%WPAE"HS;A W^WJ0?\J8F=:DQ4.V6)IEU+Y4G!6VPK(5@<<^IZ
MTF.SF?:;<F1>6H%RF-NV[3BPAV&5C+TA20.[_O ;0,_6B*,Y,QEK7-NDY^YN
M-*;=>.P93@-#R 'G]:J14&7STQUJ,U!>0'$'"E$'&3Y?UJ;-:'X2H\'[]YQ3
M:6E@@A.X;@<@?3/%#!(EPHKK:NY6IM3C\C+9/D%'S'I2Z$U9V&S6&9_!UA-L
M?5#D;4#8C*$;?P@>F<UC++M9LL=HT>F-,6)LJC3(:$@@@%;:>!6;U%>QK'%P
M;L:=[-8UH^ ?2P5J((<" DI/Z5<=6EW$SGA3?=&%U'V90KS<C<-/ZO;82E(2
M&DFLIZI/]T:P?_(WG8GI.^Z:U U+NUQ$AM/RJ(W''M7GZJ7FKA';IGY3Y9Z5
MDZQN:$YB=\M*1@%2 HCV^E>,X23/;A*$ER(M&MM52)Z&T+<;2A60%,^ U?H7
MU]DRA?T]'5K3VB7M@(;DVN&XI(Y6GC/Z5<<N->QP9=(Y>YHXVO\ O\;X+#:C
MU\1ZU:RX[NCF>CDN$RQ8UP"G<J.K XX4*Z(ZG$CGEH)L<8UQ )^\4_\ O6GY
MK$9?D<I,&LK61GXD#WVT+58K#\CD7+'VM66AS'_G-O/N@BM/S&$C\M+X'?XY
M;WCA,Z.L?E!QFD\N*7"#R91YH=3*C+_EI;7[)4":GTBJ8HK2H#_5J:C&787)
M"5MMJ3E; 3]:?E08+))$5R*TMM12SDCTJ7!1Z+61OLI93:]^U3&!BN7(D=$6
MR*J*A?\ L>*PZ-4V(^#.-H;2$^Z:+*&5VQE1\3:/^Y5*;0AA=F;7_P#$S./^
M$4_,#H;>LH<&%*!Q_=%9IY$'F,B.:;C/*"W&UDCD<IK;?DJA+(QB3I&WR4J#
M\0*W#D*2D@_7BLHK(OWC7SF5;G9IIUXY=LT8CS ;%;J>1?O LU<D*5V0Z4E)
M+:[%%*3SA3>15>9D_P#(K\RRED_9WT#)45.::ADGS"2*F6HRX^5*QQU-%1*^
MRKV=2#N59PGV:.VG'7944]2BN<^R%V>O$A#4MD_W7*U_Q#(H\@M0FZ'K#]D'
M0EINK=U7(FN&*=[;:UY2I7H?:NB.NWX7%C6=0R)FAD=E\F,\LH:;"5J[P)2H
M )!\J^1U/A_GMS/KM'X_'3P4&2+-$U!HR[N7&W)!'=[ ,UT>&Z>6EDFCS_%O
M$\6NCM8-?=HFL+Q97K:FUQEE>!E0()^M?09]2\D:9\W@QQQRN)R^1JOM 2E,
M5NPVXL-I"1DKSD5PP:B[LZYSW(@C46O5'[S3=L_==7O7R942VM1:\*2A6E[;
MA0P>%T;T ]&FZF! =TS;L_W7%@_H:C=]R>">F;?%#:YIEG!ZXE+HW7Q8G7L/
MMNSU\+TUC_AE'/\ 44Z)LE!#KC82O3KP_P#\K_PH (VYQS'_ )B>1CS$C- ]
MU#OPTMJ.^W'MSB XT4J*EY_:JCP*4N#T1V3VE^RZ#MD1P84I!61GIDU[.BAZ
M6SQ\\[F:T*)<4#U*:M/DQ?)YT^U/I=N]:?ER'RD(:2%.!9PE3>WG_P"%6.?)
M1Z&DY5'@_3$J*Q:Y^F1/2\W!>[R*,YW,K/X?<$D$>7%>?EA<O,/7T\Z6PJ)J
M/X<YM&=BSX5J&!^E.#LUEP3;.PU*=WGIZFI<Z+C!,VUL=L\%(6L!PIX4DCBI
MW-FRA%!RKO:'%X8+;"1T21PKV)\A6MLR:0)-X@(B)*I$!(1R<.*/]/.FF["D
M8?4][B-@_#N1'"HC"@I0(Y]ZVBV9SBO8P5VNLAQ[N2$ 'G(5Q5IV8R5%0X\2
MYM!!!Z\TR+&9#I2.[9 )-.+HF2LJI]N2ZPO?RH^5:XYTR)P35'.;[9&VW"ZI
MI+@'X%9(^N.F:]'%J-JH\S-IS./MOMJ+L9:PZD;$J604H2>N$BO1QY%-'E9(
M.#(RGT)5AMK"6CO2TD8+RL<GV'G5RX?!";:Y#9/>HW!XJ(<[QU0Z9_+]*F@#
M4I:EEM. 92MSG/\ *;'E^M!HAP)1) <([OO5^/\ N,I\_H<4 $&P5+<!.S'?
MK!XP/P)_6JLL26LDH"MH0H*)\\GR^E*QV!Q)Y?*CO5@*I6(<W*]: '+EH2[V
M9YU:6/B&6P2HLY5M&/2I5(R:91QG!NP5I2#R,^=--,'&B:U*0TL*="\>1'2@
MDD&6[DJ;7\WRYH >A3TN!Q+J4J4D9&?6@+'#(PVA9VI6H<I!Y/O0,<1/;3AM
M;) /J.: L?Q%* I!(]:0$=Q]#:DDI44'TZTP AV2\VXRMA:4+^4CKB@"')>[
MDAAK+:!Z=: *^:XXZ"4@XQS3$B V1G!!H3&6C24QPG.25=,4=B'TMCA"N=QR
M,4F(<9_F8 X!Q0,=#24@I=\CGCWH'0XEEAO83E))W GH4CK0%$U4YL-.M8"F
MGAP4^0_YT 1$1XYB=Z](V!!VIW<9 Z<T A\LYB,+3(<;<YR,YQSQS6<BH\!7
M)_9'2A:PXK'"AYU,2F[(#<-<Q3:6@-S>%*S6MD;1R1!4A"ULO.E[\'Y118;2
M;;G@I09>:(6!M)QQ28(<87'=DK96%8;/.XX!_6H9I$T.\,*^,[EGO%@?$-K3
ME 2.F"?>LY<F\62;JN'*AK2\XZRPVD.)'RE*CY)1Z5FT:2=HI7I3D>(U'D-.
M%MW@.D@+*?4CTH1DY45L]YEIE:FP%$ ;2!S^M:1,K%PENIV274@]XG"$YY)]
M*8$U/PK90F7$=473D*3QCU%)JRHM+L3>4)^""X,A>U>U82HY5QU%"02E?1&0
MF(@-RU*6IPC<0L>$>WUH9,5\EA;YD>5+8?E[&&@%$J'@PY^7'17U-*C5-%A'
MO3;H3$=1OPYWA2G&, <<=,YZXJ6B]R(3TIQRZM3!'2AQYQ)>"OO!@=<=#51X
M)NR59I"I&KG%A0CE:^ //%.R>T*URE3':#?(KA23W[*<IZ?RP?\ .D)NBIT5
M(?BZM(@[>^7,;4G>,I'('-#ZL:9Z N)@M:XU!:70I:Y*PIN6'"WW2@A."H'.
M/%G]ZCLM]"I;SDEV49&]$14<-;$)(V2 2 X,'!)&<^M4B2KT\]&_B1:;B2OA
M\%H28[FS<Z$X*LXR,9&1^M3($6M\09-K,-^,A#K1; =)PIU6W&XG\2<>?]*!
MG&-20H\=3YR3X_YB25=/3SHH$Q.GE2I27#'4Z#A+;<I+6[!YR#[?\Z*"SL&B
MH)3I_=<T+*EN!#3G4+4H\';Z#S%384WR-7Z:C29&L&+H4R(W>'NE)VMAP I1
MQ[]1]*I(ANCSW=;E,ODQ5SDN)4^L%62G(4X5?S#[XJTJ(;LLH)<7AU"UY*P<
M[L @>M$E9471I$.1YRMP6 C:E//7K63BT=$9J0W(F&*PY ;2EP*7E.[S^M(=
MJZ-/HUC^)W2.'VP0' 4J\U!(X'TS4RM*PM;J/I#H/[.>NG] 6-RWN0V^_B)<
M*%Y.5*\6>1Z']Z\>6=J=H]"#BEM8JX_93[17TE;T>VOC/ (\_7@4GJ9_!LI8
M^K1E[K]D_6JF]DFT1QSP6@14O7N'<6+R(9?<SJ?L=:J>=RVR6E ]>^4G_+FI
M_P 37_BQ/0P_\C4V?[)':+#;Q;KY+9<R"/\ 6"4?J,4UK895S%F4M-Y3],C:
MV[[-W;K":28VJ;8X1SM>;(_YYJ%+&W>UB>6452D75O['.W*,Z&[N];7$#JJ,
MYCCZ$53P8LCW!'5Y(JK- CLWU;$ +[TD*'4#FFM%C8GK9_(M6D;^T/YLG/GP
M<TGHH%+72"<&JHS7==PX<< X-2]%'V+6N96.:EU%"S\1:5J _*DFH_)(O\\B
M,.T93?A=MTA /4[,8I/1*N!K6)NF/M]HT+< MQ;:?,J5G^E9_DYF_GX2:SV@
M1%8[N4%#_AQ4O39,?J0>;AEP6D;7T8 'XA/Z+P:A^:O8N,<4O<MV->0U)2/B
M"3_\FQ4[LB['+3PDO2T6+&M&1CNIRT9Z['0?WS1YLR/R<7\$O^V!&,7-P@]=
MQ!Q6F/,Z>XB6CKH/^UD=?"Y.\^IJ)SLI:=H4C4+"NCZ/WJ(R5$3Q23X0\B\I
M6<)>;^N:>Y$^7+X'?XA_>0?H:>Y"V2$":E1/!I[HBV,6);7Y%T>:P>.@&=$3
MSN/'M3N3(JO86W/CNGA:>?*I<(_(_P" \AQI2@G*1FI>-?)2Y8X0WY*0?I2V
M1^Y5( 2D\)2DFG%*/0G%,2XG:,E %5;)V)#+8[Q9*-GAZY-.+C^\3Y;;30ZH
M*!P$IP>?45/OP/)&W:%=VA:>64K]PFB6Z_3T6E&2Y[(SL..I/C91]".:N-HQ
MVI/ED%^RVU_A<='/J**YY-+X]+&4:8M2B08C!'THE%>PKE[L']E;/_U-C]J5
M%[W\AC3%L"3EML\>@HH6Y_(RG2]KR,1FL_2C@7J^1?\ 9BW_ /5VC^E' TW[
ML7_9V D<16\_2ILK<+.GH10!\.@<^E-";#78H+*<EEOGUJNR7*B.NS0ELO88
M0KP[1@=#3479+G[&ZL;S:+5%CA206D!/!%>WIL\(0VL\O+B;E=EBDM[U9>;2
M=OFH4+BVV9[6<<[7+1(U0S*MO<.OQ4-X<,7^9@IR>3Q7%GGN?!Z>E@SY;=M=
MBU+V1:H1KK3MNF2+:PZI2UOI\+:<X+3BD9R",YXXR*TQ[<L/+?9U34L#\SV-
M5<C9];Z9L^O=,.N.6:XM.?=.'QQ)+> XPYZ*&01Z@@URO'+3NIG9CRQU"N"9
M4QICT>WE+9 <)(P*AKFS1-I&<DZSE!Y<;OR%GR)K>.*^3)Y6N F;M-D$#OB
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M_B20**;Z15I=L<0PRE[E0*0G=O2,I^F?6CR\KZ7 UDQQ??(XPE+[ =[AU*E
M926CU'D:T6-54A>;3W1/.7:UHF!V)W34_;]&N*T2IMK-NML C8IN<\K"WDG\
MH0./,&ML45%TC3S99VMWL>)+U=9'\-F&=*#S[[G?%S.2I1\\^]=JHO<Y+8SC
M\PH^),Q2E;>A&ZI<KX-=O N,]WH+BED#W-30)M!JGM-#"E$CS]35)4)AQA\0
M\E<-H#*AQG!/ZU2DS&4$T7MZTBE:4WN+(4AT ;9#;> E7Y0>@/O51R-< \?'
M!0*T[:Y*7'I<"6B4X?%(A\A1\U+03@GWK59I'++31?J=E?)[/;>6$O0]2-O+
MWC>J5%"%I'F .,'WJUF?N9O3+V9'9TII2USTSYRTS"VLX2H9"O3@4Y9'(E85
M%\DRY1;!J1U"8ME^'V\*6EKJ/TK)S:.A1O@;N6AH[*8_\&EN/.*!)9<R"<>0
M]Z4<C?8I85? J!&;2P$O16$+!*5 K\0/H10W9K".T<<8;0?NB,#TZ5/N4^Q*
MW4] >::%8@\]:NB6B&ZX"YM40 //TJT8-E_HW2KFI+E8]-6B Y<+QJ.5\''B
M('3Q!04M1Z)"05*QT%.<MJM&:YFHF@^T;J2RL7"V]B.B7VUZ=T27$RWFQA%Q
MNJN7WP1\P03L'IS484Y>J79OJ*C6./1QU;32&3N1N(\SU^E=:DT<DL<?8A]Q
M'_W7]*OS69^45SKJI0 6YRYG/Z5W'F]D8!V(YW0!P?.@0M"TMR XM.X)YQ0!
M(>4 GO&U82OHGS% #[$M3: 003CH10,2CN3WB5-K!=.5942/TJ6 F0TRI0W*
MS@   \46 RKQ+0C9]R$Y./\ G30%7+?8B**FO$E?."<D>V:=T"5@1'^+ +:P
M,\XIV R_&#1&X4=BL?M@6VZ0/Q<&AJAEA\,K<2C@'K4B8%1V4#<LG</>F L,
M-O-]TZZ4>8.: ";" KN X5$<DXQ@4#'V%;7BA8W #PFDP'@5]V7DX"\'J*0$
MU;K,N*VSW)W[<E0..:: @/H.](<*%;/EQ\U,"M<86X\4=VXD@_,KC^E BPB(
MDH:[M2$[!P5'J:!CK@/=]TVH;#U/7%(",L+#0=D(D+">!E.13 :A2W5R5-R2
MDM)Z#:!_6@0),IY2X[J4=ZDA2@@<;B#QS0 MU]+$AL2WEMC&4M@9Q^M2T4F3
M8=S9>E?#B1]UL4I64XR![U#1:9:I2E+24L.C"4Y(3ZYXI,=C(?[IK<Z@!*$$
M!:4_)Y]/.E0[)++2&FU.(<4MEUL>+."2?\**%91!]QI98420@G;GRS3H3#:<
M@EM(EK4E*21C/EY53$6$:$\B(M;<K>RG/W:^B4FHH:X1 ??ALAE,5)2,A(V\
M<5:0FR8J8GX;NR?$58!\\4P$P8BH\I<AZ01D90HJX%2!0W2Z/W.0)KSI"6QX
M1C X%4HTB9.R9IG3TN_2MD++KC@!0@IZ'.?\,UG-VRDN#K]LE-:IUG#M#PEH
MMZPB#'>+8*=B1E2O8[AUK.7+-X]%SJF<J"]%BPYCCZ(S2GRTKE:W.0$@'@$]
M<^E9C]RIC;D0V+L_&6JWR@$/1VT NI=0K<K(_,>@I@=2MMTA.0W3,ANL1GL%
MB0 $9W#EM?J0.H]:+&E97,N-2%QVX;CG=1Y)8ENH20H-'E'7R &.*(JV3+@X
MWVT]H3=RFO:/TY(=-NA[6Y3X7E#F#DH \QZ^M;[;X,92.:M-;R7$X0E9RD>U
M'0+DGQF)"U!#2.\^@I.0G&V:"U:6OMU>:8CP5 NK W.<) ^M*RU$W+G9)(L+
MS4B=>6>]<"0&&<K2D_WE=!15FE4B^M%KL-D@KGJ;B/2E)<RZ7 4A2?[WMUQ6
MT<:JS-Y**]R.N_RE76Z7,W!M>4)DL$$[1UR%=1C]JW6V^3!ILT>GM)6>8TE-
MLN.]F$4OA#H"7P">H]A6\90:I&6V5\G=?LYZ>E+[7-)OR7G4*22MIL^%)P%<
MX'M_7K7D^*<8CT-$O6>_OXCMV['.$[D_L:^,A[GT$UT$;B3R5U9-!_Q-1XWT
MFZ"D+1<"K.5FIW!M$/3L$>,TTQ-4(%P(Z.4[$$;@3^.BP!\>?ST6 X)*R 0L
M\T;D.@TRB>"JC<@H)4A:?F71:$*$HY^:C<AT+^*<_-18@OB5_FHL C(6/QFB
MT XV\H_BS18T+[Q?K18Z%)=<QPHTR6AQ+[H3@*H 2I;GS%1H 1W[F[ 5Q0 Z
M%K(!W&@ MSOYS0 .\7^8T **U 9W&@!H/K)QO- #@<7GYJ "43US0 630 1<
M*//K0 $NJ5^*@ ^\(ZDT &'B. : "*RHYS0 >]7K0 6Y7K0  I2>BC0 ??'U
M- !=YGB@ T;RH!"0H^0)Q2? URQ+8>4E:P'E)!Y*VP@)_4\8IH4G13S->:.L
MS_=W36=@A.CA3<JYL(Q[G*A6T<3R<&#U/E<M69?4?VE^P+3#;CU^[:-(M(;!
M^[BR#*<4?^%O)_;-=6/1_<REX@G^X<*U9]O?L_U)<EZ>[ [%VCZ[NK*>\(L=
MO0EM6.N04*5M]R ?2N['H\?[W)RY=7DE5<&/OWVI?M:6^TNZEG_9>CP($4;P
M]?+RI,A*/1314GK_ ,(KHC##C[1S/SLG3(NB?](5;+Q)1'[=.R>X:0A35-,Q
MK[8Y#IC,NY\"G 21@'E1&>/PFM+Q3]C/R\L'V>B'>U'M-@:AL\>XWF?>[+J-
MUF-:;_:XNZ,M]T M-/I1PV2",/)!94#^!0(KASZ;=])Z&#,HKU'/_P#2 :KD
M08M@T*NXJE2&(Y<>+F"IQPGQ9_:N#:X9''X/6TJO%N^3PC>[ZY*6F&#E)&U.
M!C KH;I&L5ZJ*63;FW0$X)_6I-6PUV&7\*'&W!M\J+);*J1:9K:PMQ \/)YJ
MK$TR9;8\IYU"6PH#/.T<TR#JVDGW4-)MDMI+T=0_E+R I/YL#SJ9+W-82]A_
M4?9M;TQG[S8;A(C=V M4*:G)6?5"D\8'O24GTPE!/F)@'8K00(]R0P2?O/O$
M%>WRY(Z53D9;5[DRW6:QX!%OCGT6CD*_2I\QE>5%EG(@Q8^QV$A+.T9..A-+
M?97EUT9R[29#KA4$8<R1O2,''Z52=&;C9F7;6EQQ3Z_"KIDGFM%(SVB.&&MF
MXGWS5(AC R#FJ0#YSLW5HB9,#";=$B&XSTODG<IM70#9U_7S]A3.>3HZOHFY
MS.PKLG?[9]0#9KK7[;]MT?$<3M-O@K&'9N.H*L82<<\5C)[Y;?@UPK;C\Q]L
MX7'@/%E*UA2W"5*6HGE:B<J4?4DDDFMD]IC6[H$>T7"[W!FTV6V3)TZ00EN-
M':*UJ]P!R?I5;@4&2?[':H_^-.]?_@YVEN*HP>^*E:/ XO'1./.O7L\2B0MY
M3J0AR(G .0H]::$T0GW=CXPG;FJ1-# 6Z75;ED@XH8R2X\M&S8/%C(-(1'EW
MIXK"4C("<'ZTAC O"<8<CY/UHM!3$KO<I2.Z8RT@# QZ4#H@G).Y1R?6I 7'
ME.QU[T$A(/-"?R%%L@-7%L+C+#CHZMN<8JKL5!1V7$22 >!0V)%LVK"3D9'I
M2;&17(Y="W$NG(Y":+ 00M24 K(6 235"'F74AI6]6Y2A@G% QV+]V 5=/P@
M^52QI$IUUD,_,A*AP"H$\4ATB5%<4ZT&XB&5*V\J'% F4\Y<]LAL--A6XYJD
M)CQ<EEG8N.#L'*D\DTP&0I$F.4%Q0!'*3U% $N)'#,<,J&6R/EJ; :D/,J7W
M'?.N,_7BGR A28*CRVEK/7FE; ;EJ1%<:0EH]VA/W93UY]* '<K?:[\HSC!.
M1XL4 .H$2=E AK(6,  8X\^:"DR=&:,5:%Q8JR%8#G>JXV8X_6I8QINY+B2'
MF_&M2NB5#PI'M4<B)#TI]]DE$MDI('>;1M*,=!5(92)>7)E*:BK"ECYEN\ _
M2F!/;M_Q#"TK+8 Y<W?AQYB@")-NR)W^K00M:&L#)XSBJ21+;&@H@AR:@(0.
M01UIT(<C)<F/Y9"E- Y"U\"BAVQ-XNB'T,065_=LD]XL>=&U"LKX4)ZYOL,M
M@I;.,X\O>G)I E9TNS)186T6I'W<Z6DA4A'5*?3V)KFDS:*.B:<M,G3]E87#
M<6N;%:4^XXX/"DJR-X/J,FLVV:=+@RFL;FP\EZ?&2XJ3WX4M*AC,<82""/QE
M63]*$DQ>Y=Z48?=,F/<HZX\R5W<EH Y2&T\[L],]/UI,I'0;J5MVTQ5.KDN/
M24(W):VH;7YD)/16#XJ=67:1S?MB[06]*P7='V%;:KRL=Y+DMK\+",8VI\BH
MC-:J/LCGG(\]-J[MP<JR.0%')&?6M8I)48MVRRC_ 'BPL\CSI20TS;Z(_A[$
MU+DW*6E'J3E(\NG7K6+[-X<]G>8;%EC6!=UL[*7U,,I>[[G:\=V%(2/)21SB
MFC27'1SW4#ESNMV<DPY)>85A0*%E*'49^;'KU_:AM(Q]38RS9VO@UQY<-6$\
M%).$+0K\1!XY%'F/H>R^R$IQBV)<<2XG<WPVP%>%MO\ \.M3O?R4TBK1JIUF
M<Z(,I[N^X+)<4<'%"R23[(:1[:^Q5+E:QU78[](?4ZNSPGPK=U1M\*3^N:X]
M?GE*-29VZ2"3M(]KDC"@G@!1/ZGK7RK;4N#V>UR# QFJW,5('2DVV%#C;S:<
MX%)V EYP+((XJX?<EH-I*5)RH9YJJ%0ONT?E%%!0.[1^444%$A  0!CRJ&N2
MDD)6A0Y3Q10A:D*5\W-, !!STHH0L)4#R:JB0P,G HH RV3U%%(!;:5 \&BD
M-#^"!S1108ZTQ"R<=* H/)*<'I0)B.[YRGB@0L;P,9H"T#+GK0%H3M7ZT 'A
M9X*J ##6#G% "N[5G<.E-"82DKQUIT*Q&U?K28TP;/S<TA@V?EXIH3%!LGKS
M3H5A]U["B@!L(Z44%A+\(HX#D Z"C@7(K H'81;X\#6]7X4YQD^F:*"QEUV-
M&A+EON;&63EYY;B$-LD=4J<40G K;'BOLS\RCR[VM?;[[/\ 3]Y5H#L4M+O:
M?K21(,:/'MC:A";4/Q*=_&0>NWP\<FM%HI3?=(F6IC#HYY;>R_[4_P!H3M#1
M&[:NU&19=/I0%SH^FI'=(AX&Y3.[Y=R1U4":J.*.+A+^9,IO(K;-R]]GC[ V
MD;?+E7*'<M7K:6I+\B9,>FN I\P20E*L^E=\=DHTNSDK(I6^CG\/[/?V;=:6
MZ9JNT]B+ND--1%G_ .N"ZW5:5J2/PML$>,GR _4TI34%1I&+D=)[#=9:?L\&
MYZ:['=(-V32EOBK4[*<($R4L=7''4@';QP@' R>M*.63]RI8HJFSAW;!J>]]
MH4J9:HTMY]F2K:OQE0QT%#C%\L>YI4CN_9QHO2$^PM]C.N=,0KQINYVT'N7T
M^%#@2-R@1R%#)4#GY@*6&6UTNA3COYD67V(XNLNRSM"U5]G+45TE7&R::C.W
MK1CKR=R)EG?=VAQMSR+2LH*/(J]J[,DMD.#CBKE3.#_:6U$SKSMKU Y,<=D-
MVY:8+ 4.6P/0#JH^=>3CD\DG)^Y]+&"Q045Q2."7.V6AI]9;0@.\X )P#[UH
M^Z"'9D+E<1&<PT,X/E3BK%-I!QKAJ*:T8<*(MU*N4X'04-)$1;?!6W"VZM2O
M(3C'/CJE. 2CD'+%?9-NDB->6MF58W)\ZKA]$*37#.S6K4EF<8;=@LLJPTD%
MM62L+\U$@\_2LGQV;JO8T\;6-H;CI<4&'5MD!7<L*2$GW!S@^U0^32+KL#\J
MQRB9UOB(<>?&%[D)2?V_\*S=^YLMKY1GKC$LJMSDBUF,]GA;. %?\0I<^P<?
M!EKB4!2T?$H6@'A*?+ZU2LSD4TZ2VT$%*0,52MF<G1F9TQMQ:SZUO%&$F5;K
MF2 .E:I&=H6@[C@\BF2V36XDET0PW&=+,IU32'MO"U)(24I'XCE0]J%)$237
M9L>S'LM@:\UZ&;_>HUNT)HJ.J?J=]05N9"?$J,M9.%+=4,93Y5,\FU<=LB&-
MY9<=+LS/:7KS4';?V@SM51;*L0HK*F[%;"X&VH%M9&UM"/7@ D>9HQP\J-3[
M'DFF_1T)L]I0N4(9DA:6V\NOJX21C)6/8<C'M4Y,M<FV'&NSITNXQ_L_=E+O
M:,EIZ-KS7##D#2B#@+MUM2G:Y//FE923M\]Q!'2EB;S2XZ0L[\N-KMGE[^W.
MI?\ X_M0_P#RV[_]-7=L^QYOJ_\ (@NW >%#"TMN_F/]:](\\4MV0&TNJ=;<
M5D#P]:$)]$.>\LJ25)Q@]:I$$9V8,#'!'4U5@./3PB,/SD<*\\4FZ!+D@M[W
MCN"CR:2YY&^ GVU)4!FAH$$4JZ>5%!8H-<=#3H5@0UG@CBA(=A)4ZVYWR%$+
M'X@>:FO<++:'<42FTLOI#;A(!4!@FEV@9:M)4WC:-Z/,FH;$!3/)=0,>7%"8
M$5<;O%84I8 _*>:M,8N/'BI6=V\)2,J*O2G8#SCS*T*$(!W\E2RD*4ER6EE*
M'$L+0<.)'G2L8_)<$1SNFUC<ZGNRI/!0/6FB60/_ $F2AAQ1'=?BSROW-6A#
MRY;L12'$9 <.%CT%, /"W/(7)C(<6[OPM*>F/6@!;US9<<1&A +;"0%*\TGT
MJ0&U./,.EX!D17AA#6/$#ZT (4PD)#KR0M*CCGFC[ *#R=P*\$-?+G\/TH :
MCW(-;4I;[QYLDG\Q3_\ "HH+):9[#:"AGO"J1XD@GA '7'I28T.1GY^Y"' I
M;(45*<4<TNRB>78\A'>H;3N;^1XC(!]QYU,D)C,MYA;'^LM(&?F= P%_0>5-
M 1O@6E[ \EKX7;N*B/$/<50RKF3?C@J-!+B&0=F[/*TCUI@)8W,I[MCE0X*Q
MU-,ACG>1FDJ7<9.XCHVD^+]:8B+)OLA]OX:$A2&,8)'44NQB85LE2DE*4^%7
M)'D?K3X TML98M ^(4X'9 &4L)X0@^N[S%92944:W2UM5<[JVR^XI+Z9&Y3L
MG.SD>$8]O6LI=&Z1TK5B9MHMC4>1=W4*6CN4-#'WF>O ^88]:R&SG4UJ>Y=V
M&!N6P%I[UPK\ORXK1="BK9T.WPYDE]ACX'>5N!00DXV( XQZYXXJ7R7T1>TW
MM,CZ4C*MMIF1YNH9[96YX?!$\CSY*Q6D#')*CS9*E2);[DF5(+[RW"M3JCE2
MR?/-:Q5&#E8RAL*(XZ5I1-\DQDEI0Y\/I4LT1<VV7W2^^8;!42 H^@%8R1<9
M<T=1T_JYUBW&SLRA';DH\3BS]V5CGQ9\ZBS?M#SETC_ 1>[AE&WO&U%M6 1U
M*A]14,=\&9N6K-Z5($ES<H$!@JR%)]S4T0Y&4?NTV1W[R>[.\@$?FQTJMIFG
M9)@-S;B4M/M!)6H"G5%I<GTC_P!'WH:;9=#WC64LH+%P?3 @*QR4(&7"3ZYX
MKQ?$LE*CT]+$]8)QGIUKQERK/0'$HW'% "PV$_,,TTK%8"VV>B,?056T5A=R
M.H'%-*@[ $G=A/ I@.;#0 \TT"!D"IL!W:!Q@<4Z )(!/(S10#FT>@J0 $<T
MQ"L#T%42#:GT% !X2?F.!0 :4-YX7_6FA-T*)2/Q$TZ%N!D'I10;A:.1S10;
MAU &WI4L:=BL#TH&'M:'*EX]JI&;?(/!Y#BF*Q!ZU!J#IS0 -XH ,.A/7I30
MF O(5P$TR0!2<]*&-!+4G'05)0T'/%30F++@&,51(6\GG- !Y/J: $K6-N,5
M#[-$AH/.(_ "/*@=$:1<41FI,EZ1&;;CC,IUQWNV64^NY7 JC,\I]L'^D%[/
MM$ORM.=F<&5K[4*%[.\@.%-N;5Y;GCUY\D"NC'IY2YEPC&>5+A<GD_M%UE]I
M'[1LE,#M)U(_;[6\K=%L-J08\,[CPE13C>HYQS77&<,?TF4L<Y=GK[[-'83I
MOLKTS(AZ?L85?Y[28\V=M!<WG&8[2^H;P>0/FZ^5=.&:;W,C)B]-%Q]HS4@T
M)H(]FFEI!;D%)_BLF.K;O63GN01U2D<$^9K'43BY<&F'$TK9YD@Z]MVCK,VU
M<V%O1AM[^,CJ_P">WV/O6$9N+LTG%-41]8=LFM>V^Y6W3J8"+-9HX"(MOC9V
M)1C&Y1\U$=:6^V/;2/1;=A:[+>QAVUM-);N=S:R=A\7=XZ>P.:ZEB>.I/W.;
MS5D;2]CG>@=-6BP627J_611'C- +""<%P>@_6KET-'4>QW4RM3.P-0LQ7(K)
MFN,QPHY460.#GWR:RAQ.BG]#.W1=56W36G[W?DPXCER@1G4026QWB$K/B"3U
M )2DD=.!5Z_*X8^"?#\2S9TI'S*D:Y=5J.^W2XM[Y4V2XX<K^5PJ(R/>N/3J
MXH]S++;)E')BID%Q:.%K42H>YK5]F>-6R5I'LM=U+/\ B9^&;?'.77,<?K34
MJ'L<GR=*<MVC]+- 0DL[PV/$E !J)IR-(.,&<BU]J* T_(>21LYV('5/UK.&
M-IAERIG&96K&YUT$122O<K %>CCQ>FSRYY?71J;9<Y4!#:FUE+8Y",U$X&L9
MFEA:K45I4X\O=Y^*L'&C>,[-/"U6CYG,K(2,97MQ6<D=$9#\G4\=UD9:&2>2
M5[JE1+<RFFW&$I1P<%1%51#:**Y2F,J27CZCGI5Q1E,RSTA*5J"5$CY<^YKJ
M@CDG*B,Q)[UTHW$XXJW$RW%Q&C=\A3;2$E]12E(*\#!5RKUX'Z9K)\&BY-C8
MW+K,OSG9-HE3MRO-P>2U':=4%?". C*VSCP*VJ)....:SR+:MS)4O-EY<30]
MO-YT]V<Z=/V:NS]\KMEM>$[5MR6O'\1NQ&0VI7SK0V>IZ;_#TI84\K\QEY*P
M1\I='(;/:F-,71FYW"[]Q;$-J83,AK[]<A91N[I+?X"3X5*\@:WG+S%P81C3
MMG6^SNS6Z[W&?J'M"9C6NP6F*F[7AJ.WM:8B(3N::0?-QQ0"<>?)Q7%.%R4%
M[G7')MB[//\ VV=L-W[9=>S=:WA*([+B1'M\%'\N%#;.&F$CRP/$3YFO5TV!
M88J*/*S:AY);V83^*._[Q7[UTF'G,>7#<;'>O9VBM[.:A3$YEA1QD\46F)JR
M'+E.R'B03@>5%\\ D-(#QRO&=M6K!I#S<9UTA2LX/04ZOEDW[(LHT;N\M$#)
MYZ4[$-/1]K@!]>M%@.JM[SQ6M"1A/2BPHC[6D\+)"AU^M,8;K7=.I(Z$ T6
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M1^]!($YSXNM #O3K0 RLC(Y%  RD\;A^]  PD<[A^] !*<"1D$4 $W* )^E
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M.#UHL!!<).<<^M)T _%NTJ(O<M9=1^0FH?'8_P!"VAWV-)7M<VLD]![U+7/
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M;8]Q--Q8>;*T/;%H/WP/''MZU.T1-7/S%0!)&](Y&><5.QCL;AST26>[+P!
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MENR33_\  ]-PFVE.8+\C:"M>/?RKY_49WEZ/5QXMANO.L8;4N>S9@4H?+4H
M!!ZTVP%MH*E8XI .I9QUQ0 91MZ44 :4*5T% #K;*RGRZT *[@^>* !\.?\
MX#0 .Y7[4 #N#0 KNSYI%!5H&Q)XV#F@+%I80![T62&&B#D#]J % *'5)% "
MJ #3CSH <!*NIH 4./.@ ;2KD8H &P^U !XQYB@!7>)''- #2G4'I0 86G'B
MS0 7>I]Z "4\D#/- !)DC/XJ  '-ZC0 J@ 4 )6%'Y: (JWS%=4H\JV;@3\J
M0/,G^M6FDN26>9?M%?:*TEV*Z.';1-GIO>KM11W;=HRRXPS'9SM>E.>9!6E/
MZ) '55?1:3'Y./S&>3GGOEM1X9[*>SO5G:MVHQNT'M0NQE7J]S6W^\G(*\J6
MX,DI/3:#X4]/VK#+J5D;2-<6&NSV=VM3439[D=* M+2RA!)SG!P"?T%<+QN+
MN)Z"<8JCS]?7&X-X#(\)!W#;TZUK%>[,).F>I(^MK<UV/.ZO_BS:[N[!3#;B
M#JE1&%J/H,>='F17I-(K=R>).Q+O9?;-K2]2.5,AJ.E?ID%2JTDJ@D<ZG^T=
MFP_L+?NU7M)CZ5MSBVF9TO<_)!_D1D\N.'TPG('N146HJS2G)TBU^T#K*-=[
M@UV<Z-AMQ-,:8;%NAL,G"5I1_M%'S43DGW)KG2YW,N?_ (HG]@?9\W%<=U3,
M;RXA 2T@C@#U^M56[@(\*ST1HBVB1.5+6"5+7DCR KIQ*N#'+(Z:N+]ZD@<8
MK?:SE3^26Y"+K06A6U2>*E\%&=U_<HUJT])4XI2E!A0&!GDBLY.S?&J1\X^T
MZ0J3>')((P-R3ZY-9M#;-%V&:<0]<$W%YL./J6$-CKP:%%BW(]3:_P!:_P#1
MGI)K3UJ4I%VGM)+A0,[6B/,GH?;%7::X"CG>H;?(UOH=OM;N*WX1T[#_ (?*
M>:4$J0I"<B0M"AM<0ZV2V$>:@,G%;Q9FI<TS@%_M5M2_%UBA=P=A28<E&94?
M+P?.WNEN,@X" 2"D<%1QY4I-&J9=SHT<W).G)%JN5PN2L3'X<QM/<101W9<6
MY\JOO-RRHD!*O",8IQ>[H'71GK_9=)HU;-?E7> 92(QB)#:%I,-I;>W)2CE>
M.5;@2,XYJ_L92H;B/Q=;7VT:*^';8MC2&+:APO=T[W2/O!<2YG[Q96/%M&X;
M@.AQ1T1:9K8FD]/08%REWR[/=YIZZ"&Y.4TG,=]U)=86D)QAI/RJ Y2I9..<
M5#?'!2HP5JMFH9#$W2S<-YZ-?[BMUR#'2I<B5(YVML!."&@HA00.#U/2MHR1
ME+@[]I'L"M&@);-][9GTW&>MEE2= 1EA;(<2G(5<G02<;N>[0K=Y*..*IM0[
M,E&4WQT;F^]I#K\D7*]34-"&ULBQVMJ(L-&,!MI)&$( XP.:SQ;LDN2\VS%#
MCLB:!TWK'MNN1M>FX2H&GXJDHDSB-C:4$DGND_E/.3UKV,<%%51\_GS2E.VS
MTMJ'679O]E[L_+-K?;7=WVML5MK"WUGS40,J(_2HS9HP56:8,$\CW-'DW6'V
MG^U#4;JITZV&/#4<LJDROAF\GH4IZDD>M>7EU>/Z/@]C!I,R>]=,Q<W[5/:%
MIEV.S#OD&WRG!_)4XJX?0;%90@_6N.66,COQXI0=NCE':)VRZWU]K%C6^IKF
MY<[S$:^%B+>_D0VO,M-)\(5GS\JPG)R53Z.J-)W7)C5RKW.6\^J.@./'*W75
M%95^GE66_'#HMQG+H8_AT6.Z)=Q<[YT\@(.!GZ56YLG9&(^U(N$^0FWVB Z\
MXO@)2@DD_IFC;S;!Y'5(ZMH7[.FHKJEJX:LG*@-/>-+2,*=4/3/E^M1++&(1
MQ2ERSHW_ ).VB/\ ?S/_ '85G^9+_+GC:(Y 4A"O%WRE9R>AXZ5].SPT+F*:
M?>#JSO[GJD=0:DID%316A^8VC"\9\1 Q5Q[,I$RWW'XJ&AB:RVZ#D##@Z^A]
MJZ*X,P241$-H999>964J)61A)Q[^WE4-#(J'=A6N.ZI9VA/><[0<=,?KS4B$
MI6P^[EZ6X\ZE.#ZCW-4,K):D1MS;;I?*SN4E?0^PJUT2^Q46Y15(4I3*D(VX
M",?*:*$07B7'>\3G%"*H86@EOO%^'^Z>M584(+*W%@CPISSFDV,#ZT-H+2.5
M'S% F05%25;7?%GS'E2;:[#]!2F=B&U_[U.X?3-"=JQ,-!P>:I,35BAXU "@
M$B:PVI++A04I*2.3290;1<D<9Y''UH7 F**'F4DH'C/"L],4[)&$!UO/=H.U
M/K5+H+'(P<<*G2G&3GK0# 75(<6VF*WAP8R12H!+C"49=WDN8\NE%!9'2E6T
M+0HI'I3H887(3E+9("OF'K2:!<#KUSEN]VE3@(1QX>,5-(>YDAN^NA'<E"LI
M^0^E)Q3&I-$AK4,]@_<2 E*AA0(SDTO+'YA<V+5LZU2A*9DK#IQM).0/48/D
M:F6,<9FXTSJE]YU#,NYJ3]ZMWO UO4$D9*<#C&< 5GMHTW6;ZX:-M^J-$N14
MVZ25REH*5+Y4E9Z*3Z8\Z5>P]M\G-[!;W[K+N79U>-^T'N^\4G"F7T_RW$_W
M2?UI#[X,W(LRIT.?9I#13/A]XV>,;74<GCKSU%4N49M4Z.A=EUW_ (]IZ/%D
MQT/RK>I3R0KP!Q*?"MM?F<IZ>XJ:LUB6VN+3'OMDCSV$;G8F65MA/B^?'!Z8
M%11HTI4<ZN]J1;8[Z%+7LQY'J?K2CV/(E&)RUQSO'%J!.<],5VMI'!1;6RSJ
M>*''W4;%'E.#D4MU!5E]:+5!"U[<;TGC-9N3-$D:.)9@'4AQ*-AX*B=H2/7/
MM4=FJ1<IC(CP4F2IN0R%I'?9\: ?+ _QI44B3%8;5 <,-QI1WDH.[Q$=,$>>
M:4D6BLDY"F$/0G$-;MV!@*"O/=4]"<45%TLQ:=<^(;*_B#O;4.A]L>M6I&4X
M&5D,&,ZIE;920>0?+VK5.S"4:&V%?#.AT(22?7K39*X=FOTY+>F268K:U]XI
M25AM!P5>X]D_TSFLFJ.F,K.ZZ6-VMJK/-A3#W3LI:"CR4C')*O0=,'I4.=%;
M3W%]G71]C9M$[M(BPV';IJ ?ZRI*=J$=WP-N/85X^LR\G?IX':$Y4.F*\H[!
MU,=2AN!''- "?AUE6<T .AA6,9% "FV5)5DGRH >2V5< BF@%I9_-S18"DA#
M?!23FD Y@'Y1B@ NE  H 27,'&#0 L D9H &/<4 'L'J* %)'B&2* '5;4#<
M#S0 VITJ&#B@!&10 1/I0 :5D4  O$>1H 4A[CH: %=][&@!)4LG(H ;/>9^
M:@!&54 +"R2!CK0 [W9H !:)'- !!K!S0 L)P: # S0 >TT #:: .>]M_:9:
M>R[2C%TN,<RESI(C)8R $H((6^3Z("J>.#R3VC;J)\]>U;0S7:M]J?46F)UP
MWQ>S"S6V- @(!")3: @N.8/0;G"LXZ\5]#*3CBH\BD\IU?0>G'+?K&%=@TEU
MN&!("5#S;)Z>7.17GQ51L[JY+V_ROB+JIF3PH#O%'RYYQ5KDIG$-?0I+%P^-
M"@4YZ#.<9JXHRR'16<)T(T0VDM]VE6X=5;AY5SR7J-L?1RCL/A(@R-;W=9V*
M-U"2HC)P$X./WK:4K21S;:FV=]L4&-V(]FEX[0;]WC6I-79CPV5D!;<0#[O:
M/+=N*E?I6+ENX1T5L>YG#-,:;NNI9R7UQ=C2G,E>#E1)Y-4T3V>H-/Z;C6.P
M(B,D=X4C=4Q[')\&^T-;>Z;2I0&3[5U8SFRFV=BK<>;"$\'K751SDA^,ZUL6
ME.X'P$#U]:QD6CA?;[J1%MM$B(A1[X@@X(Z5B^SHCT>#M4O_ !5Y^&"\EQ05
MCU]:=$GI7[+VG(DXJO#K7W4-)()' 4GGFI?P-1]R=?DNZ\[1%R7P5)6M3:<\
M@)SQ1[!9T7M#USV>=BNC+':=;-H39+Q-$*Z..,E\QHRP EX-_*=JR%8/.T'%
M:XO4Z(GZ>3EFIVK#V?WR/:;JN<_"D26;I]PREQB0V4[6)+"N062D)V+)(1^(
M5LX$^8O8Q/:-9+C>%@VR\VMN#<XCCTU3,])2O+V&&_#A+B]RE<?*HX)&14KT
MER=F$CZ;FB!-M"(T^ '9#%K?O#C(:<?2CEIAI1SU4I6\IP,$"GN)HE/]E=UO
M#KYTU;%W"[6@IM%BA,,_>G=@]YW:>=[93R%^>">*.62Z7)IGNSBTZ;E3;[VO
M=H-JLKMQDIE*L,%U-SF*<VX6I4=!V,O$I&[O55I&'/)D\GP3;5VWV70\21:.
MQG3$JQ+E@IF7R61)O$[((*EOK&V.DY^1D) XZXK5)+HQE+Y*:UWS7=\7W5KA
M.K+BCN2VHK//XE+/7W/6FH*3Y,Y:GR^O<ZUHK[/?Q7PVI>V[4285L"]S5O4H
MYD+ZI2A Y43^U5DR8L$;;.>./-JY5$VNJ_MA=FVAK-)T=V?1H]I-M3W9<=;*
MG6W1^%*$>>/7CFN#)XQD:VI<'?@\#A#U9';/+.N.W34NI[JJ\VA?PTAUPN*F
M/MA;[R3T0?)*?I@UPSR3R\V>ICPPQ*DCGEVF7'4CWQ5[GJENY)P\2I(SZ#I6
M>YQX9MM3Y("; 7G,1SM;/4;<Y^GI1O#8BUBZ;4A.$,E9^E9;I-ETDB:=*W62
MH,QV'$YZ#:2H_0#DUHHI\LAM^QM=(_9NNNH%H?N[*XT4J&X*5ES;Y^$<CZFG
M++&(UBE+L[;8]':'[.(G<0XS+#S:>7$C+JS[J/3]*PGD<TZ-(P4646J.U"VV
MYI;;:F8Z%?[L[5*QZ^1K...4BI3BC!?].%O_ .N*_P"^*T_+R,_.1Y7=D1V9
MB&UVY;09^515P2>GTKZD\"Z)QC'N524QP"X<JPK.XU-EU:*F?<H+#19G-[ Y
MX<=<5O")C)T.,731\>*TCN4A2<@K'O\ Y5N^C,M4WFV_#+[I7?MIVG[XY'7H
M*EQ"QA:/B$F,VA+:#N<R/WQBIV@0V+A$: 0U$[MS&5%74CZ>5+H+"=,&0HR5
M10VIL=,YW4K%5E6N>E:5AN,E(4>//%4F!'[X)_FM[?>D:)@/B!<>0"K_ '><
M8]\TPLBKD!:5(;1N*0=Y!\*1ZY\Z?1"8TS%<D$-QFG7Y!^5MI!7D?44;DA]E
MQ;.S/7UY<;3 TS-><=44H0$@$D#)ZG/ YI>IOH.B'J6RW#3[L*V76*J-*;C?
M>-*P2D[CUQ37%)B[*<TP%,N; O<C/3'--,99-H^(C; KN\\D]:3&$TAQ*LIX
M"1C/K0)JPP[)QE:."2-U MH:E@!;;*^\P.N,52? J(JEQR$A270L?, >":=V
M')(23W.U/)/0GJ*=CH#3!5\SN?THL-HA7=[@P H;3G.WK2L*)334=9&7 .?2
MDVP40G8T!M?W9VY^8XSFI5E4#^%-*27@YX1YXI[@HA.1=BE;59]..M4*D(2Q
M(0.\=24C\/O1'GL4D6=GO AW)B0X,*:(V[CQ42C8U*CK&A>TE=NEJ@N/A<.6
MZ24G+BTJ4>0D C"0*Q<:9M#):HM^TB/#3,M.MH##[*EO!MY]@X2\U[@_C0??
MSJ64E7)4:O0XU=H&K6BD"Z-)2ZD8*ENI& 58_$H#GWII^PI<^HK= K8@ZGN-
MJ=0I*9!46$!6T@*Y*3ZC/G3J@A*SJ5L<E/QE6!Q#'?*"MC:EX<61T(_,>#4M
M&JX=G(.UNX_P=;.FH)"G'.7%$^(9IPQ\F>;+:HC:(T_9+E"^%6VRJ4L[0YNS
ME?IBKFF9P]9"O5J=LEU5$?:3AO/>%!^4CRQU/U%2K%/T\$9DM)2F4V,MJ5XP
M5;5 >H]?I3"-HT,&=(8B.-=^)\1X;T/, $I ZI4D^=)FB=FBC09:D.2DN+=2
MI&'&W"D#NU=-OL*5%K@F6]F#,9^%9A%M$CP=_P!4J2GH!CG.>@I!=B3"<,]R
M)"9<?>0"5M.'PJ7^)2<],#''-2U8R$]%CRFPF.'$N,K"WRZ,\= 1^7ZU-4/L
MR&K(:4/K6DCY]N>IQCS/F:T@S')&C,R4$K3M5Q]*UODPVVB\TU(<CRD.15*,
MAD[@H?,,^0/I[>]9S-,7!ZFAIN,RWZ>BV6,PD2(B5-L(1G<ZXO"D$=22?.N+
M)DVV=BCN/H7V/Z/.B^SJ'9YOW+K2"7$E&,*4,E./+!R/TKPM3+S9'HX8[4:D
MM[B,<5@:$EI&W"3SY4 .%I..!3L DM9-%@++/HK^E(2#0UM)RJ@8O8/S4 $4
M@$'.: #W#Z4 $<'SH *@ ]@/- J$*=V?AZ>].AA<]<TA6+R?6@8"%$8!- "-
MC@Y*L_I3;  2HT@%!)% "@DF@ ]AH 4EK(H /9MXQ0 81D=* %A( Z4 )*!F
M@ ]J* # 0/*@!16D#.* $%T$8P/WH 3O%  WB@ PL#_X= #C>7,[1TH&E8YW
M"L=1GT\Z3OV0Z7R<#^U[:G;MV?KBH9#BWT"WLA2<'O)#[2$@'U)P/WK?2RVY
M4VC/)Q&7V1QWM+[,6[;]M2'VF6-U LNKM(OQ)CB$D(1/BMICNH4?//=A6?8^
ME>MEU$)0='%#2R616^RZL"&(;*PPA2U#*? -VT+<2GKY\J-<\I>DZ8JT8QNY
M-7.^7V8Z@K9C/K;&3C"=Q HAP%69K5-NBWNWJ$=T!\9 1MR,?6K3HF:M%19+
ME<F8$>SW!>UJ.TIM(SX5J/R\TI1OD4)[>#H'V2NSUO44:ZW:;':5#;U!+=6I
M8R'BC: WCS/F?05SY)[>#7'BWO<:CMCAZ;U)J55^U?.=+4%'<QH2!E*,>GU/
MM4PW-4BLB7;*C2:8[TYEFV0#&C);W!*AG)]*VC';V96=8C6_<TVC&5K(.<>5
M4H\DM^YN;8U"L-O5<+E(;CQV4@K6KRKH2V*SG?K=$*/VLZ3E/J:AO;PDX"R<
M9J/S5\4-Z5I79/7JZ*!\0VZ'$'*L9QCBEYU^P>4T>0.V_4YN-TG%3A*%+*1X
MNG6EV[*]J/+TMX/79V2D96@AEOGS/G6A/1[F[%['_!>RU+$9.Q^6WWSBL<G(
MQBL9/DU71*[,]*+=U [)=9PW%)4215HSDCFG^D#CM7+LS+XG,QOX=(2XVIU6
M$O@.#[GIXCSNP/2JP\.@R\P/)G9)]JS4W9O9V]#ZKTY!UKI&,L_#P+@LI=M^
M[YQ#DI\32%9Y;.4GTKNC)>YPSBT^#I=N^UAV$PP7K1V,ZQC*2\9"&!?FEL!>
M1TRWN \@!T!Z9K+)"^F;Q;LH;Q]J/0^I[@CX?1:+<TRZ'&X]UDOW!IL@Y&$$
MA/"N>G6B&+W;)EF_=2+5.O'^T&Y&;)[3@7I945-HE"'DG&!A.T^6.3Z5M&*^
M3"<V;32_8;'NKI=!2\I9WCN7$J4LGYE*6"0<]?6ME&/R<[G*^CLVF?LX:;AH
M9DW5#<1@J5R^LY6H#. #UXYJ,DH8E=D1\S++:D3=1]H'9EV;NFRZ8C?&3DM8
M5(8:R@ ]4CR!KS,VLE-5!4>QIO#XX^<CNSSQKG5.NM27.>W<-8S$L+2%(:0?
M]G^%!/4<>F*\^4FW;/1C%1XCP81NPO"7L;6IP@>-2D D^V:>Z-<H-LKX8^SI
M9]Q6$L!.5'"0*SEDKHM1^326#LHN]Z=Q'B'".%*4,#]*R>6NRU!OHZ58NP9R
M, J1'[TJ&>F*7F;NF5Y1L+?V-PV,%Z,&P1YIS6KR12,EC;9;-V;1&B=\IU^(
M7AU<607#^OE^E8/+*7"1T1Q12MLP>M^W6Q6UIQ$62PRV 05).TD?\7G6L,,I
M=D3RQCT>>];_ &AWY)=8M)<DDIPD).0?^UY5U8]-SRSDR:AUPCETZ\:EU2K=
M<I2TL*.2TG.[VYKK4(P.93<A/]F4^LC_ +QHM?!>U_)/U'8HKZ$3(K"G!+/B
M(7PDCIBO9:H\I]E5;U/69EE,W*^\WY"@<)(Z#/2LGV:KHRVL-PNG>E&UIQ"2
MGTW>==$'79SS[*,+2>/F%:631-B2U,%9<\32P 03T^E4K[)+>/=U1RIQ1"RZ
MI)&5= .@I[; F2IC,]/>)*0^3E>/(5FU0%?*F!8$=M>0CC=YJI;2DB.E0V*6
M5IVI.#U 'L2:0465HTUJ"^!"K?99TQ*U;=[3"BWGV7\I'J:%R!K[?V-WB8Z(
M]VN:(ZO-,9E3KA'IGY:JF%F]TMV Z>#K(=M3SR]V=\YS=M]/ GC]ZC:BDF:=
MOL[GV="X3,> V[)!$8QQMW#/"1@=?*E;NBE$MEZ;D]GMD>?NCD9S4,L;-O?A
M28+6?D&#DN'S/D#BB3<0=' ^W*PJB.0;XVR/]84I#R@K(SU'7]:(MV0Z.5'K
MQTK5DCKK92RAP#YB<TWT-$AATK8#:%(2X3P%'&12&3!)+:$M%M"O-2@?/TI4
M :YR5$H^'4I!&,@>='0#C#"%Q%I0C81G"C\QI7040F7G8^ I&\CKD5284+8<
M!"WE YR3CRI@&R@*\3:R<<\T6("I:]Y<61SY8IC%K[H-I>(Q]*!#B0PZI#+6
M"M?3?P*D8"Q)0H-EY!_N)/EZTK$/(;0'#O ("<@^]*QD:85K6/%E/D/2JB2R
M&XAL$+4GD=*HGDL=/NMLRVW\K1XU)[P<;,CK431<&=L3J"/J3L_N]F>+#T<(
M6&R49+:PD*"DD<@C'ZUD=%\%<]&;?[)H[[\QE2H\AIY!1PI/.":2[$_I,CHY
MQ,K6[#BGEB2IK:E8YV^+D'Z#FJ9&/LZ%<KNS;+4N6S+R_$EO)8E*1XTMY\1S
M[TDK-)2HX3>+K*O][>NDM9*G.$J/X1ZULEM=G._43[==)L-Q*(D@1L$%+R$C
M<E6>5>F:3Y'![39KUA;KHT&;Y;HTT+2&D*=RE;8_.5#DDGFD5)WR3).E+0]!
M4]8[U%+K02M<>0=BD9('@<'A)Y\ZF@1&5;KI:4.LS8S25N8*'5^!21]1X3G^
MM)HM&D@36EPTL*;"'L[74K&\-\<DC\I]10.RZM,:VH4%M=S'\90@MGP) XSM
MZC/KZT4-,D)4A$OXIUE&^-X&74K(7W1Z@^6[SYYQ2HH@W>&VB/,^%4$-*(;=
MV@EQ6>0/^ ^O7K2<>!71B-9P&8Z"V'0AK 6VM?!*B.1^^:A<,4^48=MI6X-G
MG!SFMN^3#HU^D;>B1-;;::4IYQ/!2,C(/G7/DD;8XV?6+L%[#--:?TWIO6]S
MMB5WUZS,G+@RA@@<;$] 3G.[KFO&U&:FT>ICQ<'<T,A3 :>/># R3YGUKS'*
MV=<8TA@,\T$CH2,B@!92D#.: "RGRH !5CRH +<30).P9/K0,(D^0S0 D[C0
M 80HC.: '$MG% "PWQUH 0J,E7XC3L NY_O&G0J'4,@\[J*&*[L5( #8%  4
ME.* "VH]: # 2.G- !C!\J #WH1PK_"@ PZG'A2"* #W \[: $E7/2@ L$T
M-X50  %4 &6SCK0 A3:P,C- "0ATGI0 KNW/2@ PRZ<G' ZT .,-/NK#,5+B
MG%=../UH4'-\$N>TN5VU<*"]*RE^8TG.S/ 'I7LZ32;NSBRZFCD&J=0:4OPD
M0]8PGG)-K?1-9:0Z$)+B,]TLY_(25 ="<5Z,?#(Y&FNS&>I_9S_0QES:T6;:
MA%MERS)AVM46$B>4E;JU;G)$E7. <-I3C^\KUKS=3X?Y$6V=VGS^9EBG\/\
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M8T9EAF*DI8890RTCR"4IP/\ "OG\DG-NSUXNDA>X],"LU&BMS$X'I3)"P:
M4@C%  #:0>IH ,H2?,T &AM)\S0*A7=)]30,)2 GI0 @E(X*3^E #B!N3D#
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MJ=%I<!=^?S4Z"A_O6Z*"A(6<\FE0"RL <=:1(27%DX*J!V+W[>2: L >QT-
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MLH1LP? D8-&YE5[DR/:&T*7/=1R/#A?5/T'G1R%EU9XB'I3,HA"W4-E&'6R
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M>'"@_E!Y]JWE-I&6U29Z?TAI1-K8#C@!?Z<CD5Y^66YG9AAM-W;K84I0#UR
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M(GS,$$(7_P =/U/H7!=6ZYRHP03!AJ*AQE)S2:^1%BBXO]X%.6YK8I62MM6
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M'4TVEM7.T8'TKSGSR=S5(&,<44$5:"+@'&:*'0V5\T4.@LBBA4)K0@ 7STH
M6ESD4 +4YQ28X]B0GG=4F@TXK;S31,A 7NJB 'E0Q4LN(X.E(H;D?RO>FA,;
MC.'A% >Y+*.:@0-E A;; \S0.@; .:!"N* !QY4## YZ4@0%MMK&%CCZ4#[(
MRK>%$J9)!I@,.-W:,0ONN\0/Z5<%9,G70A%_2VX$28JD*^AQ5[4*RR8N;,D
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M&2G8T[=KB_)4ISR2$-E"5?J"*MZAD^6O@Y;=-==LNLT.1]8:@1!MRAC^&6A
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MJ%'FLU&;+<D4$_M"TO;'%*$Q*BGCC%;PPRDZ9&]+DQUY[<HD-2U6]I3JNGB
M(Q73'2DO*C WSMXU#(W)B*0V.<[>#BNC%I;?)A/+71SZ[]K-V=63*N13G/XJ
MZ%I8F+S,S$SM1::"E?Q(+]=Q.:T6!(CSF5/_ $O-+R$27" <80#6BPHB69D6
M3VG3I0[N+&>7GHI0JO*0O,;1!5?]32B5=UW:%=-QJUB)>1E?=+S>;;A2;BI#
MKP\0:'0>G-2X4Q[N"(M$BZQ$O2+@Z0HXX/.?>K4"6QGX.(!A;>X^N:K:B!P6
MF&4A7<M\_O1M06268R&/D:3CU*1FJI%"'FW,E85X?,4< 1E.OI) .?0&BP&"
M7'.'A^U*P$.(0$' Q]:+0J("F$;BK*@D#*B.<#UQ35 RQT]I^[Z@N2+;9+=(
MER%)4X4H3G:A(R5*]!BGYB?!&UKDL;8^9=IN4"3(FVQH/-EB4F,HEN2VOPN)
M*?%@#<D^RB#7%J?4CJPLTERMO\3LEXUMINQORD6UP";.C,*2Q&23A"59))/3
M*@3CSQFN#'':COGD4D55CU):=5$6FZ*;C71. %G&)0/IY;A_6NR*3BF<M\G8
M^RM]5C6=':@:E2[4ZE:8C[;"G'(#A_#QR4>>T]#3X1I%T3;M*T)V5VN2^_<W
MVUN.%<ZYW*0ERY3CY;R!X4CR3G K#/..;G&_^2\>/R/5D9YR[3/M0J:MSS.D
M6/@XG+27UH\<D],)SRKZ^5>AI/"-1J(>8ULC\_/V^YS9O$8*6R!Y>N]]U%K.
MXK?O$YU\.+\#.[<#[&O:TGA2Q2X5GE9M9/)Q ]B?94^PY<-1HB:[[4(;ENL[
MVU4:$K*95P1U 'FTU_>/)&<5U:OQ/!X=%X\/JF_@K!H<F?(I3^D^B]FTE9=(
MVEC^Q5NBVMF*$MB%#1L9*!T.T?[3U7U5YU\KDRRRY/-G/^![>+3PQ*D3;Q)3
M/4S<63XSX7$^:1Z&E*.3=YCZ*7P1I5YC0%(2M1RH83A)(*CT!QT^M4)NCE':
MS]H&QZ!:D62UPFK[J60VI*[:XYB+";/'>2E#A(&0=@\1'' -/A&;G9Y3?=OE
MWGOW75-U=N=R?X5,X2EEL\I;CH'A0T!P$^G4DU(F-%8CM$AM*$@D!(]*5D]%
M/.N++:3O7A5.S-LR]PO*"XXA*<XZYZ'W^M#D0ER<_P!=ZC#=EDI94I2E-J0
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MF7CPN3$ [NZ!'&TX'/7&:4I*"^Y+3D_L:]Q2)DM3^_(X2VA(PAM &$H2/0
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MQ;".1PD J^IP*F3IE.)R2,@MN-EWPE/!2:T_=)BKD7:F47*W+MS8)DK<0(H
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MJ5V[RCWA<5M;&.GO4*-]C3+2%$+:7$(."ZYXC].*M*A/DLI,5"&'F7$A25-
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MK2>5;6G4\^@Q5J .97R+Q<'U]XN4OGRSQ5*"0MQ#<ASI2U/9SD>9HD@NR/\
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M'>O!>58\@>*ZH--<D-44MY=8<EH4E6Y"#Z^=*32Z)Y*]Z:C&Q)Q6;8R.J0"
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M)#@,Z8D[&R.5%0X(/F<8!-:>PH]G+)T-JZOILUTF.,6FUG$PH!W//'D,H/\
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MID'NV&\K/0#SJMB70M]=D=^V;5J2Z-I!Q@T;65N3&$VQ.2 ,@T/CL:D*-I9
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M/@I<\FDM_: $JPE6??/6EN9M!1?9I;=VFF.1E:5I/4'RI/(URI,IXXY.&(U
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M42LGSZ4)>['V;C2EL2L MME:EG:A*1E2E;MH ]R2!^M<6?(E9TPB?:7[*/9
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MZIC22]<V8$62X>\4R,O.(\DY\A7UV7Q['I].L48W->ZX/)Q>&N>L>JG+T_\
MC1R_4O:-,N5M7I?3*'+?:75;Y#B%_>/GT)_*?2OD\LLFKR/-E=_!ZN;41AZ(
M*K,.FW)1\IX4>1Y >@_6A4EP<7-V.HMS0.Y0R,8QBGNH&FW8E5K86<=WG/\
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M'3ZUMB5P01YFSFDV>RP7W'7N_D*X" >!^M;HWE%15D71M[GP[FF-/ :8=<W
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M$7)G*3,DJ*4\[?7-)IMB*5;+0"68S>T>F*FAEM#MK=O:3)D( 4H^%/K[U25
M9+4\1YJY"4%*"58.*F78$N)*VAMQM?B. ?:D!;K8:>6E\#E0\5.A$*\Q>_BL
M,I=4TW'=W$#D%/H12: LM)VR+(>=DQ65-..H4<MJVA(Z# _K510%E-1(M,HM
MVYP37GD ++O"D) Y2/7-55 ,*<C1(K7>,K$E84$AY/XCT!(]#YU-#%P[1#MT
M=<]AY$=]3:=W=^+>HGFBN 0[MG0VS,DMJ?(\2$H&2:%P4<VU+.D:AU/&@,LN
MJD1\_<D8*2>N?0 >=9M\T#Z#&DKI=WU#^,E,9(*U=QT&.",T.-DW0U=-"VN+
M#:<B!]YU:2HJ4Y_E24$N1VV5+J;C$0TEA)2&SXO0CT)IU8BJO5M1@7."TI*<
MY=1CY3ZCVK#)#:]R*B_8<@ZL?AJ9'PX*4\+\?S"CSOL&PT\G2L'4$3^(VET=
MZH;TX]:U<5)<B3HH'[8N?(-KO*A$NJ!]T\X<-O ?A)\C[UE*&[B78UQRC.RX
MC\*0N-*96TX@X*5#D5A);71:=C-%C%( W J/&>:J"5VP9I=.:@3!?_ATM]2X
MB_Y:E=4*_P"5="E4MIG7%EGJ1!:AA:2,XW<>AK1$F,[]59>8:4=O?5_$8:)T
M=Q1"24+2.J5#R-$K1I&I(I7)2DQEE/@<2L$ >HYS4M6J*B]LD?2?L.UI#UIV
M76;4C:TE:6&XSJ >$K;&T_O7@9H>5D\I=,^EQOS8QR/V*7M#ODMB\N0X3A!F
M 8QY ?\ PZN-P]/P;1BK<F0-.V1ZY/=S\* $_P U?.5*]:UAZF&7)Q0-<Z>7
M#BMOQ,I,904<>?UJLD=IA"3:HUMMU%\;IIJ0RL;TH""/+(K#&Z9KD@MMC;3J
MWD. C;M&5+</!^E=#?N1C*.9,CMOI&[(]1T-<T[9V0?'(&0;BS*B*Y1):4TH
M>WK4XFW+D6:-0:/F?KFV?P76=XMC[10IB>LI!'X?*O>P]'QFHA4F0XR0DCSY
MJY6_<SBMI.::Y*AY^5(;=DUEA(3N)-*Q"=SBLI0G'O18(EP+49"PIXDGT/2B
MS1*S3Q;2RR$+#:<BDV^C102Y+,P&IK996C(<!;/]T$=145MD4_5$X-,BN1)D
MB*5$*:=6A0/J#6\+HY'V,C<!XN35?J2P\^PI@'QZ4 '@>E*QTA]I*?/BK)'
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M>E>?#]FJ1W;5+D4MM0.\$$"F,<;7D84D$>8- #B68[N5-H&1UI6 RXAO(3L
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M5.':>@)K3:0I6-E*R DGBDT.[!L+?C]*@JJ$K6'!M(SYT!R-O*>0D+WG&<4
M(+J"G! )H]T-(@SHI4E+P6EHMJ#@<<5A''X3]:,OH=CO<J/->GOLD]@^B.UN
M3VR::TNX-2//.3&U.SR^Q$>7G>ZVSCJ<GDGC-:9-9)XMH0TT5+<=+;6LCX=
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M/J:8%)(*'I"MPR!R*FBT9K7MS;A6.4Q'7W;KF$ CWK&3+]CG&EHC+UQ:0L)
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M@UY:/=[2@<>/?QU X-?.8L5XXO\ ^++W /A)/K6*X-URB,7"X>* 8.3TZ^5
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M--,!87Q5V*@BKWHL*"H"D& ?2G3%P.1\[\ $D] /.F@)+:2L;DC('!QS2;5
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M]ZI,:C9T&T:,M+#C??N_$NE0"2@[$@Y\ZB4S98DC7.6=ZT/_  @AM1'-N\\
M[D^N:<7?!>VD M-A.]S*E>W2ME$R8RI2>0EK;[T]M$,2%;1S30(;6I((.:&(
M2MQ6!2&-;U#K0QH-MT%6,\UK RF>Q/L17:T1['?K4[<HS=SDS4K8BK<"7'$!
M')2D]?TKR]=&4I-/HVBELBW]ST\EUL (W=!R?(?4]!7EJ>.2V0[+<J%D,I2%
MI4.><BIDJ5#BVR(0E_.P[/I6#[-ND-MX:!VOD^U$IL$(=>X)*MJL<>U8.;-5
M0U#DA]AQ6U2@/Q[3BJBVR714ZIU5IG2%E-]U'>HT"+C*5.D%3O\ =0D_,?\
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M:(E-S#YUDT.)*:=4I.*S:.B(I,@@\DU5C:)"9&1P35(AH,O$#J:H@:4YN\Z
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M^QIUYQY16XXI:E<DD]:S<FQI"*ANACC248"G,[<],=::YY9+^Q[3^Q^JPQ]
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M40,[VD6T.V[^(1\[FE;CY\5$^%P-$RSR43],M.D\);Y\^:CM6(YS<TKN5U#
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M-NOVKM&6R7=[;)$EB66PCO"#D,NI3@NMDC&U7K514'TQQ?\ Y%;_ -!VF?\
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MQM23_A5B+1.M[9IQIF(\AR4XVK)"#@5+R+'V.F^B>KM1M<EQ,@;FDJ  2?\
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MW';6^"A3CB7>5$CI5("2JWME:$I>W! QC^[Z55"$H6XTM:%!(:5X0HG(0*
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M3(T;::5%P[+2.@(/UJ&CJBR0 ,E7I4;;- ^]!&:-H@N^4.!THH!27%_-ZTZ
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MMSVKE%85&AM)\*>Z\>!Y$\ 'K71=\@^'1#N=X%TBB9,6I3?3NT8"E#TZY/\
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MR.E6H<$N5<"DQLJJMHG(=1'3YBK416/I !- [+]A"JJB!80A XJP%I:4H9-
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MGAEG;([3#??N$J4H\ <FJC':9RE9<1(BE)[YU.$D\#SJF23VF^<>E- 2$8(
M3U"AFN[1X=\R<DZB3E* 5M2.*^I@J6T\E^IB%').*T)$;A0*POF'44DA4#:
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MN#[LJ3D$<T) WN'$#"0DU1.T,C"A0%4*VI(S3$!"=A*AU-.@%9)Y-  2K"L
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M.Y@2@!6310-V.;*="%!)5T%,!U+9!&X]*=4"'4@9Q18Z0ZE"1S38Z%8'I2
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MA2G]J6U!8W(BQ]P24 )Q1M1=C?PK24!+)0K/X?6EM06156Z*%E$@J6I71('
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MON^+6: 'V9Y+>"O/_9HL!MM[O7EC%  4V4K^%"]I/.: &G>_2ZEI1&P]5>=
M!)=,9MQ2/O"E6[:>*$ &E$)*ELA)<\22#GD\4[ BEPY=: 2KN\)6E0ZU+8(D
M0]BVU;2KP^+"C\OL*2&Q+WC:5_?.:3&B IQ3!#"?KFH9:'U(+C"5-\+(YJ+*
MVWR-J;W!M#G*@,'ZTK#8-NH;6I8<_EI&/>G96PK9#BX1[QMX]U_M!CFBQ;!A
M]"GPB?$>*)"#O20,92.:S?R%FPT!VBRBRF,XC:6D+W(5SGWS4-6BE*CI:K7$
MU-&0F6T%(E1@X01YYX_K6,H<&T,ELS__ $-(_P#9_P!*YN3J/__94$L#!!0
M   ( ,D]058D6*GM+W<% "=W!0 0    >%]C;W9E<F9R;VYT+FIP9Y1X55 <
MW1/O$MQAT>"RN 6".RRZ^.+N+L$UN 8(LEA8W!V":P(DP3]\<4AP@CL$O_Q?
M[M-]N3U573.G3Y_NF6KY];PLOJP#"" *R@H )*0W *;7"_"R @ #D-_\C_['
MD5\)!0WE?X2!AH:*AHF!A86)@8F)A8./@X6-AXV)B4N(BX=/0$!(@(4#) (2
M$+W>$_SO$*3_:2*C8+PJ$F!C8A/\?]-+'X 0 U4#N1\9B1#PAA )F1#IY1>
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M^7&(8>KX_)@1Q>DX6W4XIH,)'B"$,KH+$UBX/(K:04E=NBA^L(9\@@U(P&^
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M*M<<$.F=Q&QL/Y1%'8 9*#;B@Y+4 54F9BZMEPBODD%TA!*2V:Y;"X"BK<E
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MS[\T"=:RZ(:=E;"&1Z45.-45_\+I]DS>$->,.8K.(RZAPV=O]6/WE1,?49[
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M.LHJQZFT+E\K[ YM6"8WGF]&5:M.-.O7\8J.E-X?[7]2,L)?\=]\];JW R3
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M0]X^)VL?/\,T5Z,_EH9)X'DN)R^!C\W\A.3&T1]>ZR3Z/4T.NOE/ </BS1<
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MSOFR8.8+X'H;_W&#9)?_S_?8UW>HGPMM+WCBN;"O#A&;)REIZ:!]6DY] >3
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M[4.SOM<MCME:D O26_Y]KF?RWL A64X.%@$ [D'(QGBMN#6Z?J$=B??R??\
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M[7"5WY/N=#I74<FOW*<:KS78TG_D_+K<1=-9V53BS;OEX<S:?I3(*UHR/0E
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M_7[SE]4Z>]!GVK[+Y7R]/N+MWYK><TP^V+__ "K+BO/_ ,(K_P#-&Z\_#_\
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M5BF5. W*5@D;>E)\L$ZX,K[9OAYTSVOANZ&2JSW]AL--W!MO>EUL?2AY&1O
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MN'!JCDY'[+R%JR.M4[7YFA37D.-J5#D=*18TFK&$QDK&$],5IQND9,D;(*1
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MLH_U;)Z(TWL+^&?17P\2+[<]+WR^W3^,QF6Y"9P:64)9*UCNTM(!*CO/'.>
M!FM.#31TK;BWR9]1J9:NE-+@:K^,;X6U$H=[48R5))!2;7-!!\P1W/!]J3U^
M)_Q?F+_3LR[1_(U33MWTMJS3L#5FF;C%N%GN<<2XLQ'"%M'/B\6"G&#D$ @@
M@XP:MCDWK=%\&:6+9)QDN48_,^+SX6RI:5]J$+P$@E-OEE/'4@AK!'N.*A'J
M.&*K=^9=+I>>3O;^1J$"!:;U:HU]A+/R,V.B6RMUI3)[E2=P4I*P%(\)SX@"
M!UQ6Z&?<K,$]/3<68;K3XJ/AQTA/=MB]9KO$EE10X++!7+;2H'D=Z,-G_JJ-
M9I]4P8W5W\B^'1]1D5I5\PFBOB2[!-?W%FT6O68M\^0L(9CWB*J$75'HE*U9
M;)/INR:MQ=4P972E3^/!5FZ/GPK<XVOAR7#METX&>R/6[Q; +>GK@KIR,1UF
MIZK*WAFO@_R*])I]NH@_BOS/EYHMOOM8:?:_KNT%/ZOMBO)8N,D?FOS/;9E>
M.2^#_(^@_:7VZ=A_9=J"7IR^ZD=F7:*ZI$F):HAE*CJ!^EQ0(0E7JG=D>8%>
MOS=6P8);9.W\#Q>#H^?/%2BJ7QX)CLG[5>R/M?F*MVC-2A=S;0756V;'5&E%
M ZJ2A7"P/,H)QYXHQ=1Q:IU!\^A'-TS-I%>1<>O=&PMZ90P@?RTGSSBK)96B
MF.%,Q_5_Q3_#KHJ8Y:Y^LS<YK"BAYJS0US4H4#RDN)PWG[*-89]3PP=-_@='
M'TG/D5J-?/@C[!\8OPVWV6B$K5$ZSJ<.T.72U.LM9_O.)WI3]S@5&/5L,G5U
M\T2ET?/%75_)FPMIBRX[$VVRF),:4A+C+S#B5MNH5]*DJ!(4#Y$'%=+NDTSC
MN&UM,R"5\5GP[LEYE_M#CI6T5(6# E'!22#_ -'Y8-8EU+31?V_Y,W_Z1JVO
ML?S0\[2.V_LB[,1'9U5J4?.RV&Y3,&%'5(DEE:0I"U(3_9@@@C>4Y\JOS]0P
MX/MOGT*]/TS/J?L1X7F^$1G9S\1/8IVE7EG3UEU"[#NDE6R-%ND0Q52%^26U
M$E"E'R3N!/D#56+J>#.]L7S\2S/TG4:>.^4;7PY-8EV8M)&U./85O3LYK6TQ
M77?Q(=D&@;J]9+GJ-V=<(ZBA^/;(QDEE0ZI6L$("AYC<2/,"L6;J.GP2VRE;
M^')T,'2]5J([XQI?'@7TA\0O9)K*)/FVK5!85;(KDV5&F1ULOH8;3N6XE'/>
M!(&3L*B/2IX>H:?,FXR[<\]R.?IFJP-*4>[JUVO_ #U%+3\2/8G?;I#LMKUP
MS(FSWVXT=H0Y [QU:@E*<EL 9)'4XI1ZEIIR48RY?P83Z5J\<7.4.%\5^IJ*
MHJ$-EUPH0E*2I2E' 2 ,DDG@ #SK=9S^[HR'4?Q6=A&EIJX#FIY%V>:44N?P
MF$J2VDCJ.\RE!_ZI-<W+U730=;K^7)UL/1]5D5[:^;HL?9W\2/8?VAW)FS6;
M5HAW*0H(9AW6.J&MY1Z)0I64*5Z *R?(48>H8,\ML9<_'@,O2]1@6Z4;7PY-
M>7'7')R2,'&/2MDK,35"C3H5A.X#W)X'WJ-BCR?,'XDNV&?VQ=I<^XMRG#8K
M4ZY!LL?/A2PE6%.X_K=(W$^FT=$UY/6ZEZG*WY+M_GQ/:Z#2QTN%+S?+_P ^
M!H78!\(R.T+2;/:)KR?,AVB<5&VPHA"'93:24EY:R#L02"$@#*L$Y QG;T_I
MBU,?%R/CR2.?U/J[TD_"PKGS;\BQ]I?P=:99L$NX]G<NXQ[G#:4\B)+D=^U*
MVC)0%$!2%$#@Y(S@$<Y&S4]%Q^&Y8&[7D^;.?HNOY7D4=0DXOS7%'E33FIKC
MI*^P=36.8&)UN>3(95NQDCJDCT4,I(\P2*\]BS2PS62#Y1ZG-ACGQO%-</@^
ME.G[Q%U)8K;?X/\ WO=(C,MH YPEQ 4!^6<?E7O<<UE@IKLU9\URXWAR2QR[
MIM?@4[6G;OV5:#F.6R^:I;<GM'#D2"TJ2ZV?1>SPI/L2#[5ES]1T^G>V<N?1
M<FW3],U>JCNQPX]7P5^T?%%V+7B2F*N_S+:I9P'+A 6TW^:T[@G\\"J8=7TD
MW6ZOFB_)T36XU>U/Y,U:(J//BM38$EF3'?0'&GFEA:'$'HI*AP1[BNDJFK7*
M.5).#VRX92-2=M79?HV^R-.ZDU:U!N,39WS!C/J*-R0I/*4$'*5 \'SK)EU^
MGP3>/)*FOF;,73-5J8+)BA:?Q7ZDNYVR=EMHTC#U[<]81T6>X+<;A+#3A=E*
M;44K2VSMWJ((()Q@>9Z5&>OP1QK*Y</M\?N)8^F:F>5X5'WEW^'W]A/1OQ9?
M#]J:Y,V,ZBG6J0^ONVG;K 5'CK43@#O<J2C/]_:/>LL.JZ?).DZ^:-\NC:G%
MCMI/Y.R\]J':/V=]EEO;G:TU Q 2^2F,RE!=?D$=>[;1E2@/,]!YFMF;5XM/
M&\CHP8-%FU,G'%&S)[%\6/8G?KDBW?QV=;%.KV-O7*"IEDDGC+@*@C[JP/>L
MV/JVER2VW7S1JR=%U>..ZD_D[9KETNUNLEHEWRY2DM084=<I]_!6$M)3N4OP
MY)&T9XSGRKH2G&$7*79'+A"622A'N^#/[3\2/8K>KI#L]LUPR_,GOMQH[0AR
M 7'%J"4IR6P!DD#FLD>I:6<E&,^7\&;I]*U>.+G*'"^*_42UW\278_H&[.V*
M\7Q^;<8ZBB1'ML4R2PL=4K5D("AYIW$CS J.?J6GT\MDG;^')+3=*U6ICOC&
ME\718NS7M3[-^UYIY.B[V)$N*D+?@R&2Q*;23C=W:OJ3GC<DD9(!QFK=/K,.
MJ_=OGT\RG5:'/HW^UCQZ]T5777Q&]C6A+L]8KAJ!Z?/C*+<AFUQ3)#*QU2I8
M(0%#S )(\\55DZIIL#<).W\%9=AZ/JM3%3C&E\718.S#M?[..U-UR+H_4'>S
M6$=XY!DM*8DI1YJ"%?4D>922!YXJ>#6X=5QC?/IYE>HZ;GTG.1<>JY15/BCT
MKV'7Z-88W:IKI[2=W2V^JUSF8;DDN,[D]ZA:$I(4G<4GJD@]#@D5CZG#3345
MFEM?DSH=)EJL3D\,=T?-=BP_!IH_L*LC.H&.R?7;^K;P41S=YST-R,6V2I7=
M-H0I("4;@L\%1)')X K+HH8(7X4MS\S9KGJ,M/-':O)&Q]H_;SV/]C2D1^T'
M6<:%.<0'&[<PVN3,6@]%=RV"4I/D5;0?(U9FSX\/$F58--DS<P7!1+7_ ,HA
M\-:Y(C/W#5,1!.._=L2RV/<A"U*Q_P!6L?UW$WYF]:'*EY?B>A.S[M'T)VH6
M5.I.S[55OOMN*N[4[$<R6EXSL<00%MJQ^%0!K1"<<BN+LSY(2QNI*A37_:5H
M+LLL9U)VAZKM]AM^[NT.RW,*>7C.QM !6XK'X4@FE.<<:N3%#'+(ZBK,#E_\
MHW\,K$LQVYVJI38./F&K"H-GW 6M*L?]6J/KF+XFE:'-\/Q-8[*?B([%^VM3
MD?L[UK$GSV6RZ[;GVUQIJ$#JKN7 %*2/-2=P'F:MQYH9?LLIR8<F+[:,]^-7
M3O8)J30MGMW;CK*1I3,]PV*[1HRWW6I(:RZC8E"@I"D8W)5CHD@@BJ]2L;BE
MD=>A;I99(R;QJ_4SWX(]$_#%I35EW/9;VJRM=:P=MJBZ_(MKL-,2!WJ L-(4
MC&5++84HJ*B   !G->FCBC)[';+=5++**WJD>KM5ZMTKH>QOZEUGJ"WV6U1<
M=[+G/I:;23T3D]5'R2,D^0K7*48JY,QQBY.HKD\_7;_E"_AD@3%0X]\U!<$)
M.TR(=B=+1]P5E"B/^K6=ZS$C2M%E?-&D=EWQ"=C?;.I47L_UK#GSD(+CEN>0
MJ-,2D=5=RX I0'F4[@/,U;CS0R/W653P9,?VD6G6NK-,Z TO<-8ZNN2+=9K4
MVEZ7*4VM8:05I0#M0"H^)21P#UJZ4XP6Z78I6-S>V/<SC2WQ4?#YKW4MNT;I
M/M"8N-XNSWR\.*F!*077-I5MW+;"1PD]2.E1AJL4I*,7W)3TF6$7*2X*)V@?
M&)\/NB+](L4G5$J[RXKA;D"S03*::6."DNY2@D'@A)5BI2ZAAQNF[^11'IN?
M+[R5?,NW93VU]EG;/#?_ .;_ %0B9*B)#DF!(:5'ELH)P%*:7R4YXW)RG/&:
MMQ:G'J'[C*L^ER:=>^BP7B'A:AC/-;8LYF1%9EP2GQ)X^U:%D78SO'YC1MQ4
M=05N/A.:MM-%=-,G86HNZ1]1_6J)01HCD99K/?$R2E/F1FL^2"4;-4,CLMD9
M8<;"L5D:5G0A)M J;2?(4G+:61ANL35%;5U0,?:C>1>,4;90E(&!493Y)1Q\
M E+?0I%1WCV!L;1QP*L3L@XT$2=W%-K@@G[P<*"./.J2XXN9H #?3L5!D\I*
MO2FN2N?#"=Z*9 [ODCC%%@"N4V!].*+ C7;T@ _:KW J\4!B^MJ(220#1L0>
M*+JNT?'!S]Z-A+Q".GW!*D9 J4841EDM%?ESBLGQ'BKX1,LY$2[)._A56J)2
M[ER(JD*)^JC:A;6$,D^9HHDW2$5OGGDU*BML;JE#!)J5"L3,L8\Z:[A)\!3)
M!'&:D5V-'I2L$%1I=B0Q7()SDFA$9,:/2.#R:L2X*F^1F[*XI-#3&3TWRJ2H
MA8R=DJ)^HU(DF$+F>34"="2G #DT)\B:X$G'A3;(T-UR=OG3CR)\"7S9/F:*
M"Q-;V><T-T+N)[P?.D% ;_>E8Z."QFBPH4"AY4Q4<3F@*.P/2I#/8B',*_\
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M4C^D+(V*'0DI/4')TG5RQ95A;]V7\G_<?6M%'-A>>*]Z/\U_8K7Q6#;V]:G
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MM;SL>P0-Q[MB,DD=\4]"ZX!O4KK@A(X2!5.?,\LK\O(NT^%885Y^9Z&[*_\
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MDVI1B(6I:&'%/+6I 40"?"ML\CSK/U.<LLL>22JXFKH\(8HY<4'=2[_<:7\
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M=-A#)YZT$6G9W?GUH$*B1R*5DA825$XIM@"7JA9*@.]/M33H&=WI]J=D>#V
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M*SZ10EV?ZG"U>>6GUTIQ[K]$>0>T'X1^W;L[N[C4;1\_4,%IS=&NEC:5(0L
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M'^TKG=9:^M?<CK=!7_=/O9>OAY[I?PI=H[H<20DW;D'('^HMUJZ>U]0R_?\
MD8NII_ZEA_\ 3^;/,.C'F3J_3^'V^;K"_&/]NBN'A?[2/S7YGHLZ?A2^3_(^
MH':*XE&BM4Y./^Y-P_\ (.5[?4?NI_)_D?/=+^^A\U^:/EE8'F?XK:_Y[?\
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MU^19T_I_UG]ID^S^?]CQ#\[VS]LEX?=:D:PUA<4CO'@RJ1*+8/0E*/"V/08
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M^]9I_P#FCS2T.I__ "V3>DNWOL=US?&=-:.[3++>+K)0XXU#BOJ4XM*$E2R
M4C@)!)HAJ,626V$DV&339L<=TXM(OY*3C'7SJ\SB[/T57+N6P[!ZB2.H Z@
MA&1@U)%;")2 H8ID%W!<44@8H)"96#]= '!>.$=* .+BB,'% !T(3@*\S0 5
M3*5<E-2L7(4(P0<8_*E8T&*4DY)HX)T"E )XH9)<"J$E/4T@#5%@" ,4@!H
M5'04 +;15=$P>[/I1P .Q7I3 ,ALD\BDV-*P_=CTI62VG%(2*38T@ 1CFE9*
M@P)QP:+)*(.5>M%AM"[S19&CMY\Z+"@=_H:+"@-_K184=O\ 2BPH$*5ZT6-1
M!RKUHL>T $\TTR*B0MW@]_A)&16B'8RY5R,6;$A?A+(P?/%2\:BKP+%QIME'
M/=@_G47GLDM*"+ V3PU4?%9+ZLA[&LS3:2%M#FHSRR?8MQ:>*NQ7^#L$[NY%
M5^)(L\"(LQ:F6U;DM8-2\1T26)(>IC,CDIY\ZKE,FDD*%IO'TTMQ*HC=UA"T
M$!/..*:ER)Q54-/E5_TU+>0\([Y92>=M&ZPV;>0'$MI20H<U*R$B->82^YN
MX'%3C(JDK.1%2VK!3Q4MY'8*/.,M("0!QQ4E.^",HTB!N4Q!! /K5ZBI<F>4
MVN"M.)"^5#.*OC(S/D9O-MJ5C:/TJS>5O&-EQ03PD8^U0;8; S4=M)R4BCWF
M2BMO<6PV.J114A^Z%):!HJ0>Z(OO(2,"DU(:VD;(?14_>HJ]VQL=BNO^-%,&
MXA.Z;]3^M3J132"%"0?.D[)))<A58 X\Z52)7%B9V@Y SGUH]Y";B"@(5P4B
MCDC<100VE\[!S4E85%G?P]@?]&/TI\AM0?\ @[9&0A/Z4UD!XR.GV1M]6$MX
MS3WVR'A41CNEAGRH<Q+$+1M'H<4,@?K1N&L?)/0]'M-)!+:3FD\E=R:PV/DZ
M8;4/[))QZ57XUEJP(*K2NXX2P/TH\4?@(.G0I<&\QN32\9C\!!?]"$@X^7Z>
MU+Q@^KHD&="MK'+0J/CEGU9"4O0Y:2K#(_2A9G="EIE1&.Z.)X[BK/%93X*"
M(T4M9PEFD\M$OJZEV%_] W?]B*/%#ZJQQNK88.4 21R* 3"DD]30,#=MXH"@
MI=YH%09MX]XCG\0_QH#R/E/<^;I-_P#PI[_RBJ^<R^T_FSZI#[*^2_(T+3WP
MY=L>J;'!U%8M,-R+?<F$R(SIN,=!6V>AVJ6".G0BMN/IFJS062$>'\4<_+U?
M1X)O'DE37?A_H2"_A2[>5(4D:.:R4D#_ +J1O3_?J?\ H^L_X?S7ZE?^N:#_
M )_R?Z&G_%Y=+M9.S7LVT#*W,GY1+TYL*!!=C1VFDI)'!VJ6X?3H:Z'692QX
M,6%^G/W)(YG08QRZG/G7KQ][;(+X'M,6R[]H]VU'<(Z'G=/VY+D/<,]V^\YL
M[P?W@A*P#Y;LUGZ'BC//*<OX5Q]YI]HL\\>GCCB_M/GY(]9]L.F[;KCLQU)I
MZZM)=0Y;WY#"E#)9D--J6VXGT4%)'/H2/.O1:S%'/@G"7I_-'E]#GGI]3"<7
MYK\'W/FEI'4,W3&I;-JBW.%N3;9D>:V4^12L*(^Q&1]B:\-AR/%..2/=-,^B
M9\4<V.6.79IHVSXW5H<[:&7&QA*K#"*1Z K>(KJ=;_W7W+^IR/9^OJG'_)_T
M)CX.>Q;2VO'+QK;65L:N<6TR&X4*$^-S*WRC>MQQ/1>U)0 D\9420<"I](T>
M//NRY5:7"15US7Y=/MPX73?+?P-E^*S3M@T_V :@18;#;;8EZ;;>\$.(VP%[
M9"=N[8!G&3C/K72ZKCACTDMB2Y7;YG)Z/ER9-;'?)OB7=WY'D3X?M+6C6G;/
MI+3=^C)DV^5/WR&%?2\AMM;FQ7]U10 ?8D5Y[0XXY=3"$NUGJ>I998-+.<.]
M?V/9WQ?Z4T_,[!;Q<%VB&B39%Q)$%UMA"%,$OH;4E)2!A)0L@I''3C@5Z'JV
M.#TK==JK\3RW1<LXZQ*^'=_@>)NQ'2]LUIVO:0TM>F0];[C=FFY31. XTG*U
M(/LH(P?8FO-Z7&LN>$)=FSUFMRRPZ>>2/=(]W_%;H_34WX?-2/+L<%MRQQ6I
MEN4U&0@QEH=0G#>T#:DI4I) X(->CZCC@]++CMV/*=+RSCK(<]^'\3PW\/2U
MM]NV@2VHI/\ I#$3D>A5@_L37G='_N(?-'JM?_M<GR9]5FU*& #7K^/,\4N!
MPE;IP 22>  *? K9YE^(?XTK'V?JE:.[,%1;WJ1O<U(GG#D*W+Z$#'#[H_I!
MV)/U$G*:X^LZC'%<,7,OY+]3MZ+I<LU9,W$?3S?Z'BRPZ<[3.WC7CL:V,W#4
MFH[JYW\N2\O.T="Z\X?"VV.F3@  !(Z"N)&&759..6SOSGBTF.WQ%?YP?1+L
M;^'NW=B799>]/PI*;AJ"]6^0JYW!*"D//?+K2VTT#R&D%1"<\DJ4H\G ]#I]
M*M-B<5RWW/,:G62U692?$4^%]Y\M2E0AE!'B#.TCWVUY?R/7^9]G]$.MS=%:
M=F1E;F7[/!<01T*3';(KV.*G!/X(\/E59))^K_,QOXZG6H_PWWE+Q 4_=+8T
MWGS5WX5_@E58>ITL#^XW=*7_ 'E/X,\+_#'$?F_$-V>,1@=XO\=PX\DHW+4?
M^RDUQ=(KSPKU._KG6FG?H>ROB*^,:^=AG:.="0- VV\-)ML6=\S(N#K*\N[L
MIVI21@;>N?.NMJ=?+3Y-BC9Q='TV.IQ^(Y5SZ&8+_P"4JU2A"E_\T5D.U)./
MXN_S@?\ R.L_^K2_X?S-7^BP_P";_!&E_')>%:B^%FP:@<CH87=+G9IRFDJ*
M@V78SKA2">2!NQGVJ_J$]^F3]6BCIL-FJ:]$_P SP)H[2.H->:GMVCM*PA,N
M]V>[B(P74MAQS:58W*(2.$GJ:XD(2R248]V=[)DCBBYR[(U\?!!\3AY_T 9_
M^;,/_P"B5J^H:C_C_-&7_4--_P OY,UWX4OA>[<.S+MNL^L=;:2:@VB)$G-/
M/IN4=XI4Y'4A V(65'*B!TXK3H])EQ9E.:XY,>NUF'-@<,;YX\F>[%[Q])Q7
M9M'$VL.VX\E. ,U7)\A30LTM:N5<>U)4%L6I%B[!D 'J* #J:&#@5'</:AN4
M%*O.G"7/)&4%5HXISU&:NN)73"J:!Z"E<14SDM@#E-%Q"F IK)R!BBXA3!"%
M@<$T7$*8;!]Z=Q"F=M]J+B-)IG=V/05&T6<ADIVG(%%H%;#I]QFE:'0=*0>H
MJ$WZ#2#I;3CZ:A;!H.&TX^FGN)*(<-IQ]-&X>T4VCTJ-DZ0.<=:04@4K3GD4
M!M0<J2?I&*&R4(JSD\GFHMLLI"O=A1Z4K84@_P LW_0*.0H(60#@ 4<C''<-
M8_LQTID1+Y='](I<CI *C) SM%,7 3N$C\(I<CH.VPV<[D T"HY<=&? D"AA
M09#"-OB2,TT.@JF!N. ,5%L  QCR%%L*"/Q$.'(0*GXDNR9%XXON@6HK:4$*
M;!-1;'&"0<1V@,A S45=EKVI<AFVD GPBI)L@Z%.[1_2*&V-(X(2.@I6QT<$
MI!R!S3Y9%B:BG)SBHN+87'S.<<C <*&:>UANB(EQ '04;6"E&PBI"$C-"BQN
M:$'IB G\ZG"+3*IS31$SYX&,'KFM$8HRS?H(1YJ0DG/G4I12[$8S=!)%Q\7"
M_*EM0.;]1@_+6O)WG!J<8+T*Y3;\R&EJRHDFKXVEP42IC!TD#BI+N4OCL,W3
M@Y]*M2\R&YW0F7O>G;&)%[!ZTDV18FY(Z<T[8A%V0,9S35B?<:KD9'*J'8^!
MJI:5$Y&:FNQ6^X'?)Z8H$<IW"3C--V,1*R?.A78I=C@-W!J?<AP 6QD#UJ,A
M#EJ-A.2.M*B20H$EOBC=18HCR)"<D'/K4-[ON2V<$HJTNA(X\JK<D6J#H0-G
MD+'A:_:DI\@\8DNQ/8W+:Z>=3X([6*1+80YM*?*HRDJX)1B[)Z- &U*=HS5,
MYE\,=D];K$A2%$M)Y(ZUGED:\S5#"FNQ(HT^R!GN$Y^U+Q7ZD_ 7H+)M6P!(
M0 ![4GEEZAX"]!%5I25'P)Z^E1\27J/P5Z )@H9_ .*GV%2$I##;@(* 2::;
ML3BJY&OR$?.5,IJ6Z7J5[(>@9,..DY2TD?E1ND_,DHQ79!NX;_H'Z4KD.D9=
M7;/.!5DX'- !,GUH "@#L4 <C^U1_O#_ !H!]CY67+_X*3/_ ,*>_P#**KYQ
M+[3/J</L+Y+\CZ*=@G_UEM$__J9C_.O==._VF/Y(^=]4_P![E_ZF7Y/6MK,!
MYX^-/1,V^Z&M>L(#*G3IN2X)82,E,9\)!7]DK0C/H%9\JX/7,$LF&.5?P]_D
MST/L[J8XL\L,OXEQ\U_8P_X6NU.R]F':!(5J>3\K:+W$^2D22DE,=Q*PMIQ0
M'.S.Y)(Z;L] :Y'2M5'2YGXG$6J.[UG13UF!>'S*+NO7U/3';;\0?9WI_L\N
MT?3VKK9>+S=8;L.#'@24OE)=24%U91D(2E*B>3DG  YKN:[J&''ADH23DU2K
MGN><Z=TO49=1%Y(-13MMJNWD>+^R;0L[M$[0;%I"WLJ4F3*;5(6!D,Q6R%.N
M*] $ _F0/.O,:3 ]1FCCC_B\SV.MU"TV"667I_/R-3^-]*4]M+02,#^!0B!Z
M#>]Q6_K?^Z^Y?U.9[/JM)7_F?]#9O@*1N[,M0G_[_G_S9JM_1/W,OG_1'-]H
M/]Q'Y?U9;_C);V_#]?%8_P#AVW?^<IK1U;_:2^:_,S=$_P!Y'Y/\CR'\*//Q
M"Z,__"G_ /S5ZO/]-_W</\\F>FZMSHY_YYH]G_%J/_R>-6G_ .)Q/_.F:]!U
M3_:3^[\SS/2%6LA]_P"3/$_PPC/Q!Z#'_P!]Q_Y)RO.:#_=0^9ZGJ?\ M,GR
M/>'Q0H(^'C71.>+6G_RS5>BZC_MI_(\MTQ?]\Q_/^AX"^'E.[MY[/T^NHX8_
M\.O-:/\ W$/FCUNNYTV3Y,^L;; &!@5ZQMV>-25'E#XY>WFZ:(AQ>R?1LY<.
MYWF)\U=I;*MKC$-9*4,H4.4J<VJ*E#D(&!C=FN3U+5RQKP8/E]_D=GI6CCE?
MC37"[?/^QX6L35D=NT-G44R9#M1=2)3L*.EY]#7GW:%*2DJ\AD@#.3TQ7"CM
MM;NQZ&;EM>WN>V.S7XN_A<[)-/MZ:T/H/5T&*"%/NF%'6_+< _M'G"]EQ7WX
M'1( XKM8M?IL$-F.+7X?J<'-TW5ZB>_))/\ '^7!L_8[\6O9MVTZR&C-)V;4
M,>>F&]/WW",RAHH:*=PRAQ1R=XP,>M:<&NQYY[(IF/4=.RZ:&^;5'@;XE^R>
M=V/]KMZL*HJT6J>^Y<[.Z4^%V(ZLJ"0?5M14VH>12/45P]5A>'*X^7='H=%G
M6HPJ7FN'\ST_\+/QD]F]F[-K9V?]J]Z<LMPTZS\G$G.1W'6)<1/]D"IM*BAQ
M"? 01@A*2#G(KHZ37PCC6/(Z:.9K>G9)97DQ*TS,?C/^)W3/;"BU:%[.WI$G
M3]KDF?+GNLJ9$R3M*&TMH5A7=H2I9W* *E*X&!DY]=JXYZA#LC5T[12T]SR=
MV2G_ ">G9)/OVO9O:U/B*3:M-LNPH+BD\/3WD;5;?7NVE*)/D7$BGTW$Y3\5
M]E^8=4S*,%B7=_D>GNUWX/NS/MJU@K6^K+GJ)B>J(S"V0);3;7=M;MIPIM1S
MXCGFNAFT>//+?)NSFX-;DT\-D*HI:O\ DX^PM22DWW6>% @_]T&//_\ $53_
M *;A]7^/]B[_ %7/Z+_/O$_CVLL73WPQVBQ0E.*CVR\VF$RIP@K+;3#R$E1
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MT&:30 =SCR-% *H;PD4B2.Z<4 $X]:F1!VI_J%*D *4)ZYHH078-QYHH8=
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M(Q%<MT$^E*DA[VQ)4]U/4X%&T>YB*IY3R58I[2.Y )N2E$#>*>U@Y(4^>/\
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MOX'5TO3<VIBI]EZO]#(&?^4A83*'?=CR_EL\[+X.]Q^;.VL'^K?^3^?]C?\
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MI1@)SHAKC?DL@(9W9YSQ6G%B4KLRZC*U5$&_=Y4E60%5:H11FWR8K$<DK W
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M3QZ7$YOB,4>U4? -V4C3P@N:GU&J\=U@W-+K8:[S'U"/MQLS^'=G'XLUW_\
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MFNQWY.+VX% HJ&X>?- 6=E7K1M%N.*RA0SR*6VN04K% XE7X<4R8)(/G2:L
MBW WCC.:$J (921^$TQ-T&3(2K\)%-*Q6"5C/%1:&@W'K2H9W'K0 ?;E).:E
MW$% Q22&& SYTQ  #UH"P<#UH"PA<2DX(SB@8D9202-IXH(N5")D<'@TU%V0
M>1#%]Y9!JZBER&CCAV\'!IT0L8R$J=&%JX%615%<V1S\0*0K"AQZU?!HRS7J
M5NX([M1 3GBM$&9,A&+5A&0DU)D855B/?*QYTU&PE)(40ZI0XR/SI#M"B'5
MX%/L1[]ATQ+6C@DFHMIC3<>X^;N3A&W)_6JW NCEO@*J2HG)-"C0VVPID$?B
MJ7#!(37*(/U4]EB<TA>),.[PKYJ$N'5$HSLE4OK(!+@&:ID_@7Q=^8HU<5(X
M[W/YU':R7B(1D7)223WN,>]-1MBEDI6,W;LI8*>\/ZU:H%/C6-7;FK'UD_G5
MD<95DF$3= .>?UIO&16443>'>B'2!]ZCX99X@J+O)Q@.DT;4O(3RL%N<ZI62
MI63UYI;(LE'*R39NCZ<>,_K2<(^A;'(_4E(]T<3U4>?>LOA%ZR-DBQ>%-D*W
MG(]ZA/%:I%\,NSWF++O"WQM*NM5K$X]RQY5D[ 1[<B6M2G5A0XQ[4W+9Y!''
MN[LD8]EC)Z 51/*R^.&(^;ML9OPC;]\54\K[%G@KO8L$QFAM.#CTJ#<I%B48
MC.5.:9R4JX]C6J.-M(RRRI/L13M_2D$#=^M36G;\RJ6I2\B/?U K!)5^]6+3
MM>91+4)^1&N:AW*VD$C[U='&TRAY1E-NA?:*4$I]<FIQA3LA*>Y4BI3FUAPJ
M6O=G-:XS4EV,.2#B[;(MX[3]JFF)4,GEK*BI*L ^533(M6Q!;B^F:?<C=".]
MS^JBT1 [USUHM!814A8IBW!#)4!GFF&X*92CT)%%!N#(EJ2,$U%Q))V&$Q1\
MS^M+:,'YD^O[T;1@B23GD_K10"!?5@\U*A""W7#YTF@[!5.X3S32H5C=P[CF
MBK$W8F1FC: =I/.#2VC4J'(VH&:E5!NLF;0VVX05CJ*H?<L2\RV1&8C>,X)J
M+1=&0_0ZV'4@('6J)1?J:(M$O&DMH'*./:JG%^I8FAT'$J!V^=.MH/D2;C;E
M%2E#]*.)=AJ5=QR"EO  I.+'NL*ZZ5'P\"CL0=B>3ZTA<B*TK'.X5-<$7;$E
M$[3S4D^2+BUR)%6!5E%;E8FI61Q4NQ%H0.[)P:5D:$E*+9PKG-"Y&G0WD.\<
M"ADE(AI<ET+4D9H2X%:L9+>?<X 5^M.PL.U&>)\:L_E33(D@Q'*/,&I\$&QQ
MLQSFD%@I.TYHL$P=Y]*=CLCR/85<90",4T %2 ZH2[DD"$D\U$ DJWLSXCT*
M6UWC$EI;+J#G"T*24J3QSR"10UN5/L.-Q:DNYG4?X9NPV(ZU(C]FUM;6PM+C
M:@X_X5)(*3RYY$"L*Z;I$[6-?S.B^K:Z2IY'_+]!/MJ[>](]CL!;4QU-RU"^
MC?%M+2_&<]''B/[)OW/B5^$'J#6Z_%HUSS+R7Z^B#IW3,NOEQQ#S?Z>K_P 9
M\_ILK4_:1K)^88[UTOVHIRG.Y8;\3S[BL[4)'0>0\@!SP,UX^4IZG*WWE)GN
MXQQZ3"H]HQ7\D>BOB.T?*[+?AW[/.SQU]+CC=S<>G+0? N3W*W%X]0%NJ /F
M$@UV>HX7I='BP_'GYU_<\_TG/]<ZAFU'E7'RNOZ%,^"^(S)[>;<\ZD$P[;<)
M#?LON@@']%FLG2([M4ODS?UR6W1OXM?F?1%#YQC%>MVGA]R/GU\<$-F-V[.R
M&D@*F66 ^Y[J 6C/Z(3^E>4ZQ';JOFD>VZ#/=H_DV:7\#M@L6O>S37>A-7VM
MNYV5=V@R%Q'E*"%*+1/5)!^IE!Z^0K1TF$<V*>.:M6C/UF<L.;'EQNG3_P _
MF>D](?#QV+:*U!#U1I3L\MUNNT%2C&E-./J6V5)*#@*61RE1'3SKH0T>#'+=
M"--'*GK]1FBX3G:?R,[^)SXP-/=G%LN.@^S^6S=-7OM+BO/LJ"X]HW I4I:A
MPM\ G#8^DX*B,;3BUNNCB3QX^9?E_<Z&@Z=+,UDR<1_/^QX3[*^S#4?:_K6W
MZ%TU&6MV:H?,R""40XH(#C[A\DI!/^\K ')KAX<,L\U")Z#/GAIX/)+_ #X'
MU8U5V&=D&OH=DAZUT/#O;>G82;=;3)<=26& $C:.[6D<[$DYSTKT>338\B2D
MKH\M#5Y<5N#J^Y(:$[.^R/L0MUXGZ/T]:]*0)"$2;H_\PM+12T%;5N+=60D)
M"E<Y YJ,<&/"FXJD.6IRZAI3=OR/#WQF?%[;NU^(.R_LY"U:6C2T29MS<24*
MN;S>>[#:#REA).X%7B60#@ #/(U>J67W(=OS.[H=&\/[3)W]/00_Y/OL:O.J
M^U6-VKS8CC.GM(*=6U(6G"95Q4V4(:0?Q; LK61TP@=54M%A<Y[_ "0^H:B.
M.'AKN_R/IFEQ.!BNK5'&W6+)D82 !106@X>R>E,89Q+A/ 'ZTGR"=!3WK:<D
M#%*B6X*''%=,44&X!96<;B!]J*!2"$C/6FD1<@R>4]:*%N0H@$C&34&N2V/8
M4PJCDD< K.*0"H&!C-20'$XH8!5*5CBA<D9.A%3Q0>O6G1'<Q-<M0.-N?SII
M$7/D(7BH[NF:>T6\*54)"<A%;V. *DBIL1)2H\]*F(:O)YRDYH7<&-G$G!S5
MI5(;/-X3P>M27!4^2&FP"[E1'[5=&9GGCLAY-N4D$<_I5B=E>VE0P5#4.,']
M*NBRJ2.[DM=101NP@.#FF 8.<^5*@%!(V<BE0UP<9:CUHVDK"+>6KD' HH3D
M_(24K.%E1V\[B/*E:0*+? =A]#6TK>0DE)7@GR]:B\L5W+(X)OL#-U;;H;+:
MG9*$!32E@J5P<5FR:B!LQZ7(R+7KZSJ:2N-(WD\=>E4_6X>1H^HY!NUJH3UK
MVK3E/TC=]5+ZU'N#T,Z")U3')+3A"5@] <U;'5Q,\M!-$@W/9D-A27A]LUH6
M>,NQGEI9+N*JW*90[WG*L\#FK%)-%$L;BSHO?N+*><#G-24DB*BR3@Q),@[@
MDXSY5!Y$6K"V2Z+6^@ D$?E5>\L\%I =RZE0R#UHW6&V29)H0I*2<]*J7)HN
MALX^M"L;SBC;8GDXH%N<6CN*\T>&..6B1A:A4V2D$#IYU&6$MCG)J'J)('C(
M.?4U5+ 6K4#IW4C83X2/UJ/@(E]9(V3J+=G! _.CP"#U)%2[V7,^+'YU?'$9
MYYR"D7E0_%^]7QQ&:6<9O712D'Q?O4_#(/*-A<5$]?WH<*1%9;8H)Z<'*J6U
M$MXRE2>](X'&:E%45S>XC9/.:L(#-0)&*F@$%IP>M316^XDK \ZB(*H8!- =
MQLZH=!1N&H"15QS3B[%*-""G23@#I4K%07O32Y#L&2[G@_XTTA6*!SU4<4J)
M)\!0^$DX-!+<$[X>HH(6<'TGR!_.@052\T6,(3FG$8!.*D 9M7.:BWR(52K<
MLBCN!*P%+; P/*JW'DL3X)EB4X?,\>]5M-%L6B:C.J4A*SU-5/U+TR38=5MQ
MFJVBQ,?QWE="/*HM#W#M#G'6B*$Y'=\?.I4&X(I_!\J*(N0'?_:G0K"J="O*
MD%B9Q@]?TII<B;X$5G"#5A6(%:@/II-CNPF23R,4A!'AD8J2[$6-'6R1@4 A
MFY#*R<@_I4EV$WR U 2WR>?O37!%L6#*$C@5*@LX  8I6(!1P*$ 0JIT)NCM
MWO3HAO"_+CTJRR.TXQQZ&A2H&@IC ] JGN%0'RGLJHMMC0=,4@<"BQTA=+6$
MC/D*=@>:OB8^*(]GTB1V?]GKK3NHTIVSYZ@%HMN1D(0D\+?P0>>$9&05<#B=
M2ZIX#>'#]KS?I_?\CT'2>D?64L^?['DO7^WYGE#0'9OVB=N&K7H&GHLFYSGU
M_,7&XRUJ+3 4>77W3D\^0Y4KH ?+S^'!FUF2H\OS;_JST^HU.#08KGPO)+\D
MCWSV(?#3I/L9B"7&:<NNHGV]DF[/,X4 >K;*.>Z;_,J5^(^0]3HM!CT:M<R]
M?T]#QG4.I9=>Z?$?3]?5E/\ CETC*NW8ZQ?(S"BK3UU9E/#'*6'4J94K[!2V
MZS]:QN>G4O\ B_[&OH&18]2X_P#)5]ZY/*_PM:J@Z0[<M-S;K(2Q#G+>M;SJ
MU;4H^804()/D.\V?K7#Z;F6'4QD_/C\3T75L#U&DG&/=<_@?2\15)5L*5!6<
M;?//I]Z]AO9X/PT?-OXN-50=5]NU^<MLA+\:U-L6A+B#E*EL(PY@^8#BEC_J
MUY'JF99M5)KRI?@>YZ-@>#1Q3[NW^/\ 8],_ -IA^T=E=UU)*;*/X_=U+8*N
M-S,= ;W?;>7.?[M=3H^-QPN;\W^1R>MY5/.H+^%?GR9U\3'QC7*]29O9]V17
M-<.TM%4>=>V%%+TTCA2(ZARVUU&\>)?D4I^K%K>HN;>/"^/7U^7P-O3^E1@E
MESKGR7I\_C^1D?81\->O>W6X=[:F#:].QW>[F7J0RI323U+;*>.^=YZ @#/B
M4//'I=%DU3N/"]3?K-?BT:J7,O3_ #L?1_LE[&-%=BVG?]']$VAQM3NU4V<^
M-\J<X/QNKP.G.$#"4^0ZD^@P:>&GCM@O[GE]1JIZF6[(_N\D3NM==Z>[.=+7
M#6.KYXA6NV-=X\YMW+42<);0GJI:E$)2GS)],D3R9(XHN<^R(8H3SS6.'+9\
MR_B"^)S6_;O<EQ)+CEHTK'=WP[*TYE)P?"[(4/[5W[^%/X1YGSFIU<]2_2/I
M^IZS1Z&&E5]Y>OZ&F_#E\#M^UVF)K/M:9FV73SFUZ/:TI4W.N"#R"LXS':(\
M_P"T4.@2/%6C2].EDJ>7A>GF_P!#)K.JQQ7CP\OU\E^I]!K!9;9I2R0]/:;L
M\>V6NWM!F-%C,=VTR@>0'[DGDDDDDG-=F.*,54>QP99I3END[;)5J8Y@))'%
M)XD-9I(<HFYX)'%'AI$UD%/FD_U"J]B+/$89,PIX#E&Q \C#?-K5P5YH< 61
M@%_/XOTJ+B2WA3(">J_UJ-4&\Y,@'HH4^?(3E?<.F44C Q1R*T*HE#@Y%)Q\
MRR.3R%T2BKR'Z4J+%,4#Q) P*-H]XH%DGRJ+30*5LXDGBA<BDVA-U:T)X YJ
M25%=R?<9J4I1R:8<A=N>331&2M\@[0*9&@"?*@38W4@*ZDTPH2*1BI"$U) %
M.*Y%+L-)+B@.,=:M2*&QJ'%.'!QQ3HB&6V"D@"G="(Y^,A2B%)-61DZ(2BFQ
MHY;4]4@X^]2\1HAX<61\B$XK(*3Q5GB292\:1'O074=$G%-2=T1VH:J9=!Z5
M99&D$4%H&5=*5@HV)J>2E.4K2H^8W8Q4)98Q+%@G/L0MUU3$A,J*T*"DY'"_
MTK)FU:7V39I]#-_;*3J+M&7\NN#!C2-LH (<"^,CJ?RK!DUTNR.MAZ;#NRK*
MU9J25O"4J6ZU$5A(7@J0."?OS6.6IG)V;HZ3'!4BN6>]7-J6Q$OJW)*$[FW-
MSG"4GT]*J\1ON7>%%=AW'N5RMW?M-M)?82X$-E)RYR?-/^=0W,MVDW9]4+;<
M:B&7&0_WF5*<44 I_I&?Q>]/<+:60/K#Q"EA0<!6VI*204C^]TJ2DT1>-2[C
MEZ2ZJ.S.MSZ@VE12\VM7)(&<#TJZ&>4>2F>EA(>1=8.Q[2U*:6EX*=V;2,D#
MS'W%;(:QI&'+T^#98[1V@V-4*1,>>2VD8<:.,G9T((\SD58]99E_T]+L7'1&
MN+!=HH2U)2TX" .]1C)/7C[TX9XR[LC+3S@^$:(\S&V!0?;=! .$<58LG(O"
MDT14B."<XZ5<G9GECDAF[(*$D<8IJRIM$9,E)"%*!YXJZ"M\E$Y)*UW(YR;D
M?55VU%/B285$O)R#^E&U,/$DA871U' 4!47CB^Y)99BC=S=6/K%1V)=A^+)]
MP'IZA^*AQ0MS8T<FK(^JK%!(BYLCW7/-1Y\J:X(-6-')2L8!%,.XFF4L'DBA
M\\"22=@_-H'))-+:B5L(Y/0G@9YI[41;8DJ6'.G2BA6)E]*?.IKL%C9;^5'D
M46*ANZ\$_2:;$A-<I6T].E(.PV4^.IQ3VH-[$')8 ZBA)(C*3:$%24#G/7UI
MD;814M.>HJ2$[ ^;3_4/UIBIAOG$D=:*3';0F9:,GQ"HT@W,25, Z$4Z0N0J
M9A!R,?I1P.QPF5N3DX_*BD&YATOH\SBBO0:EZG*>2?I-'(;T%[\A7&*:C?<@
M\C'$=[^8"?.EMIDU)/N3T9ULM9/ETJ,F31(15H5U-4MMER18X49;C2 CD=*J
MEV+4G9.Q+8HI!4E54;B^,6/$05(\C^M)R);0RHZQC -"8;1-QM0&3P9<O650
M&\[S!QPTD!8/4$AP39 6"A1W2]"$X%20%BD6H%B!XNY62G$(!"TN;6EQ+<4I
M7B2XE*+%^GWZ^S\OGIGGQ=[N[-S,S=WL[F?W9N>NK--2CVJ(R4^25RNY1- ?
M,Z'AJD>R=HYKHIX5D"YV4G'F8KDWPL2)(X%.L%*4]F>0%$HV5V'1,9144[D5
M!$]=%<HM'(+.1E^XK !<11N#ZD7V"+1CM@'H&# *<B=GDN'B4^1LMK<(/E5,
MF67A>DJX.7RF _ ,];_^8];^#,C P5U:8 :U>CH:2#*1N7J@KMGPA0U6_"$;
M)Q)1,>Z2)@/CD4M?0**U=LG41)_20,NVWXMTQSP?A@95\Q"F^FM\9-P6:_C5
MCC=:V^C9+,"8]4H^'93T+@;QX>YBR<&%_;A-,;B8?2"Y8=?E>=FLU4OR@B^6
M+*\"UQ8B1,[IF]8AT2J '&S:AE&B;K(Q^8_!Y#QA<[;OL)L)CO\ W^\[<?P-
M<AK]ZS3T'V"BW/?RZ[_@RZ2U>_7FC]:15OL7)IZV#U\@Q0NO/DU\H%IZ^E'M
M_<DOD1_LSPU@<LA,9"N;P@.QB7;VD,\?]=ID/AWZ/2G)I'J9*0K/_I"R_G<I
MB/6LWY;9D2:+ON:CN2L#]=&PA@.% AV/V[D^4>=W^JKG CG43)4::7KWS:[^
MEA6-[_W>7?N,V_RJ"OL04[-H/EFL^V@>-Z:LHR1*XSL>\"C>A>;@%S91L>IZ
M2K$=CYIK_W&YJ7=Z()1W&_L?8%2T^TNO(MO9EO/%"T9JTO>NN3K!(^V*XSH(
MS0"5W)\+T@&A'D0;ZJ"\MQIIQJ*,6E.)#4_CM-@?#P\&?8D^]^FQ:KU-#I"P
M$K;@B^AT%"O:V>8J0LX[3CM;U,O 1:+$/Q@S/#YX>=6<TL_!EBH_JF]@6H,>
M'O53:KWL/OZ52.JCS 9PL0J:WBC/^SZNX/J#K7">2]*E\265#CD/ (?_74-O
MX5BKKXVD+P#RY@&-C!*M4C E$Y?U;=:] A]1>C?)'Z^1!Q@NK;_NKZ(FWES?
MOS]Y>Q4D]?12J3=N]X_2RE=2MY_W9-<NL6-+:0X1@^DG0I-8MX;8V,RR$EB)
MQ'RF 9P3:""_8?=#"T](ZT_BZ/K^%-G+F"9J$*?U-EN]STKM6_,5U$7% 8TN
M0!=X4"BJLVYX>#\6'_D/()-;F8HXH#$C'!O\]@OX#[ ZG?=_RV;XWC,]^M#)
MJM3]UD&A9%'.=RS9]>-/C$[D[4ZZ8L_[G+>L6(AQ>C4<A6#OCQTO'DPU7\G)
M?V/$_XE:<*=TG?'5=E)9='XC#;/D+HQ=R8=[L%4 ;RK)AHM5_=H3]>$7:EZ)
MEK!(O?((52NOXF7 >ZMU6C(N*68K6,[C5!LTS4RL'T!ZO_*W8'9BIQOU8J@L
MJS[INBC9W; \*HA6&]$)<":OTXWPF'XJG2 T5%Q;IROP6S+1Y[2L-BFZ%_)9
M2 ;]YP;OWGA'1(Y=TMOEL9[QZKC-:"O*A]Q$AN0,WYIFQ"#.:@KC:!<I_"QN
M$OHPUM'P44!NY\Y$5FA>(QV]^S,H^HMFN%%"V1O^*NY'@4%0GK!L["',&U)=
M5+>V6:/IYT.G@T#(&W&#6J&&8A5CX"(])HW<6KJPB3C:.1?>M%Y)L59*.9:W
M1'< -$^1V=F?X+Z_0IE6#BI$43\%W+<]U<\H&?IQ'H(?*ZT6"G!]W!_G+#3=
MB\U.7L+<O;QNE3P)HX<?YWF&EYM+Q#,GF,K\#OMK7KY/0Q->'>WP)+69>&]?
M)U+\T/J4+H\<Y[++S"/]@Y;O['WAQ_&NH3MNGY/5KY^.+D*Q([Y]/R+9H^D5
M] QQ4K'!/]@'H]?.9[V3+S5YX',H0"GHQBF=<]@7\/&W:O*B2_P_WU> P= \
MDG0V*LH"%+\9-C7_UU9&RR 9[VZ1&'F=E:@MB)WIH!%\G<_S:Z*X-6\"ON[5
MHA;%;8O^-#O(Y]OIUR/([O'5WS*DI]:LZ?W;.SI&10/8\R*<'&WZ*J*S*U+^
M=[+3ZZ'SHDGXX:[+'E*N7G]++(?]C)2J>S8L&^(LYR/T;?=,O;41@GY=QB[$
M^RRTGGPE4/RAGE1T8]:PV7!H;[N><N#,'"4ZS"4M.=6'E$.)#@A>Q(-1)"X'
M3V[=X.IWXO1N6KQ*<#WVV"UOXXO^'3T[A_"ZWNR6%_\!F$.=F\V^6"[84U6^
M_M:V?!$+ZEO);['X&6;*:)GX)%!4<WG2T;9%Y(Y[<B;KE-CK:;H5(1*9X_.:
M]%>^[[YEOC74L9+T?G]9NM+T.KIL6?]XTC4B/4D?/KN1,)UN8,!;Y0@[HT_G
M_*63$^%O@L^RP[N62&OQX]25*;%LY)XZZ= 'G=1"&<2PXZYM62A50OB?"B2O
M5?BR3RK& R8=N5H7B%P5E"Y5[9EZ:[6J)6'$FDKO >]8>?%>U_L1&I,'SC&*
M;:;WBNS5@$N7NW"UZOVHBQ]OC,?9P%/"-$"S<?4T A+;K\--KH('E/SU>18E
M[U>=&1N\Y&KE7C+I'LT "4,C*_VZ^W8SZ!8YFX3/)%G99E53 [8+P]',>502
MX5VT!>YZ"D445H;2G=(X77N[\481,IA -5=H^HDV6<!K=YI<@'#DH@E ?]?)
M$DGX4,?%_H//5F%P,VU0?37.O3+3CU+F\'>O5F":KRJ%03%IR6\T&NY>.*G_
M>=X[V5$"*=K*RXTTX^F=J'#X*"Z:[?'KE*_7SGX"_Y9B.M&Q_H)8W6="JBS'
M!"%+^,GH%+4FBU',3MSCJR7K4;F1F(JH1;A#S)8:\C(DN=N47Q!H&8/SETM*
MM.R)0=$J/(Q\W.7*Z@6AFD#P!=T\KV'5JZ)N!\.)P7XP&:<4K3M6V07H*@BB
M]TU/)MHS61?*+FR( :;*E(N3>) [%@GK]76R"19R580VA.A5 $!&B>EF#\+O
M8J(!@%$D0 %@;DJ[1=[@)N7\A[*-)J2CM$2 B$]-,137=N<9A\"^X&+8,VYF
M-@9- H3D)A] JSB+:VVP)]*5#P('I5_08BF/_P,L&NSH!,^ST V:2"6-H?CQ
MV"2>YO7PNP<<.!64["F3,BF,]SD<@J%15: X 4O%:*#(O<A#Q/_Z;C^6?L[P
MZ<M?.DA0H(_SB/'J^J?YKZ2/U^TJ%O\A,Q)A[Z1*_R"=EX_3G5X!<,SH\7"T
MM=<Z4"H4B*^T^7:LTD5.;I@_AO&M1[C?JP5R-?X'F /O6ZM2R,PKJ>B$1,HH
M*-\*KL1]Y4D%%MR2$6]-H4!(E2&5&[Q3'^YQ=Y2A# 4'3J3X-ZUWM$6]E@4]
M;^ZQM OD.[":/XX;!%DX\[RHB)Y=A9'&$Z6AFO4%,1)5$WRJ.R!M0K8MLG.T
MK:B_$962+QOGX-7/E;NXEDG0TZA]'1N1.G\G!O#L+LI:UZ'D)*&8T:7HH[TS
MFU2L"&6I1WWZ$?:\=&\,\2!W[2;SPTS!Q"E_-=#E@CZH*:BQW!_(4X)$&R7T
MX9H50Y?X-K$YM>Y,'V8RM,9>XW:9_Z1 GS^MUK$+I)"/UUUD_HZX=72.OC&A
MM?+PVTS !_&0CJA^+ E*=WFB7*_T8# S;"/;J]O_1)5Z6)FG6U57'\L@;OB!
MQ^ E<W1XYBZR7KJL,2S561N_%8%J?,0E7O-YO!:\7^UTYT\$&T&BO@Q$/9Y7
M6I[>G"W6[:EIZ?LCH:J5/?;."$TA3X;)W3G]+W?!:+NNH+6HY]^M/+GL/[L4
M)2,0.U=^,^2+^0)HF(:[Z?/%,J:EX*O)KQ =7S+.P'KI:^.'+LP:YFSN69F%
M97]RN-I(?9Z_C0M>+^.1ONDU_CK5T'TJ*_HA.KJZZ543XCY0U3S0#H9 ')/)
MK_]">;+V#;QL^FL+?]6<=5DZ41R\TIVP=;WTQC]LX#%4-#9G>&,6-Y#9'Z^>
MOM'RSF3-X+3\:1"<!G8?N"+T176%^;FFE\A,6$+Y4Z.7IG>NBUF4<)#^5>RL
M8EZ+;"7T#W;H4R<?5:C!C_P_=[-3TSA7^VT.GO^S).+W3'=].L/8I38^^O[*
MQ&VXYK=VL&>5EZITA4Q?92KD#9_0(K#B4,OXJ_#66O%  "5GX*XKII6IY[KH
M Y$''1?JQ:.FZ G:O0H%TS9><-+OF_+RC"' <I/SH\U:5B*EAV1N!U!&KK('
MS.=03$XT_LA(%,W@:-6<.]]TH?LQ2FQU^'U&_QYRH#794*2W]GWV1G-$\"&$
MX]1:#2XP]P0SR4CW^_"DZ,,6JPB9?)Z5]L]&&DY_F@E<6T;C.[XR.=U\V_0V
M1-;>?>D &E?>0J6CLKL3<8V]\G2II0G]#:.QCXV<*6SV7!]96L.QKM(^LO,J
MQXIYTV.3>UN).IZ-GJ\4'K%KMU>\VZEFJVG\VSBY_[1J554^ XH+J&YZ@SB]
M-O5A*I59=SAY=VK4"7]>)&/]C:^6\J2R67+32!0^SO_^V:O<3LK1^7)7U,E]
MP_@?%$EI+["\5<:U@_U\]).#=TU?8H/L-DOKN<LBM;WC[N86X$B2X9 YR:@0
MYFJ#1L]:[(%.K_>CL.#HEB]-Q$:]9L>T9K,;U=+E]HYL?GCY]&KQ((:W1'GC
MOL[E@@@EI]BA6QWV]XF]-NO6@6]553U-NT4NQ WNZ+Z(@PR;8,2,?M,]C>*:
M]VI(Y!6"LL;7EVS72_-.Q\C@V ;7BDZXGY"&YTR()F+U['79R2,-9IGRR66G
M9G2$?/%JMY"G!>5S5"&F99B4U)2=B3C0!\XP WP.:=)$YDKI-9>=HSTXU7MR
M,=G%&7'[8$U3*OZV_)<ZU$["TZ":9V<3YQTBNYKPPQXM6W:.LZNF^@\0*;.G
M;=)=.KL622_N$ #DK?ZDHYM5$,[#>S)1GH>)JUM)'_Z2O__1:)@:H8QT%^NW
M*/*/V'3N+<PXEY .S%%U28^06GZSQ)CH_T'3R[H0YR4@UX"/($,@E?;'J4S9
M>D4@IT(?SGWO1#W3_RD*W]XU.GDXJGY+L:.0+YOJ/N]_91*!7V_+W7DY\$)"
M;?P[..4*_7N<IE).V.2Q($1?Q_'>22\*5IKPH-.@SB'$0=<&"MKI$^)M>]':
M[R@Z)#:3\N [43]Q,&7(-FP!I$K#Z:9(9Q2W4J.30B:6JC^?W)P0;YVVPB@$
M=Z=_T'D/$)3N2O65B$]S;F-$DDN:*L=:/?^I16K*DW'J T<!WG\FQ258QYR(
M(:HL&%<_$.,K4S3#B6HQO<42AV2G/P5,N':EVW^/8QIO>ZF8OI] )C;:=*?5
MD$,X\"OR':O<1E++CD8$\-+-6E>PO8*B?^P-<L,WRNC9T]65O_1*<"=O29*O
M4>'_ 0[+W=B[OT:1>?[%N%%%<R3W S@F$CKKH,_RU:X,2Z@%-1:"M !_,T1Z
M77G<DGF.\B>JZEQ(U6 R"X@OY,6J PDIH4I.EJ$A&+0LJE6/]-+8%<HQ$4?W
MO0]^E)X_D1O3=\E20PWVE72V@#FLDEZA6;I@HP;S&?%*PS1.-G0>7*>W^,>=
M-:09T#+HJW*+,YY&0JV>))>\-V3#>-OQD#G2_5E8/-IKL->4^(!/;6#*W$ZC
M;F"M@C,J/M$H90N1J>X9LH,2 ;*LL^!')OC @E-6J=B92MT,&MN^_M634_QW
MS&"7E.PEVY9TQ>*[@&<00L:DXRU\H$G#(ZX.^ R_16FZH^8@]56E;$#F%G1+
MA1P'V0?$]LLQ7K$R,%B16JDEHC4><4L>,8AA"6^0V$))91](0(5W"KO^X0A3
MA+*/ESNXXU+Y Y/_5%7B# -AA$DA.* F +\(,3/N/CHKZEGC;?4ER=:+<UB:
MG>VC+$1P28<?TI3?P@Y59^GZIJ0W:T+UI4S^>'$CTZ98O2+L&(\W;RAF29]5
MLMSLLDBKUUY/B"^<]5DVV-W_DUT,$YK-[!B0_#8"-TAK*>WUL *#9YE95TX\
M#=</<%8(F=_VR62>_ MR=:&J'BP15/UL2>(ZU)PKY3C?X%.9XZJ&O.]Z='T;
M77!/EXOW^\>5ZN4>U.XF5_0E274*2O#^-)3FHL6+FYA*TQ=O^=-;%B/MOAG9
MD<*<D)1GBV\Z3(2S&]]-]!:Z6*H.[0?.Z?&UM$B5'6'$$BK9WEQ,TU@X)!FH
MU.2FRJ_$9RYV5R<>F"M@!R0YJN?LIQPT:H:8]D3A$NY1CU%WEE991ODK_2OX
M&W7&5 Z_$<KIBIO;OXH>OX<K1HWNRV(*J\XHMZ57> _@4_SS:BE,+5V?CL)+
M#H9\!WF^-ZD9!;V0S];\'/V#9P@359_Q8,Q1Q8ST]X&I\*9]:5 X6>=;_CYO
MB8[P U6Y,J,UX1*A O8O0=-.PZVE9MZ7M#\@QM\]HN-_>9O4Y9T1;@&>C?;R
M?YN<[5#RSG%MFLT=E_;%K3BF]8^S^NY?UN6+Y_C,1]^M5:%A[L4RTSZP^T]8
MQ&=2VM+#2?.I;_XHGP&>V2_G9DC(U ^%1?2W#IKZ\08T1(-D?OXHRUP&[J%U
MPU2K)-I2V"*HYPML79]H<^G(Q]N7TEAD)!=]9>V6L=Q8>N\8SNNBIJ*<=FE4
MZ%K_*HY0:I/5//=X :_/D$X0^*5'/1SUPG_8U'$OC?O'Z\PN*YU\,3;XL(HE
M@CKP2$A3^+CWF_E;T7L;APEO5&^TOC<-/U_2/LYUO@L.63O]#_##TOV,\N=G
MV]%):\'KLM)/L@>V!KO;VX_K5;!-G!<QYH!FS[$?!NR^&U90JU:!D.,$+KT'
MURH]SWA#.BLM7M:91N,&EL22H?)W#5L8!PM/7BN3)&90?1]F-&QYQ1@$I?;=
MT1C;_7-71,PX.8=D ^5'7E<BD^2J$T!T;>PYL/V1%I'80UH-TI=OA^-'Y@I[
M453W]:+>MI:=5XL-:FHE>>Y+LCI+/&PX+UMKO$_F3W3L:'_Y&L@^-=7B(<#(
M3J0F=C($W%$VG-_-NJ9 RO0GX\@7"/$_R"3/F<I)R:?#;N<7P.FNW]#-NQ'S
M3;*'Q)8F!A=.BCP<D5&_O=+?(><M>>)/<?+I-8/=U!<8'<W]763;[)O]&3_[
M#P^?*(A<TJ.N9=T#$?+YR/)=OT-'"U$YDH<-J49=B!O\U6A/V'@ !8PM]PO4
M4,>)DP/9+%LCEZZC6CU/[]8 7)*!\2@6Y<\$<5^EGK)5UF,.I%4_OD'@SGIW
M=7:5B*1S,\D)Q9]5F[?RJ53]1U\=FR>5E?'B/YN=ZE)PTB8J]R/[%8P<?B:I
M%PS?\=ZTC9=*FF^HJG&>6&UNI:ZES7F&1L[9IFH[X'AS)N<GA8PPG+OT^MY)
M$Q]"BV(&;$X ^-];.R:N+[]5]RIQU5?OF'T'[FAN[9JLO$W.BJ8;."Y$U'\!
MBO"&H/=!IAVE-#BF*%WBA*D.>/9:,)U1$&OJ/IR^$VI46ZA7WH^TS"JG]'$\
MN]VQI,+#YTF-F@7 O+:'Z['_ QXR]5V*<AA=NF9-QU(JPT1)V>-H7[DV",2S
M)#4Q+[*D7KSM&:3-S=!\D3IH6N*/T(*584S(X)[FROPMZ3<EIXP;;1?*XZPM
MQUM!O<C)>!NMB3?(O$V1 HHO!4E#&6&QP T-2(1FTE+Q3!O0QQ94PC,P5=2S
MTG4!,\W5'VM^< <&)='<9>B;M6O,>57V.2FRVX<[H7.U3G1'L;$EJ5NZ7^7>
MDLDOKM7:K_P_S]#+"O'K=%^"">.?GT">!63] Y)E=KJ?0HEAY\6^OM;01&RP
MX+) 8N1PW%2*GFYUA\'&WS/74^-:$EK;\F)_JL(@ VC"5 O7@=P&Y2[COPT0
M%Y =>?97,ULWDBXHR_/'415. X$ H>/2V>:08\!)F(X'5<%-TO7/:B:(_J6P
MY]JM0^T\5(+HNX,G1C(I>86AH^(BTX7Q.0B^@\JIIA8C!$S0Z!I+/09K:[KQ
MY%OH-HNM)+L4:"A_A"7205=HX:(8/76,*F\@?Q$A#F/^LZN7G8N&E,2)U)9T
MTER&H=O!^2#K?L*7TQLTARFM1V_P@Z3Y[-R4//)_@!WZQN>\K/5#AXV^><!3
M@PQS:'KXD1B/W:# I]OR/T5']YZN#/T'>/$&&20&#(8U52M8_E/CY<GI3#:>
MK39DOQ[XPRVJ:F8PYF!.>O21#D-?N&9P8!"8?-3U'X :6(!KE9>B:&88![O2
M4(5[CS'^T7?:)B 8AQGJ2N)0)*Z3:@,AU@_9QS8I-J0F!A'F@Z,_P\RW<KTE
M=TY'Y!Y^2A,SBR^SK\1BE[5W@=7/AOE$6>:ZR2MB&TXLL*XZ.JDYZJX0QSN=
M)K[WJE@:J@1WGTW*U\R^#$I^Q!W3<B^DX'(1[6$E,(S=B5UQDKS.94_2FUST
MNS^3\)!)F+<V2T^*:$BN;J9M[I74JSK'[;PD%Q6D"D$@J>FYWR,/I[E&]T]&
M.J:3'5#T/_0=G*4=+ONB3$T=-E.P5(>/'FSF,@-X!.!U7VO2NXA-1? )0:(Y
M,9-LM(\<OO4ELF";I+&#_XX2.)(Q\KJ$="' --4\<=80!K\8J(:_0-C6OWVD
M!^=-6WQ0'W;3W1*,"4AX"CU]D?>NOD% HTU<+7$1M*!JW)H<5$Q@B/TBFR;1
M&%^SV+AMZ"WG/D<IZKIX'=4^N,[U)/?A>>5JWOA;_G>EAK]819KS[AO8J'D\
M6LVH?Q1VZ4>T<343O6%0E^KO?RACK]D\8-5OYJ'EG<Y\1TV.Z"KCT\!6*KSW
MH7SM6!W2MG9KH"]^0>/+SB #;X8;Z4D3Y=: W72LAGB?.C_4,@7+M_WA@&/^
M J[_,P ?FYUB%$'U)BQ:7Z('31*A7C[%F5QXL?,? )3]W(7!Y'VHB-%[=1]Y
M%A#6F@2$6$GZ<0-W3*GDX:MB0P@+^C@D\((K?:; XL#+<7Y*2'YWP)S)]9[!
MV\$DODF6'H[^3Z/GC%]5X-D/7MU;EGKM] .+*4U.&8KU<3DE;P=O#1)60>I=
M/(J-84LYT_IV-T)L19!P&J(=8YG,*K5&=<-U1WQ;IK!M9+&(4O!FY:)%@6+B
M.(B $1#2F%W7]:)+#*U891XC(STK<] #V$;$,R#'#,?W'KK2%WYWZI55YXOS
MK+N_PG/%>(WZG!3,>YB'["3C+UN?S<MQD"A^'<+(EQ>[?(>C>V(;V56'RBO(
MD=B(G;-VP;FA*=?J-T;:(8U_I ;J&ER>:U,NM#"F&CT2]H+=R#0>Y3E!4OAS
M7E/*N0 +RMJ(ZT@<G7/*<_(5X4Y>T9\M<Z-<9[K\FV(?Q752'0M"\QS=P=S[
M4C00XL#MU0C#E,3T0 &)[83@T@%$AX0AG8?*P%I5#";2B11*9U*F75A)0IYE
MF)K\B#6%G,C9)N1QC _)E-'R?2JB)9P\ ?6QVR:)R[B1FMJQ1!--;_3>WS@%
MWA#VCC 5VI,K\\1).[S-Q@XZ28LNG)2H(NVWT&DEWYFI CSB]1OK)$.';#L:
M[HL:&,"9 9>@TDYYHT*ST#D^]5@*A.6=XX(3%5:&2Y(=K6@E4A(JLPV)&7WU
M(W?F#6"N^5KR52LY/6.?PV^2CCLW,NR-GY6/[K1X).W<[N6\"C:B4""'%:)E
MQ"9W]+N2E43SD;IZ #-%!#BB\5<Z@H"/55'Y@O&GF<DZSSTN_YMR-5EOJ4*7
M2C,A6#OO85,BQ,=SKZA?^]%P\40<TY3/_Q@57F,V0F<(T+^<G<*BV@,-787R
MVO_2/"Z+B0G(E(9M_3(5CHU](N4S^,;SHFR-\VA6B5NI)*CQ,T:),N18^H;G
MK+2>_SY5C@WXE#CO:!9<6ZBYMR_ *O?);-U!XB V98'Y[XA2-5.WDUPK:LN%
M"<S\Z>\!)*I1=/+O-XQ5+OG8H#*ZUI*XT!GJ8-Y,S[@*%NNEACS7*L!G]M(4
M-Q;(&GMX#:^T<C3.AS"R#32$[#FNT(B9$Y:R.3.HT>1PIF&T2M_#$45U2"?A
MC9,7ESS;W#%N4 CH9'R&&H"?D'QRFTA4+2**C?@3#!;@U<#G'FO_33'PBFCF
MTN7_#U":6R]G^#[S2(L2[.I-35=(L_H?8(FC^O$:]U=2C06;Z"NM/9V>)S:9
M3#^(X4V"205!37R9?$](>Z9?HF4+/'\9],8Q=/."GM$JIER-KZD_ 8=6+*6E
MIEQ-96H0!!)J"(I%K3T-G18$J<]E(75D3U=1F184ZX0.2==*/8+LISB6)!;U
M\J56"TW?@3USZ$]OK]^K.G69/\]LKR)Z.NNZ O68B=$K1R7VW\(VS)I8L_I$
M&HK+)MOT8:+[N1-7,K2 -*[ DYKCZL7P[!.+:LO!<X/')>-55H/,@DSJY8$G
M";0%#\0FVCZDE3ER&T</NR@+DY9X#>(E'P_V%CZQ@,,,.V76*E\1+()_?CZN
MIYF/8Z,BU#_B.RR ,B"[PJH;RZ?6)T(Q$JGA.+95MZ0F<SO!JD5+G3VXJH_M
MP.1R<@YD7XMBI2UT# K-F?S-L,^74+-FL/#^<'A 6V:]U/'P#!)[+,3,9#F/
MDP[UYN"=KDM1+WRN[S,HQZ5?GB-PCP6ZV=@5@(H3%DF>,'.9*/G<)=>2.%:D
MF#W)DK65$$_8_K-?#H^7FUJG?MZ5_-5_'#HP(DPFNX5SV<Z*G/^7" X 0A^\
M5+=_(;..>NYQ49A77_UP]:98QR+X?EL,\"_^6*GZ2<GS=!%WC"L]N^[;ZHW^
M#1>.T=G=9*-M95( G&"7NADE=3TEH>Z"C%\0BQ;J[GR)3L2&AVWDP1VJTHVT
M W=>^,UOHXW#GZTD/U!(:BDH\Z8)L]Z?N>G-UFLK9D$F$:DB4[I>]Z=+%;R^
MFLGE/=>3>CZC,@K1OG@1$P)C*B4\3@[7Q@)P@E ^@60E_],:Y)/?A.SY\[?:
M^SAE=C'S,AY]Z5(%Q]+.W\9R<5.&MW2L/#R,S-R]8(X-(]2B9$+!@&UO!R/S
M??1L7X3A&##;<EQ6IH?7-O;IRSKF?O<L]G0CQH).%UYKK>Q4W4<E/D%CZQ+=
M_K1&VYS';Y!.W'ZTV6P(P[W!TW):-"$YOJ (L(<987VFIT[*2^,T"M?$S_'/
M>$^+$^KE(H@]?QE/BFQ]8\N;N@0\2/9CY-7X2&<1:J"TK@&:!6&EY2^-<^)"
M*H<0" FAV@Q3DF>[E'U.SR4\%K41I51T;B7X>$S1!.?:;&P62J;7W#%Y=KPS
MYRZ=1J$+BZ)<$[ZRU,DQ RE"E7X$?5&28IFMBL3Z_JN$T$7M^X(6,9W_ 5C!
M&FM/ 3#E5^6"R<YZO?;WRGOI"+K5:H7EAE7<L8,CT&!TO33.F7CEK*PIF$A-
M0K"Q8T-$NM=,B &.V-.@\U!^KJB9"^I$@+-YL^0BP')R@!-MN=P094/))S,&
M[J1V-MEQ#&D4AM@9G+I+,-TO#;):;U9!D<SL/E<@^UHP*79+F234CSPC+;;1
MNWM/(\F!"SB%KIV'A2B[/+/S-X28=Y.N@$A> MV:B)IR6^:#Y[\O'"B[V+N<
M%TC5J3<DTT#'X/1B;0IP=2D C^>&<@Y)0,%9N;N6@[%&QW='"Y7FGK<<948Z
MOLX49KWZ#QE"ED9TL&Q1/A*N5*'/(^R.86XT=^GNI9)!PKJ9_D(-6,"/M,$B
M83?293EAQK\$5A^HB^>]Z8IX<(0WQR_I"8AC@U<>-<9C> _F;# R+TL=*=SG
MMA2;, EF?P<^6I$,3-U!T[1BHG-;#8&N8**%"(#WJC(Y2'IE#$Q]YC\&IY8A
M#@$P4?91$:D<Y:LHDYGI+Z<3,W !!\;5"-S9R'8E68-0Y*-%ZE6E)9Q=,V?%
M<\Y3L&]&1Q[O)=Q_;;D''Q'&\Q%],[F'RMF/Q_)\\S]7HZ43T6T<RB+%W:'L
MA$-]/<]RIHT&BMHDU2#O+;5%N.P]-AD\/HG_],W?OTBBO94>\:OV+LO%GRL\
M5&]V>^OU>&P2-0% K$^T'J?,H9AI=+%L\\9U;+Y[F"$OLT*;F!B^KD<?C7<.
M4![.>5,Q%,U=Y*89(*Q>D7BJVKCSLTI.NHMR%Z:34LM0&[:84;FO<$O-4@EO
M:0OTGN\]$LZS8H<;59&>82$T&Z5@9^D@O^I 8O!O;0Y39'6E@->#-#K' 1T[
M#@M'0QFS=*OFH8DJAEA7=8>(MN;Y"VO*/FK?/2,T][=?A@NYOS#-P?+NX6>2
M10P/[2*.33-K&9+H0QG'3D><XL3U!5/HS;$P90M-+?FC[-Q&TR9Q\@OGYRL%
M6M&WI,9_CL??2H&' @A6/(<M7XXQD9_-#%EZG>/W.X4M?84N[K$&J1WH<YM^
MT^BCM42&L!S+_/.&<<JL8YO'8TNR>N^'/U@)]%^JMZ9^N4P@A%+ ^(#Q1[+L
MLM.[)K8YCBGEDRV?G!;\;?\#R-'I7VRX4,<H1;&I[*$YQW<,(I^,+DWYYUI\
M^0_@AOU#NTA=))[6!#<A!S7TER%_%O=^M'PW\F-S@3SEX%Q\S;"QH 0<+P 5
M6#AX/(?MW"SZD'*M7PZX:TQ/^"(:,7%Y@G?F+Y5S]4=COY[B&IMT+?^$RA_#
MY2C_%*9@G:&A>C"U4!TA)H9433^\,]\:F55'%2:U4.90YOXA2ZD0")?J ?-F
MN+->U&]]7;SM.%M.G%E;V%G4*:KES%:&,Q75$_-"]&;21"5KH*3GO#SH]0;7
MJTU6'K/$%MF@9?#[ I\??2\;FSSJ=D_=I.K/?DTA<_S(VZ =0N)K\-Z@O/S@
M#A&:OK#1/AOLH&]%-?7 AT0_^A!DU;&5,[$O5R<<JP;L-M&JH_2A\R32+.&*
MSTUTE]W*KA,%V?4AXVOTC=#ZL7P06C03D?2.42-*L.Z!OA]Y:6X&OG&?3$C^
MV20O;:R#+O?'J7!:/$FL"1'EX(@ZB9]Q 8/U>0$QC-1N4MTL0[MJ%R#N;X@@
M4>ZFSJ#79E63#98-!L3' E;$E$F4F5P/G%:P9E4_&^%96*6X\X+7^CJB0K^#
MILC'U7':$'T]?H3"9_*M*SW.13;.9'E)"%M8V*U2NQ!;)(D !*X&5O,SG50&
M^:@M9X0LC5T4=1QNOQY_YN.EL%U[EQ;0)UAGJ/I3@>I!K=QG/U;2I1PM1B&N
M6ACI7]:X#7I4084+$G_ QDG"LOO&R5%"4_FF]N^'>9QSS$]AI<KSHEFBQ6O4
MH$AACVO43;DK(]>3;9*<"8\Z/I74&?V'J*+7R38#UV/,]ESU2E3\@[T@YU'I
M7CZN(:9N7$,B3":T.\@F!AD,10>\U90S)H>T'DTY9'M)SSJFR%D74,\ZD#2S
M @XB@TEYK]!U.'L74QR30F$GIRTC6X]WQ+S#SR,VMO6+LE9EW_;M1>"S*]9'
M1+.FA;A6(J(GIZZ 5<JY5#_\5S1R3NU'X%I7O#NX1.C>4FSUI^>Q(CS?6.M0
MAZSI]6$_*V04!DS'H6EKL_E6/QZ:YSNM_/):DOVB0_41@BUHSJ :YL@4&GXQ
M\D6KJI^J',6YJ'CDNG1I4^XZ N(I?8>439HO*K9[7WCC5>_'<Z_2EKA<V]]D
M3IMBG<UI*4+NW0#IGX_CM8] X-8U$*UG_GVD)7F)>GIYA@@.FML?&X=!4/$W
M%H"Z+GD@6,/4HH&A(<+FJ#^%"14:IQ]7,;:)R;KM0N]B(T]21B6D).G;Q'"2
MZXX]Y4(L))*,W*_L2$??#2I\UZIQ<E*'4MQI@ 46]TT+)&ME6"9JR#"GF 7-
MQ" /::LC_/A4%%_5B\]7]0N:0^/,G90MDJTL VP+E/P;>NIQ22]9G8!A%&JY
M\['4/K1BS56A]9^_X&@PBH/"7]Y^EAZ LP7];?K$,C+ZR\.8Y#^ (&Y0)T+D
M8Y6@AX;CDU*M^9C7[F\93X=":Z]U.M&6/B"2V\G.F]U]#_'G_9OZBE'6K>7"
M$O/=BYE=WNN*2*V4BVKCWG<^EZB@_?QFEGGD6O31I^8BACI=V.NP'@[ZX'/&
M2KURWXW9K=W3E^*'K^,:]% O?E@$,D/D(X1AB\+W=S4#/W^97C"W395+Z<@$
MQEJRN.JU=>3?ZR2-MUVN\!0X>R-'8:TP"3PM]XW^T/GR&WAABD;M"KT8(^P!
MO@32D*8J3K6D'>GKM2MO\(:=EVQFS?!_[DVC6WX_<(-O9(=&0&(+<SZ<XQ%%
MV+ZQ>AXA*,=\L5WSO\A#3E$T+MT=_/J#K4;A'YOV:<X"]&@TRE8GY0DAZ>E$
M<6N#8R?(^9#E%B["3Y<@QZ1VZ,\QDSG1L\W UQ&4OURT]B@UPC*]_:O6+\T)
M12$Z[$8&_O1FN]"M(6[8<">6DC/_P0=D@\-GMV!8H'HB3'J"+,V'Z/K7X=\S
M<SA%BR\[QW)VXFI9HT  X+N2O[S8GU#DV["N-_ZI";2>=9)?3/R-"MT@&<%5
M_WLO^R=7K6#!XKU"$ *B7%*"Z!5CYN$L.8E-MQ^T^ET.5WM4=, "&MTP*9_+
M,SN/7P(A *"<QQD/PK"[5-K19/7Z?K<P@&H$R40LP/T#,C=8^I_# 6!%'YY.
M)'1,6ALQY!E?&RUK/>,7*/KJ](3SYF&XP:^_4[YAAL7Q5D%*\TFT4KF+='V_
MYA.Z*^3:%+\V08*IMZ=\$D/7(N2\P&2Z6H9 0[)O8DD6FX>RC93V/E:3BV /
M\X5)"5<0Z<.\DMA'Y,-RK8KF$F8W8LJC)+'57[168P-J\;,W#XPX4GH5.AN-
MQ2ZW'18E:7_>/]#\#Q "E]NXQ?\\ LEM].>*K&H%M)X5^Z)^BBHX+(.Q#C06
MF6L0]5B,"D0#9!66P,6]+%,9JYHG7PY@.0<335'F*B<64(_6EA)W6F$ OVA2
M"JB!Y,%,VJ0OTE9R&.N\)%+A5',!MBJ?"J3QJ5@"2OB0A;C8;BTBM3_<6J*%
M?AZJ87K*,9'056CPUO.*9L?X3\1[ZDL?I8*_Z;XAM;_^3Z<5#?G_5.*V@F<(
MC@QVSF9 *5-:<-H5>AFB?]BN,J*PJN6CY.\-!GKG&VE$CLDUZ$9.?FI0=I'[
M)$'^_PH?1X@:>0[V7WH[4E68V"U5#6'CO-K$[82U$D,+Z#I'<:AW!Q([MI]/
M^O*CRQ].8RW(-W([_&P^?VE >2?9%DY.,[]XAXQ]NQD0A21\>)WV@:\EY(2J
M4)I2YJS<T)R/&G*?!RN@F"$HJCV$B0%;S,UU5M/%Y)D34WSKY[V?[%=^P(FS
MM5\2$7!7]9-P80NWR,56'^ %IF+U)?1%!_IB?V:MY5Q9LFF]NZC T6_';WS9
MG0&GEZ3ZL8=6'.K4<8C2?'N.$/#)4+.65.**GUF/Y[LO>/]%]R0CD+Z7NTZA
MO9Z>?N=T98JU:. 35XTG>#*DO1\ZEKQ0]-4W.S]3$#%?Y)&V:8!SZ&77O91A
M^7BLRE#+2T]N\#77:@G<^#"YZ2/2@DCH1& FW=S2Q/1^#:QC[R6JLZ,_XV7?
MMTMF\C<^+BV/'>GI4U.2'V[$+I%[''/7U$=" T.3:V6T#4><DO@1G"X^OMC!
M!*ZR 5,6Y^"2ZR2>)&2S:.R+:N9*N_2OE)1!JNPN,)[/Z(?+4KXL'(;_ >Y_
M;U(UL4YWS/BT;VY29N21^/FFHKE9&1"2[R:/^3O*=W]YY9RF4Q]OLWLP(=+N
M:Z/9'PK61Z]<U6WG_+TQ.1!]PC(RO6JY?^X7J;W!F2J.M6!7_7HGN(M;;(A,
MJ\<N4P(XR'.EP<Y#0T5T+'C*>)\V*=(]DMZ#'N8;_-O,+6/4D$R)]@D%^;T+
M?%M4E!9%ZPJ)3@]3QQIK] #B?[] SRB2!&2=D">L'W4'M-05]Z@>)=(=J<S[
M%O>HF<T&[5V79AY;FH'L\,]XQUNE@C,Q.1O\"9V-0@E"/"1#V1G)Z8&J/CI%
MO4U$2Y[?'4A#UZ$8YR:MD'9'L4BM*;CX/I+# 5TN$6$B-EC>4>,:^4%F@%(>
M,_<XFG&]&LS__:<&6;1@:O%% 5GH*!M<134X6<RP\!#4L+J9K6*#A+3#'<>!
M$-I7.;1:N3I8J[JQE)<2;CRUAYL)J[72MB&:*[.A%_83":MU4,M";2DNA;S[
MPIA]J4B1DG&;>>9/_?^[;R)RT1J*H\+#WV^E:$1.@8MR4QP.TLWP7/+L0*0-
M)"^]>/&>16LTZ5HP";: BN9CC49N>S2X*>_SN'4=^:'6Z3_&=KQR$JNOZP0C
MYED/%ESNBDCMDHI/=/AT[QY+'UR*^#W##KK04!I,4S<+QE-W% 5S=PR4='6Q
M4TF$#(8+=?;*WK'W24>Q6B<AF8D#8O:1K=QE[2FSX8]5C<8PQ?P_N7/0)N'1
MO;IXV&@&@BZ-I%>#KI;&+T^P<%81+FAR[S,0W%S@&@K47(%;TJMC%KS@;V7P
M:.%"Y=_0%^FI12BOWME4S_B_T\;,L+KUYT);+/C63-A3[*0OT&'',(")7_%Y
M0@>VUY"PGTWPRKHEAU.[, GRWS^N^@^ N'4TVUYGK'HFD-_.%*5+DV9P^A\@
M 9+L\BPZ(:E<J9VRE#\;N#&FF*)+^OB9ZPV^3B(K-%L;-5!FK>SC<%K6%N=$
M=PBTL,S:85OB0&8D%W\JWM&(^)\L+ A_;[B#3N)V$)W<=(QVDPF<LK="^X0G
M O PA0-JI[4D!>_)0&%+:'Q31)MD%WI95J!4R:*W>FAU=O?T&]T+/^MXB_BN
MF1R8%>NQ^5*+?<-D=67HT#PQ!5)+( 33'_Y4R"VEB]90^T1BTEGW#8L=ETC)
M>I[3P$5]N8>V3P0IK^"Q3#7E!'P^:\Z-F:E$Q!PPSM*RJ _S)CJ]P -NN7&M
M&,Y:VJZ)9:T/DD#N;9P:[QM8$Q\4UCEX5K' GS7BI'P';2D7+6FTDFTBD<9;
MI!(_._] W* 5WR;+=Z^RGLE+;P#]R!4E8PC,N<18VNWPFSR)$'EK98E'21]-
MN_PDJS,>))$DP-::>"B@'.W2I3*2ZHH%D;-6?D2DC4  1X\_ZWC"A/A(RR I
M>"U/;+IKS,.8X-0_:-R\'5"ZX"V-,%LDIY;&U]Q[AYQ*(Z$1 <0+[:Q/-*UK
M6J462[4-&QV_SO@0GG;P ^?%C=\8F;M7.A7R4T0%*6\\'O!N_MXG+F*DT5)\
M*F"M1D/\_OF32U1W@FQX-<]GU?2\&#85!:<;Y\$,HE>VFSQMBQ+)5G(SN=W=
M_7R<9WNFRQNZWZ;E-'./]"HF;0]F1+.],EU:3#"3.H;LP.#5IWEBE].S[(/H
MA_;ZR-%29T8?1TA#(B4/=+-I8 3R,B5H.P]KO,"GY:,UD1L!8#64$3@OIZ.I
M-03 ZFOR5Y4!F75G:/(J]@,)4 1M,CTY3'R@%[5 )L0^Y=TS;MW$5B=AYJ+E
MK,<$075RHJR;H&@J)HBAL52J/R:->RWTXI^YV<Q&CC:KQNA!(Z?"H1!-#5EN
MPMA$XSM!6G=/Q#G4Y6'F.4.*X7R<CU@]0<3*SO9 #[XO,(HE$]'*F1J:U>LY
MDZ K;EFO)BX4 'OV@N4*OHH7)CIA3-?DH%$MU#02*5+?EXT["PO-^T.T4]-
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M$D36Q#5OCY("2QN/^\>:NC]E&9JYL6BI6XQ#;<QA24*//KE--,62([GE3+*
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M*M_(V>?;V'!%6PB1G)$0_/2TY]6/+K5\<>[@R9,BBK0G_$0O@+Z>]3\$I^L
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M"3#L\NX/O*=<1E#0)Y3E(R1^G[U9$HDT.UZDC65LW&4R\IMMU#3K320<@X(
M'L.*MOBBAQ;=H]R_!-VN=D]U>EZ7L-^D1[Q<U)?CVR8R&RI;0Y4THG#BE _1
MQC'G6G3Y4N&S%J,,Y.SV3W+:@-S?/GN&#GW]ZV-MF-1V@AAK/]F*$Z&^1*1%
M9<\/=)YH;;))4 S&#1^D 4FV-#I* H8Q4-\BQ10NS'"@?#2W-EFR)RXJ<_11
M;#;$17&\1P!33]2J47? F65@X!HM!M8JAYW(RLTFQH?MDJ'B.:1.D&V)]*+"
M@"E(\J+"A-24JZC.*:Y(L;NH2%<"II$!%0 /%)@!4DR#?(U/4_>G;#R J0Q-
M7U >5  *  X%  (ZFD".<41C!ID6Z"=XK^J@CN8=))&2:DA6PX2OJ*K?<8/-
M' _> /2K*(!<GUHI#!WJ'G2I!;$W23C\Z:X[!W&3H&34ER)\".-J21P:C;["
MJPR'2CE1S4UR1;?D/6'CGK5,HHLC)L?A:L<FJ?XJ-"2JQN[(4,@*J]114Y,;
MJ?41A1S4E%,AN8V4XCG(J:BEV(2E8S>60H;.!5L49\CYX$%*5G)-3VQ91*4E
MV%$(6Z ,\4FU'@L@I25AS;$+&5M@FEXA+P+[H4-DBGZFDU'ZU/U)/I\!)5FB
M)6,;:?UB;\R/U*"$)4&(T@@;2:G'+-]RN>EQKL0\N/$P-Z4XSQ6B$I/L8\^.
M&-6QKW$'T3^M67/U,W[/T+FJ4H#)KF;4>CW!F9A).3^M1E$E&0X,@D#;@5#:
MB6X#YE0ZFBD.SOF%*X!HI!8RD)?*R=H(S5L51FF^61KO\O(/G5Z*&-RD$$8%
M3(6'04H&,4@[C:6X,&IQ*YD#.>QC\ZU8U9AS.J(QQS)JU11EE(24KC XIU7!
M&[.;''/- !TMI)S@5%D8NV2+*4LC.!ZU#<S1&%JP'%J</"B*3=DA:,CQ9/I4
M9=B4.6.=H]*KLMH68;"@>!1W'0KW7VHH!>.2D[<U"2+L<J%7U<4DBR<B(=4H
MG&35M&)L2"%;NIJ5%>[D.<H&[-+L2NQ-4@I&2:GCY9";I#=<YX'P<U8XE>\+
M_$7!]?6EM#< +H0K'^=%!N8G(FJ4-P4>:E1%R(UV<O/UJZ^M6)%4I@HDKSPH
MY\N:@E1/>+M2I"EA*U*P?>BF&X<I=4#DFEM'8;OE'H:=!9W?K'F:6T0HT^3U
MHVCW4/&GSD<U5*!;&9+PE9Y]JIFN#5C=D['?(QR?UK)/N=#&QXW).]../SJN
MB],=J>);ZTJHDY<#;OW$*)WJY]Z:*Y,4+N\95R?>B<-RLC&>UF<=M_9W![4.
MS>_:&D,I6Y<8_>QO""4R&SN:^V3Q]JQ=0P>-I]_H=+H^=:34\_Q'C'1)ONFM
M Q-+WQU2_E I*02<%(4=F1ZCI^5>)E/G:CZ/MWQ4V2&B=]PU"A3BN\.[@ \I
M]JAJ.,9;IE<CT18K?%C_ ,Q)V!6 H#S^]89=C6E;H&;$>6LQPK_5U%12DY*5
M'W'G4\<N"QPX(6[Z1MC;253VH[97C:U'7W2E9] .:ESY%D6HKD:RNR82XR)D
M!<ZWI8(VJ>N"E9/]T9J[')WR9\N2U4>Y"J[*M,6EXW/4ERE2GD!2]I)\*C].
M4]3GVK0IKLBE8IS=LNW9]9G;<EBY7#YA29!)CQBY_+2!T(0>1Q4,FI6)4AO2
M3;]XM\LN=U)E2(Z6EO)*FP$XV)\L9Z5QM3E\5FS#B\)%7BI?<TY*N+?" ZK(
M]14<>.D7J6^1Y&[:[X[)G*AOK5L*U$)W' YKH:'%3LS]1G44BEVF()=@<M[D
MEII6_A"QRHGD#/E]ZZ$G3LY>-7&C2^R6Y'3^IHLL2V@J8P6'FV"?J2><XZ[A
M^N*I<VN2W8OQ/0D*9:')*EW!IR*V5CN4NK)2I/FM('XA_2KBH^.71P*B?_T!
MTOJE1=9N\9T)RKO'QC)QT)3@%7LGC%2>1Y%2(;%!VRH:D[!4.2FD0M:72VK=
M3O;^6>4M*@.N$$JZ?E54M0\7=$UC4^S:,EUYV):.:M4^Z7G65XG2;:O=+2XM
MU0+7D2D#"><U/%K'-\(JS:6^;*:O3'9]"$9_3C[/S#L<.OA$=3[+" >"I9&0
MX4\[:OEJ)>96M$N\2X:8TM&UC?%J1;K:S8(Z,([V#_-<3CQ>7'/G6>>9I?$O
M6G7IP+ZYM.D["RY#LNF[=RG8I3,+=X?0E1J$92D[;'+'!*DCS%VB_+L.,K9A
M!&7%;=J0 /3SKL:9VCS^M6U\%=0^XXP,D_?-:^QA7*'4"00-N20.>M CK@OO
MTD!12"#TXIE<E8@SJN$W'3;FDDAI)6^I)QC! Y_>IIE;A95]6ZI;E1F@TSM(
M<7(!\U)"2E)/ZBI+D55P5S3FJ;U:;E"GV^X.L3&G$.,K[Q0PI'.01T--\$TD
M?<SX9^T:7VK=A>CM93E9?E6[:\Z#DN.-;D*43YDD5T\4K@FSA9HJ.1HU0=*M
M*EW!Z>+CBHV7;4<'$$X61BE8FJ',=47<>3^=+@DK'O>1$)X(&:1,;./1U*_M
M#2&$+C?D,CUID=U'=XC^D?I2H>X*%(_H _*I,K0Y9Z4BP4I =C-,!!X%/G3(
M,;J))Y-31$27]5)B J16^XU/4_>@?D!4QB3A\5 !,D]30 *3@TT1;H(Z><4Z
M*I,*GI2EW!<H7:' IHD*U4WR6J/!QH3!K@143N S5I2#0 1TD 8.* $B22,D
MT#\A)T#TJ7D18W5])J'F-!%=*FBN7<<17!GD=*3"+))*B.IK/_$:HO@1?4DY
MP!5WD18D$!8Q3;VJR"6YT$<C#R%)3"6(:R&0CRYJ['*T9\D=K&:D^+'E5R91
M)#R*0$@ #BLV1^\S3B:44.E'"0<GI4&V:$T,9+DA(.%G[9JR.TRY'D1%/R9Q
M.!G)J^"C9@G/*1LQRX%).59^]:HQB99O-ZD6[\XH_P Y2B/+FKU&/D99/(_M
M">QSU/ZTZ(4S0+C,C+ [I0S]ZY,,>T]3/+N(S)6K/-6R?%&=JV/XBB@<U6RZ
M Z*@LA7MBH-%O=V'0I"#N) J.U]R:DD$ESD[,9!Q[TXP=D,F9517YDT$D@BM
MD(<4<W)D5V,?GP1@X_6K'AVE*R[@R%N.#PH./85'B+LM46QK)4K!!!JR,E(S
M94XD++<\6,^=71B8I3HCW%<\\9JQ*BJ4MQR2K'"<^]#'&Z%6T*/.VFJ)<D@U
M;^\&2,9&:@Y$UC'#4+!!/%0<K1?''3'B6DI3D$&J"YL(YD)SBFNX@4+&.H_6
MK&K(V*MS$L@C(Y]Z54-20Z8=+^#C@U6^Y;&F*K2&U$TEV!KD14M3A(VFE=A0
MB8GF<BK-Q3M!:B*4XE)2>3Z4I2X)1ARA\BW<=*JWEWA",BT@#=ZFI1E;(SQT
MA@[;E(S@']*LW49WC(R9%4DX"#T]*MA+@HG%Q9%.1W K.U7Z5=&2*96 M#NP
M>!7Z5*D^0YH3*5_T']*DDBIMAXL9R0H H5R<=*C.20\5S9:;;IH+0%$&LN3-
MM1T<6CW.Q^O30#>,52M46RT0T7IU39RE*N?:IQSJ97+3. V<MBTJ V*_2K%E
M14\##HLJWE;BE7Z4I92,=,WR2,:R!I(JMY4:H:<5[LLG '2J&RU1H<M2B!TI
M=RY.A835).X \440\8-_$G%<8-.@\4[Y]S^DT;0\4%N>O>"4GH:KRK@LQ3N:
MD_B,;W</EK9*N*EA'R;:G05' R 3_P *IUF58-.Y/T-.FP/698XH^IXEU[>V
MKS>TP0V0[W(<! ^HK<*CCUQFOFN*=R<OB?8M3"\<8^B18NS>Q,1'%N"(PM8/
MB6H'DU'492>EP)1-R@1GMB'00"4@ #[5DW6:E&AR(JGGD%F62ZDY4?*CMR'?
M@92YDBV3DOO0$NA.?YFTD\\<8!JR&0-@VN%\O5RCNPK3;Y<;>GZEM%*>O7GK
M^E7K*)K;R'M6D9+<E,JYOF7(*<I('A;./2D\U%;Y+9W:(DA ;4I9*$E9(X2:
MRYI[T."J6X'5.6-/JD%02^^>Z923@[3U./2LVWR+HO=DW%8,.3_HE*4VE3:$
M'Q!0QN^WK6K#B:A99DS)YF>4NU_1SMTFB8TA:4DGQ$''ZU?I<FR5,JUV+?%-
M$-H[2CK2>\?;5WJO;RK3DR7V.?BQ-=RU62;:[,5L,*CL2$N94E2<K<_/RK/.
M+ER:8RC'@UO1DJVZACAJ6M*%XR"KSK/*XLTPIHLW\%NEN4&[/=S'[W@MYRV!
MUS0FGW)[J[#A&G=9W;:^J^0CL\(6T[XD_?-2VH/%:)6WZ%=M\>7$ONI%SF+L
MRIA:&T!>#[U./"X1ES/?(KL/L[TGIB.N);D[EN K<*N.GJ!4)Y&WR78L:BN"
MDZPO+5MCJ#2=H3XP!3QO<Z)Y<=1LQG4VHQ)+K0D$A0)!'3]>M;\<3E9>]& ]
MHI,];1#B<YXP:ZN!4CS^L=S*\RE3+8;<Z8Y%:+,=4QY%4E*,@<CFF 24Z<=[
MY@'BF1979@:C6]95C,I>,4 N"L7%ER62TT#L:3M'Y59#A%<^6-H$513E8\3+
MG(^W-$V3QGVT^"JUR]+?#)V?VZ:#N=@N2TH(P1WCJU $>N"#^=='!Q!''U$_
M?9M_S+[GA2TKGC.*UKM9DW7P$<CS%I*<*_2A94*6"QHNSW,_S&0K=ZX.*FLF
MY\E,\,L:M#8Q+ZA6W-/=%>97^T]!=N'='.9!)QTJ2FEV'&,G]H>LP)0(!S5,
MYFF&,?LQ74#"P2:IW66[!R&B/(_I2;+8\#D-)XY%(+%=J<X*A49=@7<=QH2%
MX45 ?<U2T32%G64H3M20?M1%T6**&3B"#R,5:I$910SE-;E#:/+R%33*I1H;
M%I0XVFIJ213+&Y!"T03D&GXB*_!84MJQT/Z4]R'L:&@84>@/Z59N(TV).1U(
M.\I/%+=? ]C7(DHFG1&3"YJ5%>X#('4TAV 5 >8J27!!OD4:="3C(I$TQR'
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M1BBT+:&' I,DN$*A> !BI(8;>.E5"H$G S0(*%Y.,4 T"KI0("@#J !!Q33
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MRHI .>M%#W"2L*J<$#=BK"$J3R*;)(,I"0< 56P8"O"GBD 3>KUJU =N5ZT
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MY:VU+CIVNH4WQM43TK@^+&6627DV=7 F\<6_0SF/VK:UEO%LR(Z0% +W;E$
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MT2<Y$FZPUS+4GY6X,#NY#)&=Q]<^]0BJ[FV&HE/BJ)WLY[09FF%_)W);;:5
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ML1;5;C;X,?$4H!=2D<$YP/RS7'G-RE;.A!*/8S3M/OC4-IUZ1@O;5)#;>2A
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M@^F&+S;[\P\\V6F.\!2<$*]\U5/-CRPJ,DV2BFGRCUGIS5\.#:FXTM29*'D
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M3AQ>[$1Z9#:1R6F7@E*O<\9/ZU5FZD\JJ44=OIGL7H^F9/$Q3E\N$3/RC1P
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M&/:K([>2LWRYH>9"4J/.>*U8HV3HH<[PK4YZFMB5(D,N_IC/4^GHY;M91=G
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M3))<D*W,):KE_#I1:?9*$J'A.//R'W/E5<X^*MTOD6<8T771MHN-PE.W:XM
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MYHZ-I/2D5<>%#;4=VX%<M9/B6XKJ5'J2:]QI]/'3-XX^1^;M9K\O5LGUG/\
M:D_R/'T*>F?VE=H[AX,6ZM(2">B>Z&*\]KN<IZ/3K;@9-!2Y"RA0\(YYKGT;
M4^!-!2IP(40$D\&B@L5$9!=* K)3U]*-J%O8:6ZU&8 !.[(Z#-+:2C.V<6'
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MG-TL_&ULY+M%)??W9:$\@>M8WW.^G8HWQD'SJ+ 620!@U$B=E/G0)@;E9P*
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M'FC:+<T%);2,$]:E'@A)V(+V'C-2LB(E#>>33(L;N(8YY_:DQB!;;ZY%.B
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MI3T^3GL>"]M_9'#[0:>6; JE!?C_ )9[7D2HTVTINK4@/L/-[VWFB%H<!'U
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MJ+:V4-@)2 C& /SKZ;_K/L?FK9P_DSYEC]D/I(TN)^+SZ<Q%'H,U!VBWD?\
MR-TH(_2K<N;V6SQYDO\ VBP],]O],_?A?_K0V<T]=YHPZPXG/![]\_YFN+EZ
MS[*=/G4$Y2\O==7^1Z+3^R?MAU>-9FX1?=[DZ7F^Z',70$M0!"8>[RZD_O4)
M_2%TO3/:].E\O[(W+Z(NI.%QU3;^/_\ T+/:.GQ$[R&R <;4M UW>G^VO0M9
MQX=-^M_U1XWJOT8^TN@EXT<UQ7DJ_6QNW%O< J$!4J-N&#W1*1^G2M&31>S7
M4GXF11_]U?U,,-7[9=)_987)?%1O^@FY)U1%4"]>YIW<@$'_ "JM^SWLEGXV
M)5__ %/[ET?:?V\T;7B9YN^W[&_Z"+^HM7(&R'(E/*\@AH+/[BN7K/97V4CR
MG7_K?ZGH=![9^W>1TH[OG!+\XC-V]:O97OGSY33W4)* D#TXQBKM)[(]!U.!
M1Q4UZ[[?X79#7?2-[9=,U#6>3BU5Q\-5V_Y[:?\ 0>6[7T^&0U?;>IY.<]_'
M/B/^^@\?I^E>;ZS]'F;3RW]/GN7HU^K/6^SGTUX=1%8NN8]K\Y17YI)%VME_
MM=U828LQ"W2-Q;'UA/J4]17S[6]+U>D;6JC1]?Z;USI_5EX_2<BG'S3X?\_O
M!>?6C:<%T+) ('TGWK)CB_X.$;LFICK9*>-;:[KU_(93 X6U+(Q5L2K*G5D,
MX4J2M1'M5\>YRY--6RNW%:0VL$' /U>0K;C./JJIB-C;G2Y):@Q''"X<%:?H
M ]U=!4LB2]YE.CE*WL7+(;M TC:+-$9<NUQ4[.D2%N@QE93'0,93M/"_4BMF
MFRRR<+L<OJV@QZ=*.67,G?'E^IZ5^#CXCI6GKS'^'[7MS2II\$Z7DD;=N_DM
M;C^%?X1S@C%=S19JDD^Q\G]LNB>!N4%SW^:/<(FLMH* !N!QQTKL[>;\CYRD
MH8]K[A0_GR_>E1"PW>?>@+.[T#ZB0* L*I]/X?%3JQ-A>_1^+PT4(*J2V#C.
M::0'?, \A.1]Z= #WW]W]Z  +F!G%,!+YAM7&,9IT0H#>W_7^U% "'&Q^+/Y
M4P.*T*'AYH (I:$C!.*FBM@ A0R#FI$4 7$ X*N:+&)%QOGQ4N $EJ"OPXI
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MX_SXET?I/T^-*,]+)/YO_P#9"/?$EIP(RFSW18/DE+9__>H_[._^;_/Q+?\
M[4]'7&FE^/\ _*1,WXBM)J6DKLUUCNJ^E94C(/V!R:;Z!*/G_GXF&?TFZ7._
M>PM?Y\C0^S'MOTOV@S?X)'DNLW!MHN!M](1WH'!V\]1YBN3K>CRT<'E78]3T
M'VUT?6\RTD(U-J^?AZ&FUR3V *<<T"9WG^=61$-;LUWEOE#IENM>G=21GU'V
M&8)\/JC%UU>&7N J<YCU'->JD_=3/@/4E>OSW_R9[LL,I+L=(!SM2//VJJSG
MM#V=,0TT)!1@8R1BH2[$$_>2&5DDLWAAYPA:<JP <CI52LO?8?&''B@R5O\
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MQ(M*3M23[5E-K,_UNM4Z1'A Y"EYP*Z&G]V-G"ZG^TFL:)=MYNQ6I+(([YQ
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M&+QR["M^9HG9/JNXW6WNVJ_N=Z&W"%)4?(5AUN/9[T2::OD?:R5IV ZVJS,
M@ []Q_6C3^)M]\)4^Q#VB\*@+6MI/\B8T0O^ZKRJ_+!MVA(>1K"Y+6Z_$=*F
MVR%E.<??BJ9225!?(&M>\=AL/VQ8#B$[5)!QQBJ]+D<)/>)C'2D54HH5<6RG
M:03GS-79LJ_A(II=S6VI-MAQ(\B.E(4!A>!YUPLV.>27).+0SF(=ER=\>3W
M6"3@]:ACO%*GV%*WV(& NSVBYNO/W1:G7L[T;P,#\ZZT7*<?=,\XY/0L(NVB
MM)/L7%$=+IE8*CC/)JMQRRXD0E&<D6V[ZBTC<X\>%<H 8$Q/A4I)ZFL\O$Q<
MQ)84TZ9"6K3VB;;=UQ4;"MWG:DYR#TJ#GJ,JM+@VW&/<::TM;%@<2S":0TP]
MSG;G/M5N)-\^9"TS)[GJ.TVRYAKN5=ZI0R1TKH+#.<+HCQ9LUBN=M?TTF1))
M4D(!VE5<#+@E+-[J[%ZDJH"+VC1'&3:[<SW*DI!Z'G\ZCDT<W+<T70R1BJ9'
M:@[38=DCJ,C/>$=!ZXJW#H)9)6BN62*14GNT8:CV-1&^[5M&2!5V70K']HA'
M)Z&F6>&T+:$2Y6Y13T/VKEXU+=V-$WQR/95GBMV0IQMWC@XJ>3,DZ9EV+=:,
MZNK;EO02AX <X.:G')&[99&5]B/TLPY(O;;4H%;B5J4%'U'_ +ZGJLG[%GL_
M87!]9ZQC]%S^!IKB24(;1TQD_P"]GFN&DUR?J5P:33[-*OP(^'8+;>E3(ESC
M)E1EK2HLKSM6I)R,_:M<=3/3QW8^YR<_3,74,/U74Q]VTRR/K$=I2&@$IQM"
M1P !61Y)YY;\BY.G/3X8PAC@J42#(5T6XK]:M;7<LRZM7<(*_DA=AOO5;$)*
MC]Z@YQ7\)1'Q<W+DE]Q*1K?%B +VD%/)R<U2]S[RLUSG-\NG]U K;=EKWK([
ME)X1CK4HS6/[*Y];%&I<?9?J/VSL2$H  ]*J47NW2*? A*5S;?QMAR4A.<')
M]Z)2DW5!*&522A-5\ABXMQ2]J6P/?BK4HM<EV;$I4Y3<O@K0NA"TIPH@GV&*
M@JCP@J"X@FE\78-'<DF%*3Y*HW/T!2CYQ VJ_JHW,;E#RB%V*"@0D8^U/:O^
M00EN7O6OO#J)*,;!FHTUYE#Q)2W)M_>1D^TMRFU(4WRK/.>GO5F.;B^0RXH2
MA3(2/KF/I:\,::OTLI:DD")*</'^ZH^74 $UK6F>>+R8UV[G!R:^&@S+3ZAT
MGV?]&: TM*L%(3E0R=ISFLKCL[G4C.+5H*^I*VR4\[A@^]'>J)8_MMOL8[<=
M-"R]K#=TB*2EFY,@C(X0M)Y_45Z71Y=^';YGR3VSZ=/3:SQJ]V1ZLT-)87;V
MW$H!2G&<UI2L\-)I=R_L7(1X3LN>ZTPPUPOD [?0>Y\J4\D<:;9;IM#FUF10
MQ1NS)=;ZVD7QP0$QTQH#"\MMI/B>_ON'U]JX6JU;R\6?8?9?V5P]/BM35Y/0
MHLB6I3Q2ZKO @80X>,#TQ7-;DT>W\&.[QI\2[41$J9\PL-H5PDG/E5T<4DK8
M:B$L23D<PA(!=R-J?J4> *.[I%2G'''>WP05V[3[) D&V69#UZN"3@1H:-Z0
M3_4OH*T1TDZW3X1Q=5UW33EX6GN<_1)_GV(.ZVKM,UK&=^>NT?34=8(3'B#O
MG2#ZJ/ -:,6?2Z=\+<SGZOIG6.KXGBR9%ACY5R_OY,^C_#5=(4Q5SA]H$QN:
MLE7?!K"L^65 Y_2NG'KN.*K9_GX'D8_15G67Q/KW/KM=_C9*1^RWMJB_R8O:
MWM:/7O-ZC^_/[U7/JFA;OPOR_0</9'VET7[/3ZRX^O/ZV"[V7]M<8%]GM72Z
MM'(W%Q(S3CU703XGBK\/T)/V/]IX^]BUFY^C;_-ND,W+W\1.D.)]G3J!EOGO
MBE+G'KX,*_:M"Q]-UO$95^)ES:KVVZ!^]QN<?FG^38@GXD;Y"5W-_P!!/LJ!
MY[LK;5^BD_YU!^S^!\QR$M+])FJTMO4Z1MOOR_ZHF;?\3&D7%!$ZU7*$3U*F
MTN#],YK+D]GI?P2.OA^D_IN=UJ=/*/WW_0N]C[3M$:EV_P -U)#4XYT:=7W2
M_MM56#)TK4:?AQL]7TWVJZ-U#C2Y:^$F[O[Z+(VZAXX:5N^W(_6L62+Q_:5'
MI)<1W6G\FG^0LEUL  JP?<5'8VK0X>]&T*A:",A0Q]ZBR$LL(\-@%:>G(SZB
MBBQ<@*^DX(_6D5O+&+IOD:K7E6 :FD1>6(NU'4?$1^]1<MHXSC(<)#:2/^%/
M;)JS0EP*%2>H/%"BV4RDE+;YG(_F?3S2DMG<)>[RQ0D)'BJ+3[@GN[#%<E*U
M!(.<G'2K(XI/E%O@9&MR7"%BXAALJ4>0*%%V0C"4EN2,X[0]0%EA3+:OKXQ7
M5T.-.7)Y7K^L4,?AI\E(T?$^:GI6H>?/ZUMU$ML3R_3<<LF5&ZV1L-Q$)'05
MYW([DSZ3B26.*1)2I"&&5+6K QQ5:Y9-]K*]9[*J7+7>YB"H-Y[M!\_>M4LJ
M4=D3F0P.67QIB-P"95RWJ'@2>!Z"B/$24JE/DG+/'RCP#SJN3MFR"I<$XH!M
MH>W)I*+[D7-;J,\U]<4QH$IU2\ ()SCR%;-%C<\B2.5U6<H:>63RH\XZ-0+S
MKYIQ8*@'L\#R\J]1GBX:=H^5='QO6=3M<K^YZKO[Z86DWG-P 0U_EQ7E-/%O
M+M?>S[!JWMTLIQ[)'DFSI=?O,Y]Q&%+?4HY/OQ7L6TH)'Q;0M3U$Y?$U6Q>
M(Q_2*Y&;N>WTJY5$^XI1;ROC^FLK[JCH9LD9S45Y=S-=1-")K!\I"4";'1(P
M5 <@[<UU\+W02/)ZEP6O?HT?03X"=<O:A[$WM+2G4N2='7-Z$G*O$([_ /-;
M_(>("NOH9\.!\A]KM$\6H\2*]U>9Z.+@2KK]72NDK9XZ45"7S![TGSIVA\@]
MX!]1H"F IY(Z*H%042$JX"J H$Y5SZT (*;RHG'G4D)L2<</EUJ:(VA,%:OJ
MSFGP*F).%]/(''WIJK%.T@F5]<'/WJ95N9Q6L=<_K0%@=XJ@+#).1DT".*TC
MJ: "]ZC^K]J="W(2+N 3FDHNQ.2 2XVH_5S]JM9 3==3G /-)(0DIU0&0:84
M-U.I5G<KD=*.X=A!;J]W!H2"T%6^X$TZ(L:*<<<)&/.BF,3*O_BE664""N\S
MD"BQIA"ZL>9%'!+<"J6_MQDJIJF%H3^:>]*-J':/G/I*' O:5R9,] <Z(3OX
M57B\T7'L>F318;!:+-&NZYKY"7$)4E(/'/J*LQ3;C2*YHA[G;[-JF]JDRH;R
MT,*"4Y'''6B>644$4DB?CV6QQ4E<.V(2M(\*EI&:S^)DEW)77!#W&P7?4TQM
M+W<LL)X\1P:FM0L(4$9[.TZ>FF:AY!.,$-KSD^]59-='+PA%(N>A]77B;\TR
M4B*5$9*R".?M6R&IAM"Q4Z*N-L1W<JZ@A/3"JE]84NQ&V7+2.C92=UP7=\-$
M8(4KR-8L^H7:A.1;+'H6#=I+X+84AL$A6>O/2LWB1?F5RFT.IFGK3;&2\U!5
MB.><IQ5SA?V6$);GR-)Z;/+@HD1)"$*2/$C/G5?@R+TZ("XW6*M@/,/E"F5!
M*P>"1[5'P:?))/DI_:C:V+?&3J6# +B'T;@HJ()X\ZZ.C<9/8$@W9++A:XMT
MNS3T!,B+@H+AX''&#4]8O#Y17)4+:QU5<7@BQ2T#,!00'4]?N/6L^/&FK9"J
MY+!V/V-^Y78W6YW%2L*&T*4<X%5:K+''"HEBN1.]M.K;; <9@EQ1V$G<D UG
MT."<Y;F7224>#!]1O(GQESHCB2XDY&>HKO8UX:IF>^24T?K^:J*BV2LJ5MQU
MXJK+IXM[D2<J-5TH[;KW'<CI;[N2VDG('!_.L63'1%S:*;J'25SO=Q<CREA#
M2#U*B,BI8LT<:KS)IIHM/9UH>TQ'@T7D.J\L'./O6'5Y)97P351+U>C%M:=A
M>*2DBL$,;EV)SR614[64FXQQ;K,A3RVQA1QQ4I:14W(4)4[*PB/,[MQ<YO>Y
MD^!1/7RJO)!)I(NQRC39)Z>_U6\Q_GCW3L\EIE!_$4HWJV_D*KU6*4\>V'D?
M6?HQAI<&LEFU+K=&H_%\/\B]H<06]K'B"203Z?>N,XR@ZD?><V)I+ZPZ7D.K
M.VVAAQ]./&HDTY>2'@QY(1]_S[?(:7&9@G)_2I1B1RSI$>PI3[@"0:D^#-&Y
MND6&-&;C,Y6!O//%9W+<S=".U"@W.D$?3YY]*78E=BZ D82D<4@?85  &*9$
M1?="$^=-(E%A&<*!4K/M38Q8'-5L IZTT %,#J .H Z@ %_0K[4"9BW;3:W+
MO*@QF4>,J(SC.#QS7;Z9)0A*SQ'M3B>;+C45ZET[);M?XML%GORMZ8G\N/*<
M/B4G^E1K-K8P<MT3;T9YXXO#R^79FBK.[*L  \U@['>^S%,H?:,TMB+&NS"/
M'"?2X3YX\_RQ75T&6GM/,^V6C>IT:G%<KDVCL^OEO7IQ%XDK4E#B 6$CJ]_N
M^]=749UA7!\IZ;T?+U;)MBN!MJ+4\JX/9<.4-I*64 X2@>N/-7O7G\VKED9]
M=Z/[.X>FP7B+DI]PN'53B^?7RK-S)GHEB?:!#S)\<,KD3'4LQV?&MYU02A&/
M4GI6B.&351[E>2<M%%YMZ2[-MU2\S)M5?$5HJSJ5$L*%WR800CNP0RE7IN\S
M]JZ.#HN9M3R.D>!ZA[>=)T,W'IR>7*_POX-/D9:<L/:-VK.MW#6=W=M5E4=S
M=OC$H4H>BL<XQ5^HSZ;1+;!6RK1Z+K_M)*.JZC)QQ>4?\1L%ETS:M-0TP+/"
M:9;0,;@GQ'[GJ:X.3/DU,N6?1M%I='I<2Q88I/U\R1X5R0,U4TX/:;HQI4P-
MB?2F ?8GTJ-E()!/"3@^M"X%/8XM2[#=UE2@=Z@.?ZLU8IS_ ("W#+%&-8X7
M\POR\9W"5COB!SNP<?E3\?4X^6Q2Q3D[R027W_U&4_35BN+)CS;-!?:5U#C"
M/^%:,74=1'LSCZKH/2=5_N,*E\D9WJ+X>]"712WH27[1(6,[HSN]&?\ <5_E
MBNI@ZWJH*GRCR?4/HVZ/U&>[20EC?RX_G94U=AW:'9E$:2[07"E)R ZMQI7V
MQDIQ^5;O]9TDU^WA_GXG!G]'77^BR\3IVJ7W2I_A0\-P^)#2S2?F(T&],-C;
ME"$K( ]\A7Z"HQQ=)U3W1X;_ ,]24=5[<=.GXDL?UCUX<OR29T;M^NMK4&=9
M:"N$=6?[1"5C]E#'[T3Z+CGSAR(UQ^DOJ&G?A]1T+Q?)27_ZQ-Q?B/[.)"BV
MZJXQU#J%,;_\#61] U?_ #7^?<;L'TJ=(@O?A+\$_P#Z@)GQ$]G#:"(LJXRU
M?TLQ2"/UQ4%T'57]M?Y]Q?+Z4>@?;>/(_E%7_P#K#>/\2&B7%]T;7>4G^_'!
M_P ZL7L_JO\ FO\ /N,C^E'I4I5".6*^2_4MMA[7]!W97=BZ(@N*P ):2UDG
MRR>*JS=%U>%7]H[FC^D+H>L:A++*+_\ .DOPY+FU/0Z@.,K;4V1D+2K*5#V(
MKE3TV2#_ &G!ZK%DZ=JH>)@RJ?RI_D+(67.<Y!\ZSM;)>YV+H^&L?:F+HPCH
M:E>_N5JY/D1??=YP@8]ZBXXY<62AX<?MR:_ YA3?XPCWI*-/@A+'NDGBR-_@
M,;U-CL1U%#@R1@#-7XX3<J91K9YH1][@PK7%X?EW9+&? .OWKTFGPJ$-Q\\Z
MI/'*=QE;)W04<%P+(YK-JWP;NBQN1L5O(3&!'E7 G]H]Y"MB'"8B[DX$Y 0C
MGFC[)"3ON.99;C15):3@8P<5*,;?(FTXV4J5) E<9Y4<5K4.#F9)5,N=C"4Q
MPI7G67(N>#HY+2X%ISV&UIW[1C!4> /UI1<D[+,,\<8N;5M>7J8WVOW=$2S2
MFT/!2BV1QZ5V>F8Y3R71XCVGU-Z65^Z8MV2:MT[8[V_=;U/",*&Q"$%3BO8
M5W-5H\NJQ[('S7V=Z[H>EYY9M3*UVI=_Z&J=I7;[8V]/K@0K7-=[QO:-[R48
MSYD8K-I>AO#+?.2L[O4_I,TLL$L&FT[Y\W_\GGZQ:V@VYU:W8+ZRM14-JT^?
MWZUUGIF^$>$T'M-#3R;R1Y;+E%[:K3&*4JL$I9Z9[Q(/Z5FGT]R\SN?]N\<&
MJQO_ #[QY([<;:6QMTX\5)\E.@$?M273:7<U2^DG+&&V$'16[SVIPKU<(DMR
MS/1A'0I!/>@D@].N*MAHW#LSC2]L(Y\RR9$SU5_R>':1 E=L5_TU%G.H8O5D
M[T,.)QOD1U>$C_JK7^@K9HHRQY;//^UNNTG5<3E@X_QGT3#Q#:$]:Z5;I,\+
M>R$8L'YC9R<T;16 N4G R3340W I>2I)I[0W =ZD))%&T-S.$O QDT4%G&4#
M5BCP5R8T,D YYXJ=%3D")JU\%/%%"WL#YA*O#@T50]S?!V\>AIB"..IXX-%@
M"VI)220>M  ]XCRS0 52D+X .:5@)'K5A4$<4$I.?2A -PZ"<)!S4@&SKRTK
MY!I>8 =XXH''%,!LX7$\FA$6$#X"-R@K]*!"2Y*7!X58]C4D^ H*AY">II@$
M'.305'!24G.1Q37<0FZ^#P *E8Q/OPGJ <TT)A/FD_T5(5'SRO/9[_!'G;IH
MTF3;RX7"ALY4@GDY]/M7CL>:.6--'H89*X89MR/>&69B5+86T=K@7P<^?%4-
MO&W1;W)E=VT[:H.Y$A </)'J:H_:3?8:BR NFK[6ZUO$AU"@/"$\YJ]0DD/:
MSM-W-J^//(F2I*'1_9XXJN>))6R78?7G3NI(L-4U,U6-N]*5*Y(I8?";J@:I
M64J\:KU':;8&&Y!"2>4^=;8X<;Y1'N4N9?KI,DH7-E/AO<,^+J*U1QPCQ0K0
M-V[0+NPY&@V:<MMOHH*5N!_2E]7QR?*'W- [/NT?5^GEI=G2&WVG"!@#'4].
M:R9M)BEV16X6>BV;G$N]F;<F,(6E](*MO&,USWBE"5197MVE&E6_3]NN#L6.
MM'\Q6=JCSFB7B(FK8TBPK:_<BQ*MA2D8R<<$>1JJ>1J-EN->19=5V2P7'0<N
M%W*%%ELJ;^WIBL'3\V1:FV^">14>>-&N1[;*?=@)++Z"0HYZ@=!7J-0MRY(,
M5O3JY+X?E?63XCZGUK.N%2$;%V9P(*K,B8'0TH)/^%<K60E*6V).#1FVMF8M
M]OCL=QX.;20,GI6W3SG@A30I<D-;=$K+3Y0D%&,8ZUL^MQGWX*6J(!-I1"FE
M7=EO!-:E.,EP.RWZ?U"S9);4A+N4K(2KG%9,L6^PU&RVZY=_B5E5>;/((/=Y
M7L\N*IQ**=27(DG%E3[+K_)AQG9CTE17N)W*\Z-3CC=(E+D5U_K*7,DE+,S>
M',) 3Y5FTN'8N0JR[=FRHVGK3\]+4%N/)\15Y51JY;N(ED(VZ)2=J*P)=+CK
MB-SA\/W]*YCQY)/@VXMM516]?:-N>M;/;)>G;BN%<K>X9L0ES:%!6!C</I)
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MJF@VVR!A8!'M7'U<GZ'K^DX\L*:A?WHTR.LH0$XSZ>]<:49-VCVF-II17?\
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MM0 (K)CFKVL"TZ4U"J-IU<=.Y*FPH$U9'%%SL3>TQVX7];-T?FO/J*5/XY)
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M>@SU3_PKI9(>+%J/<\#I-=J?9_-]7U/,/\['I?LXN%NN<3YF,XW(CG&'&CG
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MJV\\UYK4:Z>HM1/KG2?9[!T^I9%;+Y"@-Q4A(2!CI7.<I+AGIG''QL'H0/I
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MR*%,;/!%,7(SE(1DX'%6+L4/NP@?" 2DXXIA05%QPH!1S0*@S\I:D%32B.E
M=A%B0VA:E.IR<4!854EEQ> D"@%R+MM-*Y/% 6&=0E'B'- UR"W+V) )X\J!
M4-I$LD^!6*+)""Y2=X'O18 E:"=^T4R 1U]*$Y''- F)BY,$A! )IV*A8+BN
MIPHA)/3WIB&K\=IO.W!\\TJ&-"2E1QQ4EV$*%1<2!FF D62E0(XQ0 904>5'
M.*8GV"*"@-Q/%')6([F%G#AQCSI\ =B)_M*.!\F,V^\]GLA&]BX0E#V(S7S:
M6FC!T=;?D]"31=M$. (1)CJ(Y #E-Z256F1<I/NA['EV<$+9D$#R*%DU1+$[
M]X-[0-[T=I?5\0HEQ6758X<7C=FKHN251!9FNYD>LNRU-DCK=CQBI@>!8!R,
M&HIRA*V6QS)]CS)VAZ$_A%];GQ06H[ZBE0'&TGS'O7<T>J62-,U1G:)S34.X
M0H ?$I+K /*%<C'_ !J&H:W<$D[9;4OQ[[;W+?$C*;4I)3QP,^]88[L>2VRQ
MT9'<]'V>TW"3'G.E<A]1*$J.<'VKNPG:LK;LH\Z1==+SBM+KC:%'"$(44C'K
M@5;2DNPUR:#HO5;UR:+3[BU$@?4HFL>?$HTTA<AM1 (WO =*LQ-25"9'Z;=<
M?F)GQ%$.(.%X.-P'K4,N.HTP1HK\VUNVTW%Y?=R\9*1QS67%!W06BK1=2.3]
MZ59/RRB59\QFM$\-<D>Q8YUGMTF$W<$N$)4@YQYU0IN+H+$[3(24*CQUG: 0
M3GVJR*4F1DN+$^SJ[LF_3+=(5EQ"RM!/4$=*>IQM0M&O"UMY--=N;UY:>L]T
M0/&,(4>36+&TWP+*S .T#1LK3=S7*0HJ:R5)]QFNEBS*7NF>QUHW4#L-Y+V"
M-N,8\JCEC3&S6I"S>(+5T;\.<'(K+-I\%4N"FZ]M+-TMRW1PM(QN'7]:A@R>
M'*F1C*C*M+K^3FNM.DG@C)-='-S"T7Q3+/9'),5;ZF\EM0)//M6&79%FW@U#
ML=[QQ=SF.J)_EH0,G[G_ #%>?ZX[44C[C]$>FK%J\S7/NJ_Q- CN,H9;4\ZE
MM (.2H ?O7'QPG.]G<^QX9[<<6Z[>?\ <4NMS@K\")2%@CJEP&I1QYH>7\B.
M;+*?$6OY?J=#E6ZW1%3'7RCRR#D_H.3^5.&+/J<BQPAN?P%J-5CZ3@^LZJ:C
M'U?]K$$ZJC*6&8,.6\M9R2I&Q(_-1S^U>LT_L1U34Q4LD-B^/]F>&U?TJ>S6
ME;>+(\DEY)TOYH>BZ2EJ#*(R KSW.YR?RKJ1^CK51J6HSPV>5)IU\6<%_35T
M_/OCH]).63R]Y5?RHM%@TTB9ER=/?"2 K:RI)Q7HL?L9T?'AVQDY3^?ZH^?:
MKZ3_ &MQZIY,V-8\7DG'G\4QW<].Q(12Z]>BF$1RL,@*(]AG.:XFM]C=!H%X
MVHS*/PYO\CU'1_I4ZGUB7U'!IG.;XWJE%?<W99-(]ING=(M!BRZ>>E#.''''
M^Y+W_5ZFN7'VATG2WX>GQI_%I-_B=76_1KUCK<EEZIJ=F[R]ZO7E)N_U-$M7
MQ*6R.A*).FYS:?1J0A>#]B :N7M=BR_;@<C-]$&KP?[?51?W2+&Q\2W9P\E*
M;RBX(3^$+@AP ^?G5G^N=/S?;A^7Z&./T9>TZ;^KY-U?\;7XVR9@=N/8%,&V
M2N$ >IDV-7_"JY:_H\N\5^"_0)>Q?MOH_LRG_P"__P#F)F)K3X6;NK9*_P!$
M7%+XW+MQ9 _:H//TC)]G:ON_L4RZ9[;Z7F2ROXJ?'X;B1'9G\,>K !";TRO=
MQNC7'N3^0"JK>DZ=F^RE]W!3_P!H/:O02J<Y+_JM_P!1.=\'?9)<F^]LUPNT
M  =6Y27TG[9SQ5$N@:>7,6;</TG]<P^YE4'7_E?ZE:G_  .VH@FV:]E-<<"5
M"SG]*S3]G?\ A([.G^EC41_?XD_E_<K-Q^"?5+ )M^L;3(]$NLNHS_C6:?0,
MOE)'8Q?2SI9_O-/*/WHJ5X^$[MBMJ5.1;7 GM)/5B4$Y^P5S5'^@ZF^%9U,/
MTF=$GSFGL7Q3?Y(SW4W9SK?10;=U1I:9;F7'.[0^[RVXO&=H.>3@9KFZC19=
M,_?5'JNE>T72^OO;H\RD_@FOZ$0^5L-(>0=@1D[ASSY)V^9)X'OBJL47+W5Y
MFS/JEAC*.7B*\_\ .3S]VX=J-^1?)79_I:W.JO#+R([J0$K[EPX)!'FX,X./
MI/O7I.F=+V_M,G)\L]K_ &Q<8_4^F.UYR_OQROY%/T[\-W: O5;MOU1;I_S3
M:&9;N65K<(= 4"KC).#UKH:O/X$:2.'[,]*AKL_BZJ5^;M_J>A[;HQ&F80:$
M&3'2$[27(BF^GKD5Y#+ES9I\JS[;TJ&DTV11TZX^XD&@C'  _/K66YKLCL2Q
M*V]R%4MA2AX^<^M)RF^Z(NXI]API)2@\C/KBH[6&-P:Y3$-A6H!1..O'%/F(
M/(X.\:Y^/(KW24 8SS[TK*9YYR^U7X %/HGBB[[D(YDN'+^03IS@?I1QZEJ@
MLOK]S.R@\E8!]*=3\NQ*LD7L4'2^*$%*2"?&.M26_P!"2Q2EWB_Q1U%$#CTH
MH:[A:9.D!YU) P%=:9!L"@5L$=:!IL72UE(-1L3"NNI P!BFD-L2 W*&:8A3
M9CFHV%G4@!H ,@ @Y% "B0,]*!,5 V^*I+D5D%>I.U)SZ\5=!^AGU-QB9[J+
MNG'<J ..>:Z6"TN#RVLIRMD89*$PBD'GI6A*WR87-;*1&04I%Z9)Q@DFK9NX
M-&/'!>-&S0)"746!Y;).)"N[Q[#FN3C2\7D]7GBGI6Z[B%OM/=M("1A1 )Q4
MLN3D,&!;$BQP6RR4I\ZR3=]SL857!.#Q1%;N?O54>&79."I3F0)&[:.3Z5N@
M^#BYXU(E+>Z41SS5&>//!U,<TD9)VN7))2F*%'*E8KN]-QTK/G?M;J4VX1*5
MH&(96I>]_I(%;]9*L1YGH6+?J4>L[2S\O9$J]A_A7CIVY-GVG$U%1B8/VP20
M[+#8'/>BO1],50/!>UL[RJ*(&T.(:92"/$,XK7EMLY>DG4$6*URG%[R1UX%8
M<D3KZ?(^6/9:"I"4GJ#4(NB_+R0MS^LY]#6F!AS%"OR 9$5\]$A31]\\UT,1
MYG5_:0[[+-0M:2[8='ZE?6I$>)>(Q?*3C+2EA"ORVJ-:HMQDF><ZQC67#*+\
MSZUOI6VM;:QRE:D$>22!P!^1%>@M2BFCY"L;QY)J06,XAG*B@'/'2I\%"MJQ
MVJ?D! \Z Y$R3U)--)$6V*-@N> 'FG2(VT&+"^A43BF*Q' Z8H&,D1RI]:<_
M;VJ-#'J(W=M[ED[:DB#=D;)6E"\I43SZT#05M04H8&* H?-N$(Y/- COYCHP
M%J_6@D@'XRT-I.X]/6BAC9L_U']:D5-L*HQE J0KGRHX"V)J64I)R>*& )6A
M;>%4N Y"IMS"U;RL@=>*=!85MEI4K:'%$ >9II(+.=7W:R@$D?>F FXXE*=Q
M IB$42DY/&* !,K>, T <VE:O$5'% ";LD EHBBQ4ADX@J)63UH!B&PT$3YE
MQ;7?;6P(RM[:4*4G<TK"J\M>*7)Z/?$(8MTBR$3A=IZ%H)P [US[5.+A+A Z
MD:UV9]H=X8;_ (%(NCY.,MEPY!]LUS]5C7<HGB7<U"W]H5^M3R8]P3N3U"D\
MG%<ZTNQ0\29;K=VG:5N"%1+S< PESA1=3C'YFI*#S.B#Q278H_:%I#3]\9=D
MV6:Q<(2QE)0L**%>P'E2EOTLNQ=CDUPS+?X+)M<)Z RK \B:U1S+-3-<6BJQ
MM8"RW$P4?S'D$%2D\BMRPJ<=PV['&LH5OFS8VJ2WM*V_'G[<5;B[;2I/FC&M
M:WB3>YRD16E%IH8R$UNAPN2V-+N2O9?9;PN\,%F*I;3GUDI/A]*HU$EM&VF:
M=KBSM6=+2I.P*<&< ]!TK'IY-.T0LJEELTJ-<&W+3RA;A6YCG@UHS33C;!LU
M7_0:Q7N"A]Z5W<A2<K&['-<V&>49=N"F4GY$8WH/3]J==C_/!*G!P"H9-7/5
M3GV1*V2D*UVYF+_!W9Z5.+.$)W#)_P#55?O2]Z@MG(T=%A2@AN2TAUSZ05@&
MG')).VBV[B4.\Z8O>D;^_>(Z5X5DI.TX)^]:UFCE56$)<$KIC4]YU/$=#X+<
MM!SDC&0#QBJ,D88>4R5MB^I[@J7:#&NP_P!:5X4YI8U[VZ)!JF4:-H75C$-R
M\6MOO6 ?$-I/%:G-2X9&TC5>RG4#5TCKL,M@H &%#^E7I7/U%XY-HE**<;&.
MO82[1=BVP"(SF<\51A?BLI43%;O9I\*^!]"%[%]#M.*ZV/)&<:LN3:'UBOZA
M<%V><A25K\()&.#2S8U2:+HR[6;IV6QXT+2,R4T1NF277!S]6 $@CUX2*\GU
M>_&J78_2'T8::./HCSQYW.5_"K2OTOR+!.A29=O2TQ'[W81D%.> /_77<]C-
M7I-%K)SUE;7'B_6T/Z1^EZ[JO3L.'IS>Y23=<\4U\3/KEI*=,N0!LQ )_"T>
M?TKZ.^K="F^7&OFOU/AL_97VHA*HN?X?V+C;=(3C'[EB&EE.W:I9(3C\C56H
M]K.@])R+P8[I=^%:_&SK:/Z/?:;KVEGI-1+;!NFY.GV\DT3EJTN& >\=;*AU
M(R":\]U7Z2]1E?[&"2_SX'KNA?05TWI<*UN1S;[TOT98;?;VTI(6,?TGK7@^
MK^T>LZMSFR-I^5+C\#ZAT/V-Z9[-*,NG8DW_ .:U_5CHO+C A"L#UZ<US=/F
MR:=7CDU_,]'K=%@U<5)8UN\_3\1FE;TE84^^](4#D%]PYJ[5ZR>J_?.RG1]*
MT^B7BZ:*Q+_C'G\^1ZDJ3A) R>A]*YRE&"J*-L<./-+QI-I+\7]P?Q?B /YU
M!K?V+=T(?NV_P"DI'.VB.'9S)V1E++GXOMZ\!@M7]1J6R)#PDOM)?B"#GE7/
MY4U%K[+#Q/#6V,0^$YR#C[<59')./F+[?\*)"!?;[;>85^N,,>19E+3_ (&K
M8ZK(NS,N?2Z+4K;FPJ18HG:]VJPDE,7M%OC8Q@;IBE_^-FM4.I:B/.XXV3V2
MZ!F=ST<7]\E_4L%H^)/MGM"4H&N790'E+C-N[ON<5H76]4W>YG/U/T?^SF=?
MLM,H?)R_JRTVWXQ^TV(M)GP+3. X42R6R?S!_P JTQZ[FJI'"S_19TU^]BG*
M/RY_,J':UVT7GMA?B2+K;&K=&MK9_P!79>*VEO'ZG,GH<<5SM7JY:B5O@[W0
M/9C#[-O=AR.;?P7X<'F/M-[?Y_9_/$#2,!J3?9#99BN.)W_*)7Q\PV.G>8R$
M%0XY/I71Z9HU]N9P?;CJTXP6ET_,I=TGS7DVNZOR_$NW9#JOX9- Z;M&K6NQ
M/6.HNT]MQV2Z[+8"6UOGDK+JEE"1G&5%)40<CFO2_P"HZ;!'WJOYGRE>RO5M
M>XK30DD_A^=GH#LF^)F%IF'(O&LM$2)6H[M*5.G.PG4I893C#<=K=R4MIPD$
M\G&:Y$^O8]S35GN</T6]1Q88Q\2.ZN?>-?LGQ8]C]\9,._VRX6QM0X;E04R&
MS^:?\Q4\?6-&_M1.?K/HZZ_IENPY(OY2_L22M=_"3=?YTQ&FW%.=0]:U(Q^@
MJ7C=-RNW2.;_ *-[6:5<.;K[_P"A*6Z!\)=_06K9#T8LK\(;W]R59\O$4U)X
M>EY.%)?C_<I^L>V&D>]1R<<WM_L,KI\/_P ,<U?S+J[7#2KDHCWT)0/R"JK^
MHZ!=I+\?[F_#[7>VL56[)_\ P_\ ^4!'PQ_#].8V69AIQ?\ M6;UO5C[9-27
M2]#F5*7X,KR^W/M?@=Y9-_"4:7_ZI#7+X+>SZ0%+A:@O,;/("%-O)'Z@&JW[
M/XI?8D;=+]*W6=)_N,<7]_\ 8J$SX*(2-Z[?VB%!!X#]N(_<*J,_9AR\SK0^
MFC4Y.^"-?]7]BM73X1M7PTE5OU9:)N.@*%MY_6JG[*9OX:_$UXOI=T,W_P![
MQR7_ $J_T*?<_AT[4[;E8LT64%_BCRD'/Y$@UER^S>M@Z2X_$[NG^DWH.>*K
M(U\U3_,A)?9'VEV]DN2='R/#TVE+F1^1K'/H6M3^R_P_L=+%[:>S^?\ _>:_
M#]2I384^W+[NX0),90ZI>:4@C]1666CSP^U!K[F>BP]4T6H_=YH/Y23_ *C?
M<E0R""/:JI8W'NC;!J7,>0N:KIEEH$ D\#--(4I**ML*>3QY=:;X[E>^+[,+
MN3G&X9^]"5\H$TU:'#*3C.#46Z[B4D^S"O/@>#(R/+--*RQII=A'<#YBI4Q*
M+EV0LWPDYJ#&#2(@9'K3 [(]: #M\@TAH<-@XZ4F0EW E.;6CFK(]Q=T4G4E
MT:BMN+=4.!ZUMPXMW8X_4=6L,;D9)?-4M.N*"7B<JKMX-/2/"ZGJ*FWR1\:^
MF0L-)(R#CK5LL-%$-4Y<(DF)6VX1SC+FX ?<U5*%19KQ9/VL?4UF\M+B6N%#
M405(;W*]B?+[UP\;O))GM=3%PT\(>8%J5O*1U^U0R=R>E>Y$NI.UQ(%4V=)4
MF2K?_>ROM4%W)92JW-6Q9)]:W0Y./G=,*W/2B"K<K&,TYPW2!YZC9AG:%=?F
M[LK8XK#9W8(ZUZ+10VP/F/M!J/%S/D>]E4,+F*?'.Y=5=0E4*-'LUBO*I'J1
M]09LS 2>0V 0/+BO,<-?>?5.5/X'F[M5<W74<?\ 25Z/IR]P^=^U,KSD+ </
M=(0$DYS6J:Y.=II>XBS6/.%@*&$^]8\J.QIF3A1WPW$]*SITSH-;U9!7I24*
MR$GCVK3 P9VD4&_NCY)*@DY;D!1]L@BNCB1YC5<\_$K-V#J T\SD.#QI..BA
MR/W%:#CZJ.]-'UN[*-4-ZX[+]+:J& ;E:V7#SG+@0$N'\U)57;TLMV-6?)>K
M0\+42I=RSL,A+HW''/G6KN^#E1XA3[AU-)[Y6%#%% +;4@#Q#]:DBMA5*[H@
MYQGI[TQ"9=EJ4=BN/*D 9UJ41G<,4 -'0XD\+&X>]*AH5 D=P2IQ()' )IJQ
M,28CK[LJ=<3U]:8FPG"5]10 N$I6,[A^M @I7W*^#2)(6=EE3*<<\4[&,9+8
M(SNZ\]:;*_,:H9"%)43@9%(+'"]RD'NR-WE4F)! 'PG^8H$4@8FXYM P<^N*
M0(3,H X*L&I(=!7)&4TPX&J7E%9&#C[4T)@J=5W@X-,0X;E1=VWC=Z4 +F1@
M%)!P>M/D0U?>9(P" ?>D,1'=+(W*! ID9=A?9%]13HCR?.?5]BN<*]RD-+5W
M:%9"<CS\Z\+CG:.]#E65AR.XH^)TD@\U>IEC] 6Q,B$/Q9.Q;9"P,]2/*INI
MDO(U_0VIV]6P?E)N&IS R-QY-<W48?#EN13)5R#J*PN3X;T7O2V^ 2GWJC!E
M\.=A!T8?<+AK70MR7-MDIT]P"7&@Z2A8_J*>@_*O0P6/4PIEG#9IFE];LZSM
M:);C8;<(&Y)ZY\ZX>JTDM)/=C%5<$!J'1#4:XKOL=2E)7RMI/D*UZ?7<>'D)
MHG3&L]XLC,=95_+&%@GZ:U;G%W#L5/[1!M:6TA;N\EL!#ZN<HZY-6/+D? ^2
M-FZTN<$!BRVIB* < [>?VJSPU./O#2(O5]TN%TM*'9:SWH3SQ4L*C%T2HKNF
MM>SK-.$*4R%,.@)"A]23[U/-IXS5()1X+PU(G/2F9EGG/*W>(H*LA58)Q\-4
M**+%(T'?=0+CW)=R6R4<JYQCVI8\L:I$FZ#7/3\.SE%R3<5KDL#:D;LTU*3^
M1%<CG0MEOFK-5HN4]USY)A2<'R.*EDR0CCVE>6:QHV'M,_T#;TXAB: A:$GG
M=R3CBN?C@VN#+ARSE,\WQ[VW#DJ5:6\M$[4$'-:EA61>\=)2=#Z]6^8["CWR
M:I7=$E7/3I5>'*HR>-$'R6OL?OJE1)EKN">]94D*3SP <U?-J+*9Q\R$N\E6
MD=4E^T,E33K^Y:4CR-+(ED5%D%<30]86IG6.CV[M#1MDI2%$ <CBN5XGU:=#
M1ESL:+/L<=N4G#[:L*4>O!JV$MDN"WN*7#LYT]>=.OW&.0FX,(4I(SR2.4]/
M+.*Z6+*WPR-.^#2K#9A!T5;(Y.7X<1EE;GFI6 5!7KSG%=SJNEZ5J^E>-%_M
M5_GH?1O9+5=<Z)U*'3::PY.?AZ\\_'T+/#.R$IY0V[N?O7R9\O:_(_3>-*&.
MX]EP# 9WN_,GH/.B7:B.--^\+//A!5D\J/%2@N";=<L/$;42''$X4?6HS817
MFQ[NV<@U43[C9:E/DHQQ4EP1J^!5IL)&:5DJH5'6E+L(-58 *Z5*(F%J8A1'
MTT &P:!6' .*+(AC40"X-3W  4DCZMN#G-'$N MKG_*\RL=J&N86B=,3'WMA
M4RWO*"K:7%D82@?<]?05T>G:=ZJ7O^1YGK/5L?3,&35>2^S\_)?>8OV0:,FZ
MNO$GM!U6V77Y3NY(/TXQQ@>0 P /2NEKM9'2Q6*!Y;V9Z+EZGDEU+6<RD^?\
M^!OD:VM1\8:2".!CTKS<LCRRL^GXL2T\-J'(04\4VJX''E!D'!I#8N%<=:A0
M<B:RD@H4D$'U%23KE=QIV^060GJME&$],"F\N0)X\3#(D.1QB/(<8YSN;*@?
MMQ36;,N8NC++2Z>?VH*?P:3^_DD8NL-50/\ O35-W9QT[J:Z/VW8J^&LUD>T
MV9Y]%Z9G_>Z6'_MC^A,1NV+M/BD=UKR]X3T"Y)6G]#FM,>JZO'WF_P 7^IS]
M3[)=%R<0TD/_ &K]"=A?$;VLPL)<OK$](_#(AMG/Y@ ULQ^T.KC_ !'"S_1K
MT'4WN6SY.OZ$BCXF]:$]Y)L5G6L\G8E:/\S6V'M?JX>ZZ_#^YQ,OT/\ 19S;
MQ2G\]RK\K)&-\3<EW'\1T@VGU,>202?SKI8/;.$?WL?P.-K/H:3_ '&IC'_J
M4G^2'2NW31EZ;"+LXY''3N94+*/S(R,5W</7NCZKB:;^;3_H>5U7T8>V.@_:
M:/(II?\ "U^;1'W"V]EVJTF1&8LZ7E#P*BNEI6?[J<@?M6GZET?7O9%5?FJ7
M]#FKJ?ME[/\ [URW1\I6[_\ TBM3>S'3JE%3%YDLCR2E*7/\:IS>QF@RK]DY
M?C_8Z>E^EKKFCXUCQ_)P=_F5JY=GL]I1-NN;+B!_M62@D?<&N7D]@XKG#FY^
M-_H>DTGTTJ_^\:7<O54E_,@W]+7YIS)8CJV^:98Y_(CBL,_8C7KC'.+^YGI,
M7TP]$FO^\87'[U_1#9R/<8[G=RK6]D#/>-[5I ^XK%G]C.K:>.^237P5+\SI
M:'Z4_9763\&.H49_\7=_/A4$^;:*=B920H=4JRDC[BO/Y])GTC]^%GMM)U#2
M=0CNTZM>J:0W4Z%'A(4H^:1UK-N4OA\#2L3Q2WY)M1?:W:'#"0D$K; _WJBX
MR?9A*2F_V4[^7 )6D>=*B8!7D8)IT, <]*8@<$5%DHBS()Z4F*0Z .WI46O,
MJ^!&7V8F/$65'E(S6C#CWLJSY5@@VSSUV@:T<?E/1HRP1C'%>FTFEV)-GS#K
M?5I9\DHKL9]W[SA+BG.*Z:BD>:4]S++IBV*D*2ZM)ZYK-FG1VNGX7,M^FK0N
M[:SB1-I[MA7?.''"4I]:PY\FW$V=G0Z=YM9&'D:1J:07I#A'"$G@_E7'P+D]
M?JI"&G70H#GSJ.H5,ATV=V3SB@'$J)XK*CIR?)*,+2J*K!\C44N2SR*E>U_S
M" >A-='%V.1J>Y"S9'<1'=QSD'_"M6*&Z1S,V;PL;,.U ^9<UY8.<+[O\J[^
M%;4?+^IY?$R,T/LF@IW-%*2<K%<SJ4N&>R]EL#E%,]!7!7=0<'@D<5YB*N1]
M&EQ&CS5VH2%+O>W^ES/Y5Z[IRK&?*_:?)>IH965*G&\[?6K<G#*-&K@BP6G*
M5*2/,\UFS'6P<%G;;V-9 X%8+Y.K&-0*Q?5$$GWK;C.3J7R46[H[V'-">2$=
MY^8.:Z,&>>SI/$R!FA2H:'5<%O!/_"K_ #.7+]VSWW\"6LOX]V*_P26^D/::
MN;D5ILGD1W1WB/R!W"NGH7[KB?,O:3%MS1F>EN\C+5N4ZGD"NA!5$\U/G*W\
M OAZ@\5,A+L$7/99.PIW<9SBI6558E+F)?0V6O+J/2DV-((],6RA);Y./2BP
MH61-66<*X53L&B/+SBY&2.IHL0XDR@=B0KD4Q) H=W(P: :"H225'!H&P^4(
M&5'%!$*7D.#PJR:!K@;K>4UPK@"@* +Q<%!$"0L*CH2@Y4GG%,/,".ZK@&D#
M'&X*X)IV+@:O )R?6D,8/ *7N'.*D@80R$!&U2\&I6(%M]K:,K&:DGP H%H/
M10J0AN$9D]XGD>M+S 67*=;5DHR!UHL*"J>:D)V[,*ZT=P[#7*TK(Z"D@EV#
M9=_J%2('A+MAB/6O43%U9D#N)3>4>+PJKPFGCOC2.]A=1IE60U'N*$N.Y;6?
M0<?K4Y)P=,G3L;S+&ZPGO X%(/.0K(I*;NB?D,;5<E6"\1[BV\265 ^%7"O4
M&K\N"<X40:XH]%0Y5KUE84W6RK2XZTD=ZA/5)\\UR,F)X%4RBFF4O5UB9?B.
M/B&VH[<.?:C2ZB6*:Y+4RF6O05VT\^J^6J'(D6^9COPR"ONS[)KN99+- 6]=
MBV/-3;7"3*E1B]$6.3U('N/*N)EP*?\ U$E-=B(DV-#S+D^UN]XA0RMO=@C\
MJOT^I>%K'E[C:ODS:7>9=CN#@^3=*"=I!&?VKOQVRC:$3K#CUUAIDQFDI(&3
MD<U5)T^1H:/][-0J'+2.!C)&*BZ3M!93KIHM^7*;9AH6H;LA2.:N6915LFF:
M5I/2ITK;Q.N4GQ[<A"U9(_*L&::S2]P:BT.Y7:!,N2#;8H+30X*QP:4-/X?+
M$R0T_89.HT*B]RXVT%@[B<Y'WI/,H<,JE-+DT2X7NT=GE@#*D)2Z&^H'4_>L
M\8>-/A\&:4996>9M;ZYGZMGO*5)>$=HJ24(4>?2NKCPQ@:X8U%%F[*K$S.94
MRIA00MHD*6><UFU618U[K+51H[UN<7H!ZV.MH4^PM03D_A^]<=9\<<ZDV+;Z
M%;T/:;A ;<=/@*_#@J\JMU6KA)K:1<62EXL$J=.CS$/_ -D<J3ZU%:N#B"]U
M<E[LT^8NS.0$QR1TZ=:Q3K+*[(N<8F?:KLAC0US4IV8SE(-3TN7W]DRZ/OQW
M+L4G1VJMU[_A;:EY,A#)!YY4?\*[.>#PX7E\J.ATS#]9UV+3^<I)&\77O6[>
MD1SU4R,9P/>O(:3)-2EXCX=GZVGI]+)8I2CS!5?X+^A,N8#3,=/F@ CWK-YN
M3.JDXQ<?5V.,HC,I:&=Y\J5.3LG]E!&F2%]Z]RKR'48J?94**IVQZT"1O/ S
M54O0L3\PKCBE$I122"P6T[1R.M!)*AP-H!R:B1W #@]:'RA6&'/ J&UA9Q23
M4H\ W8*4X'--LB'"..*$PL,$G%%D6&I =0 7>,9YH::[B;V]Q*5):CLJ=6>G
M !Z9]_:I8XRE))%6;)L@VO\ %Y_R/-=Y>G=M':6EAE6;#:7=B H9#B@?&KWR
M>![ 5ZA[=#I]R[GRW)CE[3=56FPO]A!TKX^;/0EEL\:UQ$Q([24(; "0D8%>
M7R97FENF?5\6+'IX+%B55W)$H-0;7D33;[A%#!P:E%VN1NO(%*/,T-@&4H"B
M[$%/)S4>5V$J\SCGH.E2WR#9 *0H^=)MSX8X[,?*5G86.AJ.Q>3&W"?VH_S8
M"MV?$K'Y5*-Q"*A#[,?YL#CUS4KD2_D 4I(R%$'TQ366:XH2E)2Y5H#QCHNB
MU+[2"<,<^\1)>Y?XL?84HU%^ZJ%CC##V6[Y\!"@$;>Z'/XBHY%7K-/LYNO0C
M.*GS))K_ (TJ?W]T+LRY<7F-(?01P,.D#_&KL6NSX7>.;7\_S.?J>DZ+6K;E
MQ)+\1R+W>U'"KF]@>1.X5V=-[6]7T?V,V[X-)5_(\SK?HW]FM8D\FG3?SDOR
M8NB]7;\;S;@']::Z>+V^ZBOWJ3_SY' U7T0]"RK]BMGXO\Y"CFI'$,J#\4CC
M_HB /TKT&@]OL<G^WC3^')Y3J?T+24']1R[EZ.H\_.[*])DP[KO3)BL[%?U<
MK'_"O78>J=*ZTENIOX\?S/F^HZ![1^R,V\>/;%><6YO\*9'F*N(UMM<QU"".
M$/#> /OU%<W6^PFAU4I9L;IOGCE?C9VND?2SUCISC#4Q>6*\I)Q?WI*T<BZ2
M6FB)*$R%?W#M_P <5Y75?1WJ]UX*KYGTK2_3=TW-%+/C>'_I3E^= )O\= /S
M$28R!YJ1O'Z@UP<_L9U?!]J"?R=_T/2Z7Z3?9[4\+))?-5_4,G4MB40E5R:;
M)\G,I_Q%<K+T3J&'[>*7X/\ 0]'IO:CHVKKP]3"_C)+^H^CSX#Y_D3H[N?)#
MJ2?\:PY-)GQ_:@_P9TX=0T>3[&:#^4D_ZCLH60,()SZ5G4).^']Z->.<9=F+
M1P1UJ#:NF2R+:K%W'4-HR3GV JQ03CW7XF;%/?/A.OEP9KVLZA<@6-XQRI)6
M=H)&.*ZG3\-.WS\N3B>U&I^JX:3[^G)YR4EV4ZY)6[O*O4^=>E34$K1\CS;I
M2;?F+,,;REL#G/-2D^++L6';W-#TVR([ 7@#PX!]*YV9V>ET"\-<F@]G5O;M
MUGF:CD\OSG"VT2.C:?/\S7+U612?AH]1TC#X,):F7GP&N)7(94YNY)/Z53B6
MV7)?GFIQ; TYEKPJ/-1U/+M$>F/8VF6!XE6P#R%9%P=B;I$K".Z(2/(&H/N7
M0>Z'!4[ZYM6H@>9KHX.4<C62V=RBZHNBD1W,KVX'E74TF/D\KU;4J,&9.I:G
ME*6<DN.E8^PKL)'SW+<\EFW]D< =RRY@<J!Z^E>>ZGD2='U+V6@L>%2:-=OF
MY$3GR237%Q/FCV$Y1\/=9Y>[0Y(=ORTG.2HCI7L-#!QQGR#VEM:JVT+Z?4.X
MW>0XHS*F6:224$3]H +Y3YE6:R97P=?35)EE?=2U'.?.L45<CKS]S&5:X+$C
M<<YK;#@XF5[BIS@WO>8./YR"C]16_'V.-GBU!JBK( =MQRHA>#G SST%:$N;
M.0H[X-'I3X -3,PM6ZDT(Z-KEWBHG,JW<E;!\20/4I5^QK?HI*,Z?F>(]IM-
M+)CWPKCGN>[&6 C:K<5 Y&?+BNO5<'S^+W>\/G5-[ $$YQS4D18U7(8CI_G(
MSD^0S3HK.2]#4=^U0SZ)HH+#/2F5I"4-\ 8Y% "8G(6" @>E%C#,LH6H$TR+
M".--=[STH <H^7;3D_;F@1RIL9E"B-O-,"(EW!#[H".!C'2D-<!6GMBLF@8N
MZ$/I\)&3ZT ).C8  I/ZTZ%0W*UXZ_O2"A9E:4)WJSQ018Y2=R=XZ4TK%0F'
M8ZR4+5C'M10<B3T=&TJ0014EP'<9(CI>4<=1ZT<!R-WV<[@UC*>N:DNP=ADW
M(<2HA1Z>E%CH>MR6T<'.3[4TQ4$?D)5PD\T,*$6U.K!4CG% ^!!:WU.;<8QZ
MTA-6*Y>]J=D=K/-FN;7V1*[*,.+=>FQ&R&'%+R4D#_"OF.BR:GZPU+L>DDHK
ML>5X6K&[@TFWQ'=Q0D@@=< \&O5+"FK9&A]"U!-0VJ+*.U@G "NM0G@CW0B/
MEZ9E*?\ XC;)"W0>5-Y\./\ C3QY-ONR(LL^@]93-&73YJ&I;+#R@B6P3U/3
M/VJO5Z>.IC2$U9OA1'O%M9NC24KCRT;O#T%>=EB>&3B_(I=V3/9)JJS:-NTB
MR:E*!:9?]FIT A)/D:Z?3M0I/]H9\\)25Q[FHZW[--/W*S*EV-A+L5]'>E+8
MX&>GMBMNIP1?OXS!ASY(RJ9YCO\ IVY:*O#HCM$QW"3ST^U<O)A\17YG:Q95
M-40>J(]O^41>V( =5T>;P"4C&:MT6:<7LFRRB-LNH-.RF0M#?= ?4G'(^];Y
MWW"F3\.PV?4([R&WC^\>!666J>-TP<&D24'2-FMBBZY+:2[T2-PP#56353GQ
M%$86*'LT:U-)+DZYI6A1RE+:\#%51U#Q]T3E-I$Q;NR'1,!P&1, 6.-N[G-5
MY.H9'PD*VRV,0[#9(Y8A/,-I .,D9K.LF7)Y%;A;*CJ6S66_.?Z[(:=QT3NX
M-14\^.7"+HQ2*\CL^T^@%,>T,K!.<IQ2EJ]3NHDVJ)&-946MK$>(B,!TPFJI
M2SY>[%O0?8QM4'G4A"ATQ57@Y$P\1"L8V880A]O(&.*4\>2@W6-KK=+3;0$A
MP%?F12AILLT(BX&LHGSX81-*!Y^E:5HYQ1"4+"WK7NGY27+/*[LN+!"5#&,T
MXXI+]JBS&G&"B9KHC1<^/VDM37X:T,##X63X3CH:Z>NU<9:)Q]4>R]AM&]9U
MO$ZM1E?X&[7%3BE6]AMI3G>3$I5CR2/,^U>7Q=F_@?IN<=NR-7<B>9:W+#RA
MPD$C\S5$O0Z<?4*ZL!PO*.5'Z0/*I1[4*_XO,%"RX1CJ3DU)\!=C\GP[1Q5#
M+@J$$'<><T D+  U$;!')Q3*PVP^M*P."2GGK1W ,#GRI-4 (&:!6*)X%!%@
MT =0 7>#QBG5"L(K."E.<T-[F#]Y&3]NFL94.W-Z5T\Z1<+D>Z7L/B0A74^Q
M(KM=,TRW>)/L>+]J-?.&#ZK@?O2?WTR8[(]#L:2T^REZ.CYMU(4\Y@[B?3FL
M?5-6\T_#AV1V.@](ATS1QRU[[[F@)QN5CIQ7-7"IGHFEM4O-AJ"(DY]=61[
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M.G- 4!MSUXI]B2X"J&#BFAV%(.: W 4!83N_>@*.[OWH"@4IP<YH'0;.T9H
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M"D9HL84@YXJ5BH(4\T"L!20.E"+ * .H *LX'WH!B"Q@_>I(B<E((R:&P#;
M/6E8"B4# ZT *IVI\ZCR2 4]CH:DD5TA%Q]9X.,4Z#L1\AY:B0"*L2*Y2;&:
MRKS-2*VVP K'F:!('>YCP@$>XIJ"EW*I9<<)5)M,87%I3J"5M)5Z>$<5;B6'
M&^2&;9G7$S+>TG34>[0927HZ"I0"@O&"".A]Z[VBUDL323X/F_M-T?2ZS'+P
MX^]Z\<_$PV [==+370E]<9Y/ '5"T^NWHH'UZBO3Q6+5XW*7='QQK6](U%1;
M2LU76%^+,2VZ=9(*H\5#T@HX'?+&5YK@PP^^Y'U'J7592TFGTJ\TF_FU96F=
MSJ4E*.,$YK1)UP<O%A48M/O:+GI?P8/0@"L.HY/2],6TNK4@@(Q^'TKF[#TT
M<E4--0WHL1<$D[@  .N:LP8+9FZAJGCCP3.CKC<5Z6F/PEH;(<2WNVE:@3[9
M KTO0?9?%UO4R69U%>OR/&^T/M[K_9;01R=/P;Y2=-M6N]>J[%2U<W+<24W.
M\3).1@(R&P/^SR?UKV4?9'0:*$GC\O\ /0^7=3]ONKZ_)'+K);7+RA:_J9#J
M%ALN"*PE#CIY"'<J/MZ_X5RM;#3:?]V8M-/6:U^^W.R3T%:9[$_#B64K61E*
ME;@/RK##K,]&[Q]_(])IO9)]0_9ZCW8/O\CU3HM$K+:W5I2X&@@%"0 $^@KQ
M?7NO9NHSVZB3_$^X^R/LOH?9["IZ:*?X?HA]JE"DLJ2IQ24]<@D9/Y5QM-&F
ME%'K,^LQ3C*2MNNWH>3M9K+FJ'P#T>"<Y/2O::;='&N#X)UGWM9+W7W+'I4'
M<'2$K)..:HU$U+[2/2=(CAC#EM%Y^>#$<@I'2N=M@WV/22RXX0XF_P 2BW:X
M*D79+2">5=!70Q1J'!YS49EDS5W+E:HVV&-P''-<Z<GO/08H*.'DH.N9&9JV
MVCDC@$5U=.J@>8ZMDV988U_G)7Y3*D7%U:^2MIOJ..15T7P<R4O"SN3*]<6R
M)B5_4$\G)\JO7*.5J)26?=(]W_ )JI-W[/+WHLO_ .LV"Y?,L(4?_A60D* '
MV4#^M;M#.[AZ'A_:7#LFLOJZ_J>HI;F_:A&>!C\ZZB/)L22EY#6U8ZG-294*
MQ4# 5R:0-ATA)<5E">I\JD1&\ML+DALH  ]!0^X(YR,-IQG%%  4I2R0.M"$
MQ!M"5A143^5,07OQ'4$@9!I-T.(HN9'*<N-D''E18Q%,]K&T(5BA,31QD)SP
M.*8ANY.=&0%5.@L"'+<2/$D4)";$))>>>R@4=P09!DI!"@!QZ4!P1LAZ7WG\
MLXQ28Q>"_+62ET@^E"8F$D27>^V<9HL8\;<6TV%'G(\ZFB(9#KN=R,<T[ 24
M^XLXP,T#H!UUYMM22<<4"H8=\Z7.%_K2)!LEG^:I0.>.::$U8;YT?THIV1VF
M0WJ;#U-IV/"FQUF6T0O<G/!\J^=O*MUHVQAL?!0-0=C,#5+[,E;SJ'6DCQ8(
MYJR&LR0X+XY-I/:;['EVJU.6I4YQ^*[G<VH>9Z\U3+*WE4_,4M0RC:I^&5ZW
MARXZ8VI<7SW?7G\ZZRU/%3)8M1:Y,KU!V9:[M*?FI%A<<6WR0R"<U8M1C[&A
M9(L4L%SFH;3 N\!4->/"I])3L]C5$U"?,1.C5>SG5S=KG?PZ8[_JTWHX?I37
M*U."^2N2]"7U'&4Q(=DVIX'=E;:AT"O(UCA/;FLFDIKWC5NP_5<[5NC2S=8X
M1)9<+;@/!P#P:Z^7*N[,.;&H/@S#XH^S)_6EA1=+2R'7X94'$CG<D \?X<U?
MH]1&#I%^#+*/%F+?#]HZYC5D32\^;MC2D$.(4<!!]!3ZHX/#OKE&U24F:?\
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M%.. #E"ED#\Q7.AUW7:I5DR=_@CT&7V1Z3H82G#%[R[6V_S9FKL=IIW8PVE
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MG (&>*E=D9*NP9I]"65$=0,BG2(!X+R'CE7)/-)#=#E;#:W.\R,TPX$)#J$
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MGQT=,E:3[U=NV\C3KDO%D@B'%3)5^%(Y-8LV3Q'P!.:!>E776[#[Y'<,!TH
M]<;:R]1_9:5GNOHZP>-UZ+?DI/\ D;%(6AE(SQE7G7D,5Y=U'Z0U&1)07HD-
MY4XQF4OI7MQQN^]:\,-W!GGJO CO&,W2\?7+4;^(3GS:8SBTN1V5A/S#G]Y7
M]*>1QYFM\=5+1\07O'$U/0<?M1)+/-K'%WQYO]"6CZ$T='CHC?Z)VX-H&$A:
M-R@/<GK6/)U75M\,Z&#V/Z'IX;'AM_&PJNSK0SH)7I2V9_\ D _XT1ZMJUYD
M_P#LAT1_:T]_BA%WLO[/7 4N:8A)_P#D8*#^QJ7^KZOU*9>PW1LG;3_S?ZD5
M+["NS^6I3C5N>8"CG^7+5D?KFKX==SQ52[F'4^P'L]D6U8)0EYO=)_R(2=\.
M.G'O^\KI<8OYH7_B!6J'M!)=T<3)]%O3,K]S4RC]S?\ 5$.OX>;_  G"]8=7
MJ:XXWJ<0 ?\ JDUHC[0Z;+Q*/\O['/S?1AJ])SH]6Y?-./\ ]3$7="=NUG04
MVW4CLI"?]C.*2?L%BKXZSIV7[21@?LO[6Z7_ &N7E=O>7Y-@L._$;;$%3C,^
M4E/ 2M#+P/\ @30UTS+VH<=1[;]-_>-O[HL41VO]J=D(3?-'<IX4HQG$9_[)
M(3]Z@^E:#/\ 9E_/^Y?'V]Z_HW_WW3[U\G&OP1+P?B1M)(;NVG);"MO*FG4G
M]E8-9<GL^W^YE_GXG2P?2A%_OL#C^+_-%DMW;OV?2D)#C\Z.3YNQS@?F,UDE
MT+5QXX.QA^D?IDZ<YM?^DE6NUWL[?)"-1,Y3Y%"L_P"%5/HNL]/R.IB]O?9_
M)]O.U_Z&1-S[;M'1@ZW D.2G$-*=RA)2V%IZ-[R/J5]N*OT_1,N5UF='&ZG]
M)6ATC_[CC>;\8_T8SLG;UI>Z[$WF _!7C'>@=\V/S'/[5;F]G\N-?L)64=/^
MDKIFLE74<+Q?C*_Y(M]KU=H^Y%)MFIXJU*.-BE]V3^2JY>3IFLA^\B>KT/M1
MT37M1TF50?Q?_P"T3K4B0Y@,24.(//AP?W%9I8'BYVNST4? 4=\<D9?*2_*Q
M?O)"?KY_*J:?FBR+W_8:_% H>R2D\'RXHVQ\A9'DQ5N2=_$61C:?%5<J".24
MOX?YBJ"<8&#^=0X%+:W[SI@Y/H/UJ:DD1\.'_('+?FH_I2VY.Z)*&=\.*KYH
M'O$CS_:C]IYD_J[:Y7\SMX5T(H1#PMG((&/.I.5H6Z^ :B!U!"0=/3K0)":_
MJ-3CV)KL%J0P^!Z54 !Z4UW +5@!7!QQ28"!3NI)T2L*IG)S18UR)F-DY%.Q
MT)KA>I_:BR$@IAC'6G;$(?+D>M6$?": 6T0G(!I4-1KD3\0]12HEN09M1!.3
M11%R%PK(SFA#NQ%\9&:"N:LC9#?6K$S+.(S6C=P:L[&/*K5%3U9;DO1EI3P@
MI(4<>6*Z>EG1P.I87X;</0RN?JA=[M L38*64)"7W,_44G&Q'KP/$37K^E=(
M^LR\5GQWVE]L/!T;Z?B[O[7^?,JUKTI+?E+<?DEN.TO "$\GV3Z)(QFK=9F^
MKS\-''Z)T;_5XJ?:*+A:K5!@NYA16V>>2!E1_P"M7$S9G+S/HG3^G8="JI67
MZS*)P#DGCD\UR\[W'K-!-\DG=$+,4[3PGG]JS8Z4K.CJDY0X+796OE='P6L<
MALG]236+.]VH;.SHH[.GPB_1F;:W7E;B/7-=K1KA'BNLOWVBBMCFNE?!YN,>
M32^SB/E[=Z>U</7RX/<>SF.YIFS6%.&2,5PI]SV[5$-JE)4VZ/;_ "K3@[HS
M:K[!YEUNV$WU1X&#7K]+^[/AWM!';JV/K3,[IM*0>M+*K.AH<U0186$N* 5^
M$UC;IG?Q\H>-!04,# J$N622:EP.&P5D@BJWP:(\B0CAITN'SJ;=]B&&&QV5
M[4;.]A#XY[M1/^5:,+IT<OJ$;6XI=V8<4P%YQP:WP9Y[5)[2DN[DJ.[J"0,>
M_%7\4>8S*W3/JWV*ZM<UOV0Z,U*ZH=\]:FV'\'/\UK^6K_Q:[&EE^Q/GW5H-
M:R_\\B\"02D<=%5HCV.=/ECE\A<<%.,^U,@,6U%LY4#CWIH@U;'[:F7QC&.*
M?<C5";\5E*%$* ('K3$AC"8""M61UI=B1()+:1_,Z4GR2.4B(H$I(W>5)*@Y
M$=ZV.%D<\C[4P[@_-[D@4T1:Y$EI97XBKD]:8APR4@8R.GK0.Q"2$D$#'(I)
M!8V+J6&B21D>M671'N,I&'D[LXYI#"HD]WX.N:+ -EG:2Z>O2F AWL1#WM2
M76MM: I!!!Z<T "G&!TH 2\)]#3 3<1XLCK3 2PO."* .[IM.5.^= !=L6C@
M#Y[:'U$N/.9_UIU2-VTGR%>/U>F\2-H[>U,]!3+HZ[9F50+BIO.-RP-W%<7!
MFFLCQ-=BG)CCPS,NTG4NM(20V'(LF,4^%;@VJ%=W!614Q0A'R,X>U%+O+(M\
MQ/=+Z@^1JWP%&6Y%^VALJ#>XJ@\O*D)_LU(&5)^]2<O4."YZ)[0K[!>39Y:W
M'6UCCO!@8K/.*7O1*IP3[$E>)URTW=TZMLJ51Y(Y=:0/ \.M&+(LG#(J*JI&
MN]FO;C8];H3#FO-,3TC8K*L95Z57J-/)KL9)X7BE<1]K2(Z;S$N,PJ4VTI*T
M*'IFLBBL<6D265RE3)[7.H+-='H2V9"7@XG:2%9"5<8K-IHTW9.:;7!8TM)N
M6C$JSE43(5CR%43N.;X$XO@\X=OML1<M%S5.#F*YO'MQQ72Z<]N5EF-M,\?O
MOJ0H9&">2/0UZ5*S>HV7_LYN ,1YJ0-P'1/M6?/"^Q3/AG3IE@DS)#<IM"-P
MP-WG4HII 5&Z:?6P\I4)7?-@9RGFK=S+(Y/)D1L6RX M)2?>G9.U)%W;BPG[
M#%NH>07&2$'GI[?M5;LI?#+'I:Y$R6G">%>&L.HQ[^2(&L[$PW<F+T1@A6[=
M^=&ER[KBQWQ1#ZA5#O(0].><2AH#"4]"!YUJA[MH2>U\#)-RMA6V82@I*1@#
M/(J$H< U7<O=BWWZ((K9V)"0,U@E!QE8%JL7\-TG?HL9U2&S-2F,TXLX25I.
MXC)\R#C\JRZR,L^+91]'^C/4Z?2]6\;4S48N,DF^UM4E^/!=M2W )BJ4E62W
MDG'.*X&FP>%/:_,^W]2RO'%2?9KCX_(C$S;A=+!+CV<MJG.-[8V\93OXP3]N
MOY5IQP6/)<^$<G5YLNITKAIN9^7S+U;8#&GK)&M#;A=3%0EM2B.5KQE2_P R
M37.U$Y9,[<7P>NZ7I\FBT$(737#OCY_BQPXXE9 4A0XK-MG?<WW/&]VY,%"T
M-#:E .[GFI-3_P"0Y9\F?WI.JXX%$EMPY4VG/VI5/_D"SY8=I,<)0@)PE('V
M%1^9/QLTN92;^8);4>CRT_8TMU>0>+#M+$G]P?QYR3^E%XW_  D%C^-_,[Q9
MZN'V/2C;%^1+P5+AJ*^*O=]P8 GJD"A5$?A1ARG8"FBH8W%0/EU%2WR?V702
M>-JLD$T-).FK'/&9UE@O\8_F1T$_X5?#5ZK%]C)_,Y6HZ+TK5?O-/%_<B&D=
MDO9]/42[I6(C/7NP6_\ Q36N'6M7C52E;.1J/8CH&=7X"3^"H9GL0[.VUH4B
MR.D)_ )3A0?N,\U-]?U?J<[%]''0YR]Z%%EMFG+%:88AV^R1&&0,;$L)_<D$
MG[UBS:W4ZAWOK[ST^G]G^E:*"QZ?#%5Q==R)O/9CH?4 4N;IQEI\_P#21R6E
M ^N1@?M5VGZKJ]+QNLY'4/8?I?4VWEBD_P#/@5B;\/>G7A_J%XN$8^BPAWG[
MD5TH>T>3^.-GF=3]%73*_999I_\ I?\ 0A%=@FIH+A-GUNXVWGA.U;?ZD&M*
MZ_IG]O'_ )^)RE]&?4\$MVEU:2^+:_) .=F';'%)^0UD74XP!\\X@_N/\ZFN
MJ=/R_:C17D]E/:K2?NL^[Y2?Z#9JZ=N^D72FX6^5<&$#@J2)">/<>*I>!TW6
M_9DE17AUWMET-MSQ2RI^J<DJ_ <M=N&M&$?Z[I-L*'4=V\C_ !SBE_HNCEVD
M6?\ VC]=T_&7307S4OU',?XA[FV,2M'''JB0?\TU"7L]A?,9$X_2GEN]3IDY
M?#M_-CQKXB[8/%*TY-1GKMD)/['%5OV<CY2-6/Z5=.OM:;\OU)&-\0.DE#+\
M">U]@E7^=4R]GLOE+_/P-V/Z4NG9.)PFOE7ZDE&[<=!R!AV=)9_^215?Y5GE
M[/ZF/*Y-^+Z0>AY.7.2?QJOOHDH_:KV?R%#N]2Q4$_A=)1_B*IETG5+_ ,-G
M4P>VG1\[_P!Q'\26BZRTO.P(VHK<X3T D)S_ (UFR=.U,%;QO\#JPZ_TG*KA
MJ(/[R11<(CG]E,87G^EU)_SK.]-ECWBS5CZAI<G[O)%_>*]Z>.<YJMP:[G0Q
M0EF6Z"M =]SC/[5&B,JA]K@'>34TN"OQ<?JCBYCJ:EM8_$AZAN\)JE.+[$YO
MP_M\ [SY\"I)!#]I]GD,!GI4GQW%*2CPSE(..AJ&]/A,+25C92TI))4!B@<?
M>["+EP:2/K!(]ZDE9-_L_M#%Z](:&01^M36.RF>H21'R]5AI.20![FKXX&S#
MDUT8/ED3)UXRP?&M"?S%71T<GV1BGUG'#NQJ.TFWJX[[K_>JQZ*:[HJ_U_%Y
ML<-:_MK@YD)'N55%Z2?9(NQ=;PY'M4A_'U'!E#+;Z#GS*NM5RT\X=T;(Z[%+
M^(>MS6U>:?;FJ)1HTPSQEV8J'=W3 J-$_$2!4X-N"1FC:R+FGV&SIR,&FDRN
M7(S4GQ9JUO@R2C;(V]1 ]#>)S@ YQUZ5HTT_?29BUN)>!.7HF>;M%V^7/U+<
M+>@8C-R7<K4G.TA9_4U[[%U-Z'3I1?)^<M)[.OKG4LL:]UMW+R[LUV7IF&S:
MDHB-%+C67BOZBX3UR?7V'%>8R:N>HRN<C[#AZ+ATFC4--PX</XV5L*2E0XV\
M9(]ZNJT<UXZ=MEAL<C^8E)/VK'FB=71Y7:189N#%(\B:Q)-2.Y-IXRWOMJCV
M2.QM(V,IX/VK&GNRMG<2\/2QA\#)-8+WO*']XUZ#2*D>!ZL[FRJH0=W'K6MN
MD<2*MFK]G#!">\QY5P.H/D]][.0YLUBT I9(4,9KCR[GK9]R%U+]*CZ?\*TX
M.Z,NJM0/,/:*K9>5K/ W'FO8:3["/B/M))?66#9<K[LJ0:EDH73I/:K+Q V!
MD%0P1ZUSIIV>NT[6WD%Q_P =1H<I^\2,)(/)/6JY&K$K FL[LA(SZXHQOU)Y
M85V(B]0Q_"GL(.=N?WJ['->(DC!JL6[$Z*#?,-QD#&?:NEC/,ZM)1HHLU (6
MM*<9"N:T=T>5S1IL^@'P,ZC1>NPM%K4I(78;B^PKGHES"TG\_%^AKIZ.5PVG
MANL0_:>+7'J>@6G5D' .,UO//][8ZBO8"@ILDTP8JXV7DC<G ]Z!=A/Y@,>$
M$<T=@="#BG'3XD'%2LKH.RV H8ZTI=N!I/S%UJ24[<C/I21(C'RI"]P%,83O
MG7W!N&T 8YI<AP+ND,L^%6XU)71!\L0;?(05.<$^M" 52^2..:=$!N]+<2L9
MR.:/,812%25;U'-2 36A9_E[3CKFD GW?.!S0D 5Q"@.E.@&ZRT$$.(R<T#"
ML.DG8A.$CI2"AUO6!DT4*A-EP>9J:: 6#J$@G<*+0""I6#N!I!0#I4M&[!(H
M :^/^DT#/FQ9Y<&TV5#+CI4\HCGG.?6N%)6CMLVWLPNJ;E;/X<ZLJ6$;AN.<
MUP-3B\+)O7F59>QVNX*YUD4YLW*0HC'VK1I)>\5P=,RJ+%'=N=XV I"B0<^5
M=')+FC1N&[5\=CK4AJ4.\Z#<"134-T1-%JLT]=WLTB,D($^..\0L(P5J]![5
MG4*;3(?99H&E+6YK71J)3L<_,- A0(^DCCFLV3]A*RJ<N3&;W946/7+34TR(
M;X<26WFE[4YSY@=:Z49^+ALT)IH]03]3+MVEH##S/SC+[*1O/*C7!P_MG*_(
MQRQK=:*5-*&'>^MH>1@Y4TX>00<DC-)6F6)>IL'8E?D:EC7&S2'@5K;)0A7&
M<5DU+<>0DMO)0^U2Q]_:KW;GF\$(S@^U7:#)^U1-'A:[Q"[=Y#,1&X)60,\=
M*]=&7!MQM1CR7/1D%=NM<F5+2&\H\)SG-53=LKG[SLJ%SE*?EE;:@1SSG%6I
M$XJD,V[C+'A[]1!XZU*BQP3)_3,NVSRN%<V$[E<)64YQ2DBF>-P=H=SM,3&W
M4LVR1O8=6#W84/UJN^04O4>]S+T^^PRZE25$Y'F*KFK17\31)L5%UT8J:$!:
MT 'GRXKF0EX>7;ZDBIHE68P&U.X.? KPY(KJ).K(L0;T/:K@\NXVN1E2AN+?
M0#%*3H-S:IDUHQW^&W(Q'U; #YUDR6QHT"^:*B:^T]'MTUQ3"PM4IN0GDI61
MP<'J,8&.N*X.7J/U;,W5H^V>SGLQI^K=$6'-[F1NT_O?R*!,[/>UC2K)%HU.
M)\=']FSWZDY]BA>1^AKH8M;I=53:IF//[.>T?192CAR;XKMS?\FV:#V'1+_(
MC7"XZBMCD-3#I:;Z[75=21]JYO4I0X4&>[]ALG4)RG+78Z2X\N6:+(FAV6U'
M)YSN4/L*XM.K/;YY[L])\"JWPI?7IQ^51H;ER'2K/-!.+L78/BR:@RZ+'R?I
M!J!:".>E (/02!'6@2# $\"@D'0E6>E*R$A=MLX.10V10)&#2&@,BD-L#!H
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M9[2!TRV\D_IS32Z9J>6T@6H]LND?9BY5\G^HS:[<^T"S$HO^E#X.%;VW&?\
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M)2<$_P"%9U'8Z1Z..9Y\*E.B.0W;H%XCS]Z49/<NE./$E? S^>*L>YQHYO\
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M<7E$C_V.ULOM9_S_ %(][L?D=7]0AWD9*F"3_C5BU^-\;24?8;/D=?6.?O\
MU(:_]F2;.&%*NG>%[<?[(CI^=70U$9]D<S7>R6;1/W\J?W?W*Z[I78G)EI_)
M-3WG+ET;A^]_(W7X'T_P7MV9;^8252[3,91Q^/:%#_"M&ER)9%P<GJG3I8M.
MZD>_A<7_ )G8H;O7BNO?H>/4'%5)V23$E2%I4> ?6F)HE_FU*:"6U=122MA=
M(8*?==4$I(ZXZ58D5M\T/(["V0I:G4\CGBH$V@RW&D9<W FFF)K@8/.%Q?.-
MH/I3%0*A%4 D)&?.@7(A)8#("FAC-)\#3L*YWB4@ ^5278!)$AQH^(?M3L!!
MUQ;QX/Z4@&DE"VSM"E8]S1Y@-\E'B3U%3%8JB8%#8>M($@"X <@]:"0)<44^
M'% #-3I0Z"HTK&.OF6O(T6*A)Q"'>4$<T#$W8B1P%BF0L;K:4VD[5=*!C8/!
MMS<H^1I=@ 00\HJ)/'-( ^6O_8T[&>!IEBA3F$W2WO=V^,AQM/XO4FO-8\C<
MMC.T5V=;RILN(&%(/6M2E3I@+Z6?=$Y*)+ZE) Z$\57FBG&QFU6MAUB/&>:S
MXAD$5S-)EK(TRC)%%8UY&?DQG$2B2@<@FNFU<K1'&RCVJ7 A69U.\?RW5)S]
MJCEQO)YES5E[T4Z_)WJ"2(K@ 4KR-<C68W!+D@U18F40XZ78["4NHW]>N#1'
M+-*FRI? 71%<F.(:0A;BR<(0D9)/VJEM1=H>V3-1TAV+R2TFZ:NE-6>'M[PI
M</C6/0'[>59IZB^(<L5J/#+DKM+TMHZ*;5H>U(=6@;?F7!C<?7WJCZK+(]V0
MD\B78ITO5%\U),+T^8XXM1P4@X2GV%7PQQAPB#N78@M;ZEM.C+>;AJ&XH91C
MPI!PM5:L.*6:510HXFS*)G;2-0VZ0WIW^4UR-ZSAQ0]16Q:)XW<RY85%\HHR
M9K<F2?GLO/.#)4X<JK5!*'8N7!&?Z+.M7!R0U"><7*(*5XY2GT%6O,DN6-MU
M1:K?HV>NU[VRAIPG'\T<UCEJH)T14TNPO:>SA;;XDS+JRV,_@&3FJ,NN4>RL
M6Y#M?9':WKNBXIO2D*]6V_\ &I+JZ4:VANXHMI[&M-W2/M<U \%D84=G)J$.
MIRE?NE,\RQ]T,Q\,K2FG/X1JE6_DI2ZGSJ_%U&WRB'UN*\C)NT;L_P"TCL]X
MN3'?0%G*93"=J1['VKIX9QSQ<D:L.>&1?,O'9 F9<^S]RYRT(#HN"TM$(/T!
M*0,'S&<C[BO/]6S/QXXT^&?<_HYZ<\?3IZI?Q2VOXI).OE9:TDLOD.)VDUSG
M31[17"7(LJ2D(*2:2CR71RI-;NP7,>XJ1 >"7$OE*"E7((!SC]J+V6NS*N-5
MD2FKCV_0LJ%-*>[Q(!4K_P 45SI24Y5N['H5CR)T^(^0_2XA)"4L/??9Q2\.
M7DTS;'#*O>G!+_JY'K.XI).U/MFJY.4.'$M7AQXBW(<M]!DI/YU!N3[1+5&+
M?+8L.E1Y\R327"#A.WD"@5AFQE0S28T.4@=,5$;[!QQTH(A54 !0!U!%G#K0
M"#4$CJ !Z4 &223R:3 %9('%" )N5ZTP.W*]: .)SUH *2<T$6SLF@D%4HA0
M&:8(!SZ#0B5(0-2"D@BB: 8FXI0\Z:(V-U*)ZFF0;&[CI'&::1%R20U>>&*M
M43+DR41<R>E (SSBKH8[,&74404VX?WNM:XXUZ',S:@AY5P(&035\8(Y^3,,
ME3E*/UU8H49I9;#)?)2?%]ZE0MXUD;5^'8%5.-F?([(]UDY)",9JY,SR3$BP
MYMVI.!YBIVBEXFQ),5WTIVBKPI"J6G@2 <4K&HR%DH#B2E*?$!0F2VMJD0UT
MM$HX=02,BKH31P-?I,C=E?><GQCC!SGUK0FI'G\D)XGR$1>I[:@4\8]54/%&
M01UF3%V8^8U9<FU)(<P1U.ZH/31]#7BZQGASN9,QNT:;'.WG XSNZU1+11?D
M=+'[2Y8*I.R01VH./)VR8PP/,XYJM:%+LC;C]K%'^$1=UE9IC/>/QPA2A@H)
M!-6QP3CV(Y?:'2:E5DA;96+M'L5Q"GH[C?B&%)/7!_PJ^.Y'GM:M-E7N%<%J
M9MK_ 'S,A1P,;<^0.?\ &KN7W.,L4,,MZ(>_SGIQREU1;R$[?SJV$4C+K,LI
MJFS320VQ&<>Z%I *C]JQ))ON>TS16*$9=N$:KV1!7^C$Y\)P%SU('Y('_&N!
MU2ED2;/I'L)DA'2Y)ONW^@;5$DI;45.;3[TM+Y5$MZGJX-./G\3)[[?+; <<
M=ESF$$=$@Y)_*N[CQN2X/G74.I8,,FLL_P *&^G^U^WV=\-1;0_,<)SGO$M_
M\:,O3WJ>[I%&@]MX]->[%C<I>2\OU-7MJM3]K!CB])-JL4?:M*6L[W7/+@\J
M_P![Z:Q3^J]+3V<R]3T.GT_7/;S(LFJQ^%@]$G3_ ![FEVS0FE+/'0J%9TK<
M3C+LG^8O/J<\#\A7&U'5<^5TI\'N^F>Q'2^EI.>%2?J^XC>&T-H6&T)1CC"4
M@#]!5&-N3N3Y.MGQ0Q)K%&E\#%]?QP&W%]"<\BO0Z.3JCYQ[11X;92K,H(=*
M$JSCFNAD['C]*[ER7JTI*F]RJP9>Y[?106SL2JVFFR" #GRK/;HW[MO"'+*T
MD8  _*H.RZ,[$'2<E7G4J*YN^XAL*U D<9J7?AE+@NZ16>T,E%KB.9X2\I ^
MVVM6D^TT</KT%'%%HSQ:5=WN!ZUT?,\I.*\)MEN^'6\*L?;OI&:1E*YBHZO<
M.-J3C]2*LQ-QG%KU.)U+'&6.::XI_D?1IB/,*RY@@9XKO-\GS:"I-/U)1ONP
MVDS5[,?BIKXD7?D*?/12-D.1DCC(I\>1'GS$X[JHI)>.[SYIIM TF<Q/?EOE
ME((2KC[5%$FVA9U"VDY6HD9\Z=4+<V&04N)P#CS-,0W6MME61R?6DQ]SOFR\
MGQ'(%%V% +=4H]>*?(<":RHCKQ1R  0D<A-,0VD.(YW@$T (@M;<[!4@H0[M
M"G,A- PRDHX&WI28 @H0@C%-"8T?V*Y*110<B"R$-E5*AV-X\["B-QH0"REK
M6,A1IB$5N2!U)(I<@-5;W7 E2>O-(8ON0RWM0@9/%,!#<O\ I-(1XCNEI?LC
M[<N'XH3Z?YA]":\SQ)TNYV(NR&GQ1'S*;.YA?3SYJV$K>U]T6$&I/</_ #J<
M@$$X'%7/F-"-NT;,%XTZTE*O$WYYY'2N)FCX.;@A-7R.M6V9^;:TEN+W@(QD
M>==".:HV9XNF4BU:4T_;X4AF_$.+D+4M+20,ISY53FU,I*H%V\FX#;@0F#;6
MRF/P$[1@^U8YMU<Q.1IVENR2YW%IN?=4"W1=NY;KIP5#SP/6L&75*+J/(;5$
MN(U-H+0#'RFF(#5SN"1A3[R00@^9!-5QQY,W,^$1W^I3+OJW4&J))-QN3CJ"
M<I:23W:/RK7#%''V1%\C)U,.$I'\4EAEO/ /XOM5MWV(K&V6YZ59K+9$7!ES
M<7-NQ2N<#-4QBYRH5N+H\\]M6E;CK6^(E_Q@K:)&U.<I&!Z>5=?2ZB&GCM:Y
M-6+)2W$'ISLZ3:D;9#ZI*T]1C!%2RZU9G412R<V6J)I5"EA;%N"E>J@":PRG
M+U%XA9(6DKG)*2A!XX&T50YRON)Y"?A=F5WE@#Y5U?\ =)-4//'<1NBP6[L=
MNZU )M0!\RM6!5<]1%2%N+;"['I;325//1$>J=W(JO=?*1'<2;/9K#BD;[DR
M@GGPG-362<OLHKG*/\1(LZ/@1U!1N061YBG>9>17<&%O6G=,W>(NR7Y:),9Y
ME>4K2%8_6M.GU67 I7YM"E^]AM])/\#)+W:=-: 3#MEA2ERR=R6E@ !*5E95
MM/HK/2M'6.EY)XXZA=_['Z+^CGJ:6DQZ2?"ESS\5_E,B+A8FYP[^U.AY.-W=
MGJ*\_CRN/$CZ/J-(I^]C=_ @WX3J 4.L%*AYFM+E[K:.3/$TZDABQ%2B?'<=
M4Z!X@.[7M4#Y$&O3>S?3L/4NI+!G?#3_ )(\7[<]5U'0>C9=7IDVU/&N._,J
M+7:;-,<D )NTX(SX>]2VO\LX'%>SU'L-TS-%N$Z=_$^;:;Z5>LZ+(_&BW'LK
MHN\#0^HY[J!'N=N*?1Q"DJ/YIXKS>L]@<45^PRW^)['IOTP*7.ITOW[E^A,)
M[+-:H7AFUIE[N?Y#Z5?EX@*\_E]CNH8/LJU_GQ/::7Z7>AYDHYY;'Z4_Z(-)
M[->T."WW[^C;BEOU"0L?^#7(S](UFG=27^?B>GTGMAT'7+='45]TOT(:1 N,
M J3/A/Q5'KWS2D;3]R*YTL<XO;)<H]#@U>FSQ4\,U*+[.^X0#@>))]\U!Q9I
MW1?87:1@9XJEC0?(]:!2[ Y-(@=U]Z Y.Q0'(8=*"2 .<\4$6"*"2%3C'E41
MTQ*I"!^U '<F@ *  .<\4"8'- CJ!'4$PJCP33!"2UDI(IT3H3S[TP$W3@ Y
MIHBV-EK/4FG16V-W7"#UJ216Y$?)D%*CS^]6QC9FR9*(F7<"#@$_K6B,#G9L
MY!7&X$\!T5JA XV;4-^9 2)2RI6TDGRYK5&*.?DRNR.6ZM:B5$[O3-6J)DE-
M@I"P-Q/[TVA)L.R\=Q'-*@W +?(7C-22X*Y3Y#)>1T5U-)\$DTQ5*&Z-S#<D
MZ'#;2?\ 8TMQ=!)^0H83;H(3C)]J6ZB7@IB9MH:&=N?M3WD? V<L,W%0^H,]
MV1GUI[VB+T\<O%"CFCXL@82E.?/BH_6G AEZ%CRKL1LWLU;=P4,!0SG(JV&M
MLYV;V63^RB'?[-EY46XR@,XJ]:Q=CDYO9C(I>ZAD[V=S$#PM* \JL6K3,S]E
M\[YH;K[.YJ_P*J?UI%4O9C.AE*[/I8RON3NZ[O.I+4I\&/)T'41\B'E:0N#!
M.Q*@3U5N.:M66)S\G3L^/[1#2;5=6%'>M2ATZFK%)/L8YX9Q^T1$I#Z0M#@P
M-IQCUR*L3X,.:+1K5ZCN)L"'6B4N(80I) SSCIBN;!QW>\?0>HJ:TR<%?"%]
M-)[7V=(1&K#&G,P9!6\A92@%63C=N/VJ.5Z'?^T[G.Z='VCE@K0Q:B_2OU*U
M=M.]K<]1;O5P?0V3XBY)"L_DFKXY-)%_L_\ /Y&;)TWVARK_ +Q:^_\ N(VW
MLU96\E5TN#KZU*RIM"=H)_WCS2R:FE[A/2>R[G/=J9W\/[FW=GG9[IZ*6GVK
M- ;P1G<P'%'\S7"UO4,C36-GU3V;]GNE:6.Z>#<_5TZ_%&Q,H:;>1L;">@R/
M3TK@R63)%O(SZ#IXSC!['PNR[4/'EH#:L<$U"$*(/39I^])E8NZ24K.:TX9W
M*C%J&MCB8[VB##+O->CT78^;^T79E#LB$[RX?(5TLAXO2?:+O:Y38PGVK!E1
M[?1S2B/W'-XW@GFJ:+Y2YL?0_HYJ#1HQ/@(\G<H<F@E)6"D!/!I@^Q6NT9CO
M=.[V_P ,M./;BK](_?.+U^-X+7J9S-268R,CR%=-/D\ADXPB_9Q<1;^T_3$[
MRCW>(L__ "P#_.K(/WD<;7K=CG\G^1]15OR$2%M-9PE1_P :[R=GS9QIL;W)
M+CS24K)!\Q4F5 0VDH0E,1(+@ "N/.A"9+J;VQ05CGU-2\B'F-VY'RZ\H2-U
M ^X=Z>\ZV4+0,&AL*$VE$YY/2D-A%!LK"G2< T!\A5U]E+>YH# '/'G0*ABF
MZC?LVU./8&A&5//..*&%!!)6Z!A2A^=( 2[YGFA(!N\_NRE/'VJ5CH31)*3C
MFD%!)+[H;W-DYH&,C->2G^83STYH$PZ9/>(VYIV1$7"L I*CC[TAB2&,G(/7
MF@&$=:FM<[CQSUH#@17<):4D.=/.BQT$#ZR.\2HY^](8JI]S8*+%07YAWU-*
MPH\=V6]1G8RK'=P"U(!2@GH#Y5Y[+@3]^/<ZKCM[$1,B*M4LVIT[HQ.UM7EC
M[U"G5^8XRL2N5MC1XP;2G^T&4FKL>137(['^A[A<=,3R'=QAR4^(XX%9]5&.
M56NZ$W9:+KKR3(0J!;%!MOIS^+[>M84G7OE3BNX^T7V>7[5KXDHB]VSU5)<2
M1M^Q-59,\8<!:B:M"AZ)[/1A@&[7(C\7B;2?7/WK*X3S_!#W-D-J#5U\O_AD
M2#W*?^B0=J!]AYU;#%&'8A2(IF \\0IP[ ?-7%2<E$5!)4R';6BU' +JCC>#
MQ46W(<5ZD/>KNJ^-H1)8!=0-J5*_RIPC1/=M"LP[[<6&XR%276T#;M3D"I\(
MBY(FK=V>SUH2XZPVP@_B6KFDY\6F0W66"#H"T-*'SET*SYI0<U5XN6?85LLE
MKT[I>&K^5 >?/]Y6*@WD8M[+9%G1K</]2LT-GT*E"H>%*7<DI!IFM6F6R'[I
M!C$#D)(XJ/@33J*)MV9YJ+MZT+I]Y3-PU>"H=4-$9S6O%H,V3[2!0<NR*)<_
MB_T'$*T1&Y<PCC."/WK1'I$KMD_ F^:&=N^+R'<@LPM).N;. 2L9K9'ITH+A
ME>31J;]\!WXLKWW+GR&BV5+2HC^8L[OVH6C2?+(K18D)V+XCNT"_2VU.:+AH
MCNO(96LKY1S]7/.*KU.FQ*%R?;DV:+0QS:B&**O<TOQ=,E[PX\AQ\/-)=3.4
M>^95]."?_;W\ZW>SO7\%_4-9^[;O_/P/N/M3[+ZO3Z;'U#HT?VN+''']T.WD
M^+9#NR95O;0Y;9+@#7 :D^%0']USH?SK=U+V2JY:62FN_'/Y'+Z1](6H=+6P
M:KCWUM?XA#K5U(0B8E1.>/F$'G[*&0?UKR.;I632M^)%IGO-/[4:76Q2C-4_
M+R_$>0+BS='7&E1FMJ0#X4\UCDIZ-J<94V=C3/2]6B\4H)I>A-0HR&%A;(DH
M(YRVXK]P>,5OTW7^L:5_L\U+Y_V,.H]B_9[J"<984Y?^:TONI]RV6O5]YMN/
MEQ&="<<.M$G\SQ73Q^VG4L?[^6X\[F^B+HNHG<*A_P!//YEYT]VT7:(L&Y6>
M,MI)Y^5<*"?R5GFM,?;IOAXTOG9@UOT+:2-?5]3-\?\ &)I5C^(G2:2D2(5W
M@'\2CM<3_P"#S6K'[5].S?[B'X?_ ">7U?T0]=Q_['+%_P#4Z_*)IFF^VCLI
MO3*6Y>JH!<(\2;@T48/ON3BK)]8Z;G51^SY?Y9R/^POM1TUW+&W)=W&VG\G7
M):6]*=C6J %S+-I:>'!G<VXT,@^?@(K)+3],U7*:_'^Y./5/:KH_$7EC_P"E
M_P!4(K^&#L/O"ML*RNQEGA/RL\CG]ZQRZ-HI>:^YG4A](7M/#]YED_\ J27]
M!I)^"_LY4?Y=SOL<GHD/-K_<IK++H&FF_<DU]QOA])_5\2O)"$OFW9#S_@HT
MLH$0=:71D^0=CMN?X8-4R]G(/ME?X(VX?I:UB^W@7W-E8N?P67MG!M&LXSV2
M1AR(M!_,BL\_9R45>/(G\^#JZ?Z7876IT\Z^"LK5T^#WM;AI+T)FUW%"?]E+
MV*^VU0%8I]$U*\D_D>ATWTG=)S?;<X?.*_4I]R[ ^UZU!3DGL_NA0@9*F6P\
MG]4$UCR],U&)TXL[VE]M^CZI>[F3_P"II/\ "RKR],:CMRBW/T]<XRAU2Y$6
MG'ZBLLL&>'DSJX^L=/U',<L/_<OU(]R,MKEUAQ'^^@C_ !JMX\WFC5#5QG^[
MFG\F)A,?R(S]ZK<,IKC]:FN'P=L'7PC\Z=R1%Q4>]O[CEA24[@H?E2O=Q(-T
M)^ZX/[U2"HW=3G]*>V*![8]DOQ#+ &-V>>E%+^$AORR_=+\!)6W=M\\9Q4XM
MH?O_ ,8 Z=:E=D6O0'(]: "$@#DU$L$*D !/% Q-PC'6@3$'5# P1316W0T>
M<3_4*LBB&ZB/E/;<X(JQ(RY<E$5*>W9)J^*.7EG;LA9CCJR0!QFKXHYF5MLB
MGV'7%$X./M6E22,<HMC7Y$\J4D_\:LWE;Q>HFN"<X2V=Q\B*:F0\'T$'(+B3
MXV\?:I[T1>)Q[B#C:DC&T_I4D[,N2(R<7MX/%6QC9DG+:(JE%&"*L4"EYJ%$
MW0)YQDU'PBOZW3%H]V4%E7I2>(NAKJ'\>_[25*6CGJ-N*A+ :H:]+S'7\<;=
M&P#K4/!<>2[Z^I*@S4ILKW)4G)\LU"46..:++):7D*V]Y63,FCL:*<7W+*R&
M%I&16&4FCO8X0F**@LK/TYJ/B,LEI8-\'&U1U#!%269HB]+'L(+M<<<=VCCW
MJQ9F4ST<?0C)%HBK/05?',T8<NBBR!N.F([J#AM(.:U8]51QM1TE9%V*Y.T8
MAS( YZ\BMD-59Q-1[/Q:N78J=UT*V"H) ;6L%.Y2<C!K7#4[N#S6MZ'L]^*[
M%?G:]2W%_A-SM$EF2SEKA6 L8P#C\A5BP<-HY>7K]X/JN:'*?!Z8ML$VS2MK
MMQ2<1X;2<>8RD$_N:\KF=9G\S[MTAXO].PQ@J>U?E91M3G#G P*Z&G=\GF=:
MG%4_B5NW-..RT8S]5:\LJ1R<,'*9M6BH6R/G\Z\WJWR?2>D0J);& ?F,X\ZQ
MK[)V9CB0?Y9I(J97KD 6UYYK1C[F'4UM,>[0@V6G>.H(%>CT78^=>T=;&9U:
M5%HIW+!(./M74DCPNEEMDRVVQ&]Q(K'D/6Z1IHL;<=LH3D>59F=J$%2'3(\!
M&*J9ICV!4D9H(A2D$]137<1"ZVC=]I.<@9X"3^A%6Z9_M#G]3C>@D9A<TYCD
M^W[5USP\H?LE\V5^#*-KND2?R/EI#;P_ZJP?\JG9QLG\1]:+-*,EEE\CA]M#
MH/J%)"O\Z[4':C\CYQJ8[<L_FQ[=DQ_ IQ/W-7HS,&W2HXSW394!Y@9J4NQ"
M"Y!E!#I!=4$<_B.*(!,2,4'QMG=CGCFIT0L$( 3A1 ^])\( NU;/\Q(R#Q42
M0FX@2QX\#;ZTTA#5:&V<H2M)SSP:8#1Y"-^Y:@,^IJ2$('8DG:,_;FF'<YW_
M "H&)*'A.?2DQA$;1^(5$D E*E.>%)/V% '/MDMD$4V!'F/CE61]Z0F)[6TK
MR%#]:!"KA+C81O 'WH CU%QIWP'(!\J0QSWRW4Y((IB&+W>*6!G-)DA9M* G
M"B*!#E*&-@R0/SIB.[MC^H?K0(\*.14I;5&<=*'FSE*B#U%</[/*.PI*0:$B
M=>&U6Z4E14GZ7CP!^M59)*'O/S')*/*)+NVK>P+=)4'UH'"ST'YUAE)[O=(V
M.K%IN_ZGEIC6N*ZL9VJ./"D>N>E0RYH8EWY%\36-/:!TMH7;<-43OXG,'*8[
M8!"#Z5DEDR:B-)40;;'E[UO<+KB'!0F)#'"6$#:=OD#BE#3QQKGN+A$6&71_
M/?<W?<U9N2X1%L15)&[^6V5^PJ#L:^(H;9=[F 4A24?TJ.!5.[GDGY6!_H@&
MUCOWDI)YPDDD^U261$7+T).WVF%&64L0"5\94[C'Y9I[K[,KN^Y)S[NFPLI7
M/D,QTGH$)Z_^NHQB\CJ).,%+L57M%[2TZ%L+%_-K=EHE?V9<5@$>N*U:;2^-
M+EEBQ-O:8W</BHU)(=*+=:&&4CZ><UUO]-QQ7<M^K.K;'<WMJ[0K@PR4W-3!
M=2" V@#RJ,=-C7!5X21!7C6VLC$R[J.8@+&W._UJ^.#'9-00GH67==02'XDF
M?*D/C(!4^K'2HY<48<HEM5D:OLGO-UNTA<F[Q8Q4O@+42H#\ZMCE2A:+DU%4
MD3UN^&VZ3YC;(U#'6UP58QDU3DURQDE*3[(NS'8Y8-$H6^\YO6@97XO2LKUL
M\W$459(3?+*\YK#1T*0MB##2MY*L'CBAX,\^69VN0I[28UMN,0J95W'?)"VV
M4#@*(&3]NM4YNFRS8Y;I<G9Z'J8]/U^'/D7"DG]R:LV%3L69!0^T]WZL!Q)'
MF".*\K*$\4JJFC]:1U,>J0>ITW[B22;_ )W7?T\B,N%H:EM+5'<4RI758&<_
MD>#^==CI_7M9I9>Y,\UU[V8T6O@_K&)7ZQJ)5;A;)T=02IY#[8_J)3D?;H/R
MKV.#VKPYH[-7A4F_/@^6:SZ/=9BEXN@SN,5SM=MOX+E$GH%F4AZ:9"%I!"0
M59!Y\NM</VIU.@UL8O2QI_\ Q\#TWL!H.I]+RS6NG_G/Q9>F2,[<XP*\=)4^
M.U'UG!C2AODN6QXUN!X3FJY)OSHU+'!]G0[;4?) %0^S]KDL6!?\G^+'+17U
MVBHN,&3V5V;%$)7N)*F_^SS34G'B+#=!^ZXR_P#=Q^ X0L-?V:G,^QIK/D7F
M#T^&?>*^]6/(EWN<4A4>?/:VG/@E+0?_  55):G(NS*,G3\63[<<;_\ \:++
M;NUGM(M*4IMNM[VPA/1 F+5_B35L=?GAS&3OYLY>?V9Z9J>,N"'S44OZ%C@?
M$MVS0"DM:R=<Q_MV&W"?U%:8=9UD>\E^!Q\WT?\ 0\G/A5\G1:[?\97:G&"4
M3HEEG!/FY&*5?D0>*T8^NZB/VZ?W')U/T9]+RK]FYQ_]1:K7\;+O";[H4N'^
MN+-QC_JJ%;8>T=?:B<'4?11*5^!J4O\ J3?]2TV[XT.S]8!FZ<O["B<':M!&
M/R(K1_VAQ2_AX./D^BKJ6/ME4W\$TOYLL4#XKNQBY';)NLR(1PE$J"I6T?=.
M<UHCU;I\N9NO\^1S\GL#[2X.,..U\U^I88':=V"Z@P6]5:>D*5R4R&D(P?3Q
MIJ_ZWH\ZI;?P_L<C)T#V@Z=)RR1R)_"3K^3%I/9UV(:SRXC26EYW'U1UMI(]
MQL(H6ET^7A)$'UWK>B[Y<JKUE(@+C\+/8G<D*4U9)<16.#&E'C]<C]:IR]"T
M[^RFOO.AI/I$ZW@[Y5+YQ?ZE0NOP4:+D@N6;5=VB.$^%"T(=P//CBL4N@XGP
MI4>BQ?2QU6*VZC%&4?AP_P 2L3?@BOB<JM&NX"CG&V5'6@X_(XK+D]G_ $FF
M=G3?2Q@:_:Z5_P#NC^A79_P:=IL3):NEEEE7TA#ZA_B*I_T'-#[*LZ"^EGIR
M:CL>/Y\W^!6KG\+O;7:6E/HTF)*1SF,^APD?;.:S3Z5J5QL?\CLZ7Z0.BZI7
MDSI?-/\ 0IMR[,.T.U;E7'1-[8 ZE<)0'[9%9LFAU&-^]!H[&#VEZ1J.,&HB
M_P ?T*[)AR81*9D5^.4G!#K2D8/YBL[Q37D=G#FAJ/W4D_O0Q6ZVKZ59J3Q3
M7=&AJNX4]/\ +SJOSH@FFZ$U* XZ'WXJ6UDFZ&[C@SM"P3Z Y-.BK=;X&CSR
M>@53BK%*+2L8R',\@U=M<>YBR9$,'7%$=*?",623D1\@*6,@]:MBT9IPDU8W
M3$6OK5RD97C?F#\BD?4,4*8U@")@)4K@<#IQ4W)T-:9OF@5V]2U94!QZ"HJ=
M ].WW&KUL]LXJ:R%&3!2(:= 6"=J36K'-'-S89/LB EP72> ?>M<9I'-RX'Y
MH9/0'5C S5BR(P9,$_)#141Y!( .15BDF89Z;*O(($NHW]>:D9Y0R1!#B\X)
MH(>+-!Q)<2Z=JL\5';?<?CR0NU<76RE>?/%)P3+\>L<>[)>+J1QA7B!/I@U7
M+3IG0Q=44?,G8&LLX*DJQZYK)DT:?8Z^#K7JRPP=61W" 5']:QSTC7D=W3]7
MQS7+)EN],E(PL?G666!KR.E#7*2X81RY(5R"#4EB:'+5I]AJY-1GCFK5C*)9
MO/R&C\]M.=^$CUJ<<3?8S9=5&O=(2YZBC1T*0 "3TK3CT\[[''U'55"TT9UJ
MW5I0TI36Y1Z;4GGGTKIXL%*SQ_5.O2<MF.)..62+=!:BM@/%]322'$#<,D>=
M9YZB<8R^!T(],TVLABEX=RDUZ>ILUP2VRRXA). > ?3  _PKSJD\D[9]6UOA
MX88X88THI+^1FNI 7"23CFNQ@I=CQ.OY=#/3\0+EH./Q5+42I<%&BQ;IHVC3
M$?NH941@5Y[4R4GP?0^GPV0Y)MA0W"LZX1NER&D*&P\T(I9 7$^%6*TXS#J>
M8F/=H *FUC'F:]%HNQ\\]H4]C,RAE291&/Q5UWV/G^)U,N-L<*%[\<8%8\B/
M5Z*=)%C8?60!CFLDNYWL>2T2+)5LR?.J6;8.D"K:5#!\Z1%T$(P2::$EZ#+4
MC>^Q36L<%A1_2IZ=U.V9=:M^BG%&53F=]M"P,C8FNQ%VSQ3BEA294;B,%7EA
M.:L//Y5M<FSZC]EM]<N^@=,74C?\W:(KN[_\6!_B#79PMN*/GNO@X9I7YEP>
M+4[ZW,)-:4<YNA:"MJ&KNDMY3TSZU*7P(Q[VQS<H0D(*F^3C-./ INR$81-;
M<#25'!/--6(5<943_,>PKTH:!,"3&F*924N$)"LYS4=K':&+TM(3W7?X7]CS
M0AC5I+Z25*R1G.: $IQW[%%6*FNQ$Y3W=H!2,G%, $L/.^+O#SS10":D%/U/
M'[4,852FTC)5T]JB2L*F:ELY2ORH%:$)$XG"@<C- Q'YOODD9H$QNL+2OI0(
M*MXHX)Z4 @@4!XE' /- QZA3:V<#]:!$2_'>#V6E[B*BR2#;5[/YA(53 ;/O
M/8*$JZ4@&O>SO55(?!YAFZ=9D%F9=I7=R!SW2?,^]>5R:V2]V"LZ3X[#UBRW
M*YD,6Z I9QC8@<K%9I3_ (FR&[U+A9NR6! 0BYZO?[IL#=\ENR3]ZJ>9RXB)
MR]"5?U(W":,'3#3=OCCCP)R33CA4O>GW%;7<APR_*65E)6I?)6I7/Z5:Y*/
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MYUV,'8\7K%[PMI:,5R4G'&ZHZJ=(NZ?"YHV&T-AN!C'6O/Y'[Q[[3QJ!(M(
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M585YT#$GXF_Z5G%)H+#LE:6]OG18#53KK4@$I)YI>8PZY#JN5-X3]J8 CN2
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M+8^H]":5$7?=D)<9CWS2''D)4I!ZGSI-;UQY%^.*:9IG9F\]<+W#>4VE33:
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MZACT.*FDY"\58U5";Q0 .\*B1TXR/SJ<;P\=[,[EXG,:5?<1\E<=8PIAD_=
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M(\TFK0?$UOL\U RA;K4EPH"AR,\'W-<S/!W:$^2>T7J^3IS4*5)EA<*2XHN
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M[M/ZC;=2D\=W<7&E8]0DG K0NIZ//^\C11+V!]I>F>]HLZE_T2?]CEWGXBK
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M2ELY!YXI;Q;&6:T6_/B5N'I54I%T(4BXVR,RTD;VTGBL\F:H(GVVWGTI;0D
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MB_V>5-^EU_.Q5GLF[6(WABWU(0.A$YQ'[*%2_P!1TC[HFO87VGA]B7_^Q?\
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M>]X@><&A#L<.]RL80VD?84"!1W3;658)H!=R/3);+JBM(./6HV64%+;3KF5
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M\HW='5IFLW!*&HH;5U4?SS6+S.V^QT"T(2E"E(PI2?(>50<B<8)#J3:$)25
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M: "AKN9.,Y%+S)'3-K64Y'/%#&B-*0%@^7G2)!)3Z$M82<'-)@D),+*T>?%
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M2H.): ,J;)]\4[%0'?)>/#9Q2[AV"[DMDC(^U "8?:4YA+9S18Z8*PDJ 6<
M]:2#D<-EO9L21]ZDA":LE6 *3)1.VJ]*1*D?/R+;3,=2W'5WW>':0#G@U@W;
M59T&Z-[[.='0K/!;4IM+9*05BN+J<SG.D53=E>[4>T12'5:=L3R"YRAS:<82
M:OTVE4?>9*$3-;!(<M]U<W# 4 -W]7O6^78L:.U'<@]<$Q-V>1Y>U$.P$=>
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MBB7AY<^U*B]2%4N ]>*C)$MP?O!QS40W!@JFB28)4"*9*PH7DX!H(V%[P^=
M;CBOC(IBW!0YCK11"3X"*43S3HI;"%?D3P::0K$2M0X\J=$&(NN)W8!\JG%%
M<GR-7G0<@&KDBJ3L0*RDY'2G14VTP$KRH#-%"3%DN  I)Y-*B:F*)>"0.>M&
MTDLE!P\D<'@>5+:2\0 R1ZYQ2<1/("E[D@\"EM!9 P4#]*N:8=PI1YE5 4$(
M/IS4D)H;N[CD;:FC-/D;K:43C'AZFK$RC8QNZ@)XQFI-E<HI"!923DHJ292X
M((\>[3EHI ]ZFN2/$4-UNH0"2M.[SQ4]EE$IQ1'OS0"2'.M34#%DU*7%C!V6
M<?55J@<_)J>1DY,QR%#\^*N4#'FU-=A@],4ZHI2KGT'2IJ*1S,FHG)T%9C2)
M*OY25*)./ISS2E)1'BTT\[X1=M.Z#ER@'7D$9QU%8=1K(X^QZCIWL]DR<M&D
MV?1\2$$*<:!(\\5Q<^N<NQ]"T'0H88IM%C:@,I 2TUT]!6'Q'/EG86*.+W4/
MF+7N&YP8^YI-DTD!,N-OMC1(* M/!R:>/'DR.B.;4XL,+;,_U/K]AK^6TO*C
MP,'/-=?!H/-GD>H=<AC3469O=+_,N"R5OGKTKK8\"@>)U?5LFH?+(QQY9&XK
MR?2M&VD<>>5R?(S=4HJ&!UIIT9I)R8C+1W3(6H8R10G837AQY(B=(42HCI5D
M4<_+,@9\E6T@=:NBCGY)<D*LE2CZDU.S.TFQ:VRFV)*2XO&Y0'[TI+<04U&X
MFK=C%TFL:I<M$=S^9<&2E(SR5I5@C]*R:J/NV/I>5PS-+S/8.E;)&M40)6A*
MG2D*5DC@GWK@YIVSU6.%$XZ^&ML=IL[R<[@/+TS5'Q-2=K:1[\<J4Y)DN]TA
M&,8.2H^F*:8./FR'N+,IY274-)9;(VCNR"I/L!Z'SS5D&EP4S39%)M96LQFP
MVT!R\4@X_(GDFI[B&WR.<91#CNM1$*< /C)R=OOSR3^U-.V)QI<$<["6DMM*
M8PR]@K#A&XY\ZNC(RRBT.V6.^>"FL H!YSC<1Y5(BT-+D%*9<^93WBMJ6SL&
MW>H=2/7 XYZU)%<OB-&$()2$Q'VB4%07OSW&.BL>_E4B!'W7O&(SK30#JI"0
MA *BA&,Y4M6.2KV%-<L.R9B/:%,DF:L#+NPY VA *1P$@>WK6_$N#DZB7/)G
MS9W!2'F"\0LX*SA)]QYY_P"%::,,G:+EV:/H:ORH7\Q@R_KWK!"\#@G'G2G]
MDRZB-P-SL4&7*(2VDK'3.:ABCN9R)>Z:5:-,MQ4!Q?"N*Z^'#7)EGD+%$B(:
MQD8 K=M,[F)SGDMG<T>!15!=BD<=^C<?2I$6*)9^H)% K"I8PL;Q@&@8\=B%
MEL%"?>AH<0S#6$!9'B(YJ-#8B4*6_N6./6@GY#=]MU*AN6>O-(83PA6:788!
M#RE'"?#CK0 BT'$.DJ&!Y\T "\6UGP<^M-@*!QE#6"BCL D%H5RCCVI -92%
M;MR5?>AC01E82O)-1)@OJ<6?",TP#-.+0/&,4(BSER%#E)H8) ?-J]:"5'C'
MLDT-*?D_/K<)2">1TQZ5QM7E48TC?D=FC=H6M6M-0!:[>EM;SJ=BU)5]/'G6
M3287-N4BJ,6V88LP)SRYI+J9N[*E$\$_>NHN%1>N![$<_F)+JD[QQP?*HM6@
M?(VOCK3<ME\@JRL)RD9IQ5 'O$5EQ^,7G.B1QFG%T+L2]M0A 4R5 $I.">G2
MJ))W8RMR(ZQ/6V<83R3Y5=:$D2KUTE7!A#4M#8[H81L.<CWJ+0Z)73%C,I:5
MS$X:3XOO562:2H4N#6+0^AII,=EL):;'"@/V-8)OFV5/DV7LXT'%D1/]*M4O
M?*P&#N2TL86X,9R,UAS9-SV0[E=TZ$NT7M<B/07D1T(BVJ$,):"L=]CIFIZ;
M3\U+E@XO=:/+>H>T\7W4)N"4E09)#8W8V_EYUV<>'8B^,4ER5_6VM95X@=P_
M';1D8R*NC&NQ)1Y,V8:>DR$QVTJ6I2@G"1FK>:Y+VJ5ED1ID0(YES'6VU#H%
M'G)XI7?"*7-RX0-CT]==62G;5;XA>D@[<'HGWR.*IR9H:=7-DE[KLMC5BTWV
M7R +S<47*[ 8,-!"D-'KR:RO+/5\8TTA3;F1B=7ZENMR^890I#"2=K#8\+8]
MCYU;'28X*WW(NJHT70_:/J#2UXBW,-*#(4$K/J#UK+JM/'48W!!B;@[-/[2Y
M-MNT)K45N=WH= <43ZXY_?->4T<'I]0\)JRR\2.XQZY7RPSLMRFU)4#@DC&3
M7JX1E5&!)ID2[;[6\"Y'E[>">35JO[+[%B7O++Z&YZ!UY<;'%CN1&A(CK925
M,*7C<<#Z?Z>*CT_KFHZ3EE%?9_D?9<WL;H?:/I.FRP>V<XIIORM=_@;KH[M<
MT+?&&X=X6U  ,4#.O]X^%<>Y *2K_=.",?>O30]H-)U&.W4QK\OS/$:OV(ZO
MT.?B:-;TO/G^B+M([&>R_5J!)CV=,,R!GO[;)*D*/IMY3[XK!J>BZ'6<XYTO
MA1NT?MKUSI*V9X_"G:(65\),)Q*Q9^T M[>0S)AC"<] 5)/'Z5PM5[,USC:9
MZK0_26I?[J'X?_)2[Q\+_:A:]RHC=NNB2<H$>2$N*'KM5BN5DZ%JL/V8VCT^
MG]O.BZKASV/T=+^I1;OV?:ZL.Y-XTA=HVSJI492D_P#:&0?UK#/298=T>AP]
M4T6HCNQY8O[T5]:'&22\TXCU"D$$52X-.F:X3C-)P=_+D2+J<;DJ*AZ@'BC9
M\2;BU]KCYAPL[3N(0#_5Q4./)D=[[06[Y<A"L)(&X'/I4E%^A9%/NU7YAD+3
MGJ*3M>1--^@<.[>@S]JC3EY$KKNZ%$NE7)!I.#0]R?FA49(ZTE\1[D=SZBGP
M&]'9.,@]* WH#)]:.!;T$)5N !&*E0.7)RE8^JG1&35"2G,*(\J>UE+8DIT^
M522HBY[1!QQ7K4TB#R#=3N5 ^QJ215*5L;J7D<U8BO>EW$%.GUJ5(H>0+WP'
M(I[2+R!DR,^9S1M$IB@=/G2H:F'#BE#@CCI2HEN88*)&#UJ+)<L50=QX\A2)
MJV*HSFHLLC8JCQY/I2)KD,623QCFA,FXV$5!5DY\ZEO5%3PL*J"=O44ED0O
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M!%9WFLZ^/0QBNPZ;MK:2,IX%5O)9HC@4?(=-1FT#H*KDVRY10;^4G@8J(?(
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M.%<%$F.W&%MI\)))Z5<0&PMXD'_6$;OSI423'[$**RP4A) ]*!C9#*$Y0G%
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MV-=Y(59?QSG@5&4249T/D+SM\0.ZJ6:89.4.FE^H_.JVC7"5CE!RGKR*K9?
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M;WUS4TTC",9Q4[)I\$WH?3CTC4S2"SO;;\1SZU#+*D0G+@]9Z+LS,.(E]X!
M">/<US6W,PY9<C36-VC0(3LV=(2TEQ);3GR\JECQCQ*V>;=2V1\252TK,E#N
M?YF?I2:WQ:2HVKL1%IMN)94$\] :;Y!VT7@-!F"EM*MBE#"U>U09!,I^O'$=
MPAMCQ)XW*%3@BR)3(A<*\(05J\@*MD^"<BU:2M$Y-P,N4T4MG&<^?4_Y55-V
MB#:[(V;3ROFNRV>RUT5+)_/-<_-QGB0DQ&S6YF3-9CN/*2K<#M \J>:7%E>Z
MC2I7:-9-/-LV6#9&I/R1 6XY^''/GUKG?4IY/?L7<I>LNUZ^:Z;5;=&ZT%M;
M02E<=M6SGH1Q4]+T_%I'NE&V6I5W,DE62^PI"G+U<)+SXY+W>%05[<UUHSA+
M['!-,@;E>(44J0RVGOQU5U5GV/E5T58<MFF:%-E=T!*ODUI#LA2T@E?/.?2H
M2XX19M U(4L3HZH2.[2$(6DHX(QSUJFG.+14^#;M)WE^9:8ETW;FR@)7D<'%
M>(U\'#(X?%$XL9ZQOECL\F.Z[AIN80AQ!2"A7WS1IL6349;POL7QDDN1'M&9
M@3NS7-O"?EFTC8VD\ "IZ">3ZW^U^T1RTU9YLBWQNQK<6$;EN**@,9(KV;@Y
M49H=QRQ,CVQM$L/AZ5(6$%)Y(W'T_.ISQM(MQ4VCWEV>QBW"BA9"B66_#TP=
MH'E7E-0_?D?2-+2P8U\OR-=LC2TJ#B&$J7@C&\T\/8GD[BNI;.QJ*R3;%>D-
M_)3V'([J=V? I/)^XZCW%6M[7:'BGLX?F?.S56GKAHS5-RTO=D[9-N?4WNQ@
M+3^!0]BG!KHQ]Z-F_2YY0>V1'!_P@@@D^="1N>6#5R[C9UX#"3MX]JDHLP9<
MZ78.EU*CDFG3(+-?D&(:Q]5%$WE?DD1UPLEGN*5&5"96HCZR,*'YCFIJ;B8)
MZ+3ZA>^J*Y,T2[!69FE;B\PO\2"O8#Z;2.OYU<LRE[LCC9>ERP2WZ67(I&US
MJC3:D,:GM;KK?TAT'*C[\<&H3P8\GV39IO:#J/3VHYE:_P ^!<K3VEZ:E[ ;
MPEA2L#NWD[2#[GRK)/12CS1ZK1^U/3LW[SW9?>7*'>F9*-S3C:TXRE31W!7Y
MYK)DT[1Z+3=0TNI_=R)-B:A:4Y\.>H(Q69XZ.I')&-).QZEUI1\)JMQ-49IC
ME#Z< >E5-%RRBFX==U+:3W([O$^M%$MXDIWQ=::B1W\@F2VD<U/8/Q*[A#*0
M?.GL*Y9:$7)S8X%/85/.A%<WPX&>:FH<%4L_D<RDNJ)/0TGP."W/DE(\)H[<
M-]>O-42D;L6!,DXT%@C(:3GUJES9MA@C78DF8;03](J+D:88D.6V&D<@<U%M
MLTJ*0Z90T<DIJ+1))"BBRG&U-*O4.#@XVGH**"T<7T9SQFB@W ?,M>8H"T#\
MPSZT<AP%+S!'!HICL3+J,\+Q3HBV@4OH1RIS(^U%-AN!_B+">JN12V,-\0JK
MJT>2M-2\,KEE5]Q!Z_16AE3H%-8FRIZF,>[(^5JV*T@J#R!Z<U9'3-LIR=2T
M\%R^2#G]H\",/[=)^U:H:)LYN;KFEQ^95[IVJQ1E+9R0/(UHAT_U.3F]J,&)
M<%2NO:BXL*[MW8D^I%:\>@2Y/.ZKVP3;J5%.N7:&VXI07<R2?PI.:V8]';['
MF-=[6=VY65V9K&2\HK8;2H#\3J_\!6V&BV]SS>I]JIS_ '<2%EZ@N4DD"8 D
M]0VG&*OA@@CBZGJ^JS]Y?R(\K4ZO<X7'"2$J7RHI!Z?<^@J;2ARC YSR.I/D
MWKL2[ W9KS>I]:0@&$$+B1'?^E)Z*<]..@KD:[7Q@JB^3T/2NDSRO?-<'K&S
MZ?+'=L1X;;90VG8 ,>''"<>6!Q7 N<WN;/834(14(+E%SC1P$EJ8@H6I 2G<
MGS/VJ=J/!F5^8[EL?+VUZ.HJ[Q3R6MP/AV=<5%KDFV1JXT5AJ6J623M"62%!
M.S/G4:]"+? C'?@B0XN'/9>1$4A2MBMZBK'GD?X4]OJ0W<\!IMPM\9I%Z6KY
MAQW">YV[3GGR\Q[BFXOL3C)=R/=E*-O4VF&P5R'$NK=4WR@$X[H']\TJY)65
M^\79YJ+)BK2AEIISA0/7'&3YG\ZLBO,HG+NB@W"Y3TI*&'VULNH4DK&$%*4_
M2D?;_"KDD9Y2?D46\WU^0 P(SBGD\]XI63@=..N#U^U:801ER9&4N7J%2B_\
MPZ^EP_R6$MJ)/''IR/\ CFM*A1CED;&T.%)G*4ZJ4H=TD)0A*BI*<_2,_BYS
MP.E2M(JY9)-Z>D%XM+G.OJ;.X!HX2I8'51Z 9I.7!)1=BSC$-#;,-]TJ9C-!
MQPH RIU7"4 CJK_B:$Q-(07&DN-.JF=RP%K 0E1\"%JZX/7<!GGVIV+LG8TO
M8#K#<:(5(C12IEEQ9P5*VY6\?7.//RQ5T%1BR7)\%#G2PVMIE!2.Z;*CCGD^
M>?7WK2EP5-5P1;06XVD14!3KY*6D'U]:FG17)C:XQKC!N41B0EQAY&"LMD[2
MH'J#67+FWK@QSRV:K9)5PE.15275.(2!R>E8W!UR4W;)/6^HGXT!34%2B\M(
M QSS3QXZY'148L/O&8]P<22[P5Y/5576%$E>YL*TPG+FZD!U2,('O48\NAHH
MV@+R^K4$B0\HE3A*N12U$:B$H^9H5UEM)CNNJ'7FL"=HJ3HSV\/2Y\<-PD%Q
M2U'@>E68&HOD$[9;.S>Q*M2BY<7@ >>>*MRY-W8;1<+SVG1+8DVZWG=M&/#R
M:AX:OD**%<M:WJ8\I_OGDI\@:TXX+L*BOR-:SU/D=^L!/6G+&+DM>F[F],2A
M\K)R,U!*@:).?J J7W!<Q@XQ2;HDD3VF+AXP-W6HJ=< T76$M;KX+8XK3!V5
M,-<HSLZ4&TIR*T(1*Q; ]!2EY'A4#U]JTX^Q!\ELB%/RR4EP ^9K5&7!5M$7
M1&;7O+@)^]0<N0H9W!)>CJ"#G-0E(G%#6V2%1$D.'@&HK+M+-MDM&O$>4H[7
M ,<4UJ+97+&+!_#Q5NSZ&KG.U975.AC?I>6MU8LCY+8D9;)+#Z"A8RKUJ["_
M=$T/(#"&I*E#C/6KL2Y(3[$BXXZ$G8K K6BD0;6^YSO-,4A;:JI$#RNS!-W@
M#'5..:YC='7*Z];C%GY)Z<'WJ2::$V;;V6:#8<C,W%QLEQX@A21SBL.?(W+:
MBG+.D; ];$-]Q#3N0V!DD]>.M2C!1XHQ1>Y-L\Y]N.LXUUU$WIB+XXS/U^A(
M'G^=:80->"#2ME0L]_9C-BV3SOCO#*5K.<"I-4:5W'=KBQ9$]3\<@-CHD=*A
M;%+@=7=#[S2X[*B%.#: #YT)KS%1$?Z%W*XL]U)4H-G!4?3%2WT%T.XVG=+V
M!)<4ZEQ:1XE*Y.?2ARL3;?<15J."\5QX92 0=A3[4MK8TC1NSO8]HZ5"P""[
MNQY9P*PZKB:9&;Y)?3\1$$2;Q*P4,H(03ZU7*6YT0?)1=57DN1GI#I/>R,[5
M>8'I6S'V))(SV$J'9'3*>EJ[Q7.<\U>[GPRR[#.=I5T#RHSR&I,<\*'4X\\>
M]0^JKNBQ0;5B/\*LFHPJ7"FMPY*N RKJHU--P^T1N473+A"8?T_HI5B=9W27
MGD$8^DIYYJK=<K+'*UP*JGJF?+J4XHK:VM+!/KQ37"*9&R=E$U,G3\NSK<)7
M&6=H/E7D>M0>.2R^1+&/+W:86HM/2&;DPEU<3*T9&5 CS%8-#F>DS*<72D7]
MRF1]<6Z9V9S;<U">2\P5M[%=00HUU9Z64=?XZ?#_ +"E)51YXN$Q;+Q<=W!6
M3PH\I]J]5%53*HQW=B4TO:[A(N<65(8"@X\VD%7.,J'-+/+W&RW#']HHKL?1
M?L_8"PDN+PV$!)/IM %>.G<INSZ)ITEBB:W9@D-A;S24$#" !]8]:FN.Q-\]
MQ>;&26UN%" WM(45#@<<?OBK%R53GLYJSRQ\6O9\)K#7:79FWG+A$9;C7:..
MG=#A+H^WG[5LTV3^%DIY9?O$>8V)H5E*7$8'3[>7_OK:XHG'5-KN=WBG%8.%
M>XI4'BREY@J>4T3D<4Z3$\TX=V.8RVGAG=FHM$X9XS[@A10LXZ^5-$)KD(5*
MR>,9ZT4B#G2I"K+K,A)9D!"QYAP9!_6ERNQ;#-":V9%9$S]!::N"BXAER,I?
MU!E6U/Z>=61S3B9<O1]+J'?V?D1:^SZ^VY._3M^4HCG:HJ:*?;(.#4_%A+[:
M,SZ+K<#W::38LQJ'M2L& ]$^;;1R<HWC]1UI2PZ?)SV+8]2Z[H5M:;7QM_U'
M\/MON,4YO5@=2-P&YOP8_(]:HET^$OLLZ&G]M]5IG^WQI_Y\RV0.V?2\D#YA
M\PS_ /' *<_XUFGTN2Y3._I_;G0ZAKQE*'X46B!K*R7)L*C71AX'&.[4 1]\
MXXK)+1Y(>1Z/3]=Z?F2\//'Y-\DL9REI"FRVM/FI)'_&JO"?H=*.KPY%Q)OY
M"2K@E)P2D_XTUB?H$LN*K3D(JN*%'%3\%E+U$5V;8DN>D< @9IK'1!ZB,OM-
MH3^8).0:>TAXL5VL<QCWIP<'[U7/C@NQM3Y:9)1P$X^FJ9<FW'#TLD8[ZT8&
MT>U4N"9LQYE$?-2U('TU!XT:XZF/873<CCT%1\+XEJSP7F&3=$IY*L?>EX;\
MB3U<*XY#B\)'1[]Z7ALC]=2\F<+TA/5S/OFFL;']=@_)A';TGZDN) ]Z:QL/
MKV-=Q+^/M@8[Y&:/!;*WJX/WK8BO4"/]NW5BP,JEU+#'NV).:E8 _MTTUII%
M<NHI>:&ZM6QD]9(_6K%I&9WU9+NQD]KF(A6WOTDU9'1,S3Z]CAW:(]_M#C()
M =S_ +IJSZDV99>U.)=FB-D]I338)0M1^ZNE6+0G/S^U\8]FB%E]JH&0AX$^
M_-7QT'P.1J/;%=[*]<NU1]05_KB$>Q5BM,- O0XV?VWFNQ7)?:4^[E)FJ5SY
M))'_ *ZTQT*7D<34>U\LK9"S-<OR!AEIQ1]S5\=&CBYO:/)-W9$/ZAN4C.2E
MHD8\)YK1'317<YN7K.?)V;&3LA]X?SGUK_WCFKU",>QS<F?-E^V^ @)Z5(I7
M'8*H 8(ZBEP3W,.E+DM?=I0XZ\<):2CDJ)/0)\ZADK'R2A>5[4>D>P_X>T)$
M;4VKHW>3O[6/%5]#0\E*!_%[=!7#UNO5[(L]-TSI3262:/3MMMT=AMM 90 L
M8QMQG\J\_).<K9ZZ$E&.V/!-QH+K2FT)40X#X5#J .?\*GN:137)*M3UQGRS
M+>46U^%2CSQ_NU#N6\+N.7$Q4Y@OS'C =(<0^A65.*_I]JM1FF_3L1JY\9@H
M8;4TKO1W>YP94D$_6KV%/;;!M;0)#B[2[(M=E97-0O#B5%(P7<<JS_3CI34;
MY95==AM<H\2,P2;>\XZB/N[X+ &2>=I/4#SQS49)V33X9!.2HL1I+SUM6N,V
M@.; X5I"^?$<\X^]3BB$I.K,]O[RC)7*2XV25;G"T,)QY#'VJ])%+;JV4J\7
MB+O<QA\N9PA7(;;!.XCW)P!^=71@9IY$9_>[K%:C!QMY2GIIP@MG!0W^(@^W
M3\SZ5IC%HQY,@WLMG:NTUN&XE3(;1WCBRHI"$=0,^61BI2X17%*3+P[:;7;H
MK26%1HKI=W+P^I3C:0.-B>F/4D^=4J5E^U)%<N%ODW1XPK<[-5$4?]8+9+00
M/7'GD<DG/ZU8J\RJ2?D-5RXUO;;1:[<\['CN*>=D3%;0I70*2A/)'H3ZY\ZE
M1"QI"5-FN$SXPV)\8R<A:UD$C'3@9/'I4E78JDR!U;J%B6E4:*V U@C</,$8
M(_05HQ0;,TYUV*5E3SZ68[2W$NGNTI2<+6O'TI/I6K;M7)FE/BR_M:#3I2+"
MNEU<;-P?2"AHN^&,DC.W'FNL&LRRJH.C'.;ON)7U$,QFICR4K!( W#.*RXI.
MN2MT62S(91;4NH.!MX JY3W*F*BE:WN-PBW>(62ONU'!YJ:)VD3MJ?[YH=\P
MG"4A0&.IJ22(ODI^LI4^[.KA-M8#7TU%<,5$'HI#_P#'=K@VJ3PH>I]:KUDJ
M@2D:9J".ER IE)VJV\D5@BU:*:(2R1HUG@*E7!>%#E!/I4U%Y)-(FE2&[NKN
M_BR%,YRDX&#4_"<'R .FK4F<I4^5]3O3-:75DZ7<D;JQ CM*;5M'AZXJR%D6
M9S(8#S[B&OI*NM2;(&CZ,;;98;CK R1Q5>1TAB-^M+S4LO-*.,YK)OL"6L<T
MQ-A63D=:@I7(.YJVB;C"?;*W\*.//RKIX:7<JDBQPVV'Y^]L) !\JM4E9!DU
M,?94@-# K7&<:(T)K>CLQR KG%.4TNP;2'8<^<=5M<4,'UJC<V^XZHE^[2F*
M0.3CK5]I+D<2I7.^MQ"II0R:R9)T6I#&QW%3TP;5G!5TS693Y%(T.*V%QTG'
M..M=+%D6Q69VN2&U1)$6,,CRK/EDFRR*(73Y5()6E1'G4\+=@TD6:*T0H+)^
M];X*BJ0_4$EK">35Z94T$;!03X.M6(JD'WG^C]J9&CQYH35T4RV8,O(6X=GL
M<US<L:1V)1:+]=-/-S+W$@PT;A*4G<0,\=:SJ>U.R%TCTGI/3K%JM\>.$X[E
ML \8\JJQ0\1[F<W-DYH@NT+5$+3=KE3'U?0@XYJ^/O2LEBBVZ/*2[!#U8_*O
M4-T]ZI:G!XN>:O<MJ.C]E$,TTHN*B.I!6T=I'VH;M6$2U1%1;/ 3Z_O4 D,'
MM;08KJ^Z22XD>'*?.AQ)4)LZLGN)7N^EP>1IJ/ J*/<%R3,<[UU1"SN W9JQ
M4B2[#K3D=3UW:CX/C!&*)S2CP$NQZ@T)8!$M+4=*<]X-W ]L5R,LO$9EG('6
MS*F66K/'\.[*W"..*6./-B@[1Y\UYJ%*;FNWL\I9!1UZ&NGBAP:(1LH:UNK5
MXE$_<UHM&A)(/'94MU"4G;E0&_\ I]Z5L&Z+M9KKH_3]G5\Y&^=N142A:1T-
M536\@DY\D7_IS>E2^^[T!L'"6B,@)^]1>*D/8632T^)=PZ6\B0%;E@^?IBJ\
MONHJFJ-+T'<Y-IO\="0H(?4&U@^IKC]2PQU&!Q8H,UJ.E,'4#D5P?RY"><^I
MKQ^5.4$EWB7IF2Z]LXTY<YT2*/#.)*0!ZBO1Z#5?6XQON1DN3*+;V>.J?6N>
MX5I424@^E>EWI5$LCR:-H'3SLK4]L@,E)5\PVXOS&$C.*S:B=8VV:M'!3S)(
M]I:)6(DE*=H(1R:\VE=L]Y]E)(U2$ME304X1A0II#8RE]RHK"5D#'F>#5T8V
MBOB^3)^UW76G](:<EOWR2@?.1WV(S11O[]S8?#@=>O/M6C2:>4YF36Z^&G@>
M#)MCND!B'-6RRTF<RF0EI"N&L_A/F.F1GG!%=O)A<*LXFGU_BV+1''D.)#Z"
M/7CBL\HG8PY[)Q$<36B4$ #I5-TSKPPK4PI$1-BRK4Y\V%>$=?2K(M2.9J,4
M]-(=Q9;5Q83)AJ&\]<U%JBV&7Q 4)2XM24DY_%0#7(S?WL.Y2#FI)&:=Q=G-
MW=3*PI?><?T'_&AX['#621,1KFT[@E2O%Y*(JMPHZ6#J+?#)5J2A7054X-G7
MPZA2XO@,ZS;YG\N8RPO/];8-1N<35*&":]^"9$3^S_24TJ<1#2PYG)6V.[R?
M7-6QU&2/F<W-T#0YKDX;;]'9 RNR)AP[K;>G&5>>]&<_]G%7+7I<21S,GLA"
M7.GS?BO[C=OLTU1;LF!>FRX?I6)#B-I_W>E3^M8Y=T8Y^S74,3O%+_\ 2_N%
M-M[5;>YA%U6\ ,>&2"?_  J>_!D5%;T?6]/S?'_4F +EVKQ4Y5W[_P#=+3:Q
M^H(-'AX6+ZUUK"N_Y'#6/:(T0F3:&CGI_(6#_P"":3T^)]F-=9ZO'[:O[A1/
M:;JF.<2=/*(3P5)0XG_*E]5QOLR^'M3U+#WC_+^P^C=M<V)@/6$!(\U+(/Z$
M5&6@A+FS=C]M]5']YAM_.OZ$HQV^1=H#MC/3\#B,_O53Z='U-^/V_P B[Z?_
M /2_L/D?$#9 UE=JFC'EX?\ C5#Z0WS9>OI"@N^/_/P.5\0>G0E)-MF?;<G_
M (T?Z1+U)_\ VB8TOW?^?@+)[=K(^T7&[?,!\@%IS^FZI+HTGYF>?TC0\H?Y
M^ B[VXVYP;&[?,W=?&I./\:G'H^QW)E*^D=7[F*_OK^@S=[;=W MSR<?3XT\
M_I5JZ5'U*I_2/E?_ ('_ .E_8:K[:9KF0+:]N'"?'U%272HKS,>3Z0-1DY6*
MO_4_T&[G:Y?U#_X#K(_WU'_ 5)=+AZF2?MUJGVQ_S?Z#1SM0U(OEJSIP>FY;
MF?\ "I+IT%Q94_;;J$N(\+T$#VC:G4<B&RD^ASQ^]36@QE$O:S7S[M?R_01?
MU]JQP'8AE/W=J2T4#)/VCUK_ (R-<UGJ%SE^4VD__$QS^56K1P1CR=?U<E6X
M8/ZFO:U9^=DD>F!4UI\:\C,^JZN?>7\QL;W=ED]Y->2#TW ?Y5)88+LBF>NU
M$OM2&SLB4Z=STQ;GI@D8J2A%>13+/.?\3$]Z@>%J_6I5'T*W/*NS"J&Y1*AG
M[\T<!ND^[ Y' SBF*XAL8Z U,6Z(4Y/E^U1I#>23!"5'RHX0ZDSL'.,<F@01
MT$H)0HYZD#S1YG_#]:A/M9."MT>G>P3L27!$;6VHV4B8IOO(41Q/AB@CZSZJ
M(KS^NU_/AH]5TKI+59I'I&QVWN$I4E*B5J*$I(YP/0>E<5P<I;F>JC));461
M,$-H2C()6.?44W[J*YK9R=&0^AU]DJ#H"0$]^>..?#BDUYE:D.DRX)DQW[<A
M2XY&PET95  F0-F_=1X[L_?IDTDGYECEQP-KD7(D@LO6RX*<<Y*65C _K('V
MJVC/%WW'K,>2A++TU2)$5_EU2TCO$X'TC'7PXZ>=2BN2$I<T,8+?<OM?RU.-
MN IBI"RDI&[HK\O(U.B"9$:C66)283J%)>#BNYCDG8ZOUP>#@9\QY4FB42M.
MWI]J.]!@L@0W"E9*F>\VX)W @G &<5!HFO1&;:DOGRL>2V,O*==*5 D)'7*M
MF./0=*T8U9ES2VJC++W*<N$]U;* UT*MF=B<G:/\<"M\(\'*R2MB=IL8DS$F
M7&<*XZ<H0%)*4M)_K4/(D<#KFASH6VR^6#3L9;&^1(D-O/'*T@;2?-(..H\\
M>U43ROL:<>+BV'F08WS2E*2Z^EDA&" D#)QP,9(I)LDXH@KK,DO(E##X89PR
M@)&&D\X*L=20D'KFK(E63L1[#:4,25./!;*D85N1MWYX; /H.35BY,TN$535
M6L$0X'\.M#N'GP"^\>2T@^21_O<J\\5IQ8]W<R9,M=C/$K=DDLO+*E=%$=%$
M=2/:MB6Q&5O=W+1H"\Z<LUT"KB1(FE13&W)\$=/XO^L?6J9Y=_!ER2ITB^:S
M3;9*$2X;Y>X"@E1SMR*S9X<%#9%*D6G^"-Q+IC(-50FE'L,=6R0QW89:_L .
M/M2CD4G0T5::C^+WU6W/=H.!FK45R?)/.R46Q3$-6/YG&?RJ18NQ77FVEWEQ
MLDY(S1\220:S65N-<G9B!Q6+6<I T2<ZY,MMO/.'Z/7SK/M[%:,]U!J)V[+"
M6<@-G:!ZX]JZ&'%M]X?<G-/Z=4]!3WIQO()SQ4,\K'7!:FU0K/&//T#/6HQ;
M;*TRDZEORIZU?+C 2<9K=!<#?(ULMO><'?N=.M4SX9%(F[/=>XNZ&LX">*KR
M<Q"^2]37&W6>]5@^&L:1(JY?4N1AOIFHPXD-=BW:;F+CEM!)Y/K6_=2X(M6;
M#9V=EM,DGRSDU%9'96T5N9?E(F'Q']:OCD? 4.)5Y4_&2E)P2/6K7.PH>V *
M#9=6K'W-.$N2,EP+7.\EI!0#QSGFHY,K0HHHEZN+"E%04,\YR:Q9,K9<NP;2
M\Y+DP8Z9JJ,^2+-5A3D181=4><5KAE\BNK92=17PW&:(XZ#BIMMEJC18K"TU
M"@]Z<9/K5N&=,JD.$WA#JBVGC%="&2V5-$A%7WHW%7[UIBRF0X[T)( -71*I
M(/N3ZU,5GS[@+<C367TH.6UA7Y5C9W9=CU=V6N19S<>Z/84H('=GT-<K.^:,
M.;L;-%O1[DH60"1R<]:,,MD:,+A;/._;I?&[U-18TS5)0A04YW9]SQ5^%;>3
M?ACM*GIJX6>UO_)QHJD;TD%:AU-6R5NR_)[R(#43[:+P^8#7\Q#9*U)'2I$4
MJ1&RILR2T' K( _6@9'VR.;H^\'TD*'4'J*DQL4F-OVIQ*2TI+:N 2, T*FP
M[@HA15!,I:-ZE'"0/6B]O 66S1FDE_QAJX J*U#@?TU3FFMM$7*D>J>S^P&'
M;5SYJLI:1N3GUQ6+%&K.=EE;I&;]K5V;L%FD7Q:@M;I4EI.>3]JMQ0]ZR_#&
MV>3YTER;,>EO$%;RBM1'J:Z,8\'12I"%)C0LAUUMI:$))"@030*DWR-=I\ZD
M66' 2>"0*BT1)_2UP%JN;4EC^8H=4IY-0R0W(IR)M&O1+V+GW4Z!X'VU)4?7
MK7+RXMD6O4KBN3<9>Z6U;[GG>5[2M0Z=*\/J4X99(U1JB*[98+$+3[.J&XR'
M'&$8W5JZ+E<\TH,-J2L\RWG7TRZO-L-L+A!(P745[R&%;2,I<<&L?#65W_7Z
M"ZY_)9ANR5N8.$GA"<_?FL/4:CAHZG0L._6;V>T].VYI!*FL%7J>BJ\ZY4DC
MV^-5DF_4O+?=_+)!4UP/(\TU-@XIE9U7J*VZ>M,R]W5Y+<*$VIQUP] .G'N>
M@'K6G%!YY*)1E<<$'D?D>&.TW7]P[0K](NEU=2Q;;<D.1H@/@:;)P$^ZE#DG
MU->KT^#P((\!K-:];E:90H?^D-UC3I,V(]W3R1)MK93@OH!VC9ZX2!5DEXJ*
ML>3P9H0AW=)>5%?42H*(Q@\>Q]*QSQ[3M8=5?)+L3!$6#O'<JYXZ)K'.#?)Z
M#1]06-IEDC?*72,&WTM%"AQD]:RR3BSUF!X.HQJ:*Y=K3,L;IFQ& 8RAXT!/
MTCUK3#+#(J/.=2Z=J.G9?)Q$3("FD2&4[D?BQSBK-J,;R<;XM"R^[F,=^V1D
M<$U#LZ)R2R1LKET"HX*@=V3BKXG)RNF-X<\A24;PD=2?>I.)''FVLL4:ZNHQ
MSGBJ90.GBUFU$M'NC:FN5 X5Q[U5*%'3PZZT/UST[0LG JK:=#ZYL28DNZI"
MLAU)&/6GL*_]1Y[A1?&TCQ.8_.GX(Y=5^(C(O<=2L]Z3]SQ36)KDS3ZDI>8Q
M<OK:23D 59X9EGU)Q[#![57<DX!Y\_2I+%9GEU><>S&;VMY24924N)!Y&1G]
MZDL)GEU;(_,:.:^65<P6G$\<%*5&IK%\2O\ U254X)_&ANYK=ITG_N1&SZ&,
M#BI>'\2F6MW=\:_ 9NZF8>_^PT<G_P#!T_\ &IJ/Q,\M0O\ \M?@+0;O#6@N
M/VB-G.0I49/_ !J2A?F9IZE?\%^ LY?6$\(@PDCU$<9J2QOU,\M1#_@AFY?>
M3W<5C/\ \AV_O4U!^I1+/'^&*0U5?)I4=D1@?G4MA4\X15ZG*ZA"/9!ZU)07
MF1>>7\(DJZW%2LI? 'WHV(2SR.$V>L;C)&3[TMH_%ON(*<DDDES))S4J*W-,
M+CVJ0@<'TH [:?0T =M.<X-*B(!2H]$FE0'!L?C.#[TT!Q&!@<BF &U7H:D@
M.VJ]*9(.JH$4< H>5%)]R=M<Q!47&/I)0LCZMFXI!ZD5&1)*,.?,VKX>.Q=W
M5-P:U5J&V@VF+M,%IP8^86"<.*_NCKCSKC]0URQ144=_I73)9I>++L>O[/8P
MAHN.;LLC*B1T3Y''D*\Y?B2L]ENV1V%E;A(9CHGI64]WA06/JVGH4U-QLBYJ
M'!(2HKL-*93["MCP&YT="D]3_P"WO342F>1MG.BU2V$MP7&TR$)RVE/X_P#=
M]4^HZYJ5M=R,5YD ZG DVP-LOW%#F0APEH+2/$H=<;>F0>>:*\RW=Q7F+MR)
MK5O6VR^N"\ZL)<=5@1EI_H2H_P#&I)%4GP*"X*@MFTW$!2'!F),0-R6#Y\CI
MFG\44USR15X*(+"95KG27)#*DE;C;^WO"?,)QXABE?J6)>A6[[>$)C.2G'X\
MGN,O%MT=VM;GDE(SS[GRJ"CN98Y4C,;YKB#'96X'4I>)(2M"<*8!ZJ Z9R<
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M8H .IE6<)2B@#@P3PK;GR H $QE)&5-X^] !.Z3_ $T".4TE(R4T )B/SG%
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M##A&5>1]* .>;*QE1SY=*5@-%-;3C;3 36G=QLQBD (:/]%,#N[&\)V]?.@
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M3M?ZP];BFUJ3]29*5A2?UR?TJ[A+DI2=<$.A!VCO -WGCU\Z!H.TA!XVX^U
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MA/MS5J?!6U;)/YY:E)3WP2DJ"=R^4ISQR*38ZHS2\1W+7?9T%Q:2$.[D!)R
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MRZZ]_,7D%7)%7))&5)MBC;*B1@ GT)P/SHDJD34B2L%D=O"GI<9P+,52F5(
MX#GV\\>1JK42V1X,V;)M=#U5LO%@0M;K:ECE7/KY5CC)UR9+<F14![^..J_B
MP7'3NX0#CGUI;][VEDH+;R6RTZI:M$E-JD/I<B+3L\9X J;[%'@N+W%J[Z F
MU+M$V,A^TS3X74#*HI(QD>U0BFTR4I[UM*6SI&?I>XJ=(+T-W^R?3T6GR/WJ
MK8TRA8'C>YE<U)/N-IN!>A27%)<5GN\U8I%JR<]R4T_K:=)5_/94VI(QFJ\F
M2N"3RLE;O>'&H!F.$@D9QGJ:HQ^\5N5&:7K4$A]*BC*"LX*AUQ6S%C]ZV3Q1
M<WR3O9KJBZ6^:60IPQCPL9XP:6;#;M%C6U\%YOCC+4PRV4#:XG=@"E%^1%,S
M'5FIGY;RXB@I+8R /(UIC&RR$7+L2?9Q:$W!X' Y4,_85#//;$FW[M&JZ\N#
MT"S,66 D[UHV*V^]8<:VW-F5*V9LN!$TY"*WBE4UX9&>O/E492^LNEY%GV2%
M=*;4P;DZK+Z^,'WK9CCPD)*RN+4E];S[ZMKBAE(]:W*/!;%4J1;=)6YUQ@+!
MX)K'EX977O62M_?$*UR"M6%<I3^E&/DDRI:,B3I5Q:4W'RT%'<K[UHFN$R4T
MK+Y?K>E+0&[>=OGY>U5+(D*2M#71]O4+@M2^$'%1G3]XIBB6U?"=;6A;"<-^
MWG65R),BH;9<^OFL\[8Q=3/?OI:SCD9-2QPOD&7-F &6F4-IR"D=*AF=,5C&
MZVR3,<2VPTYR<$"H05B;'K>CIL>!W@;7G&>16F*H6XK\QFZM!3;B%;15F[@D
MG97Y4CY516OC%4I\D9.B.EW_ +]&T>*M27 -^[8-C<!=4O !4<UGR61A[S+]
M"N\-N/W1QFKH0M$X%HTSJBWQU!"G0![UOPK;$C,M=VOEEE025+:62FKMQ&)E
M$HH=G*4S].[C%5299=#[Q>IJ-AO+1VUM-076-2Q4@H[KQ@#CI5'3,CVN,B"9
MYLDO.7&Y*DK0 EU7> 8Z#IBNS%4BWLB4TQ$3<-0)&!MC N??%1D1?")N;J-$
M34#<AY/^KJ&SIP"*@HV)(<,]H'\.DARQQ3WI)_FJ'A--Q)I+S&6IKN-03&9]
MP<W2 ,N$'(SY@>U-*B+==A]:+4\Y%[Y3*"%< %-)L46,KJN-;'!$97_/<.U8
MST^U2\P+19/Y=K 3X1QP.*R9?M41GV#O-_,R4 \AL[R#TJ:5((K@6D.!H.2_
M)M(P*8/X%?BQ3,FN25$D/>1YJ3]U63?"*OK/3CEHG)D%($=>T\#'/G4\6130
M\<O(C;O?Y$^,S;6240XP"4)!(!^XJW:D[)1C7+-,[)+]<;1)CPE[C%6,[B3^
ME9\L4TRK)SV-[U9"MU_TK(F)P'V&@$8')5Y5S\<W&>TK@ZX/+;#%RN.M.XDE
M7=0WLJ'.,5U$THEDJ4?B;/J_42+;I=*F4C>VV /TJE.Y%,5;/.]UOLZ^.I0K
M* HD\'K6F/8UQBH\L3M3;K<KN&T D=58Z5"78=WR67334AB['YU14WG(R<U5
MY ^4;QI:S-7MF&N$2E3;@1D<'DUR];'<BO#+]IX==SU'I;3;-HMD&WQW5-]P
M072I6Y(4KK@#I7 R23BY'TCIVE>FP+$ERR^6YF0V[@94!Y#SJF*3[G3;EA7"
MLEUNML,KE/O-Q4-)*U%WH .3DFM<$Y_LTNYFE-?O<G%'E#MB[>K;K"Z?Z&Z.
MGNLV@J7_ !"7@I7.Q_T+7FE)/!5YCI7I>G].45<NYXSK'66VX8NQY_U;%CQ&
M@VJ.J0NX+2GY5H^!*!U:1_2<8'W.:[$EM]TX"6[]I9#MPI+4QUZ2VAN2L[5-
M('#*1]"?N >3YFH .6(,Q;Y4"K%-("15IU<M"@\@ $=<<T]HKHKT[3=QM[RS
M'Q(C;#E&/$G\ZBU1),C8K?>$IQM*?PD\BHL8L^-R%) \J #?)I,1:6P$$H4K
MPG9SCS- &@:/L'P_?P@?\XO:'J3O'&TNO)M5L1MC$ ^!*ED=X#SE0]*LBH?Q
M,A)S_A1G]\3;!=9)LO>KMV<0WG3A;K'X%*2. HCKBJW7D25^9$K. <&@8@%*
MQU/ZT#08=*!BK/O01'K;J2DC'E0 BO(2<=: )C3<G>\^P!QUQ30B=64I0HD
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MQV5/ #'0D\^] $HQ&(.TA/3/6F("6XEM&TI3CU'6AC$HD)4E06LD-I\U<4)
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MY+2DJQ6C'--6Q-,-?&+7NV0FD_I4,B3[!'XA+/98Y<2\XD YJJ"29*546O\
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MN9<7)2 B=N[QOPH6X 5MI],UIA RSR$=_#A+6%%PX'0GG-7J5%$EN'C=F$=
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M1MH+JW$-(/"CSQ5.=I(B^Y*:@9BMJ:0R LXRHBJ\+F^[$W3(H.JD.)C!)(]
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M.J>,UH+11MP$$GDXI6,;.@$Y(Y%(#HZAW@WJ.V@!TIQL#PJS3 2>7O3P3Q2
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MO7(- PB_$@HP<('7% #0JP<T@![W'YT "I&1G<.?>@! H2@[R: #-O$G.#0
MX2]WG@/E0 @9 ;/YT .T#*AZ$]: !D.AJ0T,;@5!)QSUI@6*XN*[PMLI(4V-
MN<=1FI"0I;^[0@G<I#AZC'6@&#(?VH(V ?GG- "7?I+:5-R4I63C:D>+]: (
MZX+=;F (>4L@_P W)!)_2D 546--<=<4O:=N R3PND,;_(-M [5#\C10";T9
M)0G8M(/KFD2$@ZLG!*?#QQ0 /?8SC]J $7'B4*R#^= F-7=R]I /3'2@0FG(
M70 L72.,$T )EU0/TD?E0 9N6\$GE/%  IGN[AN(Q0 X,Q00-AYSZT ';DK<
M4DK(\/I0 HN9DE1.T#C).* #(?YY.//K0 NW)2I6SYLIQY"F(6$A2AW.21_5
MY4 +(>65J"1XL<9I@+!]P)2VV 5'^T]Z .4ZHC^8GB@8D'VT*.TK2",':!S]
M\T"$G8\!:2\EMM#GJC@G[T@ 2W-BH"H[Q*3SLYP?SZ4T)CV-<WMJC)@@!(\2
MDD?N10(5L-VT?;-966^ZPL<N[V%B2%7&WQ7NZ=D- \X/G@9X\Q6?4>)*#42_
M"HIVS4>W#4?8/J>_6.Z]B,L1+=/2MZ? 4CNU1&F\ (6@\@^P.3]JYO38:G&W
MXIHU3QR7NE;O7:<S8EM-3KS#>CI3B-\O(PI ]TCIQ77<Z.>H7V$X?:,W=RGY
M)UATJZ=[-X^^":-S8;1/5VI;S"L[[UJN%OG3$H.8L$E?RB-I\:N!WA_NIH<Z
M1*$59;F+'=^P#L7/:5=G$.=I^NVTQ[=\R=[UFM:F\J=_^)J<!XX&./>IQ]R+
M?FR,FLDMO\*/,=QN@3'#,)'!0$%P_6YZE7ZG[U7V+>Y&M;A@N$$GDT(0+_(.
M/VIL$% X'%,!0 Y'% "R$C/ET-  -@]RR,'.#F@&&(/F* "+\J "T#1U F*)
M'A'%  ,G#ZAGR/% PASYYH&=01 *=X[M,</+5PE)..?6CR8T>B>QJ;J72NNK
M5(1'<3'EH0R^A Y*%)&#CTSYUR)_;8"O:!I^X:;[2+TRM:@W)69#>3Y*ZX_.
MI7P**LP_4NDYEWNK[B&?&2/&1C-5MM=A)RB^"X]GO9'?8=O>U%=H11$C(R%K
M!VJ'M53@Y2W%35SME:U2G^(ONKC)V@9V\8_2IR5(OB(Z<3,=MCS4T;E)5G&.
MM4SY(9G97W++>KK<G8\"& "<#BK,27<CBQKN6JQ=ESUL0F==(XW'IGUJ^7O(
MTNWW)B!IUUZ8>Y9V#<.@K'.!"2LM6L[O:]-:=!8P92&SGG/-&*/)*,://5_U
M%,O[H4Z-J?2NA'A47)4[86Q6I^3(#P! 1R..M0G.D0G-/A&@PH+[=N6H@Y//
M(K/WY*@+2R79*F\< >E (=W^.Z[;'(T?)6M!2,>1HA*F#&&G+!!T[&5*N*D*
MDJ\2>1P*GDR#;OED_:>TNW,2A&F1FW8X.U6X=!ZU7DQ[HV1M$QJ#3UGEN-ZE
MLVP,NC.U'E4,3\F21&3$VX1.]N"D[0-P!/G5Z(ODHMYU)/N,IN%$P(N[:D#K
MBK(\$\;-/[-;84-_,O A+ "QD5BSSMTB.=VB [3M23=0W5-JA'CS] *,26")
M#X%.EP50$"/%(^:)PL^E1C*W;%5$=+AMK=;:))>5]6*UX(MNPNA)"!'G-M+2
M<'CI5V:-<D9=BZZ5AQ8[I7@D$]<5BGDH<43L=EJ;=2ZT,I8!)/49JC=98F%7
M)"G'%'S)ZT61;&J8[DATJ'0U&MS*V7#1VGY4A9?3G"?:NEIL95)CK6D\QF!'
M"3X>N!TJ_-+:R-C;3&M$QVPTJ20!4\.2E8-IB6L-3LS$!#;VXG'%$Y[B-D?I
MF3W:DJQU-*#Y'9=/GE?TG]*OW"'G:GJ%JT6=R-"("BCNVTCDJ'M67!%REND6
MQY//-B[/M4:PF!+,-Y(6K<M2F^ ":UY,T,2Y9<YJ/8W#3_8!I:R,-7/5MQ06
MFD>-I"L*]2"*PO5SFZBK*WE;-1TIK[0=_BR-%Z<LH;BPVBVH8Y<XX-<S4X<R
MFLU$H]K;/-%\TP1JR9'7%4VA+ZM@(Z"NY">Z"HE:\B4AS4V^8FVQ%!*VTC./
M3UJ&2-JR,E8ZO^D4ZIMBFPK?) *MPZU5#(X.D$;1EJ;.(3DF$^V5J:& H_A-
M=!2LG; EZA@FV(@]V ^WD9_IJ;6[@E&+LKT6&B0EUQ3H0K&Y.?,YZ46UP6-T
M:_V4ZS1<,:5O#.6U)"4YZ>_^58M5A27B1[HHG&N4/NT+LK9M\5ZZ6P%:5^-"
M$#/Y57H]:M0MLN&139CDEW:R6I$92%I)201R,5M;VHM2+!V;LR&;RU<6P4H2
MZ$_G5>J6['P$SUAJ&1_&^S1;WUK:8*2!ZUY;"GCU%^14>5M&:<C:JU>Q;0<!
M;[CSK?F #YUZ?/D\/#N98W43TOK+55OT!I!Y47:VW%;2W''J<8R/SXK@Z6,M
M3FN12H[F>>[Y\YJK2;NIIKFZ4M9W ?@ZX%>B5+A&E)+A&;_-S7BA8=45-X2@
M#DD^E7UP6TD>C^PBS7V:69LJ(XA"DA&Y:<$Y]*YNIFEPF9<DEY&Z/0FK0ER-
M9W J6^,/NJ/#0K$I6C,DVS!^V*(C^*0TH=[Y2$D+5UY-=/16XTS3#L4%$?N^
M[P/$D *'H:V^1(=MD>= PJG-K@01P>#1V 06$ */=GK2 1"DN?V:>E !20GJ
M<4 (/D+ V'/VH 43P@$]* !W)0 L*'- !.["CGUYH <PU+2Z0I6]*>4@?B]J
M %T-?.RF_ M" XG<!UZTP+"5Q_F772I9"5N;=W3ZJD(1_B [S*>">#2 ;.R#
MN4#YF@8V"E)\:%\4@"N/;B5I:(6>J_6@!J[$#KB5+CICD\]XTZ5*5[D>5 !6
MX\D)*N]R/\:0 MJ*LI4/N*"5A\LIYV4 $3M6HX\/'6@+"K2DG <"L>E F%[I
M9.U*L T"$U,(0LH*@30  BK4?"O[ 4  [%<(QWE !$Q4H2<CI0 *(^%#*"<]
M!B@!PEMHC;MVF@!0,!'..M !VFV=_P#K"0I&/I]Z !#2>?!D9X]A0 ;#+8R$
M<_:@!Q&6E0VJ.&_,^E,0NM:/[!M6<?\ 2#H:8SB%)&XY'N.M, ^QAM&Y#RU$
M]0:0"*T%>.* $EQE+/A<VE/44A -_.MKVMK*T]2D4T HN>ZA2678JEMKY5D[
M=A'3[T"$9+D2YI#;OB!_ L=WC]*5OL*4>$TRMW"UO1G/FK>K9@X..:3X[$FK
M7+(&6P^_(4J7XR>BJCM3))UV.:>=AD=P0E8\Z*0=RR677 MZPJ1%>6IO"D%M
M>P[P04X/ER!46@2'?:+VMZW[5+R;]K?4$R9,^7:@E#0 ;2PW] &.HP>OG4VV
M^6-1C%5$J2D[75[5 MY&SV&/.DR(%  [TC@J%%!09(*OI&:D X2VLJ VGK0
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M1DU1L42$N';^U#CN-VBUH9*!A/=@#/WJ<=,V[F36*^Y1;YVHWZ^1#(GSB >
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MV0;*[+D27GC'NML[YD<=*OA E8G.T_IK4$7Y)A 8<3TR,8/K4Z<>1-\%*O\
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M&%>Q]J>XC015VLSR>[$A"3Z*\J+"AG(CVMU07\\Q^M)C(Z5;;2>3>,#SPJD
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MH$%>E\[D+P>E Q(2<DE;A_6@:0824@YWT!0JF;QU% GP%,G))W4"%0^DC\-
MPJG=B@-Y_.@#E/DCA=  LNJ*B%<\>= "@3XN"1F@!0!:2$I.<^M #AIC<0HG
M]: L=--D;AC&WI0 NH92-W'%, RG $@#ZO.@!(I"<JWJ.?4T -G XM>$]/6D
M VD=ZG 4$D9I+9N%5]-?W,>_HT%!!2:-I#!*Z<;1;/3H-.@84M+HZ*[!0!#&
MB $#AH"C1%20SDFWQ.A04<'\^?@\YSGW'_B\[SGW_;JO<^Z]S?UFK9I*12NT
MD>X^S %!7^-#9F:OK&B#49>(4X5S43R?HDY17Q0N2[/3(W!JZ=0$"SJX]A$"
MI%<-@M(_S,^! RY:+ 5 L4/O 93A^;X"%<.D\O<<3IR_DS@?,Q5+]HG#",['
MGFGY2B+%@IV6ZEZY!'"9>E"-3"7[Y<S7;U@=NO(%A$254L@&QPS',GJ%;J1<
MO-H6(F_7S "H-(^K\GSC]+S#/J!>/5F^SI)&+-,MYTY;4/6A :6T8MAU_+@D
MK0?&IVQ(WF+'&:C-5JY@<E->EGA6K&1C3?MH6UCN54M>@GTE6B4U2.:_F/)-
M\7=M"Q.6PC/W,X@)@^!3BB6$O.HH6Y?=A=K0G2(K'UJJQ-JNTK>V5J=!MC5/
M9Z1?&EMY(QVXENBD;(P<S78+5$V]B#U9@9DWNV2S[M[\P&$-SY0B$LJ& NAH
M[])]R"L7-7!FT'8MR1S='>Y0&S'?U&16S@IW#[_*L698V729R&+(8!MXI4?_
MY-C.^KCA+T!-JC&?5*AJZ1V4M5Q\E4H^5"HSC+GK\)\]A<WXG9'23]:\A[8-
M,07"G<;IYGP2K"D5$A[GS)_@B:).O]IG4<K*E.<]XAW\VZ:Y=AVER(*U8AU>
M_QO<AM8W=/5J/CS864R8O6YTT1!\J_ <P93?-@OZWN,SU^#AHV1[Z]"TAFS5
M[3L:.801/V]E5A@?)+^0B2HX+&AD?87UC9201)6LZ/+T)XUBMS,TJ$FQ]8MA
M,H/HM(JPP'>%WP-&(S8D:P^<3]Q+RH1J3A;/I$>1N^>"<O TD6L)I9'605NU
MW</P+*&%)>E)?[W1IS6;.DRKQRFIYBD+?*9W-5IR:)SWB\H:0Z^G9&?<S+Y?
M7"1WIUBQGW(E"(M!?%#^"-;:O=3X2WNVJ*%RZ?'&UC3FWD9>R0*GOE!@O.\2
M]1?6'7'!'4)TCHZ/0IU)IU-9U J8"6DO3$\_W9!91@Z7>J\HF'^58%CJ1I>F
M?LVN<U)W2G6=O_YMG0[+=\DB0;>#D<EJ(_&^*R8L?OH(2DJ*^[?"R385;D9A
M?L_2ZYL1/MPLSV;N&_<-^-@/:UT::)KG0J\(:D25S#$@)0-&_+[>*$BV36+N
MM\EWO@KC&F\;_UA$8I74E,T^EIN=[8\92^=4#(!843*[;KT9O/\7:+M#]/TL
M9-=6[/+!($MO.YGF<PH($8P*<NX<T3N%PPUBV70/A[GQJ59.'S?E6EL/+5BO
M%+)(!$]P5]L2LA3Q\[IV*8*B?*L1 P*?OWF19S\WJ8HN.L;^!7I(BM>YF5*8
M;,47R0L/\'6*0+[2M=//9Z-,7WL;_-:$,-@:,EOQ?%F^VN GPF5255SO@>L3
M#==RRS>S3><OIA94IKJ"\VAATE<-'4]J2ME$UK>TSKX4$B[K^XFH8:TU<HAP
M(JW]_/EQ1@T6^;EK0*%)=L" Z>GVJE^UPK>F4UQ#9E8&3*+7@6L(8[_DYS96
M8!/3FT,E__S">#EW<=7,ES<R?5JAY]HBZ=>XM?$LX8?*F 7$2"PX/T=VQ^'L
MT#HB#1N)/@Z(\H.N(">$I!A&[B>RN-B)_.?90AF#5/&^4!I1/V]L\>ZLS^ Z
M7Q!T!G^"*9;S,W8$B_$^% N9Z*D->ZY99M _K._'^/.L;/&/7UBY"3[ <]%M
M*^M)\X0=TT?-(7M[$S\2,D>>XCRD$1G;D#?7O+QV:W/OT\U.6>E'K,@,TL&\
M@M,\E?,MV>9'\)R/\]W<#M]+(L8VX%*KT<S'GQ?$>$YQH]2&$?#!5;'YBF=B
MZI9%-DK?]4-(3>3J0ZT9GN9!)BN))SOO-S<J-(-L#<$&[\QS_)%%:W<%ZT92
M87U"S2I?WS9>6<=.RQ)@[W?'UOJ==^\$6?T(6F"O+I?RXI,DIO,(&Y ZZ4V>
M^P4_"W+JH-*^('(.RV;THXU?>];NR@IA57[7 <X.N@(-_]BEE[4H0J8.QS+&
M5/,3<#3S%T"4!4A].HH;4+.M+.4&:&+M_]W@ARU]1)EVO%2F\( B/$W @HJ5
M\4/',!FX_7'T]<K!(*+Q3$X<Y+4>0XB=J9=6J7S%5LJVP)^PC.+A>\?U3V)(
M>_V1.&K1YI9.553,"RA=:)T G=$P?S$.X-U",6T$BH<,E0'7YJYF)D %^3^[
MDEA0(W:("!Q:VZ:35Y3);@^Z#/;O;G:#G.,23B$]]^ZUF_=0L5QZ30)JAMAQ
M-E F//Z4':BW()7F?,+1FY+P;@K CI2[EPI.A]@QPJ3Z%O?@)(FN#]TLOZ#P
M5@N.IJX5_OJ/6KVNQV<^H"&:>\^%4&P29F%D:CM$J]D5.A2/.MLKKB,H<SY#
M1?0TR[_]<$[&6B-"H,QE?,N!_UR3OQ+%^G^?&*ZZBTBJGN'\+01NQM$##U T
M$9'L0-T!E&:9&1"X2#SA$^=FQ7FY_R2#T)7R"5!RX+Y17QT?G6Z2[[\D',LL
MXE>?U7K-0!ERJ)BLR&4?RH"K1#CGS3A+S:6O-[;4OI@-GO:-= W9KFX+2+%=
M;%7)O'NI>6>Y*>.*=E[8])^C#$3:HVJO=_FSC[\-/4$NO4]P8GKBSAUB]1?
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MD+@<*R@UOU5*D-'JM1$MP^.8?="RI^(+B<V[OH"-) (%H7 #2I3JQ.SZ0UI
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M*/DIJ1=$#\2QP#Q576,DA$MJA?*/?=]N<P2+AY^//_N4XJ/S+/1[?MZF4&:
MC;_B%9['!P)SE:$UT6F6CC+5P5!J149/N(W'XJ> H7N]TU+('PZ!\].KDW,L
MQ0W":+DO$"R788FHM"96M=I#Z(NL-X0^Y+XSY8=-O?)BI543E\F<RY_=3W^F
M[QL]@O=!^8"SFF6780.Y(EFA]30A^+).";,74'>92MQ&1-GG5W]_.+&0/KHA
M],%QVST.@)_WIXW3?7IWP31*6;^'VMIOG2V1D5#B>/YPI=E<E5M\1HVVWPNU
M!09D1+SJH&]U>G!ON.0Y!X<B1J,*LYUG8RK/EY^IB^!R"%(1PYOJD^>6(#4*
MF2N5K6/Z$#%1P^DJ3I$3=.N$LGFML8!9V%827D.Z.23/]D>A>&O&,A@WA<KH
M*9+TS\PM%RY!#'5W[O$8:*3).W<1:F$P>'L>-M$:G\UTT\<@XUIAYP3A%J]
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M\81" I32PFG!$6DW'D:)J8LE@/5>N%:M-!6V5Z4X^IAFC:Q\8T-DGO<WW.2
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MO5;N"SA7^&;R?]C+M "Y-W?B4H*Z/;_&?4_Y84%E6/!G %!RDF 4$;=0!PU
M^LI/TZE1G0HL[P3X9AE;?@&T27DE-#"2SK#M^.-0(+CL$,*P;%@&2-185)#)
M(#*&G88V6!PT9E+6);%;!H1VUI!M\TZ,J.EMMWV8SFZ6H1#L24FGVWSB(/!'
M2XDU(Q:>-\N-L5G 3>O@R*DNG,X5T.8VANKQ[&5_)G1("?!0<";>&U1?#8Z
M'D"9/SB.&)D"]&-:KWBIL6ID=9%[B\9-?P&%R^5JZDF%XNU//UL5OF4RM\JN
M*6/02$/*][%-F16@4HO#'<8@MDK?+G ,Q7*E%I*(-/X"H'?@HWK\L-9OLL+
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M?'QWOZ\618GP^W2R*[KSNKY?BW]LM@9BF.+!Q.O#&1*RP)?6EOV7 DQ+#D*
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M,3)?,2YH=&U02P$"% ,4    " #)/4%6M-M4@T(&  !J%P  %0
M    @ &!!@  83(S,#(P,3(P9BUE>#$R7S(N:'1M4$L! A0#%     @ R3U!
M5C&[=2:& P  50D  !4              ( !]@P  &$R,S R,#$R,&8M97@Q
M,U\Q+FAT;5!+ 0(4 Q0    ( ,D]058.>_$@? ,  $8)   5
M  "  :\0  !A,C,P,C Q,C!F+65X,3-?,BYH=&U02P$"% ,4    " #)/4%6
MJK>,L3<"  #8!P  %0              @ %>%   83(S,#(P,3(P9BUE>#$U
M7S$N:'1M4$L! A0#%     @ R3U!5JXQX!(: @  F@<  !4
M ( !R!8  &$R,S R,#$R,&8M97@Q-5\R+FAT;5!+ 0(4 Q0    ( ,D]059B
M,*2WJT<   ER 0 4              "  149  !A,C,P,C Q,C!F+65X,E\T
M+FAT;5!+ 0(4 Q0    ( ,D]059XA$/DT=P  /;A   -              "
M ?)@  !C;V=O7S P,#(N9VEF4$L! A0#%     @ R3U!5B;V,M13J0  )JT
M  T              ( ![CT! &-O9V]?,# P-2YG:6902P$"% ,4    " #)
M/4%6!QU88N]^  !Q@@  #0              @ %LYP$ 8V]G;U\P,#(Q+F=I
M9E!+ 0(4 Q0    ( ,D]0581CM+;#R<  #(G   -              "  89F
M @!C;V=O7S P,C4N:G!G4$L! A0#%     @ R3U!5NI#?DL17@  S5X   T
M             ( !P(T" &-O9V]?,# R-BYG:6902P$"% ,4    " #)/4%6
M^Q"&8+IY  #W>P  #0              @ '\ZP( 8V]G;U\P,#(W+F=I9E!+
M 0(4 Q0    ( ,D]058HC3J-SR\  /<O   -              "  >%E P!C
M;V=O7S P,C@N:G!G4$L! A0#%     @ R3U!5L@4A]ZT*   XB@   T
M         ( !VY4# &-O9V]?,# S,"YJ<&=02P$"% ,4    " #)/4%648#.
MQ/HG   B*   #0              @ &ZO@, 8V]G;U\P,#,R+FIP9U!+ 0(4
M Q0    ( ,D]05:N\@ *.B@  &0H   -              "  =_F P!C;V=O
M7S P,S,N:G!G4$L! A0#%     @ R3U!5DL*OC@:,   0C    T
M     ( !1 \$ &-O9V]?,# S-2YJ<&=02P$"% ,4    " #)/4%6!H?-MLHI
M  #K*0  #0              @ &)/P0 8V]G;U\P,#,V+FIP9U!+ 0(4 Q0
M   ( ,D]05:4Y62$@B8  *,F   -              "  7YI! !C;V=O7S P
M,S<N:G!G4$L! A0#%     @ R3U!5FO_.(+])P  )"@   T
M ( !*Y $ &-O9V]?,# S."YJ<&=02P$"% ,4    " #)/4%64Q (6B%R   -
M=   #0              @ %3N 0 8V]G;U\P,#,Y+F=I9E!+ 0(4 Q0    (
M ,D]05995=$S-R<  %XG   -              "  9\J!0!C;V=O7S P-#,N
M:G!G4$L! A0#%     @ R3U!5CJPS^DT*0  6RD   T              ( !
M 5(% &-O9V]?,# T-"YJ<&=02P$"% ,4    " #)/4%6] : RL@G  #P)P
M#0              @ %@>P4 8V]G;U\P,#0U+FIP9U!+ 0(4 Q0    ( ,D]
M0593^Q=7,"0  %8D   -              "  5.C!0!C;V=O7S P-#<N:G!G
M4$L! A0#%     @ R3U!5ID?[#LU+0  7RT   T              ( !KL<%
M &-O9V]?,# T.2YJ<&=02P$"% ,4    " #)/4%6)TKE_:9!  !D1   #0
M            @ $.]04 8V]G;U\P,#4Y+F=I9E!+ 0(4 Q0    ( ,D]058"
MER*6?5T  /%=   -              "  =\V!@!C;V=O7S P-C N9VEF4$L!
M A0#%     @ R3U!5D0BNHT\7P  CE\   T              ( !AY0& &-O
M9V]?,# V,2YG:6902P$"% ,4    " #)/4%69'3]R(BF  !VJ   #0
M        @ 'N\P8 8V]G;U\P,#8R+F=I9E!+ 0(4 Q0    ( ,D]05:%<<@I
M/JD  )&M   -              "  :&:!P!C;V=O7S P-C,N9VEF4$L! A0#
M%     @ R3U!5M)J3H@6;   H6X   T              ( !"D0( &-O9V]?
M,# V-"YG:6902P$"% ,4    " #)/4%6#YX$-<U<   U70  #0
M    @ %+L @ 8V]G;U\P,#8U+F=I9E!+ 0(4 Q0    ( ,D]058PJV*O_UH
M %);   -              "  4,-"0!C;V=O7S P-C8N9VEF4$L! A0#%
M  @ R3U!5@]V/'1G7@  -5\   T              ( !;6@) &-O9V]?,# V
M-RYG:6902P$"% ,4    " #)/4%6B!7\T:I<  #\7   #0
M@ '_Q@D 8V]G;U\P,#8X+F=I9E!+ 0(4 Q0    ( ,D]05;9:8A_K%\  /%?
M   -              "  =0C"@!C;V=O7S P-CDN9VEF4$L! A0#%     @
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M2P$"% ,4    " #)/4%6^TV][3:H   UK   #0              @ '/UPP
M8V]M<%\P,# V+F=I9E!+ 0(4 Q0    ( ,D]05;@$H%EMN\! )G] 0 -
M          "  3" #0!C;VUP7S P,#<N9VEF4$L! A0#%     @ R3U!5CG4
MQE?Z4 $ )EP!  T              ( !$7 / &-O;7!?,# P."YG:6902P$"
M% ,4    " #)/4%6FM(:#+WU  !M^P  #0              @ $VP1  8V]M
M<%\P,# Y+F=I9E!+ 0(4 Q0    ( ,D]059*OI/U^S@! !Y" 0 -
M      "  1ZW$0!C;VUP7S P,3 N9VEF4$L! A0#%     @ R3U!5H%#;R,M
M&P( \R4"  T              ( !1/ 2 &-O;7!?,# Q,BYG:6902P$"% ,4
M    " #)/4%6P#"39_&@ @!,L0( #0              @ &<"Q4 8V]M<%\P
M,#$T+F=I9E!+ 0(4 Q0    ( ,D]05;0]J)MA3D" "I" @ -
M  "  ;BL%P!C;VUP7S P,38N9VEF4$L! A0#%     @ R3U!5C.B5*@5M@
MR+L   T              ( !:.89 &-O;7!?,# R,RYG:6902P$"% ,4
M" #)/4%6?3Q:V1UT @"9@0( #0              @ &HG!H 8V]M<%\P,#(V
M+F=I9E!+ 0(4 Q0    ( ,D]05;"L,E;-0L  .$+   -              "
M ? 0'0!C;VUP7S P,C@N9VEF4$L! A0#%     @ R3U!5BL616[J40  $54
M  T              ( !4!P= &-O;7!?,# R.2YG:6902P$"% ,4    " #)
M/4%6'\(*3XE6  #860  #0              @ %E;AT 8V]M<%\P,#,P+F=I
M9E!+ 0(4 Q0    ( ,D]05:(7,CGU8T" %Z: @ -              "  1G%
M'0!C;VUP7S P,S$N9VEF4$L! A0#%     @ R3U!5L()\+H^HP@ D..< !
M             ( !&5,@ &YV<RTR,#(R,3(S,2YH=&U02P$"% ,4    " #)
M/4%6?[B_)_.6  !F%@@ $               @ &%]B@ ;G9S+3(P,C(Q,C,Q
M+GAS9%!+ 0(4 Q0    ( ,D]05:\[V0]Q1P  %_H 0 4              "
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M:6=N+69U;&PN:G!G4$L! A0#%     @ R3U!5D[7^FM^%   KBT   T
M         ( !C,\N '-I9VXM:&%L9BYJ<&=02P$"% ,4    " #)/4%6SFF)
M'MH7  #!+@  "P              @ $UY"X <VMI;&PM9RYJ<&=02P$"% ,4
M    " #)/4%6O-E9YT89  !>,   "P              @ $X_"X <VMI;&PM
M;"YJ<&=02P$"% ,4    " #)/4%6G?LH4#P@  "?10  "P
M@ &G%2\ <VMI;&PM;2YJ<&=02P$"% ,4    " #)/4%6Z,MZK1H6  "L+
M"P              @ $,-B\ <VMI;&PM>"YJ<&=02P$"% ,4    " #)/4%6
MWVQ@U9P8  "J,   "P              @ %/3"\ <VMI;&PM>2YJ<&=02P$"
M% ,4    " #)/4%61_S"4T 8  !$+P  "P              @ $492\ <VMI
M;&PM>BYJ<&=02P$"% ,4    " #)/4%6=TA1,L(F!0#-- 4 #P
M    @ %]?2\ >%]C;W9E<F)A8VLN:G!G4$L! A0#%     @ R3U!5B18J>TO
M=P4 )W<% !               ( !;*0T 'A?8V]V97)F<F]N="YJ<&=02P4&
2     $@ 2 #J$   R1LZ

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
